Cancer_type	QTL_type	tag_SNP	LD	SNP	SNP_position	Alleles	Methylation_probe	Methylation_position	Probe_related_gene	Beta	t-stat	Correlation_coefficient (r)	p-value	Traits
SARC	cis	rs2075371	0.829	rs11770521	chr7:133936251	A/C	cg11752832	chr7:134001865	SLC35B4	0.48	5.73	0.35	3.1e-8	Mean platelet volume;
SARC	cis	rs4664308	0.806	rs4665162	chr2:161060184	A/G	cg03641300	chr2:160917029	PLA2R1	-0.63	-8.16	-0.47	2.14e-14	Idiopathic membranous nephropathy;
SARC	cis	rs9640161	0.830	rs3757425	chr7:150067640	A/C	cg10018233	chr7:150070692	REPIN1	0.73	11.92	0.62	6.76e-26	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg18876405	chr7:65276391	NA	0.49	5.64	0.35	4.8e-8	Aortic root size;
SARC	cis	rs12701220	0.553	rs34062359	chr7:1139076	C/T	cg00990874	chr7:1149470	C7orf50	-0.63	-6.13	-0.37	3.69e-9	Bronchopulmonary dysplasia;
SARC	cis	rs4689388	0.890	rs4689397	chr4:6299387	G/A	cg14416269	chr4:6271139	WFS1	0.33	5.04	0.31	9.55e-7	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg04267008	chr7:1944627	MAD1L1	-0.53	-6.22	-0.38	2.27e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs9443189	0.570	rs504323	chr6:76294965	A/G	cg01950844	chr6:76311363	SENP6	-0.81	-6.79	-0.41	9.41e-11	Prostate cancer;
SARC	cis	rs2115630	1.000	rs56074163	chr15:85351332	C/T	cg12501888	chr15:85177176	SCAND2	-0.47	-5.83	-0.36	1.88e-8	P wave terminal force;
SARC	cis	rs4689388	0.926	rs28420833	chr4:6279504	G/A	cg25554036	chr4:6271136	WFS1	0.42	6.89	0.41	5.09e-11	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs6430585	0.528	rs3112496	chr2:136711064	C/T	cg07169764	chr2:136633963	MCM6	0.93	12.29	0.63	4.26e-27	Corneal structure;
SARC	cis	rs7520050	1.000	rs7540699	chr1:46338585	A/G	cg24296786	chr1:45957014	TESK2	0.39	4.92	0.31	1.63e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.66	-7.62	-0.45	6.27e-13	Gut microbiome composition (summer);
SARC	cis	rs6120849	0.754	rs6120812	chr20:33629427	T/C	cg24642439	chr20:33292090	TP53INP2	0.57	5.48	0.34	1.1e-7	Protein C levels;
SARC	cis	rs11718455	0.960	rs13059547	chr3:44004492	G/A	cg08738300	chr3:44038990	NA	0.53	5.9	0.36	1.3e-8	Coronary artery disease;
SARC	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg16405210	chr4:1374714	KIAA1530	0.54	6.53	0.39	4.16e-10	Obesity-related traits;
SARC	cis	rs9640161	0.659	rs7806429	chr7:150013393	A/G	cg17279839	chr7:150038598	RARRES2	0.42	6.35	0.38	1.1e-9	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs6466055	0.748	rs6962856	chr7:104953466	A/T	cg04380332	chr7:105027541	SRPK2	-0.47	-5.53	-0.34	8.57e-8	Schizophrenia;
SARC	cis	rs7833790	0.654	rs7835342	chr8:82698092	A/G	cg06027949	chr8:82754900	SNX16	-0.46	-5.55	-0.34	7.83e-8	Diastolic blood pressure;
SARC	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg12373951	chr3:133503437	NA	0.42	5.98	0.36	8.19e-9	Iron status biomarkers;
SARC	trans	rs7395662	0.591	rs12807777	chr11:48593754	A/T	cg15704280	chr7:45808275	SEPT13	-0.5	-6.77	-0.41	1.06e-10	HDL cholesterol;
SARC	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg18252515	chr7:66147081	NA	1.29	11.21	0.59	1.32e-23	Diabetic kidney disease;
SARC	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg13206674	chr6:150067644	NUP43	0.49	6.36	0.38	1.04e-9	Lung cancer;
SARC	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs3815700	0.920	rs10426856	chr19:33096406	A/G	cg24916020	chr19:33096688	ANKRD27	0.55	5.59	0.34	6.43e-8	Eosinophilic esophagitis;
SARC	trans	rs2727020	0.729	rs4980439	chr11:49342246	G/C	cg15704280	chr7:45808275	SEPT13	-0.82	-13.34	-0.66	1.54e-30	Coronary artery disease;
SARC	cis	rs7666738	0.830	rs6839277	chr4:99015563	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.51	6.27	0.38	1.72e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7681440	0.904	rs1372521	chr4:90765223	G/A	cg02192967	chr4:90758406	SNCA	0.36	5.13	0.32	6.11e-7	Dementia with Lewy bodies;
SARC	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg10295955	chr4:187884368	NA	-1.08	-20.57	-0.8	2.62e-54	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs782590	0.738	rs4312532	chr2:55812061	A/G	cg18811423	chr2:55921094	PNPT1	-0.6	-8.1	-0.47	3.09e-14	Metabolic syndrome;
SARC	cis	rs4253772	0.530	rs8140573	chr22:46800363	G/C	cg24881330	chr22:46731750	TRMU	0.7	5.8	0.36	2.14e-8	LDL cholesterol;Cholesterol, total;
SARC	trans	rs11098499	0.909	rs10014719	chr4:120320715	G/A	cg25214090	chr10:38739885	LOC399744	0.57	7.46	0.44	1.7e-12	Corneal astigmatism;
SARC	cis	rs7412746	0.658	rs4970988	chr1:150950062	A/G	cg10589385	chr1:150898437	SETDB1	-0.37	-4.81	-0.3	2.71e-6	Melanoma;
SARC	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg04756594	chr16:24857601	SLC5A11	-0.45	-6.31	-0.38	1.39e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg14851345	chr6:64423797	PHF3	0.54	7.92	0.46	9.52e-14	Thyroid stimulating hormone;
SARC	cis	rs9788721	0.836	rs17483721	chr15:78733731	C/T	cg06917634	chr15:78832804	PSMA4	0.52	5.81	0.36	2.07e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs7666738	0.753	rs13120995	chr4:98972762	A/G	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg04267008	chr7:1944627	MAD1L1	-0.49	-5.6	-0.34	5.98e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs936229	0.749	rs8031937	chr15:75181121	A/G	cg10253484	chr15:75165896	SCAMP2	-0.56	-6.04	-0.37	5.94e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg09165964	chr15:75287851	SCAMP5	0.53	7.02	0.42	2.42e-11	Breast cancer;
SARC	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg13175981	chr1:150552382	MCL1	-0.54	-6.9	-0.41	4.87e-11	Tonsillectomy;
SARC	cis	rs13082711	0.911	rs35262121	chr3:27508277	G/A	cg02860705	chr3:27208620	NA	0.44	5.68	0.35	3.91e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs9457247	0.663	rs9459845	chr6:167440501	C/G	cg07741184	chr6:167504864	NA	0.37	7.22	0.43	7.5e-12	Crohn's disease;
SARC	cis	rs7927771	0.524	rs12421563	chr11:47780222	G/A	cg20307385	chr11:47447363	PSMC3	-0.49	-6.63	-0.4	2.36e-10	Subjective well-being;
SARC	cis	rs2832191	0.791	rs2832178	chr21:30479858	T/G	cg08807101	chr21:30365312	RNF160	-0.84	-11.84	-0.61	1.2e-25	Dental caries;
SARC	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg08219700	chr8:58056026	NA	0.59	6.27	0.38	1.76e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9467711	0.591	rs3752417	chr6:26045905	G/C	cg21479132	chr6:26055353	NA	0.89	6.1	0.37	4.27e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg03709012	chr19:19516395	GATAD2A	-0.95	-15.25	-0.71	7.23e-37	Tonsillectomy;
SARC	cis	rs10791323	0.604	rs2257010	chr11:133712348	G/A	cg14349672	chr11:133703707	NA	-0.38	-5.53	-0.34	8.67e-8	Childhood ear infection;
SARC	cis	rs2250402	0.510	rs8031319	chr15:40323692	A/G	cg10636054	chr15:40330586	SRP14	1.0	7.61	0.45	6.65e-13	Corneal curvature;
SARC	cis	rs1318878	0.565	rs10161242	chr12:15465854	A/C	cg08258403	chr12:15378311	NA	0.51	7.05	0.42	2.01e-11	Intelligence (multi-trait analysis);
SARC	cis	rs11098499	0.954	rs7687843	chr4:120421211	C/T	cg09307838	chr4:120376055	NA	0.93	12.73	0.64	1.6e-28	Corneal astigmatism;
SARC	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg15049968	chr18:44337910	ST8SIA5	0.34	5.24	0.32	3.59e-7	Personality dimensions;
SARC	cis	rs8114671	0.562	rs6087651	chr20:33518353	C/T	cg07148914	chr20:33460835	GGT7	0.42	5.04	0.31	9.19e-7	Height;
SARC	cis	rs9398803	0.661	rs864937	chr6:127015083	G/A	cg19875578	chr6:126661172	C6orf173	-0.62	-8.6	-0.49	1.15e-15	Male-pattern baldness;
SARC	cis	rs8180040	1.000	rs7613282	chr3:47389409	C/T	cg27129171	chr3:47204927	SETD2	-0.7	-9.86	-0.54	2.22e-19	Colorectal cancer;
SARC	cis	rs7582720	1.000	rs72928609	chr2:203837573	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs35213789	0.810	rs210598	chr7:69241558	C/T	cg10619644	chr7:69149951	AUTS2	0.43	5.73	0.35	3.02e-8	Childhood ear infection;
SARC	cis	rs11098499	0.731	rs10015579	chr4:120271802	T/C	cg09307838	chr4:120376055	NA	0.75	10.26	0.56	1.31e-20	Corneal astigmatism;
SARC	cis	rs11874712	0.965	rs11661945	chr18:43672194	T/A	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	6.37	0.38	1.02e-9	Migraine - clinic-based;
SARC	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg05861140	chr6:150128134	PCMT1	-0.41	-5.34	-0.33	2.19e-7	Lung cancer;
SARC	cis	rs67460515	0.563	rs34630898	chr3:160827038	A/G	cg17135325	chr3:160939158	NMD3	0.63	7.8	0.46	2.04e-13	Parkinson's disease;
SARC	cis	rs6772849	0.930	rs55987729	chr3:128340110	T/C	cg08795948	chr3:128337044	NA	0.53	7.38	0.44	2.71e-12	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg13206674	chr6:150067644	NUP43	0.42	5.41	0.33	1.59e-7	Lung cancer;
SARC	cis	rs611744	0.967	rs636399	chr8:109235569	G/A	cg21045802	chr8:109455806	TTC35	0.46	5.43	0.34	1.38e-7	Dupuytren's disease;
SARC	cis	rs898097	0.783	rs11650335	chr17:80835111	A/G	cg15369054	chr17:80825471	TBCD	0.54	7.56	0.44	9.09e-13	Breast cancer;
SARC	cis	rs7169223	0.615	rs8038189	chr15:79099026	G/C	cg06917634	chr15:78832804	PSMA4	-0.5	-5.28	-0.33	2.98e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
SARC	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg19748678	chr4:122722346	EXOSC9	0.78	9.85	0.54	2.39e-19	Type 2 diabetes;
SARC	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9858542	0.953	rs9811982	chr3:49624377	A/C	cg03060546	chr3:49711283	APEH	-0.61	-7.75	-0.45	2.75e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs9916302	0.706	rs9908131	chr17:37520449	T/C	cg15445000	chr17:37608096	MED1	-0.46	-4.97	-0.31	1.32e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs9790314	0.631	rs2061804	chr3:161102474	C/A	cg17135325	chr3:160939158	NMD3	0.47	5.73	0.35	3.08e-8	Morning vs. evening chronotype;
SARC	cis	rs57083693	0.518	rs10778113	chr12:101741961	G/A	cg22051763	chr12:101673672	UTP20	-0.46	-5.59	-0.34	6.32e-8	Alcohol dependence (age at onset);
SARC	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg20607798	chr8:58055168	NA	0.53	5.13	0.32	6.12e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6568686	0.530	rs56340018	chr6:111941295	G/A	cg15721981	chr6:111408429	SLC16A10	0.71	5.82	0.36	1.89e-8	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg13206674	chr6:150067644	NUP43	-0.46	-5.92	-0.36	1.13e-8	Lung cancer;
SARC	cis	rs820218	0.926	rs820205	chr17:73641052	A/T	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.66	9.13	0.51	3.29e-17	Rotator cuff tears;
SARC	cis	rs6484504	0.532	rs11031330	chr11:31275073	G/A	cg02090638	chr11:31391270	DNAJC24;DCDC1	-0.43	-5.52	-0.34	9.01e-8	Red blood cell count;
SARC	trans	rs61931739	0.500	rs7309931	chr12:34483471	A/C	cg26384229	chr12:38710491	ALG10B	0.83	12.44	0.63	1.43e-27	Morning vs. evening chronotype;
SARC	cis	rs11190604	1.000	rs11190613	chr10:102313997	C/T	cg07080220	chr10:102295463	HIF1AN	-0.82	-10.66	-0.57	7.21e-22	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.83	7.96	0.46	7.75e-14	Platelet count;
SARC	cis	rs11190604	1.000	rs2295776	chr10:102295629	G/T	cg07080220	chr10:102295463	HIF1AN	0.81	9.96	0.55	1.07e-19	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs17384381	0.700	rs11161617	chr1:85913538	A/G	cg16011679	chr1:85725395	C1orf52	0.55	5.72	0.35	3.24e-8	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg11479843	chr12:15941373	EPS8	-0.56	-6.49	-0.39	5.01e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs7044106	0.690	rs10739569	chr9:123361027	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	8.02	0.47	5.21e-14	Hip circumference adjusted for BMI;
SARC	cis	rs10227331	0.632	rs10215531	chr7:157301180	A/G	cg04156418	chr7:157293606	NA	0.39	6.17	0.37	3e-9	Inattentive symptoms;
SARC	cis	rs10791097	0.690	rs12284540	chr11:130729772	T/C	cg12179176	chr11:130786555	SNX19	0.65	9.14	0.51	3.26e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs12477438	0.765	rs17708262	chr2:99696313	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.92	-14.56	-0.69	1.35e-34	Chronic sinus infection;
SARC	cis	rs113835537	0.529	rs61561111	chr11:66275923	T/C	cg24851651	chr11:66362959	CCS	0.37	4.73	0.3	3.84e-6	Airway imaging phenotypes;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg20620272	chr3:167968129	C3orf50	-0.56	-6.58	-0.4	3.02e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs76419734	0.510	rs6820671	chr4:106613821	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.79	9.72	0.54	5.66e-19	Post bronchodilator FEV1;
SARC	cis	rs3796352	0.764	rs34872575	chr3:52986277	G/A	cg15956490	chr3:53032818	SFMBT1	0.89	5.76	0.35	2.62e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs838721	0.574	rs13003198	chr2:234257105	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.4	5.19	0.32	4.54e-7	Total body bone mineral density;
SARC	cis	rs7264396	0.561	rs66483315	chr20:34573575	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-6.47	-0.39	5.65e-10	Total cholesterol levels;
SARC	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg10435706	chr6:150039699	LATS1	0.36	4.79	0.3	2.94e-6	Lung cancer;
SARC	cis	rs921968	0.613	rs2556388	chr2:219541056	T/C	cg02176678	chr2:219576539	TTLL4	-0.35	-5.06	-0.31	8.59e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg18252515	chr7:66147081	NA	-0.44	-4.75	-0.3	3.5e-6	Aortic root size;
SARC	cis	rs1865760	0.568	rs2032450	chr6:25993114	C/G	cg16482183	chr6:26056742	HIST1H1C	0.5	6.68	0.4	1.75e-10	Height;
SARC	cis	rs9457247	0.765	rs10484531	chr6:167454434	G/A	cg23791538	chr6:167370224	RNASET2	-0.55	-7.12	-0.42	1.33e-11	Crohn's disease;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg13378886	chr1:26232871	STMN1	0.5	6.32	0.38	1.31e-9	Breast cancer;
SARC	cis	rs9457247	1.000	rs239935	chr6:167411788	G/A	cg23791538	chr6:167370224	RNASET2	-0.61	-8.21	-0.47	1.56e-14	Crohn's disease;
SARC	cis	rs6456156	0.528	rs6936261	chr6:167469676	A/C	cg23791538	chr6:167370224	RNASET2	-0.51	-6.78	-0.41	1.01e-10	Primary biliary cholangitis;
SARC	cis	rs2425143	1.000	rs6060639	chr20:34438183	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-5.46	-0.34	1.21e-7	Blood protein levels;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg25281562	chr12:121454272	C12orf43	-0.78	-6.27	-0.38	1.75e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs34172651	0.917	rs12923476	chr16:24798079	G/A	cg00339695	chr16:24857497	SLC5A11	0.31	4.82	0.3	2.58e-6	Intelligence (multi-trait analysis);
SARC	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg20102877	chr2:27665638	KRTCAP3	-0.38	-5.45	-0.34	1.3e-7	Total body bone mineral density;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg17007365	chr11:117186700	BACE1	0.51	6.63	0.4	2.35e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg07850407	chr2:67387038	NA	0.41	6.28	0.38	1.65e-9	Thyroid stimulating hormone;
SARC	cis	rs5753618	0.583	rs5749270	chr22:31812853	C/T	cg07713946	chr22:31675144	LIMK2	0.35	4.88	0.3	1.94e-6	Colorectal cancer;
SARC	trans	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg23258320	chr21:34144322	C21orf66;C21orf49	0.49	7.04	0.42	2.08e-11	Immature fraction of reticulocytes;
SARC	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg12463550	chr7:65579703	CRCP	-0.7	-5.31	-0.33	2.51e-7	Diabetic kidney disease;
SARC	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7647973	0.626	rs1996664	chr3:49878395	A/G	cg13072238	chr3:49761600	GMPPB	0.59	5.9	0.36	1.25e-8	Menarche (age at onset);
SARC	cis	rs9393777	0.623	rs56296968	chr6:26474571	C/T	cg12826209	chr6:26865740	GUSBL1	0.81	7.39	0.44	2.59e-12	Intelligence (multi-trait analysis);
SARC	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg06108461	chr20:60628389	TAF4	-0.92	-12.69	-0.64	2.14e-28	Body mass index;
SARC	cis	rs7572733	0.555	rs2342558	chr2:198920142	T/C	cg00792783	chr2:198669748	PLCL1	0.43	4.85	0.3	2.24e-6	Dermatomyositis;
SARC	cis	rs7681440	0.904	rs7698219	chr4:90771351	C/A	cg02192967	chr4:90758406	SNCA	0.37	5.26	0.33	3.22e-7	Dementia with Lewy bodies;
SARC	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg22920501	chr2:26401640	FAM59B	0.62	8.22	0.47	1.46e-14	Gut microbiome composition (summer);
SARC	cis	rs4646312	0.555	rs737864	chr22:19930159	C/T	cg07194846	chr22:19930177	COMT;TXNRD2	0.52	6.8	0.41	8.56e-11	Schizophrenia;
SARC	cis	rs3784262	1.000	rs12910113	chr15:58248373	A/C	cg12031962	chr15:58353849	ALDH1A2	-0.42	-6.35	-0.38	1.13e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs6430585	0.528	rs16832417	chr2:136744678	C/T	cg07169764	chr2:136633963	MCM6	1.01	12.7	0.64	2.01e-28	Corneal structure;
SARC	cis	rs3815700	1.000	rs10407204	chr19:33097353	C/T	cg24916020	chr19:33096688	ANKRD27	0.53	5.35	0.33	2.05e-7	Eosinophilic esophagitis;
SARC	cis	rs3857536	0.776	rs1002764	chr6:66945760	C/A	cg07460842	chr6:66804631	NA	-0.45	-5.19	-0.32	4.5e-7	Blood trace element (Cu levels);
SARC	cis	rs11792861	0.926	rs76689835	chr9:111833792	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.66	7.6	0.45	7.38e-13	Menarche (age at onset);
SARC	cis	rs6991838	0.584	rs10092109	chr8:66539918	C/T	cg13398993	chr8:66546079	ARMC1	0.62	8.19	0.47	1.72e-14	Intelligence (multi-trait analysis);
SARC	cis	rs13166103	0.657	rs11953112	chr5:57704745	A/C	cg10487770	chr5:57879443	RAB3C	-0.5	-5.34	-0.33	2.2e-7	Type 2 diabetes (age of onset);
SARC	cis	rs910316	1.000	rs175425	chr14:75626131	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.53	-7.28	-0.43	5.2e-12	Height;
SARC	cis	rs3768617	0.510	rs10797843	chr1:183081995	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.8e-21	Fuchs's corneal dystrophy;
SARC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.45	0.53	3.64e-18	Prudent dietary pattern;
SARC	cis	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg25427524	chr10:38739819	LOC399744	-0.62	-9.95	-0.55	1.16e-19	Extrinsic epigenetic age acceleration;
SARC	cis	rs10870270	0.913	rs4880326	chr10:133745547	C/A	cg26149184	chr10:133730230	NA	0.46	5.27	0.33	3.11e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs73242632	1.000	rs10002090	chr4:57859592	T/C	cg20415529	chr4:57845134	POLR2B;C4orf14	1.07	6.6	0.4	2.74e-10	Congenital heart disease (maternal effect);
SARC	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg10523679	chr1:76189770	ACADM	-0.51	-6.7	-0.4	1.54e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs4780401	0.933	rs11075010	chr16:11826013	C/T	cg01061890	chr16:11836724	TXNDC11	-0.52	-6.78	-0.41	9.57e-11	Rheumatoid arthritis;
SARC	cis	rs7819412	0.521	rs4451268	chr8:11034859	A/G	cg12395012	chr8:11607386	GATA4	0.32	5.47	0.34	1.14e-7	Triglycerides;
SARC	cis	rs7223966	1.000	rs8076717	chr17:61850301	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.65	-7.15	-0.42	1.14e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs992157	0.731	rs1399132	chr2:219159770	G/A	cg00012203	chr2:219082015	ARPC2	0.66	9.49	0.53	2.9e-18	Colorectal cancer;
SARC	cis	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg11266682	chr4:10021025	SLC2A9	0.41	7.52	0.44	1.21e-12	Bone mineral density;
SARC	cis	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg17676765	chr20:3388398	C20orf194	0.37	5.18	0.32	4.88e-7	Immature fraction of reticulocytes;
SARC	cis	rs12930096	1.000	rs12929430	chr16:11679467	C/T	cg07439791	chr16:11680400	LITAF	0.55	5.81	0.36	2.03e-8	QT interval;
SARC	cis	rs1153858	1.000	rs12593370	chr15:45617417	C/T	cg15395560	chr15:45543142	SLC28A2	-0.26	-4.85	-0.3	2.31e-6	Homoarginine levels;
SARC	cis	rs854765	0.618	rs8068820	chr17:17834119	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.43	5.58	0.34	6.58e-8	Total body bone mineral density;
SARC	cis	rs1113500	0.897	rs10785832	chr1:108638899	G/A	cg06207961	chr1:108661230	NA	0.44	5.81	0.36	2.02e-8	Growth-regulated protein alpha levels;
SARC	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg11317459	chr13:21872234	NA	0.45	5.23	0.32	3.81e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs7824557	0.602	rs7828711	chr8:11205665	G/C	cg21775007	chr8:11205619	TDH	0.67	8.67	0.49	7.48e-16	Retinal vascular caliber;
SARC	trans	rs9650657	0.740	rs7002282	chr8:10666993	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.65	-0.4	2.01e-10	Neuroticism;
SARC	cis	rs6083	0.536	rs4528512	chr15:58852226	A/T	cg05156742	chr15:59063176	FAM63B	0.59	7.46	0.44	1.68e-12	Schizophrenia;
SARC	cis	rs6429082	0.764	rs2481095	chr1:235695756	T/C	cg26050004	chr1:235667680	B3GALNT2	-0.68	-7.93	-0.46	9.2e-14	Adiposity;
SARC	cis	rs9787249	0.957	rs11206754	chr1:40216234	A/G	cg24920358	chr1:40204285	PPIE	0.43	5.22	0.32	3.92e-7	Blood protein levels;
SARC	trans	rs9354308	0.838	rs9363453	chr6:66544051	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.56	-6.64	-0.4	2.19e-10	Metabolite levels;
SARC	cis	rs5167	0.566	rs7253458	chr19:45482570	C/T	cg10169327	chr19:45448959	APOC2	0.33	4.86	0.3	2.18e-6	Blood protein levels;
SARC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.77	9.35	0.52	7.54e-18	Prudent dietary pattern;
SARC	cis	rs7824557	0.591	rs2736282	chr8:11225480	C/T	cg14752069	chr8:11977206	FAM66D	0.31	5.09	0.32	7.32e-7	Retinal vascular caliber;
SARC	cis	rs7246657	0.722	rs1291	chr19:38229378	G/A	cg23950597	chr19:37808831	NA	0.51	4.89	0.31	1.88e-6	Coronary artery calcification;
SARC	cis	rs7264396	0.623	rs761827	chr20:34207897	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	5.39	0.33	1.74e-7	Total cholesterol levels;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg14249877	chr10:32322959	KIF5B	0.58	8.21	0.47	1.48e-14	Thyroid stimulating hormone;
SARC	cis	rs7829975	0.511	rs2976902	chr8:8341105	T/G	cg15556689	chr8:8085844	FLJ10661	0.4	5.11	0.32	6.61e-7	Mood instability;
SARC	cis	rs10916814	0.610	rs4655223	chr1:20901688	C/G	cg24502330	chr1:20914028	CDA	-0.27	-4.74	-0.3	3.76e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs11585357	0.947	rs2977304	chr1:17611615	T/C	cg08277548	chr1:17600880	PADI3	0.46	5.32	0.33	2.47e-7	Hair shape;
SARC	trans	rs2018683	0.677	rs12531456	chr7:28970611	A/C	cg19402173	chr7:128379420	CALU	-0.53	-6.94	-0.41	3.85e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs4938330	0.600	rs2239010	chr11:117089006	G/C	cg01368799	chr11:117014884	PAFAH1B2	-0.52	-5.51	-0.34	9.61e-8	Blood protein levels;
SARC	cis	rs72781680	1.000	rs72798411	chr2:24184343	A/G	cg08917208	chr2:24149416	ATAD2B	0.94	9.09	0.51	4.53e-17	Lymphocyte counts;
SARC	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg08645402	chr16:4508243	NA	0.4	4.74	0.3	3.68e-6	Schizophrenia;
SARC	cis	rs681343	0.746	rs633372	chr19:49209226	G/A	cg07051648	chr19:49177693	NTN5;SEC1	-0.41	-5.33	-0.33	2.27e-7	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
SARC	cis	rs11758351	1.000	rs11758351	chr6:26203910	T/G	cg23601095	chr6:26197514	HIST1H3D	0.57	5.08	0.32	7.78e-7	Gout;Renal underexcretion gout;
SARC	cis	rs4481887	0.927	rs4427440	chr1:248480337	T/A	cg13385794	chr1:248469461	NA	0.33	5.08	0.32	7.75e-7	Common traits (Other);
SARC	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg18876405	chr7:65276391	NA	0.7	8.81	0.5	3e-16	Aortic root size;
SARC	cis	rs6542838	0.611	rs17758170	chr2:99531842	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-5.23	-0.32	3.71e-7	Fear of minor pain;
SARC	cis	rs554111	0.656	rs10916891	chr1:21199974	A/C	cg08890418	chr1:21044141	KIF17	-0.35	-4.86	-0.3	2.16e-6	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg13126279	chr21:47581558	C21orf56	0.48	5.84	0.36	1.73e-8	Testicular germ cell tumor;
SARC	cis	rs9398803	0.865	rs9398809	chr6:126789144	C/T	cg20229609	chr6:126660872	C6orf173	0.4	5.82	0.36	1.96e-8	Male-pattern baldness;
SARC	cis	rs2282802	0.685	rs6867870	chr5:139641896	C/A	cg26211634	chr5:139558579	C5orf32	0.41	5.28	0.33	2.98e-7	Intelligence (multi-trait analysis);
SARC	cis	rs13191362	0.935	rs34009353	chr6:163007668	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.56	5.41	0.33	1.53e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg26418112	chr1:233431487	PCNXL2	0.48	6.32	0.38	1.32e-9	Chemerin levels;
SARC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg14893161	chr1:205819251	PM20D1	-0.91	-15.65	-0.72	3.27e-38	Menarche (age at onset);
SARC	trans	rs1502172	0.550	rs7622903	chr3:135242871	A/G	cg17077762	chr15:64996104	OAZ2	0.5	6.51	0.39	4.68e-10	Visceral adipose tissue adjusted for BMI;
SARC	cis	rs13256369	0.789	rs13282500	chr8:8568489	A/T	cg17143192	chr8:8559678	CLDN23	0.49	5.99	0.37	7.91e-9	Obesity-related traits;
SARC	cis	rs11608355	0.545	rs2302709	chr12:109893697	A/G	cg05360138	chr12:110035743	NA	0.92	9.61	0.53	1.27e-18	Neuroticism;
SARC	cis	rs514024	0.708	rs574771	chr9:130483831	C/T	cg13643465	chr9:130375613	STXBP1	0.46	5.7	0.35	3.52e-8	Eating disorders (purging via substances);
SARC	cis	rs1865760	0.865	rs9467648	chr6:25957933	T/A	cg10373733	chr6:25993375	NA	0.4	4.79	0.3	2.96e-6	Height;
SARC	cis	rs796364	0.951	rs13029537	chr2:200998950	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.58	-5.34	-0.33	2.21e-7	Schizophrenia;
SARC	cis	rs7772486	0.686	rs1011596	chr6:146076433	A/G	cg05347473	chr6:146136440	FBXO30	0.52	7.2	0.43	8.28e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1044826	0.956	rs13086868	chr3:139239644	A/G	cg15131784	chr3:139108705	COPB2	0.46	5.15	0.32	5.44e-7	Obesity-related traits;
SARC	cis	rs881375	0.967	rs7039505	chr9:123705945	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	5.55	0.34	7.88e-8	Rheumatoid arthritis;
SARC	cis	rs4481887	1.000	rs9660769	chr1:248484558	C/G	cg13385794	chr1:248469461	NA	-0.39	-5.52	-0.34	8.95e-8	Common traits (Other);
SARC	cis	rs2120243	0.572	rs6803628	chr3:157125584	G/A	cg01018701	chr3:157155998	VEPH1;PTX3	0.39	4.96	0.31	1.36e-6	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg13607699	chr17:42295918	UBTF	-0.59	-7.27	-0.43	5.56e-12	Total body bone mineral density;
SARC	cis	rs9682041	0.877	rs6804688	chr3:170071191	T/G	cg11886554	chr3:170076028	SKIL	0.65	6.48	0.39	5.27e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.44	-5.08	-0.32	7.57e-7	Longevity;Endometriosis;
SARC	cis	rs870825	0.860	rs72703527	chr4:185605997	C/A	cg04058563	chr4:185651563	MLF1IP	0.79	9.54	0.53	2.02e-18	Blood protein levels;
SARC	cis	rs1865760	0.516	rs9379818	chr6:26023206	G/T	cg02841227	chr6:26021843	HIST1H4A	0.4	5.05	0.31	9.06e-7	Height;
SARC	cis	rs2730245	1.000	rs6965685	chr7:158726462	C/T	cg14689365	chr7:158441557	NCAPG2	0.41	4.91	0.31	1.72e-6	Height;
SARC	cis	rs2227564	0.700	rs2688613	chr10:75653045	C/T	cg16540259	chr10:75572220	NDST2	0.33	4.76	0.3	3.46e-6	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs7084402	0.967	rs1649077	chr10:60293906	A/G	cg07615347	chr10:60278583	BICC1	0.6	8.91	0.5	1.45e-16	Refractive error;
SARC	cis	rs10875746	0.903	rs61918806	chr12:48484433	G/A	cg26205652	chr12:48591994	NA	0.56	6.1	0.37	4.37e-9	Longevity (90 years and older);
SARC	cis	rs2033732	0.706	rs4268126	chr8:85065958	T/G	cg05716166	chr8:85095498	RALYL	0.47	5.62	0.35	5.51e-8	Body mass index;
SARC	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg08280861	chr8:58055591	NA	0.6	5.29	0.33	2.75e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1355223	0.867	rs2281908	chr11:34683578	C/T	cg18508148	chr11:34937573	PDHX;APIP	-0.4	-4.96	-0.31	1.37e-6	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs9291683	0.526	rs6827785	chr4:10018205	C/T	cg11266682	chr4:10021025	SLC2A9	0.39	6.75	0.4	1.15e-10	Bone mineral density;
SARC	cis	rs55871839	0.708	rs13261666	chr8:59814666	G/T	cg07426533	chr8:59803705	TOX	-0.44	-5.88	-0.36	1.43e-8	Pneumonia;
SARC	cis	rs6963495	0.546	rs2697020	chr7:105150046	C/T	cg19920283	chr7:105172520	RINT1	0.57	5.88	0.36	1.43e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs9322817	0.691	rs2400072	chr6:105344116	C/T	cg02098413	chr6:105308735	HACE1	0.4	6.15	0.37	3.26e-9	Thyroid stimulating hormone;
SARC	cis	rs644148	0.836	rs2686774	chr19:44999827	T/C	cg15540054	chr19:45004280	ZNF180	-0.45	-5.09	-0.32	7.24e-7	Personality dimensions;
SARC	cis	rs921968	0.643	rs3845836	chr2:219504955	C/T	cg02176678	chr2:219576539	TTLL4	0.43	6.64	0.4	2.18e-10	Mean corpuscular hemoglobin concentration;
SARC	cis	rs7769051	0.522	rs9493449	chr6:133126179	T/A	cg22852734	chr6:133119734	C6orf192	1.21	7.73	0.45	3.24e-13	Type 2 diabetes nephropathy;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg25174874	chr4:107223505	TBCK	0.48	6.84	0.41	6.95e-11	Thyroid stimulating hormone;
SARC	cis	rs79387448	0.638	rs78123896	chr2:103075417	T/C	cg09003973	chr2:102972529	NA	0.8	7.1	0.42	1.48e-11	Gut microbiota (bacterial taxa);
SARC	cis	rs9868809	0.772	rs9812200	chr3:48695667	A/G	cg07636037	chr3:49044803	WDR6	0.69	6.58	0.4	3.1e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs7264396	0.635	rs6060720	chr20:34548336	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	5.3	0.33	2.71e-7	Total cholesterol levels;
SARC	cis	rs796364	0.951	rs13029537	chr2:200998950	T/C	cg23649088	chr2:200775458	C2orf69	-0.59	-5.78	-0.35	2.43e-8	Schizophrenia;
SARC	cis	rs858239	0.669	rs1990365	chr7:23115966	T/C	cg23682824	chr7:23144976	KLHL7	0.63	7.93	0.46	8.81e-14	Cerebrospinal fluid biomarker levels;
SARC	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.03	12.03	0.62	3.06e-26	Alzheimer's disease;
SARC	cis	rs644799	1.000	rs487609	chr11:95588102	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	13.87	0.67	2.75e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg23758822	chr17:41437982	NA	0.88	11.32	0.6	6.01e-24	Menopause (age at onset);
SARC	cis	rs995000	0.931	rs636497	chr1:62920029	A/G	cg06896770	chr1:63153194	DOCK7	0.9	13.85	0.67	3.23e-32	Triglyceride levels;
SARC	cis	rs4711336	1.000	rs4711336	chr6:33659046	A/G	cg15676125	chr6:33679581	C6orf125	-0.61	-7.47	-0.44	1.64e-12	Height;
SARC	cis	rs3741151	0.686	rs12288753	chr11:73136261	A/T	cg17517138	chr11:73019481	ARHGEF17	0.66	5.48	0.34	1.08e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs2735413	0.709	rs4395084	chr16:78088011	C/G	cg04733911	chr16:78082701	NA	-0.34	-5.39	-0.33	1.73e-7	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg13628971	chr7:2884303	GNA12	0.57	6.64	0.4	2.23e-10	Height;
SARC	cis	rs5753618	0.583	rs2273251	chr22:31843567	G/C	cg13145458	chr22:31556086	RNF185	-0.5	-5.35	-0.33	2.15e-7	Colorectal cancer;
SARC	cis	rs1707322	0.721	rs11211163	chr1:46153548	C/T	cg03146154	chr1:46216737	IPP	0.53	6.35	0.38	1.12e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs651907	0.557	rs1056579	chr3:101397877	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	6.56	0.39	3.53e-10	Colorectal cancer;
SARC	cis	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg24110177	chr3:50126178	RBM5	0.63	8.44	0.48	3.41e-15	Body mass index;
SARC	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg11987759	chr7:65425863	GUSB	-0.5	-6.19	-0.38	2.62e-9	Aortic root size;
SARC	cis	rs8070128	0.597	rs4635395	chr17:17882087	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.41	4.74	0.3	3.66e-6	Total body bone mineral density;
SARC	cis	rs6088590	1.000	rs6087626	chr20:33347328	C/T	cg06115741	chr20:33292138	TP53INP2	0.56	6.78	0.41	1e-10	Coronary artery disease;
SARC	trans	rs61931739	0.500	rs7311284	chr12:34478477	C/G	cg13010199	chr12:38710504	ALG10B	0.82	11.46	0.6	2.04e-24	Morning vs. evening chronotype;
SARC	cis	rs67311347	1.000	rs11714912	chr3:40494065	A/G	cg09455208	chr3:40491958	NA	-0.4	-6.33	-0.38	1.23e-9	Renal cell carcinoma;
SARC	cis	rs6665290	0.904	rs2297415	chr1:227172903	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.07	-26.16	-0.86	2.69e-71	Myeloid white cell count;
SARC	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	7.19	0.43	8.75e-12	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg12463550	chr7:65579703	CRCP	0.5	5.9	0.36	1.27e-8	Aortic root size;
SARC	cis	rs6484504	0.600	rs1323738	chr11:31344898	T/C	cg02090638	chr11:31391270	DNAJC24;DCDC1	0.4	5.04	0.31	9.53e-7	Red blood cell count;
SARC	cis	rs16854884	0.632	rs34071449	chr3:143662861	C/T	cg06585982	chr3:143692056	C3orf58	0.66	8.73	0.5	4.92e-16	Economic and political preferences (feminism/equality);
SARC	cis	rs208520	0.690	rs6932475	chr6:66863155	G/A	cg07460842	chr6:66804631	NA	-1.06	-14.96	-0.7	6.65e-36	Exhaled nitric oxide output;
SARC	cis	rs7833986	0.501	rs2667981	chr8:56894303	T/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.68	6.78	0.41	1e-10	Height;
SARC	cis	rs9581943	0.967	rs9581927	chr13:28462645	G/T	cg16302790	chr13:28498334	PDX1	0.56	8.37	0.48	5.41e-15	Pancreatic cancer;
SARC	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg12696929	chr3:195401817	SDHAP2	-0.4	-5.42	-0.33	1.5e-7	Pancreatic cancer;
SARC	cis	rs765787	0.505	rs11630884	chr15:45532246	C/T	cg25801113	chr15:45476975	SHF	0.3	4.92	0.31	1.62e-6	Uric acid levels;
SARC	cis	rs9948	0.655	rs76653480	chr2:97375549	C/T	cg01990225	chr2:97406019	LMAN2L	-0.97	-7.08	-0.42	1.66e-11	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg06108461	chr20:60628389	TAF4	0.87	10.75	0.58	3.69e-22	Body mass index;
SARC	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg22535103	chr8:58192502	C8orf71	-0.73	-7.24	-0.43	6.52e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs11105298	0.891	rs12228177	chr12:89862030	G/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.49	-5.0	-0.31	1.11e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs1949733	1.000	rs2688223	chr4:8471398	T/C	cg11789530	chr4:8429930	ACOX3	0.82	10.96	0.58	8.15e-23	Response to antineoplastic agents;
SARC	cis	rs6121246	0.909	rs1994249	chr20:30287593	C/T	cg13852791	chr20:30311386	BCL2L1	0.86	9.16	0.51	2.76e-17	Mean corpuscular hemoglobin;
SARC	cis	rs9911578	1.000	rs302854	chr17:56683612	G/A	cg12560992	chr17:57184187	TRIM37	0.84	11.4	0.6	3.14e-24	Intelligence (multi-trait analysis);
SARC	trans	rs6894249	1.000	rs6894249	chr5:131797547	A/G	cg06191580	chr17:35870477	DUSP14	-0.43	-6.51	-0.39	4.52e-10	Asthma;
SARC	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg04267008	chr7:1944627	MAD1L1	-0.53	-6.22	-0.38	2.27e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs12594515	1.000	rs7172161	chr15:45990780	A/G	cg14863074	chr15:45997064	NA	0.34	5.24	0.32	3.57e-7	Waist circumference;Weight;
SARC	cis	rs9341808	0.529	rs4706840	chr6:81057769	T/A	cg08355045	chr6:80787529	NA	0.32	4.94	0.31	1.52e-6	Sitting height ratio;
SARC	cis	rs9303401	0.625	rs34963822	chr17:56988424	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	11.58	0.6	8.42e-25	Cognitive test performance;
SARC	cis	rs7914558	0.966	rs11191438	chr10:104637864	C/G	cg04362960	chr10:104952993	NT5C2	0.45	5.47	0.34	1.14e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg02841227	chr6:26021843	HIST1H4A	-0.52	-6.35	-0.38	1.11e-9	Intelligence (multi-trait analysis);
SARC	cis	rs5167	0.781	rs11672748	chr19:45490192	A/G	cg13119609	chr19:45449297	APOC2	0.39	5.97	0.36	8.91e-9	Blood protein levels;
SARC	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg24829409	chr8:58192753	C8orf71	-0.56	-6.25	-0.38	1.99e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1552244	0.706	rs279545	chr3:9972493	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.63	-7.26	-0.43	5.8e-12	Alzheimer's disease;
SARC	cis	rs6665290	0.904	rs1045290	chr1:227178700	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.07	-25.78	-0.86	3.44e-70	Myeloid white cell count;
SARC	cis	rs1801251	1.000	rs12990821	chr2:233617585	C/G	cg25237894	chr2:233734115	C2orf82	0.38	4.96	0.31	1.39e-6	Coronary artery disease;
SARC	cis	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg21573476	chr21:45109991	RRP1B	-0.54	-7.97	-0.46	7.02e-14	Mean corpuscular volume;
SARC	trans	rs61931739	0.517	rs10772139	chr12:34186178	A/T	cg26384229	chr12:38710491	ALG10B	0.85	12.17	0.62	1.07e-26	Morning vs. evening chronotype;
SARC	trans	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg07211511	chr3:129823064	LOC729375	-0.56	-6.45	-0.39	6.56e-10	Blood pressure (smoking interaction);
SARC	cis	rs9905704	0.846	rs302878	chr17:56762964	G/A	cg12560992	chr17:57184187	TRIM37	0.43	4.9	0.31	1.81e-6	Testicular germ cell tumor;
SARC	cis	rs12545109	0.775	rs10093388	chr8:57318799	C/T	cg21220214	chr8:57350948	NA	-0.4	-4.84	-0.3	2.33e-6	Obesity-related traits;
SARC	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg18404041	chr3:52824283	ITIH1	0.44	6.65	0.4	2.11e-10	Bipolar disorder;
SARC	cis	rs7582720	1.000	rs72926781	chr2:203808835	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs1153858	1.000	rs7402650	chr15:45701895	C/T	cg26924012	chr15:45694286	SPATA5L1	0.78	10.67	0.57	6.94e-22	Homoarginine levels;
SARC	cis	rs12048904	0.505	rs11166508	chr1:101233511	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.72	-8.54	-0.49	1.71e-15	Multiple sclerosis;
SARC	cis	rs2072499	0.750	rs55675376	chr1:156165881	C/T	cg24450063	chr1:156163899	SLC25A44	1.1	14.42	0.69	3.93e-34	Testicular germ cell tumor;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg12362369	chr4:140098382	NA	-0.8	-6.69	-0.4	1.62e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1728785	0.818	rs1814299	chr16:68581332	G/A	cg02972257	chr16:68554789	NA	-0.43	-5.01	-0.31	1.08e-6	Ulcerative colitis;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg11252118	chr10:131769845	NA	0.5	6.75	0.4	1.17e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs9677476	0.863	rs13423632	chr2:232079116	T/C	cg23338755	chr2:231921595	PSMD1	0.45	5.28	0.33	2.98e-7	Food antigen IgG levels;
SARC	cis	rs6963495	0.818	rs75116202	chr7:105160059	C/T	cg13798780	chr7:105162888	PUS7	0.6	5.45	0.34	1.31e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs4253772	0.744	rs4253760	chr22:46622384	T/G	cg24881330	chr22:46731750	TRMU	0.53	6.0	0.37	7.67e-9	LDL cholesterol;Cholesterol, total;
SARC	trans	rs1814175	0.935	rs11040462	chr11:49683158	G/A	cg15704280	chr7:45808275	SEPT13	-0.92	-16.38	-0.73	1.19e-40	Height;
SARC	cis	rs2742234	0.541	rs60845448	chr10:43721462	C/T	cg15436174	chr10:43711423	RASGEF1A	0.43	5.01	0.31	1.08e-6	Hirschsprung disease;
SARC	cis	rs9987353	0.566	rs13260067	chr8:9071033	A/G	cg15556689	chr8:8085844	FLJ10661	-0.43	-5.14	-0.32	5.95e-7	Recombination measurement;
SARC	cis	rs6429082	0.818	rs834198	chr1:235671987	A/G	cg26050004	chr1:235667680	B3GALNT2	0.66	7.61	0.45	6.89e-13	Adiposity;
SARC	cis	rs3126085	0.877	rs3126055	chr1:152266364	G/A	cg26876637	chr1:152193138	HRNR	-0.46	-5.21	-0.32	4.22e-7	Atopic dermatitis;
SARC	cis	rs11585357	0.709	rs735281	chr1:17616194	T/C	cg08277548	chr1:17600880	PADI3	0.44	5.39	0.33	1.74e-7	Hair shape;
SARC	cis	rs9486715	0.867	rs4438964	chr6:96917563	T/G	cg18709589	chr6:96969512	KIAA0776	0.59	7.32	0.43	3.97e-12	Headache;
SARC	cis	rs7615952	0.673	rs9289270	chr3:125636979	A/T	cg05084668	chr3:125655381	ALG1L	-0.92	-8.62	-0.49	1.04e-15	Blood pressure (smoking interaction);
SARC	cis	rs6732160	0.845	rs72807999	chr2:73391695	T/C	cg01422370	chr2:73384389	NA	0.32	5.5	0.34	9.94e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7582180	0.764	rs7425449	chr2:100928393	A/G	cg14675211	chr2:100938903	LONRF2	0.52	7.62	0.45	6.2800000000000005e-13	Intelligence (multi-trait analysis);
SARC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.67	9.09	0.51	4.41e-17	Lymphocyte counts;
SARC	trans	rs17007695	0.649	rs13150149	chr4:142679315	C/G	cg11908711	chr10:97051605	PDLIM1	0.76	6.35	0.38	1.12e-9	Response to treatment for acute lymphoblastic leukemia;
SARC	cis	rs1559088	1.000	rs12979164	chr19:33553228	G/C	cg17764715	chr19:33622953	WDR88	0.48	6.25	0.38	1.96e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs7666738	0.546	rs10018080	chr4:98758436	C/A	cg05340658	chr4:99064831	C4orf37	0.6	7.3	0.43	4.4e-12	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9467773	1.000	rs9467796	chr6:26568411	A/G	cg11502198	chr6:26597334	ABT1	0.53	6.46	0.39	6.05e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7020830	0.931	rs13295115	chr9:37157964	T/G	cg14294708	chr9:37120828	ZCCHC7	1.14	19.02	0.78	2.57e-49	Schizophrenia;
SARC	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.5	5.96	0.36	9.48e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs2228479	0.850	rs17226980	chr16:89825065	G/A	cg06558623	chr16:89946397	TCF25	0.88	6.21	0.38	2.39e-9	Skin colour saturation;
SARC	cis	rs9815354	0.597	rs60690674	chr3:41997811	G/C	cg03022575	chr3:42003672	ULK4	0.7	5.95	0.36	9.58e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs4427176	0.714	rs12335065	chr8:9470384	T/C	cg21625330	chr8:9911636	MSRA	-0.65	-5.2	-0.32	4.44e-7	Mosquito bite size;
SARC	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.12	24.35	0.85	5.74e-66	Chronic sinus infection;
SARC	cis	rs908922	0.651	rs1885531	chr1:152480233	T/G	cg09873164	chr1:152488093	CRCT1	0.66	8.19	0.47	1.71e-14	Hair morphology;
SARC	cis	rs10754283	0.967	rs7546410	chr1:90109815	C/T	cg21401794	chr1:90099060	LRRC8C	0.59	8.09	0.47	3.24e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs8028182	0.636	rs8029112	chr15:75808972	T/C	cg20655648	chr15:75932815	IMP3	0.64	7.41	0.44	2.38e-12	Sudden cardiac arrest;
SARC	cis	rs1707322	0.721	rs10890333	chr1:46100322	T/C	cg03146154	chr1:46216737	IPP	0.51	6.13	0.37	3.79e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2013441	1.000	rs17686839	chr17:20039171	A/G	cg13482628	chr17:19912719	NA	0.47	6.13	0.37	3.67e-9	Obesity-related traits;
SARC	trans	rs11710567	0.734	rs7646847	chr3:57828004	G/T	cg01127878	chr19:42811035	PRR19	-0.44	-6.36	-0.38	1.08e-9	Granulocyte percentage of myeloid white cells;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg10580397	chr3:23331228	UBE2E2	0.39	6.5	0.39	4.88e-10	Thyroid stimulating hormone;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg06047995	chr3:129035211	H1FX;C3orf47	0.48	6.33	0.38	1.27e-9	Schizophrenia;
SARC	cis	rs72945132	0.660	rs67433166	chr11:70121604	T/A	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.78	-0.35	2.39e-8	Coronary artery disease;
SARC	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg18357526	chr6:26021779	HIST1H4A	0.79	9.97	0.55	1.01e-19	Intelligence (multi-trait analysis);
SARC	cis	rs4595586	0.545	rs1607041	chr12:39368206	C/T	cg26384229	chr12:38710491	ALG10B	0.52	6.09	0.37	4.61e-9	Morning vs. evening chronotype;
SARC	cis	rs9747201	0.963	rs11077982	chr17:80147377	G/C	cg17462356	chr17:80056334	FASN	-0.47	-5.24	-0.32	3.56e-7	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg17095167	chr13:21833918	NA	-0.75	-6.35	-0.38	1.09e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9326248	0.954	rs521171	chr11:117064693	C/G	cg11861562	chr11:117069780	TAGLN	0.23	5.11	0.32	6.84e-7	Blood protein levels;
SARC	cis	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.4	5.02	0.31	1.04e-6	Eosinophil percentage of white cells;
SARC	cis	rs11098499	0.820	rs13128602	chr4:120459366	C/T	cg09307838	chr4:120376055	NA	-0.89	-11.98	-0.62	4.28e-26	Corneal astigmatism;
SARC	cis	rs2952156	0.883	rs12150603	chr17:37834715	G/A	cg20243544	chr17:37824526	PNMT	0.54	7.07	0.42	1.76e-11	Asthma;
SARC	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg19223190	chr17:80058835	NA	-0.41	-5.68	-0.35	3.98e-8	Life satisfaction;
SARC	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg24060327	chr5:131705240	SLC22A5	-0.45	-5.36	-0.33	2e-7	Acylcarnitine levels;
SARC	cis	rs3796352	1.000	rs11712653	chr3:53070875	A/C	cg27565382	chr3:53032988	SFMBT1	-0.86	-6.49	-0.39	5e-10	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.11	-19.98	-0.79	2.07e-52	Prudent dietary pattern;
SARC	cis	rs2204008	0.774	rs11180977	chr12:38263094	G/T	cg13010199	chr12:38710504	ALG10B	0.81	11.31	0.6	6.33e-24	Bladder cancer;
SARC	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg11764359	chr7:65958608	NA	0.88	12.59	0.64	4.36e-28	Aortic root size;
SARC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg02725872	chr8:58115012	NA	-0.37	-6.47	-0.39	5.76e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg12463550	chr7:65579703	CRCP	0.66	5.01	0.31	1.09e-6	Diabetic kidney disease;
SARC	cis	rs6088580	0.634	rs6120669	chr20:33105028	T/C	cg08999081	chr20:33150536	PIGU	0.43	6.53	0.39	4.04e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs1691799	0.899	rs1168325	chr12:66728234	C/G	cg16791601	chr12:66731901	HELB	-0.72	-10.96	-0.58	8.23e-23	White blood cell count (basophil);
SARC	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg19077165	chr18:44547161	KATNAL2	-0.52	-7.29	-0.43	4.74e-12	Personality dimensions;
SARC	cis	rs7546	0.504	rs2075636	chr16:4938321	A/T	cg08329684	chr16:4932620	PPL	-0.43	-6.82	-0.41	7.67e-11	Cancer;
SARC	cis	rs12142240	0.698	rs10158236	chr1:46820896	G/T	cg10495392	chr1:46806563	NSUN4	0.65	6.8	0.41	8.89e-11	Menopause (age at onset);
SARC	cis	rs910316	1.000	rs175426	chr14:75624134	C/T	cg08847533	chr14:75593920	NEK9	-0.88	-14.17	-0.68	2.74e-33	Height;
SARC	cis	rs7615952	0.599	rs60847438	chr3:125746005	T/C	cg05084668	chr3:125655381	ALG1L	-0.49	-5.13	-0.32	6.24e-7	Blood pressure (smoking interaction);
SARC	cis	rs8180040	1.000	rs1638676	chr3:47327651	A/G	cg27129171	chr3:47204927	SETD2	0.67	9.24	0.52	1.54e-17	Colorectal cancer;
SARC	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg18404041	chr3:52824283	ITIH1	-0.45	-7.02	-0.42	2.39e-11	Bipolar disorder;
SARC	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg06212747	chr3:49208901	KLHDC8B	0.66	8.73	0.5	5.12e-16	Parkinson's disease;
SARC	cis	rs7818345	0.967	rs7006702	chr8:19272533	G/C	cg11303988	chr8:19266685	CSGALNACT1	0.41	5.55	0.34	7.58e-8	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs782590	0.935	rs2627776	chr2:55873301	T/A	cg18811423	chr2:55921094	PNPT1	0.69	10.28	0.56	1.09e-20	Metabolic syndrome;
SARC	cis	rs2204008	0.870	rs12369578	chr12:38444227	C/T	cg13010199	chr12:38710504	ALG10B	0.73	9.29	0.52	1.17e-17	Bladder cancer;
SARC	cis	rs12971120	1.000	rs12971120	chr18:72174023	A/G	cg26446133	chr18:72167187	CNDP2	-0.46	-6.77	-0.41	1.02e-10	Refractive error;
SARC	cis	rs2980439	0.525	rs2945238	chr8:8170136	A/C	cg06636001	chr8:8085503	FLJ10661	0.62	8.13	0.47	2.48e-14	Neuroticism;
SARC	cis	rs1348850	0.872	rs4893959	chr2:178400204	G/A	cg23306229	chr2:178417860	TTC30B	0.54	6.29	0.38	1.56e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	trans	rs10838798	0.584	rs1566732	chr11:48151494	A/C	cg15704280	chr7:45808275	SEPT13	0.46	6.23	0.38	2.14e-9	Height;
SARC	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg12463550	chr7:65579703	CRCP	0.5	5.9	0.36	1.27e-8	Aortic root size;
SARC	cis	rs2645694	0.533	rs2645681	chr4:77820949	G/A	cg03477792	chr4:77819574	ANKRD56	0.5	7.5	0.44	1.35e-12	Emphysema distribution in smoking;
SARC	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg13114125	chr14:105738426	BRF1	-0.74	-11.06	-0.59	3.88e-23	Mean platelet volume;Platelet distribution width;
SARC	cis	rs1008375	1.000	rs1121090	chr4:17676437	C/G	cg27347728	chr4:17578864	LAP3	0.45	5.54	0.34	8.23e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6991838	0.831	rs11992528	chr8:66473879	C/T	cg13398993	chr8:66546079	ARMC1	0.47	6.2	0.38	2.57e-9	Intelligence (multi-trait analysis);
SARC	cis	rs11578119	0.898	rs7519067	chr1:170395209	T/C	cg09767346	chr1:170501363	GORAB	0.42	4.85	0.3	2.21e-6	Male-pattern baldness;
SARC	cis	rs2075371	1.000	rs2504	chr7:133979545	A/T	cg20476274	chr7:133979776	SLC35B4	0.61	8.46	0.48	2.89e-15	Mean platelet volume;
SARC	cis	rs10465746	0.780	rs2389648	chr1:84403031	C/T	cg10977910	chr1:84465055	TTLL7	0.43	5.3	0.33	2.67e-7	Obesity-related traits;
SARC	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg06558623	chr16:89946397	TCF25	0.91	6.44	0.39	6.85e-10	Skin colour saturation;
SARC	cis	rs35110281	0.667	rs2250773	chr21:45087786	T/C	cg21573476	chr21:45109991	RRP1B	-0.6	-8.77	-0.5	3.8e-16	Mean corpuscular volume;
SARC	trans	rs360488	0.639	rs13384759	chr2:14291166	G/C	cg13543375	chr1:22470218	WNT4	0.58	6.54	0.39	3.85e-10	Emphysema imaging phenotypes;
SARC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg24846343	chr22:24311635	DDTL	-0.52	-6.83	-0.41	7.13e-11	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6835098	0.924	rs13125240	chr4:174151619	T/C	cg08422745	chr4:174089978	GALNT7	0.72	8.97	0.51	1.01e-16	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs4481887	0.597	rs11488132	chr1:248542353	A/G	cg13385794	chr1:248469461	NA	0.39	5.41	0.33	1.56e-7	Common traits (Other);
SARC	cis	rs10489525	0.550	rs6659415	chr1:115632211	C/T	cg01522456	chr1:115632236	TSPAN2	0.72	8.39	0.48	4.77e-15	Autism;
SARC	cis	rs11249608	0.548	rs17078991	chr5:178459426	A/C	cg01312482	chr5:178451176	ZNF879	-0.38	-4.97	-0.31	1.32e-6	Pubertal anthropometrics;
SARC	cis	rs6693567	0.507	rs863862	chr1:150352361	T/A	cg09579323	chr1:150459698	TARS2	0.44	5.64	0.35	4.85e-8	Migraine;
SARC	cis	rs7927771	0.864	rs10838724	chr11:47527052	G/T	cg20307385	chr11:47447363	PSMC3	-0.43	-5.22	-0.32	3.98e-7	Subjective well-being;
SARC	cis	rs7666738	0.830	rs7687958	chr4:99014495	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7633857	0.532	rs9839984	chr3:160768912	C/T	cg03342759	chr3:160939853	NMD3	-0.58	-7.19	-0.43	8.93e-12	Educational attainment (years of education);
SARC	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg09699651	chr6:150184138	LRP11	0.41	5.11	0.32	6.6e-7	Lung cancer;
SARC	cis	rs7246760	0.867	rs66880218	chr19:9774155	A/G	cg16876255	chr19:9731953	ZNF561	0.84	5.15	0.32	5.66e-7	Pursuit maintenance gain;
SARC	cis	rs2070677	0.935	rs12256349	chr10:135409632	G/A	cg20169779	chr10:135381914	SYCE1	-0.56	-6.68	-0.4	1.74e-10	Gout;
SARC	cis	rs936229	0.813	rs2301249	chr15:75092384	T/C	cg10253484	chr15:75165896	SCAMP2	-0.46	-4.89	-0.31	1.87e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg03709012	chr19:19516395	GATAD2A	-1.02	-17.04	-0.74	8.07e-43	Tonsillectomy;
SARC	cis	rs8114671	0.562	rs6087641	chr20:33467717	T/C	cg24642439	chr20:33292090	TP53INP2	0.51	6.26	0.38	1.79e-9	Height;
SARC	cis	rs10489202	0.955	rs17557162	chr1:167985950	A/T	cg17859187	chr1:168147929	TIPRL	-0.46	-4.81	-0.3	2.74e-6	Schizophrenia;
SARC	cis	rs9303401	0.538	rs2240259	chr17:56458129	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.02	10.23	0.56	1.6e-20	Cognitive test performance;
SARC	cis	rs2952156	0.920	rs2247862	chr17:37829129	A/G	cg07936489	chr17:37558343	FBXL20	-0.38	-4.75	-0.3	3.58e-6	Asthma;
SARC	cis	rs7714584	1.000	rs17111376	chr5:150226899	T/C	cg22134413	chr5:150180641	NA	0.78	6.54	0.39	3.82e-10	Crohn's disease;
SARC	cis	rs11098499	0.754	rs12506610	chr4:120241659	T/C	cg09307838	chr4:120376055	NA	0.81	11.15	0.59	2.11e-23	Corneal astigmatism;
SARC	cis	rs9329221	0.905	rs17709397	chr8:10249861	G/A	cg21775007	chr8:11205619	TDH	-0.39	-4.8	-0.3	2.79e-6	Neuroticism;
SARC	cis	rs7726839	0.794	rs11739663	chr5:594083	A/G	cg09021430	chr5:549028	NA	-0.47	-7.01	-0.42	2.58e-11	Obesity-related traits;
SARC	cis	rs4774830	0.744	rs62046392	chr15:56312554	C/G	cg24530489	chr15:56299380	NA	-0.82	-4.77	-0.3	3.28e-6	Delta-5 desaturase activity;
SARC	cis	rs6088580	0.634	rs4277599	chr20:33008905	A/G	cg24642439	chr20:33292090	TP53INP2	-0.6	-7.65	-0.45	5.39e-13	Glomerular filtration rate (creatinine);
SARC	trans	rs2018683	1.000	rs160837	chr7:29012732	C/G	cg19402173	chr7:128379420	CALU	-0.73	-10.02	-0.55	6.85e-20	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs9467773	1.000	rs9467797	chr6:26568473	A/T	cg11502198	chr6:26597334	ABT1	0.53	6.46	0.39	6.05e-10	Intelligence (multi-trait analysis);
SARC	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg21782813	chr7:2030301	MAD1L1	-0.4	-6.24	-0.38	2.08e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs796364	0.806	rs1509832	chr2:200874443	G/T	cg23649088	chr2:200775458	C2orf69	0.6	5.38	0.33	1.85e-7	Schizophrenia;
SARC	cis	rs9828933	0.752	rs12633353	chr3:63970280	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	-0.85	-6.2	-0.38	2.53e-9	Type 2 diabetes;
SARC	cis	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg13072238	chr3:49761600	GMPPB	-0.58	-5.82	-0.36	1.9e-8	Menarche (age at onset);
SARC	cis	rs2228479	0.850	rs62054609	chr16:89816569	C/A	cg06558623	chr16:89946397	TCF25	0.88	6.21	0.38	2.39e-9	Skin colour saturation;
SARC	cis	rs477692	0.673	rs7909964	chr10:131338714	T/C	cg14263093	chr10:131365266	MGMT	0.37	5.26	0.33	3.29e-7	Response to temozolomide;
SARC	trans	rs877282	0.898	rs11253348	chr10:765852	C/T	cg22713356	chr15:30763199	NA	1.04	10.06	0.55	5.37e-20	Uric acid levels;
SARC	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg21724239	chr8:58056113	NA	0.6	6.27	0.38	1.72e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs8005677	1.000	rs4982706	chr14:23381697	C/T	cg01529538	chr14:23388837	RBM23	0.46	5.72	0.35	3.25e-8	Cognitive ability (multi-trait analysis);
SARC	cis	rs6121246	0.909	rs7354225	chr20:30296881	C/T	cg13852791	chr20:30311386	BCL2L1	0.87	8.6	0.49	1.19e-15	Mean corpuscular hemoglobin;
SARC	cis	rs9392918	0.934	rs2327009	chr6:7718260	C/T	cg23089261	chr6:7723385	NA	0.37	5.03	0.31	9.8e-7	Height;
SARC	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg17376030	chr22:41985996	PMM1	0.76	9.53	0.53	2.21e-18	Vitiligo;
SARC	cis	rs77372450	0.551	rs11739924	chr5:157070236	C/A	cg05585991	chr5:157099197	C5orf52	0.56	5.7	0.35	3.56e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs17376456	0.542	rs10070350	chr5:93103753	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.56	5.79	0.35	2.3e-8	Diabetic retinopathy;
SARC	cis	rs6840360	0.615	rs10021407	chr4:152465002	A/G	cg22705602	chr4:152727874	NA	-0.4	-6.25	-0.38	1.92e-9	Intelligence (multi-trait analysis);
SARC	cis	rs8084125	0.832	rs62105172	chr18:74946703	C/T	cg05528293	chr18:74961138	GALR1	0.49	5.56	0.34	7.2e-8	Obesity-related traits;
SARC	cis	rs62244186	0.608	rs2888390	chr3:44511405	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.46	5.77	0.35	2.53e-8	Depressive symptoms;
SARC	cis	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg14541582	chr5:601475	NA	-0.39	-4.76	-0.3	3.39e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs2718058	0.519	rs2598047	chr7:37888488	G/T	cg15028436	chr7:37888078	TXNDC3	0.46	6.16	0.37	3.25e-9	Alzheimer's disease (late onset);
SARC	trans	rs61931739	0.500	rs12809868	chr12:34464905	C/T	cg26384229	chr12:38710491	ALG10B	0.91	13.65	0.67	1.42e-31	Morning vs. evening chronotype;
SARC	cis	rs757110	0.866	rs5213	chr11:17408404	C/T	cg04705435	chr11:17411270	KCNJ11	0.33	4.72	0.3	4.01e-6	Type 2 diabetes;
SARC	cis	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg22496380	chr5:211416	CCDC127	-0.88	-9.3	-0.52	1.07e-17	Breast cancer;
SARC	cis	rs950776	0.695	rs8025188	chr15:78912278	C/G	cg06917634	chr15:78832804	PSMA4	-0.75	-10.85	-0.58	1.8e-22	Sudden cardiac arrest;
SARC	cis	rs8114671	0.967	rs6088753	chr20:33768252	C/T	cg24642439	chr20:33292090	TP53INP2	0.51	5.88	0.36	1.4e-8	Height;
SARC	cis	rs77372450	0.591	rs62390773	chr5:157044673	C/T	cg05585991	chr5:157099197	C5orf52	0.54	5.38	0.33	1.85e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs10046574	0.831	rs10227931	chr7:135084601	C/T	cg27474649	chr7:135195673	CNOT4	0.89	7.28	0.43	5.14e-12	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg06472688	chr6:131184706	EPB41L2	0.44	6.37	0.39	1.01e-9	Thyroid stimulating hormone;
SARC	cis	rs2191566	0.576	rs393195	chr19:44493142	T/G	cg20607764	chr19:44506953	ZNF230	0.45	5.16	0.32	5.23e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs56235845	0.665	rs4976685	chr5:176766177	C/T	cg06060754	chr5:176797920	RGS14	-0.44	-6.04	-0.37	6.08e-9	Hemoglobin concentration;Hematocrit;
SARC	cis	rs1318878	0.911	rs12320690	chr12:15546158	A/T	cg08258403	chr12:15378311	NA	0.46	6.07	0.37	5.26e-9	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg08219700	chr8:58056026	NA	0.61	6.35	0.38	1.13e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs13401104	0.796	rs10929173	chr2:237116777	C/T	cg19324714	chr2:237145437	ASB18	0.58	5.77	0.35	2.5e-8	Educational attainment;
SARC	cis	rs6815814	0.950	rs45588337	chr4:38807328	A/G	cg02016764	chr4:38805732	TLR1	-0.42	-4.89	-0.31	1.89e-6	Breast cancer;
SARC	cis	rs262150	0.851	rs2527224	chr7:158769198	G/A	cg04111992	chr7:158790115	NA	-0.37	-4.91	-0.31	1.75e-6	Facial morphology (factor 20);
SARC	cis	rs8141529	1.000	rs8141529	chr22:29269692	A/G	cg15103426	chr22:29168792	CCDC117	0.62	7.64	0.45	5.54e-13	Lymphocyte counts;
SARC	cis	rs644799	0.509	rs561635	chr11:95634232	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.63	-7.04	-0.42	2.08e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg12064134	chr16:90016061	DEF8	-0.59	-5.05	-0.31	8.75e-7	Skin colour saturation;
SARC	cis	rs36051895	0.632	rs2149552	chr9:5132838	A/G	cg02405213	chr9:5042618	JAK2	-0.46	-5.6	-0.34	6.08e-8	Pediatric autoimmune diseases;
SARC	cis	rs8114671	0.935	rs945960	chr20:33762854	A/G	cg24642439	chr20:33292090	TP53INP2	0.51	5.88	0.36	1.44e-8	Height;
SARC	cis	rs7824557	0.564	rs2572399	chr8:11234520	A/G	cg21775007	chr8:11205619	TDH	-0.64	-8.54	-0.49	1.75e-15	Retinal vascular caliber;
SARC	cis	rs9640161	0.830	rs36069544	chr7:150061538	G/A	cg17279839	chr7:150038598	RARRES2	0.34	4.96	0.31	1.38e-6	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs9300255	0.739	rs4759371	chr12:123742563	T/C	cg05973401	chr12:123451056	ABCB9	0.44	4.86	0.3	2.19e-6	Neutrophil percentage of white cells;
SARC	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg11987759	chr7:65425863	GUSB	0.49	6.4	0.39	8.35e-10	Aortic root size;
SARC	trans	rs3780486	0.718	rs73645257	chr9:33132354	C/T	cg04842962	chr6:43655489	MRPS18A	0.89	10.55	0.57	1.63e-21	IgG glycosylation;
SARC	cis	rs12950390	0.853	rs11079792	chr17:45863311	T/C	cg03474202	chr17:45855739	NA	-0.43	-6.71	-0.4	1.44e-10	IgG glycosylation;
SARC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg26338869	chr17:61819248	STRADA	0.81	10.89	0.58	1.38e-22	Prudent dietary pattern;
SARC	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg22618164	chr12:122356400	WDR66	0.41	6.74	0.4	1.22e-10	Mean corpuscular volume;
SARC	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg03185022	chr7:2884158	GNA12	0.46	4.87	0.3	2.04e-6	Height;
SARC	cis	rs2486288	0.656	rs11632752	chr15:45551140	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.45	-5.57	-0.34	7.07e-8	Glomerular filtration rate;
SARC	trans	rs208520	0.526	rs9294682	chr6:66795159	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.11	-21.96	-0.82	1.1e-58	Exhaled nitric oxide output;
SARC	cis	rs514406	0.505	rs835609	chr1:53170494	T/C	cg16325326	chr1:53192061	ZYG11B	0.93	17.12	0.75	4.38e-43	Monocyte count;
SARC	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg22800045	chr5:56110881	MAP3K1	0.74	7.76	0.45	2.64e-13	Initial pursuit acceleration;
SARC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg06873352	chr17:61820015	STRADA	0.52	6.8	0.41	8.54e-11	Prudent dietary pattern;
SARC	cis	rs7089973	0.604	rs35319791	chr10:116602296	C/A	cg03647239	chr10:116582469	FAM160B1	0.5	6.49	0.39	5.19e-10	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs13256369	0.755	rs12680167	chr8:8562467	A/G	cg18904891	chr8:8559673	CLDN23	0.48	5.44	0.34	1.36e-7	Obesity-related traits;
SARC	cis	rs3126085	0.825	rs11204938	chr1:152193990	A/G	cg26876637	chr1:152193138	HRNR	0.48	5.65	0.35	4.71e-8	Atopic dermatitis;
SARC	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg13175981	chr1:150552382	MCL1	-0.48	-6.07	-0.37	5.04e-9	Tonsillectomy;
SARC	cis	rs76419734	0.557	rs17036292	chr4:106742216	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	5.2	0.32	4.29e-7	Post bronchodilator FEV1;
SARC	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-4.75	-0.3	3.56e-6	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs4319547	0.876	rs10846978	chr12:122964708	T/C	cg23029597	chr12:123009494	RSRC2	-0.41	-5.13	-0.32	6.22e-7	Body mass index;
SARC	cis	rs9868809	0.505	rs13063223	chr3:48750340	G/A	cg00383909	chr3:49044727	WDR6	0.65	6.21	0.38	2.36e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs8070128	0.601	rs8080602	chr17:17954728	G/C	cg04398451	chr17:18023971	MYO15A	0.47	6.55	0.39	3.55e-10	Total body bone mineral density;
SARC	cis	rs11574514	1.000	rs114884917	chr16:67951830	G/A	cg01866162	chr16:67596514	CTCF	1.1	6.61	0.4	2.65e-10	Crohn's disease;
SARC	cis	rs4803468	1.000	rs11670757	chr19:41913431	G/T	cg08477640	chr19:41863820	B9D2	0.41	5.22	0.32	3.9e-7	Height;
SARC	cis	rs7647973	0.593	rs62262730	chr3:49808274	T/G	cg13072238	chr3:49761600	GMPPB	0.67	6.58	0.4	3.03e-10	Menarche (age at onset);
SARC	cis	rs709400	0.930	rs28513222	chr14:104028069	A/T	cg26031613	chr14:104095156	KLC1	1.02	19.73	0.79	1.31e-51	Body mass index;
SARC	cis	rs2180341	0.814	rs9401959	chr6:127736464	T/C	cg24812749	chr6:127587940	RNF146	0.78	9.92	0.55	1.39e-19	Breast cancer;
SARC	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg13126279	chr21:47581558	C21orf56	-0.46	-5.68	-0.35	4.1e-8	Testicular germ cell tumor;
SARC	cis	rs7084402	0.967	rs1427222	chr10:60290970	A/G	cg07615347	chr10:60278583	BICC1	0.61	9.02	0.51	7.31e-17	Refractive error;
SARC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg24503407	chr1:205819492	PM20D1	0.79	12.31	0.63	3.63e-27	Menarche (age at onset);
SARC	cis	rs7681440	0.904	rs12331318	chr4:90770255	A/G	cg02192967	chr4:90758406	SNCA	0.35	4.94	0.31	1.48e-6	Dementia with Lewy bodies;
SARC	cis	rs10916814	0.632	rs10799646	chr1:20903985	G/T	cg24502330	chr1:20914028	CDA	-0.29	-5.05	-0.31	9.08e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs910316	0.789	rs4899552	chr14:75667921	C/A	cg08847533	chr14:75593920	NEK9	-0.79	-11.14	-0.59	2.13e-23	Height;
SARC	cis	rs9660992	0.700	rs7547565	chr1:205259402	G/A	cg21643547	chr1:205240462	TMCC2	0.6	7.86	0.46	1.43e-13	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg05084668	chr3:125655381	ALG1L	-0.47	-4.8	-0.3	2.87e-6	Blood pressure (smoking interaction);
SARC	cis	rs6058796	1.000	rs6141777	chr20:31249947	C/T	cg13636640	chr20:31349939	DNMT3B	0.56	4.94	0.31	1.48e-6	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs6087771	0.851	rs6087775	chr20:30325765	G/A	cg13852791	chr20:30311386	BCL2L1	0.81	9.97	0.55	9.89e-20	Subcortical brain region volumes;Putamen volume;
SARC	cis	rs644799	1.000	rs11021319	chr11:95523123	C/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.71	9.72	0.54	5.86e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9436747	0.626	rs6698653	chr1:65944850	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	-0.39	-5.0	-0.31	1.15e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs35306767	0.903	rs13377166	chr10:886259	G/A	cg20503657	chr10:835505	NA	0.86	8.12	0.47	2.66e-14	Eosinophil percentage of granulocytes;
SARC	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg11764359	chr7:65958608	NA	-0.53	-6.07	-0.37	5.09e-9	Aortic root size;
SARC	cis	rs4689388	0.853	rs13114527	chr4:6294655	T/G	cg14416269	chr4:6271139	WFS1	0.32	4.92	0.31	1.61e-6	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs1707322	0.964	rs12067716	chr1:46434428	T/A	cg03146154	chr1:46216737	IPP	0.49	5.91	0.36	1.2e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs13191362	1.000	rs34192365	chr6:163012382	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.57	5.47	0.34	1.16e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs3218477	1.000	rs3218480	chr7:152356614	A/C	cg06618968	chr7:152373420	XRCC2	0.72	4.79	0.3	2.99e-6	Mean platelet volume;
SARC	cis	rs911555	0.755	rs4906329	chr14:103942669	A/G	cg12935359	chr14:103987150	CKB	0.38	5.25	0.33	3.39e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg20007245	chr22:24372913	LOC391322	-0.7	-8.76	-0.5	4.2e-16	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg24110177	chr3:50126178	RBM5	0.4	5.05	0.31	8.73e-7	Intelligence (multi-trait analysis);
SARC	cis	rs17174870	0.821	rs9308665	chr2:112813391	C/G	cg09651315	chr2:112641899	ANAPC1	-0.42	-4.77	-0.3	3.19e-6	Multiple sclerosis;
SARC	cis	rs4727027	0.901	rs4727018	chr7:148822247	G/C	cg23583168	chr7:148888333	NA	-0.74	-10.55	-0.57	1.56e-21	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs7264396	1.000	rs224415	chr20:34135629	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-4.95	-0.31	1.45e-6	Total cholesterol levels;
SARC	trans	rs617791	0.678	rs551659	chr11:65749645	C/T	cg17712092	chr4:129076599	LARP1B	0.7	9.46	0.53	3.59e-18	Breast cancer;
SARC	cis	rs1448094	0.527	rs59445394	chr12:86237843	C/T	cg02569458	chr12:86230093	RASSF9	0.39	5.45	0.34	1.29e-7	Major depressive disorder;
SARC	cis	rs10754283	0.967	rs1934045	chr1:90107799	A/C	cg21401794	chr1:90099060	LRRC8C	-0.6	-8.27	-0.48	1.04e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg19671926	chr4:122722719	EXOSC9	-0.55	-6.08	-0.37	4.97e-9	Type 2 diabetes;
SARC	cis	rs2200578	0.732	rs56271621	chr2:99658200	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.53	4.78	0.3	3.08e-6	IgG glycosylation;
SARC	cis	rs511515	1	rs511515	chr6:33541507	A/G	cg07679836	chr6:33548423	BAK1	0.39	5.29	0.33	2.76e-7	Eosinophil counts;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
SARC	trans	rs7824557	0.675	rs2736265	chr8:11186674	A/G	cg06636001	chr8:8085503	FLJ10661	0.59	7.59	0.45	7.87e-13	Retinal vascular caliber;
SARC	cis	rs240764	0.817	rs239190	chr6:101129067	C/T	cg09795085	chr6:101329169	ASCC3	0.45	5.81	0.36	1.99e-8	Neuroticism;
SARC	cis	rs9815354	1.000	rs9857175	chr3:41822054	T/G	cg03022575	chr3:42003672	ULK4	0.59	5.73	0.35	3.14e-8	Pulse pressure;Diastolic blood pressure;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18174052	chr1:183604830	ARPC5;RGL1	-0.52	-6.85	-0.41	6.62e-11	Smoking initiation;
SARC	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg26769984	chr7:1090371	C7orf50	0.51	5.25	0.33	3.36e-7	Bronchopulmonary dysplasia;
SARC	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg19761014	chr17:28927070	LRRC37B2	0.53	4.82	0.3	2.65e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs6011674	1.000	rs1555337	chr20:61863641	A/G	cg06763829	chr20:61885236	FLJ16779;NKAIN4	-0.68	-5.08	-0.32	7.57e-7	Response to cytadine analogues (cytosine arabinoside);
SARC	cis	rs4775413	1.000	rs4635285	chr15:61838313	C/T	cg09972561	chr15:62353371	VPS13C	0.36	4.79	0.3	2.92e-6	Schizophrenia;
SARC	cis	rs13191362	0.938	rs35211042	chr6:162998703	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.56	5.41	0.33	1.53e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs7824557	0.628	rs58283816	chr8:11192551	G/C	cg21775007	chr8:11205619	TDH	0.65	8.35	0.48	6.14e-15	Retinal vascular caliber;
SARC	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.75	7.36	0.43	3.08e-12	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs1878931	0.501	rs9302871	chr16:3415512	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.74	9.51	0.53	2.48e-18	Body mass index (adult);
SARC	cis	rs763121	0.853	rs5757141	chr22:38957483	G/A	cg06022373	chr22:39101656	GTPBP1	0.89	11.44	0.6	2.47e-24	Menopause (age at onset);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg14023041	chr20:45318457	TP53RK	0.8	6.32	0.38	1.34e-9	Autism spectrum disorder or schizophrenia;
SARC	trans	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg17830980	chr10:43048298	ZNF37B	0.51	7.08	0.42	1.67e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs9796	0.866	rs544744	chr15:41366290	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.43	-5.88	-0.36	1.4e-8	Menopause (age at onset);
SARC	cis	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg18252515	chr7:66147081	NA	-1.3	-11.63	-0.61	5.98e-25	Diabetic kidney disease;
SARC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg11062466	chr8:58055876	NA	0.54	5.56	0.34	7.55e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4803468	1.000	rs11880539	chr19:41918949	A/C	cg09537434	chr19:41945824	ATP5SL	1.0	19.05	0.78	2.11e-49	Height;
SARC	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.53	-5.26	-0.33	3.29e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs644799	0.965	rs2950522	chr11:95524719	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.71	9.7	0.54	6.74e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs1853207	1.000	rs76828799	chr10:96611177	C/T	cg02737782	chr1:8014393	NA	-0.95	-6.37	-0.39	1.01e-9	Blood metabolite levels;
SARC	cis	rs2814982	0.543	rs75776386	chr6:34465215	G/A	cg17674042	chr6:34482479	PACSIN1	-0.57	-4.9	-0.31	1.81e-6	Cholesterol, total;Total cholesterol levels;
SARC	cis	rs79149102	0.579	rs7172065	chr15:75321910	C/T	cg09165964	chr15:75287851	SCAMP5	-1.07	-8.41	-0.48	4.15e-15	Lung cancer;
SARC	cis	rs8180040	0.681	rs9818382	chr3:47193034	C/T	cg27129171	chr3:47204927	SETD2	0.69	9.4	0.52	5.41e-18	Colorectal cancer;
SARC	trans	rs1853207	1.000	rs74803483	chr10:96713372	C/T	cg02737782	chr1:8014393	NA	-0.89	-6.4	-0.39	8.69e-10	Blood metabolite levels;
SARC	cis	rs9894429	1.000	rs9894429	chr17:79596811	C/T	cg18240062	chr17:79603768	NPLOC4	0.74	10.13	0.55	3.28e-20	Eye color traits;
SARC	cis	rs1707322	1.000	rs9429186	chr1:46539687	C/T	cg06784218	chr1:46089804	CCDC17	-0.36	-6.28	-0.38	1.64e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6121246	0.609	rs6060948	chr20:30376393	C/G	cg13852791	chr20:30311386	BCL2L1	0.81	9.94	0.55	1.22e-19	Mean corpuscular hemoglobin;
SARC	cis	rs9815354	0.669	rs113059632	chr3:41932858	G/A	cg03022575	chr3:42003672	ULK4	0.7	5.7	0.35	3.66e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs10911232	0.507	rs10911194	chr1:182993025	C/T	cg13390022	chr1:182993471	LAMC1	0.33	4.96	0.31	1.34e-6	Hypertriglyceridemia;
SARC	cis	rs6841333	0.674	rs4859568	chr4:76853723	C/A	cg19999035	chr4:77355817	SHROOM3	0.35	4.76	0.3	3.47e-6	Monokine induced by gamma interferon levels;
SARC	cis	rs6121246	0.909	rs6119729	chr20:30413163	A/G	cg13852791	chr20:30311386	BCL2L1	-0.85	-9.18	-0.52	2.48e-17	Mean corpuscular hemoglobin;
SARC	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg11764359	chr7:65958608	NA	0.79	9.73	0.54	5.23e-19	Aortic root size;
SARC	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg02891314	chr5:179741120	GFPT2	0.5	6.21	0.38	2.4e-9	Height;
SARC	cis	rs12701220	0.803	rs12701432	chr7:1052453	C/T	cg26769984	chr7:1090371	C7orf50	0.49	5.13	0.32	6.14e-7	Bronchopulmonary dysplasia;
SARC	cis	rs10887741	0.966	rs2077695	chr10:89435483	T/C	cg24243914	chr10:89418206	PAPSS2	0.31	4.84	0.3	2.38e-6	Exercise (leisure time);
SARC	trans	rs890100	0.736	rs2033015	chr2:56702871	A/T	cg26233084	chr5:15510258	FBXL7	0.31	6.27	0.38	1.7e-9	Gut microbiome composition (summer);
SARC	cis	rs992157	0.560	rs12992937	chr2:219087072	A/T	cg00012203	chr2:219082015	ARPC2	-0.73	-10.8	-0.58	2.61e-22	Colorectal cancer;
SARC	cis	rs9948	0.655	rs78424221	chr2:97410399	A/G	cg01990225	chr2:97406019	LMAN2L	-0.94	-6.38	-0.39	9.49e-10	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs524281	1.000	rs527897	chr11:65900777	C/T	cg14036092	chr11:66035641	RAB1B	-0.55	-6.16	-0.37	3.16e-9	Electroencephalogram traits;
SARC	cis	rs4253772	0.591	rs7291444	chr22:46656246	T/G	cg24881330	chr22:46731750	TRMU	0.6	6.66	0.4	1.93e-10	LDL cholesterol;Cholesterol, total;
SARC	cis	rs6964587	0.692	rs4727268	chr7:91840724	T/C	cg17063962	chr7:91808500	NA	0.85	13.16	0.65	6.23e-30	Breast cancer;
SARC	trans	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg21659725	chr3:3221576	CRBN	-0.56	-6.5	-0.39	4.77e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	trans	rs7824557	0.564	rs6601584	chr8:11232343	C/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.83	-0.41	7.46e-11	Retinal vascular caliber;
SARC	cis	rs2387326	1.000	rs2387328	chr10:129925986	C/T	cg16087940	chr10:129947807	NA	-0.51	-6.42	-0.39	7.41e-10	Select biomarker traits;
SARC	cis	rs6582630	0.502	rs8186661	chr12:38380781	G/A	cg26384229	chr12:38710491	ALG10B	0.91	13.46	0.66	6.11e-31	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg17830980	chr10:43048298	ZNF37B	-0.5	-6.59	-0.4	2.83e-10	Extrinsic epigenetic age acceleration;
SARC	cis	rs6570726	0.935	rs432086	chr6:145841593	C/T	cg23711669	chr6:146136114	FBXO30	-0.76	-11.36	-0.6	4.26e-24	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7607369	0.648	rs7582193	chr2:219652532	T/C	cg02176678	chr2:219576539	TTLL4	-0.5	-8.25	-0.48	1.15e-14	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	trans	rs61931739	0.517	rs11612493	chr12:34114272	A/C	cg26384229	chr12:38710491	ALG10B	0.82	11.74	0.61	2.59e-25	Morning vs. evening chronotype;
SARC	cis	rs12461016	1	rs12461016	chr19:17161687	G/A	cg16202187	chr19:17186497	HAUS8;MYO9B	0.41	4.95	0.31	1.43e-6	Diastolic blood pressure;
SARC	cis	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg00745463	chr17:30367425	LRRC37B	-0.67	-5.32	-0.33	2.4e-7	Hip circumference adjusted for BMI;
SARC	cis	rs644799	0.542	rs10831416	chr11:95467220	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.71	9.39	0.52	5.78e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs1538970	0.961	rs7543428	chr1:45839643	A/G	cg05343316	chr1:45956843	TESK2	0.69	8.2	0.47	1.61e-14	Platelet count;
SARC	cis	rs7772486	0.686	rs1337839	chr6:146010239	A/G	cg23711669	chr6:146136114	FBXO30	-0.8	-12.77	-0.64	1.14e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10892173	0.566	rs2298649	chr11:117672225	A/G	cg07621104	chr11:117668040	DSCAML1	0.62	7.81	0.46	1.89e-13	Myopia;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg19467586	chr17:45266599	CDC27	-0.51	-6.67	-0.4	1.83e-10	Height;
SARC	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs950776	0.790	rs2067808	chr15:78911780	G/A	cg06917634	chr15:78832804	PSMA4	0.74	9.96	0.55	1.1e-19	Sudden cardiac arrest;
SARC	cis	rs9650657	0.501	rs3021500	chr8:11023997	G/C	cg03403963	chr8:11986501	LOC392196;FAM66D	-0.34	-4.74	-0.3	3.64e-6	Neuroticism;
SARC	cis	rs11122272	0.766	rs2790870	chr1:231543823	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-9.71	-0.54	6.4e-19	Hemoglobin concentration;
SARC	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg06634786	chr22:41940651	POLR3H	-0.5	-5.79	-0.35	2.24e-8	Vitiligo;
SARC	cis	rs2742234	0.541	rs12416428	chr10:43708998	G/A	cg15436174	chr10:43711423	RASGEF1A	0.43	5.01	0.31	1.08e-6	Hirschsprung disease;
SARC	cis	rs2273669	0.915	rs2145766	chr6:109296261	G/C	cg01304950	chr6:109416612	SESN1;C6orf182	0.54	4.72	0.3	4.07e-6	Prostate cancer;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg23355997	chr17:7154831	DULLARD;C17orf81	0.43	6.94	0.41	3.85e-11	Chemerin levels;
SARC	cis	rs9325144	0.647	rs12830095	chr12:38864199	C/T	cg13010199	chr12:38710504	ALG10B	-0.46	-5.8	-0.35	2.19e-8	Morning vs. evening chronotype;
SARC	cis	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg08045932	chr20:61659980	NA	0.5	6.84	0.41	7.06e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs12545109	0.765	rs1960726	chr8:57411733	T/C	cg19413350	chr8:57351067	NA	-0.43	-5.37	-0.33	1.88e-7	Obesity-related traits;
SARC	cis	rs56330463	0.967	rs1432622	chr5:148203762	T/C	cg21580376	chr5:148206412	ADRB2	0.4	5.5	0.34	9.88e-8	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Monocyte percentage of white cells;Eosinophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;
SARC	cis	rs1003719	0.667	rs73201942	chr21:38475164	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.54	7.37	0.43	2.99e-12	Eye color traits;
SARC	cis	rs2486288	0.656	rs8039540	chr15:45551842	C/G	cg15395560	chr15:45543142	SLC28A2	0.29	5.63	0.35	5.17e-8	Glomerular filtration rate;
SARC	cis	rs617219	0.574	rs13177425	chr5:78625589	A/T	cg24856658	chr5:78533917	JMY	0.3	4.84	0.3	2.34e-6	Betaine levels in individuals undergoing cardiac evaluation;
SARC	cis	rs739401	0.572	rs389128	chr11:3083873	G/T	cg05729581	chr11:3078854	CARS	-0.53	-6.94	-0.41	3.84e-11	Longevity;
SARC	cis	rs2916247	1.000	rs11785362	chr8:93045784	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.66	-6.53	-0.39	4.12e-10	Intelligence (multi-trait analysis);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg16908782	chr14:55494158	SOCS4;WDHD1	-0.75	-6.38	-0.39	9.69e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9916302	0.904	rs7208274	chr17:37513796	C/T	cg20243544	chr17:37824526	PNMT	-0.53	-6.45	-0.39	6.43e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs7726839	0.540	rs7434	chr5:660804	A/G	cg09021430	chr5:549028	NA	0.43	5.68	0.35	3.96e-8	Obesity-related traits;
SARC	cis	rs1448094	0.511	rs61930585	chr12:86158461	C/A	cg02569458	chr12:86230093	RASSF9	0.36	4.78	0.3	3.12e-6	Major depressive disorder;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg23561934	chr2:121199920	NA	-0.52	-6.34	-0.38	1.19e-9	Schizophrenia;
SARC	cis	rs9788721	0.902	rs114205691	chr15:78901113	C/T	cg06917634	chr15:78832804	PSMA4	-0.55	-5.87	-0.36	1.47e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs888194	0.966	rs6606725	chr12:109905368	C/A	cg13986417	chr12:110012484	MVK;MMAB	-0.35	-5.4	-0.33	1.62e-7	Neuroticism;
SARC	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg10253484	chr15:75165896	SCAMP2	-0.39	-4.76	-0.3	3.46e-6	Breast cancer;
SARC	cis	rs1505368	0.532	rs2888093	chr2:213328348	G/A	cg20637307	chr2:213403960	ERBB4	0.49	6.29	0.38	1.58e-9	Symmetrical dimethylarginine levels;
SARC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg09436375	chr6:42928200	GNMT	-0.37	-5.78	-0.35	2.35e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs9818758	0.607	rs12715434	chr3:49295025	G/C	cg01304814	chr3:48885189	PRKAR2A	0.63	5.14	0.32	5.72e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs2594989	0.779	rs62245949	chr3:11575969	C/G	cg00170343	chr3:11313890	ATG7	-0.57	-6.31	-0.38	1.4e-9	Circulating chemerin levels;
SARC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg13397359	chr6:42928475	GNMT	-0.42	-5.5	-0.34	1.01e-7	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs9611565	0.649	rs126092	chr22:42178441	A/G	cg17376030	chr22:41985996	PMM1	-0.58	-6.81	-0.41	8.32e-11	Vitiligo;
SARC	cis	rs7412746	0.658	rs12405726	chr1:150956128	G/A	cg15448220	chr1:150897856	SETDB1	0.52	6.41	0.39	7.81e-10	Melanoma;
SARC	cis	rs317689	0.581	rs160829	chr12:69769538	G/C	cg14784868	chr12:69753453	YEATS4	0.49	5.9	0.36	1.24e-8	Response to diuretic therapy;
SARC	cis	rs9790314	0.715	rs898681	chr3:160773098	A/G	cg03342759	chr3:160939853	NMD3	-0.43	-5.24	-0.32	3.55e-7	Morning vs. evening chronotype;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg13670615	chr19:49140625	SEC1;DBP	0.53	7.04	0.42	2.11e-11	Chemerin levels;
SARC	cis	rs12681288	0.792	rs4735972	chr8:998618	A/C	cg15309053	chr8:964076	NA	0.35	5.81	0.36	1.99e-8	Schizophrenia;
SARC	cis	rs2658782	0.547	rs3020065	chr11:93059899	A/G	cg15737290	chr11:93063684	CCDC67	0.97	13.71	0.67	8.98e-32	Pulmonary function decline;
SARC	cis	rs875971	1.000	rs1144895	chr7:65541307	C/G	cg11764359	chr7:65958608	NA	-0.85	-11.95	-0.62	5.53e-26	Aortic root size;
SARC	cis	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg12395012	chr8:11607386	GATA4	0.3	5.11	0.32	6.76e-7	Triglycerides;
SARC	cis	rs2832191	0.692	rs2245734	chr21:30359965	C/T	cg24692254	chr21:30365293	RNF160	1.02	18.71	0.77	2.59e-48	Dental caries;
SARC	cis	rs9393692	0.905	rs4412192	chr6:26290377	A/G	cg13736514	chr6:26305472	NA	0.64	8.86	0.5	2.13e-16	Educational attainment;
SARC	cis	rs13191362	1.000	rs36007635	chr6:163009335	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.5	0.34	1.01e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs13191362	0.507	rs2803083	chr6:163111199	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.48	5.12	0.32	6.32e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs6963495	0.745	rs818620	chr7:105172685	G/C	cg19920283	chr7:105172520	RINT1	0.68	6.61	0.4	2.55e-10	Bipolar disorder (body mass index interaction);
SARC	cis	rs9814567	0.896	rs6790338	chr3:134208167	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.09	-0.42	1.64e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg12311346	chr5:56204834	C5orf35	-0.58	-6.01	-0.37	7.24e-9	Initial pursuit acceleration;
SARC	cis	rs796364	0.806	rs11679658	chr2:200923081	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-6.65	-0.4	2.11e-10	Schizophrenia;
SARC	cis	rs67311347	0.544	rs1902073	chr3:40333497	C/T	cg09455208	chr3:40491958	NA	0.31	5.1	0.32	7.11e-7	Renal cell carcinoma;
SARC	cis	rs240764	0.781	rs239227	chr6:101107089	C/G	cg09795085	chr6:101329169	ASCC3	0.44	5.71	0.35	3.39e-8	Neuroticism;
SARC	cis	rs7586879	0.681	rs6756609	chr2:25121125	C/A	cg04586622	chr2:25135609	ADCY3	0.32	5.45	0.34	1.28e-7	Body mass index;
SARC	cis	rs79349575	0.783	rs59270107	chr17:47026185	A/T	cg07967210	chr17:47022446	SNF8	0.37	4.71	0.3	4.19e-6	Type 2 diabetes;
SARC	cis	rs240764	0.817	rs239247	chr6:101088350	T/C	cg09795085	chr6:101329169	ASCC3	0.46	5.93	0.36	1.09e-8	Neuroticism;
SARC	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs2727020	0.558	rs1164675	chr11:49325972	C/T	cg15704280	chr7:45808275	SEPT13	0.78	12.09	0.62	1.89e-26	Coronary artery disease;
SARC	cis	rs734999	0.505	rs10797437	chr1:2539006	T/C	cg20673091	chr1:2541236	MMEL1	0.33	5.09	0.32	7.49e-7	Ulcerative colitis;
SARC	cis	rs796364	1.000	rs281762	chr2:200799201	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.76	6.88	0.41	5.42e-11	Schizophrenia;
SARC	cis	rs2180341	1.000	rs7756336	chr6:127650299	T/C	cg24812749	chr6:127587940	RNF146	0.98	13.14	0.65	7.1e-30	Breast cancer;
SARC	cis	rs9987353	0.566	rs34389718	chr8:9065525	A/G	cg15556689	chr8:8085844	FLJ10661	-0.45	-5.42	-0.33	1.5e-7	Recombination measurement;
SARC	cis	rs637571	0.522	rs556643	chr11:65733289	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.42	5.38	0.33	1.77e-7	Eosinophil percentage of white cells;
SARC	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg22535103	chr8:58192502	C8orf71	-0.59	-6.06	-0.37	5.57e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7113850	0.541	rs80336897	chr11:24224545	G/T	ch.11.24196551F	chr11:24239977	NA	0.75	5.96	0.36	9.26e-9	Bone fracture in osteoporosis;
SARC	cis	rs11724804	0.532	rs7657611	chr4:880558	G/C	cg23939001	chr4:940644	TMEM175	0.4	5.3	0.33	2.7e-7	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
SARC	cis	rs7208859	0.673	rs56146117	chr17:29153325	C/T	cg13385521	chr17:29058706	SUZ12P	0.81	6.95	0.41	3.6e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs672059	1.000	rs547905	chr1:183157924	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.48	6.54	0.39	3.92e-10	Hypertriglyceridemia;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg00850453	chr7:12726919	ARL4A	-0.52	-6.3	-0.38	1.45e-9	Breast cancer;
SARC	cis	rs2952156	0.920	rs2517951	chr17:37853097	C/T	cg20243544	chr17:37824526	PNMT	0.51	6.37	0.39	9.97e-10	Asthma;
SARC	cis	rs7937682	0.883	rs512669	chr11:111467893	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.93	-14.14	-0.68	3.55e-33	Primary sclerosing cholangitis;
SARC	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg08280861	chr8:58055591	NA	0.59	5.86	0.36	1.57e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg11833660	chr12:109181397	SSH1	0.55	6.96	0.41	3.5e-11	Breast cancer;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg14899563	chr17:80656473	RAB40B	0.5	6.41	0.39	7.84e-10	Height;
SARC	cis	rs9398803	0.706	rs9388502	chr6:126909389	G/A	cg19875578	chr6:126661172	C6orf173	0.6	8.22	0.47	1.39e-14	Male-pattern baldness;
SARC	cis	rs8103278	0.793	rs59093775	chr19:46374037	G/A	cg11657440	chr19:46296263	DMWD	-0.65	-7.53	-0.44	1.11e-12	Coronary artery disease;
SARC	cis	rs2011503	1.000	rs80007081	chr19:19626734	A/G	cg15839431	chr19:19639596	YJEFN3	-0.48	-4.77	-0.3	3.32e-6	Bipolar disorder;
SARC	cis	rs73086581	1.000	rs17215340	chr20:3970173	C/G	cg02187196	chr20:3869020	PANK2	-0.56	-5.03	-0.31	9.75e-7	Response to antidepressants in depression;
SARC	cis	rs2153535	0.580	rs2183112	chr6:8528212	G/A	cg07606381	chr6:8435919	SLC35B3	0.74	10.6	0.57	1.12e-21	Motion sickness;
SARC	cis	rs7647973	0.626	rs9824435	chr3:49674343	A/G	cg07636037	chr3:49044803	WDR6	-0.58	-5.64	-0.35	4.96e-8	Menarche (age at onset);
SARC	cis	rs9303401	0.615	rs35288118	chr17:56600748	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	11.29	0.59	7.52e-24	Cognitive test performance;
SARC	trans	rs3780486	0.846	rs10971420	chr9:33125000	T/C	cg20290983	chr6:43655470	MRPS18A	1.14	22.53	0.83	1.95e-60	IgG glycosylation;
SARC	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg04518342	chr5:131593106	PDLIM4	-0.45	-5.64	-0.35	4.85e-8	Breast cancer;
SARC	cis	rs9768139	0.733	rs13221388	chr7:158119270	G/A	cg25566285	chr7:158114605	PTPRN2	0.31	5.19	0.32	4.66e-7	Calcium levels;
SARC	cis	rs9517320	0.534	rs3858776	chr13:99161457	C/T	cg07423050	chr13:99094983	FARP1	-0.39	-5.43	-0.34	1.4e-7	Longevity;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25712316	chr17:37026004	LASP1	0.52	6.43	0.39	6.95e-10	Fibrinogen levels;
SARC	cis	rs7089973	0.872	rs7918253	chr10:116614501	T/C	cg08188268	chr10:116634841	FAM160B1	0.36	5.8	0.36	2.13e-8	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs2769264	0.593	rs4971040	chr1:151366494	A/C	cg18801370	chr1:151430492	POGZ	0.89	9.38	0.52	6.22e-18	Blood trace element (Cu levels);
SARC	cis	rs12421382	0.543	rs10890996	chr11:109328421	A/G	cg11473876	chr11:109292803	C11orf87	-0.44	-5.82	-0.36	1.95e-8	Schizophrenia;
SARC	cis	rs881375	0.967	rs10733648	chr9:123700779	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	5.96	0.36	9.28e-9	Rheumatoid arthritis;
SARC	cis	rs12022452	0.506	rs12569328	chr1:41019221	G/C	cg25568243	chr1:40974465	DEM1	0.54	5.21	0.32	4.13e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	trans	rs7980799	0.682	rs7303356	chr12:33633599	C/G	cg26384229	chr12:38710491	ALG10B	-0.53	-6.45	-0.39	6.43e-10	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs6121246	0.567	rs6060344	chr20:30207316	A/G	cg13852791	chr20:30311386	BCL2L1	0.66	5.6	0.34	6.08e-8	Mean corpuscular hemoglobin;
SARC	cis	rs568617	0.716	rs111953392	chr11:65595697	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.63	6.26	0.38	1.8e-9	Crohn's disease;
SARC	cis	rs1580019	0.885	rs1610141	chr7:32498435	C/T	cg07520158	chr7:32535189	LSM5;AVL9	0.42	4.98	0.31	1.24e-6	Cognitive ability;
SARC	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg16479474	chr6:28041457	NA	0.39	5.83	0.36	1.86e-8	Parkinson's disease;
SARC	cis	rs9815354	0.812	rs11129932	chr3:41838767	C/A	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs713477	0.967	rs4901568	chr14:55912789	T/A	cg13175173	chr14:55914753	NA	-0.3	-4.72	-0.3	4.01e-6	Pediatric bone mineral content (femoral neck);
SARC	trans	rs56279505	0.629	rs34178057	chr4:100268602	A/C	cg21156590	chr1:3420848	MEGF6	-0.83	-6.41	-0.39	8.04e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7937890	0.900	rs7118682	chr11:14274550	T/G	cg02886208	chr11:14281011	SPON1	0.42	6.03	0.37	6.27e-9	Mitochondrial DNA levels;
SARC	cis	rs3796352	1.000	rs13058817	chr3:53024139	C/T	cg12962167	chr3:53033115	SFMBT1	0.82	5.4	0.33	1.61e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs13161895	1.000	rs864482	chr5:179427873	A/G	cg04265672	chr5:179402240	RNF130	-0.52	-5.15	-0.32	5.48e-7	LDL cholesterol;
SARC	cis	rs2204008	0.630	rs1283300	chr12:38150227	C/T	cg13010199	chr12:38710504	ALG10B	-0.61	-7.7	-0.45	3.92e-13	Bladder cancer;
SARC	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.62	-0.4	2.41e-10	Total body bone mineral density;
SARC	cis	rs4927850	0.958	rs2044599	chr3:195736740	G/A	cg01181863	chr3:195395398	SDHAP2	-0.63	-7.27	-0.43	5.39e-12	Pancreatic cancer;
SARC	cis	rs6580649	0.941	rs726354	chr12:48500334	G/A	cg05342945	chr12:48394962	COL2A1	0.53	5.8	0.36	2.1e-8	Lung cancer;
SARC	cis	rs10461617	0.535	rs7709874	chr5:56047451	C/T	cg22800045	chr5:56110881	MAP3K1	0.68	7.83	0.46	1.68e-13	Type 2 diabetes;
SARC	cis	rs11574514	0.661	rs117759106	chr16:68275130	G/A	cg01866162	chr16:67596514	CTCF	1.12	6.52	0.39	4.27e-10	Crohn's disease;
SARC	cis	rs9911578	1.000	rs3744108	chr17:56585872	G/C	cg12560992	chr17:57184187	TRIM37	-0.81	-10.84	-0.58	1.9e-22	Intelligence (multi-trait analysis);
SARC	cis	rs10046574	0.831	rs77263000	chr7:135099419	C/T	cg27474649	chr7:135195673	CNOT4	0.86	6.95	0.41	3.61e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs2200578	1.000	rs62153845	chr2:99887162	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.62	5.88	0.36	1.43e-8	IgG glycosylation;
SARC	cis	rs2072499	1.000	rs2241108	chr1:156181007	C/G	cg24450063	chr1:156163899	SLC25A44	1.12	18.92	0.78	5.41e-49	Testicular germ cell tumor;
SARC	cis	rs7551222	0.646	rs10900590	chr1:204451086	C/T	cg20240347	chr1:204465584	NA	-0.29	-4.96	-0.31	1.37e-6	Schizophrenia;
SARC	cis	rs12478296	0.786	rs6721704	chr2:242994923	A/G	cg06360820	chr2:242988706	NA	-0.66	-6.41	-0.39	7.79e-10	Obesity-related traits;
SARC	cis	rs818427	0.858	rs469827	chr5:112242139	C/A	cg07820702	chr5:112228657	REEP5	-0.5	-5.44	-0.34	1.33e-7	Total body bone mineral density;
SARC	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg00933542	chr6:150070202	PCMT1	0.33	5.63	0.35	5.13e-8	Lung cancer;
SARC	cis	rs12594515	0.874	rs8032878	chr15:45998015	A/G	cg14863074	chr15:45997064	NA	0.34	5.2	0.32	4.34e-7	Waist circumference;Weight;
SARC	trans	rs56279505	0.690	rs62305761	chr4:100286694	G/A	cg21156590	chr1:3420848	MEGF6	-0.78	-6.26	-0.38	1.79e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs17539620	0.519	rs12665532	chr6:154835182	C/G	cg17771515	chr6:154831774	CNKSR3	0.52	5.06	0.31	8.48e-7	Lipoprotein (a) levels;
SARC	cis	rs870825	0.655	rs28451943	chr4:185645572	C/T	cg04058563	chr4:185651563	MLF1IP	0.8	11.35	0.6	4.56e-24	Blood protein levels;
SARC	cis	rs865483	0.895	rs2107104	chr17:35835031	G/A	cg06561646	chr17:35873369	DUSP14	-0.49	-6.55	-0.39	3.6e-10	Monocyte count;
SARC	cis	rs11122272	0.668	rs1122131	chr1:231476501	A/G	cg06096015	chr1:231504339	EGLN1	0.38	5.84	0.36	1.71e-8	Hemoglobin concentration;
SARC	cis	rs644799	0.687	rs11021318	chr11:95522996	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.63	8.29	0.48	9.28e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs6570726	0.818	rs412350	chr6:145852409	T/C	cg23711669	chr6:146136114	FBXO30	0.87	14.81	0.7	2.11e-35	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2273669	0.915	rs3734651	chr6:109295040	T/C	cg01304950	chr6:109416612	SESN1;C6orf182	0.54	4.79	0.3	3e-6	Prostate cancer;
SARC	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg01570182	chr17:44337453	NA	0.84	9.67	0.54	7.91e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs3733585	0.654	rs4447863	chr4:9938969	T/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.18	-0.43	9.12e-12	Cleft plate (environmental tobacco smoke interaction);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg21408716	chr3:52279700	PPM1M	0.51	6.34	0.38	1.16e-9	Height;
SARC	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg18252515	chr7:66147081	NA	-0.53	-5.87	-0.36	1.51e-8	Aortic root size;
SARC	cis	rs12545912	0.909	rs13262577	chr8:9477763	C/G	cg21625330	chr8:9911636	MSRA	0.5	4.81	0.3	2.66e-6	Multiple myeloma (hyperdiploidy);
SARC	cis	rs1113500	0.933	rs10881498	chr1:108634984	C/A	cg06207961	chr1:108661230	NA	0.45	5.92	0.36	1.14e-8	Growth-regulated protein alpha levels;
SARC	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg01475735	chr3:40494733	NA	0.46	5.2	0.32	4.46e-7	Renal cell carcinoma;
SARC	cis	rs11608355	0.515	rs4766609	chr12:109973297	A/G	cg05360138	chr12:110035743	NA	0.9	9.41	0.52	4.84e-18	Neuroticism;
SARC	cis	rs193541	0.632	rs4835896	chr5:122121240	C/T	cg19412675	chr5:122181750	SNX24	-0.53	-6.84	-0.41	6.86e-11	Glucose homeostasis traits;
SARC	cis	rs2354432	0.607	rs7537483	chr1:146709877	C/G	cg25205988	chr1:146714368	CHD1L	1.0	7.52	0.44	1.2e-12	Mitochondrial DNA levels;
SARC	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg26338869	chr17:61819248	STRADA	-0.62	-7.99	-0.46	6.1e-14	Prudent dietary pattern;
SARC	cis	rs9398803	0.650	rs9401874	chr6:126625617	A/C	cg19875578	chr6:126661172	C6orf173	-0.49	-6.82	-0.41	7.88e-11	Male-pattern baldness;
SARC	cis	rs6604026	0.656	rs2774953	chr1:93355254	G/A	cg17283838	chr1:93427260	FAM69A	-0.43	-4.91	-0.31	1.68e-6	Multiple sclerosis;
SARC	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg06027949	chr8:82754900	SNX16	0.5	6.22	0.38	2.23e-9	Diastolic blood pressure;
SARC	cis	rs911555	0.755	rs11620897	chr14:103944861	T/G	cg24130564	chr14:104152367	KLC1	-0.5	-5.94	-0.36	1.01e-8	Intelligence (multi-trait analysis);
SARC	cis	rs6582630	0.555	rs34884627	chr12:38443831	C/T	cg13010199	chr12:38710504	ALG10B	-0.46	-5.63	-0.35	5.19e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.75	-0.45	2.87e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs344364	0.511	rs1657134	chr16:1953127	A/G	cg26617929	chr16:1858877	NA	-0.66	-5.51	-0.34	9.69e-8	Glomerular filtration rate in chronic kidney disease;
SARC	cis	rs6840360	0.571	rs4696100	chr4:152514242	C/T	cg22705602	chr4:152727874	NA	-0.43	-6.66	-0.4	1.91e-10	Intelligence (multi-trait analysis);
SARC	cis	rs6701037	0.566	rs1014555	chr1:175134249	C/T	cg00321850	chr1:175162397	KIAA0040	0.38	5.88	0.36	1.39e-8	Alcohol dependence;
SARC	cis	rs1057510	1.000	rs1057510	chr12:6683287	C/T	cg23705119	chr12:6798806	ZNF384	0.47	4.8	0.3	2.84e-6	Myopia (pathological);
SARC	cis	rs116095464	1.000	rs6873902	chr5:313337	C/G	cg22496380	chr5:211416	CCDC127	-0.8	-6.35	-0.38	1.1e-9	Breast cancer;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg00473112	chr11:507177	RNH1	0.77	6.35	0.38	1.13e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg18252515	chr7:66147081	NA	0.55	5.79	0.35	2.29e-8	Aortic root size;
SARC	cis	rs367943	0.966	rs348945	chr5:112822889	C/T	cg12552261	chr5:112820674	MCC	-0.46	-5.27	-0.33	3.05e-7	Type 2 diabetes;
SARC	cis	rs7772486	0.720	rs6901888	chr6:146023144	A/G	cg05347473	chr6:146136440	FBXO30	-0.54	-7.43	-0.44	2e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9733	0.744	rs12125650	chr1:150760174	A/G	cg13175981	chr1:150552382	MCL1	0.61	8.2	0.47	1.66e-14	Tonsillectomy;
SARC	cis	rs7264396	0.635	rs6121073	chr20:34457513	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-7.5	-0.44	1.3e-12	Total cholesterol levels;
SARC	cis	rs1150668	0.796	rs2531825	chr6:28349264	C/T	cg13525197	chr6:28411240	ZSCAN23	-0.44	-5.36	-0.33	1.99e-7	Pubertal anthropometrics;
SARC	cis	rs854765	0.655	rs4470201	chr17:17844870	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	9.65	0.53	9.36e-19	Total body bone mineral density;
SARC	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg17971929	chr21:40555470	PSMG1	0.98	13.83	0.67	3.76e-32	Cognitive function;
SARC	trans	rs9427116	0.502	rs12125166	chr1:154582129	A/G	cg13872356	chr11:62341519	EEF1G	-0.51	-6.26	-0.38	1.83e-9	Blood protein levels;
SARC	cis	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg06558623	chr16:89946397	TCF25	0.91	6.37	0.38	1.03e-9	Skin colour saturation;
SARC	cis	rs4268898	0.610	rs55860688	chr2:24451534	T/C	cg26838691	chr2:24397539	C2orf84	-0.47	-5.29	-0.33	2.85e-7	Asthma;
SARC	cis	rs7223966	1.000	rs11658740	chr17:61751069	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	6.35	0.38	1.1e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs877282	1.000	rs877281	chr10:771557	T/G	cg22713356	chr15:30763199	NA	1.05	10.14	0.55	3.04e-20	Uric acid levels;
SARC	cis	rs36051895	0.623	rs7035456	chr9:5261440	G/A	cg02405213	chr9:5042618	JAK2	-0.44	-5.07	-0.32	7.96e-7	Pediatric autoimmune diseases;
SARC	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg09517075	chr8:22133004	PIWIL2	0.36	4.89	0.31	1.84e-6	Hypertriglyceridemia;
SARC	cis	rs607987	0.871	rs521271	chr11:30240470	T/A	cg06241208	chr11:30344200	C11orf46	-0.4	-4.81	-0.3	2.77e-6	Body mass index;
SARC	cis	rs7106204	0.764	rs79427715	chr11:24247046	G/A	ch.11.24196551F	chr11:24239977	NA	0.81	6.04	0.37	6.02e-9	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg13628971	chr7:2884303	GNA12	0.46	5.66	0.35	4.39e-8	Height;
SARC	trans	rs9329221	0.683	rs555200	chr8:9888729	A/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-9.52	-0.53	2.29e-18	Neuroticism;
SARC	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg11764359	chr7:65958608	NA	-0.69	-7.88	-0.46	1.25e-13	Aortic root size;
SARC	cis	rs778371	0.958	rs2675968	chr2:233736244	A/G	cg16596103	chr2:233749413	NGEF	-0.36	-5.53	-0.34	8.53e-8	Schizophrenia;
SARC	cis	rs4921915	0.526	rs13277738	chr8:18241507	C/T	cg18736775	chr8:18248649	NAT2	-0.65	-6.74	-0.4	1.25e-10	Iron status biomarkers (transferrin levels);
SARC	cis	rs36051895	0.632	rs11788963	chr9:5120157	C/A	cg02405213	chr9:5042618	JAK2	-0.42	-4.91	-0.31	1.73e-6	Pediatric autoimmune diseases;
SARC	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg09359103	chr1:154839909	KCNN3	-0.46	-7.68	-0.45	4.4e-13	Prostate cancer;
SARC	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg13628971	chr7:2884303	GNA12	0.5	5.95	0.36	9.6e-9	Height;
SARC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg23034840	chr1:205782522	SLC41A1	0.6	7.48	0.44	1.54e-12	Menarche (age at onset);
SARC	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg05313129	chr8:58192883	C8orf71	-0.62	-6.4	-0.39	8.54e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg11843238	chr5:131593191	PDLIM4	0.39	5.44	0.34	1.33e-7	Breast cancer;
SARC	cis	rs8014204	0.869	rs2070599	chr14:75361177	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.77	-10.79	-0.58	2.75e-22	Caffeine consumption;
SARC	trans	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.53	-6.93	-0.41	4.13e-11	Intelligence (multi-trait analysis);
SARC	cis	rs12681366	0.511	rs2919670	chr8:95456618	A/G	cg13257157	chr8:95487014	RAD54B	0.4	4.79	0.3	3.01e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs41433250	1	rs41433250	chr13:31495835	A/G	cg16711828	chr13:31191739	USPL1	-0.65	-4.72	-0.3	4.16e-6	Influenza A (H1N1) infection;Mild influenza (H1N1) infection;
SARC	cis	rs894734	0.535	rs2366143	chr12:54323256	G/A	cg17410650	chr12:54324560	NA	-0.33	-4.91	-0.31	1.74e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
SARC	cis	rs7216064	1.000	rs8071463	chr17:65938655	C/T	cg12091567	chr17:66097778	LOC651250	0.74	8.37	0.48	5.5e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.29	0.38	1.55e-9	Bipolar disorder;
SARC	cis	rs2197308	0.594	rs9705810	chr12:37895003	G/A	cg26384229	chr12:38710491	ALG10B	-0.8	-11.24	-0.59	1.04e-23	Morning vs. evening chronotype;
SARC	trans	rs7824557	0.591	rs2736282	chr8:11225480	C/T	cg06636001	chr8:8085503	FLJ10661	0.53	6.9	0.41	4.96e-11	Retinal vascular caliber;
SARC	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg02475777	chr4:1388615	CRIPAK	0.46	5.24	0.32	3.62e-7	Obesity-related traits;
SARC	cis	rs55794721	0.509	rs909834	chr1:25757996	A/G	cg03650068	chr1:25596491	NA	0.31	4.8	0.3	2.86e-6	Plateletcrit;Mean corpuscular volume;
SARC	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	trans	rs7819412	0.715	rs2409727	chr8:11043236	C/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.91	-0.41	4.48e-11	Triglycerides;
SARC	cis	rs7520050	0.778	rs3013597	chr1:46128356	C/A	cg06784218	chr1:46089804	CCDC17	0.26	4.87	0.3	2.02e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg13175981	chr1:150552382	MCL1	-0.54	-6.82	-0.41	7.54e-11	Tonsillectomy;
SARC	cis	rs72781680	0.898	rs113522526	chr2:24018476	C/T	cg08917208	chr2:24149416	ATAD2B	0.76	7.07	0.42	1.75e-11	Lymphocyte counts;
SARC	cis	rs1267303	0.682	rs1998545	chr1:46954587	C/T	cg25110126	chr1:46999211	NA	0.5	6.14	0.37	3.5e-9	Monobrow;
SARC	cis	rs897984	0.568	rs8050107	chr16:30893451	C/T	cg00531865	chr16:30841666	NA	0.49	5.1	0.32	6.94e-7	Dementia with Lewy bodies;
SARC	cis	rs4803468	1.000	rs10422956	chr19:41901261	C/T	cg09537434	chr19:41945824	ATP5SL	-0.95	-16.32	-0.73	1.9e-40	Height;
SARC	cis	rs7833986	0.501	rs2976036	chr8:57031721	G/T	cg26371346	chr8:56986568	SNORD54;RPS20	0.73	7.47	0.44	1.56e-12	Height;
SARC	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.91	10.04	0.55	5.92e-20	Platelet count;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg22928999	chr2:48046329	FBXO11	0.44	6.44	0.39	6.85e-10	Thyroid stimulating hormone;
SARC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg20607798	chr8:58055168	NA	0.58	5.55	0.34	7.69e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1048238	0.506	rs698889	chr1:16267040	A/C	cg21385522	chr1:16154831	NA	-0.44	-5.3	-0.33	2.65e-7	Systolic blood pressure;
SARC	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg02725872	chr8:58115012	NA	-0.37	-6.55	-0.39	3.71e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs12368653	0.591	rs1552842	chr12:58012163	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.43	5.68	0.35	3.94e-8	Multiple sclerosis;
SARC	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg11987759	chr7:65425863	GUSB	-0.49	-6.25	-0.38	1.96e-9	Aortic root size;
SARC	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg04317338	chr11:64019027	PLCB3	0.81	8.66	0.49	7.74e-16	Mean platelet volume;
SARC	cis	rs6964587	0.839	rs62466159	chr7:91450507	A/G	cg17063962	chr7:91808500	NA	0.84	11.92	0.62	6.93e-26	Breast cancer;
SARC	cis	rs3796352	1.000	rs11714876	chr3:53101640	C/G	cg15956490	chr3:53032818	SFMBT1	-0.81	-5.76	-0.35	2.71e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs765787	0.530	rs11634794	chr15:45534492	A/C	cg24006582	chr15:45444508	DUOX1	-0.56	-7.52	-0.44	1.15e-12	Uric acid levels;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg02566159	chr12:27175468	MED21	0.67	6.92	0.41	4.24e-11	Lung cancer in ever smokers;
SARC	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.45	-5.27	-0.33	3.12e-7	Renal function-related traits (BUN);
SARC	cis	rs9487051	0.807	rs1915835	chr6:109597483	C/T	cg01475377	chr6:109611718	NA	-0.41	-5.85	-0.36	1.66e-8	Reticulocyte fraction of red cells;
SARC	cis	rs617219	0.726	rs72764969	chr5:78451409	A/G	cg24856658	chr5:78533917	JMY	-0.3	-4.76	-0.3	3.39e-6	Betaine levels in individuals undergoing cardiac evaluation;
SARC	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	13.02	0.65	1.75e-29	Chronic sinus infection;
SARC	cis	rs10754283	0.934	rs6428563	chr1:90111583	T/A	cg21401794	chr1:90099060	LRRC8C	0.59	8.1	0.47	3.04e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs453301	0.686	rs3989373	chr8:8911308	G/T	cg11995313	chr8:8860691	ERI1	0.49	6.39	0.39	8.96e-10	Joint mobility (Beighton score);
SARC	cis	rs10791097	0.694	rs7106684	chr11:130758153	A/T	cg12179176	chr11:130786555	SNX19	0.75	11.4	0.6	3.36e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs832540	0.931	rs832534	chr5:56213672	G/A	cg14703610	chr5:56206110	C5orf35	0.54	6.83	0.41	7.24e-11	Coronary artery disease;
SARC	cis	rs2486288	0.656	rs11639349	chr15:45568260	C/T	cg19305227	chr15:45544335	SLC28A2	0.31	5.75	0.35	2.72e-8	Glomerular filtration rate;
SARC	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs13161895	1.000	rs3797763	chr5:179439516	C/T	cg04265672	chr5:179402240	RNF130	0.52	5.15	0.32	5.48e-7	LDL cholesterol;
SARC	cis	rs10979	1.000	rs9386032	chr6:143887492	A/G	cg25407410	chr6:143891975	LOC285740	-0.62	-8.34	-0.48	6.73e-15	Hypospadias;
SARC	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg03060546	chr3:49711283	APEH	0.42	5.29	0.33	2.85e-7	Parkinson's disease;
SARC	cis	rs6964587	0.967	rs34863529	chr7:91644341	C/G	cg17063962	chr7:91808500	NA	0.95	15.21	0.71	9.19e-37	Breast cancer;
SARC	cis	rs2153535	0.580	rs1119688	chr6:8460850	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	8.26	0.48	1.08e-14	Motion sickness;
SARC	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg18252515	chr7:66147081	NA	-0.49	-5.25	-0.33	3.44e-7	Aortic root size;
SARC	cis	rs6866344	0.598	rs34703961	chr5:178147874	A/G	cg03877680	chr5:178157825	ZNF354A	1.05	13.98	0.68	1.13e-32	Neutrophil percentage of white cells;
SARC	trans	rs9329221	0.527	rs34308302	chr8:10332022	C/T	cg06636001	chr8:8085503	FLJ10661	-0.6	-8.73	-0.5	5.11e-16	Neuroticism;
SARC	cis	rs7662987	0.517	rs2602873	chr4:100039032	G/C	cg13256891	chr4:100009986	ADH5	0.68	8.61	0.49	1.13e-15	Smoking initiation;
SARC	cis	rs9916302	0.706	rs6503500	chr17:37485925	C/T	cg20243544	chr17:37824526	PNMT	0.54	5.76	0.35	2.65e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs9818758	0.607	rs11706189	chr3:49210833	C/A	cg06212747	chr3:49208901	KLHDC8B	-0.71	-6.31	-0.38	1.42e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs4713118	0.662	rs149969	chr6:27977737	A/G	cg17221315	chr6:27791827	HIST1H4J	0.48	4.96	0.31	1.35e-6	Parkinson's disease;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg06692871	chr8:101964133	YWHAZ	-0.51	-6.42	-0.39	7.68e-10	Schizophrenia;
SARC	cis	rs4268898	0.662	rs35624938	chr2:24576651	T/C	cg26838691	chr2:24397539	C2orf84	-0.54	-6.23	-0.38	2.18e-9	Asthma;
SARC	cis	rs703842	1.000	rs2072052	chr12:58146719	A/C	cg00677455	chr12:58241039	CTDSP2	0.48	6.31	0.38	1.4e-9	Multiple sclerosis;
SARC	cis	rs1971762	0.583	rs3844370	chr12:54086137	G/C	cg06632207	chr12:54070931	ATP5G2	0.44	5.69	0.35	3.73e-8	Height;
SARC	cis	rs9341808	0.718	rs3828754	chr6:80900640	C/G	cg08355045	chr6:80787529	NA	0.33	5.33	0.33	2.26e-7	Sitting height ratio;
SARC	cis	rs17345786	1.000	rs73863360	chr3:101316837	G/A	cg12386194	chr3:101231763	SENP7	0.72	8.53	0.49	1.82e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs634534	0.591	rs688862	chr11:65733393	A/G	cg26695010	chr11:65641043	EFEMP2	-0.55	-7.3	-0.43	4.56e-12	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs7772486	0.754	rs13214277	chr6:146136125	G/T	cg05347473	chr6:146136440	FBXO30	0.57	7.97	0.46	6.94e-14	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2276314	0.947	rs16967319	chr18:33573525	A/G	cg05985134	chr18:33552581	C18orf21	0.69	6.92	0.41	4.31e-11	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs7762018	0.505	rs79843499	chr6:170068420	A/G	cg13015042	chr6:170102002	WDR27;C6orf120	0.69	4.85	0.3	2.23e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs712039	0.652	rs829160	chr17:35763091	T/A	cg16670864	chr17:35848621	DUSP14	0.49	5.48	0.34	1.08e-7	Tuberculosis;
SARC	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	16.55	0.74	3.34e-41	Height;
SARC	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg04166393	chr7:2884313	GNA12	0.58	6.81	0.41	8.03e-11	Height;
SARC	cis	rs9682041	0.740	rs6444929	chr3:170150076	C/T	cg11886554	chr3:170076028	SKIL	0.92	6.89	0.41	5.05e-11	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs712039	0.652	rs1829453	chr17:35809843	A/G	cg16670864	chr17:35848621	DUSP14	0.47	5.16	0.32	5.25e-7	Tuberculosis;
SARC	cis	rs4423214	0.765	rs2002064	chr11:71163420	A/G	cg05163923	chr11:71159392	DHCR7	-0.6	-6.78	-0.41	9.82e-11	Vitamin D levels;
SARC	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.5	-4.91	-0.31	1.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg21747090	chr2:27597821	SNX17	-0.55	-7.71	-0.45	3.52e-13	Total body bone mineral density;
SARC	cis	rs7336332	0.598	rs74563672	chr13:28010660	A/G	cg01674679	chr13:27998804	GTF3A	-0.55	-5.13	-0.32	5.96e-7	Weight;
SARC	cis	rs6997458	0.742	rs6988475	chr8:86383268	A/G	cg21346043	chr8:86351067	CA3	-0.35	-4.81	-0.3	2.69e-6	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg02725872	chr8:58115012	NA	-0.35	-5.93	-0.36	1.1e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs57244997	1.000	rs73026573	chr6:162405119	C/T	cg17173639	chr6:162384350	PARK2	-0.61	-5.6	-0.34	6.06e-8	Mosquito bite size;
SARC	cis	rs4889855	0.530	rs11654265	chr17:78602697	G/A	cg17956530	chr17:78667699	RPTOR	0.45	5.08	0.32	7.79e-7	Fractional excretion of uric acid;
SARC	cis	rs4660261	0.526	rs3094954	chr1:44320919	C/T	cg13606994	chr1:44402422	ARTN	-0.29	-4.77	-0.3	3.3e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9911578	0.874	rs302874	chr17:56767996	A/G	cg05425664	chr17:57184151	TRIM37	-0.66	-8.16	-0.47	2.11e-14	Intelligence (multi-trait analysis);
SARC	cis	rs6997458	0.742	rs10095352	chr8:86372432	A/C	cg21346043	chr8:86351067	CA3	-0.34	-4.74	-0.3	3.8e-6	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs910316	0.967	rs4903285	chr14:75609268	A/T	cg23033748	chr14:75592666	NEK9	0.38	5.44	0.34	1.32e-7	Height;
SARC	cis	rs6696846	0.765	rs11576867	chr1:205064676	C/T	cg07972983	chr1:205091412	RBBP5	0.54	7.08	0.42	1.72e-11	Red blood cell count;
SARC	cis	rs2766692	1.000	rs2766692	chr14:100684192	C/T	cg14866419	chr14:100704911	YY1	0.56	6.48	0.39	5.51e-10	Electroencephalographic traits in alcoholism;
SARC	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg10523679	chr1:76189770	ACADM	0.52	6.81	0.41	8.37e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg18252515	chr7:66147081	NA	-1.26	-11.14	-0.59	2.14e-23	Diabetic kidney disease;
SARC	cis	rs9467773	0.620	rs4368798	chr6:26593471	A/G	cg12292205	chr6:26970375	C6orf41	0.43	5.36	0.33	2.03e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2070997	0.607	rs11244146	chr9:133675143	A/G	cg11464064	chr9:133710261	ABL1	-0.65	-6.16	-0.37	3.23e-9	Response to amphetamines;
SARC	cis	rs7681440	0.904	rs2301135	chr4:90758389	G/C	cg06632027	chr4:90757378	SNCA	0.42	5.99	0.37	7.73e-9	Dementia with Lewy bodies;
SARC	cis	rs9916302	0.821	rs12938268	chr17:37572139	G/A	cg20243544	chr17:37824526	PNMT	0.57	6.94	0.41	3.95e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs6568686	0.578	rs56103131	chr6:111935748	G/A	cg15721981	chr6:111408429	SLC16A10	0.69	5.66	0.35	4.34e-8	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs4595586	0.655	rs11831502	chr12:39310127	A/T	cg26384229	chr12:38710491	ALG10B	0.41	5.09	0.32	7.23e-7	Morning vs. evening chronotype;
SARC	cis	rs763121	0.853	rs7289577	chr22:39042214	C/G	cg06022373	chr22:39101656	GTPBP1	0.9	11.56	0.6	9.96e-25	Menopause (age at onset);
SARC	cis	rs9790314	0.715	rs980975	chr3:160771410	G/A	cg04691961	chr3:161091175	C3orf57	-0.6	-8.18	-0.47	1.82e-14	Morning vs. evening chronotype;
SARC	cis	rs747650	0.798	rs11039086	chr11:47116033	G/C	cg03339077	chr11:47165057	C11orf49	-0.44	-6.11	-0.37	4.12e-9	Acne (severe);
SARC	cis	rs9682041	1.000	rs9682041	chr3:170091902	C/T	cg11886554	chr3:170076028	SKIL	1.03	8.2	0.47	1.65e-14	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg17376030	chr22:41985996	PMM1	0.68	8.24	0.48	1.25e-14	Vitiligo;
SARC	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg11062466	chr8:58055876	NA	0.49	4.79	0.3	2.97e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs9916302	0.610	rs11078902	chr17:37631883	C/G	cg20243544	chr17:37824526	PNMT	0.57	6.66	0.4	1.97e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs2013441	1.000	rs9900166	chr17:20192969	G/A	cg13482628	chr17:19912719	NA	-0.5	-6.47	-0.39	5.83e-10	Obesity-related traits;
SARC	cis	rs35110281	0.712	rs162345	chr21:44954155	T/G	cg01579765	chr21:45077557	HSF2BP	-0.32	-5.41	-0.33	1.57e-7	Mean corpuscular volume;
SARC	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg16479474	chr6:28041457	NA	0.37	5.44	0.34	1.37e-7	Depression;
SARC	cis	rs6988636	1.000	rs17323510	chr8:124186089	A/G	cg23067535	chr8:124195133	FAM83A	0.67	5.69	0.35	3.88e-8	Urinary uromodulin levels;
SARC	cis	rs8070624	0.574	rs9914127	chr17:17875836	A/T	cg05444541	chr17:17804740	TOM1L2	-0.32	-5.22	-0.32	3.88e-7	Total body bone mineral density;
SARC	cis	rs7927771	0.524	rs12286721	chr11:47701528	G/T	cg05585544	chr11:47624801	NA	-0.33	-4.92	-0.31	1.62e-6	Subjective well-being;
SARC	cis	rs56283067	0.887	rs9463043	chr6:44771114	T/C	cg18551225	chr6:44695536	NA	-0.36	-4.84	-0.3	2.31e-6	Total body bone mineral density;
SARC	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg05025164	chr4:1340916	KIAA1530	-0.45	-5.23	-0.32	3.69e-7	Obesity-related traits;
SARC	cis	rs17376456	0.569	rs7721668	chr5:93290995	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.47	-5.28	-0.33	2.95e-7	Diabetic retinopathy;
SARC	cis	rs17270561	0.609	rs9348695	chr6:25763010	A/T	cg16482183	chr6:26056742	HIST1H1C	0.48	5.95	0.36	9.58e-9	Iron status biomarkers;
SARC	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg08219700	chr8:58056026	NA	0.49	5.41	0.33	1.57e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9650657	0.770	rs6601529	chr8:10670550	A/G	cg21775007	chr8:11205619	TDH	-0.38	-4.74	-0.3	3.67e-6	Neuroticism;
SARC	cis	rs10464366	0.746	rs6945402	chr7:39145385	A/T	cg15212455	chr7:39170539	POU6F2	0.45	5.38	0.33	1.81e-7	IgG glycosylation;
SARC	cis	rs6809651	0.524	rs79262908	chr3:185803594	C/T	cg00760338	chr3:185826511	ETV5	-0.86	-10.99	-0.58	6.77e-23	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
SARC	cis	rs2997447	0.761	rs2783711	chr1:26428864	G/A	cg19633962	chr1:26362018	EXTL1	-0.58	-5.51	-0.34	9.42e-8	QRS complex (12-leadsum);
SARC	cis	rs2559856	0.935	rs7957666	chr12:102081551	T/C	cg12924262	chr12:102091054	CHPT1	0.58	7.62	0.45	6.2800000000000005e-13	Blood protein levels;
SARC	cis	rs11098499	0.954	rs10017543	chr4:120321420	G/A	cg09307838	chr4:120376055	NA	0.9	12.37	0.63	2.31e-27	Corneal astigmatism;
SARC	cis	rs208520	0.690	rs2126120	chr6:66742754	A/G	cg07460842	chr6:66804631	NA	1.04	13.8	0.67	4.75e-32	Exhaled nitric oxide output;
SARC	cis	rs6088590	1.000	rs6087625	chr20:33342477	A/G	cg06115741	chr20:33292138	TP53INP2	-0.53	-6.3	-0.38	1.49e-9	Coronary artery disease;
SARC	trans	rs10838798	0.523	rs4752907	chr11:48170581	G/A	cg15704280	chr7:45808275	SEPT13	-0.48	-6.47	-0.39	5.8e-10	Height;
SARC	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg13939156	chr17:80058883	NA	-0.38	-5.85	-0.36	1.62e-8	Life satisfaction;
SARC	trans	rs61931739	0.500	rs7965679	chr12:34542494	T/C	cg13010199	chr12:38710504	ALG10B	0.78	11.07	0.59	3.68e-23	Morning vs. evening chronotype;
SARC	cis	rs9911578	0.900	rs7214335	chr17:57158840	G/A	cg05425664	chr17:57184151	TRIM37	-0.6	-7.42	-0.44	2.12e-12	Intelligence (multi-trait analysis);
SARC	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg12311346	chr5:56204834	C5orf35	-0.57	-5.86	-0.36	1.56e-8	Initial pursuit acceleration;
SARC	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg06212747	chr3:49208901	KLHDC8B	0.69	9.11	0.51	3.8e-17	Parkinson's disease;
SARC	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg20126647	chr17:40714003	COASY	0.69	9.39	0.52	5.58e-18	Colorectal or endometrial cancer;
SARC	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg03213289	chr20:61660250	NA	0.46	6.43	0.39	7.22e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs11122272	0.735	rs2749716	chr1:231486908	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-9.95	-0.55	1.14e-19	Hemoglobin concentration;
SARC	cis	rs2370759	0.898	rs113412621	chr10:32579306	C/T	cg05361325	chr10:32636312	EPC1	-0.75	-6.52	-0.39	4.4e-10	Sexual dysfunction (female);
SARC	cis	rs6840360	1.000	rs3749561	chr4:152610117	C/T	cg22705602	chr4:152727874	NA	0.38	6.57	0.4	3.24e-10	Intelligence (multi-trait analysis);
SARC	cis	rs9341808	0.718	rs9343978	chr6:80971978	A/G	cg08355045	chr6:80787529	NA	0.35	5.61	0.35	5.58e-8	Sitting height ratio;
SARC	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg24209194	chr3:40518798	ZNF619	0.67	8.27	0.48	1.03e-14	Renal cell carcinoma;
SARC	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg05313129	chr8:58192883	C8orf71	-0.58	-6.5	-0.39	4.83e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs362272	0.545	rs2239725	chr4:3305739	C/T	cg06533319	chr4:3265114	C4orf44	-0.32	-4.89	-0.3	1.91e-6	Serum sulfate level;
SARC	cis	rs832540	0.966	rs33321	chr5:56206073	G/T	cg14703610	chr5:56206110	C5orf35	0.55	6.91	0.41	4.52e-11	Coronary artery disease;
SARC	cis	rs611744	0.870	rs672243	chr8:109098742	G/A	cg21045802	chr8:109455806	TTC35	0.45	5.22	0.32	3.95e-7	Dupuytren's disease;
SARC	cis	rs7582720	1.000	rs72932774	chr2:203685728	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.71	7.13	0.42	1.29e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs240764	0.578	rs9498252	chr6:101194481	A/G	cg09795085	chr6:101329169	ASCC3	0.5	6.42	0.39	7.45e-10	Neuroticism;
SARC	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg16325326	chr1:53192061	ZYG11B	0.77	12.31	0.63	3.8e-27	Monocyte count;
SARC	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg27266027	chr21:40555129	PSMG1	-0.45	-4.88	-0.3	1.93e-6	Cognitive function;
SARC	cis	rs11209002	0.614	rs4655515	chr1:67566898	T/C	cg02640540	chr1:67518911	SLC35D1	0.51	6.0	0.37	7.65e-9	Crohn's disease;
SARC	cis	rs9905704	0.647	rs6503892	chr17:57067086	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.4	-4.86	-0.3	2.14e-6	Testicular germ cell tumor;
SARC	cis	rs7027203	0.797	rs4744294	chr9:96612114	C/G	cg13679303	chr9:96623674	NA	-0.35	-5.01	-0.31	1.1e-6	DNA methylation (variation);
SARC	cis	rs9660992	0.710	rs1768586	chr1:205238275	A/G	cg19090574	chr1:205240910	TMCC2	-0.39	-4.85	-0.3	2.29e-6	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs72781680	1.000	rs6731001	chr2:24192952	A/G	cg06627628	chr2:24431161	ITSN2	-0.7	-6.71	-0.4	1.49e-10	Lymphocyte counts;
SARC	cis	rs10504229	0.593	rs58647001	chr8:58025132	G/A	cg21724239	chr8:58056113	NA	0.65	6.87	0.41	5.75e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg02297831	chr4:17616191	MED28	0.51	6.63	0.4	2.36e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4132509	0.566	rs1578275	chr1:243680442	C/G	cg21452805	chr1:244014465	NA	-0.5	-5.25	-0.33	3.48e-7	RR interval (heart rate);
SARC	cis	rs7927771	0.832	rs11601173	chr11:47401058	A/G	cg20307385	chr11:47447363	PSMC3	-0.56	-7.0	-0.42	2.78e-11	Subjective well-being;
SARC	cis	rs1568889	1.000	rs61889027	chr11:28281908	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	9.43	0.53	4.22e-18	Bipolar disorder;
SARC	cis	rs9527	0.590	rs3740386	chr10:104931051	C/T	cg04362960	chr10:104952993	NT5C2	0.43	5.12	0.32	6.5e-7	Arsenic metabolism;
SARC	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg13012494	chr21:47604986	C21orf56	0.54	6.35	0.38	1.1e-9	Testicular germ cell tumor;
SARC	cis	rs16912285	0.688	rs7126291	chr11:24312936	A/C	ch.11.24196551F	chr11:24239977	NA	0.58	5.85	0.36	1.69e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs2153535	0.580	rs2184582	chr6:8447793	G/A	cg21535247	chr6:8435926	SLC35B3	0.55	6.87	0.41	5.72e-11	Motion sickness;
SARC	cis	rs11249608	0.548	rs17078988	chr5:178459283	A/G	cg21905437	chr5:178450457	ZNF879	0.57	7.55	0.44	1.01e-12	Pubertal anthropometrics;
SARC	cis	rs6542838	0.698	rs7565736	chr2:99464952	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-5.37	-0.33	1.92e-7	Fear of minor pain;
SARC	cis	rs6088590	0.965	rs6087619	chr20:33288511	C/G	cg24642439	chr20:33292090	TP53INP2	0.9	13.32	0.66	1.84e-30	Coronary artery disease;
SARC	cis	rs35110281	0.837	rs7279958	chr21:45016016	C/A	cg01579765	chr21:45077557	HSF2BP	-0.33	-5.67	-0.35	4.19e-8	Mean corpuscular volume;
SARC	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg22800045	chr5:56110881	MAP3K1	0.65	6.86	0.41	6.06e-11	Initial pursuit acceleration;
SARC	cis	rs412050	0.547	rs76200689	chr22:22154644	G/A	cg17089214	chr22:22089827	YPEL1	0.78	6.87	0.41	5.78e-11	Attention deficit hyperactivity disorder;
SARC	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg16680214	chr1:154839983	KCNN3	-0.35	-5.5	-0.34	9.89e-8	Prostate cancer;
SARC	cis	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg19252891	chr7:75132457	SPDYE5	-0.41	-5.32	-0.33	2.39e-7	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs6542838	0.553	rs6739503	chr2:99537295	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.45	-5.77	-0.35	2.51e-8	Fear of minor pain;
SARC	cis	rs17270561	0.609	rs9358886	chr6:25758253	T/A	cg17691542	chr6:26056736	HIST1H1C	0.6	7.31	0.43	4.14e-12	Iron status biomarkers;
SARC	cis	rs72781680	1.000	rs11553491	chr2:24225901	G/C	cg06627628	chr2:24431161	ITSN2	-0.69	-6.64	-0.4	2.22e-10	Lymphocyte counts;
SARC	cis	rs7219021	0.739	rs58376900	chr17:46962853	C/G	cg16584676	chr17:46985605	UBE2Z	-0.45	-4.8	-0.3	2.85e-6	Schizophrenia or bipolar disorder;
SARC	cis	rs34172651	0.917	rs200536	chr16:24749203	G/A	cg04756594	chr16:24857601	SLC5A11	-0.38	-6.1	-0.37	4.3e-9	Intelligence (multi-trait analysis);
SARC	trans	rs11165623	0.564	rs7525803	chr1:97000791	T/C	cg10631902	chr5:14652156	NA	-0.43	-6.54	-0.39	3.89e-10	Hip circumference;Waist circumference;
SARC	cis	rs7607369	0.714	rs4674338	chr2:219647487	A/G	cg02176678	chr2:219576539	TTLL4	0.46	7.39	0.44	2.53e-12	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs2235642	0.717	rs9937922	chr16:1658154	C/G	cg09065629	chr16:1709722	CRAMP1L	0.35	4.89	0.3	1.89e-6	Coronary artery disease;
SARC	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg11494091	chr17:61959527	GH2	0.37	4.93	0.31	1.54e-6	Height;
SARC	cis	rs2599510	0.783	rs2038534	chr2:32659489	G/A	cg02381751	chr2:32503542	YIPF4	0.48	5.7	0.35	3.58e-8	Interleukin-18 levels;
SARC	cis	rs1801251	1.000	rs6738386	chr2:233602028	T/C	cg25237894	chr2:233734115	C2orf82	0.37	4.91	0.31	1.7e-6	Coronary artery disease;
SARC	cis	rs911263	0.603	rs911254	chr14:68805323	A/T	cg18825221	chr14:68749962	RAD51L1	0.42	7.2	0.43	8.04e-12	Primary biliary cholangitis;
SARC	cis	rs6840360	0.593	rs1366907	chr4:152682749	T/C	cg22705602	chr4:152727874	NA	-0.48	-8.46	-0.48	3.02e-15	Intelligence (multi-trait analysis);
SARC	cis	rs9467773	0.620	rs9295701	chr6:26627508	T/C	cg12292205	chr6:26970375	C6orf41	0.41	5.12	0.32	6.46e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7560272	0.588	rs4852959	chr2:73880601	C/A	cg20560298	chr2:73613845	ALMS1	0.51	6.98	0.42	3.07e-11	Schizophrenia;
SARC	cis	rs9309473	0.898	rs10185080	chr2:73797507	C/A	cg20560298	chr2:73613845	ALMS1	-0.48	-5.89	-0.36	1.31e-8	Metabolite levels;
SARC	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg15448220	chr1:150897856	SETDB1	0.47	6.25	0.38	1.94e-9	Tonsillectomy;
SARC	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg22535103	chr8:58192502	C8orf71	-0.6	-6.15	-0.37	3.42e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7568458	0.660	rs6722691	chr2:85758352	C/T	cg02493740	chr2:85810744	VAMP5	-0.41	-5.39	-0.33	1.76e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs4141404	0.851	rs9606833	chr22:31750013	T/C	cg13145458	chr22:31556086	RNF185	-0.55	-5.48	-0.34	1.08e-7	Paclitaxel-induced neuropathy;
SARC	cis	rs7847628	0.666	rs2031974	chr9:123527521	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	7.16	0.42	1.02e-11	Birth weight;
SARC	cis	rs9921222	0.656	rs12719801	chr16:381141	C/T	cg12437481	chr16:420112	MRPL28	-0.59	-10.07	-0.55	4.84e-20	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs4561483	0.801	rs33640	chr16:11986874	C/T	cg08843971	chr16:11963173	GSPT1	-0.41	-4.99	-0.31	1.2e-6	Testicular germ cell tumor;
SARC	cis	rs1144333	0.655	rs75146987	chr1:76467878	T/G	cg03433033	chr1:76189801	ACADM	0.63	5.15	0.32	5.47e-7	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs6493487	0.512	rs35134521	chr15:51317759	C/G	cg02338191	chr15:51200825	AP4E1	0.53	4.83	0.3	2.44e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs4253772	0.575	rs6008684	chr22:46719100	C/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.64	4.91	0.31	1.74e-6	LDL cholesterol;Cholesterol, total;
SARC	cis	rs826838	0.709	rs4882355	chr12:38721462	A/T	cg04568710	chr12:38710424	ALG10B	0.4	4.98	0.31	1.24e-6	Heart rate;
SARC	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg18876405	chr7:65276391	NA	0.49	6.07	0.37	5.21e-9	Aortic root size;
SARC	cis	rs668210	0.793	rs502363	chr11:65775592	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.67	7.26	0.43	5.63e-12	Cerebrospinal fluid biomarker levels;
SARC	cis	rs796364	0.755	rs6739563	chr2:201134216	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.73	5.75	0.35	2.78e-8	Schizophrenia;
SARC	cis	rs7980687	0.574	rs10744149	chr12:123708490	T/A	cg05973401	chr12:123451056	ABCB9	0.48	5.41	0.33	1.58e-7	Height;Educational attainment;Head circumference (infant);
SARC	cis	rs2749592	0.550	rs7917262	chr10:37874602	A/C	cg00409905	chr10:38381863	ZNF37A	0.54	7.39	0.44	2.59e-12	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs1153858	1.000	rs9788780	chr15:45685487	T/A	cg26924012	chr15:45694286	SPATA5L1	0.78	10.68	0.57	6.18e-22	Homoarginine levels;
SARC	cis	rs116095464	1.000	rs56235400	chr5:312625	G/A	cg22496380	chr5:211416	CCDC127	-0.8	-6.35	-0.38	1.1e-9	Breast cancer;
SARC	cis	rs7246657	0.943	rs12981532	chr19:37889280	G/A	cg23950597	chr19:37808831	NA	-0.62	-6.05	-0.37	5.66e-9	Coronary artery calcification;
SARC	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg11766577	chr21:47581405	C21orf56	0.47	5.68	0.35	3.95e-8	Testicular germ cell tumor;
SARC	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg04277193	chr17:41438351	NA	0.45	4.93	0.31	1.59e-6	Menopause (age at onset);
SARC	cis	rs80130819	0.515	rs6580656	chr12:48570604	C/T	cg24011408	chr12:48396354	COL2A1	0.47	5.29	0.33	2.8e-7	Prostate cancer;
SARC	cis	rs155076	1.000	rs9509638	chr13:21860193	G/A	cg25811766	chr13:21894605	NA	-0.52	-5.6	-0.34	5.96e-8	White matter hyperintensity burden;
SARC	cis	rs501120	1.000	rs552794	chr10:44771666	G/A	cg09554077	chr10:44749378	NA	0.47	6.39	0.39	8.81e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs7624766	0.594	rs1839017	chr3:160577670	A/G	cg22637730	chr3:160473554	PPM1L	-0.41	-5.04	-0.31	9.14e-7	Response to methotrexate in rheumatoid arthritis;
SARC	cis	rs7027203	0.717	rs7869328	chr9:96588782	A/G	cg13679303	chr9:96623674	NA	-0.33	-4.71	-0.3	4.2e-6	DNA methylation (variation);
SARC	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-7.83	-0.46	1.71e-13	Alzheimer's disease;
SARC	cis	rs7647973	0.593	rs7652179	chr3:49808618	T/A	cg06212747	chr3:49208901	KLHDC8B	-0.6	-5.74	-0.35	2.91e-8	Menarche (age at onset);
SARC	cis	rs4925386	0.840	rs6143035	chr20:60920700	C/T	cg24112000	chr20:60950667	NA	0.35	5.36	0.33	1.96e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs8180040	0.871	rs11716661	chr3:47517773	G/T	cg27129171	chr3:47204927	SETD2	-0.69	-9.56	-0.53	1.82e-18	Colorectal cancer;
SARC	cis	rs5753618	0.509	rs2079431	chr22:31564334	C/T	cg13145458	chr22:31556086	RNF185	0.45	4.95	0.31	1.44e-6	Colorectal cancer;
SARC	cis	rs763121	0.853	rs8142098	chr22:39058757	T/G	cg21395723	chr22:39101663	GTPBP1	0.58	6.43	0.39	7.23e-10	Menopause (age at onset);
SARC	cis	rs12545109	0.879	rs2609994	chr8:57365844	A/G	cg19413350	chr8:57351067	NA	-0.45	-4.92	-0.31	1.61e-6	Obesity-related traits;
SARC	cis	rs918629	0.679	rs57471342	chr5:95272429	A/C	cg16656078	chr5:95278638	ELL2	-0.66	-7.39	-0.44	2.61e-12	IgG glycosylation;
SARC	cis	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg25427524	chr10:38739819	LOC399744	-0.52	-8.17	-0.47	1.91e-14	Extrinsic epigenetic age acceleration;
SARC	cis	rs8031584	0.958	rs35256769	chr15:31237776	G/A	cg08109568	chr15:31115862	NA	-0.47	-5.8	-0.35	2.2e-8	Huntington's disease progression;
SARC	cis	rs79057730	0.599	rs6951032	chr7:794092	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.73	5.35	0.33	2.09e-7	Initial pursuit acceleration;
SARC	cis	rs4763879	0.729	rs10844472	chr12:9843733	A/G	cg27502298	chr12:9555721	NA	0.44	4.88	0.3	2.01e-6	Type 1 diabetes;
SARC	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-6.87	-0.41	5.85e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs2075371	0.897	rs1646733	chr7:134002228	C/A	cg00033643	chr7:134001901	SLC35B4	0.53	6.6	0.4	2.73e-10	Mean platelet volume;
SARC	cis	rs9291683	0.530	rs11723970	chr4:9980462	T/C	cg00071950	chr4:10020882	SLC2A9	0.4	6.43	0.39	7.09e-10	Bone mineral density;
SARC	cis	rs6901004	0.596	rs411604	chr6:111565847	A/G	cg15721981	chr6:111408429	SLC16A10	-0.59	-6.79	-0.41	9.06e-11	Blood metabolite levels;
SARC	cis	rs5757676	1.000	rs5757676	chr22:39841700	T/C	cg24399712	chr22:39784796	NA	-0.39	-4.82	-0.3	2.55e-6	IgG glycosylation;
SARC	cis	rs9309473	0.950	rs6546849	chr2:73831037	A/G	cg07208825	chr2:73871855	ALMS1P	0.35	5.14	0.32	5.87e-7	Metabolite levels;
SARC	cis	rs10870270	1.000	rs6560694	chr10:133773448	G/A	cg26149184	chr10:133730230	NA	0.48	5.28	0.33	2.99e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs9303401	0.659	rs12952325	chr17:56899371	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	11.37	0.6	4.08e-24	Cognitive test performance;
SARC	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg19671926	chr4:122722719	EXOSC9	-0.56	-6.27	-0.38	1.69e-9	Type 2 diabetes;
SARC	cis	rs1801251	1.000	rs3817311	chr2:233612557	C/T	cg25237894	chr2:233734115	C2orf82	0.38	4.96	0.31	1.39e-6	Coronary artery disease;
SARC	cis	rs9400467	0.506	rs78344470	chr6:111761783	G/A	cg15721981	chr6:111408429	SLC16A10	0.65	5.65	0.35	4.61e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs1865760	0.566	rs3752420	chr6:26027135	G/A	cg10373733	chr6:25993375	NA	0.4	4.89	0.3	1.92e-6	Height;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg10004563	chr19:7528638	ARHGEF18	-0.47	-6.31	-0.38	1.41e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs910316	1.000	rs175512	chr14:75523382	T/C	cg08847533	chr14:75593920	NEK9	-0.92	-14.96	-0.7	6.48e-36	Height;
SARC	cis	rs2251381	0.722	rs2251278	chr21:30529234	A/G	cg08807101	chr21:30365312	RNF160	0.77	10.34	0.56	6.99e-21	Selective IgA deficiency;
SARC	cis	rs1801251	1.000	rs283474	chr2:233654627	A/G	cg25237894	chr2:233734115	C2orf82	0.37	4.87	0.3	2.09e-6	Coronary artery disease;
SARC	cis	rs6665290	0.935	rs17600669	chr1:227201871	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.08	-24.68	-0.85	6e-67	Myeloid white cell count;
SARC	cis	rs35110281	0.805	rs2838319	chr21:44991901	A/G	cg01579765	chr21:45077557	HSF2BP	-0.31	-5.28	-0.33	2.96e-7	Mean corpuscular volume;
SARC	cis	rs1008375	0.966	rs10939735	chr4:17578891	A/G	cg02297831	chr4:17616191	MED28	0.48	5.93	0.36	1.06e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg11494091	chr17:61959527	GH2	-0.55	-8.21	-0.47	1.47e-14	Prudent dietary pattern;
SARC	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg13699009	chr12:122356056	WDR66	0.55	8.22	0.47	1.4e-14	Mean corpuscular volume;
SARC	trans	rs7937682	0.921	rs34584980	chr11:111441537	G/A	cg18187862	chr3:45730750	SACM1L	-0.54	-6.4	-0.39	8.26e-10	Primary sclerosing cholangitis;
SARC	cis	rs2439831	0.867	rs933941	chr15:43632226	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.78	8.1	0.47	3.18e-14	Lung cancer in ever smokers;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg21495713	chr13:111331324	CARS2	-0.78	-6.33	-0.38	1.23e-9	Obesity-related traits;
SARC	cis	rs6456156	0.586	rs2285148	chr6:167490999	G/T	cg07741184	chr6:167504864	NA	0.37	7.01	0.42	2.51e-11	Primary biliary cholangitis;
SARC	cis	rs898097	0.812	rs56274787	chr17:80862682	C/T	cg20578329	chr17:80767326	TBCD	-0.53	-6.96	-0.41	3.52e-11	Breast cancer;
SARC	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg21782813	chr7:2030301	MAD1L1	0.44	7.06	0.42	1.89e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs3617	0.625	rs6769789	chr3:52874446	C/T	cg04865290	chr3:52927548	TMEM110	0.33	4.76	0.3	3.37e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg08280861	chr8:58055591	NA	0.61	5.96	0.36	9.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg23758822	chr17:41437982	NA	0.89	10.96	0.58	8.18e-23	Menopause (age at onset);
SARC	cis	rs6815814	0.950	rs5743595	chr4:38802644	A/G	cg06935464	chr4:38784597	TLR10	0.65	6.5	0.39	4.8e-10	Breast cancer;
SARC	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg13206674	chr6:150067644	NUP43	0.44	5.72	0.35	3.23e-8	Lung cancer;
SARC	cis	rs12780845	0.540	rs10904904	chr10:17240640	G/C	cg11116878	chr10:17243438	TRDMT1	0.4	5.01	0.31	1.05e-6	Homocysteine levels;
SARC	cis	rs228437	0.609	rs7749956	chr6:134961973	C/T	cg24504307	chr6:134963096	NA	-0.41	-4.91	-0.31	1.69e-6	Melanoma;
SARC	cis	rs1144333	0.655	rs4949619	chr1:76463974	C/G	cg03433033	chr1:76189801	ACADM	0.63	5.15	0.32	5.47e-7	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs7123876	0.504	rs1157343	chr11:72429141	A/G	cg03713592	chr11:72463424	ARAP1	-0.51	-6.08	-0.37	4.93e-9	Body mass index;
SARC	cis	rs1153858	1.000	rs7171577	chr15:45627979	G/A	cg26924012	chr15:45694286	SPATA5L1	0.75	10.32	0.56	8.54e-21	Homoarginine levels;
SARC	cis	rs7528419	0.927	rs660240	chr1:109817838	T/C	cg00908766	chr1:109817496	CELSR2	0.59	7.36	0.43	3.21e-12	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
SARC	cis	rs16866061	0.517	rs7594223	chr2:225472985	T/C	cg12698349	chr2:225449008	CUL3	0.4	5.08	0.32	7.83e-7	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	6.02	0.37	6.63e-9	Prudent dietary pattern;
SARC	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	10.75	0.58	3.69e-22	Alzheimer's disease;
SARC	cis	rs501120	1.000	rs527785	chr10:44762686	G/A	cg09554077	chr10:44749378	NA	0.48	6.45	0.39	6.23e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.84	-0.5	2.33e-16	Alzheimer's disease;
SARC	cis	rs1003719	0.591	rs2040125	chr21:38549236	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.58	8.17	0.47	1.91e-14	Eye color traits;
SARC	cis	rs2273669	0.667	rs12206606	chr6:109353519	C/A	cg05315195	chr6:109294784	ARMC2	-0.63	-5.73	-0.35	3.16e-8	Prostate cancer;
SARC	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg00149659	chr3:10157352	C3orf10	0.64	6.01	0.37	7.21e-9	Alzheimer's disease;
SARC	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg14784868	chr12:69753453	YEATS4	0.5	6.69	0.4	1.68e-10	Blood protein levels;
SARC	cis	rs950169	0.579	rs11633088	chr15:84672181	A/T	cg24253500	chr15:84953950	NA	-0.35	-4.79	-0.3	2.98e-6	Schizophrenia;
SARC	cis	rs3784262	0.692	rs12914388	chr15:58283843	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.36	-5.34	-0.33	2.25e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs10752881	1.000	rs4402094	chr1:182986441	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.7	0.57	5.56e-22	Colorectal cancer;
SARC	cis	rs651907	0.535	rs34648996	chr3:101511202	A/G	cg12386194	chr3:101231763	SENP7	0.48	5.43	0.34	1.42e-7	Colorectal cancer;
SARC	cis	rs7617773	0.817	rs9847953	chr3:48282695	A/G	cg11946769	chr3:48343235	NME6	0.71	9.48	0.53	3.15e-18	Coronary artery disease;
SARC	cis	rs7568458	0.709	rs11895399	chr2:85753806	C/A	cg02493740	chr2:85810744	VAMP5	-0.42	-5.5	-0.34	9.81e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg08219700	chr8:58056026	NA	0.73	6.39	0.39	9.16e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs3091242	0.933	rs3093584	chr1:25668714	T/C	cg02931644	chr1:25747376	RHCE	-0.47	-7.94	-0.46	8.47e-14	Erythrocyte sedimentation rate;
SARC	cis	rs554111	0.634	rs7551785	chr1:21524297	C/G	cg08890418	chr1:21044141	KIF17	0.37	4.99	0.31	1.16e-6	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs8064299	0.967	rs878907	chr17:72769694	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.53	6.51	0.39	4.62e-10	Monocyte count;
SARC	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg06028808	chr11:68637592	NA	0.48	6.23	0.38	2.15e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7465272	0.530	rs10103161	chr8:143738571	A/G	cg24634471	chr8:143751801	JRK	0.59	7.52	0.44	1.18e-12	Bipolar disorder and schizophrenia;
SARC	cis	rs4919087	0.810	rs10736115	chr10:99031685	A/G	cg25902810	chr10:99078978	FRAT1	0.48	6.09	0.37	4.73e-9	Monocyte count;
SARC	cis	rs6484504	0.576	rs208066	chr11:31156206	C/G	cg02090638	chr11:31391270	DNAJC24;DCDC1	-0.39	-4.81	-0.3	2.72e-6	Red blood cell count;
SARC	cis	rs865483	0.895	rs2522965	chr17:35816318	C/G	cg06561646	chr17:35873369	DUSP14	-0.46	-6.2	-0.38	2.6e-9	Monocyte count;
SARC	cis	rs10911232	0.507	rs10911222	chr1:183047363	G/A	cg13390022	chr1:182993471	LAMC1	0.33	5.03	0.31	9.72e-7	Hypertriglyceridemia;
SARC	cis	rs950776	0.518	rs12591557	chr15:78811732	A/G	cg22563815	chr15:78856949	CHRNA5	0.41	6.71	0.4	1.49e-10	Sudden cardiac arrest;
SARC	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg24549020	chr5:56110836	MAP3K1	0.68	7.6	0.45	7.13e-13	Type 2 diabetes;
SARC	cis	rs2354432	0.825	rs10900347	chr1:146800107	G/C	cg25205988	chr1:146714368	CHD1L	0.98	10.66	0.57	7.29e-22	Mitochondrial DNA levels;
SARC	cis	rs3796352	1.000	rs34943350	chr3:53012888	C/T	cg27565382	chr3:53032988	SFMBT1	0.98	6.57	0.4	3.21e-10	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg01475735	chr3:40494733	NA	-0.45	-4.98	-0.31	1.25e-6	Renal cell carcinoma;
SARC	cis	rs2576037	0.899	rs2571034	chr18:44578565	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.36	-4.96	-0.31	1.39e-6	Personality dimensions;
SARC	cis	rs10493773	0.894	rs12067749	chr1:86197922	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.48	-6.97	-0.42	3.29e-11	Urate levels in overweight individuals;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg24143611	chr19:48258154	SNORD23;GLTSCR2	0.47	6.28	0.38	1.61e-9	Schizophrenia;
SARC	cis	rs11098499	0.554	rs2175381	chr4:120265967	T/C	cg09307838	chr4:120376055	NA	0.75	10.42	0.56	4.08e-21	Corneal astigmatism;
SARC	cis	rs898097	0.841	rs8180	chr17:80901036	C/G	cg15664640	chr17:80829946	TBCD	0.5	7.78	0.45	2.27e-13	Breast cancer;
SARC	cis	rs4889855	0.585	rs72855201	chr17:78530597	A/G	cg17956530	chr17:78667699	RPTOR	0.42	4.82	0.3	2.61e-6	Fractional excretion of uric acid;
SARC	cis	rs7772486	0.790	rs7742333	chr6:146159029	A/G	cg23711669	chr6:146136114	FBXO30	-0.83	-13.8	-0.67	4.48e-32	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg05255149	chr17:80675120	FN3KRP	-0.47	-6.14	-0.37	3.54e-9	Glycated hemoglobin levels;
SARC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg18402987	chr7:1209562	NA	0.44	5.68	0.35	4.05e-8	Longevity;Endometriosis;
SARC	cis	rs7412746	0.587	rs3849279	chr1:150944707	T/C	cg10589385	chr1:150898437	SETDB1	0.38	5.02	0.31	1.03e-6	Melanoma;
SARC	cis	rs7766436	0.583	rs6939360	chr6:22557097	C/T	cg13666174	chr6:22585274	NA	-0.6	-6.25	-0.38	1.89e-9	Coronary artery disease;
SARC	cis	rs7481584	0.564	rs7948848	chr11:2981896	G/A	cg25174290	chr11:3078921	CARS	-0.49	-6.83	-0.41	7.31e-11	Calcium levels;
SARC	cis	rs6963495	0.769	rs117986187	chr7:105167311	G/A	cg19920283	chr7:105172520	RINT1	0.66	5.62	0.35	5.45e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs11770686	0.570	rs2285873	chr7:75311021	C/T	cg17787366	chr7:75369077	HIP1	0.39	4.85	0.3	2.28e-6	Essential tremor;
SARC	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg16606324	chr3:10149918	C3orf24	0.49	4.82	0.3	2.56e-6	Alzheimer's disease;
SARC	cis	rs3796352	0.881	rs13100714	chr3:53074824	T/G	cg12962167	chr3:53033115	SFMBT1	0.71	4.97	0.31	1.28e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs9296092	0.522	rs62405955	chr6:33527176	T/C	cg13560919	chr6:33536144	NA	-0.52	-6.41	-0.39	8.07e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs17539620	0.624	rs62432735	chr6:154834055	T/C	cg17771515	chr6:154831774	CNKSR3	0.53	5.06	0.31	8.7e-7	Lipoprotein (a) levels;
SARC	cis	rs7826238	0.502	rs10503377	chr8:8378422	C/T	cg06636001	chr8:8085503	FLJ10661	0.54	5.55	0.34	7.85e-8	Systolic blood pressure;
SARC	cis	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg04055107	chr11:65626734	MUS81;CFL1	0.42	5.26	0.33	3.31e-7	Eosinophil percentage of white cells;
SARC	cis	rs79349575	0.749	rs2546491	chr17:46977916	A/G	cg16584676	chr17:46985605	UBE2Z	0.54	6.58	0.4	3.1e-10	Type 2 diabetes;
SARC	cis	rs6121246	0.567	rs6087701	chr20:30217708	A/C	cg21427119	chr20:30132790	HM13	-0.46	-5.05	-0.31	8.92e-7	Mean corpuscular hemoglobin;
SARC	cis	rs3817198	1.000	rs3817198	chr11:1909006	A/G	cg23636072	chr11:1216443	NA	0.35	4.88	0.3	1.93e-6	Breast cancer;Mammographic density (dense area);
SARC	cis	rs9902453	0.933	rs2054846	chr17:28507693	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.49	-6.21	-0.38	2.46e-9	Coffee consumption (cups per day);
SARC	cis	rs4853036	0.680	rs12612925	chr2:70112580	C/T	cg02498382	chr2:70120550	SNRNP27	-0.39	-4.75	-0.3	3.48e-6	Colorectal or endometrial cancer;
SARC	cis	rs9359856	0.564	rs1179902	chr6:90321545	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.66	-5.23	-0.32	3.79e-7	Bipolar disorder;
SARC	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg05368731	chr17:41323189	NBR1	-0.77	-9.26	-0.52	1.43e-17	Menopause (age at onset);
SARC	cis	rs809367	1.000	rs809367	chr10:89741806	A/G	cg06689259	chr10:90655537	STAMBPL1	0.49	4.91	0.31	1.68e-6	Parental extreme longevity (95 years and older);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg05959111	chr1:211999985	LPGAT1	0.5	7.64	0.45	5.7e-13	Thyroid stimulating hormone;
SARC	cis	rs4588572	0.644	rs1159930	chr5:77768943	C/T	cg18281939	chr5:77783895	LHFPL2	-0.35	-4.86	-0.3	2.18e-6	Triglycerides;
SARC	cis	rs35110281	0.744	rs162373	chr21:44927107	C/A	cg21573476	chr21:45109991	RRP1B	0.43	6.3	0.38	1.46e-9	Mean corpuscular volume;
SARC	cis	rs483180	0.512	rs612430	chr1:120216025	A/G	cg19096424	chr1:120255104	PHGDH	0.53	6.2	0.38	2.58e-9	Macular telangiectasia type 2;
SARC	cis	rs965469	0.779	rs6037548	chr20:3299299	G/A	cg25506879	chr20:3388711	C20orf194	-0.45	-4.96	-0.31	1.37e-6	IFN-related cytopenia;
SARC	cis	rs6696846	0.905	rs12117194	chr1:205040943	C/G	cg07972983	chr1:205091412	RBBP5	-0.42	-5.25	-0.33	3.46e-7	Red blood cell count;
SARC	cis	rs7520050	0.966	rs785491	chr1:46583418	G/A	cg24296786	chr1:45957014	TESK2	0.38	4.83	0.3	2.48e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs1008375	0.800	rs35463363	chr4:17613423	G/T	cg16339924	chr4:17578868	LAP3	0.65	8.4	0.48	4.42e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1401999	0.659	rs4912518	chr3:183752027	C/T	cg01324343	chr3:183735012	ABCC5	-0.62	-10.99	-0.58	6.56e-23	Anterior chamber depth;
SARC	cis	rs11122272	0.735	rs2572254	chr1:231512593	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-9.79	-0.54	3.66e-19	Hemoglobin concentration;
SARC	cis	rs9467773	1.000	rs9357010	chr6:26527945	C/G	cg11502198	chr6:26597334	ABT1	0.47	5.94	0.36	1.03e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9300255	0.739	rs10846491	chr12:123753492	C/G	cg05973401	chr12:123451056	ABCB9	0.44	4.76	0.3	3.41e-6	Neutrophil percentage of white cells;
SARC	cis	rs2290159	0.948	rs9852128	chr3:12635623	A/G	cg23032965	chr3:12705835	RAF1	0.67	7.15	0.42	1.09e-11	Cholesterol, total;
SARC	cis	rs9814567	0.806	rs4955526	chr3:134317337	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.5	-6.67	-0.4	1.81e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs57561814	1.000	rs6949149	chr7:22749157	G/T	cg26061582	chr7:22766209	IL6	1.09	8.4	0.48	4.33e-15	Tonsillectomy;
SARC	cis	rs2735413	0.918	rs4887932	chr16:78078350	C/A	cg04733911	chr16:78082701	NA	-0.31	-5.61	-0.34	5.78e-8	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs6942407	0.546	rs10952896	chr7:86765763	G/A	cg02420886	chr7:86849541	C7orf23	0.64	5.47	0.34	1.18e-7	Food allergy;
SARC	cis	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg25427524	chr10:38739819	LOC399744	-0.53	-8.44	-0.48	3.37e-15	Extrinsic epigenetic age acceleration;
SARC	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg22875332	chr1:76189707	ACADM	0.47	6.68	0.4	1.74e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs73206853	0.841	rs78843188	chr12:110827923	G/C	cg10860002	chr12:110842031	ANAPC7	0.63	5.03	0.31	9.95e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg00149659	chr3:10157352	C3orf10	0.64	6.01	0.37	7.21e-9	Alzheimer's disease;
SARC	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg11608241	chr8:8085544	FLJ10661	0.41	5.16	0.32	5.3e-7	Systolic blood pressure;
SARC	cis	rs17270561	0.636	rs4360128	chr6:25734558	A/G	cg17691542	chr6:26056736	HIST1H1C	0.58	7.09	0.42	1.6e-11	Iron status biomarkers;
SARC	cis	rs9304742	0.962	rs12459008	chr19:53454789	A/T	cg24044776	chr19:53454761	ZNF816A	0.41	5.82	0.36	1.95e-8	Psoriasis;
SARC	cis	rs3845702	0.736	rs3843323	chr2:180856459	T/C	cg01881094	chr2:180872142	CWC22	-1.14	-8.73	-0.5	5.07e-16	Schizophrenia;
SARC	cis	rs11690935	0.589	rs2271758	chr2:172701157	T/G	cg13550731	chr2:172543902	DYNC1I2	0.65	9.04	0.51	6.31e-17	Schizophrenia;
SARC	cis	rs7712401	0.601	rs35339188	chr5:122317685	A/T	cg19412675	chr5:122181750	SNX24	-0.43	-5.47	-0.34	1.15e-7	Mean platelet volume;
SARC	cis	rs9462027	0.628	rs9689820	chr6:34752963	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.85	-0.36	1.69e-8	Systemic lupus erythematosus;
SARC	cis	rs9398803	0.965	rs9388489	chr6:126698719	C/T	cg20229609	chr6:126660872	C6orf173	-0.41	-5.84	-0.36	1.71e-8	Male-pattern baldness;
SARC	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg11062466	chr8:58055876	NA	0.51	5.26	0.33	3.22e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs9951602	0.512	rs1599634	chr18:76643645	T/C	cg02800362	chr5:177631904	HNRNPAB	0.68	8.61	0.49	1.13e-15	Obesity-related traits;
SARC	cis	rs4803468	1.000	rs2241706	chr19:41912807	A/G	cg09537434	chr19:41945824	ATP5SL	-0.97	-16.94	-0.74	1.74e-42	Height;
SARC	cis	rs2228479	0.850	rs11647174	chr16:89958538	G/A	cg00800038	chr16:89945340	TCF25	-0.75	-5.23	-0.32	3.82e-7	Skin colour saturation;
SARC	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg02461776	chr11:598696	PHRF1	0.48	5.28	0.33	2.89e-7	Systemic lupus erythematosus;
SARC	cis	rs710216	0.957	rs2886876	chr1:43432741	A/G	cg22176566	chr1:43424700	SLC2A1	-0.51	-5.13	-0.32	6.12e-7	Red cell distribution width;
SARC	cis	rs3126085	1.000	rs72696989	chr1:152248674	A/C	cg03465714	chr1:152285911	FLG	0.46	4.84	0.3	2.31e-6	Atopic dermatitis;
SARC	cis	rs8017423	0.967	rs7150093	chr14:90724661	C/T	cg20276874	chr14:90721474	PSMC1	0.37	5.23	0.32	3.7e-7	Mortality in heart failure;
SARC	trans	rs7824557	0.527	rs2572369	chr8:11238597	C/T	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.73	-0.45	3.2e-13	Retinal vascular caliber;
SARC	cis	rs9457247	1.000	rs408918	chr6:167399282	G/T	cg23791538	chr6:167370224	RNASET2	-0.6	-8.24	-0.48	1.22e-14	Crohn's disease;
SARC	cis	rs9902453	0.904	rs4461132	chr17:28423430	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	7.08	0.42	1.73e-11	Coffee consumption (cups per day);
SARC	cis	rs644799	1.000	rs586498	chr11:95537828	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	14.15	0.68	3.08e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg07701084	chr6:150067640	NUP43	0.41	5.39	0.33	1.68e-7	Lung cancer;
SARC	cis	rs7927592	0.956	rs10896343	chr11:68317860	G/C	cg01657329	chr11:68192670	LRP5	-0.4	-4.76	-0.3	3.4e-6	Total body bone mineral density;
SARC	cis	rs7264396	0.790	rs2207889	chr20:34224898	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-7.98	-0.46	6.71e-14	Total cholesterol levels;
SARC	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg16049864	chr8:95962084	TP53INP1	-0.47	-7.63	-0.45	5.89e-13	Type 2 diabetes;
SARC	cis	rs12048904	0.505	rs6577209	chr1:101255080	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.68	7.87	0.46	1.31e-13	Multiple sclerosis;
SARC	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	5.99	0.37	7.8e-9	Height;
SARC	cis	rs6940638	0.688	rs9379960	chr6:27121325	A/C	cg12826209	chr6:26865740	GUSBL1	0.57	6.31	0.38	1.37e-9	Intelligence (multi-trait analysis);
SARC	cis	rs9911578	1.000	rs9892795	chr17:57023054	G/C	cg05425664	chr17:57184151	TRIM37	-0.66	-8.25	-0.48	1.17e-14	Intelligence (multi-trait analysis);
SARC	cis	rs9916302	0.904	rs7223331	chr17:37482930	A/G	cg00129232	chr17:37814104	STARD3	0.59	7.31	0.43	4.18e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs9325144	0.624	rs7312879	chr12:39150752	G/A	cg13010199	chr12:38710504	ALG10B	-0.49	-6.14	-0.37	3.46e-9	Morning vs. evening chronotype;
SARC	cis	rs7264396	0.790	rs6060565	chr20:34285442	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-8.17	-0.47	1.93e-14	Total cholesterol levels;
SARC	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg00825309	chr19:58991885	ZNF446	-0.55	-7.73	-0.45	3.15e-13	Uric acid clearance;
SARC	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg11644478	chr21:40555479	PSMG1	-0.9	-11.49	-0.6	1.65e-24	Cognitive function;
SARC	cis	rs78487399	0.710	rs79629200	chr2:43602932	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-4.85	-0.3	2.26e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs9309711	0.698	rs9750503	chr2:3491772	A/G	cg10845886	chr2:3471009	TTC15	0.6	7.09	0.42	1.63e-11	Neurofibrillary tangles;
SARC	cis	rs9807989	0.811	rs11688559	chr2:102969913	C/T	cg09003973	chr2:102972529	NA	0.41	5.57	0.34	7.03e-8	Asthma;
SARC	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg16479474	chr6:28041457	NA	-0.33	-5.33	-0.33	2.27e-7	Depression;
SARC	cis	rs651907	0.557	rs7629753	chr3:101371922	C/T	cg12386194	chr3:101231763	SENP7	-0.49	-5.82	-0.36	1.95e-8	Colorectal cancer;
SARC	cis	rs7179456	0.547	rs6494035	chr15:59015888	C/G	cg05156742	chr15:59063176	FAM63B	0.66	8.43	0.48	3.62e-15	Asperger disorder;
SARC	cis	rs9303401	0.592	rs66583824	chr17:56639853	C/T	cg25039879	chr17:56429692	SUPT4H1	0.67	6.21	0.38	2.4e-9	Cognitive test performance;
SARC	cis	rs7208859	0.673	rs11652370	chr17:29097223	G/A	cg13385521	chr17:29058706	SUZ12P	0.84	7.73	0.45	3.25e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg24034106	chr12:99039011	APAF1;IKBIP	-0.49	-6.37	-0.39	9.89e-10	Thyroid cancer;
SARC	cis	rs12153160	1.000	rs12515594	chr5:152955867	C/T	cg16532600	chr5:153857824	HAND1	0.51	4.8	0.3	2.85e-6	Middle childhood and early adolescence aggressive behavior;
SARC	cis	rs10752881	1.000	rs10752883	chr1:182980963	G/A	cg13390022	chr1:182993471	LAMC1	0.33	5.06	0.31	8.36e-7	Colorectal cancer;
SARC	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7246657	0.943	rs1559229	chr19:37876197	T/C	cg23950597	chr19:37808831	NA	-0.56	-5.69	-0.35	3.84e-8	Coronary artery calcification;
SARC	cis	rs67614146	1	rs67614146	chr6:87821827	AC/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.77	-11.26	-0.59	9.08e-24	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	trans	rs7937682	0.924	rs6589244	chr11:111534333	T/C	cg18187862	chr3:45730750	SACM1L	0.57	7.05	0.42	1.99e-11	Primary sclerosing cholangitis;
SARC	cis	rs2916247	0.954	rs2165905	chr8:93006556	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.58	-6.07	-0.37	5.24e-9	Intelligence (multi-trait analysis);
SARC	cis	rs12142240	0.698	rs17361819	chr1:46828109	A/G	cg14993813	chr1:46806288	NSUN4	-0.53	-5.62	-0.35	5.48e-8	Menopause (age at onset);
SARC	cis	rs7264396	0.563	rs2425088	chr20:34303902	C/A	cg01084648	chr20:34329383	RBM39	0.57	4.95	0.31	1.45e-6	Total cholesterol levels;
SARC	cis	rs8180040	0.620	rs11709660	chr3:47074927	G/A	cg27129171	chr3:47204927	SETD2	-0.7	-9.5	-0.53	2.59e-18	Colorectal cancer;
SARC	cis	rs7429990	0.965	rs62260764	chr3:47990500	G/C	cg11946769	chr3:48343235	NME6	0.65	6.79	0.41	9.49e-11	Educational attainment (years of education);
SARC	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg20503657	chr10:835505	NA	1.11	10.51	0.57	2.11e-21	Eosinophil percentage of granulocytes;
SARC	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg00149659	chr3:10157352	C3orf10	0.64	6.3	0.38	1.45e-9	Alzheimer's disease;
SARC	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg06028808	chr11:68637592	NA	0.45	5.64	0.35	5.02e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9381107	0.505	rs9369420	chr6:9486467	A/G	cg14735645	chr6:9486422	NA	0.47	5.75	0.35	2.73e-8	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg08677398	chr8:58056175	NA	-0.43	-5.07	-0.32	8.14e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg14893161	chr1:205819251	PM20D1	1.03	20.69	0.8	1.11e-54	Menarche (age at onset);
SARC	cis	rs916888	0.610	rs199446	chr17:44813169	G/A	cg01570182	chr17:44337453	NA	-0.67	-8.16	-0.47	2.07e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg14983838	chr19:29218262	NA	0.76	10.08	0.55	4.62e-20	Methadone dose in opioid dependence;
SARC	cis	rs7712401	0.623	rs30032	chr5:122238387	G/T	cg19412675	chr5:122181750	SNX24	0.41	5.15	0.32	5.53e-7	Mean platelet volume;
SARC	cis	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg13072238	chr3:49761600	GMPPB	-0.42	-5.54	-0.34	8.33e-8	Intelligence (multi-trait analysis);
SARC	cis	rs56011263	0.687	rs4690188	chr4:703930	G/C	cg17689763	chr4:710664	PCGF3	-0.67	-9.36	-0.52	6.99e-18	White blood cell count;
SARC	cis	rs2712184	0.756	rs2712181	chr2:217654869	C/T	cg05032264	chr2:217675019	NA	0.53	6.73	0.4	1.33e-10	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
SARC	cis	rs2832077	0.943	rs2272701	chr21:30190907	C/T	cg24692254	chr21:30365293	RNF160	-0.52	-4.78	-0.3	3.09e-6	Cognitive test performance;
SARC	cis	rs875971	0.545	rs75840613	chr7:65841386	G/A	cg11764359	chr7:65958608	NA	0.67	6.64	0.4	2.16e-10	Aortic root size;
SARC	cis	rs1348850	0.914	rs1453370	chr2:178327727	C/T	cg23306229	chr2:178417860	TTC30B	0.55	6.42	0.39	7.58e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs765787	0.530	rs2554456	chr15:45521138	A/C	cg26924012	chr15:45694286	SPATA5L1	-0.41	-5.08	-0.32	7.58e-7	Uric acid levels;
SARC	cis	rs2153535	0.580	rs1932276	chr6:8442593	G/A	cg07606381	chr6:8435919	SLC35B3	0.78	11.09	0.59	3.11e-23	Motion sickness;
SARC	trans	rs6894249	1.000	rs6894249	chr5:131797547	A/G	cg21331821	chr19:58545149	ZSCAN1	-0.47	-6.65	-0.4	2.06e-10	Asthma;
SARC	cis	rs9314323	0.524	rs7816609	chr8:26202482	A/C	cg11498726	chr8:26250323	BNIP3L	-0.41	-4.94	-0.31	1.49e-6	Red cell distribution width;
SARC	cis	rs10276381	0.786	rs10255700	chr7:28220228	C/T	cg23620719	chr7:28220237	JAZF1	0.77	5.89	0.36	1.33e-8	Crohn's disease;
SARC	cis	rs514024	0.765	rs497632	chr9:130475442	A/C	cg13643465	chr9:130375613	STXBP1	0.4	5.05	0.31	8.93e-7	Eating disorders (purging via substances);
SARC	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg26818010	chr10:134567672	INPP5A	-0.64	-6.89	-0.41	5.14e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	trans	rs7824557	0.767	rs7837036	chr8:11175489	A/G	cg06636001	chr8:8085503	FLJ10661	0.59	7.21	0.43	7.84e-12	Retinal vascular caliber;
SARC	cis	rs11770686	0.666	rs2269885	chr7:75308569	C/T	cg17787366	chr7:75369077	HIP1	0.39	5.03	0.31	9.98e-7	Essential tremor;
SARC	cis	rs11676348	0.838	rs17844697	chr2:218999255	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.48	-6.17	-0.37	3.05e-9	Ulcerative colitis;
SARC	cis	rs3824867	0.879	rs4752837	chr11:47465955	G/A	cg20307385	chr11:47447363	PSMC3	0.48	5.24	0.32	3.68e-7	Mean corpuscular hemoglobin;
SARC	cis	rs7666738	0.830	rs4334758	chr4:98971875	A/G	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs76693355	0.512	rs11217874	chr11:120325548	G/A	cg15690696	chr11:120217718	ARHGEF12	-0.39	-4.8	-0.3	2.86e-6	Intraocular pressure;
SARC	cis	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg18200150	chr17:30822561	MYO1D	-0.46	-7.08	-0.42	1.72e-11	Schizophrenia;
SARC	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg04317338	chr11:64019027	PLCB3	0.61	7.07	0.42	1.84e-11	Platelet count;
SARC	cis	rs1707322	0.827	rs6694302	chr1:46245645	A/T	cg06784218	chr1:46089804	CCDC17	0.35	6.29	0.38	1.59e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7824557	0.606	rs2736264	chr8:11186639	G/C	cg21775007	chr8:11205619	TDH	0.67	9.0	0.51	7.97e-17	Retinal vascular caliber;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg07429394	chr1:153918709	DENND4B	-0.5	-6.33	-0.38	1.27e-9	Height;
SARC	cis	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.76	-0.45	2.73e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs12956009	0.518	rs983095	chr18:44899258	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	7.64	0.45	5.68e-13	Educational attainment (years of education);
SARC	trans	rs61931739	0.534	rs2625897	chr12:34064295	G/A	cg26384229	chr12:38710491	ALG10B	0.73	10.04	0.55	6.12e-20	Morning vs. evening chronotype;
SARC	cis	rs3733585	0.673	rs9994266	chr4:9954450	C/T	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.23	-0.32	3.85e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs2933343	1.000	rs1680795	chr3:128620388	T/C	cg24203234	chr3:128598194	ACAD9	0.54	5.99	0.37	8e-9	IgG glycosylation;
SARC	cis	rs77633900	0.614	rs2170998	chr15:77007159	C/T	cg21673338	chr15:77095150	SCAPER	0.65	5.8	0.35	2.2e-8	Non-glioblastoma glioma;Glioma;
SARC	cis	rs920590	0.758	rs62496731	chr8:19659543	C/G	cg01411142	chr8:19674711	INTS10	0.52	6.05	0.37	5.72e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs858239	0.601	rs764533	chr7:23153875	C/T	cg23682824	chr7:23144976	KLHL7	0.71	9.25	0.52	1.53e-17	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9314323	0.964	rs2304300	chr8:26249018	G/A	cg11498726	chr8:26250323	BNIP3L	-0.62	-8.21	-0.47	1.53e-14	Red cell distribution width;
SARC	cis	rs6502050	0.787	rs8080682	chr17:80058901	G/A	cg13939156	chr17:80058883	NA	0.42	6.72	0.4	1.36e-10	Life satisfaction;
SARC	cis	rs698833	0.926	rs786624	chr2:44604941	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.61	-7.64	-0.45	5.78e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs3796352	0.892	rs35076015	chr3:53026366	C/T	cg12962167	chr3:53033115	SFMBT1	0.82	5.4	0.33	1.61e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2070997	0.607	rs7856783	chr9:133713507	T/C	cg11464064	chr9:133710261	ABL1	0.63	6.12	0.37	4.01e-9	Response to amphetamines;
SARC	cis	rs1448094	0.842	rs7966352	chr12:86438705	A/C	cg02569458	chr12:86230093	RASSF9	0.38	5.49	0.34	1.03e-7	Major depressive disorder;
SARC	cis	rs9814567	0.686	rs1404289	chr3:134358109	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.48	6.08	0.37	5e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs6540556	0.723	rs12060420	chr1:209906819	T/G	cg05527609	chr1:210001259	C1orf107	-0.65	-6.23	-0.38	2.15e-9	Red blood cell count;
SARC	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg06558623	chr16:89946397	TCF25	-0.63	-5.53	-0.34	8.58e-8	Skin colour saturation;
SARC	cis	rs9916302	0.595	rs4795371	chr17:37636695	T/G	cg00129232	chr17:37814104	STARD3	-0.64	-7.65	-0.45	5.28e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg06221963	chr1:154839813	KCNN3	-0.45	-6.92	-0.41	4.42e-11	Prostate cancer;
SARC	cis	rs3888647	0.622	rs4758618	chr11:2995186	A/T	cg08508325	chr11:3079039	CARS	-0.32	-7.91	-0.46	1.05e-13	Type 2 diabetes;
SARC	cis	rs7224737	1.000	rs9889618	chr17:40293467	C/T	cg20291162	chr17:40259547	DHX58	-0.33	-4.85	-0.3	2.24e-6	Fibrinogen levels;
SARC	cis	rs3087591	1.000	rs9902427	chr17:29625430	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.55	-6.76	-0.4	1.1e-10	Hip circumference;
SARC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg21280719	chr6:42927975	GNMT	-0.47	-8.15	-0.47	2.22e-14	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs7000551	0.725	rs2249102	chr8:22400193	C/G	cg12081754	chr8:22256438	SLC39A14	0.57	7.84	0.46	1.59e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg24110177	chr3:50126178	RBM5	-0.6	-7.89	-0.46	1.18e-13	Intelligence (multi-trait analysis);
SARC	cis	rs741702	0.890	rs2967897	chr19:13031210	T/C	cg11738485	chr19:12877000	HOOK2	0.43	4.73	0.3	3.89e-6	Red blood cell traits;
SARC	cis	rs3126085	0.825	rs11204938	chr1:152193990	A/G	cg03465714	chr1:152285911	FLG	-0.48	-5.85	-0.36	1.63e-8	Atopic dermatitis;
SARC	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg10591111	chr5:226296	SDHA	-0.56	-5.08	-0.32	7.89e-7	Breast cancer;
SARC	cis	rs12586317	0.620	rs28404080	chr14:35539418	G/T	cg05294307	chr14:35346193	BAZ1A	-0.47	-4.72	-0.3	4.03e-6	Psoriasis;
SARC	cis	rs7208859	0.623	rs57486336	chr17:29085731	G/T	cg13385521	chr17:29058706	SUZ12P	0.9	7.81	0.46	1.96e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg18876405	chr7:65276391	NA	0.54	6.76	0.41	1.07e-10	Calcium levels;
SARC	cis	rs2952156	0.920	rs2517953	chr17:37841211	G/C	cg20243544	chr17:37824526	PNMT	0.55	7.13	0.42	1.27e-11	Asthma;
SARC	cis	rs559928	0.606	rs57021319	chr11:63956102	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.67	5.04	0.31	9.14e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs8180040	0.764	rs13062022	chr3:47169375	G/A	cg27129171	chr3:47204927	SETD2	0.67	9.54	0.53	2.03e-18	Colorectal cancer;
SARC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg10295955	chr4:187884368	NA	-1.04	-17.49	-0.75	2.6e-44	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg18876405	chr7:65276391	NA	-0.43	-4.72	-0.3	4.07e-6	Aortic root size;
SARC	cis	rs7264396	0.563	rs6060566	chr20:34288226	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.6	5.56	0.34	7.46e-8	Total cholesterol levels;
SARC	cis	rs7927771	0.864	rs2293577	chr11:47437202	C/T	cg20307385	chr11:47447363	PSMC3	0.6	7.61	0.45	6.72e-13	Subjective well-being;
SARC	trans	rs459571	0.959	rs455381	chr9:136905577	C/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.59	-6.57	-0.4	3.29e-10	Platelet distribution width;
SARC	cis	rs5167	0.525	rs11083752	chr19:45454363	G/A	cg13119609	chr19:45449297	APOC2	0.5	8.44	0.48	3.42e-15	Blood protein levels;
SARC	cis	rs8016982	0.633	rs55822231	chr14:81708677	C/T	cg01989461	chr14:81687754	GTF2A1	0.71	10.43	0.56	3.66e-21	Schizophrenia;
SARC	cis	rs78487399	0.908	rs6759861	chr2:43805608	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.49	-4.75	-0.3	3.51e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg12756686	chr19:29218302	NA	0.68	8.91	0.5	1.46e-16	Methadone dose in opioid dependence;
SARC	cis	rs9790314	0.846	rs7627528	chr3:160990878	A/G	cg04691961	chr3:161091175	C3orf57	-0.64	-8.76	-0.5	4.21e-16	Morning vs. evening chronotype;
SARC	cis	rs1707322	0.964	rs796773	chr1:46564475	C/T	cg03146154	chr1:46216737	IPP	-0.48	-5.8	-0.36	2.13e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs854765	0.547	rs2955378	chr17:17930253	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.43	5.5	0.34	9.88e-8	Total body bone mineral density;
SARC	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg03060546	chr3:49711283	APEH	0.42	5.24	0.32	3.51e-7	Parkinson's disease;
SARC	cis	rs17174870	0.738	rs6760032	chr2:112815290	C/G	cg09651315	chr2:112641899	ANAPC1	-0.42	-4.77	-0.3	3.23e-6	Multiple sclerosis;
SARC	cis	rs7539542	0.556	rs10732292	chr1:202891366	T/C	cg08940984	chr1:202857613	RABIF	0.37	4.99	0.31	1.21e-6	Mean platelet volume;
SARC	cis	rs9911578	0.935	rs420878	chr17:56709077	A/G	cg05425664	chr17:57184151	TRIM37	-0.68	-8.49	-0.49	2.48e-15	Intelligence (multi-trait analysis);
SARC	cis	rs4423214	0.879	rs4945008	chr11:71221248	A/G	cg24826892	chr11:71159390	DHCR7	0.45	5.57	0.34	6.95e-8	Vitamin D levels;
SARC	cis	rs854765	0.547	rs6502632	chr17:17913057	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.46	5.95	0.36	9.79e-9	Total body bone mineral density;
SARC	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs995000	0.965	rs10789119	chr1:63098235	G/A	cg06896770	chr1:63153194	DOCK7	0.98	15.08	0.7	2.62e-36	Triglyceride levels;
SARC	cis	rs7726839	0.540	rs7434	chr5:660804	A/G	cg07777115	chr5:623756	CEP72	0.54	4.96	0.31	1.39e-6	Obesity-related traits;
SARC	cis	rs7084402	0.967	rs1649049	chr10:60324095	G/A	cg07615347	chr10:60278583	BICC1	0.6	8.78	0.5	3.68e-16	Refractive error;
SARC	cis	rs9325144	0.560	rs61929893	chr12:38653366	G/A	cg26384229	chr12:38710491	ALG10B	-0.63	-8.12	-0.47	2.64e-14	Morning vs. evening chronotype;
SARC	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg18404041	chr3:52824283	ITIH1	-0.4	-6.0	-0.37	7.68e-9	Electroencephalogram traits;
SARC	cis	rs4427176	0.769	rs35039536	chr8:9578146	T/C	cg21625330	chr8:9911636	MSRA	-0.55	-4.71	-0.3	4.19e-6	Mosquito bite size;
SARC	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	11.6	0.61	7.26e-25	Alzheimer's disease;
SARC	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg11764359	chr7:65958608	NA	0.59	6.98	0.42	3.1e-11	Aortic root size;
SARC	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg11644478	chr21:40555479	PSMG1	-0.59	-7.16	-0.42	1.06e-11	Menarche (age at onset);
SARC	cis	rs7940866	0.774	rs10894292	chr11:130820757	C/T	cg12179176	chr11:130786555	SNX19	0.68	9.47	0.53	3.29e-18	Schizophrenia;
SARC	cis	rs10875746	0.903	rs12315625	chr12:48472453	G/A	cg26205652	chr12:48591994	NA	0.56	6.05	0.37	5.72e-9	Longevity (90 years and older);
SARC	cis	rs7027203	0.828	rs3957506	chr9:96588133	C/T	cg13679303	chr9:96623674	NA	-0.35	-5.07	-0.32	8.12e-7	DNA methylation (variation);
SARC	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-9.19	-0.52	2.21e-17	Chronic sinus infection;
SARC	cis	rs607987	0.836	rs4267046	chr11:30282779	A/C	cg06241208	chr11:30344200	C11orf46	0.41	4.97	0.31	1.31e-6	Body mass index;
SARC	cis	rs2997447	0.846	rs3008230	chr1:26401331	A/G	cg19633962	chr1:26362018	EXTL1	-0.59	-5.11	-0.32	6.82e-7	QRS complex (12-leadsum);
SARC	cis	rs12477438	0.765	rs7571390	chr2:99626593	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-10.0	-0.55	7.93e-20	Chronic sinus infection;
SARC	cis	rs6088580	0.634	rs6120666	chr20:33090718	A/G	cg24642439	chr20:33292090	TP53INP2	0.68	8.88	0.5	1.87e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs7582720	1.000	rs72936309	chr2:204040296	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	7.84	0.46	1.65e-13	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs12477438	0.765	rs12470471	chr2:99689141	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.58	7.53	0.44	1.08e-12	Chronic sinus infection;
SARC	cis	rs7223966	1.000	rs8073373	chr17:61703320	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.56	-6.52	-0.39	4.4e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs11676348	0.808	rs12694430	chr2:219015799	T/C	cg00012203	chr2:219082015	ARPC2	-0.41	-5.36	-0.33	2.02e-7	Ulcerative colitis;
SARC	cis	rs1113500	0.933	rs1419003	chr1:108616955	A/C	cg06207961	chr1:108661230	NA	0.45	5.93	0.36	1.07e-8	Growth-regulated protein alpha levels;
SARC	cis	rs6120849	0.754	rs3818253	chr20:33596876	C/T	cg06115741	chr20:33292138	TP53INP2	0.58	5.5	0.34	1e-7	Protein C levels;
SARC	cis	rs67460515	0.665	rs28384382	chr3:160939141	C/T	cg04691961	chr3:161091175	C3orf57	-0.46	-5.58	-0.34	6.81e-8	Parkinson's disease;
SARC	cis	rs11105298	0.891	rs11105313	chr12:89923376	A/T	cg08166232	chr12:89918718	WDR51B;GALNT4	0.52	5.22	0.32	3.88e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs7223966	0.729	rs2003549	chr17:62008437	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	6.38	0.39	9.65e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1348850	0.558	rs4337505	chr2:178529714	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.41	4.8	0.3	2.85e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	trans	rs3780486	0.522	rs1328898	chr9:33163271	A/G	cg04842962	chr6:43655489	MRPS18A	0.88	12.37	0.63	2.34e-27	IgG glycosylation;
SARC	cis	rs12155623	0.668	rs6472114	chr8:49789561	T/C	cg22283653	chr8:49824208	NA	-0.53	-8.11	-0.47	2.91e-14	Sudden cardiac arrest;
SARC	cis	rs7552404	0.889	rs2211080	chr1:76243438	G/A	cg03433033	chr1:76189801	ACADM	0.49	6.7	0.4	1.59e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs8067545	0.586	rs8080649	chr17:20069677	G/C	cg13482628	chr17:19912719	NA	0.56	7.36	0.43	3.08e-12	Schizophrenia;
SARC	cis	rs4727027	0.933	rs917122	chr7:148848257	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	5.6	0.34	5.91e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs12142240	0.698	rs1057535	chr1:46815898	T/C	cg10495392	chr1:46806563	NSUN4	0.65	6.83	0.41	7.25e-11	Menopause (age at onset);
SARC	trans	rs9951602	0.512	rs9304070	chr18:76654890	A/C	cg02800362	chr5:177631904	HNRNPAB	0.63	7.9	0.46	1.07e-13	Obesity-related traits;
SARC	cis	rs9790314	0.715	rs898681	chr3:160773098	A/G	cg04691961	chr3:161091175	C3orf57	-0.61	-8.23	-0.47	1.32e-14	Morning vs. evening chronotype;
SARC	cis	rs13401104	0.796	rs60159414	chr2:237119178	T/C	cg19324714	chr2:237145437	ASB18	0.57	5.66	0.35	4.32e-8	Educational attainment;
SARC	cis	rs2250402	0.510	rs7535	chr15:40328575	G/C	cg01081584	chr15:40268610	EIF2AK4	-0.7	-5.98	-0.36	8.53e-9	Corneal curvature;
SARC	cis	rs9443189	0.570	rs569731	chr6:76357593	G/A	cg01950844	chr6:76311363	SENP6	0.85	8.16	0.47	2.07e-14	Prostate cancer;
SARC	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg02951883	chr7:2050386	MAD1L1	-0.48	-6.37	-0.38	1.02e-9	Schizophrenia;
SARC	cis	rs6963495	0.818	rs73192125	chr7:105175068	A/C	cg13798780	chr7:105162888	PUS7	0.58	5.39	0.33	1.75e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs17102884	0.506	rs4899541	chr14:75403437	T/G	cg06637938	chr14:75390232	RPS6KL1	-0.41	-5.45	-0.34	1.25e-7	Neuroticism;
SARC	cis	rs6120849	0.901	rs6060266	chr20:33733078	T/C	cg24642439	chr20:33292090	TP53INP2	0.57	5.79	0.35	2.26e-8	Protein C levels;
SARC	cis	rs9462027	0.606	rs2815001	chr6:34634353	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-6.02	-0.37	6.85e-9	Systemic lupus erythematosus;
SARC	cis	rs13401104	1.000	rs13401104	chr2:237105518	C/T	cg19324714	chr2:237145437	ASB18	0.52	4.85	0.3	2.22e-6	Educational attainment;
SARC	cis	rs7647973	0.710	rs6797299	chr3:49609794	G/T	cg03060546	chr3:49711283	APEH	0.72	6.71	0.4	1.44e-10	Menarche (age at onset);
SARC	cis	rs712039	0.652	rs853222	chr17:35790022	G/T	cg16670864	chr17:35848621	DUSP14	0.46	5.06	0.31	8.59e-7	Tuberculosis;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg02573089	chr17:57233042	PRR11;SKA2	0.48	6.36	0.38	1.07e-9	Thyroid stimulating hormone;
SARC	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg05793240	chr7:2802953	GNA12	-0.37	-5.33	-0.33	2.34e-7	Height;
SARC	cis	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg07541023	chr7:19748670	TWISTNB	-0.44	-5.68	-0.35	4e-8	Thyroid stimulating hormone;
SARC	cis	rs131777	0.575	rs131760	chr22:51011936	T/C	cg02245810	chr22:51017432	CPT1B;CHKB;CHKB-CPT1B	0.31	4.95	0.31	1.42e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs1355223	0.902	rs448016	chr11:34706593	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.39	4.91	0.31	1.72e-6	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs611744	0.934	rs609102	chr8:109227406	A/G	cg21045802	chr8:109455806	TTC35	0.44	5.26	0.33	3.18e-7	Dupuytren's disease;
SARC	cis	rs9831754	1.000	rs1028024	chr3:78371577	A/C	cg06138941	chr3:78371609	NA	-0.58	-6.9	-0.41	4.79e-11	Calcium levels;
SARC	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg18357526	chr6:26021779	HIST1H4A	0.46	5.89	0.36	1.34e-8	Blood metabolite levels;
SARC	cis	rs8141529	0.529	rs5762816	chr22:29206209	T/C	cg02153584	chr22:29168773	CCDC117	0.66	6.58	0.4	3.11e-10	Lymphocyte counts;
SARC	cis	rs2439831	1.000	rs28666488	chr15:43741090	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.81	8.49	0.49	2.5e-15	Lung cancer in ever smokers;
SARC	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg10664184	chr19:17420304	DDA1	-0.48	-5.13	-0.32	6.05e-7	Systemic lupus erythematosus;
SARC	cis	rs10911232	0.507	rs4072709	chr1:183028855	C/T	cg13390022	chr1:182993471	LAMC1	0.34	5.18	0.32	4.78e-7	Hypertriglyceridemia;
SARC	cis	rs35213789	0.722	rs41851	chr7:69013219	G/T	cg10619644	chr7:69149951	AUTS2	-0.4	-5.16	-0.32	5.35e-7	Childhood ear infection;
SARC	cis	rs12478296	1.000	rs7420157	chr2:243005204	G/A	cg06360820	chr2:242988706	NA	-0.7	-6.45	-0.39	6.25e-10	Obesity-related traits;
SARC	cis	rs8180040	0.934	rs12630641	chr3:47534836	G/T	cg27129171	chr3:47204927	SETD2	0.68	9.36	0.52	6.78e-18	Colorectal cancer;
SARC	cis	rs9467773	1.000	rs6926629	chr6:26499903	T/C	cg12292205	chr6:26970375	C6orf41	0.43	5.25	0.33	3.5e-7	Intelligence (multi-trait analysis);
SARC	cis	rs3796352	1.000	rs13076033	chr3:52898427	T/C	cg15956490	chr3:53032818	SFMBT1	0.92	5.99	0.37	8.04e-9	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs8060686	0.545	rs10500543	chr16:68281311	T/C	cg27539214	chr16:67997921	SLC12A4	-0.59	-5.76	-0.35	2.67e-8	HDL cholesterol;Metabolic syndrome;
SARC	cis	rs17001868	0.568	rs9611315	chr22:40736900	A/T	cg07138101	chr22:40742427	ADSL	0.54	5.94	0.36	1.01e-8	Mammographic density (dense area);
SARC	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg08219700	chr8:58056026	NA	0.47	5.01	0.31	1.07e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs9346455	0.614	rs9364151	chr6:71997071	T/C	cg27238071	chr6:71998145	OGFRL1	0.56	4.77	0.3	3.29e-6	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
SARC	cis	rs8180040	0.726	rs4682837	chr3:46999707	C/T	cg27129171	chr3:47204927	SETD2	0.67	9.23	0.52	1.69e-17	Colorectal cancer;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg18927181	chr12:29787945	TMTC1	0.44	6.37	0.39	9.88e-10	Thyroid stimulating hormone;
SARC	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg11502198	chr6:26597334	ABT1	0.66	8.92	0.5	1.41e-16	Intelligence (multi-trait analysis);
SARC	cis	rs10791323	0.633	rs2171006	chr11:133728323	T/C	cg14349672	chr11:133703707	NA	-0.32	-4.83	-0.3	2.5e-6	Childhood ear infection;
SARC	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg09699651	chr6:150184138	LRP11	0.5	5.81	0.36	2.03e-8	Lung cancer;
SARC	cis	rs2295359	1.000	rs12043240	chr1:67624304	C/T	cg11235152	chr1:67600687	NA	0.47	6.9	0.41	4.83e-11	Psoriasis;
SARC	cis	rs10463554	0.759	rs34815	chr5:102434265	C/T	cg23492399	chr5:102201601	PAM	-0.53	-5.73	-0.35	3.04e-8	Parkinson's disease;
SARC	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg18876405	chr7:65276391	NA	-0.48	-5.9	-0.36	1.24e-8	Aortic root size;
SARC	cis	rs963731	0.649	rs4142729	chr2:39222915	A/G	cg04010122	chr2:39346883	SOS1	-0.82	-5.02	-0.31	1e-6	Corticobasal degeneration;
SARC	cis	rs73206853	0.698	rs871922	chr12:111114942	T/C	cg10860002	chr12:110842031	ANAPC7	0.58	5.01	0.31	1.1e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg08564027	chr20:61660810	NA	0.76	11.8	0.61	1.69e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs6580649	0.941	rs1793933	chr12:48396450	G/T	cg05342945	chr12:48394962	COL2A1	-0.56	-5.73	-0.35	3.02e-8	Lung cancer;
SARC	cis	rs1843834	0.574	rs6436499	chr2:225456551	A/T	cg12698349	chr2:225449008	CUL3	0.65	7.95	0.46	7.87e-14	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs7084402	0.967	rs3001714	chr10:60285494	A/G	cg07615347	chr10:60278583	BICC1	0.59	8.56	0.49	1.58e-15	Refractive error;
SARC	cis	rs7551222	0.752	rs4951400	chr1:204534571	C/G	cg20240347	chr1:204465584	NA	-0.33	-5.76	-0.35	2.6e-8	Schizophrenia;
SARC	cis	rs6598163	0.700	rs12813179	chr12:132302228	C/G	cg07389463	chr12:132296394	NA	0.37	5.51	0.34	9.25e-8	Migraine;
SARC	cis	rs17376456	0.825	rs17372725	chr5:93135588	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.72	6.77	0.41	1.06e-10	Diabetic retinopathy;
SARC	trans	rs9388451	1.000	rs9388451	chr6:126090377	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.55	-7.14	-0.42	1.15e-11	Brugada syndrome;
SARC	cis	rs9916302	0.706	rs801427	chr17:37436711	A/G	cg00129232	chr17:37814104	STARD3	-0.56	-6.07	-0.37	5.25e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs5760092	0.755	rs6003959	chr22:24264395	C/T	cg11141652	chr22:24348549	GSTTP1	-0.49	-5.26	-0.33	3.18e-7	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs2153535	0.580	rs7341201	chr6:8470270	T/C	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg08859206	chr1:53392774	SCP2	-0.39	-5.55	-0.34	7.87e-8	Monocyte count;
SARC	cis	rs12926788	0.689	rs1862450	chr16:24856775	A/G	cg00339695	chr16:24857497	SLC5A11	-0.36	-4.87	-0.3	2.07e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs765787	0.530	rs4331289	chr15:45515338	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.43	-5.39	-0.33	1.73e-7	Uric acid levels;
SARC	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg11644478	chr21:40555479	PSMG1	-0.99	-14.07	-0.68	6.03e-33	Cognitive function;
SARC	cis	rs7552404	0.731	rs10732723	chr1:76392437	C/T	cg03433033	chr1:76189801	ACADM	-0.46	-5.65	-0.35	4.56e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs10781543	0.763	rs10781539	chr9:139320965	G/A	cg14169450	chr9:139327907	INPP5E	0.44	6.2	0.38	2.59e-9	Monocyte percentage of white cells;
SARC	cis	rs3749237	0.555	rs2117939	chr3:49415179	C/A	cg07636037	chr3:49044803	WDR6	0.62	8.07	0.47	3.76e-14	Resting heart rate;
SARC	cis	rs2276314	0.857	rs4799409	chr18:33592602	C/T	cg19628046	chr18:33552617	C18orf21	0.58	5.87	0.36	1.51e-8	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg00933542	chr6:150070202	PCMT1	0.32	5.4	0.33	1.68e-7	Lung cancer;
SARC	cis	rs2857078	0.745	rs4793085	chr17:42320732	A/C	cg13607699	chr17:42295918	UBTF	-0.86	-13.55	-0.66	3.08e-31	Red cell distribution width;Reticulocyte count;
SARC	cis	rs5753618	0.509	rs5749229	chr22:31587218	T/C	cg07713946	chr22:31675144	LIMK2	-0.38	-5.29	-0.33	2.76e-7	Colorectal cancer;
SARC	cis	rs2898681	0.519	rs6848200	chr4:53730181	A/G	cg00338735	chr4:53728038	RASL11B	0.49	5.41	0.33	1.57e-7	Optic nerve measurement (cup area);
SARC	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg03575189	chr17:44344142	NA	-0.53	-5.2	-0.32	4.37e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs2882877	0.648	rs17198955	chr2:190387243	C/T	cg21926118	chr2:190387206	NA	0.41	5.09	0.32	7.35e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs2046867	0.818	rs17690720	chr3:72866030	T/C	cg25664220	chr3:72788482	NA	-0.29	-4.77	-0.3	3.27e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
SARC	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.62	-6.33	-0.38	1.24e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.45	0.56	3.22e-21	Prudent dietary pattern;
SARC	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg08280861	chr8:58055591	NA	0.7	5.74	0.35	2.91e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs965469	1.000	rs6051724	chr20:3279338	T/C	cg25506879	chr20:3388711	C20orf194	-0.47	-4.76	-0.3	3.42e-6	IFN-related cytopenia;
SARC	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg12373951	chr3:133503437	NA	-0.37	-5.34	-0.33	2.21e-7	Iron status biomarkers;
SARC	cis	rs11874712	1.000	rs11872985	chr18:43686578	A/G	cg25174615	chr18:43684699	ATP5A1;HAUS1	0.42	4.91	0.31	1.68e-6	Migraine - clinic-based;
SARC	cis	rs2014572	0.967	rs10426174	chr19:57756055	G/A	cg24459738	chr19:57751996	ZNF805	-0.47	-5.58	-0.34	6.62e-8	Hyperactive-impulsive symptoms;
SARC	cis	rs10097215	1.000	rs10097215	chr8:2506899	A/G	cg08586913	chr8:1897020	ARHGEF10	0.52	4.77	0.3	3.26e-6	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
SARC	cis	rs10875746	0.903	rs11168420	chr12:48515896	C/T	cg27446233	chr12:48516484	PFKM	-0.41	-4.78	-0.3	3.06e-6	Longevity (90 years and older);
SARC	cis	rs7829975	0.514	rs2979139	chr8:8268313	A/G	cg08975724	chr8:8085496	FLJ10661	0.54	6.51	0.39	4.67e-10	Mood instability;
SARC	cis	rs67311347	0.956	rs11714871	chr3:40428938	T/G	cg24209194	chr3:40518798	ZNF619	0.59	7.37	0.43	3.02e-12	Renal cell carcinoma;
SARC	cis	rs7223966	0.961	rs35844156	chr17:61837568	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.49	-4.95	-0.31	1.44e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	7.77	0.45	2.56e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs734999	0.588	rs3748817	chr1:2525665	T/C	cg18854424	chr1:2615690	NA	0.33	5.22	0.32	3.88e-7	Ulcerative colitis;
SARC	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg23806715	chr17:73775811	H3F3B	0.54	5.6	0.34	6.04e-8	Psoriasis;
SARC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.44	0.53	4.06e-18	Prudent dietary pattern;
SARC	cis	rs6570726	0.791	rs370112	chr6:145859853	T/G	cg23711669	chr6:146136114	FBXO30	0.87	14.7	0.69	4.63e-35	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.65	0.53	9.21e-19	Prudent dietary pattern;
SARC	cis	rs10504229	0.679	rs16921683	chr8:58053270	T/C	cg08280861	chr8:58055591	NA	0.56	5.13	0.32	6.02e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7819412	0.502	rs11777918	chr8:11036919	A/G	cg21775007	chr8:11205619	TDH	0.4	4.96	0.31	1.35e-6	Triglycerides;
SARC	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg09699651	chr6:150184138	LRP11	0.39	4.82	0.3	2.59e-6	Lung cancer;
SARC	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg11766577	chr21:47581405	C21orf56	0.43	5.03	0.31	9.88e-7	Testicular germ cell tumor;
SARC	cis	rs4280164	1.000	rs4280164	chr14:24771285	G/A	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.58	-5.46	-0.34	1.24e-7	Parent of origin effect on language impairment (paternal);
SARC	cis	rs7819412	0.505	rs17782536	chr8:11021682	A/G	cg12395012	chr8:11607386	GATA4	0.29	4.94	0.31	1.5e-6	Triglycerides;
SARC	cis	rs1348850	0.914	rs10170667	chr2:178336878	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.72	9.15	0.51	2.9e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs6570726	1.000	rs436066	chr6:145847127	C/T	cg23711669	chr6:146136114	FBXO30	0.77	11.8	0.61	1.68e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1003719	0.680	rs7276569	chr21:38578207	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-8.88	-0.5	1.88e-16	Eye color traits;
SARC	cis	rs4253772	0.591	rs6007727	chr22:46650959	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.64	6.81	0.41	8.27e-11	LDL cholesterol;Cholesterol, total;
SARC	cis	rs2033732	0.643	rs9643459	chr8:85058753	A/G	cg05716166	chr8:85095498	RALYL	0.47	5.62	0.35	5.51e-8	Body mass index;
SARC	cis	rs12142240	0.667	rs41293287	chr1:46808852	C/T	cg00530320	chr1:46809349	NSUN4	0.58	7.07	0.42	1.74e-11	Menopause (age at onset);
SARC	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	13.6	0.67	2.11e-31	Chronic sinus infection;
SARC	cis	rs10744422	0.858	rs7980541	chr12:123379477	C/T	cg25930673	chr12:123319894	HIP1R	-0.65	-4.73	-0.3	3.87e-6	Schizophrenia;
SARC	cis	rs921968	0.678	rs2230115	chr2:219509618	C/A	cg02176678	chr2:219576539	TTLL4	0.35	5.26	0.33	3.2e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs9517313	0.615	rs4772079	chr13:99090837	C/G	cg03461548	chr13:99121358	STK24	-0.38	-4.82	-0.3	2.58e-6	Neuroticism;
SARC	cis	rs1707322	1.000	rs11211232	chr1:46411146	C/T	cg03146154	chr1:46216737	IPP	0.48	5.81	0.36	2.08e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6009527	0.752	rs7288176	chr22:49568462	A/G	cg12746016	chr22:49560550	NA	-0.33	-5.79	-0.35	2.26e-8	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
SARC	cis	rs9911578	0.967	rs405684	chr17:56777148	T/C	cg12560992	chr17:57184187	TRIM37	0.83	11.24	0.59	1.02e-23	Intelligence (multi-trait analysis);
SARC	cis	rs2204008	0.905	rs8189449	chr12:38437377	C/A	cg13010199	chr12:38710504	ALG10B	0.72	9.15	0.51	3.01e-17	Bladder cancer;
SARC	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg20607798	chr8:58055168	NA	0.56	5.42	0.33	1.46e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs3008870	1.000	rs11208979	chr1:67442275	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.89	-11.03	-0.59	4.76e-23	Lymphocyte percentage of white cells;
SARC	cis	rs2952156	1.000	rs2952156	chr17:37876835	A/G	cg00129232	chr17:37814104	STARD3	-0.66	-8.31	-0.48	8.01e-15	Asthma;
SARC	cis	rs9916302	0.904	rs4239222	chr17:37696235	A/C	cg20243544	chr17:37824526	PNMT	-0.54	-6.34	-0.38	1.16e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs4253772	0.591	rs6008546	chr22:46686377	T/G	cg24881330	chr22:46731750	TRMU	0.68	6.16	0.37	3.22e-9	LDL cholesterol;Cholesterol, total;
SARC	cis	rs193541	0.632	rs173481	chr5:122254552	G/A	cg19412675	chr5:122181750	SNX24	0.51	6.48	0.39	5.3e-10	Glucose homeostasis traits;
SARC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg09373136	chr17:61933544	TCAM1	-0.45	-6.15	-0.37	3.36e-9	Prudent dietary pattern;
SARC	cis	rs72781680	0.898	rs718139	chr2:23975911	G/A	cg08917208	chr2:24149416	ATAD2B	0.95	8.98	0.51	9.26e-17	Lymphocyte counts;
SARC	cis	rs9790314	0.586	rs16832246	chr3:161109916	A/G	cg17135325	chr3:160939158	NMD3	-0.54	-6.72	-0.4	1.41e-10	Morning vs. evening chronotype;
SARC	cis	rs703842	0.560	rs11533604	chr12:58047713	G/A	cg00677455	chr12:58241039	CTDSP2	0.52	5.75	0.35	2.8e-8	Multiple sclerosis;
SARC	cis	rs7769051	0.522	rs62424539	chr6:133173272	C/T	cg22852734	chr6:133119734	C6orf192	0.97	7.46	0.44	1.67e-12	Type 2 diabetes nephropathy;
SARC	cis	rs3733585	0.699	rs12498150	chr4:9950537	C/T	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.56	-0.34	7.46e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs2153535	0.580	rs1119691	chr6:8460452	C/T	cg23788917	chr6:8435910	SLC35B3	0.62	8.19	0.47	1.76e-14	Motion sickness;
SARC	cis	rs1707322	0.752	rs10789467	chr1:46118745	C/G	cg03146154	chr1:46216737	IPP	0.52	6.32	0.38	1.33e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg13939156	chr17:80058883	NA	-0.41	-6.34	-0.38	1.21e-9	Life satisfaction;
SARC	cis	rs3099143	1.000	rs901008	chr15:77097018	C/A	cg21673338	chr15:77095150	SCAPER	-0.6	-5.01	-0.31	1.08e-6	Recalcitrant atopic dermatitis;
SARC	cis	rs2952156	0.652	rs11869286	chr17:37813856	C/G	cg20243544	chr17:37824526	PNMT	0.64	8.45	0.48	3.21e-15	Asthma;
SARC	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg16479474	chr6:28041457	NA	0.36	5.67	0.35	4.13e-8	Depression;
SARC	cis	rs2370759	1.000	rs11008865	chr10:32574842	C/T	cg18270830	chr10:32634957	EPC1	0.65	5.77	0.35	2.46e-8	Sexual dysfunction (female);
SARC	cis	rs17539620	0.624	rs62432738	chr6:154835674	T/C	cg20019720	chr6:154832845	CNKSR3	0.41	4.84	0.3	2.39e-6	Lipoprotein (a) levels;
SARC	cis	rs72781680	0.768	rs56339558	chr2:24125234	G/A	cg08917208	chr2:24149416	ATAD2B	0.61	6.31	0.38	1.38e-9	Lymphocyte counts;
SARC	cis	rs35110281	0.720	rs162374	chr21:44927089	T/C	cg01579765	chr21:45077557	HSF2BP	0.36	6.12	0.37	3.84e-9	Mean corpuscular volume;
SARC	cis	rs4803468	1.000	rs11883104	chr19:41923799	T/C	cg14132834	chr19:41945861	ATP5SL	-0.57	-7.6	-0.45	7.31e-13	Height;
SARC	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg26681399	chr22:41777847	TEF	-0.48	-5.21	-0.32	4.17e-7	Vitiligo;
SARC	cis	rs12142240	0.659	rs111723629	chr1:46853361	G/T	cg14993813	chr1:46806288	NSUN4	-0.52	-5.56	-0.34	7.46e-8	Menopause (age at onset);
SARC	cis	rs67460515	0.892	rs11929238	chr3:161045937	A/T	cg03342759	chr3:160939853	NMD3	-0.68	-8.66	-0.49	8.12e-16	Parkinson's disease;
SARC	cis	rs4974559	0.790	rs7654152	chr4:1325042	G/A	cg02980000	chr4:1222292	CTBP1	0.65	4.98	0.31	1.23e-6	Systolic blood pressure;
SARC	cis	rs986417	0.901	rs2351172	chr14:61008687	A/G	cg27398547	chr14:60952738	C14orf39	0.96	8.75	0.5	4.38e-16	Gut microbiota (bacterial taxa);
SARC	trans	rs11098499	0.954	rs71629403	chr4:120372567	C/T	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg13680864	chr10:17686119	STAM	0.49	6.77	0.41	1.02e-10	Chemerin levels;
SARC	cis	rs722599	0.748	rs55707505	chr14:75362552	T/C	cg08847533	chr14:75593920	NEK9	-0.49	-5.84	-0.36	1.79e-8	IgG glycosylation;
SARC	cis	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg08045932	chr20:61659980	NA	0.5	6.84	0.41	7.06e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg16405210	chr4:1374714	KIAA1530	-0.52	-6.22	-0.38	2.3e-9	Obesity-related traits;
SARC	cis	rs13401104	0.796	rs1530955	chr2:237111003	C/T	cg19324714	chr2:237145437	ASB18	0.6	6.62	0.4	2.46e-10	Educational attainment;
SARC	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg23248424	chr5:179741104	GFPT2	0.45	5.66	0.35	4.5e-8	Height;
SARC	cis	rs2075371	0.829	rs35897242	chr7:134004041	G/A	cg20476274	chr7:133979776	SLC35B4	0.55	7.04	0.42	2.19e-11	Mean platelet volume;
SARC	cis	rs73206853	0.841	rs73191808	chr12:110904685	T/C	cg10860002	chr12:110842031	ANAPC7	0.64	5.1	0.32	7.2e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs3018712	0.505	rs7102308	chr11:68413230	T/C	cg01657329	chr11:68192670	LRP5	0.57	5.22	0.32	3.88e-7	Total body bone mineral density;
SARC	cis	rs921968	0.565	rs755112	chr2:219606052	C/T	cg02176678	chr2:219576539	TTLL4	-0.33	-5.02	-0.31	1.05e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs7524258	0.868	rs10779678	chr1:7300573	A/G	cg07173049	chr1:7289937	CAMTA1	0.39	7.59	0.45	7.75e-13	Tourette's syndrome or obsessive-compulsive disorder;
SARC	cis	rs2732480	0.500	rs2450986	chr12:48661688	G/A	cg24011408	chr12:48396354	COL2A1	0.46	5.38	0.33	1.82e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	trans	rs17066873	1.000	rs28786144	chr13:77471470	T/C	cg21804574	chr18:76126700	NA	0.88	6.5	0.39	4.87e-10	Pharmacokinetics of antiepileptic drugs in severe mental disorder (concentration drug ratio);
SARC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.5	0.8	4.35e-54	Prudent dietary pattern;
SARC	cis	rs3126085	0.935	rs12407553	chr1:152297517	A/G	cg26876637	chr1:152193138	HRNR	-0.5	-5.61	-0.34	5.74e-8	Atopic dermatitis;
SARC	cis	rs2204008	0.604	rs2320521	chr12:38253789	A/G	cg13010199	chr12:38710504	ALG10B	0.81	11.31	0.6	6.15e-24	Bladder cancer;
SARC	cis	rs6582630	0.533	rs2120464	chr12:38280289	A/C	cg14851346	chr12:38532713	NA	0.46	5.65	0.35	4.75e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9348729	1	rs9348729	chr6:26664268	T/C	cg12826209	chr6:26865740	GUSBL1	0.66	5.91	0.36	1.23e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2153535	0.580	rs6421948	chr6:8531020	T/C	cg23788917	chr6:8435910	SLC35B3	0.64	8.64	0.49	9.33e-16	Motion sickness;
SARC	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg11987759	chr7:65425863	GUSB	0.48	5.92	0.36	1.13e-8	Aortic root size;
SARC	cis	rs9325144	0.647	rs10875953	chr12:39050536	G/C	cg13010199	chr12:38710504	ALG10B	-0.54	-6.87	-0.41	5.86e-11	Morning vs. evening chronotype;
SARC	cis	rs9303280	0.776	rs9910826	chr17:38035648	A/G	cg20243544	chr17:37824526	PNMT	0.43	5.63	0.35	5.08e-8	Self-reported allergy;
SARC	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg11062466	chr8:58055876	NA	0.55	5.4	0.33	1.65e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1957429	0.614	rs73279812	chr14:65348012	G/A	cg23373153	chr14:65346875	NA	-0.96	-7.3	-0.43	4.39e-12	Pediatric areal bone mineral density (radius);
SARC	cis	rs1003719	0.788	rs59637309	chr21:38475398	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.63	9.05	0.51	5.67e-17	Eye color traits;
SARC	cis	rs3099143	1.000	rs3099138	chr15:77115524	G/A	cg21673338	chr15:77095150	SCAPER	-0.76	-6.25	-0.38	1.93e-9	Recalcitrant atopic dermatitis;
SARC	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg11016663	chr3:52273305	TWF2	0.49	6.54	0.39	3.77e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs5762534	0.556	rs5762456	chr22:28427336	G/T	cg15103426	chr22:29168792	CCDC117	-0.56	-4.71	-0.3	4.2e-6	Menopause (age at onset);
SARC	cis	rs8141529	0.636	rs5762813	chr22:29203314	C/T	cg02153584	chr22:29168773	CCDC117	0.72	8.48	0.49	2.56e-15	Lymphocyte counts;
SARC	cis	rs9291683	0.507	rs3775940	chr4:10025163	A/T	cg00071950	chr4:10020882	SLC2A9	0.33	5.07	0.32	7.93e-7	Bone mineral density;
SARC	trans	rs2018683	0.707	rs917219	chr7:28975343	A/G	cg19402173	chr7:128379420	CALU	-0.5	-6.34	-0.38	1.17e-9	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs965469	0.843	rs6037597	chr20:3408374	A/G	cg25506879	chr20:3388711	C20orf194	-0.5	-5.26	-0.33	3.33e-7	IFN-related cytopenia;
SARC	cis	rs763121	0.853	rs5750659	chr22:39068789	T/C	cg14440974	chr22:39074834	NA	-0.33	-4.8	-0.3	2.84e-6	Menopause (age at onset);
SARC	cis	rs56330463	0.967	rs2053044	chr5:148205372	A/G	cg21580376	chr5:148206412	ADRB2	0.39	5.44	0.34	1.32e-7	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Monocyte percentage of white cells;Eosinophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;
SARC	cis	rs9436747	0.648	rs1782758	chr1:66016942	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.52	-5.1	-0.32	7.17e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs62344088	0.590	rs73016639	chr5:172465	C/T	cg22496380	chr5:211416	CCDC127	-0.85	-5.56	-0.34	7.45e-8	Asthma (childhood onset);
SARC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg21782813	chr7:2030301	MAD1L1	0.43	6.66	0.4	1.95e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs1034435	0.755	rs9615336	chr22:48893090	G/C	cg05992904	chr22:48892994	FAM19A5	-0.48	-7.04	-0.42	2.14e-11	Late-onset Alzheimer's disease;
SARC	cis	rs7829975	0.684	rs546603	chr8:8595838	T/G	cg06636001	chr8:8085503	FLJ10661	-0.64	-8.24	-0.48	1.21e-14	Mood instability;
SARC	cis	rs1008375	1.000	rs2215450	chr4:17675394	T/G	cg27347728	chr4:17578864	LAP3	0.44	5.55	0.34	7.92e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2559856	1.000	rs2695299	chr12:102082664	G/A	cg12924262	chr12:102091054	CHPT1	0.58	7.72	0.45	3.31e-13	Blood protein levels;
SARC	cis	rs2439831	0.850	rs61390361	chr15:44159842	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	7.77	0.45	2.55e-13	Lung cancer in ever smokers;
SARC	cis	rs7208859	0.725	rs9910051	chr17:29161202	A/T	cg13385521	chr17:29058706	SUZ12P	0.77	6.79	0.41	9.01e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg03517284	chr6:25882590	NA	-0.43	-5.64	-0.35	4.78e-8	Intelligence (multi-trait analysis);
SARC	cis	rs11098499	0.954	rs4577559	chr4:120404043	T/G	cg09307838	chr4:120376055	NA	0.93	12.78	0.64	1.08e-28	Corneal astigmatism;
SARC	cis	rs7412746	0.611	rs12410869	chr1:150856153	G/T	cg13175981	chr1:150552382	MCL1	-0.53	-6.51	-0.39	4.58e-10	Melanoma;
SARC	cis	rs9640161	0.702	rs1962004	chr7:150020381	G/A	cg21361702	chr7:150065534	REPIN1	0.56	5.57	0.34	7.01e-8	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.94	-8.57	-0.49	1.41e-15	Alzheimer's disease;
SARC	cis	rs9304742	0.854	rs11084211	chr19:53460861	C/T	cg24044776	chr19:53454761	ZNF816A	-0.42	-5.97	-0.36	8.67e-9	Psoriasis;
SARC	cis	rs7084783	0.600	rs11191738	chr10:105345984	A/T	cg00126946	chr10:105363258	SH3PXD2A	-0.32	-5.57	-0.34	7.12e-8	Fear of pain;
SARC	cis	rs473651	0.904	rs501333	chr2:239336045	G/A	cg18131467	chr2:239335373	ASB1	0.96	16.52	0.73	4.08e-41	Multiple system atrophy;
SARC	cis	rs2933343	0.621	rs6764682	chr3:128568383	G/A	cg25356066	chr3:128598488	ACAD9	-0.66	-8.57	-0.49	1.48e-15	IgG glycosylation;
SARC	trans	rs12310956	0.510	rs11612987	chr12:33879130	T/C	cg13010199	chr12:38710504	ALG10B	0.56	7.21	0.43	7.81e-12	Morning vs. evening chronotype;
SARC	cis	rs13088645	0.532	rs9857134	chr3:134161607	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.43	5.2	0.32	4.46e-7	Coronary artery disease;
SARC	trans	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg00778905	chr1:3541386	TPRG1L	-0.68	-6.42	-0.39	7.56e-10	Cutaneous psoriasis;
SARC	cis	rs72781680	0.611	rs55868657	chr2:24295385	G/A	cg06627628	chr2:24431161	ITSN2	-0.57	-5.92	-0.36	1.13e-8	Lymphocyte counts;
SARC	cis	rs1865760	0.865	rs1436306	chr6:25948421	A/G	cg17691542	chr6:26056736	HIST1H1C	0.58	7.24	0.43	6.52e-12	Height;
SARC	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg12463550	chr7:65579703	CRCP	0.48	5.79	0.35	2.23e-8	Aortic root size;
SARC	cis	rs2070488	1.000	rs2268758	chr3:38514049	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	14.21	0.68	1.99e-33	Electrocardiographic conduction measures;
SARC	cis	rs2304069	0.545	rs9686746	chr5:149399968	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.59	6.94	0.41	3.92e-11	HIV-1 control;
SARC	cis	rs10504229	0.679	rs2317991	chr8:58035080	C/T	cg11062466	chr8:58055876	NA	-0.48	-4.86	-0.3	2.14e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs4722166	0.695	rs56061963	chr7:22800397	T/C	cg26061582	chr7:22766209	IL6	0.48	5.52	0.34	9.1e-8	Lung cancer;
SARC	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg11062466	chr8:58055876	NA	0.6	5.76	0.35	2.68e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs765787	0.530	rs1706830	chr15:45516229	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.43	-5.39	-0.33	1.73e-7	Uric acid levels;
SARC	cis	rs2562456	0.793	rs627522	chr19:21495804	C/T	cg00455402	chr19:21769736	NA	-0.39	-4.98	-0.31	1.21e-6	Pain;
SARC	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg05368731	chr17:41323189	NBR1	0.79	9.6	0.53	1.33e-18	Menopause (age at onset);
SARC	cis	rs6570726	0.693	rs450921	chr6:145864260	C/T	cg23711669	chr6:146136114	FBXO30	0.87	14.71	0.69	4.26e-35	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7539542	0.556	rs6686801	chr1:202874730	C/T	cg08940984	chr1:202857613	RABIF	0.39	5.34	0.33	2.17e-7	Mean platelet volume;
SARC	cis	rs453301	0.686	rs11785634	chr8:8892597	G/T	cg11995313	chr8:8860691	ERI1	0.44	5.7	0.35	3.56e-8	Joint mobility (Beighton score);
SARC	cis	rs8180040	0.874	rs11130123	chr3:47285912	A/G	cg27129171	chr3:47204927	SETD2	0.7	9.54	0.53	1.99e-18	Colorectal cancer;
SARC	cis	rs765787	0.556	rs12915965	chr15:45512647	T/C	cg24006582	chr15:45444508	DUOX1	0.43	5.5	0.34	9.82e-8	Uric acid levels;
SARC	cis	rs6964587	0.692	rs2027950	chr7:91863700	C/G	cg17063962	chr7:91808500	NA	-0.82	-12.84	-0.64	6.99e-29	Breast cancer;
SARC	cis	rs4555082	1.000	rs7146683	chr14:105759385	A/G	cg10792982	chr14:105748885	BRF1	0.5	7.52	0.44	1.15e-12	Mean platelet volume;Platelet distribution width;
SARC	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg11987759	chr7:65425863	GUSB	-0.5	-6.09	-0.37	4.6e-9	Aortic root size;
SARC	cis	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg16025567	chr3:186285328	TBCCD1	0.53	5.84	0.36	1.76e-8	Myopia (pathological);
SARC	cis	rs34779708	0.966	rs4934539	chr10:35472199	A/G	cg03585969	chr10:35415529	CREM	0.41	5.1	0.32	6.88e-7	Inflammatory bowel disease;Crohn's disease;
SARC	trans	rs7395662	0.591	rs4882012	chr11:48560597	T/A	cg15704280	chr7:45808275	SEPT13	-0.49	-6.71	-0.4	1.44e-10	HDL cholesterol;
SARC	cis	rs62244186	0.566	rs2135531	chr3:44881158	C/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.61	7.93	0.46	8.87e-14	Depressive symptoms;
SARC	cis	rs875971	1.000	rs2220626	chr7:65546062	C/T	cg18876405	chr7:65276391	NA	-0.46	-5.6	-0.34	6.05e-8	Aortic root size;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg11458134	chr5:102091118	NA	0.48	6.36	0.38	1.08e-9	Lung adenocarcinoma;
SARC	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg00933542	chr6:150070202	PCMT1	0.3	5.1	0.32	7.09e-7	Lung cancer;
SARC	cis	rs3106136	1.000	rs3106134	chr4:95128091	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.38	-5.82	-0.36	1.98e-8	Capecitabine sensitivity;
SARC	cis	rs4926611	0.730	rs2950252	chr1:54048719	C/G	cg08927728	chr1:54059983	GLIS1	-0.29	-4.9	-0.31	1.78e-6	Hand grip strength;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg16163324	chr1:46712932	RAD54L	0.5	6.59	0.4	2.97e-10	Chemerin levels;
SARC	cis	rs9790314	0.967	rs457272	chr3:161096746	A/G	cg04691961	chr3:161091175	C3orf57	-0.82	-12.33	-0.63	3.23e-27	Morning vs. evening chronotype;
SARC	cis	rs3820928	0.874	rs13413235	chr2:227893863	C/T	cg11843606	chr2:227700838	RHBDD1	-0.55	-6.84	-0.41	6.88e-11	Pulmonary function;
SARC	cis	rs644799	1.000	rs525404	chr11:95566520	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.67	9.02	0.51	6.99e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2712184	0.729	rs4674115	chr2:217659628	C/G	cg05032264	chr2:217675019	NA	-0.5	-6.45	-0.39	6.26e-10	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
SARC	cis	rs11098499	1.000	rs58601355	chr4:120186367	T/C	cg09307838	chr4:120376055	NA	0.79	10.22	0.56	1.71e-20	Corneal astigmatism;
SARC	cis	rs7769051	0.522	rs7775241	chr6:133109022	T/C	cg22852734	chr6:133119734	C6orf192	1.18	7.86	0.46	1.43e-13	Type 2 diabetes nephropathy;
SARC	cis	rs9916302	0.851	rs12936996	chr17:37665554	A/G	cg20243544	chr17:37824526	PNMT	-0.57	-6.76	-0.41	1.08e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs6500602	0.739	rs4786502	chr16:4537104	T/C	cg08645402	chr16:4508243	NA	0.44	5.7	0.35	3.57e-8	Schizophrenia;
SARC	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.32	-4.75	-0.3	3.62e-6	Total body bone mineral density;
SARC	cis	rs1348850	0.632	rs11682717	chr2:178499240	C/G	cg22681709	chr2:178499509	PDE11A	-0.42	-5.79	-0.35	2.26e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs5753618	0.583	rs5753615	chr22:31828027	T/C	cg02404636	chr22:31891804	SFI1	0.5	5.33	0.33	2.33e-7	Colorectal cancer;
SARC	cis	rs2952156	0.883	rs907088	chr17:37833567	G/C	cg20243544	chr17:37824526	PNMT	0.56	7.44	0.44	1.94e-12	Asthma;
SARC	cis	rs7843479	0.965	rs11784535	chr8:21857787	G/A	cg17168535	chr8:21777572	XPO7	0.62	7.91	0.46	1.04e-13	Mean corpuscular volume;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20683565	chr10:104179492	FBXL15;PSD	-0.53	-6.54	-0.39	3.86e-10	Fibrinogen levels;
SARC	cis	rs2276314	1.000	rs2298716	chr18:33552598	C/T	cg19628046	chr18:33552617	C18orf21	0.58	6.01	0.37	7.23e-9	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs10489202	0.686	rs11585936	chr1:167847069	G/T	cg24449463	chr1:168025552	DCAF6	-0.64	-5.56	-0.34	7.22e-8	Schizophrenia;
SARC	cis	rs5753618	0.583	rs9606843	chr22:31853371	A/C	cg13145458	chr22:31556086	RNF185	-0.46	-5.02	-0.31	1.02e-6	Colorectal cancer;
SARC	cis	rs1348850	0.914	rs7591807	chr2:178252986	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.71	9.15	0.51	2.89e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2204008	0.811	rs11525004	chr12:38333807	T/A	cg26384229	chr12:38710491	ALG10B	0.87	12.6	0.64	4.2e-28	Bladder cancer;
SARC	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg06558623	chr16:89946397	TCF25	0.71	5.97	0.36	8.69e-9	Skin colour saturation;
SARC	cis	rs748404	0.697	rs546170	chr15:43564849	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	6.57	0.4	3.25e-10	Lung cancer;
SARC	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.72	7.6	0.45	7.36e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs11581859	0.613	rs4515813	chr1:99197193	C/T	cg20286094	chr1:99190917	SNX7	-0.42	-4.93	-0.31	1.55e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs3784262	0.679	rs11071366	chr15:58334244	A/T	cg12031962	chr15:58353849	ALDH1A2	-0.36	-5.24	-0.32	3.58e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs3768617	0.510	rs7529465	chr1:183096880	A/G	cg13390022	chr1:182993471	LAMC1	0.31	4.79	0.3	3.01e-6	Fuchs's corneal dystrophy;
SARC	cis	rs9914988	0.613	rs7214943	chr17:27280228	A/G	cg10538030	chr17:27276405	PHF12	-0.62	-5.07	-0.32	8.01e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs7829975	0.511	rs2948286	chr8:8130160	A/G	cg08975724	chr8:8085496	FLJ10661	0.69	9.3	0.52	1.09e-17	Mood instability;
SARC	cis	rs13034020	0.594	rs62150966	chr2:61199056	A/G	cg18625361	chr2:61244694	PEX13;PUS10	0.66	4.97	0.31	1.3e-6	Hodgkin's lymphoma;
SARC	cis	rs6121246	0.580	rs6121016	chr20:30245239	C/T	cg13852791	chr20:30311386	BCL2L1	0.87	9.26	0.52	1.42e-17	Mean corpuscular hemoglobin;
SARC	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg06634786	chr22:41940651	POLR3H	0.55	6.45	0.39	6.23e-10	Vitiligo;
SARC	cis	rs6910061	0.830	rs10946959	chr6:11096401	G/A	cg27233058	chr6:11094804	LOC221710	0.6	5.51	0.34	9.49e-8	Diabetic kidney disease;
SARC	cis	rs6772849	0.930	rs13434160	chr3:128374770	T/C	cg01163369	chr3:128370232	RPN1	-0.34	-4.94	-0.31	1.47e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs13166103	0.689	rs17709589	chr5:57717643	G/A	cg10487770	chr5:57879443	RAB3C	0.52	5.46	0.34	1.19e-7	Type 2 diabetes (age of onset);
SARC	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg17971929	chr21:40555470	PSMG1	0.96	11.73	0.61	2.76e-25	Cognitive function;
SARC	cis	rs35110281	0.743	rs2329443	chr21:45059431	C/T	cg21573476	chr21:45109991	RRP1B	-0.58	-8.43	-0.48	3.51e-15	Mean corpuscular volume;
SARC	cis	rs2239547	0.563	rs4687560	chr3:52898121	T/G	cg11645453	chr3:52864694	ITIH4	0.32	4.81	0.3	2.68e-6	Schizophrenia;
SARC	cis	rs9987353	0.620	rs34455383	chr8:9066458	C/T	cg15556689	chr8:8085844	FLJ10661	-0.42	-4.73	-0.3	3.96e-6	Recombination measurement;
SARC	cis	rs9815354	1.000	rs1717033	chr3:41910216	C/T	cg03022575	chr3:42003672	ULK4	0.55	5.26	0.33	3.22e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs79149102	0.579	rs7167415	chr15:75302570	C/T	cg09165964	chr15:75287851	SCAMP5	-0.95	-8.86	-0.5	2.03e-16	Lung cancer;
SARC	cis	rs13401104	0.633	rs11679598	chr2:237112451	A/C	cg19324714	chr2:237145437	ASB18	0.58	6.05	0.37	5.77e-9	Educational attainment;
SARC	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg00684032	chr4:1343700	KIAA1530	0.37	5.36	0.33	1.99e-7	Obesity-related traits;
SARC	cis	rs9381040	0.655	rs4140578	chr6:41041829	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.48	-5.51	-0.34	9.45e-8	Alzheimer's disease (late onset);
SARC	cis	rs3126085	0.935	rs3126043	chr1:152256030	C/G	cg26876637	chr1:152193138	HRNR	0.43	4.95	0.31	1.44e-6	Atopic dermatitis;
SARC	cis	rs3820928	0.839	rs13404750	chr2:227876129	G/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-6.45	-0.39	6.3e-10	Pulmonary function;
SARC	cis	rs11122272	0.735	rs2009873	chr1:231499236	C/T	cg06096015	chr1:231504339	EGLN1	0.39	5.88	0.36	1.41e-8	Hemoglobin concentration;
SARC	cis	rs2463822	1.000	rs72921498	chr11:62113090	C/T	cg06239285	chr11:62104954	ASRGL1	-0.88	-9.32	-0.52	9.26e-18	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs2836974	0.549	rs34160989	chr21:40554118	C/G	cg11644478	chr21:40555479	PSMG1	0.78	6.62	0.4	2.51e-10	Cognitive function;
SARC	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg14019146	chr3:50243930	SLC38A3	-0.31	-4.87	-0.3	2.04e-6	Body mass index;
SARC	cis	rs17401966	1.000	rs12755094	chr1:10305711	T/C	cg15208524	chr1:10270712	KIF1B	0.58	6.64	0.4	2.13e-10	Hepatocellular carcinoma;
SARC	cis	rs3818285	0.959	rs492943	chr10:111629030	A/T	cg00817464	chr10:111662876	XPNPEP1	0.4	5.38	0.33	1.86e-7	Superior crus of antihelix expression;
SARC	cis	rs7044106	0.791	rs7036766	chr9:123479621	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	9.79	0.54	3.5e-19	Hip circumference adjusted for BMI;
SARC	cis	rs7178572	0.568	rs8037561	chr15:77680462	A/G	cg22256960	chr15:77711686	NA	-0.51	-5.59	-0.34	6.36e-8	Type 2 diabetes;
SARC	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	10.28	0.56	1.08e-20	Platelet count;
SARC	cis	rs992157	0.798	rs10206064	chr2:219157959	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.62	8.62	0.49	1.03e-15	Colorectal cancer;
SARC	cis	rs9916302	0.800	rs8069451	chr17:37504933	C/T	cg20243544	chr17:37824526	PNMT	0.57	6.87	0.41	5.91e-11	Glomerular filtration rate (creatinine);
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg05297461	chr19:4402971	CHAF1A	0.55	6.59	0.4	2.83e-10	Blood pressure;
SARC	cis	rs6088813	1.000	rs62211529	chr20:33959315	T/C	cg14752227	chr20:34000481	UQCC	-0.37	-4.72	-0.3	4.02e-6	Height;
SARC	cis	rs4975616	0.836	rs13178866	chr5:1323212	C/T	cg26373071	chr5:1325741	CLPTM1L	0.32	5.25	0.33	3.41e-7	Lung cancer;
SARC	cis	rs16866061	1.000	rs7588380	chr2:225341304	A/T	cg12698349	chr2:225449008	CUL3	-0.72	-10.05	-0.55	5.86e-20	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	cis	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg24110177	chr3:50126178	RBM5	-0.54	-7.17	-0.43	9.69e-12	Intelligence (multi-trait analysis);
SARC	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg08859206	chr1:53392774	SCP2	0.42	6.01	0.37	7.26e-9	Monocyte count;
SARC	cis	rs7546668	0.640	rs10803386	chr1:15811692	C/T	cg21858823	chr1:15850916	CASP9	0.47	5.68	0.35	4.05e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs9916302	0.706	rs7503081	chr17:37482673	A/G	cg20243544	chr17:37824526	PNMT	-0.54	-5.76	-0.35	2.67e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs2463822	0.858	rs2513037	chr11:62084822	A/T	cg06239285	chr11:62104954	ASRGL1	-0.87	-9.39	-0.52	5.67e-18	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs3820928	0.605	rs10186145	chr2:227781150	A/G	cg11843606	chr2:227700838	RHBDD1	-0.56	-7.55	-0.44	9.57e-13	Pulmonary function;
SARC	cis	rs3106136	0.649	rs4699440	chr4:95306151	T/A	cg11021082	chr4:95130006	SMARCAD1	0.33	4.93	0.31	1.53e-6	Capecitabine sensitivity;
SARC	cis	rs17095355	1.000	rs7921609	chr10:111691599	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.41	-4.84	-0.3	2.38e-6	Biliary atresia;
SARC	trans	rs6076960	0.623	rs6038407	chr20:6267326	A/G	cg21095983	chr6:86352623	SYNCRIP	0.46	6.55	0.39	3.65e-10	Smooth-surface caries;
SARC	cis	rs7833986	0.501	rs72653962	chr8:56997505	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.73	7.37	0.43	2.98e-12	Height;
SARC	cis	rs1185460	0.967	rs1184902	chr11:118945337	A/G	cg23280166	chr11:118938394	VPS11	0.81	11.72	0.61	3e-25	Coronary artery disease;
SARC	cis	rs3087591	0.960	rs12942397	chr17:29462498	C/A	cg24425628	chr17:29625626	OMG;NF1	0.54	6.84	0.41	7.08e-11	Hip circumference;
SARC	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg17971929	chr21:40555470	PSMG1	0.85	11.17	0.59	1.82e-23	Cognitive function;
SARC	cis	rs4332037	0.707	rs10268797	chr7:1873756	C/G	cg12591125	chr7:1885375	MAD1L1	-0.46	-4.76	-0.3	3.44e-6	Bipolar disorder;
SARC	cis	rs10782582	0.593	rs6664254	chr1:76235084	G/T	cg10523679	chr1:76189770	ACADM	-0.43	-5.16	-0.32	5.33e-7	Daytime sleep phenotypes;
SARC	cis	rs7264396	0.563	rs59064961	chr20:34307950	T/C	cg01084648	chr20:34329383	RBM39	0.56	4.93	0.31	1.57e-6	Total cholesterol levels;
SARC	cis	rs2153904	0.793	rs12132270	chr1:205660940	C/T	cg11965913	chr1:205819406	PM20D1	-0.57	-5.07	-0.32	8.06e-7	Prostate-specific antigen levels;
SARC	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg20607798	chr8:58055168	NA	0.56	5.27	0.33	3.12e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs13256369	0.853	rs13256216	chr8:8577883	C/T	cg17143192	chr8:8559678	CLDN23	0.49	5.56	0.34	7.41e-8	Obesity-related traits;
SARC	cis	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg23422044	chr7:1970798	MAD1L1	-0.46	-5.03	-0.31	9.68e-7	Bipolar disorder;
SARC	cis	rs9420	1.000	rs9420	chr11:57510294	A/G	cg23127183	chr11:57508653	C11orf31	0.51	6.01	0.37	6.94e-9	Schizophrenia;
SARC	cis	rs2153535	0.541	rs9328471	chr6:8468842	T/C	cg07606381	chr6:8435919	SLC35B3	0.77	10.83	0.58	2.14e-22	Motion sickness;
SARC	cis	rs1865760	0.566	rs3752420	chr6:26027135	G/A	cg18357526	chr6:26021779	HIST1H4A	0.44	5.43	0.34	1.39e-7	Height;
SARC	cis	rs12612619	0.689	rs11681145	chr2:27290525	A/G	cg17611932	chr2:27505586	TRIM54	-0.27	-4.94	-0.31	1.48e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
SARC	cis	rs875971	0.545	rs7787063	chr7:65628999	G/A	cg25894440	chr7:65020034	NA	0.51	4.74	0.3	3.69e-6	Aortic root size;
SARC	trans	rs17025426	1.000	rs17025455	chr1:110651022	A/C	cg03529568	chr17:30676722	ZNF207;MIR632	0.69	6.27	0.38	1.75e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs9902453	0.933	rs7216487	chr17:28502642	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	6.66	0.4	1.98e-10	Coffee consumption (cups per day);
SARC	cis	rs8017423	0.607	rs10142482	chr14:90848280	G/T	cg20276874	chr14:90721474	PSMC1	0.37	4.97	0.31	1.28e-6	Mortality in heart failure;
SARC	cis	rs73198271	0.562	rs17631022	chr8:8662197	G/A	cg01851573	chr8:8652454	MFHAS1	0.42	5.14	0.32	5.88e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs2295359	0.824	rs12060309	chr1:67604219	T/C	cg11235152	chr1:67600687	NA	0.52	6.94	0.41	3.79e-11	Psoriasis;
SARC	cis	rs12348691	0.503	rs7048394	chr9:100605433	T/C	cg13688889	chr9:100608707	NA	-0.47	-5.04	-0.31	9.54e-7	Alopecia areata;
SARC	cis	rs56307353	0.652	rs4807191	chr19:1990309	C/T	cg01980928	chr19:1952821	C19orf34;CSNK1G2	0.34	5.15	0.32	5.45e-7	Coronary artery disease;
SARC	cis	rs897984	0.553	rs2335013	chr16:30877346	T/G	cg00531865	chr16:30841666	NA	0.44	4.75	0.3	3.49e-6	Dementia with Lewy bodies;
SARC	cis	rs79149102	0.579	rs7173218	chr15:75315328	A/G	cg00629941	chr15:75287862	SCAMP5	-0.65	-5.4	-0.33	1.62e-7	Lung cancer;
SARC	cis	rs11581859	0.613	rs11166092	chr1:99198305	C/T	cg20286094	chr1:99190917	SNX7	-0.42	-4.99	-0.31	1.2e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs526231	0.511	rs2288389	chr5:102353808	C/G	cg23492399	chr5:102201601	PAM	-0.51	-5.77	-0.35	2.47e-8	Primary biliary cholangitis;
SARC	cis	rs2304069	1.000	rs10072275	chr5:149401596	T/C	cg12661370	chr5:149340060	SLC26A2	0.61	6.21	0.38	2.35e-9	HIV-1 control;
SARC	cis	rs1670533	0.932	rs10902753	chr4:1056223	G/A	cg27284194	chr4:1044797	NA	0.47	4.96	0.31	1.37e-6	Recombination rate (females);
SARC	cis	rs9302635	0.513	rs12444701	chr16:72155240	C/T	cg16558253	chr16:72132732	DHX38	-0.52	-6.76	-0.41	1.08e-10	Blood protein levels;
SARC	trans	rs9395865	0.501	rs2067833	chr6:53330356	A/G	cg06589161	chr5:180618230	NA	-0.51	-6.33	-0.38	1.28e-9	Electroencephalographic traits in alcoholism;
SARC	trans	rs1814175	0.817	rs4405313	chr11:50013636	G/A	cg03929089	chr4:120376271	NA	-0.87	-13.86	-0.67	2.91e-32	Height;
SARC	cis	rs74181299	0.964	rs2540948	chr2:65284623	T/C	cg20592124	chr2:65290738	CEP68	0.44	6.28	0.38	1.62e-9	Pulse pressure;
SARC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.72	-9.91	-0.54	1.5e-19	Lymphocyte counts;
SARC	cis	rs1008375	0.900	rs6812675	chr4:17597549	A/G	cg02297831	chr4:17616191	MED28	0.49	5.98	0.36	8.2e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs17376456	0.569	rs10076965	chr5:93094972	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.5	5.05	0.31	8.86e-7	Diabetic retinopathy;
SARC	cis	rs2204008	0.837	rs7974888	chr12:37945215	A/G	cg13010199	chr12:38710504	ALG10B	0.76	10.09	0.55	4.4e-20	Bladder cancer;
SARC	cis	rs897080	0.515	rs1067336	chr2:44625876	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.57	0.4	3.21e-10	Height;
SARC	cis	rs858239	0.632	rs13438452	chr7:23174182	A/G	cg23682824	chr7:23144976	KLHL7	0.72	9.7	0.54	6.44e-19	Cerebrospinal fluid biomarker levels;
SARC	trans	rs7824557	0.652	rs12677504	chr8:11133175	G/A	cg06636001	chr8:8085503	FLJ10661	-0.6	-7.27	-0.43	5.5e-12	Retinal vascular caliber;
SARC	cis	rs7246657	0.882	rs10412043	chr19:37826626	A/C	cg14683738	chr19:37701593	ZNF585B	0.51	4.94	0.31	1.52e-6	Coronary artery calcification;
SARC	cis	rs13392177	0.684	rs11682371	chr2:219079513	G/A	cg00012203	chr2:219082015	ARPC2	-0.69	-9.52	-0.53	2.33e-18	Pyoderma gangrenosum in inflammatory bowel disease;
SARC	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg13393036	chr8:95962371	TP53INP1	-0.36	-6.1	-0.37	4.39e-9	Type 2 diabetes;
SARC	cis	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg22496380	chr5:211416	CCDC127	-0.88	-9.19	-0.52	2.18e-17	Breast cancer;
SARC	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg08280861	chr8:58055591	NA	0.62	5.68	0.35	4.06e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10463554	0.927	rs34798	chr5:102425751	C/G	cg23492399	chr5:102201601	PAM	-0.59	-6.45	-0.39	6.28e-10	Parkinson's disease;
SARC	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg03433033	chr1:76189801	ACADM	0.54	7.65	0.45	5.14e-13	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6910061	0.956	rs9468419	chr6:11102576	T/C	cg27233058	chr6:11094804	LOC221710	0.58	5.59	0.34	6.22e-8	Diabetic kidney disease;
SARC	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg12648201	chr2:27665141	KRTCAP3	-0.32	-4.87	-0.3	2.04e-6	Total body bone mineral density;
SARC	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	13.84	0.67	3.51e-32	Chronic sinus infection;
SARC	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg12696929	chr3:195401817	SDHAP2	0.39	5.2	0.32	4.4e-7	Pancreatic cancer;
SARC	trans	rs453301	0.624	rs330060	chr8:9090902	A/G	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.84	-0.41	6.91e-11	Joint mobility (Beighton score);
SARC	trans	rs36093844	0.752	rs17817343	chr11:85598312	C/T	cg15359163	chr5:122429178	PRDM6	-0.53	-6.4	-0.39	8.22e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg05673432	chr3:15919505	NA	-0.52	-6.54	-0.39	3.75e-10	Height;
SARC	cis	rs9905704	0.881	rs302846	chr17:56687536	T/A	cg12560992	chr17:57184187	TRIM37	0.42	4.87	0.3	2.03e-6	Testicular germ cell tumor;
SARC	cis	rs1957429	0.614	rs79411360	chr14:65378856	T/C	cg23373153	chr14:65346875	NA	-1.03	-6.42	-0.39	7.58e-10	Pediatric areal bone mineral density (radius);
SARC	cis	rs7592578	0.508	rs10931451	chr2:191270888	G/A	cg10560079	chr2:191398806	TMEM194B	-0.61	-6.82	-0.41	7.56e-11	Diastolic blood pressure;
SARC	cis	rs17401966	1.000	rs12117765	chr1:10268170	A/G	cg15208524	chr1:10270712	KIF1B	0.56	6.36	0.38	1.06e-9	Hepatocellular carcinoma;
SARC	trans	rs62103177	0.810	rs62103191	chr18:77628769	C/G	cg05926928	chr17:57297772	GDPD1	1.09	9.19	0.52	2.24e-17	Opioid sensitivity;
SARC	trans	rs561341	1.000	rs2470267	chr17:30274132	G/A	cg20587970	chr11:113659929	NA	-1.19	-11.52	-0.6	1.34e-24	Hip circumference adjusted for BMI;
SARC	cis	rs9581857	0.725	rs1924074	chr13:28015387	C/G	cg01674679	chr13:27998804	GTF3A	0.62	4.91	0.31	1.73e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	cis	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg03060546	chr3:49711283	APEH	0.59	7.48	0.44	1.54e-12	Resting heart rate;
SARC	cis	rs761746	0.960	rs5998035	chr22:31939612	G/A	cg15823100	chr22:32027580	PISD	-0.32	-4.8	-0.3	2.81e-6	Intelligence;
SARC	cis	rs6580649	0.941	rs4760615	chr12:48428150	A/G	cg24011408	chr12:48396354	COL2A1	0.53	5.71	0.35	3.36e-8	Lung cancer;
SARC	cis	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg00262122	chr8:11665843	FDFT1	-0.43	-5.46	-0.34	1.24e-7	Systolic blood pressure;
SARC	cis	rs9436747	0.933	rs4655811	chr1:65923157	C/G	cg14976592	chr1:65886160	LEPROT;LEPR	-0.51	-5.51	-0.34	9.52e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs3812831	0.662	rs407531	chr13:114929218	G/A	cg08824895	chr13:115047677	UPF3A	0.51	6.66	0.4	1.96e-10	Schizophrenia;
SARC	cis	rs9341808	0.558	rs3805911	chr6:80933996	A/C	cg08355045	chr6:80787529	NA	0.35	5.31	0.33	2.51e-7	Sitting height ratio;
SARC	cis	rs41433250	1	rs41433250	chr13:31495835	A/G	cg15545871	chr13:31191737	USPL1	-0.76	-5.66	-0.35	4.45e-8	Influenza A (H1N1) infection;Mild influenza (H1N1) infection;
SARC	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.54	-5.37	-0.33	1.91e-7	Lung function (FEV1/FVC);
SARC	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg03433033	chr1:76189801	ACADM	-0.54	-7.49	-0.44	1.41e-12	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs10875746	0.855	rs10875731	chr12:48432743	G/A	cg26205652	chr12:48591994	NA	0.52	5.62	0.35	5.32e-8	Longevity (90 years and older);
SARC	cis	rs11098499	0.909	rs28714195	chr4:120316950	A/T	cg09160332	chr4:120329925	NA	-0.33	-4.77	-0.3	3.27e-6	Corneal astigmatism;
SARC	trans	rs61931739	0.553	rs68124042	chr12:34064431	C/A	cg26384229	chr12:38710491	ALG10B	0.87	12.36	0.63	2.53e-27	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.520	rs55967509	chr8:57992448	A/G	cg21724239	chr8:58056113	NA	0.63	6.05	0.37	5.78e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg05890377	chr2:74357713	NA	0.61	7.34	0.43	3.62e-12	Gestational age at birth (maternal effect);
SARC	cis	rs2425143	0.730	rs6060624	chr20:34413663	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	5.11	0.32	6.64e-7	Blood protein levels;
SARC	cis	rs2070488	1.000	rs4147024	chr3:38456664	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	14.48	0.69	2.54e-34	Electrocardiographic conduction measures;
SARC	cis	rs9916302	0.904	rs8065963	chr17:37681332	C/T	cg20243544	chr17:37824526	PNMT	0.53	6.09	0.37	4.5e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg05165339	chr4:1420672	NA	-0.23	-4.94	-0.31	1.49e-6	Longevity;
SARC	cis	rs4074493	1.000	rs4074493	chr1:231172281	C/T	cg22172038	chr1:231176991	FAM89A	0.32	4.74	0.3	3.78e-6	Carotid plaque burden (smoking interaction);
SARC	cis	rs4601821	0.858	rs7945132	chr11:113262473	A/T	cg14159747	chr11:113255604	NA	0.4	5.22	0.32	3.94e-7	Alcoholic chronic pancreatitis;
SARC	cis	rs10779751	0.770	rs7553827	chr1:11222393	C/T	cg08854313	chr1:11322531	MTOR	0.77	10.22	0.56	1.73e-20	Body mass index;
SARC	cis	rs7086627	0.515	rs11202959	chr10:82209672	A/G	cg01528321	chr10:82214614	TSPAN14	0.57	8.41	0.48	4.07e-15	Post bronchodilator FEV1;
SARC	cis	rs4906332	0.933	rs34606394	chr14:103915636	G/A	cg26031613	chr14:104095156	KLC1	-0.48	-5.69	-0.35	3.72e-8	Coronary artery disease;
SARC	cis	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg24110177	chr3:50126178	RBM5	-0.55	-7.3	-0.43	4.44e-12	Intelligence (multi-trait analysis);
SARC	cis	rs1865760	0.516	rs10807007	chr6:26048931	A/C	cg02841227	chr6:26021843	HIST1H4A	0.39	4.82	0.3	2.53e-6	Height;
SARC	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg16479474	chr6:28041457	NA	0.36	5.45	0.34	1.25e-7	Depression;
SARC	cis	rs9473924	0.618	rs61236902	chr6:50813055	C/G	cg14470998	chr6:50812995	TFAP2B	0.69	6.11	0.37	4.24e-9	Body mass index;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg09377149	chr3:69101222	TMF1	-0.79	-6.75	-0.4	1.17e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs67311347	1.000	rs4973997	chr3:40460145	G/A	cg24209194	chr3:40518798	ZNF619	0.61	7.95	0.46	7.78e-14	Renal cell carcinoma;
SARC	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.36	0.38	1.07e-9	Bipolar disorder;
SARC	cis	rs1008375	0.932	rs7697329	chr4:17657853	C/A	cg02297831	chr4:17616191	MED28	0.47	5.95	0.36	9.7e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs17376456	0.877	rs10057605	chr5:93443950	T/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.73	0.35	3.03e-8	Diabetic retinopathy;
SARC	cis	rs2354432	0.607	rs66486822	chr1:146802653	T/A	cg25205988	chr1:146714368	CHD1L	-1.06	-7.79	-0.45	2.22e-13	Mitochondrial DNA levels;
SARC	cis	rs9457247	1.000	rs402749	chr6:167386104	C/T	cg07741184	chr6:167504864	NA	0.29	5.49	0.34	1.04e-7	Crohn's disease;
SARC	cis	rs9902453	0.845	rs3102559	chr17:28029723	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	7.08	0.42	1.73e-11	Coffee consumption (cups per day);
SARC	cis	rs6782228	0.585	rs2811492	chr3:128356279	A/G	cg08795948	chr3:128337044	NA	0.37	5.08	0.32	7.87e-7	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
SARC	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10463554	0.667	rs34782	chr5:102454470	G/T	cg23492399	chr5:102201601	PAM	-0.52	-5.72	-0.35	3.2e-8	Parkinson's disease;
SARC	cis	rs3780378	0.934	rs10815146	chr9:5015901	T/A	cg02405213	chr9:5042618	JAK2	-0.41	-5.04	-0.31	9.35e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
SARC	cis	rs3820928	1.000	rs4675120	chr2:227774888	C/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-6.88	-0.41	5.56e-11	Pulmonary function;
SARC	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg13939156	chr17:80058883	NA	0.37	5.69	0.35	3.78e-8	Life satisfaction;
SARC	cis	rs72949976	0.934	rs10197392	chr2:214038178	G/A	cg08319019	chr2:214017104	IKZF2	-0.47	-6.21	-0.38	2.4e-9	Lung cancer;Squamous cell lung carcinoma;
SARC	trans	rs12967884	0.892	rs4799203	chr18:76559621	C/T	cg10946435	chr1:154843044	KCNN3	0.57	6.36	0.38	1.06e-9	Subcutaneous adipose tissue;
SARC	cis	rs2204008	0.546	rs11519978	chr12:37998170	C/T	cg13010199	chr12:38710504	ALG10B	0.78	10.73	0.57	4.45e-22	Bladder cancer;
SARC	cis	rs2816062	0.813	rs2816053	chr1:18895819	A/G	cg10574377	chr1:18908098	NA	0.35	5.02	0.31	1.02e-6	Urate levels in lean individuals;
SARC	cis	rs1215050	0.904	rs165246	chr4:98688541	C/T	cg05340658	chr4:99064831	C4orf37	0.38	4.82	0.3	2.57e-6	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.97e-8	Aortic root size;
SARC	trans	rs1853207	1.000	rs74154119	chr10:96632871	C/T	cg02737782	chr1:8014393	NA	-0.86	-6.27	-0.38	1.72e-9	Blood metabolite levels;
SARC	cis	rs3758785	0.641	rs7949222	chr11:94098501	T/C	cg13023536	chr11:94226537	MRE11A;ANKRD49	-0.44	-5.72	-0.35	3.21e-8	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
SARC	cis	rs4975616	0.869	rs465498	chr5:1325803	A/G	cg26373071	chr5:1325741	CLPTM1L	0.33	5.55	0.34	7.56e-8	Lung cancer;
SARC	cis	rs11098499	0.663	rs28369503	chr4:120238925	G/A	cg09307838	chr4:120376055	NA	0.84	11.54	0.6	1.15e-24	Corneal astigmatism;
SARC	cis	rs7674212	0.539	rs7676041	chr4:104126421	T/A	cg16532752	chr4:104119610	CENPE	-0.47	-5.83	-0.36	1.8e-8	Type 2 diabetes;
SARC	cis	rs796364	0.806	rs12619136	chr2:200910347	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-6.47	-0.39	5.62e-10	Schizophrenia;
SARC	cis	rs4774830	0.744	rs60931351	chr15:56305541	A/T	cg24530489	chr15:56299380	NA	-0.84	-4.97	-0.31	1.28e-6	Delta-5 desaturase activity;
SARC	cis	rs2857078	0.745	rs4793085	chr17:42320732	A/C	cg09913183	chr17:42254507	C17orf65;ASB16	-0.44	-5.78	-0.35	2.38e-8	Red cell distribution width;Reticulocyte count;
SARC	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg18252515	chr7:66147081	NA	0.48	5.18	0.32	4.86e-7	Aortic root size;
SARC	cis	rs6696846	0.691	rs11240370	chr1:205118336	T/G	cg00857998	chr1:205179979	DSTYK	0.51	6.61	0.4	2.6200000000000003e-10	Red blood cell count;
SARC	cis	rs9682041	0.673	rs1511175	chr3:170076006	C/G	cg11886554	chr3:170076028	SKIL	1.14	8.87	0.5	1.96e-16	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2302729	0.625	rs10848693	chr12:2833013	A/T	cg19945202	chr12:2788847	CACNA1C	0.54	5.29	0.33	2.8e-7	Sleep quality;
SARC	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg03709012	chr19:19516395	GATAD2A	0.89	13.41	0.66	8.77e-31	Tonsillectomy;
SARC	cis	rs6570726	0.846	rs6570698	chr6:145918635	C/G	cg23711669	chr6:146136114	FBXO30	0.78	12.25	0.63	5.73e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9916302	0.665	rs4795369	chr17:37609120	G/A	cg20243544	chr17:37824526	PNMT	0.56	6.75	0.4	1.17e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs9815354	1.000	rs1629460	chr3:41927449	T/G	cg03022575	chr3:42003672	ULK4	-0.56	-5.38	-0.33	1.79e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2066819	1.000	rs808919	chr12:56647911	C/G	cg26316697	chr12:56727976	PAN2	-0.85	-6.12	-0.37	3.92e-9	Psoriasis vulgaris;
SARC	cis	rs7412746	0.646	rs10399947	chr1:150861960	G/A	cg15448220	chr1:150897856	SETDB1	0.51	6.68	0.4	1.69e-10	Melanoma;
SARC	cis	rs2204008	0.715	rs3899385	chr12:38169880	C/G	cg13010199	chr12:38710504	ALG10B	0.78	10.64	0.57	8.11e-22	Bladder cancer;
SARC	cis	rs9814567	1.000	rs13096604	chr3:134250099	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	7.08	0.42	1.73e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg21782813	chr7:2030301	MAD1L1	0.32	4.85	0.3	2.31e-6	Schizophrenia;
SARC	cis	rs7246657	0.943	rs7258692	chr19:37818829	C/A	cg14683738	chr19:37701593	ZNF585B	0.52	4.87	0.3	2.04e-6	Coronary artery calcification;
SARC	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg03060546	chr3:49711283	APEH	0.46	5.78	0.35	2.41e-8	Parkinson's disease;
SARC	cis	rs9457247	0.967	rs377753	chr6:167389496	A/T	cg07741184	chr6:167504864	NA	0.29	5.49	0.34	1.04e-7	Crohn's disease;
SARC	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.32	-4.84	-0.3	2.36e-6	Total body bone mineral density;
SARC	cis	rs7605378	0.528	rs7592587	chr2:200786516	C/G	cg23649088	chr2:200775458	C2orf69	0.79	10.91	0.58	1.2e-22	Osteoporosis;
SARC	cis	rs9291683	0.620	rs11722946	chr4:10125990	A/G	cg11266682	chr4:10021025	SLC2A9	-0.37	-6.45	-0.39	6.49e-10	Bone mineral density;
SARC	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	11.6	0.61	7.26e-25	Alzheimer's disease;
SARC	cis	rs11651000	0.625	rs4794067	chr17:45808828	T/C	cg03474202	chr17:45855739	NA	-0.38	-5.56	-0.34	7.43e-8	IgG glycosylation;
SARC	cis	rs17023223	0.553	rs11484962	chr1:119725186	G/A	cg05756136	chr1:119680316	WARS2	-0.49	-5.62	-0.35	5.47e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs4853036	0.540	rs10182437	chr2:70004024	A/G	cg02498382	chr2:70120550	SNRNP27	-0.35	-4.86	-0.3	2.13e-6	Colorectal or endometrial cancer;
SARC	cis	rs3888647	0.561	rs4758617	chr11:2995185	T/A	cg25174290	chr11:3078921	CARS	0.56	8.03	0.47	4.68e-14	Type 2 diabetes;
SARC	trans	rs61931739	0.500	rs11053236	chr12:34507962	C/G	cg13010199	chr12:38710504	ALG10B	0.82	11.59	0.6	7.83e-25	Morning vs. evening chronotype;
SARC	cis	rs4889855	0.505	rs8082303	chr17:78605012	A/G	cg17956530	chr17:78667699	RPTOR	-0.47	-5.4	-0.33	1.65e-7	Fractional excretion of uric acid;
SARC	cis	rs1538970	0.962	rs9429076	chr1:45819489	A/G	cg05343316	chr1:45956843	TESK2	0.64	7.53	0.44	1.09e-12	Platelet count;
SARC	cis	rs796364	1.000	rs4410273	chr2:200818258	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.78	7.23	0.43	6.92e-12	Schizophrenia;
SARC	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-9.57	-0.53	1.66e-18	Chronic sinus infection;
SARC	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg05368731	chr17:41323189	NBR1	0.67	7.85	0.46	1.5e-13	Menopause (age at onset);
SARC	cis	rs7264396	0.733	rs2425105	chr20:34312834	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-8.49	-0.49	2.46e-15	Total cholesterol levels;
SARC	cis	rs8077889	1.000	rs17675122	chr17:41886190	A/G	cg26893861	chr17:41843967	DUSP3	0.93	11.15	0.59	1.97e-23	Triglycerides;
SARC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.68	-8.82	-0.5	2.66e-16	Prudent dietary pattern;
SARC	cis	rs6701037	0.555	rs10912899	chr1:175120715	C/T	cg00321850	chr1:175162397	KIAA0040	0.39	5.88	0.36	1.43e-8	Alcohol dependence;
SARC	cis	rs12950390	0.853	rs56363619	chr17:45854621	T/C	cg24803719	chr17:45855879	NA	-0.48	-7.83	-0.46	1.72e-13	IgG glycosylation;
SARC	cis	rs9393692	0.557	rs6918325	chr6:26327965	T/G	cg13736514	chr6:26305472	NA	-0.4	-4.78	-0.3	3.16e-6	Educational attainment;
SARC	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	8.28	0.48	9.57e-15	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs9457247	0.646	rs239934	chr6:167412048	G/A	cg23791538	chr6:167370224	RNASET2	-0.57	-7.69	-0.45	4.09e-13	Crohn's disease;
SARC	cis	rs6582630	0.519	rs4002438	chr12:38484880	C/T	cg26384229	chr12:38710491	ALG10B	0.84	12.0	0.62	3.64e-26	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg06713675	chr4:122721982	EXOSC9	-0.51	-6.87	-0.41	5.92e-11	Type 2 diabetes;
SARC	cis	rs4642101	0.662	rs1969154	chr3:12829156	A/G	cg24848339	chr3:12840334	CAND2	0.33	4.99	0.31	1.17e-6	QRS complex (12-leadsum);
SARC	cis	rs11097912	0.603	rs7665946	chr4:107189328	T/C	cg09646026	chr4:107269030	AIMP1	-0.44	-4.74	-0.3	3.68e-6	Airflow obstruction;
SARC	cis	rs8180040	0.800	rs11921117	chr3:47294000	T/C	cg27129171	chr3:47204927	SETD2	-0.72	-9.53	-0.53	2.16e-18	Colorectal cancer;
SARC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.44	-4.92	-0.31	1.64e-6	Longevity;Endometriosis;
SARC	cis	rs4971059	0.629	rs9297	chr1:155106550	A/G	cg22049894	chr1:155113146	DPM3	0.39	4.83	0.3	2.5e-6	Breast cancer;
SARC	cis	rs28374715	0.662	rs16971558	chr15:41458619	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.99	-12.94	-0.65	3.08e-29	Ulcerative colitis;
SARC	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.93	14.0	0.68	9.68e-33	Chronic sinus infection;
SARC	cis	rs9911578	1.000	rs12952832	chr17:56906254	T/C	cg12560992	chr17:57184187	TRIM37	0.85	11.82	0.61	1.41e-25	Intelligence (multi-trait analysis);
SARC	cis	rs9911578	1.000	rs7223955	chr17:56917053	C/A	cg12560992	chr17:57184187	TRIM37	0.86	12.1	0.62	1.84e-26	Intelligence (multi-trait analysis);
SARC	trans	rs9329221	0.905	rs28712068	chr8:10251145	G/C	cg06636001	chr8:8085503	FLJ10661	-0.68	-9.33	-0.52	8.68e-18	Neuroticism;
SARC	cis	rs10870270	0.956	rs4880405	chr10:133787021	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.82	-9.55	-0.53	1.83e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs1044826	1.000	rs4683818	chr3:139229619	G/T	cg15131784	chr3:139108705	COPB2	0.47	5.27	0.33	3.09e-7	Obesity-related traits;
SARC	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg11890956	chr21:40555474	PSMG1	-1.05	-16.08	-0.73	1.19e-39	Cognitive function;
SARC	cis	rs7769051	1.000	rs3813347	chr6:133119778	G/A	cg07930552	chr6:133119739	C6orf192	0.9	8.04	0.47	4.47e-14	Type 2 diabetes nephropathy;
SARC	cis	rs7937682	0.883	rs1789358	chr11:111474116	G/A	cg22437258	chr11:111473054	SIK2	0.76	10.57	0.57	1.42e-21	Primary sclerosing cholangitis;
SARC	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg12564285	chr5:131593104	PDLIM4	0.35	5.25	0.33	3.46e-7	Breast cancer;
SARC	cis	rs554111	0.891	rs671905	chr1:21047092	A/T	cg04902671	chr1:21058625	SH2D5	-0.44	-5.09	-0.32	7.24e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs806795	0.605	rs809871	chr6:26256526	C/G	cg13736514	chr6:26305472	NA	0.58	6.89	0.41	5.24e-11	Mosquito bite size;
SARC	cis	rs7582180	0.663	rs2309794	chr2:100954270	G/A	cg14675211	chr2:100938903	LONRF2	0.49	7.17	0.43	9.59e-12	Intelligence (multi-trait analysis);
SARC	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg12016809	chr21:47604291	C21orf56	0.43	5.13	0.32	6.19e-7	Testicular germ cell tumor;
SARC	cis	rs8038465	0.622	rs17185294	chr15:73858415	C/T	cg15420318	chr15:73925796	NPTN	-0.66	-7.56	-0.44	9.43e-13	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs644799	0.622	rs1255167	chr11:95500213	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.74	10.17	0.55	2.4e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9790314	0.967	rs9821201	chr3:160996155	G/C	cg04691961	chr3:161091175	C3orf57	-0.79	-11.72	-0.61	3.09e-25	Morning vs. evening chronotype;
SARC	cis	rs57561814	0.826	rs116542785	chr7:22747720	G/A	cg26061582	chr7:22766209	IL6	1.09	8.42	0.48	3.93e-15	Tonsillectomy;
SARC	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.38	4.71	0.3	4.2e-6	Tonsillectomy;
SARC	cis	rs13256369	0.950	rs13255655	chr8:8577736	C/T	cg18904891	chr8:8559673	CLDN23	0.51	5.56	0.34	7.33e-8	Obesity-related traits;
SARC	cis	rs4443100	0.837	rs6003490	chr22:23388447	G/A	cg14186256	chr22:23484241	RTDR1	0.49	5.0	0.31	1.13e-6	Serum parathyroid hormone levels;
SARC	cis	rs751728	1.000	rs2296747	chr6:33744882	C/G	cg15252951	chr6:33757062	LEMD2	0.59	6.96	0.42	3.36e-11	Crohn's disease;
SARC	cis	rs2730245	1.000	rs2657365	chr7:158722753	A/T	cg14689365	chr7:158441557	NCAPG2	-0.44	-4.89	-0.31	1.89e-6	Height;
SARC	cis	rs7824557	0.628	rs11991153	chr8:11203107	A/T	cg21775007	chr8:11205619	TDH	0.65	8.4	0.48	4.48e-15	Retinal vascular caliber;
SARC	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg18876405	chr7:65276391	NA	-0.45	-4.94	-0.31	1.46e-6	Aortic root size;
SARC	cis	rs10504229	0.679	rs16921606	chr8:58034477	A/C	cg08219700	chr8:58056026	NA	0.53	5.49	0.34	1.04e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs988958	0.883	rs7559730	chr2:42303937	G/A	cg02435573	chr1:94712239	NA	-0.51	-6.73	-0.4	1.32e-10	Hypospadias;
SARC	cis	rs7769051	0.711	rs9493436	chr6:133088275	T/C	cg07930552	chr6:133119739	C6orf192	0.87	7.69	0.45	4.08e-13	Type 2 diabetes nephropathy;
SARC	cis	rs2816062	0.735	rs2816054	chr1:18896431	C/T	cg18795169	chr1:18902165	NA	-0.79	-12.77	-0.64	1.18e-28	Urate levels in lean individuals;
SARC	cis	rs4466137	0.951	rs336958	chr5:82973396	A/G	cg16102102	chr5:83017553	HAPLN1	-0.68	-8.32	-0.48	7.42e-15	Prostate cancer;
SARC	cis	rs9329221	0.905	rs13252982	chr8:10255105	C/G	cg21775007	chr8:11205619	TDH	-0.42	-5.05	-0.31	9e-7	Neuroticism;
SARC	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg13628971	chr7:2884303	GNA12	0.42	4.81	0.3	2.69e-6	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
SARC	cis	rs11793049	0.515	rs17203945	chr9:116774010	A/G	cg14436106	chr9:116817641	ZNF618	-0.43	-5.15	-0.32	5.47e-7	Coronary artery aneurysm in Kawasaki disease;
SARC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg16405210	chr4:1374714	KIAA1530	-0.86	-11.3	-0.59	6.99e-24	Longevity;
SARC	cis	rs1046896	0.520	rs9895409	chr17:80902719	C/T	cg22027946	chr17:80790580	TBCD;ZNF750	0.39	4.84	0.3	2.4e-6	Glycated hemoglobin levels;
SARC	cis	rs76419734	0.558	rs73837046	chr4:106523319	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.67	5.85	0.36	1.66e-8	Post bronchodilator FEV1;
SARC	cis	rs11122272	0.735	rs2790893	chr1:231508976	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs2070488	0.965	rs7372849	chr3:38524328	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.83	13.44	0.66	7.26e-31	Electrocardiographic conduction measures;
SARC	cis	rs7769051	1.000	rs6934161	chr6:133124077	C/T	cg22852734	chr6:133119734	C6orf192	-1.11	-11.33	-0.6	5.43e-24	Type 2 diabetes nephropathy;
SARC	cis	rs6582630	0.623	rs12299293	chr12:38436288	G/A	cg26384229	chr12:38710491	ALG10B	-0.57	-7.13	-0.42	1.24e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg25894440	chr7:65020034	NA	-0.76	-5.85	-0.36	1.63e-8	Diabetic kidney disease;
SARC	cis	rs2549003	1.000	rs17848418	chr5:131821188	C/T	cg21138405	chr5:131827807	IRF1	0.27	5.32	0.33	2.4e-7	Asthma (sex interaction);
SARC	cis	rs10782582	0.609	rs72979226	chr1:76302222	C/A	cg03433033	chr1:76189801	ACADM	-0.39	-4.98	-0.31	1.24e-6	Daytime sleep phenotypes;
SARC	cis	rs4595586	0.545	rs1319791	chr12:39372486	G/T	cg26384229	chr12:38710491	ALG10B	0.52	6.21	0.38	2.4e-9	Morning vs. evening chronotype;
SARC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-4.93	-0.31	1.59e-6	Total body bone mineral density;
SARC	cis	rs9290065	0.519	rs1562465	chr3:160701442	G/A	cg17135325	chr3:160939158	NMD3	0.4	4.73	0.3	3.91e-6	Kawasaki disease;
SARC	cis	rs2120243	0.539	rs1840673	chr3:157117977	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.39	4.96	0.31	1.37e-6	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs4555082	0.874	rs28822720	chr14:105746282	T/C	cg10792982	chr14:105748885	BRF1	0.51	7.84	0.46	1.63e-13	Mean platelet volume;Platelet distribution width;
SARC	cis	rs1971762	0.583	rs2365345	chr12:54086820	C/T	cg06632207	chr12:54070931	ATP5G2	0.44	5.73	0.35	3.16e-8	Height;
SARC	cis	rs6733011	0.628	rs10188156	chr2:99465875	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.41	-5.12	-0.32	6.48e-7	Bipolar disorder;
SARC	cis	rs2191566	1.000	rs7256908	chr19:44528898	C/T	cg20607764	chr19:44506953	ZNF230	-0.42	-4.76	-0.3	3.33e-6	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs3733589	0.744	rs3775943	chr4:10019984	T/C	cg16430538	chr4:10459836	ZNF518B	0.62	4.97	0.31	1.27e-6	Renal overload gout;
SARC	cis	rs7223966	1.000	rs8080211	chr17:61729882	A/G	cg00588841	chr17:61851480	DDX42;CCDC47	-0.65	-6.79	-0.41	9.36e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1568889	1.000	rs12802830	chr11:28321196	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.73	9.62	0.53	1.13e-18	Bipolar disorder;
SARC	cis	rs698833	0.886	rs2289463	chr2:44565447	A/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.6	7.5	0.44	1.3e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs11581859	0.613	rs6577375	chr1:99197496	G/A	cg20286094	chr1:99190917	SNX7	-0.42	-4.93	-0.31	1.55e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs356220	0.656	rs181489	chr4:90635020	T/C	cg06632027	chr4:90757378	SNCA	0.39	5.0	0.31	1.13e-6	Parkinson's disease;
SARC	cis	rs3768617	0.811	rs12022720	chr1:183017223	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	8.26	0.48	1.09e-14	Fuchs's corneal dystrophy;
SARC	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg21724239	chr8:58056113	NA	0.58	5.69	0.35	3.74e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7582720	1.000	rs72926782	chr2:203811628	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs7561528	0.501	rs11678744	chr2:127888784	C/G	cg12632573	chr2:127783243	NA	0.65	5.84	0.36	1.74e-8	Alzheimer's disease;Alzheimer's disease (late onset);
SARC	cis	rs9303401	0.659	rs17822735	chr17:56620167	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	12.28	0.63	4.56e-27	Cognitive test performance;
SARC	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7833986	0.501	rs2953910	chr8:56968761	C/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.72	7.24	0.43	6.48e-12	Height;
SARC	cis	rs7552404	0.731	rs931507	chr1:76401577	G/A	cg10523679	chr1:76189770	ACADM	-0.44	-5.13	-0.32	6.17e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs1707322	0.928	rs925524	chr1:46496709	A/G	cg06784218	chr1:46089804	CCDC17	-0.35	-6.14	-0.37	3.6e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs11764590	0.724	rs62444917	chr7:2107262	A/C	cg21782813	chr7:2030301	MAD1L1	-0.38	-5.41	-0.33	1.56e-7	Neuroticism;
SARC	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg25072359	chr17:41440525	NA	0.53	6.3	0.38	1.49e-9	Menopause (age at onset);
SARC	cis	rs12478296	1.000	rs55767645	chr2:242999350	G/A	cg18898632	chr2:242989856	NA	-0.64	-4.89	-0.3	1.9e-6	Obesity-related traits;
SARC	cis	rs17854409	1.000	rs17854409	chr20:61491494	T/C	cg05147244	chr20:61493195	TCFL5	0.92	5.97	0.36	8.96e-9	Obesity-related traits;
SARC	cis	rs1153858	1.000	rs1049503	chr15:45653707	T/C	cg21132104	chr15:45694354	SPATA5L1	0.77	10.99	0.58	6.68e-23	Homoarginine levels;
SARC	cis	rs8081692	1	rs8081692	chr17:38154595	A/G	cg17467752	chr17:38218738	THRA	0.47	5.95	0.36	9.64e-9	Neutrophil count;
SARC	cis	rs929354	0.772	rs3802125	chr7:156970563	A/C	cg05182265	chr7:156933206	UBE3C	-0.34	-5.17	-0.32	4.93e-7	Body mass index;
SARC	cis	rs6693567	0.565	rs11205373	chr1:150404708	A/G	cg09579323	chr1:150459698	TARS2	0.45	5.84	0.36	1.74e-8	Migraine;
SARC	cis	rs2361710	1.000	rs2361710	chr17:78111877	C/T	cg06718696	chr17:78121285	EIF4A3	-0.44	-5.34	-0.33	2.17e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
SARC	cis	rs9818758	0.505	rs11716159	chr3:49631585	G/A	cg03060546	chr3:49711283	APEH	-0.63	-5.25	-0.33	3.43e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs7681440	0.933	rs10005233	chr4:90743331	C/T	cg06632027	chr4:90757378	SNCA	0.43	6.1	0.37	4.48e-9	Dementia with Lewy bodies;
SARC	cis	rs6964587	0.810	rs408	chr7:91556284	A/G	cg17063962	chr7:91808500	NA	-0.92	-14.18	-0.68	2.46e-33	Breast cancer;
SARC	cis	rs7607369	0.526	rs4674322	chr2:219513782	C/T	cg02176678	chr2:219576539	TTLL4	0.45	6.07	0.37	5.18e-9	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs12824058	0.831	rs11608407	chr12:130805869	G/A	cg26677194	chr12:130822605	PIWIL1	0.54	7.22	0.43	7.52e-12	Menopause (age at onset);
SARC	cis	rs6733011	0.578	rs4851171	chr2:99510817	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-5.41	-0.33	1.57e-7	Bipolar disorder;
SARC	trans	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg00938859	chr5:1591904	SDHAP3	0.76	7.39	0.44	2.55e-12	Breast cancer;
SARC	cis	rs9303401	0.704	rs740605	chr17:56604811	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.37	0.33	1.87e-7	Cognitive test performance;
SARC	cis	rs4911259	0.552	rs6058925	chr20:31465374	G/A	cg13636640	chr20:31349939	DNMT3B	-0.69	-9.6	-0.53	1.34e-18	Inflammatory bowel disease;
SARC	cis	rs9527	0.590	rs10509764	chr10:104776475	G/A	cg04362960	chr10:104952993	NT5C2	0.45	5.49	0.34	1.05e-7	Arsenic metabolism;
SARC	cis	rs950776	0.518	rs4886571	chr15:78833758	G/A	cg22563815	chr15:78856949	CHRNA5	-0.4	-6.75	-0.4	1.15e-10	Sudden cardiac arrest;
SARC	cis	rs6840360	1.000	rs28710456	chr4:152667171	T/C	cg22705602	chr4:152727874	NA	-0.37	-6.51	-0.39	4.54e-10	Intelligence (multi-trait analysis);
SARC	cis	rs6912958	0.781	rs3918467	chr6:88180388	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.4	-0.39	8.31e-10	Monocyte percentage of white cells;
SARC	cis	rs9309473	0.898	rs7580750	chr2:73788126	A/G	cg07208825	chr2:73871855	ALMS1P	0.32	4.78	0.3	3.16e-6	Metabolite levels;
SARC	cis	rs9916302	0.904	rs7223331	chr17:37482930	A/G	cg07936489	chr17:37558343	FBXL20	0.68	9.16	0.51	2.78e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs13314892	0.734	rs1549746	chr3:69851350	C/T	cg17445875	chr3:69859618	MITF	-0.57	-5.69	-0.35	3.83e-8	QRS complex (12-leadsum);
SARC	cis	rs72945132	0.882	rs1061328	chr11:70185325	C/T	cg05964544	chr11:70165517	PPFIA1	-0.57	-5.54	-0.34	8.15e-8	Coronary artery disease;
SARC	cis	rs34172651	0.917	rs200533	chr16:24754771	C/T	cg06028605	chr16:24865363	SLC5A11	-0.27	-4.96	-0.31	1.38e-6	Intelligence (multi-trait analysis);
SARC	cis	rs10927875	0.541	rs1739840	chr1:16342237	A/G	cg21385522	chr1:16154831	NA	0.55	6.64	0.4	2.24e-10	Dilated cardiomyopathy;
SARC	cis	rs11098499	0.954	rs12510138	chr4:120423935	C/G	cg24375607	chr4:120327624	NA	0.41	5.03	0.31	9.67e-7	Corneal astigmatism;
SARC	cis	rs3768617	0.610	rs10911228	chr1:183049792	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	7.98	0.46	6.71e-14	Fuchs's corneal dystrophy;
SARC	cis	rs72781680	1.000	rs7594510	chr2:24173377	A/G	cg06627628	chr2:24431161	ITSN2	-0.7	-6.69	-0.4	1.64e-10	Lymphocyte counts;
SARC	cis	rs796364	0.806	rs1106400	chr2:201004089	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.66	-6.39	-0.39	8.99e-10	Schizophrenia;
SARC	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg00825309	chr19:58991885	ZNF446	-0.55	-7.7	-0.45	3.88e-13	Uric acid clearance;
SARC	cis	rs10463554	0.927	rs34769	chr5:102447227	T/C	cg23492399	chr5:102201601	PAM	-0.52	-5.72	-0.35	3.2e-8	Parkinson's disease;
SARC	cis	rs11605924	0.934	rs7945565	chr11:45878992	A/G	ch.11.939596F	chr11:45881766	CRY2	-0.47	-5.65	-0.35	4.72e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs2304069	0.954	rs10068537	chr5:149403193	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.9	9.74	0.54	4.99e-19	HIV-1 control;
SARC	cis	rs722599	1.000	rs722599	chr14:75327443	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.49	-6.47	-0.39	5.72e-10	IgG glycosylation;
SARC	trans	rs61931739	0.534	rs4931770	chr12:34044479	G/T	cg26384229	chr12:38710491	ALG10B	0.85	12.34	0.63	2.98e-27	Morning vs. evening chronotype;
SARC	cis	rs796364	0.806	rs10445792	chr2:201078821	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.61	-4.82	-0.3	2.64e-6	Schizophrenia;
SARC	cis	rs6542838	0.704	rs12474283	chr2:99527310	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-6.17	-0.37	3.06e-9	Fear of minor pain;
SARC	trans	rs61931739	0.929	rs10844740	chr12:34067930	C/T	cg13010199	chr12:38710504	ALG10B	-0.54	-7.21	-0.43	7.57e-12	Morning vs. evening chronotype;
SARC	cis	rs300774	0.925	rs300779	chr2:111486	G/A	cg06380356	chr2:467891	NA	-0.35	-4.82	-0.3	2.61e-6	Suicide attempts in bipolar disorder;
SARC	cis	rs7551222	0.752	rs10900596	chr1:204522457	T/C	cg20240347	chr1:204465584	NA	-0.33	-5.9	-0.36	1.25e-8	Schizophrenia;
SARC	cis	rs36051895	0.632	rs72701654	chr9:5161453	T/C	cg02405213	chr9:5042618	JAK2	-0.45	-5.02	-0.31	1.01e-6	Pediatric autoimmune diseases;
SARC	cis	rs1215050	0.791	rs7434393	chr4:98768576	T/C	cg05340658	chr4:99064831	C4orf37	0.44	5.85	0.36	1.62e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg20619563	chr6:84621458	CYB5R4	0.53	7.61	0.45	6.76e-13	Thyroid stimulating hormone;
SARC	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg18252515	chr7:66147081	NA	1.29	11.21	0.59	1.32e-23	Diabetic kidney disease;
SARC	trans	rs459571	0.916	rs467303	chr9:136904835	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.59	-6.67	-0.4	1.89e-10	Platelet distribution width;
SARC	cis	rs7659604	0.846	rs60340409	chr4:122666355	G/C	cg19748678	chr4:122722346	EXOSC9	0.41	4.96	0.31	1.38e-6	Type 2 diabetes;
SARC	cis	rs7123876	0.587	rs184654	chr11:72364405	C/G	cg03713592	chr11:72463424	ARAP1	0.56	5.05	0.31	8.89e-7	Body mass index;
SARC	cis	rs2153535	0.601	rs7738877	chr6:8542230	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	6.42	0.39	7.42e-10	Motion sickness;
SARC	cis	rs8141529	0.636	rs5762813	chr22:29203314	C/T	cg15103426	chr22:29168792	CCDC117	0.62	6.84	0.41	6.78e-11	Lymphocyte counts;
SARC	cis	rs634534	0.561	rs655744	chr11:65776585	G/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.58	-9.13	-0.51	3.33e-17	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg14541582	chr5:601475	NA	-0.4	-4.93	-0.31	1.54e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs858239	0.539	rs2178139	chr7:23191636	A/G	cg23682824	chr7:23144976	KLHL7	0.74	9.66	0.53	8.86e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs1843834	0.539	rs2068244	chr2:225440011	A/G	cg22509189	chr2:225307070	NA	0.72	8.62	0.49	1.04e-15	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs8077889	0.672	rs4793028	chr17:41857212	T/C	cg26893861	chr17:41843967	DUSP3	0.98	15.6	0.71	4.78e-38	Triglycerides;
SARC	cis	rs17376456	0.877	rs10476601	chr5:93402522	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.68	0.35	3.93e-8	Diabetic retinopathy;
SARC	trans	rs61931739	0.817	rs1687002	chr12:34170263	T/C	cg26384229	chr12:38710491	ALG10B	0.62	8.31	0.48	8.09e-15	Morning vs. evening chronotype;
SARC	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg24399712	chr22:39784796	NA	-0.43	-5.81	-0.36	2.09e-8	Intelligence (multi-trait analysis);
SARC	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg26119090	chr2:26468346	HADHA;HADHB	0.95	13.96	0.67	1.32e-32	Gut microbiome composition (summer);
SARC	cis	rs6696846	0.715	rs12139373	chr1:205054879	A/C	cg07972983	chr1:205091412	RBBP5	0.53	6.82	0.41	7.74e-11	Red blood cell count;
SARC	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg11062466	chr8:58055876	NA	0.56	5.69	0.35	3.79e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-9.71	-0.54	6.27e-19	Chronic sinus infection;
SARC	cis	rs7208859	0.673	rs55904046	chr17:29215391	G/A	cg13385521	chr17:29058706	SUZ12P	0.86	7.33	0.43	3.87e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg01181863	chr3:195395398	SDHAP2	-0.57	-6.51	-0.39	4.68e-10	Pancreatic cancer;
SARC	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.66	-6.94	-0.41	3.82e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg11203670	chr7:100026453	MEPCE;ZCWPW1	0.51	4.94	0.31	1.49e-6	Platelet count;
SARC	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg14820908	chr5:178986412	RUFY1	0.34	4.72	0.3	4.01e-6	Lung cancer;
SARC	cis	rs6088580	0.524	rs6088564	chr20:33249444	A/G	cg08999081	chr20:33150536	PIGU	-0.34	-4.99	-0.31	1.17e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs1008375	0.932	rs6841784	chr4:17626418	G/A	cg16339924	chr4:17578868	LAP3	0.63	8.23	0.47	1.33e-14	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1728785	0.591	rs10775305	chr16:68656460	A/G	cg02972257	chr16:68554789	NA	-0.43	-5.07	-0.32	8.2e-7	Ulcerative colitis;
SARC	cis	rs9325144	0.555	rs2387847	chr12:38687434	C/T	cg13010199	chr12:38710504	ALG10B	0.55	7.22	0.43	7.12e-12	Morning vs. evening chronotype;
SARC	cis	rs2197308	0.610	rs10880837	chr12:37864924	C/T	cg13010199	chr12:38710504	ALG10B	0.8	11.0	0.58	6.14e-23	Morning vs. evening chronotype;
SARC	trans	rs62103177	0.810	rs62103175	chr18:77622467	C/T	cg05926928	chr17:57297772	GDPD1	1.08	9.41	0.52	5.04e-18	Opioid sensitivity;
SARC	cis	rs526231	0.543	rs34770	chr5:102447646	A/C	cg23492399	chr5:102201601	PAM	-0.52	-5.62	-0.35	5.5e-8	Primary biliary cholangitis;
SARC	cis	rs4481887	1.000	rs4481887	chr1:248496863	A/G	cg13385794	chr1:248469461	NA	0.36	5.35	0.33	2.06e-7	Common traits (Other);
SARC	cis	rs7412746	0.658	rs17660092	chr1:150797748	T/C	cg13175981	chr1:150552382	MCL1	-0.5	-6.13	-0.37	3.73e-9	Melanoma;
SARC	cis	rs2180341	0.920	rs6916990	chr6:127698759	G/A	cg24812749	chr6:127587940	RNF146	1.03	13.28	0.66	2.34e-30	Breast cancer;
SARC	cis	rs17376456	0.877	rs28539612	chr5:93499099	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.02	0.31	1.01e-6	Diabetic retinopathy;
SARC	cis	rs3126085	0.935	rs3120660	chr1:152258701	G/T	cg03465714	chr1:152285911	FLG	0.46	5.55	0.34	7.61e-8	Atopic dermatitis;
SARC	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg00800038	chr16:89945340	TCF25	-0.6	-4.92	-0.31	1.61e-6	Skin colour saturation;
SARC	cis	rs4919087	0.620	rs1253427	chr10:98981092	G/A	cg25902810	chr10:99078978	FRAT1	-0.57	-5.74	-0.35	2.87e-8	Monocyte count;
SARC	cis	rs7264396	1.000	rs6088881	chr20:34165609	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.48	5.45	0.34	1.25e-7	Total cholesterol levels;
SARC	cis	rs3764563	1.000	rs2283603	chr19:15731128	T/C	cg20725493	chr19:15740067	CYP4F8	-0.73	-5.73	-0.35	3.07e-8	Inflammatory biomarkers;
SARC	cis	rs9394159	0.583	rs4713650	chr6:33616828	C/T	cg14003231	chr6:33640908	ITPR3	-0.34	-5.95	-0.36	9.95e-9	Graves' disease;
SARC	cis	rs17445774	1.000	rs17445774	chr2:200859249	A/G	cg17644776	chr2:200775616	C2orf69	-0.44	-5.43	-0.34	1.43e-7	LDL cholesterol to HDL cholesterol ratio;
SARC	cis	rs16944613	0.541	rs6496690	chr15:91097401	T/C	cg26821196	chr15:91095069	CRTC3	0.58	5.79	0.35	2.31e-8	Colorectal cancer;
SARC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg26338869	chr17:61819248	STRADA	0.8	10.83	0.58	2.04e-22	Prudent dietary pattern;
SARC	cis	rs9815354	0.812	rs73069357	chr3:41753319	T/G	cg03022575	chr3:42003672	ULK4	0.62	4.82	0.3	2.56e-6	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs448720	0.811	rs420790	chr15:68184040	G/A	cg05925327	chr15:68127851	NA	-0.35	-5.07	-0.32	8.1e-7	Cognitive performance;
SARC	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg04267008	chr7:1944627	MAD1L1	-0.52	-5.98	-0.36	8.25e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs1707322	0.721	rs11211151	chr1:46112752	T/C	cg06784218	chr1:46089804	CCDC17	0.36	6.25	0.38	1.93e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7246657	0.943	rs10417503	chr19:37842735	T/C	cg23950597	chr19:37808831	NA	-0.6	-5.85	-0.36	1.67e-8	Coronary artery calcification;
SARC	cis	rs673253	0.686	rs11580258	chr1:44016015	G/A	cg10881128	chr1:44031826	PTPRF	0.4	5.12	0.32	6.47e-7	Intelligence (multi-trait analysis);
SARC	cis	rs713587	0.646	rs2384061	chr2:25135620	C/T	cg04586622	chr2:25135609	ADCY3	0.32	5.34	0.33	2.16e-7	Body mass index in non-asthmatics;
SARC	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs10845606	1.000	rs11055013	chr12:12829037	T/C	cg09462578	chr12:12878428	APOLD1	-0.53	-5.35	-0.33	2.1e-7	Systemic lupus erythematosus;
SARC	cis	rs72945132	1.000	rs72945132	chr11:70113901	G/C	cg05964544	chr11:70165517	PPFIA1	-0.56	-5.33	-0.33	2.35e-7	Coronary artery disease;
SARC	cis	rs2832270	0.525	rs73192156	chr21:30457526	C/G	cg24692254	chr21:30365293	RNF160	-0.64	-5.39	-0.33	1.73e-7	Response to mTOR inhibitor (everolimus);
SARC	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg25894440	chr7:65020034	NA	-0.71	-5.4	-0.33	1.62e-7	Diabetic kidney disease;
SARC	trans	rs7824557	0.564	rs2572386	chr8:11236975	A/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.03	-0.42	2.32e-11	Retinal vascular caliber;
SARC	cis	rs700651	0.789	rs10497812	chr2:198911245	A/G	cg00792783	chr2:198669748	PLCL1	-0.43	-4.8	-0.3	2.86e-6	Intracranial aneurysm;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg25408271	chr1:91486822	ZNF644	-0.6	-6.57	-0.4	3.33e-10	Lung cancer in ever smokers;
SARC	cis	rs7216064	0.911	rs6504551	chr17:65903326	T/G	cg12091567	chr17:66097778	LOC651250	-0.61	-7.21	-0.43	7.7e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs834603	0.687	rs11763044	chr7:47481602	G/A	cg23694490	chr7:47445681	TNS3	0.35	6.22	0.38	2.29e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg22168489	chr12:122356033	WDR66	0.74	11.71	0.61	3.35e-25	Mean corpuscular volume;
SARC	cis	rs2011503	0.891	rs2965186	chr19:19497195	T/G	cg15839431	chr19:19639596	YJEFN3	0.5	4.9	0.31	1.78e-6	Bipolar disorder;
SARC	cis	rs1451375	0.756	rs11761683	chr7:50542879	C/T	cg18232548	chr7:50535776	DDC	-0.43	-4.8	-0.3	2.89e-6	Malaria;
SARC	cis	rs9326248	0.581	rs10892053	chr11:116857003	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.64	8.26	0.48	1.11e-14	Blood protein levels;
SARC	cis	rs7236492	0.683	rs79747802	chr18:77198964	C/T	cg15644404	chr18:77186268	NFATC1	-0.66	-6.68	-0.4	1.77e-10	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs9790314	0.905	rs7633186	chr3:161003124	A/G	cg03342759	chr3:160939853	NMD3	-0.63	-8.02	-0.47	5.13e-14	Morning vs. evening chronotype;
SARC	trans	rs629535	0.508	rs56207225	chr8:70146628	C/A	cg21567404	chr3:27674614	NA	-0.94	-10.24	-0.56	1.44e-20	Dupuytren's disease;
SARC	cis	rs981844	0.778	rs55895613	chr4:154638121	G/T	cg14289246	chr4:154710475	SFRP2	0.51	5.26	0.33	3.19e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs12421382	0.570	rs10789736	chr11:109478039	G/C	cg27471124	chr11:109292789	C11orf87	0.35	4.75	0.3	3.57e-6	Schizophrenia;
SARC	cis	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg24110177	chr3:50126178	RBM5	0.69	9.37	0.52	6.58e-18	Body mass index;
SARC	cis	rs6871536	1.000	rs1986009	chr5:131887986	C/A	cg11797159	chr5:131991491	NA	0.39	4.79	0.3	2.92e-6	Asthma (childhood onset);
SARC	cis	rs11578119	0.933	rs6675683	chr1:170453146	C/G	cg09767346	chr1:170501363	GORAB	0.44	5.15	0.32	5.49e-7	Male-pattern baldness;
SARC	cis	rs9596270	0.772	rs11842790	chr13:50924448	A/G	cg12378878	chr13:50700606	DLEU2	-0.42	-5.01	-0.31	1.06e-6	Multiple sclerosis;
SARC	cis	rs10197940	0.624	rs4461258	chr2:152429679	A/G	cg19508488	chr2:152266495	RIF1	-0.48	-5.31	-0.33	2.61e-7	Lung cancer;
SARC	cis	rs7586879	0.662	rs2384059	chr2:25100338	C/T	cg04586622	chr2:25135609	ADCY3	0.32	5.46	0.34	1.22e-7	Body mass index;
SARC	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg11941060	chr3:133502564	NA	-0.41	-5.77	-0.35	2.51e-8	Iron status biomarkers;
SARC	cis	rs72781680	0.898	rs72786277	chr2:24062818	T/G	cg08917208	chr2:24149416	ATAD2B	0.78	7.5	0.44	1.3e-12	Lymphocyte counts;
SARC	cis	rs7113850	0.541	rs76671714	chr11:24231278	C/G	ch.11.24196551F	chr11:24239977	NA	0.76	5.48	0.34	1.12e-7	Bone fracture in osteoporosis;
SARC	cis	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg05084668	chr3:125655381	ALG1L	-0.5	-5.28	-0.33	2.92e-7	Blood pressure (smoking interaction);
SARC	cis	rs523522	0.926	rs10849766	chr12:121025894	G/A	cg27279351	chr12:120934652	DYNLL1	0.72	8.85	0.5	2.22e-16	High light scatter reticulocyte count;
SARC	trans	rs208520	0.690	rs864314	chr6:66814830	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.09	-20.58	-0.8	2.52e-54	Exhaled nitric oxide output;
SARC	cis	rs4737010	0.644	rs555466	chr8:41610346	G/A	cg08923054	chr8:41654455	ANK1	-0.39	-4.8	-0.3	2.78e-6	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
SARC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg09373136	chr17:61933544	TCAM1	0.42	5.82	0.36	1.92e-8	Prudent dietary pattern;
SARC	cis	rs2115630	1.000	rs58581703	chr15:85276935	C/T	cg12501888	chr15:85177176	SCAND2	-0.44	-5.26	-0.33	3.3e-7	P wave terminal force;
SARC	cis	rs2999052	0.951	rs2955117	chr3:127881613	G/A	cg19755928	chr3:128723491	CCDC48	0.4	4.9	0.31	1.76e-6	Hypospadias;
SARC	cis	rs7626444	0.625	rs2669637	chr3:196477369	G/A	cg12930392	chr3:196481615	PAK2	0.25	5.0	0.31	1.13e-6	Monocyte count;
SARC	cis	rs72781680	0.611	rs36052574	chr2:24306587	A/C	cg08917208	chr2:24149416	ATAD2B	0.62	6.39	0.39	9.18e-10	Lymphocyte counts;
SARC	cis	rs79839061	0.610	rs73207794	chr4:872020	T/C	cg07828340	chr4:882639	GAK	0.69	5.16	0.32	5.26e-7	Intelligence (multi-trait analysis);
SARC	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg03060546	chr3:49711283	APEH	0.44	5.43	0.34	1.39e-7	Parkinson's disease;
SARC	cis	rs6685188	0.920	rs6593964	chr1:205662337	G/T	cg26354017	chr1:205819088	PM20D1	0.44	4.73	0.3	3.9e-6	White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs10931896	0.531	rs295117	chr2:201146828	C/T	cg23649088	chr2:200775458	C2orf69	0.59	8.56	0.49	1.57e-15	Systolic blood pressure;
SARC	trans	rs61931739	0.500	rs7310237	chr12:34483435	G/A	cg13010199	chr12:38710504	ALG10B	0.77	10.92	0.58	1.08e-22	Morning vs. evening chronotype;
SARC	trans	rs9329221	0.683	rs658385	chr8:9892177	C/T	cg21775007	chr8:11205619	TDH	-0.48	-6.35	-0.38	1.14e-9	Neuroticism;
SARC	cis	rs79349575	0.651	rs4378658	chr17:46993370	G/A	cg16584676	chr17:46985605	UBE2Z	0.53	6.38	0.39	9.28e-10	Type 2 diabetes;
SARC	cis	rs78456975	1.000	rs10205916	chr2:1558451	A/T	cg26248373	chr2:1572462	NA	0.6	6.15	0.37	3.34e-9	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs2153535	0.580	rs2143356	chr6:8517675	C/T	cg07606381	chr6:8435919	SLC35B3	0.77	10.87	0.58	1.55e-22	Motion sickness;
SARC	cis	rs113835537	0.529	rs10896125	chr11:66288733	G/C	cg24851651	chr11:66362959	CCS	0.37	4.79	0.3	2.92e-6	Airway imaging phenotypes;
SARC	cis	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg14726769	chr10:65224694	JMJD1C;LOC84989	-0.56	-5.28	-0.33	3.03e-7	Cutaneous psoriasis;
SARC	trans	rs9427116	0.502	rs12125166	chr1:154582129	A/G	cg00687095	chr1:176176785	RFWD2	-0.53	-6.67	-0.4	1.84e-10	Blood protein levels;
SARC	cis	rs1008375	0.931	rs6449328	chr4:17700474	C/T	cg16339924	chr4:17578868	LAP3	0.55	7.04	0.42	2.16e-11	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	12.4	0.63	1.88e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs10512697	0.803	rs13189635	chr5:3575571	T/A	cg19473799	chr5:3511975	NA	-0.66	-4.86	-0.3	2.16e-6	Immune response to smallpox vaccine (IL-6);
SARC	cis	rs870825	0.616	rs55674580	chr4:185626605	C/G	cg04058563	chr4:185651563	MLF1IP	0.81	11.25	0.59	9.68e-24	Blood protein levels;
SARC	cis	rs11785400	0.793	rs12546978	chr8:143750205	T/A	cg10596483	chr8:143751796	JRK	-0.53	-6.67	-0.4	1.89e-10	Schizophrenia;
SARC	cis	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg12463550	chr7:65579703	CRCP	0.69	5.23	0.32	3.81e-7	Diabetic kidney disease;
SARC	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg05863683	chr7:1912471	MAD1L1	-0.33	-5.06	-0.31	8.66e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg04944784	chr2:26401820	FAM59B	-0.47	-5.9	-0.36	1.28e-8	Gut microbiome composition (summer);
SARC	cis	rs7624766	0.555	rs9866566	chr3:160543742	G/C	cg22637730	chr3:160473554	PPM1L	0.38	4.84	0.3	2.37e-6	Response to methotrexate in rheumatoid arthritis;
SARC	trans	rs9329221	0.905	rs4610752	chr8:10248962	A/G	cg06636001	chr8:8085503	FLJ10661	-0.69	-9.54	-0.53	2.09e-18	Neuroticism;
SARC	trans	rs61931739	0.517	rs860950	chr12:34104376	C/G	cg13010199	chr12:38710504	ALG10B	0.67	8.91	0.5	1.51e-16	Morning vs. evening chronotype;
SARC	cis	rs9486719	0.895	rs4486019	chr6:96883814	T/C	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.01	-0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs6088580	0.634	rs6087588	chr20:33066369	T/C	cg24642439	chr20:33292090	TP53INP2	0.66	8.69	0.49	6.68e-16	Glomerular filtration rate (creatinine);
SARC	trans	rs8073060	0.586	rs6505485	chr17:33996102	C/T	cg19694781	chr19:47549865	TMEM160	-0.71	-7.25	-0.43	6e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs9324022	0.580	rs10151519	chr14:101175798	G/A	cg18089426	chr14:101175970	NA	0.54	5.99	0.37	7.93e-9	Plateletcrit;
SARC	cis	rs11583043	1.000	rs7521424	chr1:101475901	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.49	5.88	0.36	1.42e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-7.47	-0.44	1.58e-12	Alzheimer's disease;
SARC	cis	rs10504229	0.593	rs80174614	chr8:58024631	G/A	cg08219700	chr8:58056026	NA	0.66	6.49	0.39	5.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1538970	1.000	rs2050884	chr1:45830824	A/G	cg05343316	chr1:45956843	TESK2	0.65	7.57	0.44	8.85e-13	Platelet count;
SARC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg18404041	chr3:52824283	ITIH1	-0.37	-5.55	-0.34	7.63e-8	Bipolar disorder;
SARC	cis	rs2816062	0.813	rs2816044	chr1:18892826	A/G	cg18795169	chr1:18902165	NA	-0.78	-12.32	-0.63	3.49e-27	Urate levels in lean individuals;
SARC	cis	rs9682041	0.561	rs9856511	chr3:170140165	C/G	cg11886554	chr3:170076028	SKIL	0.79	7.36	0.43	3.15e-12	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs7666738	0.830	rs7663924	chr4:99037679	A/G	cg05340658	chr4:99064831	C4orf37	-0.69	-9.63	-0.53	1.08e-18	Colonoscopy-negative controls vs population controls;
SARC	cis	rs875971	0.571	rs78668714	chr7:65939451	G/A	cg11764359	chr7:65958608	NA	0.64	6.18	0.38	2.89e-9	Aortic root size;
SARC	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg08645402	chr16:4508243	NA	0.43	5.53	0.34	8.54e-8	Schizophrenia;
SARC	cis	rs9462027	0.606	rs4513788	chr6:34694779	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.91	-0.36	1.19e-8	Systemic lupus erythematosus;
SARC	cis	rs12142240	0.698	rs72679807	chr1:46846490	G/A	cg10495392	chr1:46806563	NSUN4	0.65	6.88	0.41	5.6e-11	Menopause (age at onset);
SARC	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg07701084	chr6:150067640	NUP43	0.42	5.35	0.33	2.14e-7	Lung cancer;
SARC	cis	rs12579753	0.917	rs7132732	chr12:82206053	C/G	cg07988820	chr12:82153109	PPFIA2	-0.52	-6.11	-0.37	4.18e-9	Resting heart rate;
SARC	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg07701084	chr6:150067640	NUP43	0.37	4.89	0.31	1.86e-6	Lung cancer;
SARC	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg08280861	chr8:58055591	NA	0.72	6.19	0.38	2.62e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg18816107	chr1:151227233	PSMD4	-0.51	-6.46	-0.39	6.12e-10	Breast cancer;
SARC	cis	rs8114671	0.562	rs2076667	chr20:33506964	G/A	cg24642439	chr20:33292090	TP53INP2	0.5	6.12	0.37	3.89e-9	Height;
SARC	cis	rs910316	0.967	rs35446981	chr14:75637351	A/T	cg06637938	chr14:75390232	RPS6KL1	-0.53	-7.28	-0.43	5.2e-12	Height;
SARC	cis	rs6500395	1.000	rs9933237	chr16:48676562	T/C	cg04672837	chr16:48644449	N4BP1	0.46	6.28	0.38	1.65e-9	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs9457247	0.967	rs2149092	chr6:167372978	C/T	cg07741184	chr6:167504864	NA	-0.3	-5.61	-0.34	5.78e-8	Crohn's disease;
SARC	cis	rs8018967	0.622	rs2041073	chr14:73972535	C/T	cg09844916	chr14:74004424	HEATR4;ACOT1	-0.44	-5.66	-0.35	4.33e-8	Blood metabolite ratios;
SARC	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg11890956	chr21:40555474	PSMG1	1.16	19.07	0.78	1.72e-49	Cognitive function;
SARC	cis	rs847851	0.798	rs2177381	chr6:34977375	A/G	cg17149859	chr6:34856158	ANKS1A;TAF11	0.44	4.77	0.3	3.24e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg16405210	chr4:1374714	KIAA1530	-0.43	-4.77	-0.3	3.3e-6	Obesity-related traits;
SARC	cis	rs9911578	0.935	rs304261	chr17:56813782	A/G	cg12560992	chr17:57184187	TRIM37	0.88	12.09	0.62	1.98e-26	Intelligence (multi-trait analysis);
SARC	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg11890956	chr21:40555474	PSMG1	-0.72	-9.54	-0.53	2.04e-18	Menarche (age at onset);
SARC	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg08280861	chr8:58055591	NA	0.58	5.23	0.32	3.69e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9660992	0.573	rs1172161	chr1:205206495	C/T	cg07972983	chr1:205091412	RBBP5	0.57	7.02	0.42	2.35e-11	Mean corpuscular volume;Mean platelet volume;
SARC	trans	rs56341938	0.757	rs1420465	chr3:168715138	C/G	cg14930269	chr3:49142045	QARS	-0.49	-6.27	-0.38	1.7e-9	Lung function (FEV1/FVC);
SARC	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg11764359	chr7:65958608	NA	-0.52	-6.18	-0.38	2.79e-9	Aortic root size;
SARC	cis	rs6831352	0.918	rs4699714	chr4:100060538	A/G	cg13256891	chr4:100009986	ADH5	-0.65	-8.0	-0.46	5.94e-14	Alcohol dependence;
SARC	cis	rs1153858	1.000	rs7169587	chr15:45640379	A/G	cg26924012	chr15:45694286	SPATA5L1	0.75	10.34	0.56	7.26e-21	Homoarginine levels;
SARC	cis	rs7172118	1	rs7172118	chr15:78862453	C/A	cg06917634	chr15:78832804	PSMA4	-0.53	-5.77	-0.35	2.48e-8	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg19346786	chr7:2764209	NA	-0.34	-5.12	-0.32	6.45e-7	Height;
SARC	cis	rs2120243	0.539	rs2047649	chr3:157085605	G/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.4	4.9	0.31	1.76e-6	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs9467711	0.606	rs9379899	chr6:26603015	T/A	cg12826209	chr6:26865740	GUSBL1	0.74	4.98	0.31	1.27e-6	Autism spectrum disorder or schizophrenia;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg23924603	chr19:38826365	CATSPERG	0.52	6.83	0.41	7.26e-11	Tetralogy of Fallot;
SARC	cis	rs425277	1.000	rs427811	chr1:2075560	T/G	cg21442419	chr1:2182373	SKI	-0.53	-6.68	-0.4	1.78e-10	Height;
SARC	cis	rs7551222	0.680	rs2125855	chr1:204546947	T/C	cg20240347	chr1:204465584	NA	-0.29	-5.01	-0.31	1.1e-6	Schizophrenia;
SARC	cis	rs7944584	0.611	rs10838696	chr11:47363285	A/G	cg20307385	chr11:47447363	PSMC3	-0.63	-8.08	-0.47	3.58e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs73206853	0.563	rs57488849	chr12:111181785	C/T	cg10860002	chr12:110842031	ANAPC7	0.58	4.95	0.31	1.41e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs3008870	0.755	rs4655660	chr1:67402953	G/A	cg02640540	chr1:67518911	SLC35D1	0.45	5.19	0.32	4.55e-7	Lymphocyte percentage of white cells;
SARC	cis	rs17376456	0.877	rs10066791	chr5:93350255	G/T	cg21475434	chr5:93447410	FAM172A	0.85	7.56	0.44	9.4e-13	Diabetic retinopathy;
SARC	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg11952622	chr19:58962976	ZNF324B	0.55	7.36	0.43	3.21e-12	Uric acid clearance;
SARC	cis	rs2153535	0.504	rs4493781	chr6:8473941	G/C	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg24531977	chr5:56204891	C5orf35	-0.56	-5.89	-0.36	1.37e-8	Initial pursuit acceleration;
SARC	cis	rs3126085	0.867	rs36033453	chr1:152221226	T/G	cg26876637	chr1:152193138	HRNR	-0.5	-5.63	-0.35	5.07e-8	Atopic dermatitis;
SARC	cis	rs78487399	0.710	rs7567685	chr2:43668169	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-5.69	-0.35	3.78e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs6912958	0.781	rs3757368	chr6:88224495	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-5.79	-0.35	2.32e-8	Monocyte percentage of white cells;
SARC	cis	rs5758511	0.680	rs58654759	chr22:42642576	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.46	6.9	0.41	4.87e-11	Birth weight;
SARC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg11301795	chr4:187892539	NA	-0.74	-11.19	-0.59	1.49e-23	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9398803	0.865	rs2050644	chr6:126805255	A/G	cg19875578	chr6:126661172	C6orf173	0.63	8.72	0.5	5.32e-16	Male-pattern baldness;
SARC	cis	rs2777491	0.872	rs7176588	chr15:41588872	C/T	cg01768344	chr15:41576519	LOC729082	0.46	5.29	0.33	2.87e-7	Ulcerative colitis;
SARC	cis	rs2594989	0.565	rs62245958	chr3:11601493	C/G	cg00170343	chr3:11313890	ATG7	-0.52	-5.42	-0.33	1.49e-7	Circulating chemerin levels;
SARC	cis	rs1691799	0.867	rs1168339	chr12:66759236	T/G	cg16791601	chr12:66731901	HELB	-0.72	-10.84	-0.58	2.01e-22	White blood cell count (basophil);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg27536708	chr12:21654836	RECQL;GOLT1B	0.52	6.35	0.38	1.1e-9	Breast cancer;
SARC	cis	rs524281	0.861	rs7120326	chr11:65849256	C/T	cg14036092	chr11:66035641	RAB1B	-0.48	-5.09	-0.32	7.33e-7	Electroencephalogram traits;
SARC	cis	rs477692	0.870	rs475250	chr10:131412558	C/G	cg05714579	chr10:131428358	MGMT	0.61	8.06	0.47	3.88e-14	Response to temozolomide;
SARC	cis	rs12681288	0.676	rs935820	chr8:1022168	A/G	cg15309053	chr8:964076	NA	0.41	6.76	0.41	1.09e-10	Schizophrenia;
SARC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg03647317	chr4:187891568	NA	-0.35	-5.15	-0.32	5.66e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1008375	0.863	rs10003291	chr4:17600728	A/C	cg16339924	chr4:17578868	LAP3	0.68	8.67	0.49	7.64e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7717697	0.797	rs7711739	chr5:82752134	G/A	cg19814134	chr5:82768288	VCAN	0.44	5.15	0.32	5.61e-7	Vertical cup-disc ratio;
SARC	cis	rs4253772	0.530	rs9615990	chr22:46804154	G/A	cg24881330	chr22:46731750	TRMU	0.68	5.25	0.33	3.38e-7	LDL cholesterol;Cholesterol, total;
SARC	cis	rs7223966	1.000	rs7223672	chr17:61720565	T/C	cg00588841	chr17:61851480	DDX42;CCDC47	-0.62	-6.85	-0.41	6.45e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg04317338	chr11:64019027	PLCB3	0.82	8.84	0.5	2.47e-16	Attention deficit hyperactivity disorder;
SARC	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.7	5.04	0.31	9.44e-7	Initial pursuit acceleration;
SARC	cis	rs3768617	0.811	rs4396114	chr1:183007441	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.61	8.21	0.47	1.53e-14	Fuchs's corneal dystrophy;
SARC	cis	rs17253792	0.822	rs2274075	chr14:56096731	A/G	cg01858014	chr14:56050164	KTN1	-0.68	-5.37	-0.33	1.86e-7	Putamen volume;
SARC	cis	rs3741151	0.773	rs79994237	chr11:73147974	T/C	cg17517138	chr11:73019481	ARHGEF17	0.91	6.78	0.41	9.78e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs1346751	0.512	rs4832591	chr2:16606596	A/G	cg09580478	chr2:16689509	NA	0.43	4.95	0.31	1.45e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
SARC	cis	rs2832191	0.791	rs57721945	chr21:30498744	T/C	cg08807101	chr21:30365312	RNF160	-0.79	-10.93	-0.58	1.04e-22	Dental caries;
SARC	cis	rs9309473	1.000	rs7585004	chr2:73666645	C/G	cg20560298	chr2:73613845	ALMS1	-0.52	-5.92	-0.36	1.14e-8	Metabolite levels;
SARC	cis	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg15556689	chr8:8085844	FLJ10661	-0.46	-5.31	-0.33	2.55e-7	Mood instability;
SARC	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg17376030	chr22:41985996	PMM1	0.72	8.93	0.51	1.28e-16	Vitiligo;
SARC	cis	rs6570726	0.935	rs369458	chr6:145812809	A/G	cg05220968	chr6:146057943	EPM2A	-0.29	-4.83	-0.3	2.44e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9660992	0.573	rs12140703	chr1:205182865	G/C	cg21643547	chr1:205240462	TMCC2	-0.6	-7.74	-0.45	2.95e-13	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs5760092	0.755	rs6003959	chr22:24264395	C/T	cg12419862	chr22:24373484	LOC391322	0.76	8.71	0.5	5.86e-16	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs17376456	0.825	rs13171131	chr5:93223028	C/T	cg21475434	chr5:93447410	FAM172A	0.81	7.11	0.42	1.42e-11	Diabetic retinopathy;
SARC	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg08677398	chr8:58056175	NA	0.43	5.05	0.31	8.92e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs12477438	1.000	rs6732980	chr2:99921613	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-6.6	-0.4	2.72e-10	Chronic sinus infection;
SARC	cis	rs2228479	0.850	rs62054611	chr16:89817017	T/C	cg26513180	chr16:89883248	FANCA	0.72	4.79	0.3	2.99e-6	Skin colour saturation;
SARC	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg11764359	chr7:65958608	NA	0.76	8.99	0.51	8.48e-17	Aortic root size;
SARC	cis	rs7904368	0.806	rs6602161	chr10:16862280	A/G	cg14835575	chr10:16859367	RSU1	0.85	9.18	0.52	2.37e-17	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.54	6.14	0.37	3.48e-9	Prudent dietary pattern;
SARC	cis	rs4595586	0.545	rs4411311	chr12:39363612	C/G	cg13010199	chr12:38710504	ALG10B	0.4	4.75	0.3	3.57e-6	Morning vs. evening chronotype;
SARC	cis	rs77633900	0.614	rs7162982	chr15:76961559	G/A	cg21673338	chr15:77095150	SCAPER	0.55	5.05	0.31	8.72e-7	Non-glioblastoma glioma;Glioma;
SARC	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg25894440	chr7:65020034	NA	-0.75	-5.59	-0.34	6.48e-8	Diabetic kidney disease;
SARC	trans	rs9650657	0.537	rs7016385	chr8:10779472	A/G	cg06636001	chr8:8085503	FLJ10661	0.55	7.17	0.43	9.75e-12	Neuroticism;
SARC	cis	rs6570726	0.935	rs367643	chr6:145859602	A/C	cg05220968	chr6:146057943	EPM2A	-0.3	-5.08	-0.32	7.76e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6568686	0.627	rs17539951	chr6:111664969	G/A	cg15721981	chr6:111408429	SLC16A10	0.64	5.51	0.34	9.48e-8	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs7843479	0.965	rs1564305	chr8:21803816	A/C	cg17168535	chr8:21777572	XPO7	0.61	7.9	0.46	1.08e-13	Mean corpuscular volume;
SARC	cis	rs13161895	0.702	rs73810942	chr5:179499267	C/A	cg02702477	chr5:179499311	RNF130	0.8	7.39	0.44	2.54e-12	LDL cholesterol;
SARC	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg23034840	chr1:205782522	SLC41A1	0.75	8.6	0.49	1.19e-15	Prostate-specific antigen levels;
SARC	cis	rs7659604	0.521	rs4833234	chr4:122694799	T/C	cg19748678	chr4:122722346	EXOSC9	-0.41	-5.08	-0.32	7.74e-7	Type 2 diabetes;
SARC	cis	rs2204008	0.606	rs6582502	chr12:38543352	C/T	cg14851346	chr12:38532713	NA	-0.44	-5.29	-0.33	2.81e-7	Bladder cancer;
SARC	trans	rs61931739	0.534	rs12831685	chr12:34038392	C/T	cg13010199	chr12:38710504	ALG10B	0.66	8.91	0.5	1.5e-16	Morning vs. evening chronotype;
SARC	cis	rs752010	0.902	rs60743712	chr1:42076629	G/A	cg06885757	chr1:42089581	HIVEP3	0.32	5.14	0.32	5.91e-7	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs11638352	0.661	rs2555382	chr15:44424316	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	5.91	0.36	1.23e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg05368731	chr17:41323189	NBR1	0.81	9.9	0.54	1.66e-19	Menopause (age at onset);
SARC	cis	rs7474896	0.526	rs1742235	chr10:38052256	T/C	cg00409905	chr10:38381863	ZNF37A	-0.45	-4.92	-0.31	1.6e-6	Obesity (extreme);
SARC	cis	rs9462027	0.606	rs7768759	chr6:34795685	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-6.1	-0.37	4.37e-9	Systemic lupus erythematosus;
SARC	cis	rs6474412	0.581	rs4737069	chr8:42626560	A/G	cg07906724	chr8:42623946	CHRNA6	-0.3	-5.08	-0.32	7.74e-7	Smoking behavior;
SARC	cis	rs593982	0.777	rs72941015	chr11:65457514	A/C	cg08755490	chr11:65554678	OVOL1	-0.87	-8.36	-0.48	5.77e-15	Atopic dermatitis;
SARC	cis	rs34779708	0.966	rs34630580	chr10:35449228	A/G	cg03585969	chr10:35415529	CREM	0.38	4.74	0.3	3.76e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	12.2	0.62	8.47e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs11785693	0.730	rs62489552	chr8:4956801	T/C	cg26367366	chr8:4980734	NA	0.58	4.96	0.31	1.37e-6	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs2120243	0.539	rs7617727	chr3:157105558	A/C	cg24825693	chr3:157122686	VEPH1	0.48	6.8	0.41	8.83e-11	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	17.95	0.76	7.94e-46	Prudent dietary pattern;
SARC	cis	rs3131513	0.596	rs2206047	chr1:25194700	A/G	cg22509179	chr1:25234806	RUNX3	-0.39	-5.24	-0.32	3.58e-7	Alcohol dependence;
SARC	cis	rs870825	0.929	rs72689273	chr4:185592750	C/T	cg04058563	chr4:185651563	MLF1IP	0.77	8.75	0.5	4.36e-16	Blood protein levels;
SARC	trans	rs75763843	0.793	rs8094405	chr18:42094823	G/A	cg07323648	chr17:35291127	NA	-0.54	-6.24	-0.38	2.04e-9	Mean platelet volume;
SARC	cis	rs2963155	0.518	rs72801080	chr5:142751990	T/C	cg17617527	chr5:142782415	NR3C1	0.84	5.51	0.34	9.38e-8	Breast cancer;
SARC	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	10.98	0.58	6.89e-23	Platelet count;
SARC	cis	rs9811216	1.000	rs3821383	chr3:169489946	A/G	cg14222479	chr3:169487675	ARPM1	0.42	4.99	0.31	1.17e-6	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs1784581	0.588	rs10945792	chr6:162423484	C/T	cg17173639	chr6:162384350	PARK2	0.51	6.48	0.39	5.48e-10	Itch intensity from mosquito bite;
SARC	cis	rs7223966	0.921	rs34699959	chr17:61960720	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.46	5.12	0.32	6.53e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs703842	0.964	rs2014886	chr12:58177437	C/T	cg00677455	chr12:58241039	CTDSP2	0.5	6.53	0.39	4.05e-10	Multiple sclerosis;
SARC	cis	rs372883	0.935	rs1153295	chr21:30704080	T/G	cg24692254	chr21:30365293	RNF160	-0.4	-4.9	-0.31	1.76e-6	Pancreatic cancer;
SARC	cis	rs9616064	0.531	rs867212	chr22:47063330	C/T	cg05621596	chr22:47072043	GRAMD4	0.57	8.33	0.48	7.05e-15	Urate levels in obese individuals;
SARC	cis	rs15676	0.783	rs4489410	chr9:131591649	A/C	cg00228799	chr9:131580591	ENDOG	-0.62	-7.65	-0.45	5.3e-13	Blood metabolite levels;
SARC	cis	rs735396	0.965	rs2257962	chr12:121445808	T/C	cg25281562	chr12:121454272	C12orf43	0.5	6.13	0.37	3.82e-9	N-glycan levels;
SARC	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg12463550	chr7:65579703	CRCP	0.5	5.52	0.34	9.19e-8	Aortic root size;
SARC	cis	rs6582630	0.555	rs11181053	chr12:38271364	T/C	cg13010199	chr12:38710504	ALG10B	-0.54	-6.74	-0.4	1.26e-10	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9894429	0.646	rs7405937	chr17:79597811	G/A	cg18240062	chr17:79603768	NPLOC4	0.6	7.44	0.44	1.94e-12	Eye color traits;
SARC	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg21442419	chr1:2182373	SKI	0.39	5.03	0.31	9.62e-7	Height;
SARC	cis	rs12995491	0.933	rs34366691	chr2:88537451	G/A	cg04511125	chr2:88470314	THNSL2	-0.4	-5.9	-0.36	1.25e-8	Response to metformin (IC50);
SARC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-5.16	-0.32	5.33e-7	Prudent dietary pattern;
SARC	cis	rs4889855	0.530	rs8079792	chr17:78609394	A/G	cg17956530	chr17:78667699	RPTOR	-0.47	-5.38	-0.33	1.86e-7	Fractional excretion of uric acid;
SARC	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg21782813	chr7:2030301	MAD1L1	0.44	6.98	0.42	2.97e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs116095464	0.558	rs9312956	chr5:201812	T/C	cg22857025	chr5:266934	NA	-1.15	-10.78	-0.58	2.97e-22	Breast cancer;
SARC	cis	rs4803468	0.967	rs3786553	chr19:41902746	T/G	cg08477640	chr19:41863820	B9D2	0.41	5.27	0.33	3.14e-7	Height;
SARC	cis	rs12142240	0.660	rs72886903	chr1:46813860	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-5.46	-0.34	1.22e-7	Menopause (age at onset);
SARC	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg04518342	chr5:131593106	PDLIM4	0.39	5.36	0.33	1.96e-7	Acylcarnitine levels;
SARC	cis	rs1580019	0.547	rs56981934	chr7:32535202	C/G	cg07520158	chr7:32535189	LSM5;AVL9	0.61	8.12	0.47	2.79e-14	Cognitive ability;
SARC	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-5.58	-0.34	6.81e-8	Bipolar disorder;
SARC	cis	rs7084402	0.967	rs10763551	chr10:60273898	G/A	cg07615347	chr10:60278583	BICC1	-0.58	-8.42	-0.48	3.92e-15	Refractive error;
SARC	cis	rs11871801	0.517	rs646123	chr17:40720632	G/A	cg20126647	chr17:40714003	COASY	0.52	5.6	0.34	6.03e-8	Crohn's disease;
SARC	cis	rs12950390	0.853	rs11658511	chr17:45856918	T/C	cg03474202	chr17:45855739	NA	-0.43	-6.74	-0.4	1.22e-10	IgG glycosylation;
SARC	trans	rs1814175	0.669	rs12416837	chr11:49669761	G/T	cg15704280	chr7:45808275	SEPT13	-0.77	-11.76	-0.61	2.19e-25	Height;
SARC	cis	rs7005380	0.538	rs1879149	chr8:120931825	C/G	cg21744203	chr8:120868354	DSCC1	0.43	4.95	0.31	1.42e-6	Interstitial lung disease;
SARC	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg07636037	chr3:49044803	WDR6	0.73	10.37	0.56	5.92e-21	Parkinson's disease;
SARC	trans	rs6600671	1.000	rs4844607	chr1:121184059	C/T	cg00646200	chr1:148855367	NA	-0.53	-7.47	-0.44	1.59e-12	Hip geometry;
SARC	cis	rs36051895	0.659	rs2149555	chr9:5053743	C/T	cg02405213	chr9:5042618	JAK2	-0.5	-5.66	-0.35	4.42e-8	Pediatric autoimmune diseases;
SARC	cis	rs11098499	0.865	rs2389809	chr4:120377399	T/C	cg09307838	chr4:120376055	NA	0.92	13.13	0.65	7.35e-30	Corneal astigmatism;
SARC	cis	rs7246657	0.943	rs4803229	chr19:37864682	T/G	cg23950597	chr19:37808831	NA	-0.56	-5.67	-0.35	4.18e-8	Coronary artery calcification;
SARC	cis	rs2439831	0.850	rs9944216	chr15:44160773	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.82	-7.92	-0.46	9.79e-14	Lung cancer in ever smokers;
SARC	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	7.02	0.42	2.46e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6991838	0.798	rs62507575	chr8:66478721	C/T	cg13398993	chr8:66546079	ARMC1	0.43	5.48	0.34	1.08e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1549733	0.515	rs6714760	chr2:218439027	C/A	cg15248979	chr2:219434002	USP37;RQCD1	0.58	5.08	0.32	7.6e-7	Optic disc area;
SARC	cis	rs6545977	0.531	rs2539982	chr2:63111004	G/A	cg17519650	chr2:63277830	OTX1	0.45	6.05	0.37	5.71e-9	Prostate cancer;
SARC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg06873352	chr17:61820015	STRADA	0.53	6.85	0.41	6.67e-11	Prudent dietary pattern;
SARC	cis	rs950776	0.714	rs514743	chr15:78884227	A/T	cg06917634	chr15:78832804	PSMA4	-0.76	-10.22	-0.56	1.66e-20	Sudden cardiac arrest;
SARC	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg11764359	chr7:65958608	NA	-0.8	-9.85	-0.54	2.31e-19	Aortic root size;
SARC	cis	rs17270561	0.609	rs9358876	chr6:25738956	A/G	cg16482183	chr6:26056742	HIST1H1C	0.43	5.22	0.32	3.92e-7	Iron status biomarkers;
SARC	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg18404041	chr3:52824283	ITIH1	0.39	5.93	0.36	1.08e-8	Electroencephalogram traits;
SARC	cis	rs896623	0.639	rs13133584	chr4:122083112	A/T	cg19463078	chr4:122099598	TNIP3	-0.33	-4.79	-0.3	2.97e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg12564285	chr5:131593104	PDLIM4	0.41	5.96	0.36	9.22e-9	Acylcarnitine levels;
SARC	cis	rs1949733	0.523	rs16842563	chr4:8545146	C/T	cg13073564	chr4:8508604	NA	0.47	7.12	0.42	1.31e-11	Response to antineoplastic agents;
SARC	cis	rs9911578	1.000	rs8079774	chr17:56908188	A/G	cg05425664	chr17:57184151	TRIM37	-0.63	-7.79	-0.45	2.23e-13	Intelligence (multi-trait analysis);
SARC	cis	rs2985684	1.000	rs1957977	chr14:50090603	A/G	cg04989706	chr14:50066350	PPIL5	-0.55	-5.84	-0.36	1.79e-8	Carotid intima media thickness;
SARC	cis	rs918629	0.761	rs6881872	chr5:95286726	A/C	cg16656078	chr5:95278638	ELL2	-0.7	-8.29	-0.48	8.84e-15	IgG glycosylation;
SARC	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg05535760	chr7:792225	HEATR2	0.84	8.3	0.48	8.65e-15	Cerebrospinal P-tau181p levels;
SARC	cis	rs8180040	0.932	rs1531875	chr3:47452786	G/A	cg27129171	chr3:47204927	SETD2	0.66	9.17	0.51	2.63e-17	Colorectal cancer;
SARC	cis	rs1865760	0.865	rs2164485	chr6:25952106	G/A	cg18357526	chr6:26021779	HIST1H4A	0.38	4.72	0.3	4.13e-6	Height;
SARC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg14159672	chr1:205819179	PM20D1	0.59	8.0	0.46	5.9e-14	Menarche (age at onset);
SARC	cis	rs7772486	0.743	rs2092262	chr6:146037105	C/T	cg05347473	chr6:146136440	FBXO30	-0.49	-6.55	-0.39	3.64e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1451375	0.617	rs12671474	chr7:50591395	C/A	cg18232548	chr7:50535776	DDC	0.48	4.8	0.3	2.78e-6	Malaria;
SARC	cis	rs12597458	0.789	rs7186207	chr16:72035359	C/T	cg01557791	chr16:72042693	DHODH	-0.76	-12.54	-0.63	6.49e-28	Prostate cancer;
SARC	cis	rs9868809	0.649	rs3733086	chr3:48699519	C/T	cg00383909	chr3:49044727	WDR6	0.59	4.97	0.31	1.28e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.95	13.96	0.67	1.32e-32	Gut microbiome composition (summer);
SARC	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg03670153	chr3:184079754	CLCN2;POLR2H	0.48	7.14	0.42	1.18e-11	Cancer;
SARC	cis	rs820218	0.743	rs820183	chr17:73617377	A/G	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.52	6.37	0.38	1.01e-9	Rotator cuff tears;
SARC	cis	rs763121	0.853	rs1065201	chr22:39069510	T/C	cg06022373	chr22:39101656	GTPBP1	0.86	10.88	0.58	1.41e-22	Menopause (age at onset);
SARC	cis	rs10911363	0.570	rs2702204	chr1:183457396	A/G	cg09173681	chr1:183549694	NCF2	0.31	4.99	0.31	1.17e-6	Systemic lupus erythematosus;
SARC	cis	rs3020736	0.500	rs2839708	chr22:42500745	A/G	cg15557168	chr22:42548783	NA	0.35	4.8	0.3	2.85e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs11697848	1.000	rs77116439	chr20:48509741	T/C	cg17849948	chr20:48532315	SPATA2	0.86	5.17	0.32	4.97e-7	Systemic lupus erythematosus;
SARC	cis	rs1434579	0.526	rs204547	chr19:44947184	T/C	cg15540054	chr19:45004280	ZNF180	-0.42	-5.41	-0.33	1.57e-7	Tuberculosis;
SARC	cis	rs2404602	0.583	rs2176623	chr15:76568579	C/T	cg22467129	chr15:76604101	ETFA	-0.35	-4.72	-0.3	4.05e-6	Blood metabolite levels;
SARC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg05165339	chr4:1420672	NA	0.24	5.41	0.33	1.58e-7	Longevity;
SARC	cis	rs7769051	0.522	rs60631157	chr6:133094817	G/A	cg22852734	chr6:133119734	C6orf192	1.21	8.23	0.47	1.33e-14	Type 2 diabetes nephropathy;
SARC	cis	rs896854	0.714	rs572547	chr8:95966286	A/G	cg09323728	chr8:95962352	TP53INP1	0.29	4.76	0.3	3.33e-6	Type 2 diabetes;
SARC	trans	rs9325144	0.555	rs7968322	chr12:38792348	T/C	cg23762105	chr12:34175262	ALG10	0.49	6.41	0.39	7.83e-10	Morning vs. evening chronotype;
SARC	cis	rs7246657	0.525	rs10401417	chr19:37467540	C/T	cg14683738	chr19:37701593	ZNF585B	0.56	4.95	0.31	1.44e-6	Coronary artery calcification;
SARC	cis	rs7714584	1.000	rs76548544	chr5:150223515	T/A	cg22134413	chr5:150180641	NA	0.78	6.56	0.39	3.42e-10	Crohn's disease;
SARC	cis	rs6088813	1.000	rs6087704	chr20:34001058	C/T	cg14752227	chr20:34000481	UQCC	-0.36	-4.71	-0.3	4.2e-6	Height;
SARC	cis	rs870825	0.655	rs12502771	chr4:185635834	T/C	cg04058563	chr4:185651563	MLF1IP	0.84	11.36	0.6	4.49e-24	Blood protein levels;
SARC	cis	rs1008375	1.000	rs9991307	chr4:17662408	A/G	cg27347728	chr4:17578864	LAP3	0.45	5.56	0.34	7.29e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs820218	0.962	rs820129	chr17:73668107	A/G	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.7	9.75	0.54	4.74e-19	Rotator cuff tears;
SARC	cis	rs7927771	1.000	rs35902101	chr11:47795169	C/T	cg20307385	chr11:47447363	PSMC3	-0.47	-5.59	-0.34	6.3e-8	Subjective well-being;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg11208348	chr7:111849025	ZNF277	0.51	6.94	0.41	3.88e-11	Thyroid stimulating hormone;
SARC	cis	rs72781680	0.611	rs7596060	chr2:24334361	A/G	cg06627628	chr2:24431161	ITSN2	0.49	5.25	0.33	3.43e-7	Lymphocyte counts;
SARC	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.5	-4.99	-0.31	1.2e-6	Lung function (FEV1/FVC);
SARC	cis	rs35110281	0.548	rs2838350	chr21:45109972	T/C	cg21573476	chr21:45109991	RRP1B	-0.61	-8.87	-0.5	1.98e-16	Mean corpuscular volume;
SARC	cis	rs7681440	0.606	rs2583974	chr4:90748297	T/C	cg06632027	chr4:90757378	SNCA	-0.42	-5.25	-0.33	3.41e-7	Dementia with Lewy bodies;
SARC	cis	rs2387326	0.717	rs10829335	chr10:129943515	A/G	cg16087940	chr10:129947807	NA	-0.44	-5.48	-0.34	1.08e-7	Select biomarker traits;
SARC	cis	rs965469	1.000	rs6051732	chr20:3294182	G/A	cg25506879	chr20:3388711	C20orf194	-0.51	-5.17	-0.32	5.02e-7	IFN-related cytopenia;
SARC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	10.46	0.57	2.97e-21	Platelet count;
SARC	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.99	11.37	0.6	4.16e-24	Platelet count;
SARC	cis	rs9611519	0.567	rs8141730	chr22:41473061	A/G	cg03806693	chr22:41940476	POLR3H	-0.53	-6.88	-0.41	5.56e-11	Neuroticism;
SARC	cis	rs4737010	0.644	rs552904	chr8:41610114	C/T	cg08923054	chr8:41654455	ANK1	-0.4	-4.86	-0.3	2.16e-6	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
SARC	cis	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg00409905	chr10:38381863	ZNF37A	-0.55	-8.04	-0.47	4.63e-14	Extrinsic epigenetic age acceleration;
SARC	trans	rs8020941	0.585	rs79635431	chr14:97495134	G/C	cg05136476	chr3:53190709	NA	-0.62	-6.35	-0.38	1.1e-9	Diabetic kidney disease;
SARC	cis	rs7223966	1.000	rs7217982	chr17:61832150	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	6.96	0.41	3.49e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1728785	0.901	rs1170420	chr16:68635877	G/C	cg02972257	chr16:68554789	NA	-0.43	-4.99	-0.31	1.17e-6	Ulcerative colitis;
SARC	cis	rs1920116	0.778	rs35510081	chr3:169549774	A/T	cg08193579	chr3:169529701	LRRC34	0.42	4.91	0.31	1.68e-6	Glioma (high-grade);
SARC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	9.8	0.54	3.29e-19	Platelet count;
SARC	cis	rs7264396	0.635	rs6088971	chr20:34535373	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-7.48	-0.44	1.54e-12	Total cholesterol levels;
SARC	cis	rs2147959	0.941	rs6426503	chr1:228651011	A/G	cg16894439	chr1:228634806	NA	-0.46	-4.97	-0.31	1.27e-6	Adult asthma;
SARC	cis	rs9381040	0.655	rs2294695	chr6:41036770	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-4.75	-0.3	3.5e-6	Alzheimer's disease (late onset);
SARC	cis	rs992157	0.835	rs4674282	chr2:219144230	A/T	cg00012203	chr2:219082015	ARPC2	-0.64	-9.33	-0.52	8.48e-18	Colorectal cancer;
SARC	cis	rs7824557	0.527	rs2736296	chr8:11234844	G/A	cg21775007	chr8:11205619	TDH	-0.65	-8.67	-0.49	7.44e-16	Retinal vascular caliber;
SARC	cis	rs2120243	0.539	rs1545596	chr3:157118526	C/T	cg24825693	chr3:157122686	VEPH1	-0.46	-6.42	-0.39	7.36e-10	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg22920501	chr2:26401640	FAM59B	0.6	7.73	0.45	3.17e-13	Gut microbiome composition (summer);
SARC	cis	rs9916302	0.752	rs6503513	chr17:37561613	A/G	cg07936489	chr17:37558343	FBXL20	0.76	9.73	0.54	5.39e-19	Glomerular filtration rate (creatinine);
SARC	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-10.43	-0.56	3.68e-21	Chronic sinus infection;
SARC	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.58	5.48	0.34	1.1e-7	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs910316	1.000	rs12589376	chr14:75561152	C/T	cg11812906	chr14:75593930	NEK9	0.87	13.66	0.67	1.39e-31	Height;
SARC	cis	rs7772486	0.743	rs62433835	chr6:146032688	C/G	cg23711669	chr6:146136114	FBXO30	-0.8	-12.29	-0.63	4.15e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs854765	0.583	rs11078404	chr17:17820487	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.66	10.0	0.55	7.86e-20	Total body bone mineral density;
SARC	cis	rs6912958	0.781	rs9444522	chr6:88309705	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.54	-0.34	8.32e-8	Monocyte percentage of white cells;
SARC	cis	rs1348850	0.914	rs4893961	chr2:178411075	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.67	8.31	0.48	7.89e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	trans	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg21659725	chr3:3221576	CRBN	0.58	6.41	0.39	8.15e-10	Resting heart rate;
SARC	cis	rs1003719	0.715	rs2212742	chr21:38578685	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-8.88	-0.5	1.88e-16	Eye color traits;
SARC	cis	rs9868809	0.505	rs9811027	chr3:48725014	G/C	cg07636037	chr3:49044803	WDR6	-0.71	-6.77	-0.41	1.04e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg07414643	chr4:187882934	NA	-0.42	-6.18	-0.38	2.81e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9640161	0.750	rs3800780	chr7:150027284	C/A	cg10018233	chr7:150070692	REPIN1	0.68	8.6	0.49	1.22e-15	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs72781680	0.898	rs72782126	chr2:24039901	A/C	cg06627628	chr2:24431161	ITSN2	-0.67	-6.31	-0.38	1.39e-9	Lymphocyte counts;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg16142977	chr19:3985688	EEF2	-0.5	-6.45	-0.39	6.44e-10	Height;
SARC	cis	rs7084402	0.967	rs1649084	chr10:60292117	T/A	cg07615347	chr10:60278583	BICC1	0.61	8.99	0.51	8.99e-17	Refractive error;
SARC	trans	rs66573146	0.572	rs66734745	chr4:6948765	T/C	cg07817883	chr1:32538562	TMEM39B	1.07	8.38	0.48	5.02e-15	Granulocyte percentage of myeloid white cells;
SARC	cis	rs9341808	0.558	rs2490234	chr6:80816966	G/C	cg08355045	chr6:80787529	NA	0.35	5.33	0.33	2.34e-7	Sitting height ratio;
SARC	cis	rs2832191	0.716	rs9983051	chr21:30371890	C/T	cg08807101	chr21:30365312	RNF160	0.9	14.06	0.68	6.56e-33	Dental caries;
SARC	cis	rs611744	0.529	rs13282825	chr8:109263237	T/C	cg21045802	chr8:109455806	TTC35	0.57	7.21	0.43	7.54e-12	Dupuytren's disease;
SARC	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg02931644	chr1:25747376	RHCE	-0.44	-7.31	-0.43	4.34e-12	Erythrocyte sedimentation rate;
SARC	cis	rs765787	0.530	rs12909987	chr15:45512207	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.39	-4.83	-0.3	2.42e-6	Uric acid levels;
SARC	cis	rs9646954	0.560	rs4149507	chr2:101032745	C/T	cg14675211	chr2:100938903	LONRF2	0.55	8.13	0.47	2.52e-14	Intelligence (multi-trait analysis);
SARC	cis	rs7639513	0.737	rs13070228	chr3:12706914	G/A	cg23032965	chr3:12705835	RAF1	0.85	12.42	0.63	1.59e-27	Itch intensity from mosquito bite;
SARC	cis	rs9910055	0.529	rs575798	chr17:42181796	A/C	cg19774624	chr17:42201019	HDAC5	0.56	6.82	0.41	7.78e-11	Total body bone mineral density;
SARC	cis	rs13191362	1.000	rs34344906	chr6:162993378	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.57	5.49	0.34	1.03e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs672059	1.000	rs549844	chr1:183158143	A/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.51	-6.96	-0.41	3.42e-11	Hypertriglyceridemia;
SARC	cis	rs4481887	0.893	rs1934544	chr1:248505582	G/A	cg00666640	chr1:248458726	OR2T12	0.34	5.82	0.36	1.96e-8	Common traits (Other);
SARC	cis	rs2120243	0.539	rs1840668	chr3:157098721	T/C	cg24825693	chr3:157122686	VEPH1	-0.45	-6.27	-0.38	1.74e-9	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs10771431	0.597	rs7976807	chr12:9352459	G/A	cg08997352	chr12:9597637	DDX12	-0.58	-7.86	-0.46	1.39e-13	Breast size;
SARC	cis	rs7568458	0.905	rs6739015	chr2:85755357	A/G	cg17127132	chr2:85788382	GGCX	0.42	5.52	0.34	8.92e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	19.66	0.79	2.12e-51	Prudent dietary pattern;
SARC	cis	rs6016377	0.689	rs6029183	chr20:39181070	C/G	cg06424997	chr20:39929561	ZHX3	0.37	4.8	0.3	2.86e-6	Birth weight;
SARC	cis	rs501120	0.636	rs3123689	chr10:44773121	G/A	cg09554077	chr10:44749378	NA	0.47	6.39	0.39	8.81e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg18364779	chr6:26104403	HIST1H4C	-0.43	-5.17	-0.32	5e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2425143	1.000	rs8115150	chr20:34397189	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-5.84	-0.36	1.71e-8	Blood protein levels;
SARC	trans	rs9951602	0.512	rs1903722	chr18:76646539	G/A	cg02800362	chr5:177631904	HNRNPAB	0.67	8.35	0.48	6.27e-15	Obesity-related traits;
SARC	trans	rs1814175	0.645	rs28478790	chr11:50054322	C/A	cg15704280	chr7:45808275	SEPT13	-0.91	-14.49	-0.69	2.43e-34	Height;
SARC	cis	rs1448094	0.549	rs12308898	chr12:86233678	G/A	cg02569458	chr12:86230093	RASSF9	0.39	5.41	0.33	1.57e-7	Major depressive disorder;
SARC	cis	rs1790761	0.607	rs656652	chr11:67343957	C/T	cg00290607	chr11:67383545	NA	0.39	5.28	0.33	3.01e-7	Mean corpuscular volume;
SARC	cis	rs9611519	0.894	rs13053242	chr22:41459486	G/A	cg03806693	chr22:41940476	POLR3H	-0.58	-7.06	-0.42	1.95e-11	Neuroticism;
SARC	cis	rs7710178	0.816	rs468494	chr5:156123671	A/C	cg26439139	chr5:155924786	SGCD	-0.48	-4.8	-0.3	2.79e-6	Airway responsiveness in chronic obstructive pulmonary disease;
SARC	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg20607798	chr8:58055168	NA	0.49	4.83	0.3	2.43e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs12303914	0.762	rs1600130	chr12:10454496	A/G	cg16417563	chr12:10365564	GABARAPL1	-0.4	-4.72	-0.3	4.02e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg12311346	chr5:56204834	C5orf35	-0.39	-4.76	-0.3	3.46e-6	Coronary artery disease;
SARC	cis	rs1008375	0.932	rs9884565	chr4:17655096	A/G	cg16339924	chr4:17578868	LAP3	0.64	8.49	0.49	2.48e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2439831	0.681	rs1549525	chr15:43627855	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	8.94	0.51	1.19e-16	Lung cancer in ever smokers;
SARC	cis	rs1256061	0.603	rs1269056	chr14:64743890	T/C	cg23250157	chr14:64679961	SYNE2	0.46	6.37	0.38	1.02e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs7712401	0.584	rs28373879	chr5:122372402	G/C	cg19412675	chr5:122181750	SNX24	0.44	5.75	0.35	2.75e-8	Mean platelet volume;
SARC	cis	rs7818688	0.697	rs3802191	chr8:95987584	C/T	cg23172400	chr8:95962367	TP53INP1	-0.38	-4.91	-0.31	1.71e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs9300255	0.596	rs10773002	chr12:123746961	A/T	cg00376283	chr12:123451042	ABCB9	-0.54	-6.14	-0.37	3.58e-9	Neutrophil percentage of white cells;
SARC	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg07701084	chr6:150067640	NUP43	0.44	5.7	0.35	3.68e-8	Lung cancer;
SARC	trans	rs35847492	1.000	rs17730481	chr8:9276163	A/G	cg06636001	chr8:8085503	FLJ10661	-0.6	-6.83	-0.41	7.15e-11	Neuroticism;
SARC	cis	rs6582630	0.502	rs11520278	chr12:38359642	T/A	cg13010199	chr12:38710504	ALG10B	0.8	11.05	0.59	4.21e-23	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs698833	0.780	rs9309115	chr2:44510146	A/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.66	8.16	0.47	2.07e-14	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs6752107	1.000	rs6752107	chr2:234161448	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.5	6.83	0.41	7.16e-11	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs9303542	0.625	rs7225995	chr17:46596268	G/C	cg04904318	chr17:46607828	HOXB1	-0.47	-5.32	-0.33	2.41e-7	Ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs826838	0.585	rs12296822	chr12:38625829	A/T	cg13010199	chr12:38710504	ALG10B	-0.52	-6.43	-0.39	7.32e-10	Heart rate;
SARC	cis	rs2153535	0.601	rs2327054	chr6:8443130	T/C	cg07606381	chr6:8435919	SLC35B3	0.8	11.25	0.59	9.89e-24	Motion sickness;
SARC	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg11878867	chr6:150167359	LRP11	-0.34	-4.74	-0.3	3.7e-6	Lung cancer;
SARC	cis	rs7089973	0.604	rs7915943	chr10:116618077	G/A	cg08188268	chr10:116634841	FAM160B1	0.28	4.73	0.3	3.84e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs7829975	0.511	rs1543238	chr8:8134809	A/G	cg06636001	chr8:8085503	FLJ10661	0.78	11.19	0.59	1.53e-23	Mood instability;
SARC	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg09699651	chr6:150184138	LRP11	0.47	6.02	0.37	6.85e-9	Testicular germ cell tumor;
SARC	cis	rs2760061	0.598	rs632832	chr1:228121838	G/T	cg02753203	chr1:228287806	NA	-0.54	-7.66	-0.45	4.9e-13	Diastolic blood pressure;
SARC	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg22968622	chr17:43663579	NA	-0.85	-10.43	-0.56	3.66e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs11190604	1.000	rs2495752	chr10:102326115	T/C	cg07080220	chr10:102295463	HIF1AN	0.8	8.86	0.5	2.11e-16	Palmitoleic acid (16:1n-7) levels;
SARC	trans	rs9329221	0.655	rs656319	chr8:9814411	A/G	cg06636001	chr8:8085503	FLJ10661	-0.69	-9.6	-0.53	1.33e-18	Neuroticism;
SARC	cis	rs7520050	0.778	rs12404197	chr1:46232420	G/A	cg06784218	chr1:46089804	CCDC17	-0.27	-4.83	-0.3	2.49e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs80130819	0.748	rs987986	chr12:48645427	C/G	cg05342945	chr12:48394962	COL2A1	-0.51	-5.47	-0.34	1.17e-7	Prostate cancer;
SARC	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg22535103	chr8:58192502	C8orf71	-0.52	-5.35	-0.33	2.07e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs12142240	0.738	rs17361749	chr1:46806480	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-5.55	-0.34	7.87e-8	Menopause (age at onset);
SARC	cis	rs751728	1.000	rs943477	chr6:33750931	T/C	cg15252951	chr6:33757062	LEMD2	0.58	6.86	0.41	6.27e-11	Crohn's disease;
SARC	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg16414030	chr3:133502952	NA	-0.39	-5.39	-0.33	1.73e-7	Iron status biomarkers;
SARC	cis	rs11864453	0.927	rs1035560	chr16:72032730	T/C	cg16558253	chr16:72132732	DHX38	-0.5	-7.48	-0.44	1.55e-12	Fibrinogen levels;
SARC	cis	rs17376456	0.569	rs1026279	chr5:93209581	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.56	-5.84	-0.36	1.73e-8	Diabetic retinopathy;
SARC	cis	rs1008375	1.000	rs10019856	chr4:17615742	T/A	cg27347728	chr4:17578864	LAP3	0.46	5.64	0.35	4.93e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7552404	0.731	rs11161836	chr1:76354333	C/T	cg10523679	chr1:76189770	ACADM	0.45	5.29	0.33	2.76e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg09699651	chr6:150184138	LRP11	0.39	4.86	0.3	2.13e-6	Lung cancer;
SARC	cis	rs1865760	0.713	rs1130000	chr6:25985396	A/G	cg16482183	chr6:26056742	HIST1H1C	0.5	6.54	0.39	3.86e-10	Height;
SARC	cis	rs6582630	0.555	rs7301250	chr12:38596244	G/T	cg13010199	chr12:38710504	ALG10B	0.71	9.71	0.54	6.4e-19	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.52	-6.54	-0.39	3.77e-10	Lymphocyte counts;
SARC	cis	rs12579753	0.872	rs11519752	chr12:82207300	A/G	cg07988820	chr12:82153109	PPFIA2	-0.52	-6.11	-0.37	4.18e-9	Resting heart rate;
SARC	cis	rs7772486	0.754	rs4896832	chr6:145964151	G/A	cg23711669	chr6:146136114	FBXO30	0.86	14.16	0.68	3.03e-33	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs453301	0.658	rs12114954	chr8:8904862	T/G	cg11995313	chr8:8860691	ERI1	0.46	5.94	0.36	1.05e-8	Joint mobility (Beighton score);
SARC	cis	rs9467773	1.000	rs6925895	chr6:26572165	G/T	cg11502198	chr6:26597334	ABT1	0.53	6.46	0.39	6.05e-10	Intelligence (multi-trait analysis);
SARC	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg14983838	chr19:29218262	NA	0.77	10.45	0.56	3.27e-21	Methadone dose in opioid dependence;
SARC	cis	rs9916302	0.904	rs34363096	chr17:37594294	G/A	cg15445000	chr17:37608096	MED1	0.42	5.01	0.31	1.09e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs748404	0.723	rs512431	chr15:43541939	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.54	-6.41	-0.39	7.96e-10	Lung cancer;
SARC	cis	rs77633900	0.614	rs2468120	chr15:76909975	G/A	cg21673338	chr15:77095150	SCAPER	-0.75	-6.14	-0.37	3.52e-9	Non-glioblastoma glioma;Glioma;
SARC	cis	rs4595586	0.679	rs7131749	chr12:39405462	A/G	cg26384229	chr12:38710491	ALG10B	-0.44	-5.43	-0.34	1.39e-7	Morning vs. evening chronotype;
SARC	cis	rs1580019	0.520	rs6945238	chr7:32646096	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.88	-11.93	-0.62	6.53e-26	Cognitive ability;
SARC	cis	rs9790314	0.586	rs73021449	chr3:161128941	G/A	cg03342759	chr3:160939853	NMD3	-0.61	-7.5	-0.44	1.3e-12	Morning vs. evening chronotype;
SARC	cis	rs7659604	0.605	rs2071486	chr4:122740162	C/T	cg19671926	chr4:122722719	EXOSC9	-0.65	-7.66	-0.45	4.95e-13	Type 2 diabetes;
SARC	cis	rs6693567	0.565	rs696617	chr1:150376311	G/T	cg09579323	chr1:150459698	TARS2	0.46	5.83	0.36	1.87e-8	Migraine;
SARC	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg27266027	chr21:40555129	PSMG1	0.48	5.12	0.32	6.54e-7	Cognitive function;
SARC	cis	rs4901847	0.967	rs7143063	chr14:58549178	A/G	cg15908186	chr14:58618357	C14orf37	-0.44	-4.97	-0.31	1.28e-6	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs2046867	0.908	rs62251648	chr3:72806083	A/G	cg25664220	chr3:72788482	NA	-0.29	-4.81	-0.3	2.66e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
SARC	cis	rs7582720	1.000	rs72934510	chr2:203925360	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.72	0.45	3.5e-13	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs6908034	0.660	rs111509549	chr6:19798370	A/G	cg02682789	chr6:19804855	NA	0.71	5.1	0.32	7.14e-7	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs9790314	0.502	rs2404342	chr3:161092562	C/T	cg04691961	chr3:161091175	C3orf57	-0.52	-6.56	-0.39	3.5e-10	Morning vs. evening chronotype;
SARC	cis	rs3617	0.573	rs56383738	chr3:52908398	T/C	cg18404041	chr3:52824283	ITIH1	0.36	5.23	0.32	3.69e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs2952156	0.920	rs1018246	chr17:37835240	C/T	cg20243544	chr17:37824526	PNMT	0.56	7.49	0.44	1.45e-12	Asthma;
SARC	cis	rs17270561	0.639	rs9356989	chr6:25781950	A/G	cg16482183	chr6:26056742	HIST1H1C	0.52	6.44	0.39	6.85e-10	Iron status biomarkers;
SARC	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg11987759	chr7:65425863	GUSB	0.53	6.72	0.4	1.39e-10	Aortic root size;
SARC	cis	rs2948294	0.524	rs13270062	chr8:8112650	C/A	cg14343924	chr8:8086146	FLJ10661	0.43	4.9	0.31	1.81e-6	Red cell distribution width;
SARC	cis	rs11190604	1.000	rs2495758	chr10:102321900	C/G	cg07080220	chr10:102295463	HIF1AN	0.8	8.81	0.5	2.98e-16	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs9359856	0.673	rs1179897	chr6:90318624	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.57	-5.1	-0.32	7.13e-7	Bipolar disorder;
SARC	cis	rs9911578	1.000	rs9892795	chr17:57023054	G/C	cg12560992	chr17:57184187	TRIM37	0.85	11.72	0.61	3.03e-25	Intelligence (multi-trait analysis);
SARC	cis	rs9916302	0.706	rs9908131	chr17:37520449	T/C	cg20243544	chr17:37824526	PNMT	-0.56	-5.96	-0.36	9.3e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs7839435	0.666	rs11777131	chr8:27453762	C/T	cg24592790	chr8:27450047	NA	0.46	4.74	0.3	3.78e-6	Lung adenocarcinoma;
SARC	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg18404041	chr3:52824283	ITIH1	-0.38	-5.59	-0.34	6.45e-8	Bipolar disorder;
SARC	trans	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg00938859	chr5:1591904	SDHAP3	0.79	7.66	0.45	5.1e-13	Breast cancer;
SARC	cis	rs6912958	0.702	rs6906769	chr6:88235949	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-5.72	-0.35	3.18e-8	Monocyte percentage of white cells;
SARC	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg24399712	chr22:39784796	NA	-0.43	-5.64	-0.35	5.01e-8	Intelligence (multi-trait analysis);
SARC	cis	rs12142240	0.698	rs72677585	chr1:46812374	T/C	cg10495392	chr1:46806563	NSUN4	0.65	6.8	0.41	8.47e-11	Menopause (age at onset);
SARC	cis	rs6456156	0.792	rs2039321	chr6:167516299	C/T	cg07741184	chr6:167504864	NA	0.37	7.04	0.42	2.2e-11	Primary biliary cholangitis;
SARC	cis	rs2242194	0.816	rs6671688	chr1:154994265	T/C	cg16680214	chr1:154839983	KCNN3	-0.33	-5.11	-0.32	6.56e-7	Schizophrenia;
SARC	cis	rs7264396	0.563	rs6060569	chr20:34290731	C/A	cg01084648	chr20:34329383	RBM39	0.56	4.93	0.31	1.57e-6	Total cholesterol levels;
SARC	cis	rs11608355	0.545	rs11609019	chr12:109895958	G/A	cg05360138	chr12:110035743	NA	0.92	9.61	0.53	1.27e-18	Neuroticism;
SARC	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.91	-14.54	-0.69	1.6e-34	Chronic sinus infection;
SARC	cis	rs2795502	1.000	rs2795503	chr10:43347224	T/A	cg20628663	chr10:43360327	NA	-0.49	-6.57	-0.4	3.23e-10	Blood protein levels;
SARC	cis	rs501120	0.810	rs684666	chr10:44745847	T/C	cg09554077	chr10:44749378	NA	0.47	6.48	0.39	5.32e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs611744	0.967	rs655707	chr8:109197530	T/C	cg21045802	chr8:109455806	TTC35	0.43	5.03	0.31	9.65e-7	Dupuytren's disease;
SARC	cis	rs7264396	0.836	rs961020	chr20:34182069	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.53	-5.54	-0.34	8.32e-8	Total cholesterol levels;
SARC	cis	rs78320035	1.000	rs79725794	chr1:168166010	T/G	cg17113809	chr1:168148080	TIPRL	1.26	6.8	0.41	8.48e-11	Red cell distribution width;
SARC	cis	rs11645898	0.935	rs4788615	chr16:72192372	G/A	cg14768367	chr16:72042858	DHODH	-0.63	-5.57	-0.34	6.92e-8	Blood protein levels;
SARC	cis	rs477895	0.568	rs12418035	chr11:63871558	G/A	cg04317338	chr11:64019027	PLCB3	0.76	8.06	0.47	4.07e-14	Mean platelet volume;
SARC	cis	rs10463316	0.862	rs10071166	chr5:150768795	T/C	cg03212797	chr5:150827313	SLC36A1	-0.46	-5.52	-0.34	9.22e-8	Metabolite levels (Pyroglutamine);
SARC	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg12463550	chr7:65579703	CRCP	-0.71	-5.37	-0.33	1.9e-7	Diabetic kidney disease;
SARC	cis	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg22857025	chr5:266934	NA	-1.04	-11.38	-0.6	3.73e-24	Breast cancer;
SARC	cis	rs7223966	1.000	rs7209758	chr17:61913621	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.46	4.79	0.3	2.98e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs918629	0.798	rs3777170	chr5:95284340	T/C	cg16656078	chr5:95278638	ELL2	-0.63	-7.66	-0.45	5.03e-13	IgG glycosylation;
SARC	cis	rs6690583	0.524	rs12030837	chr1:85519383	A/G	cg22153463	chr1:85462885	MCOLN2	-0.68	-5.17	-0.32	4.95e-7	Serum sulfate level;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg02322376	chr2:220071368	ZFAND2B	-0.79	-6.28	-0.38	1.65e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg12648201	chr2:27665141	KRTCAP3	-0.32	-4.8	-0.3	2.89e-6	Total body bone mineral density;
SARC	cis	rs7084402	0.967	rs1649025	chr10:60281584	C/G	cg07615347	chr10:60278583	BICC1	-0.6	-8.82	-0.5	2.71e-16	Refractive error;
SARC	cis	rs4423214	1.000	rs12807718	chr11:71171170	T/C	cg05163923	chr11:71159392	DHCR7	0.67	9.47	0.53	3.19e-18	Vitamin D levels;
SARC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg06873352	chr17:61820015	STRADA	0.53	6.85	0.41	6.67e-11	Prudent dietary pattern;
SARC	cis	rs6484504	0.625	rs1535741	chr11:31375072	T/C	cg26647111	chr11:31128758	NA	0.39	5.0	0.31	1.13e-6	Red blood cell count;
SARC	cis	rs734999	0.545	rs6666430	chr1:2698950	G/A	cg20673091	chr1:2541236	MMEL1	0.31	4.81	0.3	2.65e-6	Ulcerative colitis;
SARC	cis	rs7843479	0.965	rs11135741	chr8:21801091	C/T	cg17168535	chr8:21777572	XPO7	0.63	8.06	0.47	3.85e-14	Mean corpuscular volume;
SARC	cis	rs7113874	0.613	rs10840066	chr11:8532003	G/A	cg09828998	chr11:8703972	RPL27A	0.51	5.52	0.34	9.2e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs56279505	0.629	rs35189763	chr4:100261252	C/A	cg21156590	chr1:3420848	MEGF6	-0.83	-6.43	-0.39	7.07e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6120849	0.707	rs6120826	chr20:33671831	G/A	cg24642439	chr20:33292090	TP53INP2	0.57	5.44	0.34	1.33e-7	Protein C levels;
SARC	cis	rs7666738	0.830	rs34070283	chr4:98893027	A/T	cg05340658	chr4:99064831	C4orf37	0.64	8.45	0.48	3.18e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg03709012	chr19:19516395	GATAD2A	0.96	15.32	0.71	4.24e-37	Tonsillectomy;
SARC	cis	rs3796352	1.000	rs58660500	chr3:53086573	C/T	cg15956490	chr3:53032818	SFMBT1	0.89	6.02	0.37	6.61e-9	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs634534	0.561	rs14157	chr11:65769780	T/G	cg04055107	chr11:65626734	MUS81;CFL1	0.41	5.16	0.32	5.21e-7	Sum eosinophil basophil counts;Eosinophil counts;
SARC	trans	rs9329221	0.905	rs17765901	chr8:10249480	G/T	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.63	-0.4	2.38e-10	Neuroticism;
SARC	cis	rs950169	0.960	rs12905475	chr15:84800495	G/A	cg17507749	chr15:85114479	UBE2QP1	0.75	8.77	0.5	3.8e-16	Schizophrenia;
SARC	cis	rs11264799	0.626	rs12726950	chr1:157575676	A/T	cg18268488	chr1:157545234	FCRL4	0.33	5.62	0.35	5.39e-8	IgA nephropathy;
SARC	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg22834771	chr12:69754056	YEATS4	-0.48	-6.29	-0.38	1.55e-9	Cerebrospinal fluid biomarker levels;
SARC	cis	rs1355223	0.583	rs2915179	chr11:34871943	C/T	cg18508148	chr11:34937573	PDHX;APIP	0.49	6.29	0.38	1.56e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg26116260	chr4:7069785	GRPEL1	-0.84	-8.98	-0.51	9.06e-17	Monocyte percentage of white cells;
SARC	trans	rs7824557	0.527	rs2572447	chr8:11239510	G/A	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.39	-0.39	8.91e-10	Retinal vascular caliber;
SARC	cis	rs754466	0.606	rs11002309	chr10:79594931	C/T	cg17075019	chr10:79541650	NA	-0.82	-12.67	-0.64	2.43e-28	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7662987	0.517	rs2851263	chr4:100030354	A/G	cg13256891	chr4:100009986	ADH5	0.68	8.56	0.49	1.59e-15	Smoking initiation;
SARC	cis	rs899997	1.000	rs12899940	chr15:79001699	A/G	cg04896959	chr15:78267971	NA	-0.5	-6.08	-0.37	4.89e-9	Coronary artery disease or large artery stroke;
SARC	trans	rs36093844	0.898	rs11234457	chr11:85591041	C/T	cg27065003	chr5:122429449	PRDM6	-0.49	-6.24	-0.38	2.06e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs3857067	0.806	rs4693375	chr4:95133241	C/A	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.1	-0.32	7.08e-7	QT interval;
SARC	cis	rs9916302	0.653	rs4239223	chr17:37717004	T/C	cg20243544	chr17:37824526	PNMT	0.54	5.65	0.35	4.73e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs4727027	0.933	rs1468369	chr7:148839840	G/C	cg23583168	chr7:148888333	NA	-0.74	-11.01	-0.59	5.64e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs4925386	1.000	rs6121990	chr20:60919263	G/A	cg24112000	chr20:60950667	NA	0.33	5.32	0.33	2.46e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs7223966	0.515	rs2727315	chr17:61961458	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	6.53	0.39	4.05e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9787249	0.957	rs12239844	chr1:40217258	T/C	cg24920358	chr1:40204285	PPIE	0.43	5.15	0.32	5.58e-7	Blood protein levels;
SARC	cis	rs453301	0.631	rs7843369	chr8:8797786	T/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.79	-0.41	9.08e-11	Joint mobility (Beighton score);
SARC	cis	rs4919087	0.715	rs34787876	chr10:98999213	T/C	cg25902810	chr10:99078978	FRAT1	-0.52	-6.2	-0.38	2.52e-9	Monocyte count;
SARC	cis	rs2933343	0.649	rs1683786	chr3:128626952	T/C	cg25356066	chr3:128598488	ACAD9	0.69	9.27	0.52	1.33e-17	IgG glycosylation;
SARC	cis	rs2075371	0.897	rs12667905	chr7:134000812	A/C	cg20476274	chr7:133979776	SLC35B4	0.59	7.66	0.45	5.05e-13	Mean platelet volume;
SARC	cis	rs10463316	0.744	rs6579869	chr5:150763621	G/A	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.28	-0.33	2.89e-7	Metabolite levels (Pyroglutamine);
SARC	trans	rs9951602	0.512	rs12454617	chr18:76656007	C/T	cg02800362	chr5:177631904	HNRNPAB	0.71	8.95	0.51	1.17e-16	Obesity-related traits;
SARC	cis	rs10463554	0.750	rs26257	chr5:102550531	C/T	cg23492399	chr5:102201601	PAM	-0.52	-5.61	-0.35	5.62e-8	Parkinson's disease;
SARC	cis	rs950169	1.000	rs34751999	chr15:84758419	T/C	cg17507749	chr15:85114479	UBE2QP1	0.75	9.12	0.51	3.59e-17	Schizophrenia;
SARC	cis	rs10504229	0.679	rs4738574	chr8:58033771	T/C	cg22535103	chr8:58192502	C8orf71	-0.55	-5.6	-0.34	5.89e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs921968	0.548	rs13427522	chr2:219438359	C/T	cg02176678	chr2:219576539	TTLL4	0.36	5.52	0.34	9.16e-8	Mean corpuscular hemoglobin concentration;
SARC	cis	rs1949733	0.523	rs56053534	chr4:8542876	G/A	cg05004818	chr4:8539015	NA	0.37	4.75	0.3	3.63e-6	Response to antineoplastic agents;
SARC	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg00149659	chr3:10157352	C3orf10	0.69	6.38	0.39	9.5e-10	Alzheimer's disease;
SARC	cis	rs7927592	0.913	rs7102898	chr11:68328870	G/A	cg01657329	chr11:68192670	LRP5	-0.43	-5.11	-0.32	6.57e-7	Total body bone mineral density;
SARC	cis	rs644799	0.710	rs1852535	chr11:95501241	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.61	8.27	0.48	1.05e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs10465746	0.780	rs12139191	chr1:84387871	A/C	cg10977910	chr1:84465055	TTLL7	0.43	5.15	0.32	5.49e-7	Obesity-related traits;
SARC	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg00431813	chr7:1051703	C7orf50	-0.31	-4.82	-0.3	2.53e-6	Longevity;Endometriosis;
SARC	cis	rs13191362	0.507	rs2846535	chr6:163034019	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.43	-4.81	-0.3	2.75e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs240764	0.578	rs6928418	chr6:101175347	T/C	cg09795085	chr6:101329169	ASCC3	0.41	5.07	0.32	8.18e-7	Neuroticism;
SARC	cis	rs2153535	0.607	rs9502722	chr6:8541483	C/T	cg21535247	chr6:8435926	SLC35B3	0.53	6.56	0.39	3.47e-10	Motion sickness;
SARC	cis	rs7223966	1.000	rs6504171	chr17:61710010	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.32	0.38	1.33e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg09373136	chr17:61933544	TCAM1	-0.45	-6.13	-0.37	3.74e-9	Prudent dietary pattern;
SARC	cis	rs7918232	0.556	rs788209	chr10:27434716	G/T	cg14442939	chr10:27389572	ANKRD26	0.7	5.03	0.31	9.84e-7	Breast cancer;
SARC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.09	0.37	4.62e-9	Prudent dietary pattern;
SARC	cis	rs56235845	0.694	rs6875461	chr5:176754665	C/T	cg06060754	chr5:176797920	RGS14	-0.45	-6.0	-0.37	7.48e-9	Hemoglobin concentration;Hematocrit;
SARC	cis	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg12064134	chr16:90016061	DEF8	-0.59	-5.05	-0.31	8.75e-7	Skin colour saturation;
SARC	cis	rs889312	0.500	rs832570	chr5:56156408	G/A	cg24549020	chr5:56110836	MAP3K1	0.4	4.79	0.3	2.94e-6	Breast cancer;Breast cancer (early onset);
SARC	cis	rs853679	0.585	rs201004	chr6:27804934	T/C	cg17221315	chr6:27791827	HIST1H4J	0.55	5.1	0.32	7.14e-7	Depression;
SARC	cis	rs6696846	0.791	rs11240352	chr1:205051711	C/G	cg07972983	chr1:205091412	RBBP5	-0.5	-6.5	-0.39	4.95e-10	Red blood cell count;
SARC	cis	rs7666738	0.830	rs6830124	chr4:99054872	C/T	cg05340658	chr4:99064831	C4orf37	-0.65	-8.77	-0.5	3.78e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg21132104	chr15:45694354	SPATA5L1	0.77	10.93	0.58	9.91e-23	Homoarginine levels;
SARC	cis	rs116095464	0.558	rs6866632	chr5:264429	C/G	cg20965017	chr5:231967	SDHA	-0.54	-4.95	-0.31	1.44e-6	Breast cancer;
SARC	cis	rs7617773	0.780	rs13066044	chr3:48377276	C/T	cg11946769	chr3:48343235	NME6	0.76	9.57	0.53	1.61e-18	Coronary artery disease;
SARC	cis	rs17376456	0.825	rs10051878	chr5:93064164	T/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.68	6.28	0.38	1.65e-9	Diabetic retinopathy;
SARC	cis	rs6963495	0.818	rs55983796	chr7:105170941	C/T	cg13798780	chr7:105162888	PUS7	0.6	5.55	0.34	7.84e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs2439831	0.681	rs825739	chr15:43592428	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.07	12.24	0.63	6.06e-27	Lung cancer in ever smokers;
SARC	cis	rs79149102	0.649	rs12443172	chr15:75119671	G/C	cg09165964	chr15:75287851	SCAMP5	-1.15	-6.66	-0.4	1.92e-10	Lung cancer;
SARC	cis	rs1448094	0.817	rs10863112	chr12:86330844	C/T	cg02569458	chr12:86230093	RASSF9	0.41	5.84	0.36	1.73e-8	Major depressive disorder;
SARC	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg15448220	chr1:150897856	SETDB1	0.45	5.99	0.37	7.81e-9	Tonsillectomy;
SARC	cis	rs11676348	0.967	rs4674258	chr2:218990586	C/T	cg00012203	chr2:219082015	ARPC2	-0.44	-5.81	-0.36	1.99e-8	Ulcerative colitis;
SARC	trans	rs7819412	0.740	rs7844536	chr8:11034028	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.13	-0.42	1.25e-11	Triglycerides;
SARC	cis	rs9902453	0.933	rs60694493	chr17:28473256	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	6.52	0.39	4.21e-10	Coffee consumption (cups per day);
SARC	cis	rs7474896	0.559	rs1735629	chr10:38178309	C/T	cg25427524	chr10:38739819	LOC399744	0.52	6.21	0.38	2.44e-9	Obesity (extreme);
SARC	cis	rs3784262	0.904	rs3784263	chr15:58253062	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.37	-5.59	-0.34	6.47e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg26839252	chr6:160211577	TCP1;MRPL18	0.57	5.08	0.32	7.61e-7	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs672059	1.000	rs625917	chr1:183157991	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.51	6.92	0.41	4.32e-11	Hypertriglyceridemia;
SARC	cis	rs2280018	0.963	rs11075255	chr16:15166232	A/G	cg07549590	chr16:15018862	NA	-0.37	-5.22	-0.32	3.98e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs4319547	1.000	rs10998	chr12:122989412	G/A	cg23029597	chr12:123009494	RSRC2	-0.42	-5.29	-0.33	2.77e-7	Body mass index;
SARC	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-9.04	-0.51	6.31e-17	Alzheimer's disease;
SARC	trans	rs3780486	0.957	rs10971434	chr9:33168891	C/A	cg20290983	chr6:43655470	MRPS18A	1.02	14.3	0.68	9.8e-34	IgG glycosylation;
SARC	cis	rs55823223	0.702	rs3785437	chr17:73906222	G/T	cg06969265	chr17:73775802	H3F3B	1.03	9.0	0.51	8.04e-17	Psoriasis;
SARC	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg11987759	chr7:65425863	GUSB	0.46	6.05	0.37	5.71e-9	Aortic root size;
SARC	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg10523679	chr1:76189770	ACADM	0.43	5.31	0.33	2.55e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs8067545	0.641	rs203450	chr17:19823070	C/T	cg04132472	chr17:19861366	AKAP10	0.39	5.24	0.32	3.59e-7	Schizophrenia;
SARC	cis	rs708547	0.647	rs1713982	chr4:57881715	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.57	7.18	0.43	9.05e-12	Response to bleomycin (chromatid breaks);
SARC	cis	rs6088580	0.634	rs4911418	chr20:32994257	G/A	cg08999081	chr20:33150536	PIGU	-0.44	-6.65	-0.4	2.07e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs1707322	0.717	rs10890345	chr1:46213927	C/T	cg03146154	chr1:46216737	IPP	0.52	6.29	0.38	1.56e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg22968622	chr17:43663579	NA	-1.13	-15.28	-0.71	5.37e-37	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg26119090	chr2:26468346	HADHA;HADHB	0.95	13.39	0.66	1.09e-30	Gut microbiome composition (summer);
SARC	cis	rs10504229	0.679	rs12679920	chr8:58051710	G/T	cg20607798	chr8:58055168	NA	0.59	5.45	0.34	1.25e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2153535	0.541	rs1414352	chr6:8485547	A/C	cg21535247	chr6:8435926	SLC35B3	0.55	6.88	0.41	5.45e-11	Motion sickness;
SARC	cis	rs79976124	0.837	rs11751994	chr6:66644028	A/C	cg07460842	chr6:66804631	NA	0.62	6.73	0.4	1.27e-10	Type 2 diabetes;
SARC	cis	rs9916302	0.904	rs9905432	chr17:37555918	C/A	cg20243544	chr17:37824526	PNMT	-0.56	-6.64	-0.4	2.19e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs4906332	0.966	rs59858038	chr14:103867102	C/T	cg26031613	chr14:104095156	KLC1	-0.53	-6.2	-0.38	2.6e-9	Coronary artery disease;
SARC	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg16339924	chr4:17578868	LAP3	0.66	8.76	0.5	4e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs854765	0.618	rs9908017	chr17:17774422	C/T	cg16928487	chr17:17741425	SREBF1	0.22	4.73	0.3	3.92e-6	Total body bone mineral density;
SARC	cis	rs9916302	0.904	rs602688	chr17:37439496	C/T	cg15445000	chr17:37608096	MED1	0.42	5.16	0.32	5.4e-7	Glomerular filtration rate (creatinine);
SARC	trans	rs330048	0.545	rs11249913	chr8:9143521	G/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.59	-0.4	2.88e-10	Systemic lupus erythematosus;
SARC	cis	rs7666738	0.830	rs4443295	chr4:99044935	G/A	cg05340658	chr4:99064831	C4orf37	0.64	8.6	0.49	1.18e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2645694	0.626	rs2703140	chr4:77830057	C/G	cg10057126	chr4:77819792	ANKRD56	0.41	6.16	0.37	3.2e-9	Emphysema distribution in smoking;
SARC	cis	rs854765	0.547	rs2955353	chr17:17948979	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.41	-5.11	-0.32	6.57e-7	Total body bone mineral density;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg13437084	chr2:26467494	HADHB;HADHA	0.58	6.26	0.38	1.79e-9	Lung cancer in ever smokers;
SARC	cis	rs1318878	0.639	rs10160901	chr12:15517754	C/T	cg08258403	chr12:15378311	NA	0.48	6.63	0.4	2.36e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7264396	0.563	rs2425120	chr20:34324456	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-7.01	-0.42	2.5e-11	Total cholesterol levels;
SARC	cis	rs4642101	0.680	rs6442330	chr3:12820501	A/G	cg12400702	chr3:12838781	CAND2	-0.26	-4.97	-0.31	1.28e-6	QRS complex (12-leadsum);
SARC	cis	rs11098499	0.909	rs11723839	chr4:120299673	G/A	cg09307838	chr4:120376055	NA	0.89	12.27	0.63	4.85e-27	Corneal astigmatism;
SARC	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg06221963	chr1:154839813	KCNN3	-0.53	-8.54	-0.49	1.74e-15	Prostate cancer;
SARC	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.77	7.62	0.45	6.49e-13	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs921968	0.565	rs2059717	chr2:219600316	A/T	cg02176678	chr2:219576539	TTLL4	-0.35	-5.21	-0.32	4.24e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.11	0.37	4.22e-9	Bipolar disorder;
SARC	cis	rs5167	0.586	rs4803774	chr19:45450872	A/G	cg10169327	chr19:45448959	APOC2	0.33	5.33	0.33	2.28e-7	Blood protein levels;
SARC	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg06221963	chr1:154839813	KCNN3	-0.53	-8.66	-0.49	8.2e-16	Prostate cancer;
SARC	cis	rs11098499	0.863	rs11098531	chr4:120465001	G/A	cg09307838	chr4:120376055	NA	0.91	12.25	0.63	5.66e-27	Corneal astigmatism;
SARC	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg06558623	chr16:89946397	TCF25	0.98	8.13	0.47	2.6e-14	Skin colour saturation;
SARC	cis	rs3857536	0.813	rs2040591	chr6:66945915	A/G	cg07460842	chr6:66804631	NA	-0.45	-5.19	-0.32	4.5e-7	Blood trace element (Cu levels);
SARC	cis	rs6088580	0.505	rs6141503	chr20:33274469	G/A	cg24642439	chr20:33292090	TP53INP2	-0.56	-6.88	-0.41	5.33e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs1185460	0.546	rs549893	chr11:118959732	A/G	cg23280166	chr11:118938394	VPS11	-0.47	-6.39	-0.39	9.03e-10	Coronary artery disease;
SARC	cis	rs513349	1.000	rs210146	chr6:33549098	A/G	cg07679836	chr6:33548423	BAK1	0.34	4.95	0.31	1.42e-6	Platelet count;
SARC	cis	rs4803468	1.000	rs284648	chr19:41926790	T/C	cg08477640	chr19:41863820	B9D2	0.44	5.56	0.34	7.43e-8	Height;
SARC	cis	rs7555523	0.887	rs2251768	chr1:165738311	A/T	cg24409356	chr1:165738333	TMCO1	0.8	6.89	0.41	5.07e-11	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg11764359	chr7:65958608	NA	-0.65	-7.58	-0.44	7.95e-13	Aortic root size;
SARC	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg06808227	chr14:105710500	BRF1	-0.52	-6.64	-0.4	2.25e-10	Mean platelet volume;Platelet distribution width;
SARC	trans	rs12310956	0.532	rs10844715	chr12:33968444	A/G	cg26384229	chr12:38710491	ALG10B	0.73	10.11	0.55	3.82e-20	Morning vs. evening chronotype;
SARC	cis	rs73086581	1.000	rs17215054	chr20:3944779	T/C	cg02187196	chr20:3869020	PANK2	0.67	6.4	0.39	8.3e-10	Response to antidepressants in depression;
SARC	cis	rs765787	0.530	rs10851423	chr15:45515950	G/A	cg26924012	chr15:45694286	SPATA5L1	0.41	4.89	0.31	1.86e-6	Uric acid levels;
SARC	cis	rs6456156	0.774	rs2021999	chr6:167529766	G/C	cg07741184	chr6:167504864	NA	-0.29	-5.41	-0.33	1.53e-7	Primary biliary cholangitis;
SARC	cis	rs637571	0.584	rs659824	chr11:65636509	A/G	cg09783858	chr11:65769428	EIF1AD;BANF1	0.37	4.78	0.3	3.05e-6	Eosinophil percentage of white cells;
SARC	cis	rs12824058	0.767	rs4759654	chr12:130815559	A/G	cg23887609	chr12:130822674	PIWIL1	0.38	5.31	0.33	2.54e-7	Menopause (age at onset);
SARC	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	12.3	0.63	3.85e-27	Personality dimensions;
SARC	cis	rs7681440	0.606	rs990086	chr4:90755090	A/T	cg06632027	chr4:90757378	SNCA	-0.44	-5.44	-0.34	1.32e-7	Dementia with Lewy bodies;
SARC	cis	rs7937682	0.575	rs7127010	chr11:111770782	C/T	cg09085632	chr11:111637200	PPP2R1B	0.83	11.32	0.6	5.8e-24	Primary sclerosing cholangitis;
SARC	cis	rs9733	0.650	rs12125672	chr1:150554470	A/T	cg17724175	chr1:150552817	MCL1	-0.4	-5.12	-0.32	6.39e-7	Tonsillectomy;
SARC	trans	rs7819412	0.595	rs2409712	chr8:10986837	A/C	cg15556689	chr8:8085844	FLJ10661	-0.48	-6.23	-0.38	2.12e-9	Triglycerides;
SARC	cis	rs897080	0.589	rs1067380	chr2:44646834	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.59	6.77	0.41	1.06e-10	Height;
SARC	cis	rs3815700	1.000	rs8113165	chr19:33096316	C/T	cg02997394	chr19:33096574	ANKRD27	0.82	8.83	0.5	2.56e-16	Eosinophilic esophagitis;
SARC	cis	rs67460515	0.892	rs4856756	chr3:160999414	G/A	cg04691961	chr3:161091175	C3orf57	-0.47	-5.81	-0.36	2.08e-8	Parkinson's disease;
SARC	cis	rs7312933	0.558	rs1796382	chr12:42840955	C/G	cg19980929	chr12:42632907	YAF2	-0.45	-6.49	-0.39	5.14e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs1008375	1.000	rs7436403	chr4:17692685	T/G	cg27347728	chr4:17578864	LAP3	-0.48	-5.81	-0.36	2.01e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs11583043	1.000	rs11584222	chr1:101480110	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	5.68	0.35	4.01e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs11711311	1.000	rs13070720	chr3:113473754	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	8.18	0.47	1.86e-14	IgG glycosylation;
SARC	cis	rs7937682	0.883	rs12804962	chr11:111442683	A/T	cg09085632	chr11:111637200	PPP2R1B	0.88	13.25	0.66	3.11e-30	Primary sclerosing cholangitis;
SARC	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.35	-0.43	3.34e-12	Gut microbiome composition (summer);
SARC	cis	rs1941023	0.584	rs2233253	chr11:60157166	C/T	cg08716584	chr11:60157161	MS4A7	-0.39	-6.29	-0.38	1.52e-9	Congenital heart disease (maternal effect);
SARC	cis	rs8078723	0.677	rs8073254	chr17:38149350	C/G	cg17467752	chr17:38218738	THRA	-0.38	-4.89	-0.31	1.88e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs73086581	1.000	rs73086595	chr20:3983448	A/G	cg02187196	chr20:3869020	PANK2	0.63	5.82	0.36	1.97e-8	Response to antidepressants in depression;
SARC	cis	rs9303401	0.614	rs12948536	chr17:56580413	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.05	11.47	0.6	2e-24	Cognitive test performance;
SARC	cis	rs8180040	0.966	rs17784882	chr3:47544003	C/A	cg27129171	chr3:47204927	SETD2	-0.68	-9.3	-0.52	1.09e-17	Colorectal cancer;
SARC	cis	rs10875746	0.903	rs4760681	chr12:48505230	C/T	cg27446233	chr12:48516484	PFKM	-0.41	-4.79	-0.3	2.92e-6	Longevity (90 years and older);
SARC	trans	rs61931739	0.746	rs1687003	chr12:34170099	T/A	cg26384229	chr12:38710491	ALG10B	0.62	8.18	0.47	1.79e-14	Morning vs. evening chronotype;
SARC	cis	rs4808199	1.000	rs7258508	chr19:19475469	T/C	cg03709012	chr19:19516395	GATAD2A	1.1	12.18	0.62	1e-26	Nonalcoholic fatty liver disease;
SARC	cis	rs17270561	0.609	rs4711096	chr6:25727054	A/G	cg17691542	chr6:26056736	HIST1H1C	0.58	7.17	0.43	9.73e-12	Iron status biomarkers;
SARC	cis	rs7264396	1.000	rs224435	chr20:34154087	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-5.37	-0.33	1.88e-7	Total cholesterol levels;
SARC	cis	rs13166103	0.628	rs34384235	chr5:57655413	G/A	cg10487770	chr5:57879443	RAB3C	0.56	6.01	0.37	7.02e-9	Type 2 diabetes (age of onset);
SARC	cis	rs2075671	0.903	rs11979818	chr7:100293639	A/G	cg16850897	chr7:100343110	ZAN	0.61	6.48	0.39	5.47e-10	Other erythrocyte phenotypes;
SARC	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg11644478	chr21:40555479	PSMG1	-0.55	-6.84	-0.41	6.95e-11	Menarche (age at onset);
SARC	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg12463550	chr7:65579703	CRCP	-0.49	-5.3	-0.33	2.65e-7	Aortic root size;
SARC	cis	rs13191362	0.507	rs2023038	chr6:163119280	C/G	cg21926612	chr6:163149169	PACRG;PARK2	-0.48	-5.25	-0.33	3.39e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg24110177	chr3:50126178	RBM5	0.39	5.04	0.31	9.18e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg18099408	chr3:52552593	STAB1	0.36	4.77	0.3	3.23e-6	Electroencephalogram traits;
SARC	cis	rs6500395	1.000	rs7190106	chr16:48705542	C/T	cg04672837	chr16:48644449	N4BP1	0.48	6.47	0.39	5.77e-10	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg22875332	chr1:76189707	ACADM	0.48	6.72	0.4	1.4e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg12419862	chr22:24373484	LOC391322	-0.71	-8.7	-0.5	6.04e-16	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs3749237	0.929	rs62260715	chr3:49829326	G/A	cg07636037	chr3:49044803	WDR6	0.54	6.15	0.37	3.3e-9	Resting heart rate;
SARC	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg11247378	chr22:39784982	NA	-0.32	-4.95	-0.31	1.46e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs854765	0.551	rs12600546	chr17:17867614	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.42	5.32	0.33	2.39e-7	Total body bone mineral density;
SARC	cis	rs950776	0.518	rs8025429	chr15:78836362	G/A	cg22563815	chr15:78856949	CHRNA5	-0.4	-6.6	-0.4	2.82e-10	Sudden cardiac arrest;
SARC	cis	rs2635047	0.901	rs2684837	chr18:44749884	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.56	7.32	0.43	4.06e-12	Educational attainment;
SARC	cis	rs1451375	0.583	rs11575320	chr7:50605298	A/G	cg18232548	chr7:50535776	DDC	-0.5	-5.0	-0.31	1.12e-6	Malaria;
SARC	cis	rs3126085	0.935	rs7534716	chr1:152198654	A/G	cg26876637	chr1:152193138	HRNR	0.46	5.37	0.33	1.88e-7	Atopic dermatitis;
SARC	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg26119090	chr2:26468346	HADHA;HADHB	0.95	13.96	0.67	1.32e-32	Gut microbiome composition (summer);
SARC	cis	rs6815814	0.851	rs73235002	chr4:38769018	A/G	cg02016764	chr4:38805732	TLR1	-0.44	-4.8	-0.3	2.81e-6	Breast cancer;
SARC	cis	rs10189230	0.967	rs12479119	chr2:222354213	C/T	cg14652038	chr2:222343519	EPHA4	0.45	6.05	0.37	5.72e-9	Urate levels in lean individuals;
SARC	cis	rs8072100	0.738	rs9895509	chr17:45549618	A/T	cg08085267	chr17:45401833	C17orf57	0.47	5.54	0.34	8.18e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs11583043	1.000	rs6675353	chr1:101459625	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	5.9	0.36	1.25e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs7819412	0.527	rs7821914	chr8:10805015	A/G	cg21775007	chr8:11205619	TDH	-0.42	-5.22	-0.32	3.99e-7	Triglycerides;
SARC	cis	rs35146811	0.586	rs34213597	chr7:99591021	C/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.41	4.84	0.3	2.4e-6	Coronary artery disease;
SARC	cis	rs3824867	0.920	rs3740684	chr11:47468820	C/T	cg20307385	chr11:47447363	PSMC3	0.47	5.13	0.32	6.23e-7	Mean corpuscular hemoglobin;
SARC	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg16680214	chr1:154839983	KCNN3	-0.37	-5.85	-0.36	1.62e-8	Prostate cancer;
SARC	cis	rs240764	0.507	rs9377193	chr6:101188198	C/T	cg09795085	chr6:101329169	ASCC3	0.4	4.81	0.3	2.67e-6	Neuroticism;
SARC	cis	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg25833597	chr17:30823145	MYO1D	-0.51	-5.06	-0.31	8.64e-7	Hip circumference adjusted for BMI;
SARC	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg13395646	chr4:1353034	KIAA1530	0.43	5.12	0.32	6.47e-7	Obesity-related traits;
SARC	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg16325326	chr1:53192061	ZYG11B	-0.81	-12.68	-0.64	2.33e-28	Monocyte count;
SARC	cis	rs372883	0.613	rs1153290	chr21:30687404	G/T	cg24692254	chr21:30365293	RNF160	-0.61	-7.84	-0.46	1.64e-13	Pancreatic cancer;
SARC	cis	rs2976388	0.669	rs1836633	chr8:143774592	G/A	cg06565975	chr8:143823917	SLURP1	0.3	5.1	0.32	6.96e-7	Urinary tract infection frequency;
SARC	cis	rs7000551	0.715	rs2461478	chr8:22378236	A/G	cg12081754	chr8:22256438	SLC39A14	0.57	7.95	0.46	7.91e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs6540556	0.723	rs3766618	chr1:209895437	G/T	cg23920097	chr1:209922102	NA	-0.55	-5.25	-0.33	3.44e-7	Red blood cell count;
SARC	cis	rs3737883	1.000	rs2275354	chr1:203036757	T/C	cg03900565	chr1:203031815	PPFIA4	0.36	5.48	0.34	1.08e-7	Early onset atrial fibrillation;
SARC	cis	rs9290065	0.519	rs2121721	chr3:160685788	A/G	cg03342759	chr3:160939853	NMD3	-0.47	-5.52	-0.34	8.82e-8	Kawasaki disease;
SARC	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg16405210	chr4:1374714	KIAA1530	-0.91	-12.87	-0.64	5.28e-29	Longevity;
SARC	cis	rs6582630	0.638	rs12425379	chr12:38523705	G/A	cg13010199	chr12:38710504	ALG10B	-0.49	-6.05	-0.37	5.66e-9	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs11583043	0.874	rs41312668	chr1:101443582	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.5	6.26	0.38	1.85e-9	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs9303401	0.538	rs12603174	chr17:56489279	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.0	10.19	0.56	2.09e-20	Cognitive test performance;
SARC	cis	rs4595586	0.545	rs1303887	chr12:39366523	C/T	cg26384229	chr12:38710491	ALG10B	0.51	6.25	0.38	1.9e-9	Morning vs. evening chronotype;
SARC	cis	rs910316	1.000	rs4903275	chr14:75512509	C/T	cg06637938	chr14:75390232	RPS6KL1	0.55	7.81	0.46	1.99e-13	Height;
SARC	cis	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg03033257	chr22:50311977	ALG12;CRELD2	0.61	5.81	0.36	2.03e-8	Schizophrenia;
SARC	cis	rs7953249	0.807	rs7310409	chr12:121424861	A/G	cg02403541	chr12:121454288	C12orf43	-0.58	-7.33	-0.43	3.7e-12	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg05313129	chr8:58192883	C8orf71	0.65	6.69	0.4	1.64e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs898097	0.510	rs10445242	chr17:80891666	G/T	cg02711726	chr17:80685570	FN3KRP	-0.37	-5.28	-0.33	2.9e-7	Breast cancer;
SARC	cis	rs7552404	0.731	rs12090849	chr1:76400261	A/G	cg10523679	chr1:76189770	ACADM	0.42	4.82	0.3	2.55e-6	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6604026	0.656	rs2774952	chr1:93355246	A/C	cg17283838	chr1:93427260	FAM69A	-0.42	-4.75	-0.3	3.59e-6	Multiple sclerosis;
SARC	cis	rs7945718	0.935	rs11022501	chr11:12809314	T/C	ch.11.340609R	chr11:12831013	TEAD1	-0.38	-5.01	-0.31	1.06e-6	Educational attainment (years of education);
SARC	cis	rs2153535	0.542	rs6912740	chr6:8439959	A/G	cg07606381	chr6:8435919	SLC35B3	0.78	11.09	0.59	3.11e-23	Motion sickness;
SARC	cis	rs1832871	0.711	rs6920506	chr6:158695017	T/A	cg07165851	chr6:158734300	TULP4	0.56	6.76	0.4	1.09e-10	Height;
SARC	cis	rs9815354	1.000	rs9876960	chr3:41985812	C/T	cg03022575	chr3:42003672	ULK4	-0.58	-5.74	-0.35	2.88e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs17253792	0.731	rs74829671	chr14:56112759	G/C	cg01858014	chr14:56050164	KTN1	-0.69	-5.45	-0.34	1.26e-7	Putamen volume;
SARC	cis	rs2486288	0.656	rs10519018	chr15:45549265	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.46	-5.79	-0.35	2.23e-8	Glomerular filtration rate;
SARC	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg24060327	chr5:131705240	SLC22A5	0.74	8.74	0.5	4.83e-16	Breast cancer;
SARC	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg08219700	chr8:58056026	NA	0.59	6.3	0.38	1.51e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs17376456	0.825	rs10051878	chr5:93064164	T/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.72	6.77	0.41	1.04e-10	Diabetic retinopathy;
SARC	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.94	-10.67	-0.57	6.55e-22	Alzheimer's disease;
SARC	cis	rs60871478	1.000	rs4721124	chr7:823761	T/C	cg05535760	chr7:792225	HEATR2	0.76	7.85	0.46	1.49e-13	Cerebrospinal P-tau181p levels;
SARC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg18099408	chr3:52552593	STAB1	-0.4	-5.27	-0.33	3.06e-7	Electroencephalogram traits;
SARC	cis	rs10492096	1.000	rs10849462	chr12:6575992	C/T	cg13857086	chr12:6580257	VAMP1	0.77	7.63	0.45	6.05e-13	Hip geometry;
SARC	trans	rs7615952	0.673	rs9289270	chr3:125636979	A/T	cg07211511	chr3:129823064	LOC729375	-0.82	-7.49	-0.44	1.41e-12	Blood pressure (smoking interaction);
SARC	cis	rs7246657	0.943	rs7248733	chr19:37996361	A/C	cg23950597	chr19:37808831	NA	-0.53	-5.18	-0.32	4.88e-7	Coronary artery calcification;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg21581312	chr15:35529473	LOC723972	-0.5	-6.55	-0.39	3.69e-10	Electrocardiographic conduction measures;
SARC	cis	rs17001868	0.527	rs73167009	chr22:40734249	T/C	cg07138101	chr22:40742427	ADSL	0.54	5.94	0.36	1.01e-8	Mammographic density (dense area);
SARC	cis	rs7178572	0.889	rs869301	chr15:77830633	T/C	cg22256960	chr15:77711686	NA	-0.54	-6.27	-0.38	1.72e-9	Type 2 diabetes;
SARC	trans	rs1853207	1.000	rs28371682	chr10:96703109	G/T	cg02737782	chr1:8014393	NA	-0.97	-6.7	-0.4	1.55e-10	Blood metabolite levels;
SARC	cis	rs1784581	1.000	rs1784581	chr6:162401127	A/C	cg17173639	chr6:162384350	PARK2	-0.8	-11.03	-0.59	4.95e-23	Itch intensity from mosquito bite;
SARC	cis	rs6546550	0.901	rs12232914	chr2:70117176	C/T	cg02498382	chr2:70120550	SNRNP27	-0.36	-5.66	-0.35	4.46e-8	Prevalent atrial fibrillation;
SARC	cis	rs6582630	0.519	rs11609739	chr12:38547969	G/A	cg13010199	chr12:38710504	ALG10B	0.78	10.69	0.57	5.79e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs10490913	0.806	rs10886238	chr10:120170705	G/A	cg23160142	chr10:120154512	NA	0.37	5.59	0.34	6.27e-8	Cancer;
SARC	trans	rs1814175	0.607	rs11493324	chr11:50011304	T/C	cg03929089	chr4:120376271	NA	-0.72	-10.36	-0.56	6.38e-21	Height;
SARC	cis	rs732765	1.000	rs10134885	chr14:75373475	C/T	cg06637938	chr14:75390232	RPS6KL1	0.45	5.34	0.33	2.19e-7	Non-small cell lung cancer;
SARC	cis	rs9487051	1.000	rs9400273	chr6:109632799	A/G	cg01475377	chr6:109611718	NA	-0.41	-5.7	-0.35	3.68e-8	Reticulocyte fraction of red cells;
SARC	cis	rs73206853	0.563	rs55885633	chr12:111189251	C/T	cg10860002	chr12:110842031	ANAPC7	0.52	4.73	0.3	3.9e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs861020	0.606	rs689210	chr1:210013723	A/C	cg05527609	chr1:210001259	C1orf107	0.75	9.44	0.53	3.92e-18	Orofacial clefts;
SARC	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg17376030	chr22:41985996	PMM1	0.61	7.55	0.44	1e-12	Vitiligo;
SARC	cis	rs7937682	0.961	rs4936682	chr11:111629743	T/G	cg22437258	chr11:111473054	SIK2	-0.68	-8.7	-0.5	6.17e-16	Primary sclerosing cholangitis;
SARC	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs35306767	0.903	rs34270014	chr10:904666	T/C	cg20503657	chr10:835505	NA	0.87	8.23	0.47	1.32e-14	Eosinophil percentage of granulocytes;
SARC	cis	rs35146811	0.844	rs12705070	chr7:99656927	A/G	cg22004693	chr7:99632812	ZKSCAN1	-0.43	-4.73	-0.3	3.93e-6	Coronary artery disease;
SARC	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.34	-4.96	-0.31	1.39e-6	Longevity;Endometriosis;
SARC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg14893161	chr1:205819251	PM20D1	1.06	20.8	0.81	5.17e-55	Menarche (age at onset);
SARC	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg15921436	chr17:44337874	NA	0.48	4.9	0.31	1.82e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs6993244	1	rs6993244	chr8:8863059	C/G	cg11995313	chr8:8860691	ERI1	-0.43	-5.46	-0.34	1.24e-7	Mean corpuscular hemoglobin;
SARC	cis	rs3091242	0.933	rs61775174	chr1:25787313	G/A	cg27572855	chr1:25598939	RHD	-0.53	-8.88	-0.5	1.84e-16	Erythrocyte sedimentation rate;
SARC	cis	rs7633770	0.786	rs4683256	chr3:46683617	T/G	cg11219411	chr3:46661640	NA	0.43	7.06	0.42	1.85e-11	Coronary artery disease;
SARC	cis	rs7044106	0.762	rs7044226	chr9:123466328	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.67	8.24	0.47	1.25e-14	Hip circumference adjusted for BMI;
SARC	cis	rs1790761	0.667	rs598811	chr11:67311676	C/T	cg24690094	chr11:67383802	NA	0.34	5.07	0.32	8.04e-7	Mean corpuscular volume;
SARC	cis	rs1003719	0.680	rs2187577	chr21:38533341	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.48	-0.53	3.11e-18	Eye color traits;
SARC	cis	rs72781680	1.000	rs72781679	chr2:24237712	G/A	cg06627628	chr2:24431161	ITSN2	-0.75	-7.14	-0.42	1.19e-11	Lymphocyte counts;
SARC	cis	rs2075371	0.829	rs35897155	chr7:134002711	G/A	cg20476274	chr7:133979776	SLC35B4	0.56	7.14	0.42	1.17e-11	Mean platelet volume;
SARC	cis	rs12311304	0.932	rs12312583	chr12:15371606	A/G	cg08258403	chr12:15378311	NA	0.51	7.53	0.44	1.1e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg07806771	chr7:64541737	NA	0.43	4.75	0.3	3.61e-6	Calcium levels;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg25837350	chr11:61584442	FADS1	0.51	6.64	0.4	2.13e-10	Chemerin levels;
SARC	cis	rs9467711	0.591	rs10484433	chr6:26030492	G/T	cg21479132	chr6:26055353	NA	0.96	7.74	0.45	2.97e-13	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg11843238	chr5:131593191	PDLIM4	0.39	5.39	0.33	1.69e-7	Breast cancer;
SARC	cis	rs11122272	0.735	rs2808595	chr1:231526238	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.65	-0.53	9.36e-19	Hemoglobin concentration;
SARC	cis	rs67311347	1.000	rs1119179	chr3:40424929	A/C	cg01475735	chr3:40494733	NA	0.42	4.76	0.3	3.48e-6	Renal cell carcinoma;
SARC	cis	rs6933660	0.744	rs35143743	chr6:151768532	T/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.41	4.92	0.31	1.62e-6	Menarche (age at onset);
SARC	cis	rs4319547	0.695	rs6488958	chr12:122880704	A/G	cg23029597	chr12:123009494	RSRC2	-0.4	-4.99	-0.31	1.17e-6	Body mass index;
SARC	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg22433210	chr17:43662623	NA	-0.95	-11.34	-0.6	4.92e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7712401	0.560	rs13168225	chr5:122347264	C/T	cg19412675	chr5:122181750	SNX24	-0.47	-6.07	-0.37	5.28e-9	Mean platelet volume;
SARC	cis	rs9815354	1.000	rs9311288	chr3:41804581	C/G	cg03022575	chr3:42003672	ULK4	0.57	5.51	0.34	9.43e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2235642	0.928	rs1057610	chr16:1605537	T/C	cg09025071	chr16:1593152	IFT140;TMEM204	0.33	4.75	0.3	3.48e-6	Coronary artery disease;
SARC	cis	rs7666738	0.830	rs28867388	chr4:98962794	A/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg06028808	chr11:68637592	NA	0.41	5.12	0.32	6.29e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg11987759	chr7:65425863	GUSB	-0.47	-6.27	-0.38	1.7e-9	Aortic root size;
SARC	cis	rs72627123	0.867	rs73301493	chr14:74472197	C/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.79	5.88	0.36	1.38e-8	Morning vs. evening chronotype;
SARC	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.6	-6.31	-0.38	1.42e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs9581943	0.967	rs7995917	chr13:28472724	T/C	cg16302790	chr13:28498334	PDX1	0.55	8.29	0.48	8.79e-15	Pancreatic cancer;
SARC	cis	rs4803468	1.000	rs2241710	chr19:41912092	G/C	cg09537434	chr19:41945824	ATP5SL	-0.97	-16.94	-0.74	1.74e-42	Height;
SARC	cis	rs6582630	0.519	rs4406888	chr12:38293312	A/C	cg13010199	chr12:38710504	ALG10B	0.79	11.02	0.59	5.26e-23	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6714710	0.603	rs6757357	chr2:98491750	T/C	cg26665480	chr2:98280029	ACTR1B	0.51	6.91	0.41	4.71e-11	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs2976388	0.609	rs2263092	chr8:143789966	A/G	cg06565975	chr8:143823917	SLURP1	0.31	5.36	0.33	2.02e-7	Urinary tract infection frequency;
SARC	cis	rs9611565	0.921	rs4822021	chr22:41726053	G/A	cg06634786	chr22:41940651	POLR3H	-0.43	-5.3	-0.33	2.7e-7	Vitiligo;
SARC	cis	rs10875746	0.669	rs11168499	chr12:48662670	A/G	cg26205652	chr12:48591994	NA	0.45	4.82	0.3	2.63e-6	Longevity (90 years and older);
SARC	cis	rs9911578	1.000	rs9901181	chr17:56964271	C/T	cg12560992	chr17:57184187	TRIM37	0.85	11.6	0.61	7.44e-25	Intelligence (multi-trait analysis);
SARC	cis	rs1707322	0.896	rs946528	chr1:46485562	C/T	cg06784218	chr1:46089804	CCDC17	-0.37	-6.54	-0.39	3.78e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	5.42	0.33	1.46e-7	Bipolar disorder;
SARC	cis	rs17384381	0.953	rs12120551	chr1:85810903	T/C	cg16011679	chr1:85725395	C1orf52	0.65	6.02	0.37	6.61e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg07157834	chr1:205819609	PM20D1	0.49	6.76	0.4	1.11e-10	Menarche (age at onset);
SARC	cis	rs616402	0.564	rs7419116	chr1:10578606	G/A	cg07384165	chr1:10488281	NA	-0.42	-5.52	-0.34	8.84e-8	Breast size;
SARC	cis	rs7552404	0.924	rs1146581	chr1:76213024	T/G	cg03433033	chr1:76189801	ACADM	0.48	7.12	0.42	1.33e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs3768617	0.510	rs3768622	chr1:183090011	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.68	9.9	0.54	1.62e-19	Fuchs's corneal dystrophy;
SARC	cis	rs1153858	1.000	rs16942568	chr15:45677390	T/C	cg26924012	chr15:45694286	SPATA5L1	0.79	11.28	0.59	7.91e-24	Homoarginine levels;
SARC	cis	rs861020	0.563	rs12046618	chr1:210043135	C/T	cg05527609	chr1:210001259	C1orf107	0.7	7.31	0.43	4.36e-12	Orofacial clefts;
SARC	cis	rs12545109	0.800	rs2576591	chr8:57423606	A/G	cg19413350	chr8:57351067	NA	-0.44	-4.94	-0.31	1.52e-6	Obesity-related traits;
SARC	cis	rs9303280	0.806	rs4795399	chr17:38061439	T/C	cg00129232	chr17:37814104	STARD3	-0.37	-4.84	-0.3	2.4e-6	Self-reported allergy;
SARC	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg07701084	chr6:150067640	NUP43	0.43	5.55	0.34	7.7e-8	Lung cancer;
SARC	cis	rs9393777	0.623	rs3734544	chr6:26468660	G/A	cg12826209	chr6:26865740	GUSBL1	0.84	7.58	0.44	8.33e-13	Intelligence (multi-trait analysis);
SARC	cis	rs9291683	0.632	rs10939669	chr4:10045827	A/G	cg11266682	chr4:10021025	SLC2A9	0.4	7.27	0.43	5.35e-12	Bone mineral density;
SARC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg23131131	chr22:24373011	LOC391322	-0.46	-5.0	-0.31	1.15e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg27286337	chr10:134555280	INPP5A	-0.62	-7.25	-0.43	6e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs1348850	0.914	rs11893448	chr2:178280013	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.7	8.98	0.51	9.48e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9462027	0.628	rs7774697	chr6:34791027	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.41	5.82	0.36	1.98e-8	Systemic lupus erythematosus;
SARC	cis	rs6815814	0.898	rs5743562	chr4:38806096	T/C	cg06935464	chr4:38784597	TLR10	0.63	6.31	0.38	1.41e-9	Breast cancer;
SARC	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg24531977	chr5:56204891	C5orf35	-0.54	-5.45	-0.34	1.26e-7	Initial pursuit acceleration;
SARC	cis	rs1348850	0.750	rs12997716	chr2:178494629	G/A	cg23306229	chr2:178417860	TTC30B	0.51	5.63	0.35	5.28e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg11062466	chr8:58055876	NA	0.54	5.56	0.34	7.55e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs709400	0.663	rs11624367	chr14:103892818	T/A	cg12935359	chr14:103987150	CKB	-0.4	-5.88	-0.36	1.4e-8	Body mass index;
SARC	cis	rs9796	0.621	rs1659228	chr15:41471978	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.55	-7.94	-0.46	8.6e-14	Menopause (age at onset);
SARC	cis	rs6568686	0.592	rs12202987	chr6:111446458	A/C	cg15721981	chr6:111408429	SLC16A10	0.69	5.98	0.36	8.31e-9	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.62	6.49	0.39	5.17e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs826838	0.933	rs1906263	chr12:38653362	T/C	cg26384229	chr12:38710491	ALG10B	0.93	14.55	0.69	1.48e-34	Heart rate;
SARC	cis	rs4780401	0.609	rs9923954	chr16:11816855	G/T	cg01061890	chr16:11836724	TXNDC11	-0.62	-8.73	-0.5	4.86e-16	Rheumatoid arthritis;
SARC	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg18252515	chr7:66147081	NA	-1.32	-11.83	-0.61	1.38e-25	Diabetic kidney disease;
SARC	cis	rs3845702	0.935	rs3845695	chr2:180796989	A/G	cg01881094	chr2:180872142	CWC22	-0.66	-6.15	-0.37	3.42e-9	Schizophrenia;
SARC	cis	rs10504229	0.724	rs72649117	chr8:58037639	A/G	cg21724239	chr8:58056113	NA	0.58	6.11	0.37	4.11e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs526231	0.575	rs62362523	chr5:102313683	C/T	cg23492399	chr5:102201601	PAM	-0.52	-6.43	-0.39	7.32e-10	Primary biliary cholangitis;
SARC	cis	rs10904908	1.000	rs7920002	chr10:17259766	T/A	cg01003015	chr10:17271136	VIM	-0.42	-5.07	-0.32	8.15e-7	Total cholesterol levels;Cholesterol, total;
SARC	cis	rs16976116	0.901	rs1061873	chr15:55496756	T/C	cg17854078	chr15:55489399	RSL24D1	0.66	6.53	0.39	4.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg13902645	chr11:5959945	NA	0.52	7.02	0.42	2.37e-11	DNA methylation (variation);
SARC	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg11644478	chr21:40555479	PSMG1	-0.56	-6.8	-0.41	8.82e-11	Menarche (age at onset);
SARC	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg08219700	chr8:58056026	NA	0.62	6.52	0.39	4.28e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs11785400	0.793	rs1137521	chr8:143739162	C/T	cg10596483	chr8:143751796	JRK	0.55	7.01	0.42	2.57e-11	Schizophrenia;
SARC	cis	rs116095464	0.558	rs10068203	chr5:206618	C/T	cg22857025	chr5:266934	NA	-1.13	-10.64	-0.57	8.44e-22	Breast cancer;
SARC	cis	rs2153535	0.580	rs1414342	chr6:8462552	A/G	cg07606381	chr6:8435919	SLC35B3	0.76	10.65	0.57	7.54e-22	Motion sickness;
SARC	cis	rs2120019	0.938	rs59094290	chr15:75308561	G/T	cg09165964	chr15:75287851	SCAMP5	-0.96	-13.98	-0.68	1.17e-32	Blood trace element (Zn levels);
SARC	cis	rs2304069	0.954	rs2340462	chr5:149415219	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.79	8.8	0.5	3.16e-16	HIV-1 control;
SARC	cis	rs7712401	0.645	rs246316	chr5:122266197	T/C	cg19412675	chr5:122181750	SNX24	0.4	5.19	0.32	4.65e-7	Mean platelet volume;
SARC	cis	rs2652822	0.525	rs11632192	chr15:63515946	A/G	cg02713581	chr15:63449717	RPS27L	0.53	6.39	0.39	8.7e-10	Metabolic traits;
SARC	cis	rs9807989	0.524	rs6543126	chr2:103027104	G/A	cg03938978	chr2:103052716	IL18RAP	0.31	4.98	0.31	1.21e-6	Asthma;
SARC	cis	rs7246657	0.943	rs7255996	chr19:37971699	G/A	cg23950597	chr19:37808831	NA	-0.55	-5.44	-0.34	1.34e-7	Coronary artery calcification;
SARC	cis	rs9354308	0.899	rs2802057	chr6:66548093	A/C	cg07460842	chr6:66804631	NA	0.48	5.48	0.34	1.12e-7	Metabolite levels;
SARC	cis	rs9354308	0.901	rs55832318	chr6:66560086	A/G	cg07460842	chr6:66804631	NA	0.47	5.41	0.33	1.59e-7	Metabolite levels;
SARC	trans	rs8073060	0.586	rs2626625	chr17:34027607	C/G	cg19694781	chr19:47549865	TMEM160	-0.71	-6.94	-0.41	3.88e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs3923518	1.000	rs4462889	chr3:38884451	T/C	cg15678707	chr3:39149194	GORASP1;TTC21A	0.46	4.82	0.3	2.64e-6	Migraine;
SARC	cis	rs2120019	1.000	rs2083731	chr15:75368538	A/C	cg09165964	chr15:75287851	SCAMP5	-0.88	-13.12	-0.65	8.12e-30	Blood trace element (Zn levels);
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg09539256	chr11:65626522	MUS81;CFL1	-0.5	-6.39	-0.39	8.87e-10	Gallstone disease;
SARC	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg00933542	chr6:150070202	PCMT1	0.3	5.17	0.32	5.14e-7	Lung cancer;
SARC	cis	rs7681440	0.904	rs28507349	chr4:90767063	G/A	cg02192967	chr4:90758406	SNCA	0.36	5.22	0.32	3.96e-7	Dementia with Lewy bodies;
SARC	cis	rs2228479	0.850	rs17233455	chr16:89816407	A/G	cg00800038	chr16:89945340	TCF25	-0.74	-5.14	-0.32	5.75e-7	Skin colour saturation;
SARC	cis	rs11690935	0.959	rs10204622	chr2:172588982	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.99	-15.92	-0.72	4.25e-39	Schizophrenia;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg10663781	chr12:109531279	ALKBH2	0.47	6.27	0.38	1.73e-9	Thyroid stimulating hormone;
SARC	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg27286337	chr10:134555280	INPP5A	0.71	8.16	0.47	2.03e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs11122272	0.701	rs2790894	chr1:231505587	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-9.79	-0.54	3.66e-19	Hemoglobin concentration;
SARC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.49	0.57	2.47e-21	Prudent dietary pattern;
SARC	cis	rs7762018	0.607	rs75010113	chr6:170057441	C/T	cg13015042	chr6:170102002	WDR27;C6orf120	0.69	5.03	0.31	9.97e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg25622597	chr3:49449489	RHOA;TCTA	-0.53	-6.69	-0.4	1.6e-10	Gallstone disease;
SARC	cis	rs12906542	0.507	rs4395040	chr15:78282533	G/A	cg22832135	chr15:78370102	TBC1D2B	0.51	4.87	0.3	2.02e-6	Breast cancer;
SARC	cis	rs2303745	0.544	rs6512180	chr19:17399153	C/T	cg04248312	chr19:17393744	ANKLE1	-0.59	-7.56	-0.44	9.06e-13	Systemic lupus erythematosus;
SARC	cis	rs2227564	0.700	rs2675677	chr10:75648249	C/A	cg16540259	chr10:75572220	NDST2	0.33	4.76	0.3	3.39e-6	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg26338869	chr17:61819248	STRADA	0.79	10.59	0.57	1.19e-21	Prudent dietary pattern;
SARC	cis	rs9326248	0.520	rs6589602	chr11:117037065	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.7	9.17	0.51	2.6e-17	Blood protein levels;
SARC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg09373136	chr17:61933544	TCAM1	-0.45	-6.21	-0.38	2.38e-9	Prudent dietary pattern;
SARC	cis	rs7412746	0.621	rs7518156	chr1:150945794	A/C	cg10589385	chr1:150898437	SETDB1	0.37	4.84	0.3	2.37e-6	Melanoma;
SARC	cis	rs992157	0.717	rs3817266	chr2:219142594	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.7	-10.25	-0.56	1.35e-20	Colorectal cancer;
SARC	cis	rs9650657	0.644	rs7012206	chr8:10697015	A/G	cg21775007	chr8:11205619	TDH	-0.39	-4.84	-0.3	2.35e-6	Neuroticism;
SARC	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg12463550	chr7:65579703	CRCP	-0.51	-5.53	-0.34	8.73e-8	Aortic root size;
SARC	cis	rs4689388	0.926	rs1801214	chr4:6303022	C/T	cg25554036	chr4:6271136	WFS1	0.36	5.65	0.35	4.72e-8	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs7223966	1.000	rs8077265	chr17:61732727	A/G	cg00588841	chr17:61851480	DDX42;CCDC47	-0.58	-6.58	-0.4	3.01e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9325144	0.560	rs10785562	chr12:38637419	A/C	cg26384229	chr12:38710491	ALG10B	-0.64	-8.24	-0.47	1.28e-14	Morning vs. evening chronotype;
SARC	cis	rs3796352	0.527	rs11714793	chr3:52924930	A/G	cg04865290	chr3:52927548	TMEM110	-0.55	-5.09	-0.32	7.42e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2486288	0.656	rs7167146	chr15:45571386	A/G	cg21132104	chr15:45694354	SPATA5L1	0.55	6.46	0.39	6.05e-10	Glomerular filtration rate;
SARC	cis	rs2228479	0.717	rs17226274	chr16:89850170	C/T	cg06558623	chr16:89946397	TCF25	0.95	7.62	0.45	6.39e-13	Skin colour saturation;
SARC	cis	rs35110281	0.774	rs162344	chr21:44954522	G/A	cg21573476	chr21:45109991	RRP1B	-0.5	-7.11	-0.42	1.39e-11	Mean corpuscular volume;
SARC	cis	rs6909279	0.678	rs6557143	chr6:151848611	G/A	cg14262678	chr6:151773367	RMND1;C6orf211	-0.44	-5.39	-0.33	1.75e-7	Bone mineral density;
SARC	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg00149659	chr3:10157352	C3orf10	0.69	6.4	0.39	8.64e-10	Alzheimer's disease;
SARC	cis	rs6909279	0.648	rs6919923	chr6:151849670	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	-0.48	-5.92	-0.36	1.17e-8	Bone mineral density;
SARC	cis	rs981844	0.753	rs62325149	chr4:154728006	G/C	cg14289246	chr4:154710475	SFRP2	0.58	6.64	0.4	2.19e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs4969178	0.930	rs4580257	chr17:76403028	T/G	cg20026190	chr17:76395443	PGS1	0.41	5.48	0.34	1.11e-7	HDL cholesterol levels;
SARC	cis	rs6089584	0.893	rs6089305	chr20:60571817	T/C	cg06108461	chr20:60628389	TAF4	-0.89	-11.73	-0.61	2.82e-25	Body mass index;
SARC	cis	rs2239547	0.563	rs4687699	chr3:53101224	C/T	cg22484793	chr3:52261325	TLR9	0.33	4.73	0.3	3.89e-6	Schizophrenia;
SARC	cis	rs9843304	0.546	rs56303133	chr3:149212479	C/A	cg08667024	chr3:149219783	TM4SF4	0.47	7.15	0.42	1.1e-11	Gallstone disease;
SARC	cis	rs4689388	0.926	rs11725500	chr4:6293919	C/G	cg00701064	chr4:6280414	WFS1	0.54	8.58	0.49	1.38e-15	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs2439831	1.000	rs9920763	chr15:43760508	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.05	8.7	0.5	6e-16	Lung cancer in ever smokers;
SARC	cis	rs1371867	0.846	rs1788167	chr8:101319996	C/T	cg11906718	chr8:101322791	RNF19A	0.66	8.62	0.49	1.01e-15	Atrioventricular conduction;
SARC	cis	rs11690935	0.843	rs9784123	chr2:172785005	T/A	cg13550731	chr2:172543902	DYNC1I2	-0.97	-13.82	-0.67	4.05e-32	Schizophrenia;
SARC	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg15049968	chr18:44337910	ST8SIA5	-0.33	-5.26	-0.33	3.32e-7	Personality dimensions;
SARC	cis	rs67460515	0.892	rs10513564	chr3:161059762	A/G	cg17135325	chr3:160939158	NMD3	0.63	8.21	0.47	1.47e-14	Parkinson's disease;
SARC	cis	rs6456156	0.524	rs6932740	chr6:167466439	G/A	cg07741184	chr6:167504864	NA	0.35	6.83	0.41	7.46e-11	Primary biliary cholangitis;
SARC	cis	rs11122272	0.735	rs2790892	chr1:231512771	G/A	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg03264133	chr6:25882463	NA	0.54	6.98	0.42	3e-11	Blood metabolite levels;
SARC	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg06212747	chr3:49208901	KLHDC8B	0.67	8.92	0.5	1.37e-16	Parkinson's disease;
SARC	cis	rs9303401	0.659	rs62083525	chr17:56658088	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.09	12.25	0.63	5.64e-27	Cognitive test performance;
SARC	cis	rs7766436	0.561	rs1342206	chr6:22593676	G/A	cg13666174	chr6:22585274	NA	-0.54	-7.15	-0.42	1.09e-11	Coronary artery disease;
SARC	cis	rs10992471	0.603	rs7873397	chr9:95205928	G/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.26	-0.33	3.34e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs6558174	0.965	rs1564595	chr8:22488939	A/G	cg03733263	chr8:22462867	KIAA1967	0.53	6.35	0.38	1.09e-9	Breast cancer;
SARC	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg00152838	chr16:24741724	TNRC6A	0.59	6.46	0.39	5.98e-10	Intelligence (multi-trait analysis);
SARC	cis	rs853679	0.506	rs1150693	chr6:28174590	T/C	cg26335602	chr6:28129616	ZNF389	0.46	5.32	0.33	2.4e-7	Depression;
SARC	cis	rs2276314	0.802	rs58906216	chr18:33630297	T/C	cg05985134	chr18:33552581	C18orf21	0.66	6.83	0.41	7.38e-11	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs595982	0.517	rs10404905	chr19:49406175	A/T	cg03707168	chr19:49379127	PPP1R15A	-0.43	-5.73	-0.35	3.1e-8	Red cell distribution width;
SARC	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg21747090	chr2:27597821	SNX17	-0.55	-7.62	-0.45	6.44e-13	Total body bone mineral density;
SARC	cis	rs9916302	0.904	rs11078898	chr17:37536480	A/G	cg00129232	chr17:37814104	STARD3	0.6	7.37	0.43	2.94e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg06873352	chr17:61820015	STRADA	0.56	7.11	0.42	1.44e-11	Prudent dietary pattern;
SARC	trans	rs61931739	0.517	rs7486246	chr12:34526419	T/G	cg26384229	chr12:38710491	ALG10B	0.85	12.62	0.64	3.51e-28	Morning vs. evening chronotype;
SARC	cis	rs9457247	0.602	rs17615336	chr6:167506734	A/G	cg07741184	chr6:167504864	NA	0.39	7.33	0.43	3.81e-12	Crohn's disease;
SARC	cis	rs733592	0.965	rs1978161	chr12:48467721	A/G	cg21466736	chr12:48725269	NA	0.32	5.38	0.33	1.79e-7	Plateletcrit;
SARC	cis	rs73198271	0.681	rs11987924	chr8:8649972	T/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-5.58	-0.34	6.53e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs10504229	0.593	rs74760806	chr8:58024785	C/T	cg08219700	chr8:58056026	NA	0.66	6.49	0.39	5.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6089584	0.606	rs2144674	chr20:60576579	G/A	cg06108461	chr20:60628389	TAF4	-0.69	-8.86	-0.5	2.09e-16	Body mass index;
SARC	cis	rs17376456	0.877	rs7702521	chr5:93484579	G/T	cg25358565	chr5:93447407	FAM172A	1.37	14.31	0.68	9.33e-34	Diabetic retinopathy;
SARC	cis	rs1953600	0.645	rs2819945	chr10:81952956	G/A	cg00277334	chr10:82204260	NA	0.36	5.1	0.32	6.89e-7	Sarcoidosis;
SARC	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg09035930	chr12:129282057	SLC15A4	0.56	8.07	0.47	3.67e-14	Systemic lupus erythematosus;
SARC	cis	rs8014204	0.604	rs11159109	chr14:75389074	G/A	cg06637938	chr14:75390232	RPS6KL1	0.92	15.13	0.7	1.73e-36	Caffeine consumption;
SARC	cis	rs7086627	0.515	rs11202957	chr10:82209592	A/G	cg00277334	chr10:82204260	NA	-0.56	-9.34	-0.52	7.82e-18	Post bronchodilator FEV1;
SARC	cis	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg14541582	chr5:601475	NA	-0.41	-5.15	-0.32	5.42e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs4242434	0.726	rs10105545	chr8:22534232	A/G	cg03733263	chr8:22462867	KIAA1967	-0.91	-14.34	-0.68	7.37e-34	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs11997175	0.838	rs10954934	chr8:33669637	T/C	ch.8.33884649F	chr8:33765107	NA	0.5	6.69	0.4	1.69e-10	Body mass index;
SARC	cis	rs9322193	0.566	rs4870118	chr6:150245013	G/A	cg01145232	chr6:150245071	RAET1G	-0.42	-4.8	-0.3	2.82e-6	Lung cancer;
SARC	cis	rs7927771	0.864	rs755553	chr11:47432303	G/A	cg20307385	chr11:47447363	PSMC3	0.59	7.57	0.44	8.65e-13	Subjective well-being;
SARC	cis	rs6141769	0.542	rs6058846	chr20:31324035	A/C	cg13636640	chr20:31349939	DNMT3B	-0.44	-4.78	-0.3	3.12e-6	Subjective well-being;
SARC	cis	rs9309473	1.000	rs7576245	chr2:73829678	C/T	cg07208825	chr2:73871855	ALMS1P	0.32	4.77	0.3	3.29e-6	Metabolite levels;
SARC	cis	rs7829975	0.533	rs13274028	chr8:8729193	A/C	cg15556689	chr8:8085844	FLJ10661	0.47	5.52	0.34	8.98e-8	Mood instability;
SARC	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg04267008	chr7:1944627	MAD1L1	-0.6	-6.9	-0.41	4.79e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs9291683	0.632	rs13137074	chr4:10042842	C/T	cg11266682	chr4:10021025	SLC2A9	0.4	7.27	0.43	5.35e-12	Bone mineral density;
SARC	cis	rs7681440	0.746	rs6812192	chr4:90817848	A/G	cg02192967	chr4:90758406	SNCA	0.39	5.36	0.33	2.05e-7	Dementia with Lewy bodies;
SARC	cis	rs2481665	0.559	rs1332630	chr1:62492215	T/G	cg18591186	chr1:62594603	INADL	-0.39	-5.24	-0.32	3.62e-7	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs910316	1.000	rs4899544	chr14:75546556	C/T	cg08847533	chr14:75593920	NEK9	0.93	15.86	0.72	6.47e-39	Height;
SARC	cis	rs9640161	0.789	rs10952250	chr7:150025966	T/C	cg21361702	chr7:150065534	REPIN1	0.46	5.05	0.31	8.83e-7	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg17376030	chr22:41985996	PMM1	-0.81	-10.22	-0.56	1.66e-20	Vitiligo;
SARC	cis	rs1707322	0.963	rs10890371	chr1:46390897	T/G	cg06784218	chr1:46089804	CCDC17	0.34	5.97	0.36	8.8e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7626444	0.625	rs1798637	chr3:196476639	C/T	cg12930392	chr3:196481615	PAK2	0.25	5.0	0.31	1.13e-6	Monocyte count;
SARC	cis	rs694739	1.000	rs694739	chr11:64097233	A/G	cg23796481	chr11:64053134	BAD;GPR137	0.75	10.02	0.55	7e-20	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	trans	rs9354308	0.868	rs1938063	chr6:66559098	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.55	-6.61	-0.4	2.63e-10	Metabolite levels;
SARC	cis	rs7772486	0.692	rs1577916	chr6:146069789	G/A	cg23711669	chr6:146136114	FBXO30	-0.88	-15.32	-0.71	4.22e-37	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg08280861	chr8:58055591	NA	0.61	5.94	0.36	1.01e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1983891	0.874	rs2395779	chr6:41511950	C/T	cg15051332	chr6:41514432	FOXP4	0.56	6.14	0.37	3.49e-9	Prostate cancer;
SARC	cis	rs2288073	0.562	rs112892911	chr2:24590800	G/A	cg26838691	chr2:24397539	C2orf84	-0.49	-5.59	-0.34	6.2e-8	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs10504073	0.647	rs4873096	chr8:49995201	A/G	cg00325661	chr8:49890786	NA	0.54	7.27	0.43	5.57e-12	Blood metabolite ratios;
SARC	cis	rs1790761	0.667	rs658768	chr11:67337808	G/A	cg00290607	chr11:67383545	NA	0.39	5.38	0.33	1.84e-7	Mean corpuscular volume;
SARC	cis	rs8028182	0.636	rs8030802	chr15:75813153	A/G	cg20655648	chr15:75932815	IMP3	0.64	7.41	0.44	2.38e-12	Sudden cardiac arrest;
SARC	cis	rs2191566	0.960	rs7255315	chr19:44510933	A/T	cg20607764	chr19:44506953	ZNF230	-0.47	-5.34	-0.33	2.17e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg24209194	chr3:40518798	ZNF619	-0.65	-8.08	-0.47	3.48e-14	Renal cell carcinoma;
SARC	cis	rs10791323	0.660	rs10791332	chr11:133732150	A/G	cg15485101	chr11:133734466	NA	0.3	5.0	0.31	1.13e-6	Childhood ear infection;
SARC	cis	rs10771431	0.597	rs10843144	chr12:9357577	C/T	cg08997352	chr12:9597637	DDX12	-0.56	-7.6	-0.45	7.09e-13	Breast size;
SARC	cis	rs453301	0.658	rs9329175	chr8:8866661	C/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-5.52	-0.34	8.8e-8	Joint mobility (Beighton score);
SARC	trans	rs637571	0.565	rs633800	chr11:65638719	G/A	cg17712092	chr4:129076599	LARP1B	-0.54	-6.94	-0.41	3.91e-11	Eosinophil percentage of white cells;
SARC	cis	rs6831352	0.918	rs13110764	chr4:100062466	C/T	cg12011299	chr4:100065546	ADH4	-0.31	-5.1	-0.32	7.06e-7	Alcohol dependence;
SARC	cis	rs2832191	0.791	rs2832179	chr21:30480366	C/T	cg08807101	chr21:30365312	RNF160	-0.84	-11.81	-0.61	1.6e-25	Dental caries;
SARC	cis	rs11583043	1.000	rs7521424	chr1:101475901	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	5.68	0.35	4.01e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs12681288	0.676	rs2600514	chr8:994175	G/A	cg15309053	chr8:964076	NA	0.44	7.09	0.42	1.59e-11	Schizophrenia;
SARC	cis	rs2075371	0.796	rs1978504	chr7:134006933	C/T	cg20476274	chr7:133979776	SLC35B4	-0.49	-6.27	-0.38	1.73e-9	Mean platelet volume;
SARC	cis	rs9303401	0.703	rs9909925	chr17:57210069	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.61	-7.45	-0.44	1.81e-12	Cognitive test performance;
SARC	cis	rs17539620	0.624	rs62432746	chr6:154838986	A/G	cg20019720	chr6:154832845	CNKSR3	0.42	4.86	0.3	2.11e-6	Lipoprotein (a) levels;
SARC	cis	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg12923728	chr3:195709715	SDHAP1	-0.69	-8.94	-0.51	1.22e-16	Pancreatic cancer;
SARC	cis	rs16954776	1	rs16954776	chr13:98700617	C/T	cg09994022	chr13:99127189	STK24	-0.8	-5.02	-0.31	1.01e-6	Smooth-surface caries;
SARC	cis	rs7208859	0.623	rs59029591	chr17:29235746	A/C	cg13385521	chr17:29058706	SUZ12P	0.86	7.14	0.42	1.2e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs10489202	0.908	rs6692861	chr1:168079553	G/C	cg24449463	chr1:168025552	DCAF6	-0.58	-6.47	-0.39	5.68e-10	Schizophrenia;
SARC	cis	rs2295359	1.000	rs9729046	chr1:67607082	C/G	cg12940439	chr1:67600707	NA	0.43	6.73	0.4	1.33e-10	Psoriasis;
SARC	cis	rs2153535	0.580	rs1414350	chr6:8472331	C/T	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	cis	rs7833790	0.700	rs7825180	chr8:82723991	T/A	cg06027949	chr8:82754900	SNX16	-0.48	-6.1	-0.37	4.28e-9	Diastolic blood pressure;
SARC	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-9.06	-0.51	5.29e-17	Alzheimer's disease;
SARC	cis	rs9902453	0.904	rs4994353	chr17:28386280	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.52	-6.87	-0.41	5.67e-11	Coffee consumption (cups per day);
SARC	trans	rs11098499	0.657	rs4463052	chr4:120313258	T/C	cg25214090	chr10:38739885	LOC399744	0.55	7.14	0.42	1.15e-11	Corneal astigmatism;
SARC	cis	rs73206853	0.609	rs55833146	chr12:110872335	A/G	cg10860002	chr12:110842031	ANAPC7	0.62	4.9	0.31	1.79e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs17376456	0.877	rs7728736	chr5:93404277	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	6.12	0.37	3.99e-9	Diabetic retinopathy;
SARC	cis	rs4765905	0.583	rs2238054	chr12:2317644	A/G	cg10668781	chr12:2307325	CACNA1C	-0.31	-4.96	-0.31	1.39e-6	Schizophrenia;
SARC	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg03575189	chr17:44344142	NA	0.6	5.71	0.35	3.5e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs2073300	0.609	rs6137948	chr20:23416845	G/A	cg16736954	chr20:23401023	NAPB	0.77	4.74	0.3	3.79e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg00409905	chr10:38381863	ZNF37A	-0.53	-7.41	-0.44	2.28e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg21724239	chr8:58056113	NA	0.6	5.85	0.36	1.64e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs7980799	0.682	rs1601007	chr12:33609675	C/G	cg13010199	chr12:38710504	ALG10B	0.54	6.53	0.39	4.05e-10	Heart rate;Heart rate variability traits (RMSSD);
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg19219661	chr10:103892701	PPRC1	0.62	6.46	0.39	6.11e-10	Lung cancer in ever smokers;
SARC	cis	rs3796352	1.000	rs71299622	chr3:52917038	G/A	cg07884673	chr3:53033167	SFMBT1	0.87	5.81	0.36	2.07e-8	Immune reponse to smallpox (secreted IL-2);
SARC	trans	rs1814175	0.817	rs4084376	chr11:49831160	T/C	cg15704280	chr7:45808275	SEPT13	-0.97	-17.82	-0.76	2.12e-45	Height;
SARC	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	8.82	0.5	2.77e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg26335602	chr6:28129616	ZNF389	0.51	5.56	0.34	7.41e-8	Parkinson's disease;
SARC	trans	rs9929218	0.954	rs9923925	chr16:68819444	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.49	-6.29	-0.38	1.59e-9	Colorectal cancer;
SARC	cis	rs1153858	1.000	rs11852800	chr15:45639131	A/G	cg10381488	chr15:45694016	SPATA5L1	-0.4	-4.76	-0.3	3.43e-6	Homoarginine levels;
SARC	cis	rs57506017	0.585	rs3815535	chr7:12270519	G/A	cg23422036	chr7:12250390	TMEM106B	0.45	5.87	0.36	1.49e-8	Neuroticism;
SARC	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg05313129	chr8:58192883	C8orf71	-0.55	-5.14	-0.32	5.74e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1215050	0.740	rs783945	chr4:99014394	G/A	cg05340658	chr4:99064831	C4orf37	-0.47	-6.43	-0.39	7.03e-10	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs3784262	1.000	rs9325	chr15:58245986	A/T	cg12031962	chr15:58353849	ALDH1A2	0.4	6.03	0.37	6.21e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg11301795	chr4:187892539	NA	-0.69	-10.22	-0.56	1.69e-20	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.45	-5.85	-0.36	1.62e-8	Longevity;Endometriosis;
SARC	cis	rs941408	1.000	rs1640272	chr19:2800192	A/T	cg06609049	chr19:2785107	THOP1	0.77	9.85	0.54	2.35e-19	Total cholesterol levels;
SARC	cis	rs7429990	0.965	rs2882668	chr3:47980306	A/G	cg11946769	chr3:48343235	NME6	0.46	5.17	0.32	4.98e-7	Educational attainment (years of education);
SARC	cis	rs6840360	0.967	rs6535815	chr4:152609700	A/C	cg22705602	chr4:152727874	NA	-0.39	-6.81	-0.41	8.35e-11	Intelligence (multi-trait analysis);
SARC	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg18404041	chr3:52824283	ITIH1	-0.44	-6.59	-0.4	2.82e-10	Bipolar disorder;
SARC	trans	rs2727020	0.612	rs603672	chr11:49234566	T/A	cg15704280	chr7:45808275	SEPT13	0.83	12.74	0.64	1.45e-28	Coronary artery disease;
SARC	cis	rs7106204	0.668	rs7119362	chr11:24218132	G/T	ch.11.24196551F	chr11:24239977	NA	0.59	6.27	0.38	1.75e-9	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg25894440	chr7:65020034	NA	0.78	5.89	0.36	1.34e-8	Diabetic kidney disease;
SARC	cis	rs9814567	1.000	rs10804632	chr3:134294501	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-7.03	-0.42	2.23e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg03213289	chr20:61660250	NA	0.46	6.43	0.39	7.22e-10	Prostate cancer (SNP x SNP interaction);
SARC	trans	rs3780486	0.718	rs7859454	chr9:33119583	T/A	cg04842962	chr6:43655489	MRPS18A	0.85	10.08	0.55	4.73e-20	IgG glycosylation;
SARC	cis	rs7412746	0.611	rs9661876	chr1:150910911	C/T	cg13175981	chr1:150552382	MCL1	-0.52	-6.43	-0.39	7.28e-10	Melanoma;
SARC	cis	rs35110281	0.626	rs10854486	chr21:45118280	G/T	cg21573476	chr21:45109991	RRP1B	-0.6	-8.42	-0.48	3.95e-15	Mean corpuscular volume;
SARC	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg08280861	chr8:58055591	NA	0.6	5.83	0.36	1.8e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg27170947	chr2:26402098	FAM59B	-0.37	-4.8	-0.3	2.79e-6	Gut microbiome composition (summer);
SARC	cis	rs11122272	0.701	rs11582413	chr1:231530098	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.14	-0.55	2.99e-20	Hemoglobin concentration;
SARC	cis	rs15676	0.783	rs2977998	chr9:131580570	A/G	cg00228799	chr9:131580591	ENDOG	0.63	7.93	0.46	9.1e-14	Blood metabolite levels;
SARC	cis	rs240764	0.578	rs12215909	chr6:101227598	T/C	cg09795085	chr6:101329169	ASCC3	-0.51	-6.52	-0.39	4.21e-10	Neuroticism;
SARC	cis	rs6570726	0.935	rs436212	chr6:145849400	G/A	cg23711669	chr6:146136114	FBXO30	0.78	12.08	0.62	2.13e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7017697	0.507	rs3816246	chr8:19682545	A/G	cg03894339	chr8:19674705	INTS10	-0.52	-5.51	-0.34	9.28e-8	Breast cancer;
SARC	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg08859206	chr1:53392774	SCP2	0.39	5.68	0.35	3.99e-8	Monocyte count;
SARC	cis	rs1318878	0.565	rs73057219	chr12:15475227	G/A	cg08258403	chr12:15378311	NA	0.51	7.05	0.42	2.01e-11	Intelligence (multi-trait analysis);
SARC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg17178900	chr1:205818956	PM20D1	0.67	9.79	0.54	3.54e-19	Menarche (age at onset);
SARC	cis	rs1008375	1.000	rs6811887	chr4:17640858	C/T	cg02297831	chr4:17616191	MED28	0.5	6.49	0.39	5.05e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs881375	0.933	rs4837804	chr9:123705304	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	5.55	0.34	7.88e-8	Rheumatoid arthritis;
SARC	cis	rs6088580	0.634	rs1205334	chr20:32930369	T/C	cg24642439	chr20:33292090	TP53INP2	-0.67	-8.62	-0.49	1.02e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg26335602	chr6:28129616	ZNF389	0.52	5.69	0.35	3.74e-8	Depression;
SARC	cis	rs524281	0.861	rs11227410	chr11:65873396	G/C	cg14036092	chr11:66035641	RAB1B	-0.51	-5.34	-0.33	2.16e-7	Electroencephalogram traits;
SARC	cis	rs1865760	0.566	rs2858993	chr6:26087856	T/A	cg18357526	chr6:26021779	HIST1H4A	0.43	5.29	0.33	2.77e-7	Height;
SARC	cis	rs1878931	0.582	rs27227	chr16:3429778	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.66	-7.41	-0.44	2.3e-12	Body mass index (adult);
SARC	cis	rs600231	0.683	rs588298	chr11:65253574	A/G	cg17120908	chr11:65337727	SSSCA1	-0.43	-5.46	-0.34	1.21e-7	Bone mineral density;
SARC	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg11987759	chr7:65425863	GUSB	-0.47	-6.27	-0.38	1.7e-9	Aortic root size;
SARC	trans	rs1814175	0.817	rs10839318	chr11:49657511	G/C	cg03929089	chr4:120376271	NA	-0.9	-14.65	-0.69	6.79e-35	Height;
SARC	cis	rs4727027	0.866	rs2373438	chr7:148780287	C/A	cg23583168	chr7:148888333	NA	-0.73	-10.67	-0.57	6.88e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs9325144	0.555	rs4550281	chr12:38689937	A/G	cg26384229	chr12:38710491	ALG10B	0.6	8.03	0.47	4.66e-14	Morning vs. evening chronotype;
SARC	cis	rs12701220	0.595	rs12532837	chr7:1122851	T/A	cg02733842	chr7:1102375	C7orf50	-0.52	-6.19	-0.38	2.74e-9	Bronchopulmonary dysplasia;
SARC	trans	rs1865760	0.929	rs9461224	chr6:25936402	G/T	cg04620101	chr15:101835123	SNRPA1	-0.52	-6.31	-0.38	1.4e-9	Height;
SARC	cis	rs748404	0.650	rs518234	chr15:43573421	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	6.6	0.4	2.68e-10	Lung cancer;
SARC	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg02524346	chr8:600233	NA	0.66	5.19	0.32	4.58e-7	IgG glycosylation;
SARC	cis	rs72949976	0.584	rs4673729	chr2:214023810	A/G	cg08319019	chr2:214017104	IKZF2	0.48	6.48	0.39	5.32e-10	Lung cancer;Squamous cell lung carcinoma;
SARC	cis	rs12824058	0.831	rs7310433	chr12:130809289	C/T	cg26677194	chr12:130822605	PIWIL1	0.54	7.4	0.44	2.4e-12	Menopause (age at onset);
SARC	cis	rs2204008	0.580	rs1315373	chr12:38179114	T/G	cg13010199	chr12:38710504	ALG10B	-0.61	-7.72	-0.45	3.36e-13	Bladder cancer;
SARC	cis	rs6831352	0.918	rs13127153	chr4:100058121	C/T	cg13256891	chr4:100009986	ADH5	-0.64	-8.0	-0.46	5.7e-14	Alcohol dependence;
SARC	cis	rs7937682	0.855	rs7934922	chr11:111500026	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.92	-14.73	-0.69	3.72e-35	Primary sclerosing cholangitis;
SARC	cis	rs36051895	0.664	rs3780370	chr9:5095167	A/C	cg02405213	chr9:5042618	JAK2	-0.47	-5.64	-0.35	4.88e-8	Pediatric autoimmune diseases;
SARC	cis	rs1670533	1.000	rs6852558	chr4:1059944	C/T	cg27284194	chr4:1044797	NA	0.45	4.81	0.3	2.67e-6	Recombination rate (females);
SARC	cis	rs1062177	1.000	rs17804178	chr5:151197729	T/G	cg00977110	chr5:151150581	G3BP1	0.57	5.59	0.34	6.19e-8	Preschool internalizing problems;
SARC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.51	5.81	0.36	2.03e-8	Prudent dietary pattern;
SARC	cis	rs6088813	1.000	rs6088820	chr20:33987298	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	-0.43	-5.24	-0.32	3.67e-7	Height;
SARC	cis	rs911555	0.692	rs7140647	chr14:103893465	A/G	cg12935359	chr14:103987150	CKB	0.4	5.46	0.34	1.23e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2304069	0.954	rs9324640	chr5:149413186	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.87	-9.15	-0.51	2.99e-17	HIV-1 control;
SARC	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	13.12	0.65	8.35e-30	Chronic sinus infection;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg22795218	chr10:114765022	TCF7L2	0.46	6.49	0.39	5.05e-10	Thyroid stimulating hormone;
SARC	cis	rs11122272	0.735	rs2491408	chr1:231519248	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg00149659	chr3:10157352	C3orf10	0.8	7.49	0.44	1.39e-12	Alzheimer's disease;
SARC	cis	rs10752881	0.935	rs3935221	chr1:182969010	A/G	cg13390022	chr1:182993471	LAMC1	0.33	5.01	0.31	1.09e-6	Colorectal cancer;
SARC	cis	rs7937890	0.904	rs11023169	chr11:14290985	C/A	cg02886208	chr11:14281011	SPON1	0.4	5.66	0.35	4.33e-8	Mitochondrial DNA levels;
SARC	cis	rs2075371	0.933	rs2544201	chr7:133963561	C/G	cg00033643	chr7:134001901	SLC35B4	0.39	4.76	0.3	3.39e-6	Mean platelet volume;
SARC	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg21782813	chr7:2030301	MAD1L1	0.48	7.75	0.45	2.91e-13	Bipolar disorder and schizophrenia;
SARC	trans	rs890100	0.673	rs11885335	chr2:56679612	C/T	cg26233084	chr5:15510258	FBXL7	-0.31	-6.45	-0.39	6.27e-10	Gut microbiome composition (summer);
SARC	cis	rs76419734	1.000	rs11732298	chr4:106701679	A/T	cg24545054	chr4:106630052	GSTCD;INTS12	-0.85	-5.41	-0.33	1.59e-7	Post bronchodilator FEV1;
SARC	cis	rs1185460	0.967	rs4545564	chr11:118937518	T/C	cg01677386	chr11:118938358	VPS11	-0.4	-4.89	-0.31	1.85e-6	Coronary artery disease;
SARC	cis	rs1882538	0.596	rs10281827	chr7:133081810	A/G	cg10665199	chr7:133106180	EXOC4	0.38	4.92	0.31	1.62e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9916302	0.561	rs12453198	chr17:37741879	T/C	cg07936489	chr17:37558343	FBXL20	-0.63	-7.02	-0.42	2.43e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs1008375	1.000	rs12648232	chr4:17612537	C/T	cg16339924	chr4:17578868	LAP3	-0.66	-8.47	-0.49	2.86e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg21659725	chr3:3221576	CRBN	-0.55	-7.38	-0.44	2.82e-12	Intelligence (multi-trait analysis);
SARC	cis	rs1048238	0.545	rs848199	chr1:16292742	C/T	cg21385522	chr1:16154831	NA	-0.53	-6.74	-0.4	1.2e-10	Systolic blood pressure;
SARC	cis	rs6752107	1.000	rs13391356	chr2:234170369	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.47	6.08	0.37	4.9e-9	Crohn's disease;Inflammatory bowel disease;
SARC	trans	rs61931739	0.534	rs1852222	chr12:34008665	C/A	cg13010199	chr12:38710504	ALG10B	0.65	8.77	0.5	3.85e-16	Morning vs. evening chronotype;
SARC	cis	rs12824058	0.831	rs12829373	chr12:130814114	G/C	cg23887609	chr12:130822674	PIWIL1	0.38	5.18	0.32	4.7e-7	Menopause (age at onset);
SARC	cis	rs16986825	0.570	rs5752822	chr22:29266025	A/G	cg15103426	chr22:29168792	CCDC117	0.63	6.92	0.41	4.26e-11	Pancreatic cancer;
SARC	cis	rs6912958	0.754	rs4587143	chr6:88292291	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.51	-6.75	-0.4	1.13e-10	Monocyte percentage of white cells;
SARC	cis	rs7937682	0.889	rs1784786	chr11:111486043	A/G	cg09085632	chr11:111637200	PPP2R1B	0.91	13.7	0.67	1e-31	Primary sclerosing cholangitis;
SARC	cis	rs2013441	0.965	rs2386485	chr17:20095246	G/A	cg13482628	chr17:19912719	NA	-0.48	-6.16	-0.37	3.1e-9	Obesity-related traits;
SARC	cis	rs2204008	0.806	rs1589382	chr12:38408565	T/A	cg13010199	chr12:38710504	ALG10B	0.75	10.21	0.56	1.86e-20	Bladder cancer;
SARC	cis	rs986417	1.000	rs6573320	chr14:61092022	A/G	cg27398547	chr14:60952738	C14orf39	0.79	6.87	0.41	5.71e-11	Gut microbiota (bacterial taxa);
SARC	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.27	-4.92	-0.31	1.61e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg12042659	chr19:58951599	ZNF132	0.44	5.87	0.36	1.5e-8	Uric acid clearance;
SARC	cis	rs9840812	0.691	rs1070232	chr3:136248087	T/G	cg15507776	chr3:136538369	TMEM22	0.51	5.59	0.34	6.32e-8	Fibrinogen levels;
SARC	cis	rs10493773	0.609	rs11161656	chr1:86182414	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.61	-9.96	-0.55	1.1e-19	Urate levels in overweight individuals;
SARC	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg13206674	chr6:150067644	NUP43	0.42	5.53	0.34	8.42e-8	Lung cancer;
SARC	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg13271783	chr10:134563150	INPP5A	-0.4	-5.16	-0.32	5.2e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs1153858	1.000	rs12593370	chr15:45617417	C/T	cg26924012	chr15:45694286	SPATA5L1	0.77	10.42	0.56	4.04e-21	Homoarginine levels;
SARC	cis	rs912057	0.601	rs1294411	chr6:6739034	T/C	cg06612196	chr6:6737390	NA	0.74	12.68	0.64	2.36e-28	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs7044106	0.791	rs735110	chr9:123488940	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	6.36	0.38	1.05e-9	Hip circumference adjusted for BMI;
SARC	cis	rs17345786	0.520	rs13062677	chr3:101305078	G/A	cg12386194	chr3:101231763	SENP7	0.58	7.02	0.42	2.34e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4664308	0.905	rs7567781	chr2:160999537	A/G	cg03641300	chr2:160917029	PLA2R1	-0.65	-8.6	-0.49	1.18e-15	Idiopathic membranous nephropathy;
SARC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg07507251	chr3:52567010	NT5DC2	0.31	4.85	0.3	2.25e-6	Electroencephalogram traits;
SARC	cis	rs796364	0.951	rs281769	chr2:200809709	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.76	6.88	0.41	5.42e-11	Schizophrenia;
SARC	cis	rs9486719	1.000	rs3798295	chr6:97052164	C/T	cg18709589	chr6:96969512	KIAA0776	-0.48	-4.83	-0.3	2.44e-6	Migraine;Coronary artery disease;
SARC	cis	rs7904368	0.806	rs3858182	chr10:16855094	C/T	cg14835575	chr10:16859367	RSU1	0.78	7.79	0.45	2.21e-13	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs4971059	0.654	rs7364524	chr1:155121922	A/G	cg22049894	chr1:155113146	DPM3	0.41	5.07	0.32	8.18e-7	Breast cancer;
SARC	cis	rs7582720	1.000	rs72934537	chr2:203969504	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	7.78	0.45	2.39e-13	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs7107174	1.000	rs731600	chr11:77963133	A/G	cg02023728	chr11:77925099	USP35	0.38	4.87	0.3	2.07e-6	Testicular germ cell tumor;
SARC	cis	rs2204008	0.687	rs2320523	chr12:38251397	T/C	cg13010199	chr12:38710504	ALG10B	0.78	10.65	0.57	7.82e-22	Bladder cancer;
SARC	cis	rs60871478	0.636	rs73045423	chr7:893952	G/A	cg05535760	chr7:792225	HEATR2	-0.73	-6.9	-0.41	4.97e-11	Cerebrospinal P-tau181p levels;
SARC	cis	rs6500602	0.787	rs7204624	chr16:4459834	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.36	5.18	0.32	4.71e-7	Schizophrenia;
SARC	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg19077165	chr18:44547161	KATNAL2	-0.51	-7.07	-0.42	1.78e-11	Personality dimensions;
SARC	cis	rs7315438	0.517	rs11067597	chr12:115873888	C/G	cg00387115	chr12:115889598	NA	-0.35	-4.72	-0.3	4.11e-6	Colorectal cancer;
SARC	cis	rs10484885	0.824	rs11967579	chr6:90540008	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.6	-5.46	-0.34	1.19e-7	QRS interval (sulfonylurea treatment interaction);
SARC	cis	rs10420951	0.535	rs75581575	chr19:18528247	A/C	cg17952467	chr19:17758336	UNC13A	0.6	4.78	0.3	3.06e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg25894440	chr7:65020034	NA	0.73	5.48	0.34	1.09e-7	Diabetic kidney disease;
SARC	cis	rs11098499	0.909	rs10020034	chr4:120294331	A/G	cg09160332	chr4:120329925	NA	-0.34	-4.88	-0.3	1.95e-6	Corneal astigmatism;
SARC	cis	rs2481665	0.608	rs2476194	chr1:62594593	C/T	cg18591186	chr1:62594603	INADL	-0.75	-12.3	-0.63	4.01e-27	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	trans	rs11165623	0.715	rs1980769	chr1:96888201	A/T	cg10631902	chr5:14652156	NA	-0.46	-7.47	-0.44	1.57e-12	Hip circumference;Waist circumference;
SARC	cis	rs9467773	0.620	rs2451737	chr6:26619041	T/C	cg12292205	chr6:26970375	C6orf41	0.4	5.04	0.31	9.34e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1046896	1.000	rs1046917	chr17:80685655	A/G	cg02711726	chr17:80685570	FN3KRP	0.67	8.49	0.49	2.46e-15	Glycated hemoglobin levels;
SARC	cis	rs4727027	0.933	rs12704063	chr7:148827909	T/C	cg23583168	chr7:148888333	NA	-0.73	-10.97	-0.58	7.57e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg16339924	chr4:17578868	LAP3	0.66	8.76	0.5	4e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2251381	0.750	rs2251087	chr21:30527999	C/T	cg24692254	chr21:30365293	RNF160	0.87	12.54	0.63	6.61e-28	Selective IgA deficiency;
SARC	cis	rs11711311	1.000	rs12632983	chr3:113481913	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	8.43	0.48	3.56e-15	IgG glycosylation;
SARC	cis	rs6570726	0.791	rs11155426	chr6:145817130	T/C	cg05347473	chr6:146136440	FBXO30	0.54	7.35	0.43	3.39e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg25036284	chr2:26402008	FAM59B	-0.43	-5.42	-0.33	1.52e-7	Gut microbiome composition (summer);
SARC	cis	rs6570726	0.791	rs436156	chr6:145874873	A/G	cg23711669	chr6:146136114	FBXO30	0.87	14.69	0.69	4.92e-35	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11997175	0.520	rs4733449	chr8:33628652	G/T	ch.8.33884649F	chr8:33765107	NA	0.51	6.5	0.39	4.78e-10	Body mass index;
SARC	cis	rs9916302	0.904	rs8079355	chr17:37473018	G/A	cg07936489	chr17:37558343	FBXL20	0.68	9.06	0.51	5.39e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs2070488	1.000	rs1002676	chr3:38444932	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.81	-12.66	-0.64	2.6e-28	Electrocardiographic conduction measures;
SARC	cis	rs854765	0.663	rs12941550	chr17:17753828	C/A	cg16928487	chr17:17741425	SREBF1	0.25	5.28	0.33	2.91e-7	Total body bone mineral density;
SARC	cis	rs17401966	0.838	rs6541089	chr1:10402785	A/G	cg15208524	chr1:10270712	KIF1B	0.46	5.42	0.33	1.46e-7	Hepatocellular carcinoma;
SARC	cis	rs4924935	0.770	rs4924946	chr17:18846525	A/T	cg26378065	chr17:18585709	ZNF286B	-0.42	-5.08	-0.32	7.92e-7	Pancreatic cancer;
SARC	cis	rs1153858	1.000	rs12909158	chr15:45621174	A/G	cg03999130	chr15:45571217	NA	0.41	5.24	0.32	3.53e-7	Homoarginine levels;
SARC	cis	rs1707322	0.752	rs7529699	chr1:46134634	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.25	0.38	1.97e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg24250549	chr1:154909240	PMVK	0.83	12.22	0.62	7.36e-27	Prostate cancer;
SARC	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg07701084	chr6:150067640	NUP43	0.41	5.4	0.33	1.62e-7	Lung cancer;
SARC	cis	rs9457247	1.000	rs416131	chr6:167406544	A/C	cg07741184	chr6:167504864	NA	-0.31	-5.84	-0.36	1.77e-8	Crohn's disease;
SARC	cis	rs4900538	0.819	rs72700604	chr14:102882307	G/A	cg18135206	chr14:102964638	TECPR2	-0.62	-7.95	-0.46	8.04e-14	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	trans	rs9388451	0.839	rs1811852	chr6:126071575	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.55	-7.04	-0.42	2.19e-11	Brugada syndrome;
SARC	cis	rs9325144	0.600	rs6582634	chr12:38748041	G/A	cg26384229	chr12:38710491	ALG10B	0.62	8.1	0.47	3e-14	Morning vs. evening chronotype;
SARC	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg10295955	chr4:187884368	NA	-1.07	-19.84	-0.79	6.01e-52	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7644634	0.624	rs35834008	chr3:105387230	C/A	cg23051926	chr3:105466016	CBLB	0.47	5.84	0.36	1.71e-8	Itch intensity from mosquito bite;
SARC	trans	rs12310956	0.532	rs2087270	chr12:33850109	C/T	cg13010199	chr12:38710504	ALG10B	0.51	6.36	0.38	1.06e-9	Morning vs. evening chronotype;
SARC	cis	rs7666738	0.830	rs6819177	chr4:99040907	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs17376456	0.825	rs17314074	chr5:93161467	T/C	cg21475434	chr5:93447410	FAM172A	0.7	5.35	0.33	2.1e-7	Diabetic retinopathy;
SARC	cis	rs763014	0.898	rs8060585	chr16:635794	C/G	cg07343612	chr16:622815	PIGQ	-0.53	-7.2	-0.43	8.25e-12	Height;
SARC	cis	rs78320035	1.000	rs78320035	chr1:168103616	G/C	cg17113809	chr1:168148080	TIPRL	1.15	6.69	0.4	1.61e-10	Red cell distribution width;
SARC	cis	rs4889855	0.530	rs7209279	chr17:78598055	T/A	cg17956530	chr17:78667699	RPTOR	-0.47	-5.4	-0.33	1.65e-7	Fractional excretion of uric acid;
SARC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg09373136	chr17:61933544	TCAM1	-0.42	-5.74	-0.35	2.94e-8	Prudent dietary pattern;
SARC	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg24549020	chr5:56110836	MAP3K1	0.53	5.83	0.36	1.82e-8	Initial pursuit acceleration;
SARC	cis	rs7683537	0.501	rs2171838	chr4:185667404	A/G	cg07424746	chr4:185654737	MLF1IP	0.48	5.19	0.32	4.59e-7	Systemic lupus erythematosus;
SARC	cis	rs7560272	0.501	rs12624267	chr2:73986931	C/T	cg20560298	chr2:73613845	ALMS1	0.45	6.12	0.37	3.95e-9	Schizophrenia;
SARC	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg22455342	chr2:225449267	CUL3	0.64	8.01	0.46	5.44e-14	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs12421382	0.636	rs60266280	chr11:109387766	A/C	cg16359550	chr11:109292809	C11orf87	0.35	5.2	0.32	4.26e-7	Schizophrenia;
SARC	cis	rs7769051	0.522	rs60133731	chr6:133095818	T/C	cg07930552	chr6:133119739	C6orf192	0.95	5.96	0.36	9.13e-9	Type 2 diabetes nephropathy;
SARC	cis	rs1018836	0.859	rs10808614	chr8:91569677	C/G	cg16814680	chr8:91681699	NA	-0.74	-11.43	-0.6	2.58e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	trans	rs7937682	0.883	rs566647	chr11:111466607	A/G	cg18187862	chr3:45730750	SACM1L	-0.54	-6.38	-0.39	9.66e-10	Primary sclerosing cholangitis;
SARC	cis	rs9910055	0.529	rs228749	chr17:42174570	A/G	cg19774624	chr17:42201019	HDAC5	0.55	6.64	0.4	2.15e-10	Total body bone mineral density;
SARC	cis	rs644799	0.648	rs1255181	chr11:95472148	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	6.2	0.38	2.59e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs3617	0.625	rs7652667	chr3:52866535	C/A	cg04865290	chr3:52927548	TMEM110	0.35	5.07	0.32	8.25e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg25036284	chr2:26402008	FAM59B	0.49	5.63	0.35	5.16e-8	Gut microbiome composition (summer);
SARC	cis	rs4423214	1.000	rs4944946	chr11:71159429	G/A	cg05163923	chr11:71159392	DHCR7	0.66	8.74	0.5	4.56e-16	Vitamin D levels;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg13184539	chr1:241683111	FH	-0.76	-6.3	-0.38	1.47e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9341808	0.519	rs3805872	chr6:81035102	G/A	cg08355045	chr6:80787529	NA	-0.38	-5.6	-0.34	6.11e-8	Sitting height ratio;
SARC	cis	rs1153858	1.000	rs56669689	chr15:45637729	A/C	cg26924012	chr15:45694286	SPATA5L1	0.76	10.58	0.57	1.3e-21	Homoarginine levels;
SARC	cis	rs858239	0.965	rs156429	chr7:23306020	A/G	cg23682824	chr7:23144976	KLHL7	0.62	7.91	0.46	1.06e-13	Cerebrospinal fluid biomarker levels;
SARC	cis	rs11786130	0.544	rs10087240	chr8:129012574	C/T	cg17583432	chr8:129005567	PVT1	0.3	4.99	0.31	1.2e-6	Eosinophil counts;Sum eosinophil basophil counts;
SARC	cis	rs1044826	0.642	rs6784684	chr3:139177634	T/C	cg15131784	chr3:139108705	COPB2	0.41	5.16	0.32	5.31e-7	Obesity-related traits;
SARC	cis	rs12135062	1.000	rs12135062	chr1:3103312	A/C	cg00254258	chr1:3105189	PRDM16	0.38	6.39	0.39	8.77e-10	Migraine;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg11059561	chr2:3428786	TTC15	0.51	6.37	0.39	9.95e-10	Schizophrenia;
SARC	cis	rs6087990	0.735	rs2424913	chr20:31374259	C/T	cg13636640	chr20:31349939	DNMT3B	0.79	12.28	0.63	4.54e-27	Ulcerative colitis;
SARC	cis	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg20965017	chr5:231967	SDHA	-0.57	-5.59	-0.34	6.35e-8	Breast cancer;
SARC	cis	rs847851	0.612	rs7768189	chr6:34742450	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.74	-0.35	2.87e-8	Colonoscopy-negative controls vs population controls;
SARC	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg16325326	chr1:53192061	ZYG11B	-0.81	-12.97	-0.65	2.49e-29	Monocyte count;
SARC	cis	rs2408955	0.522	rs11168408	chr12:48498327	G/A	cg24011408	chr12:48396354	COL2A1	-0.43	-5.2	-0.32	4.34e-7	Glycated hemoglobin levels;
SARC	cis	rs514024	0.801	rs522328	chr9:130475011	A/G	cg13643465	chr9:130375613	STXBP1	0.46	5.76	0.35	2.62e-8	Eating disorders (purging via substances);
SARC	cis	rs881375	0.900	rs1008383	chr9:123683579	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.42	5.08	0.32	7.89e-7	Rheumatoid arthritis;
SARC	cis	rs6940638	0.688	rs7744759	chr6:27119826	G/A	cg12826209	chr6:26865740	GUSBL1	0.55	5.94	0.36	1.01e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.99	11.62	0.61	6.3e-25	Platelet count;
SARC	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg00933542	chr6:150070202	PCMT1	0.31	5.25	0.32	3.5e-7	Lung cancer;
SARC	cis	rs9325144	0.505	rs1906262	chr12:38653605	A/G	cg26384229	chr12:38710491	ALG10B	0.76	10.57	0.57	1.38e-21	Morning vs. evening chronotype;
SARC	cis	rs11098499	0.954	rs12502423	chr4:120424172	A/C	cg09307838	chr4:120376055	NA	0.93	12.73	0.64	1.6e-28	Corneal astigmatism;
SARC	cis	rs17826219	0.714	rs11650821	chr17:28968150	T/C	cg13385521	chr17:29058706	SUZ12P	0.85	6.1	0.37	4.43e-9	Body mass index;
SARC	cis	rs2976388	0.609	rs2585149	chr8:143793320	T/C	cg06565975	chr8:143823917	SLURP1	0.3	5.24	0.32	3.65e-7	Urinary tract infection frequency;
SARC	cis	rs1949733	0.598	rs869602	chr4:8535371	G/T	cg13073564	chr4:8508604	NA	0.44	6.74	0.4	1.2e-10	Response to antineoplastic agents;
SARC	cis	rs208520	0.690	rs1100981	chr6:66852052	T/C	cg07460842	chr6:66804631	NA	-1.06	-14.89	-0.7	1.12e-35	Exhaled nitric oxide output;
SARC	cis	rs35213789	0.734	rs2851505	chr7:69113497	G/A	cg10619644	chr7:69149951	AUTS2	-0.36	-4.85	-0.3	2.25e-6	Childhood ear infection;
SARC	trans	rs56279505	0.629	rs3910713	chr4:100258648	T/G	cg18024358	chr1:3420815	MEGF6	-0.84	-6.43	-0.39	7.04e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs8031584	0.958	rs34294266	chr15:31246840	A/G	cg08109568	chr15:31115862	NA	-0.47	-5.74	-0.35	2.87e-8	Huntington's disease progression;
SARC	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg11742103	chr11:62369870	EML3;MTA2	0.42	6.51	0.39	4.45e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs763121	0.853	rs4821808	chr22:39065739	A/G	cg06022373	chr22:39101656	GTPBP1	0.85	10.56	0.57	1.45e-21	Menopause (age at onset);
SARC	cis	rs7395581	0.959	rs2279239	chr11:47281780	T/C	cg25783544	chr11:47291846	MADD	0.47	4.98	0.31	1.22e-6	HDL cholesterol;
SARC	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg03709012	chr19:19516395	GATAD2A	-1.02	-17.9	-0.76	1.17e-45	Tonsillectomy;
SARC	cis	rs2239547	0.522	rs9831409	chr3:52985711	A/T	cg22484793	chr3:52261325	TLR9	-0.34	-4.78	-0.3	3.11e-6	Schizophrenia;
SARC	cis	rs2573652	1.000	rs1469829	chr15:100517332	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.36	-4.81	-0.3	2.77e-6	Height;
SARC	cis	rs72781680	0.583	rs6731333	chr2:24113354	C/T	cg06627628	chr2:24431161	ITSN2	-0.54	-5.83	-0.36	1.88e-8	Lymphocyte counts;
SARC	cis	rs77372450	0.636	rs11465225	chr5:157003849	G/T	cg23851860	chr5:157002805	ADAM19	0.51	4.91	0.31	1.72e-6	Bipolar disorder (body mass index interaction);
SARC	cis	rs2486288	0.554	rs1719235	chr15:45576108	A/G	cg19305227	chr15:45544335	SLC28A2	0.31	5.57	0.34	7.13e-8	Glomerular filtration rate;
SARC	cis	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg24642439	chr20:33292090	TP53INP2	-0.8	-11.86	-0.61	1.08e-25	Coronary artery disease;
SARC	cis	rs9467711	0.606	rs13203358	chr6:26590578	A/T	cg12826209	chr6:26865740	GUSBL1	0.74	4.98	0.31	1.27e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg18252515	chr7:66147081	NA	-0.57	-6.2	-0.38	2.51e-9	Aortic root size;
SARC	cis	rs2239547	0.603	rs17304995	chr3:53070755	A/G	cg22484793	chr3:52261325	TLR9	0.36	4.84	0.3	2.41e-6	Schizophrenia;
SARC	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg09455208	chr3:40491958	NA	0.38	5.45	0.34	1.31e-7	Renal cell carcinoma;
SARC	cis	rs858239	0.539	rs1358442	chr7:23189739	C/T	cg23682824	chr7:23144976	KLHL7	0.71	9.28	0.52	1.23e-17	Cerebrospinal fluid biomarker levels;
SARC	cis	rs870825	0.616	rs745656	chr4:185637523	C/T	cg04058563	chr4:185651563	MLF1IP	0.84	11.36	0.6	4.49e-24	Blood protein levels;
SARC	cis	rs72781680	0.948	rs72796319	chr2:24133027	T/C	cg06627628	chr2:24431161	ITSN2	-0.71	-6.86	-0.41	6.2e-11	Lymphocyte counts;
SARC	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg05835009	chr4:710272	PCGF3	0.59	6.92	0.41	4.44e-11	White blood cell count;
SARC	cis	rs4718428	0.705	rs3800817	chr7:66263550	T/A	cg18876405	chr7:65276391	NA	0.48	5.35	0.33	2.05e-7	Corneal structure;
SARC	cis	rs7940866	1.000	rs7940866	chr11:130817579	A/T	cg12179176	chr11:130786555	SNX19	-0.65	-8.22	-0.47	1.39e-14	Schizophrenia;
SARC	cis	rs1008375	1.000	rs28545485	chr4:17645376	C/T	cg27347728	chr4:17578864	LAP3	0.47	5.9	0.36	1.28e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.61	7.66	0.45	4.96e-13	Lymphocyte counts;
SARC	cis	rs753778	0.629	rs2278447	chr8:142206905	G/C	cg18755752	chr8:142205143	DENND3	-0.54	-7.86	-0.46	1.4e-13	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs6058796	1.000	rs6087410	chr20:31258359	C/T	cg13636640	chr20:31349939	DNMT3B	0.56	4.94	0.31	1.49e-6	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs1878931	0.668	rs11643983	chr16:3438865	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	1.01	18.27	0.77	7.29e-47	Body mass index (adult);
SARC	cis	rs9486719	0.552	rs9399923	chr6:96850379	G/A	cg06623918	chr6:96969491	KIAA0776	0.62	7.03	0.42	2.23e-11	Migraine;Coronary artery disease;
SARC	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg11062466	chr8:58055876	NA	0.65	5.83	0.36	1.79e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9790314	0.586	rs1811483	chr3:161130900	A/G	cg04691961	chr3:161091175	C3orf57	-0.46	-5.82	-0.36	1.97e-8	Morning vs. evening chronotype;
SARC	cis	rs4481887	0.597	rs11488132	chr1:248542353	A/G	cg00666640	chr1:248458726	OR2T12	0.42	6.44	0.39	6.8e-10	Common traits (Other);
SARC	cis	rs2882877	0.648	rs11691332	chr2:190388444	A/C	cg21926118	chr2:190387206	NA	-0.4	-4.88	-0.3	1.96e-6	Mean corpuscular hemoglobin concentration;
SARC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg05064044	chr6:292385	DUSP22	0.58	7.54	0.44	1.06e-12	Menopause (age at onset);
SARC	cis	rs16854884	0.538	rs61359084	chr3:143738362	T/C	cg06585982	chr3:143692056	C3orf58	0.67	9.12	0.51	3.73e-17	Economic and political preferences (feminism/equality);
SARC	cis	rs4925386	0.759	rs2427293	chr20:60925859	A/G	cg24112000	chr20:60950667	NA	0.37	5.43	0.34	1.39e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs694739	1.000	rs646153	chr11:64089588	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.77	10.32	0.56	8.1e-21	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs6565180	0.926	rs4788409	chr16:30393771	G/A	cg17640201	chr16:30407289	ZNF48	0.95	14.73	0.69	3.62e-35	Tonsillectomy;
SARC	cis	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg07636037	chr3:49044803	WDR6	0.61	8.0	0.46	6.01e-14	Resting heart rate;
SARC	trans	rs561341	0.843	rs2028067	chr17:30239698	T/C	cg20587970	chr11:113659929	NA	-0.84	-8.43	-0.48	3.7e-15	Hip circumference adjusted for BMI;
SARC	cis	rs2242116	1.000	rs2242116	chr3:46941116	A/G	cg02527881	chr3:46936655	PTH1R	-0.4	-6.38	-0.39	9.68e-10	Birth weight;
SARC	cis	rs941408	0.515	rs1640262	chr19:2779134	C/T	cg06609049	chr19:2785107	THOP1	-0.97	-14.66	-0.69	6.2e-35	Total cholesterol levels;
SARC	cis	rs9815354	1.000	rs1716690	chr3:41922102	T/G	cg03022575	chr3:42003672	ULK4	-0.54	-5.12	-0.32	6.5e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg22105103	chr4:187893119	NA	0.51	6.91	0.41	4.69e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg07899451	chr1:157108248	ETV3	0.37	4.73	0.3	3.94e-6	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs9300255	0.602	rs884548	chr12:123634122	A/G	cg05973401	chr12:123451056	ABCB9	0.53	5.99	0.37	8.08e-9	Neutrophil percentage of white cells;
SARC	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	10.49	0.57	2.48e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs2070997	0.667	rs7042528	chr9:133686717	T/G	cg11464064	chr9:133710261	ABL1	0.53	4.82	0.3	2.54e-6	Response to amphetamines;
SARC	trans	rs9395865	0.827	rs11969450	chr6:53325093	G/A	cg15964163	chr8:67837689	SNHG6	-0.58	-6.38	-0.39	9.59e-10	Electroencephalographic traits in alcoholism;
SARC	cis	rs10489202	0.683	rs4657730	chr1:168072738	A/T	cg24449463	chr1:168025552	DCAF6	-0.58	-7.38	-0.44	2.76e-12	Schizophrenia;
SARC	cis	rs13191362	0.935	rs13212137	chr6:163010261	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.5	0.34	1.01e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs3750965	1.000	rs731974	chr11:68847156	C/T	cg06818126	chr11:68850279	TPCN2	-0.43	-4.95	-0.31	1.4e-6	Hair color;
SARC	cis	rs16858210	0.520	rs10460892	chr3:183546124	C/T	cg03417191	chr3:183542750	MAP6D1	-0.56	-5.22	-0.32	3.93e-7	Menopause (age at onset);
SARC	trans	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg21659725	chr3:3221576	CRBN	-0.8	-12.22	-0.62	7.09e-27	Intelligence (multi-trait analysis);
SARC	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg10435706	chr6:150039699	LATS1	0.36	4.8	0.3	2.88e-6	Lung cancer;
SARC	cis	rs9788721	0.836	rs55983731	chr15:78735269	C/T	cg18825076	chr15:78729989	IREB2	-0.52	-6.45	-0.39	6.47e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg16414030	chr3:133502952	NA	0.37	5.33	0.33	2.34e-7	Iron status biomarkers;
SARC	cis	rs12908161	0.853	rs12912342	chr15:85248216	T/C	cg17507749	chr15:85114479	UBE2QP1	0.49	5.85	0.36	1.65e-8	Schizophrenia;
SARC	cis	rs561341	1.000	rs55643307	chr17:30263074	T/C	cg00745463	chr17:30367425	LRRC37B	-0.68	-5.18	-0.32	4.7e-7	Hip circumference adjusted for BMI;
SARC	cis	rs748404	0.660	rs690367	chr15:43748304	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.42	-5.15	-0.32	5.46e-7	Lung cancer;
SARC	cis	rs273218	0.568	rs1644814	chr5:53365452	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.44	5.18	0.32	4.71e-7	Migraine;
SARC	cis	rs72634258	0.945	rs7522911	chr1:8097145	C/T	cg00042356	chr1:8021962	PARK7	0.89	7.97	0.46	6.99e-14	Inflammatory bowel disease;
SARC	cis	rs8044995	0.563	rs8058517	chr16:68379860	A/G	cg09835421	chr16:68378352	PRMT7	0.65	5.65	0.35	4.6e-8	Schizophrenia;
SARC	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg06634786	chr22:41940651	POLR3H	0.5	6.12	0.37	3.99e-9	Vitiligo;
SARC	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.34	-4.9	-0.31	1.76e-6	Menopause (age at onset);
SARC	cis	rs9902453	1.000	rs8065059	chr17:28417376	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.52	-6.79	-0.41	9.2e-11	Coffee consumption (cups per day);
SARC	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg27266027	chr21:40555129	PSMG1	0.52	5.68	0.35	3.9e-8	Cognitive function;
SARC	cis	rs8141529	0.702	rs469991	chr22:29307859	G/C	cg15103426	chr22:29168792	CCDC117	-0.69	-8.98	-0.51	9.04e-17	Lymphocyte counts;
SARC	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6121246	0.559	rs6058462	chr20:30367674	C/T	cg13852791	chr20:30311386	BCL2L1	0.82	9.97	0.55	9.66e-20	Mean corpuscular hemoglobin;
SARC	trans	rs10209086	0.736	rs1584436	chr2:138298878	A/G	cg15613982	chr20:18488017	SEC23B	-0.49	-6.38	-0.39	9.22e-10	Multiple system atrophy;
SARC	cis	rs1215050	0.669	rs783962	chr4:98884473	G/A	cg05340658	chr4:99064831	C4orf37	-0.43	-5.62	-0.35	5.49e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs9910055	0.529	rs575798	chr17:42181796	A/C	cg09913183	chr17:42254507	C17orf65;ASB16	-0.47	-5.48	-0.34	1.13e-7	Total body bone mineral density;
SARC	cis	rs9467773	1.000	rs9986382	chr6:26550619	T/C	cg12292205	chr6:26970375	C6orf41	0.47	5.6	0.34	6.14e-8	Intelligence (multi-trait analysis);
SARC	cis	rs4563143	0.502	rs73029061	chr19:29283980	T/A	cg04546413	chr19:29218101	NA	0.64	8.53	0.49	1.85e-15	Methadone dose in opioid dependence;
SARC	cis	rs55871839	0.708	rs4738733	chr8:59813760	T/C	cg07426533	chr8:59803705	TOX	-0.43	-5.77	-0.35	2.51e-8	Pneumonia;
SARC	cis	rs67460515	0.596	rs35127376	chr3:160927289	T/C	cg17135325	chr3:160939158	NMD3	0.68	8.66	0.49	8.01e-16	Parkinson's disease;
SARC	cis	rs2997447	0.846	rs3008429	chr1:26390833	A/G	cg19633962	chr1:26362018	EXTL1	-0.61	-4.98	-0.31	1.23e-6	QRS complex (12-leadsum);
SARC	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg16325326	chr1:53192061	ZYG11B	-0.81	-12.49	-0.63	9.6e-28	Monocyte count;
SARC	cis	rs356220	0.642	rs356173	chr4:90631716	A/G	cg06632027	chr4:90757378	SNCA	-0.41	-5.49	-0.34	1.03e-7	Parkinson's disease;
SARC	cis	rs709400	0.628	rs1989565	chr14:103862193	G/A	cg26031613	chr14:104095156	KLC1	-0.78	-11.09	-0.59	3.18e-23	Body mass index;
SARC	cis	rs1153858	1.000	rs12595087	chr15:45655232	A/G	cg26924012	chr15:45694286	SPATA5L1	0.79	11.29	0.59	7.41e-24	Homoarginine levels;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg04839849	chr1:859844	SAMD11	0.64	6.5	0.39	4.77e-10	Lung cancer in ever smokers;
SARC	cis	rs600231	0.542	rs12360896	chr11:65238306	G/T	cg17120908	chr11:65337727	SSSCA1	-0.45	-4.99	-0.31	1.17e-6	Bone mineral density;
SARC	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg04166393	chr7:2884313	GNA12	0.62	7.0	0.42	2.66e-11	Height;
SARC	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg13175981	chr1:150552382	MCL1	-0.53	-6.81	-0.41	8.11e-11	Tonsillectomy;
SARC	cis	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg25427524	chr10:38739819	LOC399744	-0.6	-9.67	-0.54	8.06e-19	Extrinsic epigenetic age acceleration;
SARC	cis	rs2439831	0.850	rs16965120	chr15:44100342	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	8.13	0.47	2.57e-14	Lung cancer in ever smokers;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg19102404	chr1:116941269	C1orf203;ATP1A1	0.46	6.29	0.38	1.58e-9	Schizophrenia;
SARC	cis	rs5758659	0.714	rs5758589	chr22:42518382	A/G	cg04733989	chr22:42467013	NAGA	-0.49	-6.08	-0.37	4.9e-9	Cognitive function;
SARC	cis	rs2273669	0.915	rs6651002	chr6:109318516	G/C	cg05315195	chr6:109294784	ARMC2	-0.48	-4.92	-0.31	1.65e-6	Prostate cancer;
SARC	cis	rs12956009	0.583	rs16951972	chr18:44898600	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	7.64	0.45	5.6e-13	Educational attainment (years of education);
SARC	cis	rs950776	0.518	rs4886571	chr15:78833758	G/A	cg06917634	chr15:78832804	PSMA4	-0.9	-14.17	-0.68	2.83e-33	Sudden cardiac arrest;
SARC	cis	rs9399135	0.684	rs1135205	chr6:135281795	C/T	cg24558204	chr6:135376177	HBS1L	0.46	6.22	0.38	2.34e-9	Red blood cell count;
SARC	cis	rs9815354	0.812	rs73077361	chr3:41850146	G/A	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6582630	0.548	rs1607870	chr12:38385964	G/T	cg14851346	chr12:38532713	NA	-0.48	-5.78	-0.35	2.36e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1023500	0.551	rs61665536	chr22:42512613	A/G	cg04733989	chr22:42467013	NAGA	-0.76	-10.57	-0.57	1.4e-21	Schizophrenia;
SARC	cis	rs6963495	0.818	rs75116202	chr7:105160059	C/T	cg19920283	chr7:105172520	RINT1	0.65	5.48	0.34	1.09e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs2120019	0.938	rs2304903	chr15:75315778	A/G	cg17294928	chr15:75287854	SCAMP5	-1.01	-15.22	-0.71	8.56e-37	Blood trace element (Zn levels);
SARC	cis	rs7589728	1.000	rs6720809	chr2:88528943	T/C	cg04511125	chr2:88470314	THNSL2	0.57	5.33	0.33	2.36e-7	Plasma clusterin levels;
SARC	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-7.96	-0.46	7.58e-14	Alzheimer's disease;
SARC	cis	rs780094	0.585	rs3739095	chr2:27556721	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.37	-6.18	-0.38	2.79e-9	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.6	0.53	1.3e-18	Prudent dietary pattern;
SARC	cis	rs2439831	0.850	rs2277531	chr15:44069069	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	8.58	0.49	1.37e-15	Lung cancer in ever smokers;
SARC	cis	rs2153535	0.606	rs11243253	chr6:8380193	T/C	cg21535247	chr6:8435926	SLC35B3	-0.58	-7.05	-0.42	2.01e-11	Motion sickness;
SARC	cis	rs9309473	0.898	rs10197755	chr2:73797623	T/A	cg20560298	chr2:73613845	ALMS1	-0.48	-5.92	-0.36	1.14e-8	Metabolite levels;
SARC	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg27266027	chr21:40555129	PSMG1	-0.53	-5.97	-0.36	8.73e-9	Cognitive function;
SARC	cis	rs17376456	0.542	rs1453003	chr5:93151611	T/C	cg21475434	chr5:93447410	FAM172A	-0.64	-6.23	-0.38	2.2e-9	Diabetic retinopathy;
SARC	cis	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg25427524	chr10:38739819	LOC399744	-0.53	-8.55	-0.49	1.66e-15	Extrinsic epigenetic age acceleration;
SARC	cis	rs12079745	0.793	rs113426965	chr1:169406545	T/C	cg09363564	chr1:169337483	NME7;BLZF1	-0.79	-5.05	-0.31	8.86e-7	QT interval;
SARC	cis	rs11608355	0.557	rs759971	chr12:109826046	A/T	cg19025524	chr12:109796872	NA	-0.42	-6.34	-0.38	1.18e-9	Neuroticism;
SARC	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg06618935	chr21:46677482	NA	-0.39	-5.14	-0.32	5.76e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs8073060	0.533	rs178736	chr17:33928158	G/T	cg19694781	chr19:47549865	TMEM160	-0.64	-6.32	-0.38	1.31e-9	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs17270561	0.609	rs4712970	chr6:25770707	G/A	cg16482183	chr6:26056742	HIST1H1C	0.5	6.12	0.37	3.98e-9	Iron status biomarkers;
SARC	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg18876405	chr7:65276391	NA	-0.72	-9.08	-0.51	4.83e-17	Aortic root size;
SARC	cis	rs854765	0.647	rs854791	chr17:18029857	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	8.64	0.49	9.13e-16	Total body bone mineral density;
SARC	cis	rs459571	0.920	rs433402	chr9:136898627	A/G	cg13789015	chr9:136890014	NCRNA00094	0.63	8.78	0.5	3.61e-16	Platelet distribution width;
SARC	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg15352829	chr14:105391018	PLD4	-0.33	-6.34	-0.38	1.19e-9	Rheumatoid arthritis;
SARC	cis	rs916888	0.610	rs199438	chr17:44791643	G/A	cg01570182	chr17:44337453	NA	0.62	7.43	0.44	2.1e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg08280861	chr8:58055591	NA	0.61	5.88	0.36	1.43e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs826838	1.000	rs11183196	chr12:38685915	G/T	cg26384229	chr12:38710491	ALG10B	0.95	15.37	0.71	2.69e-37	Heart rate;
SARC	cis	rs79349575	0.687	rs12602179	chr17:47010034	G/T	cg07967210	chr17:47022446	SNF8	0.38	4.77	0.3	3.2e-6	Type 2 diabetes;
SARC	cis	rs9457247	0.765	rs10946203	chr6:167446735	A/C	cg23791538	chr6:167370224	RNASET2	-0.55	-7.17	-0.43	9.62e-12	Crohn's disease;
SARC	cis	rs7474896	0.559	rs1208779	chr10:38077729	A/C	cg25427524	chr10:38739819	LOC399744	-0.5	-6.17	-0.37	3.04e-9	Obesity (extreme);
SARC	cis	rs941408	1.000	rs941407	chr19:2812153	A/G	cg06609049	chr19:2785107	THOP1	0.76	9.51	0.53	2.41e-18	Total cholesterol levels;
SARC	cis	rs7762018	0.891	rs3088346	chr6:170149793	T/C	cg13891659	chr6:170190454	C6orf122;C6orf208	0.55	4.9	0.31	1.81e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs7659604	1.000	rs10005932	chr4:122664782	T/C	cg19671926	chr4:122722719	EXOSC9	-0.49	-5.97	-0.36	8.79e-9	Type 2 diabetes;
SARC	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg04267008	chr7:1944627	MAD1L1	0.5	5.71	0.35	3.46e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs1008375	0.544	rs7685265	chr4:17568510	C/T	cg16339924	chr4:17578868	LAP3	0.64	7.66	0.45	5.08e-13	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1949733	0.701	rs2688222	chr4:8473735	C/A	cg13073564	chr4:8508604	NA	-0.37	-5.46	-0.34	1.22e-7	Response to antineoplastic agents;
SARC	cis	rs875971	0.545	rs801212	chr7:66015630	C/G	cg11764359	chr7:65958608	NA	-0.62	-6.06	-0.37	5.55e-9	Aortic root size;
SARC	cis	rs12579753	0.917	rs11612874	chr12:82212649	A/C	cg07988820	chr12:82153109	PPFIA2	0.53	5.52	0.34	9.16e-8	Resting heart rate;
SARC	cis	rs910316	1.000	rs10136948	chr14:75511075	C/T	cg08847533	chr14:75593920	NEK9	0.93	15.16	0.7	1.43e-36	Height;
SARC	cis	rs72945132	0.941	rs66803755	chr11:70117473	G/A	cg05964544	chr11:70165517	PPFIA1	-0.56	-5.6	-0.34	5.91e-8	Coronary artery disease;
SARC	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg15049968	chr18:44337910	ST8SIA5	0.34	5.23	0.32	3.81e-7	Personality dimensions;
SARC	cis	rs6582630	0.555	rs10880421	chr12:38423015	C/T	cg26384229	chr12:38710491	ALG10B	0.87	12.57	0.64	5.36e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9303280	0.806	rs9904624	chr17:38036586	A/G	cg20243544	chr17:37824526	PNMT	0.43	5.63	0.35	5.08e-8	Self-reported allergy;
SARC	cis	rs2153535	0.580	rs1335633	chr6:8448800	C/T	cg21535247	chr6:8435926	SLC35B3	0.55	6.87	0.41	5.72e-11	Motion sickness;
SARC	cis	rs9814567	0.806	rs6799543	chr3:134216139	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.08	-0.42	1.7e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs9640161	0.830	rs6722	chr7:150068933	T/C	cg21361702	chr7:150065534	REPIN1	0.54	6.72	0.4	1.36e-10	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs908922	0.676	rs1856120	chr1:152512441	G/A	cg09873164	chr1:152488093	CRCT1	0.65	8.66	0.49	7.93e-16	Hair morphology;
SARC	cis	rs34929064	0.672	rs2961298	chr7:22708091	A/C	cg26061582	chr7:22766209	IL6	-0.41	-4.89	-0.31	1.86e-6	Major depression and alcohol dependence;
SARC	cis	rs4803468	1.000	rs10422783	chr19:41906436	T/C	cg08477640	chr19:41863820	B9D2	0.47	6.1	0.37	4.26e-9	Height;
SARC	cis	rs4319547	1.000	rs1392236	chr12:123074890	C/G	cg23029597	chr12:123009494	RSRC2	-0.41	-5.17	-0.32	5.05e-7	Body mass index;
SARC	trans	rs12310956	0.527	rs1608910	chr12:33895414	T/C	cg13010199	chr12:38710504	ALG10B	0.63	8.45	0.48	3.15e-15	Morning vs. evening chronotype;
SARC	cis	rs644799	1.000	rs516551	chr11:95588626	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	14.6	0.69	1.05e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs11997175	0.583	rs7460295	chr8:33812288	C/T	ch.8.33884649F	chr8:33765107	NA	0.46	5.91	0.36	1.2e-8	Body mass index;
SARC	cis	rs2153535	0.580	rs6938071	chr6:8464845	A/T	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	cis	rs936229	0.705	rs936227	chr15:75131959	A/G	cg14664628	chr15:75095509	CSK	-0.65	-8.11	-0.47	2.93e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg18876405	chr7:65276391	NA	-0.72	-9.08	-0.51	4.9e-17	Aortic root size;
SARC	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg21724239	chr8:58056113	NA	0.69	6.32	0.38	1.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs11155671	0.530	rs6939761	chr6:150210994	T/C	cg09699651	chr6:150184138	LRP11	0.52	6.59	0.4	2.86e-10	Testicular germ cell tumor;
SARC	cis	rs7465272	1.000	rs35900184	chr8:143693411	C/T	cg10596483	chr8:143751796	JRK	0.57	6.12	0.37	4e-9	Bipolar disorder and schizophrenia;
SARC	trans	rs61931739	0.500	rs10844829	chr12:34304916	G/T	cg26384229	chr12:38710491	ALG10B	0.85	12.07	0.62	2.27e-26	Morning vs. evening chronotype;
SARC	cis	rs12421382	0.659	rs2165137	chr11:109381995	G/T	cg27471124	chr11:109292789	C11orf87	0.38	5.2	0.32	4.26e-7	Schizophrenia;
SARC	cis	rs1008375	0.932	rs4698630	chr4:17614692	C/G	cg02297831	chr4:17616191	MED28	0.5	6.39	0.39	9.15e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7223966	1.000	rs11657120	chr17:61857218	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	7.12	0.42	1.35e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2963155	0.518	rs864355	chr5:142633229	A/G	cg17617527	chr5:142782415	NR3C1	0.81	5.67	0.35	4.31e-8	Breast cancer;
SARC	cis	rs17376456	0.877	rs28575883	chr5:93346035	T/C	cg25358565	chr5:93447407	FAM172A	1.3	14.45	0.69	3.26e-34	Diabetic retinopathy;
SARC	cis	rs6964587	0.934	rs1544377	chr7:91687351	A/G	cg17063962	chr7:91808500	NA	0.96	16.21	0.73	4.33e-40	Breast cancer;
SARC	cis	rs4253772	0.591	rs6519994	chr22:46656805	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.65	-7.38	-0.44	2.72e-12	LDL cholesterol;Cholesterol, total;
SARC	trans	rs7824557	0.583	rs2263511	chr8:11233318	A/C	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.67	-0.4	1.8e-10	Retinal vascular caliber;
SARC	cis	rs875971	0.545	rs316306	chr7:65618674	G/A	cg11764359	chr7:65958608	NA	-0.66	-6.5	-0.39	4.83e-10	Aortic root size;
SARC	cis	rs2153535	0.601	rs2143352	chr6:8530248	G/C	cg07606381	chr6:8435919	SLC35B3	0.74	10.6	0.57	1.12e-21	Motion sickness;
SARC	cis	rs9322817	0.691	rs9391249	chr6:105343433	T/A	cg02098413	chr6:105308735	HACE1	0.4	6.15	0.37	3.26e-9	Thyroid stimulating hormone;
SARC	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg22800045	chr5:56110881	MAP3K1	0.74	7.83	0.46	1.74e-13	Initial pursuit acceleration;
SARC	cis	rs1215050	0.904	rs890469	chr4:98923293	T/C	cg05340658	chr4:99064831	C4orf37	-0.43	-5.46	-0.34	1.19e-7	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg07636037	chr3:49044803	WDR6	1.02	18.25	0.77	8.16e-47	Parkinson's disease;
SARC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg08677398	chr8:58056175	NA	0.44	5.27	0.33	3.14e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9790314	0.934	rs455386	chr3:161102495	A/T	cg04691961	chr3:161091175	C3orf57	-0.78	-11.58	-0.6	8.8e-25	Morning vs. evening chronotype;
SARC	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.45	5.13	0.32	5.97e-7	Renal function-related traits (BUN);
SARC	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg23098012	chr1:149859591	HIST2H2AB;HIST2H2BE	-0.49	-6.32	-0.38	1.33e-9	Thyroid cancer;
SARC	cis	rs7223966	0.960	rs7212379	chr17:61706122	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.45	4.9	0.31	1.78e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg11494091	chr17:61959527	GH2	0.53	8.04	0.47	4.44e-14	Prudent dietary pattern;
SARC	cis	rs826838	1.000	rs34254519	chr12:39041235	G/A	cg13010199	chr12:38710504	ALG10B	0.76	10.66	0.57	7.08e-22	Heart rate;
SARC	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg24060327	chr5:131705240	SLC22A5	0.73	8.67	0.49	7.67e-16	Breast cancer;
SARC	cis	rs35110281	0.693	rs2838344	chr21:45089877	C/T	cg04455712	chr21:45112962	RRP1B	0.34	4.77	0.3	3.26e-6	Mean corpuscular volume;
SARC	cis	rs5771225	0.544	rs909688	chr22:50689030	A/G	cg16473166	chr22:50639996	SELO	0.46	4.87	0.3	2.09e-6	Late-onset Alzheimer's disease;
SARC	cis	rs611744	0.805	rs453634	chr8:109135101	T/C	cg21045802	chr8:109455806	TTC35	0.4	4.75	0.3	3.5e-6	Dupuytren's disease;
SARC	cis	rs2370759	1.000	rs11597888	chr10:32635834	G/A	cg18270830	chr10:32634957	EPC1	0.68	6.04	0.37	5.98e-9	Sexual dysfunction (female);
SARC	cis	rs79149102	0.579	rs78664321	chr15:75339575	G/A	cg09165964	chr15:75287851	SCAMP5	-1.04	-8.21	-0.47	1.55e-14	Lung cancer;
SARC	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	16.15	0.73	6.91e-40	Chronic sinus infection;
SARC	cis	rs150213942	1	rs150213942	chr3:135846911	T/G	cg15507776	chr3:136538369	TMEM22	0.47	4.99	0.31	1.16e-6	Fibrinogen levels;
SARC	cis	rs9457247	0.565	rs55873403	chr6:167511800	C/T	cg07741184	chr6:167504864	NA	0.37	7.05	0.42	2e-11	Crohn's disease;
SARC	trans	rs2727020	0.521	rs7114564	chr11:49571231	C/T	cg03929089	chr4:120376271	NA	0.68	7.56	0.44	9.01e-13	Coronary artery disease;
SARC	cis	rs2952156	0.920	rs2934953	chr17:37832315	T/A	cg20243544	chr17:37824526	PNMT	0.47	5.85	0.36	1.62e-8	Asthma;
SARC	cis	rs672059	1.000	rs480132	chr1:183161779	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.49	6.72	0.4	1.42e-10	Hypertriglyceridemia;
SARC	cis	rs3820928	0.874	rs10182307	chr2:227875360	C/T	cg11843606	chr2:227700838	RHBDD1	-0.46	-5.57	-0.34	7.11e-8	Pulmonary function;
SARC	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs4268898	0.931	rs2551121	chr2:24539967	T/C	cg06627628	chr2:24431161	ITSN2	-0.67	-9.61	-0.53	1.22e-18	Asthma;
SARC	cis	rs4466137	0.868	rs4703962	chr5:82999808	A/G	cg16102102	chr5:83017553	HAPLN1	-0.76	-9.34	-0.52	8.23e-18	Prostate cancer;
SARC	cis	rs9398803	0.830	rs2039735	chr6:126745076	T/C	cg20229609	chr6:126660872	C6orf173	0.41	5.89	0.36	1.36e-8	Male-pattern baldness;
SARC	cis	rs1920116	1.000	rs4955677	chr3:169568510	T/C	cg14222479	chr3:169487675	ARPM1	0.44	5.48	0.34	1.09e-7	Glioma (high-grade);
SARC	cis	rs6594499	0.872	rs13161853	chr5:110446741	C/A	cg04022379	chr5:110408740	TSLP	0.45	5.68	0.35	4.02e-8	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs12142240	0.698	rs6703669	chr1:46862555	C/T	cg00530320	chr1:46809349	NSUN4	0.57	7.0	0.42	2.74e-11	Menopause (age at onset);
SARC	cis	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg20965017	chr5:231967	SDHA	-0.55	-5.26	-0.33	3.23e-7	Breast cancer;
SARC	cis	rs3771570	0.901	rs62190410	chr2:242410621	C/T	cg21155796	chr2:242212141	HDLBP	0.64	5.99	0.37	7.87e-9	Prostate cancer;
SARC	cis	rs12142240	0.698	rs7548675	chr1:46809321	C/G	cg14993813	chr1:46806288	NSUN4	-0.52	-5.45	-0.34	1.28e-7	Menopause (age at onset);
SARC	cis	rs1355223	0.902	rs1539250	chr11:34742775	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.34	-0.33	2.21e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg05896524	chr21:47604654	C21orf56	0.55	6.88	0.41	5.57e-11	Testicular germ cell tumor;
SARC	cis	rs7395581	0.918	rs4752825	chr11:47352409	G/A	cg25783544	chr11:47291846	MADD	0.5	5.49	0.34	1.05e-7	HDL cholesterol;
SARC	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg26119090	chr2:26468346	HADHA;HADHB	0.95	13.96	0.67	1.32e-32	Gut microbiome composition (summer);
SARC	trans	rs1814175	0.803	rs11040451	chr11:49650639	C/T	cg15704280	chr7:45808275	SEPT13	-0.92	-15.93	-0.72	3.71e-39	Height;
SARC	cis	rs13191362	0.872	rs35443919	chr6:163055804	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.59	4.99	0.31	1.19e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs9858542	0.537	rs2304442	chr3:49322027	A/T	cg00383909	chr3:49044727	WDR6	-0.48	-5.08	-0.32	7.79e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs240110	0.588	rs7738319	chr6:101195253	T/C	cg09795085	chr6:101329169	ASCC3	0.4	4.91	0.31	1.7e-6	Neuroticism;
SARC	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.6	5.08	0.32	7.91e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs13418717	0.793	rs3795874	chr2:127656383	A/G	cg25501666	chr2:127640322	NA	0.82	5.54	0.34	7.96e-8	Heart failure;
SARC	cis	rs7617773	0.780	rs36075665	chr3:48343087	C/T	cg11946769	chr3:48343235	NME6	0.76	9.7	0.54	6.55e-19	Coronary artery disease;
SARC	cis	rs4481887	1.000	rs4481887	chr1:248496863	A/G	cg00666640	chr1:248458726	OR2T12	0.4	6.58	0.4	3.1e-10	Common traits (Other);
SARC	cis	rs11608355	1.000	rs10850135	chr12:109866528	C/A	cg05360138	chr12:110035743	NA	0.44	4.86	0.3	2.21e-6	Neuroticism;
SARC	cis	rs78366141	0.649	rs78179026	chr4:89657456	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	0.91	4.82	0.3	2.58e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
SARC	cis	rs7666738	0.791	rs4440223	chr4:99044796	G/A	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg12463550	chr7:65579703	CRCP	0.48	5.79	0.35	2.23e-8	Aortic root size;
SARC	cis	rs2204008	0.749	rs4579984	chr12:38166266	A/G	cg26384229	chr12:38710491	ALG10B	0.87	12.39	0.63	2.07e-27	Bladder cancer;
SARC	cis	rs9790314	0.690	rs4679930	chr3:160842875	C/G	cg04691961	chr3:161091175	C3orf57	-0.56	-7.35	-0.43	3.27e-12	Morning vs. evening chronotype;
SARC	cis	rs2594989	0.733	rs2616539	chr3:11580371	C/A	cg00170343	chr3:11313890	ATG7	0.59	6.73	0.4	1.3100000000000001e-10	Circulating chemerin levels;
SARC	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg11644478	chr21:40555479	PSMG1	1.06	15.16	0.7	1.35e-36	Cognitive function;
SARC	cis	rs668210	0.947	rs559161	chr11:65761637	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.68	7.76	0.45	2.58e-13	Cerebrospinal fluid biomarker levels;
SARC	cis	rs3096299	0.586	rs4572400	chr16:89533516	T/A	cg07708487	chr16:89387014	ANKRD11	-0.25	-4.84	-0.3	2.34e-6	Multiple myeloma (IgH translocation);
SARC	cis	rs778371	0.522	rs6704768	chr2:233592501	C/T	cg16596103	chr2:233749413	NGEF	-0.35	-5.77	-0.35	2.46e-8	Schizophrenia;
SARC	cis	rs11711311	0.955	rs12630791	chr3:113387717	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.61	-7.28	-0.43	4.99e-12	IgG glycosylation;
SARC	cis	rs9467773	0.967	rs1056347	chr6:26527524	G/C	cg12292205	chr6:26970375	C6orf41	0.44	5.46	0.34	1.24e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7937682	0.632	rs11823089	chr11:111673539	A/G	cg09085632	chr11:111637200	PPP2R1B	0.8	10.69	0.57	5.93e-22	Primary sclerosing cholangitis;
SARC	cis	rs2070488	0.965	rs2284819	chr3:38557161	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.76	11.66	0.61	4.66e-25	Electrocardiographic conduction measures;
SARC	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg10523679	chr1:76189770	ACADM	0.52	6.89	0.41	5.04e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9420	0.961	rs71484461	chr11:57488890	G/A	cg19752551	chr11:57585705	CTNND1	-0.5	-6.79	-0.41	9.24e-11	Schizophrenia;
SARC	cis	rs7474896	0.559	rs1208645	chr10:38132087	C/T	cg25427524	chr10:38739819	LOC399744	0.47	5.6	0.34	6.08e-8	Obesity (extreme);
SARC	cis	rs8028182	0.577	rs28693593	chr15:75849776	A/C	cg20655648	chr15:75932815	IMP3	0.62	7.18	0.43	9.2e-12	Sudden cardiac arrest;
SARC	cis	rs2370759	1.000	rs16933225	chr10:32599464	C/T	cg01819863	chr10:32635814	EPC1	1.02	10.98	0.58	7.08e-23	Sexual dysfunction (female);
SARC	cis	rs7582180	0.652	rs4851307	chr2:100971778	C/T	cg14675211	chr2:100938903	LONRF2	0.52	7.79	0.45	2.26e-13	Intelligence (multi-trait analysis);
SARC	cis	rs7481584	0.624	rs451060	chr11:3056389	G/A	cg20651018	chr11:3035856	CARS	0.4	5.83	0.36	1.82e-8	Calcium levels;
SARC	trans	rs7824557	0.564	rs34389419	chr8:11229319	C/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.48	-0.39	5.29e-10	Retinal vascular caliber;
SARC	cis	rs11190604	1.000	rs7088827	chr10:102303865	C/G	cg07080220	chr10:102295463	HIF1AN	0.82	9.59	0.53	1.38e-18	Palmitoleic acid (16:1n-7) levels;
SARC	trans	rs1814175	0.935	rs11040438	chr11:49622521	G/A	cg03929089	chr4:120376271	NA	-0.85	-13.28	-0.66	2.49e-30	Height;
SARC	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg11764359	chr7:65958608	NA	-0.72	-8.42	-0.48	3.77e-15	Aortic root size;
SARC	cis	rs1662342	1.000	rs1662342	chr18:3255301	G/A	cg14211874	chr18:3262499	MYL12B	-0.69	-5.19	-0.32	4.51e-7	QRS duration;
SARC	cis	rs1348850	0.757	rs2166554	chr2:178455824	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.63	7.62	0.45	6.47e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1957429	0.731	rs28370916	chr14:65346094	A/G	cg23373153	chr14:65346875	NA	1.08	11.46	0.6	2.06e-24	Pediatric areal bone mineral density (radius);
SARC	cis	rs9457247	1.000	rs416131	chr6:167406544	A/C	cg23791538	chr6:167370224	RNASET2	0.58	7.9	0.46	1.1e-13	Crohn's disease;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg22038333	chr6:27818763	NA	0.51	7.07	0.42	1.79e-11	Thyroid stimulating hormone;
SARC	cis	rs3820928	0.874	rs10210997	chr2:227859108	C/T	cg11843606	chr2:227700838	RHBDD1	-0.46	-5.64	-0.35	4.89e-8	Pulmonary function;
SARC	cis	rs9811216	0.917	rs7621631	chr3:169512145	A/C	cg14222479	chr3:169487675	ARPM1	-0.42	-5.0	-0.31	1.14e-6	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs4975616	0.804	rs381949	chr5:1322468	G/A	cg26373071	chr5:1325741	CLPTM1L	0.3	4.85	0.3	2.23e-6	Lung cancer;
SARC	cis	rs8027181	0.839	rs9460	chr15:73044575	C/T	cg25996835	chr15:72978165	BBS4;HIGD2B	0.41	5.49	0.34	1.05e-7	Triglyceride levels;
SARC	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg21747090	chr2:27597821	SNX17	-0.57	-7.86	-0.46	1.45e-13	Total body bone mineral density;
SARC	cis	rs314370	0.951	rs17884589	chr7:100493711	G/A	cg10426581	chr7:100472382	SRRT	0.58	6.13	0.37	3.78e-9	Resting heart rate;
SARC	trans	rs61931739	0.517	rs2636074	chr12:34064056	C/T	cg26384229	chr12:38710491	ALG10B	0.73	10.04	0.55	6.12e-20	Morning vs. evening chronotype;
SARC	cis	rs7712401	0.580	rs10076327	chr5:122367347	A/G	cg19412675	chr5:122181750	SNX24	0.48	6.1	0.37	4.28e-9	Mean platelet volume;
SARC	cis	rs4642101	0.561	rs6766744	chr3:12801843	C/T	cg05775895	chr3:12838266	CAND2	0.52	6.88	0.41	5.45e-11	QRS complex (12-leadsum);
SARC	cis	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg03213289	chr20:61660250	NA	0.46	6.43	0.39	7.22e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs7264396	0.563	rs2225950	chr20:34333015	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	5.32	0.33	2.49e-7	Total cholesterol levels;
SARC	cis	rs10089	1.000	rs3805612	chr5:127505316	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	9.01	0.51	7.68e-17	Ileal carcinoids;
SARC	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg02461776	chr11:598696	PHRF1	0.48	5.15	0.32	5.56e-7	Systemic lupus erythematosus;
SARC	cis	rs2153535	0.542	rs9378553	chr6:8472632	T/C	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	trans	rs9951602	0.512	rs9953258	chr18:76651199	A/C	cg02800362	chr5:177631904	HNRNPAB	0.71	9.0	0.51	8.26e-17	Obesity-related traits;
SARC	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs76419734	1.000	rs72671840	chr4:106638697	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.84	5.56	0.34	7.44e-8	Post bronchodilator FEV1;
SARC	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg19346786	chr7:2764209	NA	-0.34	-5.01	-0.31	1.08e-6	Height;
SARC	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg03352830	chr11:487213	PTDSS2	0.52	5.14	0.32	5.77e-7	Body mass index;
SARC	cis	rs9843304	0.616	rs34783865	chr3:149205792	A/G	cg08667024	chr3:149219783	TM4SF4	-0.34	-4.84	-0.3	2.38e-6	Gallstone disease;
SARC	cis	rs6815814	0.904	rs2101521	chr4:38811551	C/T	cg06935464	chr4:38784597	TLR10	0.53	5.95	0.36	9.63e-9	Breast cancer;
SARC	cis	rs2832191	0.791	rs2065270	chr21:30485420	T/C	cg24692254	chr21:30365293	RNF160	-0.92	-13.86	-0.67	2.87e-32	Dental caries;
SARC	cis	rs10875746	0.669	rs11168510	chr12:48685555	A/G	cg26205652	chr12:48591994	NA	0.45	4.72	0.3	4.07e-6	Longevity (90 years and older);
SARC	trans	rs1814175	0.803	rs11040451	chr11:49650639	C/T	cg03929089	chr4:120376271	NA	-0.84	-12.91	-0.65	4.14e-29	Height;
SARC	trans	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg00938859	chr5:1591904	SDHAP3	0.79	7.66	0.45	5.1e-13	Breast cancer;
SARC	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg25072359	chr17:41440525	NA	0.5	6.0	0.37	7.48e-9	Menopause (age at onset);
SARC	trans	rs9858542	0.953	rs34363169	chr3:49537712	G/A	cg21659725	chr3:3221576	CRBN	-0.56	-6.33	-0.38	1.28e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	11.07	0.59	3.6e-23	Alzheimer's disease;
SARC	trans	rs9929218	0.817	rs3114402	chr16:68719607	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.68	-8.67	-0.49	7.57e-16	Colorectal cancer;
SARC	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg24846343	chr22:24311635	DDTL	0.57	7.99	0.46	6.03e-14	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs11098499	0.863	rs1010739	chr4:120463471	C/T	cg09307838	chr4:120376055	NA	0.84	11.06	0.59	3.99e-23	Corneal astigmatism;
SARC	cis	rs9886651	0.935	rs4582525	chr8:128800947	A/G	cg24514600	chr8:128805414	PVT1	-0.43	-5.69	-0.35	3.76e-8	Epithelial ovarian cancer;Serous invasive ovarian cancer;
SARC	cis	rs748404	0.697	rs1095389	chr15:43566671	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.41	5.13	0.32	6.14e-7	Lung cancer;
SARC	cis	rs1699337	0.930	rs2938398	chr3:12404490	T/C	cg04748988	chr3:12329223	PPARG	0.38	4.98	0.31	1.21e-6	Cholesterol, total;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg27228074	chr10:104678015	CNNM2	0.58	7.24	0.43	6.52e-12	Breast cancer;
SARC	cis	rs1185460	1.000	rs7938944	chr11:118954066	T/C	cg23280166	chr11:118938394	VPS11	0.7	9.35	0.52	7.48e-18	Coronary artery disease;
SARC	cis	rs826838	0.834	rs2387842	chr12:38736442	T/C	cg13010199	chr12:38710504	ALG10B	0.83	12.03	0.62	3.09e-26	Heart rate;
SARC	cis	rs2153535	0.521	rs6939827	chr6:8461360	C/G	cg21535247	chr6:8435926	SLC35B3	0.56	7.06	0.42	1.86e-11	Motion sickness;
SARC	cis	rs1707322	1.000	rs785486	chr1:46575148	G/C	cg06784218	chr1:46089804	CCDC17	-0.36	-6.17	-0.37	3.05e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg01339781	chr6:116989657	ZUFSP	-0.8	-7.08	-0.42	1.7e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs829883	0.934	rs1641642	chr12:98898726	A/G	cg25150519	chr12:98850993	NA	0.71	9.64	0.53	1.01e-18	Colorectal adenoma (advanced);
SARC	cis	rs9457247	0.510	rs6456151	chr6:167471851	A/C	cg23791538	chr6:167370224	RNASET2	-0.52	-6.81	-0.41	8.22e-11	Crohn's disease;
SARC	cis	rs7312933	0.701	rs10880260	chr12:42561398	A/G	cg19980929	chr12:42632907	YAF2	0.43	5.89	0.36	1.38e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs1008375	0.897	rs6820164	chr4:17630115	G/A	cg16339924	chr4:17578868	LAP3	0.65	8.51	0.49	2.12e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg22920501	chr2:26401640	FAM59B	-0.55	-7.14	-0.42	1.2e-11	Gut microbiome composition (summer);
SARC	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg16479474	chr6:28041457	NA	0.36	5.36	0.33	1.97e-7	Parkinson's disease;
SARC	cis	rs4481887	0.893	rs10888337	chr1:248428227	A/G	cg01631408	chr1:248437212	OR2T33	0.42	5.24	0.32	3.59e-7	Common traits (Other);
SARC	cis	rs1059312	0.545	rs12303387	chr12:129276733	C/T	cg09035930	chr12:129282057	SLC15A4	-0.44	-5.39	-0.33	1.7e-7	Systemic lupus erythematosus;
SARC	cis	rs1267303	0.537	rs59935547	chr1:47001423	A/G	cg25110126	chr1:46999211	NA	0.82	8.86	0.5	2.1e-16	Monobrow;
SARC	cis	rs9381107	0.505	rs1001384	chr6:9485556	G/A	cg14735645	chr6:9486422	NA	-0.49	-5.77	-0.35	2.49e-8	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs9486719	1.000	rs11153067	chr6:97039421	A/T	cg06623918	chr6:96969491	KIAA0776	0.77	8.69	0.49	6.69e-16	Migraine;Coronary artery disease;
SARC	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.41	-5.17	-0.32	4.99e-7	Lymphocyte counts;
SARC	cis	rs12702595	0.818	rs7787942	chr7:7270012	A/T	cg04827551	chr7:7268805	C1GALT1	0.44	5.4	0.33	1.61e-7	Serum dimethylarginine levels (asymmetric/symetric ratio);Symmetrical dimethylarginine levels;
SARC	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.62	7.52	0.44	1.16e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs722599	0.683	rs8014695	chr14:75301617	C/G	cg06637938	chr14:75390232	RPS6KL1	0.39	4.82	0.3	2.58e-6	IgG glycosylation;
SARC	cis	rs2204008	0.748	rs11514352	chr12:38246954	C/T	cg26384229	chr12:38710491	ALG10B	0.91	13.64	0.67	1.61e-31	Bladder cancer;
SARC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.3	-4.76	-0.3	3.39e-6	Total body bone mineral density;
SARC	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg13206674	chr6:150067644	NUP43	0.46	6.01	0.37	6.92e-9	Lung cancer;
SARC	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg04944784	chr2:26401820	FAM59B	-0.49	-6.2	-0.38	2.53e-9	Gut microbiome composition (summer);
SARC	cis	rs459571	0.959	rs410876	chr9:136893867	C/A	cg01294253	chr9:136912663	BRD3	0.42	5.4	0.33	1.6e-7	Platelet distribution width;
SARC	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg12667521	chr19:29218732	NA	0.4	5.3	0.33	2.7e-7	Methadone dose in opioid dependence;
SARC	cis	rs2425143	1.000	rs28685274	chr20:34358527	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-6.34	-0.38	1.19e-9	Blood protein levels;
SARC	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg19077165	chr18:44547161	KATNAL2	-0.49	-6.66	-0.4	1.99e-10	Personality dimensions;
SARC	cis	rs425277	1.000	rs421992	chr1:2077260	C/T	cg21442419	chr1:2182373	SKI	-0.52	-6.68	-0.4	1.76e-10	Height;
SARC	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg02841227	chr6:26021843	HIST1H4A	0.46	5.6	0.34	5.87e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2832191	0.740	rs2832175	chr21:30475606	A/G	cg08807101	chr21:30365312	RNF160	-0.91	-14.31	-0.68	9.4e-34	Dental caries;
SARC	cis	rs9527	0.640	rs7089061	chr10:104723015	C/A	cg04362960	chr10:104952993	NT5C2	0.4	4.73	0.3	3.95e-6	Arsenic metabolism;
SARC	cis	rs12681366	0.683	rs1379246	chr8:95373301	G/A	cg26464482	chr8:95565502	KIAA1429	-0.45	-5.73	-0.35	3.1e-8	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs748404	0.697	rs567357	chr15:43571390	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.44	5.48	0.34	1.08e-7	Lung cancer;
SARC	cis	rs11997175	0.550	rs7459534	chr8:33836623	G/C	ch.8.33884649F	chr8:33765107	NA	0.45	5.69	0.35	3.8e-8	Body mass index;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg08116922	chr7:55003149	NA	0.48	6.44	0.39	6.94e-10	Thyroid stimulating hormone;
SARC	cis	rs4794202	0.717	rs6503897	chr17:45957049	A/G	cg23391107	chr17:45924227	SP6	0.5	5.36	0.33	2.03e-7	Alzheimer's disease (cognitive decline);
SARC	cis	rs15676	0.783	rs3829057	chr9:131567982	A/G	cg00228799	chr9:131580591	ENDOG	0.55	7.04	0.42	2.09e-11	Blood metabolite levels;
SARC	trans	rs7937682	1.000	rs11608149	chr11:111535102	G/A	cg18187862	chr3:45730750	SACM1L	-0.6	-7.32	-0.43	3.93e-12	Primary sclerosing cholangitis;
SARC	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg06929287	chr1:210001192	C1orf107	0.4	4.85	0.3	2.21e-6	Monobrow;
SARC	cis	rs713587	0.646	rs34697209	chr2:25127394	A/G	cg04586622	chr2:25135609	ADCY3	0.34	5.73	0.35	3.08e-8	Body mass index in non-asthmatics;
SARC	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg08219700	chr8:58056026	NA	0.6	5.82	0.36	1.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10088262	0.634	rs7815695	chr8:124783978	C/G	cg02993010	chr8:124780839	FAM91A1	-0.78	-8.39	-0.48	4.71e-15	Pancreatic cancer;
SARC	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg06634786	chr22:41940651	POLR3H	-0.41	-4.91	-0.31	1.68e-6	Vitiligo;
SARC	cis	rs17666538	1.000	rs57896286	chr8:571479	T/C	cg00450029	chr8:599525	NA	-0.71	-5.05	-0.31	8.95e-7	IgG glycosylation;
SARC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg18404041	chr3:52824283	ITIH1	-0.37	-5.55	-0.34	7.63e-8	Bipolar disorder;
SARC	cis	rs6665290	0.935	rs6659424	chr1:227197875	A/G	cg14016676	chr1:227182615	CDC42BPA	0.36	5.18	0.32	4.9e-7	Myeloid white cell count;
SARC	cis	rs7412746	0.611	rs16827671	chr1:150738759	T/C	cg13175981	chr1:150552382	MCL1	-0.54	-6.57	-0.4	3.32e-10	Melanoma;
SARC	cis	rs28830936	0.528	rs11630242	chr15:42124643	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.44	-6.94	-0.41	3.82e-11	Diastolic blood pressure;
SARC	cis	rs1448094	0.621	rs7315084	chr12:86283817	A/G	cg02569458	chr12:86230093	RASSF9	0.41	5.6	0.34	5.99e-8	Major depressive disorder;
SARC	cis	rs7511006	1.000	rs7364173	chr22:50681029	C/T	cg15134628	chr22:50699649	MAPK12	-0.39	-4.72	-0.3	3.99e-6	Obesity-related traits;
SARC	cis	rs9911578	0.967	rs8072712	chr17:57162464	A/T	cg20303301	chr17:57937339	TUBD1	-0.33	-4.82	-0.3	2.59e-6	Intelligence (multi-trait analysis);
SARC	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs4711336	0.633	rs9469583	chr6:33717770	T/C	cg04676172	chr6:33757040	LEMD2	0.39	4.77	0.3	3.27e-6	Height;
SARC	trans	rs11098499	0.955	rs35197422	chr4:120169314	T/G	cg25214090	chr10:38739885	LOC399744	0.52	6.89	0.41	5.07e-11	Corneal astigmatism;
SARC	cis	rs1124376	1.000	rs1124376	chr3:20108546	A/G	cg05072819	chr3:20081367	KAT2B	-0.55	-5.36	-0.33	2.02e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg16479474	chr6:28041457	NA	0.37	5.36	0.33	2.01e-7	Depression;
SARC	cis	rs4595586	0.545	rs11615700	chr12:39365104	A/G	cg26384229	chr12:38710491	ALG10B	0.51	6.25	0.38	1.9e-9	Morning vs. evening chronotype;
SARC	cis	rs10779751	1.000	rs11121704	chr1:11293959	A/G	cg08854313	chr1:11322531	MTOR	-0.83	-11.77	-0.61	2.15e-25	Body mass index;
SARC	cis	rs10490913	0.769	rs10787831	chr10:120171587	T/C	cg23160142	chr10:120154512	NA	0.38	5.77	0.35	2.45e-8	Cancer;
SARC	cis	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.47	-5.99	-0.37	8.1e-9	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs35110281	0.591	rs162369	chr21:44931965	G/A	cg21573476	chr21:45109991	RRP1B	-0.5	-7.4	-0.44	2.43e-12	Mean corpuscular volume;
SARC	cis	rs2213920	0.679	rs6415820	chr9:118231832	A/C	cg13918206	chr9:118159781	DEC1	0.78	6.24	0.38	2.05e-9	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	9.89	0.54	1.77e-19	Alzheimer's disease;
SARC	cis	rs9916302	0.752	rs11078895	chr17:37401051	A/G	cg07936489	chr17:37558343	FBXL20	-0.77	-9.23	-0.52	1.75e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs9911578	1.000	rs2531729	chr17:56539890	C/T	cg05425664	chr17:57184151	TRIM37	-0.66	-8.06	-0.47	4.04e-14	Intelligence (multi-trait analysis);
SARC	cis	rs8103278	1.000	rs9807819	chr19:46239598	C/T	cg16681516	chr19:46297285	DMWD	0.36	6.01	0.37	6.91e-9	Coronary artery disease;
SARC	cis	rs2153535	0.601	rs1737581	chr6:8539138	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	6.49	0.39	5.16e-10	Motion sickness;
SARC	cis	rs9640161	0.750	rs11769348	chr7:150026753	C/T	cg17279839	chr7:150038598	RARRES2	-0.48	-6.66	-0.4	2e-10	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs6500395	1.000	rs4517800	chr16:48677404	T/A	cg04672837	chr16:48644449	N4BP1	0.46	6.28	0.38	1.65e-9	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs4268898	0.662	rs2891382	chr2:24511491	C/G	cg06627628	chr2:24431161	ITSN2	-0.8	-9.73	-0.54	5.4e-19	Asthma;
SARC	trans	rs7980799	0.716	rs1601008	chr12:33611352	A/G	cg13010199	chr12:38710504	ALG10B	-0.52	-6.3	-0.38	1.47e-9	Heart rate;Heart rate variability traits (RMSSD);
SARC	trans	rs11098499	0.863	rs2306456	chr4:120472422	C/G	cg25214090	chr10:38739885	LOC399744	0.57	7.25	0.43	6.27e-12	Corneal astigmatism;
SARC	cis	rs6484504	0.576	rs208083	chr11:31196880	C/T	cg02090638	chr11:31391270	DNAJC24;DCDC1	-0.39	-4.99	-0.31	1.19e-6	Red blood cell count;
SARC	cis	rs6089584	1.000	rs6089584	chr20:60564086	G/C	cg23262073	chr20:60523788	NA	-0.45	-6.47	-0.39	5.74e-10	Body mass index;
SARC	cis	rs10789491	1.000	rs7547522	chr1:47179918	C/G	cg15501359	chr1:47185051	KIAA0494	0.78	8.26	0.48	1.1e-14	Response to hepatitis C treatment;
SARC	cis	rs10781543	0.967	rs7851507	chr9:139328722	G/T	cg14169450	chr9:139327907	INPP5E	0.43	5.7	0.35	3.63e-8	Monocyte percentage of white cells;
SARC	cis	rs35213789	0.887	rs6955815	chr7:69208888	C/A	cg10619644	chr7:69149951	AUTS2	-0.43	-5.82	-0.36	1.89e-8	Childhood ear infection;
SARC	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg19660806	chr8:588740	NA	0.54	4.93	0.31	1.59e-6	IgG glycosylation;
SARC	cis	rs1707322	0.721	rs4559551	chr1:46167533	T/C	cg03146154	chr1:46216737	IPP	0.53	6.42	0.39	7.41e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs881375	0.934	rs2159778	chr9:123678129	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.43	5.25	0.33	3.45e-7	Rheumatoid arthritis;
SARC	cis	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg13636640	chr20:31349939	DNMT3B	0.68	10.79	0.58	2.87e-22	Ulcerative colitis;
SARC	cis	rs16854884	0.558	rs6768153	chr3:143667429	C/A	cg06585982	chr3:143692056	C3orf58	0.68	9.23	0.52	1.7e-17	Economic and political preferences (feminism/equality);
SARC	cis	rs6759839	0.698	rs4832633	chr2:16648888	G/A	cg09580478	chr2:16689509	NA	0.48	6.17	0.37	2.98e-9	Mean platelet volume;
SARC	cis	rs12142240	0.698	rs1053627	chr1:46827728	A/C	cg10495392	chr1:46806563	NSUN4	0.65	6.8	0.41	8.89e-11	Menopause (age at onset);
SARC	cis	rs73206853	0.841	rs9783428	chr12:111068096	C/T	cg10860002	chr12:110842031	ANAPC7	0.59	4.99	0.31	1.18e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs35213789	0.803	rs2533440	chr7:69109266	A/G	cg10619644	chr7:69149951	AUTS2	-0.43	-5.77	-0.35	2.54e-8	Childhood ear infection;
SARC	cis	rs9814567	1.000	rs12637751	chr3:134266124	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	7.08	0.42	1.73e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs2221894	0.770	rs10088428	chr8:28909523	C/T	cg07962641	chr8:28805897	HMBOX1	-0.44	-5.44	-0.34	1.34e-7	Obesity-related traits;
SARC	cis	rs13082711	0.911	rs74279676	chr3:27512944	G/A	cg02860705	chr3:27208620	NA	0.42	5.44	0.34	1.32e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs4917300	0.606	rs7015050	chr8:143100960	T/A	cg06573787	chr8:143070187	NA	0.36	4.85	0.3	2.23e-6	Amyotrophic lateral sclerosis;
SARC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.97	10.66	0.57	7.33e-22	Platelet count;
SARC	cis	rs2370759	1.000	rs2225152	chr10:32574759	T/C	cg05361325	chr10:32636312	EPC1	-0.75	-6.52	-0.39	4.4e-10	Sexual dysfunction (female);
SARC	cis	rs12824058	0.831	rs12310049	chr12:130811260	C/G	cg23887609	chr12:130822674	PIWIL1	0.37	5.15	0.32	5.48e-7	Menopause (age at onset);
SARC	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg08219700	chr8:58056026	NA	0.63	6.34	0.38	1.19e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg22875332	chr1:76189707	ACADM	0.45	5.68	0.35	3.9e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs4148883	0.651	rs10020052	chr4:100086331	C/G	cg13256891	chr4:100009986	ADH5	0.56	7.39	0.44	2.6e-12	Alcohol dependence;
SARC	cis	rs10875746	0.859	rs4760680	chr12:48466697	G/T	cg26205652	chr12:48591994	NA	0.56	6.05	0.37	5.72e-9	Longevity (90 years and older);
SARC	cis	rs9462027	0.628	rs9462006	chr6:34710327	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.87	-0.36	1.5e-8	Systemic lupus erythematosus;
SARC	cis	rs11786130	0.901	rs4733817	chr8:129005584	G/A	cg17583432	chr8:129005567	PVT1	-0.35	-6.1	-0.37	4.34e-9	Eosinophil counts;Sum eosinophil basophil counts;
SARC	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg22920501	chr2:26401640	FAM59B	-0.55	-7.11	-0.42	1.42e-11	Gut microbiome composition (summer);
SARC	cis	rs865483	0.929	rs853195	chr17:35848255	G/T	cg06561646	chr17:35873369	DUSP14	-0.54	-6.47	-0.39	5.76e-10	Monocyte count;
SARC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg14893161	chr1:205819251	PM20D1	0.93	15.67	0.72	2.75e-38	Menarche (age at onset);
SARC	cis	rs6565180	1.000	rs11646130	chr16:30376959	T/C	cg17640201	chr16:30407289	ZNF48	-0.94	-13.77	-0.67	5.69e-32	Tonsillectomy;
SARC	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.97e-8	Aortic root size;
SARC	cis	rs1050631	0.564	rs589213	chr18:33743610	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.58	7.18	0.43	9.36e-12	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs883565	0.569	rs784509	chr3:39166355	G/A	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.44	-5.12	-0.32	6.37e-7	Handedness;
SARC	cis	rs62344088	1.000	rs7710931	chr5:152286	C/T	cg20965017	chr5:231967	SDHA	-0.87	-5.07	-0.32	7.94e-7	Asthma (childhood onset);
SARC	cis	rs9911578	1.000	rs9892062	chr17:56976981	G/A	cg12560992	chr17:57184187	TRIM37	0.85	11.57	0.6	9.08e-25	Intelligence (multi-trait analysis);
SARC	cis	rs2115536	0.692	rs8036559	chr15:80170563	C/T	cg00225070	chr15:80189496	MTHFS	0.51	6.64	0.4	2.14e-10	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
SARC	cis	rs2635047	0.967	rs12960444	chr18:44607314	T/C	cg19077165	chr18:44547161	KATNAL2	-0.36	-4.82	-0.3	2.65e-6	Educational attainment;
SARC	cis	rs2120019	0.567	rs8029351	chr15:75177237	A/C	cg00629941	chr15:75287862	SCAMP5	-0.58	-5.42	-0.33	1.47e-7	Blood trace element (Zn levels);
SARC	cis	rs9948	0.786	rs62156231	chr2:97425603	G/A	cg01990225	chr2:97406019	LMAN2L	-0.96	-6.94	-0.41	3.9e-11	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg06108461	chr20:60628389	TAF4	-0.98	-13.2	-0.65	4.54e-30	Body mass index;
SARC	cis	rs911263	0.961	rs7148416	chr14:68747868	A/T	cg18825221	chr14:68749962	RAD51L1	0.49	8.52	0.49	2.06e-15	Primary biliary cholangitis;
SARC	cis	rs4689388	0.856	rs3200	chr4:6304878	C/T	cg25554036	chr4:6271136	WFS1	0.37	5.96	0.36	9.07e-9	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs10463316	0.817	rs58892766	chr5:150776115	T/C	cg03212797	chr5:150827313	SLC36A1	-0.44	-5.21	-0.32	4.14e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs12908161	0.960	rs34452033	chr15:85221993	A/G	cg17507749	chr15:85114479	UBE2QP1	0.56	6.42	0.39	7.65e-10	Schizophrenia;
SARC	cis	rs9291683	0.546	rs13139055	chr4:10038924	G/T	cg00071950	chr4:10020882	SLC2A9	0.33	4.9	0.31	1.8e-6	Bone mineral density;
SARC	cis	rs11574514	1.000	rs117648818	chr16:67791428	A/C	cg01866162	chr16:67596514	CTCF	1.13	6.68	0.4	1.7e-10	Crohn's disease;
SARC	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg18876405	chr7:65276391	NA	0.69	8.31	0.48	7.91e-15	Aortic root size;
SARC	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg20607798	chr8:58055168	NA	-0.57	-5.51	-0.34	9.45e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs58688157	0.626	rs7941198	chr11:571681	A/G	cg16486109	chr11:613632	IRF7	0.36	5.02	0.31	1.02e-6	Systemic lupus erythematosus;
SARC	cis	rs13401104	0.740	rs12475284	chr2:237118586	A/C	cg19324714	chr2:237145437	ASB18	0.55	5.45	0.34	1.25e-7	Educational attainment;
SARC	cis	rs9486719	0.741	rs2499799	chr6:96851676	T/C	cg06623918	chr6:96969491	KIAA0776	0.72	7.0	0.42	2.67e-11	Migraine;Coronary artery disease;
SARC	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.46	-5.83	-0.36	1.83e-8	Personality dimensions;
SARC	cis	rs9309473	0.950	rs13427832	chr2:73844818	G/A	cg07208825	chr2:73871855	ALMS1P	0.33	4.97	0.31	1.32e-6	Metabolite levels;
SARC	cis	rs4820294	1.000	rs929039	chr22:38071511	T/C	cg21798802	chr22:38057573	PDXP	0.41	6.12	0.37	4e-9	Fat distribution (HIV);
SARC	cis	rs2273669	0.667	rs9688896	chr6:109364698	T/C	cg05315195	chr6:109294784	ARMC2	-0.63	-5.7	-0.35	3.6e-8	Prostate cancer;
SARC	cis	rs11792861	0.781	rs11793272	chr9:111762102	G/A	cg13535736	chr9:111863775	C9orf5	-0.38	-4.71	-0.3	4.2e-6	Menarche (age at onset);
SARC	cis	rs1057510	0.858	rs11064260	chr12:6685269	T/A	cg22370296	chr12:6798801	ZNF384	0.46	4.86	0.3	2.12e-6	Myopia (pathological);
SARC	cis	rs2730245	0.527	rs62475645	chr7:158656825	G/A	cg24397884	chr7:158709396	WDR60	1.11	9.86	0.54	2.21e-19	Height;
SARC	cis	rs12908161	1.000	rs12911736	chr15:85240008	A/G	cg17507749	chr15:85114479	UBE2QP1	0.58	6.68	0.4	1.77e-10	Schizophrenia;
SARC	cis	rs752010	0.619	rs6702659	chr1:42112236	T/C	cg06885757	chr1:42089581	HIVEP3	0.45	6.28	0.38	1.66e-9	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs1552244	0.700	rs9833566	chr3:9981671	C/T	cg00149659	chr3:10157352	C3orf10	0.63	5.46	0.34	1.19e-7	Alzheimer's disease;
SARC	cis	rs9916302	0.861	rs4795377	chr17:37669056	C/T	cg00129232	chr17:37814104	STARD3	-0.65	-7.96	-0.46	7.56e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs8072100	0.713	rs8074451	chr17:45477573	C/T	cg08085267	chr17:45401833	C17orf57	-0.41	-4.76	-0.3	3.42e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs1754541	1.000	rs10875354	chr1:101646314	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.44	4.81	0.3	2.73e-6	Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;
SARC	cis	rs17376456	0.877	rs17083462	chr5:93462401	T/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	6.14	0.37	3.45e-9	Diabetic retinopathy;
SARC	cis	rs13256369	0.851	rs11249889	chr8:8564992	G/T	cg17143192	chr8:8559678	CLDN23	0.52	5.83	0.36	1.82e-8	Obesity-related traits;
SARC	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg24675658	chr1:53192096	ZYG11B	0.67	9.86	0.54	2.11e-19	Monocyte count;
SARC	cis	rs9910055	0.530	rs8072954	chr17:42294722	G/A	cg19774624	chr17:42201019	HDAC5	-0.49	-6.67	-0.4	1.84e-10	Total body bone mineral density;
SARC	cis	rs4268898	1.000	rs2303294	chr2:24432620	A/G	cg06627628	chr2:24431161	ITSN2	0.61	8.56	0.49	1.52e-15	Asthma;
SARC	cis	rs9303280	0.901	rs12103884	chr17:38045725	C/T	cg20243544	chr17:37824526	PNMT	0.43	5.76	0.35	2.66e-8	Self-reported allergy;
SARC	cis	rs6088580	0.634	rs4911419	chr20:32995873	G/A	cg24642439	chr20:33292090	TP53INP2	-0.68	-8.73	-0.5	4.96e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg16606324	chr3:10149918	C3orf24	0.49	4.97	0.31	1.32e-6	Alzheimer's disease;
SARC	cis	rs2011503	0.943	rs79370636	chr19:19614289	G/A	cg15839431	chr19:19639596	YJEFN3	-0.48	-4.78	-0.3	3.15e-6	Bipolar disorder;
SARC	cis	rs9911578	0.835	rs2301867	chr17:56480074	T/A	cg12560992	chr17:57184187	TRIM37	-0.75	-9.58	-0.53	1.51e-18	Intelligence (multi-trait analysis);
SARC	trans	rs1814175	0.817	rs10839401	chr11:49876144	C/T	cg03929089	chr4:120376271	NA	-0.9	-15.07	-0.7	2.78e-36	Height;
SARC	cis	rs11191193	0.686	rs11191159	chr10:103711274	G/A	cg15320455	chr10:103880129	LDB1	0.56	6.01	0.37	6.94e-9	Educational attainment;
SARC	cis	rs4820539	0.966	rs5759594	chr22:23470660	G/A	cg14186256	chr22:23484241	RTDR1	0.9	14.69	0.69	4.95e-35	Bone mineral density;
SARC	cis	rs11910985	0.546	rs9978916	chr21:48080492	A/C	cg23283320	chr21:48055893	PRMT2	0.98	5.78	0.35	2.39e-8	Cerebrospinal fluid t-tau:AB1-42 ratio;
SARC	cis	rs7523050	0.908	rs12036331	chr1:109398707	A/T	cg08274380	chr1:109419600	GPSM2	0.63	5.41	0.33	1.54e-7	Fat distribution (HIV);
SARC	cis	rs8067545	0.611	rs12603372	chr17:20181566	C/T	cg13482628	chr17:19912719	NA	0.56	7.38	0.44	2.83e-12	Schizophrenia;
SARC	cis	rs514406	0.505	rs395169	chr1:53174071	G/A	cg24675658	chr1:53192096	ZYG11B	-0.65	-9.47	-0.53	3.2e-18	Monocyte count;
SARC	cis	rs9467773	1.000	rs2208331	chr6:26507319	A/G	cg12292205	chr6:26970375	C6orf41	0.43	5.24	0.32	3.66e-7	Intelligence (multi-trait analysis);
SARC	trans	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg06437703	chr8:37914619	EIF4EBP1	-0.56	-6.62	-0.4	2.51e-10	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7402982	0.647	rs34038360	chr15:99201573	A/C	cg03437748	chr15:99193247	IGF1R	0.67	8.19	0.47	1.73e-14	Birth weight;
SARC	cis	rs1971762	0.523	rs7135101	chr12:54080605	G/A	cg06632207	chr12:54070931	ATP5G2	0.44	5.78	0.35	2.35e-8	Height;
SARC	cis	rs1559088	1.000	rs2161225	chr19:33551899	C/T	cg27124370	chr19:33622961	WDR88	0.41	5.23	0.32	3.71e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs992157	0.835	rs13031757	chr2:219151926	T/C	cg00012203	chr2:219082015	ARPC2	-0.63	-9.11	-0.51	3.96e-17	Colorectal cancer;
SARC	cis	rs10876993	1.000	rs10876993	chr12:58062667	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.45	-5.77	-0.35	2.53e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs599083	0.829	rs23691	chr11:68178668	G/A	cg01657329	chr11:68192670	LRP5	0.42	5.83	0.36	1.85e-8	Bone mineral density (spine);
SARC	cis	rs11638352	0.661	rs1426657	chr15:44434529	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.76	-5.91	-0.36	1.23e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	cis	rs5769765	1.000	rs764813	chr22:50286172	T/C	cg03033257	chr22:50311977	ALG12;CRELD2	0.54	5.55	0.34	7.94e-8	Schizophrenia;
SARC	cis	rs7666738	0.830	rs10014284	chr4:98681951	G/C	cg05340658	chr4:99064831	C4orf37	0.66	8.59	0.49	1.3e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs763121	0.819	rs5757126	chr22:38923675	T/C	cg21395723	chr22:39101663	GTPBP1	0.55	6.16	0.37	3.16e-9	Menopause (age at onset);
SARC	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg04317338	chr11:64019027	PLCB3	0.84	8.98	0.51	9.05e-17	Mean platelet volume;
SARC	cis	rs11997175	0.574	rs4389890	chr8:33658018	C/T	ch.8.33884649F	chr8:33765107	NA	0.53	7.15	0.42	1.12e-11	Body mass index;
SARC	cis	rs4642101	0.680	rs7626609	chr3:12806080	A/G	cg05775895	chr3:12838266	CAND2	-0.59	-8.77	-0.5	3.91e-16	QRS complex (12-leadsum);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg27391037	chr22:18560705	PEX26	0.5	6.58	0.4	3.01e-10	Chemerin levels;
SARC	cis	rs4443100	0.958	rs9608066	chr22:23387172	A/G	cg14186256	chr22:23484241	RTDR1	0.47	4.92	0.31	1.63e-6	Serum parathyroid hormone levels;
SARC	cis	rs9303401	0.659	rs35828828	chr17:56718205	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	12.07	0.62	2.2e-26	Cognitive test performance;
SARC	cis	rs6121246	0.609	rs6088997	chr20:30289824	A/G	cg13852791	chr20:30311386	BCL2L1	-0.76	-9.15	-0.51	2.98e-17	Mean corpuscular hemoglobin;
SARC	cis	rs4972806	0.849	rs1542180	chr2:177028767	C/T	cg14324370	chr2:177042789	NA	0.54	7.27	0.43	5.27e-12	IgG glycosylation;
SARC	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg11987759	chr7:65425863	GUSB	0.48	6.23	0.38	2.16e-9	Aortic root size;
SARC	cis	rs208520	0.874	rs208481	chr6:66922636	A/G	cg07460842	chr6:66804631	NA	-0.99	-12.1	-0.62	1.73e-26	Exhaled nitric oxide output;
SARC	cis	rs208520	0.770	rs2153941	chr6:66885521	A/T	cg07460842	chr6:66804631	NA	-1.06	-13.61	-0.67	1.99e-31	Exhaled nitric oxide output;
SARC	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg19346786	chr7:2764209	NA	-0.36	-5.51	-0.34	9.69e-8	Height;
SARC	cis	rs6430585	0.528	rs114760827	chr2:136661110	G/A	cg07169764	chr2:136633963	MCM6	1.05	13.66	0.67	1.29e-31	Corneal structure;
SARC	cis	rs10078	0.515	rs6872510	chr5:481610	T/C	cg26072250	chr5:443457	EXOC3;C5orf55	0.61	4.92	0.31	1.66e-6	Fat distribution (HIV);
SARC	cis	rs3126085	0.935	rs2152862	chr1:152259742	T/C	cg26876637	chr1:152193138	HRNR	-0.45	-5.21	-0.32	4.07e-7	Atopic dermatitis;
SARC	cis	rs897984	0.520	rs12928081	chr16:30885159	T/G	cg00531865	chr16:30841666	NA	0.5	5.2	0.32	4.35e-7	Dementia with Lewy bodies;
SARC	cis	rs7674212	0.541	rs17217473	chr4:104114742	A/C	cg16532752	chr4:104119610	CENPE	-0.48	-5.82	-0.36	1.94e-8	Type 2 diabetes;
SARC	cis	rs472402	0.623	rs7707877	chr5:6635946	C/G	cg27314116	chr5:6583850	LOC255167	0.3	4.73	0.3	3.83e-6	Response to amphetamines;
SARC	cis	rs7264396	0.563	rs2425132	chr20:34338390	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-6.8	-0.41	8.68e-11	Total cholesterol levels;
SARC	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg02841227	chr6:26021843	HIST1H4A	0.68	8.3	0.48	8.23e-15	Intelligence (multi-trait analysis);
SARC	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg11843238	chr5:131593191	PDLIM4	-0.41	-5.04	-0.31	9.23e-7	Breast cancer;
SARC	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg16325326	chr1:53192061	ZYG11B	0.81	12.83	0.64	7.48e-29	Monocyte count;
SARC	cis	rs910316	1.000	rs10873275	chr14:75531460	A/T	cg23033748	chr14:75592666	NEK9	0.38	5.26	0.33	3.26e-7	Height;
SARC	cis	rs9303401	0.527	rs12946522	chr17:56768103	A/C	cg25039879	chr17:56429692	SUPT4H1	0.66	5.92	0.36	1.12e-8	Cognitive test performance;
SARC	cis	rs5167	0.504	rs8100120	chr19:45466058	T/C	cg20090143	chr19:45452003	APOC2	0.29	4.81	0.3	2.66e-6	Blood protein levels;
SARC	cis	rs1008375	0.932	rs6835077	chr4:17653285	A/T	cg16339924	chr4:17578868	LAP3	0.65	8.51	0.49	2.12e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.82	10.82	0.58	2.33e-22	Prudent dietary pattern;
SARC	cis	rs2075371	1.000	rs2598296	chr7:133992985	C/T	cg11752832	chr7:134001865	SLC35B4	0.57	7.28	0.43	5.01e-12	Mean platelet volume;
SARC	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg15448220	chr1:150897856	SETDB1	0.47	6.02	0.37	6.58e-9	Melanoma;
SARC	cis	rs12893668	0.581	rs34843146	chr14:104079864	G/A	cg26031613	chr14:104095156	KLC1	-0.56	-6.15	-0.37	3.37e-9	Reticulocyte count;
SARC	cis	rs8017423	0.935	rs7158410	chr14:90704370	T/C	cg20276874	chr14:90721474	PSMC1	-0.37	-5.17	-0.32	5.12e-7	Mortality in heart failure;
SARC	cis	rs921968	0.541	rs620596	chr2:219462419	G/A	cg02176678	chr2:219576539	TTLL4	0.46	6.9	0.41	4.88e-11	Mean corpuscular hemoglobin concentration;
SARC	cis	rs2115630	1.000	rs7183401	chr15:85371944	G/T	cg17507749	chr15:85114479	UBE2QP1	-0.43	-5.31	-0.33	2.59e-7	P wave terminal force;
SARC	cis	rs11674184	0.632	rs17529680	chr2:11727087	A/C	cg07314298	chr2:11723111	GREB1	0.48	5.84	0.36	1.77e-8	Endometriosis;
SARC	cis	rs9916302	0.861	rs632202	chr17:37453294	C/A	cg20243544	chr17:37824526	PNMT	-0.55	-6.56	-0.39	3.52e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	13.12	0.65	8.35e-30	Chronic sinus infection;
SARC	cis	rs3768617	0.510	rs2027076	chr1:183073407	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.19	0.56	2.1e-20	Fuchs's corneal dystrophy;
SARC	cis	rs9503598	0.662	rs2326232	chr6:3451953	A/G	cg00476032	chr6:3446245	SLC22A23	0.3	4.74	0.3	3.79e-6	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
SARC	cis	rs950776	0.593	rs621849	chr15:78872861	G/A	cg24631222	chr15:78858424	CHRNA5	0.37	4.87	0.3	2.04e-6	Sudden cardiac arrest;
SARC	cis	rs193541	0.556	rs30024	chr5:122285160	A/G	cg19412675	chr5:122181750	SNX24	0.49	6.2	0.38	2.56e-9	Glucose homeostasis traits;
SARC	cis	rs67257959	0.586	rs8105085	chr19:17159962	G/A	cg16202187	chr19:17186497	HAUS8;MYO9B	0.41	4.97	0.31	1.28e-6	Selective IgA deficiency;
SARC	cis	rs9302635	0.513	rs12928732	chr16:72188683	C/T	cg01557791	chr16:72042693	DHODH	-0.53	-5.37	-0.33	1.87e-7	Blood protein levels;
SARC	trans	rs11634851	1.000	rs11634851	chr15:81028965	C/G	cg04669574	chr12:50297945	FAIM2	0.48	6.34	0.38	1.17e-9	Systolic blood pressure;
SARC	cis	rs832540	0.898	rs170732	chr5:56251777	C/T	cg14703610	chr5:56206110	C5orf35	0.44	5.3	0.33	2.68e-7	Coronary artery disease;
SARC	cis	rs7089973	0.668	rs7898347	chr10:116644324	G/A	cg03647239	chr10:116582469	FAM160B1	0.39	4.76	0.3	3.33e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs11578119	0.933	rs10919401	chr1:170410369	T/A	cg09767346	chr1:170501363	GORAB	0.41	4.84	0.3	2.41e-6	Male-pattern baldness;
SARC	cis	rs9309711	0.623	rs4641971	chr2:3481857	A/C	cg15541040	chr2:3486749	NA	0.44	5.92	0.36	1.14e-8	Neurofibrillary tangles;
SARC	cis	rs7412746	0.658	rs4537557	chr1:150734436	A/G	cg10589385	chr1:150898437	SETDB1	0.39	5.06	0.31	8.49e-7	Melanoma;
SARC	cis	rs239198	0.602	rs11758174	chr6:101322595	G/A	cg09795085	chr6:101329169	ASCC3	0.46	5.85	0.36	1.64e-8	Menarche (age at onset);
SARC	cis	rs36051895	0.594	rs10115464	chr9:5144268	C/T	cg02405213	chr9:5042618	JAK2	-0.48	-5.85	-0.36	1.61e-8	Pediatric autoimmune diseases;
SARC	cis	rs4481887	0.893	rs1339990	chr1:248509495	C/T	cg01631408	chr1:248437212	OR2T33	0.43	5.76	0.35	2.71e-8	Common traits (Other);
SARC	cis	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg09021430	chr5:549028	NA	-0.45	-5.7	-0.35	3.52e-8	Obesity-related traits;
SARC	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.97e-8	Aortic root size;
SARC	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	11.13	0.59	2.42e-23	Platelet count;
SARC	cis	rs858239	0.601	rs6971002	chr7:23172304	C/G	cg23682824	chr7:23144976	KLHL7	0.7	9.2	0.52	2.11e-17	Cerebrospinal fluid biomarker levels;
SARC	cis	rs36051895	0.626	rs7870694	chr9:5100628	T/C	cg02405213	chr9:5042618	JAK2	-0.49	-5.97	-0.36	8.8e-9	Pediatric autoimmune diseases;
SARC	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg19223190	chr17:80058835	NA	0.44	6.19	0.38	2.67e-9	Life satisfaction;
SARC	cis	rs10911232	0.507	rs3934697	chr1:183027512	A/G	cg13390022	chr1:182993471	LAMC1	0.35	5.29	0.33	2.8e-7	Hypertriglyceridemia;
SARC	trans	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-6.67	-0.4	1.83e-10	Intelligence (multi-trait analysis);
SARC	cis	rs8103278	1.000	rs9807819	chr19:46239598	C/T	cg14061069	chr19:46274453	DMPK	-0.48	-7.17	-0.42	1.01e-11	Coronary artery disease;
SARC	cis	rs422249	0.512	rs174546	chr11:61569830	C/T	cg19610905	chr11:61596333	FADS2	-0.4	-4.76	-0.3	3.44e-6	Trans fatty acid levels;
SARC	cis	rs412050	0.696	rs79103791	chr22:22244897	A/G	cg17089214	chr22:22089827	YPEL1	0.65	5.84	0.36	1.74e-8	Attention deficit hyperactivity disorder;
SARC	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.65	-7.61	-0.45	6.58e-13	Gut microbiome composition (summer);
SARC	cis	rs11792861	0.816	rs11788336	chr9:111688387	T/C	cg13535736	chr9:111863775	C9orf5	-0.38	-4.78	-0.3	3.16e-6	Menarche (age at onset);
SARC	cis	rs4808199	0.947	rs754255	chr19:19578890	T/C	cg03709012	chr19:19516395	GATAD2A	1.19	13.19	0.65	4.85e-30	Nonalcoholic fatty liver disease;
SARC	cis	rs7618915	0.501	rs55678971	chr3:52717229	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.38	0.39	9.3e-10	Bipolar disorder;
SARC	cis	rs2153535	0.580	rs9393033	chr6:8521446	G/A	cg23788917	chr6:8435910	SLC35B3	0.64	8.66	0.49	7.75e-16	Motion sickness;
SARC	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg21226059	chr5:178986404	RUFY1	-0.33	-4.76	-0.3	3.46e-6	Lung cancer;
SARC	cis	rs9914544	0.545	rs12452289	chr17:18781809	T/G	cg25390199	chr17:18761479	PRPSAP2	0.46	6.05	0.37	5.66e-9	Educational attainment (years of education);
SARC	cis	rs3741151	0.773	rs73544767	chr11:73204619	C/T	cg17517138	chr11:73019481	ARHGEF17	0.96	7.52	0.44	1.16e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs2549003	0.811	rs10072700	chr5:131816903	A/C	cg21138405	chr5:131827807	IRF1	0.31	5.25	0.33	3.41e-7	Asthma (sex interaction);
SARC	cis	rs11690462	0.926	rs12615704	chr2:26551903	G/C	cg26119090	chr2:26468346	HADHA;HADHB	0.42	5.42	0.33	1.5e-7	Coronary artery disease;
SARC	cis	rs3820928	0.647	rs2115597	chr2:227791218	T/C	cg05526886	chr2:227700861	RHBDD1	-0.49	-6.04	-0.37	5.91e-9	Pulmonary function;
SARC	cis	rs67311347	0.506	rs55962832	chr3:40244451	T/C	cg24209194	chr3:40518798	ZNF619	0.48	5.74	0.35	2.95e-8	Renal cell carcinoma;
SARC	cis	rs7412746	0.566	rs2864871	chr1:150766964	T/C	cg15448220	chr1:150897856	SETDB1	0.48	6.08	0.37	5e-9	Melanoma;
SARC	cis	rs11687170	0.882	rs6706625	chr2:237059992	A/C	cg19324714	chr2:237145437	ASB18	0.47	4.73	0.3	3.84e-6	Educational attainment;Educational attainment (years of education);
SARC	cis	rs1050631	0.536	rs1785928	chr18:33725931	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	-0.56	-6.68	-0.4	1.79e-10	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs2576037	0.796	rs2571032	chr18:44578250	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.67	-9.83	-0.54	2.77e-19	Personality dimensions;
SARC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg11301795	chr4:187892539	NA	-0.7	-10.28	-0.56	1.13e-20	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7296418	0.961	rs1790106	chr12:123591596	G/T	cg05973401	chr12:123451056	ABCB9	0.6	7.35	0.43	3.24e-12	Platelet count;
SARC	cis	rs7582180	0.625	rs11892034	chr2:100938952	T/C	cg14675211	chr2:100938903	LONRF2	0.51	7.68	0.45	4.44e-13	Intelligence (multi-trait analysis);
SARC	cis	rs2070433	0.756	rs2839295	chr21:47917871	A/T	cg12379764	chr21:47803548	PCNT	0.55	5.48	0.34	1.09e-7	Lymphocyte counts;
SARC	cis	rs2733201	1.000	rs2706472	chr15:44433292	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.76	-5.91	-0.36	1.23e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	cis	rs17376456	1.000	rs35184505	chr5:93561535	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.59	5.3	0.33	2.67e-7	Diabetic retinopathy;
SARC	cis	rs6484504	0.532	rs11031330	chr11:31275073	G/A	cg26647111	chr11:31128758	NA	-0.39	-5.07	-0.32	8.23e-7	Red blood cell count;
SARC	cis	rs62064224	0.791	rs2344977	chr17:30720573	C/G	cg25809561	chr17:30822961	MYO1D	0.35	5.17	0.32	5.09e-7	Schizophrenia;
SARC	cis	rs16976116	0.901	rs28564077	chr15:55495151	G/A	cg11288833	chr15:55489084	RSL24D1	0.63	6.13	0.37	3.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4601821	0.965	rs10891543	chr11:113255895	A/G	cg14159747	chr11:113255604	NA	0.38	4.94	0.31	1.47e-6	Alcoholic chronic pancreatitis;
SARC	cis	rs523522	0.962	rs4766968	chr12:120947788	G/C	cg12219531	chr12:120966889	COQ5	0.84	11.36	0.6	4.3e-24	High light scatter reticulocyte count;
SARC	cis	rs2235544	0.542	rs11206272	chr1:54470035	G/C	cg10336722	chr1:54665764	CYB5RL;MRPL37	-0.38	-4.72	-0.3	4.04e-6	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
SARC	cis	rs8177253	0.511	rs9830001	chr3:133433470	A/G	cg01448562	chr3:133502909	NA	0.33	4.81	0.3	2.71e-6	Iron status biomarkers;
SARC	cis	rs17826219	0.706	rs55764512	chr17:29085758	G/A	cg13385521	chr17:29058706	SUZ12P	0.9	7.81	0.46	1.96e-13	Body mass index;
SARC	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	16.29	0.73	2.49e-40	Height;
SARC	cis	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg15556689	chr8:8085844	FLJ10661	-0.42	-5.25	-0.33	3.47e-7	Joint mobility (Beighton score);
SARC	cis	rs7651039	0.619	rs924814	chr3:15649550	G/A	cg16303742	chr3:15540471	COLQ	0.48	7.35	0.43	3.3e-12	Coronary heart disease;
SARC	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg11987759	chr7:65425863	GUSB	0.58	7.64	0.45	5.63e-13	Aortic root size;
SARC	cis	rs916888	0.610	rs199529	chr17:44837217	A/C	cg01570182	chr17:44337453	NA	0.7	7.89	0.46	1.15e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg03213289	chr20:61660250	NA	0.46	6.43	0.39	7.22e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs826838	0.620	rs11614695	chr12:39331847	C/T	cg26384229	chr12:38710491	ALG10B	0.74	9.57	0.53	1.62e-18	Heart rate;
SARC	cis	rs12912251	0.947	rs36094159	chr15:38998395	G/A	cg01338139	chr15:38987640	C15orf53	-0.46	-5.08	-0.32	7.88e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
SARC	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg27266027	chr21:40555129	PSMG1	0.48	5.09	0.32	7.55e-7	Cognitive function;
SARC	cis	rs2084898	0.891	rs2511023	chr11:120009145	A/G	cg07435449	chr11:120005650	TRIM29	0.47	4.8	0.3	2.86e-6	Stroke (pediatric);
SARC	cis	rs35955747	0.902	rs7287402	chr22:31654823	A/G	cg13145458	chr22:31556086	RNF185	-0.39	-4.86	-0.3	2.13e-6	Neutrophil count;Sum basophil neutrophil counts;
SARC	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	5.76	0.35	2.61e-8	Bipolar disorder;
SARC	cis	rs910316	1.000	rs10142626	chr14:75555636	A/T	cg11812906	chr14:75593930	NEK9	0.89	14.1	0.68	4.63e-33	Height;
SARC	cis	rs7762018	0.660	rs78181018	chr6:170096652	A/C	cg19338460	chr6:170058176	WDR27	-0.77	-5.41	-0.33	1.58e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs8141529	0.748	rs1318025	chr22:29283757	C/T	cg02153584	chr22:29168773	CCDC117	0.76	10.97	0.58	7.54e-23	Lymphocyte counts;
SARC	cis	rs73195822	0.667	rs73194062	chr12:111223294	G/A	cg10860002	chr12:110842031	ANAPC7	0.58	4.97	0.31	1.32e-6	Itch intensity from mosquito bite;
SARC	cis	rs16976116	0.855	rs7172289	chr15:55501705	A/G	cg17854078	chr15:55489399	RSL24D1	0.66	6.53	0.39	4.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs13082711	0.595	rs62255583	chr3:27309704	G/T	cg02860705	chr3:27208620	NA	0.66	7.76	0.45	2.59e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs4919087	0.590	rs1253401	chr10:99050270	G/A	cg25902810	chr10:99078978	FRAT1	-0.55	-6.3	-0.38	1.51e-9	Monocyte count;
SARC	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg16405210	chr4:1374714	KIAA1530	-0.43	-4.98	-0.31	1.22e-6	Obesity-related traits;
SARC	cis	rs1034435	0.575	rs6007864	chr22:48883081	C/T	cg05992904	chr22:48892994	FAM19A5	0.38	4.92	0.31	1.6e-6	Late-onset Alzheimer's disease;
SARC	cis	rs11098499	0.866	rs7665125	chr4:120402079	G/T	cg09307838	chr4:120376055	NA	0.83	11.84	0.61	1.28e-25	Corneal astigmatism;
SARC	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg15847926	chr7:2749597	AMZ1	-0.3	-4.92	-0.31	1.6e-6	Height;
SARC	cis	rs17345786	1.000	rs73863360	chr3:101316837	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.45	5.0	0.31	1.11e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6893300	0.524	rs6601073	chr5:179177271	A/G	cg14593053	chr5:179126677	CANX	-0.52	-7.37	-0.43	2.98e-12	Resting heart rate;
SARC	cis	rs7551222	0.716	rs4245738	chr1:204506107	C/T	cg20240347	chr1:204465584	NA	-0.35	-6.26	-0.38	1.79e-9	Schizophrenia;
SARC	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg22920501	chr2:26401640	FAM59B	-0.57	-7.35	-0.43	3.42e-12	Gut microbiome composition (summer);
SARC	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg00149659	chr3:10157352	C3orf10	0.65	6.09	0.37	4.68e-9	Alzheimer's disease;
SARC	cis	rs861020	0.604	rs3766612	chr1:210020013	G/T	cg05527609	chr1:210001259	C1orf107	-0.92	-10.92	-0.58	1.11e-22	Orofacial clefts;
SARC	cis	rs1712517	0.835	rs2506961	chr10:105007926	G/T	cg05636881	chr10:105038444	INA	-0.32	-4.74	-0.3	3.67e-6	Migraine;
SARC	cis	rs3091242	0.728	rs706845	chr1:25730713	G/A	cg02931644	chr1:25747376	RHCE	0.47	7.82	0.46	1.77e-13	Erythrocyte sedimentation rate;
SARC	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg22903471	chr2:27725779	GCKR	-0.5	-7.57	-0.44	8.61e-13	Total body bone mineral density;
SARC	cis	rs62244186	0.659	rs9311358	chr3:44538748	C/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.45	5.62	0.35	5.32e-8	Depressive symptoms;
SARC	cis	rs9549367	0.713	rs3024761	chr13:113824090	C/G	cg18105134	chr13:113819100	PROZ	0.49	6.82	0.41	7.78e-11	Platelet distribution width;
SARC	cis	rs9894429	0.646	rs58398000	chr17:79576923	G/A	cg18240062	chr17:79603768	NPLOC4	-0.6	-7.32	-0.43	3.94e-12	Eye color traits;
SARC	cis	rs6793245	0.845	rs4073797	chr3:38590850	A/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.46	-5.35	-0.33	2.11e-7	QT interval;
SARC	cis	rs911555	0.504	rs4444269	chr14:104072724	G/C	cg26031613	chr14:104095156	KLC1	0.61	8.05	0.47	4.33e-14	Intelligence (multi-trait analysis);
SARC	cis	rs1144333	0.655	rs79322031	chr1:76391978	C/T	cg03433033	chr1:76189801	ACADM	0.64	5.23	0.32	3.71e-7	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs67311347	0.568	rs9864544	chr3:40336204	T/C	cg09455208	chr3:40491958	NA	0.3	5.01	0.31	1.08e-6	Renal cell carcinoma;
SARC	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg09033563	chr22:24373618	LOC391322	0.47	5.42	0.33	1.47e-7	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs9326248	0.911	rs11216284	chr11:117003060	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.54	5.84	0.36	1.74e-8	Blood protein levels;
SARC	cis	rs908922	0.651	rs4845444	chr1:152530125	G/A	cg09873164	chr1:152488093	CRCT1	0.6	7.89	0.46	1.16e-13	Hair morphology;
SARC	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg19223190	chr17:80058835	NA	0.44	6.19	0.38	2.67e-9	Life satisfaction;
SARC	cis	rs6570726	0.791	rs7755253	chr6:145858893	C/G	cg05347473	chr6:146136440	FBXO30	0.54	7.45	0.44	1.82e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs483180	0.531	rs539708	chr1:120208503	G/T	cg19096424	chr1:120255104	PHGDH	-0.51	-5.98	-0.36	8.45e-9	Macular telangiectasia type 2;
SARC	cis	rs738322	0.967	rs132971	chr22:38561911	T/G	cg25457927	chr22:38595422	NA	-0.26	-5.4	-0.33	1.64e-7	Cutaneous nevi;
SARC	cis	rs950169	0.614	rs12903883	chr15:84680553	A/G	cg17507749	chr15:85114479	UBE2QP1	0.71	7.77	0.45	2.47e-13	Schizophrenia;
SARC	cis	rs1865760	0.566	rs9366634	chr6:26072396	C/G	cg10373733	chr6:25993375	NA	0.41	5.07	0.32	7.99e-7	Height;
SARC	trans	rs2018683	0.707	rs4719961	chr7:28969513	C/T	cg19402173	chr7:128379420	CALU	-0.54	-7.0	-0.42	2.69e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs2120019	1.000	rs7162900	chr15:75368017	T/C	cg12414181	chr15:75287860	SCAMP5	-0.42	-4.88	-0.3	2.01e-6	Blood trace element (Zn levels);
SARC	cis	rs13191362	0.872	rs36069443	chr6:163248701	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.62	5.95	0.36	9.78e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs6456156	0.586	rs911632	chr6:167471461	T/C	cg07741184	chr6:167504864	NA	0.36	7.09	0.42	1.62e-11	Primary biliary cholangitis;
SARC	cis	rs1318878	0.565	rs2417432	chr12:15430956	A/C	cg08258403	chr12:15378311	NA	0.47	6.63	0.4	2.34e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7086627	0.515	rs7077373	chr10:82211615	C/T	cg00277334	chr10:82204260	NA	-0.57	-9.42	-0.53	4.63e-18	Post bronchodilator FEV1;
SARC	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg11987759	chr7:65425863	GUSB	-0.48	-5.87	-0.36	1.51e-8	Aortic root size;
SARC	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg03709012	chr19:19516395	GATAD2A	1.04	18.51	0.77	1.17e-47	Tonsillectomy;
SARC	cis	rs9325144	0.647	rs12831609	chr12:39051576	C/A	cg13010199	chr12:38710504	ALG10B	-0.54	-6.87	-0.41	5.86e-11	Morning vs. evening chronotype;
SARC	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	8.12	0.47	2.68e-14	Alzheimer's disease;
SARC	cis	rs79149102	0.579	rs7179097	chr15:75279240	T/G	cg09165964	chr15:75287851	SCAMP5	-0.94	-8.58	-0.49	1.34e-15	Lung cancer;
SARC	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.33	4.74	0.3	3.76e-6	Obesity-related traits;
SARC	cis	rs7208859	0.623	rs73271872	chr17:29152228	C/G	cg13385521	chr17:29058706	SUZ12P	0.85	7.66	0.45	4.88e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9420	0.784	rs12790660	chr11:57667222	T/C	cg19752551	chr11:57585705	CTNND1	-0.47	-5.46	-0.34	1.21e-7	Schizophrenia;
SARC	cis	rs10992471	0.702	rs10820967	chr9:95101729	C/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.53	-6.25	-0.38	1.95e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs3087591	0.960	rs2952976	chr17:29486152	G/A	cg24425628	chr17:29625626	OMG;NF1	0.52	6.47	0.39	5.57e-10	Hip circumference;
SARC	cis	rs950776	0.518	rs2869544	chr15:78839400	G/A	cg22563815	chr15:78856949	CHRNA5	-0.4	-6.61	-0.4	2.57e-10	Sudden cardiac arrest;
SARC	cis	rs1707322	0.721	rs6665808	chr1:46162283	C/T	cg06784218	chr1:46089804	CCDC17	0.37	6.38	0.39	9.21e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2033711	0.811	rs9304814	chr19:58951811	C/A	cg25952890	chr19:58913133	NA	0.36	4.98	0.31	1.24e-6	Uric acid clearance;
SARC	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg17971929	chr21:40555470	PSMG1	-0.86	-11.47	-0.6	1.96e-24	Cognitive function;
SARC	cis	rs6088590	0.965	rs13040449	chr20:33358901	T/A	cg06115741	chr20:33292138	TP53INP2	0.58	6.93	0.41	3.98e-11	Coronary artery disease;
SARC	cis	rs10876993	0.928	rs7136269	chr12:58075937	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.45	-5.71	-0.35	3.37e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs8028182	0.636	rs4299117	chr15:75789444	C/T	cg20655648	chr15:75932815	IMP3	0.63	7.26	0.43	5.91e-12	Sudden cardiac arrest;
SARC	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.4	-5.07	-0.32	8.18e-7	Personality dimensions;
SARC	cis	rs644799	0.582	rs473157	chr11:95596874	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	5.93	0.36	1.08e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs240764	0.817	rs11155610	chr6:101170233	T/C	cg09795085	chr6:101329169	ASCC3	-0.5	-6.48	-0.39	5.48e-10	Neuroticism;
SARC	cis	rs765787	0.530	rs2413782	chr15:45538490	A/C	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.67e-7	Uric acid levels;
SARC	cis	rs155076	0.938	rs261375	chr13:21871882	A/G	cg06138931	chr13:21896616	NA	0.43	5.14	0.32	5.83e-7	White matter hyperintensity burden;
SARC	cis	rs6500602	0.702	rs2304634	chr16:4500544	C/T	cg08645402	chr16:4508243	NA	0.48	6.23	0.38	2.15e-9	Schizophrenia;
SARC	cis	rs7666738	0.791	rs62318641	chr4:98816964	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.7	0.5	6.24e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs761746	0.739	rs5753690	chr22:31950005	C/T	cg15823100	chr22:32027580	PISD	-0.37	-4.95	-0.31	1.44e-6	Intelligence;
SARC	cis	rs9297145	0.715	rs62473008	chr7:98751541	A/G	cg05967295	chr7:98741636	SMURF1	0.76	7.8	0.45	2.1e-13	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
SARC	cis	rs2645694	0.626	rs2703129	chr4:77818548	T/C	cg03477792	chr4:77819574	ANKRD56	0.51	7.59	0.45	7.54e-13	Emphysema distribution in smoking;
SARC	cis	rs9297145	0.585	rs10953283	chr7:98782750	A/G	cg05967295	chr7:98741636	SMURF1	0.44	5.55	0.34	7.58e-8	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
SARC	trans	rs9938149	0.674	rs7500824	chr16:88299491	C/T	cg26091131	chr10:73498624	C10orf105;CDH23	-0.39	-6.39	-0.39	8.94e-10	Corneal structure;Central corneal thickness;
SARC	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg26681399	chr22:41777847	TEF	0.43	4.92	0.31	1.67e-6	Vitiligo;
SARC	cis	rs5753618	0.561	rs2413049	chr22:31686144	A/G	cg07713946	chr22:31675144	LIMK2	-0.38	-5.25	-0.33	3.39e-7	Colorectal cancer;
SARC	cis	rs11718455	1.000	rs3856744	chr3:44045812	T/C	cg21419209	chr3:44054225	NA	-0.41	-4.79	-0.3	3.02e-6	Coronary artery disease;
SARC	cis	rs12791968	0.917	rs11038239	chr11:45002012	A/G	cg11846598	chr11:44996168	LOC221122	-0.36	-5.72	-0.35	3.3e-8	Inhibitory control;
SARC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg07308232	chr7:1071921	C7orf50	-0.5	-6.06	-0.37	5.46e-9	Longevity;Endometriosis;
SARC	cis	rs362272	0.525	rs910568	chr4:3307373	A/G	cg08741688	chr4:3415352	RGS12	-0.44	-5.37	-0.33	1.91e-7	Serum sulfate level;
SARC	cis	rs7647973	0.626	rs11130217	chr3:49737323	A/G	cg13072238	chr3:49761600	GMPPB	-0.61	-6.26	-0.38	1.81e-9	Menarche (age at onset);
SARC	cis	rs787274	1.000	rs1711739	chr9:115464474	G/A	cg13803584	chr9:115635662	SNX30	0.75	5.85	0.36	1.63e-8	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs7647973	0.961	rs7626076	chr3:49298139	G/A	cg06212747	chr3:49208901	KLHDC8B	0.59	6.11	0.37	4.16e-9	Menarche (age at onset);
SARC	cis	rs9747201	0.894	rs4503854	chr17:80178696	A/T	cg17462356	chr17:80056334	FASN	-0.48	-5.05	-0.31	9.09e-7	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs72781680	0.898	rs72788302	chr2:24107246	C/T	cg08917208	chr2:24149416	ATAD2B	0.94	9.35	0.52	7.55e-18	Lymphocyte counts;
SARC	cis	rs2295359	0.892	rs6688383	chr1:67655954	C/T	cg11235152	chr1:67600687	NA	-0.52	-7.35	-0.43	3.42e-12	Psoriasis;
SARC	cis	rs35849525	0.633	rs62263602	chr3:50152491	C/T	cg24110177	chr3:50126178	RBM5	-0.48	-5.23	-0.32	3.78e-7	Intelligence (multi-trait analysis);
SARC	cis	rs854765	0.505	rs2955358	chr17:17946623	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.43	-5.48	-0.34	1.1e-7	Total body bone mineral density;
SARC	cis	rs4642101	0.662	rs4034942	chr3:12836792	C/T	cg05775895	chr3:12838266	CAND2	0.82	14.69	0.69	5.04e-35	QRS complex (12-leadsum);
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg09285213	chr2:68384741	WDR92;PNO1	-0.49	-6.29	-0.38	1.57e-9	Electrocardiographic conduction measures;
SARC	cis	rs8078723	0.763	rs4433838	chr17:38143532	C/T	cg17467752	chr17:38218738	THRA	-0.38	-4.91	-0.31	1.69e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs838147	0.844	rs12982115	chr19:49248640	A/G	cg13540341	chr19:49222985	MAMSTR	0.28	4.73	0.3	3.83e-6	Dietary macronutrient intake;
SARC	cis	rs6061231	0.755	rs11699160	chr20:60958651	T/C	cg24112000	chr20:60950667	NA	-0.43	-7.28	-0.43	5.14e-12	Colorectal cancer;
SARC	trans	rs17221829	0.733	rs11018668	chr11:89356178	C/T	cg15888699	chr11:57298252	TIMM10	-0.47	-6.37	-0.39	9.73e-10	Anxiety in major depressive disorder;
SARC	cis	rs16937	0.711	rs10751430	chr1:205107497	A/G	cg21643547	chr1:205240462	TMCC2	-0.49	-6.03	-0.37	6.52e-9	Schizophrenia;
SARC	cis	rs898097	0.578	rs2380173	chr17:80909157	G/T	cg10494973	chr17:80897199	TBCD	0.38	5.05	0.31	8.72e-7	Breast cancer;
SARC	cis	rs7769051	0.522	rs60133731	chr6:133095818	T/C	cg22852734	chr6:133119734	C6orf192	1.21	8.23	0.47	1.33e-14	Type 2 diabetes nephropathy;
SARC	cis	rs2120019	1.000	rs8033837	chr15:75353975	A/C	cg17294928	chr15:75287854	SCAMP5	-0.96	-14.22	-0.68	1.85e-33	Blood trace element (Zn levels);
SARC	cis	rs9462027	0.527	rs6939600	chr6:34822176	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.98	-0.36	8.24e-9	Systemic lupus erythematosus;
SARC	cis	rs8068544	0.818	rs79892925	chr17:40171819	A/G	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.05	-8.38	-0.48	5.18e-15	Reticulocyte fraction of red cells;Reticulocyte count;
SARC	cis	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.15	-0.37	3.35e-9	Joint mobility (Beighton score);
SARC	cis	rs9630089	0.746	rs10882873	chr10:98966485	A/G	cg25902810	chr10:99078978	FRAT1	-0.4	-4.99	-0.31	1.18e-6	Neutrophil percentage of white cells;
SARC	cis	rs4268898	0.760	rs11676939	chr2:24479057	C/T	cg06627628	chr2:24431161	ITSN2	0.48	6.45	0.39	6.34e-10	Asthma;
SARC	cis	rs9300255	0.568	rs1790102	chr12:123704890	G/A	cg00376283	chr12:123451042	ABCB9	0.55	6.53	0.39	4.09e-10	Neutrophil percentage of white cells;
SARC	cis	rs1982346	1.000	rs2544418	chr4:106741974	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	-0.67	-4.81	-0.3	2.77e-6	Lung function (FEV1);
SARC	cis	rs62064224	0.533	rs11657826	chr17:30790386	T/A	cg18200150	chr17:30822561	MYO1D	0.39	5.95	0.36	9.9e-9	Schizophrenia;
SARC	cis	rs2439831	0.850	rs7168158	chr15:44050376	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	7.55	0.44	1.01e-12	Lung cancer in ever smokers;
SARC	cis	rs4951011	0.938	rs4951005	chr1:203763325	A/G	cg05526099	chr1:203152295	CHI3L1	-0.34	-4.79	-0.3	2.93e-6	Breast cancer;
SARC	cis	rs9733	0.566	rs11204675	chr1:150570985	A/C	cg13175981	chr1:150552382	MCL1	0.65	8.49	0.49	2.45e-15	Tonsillectomy;
SARC	cis	rs12681288	0.862	rs7015529	chr8:1020249	A/G	cg15309053	chr8:964076	NA	0.41	6.89	0.41	5.16e-11	Schizophrenia;
SARC	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg12310025	chr6:25882481	NA	-0.56	-7.16	-0.42	1.02e-11	Intelligence (multi-trait analysis);
SARC	cis	rs3126085	0.867	rs36033453	chr1:152221226	T/G	cg03465714	chr1:152285911	FLG	0.49	5.78	0.35	2.41e-8	Atopic dermatitis;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg24698371	chr19:6110817	RFX2	0.46	6.25	0.38	1.9e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs2288073	0.965	rs6545338	chr2:24422156	C/T	cg06627628	chr2:24431161	ITSN2	-0.65	-7.91	-0.46	1e-13	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg05896524	chr21:47604654	C21orf56	0.58	7.07	0.42	1.76e-11	Testicular germ cell tumor;
SARC	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg18252515	chr7:66147081	NA	0.53	5.7	0.35	3.55e-8	Aortic root size;
SARC	cis	rs796364	1.000	rs4263095	chr2:200830137	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.75	-7.05	-0.42	2.06e-11	Schizophrenia;
SARC	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg04277193	chr17:41438351	NA	0.44	4.78	0.3	3.05e-6	Menopause (age at onset);
SARC	cis	rs7011049	0.908	rs72640866	chr8:53843014	C/T	cg26025543	chr8:53854495	NA	0.6	5.43	0.34	1.42e-7	Systolic blood pressure;
SARC	cis	rs7614311	0.636	rs73117047	chr3:63910779	G/A	cg22134162	chr3:63841271	THOC7	-0.46	-4.91	-0.31	1.69e-6	Lung function (FVC);Lung function (FEV1);
SARC	cis	rs9788682	0.747	rs2656074	chr15:78741384	T/C	cg24631222	chr15:78858424	CHRNA5	-0.75	-9.3	-0.52	1.08e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs8180040	0.966	rs11925823	chr3:47443065	C/G	cg27129171	chr3:47204927	SETD2	0.66	9.12	0.51	3.55e-17	Colorectal cancer;
SARC	cis	rs910316	0.699	rs175039	chr14:75468950	G/C	cg11812906	chr14:75593930	NEK9	-0.76	-10.05	-0.55	5.64e-20	Height;
SARC	cis	rs2916247	0.908	rs7016890	chr8:93176856	T/C	cg10183463	chr8:93005414	RUNX1T1	0.54	5.68	0.35	3.97e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7084402	0.870	rs1896245	chr10:60276083	T/G	cg07615347	chr10:60278583	BICC1	-0.6	-8.82	-0.5	2.78e-16	Refractive error;
SARC	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg18135555	chr8:22132992	PIWIL2	0.4	5.98	0.36	8.55e-9	Hypertriglyceridemia;
SARC	cis	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-7.72	-0.45	3.41e-13	Mood instability;
SARC	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg21747090	chr2:27597821	SNX17	-0.55	-7.65	-0.45	5.38e-13	Total body bone mineral density;
SARC	cis	rs5017598	1.000	rs5017598	chr6:169211494	A/G	cg05672967	chr6:169256475	NA	0.53	7.92	0.46	9.76e-14	Pediatric bone mineral density (femoral neck);Pediatric bone mineral density (hip);
SARC	cis	rs7714584	1.000	rs11741861	chr5:150277909	C/T	cg22134413	chr5:150180641	NA	-0.95	-7.69	-0.45	4.02e-13	Crohn's disease;
SARC	cis	rs8114671	0.562	rs6088640	chr20:33472509	C/T	cg08999081	chr20:33150536	PIGU	0.33	4.94	0.31	1.51e-6	Height;
SARC	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg04267008	chr7:1944627	MAD1L1	-0.61	-7.12	-0.42	1.35e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs7666738	0.800	rs11941885	chr4:99072921	A/C	cg05340658	chr4:99064831	C4orf37	0.63	8.43	0.48	3.73e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2235544	0.565	rs635059	chr1:54469120	G/C	cg10336722	chr1:54665764	CYB5RL;MRPL37	-0.38	-4.74	-0.3	3.66e-6	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
SARC	cis	rs10875746	0.903	rs11168370	chr12:48435280	A/C	cg26205652	chr12:48591994	NA	0.49	5.39	0.33	1.72e-7	Longevity (90 years and older);
SARC	cis	rs7769051	1.000	rs5006218	chr6:133126220	T/G	cg07930552	chr6:133119739	C6orf192	0.91	8.49	0.49	2.49e-15	Type 2 diabetes nephropathy;
SARC	cis	rs3741404	0.609	rs669913	chr11:63869879	A/G	cg18225595	chr11:63971243	STIP1	0.4	5.67	0.35	4.24e-8	Platelet count;
SARC	cis	rs6582630	0.576	rs2387836	chr12:38560070	A/G	cg14851346	chr12:38532713	NA	0.42	4.91	0.31	1.73e-6	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg18252515	chr7:66147081	NA	0.51	5.5	0.34	1.01e-7	Aortic root size;
SARC	trans	rs1814175	0.654	rs7482446	chr11:49779020	A/G	cg03929089	chr4:120376271	NA	-0.91	-14.54	-0.69	1.56e-34	Height;
SARC	cis	rs11112613	0.713	rs11112590	chr12:105951376	C/G	cg03607813	chr12:105948248	NA	-0.52	-6.79	-0.41	8.99e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg05552183	chr6:42928497	GNMT	-0.53	-7.24	-0.43	6.52e-12	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs1113500	0.933	rs2077259	chr1:108629551	T/C	cg06207961	chr1:108661230	NA	0.44	5.82	0.36	1.93e-8	Growth-regulated protein alpha levels;
SARC	cis	rs1728785	0.901	rs11075687	chr16:68655894	T/C	cg02972257	chr16:68554789	NA	-0.45	-5.24	-0.32	3.52e-7	Ulcerative colitis;
SARC	cis	rs524281	0.861	rs10750779	chr11:65974591	C/G	cg14036092	chr11:66035641	RAB1B	-0.5	-5.3	-0.33	2.74e-7	Electroencephalogram traits;
SARC	cis	rs911263	0.603	rs1956524	chr14:68800393	G/A	cg18825221	chr14:68749962	RAD51L1	0.42	7.4	0.44	2.42e-12	Primary biliary cholangitis;
SARC	cis	rs7617773	0.744	rs2125482	chr3:48323133	T/G	cg11946769	chr3:48343235	NME6	0.68	9.1	0.51	4.12e-17	Coronary artery disease;
SARC	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg18876405	chr7:65276391	NA	0.47	5.45	0.34	1.27e-7	Aortic root size;
SARC	cis	rs909674	0.731	rs6001594	chr22:39837472	C/T	cg24399712	chr22:39784796	NA	-0.4	-5.13	-0.32	6.11e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs35123781	0.696	rs13179952	chr5:139070573	C/G	cg10513866	chr5:139070639	NA	0.36	4.85	0.3	2.23e-6	Schizophrenia;
SARC	cis	rs1580019	0.523	rs9791770	chr7:32582252	C/A	cg07520158	chr7:32535189	LSM5;AVL9	0.6	7.66	0.45	4.81e-13	Cognitive ability;
SARC	cis	rs6542838	0.641	rs6542841	chr2:99489039	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.45	-5.75	-0.35	2.81e-8	Fear of minor pain;
SARC	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg15847926	chr7:2749597	AMZ1	-0.31	-4.96	-0.31	1.33e-6	Height;
SARC	cis	rs1957429	0.614	rs62621845	chr14:65403525	T/A	cg23373153	chr14:65346875	NA	-1.03	-6.42	-0.39	7.58e-10	Pediatric areal bone mineral density (radius);
SARC	cis	rs35146811	0.844	rs59261051	chr7:99650429	C/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.4	4.84	0.3	2.36e-6	Coronary artery disease;
SARC	cis	rs9911578	0.933	rs2531726	chr17:56522533	C/T	cg12560992	chr17:57184187	TRIM37	-0.75	-9.76	-0.54	4.37e-19	Intelligence (multi-trait analysis);
SARC	cis	rs57506017	0.585	rs6966915	chr7:12265988	C/T	cg23422036	chr7:12250390	TMEM106B	0.45	5.85	0.36	1.66e-8	Neuroticism;
SARC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg26338869	chr17:61819248	STRADA	0.8	10.72	0.57	4.8e-22	Prudent dietary pattern;
SARC	cis	rs796364	0.806	rs78037592	chr2:201105734	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-5.93	-0.36	1.08e-8	Schizophrenia;
SARC	cis	rs9420	0.961	rs11601320	chr11:57642617	T/C	cg19752551	chr11:57585705	CTNND1	-0.54	-7.17	-0.43	9.64e-12	Schizophrenia;
SARC	cis	rs12971120	0.891	rs4891557	chr18:72170299	C/T	cg26446133	chr18:72167187	CNDP2	-0.51	-7.2	-0.43	8.28e-12	Refractive error;
SARC	cis	rs7592578	0.771	rs12053190	chr2:191383348	A/G	cg10560079	chr2:191398806	TMEM194B	-0.78	-8.62	-0.49	1.06e-15	Diastolic blood pressure;
SARC	cis	rs12586317	0.576	rs72664862	chr14:35641572	C/T	cg16230307	chr14:35515116	FAM177A1	0.46	5.81	0.36	2.08e-8	Psoriasis;
SARC	cis	rs4774830	0.744	rs62046390	chr15:56308506	G/A	cg24530489	chr15:56299380	NA	-0.93	-4.87	-0.3	2.1e-6	Delta-5 desaturase activity;
SARC	cis	rs478304	0.514	rs75601653	chr11:65483370	C/G	cg27068330	chr11:65405492	SIPA1	-0.45	-5.27	-0.33	3.13e-7	Acne (severe);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg22792660	chr5:74349644	NA	0.77	6.33	0.38	1.22e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg06808227	chr14:105710500	BRF1	-0.53	-6.64	-0.4	2.23e-10	Mean platelet volume;Platelet distribution width;
SARC	cis	rs7833986	0.501	rs2719257	chr8:56940173	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.73	7.25	0.43	5.94e-12	Height;
SARC	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg06028808	chr11:68637592	NA	0.43	5.75	0.35	2.84e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs17376456	1.000	rs58734583	chr5:93532155	C/T	cg25358565	chr5:93447407	FAM172A	1.34	14.17	0.68	2.79e-33	Diabetic retinopathy;
SARC	cis	rs910187	0.678	rs3818009	chr20:45816514	C/T	cg27589058	chr20:45804311	EYA2	-0.3	-4.79	-0.3	3.02e-6	Migraine;
SARC	trans	rs11039798	0.582	rs1483119	chr11:48382334	A/G	cg15704280	chr7:45808275	SEPT13	-0.62	-6.35	-0.38	1.15e-9	Axial length;
SARC	cis	rs4566357	0.595	rs10201538	chr2:227914449	A/G	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.62	-0.35	5.48e-8	Coronary artery disease;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19081843	chr11:68606654	CPT1A	0.59	7.75	0.45	2.84e-13	Smoking initiation;
SARC	cis	rs2228479	1.000	rs11642267	chr16:89957635	T/C	cg12064134	chr16:90016061	DEF8	-0.55	-4.75	-0.3	3.59e-6	Skin colour saturation;
SARC	cis	rs8113308	0.752	rs73068868	chr19:52491001	A/G	cg25782003	chr19:52490127	ZNF350	0.84	5.9	0.36	1.29e-8	Survival in endocrine treated breast cancer (estrogen-receptor positive);
SARC	cis	rs11722228	0.508	rs9732	chr4:10076658	T/C	cg11266682	chr4:10021025	SLC2A9	0.33	4.8	0.3	2.79e-6	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg14403583	chr14:105418241	AHNAK2	-0.57	-7.63	-0.45	6.03e-13	Rheumatoid arthritis;
SARC	cis	rs9790314	0.846	rs13083229	chr3:161008125	G/A	cg03342759	chr3:160939853	NMD3	-0.74	-9.94	-0.55	1.25e-19	Morning vs. evening chronotype;
SARC	cis	rs9896052	0.580	rs8065142	chr17:73441060	G/A	cg27037648	chr17:73511087	CASKIN2	0.42	4.94	0.31	1.5e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg16049864	chr8:95962084	TP53INP1	-0.49	-8.21	-0.47	1.53e-14	Type 2 diabetes;
SARC	trans	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg21659725	chr3:3221576	CRBN	0.53	6.83	0.41	7.24e-11	Intelligence (multi-trait analysis);
SARC	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg17221315	chr6:27791827	HIST1H4J	0.51	5.28	0.33	2.97e-7	Parkinson's disease;
SARC	cis	rs7626444	0.625	rs1104375	chr3:196476043	C/G	cg12930392	chr3:196481615	PAK2	0.25	5.0	0.31	1.13e-6	Monocyte count;
SARC	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg12756686	chr19:29218302	NA	0.68	9.0	0.51	8.04e-17	Methadone dose in opioid dependence;
SARC	cis	rs17270561	0.609	rs9393665	chr6:25744284	G/A	cg16482183	chr6:26056742	HIST1H1C	0.43	5.08	0.32	7.76e-7	Iron status biomarkers;
SARC	cis	rs16944613	0.588	rs8024734	chr15:91107067	T/C	cg26821196	chr15:91095069	CRTC3	0.55	5.62	0.35	5.51e-8	Colorectal cancer;
SARC	cis	rs546131	0.642	rs579926	chr11:34853155	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.42	4.83	0.3	2.49e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs12142240	0.698	rs28578741	chr1:46825176	T/C	cg10495392	chr1:46806563	NSUN4	0.65	6.8	0.41	8.89e-11	Menopause (age at onset);
SARC	cis	rs5753037	0.653	rs131265	chr22:30145591	C/T	cg01021169	chr22:30184971	ASCC2	-0.46	-6.45	-0.39	6.32e-10	Type 1 diabetes;
SARC	cis	rs1949733	0.523	rs4619877	chr4:8543235	G/A	cg05004818	chr4:8539015	NA	0.37	4.75	0.3	3.63e-6	Response to antineoplastic agents;
SARC	trans	rs61931739	0.534	rs11053000	chr12:34079022	C/T	cg13010199	chr12:38710504	ALG10B	0.75	10.13	0.55	3.11e-20	Morning vs. evening chronotype;
SARC	cis	rs2730245	1.000	rs2730245	chr7:158724789	G/C	cg24397884	chr7:158709396	WDR60	-1.05	-15.51	-0.71	9.61e-38	Height;
SARC	cis	rs7100689	0.646	rs7092237	chr10:82165640	A/G	cg01528321	chr10:82214614	TSPAN14	0.74	9.99	0.55	8.93e-20	Post bronchodilator FEV1;
SARC	cis	rs3741151	1.000	rs79778136	chr11:73041339	T/C	cg17517138	chr11:73019481	ARHGEF17	0.97	7.51	0.44	1.26e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg02770112	chr12:9066984	PHC1	0.48	6.28	0.38	1.61e-9	Chemerin levels;
SARC	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg18357526	chr6:26021779	HIST1H4A	0.82	11.11	0.59	2.78e-23	Intelligence (multi-trait analysis);
SARC	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg18225595	chr11:63971243	STIP1	0.55	8.06	0.47	4.04e-14	Platelet count;
SARC	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg03433033	chr1:76189801	ACADM	-0.48	-5.33	-0.33	2.31e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9843304	0.868	rs9870457	chr3:149209610	A/G	cg08667024	chr3:149219783	TM4SF4	0.37	5.97	0.36	8.89e-9	Gallstone disease;
SARC	cis	rs3857536	0.740	rs4710572	chr6:66890361	C/A	cg07460842	chr6:66804631	NA	-0.6	-7.16	-0.42	1.04e-11	Blood trace element (Cu levels);
SARC	trans	rs1945213	0.659	rs17149979	chr11:55840862	A/G	cg15704280	chr7:45808275	SEPT13	0.66	6.87	0.41	5.94e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs2204008	0.653	rs11182569	chr12:38572452	G/A	cg13010199	chr12:38710504	ALG10B	0.78	10.83	0.58	2.05e-22	Bladder cancer;
SARC	cis	rs765787	0.530	rs11070444	chr15:45513121	T/C	cg26924012	chr15:45694286	SPATA5L1	0.43	5.34	0.33	2.2e-7	Uric acid levels;
SARC	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg23982607	chr1:1823379	GNB1	-0.65	-10.96	-0.58	8.46e-23	Body mass index;
SARC	cis	rs12545109	0.700	rs2670045	chr8:57393695	A/G	cg19413350	chr8:57351067	NA	-0.42	-4.81	-0.3	2.69e-6	Obesity-related traits;
SARC	cis	rs8180040	1.000	rs1076394	chr3:47322781	G/A	cg27129171	chr3:47204927	SETD2	-0.69	-9.6	-0.53	1.3e-18	Colorectal cancer;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg14929913	chr10:1147979	WDR37	-0.49	-6.31	-0.38	1.42e-9	Height;
SARC	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg22535103	chr8:58192502	C8orf71	-0.65	-6.02	-0.37	6.62e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs35146811	0.807	rs6953441	chr7:99617067	G/A	cg22004693	chr7:99632812	ZKSCAN1	-0.45	-4.95	-0.31	1.43e-6	Coronary artery disease;
SARC	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg26338869	chr17:61819248	STRADA	0.42	4.91	0.31	1.73e-6	Height;
SARC	cis	rs76419734	1.000	rs17036230	chr4:106715148	A/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.91	5.75	0.35	2.81e-8	Post bronchodilator FEV1;
SARC	cis	rs4846217	1.000	rs11121548	chr1:10424252	C/T	cg19092837	chr1:10271724	KIF1B	0.42	5.63	0.35	5.13e-8	Platelet count;
SARC	cis	rs12479064	0.671	rs4851207	chr2:100105775	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.43	-4.76	-0.3	3.4e-6	Chronic sinus infection;
SARC	cis	rs920590	0.796	rs11778257	chr8:19634598	A/T	cg17834443	chr8:19674713	INTS10	0.48	5.8	0.36	2.14e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs858239	0.509	rs57611130	chr7:23184552	C/A	cg23682824	chr7:23144976	KLHL7	0.72	9.39	0.52	5.63e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs35110281	0.641	rs9983670	chr21:45083425	A/G	cg04455712	chr21:45112962	RRP1B	0.34	4.8	0.3	2.87e-6	Mean corpuscular volume;
SARC	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg22484793	chr3:52261325	TLR9	0.29	4.8	0.3	2.81e-6	Bipolar disorder;
SARC	cis	rs35110281	0.744	rs230645	chr21:44918607	A/G	cg21573476	chr21:45109991	RRP1B	0.43	6.25	0.38	1.99e-9	Mean corpuscular volume;
SARC	cis	rs3781913	0.817	rs932074	chr11:72365663	C/G	cg03713592	chr11:72463424	ARAP1	-0.49	-5.91	-0.36	1.22e-8	Rheumatoid arthritis;
SARC	cis	rs473651	0.935	rs474478	chr2:239335473	C/T	cg18131467	chr2:239335373	ASB1	0.96	16.17	0.73	6.31e-40	Multiple system atrophy;
SARC	cis	rs4794202	0.700	rs11079797	chr17:45912302	C/T	cg23391107	chr17:45924227	SP6	-0.46	-4.78	-0.3	3.1e-6	Alzheimer's disease (cognitive decline);
SARC	cis	rs4820294	1.000	rs4820294	chr22:38071043	G/A	cg21798802	chr22:38057573	PDXP	0.39	5.93	0.36	1.11e-8	Fat distribution (HIV);
SARC	cis	rs11785400	1.000	rs11776301	chr8:143737142	A/G	cg24634471	chr8:143751801	JRK	0.69	9.17	0.51	2.63e-17	Schizophrenia;
SARC	cis	rs611744	0.870	rs640068	chr8:109158002	A/G	cg21045802	chr8:109455806	TTC35	0.44	5.28	0.33	3.01e-7	Dupuytren's disease;
SARC	cis	rs644799	0.930	rs631099	chr11:95563482	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.9	14.03	0.68	7.82e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg11843238	chr5:131593191	PDLIM4	-0.42	-5.14	-0.32	5.92e-7	Breast cancer;
SARC	cis	rs10911232	0.507	rs4642853	chr1:182996242	C/T	cg13390022	chr1:182993471	LAMC1	0.33	5.04	0.31	9.29e-7	Hypertriglyceridemia;
SARC	cis	rs752010	0.806	rs4641303	chr1:42091310	A/G	cg06885757	chr1:42089581	HIVEP3	0.4	6.2	0.38	2.59e-9	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg19223190	chr17:80058835	NA	-0.46	-6.49	-0.39	5.07e-10	Life satisfaction;
SARC	cis	rs6732160	0.588	rs72841902	chr2:73372212	T/A	cg01422370	chr2:73384389	NA	0.37	5.79	0.35	2.25e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2486288	0.656	rs11629859	chr15:45547121	T/G	cg15395560	chr15:45543142	SLC28A2	0.28	5.44	0.34	1.37e-7	Glomerular filtration rate;
SARC	cis	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg12064134	chr16:90016061	DEF8	-0.56	-4.79	-0.3	2.9e-6	Skin colour saturation;
SARC	cis	rs875971	0.545	rs7810213	chr7:65946579	G/C	cg11764359	chr7:65958608	NA	0.64	6.18	0.38	2.89e-9	Aortic root size;
SARC	trans	rs208520	0.690	rs4618506	chr6:66756889	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-13.6	-0.67	2.06e-31	Exhaled nitric oxide output;
SARC	trans	rs637571	0.522	rs528736	chr11:65705108	A/G	cg17712092	chr4:129076599	LARP1B	0.71	9.64	0.53	1e-18	Eosinophil percentage of white cells;
SARC	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.52	-6.62	-0.4	2.43e-10	Lymphocyte counts;
SARC	cis	rs6088580	0.634	rs6088471	chr20:32932643	C/A	cg24642439	chr20:33292090	TP53INP2	-0.64	-8.23	-0.47	1.33e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs4720575	1.000	rs4720574	chr7:47085597	A/C	cg00036614	chr7:47093842	NA	-0.44	-6.18	-0.38	2.88e-9	Angiotensin-converting enzyme inhibitor intolerance;
SARC	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg21782813	chr7:2030301	MAD1L1	0.46	7.31	0.43	4.29e-12	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7044106	0.762	rs1530370	chr9:123424552	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	4.79	0.3	3.03e-6	Hip circumference adjusted for BMI;
SARC	cis	rs6714710	0.603	rs11123974	chr2:98605982	A/G	cg26665480	chr2:98280029	ACTR1B	0.5	6.56	0.4	3.37e-10	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs6450176	1.000	rs10805455	chr5:53302302	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.67	-7.75	-0.45	2.78e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg12564285	chr5:131593104	PDLIM4	0.46	6.3	0.38	1.5e-9	Breast cancer;
SARC	cis	rs11997175	0.536	rs10096323	chr8:33776507	T/C	ch.8.33884649F	chr8:33765107	NA	0.43	5.57	0.34	7.12e-8	Body mass index;
SARC	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg15352829	chr14:105391018	PLD4	-0.33	-6.34	-0.38	1.19e-9	Rheumatoid arthritis;
SARC	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.8	7.99	0.46	6.06e-14	Mean platelet volume;
SARC	cis	rs607987	0.871	rs653452	chr11:30244235	C/T	cg06241208	chr11:30344200	C11orf46	-0.39	-4.77	-0.3	3.27e-6	Body mass index;
SARC	cis	rs7647973	0.593	rs4855885	chr3:49690199	G/A	cg06212747	chr3:49208901	KLHDC8B	0.58	5.49	0.34	1.03e-7	Menarche (age at onset);
SARC	cis	rs7512552	0.839	rs1260459	chr1:150348253	T/G	cg15654264	chr1:150340011	RPRD2	0.38	4.81	0.3	2.7e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.77	8.58	0.49	1.35e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7647973	0.710	rs9869120	chr3:49624065	T/C	cg13072238	chr3:49761600	GMPPB	-0.61	-5.33	-0.33	2.34e-7	Menarche (age at onset);
SARC	cis	rs55823223	0.564	rs4572466	chr17:73846314	A/C	cg10935138	chr17:73851978	WBP2	0.46	5.21	0.32	4.23e-7	Psoriasis;
SARC	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg09877947	chr5:131593287	PDLIM4	-0.4	-4.83	-0.3	2.48e-6	Acylcarnitine levels;
SARC	cis	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg01573921	chr16:88061006	BANP	-0.57	-6.01	-0.37	7.23e-9	Menopause (age at onset);
SARC	trans	rs7824557	0.527	rs2572369	chr8:11238597	C/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.54	-0.39	3.9e-10	Retinal vascular caliber;
SARC	cis	rs10752881	1.000	rs10911185	chr1:182971747	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.84	0.58	2.03e-22	Colorectal cancer;
SARC	cis	rs2425143	1.000	rs4504072	chr20:34448773	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.67	5.43	0.34	1.42e-7	Blood protein levels;
SARC	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-6.7	-0.4	1.53e-10	Personality dimensions;
SARC	cis	rs7647973	0.961	rs11130187	chr3:49307872	T/C	cg06212747	chr3:49208901	KLHDC8B	0.6	6.52	0.39	4.22e-10	Menarche (age at onset);
SARC	cis	rs4481887	1.000	rs4409693	chr1:248479061	C/T	cg01631408	chr1:248437212	OR2T33	-0.42	-5.22	-0.32	4e-7	Common traits (Other);
SARC	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg10523679	chr1:76189770	ACADM	0.5	6.74	0.4	1.2e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs4481887	0.745	rs4540687	chr1:248476099	C/G	cg00666640	chr1:248458726	OR2T12	0.32	5.45	0.34	1.25e-7	Common traits (Other);
SARC	cis	rs11249608	0.548	rs11951738	chr5:178491228	G/A	cg21905437	chr5:178450457	ZNF879	0.55	6.85	0.41	6.47e-11	Pubertal anthropometrics;
SARC	cis	rs7586879	0.575	rs6712981	chr2:25126230	A/G	cg04586622	chr2:25135609	ADCY3	0.32	5.4	0.33	1.64e-7	Body mass index;
SARC	cis	rs10465746	0.746	rs12749350	chr1:84456948	T/A	cg10977910	chr1:84465055	TTLL7	0.42	5.18	0.32	4.7e-7	Obesity-related traits;
SARC	cis	rs11098499	0.954	rs11940028	chr4:120411907	T/C	cg09307838	chr4:120376055	NA	0.93	12.73	0.64	1.6e-28	Corneal astigmatism;
SARC	cis	rs2933343	0.909	rs1683817	chr3:128651536	G/A	cg24203234	chr3:128598194	ACAD9	0.53	5.81	0.36	2.04e-8	IgG glycosylation;
SARC	cis	rs16973500	0.732	rs1549292	chr16:71983664	A/C	cg09427745	chr16:71932006	KIAA0174	-0.51	-5.07	-0.32	7.99e-7	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs13256369	0.755	rs11776987	chr8:8559401	C/G	cg17143192	chr8:8559678	CLDN23	0.54	5.98	0.36	8.18e-9	Obesity-related traits;
SARC	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg01475735	chr3:40494733	NA	-0.49	-5.37	-0.33	1.95e-7	Renal cell carcinoma;
SARC	cis	rs986417	0.818	rs2882601	chr14:61096879	A/T	cg27398547	chr14:60952738	C14orf39	0.76	7.3	0.43	4.54e-12	Gut microbiota (bacterial taxa);
SARC	cis	rs9788682	0.747	rs2958719	chr15:78743029	G/A	cg24631222	chr15:78858424	CHRNA5	-0.75	-9.33	-0.52	8.73e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg08092446	chr19:58987653	ZNF446	0.49	6.36	0.38	1.08e-9	Chemerin levels;
SARC	cis	rs3858526	0.883	rs10769333	chr11:5939685	A/T	cg02574844	chr11:5959923	NA	-0.41	-4.99	-0.31	1.16e-6	DNA methylation (variation);
SARC	cis	rs13191362	1.000	rs60719662	chr6:163006643	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.56	5.41	0.33	1.53e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs761746	0.960	rs5753680	chr22:31930972	A/G	cg15823100	chr22:32027580	PISD	0.35	4.97	0.31	1.32e-6	Intelligence;
SARC	cis	rs7833986	0.501	rs72653921	chr8:56897157	T/C	cg26371346	chr8:56986568	SNORD54;RPS20	0.68	6.48	0.39	5.31e-10	Height;
SARC	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg11644478	chr21:40555479	PSMG1	-0.89	-11.61	-0.61	6.87e-25	Cognitive function;
SARC	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg13770153	chr20:60521292	NA	0.54	7.35	0.43	3.3e-12	Body mass index;
SARC	cis	rs113835537	0.529	rs57724777	chr11:66236431	G/A	cg24851651	chr11:66362959	CCS	0.39	4.72	0.3	4.07e-6	Airway imaging phenotypes;
SARC	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg12463550	chr7:65579703	CRCP	0.7	5.26	0.33	3.34e-7	Diabetic kidney disease;
SARC	cis	rs9916302	0.851	rs612209	chr17:37442713	G/C	cg20243544	chr17:37824526	PNMT	-0.56	-6.87	-0.41	5.87e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg03709012	chr19:19516395	GATAD2A	-0.94	-15.03	-0.7	3.67e-36	Tonsillectomy;
SARC	cis	rs8044995	0.563	rs8059585	chr16:68376811	G/A	cg05110241	chr16:68378359	PRMT7	-0.63	-6.16	-0.37	3.22e-9	Schizophrenia;
SARC	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.74	9.31	0.52	1.01e-17	Height;
SARC	cis	rs9814567	0.806	rs4074521	chr3:134325536	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.54	6.96	0.41	3.5e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs6087990	0.735	rs1040555	chr20:31380201	A/T	cg13636640	chr20:31349939	DNMT3B	-0.78	-12.36	-0.63	2.48e-27	Ulcerative colitis;
SARC	cis	rs1355223	0.902	rs1258464	chr11:34731496	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-5.5	-0.34	1.01e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs12545109	0.800	rs1968551	chr8:57407760	T/C	cg19413350	chr8:57351067	NA	-0.43	-4.77	-0.3	3.18e-6	Obesity-related traits;
SARC	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg13206674	chr6:150067644	NUP43	0.46	5.89	0.36	1.33e-8	Lung cancer;
SARC	cis	rs9914544	0.545	rs8071458	chr17:18790840	C/A	cg25390199	chr17:18761479	PRPSAP2	0.46	6.05	0.37	5.66e-9	Educational attainment (years of education);
SARC	cis	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg09021430	chr5:549028	NA	-0.45	-5.69	-0.35	3.74e-8	Lung disease severity in cystic fibrosis;
SARC	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg22433210	chr17:43662623	NA	1.08	12.85	0.64	6.53e-29	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs3126085	0.935	rs10888468	chr1:152181539	C/T	cg26876637	chr1:152193138	HRNR	0.49	5.61	0.35	5.67e-8	Atopic dermatitis;
SARC	cis	rs2985684	0.948	rs2985685	chr14:50101370	G/A	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.47	4.86	0.3	2.21e-6	Carotid intima media thickness;
SARC	cis	rs72634258	0.554	rs1012477	chr1:7858135	C/G	cg26816564	chr1:7831052	VAMP3	-0.57	-5.21	-0.32	4.1e-7	Inflammatory bowel disease;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg25741567	chr21:35747810	FAM165B	0.58	6.63	0.4	2.27e-10	Brain volume in infants (cerebrospinal fluid);
SARC	trans	rs561341	0.941	rs8066558	chr17:30272879	G/T	cg20587970	chr11:113659929	NA	-1.21	-11.83	-0.61	1.33e-25	Hip circumference adjusted for BMI;
SARC	cis	rs7945705	0.846	rs11042055	chr11:8756856	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.4	5.35	0.33	2.12e-7	Hemoglobin concentration;
SARC	cis	rs7219021	0.674	rs9904761	chr17:46956830	C/G	cg16584676	chr17:46985605	UBE2Z	-0.5	-5.96	-0.36	9.26e-9	Schizophrenia or bipolar disorder;
SARC	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.38	-4.78	-0.3	3.08e-6	Lymphocyte counts;
SARC	trans	rs607987	1.000	rs607987	chr11:30223574	G/A	cg16771474	chr7:7776115	NA	0.49	6.58	0.4	3.07e-10	Body mass index;
SARC	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg19077165	chr18:44547161	KATNAL2	-0.53	-7.16	-0.42	1.05e-11	Personality dimensions;
SARC	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.63	-6.41	-0.39	8.13e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs7223966	1.000	rs9899491	chr17:61934384	G/C	cg00588841	chr17:61851480	DDX42;CCDC47	-0.63	-6.51	-0.39	4.45e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.58	-7.61	-0.45	6.65e-13	Mean platelet volume;
SARC	cis	rs2404602	0.716	rs12592171	chr15:76755133	G/C	cg22467129	chr15:76604101	ETFA	-0.36	-4.75	-0.3	3.52e-6	Blood metabolite levels;
SARC	trans	rs17685	0.753	rs11972240	chr7:75694079	A/C	cg19862616	chr7:65841803	NCRNA00174	0.61	7.47	0.44	1.64e-12	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs854765	0.547	rs4643387	chr17:17972973	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.44	5.68	0.35	4e-8	Total body bone mineral density;
SARC	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg22535103	chr8:58192502	C8orf71	-0.65	-6.02	-0.37	6.62e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs798554	0.704	rs798531	chr7:2770067	G/C	cg04166393	chr7:2884313	GNA12	0.45	5.56	0.34	7.34e-8	Height;
SARC	cis	rs1348850	0.914	rs7565022	chr2:178320222	A/T	cg23306229	chr2:178417860	TTC30B	0.51	5.99	0.37	7.69e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs4969178	0.965	rs8075131	chr17:76394595	T/G	cg02836325	chr17:76403955	PGS1	0.32	4.99	0.31	1.17e-6	HDL cholesterol levels;
SARC	cis	rs7512552	0.839	rs832622	chr1:150392830	A/G	cg15654264	chr1:150340011	RPRD2	0.39	5.03	0.31	9.63e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs12367572	1.000	rs7295923	chr12:45269284	C/T	cg04608330	chr12:45269318	NELL2	-0.47	-5.94	-0.36	1.05e-8	Gut microbiome composition (summer);
SARC	cis	rs10864302	0.515	rs6679411	chr1:7458393	G/A	cg01082602	chr1:7726441	CAMTA1	-0.44	-5.29	-0.33	2.83e-7	Photic sneeze reflex;
SARC	cis	rs79149102	0.649	rs78045616	chr15:75097880	G/A	cg09165964	chr15:75287851	SCAMP5	-1.02	-5.49	-0.34	1.07e-7	Lung cancer;
SARC	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg18876405	chr7:65276391	NA	0.7	8.68	0.49	6.76e-16	Aortic root size;
SARC	cis	rs56283067	0.887	rs4644056	chr6:44776136	G/T	cg18551225	chr6:44695536	NA	0.37	4.74	0.3	3.66e-6	Total body bone mineral density;
SARC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.82	10.68	0.57	6.47e-22	Prudent dietary pattern;
SARC	cis	rs11723261	0.621	rs6599307	chr4:143777	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.35	4.72	0.3	4.1e-6	Immune response to smallpox vaccine (IL-6);
SARC	cis	rs2120019	1.000	rs1867146	chr15:75354971	C/G	cg17294928	chr15:75287854	SCAMP5	-0.96	-13.74	-0.67	7.34e-32	Blood trace element (Zn levels);
SARC	cis	rs1707322	0.827	rs6683274	chr1:46241638	T/G	cg03146154	chr1:46216737	IPP	0.51	6.25	0.38	1.99e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2228479	0.850	rs11648433	chr16:89965055	G/A	cg06558623	chr16:89946397	TCF25	0.88	5.86	0.36	1.59e-8	Skin colour saturation;
SARC	cis	rs73206853	0.764	rs7953794	chr12:111081197	A/G	cg08946844	chr12:110511112	NA	0.52	4.92	0.31	1.66e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg12419862	chr22:24373484	LOC391322	-0.89	-12.94	-0.65	3.26e-29	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg08280861	chr8:58055591	NA	0.7	5.97	0.36	8.85e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7633857	0.512	rs1374787	chr3:160700144	C/T	cg04691961	chr3:161091175	C3orf57	-0.46	-5.88	-0.36	1.43e-8	Educational attainment (years of education);
SARC	cis	rs2046867	0.818	rs62249862	chr3:72867949	G/C	cg25664220	chr3:72788482	NA	-0.29	-4.77	-0.3	3.27e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
SARC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	5.55	0.34	7.8e-8	Bipolar disorder;
SARC	cis	rs17023223	0.537	rs2645300	chr1:119603067	C/A	cg05756136	chr1:119680316	WARS2	-0.43	-5.03	-0.31	9.81e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs921968	0.591	rs3731877	chr2:219602499	G/C	cg02176678	chr2:219576539	TTLL4	-0.33	-5.02	-0.31	1.05e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs6540556	0.954	rs611861	chr1:209937251	C/G	cg05527609	chr1:210001259	C1orf107	-0.62	-6.63	-0.4	2.26e-10	Red blood cell count;
SARC	cis	rs6696846	0.765	rs61822568	chr1:205081166	C/G	cg21545522	chr1:205238299	TMCC2	0.34	4.76	0.3	3.35e-6	Red blood cell count;
SARC	cis	rs787274	0.850	rs2025544	chr9:115632969	C/T	cg13803584	chr9:115635662	SNX30	0.9	5.62	0.35	5.54e-8	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg21782813	chr7:2030301	MAD1L1	0.39	6.14	0.37	3.58e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs698833	0.508	rs698765	chr2:44573671	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.64	7.59	0.45	7.58e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs10791323	0.660	rs10791330	chr11:133727535	C/T	cg15485101	chr11:133734466	NA	0.33	5.28	0.33	3.03e-7	Childhood ear infection;
SARC	cis	rs477692	0.569	rs10764887	chr10:131321719	A/T	cg05714579	chr10:131428358	MGMT	0.59	7.91	0.46	1.06e-13	Response to temozolomide;
SARC	cis	rs2594989	0.943	rs346072	chr3:11306851	A/G	cg00170343	chr3:11313890	ATG7	-0.63	-5.81	-0.36	2.06e-8	Circulating chemerin levels;
SARC	cis	rs6484504	0.532	rs2761589	chr11:31311429	C/G	cg02090638	chr11:31391270	DNAJC24;DCDC1	0.42	5.27	0.33	3.08e-7	Red blood cell count;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg04532153	chr17:27046900	SNORD42B;RPL23A	0.48	6.24	0.38	2.06e-9	Lung adenocarcinoma;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg04936382	chr20:36662003	RPRD1B;KIAA0406	-0.55	-6.35	-0.38	1.15e-9	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs2832191	0.671	rs73346699	chr21:30515529	C/T	cg24692254	chr21:30365293	RNF160	-0.68	-8.07	-0.47	3.79e-14	Dental caries;
SARC	cis	rs3749237	0.964	rs62260719	chr3:49852419	G/A	cg07636037	chr3:49044803	WDR6	0.44	4.98	0.31	1.25e-6	Resting heart rate;
SARC	cis	rs72653721	0.838	rs3798709	chr6:11001276	A/G	cg13562911	chr6:11044106	ELOVL2	0.54	6.19	0.38	2.75e-9	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg18252515	chr7:66147081	NA	0.45	4.97	0.31	1.31e-6	Aortic root size;
SARC	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg24531977	chr5:56204891	C5orf35	-0.51	-5.22	-0.32	3.87e-7	Initial pursuit acceleration;
SARC	cis	rs8180040	0.726	rs4078466	chr3:47126543	C/T	cg27129171	chr3:47204927	SETD2	0.68	9.62	0.53	1.13e-18	Colorectal cancer;
SARC	cis	rs11792861	0.926	rs12686736	chr9:111888739	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.67	7.72	0.45	3.51e-13	Menarche (age at onset);
SARC	cis	rs9325144	0.513	rs12313652	chr12:38665412	G/A	cg26384229	chr12:38710491	ALG10B	-0.63	-8.12	-0.47	2.64e-14	Morning vs. evening chronotype;
SARC	cis	rs921968	0.541	rs642520	chr2:219423605	A/G	cg02176678	chr2:219576539	TTLL4	-0.47	-7.15	-0.42	1.13e-11	Mean corpuscular hemoglobin concentration;
SARC	cis	rs11225247	0.685	rs12273698	chr11:102234776	A/G	cg11690896	chr11:102217788	BIRC2	0.68	4.91	0.31	1.74e-6	Vein graft stenosis in coronary artery bypass grafting;
SARC	cis	rs6582630	0.594	rs7308707	chr12:38450428	G/C	cg13010199	chr12:38710504	ALG10B	-0.46	-5.58	-0.34	6.52e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg21724239	chr8:58056113	NA	0.66	6.28	0.38	1.66e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg11589374	chr3:126398357	NA	0.62	8.36	0.48	5.74e-15	Lung adenocarcinoma;
SARC	cis	rs13088645	0.532	rs9835166	chr3:134166224	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.46	5.51	0.34	9.71e-8	Coronary artery disease;
SARC	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg13175981	chr1:150552382	MCL1	-0.54	-6.9	-0.41	4.97e-11	Tonsillectomy;
SARC	cis	rs208515	0.525	rs1484577	chr6:66688397	A/G	cg07460842	chr6:66804631	NA	0.87	10.25	0.56	1.41e-20	Exhaled nitric oxide levels;
SARC	cis	rs751728	0.965	rs9394165	chr6:33731408	G/A	cg25922239	chr6:33757077	LEMD2	0.81	10.8	0.58	2.55e-22	Crohn's disease;
SARC	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg03647317	chr4:187891568	NA	0.38	5.37	0.33	1.89e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs112591243	0.685	rs2839294	chr21:47917664	T/C	cg10657630	chr21:48055338	PRMT2	0.76	4.83	0.3	2.52e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs6604026	0.740	rs10782945	chr1:93304272	C/T	cg17283838	chr1:93427260	FAM69A	-0.39	-4.76	-0.3	3.37e-6	Multiple sclerosis;
SARC	cis	rs2075371	0.611	rs12531769	chr7:134016899	C/G	cg00033643	chr7:134001901	SLC35B4	0.44	5.33	0.33	2.35e-7	Mean platelet volume;
SARC	cis	rs7927771	0.524	rs4752796	chr11:47841862	A/G	cg10504702	chr11:47789108	FNBP4	-0.43	-5.62	-0.35	5.52e-8	Subjective well-being;
SARC	cis	rs6582630	0.638	rs11182428	chr12:38526387	T/C	cg26384229	chr12:38710491	ALG10B	-0.62	-7.97	-0.46	7.27e-14	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9660992	0.700	rs7547565	chr1:205259402	G/A	cg21545522	chr1:205238299	TMCC2	-0.39	-5.32	-0.33	2.44e-7	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs3796352	1.000	rs2564926	chr3:53094730	G/A	cg27565382	chr3:53032988	SFMBT1	-0.78	-6.01	-0.37	7.18e-9	Immune reponse to smallpox (secreted IL-2);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg23144649	chr7:106874008	COG5	0.47	6.28	0.38	1.62e-9	Thyroid stimulating hormone;
SARC	cis	rs62064224	0.593	rs916663	chr17:30835833	A/C	cg18200150	chr17:30822561	MYO1D	-0.45	-7.19	-0.43	8.58e-12	Schizophrenia;
SARC	cis	rs17401966	1.000	rs4348727	chr1:10265606	G/A	cg15208524	chr1:10270712	KIF1B	0.56	6.43	0.39	7.18e-10	Hepatocellular carcinoma;
SARC	cis	rs1707322	0.752	rs28545085	chr1:46201950	G/A	cg03146154	chr1:46216737	IPP	0.52	6.3	0.38	1.44e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg11764359	chr7:65958608	NA	0.88	12.58	0.64	4.89e-28	Aortic root size;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg12960467	chr5:133703730	CDKL3	0.48	6.55	0.39	3.67e-10	Thyroid stimulating hormone;
SARC	cis	rs694739	0.892	rs647152	chr11:64109118	T/G	cg26898376	chr11:64110657	CCDC88B	0.34	4.77	0.3	3.32e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs4481887	0.962	rs6686911	chr1:248476969	T/C	cg13385794	chr1:248469461	NA	0.36	5.47	0.34	1.18e-7	Common traits (Other);
SARC	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg03709012	chr19:19516395	GATAD2A	1.01	17.96	0.76	7.55e-46	Tonsillectomy;
SARC	cis	rs76419734	1.000	rs11727735	chr4:106631870	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.84	5.41	0.33	1.59e-7	Post bronchodilator FEV1;
SARC	cis	rs1941023	0.503	rs4528348	chr11:60129505	C/G	cg08716584	chr11:60157161	MS4A7	-0.38	-6.44	-0.39	6.87e-10	Congenital heart disease (maternal effect);
SARC	cis	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg07274523	chr3:49395745	GPX1	0.49	5.43	0.34	1.43e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs9309473	0.519	rs13027816	chr2:73897691	C/T	cg20560298	chr2:73613845	ALMS1	0.52	7.19	0.43	8.91e-12	Metabolite levels;
SARC	cis	rs1395	0.744	rs11126934	chr2:27476613	T/C	cg21747090	chr2:27597821	SNX17	-0.46	-5.62	-0.35	5.42e-8	Blood metabolite levels;
SARC	cis	rs208520	0.874	rs208469	chr6:66915891	T/C	cg07460842	chr6:66804631	NA	-1.0	-12.18	-0.62	9.65e-27	Exhaled nitric oxide output;
SARC	cis	rs12791968	0.765	rs12794751	chr11:44998769	C/G	cg11846598	chr11:44996168	LOC221122	-0.36	-5.44	-0.34	1.32e-7	Inhibitory control;
SARC	cis	rs922107	0.713	rs10922668	chr1:90043236	A/G	cg15422784	chr1:90023713	LRRC8B	-0.33	-4.89	-0.3	1.92e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
SARC	cis	rs1865760	0.865	rs6929805	chr6:25950834	T/A	cg17691542	chr6:26056736	HIST1H1C	0.58	7.33	0.43	3.67e-12	Height;
SARC	cis	rs5995756	0.627	rs3788568	chr22:40011273	G/T	cg10455938	chr22:40058150	CACNA1I	0.42	4.98	0.31	1.21e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.05	15.8	0.72	1.02e-38	Height;
SARC	cis	rs72781680	0.898	rs55657921	chr2:24008091	C/G	cg06627628	chr2:24431161	ITSN2	-0.66	-6.26	-0.38	1.83e-9	Lymphocyte counts;
SARC	cis	rs7647973	0.922	rs7620024	chr3:49451691	G/A	cg07636037	chr3:49044803	WDR6	-0.75	-8.19	-0.47	1.69e-14	Menarche (age at onset);
SARC	cis	rs9660992	0.573	rs1318187	chr1:205206172	T/A	cg07972983	chr1:205091412	RBBP5	0.57	7.02	0.42	2.35e-11	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs7568458	0.811	rs10175792	chr2:85761654	A/G	cg02493740	chr2:85810744	VAMP5	-0.36	-5.46	-0.34	1.23e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs9815354	1.000	rs1716993	chr3:41974556	G/C	cg03022575	chr3:42003672	ULK4	-0.6	-5.59	-0.34	6.22e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6740322	0.895	rs6544643	chr2:43560072	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.58	-7.04	-0.42	2.17e-11	Coronary artery disease;
SARC	cis	rs3820928	0.874	rs7421491	chr2:227839278	C/A	cg11843606	chr2:227700838	RHBDD1	-0.57	-7.21	-0.43	7.92e-12	Pulmonary function;
SARC	cis	rs4713118	0.955	rs9393848	chr6:27688369	C/T	cg17221315	chr6:27791827	HIST1H4J	0.5	5.3	0.33	2.7e-7	Parkinson's disease;
SARC	cis	rs12291225	0.679	rs4757245	chr11:14297872	A/C	cg19336497	chr11:14380999	RRAS2	-0.4	-6.77	-0.41	1.02e-10	Sense of smell;
SARC	cis	rs12142240	0.583	rs5013330	chr1:46815154	G/A	cg10495392	chr1:46806563	NSUN4	0.65	6.83	0.41	7.25e-11	Menopause (age at onset);
SARC	cis	rs6540556	0.723	rs9430016	chr1:209916884	A/G	cg23920097	chr1:209922102	NA	-0.56	-6.4	-0.39	8.38e-10	Red blood cell count;
SARC	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.49	6.29	0.38	1.55e-9	Personality dimensions;
SARC	cis	rs9303280	0.776	rs9891174	chr17:38031802	T/A	cg20243544	chr17:37824526	PNMT	0.43	5.64	0.35	4.93e-8	Self-reported allergy;
SARC	cis	rs7551222	0.716	rs10494852	chr1:204457786	A/G	cg20240347	chr1:204465584	NA	0.3	5.26	0.33	3.22e-7	Schizophrenia;
SARC	cis	rs9547692	0.938	rs12427600	chr13:37460648	C/T	cg01493522	chr13:37497338	NA	0.43	5.08	0.32	7.9e-7	Coronary artery disease;
SARC	cis	rs7044106	0.718	rs1960421	chr9:123394894	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	5.01	0.31	1.05e-6	Hip circumference adjusted for BMI;
SARC	cis	rs2421770	0.532	rs7945449	chr11:35369110	C/T	cg13971030	chr11:35366721	SLC1A2	-0.35	-4.81	-0.3	2.76e-6	Staphylococcus aureus nasal carriage (persistent);
SARC	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg08280861	chr8:58055591	NA	0.69	6.06	0.37	5.46e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs796364	0.806	rs11689664	chr2:201099961	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.66	-5.42	-0.33	1.51e-7	Schizophrenia;
SARC	cis	rs1348850	0.632	rs10167783	chr2:178519041	G/A	cg23306229	chr2:178417860	TTC30B	0.44	4.93	0.31	1.58e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9815354	1.000	rs1612124	chr3:41967893	C/A	cg03022575	chr3:42003672	ULK4	-0.61	-5.67	-0.35	4.25e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg15556689	chr8:8085844	FLJ10661	0.49	6.11	0.37	4.26e-9	Mood instability;
SARC	cis	rs17001868	0.568	rs2294350	chr22:40784278	C/T	cg07138101	chr22:40742427	ADSL	0.53	5.34	0.33	2.21e-7	Mammographic density (dense area);
SARC	cis	rs920590	0.642	rs6993525	chr8:19671104	A/G	cg01411142	chr8:19674711	INTS10	-0.5	-5.59	-0.34	6.42e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs4423214	1.000	rs12790558	chr11:71170905	T/C	cg24826892	chr11:71159390	DHCR7	0.44	5.61	0.35	5.6e-8	Vitamin D levels;
SARC	cis	rs2251381	0.808	rs7364112	chr21:30548968	C/A	cg08807101	chr21:30365312	RNF160	0.73	9.81	0.54	2.99e-19	Selective IgA deficiency;
SARC	cis	rs9392918	0.902	rs12198986	chr6:7720059	G/A	cg23089261	chr6:7723385	NA	0.37	4.99	0.31	1.17e-6	Height;
SARC	cis	rs12545109	0.879	rs2576588	chr8:57381627	G/A	cg19413350	chr8:57351067	NA	-0.43	-5.1	-0.32	7.07e-7	Obesity-related traits;
SARC	cis	rs72781680	0.611	rs56326157	chr2:24312407	T/C	cg08917208	chr2:24149416	ATAD2B	0.62	6.34	0.38	1.16e-9	Lymphocyte counts;
SARC	cis	rs7223966	1.000	rs1877316	chr17:61766880	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.5	-5.2	-0.32	4.44e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs4481887	0.962	rs10788769	chr1:248457426	C/T	cg13385794	chr1:248469461	NA	0.34	5.15	0.32	5.62e-7	Common traits (Other);
SARC	cis	rs4808199	0.947	rs10404728	chr19:19595014	C/T	cg03709012	chr19:19516395	GATAD2A	1.19	13.19	0.65	4.85e-30	Nonalcoholic fatty liver disease;
SARC	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg13607699	chr17:42295918	UBTF	0.6	7.23	0.43	6.86e-12	Total body bone mineral density;
SARC	cis	rs965469	0.947	rs965468	chr20:3381443	C/T	cg25506879	chr20:3388711	C20orf194	-0.57	-5.79	-0.35	2.27e-8	IFN-related cytopenia;
SARC	cis	rs1348850	0.526	rs10930802	chr2:178460095	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.61	5.82	0.36	1.99e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs3733585	0.753	rs1122141	chr4:9947278	T/C	cg00071950	chr4:10020882	SLC2A9	-0.39	-6.27	-0.38	1.71e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs2288884	0.505	rs4988334	chr19:52468998	A/G	cg24732339	chr19:52471368	ZNF350	-0.56	-4.88	-0.3	1.93e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
SARC	cis	rs13082711	0.558	rs1844983	chr3:27370203	C/T	cg02860705	chr3:27208620	NA	-0.48	-6.61	-0.4	2.6200000000000003e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs79349575	0.783	rs11079844	chr17:47028334	G/A	cg16584676	chr17:46985605	UBE2Z	0.55	6.58	0.4	3.01e-10	Type 2 diabetes;
SARC	cis	rs10982256	0.774	rs7046135	chr9:117243809	T/C	cg15903421	chr9:117267460	DFNB31	0.37	4.78	0.3	3.07e-6	Bipolar disorder;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg23557426	chr14:65944637	FUT8	-0.48	-6.61	-0.4	2.6200000000000003e-10	Alcohol dependence;
SARC	cis	rs6448317	0.954	rs13116026	chr4:24922242	T/A	cg21108841	chr4:24914750	CCDC149	-0.56	-5.94	-0.36	1.02e-8	Heschl's gyrus morphology;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg02803047	chr19:50643420	SNAR-B1;SNAR-B2	-0.58	-6.36	-0.38	1.05e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg22168489	chr12:122356033	WDR66	0.73	11.62	0.61	6.31e-25	Mean corpuscular volume;
SARC	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10892173	0.566	rs2298649	chr11:117672225	A/G	cg21014159	chr11:117668035	DSCAML1	0.44	5.64	0.35	4.93e-8	Myopia;
SARC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg01238044	chr22:24384105	GSTT1	-0.54	-6.09	-0.37	4.59e-9	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs829883	0.724	rs11109507	chr12:98904160	C/T	cg25150519	chr12:98850993	NA	0.68	8.7	0.5	5.94e-16	Colorectal adenoma (advanced);
SARC	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg10523679	chr1:76189770	ACADM	-0.48	-5.61	-0.34	5.7e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6669008	1.000	rs1891969	chr1:114185855	C/A	cg13572289	chr1:114447746	DCLRE1B;AP4B1	-0.42	-4.94	-0.31	1.51e-6	Bacteremia;
SARC	cis	rs3796352	1.000	rs6445557	chr3:53083969	C/T	cg15956490	chr3:53032818	SFMBT1	-0.6	-4.84	-0.3	2.32e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2011503	1.000	rs2965181	chr19:19512317	C/T	cg03709012	chr19:19516395	GATAD2A	0.65	5.63	0.35	5.07e-8	Bipolar disorder;
SARC	cis	rs2997447	0.761	rs61776576	chr1:26429898	G/A	cg19633962	chr1:26362018	EXTL1	-0.64	-5.32	-0.33	2.49e-7	QRS complex (12-leadsum);
SARC	cis	rs3764563	1.000	rs4371280	chr19:15715768	A/C	cg20725493	chr19:15740067	CYP4F8	-0.67	-4.74	-0.3	3.69e-6	Inflammatory biomarkers;
SARC	cis	rs8102137	0.962	rs58989684	chr19:30299796	A/T	cg27475126	chr19:30303651	CCNE1	-0.42	-5.77	-0.35	2.57e-8	Bladder cancer;
SARC	cis	rs1865760	0.566	rs2051544	chr6:26071093	C/T	cg10373733	chr6:25993375	NA	0.41	4.92	0.31	1.61e-6	Height;
SARC	cis	rs2228479	0.850	rs62054610	chr16:89816920	G/A	cg06558623	chr16:89946397	TCF25	0.88	6.21	0.38	2.39e-9	Skin colour saturation;
SARC	cis	rs63406760	1	rs63406760	chr12:123742692	TG/T	cg00376283	chr12:123451042	ABCB9	0.49	5.53	0.34	8.36e-8	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs4851254	0.961	rs13000759	chr2:100753903	A/T	cg04109781	chr2:100722022	AFF3	-0.33	-4.71	-0.3	4.18e-6	Intelligence (multi-trait analysis);
SARC	cis	rs861020	1.000	rs7555285	chr1:209970355	C/G	cg05527609	chr1:210001259	C1orf107	-0.89	-10.22	-0.56	1.66e-20	Orofacial clefts;
SARC	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg11494091	chr17:61959527	GH2	0.37	5.18	0.32	4.88e-7	Height;
SARC	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg04277193	chr17:41438351	NA	0.45	4.89	0.31	1.89e-6	Menopause (age at onset);
SARC	cis	rs2233152	0.656	rs10405633	chr19:41291703	G/A	cg07297178	chr19:42193084	CEACAM7	0.37	5.0	0.31	1.13e-6	Kawasaki disease;
SARC	cis	rs798554	0.686	rs2527690	chr7:2854250	C/T	cg13628971	chr7:2884303	GNA12	0.46	5.66	0.35	4.39e-8	Height;
SARC	cis	rs12956009	0.583	rs35970525	chr18:44882625	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	7.64	0.45	5.6e-13	Educational attainment (years of education);
SARC	cis	rs7980687	0.638	rs7299943	chr12:123593485	A/T	cg00376283	chr12:123451042	ABCB9	0.53	5.92	0.36	1.11e-8	Height;Educational attainment;Head circumference (infant);
SARC	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg15242686	chr22:24348715	GSTTP1	0.45	5.52	0.34	8.86e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs4742903	0.509	rs1605445	chr9:106958484	C/A	cg14250997	chr9:106856677	SMC2	0.39	4.87	0.3	2.03e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.76	9.5	0.53	2.75e-18	Height;
SARC	cis	rs3782089	1.000	rs11600543	chr11:65298939	G/A	cg21890820	chr11:65308645	LTBP3	0.88	5.45	0.34	1.27e-7	Height;
SARC	cis	rs2832077	0.943	rs2832084	chr21:30154798	A/G	cg03476357	chr21:30257390	N6AMT1	-0.61	-5.63	-0.35	5.26e-8	Cognitive test performance;
SARC	cis	rs6963495	0.818	rs6956234	chr7:105149707	A/G	cg13798780	chr7:105162888	PUS7	0.61	5.75	0.35	2.79e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg11203670	chr7:100026453	MEPCE;ZCWPW1	0.52	4.88	0.3	1.95e-6	Platelet count;
SARC	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.46	5.77	0.35	2.54e-8	Gut microbiome composition (summer);
SARC	cis	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg08975724	chr8:8085496	FLJ10661	-0.48	-5.79	-0.35	2.26e-8	Mood instability;
SARC	cis	rs10463316	0.894	rs4246024	chr5:150740987	C/T	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.39	-0.33	1.71e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs72945132	0.882	rs12295111	chr11:70131882	C/A	cg00319359	chr11:70116639	PPFIA1	0.68	6.37	0.39	1.01e-9	Coronary artery disease;
SARC	cis	rs9303401	0.614	rs34678056	chr17:57177549	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.97	10.17	0.55	2.42e-20	Cognitive test performance;
SARC	cis	rs10463554	0.927	rs34821	chr5:102437617	T/A	cg23492399	chr5:102201601	PAM	-0.52	-5.72	-0.35	3.2e-8	Parkinson's disease;
SARC	cis	rs910316	0.934	rs7141705	chr14:75655352	G/C	cg23033748	chr14:75592666	NEK9	-0.35	-4.89	-0.3	1.92e-6	Height;
SARC	cis	rs4595586	0.655	rs11170269	chr12:39387077	G/A	cg26384229	chr12:38710491	ALG10B	0.43	5.41	0.33	1.6e-7	Morning vs. evening chronotype;
SARC	cis	rs2425143	1.000	rs79035779	chr20:34343004	G/A	cg01084648	chr20:34329383	RBM39	0.63	4.95	0.31	1.44e-6	Blood protein levels;
SARC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg17178900	chr1:205818956	PM20D1	-0.61	-9.61	-0.53	1.22e-18	Monocyte percentage of white cells;
SARC	cis	rs7551222	0.634	rs11801289	chr1:204528969	G/C	cg20240347	chr1:204465584	NA	-0.32	-5.54	-0.34	7.98e-8	Schizophrenia;
SARC	cis	rs9814567	0.964	rs6776203	chr3:134234345	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-7.06	-0.42	1.93e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg02018176	chr4:1364513	KIAA1530	-0.46	-6.56	-0.4	3.36e-10	Obesity-related traits;
SARC	cis	rs10911232	0.526	rs41475048	chr1:183058452	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.47	-5.24	-0.32	3.51e-7	Hypertriglyceridemia;
SARC	cis	rs3741151	0.686	rs12277924	chr11:73219678	T/C	cg17517138	chr11:73019481	ARHGEF17	0.71	6.28	0.38	1.62e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs6840360	0.967	rs1511170	chr4:152701110	A/G	cg22705602	chr4:152727874	NA	-0.38	-6.65	-0.4	2.07e-10	Intelligence (multi-trait analysis);
SARC	cis	rs561341	0.609	rs7214626	chr17:30190989	G/A	cg13647721	chr17:30228624	UTP6	-0.73	-7.08	-0.42	1.73e-11	Hip circumference adjusted for BMI;
SARC	trans	rs61931739	0.500	rs11836198	chr12:34552782	T/C	cg26384229	chr12:38710491	ALG10B	0.85	12.64	0.64	3.01e-28	Morning vs. evening chronotype;
SARC	cis	rs72781680	0.716	rs2551326	chr2:23982378	T/C	cg06627628	chr2:24431161	ITSN2	-0.51	-5.43	-0.34	1.43e-7	Lymphocyte counts;
SARC	cis	rs7098414	0.531	rs3844126	chr10:82019997	T/G	cg01528321	chr10:82214614	TSPAN14	0.46	5.92	0.36	1.14e-8	Post bronchodilator FEV1;
SARC	cis	rs936229	0.656	rs2290572	chr15:75130573	A/G	cg14664628	chr15:75095509	CSK	-0.66	-8.24	-0.47	1.27e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs3820928	0.874	rs10166736	chr2:227900419	C/T	cg05526886	chr2:227700861	RHBDD1	-0.51	-6.1	-0.37	4.4e-9	Pulmonary function;
SARC	cis	rs6912958	0.781	rs4334949	chr6:88290150	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-6.8	-0.41	8.58e-11	Monocyte percentage of white cells;
SARC	cis	rs2243480	1.000	rs316315	chr7:65591205	C/T	cg18252515	chr7:66147081	NA	1.0	10.36	0.56	6.31e-21	Diabetic kidney disease;
SARC	cis	rs9300255	0.739	rs1533703	chr12:123742093	T/G	cg00376283	chr12:123451042	ABCB9	0.49	5.53	0.34	8.36e-8	Neutrophil percentage of white cells;
SARC	cis	rs7824557	0.614	rs10503421	chr8:11221313	C/T	cg21775007	chr8:11205619	TDH	0.65	8.76	0.5	4.03e-16	Retinal vascular caliber;
SARC	cis	rs6807306	1.000	rs6444471	chr3:167372727	C/T	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.53	5.3	0.33	2.69e-7	Mean platelet volume;
SARC	cis	rs16976116	0.951	rs3809540	chr15:55489412	A/C	cg11288833	chr15:55489084	RSL24D1	0.61	6.16	0.37	3.11e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs826838	0.967	rs11183514	chr12:38760744	A/T	cg26384229	chr12:38710491	ALG10B	0.96	15.61	0.71	4.51e-38	Heart rate;
SARC	cis	rs2841277	0.509	rs11850949	chr14:105408827	A/C	cg19901468	chr14:105411992	AHNAK2	-0.72	-10.63	-0.57	9.13e-22	Rheumatoid arthritis;
SARC	cis	rs9733	0.596	rs12089989	chr1:150715782	G/A	cg13175981	chr1:150552382	MCL1	-0.53	-6.66	-0.4	1.9e-10	Tonsillectomy;
SARC	cis	rs7829975	0.582	rs6982832	chr8:8792217	A/C	cg08975724	chr8:8085496	FLJ10661	-0.4	-4.88	-0.3	1.99e-6	Mood instability;
SARC	cis	rs908922	0.887	rs4596895	chr1:152528075	T/G	cg09873164	chr1:152488093	CRCT1	0.62	7.54	0.44	1.06e-12	Hair morphology;
SARC	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg13393036	chr8:95962371	TP53INP1	-0.36	-6.15	-0.37	3.29e-9	Type 2 diabetes;
SARC	trans	rs2727020	0.636	rs10839275	chr11:49438962	T/A	cg15704280	chr7:45808275	SEPT13	-0.86	-14.14	-0.68	3.47e-33	Coronary artery disease;
SARC	cis	rs9359856	0.510	rs2748298	chr6:90436877	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.53	-4.9	-0.31	1.8e-6	Bipolar disorder;
SARC	cis	rs4481887	0.741	rs6682953	chr1:248535626	T/C	cg13385794	chr1:248469461	NA	0.34	5.48	0.34	1.09e-7	Common traits (Other);
SARC	cis	rs2387326	0.717	rs10829341	chr10:129944226	G/A	cg16087940	chr10:129947807	NA	-0.45	-5.74	-0.35	2.98e-8	Select biomarker traits;
SARC	cis	rs10504229	0.679	rs2317991	chr8:58035080	C/T	cg22535103	chr8:58192502	C8orf71	0.55	5.74	0.35	2.98e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10513788	0.665	rs4241558	chr3:181990977	G/A	cg05977900	chr3:182512126	ATP11B	0.47	4.8	0.3	2.88e-6	Cognitive function;
SARC	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs838147	0.508	rs507711	chr19:49208564	C/T	cg21064579	chr19:49206444	FUT2	0.36	5.04	0.31	9.42e-7	Dietary macronutrient intake;
SARC	cis	rs7566780	0.568	rs4832615	chr2:16630784	C/T	cg09580478	chr2:16689509	NA	-0.46	-5.54	-0.34	8.31e-8	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs9815354	1.000	rs9825741	chr3:41761828	A/T	cg03022575	chr3:42003672	ULK4	-0.59	-5.84	-0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs7481584	0.624	rs436580	chr11:3063961	T/G	cg05729581	chr11:3078854	CARS	0.52	6.82	0.41	7.73e-11	Calcium levels;
SARC	cis	rs7666738	0.830	rs6846739	chr4:99016647	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.9	0.5	1.65e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg23248424	chr5:179741104	GFPT2	-0.46	-5.78	-0.35	2.43e-8	Height;
SARC	cis	rs6908034	0.607	rs12527834	chr6:19821781	A/G	cg02682789	chr6:19804855	NA	0.69	5.35	0.33	2.14e-7	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs4481887	0.861	rs1339989	chr1:248511624	C/G	cg00666640	chr1:248458726	OR2T12	0.31	5.38	0.33	1.8e-7	Common traits (Other);
SARC	cis	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg06636001	chr8:8085503	FLJ10661	-0.73	-9.92	-0.54	1.43e-19	Joint mobility (Beighton score);
SARC	cis	rs16976116	0.901	rs28708989	chr15:55498934	C/T	cg11288833	chr15:55489084	RSL24D1	0.63	6.13	0.37	3.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9400467	0.506	rs3204954	chr6:111628597	C/G	cg15721981	chr6:111408429	SLC16A10	0.69	5.85	0.36	1.67e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg16606324	chr3:10149918	C3orf24	0.47	4.92	0.31	1.63e-6	Alzheimer's disease;
SARC	cis	rs11785400	1.000	rs4297023	chr8:143733307	C/A	cg10596483	chr8:143751796	JRK	0.64	8.66	0.49	8.21e-16	Schizophrenia;
SARC	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg08975724	chr8:8085496	FLJ10661	0.45	5.37	0.33	1.91e-7	Mood instability;
SARC	cis	rs10992471	0.603	rs1535755	chr9:95202031	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.26	-0.33	3.34e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs7959452	0.570	rs10878964	chr12:69720691	T/G	cg22834771	chr12:69754056	YEATS4	-0.4	-5.27	-0.33	3.14e-7	Blood protein levels;
SARC	cis	rs7208859	0.673	rs73265612	chr17:29225983	A/G	cg13385521	chr17:29058706	SUZ12P	0.85	7.23	0.43	7.08e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs7712401	0.601	rs386602	chr5:122321957	T/G	cg19412675	chr5:122181750	SNX24	-0.43	-5.51	-0.34	9.71e-8	Mean platelet volume;
SARC	cis	rs1020064	0.895	rs2250659	chr2:105889684	A/G	cg02079111	chr2:105885981	TGFBRAP1	0.59	6.69	0.4	1.62e-10	AIDS;
SARC	cis	rs79349575	0.749	rs58838744	chr17:46998902	A/G	cg16584676	chr17:46985605	UBE2Z	0.53	6.38	0.39	9.28e-10	Type 2 diabetes;
SARC	cis	rs4481887	0.861	rs10788778	chr1:248481551	T/C	cg01631408	chr1:248437212	OR2T33	-0.42	-5.22	-0.32	4e-7	Common traits (Other);
SARC	cis	rs9788682	0.748	rs569207	chr15:78873119	A/G	cg06917634	chr15:78832804	PSMA4	0.5	5.47	0.34	1.14e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs8113308	0.752	rs11879758	chr19:52490164	G/C	cg25782003	chr19:52490127	ZNF350	0.81	5.47	0.34	1.14e-7	Survival in endocrine treated breast cancer (estrogen-receptor positive);
SARC	cis	rs3796352	1.000	rs2336540	chr3:52974589	G/A	cg12962167	chr3:53033115	SFMBT1	0.75	4.9	0.31	1.8e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs79349575	0.783	rs62075838	chr17:46996432	C/T	cg16584676	chr17:46985605	UBE2Z	0.53	6.38	0.39	9.28e-10	Type 2 diabetes;
SARC	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.6	-7.62	-0.45	6.23e-13	Prudent dietary pattern;
SARC	cis	rs12926788	0.689	rs34365165	chr16:24856208	G/A	cg04756594	chr16:24857601	SLC5A11	0.37	4.86	0.3	2.19e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs8180040	0.620	rs11720139	chr3:47036756	C/G	cg27129171	chr3:47204927	SETD2	-0.7	-9.41	-0.52	4.87e-18	Colorectal cancer;
SARC	cis	rs1707322	0.691	rs61784799	chr1:46177748	A/G	cg03146154	chr1:46216737	IPP	-0.51	-6.14	-0.37	3.49e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg10435706	chr6:150039699	LATS1	0.36	4.8	0.3	2.88e-6	Lung cancer;
SARC	cis	rs9467711	0.606	rs9379901	chr6:26603866	T/C	cg12826209	chr6:26865740	GUSBL1	0.72	4.85	0.3	2.25e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2204008	0.837	rs10876019	chr12:37985477	C/T	cg13010199	chr12:38710504	ALG10B	0.78	10.71	0.57	5.11e-22	Bladder cancer;
SARC	cis	rs765787	0.530	rs4238377	chr15:45541981	A/G	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.81e-6	Uric acid levels;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg00512374	chr17:38599682	IGFBP4	-0.82	-6.88	-0.41	5.62e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs34172651	0.917	rs2112786	chr16:24778944	C/T	cg06028605	chr16:24865363	SLC5A11	0.27	4.87	0.3	2.08e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9660992	0.710	rs1768586	chr1:205238275	A/G	cg21545522	chr1:205238299	TMCC2	0.45	6.27	0.38	1.69e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs6545883	0.718	rs2694624	chr2:61672313	C/A	cg15711740	chr2:61764176	XPO1	-0.4	-4.82	-0.3	2.64e-6	Tuberculosis;
SARC	cis	rs1580019	0.563	rs10486509	chr7:32585443	C/G	cg07520158	chr7:32535189	LSM5;AVL9	-0.6	-7.87	-0.46	1.34e-13	Cognitive ability;
SARC	cis	rs1559088	0.847	rs2287679	chr19:33600764	T/C	cg27124370	chr19:33622961	WDR88	0.43	5.69	0.35	3.82e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs7113850	0.541	rs80243979	chr11:24231811	A/C	ch.11.24196551F	chr11:24239977	NA	0.73	5.37	0.33	1.91e-7	Bone fracture in osteoporosis;
SARC	cis	rs7666738	0.606	rs10006454	chr4:99080361	G/A	cg05340658	chr4:99064831	C4orf37	0.47	5.96	0.36	9.43e-9	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7219021	0.705	rs67174000	chr17:46982380	G/A	cg16584676	chr17:46985605	UBE2Z	-0.48	-5.72	-0.35	3.22e-8	Schizophrenia or bipolar disorder;
SARC	cis	rs6831352	0.959	rs6532795	chr4:100042221	C/T	cg12011299	chr4:100065546	ADH4	-0.33	-5.9	-0.36	1.24e-8	Alcohol dependence;
SARC	cis	rs3126085	0.866	rs3126066	chr1:152276871	A/G	cg26876637	chr1:152193138	HRNR	-0.46	-4.94	-0.31	1.5e-6	Atopic dermatitis;
SARC	cis	rs2048656	0.501	rs7464226	chr8:9461093	G/A	cg21625330	chr8:9911636	MSRA	-0.51	-4.88	-0.3	1.94e-6	Schizophrenia;
SARC	cis	rs6963495	0.932	rs55700120	chr7:105148460	G/T	cg19920283	chr7:105172520	RINT1	0.67	5.8	0.36	2.14e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs6910061	1.000	rs13214777	chr6:11103597	C/G	cg27233058	chr6:11094804	LOC221710	0.58	5.59	0.34	6.22e-8	Diabetic kidney disease;
SARC	cis	rs4803468	0.934	rs8103531	chr19:41891974	C/T	cg14132834	chr19:41945861	ATP5SL	-0.57	-7.59	-0.45	7.6e-13	Height;
SARC	cis	rs747650	0.699	rs4237547	chr11:47236405	C/G	cg03339077	chr11:47165057	C11orf49	-0.46	-6.35	-0.38	1.09e-9	Acne (severe);
SARC	cis	rs2204008	0.547	rs12318267	chr12:38250905	T/G	cg26384229	chr12:38710491	ALG10B	-0.61	-7.74	-0.45	2.92e-13	Bladder cancer;
SARC	cis	rs2153535	0.580	rs9406163	chr6:8466642	C/T	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg21280719	chr6:42927975	GNMT	-0.45	-8.04	-0.47	4.38e-14	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg17691542	chr6:26056736	HIST1H1C	0.46	4.95	0.31	1.42e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg27541892	chr1:1571801	CDK11B	0.4	5.44	0.34	1.33e-7	Body mass index;
SARC	cis	rs35110281	0.659	rs11702544	chr21:45091861	C/T	cg01579765	chr21:45077557	HSF2BP	-0.33	-5.17	-0.32	4.98e-7	Mean corpuscular volume;
SARC	cis	rs12586317	0.547	rs10142667	chr14:35445090	A/G	cg26967526	chr14:35346199	BAZ1A	-0.56	-5.57	-0.34	7.1e-8	Psoriasis;
SARC	cis	rs11098499	0.909	rs1546504	chr4:120241179	C/T	cg09160332	chr4:120329925	NA	-0.35	-4.96	-0.31	1.38e-6	Corneal astigmatism;
SARC	cis	rs6484504	0.576	rs2756191	chr11:31135882	A/T	cg02090638	chr11:31391270	DNAJC24;DCDC1	0.38	4.91	0.31	1.71e-6	Red blood cell count;
SARC	cis	rs7635838	0.892	rs4684775	chr3:11436413	A/G	cg00170343	chr3:11313890	ATG7	0.61	8.29	0.48	8.94e-15	HDL cholesterol;
SARC	cis	rs1707322	1.000	rs4524994	chr1:46370263	A/G	cg03146154	chr1:46216737	IPP	0.45	5.39	0.33	1.71e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs916888	0.647	rs199449	chr17:44808902	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.52	6.12	0.37	3.84e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs67311347	1.000	rs10510708	chr3:40404770	A/G	cg24209194	chr3:40518798	ZNF619	0.64	8.04	0.47	4.47e-14	Renal cell carcinoma;
SARC	cis	rs12541335	0.536	rs4266653	chr8:22169087	A/G	cg02463440	chr8:22132932	PIWIL2	0.45	6.35	0.38	1.14e-9	Hypertriglyceridemia;
SARC	cis	rs735396	1.000	rs1169311	chr12:121440731	C/T	cg02403541	chr12:121454288	C12orf43	0.72	9.48	0.53	2.97e-18	N-glycan levels;
SARC	cis	rs921968	0.643	rs1055816	chr2:219501328	G/A	cg02176678	chr2:219576539	TTLL4	0.36	5.34	0.33	2.17e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs9790314	0.521	rs60625846	chr3:161084525	G/T	cg17135325	chr3:160939158	NMD3	0.52	6.57	0.4	3.23e-10	Morning vs. evening chronotype;
SARC	cis	rs3820928	0.904	rs4439949	chr2:227764954	T/G	cg05526886	chr2:227700861	RHBDD1	-0.51	-6.08	-0.37	4.82e-9	Pulmonary function;
SARC	cis	rs6088590	0.931	rs12625149	chr20:33425812	A/C	cg24642439	chr20:33292090	TP53INP2	-0.71	-9.42	-0.52	4.79e-18	Coronary artery disease;
SARC	cis	rs4481887	0.927	rs7524700	chr1:248472816	A/G	cg00666640	chr1:248458726	OR2T12	0.32	5.45	0.34	1.25e-7	Common traits (Other);
SARC	cis	rs4780401	0.609	rs8055247	chr16:11827543	G/A	cg01061890	chr16:11836724	TXNDC11	-0.61	-8.68	-0.49	7.09e-16	Rheumatoid arthritis;
SARC	cis	rs9814567	1.000	rs9814567	chr3:134218557	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	7.06	0.42	1.94e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-5.96	-0.36	9.37e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4481887	0.962	rs4369256	chr1:248492274	G/A	cg01631408	chr1:248437212	OR2T33	-0.44	-5.43	-0.34	1.41e-7	Common traits (Other);
SARC	cis	rs908922	0.676	rs6658925	chr1:152482801	C/T	cg09873164	chr1:152488093	CRCT1	-0.63	-8.41	-0.48	4.02e-15	Hair morphology;
SARC	cis	rs12477438	1.000	rs73963398	chr2:99887025	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-10.35	-0.56	6.77e-21	Chronic sinus infection;
SARC	cis	rs2303759	0.918	rs9749416	chr19:49885005	G/A	cg22590775	chr19:49891494	CCDC155	0.53	6.32	0.38	1.34e-9	Multiple sclerosis;
SARC	cis	rs356220	0.642	rs356210	chr4:90636193	T/C	cg06632027	chr4:90757378	SNCA	0.39	5.0	0.31	1.13e-6	Parkinson's disease;
SARC	cis	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg14541582	chr5:601475	NA	-0.39	-4.88	-0.3	2e-6	Obesity-related traits;
SARC	cis	rs1468333	0.567	rs2277067	chr5:137775273	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.57	6.69	0.4	1.66e-10	Resting heart rate;
SARC	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg22168489	chr12:122356033	WDR66	0.63	9.94	0.55	1.27e-19	Mean corpuscular volume;
SARC	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg20102877	chr2:27665638	KRTCAP3	-0.34	-4.73	-0.3	3.85e-6	Total body bone mineral density;
SARC	cis	rs7818688	0.697	rs11778553	chr8:95978260	C/T	cg13393036	chr8:95962371	TP53INP1	0.4	4.73	0.3	3.83e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs4478037	0.822	rs9863331	chr3:33123235	G/T	cg19404215	chr3:33155277	CRTAP	0.53	4.74	0.3	3.69e-6	Major depressive disorder;
SARC	cis	rs7681440	0.583	rs2619348	chr4:90746321	C/G	cg06632027	chr4:90757378	SNCA	-0.44	-5.43	-0.34	1.39e-7	Dementia with Lewy bodies;
SARC	trans	rs2727020	0.521	rs10839285	chr11:49496852	T/G	cg03929089	chr4:120376271	NA	0.71	8.31	0.48	7.99e-15	Coronary artery disease;
SARC	cis	rs2204008	0.619	rs8189576	chr12:38307275	G/A	cg13010199	chr12:38710504	ALG10B	-0.53	-6.37	-0.39	9.86e-10	Bladder cancer;
SARC	cis	rs17039065	0.920	rs12508024	chr4:109413413	A/G	cg16525761	chr4:109541525	LOC285456;RPL34	-0.55	-4.81	-0.3	2.65e-6	Gut microbiome composition (summer);
SARC	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg09699651	chr6:150184138	LRP11	0.41	5.11	0.32	6.6e-7	Lung cancer;
SARC	cis	rs854765	0.547	rs7224047	chr17:17932931	G/A	cg05444541	chr17:17804740	TOM1L2	-0.3	-4.8	-0.3	2.82e-6	Total body bone mineral density;
SARC	cis	rs6580649	0.941	rs7296913	chr12:48488920	G/A	cg24011408	chr12:48396354	COL2A1	-0.47	-5.34	-0.33	2.22e-7	Lung cancer;
SARC	cis	rs9807989	0.507	rs6749014	chr2:103006448	C/T	cg03938978	chr2:103052716	IL18RAP	0.32	5.16	0.32	5.28e-7	Asthma;
SARC	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg15847926	chr7:2749597	AMZ1	0.31	5.04	0.31	9.41e-7	Height;
SARC	cis	rs9467773	0.620	rs2101581	chr6:26622769	G/T	cg12292205	chr6:26970375	C6orf41	0.41	5.12	0.32	6.38e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg04267008	chr7:1944627	MAD1L1	-0.63	-7.28	-0.43	5.24e-12	Bipolar disorder and schizophrenia;
SARC	cis	rs2916247	1.000	rs9297902	chr8:93036884	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.58	-6.03	-0.37	6.49e-9	Intelligence (multi-trait analysis);
SARC	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg09323728	chr8:95962352	TP53INP1	-0.3	-4.93	-0.31	1.53e-6	Type 2 diabetes;
SARC	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg18876405	chr7:65276391	NA	0.46	5.25	0.33	3.41e-7	Aortic root size;
SARC	cis	rs6866344	0.598	rs11742176	chr5:178147931	C/T	cg03877680	chr5:178157825	ZNF354A	1.05	13.98	0.68	1.13e-32	Neutrophil percentage of white cells;
SARC	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg16132339	chr22:24313637	DDTL;DDT	0.42	5.47	0.34	1.19e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7568458	0.811	rs1446668	chr2:85764960	G/T	cg17127132	chr2:85788382	GGCX	0.42	5.71	0.35	3.34e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs2742234	0.541	rs11238481	chr10:43719286	A/G	cg15436174	chr10:43711423	RASGEF1A	0.43	5.07	0.32	8.1e-7	Hirschsprung disease;
SARC	cis	rs11122272	0.735	rs2250719	chr1:231486208	G/A	cg06096015	chr1:231504339	EGLN1	0.38	5.64	0.35	4.9e-8	Hemoglobin concentration;
SARC	cis	rs826838	1.000	rs826886	chr12:39095797	A/G	cg26384229	chr12:38710491	ALG10B	0.76	11.56	0.6	9.97e-25	Heart rate;
SARC	cis	rs4664308	1.000	rs16844715	chr2:160915106	A/G	cg03641300	chr2:160917029	PLA2R1	0.69	9.59	0.53	1.44e-18	Idiopathic membranous nephropathy;
SARC	cis	rs2295359	1.000	rs11465754	chr1:67631431	A/G	cg11235152	chr1:67600687	NA	0.46	6.99	0.42	2.94e-11	Psoriasis;
SARC	trans	rs13325613	0.748	rs114115904	chr3:46268664	C/T	cg12387106	chr12:133178249	NA	0.85	6.5	0.39	4.85e-10	Monocyte count;
SARC	trans	rs61931739	0.679	rs10844831	chr12:34311245	G/T	cg26384229	chr12:38710491	ALG10B	0.63	8.31	0.48	7.71e-15	Morning vs. evening chronotype;
SARC	cis	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg14541582	chr5:601475	NA	-0.4	-4.8	-0.3	2.89e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg02463440	chr8:22132932	PIWIL2	0.47	6.66	0.4	1.97e-10	Hypertriglyceridemia;
SARC	cis	rs9462027	0.628	rs9469894	chr6:34774725	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-6.0	-0.37	7.68e-9	Systemic lupus erythematosus;
SARC	cis	rs8072100	0.676	rs9905308	chr17:45409386	T/A	cg08085267	chr17:45401833	C17orf57	-0.54	-6.59	-0.4	2.85e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs9815354	0.812	rs73071236	chr3:41992042	A/G	cg03022575	chr3:42003672	ULK4	0.7	6.07	0.37	5.24e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg04166393	chr7:2884313	GNA12	0.67	7.97	0.46	6.95e-14	Height;
SARC	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg18876405	chr7:65276391	NA	0.41	4.81	0.3	2.73e-6	Aortic root size;
SARC	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg19223190	chr17:80058835	NA	0.44	6.19	0.38	2.67e-9	Blood metabolite levels;
SARC	cis	rs11098499	0.863	rs11736416	chr4:120431661	C/T	cg09307838	chr4:120376055	NA	0.9	12.13	0.62	1.43e-26	Corneal astigmatism;
SARC	cis	rs9906944	0.933	rs9906710	chr17:47091283	C/A	cg16584676	chr17:46985605	UBE2Z	-0.44	-5.37	-0.33	1.86e-7	Intelligence (multi-trait analysis);Body fat percentage;
SARC	cis	rs73206853	0.686	rs7139314	chr12:110923871	G/A	cg10860002	chr12:110842031	ANAPC7	0.6	4.88	0.3	1.95e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs1865760	1.000	rs9467636	chr6:25919549	A/C	cg16482183	chr6:26056742	HIST1H1C	0.51	6.31	0.38	1.37e-9	Height;
SARC	cis	rs4803468	0.967	rs3826713	chr19:41892269	C/T	cg08477640	chr19:41863820	B9D2	0.44	5.66	0.35	4.39e-8	Height;
SARC	cis	rs7806994	1	rs7806994	chr7:56139505	A/T	cg14187409	chr7:56174376	CHCHD2	0.76	7.63	0.45	6.01e-13	PR interval in Tripanosoma cruzi seropositivity;
SARC	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg03647317	chr4:187891568	NA	0.37	5.22	0.32	3.88e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.54e-6	Depression;
SARC	cis	rs5167	0.534	rs56803710	chr19:45481884	C/T	cg10169327	chr19:45448959	APOC2	0.33	4.86	0.3	2.18e-6	Blood protein levels;
SARC	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg00933542	chr6:150070202	PCMT1	0.31	5.36	0.33	2.04e-7	Lung cancer;
SARC	cis	rs7178572	0.568	rs11857294	chr15:77596725	C/T	cg22256960	chr15:77711686	NA	-0.53	-5.78	-0.35	2.33e-8	Type 2 diabetes;
SARC	cis	rs4919694	0.901	rs10509763	chr10:104776391	G/A	cg04362960	chr10:104952993	NT5C2	0.65	5.48	0.34	1.09e-7	Arsenic metabolism;
SARC	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg07414643	chr4:187882934	NA	-0.48	-7.06	-0.42	1.84e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs8044995	0.501	rs73613999	chr16:68390099	C/A	cg09835421	chr16:68378352	PRMT7	-0.65	-6.18	-0.38	2.86e-9	Schizophrenia;
SARC	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg24060327	chr5:131705240	SLC22A5	-0.72	-8.77	-0.5	3.82e-16	Breast cancer;
SARC	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg12311346	chr5:56204834	C5orf35	-0.57	-5.3	-0.33	2.68e-7	Type 2 diabetes;
SARC	cis	rs897080	0.552	rs1085442	chr2:44635454	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.59	6.97	0.42	3.25e-11	Height;
SARC	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg05861140	chr6:150128134	PCMT1	-0.41	-5.34	-0.33	2.19e-7	Lung cancer;
SARC	cis	rs273218	0.573	rs11742692	chr5:53343576	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.87	-9.44	-0.53	3.97e-18	Migraine;
SARC	cis	rs3087591	0.960	rs2905793	chr17:29470072	C/T	cg24425628	chr17:29625626	OMG;NF1	0.57	7.21	0.43	7.97e-12	Hip circumference;
SARC	trans	rs66573146	0.831	rs1048009	chr4:6988677	G/A	cg07817883	chr1:32538562	TMEM39B	1.08	7.35	0.43	3.28e-12	Granulocyte percentage of myeloid white cells;
SARC	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg20607798	chr8:58055168	NA	0.58	5.57	0.34	6.9e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg24997174	chr8:11141931	MTMR9	0.5	6.51	0.39	4.45e-10	Chemerin levels;
SARC	cis	rs6912958	0.630	rs9450726	chr6:88236728	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-6.51	-0.39	4.57e-10	Monocyte percentage of white cells;
SARC	cis	rs7589728	1.000	rs12473740	chr2:88527647	A/G	cg04511125	chr2:88470314	THNSL2	0.64	5.87	0.36	1.47e-8	Plasma clusterin levels;
SARC	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg01341218	chr17:43662625	NA	1.01	11.39	0.6	3.48e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.8	10.39	0.56	5.13e-21	Prudent dietary pattern;
SARC	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.8	11.98	0.62	4.34e-26	Menarche (age at onset);
SARC	cis	rs910316	0.726	rs61979167	chr14:75663610	C/T	cg11812906	chr14:75593930	NEK9	-0.73	-9.7	-0.54	6.52e-19	Height;
SARC	cis	rs7772486	0.754	rs6570703	chr6:145957052	C/T	cg23711669	chr6:146136114	FBXO30	0.77	12.2	0.62	8.53e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7582720	1.000	rs72932588	chr2:203883193	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	7.23	0.43	6.7e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg04772025	chr11:68637568	NA	0.53	6.5	0.39	4.7e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7474896	0.616	rs2505239	chr10:38440765	A/G	cg25427524	chr10:38739819	LOC399744	-0.52	-5.61	-0.35	5.68e-8	Obesity (extreme);
SARC	cis	rs9611519	1.000	rs3818003	chr22:41609690	C/T	cg03806693	chr22:41940476	POLR3H	-0.52	-6.55	-0.39	3.65e-10	Neuroticism;
SARC	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg27266027	chr21:40555129	PSMG1	-0.5	-5.5	-0.34	9.74e-8	Cognitive function;
SARC	cis	rs4481887	0.893	rs10888355	chr1:248457180	G/A	cg00666640	chr1:248458726	OR2T12	0.36	5.95	0.36	9.69e-9	Common traits (Other);
SARC	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg01238044	chr22:24384105	GSTT1	-0.8	-10.8	-0.58	2.62e-22	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg23262073	chr20:60523788	NA	-0.39	-5.63	-0.35	5.17e-8	Body mass index;
SARC	cis	rs4372836	0.543	rs10204329	chr2:28998077	C/G	cg09522027	chr2:28974177	PPP1CB	0.37	4.86	0.3	2.2e-6	Body mass index;
SARC	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg11764359	chr7:65958608	NA	0.86	12.36	0.63	2.63e-27	Aortic root size;
SARC	cis	rs2120243	0.504	rs114107407	chr3:157062635	G/A	cg24825693	chr3:157122686	VEPH1	-0.38	-5.34	-0.33	2.19e-7	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg16339924	chr4:17578868	LAP3	0.66	8.76	0.5	4e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs11874712	0.933	rs8097521	chr18:43666952	C/A	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.46	5.5	0.34	1.02e-7	Migraine - clinic-based;
SARC	trans	rs6695352	0.802	rs12026786	chr1:214969949	C/T	ch.22.243204R	chr22:25331023	NA	-0.48	-6.52	-0.39	4.32e-10	Migraine without aura;
SARC	cis	rs7539409	0.833	rs2057083	chr1:84269942	T/G	cg10977910	chr1:84465055	TTLL7	0.56	4.85	0.3	2.29e-6	Alzheimer's disease;
SARC	cis	rs78487399	0.808	rs13414140	chr2:43671176	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.54	-4.85	-0.3	2.29e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.59	7.0	0.42	2.64e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9486715	0.867	rs9384628	chr6:96960232	T/C	cg18709589	chr6:96969512	KIAA0776	0.59	7.33	0.43	3.65e-12	Headache;
SARC	cis	rs9911578	1.000	rs2643119	chr17:56827760	G/T	cg05425664	chr17:57184151	TRIM37	-0.66	-8.17	-0.47	1.99e-14	Intelligence (multi-trait analysis);
SARC	cis	rs1008375	1.000	rs7661631	chr4:17679751	T/C	cg02297831	chr4:17616191	MED28	-0.45	-5.68	-0.35	4.09e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg18876405	chr7:65276391	NA	-0.43	-4.72	-0.3	4.13e-6	Aortic root size;
SARC	trans	rs9532669	0.963	rs9532662	chr13:41500351	A/C	cg13663190	chr2:73461428	CCT7;C2orf7	0.49	6.41	0.39	7.82e-10	Cervical cancer;
SARC	cis	rs829883	0.738	rs249846	chr12:98868739	T/C	cg25150519	chr12:98850993	NA	0.85	13.77	0.67	5.78e-32	Colorectal adenoma (advanced);
SARC	cis	rs2204008	0.657	rs8186888	chr12:38334260	T/G	cg13010199	chr12:38710504	ALG10B	0.68	8.37	0.48	5.38e-15	Bladder cancer;
SARC	cis	rs9818758	0.607	rs34784192	chr3:49274823	G/T	cg03060546	chr3:49711283	APEH	-0.54	-4.73	-0.3	3.9e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	trans	rs2727020	0.636	rs11040368	chr11:49453602	C/A	cg03929089	chr4:120376271	NA	-0.78	-11.49	-0.6	1.69e-24	Coronary artery disease;
SARC	cis	rs1538970	0.851	rs61788285	chr1:45919234	A/C	cg05343316	chr1:45956843	TESK2	0.79	8.77	0.5	3.84e-16	Platelet count;
SARC	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg20607798	chr8:58055168	NA	0.61	5.41	0.33	1.57e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs79839061	0.667	rs73207777	chr4:836046	A/G	cg07828340	chr4:882639	GAK	0.77	4.85	0.3	2.26e-6	Intelligence (multi-trait analysis);
SARC	cis	rs1865760	1.000	rs3799372	chr6:25922311	A/G	cg17691542	chr6:26056736	HIST1H1C	0.57	6.98	0.42	3.05e-11	Height;
SARC	cis	rs6546550	0.935	rs2872075	chr2:70068635	G/T	cg02498382	chr2:70120550	SNRNP27	-0.4	-6.68	-0.4	1.72e-10	Prevalent atrial fibrillation;
SARC	cis	rs7223966	1.000	rs8076717	chr17:61850301	C/T	cg26338869	chr17:61819248	STRADA	-0.47	-4.96	-0.31	1.38e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs17666538	0.901	rs73177064	chr8:585293	C/G	cg02524346	chr8:600233	NA	-0.94	-7.06	-0.42	1.89e-11	IgG glycosylation;
SARC	cis	rs1113500	0.933	rs10785834	chr1:108639101	A/C	cg06207961	chr1:108661230	NA	0.45	5.93	0.36	1.07e-8	Growth-regulated protein alpha levels;
SARC	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg02725872	chr8:58115012	NA	-0.36	-6.12	-0.37	3.91e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs921968	0.541	rs523937	chr2:219437596	G/C	cg02176678	chr2:219576539	TTLL4	0.47	7.13	0.42	1.28e-11	Mean corpuscular hemoglobin concentration;
SARC	cis	rs6138458	1.000	rs227621	chr20:24910528	A/C	cg26195577	chr20:24973756	C20orf3	0.88	9.75	0.54	4.69e-19	Blood protein levels;
SARC	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg22920501	chr2:26401640	FAM59B	-0.57	-7.45	-0.44	1.82e-12	Gut microbiome composition (summer);
SARC	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg18357526	chr6:26021779	HIST1H4A	0.65	8.01	0.46	5.63e-14	Intelligence (multi-trait analysis);
SARC	cis	rs778371	0.676	rs4973563	chr2:233716421	C/T	cg16596103	chr2:233749413	NGEF	0.33	4.91	0.31	1.7e-6	Schizophrenia;
SARC	cis	rs7582180	0.764	rs13001423	chr2:100925340	A/G	cg14675211	chr2:100938903	LONRF2	0.54	7.84	0.46	1.61e-13	Intelligence (multi-trait analysis);
SARC	trans	rs10746997	0.617	rs7846740	chr9:78853612	C/T	cg22374213	chr18:67136976	DOK6	0.38	6.27	0.38	1.77e-9	Response to fenofibrate (adiponectin levels);
SARC	trans	rs3734266	0.702	rs6908462	chr6:34673149	A/G	cg08157914	chr7:2646478	IQCE	-0.49	-6.42	-0.39	7.62e-10	Systemic lupus erythematosus;
SARC	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg07701084	chr6:150067640	NUP43	-0.39	-5.06	-0.31	8.46e-7	Lung cancer;
SARC	cis	rs6088590	0.965	rs6058108	chr20:33288655	A/G	cg06115741	chr20:33292138	TP53INP2	0.49	5.94	0.36	1.02e-8	Coronary artery disease;
SARC	cis	rs7666738	0.791	rs1967978	chr4:98966152	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs61935443	0.666	rs11107780	chr12:95299142	G/A	cg21533806	chr12:95267307	NA	0.67	7.47	0.44	1.6e-12	Schizophrenia;
SARC	cis	rs1707322	0.896	rs785512	chr1:46534543	A/G	cg03146154	chr1:46216737	IPP	-0.47	-5.55	-0.34	7.91e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs16922576	0.623	rs2093446	chr9:5230371	G/C	cg02405213	chr9:5042618	JAK2	-0.42	-4.92	-0.31	1.67e-6	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs73206853	0.764	rs67715513	chr12:110562910	G/A	cg10860002	chr12:110842031	ANAPC7	0.65	5.28	0.33	2.93e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs2820315	0.505	rs10800792	chr1:201811144	G/A	cg06775570	chr1:201857621	SHISA4	0.33	5.53	0.34	8.68e-8	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
SARC	cis	rs9399135	0.967	rs6908512	chr6:135367757	A/G	cg24558204	chr6:135376177	HBS1L	0.46	6.18	0.38	2.88e-9	Red blood cell count;
SARC	cis	rs9660992	0.573	rs1172158	chr1:205208948	G/A	cg21643547	chr1:205240462	TMCC2	-0.6	-7.83	-0.46	1.76e-13	Mean corpuscular volume;Mean platelet volume;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg25091829	chr6:116601170	DSE;TSPYL1	-0.54	-6.47	-0.39	5.79e-10	Breast cancer;
SARC	cis	rs9916302	0.718	rs10445306	chr17:37591422	A/G	cg07936489	chr17:37558343	FBXL20	-0.7	-9.15	-0.51	2.94e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs7084402	0.967	rs7098606	chr10:60277089	C/T	cg07615347	chr10:60278583	BICC1	-0.59	-8.54	-0.49	1.76e-15	Refractive error;
SARC	cis	rs9790314	0.905	rs6774276	chr3:160941318	C/T	cg04691961	chr3:161091175	C3orf57	-0.74	-10.65	-0.57	7.73e-22	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg21724239	chr8:58056113	NA	0.6	5.85	0.36	1.64e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg26818010	chr10:134567672	INPP5A	-0.58	-6.53	-0.39	4.11e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs473651	0.935	rs1103770	chr2:239339281	G/C	cg00800569	chr2:239229395	TRAF3IP1	0.64	6.84	0.41	6.89e-11	Multiple system atrophy;
SARC	cis	rs7666738	0.791	rs34152299	chr4:98929862	G/C	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9393777	0.513	rs13195210	chr6:26646521	C/T	cg12826209	chr6:26865740	GUSBL1	0.66	5.95	0.36	9.98e-9	Intelligence (multi-trait analysis);
SARC	cis	rs67460515	0.892	rs11710489	chr3:161093332	G/A	cg17135325	chr3:160939158	NMD3	0.6	7.5	0.44	1.31e-12	Parkinson's disease;
SARC	cis	rs9814567	1.000	rs62269547	chr3:134214042	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-7.03	-0.42	2.3e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs56283067	0.887	rs7765371	chr6:44777204	G/A	cg18551225	chr6:44695536	NA	-0.36	-4.93	-0.31	1.54e-6	Total body bone mineral density;
SARC	cis	rs11871801	0.517	rs10454087	chr17:40735641	C/T	cg14558262	chr17:40713999	COASY	0.5	5.57	0.34	6.9e-8	Crohn's disease;
SARC	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.78	5.72	0.35	3.26e-8	Initial pursuit acceleration;
SARC	cis	rs7523050	0.730	rs12079547	chr1:109469314	A/C	cg08274380	chr1:109419600	GPSM2	1.2	9.8	0.54	3.41e-19	Fat distribution (HIV);
SARC	cis	rs9329221	0.905	rs17765901	chr8:10249480	G/T	cg21775007	chr8:11205619	TDH	-0.4	-4.89	-0.31	1.84e-6	Neuroticism;
SARC	cis	rs9291683	0.546	rs10939672	chr4:10052136	A/G	cg11266682	chr4:10021025	SLC2A9	0.4	7.06	0.42	1.87e-11	Bone mineral density;
SARC	cis	rs79349575	0.783	rs832410	chr17:46972865	C/T	cg16584676	chr17:46985605	UBE2Z	0.55	6.64	0.4	2.13e-10	Type 2 diabetes;
SARC	trans	rs2727020	0.521	rs10839299	chr11:49573981	C/T	cg15704280	chr7:45808275	SEPT13	-0.72	-8.25	-0.48	1.2e-14	Coronary artery disease;
SARC	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg00684032	chr4:1343700	KIAA1530	0.39	5.52	0.34	8.95e-8	Obesity-related traits;
SARC	cis	rs11098499	0.863	rs3736115	chr4:120488703	A/G	cg09307838	chr4:120376055	NA	-0.85	-11.6	-0.6	7.64e-25	Corneal astigmatism;
SARC	cis	rs10782582	0.609	rs5745347	chr1:76274520	C/T	cg10523679	chr1:76189770	ACADM	0.43	5.3	0.33	2.66e-7	Daytime sleep phenotypes;
SARC	cis	rs10791097	0.694	rs4459316	chr11:130756176	T/C	cg09137382	chr11:130731461	NA	0.31	4.73	0.3	3.93e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs6456156	0.586	rs9459853	chr6:167465774	C/A	cg07741184	chr6:167504864	NA	0.34	6.61	0.4	2.56e-10	Primary biliary cholangitis;
SARC	cis	rs2120243	0.508	rs12492874	chr3:157113227	C/A	cg01018701	chr3:157155998	VEPH1;PTX3	0.39	5.07	0.32	8.25e-7	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs4595586	0.525	rs10506132	chr12:39404599	C/T	cg26384229	chr12:38710491	ALG10B	0.51	6.15	0.37	3.33e-9	Morning vs. evening chronotype;
SARC	cis	rs2380220	0.872	rs4546494	chr6:95990626	A/C	cg23517279	chr6:96025343	MANEA	0.5	5.38	0.33	1.85e-7	Behavioural disinhibition (generation interaction);
SARC	cis	rs262150	0.501	rs1062610	chr7:158821175	C/T	cg04111992	chr7:158790115	NA	-0.35	-4.81	-0.3	2.71e-6	Facial morphology (factor 20);
SARC	trans	rs9329221	0.736	rs11250002	chr8:10257041	T/G	cg06636001	chr8:8085503	FLJ10661	0.59	7.3	0.43	4.47e-12	Neuroticism;
SARC	cis	rs908922	0.676	rs11205032	chr1:152527690	A/G	cg09873164	chr1:152488093	CRCT1	0.61	7.96	0.46	7.66e-14	Hair morphology;
SARC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.69	9.42	0.53	4.49e-18	Lymphocyte counts;
SARC	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg21724239	chr8:58056113	NA	-0.61	-5.67	-0.35	4.28e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs763121	0.819	rs8137829	chr22:39061030	G/A	cg21395723	chr22:39101663	GTPBP1	0.58	6.43	0.39	7.23e-10	Menopause (age at onset);
SARC	cis	rs1008375	1.000	rs2315556	chr4:17670861	T/C	cg02297831	chr4:17616191	MED28	0.43	5.42	0.33	1.47e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7937890	1.000	rs2970335	chr11:14325401	A/C	cg02886208	chr11:14281011	SPON1	-0.35	-4.89	-0.3	1.91e-6	Mitochondrial DNA levels;
SARC	cis	rs79349575	0.721	rs1008834	chr17:46968008	G/C	cg07967210	chr17:47022446	SNF8	0.39	4.86	0.3	2.15e-6	Type 2 diabetes;
SARC	cis	rs17376456	0.825	rs12153021	chr5:93073913	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.71	6.3	0.38	1.48e-9	Diabetic retinopathy;
SARC	cis	rs6495122	0.699	rs1378940	chr15:75083494	C/A	cg14664628	chr15:75095509	CSK	-0.8	-10.38	-0.56	5.43e-21	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg11644478	chr21:40555479	PSMG1	1.03	14.11	0.68	4.35e-33	Cognitive function;
SARC	cis	rs67311347	0.544	rs9864601	chr3:40345318	C/T	cg24209194	chr3:40518798	ZNF619	0.47	6.38	0.39	9.19e-10	Renal cell carcinoma;
SARC	cis	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg05084668	chr3:125655381	ALG1L	-0.5	-5.25	-0.33	3.42e-7	Blood pressure (smoking interaction);
SARC	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg24549020	chr5:56110836	MAP3K1	-0.56	-4.94	-0.31	1.46e-6	Initial pursuit acceleration;
SARC	trans	rs61931739	0.963	rs3912355	chr12:34079616	A/G	cg26384229	chr12:38710491	ALG10B	0.57	7.0	0.42	2.7e-11	Morning vs. evening chronotype;
SARC	cis	rs644799	0.965	rs10831430	chr11:95509638	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.88	13.76	0.67	6.06e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs3540	0.512	rs3930162	chr15:91075129	C/T	cg22089800	chr15:90895588	ZNF774	-0.58	-7.37	-0.44	2.86e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs57506017	0.585	rs1054169	chr7:12273496	G/A	cg23422036	chr7:12250390	TMEM106B	0.46	5.96	0.36	9.38e-9	Neuroticism;
SARC	cis	rs17270561	0.609	rs9393659	chr6:25731358	T/C	cg16482183	chr6:26056742	HIST1H1C	0.43	5.25	0.33	3.47e-7	Iron status biomarkers;
SARC	trans	rs637571	0.522	rs606978	chr11:65711517	A/C	cg17712092	chr4:129076599	LARP1B	0.69	9.32	0.52	9.24e-18	Eosinophil percentage of white cells;
SARC	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg14159672	chr1:205819179	PM20D1	-0.48	-5.55	-0.34	7.81e-8	White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs72945132	0.522	rs4367974	chr11:70248900	C/T	cg05964544	chr11:70165517	PPFIA1	-0.58	-5.67	-0.35	4.24e-8	Coronary artery disease;
SARC	trans	rs61931739	0.500	rs11052966	chr12:34019826	C/T	cg13010199	chr12:38710504	ALG10B	0.64	8.64	0.49	9.09e-16	Morning vs. evening chronotype;
SARC	cis	rs6088580	0.619	rs1205335	chr20:32927507	C/T	cg24642439	chr20:33292090	TP53INP2	-0.64	-8.23	-0.47	1.33e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs67460515	0.892	rs2054710	chr3:161090616	C/T	cg17135325	chr3:160939158	NMD3	0.61	7.53	0.44	1.1e-12	Parkinson's disease;
SARC	cis	rs4253772	0.591	rs9615934	chr22:46682310	C/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.63	4.86	0.3	2.16e-6	LDL cholesterol;Cholesterol, total;
SARC	cis	rs13191362	1.000	rs35103567	chr6:163183400	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.43	5.36	0.33	2.05e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs3923518	1.000	rs4676477	chr3:38881195	T/C	cg15678707	chr3:39149194	GORASP1;TTC21A	0.46	4.84	0.3	2.31e-6	Migraine;
SARC	cis	rs10504229	0.679	rs16921606	chr8:58034477	A/C	cg22535103	chr8:58192502	C8orf71	-0.51	-5.2	-0.32	4.37e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg17376030	chr22:41985996	PMM1	-0.8	-10.26	-0.56	1.25e-20	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs3741404	0.791	rs2282491	chr11:63918373	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.92	12.56	0.64	5.71e-28	Platelet count;
SARC	cis	rs6714710	0.603	rs34502870	chr2:98405929	A/G	cg26665480	chr2:98280029	ACTR1B	0.49	6.53	0.39	4.04e-10	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs739401	0.572	rs12276060	chr11:3015572	A/T	cg05729581	chr11:3078854	CARS	-0.53	-6.94	-0.41	3.9e-11	Longevity;
SARC	cis	rs524281	0.861	rs3825067	chr11:65878419	A/G	cg14036092	chr11:66035641	RAB1B	0.51	5.45	0.34	1.28e-7	Electroencephalogram traits;
SARC	cis	rs57506017	0.585	rs1468801	chr7:12276045	G/C	cg23422036	chr7:12250390	TMEM106B	0.47	6.07	0.37	5.1e-9	Neuroticism;
SARC	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.73	8.75	0.5	4.36e-16	Height;
SARC	cis	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg11608241	chr8:8085544	FLJ10661	0.44	5.32	0.33	2.38e-7	Joint mobility (Beighton score);
SARC	cis	rs2635047	0.566	rs8092050	chr18:44796323	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	6.45	0.39	6.53e-10	Educational attainment;
SARC	cis	rs7766436	0.885	rs12662891	chr6:22575096	C/T	cg13666174	chr6:22585274	NA	-0.56	-6.97	-0.42	3.2e-11	Coronary artery disease;
SARC	cis	rs1707322	0.964	rs7512395	chr1:46361177	G/A	cg03146154	chr1:46216737	IPP	0.5	6.16	0.37	3.17e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs11739663	0.574	rs67276442	chr5:583918	T/C	cg09021430	chr5:549028	NA	-0.54	-10.6	-0.57	1.08e-21	Ulcerative colitis;
SARC	cis	rs9868809	0.542	rs9873726	chr3:48712367	C/T	cg12468774	chr3:49236860	CCDC36	0.48	5.08	0.32	7.61e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg11494091	chr17:61959527	GH2	0.53	7.87	0.46	1.33e-13	Prudent dietary pattern;
SARC	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg00684032	chr4:1343700	KIAA1530	0.44	6.47	0.39	5.62e-10	Obesity-related traits;
SARC	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg22903471	chr2:27725779	GCKR	-0.49	-7.33	-0.43	3.78e-12	Total body bone mineral density;
SARC	cis	rs3087591	0.708	rs2854319	chr17:29694054	G/C	cg24425628	chr17:29625626	OMG;NF1	0.43	5.42	0.33	1.48e-7	Hip circumference;
SARC	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg22875332	chr1:76189707	ACADM	0.49	6.83	0.41	7.16e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg14664628	chr15:75095509	CSK	-0.44	-5.33	-0.33	2.37e-7	Breast cancer;
SARC	cis	rs6456042	0.964	rs3127418	chr6:166538176	G/T	cg11088901	chr6:166572345	T	-0.35	-5.05	-0.31	9.11e-7	Asthma;
SARC	cis	rs6500395	0.962	rs9921737	chr16:48589873	G/T	cg04672837	chr16:48644449	N4BP1	0.42	5.59	0.34	6.31e-8	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs5750830	0.620	rs1007337	chr22:39781585	C/T	cg24399712	chr22:39784796	NA	-0.42	-5.56	-0.34	7.3e-8	Intelligence (multi-trait analysis);
SARC	cis	rs6918586	0.658	rs198821	chr6:26123629	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.45	-5.74	-0.35	2.89e-8	Schizophrenia;
SARC	cis	rs1153858	0.895	rs12593402	chr15:45617392	G/A	cg26924012	chr15:45694286	SPATA5L1	0.77	10.42	0.56	4.04e-21	Homoarginine levels;
SARC	cis	rs6500602	0.893	rs4786490	chr16:4491190	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.31	-5.09	-0.32	7.43e-7	Schizophrenia;
SARC	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg04277193	chr17:41438351	NA	0.43	4.71	0.3	4.19e-6	Menopause (age at onset);
SARC	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.95	-15.47	-0.71	1.34e-37	Chronic sinus infection;
SARC	cis	rs16854884	1.000	rs35887108	chr3:143780632	C/T	cg06585982	chr3:143692056	C3orf58	0.54	6.6	0.4	2.69e-10	Economic and political preferences (feminism/equality);
SARC	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg05313129	chr8:58192883	C8orf71	-0.62	-6.34	-0.38	1.18e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs6601450	0.547	rs10105843	chr8:10197863	A/G	cg06636001	chr8:8085503	FLJ10661	0.57	7.32	0.43	4.12e-12	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs55823223	0.564	rs936396	chr17:73846829	C/G	cg10935138	chr17:73851978	WBP2	0.46	5.12	0.32	6.37e-7	Psoriasis;
SARC	cis	rs9902453	0.904	rs7225686	chr17:28356744	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.54	-7.09	-0.42	1.57e-11	Coffee consumption (cups per day);
SARC	cis	rs6500602	0.561	rs62039231	chr16:4519548	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.35	6.02	0.37	6.74e-9	Schizophrenia;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg07840454	chr19:57968785	VN1R1	0.48	6.31	0.38	1.36e-9	Thyroid stimulating hormone;
SARC	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg06212747	chr3:49208901	KLHDC8B	0.79	11.74	0.61	2.66e-25	Menarche (age at onset);
SARC	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg21782813	chr7:2030301	MAD1L1	0.45	6.86	0.41	6e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs79149102	0.579	rs73438569	chr15:75354486	T/A	cg00629941	chr15:75287862	SCAMP5	-0.71	-5.25	-0.33	3.47e-7	Lung cancer;
SARC	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg04944784	chr2:26401820	FAM59B	0.61	7.92	0.46	9.87e-14	Gut microbiome composition (summer);
SARC	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.47	0.39	5.75e-10	Bipolar disorder;
SARC	cis	rs9325144	0.560	rs11183150	chr12:38674698	A/G	cg13010199	chr12:38710504	ALG10B	-0.56	-6.95	-0.41	3.58e-11	Morning vs. evening chronotype;
SARC	cis	rs7666738	0.649	rs28865589	chr4:98954279	C/A	cg05340658	chr4:99064831	C4orf37	0.65	8.76	0.5	3.98e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg14893161	chr1:205819251	PM20D1	0.63	8.39	0.48	4.58e-15	Menarche (age at onset);
SARC	cis	rs11864453	0.647	rs2550035	chr16:72113416	C/G	cg01557791	chr16:72042693	DHODH	-0.5	-6.65	-0.4	2.11e-10	Fibrinogen levels;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg24882829	chr4:123839717	NUDT6	0.45	6.53	0.39	4.09e-10	Thyroid stimulating hormone;
SARC	cis	rs4664308	0.505	rs1037694	chr2:161028992	A/G	cg03641300	chr2:160917029	PLA2R1	-0.43	-6.05	-0.37	5.74e-9	Idiopathic membranous nephropathy;
SARC	cis	rs17666538	0.636	rs10107345	chr8:603700	G/T	cg07234876	chr8:600039	NA	0.69	5.94	0.36	1.05e-8	IgG glycosylation;
SARC	cis	rs929354	0.605	rs7806314	chr7:156946903	A/T	cg05182265	chr7:156933206	UBE3C	-0.34	-5.19	-0.32	4.49e-7	Body mass index;
SARC	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg23758822	chr17:41437982	NA	0.87	10.83	0.58	2.05e-22	Menopause (age at onset);
SARC	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg21171335	chr12:122356390	WDR66	-0.38	-6.18	-0.38	2.8e-9	Mean corpuscular volume;
SARC	cis	rs2486288	0.656	rs11632778	chr15:45551056	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.45	-5.57	-0.34	7.07e-8	Glomerular filtration rate;
SARC	cis	rs1153858	0.943	rs28605551	chr15:45641720	C/T	cg26924012	chr15:45694286	SPATA5L1	0.75	10.34	0.56	7.26e-21	Homoarginine levels;
SARC	cis	rs36051895	0.659	rs67006981	chr9:5070401	A/G	cg02405213	chr9:5042618	JAK2	-0.45	-5.26	-0.33	3.34e-7	Pediatric autoimmune diseases;
SARC	cis	rs7103648	0.932	rs7104036	chr11:47462140	A/G	cg20307385	chr11:47447363	PSMC3	0.88	14.78	0.7	2.48e-35	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs7474896	0.583	rs11011347	chr10:38019264	G/A	cg25427524	chr10:38739819	LOC399744	-0.5	-5.95	-0.36	9.59e-9	Obesity (extreme);
SARC	cis	rs11122272	0.705	rs2572260	chr1:231486189	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs240764	0.658	rs4840147	chr6:101182323	T/C	cg09795085	chr6:101329169	ASCC3	-0.49	-6.42	-0.39	7.54e-10	Neuroticism;
SARC	trans	rs11039798	0.512	rs28453037	chr11:49006929	C/A	cg15704280	chr7:45808275	SEPT13	0.66	6.89	0.41	5.12e-11	Axial length;
SARC	cis	rs6963495	0.818	rs55794529	chr7:105165747	T/C	cg13798780	chr7:105162888	PUS7	0.6	5.56	0.34	7.22e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs933688	1.000	rs6869717	chr5:90694797	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.06	13.32	0.66	1.81e-30	Smoking behavior;
SARC	cis	rs6701037	1.000	rs6683533	chr1:175125440	G/A	cg00321850	chr1:175162397	KIAA0040	-0.34	-5.02	-0.31	1.01e-6	Alcohol dependence;
SARC	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg16606324	chr3:10149918	C3orf24	0.49	4.82	0.3	2.56e-6	Alzheimer's disease;
SARC	cis	rs28602670	1	rs28602670	chr15:78768167	C/G	cg24631222	chr15:78858424	CHRNA5	0.75	9.17	0.51	2.59e-17	Post bronchodilator FEV1;
SARC	cis	rs365132	1.000	rs2292256	chr5:176333126	C/T	cg16309518	chr5:176445507	NA	-0.45	-5.97	-0.36	8.59e-9	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs73195822	0.667	rs57302533	chr12:111245613	A/C	cg10860002	chr12:110842031	ANAPC7	0.66	4.91	0.31	1.69e-6	Itch intensity from mosquito bite;
SARC	cis	rs7551222	0.716	rs10900601	chr1:204572050	A/G	cg20240347	chr1:204465584	NA	-0.28	-4.78	-0.3	3.13e-6	Schizophrenia;
SARC	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg09373136	chr17:61933544	TCAM1	0.36	4.91	0.31	1.72e-6	Prudent dietary pattern;
SARC	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.42	-5.37	-0.33	1.88e-7	Lymphocyte counts;
SARC	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg13607699	chr17:42295918	UBTF	-0.69	-8.51	-0.49	2.13e-15	Total body bone mineral density;
SARC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.45	-7.25	-0.43	5.93e-12	Longevity;Endometriosis;
SARC	cis	rs735539	0.521	rs7984503	chr13:21448486	T/C	cg16922012	chr13:21400325	XPO4	-0.44	-6.0	-0.37	7.52e-9	Dental caries;
SARC	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg16405210	chr4:1374714	KIAA1530	-0.46	-5.41	-0.33	1.52e-7	Obesity-related traits;
SARC	cis	rs910316	1.000	rs910316	chr14:75626042	A/C	cg08847533	chr14:75593920	NEK9	0.92	14.25	0.68	1.43e-33	Height;
SARC	cis	rs3813567	0.759	rs12594550	chr15:78959037	C/G	cg24631222	chr15:78858424	CHRNA5	-0.53	-5.15	-0.32	5.66e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
SARC	cis	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg09021430	chr5:549028	NA	-0.43	-5.54	-0.34	8.24e-8	Obesity-related traits;
SARC	cis	rs7027203	0.964	rs6479512	chr9:96556985	G/A	cg14598338	chr9:96623480	NA	0.52	6.93	0.41	4e-11	DNA methylation (variation);
SARC	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg12463550	chr7:65579703	CRCP	0.48	5.7	0.35	3.66e-8	Aortic root size;
SARC	trans	rs3780486	0.846	rs7850878	chr9:33126570	A/G	cg20290983	chr6:43655470	MRPS18A	1.14	22.73	0.83	4.87e-61	IgG glycosylation;
SARC	cis	rs10979	1.000	rs34960207	chr6:143886398	C/T	cg25407410	chr6:143891975	LOC285740	-0.6	-7.97	-0.46	7.24e-14	Hypospadias;
SARC	cis	rs6570726	0.846	rs973856	chr6:145781916	C/T	cg23711669	chr6:146136114	FBXO30	-0.77	-12.1	-0.62	1.86e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9467773	1.000	rs1321479	chr6:26501897	C/T	cg11502198	chr6:26597334	ABT1	-0.45	-5.47	-0.34	1.15e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1843834	0.611	rs1058360	chr2:225449242	A/T	cg22455342	chr2:225449267	CUL3	0.68	8.62	0.49	1.06e-15	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs11098499	0.866	rs6847778	chr4:120293582	A/G	cg09307838	chr4:120376055	NA	0.82	11.51	0.6	1.45e-24	Corneal astigmatism;
SARC	cis	rs7568458	0.660	rs2289972	chr2:85766545	C/T	cg02493740	chr2:85810744	VAMP5	-0.4	-5.07	-0.32	8.14e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs548181	0.736	rs540436	chr11:125512619	A/G	cg03464685	chr11:125439445	EI24	0.84	8.4	0.48	4.54e-15	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs959260	0.623	rs7207618	chr17:73321687	T/C	cg14668889	chr17:73230827	NUP85	-0.55	-7.06	-0.42	1.86e-11	Systemic lupus erythematosus;
SARC	cis	rs735539	0.521	rs693489	chr13:21423005	A/G	cg16922012	chr13:21400325	XPO4	-0.44	-6.08	-0.37	4.98e-9	Dental caries;
SARC	cis	rs7089973	0.604	rs11196942	chr10:116596872	G/A	cg08188268	chr10:116634841	FAM160B1	0.28	4.83	0.3	2.43e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.2	-0.52	2.12e-17	Developmental language disorder (linguistic errors);
SARC	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	0.38	4.71	0.3	4.2e-6	Tonsillectomy;
SARC	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg14773178	chr5:1868261	NA	0.33	5.32	0.33	2.47e-7	Cardiovascular disease risk factors;
SARC	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg26119090	chr2:26468346	HADHA;HADHB	0.94	13.03	0.65	1.64e-29	Mean corpuscular hemoglobin;
SARC	cis	rs2412459	0.831	rs6492924	chr15:40272391	G/A	cg01081584	chr15:40268610	EIF2AK4	-0.63	-5.83	-0.36	1.82e-8	Response to haloperidol in psychosis;
SARC	cis	rs12908161	1.000	rs12910012	chr15:85298662	T/C	cg17507749	chr15:85114479	UBE2QP1	0.55	6.22	0.38	2.33e-9	Schizophrenia;
SARC	trans	rs1814175	0.717	rs11040450	chr11:49650638	G/A	cg15704280	chr7:45808275	SEPT13	-0.92	-15.93	-0.72	3.71e-39	Height;
SARC	cis	rs3126085	0.935	rs3120660	chr1:152258701	G/T	cg26876637	chr1:152193138	HRNR	-0.46	-5.29	-0.33	2.86e-7	Atopic dermatitis;
SARC	cis	rs9911578	0.967	rs12944948	chr17:56951474	A/G	cg05425664	chr17:57184151	TRIM37	-0.65	-8.0	-0.46	5.84e-14	Intelligence (multi-trait analysis);
SARC	cis	rs2236918	1.000	rs2236919	chr1:242017731	A/G	cg17736920	chr1:242011382	EXO1	0.79	11.16	0.59	1.87e-23	Menopause (age at onset);
SARC	cis	rs765787	0.556	rs12915965	chr15:45512647	T/C	cg21132104	chr15:45694354	SPATA5L1	0.4	4.87	0.3	2.09e-6	Uric acid levels;
SARC	cis	rs2952156	0.920	rs2952152	chr17:37832735	T/C	cg00129232	chr17:37814104	STARD3	-0.69	-9.86	-0.54	2.14e-19	Asthma;
SARC	cis	rs1348850	0.793	rs13000048	chr2:178337089	C/A	cg23306229	chr2:178417860	TTC30B	0.53	6.24	0.38	2.02e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	trans	rs9929218	0.953	rs12920562	chr16:68737512	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.65	-8.33	-0.48	6.83e-15	Colorectal cancer;
SARC	cis	rs9828933	0.701	rs7621544	chr3:63928681	C/A	cg16258503	chr3:63850278	ATXN7;THOC7	-0.63	-6.0	-0.37	7.33e-9	Type 2 diabetes;
SARC	cis	rs644799	1.000	rs568668	chr11:95528209	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.7	9.55	0.53	1.87e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7772486	0.597	rs2485631	chr6:146190077	G/C	cg05347473	chr6:146136440	FBXO30	0.71	9.95	0.55	1.16e-19	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.68	9.08	0.51	4.82e-17	Menarche (age at onset);
SARC	cis	rs8180040	0.603	rs9854790	chr3:47101306	T/G	cg27129171	chr3:47204927	SETD2	0.7	9.6	0.53	1.35e-18	Colorectal cancer;
SARC	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.39	-4.94	-0.31	1.52e-6	Lymphocyte counts;
SARC	cis	rs734999	0.545	rs6698817	chr1:2564183	T/C	cg00980319	chr1:2560884	MMEL1	0.33	4.77	0.3	3.19e-6	Ulcerative colitis;
SARC	cis	rs911263	0.563	rs12883719	chr14:68810217	G/T	cg18825221	chr14:68749962	RAD51L1	0.42	7.42	0.44	2.2e-12	Primary biliary cholangitis;
SARC	cis	rs4144743	1.000	rs4541130	chr17:45321037	G/A	cg18085866	chr17:45331354	ITGB3	-0.73	-7.47	-0.44	1.62e-12	Body mass index;
SARC	cis	rs2439831	0.850	rs68079546	chr15:44136957	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	8.02	0.47	5.04e-14	Lung cancer in ever smokers;
SARC	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg18404041	chr3:52824283	ITIH1	-0.44	-6.58	-0.4	3.05e-10	Bipolar disorder;
SARC	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg13395646	chr4:1353034	KIAA1530	-0.55	-6.64	-0.4	2.23e-10	Obesity-related traits;
SARC	cis	rs8014131	0.615	rs12884576	chr14:85985203	G/A	cg10406690	chr14:85995726	FLRT2	0.41	5.22	0.32	3.96e-7	Menarche (age at onset);
SARC	cis	rs1348850	0.793	rs13000048	chr2:178337089	C/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.63	7.94	0.46	8.81e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs112591243	0.655	rs7510435	chr21:48059798	G/A	cg10657630	chr21:48055338	PRMT2	0.86	5.9	0.36	1.26e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs2153535	0.560	rs9379214	chr6:8480870	T/C	cg21535247	chr6:8435926	SLC35B3	0.56	7.03	0.42	2.23e-11	Motion sickness;
SARC	cis	rs7223966	1.000	rs9901507	chr17:61765524	G/A	cg00588841	chr17:61851480	DDX42;CCDC47	-0.59	-6.86	-0.41	6.03e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs11190604	1.000	rs10883508	chr10:102294413	G/A	cg07080220	chr10:102295463	HIF1AN	0.81	9.96	0.55	1.07e-19	Palmitoleic acid (16:1n-7) levels;
SARC	trans	rs61931739	0.500	rs6488211	chr12:34375620	A/T	cg13010199	chr12:38710504	ALG10B	-0.74	-10.06	-0.55	5.47e-20	Morning vs. evening chronotype;
SARC	cis	rs1113500	0.933	rs4590700	chr1:108638344	G/T	cg06207961	chr1:108661230	NA	0.44	5.9	0.36	1.29e-8	Growth-regulated protein alpha levels;
SARC	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg08222618	chr4:941054	TMEM175	0.47	7.31	0.43	4.29e-12	Sjögren's syndrome;
SARC	cis	rs929596	0.755	rs6742078	chr2:234672639	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.34	5.07	0.32	8.26e-7	Total bilirubin levels in HIV-1 infection;
SARC	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg10207240	chr12:122356781	WDR66	0.3	5.03	0.31	9.7e-7	Mean corpuscular volume;
SARC	cis	rs9815354	0.812	rs56183581	chr3:41848492	C/T	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9486715	0.867	rs9384585	chr6:96875664	C/T	cg06623918	chr6:96969491	KIAA0776	0.88	12.7	0.64	1.95e-28	Headache;
SARC	cis	rs9815354	1.000	rs4973991	chr3:41927273	C/T	cg03022575	chr3:42003672	ULK4	-0.56	-5.38	-0.33	1.79e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs8031584	0.541	rs1983459	chr15:31208749	C/T	cg14829155	chr15:31115871	NA	-0.4	-5.35	-0.33	2.12e-7	Huntington's disease progression;
SARC	cis	rs7513165	0.935	rs7538055	chr1:204161069	A/G	cg23788856	chr1:204159729	KISS1	-0.34	-5.24	-0.32	3.6e-7	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
SARC	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.72	10.46	0.57	2.99e-21	Menarche (age at onset);
SARC	cis	rs6570726	0.791	rs447992	chr6:145817184	C/T	cg23711669	chr6:146136114	FBXO30	0.87	14.62	0.69	8.73e-35	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4072980	0.545	rs7528185	chr1:38452059	C/T	cg12658694	chr1:38397304	INPP5B	-0.76	-8.42	-0.48	3.93e-15	Coronary artery disease;
SARC	cis	rs244731	0.959	rs3105419	chr5:176551396	G/C	cg06060754	chr5:176797920	RGS14	0.44	4.97	0.31	1.3e-6	Urate levels in lean individuals;
SARC	cis	rs910316	0.763	rs175490	chr14:75545685	A/G	cg06637938	chr14:75390232	RPS6KL1	0.53	7.39	0.44	2.66e-12	Height;
SARC	cis	rs3126085	0.935	rs72696997	chr1:152257099	A/C	cg26876637	chr1:152193138	HRNR	-0.5	-5.14	-0.32	5.95e-7	Atopic dermatitis;
SARC	cis	rs77741769	0.700	rs2701184	chr12:121353088	T/G	cg02403541	chr12:121454288	C12orf43	0.48	5.4	0.33	1.65e-7	Mean corpuscular volume;
SARC	cis	rs2235642	0.685	rs2667681	chr16:1653206	C/T	cg09065629	chr16:1709722	CRAMP1L	0.38	5.15	0.32	5.6e-7	Coronary artery disease;
SARC	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.45	5.22	0.32	3.91e-7	Renal function-related traits (BUN);
SARC	cis	rs751728	1.000	rs6904991	chr6:33732262	T/G	cg25922239	chr6:33757077	LEMD2	0.8	10.52	0.57	1.94e-21	Crohn's disease;
SARC	cis	rs12711979	0.509	rs10191674	chr2:3827891	C/T	cg17052675	chr2:3827356	NA	-0.49	-7.52	-0.44	1.21e-12	Itch intensity from mosquito bite adjusted by bite size;
SARC	cis	rs9733	0.818	rs11204695	chr1:150657011	T/G	cg15448220	chr1:150897856	SETDB1	-0.36	-4.72	-0.3	4.13e-6	Tonsillectomy;
SARC	cis	rs2933343	1.000	rs1683778	chr3:128644595	A/G	cg25356066	chr3:128598488	ACAD9	0.62	6.96	0.41	3.44e-11	IgG glycosylation;
SARC	cis	rs6500602	0.634	rs2270365	chr16:4526758	G/A	cg08645402	chr16:4508243	NA	0.45	5.88	0.36	1.42e-8	Schizophrenia;
SARC	cis	rs1018836	0.923	rs10808615	chr8:91569704	A/T	cg16814680	chr8:91681699	NA	-0.82	-12.94	-0.65	3.26e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs6540556	0.724	rs6679631	chr1:209935491	C/A	cg05527609	chr1:210001259	C1orf107	-0.58	-5.95	-0.36	9.56e-9	Red blood cell count;
SARC	cis	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg18252515	chr7:66147081	NA	-1.25	-11.12	-0.59	2.55e-23	Diabetic kidney disease;
SARC	cis	rs7546668	0.640	rs4661635	chr1:15808702	C/T	cg18192808	chr1:15853278	DNAJC16	0.44	5.07	0.32	8.22e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs548181	0.736	rs540723	chr11:125489621	A/G	cg03464685	chr11:125439445	EI24	1.02	9.92	0.55	1.39e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.39	0.44	2.61e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6964587	0.839	rs11767135	chr7:91551245	T/G	cg17063962	chr7:91808500	NA	-0.9	-13.54	-0.66	3.31e-31	Breast cancer;
SARC	cis	rs11690935	0.921	rs10200608	chr2:172597929	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.0	-16.05	-0.72	1.57e-39	Schizophrenia;
SARC	cis	rs7119	0.717	rs34981488	chr15:77723403	T/G	cg17802220	chr15:77601643	NA	-0.44	-5.74	-0.35	2.89e-8	Type 2 diabetes;
SARC	cis	rs2760061	0.626	rs672977	chr1:228120288	A/C	cg02753203	chr1:228287806	NA	-0.54	-7.53	-0.44	1.08e-12	Diastolic blood pressure;
SARC	cis	rs7027203	0.828	rs10821229	chr9:96595136	A/C	cg14598338	chr9:96623480	NA	-0.56	-8.14	-0.47	2.43e-14	DNA methylation (variation);
SARC	cis	rs7089973	0.604	rs2420069	chr10:116605103	A/G	cg08188268	chr10:116634841	FAM160B1	0.28	4.79	0.3	3.02e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs35213789	0.802	rs60359704	chr7:69344517	G/A	cg10619644	chr7:69149951	AUTS2	0.39	4.83	0.3	2.49e-6	Childhood ear infection;
SARC	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg20007245	chr22:24372913	LOC391322	-0.63	-7.98	-0.46	6.55e-14	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs4970988	0.787	rs1532770	chr1:150725335	G/T	cg15448220	chr1:150897856	SETDB1	0.48	6.2	0.38	2.61e-9	Urate levels;
SARC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg26338869	chr17:61819248	STRADA	0.78	10.59	0.57	1.24e-21	Prudent dietary pattern;
SARC	cis	rs4595586	0.545	rs1349257	chr12:39397139	A/G	cg26384229	chr12:38710491	ALG10B	0.49	6.09	0.37	4.63e-9	Morning vs. evening chronotype;
SARC	trans	rs9329221	0.736	rs34381075	chr8:10243785	C/G	cg08975724	chr8:8085496	FLJ10661	0.52	6.4	0.39	8.67e-10	Neuroticism;
SARC	cis	rs7615952	0.546	rs2979338	chr3:125343126	G/T	cg05084668	chr3:125655381	ALG1L	-0.53	-5.01	-0.31	1.1e-6	Blood pressure (smoking interaction);
SARC	cis	rs6912958	0.684	rs2787893	chr6:88387359	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.31	-0.33	2.58e-7	Monocyte percentage of white cells;
SARC	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg05313129	chr8:58192883	C8orf71	-0.55	-6.3	-0.38	1.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2070488	0.965	rs4679060	chr3:38536261	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.84	-13.36	-0.66	1.34e-30	Electrocardiographic conduction measures;
SARC	cis	rs3824867	0.879	rs10742806	chr11:47456226	T/A	cg20307385	chr11:47447363	PSMC3	0.49	5.32	0.33	2.47e-7	Mean corpuscular hemoglobin;
SARC	cis	rs13256369	0.802	rs13255789	chr8:8562791	T/C	cg17143192	chr8:8559678	CLDN23	0.52	5.84	0.36	1.77e-8	Obesity-related traits;
SARC	cis	rs1559088	0.600	rs7256470	chr19:33558085	C/A	cg17764715	chr19:33622953	WDR88	0.58	7.88	0.46	1.27e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg05084668	chr3:125655381	ALG1L	-0.49	-5.05	-0.31	8.79e-7	Blood pressure (smoking interaction);
SARC	cis	rs7084402	0.967	rs2577392	chr10:60329183	A/G	cg07615347	chr10:60278583	BICC1	0.58	8.58	0.49	1.36e-15	Refractive error;
SARC	trans	rs3780486	0.846	rs3780490	chr9:33129839	A/G	cg20290983	chr6:43655470	MRPS18A	1.15	22.78	0.83	3.27e-61	IgG glycosylation;
SARC	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg08280861	chr8:58055591	NA	0.6	5.28	0.33	2.92e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg04166393	chr7:2884313	GNA12	0.64	7.42	0.44	2.22e-12	Height;
SARC	cis	rs55871839	0.708	rs4738731	chr8:59809840	C/G	cg07426533	chr8:59803705	TOX	-0.43	-5.72	-0.35	3.3e-8	Pneumonia;
SARC	cis	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg06289844	chr6:126071538	HEY2	0.35	5.67	0.35	4.19e-8	Brugada syndrome;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg00712686	chr17:46102784	NA	0.62	6.34	0.38	1.21e-9	Lung cancer in ever smokers;
SARC	cis	rs2153535	1.000	rs2153535	chr6:8369679	C/G	cg07606381	chr6:8435919	SLC35B3	-0.5	-6.3	-0.38	1.49e-9	Motion sickness;
SARC	cis	rs9581857	0.685	rs9319367	chr13:28042197	T/C	cg01674679	chr13:27998804	GTF3A	-0.64	-4.83	-0.3	2.49e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	cis	rs453301	0.719	rs34004903	chr8:8892604	C/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.89	-0.41	5.18e-11	Joint mobility (Beighton score);
SARC	cis	rs11264799	0.520	rs1885561	chr1:157548669	T/A	cg18268488	chr1:157545234	FCRL4	0.32	5.75	0.35	2.73e-8	IgA nephropathy;
SARC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	10.53	0.57	1.87e-21	Platelet count;
SARC	cis	rs710216	0.797	rs841854	chr1:43400485	C/T	cg03128534	chr1:43423976	SLC2A1	0.61	5.81	0.36	2.07e-8	Red cell distribution width;
SARC	cis	rs7481584	0.624	rs449466	chr11:3047603	C/T	cg08508325	chr11:3079039	CARS	0.23	5.13	0.32	6.14e-7	Calcium levels;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg23575668	chr22:21800832	HIC2	0.51	6.54	0.39	3.79e-10	Schizophrenia;
SARC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.58	0.57	1.3e-21	Prudent dietary pattern;
SARC	cis	rs4481887	0.927	rs10749646	chr1:248429719	A/G	cg01631408	chr1:248437212	OR2T33	0.41	5.01	0.31	1.06e-6	Common traits (Other);
SARC	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	8.63	0.49	9.42e-16	Alzheimer's disease;
SARC	cis	rs11613048	0.897	rs2351221	chr12:30335349	A/C	cg12718339	chr12:29936407	TMTC1	-0.38	-5.17	-0.32	5.04e-7	Major depressive disorder;
SARC	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg18876405	chr7:65276391	NA	-0.47	-5.27	-0.33	3.15e-7	Aortic root size;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg19461344	chr2:27485922	SLC30A3	0.51	6.63	0.4	2.32e-10	Height;
SARC	cis	rs7481584	0.603	rs399467	chr11:3072348	G/A	cg20651018	chr11:3035856	CARS	0.38	5.7	0.35	3.58e-8	Calcium levels;
SARC	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg11987759	chr7:65425863	GUSB	0.45	5.38	0.33	1.82e-7	Aortic root size;
SARC	cis	rs981844	0.775	rs1020704	chr4:154736494	C/T	cg14289246	chr4:154710475	SFRP2	0.57	6.5	0.39	4.93e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs6782228	0.606	rs2811488	chr3:128336517	C/T	cg08795948	chr3:128337044	NA	0.38	5.15	0.32	5.6e-7	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
SARC	cis	rs11098499	0.691	rs9996644	chr4:120238877	G/T	cg09307838	chr4:120376055	NA	0.84	11.54	0.6	1.15e-24	Corneal astigmatism;
SARC	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg23758822	chr17:41437982	NA	0.88	11.24	0.59	1.04e-23	Menopause (age at onset);
SARC	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg08280861	chr8:58055591	NA	0.61	5.96	0.36	9.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1580019	0.537	rs7804609	chr7:32558094	A/C	cg06627557	chr7:32535165	LSM5;AVL9	0.99	18.04	0.76	4e-46	Cognitive ability;
SARC	cis	rs7246657	0.941	rs10418729	chr19:37737065	A/C	cg14683738	chr19:37701593	ZNF585B	0.56	5.06	0.31	8.61e-7	Coronary artery calcification;
SARC	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg04944784	chr2:26401820	FAM59B	0.48	5.77	0.35	2.45e-8	Gut microbiome composition (summer);
SARC	cis	rs17376456	1.000	rs59472588	chr5:93511981	A/G	cg21475434	chr5:93447410	FAM172A	0.92	7.97	0.46	6.94e-14	Diabetic retinopathy;
SARC	cis	rs7927592	0.913	rs7115374	chr11:68300076	G/T	cg01657329	chr11:68192670	LRP5	-0.4	-4.94	-0.31	1.51e-6	Total body bone mineral density;
SARC	cis	rs9916302	0.707	rs11078903	chr17:37631924	G/A	cg00129232	chr17:37814104	STARD3	-0.65	-7.82	-0.46	1.78e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.78	12.02	0.62	3.23e-26	Personality dimensions;
SARC	cis	rs314370	0.951	rs12666989	chr7:100486754	G/C	cg10426581	chr7:100472382	SRRT	0.57	6.1	0.37	4.42e-9	Resting heart rate;
SARC	cis	rs9359856	0.564	rs72915918	chr6:90430792	G/C	cg13799429	chr6:90582589	CASP8AP2	-0.58	-4.73	-0.3	3.81e-6	Bipolar disorder;
SARC	cis	rs7587476	0.906	rs62201985	chr2:215658638	A/G	cg11970703	chr2:215861251	ABCA12	-0.4	-5.79	-0.35	2.27e-8	Neuroblastoma;
SARC	cis	rs7223966	1.000	rs8068603	chr17:61755211	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.73	0.4	1.32e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs61931739	0.892	rs73309466	chr12:34093146	A/G	cg13010199	chr12:38710504	ALG10B	-0.53	-6.62	-0.4	2.44e-10	Morning vs. evening chronotype;
SARC	cis	rs7829975	0.508	rs1594437	chr8:8825875	T/C	cg06636001	chr8:8085503	FLJ10661	0.62	7.8	0.46	2.03e-13	Mood instability;
SARC	cis	rs524281	0.814	rs2270448	chr11:65835931	G/T	cg14036092	chr11:66035641	RAB1B	-0.55	-5.77	-0.35	2.52e-8	Electroencephalogram traits;
SARC	cis	rs787274	1.000	rs787301	chr9:115542737	G/T	cg13803584	chr9:115635662	SNX30	0.73	5.84	0.36	1.76e-8	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg15556689	chr8:8085844	FLJ10661	0.43	5.33	0.33	2.29e-7	Mood instability;
SARC	cis	rs12479064	0.724	rs3792143	chr2:100057020	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.7	-8.61	-0.49	1.07e-15	Chronic sinus infection;
SARC	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg18404041	chr3:52824283	ITIH1	-0.38	-5.68	-0.35	4.08e-8	Bipolar disorder;
SARC	cis	rs4561483	0.801	rs40311	chr16:11963190	C/G	cg08843971	chr16:11963173	GSPT1	0.43	5.36	0.33	1.97e-7	Testicular germ cell tumor;
SARC	trans	rs1814175	0.616	rs1851848	chr11:49992254	G/C	cg15704280	chr7:45808275	SEPT13	-0.9	-14.28	-0.68	1.15e-33	Height;
SARC	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg11644478	chr21:40555479	PSMG1	0.87	11.19	0.59	1.52e-23	Cognitive function;
SARC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg01577475	chr2:114033581	PAX8;LOC440839	-0.36	-5.37	-0.33	1.92e-7	Lymphocyte counts;
SARC	cis	rs741702	0.928	rs2293683	chr19:13039284	A/G	cg11738485	chr19:12877000	HOOK2	0.43	4.75	0.3	3.48e-6	Red blood cell traits;
SARC	cis	rs36207871	1	rs36207871	chr12:56684496	TAGGAA/T	cg26316697	chr12:56727976	PAN2	-0.9	-6.37	-0.39	9.89e-10	Inflammatory skin disease;
SARC	cis	rs8077889	0.917	rs72836547	chr17:41902799	G/T	cg26893861	chr17:41843967	DUSP3	0.92	11.34	0.6	4.92e-24	Triglycerides;
SARC	cis	rs11098499	0.863	rs7657849	chr4:120455494	T/C	cg09307838	chr4:120376055	NA	0.91	12.31	0.63	3.63e-27	Corneal astigmatism;
SARC	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.73	8.73	0.5	4.95e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg27411982	chr8:10470053	RP1L1	0.32	5.44	0.34	1.35e-7	Neuroticism;
SARC	cis	rs6500602	0.647	rs4785967	chr16:4523208	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.35	5.97	0.36	8.79e-9	Schizophrenia;
SARC	cis	rs1008375	1.000	rs7436403	chr4:17692685	T/G	cg02297831	chr4:17616191	MED28	-0.43	-5.28	-0.33	3e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs77633900	0.614	rs280008	chr15:77011815	T/C	cg21673338	chr15:77095150	SCAPER	-0.61	-5.19	-0.32	4.68e-7	Non-glioblastoma glioma;Glioma;
SARC	cis	rs2204008	0.715	rs12815986	chr12:38343869	G/A	cg13010199	chr12:38710504	ALG10B	0.82	11.16	0.59	1.93e-23	Bladder cancer;
SARC	cis	rs1569175	0.677	rs281765	chr2:200819812	T/C	cg23649088	chr2:200775458	C2orf69	-0.87	-5.1	-0.32	6.96e-7	Response to treatment for acute lymphoblastic leukemia;
SARC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg26338869	chr17:61819248	STRADA	0.76	9.85	0.54	2.37e-19	Prudent dietary pattern;
SARC	cis	rs4900538	0.963	rs8017980	chr14:102961341	C/G	cg18135206	chr14:102964638	TECPR2	0.67	9.02	0.51	7.16e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	trans	rs61931739	0.534	rs1817761	chr12:34105719	C/T	cg26384229	chr12:38710491	ALG10B	0.87	12.44	0.63	1.37e-27	Morning vs. evening chronotype;
SARC	cis	rs10140922	0.931	rs4982258	chr14:35821891	G/A	cg26967526	chr14:35346199	BAZ1A	-0.38	-4.76	-0.3	3.36e-6	Hip circumference adjusted for BMI;
SARC	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg04944784	chr2:26401820	FAM59B	-0.6	-7.95	-0.46	8.14e-14	Gut microbiome composition (summer);
SARC	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg11062466	chr8:58055876	NA	-0.6	-5.73	-0.35	3.02e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs11785400	1.000	rs4518642	chr8:143737396	T/C	cg24634471	chr8:143751801	JRK	0.69	9.4	0.52	5.47e-18	Schizophrenia;
SARC	cis	rs8180040	0.966	rs34634681	chr3:47579102	G/A	cg27129171	chr3:47204927	SETD2	-0.68	-9.48	-0.53	3.17e-18	Colorectal cancer;
SARC	cis	rs7523050	0.643	rs7551313	chr1:109399881	G/A	cg08274380	chr1:109419600	GPSM2	1.07	8.3	0.48	8.22e-15	Fat distribution (HIV);
SARC	cis	rs7084402	1.000	rs7095501	chr10:60271940	T/C	cg07615347	chr10:60278583	BICC1	-0.58	-8.51	-0.49	2.11e-15	Refractive error;
SARC	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg02951883	chr7:2050386	MAD1L1	-0.42	-5.38	-0.33	1.78e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg12463550	chr7:65579703	CRCP	0.65	5.03	0.31	9.96e-7	Diabetic kidney disease;
SARC	cis	rs372883	0.600	rs407712	chr21:30722531	G/A	cg08807101	chr21:30365312	RNF160	-0.58	-7.35	-0.43	3.34e-12	Pancreatic cancer;
SARC	cis	rs4466137	0.830	rs6886695	chr5:82994293	T/A	cg16102102	chr5:83017553	HAPLN1	-0.76	-9.56	-0.53	1.75e-18	Prostate cancer;
SARC	cis	rs4481887	0.604	rs10888330	chr1:248410506	A/T	cg13385794	chr1:248469461	NA	0.34	4.83	0.3	2.5e-6	Common traits (Other);
SARC	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg18252515	chr7:66147081	NA	0.45	4.8	0.3	2.87e-6	Aortic root size;
SARC	cis	rs2228479	0.702	rs11649501	chr16:89850957	A/T	cg00800038	chr16:89945340	TCF25	-0.79	-5.47	-0.34	1.19e-7	Skin colour saturation;
SARC	cis	rs4803468	1.000	rs10422783	chr19:41906436	T/C	cg14132834	chr19:41945861	ATP5SL	-0.55	-7.37	-0.43	2.88e-12	Height;
SARC	cis	rs6088580	0.634	rs6059905	chr20:33126946	T/C	cg08999081	chr20:33150536	PIGU	0.46	7.02	0.42	2.42e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs2013441	0.711	rs1682297	chr17:20384920	C/T	cg13482628	chr17:19912719	NA	0.4	5.15	0.32	5.57e-7	Obesity-related traits;
SARC	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg18305652	chr10:134549665	INPP5A	0.36	5.24	0.32	3.61e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs73217470	0.826	rs7332910	chr13:72756345	A/C	ch.13.1070180R	chr13:73732331	NA	-0.73	-4.83	-0.3	2.51e-6	Monocyte count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg13024275	chr3:101579557	NFKBIZ	0.49	6.7	0.4	1.56e-10	Thyroid stimulating hormone;
SARC	cis	rs12348691	0.503	rs7849834	chr9:100606188	T/C	cg13688889	chr9:100608707	NA	-0.47	-5.04	-0.31	9.54e-7	Alopecia areata;
SARC	cis	rs995000	0.931	rs2479464	chr1:63130991	G/A	cg06896770	chr1:63153194	DOCK7	-0.89	-13.48	-0.66	5.3e-31	Triglyceride levels;
SARC	cis	rs7223966	1.000	rs9912904	chr17:61763534	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.5	-5.31	-0.33	2.52e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs933688	0.938	rs7705465	chr5:90680949	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.02	12.69	0.64	2.13e-28	Smoking behavior;
SARC	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg03433033	chr1:76189801	ACADM	0.55	7.74	0.45	2.98e-13	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6908034	0.607	rs112599867	chr6:19805532	A/G	cg02682789	chr6:19804855	NA	0.72	5.45	0.34	1.31e-7	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	trans	rs1994135	0.715	rs10506110	chr12:33708552	A/C	cg26384229	chr12:38710491	ALG10B	0.82	10.28	0.56	1.09e-20	Resting heart rate;
SARC	cis	rs11581859	0.613	rs28583693	chr1:99198917	G/A	cg20286094	chr1:99190917	SNX7	-0.42	-4.99	-0.31	1.2e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg15556689	chr8:8085844	FLJ10661	0.49	6.01	0.37	7.06e-9	Neuroticism;
SARC	cis	rs1044826	0.642	rs9826544	chr3:139162831	A/G	cg15131784	chr3:139108705	COPB2	0.39	4.93	0.31	1.58e-6	Obesity-related traits;
SARC	cis	rs459571	0.959	rs2520100	chr9:136918137	A/T	cg13789015	chr9:136890014	NCRNA00094	0.61	8.48	0.49	2.57e-15	Platelet distribution width;
SARC	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg23758822	chr17:41437982	NA	0.87	11.63	0.61	5.98e-25	Menopause (age at onset);
SARC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.14	0.8	6.21e-53	Prudent dietary pattern;
SARC	cis	rs9300255	0.698	rs4759416	chr12:123746357	C/G	cg00376283	chr12:123451042	ABCB9	0.49	5.55	0.34	7.72e-8	Neutrophil percentage of white cells;
SARC	cis	rs568617	0.953	rs658938	chr11:65651830	A/G	cg00576331	chr11:65640516	EFEMP2	0.46	5.41	0.33	1.53e-7	Crohn's disease;
SARC	cis	rs9875589	0.509	rs28865280	chr3:14064958	C/T	cg19554555	chr3:13937349	NA	-0.4	-5.22	-0.32	4.03e-7	Ovarian reserve;
SARC	cis	rs9611519	0.589	rs8138917	chr22:41412425	T/C	cg03806693	chr22:41940476	POLR3H	-0.59	-7.95	-0.46	8.04e-14	Neuroticism;
SARC	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg18876405	chr7:65276391	NA	0.47	5.45	0.34	1.27e-7	Aortic root size;
SARC	cis	rs6540556	0.608	rs4314885	chr1:209902704	G/A	cg05527609	chr1:210001259	C1orf107	-0.54	-5.6	-0.34	6.1e-8	Red blood cell count;
SARC	cis	rs10911363	0.592	rs2702177	chr1:183450622	G/C	cg09173681	chr1:183549694	NCF2	0.31	4.97	0.31	1.27e-6	Systemic lupus erythematosus;
SARC	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg12463550	chr7:65579703	CRCP	-0.49	-5.42	-0.33	1.47e-7	Aortic root size;
SARC	cis	rs11719291	0.504	rs34571182	chr3:49209057	T/A	cg01304814	chr3:48885189	PRKAR2A	0.61	5.12	0.32	6.42e-7	Cognitive function;
SARC	cis	rs1215050	0.791	rs592053	chr4:98732220	C/T	cg05340658	chr4:99064831	C4orf37	0.44	5.85	0.36	1.62e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg13939156	chr17:80058883	NA	0.41	6.26	0.38	1.82e-9	Life satisfaction;
SARC	cis	rs7829975	0.511	rs2948286	chr8:8130160	A/G	cg11608241	chr8:8085544	FLJ10661	0.44	5.35	0.33	2.07e-7	Mood instability;
SARC	cis	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg14019146	chr3:50243930	SLC38A3	-0.32	-5.12	-0.32	6.54e-7	Intelligence (multi-trait analysis);
SARC	cis	rs4980532	1	rs4980532	chr11:63680719	C/T	cg27373749	chr11:63775612	MACROD1	0.33	4.77	0.3	3.22e-6	Pulse pressure;
SARC	cis	rs9916302	0.904	rs1966916	chr17:37425238	T/G	cg07936489	chr17:37558343	FBXL20	-0.69	-9.22	-0.52	1.82e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs6570726	0.935	rs432086	chr6:145841593	C/T	cg05220968	chr6:146057943	EPM2A	0.32	5.57	0.34	6.85e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4319547	0.956	rs10773302	chr12:123043145	G/T	cg23029597	chr12:123009494	RSRC2	-0.38	-4.93	-0.31	1.55e-6	Body mass index;
SARC	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg00149659	chr3:10157352	C3orf10	0.64	5.91	0.36	1.22e-8	Alzheimer's disease;
SARC	cis	rs2594989	0.831	rs7642605	chr3:11469503	T/C	cg00170343	chr3:11313890	ATG7	0.6	5.39	0.33	1.74e-7	Circulating chemerin levels;
SARC	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg18252515	chr7:66147081	NA	0.53	5.7	0.35	3.55e-8	Aortic root size;
SARC	cis	rs2644899	0.593	rs3733828	chr19:41310609	A/G	cg24958765	chr19:41283667	RAB4B	-0.49	-5.55	-0.34	7.74e-8	Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs12594515	1.000	rs7162201	chr15:45992658	A/C	cg14863074	chr15:45997064	NA	0.34	5.18	0.32	4.84e-7	Waist circumference;Weight;
SARC	trans	rs2055729	0.645	rs62489486	chr8:9741925	G/A	cg06636001	chr8:8085503	FLJ10661	0.58	6.37	0.39	9.73e-10	Multiple myeloma (hyperdiploidy);
SARC	cis	rs995000	0.965	rs1168023	chr1:63006595	A/T	cg06896770	chr1:63153194	DOCK7	-0.9	-13.49	-0.66	5.08e-31	Triglyceride levels;
SARC	cis	rs6500602	0.702	rs11645519	chr16:4538989	G/A	cg08645402	chr16:4508243	NA	0.42	5.61	0.34	5.82e-8	Schizophrenia;
SARC	cis	rs9916302	0.768	rs11078900	chr17:37614641	C/T	cg07936489	chr17:37558343	FBXL20	-0.69	-8.94	-0.51	1.21e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs7772486	0.754	rs6570703	chr6:145957052	C/T	cg05347473	chr6:146136440	FBXO30	0.51	7.11	0.42	1.4e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1448094	0.838	rs11834294	chr12:86311958	C/T	cg02569458	chr12:86230093	RASSF9	0.35	4.73	0.3	3.97e-6	Major depressive disorder;
SARC	cis	rs9486715	0.867	rs9373829	chr6:96897201	A/C	cg06623918	chr6:96969491	KIAA0776	-0.84	-11.89	-0.61	8.48e-26	Headache;
SARC	cis	rs2479724	0.792	rs7739064	chr6:41834037	C/A	cg17623882	chr6:41773611	USP49	-0.46	-5.67	-0.35	4.28e-8	Menarche (age at onset);
SARC	cis	rs9970334	0.596	rs709209	chr1:6278414	A/G	cg15892785	chr1:6309343	GPR153	-0.47	-6.61	-0.4	2.56e-10	Resting heart rate;
SARC	cis	rs870825	0.616	rs14969	chr4:185615764	C/A	cg04058563	chr4:185651563	MLF1IP	0.82	11.18	0.59	1.58e-23	Blood protein levels;
SARC	cis	rs6456156	0.586	rs12213801	chr6:167474084	T/A	cg23791538	chr6:167370224	RNASET2	-0.51	-6.78	-0.41	1.01e-10	Primary biliary cholangitis;
SARC	trans	rs7819412	0.775	rs4841489	chr8:10936811	A/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-7.07	-0.42	1.78e-11	Triglycerides;
SARC	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1348850	0.874	rs952746	chr2:178306584	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.64	8.08	0.47	3.52e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs6582630	0.555	rs12372536	chr12:38400864	C/G	cg13010199	chr12:38710504	ALG10B	0.77	10.42	0.56	4.05e-21	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9815354	0.951	rs17063653	chr3:41863817	A/G	cg03022575	chr3:42003672	ULK4	0.57	5.32	0.33	2.38e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs1843834	0.505	rs2140508	chr2:225355839	G/T	cg22509189	chr2:225307070	NA	-0.71	-9.01	-0.51	7.59e-17	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs3733585	0.699	rs7663097	chr4:9966791	T/C	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.65	-0.35	4.69e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs9868809	0.505	rs9882549	chr3:48749358	C/T	cg07636037	chr3:49044803	WDR6	-0.73	-7.1	-0.42	1.48e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs4481887	0.927	rs4916087	chr1:248493833	T/C	cg00666640	chr1:248458726	OR2T12	0.34	5.68	0.35	4.08e-8	Common traits (Other);
SARC	cis	rs9640161	0.742	rs11767726	chr7:150018096	A/C	cg17279839	chr7:150038598	RARRES2	-0.48	-7.2	-0.43	8.05e-12	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs11098499	0.863	rs3775841	chr4:120425777	A/C	cg09307838	chr4:120376055	NA	0.89	11.86	0.61	1.06e-25	Corneal astigmatism;
SARC	cis	rs9875589	0.509	rs2733548	chr3:14094478	C/T	cg19554555	chr3:13937349	NA	-0.39	-4.91	-0.31	1.72e-6	Ovarian reserve;
SARC	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg13939156	chr17:80058883	NA	0.4	6.25	0.38	1.92e-9	Life satisfaction;
SARC	cis	rs7740797	0.875	rs12523716	chr6:155145017	C/T	cg02865717	chr6:155053990	RBM16	0.34	4.94	0.31	1.48e-6	Colorectal or endometrial cancer;
SARC	cis	rs7412746	0.634	rs12096831	chr1:150864113	T/G	cg15448220	chr1:150897856	SETDB1	0.5	6.47	0.39	5.73e-10	Melanoma;
SARC	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	15.18	0.71	1.22e-36	Chronic sinus infection;
SARC	cis	rs2562456	0.874	rs2562408	chr19:21709881	C/G	cg00806126	chr19:22604979	ZNF98	0.48	4.9	0.31	1.82e-6	Pain;
SARC	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg09323728	chr8:95962352	TP53INP1	-0.29	-4.96	-0.31	1.35e-6	Type 2 diabetes;
SARC	cis	rs2011503	0.943	rs8102502	chr19:19652746	T/C	cg03709012	chr19:19516395	GATAD2A	0.63	6.13	0.37	3.73e-9	Bipolar disorder;
SARC	cis	rs2425143	1.000	rs73902914	chr20:34432882	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-6.01	-0.37	7e-9	Blood protein levels;
SARC	cis	rs113835537	0.529	rs12099041	chr11:66232773	C/T	cg24851651	chr11:66362959	CCS	0.38	4.75	0.3	3.51e-6	Airway imaging phenotypes;
SARC	cis	rs16976116	0.951	rs12385963	chr15:55482851	A/G	cg11288833	chr15:55489084	RSL24D1	0.62	6.05	0.37	5.78e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg25894440	chr7:65020034	NA	-0.73	-5.48	-0.34	1.09e-7	Diabetic kidney disease;
SARC	cis	rs6752107	1.000	rs2289474	chr2:234181848	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.51	6.66	0.4	1.95e-10	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg17971929	chr21:40555470	PSMG1	-0.56	-7.02	-0.42	2.39e-11	Menarche (age at onset);
SARC	cis	rs17376456	0.569	rs17083377	chr5:93164870	C/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.49	5.03	0.31	9.71e-7	Diabetic retinopathy;
SARC	cis	rs2439831	0.867	rs6493085	chr15:43654182	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.04	10.9	0.58	1.25e-22	Lung cancer in ever smokers;
SARC	cis	rs1865721	0.771	rs7235563	chr18:73139335	C/G	cg26385618	chr18:73139727	C18orf62	-0.39	-5.34	-0.33	2.25e-7	Intelligence;
SARC	cis	rs7429990	0.932	rs13085054	chr3:48134137	C/T	cg11946769	chr3:48343235	NME6	-0.46	-5.42	-0.33	1.46e-7	Educational attainment (years of education);
SARC	cis	rs1153858	1.000	rs7179743	chr15:45638331	G/C	cg14582100	chr15:45693742	SPATA5L1	0.37	5.03	0.31	9.67e-7	Homoarginine levels;
SARC	cis	rs2033732	0.706	rs4740000	chr8:85075376	G/T	cg05716166	chr8:85095498	RALYL	0.5	5.75	0.35	2.83e-8	Body mass index;
SARC	cis	rs2276314	0.857	rs8087539	chr18:33631537	C/T	cg05985134	chr18:33552581	C18orf21	0.7	7.44	0.44	1.98e-12	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs933688	1.000	rs10073657	chr5:90689749	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.01	13.26	0.66	2.81e-30	Smoking behavior;
SARC	cis	rs7674212	0.539	rs6854709	chr4:104129786	A/G	cg16532752	chr4:104119610	CENPE	-0.49	-6.04	-0.37	6.19e-9	Type 2 diabetes;
SARC	cis	rs472402	0.580	rs7706809	chr5:6635971	G/T	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.42	-5.2	-0.32	4.32e-7	Response to amphetamines;
SARC	cis	rs9790314	0.690	rs1599390	chr3:160833246	A/G	cg03342759	chr3:160939853	NMD3	-0.57	-7.22	-0.43	7.37e-12	Morning vs. evening chronotype;
SARC	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.51	-6.17	-0.37	3.01e-9	Bipolar disorder;
SARC	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	11.31	0.6	6.28e-24	Alzheimer's disease;
SARC	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-5.45	-0.34	1.28e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs1018836	0.663	rs2205151	chr8:91483468	A/C	cg16814680	chr8:91681699	NA	-0.76	-11.66	-0.61	4.77e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs763121	0.853	rs1569492	chr22:38975511	A/G	cg06022373	chr22:39101656	GTPBP1	-0.76	-9.85	-0.54	2.36e-19	Menopause (age at onset);
SARC	cis	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.63	-0.45	5.8e-13	Joint mobility (Beighton score);
SARC	cis	rs7647973	0.710	rs11130208	chr3:49615624	G/T	cg13072238	chr3:49761600	GMPPB	-0.61	-5.33	-0.33	2.34e-7	Menarche (age at onset);
SARC	cis	rs9677476	0.863	rs57199832	chr2:232069083	T/G	cg23338755	chr2:231921595	PSMD1	0.44	5.18	0.32	4.88e-7	Food antigen IgG levels;
SARC	cis	rs7216064	1.000	rs2052187	chr17:65834737	T/C	cg12091567	chr17:66097778	LOC651250	-0.76	-8.43	-0.48	3.68e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs7666738	0.612	rs6830172	chr4:99093947	G/A	cg05340658	chr4:99064831	C4orf37	0.6	7.76	0.45	2.62e-13	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9611519	0.929	rs9611509	chr22:41565827	A/G	cg17376030	chr22:41985996	PMM1	0.45	5.02	0.31	1.03e-6	Neuroticism;
SARC	cis	rs4478037	0.822	rs9868526	chr3:33124269	A/G	cg19404215	chr3:33155277	CRTAP	-0.55	-4.94	-0.31	1.52e-6	Major depressive disorder;
SARC	cis	rs7635838	0.751	rs6442260	chr3:11590751	C/T	cg00170343	chr3:11313890	ATG7	-0.59	-8.05	-0.47	4.27e-14	HDL cholesterol;
SARC	cis	rs9786986	0.710	rs73116639	chr1:235654172	A/G	cg26050004	chr1:235667680	B3GALNT2	0.61	5.48	0.34	1.08e-7	Body mass index;
SARC	cis	rs7937682	0.632	rs7128862	chr11:111755435	C/T	cg09085632	chr11:111637200	PPP2R1B	0.77	9.97	0.55	1e-19	Primary sclerosing cholangitis;
SARC	cis	rs611744	0.967	rs677288	chr8:109177539	T/C	cg21045802	chr8:109455806	TTC35	0.44	5.3	0.33	2.64e-7	Dupuytren's disease;
SARC	cis	rs3935695	0.950	rs4358147	chr2:239923784	A/G	cg05924068	chr2:240046735	HDAC4	0.44	4.77	0.3	3.32e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg06558623	chr16:89946397	TCF25	0.92	6.39	0.39	8.93e-10	Skin colour saturation;
SARC	cis	rs796364	0.951	rs2881593	chr2:201000347	A/G	cg23649088	chr2:200775458	C2orf69	-0.62	-6.8	-0.41	8.54e-11	Schizophrenia;
SARC	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	9.15	0.51	3.02e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs1973993	0.903	rs2038646	chr1:96940371	C/G	cg10631902	chr5:14652156	NA	0.45	7.65	0.45	5.36e-13	Weight;
SARC	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	15.93	0.72	3.88e-39	Chronic sinus infection;
SARC	cis	rs17376456	0.741	rs7718842	chr5:93480568	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.06	0.31	8.57e-7	Diabetic retinopathy;
SARC	cis	rs79149102	0.649	rs4886620	chr15:75105878	G/A	cg09165964	chr15:75287851	SCAMP5	-0.89	-5.25	-0.33	3.44e-7	Lung cancer;
SARC	cis	rs9486719	1.000	rs2092096	chr6:96870919	A/G	cg06623918	chr6:96969491	KIAA0776	0.73	7.77	0.45	2.42e-13	Migraine;Coronary artery disease;
SARC	cis	rs959260	0.925	rs9901434	chr17:73388770	A/G	cg14668889	chr17:73230827	NUP85	-0.43	-4.78	-0.3	3.06e-6	Systemic lupus erythematosus;
SARC	cis	rs2729354	0.953	rs1846567	chr11:57357593	T/C	cg02958346	chr11:57425731	CLP1	0.51	5.08	0.32	7.75e-7	Blood protein levels;
SARC	cis	rs7106204	0.534	rs7928616	chr11:24296060	T/C	ch.11.24196551F	chr11:24239977	NA	0.56	5.61	0.35	5.58e-8	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg19729930	chr2:74357872	NA	0.71	10.56	0.57	1.44e-21	Gestational age at birth (maternal effect);
SARC	cis	rs9902453	0.845	rs2617875	chr17:28090024	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	7.39	0.44	2.65e-12	Coffee consumption (cups per day);
SARC	cis	rs2075371	1.000	rs8134	chr7:133974519	A/G	cg00033643	chr7:134001901	SLC35B4	0.41	4.99	0.31	1.18e-6	Mean platelet volume;
SARC	cis	rs9290065	0.519	rs6808386	chr3:160673263	A/T	cg17135325	chr3:160939158	NMD3	0.4	4.78	0.3	3.07e-6	Kawasaki disease;
SARC	cis	rs9948	0.786	rs62156225	chr2:97414118	T/C	cg01990225	chr2:97406019	LMAN2L	-0.97	-6.96	-0.42	3.35e-11	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs10791097	0.739	rs12279359	chr11:130730544	G/A	cg09137382	chr11:130731461	NA	0.33	5.15	0.32	5.48e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs9303401	0.659	rs11495824	chr17:56918882	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	11.58	0.6	8.42e-25	Cognitive test performance;
SARC	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg04944784	chr2:26401820	FAM59B	-0.47	-5.93	-0.36	1.1e-8	Gut microbiome composition (summer);
SARC	cis	rs7712401	0.715	rs451195	chr5:122359640	T/C	cg19412675	chr5:122181750	SNX24	-0.42	-5.3	-0.33	2.65e-7	Mean platelet volume;
SARC	cis	rs4481887	0.893	rs4297335	chr1:248473421	C/T	cg00666640	chr1:248458726	OR2T12	0.32	5.45	0.34	1.25e-7	Common traits (Other);
SARC	cis	rs933688	0.532	rs2973477	chr5:90553722	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.44	-4.94	-0.31	1.5e-6	Smoking behavior;
SARC	cis	rs1538970	0.847	rs781230	chr1:45880751	C/T	cg05343316	chr1:45956843	TESK2	-0.69	-8.26	-0.48	1.09e-14	Platelet count;
SARC	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg20887711	chr4:1340912	KIAA1530	0.78	9.96	0.55	1.04e-19	Longevity;
SARC	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.53	8.15	0.47	2.22e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs4969178	0.965	rs4969186	chr17:76398404	C/G	cg02836325	chr17:76403955	PGS1	0.33	5.17	0.32	5.07e-7	HDL cholesterol levels;
SARC	cis	rs6831352	0.819	rs13832	chr4:99993075	C/A	cg12011299	chr4:100065546	ADH4	0.3	5.37	0.33	1.9e-7	Alcohol dependence;
SARC	cis	rs2115630	1.000	rs7183401	chr15:85371944	G/T	cg12501888	chr15:85177176	SCAND2	-0.48	-6.13	-0.37	3.74e-9	P wave terminal force;
SARC	cis	rs5753618	0.583	rs71324184	chr22:31752061	C/G	cg07713946	chr22:31675144	LIMK2	0.32	5.0	0.31	1.13e-6	Colorectal cancer;
SARC	cis	rs11690935	0.959	rs3770452	chr2:172668682	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.95	-14.73	-0.69	3.68e-35	Schizophrenia;
SARC	cis	rs11122272	0.701	rs2491402	chr1:231494338	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-9.83	-0.54	2.61e-19	Hemoglobin concentration;
SARC	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg11987759	chr7:65425863	GUSB	-0.5	-5.98	-0.37	8.12e-9	Aortic root size;
SARC	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg00431813	chr7:1051703	C7orf50	-0.32	-4.72	-0.3	4.14e-6	Longevity;Endometriosis;
SARC	cis	rs1790761	0.520	rs7124513	chr11:67395714	C/T	cg23188684	chr11:67383651	NA	-0.42	-5.66	-0.35	4.38e-8	Mean corpuscular volume;
SARC	cis	rs4988958	0.584	rs12712149	chr2:103045193	A/G	cg03938978	chr2:103052716	IL18RAP	0.32	5.18	0.32	4.72e-7	Asthma (childhood onset);
SARC	cis	rs2652822	0.509	rs7163254	chr15:63439403	G/T	cg02713581	chr15:63449717	RPS27L	0.44	4.78	0.3	3.16e-6	Metabolic traits;
SARC	cis	rs11155671	0.530	rs4870080	chr6:150202644	T/C	cg05036130	chr6:150231994	NA	0.31	5.24	0.32	3.63e-7	Testicular germ cell tumor;
SARC	cis	rs62344088	0.590	rs73016639	chr5:172465	C/T	cg22857025	chr5:266934	NA	-0.85	-5.4	-0.33	1.61e-7	Asthma (childhood onset);
SARC	cis	rs4971059	0.654	rs4971076	chr1:155124772	C/A	cg22049894	chr1:155113146	DPM3	0.41	5.07	0.32	8.18e-7	Breast cancer;
SARC	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg00149659	chr3:10157352	C3orf10	0.69	6.9	0.41	4.76e-11	Alzheimer's disease;
SARC	cis	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg06289844	chr6:126071538	HEY2	0.36	5.78	0.35	2.35e-8	Brugada syndrome;
SARC	cis	rs4727027	0.704	rs12704071	chr7:148904795	C/T	cg23583168	chr7:148888333	NA	-0.79	-12.19	-0.62	9.33e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.36	-5.46	-0.34	1.23e-7	Longevity;Endometriosis;
SARC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.35	0.52	7.64e-18	Prudent dietary pattern;
SARC	trans	rs11098499	0.954	rs3733520	chr4:120423480	C/G	cg25214090	chr10:38739885	LOC399744	0.55	7.01	0.42	2.53e-11	Corneal astigmatism;
SARC	cis	rs9291683	0.507	rs6845554	chr4:10013173	T/G	cg11266682	chr4:10021025	SLC2A9	0.39	6.75	0.4	1.15e-10	Bone mineral density;
SARC	cis	rs67460515	0.892	rs35310734	chr3:160943209	T/G	cg17135325	chr3:160939158	NMD3	0.61	7.7	0.45	3.87e-13	Parkinson's disease;
SARC	cis	rs798554	0.686	rs2644298	chr7:2858448	G/C	cg13628971	chr7:2884303	GNA12	0.46	5.7	0.35	3.6e-8	Height;
SARC	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg13175981	chr1:150552382	MCL1	-0.54	-6.9	-0.41	4.97e-11	Tonsillectomy;
SARC	cis	rs2991971	0.729	rs10890328	chr1:45905383	G/T	cg24296786	chr1:45957014	TESK2	-0.58	-7.87	-0.46	1.31e-13	High light scatter reticulocyte count;
SARC	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg06618935	chr21:46677482	NA	-0.42	-5.65	-0.35	4.7e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7539542	0.600	rs9943282	chr1:202895140	C/T	cg08940984	chr1:202857613	RABIF	0.37	4.94	0.31	1.49e-6	Mean platelet volume;
SARC	trans	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg16406658	chr1:27816764	WASF2	-0.66	-6.64	-0.4	2.25e-10	Cutaneous psoriasis;
SARC	cis	rs9309473	1.000	rs1403284	chr2:73726662	A/G	cg20560298	chr2:73613845	ALMS1	0.41	4.75	0.3	3.62e-6	Metabolite levels;
SARC	cis	rs113835537	0.935	rs11550057	chr11:66392880	C/T	cg24851651	chr11:66362959	CCS	0.49	5.23	0.32	3.8e-7	Airway imaging phenotypes;
SARC	cis	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg15556689	chr8:8085844	FLJ10661	0.48	5.96	0.36	9.43e-9	Mood instability;
SARC	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.8	-0.5	3.16e-16	Alzheimer's disease;
SARC	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg10295955	chr4:187884368	NA	-1.07	-20.36	-0.8	1.24e-53	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7587476	1.000	rs7587476	chr2:215653887	T/C	cg11970703	chr2:215861251	ABCA12	0.33	5.09	0.32	7.42e-7	Neuroblastoma;
SARC	cis	rs2153535	0.580	rs7763190	chr6:8484197	G/A	cg23788917	chr6:8435910	SLC35B3	0.62	8.05	0.47	4.27e-14	Motion sickness;
SARC	cis	rs6582630	0.537	rs11611326	chr12:38547958	C/A	cg13010199	chr12:38710504	ALG10B	0.78	10.69	0.57	5.79e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2439831	0.850	rs28564774	chr15:44125475	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	8.16	0.47	2.04e-14	Lung cancer in ever smokers;
SARC	cis	rs12142240	0.698	rs72677587	chr1:46813982	G/A	cg10495392	chr1:46806563	NSUN4	0.65	6.83	0.41	7.25e-11	Menopause (age at onset);
SARC	cis	rs644799	0.932	rs572015	chr11:95637416	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.89	12.96	0.65	2.82e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs4555082	0.874	rs28822720	chr14:105746282	T/C	cg06808227	chr14:105710500	BRF1	-0.58	-7.93	-0.46	8.93e-14	Mean platelet volume;Platelet distribution width;
SARC	cis	rs477895	1.000	rs7939107	chr11:64034773	C/T	cg04317338	chr11:64019027	PLCB3	0.7	6.26	0.38	1.79e-9	Mean platelet volume;
SARC	cis	rs7647973	0.710	rs9869120	chr3:49624065	T/C	cg06212747	chr3:49208901	KLHDC8B	0.73	6.49	0.39	5.02e-10	Menarche (age at onset);
SARC	cis	rs77633900	0.614	rs2454453	chr15:76913976	T/A	cg21673338	chr15:77095150	SCAPER	-0.75	-6.14	-0.37	3.52e-9	Non-glioblastoma glioma;Glioma;
SARC	cis	rs9457247	0.565	rs55873403	chr6:167511800	C/T	cg23791538	chr6:167370224	RNASET2	-0.49	-6.17	-0.37	2.99e-9	Crohn's disease;
SARC	cis	rs7219021	0.674	rs4793990	chr17:46960760	G/A	cg16584676	chr17:46985605	UBE2Z	0.51	5.99	0.37	8.08e-9	Schizophrenia or bipolar disorder;
SARC	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg25072359	chr17:41440525	NA	0.54	6.34	0.38	1.15e-9	Menopause (age at onset);
SARC	cis	rs7020830	0.867	rs7852593	chr9:37332380	A/T	cg14294708	chr9:37120828	ZCCHC7	1.12	20.7	0.8	1.01e-54	Schizophrenia;
SARC	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.62	7.45	0.44	1.8e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs10892173	0.818	rs7947524	chr11:117671091	C/T	cg07621104	chr11:117668040	DSCAML1	0.39	5.11	0.32	6.84e-7	Myopia;
SARC	cis	rs2153535	0.580	rs9406158	chr6:8464152	C/T	cg07606381	chr6:8435919	SLC35B3	0.77	10.83	0.58	2.14e-22	Motion sickness;
SARC	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg22875332	chr1:76189707	ACADM	0.47	6.72	0.4	1.35e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs13256369	0.802	rs12680019	chr8:8561698	A/G	cg18904891	chr8:8559673	CLDN23	0.48	5.27	0.33	3.12e-7	Obesity-related traits;
SARC	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg22535103	chr8:58192502	C8orf71	-0.59	-5.56	-0.34	7.4e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg24250549	chr1:154909240	PMVK	0.83	12.03	0.62	3.08e-26	Prostate cancer;
SARC	cis	rs7582180	0.629	rs11693471	chr2:100948062	G/A	cg14675211	chr2:100938903	LONRF2	0.5	7.47	0.44	1.63e-12	Intelligence (multi-trait analysis);
SARC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg20102877	chr2:27665638	KRTCAP3	-0.36	-5.09	-0.32	7.24e-7	Total body bone mineral density;
SARC	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg09323728	chr8:95962352	TP53INP1	-0.29	-4.96	-0.31	1.34e-6	Type 2 diabetes;
SARC	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.34	-4.98	-0.31	1.27e-6	Total body bone mineral density;
SARC	cis	rs611744	0.901	rs655320	chr8:109197482	T/A	cg21045802	chr8:109455806	TTC35	0.42	4.98	0.31	1.24e-6	Dupuytren's disease;
SARC	cis	rs16854884	0.657	rs920159	chr3:143753194	A/T	cg06585982	chr3:143692056	C3orf58	0.67	9.14	0.51	3.13e-17	Economic and political preferences (feminism/equality);
SARC	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg10560079	chr2:191398806	TMEM194B	0.64	9.21	0.52	1.91e-17	Pulse pressure;
SARC	cis	rs2916247	0.954	rs990747	chr8:93173000	C/T	cg10183463	chr8:93005414	RUNX1T1	0.49	5.19	0.32	4.62e-7	Intelligence (multi-trait analysis);
SARC	cis	rs4243830	0.850	rs6679649	chr1:6606608	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.92	9.72	0.54	5.89e-19	Body mass index;
SARC	cis	rs73198271	0.740	rs28402110	chr8:8647249	C/A	cg06636001	chr8:8085503	FLJ10661	-0.47	-5.0	-0.31	1.15e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs10782582	0.593	rs11163915	chr1:76130199	C/T	cg03433033	chr1:76189801	ACADM	-0.41	-5.41	-0.33	1.56e-7	Daytime sleep phenotypes;
SARC	cis	rs72781680	0.898	rs72782106	chr2:24022009	A/G	cg06627628	chr2:24431161	ITSN2	-0.7	-6.44	-0.39	6.77e-10	Lymphocyte counts;
SARC	cis	rs986417	0.901	rs4901989	chr14:61014743	G/C	cg27398547	chr14:60952738	C14orf39	0.97	8.83	0.5	2.63e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs7769051	1.000	rs9493445	chr6:133125409	C/T	cg07930552	chr6:133119739	C6orf192	0.91	8.4	0.48	4.29e-15	Type 2 diabetes nephropathy;
SARC	cis	rs7681440	0.869	rs894280	chr4:90760883	C/T	cg06632027	chr4:90757378	SNCA	0.41	5.96	0.36	9.16e-9	Dementia with Lewy bodies;
SARC	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg06212747	chr3:49208901	KLHDC8B	0.67	8.94	0.51	1.21e-16	Parkinson's disease;
SARC	trans	rs1814175	0.645	rs1721995	chr11:49915488	A/G	cg15704280	chr7:45808275	SEPT13	-0.89	-14.11	-0.68	4.34e-33	Height;
SARC	trans	rs9329221	0.905	rs10283145	chr8:10241411	C/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.31	-0.38	1.42e-9	Neuroticism;
SARC	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg24250549	chr1:154909240	PMVK	-0.82	-11.71	-0.61	3.37e-25	Prostate cancer;
SARC	cis	rs950169	0.922	rs11639244	chr15:84832650	G/A	cg24253500	chr15:84953950	NA	0.36	4.99	0.31	1.19e-6	Schizophrenia;
SARC	cis	rs5753618	0.583	rs7285619	chr22:31842554	C/T	cg02404636	chr22:31891804	SFI1	0.49	5.34	0.33	2.21e-7	Colorectal cancer;
SARC	cis	rs4660306	1.000	rs4660306	chr1:45978675	C/T	cg24296786	chr1:45957014	TESK2	-0.55	-6.36	-0.38	1.07e-9	Homocysteine levels;
SARC	cis	rs5753618	0.561	rs9606831	chr22:31732512	C/T	cg13145458	chr22:31556086	RNF185	-0.48	-5.24	-0.32	3.57e-7	Colorectal cancer;
SARC	trans	rs11119805	0.649	rs11119816	chr1:211999488	A/G	cg10581811	chr12:58257267	NA	-0.61	-6.23	-0.38	2.11e-9	Stearic acid (18:0) levels;
SARC	cis	rs7727544	0.709	rs272852	chr5:131688767	G/A	cg07395648	chr5:131743802	NA	-0.41	-4.9	-0.31	1.8e-6	Blood metabolite levels;
SARC	trans	rs330048	0.561	rs1825100	chr8:9146270	C/T	cg06636001	chr8:8085503	FLJ10661	-0.6	-7.59	-0.45	7.89e-13	Systemic lupus erythematosus;
SARC	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg26681399	chr22:41777847	TEF	-0.45	-4.96	-0.31	1.39e-6	Vitiligo;
SARC	cis	rs4689388	0.890	rs1801206	chr4:6302707	C/T	cg25554036	chr4:6271136	WFS1	0.37	5.98	0.36	8.38e-9	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs344364	0.511	rs2982433	chr16:1954508	A/G	cg26617929	chr16:1858877	NA	-0.65	-5.62	-0.35	5.36e-8	Glomerular filtration rate in chronic kidney disease;
SARC	cis	rs17376456	0.877	rs66696214	chr5:93424533	G/A	cg25358565	chr5:93447407	FAM172A	1.32	14.75	0.69	3.21e-35	Diabetic retinopathy;
SARC	cis	rs10875746	0.669	rs1021313	chr12:48638041	T/A	cg26205652	chr12:48591994	NA	0.46	5.0	0.31	1.13e-6	Longevity (90 years and older);
SARC	cis	rs1497406	0.744	rs4661718	chr1:16505908	C/T	cg06365898	chr1:16533907	ARHGEF19	0.4	5.29	0.33	2.76e-7	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.71	5.31	0.33	2.59e-7	Initial pursuit acceleration;
SARC	cis	rs9303280	0.776	rs11078926	chr17:38062976	G/A	cg00129232	chr17:37814104	STARD3	-0.37	-4.83	-0.3	2.51e-6	Self-reported allergy;
SARC	cis	rs734999	0.588	rs4648652	chr1:2535758	A/G	cg20673091	chr1:2541236	MMEL1	0.33	5.07	0.32	7.94e-7	Ulcerative colitis;
SARC	cis	rs1949733	1.000	rs3103067	chr4:8511223	A/G	cg13073564	chr4:8508604	NA	-0.47	-7.77	-0.45	2.53e-13	Response to antineoplastic agents;
SARC	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg18876405	chr7:65276391	NA	-0.47	-5.62	-0.35	5.3e-8	Aortic root size;
SARC	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg03575189	chr17:44344142	NA	-0.53	-5.2	-0.32	4.37e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs2075371	0.830	rs2077671	chr7:133951204	C/T	cg20476274	chr7:133979776	SLC35B4	0.61	8.32	0.48	7.38e-15	Mean platelet volume;
SARC	cis	rs6496667	0.632	rs6496658	chr15:90884105	A/G	cg22089800	chr15:90895588	ZNF774	0.49	5.51	0.34	9.66e-8	Rheumatoid arthritis;
SARC	cis	rs300703	0.935	rs417829	chr2:206851	A/G	cg21211680	chr2:198530	NA	0.61	5.49	0.34	1.07e-7	Blood protein levels;
SARC	cis	rs6831352	0.918	rs17218239	chr4:100057020	G/A	cg12011299	chr4:100065546	ADH4	-0.34	-5.74	-0.35	2.95e-8	Alcohol dependence;
SARC	cis	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg07777115	chr5:623756	CEP72	-0.56	-4.81	-0.3	2.68e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs1348850	0.526	rs4144278	chr2:178412378	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.74	6.82	0.41	7.94e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.36	-5.84	-0.36	1.76e-8	Longevity;Endometriosis;
SARC	cis	rs4713118	0.629	rs203888	chr6:28021589	C/T	cg16479474	chr6:28041457	NA	0.35	4.76	0.3	3.46e-6	Parkinson's disease;
SARC	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg20102877	chr2:27665638	KRTCAP3	-0.39	-5.41	-0.33	1.58e-7	Total body bone mineral density;
SARC	cis	rs2985684	0.802	rs10150823	chr14:50051751	C/T	cg04989706	chr14:50066350	PPIL5	-0.53	-5.88	-0.36	1.44e-8	Carotid intima media thickness;
SARC	cis	rs7647973	0.925	rs6446257	chr3:49253492	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.54	-5.5	-0.34	9.86e-8	Menarche (age at onset);
SARC	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.58	-6.01	-0.37	7e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-7.97	-0.46	7.21e-14	Chronic sinus infection;
SARC	cis	rs1348850	0.602	rs1453373	chr2:178221668	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.58	7.58	0.44	8.31e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs60871478	0.945	rs62432254	chr7:804175	C/T	cg05535760	chr7:792225	HEATR2	0.77	7.94	0.46	8.38e-14	Cerebrospinal P-tau181p levels;
SARC	cis	rs9660992	0.573	rs7531256	chr1:205191202	T/G	cg00857998	chr1:205179979	DSTYK	0.52	6.35	0.38	1.12e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs3018712	0.532	rs2513289	chr11:68419655	A/C	cg01657329	chr11:68192670	LRP5	0.61	5.47	0.34	1.15e-7	Total body bone mineral density;
SARC	cis	rs4642101	0.883	rs11718898	chr3:12848822	T/C	cg05775895	chr3:12838266	CAND2	0.64	8.63	0.49	9.78e-16	QRS complex (12-leadsum);
SARC	cis	rs1878931	0.507	rs8054222	chr16:3413477	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.58	-6.14	-0.37	3.45e-9	Body mass index (adult);
SARC	cis	rs11581859	0.613	rs9728629	chr1:99191881	G/A	cg20286094	chr1:99190917	SNX7	-0.42	-4.93	-0.31	1.55e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs1113500	0.933	rs4517375	chr1:108638330	A/C	cg06207961	chr1:108661230	NA	-0.44	-5.88	-0.36	1.4e-8	Growth-regulated protein alpha levels;
SARC	cis	rs208520	1.000	rs72884025	chr6:66994185	T/C	cg07460842	chr6:66804631	NA	0.9	10.25	0.56	1.39e-20	Exhaled nitric oxide output;
SARC	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg21782813	chr7:2030301	MAD1L1	0.42	6.72	0.4	1.39e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs9916302	0.851	rs11868029	chr17:37650304	A/G	cg15445000	chr17:37608096	MED1	0.42	5.05	0.31	8.76e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg16479474	chr6:28041457	NA	0.36	5.17	0.32	5.06e-7	Parkinson's disease;
SARC	cis	rs7412746	0.658	rs12068264	chr1:150727329	C/T	cg15448220	chr1:150897856	SETDB1	0.47	6.02	0.37	6.58e-9	Melanoma;
SARC	cis	rs9291683	0.509	rs6849717	chr4:9958719	T/C	cg00071950	chr4:10020882	SLC2A9	-0.4	-6.42	-0.39	7.55e-10	Bone mineral density;
SARC	cis	rs3859192	0.599	rs2227321	chr17:38171294	G/C	cg17344932	chr17:38183730	MED24;SNORD124	0.39	7.2	0.43	8.01e-12	White blood cell count;
SARC	cis	rs2997447	0.846	rs76713804	chr1:26392437	G/A	cg19633962	chr1:26362018	EXTL1	-0.68	-5.35	-0.33	2.11e-7	QRS complex (12-leadsum);
SARC	cis	rs992157	0.700	rs10165153	chr2:219159629	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.62	8.62	0.49	1.03e-15	Colorectal cancer;
SARC	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.1	0.37	4.42e-9	Electroencephalogram traits;
SARC	cis	rs2228479	0.850	rs74251568	chr16:89903416	A/C	cg12064134	chr16:90016061	DEF8	-0.56	-4.79	-0.3	2.91e-6	Skin colour saturation;
SARC	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	9.11	0.51	3.91e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg13699009	chr12:122356056	WDR66	0.57	8.69	0.49	6.7e-16	Mean corpuscular volume;
SARC	cis	rs7595412	0.709	rs2342753	chr2:199073334	T/C	cg00208931	chr2:198669586	PLCL1	-0.68	-5.13	-0.32	6.1e-7	Hip bone size;
SARC	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg00990874	chr7:1149470	C7orf50	-0.6	-6.32	-0.38	1.34e-9	Bronchopulmonary dysplasia;
SARC	cis	rs12421382	0.614	rs11213102	chr11:109385853	G/A	cg27471124	chr11:109292789	C11orf87	0.36	5.06	0.31	8.62e-7	Schizophrenia;
SARC	cis	rs3923518	1.000	rs4284929	chr3:38889656	A/G	cg15678707	chr3:39149194	GORASP1;TTC21A	0.46	4.78	0.3	3.08e-6	Migraine;
SARC	trans	rs3857536	0.642	rs7755840	chr6:66891913	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.6	-7.14	-0.42	1.19e-11	Blood trace element (Cu levels);
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg12725906	chr1:183605176	ARPC5;RGL1	0.48	6.39	0.39	8.9e-10	Gallstone disease;
SARC	cis	rs1538970	0.962	rs3219463	chr1:45806432	C/T	cg05343316	chr1:45956843	TESK2	0.73	8.06	0.47	3.96e-14	Platelet count;
SARC	cis	rs7208859	0.614	rs7216394	chr17:28825756	T/C	cg13385521	chr17:29058706	SUZ12P	-0.59	-4.84	-0.3	2.38e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs6582630	0.555	rs6582503	chr12:38557886	A/C	cg26384229	chr12:38710491	ALG10B	0.9	13.56	0.66	2.89e-31	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs3771570	0.901	rs4075818	chr2:242432142	T/C	cg21155796	chr2:242212141	HDLBP	0.64	6.0	0.37	7.52e-9	Prostate cancer;
SARC	cis	rs6988636	0.710	rs62521805	chr8:124159200	C/T	cg23067535	chr8:124195133	FAM83A	-0.65	-4.74	-0.3	3.77e-6	Urinary uromodulin levels;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg09754991	chr13:107220236	ARGLU1	0.54	6.49	0.39	5.03e-10	Blood pressure;
SARC	cis	rs6807306	1.000	rs1986640	chr3:167357683	C/T	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.5	5.05	0.31	8.99e-7	Mean platelet volume;
SARC	cis	rs10892173	0.566	rs10892175	chr11:117674355	G/A	cg21640587	chr11:117668038	DSCAML1	0.71	10.03	0.55	6.45e-20	Myopia;
SARC	cis	rs9291683	0.509	rs998676	chr4:9948564	T/C	cg00071950	chr4:10020882	SLC2A9	-0.41	-6.56	-0.39	3.45e-10	Bone mineral density;
SARC	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg05872129	chr22:39784769	NA	-0.44	-6.33	-0.38	1.23e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs1008375	1.000	rs7671752	chr4:17661398	C/T	cg02297831	chr4:17616191	MED28	0.42	5.27	0.33	3.18e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2273669	0.667	rs12195848	chr6:109279105	A/C	cg05315195	chr6:109294784	ARMC2	-0.58	-4.93	-0.31	1.57e-6	Prostate cancer;
SARC	cis	rs12824058	0.798	rs4759652	chr12:130808771	C/T	cg24838063	chr12:130822603	PIWIL1	0.62	8.84	0.5	2.42e-16	Menopause (age at onset);
SARC	cis	rs9858542	0.953	rs35261698	chr3:49537839	C/G	cg03060546	chr3:49711283	APEH	-0.57	-7.03	-0.42	2.31e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg10523679	chr1:76189770	ACADM	-0.5	-6.7	-0.4	1.51e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg00149659	chr3:10157352	C3orf10	0.64	6.01	0.37	7.21e-9	Alzheimer's disease;
SARC	cis	rs17666538	1.000	rs57255985	chr8:574131	C/T	cg00450029	chr8:599525	NA	-0.72	-5.07	-0.32	8e-7	IgG glycosylation;
SARC	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg05025164	chr4:1340916	KIAA1530	0.53	6.26	0.38	1.88e-9	Obesity-related traits;
SARC	cis	rs7246657	0.943	rs7258692	chr19:37818829	C/A	cg23950597	chr19:37808831	NA	-0.59	-5.82	-0.36	1.9e-8	Coronary artery calcification;
SARC	cis	rs77372450	0.551	rs6892478	chr5:157106968	C/T	cg05585991	chr5:157099197	C5orf52	0.55	5.42	0.33	1.46e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs35110281	0.805	rs3788062	chr21:44991159	C/T	cg01579765	chr21:45077557	HSF2BP	-0.31	-5.28	-0.33	2.96e-7	Mean corpuscular volume;
SARC	cis	rs57994353	0.760	rs4413892	chr9:139330158	G/A	cg13611204	chr9:139324423	INPP5E	-0.3	-5.28	-0.33	3e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs9815354	1.000	rs9874975	chr3:41764300	G/A	cg03022575	chr3:42003672	ULK4	0.57	5.4	0.33	1.68e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6430585	0.583	rs4594504	chr2:136625113	A/C	cg07169764	chr2:136633963	MCM6	1.1	16.99	0.74	1.18e-42	Corneal structure;
SARC	cis	rs62344088	0.590	rs73016637	chr5:172462	G/A	cg22857025	chr5:266934	NA	-0.86	-5.4	-0.33	1.63e-7	Asthma (childhood onset);
SARC	trans	rs8073060	0.586	rs7221203	chr17:34015532	T/C	cg19694781	chr19:47549865	TMEM160	-0.7	-6.9	-0.41	4.95e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs5769765	0.955	rs1321	chr22:50297435	A/G	cg03033257	chr22:50311977	ALG12;CRELD2	0.55	5.63	0.35	5.18e-8	Schizophrenia;
SARC	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.51	5.74	0.35	2.93e-8	Renal function-related traits (BUN);
SARC	cis	rs3087591	0.922	rs2905805	chr17:29502856	C/A	cg24425628	chr17:29625626	OMG;NF1	0.5	6.26	0.38	1.88e-9	Hip circumference;
SARC	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2481665	0.740	rs2457831	chr1:62633581	C/T	cg18591186	chr1:62594603	INADL	0.51	6.87	0.41	5.68e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs11155671	0.530	rs3823021	chr6:150210999	G/C	cg00933542	chr6:150070202	PCMT1	0.29	4.81	0.3	2.77e-6	Testicular germ cell tumor;
SARC	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	10.47	0.57	2.77e-21	Platelet count;
SARC	trans	rs1814175	0.817	rs7109440	chr11:49966296	C/T	cg03929089	chr4:120376271	NA	-0.89	-14.61	-0.69	9.51e-35	Height;
SARC	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg11987759	chr7:65425863	GUSB	-0.48	-6.54	-0.39	3.9e-10	Aortic root size;
SARC	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg19774624	chr17:42201019	HDAC5	-0.85	-13.4	-0.66	9.39e-31	Total body bone mineral density;
SARC	cis	rs1008375	1.000	rs10939748	chr4:17691230	T/C	cg16339924	chr4:17578868	LAP3	0.59	7.46	0.44	1.68e-12	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg05861140	chr6:150128134	PCMT1	-0.37	-4.85	-0.3	2.3e-6	Lung cancer;
SARC	cis	rs4919087	0.620	rs793518	chr10:98986970	C/T	cg25902810	chr10:99078978	FRAT1	-0.53	-5.75	-0.35	2.72e-8	Monocyte count;
SARC	cis	rs1691799	0.777	rs11176145	chr12:66719795	A/G	cg16791601	chr12:66731901	HELB	0.58	8.34	0.48	6.55e-15	White blood cell count (basophil);
SARC	cis	rs1475911	0.671	rs12483409	chr21:43521902	G/A	cg19766460	chr21:43528205	UMODL1;C21orf128	0.57	6.79	0.41	9.2e-11	IgG glycosylation;
SARC	cis	rs2730245	0.550	rs2709860	chr7:158651156	A/T	cg24397884	chr7:158709396	WDR60	0.78	10.39	0.56	4.87e-21	Height;
SARC	cis	rs6120849	0.754	rs6088682	chr20:33615702	A/C	cg24642439	chr20:33292090	TP53INP2	0.57	5.48	0.34	1.1e-7	Protein C levels;
SARC	cis	rs751728	1.000	rs4711351	chr6:33754592	G/A	cg15252951	chr6:33757062	LEMD2	0.58	6.86	0.41	6.27e-11	Crohn's disease;
SARC	cis	rs35146811	0.883	rs4134903	chr7:99711040	G/A	cg22004693	chr7:99632812	ZKSCAN1	-0.48	-5.18	-0.32	4.87e-7	Coronary artery disease;
SARC	cis	rs698833	0.518	rs2033951	chr2:44556298	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.72	8.34	0.48	6.47e-15	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs7598759	0.712	rs997400	chr2:232332847	C/T	cg19187155	chr2:232395269	NMUR1	0.6	8.52	0.49	2e-15	Noise-induced hearing loss;
SARC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.78	10.14	0.55	2.96e-20	Prudent dietary pattern;
SARC	cis	rs644799	0.542	rs10831417	chr11:95467262	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	-0.7	-9.36	-0.52	7.06e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2204008	0.687	rs1733404	chr12:38123395	G/T	cg13010199	chr12:38710504	ALG10B	-0.72	-9.76	-0.54	4.52e-19	Bladder cancer;
SARC	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.45	-5.15	-0.32	5.43e-7	Bipolar disorder;
SARC	cis	rs2439831	1.000	rs2467426	chr15:43989518	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	8.45	0.48	3.18e-15	Lung cancer in ever smokers;
SARC	cis	rs7667	1.000	rs12088915	chr1:19708363	T/C	cg15311933	chr1:19638897	PQLC2;AKR7A2	-0.45	-5.28	-0.33	2.99e-7	Crohn's disease and psoriasis;
SARC	cis	rs7824557	0.579	rs10098322	chr8:11196295	C/G	cg21775007	chr8:11205619	TDH	0.62	8.11	0.47	2.91e-14	Retinal vascular caliber;
SARC	cis	rs7264396	0.563	rs6058302	chr20:34290037	C/T	cg01084648	chr20:34329383	RBM39	0.56	4.93	0.31	1.57e-6	Total cholesterol levels;
SARC	cis	rs9479482	1.000	rs9479403	chr6:150337746	C/T	cg03788504	chr6:150331562	NA	0.32	5.29	0.33	2.85e-7	Alopecia areata;
SARC	cis	rs2404602	0.735	rs4886805	chr15:76739384	A/G	cg15268244	chr15:77196840	NA	-0.39	-4.78	-0.3	3.17e-6	Blood metabolite levels;
SARC	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg24399712	chr22:39784796	NA	-0.44	-5.62	-0.35	5.49e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg19223190	chr17:80058835	NA	0.48	6.68	0.4	1.69e-10	Life satisfaction;
SARC	cis	rs4481887	0.676	rs28684663	chr1:248548325	T/C	cg00666640	chr1:248458726	OR2T12	0.27	5.03	0.31	9.65e-7	Common traits (Other);
SARC	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg04287289	chr16:89883240	FANCA	0.85	14.44	0.69	3.44e-34	Vitiligo;
SARC	cis	rs2070677	0.935	rs4300354	chr10:135415890	C/T	cg20169779	chr10:135381914	SYCE1	-0.51	-6.05	-0.37	5.79e-9	Gout;
SARC	cis	rs7092929	0.883	rs551307	chr10:3597542	T/C	cg14308648	chr10:3568949	NA	0.51	5.13	0.32	6.23e-7	Coronary artery calcification;
SARC	cis	rs2730245	0.959	rs2527201	chr7:158738611	G/T	cg00815399	chr7:158750607	NA	-0.34	-4.73	-0.3	3.96e-6	Height;
SARC	cis	rs193541	0.632	rs39821	chr5:122295472	T/C	cg19412675	chr5:122181750	SNX24	0.48	6.16	0.37	3.15e-9	Glucose homeostasis traits;
SARC	cis	rs3106136	0.807	rs9997915	chr4:95278027	C/T	cg11021082	chr4:95130006	SMARCAD1	0.34	5.39	0.33	1.7e-7	Capecitabine sensitivity;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg05320089	chr13:111553037	ANKRD10	0.86	6.6	0.4	2.8e-10	Obesity-related traits;
SARC	cis	rs9291683	0.620	rs4444830	chr4:10124819	A/G	cg11266682	chr4:10021025	SLC2A9	-0.35	-6.04	-0.37	5.94e-9	Bone mineral density;
SARC	cis	rs826838	1.000	rs11609286	chr12:38875511	A/G	cg26384229	chr12:38710491	ALG10B	-0.93	-14.55	-0.69	1.52e-34	Heart rate;
SARC	cis	rs710216	0.536	rs710222	chr1:43413653	A/G	cg07803811	chr1:43423981	SLC2A1	0.61	8.39	0.48	4.73e-15	Red cell distribution width;
SARC	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg21782813	chr7:2030301	MAD1L1	0.42	6.29	0.38	1.55e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs9948	0.655	rs6576981	chr2:97394406	G/C	cg01990225	chr2:97406019	LMAN2L	-0.81	-6.22	-0.38	2.25e-9	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg18252515	chr7:66147081	NA	-1.33	-11.96	-0.62	5.03e-26	Diabetic kidney disease;
SARC	cis	rs79149102	0.579	rs7182286	chr15:75293839	A/G	cg09165964	chr15:75287851	SCAMP5	-0.95	-8.78	-0.5	3.63e-16	Lung cancer;
SARC	cis	rs7843479	0.601	rs11781959	chr8:21841863	C/G	cg17168535	chr8:21777572	XPO7	0.84	12.96	0.65	2.71e-29	Mean corpuscular volume;
SARC	cis	rs7084402	0.967	rs1649046	chr10:60326109	T/C	cg07615347	chr10:60278583	BICC1	0.59	8.76	0.5	4.06e-16	Refractive error;
SARC	cis	rs7666738	0.830	rs6854994	chr4:98977624	C/G	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg22496380	chr5:211416	CCDC127	-0.88	-9.28	-0.52	1.21e-17	Breast cancer;
SARC	cis	rs2204008	0.658	rs12371956	chr12:38298010	A/T	cg13010199	chr12:38710504	ALG10B	0.77	10.59	0.57	1.16e-21	Bladder cancer;
SARC	cis	rs672059	1.000	rs659307	chr1:183163078	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.5	6.86	0.41	6.22e-11	Hypertriglyceridemia;
SARC	cis	rs2236918	0.622	rs1776177	chr1:242012149	C/T	cg17736920	chr1:242011382	EXO1	0.64	8.62	0.49	1.02e-15	Menopause (age at onset);
SARC	cis	rs79349575	0.783	rs2112617	chr17:46977125	G/A	cg16584676	chr17:46985605	UBE2Z	0.54	6.49	0.39	5.21e-10	Type 2 diabetes;
SARC	cis	rs1707322	0.929	rs785500	chr1:46593044	C/T	cg03146154	chr1:46216737	IPP	-0.46	-5.33	-0.33	2.37e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg24846343	chr22:24311635	DDTL	0.52	7.49	0.44	1.43e-12	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9911578	0.934	rs8081967	chr17:57072701	T/C	cg05425664	chr17:57184151	TRIM37	-0.63	-7.79	-0.45	2.14e-13	Intelligence (multi-trait analysis);
SARC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg22903471	chr2:27725779	GCKR	-0.49	-7.42	-0.44	2.21e-12	Total body bone mineral density;
SARC	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg19346786	chr7:2764209	NA	-0.38	-5.64	-0.35	4.89e-8	Height;
SARC	cis	rs79149102	0.522	rs10459601	chr15:74865409	C/T	cg09165964	chr15:75287851	SCAMP5	-0.6	-4.85	-0.3	2.29e-6	Lung cancer;
SARC	cis	rs11122272	0.735	rs2486730	chr1:231534987	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.28	-0.56	1.11e-20	Hemoglobin concentration;
SARC	cis	rs282587	0.530	rs428853	chr13:113387222	T/C	cg02820901	chr13:113351484	ATP11A	-0.5	-4.85	-0.3	2.21e-6	Glycated hemoglobin levels;
SARC	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.64	-7.25	-0.43	6.02e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs12291225	0.877	rs2303974	chr11:14264979	G/T	cg19336497	chr11:14380999	RRAS2	-0.33	-5.1	-0.32	7.18e-7	Sense of smell;
SARC	cis	rs920590	0.721	rs920587	chr8:19663339	C/A	cg03894339	chr8:19674705	INTS10	0.56	6.68	0.4	1.7e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs910316	1.000	rs12589815	chr14:75544101	C/T	cg11812906	chr14:75593930	NEK9	0.87	13.44	0.66	7.03e-31	Height;
SARC	cis	rs12950390	0.512	rs56254413	chr17:45857545	G/T	cg24803719	chr17:45855879	NA	-0.43	-5.31	-0.33	2.54e-7	IgG glycosylation;
SARC	cis	rs1008375	1.000	rs1006722	chr4:17618713	A/G	cg16339924	chr4:17578868	LAP3	-0.67	-8.71	-0.5	5.83e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1044826	0.642	rs407958	chr3:139213632	T/C	cg15131784	chr3:139108705	COPB2	0.39	4.9	0.31	1.83e-6	Obesity-related traits;
SARC	cis	rs6449957	0.684	rs6889193	chr5:67452326	G/A	cg23036683	chr5:67512108	NA	0.47	5.14	0.32	5.87e-7	Cleft lip with or without cleft palate;
SARC	cis	rs9549260	0.755	rs4429172	chr13:41189143	C/A	cg21288729	chr13:41239152	FOXO1	0.64	8.99	0.51	8.49e-17	Red blood cell count;
SARC	cis	rs35213789	0.920	rs12698815	chr7:69368351	A/T	cg10619644	chr7:69149951	AUTS2	0.47	5.65	0.35	4.61e-8	Childhood ear infection;
SARC	cis	rs4792901	0.918	rs79868029	chr17:41622507	A/G	cg22562494	chr17:41607896	ETV4	-0.33	-5.3	-0.33	2.63e-7	Dupuytren's disease;
SARC	cis	rs7481584	0.624	rs449164	chr11:3053454	C/T	cg20651018	chr11:3035856	CARS	0.43	6.37	0.39	1.01e-9	Calcium levels;
SARC	cis	rs8067545	0.611	rs11868116	chr17:20029593	T/C	cg13482628	chr17:19912719	NA	0.53	7.11	0.42	1.42e-11	Schizophrenia;
SARC	cis	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg20965017	chr5:231967	SDHA	-0.55	-5.26	-0.33	3.23e-7	Breast cancer;
SARC	cis	rs9790314	0.521	rs13084731	chr3:161086020	G/A	cg17135325	chr3:160939158	NMD3	0.52	6.57	0.4	3.23e-10	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg08280861	chr8:58055591	NA	0.61	5.94	0.36	1.01e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs834603	0.575	rs940861	chr7:47469429	A/T	cg23694490	chr7:47445681	TNS3	-0.32	-5.89	-0.36	1.36e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg21724239	chr8:58056113	NA	0.6	6.37	0.38	1.03e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg22321522	chr19:15490619	AKAP8	0.49	6.25	0.38	1.93e-9	Lung adenocarcinoma;
SARC	cis	rs3617	0.573	rs62253582	chr3:52928333	G/A	cg18404041	chr3:52824283	ITIH1	0.33	4.75	0.3	3.52e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.99	12.23	0.63	6.97e-27	Platelet count;
SARC	cis	rs2191566	1.000	rs10418363	chr19:44525463	A/G	cg20607764	chr19:44506953	ZNF230	-0.47	-5.4	-0.33	1.6e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs11240408	1	rs11240408	chr1:205264536	A/T	cg07972983	chr1:205091412	RBBP5	-0.55	-6.63	-0.4	2.35e-10	Platelet count;
SARC	cis	rs1348850	0.609	rs1348851	chr2:178418677	C/T	cg23306229	chr2:178417860	TTC30B	-0.77	-6.59	-0.4	2.84e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs4132509	0.793	rs34477525	chr1:243966454	T/A	cg21452805	chr1:244014465	NA	0.5	5.55	0.34	7.72e-8	RR interval (heart rate);
SARC	cis	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg14019146	chr3:50243930	SLC38A3	0.3	4.74	0.3	3.79e-6	Body mass index;
SARC	cis	rs8114671	0.562	rs6119545	chr20:33522869	T/C	cg07148914	chr20:33460835	GGT7	0.42	5.04	0.31	9.19e-7	Height;
SARC	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg05457628	chr5:178986728	RUFY1	0.37	5.0	0.31	1.14e-6	Lung cancer;
SARC	cis	rs67460515	0.563	rs1599388	chr3:160846866	A/G	cg03342759	chr3:160939853	NMD3	-0.63	-7.65	-0.45	5.2e-13	Parkinson's disease;
SARC	cis	rs9818758	0.607	rs10049462	chr3:49309684	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.7	-5.94	-0.36	1.05e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs3096299	0.582	rs12935119	chr16:89542874	A/T	cg02187348	chr16:89574699	SPG7	0.61	8.57	0.49	1.42e-15	Multiple myeloma (IgH translocation);
SARC	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	11.64	0.61	5.7e-25	Alzheimer's disease;
SARC	cis	rs8017423	0.967	rs61592400	chr14:90703252	T/C	cg20276874	chr14:90721474	PSMC1	-0.36	-5.02	-0.31	1.04e-6	Mortality in heart failure;
SARC	cis	rs11574514	0.661	rs116844179	chr16:68294000	C/T	cg01866162	chr16:67596514	CTCF	1.15	6.55	0.39	3.65e-10	Crohn's disease;
SARC	cis	rs7223966	1.000	rs8081612	chr17:61724695	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.56	6.31	0.38	1.37e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs459571	0.834	rs379417	chr9:136890704	G/A	cg13789015	chr9:136890014	NCRNA00094	0.63	8.9	0.5	1.65e-16	Platelet distribution width;
SARC	cis	rs9916302	0.904	rs620686	chr17:37453617	A/G	cg20243544	chr17:37824526	PNMT	-0.55	-6.64	-0.4	2.19e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg13147721	chr7:65941812	NA	-0.52	-4.76	-0.3	3.38e-6	Diabetic kidney disease;
SARC	cis	rs7785360	0.800	rs12698886	chr7:69734781	G/A	cg10619644	chr7:69149951	AUTS2	0.43	4.97	0.31	1.32e-6	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
SARC	cis	rs11166927	0.524	rs2035088	chr8:140831403	A/G	cg16909799	chr8:140841666	TRAPPC9	-0.39	-5.51	-0.34	9.41e-8	Pediatric non-alcoholic fatty liver disease activity score;
SARC	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg16606324	chr3:10149918	C3orf24	0.51	4.94	0.31	1.48e-6	Alzheimer's disease;
SARC	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg05861140	chr6:150128134	PCMT1	-0.42	-5.48	-0.34	1.09e-7	Lung cancer;
SARC	cis	rs7044106	0.791	rs2416797	chr9:123480600	C/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	5.9	0.36	1.3e-8	Hip circumference adjusted for BMI;
SARC	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg23958373	chr8:599963	NA	1.03	7.71	0.45	3.71e-13	IgG glycosylation;
SARC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg07157834	chr1:205819609	PM20D1	0.8	13.36	0.66	1.34e-30	Menarche (age at onset);
SARC	cis	rs17376456	0.569	rs10067754	chr5:93093110	T/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.56	5.82	0.36	1.96e-8	Diabetic retinopathy;
SARC	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg22875332	chr1:76189707	ACADM	0.52	7.18	0.43	9.04e-12	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2549003	0.966	rs10072571	chr5:131816711	A/C	cg21138405	chr5:131827807	IRF1	0.27	5.44	0.34	1.32e-7	Asthma (sex interaction);
SARC	cis	rs9549260	0.604	rs9532587	chr13:41302694	A/T	cg21288729	chr13:41239152	FOXO1	0.57	5.17	0.32	5.12e-7	Red blood cell count;
SARC	cis	rs2439831	0.850	rs3759790	chr15:44121030	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.76	7.51	0.44	1.27e-12	Lung cancer in ever smokers;
SARC	cis	rs6815814	0.950	rs11722788	chr4:38810738	C/G	cg06935464	chr4:38784597	TLR10	0.63	6.34	0.38	1.16e-9	Breast cancer;
SARC	cis	rs4971059	0.617	rs12025371	chr1:155119327	A/T	cg22049894	chr1:155113146	DPM3	0.43	5.42	0.33	1.52e-7	Breast cancer;
SARC	cis	rs17666538	0.585	rs6559063	chr8:623051	C/T	cg19660806	chr8:588740	NA	0.6	5.24	0.32	3.67e-7	IgG glycosylation;
SARC	cis	rs4443100	0.874	rs5996454	chr22:23379206	A/G	cg14186256	chr22:23484241	RTDR1	0.45	4.86	0.3	2.15e-6	Serum parathyroid hormone levels;
SARC	cis	rs151234	0.741	rs11074908	chr16:28608356	C/T	cg01378222	chr16:28622494	SULT1A1	-0.46	-5.24	-0.32	3.55e-7	Platelet distribution width;
SARC	trans	rs7830939	0.586	rs9918809	chr8:9320959	A/C	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.28	-0.38	1.62e-9	Neuroticism;
SARC	cis	rs2880765	0.566	rs17553249	chr15:86006694	A/G	cg19183879	chr15:85880815	NA	-0.29	-4.78	-0.3	3.15e-6	Coronary artery disease;
SARC	cis	rs9790314	0.586	rs1839491	chr3:161126429	C/A	cg04691961	chr3:161091175	C3orf57	-0.49	-6.12	-0.37	4.02e-9	Morning vs. evening chronotype;
SARC	cis	rs2952156	0.920	rs732084	chr17:37834357	A/C	cg07936489	chr17:37558343	FBXL20	-0.4	-5.28	-0.33	2.89e-7	Asthma;
SARC	cis	rs9788721	0.802	rs56219465	chr15:78742579	A/G	cg18825076	chr15:78729989	IREB2	-0.47	-5.7	-0.35	3.69e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs12912251	1.000	rs35024396	chr15:38989770	G/A	cg01338139	chr15:38987640	C15orf53	-0.43	-5.01	-0.31	1.06e-6	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
SARC	cis	rs2075371	0.932	rs1035328	chr7:133978419	T/C	cg11752832	chr7:134001865	SLC35B4	0.58	7.6	0.45	7.35e-13	Mean platelet volume;
SARC	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg12463550	chr7:65579703	CRCP	0.48	5.79	0.35	2.23e-8	Aortic root size;
SARC	cis	rs6089584	0.606	rs7270469	chr20:60577258	G/A	cg23262073	chr20:60523788	NA	-0.37	-5.53	-0.34	8.77e-8	Body mass index;
SARC	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg18876405	chr7:65276391	NA	0.48	5.69	0.35	3.88e-8	Aortic root size;
SARC	trans	rs6600671	1.000	rs6600671	chr1:121200490	T/G	cg00646200	chr1:148855367	NA	-0.52	-6.97	-0.42	3.26e-11	Hip geometry;
SARC	cis	rs3820928	0.874	rs4675138	chr2:227884118	G/A	cg11843606	chr2:227700838	RHBDD1	-0.55	-7.01	-0.42	2.58e-11	Pulmonary function;
SARC	cis	rs17270561	0.636	rs7775354	chr6:25745266	T/A	cg17691542	chr6:26056736	HIST1H1C	0.61	7.36	0.43	3.06e-12	Iron status biomarkers;
SARC	cis	rs9303401	0.614	rs35245220	chr17:56510305	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.0	10.05	0.55	5.59e-20	Cognitive test performance;
SARC	cis	rs2303759	0.709	rs8102658	chr19:49828855	C/T	cg22307029	chr19:49891270	CCDC155	0.59	6.7	0.4	1.58e-10	Multiple sclerosis;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg02993943	chr7:39605861	C7orf36	-0.57	-6.37	-0.39	9.83e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs826838	0.510	rs10506129	chr12:39224242	A/T	cg13010199	chr12:38710504	ALG10B	0.59	6.92	0.41	4.25e-11	Heart rate;
SARC	cis	rs6546324	1.000	rs2902026	chr2:67856440	G/C	cg18237512	chr2:67827392	NA	-0.44	-5.71	-0.35	3.49e-8	Endometriosis;
SARC	cis	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg06636001	chr8:8085503	FLJ10661	0.68	9.13	0.51	3.48e-17	Mood instability;
SARC	cis	rs11711311	1.000	rs2566968	chr3:113474154	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	7.88	0.46	1.27e-13	IgG glycosylation;
SARC	cis	rs11098499	0.690	rs34818745	chr4:120257055	T/C	cg09160332	chr4:120329925	NA	-0.34	-4.82	-0.3	2.59e-6	Corneal astigmatism;
SARC	cis	rs13161895	0.702	rs12652904	chr5:179496422	C/T	cg06664874	chr5:179499304	RNF130	0.67	6.14	0.37	3.55e-9	LDL cholesterol;
SARC	cis	rs13401104	0.796	rs1377446	chr2:237119668	A/G	cg19324714	chr2:237145437	ASB18	-0.57	-5.96	-0.36	9.22e-9	Educational attainment;
SARC	cis	rs1707322	1.000	rs7547284	chr1:46319565	C/G	cg03146154	chr1:46216737	IPP	0.47	5.67	0.35	4.31e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6163	0.588	rs12763284	chr10:104508202	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.39	4.82	0.3	2.59e-6	Waist circumference;Hip circumference;
SARC	cis	rs8114671	0.967	rs9574	chr20:33764632	C/G	cg24642439	chr20:33292090	TP53INP2	0.54	6.1	0.37	4.32e-9	Height;
SARC	cis	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg02487422	chr3:49467188	NICN1	0.52	7.18	0.43	9.35e-12	Resting heart rate;
SARC	cis	rs12600053	0.554	rs4783077	chr16:84848221	A/G	cg09249803	chr16:84846936	NA	0.38	5.62	0.35	5.45e-8	Asthma (childhood onset);
SARC	cis	rs9467711	0.538	rs7766531	chr6:25886577	T/C	cg21479132	chr6:26055353	NA	0.74	4.92	0.31	1.64e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7264396	0.790	rs6060518	chr20:34217309	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.55	5.53	0.34	8.45e-8	Total cholesterol levels;
SARC	cis	rs995000	0.899	rs1781221	chr1:63006842	A/C	cg06896770	chr1:63153194	DOCK7	-0.9	-13.49	-0.66	5.08e-31	Triglyceride levels;
SARC	cis	rs1401999	0.510	rs17817736	chr3:183720313	A/T	cg01324343	chr3:183735012	ABCC5	-0.47	-8.14	-0.47	2.45e-14	Anterior chamber depth;
SARC	cis	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg24110177	chr3:50126178	RBM5	-0.56	-7.53	-0.44	1.07e-12	Intelligence (multi-trait analysis);
SARC	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg20102877	chr2:27665638	KRTCAP3	-0.36	-5.15	-0.32	5.59e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs7667	0.959	rs12049019	chr1:19713876	T/C	cg15311933	chr1:19638897	PQLC2;AKR7A2	-0.46	-5.51	-0.34	9.45e-8	Crohn's disease and psoriasis;
SARC	cis	rs4951011	0.938	rs55691630	chr1:203760434	C/T	cg05526099	chr1:203152295	CHI3L1	0.37	5.1	0.32	6.98e-7	Breast cancer;
SARC	cis	rs11809207	0.523	rs2783707	chr1:26504196	C/G	cg23602478	chr1:26503979	CNKSR1	0.28	5.03	0.31	9.98e-7	Height;
SARC	cis	rs1865760	0.623	rs12216125	chr6:25997458	C/T	cg10373733	chr6:25993375	NA	0.48	5.63	0.35	5.16e-8	Height;
SARC	cis	rs4481887	0.893	rs28787378	chr1:248504447	C/T	cg01631408	chr1:248437212	OR2T33	-0.45	-6.03	-0.37	6.35e-9	Common traits (Other);
SARC	cis	rs3126085	1.000	rs2011331	chr1:152286002	T/C	cg03465714	chr1:152285911	FLG	0.48	5.56	0.34	7.28e-8	Atopic dermatitis;
SARC	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9790314	0.779	rs12493960	chr3:160899772	T/C	cg04691961	chr3:161091175	C3orf57	-0.7	-9.46	-0.53	3.45e-18	Morning vs. evening chronotype;
SARC	cis	rs7223966	1.000	rs78172786	chr17:61847114	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.52	-5.32	-0.33	2.4e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9314323	0.624	rs117982737	chr8:26241010	C/T	cg11498726	chr8:26250323	BNIP3L	0.65	6.99	0.42	2.86e-11	Red cell distribution width;
SARC	cis	rs2230307	0.706	rs564562	chr1:100471566	T/C	cg24955406	chr1:100503596	HIAT1	0.7	5.87	0.36	1.49e-8	Carotid intima media thickness;
SARC	trans	rs11098499	0.863	rs1552095	chr4:120460306	A/G	cg25214090	chr10:38739885	LOC399744	0.58	7.43	0.44	2.06e-12	Corneal astigmatism;
SARC	trans	rs61931739	0.500	rs7484658	chr12:34515879	A/G	cg26384229	chr12:38710491	ALG10B	0.83	12.41	0.63	1.78e-27	Morning vs. evening chronotype;
SARC	cis	rs734999	0.588	rs6689711	chr1:2531467	T/C	cg18854424	chr1:2615690	NA	-0.32	-5.04	-0.31	9.17e-7	Ulcerative colitis;
SARC	cis	rs2288912	0.807	rs7251501	chr19:45455706	C/T	cg09555818	chr19:45449301	APOC2	0.55	8.91	0.5	1.5e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs9807989	0.524	rs7591246	chr2:102999403	C/A	cg03938978	chr2:103052716	IL18RAP	0.32	5.17	0.32	5.14e-7	Asthma;
SARC	cis	rs554111	0.656	rs964466	chr1:21375163	T/G	cg04902671	chr1:21058625	SH2D5	0.42	5.09	0.32	7.33e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	12.42	0.63	1.66e-27	Platelet count;
SARC	cis	rs2549003	0.870	rs61175929	chr5:131821548	C/G	cg21138405	chr5:131827807	IRF1	0.27	5.32	0.33	2.4e-7	Asthma (sex interaction);
SARC	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg00684032	chr4:1343700	KIAA1530	0.47	6.8	0.41	8.6e-11	Obesity-related traits;
SARC	cis	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg12923728	chr3:195709715	SDHAP1	-0.6	-6.82	-0.41	7.7e-11	Pancreatic cancer;
SARC	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg06808227	chr14:105710500	BRF1	-0.6	-8.05	-0.47	4.18e-14	Mean platelet volume;Platelet distribution width;
SARC	cis	rs2239547	0.603	rs17304995	chr3:53070755	A/G	cg11645453	chr3:52864694	ITIH4	0.33	4.84	0.3	2.31e-6	Schizophrenia;
SARC	cis	rs3091242	1.000	rs646867	chr1:25709258	A/C	cg03650068	chr1:25596491	NA	0.33	5.03	0.31	9.79e-7	Erythrocyte sedimentation rate;
SARC	cis	rs4589502	1.000	rs79390908	chr15:67130924	C/T	cg12317470	chr15:67143691	NA	0.7	4.75	0.3	3.49e-6	Lung cancer (smoking interaction);
SARC	cis	rs911263	0.603	rs3784108	chr14:68789683	T/C	cg18825221	chr14:68749962	RAD51L1	0.41	7.29	0.43	4.84e-12	Primary biliary cholangitis;
SARC	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg05890377	chr2:74357713	NA	0.63	7.51	0.44	1.25e-12	Gestational age at birth (maternal effect);
SARC	cis	rs17253792	0.822	rs28549152	chr14:56091239	A/G	cg01858014	chr14:56050164	KTN1	-0.67	-5.11	-0.32	6.86e-7	Putamen volume;
SARC	cis	rs6500395	1.000	rs9936467	chr16:48677983	T/C	cg04672837	chr16:48644449	N4BP1	0.46	6.28	0.38	1.65e-9	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs7772486	0.790	rs2250387	chr6:146205233	C/T	cg05347473	chr6:146136440	FBXO30	0.49	6.71	0.4	1.48e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs74181299	0.591	rs10205598	chr2:65379251	A/T	cg20592124	chr2:65290738	CEP68	-0.39	-4.98	-0.31	1.27e-6	Pulse pressure;
SARC	trans	rs7927370	1.000	rs61894245	chr11:55351631	G/C	cg07162727	chr16:4848039	ROGDI	0.84	6.28	0.38	1.67e-9	Systemic lupus erythematosus;
SARC	cis	rs7208859	0.673	rs73263785	chr17:29214808	C/T	cg13385521	chr17:29058706	SUZ12P	0.86	7.33	0.43	3.87e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg23758822	chr17:41437982	NA	0.82	9.87	0.54	2e-19	Menopause (age at onset);
SARC	cis	rs9393777	0.513	rs9379895	chr6:26592707	A/G	cg12826209	chr6:26865740	GUSBL1	0.67	6.21	0.38	2.39e-9	Intelligence (multi-trait analysis);
SARC	cis	rs6901250	0.632	rs1853080	chr6:117196157	T/C	cg12892004	chr6:117198278	RFX6	-0.36	-5.27	-0.33	3.14e-7	C-reactive protein levels;
SARC	cis	rs13314892	0.764	rs1897159	chr3:69870465	T/A	cg17445875	chr3:69859618	MITF	-0.49	-5.12	-0.32	6.44e-7	QRS complex (12-leadsum);
SARC	cis	rs2070488	0.775	rs13098946	chr3:38517784	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	12.14	0.62	1.37e-26	Electrocardiographic conduction measures;
SARC	cis	rs9400467	0.506	rs75819068	chr6:111722487	A/C	cg15721981	chr6:111408429	SLC16A10	0.65	5.65	0.35	4.61e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-5.96	-0.36	9.37e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg19748678	chr4:122722346	EXOSC9	0.78	10.43	0.56	3.8e-21	Type 2 diabetes;
SARC	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg18099408	chr3:52552593	STAB1	-0.4	-5.25	-0.33	3.49e-7	Electroencephalogram traits;
SARC	cis	rs2204008	0.560	rs4129033	chr12:38301897	A/T	cg26384229	chr12:38710491	ALG10B	-0.6	-7.47	-0.44	1.6e-12	Bladder cancer;
SARC	cis	rs12579753	1.000	rs12580330	chr12:82241280	T/G	cg07988820	chr12:82153109	PPFIA2	-0.52	-6.07	-0.37	5.24e-9	Resting heart rate;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg06075477	chr7:91875292	KRIT1;ANKIB1	0.62	6.45	0.39	6.22e-10	Lung cancer in ever smokers;
SARC	cis	rs4792901	0.802	rs2271958	chr17:41599383	C/T	cg22562494	chr17:41607896	ETV4	-0.33	-4.89	-0.3	1.9e-6	Dupuytren's disease;
SARC	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg05896524	chr21:47604654	C21orf56	0.58	6.82	0.41	7.83e-11	Testicular germ cell tumor;
SARC	cis	rs1707322	0.964	rs785516	chr1:46564758	T/G	cg03146154	chr1:46216737	IPP	-0.48	-5.73	-0.35	3.11e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs2736345	0.535	rs4366049	chr8:11398504	A/G	cg06636001	chr8:8085503	FLJ10661	0.58	7.8	0.46	2.09e-13	Sjögren's syndrome;Systemic lupus erythematosus;
SARC	cis	rs17270561	0.609	rs7754733	chr6:25745049	C/G	cg16482183	chr6:26056742	HIST1H1C	0.43	5.08	0.32	7.76e-7	Iron status biomarkers;
SARC	cis	rs6448317	0.911	rs10939013	chr4:24903015	G/A	cg21108841	chr4:24914750	CCDC149	0.55	6.27	0.38	1.69e-9	Heschl's gyrus morphology;
SARC	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg06221963	chr1:154839813	KCNN3	-0.41	-6.38	-0.39	9.66e-10	Prostate cancer;
SARC	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.8	7.48	0.44	1.46e-12	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs826838	1.000	rs11168676	chr12:38977304	A/G	cg26384229	chr12:38710491	ALG10B	0.92	14.23	0.68	1.69e-33	Heart rate;
SARC	cis	rs17331151	0.573	rs77223362	chr3:52865125	G/A	cg04865290	chr3:52927548	TMEM110	-0.62	-5.81	-0.36	2.07e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs8180040	0.676	rs66564457	chr3:47020072	G/A	cg27129171	chr3:47204927	SETD2	0.64	8.66	0.49	7.84e-16	Colorectal cancer;
SARC	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg25952890	chr19:58913133	NA	0.35	4.98	0.31	1.23e-6	Uric acid clearance;
SARC	cis	rs6087990	0.735	rs2424906	chr20:31359109	A/G	cg13636640	chr20:31349939	DNMT3B	0.81	12.78	0.64	1.11e-28	Ulcerative colitis;
SARC	cis	rs13082711	0.911	rs13075550	chr3:27427618	A/G	cg02860705	chr3:27208620	NA	0.48	6.3	0.38	1.51e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs12142240	0.698	rs17361791	chr1:46812519	A/G	cg00530320	chr1:46809349	NSUN4	0.58	7.07	0.42	1.83e-11	Menopause (age at onset);
SARC	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg02018176	chr4:1364513	KIAA1530	0.44	6.66	0.4	2e-10	Longevity;
SARC	cis	rs2486288	0.656	rs8037583	chr15:45546378	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.46	-5.63	-0.35	5.13e-8	Glomerular filtration rate;
SARC	cis	rs72945132	0.507	rs34612166	chr11:70244400	C/T	cg05964544	chr11:70165517	PPFIA1	-0.65	-6.2	-0.38	2.57e-9	Coronary artery disease;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg22960649	chr15:65134317	PLEKHO2	0.51	6.33	0.38	1.23e-9	Breast cancer;
SARC	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.73	-7.62	-0.45	6.25e-13	Platelet count;
SARC	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg18876405	chr7:65276391	NA	0.74	9.42	0.53	4.63e-18	Aortic root size;
SARC	cis	rs11997175	0.599	rs66474258	chr8:33640225	A/T	ch.8.33884649F	chr8:33765107	NA	0.51	6.82	0.41	7.61e-11	Body mass index;
SARC	trans	rs561341	1.000	rs7210970	chr17:30262169	G/A	cg20587970	chr11:113659929	NA	-0.99	-9.9	-0.54	1.65e-19	Hip circumference adjusted for BMI;
SARC	cis	rs7520050	0.807	rs4468203	chr1:46113272	T/C	cg06784218	chr1:46089804	CCDC17	0.26	4.82	0.3	2.6e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs6840360	0.593	rs10016160	chr4:152693998	A/G	cg22705602	chr4:152727874	NA	-0.5	-8.91	-0.5	1.51e-16	Intelligence (multi-trait analysis);
SARC	cis	rs2235642	0.750	rs1894649	chr16:1657284	C/G	cg03715980	chr16:1756201	MAPK8IP3	0.39	4.87	0.3	2.05e-6	Coronary artery disease;
SARC	cis	rs15676	0.783	rs2977995	chr9:131584245	A/G	cg00228799	chr9:131580591	ENDOG	0.62	7.81	0.46	1.94e-13	Blood metabolite levels;
SARC	trans	rs10209086	0.736	rs1584436	chr2:138298878	A/G	cg11942548	chr13:22248814	FGF9	-0.47	-6.31	-0.38	1.4e-9	Multiple system atrophy;
SARC	cis	rs4423214	1.000	rs12790010	chr11:71170653	T/C	cg05163923	chr11:71159392	DHCR7	0.64	8.92	0.5	1.44e-16	Vitamin D levels;
SARC	cis	rs6088580	0.584	rs2378203	chr20:32993846	A/T	cg24642439	chr20:33292090	TP53INP2	-0.67	-8.48	-0.49	2.61e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs1594829	0.553	rs17055108	chr8:26160739	G/A	cg11498726	chr8:26250323	BNIP3L	-0.4	-5.27	-0.33	3.09e-7	Height;
SARC	cis	rs3820928	0.904	rs4129884	chr2:227820943	G/A	cg05526886	chr2:227700861	RHBDD1	-0.54	-6.65	-0.4	2.03e-10	Pulmonary function;
SARC	cis	rs8017423	0.967	rs11621045	chr14:90714003	C/T	cg20276874	chr14:90721474	PSMC1	-0.36	-5.04	-0.31	9.53e-7	Mortality in heart failure;
SARC	cis	rs9399135	0.660	rs4267967	chr6:135272477	T/G	cg24558204	chr6:135376177	HBS1L	0.47	6.26	0.38	1.82e-9	Red blood cell count;
SARC	cis	rs17376456	0.877	rs9314093	chr5:93333347	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.43	0.33	1.44e-7	Diabetic retinopathy;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg08838260	chr4:140004785	ELF2	-0.51	-6.56	-0.39	3.41e-10	Schizophrenia;
SARC	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg24060327	chr5:131705240	SLC22A5	-0.46	-5.55	-0.34	7.66e-8	Acylcarnitine levels;
SARC	cis	rs459571	0.959	rs465535	chr9:136910905	C/T	cg13789015	chr9:136890014	NCRNA00094	0.6	8.38	0.48	5.17e-15	Platelet distribution width;
SARC	cis	rs6815814	0.950	rs11725779	chr4:38811668	G/A	cg06935464	chr4:38784597	TLR10	0.63	6.34	0.38	1.16e-9	Breast cancer;
SARC	cis	rs12079745	0.793	rs12067139	chr1:169254507	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.78	-4.99	-0.31	1.16e-6	QT interval;
SARC	cis	rs3859192	0.557	rs12602514	chr17:38159745	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.38	6.98	0.42	3.08e-11	White blood cell count;
SARC	cis	rs7712401	0.623	rs26372	chr5:122206447	C/T	cg19412675	chr5:122181750	SNX24	-0.43	-5.51	-0.34	9.3e-8	Mean platelet volume;
SARC	cis	rs644799	1.000	rs1944074	chr11:95511445	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.87	13.82	0.67	4.02e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs1814175	0.781	rs12286395	chr11:49954062	C/G	cg15704280	chr7:45808275	SEPT13	-0.97	-18.54	-0.77	9.52e-48	Height;
SARC	trans	rs61931739	0.500	rs28692887	chr12:34457075	G/A	cg13010199	chr12:38710504	ALG10B	0.81	11.29	0.59	7.09e-24	Morning vs. evening chronotype;
SARC	cis	rs57506017	0.585	rs7804234	chr7:12266814	A/G	cg23422036	chr7:12250390	TMEM106B	0.46	5.95	0.36	1e-8	Neuroticism;
SARC	trans	rs17685	0.712	rs869805	chr7:75688596	C/T	cg19862616	chr7:65841803	NCRNA00174	0.61	7.65	0.45	5.19e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs5769765	1.000	rs5769765	chr22:50271176	G/A	cg03033257	chr22:50311977	ALG12;CRELD2	-0.54	-5.64	-0.35	4.81e-8	Schizophrenia;
SARC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg22105103	chr4:187893119	NA	0.5	6.47	0.39	5.84e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg22535103	chr8:58192502	C8orf71	-0.74	-7.44	-0.44	1.87e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg05861140	chr6:150128134	PCMT1	-0.41	-5.34	-0.33	2.19e-7	Lung cancer;
SARC	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg15847926	chr7:2749597	AMZ1	-0.3	-5.05	-0.31	9.07e-7	Height;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg00944599	chr7:98479808	TRRAP	0.47	6.31	0.38	1.38e-9	Breast cancer;
SARC	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg04518342	chr5:131593106	PDLIM4	0.36	5.19	0.32	4.48e-7	Breast cancer;
SARC	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg02725872	chr8:58115012	NA	-0.37	-6.55	-0.39	3.71e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9486719	1.000	rs2499807	chr6:96864053	T/G	cg06623918	chr6:96969491	KIAA0776	0.73	8.01	0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-8.89	-0.5	1.75e-16	Alzheimer's disease;
SARC	cis	rs1008375	0.931	rs7672369	chr4:17604825	A/G	cg02297831	chr4:17616191	MED28	0.51	6.48	0.39	5.36e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg10523679	chr1:76189770	ACADM	0.4	5.3	0.33	2.73e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs75920871	0.588	rs7112111	chr11:116980858	T/G	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-5.21	-0.32	4.16e-7	Subjective well-being;
SARC	cis	rs73198271	0.700	rs10090152	chr8:8652104	C/A	cg06636001	chr8:8085503	FLJ10661	-0.47	-5.38	-0.33	1.85e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs8017423	0.967	rs4900033	chr14:90701963	C/A	cg20276874	chr14:90721474	PSMC1	-0.36	-5.01	-0.31	1.09e-6	Mortality in heart failure;
SARC	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg00933542	chr6:150070202	PCMT1	0.3	5.22	0.32	3.91e-7	Lung cancer;
SARC	cis	rs2204008	0.580	rs36118148	chr12:38411812	G/A	cg13010199	chr12:38710504	ALG10B	-0.49	-5.94	-0.36	1.05e-8	Bladder cancer;
SARC	cis	rs240764	0.717	rs6916468	chr6:101160325	G/C	cg09795085	chr6:101329169	ASCC3	-0.47	-5.92	-0.36	1.17e-8	Neuroticism;
SARC	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg03351412	chr1:154909251	PMVK	0.62	7.91	0.46	1.03e-13	Prostate cancer;
SARC	cis	rs11690935	0.959	rs13419987	chr2:172623914	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.0	-16.02	-0.72	1.9e-39	Schizophrenia;
SARC	cis	rs6016377	0.798	rs6029182	chr20:39179402	A/C	cg06424997	chr20:39929561	ZHX3	0.37	4.89	0.3	1.92e-6	Birth weight;
SARC	cis	rs6942407	0.546	rs2286268	chr7:86848385	C/T	cg02420886	chr7:86849541	C7orf23	0.71	6.17	0.37	3.02e-9	Food allergy;
SARC	cis	rs79349575	0.783	rs4793991	chr17:47001801	A/G	cg16584676	chr17:46985605	UBE2Z	0.53	6.37	0.39	9.89e-10	Type 2 diabetes;
SARC	cis	rs4242434	0.927	rs57594397	chr8:22475657	T/C	cg03733263	chr8:22462867	KIAA1967	1.05	16.97	0.74	1.33e-42	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs11718455	0.653	rs28533958	chr3:43974179	C/A	cg08738300	chr3:44038990	NA	0.52	5.63	0.35	5.04e-8	Coronary artery disease;
SARC	cis	rs1153858	1.000	rs2056493	chr15:45648272	A/G	cg21132104	chr15:45694354	SPATA5L1	0.77	10.83	0.58	2.16e-22	Homoarginine levels;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg26357241	chr1:109289876	STXBP3	0.49	6.29	0.38	1.57e-9	Breast cancer;
SARC	cis	rs11874712	1.000	rs7244950	chr18:43676523	G/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.46	5.49	0.34	1.06e-7	Migraine - clinic-based;
SARC	cis	rs748404	0.697	rs513970	chr15:43579566	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.55	6.42	0.39	7.52e-10	Lung cancer;
SARC	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg16606324	chr3:10149918	C3orf24	0.49	4.82	0.3	2.56e-6	Alzheimer's disease;
SARC	cis	rs8067545	0.586	rs2703819	chr17:20121401	A/G	cg13482628	chr17:19912719	NA	-0.53	-6.8	-0.41	8.58e-11	Schizophrenia;
SARC	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg07343612	chr16:622815	PIGQ	-0.59	-8.34	-0.48	6.46e-15	Height;
SARC	cis	rs1163251	0.837	rs839612	chr1:120247176	T/C	cg19096424	chr1:120255104	PHGDH	0.59	6.95	0.41	3.61e-11	Blood metabolite levels;
SARC	cis	rs17376456	0.569	rs2924374	chr5:93151141	T/C	cg21475434	chr5:93447410	FAM172A	-0.62	-6.01	-0.37	7.06e-9	Diabetic retinopathy;
SARC	cis	rs2120243	0.539	rs2085315	chr3:157112622	T/G	cg24825693	chr3:157122686	VEPH1	-0.46	-6.42	-0.39	7.47e-10	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs9790314	0.543	rs1349352	chr3:161118486	C/T	cg03342759	chr3:160939853	NMD3	-0.58	-7.19	-0.43	8.93e-12	Morning vs. evening chronotype;
SARC	cis	rs56011263	0.687	rs11734460	chr4:705074	C/T	cg20735989	chr4:730612	PCGF3	-0.47	-5.47	-0.34	1.15e-7	White blood cell count;
SARC	cis	rs17030434	0.954	rs10000558	chr4:154766835	A/T	cg14289246	chr4:154710475	SFRP2	-0.77	-7.84	-0.46	1.5700000000000001e-13	Electrocardiographic conduction measures;
SARC	cis	rs607987	0.871	rs675635	chr11:30271406	C/T	cg06241208	chr11:30344200	C11orf46	-0.41	-4.9	-0.31	1.79e-6	Body mass index;
SARC	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.47	7.43	0.44	2.07e-12	Schizophrenia;
SARC	cis	rs13095912	1.000	rs17523471	chr3:185304018	T/C	cg11274856	chr3:185301563	NA	0.35	4.87	0.3	2.07e-6	Systolic blood pressure;
SARC	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg03647317	chr4:187891568	NA	-0.34	-4.75	-0.3	3.59e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs796364	0.806	rs203769	chr2:200900866	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.66	-5.37	-0.33	1.88e-7	Schizophrenia;
SARC	cis	rs78487399	0.520	rs7609256	chr2:43672499	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.14	-0.32	5.7e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg08280861	chr8:58055591	NA	0.7	6.02	0.37	6.73e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6424115	0.679	rs2076345	chr1:24083494	C/T	cg15997130	chr1:24165203	NA	-0.45	-5.62	-0.35	5.55e-8	Immature fraction of reticulocytes;
SARC	cis	rs2075371	1.000	rs2505	chr7:133979552	C/T	cg20476274	chr7:133979776	SLC35B4	0.61	8.46	0.48	2.89e-15	Mean platelet volume;
SARC	cis	rs7552404	0.924	rs1146574	chr1:76202671	A/G	cg03433033	chr1:76189801	ACADM	0.48	6.99	0.42	2.82e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2594989	0.673	rs9855241	chr3:11602910	C/T	cg00170343	chr3:11313890	ATG7	-0.56	-5.41	-0.33	1.54e-7	Circulating chemerin levels;
SARC	cis	rs8067545	0.616	rs203465	chr17:19810720	T/G	cg04132472	chr17:19861366	AKAP10	0.39	5.1	0.32	7.18e-7	Schizophrenia;
SARC	cis	rs72781680	0.715	rs72796332	chr2:24142060	G/A	cg08917208	chr2:24149416	ATAD2B	0.58	5.88	0.36	1.42e-8	Lymphocyte counts;
SARC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg03180552	chr7:157981849	PTPRN2	0.3	4.74	0.3	3.69e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
SARC	cis	rs9747201	0.926	rs35131420	chr17:80103631	T/C	cg17462356	chr17:80056334	FASN	0.46	5.28	0.33	2.96e-7	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg18404041	chr3:52824283	ITIH1	-0.44	-6.7	-0.4	1.58e-10	Bipolar disorder;
SARC	cis	rs6570726	0.791	rs1280275	chr6:145892402	C/T	cg05347473	chr6:146136440	FBXO30	0.5	6.94	0.41	3.89e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs908922	0.676	rs545418	chr1:152497338	C/T	cg09873164	chr1:152488093	CRCT1	0.63	8.06	0.47	4.07e-14	Hair morphology;
SARC	cis	rs11581859	0.613	rs56090634	chr1:99188806	A/G	cg20286094	chr1:99190917	SNX7	-0.41	-4.88	-0.3	1.97e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs16976116	0.901	rs1050931	chr15:55497691	G/A	cg17854078	chr15:55489399	RSL24D1	0.66	6.53	0.39	4.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6840360	0.571	rs4696274	chr4:152528478	C/A	cg22705602	chr4:152727874	NA	-0.43	-6.69	-0.4	1.65e-10	Intelligence (multi-trait analysis);
SARC	cis	rs55962025	0.883	rs82332	chr4:3225466	A/G	cg06533319	chr4:3265114	C4orf44	0.32	4.95	0.31	1.45e-6	Parental longevity (mother's age at death);
SARC	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg08219700	chr8:58056026	NA	0.74	6.83	0.41	7.42e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg09699651	chr6:150184138	LRP11	0.48	5.87	0.36	1.48e-8	Lung cancer;
SARC	cis	rs77972916	0.536	rs59362315	chr2:43594931	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.47	-5.23	-0.32	3.72e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.29	-0.48	9.28e-15	Mood instability;
SARC	cis	rs6570726	0.935	rs395948	chr6:145820185	G/A	cg05220968	chr6:146057943	EPM2A	-0.29	-4.83	-0.3	2.44e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9902453	1.000	rs8065261	chr17:28418041	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.52	-6.79	-0.41	9.2e-11	Coffee consumption (cups per day);
SARC	cis	rs10463554	0.963	rs34774	chr5:102450820	G/T	cg23492399	chr5:102201601	PAM	-0.5	-5.54	-0.34	8.31e-8	Parkinson's disease;
SARC	cis	rs2645694	0.626	rs2703136	chr4:77828957	T/A	cg10057126	chr4:77819792	ANKRD56	0.41	6.16	0.37	3.2e-9	Emphysema distribution in smoking;
SARC	cis	rs3008870	0.651	rs2815376	chr1:67508531	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.44	5.68	0.35	3.99e-8	Lymphocyte percentage of white cells;
SARC	trans	rs11098499	0.863	rs11723090	chr4:120490592	T/C	cg25214090	chr10:38739885	LOC399744	0.57	7.25	0.43	6.27e-12	Corneal astigmatism;
SARC	cis	rs9948	0.708	rs116121826	chr2:97441914	A/G	cg01990225	chr2:97406019	LMAN2L	-0.96	-6.95	-0.41	3.73e-11	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs9916302	0.851	rs9909064	chr17:37500434	G/T	cg07936489	chr17:37558343	FBXL20	0.69	9.14	0.51	3.18e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs10845606	1.000	rs10845609	chr12:12838920	T/A	cg04607235	chr12:12878440	APOLD1	-0.53	-5.28	-0.33	2.93e-7	Systemic lupus erythematosus;
SARC	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg19223190	chr17:80058835	NA	0.43	6.05	0.37	5.72e-9	Life satisfaction;
SARC	cis	rs644799	1.000	rs3177463	chr11:95502128	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	9.54	0.53	1.99e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg11941060	chr3:133502564	NA	0.32	4.87	0.3	2.04e-6	Iron status biomarkers;
SARC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.08	-17.4	-0.75	5.24e-44	Prudent dietary pattern;
SARC	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg10523679	chr1:76189770	ACADM	0.53	7.0	0.42	2.67e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9916302	0.904	rs2061338	chr17:37421767	T/C	cg20243544	chr17:37824526	PNMT	0.56	6.94	0.41	3.95e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs713477	1.000	rs12886860	chr14:55911150	G/C	cg13175173	chr14:55914753	NA	-0.3	-4.74	-0.3	3.66e-6	Pediatric bone mineral content (femoral neck);
SARC	trans	rs2727020	0.553	rs3907576	chr11:49536639	A/C	cg03929089	chr4:120376271	NA	-0.75	-11.03	-0.59	5.02e-23	Coronary artery disease;
SARC	cis	rs1349547	0.510	rs12708194	chr8:39496029	T/C	cg12140000	chr8:38554703	NA	0.31	4.74	0.3	3.79e-6	HIV-1 susceptibility;
SARC	cis	rs546131	0.642	rs12794294	chr11:34827518	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-5.02	-0.31	1.03e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs79149102	0.579	rs74023908	chr15:75310710	T/C	cg09165964	chr15:75287851	SCAMP5	-1.02	-9.12	-0.51	3.52e-17	Lung cancer;
SARC	cis	rs66716358	0.744	rs11037943	chr11:44317445	A/G	cg16977035	chr11:44330474	ALX4	0.25	4.73	0.3	3.89e-6	Monobrow;
SARC	cis	rs1707322	0.752	rs28438704	chr1:46170544	G/A	cg06784218	chr1:46089804	CCDC17	0.36	6.17	0.37	2.95e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs981844	0.712	rs4632640	chr4:154742389	G/C	cg25721732	chr2:74602550	DCTN1	-0.51	-6.28	-0.38	1.63e-9	Response to statins (LDL cholesterol change);
SARC	cis	rs13256369	0.756	rs13282580	chr8:8562903	C/T	cg18904891	chr8:8559673	CLDN23	0.49	5.55	0.34	7.9e-8	Obesity-related traits;
SARC	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg03351412	chr1:154909251	PMVK	0.65	8.39	0.48	4.69e-15	Prostate cancer;
SARC	cis	rs7772486	0.782	rs7747576	chr6:146277827	C/T	cg05347473	chr6:146136440	FBXO30	-0.48	-6.53	-0.39	3.98e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7727544	0.507	rs9791170	chr5:131569627	A/G	cg04518342	chr5:131593106	PDLIM4	0.38	5.23	0.32	3.85e-7	Blood metabolite levels;
SARC	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg08280861	chr8:58055591	NA	0.59	5.8	0.36	2.12e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs710216	0.843	rs2297972	chr1:43418026	C/T	cg07803811	chr1:43423981	SLC2A1	-0.58	-6.44	-0.39	6.82e-10	Red cell distribution width;
SARC	cis	rs9457247	0.534	rs9347170	chr6:167405187	C/T	cg23791538	chr6:167370224	RNASET2	0.74	10.73	0.58	4.21e-22	Crohn's disease;
SARC	cis	rs7216064	0.531	rs62084683	chr17:66031725	A/G	cg12091567	chr17:66097778	LOC651250	0.93	11.88	0.61	9.56e-26	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg08219700	chr8:58056026	NA	0.65	6.14	0.37	3.57e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	10.42	0.56	3.99e-21	Platelet count;
SARC	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg09699651	chr6:150184138	LRP11	0.41	4.99	0.31	1.17e-6	Lung cancer;
SARC	cis	rs7520050	0.931	rs11211224	chr1:46384388	G/A	cg24296786	chr1:45957014	TESK2	0.39	4.9	0.31	1.77e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs7818688	0.697	rs11780130	chr8:95976083	A/G	cg13393036	chr8:95962371	TP53INP1	0.43	5.11	0.32	6.66e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs11676348	0.703	rs6737563	chr2:218945674	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.5	-6.46	-0.39	6e-10	Ulcerative colitis;
SARC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg11494091	chr17:61959527	GH2	0.54	8.02	0.47	5.15e-14	Prudent dietary pattern;
SARC	cis	rs9381040	0.655	rs6903444	chr6:41014220	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	0.42	4.8	0.3	2.89e-6	Alzheimer's disease (late onset);
SARC	cis	rs2645694	0.626	rs2645709	chr4:77824474	G/A	cg10057126	chr4:77819792	ANKRD56	0.43	6.64	0.4	2.14e-10	Emphysema distribution in smoking;
SARC	cis	rs9399137	0.507	rs4896118	chr6:135276065	A/G	cg24558204	chr6:135376177	HBS1L	-0.58	-7.28	-0.43	4.95e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	trans	rs1161098	0.716	rs1161179	chr12:67825924	T/A	cg14535245	chr2:47283713	TTC7A	-0.64	-6.29	-0.38	1.55e-9	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs1580019	0.885	rs4580942	chr7:32496435	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.42	5.01	0.31	1.08e-6	Cognitive ability;
SARC	cis	rs4642101	0.611	rs6442331	chr3:12820636	T/G	cg05775895	chr3:12838266	CAND2	0.71	10.56	0.57	1.52e-21	QRS complex (12-leadsum);
SARC	cis	rs1318878	0.639	rs10161094	chr12:15517979	A/G	cg08258403	chr12:15378311	NA	0.5	6.84	0.41	6.85e-11	Intelligence (multi-trait analysis);
SARC	cis	rs62408225	0.802	rs2325261	chr6:90921407	T/C	cg06866423	chr6:90926672	BACH2	0.32	5.03	0.31	9.87e-7	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg22885975	chr20:55926578	RAE1	0.83	7.03	0.42	2.25e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg06212747	chr3:49208901	KLHDC8B	0.51	6.38	0.39	9.63e-10	Resting heart rate;
SARC	cis	rs4803468	1.000	rs2288871	chr19:41917868	C/T	cg08477640	chr19:41863820	B9D2	0.41	5.2	0.32	4.46e-7	Height;
SARC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg07414643	chr4:187882934	NA	0.52	7.86	0.46	1.42e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg03161606	chr19:29218774	NA	0.5	7.12	0.42	1.33e-11	Methadone dose in opioid dependence;
SARC	cis	rs9303401	0.659	rs17222621	chr17:56695923	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	12.63	0.64	3.28e-28	Cognitive test performance;
SARC	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg18252515	chr7:66147081	NA	0.55	5.82	0.36	1.89e-8	Aortic root size;
SARC	cis	rs6496667	0.821	rs13329289	chr15:90897454	C/T	cg22089800	chr15:90895588	ZNF774	0.51	4.75	0.3	3.53e-6	Rheumatoid arthritis;
SARC	cis	rs6542838	0.611	rs1878589	chr2:99517979	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-5.4	-0.33	1.62e-7	Fear of minor pain;
SARC	cis	rs3020736	0.500	rs6002623	chr22:42513761	G/A	cg04733989	chr22:42467013	NAGA	-0.76	-10.57	-0.57	1.4e-21	Autism spectrum disorder or schizophrenia;
SARC	cis	rs17376456	0.877	rs2290937	chr5:93356515	A/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.47	0.34	1.18e-7	Diabetic retinopathy;
SARC	cis	rs6424115	0.964	rs2473375	chr1:24136545	C/T	cg15997130	chr1:24165203	NA	0.49	6.76	0.4	1.11e-10	Immature fraction of reticulocytes;
SARC	cis	rs4072980	0.545	rs7519947	chr1:38447725	T/C	cg18451016	chr1:38461880	NA	-0.36	-4.85	-0.3	2.28e-6	Coronary artery disease;
SARC	cis	rs4423214	0.840	rs1619577	chr11:71181485	C/T	cg05163923	chr11:71159392	DHCR7	-0.6	-7.29	-0.43	4.65e-12	Vitamin D levels;
SARC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg14159672	chr1:205819179	PM20D1	0.85	13.38	0.66	1.16e-30	Menarche (age at onset);
SARC	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg18305652	chr10:134549665	INPP5A	0.33	4.73	0.3	3.95e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs950169	0.922	rs67804993	chr15:85104030	T/G	cg17507749	chr15:85114479	UBE2QP1	0.79	9.68	0.54	7.68e-19	Schizophrenia;
SARC	cis	rs941408	0.515	rs56000942	chr19:2774104	G/C	cg00079169	chr19:2811669	THOP1	0.54	5.63	0.35	5.28e-8	Total cholesterol levels;
SARC	cis	rs80130819	0.748	rs2732455	chr12:48677995	C/T	cg05342945	chr12:48394962	COL2A1	-0.55	-5.79	-0.35	2.31e-8	Prostate cancer;
SARC	cis	rs7178572	0.568	rs3743479	chr15:77406396	A/G	cg22256960	chr15:77711686	NA	0.5	5.43	0.34	1.4e-7	Type 2 diabetes;
SARC	cis	rs2120243	0.539	rs7617727	chr3:157105558	A/C	cg01018701	chr3:157155998	VEPH1;PTX3	-0.4	-5.17	-0.32	5.04e-7	Hepatocellular carcinoma in hepatitis B infection;
SARC	trans	rs7937682	0.889	rs497111	chr11:111499512	G/A	cg18187862	chr3:45730750	SACM1L	0.57	7.11	0.42	1.45e-11	Primary sclerosing cholangitis;
SARC	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg12463550	chr7:65579703	CRCP	-0.7	-5.34	-0.33	2.21e-7	Diabetic kidney disease;
SARC	cis	rs6540556	0.723	rs9430016	chr1:209916884	A/G	cg05527609	chr1:210001259	C1orf107	-0.56	-5.73	-0.35	3.1e-8	Red blood cell count;
SARC	cis	rs10754283	0.967	rs10801763	chr1:90120822	C/T	cg21401794	chr1:90099060	LRRC8C	0.6	8.45	0.48	3.16e-15	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs60733400	0.782	rs4648564	chr1:2562169	C/T	cg00980319	chr1:2560884	MMEL1	0.35	4.89	0.31	1.85e-6	Multiple sclerosis;
SARC	cis	rs6500602	0.727	rs3761681	chr16:4566857	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.34	5.64	0.35	4.93e-8	Schizophrenia;
SARC	cis	rs9398803	0.713	rs1490384	chr6:126851160	C/T	cg20229609	chr6:126660872	C6orf173	0.4	5.79	0.35	2.26e-8	Male-pattern baldness;
SARC	cis	rs13040088	0.935	rs3787513	chr20:61573736	G/A	cg23096297	chr20:61557774	DIDO1	0.92	9.75	0.54	4.65e-19	Menopause (age at onset);
SARC	cis	rs7818345	0.967	rs11784873	chr8:19281113	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.41	5.44	0.34	1.36e-7	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs911555	0.755	rs17841064	chr14:103900609	A/G	cg24130564	chr14:104152367	KLC1	-0.46	-5.3	-0.33	2.63e-7	Intelligence (multi-trait analysis);
SARC	cis	rs690037	0.528	rs568833	chr3:16367836	C/T	cg23474789	chr3:16306055	DPH3;OXNAD1	-0.58	-7.09	-0.42	1.55e-11	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);
SARC	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg20607798	chr8:58055168	NA	0.54	5.18	0.32	4.82e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2153535	0.580	rs9406143	chr6:8444583	C/T	cg07606381	chr6:8435919	SLC35B3	0.78	11.09	0.59	3.11e-23	Motion sickness;
SARC	cis	rs950776	0.593	rs555018	chr15:78879242	G/A	cg06917634	chr15:78832804	PSMA4	-0.84	-12.56	-0.64	5.52e-28	Sudden cardiac arrest;
SARC	cis	rs9660992	0.649	rs12128254	chr1:205268097	C/T	cg21545522	chr1:205238299	TMCC2	0.44	5.86	0.36	1.61e-8	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs11168187	0.843	rs3764017	chr12:48120899	G/T	cg12761788	chr12:48120090	P11	0.39	5.06	0.31	8.51e-7	Vertical cup-disc ratio;
SARC	cis	rs1355223	0.902	rs35032224	chr11:34698154	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-5.4	-0.33	1.61e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs1018836	0.923	rs13267989	chr8:91581648	C/T	cg16814680	chr8:91681699	NA	-0.83	-13.35	-0.66	1.41e-30	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs7084402	0.967	rs1658485	chr10:60288331	A/G	cg07615347	chr10:60278583	BICC1	0.61	8.99	0.51	8.84e-17	Refractive error;
SARC	cis	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg03060546	chr3:49711283	APEH	-0.66	-8.37	-0.48	5.47e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs514406	0.505	rs269292	chr1:53187911	T/C	cg24675658	chr1:53192096	ZYG11B	-0.65	-9.6	-0.53	1.36e-18	Monocyte count;
SARC	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.33	-4.8	-0.3	2.79e-6	Total body bone mineral density;
SARC	cis	rs6087990	0.871	rs4911252	chr20:31330115	A/G	cg13636640	chr20:31349939	DNMT3B	-0.79	-12.57	-0.64	5.15e-28	Ulcerative colitis;
SARC	cis	rs8114671	0.562	rs4911447	chr20:33479445	T/A	cg24642439	chr20:33292090	TP53INP2	0.49	5.96	0.36	9.31e-9	Height;
SARC	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg19723775	chr5:179050963	HNRNPH1	0.44	5.44	0.34	1.36e-7	Lung cancer;
SARC	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg25072359	chr17:41440525	NA	0.51	6.24	0.38	2e-9	Menopause (age at onset);
SARC	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.37	-4.85	-0.3	2.26e-6	Bronchopulmonary dysplasia;
SARC	cis	rs6546324	1.000	rs4141819	chr2:67864675	C/T	cg18237512	chr2:67827392	NA	-0.43	-5.45	-0.34	1.31e-7	Endometriosis;
SARC	cis	rs73206853	0.764	rs56179460	chr12:111125774	C/G	cg10860002	chr12:110842031	ANAPC7	0.63	5.23	0.32	3.79e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs10504229	0.679	rs16921623	chr8:58039473	G/C	cg22535103	chr8:58192502	C8orf71	-0.57	-5.62	-0.35	5.46e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg04166393	chr7:2884313	GNA12	0.58	6.91	0.41	4.64e-11	Height;
SARC	cis	rs4642101	0.680	rs6442330	chr3:12820501	A/G	cg24848339	chr3:12840334	CAND2	0.39	5.81	0.36	2.05e-8	QRS complex (12-leadsum);
SARC	cis	rs12893668	0.514	rs3212090	chr14:104168863	C/T	cg26031613	chr14:104095156	KLC1	-0.53	-5.74	-0.35	2.95e-8	Reticulocyte count;
SARC	trans	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg20587970	chr11:113659929	NA	-0.84	-8.36	-0.48	5.74e-15	Hip circumference adjusted for BMI;
SARC	cis	rs1278769	0.786	rs3742238	chr13:113540425	C/T	cg01161842	chr13:113518337	ATP11A	0.44	4.96	0.31	1.38e-6	Interstitial lung disease;
SARC	cis	rs875971	0.545	rs801199	chr7:66025273	A/G	cg11764359	chr7:65958608	NA	-0.62	-6.06	-0.37	5.55e-9	Aortic root size;
SARC	cis	rs10752881	1.000	rs10797811	chr1:182984432	G/A	cg13390022	chr1:182993471	LAMC1	0.34	5.15	0.32	5.59e-7	Colorectal cancer;
SARC	cis	rs782590	0.837	rs782573	chr2:55912961	T/C	cg18811423	chr2:55921094	PNPT1	0.78	11.89	0.61	8.85e-26	Metabolic syndrome;
SARC	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg00933542	chr6:150070202	PCMT1	0.31	5.29	0.33	2.79e-7	Lung cancer;
SARC	cis	rs735396	0.770	rs1169315	chr12:121443753	T/G	cg02403541	chr12:121454288	C12orf43	0.84	12.51	0.63	8.09e-28	N-glycan levels;
SARC	cis	rs11098499	0.874	rs13139045	chr4:120168588	T/C	cg09307838	chr4:120376055	NA	0.79	11.29	0.59	7.28e-24	Corneal astigmatism;
SARC	cis	rs6456156	0.524	rs6934043	chr6:167466449	C/T	cg07741184	chr6:167504864	NA	0.35	6.83	0.41	7.46e-11	Primary biliary cholangitis;
SARC	cis	rs6772849	0.930	rs4467479	chr3:128369055	C/G	cg08795948	chr3:128337044	NA	0.54	7.68	0.45	4.41e-13	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg20120463	chr17:44301886	NA	-0.33	-5.17	-0.32	4.96e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs546131	0.642	rs537873	chr11:34835121	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.45	5.1	0.32	6.93e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs3741151	0.773	rs17310361	chr11:73233724	T/C	cg17517138	chr11:73019481	ARHGEF17	0.82	6.28	0.38	1.68e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg03806693	chr22:41940476	POLR3H	-0.95	-13.0	-0.65	2.1e-29	Vitiligo;
SARC	cis	rs3020736	0.500	rs1801311	chr22:42486723	G/A	cg04733989	chr22:42467013	NAGA	-0.76	-10.7	-0.57	5.23e-22	Autism spectrum disorder or schizophrenia;
SARC	cis	rs10504229	0.679	rs12375445	chr8:58040082	A/G	cg20607798	chr8:58055168	NA	0.57	5.25	0.33	3.49e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs16976116	0.901	rs28541469	chr15:55500788	G/A	cg11288833	chr15:55489084	RSL24D1	0.63	6.13	0.37	3.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs11191270	0.554	rs11191265	chr10:104102118	G/A	cg15320455	chr10:103880129	LDB1	1.01	8.77	0.5	3.94e-16	Intelligence (multi-trait analysis);
SARC	cis	rs7592578	0.766	rs12472081	chr2:191398545	G/A	cg10560079	chr2:191398806	TMEM194B	-0.78	-8.36	-0.48	5.65e-15	Diastolic blood pressure;
SARC	cis	rs7528419	1.000	rs12740374	chr1:109817590	G/T	cg00908766	chr1:109817496	CELSR2	-0.62	-7.71	-0.45	3.64e-13	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
SARC	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.09	13.64	0.67	1.6e-31	Smoking behavior;
SARC	cis	rs7647973	1.000	rs6785045	chr3:49435243	G/C	cg06212747	chr3:49208901	KLHDC8B	-0.56	-5.75	-0.35	2.8e-8	Menarche (age at onset);
SARC	cis	rs3857536	0.904	rs9342533	chr6:66901930	G/A	cg07460842	chr6:66804631	NA	-0.42	-4.97	-0.31	1.29e-6	Blood trace element (Cu levels);
SARC	cis	rs6088580	0.524	rs6088575	chr20:33273403	C/T	cg08999081	chr20:33150536	PIGU	0.38	5.59	0.34	6.24e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs36715	1.000	rs251386	chr5:127547298	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	7.16	0.42	1.04e-11	Breast cancer;
SARC	cis	rs344364	0.511	rs12599337	chr16:1946751	A/G	cg26617929	chr16:1858877	NA	0.61	5.12	0.32	6.31e-7	Glomerular filtration rate in chronic kidney disease;
SARC	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg23172400	chr8:95962367	TP53INP1	-0.32	-5.57	-0.34	7.05e-8	Type 2 diabetes;
SARC	cis	rs3087591	0.960	rs2071009	chr17:29558082	T/C	cg24425628	chr17:29625626	OMG;NF1	-0.48	-5.93	-0.36	1.09e-8	Hip circumference;
SARC	cis	rs1003719	0.667	rs8127148	chr21:38481292	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.57	7.77	0.45	2.47e-13	Eye color traits;
SARC	cis	rs6964587	0.967	rs6465340	chr7:91588664	G/A	cg17063962	chr7:91808500	NA	0.91	14.98	0.7	5.47e-36	Breast cancer;
SARC	trans	rs1814175	0.615	rs4545557	chr11:50027329	A/C	cg15704280	chr7:45808275	SEPT13	-0.9	-14.33	-0.68	7.84e-34	Height;
SARC	cis	rs2425143	0.730	rs6060624	chr20:34413663	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-6.3	-0.38	1.45e-9	Blood protein levels;
SARC	cis	rs76419734	1.000	rs72671820	chr4:106620983	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.81	4.9	0.31	1.76e-6	Post bronchodilator FEV1;
SARC	cis	rs35110281	0.720	rs230647	chr21:44919654	C/T	cg21573476	chr21:45109991	RRP1B	0.52	7.02	0.42	2.35e-11	Mean corpuscular volume;
SARC	cis	rs11676348	0.818	rs4674256	chr2:218987893	A/T	cg00012203	chr2:219082015	ARPC2	-0.55	-7.32	-0.43	3.92e-12	Ulcerative colitis;
SARC	cis	rs9325144	0.534	rs4882350	chr12:38686979	A/G	cg10518543	chr12:38710700	ALG10B	0.38	4.87	0.3	2.05e-6	Morning vs. evening chronotype;
SARC	cis	rs6088580	0.634	rs6058052	chr20:33047084	A/G	cg24642439	chr20:33292090	TP53INP2	0.66	8.69	0.49	6.68e-16	Glomerular filtration rate (creatinine);
SARC	trans	rs61931739	0.500	rs11053213	chr12:34466395	G/T	cg26384229	chr12:38710491	ALG10B	0.91	13.65	0.67	1.42e-31	Morning vs. evening chronotype;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg18803079	chr1:64014643	EFCAB7;DLEU2L	-0.57	-7.22	-0.43	7.22e-12	Height;
SARC	cis	rs73635312	0.850	rs78267753	chr10:8986557	G/A	cg24467326	chr10:9646929	NA	0.59	5.05	0.31	8.81e-7	Basal cell carcinoma;
SARC	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg27170947	chr2:26402098	FAM59B	0.37	4.8	0.3	2.79e-6	Gut microbiome composition (summer);
SARC	cis	rs778371	0.723	rs11689851	chr2:233567342	A/G	cg20388707	chr2:233749442	NGEF	-0.35	-5.02	-0.31	1.04e-6	Schizophrenia;
SARC	cis	rs11690935	1.000	rs6757773	chr2:172549630	T/A	cg13550731	chr2:172543902	DYNC1I2	0.98	15.15	0.7	1.45e-36	Schizophrenia;
SARC	cis	rs9513627	1.000	rs7321381	chr13:100126156	G/A	cg25919922	chr13:100150906	NA	-0.66	-5.0	-0.31	1.14e-6	Obesity-related traits;
SARC	trans	rs459571	0.959	rs416390	chr9:136908549	C/G	cg09836344	chr4:1243392	C4orf42;CTBP1	0.62	6.89	0.41	5.2e-11	Platelet distribution width;
SARC	trans	rs61931739	0.782	rs3903201	chr12:34248275	G/A	cg26384229	chr12:38710491	ALG10B	0.62	8.13	0.47	2.6e-14	Morning vs. evening chronotype;
SARC	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg21782813	chr7:2030301	MAD1L1	0.47	7.31	0.43	4.36e-12	Bipolar disorder and schizophrenia;
SARC	cis	rs28655083	0.828	rs9938028	chr16:77127830	A/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.41	5.71	0.35	3.38e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2361710	0.611	rs12051781	chr17:78074468	A/G	cg06718696	chr17:78121285	EIF4A3	0.58	6.76	0.4	1.12e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
SARC	cis	rs4713118	0.513	rs156739	chr6:28013410	C/A	cg26450541	chr6:28235208	ZNF187	0.48	5.0	0.31	1.11e-6	Parkinson's disease;
SARC	cis	rs12497850	0.931	rs11920534	chr3:48937761	G/T	cg07636037	chr3:49044803	WDR6	1.0	17.61	0.76	1.04e-44	Parkinson's disease;
SARC	cis	rs910316	0.763	rs175047	chr14:75479039	C/G	cg23033748	chr14:75592666	NEK9	-0.39	-5.29	-0.33	2.8e-7	Height;
SARC	cis	rs8036030	0.691	rs11852760	chr15:74718699	A/G	cg14664628	chr15:75095509	CSK	-0.45	-5.59	-0.34	6.36e-8	Airflow obstruction;
SARC	cis	rs1950500	0.565	rs3181248	chr14:24808168	G/A	cg16194253	chr14:24768981	DHRS1;C14orf21	0.61	7.57	0.44	8.61e-13	Height;
SARC	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	16.56	0.74	3.2e-41	Height;
SARC	cis	rs4555082	0.874	rs2142190	chr14:105719306	G/A	cg13114125	chr14:105738426	BRF1	-0.8	-11.51	-0.6	1.4e-24	Mean platelet volume;Platelet distribution width;
SARC	cis	rs710216	0.843	rs2297972	chr1:43418026	C/T	cg03128534	chr1:43423976	SLC2A1	-0.62	-6.88	-0.41	5.42e-11	Red cell distribution width;
SARC	cis	rs34779708	0.931	rs17583009	chr10:35320915	T/C	cg03585969	chr10:35415529	CREM	0.4	5.02	0.31	1.03e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg02733842	chr7:1102375	C7orf50	-0.5	-6.11	-0.37	4.16e-9	Bronchopulmonary dysplasia;
SARC	cis	rs6500637	0.570	rs1049205	chr16:4942099	C/T	cg08329684	chr16:4932620	PPL	-0.42	-6.52	-0.39	4.32e-10	Cancer;
SARC	cis	rs6142102	0.812	rs761236	chr20:32520051	A/G	cg24642439	chr20:33292090	TP53INP2	0.44	4.8	0.3	2.84e-6	Skin pigmentation;
SARC	cis	rs17376456	1.000	rs13174700	chr5:93554644	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.62	5.4	0.33	1.68e-7	Diabetic retinopathy;
SARC	cis	rs4319547	0.915	rs3803005	chr12:123110654	T/C	cg23029597	chr12:123009494	RSRC2	-0.43	-5.53	-0.34	8.46e-8	Body mass index;
SARC	cis	rs9788682	0.591	rs7170068	chr15:78912943	G/A	cg06917634	chr15:78832804	PSMA4	-0.44	-4.72	-0.3	4.15e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs4664308	1.000	rs1511218	chr2:160906390	T/C	cg03641300	chr2:160917029	PLA2R1	-0.67	-8.98	-0.51	9.07e-17	Idiopathic membranous nephropathy;
SARC	cis	rs4974559	0.739	rs6599298	chr4:1298122	A/G	cg02980000	chr4:1222292	CTBP1	0.72	5.7	0.35	3.68e-8	Systolic blood pressure;
SARC	cis	rs2153535	0.580	rs9393019	chr6:8462091	G/A	cg21535247	chr6:8435926	SLC35B3	0.56	7.06	0.42	1.86e-11	Motion sickness;
SARC	cis	rs17376456	1.000	rs13185608	chr5:93509688	T/G	cg21475434	chr5:93447410	FAM172A	0.91	7.6	0.45	7.17e-13	Diabetic retinopathy;
SARC	cis	rs7429990	0.932	rs11130155	chr3:48140428	A/C	cg11946769	chr3:48343235	NME6	-0.46	-5.46	-0.34	1.24e-7	Educational attainment (years of education);
SARC	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg11301795	chr4:187892539	NA	-0.69	-10.22	-0.56	1.69e-20	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg07636037	chr3:49044803	WDR6	0.97	16.95	0.74	1.54e-42	Menarche (age at onset);
SARC	cis	rs3762637	0.943	rs9289198	chr3:122277160	G/T	cg24169773	chr3:122142474	KPNA1	-0.55	-5.58	-0.34	6.82e-8	LDL cholesterol levels;
SARC	cis	rs568617	0.716	rs111953392	chr11:65595697	G/A	cg00576331	chr11:65640516	EFEMP2	-0.52	-5.14	-0.32	5.71e-7	Crohn's disease;
SARC	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg00864171	chr11:67383662	NA	-0.42	-5.62	-0.35	5.37e-8	Mean corpuscular volume;
SARC	cis	rs372883	0.600	rs1312254	chr21:30695401	A/G	cg24692254	chr21:30365293	RNF160	-0.68	-8.76	-0.5	4.05e-16	Pancreatic cancer;
SARC	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6963495	0.818	rs73192126	chr7:105175415	T/C	cg13798780	chr7:105162888	PUS7	0.61	5.59	0.34	6.18e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs7520050	0.966	rs12561806	chr1:46396776	C/T	cg24296786	chr1:45957014	TESK2	0.39	4.9	0.31	1.77e-6	Red blood cell count;Reticulocyte count;
SARC	trans	rs1814175	0.645	rs7395438	chr11:49877379	G/T	cg15704280	chr7:45808275	SEPT13	-0.88	-13.91	-0.67	1.97e-32	Height;
SARC	cis	rs4481887	0.927	rs4405158	chr1:248490647	A/C	cg00666640	chr1:248458726	OR2T12	0.35	5.75	0.35	2.83e-8	Common traits (Other);
SARC	cis	rs554111	0.891	rs609880	chr1:21055891	A/G	cg08890418	chr1:21044141	KIF17	0.51	7.1	0.42	1.47e-11	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs7103648	0.569	rs11039266	chr11:47532395	T/G	cg20307385	chr11:47447363	PSMC3	0.72	9.28	0.52	1.17e-17	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg08564027	chr20:61660810	NA	0.76	11.8	0.61	1.69e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs17209837	0.667	rs45605032	chr7:87090301	C/T	cg00919237	chr7:87102261	ABCB4	-0.5	-5.47	-0.34	1.14e-7	Gallbladder cancer;
SARC	cis	rs6580649	0.941	rs726354	chr12:48500334	G/A	cg24011408	chr12:48396354	COL2A1	-0.47	-5.29	-0.33	2.78e-7	Lung cancer;
SARC	cis	rs9916302	0.904	rs9905432	chr17:37555918	C/A	cg07936489	chr17:37558343	FBXL20	0.69	9.17	0.52	2.52e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg16680214	chr1:154839983	KCNN3	-0.35	-5.26	-0.33	3.31e-7	Prostate cancer;
SARC	cis	rs10754283	0.967	rs6657988	chr1:90106745	G/C	cg21401794	chr1:90099060	LRRC8C	0.59	8.09	0.47	3.24e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs9400467	0.506	rs12208482	chr6:111793646	T/A	cg15721981	chr6:111408429	SLC16A10	0.65	5.71	0.35	3.5e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-7.95	-0.46	8.22e-14	Chronic sinus infection;
SARC	cis	rs1957429	0.808	rs4902327	chr14:65344803	C/T	cg23373153	chr14:65346875	NA	1.01	9.94	0.55	1.22e-19	Pediatric areal bone mineral density (radius);
SARC	cis	rs7647973	0.769	rs6446204	chr3:49034879	T/C	cg07636037	chr3:49044803	WDR6	0.88	9.06	0.51	5.37e-17	Menarche (age at onset);
SARC	cis	rs2180341	0.961	rs7775493	chr6:127615000	C/A	cg24812749	chr6:127587940	RNF146	0.97	12.89	0.65	4.63e-29	Breast cancer;
SARC	cis	rs910316	0.935	rs11159119	chr14:75636967	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.51	-6.91	-0.41	4.49e-11	Height;
SARC	cis	rs9398803	0.965	rs9388490	chr6:126704795	C/T	cg19875578	chr6:126661172	C6orf173	0.6	8.13	0.47	2.6e-14	Male-pattern baldness;
SARC	cis	rs9790314	0.846	rs6768818	chr3:160951648	A/G	cg04691961	chr3:161091175	C3orf57	-0.64	-8.7	-0.5	5.91e-16	Morning vs. evening chronotype;
SARC	cis	rs634534	0.561	rs14157	chr11:65769780	T/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.57	8.9	0.5	1.6e-16	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs10752881	1.000	rs4304541	chr1:182970238	G/T	cg13390022	chr1:182993471	LAMC1	0.33	4.99	0.31	1.19e-6	Colorectal cancer;
SARC	cis	rs2732480	0.577	rs1489109	chr12:48738780	C/A	cg24011408	chr12:48396354	COL2A1	0.43	5.11	0.32	6.81e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs6582630	0.638	rs7963994	chr12:38555535	G/A	cg13010199	chr12:38710504	ALG10B	-0.52	-6.46	-0.39	5.88e-10	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs3857536	0.704	rs4710570	chr6:66890244	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.6	-7.14	-0.42	1.19e-11	Blood trace element (Cu levels);
SARC	cis	rs12142240	0.698	rs79490411	chr1:46813568	G/A	cg00530320	chr1:46809349	NSUN4	0.58	6.85	0.41	6.53e-11	Menopause (age at onset);
SARC	cis	rs3796352	0.667	rs34288509	chr3:52849493	G/C	cg27565382	chr3:53032988	SFMBT1	0.7	5.01	0.31	1.06e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs9818758	0.607	rs11706052	chr3:49064110	A/G	cg00383909	chr3:49044727	WDR6	0.78	6.77	0.41	1.04e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg18357526	chr6:26021779	HIST1H4A	0.44	5.62	0.35	5.39e-8	Blood metabolite levels;
SARC	cis	rs6570726	0.935	rs388394	chr6:145852689	C/T	cg23711669	chr6:146136114	FBXO30	0.76	11.48	0.6	1.83e-24	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs8141529	0.551	rs16986864	chr22:29350911	G/T	cg02153584	chr22:29168773	CCDC117	0.68	7.04	0.42	2.18e-11	Lymphocyte counts;
SARC	cis	rs10504229	0.906	rs28447218	chr8:58170813	T/G	cg05313129	chr8:58192883	C8orf71	-0.44	-5.18	-0.32	4.72e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7772486	0.558	rs62435775	chr6:146136415	G/C	cg23711669	chr6:146136114	FBXO30	0.86	12.71	0.64	1.8e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg05623727	chr3:50126028	RBM5	0.33	4.91	0.31	1.69e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg09699651	chr6:150184138	LRP11	0.41	4.86	0.3	2.15e-6	Lung cancer;
SARC	cis	rs6424115	0.679	rs2294495	chr1:24075876	C/T	cg15997130	chr1:24165203	NA	-0.46	-5.52	-0.34	8.92e-8	Immature fraction of reticulocytes;
SARC	cis	rs7666738	0.606	rs7663216	chr4:99088385	A/C	cg05340658	chr4:99064831	C4orf37	0.51	6.56	0.39	3.41e-10	Colonoscopy-negative controls vs population controls;
SARC	cis	rs861020	0.630	rs9308411	chr1:210005713	C/T	cg05527609	chr1:210001259	C1orf107	0.79	10.28	0.56	1.14e-20	Orofacial clefts;
SARC	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg24549020	chr5:56110836	MAP3K1	0.83	8.59	0.49	1.23e-15	Initial pursuit acceleration;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26556537	chr5:10250271	FAM173B;CCT5	-0.54	-6.46	-0.39	6.13e-10	Fibrinogen levels;
SARC	cis	rs7560272	0.723	rs13386124	chr2:73771695	C/G	cg20560298	chr2:73613845	ALMS1	-0.56	-7.32	-0.43	3.94e-12	Schizophrenia;
SARC	cis	rs9399135	0.967	rs9376085	chr6:135371224	T/C	cg22676075	chr6:135203613	NA	0.34	4.75	0.3	3.59e-6	Red blood cell count;
SARC	cis	rs1256061	0.603	rs1256045	chr14:64729760	A/C	cg23250157	chr14:64679961	SYNE2	0.48	6.62	0.4	2.49e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs9394841	0.620	rs9462746	chr6:41816279	T/A	cg08135965	chr6:41755394	TOMM6	0.6	6.43	0.39	7.03e-10	Mean corpuscular hemoglobin;Red cell distribution width;
SARC	cis	rs1949733	0.523	rs62287455	chr4:8544994	A/T	cg05004818	chr4:8539015	NA	0.38	4.98	0.31	1.21e-6	Response to antineoplastic agents;
SARC	cis	rs9486715	0.867	rs12207471	chr6:96963782	A/G	cg18709589	chr6:96969512	KIAA0776	0.61	7.52	0.44	1.16e-12	Headache;
SARC	cis	rs11098499	0.908	rs11098527	chr4:120399906	A/G	cg24375607	chr4:120327624	NA	0.42	4.97	0.31	1.29e-6	Corneal astigmatism;
SARC	trans	rs9329221	0.686	rs13264580	chr8:10250699	C/T	cg06636001	chr8:8085503	FLJ10661	0.59	7.13	0.42	1.28e-11	Neuroticism;
SARC	cis	rs6964587	0.900	rs11984136	chr7:91766953	T/C	cg17063962	chr7:91808500	NA	0.97	16.98	0.74	1.23e-42	Breast cancer;
SARC	cis	rs9911578	0.803	rs8069033	chr17:57131581	T/A	cg20303301	chr17:57937339	TUBD1	0.34	4.95	0.31	1.42e-6	Intelligence (multi-trait analysis);
SARC	cis	rs854765	0.583	rs8073001	chr17:17831716	A/C	cg04398451	chr17:18023971	MYO15A	0.4	5.66	0.35	4.38e-8	Total body bone mineral density;
SARC	cis	rs6088580	0.634	rs4258875	chr20:32924895	C/A	cg08999081	chr20:33150536	PIGU	-0.45	-6.78	-0.41	9.73e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs210143	1	rs210143	chr6:33546930	T/C	cg07679836	chr6:33548423	BAK1	0.39	5.37	0.33	1.88e-7	Neutrophil percentage of granulocytes;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);Chronic lymphocytic leukemia;
SARC	cis	rs7474896	0.537	rs2505255	chr10:38359642	C/A	cg00409905	chr10:38381863	ZNF37A	-0.47	-5.15	-0.32	5.62e-7	Obesity (extreme);
SARC	cis	rs7296418	0.636	rs11057261	chr12:123797567	T/C	cg00376283	chr12:123451042	ABCB9	0.56	6.77	0.41	1.04e-10	Platelet count;
SARC	cis	rs2115630	1.000	rs56074163	chr15:85351332	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.47	-5.68	-0.35	3.99e-8	P wave terminal force;
SARC	cis	rs6088813	1.000	rs6088812	chr20:33974163	T/A	cg23207816	chr20:34252616	CPNE1;RBM12	-0.43	-5.24	-0.32	3.67e-7	Height;
SARC	cis	rs4242434	0.672	rs7846476	chr8:22479461	T/C	cg03733263	chr8:22462867	KIAA1967	0.87	13.34	0.66	1.49e-30	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs8113308	0.752	rs11882377	chr19:52504130	G/A	cg25782003	chr19:52490127	ZNF350	0.77	5.7	0.35	3.69e-8	Survival in endocrine treated breast cancer (estrogen-receptor positive);
SARC	cis	rs11098499	0.863	rs11933966	chr4:120476715	G/A	cg09307838	chr4:120376055	NA	0.91	12.25	0.63	5.66e-27	Corneal astigmatism;
SARC	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg27266027	chr21:40555129	PSMG1	0.49	5.39	0.33	1.7e-7	Cognitive function;
SARC	cis	rs611744	0.935	rs661036	chr8:109213088	C/T	cg21045802	chr8:109455806	TTC35	0.46	5.41	0.33	1.57e-7	Dupuytren's disease;
SARC	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg22683308	chr4:1340831	KIAA1530	-0.43	-4.8	-0.3	2.83e-6	Obesity-related traits;
SARC	cis	rs965469	0.901	rs7270135	chr20:3247922	T/C	cg25506879	chr20:3388711	C20orf194	-0.57	-5.57	-0.34	7.16e-8	IFN-related cytopenia;
SARC	cis	rs6570726	0.935	rs401888	chr6:145831535	A/G	cg05220968	chr6:146057943	EPM2A	-0.29	-4.99	-0.31	1.19e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs73206853	0.841	rs3893403	chr12:111083980	G/A	cg10860002	chr12:110842031	ANAPC7	0.61	5.14	0.32	5.83e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	-0.33	-4.79	-0.3	2.94e-6	Lymphocyte counts;
SARC	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg04166393	chr7:2884313	GNA12	0.54	6.16	0.37	3.21e-9	Height;
SARC	cis	rs7953249	0.618	rs7954331	chr12:121398657	G/T	cg02403541	chr12:121454288	C12orf43	-0.73	-9.74	-0.54	4.87e-19	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs9790314	0.602	rs4679926	chr3:160677240	A/T	cg04691961	chr3:161091175	C3orf57	0.59	8.04	0.47	4.37e-14	Morning vs. evening chronotype;
SARC	cis	rs9381040	0.655	rs9381032	chr6:41044986	A/T	cg02167203	chr6:41068553	NFYA;LOC221442	-0.42	-4.74	-0.3	3.69e-6	Alzheimer's disease (late onset);
SARC	cis	rs12931792	0.712	rs56399904	chr16:30166183	C/T	cg17640201	chr16:30407289	ZNF48	0.6	7.78	0.45	2.34e-13	Tonsillectomy;
SARC	cis	rs4595586	0.525	rs1400279	chr12:39343825	T/A	cg13010199	chr12:38710504	ALG10B	0.41	4.73	0.3	3.93e-6	Morning vs. evening chronotype;
SARC	cis	rs7666738	0.830	rs9992391	chr4:98916052	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.64	0.49	9.2e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs8028182	0.636	rs7184046	chr15:75866150	G/C	cg20655648	chr15:75932815	IMP3	0.64	7.35	0.43	3.33e-12	Sudden cardiac arrest;
SARC	trans	rs61931739	1.000	rs61931739	chr12:34089973	C/T	cg13010199	chr12:38710504	ALG10B	-0.55	-6.73	-0.4	1.32e-10	Morning vs. evening chronotype;
SARC	cis	rs2290416	0.892	rs3793369	chr8:144664335	G/A	cg10810860	chr8:144639591	GSDMD	-0.71	-4.92	-0.31	1.6e-6	Attention deficit hyperactivity disorder;
SARC	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.73	6.33	0.38	1.27e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs4566357	0.615	rs10177528	chr2:227913706	G/A	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.86	-0.36	1.61e-8	Coronary artery disease;
SARC	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg17971929	chr21:40555470	PSMG1	0.99	14.14	0.68	3.32e-33	Cognitive function;
SARC	cis	rs853679	0.550	rs1225598	chr6:28160799	T/G	cg16479474	chr6:28041457	NA	0.36	5.65	0.35	4.74e-8	Depression;
SARC	cis	rs981844	0.775	rs17299211	chr4:154738284	G/A	cg14289246	chr4:154710475	SFRP2	0.57	6.22	0.38	2.32e-9	Response to statins (LDL cholesterol change);
SARC	cis	rs1003719	0.680	rs767998	chr21:38525652	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.27	-0.52	1.31e-17	Eye color traits;
SARC	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg19223190	chr17:80058835	NA	0.45	6.35	0.38	1.13e-9	Life satisfaction;
SARC	cis	rs1008375	0.900	rs13144986	chr4:17675019	C/A	cg27347728	chr4:17578864	LAP3	-0.49	-5.91	-0.36	1.22e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs11025559	0.812	rs10833336	chr11:20514288	C/G	cg19653624	chr11:20408972	PRMT3	-0.54	-6.03	-0.37	6.47e-9	Pursuit maintenance gain;
SARC	cis	rs9815354	1.000	rs7632387	chr3:41853161	C/T	cg03022575	chr3:42003672	ULK4	0.59	5.28	0.33	2.89e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg18252515	chr7:66147081	NA	0.48	5.14	0.32	5.72e-7	Aortic root size;
SARC	cis	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg22496380	chr5:211416	CCDC127	-0.88	-9.55	-0.53	1.95e-18	Breast cancer;
SARC	cis	rs7481584	0.624	rs438384	chr11:3045651	A/G	cg20651018	chr11:3035856	CARS	0.39	5.36	0.33	2e-7	Calcium levels;
SARC	cis	rs11155671	0.530	rs9397420	chr6:150206781	C/T	cg00933542	chr6:150070202	PCMT1	-0.3	-4.95	-0.31	1.4e-6	Testicular germ cell tumor;
SARC	cis	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg18252515	chr7:66147081	NA	-1.41	-12.93	-0.65	3.5e-29	Diabetic kidney disease;
SARC	cis	rs6901004	0.803	rs9400470	chr6:111478131	T/C	cg15721981	chr6:111408429	SLC16A10	-0.45	-5.51	-0.34	9.66e-8	Blood metabolite levels;
SARC	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg00933542	chr6:150070202	PCMT1	0.32	4.92	0.31	1.62e-6	Lung cancer;
SARC	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg11494091	chr17:61959527	GH2	-0.48	-7.29	-0.43	4.76e-12	Prudent dietary pattern;
SARC	cis	rs3768617	0.528	rs10737241	chr1:183098208	C/T	cg13390022	chr1:182993471	LAMC1	0.31	4.79	0.3	3.01e-6	Fuchs's corneal dystrophy;
SARC	cis	rs3857536	0.673	rs7759888	chr6:66891922	T/C	cg07460842	chr6:66804631	NA	-0.6	-7.16	-0.42	1.04e-11	Blood trace element (Cu levels);
SARC	cis	rs11969893	0.649	rs9498408	chr6:101292340	C/T	cg12253828	chr6:101329408	ASCC3	0.95	7.3	0.43	4.58e-12	Economic and political preferences (immigration/crime);
SARC	cis	rs2204008	0.643	rs1315347	chr12:38162494	C/T	cg14851346	chr12:38532713	NA	-0.43	-5.05	-0.31	8.78e-7	Bladder cancer;
SARC	cis	rs9840812	0.861	rs511154	chr3:135950921	A/G	cg15507776	chr3:136538369	TMEM22	0.49	5.23	0.32	3.85e-7	Fibrinogen levels;
SARC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg26338869	chr17:61819248	STRADA	0.8	10.69	0.57	5.79e-22	Prudent dietary pattern;
SARC	cis	rs3106136	0.681	rs28458965	chr4:95302476	A/G	cg11021082	chr4:95130006	SMARCAD1	0.33	4.91	0.31	1.73e-6	Capecitabine sensitivity;
SARC	cis	rs9660992	0.674	rs72745221	chr1:205262337	G/A	cg07972983	chr1:205091412	RBBP5	0.51	5.95	0.36	9.86e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg07701084	chr6:150067640	NUP43	0.36	4.84	0.3	2.41e-6	Lung cancer;
SARC	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg02297831	chr4:17616191	MED28	0.48	6.28	0.38	1.62e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs765787	0.556	rs2413778	chr15:45539397	C/A	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.51e-10	Uric acid levels;
SARC	cis	rs61935443	0.832	rs11107771	chr12:95276844	A/G	cg21533806	chr12:95267307	NA	0.7	8.5	0.49	2.31e-15	Schizophrenia;
SARC	cis	rs1669338	0.588	rs6788122	chr3:3171897	T/C	cg16797762	chr3:3221439	CRBN	-0.91	-9.37	-0.52	6.41e-18	White matter integrity;
SARC	cis	rs4242434	0.927	rs10099846	chr8:22534178	C/T	cg03733263	chr8:22462867	KIAA1967	-0.95	-15.32	-0.71	4.12e-37	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs1348850	0.598	rs12616259	chr2:178503803	C/T	cg23306229	chr2:178417860	TTC30B	0.51	5.79	0.35	2.25e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg16325326	chr1:53192061	ZYG11B	-0.9	-15.56	-0.71	6.73e-38	Monocyte count;
SARC	cis	rs10992471	0.535	rs34774135	chr9:95113768	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.58	-6.81	-0.41	8.24e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs644799	0.710	rs10831427	chr11:95508383	G/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.61	8.15	0.47	2.28e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7264396	0.790	rs761825	chr20:34194054	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-5.4	-0.33	1.62e-7	Total cholesterol levels;
SARC	cis	rs208515	0.525	rs10944871	chr6:66690306	A/G	cg07460842	chr6:66804631	NA	0.97	11.35	0.6	4.81e-24	Exhaled nitric oxide levels;
SARC	cis	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg00071950	chr4:10020882	SLC2A9	0.39	6.31	0.38	1.41e-9	Bone mineral density;
SARC	cis	rs73198271	0.740	rs11781430	chr8:8651733	G/C	cg06636001	chr8:8085503	FLJ10661	-0.48	-5.42	-0.33	1.49e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs6866344	0.661	rs72812606	chr5:178129094	A/T	cg03877680	chr5:178157825	ZNF354A	1.02	12.3	0.63	3.98e-27	Neutrophil percentage of white cells;
SARC	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	9.03	0.51	6.74e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2070488	0.699	rs13064938	chr3:38440237	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.78	12.02	0.62	3.34e-26	Electrocardiographic conduction measures;
SARC	cis	rs2732480	0.500	rs1387257	chr12:48636666	C/A	cg24011408	chr12:48396354	COL2A1	0.46	5.24	0.32	3.54e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs11098499	0.697	rs4373140	chr4:120307698	A/G	cg09160332	chr4:120329925	NA	-0.33	-4.77	-0.3	3.27e-6	Corneal astigmatism;
SARC	cis	rs7561528	0.501	rs59253801	chr2:127891511	G/A	cg12632573	chr2:127783243	NA	0.64	5.8	0.36	2.11e-8	Alzheimer's disease;Alzheimer's disease (late onset);
SARC	cis	rs3820928	0.874	rs2229813	chr2:227892720	C/T	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.69	-0.35	3.74e-8	Pulmonary function;
SARC	trans	rs561341	0.941	rs736678	chr17:30347423	G/T	cg20587970	chr11:113659929	NA	-1.24	-12.75	-0.64	1.33e-28	Hip circumference adjusted for BMI;
SARC	cis	rs9399135	0.967	rs1014020	chr6:135334426	C/A	cg24558204	chr6:135376177	HBS1L	0.45	6.03	0.37	6.24e-9	Red blood cell count;
SARC	cis	rs1799949	0.827	rs74252763	chr17:41402020	C/T	cg25072359	chr17:41440525	NA	0.48	5.39	0.33	1.74e-7	Menopause (age at onset);
SARC	cis	rs9815354	0.951	rs6768438	chr3:41865355	G/A	cg03022575	chr3:42003672	ULK4	0.56	5.29	0.33	2.81e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs61935443	0.501	rs4761669	chr12:95187622	T/G	cg21533806	chr12:95267307	NA	0.38	4.77	0.3	3.23e-6	Schizophrenia;
SARC	cis	rs6545883	0.862	rs11691734	chr2:61702466	C/T	cg15711740	chr2:61764176	XPO1	-0.42	-5.06	-0.31	8.65e-7	Tuberculosis;
SARC	cis	rs9916302	0.904	rs3744348	chr17:37417575	C/G	cg07936489	chr17:37558343	FBXL20	-0.68	-9.19	-0.52	2.17e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs10752881	1.000	rs10737237	chr1:182989269	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.69	0.57	6.02e-22	Colorectal cancer;
SARC	cis	rs4780401	0.609	rs4780399	chr16:11828701	A/T	cg01061890	chr16:11836724	TXNDC11	-0.61	-8.7	-0.5	6.21e-16	Rheumatoid arthritis;
SARC	cis	rs356220	0.656	rs356207	chr4:90635407	C/T	cg06632027	chr4:90757378	SNCA	0.39	5.0	0.31	1.13e-6	Parkinson's disease;
SARC	cis	rs950776	0.518	rs4886572	chr15:78837452	A/G	cg06917634	chr15:78832804	PSMA4	-0.9	-13.86	-0.67	2.98e-32	Sudden cardiac arrest;
SARC	cis	rs66887589	0.592	rs11731571	chr4:120221185	G/A	cg09307838	chr4:120376055	NA	0.61	8.34	0.48	6.51e-15	Diastolic blood pressure;
SARC	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg17971929	chr21:40555470	PSMG1	-0.85	-10.96	-0.58	8.1e-23	Cognitive function;
SARC	cis	rs7246657	0.943	rs10415024	chr19:37814724	A/G	cg23950597	chr19:37808831	NA	-0.62	-5.96	-0.36	9.11e-9	Coronary artery calcification;
SARC	cis	rs1371867	0.846	rs2919471	chr8:101232701	T/C	cg11906718	chr8:101322791	RNF19A	-0.68	-8.66	-0.49	8.2e-16	Atrioventricular conduction;
SARC	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg24829409	chr8:58192753	C8orf71	-0.59	-6.47	-0.39	5.84e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs10849893	0.576	rs889970	chr12:121856217	G/A	cg01154721	chr12:121881891	KDM2B	-0.36	-5.19	-0.32	4.54e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs7246760	0.867	rs66464474	chr19:9795149	T/C	cg16876255	chr19:9731953	ZNF561	0.82	5.05	0.31	8.72e-7	Pursuit maintenance gain;
SARC	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.59e-6	Depression;
SARC	cis	rs7089973	0.604	rs35319791	chr10:116602296	C/A	cg08188268	chr10:116634841	FAM160B1	0.28	4.79	0.3	3.02e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs35213789	0.673	rs210604	chr7:69235836	C/A	cg10619644	chr7:69149951	AUTS2	0.35	4.88	0.3	2e-6	Childhood ear infection;
SARC	trans	rs7819412	0.936	rs7814499	chr8:11040647	A/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.67	-0.45	4.73e-13	Triglycerides;
SARC	cis	rs4588572	0.601	rs4305631	chr5:77668698	G/T	cg11547950	chr5:77652471	NA	0.41	4.91	0.31	1.72e-6	Triglycerides;
SARC	cis	rs6840360	1.000	rs4696284	chr4:152595836	C/G	cg22705602	chr4:152727874	NA	-0.38	-6.51	-0.39	4.49e-10	Intelligence (multi-trait analysis);
SARC	cis	rs62064224	0.791	rs72811096	chr17:30647302	A/T	cg18200150	chr17:30822561	MYO1D	0.41	6.28	0.38	1.66e-9	Schizophrenia;
SARC	cis	rs2288073	1.000	rs6708328	chr2:24412413	A/G	cg26838691	chr2:24397539	C2orf84	-0.54	-6.83	-0.41	7.28e-11	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs2839627	0.561	rs8126478	chr21:44318668	C/A	cg03543861	chr21:44258195	NA	0.45	4.84	0.3	2.35e-6	Information processing speed;
SARC	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.47	-5.93	-0.36	1.07e-8	Lymphocyte counts;
SARC	cis	rs912057	0.671	rs1294428	chr6:6744623	A/G	cg06612196	chr6:6737390	NA	0.63	9.53	0.53	2.1e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg03517284	chr6:25882590	NA	-0.51	-6.7	-0.4	1.51e-10	Intelligence (multi-trait analysis);
SARC	cis	rs6540556	0.954	rs10863786	chr1:209937764	A/G	cg23920097	chr1:209922102	NA	-0.45	-5.14	-0.32	5.88e-7	Red blood cell count;
SARC	cis	rs2180341	0.824	rs9321076	chr6:127655614	G/A	cg27446573	chr6:127587934	RNF146	1.04	14.77	0.7	2.87e-35	Breast cancer;
SARC	cis	rs6762	0.692	rs5030778	chr11:836008	T/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.58	-7.45	-0.44	1.84e-12	Mean platelet volume;
SARC	cis	rs1348850	0.668	rs4893972	chr2:178496874	T/C	cg23306229	chr2:178417860	TTC30B	0.59	6.26	0.38	1.84e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs10425738	0.785	rs4090553	chr19:41426757	T/C	cg17435250	chr19:41386441	CYP2A7	-0.41	-4.82	-0.3	2.61e-6	nicotine metabolite ratio in current smokers;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
SARC	cis	rs2635047	0.638	rs2289133	chr18:44602249	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.51	6.57	0.4	3.17e-10	Educational attainment;
SARC	cis	rs9875589	0.957	rs1108341	chr3:13937328	T/A	cg19554555	chr3:13937349	NA	0.54	6.94	0.41	3.94e-11	Ovarian reserve;
SARC	cis	rs8017423	0.967	rs7154683	chr14:90700692	A/G	cg20276874	chr14:90721474	PSMC1	-0.36	-5.01	-0.31	1.09e-6	Mortality in heart failure;
SARC	cis	rs4481887	1.000	rs10888352	chr1:248451965	G/A	cg13385794	chr1:248469461	NA	0.33	5.04	0.31	9.35e-7	Common traits (Other);
SARC	cis	rs9790314	0.632	rs778645	chr3:160707459	A/T	cg04691961	chr3:161091175	C3orf57	-0.59	-8.01	-0.46	5.35e-14	Morning vs. evening chronotype;
SARC	cis	rs908922	0.676	rs7518654	chr1:152517845	C/G	cg09873164	chr1:152488093	CRCT1	0.6	7.75	0.45	2.84e-13	Hair morphology;
SARC	cis	rs7595412	1.000	rs11896429	chr2:199017855	T/A	cg00208931	chr2:198669586	PLCL1	-0.74	-5.87	-0.36	1.47e-8	Hip bone size;
SARC	cis	rs6500395	1.000	rs8059819	chr16:48682834	A/G	cg04672837	chr16:48644449	N4BP1	-0.48	-6.43	-0.39	7.02e-10	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs2467099	0.504	rs2608881	chr17:73936653	C/G	cg14829360	chr17:73884958	NA	-0.47	-6.33	-0.38	1.28e-9	Systolic blood pressure;
SARC	cis	rs2273669	0.588	rs12201102	chr6:109317388	A/G	cg05315195	chr6:109294784	ARMC2	-0.59	-5.45	-0.34	1.28e-7	Prostate cancer;
SARC	cis	rs3796352	1.000	rs113995589	chr3:53132372	A/T	cg27565382	chr3:53032988	SFMBT1	0.79	5.56	0.34	7.32e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs1865760	0.566	rs2858993	chr6:26087856	T/A	cg16482183	chr6:26056742	HIST1H1C	0.5	6.29	0.38	1.56e-9	Height;
SARC	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg02297831	chr4:17616191	MED28	0.49	6.43	0.39	7.3e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg13699009	chr12:122356056	WDR66	0.6	9.82	0.54	2.91e-19	Mean corpuscular volume;
SARC	cis	rs1468333	1.000	rs7729926	chr5:137514641	A/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.8	11.22	0.59	1.18e-23	Resting heart rate;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg16798617	chr7:155474109	RBM33	0.48	6.45	0.39	6.45e-10	Thyroid stimulating hormone;
SARC	cis	rs1707322	0.721	rs11211166	chr1:46157942	G/A	cg03146154	chr1:46216737	IPP	0.53	6.35	0.38	1.12e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg06420487	chr17:61919686	SMARCD2	0.46	5.09	0.32	7.48e-7	Height;
SARC	trans	rs7395662	0.591	rs4882093	chr11:48530820	G/A	cg15704280	chr7:45808275	SEPT13	-0.48	-6.59	-0.4	2.83e-10	HDL cholesterol;
SARC	cis	rs1971762	0.509	rs10783592	chr12:54037430	G/A	cg06632207	chr12:54070931	ATP5G2	0.59	7.92	0.46	9.57e-14	Height;
SARC	cis	rs9457247	0.602	rs4710175	chr6:167467800	A/G	cg07741184	chr6:167504864	NA	0.39	7.41	0.44	2.36e-12	Crohn's disease;
SARC	cis	rs6815814	0.731	rs28532329	chr4:38771368	C/T	cg06935464	chr4:38784597	TLR10	0.5	5.19	0.32	4.66e-7	Breast cancer;
SARC	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg17221315	chr6:27791827	HIST1H4J	0.47	4.81	0.3	2.76e-6	Depression;
SARC	cis	rs5758511	0.680	rs5758652	chr22:42612408	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.46	6.97	0.42	3.2e-11	Birth weight;
SARC	cis	rs17376456	0.542	rs2084916	chr5:93194961	A/T	cg25358565	chr5:93447407	FAM172A	-0.95	-10.7	-0.57	5.21e-22	Diabetic retinopathy;
SARC	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg16405210	chr4:1374714	KIAA1530	-0.52	-6.5	-0.39	4.8e-10	Obesity-related traits;
SARC	cis	rs3126085	0.734	rs3120653	chr1:152284854	A/G	cg26876637	chr1:152193138	HRNR	-0.45	-4.99	-0.31	1.18e-6	Atopic dermatitis;
SARC	cis	rs66731853	0.769	rs657624	chr1:20888348	C/T	cg04087271	chr1:20915334	CDA	-0.31	-4.72	-0.3	4.11e-6	Mean corpuscular volume;
SARC	cis	rs796364	1.000	rs71424239	chr2:200725473	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.7	-5.89	-0.36	1.37e-8	Schizophrenia;
SARC	cis	rs2282802	0.685	rs13170475	chr5:139671062	C/T	cg26211634	chr5:139558579	C5orf32	0.36	4.77	0.3	3.28e-6	Intelligence (multi-trait analysis);
SARC	cis	rs3820928	0.874	rs1917125	chr2:227798981	G/A	cg11843606	chr2:227700838	RHBDD1	-0.56	-7.12	-0.42	1.33e-11	Pulmonary function;
SARC	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg04518342	chr5:131593106	PDLIM4	0.38	5.21	0.32	4.14e-7	Acylcarnitine levels;
SARC	cis	rs10791097	0.694	rs4937583	chr11:130741606	A/G	cg09137382	chr11:130731461	NA	0.31	4.78	0.3	3.15e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg16680214	chr1:154839983	KCNN3	-0.35	-5.57	-0.34	7.12e-8	Prostate cancer;
SARC	cis	rs2304069	0.545	rs1864998	chr5:149389465	C/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.44	4.94	0.31	1.48e-6	HIV-1 control;
SARC	cis	rs7937682	0.889	rs2850247	chr11:111637202	C/A	cg09085632	chr11:111637200	PPP2R1B	1.09	20.67	0.8	1.27e-54	Primary sclerosing cholangitis;
SARC	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg07636037	chr3:49044803	WDR6	0.92	15.3	0.71	4.61e-37	Menarche (age at onset);
SARC	cis	rs4689388	0.926	rs12508672	chr4:6287965	G/A	cg14416269	chr4:6271139	WFS1	0.34	5.15	0.32	5.63e-7	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg12310025	chr6:25882481	NA	-0.38	-5.04	-0.31	9.45e-7	Intelligence (multi-trait analysis);
SARC	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg22920501	chr2:26401640	FAM59B	-0.6	-8.1	-0.47	3.11e-14	Gut microbiome composition (summer);
SARC	cis	rs2120243	0.539	rs1568609	chr3:157066839	G/A	cg24825693	chr3:157122686	VEPH1	-0.42	-5.85	-0.36	1.63e-8	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs1008375	0.897	rs67455495	chr4:17665238	A/T	cg27347728	chr4:17578864	LAP3	-0.48	-5.76	-0.35	2.65e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs240764	0.817	rs239246	chr6:101089134	G/A	cg09795085	chr6:101329169	ASCC3	0.45	5.77	0.35	2.49e-8	Neuroticism;
SARC	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg03650068	chr1:25596491	NA	0.33	5.08	0.32	7.59e-7	Erythrocyte sedimentation rate;
SARC	cis	rs9420	0.961	rs7938083	chr11:57493622	C/A	cg23127183	chr11:57508653	C11orf31	-0.55	-6.23	-0.38	2.15e-9	Schizophrenia;
SARC	cis	rs7635838	0.722	rs2594982	chr3:11379958	C/T	cg00170343	chr3:11313890	ATG7	0.64	8.81	0.5	2.97e-16	HDL cholesterol;
SARC	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg26839252	chr6:160211577	TCP1;MRPL18	0.58	5.48	0.34	1.1e-7	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs4563143	0.592	rs12151001	chr19:29283386	C/G	cg12756686	chr19:29218302	NA	0.66	8.44	0.48	3.35e-15	Methadone dose in opioid dependence;
SARC	cis	rs10823500	0.604	rs10740329	chr10:71941253	A/T	cg04118878	chr10:71993077	PPA1	-0.42	-5.14	-0.32	5.85e-7	Blood protein levels;
SARC	cis	rs35110281	0.748	rs2838322	chr21:44998615	G/C	cg01579765	chr21:45077557	HSF2BP	-0.35	-5.98	-0.36	8.25e-9	Mean corpuscular volume;
SARC	cis	rs2228479	0.850	rs62056066	chr16:89906563	G/A	cg06558623	chr16:89946397	TCF25	0.93	6.61	0.4	2.59e-10	Skin colour saturation;
SARC	cis	rs644148	0.836	rs2571111	chr19:45000581	C/A	cg15540054	chr19:45004280	ZNF180	-0.44	-5.11	-0.32	6.86e-7	Personality dimensions;
SARC	cis	rs34172651	0.876	rs2112785	chr16:24781176	C/T	cg00339695	chr16:24857497	SLC5A11	0.29	4.87	0.3	2.04e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2760061	0.819	rs708114	chr1:228197496	G/A	cg02753203	chr1:228287806	NA	0.58	7.99	0.46	6.05e-14	Diastolic blood pressure;
SARC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg11494091	chr17:61959527	GH2	0.59	9.82	0.54	2.83e-19	Prudent dietary pattern;
SARC	cis	rs78320035	1.000	rs76378020	chr1:168148092	G/A	cg17113809	chr1:168148080	TIPRL	1.29	6.84	0.41	6.96e-11	Red cell distribution width;
SARC	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg21442419	chr1:2182373	SKI	0.38	4.86	0.3	2.17e-6	Height;
SARC	cis	rs826838	0.967	rs1684413	chr12:39128704	G/A	cg13010199	chr12:38710504	ALG10B	-0.63	-8.88	-0.5	1.87e-16	Heart rate;
SARC	cis	rs920590	0.684	rs57837509	chr8:19670088	A/G	cg01411142	chr8:19674711	INTS10	0.53	6.07	0.37	5.22e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs8067354	0.645	rs9901606	chr17:57811407	A/C	cg13753209	chr17:57696993	CLTC	0.68	7.29	0.43	4.65e-12	Hemoglobin concentration;
SARC	cis	rs2070488	0.745	rs7649153	chr3:38467753	T/A	cg27533700	chr3:38537683	EXOG	-0.4	-4.97	-0.31	1.29e-6	Electrocardiographic conduction measures;
SARC	cis	rs1448094	0.512	rs1584368	chr12:86245117	A/C	cg00310523	chr12:86230176	RASSF9	0.31	4.79	0.3	3.03e-6	Major depressive disorder;
SARC	cis	rs3106136	0.967	rs17310526	chr4:95222227	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.39	-6.05	-0.37	5.71e-9	Capecitabine sensitivity;
SARC	cis	rs12421382	0.511	rs2212430	chr11:109289538	C/T	cg16359550	chr11:109292809	C11orf87	0.45	6.76	0.4	1.12e-10	Schizophrenia;
SARC	cis	rs17376456	0.825	rs17372057	chr5:93071916	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.71	6.55	0.39	3.7e-10	Diabetic retinopathy;
SARC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg23034840	chr1:205782522	SLC41A1	0.59	7.26	0.43	5.58e-12	Menarche (age at onset);
SARC	cis	rs13191362	1.000	rs13209100	chr6:163159350	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.57	5.56	0.34	7.47e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg03386556	chr1:113499109	SLC16A1	0.53	6.7	0.4	1.56e-10	Lung adenocarcinoma;
SARC	cis	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg13072238	chr3:49761600	GMPPB	-0.42	-5.54	-0.34	8.33e-8	Intelligence (multi-trait analysis);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg20103222	chr3:31667141	STT3B	0.53	7.58	0.44	8.28e-13	Thyroid stimulating hormone;
SARC	cis	rs8070624	0.574	rs11078408	chr17:17876011	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.39	4.73	0.3	3.89e-6	Total body bone mineral density;
SARC	cis	rs10911232	0.507	rs10797821	chr1:183012559	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.44	0.56	3.45e-21	Hypertriglyceridemia;
SARC	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg22875332	chr1:76189707	ACADM	0.46	6.12	0.37	3.93e-9	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6570726	0.935	rs397418	chr6:145842362	C/T	cg05347473	chr6:146136440	FBXO30	0.48	6.47	0.39	5.7e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs709400	0.663	rs7158822	chr14:103887868	C/T	cg12935359	chr14:103987150	CKB	-0.41	-5.95	-0.36	9.71e-9	Body mass index;
SARC	cis	rs965469	1.000	rs6051715	chr20:3266548	C/T	cg25506879	chr20:3388711	C20orf194	-0.47	-4.76	-0.3	3.42e-6	IFN-related cytopenia;
SARC	cis	rs17401966	0.867	rs61775872	chr1:10279308	T/C	cg15208524	chr1:10270712	KIF1B	0.47	5.59	0.34	6.49e-8	Hepatocellular carcinoma;
SARC	cis	rs1904096	0.506	rs17021463	chr4:95224812	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.49	-7.2	-0.43	8.18e-12	Type 2 diabetes;
SARC	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg11764359	chr7:65958608	NA	-0.73	-8.48	-0.49	2.55e-15	Aortic root size;
SARC	cis	rs72945132	0.882	rs12099016	chr11:70195161	C/G	cg05964544	chr11:70165517	PPFIA1	-0.56	-5.46	-0.34	1.22e-7	Coronary artery disease;
SARC	cis	rs17376456	0.757	rs10476591	chr5:93333723	G/C	cg21475434	chr5:93447410	FAM172A	0.85	7.68	0.45	4.4e-13	Diabetic retinopathy;
SARC	cis	rs7659604	1.000	rs10005932	chr4:122664782	T/C	cg20573242	chr4:122745356	CCNA2	0.44	5.82	0.36	1.99e-8	Type 2 diabetes;
SARC	cis	rs10927875	0.632	rs904911	chr1:16126932	C/T	cg07117364	chr1:16154769	NA	-0.42	-4.89	-0.31	1.86e-6	Dilated cardiomyopathy;
SARC	cis	rs910316	1.000	rs10140851	chr14:75512612	G/A	cg06637938	chr14:75390232	RPS6KL1	0.56	7.88	0.46	1.24e-13	Height;
SARC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg13397359	chr6:42928475	GNMT	0.54	7.63	0.45	6.07e-13	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs11997175	0.510	rs10503953	chr8:33797783	C/T	ch.8.33884649F	chr8:33765107	NA	0.47	6.04	0.37	6.2e-9	Body mass index;
SARC	cis	rs7584330	0.666	rs60671275	chr2:238374318	C/A	cg14458575	chr2:238380390	NA	0.6	6.7	0.4	1.54e-10	Prostate cancer;
SARC	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg21747090	chr2:27597821	SNX17	-0.55	-7.7	-0.45	3.82e-13	Total body bone mineral density;
SARC	cis	rs8114671	0.836	rs6142284	chr20:33641367	G/A	cg08999081	chr20:33150536	PIGU	-0.34	-4.86	-0.3	2.15e-6	Height;
SARC	cis	rs10046574	0.561	rs10214966	chr7:135196642	A/G	cg27474649	chr7:135195673	CNOT4	0.85	7.92	0.46	9.66e-14	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs6542838	0.641	rs13005124	chr2:99527680	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.55	-7.23	-0.43	7e-12	Fear of minor pain;
SARC	cis	rs11711311	0.712	rs10804510	chr3:113340700	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.57	7.09	0.42	1.59e-11	IgG glycosylation;
SARC	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg11987759	chr7:65425863	GUSB	0.49	6.17	0.37	3.02e-9	Aortic root size;
SARC	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg00684032	chr4:1343700	KIAA1530	0.47	6.77	0.41	1.02e-10	Obesity-related traits;
SARC	cis	rs17345786	0.906	rs59359251	chr3:101146362	A/C	cg11279151	chr3:101281821	RG9MTD1	-0.45	-4.73	-0.3	3.97e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9916302	0.904	rs2338797	chr17:37548241	G/A	cg15445000	chr17:37608096	MED1	-0.43	-5.16	-0.32	5.27e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.48	5.4	0.33	1.68e-7	Renal function-related traits (BUN);
SARC	cis	rs6496044	0.568	rs12708554	chr15:86074297	C/G	cg10818794	chr15:86012489	AKAP13	-0.39	-4.77	-0.3	3.2e-6	Interstitial lung disease;
SARC	cis	rs9381040	0.655	rs9381029	chr6:41026453	G/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.41	-4.72	-0.3	4.14e-6	Alzheimer's disease (late onset);
SARC	cis	rs6772849	1.000	rs60228913	chr3:128311331	G/A	cg08795948	chr3:128337044	NA	0.36	4.81	0.3	2.66e-6	Monocyte percentage of white cells;Monocyte count;
SARC	trans	rs877282	0.628	rs11253435	chr10:824169	T/C	cg22713356	chr15:30763199	NA	0.89	8.62	0.49	1.03e-15	Uric acid levels;
SARC	cis	rs6582630	0.537	rs2204006	chr12:38407098	A/G	cg13010199	chr12:38710504	ALG10B	0.75	10.24	0.56	1.51e-20	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg02915290	chr3:183675533	ABCC5	-0.55	-7.18	-0.43	9.36e-12	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs4742903	0.509	rs4301499	chr9:106934942	C/T	cg14250997	chr9:106856677	SMC2	0.4	4.92	0.31	1.62e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs7149337	1.000	rs4261445	chr14:51723540	G/A	cg23942311	chr14:51606299	NA	0.33	5.83	0.36	1.87e-8	Cancer;
SARC	cis	rs739401	0.611	rs494427	chr11:3048140	A/G	cg05729581	chr11:3078854	CARS	-0.5	-6.69	-0.4	1.61e-10	Longevity;
SARC	cis	rs10463554	0.963	rs62364875	chr5:102392190	T/C	cg23492399	chr5:102201601	PAM	-0.46	-5.05	-0.31	8.78e-7	Parkinson's disease;
SARC	cis	rs11785400	0.701	rs9297968	chr8:143723009	A/G	cg10596483	chr8:143751796	JRK	0.58	7.53	0.44	1.08e-12	Schizophrenia;
SARC	cis	rs986417	1.000	rs1254291	chr14:60863570	A/T	cg27398547	chr14:60952738	C14orf39	-0.97	-8.69	-0.49	6.36e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs2832191	0.632	rs2246777	chr21:30309586	T/C	cg08807101	chr21:30365312	RNF160	-0.92	-14.56	-0.69	1.3600000000000001e-34	Dental caries;
SARC	cis	rs4319547	0.695	rs7301515	chr12:122949673	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.64	-7.14	-0.42	1.19e-11	Body mass index;
SARC	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg11987759	chr7:65425863	GUSB	0.57	7.54	0.44	1.03e-12	Aortic root size;
SARC	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg16479474	chr6:28041457	NA	0.36	5.84	0.36	1.7e-8	Depression;
SARC	cis	rs73001065	0.636	rs10415849	chr19:19505087	C/T	cg03709012	chr19:19516395	GATAD2A	1.06	8.02	0.46	5.23e-14	LDL cholesterol;
SARC	cis	rs6089584	0.546	rs6061978	chr20:60615604	C/T	cg23262073	chr20:60523788	NA	-0.33	-5.03	-0.31	1e-6	Body mass index;
SARC	cis	rs9682041	0.932	rs1525362	chr3:170070702	C/T	cg11886554	chr3:170076028	SKIL	0.79	6.87	0.41	5.95e-11	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs2908197	0.699	rs2908191	chr7:75962322	A/G	cg07849177	chr7:76178544	LOC100133091	-0.41	-4.76	-0.3	3.46e-6	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs933688	1.000	rs10059163	chr5:90742444	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	12.61	0.64	3.86e-28	Smoking behavior;
SARC	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg22496380	chr5:211416	CCDC127	-0.84	-8.6	-0.49	1.19e-15	Breast cancer;
SARC	cis	rs7223966	1.000	rs78172786	chr17:61847114	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.46	4.8	0.3	2.81e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs8141529	0.529	rs73170633	chr22:29160805	C/T	cg02153584	chr22:29168773	CCDC117	0.67	6.64	0.4	2.25e-10	Lymphocyte counts;
SARC	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg19748678	chr4:122722346	EXOSC9	0.77	10.46	0.57	3.09e-21	Type 2 diabetes;
SARC	cis	rs79149102	0.579	rs8040961	chr15:75291864	G/A	cg17294928	chr15:75287854	SCAMP5	-0.99	-8.87	-0.5	1.91e-16	Lung cancer;
SARC	cis	rs826838	0.678	rs11182781	chr12:38610178	C/T	cg13010199	chr12:38710504	ALG10B	0.78	10.99	0.58	6.77e-23	Heart rate;
SARC	cis	rs1691799	0.899	rs903587	chr12:66746061	C/A	cg16791601	chr12:66731901	HELB	-0.71	-10.85	-0.58	1.89e-22	White blood cell count (basophil);
SARC	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg11644478	chr21:40555479	PSMG1	1.04	14.22	0.68	1.9e-33	Cognitive function;
SARC	cis	rs12142240	0.698	rs67487250	chr1:46811333	T/C	cg00530320	chr1:46809349	NSUN4	0.58	7.07	0.42	1.83e-11	Menopause (age at onset);
SARC	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.56	-6.22	-0.38	2.3e-9	Blood protein levels;
SARC	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg18252515	chr7:66147081	NA	0.6	6.57	0.4	3.3e-10	Aortic root size;
SARC	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg05861140	chr6:150128134	PCMT1	-0.37	-4.87	-0.3	2.08e-6	Lung cancer;
SARC	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg20965017	chr5:231967	SDHA	-0.55	-5.26	-0.33	3.23e-7	Breast cancer;
SARC	cis	rs734999	0.572	rs2985857	chr1:2532624	C/T	cg00980319	chr1:2560884	MMEL1	0.34	4.87	0.3	2.03e-6	Ulcerative colitis;
SARC	trans	rs9929218	0.906	rs34565494	chr16:68741769	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.66	-8.43	-0.48	3.57e-15	Colorectal cancer;
SARC	cis	rs1865760	0.865	rs10946800	chr6:25957773	C/T	cg17691542	chr6:26056736	HIST1H1C	0.58	7.36	0.43	3.13e-12	Height;
SARC	cis	rs7044106	0.762	rs966396	chr9:123453281	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	4.94	0.31	1.47e-6	Hip circumference adjusted for BMI;
SARC	cis	rs57506017	0.585	rs4721057	chr7:12267221	A/G	cg23422036	chr7:12250390	TMEM106B	0.45	5.71	0.35	3.44e-8	Neuroticism;
SARC	cis	rs9815354	1.000	rs6791806	chr3:41889995	C/T	cg03022575	chr3:42003672	ULK4	0.56	5.29	0.33	2.81e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs3126085	0.935	rs4845421	chr1:152173259	G/T	cg03465714	chr1:152285911	FLG	-0.47	-5.56	-0.34	7.45e-8	Atopic dermatitis;
SARC	trans	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg16469426	chr7:19748791	TWISTNB	-0.51	-6.43	-0.39	7.34e-10	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2204008	0.678	rs61929520	chr12:38446800	T/C	cg13010199	chr12:38710504	ALG10B	-0.46	-5.67	-0.35	4.17e-8	Bladder cancer;
SARC	trans	rs17685	0.697	rs28689051	chr7:75763624	G/A	cg19862616	chr7:65841803	NCRNA00174	0.61	7.33	0.43	3.71e-12	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.77	-8.03	-0.47	4.84e-14	Alzheimer's disease;
SARC	cis	rs56235845	0.665	rs4976685	chr5:176766177	C/T	cg17509989	chr5:176798049	RGS14	-0.55	-7.8	-0.46	2.02e-13	Hemoglobin concentration;Hematocrit;
SARC	cis	rs9911578	1.000	rs2079703	chr17:56603978	G/A	cg12560992	chr17:57184187	TRIM37	-0.81	-10.81	-0.58	2.5e-22	Intelligence (multi-trait analysis);
SARC	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-5.09	-0.32	7.37e-7	Total body bone mineral density;
SARC	cis	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg05084668	chr3:125655381	ALG1L	-0.5	-5.24	-0.32	3.58e-7	Blood pressure (smoking interaction);
SARC	cis	rs17376456	0.825	rs72786702	chr5:93254656	A/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	5.84	0.36	1.75e-8	Diabetic retinopathy;
SARC	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg04944784	chr2:26401820	FAM59B	-0.44	-5.46	-0.34	1.19e-7	Gut microbiome composition (summer);
SARC	cis	rs7605378	0.567	rs717915	chr2:200714766	C/T	cg23649088	chr2:200775458	C2orf69	0.77	10.57	0.57	1.35e-21	Osteoporosis;
SARC	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg27211696	chr2:191398769	TMEM194B	-0.48	-6.54	-0.39	3.79e-10	Pulse pressure;
SARC	cis	rs4077515	0.577	rs10870165	chr9:139316601	C/T	cg14169450	chr9:139327907	INPP5E	0.36	4.75	0.3	3.48e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs7945705	0.837	rs10769981	chr11:9024460	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.47	6.43	0.39	7.28e-10	Hemoglobin concentration;
SARC	cis	rs62244186	0.659	rs56234157	chr3:44516221	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.48	5.82	0.36	1.96e-8	Depressive symptoms;
SARC	cis	rs6733011	0.578	rs10169003	chr2:99508866	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.41	5.09	0.32	7.44e-7	Bipolar disorder;
SARC	cis	rs11630290	0.589	rs12324851	chr15:64163495	G/A	cg12036633	chr15:63758958	NA	0.47	5.04	0.31	9.5e-7	Iris characteristics;
SARC	cis	rs7681440	0.835	rs7656954	chr4:90784670	G/A	cg01966878	chr4:90757139	SNCA	-0.36	-4.78	-0.3	3.1e-6	Dementia with Lewy bodies;
SARC	cis	rs9640161	0.789	rs2159234	chr7:150020422	A/T	cg17279839	chr7:150038598	RARRES2	0.47	6.56	0.39	3.44e-10	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs8141529	0.732	rs6005881	chr22:29183133	A/G	cg15103426	chr22:29168792	CCDC117	0.69	9.36	0.52	7.2e-18	Lymphocyte counts;
SARC	cis	rs1215050	0.791	rs165237	chr4:98712029	T/C	cg05340658	chr4:99064831	C4orf37	0.44	5.85	0.36	1.62e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs9902453	0.817	rs2321333	chr17:28140857	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	7.12	0.42	1.31e-11	Coffee consumption (cups per day);
SARC	cis	rs73195822	0.667	rs59789826	chr12:111235110	T/C	cg10860002	chr12:110842031	ANAPC7	0.6	4.93	0.31	1.57e-6	Itch intensity from mosquito bite;
SARC	trans	rs61931739	0.500	rs7963282	chr12:34535255	A/C	cg26384229	chr12:38710491	ALG10B	0.85	12.63	0.64	3.4e-28	Morning vs. evening chronotype;
SARC	cis	rs4974559	0.501	rs900013	chr4:1240450	G/A	cg02980000	chr4:1222292	CTBP1	-0.82	-6.6	-0.4	2.74e-10	Systolic blood pressure;
SARC	cis	rs1348850	0.526	rs10497504	chr2:178370040	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.69	6.26	0.38	1.81e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9858542	0.537	rs9818758	chr3:49382925	G/A	cg00383909	chr3:49044727	WDR6	0.53	5.23	0.32	3.84e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs6688613	0.649	rs11584352	chr1:166850372	T/C	cg07049167	chr1:166818506	POGK	0.47	4.76	0.3	3.35e-6	Refractive astigmatism;
SARC	trans	rs208520	0.770	rs2224422	chr6:66883993	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.03	-12.94	-0.65	3.28e-29	Exhaled nitric oxide output;
SARC	cis	rs6484504	0.532	rs11031342	chr11:31309818	G/A	cg26647111	chr11:31128758	NA	-0.39	-4.98	-0.31	1.25e-6	Red blood cell count;
SARC	cis	rs6500602	0.727	rs6500607	chr16:4503631	C/T	cg08645402	chr16:4508243	NA	0.48	6.32	0.38	1.28e-9	Schizophrenia;
SARC	cis	rs9399137	0.507	rs6923512	chr6:135335268	A/G	cg24558204	chr6:135376177	HBS1L	-0.63	-7.93	-0.46	9.34e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs11122272	0.735	rs2790883	chr1:231532726	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.13	-0.55	3.28e-20	Hemoglobin concentration;
SARC	cis	rs7246760	0.867	rs57999229	chr19:9817357	C/T	cg16876255	chr19:9731953	ZNF561	0.79	4.88	0.3	1.96e-6	Pursuit maintenance gain;
SARC	cis	rs2898681	0.567	rs77657787	chr4:53729981	G/A	cg00338735	chr4:53728038	RASL11B	0.49	5.01	0.31	1.08e-6	Optic nerve measurement (cup area);
SARC	cis	rs7523050	0.643	rs34114412	chr1:109402866	C/T	cg08274380	chr1:109419600	GPSM2	1.02	7.68	0.45	4.37e-13	Fat distribution (HIV);
SARC	cis	rs1497406	0.744	rs12562207	chr1:16508059	G/A	cg20430773	chr1:16534157	ARHGEF19	0.48	7.3	0.43	4.57e-12	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9389248	0.690	rs6569982	chr6:135256495	C/G	cg24558204	chr6:135376177	HBS1L	0.5	6.45	0.39	6.45e-10	High light scatter reticulocyte percentage of red cells;
SARC	cis	rs17539620	0.624	rs62432752	chr6:154841074	A/G	cg17771515	chr6:154831774	CNKSR3	0.53	4.96	0.31	1.39e-6	Lipoprotein (a) levels;
SARC	cis	rs644799	1.000	rs560854	chr11:95584905	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	15.19	0.71	1.11e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs17270561	0.609	rs9348694	chr6:25753640	C/T	cg17691542	chr6:26056736	HIST1H1C	0.58	6.97	0.42	3.17e-11	Iron status biomarkers;
SARC	cis	rs1448094	0.817	rs10779220	chr12:86323543	T/A	cg02569458	chr12:86230093	RASSF9	0.41	5.83	0.36	1.88e-8	Major depressive disorder;
SARC	cis	rs17270561	0.636	rs4360128	chr6:25734558	A/G	cg16482183	chr6:26056742	HIST1H1C	0.43	5.22	0.32	3.92e-7	Iron status biomarkers;
SARC	cis	rs651907	0.557	rs34181125	chr3:101490278	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	6.56	0.39	3.46e-10	Colorectal cancer;
SARC	cis	rs6674176	0.628	rs7556565	chr1:44416090	C/T	cg13606994	chr1:44402422	ARTN	-0.33	-5.35	-0.33	2.13e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs7659604	0.540	rs11934307	chr4:122677514	G/A	cg19671926	chr4:122722719	EXOSC9	0.55	6.99	0.42	2.87e-11	Type 2 diabetes;
SARC	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg16606324	chr3:10149918	C3orf24	0.46	4.8	0.3	2.79e-6	Alzheimer's disease;
SARC	cis	rs12458462	0.892	rs3786228	chr18:77464170	C/T	cg11879182	chr18:77439856	CTDP1	-0.87	-12.71	-0.64	1.77e-28	Monocyte count;
SARC	cis	rs17079247	1.000	rs12872842	chr13:85664592	A/G	ch.13.84760847R	chr13:85862846	NA	-0.57	-4.82	-0.3	2.57e-6	Bipolar disorder (mania);
SARC	cis	rs365132	0.875	rs353477	chr5:176418927	C/T	cg16309518	chr5:176445507	NA	-0.48	-6.29	-0.38	1.53e-9	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs62344088	0.590	rs58563514	chr5:177837	C/T	cg20965017	chr5:231967	SDHA	-0.71	-5.37	-0.33	1.89e-7	Asthma (childhood onset);
SARC	cis	rs4727027	0.866	rs12666477	chr7:148812322	A/G	cg23583168	chr7:148888333	NA	-0.74	-10.37	-0.56	5.62e-21	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs6499129	0.558	rs7191281	chr16:67655133	T/C	cg01866162	chr16:67596514	CTCF	0.56	4.93	0.31	1.58e-6	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs4595586	0.525	rs12818844	chr12:39423806	A/G	cg26384229	chr12:38710491	ALG10B	0.55	6.16	0.37	3.13e-9	Morning vs. evening chronotype;
SARC	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.47	5.79	0.35	2.32e-8	Gut microbiome composition (summer);
SARC	cis	rs826838	0.654	rs7977738	chr12:38722460	G/A	cg13010199	chr12:38710504	ALG10B	0.56	7.24	0.43	6.65e-12	Heart rate;
SARC	trans	rs79976124	0.837	rs10455591	chr6:66650584	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	7.8	0.46	2.08e-13	Type 2 diabetes;
SARC	cis	rs17376456	0.825	rs6877030	chr5:93201841	C/A	cg21475434	chr5:93447410	FAM172A	0.79	6.77	0.41	1.07e-10	Diabetic retinopathy;
SARC	cis	rs698833	0.819	rs2340809	chr2:44536249	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.6	7.56	0.44	9.38e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs17023223	0.537	rs2645295	chr1:119582448	C/T	cg05756136	chr1:119680316	WARS2	-0.48	-5.82	-0.36	1.95e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs921968	0.541	rs10205073	chr2:219412784	C/A	cg02176678	chr2:219576539	TTLL4	-0.49	-7.57	-0.44	8.67e-13	Mean corpuscular hemoglobin concentration;
SARC	cis	rs1669338	0.646	rs3792415	chr3:3201780	C/G	cg16797762	chr3:3221439	CRBN	0.51	5.65	0.35	4.73e-8	White matter integrity;
SARC	cis	rs925098	0.624	rs2286537	chr4:17841465	A/G	cg02297831	chr4:17616191	MED28	0.45	4.71	0.3	4.17e-6	Birth weight;Height;
SARC	cis	rs1018836	0.923	rs12680211	chr8:91633434	C/T	cg16814680	chr8:91681699	NA	-0.81	-13.48	-0.66	5.39e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs763121	0.853	rs8140617	chr22:38970439	A/G	cg06022373	chr22:39101656	GTPBP1	-0.77	-8.95	-0.51	1.18e-16	Menopause (age at onset);
SARC	trans	rs7819412	0.594	rs17724226	chr8:10968926	C/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.54	-0.39	3.92e-10	Triglycerides;
SARC	trans	rs3942852	0.606	rs10734561	chr11:48097480	C/T	cg15704280	chr7:45808275	SEPT13	-0.59	-6.72	-0.4	1.35e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs11098499	0.954	rs1022145	chr4:120230979	A/G	cg09160332	chr4:120329925	NA	-0.34	-4.8	-0.3	2.85e-6	Corneal astigmatism;
SARC	cis	rs6570726	0.935	rs419850	chr6:145827281	A/G	cg05347473	chr6:146136440	FBXO30	0.5	6.66	0.4	1.9e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6570726	0.905	rs421032	chr6:145827771	A/G	cg05220968	chr6:146057943	EPM2A	-0.29	-4.86	-0.3	2.17e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2841277	0.738	rs1036713	chr14:105396693	C/G	cg21017887	chr14:105400489	NA	-0.5	-7.24	-0.43	6.64e-12	Rheumatoid arthritis;
SARC	cis	rs2280018	0.526	rs2966128	chr16:15153389	G/T	cg07549590	chr16:15018862	NA	-0.58	-7.42	-0.44	2.22e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs60871478	0.685	rs34421533	chr7:816638	A/G	cg09839136	chr7:766187	HEATR2;PRKAR1B	0.58	4.74	0.3	3.77e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	8.51	0.49	2.13e-15	Mean platelet volume;
SARC	cis	rs1832871	0.683	rs9457224	chr6:158666139	C/T	cg07165851	chr6:158734300	TULP4	0.56	6.79	0.41	9.29e-11	Height;
SARC	cis	rs7659604	1.000	rs28640980	chr4:122664284	T/C	cg19671926	chr4:122722719	EXOSC9	-0.48	-5.93	-0.36	1.07e-8	Type 2 diabetes;
SARC	cis	rs9868809	0.505	rs28657585	chr3:48736216	A/T	cg06212747	chr3:49208901	KLHDC8B	-0.58	-5.38	-0.33	1.84e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg06221963	chr1:154839813	KCNN3	-0.53	-8.54	-0.49	1.71e-15	Prostate cancer;
SARC	cis	rs11608355	0.545	rs6606723	chr12:109905044	C/G	cg05360138	chr12:110035743	NA	0.92	9.68	0.54	7.88e-19	Neuroticism;
SARC	cis	rs7223966	1.000	rs8067431	chr17:61817048	T/C	cg26338869	chr17:61819248	STRADA	0.48	5.02	0.31	1.01e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.03	11.32	0.6	5.81e-24	Platelet count;
SARC	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg21724239	chr8:58056113	NA	0.69	5.98	0.36	8.45e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs1814175	0.727	rs2140597	chr11:49873946	G/A	cg03929089	chr4:120376271	NA	-0.9	-15.07	-0.7	2.78e-36	Height;
SARC	cis	rs9916302	0.904	rs8068427	chr17:37511517	G/A	cg15445000	chr17:37608096	MED1	-0.46	-5.69	-0.35	3.78e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg13206674	chr6:150067644	NUP43	0.46	6.06	0.37	5.49e-9	Lung cancer;
SARC	cis	rs11098499	0.820	rs12503082	chr4:120284317	A/G	cg09307838	chr4:120376055	NA	0.83	11.82	0.61	1.46e-25	Corneal astigmatism;
SARC	cis	rs7927592	0.626	rs11228279	chr11:68309680	C/T	cg01657329	chr11:68192670	LRP5	0.36	4.99	0.31	1.18e-6	Total body bone mineral density;
SARC	cis	rs9296092	0.560	rs7765263	chr6:33525559	A/G	cg13560919	chr6:33536144	NA	-0.53	-6.45	-0.39	6.31e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	trans	rs17685	0.753	rs1859791	chr7:75786043	T/C	cg19862616	chr7:65841803	NCRNA00174	0.63	7.95	0.46	8.05e-14	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs2758596	0.850	rs2842879	chr1:156163695	G/T	cg24450063	chr1:156163899	SLC25A44	0.89	5.59	0.34	6.39e-8	Paclitaxel disposition in epithelial ovarian cancer;
SARC	cis	rs7766436	0.885	rs13211957	chr6:22573415	C/T	cg13666174	chr6:22585274	NA	-0.55	-6.65	-0.4	2.03e-10	Coronary artery disease;
SARC	cis	rs7089973	0.872	rs34683721	chr10:116619849	G/A	cg08188268	chr10:116634841	FAM160B1	0.37	5.89	0.36	1.33e-8	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs5769765	0.955	rs5769767	chr22:50276909	G/A	cg03033257	chr22:50311977	ALG12;CRELD2	-0.54	-5.64	-0.35	4.81e-8	Schizophrenia;
SARC	cis	rs28386778	0.703	rs2286565	chr17:62010232	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.62	-7.53	-0.44	1.09e-12	Prudent dietary pattern;
SARC	cis	rs11025559	0.643	rs11025570	chr11:20481109	T/A	cg04101203	chr11:20408940	PRMT3	-0.61	-5.7	-0.35	3.61e-8	Pursuit maintenance gain;
SARC	cis	rs4975709	0.569	rs931509	chr5:1858821	A/T	cg11168104	chr5:1857477	NA	-0.34	-4.81	-0.3	2.73e-6	Cardiovascular disease risk factors;
SARC	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg03647317	chr4:187891568	NA	0.42	5.92	0.36	1.12e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs911263	0.603	rs1956529	chr14:68788924	A/G	cg18825221	chr14:68749962	RAD51L1	-0.43	-7.6	-0.45	7.34e-13	Primary biliary cholangitis;
SARC	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg20607798	chr8:58055168	NA	0.57	5.53	0.34	8.58e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs8067545	0.640	rs10083840	chr17:19965972	A/G	cg13482628	chr17:19912719	NA	0.54	6.84	0.41	6.87e-11	Schizophrenia;
SARC	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg02725872	chr8:58115012	NA	-0.34	-5.38	-0.33	1.78e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg06108461	chr20:60628389	TAF4	-0.92	-12.69	-0.64	2.14e-28	Body mass index;
SARC	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg05340658	chr4:99064831	C4orf37	0.57	7.13	0.42	1.22e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg12064134	chr16:90016061	DEF8	-0.57	-4.97	-0.31	1.28e-6	Skin colour saturation;
SARC	cis	rs6484504	0.576	rs208083	chr11:31196880	C/T	cg26647111	chr11:31128758	NA	-0.38	-5.1	-0.32	7.04e-7	Red blood cell count;
SARC	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg16405210	chr4:1374714	KIAA1530	-0.51	-6.27	-0.38	1.78e-9	Longevity;
SARC	cis	rs11711311	0.784	rs13081931	chr3:113349928	G/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.51	6.05	0.37	5.64e-9	IgG glycosylation;
SARC	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	12.28	0.63	4.49e-27	Platelet count;
SARC	cis	rs7937682	0.575	rs10789851	chr11:111750955	G/C	cg22437258	chr11:111473054	SIK2	-0.46	-5.42	-0.33	1.49e-7	Primary sclerosing cholangitis;
SARC	cis	rs2439831	0.867	rs7170489	chr15:43636651	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.04	10.9	0.58	1.25e-22	Lung cancer in ever smokers;
SARC	cis	rs9303401	0.614	rs7215900	chr17:56654850	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	10.59	0.57	1.21e-21	Cognitive test performance;
SARC	cis	rs2282802	0.685	rs35214989	chr5:139636127	T/C	cg26211634	chr5:139558579	C5orf32	0.39	5.0	0.31	1.13e-6	Intelligence (multi-trait analysis);
SARC	cis	rs35213789	0.922	rs988282	chr7:69085009	C/G	cg10619644	chr7:69149951	AUTS2	-0.44	-5.73	-0.35	3.08e-8	Childhood ear infection;
SARC	cis	rs2070488	0.699	rs6599205	chr3:38529440	C/G	cg27533700	chr3:38537683	EXOG	-0.37	-4.77	-0.3	3.27e-6	Electrocardiographic conduction measures;
SARC	cis	rs6696846	0.740	rs12125465	chr1:205074854	C/A	cg07972983	chr1:205091412	RBBP5	0.58	7.58	0.44	7.93e-13	Red blood cell count;
SARC	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg07648498	chr16:89883185	FANCA	0.4	5.3	0.33	2.63e-7	Vitiligo;
SARC	cis	rs7592578	1.000	rs7592578	chr2:191439591	T/G	cg10560079	chr2:191398806	TMEM194B	0.83	9.44	0.53	3.97e-18	Diastolic blood pressure;
SARC	cis	rs27434	0.583	rs151954	chr5:96157689	A/G	cg16492584	chr5:96139282	ERAP1	-0.57	-7.11	-0.42	1.4e-11	Ankylosing spondylitis;
SARC	cis	rs2749592	0.550	rs4934881	chr10:37914346	A/C	cg25427524	chr10:38739819	LOC399744	0.48	7.06	0.42	1.93e-11	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg07636037	chr3:49044803	WDR6	1.0	17.51	0.75	2.22e-44	Parkinson's disease;
SARC	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg11764359	chr7:65958608	NA	0.76	9.06	0.51	5.44e-17	Aortic root size;
SARC	cis	rs72627123	0.867	rs73301475	chr14:74462868	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.78	6.14	0.37	3.47e-9	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	trans	rs12310956	0.532	rs11052954	chr12:33993512	C/G	cg26384229	chr12:38710491	ALG10B	0.77	10.81	0.58	2.5e-22	Morning vs. evening chronotype;
SARC	cis	rs2836974	0.583	rs2735307	chr21:40713358	C/T	cg11890956	chr21:40555474	PSMG1	0.73	9.89	0.54	1.81e-19	Cognitive function;
SARC	cis	rs10046574	0.519	rs9656456	chr7:135202208	G/A	cg27474649	chr7:135195673	CNOT4	0.84	7.94	0.46	8.38e-14	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs1153858	1.000	rs12439274	chr15:45636667	A/G	cg14582100	chr15:45693742	SPATA5L1	0.37	5.09	0.32	7.46e-7	Homoarginine levels;
SARC	cis	rs9818758	0.607	rs11552724	chr3:49156473	C/G	cg07636037	chr3:49044803	WDR6	-0.79	-6.87	-0.41	5.77e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs11770686	0.935	rs2240139	chr7:75342453	C/A	cg17787366	chr7:75369077	HIP1	0.4	4.95	0.31	1.41e-6	Essential tremor;
SARC	cis	rs7712401	0.715	rs436160	chr5:122355953	G/A	cg19412675	chr5:122181750	SNX24	-0.42	-5.3	-0.33	2.65e-7	Mean platelet volume;
SARC	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg00933542	chr6:150070202	PCMT1	0.31	5.24	0.32	3.51e-7	Lung cancer;
SARC	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg16325326	chr1:53192061	ZYG11B	-0.93	-15.89	-0.72	5.21e-39	Monocyte count;
SARC	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg09699651	chr6:150184138	LRP11	0.39	4.87	0.3	2.04e-6	Lung cancer;
SARC	cis	rs17270561	0.608	rs9358875	chr6:25738008	G/A	cg17691542	chr6:26056736	HIST1H1C	0.58	7.09	0.42	1.6e-11	Iron status biomarkers;
SARC	cis	rs3087591	1.000	rs2905800	chr17:29531980	A/G	cg24425628	chr17:29625626	OMG;NF1	0.48	5.81	0.36	2.04e-8	Hip circumference;
SARC	cis	rs2153535	0.580	rs5001130	chr6:8442298	G/A	cg21535247	chr6:8435926	SLC35B3	0.57	6.97	0.42	3.22e-11	Motion sickness;
SARC	cis	rs7927771	1.000	rs12787330	chr11:47812311	C/T	cg20307385	chr11:47447363	PSMC3	-0.47	-5.59	-0.34	6.3e-8	Subjective well-being;
SARC	cis	rs644799	0.710	rs12273579	chr11:95524421	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.62	8.27	0.48	9.95e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs3617	0.625	rs7617468	chr3:52849549	T/C	cg18404041	chr3:52824283	ITIH1	-0.34	-5.0	-0.31	1.15e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs4148883	0.689	rs2602861	chr4:100030896	C/T	cg13256891	chr4:100009986	ADH5	0.63	8.64	0.49	9.15e-16	Alcohol dependence;
SARC	cis	rs6484504	0.512	rs2761594	chr11:31318244	A/G	cg02090638	chr11:31391270	DNAJC24;DCDC1	0.42	5.31	0.33	2.51e-7	Red blood cell count;
SARC	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	cis	rs2304069	0.826	rs245076	chr5:149350648	C/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.46	4.84	0.3	2.32e-6	HIV-1 control;
SARC	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg22618164	chr12:122356400	WDR66	0.44	7.06	0.42	1.93e-11	Mean corpuscular volume;
SARC	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg25072359	chr17:41440525	NA	0.5	5.76	0.35	2.67e-8	Menopause (age at onset);
SARC	trans	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.22	-0.43	7.42e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs4763879	0.865	rs4763840	chr12:9884410	A/G	cg27502298	chr12:9555721	NA	0.47	5.07	0.32	8.15e-7	Type 1 diabetes;
SARC	cis	rs6733011	0.578	rs12468024	chr2:99495980	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.4	-5.11	-0.32	6.86e-7	Bipolar disorder;
SARC	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg27211696	chr2:191398769	TMEM194B	-0.48	-6.46	-0.39	5.9e-10	Pulse pressure;
SARC	cis	rs7829975	0.564	rs2921057	chr8:8318667	C/T	cg06636001	chr8:8085503	FLJ10661	0.7	10.12	0.55	3.45e-20	Mood instability;
SARC	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg25072359	chr17:41440525	NA	0.48	5.55	0.34	7.82e-8	Menopause (age at onset);
SARC	cis	rs1050631	0.592	rs9958282	chr18:33710440	T/A	cg25426722	chr18:33708991	SLC39A6;ELP2	-0.56	-6.78	-0.41	9.88e-11	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs2290159	0.948	rs73130305	chr3:12621075	C/T	cg23032965	chr3:12705835	RAF1	0.74	7.95	0.46	7.98e-14	Cholesterol, total;
SARC	cis	rs2013441	1.000	rs2703802	chr17:20101039	T/C	cg13482628	chr17:19912719	NA	-0.48	-6.16	-0.37	3.1e-9	Obesity-related traits;
SARC	cis	rs4479964	0.605	rs10499163	chr6:129962633	T/C	cg27192990	chr6:129479024	LAMA2	0.29	4.82	0.3	2.56e-6	Gut microbiome composition (summer);
SARC	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg11366901	chr6:160182831	ACAT2	1.0	10.19	0.56	2.07e-20	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg05313129	chr8:58192883	C8orf71	-0.63	-6.51	-0.39	4.44e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs992157	0.835	rs6707559	chr2:219142773	C/T	cg00012203	chr2:219082015	ARPC2	0.65	9.39	0.52	5.68e-18	Colorectal cancer;
SARC	cis	rs79149102	0.579	rs6495137	chr15:75295541	G/A	cg09165964	chr15:75287851	SCAMP5	-0.95	-8.78	-0.5	3.63e-16	Lung cancer;
SARC	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg15556689	chr8:8085844	FLJ10661	0.57	7.47	0.44	1.61e-12	Mood instability;
SARC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.0	17.01	0.74	1.01e-42	Prudent dietary pattern;
SARC	cis	rs9420	0.961	rs11601320	chr11:57642617	T/C	cg23127183	chr11:57508653	C11orf31	-0.6	-6.64	-0.4	2.17e-10	Schizophrenia;
SARC	cis	rs8067545	0.750	rs11870111	chr17:19992738	G/A	cg13482628	chr17:19912719	NA	0.53	7.02	0.42	2.44e-11	Schizophrenia;
SARC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.19	0.8	4.45e-53	Prudent dietary pattern;
SARC	cis	rs5753618	0.583	rs9606839	chr22:31802710	A/C	cg02404636	chr22:31891804	SFI1	0.5	5.33	0.33	2.29e-7	Colorectal cancer;
SARC	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg12042659	chr19:58951599	ZNF132	0.43	5.64	0.35	4.85e-8	Uric acid clearance;
SARC	cis	rs1144333	0.655	rs17097864	chr1:76469596	C/T	cg03433033	chr1:76189801	ACADM	0.63	5.16	0.32	5.25e-7	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs10493773	1.000	rs7523292	chr1:86134992	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.5	-7.17	-0.43	9.98e-12	Urate levels in overweight individuals;
SARC	trans	rs7829975	0.511	rs1543238	chr8:8134809	A/G	cg16141378	chr3:129829833	LOC729375	-0.59	-7.26	-0.43	5.75e-12	Mood instability;
SARC	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs1971762	0.509	rs784567	chr12:53894465	C/T	cg06632207	chr12:54070931	ATP5G2	-0.6	-8.24	-0.47	1.29e-14	Height;
SARC	cis	rs9300255	0.550	rs10772997	chr12:123719880	C/A	cg05973401	chr12:123451056	ABCB9	0.52	5.89	0.36	1.37e-8	Neutrophil percentage of white cells;
SARC	cis	rs7617773	0.780	rs11716848	chr3:48378500	G/A	cg11946769	chr3:48343235	NME6	0.76	9.57	0.53	1.61e-18	Coronary artery disease;
SARC	cis	rs908922	0.676	rs493133	chr1:152493875	G/C	cg09873164	chr1:152488093	CRCT1	0.63	8.06	0.47	4.07e-14	Hair morphology;
SARC	cis	rs892961	0.899	rs747482	chr17:75412109	T/C	cg05865280	chr17:75406074	SEPT9	0.57	8.49	0.49	2.38e-15	Airflow obstruction;
SARC	cis	rs4595586	0.525	rs34204378	chr12:39425759	C/T	cg26384229	chr12:38710491	ALG10B	0.57	6.21	0.38	2.45e-9	Morning vs. evening chronotype;
SARC	cis	rs554111	0.891	rs609880	chr1:21055891	A/G	cg04902671	chr1:21058625	SH2D5	-0.45	-5.14	-0.32	5.79e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs55794721	0.543	rs1293260	chr1:25709104	C/G	cg02931644	chr1:25747376	RHCE	0.47	7.79	0.45	2.24e-13	Plateletcrit;Mean corpuscular volume;
SARC	cis	rs6500602	0.702	rs1051308	chr16:4560301	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.29	-4.8	-0.3	2.9e-6	Schizophrenia;
SARC	cis	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg09021430	chr5:549028	NA	-0.43	-5.6	-0.34	5.99e-8	Obesity-related traits;
SARC	cis	rs16976116	0.901	rs113679855	chr15:55502428	C/T	cg11288833	chr15:55489084	RSL24D1	0.64	6.19	0.38	2.69e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg12419862	chr22:24373484	LOC391322	0.66	8.0	0.46	5.72e-14	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs11623869	0.772	rs12587310	chr14:103907286	G/A	cg26031613	chr14:104095156	KLC1	-0.8	-11.36	-0.6	4.46e-24	Bone mineral density;
SARC	cis	rs3845702	0.673	rs12468986	chr2:180862320	T/G	cg01881094	chr2:180872142	CWC22	1.04	8.14	0.47	2.43e-14	Schizophrenia;
SARC	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.62	7.44	0.44	1.95e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6904897	0.563	rs6569976	chr6:135224753	A/C	cg22676075	chr6:135203613	NA	0.7	10.45	0.57	3.17e-21	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs1448094	0.791	rs7300340	chr12:86329867	G/T	cg02569458	chr12:86230093	RASSF9	0.41	5.83	0.36	1.88e-8	Major depressive disorder;
SARC	cis	rs7264396	0.563	rs2425122	chr20:34328848	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-6.88	-0.41	5.48e-11	Total cholesterol levels;
SARC	trans	rs3942852	0.568	rs10769313	chr11:48097466	A/G	cg15704280	chr7:45808275	SEPT13	-0.66	-8.7	-0.5	6.08e-16	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs17376456	0.877	rs7701974	chr5:93311417	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.8	0.35	2.2e-8	Diabetic retinopathy;
SARC	trans	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.07	-0.42	1.8e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg11764359	chr7:65958608	NA	-0.64	-7.11	-0.42	1.42e-11	Aortic root size;
SARC	cis	rs13256369	0.802	rs13255789	chr8:8562791	T/C	cg18904891	chr8:8559673	CLDN23	0.49	5.55	0.34	7.9e-8	Obesity-related traits;
SARC	cis	rs7666738	0.747	rs2865955	chr4:99040518	A/C	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2033711	0.811	rs9304814	chr19:58951811	C/A	cg12042659	chr19:58951599	ZNF132	0.43	5.64	0.35	4.85e-8	Uric acid clearance;
SARC	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg08677398	chr8:58056175	NA	0.44	5.2	0.32	4.29e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs4589502	1.000	rs7170743	chr15:67126339	T/G	cg12317470	chr15:67143691	NA	0.75	5.19	0.32	4.58e-7	Lung cancer (smoking interaction);
SARC	cis	rs7937682	0.632	rs11214009	chr11:111683142	T/C	cg22437258	chr11:111473054	SIK2	-0.49	-5.71	-0.35	3.44e-8	Primary sclerosing cholangitis;
SARC	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.6	-7.62	-0.45	6.23e-13	Prudent dietary pattern;
SARC	cis	rs6674176	0.593	rs3791120	chr1:44431715	T/C	cg12908607	chr1:44402522	ARTN	-0.38	-6.51	-0.39	4.63e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs7772486	0.727	rs4896843	chr6:146063451	T/C	cg05347473	chr6:146136440	FBXO30	-0.54	-7.52	-0.44	1.17e-12	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs877282	0.682	rs2265092	chr10:780293	C/T	cg22713356	chr15:30763199	NA	-0.75	-8.49	-0.49	2.43e-15	Uric acid levels;
SARC	cis	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg06636001	chr8:8085503	FLJ10661	0.63	8.44	0.48	3.44e-15	Mood instability;
SARC	cis	rs8114671	0.562	rs2424999	chr20:33386430	G/A	cg24642439	chr20:33292090	TP53INP2	0.52	6.68	0.4	1.75e-10	Height;
SARC	cis	rs9296092	0.538	rs75652975	chr6:33516251	C/T	cg13560919	chr6:33536144	NA	-0.5	-5.91	-0.36	1.22e-8	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs2273669	0.667	rs2145765	chr6:109296362	C/G	cg05315195	chr6:109294784	ARMC2	-0.58	-5.3	-0.33	2.74e-7	Prostate cancer;
SARC	cis	rs6912958	0.500	rs2025486	chr6:87796886	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.59	-7.41	-0.44	2.3e-12	Monocyte percentage of white cells;
SARC	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.44	5.41	0.33	1.54e-7	Tonsillectomy;
SARC	cis	rs11098499	0.780	rs10013652	chr4:120292256	A/G	cg09307838	chr4:120376055	NA	0.83	11.82	0.61	1.43e-25	Corneal astigmatism;
SARC	cis	rs9309473	0.583	rs11126397	chr2:73588733	C/T	cg20560298	chr2:73613845	ALMS1	-0.57	-7.34	-0.43	3.56e-12	Metabolite levels;
SARC	cis	rs7769051	0.614	rs6912936	chr6:133102664	A/G	cg07930552	chr6:133119739	C6orf192	0.94	8.57	0.49	1.4e-15	Type 2 diabetes nephropathy;
SARC	cis	rs17376456	0.825	rs1470150	chr5:93138654	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.67	-6.41	-0.39	8.06e-10	Diabetic retinopathy;
SARC	cis	rs240764	0.755	rs12206564	chr6:100987009	A/G	cg09795085	chr6:101329169	ASCC3	-0.44	-5.78	-0.35	2.34e-8	Neuroticism;
SARC	cis	rs1448094	0.556	rs11610789	chr12:86169541	A/G	cg02569458	chr12:86230093	RASSF9	0.37	5.04	0.31	9.25e-7	Major depressive disorder;
SARC	cis	rs6840360	1.000	rs3792691	chr4:152635803	C/T	cg22705602	chr4:152727874	NA	0.38	6.56	0.39	3.52e-10	Intelligence (multi-trait analysis);
SARC	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg11766577	chr21:47581405	C21orf56	-0.5	-6.02	-0.37	6.68e-9	Testicular germ cell tumor;
SARC	cis	rs17270561	0.636	rs1165157	chr6:25792250	A/G	cg17691542	chr6:26056736	HIST1H1C	0.45	5.49	0.34	1.05e-7	Iron status biomarkers;
SARC	cis	rs12048904	0.505	rs4517368	chr1:101255052	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.62	-7.44	-0.44	1.92e-12	Multiple sclerosis;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg18191494	chr12:13157611	HTR7P	0.47	6.5	0.39	4.85e-10	Thyroid stimulating hormone;
SARC	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-8.76	-0.5	4.15e-16	Alzheimer's disease;
SARC	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg00933542	chr6:150070202	PCMT1	0.31	5.28	0.33	3.01e-7	Lung cancer;
SARC	cis	rs6594499	0.872	rs10038058	chr5:110443281	A/G	cg04022379	chr5:110408740	TSLP	0.46	5.7	0.35	3.59e-8	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs910316	1.000	rs175442	chr14:75603564	T/C	cg23033748	chr14:75592666	NEK9	-0.34	-4.73	-0.3	3.92e-6	Height;
SARC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg09373136	chr17:61933544	TCAM1	-0.43	-5.79	-0.35	2.21e-8	Prudent dietary pattern;
SARC	cis	rs9875589	1.000	rs9875589	chr3:13961157	A/C	cg19554555	chr3:13937349	NA	0.53	6.99	0.42	2.9e-11	Ovarian reserve;
SARC	cis	rs849898	1	rs849898	chr1:228153917	A/G	cg01200585	chr1:228362443	C1orf69	-0.39	-5.25	-0.33	3.45e-7	Parkinson's disease;
SARC	cis	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg24110177	chr3:50126178	RBM5	-0.54	-7.17	-0.43	1e-11	Intelligence (multi-trait analysis);
SARC	cis	rs2075371	1.000	rs2244700	chr7:133987374	A/G	cg00033643	chr7:134001901	SLC35B4	0.41	5.02	0.31	1.01e-6	Mean platelet volume;
SARC	cis	rs11792861	0.816	rs28361186	chr9:111704064	G/A	cg13535736	chr9:111863775	C9orf5	-0.4	-4.94	-0.31	1.48e-6	Menarche (age at onset);
SARC	cis	rs76419734	1.000	rs72671809	chr4:106611537	A/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.8	4.9	0.31	1.8e-6	Post bronchodilator FEV1;
SARC	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg06074448	chr4:187884817	NA	-0.38	-5.09	-0.32	7.53e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1707322	0.752	rs12062535	chr1:46222880	G/A	cg06784218	chr1:46089804	CCDC17	0.38	6.62	0.4	2.47e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4727027	0.704	rs7784122	chr7:148904624	A/G	cg23583168	chr7:148888333	NA	0.83	13.47	0.66	5.8e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg22857025	chr5:266934	NA	-1.05	-11.66	-0.61	4.62e-25	Breast cancer;
SARC	cis	rs6570726	0.935	rs414222	chr6:145850482	C/T	cg05347473	chr6:146136440	FBXO30	0.49	6.55	0.39	3.56e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10992471	0.533	rs331377	chr9:95243549	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.44	-5.43	-0.34	1.41e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	trans	rs9818941	0.744	rs13098886	chr3:157613783	C/T	cg04854107	chr15:38544003	SPRED1	0.61	7.32	0.43	4.06e-12	Height;
SARC	cis	rs11122272	0.735	rs973254	chr1:231521149	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-9.65	-0.53	9.22e-19	Hemoglobin concentration;
SARC	cis	rs67460515	0.500	rs1562464	chr3:160681614	G/A	cg03342759	chr3:160939853	NMD3	-0.55	-6.37	-0.39	9.82e-10	Parkinson's disease;
SARC	cis	rs412050	1.000	rs239916	chr22:22316272	G/A	cg17089214	chr22:22089827	YPEL1	0.62	5.87	0.36	1.5e-8	Attention deficit hyperactivity disorder;
SARC	cis	rs3106136	0.934	rs4693004	chr4:95168456	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.39	-6.05	-0.37	5.83e-9	Capecitabine sensitivity;
SARC	cis	rs55823223	0.648	rs11869977	chr17:73857382	C/G	cg23806715	chr17:73775811	H3F3B	0.56	5.81	0.36	2.02e-8	Psoriasis;
SARC	cis	rs912057	0.833	rs1294426	chr6:6744477	T/C	cg06612196	chr6:6737390	NA	0.63	9.19	0.52	2.21e-17	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg13395646	chr4:1353034	KIAA1530	-0.47	-5.64	-0.35	4.87e-8	Obesity-related traits;
SARC	cis	rs6456156	0.524	rs6932740	chr6:167466439	G/A	cg23791538	chr6:167370224	RNASET2	-0.52	-6.79	-0.41	9.49e-11	Primary biliary cholangitis;
SARC	cis	rs2425143	0.643	rs6119630	chr20:34190077	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-5.17	-0.32	4.98e-7	Blood protein levels;
SARC	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg11062466	chr8:58055876	NA	0.51	5.26	0.33	3.22e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6089584	0.507	rs6061990	chr20:60628429	T/G	cg06108461	chr20:60628389	TAF4	-0.67	-8.59	-0.49	1.28e-15	Body mass index;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg04952599	chr16:2479381	CCNF	0.51	6.32	0.38	1.33e-9	Breast cancer;
SARC	cis	rs4689388	0.926	rs4416547	chr4:6293967	G/A	cg25554036	chr4:6271136	WFS1	0.39	6.42	0.39	7.48e-10	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs6088590	0.965	rs6120727	chr20:33374102	T/C	cg24642439	chr20:33292090	TP53INP2	0.88	12.36	0.63	2.45e-27	Coronary artery disease;
SARC	cis	rs17023223	0.537	rs2765533	chr1:119597395	T/C	cg05756136	chr1:119680316	WARS2	-0.43	-5.06	-0.31	8.48e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs2645694	0.651	rs2703128	chr4:77819187	C/G	cg10057126	chr4:77819792	ANKRD56	0.45	6.67	0.4	1.85e-10	Emphysema distribution in smoking;
SARC	cis	rs61935443	0.614	rs11107787	chr12:95311669	C/T	cg21533806	chr12:95267307	NA	0.66	7.37	0.44	2.87e-12	Schizophrenia;
SARC	cis	rs11785693	0.862	rs73183618	chr8:4988340	T/C	cg26367366	chr8:4980734	NA	0.66	6.04	0.37	5.96e-9	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs11191270	0.554	rs77616533	chr10:104055983	A/G	cg15320455	chr10:103880129	LDB1	0.98	8.9	0.5	1.61e-16	Intelligence (multi-trait analysis);
SARC	cis	rs9398803	0.678	rs3861456	chr6:126898660	A/G	cg19875578	chr6:126661172	C6orf173	0.63	8.7	0.5	5.9e-16	Male-pattern baldness;
SARC	cis	rs644799	0.664	rs603625	chr11:95554283	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.87	13.61	0.67	1.97e-31	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs61931739	0.517	rs7975714	chr12:34055611	T/C	cg26384229	chr12:38710491	ALG10B	0.86	12.43	0.63	1.55e-27	Morning vs. evening chronotype;
SARC	cis	rs992157	0.804	rs7559525	chr2:219150307	A/G	cg00012203	chr2:219082015	ARPC2	-0.63	-9.11	-0.51	3.96e-17	Colorectal cancer;
SARC	cis	rs9911578	0.785	rs10853008	chr17:56993407	T/C	cg05425664	chr17:57184151	TRIM37	0.67	7.54	0.44	1.06e-12	Intelligence (multi-trait analysis);
SARC	cis	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg12463550	chr7:65579703	CRCP	-0.68	-5.31	-0.33	2.53e-7	Diabetic kidney disease;
SARC	trans	rs4076764	0.958	rs6688181	chr1:163384193	C/T	cg16321806	chr12:67662976	CAND1	0.49	6.38	0.39	9.24e-10	Motion sickness;
SARC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.19	0.8	4.45e-53	Prudent dietary pattern;
SARC	cis	rs7106204	0.609	rs10500976	chr11:24335921	A/G	ch.11.24196551F	chr11:24239977	NA	-0.6	-4.98	-0.31	1.25e-6	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg04622731	chr7:157956161	PTPRN2	-0.34	-5.66	-0.35	4.41e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg05745632	chr11:94706668	KDM4D;CWC15	0.5	6.5	0.39	4.82e-10	Lung adenocarcinoma;
SARC	trans	rs79976124	0.879	rs77185357	chr6:66629070	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	7.95	0.46	7.83e-14	Type 2 diabetes;
SARC	cis	rs12200560	0.505	rs211177	chr6:97074088	C/T	cg06623918	chr6:96969491	KIAA0776	0.45	5.11	0.32	6.85e-7	Coronary heart disease;
SARC	cis	rs2276314	0.857	rs4799409	chr18:33592602	C/T	cg05985134	chr18:33552581	C18orf21	0.69	7.04	0.42	2.09e-11	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs5753618	0.561	rs2413049	chr22:31686144	A/G	cg00478049	chr22:31556069	RNF185	0.44	4.78	0.3	3.07e-6	Colorectal cancer;
SARC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg06873352	chr17:61820015	STRADA	0.53	6.88	0.41	5.32e-11	Prudent dietary pattern;
SARC	cis	rs35110281	0.667	rs2250773	chr21:45087786	T/C	cg01579765	chr21:45077557	HSF2BP	-0.34	-5.53	-0.34	8.68e-8	Mean corpuscular volume;
SARC	cis	rs3126085	1.000	rs4845756	chr1:152254919	T/A	cg26876637	chr1:152193138	HRNR	0.46	5.29	0.33	2.86e-7	Atopic dermatitis;
SARC	cis	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg25894440	chr7:65020034	NA	0.71	5.45	0.34	1.27e-7	Diabetic kidney disease;
SARC	cis	rs17376456	0.877	rs10055741	chr5:93297187	C/T	cg25358565	chr5:93447407	FAM172A	1.29	14.58	0.69	1.2e-34	Diabetic retinopathy;
SARC	cis	rs607987	0.871	rs35458722	chr11:30275141	T/C	cg06241208	chr11:30344200	C11orf46	0.42	5.01	0.31	1.09e-6	Body mass index;
SARC	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.62	7.45	0.44	1.77e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1570884	0.516	rs9316463	chr13:50176844	G/A	cg08779649	chr13:50194554	NA	0.37	6.41	0.39	8.09e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs9815354	0.597	rs17283481	chr3:41924015	T/C	cg03022575	chr3:42003672	ULK4	0.69	5.65	0.35	4.69e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6582630	0.555	rs11180986	chr12:38264486	G/A	cg13010199	chr12:38710504	ALG10B	-0.51	-6.22	-0.38	2.27e-9	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7927771	0.832	rs4752990	chr11:47410393	G/A	cg20307385	chr11:47447363	PSMC3	-0.58	-7.27	-0.43	5.32e-12	Subjective well-being;
SARC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg26338869	chr17:61819248	STRADA	0.77	10.17	0.55	2.5e-20	Prudent dietary pattern;
SARC	cis	rs9303401	0.573	rs62081879	chr17:57181524	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	10.67	0.57	6.72e-22	Cognitive test performance;
SARC	cis	rs644148	0.770	rs2571113	chr19:44999814	A/G	cg15540054	chr19:45004280	ZNF180	-0.45	-5.09	-0.32	7.24e-7	Personality dimensions;
SARC	cis	rs7959452	0.640	rs11177599	chr12:69721970	G/A	cg14784868	chr12:69753453	YEATS4	0.42	5.51	0.34	9.45e-8	Blood protein levels;
SARC	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.6	-6.31	-0.38	1.42e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs11122272	0.705	rs2790879	chr1:231534389	A/C	cg06096015	chr1:231504339	EGLN1	0.35	5.19	0.32	4.47e-7	Hemoglobin concentration;
SARC	cis	rs12956009	0.583	rs11663609	chr18:44862757	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.57	7.33	0.43	3.78e-12	Educational attainment (years of education);
SARC	cis	rs6912958	1.000	rs2223880	chr6:88167897	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-5.89	-0.36	1.33e-8	Monocyte percentage of white cells;
SARC	cis	rs2777491	0.957	rs7181911	chr15:41674060	T/C	cg01768344	chr15:41576519	LOC729082	0.45	4.97	0.31	1.3e-6	Ulcerative colitis;
SARC	cis	rs1003719	0.628	rs2835635	chr21:38528866	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-8.1	-0.47	3.17e-14	Eye color traits;
SARC	cis	rs1790761	0.520	rs7124513	chr11:67395714	C/T	cg00290607	chr11:67383545	NA	-0.45	-5.78	-0.35	2.43e-8	Mean corpuscular volume;
SARC	cis	rs244731	0.919	rs12652509	chr5:176626441	A/G	cg06060754	chr5:176797920	RGS14	-0.43	-4.99	-0.31	1.19e-6	Urate levels in lean individuals;
SARC	cis	rs79349575	0.715	rs62075844	chr17:47002389	G/A	cg07967210	chr17:47022446	SNF8	0.37	4.72	0.3	4.02e-6	Type 2 diabetes;
SARC	trans	rs66573146	1.000	rs6812771	chr4:6964048	G/A	cg07817883	chr1:32538562	TMEM39B	1.45	9.08	0.51	4.59e-17	Granulocyte percentage of myeloid white cells;
SARC	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	5.35	0.33	2.05e-7	Tonsillectomy;
SARC	cis	rs1048238	0.506	rs12023422	chr1:16187625	G/A	cg21385522	chr1:16154831	NA	0.46	5.58	0.34	6.75e-8	Systolic blood pressure;
SARC	trans	rs561341	0.769	rs7217004	chr17:30178092	A/G	cg20587970	chr11:113659929	NA	1.01	8.32	0.48	7.61e-15	Hip circumference adjusted for BMI;
SARC	cis	rs742614	0.533	rs2747541	chr20:32418772	G/T	cg06304546	chr20:32448765	NA	-0.57	-7.34	-0.43	3.51e-12	Stearic acid (18:0) levels;
SARC	cis	rs11785693	0.862	rs6990234	chr8:4996812	A/G	cg26367366	chr8:4980734	NA	0.74	6.58	0.4	3.01e-10	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs6570726	0.577	rs9497315	chr6:145791967	C/T	cg23711669	chr6:146136114	FBXO30	-0.8	-11.17	-0.59	1.71e-23	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4144743	1.000	rs4144743	chr17:45323125	A/G	cg18085866	chr17:45331354	ITGB3	-0.72	-7.48	-0.44	1.48e-12	Body mass index;
SARC	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg02725872	chr8:58115012	NA	0.37	6.48	0.39	5.3e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs17376456	0.877	rs17083462	chr5:93462401	T/G	cg25358565	chr5:93447407	FAM172A	1.31	15.17	0.7	1.33e-36	Diabetic retinopathy;
SARC	cis	rs9790314	0.663	rs17826438	chr3:160640295	C/T	cg04691961	chr3:161091175	C3orf57	0.63	8.8	0.5	3.23e-16	Morning vs. evening chronotype;
SARC	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg19660806	chr8:588740	NA	0.53	4.72	0.3	4.13e-6	IgG glycosylation;
SARC	cis	rs11122272	0.735	rs2790897	chr1:231491712	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.22	-0.56	1.7e-20	Hemoglobin concentration;
SARC	cis	rs1322639	0.574	rs9364360	chr6:169580174	G/A	cg03254818	chr6:169586852	NA	0.72	7.2	0.43	8.21e-12	Pulse pressure;
SARC	cis	rs9640161	0.830	rs3757423	chr7:150067714	A/G	cg10018233	chr7:150070692	REPIN1	-0.72	-12.14	-0.62	1.37e-26	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs2842992	0.747	rs4709379	chr6:160227530	A/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.57	5.02	0.31	1.04e-6	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs6728642	0.901	rs10179966	chr2:97845100	C/T	cg26665480	chr2:98280029	ACTR1B	-0.71	-6.62	-0.4	2.41e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs2228479	0.850	rs17226973	chr16:89825248	T/C	cg06558623	chr16:89946397	TCF25	0.88	6.21	0.38	2.39e-9	Skin colour saturation;
SARC	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg08280861	chr8:58055591	NA	0.51	4.72	0.3	4.03e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs7772486	0.790	rs6917135	chr6:146152426	T/C	cg23711669	chr6:146136114	FBXO30	0.8	13.21	0.65	4.21e-30	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11122272	0.735	rs2739509	chr1:231526765	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.99	-0.55	8.42e-20	Hemoglobin concentration;
SARC	cis	rs7223966	1.000	rs72848797	chr17:61934664	G/A	cg00588841	chr17:61851480	DDX42;CCDC47	-0.62	-6.33	-0.38	1.25e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg21782813	chr7:2030301	MAD1L1	0.45	7.08	0.42	1.71e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs526231	0.543	rs75913944	chr5:102479503	G/C	cg23492399	chr5:102201601	PAM	-0.53	-5.69	-0.35	3.78e-8	Primary biliary cholangitis;
SARC	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg18225595	chr11:63971243	STIP1	0.45	5.54	0.34	8.06e-8	Mean platelet volume;
SARC	cis	rs2576037	0.796	rs2576034	chr18:44588548	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.49	6.39	0.39	9.08e-10	Personality dimensions;
SARC	cis	rs6594499	0.872	rs10051830	chr5:110452845	G/A	cg04022379	chr5:110408740	TSLP	0.46	5.8	0.36	2.12e-8	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs7927771	0.864	rs7107726	chr11:47429245	T/A	cg20307385	chr11:47447363	PSMC3	-0.59	-7.54	-0.44	1.07e-12	Subjective well-being;
SARC	cis	rs13390159	0.883	rs13429610	chr2:237156694	A/C	cg19324714	chr2:237145437	ASB18	0.48	4.73	0.3	3.84e-6	Response to statin therapy;
SARC	cis	rs35110281	0.508	rs2838351	chr21:45110784	A/G	cg01579765	chr21:45077557	HSF2BP	-0.35	-5.62	-0.35	5.42e-8	Mean corpuscular volume;
SARC	cis	rs7667	0.881	rs12033437	chr1:19749894	C/T	cg15311933	chr1:19638897	PQLC2;AKR7A2	-0.46	-5.36	-0.33	1.99e-7	Crohn's disease and psoriasis;
SARC	cis	rs3020736	0.500	rs6002614	chr22:42501802	G/A	cg15557168	chr22:42548783	NA	0.36	4.92	0.31	1.62e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg15145296	chr3:125709740	NA	-0.5	-5.05	-0.31	8.83e-7	Blood pressure (smoking interaction);
SARC	cis	rs7666738	0.822	rs6815312	chr4:99058220	T/C	cg05340658	chr4:99064831	C4orf37	0.64	8.66	0.49	7.7e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg08280861	chr8:58055591	NA	0.6	5.83	0.36	1.8e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg09263875	chr16:632152	PIGQ	0.54	8.32	0.48	7.41e-15	Height;
SARC	cis	rs9309473	0.948	rs10199224	chr2:73761446	C/G	cg20560298	chr2:73613845	ALMS1	-0.54	-6.52	-0.39	4.37e-10	Metabolite levels;
SARC	cis	rs17001868	0.568	rs6001894	chr22:40779197	T/C	cg07138101	chr22:40742427	ADSL	0.58	6.32	0.38	1.33e-9	Mammographic density (dense area);
SARC	cis	rs10911232	0.507	rs10797822	chr1:183017769	A/G	cg13390022	chr1:182993471	LAMC1	0.36	5.46	0.34	1.23e-7	Hypertriglyceridemia;
SARC	cis	rs7607369	0.536	rs12694443	chr2:219664977	G/T	cg02176678	chr2:219576539	TTLL4	-0.4	-6.17	-0.37	3e-9	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.73	8.67	0.49	7.28e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg12395012	chr8:11607386	GATA4	0.29	4.93	0.31	1.59e-6	Triglycerides;
SARC	cis	rs1801251	1.000	rs35085837	chr2:233624363	A/G	cg25237894	chr2:233734115	C2orf82	0.39	5.05	0.31	9.07e-7	Coronary artery disease;
SARC	cis	rs593982	0.920	rs1108922	chr11:65423930	C/T	cg08755490	chr11:65554678	OVOL1	-0.86	-8.05	-0.47	4.31e-14	Atopic dermatitis;
SARC	cis	rs344364	0.511	rs56077812	chr16:1948870	T/G	cg26617929	chr16:1858877	NA	-0.71	-6.06	-0.37	5.5e-9	Glomerular filtration rate in chronic kidney disease;
SARC	cis	rs9916302	0.851	rs9904919	chr17:37556431	G/C	cg07936489	chr17:37558343	FBXL20	0.67	8.85	0.5	2.27e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg24101359	chr6:42928495	GNMT	0.41	5.7	0.35	3.52e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs9911578	1.000	rs368186	chr17:56736659	A/G	cg12560992	chr17:57184187	TRIM37	0.81	11.0	0.58	6.1e-23	Intelligence (multi-trait analysis);
SARC	trans	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg00938859	chr5:1591904	SDHAP3	0.68	6.3	0.38	1.49e-9	Breast cancer;
SARC	cis	rs7644634	0.559	rs2301032	chr3:105469068	A/G	cg23051926	chr3:105466016	CBLB	0.48	5.53	0.34	8.65e-8	Itch intensity from mosquito bite;
SARC	cis	rs11098499	0.738	rs34566984	chr4:120361270	G/A	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs4742903	0.967	rs7871759	chr9:106865438	A/G	cg14250997	chr9:106856677	SMC2	0.53	7.13	0.42	1.27e-11	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs10892173	0.765	rs7125694	chr11:117670657	C/T	cg21640587	chr11:117668038	DSCAML1	0.48	6.76	0.41	1.09e-10	Myopia;
SARC	cis	rs898097	0.585	rs9893200	chr17:80893028	A/C	cg15664640	chr17:80829946	TBCD	0.34	5.41	0.33	1.56e-7	Breast cancer;
SARC	cis	rs67311347	1.000	rs4973997	chr3:40460145	G/A	cg09455208	chr3:40491958	NA	0.43	6.92	0.41	4.21e-11	Renal cell carcinoma;
SARC	cis	rs7777484	0.500	rs2533885	chr7:2835655	C/T	cg19717773	chr7:2847554	GNA12	-0.39	-5.11	-0.32	6.57e-7	Height;
SARC	cis	rs2439831	0.681	rs2242067	chr15:43699303	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.06	9.59	0.53	1.38e-18	Lung cancer in ever smokers;
SARC	cis	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg11764359	chr7:65958608	NA	0.66	6.45	0.39	6.39e-10	Aortic root size;
SARC	cis	rs9902453	0.899	rs8067580	chr17:28471248	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.49	6.35	0.38	1.12e-9	Coffee consumption (cups per day);
SARC	cis	rs9300255	0.568	rs1047158	chr12:123644056	C/A	cg00376283	chr12:123451042	ABCB9	0.58	6.9	0.41	4.89e-11	Neutrophil percentage of white cells;
SARC	cis	rs2120243	0.539	rs1563420	chr3:157119326	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.39	4.96	0.31	1.37e-6	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg22800045	chr5:56110881	MAP3K1	0.74	7.83	0.46	1.74e-13	Initial pursuit acceleration;
SARC	cis	rs2997447	0.761	rs61776596	chr1:26454968	T/C	cg19633962	chr1:26362018	EXTL1	-0.57	-4.93	-0.31	1.54e-6	QRS complex (12-leadsum);
SARC	trans	rs9329221	0.527	rs34259385	chr8:10325456	C/T	cg06636001	chr8:8085503	FLJ10661	-0.62	-8.71	-0.5	5.55e-16	Neuroticism;
SARC	cis	rs910316	0.712	rs175074	chr14:75504454	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.55	-7.59	-0.45	7.67e-13	Height;
SARC	cis	rs6570726	0.935	rs408768	chr6:145871735	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.57	0.4	3.23e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11190604	1.000	rs11190607	chr10:102303614	C/T	cg07080220	chr10:102295463	HIF1AN	0.83	9.65	0.53	9.32e-19	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg02725872	chr8:58115012	NA	-0.27	-4.86	-0.3	2.13e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs1969253	0.632	rs865808	chr3:183858939	G/T	cg21665078	chr3:183852786	EIF2B5	-0.38	-4.85	-0.3	2.29e-6	Major depressive disorder;
SARC	cis	rs11098499	0.754	rs12506487	chr4:120271361	T/G	cg09307838	chr4:120376055	NA	0.74	10.26	0.56	1.27e-20	Corneal astigmatism;
SARC	cis	rs3126085	0.935	rs55942250	chr1:152251914	G/A	cg09127314	chr1:152161683	NA	-0.45	-4.94	-0.31	1.51e-6	Atopic dermatitis;
SARC	cis	rs17376456	0.504	rs7702649	chr5:93065149	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.49	4.98	0.31	1.22e-6	Diabetic retinopathy;
SARC	cis	rs796364	0.806	rs203766	chr2:200902672	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.66	-5.45	-0.34	1.27e-7	Schizophrenia;
SARC	cis	rs7614311	0.636	rs66490742	chr3:63913653	G/A	cg22134162	chr3:63841271	THOC7	-0.47	-4.98	-0.31	1.24e-6	Lung function (FVC);Lung function (FEV1);
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg24809150	chr1:244211390	NA	0.52	6.65	0.4	2.01e-10	Lung adenocarcinoma;
SARC	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg02788857	chr8:22132959	PIWIL2	0.36	5.12	0.32	6.41e-7	Hypertriglyceridemia;
SARC	cis	rs829883	0.966	rs249853	chr12:98864908	A/C	cg25150519	chr12:98850993	NA	0.64	8.21	0.47	1.49e-14	Colorectal adenoma (advanced);
SARC	cis	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg07636037	chr3:49044803	WDR6	-0.49	-5.8	-0.36	2.17e-8	Resting heart rate;
SARC	cis	rs7246657	0.943	rs35540940	chr19:38008235	G/A	cg23950597	chr19:37808831	NA	-0.54	-5.14	-0.32	5.75e-7	Coronary artery calcification;
SARC	cis	rs2562456	0.876	rs7252585	chr19:21657943	C/T	cg00806126	chr19:22604979	ZNF98	0.49	5.31	0.33	2.51e-7	Pain;
SARC	cis	rs6782228	0.606	rs2001703	chr3:128383097	A/G	cg08795948	chr3:128337044	NA	0.37	5.09	0.32	7.54e-7	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
SARC	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs9388451	0.626	rs1935983	chr6:126068914	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.64	-8.16	-0.47	2.12e-14	Brugada syndrome;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg23344412	chr5:32602844	SUB1	0.49	6.88	0.41	5.54e-11	Thyroid stimulating hormone;
SARC	cis	rs4423214	1.000	rs12793530	chr11:71161656	G/A	cg24826892	chr11:71159390	DHCR7	0.44	5.31	0.33	2.57e-7	Vitamin D levels;
SARC	cis	rs595982	0.527	rs17206707	chr19:49361441	A/C	cg15549821	chr19:49342101	PLEKHA4	-0.67	-7.25	-0.43	5.95e-12	Red cell distribution width;
SARC	cis	rs1505368	0.836	rs10201067	chr2:213284411	A/G	cg20637307	chr2:213403960	ERBB4	-0.41	-5.06	-0.31	8.59e-7	Symmetrical dimethylarginine levels;
SARC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg11203670	chr7:100026453	MEPCE;ZCWPW1	0.51	5.07	0.32	8.19e-7	Platelet count;
SARC	cis	rs193541	0.632	rs246279	chr5:122241263	C/G	cg19412675	chr5:122181750	SNX24	-0.57	-6.21	-0.38	2.35e-9	Glucose homeostasis traits;
SARC	cis	rs6133127	0.678	rs11700307	chr20:4475923	A/T	cg14606382	chr20:4573199	NA	-0.49	-5.17	-0.32	5.04e-7	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
SARC	cis	rs3091242	0.933	rs28633797	chr1:25741629	C/A	cg03650068	chr1:25596491	NA	0.34	5.15	0.32	5.5e-7	Erythrocyte sedimentation rate;
SARC	cis	rs4763879	0.739	rs12582584	chr12:9824138	T/G	cg27502298	chr12:9555721	NA	0.45	4.97	0.31	1.28e-6	Type 1 diabetes;
SARC	cis	rs2777491	0.915	rs28578057	chr15:41621921	G/A	cg01768344	chr15:41576519	LOC729082	0.44	4.9	0.31	1.76e-6	Ulcerative colitis;
SARC	cis	rs2439831	0.681	rs484846	chr15:43600803	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.06	11.98	0.62	4.5e-26	Lung cancer in ever smokers;
SARC	cis	rs6807306	1.000	rs9841137	chr3:167441991	A/C	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.52	5.24	0.32	3.57e-7	Mean platelet volume;
SARC	cis	rs9527	0.590	rs2182348	chr10:104872684	A/G	cg04362960	chr10:104952993	NT5C2	0.43	4.94	0.31	1.47e-6	Arsenic metabolism;
SARC	cis	rs829883	0.621	rs11109516	chr12:98921035	G/A	cg25150519	chr12:98850993	NA	-0.59	-7.17	-0.43	1e-11	Colorectal adenoma (advanced);
SARC	cis	rs2425143	1.000	rs56116518	chr20:34286251	G/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.22	0.32	3.94e-7	Blood protein levels;
SARC	cis	rs13191362	0.872	rs13194619	chr6:163203657	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.4	5.08	0.32	7.57e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs9902453	0.765	rs2729440	chr17:28106874	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.56	-7.28	-0.43	5.07e-12	Coffee consumption (cups per day);
SARC	trans	rs9329221	0.905	rs17765901	chr8:10249480	G/T	cg06636001	chr8:8085503	FLJ10661	-0.67	-9.29	-0.52	1.1e-17	Neuroticism;
SARC	cis	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg06636001	chr8:8085503	FLJ10661	0.66	8.92	0.5	1.36e-16	Mood instability;
SARC	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg06618935	chr21:46677482	NA	-0.42	-5.51	-0.34	9.36e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.44	5.43	0.34	1.38e-7	Tonsillectomy;
SARC	cis	rs981844	1.000	rs2579917	chr4:154652648	T/G	cg14289246	chr4:154710475	SFRP2	0.5	5.82	0.36	1.95e-8	Response to statins (LDL cholesterol change);
SARC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	10.28	0.56	1.07e-20	Platelet count;
SARC	cis	rs11792861	0.546	rs7873569	chr9:111796753	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.41	5.15	0.32	5.56e-7	Menarche (age at onset);
SARC	cis	rs12142240	0.698	rs7515598	chr1:46818479	C/T	cg00530320	chr1:46809349	NSUN4	0.57	6.92	0.41	4.4e-11	Menopause (age at onset);
SARC	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg12463550	chr7:65579703	CRCP	0.48	5.24	0.32	3.65e-7	Aortic root size;
SARC	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.57	5.46	0.34	1.23e-7	Lung function (FEV1/FVC);
SARC	cis	rs2694528	0.844	rs2169255	chr5:60062624	C/A	cg11474532	chr5:59995715	DEPDC1B	0.74	5.23	0.32	3.77e-7	Parkinson's disease;
SARC	cis	rs7523050	0.749	rs193139	chr1:109483975	T/C	cg08274380	chr1:109419600	GPSM2	0.69	5.55	0.34	7.79e-8	Fat distribution (HIV);
SARC	cis	rs6831352	0.569	rs4140388	chr4:100065734	G/C	cg12011299	chr4:100065546	ADH4	0.31	5.64	0.35	4.82e-8	Alcohol dependence;
SARC	cis	rs9467711	0.591	rs35528636	chr6:25995701	A/C	cg21479132	chr6:26055353	NA	0.93	6.17	0.37	2.93e-9	Autism spectrum disorder or schizophrenia;
SARC	trans	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg17712092	chr4:129076599	LARP1B	0.73	10.08	0.55	4.52e-20	Eosinophil percentage of white cells;
SARC	cis	rs7520050	0.778	rs3014238	chr1:46090214	A/G	cg06784218	chr1:46089804	CCDC17	-0.28	-5.16	-0.32	5.38e-7	Red blood cell count;Reticulocyte count;
SARC	cis	rs8064299	0.597	rs3785539	chr17:72775099	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.81	11.01	0.58	5.72e-23	Monocyte count;
SARC	cis	rs9398803	0.741	rs9388501	chr6:126903011	T/C	cg19875578	chr6:126661172	C6orf173	0.6	8.22	0.47	1.39e-14	Male-pattern baldness;
SARC	cis	rs56176327	0.583	rs7613603	chr3:49812866	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.58	-5.81	-0.36	2e-8	Intelligence (multi-trait analysis);
SARC	cis	rs1865760	0.928	rs9295673	chr6:25912094	T/G	cg10373733	chr6:25993375	NA	0.46	5.54	0.34	8.23e-8	Height;
SARC	cis	rs72945132	0.882	rs7940090	chr11:70227824	C/G	cg00319359	chr11:70116639	PPFIA1	0.67	6.39	0.39	8.7e-10	Coronary artery disease;
SARC	cis	rs11792861	0.926	rs75472294	chr9:111804239	G/A	cg13535736	chr9:111863775	C9orf5	-0.39	-4.79	-0.3	2.93e-6	Menarche (age at onset);
SARC	cis	rs7824557	0.652	rs12677504	chr8:11133175	G/A	cg21775007	chr8:11205619	TDH	-0.55	-6.42	-0.39	7.64e-10	Retinal vascular caliber;
SARC	cis	rs2115630	0.641	rs11073613	chr15:85185893	G/A	cg17507749	chr15:85114479	UBE2QP1	-0.46	-5.48	-0.34	1.12e-7	P wave terminal force;
SARC	cis	rs6580649	0.941	rs72644843	chr12:48465061	A/G	cg24011408	chr12:48396354	COL2A1	-0.48	-5.38	-0.33	1.78e-7	Lung cancer;
SARC	cis	rs6815814	0.950	rs5743593	chr4:38802913	A/G	cg09316306	chr4:38807337	TLR1	0.49	5.2	0.32	4.41e-7	Breast cancer;
SARC	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg11987759	chr7:65425863	GUSB	0.48	5.92	0.36	1.13e-8	Aortic root size;
SARC	cis	rs1448094	0.511	rs10506918	chr12:86227913	A/G	cg00310523	chr12:86230176	RASSF9	-0.31	-4.92	-0.31	1.67e-6	Major depressive disorder;
SARC	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.67	6.46	0.39	6.09e-10	Platelet count;
SARC	cis	rs6840360	0.615	rs12641433	chr4:152607548	A/C	cg22705602	chr4:152727874	NA	-0.48	-8.22	-0.47	1.38e-14	Intelligence (multi-trait analysis);
SARC	cis	rs1448094	0.512	rs7303330	chr12:86255123	G/A	cg02569458	chr12:86230093	RASSF9	0.38	5.3	0.33	2.7e-7	Major depressive disorder;
SARC	cis	rs10484885	0.775	rs55926724	chr6:90417450	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.53	-4.9	-0.31	1.8e-6	QRS interval (sulfonylurea treatment interaction);
SARC	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg23758822	chr17:41437982	NA	0.87	10.68	0.57	6.2e-22	Menopause (age at onset);
SARC	cis	rs7647973	0.560	rs77473999	chr3:49777660	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.59	-5.61	-0.35	5.66e-8	Menarche (age at onset);
SARC	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg21747090	chr2:27597821	SNX17	-0.5	-6.92	-0.41	4.36e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs7587476	0.689	rs78989396	chr2:215714816	C/T	cg04004882	chr2:215674386	BARD1	0.57	6.43	0.39	6.96e-10	Neuroblastoma;
SARC	trans	rs61931739	0.500	rs35391785	chr12:34444478	C/T	cg26384229	chr12:38710491	ALG10B	0.92	13.8	0.67	4.45e-32	Morning vs. evening chronotype;
SARC	cis	rs7523050	0.730	rs11102650	chr1:109464228	C/G	cg08274380	chr1:109419600	GPSM2	1.19	10.05	0.55	5.72e-20	Fat distribution (HIV);
SARC	cis	rs9814567	1.000	rs11919350	chr3:134235970	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	7.03	0.42	2.24e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs10464366	0.544	rs12668821	chr7:39167846	T/A	cg18850127	chr7:39170497	POU6F2	0.41	5.45	0.34	1.28e-7	IgG glycosylation;
SARC	cis	rs4481887	0.741	rs28444488	chr1:248531776	C/A	cg13385794	chr1:248469461	NA	0.35	5.57	0.34	6.97e-8	Common traits (Other);
SARC	cis	rs36051895	0.632	rs62543560	chr9:5175938	C/T	cg02405213	chr9:5042618	JAK2	-0.46	-5.26	-0.33	3.2e-7	Pediatric autoimmune diseases;
SARC	cis	rs751728	0.626	rs4711348	chr6:33736295	G/A	cg25922239	chr6:33757077	LEMD2	0.59	7.59	0.45	7.44e-13	Crohn's disease;
SARC	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg12310025	chr6:25882481	NA	-0.48	-6.19	-0.38	2.63e-9	Intelligence (multi-trait analysis);
SARC	cis	rs9457247	0.612	rs2237273	chr6:167443017	T/C	cg07741184	chr6:167504864	NA	0.37	7.28	0.43	5.04e-12	Crohn's disease;
SARC	cis	rs2916247	0.954	rs923041	chr8:93165420	C/T	cg10183463	chr8:93005414	RUNX1T1	0.46	4.94	0.31	1.47e-6	Intelligence (multi-trait analysis);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg17461271	chr1:172717683	NA	-0.52	-6.46	-0.39	5.94e-10	Height;
SARC	cis	rs910316	0.870	rs7147712	chr14:75670707	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.45	-6.21	-0.38	2.39e-9	Height;
SARC	cis	rs10411936	0.962	rs10402422	chr19:16475388	G/A	cg10248733	chr19:16607483	C19orf44;CALR3	0.44	4.96	0.31	1.35e-6	White blood cell count;Multiple sclerosis;
SARC	cis	rs7712401	0.601	rs246282	chr5:122225605	G/T	cg19412675	chr5:122181750	SNX24	0.41	5.23	0.32	3.8e-7	Mean platelet volume;
SARC	cis	rs8523	0.774	rs6920155	chr6:11047956	C/A	cg13562911	chr6:11044106	ELOVL2	0.53	7.25	0.43	6.04e-12	Red blood cell fatty acid levels;
SARC	trans	rs17266958	0.892	rs79595527	chr9:83356515	C/A	cg03038418	chr19:3096512	GNA11	0.65	6.37	0.39	1e-9	Preschool internalizing problems;
SARC	cis	rs282587	0.569	rs1756076	chr13:113395819	T/C	cg02820901	chr13:113351484	ATP11A	-0.53	-5.08	-0.32	7.67e-7	Glycated hemoglobin levels;
SARC	cis	rs6963495	0.745	rs2392749	chr7:105182605	A/G	cg13798780	chr7:105162888	PUS7	0.47	4.76	0.3	3.4e-6	Bipolar disorder (body mass index interaction);
SARC	cis	rs7756236	0.521	rs6936993	chr6:36626322	C/T	cg08179530	chr6:36648295	CDKN1A	-0.5	-6.22	-0.38	2.28e-9	QRS duration;
SARC	cis	rs7223966	1.000	rs9895920	chr17:61852719	T/C	cg00588841	chr17:61851480	DDX42;CCDC47	-0.62	-7.08	-0.42	1.71e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs61935443	1.000	rs61935443	chr12:95249764	G/C	cg21533806	chr12:95267307	NA	0.64	7.94	0.46	8.33e-14	Schizophrenia;
SARC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg20007245	chr22:24372913	LOC391322	-0.62	-7.53	-0.44	1.12e-12	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg07701084	chr6:150067640	NUP43	0.4	5.37	0.33	1.91e-7	Lung cancer;
SARC	cis	rs6582630	0.555	rs7969922	chr12:38529491	C/T	cg26384229	chr12:38710491	ALG10B	0.85	12.48	0.63	1e-27	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs710216	0.957	rs841563	chr1:43429520	C/T	cg22176566	chr1:43424700	SLC2A1	0.52	5.13	0.32	6.03e-7	Red cell distribution width;
SARC	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg06028808	chr11:68637592	NA	0.44	5.46	0.34	1.22e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	trans	rs3476	0.578	rs9477725	chr6:18360101	T/C	cg10594510	chr5:1089753	SLC12A7	0.5	6.53	0.39	4.07e-10	Cancer;
SARC	trans	rs61931739	0.534	rs1608911	chr12:34010249	T/C	cg26384229	chr12:38710491	ALG10B	0.85	12.17	0.62	1.1e-26	Morning vs. evening chronotype;
SARC	cis	rs1153858	1.000	rs4774579	chr15:45651803	G/A	cg26924012	chr15:45694286	SPATA5L1	0.78	11.14	0.59	2.18e-23	Homoarginine levels;
SARC	cis	rs56036086	0.702	rs73187236	chr22:50617726	C/T	cg16473166	chr22:50639996	SELO	0.68	5.19	0.32	4.51e-7	Platelet count;Plateletcrit;
SARC	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg18404041	chr3:52824283	ITIH1	-0.43	-6.43	-0.39	7.12e-10	Bipolar disorder;
SARC	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg11890956	chr21:40555474	PSMG1	1.17	19.4	0.79	1.53e-50	Cognitive function;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg20494553	chr4:71554112	UTP3	0.5	6.64	0.4	2.2e-10	Chemerin levels;
SARC	cis	rs34172651	0.917	rs200539	chr16:24735178	T/C	cg00152838	chr16:24741724	TNRC6A	0.46	5.51	0.34	9.51e-8	Intelligence (multi-trait analysis);
SARC	cis	rs754466	0.580	rs11002301	chr10:79574078	G/A	cg17075019	chr10:79541650	NA	-0.81	-12.4	-0.63	1.82e-27	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9487051	1.000	rs9374080	chr6:109616420	C/T	cg01475377	chr6:109611718	NA	0.42	5.85	0.36	1.67e-8	Reticulocyte fraction of red cells;
SARC	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg25072359	chr17:41440525	NA	0.49	5.82	0.36	1.96e-8	Menopause (age at onset);
SARC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg11203670	chr7:100026453	MEPCE;ZCWPW1	0.52	4.88	0.3	1.95e-6	Platelet count;
SARC	cis	rs6570726	0.791	rs11155426	chr6:145817130	T/C	cg23711669	chr6:146136114	FBXO30	0.88	14.61	0.69	9.31e-35	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs13191362	0.935	rs34347104	chr6:163055716	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.62	5.27	0.33	3.07e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs9300255	0.602	rs2851438	chr12:123643689	T/C	cg05973401	chr12:123451056	ABCB9	0.53	6.13	0.37	3.64e-9	Neutrophil percentage of white cells;
SARC	cis	rs894734	0.535	rs2366144	chr12:54324069	G/T	cg17410650	chr12:54324560	NA	-0.34	-5.15	-0.32	5.44e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
SARC	cis	rs2016266	0.614	rs7303922	chr12:53654219	A/G	cg26875137	chr12:53738046	NA	0.38	4.74	0.3	3.73e-6	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs67460515	0.892	rs34771618	chr3:161059795	A/C	cg04691961	chr3:161091175	C3orf57	-0.49	-6.13	-0.37	3.72e-9	Parkinson's disease;
SARC	cis	rs9612	1.000	rs346524	chr19:44260572	T/C	cg08581076	chr19:44259116	C19orf61	0.65	7.93	0.46	9.08e-14	Exhaled nitric oxide output;
SARC	cis	rs10779751	0.734	rs2791648	chr1:11132638	G/T	cg08854313	chr1:11322531	MTOR	0.82	11.29	0.59	7.2e-24	Body mass index;
SARC	trans	rs877282	1.000	rs7100358	chr10:773681	G/A	cg22713356	chr15:30763199	NA	1.01	10.33	0.56	7.6e-21	Uric acid levels;
SARC	cis	rs8017423	0.967	rs61996919	chr14:90701803	A/C	cg20276874	chr14:90721474	PSMC1	-0.35	-4.91	-0.31	1.69e-6	Mortality in heart failure;
SARC	cis	rs1348850	0.526	rs7582179	chr2:178370631	A/G	cg23306229	chr2:178417860	TTC30B	0.79	7.68	0.45	4.31e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg18404041	chr3:52824283	ITIH1	-0.44	-6.58	-0.4	3.05e-10	Bipolar disorder;
SARC	cis	rs1163251	0.902	rs483360	chr1:120200606	C/T	cg19096424	chr1:120255104	PHGDH	-0.48	-5.4	-0.33	1.68e-7	Blood metabolite levels;
SARC	cis	rs6840360	0.806	rs11932383	chr4:152716136	T/C	cg22705602	chr4:152727874	NA	0.37	6.4	0.39	8.61e-10	Intelligence (multi-trait analysis);
SARC	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg00149659	chr3:10157352	C3orf10	0.64	6.02	0.37	6.69e-9	Alzheimer's disease;
SARC	trans	rs17685	0.632	rs1859793	chr7:75821283	G/A	cg19862616	chr7:65841803	NCRNA00174	0.57	7.01	0.42	2.62e-11	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs3820928	0.874	rs13423714	chr2:227896652	C/G	cg11843606	chr2:227700838	RHBDD1	0.52	6.41	0.39	7.86e-10	Pulmonary function;
SARC	cis	rs7772486	0.686	rs9376956	chr6:145949844	T/C	cg05347473	chr6:146136440	FBXO30	0.51	7.13	0.42	1.25e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6866344	0.697	rs72812613	chr5:178135257	G/A	cg03877680	chr5:178157825	ZNF354A	1.03	12.59	0.64	4.52e-28	Neutrophil percentage of white cells;
SARC	cis	rs16976116	0.901	rs1061821	chr15:55496111	T/C	cg11288833	chr15:55489084	RSL24D1	0.63	6.13	0.37	3.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg08045932	chr20:61659980	NA	0.5	6.84	0.41	7.06e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs1348850	0.914	rs1374437	chr2:178363423	T/C	cg23306229	chr2:178417860	TTC30B	0.57	6.84	0.41	6.79e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs748404	0.578	rs478028	chr15:43610772	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	5.7	0.35	3.65e-8	Lung cancer;
SARC	cis	rs950027	0.620	rs1719245	chr15:45623782	T/C	cg15395560	chr15:45543142	SLC28A2	-0.27	-5.13	-0.32	6e-7	Response to fenofibrate (adiponectin levels);
SARC	cis	rs10870270	1.000	rs7898755	chr10:133777122	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.85	-10.49	-0.57	2.46e-21	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs12142240	0.698	rs1057535	chr1:46815898	T/C	cg00530320	chr1:46809349	NSUN4	0.57	6.92	0.41	4.4e-11	Menopause (age at onset);
SARC	cis	rs7818345	0.967	rs7004435	chr8:19282732	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.42	5.73	0.35	3.06e-8	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs559928	0.597	rs2096706	chr11:63924446	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.66	4.94	0.31	1.5e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg04944784	chr2:26401820	FAM59B	-0.5	-6.14	-0.37	3.47e-9	Gut microbiome composition (summer);
SARC	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg27266027	chr21:40555129	PSMG1	0.52	5.64	0.35	4.9e-8	Cognitive function;
SARC	cis	rs7566780	0.661	rs6531148	chr2:16650233	A/G	cg09580478	chr2:16689509	NA	0.5	5.75	0.35	2.8e-8	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs7100689	0.577	rs873395	chr10:82037215	C/T	cg01528321	chr10:82214614	TSPAN14	-0.8	-9.16	-0.51	2.68e-17	Post bronchodilator FEV1;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg06065245	chr8:27779151	SCARA5	0.5	6.35	0.38	1.13e-9	Schizophrenia;
SARC	trans	rs61931739	0.500	rs11053243	chr12:34514155	T/C	cg13010199	chr12:38710504	ALG10B	0.76	10.85	0.58	1.77e-22	Morning vs. evening chronotype;
SARC	cis	rs2153535	0.505	rs9405395	chr6:8468622	T/A	cg21535247	chr6:8435926	SLC35B3	0.52	6.51	0.39	4.49e-10	Motion sickness;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg20417195	chr1:21767127	NBPF3	-0.77	-6.5	-0.39	4.8e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs11122272	0.735	rs2749708	chr1:231529610	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.14	-0.55	2.99e-20	Hemoglobin concentration;
SARC	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg13770153	chr20:60521292	NA	-0.48	-6.42	-0.39	7.62e-10	Body mass index;
SARC	cis	rs611744	0.647	rs2859813	chr8:109263497	G/A	cg21045802	chr8:109455806	TTC35	0.57	7.21	0.43	7.54e-12	Dupuytren's disease;
SARC	cis	rs6963495	0.606	rs6969426	chr7:105147150	G/A	cg19920283	chr7:105172520	RINT1	0.67	5.8	0.36	2.14e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs10791097	0.694	rs7107595	chr11:130758556	C/T	cg12179176	chr11:130786555	SNX19	0.74	11.41	0.6	3.02e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg11062466	chr8:58055876	NA	0.59	5.72	0.35	3.33e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs3126085	0.877	rs1552996	chr1:152171104	C/A	cg09127314	chr1:152161683	NA	0.42	4.79	0.3	3.03e-6	Atopic dermatitis;
SARC	cis	rs12579753	0.917	rs10778833	chr12:82197983	G/T	cg07988820	chr12:82153109	PPFIA2	-0.52	-6.11	-0.37	4.18e-9	Resting heart rate;
SARC	cis	rs7560272	0.538	rs17434634	chr2:73922926	T/A	cg20560298	chr2:73613845	ALMS1	0.48	6.35	0.38	1.09e-9	Schizophrenia;
SARC	cis	rs7666738	0.830	rs7686456	chr4:99019695	T/C	cg05340658	chr4:99064831	C4orf37	0.66	9.04	0.51	6.35e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs17023223	0.537	rs12097967	chr1:119702913	A/G	cg05756136	chr1:119680316	WARS2	-0.49	-5.66	-0.35	4.34e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs11190604	1.000	rs7080356	chr10:102266735	A/C	cg14256752	chr10:102295592	HIF1AN	0.42	4.77	0.3	3.2e-6	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs6060717	0.571	rs6060761	chr20:34612487	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-4.95	-0.31	1.4e-6	Hip circumference adjusted for BMI;
SARC	cis	rs36051895	0.632	rs10758674	chr9:5163645	G/A	cg02405213	chr9:5042618	JAK2	-0.44	-5.31	-0.33	2.57e-7	Pediatric autoimmune diseases;
SARC	cis	rs1538970	0.816	rs3790583	chr1:45956828	C/G	cg05343316	chr1:45956843	TESK2	0.82	8.79	0.5	3.28e-16	Platelet count;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg20751057	chr3:134226577	CEP63	0.4	6.27	0.38	1.76e-9	Tetralogy of Fallot;
SARC	cis	rs9486715	0.867	rs11152924	chr6:96877383	A/G	cg18709589	chr6:96969512	KIAA0776	0.58	7.27	0.43	5.5e-12	Headache;
SARC	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg26681399	chr22:41777847	TEF	-0.42	-4.73	-0.3	3.94e-6	Vitiligo;
SARC	cis	rs288326	0.561	rs80099669	chr2:183776981	G/T	cg09997497	chr2:183902928	NCKAP1	0.75	5.13	0.32	6.18e-7	Blood protein levels;
SARC	trans	rs66573146	0.572	rs67252699	chr4:6946411	A/G	cg07817883	chr1:32538562	TMEM39B	1.08	8.42	0.48	3.91e-15	Granulocyte percentage of myeloid white cells;
SARC	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg16606324	chr3:10149918	C3orf24	0.48	5.04	0.31	9.53e-7	Alzheimer's disease;
SARC	cis	rs782590	0.934	rs62165184	chr2:55788253	G/C	cg18811423	chr2:55921094	PNPT1	0.69	10.65	0.57	7.93e-22	Metabolic syndrome;
SARC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg05552183	chr6:42928497	GNMT	-0.41	-5.35	-0.33	2.09e-7	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs950776	0.752	rs62010327	chr15:78892784	G/A	cg17108064	chr15:78857060	CHRNA5	0.3	5.0	0.31	1.12e-6	Sudden cardiac arrest;
SARC	cis	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg07636037	chr3:49044803	WDR6	0.49	5.67	0.35	4.3e-8	Resting heart rate;
SARC	cis	rs7566780	0.575	rs4560110	chr2:16702136	A/G	cg09580478	chr2:16689509	NA	0.51	6.32	0.38	1.35e-9	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	trans	rs11098499	0.863	rs3822190	chr4:120428098	G/A	cg25214090	chr10:38739885	LOC399744	0.58	7.14	0.42	1.18e-11	Corneal astigmatism;
SARC	cis	rs7089973	0.604	rs17663670	chr10:116596269	A/C	cg08188268	chr10:116634841	FAM160B1	-0.28	-4.81	-0.3	2.69e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs6450176	1.000	rs9687611	chr5:53300288	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.67	-7.78	-0.45	2.32e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	trans	rs9354308	0.933	rs2802063	chr6:66564148	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.57	6.71	0.4	1.42e-10	Metabolite levels;
SARC	cis	rs4595586	0.525	rs11613788	chr12:39390710	T/C	cg26384229	chr12:38710491	ALG10B	0.5	6.12	0.37	3.98e-9	Morning vs. evening chronotype;
SARC	cis	rs13166103	0.723	rs726842	chr5:57740624	A/C	cg10487770	chr5:57879443	RAB3C	0.51	5.45	0.34	1.29e-7	Type 2 diabetes (age of onset);
SARC	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg12463550	chr7:65579703	CRCP	0.5	5.92	0.36	1.14e-8	Aortic root size;
SARC	cis	rs1570884	0.857	rs9535263	chr13:50137363	T/A	cg08779649	chr13:50194554	NA	0.33	5.21	0.32	4.17e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg24110177	chr3:50126178	RBM5	0.38	4.87	0.3	2.11e-6	Intelligence (multi-trait analysis);
SARC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg07414643	chr4:187882934	NA	0.44	6.43	0.39	7.31e-10	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg00482248	chr7:73589137	EIF4H	0.54	7.07	0.42	1.8e-11	Breast cancer;
SARC	cis	rs4481887	0.927	rs4578248	chr1:248434069	G/A	cg01631408	chr1:248437212	OR2T33	-0.43	-5.32	-0.33	2.38e-7	Common traits (Other);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg07281959	chr15:91421381	FURIN	-0.45	-6.36	-0.38	1.06e-9	Chemerin levels;
SARC	cis	rs10791097	0.694	rs11222369	chr11:130744670	A/G	cg12179176	chr11:130786555	SNX19	0.74	11.09	0.59	3.11e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg14820908	chr5:178986412	RUFY1	0.36	5.23	0.32	3.83e-7	Lung cancer;
SARC	cis	rs12142240	0.698	rs17357683	chr1:46815378	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-5.46	-0.34	1.22e-7	Menopause (age at onset);
SARC	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg11987759	chr7:65425863	GUSB	0.48	5.76	0.35	2.66e-8	Aortic root size;
SARC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.3	0.8	2.01e-53	Prudent dietary pattern;
SARC	cis	rs1707322	0.752	rs4607935	chr1:46117161	C/T	cg03146154	chr1:46216737	IPP	0.52	6.25	0.38	1.92e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg06028808	chr11:68637592	NA	-0.39	-4.92	-0.31	1.6e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs2933343	0.729	rs1683780	chr3:128640239	C/T	cg24203234	chr3:128598194	ACAD9	0.64	7.93	0.46	8.83e-14	IgG glycosylation;
SARC	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg26874164	chr19:58962979	ZNF324B	0.47	6.03	0.37	6.31e-9	Uric acid clearance;
SARC	cis	rs9914988	0.943	rs12453504	chr17:27119524	C/A	cg20469991	chr17:27169893	C17orf63	-0.5	-5.21	-0.32	4.1e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg22800045	chr5:56110881	MAP3K1	0.74	7.92	0.46	9.76e-14	Initial pursuit acceleration;
SARC	cis	rs123509	0.913	rs121993	chr3:42776601	T/C	cg12982090	chr3:42733453	KBTBD5	0.52	6.36	0.38	1.07e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg04546413	chr19:29218101	NA	0.63	8.52	0.49	2.01e-15	Methadone dose in opioid dependence;
SARC	cis	rs1448094	0.817	rs10863111	chr12:86330615	T/C	cg02569458	chr12:86230093	RASSF9	0.41	5.84	0.36	1.73e-8	Major depressive disorder;
SARC	cis	rs4308124	0.708	rs67816163	chr2:111963310	A/G	cg04571233	chr2:111982156	NA	-0.48	-5.59	-0.34	6.46e-8	Vitiligo;
SARC	cis	rs734999	0.588	rs2843404	chr1:2530558	T/C	cg18854424	chr1:2615690	NA	-0.32	-5.04	-0.31	9.17e-7	Ulcerative colitis;
SARC	cis	rs2228479	0.717	rs11649210	chr16:89807233	C/G	cg06558623	chr16:89946397	TCF25	0.7	5.99	0.37	7.89e-9	Skin colour saturation;
SARC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg04267008	chr7:1944627	MAD1L1	-0.6	-6.95	-0.41	3.69e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs6582630	0.539	rs12308081	chr12:38342881	C/G	cg26384229	chr12:38710491	ALG10B	-0.57	-7.02	-0.42	2.43e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7786808	0.741	rs11765319	chr7:158226790	A/G	cg09998033	chr7:158218633	PTPRN2	-0.39	-6.39	-0.39	8.88e-10	Obesity-related traits;
SARC	cis	rs7027203	0.663	rs4428726	chr9:96623559	T/G	cg13679303	chr9:96623674	NA	-0.4	-5.93	-0.36	1.07e-8	DNA methylation (variation);
SARC	cis	rs7659604	1.000	rs6846232	chr4:122664805	A/G	cg19748678	chr4:122722346	EXOSC9	0.41	5.11	0.32	6.64e-7	Type 2 diabetes;
SARC	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	10.84	0.58	2.01e-22	Alzheimer's disease;
SARC	cis	rs1448094	0.791	rs61929394	chr12:86331541	C/A	cg02569458	chr12:86230093	RASSF9	0.44	6.23	0.38	2.1e-9	Major depressive disorder;
SARC	cis	rs35110281	0.667	rs4819291	chr21:45123139	G/A	cg21573476	chr21:45109991	RRP1B	-0.59	-8.37	-0.48	5.33e-15	Mean corpuscular volume;
SARC	cis	rs9875589	0.509	rs1873005	chr3:14060223	G/A	cg19554555	chr3:13937349	NA	-0.4	-5.14	-0.32	5.95e-7	Ovarian reserve;
SARC	trans	rs9388451	0.537	rs1739383	chr6:126098915	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.58	-7.43	-0.44	1.99e-12	Brugada syndrome;
SARC	cis	rs7561528	0.501	rs4663104	chr2:127890786	C/G	cg12632573	chr2:127783243	NA	0.58	5.31	0.33	2.59e-7	Alzheimer's disease;Alzheimer's disease (late onset);
SARC	cis	rs11764590	0.694	rs10276536	chr7:2086960	C/T	cg23043544	chr7:2124092	MAD1L1	-0.36	-5.03	-0.31	9.58e-7	Neuroticism;
SARC	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg16606324	chr3:10149918	C3orf24	0.48	4.75	0.3	3.56e-6	Alzheimer's disease;
SARC	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg24209194	chr3:40518798	ZNF619	0.66	8.19	0.47	1.7e-14	Renal cell carcinoma;
SARC	cis	rs67311347	1.000	rs67311347	chr3:40533243	G/A	cg09455208	chr3:40491958	NA	0.34	5.18	0.32	4.86e-7	Renal cell carcinoma;
SARC	cis	rs8180040	0.726	rs10461018	chr3:46995242	C/T	cg27129171	chr3:47204927	SETD2	-0.69	-9.62	-0.53	1.19e-18	Colorectal cancer;
SARC	cis	rs10791097	0.702	rs10894267	chr11:130714861	C/T	cg12179176	chr11:130786555	SNX19	-0.47	-6.08	-0.37	4.98e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9796	0.870	rs2925342	chr15:41305733	A/G	cg18705301	chr15:41695430	NDUFAF1	0.41	5.73	0.35	3.06e-8	Menopause (age at onset);
SARC	cis	rs2075371	0.611	rs12707154	chr7:134015832	C/T	cg11752832	chr7:134001865	SLC35B4	0.49	6.01	0.37	7.1e-9	Mean platelet volume;
SARC	cis	rs6700896	0.931	rs79050868	chr1:66120916	G/A	cg04111102	chr1:66153794	NA	0.36	5.66	0.35	4.49e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs854765	0.647	rs854769	chr17:18019011	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.54	-7.38	-0.44	2.7e-12	Total body bone mineral density;
SARC	cis	rs6981523	0.553	rs11783045	chr8:11056175	A/G	cg12395012	chr8:11607386	GATA4	0.31	5.32	0.33	2.44e-7	Neuroticism;
SARC	cis	rs6912958	0.781	rs9450738	chr6:88267314	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.48	-0.34	1.09e-7	Monocyte percentage of white cells;
SARC	cis	rs9486715	0.867	rs9486444	chr6:96963619	A/G	cg18709589	chr6:96969512	KIAA0776	0.61	7.52	0.44	1.16e-12	Headache;
SARC	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg04944784	chr2:26401820	FAM59B	-0.47	-5.91	-0.36	1.18e-8	Gut microbiome composition (summer);
SARC	cis	rs72945132	0.882	rs7945389	chr11:70158876	C/A	cg00319359	chr11:70116639	PPFIA1	0.67	6.08	0.37	4.85e-9	Coronary artery disease;
SARC	cis	rs7917772	0.502	rs4919670	chr10:104515799	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.56	-6.68	-0.4	1.7e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg00603356	chr7:107382211	NA	0.45	6.44	0.39	6.6e-10	Thyroid stimulating hormone;
SARC	cis	rs12477438	0.520	rs2632276	chr2:99779655	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.15	25.11	0.85	3.2e-68	Chronic sinus infection;
SARC	cis	rs6835098	0.961	rs2078475	chr4:174098226	A/C	cg08422745	chr4:174089978	GALNT7	0.76	9.7	0.54	6.76e-19	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs2624839	0.704	rs12637671	chr3:50224562	G/A	cg19755318	chr3:50243323	SLC38A3	0.29	5.04	0.31	9.35e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg19223190	chr17:80058835	NA	-0.43	-6.02	-0.37	6.57e-9	Life satisfaction;
SARC	cis	rs9581857	0.579	rs3759433	chr13:27997999	C/T	cg01674679	chr13:27998804	GTF3A	-0.57	-5.07	-0.32	8.04e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	cis	rs8031584	0.918	rs61997139	chr15:31273602	C/G	cg14829155	chr15:31115871	NA	-0.43	-5.52	-0.34	8.95e-8	Huntington's disease progression;
SARC	cis	rs6580649	0.941	rs4760618	chr12:48434767	G/A	cg05342945	chr12:48394962	COL2A1	0.55	5.65	0.35	4.55e-8	Lung cancer;
SARC	cis	rs9325144	0.555	rs1813392	chr12:38692203	C/T	cg26384229	chr12:38710491	ALG10B	-0.64	-8.77	-0.5	3.77e-16	Morning vs. evening chronotype;
SARC	cis	rs9325144	0.510	rs6582599	chr12:38715965	T/G	cg26384229	chr12:38710491	ALG10B	0.61	8.09	0.47	3.22e-14	Morning vs. evening chronotype;
SARC	trans	rs3804024	1.000	rs55868605	chr21:41984089	A/T	cg03228353	chr1:161520094	FCGR3A	0.57	7.05	0.42	2.03e-11	Obesity-related traits;
SARC	cis	rs1670533	0.932	rs13108207	chr4:1054218	C/T	cg27284194	chr4:1044797	NA	0.46	4.91	0.31	1.72e-6	Recombination rate (females);
SARC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.46	0.53	3.55e-18	Prudent dietary pattern;
SARC	cis	rs2832077	0.883	rs11702413	chr21:30188395	A/C	cg24692254	chr21:30365293	RNF160	-0.52	-4.78	-0.3	3.09e-6	Cognitive test performance;
SARC	cis	rs2342371	0.756	rs3973	chr3:196124278	A/G	cg15048948	chr3:196158458	UBXN7	-0.64	-7.8	-0.45	2.12e-13	Fat distribution (HIV);
SARC	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.92	9.31	0.52	9.94e-18	Platelet count;
SARC	cis	rs2273669	0.915	rs4470881	chr6:109309287	A/G	cg05315195	chr6:109294784	ARMC2	-0.5	-4.94	-0.31	1.46e-6	Prostate cancer;
SARC	cis	rs17253792	0.822	rs12100949	chr14:56040787	T/C	cg01858014	chr14:56050164	KTN1	-0.64	-4.78	-0.3	3.14e-6	Putamen volume;
SARC	cis	rs1728785	1.000	rs1749791	chr16:68572347	C/T	cg02972257	chr16:68554789	NA	-0.44	-5.15	-0.32	5.43e-7	Ulcerative colitis;
SARC	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg12463550	chr7:65579703	CRCP	-0.5	-5.59	-0.34	6.32e-8	Aortic root size;
SARC	cis	rs2573652	0.723	rs2573655	chr15:100515709	A/C	cg09918751	chr15:100517450	ADAMTS17	-0.43	-5.36	-0.33	1.99e-7	Height;
SARC	cis	rs72634258	0.554	rs4562654	chr1:7934423	A/T	cg00042356	chr1:8021962	PARK7	0.65	5.58	0.34	6.51e-8	Inflammatory bowel disease;
SARC	cis	rs2688419	0.565	rs1817581	chr3:23078375	T/A	cg00327796	chr3:23032191	NA	-0.4	-5.66	-0.35	4.5e-8	Type 2 diabetes;
SARC	cis	rs644799	0.562	rs1313288	chr11:95520695	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.74	9.94	0.55	1.21e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs73198271	0.562	rs112717383	chr8:8663216	T/C	cg01851573	chr8:8652454	MFHAS1	0.42	5.14	0.32	5.88e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg25894440	chr7:65020034	NA	-0.75	-5.64	-0.35	4.89e-8	Diabetic kidney disease;
SARC	cis	rs35306767	0.903	rs12769873	chr10:936526	G/T	cg26597838	chr10:835615	NA	0.77	7.87	0.46	1.37e-13	Eosinophil percentage of granulocytes;
SARC	trans	rs11098499	0.909	rs35111518	chr4:120440682	A/G	cg25214090	chr10:38739885	LOC399744	0.55	6.79	0.41	9.25e-11	Corneal astigmatism;
SARC	cis	rs2361718	0.631	rs2289539	chr17:78152119	T/C	cg06718696	chr17:78121285	EIF4A3	0.43	4.9	0.31	1.75e-6	Yeast infection;
SARC	cis	rs765787	0.530	rs1706830	chr15:45516229	G/A	cg24006582	chr15:45444508	DUOX1	-0.49	-6.47	-0.39	5.7e-10	Uric acid levels;
SARC	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg03264133	chr6:25882463	NA	0.37	4.77	0.3	3.21e-6	Intelligence (multi-trait analysis);
SARC	cis	rs11690935	0.959	rs10174525	chr2:172635697	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.01	-16.42	-0.73	9.16e-41	Schizophrenia;
SARC	cis	rs918629	0.567	rs3777196	chr5:95238160	A/C	cg16656078	chr5:95278638	ELL2	-0.52	-6.52	-0.39	4.3e-10	IgG glycosylation;
SARC	cis	rs7944584	0.837	rs11039149	chr11:47276675	A/G	cg20307385	chr11:47447363	PSMC3	0.62	7.45	0.44	1.78e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.52	-5.28	-0.33	2.89e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs1953600	0.837	rs2236556	chr10:81932790	T/C	cg00277334	chr10:82204260	NA	0.36	5.26	0.33	3.34e-7	Sarcoidosis;
SARC	cis	rs2486288	0.656	rs11631021	chr15:45556829	A/G	cg15395560	chr15:45543142	SLC28A2	0.29	5.78	0.35	2.34e-8	Glomerular filtration rate;
SARC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg24846343	chr22:24311635	DDTL	-0.51	-7.42	-0.44	2.18e-12	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1318878	1.000	rs7304584	chr12:15545181	C/T	cg08258403	chr12:15378311	NA	0.47	6.23	0.38	2.15e-9	Intelligence (multi-trait analysis);
SARC	cis	rs79349575	0.783	rs4399576	chr17:47009835	G/A	cg16584676	chr17:46985605	UBE2Z	0.55	6.66	0.4	1.91e-10	Type 2 diabetes;
SARC	cis	rs2070677	1.000	rs4301745	chr10:135421636	T/G	cg20169779	chr10:135381914	SYCE1	-0.52	-6.46	-0.39	6e-10	Gout;
SARC	cis	rs11874712	1.000	rs11874712	chr18:43688576	C/A	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.52	6.22	0.38	2.3e-9	Migraine - clinic-based;
SARC	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.79	9.37	0.52	6.69e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs616402	0.527	rs589151	chr1:10567711	C/T	cg07384165	chr1:10488281	NA	-0.42	-5.51	-0.34	9.32e-8	Breast size;
SARC	cis	rs4727027	0.870	rs13237714	chr7:148884083	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.47	5.75	0.35	2.84e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg26752003	chr8:145688521	CYHR1	-0.6	-8.47	-0.49	2.82e-15	Age at first birth;
SARC	cis	rs9341808	0.718	rs2322630	chr6:80841033	A/G	cg08355045	chr6:80787529	NA	0.34	5.47	0.34	1.15e-7	Sitting height ratio;
SARC	cis	rs9640161	0.830	rs36069544	chr7:150061538	G/A	cg21361702	chr7:150065534	REPIN1	0.59	6.9	0.41	4.8e-11	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs2658782	0.951	rs2608214	chr11:93148665	C/T	cg15737290	chr11:93063684	CCDC67	0.68	7.32	0.43	3.94e-12	Pulmonary function decline;
SARC	cis	rs6696846	0.791	rs10158848	chr1:205061192	C/T	cg00857998	chr1:205179979	DSTYK	0.52	6.66	0.4	1.97e-10	Red blood cell count;
SARC	trans	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.05	-0.42	2.04e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg04944784	chr2:26401820	FAM59B	-0.48	-5.8	-0.36	2.14e-8	Gut microbiome composition (summer);
SARC	cis	rs7772486	0.806	rs4075695	chr6:146250959	A/G	cg05347473	chr6:146136440	FBXO30	-0.46	-6.13	-0.37	3.7e-9	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs2055729	0.645	rs12056944	chr8:9742525	C/G	cg06636001	chr8:8085503	FLJ10661	0.55	6.34	0.38	1.2e-9	Multiple myeloma (hyperdiploidy);
SARC	cis	rs865483	0.895	rs7501983	chr17:35783812	A/G	cg06561646	chr17:35873369	DUSP14	0.48	6.18	0.38	2.89e-9	Monocyte count;
SARC	cis	rs8044868	0.530	rs2288002	chr16:72057282	A/G	cg01557791	chr16:72042693	DHODH	-0.38	-4.79	-0.3	2.95e-6	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
SARC	cis	rs9660992	0.547	rs12143121	chr1:205199142	A/G	cg21545522	chr1:205238299	TMCC2	0.39	5.34	0.33	2.25e-7	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs11112613	0.713	rs17037317	chr12:105952058	T/C	cg03607813	chr12:105948248	NA	0.53	7.5	0.44	1.34e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg17971929	chr21:40555470	PSMG1	0.98	13.7	0.67	1e-31	Cognitive function;
SARC	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg15966229	chr18:44337664	ST8SIA5	-0.37	-4.78	-0.3	3.11e-6	Personality dimensions;
SARC	cis	rs854765	0.663	rs12941550	chr17:17753828	C/A	cg04398451	chr17:18023971	MYO15A	0.41	5.92	0.36	1.15e-8	Total body bone mineral density;
SARC	cis	rs35110281	0.641	rs4819283	chr21:45083011	T/A	cg04455712	chr21:45112962	RRP1B	0.34	4.8	0.3	2.87e-6	Mean corpuscular volume;
SARC	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg12696929	chr3:195401817	SDHAP2	0.39	5.18	0.32	4.78e-7	Pancreatic cancer;
SARC	cis	rs7106204	0.748	rs12273426	chr11:24212058	T/C	ch.11.24196551F	chr11:24239977	NA	0.64	6.8	0.41	8.62e-11	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs1707322	1.000	rs785497	chr1:46591903	G/C	cg06784218	chr1:46089804	CCDC17	-0.35	-6.01	-0.37	7.21e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9393692	0.905	rs9379838	chr6:26277133	C/T	cg05868516	chr6:26286170	HIST1H4H	0.56	7.37	0.43	2.9e-12	Educational attainment;
SARC	cis	rs7582180	0.739	rs11123822	chr2:100911582	G/T	cg14675211	chr2:100938903	LONRF2	0.5	6.84	0.41	6.86e-11	Intelligence (multi-trait analysis);
SARC	trans	rs561341	1.000	rs530715	chr17:30320544	T/G	cg20587970	chr11:113659929	NA	-1.25	-12.77	-0.64	1.2e-28	Hip circumference adjusted for BMI;
SARC	cis	rs9486715	0.867	rs11152924	chr6:96877383	A/G	cg06623918	chr6:96969491	KIAA0776	0.88	12.7	0.64	1.95e-28	Headache;
SARC	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg16606324	chr3:10149918	C3orf24	0.48	5.04	0.31	9.53e-7	Alzheimer's disease;
SARC	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.23e-9	Life satisfaction;
SARC	cis	rs240764	0.782	rs239223	chr6:101112345	A/G	cg09795085	chr6:101329169	ASCC3	0.44	5.72	0.35	3.28e-8	Neuroticism;
SARC	cis	rs8067354	0.645	rs2645467	chr17:57854783	C/T	cg02344993	chr17:57696989	CLTC	0.64	6.51	0.39	4.64e-10	Hemoglobin concentration;
SARC	cis	rs5758659	0.652	rs133327	chr22:42407689	T/C	cg04733989	chr22:42467013	NAGA	0.5	6.7	0.4	1.52e-10	Cognitive function;
SARC	trans	rs17221829	0.733	rs11018668	chr11:89356178	C/T	cg14468720	chr3:113557932	GRAMD1C	0.44	6.45	0.39	6.27e-10	Anxiety in major depressive disorder;
SARC	cis	rs9400467	0.506	rs17756732	chr6:111580154	A/G	cg15721981	chr6:111408429	SLC16A10	0.67	5.7	0.35	3.68e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs995000	0.931	rs10789117	chr1:63072265	A/C	cg06896770	chr1:63153194	DOCK7	0.89	13.09	0.65	1.03e-29	Triglyceride levels;
SARC	cis	rs644799	1.000	rs623191	chr11:95548359	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.7	9.55	0.53	1.87e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7762018	1.000	rs1127489	chr6:170107702	C/T	cg13891659	chr6:170190454	C6orf122;C6orf208	0.56	4.84	0.3	2.32e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs72781680	0.799	rs2712084	chr2:24003051	A/G	cg08917208	chr2:24149416	ATAD2B	0.6	6.04	0.37	6.17e-9	Lymphocyte counts;
SARC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg11203670	chr7:100026453	MEPCE;ZCWPW1	0.48	4.75	0.3	3.55e-6	Platelet count;
SARC	cis	rs12545109	0.775	rs10093388	chr8:57318799	C/T	cg19413350	chr8:57351067	NA	-0.46	-5.81	-0.36	2.01e-8	Obesity-related traits;
SARC	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg16479474	chr6:28041457	NA	0.36	5.27	0.33	3.04e-7	Depression;
SARC	cis	rs34779708	0.931	rs2490663	chr10:35329735	A/G	cg03585969	chr10:35415529	CREM	-0.38	-4.93	-0.31	1.59e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg16405210	chr4:1374714	KIAA1530	-0.95	-13.19	-0.65	4.98e-30	Longevity;
SARC	cis	rs1018836	0.923	rs7837230	chr8:91574281	C/T	cg16814680	chr8:91681699	NA	-0.8	-12.6	-0.64	4.28e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs1153858	1.000	rs7494956	chr15:45668565	T/C	cg03999130	chr15:45571217	NA	0.39	4.98	0.31	1.25e-6	Homoarginine levels;
SARC	cis	rs796364	0.625	rs1369843	chr2:201088171	A/G	cg05691004	chr2:201170426	SPATS2L	-0.45	-4.89	-0.3	1.92e-6	Schizophrenia;
SARC	cis	rs9400467	0.506	rs10485124	chr6:111631907	C/G	cg15721981	chr6:111408429	SLC16A10	0.69	5.85	0.36	1.67e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg12564285	chr5:131593104	PDLIM4	0.35	5.23	0.32	3.84e-7	Breast cancer;
SARC	cis	rs6815814	0.950	rs56289835	chr4:38811845	G/C	cg02016764	chr4:38805732	TLR1	-0.41	-4.86	-0.3	2.18e-6	Breast cancer;
SARC	cis	rs4595586	0.545	rs4768505	chr12:39380338	C/A	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	cis	rs9616064	0.506	rs2542038	chr22:47059282	C/T	cg25730555	chr22:47059586	GRAMD4	0.36	4.81	0.3	2.74e-6	Urate levels in obese individuals;
SARC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg09373136	chr17:61933544	TCAM1	-0.44	-6.09	-0.37	4.59e-9	Prudent dietary pattern;
SARC	cis	rs12048904	0.541	rs6699536	chr1:101276544	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.83	10.07	0.55	5.02e-20	Multiple sclerosis;
SARC	cis	rs2952156	0.684	rs881844	chr17:37810218	C/G	cg20243544	chr17:37824526	PNMT	0.62	8.15	0.47	2.17e-14	Asthma;
SARC	cis	rs12950390	0.548	rs62076098	chr17:45860584	C/T	cg03474202	chr17:45855739	NA	-0.39	-6.13	-0.37	3.66e-9	IgG glycosylation;
SARC	cis	rs600231	0.665	rs1621277	chr11:65221954	A/G	cg17120908	chr11:65337727	SSSCA1	0.42	5.21	0.32	4.16e-7	Bone mineral density;
SARC	cis	rs478304	0.654	rs7115734	chr11:65458964	G/A	cg27068330	chr11:65405492	SIPA1	-0.42	-4.86	-0.3	2.18e-6	Acne (severe);
SARC	cis	rs9309473	0.519	rs7598901	chr2:73675844	C/T	cg20560298	chr2:73613845	ALMS1	0.53	7.09	0.42	1.55e-11	Metabolite levels;
SARC	cis	rs2221894	0.506	rs17524494	chr8:28779203	A/C	cg07962641	chr8:28805897	HMBOX1	-0.76	-7.42	-0.44	2.15e-12	Obesity-related traits;
SARC	cis	rs1062177	0.826	rs2915873	chr5:151156658	G/A	cg00977110	chr5:151150581	G3BP1	0.63	6.37	0.38	1.02e-9	Preschool internalizing problems;
SARC	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg12463550	chr7:65579703	CRCP	-0.48	-5.55	-0.34	7.58e-8	Aortic root size;
SARC	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg13206674	chr6:150067644	NUP43	0.5	5.95	0.36	9.89e-9	Lung cancer;
SARC	cis	rs7639513	0.767	rs9861472	chr3:12707776	A/T	cg23032965	chr3:12705835	RAF1	-0.84	-12.2	-0.62	8.26e-27	Itch intensity from mosquito bite;
SARC	cis	rs7246657	0.943	rs13345116	chr19:37847098	A/T	cg23950597	chr19:37808831	NA	-0.54	-5.47	-0.34	1.15e-7	Coronary artery calcification;
SARC	cis	rs2290416	0.892	rs58774517	chr8:144656764	C/T	cg10810860	chr8:144639591	GSDMD	-0.72	-5.0	-0.31	1.14e-6	Attention deficit hyperactivity disorder;
SARC	cis	rs13191362	0.507	rs2510207	chr6:163086592	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.47	-5.2	-0.32	4.45e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs611744	0.647	rs6981420	chr8:109266694	T/G	cg21045802	chr8:109455806	TTC35	0.57	7.1	0.42	1.45e-11	Dupuytren's disease;
SARC	cis	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg06212747	chr3:49208901	KLHDC8B	0.51	6.48	0.39	5.37e-10	Resting heart rate;
SARC	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.52	5.93	0.36	1.06e-8	Renal function-related traits (BUN);
SARC	cis	rs1256061	0.630	rs1256030	chr14:64747170	A/G	cg23250157	chr14:64679961	SYNE2	0.47	6.54	0.39	3.8e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs7772486	0.686	rs857882	chr6:145969716	T/G	cg23711669	chr6:146136114	FBXO30	-0.86	-14.16	-0.68	3.03e-33	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7945705	0.875	rs10769947	chr11:8758114	A/G	cg14711859	chr11:8959438	ASCL3	-0.32	-5.2	-0.32	4.27e-7	Hemoglobin concentration;
SARC	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg00825309	chr19:58991885	ZNF446	-0.55	-7.76	-0.45	2.73e-13	Uric acid clearance;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg06131143	chr2:48757612	NA	0.52	6.64	0.4	2.21e-10	Breast cancer;
SARC	cis	rs8141529	0.748	rs9620841	chr22:29290981	C/T	cg15103426	chr22:29168792	CCDC117	0.66	8.64	0.49	9.17e-16	Lymphocyte counts;
SARC	cis	rs11608355	0.515	rs11609921	chr12:109918405	A/G	cg05360138	chr12:110035743	NA	0.94	9.47	0.53	3.36e-18	Neuroticism;
SARC	cis	rs9581943	0.967	rs9581929	chr13:28464203	C/T	cg16302790	chr13:28498334	PDX1	0.56	8.37	0.48	5.41e-15	Pancreatic cancer;
SARC	cis	rs11608355	0.521	rs4766469	chr12:109836890	C/G	cg19025524	chr12:109796872	NA	0.41	6.12	0.37	3.95e-9	Neuroticism;
SARC	cis	rs7251806	1	rs7251806	chr19:16499569	C/T	cg10248733	chr19:16607483	C19orf44;CALR3	0.62	6.34	0.38	1.16e-9	Lymphocyte counts;
SARC	cis	rs2276314	1.000	rs16967317	chr18:33573400	A/G	cg19628046	chr18:33552617	C18orf21	0.59	5.96	0.36	9.37e-9	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs11581859	0.562	rs993216	chr1:99206273	C/T	cg20286094	chr1:99190917	SNX7	-0.42	-4.89	-0.31	1.86e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg13939156	chr17:80058883	NA	-0.44	-6.84	-0.41	6.73e-11	Life satisfaction;
SARC	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg26769984	chr7:1090371	C7orf50	0.51	5.25	0.33	3.36e-7	Bronchopulmonary dysplasia;
SARC	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg24250549	chr1:154909240	PMVK	0.83	12.12	0.62	1.5e-26	Prostate cancer;
SARC	cis	rs1153858	0.887	rs7164139	chr15:45670851	G/A	cg03999130	chr15:45571217	NA	0.39	4.98	0.31	1.25e-6	Homoarginine levels;
SARC	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg25894440	chr7:65020034	NA	0.73	5.51	0.34	9.25e-8	Diabetic kidney disease;
SARC	cis	rs12754538	0.648	rs12028926	chr1:8818438	C/G	cg13785123	chr1:8931135	ENO1	-0.5	-5.97	-0.36	8.74e-9	Subjective well-being;
SARC	cis	rs9303401	0.659	rs34170300	chr17:56789905	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	12.31	0.63	3.57e-27	Cognitive test performance;
SARC	cis	rs1113500	0.933	rs12035689	chr1:108636756	T/C	cg06207961	chr1:108661230	NA	0.44	5.9	0.36	1.29e-8	Growth-regulated protein alpha levels;
SARC	cis	rs72781680	0.821	rs55948613	chr2:24094787	A/G	cg08917208	chr2:24149416	ATAD2B	0.61	6.43	0.39	7.08e-10	Lymphocyte counts;
SARC	cis	rs4481887	1.000	rs4244183	chr1:248471222	G/A	cg13385794	chr1:248469461	NA	0.36	5.59	0.34	6.44e-8	Common traits (Other);
SARC	cis	rs9467711	0.606	rs4634439	chr6:26598004	C/T	cg12826209	chr6:26865740	GUSBL1	-0.68	-4.9	-0.31	1.8e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs34779708	0.931	rs12240347	chr10:35359475	A/G	cg03585969	chr10:35415529	CREM	0.38	4.79	0.3	3e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs17376456	0.877	rs12716460	chr5:93416733	A/G	cg21475434	chr5:93447410	FAM172A	0.87	7.86	0.46	1.46e-13	Diabetic retinopathy;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16236394	chr2:113033084	ZC3H6	-0.49	-6.37	-0.39	9.71e-10	Smoking initiation;
SARC	cis	rs910187	0.605	rs6063079	chr20:45804275	C/G	cg27589058	chr20:45804311	EYA2	-0.34	-5.65	-0.35	4.6e-8	Migraine;
SARC	cis	rs6772849	0.896	rs61112519	chr3:128338176	T/A	cg08795948	chr3:128337044	NA	0.54	7.54	0.44	1.04e-12	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs7296418	0.922	rs12425009	chr12:123502044	C/T	cg16085171	chr12:123569118	PITPNM2	-0.38	-4.85	-0.3	2.29e-6	Platelet count;
SARC	cis	rs2439831	0.867	rs28729853	chr15:43673680	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.07	11.5	0.6	1.57e-24	Lung cancer in ever smokers;
SARC	cis	rs9902453	0.740	rs2244247	chr17:28110174	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.19	-0.43	8.82e-12	Coffee consumption (cups per day);
SARC	cis	rs2115630	1.000	rs11073730	chr15:85354596	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.49	-5.89	-0.36	1.32e-8	P wave terminal force;
SARC	cis	rs4713118	0.955	rs9380010	chr6:27683572	A/G	cg17221315	chr6:27791827	HIST1H4J	0.49	4.97	0.31	1.3e-6	Parkinson's disease;
SARC	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg27266027	chr21:40555129	PSMG1	0.5	5.52	0.34	8.99e-8	Cognitive function;
SARC	cis	rs2836950	0.762	rs8134638	chr21:40644170	T/C	cg11644478	chr21:40555479	PSMG1	-0.42	-4.91	-0.31	1.73e-6	Menarche (age at onset);
SARC	cis	rs1865760	0.663	rs9348704	chr6:26000393	A/C	cg18357526	chr6:26021779	HIST1H4A	0.38	4.84	0.3	2.35e-6	Height;
SARC	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg05313129	chr8:58192883	C8orf71	-0.62	-6.37	-0.39	9.92e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg18252515	chr7:66147081	NA	0.48	5.28	0.33	2.99e-7	Aortic root size;
SARC	cis	rs7412746	0.658	rs6677420	chr1:150946490	G/A	cg15448220	chr1:150897856	SETDB1	0.51	6.39	0.39	8.87e-10	Melanoma;
SARC	cis	rs10779751	0.690	rs2791646	chr1:11133242	C/T	cg08854313	chr1:11322531	MTOR	0.82	11.29	0.59	7.2e-24	Body mass index;
SARC	cis	rs9796	0.870	rs28581803	chr15:41326513	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.42	-5.83	-0.36	1.85e-8	Menopause (age at onset);
SARC	cis	rs9549367	0.713	rs9577211	chr13:113830718	G/C	cg18105134	chr13:113819100	PROZ	-0.5	-7.35	-0.43	3.37e-12	Platelet distribution width;
SARC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg07414643	chr4:187882934	NA	0.5	7.5	0.44	1.34e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg06108461	chr20:60628389	TAF4	-0.99	-13.11	-0.65	8.72e-30	Body mass index;
SARC	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg12463550	chr7:65579703	CRCP	0.48	5.5	0.34	9.97e-8	Aortic root size;
SARC	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg18876405	chr7:65276391	NA	-0.7	-8.72	-0.5	5.4e-16	Aortic root size;
SARC	cis	rs9389248	0.690	rs2064101	chr6:135250530	G/A	cg22676075	chr6:135203613	NA	-0.47	-5.92	-0.36	1.13e-8	High light scatter reticulocyte percentage of red cells;
SARC	trans	rs2727020	0.894	rs3862342	chr11:49357043	C/T	cg15704280	chr7:45808275	SEPT13	-0.74	-9.64	-0.53	1.03e-18	Coronary artery disease;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg24717964	chr20:61477008	DPH3B;TCFL5	0.55	6.26	0.38	1.85e-9	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs986417	0.818	rs1998189	chr14:60974987	A/T	cg27398547	chr14:60952738	C14orf39	0.99	9.02	0.51	6.89e-17	Gut microbiota (bacterial taxa);
SARC	cis	rs2180341	0.960	rs9398839	chr6:127665863	G/A	cg17762328	chr6:126965162	NA	-0.44	-4.86	-0.3	2.13e-6	Breast cancer;
SARC	trans	rs11039798	0.528	rs10769559	chr11:49032446	T/C	cg15704280	chr7:45808275	SEPT13	0.65	6.87	0.41	5.84e-11	Axial length;
SARC	cis	rs9896052	0.614	rs4789201	chr17:73440579	A/G	cg25649188	chr17:73499917	CASKIN2	0.35	5.06	0.31	8.46e-7	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.53	-5.14	-0.32	5.82e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs778371	0.697	rs11893358	chr2:233636922	T/C	cg16596103	chr2:233749413	NGEF	-0.37	-5.69	-0.35	3.83e-8	Schizophrenia;
SARC	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.2	-0.52	2.12e-17	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs751728	0.664	rs12190029	chr6:33749152	T/A	cg25922239	chr6:33757077	LEMD2	0.58	7.59	0.45	7.62e-13	Crohn's disease;
SARC	cis	rs72781680	0.848	rs6748727	chr2:24041058	G/A	cg08917208	chr2:24149416	ATAD2B	0.78	7.32	0.43	3.96e-12	Lymphocyte counts;
SARC	cis	rs10504229	0.593	rs16921589	chr8:58024387	C/A	cg08219700	chr8:58056026	NA	0.66	6.49	0.39	5.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1044826	0.642	rs6771831	chr3:139177585	C/T	cg15131784	chr3:139108705	COPB2	0.41	5.19	0.32	4.58e-7	Obesity-related traits;
SARC	cis	rs7786808	0.778	rs34212455	chr7:158224490	C/T	cg01191920	chr7:158217561	PTPRN2	-0.43	-8.04	-0.47	4.65e-14	Obesity-related traits;
SARC	cis	rs7659604	0.521	rs4833234	chr4:122694799	T/C	cg19671926	chr4:122722719	EXOSC9	0.65	8.32	0.48	7.25e-15	Type 2 diabetes;
SARC	cis	rs7326068	0.610	rs3924006	chr13:21331779	T/A	cg16922012	chr13:21400325	XPO4	-0.42	-5.55	-0.34	7.69e-8	Schizophrenia, bipolar disorder and depression (combined);
SARC	cis	rs5753618	0.561	rs9606831	chr22:31732512	C/T	cg07713946	chr22:31675144	LIMK2	0.38	5.36	0.33	2.04e-7	Colorectal cancer;
SARC	cis	rs4689388	0.926	rs10937718	chr4:6295217	T/C	cg14416269	chr4:6271139	WFS1	0.32	4.92	0.31	1.61e-6	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs6088813	1.000	rs6142379	chr20:33999267	A/G	cg14752227	chr20:34000481	UQCC	-0.37	-4.72	-0.3	4.02e-6	Height;
SARC	cis	rs7179456	0.513	rs593742	chr15:59045774	A/G	cg05156742	chr15:59063176	FAM63B	0.62	7.76	0.45	2.72e-13	Asperger disorder;
SARC	cis	rs6831352	0.879	rs4699716	chr4:100066125	G/A	cg12011299	chr4:100065546	ADH4	-0.32	-5.09	-0.32	7.33e-7	Alcohol dependence;
SARC	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg12311346	chr5:56204834	C5orf35	-0.56	-5.85	-0.36	1.67e-8	Initial pursuit acceleration;
SARC	cis	rs4969178	0.965	rs56658017	chr17:76396164	G/A	cg20026190	chr17:76395443	PGS1	0.4	5.32	0.33	2.38e-7	HDL cholesterol levels;
SARC	cis	rs10483282	0.934	rs995631	chr14:24254591	A/G	cg02879798	chr14:24800305	ADCY4	-0.33	-5.07	-0.32	7.96e-7	Alcohol dependence;
SARC	trans	rs1973993	0.662	rs6593607	chr1:96968116	G/A	cg10631902	chr5:14652156	NA	-0.41	-6.55	-0.39	3.59e-10	Weight;
SARC	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg18252515	chr7:66147081	NA	0.58	6.26	0.38	1.79e-9	Aortic root size;
SARC	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg18876405	chr7:65276391	NA	0.48	5.81	0.36	2.06e-8	Calcium levels;
SARC	cis	rs7659604	0.540	rs7698889	chr4:122671324	G/T	cg19671926	chr4:122722719	EXOSC9	0.55	6.89	0.41	5.15e-11	Type 2 diabetes;
SARC	cis	rs2153535	0.623	rs6597338	chr6:8533508	A/C	cg07606381	chr6:8435919	SLC35B3	0.74	10.59	0.57	1.15e-21	Motion sickness;
SARC	cis	rs8028182	0.549	rs7402293	chr15:75636137	A/G	cg20655648	chr15:75932815	IMP3	-0.66	-7.55	-0.44	9.59e-13	Sudden cardiac arrest;
SARC	cis	rs6502050	0.761	rs13949	chr17:80059596	T/C	cg13939156	chr17:80058883	NA	0.42	6.72	0.4	1.36e-10	Life satisfaction;
SARC	cis	rs148387471	1	rs148387471	chr3:127057551	ATAG/A	cg25436886	chr3:127056972	NA	-0.4	-5.23	-0.32	3.77e-7	Interleukin-10 levels;Interleukin-13 levels;
SARC	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg02463440	chr8:22132932	PIWIL2	0.47	6.68	0.4	1.73e-10	Hypertriglyceridemia;
SARC	cis	rs2073300	0.609	rs6132610	chr20:23403987	C/T	cg12062639	chr20:23401060	NAPB	0.99	6.67	0.4	1.81e-10	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs9393692	0.967	rs6456712	chr6:26302573	A/C	cg13736514	chr6:26305472	NA	-0.7	-9.49	-0.53	2.83e-18	Educational attainment;
SARC	cis	rs854765	0.583	rs67253360	chr17:17828973	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.43	5.57	0.34	7.01e-8	Total body bone mineral density;
SARC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg01238044	chr22:24384105	GSTT1	-0.65	-8.23	-0.47	1.29e-14	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs8077889	0.719	rs2079006	chr17:41865745	C/G	cg26893861	chr17:41843967	DUSP3	0.99	15.81	0.72	9.41e-39	Triglycerides;
SARC	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.75	-7.65	-0.45	5.37e-13	Platelet count;
SARC	cis	rs6964587	0.967	rs2282969	chr7:91583772	T/C	cg17063962	chr7:91808500	NA	-0.95	-15.51	-0.71	9.51e-38	Breast cancer;
SARC	cis	rs73206853	0.841	rs56130410	chr12:110824112	C/T	cg08946844	chr12:110511112	NA	0.59	4.75	0.3	3.56e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	trans	rs877282	0.583	rs10904564	chr10:819459	C/G	cg22713356	chr15:30763199	NA	0.92	8.68	0.49	6.81e-16	Uric acid levels;
SARC	trans	rs561341	1.000	rs484175	chr17:30309041	G/A	cg20587970	chr11:113659929	NA	-1.33	-13.84	-0.67	3.43e-32	Hip circumference adjusted for BMI;
SARC	cis	rs7555523	0.778	rs2790052	chr1:165738463	G/C	cg19769164	chr1:165738335	TMCO1	0.62	5.18	0.32	4.72e-7	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	cis	rs4689388	0.679	rs1046316	chr4:6304087	A/G	cg00701064	chr4:6280414	WFS1	0.52	7.36	0.43	3.15e-12	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.46	5.77	0.35	2.54e-8	Gut microbiome composition (summer);
SARC	cis	rs916888	0.610	rs199530	chr17:44836653	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.54	-6.27	-0.38	1.73e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	trans	rs6076960	0.684	rs3909086	chr20:6251639	A/G	cg21095983	chr6:86352623	SYNCRIP	0.48	6.78	0.41	9.72e-11	Smooth-surface caries;
SARC	cis	rs995000	0.965	rs1570694	chr1:63103217	A/G	cg06896770	chr1:63153194	DOCK7	0.97	15.02	0.7	3.98e-36	Triglyceride levels;
SARC	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg07636037	chr3:49044803	WDR6	0.91	15.5	0.71	1.03e-37	Menarche (age at onset);
SARC	cis	rs950169	0.579	rs12912716	chr15:84664263	A/T	cg17507749	chr15:85114479	UBE2QP1	0.72	7.53	0.44	1.12e-12	Schizophrenia;
SARC	cis	rs1153858	1.000	rs10519021	chr15:45631795	G/A	cg03999130	chr15:45571217	NA	0.42	5.39	0.33	1.76e-7	Homoarginine levels;
SARC	cis	rs739401	0.611	rs12284275	chr11:3024384	T/C	cg08508325	chr11:3079039	CARS	-0.33	-7.97	-0.46	7.15e-14	Longevity;
SARC	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	11.31	0.6	6.28e-24	Alzheimer's disease;
SARC	cis	rs2624839	0.679	rs2624835	chr3:50209049	G/A	cg24110177	chr3:50126178	RBM5	-0.56	-6.98	-0.42	3.13e-11	Intelligence (multi-trait analysis);
SARC	cis	rs765787	0.530	rs11636440	chr15:45535982	C/T	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.81e-6	Uric acid levels;
SARC	cis	rs7824557	0.767	rs2164273	chr8:11168499	A/G	cg21775007	chr8:11205619	TDH	0.49	5.81	0.36	2.05e-8	Retinal vascular caliber;
SARC	cis	rs881375	0.678	rs7037195	chr9:123684000	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	6.55	0.39	3.57e-10	Rheumatoid arthritis;
SARC	cis	rs2635047	0.905	rs7504798	chr18:44610879	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	7.95	0.46	7.91e-14	Educational attainment;
SARC	cis	rs7674212	0.539	rs6850461	chr4:104120041	C/T	cg16532752	chr4:104119610	CENPE	-0.49	-6.08	-0.37	4.81e-9	Type 2 diabetes;
SARC	cis	rs1008375	0.932	rs12500912	chr4:17603318	C/T	cg27347728	chr4:17578864	LAP3	0.46	5.6	0.34	6.12e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6582630	0.502	rs11520276	chr12:38359216	C/T	cg26384229	chr12:38710491	ALG10B	0.87	12.69	0.64	2.17e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg11764359	chr7:65958608	NA	-0.79	-9.75	-0.54	4.53e-19	Aortic root size;
SARC	cis	rs4595586	0.525	rs2892450	chr12:39363678	G/A	cg13010199	chr12:38710504	ALG10B	0.4	4.76	0.3	3.33e-6	Morning vs. evening chronotype;
SARC	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	-0.39	-4.72	-0.3	4.15e-6	Tonsillectomy;
SARC	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.45	-5.7	-0.35	3.68e-8	Intelligence (multi-trait analysis);
SARC	cis	rs936229	0.668	rs67411922	chr15:75187612	A/G	cg14664628	chr15:75095509	CSK	-0.84	-10.15	-0.55	2.85e-20	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs6500602	0.627	rs934929	chr16:4587789	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.36	-5.96	-0.36	9.02e-9	Schizophrenia;
SARC	cis	rs7555523	0.830	rs6426936	chr1:165684707	C/T	cg19769164	chr1:165738335	TMCO1	-0.69	-4.79	-0.3	2.99e-6	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	cis	rs13256369	1.000	rs10088439	chr8:8576699	T/G	cg18904891	chr8:8559673	CLDN23	0.49	5.75	0.35	2.82e-8	Obesity-related traits;
SARC	cis	rs3126085	0.735	rs4845752	chr1:152226576	C/A	cg26876637	chr1:152193138	HRNR	0.45	5.34	0.33	2.24e-7	Atopic dermatitis;
SARC	cis	rs7412746	0.658	rs59988025	chr1:150940358	C/T	cg13175981	chr1:150552382	MCL1	-0.49	-5.84	-0.36	1.76e-8	Melanoma;
SARC	cis	rs9581857	0.556	rs1885991	chr13:28040470	G/A	cg22138327	chr13:27999177	GTF3A	0.55	5.65	0.35	4.56e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	cis	rs7582720	1.000	rs72934745	chr2:203744454	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.31	0.43	4.24e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs8072548	1	rs8072548	chr17:38164025	T/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.29	-5.2	-0.32	4.41e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
SARC	cis	rs13082711	0.911	rs13081368	chr3:27521998	G/T	cg02860705	chr3:27208620	NA	0.46	5.78	0.35	2.43e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg10902427	chr5:176944034	DDX41	0.49	6.65	0.4	2.04e-10	Chemerin levels;
SARC	cis	rs6456156	0.586	rs13210649	chr6:167473193	T/G	cg07741184	chr6:167504864	NA	0.35	6.87	0.41	5.87e-11	Primary biliary cholangitis;
SARC	cis	rs9462027	0.583	rs2744974	chr6:34579431	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.86	-0.36	1.54e-8	Systemic lupus erythematosus;
SARC	cis	rs367943	1.000	rs348954	chr5:112821716	A/G	cg12552261	chr5:112820674	MCC	-0.45	-5.19	-0.32	4.65e-7	Type 2 diabetes;
SARC	cis	rs6582630	0.555	rs11503799	chr12:38294578	G/A	cg13010199	chr12:38710504	ALG10B	-0.55	-6.73	-0.4	1.3e-10	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs4889855	0.505	rs8076974	chr17:78621817	G/A	cg17956530	chr17:78667699	RPTOR	-0.47	-5.46	-0.34	1.24e-7	Fractional excretion of uric acid;
SARC	cis	rs787274	1.000	rs10759584	chr9:115554736	T/G	cg13803584	chr9:115635662	SNX30	-0.77	-5.88	-0.36	1.38e-8	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	11.83	0.61	1.32e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs734999	0.588	rs6701238	chr1:2520500	G/A	cg00980319	chr1:2560884	MMEL1	-0.34	-4.81	-0.3	2.71e-6	Ulcerative colitis;
SARC	cis	rs3741151	0.773	rs73542960	chr11:73115946	T/C	cg17517138	chr11:73019481	ARHGEF17	0.9	6.7	0.4	1.59e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs193541	0.632	rs34486978	chr5:122312543	G/A	cg19412675	chr5:122181750	SNX24	-0.49	-6.24	-0.38	2.05e-9	Glucose homeostasis traits;
SARC	cis	rs4253772	0.591	rs6519993	chr22:46656479	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.64	7.09	0.42	1.61e-11	LDL cholesterol;Cholesterol, total;
SARC	cis	rs11168351	0.926	rs10875719	chr12:48411158	T/C	cg24011408	chr12:48396354	COL2A1	0.42	5.13	0.32	6.13e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg00149659	chr3:10157352	C3orf10	0.69	6.44	0.39	6.6e-10	Alzheimer's disease;
SARC	cis	rs60752752	0.852	rs3006477	chr1:153353412	C/T	cg26882115	chr1:153603048	S100A1;S100A13	-0.63	-4.8	-0.3	2.82e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs72627509	0.680	rs66790703	chr4:57773908	G/A	cg26694713	chr4:57773883	REST	0.63	6.42	0.39	7.6e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs12594515	1.000	rs57299255	chr15:45996532	C/A	cg14863074	chr15:45997064	NA	0.35	5.33	0.33	2.35e-7	Waist circumference;Weight;
SARC	cis	rs2295359	1.000	rs4655682	chr1:67610967	C/T	cg11235152	chr1:67600687	NA	0.47	7.23	0.43	6.94e-12	Psoriasis;
SARC	cis	rs4319547	1.000	rs6489157	chr12:123101673	C/G	cg05707623	chr12:122985044	ZCCHC8	0.57	6.96	0.41	3.39e-11	Body mass index;
SARC	cis	rs864537	0.618	rs2995089	chr1:167431193	G/A	cg09179987	chr1:167433047	CD247	0.42	6.82	0.41	7.64e-11	Celiac disease or Rheumatoid arthritis;Celiac disease;
SARC	cis	rs2359239	0.519	rs8007145	chr14:75185748	T/A	cg06637938	chr14:75390232	RPS6KL1	0.42	5.2	0.32	4.37e-7	Neuroticism (multi-trait analysis);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg24037270	chr10:52066867	SGMS1	0.49	7.07	0.42	1.82e-11	Thyroid stimulating hormone;
SARC	cis	rs2204008	0.774	rs11615665	chr12:38328162	T/A	cg26384229	chr12:38710491	ALG10B	0.86	12.27	0.63	5.08e-27	Bladder cancer;
SARC	cis	rs3784262	1.000	rs12908953	chr15:58277812	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.37	-5.51	-0.34	9.47e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	trans	rs11039798	0.588	rs11039855	chr11:48610091	A/G	cg15704280	chr7:45808275	SEPT13	0.6	6.35	0.38	1.12e-9	Axial length;
SARC	cis	rs703842	1.000	rs10877015	chr12:58167788	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.78	11.44	0.6	2.39e-24	Multiple sclerosis;
SARC	cis	rs11650776	1	rs11650776	chr17:37641402	G/A	cg15445000	chr17:37608096	MED1	0.41	4.8	0.3	2.85e-6	Lung function (FEV1);
SARC	cis	rs6912958	0.781	rs2273129	chr6:88182439	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.29	-4.97	-0.31	1.32e-6	Monocyte percentage of white cells;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg00095027	chr7:87563525	ADAM22	0.56	7.11	0.42	1.45e-11	Breast cancer;
SARC	cis	rs4911259	0.552	rs13042651	chr20:31467423	C/T	cg13636640	chr20:31349939	DNMT3B	-0.67	-9.22	-0.52	1.78e-17	Inflammatory bowel disease;
SARC	cis	rs6088580	0.524	rs6088552	chr20:33226491	A/G	cg07148914	chr20:33460835	GGT7	-0.41	-4.97	-0.31	1.31e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs4319547	0.695	rs1803290	chr12:122865029	T/C	cg05707623	chr12:122985044	ZCCHC8	0.56	6.42	0.39	7.61e-10	Body mass index;
SARC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg06873352	chr17:61820015	STRADA	0.53	6.85	0.41	6.67e-11	Prudent dietary pattern;
SARC	cis	rs7712401	0.601	rs1990890	chr5:122182970	C/T	cg19412675	chr5:122181750	SNX24	0.42	5.44	0.34	1.33e-7	Mean platelet volume;
SARC	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg20120463	chr17:44301886	NA	-0.33	-5.16	-0.32	5.29e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs5753618	0.583	rs8138596	chr22:31786961	T/A	cg02404636	chr22:31891804	SFI1	0.48	5.12	0.32	6.37e-7	Colorectal cancer;
SARC	cis	rs9400467	0.537	rs354533	chr6:111487104	T/G	cg15721981	chr6:111408429	SLC16A10	0.64	5.65	0.35	4.55e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs9399135	0.967	rs6910530	chr6:135332770	C/T	cg24558204	chr6:135376177	HBS1L	0.43	5.75	0.35	2.73e-8	Red blood cell count;
SARC	cis	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg05084668	chr3:125655381	ALG1L	-0.48	-4.95	-0.31	1.45e-6	Blood pressure (smoking interaction);
SARC	cis	rs67460515	0.500	rs9812507	chr3:160723393	G/A	cg17135325	chr3:160939158	NMD3	0.51	6.28	0.38	1.64e-9	Parkinson's disease;
SARC	cis	rs933688	1.000	rs2059208	chr5:90732065	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.0	13.25	0.66	3.08e-30	Smoking behavior;
SARC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg07308232	chr7:1071921	C7orf50	-0.44	-5.09	-0.32	7.31e-7	Longevity;Endometriosis;
SARC	cis	rs13191362	1.000	rs34177053	chr6:163007772	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.56	5.41	0.33	1.53e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg17158414	chr2:27665306	KRTCAP3	-0.41	-6.76	-0.4	1.1e-10	Total body bone mineral density;
SARC	cis	rs9303401	0.659	rs62083525	chr17:56658088	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	11.65	0.61	5.15e-25	Cognitive test performance;
SARC	cis	rs41271473	1.000	rs17352654	chr1:228878193	T/C	cg16512390	chr1:228756714	NA	0.48	4.79	0.3	3.02e-6	Chronic lymphocytic leukemia;
SARC	cis	rs2070488	0.775	rs9838614	chr3:38537671	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.78	-11.38	-0.6	3.67e-24	Electrocardiographic conduction measures;
SARC	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg18252515	chr7:66147081	NA	0.56	5.81	0.36	2.04e-8	Aortic root size;
SARC	cis	rs2153535	0.580	rs7748455	chr6:8453625	C/T	cg21535247	chr6:8435926	SLC35B3	0.54	6.83	0.41	7.19e-11	Motion sickness;
SARC	cis	rs7520050	0.966	rs1768816	chr1:46528599	T/C	cg24296786	chr1:45957014	TESK2	0.38	4.82	0.3	2.58e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg24110177	chr3:50126178	RBM5	0.53	7.06	0.42	1.92e-11	Intelligence (multi-trait analysis);
SARC	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg18364779	chr6:26104403	HIST1H4C	0.41	4.92	0.31	1.66e-6	Intelligence (multi-trait analysis);
SARC	cis	rs910316	0.737	rs175071	chr14:75498177	A/G	cg08847533	chr14:75593920	NEK9	-0.85	-12.8	-0.64	9.47e-29	Height;
SARC	cis	rs9916302	0.904	rs587343	chr17:37440603	C/T	cg00129232	chr17:37814104	STARD3	0.58	7.3	0.43	4.56e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs240764	0.645	rs240111	chr6:101059499	C/A	cg09795085	chr6:101329169	ASCC3	0.42	5.19	0.32	4.61e-7	Neuroticism;
SARC	cis	rs7914558	0.966	rs56946876	chr10:104653545	T/C	cg15744005	chr10:104629667	AS3MT	-0.27	-4.89	-0.3	1.91e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs2370759	1.000	rs76998371	chr10:32631785	A/G	cg18270830	chr10:32634957	EPC1	0.68	6.04	0.37	5.98e-9	Sexual dysfunction (female);
SARC	cis	rs7666738	0.830	rs13133619	chr4:99067312	C/G	cg05340658	chr4:99064831	C4orf37	-0.65	-8.83	-0.5	2.61e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs11581859	0.613	rs1482138	chr1:99206788	G/A	cg20286094	chr1:99190917	SNX7	-0.41	-4.81	-0.3	2.75e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs208520	0.690	rs12192851	chr6:66705862	G/C	cg07460842	chr6:66804631	NA	1.06	14.43	0.69	3.63e-34	Exhaled nitric oxide output;
SARC	cis	rs8141529	0.732	rs6005872	chr22:29172898	T/G	cg15103426	chr22:29168792	CCDC117	0.7	9.41	0.52	5.04e-18	Lymphocyte counts;
SARC	cis	rs9457247	0.967	rs2015864	chr6:167381476	T/C	cg23791538	chr6:167370224	RNASET2	0.63	8.74	0.5	4.81e-16	Crohn's disease;
SARC	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.73	8.98	0.51	9.64e-17	Height;
SARC	cis	rs7904368	0.951	rs7074647	chr10:16855455	T/C	cg23933602	chr10:16859644	RSU1	0.59	6.38	0.39	9.61e-10	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg13206674	chr6:150067644	NUP43	0.48	6.36	0.38	1.07e-9	Lung cancer;
SARC	cis	rs2466076	0.610	rs2466070	chr8:32434617	C/T	cg14488905	chr8:32406789	NRG1	-0.42	-5.77	-0.35	2.47e-8	Thyroid cancer;
SARC	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg16680214	chr1:154839983	KCNN3	-0.36	-5.72	-0.35	3.2e-8	Prostate cancer;
SARC	trans	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.1	-0.42	1.51e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs9398803	0.835	rs1602278	chr6:126838605	A/C	cg19875578	chr6:126661172	C6orf173	0.6	8.02	0.46	5.25e-14	Male-pattern baldness;
SARC	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg26850624	chr5:429559	AHRR	-0.31	-4.77	-0.3	3.21e-6	Cystic fibrosis severity;
SARC	cis	rs9616064	0.506	rs11705341	chr22:47066294	T/C	cg05621596	chr22:47072043	GRAMD4	-0.6	-8.52	-0.49	1.97e-15	Urate levels in obese individuals;
SARC	cis	rs9517320	0.515	rs61969456	chr13:99174799	C/G	cg07423050	chr13:99094983	FARP1	-0.41	-5.42	-0.33	1.47e-7	Longevity;
SARC	cis	rs17641971	0.599	rs818555	chr8:49999211	A/G	cg00325661	chr8:49890786	NA	-0.46	-6.03	-0.37	6.31e-9	Blood metabolite levels;
SARC	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg11890956	chr21:40555474	PSMG1	1.16	19.51	0.79	6.63e-51	Cognitive function;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg16977270	chr6:16306857	ATXN1	0.52	6.43	0.39	7.26e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs981844	0.885	rs72731673	chr4:154667446	A/G	cg14289246	chr4:154710475	SFRP2	0.57	6.43	0.39	7.08e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs453301	0.686	rs28482034	chr8:8869664	G/A	cg11995313	chr8:8860691	ERI1	0.48	6.08	0.37	4.77e-9	Joint mobility (Beighton score);
SARC	cis	rs17125944	0.686	rs9646151	chr14:53354464	C/G	cg00686598	chr14:53173677	PSMC6	-0.65	-5.06	-0.31	8.62e-7	Alzheimer's disease (late onset);
SARC	cis	rs7845219	0.539	rs13271644	chr8:95853948	A/G	cg16049864	chr8:95962084	TP53INP1	-0.36	-5.96	-0.36	9.35e-9	Type 2 diabetes;
SARC	cis	rs995000	0.899	rs1168099	chr1:63122859	C/A	cg06896770	chr1:63153194	DOCK7	-0.89	-13.52	-0.66	4.03e-31	Triglyceride levels;
SARC	cis	rs7772486	0.686	rs9390349	chr6:146054430	T/G	cg23711669	chr6:146136114	FBXO30	-0.82	-13.24	-0.66	3.22e-30	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.62	7.54	0.44	1.07e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg24209194	chr3:40518798	ZNF619	0.64	7.77	0.45	2.56e-13	Renal cell carcinoma;
SARC	cis	rs1448094	0.845	rs7132262	chr12:86346304	C/T	cg02569458	chr12:86230093	RASSF9	0.42	6.04	0.37	6.16e-9	Major depressive disorder;
SARC	cis	rs7927771	0.832	rs10838699	chr11:47386073	T/C	cg20307385	chr11:47447363	PSMC3	0.56	7.09	0.42	1.6e-11	Subjective well-being;
SARC	cis	rs11792861	0.816	rs3763643	chr9:111695607	T/C	cg13535736	chr9:111863775	C9orf5	-0.39	-4.87	-0.3	2.01e-6	Menarche (age at onset);
SARC	cis	rs7568458	0.704	rs10176176	chr2:85762048	A/T	cg17127132	chr2:85788382	GGCX	0.46	6.16	0.37	3.18e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg26878734	chr2:176793622	KIAA1715	-0.54	-6.7	-0.4	1.54e-10	Alcohol dependence;
SARC	cis	rs896854	0.530	rs10956934	chr8:95992473	C/A	cg09323728	chr8:95962352	TP53INP1	-0.29	-4.8	-0.3	2.78e-6	Type 2 diabetes;
SARC	cis	rs2228479	0.717	rs9282682	chr16:89805794	A/G	cg06558623	chr16:89946397	TCF25	0.79	6.25	0.38	1.93e-9	Skin colour saturation;
SARC	cis	rs74181299	0.819	rs2252867	chr2:65296280	T/C	cg20592124	chr2:65290738	CEP68	0.52	7.7	0.45	3.8e-13	Pulse pressure;
SARC	cis	rs113835537	0.529	rs4542420	chr11:66277610	G/C	cg24851651	chr11:66362959	CCS	0.37	4.73	0.3	3.91e-6	Airway imaging phenotypes;
SARC	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg23758822	chr17:41437982	NA	0.89	11.37	0.6	3.91e-24	Menopause (age at onset);
SARC	cis	rs9309473	1.000	rs11899902	chr2:73631564	G/A	cg20560298	chr2:73613845	ALMS1	-0.52	-6.26	-0.38	1.84e-9	Metabolite levels;
SARC	trans	rs1814175	0.935	rs11040463	chr11:49685574	C/T	cg15704280	chr7:45808275	SEPT13	-0.92	-16.53	-0.73	4e-41	Height;
SARC	cis	rs12421382	0.614	rs12418827	chr11:109390649	G/C	cg27471124	chr11:109292789	C11orf87	0.36	5.12	0.32	6.52e-7	Schizophrenia;
SARC	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg11764359	chr7:65958608	NA	-0.72	-8.38	-0.48	5.18e-15	Aortic root size;
SARC	cis	rs911555	0.755	rs35233301	chr14:103885291	A/G	cg12935359	chr14:103987150	CKB	0.4	5.43	0.34	1.4e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9467711	0.591	rs6940007	chr6:25931957	A/C	cg21479132	chr6:26055353	NA	0.81	5.05	0.31	8.8e-7	Autism spectrum disorder or schizophrenia;
SARC	cis	rs12042938	0.600	rs823165	chr1:231769446	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.58	8.19	0.47	1.69e-14	Neuranatomic and neurocognitive phenotypes;
SARC	cis	rs6500602	0.634	rs2270365	chr16:4526758	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.33	5.56	0.34	7.38e-8	Schizophrenia;
SARC	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg18225595	chr11:63971243	STIP1	0.45	5.35	0.33	2.12e-7	Mean platelet volume;
SARC	cis	rs10932679	1.000	rs10932679	chr2:217652591	A/T	cg05032264	chr2:217675019	NA	0.56	5.4	0.33	1.67e-7	Pulse pressure;
SARC	cis	rs546131	0.928	rs558967	chr11:34827168	T/A	cg11058730	chr11:34937778	PDHX;APIP	0.47	5.83	0.36	1.86e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg13628971	chr7:2884303	GNA12	0.67	8.07	0.47	3.61e-14	Height;
SARC	cis	rs11231693	0.655	rs2845594	chr11:63864571	T/C	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.69	-5.08	-0.32	7.72e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
SARC	cis	rs1008375	0.966	rs3796813	chr4:17591648	A/G	cg16339924	chr4:17578868	LAP3	0.69	9.03	0.51	6.63e-17	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs8031584	0.958	rs3512	chr15:31235005	G/C	cg19680485	chr15:31195859	MTMR15	-0.52	-5.96	-0.36	9.18e-9	Huntington's disease progression;
SARC	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg18305652	chr10:134549665	INPP5A	0.33	5.02	0.31	1.01e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs7551222	0.789	rs4951408	chr1:204558984	C/G	cg20240347	chr1:204465584	NA	-0.28	-5.16	-0.32	5.41e-7	Schizophrenia;
SARC	cis	rs7429990	0.930	rs11130152	chr3:48056409	T/C	cg11946769	chr3:48343235	NME6	-0.46	-5.25	-0.33	3.49e-7	Educational attainment (years of education);
SARC	cis	rs11758351	1.000	rs78012445	chr6:26195080	G/C	cg23601095	chr6:26197514	HIST1H3D	0.63	5.47	0.34	1.15e-7	Gout;Renal underexcretion gout;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg21235903	chr8:38864411	ADAM9	0.51	6.93	0.41	4.03e-11	Thyroid stimulating hormone;
SARC	cis	rs2594989	0.943	rs77630528	chr3:11314041	A/G	cg00170343	chr3:11313890	ATG7	0.61	5.64	0.35	4.8e-8	Circulating chemerin levels;
SARC	cis	rs4144743	1.000	rs66738981	chr17:45325538	T/A	cg18085866	chr17:45331354	ITGB3	-0.72	-7.34	-0.43	3.63e-12	Body mass index;
SARC	cis	rs1003719	0.680	rs1034357	chr21:38571482	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-8.88	-0.5	1.88e-16	Eye color traits;
SARC	cis	rs6582630	0.500	rs35251810	chr12:38577666	T/C	cg26384229	chr12:38710491	ALG10B	-0.6	-7.62	-0.45	6.26e-13	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2153535	0.580	rs9505457	chr6:8479142	C/T	cg21535247	chr6:8435926	SLC35B3	0.56	7.03	0.42	2.23e-11	Motion sickness;
SARC	cis	rs2153535	0.580	rs1932275	chr6:8442333	T/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.03	0.59	4.86e-23	Motion sickness;
SARC	cis	rs1008375	0.966	rs10489036	chr4:17697687	A/G	cg27347728	chr4:17578864	LAP3	0.49	5.97	0.36	8.81e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs3942852	0.915	rs905477	chr11:48148606	T/C	cg15704280	chr7:45808275	SEPT13	-0.57	-6.5	-0.39	4.83e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs10911251	0.546	rs1547715	chr1:183113952	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	9.86	0.54	2.11e-19	Colorectal cancer;
SARC	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	12.05	0.62	2.53e-26	Chronic sinus infection;
SARC	cis	rs72781680	0.950	rs56128748	chr2:24126809	T/G	cg08917208	chr2:24149416	ATAD2B	0.82	7.93	0.46	9.04e-14	Lymphocyte counts;
SARC	cis	rs9430161	0.579	rs10864486	chr1:11040979	A/G	cg02454025	chr1:11042201	C1orf127	0.85	12.46	0.63	1.19e-27	Ewing sarcoma;
SARC	trans	rs71327718	1	rs71327718	chr3:125592857	C/G	cg07211511	chr3:129823064	LOC729375	-0.78	-7.24	-0.43	6.65e-12	Metabolite levels (HVA/5-HIAA ratio);
SARC	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.62	7.39	0.44	2.62e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs35110281	0.667	rs914197	chr21:45117439	A/G	cg01579765	chr21:45077557	HSF2BP	-0.35	-5.62	-0.35	5.35e-8	Mean corpuscular volume;
SARC	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.97	-16.2	-0.73	4.9e-40	Chronic sinus infection;
SARC	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg06420487	chr17:61919686	SMARCD2	0.5	5.85	0.36	1.67e-8	Height;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg19301934	chr1:23504295	NA	0.5	6.63	0.4	2.37e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs67311347	0.824	rs59922539	chr3:40337110	G/A	cg09455208	chr3:40491958	NA	0.38	5.92	0.36	1.17e-8	Renal cell carcinoma;
SARC	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.59	-7.75	-0.45	2.87e-13	Mean platelet volume;
SARC	cis	rs11997175	0.603	rs716584	chr8:33779748	C/G	ch.8.33884649F	chr8:33765107	NA	0.44	5.61	0.34	5.75e-8	Body mass index;
SARC	cis	rs425277	0.959	rs77665022	chr1:2065958	C/T	cg24578937	chr1:2090814	PRKCZ	0.32	5.97	0.36	8.96e-9	Height;
SARC	cis	rs11997175	0.646	rs10954936	chr8:33686165	C/T	ch.8.33884649F	chr8:33765107	NA	0.62	8.36	0.48	5.9e-15	Body mass index;
SARC	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg02034447	chr16:89574710	SPG7	0.4	5.3	0.33	2.63e-7	Multiple myeloma (IgH translocation);
SARC	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg03185022	chr7:2884158	GNA12	0.46	5.1	0.32	6.93e-7	Height;
SARC	cis	rs9894429	0.646	rs7405870	chr17:79617284	G/A	cg18240062	chr17:79603768	NPLOC4	0.59	7.19	0.43	8.72e-12	Eye color traits;
SARC	cis	rs12048904	0.964	rs8888	chr1:101338324	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.39	4.96	0.31	1.38e-6	Multiple sclerosis;
SARC	cis	rs4555082	1.000	rs4555082	chr14:105758964	C/T	cg10792982	chr14:105748885	BRF1	0.52	7.71	0.45	3.67e-13	Mean platelet volume;Platelet distribution width;
SARC	cis	rs7818345	0.904	rs6997164	chr8:19287856	G/T	cg11303988	chr8:19266685	CSGALNACT1	0.41	5.39	0.33	1.76e-7	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs12472274	1.000	rs12472274	chr2:239095422	G/A	cg17459225	chr2:239074497	NA	0.63	7.58	0.44	8.32e-13	Phospholipid levels (plasma);
SARC	cis	rs9815354	1.000	rs9846634	chr3:41894049	G/A	cg03022575	chr3:42003672	ULK4	0.67	5.73	0.35	3.13e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs72781680	1.000	rs72796351	chr2:24158425	T/C	cg06627628	chr2:24431161	ITSN2	-0.69	-6.48	-0.39	5.36e-10	Lymphocyte counts;
SARC	cis	rs9715521	0.868	rs6856620	chr4:59820960	A/G	cg11281224	chr4:60001000	NA	-0.37	-4.72	-0.3	4.05e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs1707322	0.721	rs12091503	chr1:46107868	T/C	cg03146154	chr1:46216737	IPP	0.52	6.18	0.38	2.82e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg04772025	chr11:68637568	NA	0.5	6.46	0.39	5.93e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9875589	0.628	rs62234602	chr3:14002170	A/G	cg19554555	chr3:13937349	NA	0.44	5.41	0.33	1.53e-7	Ovarian reserve;
SARC	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg11890956	chr21:40555474	PSMG1	-0.68	-9.08	-0.51	4.76e-17	Menarche (age at onset);
SARC	cis	rs11874712	1.000	rs28757346	chr18:43696540	C/T	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.54	6.51	0.39	4.61e-10	Migraine - clinic-based;
SARC	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg22618164	chr12:122356400	WDR66	0.4	6.02	0.37	6.71e-9	Mean corpuscular volume;
SARC	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg06212747	chr3:49208901	KLHDC8B	0.65	8.64	0.49	9.19e-16	Parkinson's disease;
SARC	cis	rs11122272	0.735	rs2749707	chr1:231527316	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.13	-0.55	3.3e-20	Hemoglobin concentration;
SARC	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg01475735	chr3:40494733	NA	0.49	5.77	0.35	2.53e-8	Renal cell carcinoma;
SARC	cis	rs2120019	0.938	rs8036573	chr15:75308690	C/T	cg09165964	chr15:75287851	SCAMP5	-0.95	-13.64	-0.67	1.55e-31	Blood trace element (Zn levels);
SARC	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg16145915	chr7:1198662	ZFAND2A	-0.38	-6.13	-0.37	3.74e-9	Longevity;Endometriosis;
SARC	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg02788857	chr8:22132959	PIWIL2	0.36	5.12	0.32	6.41e-7	Hypertriglyceridemia;
SARC	cis	rs7769051	0.522	rs62424539	chr6:133173272	C/T	cg07930552	chr6:133119739	C6orf192	0.84	6.16	0.37	3.24e-9	Type 2 diabetes nephropathy;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg14930269	chr3:49142045	QARS	0.51	6.94	0.41	3.76e-11	Thyroid stimulating hormone;
SARC	cis	rs7084402	0.967	rs1649074	chr10:60295342	T/G	cg07615347	chr10:60278583	BICC1	0.61	8.69	0.49	6.36e-16	Refractive error;
SARC	cis	rs874628	0.754	rs8112975	chr19:18340910	A/G	cg13670957	chr19:18329801	PDE4C	0.48	5.53	0.34	8.75e-8	Multiple sclerosis;
SARC	cis	rs9303401	0.661	rs9902820	chr17:56637545	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.18	0.32	4.76e-7	Cognitive test performance;
SARC	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg11987759	chr7:65425863	GUSB	0.44	5.91	0.36	1.18e-8	Aortic root size;
SARC	cis	rs240764	0.817	rs239245	chr6:101090377	C/A	cg09795085	chr6:101329169	ASCC3	0.45	5.77	0.35	2.49e-8	Neuroticism;
SARC	cis	rs561341	0.739	rs7213369	chr17:30211878	G/A	cg12000587	chr17:30186630	C17orf79	0.38	4.99	0.31	1.2e-6	Hip circumference adjusted for BMI;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg27169503	chr6:24646545	KIAA0319	-0.7	-6.27	-0.38	1.74e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg08222618	chr4:941054	TMEM175	0.53	8.11	0.47	2.8e-14	Sjögren's syndrome;
SARC	cis	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg12463550	chr7:65579703	CRCP	0.67	4.97	0.31	1.29e-6	Gout;
SARC	cis	rs2380220	1.000	rs2380222	chr6:95975395	C/T	cg23517279	chr6:96025343	MANEA	0.55	5.65	0.35	4.55e-8	Behavioural disinhibition (generation interaction);
SARC	cis	rs1008375	0.931	rs10019482	chr4:17578079	G/A	cg02297831	chr4:17616191	MED28	0.49	6.22	0.38	2.27e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7647973	0.925	rs6769821	chr3:49244657	G/A	cg07636037	chr3:49044803	WDR6	0.76	7.86	0.46	1.39e-13	Menarche (age at onset);
SARC	cis	rs11690462	0.963	rs7601607	chr2:26573452	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.37	-4.74	-0.3	3.74e-6	Coronary artery disease;
SARC	cis	rs4713675	0.584	rs509539	chr6:33708190	A/C	cg15676125	chr6:33679581	C6orf125	-0.56	-6.9	-0.41	4.89e-11	Plateletcrit;
SARC	cis	rs28655083	0.956	rs7184167	chr16:77069451	T/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.48	-6.95	-0.41	3.69e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.53	-6.0	-0.37	7.34e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs9948	1.000	rs9973492	chr2:97498481	T/A	cg01990225	chr2:97406019	LMAN2L	-0.64	-5.08	-0.32	7.62e-7	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs1008375	0.931	rs10008337	chr4:17593849	G/C	cg27347728	chr4:17578864	LAP3	0.47	5.76	0.35	2.71e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2777491	0.915	rs28578057	chr15:41621921	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.74	-10.89	-0.58	1.32e-22	Ulcerative colitis;
SARC	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg19077165	chr18:44547161	KATNAL2	-0.52	-7.15	-0.42	1.08e-11	Personality dimensions;
SARC	cis	rs35110281	0.666	rs2838348	chr21:45107285	C/G	cg01579765	chr21:45077557	HSF2BP	0.38	6.15	0.37	3.3e-9	Mean corpuscular volume;
SARC	cis	rs7666738	0.830	rs6829567	chr4:99047340	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs763121	0.815	rs12168758	chr22:38997269	C/G	cg21395723	chr22:39101663	GTPBP1	0.52	6.07	0.37	5.21e-9	Menopause (age at onset);
SARC	cis	rs644799	0.965	rs565771	chr11:95644179	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.88	12.94	0.65	3.13e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7103648	1.000	rs2293579	chr11:47440758	G/A	cg20307385	chr11:47447363	PSMC3	0.88	14.56	0.69	1.35e-34	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs7252981	0.632	rs11878202	chr19:19744079	T/C	cg03709012	chr19:19516395	GATAD2A	-0.59	-6.38	-0.39	9.55e-10	Perceived unattractiveness to mosquitoes;
SARC	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg24642844	chr7:1081250	C7orf50	-0.51	-5.73	-0.35	3.11e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs7712401	0.601	rs152039	chr5:122220665	C/T	cg19412675	chr5:122181750	SNX24	0.43	5.48	0.34	1.11e-7	Mean platelet volume;
SARC	cis	rs1971762	0.527	rs7300936	chr12:54030586	C/T	cg06632207	chr12:54070931	ATP5G2	0.59	7.97	0.46	6.85e-14	Height;
SARC	cis	rs765787	0.530	rs4775831	chr15:45534722	A/C	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.51e-10	Uric acid levels;
SARC	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg21782813	chr7:2030301	MAD1L1	0.31	4.73	0.3	3.84e-6	Schizophrenia;
SARC	cis	rs10791323	0.536	rs1944731	chr11:133726067	G/A	cg14349672	chr11:133703707	NA	-0.35	-5.17	-0.32	5.01e-7	Childhood ear infection;
SARC	cis	rs9344	0.869	rs2930975	chr11:69451837	C/G	cg26123414	chr11:69490316	ORAOV1	0.36	4.85	0.3	2.29e-6	Immunoglobulin light chain (AL) amyloidosis (kidney involvement);Immunoglobulin light chain (AL) amyloidosis (serum Ig light chain only lambda/kappa based profile);Immunoglobulin light chain (AL) amyloidosis;Immunoglobulin light chain (AL) amyloidosis (heart involvement);Immunoglobulin light chain (AL) amyloidosis (serum Ig light chain only lambda based profile);Immunoglobulin light chain (AL) amyloidosis (serum Ig lambda profile);
SARC	cis	rs6088580	0.634	rs6120642	chr20:33012531	A/G	cg24642439	chr20:33292090	TP53INP2	0.67	8.57	0.49	1.48e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs4938330	0.608	rs2239012	chr11:117088362	A/G	cg01368799	chr11:117014884	PAFAH1B2	-0.52	-5.45	-0.34	1.31e-7	Blood protein levels;
SARC	cis	rs9388451	0.772	rs1268064	chr6:126042578	G/A	cg05901451	chr6:126070800	HEY2	0.61	8.35	0.48	5.92e-15	Brugada syndrome;
SARC	cis	rs17741873	0.836	rs17630952	chr10:75601414	T/A	cg07699608	chr10:75541558	CHCHD1	0.5	4.96	0.31	1.36e-6	Paclitaxel disposition in epithelial ovarian cancer;
SARC	cis	rs1371867	0.875	rs962451	chr8:101331010	C/T	cg11906718	chr8:101322791	RNF19A	0.7	9.03	0.51	6.61e-17	Atrioventricular conduction;
SARC	cis	rs17376456	0.825	rs10054790	chr5:93272520	A/G	cg25358565	chr5:93447407	FAM172A	1.3	14.13	0.68	3.7e-33	Diabetic retinopathy;
SARC	cis	rs12600053	0.687	rs8058664	chr16:84849100	A/G	cg09249803	chr16:84846936	NA	0.33	4.89	0.3	1.91e-6	Asthma (childhood onset);
SARC	cis	rs11677370	0.561	rs10084170	chr2:3820204	G/C	cg17052675	chr2:3827356	NA	-0.53	-6.39	-0.39	9.09e-10	Type 2 diabetes;
SARC	cis	rs9916302	0.904	rs7223331	chr17:37482930	A/G	cg20243544	chr17:37824526	PNMT	-0.53	-6.45	-0.39	6.43e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs12579753	1.000	rs7956826	chr12:82173365	A/G	cg07988820	chr12:82153109	PPFIA2	-0.59	-6.91	-0.41	4.7e-11	Resting heart rate;
SARC	cis	rs3762637	0.943	rs9872708	chr3:122242807	C/G	cg24169773	chr3:122142474	KPNA1	-0.58	-5.89	-0.36	1.34e-8	LDL cholesterol levels;
SARC	cis	rs1144333	0.655	rs1146602	chr1:76239309	A/G	cg03433033	chr1:76189801	ACADM	-0.6	-4.86	-0.3	2.13e-6	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs9322193	0.566	rs4869768	chr6:150245203	A/G	cg01145232	chr6:150245071	RAET1G	-0.42	-4.8	-0.3	2.82e-6	Lung cancer;
SARC	cis	rs7824557	0.602	rs10096194	chr8:11207672	C/G	cg21775007	chr8:11205619	TDH	0.68	8.79	0.5	3.32e-16	Retinal vascular caliber;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg13921956	chr2:12858555	TRIB2	0.51	6.93	0.41	4.06e-11	Chemerin levels;
SARC	cis	rs705471	0.932	rs1106278	chr10:3677358	A/G	cg14308648	chr10:3568949	NA	0.56	7.07	0.42	1.77e-11	Capecitabine sensitivity;
SARC	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg16680214	chr1:154839983	KCNN3	-0.36	-5.61	-0.35	5.64e-8	Prostate cancer;
SARC	cis	rs7520050	0.966	rs1768803	chr1:46546208	T/C	cg24296786	chr1:45957014	TESK2	0.38	4.82	0.3	2.56e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs360798	0.512	rs11893131	chr2:63079528	C/A	cg17519650	chr2:63277830	OTX1	0.38	4.83	0.3	2.45e-6	Coronary artery disease;
SARC	cis	rs2073300	0.609	rs6137913	chr20:23357725	C/T	cg12062639	chr20:23401060	NAPB	0.8	5.99	0.37	7.7e-9	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg18252515	chr7:66147081	NA	0.47	5.08	0.32	7.81e-7	Aortic root size;
SARC	cis	rs9896933	0.887	rs78483419	chr17:80870884	T/C	cg15664640	chr17:80829946	TBCD	-0.47	-5.62	-0.35	5.39e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
SARC	cis	rs7927592	0.913	rs7123564	chr11:68362164	C/T	cg01657329	chr11:68192670	LRP5	-0.43	-5.07	-0.32	8.14e-7	Total body bone mineral density;
SARC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.28	0.8	2.29e-53	Prudent dietary pattern;
SARC	cis	rs4466137	0.553	rs16898	chr5:82986149	T/C	cg16102102	chr5:83017553	HAPLN1	-0.61	-8.36	-0.48	5.64e-15	Prostate cancer;
SARC	cis	rs7937682	0.737	rs679032	chr11:111423286	G/T	cg09085632	chr11:111637200	PPP2R1B	-0.68	-9.78	-0.54	3.87e-19	Primary sclerosing cholangitis;
SARC	cis	rs7223966	0.921	rs11655493	chr17:61733052	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.48	-5.0	-0.31	1.13e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs11122272	0.735	rs2790881	chr1:231534181	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.28	-0.56	1.11e-20	Hemoglobin concentration;
SARC	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg27170947	chr2:26402098	FAM59B	0.37	4.8	0.3	2.79e-6	Gut microbiome composition (summer);
SARC	cis	rs10838687	0.800	rs10838689	chr11:47334524	C/T	cg03393444	chr11:47293049	MADD	0.33	4.84	0.3	2.4e-6	Proinsulin levels;
SARC	cis	rs10465746	0.780	rs7550413	chr1:84423891	T/A	cg10977910	chr1:84465055	TTLL7	0.46	5.65	0.35	4.57e-8	Obesity-related traits;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg05001532	chr1:245027769	HNRNPU	-0.53	-6.89	-0.41	5.03e-11	Schizophrenia;
SARC	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg24886843	chr6:74126975	DDX43	0.58	8.4	0.48	4.4e-15	Thyroid stimulating hormone;
SARC	cis	rs11098499	0.909	rs6842762	chr4:120398236	A/T	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	cis	rs941873	0.803	rs2105461	chr10:81101679	A/G	cg09469691	chr10:81107165	PPIF	-0.64	-9.4	-0.52	5.49e-18	Height;
SARC	cis	rs2425143	1.000	rs2425093	chr20:34306875	C/T	cg01084648	chr20:34329383	RBM39	0.56	4.93	0.31	1.57e-6	Blood protein levels;
SARC	cis	rs7937682	0.889	rs3017767	chr11:111508098	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.93	-15.22	-0.71	8.48e-37	Primary sclerosing cholangitis;
SARC	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg11890956	chr21:40555474	PSMG1	1.17	19.44	0.79	1.14e-50	Cognitive function;
SARC	cis	rs6964587	0.967	rs12535601	chr7:91718346	A/G	cg17063962	chr7:91808500	NA	0.96	16.16	0.73	6.76e-40	Breast cancer;
SARC	cis	rs35160687	0.871	rs11127028	chr2:86537509	A/T	cg10973622	chr2:86423274	IMMT	0.37	4.82	0.3	2.56e-6	Night sleep phenotypes;
SARC	cis	rs2980439	0.525	rs1850511	chr8:8170329	T/A	cg15556689	chr8:8085844	FLJ10661	0.44	5.5	0.34	9.92e-8	Neuroticism;
SARC	cis	rs3733589	1.000	rs10516195	chr4:10001833	G/T	cg16430538	chr4:10459836	ZNF518B	0.63	4.73	0.3	3.84e-6	Renal overload gout;
SARC	cis	rs763121	0.925	rs4821815	chr22:39105707	G/A	cg06022373	chr22:39101656	GTPBP1	0.82	11.06	0.59	3.94e-23	Menopause (age at onset);
SARC	cis	rs4423214	1.000	rs12792306	chr11:71166992	T/C	cg24826892	chr11:71159390	DHCR7	0.48	6.12	0.37	3.92e-9	Vitamin D levels;
SARC	trans	rs634534	0.561	rs655744	chr11:65776585	G/T	cg17712092	chr4:129076599	LARP1B	-0.7	-9.57	-0.53	1.68e-18	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs2439831	1.000	rs2439841	chr15:43734749	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.77	7.67	0.45	4.62e-13	Lung cancer in ever smokers;
SARC	cis	rs7592578	0.882	rs16832765	chr2:191468762	T/C	cg27211696	chr2:191398769	TMEM194B	-0.5	-5.22	-0.32	4.02e-7	Diastolic blood pressure;
SARC	cis	rs6424115	0.965	rs2502979	chr1:24149315	C/A	cg15997130	chr1:24165203	NA	0.46	6.21	0.38	2.43e-9	Immature fraction of reticulocytes;
SARC	trans	rs79976124	0.837	rs12194087	chr6:66644399	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.67	7.61	0.45	6.85e-13	Type 2 diabetes;
SARC	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg18404041	chr3:52824283	ITIH1	-0.43	-6.48	-0.39	5.52e-10	Bipolar disorder;
SARC	cis	rs73635312	0.850	rs77461246	chr10:8942672	A/T	cg24467326	chr10:9646929	NA	0.56	4.88	0.3	1.95e-6	Basal cell carcinoma;
SARC	cis	rs9914988	0.943	rs9915673	chr17:27132893	G/C	cg20469991	chr17:27169893	C17orf63	-0.5	-5.25	-0.33	3.36e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs13256369	0.951	rs10503394	chr8:8565775	A/G	cg17143192	chr8:8559678	CLDN23	0.52	5.81	0.36	2.04e-8	Obesity-related traits;
SARC	trans	rs7980799	0.618	rs1482983	chr12:33690326	A/C	cg26384229	chr12:38710491	ALG10B	0.66	7.87	0.46	1.36e-13	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs4253772	0.550	rs6007823	chr22:46706249	C/T	cg24881330	chr22:46731750	TRMU	0.63	5.44	0.34	1.35e-7	LDL cholesterol;Cholesterol, total;
SARC	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg18370025	chr7:2749541	AMZ1	-0.3	-4.77	-0.3	3.21e-6	Height;
SARC	cis	rs796364	0.512	rs1653290	chr2:201078165	A/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.56	4.94	0.31	1.51e-6	Schizophrenia;
SARC	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg25894440	chr7:65020034	NA	-0.71	-5.4	-0.33	1.62e-7	Diabetic kidney disease;
SARC	cis	rs10791323	0.559	rs10750548	chr11:133729469	A/G	cg14349672	chr11:133703707	NA	-0.34	-4.95	-0.31	1.4e-6	Childhood ear infection;
SARC	cis	rs1355223	0.902	rs448016	chr11:34706593	A/C	cg18508148	chr11:34937573	PDHX;APIP	0.39	4.94	0.31	1.46e-6	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.44	5.49	0.34	1.06e-7	Tonsillectomy;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16149129	chr7:30324641	ZNRF2	-0.5	-6.52	-0.39	4.33e-10	Smoking initiation;
SARC	cis	rs77372450	0.515	rs2277948	chr5:157098233	T/C	cg05585991	chr5:157099197	C5orf52	0.54	5.83	0.36	1.81e-8	Bipolar disorder (body mass index interaction);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg11038604	chr10:14996337	DCLRE1C	-0.49	-6.33	-0.38	1.28e-9	Chemerin levels;
SARC	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg13395646	chr4:1353034	KIAA1530	-0.5	-5.98	-0.36	8.15e-9	Obesity-related traits;
SARC	cis	rs7149242	0.697	rs12882815	chr14:101183142	C/G	cg18089426	chr14:101175970	NA	-0.4	-5.67	-0.35	4.1e-8	Platelet count;
SARC	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg00031303	chr3:195681400	NA	0.51	5.83	0.36	1.83e-8	Pancreatic cancer;
SARC	cis	rs9309473	0.948	rs7607892	chr2:73818707	C/T	cg20560298	chr2:73613845	ALMS1	-0.45	-5.46	-0.34	1.23e-7	Metabolite levels;
SARC	cis	rs7766436	0.583	rs17412847	chr6:22559055	C/T	cg13666174	chr6:22585274	NA	-0.58	-6.0	-0.37	7.63e-9	Coronary artery disease;
SARC	cis	rs5758659	0.622	rs6519298	chr22:42364997	C/T	cg04733989	chr22:42467013	NAGA	0.5	6.44	0.39	6.66e-10	Cognitive function;
SARC	cis	rs7712401	0.601	rs40818	chr5:122295073	T/C	cg19412675	chr5:122181750	SNX24	0.4	5.13	0.32	5.98e-7	Mean platelet volume;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22800477	chr1:10853793	CASZ1	0.53	6.87	0.41	5.67e-11	Smoking initiation;
SARC	cis	rs9467773	1.000	rs1321481	chr6:26538210	A/T	cg11502198	chr6:26597334	ABT1	0.46	5.61	0.34	5.83e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7786808	0.552	rs2878456	chr7:158182129	A/T	cg01191920	chr7:158217561	PTPRN2	-0.29	-4.88	-0.3	1.97e-6	Obesity-related traits;
SARC	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg23758822	chr17:41437982	NA	0.93	11.74	0.61	2.6e-25	Menopause (age at onset);
SARC	cis	rs10779751	1.000	rs1205592	chr1:11305663	C/T	cg08854313	chr1:11322531	MTOR	0.82	11.58	0.6	8.83e-25	Body mass index;
SARC	cis	rs4595586	0.545	rs925829	chr12:39364167	A/G	cg13010199	chr12:38710504	ALG10B	0.4	4.75	0.3	3.57e-6	Morning vs. evening chronotype;
SARC	cis	rs9398803	0.865	rs1538172	chr6:126748493	A/G	cg20229609	chr6:126660872	C6orf173	0.4	5.85	0.36	1.67e-8	Male-pattern baldness;
SARC	cis	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg25894440	chr7:65020034	NA	-0.69	-5.29	-0.33	2.85e-7	Diabetic kidney disease;
SARC	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg26681399	chr22:41777847	TEF	0.43	4.92	0.31	1.67e-6	Vitiligo;
SARC	cis	rs71277158	0.688	rs879161	chr3:169812115	A/G	cg04067573	chr3:169899625	PHC3	0.53	4.74	0.3	3.65e-6	Prostate cancer;
SARC	cis	rs9291683	0.610	rs993173	chr4:10323935	T/C	cg11266682	chr4:10021025	SLC2A9	-0.3	-5.11	-0.32	6.74e-7	Bone mineral density;
SARC	cis	rs2652834	0.950	rs2652815	chr15:63401345	T/C	cg05507819	chr15:63340323	TPM1	0.54	5.45	0.34	1.29e-7	HDL cholesterol;
SARC	cis	rs2522056	0.808	rs1016988	chr5:131744574	T/C	cg24060327	chr5:131705240	SLC22A5	0.61	6.4	0.39	8.29e-10	Lymphocyte counts;Fibrinogen;
SARC	cis	rs6991838	0.584	rs7463740	chr8:66486185	G/A	cg13398993	chr8:66546079	ARMC1	-0.62	-8.36	-0.48	5.88e-15	Intelligence (multi-trait analysis);
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg04106641	chr2:148779564	ORC4L	0.55	7.27	0.43	5.31e-12	Alcohol dependence;
SARC	cis	rs7592578	0.639	rs13417431	chr2:191293055	A/G	cg10560079	chr2:191398806	TMEM194B	-0.68	-7.88	-0.46	1.27e-13	Diastolic blood pressure;
SARC	cis	rs7186908	0.761	rs34714490	chr16:72177099	G/T	cg01557791	chr16:72042693	DHODH	-0.55	-5.63	-0.35	5.15e-8	Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs2439831	0.850	rs3862142	chr15:44064806	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	7.74	0.45	3.01e-13	Lung cancer in ever smokers;
SARC	cis	rs13256369	0.802	rs11995449	chr8:8559898	G/A	cg17143192	chr8:8559678	CLDN23	0.51	5.57	0.34	6.95e-8	Obesity-related traits;
SARC	cis	rs9549260	0.755	rs9549252	chr13:41230141	A/G	cg21288729	chr13:41239152	FOXO1	0.66	8.55	0.49	1.63e-15	Red blood cell count;
SARC	cis	rs8067545	0.750	rs888423	chr17:19999409	G/A	cg13482628	chr17:19912719	NA	0.54	7.29	0.43	4.75e-12	Schizophrenia;
SARC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg03647317	chr4:187891568	NA	-0.35	-4.97	-0.31	1.27e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg20887711	chr4:1340912	KIAA1530	0.61	7.42	0.44	2.15e-12	Longevity;
SARC	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg12463550	chr7:65579703	CRCP	0.5	5.9	0.36	1.27e-8	Aortic root size;
SARC	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg19077165	chr18:44547161	KATNAL2	0.53	7.26	0.43	5.89e-12	Personality dimensions;
SARC	cis	rs3540	0.883	rs6496676	chr15:90988384	A/T	cg22089800	chr15:90895588	ZNF774	0.46	4.86	0.3	2.12e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg06636001	chr8:8085503	FLJ10661	0.54	7.28	0.43	5.19e-12	Joint mobility (Beighton score);
SARC	cis	rs1348850	0.561	rs1838890	chr2:178410938	C/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.69	6.66	0.4	2e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7264396	0.563	rs2425131	chr20:34337074	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-6.71	-0.4	1.47e-10	Total cholesterol levels;
SARC	cis	rs1018836	0.663	rs3950221	chr8:91478108	G/A	cg16814680	chr8:91681699	NA	-0.75	-11.47	-0.6	1.93e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs2011503	1.000	rs8110250	chr19:19559989	G/A	cg15839431	chr19:19639596	YJEFN3	-0.47	-4.74	-0.3	3.78e-6	Bipolar disorder;
SARC	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg04277193	chr17:41438351	NA	0.44	4.73	0.3	3.83e-6	Menopause (age at onset);
SARC	cis	rs6831352	0.918	rs13127153	chr4:100058121	C/T	cg12011299	chr4:100065546	ADH4	-0.34	-5.74	-0.35	2.95e-8	Alcohol dependence;
SARC	cis	rs1322639	0.614	rs6925188	chr6:169563337	T/C	cg03254818	chr6:169586852	NA	0.7	7.05	0.42	2.04e-11	Pulse pressure;
SARC	cis	rs9733	0.650	rs4970923	chr1:150608300	A/G	cg17724175	chr1:150552817	MCL1	-0.38	-4.92	-0.31	1.66e-6	Tonsillectomy;
SARC	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg00149659	chr3:10157352	C3orf10	1.09	10.0	0.55	7.87e-20	Alzheimer's disease;
SARC	cis	rs734999	0.588	rs4648562	chr1:2535613	C/A	cg18854424	chr1:2615690	NA	0.32	4.98	0.31	1.23e-6	Ulcerative colitis;
SARC	cis	rs356220	0.656	rs356206	chr4:90635049	T/C	cg06632027	chr4:90757378	SNCA	0.4	5.08	0.32	7.67e-7	Parkinson's disease;
SARC	cis	rs12022452	0.591	rs11208356	chr1:41006931	A/G	cg25568243	chr1:40974465	DEM1	0.56	5.5	0.34	1e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs9640161	0.750	rs3735169	chr7:150034378	A/G	cg17279839	chr7:150038598	RARRES2	0.49	6.82	0.41	7.56e-11	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg06074448	chr4:187884817	NA	-0.48	-6.47	-0.39	5.65e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7937682	0.814	rs1784788	chr11:111486136	T/G	cg09085632	chr11:111637200	PPP2R1B	-0.9	-14.07	-0.68	6.09e-33	Primary sclerosing cholangitis;
SARC	cis	rs703842	1.000	rs8181644	chr12:58173466	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.77	11.14	0.59	2.13e-23	Multiple sclerosis;
SARC	cis	rs637571	0.512	rs660118	chr11:65735174	G/C	cg26695010	chr11:65641043	EFEMP2	-0.52	-6.73	-0.4	1.34e-10	Eosinophil percentage of white cells;
SARC	cis	rs112790992	1	rs112790992	chr14:105758217	A/C	cg10792982	chr14:105748885	BRF1	0.49	7.46	0.44	1.67e-12	Platelet count;
SARC	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.43	-5.5	-0.34	9.82e-8	Intelligence (multi-trait analysis);
SARC	cis	rs1538970	0.816	rs61788356	chr1:46006675	C/T	cg05343316	chr1:45956843	TESK2	0.84	9.14	0.51	3.2e-17	Platelet count;
SARC	cis	rs9818758	0.607	rs9862483	chr3:49195441	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.69	-5.85	-0.36	1.61e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs72781680	1.000	rs72781663	chr2:24221694	C/G	cg06627628	chr2:24431161	ITSN2	-0.68	-6.48	-0.39	5.28e-10	Lymphocyte counts;
SARC	cis	rs9309473	1.000	rs10496193	chr2:73773503	G/A	cg20560298	chr2:73613845	ALMS1	-0.52	-6.07	-0.37	5.24e-9	Metabolite levels;
SARC	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg11764359	chr7:65958608	NA	-0.87	-12.55	-0.64	6.04e-28	Aortic root size;
SARC	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg13939156	chr17:80058883	NA	-0.42	-6.57	-0.4	3.34e-10	Life satisfaction;
SARC	cis	rs9916302	0.904	rs11078915	chr17:37715426	T/C	cg15445000	chr17:37608096	MED1	0.42	4.91	0.31	1.69e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs909674	0.775	rs8138462	chr22:39839670	G/C	cg24399712	chr22:39784796	NA	-0.44	-5.85	-0.36	1.7e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg00933542	chr6:150070202	PCMT1	-0.37	-6.42	-0.39	7.61e-10	Lung cancer;
SARC	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg19223190	chr17:80058835	NA	-0.38	-5.26	-0.33	3.18e-7	Life satisfaction;
SARC	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.5	0.34	9.98e-8	Bipolar disorder;
SARC	cis	rs3741404	0.609	rs666497	chr11:63869821	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	9.03	0.51	6.46e-17	Platelet count;
SARC	cis	rs896854	0.714	rs572547	chr8:95966286	A/G	cg13393036	chr8:95962371	TP53INP1	0.31	5.06	0.31	8.67e-7	Type 2 diabetes;
SARC	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg00908189	chr16:619842	PIGQ	0.86	12.64	0.64	3.1e-28	Height;
SARC	cis	rs4775413	0.750	rs11636157	chr15:61842557	A/C	cg09972561	chr15:62353371	VPS13C	0.37	4.88	0.3	1.95e-6	Schizophrenia;
SARC	cis	rs734999	0.588	rs2843402	chr1:2528682	T/C	cg18854424	chr1:2615690	NA	-0.32	-5.04	-0.31	9.17e-7	Ulcerative colitis;
SARC	cis	rs2236918	0.932	rs1776178	chr1:242011534	C/T	cg17736920	chr1:242011382	EXO1	-0.77	-10.95	-0.58	8.6e-23	Menopause (age at onset);
SARC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg25703541	chr22:24373054	LOC391322	0.87	12.83	0.64	7.17e-29	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg05313129	chr8:58192883	C8orf71	-0.62	-6.34	-0.38	1.18e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2120019	0.938	rs2289582	chr15:75310394	T/C	cg00629941	chr15:75287862	SCAMP5	-0.7	-8.05	-0.47	4.13e-14	Blood trace element (Zn levels);
SARC	cis	rs12079745	0.590	rs74317850	chr1:169169924	T/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.82	-5.16	-0.32	5.16e-7	QT interval;
SARC	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg12016809	chr21:47604291	C21orf56	-0.43	-5.21	-0.32	4.12e-7	Testicular germ cell tumor;
SARC	cis	rs950776	0.518	rs12906284	chr15:78825105	C/T	cg22563815	chr15:78856949	CHRNA5	0.41	6.82	0.41	7.56e-11	Sudden cardiac arrest;
SARC	cis	rs7264396	0.635	rs6060685	chr20:34512023	G/A	cg12579300	chr20:34535607	PHF20	-0.43	-4.98	-0.31	1.26e-6	Total cholesterol levels;
SARC	cis	rs7582720	1.000	rs74421437	chr2:203831252	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs9457247	0.765	rs3752520	chr6:167436159	T/C	cg23791538	chr6:167370224	RNASET2	-0.52	-6.8	-0.41	8.54e-11	Crohn's disease;
SARC	cis	rs9365169	1	rs9365169	chr6:160966347	G/C	cg12345982	chr6:160389645	IGF2R	-0.35	-5.37	-0.33	1.89e-7	Lipoprotein(a) levels adjusted for apolipoprotein(a) isoforms;
SARC	cis	rs1044826	1.000	rs2233815	chr3:139195177	C/T	cg15131784	chr3:139108705	COPB2	0.45	5.19	0.32	4.69e-7	Obesity-related traits;
SARC	cis	rs4595586	0.545	rs4623945	chr12:39364572	A/T	cg13010199	chr12:38710504	ALG10B	0.4	4.75	0.3	3.57e-6	Morning vs. evening chronotype;
SARC	cis	rs950027	0.620	rs1719246	chr15:45625479	T/A	cg15395560	chr15:45543142	SLC28A2	-0.27	-5.04	-0.31	9.55e-7	Response to fenofibrate (adiponectin levels);
SARC	trans	rs61931739	0.500	rs7133447	chr12:34041901	A/G	cg13010199	chr12:38710504	ALG10B	0.67	9.22	0.52	1.81e-17	Morning vs. evening chronotype;
SARC	cis	rs9916302	0.904	rs634365	chr17:37436966	C/T	cg15445000	chr17:37608096	MED1	0.41	5.14	0.32	5.88e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs2070677	1.000	rs743534	chr10:135349226	G/T	cg20169779	chr10:135381914	SYCE1	0.46	5.92	0.36	1.14e-8	Gout;
SARC	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.4	-4.91	-0.31	1.75e-6	Lymphocyte counts;
SARC	cis	rs7084402	1.000	rs1427202	chr10:60267917	A/T	cg07615347	chr10:60278583	BICC1	-0.53	-7.46	-0.44	1.66e-12	Refractive error;
SARC	cis	rs9790314	0.905	rs4856739	chr3:160986710	A/C	cg03342759	chr3:160939853	NMD3	-0.63	-8.09	-0.47	3.32e-14	Morning vs. evening chronotype;
SARC	cis	rs10754283	0.557	rs1215508	chr1:90088697	C/T	cg21401794	chr1:90099060	LRRC8C	0.47	6.03	0.37	6.43e-9	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs9660992	0.686	rs1668870	chr1:205239031	C/G	cg21545522	chr1:205238299	TMCC2	0.49	6.84	0.41	6.81e-11	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs3784262	1.000	rs3784262	chr15:58253106	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.38	-5.63	-0.35	5.24e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs7659604	0.935	rs73844280	chr4:122664687	G/A	cg19671926	chr4:122722719	EXOSC9	-0.5	-6.13	-0.37	3.77e-9	Type 2 diabetes;
SARC	cis	rs9788721	0.640	rs1394371	chr15:78724469	C/T	cg06917634	chr15:78832804	PSMA4	-0.52	-5.3	-0.33	2.71e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.54	5.98	0.36	8.44e-9	Prudent dietary pattern;
SARC	cis	rs288326	0.561	rs77541378	chr2:183886271	C/A	cg09997497	chr2:183902928	NCKAP1	0.74	5.1	0.32	6.97e-7	Blood protein levels;
SARC	trans	rs3808502	0.503	rs2061830	chr8:11397457	C/G	cg15556689	chr8:8085844	FLJ10661	0.52	6.71	0.4	1.43e-10	Neuroticism;
SARC	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg14664628	chr15:75095509	CSK	0.5	6.32	0.38	1.31e-9	Breast cancer;
SARC	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg11764359	chr7:65958608	NA	-0.67	-7.97	-0.46	7.24e-14	Aortic root size;
SARC	cis	rs3733585	0.664	rs28602527	chr4:9958327	G/A	cg11266682	chr4:10021025	SLC2A9	-0.35	-6.03	-0.37	6.35e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs992157	0.698	rs6746089	chr2:219170377	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.62	8.81	0.5	3e-16	Colorectal cancer;
SARC	cis	rs6665290	0.935	rs17528667	chr1:227201770	C/T	cg14016676	chr1:227182615	CDC42BPA	0.37	5.29	0.33	2.77e-7	Myeloid white cell count;
SARC	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg09455208	chr3:40491958	NA	0.39	5.69	0.35	3.81e-8	Renal cell carcinoma;
SARC	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg22920501	chr2:26401640	FAM59B	0.56	7.63	0.45	6e-13	Gut microbiome composition (summer);
SARC	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg18252515	chr7:66147081	NA	1.29	11.21	0.59	1.32e-23	Diabetic kidney disease;
SARC	cis	rs4727027	0.870	rs62507509	chr7:148795522	C/T	cg23583168	chr7:148888333	NA	-0.74	-10.41	-0.56	4.35e-21	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs6840360	1.000	rs28637056	chr4:152652501	A/G	cg22705602	chr4:152727874	NA	-0.37	-6.52	-0.39	4.44e-10	Intelligence (multi-trait analysis);
SARC	cis	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg25894440	chr7:65020034	NA	-0.74	-5.55	-0.34	7.85e-8	Diabetic kidney disease;
SARC	cis	rs736408	0.608	rs35004449	chr3:52852897	G/T	cg18404041	chr3:52824283	ITIH1	-0.47	-6.0	-0.37	7.4e-9	Bipolar disorder;
SARC	cis	rs7296418	0.738	rs1568428	chr12:123738876	A/G	cg05973401	chr12:123451056	ABCB9	-0.5	-5.92	-0.36	1.14e-8	Platelet count;
SARC	cis	rs6582630	0.555	rs2387598	chr12:38510472	G/A	cg26384229	chr12:38710491	ALG10B	-0.81	-11.87	-0.61	9.77e-26	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg26119090	chr2:26468346	HADHA;HADHB	0.95	13.71	0.67	9.5e-32	Gut microbiome composition (summer);
SARC	cis	rs10463554	0.927	rs158404	chr5:102415910	C/T	cg23492399	chr5:102201601	PAM	-0.52	-5.7	-0.35	3.63e-8	Parkinson's disease;
SARC	cis	rs4713118	0.662	rs149947	chr6:27972433	A/T	cg17221315	chr6:27791827	HIST1H4J	0.48	4.81	0.3	2.75e-6	Parkinson's disease;
SARC	cis	rs986417	1.000	rs1956554	chr14:60963775	C/T	cg27398547	chr14:60952738	C14orf39	-0.98	-9.04	-0.51	6.37e-17	Gut microbiota (bacterial taxa);
SARC	cis	rs9388451	0.505	rs6920965	chr6:126179111	G/A	cg05901451	chr6:126070800	HEY2	-0.49	-5.91	-0.36	1.24e-8	Brugada syndrome;
SARC	cis	rs7412746	0.634	rs12409208	chr1:150860055	A/G	cg10589385	chr1:150898437	SETDB1	0.41	5.48	0.34	1.12e-7	Melanoma;
SARC	cis	rs4557202	0.509	rs12690576	chr3:160647912	G/A	cg04691961	chr3:161091175	C3orf57	-0.46	-5.48	-0.34	1.08e-7	Menarche (age at onset);
SARC	cis	rs526231	0.543	rs34785	chr5:102458103	C/T	cg23492399	chr5:102201601	PAM	-0.51	-5.55	-0.34	7.77e-8	Primary biliary cholangitis;
SARC	cis	rs9916302	0.851	rs11078904	chr17:37650569	G/A	cg15445000	chr17:37608096	MED1	0.4	4.75	0.3	3.6e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2629540	0.737	rs10901821	chr10:126480556	T/C	cg08799069	chr10:126477246	METTL10	-0.58	-6.69	-0.4	1.61e-10	Cocaine dependence;
SARC	cis	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg24110177	chr3:50126178	RBM5	-0.52	-6.88	-0.41	5.43e-11	Intelligence (multi-trait analysis);
SARC	cis	rs9467711	0.606	rs9393718	chr6:26407482	G/A	cg12826209	chr6:26865740	GUSBL1	0.83	5.08	0.32	7.7300000000000005e-07	Autism spectrum disorder or schizophrenia;
SARC	cis	rs595982	0.559	rs17206714	chr19:49362001	T/A	cg15549821	chr19:49342101	PLEKHA4	-0.67	-7.15	-0.42	1.14e-11	Red cell distribution width;
SARC	cis	rs6582630	0.593	rs7134006	chr12:38596245	A/C	cg26384229	chr12:38710491	ALG10B	0.84	12.42	0.63	1.6e-27	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9467773	1.000	rs2255070	chr6:26501777	C/G	cg12292205	chr6:26970375	C6orf41	0.43	5.24	0.32	3.68e-7	Intelligence (multi-trait analysis);
SARC	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.88	-12.99	-0.65	2.26e-29	Gut microbiome composition (summer);
SARC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg09436375	chr6:42928200	GNMT	-0.37	-5.79	-0.35	2.28e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs6088590	0.748	rs6142206	chr20:33212055	G/A	cg08999081	chr20:33150536	PIGU	0.34	4.73	0.3	3.96e-6	Coronary artery disease;
SARC	cis	rs2288912	0.838	rs7251503	chr19:45455715	C/G	cg09555818	chr19:45449301	APOC2	0.55	8.91	0.5	1.5e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs2933343	0.621	rs883843	chr3:128567383	C/T	cg24203234	chr3:128598194	ACAD9	-0.62	-7.88	-0.46	1.26e-13	IgG glycosylation;
SARC	cis	rs7432375	0.610	rs6793936	chr3:136509793	A/C	cg15507776	chr3:136538369	TMEM22	0.62	7.7	0.45	3.89e-13	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg24549020	chr5:56110836	MAP3K1	0.8	8.3	0.48	8.56e-15	Initial pursuit acceleration;
SARC	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.75	9.39	0.52	5.56e-18	Height;
SARC	cis	rs514406	0.505	rs387436	chr1:53179376	C/T	cg16325326	chr1:53192061	ZYG11B	-0.95	-18.09	-0.76	2.7e-46	Monocyte count;
SARC	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg19660806	chr8:588740	NA	0.63	4.91	0.31	1.7e-6	IgG glycosylation;
SARC	cis	rs9486719	0.947	rs12210834	chr6:96890407	A/T	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.01	-0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-15.46	-0.71	1.39e-37	Chronic sinus infection;
SARC	cis	rs651907	0.557	rs17411983	chr3:101399126	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.53	-6.55	-0.39	3.73e-10	Colorectal cancer;
SARC	cis	rs6582630	0.623	rs12299293	chr12:38436288	G/A	cg14851346	chr12:38532713	NA	-0.44	-5.3	-0.33	2.64e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs3733585	0.577	rs5014939	chr4:9953253	T/A	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.39	-0.33	1.76e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7208859	0.673	rs36056619	chr17:29172284	T/C	cg13385521	chr17:29058706	SUZ12P	0.86	7.34	0.43	3.52e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	trans	rs66573146	1.000	rs6838250	chr4:6973184	C/G	cg07817883	chr1:32538562	TMEM39B	1.5	9.13	0.51	3.32e-17	Granulocyte percentage of myeloid white cells;
SARC	trans	rs11098499	0.954	rs67265404	chr4:120359270	C/T	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	trans	rs7819412	0.838	rs3021494	chr8:10983534	A/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.7	-0.5	6.02e-16	Triglycerides;
SARC	cis	rs67478160	0.634	rs2368559	chr14:104230535	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.35	-4.98	-0.31	1.21e-6	Schizophrenia;
SARC	cis	rs12497850	1.000	rs4858828	chr3:48724811	C/T	cg06212747	chr3:49208901	KLHDC8B	0.68	9.07	0.51	5.08e-17	Parkinson's disease;
SARC	cis	rs3733585	0.660	rs13122290	chr4:9933832	A/G	cg00071950	chr4:10020882	SLC2A9	-0.4	-6.38	-0.39	9.45e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg00684032	chr4:1343700	KIAA1530	-0.36	-5.14	-0.32	5.9e-7	Obesity-related traits;
SARC	cis	rs9309473	0.632	rs6706179	chr2:73578577	C/T	cg20560298	chr2:73613845	ALMS1	-0.59	-7.42	-0.44	2.2e-12	Metabolite levels;
SARC	trans	rs61931739	0.500	rs11053274	chr12:34547605	G/A	cg26384229	chr12:38710491	ALG10B	0.9	13.21	0.65	4.16e-30	Morning vs. evening chronotype;
SARC	cis	rs72627509	0.501	rs13101682	chr4:57735358	G/A	cg26694713	chr4:57773883	REST	0.45	5.22	0.32	3.93e-7	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs8078723	0.714	rs2241245	chr17:38151014	C/T	cg17467752	chr17:38218738	THRA	-0.38	-4.89	-0.31	1.88e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs6831352	0.918	rs29001203	chr4:100053091	A/G	cg13256891	chr4:100009986	ADH5	-0.62	-7.73	-0.45	3.28e-13	Alcohol dependence;
SARC	cis	rs712039	0.652	rs17137970	chr17:35771826	C/T	cg16670864	chr17:35848621	DUSP14	0.51	5.68	0.35	3.94e-8	Tuberculosis;
SARC	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg14343924	chr8:8086146	FLJ10661	0.41	4.9	0.31	1.8e-6	Mood instability;
SARC	cis	rs7818688	0.697	rs76215523	chr8:95987015	T/C	cg13393036	chr8:95962371	TP53INP1	0.39	4.77	0.3	3.24e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs4972806	0.814	rs2113560	chr2:177030986	T/C	cg14236662	chr2:176988284	HOXD9	0.41	5.77	0.35	2.46e-8	IgG glycosylation;
SARC	cis	rs3008870	0.920	rs12132532	chr1:67457015	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.89	-10.74	-0.58	3.95e-22	Lymphocyte percentage of white cells;
SARC	cis	rs12477438	0.871	rs62156364	chr2:99695097	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-6.77	-0.41	1.05e-10	Chronic sinus infection;
SARC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg11965913	chr1:205819406	PM20D1	0.9	14.93	0.7	8.33e-36	Menarche (age at onset);
SARC	cis	rs27434	0.539	rs40604	chr5:96155900	G/A	cg16492584	chr5:96139282	ERAP1	-0.56	-7.02	-0.42	2.43e-11	Ankylosing spondylitis;
SARC	cis	rs9916302	0.904	rs2338755	chr17:37419317	C/T	cg15445000	chr17:37608096	MED1	-0.41	-4.96	-0.31	1.39e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs9467711	0.559	rs6920256	chr6:26537801	G/A	cg12826209	chr6:26865740	GUSBL1	0.72	4.96	0.31	1.37e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9325144	0.554	rs1906264	chr12:38739490	A/G	cg04568710	chr12:38710424	ALG10B	0.38	4.73	0.3	3.92e-6	Morning vs. evening chronotype;
SARC	cis	rs76419734	1.000	rs11724839	chr4:106638256	T/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.84	5.56	0.34	7.44e-8	Post bronchodilator FEV1;
SARC	cis	rs6484504	0.625	rs1535741	chr11:31375072	T/C	cg02090638	chr11:31391270	DNAJC24;DCDC1	0.41	5.21	0.32	4.19e-7	Red blood cell count;
SARC	cis	rs3784262	0.631	rs6493980	chr15:58352290	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.33	-5.0	-0.31	1.15e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs72781680	0.898	rs56216411	chr2:23934533	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	8.58	0.49	1.32e-15	Lymphocyte counts;
SARC	cis	rs7561528	0.501	rs55669136	chr2:127883286	A/G	cg12632573	chr2:127783243	NA	0.67	6.1	0.37	4.44e-9	Alzheimer's disease;Alzheimer's disease (late onset);
SARC	cis	rs7481584	1.000	rs2239898	chr11:3024462	G/A	cg05729581	chr11:3078854	CARS	0.45	5.61	0.34	5.75e-8	Calcium levels;
SARC	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg24675658	chr1:53192096	ZYG11B	-0.56	-7.78	-0.45	2.32e-13	Monocyte count;
SARC	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.1	21.48	0.82	3.55e-57	Chronic sinus infection;
SARC	cis	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg12463550	chr7:65579703	CRCP	0.68	5.09	0.32	7.53e-7	Gout;
SARC	cis	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg11608241	chr8:8085544	FLJ10661	0.42	5.11	0.32	6.72e-7	Mood instability;
SARC	cis	rs72781680	0.950	rs72796402	chr2:24180104	A/G	cg08917208	chr2:24149416	ATAD2B	0.94	9.09	0.51	4.53e-17	Lymphocyte counts;
SARC	cis	rs10992471	0.603	rs4744137	chr9:95288352	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.38	-0.33	1.78e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs2120243	0.647	rs60676003	chr3:157147939	G/A	cg01018701	chr3:157155998	VEPH1;PTX3	0.51	6.56	0.4	3.36e-10	Hepatocellular carcinoma in hepatitis B infection;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg11029746	chr15:75315874	PPCDC	0.5	6.4	0.39	8.51e-10	Chemerin levels;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg25203113	chr10:28860352	WAC	0.51	7.05	0.42	2e-11	Thyroid stimulating hormone;
SARC	trans	rs9987289	0.614	rs6984305	chr8:9178268	A/T	cg21788045	chr3:115984319	LSAMP	-0.55	-6.46	-0.39	5.91e-10	HDL Cholesterol - Triglycerides (HDLC-TG);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);C-reactive protein levels or triglyceride levels (pleiotropy);LDL cholesterol;HDL cholesterol;Cholesterol, total;C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Metabolic syndrome (bivariate traits);Total cholesterol levels;Plasma lactate levels;C-reactive protein levels;LDL cholesterol levels;
SARC	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg13206674	chr6:150067644	NUP43	0.42	5.53	0.34	8.42e-8	Lung cancer;
SARC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.99	0.55	8.47e-20	Prudent dietary pattern;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg01344162	chr13:111471413	NA	0.83	6.0	0.37	7.62e-9	Obesity-related traits;
SARC	cis	rs9916302	0.851	rs677888	chr17:37461018	T/G	cg15445000	chr17:37608096	MED1	-0.45	-5.26	-0.33	3.28e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs9420	0.784	rs12790660	chr11:57667222	T/C	cg23127183	chr11:57508653	C11orf31	-0.53	-5.2	-0.32	4.35e-7	Schizophrenia;
SARC	cis	rs765787	0.530	rs4775844	chr15:45542048	T/C	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.51e-10	Uric acid levels;
SARC	cis	rs12681366	0.564	rs2165405	chr8:95454307	A/T	cg13257157	chr8:95487014	RAD54B	0.39	4.72	0.3	4.03e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg03452623	chr4:187889614	NA	-0.76	-11.73	-0.61	2.83e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7666738	0.546	rs28590002	chr4:98722642	C/T	cg05340658	chr4:99064831	C4orf37	0.59	7.24	0.43	6.58e-12	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.38	6.13	0.37	3.68e-9	Schizophrenia;
SARC	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.0	11.56	0.6	9.83e-25	Platelet count;
SARC	cis	rs4242434	0.672	rs3758042	chr8:22486951	T/C	cg03733263	chr8:22462867	KIAA1967	0.88	13.76	0.67	6.2e-32	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs854765	0.547	rs2955383	chr17:17941364	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.64	9.48	0.53	2.96e-18	Total body bone mineral density;
SARC	cis	rs2075371	0.501	rs1646653	chr7:134024686	A/G	cg20476274	chr7:133979776	SLC35B4	0.43	5.36	0.33	1.99e-7	Mean platelet volume;
SARC	trans	rs9650657	0.738	rs11250078	chr8:10666581	G/A	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.36	-0.38	1.06e-9	Neuroticism;
SARC	cis	rs2486288	0.656	rs8041702	chr15:45547093	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.49	-6.3	-0.38	1.49e-9	Glomerular filtration rate;
SARC	trans	rs9888736	0.501	rs12917100	chr15:47910531	C/T	cg01357263	chr12:122459509	BCL7A	-0.51	-6.44	-0.39	6.85e-10	Body mass index;
SARC	cis	rs9650657	0.504	rs7813802	chr8:11033976	C/T	cg00262122	chr8:11665843	FDFT1	0.43	5.12	0.32	6.47e-7	Neuroticism;
SARC	cis	rs858239	0.600	rs59073109	chr7:23133226	C/A	cg23682824	chr7:23144976	KLHL7	0.71	9.42	0.53	4.53e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.03	15.24	0.71	7.44e-37	Height;
SARC	cis	rs854765	0.647	rs854767	chr17:18018263	A/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.38	-4.87	-0.3	2.04e-6	Total body bone mineral density;
SARC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg10295955	chr4:187884368	NA	-1.08	-20.57	-0.8	2.68e-54	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6558174	0.802	rs6558171	chr8:22487422	T/C	cg03733263	chr8:22462867	KIAA1967	0.49	5.75	0.35	2.83e-8	Breast cancer;
SARC	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg08564027	chr20:61660810	NA	0.76	11.8	0.61	1.69e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs1008375	1.000	rs4698198	chr4:17656536	G/A	cg27347728	chr4:17578864	LAP3	0.47	5.88	0.36	1.42e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs12586317	0.525	rs10144430	chr14:35433682	T/A	cg16230307	chr14:35515116	FAM177A1	0.78	9.43	0.53	4.22e-18	Psoriasis;
SARC	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg19748678	chr4:122722346	EXOSC9	0.76	9.66	0.53	9.04e-19	Type 2 diabetes;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg06066128	chr3:47018377	CCDC12	0.53	6.82	0.41	7.58e-11	Lung adenocarcinoma;
SARC	cis	rs6582630	0.502	rs11181210	chr12:38298069	G/A	cg13010199	chr12:38710504	ALG10B	0.77	10.59	0.57	1.16e-21	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1981331	0.609	rs3088287	chr21:48079669	G/A	cg23283320	chr21:48055893	PRMT2	1.05	6.15	0.37	3.26e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;
SARC	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg23758822	chr17:41437982	NA	0.9	11.32	0.6	5.9e-24	Menopause (age at onset);
SARC	cis	rs3126085	0.935	rs12405678	chr1:152195308	C/G	cg26876637	chr1:152193138	HRNR	-0.51	-5.25	-0.33	3.42e-7	Atopic dermatitis;
SARC	cis	rs7412746	0.658	rs72704685	chr1:150897687	C/G	cg10589385	chr1:150898437	SETDB1	0.42	5.64	0.35	4.91e-8	Melanoma;
SARC	cis	rs10791097	0.748	rs4937580	chr11:130734270	T/C	cg09137382	chr11:130731461	NA	0.32	4.98	0.31	1.25e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs10911232	0.507	rs6668980	chr1:183018857	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.11	0.55	3.63e-20	Hypertriglyceridemia;
SARC	cis	rs607987	0.836	rs645161	chr11:30272226	A/C	cg06241208	chr11:30344200	C11orf46	-0.41	-5.04	-0.31	9.42e-7	Body mass index;
SARC	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg05313129	chr8:58192883	C8orf71	-0.63	-6.51	-0.39	4.44e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs11711311	1.000	rs9830978	chr3:113455940	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.69	8.9	0.5	1.64e-16	IgG glycosylation;
SARC	cis	rs10782582	0.586	rs112368938	chr1:76336339	C/T	cg10523679	chr1:76189770	ACADM	-0.41	-5.05	-0.31	8.87e-7	Daytime sleep phenotypes;
SARC	cis	rs6964587	0.967	rs34344935	chr7:91835436	G/A	cg17063962	chr7:91808500	NA	0.98	15.96	0.72	2.98e-39	Breast cancer;
SARC	cis	rs9467773	1.000	rs9467787	chr6:26556769	G/T	cg12292205	chr6:26970375	C6orf41	0.46	5.51	0.34	9.65e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9486715	0.838	rs4839840	chr6:96941149	T/C	cg18709589	chr6:96969512	KIAA0776	0.59	7.33	0.43	3.65e-12	Headache;
SARC	cis	rs9322193	0.566	rs4869767	chr6:150245110	A/G	cg11878867	chr6:150167359	LRP11	0.4	5.02	0.31	1.02e-6	Lung cancer;
SARC	cis	rs9399137	0.507	rs12663447	chr6:135317026	A/C	cg24558204	chr6:135376177	HBS1L	0.61	7.94	0.46	8.39e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg00149659	chr3:10157352	C3orf10	0.69	6.44	0.39	6.6e-10	Alzheimer's disease;
SARC	cis	rs17401966	0.931	rs34225619	chr1:10371987	C/T	cg15208524	chr1:10270712	KIF1B	0.63	7.12	0.42	1.34e-11	Hepatocellular carcinoma;
SARC	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg13395646	chr4:1353034	KIAA1530	0.53	6.38	0.39	9.54e-10	Obesity-related traits;
SARC	cis	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg24110177	chr3:50126178	RBM5	-0.54	-7.17	-0.43	1e-11	Intelligence (multi-trait analysis);
SARC	cis	rs1003719	0.743	rs2835615	chr21:38497303	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.65	-9.35	-0.52	7.46e-18	Eye color traits;
SARC	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg11764359	chr7:65958608	NA	0.87	12.3	0.63	4e-27	Aortic root size;
SARC	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6456156	0.774	rs6930998	chr6:167526940	A/C	cg07741184	chr6:167504864	NA	-0.28	-5.31	-0.33	2.55e-7	Primary biliary cholangitis;
SARC	cis	rs9790314	0.690	rs1599389	chr3:160836006	G/A	cg03342759	chr3:160939853	NMD3	-0.57	-7.22	-0.43	7.37e-12	Morning vs. evening chronotype;
SARC	cis	rs5167	0.645	rs1130742	chr19:45452812	C/T	cg09555818	chr19:45449301	APOC2	0.37	4.87	0.3	2.1e-6	Blood protein levels;
SARC	cis	rs9650657	0.530	rs6982381	chr8:10952500	A/T	cg00262122	chr8:11665843	FDFT1	-0.42	-5.18	-0.32	4.83e-7	Neuroticism;
SARC	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs3768617	0.811	rs12563494	chr1:183039698	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.6	8.0	0.46	5.99e-14	Fuchs's corneal dystrophy;
SARC	cis	rs644799	1.000	rs580255	chr11:95577929	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	14.8	0.7	2.24e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs3771570	1.000	rs62193171	chr2:242276523	C/A	cg21155796	chr2:242212141	HDLBP	0.67	5.74	0.35	2.99e-8	Prostate cancer;
SARC	cis	rs67311347	0.869	rs6790495	chr3:40366770	C/T	cg24209194	chr3:40518798	ZNF619	0.58	7.41	0.44	2.29e-12	Renal cell carcinoma;
SARC	cis	rs1008375	0.898	rs9998130	chr4:17593905	A/G	cg27347728	chr4:17578864	LAP3	0.51	6.24	0.38	2e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs73635312	0.850	rs74516407	chr10:8947176	A/T	cg24467326	chr10:9646929	NA	0.6	5.02	0.31	1.02e-6	Basal cell carcinoma;
SARC	cis	rs6121246	0.609	rs6089054	chr20:30323141	A/G	cg13852791	chr20:30311386	BCL2L1	0.81	9.97	0.55	9.89e-20	Mean corpuscular hemoglobin;
SARC	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg16680214	chr1:154839983	KCNN3	-0.35	-5.56	-0.34	7.22e-8	Prostate cancer;
SARC	cis	rs4430311	0.723	rs6429435	chr1:243945131	T/C	cg21452805	chr1:244014465	NA	-0.39	-5.03	-0.31	1e-6	Post-traumatic stress disorder (asjusted for relatedness);
SARC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg26338869	chr17:61819248	STRADA	0.81	10.86	0.58	1.68e-22	Prudent dietary pattern;
SARC	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg05368731	chr17:41323189	NBR1	0.81	9.93	0.55	1.35e-19	Menopause (age at onset);
SARC	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg17376030	chr22:41985996	PMM1	-0.77	-9.89	-0.54	1.76e-19	Vitiligo;
SARC	cis	rs3008870	0.755	rs1925410	chr1:67365230	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.61	-7.84	-0.46	1.62e-13	Lymphocyte percentage of white cells;
SARC	cis	rs7119	0.717	rs16968835	chr15:77734261	G/A	cg17802220	chr15:77601643	NA	-0.45	-5.81	-0.36	2.09e-8	Type 2 diabetes;
SARC	cis	rs9768139	0.733	rs12698209	chr7:158117595	A/G	cg25566285	chr7:158114605	PTPRN2	-0.31	-5.21	-0.32	4.09e-7	Calcium levels;
SARC	cis	rs7044106	0.708	rs959558	chr9:123368911	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	8.96	0.51	1.07e-16	Hip circumference adjusted for BMI;
SARC	cis	rs986417	0.892	rs57925468	chr14:60816129	G/A	cg27398547	chr14:60952738	C14orf39	-0.99	-8.65	-0.49	8.48e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs651907	0.535	rs11711903	chr3:101500748	C/G	cg12386194	chr3:101231763	SENP7	0.49	5.77	0.35	2.49e-8	Colorectal cancer;
SARC	cis	rs6831352	0.918	rs17217949	chr4:100054312	A/G	cg13256891	chr4:100009986	ADH5	-0.64	-8.0	-0.46	5.7e-14	Alcohol dependence;
SARC	cis	rs9303401	0.659	rs62081314	chr17:56778328	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	12.33	0.63	3.11e-27	Cognitive test performance;
SARC	cis	rs1256061	0.624	rs1256046	chr14:64729356	A/C	cg23250157	chr14:64679961	SYNE2	0.48	6.62	0.4	2.49e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs7937682	0.632	rs1045282	chr11:111754574	A/C	cg09085632	chr11:111637200	PPP2R1B	0.76	9.99	0.55	8.94e-20	Primary sclerosing cholangitis;
SARC	cis	rs7089973	0.604	rs11196936	chr10:116588630	C/T	cg08188268	chr10:116634841	FAM160B1	0.28	4.77	0.3	3.18e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.46	-5.9	-0.36	1.26e-8	Lymphocyte counts;
SARC	cis	rs933688	1.000	rs6452953	chr5:90723034	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.04	13.5	0.66	4.7e-31	Smoking behavior;
SARC	cis	rs11697848	1.000	rs41283584	chr20:48507781	G/A	cg17849948	chr20:48532315	SPATA2	0.86	5.17	0.32	4.97e-7	Systemic lupus erythematosus;
SARC	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg13264159	chr8:625131	ERICH1	-0.65	-5.08	-0.32	7.74e-7	IgG glycosylation;
SARC	cis	rs7674212	0.541	rs11727498	chr4:104100987	C/T	cg16532752	chr4:104119610	CENPE	-0.5	-6.07	-0.37	5.06e-9	Type 2 diabetes;
SARC	cis	rs365302	0.767	rs412690	chr6:159613544	G/A	cg14500486	chr6:159655392	FNDC1	0.39	4.76	0.3	3.37e-6	Coronary heart disease;
SARC	cis	rs17095355	1.000	rs12570607	chr10:111696704	C/A	cg00817464	chr10:111662876	XPNPEP1	-0.41	-4.74	-0.3	3.74e-6	Biliary atresia;
SARC	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.72	-7.32	-0.43	3.94e-12	Platelet count;
SARC	cis	rs12824058	0.831	rs12310049	chr12:130811260	C/G	cg24838063	chr12:130822603	PIWIL1	0.63	8.94	0.51	1.25e-16	Menopause (age at onset);
SARC	cis	rs7681440	0.606	rs356163	chr4:90696827	A/C	cg06632027	chr4:90757378	SNCA	0.42	5.28	0.33	2.92e-7	Dementia with Lewy bodies;
SARC	cis	rs9911578	0.967	rs4932693	chr17:57110327	T/C	cg20303301	chr17:57937339	TUBD1	0.34	4.95	0.31	1.42e-6	Intelligence (multi-trait analysis);
SARC	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-5.59	-0.34	6.45e-8	Bipolar disorder;
SARC	cis	rs7647973	0.593	rs58339610	chr3:49845006	T/A	cg06212747	chr3:49208901	KLHDC8B	-0.59	-5.94	-0.36	1.01e-8	Menarche (age at onset);
SARC	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg02725872	chr8:58115012	NA	-0.36	-6.12	-0.37	3.91e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6570726	0.902	rs373321	chr6:145854150	T/A	cg05220968	chr6:146057943	EPM2A	-0.3	-5.08	-0.32	7.76e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1707322	0.721	rs11211149	chr1:46112218	T/C	cg03146154	chr1:46216737	IPP	0.52	6.25	0.38	1.92e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7223966	1.000	rs11870797	chr17:61804622	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	6.88	0.41	5.45e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg12050434	chr12:43030949	NA	-0.87	-7.53	-0.44	1.14e-12	Autism spectrum disorder or schizophrenia;
SARC	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg14893161	chr1:205819251	PM20D1	-0.52	-6.57	-0.4	3.28e-10	Menarche (age at onset);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg17070539	chr3:16647103	DAZL	0.49	6.76	0.4	1.12e-10	Thyroid stimulating hormone;
SARC	cis	rs7587476	0.784	rs17424051	chr2:215688992	G/C	cg11970703	chr2:215861251	ABCA12	-0.31	-4.75	-0.3	3.63e-6	Neuroblastoma;
SARC	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg08859206	chr1:53392774	SCP2	0.39	5.68	0.35	3.99e-8	Monocyte count;
SARC	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg11890956	chr21:40555474	PSMG1	1.17	19.0	0.78	2.91e-49	Cognitive function;
SARC	cis	rs7113874	0.659	rs7931834	chr11:8525293	G/A	cg09828998	chr11:8703972	RPL27A	0.5	5.41	0.33	1.56e-7	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6088580	0.634	rs6058041	chr20:33018008	A/G	cg08999081	chr20:33150536	PIGU	0.43	6.52	0.39	4.22e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs1267303	0.675	rs1267309	chr1:46987342	G/A	cg25110126	chr1:46999211	NA	-0.69	-7.64	-0.45	5.57e-13	Monobrow;
SARC	cis	rs710216	0.879	rs710218	chr1:43427218	A/T	cg22176566	chr1:43424700	SLC2A1	0.48	5.25	0.33	3.5e-7	Red cell distribution width;
SARC	cis	rs76419734	1.000	rs11733223	chr4:106765525	A/C	cg24545054	chr4:106630052	GSTCD;INTS12	-0.82	-5.62	-0.35	5.36e-8	Post bronchodilator FEV1;
SARC	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg22535103	chr8:58192502	C8orf71	-0.59	-6.21	-0.38	2.35e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs9329221	0.683	rs555200	chr8:9888729	A/G	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.94	-0.41	3.78e-11	Neuroticism;
SARC	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg08677398	chr8:58056175	NA	0.44	5.25	0.33	3.38e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9400467	0.506	rs17510789	chr6:111702789	A/G	cg15721981	chr6:111408429	SLC16A10	0.59	5.36	0.33	1.96e-7	Blood metabolite levels;Amino acid levels;
SARC	cis	rs709400	0.663	rs10141388	chr14:103939679	A/G	cg26031613	chr14:104095156	KLC1	0.79	11.04	0.59	4.53e-23	Body mass index;
SARC	cis	rs9611565	0.512	rs5758464	chr22:42171300	A/G	cg03806693	chr22:41940476	POLR3H	0.75	7.26	0.43	5.67e-12	Vitiligo;
SARC	cis	rs240764	0.612	rs2157342	chr6:100920655	A/T	cg09795085	chr6:101329169	ASCC3	0.4	4.9	0.31	1.78e-6	Neuroticism;
SARC	cis	rs2985684	0.740	rs2883438	chr14:50044392	T/C	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.47	5.06	0.31	8.44e-7	Carotid intima media thickness;
SARC	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg01341218	chr17:43662625	NA	0.96	10.77	0.58	3.24e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7605378	0.528	rs1704190	chr2:200760629	G/A	cg17644776	chr2:200775616	C2orf69	0.53	6.62	0.4	2.4e-10	Osteoporosis;
SARC	cis	rs2273669	0.667	rs12214567	chr6:109317330	C/T	cg05315195	chr6:109294784	ARMC2	-0.59	-5.45	-0.34	1.28e-7	Prostate cancer;
SARC	cis	rs3020736	0.500	rs7364293	chr22:42506370	C/T	cg04733989	chr22:42467013	NAGA	-0.77	-10.79	-0.58	2.84e-22	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7429990	0.864	rs1464614	chr3:47654375	A/C	cg11946769	chr3:48343235	NME6	0.4	4.75	0.3	3.48e-6	Educational attainment (years of education);
SARC	cis	rs7092929	0.882	rs535539	chr10:3574757	T/C	cg14308648	chr10:3568949	NA	0.51	5.19	0.32	4.65e-7	Coronary artery calcification;
SARC	cis	rs9325144	0.555	rs4882358	chr12:38726640	A/G	cg10518543	chr12:38710700	ALG10B	0.38	4.77	0.3	3.2e-6	Morning vs. evening chronotype;
SARC	cis	rs7647973	0.710	rs7629322	chr3:49621994	C/T	cg03060546	chr3:49711283	APEH	0.73	6.76	0.4	1.12e-10	Menarche (age at onset);
SARC	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg19223190	chr17:80058835	NA	0.44	6.19	0.38	2.67e-9	Life satisfaction;
SARC	cis	rs6964587	1.000	rs6969981	chr7:91689461	G/C	cg17063962	chr7:91808500	NA	0.96	16.21	0.73	4.33e-40	Breast cancer;
SARC	cis	rs9660992	0.590	rs1779411	chr1:205238530	C/T	cg07972983	chr1:205091412	RBBP5	0.56	6.69	0.4	1.6e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs11098499	0.657	rs9996569	chr4:120299004	G/C	cg09307838	chr4:120376055	NA	0.91	12.88	0.65	4.9e-29	Corneal astigmatism;
SARC	cis	rs36051895	0.632	rs10974979	chr9:5131731	C/A	cg02405213	chr9:5042618	JAK2	-0.45	-5.31	-0.33	2.56e-7	Pediatric autoimmune diseases;
SARC	cis	rs10892173	0.846	rs12790243	chr11:117678543	C/T	cg07621104	chr11:117668040	DSCAML1	0.43	5.57	0.34	6.98e-8	Myopia;
SARC	cis	rs734999	0.549	rs2764840	chr1:2529437	C/T	cg20673091	chr1:2541236	MMEL1	-0.33	-5.07	-0.32	8.06e-7	Ulcerative colitis;
SARC	cis	rs11225247	0.881	rs11604189	chr11:102219863	T/G	cg11690896	chr11:102217788	BIRC2	0.81	5.39	0.33	1.71e-7	Vein graft stenosis in coronary artery bypass grafting;
SARC	cis	rs11574514	1.000	rs8052287	chr16:67865073	C/T	cg01866162	chr16:67596514	CTCF	0.85	5.21	0.32	4.14e-7	Crohn's disease;
SARC	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg09165964	chr15:75287851	SCAMP5	0.48	6.43	0.39	6.96e-10	Breast cancer;
SARC	cis	rs3762637	1.000	rs72958458	chr3:122185549	T/C	cg24169773	chr3:122142474	KPNA1	-0.56	-5.73	-0.35	3.07e-8	LDL cholesterol levels;
SARC	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg04267008	chr7:1944627	MAD1L1	-0.51	-5.8	-0.36	2.12e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg15320075	chr8:145703422	NA	-0.59	-7.8	-0.46	2.01e-13	Age at first birth;
SARC	cis	rs4792901	0.959	rs3765174	chr17:41623670	C/T	cg22562494	chr17:41607896	ETV4	-0.31	-4.86	-0.3	2.13e-6	Dupuytren's disease;
SARC	cis	rs9398803	0.713	rs4621656	chr6:126896168	G/C	cg19875578	chr6:126661172	C6orf173	0.61	8.36	0.48	5.79e-15	Male-pattern baldness;
SARC	cis	rs8523	0.901	rs953413	chr6:11012859	G/A	cg13562911	chr6:11044106	ELOVL2	0.36	4.78	0.3	3.11e-6	Red blood cell fatty acid levels;
SARC	cis	rs11608355	0.545	rs7139106	chr12:109908640	G/A	cg05360138	chr12:110035743	NA	0.93	9.71	0.54	6.21e-19	Neuroticism;
SARC	trans	rs1478898	0.526	rs1478897	chr8:11395232	A/T	cg06636001	chr8:8085503	FLJ10661	0.5	6.75	0.4	1.16e-10	Morning vs. evening chronotype;
SARC	cis	rs7595412	1.000	rs10168721	chr2:199002562	A/C	cg00208931	chr2:198669586	PLCL1	-0.7	-5.69	-0.35	3.73e-8	Hip bone size;
SARC	cis	rs13191362	1.000	rs67025553	chr6:163011552	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.56	5.35	0.33	2.07e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs72945132	0.882	rs72947012	chr11:70149472	G/A	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.59	-0.34	6.41e-8	Coronary artery disease;
SARC	cis	rs3820928	1.000	rs10197757	chr2:227763244	A/C	cg11843606	chr2:227700838	RHBDD1	-0.5	-6.34	-0.38	1.19e-9	Pulmonary function;
SARC	cis	rs57994353	0.861	rs34302850	chr9:139327064	A/G	cg13611204	chr9:139324423	INPP5E	-0.28	-5.08	-0.32	7.79e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs8114671	0.967	rs4911478	chr20:33782625	A/C	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.45	-0.34	1.28e-7	Height;
SARC	cis	rs9859260	0.744	rs3933	chr3:195784997	C/T	cg03462622	chr3:195777018	TFRC	-0.48	-5.73	-0.35	3.04e-8	Mean corpuscular volume;
SARC	cis	rs963731	0.649	rs297130	chr2:39299314	C/T	cg04010122	chr2:39346883	SOS1	0.93	6.37	0.39	9.86e-10	Corticobasal degeneration;
SARC	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg22903657	chr4:1355424	KIAA1530	-0.36	-4.89	-0.31	1.84e-6	Obesity-related traits;
SARC	cis	rs8054556	0.787	rs11649274	chr16:30026469	G/A	cg06015834	chr16:30021696	DOC2A	-0.37	-5.0	-0.31	1.15e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs668210	0.793	rs507672	chr11:65767153	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.53	-5.31	-0.33	2.6e-7	Cerebrospinal fluid biomarker levels;
SARC	trans	rs61931739	0.890	rs11053018	chr12:34105962	T/G	cg13010199	chr12:38710504	ALG10B	-0.56	-7.31	-0.43	4.29e-12	Morning vs. evening chronotype;
SARC	cis	rs6912958	0.712	rs9444526	chr6:88326402	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.54	-0.34	8.34e-8	Monocyte percentage of white cells;
SARC	cis	rs9479482	1.000	rs11155696	chr6:150357283	G/A	cg03788504	chr6:150331562	NA	-0.32	-5.25	-0.33	3.41e-7	Alopecia areata;
SARC	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg04518342	chr5:131593106	PDLIM4	0.42	5.76	0.35	2.64e-8	Acylcarnitine levels;
SARC	cis	rs6545883	0.929	rs10193666	chr2:61629408	C/T	cg15711740	chr2:61764176	XPO1	0.41	5.06	0.31	8.68e-7	Tuberculosis;
SARC	cis	rs7223966	1.000	rs7209435	chr17:61712964	T/C	cg00588841	chr17:61851480	DDX42;CCDC47	-0.59	-6.7	-0.4	1.59e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs10504229	0.593	rs80174614	chr8:58024631	G/A	cg21724239	chr8:58056113	NA	0.67	6.68	0.4	1.76e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg08564027	chr20:61660810	NA	-0.69	-9.98	-0.55	9.61e-20	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg01368799	chr11:117014884	PAFAH1B2	0.49	5.64	0.35	4.9e-8	Blood protein levels;
SARC	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.29	0.38	1.55e-9	Bipolar disorder;
SARC	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg02297831	chr4:17616191	MED28	0.48	6.22	0.38	2.27e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs910316	1.000	rs10143132	chr14:75525850	G/A	cg23033748	chr14:75592666	NEK9	0.36	4.96	0.31	1.33e-6	Height;
SARC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg10862848	chr6:42927986	GNMT	-0.45	-7.51	-0.44	1.28e-12	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs208520	0.690	rs74707865	chr6:66717352	A/G	cg07460842	chr6:66804631	NA	1.06	14.4	0.69	4.75e-34	Exhaled nitric oxide output;
SARC	cis	rs1008375	1.000	rs60178264	chr4:17685308	G/T	cg02297831	chr4:17616191	MED28	0.43	5.43	0.33	1.44e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2594989	0.943	rs9877694	chr3:11418873	A/C	cg00170343	chr3:11313890	ATG7	0.58	5.7	0.35	3.69e-8	Circulating chemerin levels;
SARC	cis	rs7208859	0.623	rs9916725	chr17:29107471	A/C	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg02263426	chr18:14378524	NA	-0.85	-7.39	-0.44	2.68e-12	Autism spectrum disorder or schizophrenia;
SARC	cis	rs561341	0.609	rs9906443	chr17:30185565	C/T	cg13647721	chr17:30228624	UTP6	-0.74	-6.8	-0.41	8.66e-11	Hip circumference adjusted for BMI;
SARC	cis	rs73635312	0.777	rs78400042	chr10:8934022	T/G	cg24467326	chr10:9646929	NA	0.76	5.93	0.36	1.11e-8	Basal cell carcinoma;
SARC	cis	rs5758659	0.652	rs1063392	chr22:42454950	C/T	cg04733989	chr22:42467013	NAGA	-0.54	-7.22	-0.43	7.16e-12	Cognitive function;
SARC	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg08219700	chr8:58056026	NA	0.73	6.39	0.39	9.16e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9462027	0.606	rs4624858	chr6:34802301	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-6.09	-0.37	4.62e-9	Systemic lupus erythematosus;
SARC	cis	rs651907	0.514	rs12636046	chr3:101434448	T/G	cg12386194	chr3:101231763	SENP7	0.49	5.83	0.36	1.83e-8	Colorectal cancer;
SARC	cis	rs11716531	0.574	rs13075192	chr3:27279235	C/T	cg02860705	chr3:27208620	NA	0.54	6.58	0.4	2.99e-10	Diastolic blood pressure;
SARC	cis	rs721399	0.553	rs13262341	chr8:18243097	A/G	cg18736775	chr8:18248649	NAT2	-0.68	-7.44	-0.44	1.98e-12	Blood metabolite levels;
SARC	cis	rs59482735	1	rs59482735	chr9:123643426	T/TAA	cg09419670	chr9:123605666	PSMD5;LOC253039	0.42	4.74	0.3	3.67e-6	Prostate-specific antigen levels;
SARC	cis	rs6665290	0.935	rs1929862	chr1:227199718	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.09	-25.57	-0.86	1.47e-69	Myeloid white cell count;
SARC	cis	rs12134245	0.776	rs12137878	chr1:91973210	G/T	cg02896835	chr1:92012615	NA	-0.5	-6.81	-0.41	8.19e-11	Breast cancer;
SARC	cis	rs6493487	0.512	rs58661036	chr15:51201780	A/C	cg02338191	chr15:51200825	AP4E1	0.55	5.09	0.32	7.27e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs9640161	0.711	rs3800781	chr7:150027324	T/A	cg21361702	chr7:150065534	REPIN1	0.51	5.24	0.32	3.53e-7	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs11758351	0.866	rs11757394	chr6:26206694	G/C	cg23601095	chr6:26197514	HIST1H3D	0.55	4.86	0.3	2.19e-6	Gout;Renal underexcretion gout;
SARC	cis	rs3105593	1.000	rs3109894	chr15:50878574	C/T	cg05456662	chr15:50716270	USP8	0.4	5.03	0.31	9.95e-7	QT interval;
SARC	cis	rs763121	0.853	rs6001191	chr22:39074452	T/C	cg06022373	chr22:39101656	GTPBP1	0.84	10.39	0.56	4.96e-21	Menopause (age at onset);
SARC	cis	rs7712401	0.791	rs3822367	chr5:122146272	A/G	cg19412675	chr5:122181750	SNX24	-0.39	-5.23	-0.32	3.78e-7	Mean platelet volume;
SARC	cis	rs2439831	1.000	rs689781	chr15:43792097	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	8.42	0.48	3.97e-15	Lung cancer in ever smokers;
SARC	cis	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg08564027	chr20:61660810	NA	0.76	11.8	0.61	1.69e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg08859206	chr1:53392774	SCP2	-0.42	-6.12	-0.37	3.91e-9	Monocyte count;
SARC	cis	rs12594515	1.000	rs12911309	chr15:45985719	G/C	cg14863074	chr15:45997064	NA	0.34	5.25	0.33	3.44e-7	Waist circumference;Weight;
SARC	cis	rs2814982	0.605	rs77579349	chr6:34480473	C/A	cg17674042	chr6:34482479	PACSIN1	-0.58	-4.91	-0.31	1.72e-6	Cholesterol, total;Total cholesterol levels;
SARC	cis	rs6991838	0.530	rs6472217	chr8:66547731	A/G	cg13398993	chr8:66546079	ARMC1	0.62	8.25	0.48	1.21e-14	Intelligence (multi-trait analysis);
SARC	cis	rs12311304	1.000	rs6488766	chr12:15374630	A/G	cg08258403	chr12:15378311	NA	0.45	6.82	0.41	7.6e-11	Behavioural disinhibition (generation interaction);
SARC	cis	rs921968	0.643	rs659185	chr2:219335935	C/T	cg02176678	chr2:219576539	TTLL4	0.37	5.55	0.34	7.64e-8	Mean corpuscular hemoglobin concentration;
SARC	cis	rs9291683	0.526	rs12506122	chr4:10033538	C/A	cg00071950	chr4:10020882	SLC2A9	0.35	5.27	0.33	3.11e-7	Bone mineral density;
SARC	cis	rs6582630	0.533	rs11504406	chr12:38334580	C/T	cg26384229	chr12:38710491	ALG10B	-0.58	-7.11	-0.42	1.4e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg25894440	chr7:65020034	NA	-0.74	-5.64	-0.35	4.95e-8	Diabetic kidney disease;
SARC	cis	rs7785360	0.800	rs9647931	chr7:69733185	G/A	cg10619644	chr7:69149951	AUTS2	0.42	4.9	0.31	1.77e-6	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
SARC	cis	rs933688	1.000	rs2839728	chr5:90727412	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.04	13.5	0.66	4.7e-31	Smoking behavior;
SARC	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg22105103	chr4:187893119	NA	0.48	6.57	0.4	3.33e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.38	4.79	0.3	2.91e-6	Lymphocyte counts;
SARC	cis	rs57506017	0.585	rs10281425	chr7:12280730	T/A	cg23422036	chr7:12250390	TMEM106B	0.48	6.36	0.38	1.06e-9	Neuroticism;
SARC	cis	rs9916302	0.904	rs4795356	chr17:37535631	C/T	cg00129232	chr17:37814104	STARD3	0.61	7.54	0.44	1.06e-12	Glomerular filtration rate (creatinine);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg03655940	chr16:15737228	MIR484;NDE1;KIAA0430	-0.78	-6.68	-0.4	1.71e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs11585357	0.843	rs12095095	chr1:17625832	C/G	cg08277548	chr1:17600880	PADI3	-0.45	-5.42	-0.33	1.46e-7	Hair shape;
SARC	cis	rs9921222	0.786	rs3848365	chr16:374617	C/T	cg00101154	chr16:420108	MRPL28	-0.38	-5.46	-0.34	1.2e-7	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs4595586	0.545	rs7310463	chr12:39368927	T/C	cg26384229	chr12:38710491	ALG10B	0.51	6.25	0.38	1.9e-9	Morning vs. evening chronotype;
SARC	cis	rs11969893	0.850	rs9386260	chr6:101329428	G/A	cg12253828	chr6:101329408	ASCC3	1.25	7.85	0.46	1.55e-13	Economic and political preferences (immigration/crime);
SARC	cis	rs2070488	0.766	rs4679050	chr3:38482007	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	12.8	0.64	9.33e-29	Electrocardiographic conduction measures;
SARC	cis	rs11764590	0.694	rs7801349	chr7:2085553	T/C	cg23043544	chr7:2124092	MAD1L1	-0.34	-4.78	-0.3	3.07e-6	Neuroticism;
SARC	cis	rs9906944	0.678	rs56015440	chr17:47136631	C/G	cg16584676	chr17:46985605	UBE2Z	-0.43	-5.21	-0.32	4.09e-7	Intelligence (multi-trait analysis);Body fat percentage;
SARC	cis	rs3784262	0.654	rs4646568	chr15:58344290	A/G	cg12031962	chr15:58353849	ALDH1A2	0.36	5.26	0.33	3.27e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg02725872	chr8:58115012	NA	-0.36	-6.32	-0.38	1.35e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs12586317	0.728	rs2415288	chr14:35807508	T/C	cg26967526	chr14:35346199	BAZ1A	-0.5	-4.95	-0.31	1.43e-6	Psoriasis;
SARC	cis	rs72945132	0.825	rs12287883	chr11:70122369	C/T	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.78	-0.35	2.39e-8	Coronary artery disease;
SARC	cis	rs6582630	0.539	rs8189604	chr12:38308546	G/T	cg14851346	chr12:38532713	NA	-0.45	-5.3	-0.33	2.66e-7	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs459571	0.920	rs417142	chr9:136891370	G/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.57	-6.48	-0.39	5.3e-10	Platelet distribution width;
SARC	cis	rs8018808	0.560	rs1061638	chr14:77928525	A/G	cg14520941	chr14:77935699	AHSA1	-0.34	-4.73	-0.3	3.87e-6	Myeloid white cell count;
SARC	cis	rs6704644	0.651	rs7587876	chr2:234316032	A/G	cg27060346	chr2:234359958	DGKD	-0.68	-5.2	-0.32	4.26e-7	Bilirubin levels;
SARC	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg18876405	chr7:65276391	NA	-0.44	-4.93	-0.31	1.56e-6	Aortic root size;
SARC	cis	rs1153858	1.000	rs67461176	chr15:45676819	C/T	cg26924012	chr15:45694286	SPATA5L1	0.79	11.28	0.59	7.91e-24	Homoarginine levels;
SARC	cis	rs9840812	0.623	rs1394092	chr3:136196071	C/T	cg15507776	chr3:136538369	TMEM22	0.51	5.73	0.35	3.16e-8	Fibrinogen levels;
SARC	cis	rs854765	0.618	rs9908017	chr17:17774422	C/T	cg04398451	chr17:18023971	MYO15A	0.44	6.34	0.38	1.18e-9	Total body bone mineral density;
SARC	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg15049968	chr18:44337910	ST8SIA5	-0.35	-5.6	-0.34	6.16e-8	Personality dimensions;
SARC	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg02725872	chr8:58115012	NA	-0.26	-4.74	-0.3	3.7e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg08677398	chr8:58056175	NA	0.44	5.25	0.33	3.38e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2153535	0.580	rs2327056	chr6:8443305	C/T	cg07606381	chr6:8435919	SLC35B3	0.78	11.09	0.59	3.11e-23	Motion sickness;
SARC	cis	rs7027203	0.688	rs4075733	chr9:96624645	C/T	cg13679303	chr9:96623674	NA	-0.4	-5.85	-0.36	1.62e-8	DNA methylation (variation);
SARC	cis	rs13082711	0.911	rs6773733	chr3:27502131	C/A	cg02860705	chr3:27208620	NA	0.48	6.02	0.37	6.8e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs920590	0.837	rs4398935	chr8:19649487	T/C	cg17834443	chr8:19674713	INTS10	0.46	5.71	0.35	3.41e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs10089	0.953	rs1432615	chr5:127395371	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	10.19	0.56	2.04e-20	Ileal carcinoids;
SARC	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg13206674	chr6:150067644	NUP43	0.48	6.36	0.38	1.07e-9	Lung cancer;
SARC	cis	rs3739821	0.789	rs10987787	chr9:130729153	C/G	cg13668314	chr9:130692638	PIP5KL1	-0.38	-4.94	-0.31	1.49e-6	Glaucoma (primary angle closure);
SARC	cis	rs11785400	1.000	rs11776301	chr8:143737142	A/G	cg10596483	chr8:143751796	JRK	0.65	8.64	0.49	8.79e-16	Schizophrenia;
SARC	cis	rs2147959	0.941	rs1007686	chr1:228651457	A/G	cg16894439	chr1:228634806	NA	-0.44	-4.74	-0.3	3.67e-6	Adult asthma;
SARC	cis	rs55883249	1.000	rs17362902	chr2:9768564	C/T	cg23886495	chr2:9695866	ADAM17	-0.65	-6.61	-0.4	2.55e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg11062466	chr8:58055876	NA	0.54	5.53	0.34	8.37e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4727027	0.782	rs10245343	chr7:148796333	T/C	cg15662616	chr7:148823355	ZNF425;ZNF398	0.46	5.02	0.31	1.01e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs9309473	0.950	rs7566364	chr2:73842889	T/C	cg20560298	chr2:73613845	ALMS1	-0.44	-5.2	-0.32	4.34e-7	Metabolite levels;
SARC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg23034840	chr1:205782522	SLC41A1	-0.5	-5.67	-0.35	4.11e-8	Menarche (age at onset);
SARC	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg25072359	chr17:41440525	NA	0.48	5.55	0.34	7.59e-8	Menopause (age at onset);
SARC	cis	rs933688	1.000	rs2052553	chr5:90729906	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.05	13.15	0.65	6.48e-30	Smoking behavior;
SARC	cis	rs7605378	1.000	rs7577763	chr2:200681753	C/T	cg23649088	chr2:200775458	C2orf69	0.5	5.67	0.35	4.28e-8	Osteoporosis;
SARC	cis	rs4642101	0.590	rs6799544	chr3:12812979	T/C	cg05775895	chr3:12838266	CAND2	0.55	7.68	0.45	4.3e-13	QRS complex (12-leadsum);
SARC	cis	rs35110281	0.666	rs9977076	chr21:45085829	G/A	cg21573476	chr21:45109991	RRP1B	-0.59	-8.41	-0.48	4.13e-15	Mean corpuscular volume;
SARC	cis	rs6831352	0.879	rs29001229	chr4:100046823	A/G	cg13256891	chr4:100009986	ADH5	-0.67	-8.41	-0.48	4.22e-15	Alcohol dependence;
SARC	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg19077165	chr18:44547161	KATNAL2	-0.5	-6.75	-0.4	1.18e-10	Personality dimensions;
SARC	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg11644478	chr21:40555479	PSMG1	1.06	15.09	0.7	2.33e-36	Cognitive function;
SARC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg11965913	chr1:205819406	PM20D1	0.99	18.5	0.77	1.29e-47	Menarche (age at onset);
SARC	cis	rs17376456	0.757	rs6859757	chr5:93206042	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.7	6.2	0.38	2.57e-9	Diabetic retinopathy;
SARC	cis	rs8141529	0.551	rs16986864	chr22:29350911	G/T	cg15103426	chr22:29168792	CCDC117	0.6	5.84	0.36	1.76e-8	Lymphocyte counts;
SARC	trans	rs877282	0.891	rs11599917	chr10:762288	G/A	cg22713356	chr15:30763199	NA	0.95	9.31	0.52	1e-17	Uric acid levels;
SARC	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg24642844	chr7:1081250	C7orf50	-0.57	-6.05	-0.37	5.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs3749237	0.964	rs62260719	chr3:49852419	G/A	cg03060546	chr3:49711283	APEH	0.59	7.16	0.42	1.05e-11	Resting heart rate;
SARC	cis	rs11098499	0.863	rs10004484	chr4:120442428	C/T	cg24375607	chr4:120327624	NA	0.41	4.8	0.3	2.84e-6	Corneal astigmatism;
SARC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	19.66	0.79	2.21e-51	Prudent dietary pattern;
SARC	cis	rs7264396	0.635	rs6058346	chr20:34481043	G/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	5.33	0.33	2.29e-7	Total cholesterol levels;
SARC	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg12463550	chr7:65579703	CRCP	-0.46	-5.03	-0.31	9.79e-7	Aortic root size;
SARC	cis	rs910316	1.000	rs12590452	chr14:75548756	T/C	cg08847533	chr14:75593920	NEK9	0.94	16.23	0.73	3.79e-40	Height;
SARC	cis	rs11711311	1.000	rs1043132	chr3:113528689	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	8.61	0.49	1.13e-15	IgG glycosylation;
SARC	cis	rs2952156	0.920	rs903502	chr17:37829604	C/T	cg20243544	chr17:37824526	PNMT	0.55	7.17	0.43	1e-11	Asthma;
SARC	cis	rs28602670	1	rs28602670	chr15:78768167	C/G	cg06917634	chr15:78832804	PSMA4	-0.53	-5.5	-0.34	1.02e-7	Post bronchodilator FEV1;
SARC	cis	rs9747201	1.000	rs58472289	chr17:80111895	G/T	cg17462356	chr17:80056334	FASN	0.48	5.47	0.34	1.16e-7	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs7681440	0.606	rs2583985	chr4:90755939	A/G	cg06632027	chr4:90757378	SNCA	-0.43	-5.36	-0.33	2e-7	Dementia with Lewy bodies;
SARC	cis	rs79149102	0.579	rs58068887	chr15:75286140	G/A	cg09165964	chr15:75287851	SCAMP5	-0.95	-8.68	-0.49	7.05e-16	Lung cancer;
SARC	cis	rs7312933	0.558	rs11181467	chr12:42765250	C/T	cg19980929	chr12:42632907	YAF2	0.49	6.99	0.42	2.9e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	trans	rs11098499	0.863	rs10004484	chr4:120442428	C/T	cg25214090	chr10:38739885	LOC399744	0.54	6.76	0.4	1.07e-10	Corneal astigmatism;
SARC	cis	rs3087591	1.000	rs7220483	chr17:29577248	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.51	-6.31	-0.38	1.4e-9	Hip circumference;
SARC	cis	rs7017697	1.000	rs2410612	chr8:19681647	A/G	cg03894339	chr8:19674705	INTS10	0.45	5.72	0.35	3.19e-8	Breast cancer;
SARC	cis	rs546131	0.642	rs473848	chr11:34851977	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.42	4.83	0.3	2.49e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg12463550	chr7:65579703	CRCP	0.53	5.61	0.35	5.64e-8	Aortic root size;
SARC	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg11301795	chr4:187892539	NA	0.71	10.64	0.57	8.19e-22	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs72781680	0.716	rs2712065	chr2:23973603	C/T	cg06627628	chr2:24431161	ITSN2	0.5	5.25	0.33	3.47e-7	Lymphocyte counts;
SARC	cis	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg21775007	chr8:11205619	TDH	-0.46	-5.74	-0.35	2.94e-8	Neuroticism;
SARC	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg22433210	chr17:43662623	NA	-0.95	-11.34	-0.6	4.92e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.88	13.0	0.65	2.05e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6141769	0.542	rs6057630	chr20:31318737	A/G	cg17884169	chr20:31446444	EFCAB8	-0.46	-4.95	-0.31	1.45e-6	Subjective well-being;
SARC	cis	rs875971	0.502	rs2946580	chr7:65531842	G/A	cg11764359	chr7:65958608	NA	-0.62	-5.97	-0.36	8.96e-9	Aortic root size;
SARC	cis	rs748404	0.660	rs2602141	chr15:43724646	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.52	5.85	0.36	1.63e-8	Lung cancer;
SARC	cis	rs10416265	0.528	rs3786932	chr19:33620488	T/A	cg27124370	chr19:33622961	WDR88	0.47	4.92	0.31	1.63e-6	Bone properties (heel);
SARC	cis	rs3749237	0.615	rs55957735	chr3:49438158	G/A	cg03060546	chr3:49711283	APEH	0.75	10.72	0.57	4.68e-22	Resting heart rate;
SARC	cis	rs1348850	0.801	rs11890163	chr2:178327134	G/A	cg23306229	chr2:178417860	TTC30B	0.82	7.67	0.45	4.78e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs6942407	0.592	rs886787	chr7:86850210	C/T	cg02420886	chr7:86849541	C7orf23	0.71	6.17	0.37	2.99e-9	Food allergy;
SARC	cis	rs2014572	0.967	rs8106734	chr19:57763546	C/T	cg24459738	chr19:57751996	ZNF805	-0.47	-5.43	-0.34	1.43e-7	Hyperactive-impulsive symptoms;
SARC	trans	rs9388451	0.868	rs1268083	chr6:126049040	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.56	7.05	0.42	1.96e-11	Brugada syndrome;
SARC	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg12288994	chr5:1860383	NA	0.37	6.01	0.37	7.25e-9	Cardiovascular disease risk factors;
SARC	cis	rs9715521	0.719	rs11936702	chr4:59849081	G/A	cg11281224	chr4:60001000	NA	-0.4	-5.11	-0.32	6.63e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs782590	0.764	rs935177	chr2:55826761	C/G	cg18811423	chr2:55921094	PNPT1	0.56	7.97	0.46	6.83e-14	Metabolic syndrome;
SARC	cis	rs12824058	0.799	rs4759656	chr12:130815804	G/A	cg23887609	chr12:130822674	PIWIL1	0.36	5.07	0.32	8.17e-7	Menopause (age at onset);
SARC	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg27266027	chr21:40555129	PSMG1	-0.53	-5.97	-0.36	8.73e-9	Cognitive function;
SARC	cis	rs9393692	0.537	rs2393594	chr6:26316289	G/A	cg00631329	chr6:26305371	NA	-0.57	-6.1	-0.37	4.45e-9	Educational attainment;
SARC	cis	rs2882667	0.858	rs13176497	chr5:138446074	T/C	cg04439458	chr5:138467593	SIL1	-0.29	-4.9	-0.31	1.81e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs6495122	0.501	rs7163636	chr15:75346760	C/T	cg09165964	chr15:75287851	SCAMP5	0.49	6.66	0.4	1.97e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	cis	rs4481887	0.927	rs6587445	chr1:248440915	A/G	cg13385794	chr1:248469461	NA	0.34	5.03	0.31	9.59e-7	Common traits (Other);
SARC	cis	rs12579753	0.956	rs7309624	chr12:82204266	C/A	cg07988820	chr12:82153109	PPFIA2	-0.57	-6.56	-0.39	3.53e-10	Resting heart rate;
SARC	cis	rs6582630	0.502	rs1589390	chr12:38416139	C/T	cg26384229	chr12:38710491	ALG10B	-0.56	-6.98	-0.42	3.09e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg10295955	chr4:187884368	NA	-1.07	-19.85	-0.79	5.42e-52	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1865760	0.786	rs2164487	chr6:25950800	A/C	cg16482183	chr6:26056742	HIST1H1C	0.51	6.46	0.39	5.94e-10	Height;
SARC	trans	rs66573146	0.831	rs56320732	chr4:6974319	G/A	cg07817883	chr1:32538562	TMEM39B	1.32	8.67	0.49	7.41e-16	Granulocyte percentage of myeloid white cells;
SARC	cis	rs965469	0.901	rs6037563	chr20:3326568	G/A	cg25506879	chr20:3388711	C20orf194	-0.52	-5.34	-0.33	2.2e-7	IFN-related cytopenia;
SARC	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg11764359	chr7:65958608	NA	0.58	6.93	0.41	4.06e-11	Aortic root size;
SARC	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg26513180	chr16:89883248	FANCA	0.72	4.79	0.3	2.92e-6	Skin colour saturation;
SARC	cis	rs4917300	0.606	rs2029621	chr8:143111165	T/C	cg06573787	chr8:143070187	NA	0.35	4.72	0.3	4.06e-6	Amyotrophic lateral sclerosis;
SARC	cis	rs36051895	0.658	rs10974912	chr9:5010885	A/C	cg02405213	chr9:5042618	JAK2	-0.53	-5.75	-0.35	2.79e-8	Pediatric autoimmune diseases;
SARC	cis	rs6700896	0.931	rs11208716	chr1:66158825	C/T	cg04111102	chr1:66153794	NA	0.36	5.55	0.34	7.77e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg22535103	chr8:58192502	C8orf71	-0.82	-9.34	-0.52	8.22e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs9902453	1.000	rs56280226	chr17:28429575	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	6.71	0.4	1.5e-10	Coffee consumption (cups per day);
SARC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg09373136	chr17:61933544	TCAM1	-0.44	-6.08	-0.37	4.86e-9	Prudent dietary pattern;
SARC	cis	rs8084125	0.832	rs62105178	chr18:74950635	C/T	cg05528293	chr18:74961138	GALR1	0.5	5.69	0.35	3.84e-8	Obesity-related traits;
SARC	cis	rs17250963	0.898	rs72732799	chr5:14747225	T/C	cg12465520	chr5:14733886	ANKH	0.56	4.83	0.3	2.53e-6	Homeostasis model assessment of insulin resistance (dietary factor interaction);
SARC	cis	rs2479724	0.776	rs2250428	chr6:41832772	T/A	cg17623882	chr6:41773611	USP49	-0.47	-5.73	-0.35	3.16e-8	Menarche (age at onset);
SARC	cis	rs11249608	0.548	rs2132672	chr5:178457742	A/C	cg01312482	chr5:178451176	ZNF879	-0.37	-4.97	-0.31	1.32e-6	Pubertal anthropometrics;
SARC	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg26924012	chr15:45694286	SPATA5L1	0.77	10.99	0.58	6.8e-23	Homoarginine levels;
SARC	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg22903657	chr4:1355424	KIAA1530	-0.35	-4.77	-0.3	3.31e-6	Obesity-related traits;
SARC	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg11987759	chr7:65425863	GUSB	0.47	5.71	0.35	3.48e-8	Aortic root size;
SARC	cis	rs11252926	0.583	rs2066317	chr10:520309	C/T	cg08603382	chr10:743973	NA	0.42	5.62	0.35	5.36e-8	Psychosis in Alzheimer's disease;
SARC	cis	rs7666738	0.680	rs11726233	chr4:99079773	G/A	cg05340658	chr4:99064831	C4orf37	0.55	7.02	0.42	2.46e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6570726	0.557	rs403956	chr6:145829956	T/C	cg23711669	chr6:146136114	FBXO30	0.82	11.75	0.61	2.51e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs897080	0.515	rs786403	chr2:44710788	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	6.18	0.38	2.83e-9	Height;
SARC	cis	rs67311347	0.713	rs73073505	chr3:40310693	C/T	cg09455208	chr3:40491958	NA	0.33	4.9	0.31	1.82e-6	Renal cell carcinoma;
SARC	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg15448220	chr1:150897856	SETDB1	0.48	6.29	0.38	1.58e-9	Tonsillectomy;
SARC	cis	rs11098499	0.865	rs4507344	chr4:120307485	C/A	cg09160332	chr4:120329925	NA	-0.33	-4.77	-0.3	3.27e-6	Corneal astigmatism;
SARC	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg13385521	chr17:29058706	SUZ12P	0.69	5.71	0.35	3.44e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs526231	0.543	rs26820	chr5:102528092	T/C	cg23492399	chr5:102201601	PAM	-0.53	-5.61	-0.35	5.59e-8	Primary biliary cholangitis;
SARC	cis	rs16976116	1.000	rs16976116	chr15:55480467	T/C	cg11288833	chr15:55489084	RSL24D1	0.61	6.08	0.37	4.84e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6500602	0.767	rs8060219	chr16:4480158	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.35	5.7	0.35	3.59e-8	Schizophrenia;
SARC	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg22875332	chr1:76189707	ACADM	-0.42	-5.53	-0.34	8.5e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg11764359	chr7:65958608	NA	-0.77	-9.36	-0.52	6.84e-18	Aortic root size;
SARC	cis	rs7523050	0.730	rs72984628	chr1:109460808	G/A	cg08274380	chr1:109419600	GPSM2	1.17	9.77	0.54	4.16e-19	Fat distribution (HIV);
SARC	cis	rs11581859	0.587	rs66661453	chr1:99186721	A/G	cg20286094	chr1:99190917	SNX7	-0.41	-4.88	-0.3	1.97e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs17376456	0.597	rs7733142	chr5:93322795	C/A	cg21475434	chr5:93447410	FAM172A	-0.62	-6.59	-0.4	2.84e-10	Diabetic retinopathy;
SARC	cis	rs113835537	0.935	rs3867133	chr11:66451962	A/G	cg24851651	chr11:66362959	CCS	-0.46	-4.91	-0.31	1.75e-6	Airway imaging phenotypes;
SARC	cis	rs12079745	1.000	rs10919073	chr1:169102398	T/C	cg09363564	chr1:169337483	NME7;BLZF1	-0.71	-4.96	-0.31	1.39e-6	QT interval;
SARC	cis	rs12579753	0.917	rs7306043	chr12:82191282	G/A	cg07988820	chr12:82153109	PPFIA2	-0.52	-6.09	-0.37	4.69e-9	Resting heart rate;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg24815353	chr21:46700591	POFUT2	0.49	6.26	0.38	1.82e-9	Breast cancer;
SARC	cis	rs3768617	0.510	rs2027075	chr1:183073266	A/G	cg13390022	chr1:182993471	LAMC1	0.33	4.9	0.31	1.79e-6	Fuchs's corneal dystrophy;
SARC	cis	rs13314892	0.692	rs57788691	chr3:69897450	G/T	cg17445875	chr3:69859618	MITF	-0.55	-5.66	-0.35	4.33e-8	QRS complex (12-leadsum);
SARC	cis	rs155076	1.000	rs261430	chr13:21865242	C/T	cg11317459	chr13:21872234	NA	-0.95	-11.42	-0.6	2.81e-24	White matter hyperintensity burden;
SARC	cis	rs17023223	0.537	rs10923754	chr1:119668640	T/C	cg05756136	chr1:119680316	WARS2	-0.45	-4.89	-0.31	1.85e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs3008870	0.959	rs1886686	chr1:67390468	C/G	cg08660285	chr1:67390436	MIER1;WDR78	0.93	11.48	0.6	1.77e-24	Lymphocyte percentage of white cells;
SARC	cis	rs3820928	1.000	rs4675119	chr2:227774635	A/C	cg11843606	chr2:227700838	RHBDD1	-0.53	-6.74	-0.4	1.23e-10	Pulmonary function;
SARC	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.3	-4.74	-0.3	3.65e-6	Total body bone mineral density;
SARC	cis	rs995000	0.931	rs10889344	chr1:63033941	T/C	cg06896770	chr1:63153194	DOCK7	-0.9	-13.26	-0.66	2.87e-30	Triglyceride levels;
SARC	cis	rs7937682	0.921	rs1944119	chr11:111436387	A/G	cg09085632	chr11:111637200	PPP2R1B	0.83	12.46	0.63	1.24e-27	Primary sclerosing cholangitis;
SARC	cis	rs2952156	0.920	rs14050	chr17:37828072	C/T	cg00129232	chr17:37814104	STARD3	-0.72	-10.11	-0.55	3.72e-20	Asthma;
SARC	cis	rs2120019	0.935	rs34913788	chr15:75372617	A/C	cg12414181	chr15:75287860	SCAMP5	-0.42	-4.89	-0.31	1.87e-6	Blood trace element (Zn levels);
SARC	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg03433033	chr1:76189801	ACADM	0.54	7.24	0.43	6.65e-12	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.9	-0.5	1.61e-16	Alzheimer's disease;
SARC	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-7.83	-0.46	1.71e-13	Alzheimer's disease;
SARC	cis	rs11098499	0.874	rs7661020	chr4:120106982	T/C	cg09307838	chr4:120376055	NA	0.82	11.06	0.59	3.96e-23	Corneal astigmatism;
SARC	cis	rs7429990	1.000	rs1665982	chr3:47905079	A/G	cg11946769	chr3:48343235	NME6	-0.66	-6.69	-0.4	1.68e-10	Educational attainment (years of education);
SARC	cis	rs12681366	0.708	rs2515157	chr8:95378530	G/A	cg26464482	chr8:95565502	KIAA1429	-0.44	-5.36	-0.33	1.97e-7	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg03709012	chr19:19516395	GATAD2A	-1.02	-17.9	-0.76	1.17e-45	Tonsillectomy;
SARC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg11905131	chr22:24372483	LOC391322	-0.5	-5.48	-0.34	1.09e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs734999	0.545	rs9970196	chr1:2574078	T/C	cg20673091	chr1:2541236	MMEL1	-0.32	-4.81	-0.3	2.68e-6	Ulcerative colitis;
SARC	cis	rs7647973	0.593	rs58339610	chr3:49845006	T/A	cg07636037	chr3:49044803	WDR6	-0.63	-6.43	-0.39	7.01e-10	Menarche (age at onset);
SARC	cis	rs763121	0.853	rs2281019	chr22:39064378	T/A	cg21395723	chr22:39101663	GTPBP1	0.54	6.03	0.37	6.24e-9	Menopause (age at onset);
SARC	cis	rs4975709	0.569	rs4975742	chr5:1858612	T/C	cg12288994	chr5:1860383	NA	0.41	6.49	0.39	5.25e-10	Cardiovascular disease risk factors;
SARC	cis	rs611744	0.967	rs677842	chr8:109212468	A/G	cg21045802	chr8:109455806	TTC35	0.46	5.41	0.33	1.57e-7	Dupuytren's disease;
SARC	cis	rs11718455	0.960	rs34241796	chr3:44000394	A/T	cg21419209	chr3:44054225	NA	-0.42	-5.26	-0.33	3.33e-7	Coronary artery disease;
SARC	cis	rs2303745	0.589	rs1465576	chr19:17398487	G/A	cg04248312	chr19:17393744	ANKLE1	-0.59	-7.64	-0.45	5.72e-13	Systemic lupus erythematosus;
SARC	cis	rs4234284	0.900	rs12491804	chr3:126983124	G/T	cg03987639	chr3:127174481	NA	0.43	4.81	0.3	2.66e-6	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
SARC	cis	rs10791323	0.511	rs4937837	chr11:133731134	T/C	cg03690763	chr11:133734501	NA	-0.29	-4.74	-0.3	3.64e-6	Childhood ear infection;
SARC	cis	rs4780401	0.728	rs8191290	chr16:11765954	C/A	cg01061890	chr16:11836724	TXNDC11	-0.46	-5.83	-0.36	1.88e-8	Rheumatoid arthritis;
SARC	cis	rs9400467	0.537	rs12215291	chr6:111463520	A/G	cg15721981	chr6:111408429	SLC16A10	0.67	5.86	0.36	1.57e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs208520	0.661	rs1100950	chr6:66827285	A/C	cg07460842	chr6:66804631	NA	-1.06	-14.03	-0.68	8.04e-33	Exhaled nitric oxide output;
SARC	cis	rs11122272	0.735	rs2808584	chr1:231512925	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs2576037	0.796	rs2571032	chr18:44578250	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.49	6.48	0.39	5.32e-10	Personality dimensions;
SARC	cis	rs7659604	0.537	rs6815973	chr4:122663430	A/T	cg20573242	chr4:122745356	CCNA2	-0.47	-5.76	-0.35	2.67e-8	Type 2 diabetes;
SARC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.05	0.8	1.19e-52	Prudent dietary pattern;
SARC	cis	rs6964587	1.000	rs10225892	chr7:91671020	A/G	cg17063962	chr7:91808500	NA	0.96	16.61	0.74	2.18e-41	Breast cancer;
SARC	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.68	6.96	0.42	3.35e-11	Platelet count;
SARC	cis	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg13902645	chr11:5959945	NA	-0.45	-5.18	-0.32	4.69e-7	DNA methylation (variation);
SARC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg24846343	chr22:24311635	DDTL	0.51	6.91	0.41	4.67e-11	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg19223190	chr17:80058835	NA	0.38	5.31	0.33	2.61e-7	Life satisfaction;
SARC	cis	rs703842	0.963	rs2291617	chr12:58166403	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.78	11.4	0.6	3.2e-24	Multiple sclerosis;
SARC	cis	rs9399135	0.844	rs13209789	chr6:135367916	A/G	cg24558204	chr6:135376177	HBS1L	0.46	6.24	0.38	2.09e-9	Red blood cell count;
SARC	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg17971929	chr21:40555470	PSMG1	-0.84	-10.97	-0.58	7.72e-23	Cognitive function;
SARC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.81	8.6	0.49	1.18e-15	Platelet count;
SARC	cis	rs36051895	0.559	rs7868706	chr9:5210936	T/G	cg02405213	chr9:5042618	JAK2	-0.43	-5.03	-0.31	9.65e-7	Pediatric autoimmune diseases;
SARC	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg27347728	chr4:17578864	LAP3	0.48	6.01	0.37	7.23e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs561341	1.000	rs546748	chr17:30324293	A/C	cg00745463	chr17:30367425	LRRC37B	-0.56	-4.75	-0.3	3.61e-6	Hip circumference adjusted for BMI;
SARC	cis	rs9486719	0.843	rs2472876	chr6:96845723	A/G	cg06623918	chr6:96969491	KIAA0776	0.75	7.39	0.44	2.65e-12	Migraine;Coronary artery disease;
SARC	cis	rs1355223	0.902	rs286862	chr11:34718779	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.41	5.3	0.33	2.65e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs910316	1.000	rs4903284	chr14:75592483	G/C	cg23033748	chr14:75592666	NEK9	0.37	5.22	0.32	4.05e-7	Height;
SARC	cis	rs12984174	1.000	rs403439	chr19:18142075	A/G	cg21649277	chr19:18117794	ARRDC2	-0.69	-5.78	-0.35	2.41e-8	Pulmonary function in asthmatics;
SARC	cis	rs7326068	0.610	rs2762999	chr13:21445243	G/A	cg16922012	chr13:21400325	XPO4	-0.42	-5.66	-0.35	4.45e-8	Schizophrenia, bipolar disorder and depression (combined);
SARC	cis	rs4642101	0.618	rs9877079	chr3:12821287	A/G	cg24848339	chr3:12840334	CAND2	0.36	5.85	0.36	1.64e-8	QRS complex (12-leadsum);
SARC	trans	rs61931739	0.857	rs1828514	chr12:34139600	A/G	cg26384229	chr12:38710491	ALG10B	0.58	7.83	0.46	1.68e-13	Morning vs. evening chronotype;
SARC	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg19723775	chr5:179050963	HNRNPH1	0.55	7.16	0.42	1.08e-11	Lung cancer;
SARC	cis	rs1448094	0.872	rs1026085	chr12:86355735	A/G	cg02569458	chr12:86230093	RASSF9	0.41	6.02	0.37	6.74e-9	Major depressive disorder;
SARC	cis	rs712039	0.687	rs11656455	chr17:35771885	G/A	cg16670864	chr17:35848621	DUSP14	0.5	5.49	0.34	1.02e-7	Tuberculosis;
SARC	cis	rs523522	0.962	rs12371550	chr12:120987643	C/T	cg12219531	chr12:120966889	COQ5	0.83	11.08	0.59	3.36e-23	High light scatter reticulocyte count;
SARC	cis	rs2239547	0.522	rs9311485	chr3:52987645	T/G	cg11645453	chr3:52864694	ITIH4	-0.31	-4.77	-0.3	3.31e-6	Schizophrenia;
SARC	cis	rs4243830	0.850	rs12046229	chr1:6580397	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	1.01	8.12	0.47	2.69e-14	Body mass index;
SARC	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.46	-5.77	-0.35	2.54e-8	Gut microbiome composition (summer);
SARC	cis	rs12249377	0.519	rs11186320	chr10:92576448	C/T	cg14313238	chr10:92632228	RPP30	-0.43	-5.15	-0.32	5.59e-7	White matter microstructure (global fractional anisotropy);
SARC	cis	rs1348850	0.526	rs4893829	chr2:178399810	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.59	-5.59	-0.34	6.38e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg23758822	chr17:41437982	NA	0.9	11.42	0.6	2.9e-24	Menopause (age at onset);
SARC	trans	rs9329221	0.502	rs11777364	chr8:10288546	C/G	cg06636001	chr8:8085503	FLJ10661	0.48	6.59	0.4	2.94e-10	Neuroticism;
SARC	cis	rs9393692	0.905	rs6940237	chr6:26282322	T/C	cg00631329	chr6:26305371	NA	-0.62	-9.04	-0.51	6.06e-17	Educational attainment;
SARC	cis	rs3936840	0.539	rs3742445	chr14:102975552	T/A	cg18135206	chr14:102964638	TECPR2	0.42	4.97	0.31	1.3e-6	Plateletcrit;
SARC	cis	rs13191362	1.000	rs34398656	chr6:162999612	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.56	5.41	0.33	1.53e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs1983891	1.000	rs4714483	chr6:41528214	G/A	cg15051332	chr6:41514432	FOXP4	0.54	6.0	0.37	7.67e-9	Prostate cancer;
SARC	cis	rs3820928	0.874	rs10182307	chr2:227875360	C/T	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.01	-0.31	1.09e-6	Pulmonary function;
SARC	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg12463550	chr7:65579703	CRCP	0.65	4.93	0.31	1.57e-6	Diabetic kidney disease;
SARC	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg05313129	chr8:58192883	C8orf71	-0.62	-6.37	-0.39	9.92e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9291683	0.527	rs3822247	chr4:10094671	G/A	cg00071950	chr4:10020882	SLC2A9	-0.42	-6.3	-0.38	1.47e-9	Bone mineral density;
SARC	trans	rs1814175	0.935	rs10839317	chr11:49657228	A/C	cg15704280	chr7:45808275	SEPT13	-0.92	-15.93	-0.72	3.71e-39	Height;
SARC	cis	rs4689388	0.890	rs13130845	chr4:6297646	A/C	cg00701064	chr4:6280414	WFS1	0.53	8.45	0.48	3.22e-15	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs9473924	0.505	rs9473931	chr6:50851411	C/G	cg14470998	chr6:50812995	TFAP2B	0.77	7.23	0.43	6.7e-12	Body mass index;
SARC	cis	rs1949733	0.523	rs55977448	chr4:8542918	G/T	cg11789530	chr4:8429930	ACOX3	-0.71	-8.05	-0.47	4.31e-14	Response to antineoplastic agents;
SARC	cis	rs57994353	0.759	rs35873563	chr9:139324029	C/T	cg14169450	chr9:139327907	INPP5E	0.43	5.48	0.34	1.08e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs7945705	0.782	rs3763918	chr11:8819683	T/A	cg21881798	chr11:8931708	C11orf17;ST5	0.48	6.66	0.4	1.98e-10	Hemoglobin concentration;
SARC	trans	rs1814175	0.817	rs10769613	chr11:49769692	G/A	cg15704280	chr7:45808275	SEPT13	-0.97	-18.15	-0.77	1.71e-46	Height;
SARC	cis	rs1843834	0.505	rs4674911	chr2:225345254	A/G	cg22455342	chr2:225449267	CUL3	0.64	7.92	0.46	9.64e-14	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs798554	0.660	rs1182175	chr7:2875026	C/T	cg13628971	chr7:2884303	GNA12	-0.39	-4.82	-0.3	2.63e-6	Height;
SARC	cis	rs2777491	0.957	rs8026197	chr15:41711447	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.81	-11.71	-0.61	3.25e-25	Ulcerative colitis;
SARC	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg18404041	chr3:52824283	ITIH1	-0.44	-6.58	-0.4	3.05e-10	Bipolar disorder;
SARC	cis	rs514406	0.536	rs878957	chr1:53197559	C/T	cg08859206	chr1:53392774	SCP2	0.39	5.68	0.35	4.06e-8	Monocyte count;
SARC	cis	rs208520	1.000	rs12191403	chr6:66978137	C/T	cg07460842	chr6:66804631	NA	0.9	10.32	0.56	8.16e-21	Exhaled nitric oxide output;
SARC	cis	rs7659604	0.502	rs4075066	chr4:122684283	T/C	cg19671926	chr4:122722719	EXOSC9	0.57	7.32	0.43	4.09e-12	Type 2 diabetes;
SARC	cis	rs898097	0.627	rs3785514	chr17:80888905	A/G	cg15369054	chr17:80825471	TBCD	-0.61	-8.36	-0.48	5.55e-15	Breast cancer;
SARC	cis	rs9467773	0.620	rs2504571	chr6:26643435	C/T	cg11502198	chr6:26597334	ABT1	0.63	8.54	0.49	1.78e-15	Intelligence (multi-trait analysis);
SARC	cis	rs2153535	0.580	rs9378556	chr6:8514695	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	8.21	0.47	1.56e-14	Motion sickness;
SARC	cis	rs7614311	0.731	rs73130544	chr3:63868596	G/A	cg22134162	chr3:63841271	THOC7	-0.45	-4.85	-0.3	2.25e-6	Lung function (FVC);Lung function (FEV1);
SARC	trans	rs61931739	0.534	rs10844725	chr12:34009504	C/A	cg13010199	chr12:38710504	ALG10B	0.75	10.07	0.55	4.77e-20	Morning vs. evening chronotype;
SARC	cis	rs9581857	0.556	rs9581864	chr13:28041567	T/C	cg22138327	chr13:27999177	GTF3A	0.54	5.62	0.35	5.52e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg00684032	chr4:1343700	KIAA1530	0.37	4.95	0.31	1.45e-6	Obesity-related traits;
SARC	cis	rs9733	0.744	rs12758227	chr1:150844583	C/A	cg13175981	chr1:150552382	MCL1	0.62	8.41	0.48	4.16e-15	Tonsillectomy;
SARC	cis	rs634534	0.591	rs688862	chr11:65733393	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.46	5.96	0.36	9.22e-9	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg06582575	chr6:163149167	PACRG;PARK2	0.72	6.23	0.38	2.15e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.59e-6	Depression;
SARC	cis	rs7829975	0.510	rs2921073	chr8:8307643	C/T	cg08975724	chr8:8085496	FLJ10661	0.62	8.03	0.47	4.79e-14	Mood instability;
SARC	cis	rs765787	0.530	rs7165889	chr15:45531640	T/C	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.81e-6	Uric acid levels;
SARC	cis	rs9309473	0.519	rs13009035	chr2:73845709	T/C	cg20560298	chr2:73613845	ALMS1	0.49	6.65	0.4	2.06e-10	Metabolite levels;
SARC	cis	rs6141769	0.542	rs12480157	chr20:31262920	A/G	cg17884169	chr20:31446444	EFCAB8	-0.43	-4.72	-0.3	4.05e-6	Subjective well-being;
SARC	cis	rs34375054	0.557	rs35620656	chr12:125629103	G/T	cg25124228	chr12:125621409	AACS	-0.65	-8.17	-0.47	2.01e-14	Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs2075371	0.933	rs2244548	chr7:133986234	A/G	cg20476274	chr7:133979776	SLC35B4	0.62	8.41	0.48	4.18e-15	Mean platelet volume;
SARC	cis	rs79349575	0.778	rs12950328	chr17:46967061	C/T	cg16584676	chr17:46985605	UBE2Z	0.54	6.43	0.39	7.1e-10	Type 2 diabetes;
SARC	cis	rs858239	0.600	rs6978827	chr7:23125544	A/T	cg23682824	chr7:23144976	KLHL7	0.71	9.6	0.53	1.34e-18	Cerebrospinal fluid biomarker levels;
SARC	trans	rs9427116	0.502	rs12125166	chr1:154582129	A/G	cg23367851	chr7:25165401	CYCS	-0.49	-6.23	-0.38	2.16e-9	Blood protein levels;
SARC	cis	rs616402	0.527	rs604369	chr1:10567208	C/A	cg17425144	chr1:10567563	PEX14	0.47	7.54	0.44	1.04e-12	Breast size;
SARC	cis	rs11583043	1.000	rs34915449	chr1:101476786	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.49	5.88	0.36	1.42e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	5.93	0.36	1.1e-8	Height;
SARC	cis	rs9902453	0.934	rs12453172	chr17:28441590	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	6.52	0.39	4.2e-10	Coffee consumption (cups per day);
SARC	cis	rs7769051	1.000	rs9493443	chr6:133121349	C/T	cg22852734	chr6:133119734	C6orf192	1.11	11.42	0.6	2.76e-24	Type 2 diabetes nephropathy;
SARC	cis	rs6496667	0.586	rs7162687	chr15:90889323	C/T	cg22089800	chr15:90895588	ZNF774	-0.46	-5.2	-0.32	4.35e-7	Rheumatoid arthritis;
SARC	cis	rs9303401	0.659	rs34913878	chr17:56897094	A/G	cg25039879	chr17:56429692	SUPT4H1	0.64	6.1	0.37	4.41e-9	Cognitive test performance;
SARC	cis	rs7586879	0.616	rs6726199	chr2:25126328	G/C	cg04586622	chr2:25135609	ADCY3	0.32	5.4	0.33	1.64e-7	Body mass index;
SARC	cis	rs918629	0.530	rs6889029	chr5:95251238	A/G	cg16656078	chr5:95278638	ELL2	0.54	6.95	0.41	3.64e-11	IgG glycosylation;
SARC	trans	rs36093844	0.752	rs17817308	chr11:85593529	G/A	cg27065003	chr5:122429449	PRDM6	-0.53	-6.34	-0.38	1.16e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs4780401	0.526	rs4781137	chr16:11774950	T/C	cg01061890	chr16:11836724	TXNDC11	-0.38	-4.83	-0.3	2.48e-6	Rheumatoid arthritis;
SARC	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.82	10.82	0.58	2.22e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs11155671	0.530	rs7758020	chr6:150208111	T/C	cg09699651	chr6:150184138	LRP11	0.51	6.56	0.39	3.46e-10	Testicular germ cell tumor;
SARC	cis	rs9811216	1.000	rs10936601	chr3:169528449	A/G	cg14222479	chr3:169487675	ARPM1	-0.45	-5.43	-0.34	1.38e-7	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg22109331	chr1:212003961	LPGAT1	0.63	6.24	0.38	2.04e-9	Lung cancer in ever smokers;
SARC	cis	rs5167	0.504	rs7258345	chr19:45453151	T/G	cg10169327	chr19:45448959	APOC2	0.31	5.11	0.32	6.65e-7	Blood protein levels;
SARC	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg11764359	chr7:65958608	NA	0.78	9.86	0.54	2.14e-19	Aortic root size;
SARC	cis	rs8067354	0.645	rs2271304	chr17:57814641	A/G	cg13753209	chr17:57696993	CLTC	0.65	6.57	0.4	3.32e-10	Hemoglobin concentration;
SARC	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	9.1	0.51	4.28e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg25072359	chr17:41440525	NA	0.51	6.27	0.38	1.72e-9	Menopause (age at onset);
SARC	cis	rs55823223	0.564	rs9894009	chr17:73850414	C/T	cg23806715	chr17:73775811	H3F3B	0.46	4.97	0.31	1.3e-6	Psoriasis;
SARC	cis	rs11190604	0.943	rs2495744	chr10:102329409	C/T	cg07510080	chr10:102295549	HIF1AN	0.47	4.91	0.31	1.72e-6	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs10089	1.000	rs4836366	chr5:127482494	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.81	10.17	0.55	2.39e-20	Ileal carcinoids;
SARC	cis	rs2880765	0.566	rs11630381	chr15:86012503	A/G	cg19183879	chr15:85880815	NA	-0.29	-4.72	-0.3	4.16e-6	Coronary artery disease;
SARC	cis	rs11651000	0.625	rs4794063	chr17:45804494	C/T	cg24803719	chr17:45855879	NA	-0.43	-6.77	-0.41	1.01e-10	IgG glycosylation;
SARC	cis	rs9902453	1.000	rs12600855	chr17:28279591	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	6.82	0.41	7.86e-11	Coffee consumption (cups per day);
SARC	cis	rs9715521	0.746	rs62301192	chr4:59843340	T/C	cg11281224	chr4:60001000	NA	-0.4	-5.12	-0.32	6.5e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs4481887	0.927	rs10788765	chr1:248445642	A/G	cg20433858	chr1:248101009	OR2L13	0.41	4.74	0.3	3.76e-6	Common traits (Other);
SARC	cis	rs6088580	0.505	rs6058106	chr20:33278255	T/C	cg24642439	chr20:33292090	TP53INP2	-0.55	-6.72	-0.4	1.35e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg20965017	chr5:231967	SDHA	-0.55	-5.26	-0.33	3.23e-7	Breast cancer;
SARC	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg04277193	chr17:41438351	NA	0.45	4.77	0.3	3.3e-6	Menopause (age at onset);
SARC	cis	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg14343924	chr8:8086146	FLJ10661	0.44	5.4	0.33	1.66e-7	Mood instability;
SARC	cis	rs72781680	1.000	rs72796339	chr2:24143063	T/C	cg08917208	chr2:24149416	ATAD2B	0.77	7.18	0.43	9.09e-12	Lymphocyte counts;
SARC	trans	rs1853207	1.000	rs3758581	chr10:96602623	G/A	cg02737782	chr1:8014393	NA	-0.95	-6.37	-0.39	1.01e-9	Blood metabolite levels;
SARC	cis	rs2075371	1.000	rs2598285	chr7:133971153	A/T	cg11752832	chr7:134001865	SLC35B4	0.55	7.24	0.43	6.57e-12	Mean platelet volume;
SARC	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg12463550	chr7:65579703	CRCP	0.53	5.86	0.36	1.59e-8	Aortic root size;
SARC	cis	rs9916302	0.706	rs8075737	chr17:37727316	C/T	cg00129232	chr17:37814104	STARD3	0.57	6.29	0.38	1.54e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs705471	1.000	rs59874431	chr10:3675733	C/T	cg14308648	chr10:3568949	NA	0.48	6.21	0.38	2.4e-9	Capecitabine sensitivity;
SARC	cis	rs9818758	0.607	rs73082362	chr3:49113729	C/T	cg07636037	chr3:49044803	WDR6	-0.7	-5.33	-0.33	2.3e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs6088580	0.634	rs4911153	chr20:32961547	C/T	cg24642439	chr20:33292090	TP53INP2	-0.65	-8.52	-0.49	1.97e-15	Glomerular filtration rate (creatinine);
SARC	trans	rs35833281	1.000	rs34522972	chr6:55036832	G/A	cg19977494	chr7:128431264	CCDC136	-0.74	-7.05	-0.42	1.99e-11	Morning vs. evening chronotype;
SARC	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg17971929	chr21:40555470	PSMG1	0.98	13.88	0.67	2.53e-32	Cognitive function;
SARC	cis	rs3126085	1.000	rs72696952	chr1:152172694	A/T	cg26876637	chr1:152193138	HRNR	-0.51	-5.24	-0.32	3.53e-7	Atopic dermatitis;
SARC	cis	rs4253772	0.550	rs6007779	chr22:46678615	A/C	cg24881330	chr22:46731750	TRMU	0.72	7.42	0.44	2.15e-12	LDL cholesterol;Cholesterol, total;
SARC	cis	rs13006833	0.694	rs291444	chr2:191176223	T/C	cg25963032	chr2:191064776	C2orf88	0.36	4.99	0.31	1.16e-6	Urinary metabolites;
SARC	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg15049968	chr18:44337910	ST8SIA5	-0.33	-5.21	-0.32	4.21e-7	Personality dimensions;
SARC	cis	rs17376456	0.825	rs13165400	chr5:93091427	G/A	cg21475434	chr5:93447410	FAM172A	0.74	6.27	0.38	1.77e-9	Diabetic retinopathy;
SARC	cis	rs12421382	0.636	rs1439519	chr11:109378438	A/G	cg16359550	chr11:109292809	C11orf87	0.33	4.97	0.31	1.31e-6	Schizophrenia;
SARC	cis	rs1008375	1.000	rs2058338	chr4:17678600	A/G	cg16339924	chr4:17578868	LAP3	-0.65	-8.62	-0.49	1.05e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs881375	0.967	rs7046108	chr9:123660339	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.41	-4.99	-0.31	1.17e-6	Rheumatoid arthritis;
SARC	cis	rs2276314	0.793	rs77590522	chr18:33629410	C/G	cg05985134	chr18:33552581	C18orf21	0.71	7.02	0.42	2.41e-11	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs9814567	0.806	rs2293293	chr3:134322742	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.51	-6.65	-0.4	2.02e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg09373136	chr17:61933544	TCAM1	-0.45	-6.17	-0.37	2.95e-9	Prudent dietary pattern;
SARC	cis	rs2075371	0.933	rs1901214	chr7:133945108	C/T	cg11752832	chr7:134001865	SLC35B4	-0.54	-6.97	-0.42	3.28e-11	Mean platelet volume;
SARC	cis	rs2439831	0.867	rs12323999	chr15:43683115	T/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	8.32	0.48	7.23e-15	Lung cancer in ever smokers;
SARC	cis	rs55883249	1.000	rs11676903	chr2:9763201	G/C	cg23886495	chr2:9695866	ADAM17	0.69	7.02	0.42	2.38e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs1580019	0.587	rs1597555	chr7:32546118	T/G	cg14728415	chr7:32535168	LSM5;AVL9	0.53	6.84	0.41	7.05e-11	Cognitive ability;
SARC	trans	rs1853207	1.000	rs75794524	chr10:96694591	G/A	cg02737782	chr1:8014393	NA	-0.91	-6.52	-0.39	4.4e-10	Blood metabolite levels;
SARC	cis	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg12463550	chr7:65579703	CRCP	0.65	5.04	0.31	9.53e-7	Diabetic kidney disease;
SARC	cis	rs559928	0.556	rs11607903	chr11:63932140	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	5.12	0.32	6.44e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg13175981	chr1:150552382	MCL1	-0.5	-6.06	-0.37	5.3e-9	Melanoma;
SARC	cis	rs12701220	0.504	rs12702092	chr7:1145868	G/A	cg00990874	chr7:1149470	C7orf50	-0.52	-5.21	-0.32	4.24e-7	Bronchopulmonary dysplasia;
SARC	cis	rs7614311	0.636	rs73130576	chr3:63890875	T/C	cg22134162	chr3:63841271	THOC7	-0.46	-4.95	-0.31	1.44e-6	Lung function (FVC);Lung function (FEV1);
SARC	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg23758822	chr17:41437982	NA	0.91	11.35	0.6	4.7e-24	Menopause (age at onset);
SARC	cis	rs826838	0.935	rs4583043	chr12:38645147	T/G	cg26384229	chr12:38710491	ALG10B	0.92	14.25	0.68	1.5e-33	Heart rate;
SARC	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg12648201	chr2:27665141	KRTCAP3	-0.32	-4.84	-0.3	2.36e-6	Total body bone mineral density;
SARC	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg18252515	chr7:66147081	NA	-0.54	-6.02	-0.37	6.58e-9	Aortic root size;
SARC	cis	rs12155623	0.603	rs2203065	chr8:49881987	A/G	cg22283653	chr8:49824208	NA	-0.35	-5.17	-0.32	4.99e-7	Sudden cardiac arrest;
SARC	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg13628971	chr7:2884303	GNA12	0.66	7.93	0.46	9.22e-14	Height;
SARC	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	13.88	0.67	2.59e-32	Chronic sinus infection;
SARC	cis	rs644799	0.710	rs56384142	chr11:95502075	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.94	16.24	0.73	3.62e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs950027	0.787	rs1153845	chr15:45724729	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.54	-6.59	-0.4	2.9e-10	Response to fenofibrate (adiponectin levels);
SARC	trans	rs9650657	0.707	rs10097283	chr8:10659406	G/C	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.66	-0.4	1.98e-10	Neuroticism;
SARC	cis	rs9660992	0.736	rs1180734	chr1:205255438	A/G	cg21643547	chr1:205240462	TMCC2	-0.61	-8.31	-0.48	7.69e-15	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs3733585	0.673	rs7434391	chr4:9967682	C/G	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.65	-0.35	4.69e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7264396	0.580	rs6119655	chr20:34412049	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-7.22	-0.43	7.27e-12	Total cholesterol levels;
SARC	cis	rs8016982	0.609	rs8009519	chr14:81702503	C/G	cg01989461	chr14:81687754	GTF2A1	0.74	11.14	0.59	2.16e-23	Schizophrenia;
SARC	cis	rs7552404	0.731	rs61770552	chr1:76373050	T/C	cg22875332	chr1:76189707	ACADM	0.4	4.82	0.3	2.62e-6	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7561149	0.534	rs11893004	chr2:179731655	G/A	cg17765952	chr2:179737173	CCDC141	-0.47	-6.61	-0.4	2.65e-10	QT interval;
SARC	trans	rs459571	0.715	rs401826	chr9:136890591	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.6	-6.74	-0.4	1.22e-10	Platelet distribution width;
SARC	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg11890956	chr21:40555474	PSMG1	1.16	19.69	0.79	1.79e-51	Cognitive function;
SARC	cis	rs3087591	0.960	rs2905787	chr17:29482381	G/A	cg24425628	chr17:29625626	OMG;NF1	0.56	6.91	0.41	4.51e-11	Hip circumference;
SARC	cis	rs870825	0.655	rs67798981	chr4:185619567	A/T	cg04058563	chr4:185651563	MLF1IP	0.82	11.42	0.6	2.8e-24	Blood protein levels;
SARC	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg24549020	chr5:56110836	MAP3K1	0.81	8.4	0.48	4.37e-15	Initial pursuit acceleration;
SARC	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg11644478	chr21:40555479	PSMG1	-0.55	-6.69	-0.4	1.67e-10	Menarche (age at onset);
SARC	cis	rs2290402	0.536	rs7684266	chr4:856609	T/C	cg00846425	chr4:957561	DGKQ	-0.42	-4.89	-0.31	1.89e-6	Type 2 diabetes;
SARC	cis	rs910316	1.000	rs7142235	chr14:75559963	T/C	cg23033748	chr14:75592666	NEK9	0.37	5.27	0.33	3.12e-7	Height;
SARC	cis	rs7617773	0.817	rs3729577	chr3:48228994	A/C	cg11946769	chr3:48343235	NME6	0.72	9.33	0.52	8.8e-18	Coronary artery disease;
SARC	cis	rs11690935	0.959	rs7355594	chr2:172639448	G/T	cg13550731	chr2:172543902	DYNC1I2	-1.0	-15.98	-0.72	2.61e-39	Schizophrenia;
SARC	cis	rs11676348	0.818	rs4674256	chr2:218987893	A/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.5	-6.42	-0.39	7.61e-10	Ulcerative colitis;
SARC	cis	rs4423214	0.879	rs1792282	chr11:71135166	G/A	cg05163923	chr11:71159392	DHCR7	-0.48	-5.39	-0.33	1.74e-7	Vitamin D levels;
SARC	cis	rs7513165	0.867	rs7524621	chr1:204160938	A/G	cg23788856	chr1:204159729	KISS1	0.32	4.85	0.3	2.25e-6	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
SARC	cis	rs1153858	1.000	rs16942000	chr15:45633003	C/T	cg14582100	chr15:45693742	SPATA5L1	0.36	4.96	0.31	1.37e-6	Homoarginine levels;
SARC	trans	rs61931739	0.658	rs10772149	chr12:34285498	A/G	cg13010199	chr12:38710504	ALG10B	0.56	7.37	0.43	3e-12	Morning vs. evening chronotype;
SARC	cis	rs9859260	0.710	rs366268	chr3:195782177	A/G	cg03462622	chr3:195777018	TFRC	-0.47	-5.41	-0.33	1.53e-7	Mean corpuscular volume;
SARC	cis	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg24110177	chr3:50126178	RBM5	-0.4	-5.15	-0.32	5.66e-7	Intelligence (multi-trait analysis);
SARC	cis	rs72781680	0.848	rs6754694	chr2:24155448	T/C	cg08917208	chr2:24149416	ATAD2B	0.76	7.14	0.42	1.21e-11	Lymphocyte counts;
SARC	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.54	8.13	0.47	2.5e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs9660992	0.789	rs1768584	chr1:205240145	A/G	cg21545522	chr1:205238299	TMCC2	0.45	6.35	0.38	1.1e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs7937682	0.961	rs7106104	chr11:111635655	T/C	cg22437258	chr11:111473054	SIK2	-0.68	-8.75	-0.5	4.49e-16	Primary sclerosing cholangitis;
SARC	cis	rs6062509	0.931	rs4809329	chr20:62348460	C/T	cg27236539	chr20:62289627	RTEL1	0.49	5.46	0.34	1.2e-7	Prostate cancer;
SARC	cis	rs7666738	0.791	rs4699329	chr4:99056212	G/A	cg05340658	chr4:99064831	C4orf37	0.64	8.68	0.49	7.17e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7937682	0.587	rs611607	chr11:111349765	C/T	cg22437258	chr11:111473054	SIK2	0.46	5.47	0.34	1.13e-7	Primary sclerosing cholangitis;
SARC	cis	rs9487051	0.652	rs6568559	chr6:109592751	C/T	cg01475377	chr6:109611718	NA	-0.35	-5.08	-0.32	7.66e-7	Reticulocyte fraction of red cells;
SARC	cis	rs8067545	0.641	rs1638525	chr17:19848594	G/C	cg13482628	chr17:19912719	NA	0.5	6.06	0.37	5.38e-9	Schizophrenia;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg22025132	chr6:143771787	ADAT2;PEX3	-0.8	-6.73	-0.4	1.3e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg21782813	chr7:2030301	MAD1L1	0.37	5.75	0.35	2.72e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs950880	0.710	rs1035130	chr2:103001402	C/T	cg03938978	chr2:103052716	IL18RAP	-0.34	-4.85	-0.3	2.22e-6	Serum protein levels (sST2);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg04305134	chr10:75173374	ANXA7	-0.57	-6.41	-0.39	8e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs1008375	1.000	rs1008374	chr4:17683219	G/A	cg27347728	chr4:17578864	LAP3	0.45	5.61	0.34	5.81e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6570726	0.905	rs421032	chr6:145827771	A/G	cg23711669	chr6:146136114	FBXO30	0.78	11.84	0.61	1.21e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg01017244	chr2:74357527	NA	0.6	7.33	0.43	3.83e-12	Gestational age at birth (maternal effect);
SARC	cis	rs9393692	0.557	rs62394769	chr6:26326182	C/T	cg13736514	chr6:26305472	NA	-0.42	-4.97	-0.31	1.3e-6	Educational attainment;
SARC	cis	rs798554	0.644	rs7783400	chr7:2894434	A/C	cg13628971	chr7:2884303	GNA12	-0.6	-7.17	-0.43	9.78e-12	Height;
SARC	cis	rs67460515	0.926	rs13062740	chr3:161024208	G/A	cg03342759	chr3:160939853	NMD3	-0.68	-8.68	-0.49	6.81e-16	Parkinson's disease;
SARC	cis	rs10131894	0.611	rs175001	chr14:75436452	A/C	cg08847533	chr14:75593920	NEK9	0.77	10.56	0.57	1.53e-21	Coronary artery disease;
SARC	cis	rs2380220	0.576	rs4368819	chr6:96031109	T/G	cg15832292	chr6:96025679	MANEA	0.54	5.78	0.35	2.38e-8	Behavioural disinhibition (generation interaction);
SARC	cis	rs6893300	0.506	rs35320050	chr5:179131013	C/T	cg14593053	chr5:179126677	CANX	0.49	6.71	0.4	1.5e-10	Resting heart rate;
SARC	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg11247378	chr22:39784982	NA	-0.31	-4.99	-0.31	1.19e-6	Intelligence (multi-trait analysis);
SARC	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.57	7.51	0.44	1.27e-12	Menarche (age at onset);
SARC	cis	rs938554	0.744	rs938558	chr4:9939205	G/A	cg25986240	chr4:9926439	SLC2A9	-0.3	-4.84	-0.3	2.34e-6	Blood metabolite levels;
SARC	cis	rs1882538	0.569	rs11562037	chr7:133076885	A/G	cg10665199	chr7:133106180	EXOC4	0.4	5.2	0.32	4.32e-7	Intelligence (multi-trait analysis);
SARC	cis	rs4423214	0.819	rs7938885	chr11:71170043	T/C	cg05163923	chr11:71159392	DHCR7	0.67	9.47	0.53	3.19e-18	Vitamin D levels;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg23654174	chr1:47779667	STIL	0.54	6.75	0.4	1.13e-10	Breast cancer;
SARC	cis	rs796364	0.906	rs281784	chr2:200749749	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.79	7.05	0.42	2.01e-11	Schizophrenia;
SARC	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg13939156	chr17:80058883	NA	-0.42	-6.48	-0.39	5.51e-10	Life satisfaction;
SARC	cis	rs593982	0.920	rs521678	chr11:65485727	T/G	cg08755490	chr11:65554678	OVOL1	0.84	7.74	0.45	3.06e-13	Atopic dermatitis;
SARC	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg03433033	chr1:76189801	ACADM	0.47	6.05	0.37	5.74e-9	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs1348850	0.574	rs4893835	chr2:178442592	T/C	cg23306229	chr2:178417860	TTC30B	0.72	7.63	0.45	6.12e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg16339924	chr4:17578868	LAP3	0.66	8.76	0.5	4e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs60871478	1.000	rs62432224	chr7:788284	G/A	cg05535760	chr7:792225	HEATR2	0.8	8.1	0.47	3.07e-14	Cerebrospinal P-tau181p levels;
SARC	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg03709012	chr19:19516395	GATAD2A	1.0	17.34	0.75	7.93e-44	Tonsillectomy;
SARC	cis	rs10791323	0.569	rs10750542	chr11:133713436	T/C	cg15485101	chr11:133734466	NA	0.34	5.24	0.32	3.56e-7	Childhood ear infection;
SARC	cis	rs10752881	1.000	rs10911190	chr1:182979080	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.76	0.58	3.38e-22	Colorectal cancer;
SARC	cis	rs472402	0.905	rs533251	chr5:6637637	T/G	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.39	-4.97	-0.31	1.31e-6	Response to amphetamines;
SARC	cis	rs427394	0.802	rs274694	chr5:6734079	A/G	cg10857441	chr5:6722123	POLS	-0.34	-5.1	-0.32	7.2e-7	Menopause (age at onset);
SARC	cis	rs2529049	0.727	rs886234	chr7:24769231	T/C	cg17569154	chr7:24781545	DFNA5	0.41	5.57	0.34	6.84e-8	Urate levels in obese individuals;
SARC	cis	rs262150	0.659	rs2730275	chr7:158793397	A/G	cg19418458	chr7:158789849	NA	-0.46	-6.27	-0.38	1.74e-9	Facial morphology (factor 20);
SARC	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg00149659	chr3:10157352	C3orf10	1.09	10.0	0.55	7.87e-20	Alzheimer's disease;
SARC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.64	0.53	1.01e-18	Prudent dietary pattern;
SARC	cis	rs9467711	0.651	rs16891261	chr6:26062631	A/G	cg21479132	chr6:26055353	NA	0.89	6.12	0.37	4.02e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs4780401	0.632	rs8059262	chr16:11784129	G/T	cg01061890	chr16:11836724	TXNDC11	-0.43	-5.55	-0.34	7.66e-8	Rheumatoid arthritis;
SARC	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg04166393	chr7:2884313	GNA12	0.64	7.58	0.44	7.98e-13	Height;
SARC	cis	rs16854884	0.657	rs1979910	chr3:143710268	A/C	cg06585982	chr3:143692056	C3orf58	0.68	9.31	0.52	9.62e-18	Economic and political preferences (feminism/equality);
SARC	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg07414643	chr4:187882934	NA	0.5	7.5	0.44	1.34e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg26338869	chr17:61819248	STRADA	0.8	10.82	0.58	2.2e-22	Prudent dietary pattern;
SARC	cis	rs2153535	0.580	rs6912193	chr6:8456306	T/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.04e-14	Motion sickness;
SARC	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg14829155	chr15:31115871	NA	0.51	6.59	0.4	2.86e-10	Huntington's disease progression;
SARC	cis	rs9814567	1.000	rs17694011	chr3:134213981	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-7.03	-0.42	2.3e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs10751667	0.600	rs10902266	chr11:1005697	G/T	cg20946044	chr11:1010712	AP2A2	-0.4	-5.88	-0.36	1.45e-8	Alzheimer's disease (late onset);
SARC	cis	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg01579765	chr21:45077557	HSF2BP	-0.37	-6.22	-0.38	2.3e-9	Mean corpuscular volume;
SARC	cis	rs7666738	0.830	rs28728124	chr4:99001116	G/T	cg05340658	chr4:99064831	C4orf37	0.65	8.79	0.5	3.26e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7252981	0.632	rs739461	chr19:19715794	T/C	cg03709012	chr19:19516395	GATAD2A	-0.57	-6.09	-0.37	4.7e-9	Perceived unattractiveness to mosquitoes;
SARC	cis	rs765787	0.530	rs1648285	chr15:45517505	C/G	cg24006582	chr15:45444508	DUOX1	-0.49	-6.39	-0.39	8.83e-10	Uric acid levels;
SARC	cis	rs9640161	0.711	rs55881542	chr7:150025734	G/A	cg17279839	chr7:150038598	RARRES2	0.48	6.65	0.4	2.05e-10	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	11.57	0.6	9.38e-25	Platelet count;
SARC	cis	rs1348850	0.793	rs12990917	chr2:178487259	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.56	6.24	0.38	2.03e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs11608355	0.597	rs12579285	chr12:109832712	T/C	cg19025524	chr12:109796872	NA	-0.46	-6.95	-0.41	3.57e-11	Neuroticism;
SARC	cis	rs2439831	0.681	rs825740	chr15:43592408	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.76	8.27	0.48	1.01e-14	Lung cancer in ever smokers;
SARC	cis	rs7615952	0.604	rs9837847	chr3:125623919	G/A	cg05084668	chr3:125655381	ALG1L	-0.89	-8.26	-0.48	1.09e-14	Blood pressure (smoking interaction);
SARC	cis	rs17030434	0.822	rs7686027	chr4:154680269	T/G	cg14289246	chr4:154710475	SFRP2	0.63	6.8	0.41	8.76e-11	Electrocardiographic conduction measures;
SARC	cis	rs9388490	0.522	rs853980	chr6:127044769	T/A	cg19875578	chr6:126661172	C6orf173	-0.62	-8.41	-0.48	4.1e-15	Intelligence (multi-trait analysis);
SARC	cis	rs1865760	1.000	rs3752421	chr6:25918688	G/A	cg10373733	chr6:25993375	NA	0.45	5.32	0.33	2.41e-7	Height;
SARC	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg24675658	chr1:53192096	ZYG11B	0.57	7.97	0.46	7.2e-14	Monocyte count;
SARC	cis	rs76419734	1.000	rs11731938	chr4:106725140	T/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.75	4.95	0.31	1.43e-6	Post bronchodilator FEV1;
SARC	cis	rs7772486	0.641	rs2777485	chr6:146334377	G/A	cg05347473	chr6:146136440	FBXO30	0.68	9.31	0.52	1.01e-17	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs9395865	0.520	rs6903708	chr6:53332940	A/G	cg13950403	chr5:153418565	MFAP3;FAM114A2	-0.51	-6.23	-0.38	2.14e-9	Electroencephalographic traits in alcoholism;
SARC	cis	rs2439831	1.000	rs689826	chr15:43749916	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	8.29	0.48	9.21e-15	Lung cancer in ever smokers;
SARC	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg00684032	chr4:1343700	KIAA1530	0.42	6.16	0.37	3.18e-9	Obesity-related traits;
SARC	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg14829155	chr15:31115871	NA	-0.42	-5.19	-0.32	4.6e-7	Huntington's disease progression;
SARC	cis	rs3126085	0.877	rs12133847	chr1:152170101	T/G	cg03465714	chr1:152285911	FLG	-0.47	-5.6	-0.34	6.06e-8	Atopic dermatitis;
SARC	cis	rs208520	0.690	rs866452	chr6:66849936	A/T	cg07460842	chr6:66804631	NA	-1.05	-14.33	-0.68	7.77e-34	Exhaled nitric oxide output;
SARC	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg11890956	chr21:40555474	PSMG1	1.04	15.33	0.71	3.77e-37	Cognitive function;
SARC	cis	rs6840360	0.967	rs7667197	chr4:152613952	G/A	cg22705602	chr4:152727874	NA	-0.39	-6.72	-0.4	1.38e-10	Intelligence (multi-trait analysis);
SARC	cis	rs1318878	0.543	rs11056447	chr12:15512044	A/G	cg08258403	chr12:15378311	NA	-0.44	-6.15	-0.37	3.38e-9	Intelligence (multi-trait analysis);
SARC	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg11644478	chr21:40555479	PSMG1	1.02	14.57	0.69	1.3e-34	Cognitive function;
SARC	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg15556689	chr8:8085844	FLJ10661	0.48	5.88	0.36	1.39e-8	Mood instability;
SARC	cis	rs10982256	0.870	rs10982247	chr9:117250792	C/T	cg15903421	chr9:117267460	DFNB31	0.4	5.16	0.32	5.3e-7	Bipolar disorder;
SARC	cis	rs2070488	0.965	rs6805386	chr3:38557921	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.81	-12.82	-0.64	8e-29	Electrocardiographic conduction measures;
SARC	cis	rs8180040	0.652	rs13077398	chr3:47011120	G/C	cg27129171	chr3:47204927	SETD2	0.65	8.91	0.5	1.47e-16	Colorectal cancer;
SARC	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg13628971	chr7:2884303	GNA12	0.5	5.8	0.36	2.18e-8	Height;
SARC	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg18252515	chr7:66147081	NA	0.46	5.05	0.31	8.81e-7	Aortic root size;
SARC	trans	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg17830980	chr10:43048298	ZNF37B	0.5	6.78	0.41	9.78e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs3733585	0.699	rs6449179	chr4:9969117	G/A	cg11266682	chr4:10021025	SLC2A9	-0.37	-6.48	-0.39	5.28e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7438	0.528	rs4692570	chr4:170522973	C/T	cg07701716	chr4:170533879	NEK1	0.39	4.77	0.3	3.19e-6	Schizophrenia;
SARC	cis	rs34779708	0.931	rs4007289	chr10:35269790	G/A	cg03585969	chr10:35415529	CREM	0.4	5.03	0.31	9.59e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs838147	0.537	rs632111	chr19:49208978	A/G	cg07051648	chr19:49177693	NTN5;SEC1	-0.37	-4.84	-0.3	2.32e-6	Dietary macronutrient intake;
SARC	cis	rs10861342	1.000	rs10861353	chr12:105515290	T/C	cg23923672	chr12:105501055	KIAA1033	0.7	5.14	0.32	5.77e-7	IgG glycosylation;
SARC	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg22800045	chr5:56110881	MAP3K1	0.72	7.64	0.45	5.47e-13	Initial pursuit acceleration;
SARC	cis	rs2273669	0.504	rs77608624	chr6:109442854	A/G	cg05315195	chr6:109294784	ARMC2	-0.6	-5.02	-0.31	1.01e-6	Prostate cancer;
SARC	cis	rs910187	0.605	rs62201430	chr20:45808227	A/T	cg27589058	chr20:45804311	EYA2	-0.3	-4.96	-0.31	1.36e-6	Migraine;
SARC	cis	rs6840360	0.593	rs10222925	chr4:152690215	A/G	cg22705602	chr4:152727874	NA	-0.5	-8.96	-0.51	1.1e-16	Intelligence (multi-trait analysis);
SARC	cis	rs6977660	0.607	rs10243965	chr7:19797893	G/A	cg05791153	chr7:19748676	TWISTNB	0.7	6.34	0.38	1.19e-9	Thyroid stimulating hormone;
SARC	cis	rs2303759	0.914	rs2288481	chr19:49878196	G/A	cg22307029	chr19:49891270	CCDC155	0.63	6.55	0.39	3.63e-10	Multiple sclerosis;
SARC	cis	rs11583043	1.000	rs11584222	chr1:101480110	G/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.49	5.88	0.36	1.42e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	trans	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg27590781	chr2:152266272	RIF1	-0.49	-6.8	-0.41	8.62e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs13256369	0.760	rs7816171	chr8:8575835	T/C	cg17143192	chr8:8559678	CLDN23	0.5	5.7	0.35	3.64e-8	Obesity-related traits;
SARC	cis	rs7927592	0.513	rs653056	chr11:68203625	T/C	cg01657329	chr11:68192670	LRP5	-0.41	-5.5	-0.34	1.01e-7	Total body bone mineral density;
SARC	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	10.75	0.58	3.69e-22	Alzheimer's disease;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg08568561	chr7:42834498	NA	-0.52	-6.48	-0.39	5.43e-10	Height;
SARC	cis	rs889312	0.500	rs702688	chr5:56190986	A/G	cg14703610	chr5:56206110	C5orf35	0.53	6.49	0.39	5e-10	Breast cancer;Breast cancer (early onset);
SARC	cis	rs4642101	0.686	rs13085726	chr3:12832672	A/C	cg24848339	chr3:12840334	CAND2	0.36	5.73	0.35	3.06e-8	QRS complex (12-leadsum);
SARC	trans	rs208520	0.526	rs7775830	chr6:66755249	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.07	20.3	0.8	2.01e-53	Exhaled nitric oxide output;
SARC	cis	rs2439831	0.850	rs16977798	chr15:44151948	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	7.79	0.45	2.21e-13	Lung cancer in ever smokers;
SARC	cis	rs10791323	0.569	rs2282602	chr11:133714522	G/A	cg15485101	chr11:133734466	NA	0.34	5.19	0.32	4.47e-7	Childhood ear infection;
SARC	cis	rs7829975	0.846	rs7005216	chr8:8547110	C/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-5.73	-0.35	3.09e-8	Mood instability;
SARC	cis	rs12586317	0.620	rs76293361	chr14:35570889	G/A	cg26967526	chr14:35346199	BAZ1A	-0.64	-6.96	-0.41	3.45e-11	Psoriasis;
SARC	cis	rs2439831	1.000	rs2444032	chr15:43755346	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.04	10.94	0.58	9.8e-23	Lung cancer in ever smokers;
SARC	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-6.37	-0.39	1e-9	Personality dimensions;
SARC	cis	rs798554	0.679	rs798499	chr7:2792013	G/A	cg04166393	chr7:2884313	GNA12	0.44	5.35	0.33	2.11e-7	Height;
SARC	cis	rs1059312	1.000	rs1059312	chr12:129278864	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.42	5.15	0.32	5.5e-7	Systemic lupus erythematosus;
SARC	cis	rs12142240	0.698	rs72886911	chr1:46814352	G/A	cg00530320	chr1:46809349	NSUN4	0.57	6.92	0.41	4.4e-11	Menopause (age at onset);
SARC	cis	rs644799	0.710	rs3748253	chr11:95519506	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.95	16.34	0.73	1.71e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9611519	0.929	rs73174660	chr22:41437304	T/C	cg03806693	chr22:41940476	POLR3H	-0.6	-7.69	-0.45	4.15e-13	Neuroticism;
SARC	cis	rs981844	0.712	rs3925717	chr4:154750917	C/G	cg14289246	chr4:154710475	SFRP2	-0.45	-5.36	-0.33	1.96e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs4481887	0.893	rs6702113	chr1:248486151	T/C	cg13385794	chr1:248469461	NA	0.34	5.1	0.32	6.89e-7	Common traits (Other);
SARC	cis	rs2239547	0.657	rs12488303	chr3:52862003	G/A	cg18404041	chr3:52824283	ITIH1	-0.42	-5.01	-0.31	1.05e-6	Schizophrenia;
SARC	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg22920501	chr2:26401640	FAM59B	-0.53	-6.57	-0.4	3.17e-10	Gut microbiome composition (summer);
SARC	cis	rs6692209	1	rs6692209	chr1:152506444	C/T	cg09873164	chr1:152488093	CRCT1	0.61	7.71	0.45	3.56e-13	Plantar warts;
SARC	cis	rs6728642	1.000	rs11890407	chr2:97621647	G/C	cg26665480	chr2:98280029	ACTR1B	-0.54	-4.83	-0.3	2.47e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs11633958	1	rs11633958	chr15:78862064	C/T	cg06917634	chr15:78832804	PSMA4	-0.54	-5.71	-0.35	3.48e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	trans	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.75	-10.78	-0.58	3.03e-22	Intelligence (multi-trait analysis);
SARC	trans	rs9427116	0.502	rs12125166	chr1:154582129	A/G	cg09528988	chr5:55033758	DDX4	0.49	6.28	0.38	1.66e-9	Blood protein levels;
SARC	cis	rs6540556	0.859	rs11119340	chr1:209940560	A/T	cg05527609	chr1:210001259	C1orf107	0.67	6.54	0.39	3.93e-10	Red blood cell count;
SARC	cis	rs9325144	0.534	rs4882350	chr12:38686979	A/G	cg26384229	chr12:38710491	ALG10B	0.59	7.84	0.46	1.64e-13	Morning vs. evening chronotype;
SARC	cis	rs778371	0.723	rs737027	chr2:233641083	G/C	cg20388707	chr2:233749442	NGEF	-0.36	-5.38	-0.33	1.82e-7	Schizophrenia;
SARC	cis	rs6540556	0.723	rs3765240	chr1:209918151	G/A	cg23920097	chr1:209922102	NA	-0.63	-7.26	-0.43	5.77e-12	Red blood cell count;
SARC	cis	rs7647973	0.577	rs6446247	chr3:49102001	A/T	cg07636037	chr3:49044803	WDR6	0.86	9.19	0.52	2.2e-17	Menarche (age at onset);
SARC	cis	rs7712401	1.000	rs7712401	chr5:122374459	C/T	cg19412675	chr5:122181750	SNX24	0.38	5.21	0.32	4.07e-7	Mean platelet volume;
SARC	cis	rs2832191	0.729	rs2832201	chr21:30499841	A/G	cg08807101	chr21:30365312	RNF160	-0.88	-13.69	-0.67	1.06e-31	Dental caries;
SARC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.69	0.54	6.99e-19	Prudent dietary pattern;
SARC	cis	rs7682481	1.000	rs7682481	chr4:123524026	C/G	cg16733855	chr4:122686602	TMEM155;LOC100192379	0.35	4.91	0.31	1.68e-6	Alopecia areata;
SARC	cis	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg20965017	chr5:231967	SDHA	-0.54	-5.21	-0.32	4.22e-7	Breast cancer;
SARC	cis	rs644799	0.710	rs10765771	chr11:95521044	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.85	13.62	0.67	1.82e-31	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg13206674	chr6:150067644	NUP43	-0.45	-5.36	-0.33	2e-7	Lung cancer;
SARC	cis	rs11054731	0.579	rs10772542	chr12:12393895	T/C	cg08064997	chr12:11905431	ETV6	0.39	4.72	0.3	4.13e-6	Coronary artery calcification;
SARC	cis	rs344364	0.577	rs2745194	chr16:1854038	C/T	cg01637482	chr16:1880436	FAHD1	0.37	5.18	0.32	4.8e-7	Glomerular filtration rate in chronic kidney disease;
SARC	cis	rs709400	0.663	rs9671911	chr14:103967343	T/C	cg12935359	chr14:103987150	CKB	-0.41	-5.97	-0.36	8.94e-9	Body mass index;
SARC	trans	rs61931739	0.890	rs1705753	chr12:34144594	C/T	cg13010199	chr12:38710504	ALG10B	0.54	7.33	0.43	3.76e-12	Morning vs. evening chronotype;
SARC	cis	rs4713118	0.869	rs9283883	chr6:27715470	T/A	cg17221315	chr6:27791827	HIST1H4J	0.5	5.52	0.34	8.8e-8	Parkinson's disease;
SARC	cis	rs2180341	0.960	rs3756996	chr6:127664258	G/C	cg17762328	chr6:126965162	NA	-0.45	-5.11	-0.32	6.66e-7	Breast cancer;
SARC	cis	rs34172651	0.917	rs200539	chr16:24735178	T/C	cg04756594	chr16:24857601	SLC5A11	-0.38	-6.0	-0.37	7.49e-9	Intelligence (multi-trait analysis);
SARC	trans	rs7615952	0.611	rs114419739	chr3:125722490	C/T	cg07211511	chr3:129823064	LOC729375	-0.83	-6.53	-0.39	4e-10	Blood pressure (smoking interaction);
SARC	cis	rs57506017	0.585	rs6460905	chr7:12283227	A/G	cg23422036	chr7:12250390	TMEM106B	0.48	6.35	0.38	1.12e-9	Neuroticism;
SARC	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg04267008	chr7:1944627	MAD1L1	-0.48	-5.41	-0.33	1.54e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs4742903	0.527	rs12375816	chr9:106954377	A/G	cg14250997	chr9:106856677	SMC2	-0.4	-5.01	-0.31	1.1e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs12586317	0.547	rs12435454	chr14:35466997	A/G	cg26967526	chr14:35346199	BAZ1A	-0.57	-5.71	-0.35	3.4e-8	Psoriasis;
SARC	cis	rs5167	0.504	rs7257476	chr19:45453165	C/T	cg13119609	chr19:45449297	APOC2	0.5	8.43	0.48	3.58e-15	Blood protein levels;
SARC	trans	rs2727020	0.635	rs7124266	chr11:49280857	T/G	cg15704280	chr7:45808275	SEPT13	0.76	10.37	0.56	5.93e-21	Coronary artery disease;
SARC	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg11062466	chr8:58055876	NA	0.56	5.31	0.33	2.52e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg13175981	chr1:150552382	MCL1	-0.54	-6.9	-0.41	4.97e-11	Tonsillectomy;
SARC	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg25072359	chr17:41440525	NA	0.52	6.27	0.38	1.71e-9	Menopause (age at onset);
SARC	cis	rs78456975	0.622	rs11888851	chr2:1518254	C/G	cg26248373	chr2:1572462	NA	-0.53	-6.64	-0.4	2.2e-10	Placebo response in major depressive disorder (% change in symptom score);
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg01184560	chr5:60627852	ZSWIM6	0.49	6.44	0.39	6.73e-10	Lung adenocarcinoma;
SARC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg20102877	chr2:27665638	KRTCAP3	-0.36	-5.13	-0.32	6.03e-7	Total body bone mineral density;
SARC	cis	rs2652822	0.509	rs6494394	chr15:63440938	A/G	cg02713581	chr15:63449717	RPS27L	0.5	5.66	0.35	4.42e-8	Metabolic traits;
SARC	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.66	0.35	4.44e-8	Bipolar disorder;
SARC	trans	rs1814175	0.676	rs1851859	chr11:49860405	A/T	cg15704280	chr7:45808275	SEPT13	-0.87	-13.86	-0.67	2.94e-32	Height;
SARC	cis	rs2153535	0.542	rs9393012	chr6:8439809	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	8.27	0.48	1.05e-14	Motion sickness;
SARC	trans	rs11098499	0.954	rs13145352	chr4:120409963	C/T	cg25214090	chr10:38739885	LOC399744	-0.57	-7.31	-0.43	4.29e-12	Corneal astigmatism;
SARC	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg12564285	chr5:131593104	PDLIM4	0.45	6.17	0.37	2.98e-9	Breast cancer;
SARC	cis	rs2425143	0.512	rs2425126	chr20:34331730	T/C	cg01084648	chr20:34329383	RBM39	0.59	5.13	0.32	6.17e-7	Blood protein levels;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg04082020	chr6:41068009	NFYA;LOC221442	0.5	6.69	0.4	1.63e-10	Thyroid stimulating hormone;
SARC	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg18225595	chr11:63971243	STIP1	0.43	5.15	0.32	5.43e-7	Mean platelet volume;
SARC	cis	rs11785400	0.753	rs9773415	chr8:143731170	G/A	cg24634471	chr8:143751801	JRK	0.6	7.73	0.45	3.12e-13	Schizophrenia;
SARC	cis	rs7084402	0.967	rs2114564	chr10:60314729	T/C	cg07615347	chr10:60278583	BICC1	0.56	8.09	0.47	3.2e-14	Refractive error;
SARC	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg00684032	chr4:1343700	KIAA1530	0.48	6.88	0.41	5.58e-11	Obesity-related traits;
SARC	cis	rs17376456	0.569	rs2924374	chr5:93151141	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.54	-5.6	-0.34	6.03e-8	Diabetic retinopathy;
SARC	cis	rs9393692	0.905	rs9379843	chr6:26289435	A/G	cg00631329	chr6:26305371	NA	-0.62	-9.02	-0.51	7.32e-17	Educational attainment;
SARC	cis	rs6570726	1.000	rs444564	chr6:145859795	G/C	cg23711669	chr6:146136114	FBXO30	0.74	11.07	0.59	3.66e-23	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs28595532	1.000	rs11938970	chr4:119660152	A/G	cg21605333	chr4:119757512	SEC24D	1.0	5.65	0.35	4.7e-8	Cannabis dependence symptom count;
SARC	cis	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg18252515	chr7:66147081	NA	-1.39	-12.31	-0.63	3.58e-27	Diabetic kidney disease;
SARC	cis	rs7829975	0.508	rs1594437	chr8:8825875	T/C	cg08975724	chr8:8085496	FLJ10661	0.48	5.83	0.36	1.87e-8	Mood instability;
SARC	cis	rs6831352	0.879	rs34360292	chr4:100051303	T/C	cg12011299	chr4:100065546	ADH4	-0.34	-5.74	-0.35	2.97e-8	Alcohol dependence;
SARC	cis	rs11574514	1.000	rs7200950	chr16:67689752	C/T	cg01866162	chr16:67596514	CTCF	0.82	5.15	0.32	5.46e-7	Crohn's disease;
SARC	cis	rs1153858	1.000	rs11070457	chr15:45686943	A/C	cg26924012	chr15:45694286	SPATA5L1	0.78	10.68	0.57	6.18e-22	Homoarginine levels;
SARC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.72	9.8	0.54	3.24e-19	Lymphocyte counts;
SARC	cis	rs77956314	0.515	rs4238051	chr12:117366299	A/G	cg16111737	chr12:117408163	FBXW8	-0.48	-6.17	-0.37	3.05e-9	Subcortical brain region volumes;Hippocampal volume;
SARC	cis	rs8072100	0.738	rs3736438	chr17:45486651	T/G	cg08085267	chr17:45401833	C17orf57	-0.44	-5.18	-0.32	4.76e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs9309473	0.519	rs1881246	chr2:73650122	T/A	cg20560298	chr2:73613845	ALMS1	0.51	6.88	0.41	5.45e-11	Metabolite levels;
SARC	cis	rs6570726	0.791	rs407887	chr6:145843759	C/T	cg05347473	chr6:146136440	FBXO30	0.53	7.35	0.43	3.38e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6582630	0.572	rs7315897	chr12:38449081	C/T	cg14851346	chr12:38532713	NA	-0.48	-5.93	-0.36	1.1e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6500602	0.702	rs11076834	chr16:4549583	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.3	5.23	0.32	3.79e-7	Schizophrenia;
SARC	cis	rs6840360	0.571	rs62327278	chr4:152558790	G/C	cg22705602	chr4:152727874	NA	-0.44	-6.79	-0.41	9.29e-11	Intelligence (multi-trait analysis);
SARC	cis	rs4595586	0.545	rs7958118	chr12:39376685	C/T	cg26384229	chr12:38710491	ALG10B	0.51	6.32	0.38	1.29e-9	Morning vs. evening chronotype;
SARC	cis	rs2486288	0.656	rs11632651	chr15:45550838	C/T	cg15395560	chr15:45543142	SLC28A2	0.29	5.63	0.35	5.17e-8	Glomerular filtration rate;
SARC	cis	rs1865760	0.566	rs9366634	chr6:26072396	C/G	cg18357526	chr6:26021779	HIST1H4A	0.42	5.22	0.32	3.93e-7	Height;
SARC	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg24642844	chr7:1081250	C7orf50	-0.59	-6.25	-0.38	1.98e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg18876405	chr7:65276391	NA	-0.44	-4.83	-0.3	2.43e-6	Aortic root size;
SARC	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg03709012	chr19:19516395	GATAD2A	1.02	17.28	0.75	1.26e-43	Tonsillectomy;
SARC	cis	rs7712401	0.601	rs425573	chr5:122326008	G/C	cg19412675	chr5:122181750	SNX24	-0.43	-5.43	-0.34	1.41e-7	Mean platelet volume;
SARC	cis	rs7551222	0.752	rs4245736	chr1:204486205	G/C	cg20240347	chr1:204465584	NA	-0.35	-6.16	-0.37	3.12e-9	Schizophrenia;
SARC	cis	rs4253772	0.530	rs6008616	chr22:46707954	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.61	5.02	0.31	1.05e-6	LDL cholesterol;Cholesterol, total;
SARC	cis	rs11209002	0.614	rs10732837	chr1:67573120	A/G	cg02640540	chr1:67518911	SLC35D1	0.5	5.89	0.36	1.32e-8	Crohn's disease;
SARC	trans	rs7824557	0.545	rs2572450	chr8:11229638	C/T	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.63	-0.49	9.55e-16	Retinal vascular caliber;
SARC	cis	rs12971120	0.504	rs11665154	chr18:72147006	A/C	cg25817165	chr18:72167213	CNDP2	-0.42	-7.53	-0.44	1.08e-12	Refractive error;
SARC	cis	rs713477	0.901	rs1572612	chr14:55909939	C/T	cg13175173	chr14:55914753	NA	-0.31	-4.88	-0.3	1.96e-6	Pediatric bone mineral content (femoral neck);
SARC	cis	rs4891159	0.756	rs8084155	chr18:74134952	A/G	cg24786174	chr18:74118243	ZNF516	-0.7	-11.75	-0.61	2.41e-25	Longevity;
SARC	cis	rs9325144	0.625	rs12227353	chr12:38734542	C/T	cg13010199	chr12:38710504	ALG10B	-0.52	-6.64	-0.4	2.22e-10	Morning vs. evening chronotype;
SARC	trans	rs16882447	0.817	rs33284	chr5:53512384	A/G	cg21135330	chr2:63235649	EHBP1	-0.53	-6.87	-0.41	5.76e-11	Systolic blood pressure (dietary potassium intake interaction);
SARC	cis	rs6088590	1.000	rs6058111	chr20:33310999	T/C	cg08999081	chr20:33150536	PIGU	0.33	4.78	0.3	3.13e-6	Coronary artery disease;
SARC	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg11366901	chr6:160182831	ACAT2	0.96	9.86	0.54	2.09e-19	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs1957429	0.520	rs72625647	chr14:65344106	T/C	cg23373153	chr14:65346875	NA	-0.82	-5.71	-0.35	3.45e-8	Pediatric areal bone mineral density (radius);
SARC	cis	rs6977660	0.714	rs12700075	chr7:19791476	G/T	cg05791153	chr7:19748676	TWISTNB	0.71	6.32	0.38	1.32e-9	Thyroid stimulating hormone;
SARC	trans	rs208520	0.690	rs4710564	chr6:66823478	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	12.78	0.64	1.05e-28	Exhaled nitric oxide output;
SARC	cis	rs2916247	1.000	rs1838181	chr8:92993679	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.57	-5.82	-0.36	1.92e-8	Intelligence (multi-trait analysis);
SARC	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg10295955	chr4:187884368	NA	-0.83	-10.85	-0.58	1.85e-22	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.21	-0.43	7.82e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg22535103	chr8:58192502	C8orf71	-0.66	-6.15	-0.37	3.28e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs208520	0.690	rs12201219	chr6:66748862	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	13.79	0.67	5.04e-32	Exhaled nitric oxide output;
SARC	cis	rs11758351	1.000	rs16891378	chr6:26188864	A/G	cg01420254	chr6:26195488	NA	0.54	4.74	0.3	3.71e-6	Gout;Renal underexcretion gout;
SARC	cis	rs9790314	1.000	rs336567	chr3:161073046	A/G	cg03342759	chr3:160939853	NMD3	-0.59	-7.33	-0.43	3.83e-12	Morning vs. evening chronotype;
SARC	cis	rs12421382	0.543	rs11213094	chr11:109357926	G/A	cg27471124	chr11:109292789	C11orf87	0.53	7.0	0.42	2.68e-11	Schizophrenia;
SARC	cis	rs2658782	0.756	rs3019223	chr11:93084182	G/A	cg15737290	chr11:93063684	CCDC67	0.7	7.14	0.42	1.2e-11	Pulmonary function decline;
SARC	cis	rs9381040	0.610	rs6940356	chr6:41020360	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.41	-4.88	-0.3	1.95e-6	Alzheimer's disease (late onset);
SARC	trans	rs66573146	0.831	rs67602077	chr4:7024244	A/G	cg07817883	chr1:32538562	TMEM39B	1.39	8.47	0.49	2.86e-15	Granulocyte percentage of myeloid white cells;
SARC	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg11062466	chr8:58055876	NA	0.61	5.75	0.35	2.74e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1904096	0.506	rs7697827	chr4:95184748	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.47	-6.95	-0.41	3.58e-11	Type 2 diabetes;
SARC	cis	rs10927875	0.619	rs1806991	chr1:16129441	T/C	cg21385522	chr1:16154831	NA	-0.61	-8.17	-0.47	1.9e-14	Dilated cardiomyopathy;
SARC	cis	rs796364	1.000	rs281774	chr2:200814572	C/T	cg23649088	chr2:200775458	C2orf69	0.64	6.0	0.37	7.58e-9	Schizophrenia;
SARC	cis	rs7582720	1.000	rs79539678	chr2:203740938	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.28	0.43	5.16e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs11122272	0.701	rs743120	chr1:231531232	C/T	cg06096015	chr1:231504339	EGLN1	0.38	5.7	0.35	3.54e-8	Hemoglobin concentration;
SARC	cis	rs7927771	1.000	rs34910028	chr11:47758449	T/C	cg20307385	chr11:47447363	PSMC3	-0.47	-5.61	-0.35	5.63e-8	Subjective well-being;
SARC	cis	rs858239	1.000	rs156425	chr7:23309119	C/T	cg23682824	chr7:23144976	KLHL7	-0.62	-7.73	-0.45	3.23e-13	Cerebrospinal fluid biomarker levels;
SARC	cis	rs981844	0.735	rs111822747	chr4:154734629	G/C	cg14289246	chr4:154710475	SFRP2	0.57	6.3	0.38	1.5e-9	Response to statins (LDL cholesterol change);
SARC	cis	rs698813	0.555	rs7605771	chr2:44479778	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	6.09	0.37	4.53e-9	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg18252515	chr7:66147081	NA	0.58	6.17	0.37	3.07e-9	Aortic root size;
SARC	cis	rs10992471	0.603	rs11792019	chr9:95195229	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.26	-0.33	3.34e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs8114671	0.527	rs6088650	chr20:33514465	C/T	cg08999081	chr20:33150536	PIGU	-0.33	-4.85	-0.3	2.27e-6	Height;
SARC	cis	rs2120243	0.565	rs1500919	chr3:157079048	C/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.4	4.94	0.31	1.48e-6	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg24531977	chr5:56204891	C5orf35	-0.54	-5.45	-0.34	1.26e-7	Initial pursuit acceleration;
SARC	cis	rs9300255	0.543	rs655293	chr12:123528405	G/A	cg00376283	chr12:123451042	ABCB9	0.55	6.2	0.38	2.52e-9	Neutrophil percentage of white cells;
SARC	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg15049968	chr18:44337910	ST8SIA5	0.34	5.33	0.33	2.35e-7	Personality dimensions;
SARC	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg06634786	chr22:41940651	POLR3H	-0.5	-5.84	-0.36	1.75e-8	Vitiligo;
SARC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg18876405	chr7:65276391	NA	0.54	6.72	0.4	1.41e-10	Calcium levels;
SARC	trans	rs9395865	0.501	rs2067833	chr6:53330356	A/G	cg12635606	chr4:99849853	EIF4E	-0.53	-6.56	-0.39	3.54e-10	Electroencephalographic traits in alcoholism;
SARC	cis	rs939574	1.000	rs9989854	chr2:220086280	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.54	-5.02	-0.31	1.04e-6	Platelet distribution width;
SARC	cis	rs826838	1.000	rs11183196	chr12:38685915	G/T	cg13010199	chr12:38710504	ALG10B	0.83	12.03	0.62	3.1e-26	Heart rate;
SARC	cis	rs12824058	0.844	rs7956408	chr12:130807547	A/T	cg24838063	chr12:130822603	PIWIL1	-0.53	-7.53	-0.44	1.11e-12	Menopause (age at onset);
SARC	cis	rs6087990	0.806	rs6141814	chr20:31368960	C/A	cg13636640	chr20:31349939	DNMT3B	0.78	12.15	0.62	1.2e-26	Ulcerative colitis;
SARC	cis	rs9392918	0.531	rs7751849	chr6:7700046	A/C	cg23089261	chr6:7723385	NA	0.53	6.76	0.4	1.11e-10	Height;
SARC	cis	rs644799	0.544	rs499637	chr11:95569183	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.71	9.52	0.53	2.28e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg16925003	chr2:1684003	PXDN	0.53	6.98	0.42	2.97e-11	Schizophrenia;
SARC	cis	rs6582630	0.555	rs2197308	chr12:38281261	A/G	cg26384229	chr12:38710491	ALG10B	-0.61	-7.74	-0.45	2.92e-13	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.77	11.07	0.59	3.54e-23	Total body bone mineral density;
SARC	cis	rs12479064	0.724	rs62153852	chr2:99934713	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.48	-5.35	-0.33	2.06e-7	Chronic sinus infection;
SARC	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.38	4.73	0.3	3.96e-6	Lymphocyte counts;
SARC	cis	rs9916302	0.851	rs11657899	chr17:37626963	G/A	cg00129232	chr17:37814104	STARD3	-0.65	-7.98	-0.46	6.57e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg22920501	chr2:26401640	FAM59B	-0.55	-7.0	-0.42	2.65e-11	Gut microbiome composition (summer);
SARC	trans	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.07	-0.42	1.77e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs4423214	0.802	rs4402322	chr11:71184015	C/G	cg05163923	chr11:71159392	DHCR7	-0.6	-7.21	-0.43	7.58e-12	Vitamin D levels;
SARC	cis	rs453301	0.631	rs7843789	chr8:8800561	G/C	cg11608241	chr8:8085544	FLJ10661	-0.41	-4.88	-0.3	1.93e-6	Joint mobility (Beighton score);
SARC	cis	rs2290405	0.527	rs7663192	chr4:923947	T/C	cg20916646	chr4:852691	GAK	0.39	4.89	0.31	1.84e-6	Systemic sclerosis;
SARC	cis	rs4785204	1.000	rs12446947	chr16:50095385	A/T	cg26500707	chr16:50100227	HEATR3	0.65	4.92	0.31	1.63e-6	Esophageal cancer (squamous cell);
SARC	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.76	7.36	0.43	3.06e-12	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs6964587	1.000	rs17164275	chr7:91590408	A/G	cg17063962	chr7:91808500	NA	0.95	15.98	0.72	2.68e-39	Breast cancer;
SARC	cis	rs7589728	0.858	rs1914734	chr2:88529509	T/C	cg04511125	chr2:88470314	THNSL2	0.64	6.43	0.39	7.01e-10	Plasma clusterin levels;
SARC	cis	rs3091242	0.933	rs35148262	chr1:25766623	A/G	cg27572855	chr1:25598939	RHD	0.55	9.17	0.52	2.54e-17	Erythrocyte sedimentation rate;
SARC	cis	rs3733585	0.699	rs6449177	chr4:9968050	T/C	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.4	-0.33	1.67e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs8078723	0.668	rs3859192	chr17:38128648	C/T	cg17467752	chr17:38218738	THRA	0.43	5.34	0.33	2.21e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg10580686	chr2:64881532	SERTAD2	0.5	6.46	0.39	5.95e-10	Lung adenocarcinoma;
SARC	cis	rs6604026	0.656	rs9440134	chr1:93370813	C/T	cg17283838	chr1:93427260	FAM69A	-0.42	-4.75	-0.3	3.59e-6	Multiple sclerosis;
SARC	cis	rs4242434	0.889	rs11785755	chr8:22453223	C/A	cg03733263	chr8:22462867	KIAA1967	0.92	13.66	0.67	1.31e-31	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg24110177	chr3:50126178	RBM5	0.38	4.87	0.3	2.11e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2153535	0.580	rs1414346	chr6:8471574	A/G	cg23788917	chr6:8435910	SLC35B3	0.64	8.39	0.48	4.57e-15	Motion sickness;
SARC	cis	rs17270561	0.609	rs12192077	chr6:25732794	G/A	cg16482183	chr6:26056742	HIST1H1C	0.43	5.25	0.33	3.49e-7	Iron status biomarkers;
SARC	cis	rs10876993	0.806	rs1689598	chr12:58050500	G/C	cg18357645	chr12:58087776	OS9	0.47	6.15	0.37	3.4e-9	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs11579220	1	rs11579220	chr1:205144363	G/T	cg21545522	chr1:205238299	TMCC2	0.35	4.74	0.3	3.73e-6	White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs992157	0.560	rs10932763	chr2:219085863	G/C	cg00012203	chr2:219082015	ARPC2	-0.73	-10.8	-0.58	2.61e-22	Colorectal cancer;
SARC	cis	rs13191362	1.000	rs34398656	chr6:162999612	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.57	5.51	0.34	9.61e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs10992471	0.598	rs2025389	chr9:95157674	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.4	4.94	0.31	1.48e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs2013441	1.000	rs972966	chr17:20030992	G/C	cg13482628	chr17:19912719	NA	0.48	6.34	0.38	1.17e-9	Obesity-related traits;
SARC	cis	rs13191362	0.935	rs66923841	chr6:163177317	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.43	5.36	0.33	2.05e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2013441	0.932	rs3850782	chr17:20181940	A/C	cg13482628	chr17:19912719	NA	-0.48	-6.33	-0.38	1.24e-9	Obesity-related traits;
SARC	cis	rs8067354	0.645	rs2645492	chr17:57875554	A/G	cg13753209	chr17:57696993	CLTC	-0.65	-6.82	-0.41	7.78e-11	Hemoglobin concentration;
SARC	cis	rs10504229	0.679	rs16921677	chr8:58052431	T/C	cg22535103	chr8:58192502	C8orf71	-0.57	-5.68	-0.35	4.09e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7829975	0.511	rs2955578	chr8:8137083	T/C	cg11608241	chr8:8085544	FLJ10661	0.44	5.35	0.33	2.07e-7	Mood instability;
SARC	cis	rs9309473	0.615	rs62149774	chr2:73787652	G/A	cg20560298	chr2:73613845	ALMS1	-0.5	-4.98	-0.31	1.26e-6	Metabolite levels;
SARC	trans	rs3942852	0.774	rs10838811	chr11:48186795	A/G	cg03929089	chr4:120376271	NA	-0.6	-6.75	-0.4	1.13e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs7824557	0.767	rs3808513	chr8:11157460	G/T	cg21775007	chr8:11205619	TDH	-0.52	-6.27	-0.38	1.75e-9	Retinal vascular caliber;
SARC	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg18876405	chr7:65276391	NA	0.49	6.04	0.37	6e-9	Aortic root size;
SARC	cis	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg05863683	chr7:1912471	MAD1L1	0.37	5.68	0.35	3.96e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs7246657	0.943	rs10424574	chr19:37838393	A/G	cg23950597	chr19:37808831	NA	-0.6	-5.75	-0.35	2.77e-8	Coronary artery calcification;
SARC	cis	rs7617773	0.780	rs4130522	chr3:48352313	G/A	cg11946769	chr3:48343235	NME6	0.76	9.7	0.54	6.55e-19	Coronary artery disease;
SARC	cis	rs7666738	0.830	rs7659593	chr4:98934823	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs644148	0.836	rs2571112	chr19:45000319	T/A	cg15540054	chr19:45004280	ZNF180	-0.43	-5.02	-0.31	1.05e-6	Personality dimensions;
SARC	cis	rs12586317	0.620	rs7147571	chr14:35530236	T/C	cg16230307	chr14:35515116	FAM177A1	0.95	11.13	0.59	2.41e-23	Psoriasis;
SARC	cis	rs2486288	0.656	rs11632777	chr15:45551045	C/T	cg15395560	chr15:45543142	SLC28A2	0.29	5.63	0.35	5.17e-8	Glomerular filtration rate;
SARC	cis	rs514406	0.536	rs878957	chr1:53197559	C/T	cg24675658	chr1:53192096	ZYG11B	0.7	10.56	0.57	1.44e-21	Monocyte count;
SARC	cis	rs796364	1.000	rs281788	chr2:200783705	A/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.76	7.17	0.43	9.92e-12	Schizophrenia;
SARC	cis	rs7260598	0.685	rs114404193	chr19:24063068	G/A	cg27517351	chr19:23941871	ZNF681	0.54	4.73	0.3	3.86e-6	Response to taxane treatment (placlitaxel);
SARC	cis	rs7674212	0.510	rs55715738	chr4:104130189	A/G	cg16532752	chr4:104119610	CENPE	-0.49	-6.01	-0.37	7.16e-9	Type 2 diabetes;
SARC	cis	rs1153858	0.887	rs7171163	chr15:45636395	A/C	cg14582100	chr15:45693742	SPATA5L1	0.36	5.03	0.31	9.88e-7	Homoarginine levels;
SARC	cis	rs1318878	1.000	rs984562	chr12:15547178	A/G	cg08258403	chr12:15378311	NA	0.48	6.22	0.38	2.26e-9	Intelligence (multi-trait analysis);
SARC	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg06212747	chr3:49208901	KLHDC8B	0.66	8.79	0.5	3.35e-16	Parkinson's disease;
SARC	cis	rs73242632	1.000	rs2276896	chr4:57845091	C/T	cg20415529	chr4:57845134	POLR2B;C4orf14	1.06	6.42	0.39	7.4e-10	Congenital heart disease (maternal effect);
SARC	cis	rs11711311	0.712	rs2271498	chr3:113334752	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	6.48	0.39	5.52e-10	IgG glycosylation;
SARC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.76	0.54	4.42e-19	Prudent dietary pattern;
SARC	cis	rs9640161	0.750	rs3735173	chr7:150020526	C/T	cg10018233	chr7:150070692	REPIN1	0.68	9.4	0.52	5.4e-18	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs10876993	0.890	rs799575	chr12:58069107	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.46	-5.8	-0.36	2.18e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs9902453	0.845	rs116840018	chr17:28232049	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	6.94	0.41	3.92e-11	Coffee consumption (cups per day);
SARC	cis	rs17001868	0.568	rs470113	chr22:40729614	A/G	cg07138101	chr22:40742427	ADSL	0.46	4.83	0.3	2.51e-6	Mammographic density (dense area);
SARC	cis	rs7567288	0.588	rs13026405	chr2:134450259	G/A	cg06389888	chr2:135011991	MGAT5	0.51	4.8	0.3	2.84e-6	Height;
SARC	cis	rs295140	0.605	rs10931893	chr2:201114652	A/G	cg23649088	chr2:200775458	C2orf69	-0.48	-6.77	-0.41	1.02e-10	QT interval;
SARC	cis	rs10791323	0.536	rs4937842	chr11:133734542	C/G	cg06766960	chr11:133703094	NA	0.33	5.3	0.33	2.71e-7	Childhood ear infection;
SARC	cis	rs4689388	0.926	rs4688986	chr4:6285797	C/A	cg00701064	chr4:6280414	WFS1	0.58	9.51	0.53	2.47e-18	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	trans	rs11039798	0.588	rs59777067	chr11:49015350	C/T	cg15704280	chr7:45808275	SEPT13	0.7	6.96	0.41	3.42e-11	Axial length;
SARC	cis	rs9902453	0.704	rs1972305	chr17:28533880	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	6.36	0.38	1.07e-9	Coffee consumption (cups per day);
SARC	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg21361702	chr7:150065534	REPIN1	0.5	5.13	0.32	6.13e-7	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs6582630	0.512	rs11181007	chr12:38266700	C/T	cg13010199	chr12:38710504	ALG10B	-0.55	-6.68	-0.4	1.75e-10	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7826238	0.594	rs2948285	chr8:8130538	A/T	cg08975724	chr8:8085496	FLJ10661	0.68	9.23	0.52	1.67e-17	Systolic blood pressure;
SARC	cis	rs1707322	1.000	rs12133129	chr1:46373348	C/T	cg06784218	chr1:46089804	CCDC17	0.34	5.94	0.36	1.03e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs11764590	0.724	rs1533829	chr7:2082841	A/G	cg23043544	chr7:2124092	MAD1L1	-0.37	-5.1	-0.32	6.99e-7	Neuroticism;
SARC	cis	rs7584330	0.868	rs58057291	chr2:238395479	T/A	cg11271282	chr2:238384023	NA	0.46	5.11	0.32	6.79e-7	Prostate cancer;
SARC	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg21782813	chr7:2030301	MAD1L1	0.45	7.14	0.42	1.2e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs2859741	0.935	rs2782410	chr1:37509489	G/C	cg09363841	chr1:37513479	NA	-0.27	-4.76	-0.3	3.37e-6	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
SARC	cis	rs57506017	0.585	rs12699338	chr7:12285140	C/T	cg23422036	chr7:12250390	TMEM106B	0.48	6.43	0.39	7.02e-10	Neuroticism;
SARC	cis	rs8180040	0.966	rs12632132	chr3:47477019	C/T	cg27129171	chr3:47204927	SETD2	0.68	9.53	0.53	2.17e-18	Colorectal cancer;
SARC	cis	rs708547	0.647	rs2293175	chr4:57861358	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.44	-5.49	-0.34	1.07e-7	Response to bleomycin (chromatid breaks);
SARC	cis	rs7264396	0.563	rs2066066	chr20:34329359	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.59	5.44	0.34	1.35e-7	Total cholesterol levels;
SARC	cis	rs17209837	1.000	rs67721532	chr7:87084403	A/G	cg00919237	chr7:87102261	ABCB4	-0.5	-5.12	-0.32	6.43e-7	Gallbladder cancer;
SARC	cis	rs35110281	0.774	rs162404	chr21:44963264	G/A	cg01579765	chr21:45077557	HSF2BP	-0.32	-5.45	-0.34	1.25e-7	Mean corpuscular volume;
SARC	cis	rs12893668	0.603	rs12896171	chr14:104135966	A/G	cg26031613	chr14:104095156	KLC1	-0.53	-5.83	-0.36	1.82e-8	Reticulocyte count;
SARC	cis	rs9814567	0.752	rs13084192	chr3:134336095	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.51	6.47	0.39	5.76e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg06420487	chr17:61919686	SMARCD2	0.43	4.73	0.3	3.84e-6	Height;
SARC	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg05896524	chr21:47604654	C21orf56	0.4	4.75	0.3	3.6e-6	Testicular germ cell tumor;
SARC	cis	rs4319547	0.915	rs10773208	chr12:122970156	T/C	cg23029597	chr12:123009494	RSRC2	-0.41	-5.13	-0.32	6.22e-7	Body mass index;
SARC	cis	rs17376456	0.877	rs10065056	chr5:93380123	G/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	6.12	0.37	3.99e-9	Diabetic retinopathy;
SARC	cis	rs9814567	1.000	rs9834755	chr3:134206845	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-7.15	-0.42	1.11e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs4808199	0.895	rs10421505	chr19:19459554	C/T	cg03709012	chr19:19516395	GATAD2A	1.09	11.67	0.61	4.51e-25	Nonalcoholic fatty liver disease;
SARC	cis	rs9397240	0.789	rs9371368	chr6:155551539	A/G	cg07943832	chr6:155568918	TIAM2	-0.56	-5.22	-0.32	4.04e-7	Life satisfaction;
SARC	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg24675658	chr1:53192096	ZYG11B	0.67	9.57	0.53	1.69e-18	Monocyte count;
SARC	cis	rs4595586	0.525	rs7977228	chr12:39395060	A/G	cg26384229	chr12:38710491	ALG10B	0.5	6.12	0.37	3.98e-9	Morning vs. evening chronotype;
SARC	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg06634786	chr22:41940651	POLR3H	0.54	6.41	0.39	8.14e-10	Vitiligo;
SARC	cis	rs7772486	0.686	rs2179323	chr6:145982786	T/G	cg23711669	chr6:146136114	FBXO30	-0.79	-12.62	-0.64	3.66e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs651907	0.535	rs11712309	chr3:101519097	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	5.8	0.36	2.13e-8	Colorectal cancer;
SARC	cis	rs2304069	0.913	rs9324637	chr5:149390947	T/C	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.68	6.59	0.4	2.88e-10	HIV-1 control;
SARC	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg18404041	chr3:52824283	ITIH1	-0.44	-6.69	-0.4	1.69e-10	Bipolar disorder;
SARC	trans	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg21659725	chr3:3221576	CRBN	0.54	6.26	0.38	1.79e-9	Resting heart rate;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg18403551	chr3:140770306	SPSB4	0.52	6.96	0.41	3.49e-11	Breast cancer;
SARC	cis	rs9303401	0.659	rs34351230	chr17:56782555	C/A	cg25039879	chr17:56429692	SUPT4H1	0.68	6.4	0.39	8.57e-10	Cognitive test performance;
SARC	cis	rs7762018	1.000	rs74900588	chr6:170102180	A/C	cg13891659	chr6:170190454	C6orf122;C6orf208	0.54	4.75	0.3	3.57e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg13206674	chr6:150067644	NUP43	0.37	4.81	0.3	2.68e-6	Lung cancer;
SARC	cis	rs7246657	0.943	rs10404920	chr19:37881556	T/C	cg23950597	chr19:37808831	NA	-0.62	-6.05	-0.37	5.66e-9	Coronary artery calcification;
SARC	cis	rs6570726	0.905	rs442435	chr6:145815559	C/T	cg05347473	chr6:146136440	FBXO30	0.48	6.46	0.39	6.14e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg24675658	chr1:53192096	ZYG11B	0.53	7.34	0.43	3.54e-12	Monocyte count;
SARC	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg12310025	chr6:25882481	NA	-0.43	-5.52	-0.34	9.23e-8	Intelligence (multi-trait analysis);
SARC	trans	rs7824557	0.564	rs2572389	chr8:11236392	T/C	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.0	-0.42	2.66e-11	Retinal vascular caliber;
SARC	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg11987759	chr7:65425863	GUSB	-0.6	-7.96	-0.46	7.38e-14	Aortic root size;
SARC	cis	rs9911578	0.967	rs72628392	chr17:56506160	A/G	cg12560992	chr17:57184187	TRIM37	-0.76	-9.82	-0.54	2.89e-19	Intelligence (multi-trait analysis);
SARC	cis	rs7264396	0.563	rs2425090	chr20:34304783	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-7.21	-0.43	7.81e-12	Total cholesterol levels;
SARC	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg05872129	chr22:39784769	NA	-0.45	-6.4	-0.39	8.49e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg00800038	chr16:89945340	TCF25	-0.72	-4.72	-0.3	4.08e-6	Skin colour saturation;
SARC	cis	rs7793919	0.764	rs6944865	chr7:4766383	A/T	cg09789173	chr7:4769017	FOXK1	0.55	7.75	0.45	2.74e-13	Mosquito bite size;
SARC	cis	rs72945132	0.882	rs7941933	chr11:70123351	G/A	cg00319359	chr11:70116639	PPFIA1	0.68	6.17	0.37	3.03e-9	Coronary artery disease;
SARC	cis	rs240764	0.621	rs6570930	chr6:101181258	C/A	cg09795085	chr6:101329169	ASCC3	-0.49	-6.42	-0.39	7.54e-10	Neuroticism;
SARC	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg22974920	chr21:40686053	BRWD1	0.47	5.07	0.32	8.16e-7	Cognitive function;
SARC	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg19223190	chr17:80058835	NA	0.42	5.84	0.36	1.73e-8	Life satisfaction;
SARC	cis	rs3087591	0.708	rs17885030	chr17:29655218	C/T	cg24425628	chr17:29625626	OMG;NF1	0.42	5.41	0.33	1.58e-7	Hip circumference;
SARC	trans	rs1853207	0.737	rs111309918	chr10:96711706	G/C	cg02737782	chr1:8014393	NA	-0.89	-6.4	-0.39	8.69e-10	Blood metabolite levels;
SARC	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg04277193	chr17:41438351	NA	0.44	4.82	0.3	2.59e-6	Menopause (age at onset);
SARC	cis	rs17270561	0.609	rs4145217	chr6:25743997	T/C	cg17691542	chr6:26056736	HIST1H1C	0.61	7.36	0.43	3.06e-12	Iron status biomarkers;
SARC	cis	rs8014204	0.604	rs2159906	chr14:75390912	G/T	cg11812906	chr14:75593930	NEK9	0.47	5.45	0.34	1.29e-7	Caffeine consumption;
SARC	cis	rs11697848	1.000	rs2284649	chr20:48526494	G/A	cg17849948	chr20:48532315	SPATA2	0.87	5.2	0.32	4.3e-7	Systemic lupus erythematosus;
SARC	cis	rs5760092	0.755	rs11090298	chr22:24262061	G/A	cg24846343	chr22:24311635	DDTL	-0.41	-4.86	-0.3	2.14e-6	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs17376456	0.877	rs10073039	chr5:93467709	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.89	0.36	1.36e-8	Diabetic retinopathy;
SARC	cis	rs11585357	0.895	rs2977305	chr1:17613737	A/T	cg08277548	chr1:17600880	PADI3	0.46	5.36	0.33	2.03e-7	Hair shape;
SARC	trans	rs3857536	0.740	rs7751095	chr6:66891318	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.6	-7.14	-0.42	1.19e-11	Blood trace element (Cu levels);
SARC	cis	rs3820928	1.000	rs7592387	chr2:227777095	A/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-6.88	-0.41	5.56e-11	Pulmonary function;
SARC	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg22535103	chr8:58192502	C8orf71	-0.7	-7.06	-0.42	1.93e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs4835937	0.551	rs4836344	chr5:127263443	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.58	-5.07	-0.32	8.25e-7	Cancer;
SARC	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg22920501	chr2:26401640	FAM59B	0.53	7.05	0.42	2.05e-11	Gut microbiome composition (summer);
SARC	cis	rs2650000	0.798	rs2701175	chr12:121391671	C/A	cg25281562	chr12:121454272	C12orf43	-0.46	-5.45	-0.34	1.25e-7	Metabolic traits;LDL cholesterol;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg11141711	chr14:99947712	SETD3;CCNK	0.52	7.04	0.42	2.1e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs6121246	0.909	rs6060979	chr20:30417522	C/T	cg13852791	chr20:30311386	BCL2L1	0.77	8.46	0.48	2.91e-15	Mean corpuscular hemoglobin;
SARC	cis	rs514024	0.801	rs2988580	chr9:130482966	C/G	cg13643465	chr9:130375613	STXBP1	0.48	6.04	0.37	5.98e-9	Eating disorders (purging via substances);
SARC	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg25036284	chr2:26402008	FAM59B	-0.46	-5.73	-0.35	3.13e-8	Gut microbiome composition (summer);
SARC	cis	rs12421382	0.543	rs10890996	chr11:109328421	A/G	cg15948088	chr11:109293068	C11orf87	-0.37	-4.89	-0.31	1.85e-6	Schizophrenia;
SARC	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg05368731	chr17:41323189	NBR1	0.8	9.67	0.54	8.15e-19	Menopause (age at onset);
SARC	cis	rs17001868	0.568	rs9611328	chr22:40791972	C/T	cg07138101	chr22:40742427	ADSL	0.56	6.1	0.37	4.34e-9	Mammographic density (dense area);
SARC	cis	rs7223966	0.960	rs2854222	chr17:61939015	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	7.21	0.43	7.77e-12	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs7844647	0.530	rs2953936	chr8:34161717	A/C	cg26394233	chr7:157444480	PTPRN2	0.44	6.61	0.4	2.6e-10	Body mass index;
SARC	cis	rs6539267	0.741	rs10861572	chr12:106688576	A/G	cg02476566	chr12:106696527	TCP11L2	-0.52	-5.4	-0.33	1.64e-7	Tourette syndrome;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg14858469	chr15:96874050	NR2F2	0.45	6.33	0.38	1.22e-9	Lung adenocarcinoma;
SARC	cis	rs9840812	0.691	rs7621025	chr3:136272246	T/C	cg15507776	chr3:136538369	TMEM22	0.52	5.74	0.35	2.92e-8	Fibrinogen levels;
SARC	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg26681399	chr22:41777847	TEF	-0.45	-4.9	-0.31	1.81e-6	Vitiligo;
SARC	cis	rs711830	1.000	rs1318778	chr2:177037831	C/G	cg13092806	chr2:177043255	NA	0.66	6.68	0.4	1.76e-10	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
SARC	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	8.32	0.48	7.27e-15	Mean platelet volume;
SARC	cis	rs10464366	0.746	rs62442210	chr7:39146328	G/T	cg18850127	chr7:39170497	POU6F2	0.43	5.4	0.33	1.62e-7	IgG glycosylation;
SARC	cis	rs5758659	0.653	rs133383	chr22:42473603	C/T	cg04733989	chr22:42467013	NAGA	0.49	5.87	0.36	1.47e-8	Cognitive function;
SARC	cis	rs9611519	0.929	rs4821991	chr22:41440683	T/C	cg17376030	chr22:41985996	PMM1	0.49	6.06	0.37	5.3e-9	Neuroticism;
SARC	cis	rs2120243	0.592	rs4640513	chr3:157115950	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.45	5.87	0.36	1.48e-8	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs1448094	0.872	rs7305869	chr12:86440114	A/G	cg02569458	chr12:86230093	RASSF9	0.37	5.43	0.33	1.45e-7	Major depressive disorder;
SARC	cis	rs864537	0.590	rs1214596	chr1:167427170	A/T	cg09179987	chr1:167433047	CD247	-0.39	-6.31	-0.38	1.38e-9	Celiac disease or Rheumatoid arthritis;Celiac disease;
SARC	cis	rs10779751	0.922	rs2746637	chr1:11275588	A/G	cg08854313	chr1:11322531	MTOR	0.79	11.05	0.59	4.37e-23	Body mass index;
SARC	cis	rs7731783	1	rs7731783	chr5:177060312	T/C	cg10940203	chr5:177434438	FAM153C	0.4	5.55	0.34	7.72e-8	Methadone dose in opioid dependence;
SARC	cis	rs561341	0.769	rs7217004	chr17:30178092	A/G	cg13647721	chr17:30228624	UTP6	-0.7	-5.3	-0.33	2.66e-7	Hip circumference adjusted for BMI;
SARC	cis	rs3733585	0.605	rs4697708	chr4:10121189	A/G	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.3	-0.33	2.65e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs11770686	0.600	rs2705802	chr7:75307755	A/G	cg17787366	chr7:75369077	HIP1	0.39	4.98	0.31	1.27e-6	Essential tremor;
SARC	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg00933542	chr6:150070202	PCMT1	0.3	5.08	0.32	7.56e-7	Lung cancer;
SARC	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	8.28	0.48	9.57e-15	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs34172651	0.876	rs11074653	chr16:24795959	C/T	cg04756594	chr16:24857601	SLC5A11	0.37	5.83	0.36	1.82e-8	Intelligence (multi-trait analysis);
SARC	cis	rs3008870	1.000	rs12740884	chr1:67459855	C/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.89	-11.03	-0.59	4.76e-23	Lymphocyte percentage of white cells;
SARC	cis	rs7223966	1.000	rs11657306	chr17:61704822	G/A	cg00588841	chr17:61851480	DDX42;CCDC47	-0.61	-7.07	-0.42	1.75e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs870825	0.929	rs10003354	chr4:185589782	G/A	cg04058563	chr4:185651563	MLF1IP	0.82	9.17	0.51	2.63e-17	Blood protein levels;
SARC	cis	rs9868809	0.505	rs9877685	chr3:48748588	C/T	cg07636037	chr3:49044803	WDR6	-0.69	-6.61	-0.4	2.58e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs2404602	0.716	rs56351018	chr15:76824591	T/C	cg22467129	chr15:76604101	ETFA	-0.36	-4.73	-0.3	3.89e-6	Blood metabolite levels;
SARC	cis	rs2933343	1.000	rs876755	chr3:128627933	C/T	cg25356066	chr3:128598488	ACAD9	0.6	6.79	0.41	9.22e-11	IgG glycosylation;
SARC	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg08219700	chr8:58056026	NA	0.59	6.29	0.38	1.55e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg18252515	chr7:66147081	NA	-1.4	-12.82	-0.64	8.14e-29	Diabetic kidney disease;
SARC	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg03806693	chr22:41940476	POLR3H	0.87	11.85	0.61	1.14e-25	Vitiligo;
SARC	cis	rs9309473	0.607	rs11686504	chr2:73579812	T/C	cg20560298	chr2:73613845	ALMS1	-0.59	-7.42	-0.44	2.2e-12	Metabolite levels;
SARC	cis	rs922107	0.738	rs10922665	chr1:90036508	G/C	cg15422784	chr1:90023713	LRRC8B	-0.33	-4.86	-0.3	2.18e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
SARC	cis	rs7264396	0.563	rs2225950	chr20:34333015	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-6.71	-0.4	1.47e-10	Total cholesterol levels;
SARC	cis	rs7520050	0.902	rs1355642	chr1:46598903	A/G	cg24296786	chr1:45957014	TESK2	0.38	4.78	0.3	3.05e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs2288884	0.505	rs6509602	chr19:52460145	T/C	cg24732339	chr19:52471368	ZNF350	-0.59	-5.13	-0.32	6.2e-7	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
SARC	cis	rs72627123	0.867	rs78742875	chr14:74457214	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	5.52	0.34	8.92e-8	Morning vs. evening chronotype;
SARC	cis	rs9457247	0.740	rs13195812	chr6:167443902	C/T	cg07741184	chr6:167504864	NA	0.37	7.19	0.43	8.54e-12	Crohn's disease;
SARC	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg12463550	chr7:65579703	CRCP	0.53	5.59	0.34	6.23e-8	Aortic root size;
SARC	cis	rs10876993	0.928	rs7136269	chr12:58075937	G/A	cg18357645	chr12:58087776	OS9	0.47	6.14	0.37	3.56e-9	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs2153535	0.580	rs1932284	chr6:8477694	A/T	cg21535247	chr6:8435926	SLC35B3	0.55	6.9	0.41	4.81e-11	Motion sickness;
SARC	cis	rs910316	1.000	rs1043674	chr14:75549370	T/C	cg23033748	chr14:75592666	NEK9	0.37	5.27	0.33	3.12e-7	Height;
SARC	cis	rs858239	0.730	rs858289	chr7:23248158	C/T	cg23682824	chr7:23144976	KLHL7	0.63	8.03	0.47	4.79e-14	Cerebrospinal fluid biomarker levels;
SARC	cis	rs4423214	1.000	rs11233746	chr11:71171440	A/G	cg05163923	chr11:71159392	DHCR7	0.67	9.32	0.52	9.13e-18	Vitamin D levels;
SARC	cis	rs9322817	0.691	rs2486136	chr6:105285759	C/T	cg02098413	chr6:105308735	HACE1	0.38	5.91	0.36	1.18e-8	Thyroid stimulating hormone;
SARC	cis	rs6733011	0.508	rs4851173	chr2:99520608	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-6.29	-0.38	1.56e-9	Bipolar disorder;
SARC	trans	rs61931739	0.817	rs11053071	chr12:34201400	A/G	cg13010199	chr12:38710504	ALG10B	0.56	7.36	0.43	3.15e-12	Morning vs. evening chronotype;
SARC	cis	rs72781680	0.898	rs72782113	chr2:24024952	G/C	cg08917208	chr2:24149416	ATAD2B	0.76	7.11	0.42	1.4e-11	Lymphocyte counts;
SARC	cis	rs7712401	0.755	rs1870560	chr5:122111210	G/C	cg19412675	chr5:122181750	SNX24	0.37	4.93	0.31	1.58e-6	Mean platelet volume;
SARC	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg00908189	chr16:619842	PIGQ	0.86	12.73	0.64	1.6e-28	Height;
SARC	cis	rs7208859	0.673	rs11657270	chr17:29214387	A/G	cg13385521	chr17:29058706	SUZ12P	0.88	7.42	0.44	2.17e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.47	5.88	0.36	1.42e-8	Lymphocyte counts;
SARC	cis	rs1865760	0.929	rs9467646	chr6:25957408	A/G	cg16482183	chr6:26056742	HIST1H1C	0.52	6.71	0.4	1.44e-10	Height;
SARC	cis	rs13392177	0.672	rs1877715	chr2:219052546	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.56	7.3	0.43	4.62e-12	Pyoderma gangrenosum in inflammatory bowel disease;
SARC	cis	rs4803455	0.565	rs11670143	chr19:41864971	A/G	cg08477640	chr19:41863820	B9D2	0.64	8.7	0.5	5.91e-16	Migraine;Coronary artery disease;
SARC	cis	rs7086627	0.515	rs1870147	chr10:82212541	A/T	cg00277334	chr10:82204260	NA	-0.58	-9.36	-0.52	7.05e-18	Post bronchodilator FEV1;
SARC	cis	rs17102884	0.506	rs887746	chr14:75403817	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.4	-5.43	-0.34	1.4e-7	Neuroticism;
SARC	trans	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg00938859	chr5:1591904	SDHAP3	0.78	7.58	0.44	8.08e-13	Breast cancer;
SARC	cis	rs7811528	0.656	rs7783760	chr7:2707822	G/T	cg11411865	chr7:2701802	TTYH3	-0.53	-5.32	-0.33	2.46e-7	Schizophrenia;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg11330941	chr2:17934879	GEN1;SMC6	-0.56	-7.36	-0.43	3.06e-12	Electrocardiographic conduction measures;
SARC	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg18357526	chr6:26021779	HIST1H4A	0.46	5.87	0.36	1.49e-8	Blood metabolite levels;
SARC	cis	rs9818758	0.607	rs5030795	chr3:49141116	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.65	-5.88	-0.36	1.38e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs17376456	0.877	rs13165147	chr5:93422214	G/A	cg21475434	chr5:93447410	FAM172A	0.86	7.77	0.45	2.57e-13	Diabetic retinopathy;
SARC	cis	rs2230307	0.536	rs506044	chr1:100611931	A/G	cg24955406	chr1:100503596	HIAT1	-0.67	-6.64	-0.4	2.19e-10	Carotid intima media thickness;
SARC	cis	rs10861342	1.000	rs12229846	chr12:105553066	A/C	cg23923672	chr12:105501055	KIAA1033	0.7	5.24	0.32	3.61e-7	IgG glycosylation;
SARC	cis	rs8067545	0.563	rs3850780	chr17:20181902	A/C	cg13482628	chr17:19912719	NA	-0.57	-7.57	-0.44	8.66e-13	Schizophrenia;
SARC	trans	rs7824557	0.614	rs2293858	chr8:11213881	G/C	cg06636001	chr8:8085503	FLJ10661	0.52	6.35	0.38	1.12e-9	Retinal vascular caliber;
SARC	cis	rs2228479	0.717	rs1007932	chr16:89838541	C/T	cg00800038	chr16:89945340	TCF25	-0.67	-5.2	-0.32	4.29e-7	Skin colour saturation;
SARC	cis	rs10861342	1.000	rs11112374	chr12:105510285	G/T	cg23923672	chr12:105501055	KIAA1033	0.79	6.24	0.38	2.06e-9	IgG glycosylation;
SARC	cis	rs9326248	0.581	rs11216242	chr11:116901549	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.68	8.6	0.49	1.2e-15	Blood protein levels;
SARC	cis	rs7843479	0.582	rs7818254	chr8:21798316	C/T	cg17168535	chr8:21777572	XPO7	0.87	13.85	0.67	3.2e-32	Mean corpuscular volume;
SARC	cis	rs6762	0.692	rs5030778	chr11:836008	T/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.59	-7.6	-0.45	7.13e-13	Mean platelet volume;
SARC	cis	rs1355223	0.902	rs2226113	chr11:34746289	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.32	-0.33	2.43e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg04944784	chr2:26401820	FAM59B	-0.51	-6.42	-0.39	7.4e-10	Gut microbiome composition (summer);
SARC	cis	rs9486715	0.793	rs2499777	chr6:97013814	T/C	cg18709589	chr6:96969512	KIAA0776	-0.59	-7.44	-0.44	1.88e-12	Headache;
SARC	cis	rs2235642	0.893	rs2143285	chr16:1593171	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.33	4.9	0.31	1.83e-6	Coronary artery disease;
SARC	cis	rs7647973	0.593	rs59684465	chr3:49874246	C/T	cg13072238	chr3:49761600	GMPPB	0.59	5.9	0.36	1.25e-8	Menarche (age at onset);
SARC	cis	rs3733585	0.699	rs6449202	chr4:9974043	T/C	cg11266682	chr4:10021025	SLC2A9	-0.36	-6.09	-0.37	4.58e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs13082711	0.911	rs7637211	chr3:27419868	C/T	cg02860705	chr3:27208620	NA	0.48	6.21	0.38	2.4e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.54	-6.5	-0.39	4.86e-10	Renal function-related traits (BUN);
SARC	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg03351412	chr1:154909251	PMVK	0.64	8.11	0.47	2.93e-14	Prostate cancer;
SARC	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg06634786	chr22:41940651	POLR3H	-0.55	-6.5	-0.39	4.82e-10	Vitiligo;
SARC	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.37	0.39	9.96e-10	Height;
SARC	cis	rs2075371	0.965	rs1862049	chr7:133978344	A/T	cg00033643	chr7:134001901	SLC35B4	0.41	5.03	0.31	9.75e-7	Mean platelet volume;
SARC	cis	rs1348850	0.872	rs10165785	chr2:178293295	C/T	cg23306229	chr2:178417860	TTC30B	0.51	5.81	0.36	2.04e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs13392177	0.543	rs12623716	chr2:219073018	C/T	cg00012203	chr2:219082015	ARPC2	-0.69	-9.51	-0.53	2.51e-18	Pyoderma gangrenosum in inflammatory bowel disease;
SARC	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg11062466	chr8:58055876	NA	0.63	5.36	0.33	1.99e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7762018	1.000	rs11961560	chr6:170130121	T/C	cg13891659	chr6:170190454	C6orf122;C6orf208	0.52	4.73	0.3	3.82e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg14541582	chr5:601475	NA	-0.4	-4.8	-0.3	2.85e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs1878931	0.668	rs2074366	chr16:3439676	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	1.01	17.73	0.76	4.12e-45	Body mass index (adult);
SARC	cis	rs3126085	0.935	rs991231	chr1:152211898	T/G	cg26876637	chr1:152193138	HRNR	-0.5	-5.63	-0.35	5.07e-8	Atopic dermatitis;
SARC	cis	rs34172651	0.917	rs200532	chr16:24756148	C/T	cg04756594	chr16:24857601	SLC5A11	-0.37	-6.22	-0.38	2.22e-9	Intelligence (multi-trait analysis);
SARC	cis	rs1497406	0.744	rs1007887	chr1:16509029	C/T	cg20430773	chr1:16534157	ARHGEF19	0.46	7.12	0.42	1.34e-11	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg10560079	chr2:191398806	TMEM194B	-0.62	-8.71	-0.5	5.89e-16	Pulse pressure;
SARC	cis	rs10197940	0.662	rs4592848	chr2:152337822	G/A	cg19508488	chr2:152266495	RIF1	0.52	5.71	0.35	3.34e-8	Lung cancer;
SARC	cis	rs748404	0.650	rs518234	chr15:43573421	G/A	cg12308275	chr15:43558855	TGM5	-0.4	-4.82	-0.3	2.61e-6	Lung cancer;
SARC	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg04277193	chr17:41438351	NA	0.47	5.0	0.31	1.12e-6	Menopause (age at onset);
SARC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg24846343	chr22:24311635	DDTL	0.49	6.53	0.39	4.12e-10	Liver enzyme levels (gamma-glutamyl transferase);
SARC	trans	rs61931739	0.612	rs2004961	chr12:33994599	A/G	cg13010199	chr12:38710504	ALG10B	0.52	6.61	0.4	2.53e-10	Morning vs. evening chronotype;
SARC	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg25036284	chr2:26402008	FAM59B	0.46	5.7	0.35	3.59e-8	Gut microbiome composition (summer);
SARC	trans	rs7824557	0.806	rs6601573	chr8:11094751	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.26	-0.38	1.84e-9	Retinal vascular caliber;
SARC	cis	rs7246760	0.867	rs8112764	chr19:9748907	G/A	cg16876255	chr19:9731953	ZNF561	0.83	5.14	0.32	5.73e-7	Pursuit maintenance gain;
SARC	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg16414030	chr3:133502952	NA	-0.4	-5.28	-0.33	2.92e-7	Iron status biomarkers;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg01380634	chr19:4046108	ZBTB7A	-0.46	-6.48	-0.39	5.44e-10	Chemerin levels;
SARC	cis	rs2645694	0.626	rs2703119	chr4:77823640	C/T	cg10057126	chr4:77819792	ANKRD56	0.45	6.87	0.41	5.84e-11	Emphysema distribution in smoking;
SARC	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg03060546	chr3:49711283	APEH	0.45	5.69	0.35	3.74e-8	Parkinson's disease;
SARC	cis	rs1008375	0.800	rs10008598	chr4:17607323	T/C	cg02297831	chr4:17616191	MED28	0.51	6.49	0.39	5.21e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg12373951	chr3:133503437	NA	0.37	5.4	0.33	1.61e-7	Iron status biomarkers;
SARC	cis	rs67311347	0.955	rs4974068	chr3:40376929	T/C	cg24209194	chr3:40518798	ZNF619	0.57	7.15	0.42	1.08e-11	Renal cell carcinoma;
SARC	cis	rs2153535	0.580	rs969421	chr6:8451949	A/C	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.49	1.52e-15	Motion sickness;
SARC	cis	rs4481887	0.962	rs6587452	chr1:248485931	C/T	cg01631408	chr1:248437212	OR2T33	-0.44	-5.34	-0.33	2.15e-7	Common traits (Other);
SARC	cis	rs7615952	0.741	rs13314845	chr3:125644782	C/T	cg05084668	chr3:125655381	ALG1L	-0.67	-6.67	-0.4	1.84e-10	Blood pressure (smoking interaction);
SARC	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	23.07	0.83	4.25e-62	Chronic sinus infection;
SARC	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6060717	0.536	rs3787173	chr20:34472105	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.21	0.32	4.2e-7	Hip circumference adjusted for BMI;
SARC	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg13939156	chr17:80058883	NA	0.34	5.3	0.33	2.71e-7	Life satisfaction;
SARC	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg16325326	chr1:53192061	ZYG11B	-0.9	-15.45	-0.71	1.53e-37	Monocyte count;
SARC	cis	rs910316	0.737	rs175048	chr14:75479894	A/T	cg11812906	chr14:75593930	NEK9	-0.76	-10.51	-0.57	2.08e-21	Height;
SARC	cis	rs73206853	0.764	rs60339427	chr12:110824471	G/A	cg10860002	chr12:110842031	ANAPC7	0.64	5.15	0.32	5.49e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs2486288	0.656	rs11632920	chr15:45551264	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.43	-5.14	-0.32	5.7e-7	Glomerular filtration rate;
SARC	cis	rs240764	0.578	rs62422070	chr6:101260827	T/G	cg09795085	chr6:101329169	ASCC3	0.44	5.52	0.34	8.97e-8	Neuroticism;
SARC	cis	rs10992471	0.553	rs1923599	chr9:95092568	G/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.43	-5.19	-0.32	4.63e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs372883	0.935	rs1153294	chr21:30701096	A/G	cg24692254	chr21:30365293	RNF160	-0.4	-4.9	-0.31	1.76e-6	Pancreatic cancer;
SARC	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg11764359	chr7:65958608	NA	-0.69	-8.18	-0.47	1.88e-14	Aortic root size;
SARC	cis	rs1707322	0.682	rs10890335	chr1:46100394	G/C	cg06784218	chr1:46089804	CCDC17	0.36	6.19	0.38	2.64e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg24642844	chr7:1081250	C7orf50	-0.59	-6.19	-0.38	2.62e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs9486719	0.947	rs2472893	chr6:96870048	G/C	cg06623918	chr6:96969491	KIAA0776	0.73	8.01	0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs9660992	0.639	rs1151786	chr1:205227760	G/C	cg21643547	chr1:205240462	TMCC2	-0.61	-7.82	-0.46	1.86e-13	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg07701084	chr6:150067640	NUP43	0.41	5.39	0.33	1.68e-7	Lung cancer;
SARC	cis	rs637571	0.522	rs528736	chr11:65705108	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.39	4.84	0.3	2.32e-6	Eosinophil percentage of white cells;
SARC	cis	rs6723226	0.521	rs1991626	chr2:32602450	G/A	cg02381751	chr2:32503542	YIPF4	-0.48	-5.89	-0.36	1.32e-8	Intelligence (multi-trait analysis);
SARC	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg22834771	chr12:69754056	YEATS4	-0.49	-6.42	-0.39	7.74e-10	Cerebrospinal fluid biomarker levels;
SARC	cis	rs910316	1.000	rs4903289	chr14:75623988	C/T	cg23033748	chr14:75592666	NEK9	-0.36	-5.13	-0.32	6.22e-7	Height;
SARC	cis	rs1538970	0.781	rs713358	chr1:45988267	C/G	cg05343316	chr1:45956843	TESK2	0.82	9.01	0.51	7.85e-17	Platelet count;
SARC	cis	rs9818758	0.607	rs34823813	chr3:49749976	G/A	cg01304814	chr3:48885189	PRKAR2A	0.64	5.22	0.32	3.92e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg02951883	chr7:2050386	MAD1L1	-0.43	-5.5	-0.34	1.02e-7	Bipolar disorder and schizophrenia;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg17524151	chr16:475494	RAB11FIP3	-0.8	-6.73	-0.4	1.3e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg22857025	chr5:266934	NA	-1.06	-11.63	-0.61	5.91e-25	Breast cancer;
SARC	cis	rs897080	0.553	rs1067338	chr2:44624708	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.62	7.43	0.44	2.05e-12	Height;
SARC	cis	rs2439831	1.000	rs2254321	chr15:43707542	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.81	8.46	0.48	2.98e-15	Lung cancer in ever smokers;
SARC	cis	rs4148883	0.504	rs28720150	chr4:100132790	T/G	cg13256891	chr4:100009986	ADH5	-0.56	-7.15	-0.42	1.11e-11	Alcohol dependence;
SARC	cis	rs66573146	1.000	rs6812391	chr4:6963893	G/A	cg00086871	chr4:6988644	TBC1D14	0.91	5.07	0.32	8.14e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs3784262	0.904	rs3784260	chr15:58253269	T/G	cg12031962	chr15:58353849	ALDH1A2	-0.39	-5.85	-0.36	1.64e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs72772090	0.908	rs17086588	chr5:96044914	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.52	4.83	0.3	2.49e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg13939156	chr17:80058883	NA	-0.42	-6.48	-0.39	5.51e-10	Life satisfaction;
SARC	cis	rs9486715	0.867	rs2499774	chr6:97006581	C/G	cg18709589	chr6:96969512	KIAA0776	-0.61	-7.67	-0.45	4.59e-13	Headache;
SARC	cis	rs9916302	0.904	rs8079355	chr17:37473018	G/A	cg15445000	chr17:37608096	MED1	-0.44	-5.31	-0.33	2.6e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs752092	1.000	rs7182945	chr15:101784223	C/T	cg25114630	chr15:101792522	CHSY1	0.4	4.84	0.3	2.37e-6	Corneal structure;
SARC	cis	rs9300255	0.679	rs12829456	chr12:123725395	C/T	cg00376283	chr12:123451042	ABCB9	-0.5	-4.78	-0.3	3.17e-6	Neutrophil percentage of white cells;
SARC	cis	rs698833	0.692	rs786410	chr2:44731156	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.68	8.65	0.49	8.32e-16	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs796364	0.951	rs2881593	chr2:201000347	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.56	-5.78	-0.35	2.41e-8	Schizophrenia;
SARC	cis	rs921968	0.565	rs2037622	chr2:219609440	T/C	cg02176678	chr2:219576539	TTLL4	-0.32	-4.94	-0.31	1.48e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.54	0.44	1.06e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs739401	0.611	rs2071104	chr11:3036933	G/T	cg25174290	chr11:3078921	CARS	0.57	7.96	0.46	7.36e-14	Longevity;
SARC	cis	rs2070488	0.775	rs6599207	chr3:38554901	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.76	-11.23	-0.59	1.1e-23	Electrocardiographic conduction measures;
SARC	cis	rs140330585	1	rs140330585	chr15:78866445	G/A	cg06917634	chr15:78832804	PSMA4	-0.53	-5.78	-0.35	2.44e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs2153535	0.601	rs7775274	chr6:8530303	A/G	cg21535247	chr6:8435926	SLC35B3	0.51	6.48	0.39	5.5e-10	Motion sickness;
SARC	cis	rs910316	0.737	rs175499	chr14:75535927	G/A	cg23033748	chr14:75592666	NEK9	-0.36	-4.83	-0.3	2.46e-6	Height;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg05414026	chr15:72410489	MYO9A;SENP8	0.57	7.82	0.46	1.88e-13	Tetralogy of Fallot;
SARC	cis	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg18252515	chr7:66147081	NA	-1.29	-11.31	-0.6	6.31e-24	Diabetic kidney disease;
SARC	cis	rs9818758	0.556	rs116432667	chr3:48947589	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.64	-5.46	-0.34	1.22e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs9399137	0.507	rs6918512	chr6:135284839	T/G	cg22676075	chr6:135203613	NA	0.39	4.97	0.31	1.32e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs981844	0.857	rs41320045	chr4:154720615	A/T	cg14289246	chr4:154710475	SFRP2	-0.61	-7.05	-0.42	1.99e-11	Response to statins (LDL cholesterol change);
SARC	cis	rs7586879	0.687	rs11892869	chr2:25096692	A/T	cg04586622	chr2:25135609	ADCY3	0.31	5.34	0.33	2.17e-7	Body mass index;
SARC	cis	rs7027203	0.557	rs2490997	chr9:96522109	C/T	cg14598338	chr9:96623480	NA	-0.34	-4.76	-0.3	3.43e-6	DNA methylation (variation);
SARC	cis	rs7589342	0.801	rs13031068	chr2:106455021	A/G	cg14210321	chr2:106509881	NCK2	-0.44	-5.13	-0.32	6.12e-7	Addiction;
SARC	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg22496380	chr5:211416	CCDC127	-0.88	-9.35	-0.52	7.72e-18	Breast cancer;
SARC	cis	rs9916302	0.800	rs11869259	chr17:37518141	C/A	cg15445000	chr17:37608096	MED1	-0.45	-5.48	-0.34	1.1e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs7589342	0.839	rs6747023	chr2:106431856	A/G	cg16077055	chr2:106428750	NCK2	0.34	6.14	0.37	3.6e-9	Addiction;
SARC	cis	rs3820928	1.000	rs4673173	chr2:227769493	A/C	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.01	-0.42	2.61e-11	Pulmonary function;
SARC	cis	rs1018836	0.923	rs10956749	chr8:91621573	G/A	cg16814680	chr8:91681699	NA	-0.86	-14.05	-0.68	6.71e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs12702595	0.509	rs2108784	chr7:7266745	A/G	cg04827551	chr7:7268805	C1GALT1	-0.39	-4.8	-0.3	2.78e-6	Serum dimethylarginine levels (asymmetric/symetric ratio);Symmetrical dimethylarginine levels;
SARC	cis	rs2011503	1.000	rs11670882	chr19:19649748	C/G	cg03709012	chr19:19516395	GATAD2A	0.64	6.3	0.38	1.46e-9	Bipolar disorder;
SARC	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg08219700	chr8:58056026	NA	0.65	6.11	0.37	4.13e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs17125944	0.686	rs76673112	chr14:53366692	T/C	cg00686598	chr14:53173677	PSMC6	0.82	5.7	0.35	3.69e-8	Alzheimer's disease (late onset);
SARC	cis	rs2486288	0.656	rs11629859	chr15:45547121	T/G	cg21132104	chr15:45694354	SPATA5L1	-0.5	-6.22	-0.38	2.34e-9	Glomerular filtration rate;
SARC	cis	rs4742903	0.509	rs10991159	chr9:106960542	C/A	cg14250997	chr9:106856677	SMC2	0.38	4.74	0.3	3.68e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs11191193	0.967	rs11191156	chr10:103702763	C/T	cg15320455	chr10:103880129	LDB1	-0.43	-5.1	-0.32	6.91e-7	Educational attainment;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18075287	chr12:10365459	GABARAPL1	-0.55	-6.65	-0.4	2.09e-10	Fibrinogen levels;
SARC	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg10207240	chr12:122356781	WDR66	0.3	4.99	0.31	1.2e-6	Mean corpuscular volume;
SARC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg09373136	chr17:61933544	TCAM1	-0.45	-6.13	-0.37	3.74e-9	Prudent dietary pattern;
SARC	cis	rs2153535	0.504	rs9405393	chr6:8467432	G/T	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs7197653	0.748	rs58542611	chr16:68350219	C/T	cg09835421	chr16:68378352	PRMT7	-0.63	-5.35	-0.33	2.06e-7	Magnesium levels;
SARC	cis	rs4803468	1.000	rs10409485	chr19:41920765	C/T	cg08477640	chr19:41863820	B9D2	-0.47	-6.16	-0.37	3.17e-9	Height;
SARC	trans	rs9395865	0.520	rs6903708	chr6:53332940	A/G	cg26009363	chr10:25465263	GPR158;LOC100128811	-0.49	-6.39	-0.39	9.17e-10	Electroencephalographic traits in alcoholism;
SARC	cis	rs5769765	1.000	rs2092982	chr22:50282204	C/A	cg03033257	chr22:50311977	ALG12;CRELD2	-0.54	-5.64	-0.35	4.81e-8	Schizophrenia;
SARC	cis	rs7020830	0.931	rs13297576	chr9:37142189	A/C	cg14294708	chr9:37120828	ZCCHC7	1.13	20.57	0.8	2.61e-54	Schizophrenia;
SARC	cis	rs9325144	0.600	rs6582630	chr12:38743508	A/G	cg26384229	chr12:38710491	ALG10B	-0.61	-8.09	-0.47	3.26e-14	Morning vs. evening chronotype;
SARC	cis	rs13191362	1.000	rs7764785	chr6:163009967	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.5	0.34	1.01e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs11098499	0.863	rs3822194	chr4:120471648	A/G	cg09307838	chr4:120376055	NA	0.91	12.25	0.63	5.66e-27	Corneal astigmatism;
SARC	cis	rs1580019	0.587	rs6968990	chr7:32552159	C/T	cg07520158	chr7:32535189	LSM5;AVL9	-0.6	-7.77	-0.45	2.51e-13	Cognitive ability;
SARC	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-4.86	-0.3	2.12e-6	Total body bone mineral density;
SARC	cis	rs796364	0.951	rs35618222	chr2:201065777	C/G	cg23649088	chr2:200775458	C2orf69	0.65	7.01	0.42	2.56e-11	Schizophrenia;
SARC	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs601339	1.000	rs35683065	chr12:123164062	G/C	cg18578876	chr12:123200353	GPR109B	0.42	4.81	0.3	2.67e-6	Adiponectin levels;
SARC	cis	rs2221894	0.506	rs79113316	chr8:28882437	C/T	cg07962641	chr8:28805897	HMBOX1	-0.78	-7.68	-0.45	4.24e-13	Obesity-related traits;
SARC	cis	rs6570726	0.818	rs399516	chr6:145810849	C/A	cg05347473	chr6:146136440	FBXO30	0.5	6.84	0.41	7.08e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1153858	1.000	rs12440038	chr15:45706739	A/G	cg26924012	chr15:45694286	SPATA5L1	0.78	10.67	0.57	6.94e-22	Homoarginine levels;
SARC	cis	rs2908197	0.737	rs2109857	chr7:75963169	T/C	cg24580635	chr7:76178542	LOC100133091	-0.42	-4.87	-0.3	2.08e-6	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs2011503	0.882	rs8108777	chr19:19359058	C/A	cg03709012	chr19:19516395	GATAD2A	0.58	5.35	0.33	2.09e-7	Bipolar disorder;
SARC	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg09359103	chr1:154839909	KCNN3	-0.46	-7.8	-0.46	2e-13	Prostate cancer;
SARC	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg13395646	chr4:1353034	KIAA1530	-0.49	-5.93	-0.36	1.1e-8	Obesity-related traits;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg15711268	chr19:31841952	NA	0.51	6.51	0.39	4.63e-10	Height;
SARC	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	5.94	0.36	1.02e-8	Bipolar disorder;
SARC	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg24399712	chr22:39784796	NA	-0.46	-6.34	-0.38	1.16e-9	Intelligence (multi-trait analysis);
SARC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg21280719	chr6:42927975	GNMT	-0.46	-8.16	-0.47	2.03e-14	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs8017423	0.967	rs7158180	chr14:90729117	C/T	cg20276874	chr14:90721474	PSMC1	-0.38	-5.25	-0.33	3.39e-7	Mortality in heart failure;
SARC	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg18252515	chr7:66147081	NA	0.56	6.02	0.37	6.73e-9	Aortic root size;
SARC	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg21724239	chr8:58056113	NA	0.58	5.71	0.35	3.43e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6088813	0.845	rs2378349	chr20:33925843	C/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.45	5.45	0.34	1.28e-7	Height;
SARC	cis	rs9788721	0.592	rs28564957	chr15:78906107	C/A	cg17108064	chr15:78857060	CHRNA5	-0.3	-5.1	-0.32	6.91e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg08219700	chr8:58056026	NA	0.61	6.35	0.38	1.13e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2204008	0.837	rs11180549	chr12:38236950	A/G	cg13010199	chr12:38710504	ALG10B	0.81	11.19	0.59	1.51e-23	Bladder cancer;
SARC	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.06	0.37	5.48e-9	Bipolar disorder;
SARC	cis	rs240764	0.658	rs9404054	chr6:101256597	A/G	cg09795085	chr6:101329169	ASCC3	-0.42	-5.38	-0.33	1.84e-7	Neuroticism;
SARC	cis	rs4319547	0.695	rs6488939	chr12:122858250	T/C	cg23029597	chr12:123009494	RSRC2	-0.41	-5.17	-0.32	4.93e-7	Body mass index;
SARC	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg21724239	chr8:58056113	NA	0.61	5.93	0.36	1.1e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7223966	0.921	rs2854207	chr17:61947107	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.5	-5.16	-0.32	5.32e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs981844	1.000	rs1371161	chr4:154655171	T/C	cg14289246	chr4:154710475	SFRP2	0.59	6.72	0.4	1.37e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs10870270	1.000	rs10159746	chr10:133742677	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.45	-5.37	-0.33	1.93e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs4481887	0.927	rs4336885	chr1:248473168	A/C	cg13385794	chr1:248469461	NA	0.34	5.33	0.33	2.32e-7	Common traits (Other);
SARC	cis	rs10216189	0.967	rs4724700	chr7:5526789	A/G	cg05318486	chr7:5553423	FBXL18	-0.52	-6.5	-0.39	4.79e-10	Relative hand skill in reading disability;
SARC	cis	rs4742903	0.935	rs1450681	chr9:106932435	A/G	cg14250997	chr9:106856677	SMC2	0.44	5.5	0.34	1.01e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs874628	0.686	rs72999447	chr19:18236947	G/A	cg00493341	chr19:18228948	MAST3	0.5	5.33	0.33	2.32e-7	Multiple sclerosis;
SARC	cis	rs12950390	0.512	rs11651000	chr17:45835278	G/A	cg03474202	chr17:45855739	NA	-0.42	-5.12	-0.32	6.27e-7	IgG glycosylation;
SARC	cis	rs9868809	0.505	rs28657585	chr3:48736216	A/T	cg07636037	chr3:49044803	WDR6	-0.73	-6.98	-0.42	3.1e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs2250402	0.510	rs6492926	chr15:40325829	T/G	cg20255370	chr15:40268687	EIF2AK4	-0.72	-5.94	-0.36	1.05e-8	Corneal curvature;
SARC	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.45	5.28	0.33	3.01e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs911555	0.504	rs4444269	chr14:104072724	G/C	cg24130564	chr14:104152367	KLC1	-0.7	-9.78	-0.54	3.82e-19	Intelligence (multi-trait analysis);
SARC	cis	rs711830	0.587	rs10188827	chr2:177007664	C/T	cg03858756	chr2:176994637	HOXD8	0.61	6.4	0.39	8.41e-10	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
SARC	cis	rs8027181	0.839	rs10459647	chr15:73035241	T/C	cg25996835	chr15:72978165	BBS4;HIGD2B	0.42	5.61	0.34	5.73e-8	Triglyceride levels;
SARC	cis	rs1983891	0.826	rs9381075	chr6:41515224	G/A	cg15051332	chr6:41514432	FOXP4	0.55	5.53	0.34	8.53e-8	Prostate cancer;
SARC	cis	rs9858542	0.953	rs6809216	chr3:49412559	G/A	cg03060546	chr3:49711283	APEH	-0.57	-7.14	-0.42	1.19e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.76	9.44	0.53	4.04e-18	Height;
SARC	cis	rs17666538	0.585	rs4333567	chr8:636611	C/T	cg07234876	chr8:600039	NA	0.74	5.24	0.32	3.64e-7	IgG glycosylation;
SARC	cis	rs262150	0.672	rs2730230	chr7:158788529	A/G	cg09640425	chr7:158790006	NA	-0.34	-4.84	-0.3	2.4e-6	Facial morphology (factor 20);
SARC	cis	rs9902453	0.808	rs62068617	chr17:28144728	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	7.07	0.42	1.79e-11	Coffee consumption (cups per day);
SARC	cis	rs11697848	1.000	rs11697848	chr20:48575315	C/T	cg17849948	chr20:48532315	SPATA2	0.92	5.49	0.34	1.05e-7	Systemic lupus erythematosus;
SARC	cis	rs9457247	1.000	rs385113	chr6:167403971	A/G	cg07741184	chr6:167504864	NA	0.29	5.55	0.34	7.59e-8	Crohn's disease;
SARC	cis	rs2486288	0.656	rs2413771	chr15:45553140	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.5	-6.49	-0.39	5.12e-10	Glomerular filtration rate;
SARC	cis	rs763121	0.853	rs35522482	chr22:39063015	C/A	cg06022373	chr22:39101656	GTPBP1	0.89	11.26	0.59	8.85e-24	Menopause (age at onset);
SARC	cis	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.56	8.66	0.49	7.86e-16	Eosinophil percentage of white cells;
SARC	cis	rs1348850	0.526	rs6433672	chr2:178378175	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.64	5.96	0.36	9.44e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs72792276	0.908	rs10478797	chr5:127442066	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.69	6.24	0.38	2.08e-9	Red cell distribution width;
SARC	cis	rs2921073	0.605	rs2976933	chr8:8254875	A/G	cg15556689	chr8:8085844	FLJ10661	0.52	5.88	0.36	1.42e-8	Parkinson's disease;
SARC	trans	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg20587970	chr11:113659929	NA	1.0	9.39	0.52	5.83e-18	Hip circumference adjusted for BMI;
SARC	cis	rs36051895	0.664	rs12344629	chr9:5109208	C/T	cg02405213	chr9:5042618	JAK2	-0.45	-5.33	-0.33	2.32e-7	Pediatric autoimmune diseases;
SARC	cis	rs2243480	1.000	rs958550	chr7:65635679	C/T	cg25894440	chr7:65020034	NA	0.65	4.85	0.3	2.3e-6	Diabetic kidney disease;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg17079530	chr11:117014700	PAFAH1B2	0.51	6.26	0.38	1.79e-9	Breast cancer;
SARC	cis	rs3091242	0.933	rs35148262	chr1:25766623	A/G	cg02931644	chr1:25747376	RHCE	0.44	7.13	0.42	1.27e-11	Erythrocyte sedimentation rate;
SARC	cis	rs2832191	0.671	rs68101501	chr21:30513229	G/T	cg08807101	chr21:30365312	RNF160	-0.7	-8.54	-0.49	1.76e-15	Dental caries;
SARC	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg22168489	chr12:122356033	WDR66	0.63	9.11	0.51	3.82e-17	Mean corpuscular volume;
SARC	cis	rs933688	1.000	rs4382199	chr5:90744228	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	13.03	0.65	1.61e-29	Smoking behavior;
SARC	cis	rs4642101	0.737	rs4447735	chr3:12825513	C/T	cg24848339	chr3:12840334	CAND2	0.33	5.19	0.32	4.48e-7	QRS complex (12-leadsum);
SARC	cis	rs6840360	0.593	rs7654294	chr4:152690975	T/C	cg22705602	chr4:152727874	NA	-0.5	-8.95	-0.51	1.15e-16	Intelligence (multi-trait analysis);
SARC	cis	rs807669	0.868	rs2800973	chr22:19168616	A/G	cg02655711	chr22:19163373	SLC25A1	0.53	7.27	0.43	5.37e-12	Metabolite levels;
SARC	cis	rs9291683	0.655	rs2278121	chr4:10096134	G/A	cg00071950	chr4:10020882	SLC2A9	-0.33	-5.1	-0.32	7.02e-7	Bone mineral density;
SARC	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg06634786	chr22:41940651	POLR3H	0.54	6.49	0.39	5.25e-10	Vitiligo;
SARC	trans	rs10448080	0.879	rs240946	chr8:28568905	A/G	cg04364194	chr1:202114085	ARL8A	0.51	6.68	0.4	1.71e-10	Height;
SARC	cis	rs7044106	0.791	rs10818473	chr9:123484155	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.72	9.19	0.52	2.28e-17	Hip circumference adjusted for BMI;
SARC	trans	rs9929218	0.817	rs8055912	chr16:68802068	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.53	-6.72	-0.4	1.41e-10	Colorectal cancer;
SARC	cis	rs9467711	0.606	rs28360517	chr6:26602453	A/G	cg12826209	chr6:26865740	GUSBL1	0.72	4.85	0.3	2.25e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs11097912	0.632	rs6838283	chr4:107223009	C/A	cg09646026	chr4:107269030	AIMP1	-0.45	-4.86	-0.3	2.2e-6	Airflow obstruction;
SARC	cis	rs2204008	0.774	rs11514062	chr12:38332297	A/C	cg26384229	chr12:38710491	ALG10B	0.86	12.19	0.62	9.18e-27	Bladder cancer;
SARC	cis	rs2230307	0.656	rs12145880	chr1:100446008	C/G	cg24955406	chr1:100503596	HIAT1	0.7	5.87	0.36	1.49e-8	Carotid intima media thickness;
SARC	cis	rs9879311	0.643	rs1473183	chr3:10411827	C/T	cg11030744	chr3:10328490	GHRL;GHRLOS	0.42	4.91	0.31	1.7e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	cis	rs6963495	0.818	rs6957192	chr7:105150255	A/C	cg19920283	chr7:105172520	RINT1	-0.69	-6.15	-0.37	3.29e-9	Bipolar disorder (body mass index interaction);
SARC	cis	rs36051895	0.632	rs7871515	chr9:5175288	A/G	cg02405213	chr9:5042618	JAK2	0.43	5.3	0.33	2.66e-7	Pediatric autoimmune diseases;
SARC	cis	rs1008375	0.863	rs7680984	chr4:17600884	A/G	cg02297831	chr4:17616191	MED28	0.5	6.43	0.39	7.01e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg11301795	chr4:187892539	NA	0.73	10.69	0.57	5.69e-22	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs55883249	1.000	rs17453724	chr2:9764001	A/G	cg23886495	chr2:9695866	ADAM17	0.66	6.91	0.41	4.67e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs2354432	0.607	rs7545467	chr1:146746248	A/G	cg25205988	chr1:146714368	CHD1L	-1.02	-7.73	-0.45	3.15e-13	Mitochondrial DNA levels;
SARC	trans	rs11722228	0.549	rs3796818	chr4:10097976	C/T	cg26043149	chr18:55253948	FECH	0.69	7.69	0.45	3.99e-13	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs2153535	0.580	rs2327050	chr6:8440630	A/G	cg21535247	chr6:8435926	SLC35B3	0.56	7.01	0.42	2.6e-11	Motion sickness;
SARC	cis	rs7959452	0.530	rs12811632	chr12:69755003	G/A	cg14784868	chr12:69753453	YEATS4	0.5	6.67	0.4	1.82e-10	Blood protein levels;
SARC	cis	rs721399	0.513	rs35354956	chr8:18241319	T/C	cg18736775	chr8:18248649	NAT2	-0.67	-7.31	-0.43	4.23e-12	Blood metabolite levels;
SARC	cis	rs77372450	0.636	rs11465222	chr5:157004167	C/T	cg23851860	chr5:157002805	ADAM19	0.51	4.91	0.31	1.72e-6	Bipolar disorder (body mass index interaction);
SARC	cis	rs73001065	0.551	rs79954596	chr19:19548643	T/G	cg03709012	chr19:19516395	GATAD2A	1.08	8.4	0.48	4.36e-15	LDL cholesterol;
SARC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg20007245	chr22:24372913	LOC391322	-0.69	-8.37	-0.48	5.24e-15	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg04267008	chr7:1944627	MAD1L1	-0.47	-5.0	-0.31	1.15e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs7312774	0.748	rs12320535	chr12:107295813	T/C	cg16260113	chr12:107380972	MTERFD3	0.77	6.66	0.4	1.93e-10	Severe influenza A (H1N1) infection;
SARC	cis	rs8014131	0.689	rs1543390	chr14:85984272	C/A	cg10406690	chr14:85995726	FLRT2	0.4	5.22	0.32	3.99e-7	Menarche (age at onset);
SARC	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg24209194	chr3:40518798	ZNF619	0.66	8.45	0.48	3.17e-15	Renal cell carcinoma;
SARC	cis	rs7937682	0.855	rs571462	chr11:111487106	C/G	cg22437258	chr11:111473054	SIK2	0.74	10.24	0.56	1.44e-20	Primary sclerosing cholangitis;
SARC	cis	rs1801251	1.000	rs283479	chr2:233648754	A/G	cg25237894	chr2:233734115	C2orf82	0.38	4.82	0.3	2.56e-6	Coronary artery disease;
SARC	cis	rs11578119	0.933	rs12119012	chr1:170446678	C/T	cg09767346	chr1:170501363	GORAB	0.45	5.25	0.33	3.42e-7	Male-pattern baldness;
SARC	cis	rs8031584	0.918	rs34331396	chr15:31248736	C/G	cg19680485	chr15:31195859	MTMR15	-0.54	-6.09	-0.37	4.69e-9	Huntington's disease progression;
SARC	cis	rs9303401	0.646	rs9892425	chr17:57241938	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.59	7.26	0.43	5.61e-12	Cognitive test performance;
SARC	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg22903657	chr4:1355424	KIAA1530	-0.33	-4.78	-0.3	3.16e-6	Longevity;
SARC	cis	rs10789491	1.000	rs1258061	chr1:47105000	G/A	cg15501359	chr1:47185051	KIAA0494	-0.73	-7.47	-0.44	1.57e-12	Response to hepatitis C treatment;
SARC	cis	rs172166	0.637	rs1225592	chr6:28150242	G/A	cg17221315	chr6:27791827	HIST1H4J	0.45	5.27	0.33	3.13e-7	Cardiac Troponin-T levels;
SARC	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg10935138	chr17:73851978	WBP2	0.52	5.52	0.34	8.81e-8	Psoriasis;
SARC	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg08280861	chr8:58055591	NA	0.6	5.28	0.33	2.92e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9517313	0.615	rs4772079	chr13:99090837	C/G	cg07423050	chr13:99094983	FARP1	-0.56	-8.61	-0.49	1.11e-15	Neuroticism;
SARC	cis	rs400736	0.671	rs2472862	chr1:7991203	G/A	cg25007680	chr1:8021821	PARK7	-0.41	-5.35	-0.33	2.09e-7	Response to antidepressants and depression;
SARC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.3	-4.77	-0.3	3.24e-6	Total body bone mineral density;
SARC	cis	rs7662987	0.517	rs1133485	chr4:100023811	T/A	cg12011299	chr4:100065546	ADH4	0.32	5.26	0.33	3.23e-7	Smoking initiation;
SARC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.45	-5.93	-0.36	1.11e-8	Longevity;Endometriosis;
SARC	cis	rs59918340	0.728	rs10112337	chr8:142233573	A/G	cg16341495	chr8:142228727	SLC45A4	0.36	5.14	0.32	5.83e-7	Immature fraction of reticulocytes;
SARC	cis	rs7607369	0.580	rs17573731	chr2:219652153	T/C	cg02176678	chr2:219576539	TTLL4	-0.51	-8.32	-0.48	7.33e-15	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	trans	rs79976124	0.797	rs77895756	chr6:66626782	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	8.0	0.46	5.76e-14	Type 2 diabetes;
SARC	cis	rs9640161	0.789	rs1464751	chr7:150021282	C/T	cg10018233	chr7:150070692	REPIN1	0.72	9.59	0.53	1.44e-18	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.99	12.16	0.62	1.18e-26	Platelet count;
SARC	cis	rs6942407	0.592	rs1024457	chr7:86764142	T/G	cg02420886	chr7:86849541	C7orf23	0.64	5.45	0.34	1.26e-7	Food allergy;
SARC	cis	rs11605924	0.934	rs7945689	chr11:45879006	C/T	ch.11.939596F	chr11:45881766	CRY2	-0.51	-6.06	-0.37	5.32e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs7089973	0.604	rs765174	chr10:116601888	C/T	cg08188268	chr10:116634841	FAM160B1	0.28	4.79	0.3	3.02e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs7178572	0.633	rs4886876	chr15:77838491	C/T	cg22256960	chr15:77711686	NA	-0.42	-4.71	-0.3	4.16e-6	Type 2 diabetes;
SARC	cis	rs1008375	1.000	rs10939756	chr4:17693867	C/T	cg02297831	chr4:17616191	MED28	0.39	4.86	0.3	2.14e-6	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4938330	0.608	rs12418744	chr11:117084537	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.52	-5.51	-0.34	9.61e-8	Blood protein levels;
SARC	trans	rs61931739	0.500	rs7298322	chr12:34445489	A/T	cg13010199	chr12:38710504	ALG10B	0.76	10.71	0.57	5.2e-22	Morning vs. evening chronotype;
SARC	cis	rs3733585	0.673	rs4311316	chr4:9955971	A/C	cg00071950	chr4:10020882	SLC2A9	0.39	5.94	0.36	1.03e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7818345	0.967	rs11204039	chr8:19280442	A/C	cg11303988	chr8:19266685	CSGALNACT1	0.42	5.55	0.34	7.72e-8	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs11997175	0.967	rs60586868	chr8:33776585	A/G	ch.8.33884649F	chr8:33765107	NA	0.5	6.64	0.4	2.21e-10	Body mass index;
SARC	cis	rs11122272	0.735	rs2246645	chr1:231497393	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.98	-0.55	9.29e-20	Hemoglobin concentration;
SARC	trans	rs2727020	0.729	rs1164666	chr11:49295867	C/T	cg03929089	chr4:120376271	NA	-0.77	-11.6	-0.61	7.62e-25	Coronary artery disease;
SARC	cis	rs832540	0.656	rs832573	chr5:56159578	T/C	cg24549020	chr5:56110836	MAP3K1	0.42	4.92	0.31	1.61e-6	Coronary artery disease;
SARC	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg07701084	chr6:150067640	NUP43	0.41	5.4	0.33	1.62e-7	Lung cancer;
SARC	cis	rs838147	0.534	rs2638280	chr19:49209318	G/A	cg21064579	chr19:49206444	FUT2	0.34	4.83	0.3	2.44e-6	Dietary macronutrient intake;
SARC	cis	rs875971	0.825	rs59466412	chr7:65565358	A/G	cg11764359	chr7:65958608	NA	-0.77	-9.37	-0.52	6.62e-18	Aortic root size;
SARC	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.55	5.09	0.32	7.45e-7	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg19901468	chr14:105411992	AHNAK2	-0.73	-10.79	-0.58	2.74e-22	Rheumatoid arthritis;
SARC	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg25894440	chr7:65020034	NA	-0.75	-5.77	-0.35	2.56e-8	Diabetic kidney disease;
SARC	cis	rs6500602	0.647	rs3747600	chr16:4586222	A/G	cg08645402	chr16:4508243	NA	0.4	5.13	0.32	6.06e-7	Schizophrenia;
SARC	cis	rs240764	0.658	rs9386257	chr6:101252069	A/T	cg09795085	chr6:101329169	ASCC3	0.4	5.01	0.31	1.06e-6	Neuroticism;
SARC	cis	rs4555082	1.000	rs7149013	chr14:105759840	T/C	cg10792982	chr14:105748885	BRF1	0.51	7.59	0.45	7.71e-13	Mean platelet volume;Platelet distribution width;
SARC	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg18876405	chr7:65276391	NA	0.46	5.11	0.32	6.58e-7	Aortic root size;
SARC	cis	rs763121	0.853	rs6519119	chr22:38989007	C/G	cg06022373	chr22:39101656	GTPBP1	0.87	10.89	0.58	1.39e-22	Menopause (age at onset);
SARC	cis	rs10744422	0.920	rs10773657	chr12:123327900	C/A	cg25930673	chr12:123319894	HIP1R	-0.64	-4.98	-0.31	1.26e-6	Schizophrenia;
SARC	cis	rs6912958	0.559	rs6921504	chr6:88058972	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.75	11.82	0.61	1.41e-25	Monocyte percentage of white cells;
SARC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	5.44	0.34	1.35e-7	Cognitive function;
SARC	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg07701084	chr6:150067640	NUP43	0.4	5.23	0.32	3.74e-7	Lung cancer;
SARC	cis	rs10463554	0.927	rs55641526	chr5:102251005	G/A	cg23492399	chr5:102201601	PAM	-0.47	-5.59	-0.34	6.34e-8	Parkinson's disease;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg27368511	chr5:159826822	C5orf54	0.49	6.54	0.39	3.86e-10	Chemerin levels;
SARC	cis	rs9462027	0.583	rs9462022	chr6:34761684	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.85	-0.36	1.63e-8	Systemic lupus erythematosus;
SARC	cis	rs6071524	0.818	rs10854216	chr20:37447919	A/G	cg24229276	chr20:36931287	BPI	-0.32	-5.1	-0.32	7.07e-7	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6060717	0.610	rs2590965	chr20:34613120	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.51	5.15	0.32	5.56e-7	Hip circumference adjusted for BMI;
SARC	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg27121462	chr16:89883253	FANCA	0.71	11.39	0.6	3.59e-24	Vitiligo;
SARC	cis	rs763121	0.853	rs4821812	chr22:39075235	G/C	cg06022373	chr22:39101656	GTPBP1	0.84	10.32	0.56	8.51e-21	Menopause (age at onset);
SARC	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.97e-8	Aortic root size;
SARC	cis	rs9660992	0.762	rs1172129	chr1:205244972	T/A	cg21545522	chr1:205238299	TMCC2	0.47	6.57	0.4	3.24e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs10870270	1.000	rs7199	chr10:133769848	C/G	cg26149184	chr10:133730230	NA	0.46	5.05	0.31	9e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs9914988	0.613	rs67436963	chr17:27296508	G/A	cg10538030	chr17:27276405	PHF12	-0.63	-5.1	-0.32	6.91e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg03647317	chr4:187891568	NA	-0.37	-5.1	-0.32	7.18e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9397240	0.846	rs9384310	chr6:155630653	G/A	cg07943832	chr6:155568918	TIAM2	-0.6	-5.67	-0.35	4.26e-8	Life satisfaction;
SARC	cis	rs1448094	0.765	rs4919773	chr12:86337559	C/T	cg02569458	chr12:86230093	RASSF9	0.44	6.26	0.38	1.86e-9	Major depressive disorder;
SARC	cis	rs4423214	0.592	rs10898193	chr11:71197083	A/G	cg05163923	chr11:71159392	DHCR7	0.48	4.89	0.3	1.9e-6	Vitamin D levels;
SARC	cis	rs73198271	0.632	rs57281209	chr8:8602795	C/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-5.71	-0.35	3.43e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs7223966	0.921	rs2006123	chr17:61958669	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.46	5.12	0.32	6.53e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs10875746	0.903	rs10875740	chr12:48489117	C/T	cg26205652	chr12:48591994	NA	0.56	6.05	0.37	5.81e-9	Longevity (90 years and older);
SARC	cis	rs6570726	0.791	rs6900040	chr6:145893134	C/T	cg23711669	chr6:146136114	FBXO30	0.84	13.98	0.68	1.14e-32	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11758351	0.866	rs11757394	chr6:26206694	G/C	cg01420254	chr6:26195488	NA	0.56	5.01	0.31	1.05e-6	Gout;Renal underexcretion gout;
SARC	cis	rs7223966	1.000	rs11079509	chr17:61762148	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	6.51	0.39	4.54e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs10493773	0.775	rs12564080	chr1:86196586	A/C	cg17807903	chr1:86174739	ZNHIT6	-0.51	-7.88	-0.46	1.26e-13	Urate levels in overweight individuals;
SARC	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2204008	0.537	rs28680519	chr12:38502946	C/T	cg13010199	chr12:38710504	ALG10B	0.74	10.06	0.55	5.16e-20	Bladder cancer;
SARC	cis	rs10876993	0.890	rs115106209	chr12:58059331	G/A	cg18357645	chr12:58087776	OS9	0.5	6.55	0.39	3.56e-10	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg22903471	chr2:27725779	GCKR	-0.46	-6.58	-0.4	3.11e-10	Total body bone mineral density;
SARC	cis	rs17384381	0.861	rs2300640	chr1:85823795	C/G	cg16011679	chr1:85725395	C1orf52	0.65	6.02	0.37	6.61e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg26850624	chr5:429559	AHRR	-0.33	-5.23	-0.32	3.7e-7	Cystic fibrosis severity;
SARC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg26338869	chr17:61819248	STRADA	0.82	10.97	0.58	7.45e-23	Prudent dietary pattern;
SARC	cis	rs4808199	0.948	rs7259434	chr19:19428805	A/T	cg03709012	chr19:19516395	GATAD2A	1.06	11.03	0.59	4.91e-23	Nonalcoholic fatty liver disease;
SARC	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.75	8.86	0.5	2.11e-16	Height;
SARC	cis	rs637571	0.565	rs570387	chr11:65637076	T/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.54	-7.4	-0.44	2.48e-12	Eosinophil percentage of white cells;
SARC	cis	rs4853036	1.000	rs34587942	chr2:70081501	G/A	cg02498382	chr2:70120550	SNRNP27	-0.39	-5.23	-0.32	3.72e-7	Colorectal or endometrial cancer;
SARC	cis	rs9487051	0.714	rs9487053	chr6:109619697	T/C	cg01475377	chr6:109611718	NA	-0.37	-5.3	-0.33	2.69e-7	Reticulocyte fraction of red cells;
SARC	cis	rs7635838	0.653	rs2606749	chr3:11373635	A/G	cg00170343	chr3:11313890	ATG7	0.63	8.54	0.49	1.75e-15	HDL cholesterol;
SARC	cis	rs4713675	0.584	rs6938056	chr6:33669577	C/T	cg15676125	chr6:33679581	C6orf125	0.52	6.35	0.38	1.12e-9	Plateletcrit;
SARC	trans	rs393155	0.517	rs330050	chr8:9087679	G/C	cg06636001	chr8:8085503	FLJ10661	-0.68	-9.25	-0.52	1.5e-17	Neuroticism;
SARC	cis	rs9790314	0.846	rs7652267	chr3:160998497	A/G	cg04691961	chr3:161091175	C3orf57	-0.63	-8.66	-0.49	8.12e-16	Morning vs. evening chronotype;
SARC	cis	rs360798	0.723	rs1386400	chr2:62898648	C/T	cg16915676	chr2:62734870	TMEM17	0.49	5.8	0.36	2.16e-8	Coronary artery disease;
SARC	cis	rs3099143	1.000	rs1114717	chr15:77086078	A/G	cg21673338	chr15:77095150	SCAPER	0.61	5.19	0.32	4.64e-7	Recalcitrant atopic dermatitis;
SARC	cis	rs2239547	0.522	rs7652131	chr3:52997154	C/T	cg07507251	chr3:52567010	NT5DC2	0.37	4.85	0.3	2.22e-6	Schizophrenia;
SARC	cis	rs11785693	0.862	rs17435612	chr8:4987896	C/T	cg26367366	chr8:4980734	NA	-0.69	-6.1	-0.37	4.39e-9	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs4919694	1.000	rs7099987	chr10:104807926	C/T	cg04362960	chr10:104952993	NT5C2	0.64	5.5	0.34	1.02e-7	Arsenic metabolism;
SARC	cis	rs9467711	0.651	rs7749414	chr6:26074884	G/T	cg21479132	chr6:26055353	NA	0.88	6.1	0.37	4.35e-9	Autism spectrum disorder or schizophrenia;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg02963846	chr17:33900674	SNORD7	-0.46	-6.29	-0.38	1.55e-9	Thyroid stimulating hormone;
SARC	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg04518342	chr5:131593106	PDLIM4	0.37	5.38	0.33	1.83e-7	Breast cancer;
SARC	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg20607798	chr8:58055168	NA	0.54	5.14	0.32	5.74e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs763121	0.853	rs35565791	chr22:39063011	C/A	cg21395723	chr22:39101663	GTPBP1	0.56	6.36	0.38	1.06e-9	Menopause (age at onset);
SARC	cis	rs3091242	0.933	rs3093584	chr1:25668714	T/C	cg27572855	chr1:25598939	RHD	-0.57	-9.86	-0.54	2.21e-19	Erythrocyte sedimentation rate;
SARC	cis	rs6912958	0.781	rs4707379	chr6:88310623	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.66	-0.4	1.96e-10	Monocyte percentage of white cells;
SARC	cis	rs3857536	0.813	rs9294688	chr6:66945904	C/T	cg07460842	chr6:66804631	NA	-0.45	-5.19	-0.32	4.5e-7	Blood trace element (Cu levels);
SARC	cis	rs36051895	0.632	rs61461940	chr9:5157277	T/C	cg02405213	chr9:5042618	JAK2	-0.46	-5.55	-0.34	7.66e-8	Pediatric autoimmune diseases;
SARC	cis	rs12956009	0.583	rs11662486	chr18:44868325	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.58	7.43	0.44	2e-12	Educational attainment (years of education);
SARC	cis	rs554111	0.656	rs10916930	chr1:21395357	C/T	cg08890418	chr1:21044141	KIF17	0.36	4.99	0.31	1.2e-6	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs4727027	0.933	rs7788925	chr7:148831621	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	5.58	0.34	6.5e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs9341808	0.556	rs1474791	chr6:81033097	A/G	cg08355045	chr6:80787529	NA	0.32	4.98	0.31	1.25e-6	Sitting height ratio;
SARC	cis	rs1559088	0.600	rs7256470	chr19:33558085	C/A	cg27124370	chr19:33622961	WDR88	0.47	6.04	0.37	6.01e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs5762813	0.561	rs34298044	chr22:29164855	G/C	cg02153584	chr22:29168773	CCDC117	0.66	6.62	0.4	2.38e-10	Hematocrit;Hemoglobin concentration;
SARC	cis	rs6088590	1.000	rs1998028	chr20:33344595	A/T	cg08999081	chr20:33150536	PIGU	0.34	4.86	0.3	2.2e-6	Coronary artery disease;
SARC	cis	rs72781680	1.000	rs56104215	chr2:24133590	T/C	cg06627628	chr2:24431161	ITSN2	-0.71	-6.86	-0.41	6.2e-11	Lymphocyte counts;
SARC	cis	rs2242116	0.796	rs4683296	chr3:46973820	G/C	cg27129171	chr3:47204927	SETD2	-0.62	-8.12	-0.47	2.75e-14	Birth weight;
SARC	cis	rs826838	0.967	rs826876	chr12:39123843	T/C	cg13010199	chr12:38710504	ALG10B	-0.64	-8.96	-0.51	1.06e-16	Heart rate;
SARC	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg25036284	chr2:26402008	FAM59B	-0.48	-5.78	-0.35	2.38e-8	Gut microbiome composition (summer);
SARC	cis	rs561341	0.740	rs11080174	chr17:30208521	C/A	cg12000587	chr17:30186630	C17orf79	0.37	4.88	0.3	1.96e-6	Hip circumference adjusted for BMI;
SARC	cis	rs910316	1.000	rs12589876	chr14:75544189	G/A	cg23033748	chr14:75592666	NEK9	0.36	5.0	0.31	1.12e-6	Height;
SARC	cis	rs2594989	0.806	rs2606746	chr3:11375120	A/G	cg00170343	chr3:11313890	ATG7	0.6	6.52	0.39	4.39e-10	Circulating chemerin levels;
SARC	cis	rs12190007	0.508	rs6605539	chr6:169731997	A/T	cg16388071	chr6:169726476	NA	0.54	7.22	0.43	7.29e-12	Obesity-related traits;
SARC	cis	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg22496380	chr5:211416	CCDC127	-0.88	-9.29	-0.52	1.11e-17	Breast cancer;
SARC	cis	rs6582630	0.519	rs2387812	chr12:38381480	A/G	cg13010199	chr12:38710504	ALG10B	0.78	10.79	0.58	2.78e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg03264133	chr6:25882463	NA	-0.51	-6.65	-0.4	2.06e-10	Intelligence (multi-trait analysis);
SARC	cis	rs2204008	0.837	rs12366727	chr12:38365748	A/C	cg13010199	chr12:38710504	ALG10B	0.8	11.05	0.59	4.21e-23	Bladder cancer;
SARC	cis	rs12145833	0.790	rs28533027	chr1:243476028	T/G	cg02356786	chr1:243265016	LOC731275	-0.55	-4.83	-0.3	2.44e-6	Obesity (early onset extreme);
SARC	cis	rs9486715	1.000	rs2273621	chr6:97058553	A/G	cg18709589	chr6:96969512	KIAA0776	-0.66	-8.14	-0.47	2.36e-14	Headache;
SARC	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	8.88	0.5	1.83e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.72	-10.33	-0.56	7.68e-21	Intelligence (multi-trait analysis);
SARC	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg11764359	chr7:65958608	NA	-0.53	-6.07	-0.37	5.09e-9	Aortic root size;
SARC	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.47	6.32	0.38	1.3e-9	Personality dimensions;
SARC	cis	rs17376456	0.825	rs67328989	chr5:93243133	T/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	5.82	0.36	1.93e-8	Diabetic retinopathy;
SARC	cis	rs3768617	0.510	rs1413387	chr1:183096774	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.68	10.12	0.55	3.45e-20	Fuchs's corneal dystrophy;
SARC	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg24675658	chr1:53192096	ZYG11B	-0.64	-9.34	-0.52	8.04e-18	Monocyte count;
SARC	cis	rs7587476	0.906	rs3768713	chr2:215637505	G/A	cg04530015	chr2:215796436	ABCA12	-0.38	-5.7	-0.35	3.62e-8	Neuroblastoma;
SARC	cis	rs8072100	0.544	rs7214993	chr17:45386797	C/G	cg08085267	chr17:45401833	C17orf57	-0.42	-4.98	-0.31	1.22e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg02442412	chr4:83720054	SCD5	0.77	6.36	0.38	1.04e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs4481887	0.893	rs9651175	chr1:248446888	G/T	cg01631408	chr1:248437212	OR2T33	-0.43	-5.4	-0.33	1.61e-7	Common traits (Other);
SARC	cis	rs829883	0.664	rs829874	chr12:98840615	G/A	cg25150519	chr12:98850993	NA	0.79	13.0	0.65	2.09e-29	Colorectal adenoma (advanced);
SARC	cis	rs9815354	1.000	rs1615543	chr3:41906404	C/T	cg03022575	chr3:42003672	ULK4	0.55	5.27	0.33	3.16e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6540556	0.769	rs6679405	chr1:209926468	A/C	cg05527609	chr1:210001259	C1orf107	-0.49	-5.04	-0.31	9.23e-7	Red blood cell count;
SARC	cis	rs9393692	0.557	rs17608582	chr6:26318799	C/A	cg13736514	chr6:26305472	NA	-0.39	-4.79	-0.3	2.91e-6	Educational attainment;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg27297753	chr3:10052900	LOC401052	0.53	6.52	0.39	4.28e-10	Blood pressure;
SARC	cis	rs1059312	0.966	rs2291349	chr12:129284248	T/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.48	6.77	0.41	1.03e-10	Systemic lupus erythematosus;
SARC	cis	rs4268898	0.662	rs72793967	chr2:24422902	C/T	cg26838691	chr2:24397539	C2orf84	-0.55	-6.25	-0.38	1.95e-9	Asthma;
SARC	cis	rs4853036	1.000	rs62134009	chr2:70054296	G/A	cg02498382	chr2:70120550	SNRNP27	-0.41	-5.41	-0.33	1.53e-7	Colorectal or endometrial cancer;
SARC	cis	rs28386778	0.700	rs12452767	chr17:62010503	G/A	cg09373136	chr17:61933544	TCAM1	0.44	5.91	0.36	1.23e-8	Prudent dietary pattern;
SARC	cis	rs2130392	0.962	rs35613786	chr4:185625657	A/G	cg04058563	chr4:185651563	MLF1IP	-0.34	-4.88	-0.3	1.96e-6	Kawasaki disease;
SARC	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg17971929	chr21:40555470	PSMG1	0.98	13.75	0.67	6.96e-32	Cognitive function;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg11397033	chr7:83379104	NA	0.47	6.23	0.38	2.12e-9	Schizophrenia;
SARC	trans	rs3780486	0.846	rs10758192	chr9:33131651	G/A	cg04842962	chr6:43655489	MRPS18A	1.08	19.86	0.79	4.84e-52	IgG glycosylation;
SARC	cis	rs10870270	0.500	rs9419217	chr10:133758379	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.52	-6.93	-0.41	4.06e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs796364	0.806	rs10445792	chr2:201078821	A/C	cg23649088	chr2:200775458	C2orf69	-0.64	-5.39	-0.33	1.7e-7	Schizophrenia;
SARC	cis	rs7582180	0.700	rs4851303	chr2:100962064	T/C	cg14675211	chr2:100938903	LONRF2	0.49	7.31	0.43	4.22e-12	Intelligence (multi-trait analysis);
SARC	cis	rs9818758	0.505	rs11716159	chr3:49631585	G/A	cg00383909	chr3:49044727	WDR6	0.78	6.53	0.39	4.12e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg03264133	chr6:25882463	NA	-0.44	-5.84	-0.36	1.71e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7772486	0.686	rs9399564	chr6:146078907	C/T	cg05347473	chr6:146136440	FBXO30	-0.51	-7.13	-0.42	1.23e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9398803	0.865	rs2152876	chr6:126761228	A/G	cg20229609	chr6:126660872	C6orf173	-0.39	-5.66	-0.35	4.47e-8	Male-pattern baldness;
SARC	cis	rs965469	1.000	rs6051806	chr20:3350319	C/T	cg25506879	chr20:3388711	C20orf194	-0.49	-4.99	-0.31	1.16e-6	IFN-related cytopenia;
SARC	cis	rs76419734	1.000	rs17036139	chr4:106632657	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.83	5.19	0.32	4.58e-7	Post bronchodilator FEV1;
SARC	cis	rs2153535	0.541	rs9379207	chr6:8458186	C/T	cg21535247	chr6:8435926	SLC35B3	0.52	6.55	0.39	3.66e-10	Motion sickness;
SARC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg06873352	chr17:61820015	STRADA	0.53	6.88	0.41	5.34e-11	Prudent dietary pattern;
SARC	cis	rs2777491	0.915	rs28583065	chr15:41608470	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.74	-10.89	-0.58	1.32e-22	Ulcerative colitis;
SARC	trans	rs7819412	0.775	rs11773990	chr8:10935082	T/C	cg15556689	chr8:8085844	FLJ10661	-0.54	-7.03	-0.42	2.33e-11	Triglycerides;
SARC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg26354017	chr1:205819088	PM20D1	0.86	13.48	0.66	5.39e-31	Menarche (age at onset);
SARC	trans	rs7815944	1.000	rs78225032	chr8:129426320	G/A	cg17342469	chr22:46473074	NA	0.71	6.7	0.4	1.58e-10	Atopic dermatitis;
SARC	cis	rs2645694	0.651	rs2703128	chr4:77819187	C/G	cg06046430	chr4:77819534	ANKRD56	0.55	7.86	0.46	1.39e-13	Emphysema distribution in smoking;
SARC	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg19346786	chr7:2764209	NA	-0.33	-4.91	-0.31	1.74e-6	Height;
SARC	cis	rs897080	0.552	rs1067378	chr2:44648047	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	6.5	0.39	4.81e-10	Height;
SARC	cis	rs6088580	0.524	rs7274854	chr20:33228672	A/C	cg08999081	chr20:33150536	PIGU	0.34	5.07	0.32	8.13e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs2963155	0.518	rs174048	chr5:142650404	T/C	cg17617527	chr5:142782415	NR3C1	0.84	6.0	0.37	7.45e-9	Breast cancer;
SARC	cis	rs11997175	0.603	rs4739382	chr8:33807012	C/T	ch.8.33884649F	chr8:33765107	NA	0.46	5.88	0.36	1.38e-8	Body mass index;
SARC	cis	rs2153535	0.580	rs6597330	chr6:8492076	T/C	cg07606381	chr6:8435919	SLC35B3	0.79	11.45	0.6	2.26e-24	Motion sickness;
SARC	cis	rs2573652	1.000	rs2581365	chr15:100513318	A/C	cg09918751	chr15:100517450	ADAMTS17	-0.36	-4.77	-0.3	3.28e-6	Height;
SARC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg05863683	chr7:1912471	MAD1L1	0.35	5.23	0.32	3.7e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	11.81	0.61	1.6e-25	Alzheimer's disease;
SARC	cis	rs12044355	0.892	rs12048349	chr1:231850323	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.53	7.11	0.42	1.4e-11	Alzheimer's disease;
SARC	trans	rs2018683	0.649	rs221171	chr7:29006139	C/G	cg19402173	chr7:128379420	CALU	0.57	7.26	0.43	5.9e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs7927771	0.793	rs12803525	chr11:47413475	G/A	cg20307385	chr11:47447363	PSMC3	-0.58	-7.35	-0.43	3.34e-12	Subjective well-being;
SARC	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-9.05	-0.51	5.7e-17	Alzheimer's disease;
SARC	cis	rs62191099	0.842	rs6732450	chr2:239861084	C/T	cg07215236	chr2:239865226	NA	0.38	5.01	0.31	1.07e-6	Alcohol dependence;
SARC	cis	rs1355223	0.507	rs11032903	chr11:34876176	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.5	-6.36	-0.38	1.06e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs1062177	1.000	rs2915882	chr5:151145436	T/C	cg00977110	chr5:151150581	G3BP1	0.63	6.3	0.38	1.44e-9	Preschool internalizing problems;
SARC	trans	rs1814175	0.645	rs12364337	chr11:49942580	A/T	cg03929089	chr4:120376271	NA	-0.81	-11.69	-0.61	3.89e-25	Height;
SARC	cis	rs17102884	0.506	rs4899541	chr14:75403437	T/G	cg08847533	chr14:75593920	NEK9	-0.44	-5.45	-0.34	1.29e-7	Neuroticism;
SARC	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg22633769	chr20:60982531	CABLES2	-0.49	-5.5	-0.34	9.9e-8	Colorectal cancer;
SARC	cis	rs9815354	0.680	rs57525756	chr3:41843591	A/C	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs3008870	0.755	rs4486425	chr1:67460791	T/C	cg02640540	chr1:67518911	SLC35D1	-0.45	-5.12	-0.32	6.43e-7	Lymphocyte percentage of white cells;
SARC	cis	rs12701220	0.503	rs12702047	chr7:1132720	G/A	cg00990874	chr7:1149470	C7orf50	-0.6	-5.87	-0.36	1.48e-8	Bronchopulmonary dysplasia;
SARC	trans	rs1973993	0.691	rs6658131	chr1:96889314	C/T	cg10631902	chr5:14652156	NA	0.51	8.81	0.5	2.96e-16	Weight;
SARC	cis	rs9574199	1.000	rs9574199	chr13:78808914	A/C	cg04955753	chr13:77903678	NA	-0.4	-4.85	-0.3	2.29e-6	Total ventricular volume (Alzheimer's disease interaction);
SARC	cis	rs17600642	0.642	rs72814531	chr10:72444857	G/A	cg19779893	chr10:72451501	ADAMTS14	-0.35	-5.5	-0.34	1.02e-7	Bipolar disorder;
SARC	cis	rs10411936	0.692	rs10413787	chr19:16594967	A/G	cg10248733	chr19:16607483	C19orf44;CALR3	0.62	7.5	0.44	1.34e-12	White blood cell count;Multiple sclerosis;
SARC	cis	rs290268	0.838	rs1333635	chr9:93566406	A/G	cg02608019	chr9:93564028	SYK	0.34	4.95	0.31	1.4e-6	Platelet count;
SARC	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg24549020	chr5:56110836	MAP3K1	0.81	8.4	0.48	4.37e-15	Initial pursuit acceleration;
SARC	trans	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-10.55	-0.57	1.63e-21	Intelligence (multi-trait analysis);
SARC	cis	rs933688	1.000	rs2052553	chr5:90729906	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.04	13.24	0.66	3.34e-30	Smoking behavior;
SARC	cis	rs916888	0.610	rs199442	chr17:44820122	G/A	cg15921436	chr17:44337874	NA	0.47	5.38	0.33	1.83e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	trans	rs2727020	0.595	rs11040328	chr11:49339055	T/C	cg03929089	chr4:120376271	NA	-0.57	-7.67	-0.45	4.61e-13	Coronary artery disease;
SARC	cis	rs546131	0.515	rs7128804	chr11:34857948	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-4.73	-0.3	3.88e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs6088580	0.602	rs6058064	chr20:33086622	A/G	cg24642439	chr20:33292090	TP53INP2	0.67	8.78	0.5	3.54e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs35146811	0.586	rs10267231	chr7:99595480	T/C	cg22004693	chr7:99632812	ZKSCAN1	-0.44	-4.73	-0.3	3.9e-6	Coronary artery disease;
SARC	cis	rs9840812	0.623	rs1145106	chr3:136111917	G/A	cg15507776	chr3:136538369	TMEM22	0.43	4.91	0.31	1.74e-6	Fibrinogen levels;
SARC	cis	rs12701220	0.690	rs10243973	chr7:1064983	T/C	cg02733842	chr7:1102375	C7orf50	-0.51	-6.3	-0.38	1.44e-9	Bronchopulmonary dysplasia;
SARC	cis	rs17270561	0.583	rs12662869	chr6:25784481	A/C	cg16482183	chr6:26056742	HIST1H1C	-0.47	-6.09	-0.37	4.69e-9	Iron status biomarkers;
SARC	cis	rs7666738	0.830	rs35276471	chr4:99068691	A/T	cg05340658	chr4:99064831	C4orf37	0.65	8.71	0.5	5.54e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7264396	0.635	rs6088971	chr20:34535373	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.51	5.16	0.32	5.19e-7	Total cholesterol levels;
SARC	cis	rs2180341	0.960	rs9398839	chr6:127665863	G/A	cg24812749	chr6:127587940	RNF146	1.01	13.34	0.66	1.52e-30	Breast cancer;
SARC	cis	rs17826219	0.636	rs4055314	chr17:29079769	T/C	cg13385521	chr17:29058706	SUZ12P	0.88	7.75	0.45	2.9e-13	Body mass index;
SARC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg03452623	chr4:187889614	NA	-0.81	-13.07	-0.65	1.17e-29	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg08859206	chr1:53392774	SCP2	-0.35	-5.07	-0.32	8.19e-7	Monocyte count;
SARC	cis	rs11612508	0.567	rs11054918	chr12:12608050	A/G	cg12403778	chr12:11804115	ETV6	-0.37	-5.41	-0.33	1.56e-7	Inflammatory bowel disease;
SARC	cis	rs11098499	0.826	rs12511640	chr4:120251248	T/C	cg09307838	chr4:120376055	NA	0.81	11.03	0.59	4.84e-23	Corneal astigmatism;
SARC	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	7.72	0.45	3.42e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6908034	0.607	rs76525593	chr6:19809170	G/T	cg02682789	chr6:19804855	NA	0.71	5.75	0.35	2.78e-8	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs9790314	0.765	rs4856768	chr3:161004392	G/A	cg03342759	chr3:160939853	NMD3	-0.71	-9.45	-0.53	3.83e-18	Morning vs. evening chronotype;
SARC	trans	rs1910358	0.554	rs10057796	chr5:23759746	C/T	cg17506739	chr13:50159779	RCBTB1	0.52	6.42	0.39	7.67e-10	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs72949976	0.934	rs1922794	chr2:214026181	G/A	cg08319019	chr2:214017104	IKZF2	-0.52	-7.16	-0.42	1.03e-11	Lung cancer;Squamous cell lung carcinoma;
SARC	cis	rs9467773	1.000	rs6924838	chr6:26571756	C/T	cg12292205	chr6:26970375	C6orf41	0.45	5.43	0.33	1.45e-7	Intelligence (multi-trait analysis);
SARC	cis	rs734999	0.588	rs867435	chr1:2523706	C/T	cg20673091	chr1:2541236	MMEL1	0.33	5.01	0.31	1.09e-6	Ulcerative colitis;
SARC	cis	rs9325144	0.560	rs11182979	chr12:38642562	C/A	cg26384229	chr12:38710491	ALG10B	-0.63	-8.1	-0.47	3.04e-14	Morning vs. evening chronotype;
SARC	cis	rs826838	0.510	rs10506129	chr12:39224242	A/T	cg26384229	chr12:38710491	ALG10B	0.72	9.02	0.51	7.26e-17	Heart rate;
SARC	cis	rs8180040	0.676	rs7636252	chr3:47013542	T/G	cg27129171	chr3:47204927	SETD2	0.65	8.91	0.5	1.47e-16	Colorectal cancer;
SARC	cis	rs7937682	1.000	rs10502147	chr11:111569931	G/A	cg09085632	chr11:111637200	PPP2R1B	0.97	16.4	0.73	1.06e-40	Primary sclerosing cholangitis;
SARC	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg12751644	chr20:60527061	NA	0.41	5.15	0.32	5.51e-7	Obesity-related traits;
SARC	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg06212747	chr3:49208901	KLHDC8B	0.66	8.8	0.5	3.19e-16	Parkinson's disease;
SARC	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg19346786	chr7:2764209	NA	-0.35	-5.19	-0.32	4.5e-7	Height;
SARC	cis	rs7044106	0.762	rs13291660	chr9:123392748	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	5.46	0.34	1.22e-7	Hip circumference adjusted for BMI;
SARC	cis	rs9300255	0.596	rs4460848	chr12:123677810	A/G	cg05973401	chr12:123451056	ABCB9	0.55	6.38	0.39	9.28e-10	Neutrophil percentage of white cells;
SARC	cis	rs7681440	0.606	rs356185	chr4:90704617	G/A	cg06632027	chr4:90757378	SNCA	-0.42	-5.15	-0.32	5.47e-7	Dementia with Lewy bodies;
SARC	cis	rs1707322	0.890	rs2297883	chr1:46511487	G/C	cg06784218	chr1:46089804	CCDC17	-0.38	-6.82	-0.41	7.8e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4803468	1.000	rs3810175	chr19:41904396	C/T	cg14132834	chr19:41945861	ATP5SL	0.58	7.79	0.45	2.27e-13	Height;
SARC	cis	rs6690583	0.623	rs12033900	chr1:85478559	T/C	cg22153463	chr1:85462885	MCOLN2	0.72	5.85	0.36	1.66e-8	Serum sulfate level;
SARC	cis	rs523522	0.923	rs1048830	chr12:120882217	G/T	cg27279351	chr12:120934652	DYNLL1	0.72	8.45	0.48	3.2e-15	High light scatter reticulocyte count;
SARC	cis	rs11792861	0.855	rs116127510	chr9:111868344	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.69	7.9	0.46	1.08e-13	Menarche (age at onset);
SARC	cis	rs6142102	0.923	rs3787230	chr20:32640272	A/G	cg24642439	chr20:33292090	TP53INP2	0.44	4.82	0.3	2.59e-6	Skin pigmentation;
SARC	cis	rs4319547	0.586	rs7956480	chr12:122817507	A/G	cg23029597	chr12:123009494	RSRC2	-0.4	-4.97	-0.31	1.31e-6	Body mass index;
SARC	cis	rs10499694	0.933	rs12538938	chr7:50592313	A/G	cg19499709	chr7:50660583	GRB10	-0.35	-4.79	-0.3	3.01e-6	Body mass index;
SARC	cis	rs2180341	1.000	rs6910763	chr6:127630925	T/C	cg17762328	chr6:126965162	NA	-0.46	-5.24	-0.32	3.55e-7	Breast cancer;
SARC	cis	rs6752107	0.901	rs2289477	chr2:234160345	T/G	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.5	6.91	0.41	4.54e-11	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs6540556	0.723	rs1000283	chr1:209894661	A/G	cg23920097	chr1:209922102	NA	0.54	5.63	0.35	5.27e-8	Red blood cell count;
SARC	cis	rs11997175	0.646	rs12678266	chr8:33689254	A/G	ch.8.33884649F	chr8:33765107	NA	0.62	8.36	0.48	5.9e-15	Body mass index;
SARC	cis	rs9325144	0.647	rs35254764	chr12:39102928	T/C	cg26384229	chr12:38710491	ALG10B	-0.6	-7.74	-0.45	2.98e-13	Morning vs. evening chronotype;
SARC	cis	rs3815700	1.000	rs8109990	chr19:33095636	A/G	cg02997394	chr19:33096574	ANKRD27	0.79	8.19	0.47	1.69e-14	Eosinophilic esophagitis;
SARC	cis	rs763121	0.706	rs3827356	chr22:39064806	G/T	cg21395723	chr22:39101663	GTPBP1	-0.48	-5.67	-0.35	4.1e-8	Menopause (age at onset);
SARC	trans	rs9329221	0.698	rs35388602	chr8:10259188	T/C	cg06636001	chr8:8085503	FLJ10661	0.55	6.71	0.4	1.42e-10	Neuroticism;
SARC	cis	rs7617773	0.963	rs12494304	chr3:48178029	C/T	cg11946769	chr3:48343235	NME6	-0.48	-5.78	-0.35	2.41e-8	Coronary artery disease;
SARC	cis	rs2479724	0.811	rs6905726	chr6:41750812	T/C	cg17623882	chr6:41773611	USP49	0.43	5.29	0.33	2.76e-7	Menarche (age at onset);
SARC	cis	rs752092	1.000	rs8033360	chr15:101778710	C/A	cg19997662	chr15:101784653	CHSY1	-0.49	-6.26	-0.38	1.86e-9	Corneal structure;
SARC	cis	rs3126085	0.935	rs11204937	chr1:152193851	C/T	cg09127314	chr1:152161683	NA	0.41	4.8	0.3	2.84e-6	Atopic dermatitis;
SARC	cis	rs1864400	0.696	rs2742239	chr10:43621712	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.38	-4.74	-0.3	3.68e-6	Hirschsprung disease;
SARC	cis	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg05084668	chr3:125655381	ALG1L	-0.46	-4.83	-0.3	2.46e-6	Blood pressure (smoking interaction);
SARC	cis	rs12912251	0.895	rs35795311	chr15:38998669	C/G	cg01338139	chr15:38987640	C15orf53	-0.46	-5.12	-0.32	6.33e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
SARC	cis	rs4595586	0.545	rs2388179	chr12:39364036	T/A	cg13010199	chr12:38710504	ALG10B	0.4	4.75	0.3	3.57e-6	Morning vs. evening chronotype;
SARC	cis	rs4563143	0.514	rs73029079	chr19:29294903	A/G	cg03161606	chr19:29218774	NA	0.41	5.16	0.32	5.39e-7	Methadone dose in opioid dependence;
SARC	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg17554472	chr22:41940697	POLR3H	-0.46	-5.15	-0.32	5.48e-7	Vitiligo;
SARC	cis	rs11098499	0.863	rs59732491	chr4:120489588	G/C	cg24375607	chr4:120327624	NA	0.42	4.92	0.31	1.64e-6	Corneal astigmatism;
SARC	cis	rs6087990	0.806	rs4911257	chr20:31359574	T/C	cg13636640	chr20:31349939	DNMT3B	0.75	11.55	0.6	1.07e-24	Ulcerative colitis;
SARC	cis	rs7833986	0.501	rs2953922	chr8:56977485	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.72	7.24	0.43	6.48e-12	Height;
SARC	cis	rs3126085	0.877	rs6662450	chr1:152191709	C/G	cg26876637	chr1:152193138	HRNR	0.49	5.69	0.35	3.87e-8	Atopic dermatitis;
SARC	cis	rs3091242	0.933	rs35403885	chr1:25784551	G/A	cg27572855	chr1:25598939	RHD	-0.54	-9.26	-0.52	1.44e-17	Erythrocyte sedimentation rate;
SARC	cis	rs365132	0.875	rs691141	chr5:176323298	A/G	cg16309518	chr5:176445507	NA	0.41	5.37	0.33	1.91e-7	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs372883	0.583	rs117214	chr21:30720834	A/G	cg24692254	chr21:30365293	RNF160	0.51	6.42	0.39	7.4e-10	Pancreatic cancer;
SARC	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg14517863	chr17:44321492	NA	0.42	6.1	0.37	4.49e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs4646404	0.582	rs4646371	chr17:17460674	A/G	cg19142141	chr17:17855059	TOM1L2	0.31	4.79	0.3	2.97e-6	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;
SARC	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.72	7.58	0.44	8.15e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs3617	0.625	rs2535633	chr3:52859630	C/G	cg18404041	chr3:52824283	ITIH1	0.38	5.71	0.35	3.48e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg18252515	chr7:66147081	NA	0.56	5.92	0.36	1.16e-8	Aortic root size;
SARC	trans	rs2204008	0.657	rs8186888	chr12:38334260	T/G	cg23762105	chr12:34175262	ALG10	-0.52	-6.24	-0.38	2.09e-9	Bladder cancer;
SARC	cis	rs67460515	0.563	rs16831981	chr3:160897780	T/C	cg03342759	chr3:160939853	NMD3	-0.64	-8.13	-0.47	2.47e-14	Parkinson's disease;
SARC	cis	rs13256369	1.000	rs883648	chr8:8569521	A/G	cg18904891	chr8:8559673	CLDN23	0.48	5.54	0.34	8.31e-8	Obesity-related traits;
SARC	trans	rs7615952	0.611	rs2971298	chr3:125602713	G/A	cg07211511	chr3:129823064	LOC729375	-0.82	-8.21	-0.47	1.5e-14	Blood pressure (smoking interaction);
SARC	cis	rs6540556	0.723	rs12059226	chr1:209906675	A/G	cg23920097	chr1:209922102	NA	-0.44	-4.75	-0.3	3.48e-6	Red blood cell count;
SARC	cis	rs8072100	0.840	rs9900360	chr17:45491979	C/T	cg08085267	chr17:45401833	C17orf57	-0.41	-4.88	-0.3	2.01e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.45	5.13	0.32	5.97e-7	Renal function-related traits (BUN);
SARC	cis	rs73206853	0.841	rs73206870	chr12:110819953	T/C	cg10860002	chr12:110842031	ANAPC7	0.64	5.02	0.31	1.03e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg14298792	chr15:30685198	CHRFAM7A	0.49	5.51	0.34	9.26e-8	Huntington's disease progression;
SARC	cis	rs7178572	1.000	rs2055901	chr15:77759295	G/A	cg22256960	chr15:77711686	NA	-0.57	-6.73	-0.4	1.34e-10	Type 2 diabetes;
SARC	cis	rs1707322	0.717	rs2991988	chr1:46082431	C/A	cg06784218	chr1:46089804	CCDC17	-0.39	-6.88	-0.41	5.34e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg20007245	chr22:24372913	LOC391322	-0.64	-7.62	-0.45	6.25e-13	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2070433	0.539	rs1008549	chr21:47959698	C/T	cg12379764	chr21:47803548	PCNT	0.52	5.73	0.35	3.15e-8	Lymphocyte counts;
SARC	cis	rs9325144	0.671	rs7486919	chr12:38767997	A/G	cg13010199	chr12:38710504	ALG10B	-0.5	-6.38	-0.39	9.31e-10	Morning vs. evening chronotype;
SARC	cis	rs912057	0.833	rs1294421	chr6:6743149	A/C	cg06612196	chr6:6737390	NA	0.66	9.67	0.54	8.11e-19	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg05255149	chr17:80675120	FN3KRP	0.46	5.14	0.32	5.72e-7	Glycated hemoglobin levels;
SARC	cis	rs1355223	0.902	rs836467	chr11:34737432	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-5.27	-0.33	3.11e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs3020736	0.500	rs4147638	chr22:42487900	G/A	cg15557168	chr22:42548783	NA	0.35	4.81	0.3	2.67e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7208859	0.623	rs8067338	chr17:29102345	T/C	cg13385521	chr17:29058706	SUZ12P	0.84	7.02	0.42	2.44e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg11987759	chr7:65425863	GUSB	0.58	7.64	0.45	5.63e-13	Aortic root size;
SARC	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.94	11.83	0.61	1.3e-25	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs9660992	0.762	rs1668871	chr1:205237137	T/C	cg07972983	chr1:205091412	RBBP5	0.55	6.86	0.41	6.08e-11	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs9325144	0.600	rs34138871	chr12:38735261	A/G	cg13010199	chr12:38710504	ALG10B	0.53	6.66	0.4	1.91e-10	Morning vs. evening chronotype;
SARC	cis	rs7223966	0.961	rs35844156	chr17:61837568	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	7.11	0.42	1.43e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.97e-8	Aortic root size;
SARC	cis	rs1008375	0.897	rs4334752	chr4:17615430	C/T	cg02297831	chr4:17616191	MED28	0.5	6.43	0.39	7.05e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6701037	0.875	rs1057301	chr1:175126524	T/C	cg00321850	chr1:175162397	KIAA0040	-0.36	-5.38	-0.33	1.83e-7	Alcohol dependence;
SARC	cis	rs6582630	0.555	rs11182193	chr12:38474090	C/G	cg13010199	chr12:38710504	ALG10B	0.75	10.21	0.56	1.79e-20	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg19671926	chr4:122722719	EXOSC9	-0.56	-6.1	-0.37	4.3e-9	Type 2 diabetes;
SARC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg22105103	chr4:187893119	NA	0.5	6.77	0.41	1.05e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3008870	1.000	rs2815357	chr1:67491854	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.9	11.27	0.59	8.39e-24	Lymphocyte percentage of white cells;
SARC	cis	rs7819412	0.521	rs9329238	chr8:11033737	C/T	cg21775007	chr8:11205619	TDH	-0.44	-5.71	-0.35	3.39e-8	Triglycerides;
SARC	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg03517284	chr6:25882590	NA	0.49	6.38	0.39	9.53e-10	Blood metabolite levels;
SARC	cis	rs611744	0.967	rs598477	chr8:109187874	G/T	cg21045802	chr8:109455806	TTC35	0.44	5.3	0.33	2.64e-7	Dupuytren's disease;
SARC	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg11489262	chr17:43973426	MAPT;LOC100128977;LOC100130148	0.46	4.91	0.31	1.69e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg15145296	chr3:125709740	NA	-0.49	-4.88	-0.3	1.98e-6	Blood pressure (smoking interaction);
SARC	trans	rs4295623	0.553	rs34962960	chr8:11594597	G/A	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.44	-0.44	1.96e-12	Morning vs. evening chronotype;
SARC	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg27266027	chr21:40555129	PSMG1	-0.49	-5.44	-0.34	1.34e-7	Cognitive function;
SARC	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg13395646	chr4:1353034	KIAA1530	0.41	4.83	0.3	2.48e-6	Obesity-related traits;
SARC	cis	rs7598759	0.584	rs4973409	chr2:232311871	C/T	cg19187155	chr2:232395269	NMUR1	0.51	6.46	0.39	5.93e-10	Noise-induced hearing loss;
SARC	cis	rs7937682	0.961	rs17113227	chr11:111620491	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.06	-20.46	-0.8	5.82e-54	Primary sclerosing cholangitis;
SARC	trans	rs1814175	0.817	rs12290508	chr11:49621037	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-17.82	-0.76	2.12e-45	Height;
SARC	cis	rs6813479	0.524	rs2612114	chr4:137745484	G/T	cg16185213	chr4:137733633	NA	0.39	5.31	0.33	2.54e-7	Longevity;
SARC	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg22535103	chr8:58192502	C8orf71	0.58	6.08	0.37	5e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1395	0.744	rs62130709	chr2:27505782	C/T	cg21747090	chr2:27597821	SNX17	-0.54	-6.31	-0.38	1.42e-9	Blood metabolite levels;
SARC	cis	rs4481887	0.861	rs10888345	chr1:248447533	A/G	cg01631408	chr1:248437212	OR2T33	-0.45	-5.74	-0.35	2.89e-8	Common traits (Other);
SARC	cis	rs4780401	0.933	rs4780395	chr16:11809940	A/G	cg01061890	chr16:11836724	TXNDC11	-0.52	-6.72	-0.4	1.4e-10	Rheumatoid arthritis;
SARC	cis	rs644799	0.965	rs573758	chr11:95539591	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	15.35	0.71	3.21e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	5.67	0.35	4.12e-8	Bipolar disorder;
SARC	cis	rs8067545	0.641	rs203466	chr17:19809953	C/G	cg04132472	chr17:19861366	AKAP10	-0.4	-5.19	-0.32	4.56e-7	Schizophrenia;
SARC	cis	rs4481887	0.927	rs4409694	chr1:248485498	C/T	cg13385794	chr1:248469461	NA	0.32	4.84	0.3	2.37e-6	Common traits (Other);
SARC	cis	rs1003719	0.788	rs9977314	chr21:38471963	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.7	0.5	5.92e-16	Eye color traits;
SARC	cis	rs12042938	1.000	rs4366301	chr1:231806286	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-8.75	-0.5	4.28e-16	Neuranatomic and neurocognitive phenotypes;
SARC	cis	rs4851254	0.961	rs11682173	chr2:100759810	C/T	cg17356467	chr2:100759845	AFF3	0.29	4.84	0.3	2.39e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9381040	1.000	rs9381040	chr6:41154650	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.45	-5.31	-0.33	2.53e-7	Alzheimer's disease (late onset);
SARC	cis	rs2286885	0.965	rs10987301	chr9:129250688	T/C	cg14319473	chr9:129242481	FAM125B	-0.38	-4.78	-0.3	3.14e-6	Intraocular pressure;
SARC	cis	rs2070488	1.000	rs13058903	chr3:38513365	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.85	-14.62	-0.69	8.95e-35	Electrocardiographic conduction measures;
SARC	cis	rs11651000	0.761	rs11657388	chr17:45820707	C/G	cg03474202	chr17:45855739	NA	-0.36	-5.22	-0.32	3.93e-7	IgG glycosylation;
SARC	cis	rs1008375	1.000	rs12648232	chr4:17612537	C/T	cg27347728	chr4:17578864	LAP3	-0.46	-5.61	-0.34	5.75e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs3733585	0.699	rs6834893	chr4:9959123	C/T	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.55	-0.34	7.65e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	trans	rs17221829	0.733	rs11018668	chr11:89356178	C/T	cg24109975	chr19:59055787	TRIM28	-0.49	-6.7	-0.4	1.55e-10	Anxiety in major depressive disorder;
SARC	cis	rs17253792	0.822	rs77415412	chr14:56154146	A/G	cg01858014	chr14:56050164	KTN1	-0.63	-4.8	-0.3	2.9e-6	Putamen volume;
SARC	cis	rs11864453	0.927	rs1035560	chr16:72032730	T/C	cg01557791	chr16:72042693	DHODH	-0.68	-9.51	-0.53	2.55e-18	Fibrinogen levels;
SARC	cis	rs11122272	0.735	rs2749699	chr1:231520279	A/C	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs9905704	0.671	rs28709536	chr17:57008912	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.39	-4.78	-0.3	3.11e-6	Testicular germ cell tumor;
SARC	cis	rs1552244	0.554	rs3846169	chr3:9997054	A/G	cg00149659	chr3:10157352	C3orf10	-0.43	-4.94	-0.31	1.49e-6	Alzheimer's disease;
SARC	cis	rs2075371	0.966	rs722657	chr7:133994956	T/C	cg11752832	chr7:134001865	SLC35B4	0.56	7.1	0.42	1.47e-11	Mean platelet volume;
SARC	cis	rs7927592	0.956	rs6591341	chr11:68335478	C/T	cg01657329	chr11:68192670	LRP5	-0.39	-4.94	-0.31	1.47e-6	Total body bone mineral density;
SARC	cis	rs8070624	0.574	rs9914127	chr17:17875836	A/T	cg04398451	chr17:18023971	MYO15A	-0.46	-6.24	-0.38	2e-9	Total body bone mineral density;
SARC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg24101359	chr6:42928495	GNMT	0.46	6.34	0.38	1.15e-9	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg13206674	chr6:150067644	NUP43	0.41	5.39	0.33	1.74e-7	Lung cancer;
SARC	cis	rs7084402	0.967	rs1649030	chr10:60279830	G/A	cg07615347	chr10:60278583	BICC1	-0.6	-8.82	-0.5	2.78e-16	Refractive error;
SARC	cis	rs524281	0.861	rs10896091	chr11:65950825	T/C	cg14036092	chr11:66035641	RAB1B	-0.51	-5.52	-0.34	9.19e-8	Electroencephalogram traits;
SARC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg03647317	chr4:187891568	NA	-0.35	-4.95	-0.31	1.39e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs698833	0.886	rs698775	chr2:44588941	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.76	9.96	0.55	1.08e-19	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs17539620	0.628	rs62432729	chr6:154830044	T/C	cg17771515	chr6:154831774	CNKSR3	0.52	4.93	0.31	1.56e-6	Lipoprotein (a) levels;
SARC	cis	rs2180341	0.920	rs4472373	chr6:127705983	G/A	cg27446573	chr6:127587934	RNF146	1.06	14.34	0.68	7.2e-34	Breast cancer;
SARC	cis	rs9916302	0.904	rs679995	chr17:37441679	A/T	cg07936489	chr17:37558343	FBXL20	0.7	9.39	0.52	5.71e-18	Glomerular filtration rate (creatinine);
SARC	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg08859206	chr1:53392774	SCP2	-0.38	-5.57	-0.34	6.91e-8	Monocyte count;
SARC	cis	rs898097	0.841	rs11656358	chr17:80853956	G/A	cg15664640	chr17:80829946	TBCD	-0.56	-8.65	-0.49	8.65e-16	Breast cancer;
SARC	cis	rs7216064	1.000	rs6504549	chr17:65888784	A/G	cg12091567	chr17:66097778	LOC651250	-0.7	-7.7	-0.45	3.92e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs17253792	0.822	rs79024594	chr14:56092997	T/G	cg01858014	chr14:56050164	KTN1	-0.67	-5.15	-0.32	5.5e-7	Putamen volume;
SARC	trans	rs61931739	0.500	rs11053280	chr12:34559297	G/T	cg13010199	chr12:38710504	ALG10B	0.83	11.77	0.61	2.09e-25	Morning vs. evening chronotype;
SARC	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg04944784	chr2:26401820	FAM59B	-0.6	-7.95	-0.46	8.14e-14	Gut microbiome composition (summer);
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg24879809	chr1:92351641	TGFBR3	-0.5	-6.24	-0.38	2.05e-9	Schizophrenia;
SARC	cis	rs17401966	1.000	rs12407992	chr1:10311983	A/C	cg15208524	chr1:10270712	KIF1B	0.54	5.99	0.37	8.03e-9	Hepatocellular carcinoma;
SARC	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.77	-11.24	-0.59	1.07e-23	Personality dimensions;
SARC	cis	rs677665	0.537	rs72641832	chr1:9336116	C/A	cg25755851	chr1:9335794	NA	0.63	8.53	0.49	1.92e-15	Eosinophil percentage of white cells;
SARC	cis	rs9381040	1.000	rs2093395	chr6:41155026	C/G	cg09580153	chr6:41068724	NFYA;LOC221442	0.47	5.43	0.33	1.44e-7	Alzheimer's disease (late onset);
SARC	trans	rs11098499	0.863	rs11731756	chr4:120478696	T/G	cg25214090	chr10:38739885	LOC399744	0.57	7.25	0.43	6.27e-12	Corneal astigmatism;
SARC	cis	rs2051211	1.000	rs2051211	chr3:38559749	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.63	-7.1	-0.42	1.47e-11	QRS duration;
SARC	trans	rs11098499	0.954	rs2389802	chr4:120325732	C/A	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	cis	rs78545713	0.892	rs76182849	chr6:26257950	C/T	cg13736514	chr6:26305472	NA	-0.66	-5.49	-0.34	1.04e-7	Iron status biomarkers (total iron binding capacity);
SARC	trans	rs61931739	0.500	rs11052990	chr12:34058647	T/A	cg13010199	chr12:38710504	ALG10B	0.76	10.39	0.56	4.9e-21	Morning vs. evening chronotype;
SARC	trans	rs1814175	0.615	rs10839378	chr11:49806943	C/T	cg15704280	chr7:45808275	SEPT13	-0.88	-13.93	-0.67	1.68e-32	Height;
SARC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg12419862	chr22:24373484	LOC391322	-0.8	-11.29	-0.59	7.33e-24	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7098414	0.511	rs7899545	chr10:82150635	G/C	cg01528321	chr10:82214614	TSPAN14	0.57	7.98	0.46	6.5e-14	Post bronchodilator FEV1;
SARC	cis	rs28655083	0.673	rs2220233	chr16:77050294	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.44	-5.57	-0.34	7.06e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg04267008	chr7:1944627	MAD1L1	-0.48	-5.26	-0.33	3.19e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs1707322	0.721	rs4660883	chr1:46236098	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.43	0.39	7.08e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs826838	0.904	rs10880981	chr12:38763911	G/A	cg26384229	chr12:38710491	ALG10B	0.96	15.61	0.71	4.51e-38	Heart rate;
SARC	cis	rs9398803	0.865	rs9398810	chr6:126815604	C/A	cg19875578	chr6:126661172	C6orf173	0.63	8.62	0.49	1.02e-15	Male-pattern baldness;
SARC	cis	rs7084402	0.967	rs1593674	chr10:60291908	A/C	cg07615347	chr10:60278583	BICC1	0.61	8.99	0.51	8.99e-17	Refractive error;
SARC	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg18252515	chr7:66147081	NA	0.44	4.75	0.3	3.5e-6	Aortic root size;
SARC	cis	rs7659604	0.605	rs1396080	chr4:122740454	T/G	cg20573242	chr4:122745356	CCNA2	0.69	9.02	0.51	7.19e-17	Type 2 diabetes;
SARC	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9300255	0.602	rs1727317	chr12:123618942	T/C	cg05973401	chr12:123451056	ABCB9	0.53	4.96	0.31	1.34e-6	Neutrophil percentage of white cells;
SARC	cis	rs6840360	1.000	rs6535809	chr4:152592933	A/G	cg22705602	chr4:152727874	NA	-0.38	-6.57	-0.4	3.17e-10	Intelligence (multi-trait analysis);
SARC	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg05793240	chr7:2802953	GNA12	-0.36	-5.1	-0.32	7.07e-7	Height;
SARC	cis	rs72781680	1.000	rs11125372	chr2:24257582	A/T	cg06627628	chr2:24431161	ITSN2	0.65	6.15	0.37	3.38e-9	Lymphocyte counts;
SARC	cis	rs898097	0.756	rs56249965	chr17:80806603	C/G	cg15664640	chr17:80829946	TBCD	-0.55	-8.26	-0.48	1.12e-14	Breast cancer;
SARC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg07157834	chr1:205819609	PM20D1	-0.63	-10.14	-0.55	3.07e-20	Monocyte percentage of white cells;
SARC	cis	rs9467711	0.651	rs1045537	chr6:26096748	G/C	cg21479132	chr6:26055353	NA	0.91	6.86	0.41	6.03e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs12682352	0.602	rs1473029	chr8:8668917	A/C	cg06636001	chr8:8085503	FLJ10661	0.55	6.93	0.41	3.98e-11	Neuroticism;
SARC	cis	rs72945132	0.882	rs72949081	chr11:70219070	A/G	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.74	-0.35	2.91e-8	Coronary artery disease;
SARC	cis	rs6964587	1.000	rs6950470	chr7:91680641	G/A	cg17063962	chr7:91808500	NA	0.97	16.79	0.74	5.2e-42	Breast cancer;
SARC	cis	rs3806843	0.676	rs753280	chr5:140024042	C/T	cg16577123	chr5:140027231	NDUFA2;IK	0.44	5.35	0.33	2.05e-7	Depressive symptoms (multi-trait analysis);
SARC	cis	rs12701220	0.817	rs1058729	chr7:1087283	C/T	cg26769984	chr7:1090371	C7orf50	0.44	4.88	0.3	1.97e-6	Bronchopulmonary dysplasia;
SARC	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg20887711	chr4:1340912	KIAA1530	0.55	6.82	0.41	7.79e-11	Longevity;
SARC	cis	rs4927850	0.794	rs2019472	chr3:195735371	T/C	cg01181863	chr3:195395398	SDHAP2	-0.82	-9.25	-0.52	1.48e-17	Pancreatic cancer;
SARC	cis	rs7020830	0.571	rs3780335	chr9:37376587	A/G	cg14294708	chr9:37120828	ZCCHC7	-0.76	-7.85	-0.46	1.51e-13	Schizophrenia;
SARC	cis	rs9462027	0.628	rs2814961	chr6:34706951	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.87	-0.36	1.5e-8	Systemic lupus erythematosus;
SARC	cis	rs4319547	0.956	rs10773302	chr12:123043145	G/T	cg05707623	chr12:122985044	ZCCHC8	-0.59	-7.12	-0.42	1.35e-11	Body mass index;
SARC	cis	rs7712401	0.607	rs246270	chr5:122258649	T/C	cg19412675	chr5:122181750	SNX24	0.41	5.24	0.32	3.56e-7	Mean platelet volume;
SARC	cis	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg22496380	chr5:211416	CCDC127	-0.89	-9.38	-0.52	6.06e-18	Breast cancer;
SARC	cis	rs11083475	0.714	rs7248584	chr19:39258110	C/T	cg07905965	chr19:39260460	NA	0.49	8.09	0.47	3.31e-14	Heart rate;
SARC	cis	rs4901847	0.562	rs11627221	chr14:58617216	G/T	cg15908186	chr14:58618357	C14orf37	0.64	8.59	0.49	1.3e-15	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs12079745	0.793	rs114133365	chr1:169270540	G/C	cg09363564	chr1:169337483	NME7;BLZF1	-0.91	-5.55	-0.34	7.82e-8	QT interval;
SARC	cis	rs6831352	0.879	rs35146617	chr4:100066686	C/T	cg12011299	chr4:100065546	ADH4	-0.33	-5.27	-0.33	3.14e-7	Alcohol dependence;
SARC	cis	rs147144681	1	rs147144681	chr15:78900908	C/T	cg18825076	chr15:78729989	IREB2	-0.45	-5.34	-0.33	2.17e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg11764359	chr7:65958608	NA	0.66	6.45	0.39	6.39e-10	Aortic root size;
SARC	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg17971929	chr21:40555470	PSMG1	0.85	11.18	0.59	1.68e-23	Cognitive function;
SARC	trans	rs10448080	0.879	rs240946	chr8:28568905	A/G	cg08494300	chr11:93474945	TAF1D;C11orf54	0.48	6.25	0.38	1.97e-9	Height;
SARC	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg03060546	chr3:49711283	APEH	0.41	5.14	0.32	5.86e-7	Parkinson's disease;
SARC	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg02018176	chr4:1364513	KIAA1530	0.37	5.32	0.33	2.4e-7	Obesity-related traits;
SARC	cis	rs6772849	0.775	rs12486377	chr3:128414853	G/C	cg01163369	chr3:128370232	RPN1	-0.37	-5.13	-0.32	6.17e-7	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs8005677	1.000	rs4982709	chr14:23394699	C/T	cg01529538	chr14:23388837	RBM23	0.45	5.61	0.34	5.71e-8	Cognitive ability (multi-trait analysis);
SARC	cis	rs796364	1.000	rs281788	chr2:200783705	A/T	cg23649088	chr2:200775458	C2orf69	0.62	5.94	0.36	1.06e-8	Schizophrenia;
SARC	cis	rs870825	0.616	rs6817521	chr4:185649827	A/G	cg04058563	chr4:185651563	MLF1IP	-0.74	-10.4	-0.56	4.73e-21	Blood protein levels;
SARC	cis	rs2251381	0.778	rs2245021	chr21:30546841	C/T	cg24692254	chr21:30365293	RNF160	0.84	12.29	0.63	4.28e-27	Selective IgA deficiency;
SARC	cis	rs9316337	0.902	rs12430301	chr13:21970729	C/T	cg18095732	chr13:22033692	ZDHHC20	0.37	4.81	0.3	2.74e-6	Schizophrenia;
SARC	cis	rs4891159	0.790	rs72975929	chr18:74144630	G/C	cg24786174	chr18:74118243	ZNF516	-0.63	-9.03	-0.51	6.45e-17	Longevity;
SARC	cis	rs881375	0.967	rs1014529	chr9:123684943	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	5.53	0.34	8.39e-8	Rheumatoid arthritis;
SARC	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg04772025	chr11:68637568	NA	0.49	6.22	0.38	2.32e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs11722228	0.549	rs73212830	chr4:10078759	A/T	cg11266682	chr4:10021025	SLC2A9	0.32	4.73	0.3	3.97e-6	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs7412746	0.611	rs1889740	chr1:150799755	C/T	cg15448220	chr1:150897856	SETDB1	0.5	6.55	0.39	3.57e-10	Melanoma;
SARC	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg07701084	chr6:150067640	NUP43	0.4	5.27	0.33	3.09e-7	Lung cancer;
SARC	cis	rs12142240	0.698	rs41293273	chr1:46806393	T/C	cg14993813	chr1:46806288	NSUN4	-0.53	-5.62	-0.35	5.53e-8	Menopause (age at onset);
SARC	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg04166393	chr7:2884313	GNA12	0.63	7.33	0.43	3.7e-12	Height;
SARC	cis	rs6732160	0.932	rs6546803	chr2:73381315	C/G	cg01422370	chr2:73384389	NA	0.3	4.81	0.3	2.74e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9467773	1.000	rs1884949	chr6:26568067	G/A	cg11502198	chr6:26597334	ABT1	0.53	6.46	0.39	6.05e-10	Intelligence (multi-trait analysis);
SARC	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg00800038	chr16:89945340	TCF25	-0.72	-5.35	-0.33	2.12e-7	Skin colour saturation;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg01973587	chr1:228161476	NA	0.44	6.24	0.38	2.05e-9	Schizophrenia;
SARC	cis	rs7223966	1.000	rs11654335	chr17:61797579	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.53	-5.55	-0.34	7.66e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs13256369	1.000	rs873064	chr8:8572380	G/A	cg18904891	chr8:8559673	CLDN23	0.49	5.71	0.35	3.48e-8	Obesity-related traits;
SARC	cis	rs9916302	0.904	rs34363096	chr17:37594294	G/A	cg20243544	chr17:37824526	PNMT	0.56	6.69	0.4	1.68e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs228437	0.913	rs7763821	chr6:134939618	A/G	cg24504307	chr6:134963096	NA	-0.48	-5.62	-0.35	5.4e-8	Melanoma;
SARC	cis	rs6952809	0.532	rs2057840	chr7:2432797	C/G	cg23289794	chr7:2394357	EIF3B	-0.59	-6.0	-0.37	7.47e-9	Multiple sclerosis;
SARC	cis	rs7582180	0.638	rs7581011	chr2:100954659	A/G	cg14675211	chr2:100938903	LONRF2	-0.5	-7.34	-0.43	3.53e-12	Intelligence (multi-trait analysis);
SARC	cis	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg22857025	chr5:266934	NA	-1.06	-11.63	-0.61	5.91e-25	Breast cancer;
SARC	cis	rs4481887	1.000	rs4457616	chr1:248492198	A/G	cg01631408	chr1:248437212	OR2T33	-0.44	-5.43	-0.34	1.41e-7	Common traits (Other);
SARC	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg13012494	chr21:47604986	C21orf56	0.56	6.62	0.4	2.44e-10	Testicular germ cell tumor;
SARC	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	12.47	0.63	1.07e-27	Platelet count;
SARC	cis	rs5762813	0.524	rs5752815	chr22:29230733	C/A	cg15103426	chr22:29168792	CCDC117	0.62	6.5	0.39	4.81e-10	Hematocrit;Hemoglobin concentration;
SARC	cis	rs2731664	0.792	rs337374	chr5:176890416	A/G	cg23176889	chr5:176863531	GRK6	0.57	8.64	0.49	9.37e-16	Intelligence (multi-trait analysis);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg24376286	chr2:198245629	NA	-0.49	-6.42	-0.39	7.68e-10	Height;
SARC	cis	rs2439831	0.702	rs495175	chr15:43798684	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.08	10.8	0.58	2.69e-22	Lung cancer in ever smokers;
SARC	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg26335602	chr6:28129616	ZNF389	0.48	5.22	0.32	4.01e-7	Parkinson's disease;
SARC	cis	rs734999	0.572	rs3748816	chr1:2526746	A/G	cg20673091	chr1:2541236	MMEL1	0.33	5.13	0.32	6.14e-7	Ulcerative colitis;
SARC	cis	rs6545883	0.929	rs55806663	chr2:61740487	G/T	cg15711740	chr2:61764176	XPO1	-0.44	-5.45	-0.34	1.27e-7	Tuberculosis;
SARC	cis	rs748404	0.660	rs2602141	chr15:43724646	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.41	4.91	0.31	1.68e-6	Lung cancer;
SARC	cis	rs67478160	0.619	rs2368560	chr14:104273311	C/T	cg08213375	chr14:104286397	PPP1R13B	0.27	4.79	0.3	3.01e-6	Schizophrenia;
SARC	cis	rs2075371	1.000	rs1862051	chr7:133981021	G/A	cg00033643	chr7:134001901	SLC35B4	0.39	4.75	0.3	3.53e-6	Mean platelet volume;
SARC	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg12000995	chr2:27665139	KRTCAP3	-0.31	-4.76	-0.3	3.39e-6	Menopause (age at onset);
SARC	trans	rs3780486	0.522	rs7029897	chr9:33124042	T/C	cg04842962	chr6:43655489	MRPS18A	0.88	12.52	0.63	7.39e-28	IgG glycosylation;
SARC	cis	rs6693567	0.565	rs4926422	chr1:150315436	T/C	cg09579323	chr1:150459698	TARS2	0.42	5.31	0.33	2.56e-7	Migraine;
SARC	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg22875332	chr1:76189707	ACADM	0.37	5.03	0.31	9.85e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	11.64	0.61	5.7e-25	Alzheimer's disease;
SARC	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg17971929	chr21:40555470	PSMG1	0.95	13.28	0.66	2.35e-30	Cognitive function;
SARC	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg12923728	chr3:195709715	SDHAP1	-0.69	-8.63	-0.49	9.95e-16	Pancreatic cancer;
SARC	cis	rs3744061	0.520	rs4322697	chr17:74648642	C/T	cg27546012	chr17:74684504	MXRA7	-0.34	-4.93	-0.31	1.54e-6	Retinal arteriolar caliber;
SARC	trans	rs904095	0.583	rs3133158	chr4:100270612	C/G	cg01588345	chr2:120023921	NA	0.43	6.28	0.38	1.62e-9	Alcohol dependence;
SARC	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.55	-7.14	-0.42	1.18e-11	Mean platelet volume;
SARC	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-9.15	-0.51	2.85e-17	Alzheimer's disease;
SARC	cis	rs11874712	0.899	rs11872954	chr18:43686450	A/G	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.52	6.22	0.38	2.3e-9	Migraine - clinic-based;
SARC	cis	rs4722166	0.695	rs6946509	chr7:22809490	T/C	cg26061582	chr7:22766209	IL6	0.47	5.5	0.34	9.95e-8	Lung cancer;
SARC	cis	rs17376456	0.877	rs34673483	chr5:93315079	C/A	cg25358565	chr5:93447407	FAM172A	1.28	14.54	0.69	1.6e-34	Diabetic retinopathy;
SARC	cis	rs7520050	0.966	rs4076006	chr1:46438076	C/T	cg24296786	chr1:45957014	TESK2	0.38	4.87	0.3	2.02e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs13202913	0.652	rs9371528	chr6:151832668	G/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.53	5.06	0.31	8.45e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs297755	0.675	rs297767	chr20:4487760	A/G	cg14606382	chr20:4573199	NA	-0.54	-6.6	-0.4	2.76e-10	Current cigarettes per day in chronic obstructive pulmonary disease;
SARC	cis	rs9457247	0.935	rs1794697	chr6:167395410	C/T	cg07741184	chr6:167504864	NA	0.29	5.55	0.34	7.66e-8	Crohn's disease;
SARC	cis	rs7666738	0.927	rs6832373	chr4:99051967	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.96	0.51	1.05e-16	Colonoscopy-negative controls vs population controls;
SARC	trans	rs17685	0.712	rs10235738	chr7:75773460	G/A	cg19862616	chr7:65841803	NCRNA00174	0.6	7.38	0.44	2.77e-12	Coffee consumption;Coffee consumption (cups per day);
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg04274916	chr22:41252959	ST13;XPNPEP3	-0.52	-6.62	-0.4	2.5e-10	Electrocardiographic conduction measures;
SARC	cis	rs1153858	0.943	rs8038342	chr15:45651537	T/C	cg26924012	chr15:45694286	SPATA5L1	0.78	11.14	0.59	2.18e-23	Homoarginine levels;
SARC	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.44	7.06	0.42	1.95e-11	Schizophrenia;
SARC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg22903471	chr2:27725779	GCKR	-0.5	-7.57	-0.44	8.89e-13	Total body bone mineral density;
SARC	cis	rs240764	0.853	rs2398132	chr6:100981200	A/C	cg09795085	chr6:101329169	ASCC3	-0.44	-5.77	-0.35	2.54e-8	Neuroticism;
SARC	cis	rs10791097	0.694	rs4370948	chr11:130755700	A/C	cg09137382	chr11:130731461	NA	0.32	4.99	0.31	1.17e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs1018836	0.923	rs13268594	chr8:91588545	G/T	cg16814680	chr8:91681699	NA	-0.81	-12.82	-0.64	7.95e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs1920116	1.000	rs16847897	chr3:169568116	C/G	cg14222479	chr3:169487675	ARPM1	-0.45	-5.52	-0.34	9.06e-8	Glioma (high-grade);
SARC	cis	rs11098499	0.909	rs35111518	chr4:120440682	A/G	cg24375607	chr4:120327624	NA	0.42	4.94	0.31	1.47e-6	Corneal astigmatism;
SARC	cis	rs3796352	1.000	rs71301808	chr3:53085577	C/G	cg15956490	chr3:53032818	SFMBT1	0.88	6.06	0.37	5.5e-9	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs933688	0.938	rs1477348	chr5:90707823	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.02	12.78	0.64	1.09e-28	Smoking behavior;
SARC	cis	rs74417235	0.684	rs12655636	chr5:154057618	T/C	cg17344516	chr5:154026930	NA	0.52	5.25	0.33	3.39e-7	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
SARC	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs2916247	1.000	rs28716374	chr8:93030411	G/T	cg10183463	chr8:93005414	RUNX1T1	-0.59	-6.27	-0.38	1.76e-9	Intelligence (multi-trait analysis);
SARC	cis	rs55962025	0.804	rs362268	chr4:3242148	C/G	cg06533319	chr4:3265114	C4orf44	0.32	4.72	0.3	4.15e-6	Parental longevity (mother's age at death);
SARC	cis	rs9815354	0.812	rs73071344	chr3:41827062	C/T	cg03022575	chr3:42003672	ULK4	0.69	5.74	0.35	2.92e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9815354	1.000	rs6783001	chr3:41862232	C/A	cg03022575	chr3:42003672	ULK4	0.55	5.25	0.33	3.46e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs11997175	0.624	rs17701219	chr8:33728795	T/A	ch.8.33884649F	chr8:33765107	NA	0.64	8.84	0.5	2.43e-16	Body mass index;
SARC	cis	rs796364	0.806	rs79053279	chr2:201057443	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-6.4	-0.39	8.29e-10	Schizophrenia;
SARC	cis	rs12142240	0.698	rs17357635	chr1:46808668	G/A	cg10495392	chr1:46806563	NSUN4	0.64	6.76	0.4	1.09e-10	Menopause (age at onset);
SARC	cis	rs76419734	0.557	rs72671881	chr4:106666335	C/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.76	4.98	0.31	1.23e-6	Post bronchodilator FEV1;
SARC	cis	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg08975724	chr8:8085496	FLJ10661	0.53	6.57	0.4	3.2e-10	Mood instability;
SARC	cis	rs2985684	0.894	rs6572586	chr14:50021941	A/C	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.44	4.88	0.3	1.95e-6	Carotid intima media thickness;
SARC	cis	rs9916302	0.706	rs9890198	chr17:37457480	A/C	cg07936489	chr17:37558343	FBXL20	0.76	8.91	0.5	1.48e-16	Glomerular filtration rate (creatinine);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg18698690	chr3:129612569	TMCC1	0.58	7.87	0.46	1.29e-13	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs4901847	0.967	rs12897032	chr14:58557801	A/G	cg15908186	chr14:58618357	C14orf37	0.43	4.96	0.31	1.34e-6	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs6500602	0.647	rs4786501	chr16:4536165	G/T	cg08645402	chr16:4508243	NA	-0.48	-6.49	-0.39	5.04e-10	Schizophrenia;
SARC	cis	rs858239	1.000	rs166663	chr7:23316742	A/C	cg23682824	chr7:23144976	KLHL7	0.62	7.64	0.45	5.46e-13	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9635726	0.638	rs2952155	chr17:37861718	T/C	cg07936489	chr17:37558343	FBXL20	-0.46	-5.28	-0.33	2.92e-7	Primary biliary cholangitis;
SARC	cis	rs66573146	0.831	rs11546450	chr4:7032180	G/A	cg00086871	chr4:6988644	TBC1D14	0.9	5.21	0.32	4.23e-7	Granulocyte percentage of myeloid white cells;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg01434672	chr5:92955518	FAM172A	0.49	6.78	0.41	9.81e-11	Thyroid stimulating hormone;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg27266822	chr1:16073415	TMEM82	-0.53	-6.26	-0.38	1.82e-9	Lung cancer in ever smokers;
SARC	cis	rs73195822	0.667	rs2339634	chr12:111231277	C/T	cg10860002	chr12:110842031	ANAPC7	0.67	5.0	0.31	1.15e-6	Itch intensity from mosquito bite;
SARC	cis	rs6700896	0.931	rs11208717	chr1:66158994	T/C	cg04111102	chr1:66153794	NA	0.36	5.55	0.34	7.77e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs6542838	0.641	rs11123756	chr2:99508012	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.49	6.13	0.37	3.76e-9	Fear of minor pain;
SARC	cis	rs1322639	0.806	rs1322640	chr6:169586887	T/C	cg04662567	chr6:169592167	NA	0.5	6.47	0.39	5.63e-10	Pulse pressure;
SARC	cis	rs10085978	0.583	rs7822913	chr8:143227933	A/G	cg24634471	chr8:143751801	JRK	0.45	5.13	0.32	6.19e-7	Mosquito bite size;
SARC	cis	rs6120849	0.754	rs11167253	chr20:33614449	T/C	cg24642439	chr20:33292090	TP53INP2	0.57	5.48	0.34	1.1e-7	Protein C levels;
SARC	cis	rs2228479	0.681	rs11642428	chr16:89971909	A/T	cg06558623	chr16:89946397	TCF25	0.61	5.3	0.33	2.63e-7	Skin colour saturation;
SARC	cis	rs7481584	1.000	rs12798150	chr11:3019260	C/T	cg08508325	chr11:3079039	CARS	0.22	4.87	0.3	2.02e-6	Calcium levels;
SARC	cis	rs763121	0.925	rs17032	chr22:39130843	C/G	cg21395723	chr22:39101663	GTPBP1	0.52	6.31	0.38	1.39e-9	Menopause (age at onset);
SARC	cis	rs4481887	1.000	rs6697863	chr1:248495588	G/A	cg01631408	chr1:248437212	OR2T33	-0.43	-5.4	-0.33	1.68e-7	Common traits (Other);
SARC	cis	rs6446731	0.517	rs2071668	chr4:3269905	A/G	cg06533319	chr4:3265114	C4orf44	0.31	4.85	0.3	2.26e-6	Mean platelet volume;
SARC	cis	rs4555082	0.957	rs3825762	chr14:105752404	T/C	cg13114125	chr14:105738426	BRF1	-0.73	-10.87	-0.58	1.59e-22	Mean platelet volume;Platelet distribution width;
SARC	cis	rs13256369	0.853	rs13256216	chr8:8577883	C/T	cg18904891	chr8:8559673	CLDN23	0.48	5.47	0.34	1.15e-7	Obesity-related traits;
SARC	cis	rs9487051	0.837	rs1915834	chr6:109597624	C/A	cg01475377	chr6:109611718	NA	-0.41	-5.85	-0.36	1.66e-8	Reticulocyte fraction of red cells;
SARC	cis	rs9325144	0.650	rs6582631	chr12:38744135	T/C	cg26384229	chr12:38710491	ALG10B	0.61	7.98	0.46	6.49e-14	Morning vs. evening chronotype;
SARC	cis	rs7766436	0.648	rs3734214	chr6:22571414	C/G	cg13666174	chr6:22585274	NA	-0.48	-6.16	-0.37	3.1e-9	Coronary artery disease;
SARC	cis	rs74181299	0.554	rs6748462	chr2:65359282	T/G	cg20592124	chr2:65290738	CEP68	-0.36	-4.75	-0.3	3.56e-6	Pulse pressure;
SARC	cis	rs7824557	0.751	rs2099456	chr8:11127001	A/C	cg21775007	chr8:11205619	TDH	0.52	6.3	0.38	1.51e-9	Retinal vascular caliber;
SARC	cis	rs7216064	0.953	rs11079705	chr17:65835452	A/T	cg12091567	chr17:66097778	LOC651250	-0.69	-6.99	-0.42	2.89e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs698833	0.788	rs1142523	chr2:44545576	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.72	9.43	0.53	4.34e-18	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs13314892	0.764	rs4579020	chr3:69878028	A/C	cg17445875	chr3:69859618	MITF	-0.48	-5.12	-0.32	6.53e-7	QRS complex (12-leadsum);
SARC	trans	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg20587970	chr11:113659929	NA	1.0	9.39	0.52	5.65e-18	Hip circumference adjusted for BMI;
SARC	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg13607699	chr17:42295918	UBTF	0.58	7.15	0.42	1.11e-11	Total body bone mineral density;
SARC	cis	rs3749237	0.595	rs4955412	chr3:49418168	A/C	cg07636037	chr3:49044803	WDR6	0.64	8.25	0.48	1.2e-14	Resting heart rate;
SARC	cis	rs36051895	0.659	rs62541556	chr9:5049092	G/T	cg02405213	chr9:5042618	JAK2	-0.52	-5.79	-0.35	2.21e-8	Pediatric autoimmune diseases;
SARC	cis	rs13191362	1.000	rs13209100	chr6:163159350	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.56	5.43	0.34	1.43e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs8017423	1.000	rs8017423	chr14:90679910	A/G	cg20276874	chr14:90721474	PSMC1	-0.35	-4.95	-0.31	1.45e-6	Mortality in heart failure;
SARC	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg20607798	chr8:58055168	NA	-0.55	-4.75	-0.3	3.57e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg25894440	chr7:65020034	NA	-0.74	-5.63	-0.35	5.28e-8	Diabetic kidney disease;
SARC	trans	rs9929218	0.559	rs12923775	chr16:68756450	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.8	12.91	0.65	3.95e-29	Colorectal cancer;
SARC	cis	rs832540	0.966	rs252925	chr5:56203773	G/A	cg14703610	chr5:56206110	C5orf35	0.56	7.04	0.42	2.09e-11	Coronary artery disease;
SARC	cis	rs4836694	0.574	rs4837476	chr9:132937533	T/C	cg05251000	chr9:132935664	FREQ	0.38	4.98	0.31	1.22e-6	Alzheimer's disease (cognitive decline);
SARC	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg24209194	chr3:40518798	ZNF619	0.66	7.98	0.46	6.78e-14	Renal cell carcinoma;
SARC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.0	12.68	0.64	2.34e-28	Platelet count;
SARC	cis	rs2806561	0.765	rs605367	chr1:23518524	T/C	cg12483005	chr1:23474871	LUZP1	0.45	5.96	0.36	9.45e-9	Height;
SARC	cis	rs12754538	0.715	rs12028347	chr1:8708925	A/G	cg13785123	chr1:8931135	ENO1	-0.48	-5.38	-0.33	1.8e-7	Subjective well-being;
SARC	cis	rs1957429	0.520	rs230715	chr14:65320549	G/C	cg23373153	chr14:65346875	NA	-0.65	-5.4	-0.33	1.64e-7	Pediatric areal bone mineral density (radius);
SARC	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg06558623	chr16:89946397	TCF25	0.71	5.97	0.36	8.69e-9	Skin colour saturation;
SARC	cis	rs9325144	0.624	rs7312879	chr12:39150752	G/A	cg26384229	chr12:38710491	ALG10B	-0.57	-7.28	-0.43	5.14e-12	Morning vs. evening chronotype;
SARC	cis	rs1865760	0.820	rs9348697	chr6:25890834	C/T	cg10373733	chr6:25993375	NA	0.48	5.87	0.36	1.5e-8	Height;
SARC	cis	rs5022636	0.533	rs4971029	chr1:151277259	T/C	cg13175981	chr1:150552382	MCL1	0.54	5.53	0.34	8.76e-8	Gut microbiota (functional units);
SARC	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.92	10.24	0.56	1.46e-20	Platelet count;
SARC	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg06221963	chr1:154839813	KCNN3	-0.52	-8.26	-0.48	1.11e-14	Prostate cancer;
SARC	cis	rs1505368	0.567	rs2054617	chr2:213355890	T/C	cg16329650	chr2:213403929	ERBB4	0.44	5.97	0.36	8.81e-9	Symmetrical dimethylarginine levels;
SARC	cis	rs6570726	0.846	rs411468	chr6:145832792	A/G	cg05220968	chr6:146057943	EPM2A	-0.29	-4.99	-0.31	1.19e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg22496380	chr5:211416	CCDC127	-0.88	-9.35	-0.52	7.72e-18	Breast cancer;
SARC	cis	rs9858542	0.953	rs11715915	chr3:49455330	A/G	cg03060546	chr3:49711283	APEH	0.6	7.33	0.43	3.7e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs2439831	1.000	rs2264239	chr15:43765533	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.1	11.21	0.59	1.36e-23	Lung cancer in ever smokers;
SARC	cis	rs7412746	0.658	rs6657388	chr1:150748786	A/G	cg15448220	chr1:150897856	SETDB1	0.47	6.04	0.37	5.89e-9	Melanoma;
SARC	cis	rs11724804	0.532	rs73207782	chr4:848764	G/C	cg20916646	chr4:852691	GAK	0.54	6.1	0.37	4.27e-9	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
SARC	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg05368731	chr17:41323189	NBR1	0.81	9.9	0.54	1.66e-19	Menopause (age at onset);
SARC	cis	rs1468333	0.538	rs13182414	chr5:137639838	T/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.7	8.48	0.49	2.67e-15	Resting heart rate;
SARC	cis	rs6582630	0.502	rs11504451	chr12:38425294	G/A	cg13010199	chr12:38710504	ALG10B	0.71	9.1	0.51	4.04e-17	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1185460	0.565	rs1182922	chr11:118932859	G/A	cg23280166	chr11:118938394	VPS11	-0.57	-7.28	-0.43	5.15e-12	Coronary artery disease;
SARC	cis	rs8014204	0.868	rs2230237	chr14:75359670	G/A	cg17347104	chr14:75034677	LTBP2	0.4	4.94	0.31	1.5e-6	Caffeine consumption;
SARC	cis	rs9747201	0.963	rs11077982	chr17:80147377	G/C	cg09264619	chr17:80180166	NA	-0.52	-6.01	-0.37	7.09e-9	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg19859486	chr3:45730655	SACM1L	-0.56	-6.53	-0.39	4.02e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs1784581	0.588	rs9355971	chr6:162421242	A/G	cg17173639	chr6:162384350	PARK2	0.5	6.36	0.38	1.07e-9	Itch intensity from mosquito bite;
SARC	cis	rs57994353	0.865	rs13290734	chr9:139330701	G/A	cg13611204	chr9:139324423	INPP5E	-0.3	-5.28	-0.33	3e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs7551222	0.752	rs11240754	chr1:204477977	A/G	cg20240347	chr1:204465584	NA	-0.35	-6.18	-0.38	2.78e-9	Schizophrenia;
SARC	cis	rs67460515	0.926	rs66508859	chr3:160946351	C/T	cg17135325	chr3:160939158	NMD3	0.63	7.94	0.46	8.51e-14	Parkinson's disease;
SARC	cis	rs8067545	0.750	rs4925077	chr17:19982276	C/T	cg13482628	chr17:19912719	NA	0.55	7.36	0.43	3.21e-12	Schizophrenia;
SARC	cis	rs7772486	0.754	rs1415746	chr6:146077107	A/G	cg23711669	chr6:146136114	FBXO30	-0.92	-16.51	-0.73	4.55e-41	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.61	-6.27	-0.38	1.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs4423214	1.000	rs2276360	chr11:71169547	C/G	cg24826892	chr11:71159390	DHCR7	0.47	5.9	0.36	1.3e-8	Vitamin D levels;
SARC	trans	rs7815944	1.000	rs1464156	chr8:129444147	A/T	cg25487405	chr22:46473039	NA	0.64	6.35	0.38	1.09e-9	Atopic dermatitis;
SARC	trans	rs35833281	0.729	rs3134707	chr6:55079787	G/A	cg19977494	chr7:128431264	CCDC136	0.74	7.01	0.42	2.48e-11	Morning vs. evening chronotype;
SARC	cis	rs4742903	0.509	rs7020317	chr9:106872682	T/A	cg14250997	chr9:106856677	SMC2	0.5	6.28	0.38	1.63e-9	High-grade serous ovarian cancer;Breast cancer;
SARC	trans	rs9388451	0.626	rs1343115	chr6:126069817	C/G	cg05039488	chr6:79577232	IRAK1BP1	-0.64	-8.22	-0.47	1.43e-14	Brugada syndrome;
SARC	trans	rs7922314	0.571	rs61865718	chr10:64740407	C/A	cg16218721	chr2:177017352	HOXD4	-0.84	-6.32	-0.38	1.35e-9	Cutaneous psoriasis;
SARC	cis	rs57506017	0.585	rs7805419	chr7:12282451	T/C	cg23422036	chr7:12250390	TMEM106B	0.45	5.77	0.35	2.47e-8	Neuroticism;
SARC	cis	rs7178572	1.000	rs62007299	chr15:77711719	G/A	cg22256960	chr15:77711686	NA	-0.55	-6.51	-0.39	4.55e-10	Type 2 diabetes;
SARC	cis	rs11190604	0.767	rs4559620	chr10:102199935	C/T	cg07080220	chr10:102295463	HIF1AN	0.72	8.38	0.48	5.08e-15	Palmitoleic acid (16:1n-7) levels;
SARC	trans	rs1814175	0.527	rs3974435	chr11:49619533	G/A	cg03929089	chr4:120376271	NA	-0.73	-8.54	-0.49	1.72e-15	Height;
SARC	cis	rs7666738	0.830	rs10007261	chr4:98926155	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1865760	0.516	rs9393683	chr6:26066198	A/G	cg16482183	chr6:26056742	HIST1H1C	0.47	6.05	0.37	5.65e-9	Height;
SARC	cis	rs4144743	1.000	rs11871251	chr17:45331427	G/A	cg18085866	chr17:45331354	ITGB3	-0.73	-7.27	-0.43	5.37e-12	Body mass index;
SARC	cis	rs796364	0.906	rs281766	chr2:200820505	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.75	7.03	0.42	2.27e-11	Schizophrenia;
SARC	trans	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg15556689	chr8:8085844	FLJ10661	0.49	6.28	0.38	1.64e-9	Neuroticism;
SARC	cis	rs4975616	0.804	rs459961	chr5:1337106	T/A	cg06550200	chr5:1325588	CLPTM1L	-0.6	-8.82	-0.5	2.82e-16	Lung cancer;
SARC	cis	rs2522056	1.000	rs2522050	chr5:131796609	C/T	cg24060327	chr5:131705240	SLC22A5	0.48	4.76	0.3	3.38e-6	Lymphocyte counts;Fibrinogen;
SARC	cis	rs400736	0.860	rs371452	chr1:8084051	C/T	cg25007680	chr1:8021821	PARK7	0.5	6.5	0.39	4.9e-10	Response to antidepressants and depression;
SARC	cis	rs2306032	0.669	rs10838622	chr11:46856536	T/C	cg03339077	chr11:47165057	C11orf49	-0.37	-4.87	-0.3	2.08e-6	Total body bone mineral density;
SARC	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg07648498	chr16:89883185	FANCA	0.39	5.22	0.32	3.91e-7	Vitiligo;
SARC	cis	rs1003719	0.788	rs4411798	chr21:38453183	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.63	9.23	0.52	1.71e-17	Eye color traits;
SARC	cis	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg20965017	chr5:231967	SDHA	-0.56	-5.33	-0.33	2.28e-7	Breast cancer;
SARC	trans	rs3857536	0.740	rs9354390	chr6:66890162	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	7.08	0.42	1.73e-11	Blood trace element (Cu levels);
SARC	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg22875332	chr1:76189707	ACADM	-0.46	-6.51	-0.39	4.57e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2302729	0.860	rs6489375	chr12:2777768	A/G	cg19945202	chr12:2788847	CACNA1C	-0.67	-7.66	-0.45	4.98e-13	Sleep quality;
SARC	cis	rs1448094	0.512	rs61930862	chr12:86246567	A/G	cg02569458	chr12:86230093	RASSF9	0.38	5.39	0.33	1.71e-7	Major depressive disorder;
SARC	cis	rs7246657	0.943	rs4803460	chr19:37885228	T/C	cg23950597	chr19:37808831	NA	-0.56	-5.6	-0.34	5.96e-8	Coronary artery calcification;
SARC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.54	6.15	0.37	3.35e-9	Prudent dietary pattern;
SARC	cis	rs11608355	1.000	rs10774692	chr12:109862324	G/T	cg05360138	chr12:110035743	NA	0.43	4.8	0.3	2.86e-6	Neuroticism;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg00215431	chr7:129689808	ZC3HC1	0.49	7.04	0.42	2.17e-11	Thyroid stimulating hormone;
SARC	cis	rs829661	0.532	rs11678346	chr2:30767508	C/T	cg12454169	chr2:30669597	LCLAT1	-0.43	-5.64	-0.35	5.03e-8	Midgestational circulating levels of PBDEs (fetal genetic effect);
SARC	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg22535103	chr8:58192502	C8orf71	-0.53	-5.35	-0.33	2.13e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9916302	0.706	rs12950186	chr17:37393395	A/C	cg07936489	chr17:37558343	FBXL20	-0.78	-9.26	-0.52	1.41e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs7103648	0.569	rs11039266	chr11:47532395	T/G	cg10504702	chr11:47789108	FNBP4	0.66	8.04	0.47	4.53e-14	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs6582630	0.533	rs11504406	chr12:38334580	C/T	cg13010199	chr12:38710504	ALG10B	-0.51	-6.07	-0.37	5.2e-9	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg24250549	chr1:154909240	PMVK	-0.75	-10.37	-0.56	5.79e-21	Prostate cancer;
SARC	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg11843238	chr5:131593191	PDLIM4	0.39	5.53	0.34	8.43e-8	Breast cancer;
SARC	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg09455208	chr3:40491958	NA	0.4	5.76	0.35	2.7e-8	Renal cell carcinoma;
SARC	cis	rs7624766	0.935	rs6441331	chr3:160443738	A/C	cg22637730	chr3:160473554	PPM1L	0.4	5.18	0.32	4.9e-7	Response to methotrexate in rheumatoid arthritis;
SARC	cis	rs1153858	1.000	rs12437840	chr15:45669055	C/A	cg21132104	chr15:45694354	SPATA5L1	0.78	11.01	0.59	5.55e-23	Homoarginine levels;
SARC	cis	rs6142102	0.961	rs1555075	chr20:32610401	T/C	cg24642439	chr20:33292090	TP53INP2	0.43	4.73	0.3	3.88e-6	Skin pigmentation;
SARC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg25703541	chr22:24373054	LOC391322	-0.81	-10.37	-0.56	5.71e-21	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg21442419	chr1:2182373	SKI	0.45	5.7	0.35	3.64e-8	Height;
SARC	cis	rs559928	0.597	rs947939	chr11:63885287	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	5.26	0.33	3.29e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs721399	1.000	rs11784251	chr8:18260013	A/G	cg18736775	chr8:18248649	NAT2	0.39	5.25	0.33	3.48e-7	Blood metabolite levels;
SARC	cis	rs72781680	0.898	rs72780121	chr2:23995918	T/C	cg06627628	chr2:24431161	ITSN2	-0.67	-6.35	-0.38	1.14e-9	Lymphocyte counts;
SARC	cis	rs733592	0.524	rs10875741	chr12:48492922	A/C	cg21466736	chr12:48725269	NA	0.32	5.7	0.35	3.61e-8	Plateletcrit;
SARC	cis	rs920590	0.721	rs67989257	chr8:19660278	G/A	cg01411142	chr8:19674711	INTS10	0.48	5.52	0.34	9.13e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs8017423	0.935	rs17188598	chr14:90722473	A/T	cg20276874	chr14:90721474	PSMC1	-0.37	-5.22	-0.32	3.93e-7	Mortality in heart failure;
SARC	cis	rs6963495	0.818	rs818621	chr7:105173029	T/C	cg19920283	chr7:105172520	RINT1	0.69	6.74	0.4	1.25e-10	Bipolar disorder (body mass index interaction);
SARC	cis	rs911555	0.755	rs1138400	chr14:103956833	A/G	cg24130564	chr14:104152367	KLC1	-0.5	-5.94	-0.36	1.01e-8	Intelligence (multi-trait analysis);
SARC	cis	rs1545257	0.537	rs3108793	chr2:24648138	A/C	cg06627628	chr2:24431161	ITSN2	-0.56	-7.27	-0.43	5.5e-12	Sjögren's syndrome;
SARC	cis	rs8180040	0.654	rs13078131	chr3:47204939	G/T	cg02527881	chr3:46936655	PTH1R	-0.3	-4.77	-0.3	3.26e-6	Colorectal cancer;
SARC	cis	rs2290159	0.800	rs9809947	chr3:12655944	T/C	cg23032965	chr3:12705835	RAF1	0.73	7.91	0.46	1.06e-13	Cholesterol, total;
SARC	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg12564285	chr5:131593104	PDLIM4	0.36	5.37	0.33	1.93e-7	Breast cancer;
SARC	cis	rs10463554	0.927	rs34796	chr5:102424429	T/C	cg23492399	chr5:102201601	PAM	-0.54	-5.89	-0.36	1.31e-8	Parkinson's disease;
SARC	cis	rs3106136	0.546	rs4693003	chr4:95145469	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.48	-7.12	-0.42	1.37e-11	Capecitabine sensitivity;
SARC	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.89	12.88	0.64	4.91e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7772486	0.686	rs9403739	chr6:146015357	A/G	cg23711669	chr6:146136114	FBXO30	-0.83	-13.74	-0.67	7.24e-32	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2204008	0.805	rs2874289	chr12:38258420	G/A	cg26384229	chr12:38710491	ALG10B	0.91	13.59	0.66	2.36e-31	Bladder cancer;
SARC	cis	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg25894440	chr7:65020034	NA	-0.77	-5.9	-0.36	1.24e-8	Diabetic kidney disease;
SARC	cis	rs965469	1.000	rs6139103	chr20:3361140	T/C	cg25506879	chr20:3388711	C20orf194	-0.51	-5.12	-0.32	6.26e-7	IFN-related cytopenia;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg03324123	chr1:231004380	C1orf198	0.5	6.38	0.39	9.22e-10	Chemerin levels;
SARC	cis	rs11690935	0.655	rs12052995	chr2:172537212	A/G	cg13550731	chr2:172543902	DYNC1I2	0.65	9.14	0.51	3.25e-17	Schizophrenia;
SARC	cis	rs1971762	0.527	rs7952858	chr12:54039692	C/G	cg06632207	chr12:54070931	ATP5G2	0.59	7.9	0.46	1.12e-13	Height;
SARC	cis	rs9814567	1.000	rs4367113	chr3:134287975	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.04	-0.42	2.19e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg22875332	chr1:76189707	ACADM	-0.43	-5.57	-0.34	6.88e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs4746059	0.610	rs10999479	chr10:72477232	A/C	cg18679544	chr10:72432482	ADAMTS14	-0.38	-4.92	-0.31	1.63e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4423214	1.000	rs2276362	chr11:71174452	A/G	cg05163923	chr11:71159392	DHCR7	0.67	9.5	0.53	2.71e-18	Vitamin D levels;
SARC	cis	rs12142240	0.698	rs17413694	chr1:46818416	A/C	cg14993813	chr1:46806288	NSUN4	-0.52	-5.46	-0.34	1.22e-7	Menopause (age at onset);
SARC	cis	rs6910061	0.913	rs28712814	chr6:11108745	T/G	cg27233058	chr6:11094804	LOC221710	0.55	5.28	0.33	2.98e-7	Diabetic kidney disease;
SARC	cis	rs9858542	0.953	rs11926781	chr3:49603289	C/T	cg07274523	chr3:49395745	GPX1	0.51	5.9	0.36	1.28e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg16325326	chr1:53192061	ZYG11B	-0.83	-13.56	-0.66	2.87e-31	Monocyte count;
SARC	cis	rs9840812	0.637	rs698270	chr3:136109512	A/G	cg15507776	chr3:136538369	TMEM22	0.48	5.57	0.34	6.92e-8	Fibrinogen levels;
SARC	cis	rs3204955	1.000	rs3811007	chr1:116240199	A/T	cg20810993	chr1:116250018	CASQ2	-0.47	-5.21	-0.32	4.07e-7	Itch intensity from mosquito bite adjusted by bite size;
SARC	cis	rs2952156	0.959	rs2941503	chr17:37828745	A/G	cg20243544	chr17:37824526	PNMT	0.5	6.28	0.38	1.65e-9	Asthma;
SARC	trans	rs61931739	0.534	rs4931770	chr12:34044479	G/T	cg13010199	chr12:38710504	ALG10B	0.76	10.32	0.56	8.23e-21	Morning vs. evening chronotype;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg00614832	chr16:73092394	ZFHX3	0.79	6.46	0.39	5.92e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9392918	0.967	rs9379130	chr6:7702659	C/G	cg23089261	chr6:7723385	NA	0.4	5.39	0.33	1.75e-7	Height;
SARC	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg24549020	chr5:56110836	MAP3K1	0.81	8.35	0.48	6.19e-15	Initial pursuit acceleration;
SARC	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.69	8.54	0.49	1.8e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs950169	0.881	rs34591918	chr15:84950833	C/T	cg24253500	chr15:84953950	NA	0.36	5.21	0.32	4.19e-7	Schizophrenia;
SARC	cis	rs611744	0.967	rs608115	chr8:109231948	T/A	cg21045802	chr8:109455806	TTC35	0.45	5.39	0.33	1.69e-7	Dupuytren's disease;
SARC	cis	rs72781680	1.000	rs12620594	chr2:24194490	G/A	cg08917208	chr2:24149416	ATAD2B	0.79	7.55	0.44	9.78e-13	Lymphocyte counts;
SARC	cis	rs57221529	0.766	rs12519469	chr5:581772	A/G	cg14541582	chr5:601475	NA	-0.39	-4.72	-0.3	4.16e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs8072100	0.748	rs9912592	chr17:45556945	G/A	cg08085267	chr17:45401833	C17orf57	-0.49	-6.02	-0.37	6.7e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg07157834	chr1:205819609	PM20D1	0.48	6.55	0.39	3.56e-10	Menarche (age at onset);
SARC	cis	rs2276314	1.000	rs2276314	chr18:33557466	C/T	cg05985134	chr18:33552581	C18orf21	-0.76	-8.35	-0.48	6.02e-15	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs4689388	0.926	rs12508672	chr4:6287965	G/A	cg25554036	chr4:6271136	WFS1	0.41	6.53	0.39	3.99e-10	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs539096	0.566	rs3011220	chr1:44308867	A/G	cg12908607	chr1:44402522	ARTN	-0.32	-5.69	-0.35	3.82e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9640161	0.750	rs3735173	chr7:150020526	C/T	cg17279839	chr7:150038598	RARRES2	0.48	7.19	0.43	8.66e-12	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs57994353	0.632	rs68142670	chr9:139324573	T/C	cg13611204	chr9:139324423	INPP5E	-0.29	-5.07	-0.32	7.93e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs10791323	0.604	rs2723607	chr11:133711018	C/G	cg15485101	chr11:133734466	NA	0.33	5.08	0.32	7.91e-7	Childhood ear infection;
SARC	cis	rs8062405	0.824	rs240702	chr16:28531353	C/T	cg08761264	chr16:28874980	SH2B1	-0.42	-4.76	-0.3	3.43e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs9398803	0.678	rs4380768	chr6:126867351	G/C	cg19875578	chr6:126661172	C6orf173	0.63	8.72	0.5	5.28e-16	Male-pattern baldness;
SARC	cis	rs4808199	0.901	rs11669516	chr19:19532682	G/A	cg03709012	chr19:19516395	GATAD2A	1.16	13.02	0.65	1.75e-29	Nonalcoholic fatty liver disease;
SARC	cis	rs6540556	0.769	rs6540553	chr1:209929044	C/G	cg23920097	chr1:209922102	NA	-0.63	-7.21	-0.43	7.83e-12	Red blood cell count;
SARC	cis	rs3733589	1.000	rs35933067	chr4:10000508	A/G	cg16430538	chr4:10459836	ZNF518B	0.64	4.74	0.3	3.71e-6	Renal overload gout;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg19402405	chr10:64576514	EGR2	0.47	6.44	0.39	6.58e-10	Tetralogy of Fallot;
SARC	cis	rs12188164	1.000	rs34453673	chr5:434722	G/C	cg21144161	chr5:423903	AHRR	0.31	4.97	0.31	1.33e-6	Cystic fibrosis severity;
SARC	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg03452623	chr4:187889614	NA	-0.75	-11.34	-0.6	4.97e-24	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg18252515	chr7:66147081	NA	-1.31	-11.71	-0.61	3.25e-25	Diabetic kidney disease;
SARC	cis	rs2070433	0.559	rs11089057	chr21:47721228	T/A	cg12379764	chr21:47803548	PCNT	0.56	4.79	0.3	2.92e-6	Lymphocyte counts;
SARC	cis	rs1152591	1.000	rs2738413	chr14:64679960	A/G	cg23250157	chr14:64679961	SYNE2	0.55	8.35	0.48	6.16e-15	Atrial fibrillation;
SARC	cis	rs7178909	0.902	rs8038480	chr15:90441597	T/C	cg19708238	chr15:90437601	AP3S2	0.64	8.64	0.49	8.91e-16	Common traits (Other);
SARC	cis	rs898097	0.812	rs72859941	chr17:80837459	G/A	cg20578329	chr17:80767326	TBCD	-0.5	-6.76	-0.4	1.1e-10	Breast cancer;
SARC	cis	rs2712184	0.687	rs62180470	chr2:217645451	A/G	cg05032264	chr2:217675019	NA	0.51	6.93	0.41	4.15e-11	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
SARC	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.82	12.64	0.64	3.01e-28	Personality dimensions;
SARC	cis	rs17376456	0.757	rs1031424	chr5:93139706	G/C	cg21475434	chr5:93447410	FAM172A	0.72	6.28	0.38	1.62e-9	Diabetic retinopathy;
SARC	cis	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg03060546	chr3:49711283	APEH	0.73	6.76	0.4	1.11e-10	Menarche (age at onset);
SARC	cis	rs1008375	0.966	rs7675735	chr4:17587137	T/A	cg16339924	chr4:17578868	LAP3	0.69	9.17	0.51	2.59e-17	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg13206674	chr6:150067644	NUP43	0.39	5.02	0.31	1.03e-6	Lung cancer;
SARC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg11494091	chr17:61959527	GH2	0.53	8.08	0.47	3.55e-14	Prudent dietary pattern;
SARC	cis	rs11122272	0.735	rs2739506	chr1:231529183	T/G	cg06096015	chr1:231504339	EGLN1	0.39	5.81	0.36	1.99e-8	Hemoglobin concentration;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg00974835	chr14:74960278	NPC2;ISCA2	-0.52	-6.36	-0.38	1.06e-9	Schizophrenia;
SARC	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg07636037	chr3:49044803	WDR6	1.0	17.66	0.76	6.92e-45	Parkinson's disease;
SARC	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg27266027	chr21:40555129	PSMG1	0.51	5.61	0.34	5.75e-8	Cognitive function;
SARC	cis	rs2985684	0.625	rs4900931	chr14:50022793	A/T	cg04989706	chr14:50066350	PPIL5	-0.51	-5.77	-0.35	2.56e-8	Carotid intima media thickness;
SARC	cis	rs10779751	0.770	rs12075896	chr1:11200350	C/A	cg08854313	chr1:11322531	MTOR	-0.76	-10.08	-0.55	4.57e-20	Body mass index;
SARC	cis	rs778371	0.723	rs34707169	chr2:233699459	C/T	cg16596103	chr2:233749413	NGEF	0.34	5.15	0.32	5.6e-7	Schizophrenia;
SARC	cis	rs1044826	0.642	rs295481	chr3:139228811	C/T	cg15131784	chr3:139108705	COPB2	0.4	5.06	0.31	8.66e-7	Obesity-related traits;
SARC	cis	rs3087591	0.708	rs2854320	chr17:29694063	C/A	cg24425628	chr17:29625626	OMG;NF1	0.41	5.17	0.32	4.94e-7	Hip circumference;
SARC	cis	rs6545883	0.929	rs2592352	chr2:61665336	C/T	cg15711740	chr2:61764176	XPO1	-0.42	-5.19	-0.32	4.65e-7	Tuberculosis;
SARC	cis	rs826838	0.967	rs826879	chr12:39088999	A/C	cg26384229	chr12:38710491	ALG10B	-0.79	-12.54	-0.63	6.45e-28	Heart rate;
SARC	cis	rs60871478	0.947	rs62432862	chr7:807719	G/C	cg19087971	chr7:751233	PRKAR1B	-0.43	-4.88	-0.3	2.01e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs5753618	0.583	rs5753631	chr22:31863022	A/C	cg02404636	chr22:31891804	SFI1	0.52	5.63	0.35	5.22e-8	Colorectal cancer;
SARC	cis	rs9303401	0.659	rs714959	chr17:56628601	A/G	cg25039879	chr17:56429692	SUPT4H1	0.62	5.53	0.34	8.46e-8	Cognitive test performance;
SARC	cis	rs11871801	0.517	rs645692	chr17:40701073	C/T	cg14558262	chr17:40713999	COASY	0.53	5.81	0.36	2.02e-8	Crohn's disease;
SARC	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg18876405	chr7:65276391	NA	-0.45	-5.13	-0.32	6.15e-7	Aortic root size;
SARC	cis	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.58	9.1	0.51	4.09e-17	Breast cancer;
SARC	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg00933542	chr6:150070202	PCMT1	0.29	5.09	0.32	7.37e-7	Lung cancer;
SARC	cis	rs854765	0.623	rs9893690	chr17:17753846	A/T	cg05444541	chr17:17804740	TOM1L2	0.3	5.13	0.32	6.23e-7	Total body bone mineral density;
SARC	cis	rs10752881	0.935	rs4652771	chr1:183023503	G/A	cg13390022	chr1:182993471	LAMC1	0.36	5.41	0.33	1.6e-7	Colorectal cancer;
SARC	cis	rs72781680	0.898	rs12619525	chr2:23999565	G/C	cg08917208	chr2:24149416	ATAD2B	0.77	7.29	0.43	4.79e-12	Lymphocyte counts;
SARC	cis	rs2916247	0.954	rs4735107	chr8:93160055	C/T	cg10183463	chr8:93005414	RUNX1T1	0.53	5.37	0.33	1.91e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6545883	0.965	rs3771258	chr2:61764140	C/T	cg15711740	chr2:61764176	XPO1	-0.44	-5.35	-0.33	2.12e-7	Tuberculosis;
SARC	cis	rs2439831	1.000	rs2245054	chr15:43751909	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	8.4	0.48	4.54e-15	Lung cancer in ever smokers;
SARC	trans	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg07211511	chr3:129823064	LOC729375	-0.61	-6.46	-0.39	6.08e-10	Blood pressure (smoking interaction);
SARC	cis	rs4792901	0.918	rs12603189	chr17:41618677	C/G	cg22562494	chr17:41607896	ETV4	0.31	5.17	0.32	5.07e-7	Dupuytren's disease;
SARC	cis	rs7633770	0.735	rs12491236	chr3:46688481	C/T	cg11219411	chr3:46661640	NA	-0.43	-6.9	-0.41	4.97e-11	Coronary artery disease;
SARC	cis	rs2463822	1.000	rs2513747	chr11:62098735	T/C	cg06239285	chr11:62104954	ASRGL1	0.9	9.65	0.53	9.5e-19	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs2380220	0.720	rs9398251	chr6:95984709	C/T	cg15832292	chr6:96025679	MANEA	0.5	5.59	0.34	6.44e-8	Behavioural disinhibition (generation interaction);
SARC	cis	rs2180341	0.961	rs910720	chr6:127619070	T/C	cg27446573	chr6:127587934	RNF146	1.02	14.46	0.69	2.89e-34	Breast cancer;
SARC	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg02725872	chr8:58115012	NA	0.37	6.57	0.4	3.25e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg24829409	chr8:58192753	C8orf71	-0.65	-7.1	-0.42	1.49e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs9911578	0.967	rs2643124	chr17:56741672	T/C	cg05425664	chr17:57184151	TRIM37	-0.66	-8.18	-0.47	1.83e-14	Intelligence (multi-trait analysis);
SARC	cis	rs2735413	0.918	rs12925605	chr16:78071715	G/A	cg04733911	chr16:78082701	NA	-0.3	-5.44	-0.34	1.34e-7	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg11062466	chr8:58055876	NA	0.54	5.53	0.34	8.37e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.74	8.89	0.5	1.69e-16	Height;
SARC	cis	rs4128725	1.000	rs74355389	chr1:159357049	C/T	cg25076881	chr1:159409836	OR10J1	0.4	4.78	0.3	3.16e-6	Select biomarker traits;
SARC	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg26818010	chr10:134567672	INPP5A	0.63	6.89	0.41	5.09e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs4588572	0.706	rs72760906	chr5:77652457	T/C	cg11547950	chr5:77652471	NA	0.39	4.79	0.3	2.96e-6	Triglycerides;
SARC	cis	rs12142240	0.667	rs55887761	chr1:46826587	C/A	cg14993813	chr1:46806288	NSUN4	-0.51	-5.34	-0.33	2.19e-7	Menopause (age at onset);
SARC	cis	rs3126085	0.935	rs12746239	chr1:152246726	G/A	cg26876637	chr1:152193138	HRNR	-0.5	-5.67	-0.35	4.16e-8	Atopic dermatitis;
SARC	cis	rs1538970	1.000	rs1417578	chr1:45850590	A/G	cg05343316	chr1:45956843	TESK2	0.65	7.93	0.46	8.82e-14	Platelet count;
SARC	cis	rs1348850	0.626	rs1901825	chr2:178225331	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.65	8.42	0.48	3.93e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg24642844	chr7:1081250	C7orf50	-0.6	-6.11	-0.37	4.06e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs735396	0.770	rs1169300	chr12:121431225	G/A	cg02403541	chr12:121454288	C12orf43	0.84	12.08	0.62	2.05e-26	N-glycan levels;
SARC	cis	rs3768617	1.000	rs1360704	chr1:183099380	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.6	-7.97	-0.46	7.25e-14	Fuchs's corneal dystrophy;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg02566288	chr6:166667022	NA	0.46	6.47	0.39	5.66e-10	Height;
SARC	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg21782813	chr7:2030301	MAD1L1	0.44	6.93	0.41	4.02e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs11690935	0.921	rs7594711	chr2:172895637	T/G	cg13550731	chr2:172543902	DYNC1I2	-0.96	-14.02	-0.68	8.59e-33	Schizophrenia;
SARC	trans	rs9325144	0.505	rs1906262	chr12:38653605	A/G	cg23762105	chr12:34175262	ALG10	-0.51	-6.37	-0.39	1e-9	Morning vs. evening chronotype;
SARC	cis	rs9527	0.615	rs10883804	chr10:104706520	G/A	cg04362960	chr10:104952993	NT5C2	0.41	4.77	0.3	3.32e-6	Arsenic metabolism;
SARC	cis	rs2200578	1.000	rs12053519	chr2:99875018	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.61	5.82	0.36	1.91e-8	IgG glycosylation;
SARC	cis	rs826838	0.967	rs1352122	chr12:39130885	G/A	cg13010199	chr12:38710504	ALG10B	-0.63	-8.88	-0.5	1.87e-16	Heart rate;
SARC	cis	rs1707322	1.000	rs11211205	chr1:46321874	C/T	cg06784218	chr1:46089804	CCDC17	0.33	5.78	0.35	2.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs72781680	1.000	rs56068891	chr2:24230633	A/G	cg06627628	chr2:24431161	ITSN2	-0.73	-6.9	-0.41	4.77e-11	Lymphocyte counts;
SARC	cis	rs4853036	1.000	rs3816491	chr2:70048534	A/G	cg02498382	chr2:70120550	SNRNP27	0.42	5.77	0.35	2.53e-8	Colorectal or endometrial cancer;
SARC	cis	rs554111	0.636	rs10916935	chr1:21432112	T/C	cg04902671	chr1:21058625	SH2D5	0.43	5.31	0.33	2.57e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs13191362	1.000	rs34918316	chr6:163005386	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.49	0.34	1.04e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs6963495	0.932	rs55700120	chr7:105148460	G/T	cg13798780	chr7:105162888	PUS7	0.61	5.75	0.35	2.79e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs796364	0.951	rs35618222	chr2:201065777	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.53	5.26	0.33	3.29e-7	Schizophrenia;
SARC	cis	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.84	12.43	0.63	1.5e-27	Eosinophil percentage of white cells;
SARC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.79	10.1	0.55	4.02e-20	Prudent dietary pattern;
SARC	trans	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg21659725	chr3:3221576	CRBN	-0.54	-7.06	-0.42	1.85e-11	Intelligence (multi-trait analysis);
SARC	cis	rs6728642	0.908	rs10207116	chr2:98018281	G/A	cg26665480	chr2:98280029	ACTR1B	-0.64	-5.94	-0.36	1.05e-8	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs7296418	0.517	rs73231928	chr12:123724325	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-5.08	-0.32	7.65e-7	Platelet count;
SARC	cis	rs936229	0.749	rs4886633	chr15:75178207	G/A	cg10253484	chr15:75165896	SCAMP2	-0.56	-6.04	-0.37	5.94e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs7084402	0.935	rs12248958	chr10:60278255	G/A	cg07615347	chr10:60278583	BICC1	-0.6	-8.82	-0.5	2.78e-16	Refractive error;
SARC	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg01448562	chr3:133502909	NA	-0.49	-7.52	-0.44	1.21e-12	Iron status biomarkers;
SARC	cis	rs739401	0.611	rs2239899	chr11:3024624	A/G	cg08508325	chr11:3079039	CARS	0.33	7.91	0.46	1.02e-13	Longevity;
SARC	cis	rs3812831	0.654	rs6560933	chr13:114937294	A/G	cg22348356	chr13:114891224	RASA3	-0.36	-5.11	-0.32	6.71e-7	Schizophrenia;
SARC	cis	rs6952808	0.636	rs73048162	chr7:1949328	T/C	cg05863683	chr7:1912471	MAD1L1	0.37	5.64	0.35	4.85e-8	Bipolar disorder and schizophrenia;
SARC	trans	rs459571	0.629	rs441233	chr9:136876021	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	0.68	8.18	0.47	1.84e-14	Platelet distribution width;
SARC	cis	rs2658782	0.724	rs2605627	chr11:93259515	A/G	cg15737290	chr11:93063684	CCDC67	0.72	7.99	0.46	6.38e-14	Pulmonary function decline;
SARC	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg04277193	chr17:41438351	NA	0.45	4.84	0.3	2.4e-6	Menopause (age at onset);
SARC	cis	rs899997	0.773	rs8032156	chr15:78964498	A/G	cg04896959	chr15:78267971	NA	0.45	4.88	0.3	2e-6	Coronary artery disease or large artery stroke;
SARC	cis	rs2408955	0.522	rs7139330	chr12:48483484	A/C	cg24011408	chr12:48396354	COL2A1	-0.41	-4.99	-0.31	1.2e-6	Glycated hemoglobin levels;
SARC	cis	rs7829975	0.572	rs28446104	chr8:8795901	C/G	cg08975724	chr8:8085496	FLJ10661	-0.4	-4.83	-0.3	2.48e-6	Mood instability;
SARC	cis	rs60871478	1.000	rs62432223	chr7:787959	A/G	cg05535760	chr7:792225	HEATR2	0.81	8.17	0.47	1.94e-14	Cerebrospinal P-tau181p levels;
SARC	cis	rs12586317	0.620	rs2295104	chr14:35579927	A/G	cg16230307	chr14:35515116	FAM177A1	-1.0	-11.11	-0.59	2.66e-23	Psoriasis;
SARC	cis	rs9916302	0.851	rs612209	chr17:37442713	G/C	cg07936489	chr17:37558343	FBXL20	0.69	9.22	0.52	1.82e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs12586317	0.547	rs74462850	chr14:35500093	G/T	cg26967526	chr14:35346199	BAZ1A	-0.57	-5.71	-0.35	3.4e-8	Psoriasis;
SARC	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg16405210	chr4:1374714	KIAA1530	-0.45	-5.32	-0.33	2.44e-7	Obesity-related traits;
SARC	cis	rs3733585	0.673	rs116046986	chr4:9957794	A/G	cg11266682	chr4:10021025	SLC2A9	-0.35	-6.03	-0.37	6.35e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7000551	0.700	rs7431	chr8:22398462	G/A	cg12081754	chr8:22256438	SLC39A14	0.55	7.7	0.45	3.77e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs12497850	0.966	rs6792510	chr3:48723302	G/C	cg03060546	chr3:49711283	APEH	0.41	5.04	0.31	9.27e-7	Parkinson's disease;
SARC	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg03352830	chr11:487213	PTDSS2	0.54	5.48	0.34	1.09e-7	Body mass index;
SARC	cis	rs4319547	1.000	rs6489156	chr12:123100397	C/T	cg23029597	chr12:123009494	RSRC2	-0.39	-5.1	-0.32	7.04e-7	Body mass index;
SARC	cis	rs9303401	0.659	rs8074016	chr17:56840587	A/G	cg25039879	chr17:56429692	SUPT4H1	0.63	5.87	0.36	1.51e-8	Cognitive test performance;
SARC	cis	rs1832871	0.711	rs62439861	chr6:158700531	A/G	cg07165851	chr6:158734300	TULP4	0.51	6.18	0.38	2.85e-9	Height;
SARC	cis	rs739401	0.611	rs2239900	chr11:3030992	C/T	cg05729581	chr11:3078854	CARS	-0.5	-6.4	-0.39	8.25e-10	Longevity;
SARC	cis	rs11687170	0.882	rs75644244	chr2:237061548	C/T	cg19324714	chr2:237145437	ASB18	0.47	4.73	0.3	3.82e-6	Educational attainment;Educational attainment (years of education);
SARC	cis	rs17376456	0.542	rs10061069	chr5:93071630	G/C	cg21475434	chr5:93447410	FAM172A	0.54	5.48	0.34	1.09e-7	Diabetic retinopathy;
SARC	cis	rs9326248	0.954	rs8521	chr11:117067699	C/T	cg10130564	chr11:117069849	TAGLN	0.23	5.13	0.32	6.18e-7	Blood protein levels;
SARC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg21782813	chr7:2030301	MAD1L1	-0.35	-5.47	-0.34	1.16e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs7666738	0.830	rs7662389	chr4:99019892	G/A	cg05340658	chr4:99064831	C4orf37	0.65	9.0	0.51	7.95e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg04287289	chr16:89883240	FANCA	-0.84	-14.22	-0.68	1.81e-33	Vitiligo;
SARC	cis	rs9399137	0.507	rs6569986	chr6:135311641	T/C	cg24558204	chr6:135376177	HBS1L	0.61	7.94	0.46	8.39e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg25427524	chr10:38739819	LOC399744	-0.53	-8.46	-0.48	2.95e-15	Extrinsic epigenetic age acceleration;
SARC	cis	rs2153535	0.580	rs7775909	chr6:8477778	A/G	cg21535247	chr6:8435926	SLC35B3	0.55	6.9	0.41	4.81e-11	Motion sickness;
SARC	cis	rs7582180	0.607	rs6723909	chr2:100880058	A/T	cg14675211	chr2:100938903	LONRF2	0.36	4.92	0.31	1.65e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9611565	0.512	rs139572	chr22:42214532	C/T	cg03806693	chr22:41940476	POLR3H	-0.88	-9.77	-0.54	3.94e-19	Vitiligo;
SARC	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.65	7.8	0.46	2.01e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs12249377	0.519	rs4520504	chr10:92602373	T/C	cg14313238	chr10:92632228	RPP30	0.42	4.93	0.31	1.59e-6	White matter microstructure (global fractional anisotropy);
SARC	cis	rs910316	1.000	rs10873275	chr14:75531460	A/T	cg11812906	chr14:75593930	NEK9	0.89	13.87	0.67	2.66e-32	Height;
SARC	cis	rs6570726	0.967	rs374728	chr6:145854598	T/A	cg05347473	chr6:146136440	FBXO30	0.49	6.58	0.4	3.04e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1559088	0.948	rs12460195	chr19:33584479	G/A	cg17764715	chr19:33622953	WDR88	0.49	6.72	0.4	1.4e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs7617773	0.817	rs13100815	chr3:48287449	A/C	cg11946769	chr3:48343235	NME6	0.72	9.28	0.52	1.22e-17	Coronary artery disease;
SARC	cis	rs7819412	0.521	rs10100660	chr8:11038885	T/A	cg21775007	chr8:11205619	TDH	-0.46	-5.85	-0.36	1.69e-8	Triglycerides;
SARC	cis	rs9818758	0.607	rs11716445	chr3:49406095	C/T	cg01304814	chr3:48885189	PRKAR2A	0.84	6.3	0.38	1.46e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg01475735	chr3:40494733	NA	-0.46	-5.25	-0.33	3.46e-7	Renal cell carcinoma;
SARC	cis	rs950776	0.518	rs12594391	chr15:78816240	A/G	cg17108064	chr15:78857060	CHRNA5	0.29	4.88	0.3	1.95e-6	Sudden cardiac arrest;
SARC	cis	rs2230307	0.536	rs57637634	chr1:100447467	G/A	cg24955406	chr1:100503596	HIAT1	0.65	6.61	0.4	2.6200000000000003e-10	Carotid intima media thickness;
SARC	cis	rs9300255	0.506	rs61388686	chr12:123810873	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-5.03	-0.31	9.74e-7	Neutrophil percentage of white cells;
SARC	cis	rs6545883	0.831	rs1186704	chr2:61672991	A/G	cg15711740	chr2:61764176	XPO1	-0.43	-5.19	-0.32	4.68e-7	Tuberculosis;
SARC	cis	rs6500602	0.702	rs2270366	chr16:4558615	A/G	cg08645402	chr16:4508243	NA	-0.42	-5.73	-0.35	3.11e-8	Schizophrenia;
SARC	cis	rs12477438	0.605	rs4585080	chr2:99557327	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-9.56	-0.53	1.72e-18	Chronic sinus infection;
SARC	cis	rs739401	0.572	rs739399	chr11:3016452	A/G	cg25174290	chr11:3078921	CARS	0.56	7.98	0.46	6.53e-14	Longevity;
SARC	trans	rs3780486	0.846	rs7873903	chr9:33142728	G/A	cg20290983	chr6:43655470	MRPS18A	1.14	21.11	0.81	5.2e-56	IgG glycosylation;
SARC	cis	rs10078	0.571	rs2671890	chr5:456457	A/G	cg07599136	chr5:415885	AHRR	0.66	5.83	0.36	1.81e-8	Fat distribution (HIV);
SARC	cis	rs77372450	0.551	rs62390781	chr5:157061507	G/A	cg05585991	chr5:157099197	C5orf52	0.54	5.38	0.33	1.85e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs9788682	0.747	rs2938674	chr15:78757913	C/A	cg24631222	chr15:78858424	CHRNA5	0.74	8.9	0.5	1.61e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs796364	0.789	rs1653297	chr2:201075483	C/T	cg05691004	chr2:201170426	SPATS2L	-0.46	-5.51	-0.34	9.43e-8	Schizophrenia;
SARC	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg08048268	chr3:133502702	NA	-0.43	-5.72	-0.35	3.18e-8	Iron status biomarkers;
SARC	cis	rs854765	0.693	rs9907287	chr17:17774118	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.66	-9.8	-0.54	3.22e-19	Total body bone mineral density;
SARC	cis	rs4664304	0.742	rs67017730	chr2:160732793	T/G	cg18514922	chr2:160761262	LY75	-0.33	-4.72	-0.3	4e-6	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs644799	1.000	rs560854	chr11:95584905	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	14.38	0.69	5.31e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7937682	0.889	rs559482	chr11:111497902	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.92	-14.73	-0.69	3.72e-35	Primary sclerosing cholangitis;
SARC	cis	rs11098499	0.913	rs68128210	chr4:120137819	T/G	cg09307838	chr4:120376055	NA	0.82	11.05	0.59	4.35e-23	Corneal astigmatism;
SARC	cis	rs8141529	0.600	rs916332	chr22:29308414	C/T	cg15103426	chr22:29168792	CCDC117	0.61	6.22	0.38	2.32e-9	Lymphocyte counts;
SARC	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg20573242	chr4:122745356	CCNA2	0.68	8.67	0.49	7.41e-16	Type 2 diabetes;
SARC	cis	rs568617	0.626	rs10896050	chr11:65577516	G/T	cg04055107	chr11:65626734	MUS81;CFL1	0.54	5.91	0.36	1.2e-8	Crohn's disease;
SARC	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	6.03	0.37	6.39e-9	Tonsillectomy;
SARC	cis	rs7666738	0.519	rs11732209	chr4:98801643	A/G	cg05340658	chr4:99064831	C4orf37	0.59	7.24	0.43	6.56e-12	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7566780	0.516	rs1346752	chr2:16676846	C/T	cg09580478	chr2:16689509	NA	-0.53	-6.69	-0.4	1.66e-10	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs7312774	0.618	rs10861680	chr12:107323730	T/C	cg16260113	chr12:107380972	MTERFD3	0.83	6.9	0.41	4.89e-11	Severe influenza A (H1N1) infection;
SARC	cis	rs2228479	0.702	rs17233441	chr16:89817998	C/G	cg06558623	chr16:89946397	TCF25	0.88	6.21	0.38	2.39e-9	Skin colour saturation;
SARC	cis	rs57994353	0.865	rs13290734	chr9:139330701	G/A	cg14169450	chr9:139327907	INPP5E	0.4	5.12	0.32	6.39e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs9486719	0.656	rs4839826	chr6:96853616	A/G	cg18709589	chr6:96969512	KIAA0776	-0.45	-5.04	-0.31	9.53e-7	Migraine;Coronary artery disease;
SARC	cis	rs748404	0.660	rs690012	chr15:43719755	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.4	4.78	0.3	3.13e-6	Lung cancer;
SARC	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg11062466	chr8:58055876	NA	0.52	5.32	0.33	2.43e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7223966	1.000	rs9891018	chr17:61827856	A/G	cg00588841	chr17:61851480	DDX42;CCDC47	-0.68	-7.54	-0.44	1.05e-12	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.44	5.49	0.34	1.03e-7	Tonsillectomy;
SARC	cis	rs7659604	1.000	rs35901586	chr4:122664757	T/A	cg19748678	chr4:122722346	EXOSC9	0.42	5.19	0.32	4.59e-7	Type 2 diabetes;
SARC	cis	rs796364	0.806	rs12619136	chr2:200910347	C/A	cg23649088	chr2:200775458	C2orf69	-0.64	-5.54	-0.34	8.17e-8	Schizophrenia;
SARC	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg11890956	chr21:40555474	PSMG1	1.18	16.92	0.74	1.98e-42	Cognitive function;
SARC	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.58	5.48	0.34	1.1e-7	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs7520050	0.898	rs4660885	chr1:46243756	C/T	cg06784218	chr1:46089804	CCDC17	-0.26	-4.76	-0.3	3.47e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg05368731	chr17:41323189	NBR1	0.77	9.17	0.52	2.53e-17	Menopause (age at onset);
SARC	cis	rs9948	0.655	rs62156221	chr2:97410850	A/G	cg01990225	chr2:97406019	LMAN2L	-0.94	-6.38	-0.39	9.49e-10	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs2153535	0.563	rs3117071	chr6:8537908	C/T	cg07606381	chr6:8435919	SLC35B3	0.78	10.92	0.58	1.11e-22	Motion sickness;
SARC	trans	rs61931739	0.612	rs1906137	chr12:33939676	T/A	cg26384229	chr12:38710491	ALG10B	0.58	7.43	0.44	2.1e-12	Morning vs. evening chronotype;
SARC	cis	rs6723226	0.650	rs6729952	chr2:32764922	T/C	cg02381751	chr2:32503542	YIPF4	0.72	9.78	0.54	3.79e-19	Intelligence (multi-trait analysis);
SARC	cis	rs6665290	0.904	rs3768425	chr1:227178127	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.07	-25.78	-0.86	3.44e-70	Myeloid white cell count;
SARC	cis	rs10504073	0.647	rs56057508	chr8:49982793	G/T	cg00325661	chr8:49890786	NA	0.53	6.8	0.41	8.74e-11	Blood metabolite ratios;
SARC	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg10523679	chr1:76189770	ACADM	0.52	6.76	0.4	1.1e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs10504229	0.593	rs7000752	chr8:58026980	C/G	cg22535103	chr8:58192502	C8orf71	-0.54	-5.36	-0.33	2.02e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs17685	0.712	rs10235086	chr7:75833138	G/T	cg19862616	chr7:65841803	NCRNA00174	0.62	7.66	0.45	5e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs7537052	0.646	rs795045	chr1:36650055	T/C	cg24686825	chr1:36642396	MAP7D1	-0.71	-10.01	-0.55	7.37e-20	Schizophrenia;
SARC	cis	rs4906332	1.000	rs3783398	chr14:103949378	C/T	cg26031613	chr14:104095156	KLC1	0.53	6.32	0.38	1.29e-9	Coronary artery disease;
SARC	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg27266027	chr21:40555129	PSMG1	0.5	5.41	0.33	1.54e-7	Cognitive function;
SARC	cis	rs9807989	0.765	rs6751967	chr2:102967413	T/C	cg09003973	chr2:102972529	NA	0.41	5.6	0.34	6.11e-8	Asthma;
SARC	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.46	5.34	0.33	2.17e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs4595586	0.545	rs3911798	chr12:39389901	A/G	cg26384229	chr12:38710491	ALG10B	0.49	5.93	0.36	1.11e-8	Morning vs. evening chronotype;
SARC	cis	rs28655083	1.000	rs8045658	chr16:77056343	A/C	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.42	-5.88	-0.36	1.44e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg26335602	chr6:28129616	ZNF389	0.53	5.88	0.36	1.43e-8	Depression;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg16024933	chr3:176915599	TBL1XR1	-0.54	-6.83	-0.41	7.38e-11	Schizophrenia;
SARC	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg17221315	chr6:27791827	HIST1H4J	0.5	5.18	0.32	4.89e-7	Parkinson's disease;
SARC	cis	rs1050631	1.000	rs1107840	chr18:33707164	A/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.47	5.59	0.34	6.27e-8	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs4803468	1.000	rs4803465	chr19:41918158	A/G	cg09537434	chr19:41945824	ATP5SL	0.94	17.1	0.75	4.94e-43	Height;
SARC	cis	rs7084402	0.967	rs1649034	chr10:60279324	G/A	cg07615347	chr10:60278583	BICC1	-0.59	-8.54	-0.49	1.76e-15	Refractive error;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg09285213	chr2:68384741	WDR92;PNO1	0.55	6.98	0.42	3.06e-11	Lung adenocarcinoma;
SARC	cis	rs1008375	0.932	rs4698626	chr4:17605821	G/C	cg27347728	chr4:17578864	LAP3	0.45	5.52	0.34	9.09e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg05872129	chr22:39784769	NA	-0.45	-6.4	-0.39	8.31e-10	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg12463550	chr7:65579703	CRCP	-0.5	-5.59	-0.34	6.32e-8	Aortic root size;
SARC	cis	rs2997447	0.761	rs55815920	chr1:26457662	A/C	cg19633962	chr1:26362018	EXTL1	-0.57	-4.93	-0.31	1.54e-6	QRS complex (12-leadsum);
SARC	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg22920501	chr2:26401640	FAM59B	-0.53	-6.69	-0.4	1.61e-10	Gut microbiome composition (summer);
SARC	cis	rs7592578	0.679	rs62181020	chr2:191325601	A/C	cg25963032	chr2:191064776	C2orf88	-0.44	-5.11	-0.32	6.74e-7	Diastolic blood pressure;
SARC	cis	rs7937682	0.564	rs9633937	chr11:111372799	C/T	cg09085632	chr11:111637200	PPP2R1B	0.51	6.27	0.38	1.74e-9	Primary sclerosing cholangitis;
SARC	cis	rs36051895	0.632	rs10974980	chr9:5140671	C/G	cg02405213	chr9:5042618	JAK2	-0.45	-5.31	-0.33	2.53e-7	Pediatric autoimmune diseases;
SARC	cis	rs3540	0.553	rs8042861	chr15:90977333	G/T	cg22089800	chr15:90895588	ZNF774	0.64	8.53	0.49	1.94e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs981844	0.712	rs6855082	chr4:154754039	A/G	cg14289246	chr4:154710475	SFRP2	-0.45	-5.36	-0.33	1.96e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs7264396	0.563	rs2425089	chr20:34304036	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-7.21	-0.43	7.81e-12	Total cholesterol levels;
SARC	cis	rs4660261	0.526	rs2906466	chr1:44322220	A/G	cg09903430	chr1:44172605	ST3GAL3	0.37	4.78	0.3	3.05e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7179456	0.700	rs12916216	chr15:59251507	T/A	cg05156742	chr15:59063176	FAM63B	0.57	7.32	0.43	3.94e-12	Asperger disorder;
SARC	cis	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg23422044	chr7:1970798	MAD1L1	-0.46	-5.03	-0.31	9.79e-7	Bipolar disorder;
SARC	cis	rs1371867	0.846	rs2439460	chr8:101312665	C/T	cg11906718	chr8:101322791	RNF19A	0.66	8.62	0.49	1.01e-15	Atrioventricular conduction;
SARC	cis	rs7666738	0.830	rs62321569	chr4:98984250	T/A	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs910316	0.712	rs175037	chr14:75465038	T/C	cg23033748	chr14:75592666	NEK9	-0.38	-5.24	-0.32	3.62e-7	Height;
SARC	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg07157834	chr1:205819609	PM20D1	0.41	4.96	0.31	1.36e-6	Parkinson's disease;
SARC	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg03575189	chr17:44344142	NA	0.61	5.88	0.36	1.41e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs2290159	0.706	rs11923427	chr3:12663835	C/G	cg23032965	chr3:12705835	RAF1	0.73	7.3	0.43	4.42e-12	Cholesterol, total;
SARC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg09033563	chr22:24373618	LOC391322	0.51	6.31	0.38	1.4e-9	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs17401966	0.838	rs10492971	chr1:10342975	G/A	cg15208524	chr1:10270712	KIF1B	0.46	5.53	0.34	8.69e-8	Hepatocellular carcinoma;
SARC	cis	rs6690583	0.538	rs963488	chr1:85542687	C/T	cg22153463	chr1:85462885	MCOLN2	-0.46	-4.97	-0.31	1.32e-6	Serum sulfate level;
SARC	cis	rs4423214	0.559	rs7949129	chr11:71193135	G/C	cg05163923	chr11:71159392	DHCR7	-0.57	-5.72	-0.35	3.2e-8	Vitamin D levels;
SARC	cis	rs13144136	0.687	rs13119277	chr4:10658129	C/T	cg10242279	chr4:10666415	CLNK	-0.42	-6.91	-0.41	4.62e-11	Resistance to antihypertensive treatment in hypertension;
SARC	cis	rs16976116	0.901	rs8027256	chr15:55492323	C/A	cg17854078	chr15:55489399	RSL24D1	0.69	6.65	0.4	2.07e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs66573146	0.572	rs67252699	chr4:6946411	A/G	cg26116260	chr4:7069785	GRPEL1	-0.69	-5.09	-0.32	7.44e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg01316550	chr5:56110833	MAP3K1	0.52	4.82	0.3	2.54e-6	Initial pursuit acceleration;
SARC	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	8.28	0.48	9.57e-15	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.37	5.06	0.31	8.54e-7	Obesity-related traits;
SARC	cis	rs9790314	1.000	rs9790314	chr3:161019558	T/C	cg03342759	chr3:160939853	NMD3	-0.61	-7.69	-0.45	4.18e-13	Morning vs. evening chronotype;
SARC	cis	rs13256369	1.000	rs10098234	chr8:8576692	G/A	cg17143192	chr8:8559678	CLDN23	0.52	5.99	0.37	7.84e-9	Obesity-related traits;
SARC	cis	rs10131894	0.611	rs175000	chr14:75436367	T/C	cg11812906	chr14:75593930	NEK9	-0.65	-8.17	-0.47	1.97e-14	Coronary artery disease;
SARC	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg17971929	chr21:40555470	PSMG1	1.0	14.01	0.68	9.02e-33	Cognitive function;
SARC	cis	rs2204008	0.619	rs11178987	chr12:38201258	C/T	cg14851346	chr12:38532713	NA	-0.44	-5.33	-0.33	2.32e-7	Bladder cancer;
SARC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.34	4.97	0.31	1.29e-6	Cognitive function;
SARC	cis	rs9786986	0.665	rs12402210	chr1:235701708	T/A	cg08848088	chr1:235714526	GNG4	0.57	5.84	0.36	1.75e-8	Body mass index;
SARC	cis	rs9815354	1.000	rs1716683	chr3:41923074	A/G	cg03022575	chr3:42003672	ULK4	-0.54	-5.12	-0.32	6.5e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs11122272	0.735	rs2808591	chr1:231523421	G/A	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs1865760	1.000	rs6910138	chr6:25904352	C/G	cg16482183	chr6:26056742	HIST1H1C	0.49	6.13	0.37	3.78e-9	Height;
SARC	cis	rs7312774	0.618	rs7953093	chr12:107334540	G/A	cg16260113	chr12:107380972	MTERFD3	0.98	7.83	0.46	1.73e-13	Severe influenza A (H1N1) infection;
SARC	cis	rs6696846	0.749	rs61822566	chr1:205078660	T/C	cg21545522	chr1:205238299	TMCC2	0.37	5.0	0.31	1.12e-6	Red blood cell count;
SARC	cis	rs10791097	0.720	rs7119425	chr11:130733185	C/T	cg12179176	chr11:130786555	SNX19	0.69	10.18	0.55	2.31e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs11613048	0.828	rs12831473	chr12:30336326	G/A	cg12718339	chr12:29936407	TMTC1	-0.35	-4.79	-0.3	3e-6	Major depressive disorder;
SARC	cis	rs8014204	0.604	rs11625594	chr14:75389833	G/A	cg08847533	chr14:75593920	NEK9	0.5	5.82	0.36	1.95e-8	Caffeine consumption;
SARC	cis	rs9300255	0.596	rs1568427	chr12:123738678	A/G	cg05973401	chr12:123451056	ABCB9	0.52	5.69	0.35	3.81e-8	Neutrophil percentage of white cells;
SARC	cis	rs11098499	0.954	rs3733524	chr4:120423729	T/C	cg09307838	chr4:120376055	NA	0.94	13.07	0.65	1.21e-29	Corneal astigmatism;
SARC	cis	rs11578119	0.933	rs11587811	chr1:170482352	C/T	cg09767346	chr1:170501363	GORAB	0.4	4.73	0.3	3.91e-6	Male-pattern baldness;
SARC	trans	rs7615952	0.609	rs13088451	chr3:125553499	G/C	cg07211511	chr3:129823064	LOC729375	-0.79	-9.16	-0.51	2.83e-17	Blood pressure (smoking interaction);
SARC	cis	rs3741404	0.620	rs11231722	chr11:63967770	C/G	cg04317338	chr11:64019027	PLCB3	0.44	5.27	0.33	3.1e-7	Platelet count;
SARC	cis	rs7086627	0.515	rs11202960	chr10:82209807	G/A	cg01528321	chr10:82214614	TSPAN14	0.57	8.41	0.48	4.07e-15	Post bronchodilator FEV1;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg21217129	chr21:46554127	ADARB1	-0.5	-6.42	-0.39	7.43e-10	Blood pressure;
SARC	cis	rs10504229	0.906	rs28447218	chr8:58170813	T/G	cg22535103	chr8:58192502	C8orf71	-0.63	-7.47	-0.44	1.57e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs950169	1.000	rs12902672	chr15:84716986	G/A	cg24253500	chr15:84953950	NA	0.35	5.08	0.32	7.66e-7	Schizophrenia;
SARC	cis	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg06636001	chr8:8085503	FLJ10661	0.65	8.6	0.49	1.2e-15	Mood instability;
SARC	cis	rs9326248	0.581	rs10892072	chr11:116960313	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.68	8.67	0.49	7.57e-16	Blood protein levels;
SARC	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2304069	0.954	rs1962603	chr5:149393006	G/T	cg12661370	chr5:149340060	SLC26A2	0.6	5.8	0.36	2.13e-8	HIV-1 control;
SARC	cis	rs7223966	1.000	rs992416	chr17:61745905	A/C	cg00588841	chr17:61851480	DDX42;CCDC47	-0.61	-6.68	-0.4	1.76e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs3126085	0.877	rs12065368	chr1:152253497	C/T	cg03465714	chr1:152285911	FLG	-0.45	-5.45	-0.34	1.25e-7	Atopic dermatitis;
SARC	cis	rs4924935	0.509	rs8074020	chr17:18801380	T/C	cg25390199	chr17:18761479	PRPSAP2	0.46	6.04	0.37	5.89e-9	Pancreatic cancer;
SARC	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg13939156	chr17:80058883	NA	-0.44	-6.73	-0.4	1.32e-10	Life satisfaction;
SARC	cis	rs2120019	0.567	rs72625793	chr15:75207083	A/G	cg09165964	chr15:75287851	SCAMP5	-0.96	-10.76	-0.58	3.44e-22	Blood trace element (Zn levels);
SARC	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg05863683	chr7:1912471	MAD1L1	0.36	5.5	0.34	1.02e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg05623727	chr3:50126028	RBM5	-0.33	-5.01	-0.31	1.08e-6	Intelligence (multi-trait analysis);
SARC	cis	rs3204270	0.639	rs11871678	chr17:79654285	G/A	cg26965718	chr17:79658957	HGS	-0.59	-4.78	-0.3	3.11e-6	Dental caries;
SARC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg06877462	chr1:205807181	PM20D1	0.34	4.79	0.3	2.96e-6	Menarche (age at onset);
SARC	cis	rs4742903	0.967	rs2274725	chr9:106864570	C/T	cg21169611	chr9:106856078	SMC2	0.39	4.83	0.3	2.52e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.9	-0.5	1.61e-16	Alzheimer's disease;
SARC	cis	rs7647973	1.000	rs7647973	chr3:49510931	G/A	cg07636037	chr3:49044803	WDR6	-0.75	-7.99	-0.46	6.22e-14	Menarche (age at onset);
SARC	cis	rs2562456	0.917	rs2681389	chr19:21692575	G/A	cg00806126	chr19:22604979	ZNF98	0.47	4.85	0.3	2.27e-6	Pain;
SARC	cis	rs9303280	0.901	rs2313430	chr17:37929816	T/C	cg00129232	chr17:37814104	STARD3	0.36	4.79	0.3	3e-6	Self-reported allergy;
SARC	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg08975724	chr8:8085496	FLJ10661	0.68	8.9	0.5	1.58e-16	Neuroticism;
SARC	trans	rs61931739	0.534	rs11052957	chr12:33995354	G/A	cg26384229	chr12:38710491	ALG10B	0.74	10.62	0.57	9.83e-22	Morning vs. evening chronotype;
SARC	cis	rs1062177	1.000	rs6890099	chr5:151151962	A/G	cg00977110	chr5:151150581	G3BP1	0.63	6.33	0.38	1.22e-9	Preschool internalizing problems;
SARC	cis	rs1448094	0.967	rs10863118	chr12:86339232	C/G	cg02569458	chr12:86230093	RASSF9	0.4	5.83	0.36	1.85e-8	Major depressive disorder;
SARC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg06873352	chr17:61820015	STRADA	0.52	6.76	0.4	1.1e-10	Prudent dietary pattern;
SARC	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	11.35	0.6	4.58e-24	Platelet count;
SARC	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg04944784	chr2:26401820	FAM59B	0.6	7.95	0.46	8.14e-14	Gut microbiome composition (summer);
SARC	cis	rs6546550	0.901	rs12613947	chr2:70161342	A/G	cg02498382	chr2:70120550	SNRNP27	-0.34	-5.4	-0.33	1.66e-7	Prevalent atrial fibrillation;
SARC	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg16325326	chr1:53192061	ZYG11B	-0.81	-12.97	-0.65	2.49e-29	Monocyte count;
SARC	cis	rs1699337	0.527	rs1562041	chr3:12285734	G/T	cg04748988	chr3:12329223	PPARG	0.36	4.79	0.3	3.03e-6	Cholesterol, total;
SARC	cis	rs2153535	0.601	rs9379224	chr6:8538413	A/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.41	0.48	4.06e-15	Motion sickness;
SARC	cis	rs12592111	1	rs12592111	chr15:78767346	G/A	cg24631222	chr15:78858424	CHRNA5	-0.45	-5.8	-0.36	2.12e-8	Parental longevity (combined parental age at death);Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
SARC	cis	rs1448094	0.512	rs7137596	chr12:86239884	C/G	cg02569458	chr12:86230093	RASSF9	0.39	5.49	0.34	1.07e-7	Major depressive disorder;
SARC	cis	rs6582630	0.599	rs7967598	chr12:38540760	C/T	cg13010199	chr12:38710504	ALG10B	-0.51	-6.36	-0.38	1.08e-9	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1580019	0.587	rs6972365	chr7:32548931	T/A	cg06627557	chr7:32535165	LSM5;AVL9	0.97	17.34	0.75	8e-44	Cognitive ability;
SARC	cis	rs4803468	0.934	rs8103531	chr19:41891974	C/T	cg08477640	chr19:41863820	B9D2	0.41	5.24	0.32	3.6e-7	Height;
SARC	cis	rs9814567	1.000	rs4955485	chr3:134295843	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-6.93	-0.41	4.18e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs9300255	0.510	rs1790109	chr12:123637752	C/G	cg05973401	chr12:123451056	ABCB9	0.53	6.05	0.37	5.67e-9	Neutrophil percentage of white cells;
SARC	cis	rs920590	0.758	rs1907799	chr8:19664668	A/G	cg03894339	chr8:19674705	INTS10	-0.56	-6.62	-0.4	2.38e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.68	9.08	0.51	4.82e-17	Menarche (age at onset);
SARC	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg24399712	chr22:39784796	NA	-0.44	-5.88	-0.36	1.42e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.08	18.64	0.77	4.34e-48	Prudent dietary pattern;
SARC	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg05313129	chr8:58192883	C8orf71	-0.55	-5.14	-0.32	5.74e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10046574	0.519	rs34274894	chr7:135214725	G/C	cg27474649	chr7:135195673	CNOT4	0.79	7.57	0.44	8.67e-13	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs367943	0.966	rs348932	chr5:112812457	G/A	cg12552261	chr5:112820674	MCC	-0.45	-5.19	-0.32	4.65e-7	Type 2 diabetes;
SARC	cis	rs13034020	0.522	rs13005116	chr2:61241567	G/C	cg18625361	chr2:61244694	PEX13;PUS10	0.71	6.13	0.37	3.79e-9	Hodgkin's lymphoma;
SARC	cis	rs72653721	0.793	rs9468122	chr6:10965925	T/C	cg13562911	chr6:11044106	ELOVL2	0.56	6.05	0.37	5.69e-9	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	cis	rs2153535	0.580	rs5001324	chr6:8451604	A/T	cg23788917	chr6:8435910	SLC35B3	0.64	8.54	0.49	1.8e-15	Motion sickness;
SARC	cis	rs9747201	0.926	rs8065606	chr17:80063526	G/A	cg09264619	chr17:80180166	NA	0.47	5.34	0.33	2.23e-7	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg06636001	chr8:8085503	FLJ10661	0.63	8.37	0.48	5.36e-15	Mood instability;
SARC	cis	rs986417	0.901	rs1884094	chr14:61016933	C/G	cg27398547	chr14:60952738	C14orf39	0.86	7.63	0.45	6.06e-13	Gut microbiota (bacterial taxa);
SARC	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	11.07	0.59	3.6e-23	Alzheimer's disease;
SARC	cis	rs4072980	0.545	rs16824518	chr1:38415315	A/C	cg18451016	chr1:38461880	NA	-0.34	-4.84	-0.3	2.33e-6	Coronary artery disease;
SARC	cis	rs9818758	0.607	rs9855123	chr3:49229457	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.74	-6.42	-0.39	7.64e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs11992186	0.570	rs17628941	chr8:8587534	G/C	cg06636001	chr8:8085503	FLJ10661	-0.45	-5.35	-0.33	2.14e-7	Neuroticism;
SARC	cis	rs12421382	0.616	rs2357795	chr11:109381135	C/T	cg27471124	chr11:109292789	C11orf87	0.37	5.27	0.33	3.1e-7	Schizophrenia;
SARC	cis	rs9916302	0.821	rs412430	chr17:37737094	C/G	cg07936489	chr17:37558343	FBXL20	-0.68	-8.42	-0.48	3.9e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs9354352	1.000	rs9354352	chr6:66696272	T/C	cg07460842	chr6:66804631	NA	0.59	7.69	0.45	4.08e-13	Initial pursuit acceleration in psychotic disorders;
SARC	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg24209194	chr3:40518798	ZNF619	0.67	8.13	0.47	2.49e-14	Renal cell carcinoma;
SARC	cis	rs926392	0.932	rs6513588	chr20:37686281	T/C	cg16355469	chr20:37678765	NA	0.57	7.36	0.43	3.16e-12	Dialysis-related mortality;
SARC	cis	rs4900538	0.855	rs12590993	chr14:102844064	A/G	cg18135206	chr14:102964638	TECPR2	-0.6	-7.7	-0.45	3.94e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg02725872	chr8:58115012	NA	-0.35	-6.03	-0.37	6.27e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg21157234	chr9:101984918	ALG2;SEC61B	-0.53	-6.39	-0.39	9.1e-10	Blood pressure;
SARC	cis	rs7586879	0.593	rs6733224	chr2:25130907	C/T	cg04586622	chr2:25135609	ADCY3	-0.29	-4.95	-0.31	1.4e-6	Body mass index;
SARC	cis	rs2013441	1.000	rs2703818	chr17:20119976	T/A	cg13482628	chr17:19912719	NA	-0.46	-6.0	-0.37	7.53e-9	Obesity-related traits;
SARC	cis	rs4689388	0.791	rs1046317	chr4:6304242	T/C	cg25554036	chr4:6271136	WFS1	0.4	5.79	0.35	2.31e-8	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs2841277	0.676	rs10438247	chr14:105411781	G/A	cg15352829	chr14:105391018	PLD4	-0.32	-5.97	-0.36	8.93e-9	Rheumatoid arthritis;
SARC	cis	rs1008375	1.000	rs2058337	chr4:17678649	C/T	cg16339924	chr4:17578868	LAP3	0.64	8.46	0.48	2.98e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs910316	1.000	rs910316	chr14:75626042	A/C	cg11812906	chr14:75593930	NEK9	0.87	12.71	0.64	1.87e-28	Height;
SARC	cis	rs72781680	0.581	rs116520786	chr2:24272645	C/T	cg06627628	chr2:24431161	ITSN2	-0.61	-6.04	-0.37	6.18e-9	Lymphocyte counts;
SARC	trans	rs36093844	0.752	rs17744699	chr11:85597163	C/T	cg15359163	chr5:122429178	PRDM6	-0.53	-6.4	-0.39	8.22e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs35160687	0.814	rs7563887	chr2:86516121	C/T	cg10973622	chr2:86423274	IMMT	0.42	5.61	0.35	5.64e-8	Night sleep phenotypes;
SARC	cis	rs6580649	1.000	rs9805048	chr12:48403692	C/T	cg05342945	chr12:48394962	COL2A1	-0.47	-5.14	-0.32	5.69e-7	Lung cancer;
SARC	cis	rs3858526	0.920	rs11511938	chr11:5928793	A/G	cg02574844	chr11:5959923	NA	-0.42	-5.24	-0.32	3.58e-7	DNA methylation (variation);
SARC	cis	rs8058578	1.000	rs67456513	chr16:30714828	A/T	cg02466173	chr16:30829666	NA	-0.39	-5.18	-0.32	4.74e-7	Multiple myeloma;
SARC	cis	rs826838	0.967	rs7299170	chr12:38789536	G/A	cg13010199	chr12:38710504	ALG10B	0.79	11.13	0.59	2.42e-23	Heart rate;
SARC	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.5	-0.44	1.37e-12	Gut microbiome composition (summer);
SARC	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.47	-5.82	-0.36	1.93e-8	Tonsillectomy;
SARC	cis	rs2075371	0.932	rs2241332	chr7:133969439	A/G	cg20476274	chr7:133979776	SLC35B4	0.59	7.85	0.46	1.53e-13	Mean platelet volume;
SARC	cis	rs3106136	0.710	rs6825431	chr4:95312121	T/A	cg11021082	chr4:95130006	SMARCAD1	0.32	4.88	0.3	1.95e-6	Capecitabine sensitivity;
SARC	cis	rs7824557	0.767	rs6985146	chr8:11170721	A/C	cg21775007	chr8:11205619	TDH	0.48	5.81	0.36	2e-8	Retinal vascular caliber;
SARC	cis	rs6674970	0.966	rs2091219	chr1:151012060	A/G	cg11822372	chr1:151115635	SEMA6C	0.44	5.66	0.35	4.38e-8	Childhood ear infection;
SARC	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg12564285	chr5:131593104	PDLIM4	0.35	5.23	0.32	3.68e-7	Breast cancer;
SARC	cis	rs524281	0.861	rs2177053	chr11:65966145	A/C	cg14036092	chr11:66035641	RAB1B	-0.49	-5.18	-0.32	4.9e-7	Electroencephalogram traits;
SARC	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg13770153	chr20:60521292	NA	-0.47	-6.2	-0.38	2.5e-9	Body mass index;
SARC	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs832540	0.931	rs1466008	chr5:56213406	G/C	cg14703610	chr5:56206110	C5orf35	0.53	6.7	0.4	1.58e-10	Coronary artery disease;
SARC	cis	rs72945132	0.882	rs60917762	chr11:70211384	C/T	cg05964544	chr11:70165517	PPFIA1	-0.56	-5.41	-0.33	1.57e-7	Coronary artery disease;
SARC	cis	rs744373	0.517	rs72838284	chr2:127891663	T/C	cg12632573	chr2:127783243	NA	0.64	5.8	0.36	2.11e-8	Alzheimer's disease;Alzheimer's disease (late onset);
SARC	cis	rs4148883	0.628	rs34195655	chr4:100073795	C/T	cg13256891	chr4:100009986	ADH5	0.57	7.74	0.45	2.93e-13	Alcohol dependence;
SARC	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.33	-4.76	-0.3	3.37e-6	Bipolar disorder;
SARC	cis	rs7178572	0.889	rs7170877	chr15:77832019	C/G	cg22256960	chr15:77711686	NA	-0.54	-6.37	-0.39	9.77e-10	Type 2 diabetes;
SARC	cis	rs17376456	0.741	rs10036829	chr5:93309897	G/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.8	0.35	2.2e-8	Diabetic retinopathy;
SARC	cis	rs1983170	0.808	rs6685254	chr1:92018415	T/C	cg25838465	chr1:92012736	NA	0.44	5.38	0.33	1.82e-7	Eosinophil percentage of white cells;
SARC	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg04277193	chr17:41438351	NA	0.44	4.86	0.3	2.18e-6	Menopause (age at onset);
SARC	cis	rs6772849	0.930	rs55987729	chr3:128340110	T/C	cg01163369	chr3:128370232	RPN1	-0.34	-4.87	-0.3	2.06e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg25427524	chr10:38739819	LOC399744	0.57	9.2	0.52	2.05e-17	Extrinsic epigenetic age acceleration;
SARC	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs7635838	0.819	rs2454476	chr3:11545442	G/A	cg00170343	chr3:11313890	ATG7	0.6	8.21	0.47	1.51e-14	HDL cholesterol;
SARC	cis	rs1030877	0.960	rs3792050	chr2:105902255	T/C	cg02079111	chr2:105885981	TGFBRAP1	-0.55	-8.1	-0.47	3.17e-14	Obesity-related traits;
SARC	cis	rs7520050	0.831	rs61783170	chr1:46256329	T/C	cg06784218	chr1:46089804	CCDC17	-0.26	-4.74	-0.3	3.69e-6	Red blood cell count;Reticulocyte count;
SARC	trans	rs1814175	0.645	rs28441045	chr11:50048971	C/T	cg03929089	chr4:120376271	NA	-0.83	-11.84	-0.61	1.24e-25	Height;
SARC	cis	rs950776	0.745	rs3743075	chr15:78909452	T/C	cg24631222	chr15:78858424	CHRNA5	0.38	4.86	0.3	2.12e-6	Sudden cardiac arrest;
SARC	cis	rs3733585	0.605	rs4697926	chr4:10124567	G/T	cg11266682	chr4:10021025	SLC2A9	0.42	7.1	0.42	1.52e-11	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg22105103	chr4:187893119	NA	-0.48	-6.42	-0.39	7.5e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2304069	0.550	rs216144	chr5:149445480	T/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.58	6.21	0.38	2.42e-9	HIV-1 control;
SARC	cis	rs1878931	0.543	rs17612463	chr16:3420479	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.68	7.72	0.45	3.36e-13	Body mass index (adult);
SARC	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg16405210	chr4:1374714	KIAA1530	-0.56	-6.93	-0.41	4.08e-11	Longevity;
SARC	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg04277193	chr17:41438351	NA	0.45	4.84	0.3	2.4e-6	Menopause (age at onset);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg02723399	chr22:19420170	HIRA;MRPL40	0.5	6.6	0.4	2.67e-10	Thyroid stimulating hormone;
SARC	cis	rs7208859	0.673	rs11080135	chr17:29176481	A/G	cg13385521	chr17:29058706	SUZ12P	0.86	7.34	0.43	3.52e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9486715	0.867	rs9372106	chr6:96875058	T/C	cg06623918	chr6:96969491	KIAA0776	0.83	11.86	0.61	1.04e-25	Headache;
SARC	cis	rs2408955	0.522	rs3997	chr12:48481587	T/C	cg24011408	chr12:48396354	COL2A1	-0.43	-5.08	-0.32	7.84e-7	Glycated hemoglobin levels;
SARC	trans	rs11722228	0.549	rs73212853	chr4:10096230	C/T	cg26043149	chr18:55253948	FECH	0.67	7.55	0.44	9.94e-13	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs4481887	1.000	rs10888358	chr1:248471467	C/A	cg01631408	chr1:248437212	OR2T33	-0.41	-5.16	-0.32	5.18e-7	Common traits (Other);
SARC	cis	rs7940866	0.804	rs10894289	chr11:130808685	C/T	cg12179176	chr11:130786555	SNX19	0.67	9.79	0.54	3.51e-19	Schizophrenia;
SARC	cis	rs12586317	0.547	rs4982236	chr14:35468046	C/G	cg16230307	chr14:35515116	FAM177A1	1.02	11.85	0.61	1.18e-25	Psoriasis;
SARC	cis	rs72781680	0.821	rs2339887	chr2:24198376	G/A	cg06627628	chr2:24431161	ITSN2	-0.57	-6.01	-0.37	6.93e-9	Lymphocyte counts;
SARC	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg08280861	chr8:58055591	NA	0.6	5.3	0.33	2.66e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs981844	0.712	rs1456397	chr4:154744554	C/G	cg25721732	chr2:74602550	DCTN1	0.5	6.31	0.38	1.42e-9	Response to statins (LDL cholesterol change);
SARC	cis	rs35110281	0.805	rs162402	chr21:44963418	G/C	cg21573476	chr21:45109991	RRP1B	-0.47	-6.85	-0.41	6.7e-11	Mean corpuscular volume;
SARC	cis	rs7772486	0.625	rs2050027	chr6:146116113	C/G	cg05220968	chr6:146057943	EPM2A	0.28	4.87	0.3	2.03e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10276381	0.786	rs10281102	chr7:28243473	A/G	cg23620719	chr7:28220237	JAZF1	0.71	5.55	0.34	7.92e-8	Crohn's disease;
SARC	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg24209194	chr3:40518798	ZNF619	0.67	8.21	0.47	1.48e-14	Renal cell carcinoma;
SARC	cis	rs9309473	0.687	rs11693531	chr2:73608614	C/G	cg20560298	chr2:73613845	ALMS1	-0.53	-6.87	-0.41	5.83e-11	Metabolite levels;
SARC	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	8.66	0.49	8.06e-16	Alzheimer's disease;
SARC	cis	rs10089	1.000	rs2898096	chr5:127433214	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.82	10.24	0.56	1.51e-20	Ileal carcinoids;
SARC	trans	rs9302817	0.891	rs13332701	chr16:6164745	C/T	cg20068074	chr3:48672407	SLC26A6	-0.71	-6.53	-0.39	4.12e-10	Body mass index;
SARC	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.63	7.75	0.45	2.76e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs10463316	0.894	rs12153347	chr5:150765471	C/T	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.26	-0.33	3.27e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs8180040	0.966	rs59586735	chr3:47518325	C/T	cg27129171	chr3:47204927	SETD2	-0.69	-9.67	-0.54	8.31e-19	Colorectal cancer;
SARC	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg18404041	chr3:52824283	ITIH1	-0.43	-6.44	-0.39	6.8e-10	Bipolar disorder;
SARC	cis	rs9814567	1.000	rs2056604	chr3:134312648	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-6.93	-0.41	4.14e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs7084402	0.967	rs2393448	chr10:60333260	T/G	cg07615347	chr10:60278583	BICC1	0.57	8.32	0.48	7.58e-15	Refractive error;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg02259775	chr5:98104877	RGMB	0.47	6.33	0.38	1.28e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg08283932	chr20:43280707	ADA	-0.8	-6.91	-0.41	4.58e-11	Autism spectrum disorder or schizophrenia;
SARC	trans	rs7980799	0.716	rs1601008	chr12:33611352	A/G	cg26384229	chr12:38710491	ALG10B	-0.62	-7.7	-0.45	3.9e-13	Heart rate;Heart rate variability traits (RMSSD);
SARC	trans	rs7824557	0.564	rs4631424	chr8:11236809	T/C	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.72	-0.5	5.49e-16	Retinal vascular caliber;
SARC	cis	rs10046574	0.516	rs7802453	chr7:135200638	T/C	cg27474649	chr7:135195673	CNOT4	0.84	7.94	0.46	8.38e-14	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg21321885	chr16:15744194	NDE1	0.58	6.54	0.39	3.85e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs1030877	0.515	rs2576736	chr2:105890971	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.59	6.69	0.4	1.62e-10	Obesity-related traits;
SARC	cis	rs11122272	0.668	rs2472261	chr1:231505701	G/A	cg06096015	chr1:231504339	EGLN1	0.39	5.82	0.36	1.95e-8	Hemoglobin concentration;
SARC	cis	rs9420	0.796	rs685149	chr11:57657413	A/G	cg19752551	chr11:57585705	CTNND1	0.42	5.79	0.35	2.21e-8	Schizophrenia;
SARC	cis	rs208520	1.000	rs208529	chr6:66957549	T/C	cg07460842	chr6:66804631	NA	-0.79	-8.8	-0.5	3.1e-16	Exhaled nitric oxide output;
SARC	cis	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg18252515	chr7:66147081	NA	-1.35	-11.94	-0.62	5.84e-26	Diabetic kidney disease;
SARC	trans	rs9354308	0.901	rs12197136	chr6:66590953	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.58	6.82	0.41	7.77e-11	Metabolite levels;
SARC	cis	rs995000	0.868	rs10889360	chr1:63173918	C/T	cg06896770	chr1:63153194	DOCK7	0.94	14.39	0.69	4.95e-34	Triglyceride levels;
SARC	cis	rs11697848	0.748	rs2281221	chr20:48488686	A/C	cg17849948	chr20:48532315	SPATA2	0.81	4.87	0.3	2.09e-6	Systemic lupus erythematosus;
SARC	cis	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg06212747	chr3:49208901	KLHDC8B	0.52	6.42	0.39	7.41e-10	Resting heart rate;
SARC	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg27211696	chr2:191398769	TMEM194B	-0.49	-6.48	-0.39	5.25e-10	Pulse pressure;
SARC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.28	0.8	2.29e-53	Prudent dietary pattern;
SARC	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.44	5.45	0.34	1.27e-7	Tonsillectomy;
SARC	cis	rs10992471	0.603	rs10118939	chr9:95293641	C/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.38	-0.33	1.82e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	trans	rs1994135	0.608	rs1482994	chr12:33713631	T/C	cg26384229	chr12:38710491	ALG10B	0.85	10.48	0.57	2.72e-21	Resting heart rate;
SARC	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg11987759	chr7:65425863	GUSB	-0.61	-8.41	-0.48	4.01e-15	Aortic root size;
SARC	cis	rs8014204	0.804	rs2241274	chr14:75251331	G/A	cg06637938	chr14:75390232	RPS6KL1	0.72	10.47	0.57	2.78e-21	Caffeine consumption;
SARC	cis	rs17376456	0.825	rs28610997	chr5:93248374	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.82	0.36	1.92e-8	Diabetic retinopathy;
SARC	cis	rs9329289	0.510	rs10903785	chr10:2550063	C/T	cg15501526	chr10:2543763	NA	0.37	5.57	0.34	6.85e-8	Age-related hearing impairment;
SARC	cis	rs9902453	0.967	rs4994355	chr17:28386284	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.53	-6.96	-0.41	3.47e-11	Coffee consumption (cups per day);
SARC	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg16145915	chr7:1198662	ZFAND2A	-0.38	-4.96	-0.31	1.38e-6	Bronchopulmonary dysplasia;
SARC	cis	rs1059312	1.000	rs2291350	chr12:129283711	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.48	6.89	0.41	5.18e-11	Systemic lupus erythematosus;
SARC	cis	rs4803468	1.000	rs11883104	chr19:41923799	T/C	cg09537434	chr19:41945824	ATP5SL	-0.98	-17.65	-0.76	7.82e-45	Height;
SARC	cis	rs4566357	0.615	rs10198214	chr2:227913314	A/C	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.86	-0.36	1.53e-8	Coronary artery disease;
SARC	cis	rs2011503	1.000	rs78010159	chr19:19615905	C/T	cg03709012	chr19:19516395	GATAD2A	0.61	5.36	0.33	1.95e-7	Bipolar disorder;
SARC	cis	rs883565	0.527	rs11715262	chr3:39003853	A/T	cg26331595	chr3:39149181	GORASP1;TTC21A	0.44	5.13	0.32	5.99e-7	Handedness;
SARC	cis	rs2694528	0.844	rs16878376	chr5:60059132	C/T	cg11474532	chr5:59995715	DEPDC1B	-0.65	-4.79	-0.3	2.94e-6	Parkinson's disease;
SARC	trans	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.21	-0.43	7.82e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.03	0.37	6.41e-9	Prudent dietary pattern;
SARC	cis	rs2486288	0.656	rs12440356	chr15:45567529	T/C	cg15395560	chr15:45543142	SLC28A2	-0.32	-6.25	-0.38	1.93e-9	Glomerular filtration rate;
SARC	cis	rs9462027	0.585	rs188190	chr6:34551086	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-6.09	-0.37	4.53e-9	Systemic lupus erythematosus;
SARC	cis	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg25427524	chr10:38739819	LOC399744	-0.57	-9.09	-0.51	4.44e-17	Extrinsic epigenetic age acceleration;
SARC	cis	rs2916247	0.954	rs7012562	chr8:93020557	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.58	-6.04	-0.37	5.91e-9	Intelligence (multi-trait analysis);
SARC	cis	rs57506017	0.585	rs6460902	chr7:12255511	G/A	cg23422036	chr7:12250390	TMEM106B	0.5	6.64	0.4	2.19e-10	Neuroticism;
SARC	cis	rs2832191	0.692	rs8134627	chr21:30349069	C/T	cg08807101	chr21:30365312	RNF160	-0.9	-14.19	-0.68	2.36e-33	Dental caries;
SARC	cis	rs832540	0.552	rs252924	chr5:56205643	A/G	cg12311346	chr5:56204834	C5orf35	-0.41	-4.99	-0.31	1.16e-6	Coronary artery disease;
SARC	cis	rs4718428	1.000	rs1830070	chr7:66349671	T/C	cg18252515	chr7:66147081	NA	-0.47	-5.09	-0.32	7.54e-7	Corneal structure;
SARC	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg05368731	chr17:41323189	NBR1	0.79	9.45	0.53	3.89e-18	Menopause (age at onset);
SARC	cis	rs10744422	1.000	rs3852537	chr12:123361501	T/C	cg25930673	chr12:123319894	HIP1R	-0.65	-4.73	-0.3	3.87e-6	Schizophrenia;
SARC	cis	rs16854884	0.657	rs10513235	chr3:143698664	T/C	cg06585982	chr3:143692056	C3orf58	0.66	8.66	0.49	8.05e-16	Economic and political preferences (feminism/equality);
SARC	cis	rs1707322	1.000	rs7531911	chr1:46330423	A/G	cg03146154	chr1:46216737	IPP	0.47	5.67	0.35	4.31e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7264396	0.563	rs2425103	chr20:34312329	G/A	cg01084648	chr20:34329383	RBM39	0.56	4.93	0.31	1.57e-6	Total cholesterol levels;
SARC	cis	rs9393777	0.513	rs1104871	chr6:26665235	T/G	cg12826209	chr6:26865740	GUSBL1	0.66	5.91	0.36	1.23e-8	Intelligence (multi-trait analysis);
SARC	cis	rs72945132	0.769	rs3781644	chr11:70190375	G/A	cg05964544	chr11:70165517	PPFIA1	-0.58	-5.6	-0.34	5.95e-8	Coronary artery disease;
SARC	cis	rs933688	0.502	rs4916858	chr5:90601290	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.56	-6.41	-0.39	8.13e-10	Smoking behavior;
SARC	cis	rs6062302	0.549	rs4809586	chr20:62249402	C/T	cg16989086	chr20:62203971	PRIC285	0.47	4.73	0.3	3.92e-6	Glioblastoma;
SARC	cis	rs9859260	0.744	rs492288	chr3:195784210	C/T	cg03462622	chr3:195777018	TFRC	-0.46	-5.38	-0.33	1.81e-7	Mean corpuscular volume;
SARC	cis	rs11785693	0.862	rs11786657	chr8:5001792	T/C	cg26367366	chr8:4980734	NA	0.59	5.14	0.32	5.74e-7	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs1152591	0.562	rs1272715	chr14:64651989	A/T	cg23250157	chr14:64679961	SYNE2	0.39	5.36	0.33	2e-7	Atrial fibrillation;
SARC	cis	rs11718455	0.960	rs11921942	chr3:44007957	T/C	cg21419209	chr3:44054225	NA	-0.42	-5.21	-0.32	4.18e-7	Coronary artery disease;
SARC	cis	rs7264396	0.561	rs6058387	chr20:34568092	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-5.81	-0.36	2e-8	Total cholesterol levels;
SARC	trans	rs9329221	0.543	rs2952205	chr8:10139865	A/G	cg06636001	chr8:8085503	FLJ10661	0.49	6.55	0.39	3.66e-10	Neuroticism;
SARC	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg24209194	chr3:40518798	ZNF619	0.66	8.11	0.47	2.87e-14	Renal cell carcinoma;
SARC	cis	rs763121	0.853	rs5757211	chr22:39051705	C/T	cg21395723	chr22:39101663	GTPBP1	0.58	6.67	0.4	1.85e-10	Menopause (age at onset);
SARC	cis	rs1971762	0.527	rs6580950	chr12:53926656	T/A	cg06632207	chr12:54070931	ATP5G2	0.56	7.72	0.45	3.32e-13	Height;
SARC	cis	rs8141529	0.748	rs5997412	chr22:29276747	G/A	cg02153584	chr22:29168773	CCDC117	0.79	11.51	0.6	1.49e-24	Lymphocyte counts;
SARC	cis	rs7465272	0.957	rs11994668	chr8:143687392	G/T	cg10596483	chr8:143751796	JRK	0.55	5.94	0.36	1.04e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs4509693	0.782	rs12268880	chr10:102495285	G/C	cg11654490	chr10:102505349	PAX2	0.52	4.83	0.3	2.51e-6	Alzheimer's disease;
SARC	cis	rs9462027	0.628	rs6905393	chr6:34776626	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.86	-0.36	1.54e-8	Systemic lupus erythematosus;
SARC	cis	rs76878669	0.561	rs1784029	chr11:66099987	C/T	cg14036092	chr11:66035641	RAB1B	0.41	4.95	0.31	1.45e-6	Educational attainment (years of education);
SARC	cis	rs11098499	0.738	rs34965784	chr4:120361586	G/C	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	cis	rs9397240	0.789	rs12216139	chr6:155603671	A/G	cg07943832	chr6:155568918	TIAM2	-0.6	-5.68	-0.35	3.96e-8	Life satisfaction;
SARC	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg21782813	chr7:2030301	MAD1L1	0.38	6.06	0.37	5.4e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs8177253	0.555	rs4481157	chr3:133464684	G/A	cg01448562	chr3:133502909	NA	-0.46	-6.99	-0.42	2.89e-11	Iron status biomarkers;
SARC	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg00933542	chr6:150070202	PCMT1	0.3	5.14	0.32	5.77e-7	Lung cancer;
SARC	cis	rs6912958	0.781	rs6454631	chr6:88225863	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-5.86	-0.36	1.54e-8	Monocyte percentage of white cells;
SARC	cis	rs11249608	0.548	rs13156530	chr5:178475017	C/T	cg01312482	chr5:178451176	ZNF879	-0.41	-5.23	-0.32	3.81e-7	Pubertal anthropometrics;
SARC	cis	rs9916302	0.784	rs4795361	chr17:37573446	G/A	cg00129232	chr17:37814104	STARD3	-0.63	-7.66	-0.45	5.09e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs17666538	1.000	rs17666538	chr8:566207	T/C	cg07685180	chr8:600429	NA	-0.78	-5.61	-0.34	5.74e-8	IgG glycosylation;
SARC	cis	rs17376456	1.000	rs9968691	chr5:93509756	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.49	0.34	1.03e-7	Diabetic retinopathy;
SARC	cis	rs9316337	0.843	rs61950006	chr13:21954033	G/A	cg18095732	chr13:22033692	ZDHHC20	0.38	4.81	0.3	2.7e-6	Schizophrenia;
SARC	cis	rs7635838	0.785	rs2574698	chr3:11557126	G/A	cg00170343	chr3:11313890	ATG7	0.62	8.67	0.49	7.67e-16	HDL cholesterol;
SARC	cis	rs6089584	1.000	rs3787424	chr20:60559219	G/A	cg23262073	chr20:60523788	NA	-0.45	-6.35	-0.38	1.09e-9	Body mass index;
SARC	cis	rs2276314	0.857	rs62101376	chr18:33582955	T/C	cg05985134	chr18:33552581	C18orf21	0.7	7.05	0.42	2.01e-11	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs412050	0.793	rs238782	chr22:22341992	G/A	cg17089214	chr22:22089827	YPEL1	0.63	5.78	0.35	2.43e-8	Attention deficit hyperactivity disorder;
SARC	cis	rs8141529	0.764	rs5752807	chr22:29223169	A/G	cg02153584	chr22:29168773	CCDC117	0.8	11.69	0.61	3.83e-25	Lymphocyte counts;
SARC	cis	rs7772486	0.686	rs857879	chr6:145974043	C/A	cg05347473	chr6:146136440	FBXO30	-0.51	-7.1	-0.42	1.46e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg03033257	chr22:50311977	ALG12;CRELD2	0.58	5.79	0.35	2.3e-8	Schizophrenia;
SARC	cis	rs3087591	0.960	rs2953012	chr17:29496486	A/G	cg24425628	chr17:29625626	OMG;NF1	0.5	6.27	0.38	1.77e-9	Hip circumference;
SARC	cis	rs796364	0.951	rs6722092	chr2:201059371	G/T	cg23649088	chr2:200775458	C2orf69	0.65	7.13	0.42	1.23e-11	Schizophrenia;
SARC	cis	rs12052479	0.566	rs12693006	chr2:173467213	C/T	cg17679246	chr2:173420265	PDK1	0.5	5.14	0.32	5.68e-7	Blood protein levels;
SARC	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg00149659	chr3:10157352	C3orf10	0.64	6.01	0.37	7.21e-9	Alzheimer's disease;
SARC	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg16606324	chr3:10149918	C3orf24	0.48	4.75	0.3	3.56e-6	Alzheimer's disease;
SARC	cis	rs7588746	0.521	rs73054585	chr2:201144386	T/A	cg23649088	chr2:200775458	C2orf69	-0.65	-7.18	-0.43	9.45e-12	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs6582630	0.555	rs34884627	chr12:38443831	C/T	cg14851346	chr12:38532713	NA	-0.47	-5.76	-0.35	2.6e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2075371	0.932	rs2241333	chr7:133970750	C/T	cg20476274	chr7:133979776	SLC35B4	0.6	8.3	0.48	8.37e-15	Mean platelet volume;
SARC	cis	rs6714710	0.603	rs953320	chr2:98606770	T/C	cg26665480	chr2:98280029	ACTR1B	0.54	7.09	0.42	1.61e-11	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs67366981	1.000	rs56357623	chr14:77697393	C/A	cg06779847	chr14:77687015	TMEM63C	-0.54	-6.08	-0.37	4.93e-9	Obsessive-compulsive symptoms;
SARC	cis	rs6867032	0.834	rs10043083	chr5:1995687	C/G	cg26168224	chr5:2018326	NA	-0.7	-9.21	-0.52	2.01e-17	Gut microbiome composition (winter);
SARC	cis	rs1568889	1.000	rs12797689	chr11:28076042	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	9.59	0.53	1.45e-18	Bipolar disorder;
SARC	cis	rs11155671	0.530	rs6935829	chr6:150217811	C/T	cg09699651	chr6:150184138	LRP11	0.52	6.72	0.4	1.41e-10	Testicular germ cell tumor;
SARC	cis	rs7959452	0.535	rs1350166	chr12:69636314	G/T	cg22834771	chr12:69754056	YEATS4	-0.44	-5.82	-0.36	1.93e-8	Blood protein levels;
SARC	cis	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg24110177	chr3:50126178	RBM5	-0.39	-5.04	-0.31	9.46e-7	Intelligence (multi-trait analysis);
SARC	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg24675658	chr1:53192096	ZYG11B	0.57	8.08	0.47	3.54e-14	Monocyte count;
SARC	cis	rs4742903	0.527	rs10991152	chr9:106952669	T/C	cg14250997	chr9:106856677	SMC2	0.39	4.85	0.3	2.3e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg22535103	chr8:58192502	C8orf71	-0.58	-5.54	-0.34	7.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg04398451	chr17:18023971	MYO15A	0.54	7.91	0.46	1.03e-13	Total body bone mineral density;
SARC	trans	rs2727020	0.664	rs4929893	chr11:49196332	C/T	cg15704280	chr7:45808275	SEPT13	-0.78	-11.74	-0.61	2.59e-25	Coronary artery disease;
SARC	cis	rs9916302	0.653	rs11654954	chr17:37745979	C/T	cg20243544	chr17:37824526	PNMT	-0.52	-5.44	-0.34	1.37e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs6735179	1.000	rs59771193	chr2:1778157	C/T	cg08534653	chr2:1747700	PXDN	0.4	4.86	0.3	2.19e-6	Response to antipsychotic treatment;
SARC	cis	rs17376456	0.542	rs10476588	chr5:93208330	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.5	-5.02	-0.31	1.02e-6	Diabetic retinopathy;
SARC	cis	rs1801251	0.752	rs2675966	chr2:233735543	T/C	cg25237894	chr2:233734115	C2orf82	-0.34	-4.82	-0.3	2.57e-6	Coronary artery disease;
SARC	cis	rs9916302	0.706	rs584377	chr17:37460128	G/A	cg07936489	chr17:37558343	FBXL20	0.75	8.92	0.5	1.37e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs870825	0.616	rs57271221	chr4:185627198	C/T	cg04058563	chr4:185651563	MLF1IP	0.83	11.25	0.59	9.69e-24	Blood protein levels;
SARC	cis	rs854765	0.583	rs67253360	chr17:17828973	T/C	cg05444541	chr17:17804740	TOM1L2	-0.3	-5.05	-0.31	9.06e-7	Total body bone mineral density;
SARC	cis	rs9457247	0.663	rs2237277	chr6:167442107	G/A	cg07741184	chr6:167504864	NA	0.35	6.99	0.42	2.9e-11	Crohn's disease;
SARC	cis	rs7927771	0.864	rs60075622	chr11:47449101	T/G	cg20307385	chr11:47447363	PSMC3	-0.59	-7.47	-0.44	1.59e-12	Subjective well-being;
SARC	cis	rs9807841	0.592	rs10401513	chr19:10778763	A/T	cg17710535	chr19:10819994	QTRT1	0.43	5.1	0.32	7.12e-7	Inflammatory skin disease;
SARC	cis	rs6542838	0.641	rs7565510	chr2:99494833	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.43	-5.39	-0.33	1.76e-7	Fear of minor pain;
SARC	cis	rs10463554	0.927	rs12055075	chr5:102380257	T/C	cg23492399	chr5:102201601	PAM	-0.51	-5.55	-0.34	7.92e-8	Parkinson's disease;
SARC	cis	rs950169	0.959	rs12911210	chr15:84792083	A/C	cg17507749	chr15:85114479	UBE2QP1	0.74	9.15	0.51	2.88e-17	Schizophrenia;
SARC	cis	rs883565	0.569	rs1274970	chr3:39163252	A/G	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.46	-5.39	-0.33	1.7e-7	Handedness;
SARC	cis	rs9457247	0.967	rs1187532	chr6:167382020	G/A	cg07741184	chr6:167504864	NA	0.3	5.61	0.35	5.69e-8	Crohn's disease;
SARC	cis	rs57506017	0.585	rs13229988	chr7:12267837	A/G	cg23422036	chr7:12250390	TMEM106B	0.45	5.87	0.36	1.46e-8	Neuroticism;
SARC	cis	rs6674970	0.966	rs4512652	chr1:151115690	G/C	cg11822372	chr1:151115635	SEMA6C	0.45	5.37	0.33	1.88e-7	Childhood ear infection;
SARC	cis	rs2115630	1.000	rs2879828	chr15:85361977	G/T	cg17507749	chr15:85114479	UBE2QP1	-0.45	-5.52	-0.34	8.83e-8	P wave terminal force;
SARC	cis	rs3733585	0.605	rs4235354	chr4:10122942	C/A	cg00071950	chr4:10020882	SLC2A9	-0.39	-5.7	-0.35	3.57e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs1707322	0.721	rs11211157	chr1:46132844	T/C	cg06784218	chr1:46089804	CCDC17	0.36	6.25	0.38	1.93e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1865760	1.000	rs9358895	chr6:25924655	C/T	cg17691542	chr6:26056736	HIST1H1C	0.57	6.97	0.42	3.2e-11	Height;
SARC	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg21724239	chr8:58056113	NA	0.61	5.93	0.36	1.1e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg05861140	chr6:150128134	PCMT1	-0.44	-5.72	-0.35	3.18e-8	Lung cancer;
SARC	cis	rs34779708	0.966	rs12782948	chr10:35450607	G/A	cg03585969	chr10:35415529	CREM	0.38	4.89	0.31	1.88e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs3784262	1.000	rs12903474	chr15:58276747	A/C	cg12031962	chr15:58353849	ALDH1A2	0.35	5.1	0.32	7.18e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg13175981	chr1:150552382	MCL1	-0.54	-6.9	-0.41	4.97e-11	Tonsillectomy;
SARC	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg06074448	chr4:187884817	NA	-0.46	-6.5	-0.39	4.74e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6674176	0.932	rs4660761	chr1:44440146	G/A	cg12908607	chr1:44402522	ARTN	-0.37	-5.93	-0.36	1.08e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs4509693	0.941	rs7914169	chr10:102495725	A/G	cg15234845	chr10:102496500	NA	0.32	4.96	0.31	1.37e-6	Alzheimer's disease;
SARC	cis	rs3733585	0.664	rs17185870	chr4:9958214	C/A	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.29	-0.33	2.79e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg17376030	chr22:41985996	PMM1	0.77	9.73	0.54	5.3e-19	Vitiligo;
SARC	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg25072359	chr17:41440525	NA	0.5	5.94	0.36	1.04e-8	Menopause (age at onset);
SARC	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9291683	0.597	rs11723016	chr4:10126189	A/G	cg00071950	chr4:10020882	SLC2A9	-0.32	-5.06	-0.31	8.52e-7	Bone mineral density;
SARC	cis	rs6133127	0.671	rs6133130	chr20:4489042	C/A	cg14606382	chr20:4573199	NA	-0.44	-4.83	-0.3	2.49e-6	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
SARC	cis	rs6732160	0.845	rs9989755	chr2:73361948	T/C	cg01422370	chr2:73384389	NA	0.33	5.34	0.33	2.26e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2624839	0.704	rs13067082	chr3:50221715	A/G	cg14019146	chr3:50243930	SLC38A3	0.42	6.84	0.41	7e-11	Intelligence (multi-trait analysis);
SARC	cis	rs12681288	0.645	rs2600509	chr8:989022	C/G	cg15309053	chr8:964076	NA	-0.48	-7.85	-0.46	1.48e-13	Schizophrenia;
SARC	cis	rs6121246	0.567	rs6120937	chr20:30219721	C/T	cg21427119	chr20:30132790	HM13	-0.46	-5.05	-0.31	8.92e-7	Mean corpuscular hemoglobin;
SARC	cis	rs965469	0.948	rs6139079	chr20:3314374	C/T	cg25506879	chr20:3388711	C20orf194	0.5	5.05	0.31	8.86e-7	IFN-related cytopenia;
SARC	cis	rs6088580	0.524	rs6142210	chr20:33223012	C/T	cg24642439	chr20:33292090	TP53INP2	-0.55	-6.76	-0.4	1.1e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs9316337	0.933	rs3759472	chr13:21948988	C/T	cg21080246	chr13:22033151	ZDHHC20	0.38	4.74	0.3	3.76e-6	Schizophrenia;
SARC	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.75	10.74	0.58	4.15e-22	Personality dimensions;
SARC	cis	rs9304742	0.962	rs12461796	chr19:53455088	T/A	cg24044776	chr19:53454761	ZNF816A	-0.4	-5.6	-0.34	6.09e-8	Psoriasis;
SARC	cis	rs7666738	0.830	rs17484966	chr4:99014432	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7223966	1.000	rs2854219	chr17:61942682	C/T	cg00588841	chr17:61851480	DDX42;CCDC47	-0.61	-6.27	-0.38	1.73e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1564271	0.528	rs2209350	chr10:26987779	A/G	cg13837822	chr10:26931731	LOC731789	0.42	6.33	0.38	1.23e-9	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
SARC	cis	rs7011049	0.778	rs12375305	chr8:53869051	C/T	cg26025543	chr8:53854495	NA	0.55	4.96	0.31	1.33e-6	Systolic blood pressure;
SARC	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg00933542	chr6:150070202	PCMT1	0.32	5.48	0.34	1.12e-7	Lung cancer;
SARC	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg10207240	chr12:122356781	WDR66	-0.29	-4.83	-0.3	2.46e-6	Mean corpuscular volume;
SARC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg09436375	chr6:42928200	GNMT	-0.35	-5.25	-0.33	3.41e-7	Alzheimer's disease in APOE e4+ carriers;
SARC	trans	rs61931739	0.517	rs7960878	chr12:34055645	C/A	cg26384229	chr12:38710491	ALG10B	0.86	12.43	0.63	1.55e-27	Morning vs. evening chronotype;
SARC	cis	rs6840360	0.571	rs11099823	chr4:152510565	T/G	cg22705602	chr4:152727874	NA	-0.41	-6.47	-0.39	5.71e-10	Intelligence (multi-trait analysis);
SARC	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg15921436	chr17:44337874	NA	0.49	4.92	0.31	1.61e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs981844	0.961	rs56288418	chr4:154668228	C/A	cg14289246	chr4:154710475	SFRP2	0.57	6.43	0.39	7.08e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs138249	0.527	rs138251	chr22:50570852	A/G	cg16473166	chr22:50639996	SELO	0.47	5.22	0.32	3.91e-7	Gestational age at birth in labor-initiated deliveries (child effect);
SARC	cis	rs7712401	0.601	rs35157167	chr5:122318201	G/C	cg19412675	chr5:122181750	SNX24	-0.43	-5.47	-0.34	1.15e-7	Mean platelet volume;
SARC	cis	rs6840360	0.615	rs4696095	chr4:152467243	A/G	cg22705602	chr4:152727874	NA	-0.42	-6.55	-0.39	3.67e-10	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg11062466	chr8:58055876	NA	0.54	5.56	0.34	7.55e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg05861140	chr6:150128134	PCMT1	-0.44	-5.72	-0.35	3.18e-8	Lung cancer;
SARC	cis	rs2228479	0.850	rs79244293	chr16:89896220	T/C	cg06558623	chr16:89946397	TCF25	0.91	6.5	0.39	4.78e-10	Skin colour saturation;
SARC	cis	rs12971120	0.504	rs11665154	chr18:72147006	A/C	cg26446133	chr18:72167187	CNDP2	-0.43	-7.88	-0.46	1.22e-13	Refractive error;
SARC	cis	rs6121246	0.567	rs7266471	chr20:30220599	T/A	cg21427119	chr20:30132790	HM13	-0.46	-5.11	-0.32	6.71e-7	Mean corpuscular hemoglobin;
SARC	cis	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.04	-0.37	6.02e-9	Mood instability;
SARC	cis	rs4319547	0.656	rs7975747	chr12:122816995	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.59	-6.78	-0.41	9.72e-11	Body mass index;
SARC	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg12000995	chr2:27665139	KRTCAP3	-0.31	-4.79	-0.3	2.9e-6	Total body bone mineral density;
SARC	trans	rs61931739	1.000	rs11502817	chr12:34010676	T/C	cg26384229	chr12:38710491	ALG10B	-0.57	-7.13	-0.42	1.23e-11	Morning vs. evening chronotype;
SARC	cis	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg20965017	chr5:231967	SDHA	-0.55	-5.26	-0.33	3.23e-7	Breast cancer;
SARC	cis	rs7927592	0.871	rs113020558	chr11:68296832	G/A	cg01657329	chr11:68192670	LRP5	-0.41	-5.0	-0.31	1.15e-6	Total body bone mineral density;
SARC	cis	rs1355223	1.000	rs1355223	chr11:34764479	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.13	-0.37	3.69e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs7666738	0.830	rs6846229	chr4:99016546	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.9	0.5	1.65e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6540556	0.954	rs2076150	chr1:209933540	A/G	cg23920097	chr1:209922102	NA	-0.63	-7.33	-0.43	3.65e-12	Red blood cell count;
SARC	cis	rs2841277	0.771	rs2819469	chr14:105394859	G/A	cg19901468	chr14:105411992	AHNAK2	0.76	10.86	0.58	1.68e-22	Rheumatoid arthritis;
SARC	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg11494091	chr17:61959527	GH2	0.36	5.14	0.32	5.83e-7	Height;
SARC	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg25036284	chr2:26402008	FAM59B	0.46	5.7	0.35	3.59e-8	Gut microbiome composition (summer);
SARC	cis	rs11098699	0.821	rs11942230	chr4:124199453	A/G	cg09941581	chr4:124220074	SPATA5	0.39	4.81	0.3	2.68e-6	Mosquito bite size;
SARC	cis	rs765787	0.530	rs12439643	chr15:45529767	A/G	cg24006582	chr15:45444508	DUOX1	0.46	5.79	0.35	2.28e-8	Uric acid levels;
SARC	cis	rs9462027	0.606	rs7341253	chr6:34726838	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.85	-0.36	1.69e-8	Systemic lupus erythematosus;
SARC	cis	rs11764590	0.671	rs3800872	chr7:2110272	C/G	cg21782813	chr7:2030301	MAD1L1	-0.38	-5.09	-0.32	7.51e-7	Neuroticism;
SARC	cis	rs11785693	0.862	rs6994323	chr8:4996786	T/A	cg26367366	chr8:4980734	NA	0.75	6.64	0.4	2.24e-10	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg03264133	chr6:25882463	NA	-0.52	-6.81	-0.41	8.04e-11	Intelligence (multi-trait analysis);
SARC	cis	rs7633770	0.710	rs34820891	chr3:46698059	A/G	cg11219411	chr3:46661640	NA	-0.41	-6.47	-0.39	5.77e-10	Coronary artery disease;
SARC	cis	rs11785400	0.793	rs10956992	chr8:143736235	A/C	cg24634471	chr8:143751801	JRK	0.61	8.06	0.47	3.99e-14	Schizophrenia;
SARC	cis	rs1865760	0.593	rs9295678	chr6:25937033	G/A	cg16482183	chr6:26056742	HIST1H1C	0.46	5.7	0.35	3.67e-8	Height;
SARC	cis	rs2635047	0.638	rs2668762	chr18:44667871	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	5.55	0.34	7.61e-8	Educational attainment;
SARC	cis	rs7208859	0.623	rs9915546	chr17:29132144	G/T	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg11494091	chr17:61959527	GH2	0.54	8.06	0.47	4.03e-14	Prudent dietary pattern;
SARC	cis	rs9816226	0.591	rs75135487	chr3:185805294	C/G	cg00760338	chr3:185826511	ETV5	-0.8	-7.91	-0.46	1.06e-13	Obesity;Body mass index;
SARC	cis	rs17095355	1.000	rs72828232	chr10:111725298	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.47	-4.82	-0.3	2.54e-6	Biliary atresia;
SARC	cis	rs941408	0.928	rs2741991	chr19:2802092	T/C	cg06609049	chr19:2785107	THOP1	0.78	10.63	0.57	9.2e-22	Total cholesterol levels;
SARC	cis	rs8114671	0.562	rs34837802	chr20:33424908	C/G	cg07148914	chr20:33460835	GGT7	0.43	5.24	0.32	3.6e-7	Height;
SARC	cis	rs11690935	0.851	rs7581072	chr2:172859849	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.95	-14.2	-0.68	2.1e-33	Schizophrenia;
SARC	cis	rs1941023	0.584	rs10750937	chr11:60172087	C/T	cg08716584	chr11:60157161	MS4A7	-0.41	-6.65	-0.4	2.09e-10	Congenital heart disease (maternal effect);
SARC	cis	rs1124376	1.000	rs73038113	chr3:20139025	T/A	cg05072819	chr3:20081367	KAT2B	0.5	4.72	0.3	4.16e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs9325144	0.555	rs2387847	chr12:38687434	C/T	cg26384229	chr12:38710491	ALG10B	0.59	7.85	0.46	1.51e-13	Morning vs. evening chronotype;
SARC	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg18252515	chr7:66147081	NA	1.35	12.11	0.62	1.7e-26	Diabetic kidney disease;
SARC	cis	rs4595586	0.525	rs17467376	chr12:39377551	T/G	cg26384229	chr12:38710491	ALG10B	0.52	6.21	0.38	2.4e-9	Morning vs. evening chronotype;
SARC	cis	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.75	10.42	0.56	4.13e-21	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs6545883	0.965	rs12713439	chr2:61752154	G/A	cg15711740	chr2:61764176	XPO1	-0.44	-5.43	-0.34	1.43e-7	Tuberculosis;
SARC	cis	rs703842	0.616	rs4760171	chr12:58225904	A/G	cg00677455	chr12:58241039	CTDSP2	0.58	7.8	0.46	2.07e-13	Multiple sclerosis;
SARC	cis	rs41271473	0.519	rs9660783	chr1:228886880	C/T	cg10167378	chr1:228756711	NA	0.43	5.42	0.33	1.47e-7	Chronic lymphocytic leukemia;
SARC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg07167872	chr1:205819463	PM20D1	0.75	11.75	0.61	2.35e-25	Menarche (age at onset);
SARC	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg05313129	chr8:58192883	C8orf71	-0.51	-4.94	-0.31	1.49e-6	Developmental language disorder (linguistic errors);
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg19051815	chr11:64949046	CAPN1	0.63	6.54	0.39	3.91e-10	Lung cancer in ever smokers;
SARC	cis	rs6456156	0.875	rs55802221	chr6:167517320	G/A	cg07741184	chr6:167504864	NA	-0.35	-6.6	-0.4	2.69e-10	Primary biliary cholangitis;
SARC	cis	rs9911578	1.000	rs172565	chr17:56808996	A/T	cg12560992	chr17:57184187	TRIM37	0.83	11.23	0.59	1.1e-23	Intelligence (multi-trait analysis);
SARC	cis	rs2153535	0.580	rs6597334	chr6:8504779	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	7.31	0.43	4.22e-12	Motion sickness;
SARC	cis	rs10463554	0.963	rs67068617	chr5:102375681	C/G	cg23492399	chr5:102201601	PAM	-0.53	-5.81	-0.36	2.09e-8	Parkinson's disease;
SARC	cis	rs1497406	0.744	rs12057175	chr1:16508375	A/G	cg20430773	chr1:16534157	ARHGEF19	0.53	7.96	0.46	7.62e-14	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1215050	0.744	rs966380	chr4:98435389	C/T	cg05340658	chr4:99064831	C4orf37	0.45	5.65	0.35	4.64e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs35146811	0.844	rs10281368	chr7:99655897	A/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.4	4.94	0.31	1.5e-6	Coronary artery disease;
SARC	cis	rs11098499	0.754	rs7689729	chr4:120256192	A/G	cg09307838	chr4:120376055	NA	0.81	11.03	0.59	4.84e-23	Corneal astigmatism;
SARC	cis	rs3796352	0.881	rs35385050	chr3:52997945	C/A	cg27565382	chr3:53032988	SFMBT1	0.95	6.34	0.38	1.17e-9	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg26681399	chr22:41777847	TEF	-0.42	-4.72	-0.3	4.08e-6	Vitiligo;
SARC	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg23262073	chr20:60523788	NA	-0.38	-5.12	-0.32	6.29e-7	Body mass index;
SARC	cis	rs12594515	1.000	rs8032361	chr15:45988553	T/C	cg14863074	chr15:45997064	NA	0.35	5.41	0.33	1.54e-7	Waist circumference;Weight;
SARC	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg09263875	chr16:632152	PIGQ	0.55	8.45	0.48	3.09e-15	Height;
SARC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.03	0.37	6.27e-9	Prudent dietary pattern;
SARC	cis	rs11719291	0.833	rs73080361	chr3:48832146	G/A	cg07636037	chr3:49044803	WDR6	-0.7	-5.5	-0.34	9.76e-8	Cognitive function;
SARC	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg06212747	chr3:49208901	KLHDC8B	0.66	8.8	0.5	3.19e-16	Parkinson's disease;
SARC	cis	rs763121	0.853	rs3747174	chr22:39069181	T/C	cg21395723	chr22:39101663	GTPBP1	0.54	6.14	0.37	3.53e-9	Menopause (age at onset);
SARC	cis	rs7582720	1.000	rs72936873	chr2:203791333	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs1008375	1.000	rs4698199	chr4:17656738	G/C	cg27347728	chr4:17578864	LAP3	0.47	5.88	0.36	1.42e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2197308	0.765	rs11182900	chr12:37934009	C/T	cg13010199	chr12:38710504	ALG10B	0.8	11.14	0.59	2.24e-23	Morning vs. evening chronotype;
SARC	cis	rs7615952	0.932	rs9841157	chr3:125635655	C/A	cg05084668	chr3:125655381	ALG1L	-0.66	-6.41	-0.39	8.14e-10	Blood pressure (smoking interaction);
SARC	cis	rs7829975	0.511	rs1401390	chr8:8136410	C/T	cg06636001	chr8:8085503	FLJ10661	0.76	10.71	0.57	5.18e-22	Mood instability;
SARC	cis	rs11098499	0.615	rs28551750	chr4:120264901	C/T	cg09307838	chr4:120376055	NA	0.75	10.43	0.56	3.87e-21	Corneal astigmatism;
SARC	cis	rs798554	0.679	rs7807978	chr7:2814635	C/T	cg13628971	chr7:2884303	GNA12	0.43	5.51	0.34	9.43e-8	Height;
SARC	cis	rs9486715	1.000	rs6902835	chr6:97063005	C/G	cg06623918	chr6:96969491	KIAA0776	-0.8	-11.05	-0.59	4.33e-23	Headache;
SARC	cis	rs11997175	0.545	rs4428637	chr8:33666944	T/G	ch.8.33884649F	chr8:33765107	NA	0.49	6.17	0.37	2.95e-9	Body mass index;
SARC	cis	rs2439831	0.850	rs3736180	chr15:44106624	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	7.66	0.45	4.94e-13	Lung cancer in ever smokers;
SARC	cis	rs61989804	0.826	rs1383595	chr14:65710211	C/T	cg15999311	chr14:65749247	NA	0.52	5.01	0.31	1.09e-6	Midgestational circulating levels of PCBs (fetal genetic effect);
SARC	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg00933542	chr6:150070202	PCMT1	0.3	5.1	0.32	7.1e-7	Lung cancer;
SARC	cis	rs1801251	1.000	rs36007169	chr2:233621834	A/G	cg25237894	chr2:233734115	C2orf82	0.39	5.05	0.31	9.07e-7	Coronary artery disease;
SARC	cis	rs612683	0.524	rs11166456	chr1:100925633	C/T	cg06223162	chr1:101003688	GPR88	0.26	4.88	0.3	1.99e-6	Breast cancer;
SARC	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg21144161	chr5:423903	AHRR	0.31	4.87	0.3	2.05e-6	Cystic fibrosis severity;
SARC	cis	rs7171869	1	rs7171869	chr15:78900909	A/G	cg24631222	chr15:78858424	CHRNA5	-0.72	-9.76	-0.54	4.35e-19	Post bronchodilator FEV1;
SARC	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg00800038	chr16:89945340	TCF25	-0.66	-5.63	-0.35	5.07e-8	Skin colour saturation;
SARC	trans	rs17685	0.753	rs2302435	chr7:75676987	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.6	-7.57	-0.44	8.55e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs10782582	0.593	rs12130832	chr1:76234294	T/C	cg10523679	chr1:76189770	ACADM	-0.42	-5.12	-0.32	6.52e-7	Daytime sleep phenotypes;
SARC	cis	rs4595586	0.545	rs11609541	chr12:39378331	T/C	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	cis	rs9398803	0.651	rs4339479	chr6:126936953	G/A	cg20229609	chr6:126660872	C6orf173	0.37	5.28	0.33	2.99e-7	Male-pattern baldness;
SARC	cis	rs7264396	0.563	rs2425089	chr20:34304036	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	5.7	0.35	3.66e-8	Total cholesterol levels;
SARC	cis	rs2933343	0.649	rs2638845	chr3:128587369	A/G	cg24203234	chr3:128598194	ACAD9	0.63	8.15	0.47	2.18e-14	IgG glycosylation;
SARC	cis	rs2594989	0.779	rs2447603	chr3:11590261	T/C	cg00170343	chr3:11313890	ATG7	-0.55	-6.02	-0.37	6.83e-9	Circulating chemerin levels;
SARC	cis	rs1152591	0.562	rs872227	chr14:64656165	T/C	cg23250157	chr14:64679961	SYNE2	0.42	5.89	0.36	1.32e-8	Atrial fibrillation;
SARC	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg17376030	chr22:41985996	PMM1	0.62	7.43	0.44	2.06e-12	Vitiligo;
SARC	cis	rs4319547	0.661	rs10846830	chr12:122897220	C/G	cg23029597	chr12:123009494	RSRC2	-0.42	-5.21	-0.32	4.18e-7	Body mass index;
SARC	cis	rs2304069	0.909	rs30831	chr5:149359053	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.83	-8.45	-0.48	3.16e-15	HIV-1 control;
SARC	cis	rs8141529	0.748	rs5762882	chr22:29290680	C/A	cg15103426	chr22:29168792	CCDC117	0.63	8.2	0.47	1.63e-14	Lymphocyte counts;
SARC	cis	rs57221529	0.825	rs72703051	chr5:582997	G/A	cg07777115	chr5:623756	CEP72	-0.6	-4.96	-0.31	1.33e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs9300255	0.602	rs2695479	chr12:123689386	T/C	cg05973401	chr12:123451056	ABCB9	0.55	5.22	0.32	3.89e-7	Neutrophil percentage of white cells;
SARC	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.5	6.37	0.38	1.02e-9	Personality dimensions;
SARC	cis	rs36051895	0.632	rs117896567	chr9:5141281	C/G	cg02405213	chr9:5042618	JAK2	-0.43	-5.14	-0.32	5.83e-7	Pediatric autoimmune diseases;
SARC	cis	rs3126085	0.935	rs12729662	chr1:152185750	G/A	cg09127314	chr1:152161683	NA	-0.42	-4.72	-0.3	4.07e-6	Atopic dermatitis;
SARC	cis	rs13161895	1.000	rs12654148	chr5:179438920	T/A	cg06664874	chr5:179499304	RNF130	-0.49	-4.78	-0.3	3.14e-6	LDL cholesterol;
SARC	cis	rs6580649	0.883	rs4760621	chr12:48561262	A/G	cg05342945	chr12:48394962	COL2A1	-0.51	-5.58	-0.34	6.59e-8	Lung cancer;
SARC	cis	rs72945132	0.678	rs12786421	chr11:70235314	G/C	cg05964544	chr11:70165517	PPFIA1	-0.66	-6.64	-0.4	2.14e-10	Coronary artery disease;
SARC	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg04944784	chr2:26401820	FAM59B	-0.48	-6.0	-0.37	7.54e-9	Gut microbiome composition (summer);
SARC	cis	rs7644634	0.688	rs3772521	chr3:105476761	A/G	cg23051926	chr3:105466016	CBLB	0.47	5.87	0.36	1.5e-8	Itch intensity from mosquito bite;
SARC	trans	rs11098499	0.779	rs7674500	chr4:120303593	C/T	cg25214090	chr10:38739885	LOC399744	0.55	7.14	0.42	1.15e-11	Corneal astigmatism;
SARC	cis	rs981844	0.775	rs56101345	chr4:154764261	C/T	cg14289246	chr4:154710475	SFRP2	0.6	6.83	0.41	7.15e-11	Response to statins (LDL cholesterol change);
SARC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.88	9.81	0.54	3.11e-19	Platelet count;
SARC	cis	rs876084	0.505	rs9969404	chr8:121107102	A/C	cg06265175	chr8:121136014	COL14A1	0.58	7.56	0.44	9.46e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs2033732	0.706	rs6473526	chr8:85070305	T/C	cg05716166	chr8:85095498	RALYL	0.47	5.64	0.35	4.83e-8	Body mass index;
SARC	cis	rs356220	0.532	rs356179	chr4:90628439	C/G	cg06632027	chr4:90757378	SNCA	0.4	4.99	0.31	1.16e-6	Parkinson's disease;
SARC	cis	rs7312933	0.618	rs12366848	chr12:42682215	A/G	cg19980929	chr12:42632907	YAF2	0.45	6.52	0.39	4.24e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs992157	0.735	rs2271541	chr2:219082119	G/T	cg00012203	chr2:219082015	ARPC2	0.85	13.89	0.67	2.35e-32	Colorectal cancer;
SARC	cis	rs2952156	0.883	rs2941505	chr17:37832704	A/G	cg07936489	chr17:37558343	FBXL20	-0.39	-5.17	-0.32	5.02e-7	Asthma;
SARC	cis	rs10908458	0.584	rs10908455	chr1:155067283	C/T	cg22049894	chr1:155113146	DPM3	-0.39	-4.9	-0.31	1.83e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg06221963	chr1:154839813	KCNN3	-0.48	-7.47	-0.44	1.58e-12	Prostate cancer;
SARC	cis	rs459571	0.839	rs2519831	chr9:136886257	T/A	cg13789015	chr9:136890014	NCRNA00094	0.64	9.0	0.51	8.35e-17	Platelet distribution width;
SARC	cis	rs7615952	0.611	rs2971298	chr3:125602713	G/A	cg05084668	chr3:125655381	ALG1L	-0.79	-7.71	-0.45	3.69e-13	Blood pressure (smoking interaction);
SARC	cis	rs8014131	0.689	rs1955434	chr14:85987163	A/G	cg10406690	chr14:85995726	FLRT2	0.39	5.02	0.31	1.03e-6	Menarche (age at onset);
SARC	cis	rs7667	0.812	rs12045440	chr1:19765518	G/T	cg15311933	chr1:19638897	PQLC2;AKR7A2	0.41	4.78	0.3	3.08e-6	Crohn's disease and psoriasis;
SARC	cis	rs7727544	0.507	rs9791170	chr5:131569627	A/G	cg18758796	chr5:131593413	PDLIM4	0.4	5.34	0.33	2.19e-7	Blood metabolite levels;
SARC	cis	rs7659604	0.846	rs35986491	chr4:122664528	A/T	cg20573242	chr4:122745356	CCNA2	0.44	5.8	0.36	2.16e-8	Type 2 diabetes;
SARC	cis	rs1707322	0.716	rs6694889	chr1:46101806	A/C	cg06784218	chr1:46089804	CCDC17	0.36	6.19	0.38	2.64e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9300255	0.539	rs1969355	chr12:123742061	G/A	cg05973401	chr12:123451056	ABCB9	0.48	5.28	0.33	2.9e-7	Neutrophil percentage of white cells;
SARC	cis	rs2250402	1.000	rs2250402	chr15:40322552	G/T	cg10636054	chr15:40330586	SRP14	1.0	7.04	0.42	2.11e-11	Corneal curvature;
SARC	cis	rs7666738	0.791	rs13127542	chr4:98949159	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6759839	0.591	rs4290656	chr2:16693471	C/T	cg09580478	chr2:16689509	NA	0.43	5.8	0.35	2.2e-8	Mean platelet volume;
SARC	cis	rs9436116	1	rs9436116	chr1:150454724	G/T	cg09579323	chr1:150459698	TARS2	0.44	5.57	0.34	7.02e-8	Morning vs. evening chronotype;
SARC	cis	rs838721	0.574	rs11679046	chr2:234258101	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.37	4.84	0.3	2.41e-6	Total body bone mineral density;
SARC	cis	rs7917772	0.636	rs7069489	chr10:104525371	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	6.03	0.37	6.29e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs16854884	0.657	rs35193361	chr3:143716420	A/G	cg06585982	chr3:143692056	C3orf58	0.65	8.54	0.49	1.75e-15	Economic and political preferences (feminism/equality);
SARC	cis	rs9916302	0.904	rs8066704	chr17:37477218	C/T	cg07936489	chr17:37558343	FBXL20	0.69	9.16	0.51	2.69e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs1008375	0.898	rs61047804	chr4:17593965	G/A	cg02297831	chr4:17616191	MED28	0.51	6.39	0.39	8.91e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs362296	0.597	rs3129320	chr4:3265130	G/C	cg06533319	chr4:3265114	C4orf44	0.31	5.31	0.33	2.53e-7	Parental longevity (mother's age at death);
SARC	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg18252515	chr7:66147081	NA	-0.65	-6.9	-0.41	4.73e-11	Aortic root size;
SARC	cis	rs6871536	1.000	rs10463894	chr5:131933907	T/C	cg11797159	chr5:131991491	NA	0.38	4.9	0.31	1.82e-6	Asthma (childhood onset);
SARC	cis	rs1163251	0.902	rs639216	chr1:120217414	C/T	cg19096424	chr1:120255104	PHGDH	0.53	6.2	0.38	2.58e-9	Blood metabolite levels;
SARC	cis	rs2522056	1.000	rs10900807	chr5:131757480	G/C	cg24060327	chr5:131705240	SLC22A5	0.57	5.78	0.35	2.39e-8	Lymphocyte counts;Fibrinogen;
SARC	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg03709012	chr19:19516395	GATAD2A	1.04	18.51	0.77	1.17e-47	Tonsillectomy;
SARC	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg16405210	chr4:1374714	KIAA1530	-0.47	-5.93	-0.36	1.09e-8	Longevity;
SARC	cis	rs9296092	0.538	rs80012910	chr6:33519542	G/A	cg13560919	chr6:33536144	NA	-0.5	-6.31	-0.38	1.38e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.63	-0.4	2.34e-10	Total body bone mineral density;
SARC	cis	rs13336428	0.730	rs28653458	chr16:1525850	T/C	cg08008072	chr16:1524255	CLCN7	-0.5	-8.59	-0.49	1.26e-15	Bone mineral density;
SARC	cis	rs9715521	0.815	rs7441547	chr4:59838120	A/G	cg11281224	chr4:60001000	NA	-0.41	-5.22	-0.32	3.96e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs3812831	0.662	rs418027	chr13:114929344	A/C	cg06611532	chr13:114900021	NA	0.34	5.75	0.35	2.77e-8	Schizophrenia;
SARC	cis	rs1395	0.778	rs11126918	chr2:27438710	G/A	cg21747090	chr2:27597821	SNX17	-0.49	-5.87	-0.36	1.5e-8	Blood metabolite levels;
SARC	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg16049864	chr8:95962084	TP53INP1	-0.48	-7.77	-0.45	2.51e-13	Type 2 diabetes;
SARC	trans	rs747334	0.846	rs7897603	chr10:92708759	C/G	cg02555585	chr20:42090853	SFRS6	-0.47	-6.42	-0.39	7.68e-10	Fibroblast growth factor basic levels;
SARC	cis	rs11190604	0.725	rs9420796	chr10:102323092	G/C	cg07080220	chr10:102295463	HIF1AN	0.8	8.93	0.5	1.31e-16	Palmitoleic acid (16:1n-7) levels;
SARC	trans	rs2667100	0.614	rs11733314	chr4:143001803	C/G	cg03726209	chr4:186509045	SORBS2	0.66	6.24	0.38	2.09e-9	Amyotrophic lateral sclerosis (sporadic);
SARC	trans	rs61931739	0.500	rs6488222	chr12:34526289	G/A	cg26384229	chr12:38710491	ALG10B	0.91	13.78	0.67	5.4e-32	Morning vs. evening chronotype;
SARC	cis	rs7044106	0.791	rs10985009	chr9:123493039	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.54	-6.91	-0.41	4.65e-11	Hip circumference adjusted for BMI;
SARC	cis	rs1451375	0.617	rs7790758	chr7:50561544	G/A	cg18232548	chr7:50535776	DDC	-0.46	-4.81	-0.3	2.77e-6	Malaria;
SARC	cis	rs8067545	0.641	rs850623	chr17:19837130	C/T	cg04132472	chr17:19861366	AKAP10	0.38	5.08	0.32	7.88e-7	Schizophrenia;
SARC	cis	rs72781680	0.898	rs72780125	chr2:24000145	T/C	cg06627628	chr2:24431161	ITSN2	-0.71	-6.5	-0.39	4.95e-10	Lymphocyte counts;
SARC	cis	rs1545257	0.537	rs2249387	chr2:24649801	C/G	cg06627628	chr2:24431161	ITSN2	0.55	7.24	0.43	6.65e-12	Sjögren's syndrome;
SARC	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg12419862	chr22:24373484	LOC391322	-0.74	-9.42	-0.53	4.49e-18	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg25036284	chr2:26402008	FAM59B	0.43	5.42	0.33	1.52e-7	Gut microbiome composition (summer);
SARC	cis	rs1008375	0.902	rs12503164	chr4:17656107	C/T	cg02297831	chr4:17616191	MED28	0.49	6.31	0.38	1.39e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2845885	1.000	rs11231698	chr11:63877163	C/T	cg24431193	chr11:63883947	FLRT1;MACROD1	0.76	5.0	0.31	1.11e-6	Body mass index;
SARC	cis	rs11792861	0.926	rs56899598	chr9:111867271	A/G	cg13535736	chr9:111863775	C9orf5	-0.4	-4.89	-0.31	1.87e-6	Menarche (age at onset);
SARC	cis	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg07777115	chr5:623756	CEP72	-0.65	-5.82	-0.36	1.89e-8	Obesity-related traits;
SARC	cis	rs554111	0.660	rs541464	chr1:21067095	C/T	cg08890418	chr1:21044141	KIF17	0.45	6.35	0.38	1.13e-9	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs72829446	0.530	rs66616380	chr17:7380188	C/A	cg07168214	chr17:7380112	ZBTB4	-0.4	-4.71	-0.3	4.17e-6	Androgen levels;
SARC	cis	rs12155623	0.619	rs17641604	chr8:49842784	C/T	cg01449144	chr8:49782592	NA	0.3	5.08	0.32	7.81e-7	Sudden cardiac arrest;
SARC	cis	rs1966248	0.543	rs12203224	chr6:134101494	G/T	cg25632230	chr6:134101081	NA	-0.53	-7.04	-0.42	2.09e-11	Coronary artery disease;
SARC	cis	rs7178909	0.831	rs1910587	chr15:90440487	A/C	cg19708238	chr15:90437601	AP3S2	0.64	8.66	0.49	8.21e-16	Common traits (Other);
SARC	cis	rs9818758	0.556	rs9813813	chr3:49207093	T/A	cg01304814	chr3:48885189	PRKAR2A	0.65	5.43	0.34	1.39e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs9916302	0.706	rs9646419	chr17:37597185	A/G	cg00129232	chr17:37814104	STARD3	-0.55	-5.83	-0.36	1.82e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg05368731	chr17:41323189	NBR1	0.66	7.87	0.46	1.32e-13	Menopause (age at onset);
SARC	cis	rs4713118	0.513	rs156738	chr6:28014025	G/C	cg26335602	chr6:28129616	ZNF389	0.44	4.96	0.31	1.34e-6	Parkinson's disease;
SARC	cis	rs7264396	0.690	rs17093156	chr20:34438583	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.51	5.08	0.32	7.84e-7	Total cholesterol levels;
SARC	cis	rs7824557	0.606	rs1435277	chr8:11196970	C/T	cg12395012	chr8:11607386	GATA4	-0.29	-4.73	-0.3	3.87e-6	Retinal vascular caliber;
SARC	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg20887711	chr4:1340912	KIAA1530	0.53	6.46	0.39	5.96e-10	Longevity;
SARC	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg03647317	chr4:187891568	NA	-0.38	-5.31	-0.33	2.52e-7	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs208520	0.661	rs7740835	chr6:66865548	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-13.93	-0.67	1.73e-32	Exhaled nitric oxide output;
SARC	cis	rs6545883	0.931	rs778768	chr2:61790289	C/G	cg15711740	chr2:61764176	XPO1	-0.43	-5.33	-0.33	2.36e-7	Tuberculosis;
SARC	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg06634786	chr22:41940651	POLR3H	0.48	5.59	0.34	6.39e-8	Vitiligo;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg26051433	chr10:75001410	FAM149B1	0.45	6.3	0.38	1.49e-9	Thyroid stimulating hormone;
SARC	cis	rs11190604	1.000	rs2295774	chr10:102265847	A/C	cg07080220	chr10:102295463	HIF1AN	0.75	8.5	0.49	2.24e-15	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs72781680	0.611	rs72781699	chr2:24277709	G/A	cg06627628	chr2:24431161	ITSN2	-0.61	-6.21	-0.38	2.39e-9	Lymphocyte counts;
SARC	cis	rs898097	0.812	rs8065641	chr17:80820259	A/G	cg05255149	chr17:80675120	FN3KRP	-0.39	-4.79	-0.3	2.95e-6	Breast cancer;
SARC	cis	rs6963495	0.651	rs3892298	chr7:105152187	A/G	cg13798780	chr7:105162888	PUS7	0.58	5.2	0.32	4.42e-7	Bipolar disorder (body mass index interaction);
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg05823146	chr10:99496860	ZFYVE27	0.5	6.32	0.38	1.31e-9	Lung adenocarcinoma;
SARC	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg19223190	chr17:80058835	NA	0.51	7.26	0.43	5.72e-12	Life satisfaction;
SARC	trans	rs7824557	0.583	rs6601585	chr8:11233659	A/G	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.4	-0.48	4.4e-15	Retinal vascular caliber;
SARC	cis	rs2011503	1.000	rs74950305	chr19:19639448	C/T	cg03709012	chr19:19516395	GATAD2A	0.6	5.29	0.33	2.8e-7	Bipolar disorder;
SARC	cis	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg21144161	chr5:423903	AHRR	0.31	4.84	0.3	2.39e-6	Cystic fibrosis severity;
SARC	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg25427524	chr10:38739819	LOC399744	-0.61	-9.33	-0.52	8.66e-18	Extrinsic epigenetic age acceleration;
SARC	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.37	5.06	0.31	8.53e-7	Total body bone mineral density;
SARC	cis	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg22496380	chr5:211416	CCDC127	-0.88	-9.35	-0.52	7.72e-18	Breast cancer;
SARC	cis	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg22857025	chr5:266934	NA	-1.06	-11.8	-0.61	1.74e-25	Breast cancer;
SARC	cis	rs1707322	0.686	rs2991977	chr1:46053683	G/A	cg06784218	chr1:46089804	CCDC17	-0.4	-6.98	-0.42	3.11e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs10751667	0.600	rs7950955	chr11:1011490	G/A	cg20946044	chr11:1010712	AP2A2	-0.42	-6.04	-0.37	5.99e-9	Alzheimer's disease (late onset);
SARC	cis	rs1005277	0.540	rs289638	chr10:37923731	G/A	cg00409905	chr10:38381863	ZNF37A	-0.53	-7.32	-0.43	4.05e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs4588572	0.643	rs1560197	chr5:77768302	T/C	cg11547950	chr5:77652471	NA	-0.41	-5.03	-0.31	9.86e-7	Triglycerides;
SARC	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.43	0.39	7.26e-10	Height;
SARC	cis	rs854765	0.583	rs8070128	chr17:17804725	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.64	-9.78	-0.54	3.71e-19	Total body bone mineral density;
SARC	cis	rs6912958	0.712	rs4587138	chr6:88356915	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.54	-0.34	8.09e-8	Monocyte percentage of white cells;
SARC	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg11062466	chr8:58055876	NA	0.61	5.75	0.35	2.74e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6429082	0.521	rs291390	chr1:235649678	T/C	cg26050004	chr1:235667680	B3GALNT2	0.79	12.76	0.64	1.25e-28	Adiposity;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg26347379	chr8:99956585	OSR2	0.79	6.39	0.39	8.91e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9894429	0.646	rs12948797	chr17:79617384	G/A	cg10661904	chr17:79619235	PDE6G	-0.45	-6.21	-0.38	2.4e-9	Eye color traits;
SARC	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg21782813	chr7:2030301	MAD1L1	-0.36	-5.66	-0.35	4.36e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs2153535	0.580	rs1115079	chr6:8449615	G/C	cg21535247	chr6:8435926	SLC35B3	0.55	6.91	0.41	4.48e-11	Motion sickness;
SARC	cis	rs7395581	0.959	rs7120118	chr11:47286290	T/C	cg25783544	chr11:47291846	MADD	0.48	4.99	0.31	1.2e-6	HDL cholesterol;
SARC	cis	rs9815354	0.812	rs17218264	chr3:41975847	C/T	cg03022575	chr3:42003672	ULK4	-0.72	-5.97	-0.36	8.99e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg16680214	chr1:154839983	KCNN3	-0.35	-5.66	-0.35	4.46e-8	Prostate cancer;
SARC	cis	rs3820928	1.000	rs6723774	chr2:227770592	C/T	cg05526886	chr2:227700861	RHBDD1	0.52	6.57	0.4	3.27e-10	Pulmonary function;
SARC	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg22920501	chr2:26401640	FAM59B	-0.55	-7.26	-0.43	5.77e-12	Gut microbiome composition (summer);
SARC	cis	rs2486288	0.656	rs1719232	chr15:45572072	A/G	cg19305227	chr15:45544335	SLC28A2	0.3	5.63	0.35	5.22e-8	Glomerular filtration rate;
SARC	cis	rs939574	1.000	rs2293078	chr2:220100683	C/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.63	4.98	0.31	1.22e-6	Platelet distribution width;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg24663683	chr5:39721720	NA	-0.55	-6.92	-0.41	4.32e-11	Height;
SARC	cis	rs7786808	0.615	rs4909209	chr7:158194329	C/T	cg01191920	chr7:158217561	PTPRN2	-0.32	-5.52	-0.34	9.11e-8	Obesity-related traits;
SARC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg26338869	chr17:61819248	STRADA	0.8	10.82	0.58	2.2e-22	Prudent dietary pattern;
SARC	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg05368731	chr17:41323189	NBR1	0.8	9.59	0.53	1.43e-18	Menopause (age at onset);
SARC	cis	rs4568518	0.869	rs12699943	chr7:18037780	G/A	cg00911873	chr7:18067463	PRPS1L1	-0.33	-4.72	-0.3	4.15e-6	Measles;
SARC	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg18252515	chr7:66147081	NA	0.52	5.57	0.34	6.9e-8	Aortic root size;
SARC	cis	rs6582630	0.560	rs12315134	chr12:38419857	T/A	cg26384229	chr12:38710491	ALG10B	-0.57	-7.05	-0.42	2.02e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2153535	0.580	rs9393021	chr6:8466123	A/G	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	cis	rs11881751	0.829	rs67614507	chr19:5022857	T/C	cg04571196	chr19:4910051	UHRF1	0.47	5.12	0.32	6.26e-7	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg18876405	chr7:65276391	NA	0.47	5.31	0.33	2.53e-7	Aortic root size;
SARC	cis	rs2980439	0.525	rs1850511	chr8:8170329	T/A	cg08975724	chr8:8085496	FLJ10661	0.52	6.64	0.4	2.23e-10	Neuroticism;
SARC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.3	-4.77	-0.3	3.24e-6	Total body bone mineral density;
SARC	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg13206674	chr6:150067644	NUP43	0.43	5.66	0.35	4.37e-8	Lung cancer;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg02755370	chr5:145587156	RBM27	0.45	6.52	0.39	4.43e-10	Thyroid stimulating hormone;
SARC	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg11987759	chr7:65425863	GUSB	0.56	7.53	0.44	1.08e-12	Aortic root size;
SARC	cis	rs6540556	0.723	rs12116437	chr1:209897027	G/A	cg23920097	chr1:209922102	NA	-0.53	-5.34	-0.33	2.17e-7	Red blood cell count;
SARC	cis	rs1044826	0.956	rs7374385	chr3:139118544	A/C	cg15131784	chr3:139108705	COPB2	0.45	5.23	0.32	3.68e-7	Obesity-related traits;
SARC	cis	rs9650657	0.504	rs6601566	chr8:11042974	G/T	cg21775007	chr8:11205619	TDH	-0.43	-5.42	-0.33	1.51e-7	Neuroticism;
SARC	cis	rs11599315	0.507	rs12220555	chr10:1341858	C/T	cg09624528	chr10:1369823	ADARB2	0.43	6.79	0.41	9.47e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs11190604	1.000	rs17746014	chr10:102315354	T/C	cg07080220	chr10:102295463	HIF1AN	0.81	8.98	0.51	9.37e-17	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs7582720	0.731	rs934287	chr2:203708307	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	-0.49	-5.37	-0.33	1.93e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg24324837	chr19:49891574	CCDC155	0.43	5.32	0.33	2.43e-7	Multiple sclerosis;
SARC	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-4.84	-0.3	2.41e-6	Total body bone mineral density;
SARC	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg03575189	chr17:44344142	NA	-0.53	-5.2	-0.32	4.37e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.72	7.44	0.44	1.87e-12	Platelet count;
SARC	cis	rs3771570	0.892	rs59715783	chr2:242366262	C/T	cg21155796	chr2:242212141	HDLBP	0.7	6.27	0.38	1.74e-9	Prostate cancer;
SARC	cis	rs7246657	0.525	rs1667357	chr19:37484352	T/C	cg14683738	chr19:37701593	ZNF585B	0.57	5.09	0.32	7.49e-7	Coronary artery calcification;
SARC	cis	rs1144333	0.655	rs1361487	chr1:76430471	A/C	cg03433033	chr1:76189801	ACADM	0.6	4.9	0.31	1.77e-6	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs9916302	0.851	rs7220650	chr17:37487168	A/G	cg07936489	chr17:37558343	FBXL20	0.7	9.5	0.53	2.75e-18	Glomerular filtration rate (creatinine);
SARC	cis	rs3126085	0.935	rs12729662	chr1:152185750	G/A	cg26876637	chr1:152193138	HRNR	-0.45	-5.04	-0.31	9.54e-7	Atopic dermatitis;
SARC	cis	rs11645898	0.935	rs8047881	chr16:72193906	A/G	cg14768367	chr16:72042858	DHODH	-0.55	-5.19	-0.32	4.57e-7	Blood protein levels;
SARC	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg12311346	chr5:56204834	C5orf35	-0.56	-6.0	-0.37	7.46e-9	Initial pursuit acceleration;
SARC	cis	rs3796352	1.000	rs35507120	chr3:53053924	C/T	cg15956490	chr3:53032818	SFMBT1	0.87	5.74	0.35	3.01e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs9457247	0.565	rs12193698	chr6:167512073	C/A	cg23791538	chr6:167370224	RNASET2	-0.5	-6.27	-0.38	1.72e-9	Crohn's disease;
SARC	cis	rs10463554	0.927	rs257315	chr5:102421429	C/A	cg23492399	chr5:102201601	PAM	-0.46	-5.07	-0.32	8.13e-7	Parkinson's disease;
SARC	cis	rs9392918	0.902	rs881891	chr6:7728428	C/G	cg23089261	chr6:7723385	NA	-0.42	-5.55	-0.34	7.78e-8	Height;
SARC	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg17971929	chr21:40555470	PSMG1	0.96	13.39	0.66	1.04e-30	Cognitive function;
SARC	cis	rs9902453	0.967	rs56326816	chr17:28492805	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	6.66	0.4	1.91e-10	Coffee consumption (cups per day);
SARC	cis	rs765787	0.530	rs1706834	chr15:45517854	G/A	cg25801113	chr15:45476975	SHF	0.29	4.81	0.3	2.67e-6	Uric acid levels;
SARC	cis	rs6580649	0.783	rs1635526	chr12:48396785	C/T	cg24011408	chr12:48396354	COL2A1	0.65	7.32	0.43	4.11e-12	Lung cancer;
SARC	cis	rs9325144	0.532	rs12812406	chr12:38719802	G/A	cg26384229	chr12:38710491	ALG10B	-0.64	-8.36	-0.48	5.61e-15	Morning vs. evening chronotype;
SARC	trans	rs3808502	0.526	rs7822958	chr8:11422442	C/A	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.55	-0.39	3.57e-10	Neuroticism;
SARC	cis	rs12291225	0.679	rs34238445	chr11:14315915	C/T	cg19336497	chr11:14380999	RRAS2	-0.41	-6.96	-0.41	3.49e-11	Sense of smell;
SARC	cis	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg22857025	chr5:266934	NA	-1.05	-11.61	-0.61	6.67e-25	Breast cancer;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg08829281	chr12:133264318	PXMP2;POLE	0.54	7.18	0.43	9.27e-12	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs7130144	0.541	rs7925596	chr11:130463610	C/G	cg26307797	chr11:130446613	NA	-0.66	-5.11	-0.32	6.62e-7	Urate levels in lean individuals;
SARC	cis	rs9815354	0.812	rs73079324	chr3:41864564	T/C	cg03022575	chr3:42003672	ULK4	0.56	5.29	0.33	2.81e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs787274	1.000	rs787276	chr9:115551891	T/C	cg13803584	chr9:115635662	SNX30	-0.77	-5.88	-0.36	1.38e-8	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg18252515	chr7:66147081	NA	0.56	6.01	0.37	7.21e-9	Aortic root size;
SARC	cis	rs62344088	0.590	rs7700533	chr5:180646	C/T	cg20965017	chr5:231967	SDHA	-0.73	-5.27	-0.33	3.15e-7	Asthma (childhood onset);
SARC	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs73195822	0.527	rs73194059	chr12:111221740	G/A	cg10860002	chr12:110842031	ANAPC7	0.58	5.05	0.31	8.84e-7	Itch intensity from mosquito bite;
SARC	cis	rs763121	0.719	rs138699	chr22:39129708	G/A	cg06022373	chr22:39101656	GTPBP1	0.87	10.95	0.58	8.93e-23	Menopause (age at onset);
SARC	cis	rs9300255	0.537	rs1618679	chr12:123650714	A/G	cg00376283	chr12:123451042	ABCB9	0.58	6.95	0.41	3.55e-11	Neutrophil percentage of white cells;
SARC	trans	rs1814175	0.645	rs12364337	chr11:49942580	A/T	cg15704280	chr7:45808275	SEPT13	-0.88	-14.0	-0.68	1.02e-32	Height;
SARC	cis	rs73198271	0.740	rs10105690	chr8:8649232	G/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-5.22	-0.32	3.95e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg17221315	chr6:27791827	HIST1H4J	-0.48	-5.33	-0.33	2.3e-7	Depression;
SARC	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg03352830	chr11:487213	PTDSS2	0.54	5.48	0.34	1.09e-7	Body mass index;
SARC	cis	rs1105228	0.625	rs57900131	chr6:165690125	C/T	cg20535254	chr6:165714960	C6orf118	-0.33	-4.73	-0.3	3.97e-6	Number of pregnancies;Number of children;
SARC	cis	rs7914558	0.966	rs943035	chr10:104839152	T/C	cg04362960	chr10:104952993	NT5C2	0.4	4.85	0.3	2.27e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs2439831	0.681	rs524527	chr15:43599116	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	-1.02	-11.29	-0.59	7.27e-24	Lung cancer in ever smokers;
SARC	cis	rs1559088	0.847	rs3760891	chr19:33599708	C/T	cg27124370	chr19:33622961	WDR88	0.44	5.87	0.36	1.49e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs7551222	0.614	rs7519417	chr1:204449952	T/C	cg20240347	chr1:204465584	NA	-0.29	-4.98	-0.31	1.23e-6	Schizophrenia;
SARC	cis	rs981844	0.743	rs17371461	chr4:154759220	C/T	cg14289246	chr4:154710475	SFRP2	0.61	6.94	0.41	3.92e-11	Response to statins (LDL cholesterol change);
SARC	cis	rs6952808	0.929	rs4721217	chr7:1973579	C/T	cg04267008	chr7:1944627	MAD1L1	-0.64	-7.44	-0.44	1.94e-12	Bipolar disorder and schizophrenia;
SARC	cis	rs13314892	0.764	rs56155813	chr3:69879509	A/G	cg17445875	chr3:69859618	MITF	-0.48	-5.12	-0.32	6.53e-7	QRS complex (12-leadsum);
SARC	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg03354898	chr7:1950403	MAD1L1	-0.37	-5.04	-0.31	9.23e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs2486288	0.656	rs8039540	chr15:45551842	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.45	-5.57	-0.34	7.07e-8	Glomerular filtration rate;
SARC	cis	rs9486715	1.000	rs7752277	chr6:97065131	C/T	cg06623918	chr6:96969491	KIAA0776	-0.79	-10.79	-0.58	2.79e-22	Headache;
SARC	cis	rs1355223	0.506	rs7130678	chr11:34869181	A/G	cg11622362	chr11:34938112	PDHX;APIP	0.43	5.55	0.34	7.64e-8	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	5.78	0.35	2.39e-8	Height;
SARC	cis	rs11785400	0.793	rs11785012	chr8:143748355	G/A	cg24634471	chr8:143751801	JRK	0.57	7.17	0.42	1.01e-11	Schizophrenia;
SARC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg07167872	chr1:205819463	PM20D1	-0.68	-10.95	-0.58	8.47e-23	Monocyte percentage of white cells;
SARC	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg04944784	chr2:26401820	FAM59B	-0.48	-5.97	-0.36	8.88e-9	Gut microbiome composition (summer);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg13220209	chr6:52926654	ICK	0.47	6.37	0.39	1.03e-9	Chemerin levels;
SARC	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg16405210	chr4:1374714	KIAA1530	-0.47	-5.48	-0.34	1.12e-7	Obesity-related traits;
SARC	cis	rs6088580	0.634	rs4911421	chr20:32998948	T/C	cg08999081	chr20:33150536	PIGU	-0.44	-6.65	-0.4	2.07e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs6964587	1.000	rs2282974	chr7:91761617	G/A	cg17063962	chr7:91808500	NA	0.96	16.36	0.73	1.42e-40	Breast cancer;
SARC	cis	rs2070488	1.000	rs1841777	chr3:38484819	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	14.64	0.69	7.76e-35	Electrocardiographic conduction measures;
SARC	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.53	-6.48	-0.39	5.5e-10	Systemic lupus erythematosus;
SARC	cis	rs2180341	0.814	rs6940933	chr6:127732740	C/G	cg27446573	chr6:127587934	RNF146	0.79	10.07	0.55	4.82e-20	Breast cancer;
SARC	trans	rs1814175	0.791	rs10839468	chr11:49986288	A/G	cg03929089	chr4:120376271	NA	-0.89	-14.59	-0.69	1.1e-34	Height;
SARC	cis	rs113835537	0.529	rs57691879	chr11:66236604	C/T	cg24851651	chr11:66362959	CCS	0.38	4.75	0.3	3.51e-6	Airway imaging phenotypes;
SARC	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg07701084	chr6:150067640	NUP43	-0.42	-5.5	-0.34	9.95e-8	Lung cancer;
SARC	cis	rs2046867	0.818	rs11928620	chr3:72863209	A/C	cg25664220	chr3:72788482	NA	-0.3	-4.82	-0.3	2.63e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
SARC	cis	rs7005380	0.581	rs7813430	chr8:120939074	C/T	cg21744203	chr8:120868354	DSCC1	0.45	5.35	0.33	2.15e-7	Interstitial lung disease;
SARC	cis	rs7395581	0.918	rs10838692	chr11:47345100	T/C	cg25783544	chr11:47291846	MADD	0.48	5.39	0.33	1.75e-7	HDL cholesterol;
SARC	cis	rs4792901	0.759	rs12948043	chr17:41615830	T/C	cg22562494	chr17:41607896	ETV4	-0.32	-5.03	-0.31	9.97e-7	Dupuytren's disease;
SARC	cis	rs76917914	0.954	rs111292969	chr9:100788191	A/C	cg03040243	chr9:100819229	NANS	0.57	5.86	0.36	1.59e-8	Immature fraction of reticulocytes;
SARC	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg12463550	chr7:65579703	CRCP	0.49	5.57	0.34	7.12e-8	Aortic root size;
SARC	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg26354017	chr1:205819088	PM20D1	0.6	6.9	0.41	4.98e-11	Prostate-specific antigen levels;
SARC	cis	rs1790761	0.667	rs591434	chr11:67337814	C/T	cg24690094	chr11:67383802	NA	0.37	5.52	0.34	8.98e-8	Mean corpuscular volume;
SARC	cis	rs6570726	0.846	rs453834	chr6:145886261	T/C	cg23711669	chr6:146136114	FBXO30	0.78	12.35	0.63	2.76e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3733585	0.699	rs7658170	chr4:9966593	C/T	cg11266682	chr4:10021025	SLC2A9	0.37	6.29	0.38	1.57e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	11.03	0.59	4.93e-23	Alzheimer's disease;
SARC	cis	rs9486715	0.867	rs1855533	chr6:97050265	T/C	cg18709589	chr6:96969512	KIAA0776	-0.6	-7.48	-0.44	1.55e-12	Headache;
SARC	cis	rs1008375	1.000	rs6854733	chr4:17640526	C/T	cg02297831	chr4:17616191	MED28	0.5	6.47	0.39	5.62e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs9388451	0.626	rs2875881	chr6:126072853	C/G	cg05039488	chr6:79577232	IRAK1BP1	-0.63	-8.04	-0.47	4.4e-14	Brugada syndrome;
SARC	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg19223190	chr17:80058835	NA	-0.42	-5.73	-0.35	3.09e-8	Life satisfaction;
SARC	cis	rs3106136	0.872	rs2016476	chr4:95229004	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.38	-5.74	-0.35	2.94e-8	Capecitabine sensitivity;
SARC	cis	rs796364	0.715	rs11688872	chr2:201052418	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.65	-5.42	-0.33	1.5e-7	Schizophrenia;
SARC	cis	rs7819412	0.521	rs4451268	chr8:11034859	A/G	cg21775007	chr8:11205619	TDH	-0.45	-5.68	-0.35	3.92e-8	Triglycerides;
SARC	trans	rs2898290	0.540	rs12677146	chr8:11450737	C/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.83	-0.41	7.28e-11	Systolic blood pressure;
SARC	cis	rs9467773	1.000	rs11756120	chr6:26529808	G/C	cg12292205	chr6:26970375	C6orf41	0.45	5.43	0.34	1.41e-7	Intelligence (multi-trait analysis);
SARC	cis	rs17023223	0.537	rs61319010	chr1:119743011	T/A	cg05756136	chr1:119680316	WARS2	-0.48	-5.35	-0.33	2.08e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs2204008	0.777	rs2387813	chr12:38382091	A/C	cg13010199	chr12:38710504	ALG10B	0.78	10.79	0.58	2.78e-22	Bladder cancer;
SARC	cis	rs7584330	0.704	rs72620820	chr2:238358844	G/A	cg14458575	chr2:238380390	NA	0.63	6.77	0.41	1.02e-10	Prostate cancer;
SARC	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	5.86	0.36	1.54e-8	Bipolar disorder;
SARC	cis	rs7617480	0.648	rs6806356	chr3:48727636	G/A	cg07636037	chr3:49044803	WDR6	0.76	8.02	0.47	5.02e-14	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	trans	rs3942852	0.568	rs10769312	chr11:48094769	C/T	cg03929089	chr4:120376271	NA	0.56	6.86	0.41	6.16e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs72781680	0.716	rs2712061	chr2:24026411	G/A	cg06627628	chr2:24431161	ITSN2	-0.53	-5.56	-0.34	7.38e-8	Lymphocyte counts;
SARC	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg13175981	chr1:150552382	MCL1	-0.48	-5.79	-0.35	2.23e-8	Melanoma;
SARC	cis	rs12477438	0.605	rs4585080	chr2:99557327	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-7.82	-0.46	1.87e-13	Chronic sinus infection;
SARC	cis	rs6456156	0.792	rs4710179	chr6:167513692	G/T	cg07741184	chr6:167504864	NA	0.36	7.05	0.42	2.02e-11	Primary biliary cholangitis;
SARC	cis	rs6496667	0.533	rs2589949	chr15:90955015	C/T	cg22089800	chr15:90895588	ZNF774	0.45	5.16	0.32	5.36e-7	Rheumatoid arthritis;
SARC	cis	rs4819052	0.679	rs2236450	chr21:46702553	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.54	6.56	0.4	3.37e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6964587	1.000	rs12533199	chr7:91757393	C/T	cg17063962	chr7:91808500	NA	0.96	16.11	0.73	9.53e-40	Breast cancer;
SARC	cis	rs1559088	0.600	rs6510344	chr19:33583942	C/A	cg27124370	chr19:33622961	WDR88	0.5	6.67	0.4	1.82e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs1371867	0.846	rs2047249	chr8:101234126	A/G	cg11906718	chr8:101322791	RNF19A	-0.7	-8.13	-0.47	2.61e-14	Atrioventricular conduction;
SARC	cis	rs448720	0.811	rs1996120	chr15:68181534	G/A	cg05925327	chr15:68127851	NA	-0.35	-5.02	-0.31	1.05e-6	Cognitive performance;
SARC	trans	rs637571	0.565	rs570387	chr11:65637076	T/C	cg17712092	chr4:129076599	LARP1B	-0.57	-7.52	-0.44	1.21e-12	Eosinophil percentage of white cells;
SARC	cis	rs734999	0.545	rs28532547	chr1:2561286	T/G	cg18854424	chr1:2615690	NA	-0.31	-4.91	-0.31	1.73e-6	Ulcerative colitis;
SARC	cis	rs2992756	1.000	rs2992756	chr1:18807339	T/C	cg20200200	chr1:18807388	KLHDC7A	-0.3	-4.77	-0.3	3.2e-6	Breast cancer;
SARC	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	22.95	0.83	9.94e-62	Chronic sinus infection;
SARC	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	13.51	0.66	4.16e-31	Chronic sinus infection;
SARC	cis	rs34311866	0.808	rs3755958	chr4:963042	C/A	cg07828340	chr4:882639	GAK	0.7	5.49	0.34	1.04e-7	Parkinson's disease;
SARC	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.95	13.71	0.67	9.26e-32	Gut microbiome composition (summer);
SARC	cis	rs10504073	0.647	rs341807	chr8:50032676	C/T	cg00325661	chr8:49890786	NA	0.54	7.38	0.44	2.7e-12	Blood metabolite ratios;
SARC	cis	rs916888	0.610	rs199444	chr17:44818276	T/C	cg15921436	chr17:44337874	NA	0.47	5.38	0.33	1.83e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7103648	0.966	rs896817	chr11:47394305	A/G	cg20307385	chr11:47447363	PSMC3	-0.82	-11.97	-0.62	4.84e-26	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg11644478	chr21:40555479	PSMG1	1.02	14.38	0.69	5.5e-34	Cognitive function;
SARC	cis	rs3092073	0.624	rs11906879	chr20:44591324	C/T	cg17986701	chr20:44574422	PCIF1	-0.34	-4.8	-0.3	2.81e-6	Intelligence (multi-trait analysis);
SARC	trans	rs17685	0.753	rs55812043	chr7:75747241	T/C	cg19862616	chr7:65841803	NCRNA00174	0.6	7.35	0.43	3.25e-12	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs35110281	0.667	rs2155722	chr21:45096206	A/G	cg21573476	chr21:45109991	RRP1B	0.57	8.22	0.47	1.42e-14	Mean corpuscular volume;
SARC	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.58	7.69	0.45	4.21e-13	Menarche (age at onset);
SARC	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-8.06	-0.47	3.94e-14	Chronic sinus infection;
SARC	cis	rs9916302	0.595	rs4795371	chr17:37636695	T/G	cg07936489	chr17:37558343	FBXL20	-0.69	-8.66	-0.49	7.92e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs7727544	0.684	rs274567	chr5:131714409	C/T	cg07395648	chr5:131743802	NA	0.4	4.77	0.3	3.29e-6	Blood metabolite levels;
SARC	trans	rs6479527	0.806	rs1316814	chr9:96742718	A/G	ch.6.2893423F	chr6:150056792	NUP43	-0.54	-6.3	-0.38	1.44e-9	Esophageal adenocarcinoma;
SARC	cis	rs763121	0.853	rs4821808	chr22:39065739	A/G	cg14440974	chr22:39074834	NA	-0.34	-4.96	-0.31	1.38e-6	Menopause (age at onset);
SARC	cis	rs921968	0.643	rs492400	chr2:219349752	C/T	cg02176678	chr2:219576539	TTLL4	0.31	4.76	0.3	3.42e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs6570726	0.846	rs411468	chr6:145832792	A/G	cg23711669	chr6:146136114	FBXO30	0.78	11.86	0.61	1.04e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7666738	0.677	rs13120306	chr4:99036099	A/T	cg05340658	chr4:99064831	C4orf37	0.66	8.81	0.5	2.97e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs11676348	0.772	rs12694427	chr2:218945045	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.38	-4.86	-0.3	2.2e-6	Ulcerative colitis;
SARC	trans	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg19608455	chr18:48086580	MAPK4	0.42	6.3	0.38	1.45e-9	Immature fraction of reticulocytes;
SARC	cis	rs3806933	0.522	rs17553936	chr5:110454681	A/G	cg04022379	chr5:110408740	TSLP	0.71	9.32	0.52	9.12e-18	Eosinophilic esophagitis;
SARC	cis	rs2011503	1.000	rs45556231	chr19:19654189	G/A	cg03709012	chr19:19516395	GATAD2A	0.6	5.29	0.33	2.8e-7	Bipolar disorder;
SARC	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	11.3	0.59	7.02e-24	Alzheimer's disease;
SARC	cis	rs16854884	0.802	rs6786460	chr3:143805895	A/G	cg06585982	chr3:143692056	C3orf58	0.62	8.22	0.47	1.38e-14	Economic and political preferences (feminism/equality);
SARC	cis	rs5753618	0.509	rs2413033	chr22:31574213	A/G	cg13145458	chr22:31556086	RNF185	0.47	5.2	0.32	4.29e-7	Colorectal cancer;
SARC	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg24675658	chr1:53192096	ZYG11B	0.73	11.05	0.59	4.33e-23	Monocyte count;
SARC	cis	rs11098499	0.954	rs10014845	chr4:120301077	T/G	cg09307838	chr4:120376055	NA	0.91	12.88	0.65	4.9e-29	Corneal astigmatism;
SARC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg06873352	chr17:61820015	STRADA	0.53	6.79	0.41	9.48e-11	Prudent dietary pattern;
SARC	cis	rs910316	0.712	rs175037	chr14:75465038	T/C	cg11812906	chr14:75593930	NEK9	-0.79	-11.12	-0.59	2.62e-23	Height;
SARC	cis	rs910316	0.737	rs175049	chr14:75481368	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.46	-6.1	-0.37	4.46e-9	Height;
SARC	cis	rs2073300	0.609	rs74273791	chr20:23418067	A/T	cg16736954	chr20:23401023	NAPB	0.77	4.79	0.3	3.02e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg19748678	chr4:122722346	EXOSC9	0.78	10.53	0.57	1.85e-21	Type 2 diabetes;
SARC	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg11211951	chr8:145729740	GPT	0.42	6.29	0.38	1.56e-9	Age at first birth;
SARC	cis	rs7605378	0.528	rs1704191	chr2:200816393	C/A	cg23649088	chr2:200775458	C2orf69	0.79	11.44	0.6	2.5e-24	Osteoporosis;
SARC	cis	rs3858526	0.883	rs10769320	chr11:5932831	G/C	cg13902645	chr11:5959945	NA	-0.44	-5.2	-0.32	4.4e-7	DNA methylation (variation);
SARC	trans	rs3780486	0.846	rs3780487	chr9:33139237	T/C	cg20290983	chr6:43655470	MRPS18A	1.14	22.68	0.83	6.7e-61	IgG glycosylation;
SARC	cis	rs13082711	0.522	rs11927257	chr3:27334294	C/T	cg02860705	chr3:27208620	NA	0.47	6.28	0.38	1.61e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg01516881	chr6:292596	DUSP22	-0.67	-8.49	-0.49	2.46e-15	Menopause (age at onset);
SARC	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg00933542	chr6:150070202	PCMT1	0.32	5.4	0.33	1.68e-7	Lung cancer;
SARC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.12	0.37	3.95e-9	Prudent dietary pattern;
SARC	cis	rs6582630	0.539	rs35114325	chr12:38320886	G/T	cg13010199	chr12:38710504	ALG10B	-0.5	-5.94	-0.36	1.02e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9457247	0.902	rs366938	chr6:167403538	T/C	cg07741184	chr6:167504864	NA	0.29	5.55	0.34	7.65e-8	Crohn's disease;
SARC	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg02725872	chr8:58115012	NA	0.33	4.93	0.31	1.54e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg24829409	chr8:58192753	C8orf71	-0.58	-5.88	-0.36	1.38e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs3087591	0.683	rs2525567	chr17:29675673	C/A	cg24425628	chr17:29625626	OMG;NF1	0.42	5.33	0.33	2.36e-7	Hip circumference;
SARC	cis	rs1215050	0.765	rs687795	chr4:98754912	C/G	cg05340658	chr4:99064831	C4orf37	0.44	5.85	0.36	1.62e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs4713118	0.955	rs9368528	chr6:27683798	G/A	cg17221315	chr6:27791827	HIST1H4J	0.49	4.97	0.31	1.3e-6	Parkinson's disease;
SARC	cis	rs4481887	0.888	rs12042602	chr1:248482053	C/T	cg00666640	chr1:248458726	OR2T12	0.33	5.48	0.34	1.12e-7	Common traits (Other);
SARC	cis	rs1355223	0.872	rs12785367	chr11:34715269	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.4	-5.07	-0.32	8.21e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs6088590	1.000	rs2076668	chr20:33437621	G/A	cg24642439	chr20:33292090	TP53INP2	0.85	11.56	0.6	1.02e-24	Coronary artery disease;
SARC	cis	rs2439831	0.717	rs10518820	chr15:43888976	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.99	8.49	0.49	2.45e-15	Lung cancer in ever smokers;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg15115510	chr20:33872603	EIF6	-0.58	-6.68	-0.4	1.72e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs6582630	0.555	rs7305352	chr12:38473800	T/C	cg26384229	chr12:38710491	ALG10B	0.87	12.52	0.63	7.68e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs3820928	0.874	rs6718057	chr2:227834349	T/G	cg05526886	chr2:227700861	RHBDD1	-0.56	-6.78	-0.41	9.69e-11	Pulmonary function;
SARC	cis	rs11122272	0.701	rs11122273	chr1:231476789	A/G	cg06096015	chr1:231504339	EGLN1	0.38	5.78	0.35	2.38e-8	Hemoglobin concentration;
SARC	cis	rs9640161	0.830	rs1051760	chr7:150070630	A/G	cg21361702	chr7:150065534	REPIN1	0.52	6.61	0.4	2.59e-10	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs7044106	0.762	rs1470307	chr9:123433039	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	9.04	0.51	6.18e-17	Hip circumference adjusted for BMI;
SARC	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	cis	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg13152082	chr4:100010005	ADH5	-0.39	-5.07	-0.32	7.99e-7	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7666738	0.830	rs11097600	chr4:98959564	T/G	cg05340658	chr4:99064831	C4orf37	0.65	8.73	0.5	5.13e-16	Colonoscopy-negative controls vs population controls;
SARC	trans	rs208515	0.518	rs12209790	chr6:66662965	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.01	11.59	0.6	7.98e-25	Exhaled nitric oxide levels;
SARC	cis	rs708547	0.836	rs1718882	chr4:57859533	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.77	10.79	0.58	2.73e-22	Response to bleomycin (chromatid breaks);
SARC	cis	rs6963495	0.745	rs73192153	chr7:105212418	A/T	cg13798780	chr7:105162888	PUS7	0.57	5.19	0.32	4.5e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs273218	0.694	rs274369	chr5:53379987	G/C	ch.5.1024479R	chr5:53302184	ARL15	0.53	6.23	0.38	2.16e-9	Migraine;
SARC	cis	rs6901004	0.803	rs354524	chr6:111508109	A/G	cg15721981	chr6:111408429	SLC16A10	0.43	5.17	0.32	4.99e-7	Blood metabolite levels;
SARC	cis	rs6807306	1.000	rs6768525	chr3:167373457	A/G	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.5	4.89	0.3	1.92e-6	Mean platelet volume;
SARC	cis	rs705471	1.000	rs705471	chr10:3667726	A/G	cg14308648	chr10:3568949	NA	0.49	6.25	0.38	1.89e-9	Capecitabine sensitivity;
SARC	cis	rs7584330	0.868	rs2325839	chr2:238386286	T/C	cg11271282	chr2:238384023	NA	0.5	5.78	0.35	2.34e-8	Prostate cancer;
SARC	cis	rs1497406	0.802	rs28629977	chr1:16497272	G/C	cg20430773	chr1:16534157	ARHGEF19	0.43	6.53	0.39	4.07e-10	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2273669	0.667	rs6651000	chr6:109281411	G/T	cg05315195	chr6:109294784	ARMC2	-0.6	-5.43	-0.34	1.41e-7	Prostate cancer;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg14410072	chr9:139838381	C8G;FBXW5	-0.56	-6.94	-0.41	3.91e-11	Breast cancer;
SARC	cis	rs7219021	0.634	rs9905428	chr17:46948709	C/G	cg16584676	chr17:46985605	UBE2Z	-0.49	-5.93	-0.36	1.06e-8	Schizophrenia or bipolar disorder;
SARC	cis	rs2273669	0.667	rs12196010	chr6:109302173	C/A	cg05315195	chr6:109294784	ARMC2	-0.57	-5.04	-0.31	9.39e-7	Prostate cancer;
SARC	cis	rs7551222	0.749	rs11240761	chr1:204566700	C/A	cg20240347	chr1:204465584	NA	-0.27	-4.81	-0.3	2.69e-6	Schizophrenia;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg01973725	chr5:80608537	RNU5E;RNU5D;ZCCHC9	-0.85	-7.1	-0.42	1.47e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg11062466	chr8:58055876	NA	0.54	5.53	0.34	8.37e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1873147	1.000	rs1873149	chr15:63312428	A/C	cg05507819	chr15:63340323	TPM1	0.44	4.88	0.3	1.94e-6	Orofacial clefts;
SARC	cis	rs698833	0.663	rs698777	chr2:44740613	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	6.5	0.39	4.86e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs6964587	1.000	rs1859113	chr7:91679887	T/C	cg17063962	chr7:91808500	NA	0.94	15.98	0.72	2.68e-39	Breast cancer;
SARC	cis	rs2832191	0.720	rs7277028	chr21:30494604	T/C	cg08807101	chr21:30365312	RNF160	-0.82	-11.26	-0.59	9.12e-24	Dental caries;
SARC	cis	rs2153535	0.580	rs7767780	chr6:8453462	A/G	cg23788917	chr6:8435910	SLC35B3	0.67	8.94	0.51	1.21e-16	Motion sickness;
SARC	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg16606324	chr3:10149918	C3orf24	0.48	4.75	0.3	3.56e-6	Alzheimer's disease;
SARC	cis	rs4074493	0.928	rs4310430	chr1:231172881	T/G	cg22172038	chr1:231176991	FAM89A	0.34	4.93	0.31	1.53e-6	Carotid plaque burden (smoking interaction);
SARC	cis	rs754466	0.580	rs12357670	chr10:79558180	T/C	cg17075019	chr10:79541650	NA	-0.84	-12.99	-0.65	2.14e-29	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg01475735	chr3:40494733	NA	-0.46	-5.04	-0.31	9.24e-7	Renal cell carcinoma;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg23921342	chr1:34630923	CSMD2	-0.61	-6.5	-0.39	4.81e-10	Lung cancer in ever smokers;
SARC	cis	rs950776	0.518	rs62008194	chr15:78813805	G/T	cg06917634	chr15:78832804	PSMA4	0.89	13.72	0.67	8.8e-32	Sudden cardiac arrest;
SARC	cis	rs7216064	0.906	rs1976052	chr17:65830578	C/T	cg12091567	chr17:66097778	LOC651250	-0.65	-6.55	-0.39	3.54e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg09839136	chr7:766187	HEATR2;PRKAR1B	0.56	4.97	0.31	1.32e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs7520050	0.966	rs6669522	chr1:46397941	A/G	cg06784218	chr1:46089804	CCDC17	-0.26	-4.75	-0.3	3.57e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs1124769	0.778	rs2614787	chr15:51200218	T/C	cg21246271	chr15:51200259	AP4E1	0.57	5.38	0.33	1.77e-7	Cognitive performance;
SARC	cis	rs752010	0.746	rs10749837	chr1:42089471	T/C	cg06885757	chr1:42089581	HIVEP3	0.44	6.93	0.41	4.11e-11	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs1707322	0.721	rs4660883	chr1:46236098	C/T	cg03146154	chr1:46216737	IPP	0.55	6.88	0.41	5.33e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs3857536	0.740	rs7769722	chr6:66891363	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.6	-7.14	-0.42	1.19e-11	Blood trace element (Cu levels);
SARC	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg22535103	chr8:58192502	C8orf71	-0.7	-6.64	-0.4	2.17e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg24101359	chr6:42928495	GNMT	0.46	6.22	0.38	2.32e-9	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs11098499	0.863	rs7699064	chr4:120428309	A/G	cg09307838	chr4:120376055	NA	-0.89	-11.61	-0.61	6.96e-25	Corneal astigmatism;
SARC	cis	rs240764	0.658	rs10872634	chr6:101199579	C/T	cg09795085	chr6:101329169	ASCC3	-0.49	-6.47	-0.39	5.78e-10	Neuroticism;
SARC	cis	rs10870270	0.956	rs7904594	chr10:133734671	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.8	-10.37	-0.56	5.78e-21	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs2180341	0.960	rs1543432	chr6:127698018	T/C	cg24812749	chr6:127587940	RNF146	1.03	13.28	0.66	2.34e-30	Breast cancer;
SARC	cis	rs796364	0.906	rs281766	chr2:200820505	T/G	cg23649088	chr2:200775458	C2orf69	0.61	5.93	0.36	1.07e-8	Schizophrenia;
SARC	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	6.7	0.4	1.52e-10	Schizophrenia;
SARC	cis	rs9733	0.687	rs12410050	chr1:150857141	A/G	cg13175981	chr1:150552382	MCL1	0.6	8.17	0.47	1.91e-14	Tonsillectomy;
SARC	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg24250549	chr1:154909240	PMVK	0.82	11.88	0.61	9.15e-26	Prostate cancer;
SARC	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg01181863	chr3:195395398	SDHAP2	-0.52	-5.84	-0.36	1.74e-8	Pancreatic cancer;
SARC	cis	rs9790314	0.747	rs9848239	chr3:160823488	A/C	cg04691961	chr3:161091175	C3orf57	-0.67	-9.54	-0.53	2.09e-18	Morning vs. evening chronotype;
SARC	cis	rs4971059	0.629	rs11264333	chr1:155108287	G/A	cg22049894	chr1:155113146	DPM3	0.39	4.82	0.3	2.56e-6	Breast cancer;
SARC	trans	rs561341	1.000	rs554078	chr17:30330109	A/C	cg20587970	chr11:113659929	NA	-1.31	-13.87	-0.67	2.62e-32	Hip circumference adjusted for BMI;
SARC	cis	rs9322817	0.691	rs2499652	chr6:105269959	G/A	cg02098413	chr6:105308735	HACE1	0.38	5.91	0.36	1.18e-8	Thyroid stimulating hormone;
SARC	cis	rs13314892	0.689	rs57829272	chr3:69863286	A/G	cg17445875	chr3:69859618	MITF	-0.49	-5.14	-0.32	5.68e-7	QRS complex (12-leadsum);
SARC	cis	rs3008870	0.583	rs2031495	chr1:67421714	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.83	8.91	0.5	1.46e-16	Lymphocyte percentage of white cells;
SARC	cis	rs9309473	0.660	rs79370894	chr2:73683515	C/A	cg20560298	chr2:73613845	ALMS1	-0.54	-5.23	-0.32	3.74e-7	Metabolite levels;
SARC	cis	rs9788721	0.836	rs2656052	chr15:78740932	A/C	cg18825076	chr15:78729989	IREB2	-0.47	-5.96	-0.36	9.44e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg15556689	chr8:8085844	FLJ10661	0.46	5.85	0.36	1.69e-8	Mood instability;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg06865749	chr1:203764655	ZC3H11A	0.49	6.28	0.38	1.66e-9	Lung adenocarcinoma;
SARC	cis	rs10791323	0.604	rs2250025	chr11:133710914	G/A	cg14349672	chr11:133703707	NA	-0.38	-5.42	-0.33	1.47e-7	Childhood ear infection;
SARC	cis	rs10845606	1.000	rs10845609	chr12:12838920	T/A	cg09462578	chr12:12878428	APOLD1	-0.53	-5.14	-0.32	5.94e-7	Systemic lupus erythematosus;
SARC	cis	rs526231	0.543	rs34784	chr5:102457330	G/C	cg23492399	chr5:102201601	PAM	-0.52	-5.58	-0.34	6.67e-8	Primary biliary cholangitis;
SARC	trans	rs17066873	1.000	rs17066893	chr13:77476542	A/T	cg21804574	chr18:76126700	NA	-0.9	-6.78	-0.41	9.98e-11	Pharmacokinetics of antiepileptic drugs in severe mental disorder (concentration drug ratio);
SARC	cis	rs67478160	0.643	rs4900594	chr14:104251006	C/T	cg26031613	chr14:104095156	KLC1	-0.4	-4.83	-0.3	2.43e-6	Schizophrenia;
SARC	cis	rs35213789	0.960	rs35322474	chr7:69301510	T/G	cg10619644	chr7:69149951	AUTS2	0.45	5.67	0.35	4.17e-8	Childhood ear infection;
SARC	cis	rs2721811	0.531	rs2711091	chr7:24622086	A/G	cg17569154	chr7:24781545	DFNA5	0.37	4.86	0.3	2.19e-6	Depressive symptoms (multi-trait analysis);
SARC	cis	rs2177596	0.534	rs3923085	chr2:227948746	C/T	cg11843606	chr2:227700838	RHBDD1	-0.46	-4.83	-0.3	2.51e-6	Body mass index;
SARC	cis	rs854765	0.693	rs35451946	chr17:17764061	C/G	cg05444541	chr17:17804740	TOM1L2	0.31	5.27	0.33	3.04e-7	Total body bone mineral density;
SARC	cis	rs3020736	0.500	rs5996110	chr22:42493767	A/G	cg04733989	chr22:42467013	NAGA	-0.76	-10.7	-0.57	5.23e-22	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6582630	0.554	rs7299735	chr12:38450890	A/C	cg13010199	chr12:38710504	ALG10B	-0.48	-5.87	-0.36	1.48e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg15448220	chr1:150897856	SETDB1	0.48	6.2	0.38	2.54e-9	Melanoma;
SARC	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg20102877	chr2:27665638	KRTCAP3	-0.35	-4.95	-0.31	1.42e-6	Total body bone mineral density;
SARC	cis	rs876084	0.545	rs10096311	chr8:121102031	A/G	cg06265175	chr8:121136014	COL14A1	0.58	7.73	0.45	3.3e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs7760949	0.889	rs9475816	chr6:13935425	T/C	cg27413430	chr6:13925136	RNF182	0.43	5.19	0.32	4.59e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs4453791	0.505	rs13099628	chr3:38927854	T/G	cg26331595	chr3:39149181	GORASP1;TTC21A	0.46	4.8	0.3	2.82e-6	Social communication problems;
SARC	cis	rs17345786	0.906	rs11710016	chr3:101120030	A/C	cg12386194	chr3:101231763	SENP7	-0.85	-9.87	-0.54	1.98e-19	Colonoscopy-negative controls vs population controls;
SARC	cis	rs933688	0.532	rs2973478	chr5:90553428	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.48	-5.27	-0.33	3.14e-7	Smoking behavior;
SARC	cis	rs72781680	0.898	rs72780188	chr2:24006065	G/A	cg06627628	chr2:24431161	ITSN2	-0.66	-6.26	-0.38	1.83e-9	Lymphocyte counts;
SARC	cis	rs7587476	1.000	rs3768707	chr2:215645135	C/T	cg11970703	chr2:215861251	ABCA12	-0.33	-5.1	-0.32	7.18e-7	Neuroblastoma;
SARC	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg22508957	chr16:3507546	NAT15	0.36	5.34	0.33	2.26e-7	Tuberculosis;
SARC	cis	rs10782582	0.569	rs1770892	chr1:76389359	T/C	cg10523679	chr1:76189770	ACADM	-0.4	-4.86	-0.3	2.16e-6	Daytime sleep phenotypes;
SARC	cis	rs4975616	0.869	rs401681	chr5:1322087	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.54	-8.01	-0.46	5.43e-14	Lung cancer;
SARC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.62	-6.6	-0.4	2.8e-10	Platelet count;
SARC	cis	rs2832077	0.943	rs11701777	chr21:30155828	T/C	cg03476357	chr21:30257390	N6AMT1	-0.63	-5.95	-0.36	9.75e-9	Cognitive test performance;
SARC	cis	rs12681366	0.683	rs2046665	chr8:95387959	G/A	cg26464482	chr8:95565502	KIAA1429	-0.44	-5.44	-0.34	1.37e-7	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs273218	1.000	rs156384	chr5:53371333	A/G	ch.5.1024479R	chr5:53302184	ARL15	0.62	6.91	0.41	4.66e-11	Migraine;
SARC	cis	rs4711350	1.000	rs943472	chr6:33738442	T/C	cg18005901	chr6:33739558	LEMD2	-0.45	-4.9	-0.31	1.76e-6	Schizophrenia;
SARC	cis	rs763121	0.752	rs6001190	chr22:39073811	T/C	cg21395723	chr22:39101663	GTPBP1	0.52	5.77	0.35	2.51e-8	Menopause (age at onset);
SARC	cis	rs9549260	0.753	rs2297628	chr13:41233905	T/C	cg21288729	chr13:41239152	FOXO1	0.59	6.07	0.37	5.07e-9	Red blood cell count;
SARC	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.78	7.64	0.45	5.71e-13	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs3126085	0.877	rs7543541	chr1:152230878	T/C	cg03465714	chr1:152285911	FLG	-0.45	-5.38	-0.33	1.85e-7	Atopic dermatitis;
SARC	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg08125733	chr17:73851984	WBP2	0.64	7.0	0.42	2.63e-11	Psoriasis;
SARC	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg18230493	chr5:56204884	C5orf35	-0.56	-5.03	-0.31	9.82e-7	Initial pursuit acceleration;
SARC	cis	rs12912251	1.000	rs71403553	chr15:38989121	C/A	cg01338139	chr15:38987640	C15orf53	-0.46	-5.41	-0.33	1.6e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
SARC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	9.15	0.51	2.97e-17	Prudent dietary pattern;
SARC	cis	rs72634258	0.786	rs6682709	chr1:8173796	A/C	cg00042356	chr1:8021962	PARK7	-0.64	-5.92	-0.36	1.12e-8	Inflammatory bowel disease;
SARC	cis	rs708547	0.735	rs1277280	chr4:57866872	T/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.74	9.73	0.54	5.45e-19	Response to bleomycin (chromatid breaks);
SARC	cis	rs3540	0.597	rs3539	chr15:91045419	G/T	cg22089800	chr15:90895588	ZNF774	-0.59	-7.63	-0.45	5.79e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs7599312	0.534	rs2128321	chr2:213405276	G/T	cg16329650	chr2:213403929	ERBB4	0.7	10.78	0.58	3.11e-22	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs9916302	0.851	rs612209	chr17:37442713	G/C	cg00129232	chr17:37814104	STARD3	0.59	7.39	0.44	2.69e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs1609391	0.543	rs6761993	chr3:136625902	C/T	cg15507776	chr3:136538369	TMEM22	0.83	11.54	0.6	1.17e-24	Neuroticism;
SARC	cis	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg07636037	chr3:49044803	WDR6	0.48	5.61	0.35	5.67e-8	Resting heart rate;
SARC	cis	rs1707322	0.686	rs3014242	chr1:46087577	G/A	cg06784218	chr1:46089804	CCDC17	-0.38	-6.57	-0.4	3.31e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs796364	0.760	rs2881594	chr2:201026183	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.73	-6.24	-0.38	2e-9	Schizophrenia;
SARC	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.71	-7.18	-0.43	9.41e-12	Platelet count;
SARC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.54	6.26	0.38	1.85e-9	Prudent dietary pattern;
SARC	cis	rs752010	1.000	rs6656183	chr1:42094025	A/G	cg06885757	chr1:42089581	HIVEP3	0.34	5.47	0.34	1.13e-7	Lupus nephritis in systemic lupus erythematosus;
SARC	trans	rs61931739	0.534	rs1352207	chr12:34036862	C/T	cg26384229	chr12:38710491	ALG10B	-0.75	-10.37	-0.56	6.01e-21	Morning vs. evening chronotype;
SARC	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg06028808	chr11:68637592	NA	0.43	5.49	0.34	1.03e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs11809207	0.574	rs2783633	chr1:26505265	A/G	cg23602478	chr1:26503979	CNKSR1	0.27	5.0	0.31	1.15e-6	Height;
SARC	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg21747090	chr2:27597821	SNX17	-0.54	-7.53	-0.44	1.13e-12	Total body bone mineral density;
SARC	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg12311346	chr5:56204834	C5orf35	-0.58	-6.01	-0.37	7.24e-9	Initial pursuit acceleration;
SARC	cis	rs3768617	0.510	rs2027083	chr1:183088330	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.1	0.55	4.11e-20	Fuchs's corneal dystrophy;
SARC	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.47	-5.93	-0.36	1.1e-8	Lymphocyte counts;
SARC	cis	rs11209002	0.567	rs2755268	chr1:67539881	T/C	cg02640540	chr1:67518911	SLC35D1	0.59	6.66	0.4	1.99e-10	Crohn's disease;
SARC	cis	rs10489202	0.913	rs380753	chr1:168035273	G/T	cg17859187	chr1:168147929	TIPRL	0.44	4.94	0.31	1.52e-6	Schizophrenia;
SARC	cis	rs12145833	1.000	rs12145833	chr1:243483754	G/T	cg02356786	chr1:243265016	LOC731275	-0.58	-5.13	-0.32	6.08e-7	Obesity (early onset extreme);
SARC	trans	rs1814175	0.592	rs1794161	chr11:49898825	A/C	cg15704280	chr7:45808275	SEPT13	-0.88	-13.99	-0.68	1.12e-32	Height;
SARC	cis	rs11718455	0.960	rs35666538	chr3:44004826	A/G	cg21419209	chr3:44054225	NA	-0.41	-4.97	-0.31	1.31e-6	Coronary artery disease;
SARC	cis	rs10463316	0.779	rs6861968	chr5:150817725	C/T	cg03212797	chr5:150827313	SLC36A1	-0.44	-5.02	-0.31	1.01e-6	Metabolite levels (Pyroglutamine);
SARC	cis	rs7953249	0.773	rs7979478	chr12:121420263	A/G	cg02403541	chr12:121454288	C12orf43	-0.56	-7.11	-0.42	1.43e-11	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs763121	0.853	rs5750673	chr22:39110124	G/A	cg06022373	chr22:39101656	GTPBP1	0.84	10.44	0.56	3.62e-21	Menopause (age at onset);
SARC	cis	rs1008375	0.966	rs3775923	chr4:17585625	T/C	cg02297831	chr4:17616191	MED28	0.48	5.93	0.36	1.06e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg04673462	chr1:38461896	NA	0.31	5.34	0.33	2.18e-7	Coronary artery disease;
SARC	cis	rs11098499	0.863	rs3775858	chr4:120486028	A/G	cg24375607	chr4:120327624	NA	0.41	4.83	0.3	2.44e-6	Corneal astigmatism;
SARC	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-4.82	-0.3	2.59e-6	Total body bone mineral density;
SARC	cis	rs2439831	0.867	rs28461955	chr15:43661459	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.07	11.41	0.6	3.09e-24	Lung cancer in ever smokers;
SARC	cis	rs6545883	0.929	rs6705235	chr2:61713580	G/C	cg15711740	chr2:61764176	XPO1	-0.45	-5.28	-0.33	3.01e-7	Tuberculosis;
SARC	cis	rs12950390	0.776	rs4793646	chr17:45853966	A/C	cg03474202	chr17:45855739	NA	-0.43	-6.72	-0.4	1.4e-10	IgG glycosylation;
SARC	cis	rs10932679	0.595	rs11688933	chr2:217636105	A/G	cg05032264	chr2:217675019	NA	0.54	5.36	0.33	1.97e-7	Pulse pressure;
SARC	cis	rs9810089	0.802	rs10935182	chr3:136137422	G/A	cg15507776	chr3:136538369	TMEM22	0.47	5.27	0.33	3.05e-7	Gestational age at birth (child effect);
SARC	trans	rs2727020	0.734	rs1164664	chr11:49295542	T/G	cg03929089	chr4:120376271	NA	0.7	8.17	0.47	1.93e-14	Coronary artery disease;
SARC	cis	rs9399135	0.967	rs9389261	chr6:135371148	C/G	cg24558204	chr6:135376177	HBS1L	0.46	6.18	0.38	2.88e-9	Red blood cell count;
SARC	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg17971929	chr21:40555470	PSMG1	0.98	13.69	0.67	1.06e-31	Cognitive function;
SARC	cis	rs2228479	0.850	rs17232630	chr16:89851179	C/T	cg06558623	chr16:89946397	TCF25	0.93	6.44	0.39	6.63e-10	Skin colour saturation;
SARC	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg11062466	chr8:58055876	NA	0.61	5.75	0.35	2.74e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2455799	0.574	rs2102212	chr3:15704223	C/T	cg16303742	chr3:15540471	COLQ	-0.36	-5.22	-0.32	3.99e-7	Mean platelet volume;
SARC	cis	rs3796352	1.000	rs58660500	chr3:53086573	C/T	cg27565382	chr3:53032988	SFMBT1	0.98	6.93	0.41	4.19e-11	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg20102877	chr2:27665638	KRTCAP3	-0.38	-5.31	-0.33	2.53e-7	Total body bone mineral density;
SARC	cis	rs13191362	1.000	rs34066731	chr6:163011047	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.5	0.34	1.01e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs7255045	0.742	rs6511842	chr19:12955178	C/T	cg21491176	chr19:12958399	MAST1	-0.35	-4.86	-0.3	2.16e-6	Mean corpuscular volume;
SARC	cis	rs9303401	0.659	rs56162835	chr17:56687315	A/G	cg25039879	chr17:56429692	SUPT4H1	0.69	6.6	0.4	2.68e-10	Cognitive test performance;
SARC	trans	rs1991651	0.507	rs17778581	chr8:10743421	C/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.6	-0.4	2.77e-10	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
SARC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg05064044	chr6:292385	DUSP22	-0.54	-6.96	-0.41	3.48e-11	Menopause (age at onset);
SARC	cis	rs4555082	0.957	rs2816608	chr14:105718407	A/G	cg10792982	chr14:105748885	BRF1	-0.47	-6.99	-0.42	2.85e-11	Mean platelet volume;Platelet distribution width;
SARC	cis	rs1881797	0.872	rs12408686	chr1:247691141	C/T	cg11166453	chr1:247681781	NA	0.47	5.31	0.33	2.61e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs826838	0.586	rs1843903	chr12:38627524	C/T	cg26384229	chr12:38710491	ALG10B	0.73	9.77	0.54	4.05e-19	Heart rate;
SARC	cis	rs9611519	0.929	rs12484477	chr22:41429084	G/A	cg17376030	chr22:41985996	PMM1	0.5	6.05	0.37	5.85e-9	Neuroticism;
SARC	cis	rs921968	0.643	rs2278530	chr2:219501133	G/A	cg02176678	chr2:219576539	TTLL4	0.41	6.33	0.38	1.22e-9	Mean corpuscular hemoglobin concentration;
SARC	cis	rs4787491	0.729	rs11150584	chr16:30039678	C/A	cg06326092	chr16:30034487	C16orf92	0.27	4.72	0.3	4.06e-6	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs3126085	0.799	rs11589532	chr1:152176539	G/A	cg03465714	chr1:152285911	FLG	0.49	5.72	0.35	3.28e-8	Atopic dermatitis;
SARC	cis	rs6121246	0.559	rs6121243	chr20:30415094	C/G	cg13852791	chr20:30311386	BCL2L1	0.88	11.02	0.59	5.44e-23	Mean corpuscular hemoglobin;
SARC	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	11.09	0.59	3.12e-23	Alzheimer's disease;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg18915170	chr5:102548823	NA	0.54	7.58	0.44	8.22e-13	Thyroid stimulating hormone;
SARC	cis	rs1008375	0.898	rs7678654	chr4:17575376	T/G	cg27347728	chr4:17578864	LAP3	0.47	5.75	0.35	2.8e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs898097	0.841	rs8180	chr17:80901036	C/G	cg15369054	chr17:80825471	TBCD	-0.52	-7.64	-0.45	5.67e-13	Breast cancer;
SARC	trans	rs7395662	0.500	rs1304199	chr11:48699032	A/G	cg15704280	chr7:45808275	SEPT13	-0.53	-7.19	-0.43	8.66e-12	HDL cholesterol;
SARC	cis	rs2251381	0.722	rs2776252	chr21:30531705	G/A	cg24692254	chr21:30365293	RNF160	0.88	12.49	0.63	9.45e-28	Selective IgA deficiency;
SARC	cis	rs9660992	0.710	rs1172138	chr1:205246019	G/A	cg00857998	chr1:205179979	DSTYK	0.51	6.02	0.37	6.78e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs7264396	0.690	rs2425178	chr20:34446395	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	5.52	0.34	8.89e-8	Total cholesterol levels;
SARC	cis	rs1949733	1.000	rs2688223	chr4:8471398	T/C	cg13073564	chr4:8508604	NA	-0.46	-7.49	-0.44	1.39e-12	Response to antineoplastic agents;
SARC	cis	rs9393692	0.557	rs2393649	chr6:26338538	T/G	cg13736514	chr6:26305472	NA	-0.43	-5.1	-0.32	7.12e-7	Educational attainment;
SARC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.76	9.86	0.54	2.16e-19	Prudent dietary pattern;
SARC	cis	rs1707322	0.752	rs6662164	chr1:46146230	T/A	cg03146154	chr1:46216737	IPP	0.52	6.36	0.38	1.05e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs11098499	0.863	rs13140409	chr4:120503460	A/G	cg09307838	chr4:120376055	NA	0.91	12.25	0.63	5.66e-27	Corneal astigmatism;
SARC	cis	rs11785400	0.793	rs34875149	chr8:143736131	G/A	cg10596483	chr8:143751796	JRK	0.55	7.07	0.42	1.8e-11	Schizophrenia;
SARC	cis	rs763121	1.000	rs138464	chr22:38906432	C/T	cg06022373	chr22:39101656	GTPBP1	-0.76	-9.93	-0.55	1.36e-19	Menopause (age at onset);
SARC	cis	rs910316	1.000	rs4322591	chr14:75600697	C/T	cg06637938	chr14:75390232	RPS6KL1	0.5	7.15	0.42	1.09e-11	Height;
SARC	cis	rs864537	0.646	rs2995091	chr1:167434277	T/C	cg09179987	chr1:167433047	CD247	0.41	6.48	0.39	5.33e-10	Celiac disease or Rheumatoid arthritis;Celiac disease;
SARC	cis	rs7617773	0.539	rs13082217	chr3:48383264	T/C	cg11946769	chr3:48343235	NME6	0.55	6.76	0.4	1.11e-10	Coronary artery disease;
SARC	cis	rs826838	0.967	rs1684411	chr12:39128494	C/T	cg13010199	chr12:38710504	ALG10B	-0.63	-8.68	-0.49	6.88e-16	Heart rate;
SARC	cis	rs1878931	0.582	rs27232	chr16:3436782	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.66	-7.27	-0.43	5.27e-12	Body mass index (adult);
SARC	cis	rs3857536	0.904	rs10806526	chr6:66900531	T/C	cg07460842	chr6:66804631	NA	-0.46	-5.45	-0.34	1.26e-7	Blood trace element (Cu levels);
SARC	cis	rs77633900	0.614	rs280005	chr15:77009185	G/C	cg21673338	chr15:77095150	SCAPER	-0.61	-5.19	-0.32	4.68e-7	Non-glioblastoma glioma;Glioma;
SARC	cis	rs826838	0.654	rs7977738	chr12:38722460	G/A	cg04568710	chr12:38710424	ALG10B	0.38	4.71	0.3	4.19e-6	Heart rate;
SARC	cis	rs2644899	0.785	rs7249450	chr19:41300771	T/C	cg24958765	chr19:41283667	RAB4B	-0.59	-6.47	-0.39	5.69e-10	Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs4808199	0.948	rs2301671	chr19:19466269	C/T	cg03709012	chr19:19516395	GATAD2A	1.05	10.92	0.58	1.08e-22	Nonalcoholic fatty liver disease;
SARC	cis	rs6141769	0.542	rs6057627	chr20:31306728	C/G	cg17884169	chr20:31446444	EFCAB8	-0.44	-4.78	-0.3	3.09e-6	Subjective well-being;
SARC	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg16405210	chr4:1374714	KIAA1530	-0.45	-5.2	-0.32	4.42e-7	Obesity-related traits;
SARC	cis	rs2250402	0.510	rs8031319	chr15:40323692	A/G	cg20255370	chr15:40268687	EIF2AK4	-0.7	-5.84	-0.36	1.79e-8	Corneal curvature;
SARC	cis	rs7208859	0.573	rs11656278	chr17:29075188	C/T	cg13385521	chr17:29058706	SUZ12P	0.88	7.94	0.46	8.37e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs11874712	0.932	rs8092674	chr18:43665982	C/T	cg25174615	chr18:43684699	ATP5A1;HAUS1	0.4	4.75	0.3	3.52e-6	Migraine - clinic-based;
SARC	cis	rs7520050	0.807	rs6671802	chr1:46124663	A/G	cg06784218	chr1:46089804	CCDC17	0.26	4.75	0.3	3.53e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs9640161	0.636	rs3735171	chr7:150033882	A/G	cg17279839	chr7:150038598	RARRES2	0.48	6.8	0.41	8.77e-11	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs155076	1.000	rs9509638	chr13:21860193	G/A	cg11317459	chr13:21872234	NA	-0.95	-11.7	-0.61	3.57e-25	White matter hyperintensity burden;
SARC	cis	rs8014204	0.550	rs7152906	chr14:75125540	T/C	cg17347104	chr14:75034677	LTBP2	-0.47	-6.19	-0.38	2.68e-9	Caffeine consumption;
SARC	cis	rs17270561	0.609	rs4464787	chr6:25733558	G/C	cg17691542	chr6:26056736	HIST1H1C	0.58	7.09	0.42	1.6e-11	Iron status biomarkers;
SARC	cis	rs7582720	1.000	rs72932561	chr2:203848402	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs7000551	0.715	rs7839577	chr8:22307325	T/A	cg12081754	chr8:22256438	SLC39A14	0.6	8.24	0.48	1.21e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs3087591	0.960	rs2952999	chr17:29509801	G/T	cg24425628	chr17:29625626	OMG;NF1	0.47	5.79	0.35	2.29e-8	Hip circumference;
SARC	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg04267008	chr7:1944627	MAD1L1	-0.62	-7.3	-0.43	4.42e-12	Bipolar disorder and schizophrenia;
SARC	cis	rs7662987	0.540	rs2851257	chr4:100039499	G/C	cg12011299	chr4:100065546	ADH4	0.33	5.47	0.34	1.13e-7	Smoking initiation;
SARC	cis	rs2735413	0.846	rs72800943	chr16:78079555	G/A	cg04733911	chr16:78082701	NA	-0.3	-5.42	-0.33	1.51e-7	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg13397359	chr6:42928475	GNMT	0.57	7.94	0.46	8.65e-14	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg18252515	chr7:66147081	NA	0.53	5.7	0.35	3.55e-8	Aortic root size;
SARC	cis	rs4742903	0.935	rs10120101	chr9:107000909	C/T	cg14250997	chr9:106856677	SMC2	0.38	4.75	0.3	3.57e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs9354308	0.868	rs9453450	chr6:66545431	T/A	cg07460842	chr6:66804631	NA	-0.45	-5.23	-0.32	3.77e-7	Metabolite levels;
SARC	cis	rs6570726	0.935	rs415590	chr6:145851244	T/C	cg05220968	chr6:146057943	EPM2A	-0.29	-5.04	-0.31	9.48e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs73086581	0.687	rs16989002	chr20:3850703	G/C	cg02187196	chr20:3869020	PANK2	0.65	5.74	0.35	2.86e-8	Response to antidepressants in depression;
SARC	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg08859206	chr1:53392774	SCP2	0.43	6.13	0.37	3.76e-9	Monocyte count;
SARC	cis	rs9640161	0.789	rs60283368	chr7:150023258	G/A	cg10018233	chr7:150070692	REPIN1	0.7	9.92	0.54	1.46e-19	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs933688	0.532	rs868557	chr5:90550379	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.48	-5.27	-0.33	3.14e-7	Smoking behavior;
SARC	cis	rs6545883	0.929	rs6545877	chr2:61741947	T/C	cg15711740	chr2:61764176	XPO1	-0.43	-5.36	-0.33	1.97e-7	Tuberculosis;
SARC	cis	rs274567	0.711	rs404771	chr5:131635092	A/T	cg04518342	chr5:131593106	PDLIM4	0.42	5.32	0.33	2.38e-7	Blood metabolite levels;
SARC	cis	rs6493487	0.512	rs7170009	chr15:51323648	C/A	cg02338191	chr15:51200825	AP4E1	0.53	4.83	0.3	2.44e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg15049968	chr18:44337910	ST8SIA5	-0.36	-5.62	-0.35	5.52e-8	Personality dimensions;
SARC	cis	rs17125944	0.505	rs77137752	chr14:53230496	G/T	cg00686598	chr14:53173677	PSMC6	1.3	9.0	0.51	8.31e-17	Alzheimer's disease (late onset);
SARC	cis	rs910316	1.000	rs10142626	chr14:75555636	A/T	cg08847533	chr14:75593920	NEK9	0.94	16.23	0.73	3.78e-40	Height;
SARC	cis	rs7178572	0.568	rs12910480	chr15:77664212	G/C	cg22256960	chr15:77711686	NA	-0.52	-5.7	-0.35	3.62e-8	Type 2 diabetes;
SARC	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg10523679	chr1:76189770	ACADM	0.52	6.85	0.41	6.67e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg24549020	chr5:56110836	MAP3K1	0.83	8.7	0.5	5.98e-16	Initial pursuit acceleration;
SARC	cis	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg00409905	chr10:38381863	ZNF37A	-0.55	-7.94	-0.46	8.52e-14	Extrinsic epigenetic age acceleration;
SARC	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-7.88	-0.46	1.24e-13	Chronic sinus infection;
SARC	cis	rs2594989	0.673	rs62245959	chr3:11601797	G/T	cg00170343	chr3:11313890	ATG7	-0.53	-5.09	-0.32	7.47e-7	Circulating chemerin levels;
SARC	cis	rs651907	0.557	rs7651404	chr3:101393294	C/A	cg12386194	chr3:101231763	SENP7	0.49	5.85	0.36	1.61e-8	Colorectal cancer;
SARC	cis	rs7833986	0.501	rs2719261	chr8:56941982	C/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.74	7.64	0.45	5.66e-13	Height;
SARC	cis	rs9325144	0.534	rs6582538	chr12:38629997	A/C	cg13010199	chr12:38710504	ALG10B	-0.55	-7.13	-0.42	1.26e-11	Morning vs. evening chronotype;
SARC	cis	rs9300255	0.544	rs2049114	chr12:123657338	T/C	cg00376283	chr12:123451042	ABCB9	0.58	6.82	0.41	7.75e-11	Neutrophil percentage of white cells;
SARC	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg13395646	chr4:1353034	KIAA1530	-0.52	-6.26	-0.38	1.88e-9	Obesity-related traits;
SARC	cis	rs8114671	0.527	rs2253484	chr20:33405263	A/T	cg24642439	chr20:33292090	TP53INP2	-0.53	-6.44	-0.39	6.89e-10	Height;
SARC	cis	rs11123694	1.000	rs11123694	chr2:109064563	C/T	cg01745370	chr2:109065127	GCC2	0.34	5.02	0.31	1.01e-6	Mean platelet volume;
SARC	cis	rs16944613	0.588	rs6496697	chr15:91131832	C/T	cg26821196	chr15:91095069	CRTC3	-0.5	-5.64	-0.35	4.89e-8	Colorectal cancer;
SARC	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg11062466	chr8:58055876	NA	0.52	5.4	0.33	1.64e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg13939156	chr17:80058883	NA	-0.44	-6.7	-0.4	1.58e-10	Life satisfaction;
SARC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg11203670	chr7:100026453	MEPCE;ZCWPW1	0.51	5.07	0.32	8.19e-7	Platelet count;
SARC	cis	rs239198	0.555	rs9386258	chr6:101286336	C/G	cg09795085	chr6:101329169	ASCC3	0.51	6.31	0.38	1.37e-9	Menarche (age at onset);
SARC	cis	rs2070997	0.607	rs2772028	chr9:133707940	C/T	cg11464064	chr9:133710261	ABL1	0.59	5.32	0.33	2.48e-7	Response to amphetamines;
SARC	cis	rs3740540	0.507	rs942014	chr10:126290070	C/T	cg04949429	chr10:126290192	LHPP	0.43	6.14	0.37	3.45e-9	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
SARC	cis	rs7429990	0.932	rs6803741	chr3:48123540	C/T	cg11946769	chr3:48343235	NME6	-0.48	-5.46	-0.34	1.21e-7	Educational attainment (years of education);
SARC	cis	rs5167	0.566	rs60876330	chr19:45488133	C/T	cg13119609	chr19:45449297	APOC2	0.39	5.53	0.34	8.77e-8	Blood protein levels;
SARC	cis	rs708547	0.874	rs1713978	chr4:57875879	G/A	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.47	-5.2	-0.32	4.43e-7	Response to bleomycin (chromatid breaks);
SARC	cis	rs8114671	0.562	rs725521	chr20:33516071	T/C	cg24642439	chr20:33292090	TP53INP2	0.5	6.15	0.37	3.35e-9	Height;
SARC	cis	rs3758785	0.510	rs483476	chr11:94069815	C/T	cg13023536	chr11:94226537	MRE11A;ANKRD49	-0.44	-5.65	-0.35	4.61e-8	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
SARC	cis	rs1707322	0.662	rs11211160	chr1:46146229	T/A	cg03146154	chr1:46216737	IPP	0.52	6.38	0.39	9.66e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg04248312	chr19:17393744	ANKLE1	-0.61	-8.03	-0.47	4.94e-14	Systemic lupus erythematosus;
SARC	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg18876405	chr7:65276391	NA	0.49	6.04	0.37	6e-9	Aortic root size;
SARC	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg02725872	chr8:58115012	NA	-0.32	-4.84	-0.3	2.41e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs8114671	0.562	rs959829	chr20:33346047	T/C	cg24642439	chr20:33292090	TP53INP2	-0.53	-6.56	-0.39	3.44e-10	Height;
SARC	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	9.06	0.51	5.34e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg06319359	chr1:22109595	USP48	0.62	6.39	0.39	9.05e-10	Lung cancer in ever smokers;
SARC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg20007245	chr22:24372913	LOC391322	0.69	8.26	0.48	1.07e-14	Liver enzyme levels (gamma-glutamyl transferase);
SARC	trans	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg21659725	chr3:3221576	CRBN	-0.52	-6.72	-0.4	1.42e-10	Intelligence (multi-trait analysis);
SARC	cis	rs616402	0.527	rs604814	chr1:10567122	G/A	cg17425144	chr1:10567563	PEX14	0.45	7.39	0.44	2.61e-12	Breast size;
SARC	cis	rs559928	0.597	rs947939	chr11:63885287	C/T	cg05555928	chr11:63887634	MACROD1	-0.51	-4.85	-0.3	2.26e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs9787249	0.957	rs7547787	chr1:40220806	C/T	cg24920358	chr1:40204285	PPIE	0.43	5.21	0.32	4.07e-7	Blood protein levels;
SARC	cis	rs7223966	1.000	rs9747164	chr17:61864787	T/C	cg00588841	chr17:61851480	DDX42;CCDC47	-0.64	-6.7	-0.4	1.59e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs8177253	0.633	rs10935073	chr3:133439184	T/C	cg01448562	chr3:133502909	NA	-0.44	-6.42	-0.39	7.59e-10	Iron status biomarkers;
SARC	cis	rs7223966	0.921	rs2854207	chr17:61947107	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	6.97	0.42	3.31e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6429082	0.818	rs210037	chr1:235649501	A/G	cg26050004	chr1:235667680	B3GALNT2	0.65	7.49	0.44	1.46e-12	Adiposity;
SARC	cis	rs3768617	0.510	rs6691755	chr1:183099821	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.66e-21	Fuchs's corneal dystrophy;
SARC	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs3796352	1.000	rs71301814	chr3:53117663	G/A	cg27565382	chr3:53032988	SFMBT1	0.99	6.8	0.41	8.62e-11	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs910316	0.763	rs175490	chr14:75545685	A/G	cg23033748	chr14:75592666	NEK9	0.36	4.9	0.31	1.82e-6	Height;
SARC	cis	rs60871478	1.000	rs4720917	chr7:806998	C/G	cg19087971	chr7:751233	PRKAR1B	-0.43	-4.88	-0.3	2.01e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs172166	0.637	rs1225595	chr6:28151340	A/T	cg17221315	chr6:27791827	HIST1H4J	0.46	5.33	0.33	2.34e-7	Cardiac Troponin-T levels;
SARC	cis	rs2228479	0.702	rs62056090	chr16:89930087	T/A	cg04013166	chr16:89971882	TCF25	0.55	4.86	0.3	2.16e-6	Skin colour saturation;
SARC	cis	rs35306767	0.903	rs12244355	chr10:944465	T/C	cg20503657	chr10:835505	NA	0.77	7.29	0.43	4.8e-12	Eosinophil percentage of granulocytes;
SARC	cis	rs17401966	1.000	rs60743860	chr1:10442926	G/C	cg15208524	chr1:10270712	KIF1B	0.58	6.32	0.38	1.29e-9	Hepatocellular carcinoma;
SARC	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg05368731	chr17:41323189	NBR1	0.8	9.77	0.54	3.97e-19	Menopause (age at onset);
SARC	cis	rs35213789	0.853	rs11763186	chr7:69270649	T/C	cg10619644	chr7:69149951	AUTS2	0.36	4.73	0.3	3.88e-6	Childhood ear infection;
SARC	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg05861140	chr6:150128134	PCMT1	-0.4	-5.23	-0.32	3.79e-7	Lung cancer;
SARC	cis	rs3008870	0.727	rs2755270	chr1:67474503	C/T	cg02640540	chr1:67518911	SLC35D1	0.46	5.26	0.33	3.34e-7	Lymphocyte percentage of white cells;
SARC	cis	rs936229	0.656	rs12898397	chr15:75130093	T/C	cg14664628	chr15:75095509	CSK	-0.64	-7.59	-0.45	7.6e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs6540556	1.000	rs6540556	chr1:209936631	G/A	cg05527609	chr1:210001259	C1orf107	-0.63	-6.42	-0.39	7.75e-10	Red blood cell count;
SARC	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg05861140	chr6:150128134	PCMT1	-0.39	-4.83	-0.3	2.46e-6	Lung cancer;
SARC	cis	rs5753618	0.504	rs9606848	chr22:31901867	G/A	cg07713946	chr22:31675144	LIMK2	0.37	5.19	0.32	4.56e-7	Colorectal cancer;
SARC	cis	rs1728785	0.901	rs12929568	chr16:68596689	A/G	cg02972257	chr16:68554789	NA	-0.47	-5.52	-0.34	8.85e-8	Ulcerative colitis;
SARC	cis	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg21775007	chr8:11205619	TDH	0.45	6.0	0.37	7.56e-9	Neuroticism;
SARC	cis	rs11676348	0.755	rs6436026	chr2:218951738	T/A	cg00012203	chr2:219082015	ARPC2	-0.51	-6.82	-0.41	7.56e-11	Ulcerative colitis;
SARC	cis	rs9487051	0.714	rs1546722	chr6:109625797	A/G	cg21918786	chr6:109611834	NA	-0.34	-4.75	-0.3	3.49e-6	Reticulocyte fraction of red cells;
SARC	cis	rs765787	0.530	rs11634794	chr15:45534492	A/C	cg25801113	chr15:45476975	SHF	0.3	4.92	0.31	1.64e-6	Uric acid levels;
SARC	cis	rs2197308	0.703	rs10880251	chr12:37903297	G/A	cg13010199	chr12:38710504	ALG10B	0.8	11.02	0.59	5.3e-23	Morning vs. evening chronotype;
SARC	cis	rs11758351	0.660	rs75156165	chr6:26235699	C/A	cg01420254	chr6:26195488	NA	0.56	4.73	0.3	3.97e-6	Gout;Renal underexcretion gout;
SARC	cis	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg25427524	chr10:38739819	LOC399744	-0.52	-8.14	-0.47	2.31e-14	Extrinsic epigenetic age acceleration;
SARC	cis	rs2228479	0.850	rs62054609	chr16:89816569	C/A	cg00800038	chr16:89945340	TCF25	-0.74	-5.14	-0.32	5.75e-7	Skin colour saturation;
SARC	cis	rs7712401	0.715	rs424262	chr5:122348012	G/A	cg19412675	chr5:122181750	SNX24	-0.41	-5.26	-0.33	3.18e-7	Mean platelet volume;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg10345337	chr14:65569751	MAX	-0.83	-7.14	-0.42	1.17e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1055129	0.537	rs10852766	chr17:73951864	T/C	cg14829360	chr17:73884958	NA	0.54	7.83	0.46	1.74e-13	White matter hyperintensity burden;
SARC	cis	rs7937682	0.855	rs490897	chr11:111487914	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.87	-13.3	-0.66	2.02e-30	Primary sclerosing cholangitis;
SARC	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg13770153	chr20:60521292	NA	-0.46	-6.33	-0.38	1.23e-9	Body mass index;
SARC	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg26818010	chr10:134567672	INPP5A	-0.64	-7.01	-0.42	2.58e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs2177596	0.541	rs10206634	chr2:227948980	T/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-4.88	-0.3	1.98e-6	Body mass index;
SARC	cis	rs9291683	0.595	rs11731110	chr4:10037346	T/C	cg11266682	chr4:10021025	SLC2A9	0.4	7.09	0.42	1.58e-11	Bone mineral density;
SARC	cis	rs6964587	1.000	rs10274756	chr7:91740796	G/A	cg17063962	chr7:91808500	NA	0.93	15.65	0.72	3.24e-38	Breast cancer;
SARC	cis	rs2072499	0.722	rs61462713	chr1:156161682	C/T	cg25208724	chr1:156163844	SLC25A44	0.86	9.9	0.54	1.67e-19	Testicular germ cell tumor;
SARC	cis	rs7312933	1.000	rs3229	chr12:42475888	G/A	cg19980929	chr12:42632907	YAF2	0.33	4.72	0.3	4.07e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs2273669	0.667	rs12153822	chr6:109315115	T/C	cg05315195	chr6:109294784	ARMC2	-0.59	-5.45	-0.34	1.28e-7	Prostate cancer;
SARC	cis	rs17376456	0.877	rs9314099	chr5:93447375	T/C	cg25358565	chr5:93447407	FAM172A	1.31	15.17	0.7	1.33e-36	Diabetic retinopathy;
SARC	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg12463550	chr7:65579703	CRCP	0.67	5.06	0.31	8.43e-7	Diabetic kidney disease;
SARC	cis	rs7223966	0.883	rs2955250	chr17:61959740	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	7.07	0.42	1.75e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg17376030	chr22:41985996	PMM1	-0.73	-8.97	-0.51	1.01e-16	Vitiligo;
SARC	cis	rs72781680	0.821	rs111571980	chr2:24201695	C/G	cg06627628	chr2:24431161	ITSN2	-0.57	-6.13	-0.37	3.63e-9	Lymphocyte counts;
SARC	cis	rs9790314	0.580	rs960212	chr3:161047974	C/T	cg03342759	chr3:160939853	NMD3	-0.53	-6.45	-0.39	6.23e-10	Morning vs. evening chronotype;
SARC	cis	rs4819052	0.788	rs9978857	chr21:46705155	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	7.01	0.42	2.55e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6565180	1.000	rs11863150	chr16:30385503	C/T	cg17640201	chr16:30407289	ZNF48	0.99	16.98	0.74	1.28e-42	Tonsillectomy;
SARC	cis	rs55823223	0.564	rs936396	chr17:73846829	C/G	cg23806715	chr17:73775811	H3F3B	0.46	4.87	0.3	2.04e-6	Psoriasis;
SARC	trans	rs61931739	0.534	rs4931772	chr12:34044590	G/A	cg26384229	chr12:38710491	ALG10B	0.75	10.62	0.57	9.96e-22	Morning vs. evening chronotype;
SARC	cis	rs2439831	0.850	rs28524541	chr15:44124831	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	7.69	0.45	4.23e-13	Lung cancer in ever smokers;
SARC	cis	rs6089584	1.000	rs6089580	chr20:60558976	G/A	cg23262073	chr20:60523788	NA	-0.44	-6.42	-0.39	7.39e-10	Body mass index;
SARC	cis	rs2315504	0.605	rs2469816	chr17:39005954	C/T	cg05063374	chr17:38953512	KRT28	0.28	4.86	0.3	2.13e-6	Height;
SARC	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg27266027	chr21:40555129	PSMG1	0.51	5.52	0.34	9.21e-8	Cognitive function;
SARC	cis	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg25894440	chr7:65020034	NA	-0.77	-5.9	-0.36	1.24e-8	Diabetic kidney disease;
SARC	cis	rs9916302	0.861	rs8079590	chr17:37426201	T/C	cg15445000	chr17:37608096	MED1	0.41	5.08	0.32	7.87e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs7560272	0.695	rs13022149	chr2:73641515	T/A	cg20560298	chr2:73613845	ALMS1	0.52	7.14	0.42	1.17e-11	Schizophrenia;
SARC	cis	rs76419734	0.510	rs2544417	chr4:106745405	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	-0.74	-7.55	-0.44	9.63e-13	Post bronchodilator FEV1;
SARC	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg04267008	chr7:1944627	MAD1L1	0.54	6.15	0.37	3.28e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg08219700	chr8:58056026	NA	0.57	5.21	0.32	4.17e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs240764	0.817	rs239216	chr6:101147892	T/G	cg09795085	chr6:101329169	ASCC3	0.45	5.91	0.36	1.21e-8	Neuroticism;
SARC	cis	rs12477438	0.605	rs4585080	chr2:99557327	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.93	-14.31	-0.68	9.64e-34	Chronic sinus infection;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18648343	chr14:39644430	PNN	-0.54	-6.61	-0.4	2.59e-10	Fibrinogen levels;
SARC	cis	rs7927771	0.524	rs10838769	chr11:47825333	A/G	cg20307385	chr11:47447363	PSMC3	-0.49	-6.63	-0.4	2.36e-10	Subjective well-being;
SARC	trans	rs7980799	0.682	rs1580396	chr12:33615841	C/A	cg13010199	chr12:38710504	ALG10B	-0.53	-6.27	-0.38	1.78e-9	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs4595586	0.545	rs12823487	chr12:39391286	A/G	cg26384229	chr12:38710491	ALG10B	0.5	6.12	0.37	3.98e-9	Morning vs. evening chronotype;
SARC	cis	rs7617773	0.815	rs6793150	chr3:48351560	G/A	cg11946769	chr3:48343235	NME6	0.76	9.7	0.54	6.55e-19	Coronary artery disease;
SARC	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg22618164	chr12:122356400	WDR66	0.43	6.98	0.42	3.04e-11	Mean corpuscular volume;
SARC	cis	rs9341808	0.667	rs3805919	chr6:80906809	C/G	cg08355045	chr6:80787529	NA	0.36	5.8	0.36	2.17e-8	Sitting height ratio;
SARC	cis	rs734999	0.588	rs2843404	chr1:2530558	T/C	cg20673091	chr1:2541236	MMEL1	-0.33	-5.09	-0.32	7.54e-7	Ulcerative colitis;
SARC	cis	rs6570726	0.935	rs434298	chr6:145846873	G/A	cg05220968	chr6:146057943	EPM2A	-0.28	-4.86	-0.3	2.17e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg11062466	chr8:58055876	NA	0.66	6.04	0.37	6.14e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1568889	0.877	rs1384903	chr11:28124359	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	8.8	0.5	3.23e-16	Bipolar disorder;
SARC	cis	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg08975724	chr8:8085496	FLJ10661	0.49	6.33	0.38	1.26e-9	Mood instability;
SARC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg02592271	chr2:27665507	KRTCAP3	-0.42	-6.45	-0.39	6.22e-10	Total body bone mineral density;
SARC	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg24642844	chr7:1081250	C7orf50	-0.59	-6.06	-0.37	5.31e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs9790314	1.000	rs6794601	chr3:160946769	C/T	cg03342759	chr3:160939853	NMD3	-0.62	-7.93	-0.46	9.29e-14	Morning vs. evening chronotype;
SARC	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	7.77	0.45	2.56e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2153535	0.580	rs9392220	chr6:8457946	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	6.55	0.39	3.66e-10	Motion sickness;
SARC	cis	rs7524258	0.868	rs4908451	chr1:7299618	C/G	cg07173049	chr1:7289937	CAMTA1	-0.38	-7.22	-0.43	7.19e-12	Tourette's syndrome or obsessive-compulsive disorder;
SARC	cis	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg22857025	chr5:266934	NA	-1.06	-11.8	-0.61	1.74e-25	Breast cancer;
SARC	cis	rs2011503	0.943	rs10406278	chr19:19494725	A/C	cg03709012	chr19:19516395	GATAD2A	-0.65	-5.63	-0.35	5.07e-8	Bipolar disorder;
SARC	cis	rs6011674	0.803	rs6011692	chr20:61867828	G/A	cg06763829	chr20:61885236	FLJ16779;NKAIN4	0.63	4.84	0.3	2.39e-6	Response to cytadine analogues (cytosine arabinoside);
SARC	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg01316550	chr5:56110833	MAP3K1	0.54	4.86	0.3	2.17e-6	Type 2 diabetes;
SARC	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg13395646	chr4:1353034	KIAA1530	-0.55	-6.58	-0.4	3.03e-10	Obesity-related traits;
SARC	cis	rs11098499	0.863	rs12498539	chr4:120468370	C/T	cg09307838	chr4:120376055	NA	0.91	12.25	0.63	5.66e-27	Corneal astigmatism;
SARC	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg24642844	chr7:1081250	C7orf50	-0.38	-5.23	-0.32	3.7e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs35110281	0.720	rs162394	chr21:44943550	C/G	cg01579765	chr21:45077557	HSF2BP	0.34	5.78	0.35	2.36e-8	Mean corpuscular volume;
SARC	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg01341218	chr17:43662625	NA	0.69	8.32	0.48	7.4e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg11062466	chr8:58055876	NA	0.65	5.83	0.36	1.79e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs28655083	1.000	rs28655083	chr16:77061214	C/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.41	-5.82	-0.36	1.9e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11648796	0.757	rs66649828	chr16:766078	A/G	cg04709771	chr16:646395	RAB40C	0.4	5.2	0.32	4.45e-7	Height;
SARC	cis	rs36051895	0.632	rs7850425	chr9:5170645	G/T	cg02405213	chr9:5042618	JAK2	-0.49	-5.6	-0.34	6.08e-8	Pediatric autoimmune diseases;
SARC	cis	rs9443189	0.855	rs2842554	chr6:76455557	C/A	cg01950844	chr6:76311363	SENP6	-0.69	-6.47	-0.39	5.78e-10	Prostate cancer;
SARC	cis	rs6582630	0.519	rs8189623	chr12:38351436	G/A	cg13010199	chr12:38710504	ALG10B	0.78	10.77	0.58	3.24e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs3540	0.574	rs2526000	chr15:90962626	C/T	cg22089800	chr15:90895588	ZNF774	0.65	8.18	0.47	1.89e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	15.47	0.71	1.27e-37	Chronic sinus infection;
SARC	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg25072359	chr17:41440525	NA	0.51	6.13	0.37	3.66e-9	Menopause (age at onset);
SARC	cis	rs4722166	0.630	rs13311199	chr7:22789793	A/C	cg26061582	chr7:22766209	IL6	0.54	6.05	0.37	5.76e-9	Lung cancer;
SARC	cis	rs9462027	0.628	rs9348950	chr6:34673678	G/A	cg07306190	chr6:34760872	UHRF1BP1	0.43	6.18	0.38	2.89e-9	Systemic lupus erythematosus;
SARC	cis	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg05623727	chr3:50126028	RBM5	-0.32	-4.78	-0.3	3.13e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2576037	0.796	rs6507718	chr18:44581284	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.69	-10.0	-0.55	8.13e-20	Personality dimensions;
SARC	cis	rs7769051	0.711	rs7770081	chr6:133089569	G/T	cg07930552	chr6:133119739	C6orf192	0.9	7.94	0.46	8.74e-14	Type 2 diabetes nephropathy;
SARC	cis	rs11190604	1.000	rs10883513	chr10:102316964	A/G	cg07080220	chr10:102295463	HIF1AN	0.83	8.6	0.49	1.21e-15	Palmitoleic acid (16:1n-7) levels;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg24717964	chr20:61477008	DPH3B;TCFL5	-0.85	-7.0	-0.42	2.76e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg12463550	chr7:65579703	CRCP	0.5	5.91	0.36	1.21e-8	Aortic root size;
SARC	cis	rs2832191	0.935	rs11910475	chr21:30519702	T/C	cg24692254	chr21:30365293	RNF160	-0.78	-10.82	-0.58	2.3e-22	Dental caries;
SARC	cis	rs9486719	1.000	rs926276	chr6:96868735	C/T	cg06623918	chr6:96969491	KIAA0776	0.73	8.33	0.48	6.81e-15	Migraine;Coronary artery disease;
SARC	cis	rs2011503	0.941	rs2315023	chr19:19413393	C/T	cg03709012	chr19:19516395	GATAD2A	0.65	5.81	0.36	2.06e-8	Bipolar disorder;
SARC	cis	rs950776	0.714	rs3743074	chr15:78909480	G/A	cg06917634	chr15:78832804	PSMA4	-0.7	-9.36	-0.52	6.84e-18	Sudden cardiac arrest;
SARC	cis	rs8028182	0.636	rs28610581	chr15:75812474	A/G	cg20655648	chr15:75932815	IMP3	0.64	7.38	0.44	2.83e-12	Sudden cardiac arrest;
SARC	cis	rs9467773	1.000	rs9393728	chr6:26509330	C/G	cg12292205	chr6:26970375	C6orf41	0.43	5.24	0.32	3.66e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2832191	1.000	rs2832185	chr21:30483761	C/G	cg24692254	chr21:30365293	RNF160	-0.77	-10.73	-0.58	4.22e-22	Dental caries;
SARC	cis	rs9902453	0.967	rs9904336	chr17:28357080	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.53	-6.96	-0.41	3.52e-11	Coffee consumption (cups per day);
SARC	cis	rs8071789	1.000	rs8071789	chr17:38006333	C/T	cg20243544	chr17:37824526	PNMT	0.43	5.74	0.35	3e-8	Selective IgA deficiency;
SARC	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg18305652	chr10:134549665	INPP5A	0.36	5.15	0.32	5.46e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs35213789	0.734	rs2533429	chr7:69139856	G/A	cg10619644	chr7:69149951	AUTS2	-0.35	-4.86	-0.3	2.18e-6	Childhood ear infection;
SARC	cis	rs9398803	0.661	rs853985	chr6:127020173	C/T	cg19875578	chr6:126661172	C6orf173	-0.64	-8.9	-0.5	1.56e-16	Male-pattern baldness;
SARC	cis	rs3744061	0.520	rs9908979	chr17:74645486	T/G	cg27546012	chr17:74684504	MXRA7	-0.36	-5.02	-0.31	1.02e-6	Retinal arteriolar caliber;
SARC	trans	rs877282	0.898	rs12357016	chr10:765675	C/T	cg22713356	chr15:30763199	NA	1.04	10.06	0.55	5.37e-20	Uric acid levels;
SARC	cis	rs7264396	0.790	rs2425160	chr20:34425968	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.2	-0.43	8.46e-12	Total cholesterol levels;
SARC	cis	rs11871801	0.517	rs668799	chr17:40716235	C/T	cg20126647	chr17:40714003	COASY	0.49	5.34	0.33	2.22e-7	Crohn's disease;
SARC	cis	rs9467773	0.935	rs9461270	chr6:26544110	A/G	cg12292205	chr6:26970375	C6orf41	0.45	5.42	0.33	1.45e-7	Intelligence (multi-trait analysis);
SARC	cis	rs8038465	0.622	rs17185525	chr15:73885539	T/C	cg15420318	chr15:73925796	NPTN	0.63	7.19	0.43	8.78e-12	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs72781680	0.821	rs56064672	chr2:24156769	G/T	cg08917208	chr2:24149416	ATAD2B	0.58	5.89	0.36	1.34e-8	Lymphocyte counts;
SARC	cis	rs155076	0.938	rs9509630	chr13:21844314	G/A	cg06138931	chr13:21896616	NA	-0.39	-5.08	-0.32	7.88e-7	White matter hyperintensity burden;
SARC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg26354017	chr1:205819088	PM20D1	0.86	13.67	0.67	1.23e-31	Menarche (age at onset);
SARC	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg04277193	chr17:41438351	NA	0.45	4.93	0.31	1.59e-6	Menopause (age at onset);
SARC	cis	rs1707322	1.000	rs1707317	chr1:46510642	C/T	cg06784218	chr1:46089804	CCDC17	-0.36	-6.46	-0.39	6.21e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2836633	0.895	rs61085980	chr21:40032140	C/T	cg12884169	chr21:40033163	ERG	0.45	8.43	0.48	3.58e-15	Coronary artery disease;
SARC	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg19671926	chr4:122722719	EXOSC9	-0.51	-5.89	-0.36	1.32e-8	Type 2 diabetes;
SARC	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.49	5.62	0.35	5.33e-8	Renal function-related traits (BUN);
SARC	cis	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.67	-0.45	4.59e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.37	0.39	9.97e-10	Bipolar disorder;
SARC	cis	rs10779751	0.734	rs2791658	chr1:11127871	A/G	cg08854313	chr1:11322531	MTOR	0.82	11.26	0.59	8.86e-24	Body mass index;
SARC	cis	rs10504073	0.647	rs12546839	chr8:50009020	C/T	cg00325661	chr8:49890786	NA	0.55	7.4	0.44	2.49e-12	Blood metabolite ratios;
SARC	cis	rs7829975	0.582	rs448231	chr8:8790059	A/T	cg14343924	chr8:8086146	FLJ10661	-0.39	-4.74	-0.3	3.7e-6	Mood instability;
SARC	cis	rs9394169	0.536	rs3998115	chr6:33784833	G/C	cg25922239	chr6:33757077	LEMD2	0.4	4.91	0.31	1.69e-6	Essential tremor;
SARC	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.43	0.39	7.26e-10	Height;
SARC	cis	rs826838	1.000	rs11168217	chr12:38884278	T/C	cg26384229	chr12:38710491	ALG10B	0.92	14.37	0.69	6.03e-34	Heart rate;
SARC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.14	0.8	6.21e-53	Prudent dietary pattern;
SARC	cis	rs9486719	1.000	rs926276	chr6:96868735	C/T	cg18709589	chr6:96969512	KIAA0776	0.47	4.99	0.31	1.16e-6	Migraine;Coronary artery disease;
SARC	cis	rs7647973	1.000	rs11720542	chr3:49357427	A/G	cg07636037	chr3:49044803	WDR6	0.71	8.08	0.47	3.58e-14	Menarche (age at onset);
SARC	cis	rs858239	0.539	rs3950345	chr7:23191114	T/C	cg23682824	chr7:23144976	KLHL7	0.74	9.66	0.53	8.86e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs910316	0.967	rs4384542	chr14:75658013	A/C	cg08847533	chr14:75593920	NEK9	-0.87	-13.66	-0.67	1.33e-31	Height;
SARC	cis	rs6714710	0.627	rs6748124	chr2:98519014	T/C	cg26665480	chr2:98280029	ACTR1B	0.51	6.94	0.41	3.94e-11	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs56235845	0.694	rs6876677	chr5:176755342	T/C	cg16006841	chr5:176797999	RGS14	0.53	7.17	0.43	9.62e-12	Hemoglobin concentration;Hematocrit;
SARC	cis	rs11105298	0.891	rs10858851	chr12:89830870	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.48	-4.71	-0.3	4.19e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs9394169	0.709	rs6919321	chr6:33724004	G/A	cg04676172	chr6:33757040	LEMD2	0.43	5.2	0.32	4.35e-7	Essential tremor;
SARC	cis	rs3741404	0.609	rs641430	chr11:63869531	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.71	-8.77	-0.5	3.73e-16	Platelet count;
SARC	cis	rs6728642	1.000	rs73959416	chr2:97604518	A/T	cg26665480	chr2:98280029	ACTR1B	-0.53	-4.77	-0.3	3.2e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs4423214	0.879	rs1790324	chr11:71150520	A/C	cg05163923	chr11:71159392	DHCR7	-0.57	-7.01	-0.42	2.54e-11	Vitamin D levels;
SARC	cis	rs796364	0.950	rs188146	chr2:200750444	C/T	cg23649088	chr2:200775458	C2orf69	0.62	5.65	0.35	4.7e-8	Schizophrenia;
SARC	cis	rs8114671	0.933	rs6142327	chr20:33793147	T/A	cg24642439	chr20:33292090	TP53INP2	-0.43	-4.8	-0.3	2.86e-6	Height;
SARC	cis	rs4689388	0.926	rs10937720	chr4:6295451	A/G	cg25554036	chr4:6271136	WFS1	0.39	6.42	0.39	7.48e-10	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs13161895	1.000	rs35973843	chr5:179466502	T/C	cg02702477	chr5:179499311	RNF130	0.65	6.2	0.38	2.6e-9	LDL cholesterol;
SARC	cis	rs6693567	0.565	rs834234	chr1:150352494	C/G	cg09579323	chr1:150459698	TARS2	-0.41	-5.38	-0.33	1.84e-7	Migraine;
SARC	cis	rs3741151	0.773	rs74881062	chr11:73245769	G/A	cg17517138	chr11:73019481	ARHGEF17	0.93	6.94	0.41	3.77e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs4986172	0.726	rs12946454	chr17:43208121	A/T	cg27395066	chr17:43221220	ACBD4	0.41	5.52	0.34	8.86e-8	Height;
SARC	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg19671926	chr4:122722719	EXOSC9	-0.51	-5.9	-0.36	1.28e-8	Type 2 diabetes;
SARC	cis	rs9300255	0.596	rs10734900	chr12:123743445	G/A	cg05973401	chr12:123451056	ABCB9	0.48	5.24	0.32	3.53e-7	Neutrophil percentage of white cells;
SARC	cis	rs6493487	0.512	rs7165920	chr15:51229808	G/A	cg02338191	chr15:51200825	AP4E1	0.55	5.09	0.32	7.52e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	trans	rs7824557	0.603	rs2250028	chr8:11213589	T/G	cg06636001	chr8:8085503	FLJ10661	0.61	8.03	0.47	4.84e-14	Retinal vascular caliber;
SARC	cis	rs12762955	0.561	rs1904671	chr10:1014603	G/A	cg18964960	chr10:1102726	WDR37	-0.57	-6.46	-0.39	6.17e-10	Response to angiotensin II receptor blocker therapy;
SARC	trans	rs9650657	0.515	rs6601560	chr8:10950866	T/C	cg08975724	chr8:8085496	FLJ10661	-0.59	-7.79	-0.45	2.2e-13	Neuroticism;
SARC	cis	rs6696846	0.777	rs9651228	chr1:205049383	A/G	cg21545522	chr1:205238299	TMCC2	0.34	4.86	0.3	2.18e-6	Red blood cell count;
SARC	cis	rs1549118	0.595	rs7160485	chr14:78332734	C/G	cg21497246	chr14:78225524	SNW1;C14orf178	0.51	5.31	0.33	2.58e-7	Resting heart rate;
SARC	cis	rs1983891	0.706	rs9381084	chr6:41570350	C/T	cg15051332	chr6:41514432	FOXP4	0.51	5.6	0.34	5.87e-8	Prostate cancer;
SARC	cis	rs909674	0.662	rs2899318	chr22:39837625	A/G	cg05872129	chr22:39784769	NA	-0.4	-5.38	-0.33	1.78e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs6840360	1.000	rs907237	chr4:152601146	T/G	cg22705602	chr4:152727874	NA	-0.38	-6.55	-0.39	3.72e-10	Intelligence (multi-trait analysis);
SARC	cis	rs12586317	0.924	rs4981276	chr14:35696818	A/G	cg16230307	chr14:35515116	FAM177A1	0.81	9.14	0.51	3.13e-17	Psoriasis;
SARC	cis	rs8180040	0.900	rs10865946	chr3:47425060	T/G	cg27129171	chr3:47204927	SETD2	0.66	9.12	0.51	3.55e-17	Colorectal cancer;
SARC	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg26335602	chr6:28129616	ZNF389	0.53	5.88	0.36	1.43e-8	Depression;
SARC	cis	rs8031584	0.918	rs34095794	chr15:31269691	C/T	cg08109568	chr15:31115862	NA	-0.48	-6.1	-0.37	4.41e-9	Huntington's disease progression;
SARC	cis	rs7599312	0.534	rs7596285	chr2:213406961	G/A	cg16329650	chr2:213403929	ERBB4	0.68	10.3	0.56	9.87e-21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs35110281	0.659	rs2236667	chr21:45112939	A/G	cg01579765	chr21:45077557	HSF2BP	-0.36	-5.84	-0.36	1.73e-8	Mean corpuscular volume;
SARC	cis	rs1707322	0.896	rs785518	chr1:46568422	A/T	cg03146154	chr1:46216737	IPP	-0.48	-5.8	-0.36	2.13e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg06212747	chr3:49208901	KLHDC8B	0.65	8.63	0.49	9.91e-16	Parkinson's disease;
SARC	cis	rs7666738	0.822	rs28512427	chr4:98919029	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.7	0.49	6.28e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs459571	0.959	rs410876	chr9:136893867	C/A	cg13789015	chr9:136890014	NCRNA00094	0.63	8.59	0.49	1.26e-15	Platelet distribution width;
SARC	cis	rs2832077	0.943	rs2832094	chr21:30165910	G/A	cg03476357	chr21:30257390	N6AMT1	-0.64	-5.88	-0.36	1.4e-8	Cognitive test performance;
SARC	trans	rs17221829	0.733	rs11018668	chr11:89356178	C/T	cg17533847	chr17:77812622	CBX4	0.48	6.55	0.39	3.61e-10	Anxiety in major depressive disorder;
SARC	cis	rs1448094	0.556	rs11610627	chr12:86167752	C/T	cg00310523	chr12:86230176	RASSF9	0.32	4.96	0.31	1.38e-6	Major depressive disorder;
SARC	cis	rs2288884	0.505	rs17835435	chr19:52434706	T/C	cg24732339	chr19:52471368	ZNF350	-0.57	-4.92	-0.31	1.6e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
SARC	cis	rs11874712	1.000	rs1800636	chr18:43670420	C/T	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.46	5.5	0.34	1.02e-7	Migraine - clinic-based;
SARC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg24846343	chr22:24311635	DDTL	0.52	6.99	0.42	2.83e-11	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg07777115	chr5:623756	CEP72	-0.62	-5.52	-0.34	9.22e-8	Obesity-related traits;
SARC	cis	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg22496380	chr5:211416	CCDC127	-0.88	-9.21	-0.52	1.91e-17	Breast cancer;
SARC	cis	rs9398803	0.965	rs9388489	chr6:126698719	C/T	cg19875578	chr6:126661172	C6orf173	-0.62	-8.46	-0.48	3.07e-15	Male-pattern baldness;
SARC	cis	rs2439831	0.850	rs12441127	chr15:44021175	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.01	8.43	0.48	3.63e-15	Lung cancer in ever smokers;
SARC	cis	rs4481887	0.741	rs6587471	chr1:248560741	C/T	cg00666640	chr1:248458726	OR2T12	0.31	5.45	0.34	1.3e-7	Common traits (Other);
SARC	cis	rs477895	1.000	rs7947143	chr11:64090422	G/A	cg04317338	chr11:64019027	PLCB3	0.67	5.53	0.34	8.45e-8	Mean platelet volume;
SARC	cis	rs9435341	0.965	rs1762482	chr1:107599002	A/C	cg09367891	chr1:107599246	PRMT6	-0.72	-8.81	-0.5	2.93e-16	Facial morphology (factor 21, depth of nasal alae);
SARC	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-8.89	-0.5	1.75e-16	Alzheimer's disease;
SARC	cis	rs9914988	0.613	rs1873477	chr17:27311532	A/G	cg10538030	chr17:27276405	PHF12	-0.62	-5.06	-0.31	8.67e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs67460515	0.563	rs11713441	chr3:160906855	T/C	cg17135325	chr3:160939158	NMD3	0.68	8.69	0.49	6.32e-16	Parkinson's disease;
SARC	cis	rs765787	0.530	rs7165889	chr15:45531640	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.67e-7	Uric acid levels;
SARC	cis	rs76917914	0.589	rs10985065	chr9:100866903	C/T	cg03040243	chr9:100819229	NANS	0.53	5.66	0.35	4.47e-8	Immature fraction of reticulocytes;
SARC	cis	rs9790314	1.000	rs336567	chr3:161073046	A/G	cg04691961	chr3:161091175	C3orf57	-0.8	-11.79	-0.61	1.78e-25	Morning vs. evening chronotype;
SARC	cis	rs7647973	0.925	rs4384984	chr3:49289878	T/G	cg06212747	chr3:49208901	KLHDC8B	0.6	6.56	0.39	3.46e-10	Menarche (age at onset);
SARC	cis	rs3008870	0.755	rs2815364	chr1:67498384	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.6	7.66	0.45	4.92e-13	Lymphocyte percentage of white cells;
SARC	cis	rs3806843	0.676	rs778593	chr5:140027216	T/C	cg16577123	chr5:140027231	NDUFA2;IK	-0.46	-5.33	-0.33	2.27e-7	Depressive symptoms (multi-trait analysis);
SARC	cis	rs7819412	0.521	rs9329238	chr8:11033737	C/T	cg12395012	chr8:11607386	GATA4	0.32	5.61	0.34	5.8e-8	Triglycerides;
SARC	cis	rs3762637	0.943	rs6762156	chr3:122236025	A/C	cg24169773	chr3:122142474	KPNA1	-0.58	-5.86	-0.36	1.57e-8	LDL cholesterol levels;
SARC	cis	rs7666738	0.830	rs7678557	chr4:99057329	A/G	cg05340658	chr4:99064831	C4orf37	0.64	8.6	0.49	1.22e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6665290	0.904	rs1343743	chr1:227183125	C/T	cg14016676	chr1:227182615	CDC42BPA	0.36	5.18	0.32	4.73e-7	Myeloid white cell count;
SARC	cis	rs1057510	1.000	rs1057510	chr12:6683287	C/T	cg18050734	chr12:6798793	ZNF384	0.5	5.06	0.31	8.64e-7	Myopia (pathological);
SARC	cis	rs7929679	0.521	rs11499809	chr11:34790743	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.36	4.76	0.3	3.47e-6	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
SARC	cis	rs2011503	1.000	rs75525243	chr19:19638218	G/A	cg03709012	chr19:19516395	GATAD2A	0.6	5.29	0.33	2.8e-7	Bipolar disorder;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg21830480	chr12:72057690	THAP2;ZFC3H1	0.55	6.71	0.4	1.49e-10	Blood pressure;
SARC	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg07343612	chr16:622815	PIGQ	-0.53	-7.24	-0.43	6.33e-12	Height;
SARC	cis	rs3213545	0.659	rs2259693	chr12:121457995	G/A	cg02403541	chr12:121454288	C12orf43	0.75	10.63	0.57	8.65e-22	Subjective well-being;Cardiovascular disease risk factors;
SARC	cis	rs11122272	0.735	rs2474631	chr1:231541341	T/A	cg06096015	chr1:231504339	EGLN1	0.4	5.93	0.36	1.08e-8	Hemoglobin concentration;
SARC	cis	rs9906944	0.707	rs12942084	chr17:47114392	A/G	cg16584676	chr17:46985605	UBE2Z	-0.43	-5.27	-0.33	3.07e-7	Intelligence (multi-trait analysis);Body fat percentage;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg00502533	chr1:113498761	SLC16A1	-0.53	-6.97	-0.42	3.31e-11	Electrocardiographic conduction measures;
SARC	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg03354898	chr7:1950403	MAD1L1	-0.36	-4.84	-0.3	2.39e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs6088590	0.735	rs6088618	chr20:33409350	G/A	cg24642439	chr20:33292090	TP53INP2	0.76	10.07	0.55	4.99e-20	Coronary artery disease;
SARC	cis	rs6540556	0.723	rs6679099	chr1:209895852	T/G	cg23920097	chr1:209922102	NA	-0.52	-5.27	-0.33	3.08e-7	Red blood cell count;
SARC	cis	rs765787	0.530	rs4270107	chr15:45535350	A/G	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.81e-6	Uric acid levels;
SARC	cis	rs7635838	0.617	rs347590	chr3:11289561	G/A	cg00170343	chr3:11313890	ATG7	0.76	10.3	0.56	9.46e-21	HDL cholesterol;
SARC	cis	rs7552404	0.920	rs1612097	chr1:76218875	C/T	cg03433033	chr1:76189801	ACADM	0.48	6.89	0.41	5.18e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs950027	0.620	rs1617984	chr15:45622662	A/G	cg15395560	chr15:45543142	SLC28A2	-0.27	-5.13	-0.32	6e-7	Response to fenofibrate (adiponectin levels);
SARC	cis	rs8141529	1.000	rs132534	chr22:29299806	T/C	cg15103426	chr22:29168792	CCDC117	-0.63	-7.77	-0.45	2.55e-13	Lymphocyte counts;
SARC	cis	rs12142240	0.698	rs56284503	chr1:46847127	C/G	cg00530320	chr1:46809349	NSUN4	0.57	7.0	0.42	2.74e-11	Menopause (age at onset);
SARC	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg05896524	chr21:47604654	C21orf56	0.42	5.04	0.31	9.35e-7	Testicular germ cell tumor;
SARC	cis	rs7647973	0.626	rs35129566	chr3:49866584	T/G	cg07636037	chr3:49044803	WDR6	-0.63	-6.43	-0.39	7.01e-10	Menarche (age at onset);
SARC	cis	rs4443100	0.916	rs2078726	chr22:23382483	T/C	cg14186256	chr22:23484241	RTDR1	0.46	4.85	0.3	2.22e-6	Serum parathyroid hormone levels;
SARC	cis	rs56330463	0.967	rs11958940	chr5:148201485	A/T	cg21580376	chr5:148206412	ADRB2	0.41	5.78	0.35	2.38e-8	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Monocyte percentage of white cells;Eosinophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;
SARC	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg17971929	chr21:40555470	PSMG1	0.98	13.77	0.67	5.73e-32	Cognitive function;
SARC	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg23758822	chr17:41437982	NA	0.91	11.48	0.6	1.86e-24	Menopause (age at onset);
SARC	trans	rs66573146	1.000	rs56178503	chr4:6961748	C/T	cg07817883	chr1:32538562	TMEM39B	1.42	9.05	0.51	5.74e-17	Granulocyte percentage of myeloid white cells;
SARC	trans	rs1945213	0.694	rs9888298	chr11:55865704	T/C	cg15704280	chr7:45808275	SEPT13	0.67	6.97	0.42	3.23e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9788721	0.630	rs77681598	chr15:78906103	C/A	cg24631222	chr15:78858424	CHRNA5	0.39	5.16	0.32	5.38e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs2952156	0.876	rs903501	chr17:37839493	T/C	cg00129232	chr17:37814104	STARD3	-0.69	-9.1	-0.51	4.06e-17	Asthma;
SARC	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.73	6.92	0.41	4.39e-11	Platelet count;
SARC	cis	rs2230307	0.536	rs834164	chr1:100603948	A/C	cg24955406	chr1:100503596	HIAT1	-0.68	-6.76	-0.4	1.11e-10	Carotid intima media thickness;
SARC	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg26513180	chr16:89883248	FANCA	0.91	16.79	0.74	5.45e-42	Vitiligo;
SARC	cis	rs1559088	0.847	rs6510348	chr19:33601946	G/A	cg17764715	chr19:33622953	WDR88	0.49	6.72	0.4	1.4e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs1707322	1.000	rs12077546	chr1:46431806	C/T	cg03146154	chr1:46216737	IPP	0.46	5.5	0.34	9.8e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6424115	1.000	rs4237	chr1:24114129	C/T	cg15997130	chr1:24165203	NA	0.44	5.86	0.36	1.55e-8	Immature fraction of reticulocytes;
SARC	cis	rs875971	1.000	rs2220626	chr7:65546062	C/T	cg11764359	chr7:65958608	NA	-0.86	-12.08	-0.62	2.1e-26	Aortic root size;
SARC	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg17971929	chr21:40555470	PSMG1	-0.86	-11.35	-0.6	4.61e-24	Cognitive function;
SARC	cis	rs722599	0.748	rs1059326	chr14:75369385	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.38	-4.75	-0.3	3.52e-6	IgG glycosylation;
SARC	cis	rs17376456	0.877	rs34595581	chr5:93369422	G/A	cg25358565	chr5:93447407	FAM172A	1.3	14.56	0.69	1.43e-34	Diabetic retinopathy;
SARC	cis	rs7582720	0.943	rs114372659	chr2:203715514	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	7.63	0.45	5.82e-13	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs7617480	0.549	rs9879978	chr3:48846600	T/G	cg07636037	chr3:49044803	WDR6	0.85	9.05	0.51	5.63e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs7769051	1.000	rs58832890	chr6:133127139	C/T	cg22852734	chr6:133119734	C6orf192	1.06	10.5	0.57	2.33e-21	Type 2 diabetes nephropathy;
SARC	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg24399712	chr22:39784796	NA	-0.45	-6.01	-0.37	6.93e-9	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg08219700	chr8:58056026	NA	0.61	6.49	0.39	5.14e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9399137	0.507	rs7761964	chr6:135314265	T/C	cg24558204	chr6:135376177	HBS1L	0.61	7.94	0.46	8.39e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg20007245	chr22:24372913	LOC391322	0.71	8.75	0.5	4.46e-16	Liver enzyme levels (gamma-glutamyl transferase);
SARC	trans	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg21775007	chr8:11205619	TDH	0.53	6.62	0.4	2.44e-10	Systolic blood pressure;
SARC	cis	rs898097	0.841	rs2271918	chr17:80861206	A/G	cg15664640	chr17:80829946	TBCD	-0.59	-8.6	-0.49	1.21e-15	Breast cancer;
SARC	cis	rs2014572	0.933	rs8109882	chr19:57755618	C/G	cg24459738	chr19:57751996	ZNF805	-0.47	-5.62	-0.35	5.46e-8	Hyperactive-impulsive symptoms;
SARC	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg26681399	chr22:41777847	TEF	0.47	5.14	0.32	5.91e-7	Vitiligo;
SARC	cis	rs7872515	0.838	rs7860518	chr9:94826465	C/T	cg01248375	chr9:94877805	SPTLC1	0.56	5.28	0.33	2.93e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg12463550	chr7:65579703	CRCP	0.69	5.31	0.33	2.54e-7	Gout;
SARC	cis	rs11809207	0.574	rs2783631	chr1:26504756	C/T	cg00300879	chr1:26503847	CNKSR1	0.3	4.76	0.3	3.48e-6	Height;
SARC	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg24060327	chr5:131705240	SLC22A5	0.76	9.18	0.52	2.34e-17	Breast cancer;
SARC	cis	rs7149337	0.836	rs4901087	chr14:51668499	T/C	cg23942311	chr14:51606299	NA	0.35	6.28	0.38	1.67e-9	Cancer;
SARC	cis	rs10979	0.965	rs34373782	chr6:143888258	A/G	cg25407410	chr6:143891975	LOC285740	-0.64	-8.66	-0.49	8.14e-16	Hypospadias;
SARC	cis	rs28386778	0.700	rs4968672	chr17:62011352	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.66	-8.08	-0.47	3.42e-14	Prudent dietary pattern;
SARC	trans	rs1941687	0.563	rs9953034	chr18:31335294	A/G	cg27147174	chr7:100797783	AP1S1	-0.5	-6.35	-0.38	1.12e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
SARC	trans	rs61931739	0.500	rs11053210	chr12:34461771	A/G	cg13010199	chr12:38710504	ALG10B	-0.78	-9.78	-0.54	3.91e-19	Morning vs. evening chronotype;
SARC	cis	rs10465746	0.780	rs4907190	chr1:84409168	T/C	cg10977910	chr1:84465055	TTLL7	0.46	5.68	0.35	3.92e-8	Obesity-related traits;
SARC	cis	rs2013441	1.000	rs2703817	chr17:20119677	A/C	cg13482628	chr17:19912719	NA	-0.47	-6.25	-0.38	1.99e-9	Obesity-related traits;
SARC	cis	rs9486719	1.000	rs67996804	chr6:96884387	C/T	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.01	-0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.8	8.04	0.47	4.43e-14	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg24846343	chr22:24311635	DDTL	0.49	7.25	0.43	6.25e-12	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs910316	1.000	rs876402	chr14:75601862	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.51	-7.19	-0.43	8.82e-12	Height;
SARC	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.49	-6.12	-0.37	3.97e-9	Lymphocyte counts;
SARC	cis	rs10131894	0.611	rs175000	chr14:75436367	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.55	-7.47	-0.44	1.56e-12	Coronary artery disease;
SARC	trans	rs61931739	0.926	rs13377754	chr12:34051765	T/C	cg26384229	chr12:38710491	ALG10B	-0.57	-6.89	-0.41	5.01e-11	Morning vs. evening chronotype;
SARC	cis	rs921968	0.643	rs2556385	chr2:219532905	G/A	cg02176678	chr2:219576539	TTLL4	-0.36	-5.48	-0.34	1.11e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs113835537	0.529	rs75003264	chr11:66256099	G/A	cg24851651	chr11:66362959	CCS	0.39	4.81	0.3	2.68e-6	Airway imaging phenotypes;
SARC	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.97e-8	Aortic root size;
SARC	cis	rs11651000	0.625	rs4794063	chr17:45804494	C/T	cg03474202	chr17:45855739	NA	-0.38	-5.65	-0.35	4.7e-8	IgG glycosylation;
SARC	cis	rs17001868	0.527	rs11913132	chr22:40778778	A/G	cg07138101	chr22:40742427	ADSL	0.52	5.8	0.36	2.13e-8	Mammographic density (dense area);
SARC	cis	rs9303280	0.806	rs9904624	chr17:38036586	A/G	cg17467752	chr17:38218738	THRA	-0.37	-4.76	-0.3	3.34e-6	Self-reported allergy;
SARC	cis	rs3784262	1.000	rs12915901	chr15:58279432	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.36	-5.39	-0.33	1.74e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs7666738	0.830	rs17550630	chr4:99008332	G/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6840360	0.533	rs4696295	chr4:152717430	T/C	cg22705602	chr4:152727874	NA	0.48	8.17	0.47	2e-14	Intelligence (multi-trait analysis);
SARC	cis	rs3784262	0.904	rs17820823	chr15:58239358	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.37	-5.37	-0.33	1.91e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs2180341	0.961	rs9375501	chr6:127652539	C/T	cg17762328	chr6:126965162	NA	-0.45	-5.11	-0.32	6.78e-7	Breast cancer;
SARC	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.47	0.39	5.63e-10	Bipolar disorder;
SARC	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg26681399	chr22:41777847	TEF	0.45	4.98	0.31	1.23e-6	Vitiligo;
SARC	cis	rs10779751	0.690	rs28729193	chr1:11180151	T/C	cg08854313	chr1:11322531	MTOR	-0.77	-10.11	-0.55	3.67e-20	Body mass index;
SARC	cis	rs617219	0.889	rs1622238	chr5:78437340	A/G	cg24856658	chr5:78533917	JMY	-0.32	-4.72	-0.3	4.1e-6	Betaine levels in individuals undergoing cardiac evaluation;
SARC	cis	rs356220	0.606	rs356175	chr4:90630814	C/T	cg06632027	chr4:90757378	SNCA	0.41	5.41	0.33	1.57e-7	Parkinson's disease;
SARC	cis	rs1707322	1.000	rs4390216	chr1:46266456	C/T	cg03146154	chr1:46216737	IPP	0.47	5.62	0.35	5.38e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs898097	0.841	rs12453162	chr17:80859971	C/T	cg15369054	chr17:80825471	TBCD	0.55	7.69	0.45	4.22e-13	Breast cancer;
SARC	cis	rs526231	0.543	rs34765	chr5:102506864	G/C	cg23492399	chr5:102201601	PAM	-0.53	-5.63	-0.35	5.27e-8	Primary biliary cholangitis;
SARC	cis	rs6121246	0.909	rs6119651	chr20:30259246	G/T	cg13852791	chr20:30311386	BCL2L1	0.85	9.22	0.52	1.88e-17	Mean corpuscular hemoglobin;
SARC	cis	rs9790314	0.967	rs6762645	chr3:160948349	T/G	cg03342759	chr3:160939853	NMD3	-0.61	-7.73	-0.45	3.22e-13	Morning vs. evening chronotype;
SARC	cis	rs7828089	0.744	rs10108011	chr8:22320806	C/T	cg12081754	chr8:22256438	SLC39A14	0.52	6.93	0.41	4.01e-11	Verbal declarative memory;
SARC	cis	rs6963495	0.818	rs73190189	chr7:105164452	G/A	cg13798780	chr7:105162888	PUS7	0.6	5.5	0.34	1e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg18252515	chr7:66147081	NA	-0.44	-4.75	-0.3	3.5e-6	Aortic root size;
SARC	cis	rs13161895	0.877	rs75654641	chr5:179486021	C/T	cg06664874	chr5:179499304	RNF130	0.6	5.57	0.34	7.1e-8	LDL cholesterol;
SARC	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg04511125	chr2:88470314	THNSL2	0.81	7.27	0.43	5.44e-12	Plasma clusterin levels;
SARC	cis	rs112591243	0.685	rs2839282	chr21:47902822	C/G	cg26904215	chr21:47823096	PCNT	0.75	5.07	0.32	7.98e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs6815814	0.950	rs67719080	chr4:38787252	A/G	cg06935464	chr4:38784597	TLR10	0.58	6.0	0.37	7.42e-9	Breast cancer;
SARC	cis	rs9581943	0.901	rs9579127	chr13:28477268	A/G	cg17352152	chr13:28491409	NA	0.37	5.02	0.31	1.03e-6	Pancreatic cancer;
SARC	cis	rs11608355	0.618	rs11066368	chr12:109790342	C/T	cg19025524	chr12:109796872	NA	-0.48	-6.9	-0.41	4.84e-11	Neuroticism;
SARC	cis	rs8141529	0.732	rs5762784	chr22:29171298	C/T	cg15103426	chr22:29168792	CCDC117	0.68	9.1	0.51	4.27e-17	Lymphocyte counts;
SARC	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg11843238	chr5:131593191	PDLIM4	-0.39	-4.8	-0.3	2.78e-6	Breast cancer;
SARC	cis	rs9660992	0.508	rs113817010	chr1:205104581	C/A	cg21545522	chr1:205238299	TMCC2	0.37	5.21	0.32	4.18e-7	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs35955747	0.869	rs28715	chr22:31730169	C/T	cg13145458	chr22:31556086	RNF185	-0.45	-5.62	-0.35	5.56e-8	Neutrophil count;Sum basophil neutrophil counts;
SARC	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-5.45	-0.34	1.28e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs7592578	0.771	rs62181034	chr2:191354963	C/A	cg27211696	chr2:191398769	TMEM194B	-0.53	-5.61	-0.34	5.8e-8	Diastolic blood pressure;
SARC	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg05368731	chr17:41323189	NBR1	0.76	9.01	0.51	7.77e-17	Menopause (age at onset);
SARC	cis	rs739401	0.611	rs450817	chr11:3056712	A/G	cg25174290	chr11:3078921	CARS	0.6	8.57	0.49	1.42e-15	Longevity;
SARC	cis	rs6964587	1.000	rs2269727	chr7:91752690	C/A	cg17063962	chr7:91808500	NA	0.96	16.11	0.73	9.53e-40	Breast cancer;
SARC	cis	rs7717697	0.830	rs7731805	chr5:82752328	T/C	cg19814134	chr5:82768288	VCAN	0.44	5.15	0.32	5.55e-7	Vertical cup-disc ratio;
SARC	cis	rs11758351	0.929	rs75475698	chr6:26190609	C/G	cg23601095	chr6:26197514	HIST1H3D	0.64	5.51	0.34	9.33e-8	Gout;Renal underexcretion gout;
SARC	cis	rs4662750	0.619	rs2244042	chr2:128404998	A/G	cg12745632	chr2:128407154	GPR17;LIMS2	0.33	4.79	0.3	2.9e-6	Renal cell carcinoma;
SARC	cis	rs16854884	1.000	rs34730687	chr3:143813193	A/G	cg06585982	chr3:143692056	C3orf58	0.54	6.28	0.38	1.61e-9	Economic and political preferences (feminism/equality);
SARC	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg06108461	chr20:60628389	TAF4	-0.99	-13.11	-0.65	8.72e-30	Body mass index;
SARC	cis	rs10791323	0.569	rs546381	chr11:133760651	T/G	cg15485101	chr11:133734466	NA	0.33	5.34	0.33	2.17e-7	Childhood ear infection;
SARC	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg12310025	chr6:25882481	NA	-0.45	-5.77	-0.35	2.56e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg22307029	chr19:49891270	CCDC155	0.62	7.41	0.44	2.33e-12	Multiple sclerosis;
SARC	cis	rs7091068	0.518	rs1572772	chr10:95432862	A/G	cg20715218	chr10:95462985	C10orf4	-0.45	-5.56	-0.34	7.32e-8	Urinary tract infection frequency;
SARC	cis	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg09021430	chr5:549028	NA	-0.45	-5.72	-0.35	3.18e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs3784262	0.900	rs12911071	chr15:58314848	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.38	-5.75	-0.35	2.77e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs735539	0.521	rs1348370	chr13:21404658	A/C	cg16922012	chr13:21400325	XPO4	-0.43	-6.02	-0.37	6.57e-9	Dental caries;
SARC	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	0.54	5.53	0.34	8.43e-8	Lung function (FEV1/FVC);
SARC	trans	rs2018683	0.803	rs12700920	chr7:28984924	A/G	cg19402173	chr7:128379420	CALU	-0.7	-9.09	-0.51	4.42e-17	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs4803468	1.000	rs284657	chr19:41929915	G/C	cg14132834	chr19:41945861	ATP5SL	-0.59	-7.82	-0.46	1.8e-13	Height;
SARC	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg14061069	chr19:46274453	DMPK	0.65	11.2	0.59	1.36e-23	Coronary artery disease;
SARC	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.0	11.56	0.6	9.97e-25	Platelet count;
SARC	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg25072359	chr17:41440525	NA	0.48	5.62	0.35	5.43e-8	Menopause (age at onset);
SARC	trans	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.73	10.55	0.57	1.63e-21	Intelligence (multi-trait analysis);
SARC	cis	rs2439831	0.850	rs28707214	chr15:44131623	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	8.16	0.47	2.04e-14	Lung cancer in ever smokers;
SARC	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg11366901	chr6:160182831	ACAT2	0.86	8.78	0.5	3.47e-16	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs2075371	0.611	rs11762920	chr7:134018514	C/T	cg20476274	chr7:133979776	SLC35B4	0.38	4.72	0.3	4.03e-6	Mean platelet volume;
SARC	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg24642844	chr7:1081250	C7orf50	-0.59	-6.21	-0.38	2.41e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs2153535	0.547	rs9505475	chr6:8542890	A/G	cg07606381	chr6:8435919	SLC35B3	0.78	11.14	0.59	2.2e-23	Motion sickness;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg26158983	chr14:24835040	NFATC4	0.49	6.41	0.39	7.92e-10	Chemerin levels;
SARC	cis	rs208520	0.690	rs1351867	chr6:66760995	A/G	cg07460842	chr6:66804631	NA	1.09	14.54	0.69	1.57e-34	Exhaled nitric oxide output;
SARC	cis	rs6500602	0.592	rs3747585	chr16:4519140	C/G	cg08645402	chr16:4508243	NA	0.38	4.78	0.3	3.14e-6	Schizophrenia;
SARC	cis	rs1448094	0.527	rs59445394	chr12:86237843	C/T	cg00310523	chr12:86230176	RASSF9	0.32	5.16	0.32	5.23e-7	Major depressive disorder;
SARC	trans	rs634534	0.622	rs624273	chr11:65712413	A/G	cg17712092	chr4:129076599	LARP1B	0.63	8.27	0.48	1.02e-14	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs146009840	1	rs146009840	chr15:78906177	A/T	cg18825076	chr15:78729989	IREB2	-0.47	-5.39	-0.33	1.72e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg24110177	chr3:50126178	RBM5	0.54	7.22	0.43	7.13e-12	Intelligence (multi-trait analysis);
SARC	cis	rs7546668	0.640	rs3820071	chr1:15808767	G/A	cg18192808	chr1:15853278	DNAJC16	0.44	5.06	0.31	8.63e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.48	6.22	0.38	2.32e-9	Lymphocyte counts;
SARC	cis	rs10883723	0.810	rs7079810	chr10:104243883	C/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.56	7.34	0.43	3.6e-12	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs11098499	0.697	rs10020027	chr4:120381879	G/C	cg09160332	chr4:120329925	NA	-0.33	-4.74	-0.3	3.75e-6	Corneal astigmatism;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg10724490	chr7:6523886	KDELR2	0.47	6.27	0.38	1.7e-9	Thyroid stimulating hormone;
SARC	cis	rs78545713	1.000	rs78661760	chr6:26250033	A/T	cg00631329	chr6:26305371	NA	-0.74	-6.66	-0.4	2e-10	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs2153535	0.580	rs915351	chr6:8442793	C/T	cg07606381	chr6:8435919	SLC35B3	0.78	11.09	0.59	3.11e-23	Motion sickness;
SARC	cis	rs1008375	0.898	rs4698623	chr4:17594702	T/C	cg16339924	chr4:17578868	LAP3	0.66	8.4	0.48	4.52e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6840360	0.571	rs12647566	chr4:152482525	C/T	cg22705602	chr4:152727874	NA	-0.42	-6.43	-0.39	6.99e-10	Intelligence (multi-trait analysis);
SARC	trans	rs877282	0.945	rs10904550	chr10:774177	C/T	cg22713356	chr15:30763199	NA	0.98	10.16	0.55	2.56e-20	Uric acid levels;
SARC	cis	rs4713675	0.565	rs4713674	chr6:33708169	C/T	cg15676125	chr6:33679581	C6orf125	-0.58	-7.12	-0.42	1.29e-11	Plateletcrit;
SARC	cis	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg25427524	chr10:38739819	LOC399744	0.59	9.38	0.52	5.98e-18	Extrinsic epigenetic age acceleration;
SARC	cis	rs9394841	0.536	rs6899876	chr6:41796970	A/G	cg08135965	chr6:41755394	TOMM6	0.58	6.48	0.39	5.52e-10	Mean corpuscular hemoglobin;Red cell distribution width;
SARC	cis	rs763121	0.962	rs138711	chr22:39139913	C/T	cg06022373	chr22:39101656	GTPBP1	0.68	7.83	0.46	1.74e-13	Menopause (age at onset);
SARC	cis	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg21782813	chr7:2030301	MAD1L1	0.37	5.73	0.35	3.04e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs16937	0.597	rs3862949	chr1:205103070	A/T	cg00857998	chr1:205179979	DSTYK	0.4	4.75	0.3	3.51e-6	Schizophrenia;
SARC	cis	rs9788721	0.868	rs17486278	chr15:78867482	A/C	cg06917634	chr15:78832804	PSMA4	-0.57	-6.2	-0.38	2.55e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs2425143	1.000	rs17093027	chr20:34319118	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-6.02	-0.37	6.75e-9	Blood protein levels;
SARC	cis	rs1983891	0.955	rs4714487	chr6:41547312	T/C	cg15051332	chr6:41514432	FOXP4	0.52	5.67	0.35	4.12e-8	Prostate cancer;
SARC	cis	rs6809651	0.524	rs7622914	chr3:185790895	T/C	cg00760338	chr3:185826511	ETV5	-0.8	-10.21	-0.56	1.87e-20	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
SARC	cis	rs9911578	0.817	rs304264	chr17:56749628	A/G	cg12560992	chr17:57184187	TRIM37	0.82	11.06	0.59	3.83e-23	Intelligence (multi-trait analysis);
SARC	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg13206674	chr6:150067644	NUP43	0.41	5.05	0.31	8.84e-7	Lung cancer;
SARC	cis	rs3796352	1.000	rs11718834	chr3:52963668	A/C	cg27565382	chr3:53032988	SFMBT1	0.82	5.62	0.35	5.56e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs933688	0.502	rs4916858	chr5:90601290	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.51	-5.63	-0.35	5.24e-8	Smoking behavior;
SARC	cis	rs71636778	0.631	rs12735407	chr1:27198937	C/G	cg04852280	chr1:26496234	ZNF593	0.58	5.12	0.32	6.47e-7	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs4481887	1.000	rs7527822	chr1:248467301	A/G	cg00666640	chr1:248458726	OR2T12	0.38	6.45	0.39	6.49e-10	Common traits (Other);
SARC	cis	rs7633857	0.532	rs9873705	chr3:160768818	A/T	cg04691961	chr3:161091175	C3orf57	-0.48	-5.99	-0.37	7.8e-9	Educational attainment (years of education);
SARC	cis	rs2204008	0.744	rs11168870	chr12:37973333	A/G	cg13010199	chr12:38710504	ALG10B	0.79	10.99	0.58	6.51e-23	Bladder cancer;
SARC	cis	rs11785400	0.793	rs12546978	chr8:143750205	T/A	cg24634471	chr8:143751801	JRK	-0.56	-7.06	-0.42	1.93e-11	Schizophrenia;
SARC	cis	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg00800038	chr16:89945340	TCF25	-0.76	-5.28	-0.33	2.94e-7	Skin colour saturation;
SARC	cis	rs3741151	1.000	rs7125978	chr11:73039229	G/A	cg17517138	chr11:73019481	ARHGEF17	0.82	7.22	0.43	7.33e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	trans	rs1945213	0.625	rs7128190	chr11:55858550	A/T	cg15704280	chr7:45808275	SEPT13	0.66	6.9	0.41	5e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9650657	0.615	rs2271355	chr8:10692158	C/T	cg21775007	chr8:11205619	TDH	-0.4	-4.97	-0.31	1.3e-6	Neuroticism;
SARC	cis	rs3767633	0.925	rs10733044	chr1:161903534	A/G	cg09175582	chr1:161736000	ATF6	-0.67	-5.87	-0.36	1.52e-8	IgG glycosylation;
SARC	cis	rs1408799	0.720	rs13284467	chr9:12724345	A/G	cg05274944	chr9:12693694	TYRP1	0.34	5.04	0.31	9.37e-7	Eye color;Blue vs. green eyes;
SARC	cis	rs897080	0.516	rs1067361	chr2:44661217	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	6.45	0.39	6.43e-10	Height;
SARC	cis	rs7949030	0.626	rs61296092	chr11:62320838	T/C	cg13298116	chr11:62369859	EML3;MTA2	0.48	7.26	0.43	5.7e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg05910138	chr5:74632922	HMGCR	0.51	6.35	0.38	1.11e-9	Breast cancer;
SARC	cis	rs7959452	0.640	rs4274230	chr12:69700772	T/G	cg22834771	chr12:69754056	YEATS4	-0.41	-5.49	-0.34	1.06e-7	Blood protein levels;
SARC	cis	rs10513432	1.000	rs75671901	chr3:152406234	G/A	cg04845053	chr3:152552877	P2RY1	0.88	4.96	0.31	1.36e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg05863683	chr7:1912471	MAD1L1	0.35	5.2	0.32	4.44e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.38	-0.44	2.75e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs2228479	0.850	rs12597299	chr16:89822364	C/A	cg06558623	chr16:89946397	TCF25	0.88	6.21	0.38	2.39e-9	Skin colour saturation;
SARC	cis	rs36051895	0.632	rs12336875	chr9:5138404	C/A	cg02405213	chr9:5042618	JAK2	-0.46	-5.66	-0.35	4.37e-8	Pediatric autoimmune diseases;
SARC	cis	rs16976116	0.901	rs28489312	chr15:55494048	A/C	cg17854078	chr15:55489399	RSL24D1	0.66	6.53	0.39	4.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9393692	0.537	rs2393594	chr6:26316289	G/C	cg13736514	chr6:26305472	NA	-0.4	-4.96	-0.31	1.35e-6	Educational attainment;
SARC	cis	rs4713118	0.516	rs6931858	chr6:28078411	A/T	cg16479474	chr6:28041457	NA	0.38	5.45	0.34	1.29e-7	Parkinson's disease;
SARC	cis	rs76419734	1.000	rs72671854	chr4:106647023	T/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.84	5.56	0.34	7.44e-8	Post bronchodilator FEV1;
SARC	cis	rs7264396	0.635	rs6060673	chr20:34482396	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	-0.5	-5.05	-0.31	8.86e-7	Total cholesterol levels;
SARC	trans	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg15929573	chr12:49658188	TUBA1C	-0.51	-6.27	-0.38	1.76e-9	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7833790	0.963	rs6473312	chr8:82732515	C/A	cg17211192	chr8:82754475	SNX16	-0.59	-6.45	-0.39	6.36e-10	Diastolic blood pressure;
SARC	cis	rs7255436	0.931	rs7249520	chr19:8446056	G/A	cg10174797	chr19:8464628	RAB11B	0.45	6.5	0.39	4.91e-10	HDL cholesterol;
SARC	cis	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg06636001	chr8:8085503	FLJ10661	-0.69	-9.77	-0.54	3.97e-19	Mood instability;
SARC	cis	rs17854409	0.536	rs3765464	chr20:61485236	T/C	cg05147244	chr20:61493195	TCFL5	1.02	7.15	0.42	1.11e-11	Obesity-related traits;
SARC	cis	rs524281	1.000	rs565198	chr11:65913508	A/T	cg14036092	chr11:66035641	RAB1B	0.52	6.06	0.37	5.3e-9	Electroencephalogram traits;
SARC	cis	rs3892630	0.878	rs8112955	chr19:33191192	C/T	cg22980127	chr19:33182716	NUDT19	1.06	9.77	0.54	4.14e-19	Red blood cell traits;
SARC	cis	rs9818758	0.607	rs66991555	chr3:49228643	A/G	cg07636037	chr3:49044803	WDR6	-0.76	-6.8	-0.41	8.54e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs7089973	0.624	rs10885613	chr10:116589400	G/A	cg03647239	chr10:116582469	FAM160B1	0.49	6.3	0.38	1.48e-9	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs2120243	0.539	rs7618737	chr3:157095621	G/A	cg01018701	chr3:157155998	VEPH1;PTX3	0.39	4.9	0.31	1.78e-6	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg03806693	chr22:41940476	POLR3H	0.88	12.16	0.62	1.15e-26	Vitiligo;
SARC	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg06212747	chr3:49208901	KLHDC8B	0.71	9.75	0.54	4.8e-19	Parkinson's disease;
SARC	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg18252515	chr7:66147081	NA	-0.47	-5.09	-0.32	7.32e-7	Aortic root size;
SARC	cis	rs2908197	0.843	rs2908193	chr7:75945945	A/G	cg22830091	chr7:75961684	YWHAG	-0.34	-5.04	-0.31	9.45e-7	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs916888	0.610	rs199442	chr17:44820122	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.52	6.12	0.37	3.84e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs910316	1.000	rs12889309	chr14:75593902	C/T	cg11812906	chr14:75593930	NEK9	0.87	13.87	0.67	2.61e-32	Height;
SARC	cis	rs896854	0.738	rs527234	chr8:95963798	C/G	cg09323728	chr8:95962352	TP53INP1	0.28	4.73	0.3	3.9e-6	Type 2 diabetes;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16416718	chr1:6844519	CAMTA1	-0.51	-6.24	-0.38	2.04e-9	Fibrinogen levels;
SARC	cis	rs6088580	0.634	rs2225837	chr20:33005634	C/T	cg08999081	chr20:33150536	PIGU	-0.44	-6.65	-0.4	2.07e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs2276314	0.857	rs56230698	chr18:33628885	A/G	cg05985134	chr18:33552581	C18orf21	0.7	7.42	0.44	2.16e-12	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs13202913	0.639	rs9383892	chr6:151747152	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.6	5.01	0.31	1.07e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs36051895	0.632	rs12352022	chr9:5161836	T/G	cg02405213	chr9:5042618	JAK2	-0.41	-4.73	-0.3	3.84e-6	Pediatric autoimmune diseases;
SARC	cis	rs787274	1.000	rs1965335	chr9:115504483	C/T	cg13803584	chr9:115635662	SNX30	0.79	5.41	0.33	1.56e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs950776	0.593	rs481134	chr15:78877563	C/T	cg17108064	chr15:78857060	CHRNA5	0.31	5.35	0.33	2.08e-7	Sudden cardiac arrest;
SARC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.52	6.91	0.41	4.71e-11	Lymphocyte counts;
SARC	cis	rs7824557	0.510	rs1435274	chr8:11235910	G/A	cg21775007	chr8:11205619	TDH	-0.58	-7.61	-0.45	6.75e-13	Retinal vascular caliber;
SARC	cis	rs9611565	0.559	rs1006407	chr22:41972032	T/C	cg17376030	chr22:41985996	PMM1	0.77	8.75	0.5	4.46e-16	Vitiligo;
SARC	cis	rs9660992	0.573	rs12125276	chr1:205199440	C/T	cg00857998	chr1:205179979	DSTYK	0.51	6.31	0.38	1.39e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs9814567	1.000	rs6782563	chr3:134295959	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.56	6.93	0.41	4.18e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs698833	0.892	rs1067403	chr2:44675851	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.63	7.67	0.45	4.69e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs11122272	0.701	rs2486725	chr1:231540288	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.04	-0.55	6e-20	Hemoglobin concentration;
SARC	cis	rs3845702	0.736	rs3845701	chr2:180826781	A/G	cg01881094	chr2:180872142	CWC22	-1.12	-9.33	-0.52	8.63e-18	Schizophrenia;
SARC	cis	rs1865760	0.566	rs2794720	chr6:26087202	G/C	cg17691542	chr6:26056736	HIST1H1C	0.52	6.41	0.39	8.05e-10	Height;
SARC	cis	rs7512552	0.966	rs1122967	chr1:150258838	C/G	cg15654264	chr1:150340011	RPRD2	-0.37	-4.85	-0.3	2.22e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg02841227	chr6:26021843	HIST1H4A	0.47	5.22	0.32	3.88e-7	Intelligence (multi-trait analysis);
SARC	cis	rs4423214	1.000	rs4944956	chr11:71167765	C/T	cg05163923	chr11:71159392	DHCR7	0.68	9.39	0.52	5.59e-18	Vitamin D levels;
SARC	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.46	-5.87	-0.36	1.53e-8	Gut microbiome composition (summer);
SARC	cis	rs6582630	0.638	rs12831496	chr12:38552604	G/A	cg13010199	chr12:38710504	ALG10B	-0.49	-6.11	-0.37	4.26e-9	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs131777	0.577	rs131748	chr22:51024837	A/G	cg25309564	chr22:51001381	C22orf41	-0.39	-5.18	-0.32	4.87e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs7940866	0.903	rs1820353	chr11:130870765	A/G	cg12179176	chr11:130786555	SNX19	0.64	8.53	0.49	1.91e-15	Schizophrenia;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg27042667	chr1:163295979	NUF2	-0.47	-6.31	-0.38	1.38e-9	Alcohol dependence;
SARC	cis	rs73635312	0.850	rs112085461	chr10:8941641	A/G	cg24467326	chr10:9646929	NA	0.6	5.03	0.31	9.81e-7	Basal cell carcinoma;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14756353	chr3:121468984	GOLGB1	-0.53	-6.31	-0.38	1.37e-9	Fibrinogen levels;
SARC	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg11764359	chr7:65958608	NA	-0.69	-8.18	-0.47	1.88e-14	Aortic root size;
SARC	cis	rs11249608	0.789	rs7706393	chr5:178437737	G/T	cg21905437	chr5:178450457	ZNF879	-0.52	-7.17	-0.43	9.74e-12	Pubertal anthropometrics;
SARC	cis	rs6570726	0.526	rs9376934	chr6:145738702	A/G	cg05347473	chr6:146136440	FBXO30	0.46	5.64	0.35	4.89e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7614311	0.636	rs73117066	chr3:63926236	A/G	cg22134162	chr3:63841271	THOC7	-0.43	-4.77	-0.3	3.2e-6	Lung function (FVC);Lung function (FEV1);
SARC	cis	rs7566780	0.656	rs2163216	chr2:16673730	A/C	cg09580478	chr2:16689509	NA	-0.38	-5.28	-0.33	3.02e-7	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg11764359	chr7:65958608	NA	-0.75	-8.74	-0.5	4.7e-16	Aortic root size;
SARC	cis	rs1355223	0.934	rs5010670	chr11:34766649	A/C	cg11058730	chr11:34937778	PDHX;APIP	-0.5	-6.46	-0.39	6e-10	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs17001868	0.568	rs55769635	chr22:40790101	G/A	cg07138101	chr22:40742427	ADSL	0.54	6.05	0.37	5.62e-9	Mammographic density (dense area);
SARC	cis	rs17376456	0.757	rs1031424	chr5:93139706	G/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.7	6.42	0.39	7.41e-10	Diabetic retinopathy;
SARC	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg25072359	chr17:41440525	NA	0.53	6.28	0.38	1.61e-9	Menopause (age at onset);
SARC	cis	rs3857536	0.813	rs1891599	chr6:66941699	A/G	cg07460842	chr6:66804631	NA	-0.51	-5.83	-0.36	1.86e-8	Blood trace element (Cu levels);
SARC	cis	rs5753618	0.509	rs2413033	chr22:31574213	A/G	cg02404636	chr22:31891804	SFI1	-0.49	-5.4	-0.33	1.61e-7	Colorectal cancer;
SARC	cis	rs36051895	0.659	rs72701605	chr9:5062056	G/A	cg02405213	chr9:5042618	JAK2	-0.45	-5.09	-0.32	7.22e-7	Pediatric autoimmune diseases;
SARC	cis	rs5753037	0.653	rs140107	chr22:30130516	C/A	cg01021169	chr22:30184971	ASCC2	-0.42	-5.62	-0.35	5.42e-8	Type 1 diabetes;
SARC	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.47	-5.93	-0.36	1.07e-8	Lymphocyte counts;
SARC	cis	rs6446731	0.517	rs2071667	chr4:3269926	C/A	cg06533319	chr4:3265114	C4orf44	0.31	4.9	0.31	1.81e-6	Mean platelet volume;
SARC	cis	rs7953249	0.564	rs1183910	chr12:121420807	G/A	cg02403541	chr12:121454288	C12orf43	0.77	10.36	0.56	6.32e-21	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs7666738	0.830	rs11727235	chr4:98946331	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6484504	0.532	rs12222329	chr11:31274340	T/C	cg02090638	chr11:31391270	DNAJC24;DCDC1	-0.43	-5.39	-0.33	1.72e-7	Red blood cell count;
SARC	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg11890956	chr21:40555474	PSMG1	-1.05	-15.51	-0.71	9.36e-38	Cognitive function;
SARC	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg04756594	chr16:24857601	SLC5A11	0.43	5.52	0.34	9.14e-8	Intelligence (multi-trait analysis);
SARC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.8	10.38	0.56	5.49e-21	Prudent dietary pattern;
SARC	cis	rs6493487	0.512	rs71471585	chr15:51262700	C/G	cg02338191	chr15:51200825	AP4E1	0.55	5.09	0.32	7.21e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs4319547	0.661	rs7398014	chr12:122943980	T/C	cg23029597	chr12:123009494	RSRC2	-0.41	-5.1	-0.32	6.95e-7	Body mass index;
SARC	cis	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg22857025	chr5:266934	NA	-1.06	-11.8	-0.61	1.74e-25	Breast cancer;
SARC	cis	rs9660992	0.547	rs748012	chr1:205216573	C/T	cg07972983	chr1:205091412	RBBP5	0.54	6.74	0.4	1.26e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg10435706	chr6:150039699	LATS1	0.36	4.81	0.3	2.7e-6	Lung cancer;
SARC	cis	rs4713118	0.955	rs9368529	chr6:27684631	G/A	cg17221315	chr6:27791827	HIST1H4J	0.49	4.97	0.31	1.3e-6	Parkinson's disease;
SARC	cis	rs10911363	0.592	rs2702203	chr1:183462513	A/T	cg09173681	chr1:183549694	NCF2	0.31	4.97	0.31	1.27e-6	Systemic lupus erythematosus;
SARC	cis	rs2777491	1.000	rs316609	chr15:41743828	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.81	-12.13	-0.62	1.47e-26	Ulcerative colitis;
SARC	cis	rs4891159	0.790	rs59762437	chr18:74153146	G/A	cg24786174	chr18:74118243	ZNF516	-0.64	-9.02	-0.51	7.25e-17	Longevity;
SARC	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg11644478	chr21:40555479	PSMG1	1.04	12.99	0.65	2.26e-29	Cognitive function;
SARC	cis	rs16976116	0.851	rs28784096	chr15:55503312	C/T	cg17854078	chr15:55489399	RSL24D1	0.66	6.53	0.39	4.18e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7197653	0.748	rs11350	chr16:68335392	A/G	cg05110241	chr16:68378359	PRMT7	-0.58	-4.95	-0.31	1.4e-6	Magnesium levels;
SARC	cis	rs9309473	0.519	rs13017182	chr2:73891004	G/T	cg20560298	chr2:73613845	ALMS1	0.51	6.89	0.41	5.18e-11	Metabolite levels;
SARC	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg01341218	chr17:43662625	NA	-0.71	-8.36	-0.48	5.74e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs72781680	0.821	rs17046004	chr2:24144873	A/G	cg08917208	chr2:24149416	ATAD2B	0.57	5.77	0.35	2.54e-8	Lymphocyte counts;
SARC	cis	rs4727027	0.801	rs12666337	chr7:148796253	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	5.84	0.36	1.72e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04405538	chr19:58874322	ZNF497	-0.52	-6.42	-0.39	7.56e-10	Smoking initiation;
SARC	cis	rs11122272	0.735	rs2474634	chr1:231487017	T/C	cg06096015	chr1:231504339	EGLN1	0.37	5.6	0.34	6.04e-8	Hemoglobin concentration;
SARC	cis	rs262150	0.630	rs2730274	chr7:158796062	C/A	cg04111992	chr7:158790115	NA	-0.36	-4.99	-0.31	1.2e-6	Facial morphology (factor 20);
SARC	cis	rs765787	0.530	rs12440238	chr15:45512905	T/C	cg26924012	chr15:45694286	SPATA5L1	0.43	5.36	0.33	1.98e-7	Uric acid levels;
SARC	cis	rs370915	0.542	rs1425953	chr4:187833652	A/C	cg19519643	chr4:187840862	NA	-0.53	-7.43	-0.44	2.06e-12	Gout;
SARC	cis	rs67311347	0.544	rs2123998	chr3:40359005	C/G	cg24209194	chr3:40518798	ZNF619	-0.49	-6.49	-0.39	5.02e-10	Renal cell carcinoma;
SARC	cis	rs854765	0.619	rs6502636	chr17:17983817	A/T	cg23370820	chr17:17987590	NA	-0.25	-4.74	-0.3	3.65e-6	Total body bone mineral density;
SARC	cis	rs995000	0.931	rs1690766	chr1:62987289	T/C	cg06896770	chr1:63153194	DOCK7	-0.88	-12.57	-0.64	5.16e-28	Triglyceride levels;
SARC	trans	rs7395662	0.591	rs10838968	chr11:48595046	A/G	cg15704280	chr7:45808275	SEPT13	-0.5	-6.77	-0.41	1.06e-10	HDL cholesterol;
SARC	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg05036130	chr6:150231994	NA	0.3	5.14	0.32	5.87e-7	Testicular germ cell tumor;
SARC	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg25072359	chr17:41440525	NA	0.52	6.17	0.37	3.07e-9	Menopause (age at onset);
SARC	cis	rs9457247	1.000	rs400063	chr6:167386592	C/T	cg23791538	chr6:167370224	RNASET2	-0.55	-7.55	-0.44	9.64e-13	Crohn's disease;
SARC	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg11644478	chr21:40555479	PSMG1	1.03	12.82	0.64	8.07e-29	Cognitive function;
SARC	cis	rs7428	0.527	rs1053560	chr2:85546192	C/T	cg03728395	chr2:85555865	TGOLN2	-0.49	-7.0	-0.42	2.74e-11	Ear protrusion;
SARC	cis	rs6831352	0.918	rs1042364	chr4:100045574	T/C	cg13256891	chr4:100009986	ADH5	0.66	8.4	0.48	4.51e-15	Alcohol dependence;
SARC	cis	rs796364	0.806	rs77853713	chr2:201006880	A/T	cg23649088	chr2:200775458	C2orf69	-0.61	-5.45	-0.34	1.28e-7	Schizophrenia;
SARC	cis	rs9788721	0.836	rs1504550	chr15:78766250	A/G	cg06917634	chr15:78832804	PSMA4	-0.51	-5.31	-0.33	2.57e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs950776	0.642	rs7178007	chr15:78965254	G/A	cg06917634	chr15:78832804	PSMA4	0.46	5.15	0.32	5.46e-7	Sudden cardiac arrest;
SARC	cis	rs10489202	1.000	rs66950781	chr1:168018779	C/A	cg24449463	chr1:168025552	DCAF6	-0.64	-7.05	-0.42	2.01e-11	Schizophrenia;
SARC	cis	rs9858542	0.953	rs12330269	chr3:49513910	G/A	cg03060546	chr3:49711283	APEH	-0.58	-7.13	-0.42	1.28e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs1050631	0.574	rs1789507	chr18:33732354	A/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.59	7.25	0.43	6.16e-12	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs9300255	0.537	rs1727334	chr12:123714236	A/G	cg00376283	chr12:123451042	ABCB9	0.52	6.03	0.37	6.37e-9	Neutrophil percentage of white cells;
SARC	trans	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg21659725	chr3:3221576	CRBN	-0.8	-12.22	-0.62	7.09e-27	Intelligence (multi-trait analysis);
SARC	cis	rs12681288	0.644	rs2123058	chr8:1000304	A/G	cg15309053	chr8:964076	NA	0.43	6.91	0.41	4.55e-11	Schizophrenia;
SARC	cis	rs908922	0.542	rs4845785	chr1:152510143	C/T	cg09873164	chr1:152488093	CRCT1	0.63	8.2	0.47	1.6e-14	Hair morphology;
SARC	cis	rs986417	0.901	rs2351171	chr14:61000322	T/C	cg27398547	chr14:60952738	C14orf39	0.96	8.88	0.5	1.87e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs7568458	0.870	rs6757263	chr2:85803542	A/G	cg23752985	chr2:85803571	VAMP8	0.35	5.16	0.32	5.29e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs6772849	0.896	rs9816260	chr3:128352083	A/T	cg08795948	chr3:128337044	NA	0.55	7.62	0.45	6.32e-13	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs7179456	0.654	rs11633839	chr15:59234376	G/A	cg05156742	chr15:59063176	FAM63B	-0.58	-7.55	-0.44	9.99e-13	Asperger disorder;
SARC	cis	rs4319547	0.656	rs9788145	chr12:122899522	C/T	cg23029597	chr12:123009494	RSRC2	-0.41	-5.1	-0.32	7.15e-7	Body mass index;
SARC	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg06221963	chr1:154839813	KCNN3	-0.51	-8.05	-0.47	4.32e-14	Prostate cancer;
SARC	cis	rs8058578	1.000	rs7187359	chr16:30703155	G/A	cg02466173	chr16:30829666	NA	-0.38	-4.93	-0.31	1.6e-6	Multiple myeloma;
SARC	cis	rs858239	0.508	rs7805071	chr7:23190212	C/T	cg23682824	chr7:23144976	KLHL7	0.65	8.09	0.47	3.33e-14	Cerebrospinal fluid biomarker levels;
SARC	cis	rs6714710	0.603	rs17488897	chr2:98365164	G/C	cg26665480	chr2:98280029	ACTR1B	0.53	7.08	0.42	1.73e-11	Posterior cortical atrophy and Alzheimer's disease;
SARC	trans	rs11039798	0.588	rs7479642	chr11:48553808	G/T	cg15704280	chr7:45808275	SEPT13	0.64	6.54	0.39	3.92e-10	Axial length;
SARC	cis	rs17376456	0.825	rs1470150	chr5:93138654	C/T	cg25358565	chr5:93447407	FAM172A	-1.12	-12.11	-0.62	1.64e-26	Diabetic retinopathy;
SARC	cis	rs6700896	0.864	rs12030956	chr1:66115298	G/T	cg04111102	chr1:66153794	NA	0.35	5.55	0.34	7.6e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.48	5.5	0.34	9.88e-8	Renal function-related traits (BUN);
SARC	cis	rs1153858	1.000	rs1719247	chr15:45620985	C/T	cg26924012	chr15:45694286	SPATA5L1	0.73	10.03	0.55	6.32e-20	Homoarginine levels;
SARC	cis	rs7208859	0.673	rs73271887	chr17:29154935	T/C	cg13385521	chr17:29058706	SUZ12P	0.85	7.66	0.45	4.88e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg00409905	chr10:38381863	ZNF37A	-0.46	-6.01	-0.37	6.95e-9	Extrinsic epigenetic age acceleration;
SARC	cis	rs10791097	0.694	rs12361892	chr11:130744490	T/G	cg12179176	chr11:130786555	SNX19	0.73	10.9	0.58	1.26e-22	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs7000551	0.725	rs2249098	chr8:22400098	T/C	cg12081754	chr8:22256438	SLC39A14	0.55	7.8	0.46	2.03e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	trans	rs9818941	0.744	rs13098886	chr3:157613783	C/T	cg08793459	chr17:57784647	PTRH2;TMEM49	0.54	6.23	0.38	2.14e-9	Height;
SARC	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg13206674	chr6:150067644	NUP43	0.46	6.1	0.37	4.48e-9	Lung cancer;
SARC	cis	rs3923518	1.000	rs4676590	chr3:38881080	T/A	cg15678707	chr3:39149194	GORASP1;TTC21A	0.46	4.82	0.3	2.64e-6	Migraine;
SARC	cis	rs17401966	1.000	rs12129035	chr1:10291166	G/A	cg15208524	chr1:10270712	KIF1B	0.6	6.91	0.41	4.59e-11	Hepatocellular carcinoma;
SARC	cis	rs17384381	0.953	rs2284797	chr1:85792383	C/T	cg16011679	chr1:85725395	C1orf52	0.64	5.64	0.35	4.94e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1941023	0.503	rs4939348	chr11:60135871	A/C	cg08716584	chr11:60157161	MS4A7	-0.41	-6.78	-0.41	9.8e-11	Congenital heart disease (maternal effect);
SARC	cis	rs6450176	0.633	rs10054623	chr5:53343821	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.6	-7.03	-0.42	2.32e-11	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs55794721	0.509	rs7554255	chr1:25778106	C/T	cg02931644	chr1:25747376	RHCE	0.43	6.98	0.42	3.08e-11	Plateletcrit;Mean corpuscular volume;
SARC	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg12463550	chr7:65579703	CRCP	0.69	5.23	0.32	3.77e-7	Diabetic kidney disease;
SARC	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg02018176	chr4:1364513	KIAA1530	-0.35	-4.96	-0.31	1.36e-6	Obesity-related traits;
SARC	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg16049864	chr8:95962084	TP53INP1	-0.49	-7.9	-0.46	1.13e-13	Type 2 diabetes;
SARC	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg22834771	chr12:69754056	YEATS4	-0.44	-5.73	-0.35	3.1e-8	Blood protein levels;
SARC	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-5.96	-0.36	9.37e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs11098499	0.818	rs10008791	chr4:120431469	A/C	cg25214090	chr10:38739885	LOC399744	0.58	7.28	0.43	4.95e-12	Corneal astigmatism;
SARC	cis	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg09021430	chr5:549028	NA	-0.45	-5.79	-0.35	2.27e-8	Obesity-related traits;
SARC	cis	rs9420	0.961	rs11570190	chr11:57560452	A/C	cg23127183	chr11:57508653	C11orf31	-0.6	-6.88	-0.41	5.6e-11	Schizophrenia;
SARC	cis	rs6071524	0.818	rs6101326	chr20:37457184	C/G	cg24229276	chr20:36931287	BPI	-0.3	-4.79	-0.3	2.97e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1348850	0.958	rs4893965	chr2:178463852	G/T	cg23306229	chr2:178417860	TTC30B	0.56	6.47	0.39	5.64e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7624766	0.743	rs2886905	chr3:160492850	C/T	cg22637730	chr3:160473554	PPM1L	0.44	5.67	0.35	4.26e-8	Response to methotrexate in rheumatoid arthritis;
SARC	cis	rs3091242	0.933	rs28633797	chr1:25741629	C/A	cg02931644	chr1:25747376	RHCE	0.47	7.79	0.45	2.25e-13	Erythrocyte sedimentation rate;
SARC	cis	rs1707322	0.752	rs3811435	chr1:46125790	C/A	cg03146154	chr1:46216737	IPP	0.52	6.32	0.38	1.33e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs3540	0.960	rs8030390	chr15:90943471	C/T	cg22089800	chr15:90895588	ZNF774	0.55	6.12	0.37	3.9e-9	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg16325326	chr1:53192061	ZYG11B	0.71	10.16	0.55	2.66e-20	Monocyte count;
SARC	cis	rs1670533	0.697	rs658846	chr4:1084723	G/C	cg02018176	chr4:1364513	KIAA1530	0.47	5.36	0.33	1.96e-7	Recombination rate (females);
SARC	cis	rs10089	1.000	rs10089	chr5:127522543	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	8.58	0.49	1.39e-15	Ileal carcinoids;
SARC	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg01765077	chr12:122356316	WDR66	0.31	4.91	0.31	1.75e-6	Mean corpuscular volume;
SARC	cis	rs9487051	0.844	rs9386792	chr6:109609975	G/A	cg01475377	chr6:109611718	NA	-0.42	-5.94	-0.36	1.01e-8	Reticulocyte fraction of red cells;
SARC	cis	rs4975709	0.610	rs6886669	chr5:1867830	T/C	cg19770292	chr5:1868693	NA	0.29	4.74	0.3	3.76e-6	Cardiovascular disease risk factors;
SARC	cis	rs10979	1.000	rs11155300	chr6:143894576	A/G	cg25407410	chr6:143891975	LOC285740	-0.64	-8.78	-0.5	3.67e-16	Hypospadias;
SARC	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg12000995	chr2:27665139	KRTCAP3	-0.31	-4.88	-0.3	1.94e-6	Total body bone mineral density;
SARC	cis	rs57221529	0.655	rs11948381	chr5:568413	A/T	cg09021430	chr5:549028	NA	-0.47	-6.26	-0.38	1.82e-9	Lung disease severity in cystic fibrosis;
SARC	cis	rs2153535	0.541	rs9328477	chr6:8519109	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	8.28	0.48	9.37e-15	Motion sickness;
SARC	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg24829409	chr8:58192753	C8orf71	-0.6	-6.6	-0.4	2.74e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg26335602	chr6:28129616	ZNF389	0.52	5.88	0.36	1.44e-8	Depression;
SARC	trans	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.53	6.85	0.41	6.38e-11	Intelligence (multi-trait analysis);
SARC	cis	rs2295359	0.892	rs17375018	chr1:67655147	A/G	cg12940439	chr1:67600707	NA	-0.43	-6.33	-0.38	1.24e-9	Psoriasis;
SARC	cis	rs1832871	0.711	rs9459954	chr6:158709345	G/T	cg07165851	chr6:158734300	TULP4	0.54	6.3	0.38	1.46e-9	Height;
SARC	cis	rs9905704	0.647	rs9898048	chr17:57108543	C/T	cg12560992	chr17:57184187	TRIM37	0.44	5.49	0.34	1.07e-7	Testicular germ cell tumor;
SARC	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg09359103	chr1:154839909	KCNN3	-0.41	-6.78	-0.41	9.8e-11	Prostate cancer;
SARC	cis	rs2645424	0.530	rs1293303	chr8:11720227	C/G	cg21281001	chr8:11725306	CTSB	-0.46	-5.68	-0.35	3.91e-8	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
SARC	cis	rs7617773	0.780	rs71323396	chr3:48374734	T/G	cg11946769	chr3:48343235	NME6	0.74	9.34	0.52	8.09e-18	Coronary artery disease;
SARC	cis	rs3733585	0.673	rs7378340	chr4:9955198	C/T	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.55	-0.34	7.58e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs9326248	0.581	rs6589582	chr11:116829200	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.64	8.12	0.47	2.7e-14	Blood protein levels;
SARC	cis	rs2916247	0.954	rs11991256	chr8:93077207	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.66	-7.11	-0.42	1.42e-11	Intelligence (multi-trait analysis);
SARC	cis	rs9914988	0.943	rs67327562	chr17:27108828	G/A	cg20469991	chr17:27169893	C17orf63	-0.49	-5.1	-0.32	6.99e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs734999	0.588	rs6668149	chr1:2558308	A/C	cg00980319	chr1:2560884	MMEL1	0.34	4.9	0.31	1.83e-6	Ulcerative colitis;
SARC	cis	rs2732480	0.500	rs2932093	chr12:48648271	G/T	cg24011408	chr12:48396354	COL2A1	0.46	5.34	0.33	2.18e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs2652834	1.000	rs2652832	chr15:63396928	T/C	cg05507819	chr15:63340323	TPM1	0.54	5.36	0.33	2e-7	HDL cholesterol;
SARC	cis	rs600231	0.708	rs2957269	chr11:65243007	C/G	cg17120908	chr11:65337727	SSSCA1	-0.43	-5.51	-0.34	9.24e-8	Bone mineral density;
SARC	cis	rs67460515	0.500	rs1562464	chr3:160681614	G/A	cg04691961	chr3:161091175	C3orf57	-0.44	-5.07	-0.32	8.07e-7	Parkinson's disease;
SARC	cis	rs6582630	0.679	rs7301806	chr12:38596667	G/A	cg26384229	chr12:38710491	ALG10B	0.6	7.81	0.46	1.9e-13	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2731664	0.792	rs385981	chr5:176886539	C/T	cg23176889	chr5:176863531	GRK6	-0.57	-8.54	-0.49	1.77e-15	Intelligence (multi-trait analysis);
SARC	cis	rs17539620	0.519	rs871071	chr6:154837667	T/C	cg17771515	chr6:154831774	CNKSR3	0.52	5.07	0.32	8.08e-7	Lipoprotein (a) levels;
SARC	cis	rs6539288	0.933	rs1037012	chr12:107302677	T/C	cg07730007	chr12:107377277	MTERFD3	0.38	4.79	0.3	2.97e-6	Total body bone mineral density;
SARC	cis	rs2486288	0.656	rs7165039	chr15:45570413	C/G	cg21132104	chr15:45694354	SPATA5L1	-0.54	-6.81	-0.41	8.2e-11	Glomerular filtration rate;
SARC	trans	rs11722228	0.549	rs56146302	chr4:10081052	C/T	cg26043149	chr18:55253948	FECH	0.68	7.6	0.45	7.08e-13	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs2387326	0.672	rs10829344	chr10:129944569	A/C	cg16087940	chr10:129947807	NA	-0.45	-5.74	-0.35	2.98e-8	Select biomarker traits;
SARC	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg25703541	chr22:24373054	LOC391322	-0.83	-11.09	-0.59	3.18e-23	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.99	12.16	0.62	1.18e-26	Platelet count;
SARC	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg19223190	chr17:80058835	NA	0.45	6.24	0.38	2.06e-9	Life satisfaction;
SARC	cis	rs13256369	0.901	rs12679831	chr8:8566411	T/G	cg18904891	chr8:8559673	CLDN23	0.5	5.73	0.35	3.14e-8	Obesity-related traits;
SARC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg11494091	chr17:61959527	GH2	0.53	7.86	0.46	1.4e-13	Prudent dietary pattern;
SARC	cis	rs7666738	0.830	rs2019163	chr4:99022747	C/T	cg05340658	chr4:99064831	C4orf37	0.66	9.04	0.51	6.35e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7552404	0.628	rs5745442	chr1:76342858	T/G	cg10523679	chr1:76189770	ACADM	0.47	5.36	0.33	2.05e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs12421382	0.659	rs1837396	chr11:109389257	G/A	cg27471124	chr11:109292789	C11orf87	0.36	5.18	0.32	4.89e-7	Schizophrenia;
SARC	cis	rs7246657	0.943	rs7255952	chr19:37988797	A/G	cg23950597	chr19:37808831	NA	-0.54	-5.15	-0.32	5.49e-7	Coronary artery calcification;
SARC	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg03999130	chr15:45571217	NA	0.39	5.09	0.32	7.55e-7	Homoarginine levels;
SARC	cis	rs57221529	0.766	rs12519469	chr5:581772	A/G	cg07777115	chr5:623756	CEP72	-0.56	-4.84	-0.3	2.35e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs2916247	0.954	rs4623481	chr8:93079345	T/G	cg10183463	chr8:93005414	RUNX1T1	-0.54	-5.88	-0.36	1.43e-8	Intelligence (multi-trait analysis);
SARC	cis	rs735396	1.000	rs2259816	chr12:121435587	A/C	cg02403541	chr12:121454288	C12orf43	-0.73	-9.58	-0.53	1.55e-18	N-glycan levels;
SARC	cis	rs9436747	0.667	rs12033452	chr1:66038435	C/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.48	5.22	0.32	3.96e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs910316	0.967	rs10142770	chr14:75525449	G/A	cg23033748	chr14:75592666	NEK9	0.37	5.12	0.32	6.26e-7	Height;
SARC	cis	rs854765	0.663	rs12941550	chr17:17753828	C/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.39	-5.11	-0.32	6.57e-7	Total body bone mineral density;
SARC	cis	rs155076	1.000	rs261406	chr13:21855854	G/A	cg11317459	chr13:21872234	NA	-0.96	-11.94	-0.62	6.08e-26	White matter hyperintensity burden;
SARC	cis	rs7223966	1.000	rs13380863	chr17:61780793	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	7.03	0.42	2.28e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs3812831	0.695	rs7995986	chr13:114938802	A/G	cg08824895	chr13:115047677	UPF3A	0.49	6.54	0.39	3.91e-10	Schizophrenia;
SARC	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg17554472	chr22:41940697	POLR3H	-0.43	-4.77	-0.3	3.27e-6	Vitiligo;
SARC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg26902098	chr5:78103644	ARSB	0.52	6.42	0.39	7.51e-10	Gut microbiota (bacterial taxa);
SARC	cis	rs796364	0.806	rs11674293	chr2:201026743	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.73	-6.24	-0.38	2e-9	Schizophrenia;
SARC	cis	rs921968	0.540	rs10190250	chr2:219457731	C/T	cg02176678	chr2:219576539	TTLL4	-0.49	-7.39	-0.44	2.63e-12	Mean corpuscular hemoglobin concentration;
SARC	cis	rs6582630	0.537	rs1949611	chr12:38373092	C/T	cg13010199	chr12:38710504	ALG10B	-0.72	-9.92	-0.54	1.46e-19	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1003719	0.680	rs2835670	chr21:38581114	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.18	-0.52	2.43e-17	Eye color traits;
SARC	cis	rs9486715	0.867	rs4240553	chr6:96965324	T/C	cg06623918	chr6:96969491	KIAA0776	0.89	12.69	0.64	2.17e-28	Headache;
SARC	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-8.22	-0.47	1.41e-14	Alzheimer's disease;
SARC	cis	rs79839061	0.520	rs11730111	chr4:942833	C/T	cg07828340	chr4:882639	GAK	0.81	6.2	0.38	2.56e-9	Intelligence (multi-trait analysis);
SARC	cis	rs8180040	0.800	rs6768221	chr3:47296899	C/G	cg27129171	chr3:47204927	SETD2	-0.72	-9.53	-0.53	2.16e-18	Colorectal cancer;
SARC	cis	rs2050392	0.517	rs603072	chr10:30755778	C/T	cg25182066	chr10:30743637	MAP3K8	-0.45	-6.55	-0.39	3.71e-10	Inflammatory bowel disease;
SARC	cis	rs1044826	0.692	rs188420	chr3:139233865	G/A	cg15131784	chr3:139108705	COPB2	-0.4	-5.12	-0.32	6.51e-7	Obesity-related traits;
SARC	cis	rs4423214	0.959	rs11233747	chr11:71171642	G/A	cg24826892	chr11:71159390	DHCR7	0.44	5.64	0.35	5.01e-8	Vitamin D levels;
SARC	trans	rs61931739	0.614	rs6488172	chr12:33745669	A/G	cg26384229	chr12:38710491	ALG10B	0.54	6.82	0.41	7.85e-11	Morning vs. evening chronotype;
SARC	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.69	-0.4	1.62e-10	Total body bone mineral density;
SARC	cis	rs9310709	0.538	rs822770	chr3:23032988	T/C	cg00327796	chr3:23032191	NA	0.34	4.95	0.31	1.39e-6	Chronic kidney disease and serum creatinine levels;
SARC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.52	6.65	0.4	2.03e-10	Lymphocyte counts;
SARC	cis	rs4889855	0.556	rs11547301	chr17:78518780	C/T	cg17956530	chr17:78667699	RPTOR	0.42	4.8	0.3	2.87e-6	Fractional excretion of uric acid;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg21673338	chr15:77095150	SCAPER	0.49	6.78	0.41	9.65e-11	Thyroid stimulating hormone;
SARC	cis	rs2387326	0.767	rs12257487	chr10:129943286	A/G	cg16087940	chr10:129947807	NA	-0.47	-5.74	-0.35	3e-8	Select biomarker traits;
SARC	cis	rs7264396	1.000	rs224436	chr20:34154124	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-5.37	-0.33	1.88e-7	Total cholesterol levels;
SARC	cis	rs6089584	0.566	rs55881457	chr20:60608424	G/A	cg13770153	chr20:60521292	NA	-0.39	-5.66	-0.35	4.44e-8	Body mass index;
SARC	trans	rs9929218	1.000	rs9928847	chr16:68797893	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.53	-6.69	-0.4	1.63e-10	Colorectal cancer;
SARC	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	7.28	0.43	5.23e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7224737	0.750	rs13380830	chr17:40297658	C/G	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-0.5	-4.74	-0.3	3.78e-6	Fibrinogen levels;
SARC	cis	rs3091242	0.902	rs36003018	chr1:25784318	A/G	cg02931644	chr1:25747376	RHCE	-0.45	-7.45	-0.44	1.78e-12	Erythrocyte sedimentation rate;
SARC	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg25952890	chr19:58913133	NA	0.35	4.98	0.31	1.23e-6	Uric acid clearance;
SARC	cis	rs9790314	0.846	rs4856714	chr3:160961824	T/C	cg03342759	chr3:160939853	NMD3	-0.73	-9.94	-0.55	1.26e-19	Morning vs. evening chronotype;
SARC	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg22496380	chr5:211416	CCDC127	-0.88	-9.35	-0.52	7.72e-18	Breast cancer;
SARC	cis	rs986417	0.748	rs10142927	chr14:61041956	A/G	cg27398547	chr14:60952738	C14orf39	0.78	7.75	0.45	2.74e-13	Gut microbiota (bacterial taxa);
SARC	cis	rs950027	0.549	rs11070452	chr15:45594836	C/A	cg21132104	chr15:45694354	SPATA5L1	-0.52	-6.3	-0.38	1.46e-9	Response to fenofibrate (adiponectin levels);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg03150474	chr6:10695108	C6orf52;PAK1IP1	-0.56	-6.33	-0.38	1.26e-9	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs8067545	0.611	rs2703776	chr17:20137709	C/A	cg13482628	chr17:19912719	NA	-0.57	-7.57	-0.44	8.93e-13	Schizophrenia;
SARC	cis	rs922107	0.713	rs2031119	chr1:90042745	C/T	cg15422784	chr1:90023713	LRRC8B	-0.34	-4.97	-0.31	1.3e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
SARC	cis	rs8014204	0.804	rs34956813	chr14:75254167	G/A	cg06637938	chr14:75390232	RPS6KL1	0.7	10.1	0.55	3.94e-20	Caffeine consumption;
SARC	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg13939156	chr17:80058883	NA	0.37	5.65	0.35	4.6e-8	Life satisfaction;
SARC	cis	rs7927771	0.839	rs59360790	chr11:47669175	T/C	cg05585544	chr11:47624801	NA	-0.38	-5.39	-0.33	1.75e-7	Subjective well-being;
SARC	cis	rs9394841	0.667	rs10807268	chr6:41777591	A/T	cg08135965	chr6:41755394	TOMM6	0.61	6.46	0.39	6.11e-10	Mean corpuscular hemoglobin;Red cell distribution width;
SARC	cis	rs9486715	0.838	rs9386576	chr6:96954717	C/T	cg18709589	chr6:96969512	KIAA0776	0.59	7.33	0.43	3.65e-12	Headache;
SARC	cis	rs6840360	1.000	rs2278304	chr4:152593409	C/T	cg22705602	chr4:152727874	NA	0.38	6.5	0.39	4.76e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7224737	1.000	rs739637	chr17:40280944	G/C	cg20291162	chr17:40259547	DHX58	-0.33	-4.87	-0.3	2.08e-6	Fibrinogen levels;
SARC	cis	rs9436747	0.704	rs1137100	chr1:66036441	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.49	4.82	0.3	2.58e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg26681399	chr22:41777847	TEF	0.43	4.92	0.31	1.67e-6	Vitiligo;
SARC	cis	rs2380220	0.720	rs9374178	chr6:95979974	G/T	cg15832292	chr6:96025679	MANEA	0.5	5.54	0.34	8.02e-8	Behavioural disinhibition (generation interaction);
SARC	cis	rs6570726	0.791	rs378937	chr6:145834745	C/T	cg23711669	chr6:146136114	FBXO30	0.86	14.2	0.68	2.22e-33	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2043112	1.000	rs13168867	chr5:38975458	T/C	cg04869206	chr5:39074266	RICTOR	0.51	6.19	0.38	2.72e-9	Obesity-related traits;
SARC	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg13206674	chr6:150067644	NUP43	0.45	5.67	0.35	4.18e-8	Lung cancer;
SARC	cis	rs9788682	0.747	rs8042494	chr15:78908010	C/T	cg06917634	chr15:78832804	PSMA4	-0.47	-5.34	-0.33	2.21e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg09165964	chr15:75287851	SCAMP5	0.52	7.0	0.42	2.74e-11	Breast cancer;
SARC	cis	rs6500602	0.727	rs4238849	chr16:4538114	G/A	cg08645402	chr16:4508243	NA	0.42	5.44	0.34	1.34e-7	Schizophrenia;
SARC	cis	rs8058578	0.775	rs8046391	chr16:30836648	G/C	cg00531865	chr16:30841666	NA	-0.47	-5.23	-0.32	3.71e-7	Multiple myeloma;
SARC	cis	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg24110177	chr3:50126178	RBM5	0.55	7.32	0.43	3.92e-12	Intelligence (multi-trait analysis);
SARC	cis	rs9303401	0.580	rs2013166	chr17:56637630	C/T	cg25039879	chr17:56429692	SUPT4H1	0.67	6.21	0.38	2.4e-9	Cognitive test performance;
SARC	cis	rs2832191	0.716	rs2249028	chr21:30365322	G/A	cg24692254	chr21:30365293	RNF160	1.02	18.47	0.77	1.63e-47	Dental caries;
SARC	cis	rs67460515	0.892	rs1382429	chr3:161015153	T/C	cg04691961	chr3:161091175	C3orf57	-0.5	-6.18	-0.38	2.79e-9	Parkinson's disease;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg23815043	chr16:88729854	MGC23284;MVD	-0.52	-6.49	-0.39	5.08e-10	Height;
SARC	cis	rs2688608	0.592	rs7923045	chr10:75487498	A/T	cg13887666	chr10:75432598	NA	-0.35	-5.0	-0.31	1.13e-6	Inflammatory bowel disease;
SARC	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg11987759	chr7:65425863	GUSB	-0.49	-6.02	-0.37	6.86e-9	Aortic root size;
SARC	cis	rs6089584	0.546	rs6061978	chr20:60615604	C/T	cg13770153	chr20:60521292	NA	-0.36	-5.29	-0.33	2.81e-7	Body mass index;
SARC	cis	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg06558623	chr16:89946397	TCF25	0.91	6.37	0.39	9.81e-10	Skin colour saturation;
SARC	cis	rs7103648	0.630	rs7934481	chr11:47883337	C/T	cg20307385	chr11:47447363	PSMC3	0.74	10.09	0.55	4.28e-20	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs9479482	0.967	rs13209192	chr6:150350099	A/G	cg03788504	chr6:150331562	NA	-0.31	-5.13	-0.32	5.99e-7	Alopecia areata;
SARC	cis	rs1865760	0.533	rs1408270	chr6:25873184	A/G	cg10373733	chr6:25993375	NA	0.4	4.72	0.3	4.08e-6	Height;
SARC	cis	rs7945705	0.869	rs7925728	chr11:9013002	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.47	-6.68	-0.4	1.73e-10	Hemoglobin concentration;
SARC	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.42	-6.87	-0.41	5.71e-11	Total body bone mineral density;
SARC	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg24633833	chr3:10029261	TMEM111	0.52	5.25	0.33	3.43e-7	Alzheimer's disease;
SARC	cis	rs78456975	1.000	rs10208340	chr2:1563100	G/A	cg26248373	chr2:1572462	NA	-0.6	-5.91	-0.36	1.2e-8	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg23262073	chr20:60523788	NA	0.41	5.37	0.33	1.86e-7	Body mass index;
SARC	cis	rs7818345	0.845	rs7821446	chr8:19268822	A/G	cg11303988	chr8:19266685	CSGALNACT1	-0.4	-5.15	-0.32	5.54e-7	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs478304	0.718	rs1151490	chr11:65390485	A/C	cg27068330	chr11:65405492	SIPA1	0.41	5.16	0.32	5.33e-7	Acne (severe);
SARC	cis	rs2153535	0.580	rs6921036	chr6:8455400	G/A	cg07606381	chr6:8435919	SLC35B3	0.76	10.7	0.57	5.36e-22	Motion sickness;
SARC	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.38	4.71	0.3	4.2e-6	Tonsillectomy;
SARC	cis	rs2204008	0.580	rs11174421	chr12:38105138	A/G	cg13010199	chr12:38710504	ALG10B	0.75	9.04	0.51	6.15e-17	Bladder cancer;
SARC	cis	rs9894429	0.646	rs12948797	chr17:79617384	G/A	cg18240062	chr17:79603768	NPLOC4	0.6	7.27	0.43	5.25e-12	Eye color traits;
SARC	cis	rs13006833	0.668	rs291462	chr2:191181678	T/C	cg25963032	chr2:191064776	C2orf88	0.36	4.99	0.31	1.16e-6	Urinary metabolites;
SARC	cis	rs7681440	0.904	rs1442153	chr4:90775719	T/G	cg06632027	chr4:90757378	SNCA	0.4	5.68	0.35	3.91e-8	Dementia with Lewy bodies;
SARC	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	11.07	0.59	3.59e-23	Alzheimer's disease;
SARC	cis	rs9815354	0.723	rs77572508	chr3:41938044	C/A	cg03022575	chr3:42003672	ULK4	0.7	5.7	0.35	3.66e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs13256369	0.950	rs13248096	chr8:8577476	C/T	cg18904891	chr8:8559673	CLDN23	0.52	5.86	0.36	1.58e-8	Obesity-related traits;
SARC	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg11764359	chr7:65958608	NA	-0.86	-12.18	-0.62	9.99e-27	Aortic root size;
SARC	cis	rs2073300	0.609	rs2281434	chr20:23378101	C/A	cg12062639	chr20:23401060	NAPB	0.95	6.5	0.39	4.74e-10	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg23758822	chr17:41437982	NA	0.88	11.24	0.59	1.04e-23	Menopause (age at onset);
SARC	trans	rs9650657	0.572	rs4841465	chr8:10819854	C/T	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.8	-0.5	3.18e-16	Neuroticism;
SARC	cis	rs11874712	0.545	rs12963615	chr18:43641707	C/T	cg26436583	chr18:43649176	PSTPIP2	-0.44	-5.69	-0.35	3.72e-8	Migraine - clinic-based;
SARC	cis	rs2797160	1.000	rs1739357	chr6:126019655	T/G	cg05901451	chr6:126070800	HEY2	0.42	5.01	0.31	1.09e-6	Endometrial cancer;
SARC	cis	rs17345786	1.000	rs3804778	chr3:101294572	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.43	-4.76	-0.3	3.35e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6952808	0.929	rs2280548	chr7:1976667	G/T	cg04267008	chr7:1944627	MAD1L1	-0.65	-7.38	-0.44	2.77e-12	Bipolar disorder and schizophrenia;
SARC	cis	rs9787249	0.874	rs7520588	chr1:40214525	T/A	cg02773041	chr1:40204384	PPIE	0.53	6.46	0.39	6.11e-10	Blood protein levels;
SARC	cis	rs826838	0.967	rs7970069	chr12:38810631	T/C	cg13010199	chr12:38710504	ALG10B	0.78	11.14	0.59	2.27e-23	Heart rate;
SARC	cis	rs36051895	0.632	rs62541958	chr9:5175621	T/C	cg02405213	chr9:5042618	JAK2	-0.45	-5.11	-0.32	6.66e-7	Pediatric autoimmune diseases;
SARC	cis	rs4466137	0.904	rs6887104	chr5:83003535	G/A	cg16102102	chr5:83017553	HAPLN1	-0.75	-9.37	-0.52	6.72e-18	Prostate cancer;
SARC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg05064044	chr6:292385	DUSP22	-0.57	-7.26	-0.43	5.83e-12	Menopause (age at onset);
SARC	cis	rs4466137	0.903	rs3734092	chr5:83016743	C/T	cg16102102	chr5:83017553	HAPLN1	-0.75	-9.27	-0.52	1.27e-17	Prostate cancer;
SARC	cis	rs11585357	0.895	rs2501795	chr1:17633499	A/G	cg08277548	chr1:17600880	PADI3	-0.44	-5.28	-0.33	3.02e-7	Hair shape;
SARC	cis	rs6088580	0.634	rs1205338	chr20:32925625	C/G	cg08999081	chr20:33150536	PIGU	-0.43	-6.57	-0.4	3.3e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs2652822	0.662	rs34367270	chr15:63410912	G/A	cg02713581	chr15:63449717	RPS27L	0.6	7.47	0.44	1.58e-12	Metabolic traits;
SARC	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg27211696	chr2:191398769	TMEM194B	0.5	6.94	0.41	3.94e-11	Pulse pressure;
SARC	cis	rs1865721	0.839	rs59718187	chr18:73144032	C/T	cg26385618	chr18:73139727	C18orf62	-0.38	-5.24	-0.32	3.6e-7	Intelligence;
SARC	cis	rs79349575	0.783	rs9747646	chr17:47016882	C/T	cg07967210	chr17:47022446	SNF8	0.38	4.77	0.3	3.2e-6	Type 2 diabetes;
SARC	cis	rs17401966	0.898	rs1396	chr1:10247143	C/A	cg15208524	chr1:10270712	KIF1B	0.48	5.2	0.32	4.29e-7	Hepatocellular carcinoma;
SARC	cis	rs9486719	1.000	rs4078038	chr6:96904366	A/G	cg06623918	chr6:96969491	KIAA0776	-0.72	-7.54	-0.44	1.03e-12	Migraine;Coronary artery disease;
SARC	cis	rs4128725	0.925	rs4656826	chr1:159413926	C/A	cg25076881	chr1:159409836	OR10J1	0.4	4.81	0.3	2.67e-6	Select biomarker traits;
SARC	cis	rs13166103	0.657	rs10940611	chr5:57696279	C/T	cg10487770	chr5:57879443	RAB3C	0.44	4.81	0.3	2.7e-6	Type 2 diabetes (age of onset);
SARC	cis	rs7937682	0.575	rs34888817	chr11:111756455	C/T	cg09085632	chr11:111637200	PPP2R1B	0.78	10.39	0.56	4.99e-21	Primary sclerosing cholangitis;
SARC	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg08219700	chr8:58056026	NA	0.62	5.9	0.36	1.29e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs858239	0.896	rs1637192	chr7:23260514	G/A	cg23682824	chr7:23144976	KLHL7	0.59	7.37	0.43	3.01e-12	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9296092	0.517	rs56206922	chr6:33522567	C/T	cg13560919	chr6:33536144	NA	-0.5	-6.31	-0.38	1.38e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs600231	0.665	rs1616810	chr11:65220105	A/G	cg17120908	chr11:65337727	SSSCA1	-0.4	-5.1	-0.32	6.91e-7	Bone mineral density;
SARC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg18404041	chr3:52824283	ITIH1	-0.33	-4.97	-0.31	1.29e-6	Electroencephalogram traits;
SARC	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg02725872	chr8:58115012	NA	-0.34	-5.37	-0.33	1.91e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2204008	0.811	rs12368410	chr12:38305705	C/T	cg13010199	chr12:38710504	ALG10B	0.8	11.11	0.59	2.74e-23	Bladder cancer;
SARC	cis	rs2075371	0.897	rs1646743	chr7:134003451	C/A	cg00033643	chr7:134001901	SLC35B4	0.52	6.56	0.39	3.53e-10	Mean platelet volume;
SARC	cis	rs9911578	0.935	rs34523895	chr17:57034095	T/C	cg05425664	chr17:57184151	TRIM37	-0.57	-6.93	-0.41	4.07e-11	Intelligence (multi-trait analysis);
SARC	trans	rs1853207	1.000	rs17110194	chr10:96441949	G/A	cg02737782	chr1:8014393	NA	-1.15	-6.68	-0.4	1.7e-10	Blood metabolite levels;
SARC	trans	rs637571	0.584	rs7107912	chr11:65603252	G/A	cg17712092	chr4:129076599	LARP1B	-0.51	-6.5	-0.39	4.96e-10	Eosinophil percentage of white cells;
SARC	cis	rs607987	0.841	rs11031030	chr11:30304455	T/C	cg06241208	chr11:30344200	C11orf46	0.42	5.03	0.31	9.7e-7	Body mass index;
SARC	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg09359103	chr1:154839909	KCNN3	-0.49	-8.58	-0.49	1.39e-15	Prostate cancer;
SARC	cis	rs4764124	0.646	rs10846062	chr12:14965781	T/C	cg19759883	chr12:14956454	WBP11;C12orf60	0.73	10.48	0.57	2.73e-21	Pubertal anthropometrics;
SARC	cis	rs712039	0.617	rs853201	chr17:35804187	C/A	cg16670864	chr17:35848621	DUSP14	0.46	4.97	0.31	1.28e-6	Tuberculosis;
SARC	cis	rs1346751	0.535	rs1001129	chr2:16605354	G/A	cg09580478	chr2:16689509	NA	0.52	4.92	0.31	1.65e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
SARC	cis	rs4900538	0.819	rs72698591	chr14:102838896	G/A	cg18135206	chr14:102964638	TECPR2	-0.59	-7.58	-0.44	8.39e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg04277193	chr17:41438351	NA	0.44	4.82	0.3	2.59e-6	Menopause (age at onset);
SARC	cis	rs3858526	0.959	rs11039540	chr11:5928334	C/T	cg02574844	chr11:5959923	NA	-0.42	-5.24	-0.32	3.58e-7	DNA methylation (variation);
SARC	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg09839136	chr7:766187	HEATR2;PRKAR1B	-0.6	-5.15	-0.32	5.45e-7	Cerebrospinal P-tau181p levels;
SARC	cis	rs4780401	0.609	rs7205994	chr16:11815964	C/T	cg01061890	chr16:11836724	TXNDC11	-0.62	-8.73	-0.5	4.86e-16	Rheumatoid arthritis;
SARC	cis	rs11722228	1.000	rs11722228	chr4:9915741	C/T	cg11266682	chr4:10021025	SLC2A9	0.32	5.17	0.32	4.97e-7	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs4664308	0.967	rs17241973	chr2:160918601	A/G	cg03641300	chr2:160917029	PLA2R1	-0.67	-9.03	-0.51	6.88e-17	Idiopathic membranous nephropathy;
SARC	cis	rs2120019	0.938	rs8030089	chr15:75290377	C/T	cg00629941	chr15:75287862	SCAMP5	-0.7	-8.25	-0.48	1.2e-14	Blood trace element (Zn levels);
SARC	cis	rs931812	1.000	rs931812	chr8:101919321	A/G	cg07585502	chr8:101912084	NA	0.4	4.77	0.3	3.2e-6	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs597539	0.727	rs632984	chr11:68620271	C/T	cg06028808	chr11:68637592	NA	0.45	5.53	0.34	8.7e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs1707322	1.000	rs1622208	chr1:46498375	A/G	cg03146154	chr1:46216737	IPP	-0.49	-5.93	-0.36	1.08e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9462027	0.651	rs9469870	chr6:34744349	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.91	-0.36	1.22e-8	Systemic lupus erythematosus;
SARC	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg18252515	chr7:66147081	NA	-0.53	-5.69	-0.35	3.86e-8	Aortic root size;
SARC	cis	rs2153535	0.580	rs9406167	chr6:8502852	T/C	cg07606381	chr6:8435919	SLC35B3	0.79	11.04	0.59	4.5e-23	Motion sickness;
SARC	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg22535103	chr8:58192502	C8orf71	-0.65	-6.08	-0.37	4.79e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg05623727	chr3:50126028	RBM5	-0.33	-5.08	-0.32	7.7300000000000005e-07	Intelligence (multi-trait analysis);
SARC	cis	rs6120849	0.754	rs752448	chr20:33592248	C/T	cg06115741	chr20:33292138	TP53INP2	0.54	5.24	0.32	3.64e-7	Protein C levels;
SARC	cis	rs9916302	0.851	rs7225096	chr17:37664443	T/C	cg00129232	chr17:37814104	STARD3	-0.64	-7.93	-0.46	8.9e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs933688	1.000	rs61612071	chr5:90741470	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.0	12.52	0.63	7.66e-28	Smoking behavior;
SARC	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.08	22.63	0.83	9.78e-61	Chronic sinus infection;
SARC	cis	rs9393692	0.905	rs9379843	chr6:26289435	A/G	cg05868516	chr6:26286170	HIST1H4H	0.6	8.11	0.47	2.84e-14	Educational attainment;
SARC	cis	rs1957429	0.520	rs12435626	chr14:65295215	A/G	cg23373153	chr14:65346875	NA	0.65	5.04	0.31	9.21e-7	Pediatric areal bone mineral density (radius);
SARC	cis	rs7589342	0.628	rs11893695	chr2:106401300	C/G	cg16077055	chr2:106428750	NCK2	-0.33	-5.72	-0.35	3.2e-8	Addiction;
SARC	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg18876405	chr7:65276391	NA	-0.7	-8.53	-0.49	1.88e-15	Aortic root size;
SARC	cis	rs8072548	1	rs8072548	chr17:38164025	T/G	cg17467752	chr17:38218738	THRA	0.44	5.92	0.36	1.17e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
SARC	cis	rs7772486	0.597	rs2246132	chr6:146182515	C/G	cg05347473	chr6:146136440	FBXO30	0.68	9.44	0.53	3.91e-18	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs17376456	0.877	rs13156865	chr5:93390908	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	6.12	0.37	3.99e-9	Diabetic retinopathy;
SARC	cis	rs820218	0.743	rs3744000	chr17:73704333	C/T	cg01592526	chr17:73663357	RECQL5;SAP30BP	-0.6	-7.63	-0.45	6.12e-13	Rotator cuff tears;
SARC	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg23172400	chr8:95962367	TP53INP1	-0.31	-5.31	-0.33	2.57e-7	Type 2 diabetes;
SARC	cis	rs7681440	0.874	rs7687945	chr4:90764699	C/T	cg02192967	chr4:90758406	SNCA	0.36	5.14	0.32	5.76e-7	Dementia with Lewy bodies;
SARC	cis	rs7666738	0.716	rs13108535	chr4:99046324	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs965469	0.895	rs6139124	chr20:3398144	C/T	cg25506879	chr20:3388711	C20orf194	-0.56	-5.74	-0.35	2.99e-8	IFN-related cytopenia;
SARC	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg26335602	chr6:28129616	ZNF389	0.53	5.91	0.36	1.2e-8	Depression;
SARC	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg13939156	chr17:80058883	NA	0.37	5.73	0.35	3.11e-8	Life satisfaction;
SARC	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg17971929	chr21:40555470	PSMG1	-0.86	-11.22	-0.59	1.2e-23	Cognitive function;
SARC	cis	rs12980942	0.872	rs12976536	chr19:41799886	T/A	cg25627403	chr19:41769009	HNRNPUL1	0.6	4.99	0.31	1.16e-6	Coronary artery disease;
SARC	cis	rs5753618	0.561	rs2413047	chr22:31666026	A/G	cg07713946	chr22:31675144	LIMK2	-0.37	-5.15	-0.32	5.57e-7	Colorectal cancer;
SARC	cis	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg25894440	chr7:65020034	NA	0.72	5.62	0.35	5.37e-8	Diabetic kidney disease;
SARC	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg09263875	chr16:632152	PIGQ	0.53	8.17	0.47	1.93e-14	Height;
SARC	cis	rs11112613	0.713	rs12316204	chr12:105944244	G/A	cg03607813	chr12:105948248	NA	0.54	7.11	0.42	1.44e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs11690935	0.959	rs12692974	chr2:172663256	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.98	-15.73	-0.72	1.73e-38	Schizophrenia;
SARC	cis	rs6448317	0.556	rs11943001	chr4:24910944	A/G	cg21108841	chr4:24914750	CCDC149	-0.54	-4.83	-0.3	2.44e-6	Heschl's gyrus morphology;
SARC	cis	rs9326248	0.520	rs236919	chr11:117095361	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.75	10.39	0.56	5.08e-21	Blood protein levels;
SARC	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg12463550	chr7:65579703	CRCP	0.48	5.24	0.32	3.65e-7	Aortic root size;
SARC	cis	rs778371	1.000	rs709937	chr2:233744021	A/G	cg20388707	chr2:233749442	NGEF	-0.35	-4.98	-0.31	1.25e-6	Schizophrenia;
SARC	cis	rs897080	0.515	rs698792	chr2:44683219	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.49	-5.5	-0.34	9.92e-8	Height;
SARC	cis	rs523522	0.962	rs11065145	chr12:120947419	A/G	cg27279351	chr12:120934652	DYNLL1	0.73	9.05	0.51	5.73e-17	High light scatter reticulocyte count;
SARC	cis	rs6866344	0.697	rs11748495	chr5:178130000	A/G	cg03877680	chr5:178157825	ZNF354A	-1.0	-12.95	-0.65	2.96e-29	Neutrophil percentage of white cells;
SARC	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.64	-7.41	-0.44	2.37e-12	Gut microbiome composition (summer);
SARC	cis	rs7216064	0.953	rs1966410	chr17:65837215	T/C	cg12091567	chr17:66097778	LOC651250	-0.74	-8.17	-0.47	1.97e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs9660992	0.710	rs4951184	chr1:205240659	A/T	cg19090574	chr1:205240910	TMCC2	-0.41	-5.26	-0.33	3.26e-7	Mean corpuscular volume;Mean platelet volume;
SARC	trans	rs629535	0.814	rs506931	chr8:70068129	T/G	cg21567404	chr3:27674614	NA	1.04	13.3	0.66	2.13e-30	Dupuytren's disease;
SARC	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg27286337	chr10:134555280	INPP5A	0.66	8.31	0.48	8e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs7914558	0.966	rs10450373	chr10:104728616	T/C	cg04362960	chr10:104952993	NT5C2	0.4	4.79	0.3	2.92e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs9393692	0.905	rs1124999	chr6:26287043	G/T	cg00631329	chr6:26305371	NA	-0.62	-9.06	-0.51	5.4e-17	Educational attainment;
SARC	cis	rs7084402	0.902	rs1582826	chr10:60297175	C/T	cg07615347	chr10:60278583	BICC1	0.6	8.91	0.5	1.45e-16	Refractive error;
SARC	cis	rs12311304	0.965	rs16910692	chr12:15370010	T/C	cg08258403	chr12:15378311	NA	0.46	7.2	0.43	8.2e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs754466	0.580	rs1344966	chr10:79534527	T/C	cg17075019	chr10:79541650	NA	-0.84	-13.17	-0.65	5.7e-30	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg24503407	chr1:205819492	PM20D1	0.92	17.08	0.75	5.82e-43	Menarche (age at onset);
SARC	cis	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg25427524	chr10:38739819	LOC399744	-0.6	-9.92	-0.55	1.38e-19	Extrinsic epigenetic age acceleration;
SARC	cis	rs67460515	0.563	rs13256	chr3:160796505	G/A	cg17135325	chr3:160939158	NMD3	0.59	6.81	0.41	8.44e-11	Parkinson's disease;
SARC	cis	rs898097	0.578	rs6502021	chr17:80907728	T/C	cg15664640	chr17:80829946	TBCD	0.33	5.18	0.32	4.91e-7	Breast cancer;
SARC	trans	rs61931739	0.534	rs11053075	chr12:34207009	A/G	cg26384229	chr12:38710491	ALG10B	-0.84	-12.07	-0.62	2.25e-26	Morning vs. evening chronotype;
SARC	trans	rs1814175	0.817	rs1390676	chr11:50056778	C/T	cg15704280	chr7:45808275	SEPT13	-0.96	-18.23	-0.77	9.55e-47	Height;
SARC	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg13939156	chr17:80058883	NA	0.4	6.25	0.38	1.92e-9	Life satisfaction;
SARC	cis	rs79149102	0.522	rs59665282	chr15:74864568	T/C	cg09165964	chr15:75287851	SCAMP5	-0.65	-5.02	-0.31	1.04e-6	Lung cancer;
SARC	cis	rs7772486	0.622	rs1292333	chr6:145982344	C/T	cg05220968	chr6:146057943	EPM2A	0.27	4.73	0.3	3.96e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12971120	1.000	rs2278162	chr18:72175814	A/G	cg26446133	chr18:72167187	CNDP2	-0.45	-6.73	-0.4	1.27e-10	Refractive error;
SARC	cis	rs12478296	0.515	rs13412492	chr2:243000583	T/G	cg06360820	chr2:242988706	NA	-0.47	-4.72	-0.3	4.11e-6	Obesity-related traits;
SARC	cis	rs920590	0.527	rs79929516	chr8:19650050	G/C	cg01411142	chr8:19674711	INTS10	0.58	6.0	0.37	7.66e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs876084	0.505	rs4409431	chr8:121104019	C/G	cg06265175	chr8:121136014	COL14A1	0.57	7.49	0.44	1.37e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs7659604	0.628	rs3828485	chr4:122722368	G/A	cg06713675	chr4:122721982	EXOSC9	-0.54	-7.24	-0.43	6.41e-12	Type 2 diabetes;
SARC	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg11644478	chr21:40555479	PSMG1	1.02	14.32	0.68	8.73e-34	Cognitive function;
SARC	cis	rs9916302	0.904	rs9904334	chr17:37468336	G/A	cg07936489	chr17:37558343	FBXL20	0.68	9.06	0.51	5.39e-17	Glomerular filtration rate (creatinine);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg21519867	chr5:159846116	SLU7	-0.55	-6.31	-0.38	1.43e-9	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs17376456	0.542	rs2043979	chr5:93120782	T/A	cg21475434	chr5:93447410	FAM172A	-0.54	-5.37	-0.33	1.91e-7	Diabetic retinopathy;
SARC	cis	rs11792861	0.890	rs3750465	chr9:111900677	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.68	7.62	0.45	6.51e-13	Menarche (age at onset);
SARC	cis	rs9322193	0.567	rs7742692	chr6:150213499	A/G	cg00933542	chr6:150070202	PCMT1	0.29	4.83	0.3	2.46e-6	Lung cancer;
SARC	cis	rs826838	0.616	rs7977357	chr12:38626008	C/G	cg13010199	chr12:38710504	ALG10B	-0.52	-6.43	-0.39	7.32e-10	Heart rate;
SARC	cis	rs2070433	0.752	rs11700468	chr21:47776391	C/T	cg12379764	chr21:47803548	PCNT	0.55	4.82	0.3	2.6e-6	Lymphocyte counts;
SARC	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg15049968	chr18:44337910	ST8SIA5	-0.35	-5.48	-0.34	1.11e-7	Personality dimensions;
SARC	cis	rs2594989	0.943	rs4684780	chr3:11478960	C/T	cg00170343	chr3:11313890	ATG7	0.48	4.79	0.3	2.9e-6	Circulating chemerin levels;
SARC	cis	rs11098499	0.865	rs9996417	chr4:120295862	T/C	cg09160332	chr4:120329925	NA	-0.33	-4.72	-0.3	4.16e-6	Corneal astigmatism;
SARC	cis	rs1318878	0.565	rs10466856	chr12:15456242	C/T	cg08258403	chr12:15378311	NA	-0.46	-6.51	-0.39	4.64e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7914558	1.000	rs12255047	chr10:104760752	G/A	cg04362960	chr10:104952993	NT5C2	0.46	5.68	0.35	4.05e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg25036284	chr2:26402008	FAM59B	0.48	5.94	0.36	1.04e-8	Gut microbiome composition (summer);
SARC	cis	rs5757676	0.858	rs6001585	chr22:39812986	G/T	cg05872129	chr22:39784769	NA	-0.38	-4.84	-0.3	2.41e-6	IgG glycosylation;
SARC	cis	rs1580019	0.510	rs4723162	chr7:32543804	C/A	cg07520158	chr7:32535189	LSM5;AVL9	0.61	7.94	0.46	8.54e-14	Cognitive ability;
SARC	cis	rs1580019	0.922	rs59938271	chr7:32484844	T/C	cg07520158	chr7:32535189	LSM5;AVL9	0.42	4.99	0.31	1.16e-6	Cognitive ability;
SARC	trans	rs8020941	0.585	rs75040172	chr14:97498728	T/C	cg05136476	chr3:53190709	NA	-0.63	-6.39	-0.39	8.99e-10	Diabetic kidney disease;
SARC	cis	rs7712401	0.502	rs30066	chr5:122293702	A/G	cg19412675	chr5:122181750	SNX24	0.48	6.16	0.37	3.1e-9	Mean platelet volume;
SARC	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg05313129	chr8:58192883	C8orf71	-0.51	-4.94	-0.31	1.49e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs6964587	0.610	rs4729008	chr7:91457054	G/T	cg17063962	chr7:91808500	NA	0.69	9.83	0.54	2.67e-19	Breast cancer;
SARC	cis	rs10870270	0.956	rs4131689	chr10:133744328	A/C	cg17892150	chr10:133769511	PPP2R2D	0.79	10.38	0.56	5.27e-21	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg05368731	chr17:41323189	NBR1	0.72	8.49	0.49	2.49e-15	Menopause (age at onset);
SARC	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg19223190	chr17:80058835	NA	0.44	6.16	0.37	3.17e-9	Life satisfaction;
SARC	cis	rs7589342	0.536	rs10201738	chr2:106386294	C/T	cg16077055	chr2:106428750	NCK2	0.3	6.16	0.37	3.19e-9	Addiction;
SARC	cis	rs10751667	0.600	rs14346	chr11:1011829	T/C	cg20946044	chr11:1010712	AP2A2	-0.42	-6.04	-0.37	5.99e-9	Alzheimer's disease (late onset);
SARC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg26338869	chr17:61819248	STRADA	0.77	10.3	0.56	9.52e-21	Prudent dietary pattern;
SARC	cis	rs12824058	0.831	rs4759655	chr12:130815740	A/G	cg23887609	chr12:130822674	PIWIL1	-0.36	-5.07	-0.32	8.02e-7	Menopause (age at onset);
SARC	cis	rs2997447	0.761	rs868174	chr1:26473224	G/C	cg19633962	chr1:26362018	EXTL1	-0.6	-5.11	-0.32	6.85e-7	QRS complex (12-leadsum);
SARC	cis	rs13161895	1.000	rs27012	chr5:179402211	A/C	cg04265672	chr5:179402240	RNF130	-0.53	-5.04	-0.31	9.51e-7	LDL cholesterol;
SARC	cis	rs526231	0.575	rs62362524	chr5:102314227	G/T	cg23492399	chr5:102201601	PAM	-0.53	-6.48	-0.39	5.38e-10	Primary biliary cholangitis;
SARC	cis	rs8114671	0.836	rs6141526	chr20:33615255	G/T	cg24642439	chr20:33292090	TP53INP2	-0.55	-6.5	-0.39	4.72e-10	Height;
SARC	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg11890956	chr21:40555474	PSMG1	-0.7	-9.11	-0.51	3.95e-17	Menarche (age at onset);
SARC	cis	rs9487051	0.676	rs6910119	chr6:109599263	A/G	cg01475377	chr6:109611718	NA	-0.36	-5.23	-0.32	3.83e-7	Reticulocyte fraction of red cells;
SARC	cis	rs918629	0.716	rs6897997	chr5:95270241	C/T	cg16656078	chr5:95278638	ELL2	-0.62	-7.48	-0.44	1.52e-12	IgG glycosylation;
SARC	cis	rs9807841	0.617	rs2360944	chr19:10769974	T/C	cg17710535	chr19:10819994	QTRT1	0.42	4.76	0.3	3.41e-6	Inflammatory skin disease;
SARC	cis	rs2153535	0.580	rs962590	chr6:8450899	A/G	cg21535247	chr6:8435926	SLC35B3	0.55	6.86	0.41	6.15e-11	Motion sickness;
SARC	cis	rs8141529	0.529	rs5762767	chr22:29141241	C/T	cg15103426	chr22:29168792	CCDC117	0.59	5.58	0.34	6.73e-8	Lymphocyte counts;
SARC	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg04756594	chr16:24857601	SLC5A11	-0.44	-6.22	-0.38	2.25e-9	Intelligence (multi-trait analysis);
SARC	cis	rs9354308	0.838	rs7769057	chr6:66540229	T/C	cg07460842	chr6:66804631	NA	-0.45	-5.23	-0.32	3.77e-7	Metabolite levels;
SARC	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/C	cg06212747	chr3:49208901	KLHDC8B	0.67	8.91	0.5	1.49e-16	Parkinson's disease;
SARC	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg11987759	chr7:65425863	GUSB	0.48	5.91	0.36	1.22e-8	Aortic root size;
SARC	cis	rs4268898	0.662	rs714531	chr2:24399877	G/A	cg26838691	chr2:24397539	C2orf84	-0.55	-6.33	-0.38	1.24e-9	Asthma;
SARC	cis	rs910316	1.000	rs12590452	chr14:75548756	T/C	cg06637938	chr14:75390232	RPS6KL1	0.54	7.72	0.45	3.41e-13	Height;
SARC	cis	rs11770686	0.935	rs6467446	chr7:75339872	T/A	cg17787366	chr7:75369077	HIP1	0.43	5.34	0.33	2.18e-7	Essential tremor;
SARC	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.47	-5.93	-0.36	1.1e-8	Lymphocyte counts;
SARC	cis	rs2997447	0.706	rs55657303	chr1:26421012	A/G	cg19633962	chr1:26362018	EXTL1	-0.66	-5.62	-0.35	5.56e-8	QRS complex (12-leadsum);
SARC	cis	rs11249608	0.548	rs10479520	chr5:178451447	C/A	cg21905437	chr5:178450457	ZNF879	0.58	8.02	0.47	5.2e-14	Pubertal anthropometrics;
SARC	cis	rs7084402	0.967	rs1649082	chr10:60292434	A/C	cg07615347	chr10:60278583	BICC1	0.61	8.99	0.51	8.94e-17	Refractive error;
SARC	cis	rs898097	0.510	rs10445242	chr17:80891666	G/T	cg10494973	chr17:80897199	TBCD	-0.42	-5.69	-0.35	3.84e-8	Breast cancer;
SARC	cis	rs9303401	0.659	rs17741087	chr17:56550300	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.05	11.4	0.6	3.25e-24	Cognitive test performance;
SARC	cis	rs2832191	0.647	rs11170	chr21:30378090	C/T	cg08807101	chr21:30365312	RNF160	0.86	13.16	0.65	6.09e-30	Dental caries;
SARC	cis	rs7568458	0.837	rs35215812	chr2:85792384	G/A	cg02493740	chr2:85810744	VAMP5	-0.33	-4.75	-0.3	3.63e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs79149102	0.579	rs8039433	chr15:75367367	T/C	cg09165964	chr15:75287851	SCAMP5	-0.91	-8.32	-0.48	7.54e-15	Lung cancer;
SARC	cis	rs34172651	0.837	rs1978451	chr16:24818286	C/G	cg04756594	chr16:24857601	SLC5A11	0.37	5.78	0.35	2.33e-8	Intelligence (multi-trait analysis);
SARC	cis	rs734999	0.588	rs10910098	chr1:2533250	C/A	cg18854424	chr1:2615690	NA	0.3	4.79	0.3	2.96e-6	Ulcerative colitis;
SARC	cis	rs2072499	0.554	rs1052067	chr1:156206121	C/T	cg24450063	chr1:156163899	SLC25A44	0.74	7.57	0.44	8.41e-13	Testicular germ cell tumor;
SARC	cis	rs6908034	0.607	rs75110577	chr6:19814523	C/T	cg02682789	chr6:19804855	NA	0.69	5.56	0.34	7.3900000000000007e-08	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs7666738	0.822	rs17484018	chr4:98988960	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7264396	1.000	rs224409	chr20:34124920	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.45	-5.07	-0.32	7.93e-7	Total cholesterol levels;
SARC	cis	rs10089	1.000	rs4835945	chr5:127526481	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	9.3	0.52	1.02e-17	Ileal carcinoids;
SARC	cis	rs9916302	0.706	rs597069	chr17:37458512	G/T	cg20243544	chr17:37824526	PNMT	-0.54	-5.61	-0.35	5.6e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs738322	1.000	rs133009	chr22:38569653	G/C	cg25457927	chr22:38595422	NA	-0.28	-5.78	-0.35	2.4e-8	Cutaneous nevi;
SARC	cis	rs1982346	1.000	rs2553467	chr4:106724328	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	-0.74	-4.88	-0.3	1.96e-6	Lung function (FEV1);
SARC	cis	rs7633770	0.786	rs1402148	chr3:46678295	C/T	cg11219411	chr3:46661640	NA	0.4	6.44	0.39	6.58e-10	Coronary artery disease;
SARC	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.78	7.59	0.45	7.81e-13	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs6840360	0.571	rs7685697	chr4:152558849	A/G	cg22705602	chr4:152727874	NA	-0.41	-6.44	-0.39	6.64e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7044106	0.734	rs12553070	chr9:123485266	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	6.54	0.39	3.88e-10	Hip circumference adjusted for BMI;
SARC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg26354017	chr1:205819088	PM20D1	0.84	13.0	0.65	1.98e-29	Menarche (age at onset);
SARC	cis	rs11731606	0.508	rs28497379	chr4:95283789	G/T	cg00507259	chr4:95128692	SMARCAD1	0.57	5.42	0.33	1.47e-7	Mean platelet volume;
SARC	trans	rs641862	1	rs641862	chr13:110790232	C/T	cg24098588	chr13:113869726	CUL4A	0.88	6.49	0.39	5.02e-10	Obesity-related traits;
SARC	cis	rs12824058	0.831	rs12829373	chr12:130814114	G/C	cg26677194	chr12:130822605	PIWIL1	0.55	7.58	0.44	8.33e-13	Menopause (age at onset);
SARC	cis	rs7766436	0.621	rs9460765	chr6:22601221	G/A	cg13666174	chr6:22585274	NA	-0.48	-6.58	-0.4	3.05e-10	Coronary artery disease;
SARC	cis	rs1468333	1.000	rs6867242	chr5:137561186	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.82	11.81	0.61	1.56e-25	Resting heart rate;
SARC	cis	rs734999	0.566	rs12748729	chr1:2558740	C/T	cg18854424	chr1:2615690	NA	-0.31	-4.91	-0.31	1.73e-6	Ulcerative colitis;
SARC	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg00684032	chr4:1343700	KIAA1530	0.4	5.81	0.36	1.99e-8	Obesity-related traits;
SARC	cis	rs17270561	0.609	rs1892245	chr6:25764833	G/T	cg16482183	chr6:26056742	HIST1H1C	0.48	5.95	0.36	9.58e-9	Iron status biomarkers;
SARC	cis	rs1568889	0.838	rs10767708	chr11:28294847	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.87	14.7	0.69	4.86e-35	Bipolar disorder;
SARC	cis	rs6964587	0.692	rs6970629	chr7:91846599	T/C	cg17063962	chr7:91808500	NA	0.84	13.09	0.65	1.05e-29	Breast cancer;
SARC	cis	rs16854884	1.000	rs1961542	chr3:143765503	G/A	cg06585982	chr3:143692056	C3orf58	0.54	6.61	0.4	2.6200000000000003e-10	Economic and political preferences (feminism/equality);
SARC	cis	rs2354432	0.607	rs7511989	chr1:146720160	A/G	cg25205988	chr1:146714368	CHD1L	-1.04	-7.58	-0.44	8.14e-13	Mitochondrial DNA levels;
SARC	cis	rs523522	0.962	rs9788155	chr12:120938408	G/A	cg12219531	chr12:120966889	COQ5	0.83	11.18	0.59	1.61e-23	High light scatter reticulocyte count;
SARC	trans	rs877282	0.520	rs12360072	chr10:813082	C/T	cg22713356	chr15:30763199	NA	0.62	6.89	0.41	5.07e-11	Uric acid levels;
SARC	cis	rs507506	0.771	rs929229	chr17:7105399	C/T	cg13729891	chr17:7108468	DLG4	-0.42	-6.57	-0.4	3.28e-10	Adiponectin levels;
SARC	trans	rs208520	0.690	rs12213575	chr6:66735989	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	13.86	0.67	2.98e-32	Exhaled nitric oxide output;
SARC	trans	rs2055729	0.645	rs12543685	chr8:9747056	T/C	cg06636001	chr8:8085503	FLJ10661	0.59	6.55	0.39	3.73e-10	Multiple myeloma (hyperdiploidy);
SARC	cis	rs3790022	0.915	rs12855373	chr13:51577701	C/T	cg06048102	chr13:51575027	GUCY1B2	0.4	4.9	0.31	1.77e-6	Rheumatoid arthritis (ACPA-negative);
SARC	cis	rs7429990	0.965	rs1061003	chr3:47892579	G/C	cg11946769	chr3:48343235	NME6	0.47	5.33	0.33	2.32e-7	Educational attainment (years of education);
SARC	cis	rs7011049	1.000	rs11997775	chr8:53833571	C/T	cg26025543	chr8:53854495	NA	-0.6	-5.54	-0.34	8.14e-8	Systolic blood pressure;
SARC	trans	rs61931739	0.517	rs1843737	chr12:34015305	A/G	cg13010199	chr12:38710504	ALG10B	0.61	8.12	0.47	2.7e-14	Morning vs. evening chronotype;
SARC	cis	rs9815354	1.000	rs73069394	chr3:41787233	G/A	cg03022575	chr3:42003672	ULK4	0.58	5.6	0.34	5.92e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6570726	0.935	rs425717	chr6:145838620	A/T	cg05220968	chr6:146057943	EPM2A	-0.29	-4.99	-0.31	1.19e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10911232	0.507	rs10911198	chr1:182997318	G/T	cg13390022	chr1:182993471	LAMC1	0.33	4.97	0.31	1.31e-6	Hypertriglyceridemia;
SARC	cis	rs7833986	1.000	rs34230678	chr8:57083117	T/C	cg26371346	chr8:56986568	SNORD54;RPS20	0.59	5.27	0.33	3.09e-7	Height;
SARC	cis	rs9916302	0.904	rs1077715	chr17:37683548	A/T	cg07936489	chr17:37558343	FBXL20	-0.67	-8.64	-0.49	8.88e-16	Glomerular filtration rate (creatinine);
SARC	trans	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg26074535	chr5:134094528	DDX46	-0.66	-6.25	-0.38	1.95e-9	Cutaneous psoriasis;
SARC	cis	rs2153535	0.580	rs9505458	chr6:8479215	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	7.33	0.43	3.7e-12	Motion sickness;
SARC	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg11168104	chr5:1857477	NA	-0.34	-4.81	-0.3	2.73e-6	Cardiovascular disease risk factors;
SARC	cis	rs3008870	0.755	rs1535365	chr1:67497613	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.62	8.03	0.47	4.73e-14	Lymphocyte percentage of white cells;
SARC	cis	rs8180040	0.726	rs7628747	chr3:47001990	A/T	cg02527881	chr3:46936655	PTH1R	-0.31	-4.82	-0.3	2.63e-6	Colorectal cancer;
SARC	cis	rs453301	0.606	rs7462373	chr8:8899318	G/C	cg11995313	chr8:8860691	ERI1	0.46	6.03	0.37	6.32e-9	Joint mobility (Beighton score);
SARC	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg19223190	chr17:80058835	NA	0.45	6.16	0.37	3.2e-9	Life satisfaction;
SARC	cis	rs4689388	0.856	rs1046314	chr4:6303955	A/G	cg25554036	chr4:6271136	WFS1	-0.37	-5.98	-0.36	8.47e-9	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs7824557	0.602	rs7817658	chr8:11206543	A/G	cg21775007	chr8:11205619	TDH	0.67	8.67	0.49	7.42e-16	Retinal vascular caliber;
SARC	cis	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg25427524	chr10:38739819	LOC399744	-0.52	-8.23	-0.47	1.32e-14	Extrinsic epigenetic age acceleration;
SARC	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg05313129	chr8:58192883	C8orf71	-0.63	-6.51	-0.39	4.44e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6484504	0.625	rs7112412	chr11:31370271	T/C	cg19308365	chr11:31391254	DNAJC24;DCDC1	0.38	4.74	0.3	3.65e-6	Red blood cell count;
SARC	cis	rs72792276	1.000	rs13357283	chr5:127423114	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	6.65	0.4	2.11e-10	Red cell distribution width;
SARC	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg22920501	chr2:26401640	FAM59B	-0.56	-7.4	-0.44	2.5e-12	Gut microbiome composition (summer);
SARC	cis	rs950776	0.518	rs12915428	chr15:78823368	G/A	cg06917634	chr15:78832804	PSMA4	0.91	14.24	0.68	1.6e-33	Sudden cardiac arrest;
SARC	cis	rs5753618	0.583	rs7287267	chr22:31748415	C/T	cg02404636	chr22:31891804	SFI1	0.51	5.61	0.35	5.63e-8	Colorectal cancer;
SARC	cis	rs300703	0.935	rs12714403	chr2:273070	A/G	cg21211680	chr2:198530	NA	0.62	5.77	0.35	2.53e-8	Blood protein levels;
SARC	cis	rs1971762	0.527	rs1247956	chr12:53963814	G/T	cg06632207	chr12:54070931	ATP5G2	-0.59	-8.05	-0.47	4.35e-14	Height;
SARC	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg14403583	chr14:105418241	AHNAK2	-0.58	-7.63	-0.45	5.95e-13	Rheumatoid arthritis;
SARC	cis	rs7264396	0.790	rs4519606	chr20:34324648	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-7.52	-0.44	1.18e-12	Total cholesterol levels;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg10566763	chr6:106773518	ATG5	0.49	6.25	0.38	1.93e-9	Height;
SARC	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg25894440	chr7:65020034	NA	-0.75	-5.62	-0.35	5.47e-8	Diabetic kidney disease;
SARC	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg19346786	chr7:2764209	NA	-0.41	-5.91	-0.36	1.18e-8	Height;
SARC	cis	rs76419734	1.000	rs72673858	chr4:106758056	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	5.31	0.33	2.52e-7	Post bronchodilator FEV1;
SARC	cis	rs4588572	0.643	rs6874309	chr5:77774498	A/T	cg11547950	chr5:77652471	NA	0.43	5.27	0.33	3.09e-7	Triglycerides;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg24654547	chr16:68057165	DUS2L;DDX28	-0.56	-6.36	-0.38	1.08e-9	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs2228479	0.850	rs11649100	chr16:89798179	A/G	cg00800038	chr16:89945340	TCF25	-0.7	-4.71	-0.3	4.18e-6	Skin colour saturation;
SARC	cis	rs9300255	0.770	rs28683528	chr12:123845351	C/T	cg00376283	chr12:123451042	ABCB9	-0.45	-4.75	-0.3	3.5e-6	Neutrophil percentage of white cells;
SARC	cis	rs12594515	1.000	rs6493169	chr15:45986994	A/G	cg14863074	chr15:45997064	NA	-0.33	-5.03	-0.31	9.75e-7	Waist circumference;Weight;
SARC	cis	rs9916302	0.904	rs8076494	chr17:37516722	A/G	cg15445000	chr17:37608096	MED1	-0.46	-5.3	-0.33	2.69e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs4846217	1.000	rs6670157	chr1:10458439	A/G	cg19092837	chr1:10271724	KIF1B	-0.44	-6.2	-0.38	2.56e-9	Platelet count;
SARC	cis	rs13082711	0.522	rs6790344	chr3:27336531	G/C	cg02860705	chr3:27208620	NA	0.47	6.26	0.38	1.86e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs2486288	0.656	rs9921035	chr15:45546660	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.47	-5.82	-0.36	1.92e-8	Glomerular filtration rate;
SARC	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.5	-5.69	-0.35	3.79e-8	Systemic lupus erythematosus;
SARC	cis	rs9398803	0.835	rs59698523	chr6:126733094	T/C	cg19875578	chr6:126661172	C6orf173	0.58	7.71	0.45	3.58e-13	Male-pattern baldness;
SARC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg11494091	chr17:61959527	GH2	0.53	7.94	0.46	8.67e-14	Prudent dietary pattern;
SARC	cis	rs2303745	0.589	rs6512179	chr19:17399105	T/C	cg22549504	chr19:17448937	GTPBP3	0.51	5.13	0.32	5.96e-7	Systemic lupus erythematosus;
SARC	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.0	11.76	0.61	2.19e-25	Alzheimer's disease;
SARC	cis	rs11214589	0.905	rs1078	chr11:113241877	C/T	cg14159747	chr11:113255604	NA	0.34	4.86	0.3	2.12e-6	Neuroticism;
SARC	cis	rs9650657	0.615	rs7012199	chr8:10696997	A/C	cg21775007	chr8:11205619	TDH	-0.39	-4.8	-0.3	2.83e-6	Neuroticism;
SARC	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg16606324	chr3:10149918	C3orf24	0.48	4.75	0.3	3.56e-6	Alzheimer's disease;
SARC	cis	rs765787	0.530	rs4775819	chr15:45525966	C/T	cg25801113	chr15:45476975	SHF	0.28	4.78	0.3	3.18e-6	Uric acid levels;
SARC	cis	rs13256369	0.851	rs11249889	chr8:8564992	G/T	cg18904891	chr8:8559673	CLDN23	0.49	5.49	0.34	1.04e-7	Obesity-related traits;
SARC	cis	rs6668108	1	rs6668108	chr1:165691320	A/G	cg19769164	chr1:165738335	TMCO1	0.64	5.0	0.31	1.14e-6	Intraocular pressure;
SARC	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg07701084	chr6:150067640	NUP43	0.41	5.42	0.33	1.5e-7	Lung cancer;
SARC	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg22535103	chr8:58192502	C8orf71	-0.71	-7.06	-0.42	1.89e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	7.24	0.43	6.34e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2120243	0.539	rs9990136	chr3:157075834	C/T	cg24825693	chr3:157122686	VEPH1	-0.46	-6.39	-0.39	9.09e-10	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs1419980	0.630	rs2080126	chr12:7774524	A/C	cg10578777	chr12:7781093	NA	0.56	6.01	0.37	6.92e-9	HDL cholesterol levels;
SARC	cis	rs921968	0.643	rs2278529	chr2:219502132	C/T	cg02176678	chr2:219576539	TTLL4	0.4	6.22	0.38	2.33e-9	Mean corpuscular hemoglobin concentration;
SARC	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg25405998	chr7:65216604	CCT6P1	-0.56	-6.51	-0.39	4.52e-10	Calcium levels;
SARC	cis	rs10876993	0.890	rs1689584	chr12:58081478	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.4	-5.0	-0.31	1.14e-6	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg08280861	chr8:58055591	NA	0.7	6.12	0.37	3.95e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2228479	0.619	rs77847775	chr16:89896243	C/T	cg00800038	chr16:89945340	TCF25	-0.82	-5.9	-0.36	1.27e-8	Skin colour saturation;
SARC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg11301795	chr4:187892539	NA	-0.69	-10.55	-0.57	1.64e-21	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7084402	1.000	rs6481400	chr10:60268783	T/C	cg07615347	chr10:60278583	BICC1	-0.58	-8.47	-0.49	2.82e-15	Refractive error;
SARC	trans	rs3808502	0.526	rs7823101	chr8:11422492	C/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-9.02	-0.51	7.33e-17	Neuroticism;
SARC	cis	rs5762813	0.561	rs5762821	chr22:29219472	G/A	cg15103426	chr22:29168792	CCDC117	0.61	5.94	0.36	1.03e-8	Hematocrit;Hemoglobin concentration;
SARC	cis	rs870825	0.655	rs28604350	chr4:185638723	G/A	cg04058563	chr4:185651563	MLF1IP	0.84	11.26	0.59	8.84e-24	Blood protein levels;
SARC	cis	rs9894429	0.621	rs7502337	chr17:79588470	T/C	cg18240062	chr17:79603768	NPLOC4	0.6	7.3	0.43	4.56e-12	Eye color traits;
SARC	cis	rs6582630	0.519	rs11495724	chr12:38337507	T/C	cg13010199	chr12:38710504	ALG10B	0.79	10.84	0.58	1.96e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg11366901	chr6:160182831	ACAT2	0.64	6.7	0.4	1.51e-10	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs28655083	0.828	rs7190227	chr16:77119568	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.48	6.78	0.41	9.84e-11	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs12310956	0.510	rs10844690	chr12:33854752	C/A	cg26384229	chr12:38710491	ALG10B	0.64	8.45	0.48	3.24e-15	Morning vs. evening chronotype;
SARC	cis	rs9462027	0.628	rs6457795	chr6:34819366	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-6.09	-0.37	4.69e-9	Systemic lupus erythematosus;
SARC	cis	rs2412459	0.831	rs6492924	chr15:40272391	G/A	cg20255370	chr15:40268687	EIF2AK4	-0.64	-5.73	-0.35	3.04e-8	Response to haloperidol in psychosis;
SARC	cis	rs7412746	0.611	rs66847267	chr1:150875173	C/A	cg13175981	chr1:150552382	MCL1	-0.51	-6.28	-0.38	1.64e-9	Melanoma;
SARC	cis	rs7089973	0.604	rs11196937	chr10:116589500	G/C	cg08188268	chr10:116634841	FAM160B1	0.28	4.77	0.3	3.18e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs10276381	0.892	rs7786444	chr7:28154384	C/T	cg23620719	chr7:28220237	JAZF1	0.62	5.15	0.32	5.44e-7	Crohn's disease;
SARC	cis	rs2486288	0.656	rs8039354	chr15:45551756	A/G	cg21132104	chr15:45694354	SPATA5L1	0.51	6.38	0.39	9.68e-10	Glomerular filtration rate;
SARC	cis	rs4919694	1.000	rs58700372	chr10:104800205	T/C	cg04362960	chr10:104952993	NT5C2	0.65	5.56	0.34	7.45e-8	Arsenic metabolism;
SARC	cis	rs9733	0.650	rs1971378	chr1:150597261	C/T	cg17724175	chr1:150552817	MCL1	-0.39	-5.11	-0.32	6.77e-7	Tonsillectomy;
SARC	cis	rs8051517	0.744	rs74024437	chr16:68326247	G/A	cg01866162	chr16:67596514	CTCF	0.86	5.4	0.33	1.64e-7	Blood protein levels;
SARC	cis	rs12200782	1.000	rs3927423	chr6:26393487	C/T	cg11502198	chr6:26597334	ABT1	-0.69	-4.81	-0.3	2.69e-6	Small cell lung carcinoma;
SARC	cis	rs796364	0.662	rs11687313	chr2:201146399	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-5.75	-0.35	2.81e-8	Schizophrenia;
SARC	cis	rs4595586	0.525	rs17464772	chr12:39247777	G/A	cg13010199	chr12:38710504	ALG10B	0.56	6.6	0.4	2.7e-10	Morning vs. evening chronotype;
SARC	cis	rs7772486	0.764	rs7745696	chr6:146162829	T/C	cg05347473	chr6:146136440	FBXO30	0.51	7.21	0.43	7.61e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9303401	0.659	rs12944971	chr17:56988801	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	11.33	0.6	5.52e-24	Cognitive test performance;
SARC	cis	rs12190007	0.547	rs2981945	chr6:169819839	G/A	cg15038512	chr6:170123185	PHF10	-0.49	-6.69	-0.4	1.62e-10	Obesity-related traits;
SARC	cis	rs73206853	0.841	rs56122570	chr12:110816291	G/A	cg10860002	chr12:110842031	ANAPC7	0.63	5.03	0.31	9.95e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs17376456	0.825	rs10061377	chr5:93174513	T/C	cg25358565	chr5:93447407	FAM172A	1.25	12.31	0.63	3.57e-27	Diabetic retinopathy;
SARC	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.61	-6.27	-0.38	1.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	trans	rs1814175	0.645	rs7123448	chr11:49764865	T/G	cg15704280	chr7:45808275	SEPT13	-0.88	-14.01	-0.68	8.97e-33	Height;
SARC	cis	rs2832191	0.791	rs2832178	chr21:30479858	T/G	cg24692254	chr21:30365293	RNF160	-0.94	-14.32	-0.68	8.91e-34	Dental caries;
SARC	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg03934478	chr11:495069	RNH1	0.53	4.94	0.31	1.52e-6	Body mass index;
SARC	cis	rs12754538	0.715	rs12029088	chr1:8708876	T/C	cg13785123	chr1:8931135	ENO1	-0.48	-5.38	-0.33	1.8e-7	Subjective well-being;
SARC	cis	rs7584330	0.657	rs7599658	chr2:238352898	A/C	cg14458575	chr2:238380390	NA	-0.54	-6.6	-0.4	2.81e-10	Prostate cancer;
SARC	cis	rs2933343	1.000	rs2933343	chr3:128658492	G/A	cg24203234	chr3:128598194	ACAD9	0.55	6.02	0.37	6.6e-9	IgG glycosylation;
SARC	cis	rs735396	1.000	rs2259816	chr12:121435587	A/C	cg04422896	chr12:121454269	C12orf43	-0.4	-4.76	-0.3	3.43e-6	N-glycan levels;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg01373705	chr2:9696302	ADAM17	0.56	7.09	0.42	1.62e-11	Breast cancer;
SARC	cis	rs3733585	0.638	rs6449155	chr4:9956547	T/G	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.39	-0.33	1.73e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs908922	0.676	rs6674451	chr1:152531054	C/T	cg09873164	chr1:152488093	CRCT1	0.61	7.84	0.46	1.6e-13	Hair morphology;
SARC	cis	rs11785693	0.862	rs11774044	chr8:4988035	C/G	cg26367366	chr8:4980734	NA	0.72	6.42	0.39	7.56e-10	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg14664628	chr15:75095509	CSK	-0.5	-6.11	-0.37	4.19e-9	Breast cancer;
SARC	cis	rs7833986	0.534	rs72653924	chr8:56906088	C/T	cg26371346	chr8:56986568	SNORD54;RPS20	0.67	6.53	0.39	4.13e-10	Height;
SARC	cis	rs34779708	0.966	rs12775759	chr10:35400183	G/T	cg03585969	chr10:35415529	CREM	0.42	5.17	0.32	5.03e-7	Inflammatory bowel disease;Crohn's disease;
SARC	trans	rs3780486	0.505	rs10813959	chr9:33166234	C/T	cg20290983	chr6:43655470	MRPS18A	-0.87	-12.4	-0.63	1.92e-27	IgG glycosylation;
SARC	cis	rs9513627	0.831	rs9582301	chr13:100125814	C/T	cg25919922	chr13:100150906	NA	-0.69	-5.23	-0.32	3.82e-7	Obesity-related traits;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg27394046	chr20:21283521	XRN2	-0.56	-6.33	-0.38	1.25e-9	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg21724239	chr8:58056113	NA	0.58	6.14	0.37	3.49e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs55692411	0.517	rs62262106	chr3:49991427	A/G	cg24110177	chr3:50126178	RBM5	-0.51	-5.66	-0.35	4.34e-8	Intelligence (multi-trait analysis);
SARC	trans	rs9929218	0.953	rs34909703	chr16:68740097	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.65	-8.33	-0.48	7.07e-15	Colorectal cancer;
SARC	cis	rs4462272	0.525	rs34955138	chr10:102039187	T/G	cg11888571	chr10:102027403	CWF19L1	-0.39	-4.76	-0.3	3.38e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg14852238	chr1:28562670	ATPIF1	0.5	6.74	0.4	1.26e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs7932354	0.528	rs10769234	chr11:47084061	G/C	cg03339077	chr11:47165057	C11orf49	-0.39	-5.23	-0.32	3.76e-7	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	12.4	0.63	1.87e-27	Platelet count;
SARC	cis	rs752010	0.714	rs10789403	chr1:42085869	G/A	cg06885757	chr1:42089581	HIVEP3	0.41	6.43	0.39	7.11e-10	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs9303280	0.517	rs12939566	chr17:38038390	A/T	cg20243544	chr17:37824526	PNMT	0.43	5.63	0.35	5.07e-8	Self-reported allergy;
SARC	cis	rs11931598	0.514	rs10937779	chr4:7039326	G/A	cg26116260	chr4:7069785	GRPEL1	0.39	4.99	0.31	1.21e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs3768617	0.510	rs10797835	chr1:183072908	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.2	0.56	2e-20	Fuchs's corneal dystrophy;
SARC	cis	rs7659604	0.846	rs35986491	chr4:122664528	A/T	cg19671926	chr4:122722719	EXOSC9	-0.49	-6.04	-0.37	5.99e-9	Type 2 diabetes;
SARC	cis	rs9715521	0.835	rs9714848	chr4:59824650	C/T	cg11281224	chr4:60001000	NA	-0.37	-4.74	-0.3	3.74e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs6500395	0.928	rs7199206	chr16:48702538	A/G	cg04672837	chr16:48644449	N4BP1	-0.45	-5.98	-0.36	8.39e-9	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs7681440	0.869	rs7680557	chr4:90763360	C/A	cg02192967	chr4:90758406	SNCA	0.36	5.14	0.32	5.76e-7	Dementia with Lewy bodies;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg19063972	chr13:95364908	SOX21	0.48	6.42	0.39	7.6e-10	Breast cancer;
SARC	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg16405210	chr4:1374714	KIAA1530	-0.51	-6.07	-0.37	5.28e-9	Obesity-related traits;
SARC	cis	rs9807989	0.839	rs3771166	chr2:102986222	G/A	cg09003973	chr2:102972529	NA	0.4	5.41	0.33	1.53e-7	Asthma;
SARC	cis	rs7666738	0.830	rs4699589	chr4:98973889	A/G	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9815354	0.812	rs73077365	chr3:41851559	T/C	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9916302	0.851	rs12936996	chr17:37665554	A/G	cg15445000	chr17:37608096	MED1	-0.41	-4.87	-0.3	2.04e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs636291	0.500	rs655271	chr1:10536635	G/A	cg17425144	chr1:10567563	PEX14	0.36	5.9	0.36	1.29e-8	Prostate cancer;
SARC	trans	rs3945119	0.838	rs6660690	chr1:91154356	T/C	cg01730148	chr2:3698421	NA	0.35	6.54	0.39	3.92e-10	Intelligence (multi-trait analysis);
SARC	cis	rs909674	0.818	rs5757680	chr22:39844793	C/T	cg24399712	chr22:39784796	NA	0.43	5.64	0.35	4.97e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs4911259	0.533	rs6058931	chr20:31471012	C/T	cg13636640	chr20:31349939	DNMT3B	-0.66	-8.84	-0.5	2.47e-16	Inflammatory bowel disease;
SARC	cis	rs722599	0.748	rs61978948	chr14:75363369	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.41	-5.09	-0.32	7.25e-7	IgG glycosylation;
SARC	cis	rs6424115	0.692	rs573361	chr1:24053674	A/T	cg15997130	chr1:24165203	NA	0.38	4.79	0.3	2.95e-6	Immature fraction of reticulocytes;
SARC	cis	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg21573476	chr21:45109991	RRP1B	-0.56	-8.21	-0.47	1.55e-14	Mean corpuscular volume;
SARC	cis	rs1005277	0.683	rs7923868	chr10:37989766	T/C	cg25427524	chr10:38739819	LOC399744	-0.51	-7.8	-0.45	2.1e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs11122272	0.766	rs2790867	chr1:231548059	A/C	cg06096015	chr1:231504339	EGLN1	-0.38	-5.64	-0.35	4.85e-8	Hemoglobin concentration;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10867947	chr8:95835263	INTS8	-0.51	-6.46	-0.39	6.03e-10	Smoking initiation;
SARC	cis	rs7084402	0.902	rs3001715	chr10:60285509	A/G	cg07615347	chr10:60278583	BICC1	0.59	8.56	0.49	1.58e-15	Refractive error;
SARC	cis	rs9486719	1.000	rs12208884	chr6:96885572	G/A	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.01	-0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs193541	0.632	rs168913	chr5:122225793	G/A	cg19412675	chr5:122181750	SNX24	0.49	6.31	0.38	1.37e-9	Glucose homeostasis traits;
SARC	cis	rs2425143	0.818	rs12481545	chr20:34407698	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-5.84	-0.36	1.73e-8	Blood protein levels;
SARC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg03354898	chr7:1950403	MAD1L1	-0.4	-5.45	-0.34	1.25e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.57	0.8	2.65e-54	Prudent dietary pattern;
SARC	cis	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg20965017	chr5:231967	SDHA	-0.55	-5.28	-0.33	2.98e-7	Breast cancer;
SARC	cis	rs9814567	1.000	rs1874883	chr3:134205071	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-6.89	-0.41	5.19e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs7914558	1.000	rs11191542	chr10:104824324	T/A	cg04362960	chr10:104952993	NT5C2	0.41	4.94	0.31	1.5e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	trans	rs6716963	0.585	rs11687224	chr2:194568323	A/G	cg06333435	chr8:22102724	POLR3D;MIR320A	0.54	6.39	0.39	9.02e-10	Schizophrenia;
SARC	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg11764359	chr7:65958608	NA	-0.55	-6.4	-0.39	8.66e-10	Aortic root size;
SARC	cis	rs523522	0.962	rs4767912	chr12:120981202	A/G	cg12219531	chr12:120966889	COQ5	0.84	11.3	0.59	6.87e-24	High light scatter reticulocyte count;
SARC	cis	rs580438	1.000	rs57635268	chr3:13347705	T/C	cg05446471	chr3:13522740	HDAC11	0.31	5.01	0.31	1.1e-6	Myringotomy;
SARC	trans	rs9395865	0.520	rs6903708	chr6:53332940	A/G	cg06382459	chr1:2159373	SKI	-0.48	-6.38	-0.39	9.41e-10	Electroencephalographic traits in alcoholism;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg08965527	chr16:84178213	HSDL1;LRRC50	-0.63	-7.28	-0.43	4.96e-12	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs763121	0.819	rs5757161	chr22:38990662	G/A	cg06022373	chr22:39101656	GTPBP1	0.83	10.79	0.58	2.79e-22	Menopause (age at onset);
SARC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg26354017	chr1:205819088	PM20D1	0.56	7.32	0.43	3.89e-12	Menarche (age at onset);
SARC	trans	rs9650657	0.769	rs2116093	chr8:10613299	C/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.58	-0.4	3.1e-10	Neuroticism;
SARC	cis	rs763121	0.853	rs6519120	chr22:38991393	A/C	cg21395723	chr22:39101663	GTPBP1	-0.57	-6.19	-0.38	2.68e-9	Menopause (age at onset);
SARC	cis	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg07636037	chr3:49044803	WDR6	0.62	8.16	0.47	2.09e-14	Resting heart rate;
SARC	cis	rs1062177	1.000	rs12654573	chr5:151207473	T/G	cg00977110	chr5:151150581	G3BP1	0.53	5.24	0.32	3.61e-7	Preschool internalizing problems;
SARC	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg22903657	chr4:1355424	KIAA1530	-0.37	-5.02	-0.31	1.01e-6	Obesity-related traits;
SARC	cis	rs478304	0.619	rs10791822	chr11:65428706	T/C	cg27068330	chr11:65405492	SIPA1	-0.45	-5.37	-0.33	1.87e-7	Acne (severe);
SARC	cis	rs9398803	0.687	rs853962	chr6:127027650	G/T	cg20229609	chr6:126660872	C6orf173	-0.35	-5.09	-0.32	7.54e-7	Male-pattern baldness;
SARC	cis	rs698833	0.926	rs1067406	chr2:44674450	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.6	7.37	0.43	2.99e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg11987759	chr7:65425863	GUSB	-0.48	-6.54	-0.39	3.9e-10	Aortic root size;
SARC	cis	rs6121246	0.609	rs6060843	chr20:30297047	G/C	cg13852791	chr20:30311386	BCL2L1	0.82	9.99	0.55	8.52e-20	Mean corpuscular hemoglobin;
SARC	cis	rs478304	0.651	rs11227299	chr11:65549570	C/G	cg26695010	chr11:65641043	EFEMP2	0.4	4.74	0.3	3.66e-6	Acne (severe);
SARC	cis	rs6570726	0.846	rs7762536	chr6:145923145	T/C	cg05347473	chr6:146136440	FBXO30	0.49	6.75	0.4	1.14e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1448094	0.791	rs10863124	chr12:86352548	A/T	cg02569458	chr12:86230093	RASSF9	0.43	6.11	0.37	4.16e-9	Major depressive disorder;
SARC	cis	rs4714291	0.963	rs4714292	chr6:40003679	A/C	cg09256477	chr6:40556568	LRFN2	0.26	4.75	0.3	3.62e-6	Strep throat;
SARC	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg11644478	chr21:40555479	PSMG1	1.04	12.99	0.65	2.26e-29	Cognitive function;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg00356811	chr19:4639239	TNFAIP8L1	-0.5	-6.36	-0.38	1.07e-9	Breast cancer;
SARC	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg08219700	chr8:58056026	NA	0.49	5.01	0.31	1.07e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs1662342	1.000	rs56309710	chr18:3252391	C/A	cg14211874	chr18:3262499	MYL12B	-0.72	-5.41	-0.33	1.56e-7	QRS duration;
SARC	cis	rs9527	0.614	rs11191589	chr10:104930382	T/C	cg04362960	chr10:104952993	NT5C2	0.43	5.12	0.32	6.5e-7	Arsenic metabolism;
SARC	cis	rs17539620	0.534	rs76931320	chr6:154833508	G/A	cg17771515	chr6:154831774	CNKSR3	0.53	5.0	0.31	1.15e-6	Lipoprotein (a) levels;
SARC	trans	rs12310956	0.532	rs11052951	chr12:33986181	T/A	cg26384229	chr12:38710491	ALG10B	0.74	10.45	0.56	3.31e-21	Morning vs. evening chronotype;
SARC	cis	rs7824557	0.767	rs3808509	chr8:11163256	G/T	cg21775007	chr8:11205619	TDH	0.53	6.34	0.38	1.17e-9	Retinal vascular caliber;
SARC	cis	rs7953249	0.564	rs11065385	chr12:121423386	A/G	cg25281562	chr12:121454272	C12orf43	-0.52	-6.37	-0.39	9.76e-10	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.59e-6	Depression;
SARC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.8	10.38	0.56	5.49e-21	Prudent dietary pattern;
SARC	cis	rs7833790	0.700	rs7825180	chr8:82723991	T/A	cg27398817	chr8:82754497	SNX16	-0.43	-5.42	-0.33	1.46e-7	Diastolic blood pressure;
SARC	cis	rs189218934	1	rs189218934	chr15:78903987	T/C	cg24631222	chr15:78858424	CHRNA5	-0.7	-9.41	-0.52	4.9e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs6456156	0.792	rs10946215	chr6:167516181	A/G	cg07741184	chr6:167504864	NA	-0.36	-6.73	-0.4	1.28e-10	Primary biliary cholangitis;
SARC	cis	rs1152591	0.505	rs968257	chr14:64680285	T/C	cg23250157	chr14:64679961	SYNE2	0.45	6.02	0.37	6.85e-9	Atrial fibrillation;
SARC	cis	rs9916302	0.808	rs12948906	chr17:37644854	C/T	cg20243544	chr17:37824526	PNMT	0.55	6.5	0.39	4.87e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg00933542	chr6:150070202	PCMT1	0.29	4.99	0.31	1.17e-6	Lung cancer;
SARC	cis	rs77372450	0.551	rs11134891	chr5:157103373	G/A	cg05585991	chr5:157099197	C5orf52	0.54	5.39	0.33	1.69e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs7264396	0.561	rs6058388	chr20:34571846	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-6.47	-0.39	5.65e-10	Total cholesterol levels;
SARC	cis	rs1215050	0.791	rs783950	chr4:98878395	C/T	cg05340658	chr4:99064831	C4orf37	-0.45	-5.97	-0.36	8.99e-9	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs4073582	0.595	rs528842	chr11:66032390	G/A	cg14036092	chr11:66035641	RAB1B	0.62	8.92	0.5	1.41e-16	Gout;
SARC	cis	rs72634258	0.786	rs7539807	chr1:8183789	C/T	cg00042356	chr1:8021962	PARK7	0.61	5.47	0.34	1.18e-7	Inflammatory bowel disease;
SARC	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg05368731	chr17:41323189	NBR1	0.8	9.59	0.53	1.43e-18	Menopause (age at onset);
SARC	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg19223190	chr17:80058835	NA	0.45	6.22	0.38	2.33e-9	Life satisfaction;
SARC	cis	rs9300255	0.664	rs12316131	chr12:123817796	T/C	cg00376283	chr12:123451042	ABCB9	-0.47	-4.85	-0.3	2.22e-6	Neutrophil percentage of white cells;
SARC	cis	rs4276643	0.531	rs2726943	chr8:27817484	A/G	cg25028855	chr8:28560486	EXTL3	-0.32	-4.93	-0.31	1.53e-6	Low vWF levels;
SARC	cis	rs1345301	1.000	rs1420093	chr2:102870458	T/C	cg12451869	chr2:102867685	NA	0.39	5.52	0.34	9.24e-8	Waist circumference;
SARC	cis	rs763121	0.853	rs5750627	chr22:38982321	A/G	cg21395723	chr22:39101663	GTPBP1	0.57	6.6	0.4	2.72e-10	Menopause (age at onset);
SARC	cis	rs6840360	0.615	rs66852535	chr4:152472227	C/A	cg22705602	chr4:152727874	NA	-0.4	-6.25	-0.38	1.92e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg06713675	chr4:122721982	EXOSC9	-0.38	-4.96	-0.31	1.39e-6	Type 2 diabetes;
SARC	cis	rs7614311	0.731	rs17401592	chr3:63954490	A/G	cg22134162	chr3:63841271	THOC7	-0.46	-4.98	-0.31	1.22e-6	Lung function (FVC);Lung function (FEV1);
SARC	cis	rs6665290	0.935	rs6693535	chr1:227197685	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.09	-25.55	-0.86	1.65e-69	Myeloid white cell count;
SARC	cis	rs11945232	1.000	rs28406846	chr4:88343468	C/G	cg23841344	chr4:88312519	HSD17B11	-0.6	-7.91	-0.46	1.03e-13	Intelligence (multi-trait analysis);
SARC	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg17971929	chr21:40555470	PSMG1	0.96	11.7	0.61	3.58e-25	Cognitive function;
SARC	cis	rs4423214	1.000	rs2282621	chr11:71183474	C/T	cg24826892	chr11:71159390	DHCR7	0.48	6.11	0.37	4.13e-9	Vitamin D levels;
SARC	cis	rs1153858	1.000	rs7163720	chr15:45639374	G/A	cg21132104	chr15:45694354	SPATA5L1	0.77	10.71	0.57	5.01e-22	Homoarginine levels;
SARC	cis	rs4557202	0.509	rs12690576	chr3:160647912	G/A	cg03342759	chr3:160939853	NMD3	-0.47	-5.28	-0.33	2.89e-7	Menarche (age at onset);
SARC	cis	rs2486288	0.656	rs1060896	chr15:45554267	C/A	cg21132104	chr15:45694354	SPATA5L1	-0.51	-6.41	-0.39	7.95e-10	Glomerular filtration rate;
SARC	cis	rs9303401	0.659	rs17822908	chr17:56801778	T/C	cg25039879	chr17:56429692	SUPT4H1	0.68	6.4	0.39	8.57e-10	Cognitive test performance;
SARC	cis	rs4666002	0.956	rs34502053	chr2:27854524	G/A	cg12648201	chr2:27665141	KRTCAP3	0.33	4.72	0.3	4.12e-6	Phospholipid levels (plasma);
SARC	trans	rs1853207	0.609	rs112804082	chr10:96635396	T/C	cg02737782	chr1:8014393	NA	-0.97	-6.42	-0.39	7.44e-10	Blood metabolite levels;
SARC	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg14403583	chr14:105418241	AHNAK2	-0.58	-7.63	-0.45	6.09e-13	Rheumatoid arthritis;
SARC	cis	rs5167	0.781	rs11672748	chr19:45490192	A/G	cg09555818	chr19:45449301	APOC2	0.41	5.89	0.36	1.36e-8	Blood protein levels;
SARC	cis	rs4820539	0.902	rs4822359	chr22:23474972	A/G	cg14186256	chr22:23484241	RTDR1	0.9	14.71	0.69	4.4e-35	Bone mineral density;
SARC	cis	rs3820928	0.648	rs1997484	chr2:227898962	T/A	cg05526886	chr2:227700861	RHBDD1	-0.5	-5.99	-0.37	8e-9	Pulmonary function;
SARC	cis	rs9902453	0.868	rs9902340	chr17:28476458	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.5	-6.57	-0.4	3.34e-10	Coffee consumption (cups per day);
SARC	cis	rs3796352	1.000	rs11717619	chr3:53003179	A/C	cg27565382	chr3:53032988	SFMBT1	0.75	5.31	0.33	2.52e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg16132339	chr22:24313637	DDTL;DDT	0.42	5.65	0.35	4.67e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg22857025	chr5:266934	NA	-1.05	-11.66	-0.61	4.62e-25	Breast cancer;
SARC	cis	rs1371867	0.875	rs962452	chr8:101331369	G/A	cg11906718	chr8:101322791	RNF19A	0.66	8.65	0.49	8.33e-16	Atrioventricular conduction;
SARC	cis	rs1062177	0.756	rs2964588	chr5:151118386	C/T	cg00977110	chr5:151150581	G3BP1	-0.54	-5.44	-0.34	1.35e-7	Preschool internalizing problems;
SARC	cis	rs6570726	0.791	rs6570692	chr6:145904401	T/A	cg23711669	chr6:146136114	FBXO30	0.85	14.24	0.68	1.55e-33	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3824867	0.920	rs80241400	chr11:47453828	T/C	cg20307385	chr11:47447363	PSMC3	-0.48	-5.3	-0.33	2.72e-7	Mean corpuscular hemoglobin;
SARC	cis	rs9790314	0.779	rs12493960	chr3:160899772	T/C	cg03342759	chr3:160939853	NMD3	-0.48	-5.61	-0.34	5.78e-8	Morning vs. evening chronotype;
SARC	cis	rs6089584	0.893	rs6089305	chr20:60571817	T/C	cg13770153	chr20:60521292	NA	-0.54	-7.64	-0.45	5.5e-13	Body mass index;
SARC	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.19	-0.56	2.08e-20	Chronic sinus infection;
SARC	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg13175981	chr1:150552382	MCL1	-0.54	-6.9	-0.41	4.97e-11	Tonsillectomy;
SARC	cis	rs7945705	0.935	rs11042103	chr11:8888700	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.41	5.59	0.34	6.21e-8	Hemoglobin concentration;
SARC	cis	rs818427	0.896	rs712663	chr5:112223594	T/C	cg07820702	chr5:112228657	REEP5	-0.52	-5.91	-0.36	1.21e-8	Total body bone mineral density;
SARC	cis	rs17376456	1.000	rs17323433	chr5:93551028	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.62	5.4	0.33	1.68e-7	Diabetic retinopathy;
SARC	cis	rs9747201	1.000	rs36048409	chr17:80096961	T/A	cg17462356	chr17:80056334	FASN	0.46	5.28	0.33	2.96e-7	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg24829409	chr8:58192753	C8orf71	-0.62	-6.4	-0.39	8.61e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7786808	0.741	rs35059736	chr7:158224692	C/T	cg09998033	chr7:158218633	PTPRN2	-0.39	-6.33	-0.38	1.23e-9	Obesity-related traits;
SARC	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg10295955	chr4:187884368	NA	-1.07	-20.91	-0.81	2.19e-55	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9790314	0.846	rs7652267	chr3:160998497	A/G	cg03342759	chr3:160939853	NMD3	-0.73	-9.96	-0.55	1.08e-19	Morning vs. evening chronotype;
SARC	cis	rs8180040	0.966	rs807932	chr3:47354241	C/T	cg27129171	chr3:47204927	SETD2	0.67	9.36	0.52	7.09e-18	Colorectal cancer;
SARC	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg18252515	chr7:66147081	NA	0.47	5.11	0.32	6.8e-7	Aortic root size;
SARC	cis	rs9790314	0.715	rs9290065	chr3:160776964	A/G	cg04691961	chr3:161091175	C3orf57	0.59	7.84	0.46	1.5700000000000001e-13	Morning vs. evening chronotype;
SARC	cis	rs2839186	0.605	rs2839170	chr21:47671305	A/G	cg03841560	chr21:47649172	MCM3APAS;LSS	0.36	4.87	0.3	2.07e-6	Testicular germ cell tumor;
SARC	cis	rs73206853	0.841	rs73206845	chr12:110660556	T/C	cg08946844	chr12:110511112	NA	0.59	4.81	0.3	2.67e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs11025559	0.812	rs16906280	chr11:20472242	T/C	cg04101203	chr11:20408940	PRMT3	-0.52	-5.53	-0.34	8.37e-8	Pursuit maintenance gain;
SARC	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg02725872	chr8:58115012	NA	0.33	5.13	0.32	6.08e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg14820908	chr5:178986412	RUFY1	0.34	4.72	0.3	4.08e-6	Lung cancer;
SARC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.42	-6.42	-0.39	7.6e-10	Total body bone mineral density;
SARC	cis	rs7937682	0.824	rs577044	chr11:111490420	G/T	cg22437258	chr11:111473054	SIK2	0.72	9.91	0.54	1.54e-19	Primary sclerosing cholangitis;
SARC	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg08280861	chr8:58055591	NA	0.58	5.32	0.33	2.48e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6502050	0.787	rs59251877	chr17:80056498	G/A	cg19223190	chr17:80058835	NA	-0.45	-6.19	-0.38	2.63e-9	Life satisfaction;
SARC	cis	rs9906944	0.707	rs8068981	chr17:47122525	T/C	cg16584676	chr17:46985605	UBE2Z	-0.43	-5.26	-0.33	3.29e-7	Intelligence (multi-trait analysis);Body fat percentage;
SARC	cis	rs11758351	0.587	rs16891466	chr6:26235737	G/A	cg01420254	chr6:26195488	NA	0.56	4.73	0.3	3.97e-6	Gout;Renal underexcretion gout;
SARC	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg17971929	chr21:40555470	PSMG1	-0.6	-7.55	-0.44	9.65e-13	Menarche (age at onset);
SARC	cis	rs208520	0.690	rs4710564	chr6:66823478	A/G	cg07460842	chr6:66804631	NA	0.99	12.99	0.65	2.26e-29	Exhaled nitric oxide output;
SARC	cis	rs1008375	0.932	rs6449315	chr4:17590219	A/G	cg02297831	chr4:17616191	MED28	0.48	5.94	0.36	1.06e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs733592	0.560	rs2158515	chr12:48507668	T/C	cg21466736	chr12:48725269	NA	0.32	5.77	0.35	2.45e-8	Plateletcrit;
SARC	cis	rs9457247	0.765	rs10455982	chr6:167448728	C/T	cg23791538	chr6:167370224	RNASET2	-0.55	-7.27	-0.43	5.33e-12	Crohn's disease;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg06506598	chr5:79783889	FAM151B	0.49	6.47	0.39	5.81e-10	Chemerin levels;
SARC	cis	rs62244186	0.748	rs12635624	chr3:44678498	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.46	5.8	0.35	2.2e-8	Depressive symptoms;
SARC	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg13206674	chr6:150067644	NUP43	0.45	5.83	0.36	1.81e-8	Lung cancer;
SARC	cis	rs9309473	0.948	rs2421577	chr2:73840998	G/T	cg20560298	chr2:73613845	ALMS1	-0.45	-5.21	-0.32	4.24e-7	Metabolite levels;
SARC	trans	rs12310956	0.532	rs7306007	chr12:33975209	C/G	cg26384229	chr12:38710491	ALG10B	0.75	10.53	0.57	1.89e-21	Morning vs. evening chronotype;
SARC	cis	rs3857536	0.741	rs9363558	chr6:66937260	C/T	cg07460842	chr6:66804631	NA	-0.51	-5.83	-0.36	1.86e-8	Blood trace element (Cu levels);
SARC	cis	rs8028182	0.636	rs8023815	chr15:75814704	G/A	cg20655648	chr15:75932815	IMP3	0.64	7.41	0.44	2.38e-12	Sudden cardiac arrest;
SARC	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg10207240	chr12:122356781	WDR66	0.29	4.88	0.3	1.98e-6	Mean corpuscular volume;
SARC	cis	rs11785400	0.793	rs7017851	chr8:143722038	G/T	cg24634471	chr8:143751801	JRK	0.6	7.85	0.46	1.51e-13	Schizophrenia;
SARC	cis	rs4891159	0.527	rs689642	chr18:74119120	A/C	cg24786174	chr18:74118243	ZNF516	0.77	12.9	0.65	4.39e-29	Longevity;
SARC	cis	rs6570726	0.935	rs419854	chr6:145844085	A/C	cg23711669	chr6:146136114	FBXO30	0.77	11.79	0.61	1.79e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4727027	0.865	rs13236754	chr7:148845773	G/A	cg23583168	chr7:148888333	NA	-0.74	-11.25	-0.59	9.45e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs13034020	0.522	rs12996059	chr2:61245551	G/C	cg18625361	chr2:61244694	PEX13;PUS10	0.71	6.07	0.37	5.05e-9	Hodgkin's lymphoma;
SARC	cis	rs698833	0.962	rs1085447	chr2:44670996	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.6	-7.21	-0.43	7.74e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs2859741	0.546	rs2134846	chr1:37500723	G/A	cg09363841	chr1:37513479	NA	-0.3	-5.2	-0.32	4.44e-7	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
SARC	cis	rs2033711	0.870	rs4801583	chr19:58918405	A/G	cg11952622	chr19:58962976	ZNF324B	0.53	6.95	0.41	3.61e-11	Uric acid clearance;
SARC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg17178900	chr1:205818956	PM20D1	0.67	9.97	0.55	1.01e-19	Menarche (age at onset);
SARC	cis	rs524281	0.861	rs10896095	chr11:65962560	A/G	cg14036092	chr11:66035641	RAB1B	-0.49	-5.32	-0.33	2.47e-7	Electroencephalogram traits;
SARC	cis	rs10791097	0.720	rs6590517	chr11:130733505	C/T	cg09137382	chr11:130731461	NA	0.33	5.19	0.32	4.66e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs9326248	0.539	rs660443	chr11:116760693	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.62	7.75	0.45	2.84e-13	Blood protein levels;
SARC	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg06636001	chr8:8085503	FLJ10661	0.8	11.22	0.59	1.22e-23	Neuroticism;
SARC	cis	rs9462027	0.628	rs2744961	chr6:34655000	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-6.01	-0.37	7.1e-9	Systemic lupus erythematosus;
SARC	cis	rs57506017	0.585	rs7785189	chr7:12257527	C/T	cg23422036	chr7:12250390	TMEM106B	0.49	6.45	0.39	6.32e-10	Neuroticism;
SARC	cis	rs2370759	1.000	rs75984055	chr10:32591276	T/C	cg05361325	chr10:32636312	EPC1	-0.7	-6.28	-0.38	1.62e-9	Sexual dysfunction (female);
SARC	cis	rs7959452	0.868	rs10878967	chr12:69740869	T/C	cg14784868	chr12:69753453	YEATS4	0.41	5.41	0.33	1.59e-7	Blood protein levels;
SARC	cis	rs34779708	0.931	rs13376801	chr10:35370443	T/C	cg03585969	chr10:35415529	CREM	0.39	4.97	0.31	1.32e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg26513180	chr16:89883248	FANCA	0.75	4.84	0.3	2.35e-6	Skin colour saturation;
SARC	cis	rs10861342	1.000	rs12320123	chr12:105492167	C/T	cg23923672	chr12:105501055	KIAA1033	0.8	5.73	0.35	3.06e-8	IgG glycosylation;
SARC	cis	rs11608355	1.000	rs7958625	chr12:109869218	A/T	cg05360138	chr12:110035743	NA	0.45	5.13	0.32	6.13e-7	Neuroticism;
SARC	cis	rs12762955	0.519	rs10795306	chr10:1019138	A/T	cg18964960	chr10:1102726	WDR37	-0.53	-6.03	-0.37	6.44e-9	Response to angiotensin II receptor blocker therapy;
SARC	cis	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg20965017	chr5:231967	SDHA	-0.55	-5.3	-0.33	2.67e-7	Breast cancer;
SARC	cis	rs651907	0.557	rs11925001	chr3:101373966	C/T	cg12386194	chr3:101231763	SENP7	0.52	6.27	0.38	1.76e-9	Colorectal cancer;
SARC	cis	rs8114671	0.869	rs2038503	chr20:33675900	G/A	cg08999081	chr20:33150536	PIGU	-0.34	-4.78	-0.3	3.12e-6	Height;
SARC	cis	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg05623727	chr3:50126028	RBM5	0.33	4.77	0.3	3.18e-6	Body mass index;
SARC	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg06713675	chr4:122721982	EXOSC9	-0.51	-6.72	-0.4	1.39e-10	Type 2 diabetes;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg23181493	chr5:38934012	OSMR	0.48	6.72	0.4	1.38e-10	Thyroid stimulating hormone;
SARC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.82	10.68	0.57	6.47e-22	Prudent dietary pattern;
SARC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	10.53	0.57	1.87e-21	Platelet count;
SARC	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg04546413	chr19:29218101	NA	0.63	8.52	0.49	2.01e-15	Methadone dose in opioid dependence;
SARC	cis	rs898097	0.841	rs4986136	chr17:80865119	A/G	cg15664640	chr17:80829946	TBCD	0.53	7.81	0.46	1.94e-13	Breast cancer;
SARC	cis	rs6598955	0.670	rs11247892	chr1:26592727	A/G	cg04990556	chr1:26633338	UBXN11	-0.59	-8.08	-0.47	3.47e-14	Obesity-related traits;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg17148978	chr1:151584446	SNX27	0.5	6.39	0.39	8.78e-10	Lung adenocarcinoma;
SARC	cis	rs6570726	0.935	rs386823	chr6:145841365	C/T	cg05220968	chr6:146057943	EPM2A	-0.29	-4.99	-0.31	1.19e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9816226	0.591	rs1516725	chr3:185824004	T/C	cg00760338	chr3:185826511	ETV5	0.87	8.54	0.49	1.76e-15	Obesity;Body mass index;
SARC	cis	rs7772486	0.754	rs10872580	chr6:146140281	C/T	cg05347473	chr6:146136440	FBXO30	-0.53	-7.37	-0.44	2.86e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg04277193	chr17:41438351	NA	0.44	4.76	0.3	3.35e-6	Menopause (age at onset);
SARC	cis	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg07636037	chr3:49044803	WDR6	0.45	4.97	0.31	1.29e-6	Resting heart rate;
SARC	cis	rs2645694	0.626	rs2703121	chr4:77822328	C/G	cg18351406	chr4:77819688	ANKRD56	0.45	6.31	0.38	1.37e-9	Emphysema distribution in smoking;
SARC	cis	rs798554	0.644	rs7783400	chr7:2894434	A/C	cg04166393	chr7:2884313	GNA12	-0.61	-7.3	-0.43	4.43e-12	Height;
SARC	cis	rs5758659	0.652	rs133301	chr22:42390093	C/T	cg04733989	chr22:42467013	NAGA	0.5	6.68	0.4	1.75e-10	Cognitive function;
SARC	cis	rs3796352	1.000	rs35576914	chr3:53092270	G/A	cg12962167	chr3:53033115	SFMBT1	0.81	5.46	0.34	1.22e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg13175981	chr1:150552382	MCL1	-0.54	-6.84	-0.41	6.75e-11	Tonsillectomy;
SARC	cis	rs7872515	1.000	rs10992221	chr9:94832043	A/G	cg01248375	chr9:94877805	SPTLC1	-0.66	-5.12	-0.32	6.31e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs7246657	0.765	rs10402455	chr19:37728707	G/A	cg23950597	chr19:37808831	NA	-0.6	-5.22	-0.32	3.97e-7	Coronary artery calcification;
SARC	cis	rs3764563	1.000	rs4808326	chr19:15726147	A/G	cg20725493	chr19:15740067	CYP4F8	-0.65	-4.85	-0.3	2.24e-6	Inflammatory biomarkers;
SARC	trans	rs17685	0.712	rs6953342	chr7:75776753	T/C	cg19862616	chr7:65841803	NCRNA00174	0.6	7.38	0.44	2.77e-12	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg03433033	chr1:76189801	ACADM	0.53	7.72	0.45	3.49e-13	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs11098499	0.820	rs28535956	chr4:120536858	C/T	cg09307838	chr4:120376055	NA	-0.82	-11.23	-0.59	1.17e-23	Corneal astigmatism;
SARC	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.99	11.36	0.6	4.27e-24	Platelet count;
SARC	cis	rs9868809	0.772	rs9809222	chr3:48714411	C/T	cg07636037	chr3:49044803	WDR6	-0.71	-6.68	-0.4	1.78e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	trans	rs7819412	0.645	rs4841508	chr8:11065003	C/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.91	-0.41	4.64e-11	Triglycerides;
SARC	cis	rs6062302	0.522	rs6090476	chr20:62248001	G/A	cg16989086	chr20:62203971	PRIC285	0.47	4.73	0.3	3.92e-6	Glioblastoma;
SARC	cis	rs2304069	0.954	rs6579767	chr5:149406271	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.93	10.3	0.56	9.88e-21	HIV-1 control;
SARC	cis	rs7829975	0.606	rs10112585	chr8:8795030	A/T	cg08975724	chr8:8085496	FLJ10661	-0.41	-5.14	-0.32	5.77e-7	Mood instability;
SARC	cis	rs9322817	0.691	rs9391241	chr6:105223663	T/C	cg02098413	chr6:105308735	HACE1	-0.39	-6.13	-0.37	3.69e-9	Thyroid stimulating hormone;
SARC	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	4.86	0.3	2.12e-6	Personality dimensions;
SARC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7084402	0.967	rs1658429	chr10:60330422	T/C	cg07615347	chr10:60278583	BICC1	0.58	8.49	0.49	2.37e-15	Refractive error;
SARC	cis	rs17376456	0.935	rs13156002	chr5:93508931	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.26	0.33	3.27e-7	Diabetic retinopathy;
SARC	cis	rs6963495	0.818	rs56268110	chr7:105166712	T/C	cg19920283	chr7:105172520	RINT1	0.67	5.67	0.35	4.21e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs826838	0.934	rs10875647	chr12:38856995	G/A	cg26384229	chr12:38710491	ALG10B	0.93	14.91	0.7	9.31e-36	Heart rate;
SARC	cis	rs9875589	0.509	rs2733555	chr3:14099649	C/T	cg19554555	chr3:13937349	NA	-0.4	-5.09	-0.32	7.32e-7	Ovarian reserve;
SARC	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg11890956	chr21:40555474	PSMG1	-1.05	-15.51	-0.71	9.36e-38	Cognitive function;
SARC	trans	rs9354308	0.868	rs9453438	chr6:66540534	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.53	-6.32	-0.38	1.32e-9	Metabolite levels;
SARC	cis	rs3617	0.532	rs9836499	chr3:52904524	G/T	cg18404041	chr3:52824283	ITIH1	0.33	4.83	0.3	2.52e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg11644478	chr21:40555479	PSMG1	-0.53	-6.5	-0.39	4.93e-10	Menarche (age at onset);
SARC	cis	rs28830936	0.510	rs7175346	chr15:42100674	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.47	-7.47	-0.44	1.58e-12	Diastolic blood pressure;
SARC	cis	rs2486288	0.656	rs8039540	chr15:45551842	C/G	cg21132104	chr15:45694354	SPATA5L1	-0.51	-6.44	-0.39	6.68e-10	Glomerular filtration rate;
SARC	cis	rs7395581	0.918	rs11039166	chr11:47316691	A/C	cg25783544	chr11:47291846	MADD	0.51	5.83	0.36	1.87e-8	HDL cholesterol;
SARC	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg24642844	chr7:1081250	C7orf50	-0.59	-6.23	-0.38	2.22e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg16132339	chr22:24313637	DDTL;DDT	0.39	5.3	0.33	2.71e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7264396	0.790	rs3746410	chr20:34190870	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-6.27	-0.38	1.71e-9	Total cholesterol levels;
SARC	cis	rs72615157	0.539	rs72615159	chr7:99674286	G/A	cg22004693	chr7:99632812	ZKSCAN1	0.74	9.18	0.52	2.39e-17	Lung function (FEV1/FVC);
SARC	cis	rs2120019	1.000	rs35577967	chr15:75354621	G/A	cg09165964	chr15:75287851	SCAMP5	-0.93	-13.71	-0.67	9.36e-32	Blood trace element (Zn levels);
SARC	cis	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg22496380	chr5:211416	CCDC127	-0.88	-9.35	-0.52	7.72e-18	Breast cancer;
SARC	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg19500275	chr17:80737654	TBCD	0.43	5.12	0.32	6.31e-7	Glycated hemoglobin levels;
SARC	cis	rs2832077	0.527	rs59730679	chr21:30226244	T/C	cg08807101	chr21:30365312	RNF160	-0.56	-6.3	-0.38	1.45e-9	Cognitive test performance;
SARC	cis	rs950027	0.620	rs1153860	chr15:45636584	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.53	-6.85	-0.41	6.4e-11	Response to fenofibrate (adiponectin levels);
SARC	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg14456004	chr13:21872349	NA	1.12	16.65	0.74	1.55e-41	White matter hyperintensity burden;
SARC	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg06618935	chr21:46677482	NA	-0.39	-5.14	-0.32	5.72e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs765787	0.530	rs4774550	chr15:45542312	C/T	cg24006582	chr15:45444508	DUOX1	-0.5	-6.53	-0.39	4.09e-10	Uric acid levels;
SARC	cis	rs6964587	1.000	rs10281556	chr7:91660053	C/T	cg17063962	chr7:91808500	NA	-0.95	-16.35	-0.73	1.54e-40	Breast cancer;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg00016718	chr6:49405490	MUT	0.53	7.25	0.43	5.94e-12	Thyroid stimulating hormone;
SARC	cis	rs55823223	0.648	rs11867582	chr17:73857306	A/G	cg08125733	chr17:73851984	WBP2	0.63	6.94	0.41	3.89e-11	Psoriasis;
SARC	cis	rs7589342	0.745	rs11124066	chr2:106516925	T/A	cg14210321	chr2:106509881	NCK2	-0.45	-5.14	-0.32	5.84e-7	Addiction;
SARC	cis	rs9875589	0.509	rs1601870	chr3:14024162	T/C	cg19554555	chr3:13937349	NA	-0.4	-5.14	-0.32	5.95e-7	Ovarian reserve;
SARC	cis	rs9326248	1.000	rs4938354	chr11:117051165	A/G	cg10130564	chr11:117069849	TAGLN	0.24	4.95	0.31	1.39e-6	Blood protein levels;
SARC	cis	rs7089973	0.872	rs35010779	chr10:116631816	A/C	cg08188268	chr10:116634841	FAM160B1	0.35	5.66	0.35	4.34e-8	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs2742234	0.541	rs11238483	chr10:43728780	A/G	cg15436174	chr10:43711423	RASGEF1A	0.42	5.05	0.31	9.01e-7	Hirschsprung disease;
SARC	cis	rs7027203	0.663	rs4428726	chr9:96623559	T/G	cg14396892	chr9:96623032	NA	-0.32	-4.93	-0.31	1.53e-6	DNA methylation (variation);
SARC	cis	rs72945132	0.882	rs7929271	chr11:70165749	A/G	cg00319359	chr11:70116639	PPFIA1	0.67	6.08	0.37	4.85e-9	Coronary artery disease;
SARC	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg12311346	chr5:56204834	C5orf35	0.75	7.39	0.44	2.64e-12	Initial pursuit acceleration;
SARC	cis	rs881375	0.934	rs1468671	chr9:123657502	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.41	5.07	0.32	8.03e-7	Rheumatoid arthritis;
SARC	cis	rs57502260	0.790	rs7128942	chr11:68387984	C/T	cg01657329	chr11:68192670	LRP5	-0.55	-5.83	-0.36	1.84e-8	Total body bone mineral density (age 45-60);
SARC	cis	rs986417	1.000	rs1956875	chr14:60846212	T/C	cg27398547	chr14:60952738	C14orf39	-1.0	-8.65	-0.49	8.38e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs13223928	0.666	rs9986825	chr7:3151177	C/T	cg19214707	chr7:3157722	NA	0.36	5.04	0.31	9.25e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
SARC	cis	rs1448094	0.817	rs61929421	chr12:86342330	T/C	cg02569458	chr12:86230093	RASSF9	0.41	5.88	0.36	1.41e-8	Major depressive disorder;
SARC	cis	rs2180341	1.000	rs7453272	chr6:127633959	C/T	cg24812749	chr6:127587940	RNF146	-0.95	-11.34	-0.6	4.97e-24	Breast cancer;
SARC	cis	rs9640161	0.830	rs76741564	chr7:150059529	A/T	cg21361702	chr7:150065534	REPIN1	0.59	6.98	0.42	3.13e-11	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs9303401	0.614	rs28651036	chr17:57080471	G/A	cg25039879	chr17:56429692	SUPT4H1	0.56	5.06	0.31	8.59e-7	Cognitive test performance;
SARC	cis	rs17270561	0.609	rs4712963	chr6:25740502	C/T	cg16482183	chr6:26056742	HIST1H1C	0.43	5.12	0.32	6.27e-7	Iron status biomarkers;
SARC	cis	rs4727027	0.645	rs12704072	chr7:148904888	G/A	cg23583168	chr7:148888333	NA	-0.84	-13.59	-0.66	2.36e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs2228479	0.867	rs12930056	chr16:89946649	C/A	cg06558623	chr16:89946397	TCF25	0.98	8.13	0.47	2.6e-14	Skin colour saturation;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg04407147	chr2:160606257	MARCH7	0.53	7.22	0.43	7.31e-12	Thyroid stimulating hormone;
SARC	cis	rs751728	0.965	rs4713681	chr6:33754817	T/C	cg15252951	chr6:33757062	LEMD2	0.57	6.74	0.4	1.25e-10	Crohn's disease;
SARC	cis	rs10463554	0.927	rs34806	chr5:102428437	T/C	cg23492399	chr5:102201601	PAM	-0.47	-5.21	-0.32	4.1e-7	Parkinson's disease;
SARC	cis	rs448720	0.840	rs405390	chr15:68169242	A/G	cg05925327	chr15:68127851	NA	0.36	5.08	0.32	7.87e-7	Cognitive performance;
SARC	cis	rs7103648	0.630	rs7120548	chr11:47662932	A/G	cg10504702	chr11:47789108	FNBP4	0.66	8.7	0.5	6.24e-16	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs17270561	0.609	rs4712957	chr6:25719814	C/T	cg17691542	chr6:26056736	HIST1H1C	0.59	7.21	0.43	7.66e-12	Iron status biomarkers;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg15705930	chr5:123973317	ZNF608	0.46	6.37	0.39	1.01e-9	Thyroid stimulating hormone;
SARC	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg13939156	chr17:80058883	NA	-0.42	-6.58	-0.4	3.07e-10	Life satisfaction;
SARC	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	5.79	0.35	2.23e-8	Electroencephalogram traits;
SARC	cis	rs7589342	0.745	rs933793	chr2:106511846	C/T	cg16077055	chr2:106428750	NCK2	-0.32	-5.74	-0.35	2.87e-8	Addiction;
SARC	cis	rs7296418	0.630	rs7974099	chr12:123771475	A/G	cg05973401	chr12:123451056	ABCB9	0.49	5.61	0.35	5.66e-8	Platelet count;
SARC	cis	rs6582630	0.519	rs11519914	chr12:38287014	A/G	cg13010199	chr12:38710504	ALG10B	0.77	10.47	0.57	2.85e-21	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg05185784	chr16:90016020	DEF8	-0.45	-4.76	-0.3	3.32e-6	Skin colour saturation;
SARC	cis	rs1707322	0.721	rs12069121	chr1:46231984	G/A	cg06784218	chr1:46089804	CCDC17	0.39	6.86	0.41	6.15e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6912958	0.559	rs242270	chr6:88062190	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.78	-12.13	-0.62	1.42e-26	Monocyte percentage of white cells;
SARC	cis	rs5167	0.504	rs8100120	chr19:45466058	T/C	cg09555818	chr19:45449301	APOC2	0.56	9.2	0.52	2.07e-17	Blood protein levels;
SARC	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4595586	0.545	rs9668716	chr12:39378833	G/T	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	cis	rs526231	0.543	rs27361	chr5:102548967	G/A	cg23492399	chr5:102201601	PAM	-0.52	-5.66	-0.35	4.32e-8	Primary biliary cholangitis;
SARC	cis	rs1003719	0.788	rs4816560	chr21:38487561	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.64	8.86	0.5	2.03e-16	Eye color traits;
SARC	cis	rs1153858	0.621	rs1706824	chr15:45579948	C/T	cg19305227	chr15:45544335	SLC28A2	-0.29	-5.08	-0.32	7.57e-7	Homoarginine levels;
SARC	cis	rs2242194	0.816	rs11264296	chr1:154994750	T/C	cg09359103	chr1:154839909	KCNN3	-0.34	-5.36	-0.33	2.03e-7	Schizophrenia;
SARC	trans	rs7722711	1.000	rs7722711	chr5:75906851	C/T	cg22490695	chr16:31271240	ITGAM	0.7	6.5	0.39	4.89e-10	Mean platelet volume;
SARC	cis	rs155076	1.000	rs484365	chr13:21845944	G/T	cg11317459	chr13:21872234	NA	-0.98	-12.36	-0.63	2.52e-27	White matter hyperintensity burden;
SARC	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg22618164	chr12:122356400	WDR66	0.38	5.83	0.36	1.87e-8	Mean corpuscular volume;
SARC	cis	rs600231	0.706	rs11227221	chr11:65319265	T/C	cg21890820	chr11:65308645	LTBP3	-0.38	-4.88	-0.3	1.93e-6	Bone mineral density;
SARC	cis	rs1983891	0.553	rs3800283	chr6:41558358	A/G	cg15051332	chr6:41514432	FOXP4	0.48	5.09	0.32	7.39e-7	Prostate cancer;
SARC	cis	rs79349575	0.679	rs9894239	chr17:46997959	C/T	cg16584676	chr17:46985605	UBE2Z	-0.54	-6.88	-0.41	5.51e-11	Type 2 diabetes;
SARC	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	7.67	0.45	4.58e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs10876993	0.855	rs1689604	chr12:58048304	T/C	cg18357645	chr12:58087776	OS9	0.46	5.92	0.36	1.13e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs9457247	0.765	rs9459836	chr6:167419105	G/A	cg07741184	chr6:167504864	NA	0.34	6.53	0.39	4.1e-10	Crohn's disease;
SARC	cis	rs4853036	1.000	rs4853036	chr2:70059824	G/A	cg02498382	chr2:70120550	SNRNP27	-0.43	-6.57	-0.4	3.17e-10	Colorectal or endometrial cancer;
SARC	cis	rs6459804	0.967	rs4289696	chr7:157508399	C/T	cg05731713	chr7:157510257	PTPRN2	0.3	5.75	0.35	2.83e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg24101359	chr6:42928495	GNMT	0.42	5.81	0.36	2.03e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs67311347	0.955	rs1129200	chr3:40532257	T/C	cg01475735	chr3:40494733	NA	-0.44	-5.15	-0.32	5.48e-7	Renal cell carcinoma;
SARC	cis	rs1865760	0.928	rs9295673	chr6:25912094	T/G	cg16482183	chr6:26056742	HIST1H1C	0.5	6.22	0.38	2.27e-9	Height;
SARC	cis	rs7659604	0.540	rs13140070	chr4:122713899	C/T	cg19671926	chr4:122722719	EXOSC9	0.67	8.64	0.49	9.26e-16	Type 2 diabetes;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg15699942	chr12:50677255	LIMA1	-0.53	-7.0	-0.42	2.67e-11	Schizophrenia;
SARC	cis	rs753778	0.628	rs11579	chr8:142205132	G/A	cg16341495	chr8:142228727	SLC45A4	-0.39	-5.35	-0.33	2.12e-7	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs13166103	0.723	rs13176857	chr5:57724741	A/G	cg10487770	chr5:57879443	RAB3C	0.51	5.27	0.33	3.08e-7	Type 2 diabetes (age of onset);
SARC	cis	rs7552404	0.924	rs2275378	chr1:76198436	T/C	cg22875332	chr1:76189707	ACADM	0.46	6.69	0.4	1.64e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg11266682	chr4:10021025	SLC2A9	0.41	7.29	0.43	4.74e-12	Bone mineral density;
SARC	trans	rs9929218	1.000	rs28450087	chr16:68803726	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.52	-6.72	-0.4	1.36e-10	Colorectal cancer;
SARC	cis	rs8042849	1	rs8042849	chr15:78817929	C/T	cg06917634	chr15:78832804	PSMA4	0.47	5.13	0.32	6.04e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Parental lifespan;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg11764359	chr7:65958608	NA	0.86	12.33	0.63	3.29e-27	Aortic root size;
SARC	cis	rs9811216	0.876	rs3950296	chr3:169493283	C/G	cg14222479	chr3:169487675	ARPM1	0.47	5.34	0.33	2.25e-7	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs2425143	1.000	rs6058304	chr20:34299851	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.68	5.52	0.34	9.15e-8	Blood protein levels;
SARC	cis	rs35213789	0.727	rs17140982	chr7:69327126	G/A	cg10619644	chr7:69149951	AUTS2	0.39	4.78	0.3	3.12e-6	Childhood ear infection;
SARC	cis	rs6484504	0.625	rs7940420	chr11:31366700	T/A	cg02090638	chr11:31391270	DNAJC24;DCDC1	0.41	5.21	0.32	4.2e-7	Red blood cell count;
SARC	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg16486109	chr11:613632	IRF7	0.45	6.04	0.37	6.13e-9	Systemic lupus erythematosus;
SARC	cis	rs1728785	0.818	rs1170430	chr16:68604954	T/C	cg02972257	chr16:68554789	NA	-0.47	-5.56	-0.34	7.2e-8	Ulcerative colitis;
SARC	cis	rs7666738	0.830	rs13112037	chr4:98976986	A/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs770189	0.869	rs10462476	chr5:88086112	T/C	cg18498987	chr5:88179539	MEF2C	-0.38	-4.72	-0.3	4.01e-6	Tonometry;
SARC	cis	rs11098499	0.708	rs11732686	chr4:120252330	C/A	cg09307838	chr4:120376055	NA	0.81	11.03	0.59	4.84e-23	Corneal astigmatism;
SARC	cis	rs8114671	0.562	rs6119545	chr20:33522869	T/C	cg24642439	chr20:33292090	TP53INP2	0.51	6.17	0.37	3.06e-9	Height;
SARC	cis	rs981844	0.922	rs2118863	chr4:154657579	C/T	cg14289246	chr4:154710475	SFRP2	0.58	6.64	0.4	2.14e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg13395646	chr4:1353034	KIAA1530	-0.43	-5.25	-0.32	3.5e-7	Obesity-related traits;
SARC	cis	rs34172651	0.876	rs2112785	chr16:24781176	C/T	cg00152838	chr16:24741724	TNRC6A	-0.42	-5.31	-0.33	2.5e-7	Intelligence (multi-trait analysis);
SARC	cis	rs8067545	0.611	rs2189709	chr17:20083226	T/A	cg13482628	chr17:19912719	NA	-0.55	-7.09	-0.42	1.54e-11	Schizophrenia;
SARC	cis	rs73206853	0.764	rs7300001	chr12:110581731	A/G	cg10860002	chr12:110842031	ANAPC7	0.66	4.86	0.3	2.12e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg27170947	chr2:26402098	FAM59B	-0.37	-4.8	-0.3	2.79e-6	Gut microbiome composition (summer);
SARC	cis	rs9790314	0.613	rs6809177	chr3:160630477	G/T	cg04691961	chr3:161091175	C3orf57	0.55	7.31	0.43	4.34e-12	Morning vs. evening chronotype;
SARC	cis	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg00071950	chr4:10020882	SLC2A9	0.39	6.31	0.38	1.4e-9	Bone mineral density;
SARC	cis	rs7582720	0.943	rs72936866	chr2:203787120	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs17376456	0.825	rs13164315	chr5:93147421	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.71	6.43	0.39	7.19e-10	Diabetic retinopathy;
SARC	cis	rs17270561	0.636	rs6923839	chr6:25745853	G/A	cg16482183	chr6:26056742	HIST1H1C	0.43	5.08	0.32	7.76e-7	Iron status biomarkers;
SARC	cis	rs9462027	0.628	rs2764206	chr6:34712900	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.4	-5.7	-0.35	3.69e-8	Systemic lupus erythematosus;
SARC	cis	rs694739	0.536	rs671976	chr11:64046029	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.48	6.13	0.37	3.66e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg08219700	chr8:58056026	NA	0.47	4.84	0.3	2.39e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs9419702	0.568	rs7093241	chr10:133556596	G/A	cg23460707	chr10:133558971	NA	0.34	4.98	0.31	1.25e-6	Survival in rectal cancer;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg14421717	chr5:54603624	DHX29;SKIV2L2	-0.46	-6.25	-0.38	1.97e-9	Neuroticism;
SARC	cis	rs7412746	0.553	rs59337856	chr1:150746406	G/T	cg15448220	chr1:150897856	SETDB1	0.48	6.25	0.38	1.99e-9	Melanoma;
SARC	cis	rs10504073	0.545	rs4406405	chr8:49957261	G/C	cg00325661	chr8:49890786	NA	0.52	6.78	0.41	9.87e-11	Blood metabolite ratios;
SARC	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg22496380	chr5:211416	CCDC127	-0.88	-9.35	-0.52	7.72e-18	Breast cancer;
SARC	cis	rs10911232	0.507	rs4483371	chr1:182988352	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.7	0.57	5.56e-22	Hypertriglyceridemia;
SARC	cis	rs1448094	0.527	rs1900700	chr12:86232166	C/T	cg00310523	chr12:86230176	RASSF9	0.33	5.37	0.33	1.89e-7	Major depressive disorder;
SARC	cis	rs2011503	0.943	rs756997	chr19:19467085	G/C	cg15839431	chr19:19639596	YJEFN3	0.49	4.77	0.3	3.18e-6	Bipolar disorder;
SARC	trans	rs9388451	0.903	rs9388446	chr6:126064920	T/A	cg05039488	chr6:79577232	IRAK1BP1	-0.57	-7.31	-0.43	4.17e-12	Brugada syndrome;
SARC	cis	rs4742903	1.000	rs7350148	chr9:106883085	T/G	cg14250997	chr9:106856677	SMC2	0.53	7.04	0.42	2.09e-11	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg17294928	chr15:75287854	SCAMP5	0.47	6.03	0.37	6.35e-9	Breast cancer;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg14645856	chr6:18368844	NA	-0.49	-6.42	-0.39	7.56e-10	Height;
SARC	cis	rs1371867	0.846	rs1660317	chr8:101333252	G/T	cg11906718	chr8:101322791	RNF19A	0.71	9.13	0.51	3.37e-17	Atrioventricular conduction;
SARC	cis	rs1355223	1.000	rs12792532	chr11:34765782	G/T	cg18508148	chr11:34937573	PDHX;APIP	-0.45	-5.89	-0.36	1.36e-8	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs2200578	0.786	rs62154639	chr2:99646954	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.63	5.91	0.36	1.22e-8	IgG glycosylation;
SARC	cis	rs9303401	0.659	rs2072316	chr17:56604813	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.09	12.17	0.62	1.05e-26	Cognitive test performance;
SARC	cis	rs9815354	0.951	rs55835726	chr3:41763049	C/T	cg03022575	chr3:42003672	ULK4	0.65	5.52	0.34	8.91e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs60871478	1.000	rs67721251	chr7:825114	T/C	cg05535760	chr7:792225	HEATR2	0.75	7.7	0.45	3.82e-13	Cerebrospinal P-tau181p levels;
SARC	cis	rs8102137	1.000	rs62104478	chr19:30295306	G/A	cg27475126	chr19:30303651	CCNE1	-0.42	-5.87	-0.36	1.48e-8	Bladder cancer;
SARC	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg18230493	chr5:56204884	C5orf35	0.59	5.39	0.33	1.74e-7	Initial pursuit acceleration;
SARC	cis	rs62408225	0.722	rs2064870	chr6:90903990	T/C	cg06866423	chr6:90926672	BACH2	0.32	5.07	0.32	8.17e-7	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs7940866	0.834	rs7939417	chr11:130853832	T/A	cg12179176	chr11:130786555	SNX19	0.66	8.65	0.49	8.25e-16	Schizophrenia;
SARC	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.93	13.87	0.67	2.78e-32	Gut microbiome composition (summer);
SARC	cis	rs10791097	0.694	rs3190331	chr11:130748131	C/T	cg09137382	chr11:130731461	NA	-0.32	-4.9	-0.31	1.77e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg03022926	chr14:92248966	TC2N	-0.42	-6.24	-0.38	2.05e-9	Alcohol dependence;
SARC	cis	rs2576037	0.901	rs6507719	chr18:44581310	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.69	-10.1	-0.55	4e-20	Personality dimensions;
SARC	cis	rs5167	0.750	rs3786505	chr19:45490570	A/G	cg13119609	chr19:45449297	APOC2	0.39	5.97	0.36	8.91e-9	Blood protein levels;
SARC	cis	rs17401966	1.000	rs12136376	chr1:10296452	C/T	cg15208524	chr1:10270712	KIF1B	0.59	6.8	0.41	8.49e-11	Hepatocellular carcinoma;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg12526120	chr1:193074554	GLRX2	0.62	6.49	0.39	5.23e-10	Lung cancer in ever smokers;
SARC	cis	rs4901847	0.901	rs10144315	chr14:58546621	A/T	cg15908186	chr14:58618357	C14orf37	0.45	5.23	0.32	3.75e-7	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs6540556	0.834	rs6700223	chr1:209935031	G/A	cg05527609	chr1:210001259	C1orf107	-0.48	-5.06	-0.31	8.57e-7	Red blood cell count;
SARC	cis	rs10876993	0.890	rs1092472	chr12:58036688	G/T	cg18357645	chr12:58087776	OS9	0.44	5.83	0.36	1.83e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs17253792	0.822	rs75763956	chr14:56071176	A/G	cg01858014	chr14:56050164	KTN1	-0.71	-5.63	-0.35	5.25e-8	Putamen volume;
SARC	cis	rs765787	0.530	rs2433228	chr15:45515371	A/C	cg25801113	chr15:45476975	SHF	0.28	4.72	0.3	4.06e-6	Uric acid levels;
SARC	trans	rs36093844	0.898	rs80079882	chr11:85590955	T/C	cg27065003	chr5:122429449	PRDM6	-0.49	-6.24	-0.38	2.06e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs12142240	0.698	rs58162700	chr1:46816659	T/A	cg10495392	chr1:46806563	NSUN4	0.65	6.83	0.41	7.25e-11	Menopause (age at onset);
SARC	cis	rs6456156	0.586	rs7746628	chr6:167483235	A/G	cg23791538	chr6:167370224	RNASET2	-0.53	-6.99	-0.42	2.86e-11	Primary biliary cholangitis;
SARC	cis	rs9325144	0.600	rs34138871	chr12:38735261	A/G	cg26384229	chr12:38710491	ALG10B	0.59	7.65	0.45	5.15e-13	Morning vs. evening chronotype;
SARC	cis	rs57244997	0.556	rs73030428	chr6:162437606	T/C	cg17173639	chr6:162384350	PARK2	-0.47	-4.79	-0.3	3.03e-6	Mosquito bite size;
SARC	cis	rs7412746	0.611	rs16827671	chr1:150738759	T/C	cg15448220	chr1:150897856	SETDB1	0.48	6.25	0.38	1.99e-9	Melanoma;
SARC	cis	rs72781680	0.821	rs17045981	chr2:24109316	A/G	cg06627628	chr2:24431161	ITSN2	-0.57	-5.82	-0.36	1.91e-8	Lymphocyte counts;
SARC	cis	rs41278232	0.557	rs843850	chr20:62607659	G/T	cg07620230	chr20:62328084	TNFRSF6B	0.34	4.78	0.3	3.09e-6	Tonsillectomy;
SARC	cis	rs9682041	0.877	rs12489967	chr3:170073339	A/C	cg11886554	chr3:170076028	SKIL	0.74	6.69	0.4	1.65e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs13191362	0.935	rs35942036	chr6:163163297	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.72	6.11	0.37	4.25e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs35146811	0.844	rs2070215	chr7:99696797	T/C	cg22004693	chr7:99632812	ZKSCAN1	-0.49	-5.17	-0.32	5.05e-7	Coronary artery disease;
SARC	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg06618935	chr21:46677482	NA	-0.41	-5.37	-0.33	1.92e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2290159	0.800	rs56363132	chr3:12680403	T/C	cg23032965	chr3:12705835	RAF1	0.78	8.68	0.49	6.94e-16	Cholesterol, total;
SARC	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg03060546	chr3:49711283	APEH	0.75	10.86	0.58	1.67e-22	Resting heart rate;
SARC	cis	rs7662987	0.517	rs2602883	chr4:100040914	A/T	cg12011299	chr4:100065546	ADH4	0.33	5.51	0.34	9.41e-8	Smoking initiation;
SARC	cis	rs9300255	0.510	rs1727323	chr12:123698790	T/C	cg05973401	chr12:123451056	ABCB9	0.52	5.89	0.36	1.34e-8	Neutrophil percentage of white cells;
SARC	cis	rs765787	0.530	rs12917187	chr15:45538297	A/G	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.51e-10	Uric acid levels;
SARC	cis	rs12477438	0.765	rs2309521	chr2:99592069	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-8.51	-0.49	2.09e-15	Chronic sinus infection;
SARC	cis	rs16976116	0.901	rs1061822	chr15:55496058	A/C	cg17854078	chr15:55489399	RSL24D1	0.66	6.53	0.39	4.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg18876405	chr7:65276391	NA	-0.66	-8.24	-0.48	1.21e-14	Aortic root size;
SARC	cis	rs11608355	0.705	rs6663	chr12:109886603	G/A	cg05360138	chr12:110035743	NA	0.55	5.98	0.36	8.52e-9	Neuroticism;
SARC	cis	rs829880	0.570	rs4488248	chr12:98853688	G/C	cg25150519	chr12:98850993	NA	0.77	10.99	0.58	6.58e-23	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg10523679	chr1:76189770	ACADM	0.45	5.38	0.33	1.83e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs11724804	0.532	rs7657611	chr4:880558	G/C	cg16931447	chr4:875861	GAK	-0.49	-5.13	-0.32	6.17e-7	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
SARC	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg11878867	chr6:150167359	LRP11	-0.34	-4.84	-0.3	2.42e-6	Lung cancer;
SARC	cis	rs1483890	0.638	rs1564756	chr3:69402489	T/G	cg22125112	chr3:69402811	FRMD4B	-0.28	-4.72	-0.3	4.14e-6	Resting heart rate;
SARC	trans	rs61931739	0.534	rs1352206	chr12:34036668	G/A	cg13010199	chr12:38710504	ALG10B	0.66	9.05	0.51	5.8e-17	Morning vs. evening chronotype;
SARC	cis	rs6570726	0.935	rs454370	chr6:145846729	T/G	cg05220968	chr6:146057943	EPM2A	-0.29	-5.04	-0.31	9.48e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs8114671	0.562	rs6087649	chr20:33510662	A/G	cg08999081	chr20:33150536	PIGU	0.32	4.72	0.3	3.99e-6	Height;
SARC	cis	rs1008375	0.797	rs6843530	chr4:17593605	G/T	cg02297831	chr4:17616191	MED28	0.51	6.39	0.39	8.91e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1580019	0.587	rs7804457	chr7:32557981	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.99	18.06	0.76	3.58e-46	Cognitive ability;
SARC	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg08219700	chr8:58056026	NA	0.47	5.04	0.31	9.15e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7769051	0.522	rs73554461	chr6:133139087	T/G	cg22852734	chr6:133119734	C6orf192	1.2	7.65	0.45	5.22e-13	Type 2 diabetes nephropathy;
SARC	cis	rs7829975	0.774	rs1703982	chr8:8598388	A/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-5.71	-0.35	3.37e-8	Mood instability;
SARC	cis	rs7818345	1.000	rs6984145	chr8:19294111	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.38	5.2	0.32	4.35e-7	Language performance in older adults (adjusted for episodic memory);
SARC	trans	rs7615952	0.741	rs13314845	chr3:125644782	C/T	cg07211511	chr3:129823064	LOC729375	-0.97	-10.83	-0.58	2.17e-22	Blood pressure (smoking interaction);
SARC	cis	rs8523	0.901	rs3798707	chr6:10991935	C/T	cg13562911	chr6:11044106	ELOVL2	0.39	5.15	0.32	5.47e-7	Red blood cell fatty acid levels;
SARC	cis	rs4481887	0.927	rs4282853	chr1:248475127	A/G	cg01631408	chr1:248437212	OR2T33	-0.38	-4.92	-0.31	1.67e-6	Common traits (Other);
SARC	trans	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg21659725	chr3:3221576	CRBN	-0.53	-6.97	-0.42	3.24e-11	Intelligence (multi-trait analysis);
SARC	cis	rs6674176	0.597	rs2352990	chr1:44393276	T/A	cg13606994	chr1:44402422	ARTN	-0.34	-5.58	-0.34	6.68e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs2439831	0.867	rs2260160	chr15:43895643	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.75	7.63	0.45	6.15e-13	Lung cancer in ever smokers;
SARC	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg06618935	chr21:46677482	NA	-0.39	-5.14	-0.32	5.72e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs854765	0.583	rs9890341	chr17:17823175	G/C	cg04398451	chr17:18023971	MYO15A	-0.39	-5.48	-0.34	1.12e-7	Total body bone mineral density;
SARC	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg18876405	chr7:65276391	NA	-0.46	-5.68	-0.35	3.96e-8	Aortic root size;
SARC	cis	rs1476670	0.710	rs2485993	chr1:44503040	C/T	cg09470012	chr1:44509516	NA	-0.43	-5.55	-0.34	7.56e-8	Eotaxin levels;
SARC	cis	rs35110281	0.693	rs2838344	chr21:45089877	C/T	cg01579765	chr21:45077557	HSF2BP	-0.31	-4.92	-0.31	1.64e-6	Mean corpuscular volume;
SARC	cis	rs561341	0.883	rs886224	chr17:30229902	T/C	cg13647721	chr17:30228624	UTP6	0.63	5.12	0.32	6.53e-7	Hip circumference adjusted for BMI;
SARC	cis	rs11098499	0.908	rs7696649	chr4:120322177	G/A	cg24375607	chr4:120327624	NA	0.4	4.75	0.3	3.5e-6	Corneal astigmatism;
SARC	cis	rs4969178	0.965	rs8075131	chr17:76394595	T/G	cg20026190	chr17:76395443	PGS1	0.39	5.3	0.33	2.71e-7	HDL cholesterol levels;
SARC	cis	rs2921036	0.545	rs4840975	chr8:8363258	C/T	cg08975724	chr8:8085496	FLJ10661	-0.42	-4.99	-0.31	1.19e-6	Neuroticism;
SARC	trans	rs9329221	0.736	rs34381075	chr8:10243785	C/G	cg06636001	chr8:8085503	FLJ10661	0.62	7.86	0.46	1.45e-13	Neuroticism;
SARC	cis	rs754466	0.580	rs12354903	chr10:79536465	T/C	cg17075019	chr10:79541650	NA	-0.85	-13.43	-0.66	7.68e-31	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs710216	0.763	rs841857	chr1:43400016	C/T	cg03128534	chr1:43423976	SLC2A1	0.61	5.81	0.36	2.07e-8	Red cell distribution width;
SARC	cis	rs9640161	0.742	rs2159235	chr7:150017228	T/C	cg21361702	chr7:150065534	REPIN1	0.46	4.82	0.3	2.55e-6	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs73206853	0.764	rs16940935	chr12:111107470	A/G	cg10860002	chr12:110842031	ANAPC7	0.56	4.72	0.3	4.08e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs1018836	0.847	rs4735225	chr8:91569100	G/C	cg16814680	chr8:91681699	NA	-0.82	-12.94	-0.65	3.26e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs12709013	0.636	rs257624	chr16:58794898	C/G	cg04273148	chr16:57808038	KIFC3	0.32	4.72	0.3	4.08e-6	Blood metabolite ratios;
SARC	cis	rs2050392	0.767	rs10763786	chr10:30693567	G/C	cg25182066	chr10:30743637	MAP3K8	-0.43	-5.74	-0.35	2.88e-8	Inflammatory bowel disease;
SARC	cis	rs2916247	0.954	rs10110490	chr8:93147036	G/T	cg10183463	chr8:93005414	RUNX1T1	0.55	5.8	0.36	2.18e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9733	0.650	rs11204684	chr1:150608894	A/G	cg13175981	chr1:150552382	MCL1	0.69	9.34	0.52	8.2e-18	Tonsillectomy;
SARC	cis	rs7647973	0.588	rs62262675	chr3:49673662	A/G	cg13072238	chr3:49761600	GMPPB	0.72	6.55	0.39	3.66e-10	Menarche (age at onset);
SARC	cis	rs77741769	0.926	rs4767941	chr12:121359586	G/A	cg02403541	chr12:121454288	C12orf43	0.58	7.01	0.42	2.48e-11	Mean corpuscular volume;
SARC	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg13939156	chr17:80058883	NA	-0.42	-6.48	-0.39	5.51e-10	Life satisfaction;
SARC	cis	rs73001065	0.901	rs8107974	chr19:19388500	A/T	cg03709012	chr19:19516395	GATAD2A	0.99	5.7	0.35	3.53e-8	LDL cholesterol;
SARC	cis	rs1008375	0.966	rs4698636	chr4:17632834	T/C	cg16339924	chr4:17578868	LAP3	0.66	8.65	0.49	8.64e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7178909	0.902	rs8033554	chr15:90441569	C/A	cg19708238	chr15:90437601	AP3S2	0.63	8.34	0.48	6.38e-15	Common traits (Other);
SARC	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg00933542	chr6:150070202	PCMT1	0.31	5.2	0.32	4.26e-7	Lung cancer;
SARC	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg05896524	chr21:47604654	C21orf56	0.43	5.15	0.32	5.45e-7	Testicular germ cell tumor;
SARC	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg25036284	chr2:26402008	FAM59B	-0.46	-5.7	-0.35	3.59e-8	Gut microbiome composition (summer);
SARC	cis	rs35110281	0.667	rs4819287	chr21:45120147	A/G	cg21573476	chr21:45109991	RRP1B	-0.62	-8.99	-0.51	8.91e-17	Mean corpuscular volume;
SARC	cis	rs477692	0.905	rs576560	chr10:131420697	C/A	cg05714579	chr10:131428358	MGMT	0.58	7.77	0.45	2.46e-13	Response to temozolomide;
SARC	cis	rs7772486	0.764	rs2247211	chr6:146216379	G/A	cg05347473	chr6:146136440	FBXO30	0.47	6.41	0.39	7.77e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs8028182	0.636	rs4886715	chr15:75831449	C/T	cg20655648	chr15:75932815	IMP3	0.63	7.33	0.43	3.65e-12	Sudden cardiac arrest;
SARC	trans	rs36093844	0.752	rs77497327	chr11:85586941	G/A	cg27065003	chr5:122429449	PRDM6	-0.55	-6.54	-0.39	3.91e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg00409905	chr10:38381863	ZNF37A	-0.55	-7.61	-0.45	6.85e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs12701220	0.744	rs35588238	chr7:1012006	G/A	cg10374962	chr7:1011985	COX19	-0.51	-6.55	-0.39	3.71e-10	Bronchopulmonary dysplasia;
SARC	trans	rs80052780	0.579	rs298467	chr4:139262538	A/C	cg09529783	chr8:1958930	NA	-0.62	-6.48	-0.39	5.26e-10	Response to paliperidone in schizophrenia (Multivariate);
SARC	cis	rs6570726	0.526	rs72994723	chr6:145722948	G/A	cg05347473	chr6:146136440	FBXO30	-0.44	-5.47	-0.34	1.13e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7481584	0.581	rs406598	chr11:3076285	G/A	cg25174290	chr11:3078921	CARS	-0.56	-7.75	-0.45	2.89e-13	Calcium levels;
SARC	cis	rs4555082	0.874	rs56263609	chr14:105756944	C/T	cg10792982	chr14:105748885	BRF1	0.55	8.0	0.46	5.93e-14	Mean platelet volume;Platelet distribution width;
SARC	cis	rs12477438	0.765	rs2309521	chr2:99592069	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-10.27	-0.56	1.2e-20	Chronic sinus infection;
SARC	cis	rs9457247	0.765	rs3752520	chr6:167436159	T/C	cg07741184	chr6:167504864	NA	0.38	7.27	0.43	5.42e-12	Crohn's disease;
SARC	cis	rs7098414	0.511	rs10466236	chr10:82149717	C/T	cg00277334	chr10:82204260	NA	0.4	5.88	0.36	1.44e-8	Post bronchodilator FEV1;
SARC	cis	rs9902453	0.791	rs7219163	chr17:28210703	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	7.17	0.43	9.84e-12	Coffee consumption (cups per day);
SARC	cis	rs1215050	0.791	rs548892	chr4:98724701	C/T	cg05340658	chr4:99064831	C4orf37	0.44	5.81	0.36	2.02e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs10752881	0.967	rs6695837	chr1:182991462	T/C	cg13390022	chr1:182993471	LAMC1	0.34	5.23	0.32	3.79e-7	Colorectal cancer;
SARC	cis	rs17401966	0.838	rs12127604	chr1:10352800	T/G	cg15208524	chr1:10270712	KIF1B	0.45	5.41	0.33	1.53e-7	Hepatocellular carcinoma;
SARC	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.32	-4.8	-0.3	2.78e-6	Total body bone mineral density;
SARC	cis	rs9549260	0.534	rs4943809	chr13:41297404	T/A	cg21288729	chr13:41239152	FOXO1	0.54	4.91	0.31	1.69e-6	Red blood cell count;
SARC	cis	rs73206853	0.841	rs73191839	chr12:110967652	G/T	cg10860002	chr12:110842031	ANAPC7	0.61	5.07	0.31	8.28e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs3126085	0.935	rs1390490	chr1:152161354	T/C	cg03465714	chr1:152285911	FLG	-0.48	-5.51	-0.34	9.66e-8	Atopic dermatitis;
SARC	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	7.3	0.43	4.39e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7084402	0.905	rs7914888	chr10:60308558	T/C	cg07615347	chr10:60278583	BICC1	-0.54	-7.78	-0.45	2.33e-13	Refractive error;
SARC	cis	rs2985684	0.846	rs4476096	chr14:50019391	A/C	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.47	5.23	0.32	3.83e-7	Carotid intima media thickness;
SARC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg24503407	chr1:205819492	PM20D1	-0.79	-12.48	-0.63	1.03e-27	Menarche (age at onset);
SARC	cis	rs3820928	0.904	rs4129884	chr2:227820943	G/A	cg11843606	chr2:227700838	RHBDD1	-0.56	-7.06	-0.42	1.91e-11	Pulmonary function;
SARC	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg01448562	chr3:133502909	NA	0.51	7.89	0.46	1.16e-13	Iron status biomarkers;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg14839808	chr12:28343774	NA	0.49	6.4	0.39	8.56e-10	Chemerin levels;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg05762101	chr4:1857817	LETM1	0.48	6.69	0.4	1.61e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs7772486	0.632	rs9386128	chr6:146049053	G/A	cg23711669	chr6:146136114	FBXO30	-0.8	-12.86	-0.64	5.93e-29	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2576037	0.796	rs2571020	chr18:44584189	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.5	6.54	0.39	3.91e-10	Personality dimensions;
SARC	cis	rs72627123	0.867	rs73303122	chr14:74486797	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.76	5.99	0.37	7.73e-9	Morning vs. evening chronotype;
SARC	cis	rs3859192	0.557	rs12602514	chr17:38159745	A/G	cg17467752	chr17:38218738	THRA	-0.4	-5.14	-0.32	5.89e-7	White blood cell count;
SARC	trans	rs7815944	1.000	rs78225032	chr8:129426320	G/A	cg25487405	chr22:46473039	NA	0.64	6.35	0.38	1.09e-9	Atopic dermatitis;
SARC	cis	rs738322	0.967	rs2092180	chr22:38571563	A/G	cg25457927	chr22:38595422	NA	-0.29	-5.95	-0.36	9.77e-9	Cutaneous nevi;
SARC	cis	rs4742903	0.967	rs10125661	chr9:106868443	A/G	cg21169611	chr9:106856078	SMC2	0.39	4.72	0.3	4.02e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs892961	0.932	rs12452788	chr17:75406866	T/C	cg05865280	chr17:75406074	SEPT9	0.56	8.34	0.48	6.36e-15	Airflow obstruction;
SARC	cis	rs943466	1.000	rs6930201	chr6:33738749	A/C	cg04676172	chr6:33757040	LEMD2	0.45	4.8	0.3	2.82e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
SARC	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg06212747	chr3:49208901	KLHDC8B	0.71	9.58	0.53	1.57e-18	Parkinson's disease;
SARC	cis	rs9640161	0.711	rs60268791	chr7:150023800	G/T	cg10018233	chr7:150070692	REPIN1	0.7	9.92	0.54	1.46e-19	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs80282103	0.764	rs12268949	chr10:1104257	A/G	cg08668510	chr10:1095578	IDI1	0.75	4.9	0.31	1.82e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs11608355	0.846	rs4766472	chr12:109853602	C/G	cg05360138	chr12:110035743	NA	0.59	6.3	0.38	1.46e-9	Neuroticism;
SARC	cis	rs9916302	0.904	rs12952384	chr17:37669536	T/C	cg00129232	chr17:37814104	STARD3	-0.65	-7.96	-0.46	7.56e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs1580019	0.961	rs2392056	chr7:32498953	T/C	cg14728415	chr7:32535168	LSM5;AVL9	0.43	5.08	0.32	7.62e-7	Cognitive ability;
SARC	cis	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg05084668	chr3:125655381	ALG1L	-0.47	-4.89	-0.31	1.88e-6	Blood pressure (smoking interaction);
SARC	cis	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg07777115	chr5:623756	CEP72	-0.62	-5.57	-0.34	6.94e-8	Obesity-related traits;
SARC	cis	rs16976116	0.901	rs28508034	chr15:55499010	T/C	cg11288833	chr15:55489084	RSL24D1	0.63	6.13	0.37	3.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9300255	0.596	rs7304782	chr12:123719444	A/G	cg00376283	chr12:123451042	ABCB9	-0.54	-6.26	-0.38	1.8e-9	Neutrophil percentage of white cells;
SARC	trans	rs453301	0.624	rs330056	chr8:9089695	A/T	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.89	-0.41	5.01e-11	Joint mobility (Beighton score);
SARC	cis	rs240764	0.579	rs240151	chr6:101067720	A/T	cg09795085	chr6:101329169	ASCC3	0.43	5.25	0.33	3.43e-7	Neuroticism;
SARC	cis	rs6088590	1.000	rs55753039	chr20:33394940	C/T	cg24642439	chr20:33292090	TP53INP2	0.88	12.57	0.64	5.37e-28	Coronary artery disease;
SARC	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg19077165	chr18:44547161	KATNAL2	-0.49	-6.79	-0.41	9.33e-11	Personality dimensions;
SARC	cis	rs4588572	0.643	rs3922654	chr5:77684726	G/A	cg11547950	chr5:77652471	NA	0.4	4.83	0.3	2.43e-6	Triglycerides;
SARC	trans	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg21659725	chr3:3221576	CRBN	-0.52	-6.76	-0.4	1.08e-10	Intelligence (multi-trait analysis);
SARC	cis	rs17376456	0.825	rs10214278	chr5:93237679	C/T	cg25358565	chr5:93447407	FAM172A	-1.21	-13.45	-0.66	6.54e-31	Diabetic retinopathy;
SARC	cis	rs72781680	0.716	rs72788284	chr2:24097539	A/G	cg06627628	chr2:24431161	ITSN2	-0.54	-5.79	-0.35	2.21e-8	Lymphocyte counts;
SARC	cis	rs11122272	0.735	rs2749709	chr1:231530476	G/T	cg06096015	chr1:231504339	EGLN1	0.38	5.61	0.34	5.74e-8	Hemoglobin concentration;
SARC	cis	rs11690935	0.632	rs12998411	chr2:172530707	G/C	cg13550731	chr2:172543902	DYNC1I2	0.68	9.4	0.52	5.24e-18	Schizophrenia;
SARC	trans	rs12310956	0.527	rs10772117	chr12:33900096	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.61	0.53	1.27e-18	Morning vs. evening chronotype;
SARC	cis	rs400736	0.894	rs172811	chr1:8039949	A/G	cg25007680	chr1:8021821	PARK7	0.5	6.56	0.39	3.46e-10	Response to antidepressants and depression;
SARC	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg18876405	chr7:65276391	NA	0.68	8.15	0.47	2.28e-14	Aortic root size;
SARC	cis	rs2072499	0.966	rs2853641	chr1:156181770	A/G	cg24450063	chr1:156163899	SLC25A44	0.97	15.3	0.71	4.87e-37	Testicular germ cell tumor;
SARC	trans	rs459571	0.959	rs378740	chr9:136890876	C/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.57	-6.39	-0.39	8.89e-10	Platelet distribution width;
SARC	cis	rs12579753	1.000	rs12827923	chr12:82242067	G/A	cg07988820	chr12:82153109	PPFIA2	-0.52	-6.07	-0.37	5.24e-9	Resting heart rate;
SARC	cis	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg05623727	chr3:50126028	RBM5	-0.34	-5.27	-0.33	3.18e-7	Intelligence (multi-trait analysis);
SARC	cis	rs3857536	0.813	rs2040594	chr6:66943966	A/G	cg07460842	chr6:66804631	NA	-0.45	-5.16	-0.32	5.28e-7	Blood trace element (Cu levels);
SARC	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg24829409	chr8:58192753	C8orf71	-0.65	-6.15	-0.37	3.28e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs17221829	0.733	rs11018668	chr11:89356178	C/T	cg21889116	chr8:56685548	TMEM68;TGS1	-0.47	-6.53	-0.39	4.13e-10	Anxiety in major depressive disorder;
SARC	cis	rs9660992	0.547	rs748012	chr1:205216573	C/T	cg19090574	chr1:205240910	TMCC2	-0.38	-4.89	-0.31	1.88e-6	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs7551222	0.646	rs4951384	chr1:204452514	A/T	cg20240347	chr1:204465584	NA	-0.3	-5.08	-0.32	7.7e-7	Schizophrenia;
SARC	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg00933542	chr6:150070202	PCMT1	0.3	5.08	0.32	7.56e-7	Lung cancer;
SARC	cis	rs11723261	0.527	rs11731581	chr4:87932	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.4	5.39	0.33	1.72e-7	Immune response to smallpox vaccine (IL-6);
SARC	cis	rs1549733	0.559	rs4674193	chr2:218444361	C/T	cg15248979	chr2:219434002	USP37;RQCD1	0.63	5.54	0.34	8.25e-8	Optic disc area;
SARC	cis	rs1153858	1.000	rs56806728	chr15:45637814	A/G	cg14582100	chr15:45693742	SPATA5L1	0.36	5.03	0.31	9.88e-7	Homoarginine levels;
SARC	cis	rs2153535	0.504	rs9405393	chr6:8467432	G/T	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	trans	rs7824557	0.815	rs2572430	chr8:11105304	G/T	cg06636001	chr8:8085503	FLJ10661	0.52	6.49	0.39	5.13e-10	Retinal vascular caliber;
SARC	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg24531977	chr5:56204891	C5orf35	-0.52	-5.29	-0.33	2.8e-7	Initial pursuit acceleration;
SARC	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg23172400	chr8:95962367	TP53INP1	-0.31	-5.34	-0.33	2.26e-7	Type 2 diabetes;
SARC	cis	rs9807841	0.592	rs3810155	chr19:10764867	C/G	cg17710535	chr19:10819994	QTRT1	0.4	4.86	0.3	2.15e-6	Inflammatory skin disease;
SARC	cis	rs2011503	1.000	rs11669730	chr19:19648713	G/A	cg15839431	chr19:19639596	YJEFN3	-0.48	-4.77	-0.3	3.32e-6	Bipolar disorder;
SARC	cis	rs57506017	0.585	rs1548884	chr7:12279761	A/C	cg23422036	chr7:12250390	TMEM106B	0.48	6.36	0.38	1.06e-9	Neuroticism;
SARC	cis	rs910316	1.000	rs12897094	chr14:75579416	C/T	cg06637938	chr14:75390232	RPS6KL1	0.51	7.22	0.43	7.44e-12	Height;
SARC	cis	rs2120243	0.508	rs1456106	chr3:157123456	T/C	cg24825693	chr3:157122686	VEPH1	-0.46	-6.45	-0.39	6.37e-10	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs73242632	0.867	rs35680048	chr4:57932199	A/T	cg20415529	chr4:57845134	POLR2B;C4orf14	0.97	5.81	0.36	2.09e-8	Congenital heart disease (maternal effect);
SARC	cis	rs11112613	0.595	rs871219	chr12:105938519	C/A	cg03607813	chr12:105948248	NA	0.53	7.06	0.42	1.9e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg10523679	chr1:76189770	ACADM	0.52	6.8	0.41	8.82e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg16479474	chr6:28041457	NA	0.35	5.03	0.31	9.78e-7	Parkinson's disease;
SARC	cis	rs1318878	1.000	rs61307591	chr12:15546827	A/T	cg08258403	chr12:15378311	NA	0.46	6.07	0.37	5.26e-9	Intelligence (multi-trait analysis);
SARC	cis	rs10089	0.953	rs2016015	chr5:127527253	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	9.3	0.52	1.02e-17	Ileal carcinoids;
SARC	cis	rs1707322	1.000	rs4660905	chr1:46461587	C/T	cg06784218	chr1:46089804	CCDC17	-0.36	-6.34	-0.38	1.15e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs3733585	0.638	rs28715627	chr4:9958140	T/A	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.36	-0.33	1.96e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs1008375	0.900	rs13144986	chr4:17675019	C/A	cg02297831	chr4:17616191	MED28	-0.42	-5.07	-0.32	8.02e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs71636778	0.631	rs74465889	chr1:27209439	A/G	cg04852280	chr1:26496234	ZNF593	0.58	5.12	0.32	6.47e-7	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg11843238	chr5:131593191	PDLIM4	0.44	6.03	0.37	6.41e-9	Acylcarnitine levels;
SARC	cis	rs9910055	0.530	rs8072954	chr17:42294722	G/A	cg13607699	chr17:42295918	UBTF	0.85	13.59	0.67	2.25e-31	Total body bone mineral density;
SARC	cis	rs12681366	0.663	rs2930970	chr8:95464337	A/G	cg13257157	chr8:95487014	RAD54B	0.39	4.91	0.31	1.68e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs6963495	0.719	rs73190172	chr7:105161210	T/C	cg19920283	chr7:105172520	RINT1	0.65	5.48	0.34	1.09e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs9362426	1.000	rs1203156	chr6:88079694	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.41	4.93	0.31	1.54e-6	Depressive episodes in bipolar disorder;
SARC	cis	rs3733585	0.579	rs4235356	chr4:10123106	G/C	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.26	-0.33	3.34e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	cis	rs8078723	1.000	rs6503530	chr17:38161823	T/C	cg17467752	chr17:38218738	THRA	0.46	5.86	0.36	1.55e-8	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs8014204	0.570	rs7147721	chr14:75186010	A/G	cg17347104	chr14:75034677	LTBP2	-0.44	-5.47	-0.34	1.13e-7	Caffeine consumption;
SARC	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	9.56	0.53	1.74e-18	Platelet count;
SARC	cis	rs11673344	0.566	rs256733	chr19:37875631	C/T	cg14683738	chr19:37701593	ZNF585B	-0.42	-5.03	-0.31	9.8e-7	Obesity-related traits;
SARC	cis	rs4595586	0.525	rs7968566	chr12:39377200	C/T	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	cis	rs12142240	0.660	rs72885163	chr1:46807117	C/A	cg10495392	chr1:46806563	NSUN4	0.65	6.96	0.41	3.41e-11	Menopause (age at onset);
SARC	cis	rs10781543	0.839	rs4379550	chr9:139376426	C/T	cg14169450	chr9:139327907	INPP5E	-0.44	-6.32	-0.38	1.29e-9	Monocyte percentage of white cells;
SARC	cis	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.63	-0.45	5.88e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs9457247	0.935	rs1044059	chr6:167369897	C/A	cg23791538	chr6:167370224	RNASET2	0.62	8.55	0.49	1.67e-15	Crohn's disease;
SARC	trans	rs2727020	0.729	rs1164666	chr11:49295867	C/T	cg15704280	chr7:45808275	SEPT13	-0.83	-13.64	-0.67	1.56e-31	Coronary artery disease;
SARC	cis	rs6060717	0.536	rs7271036	chr20:34467215	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.67	5.64	0.35	5.01e-8	Hip circumference adjusted for BMI;
SARC	cis	rs735539	0.521	rs574139	chr13:21425816	T/G	cg16922012	chr13:21400325	XPO4	-0.44	-6.08	-0.37	4.98e-9	Dental caries;
SARC	cis	rs68130068	0.764	rs12620193	chr2:173164565	A/T	cg26817877	chr2:173539621	NA	0.38	4.75	0.3	3.49e-6	HER2 status in breast cancer;
SARC	cis	rs4800452	0.956	rs4239437	chr18:20732224	A/G	cg13313047	chr18:20735648	CABLES1	-0.46	-5.25	-0.33	3.49e-7	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
SARC	cis	rs2033732	0.706	rs4598249	chr8:85073702	C/T	cg05716166	chr8:85095498	RALYL	0.47	5.64	0.35	4.83e-8	Body mass index;
SARC	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg20203395	chr5:56204925	C5orf35	-0.58	-5.12	-0.32	6.46e-7	Initial pursuit acceleration;
SARC	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg24060327	chr5:131705240	SLC22A5	-0.5	-5.98	-0.36	8.28e-9	Acylcarnitine levels;
SARC	cis	rs9916302	0.904	rs8077104	chr17:37530510	A/G	cg07936489	chr17:37558343	FBXL20	0.69	9.22	0.52	1.85e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs17666538	0.636	rs10107345	chr8:603700	G/T	cg02524346	chr8:600233	NA	0.64	5.49	0.34	1.04e-7	IgG glycosylation;
SARC	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg16405210	chr4:1374714	KIAA1530	0.52	6.13	0.37	3.76e-9	Obesity-related traits;
SARC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg09373136	chr17:61933544	TCAM1	-0.45	-6.16	-0.37	3.18e-9	Prudent dietary pattern;
SARC	cis	rs9486719	0.947	rs12213375	chr6:96902134	A/G	cg18709589	chr6:96969512	KIAA0776	-0.57	-5.78	-0.35	2.42e-8	Migraine;Coronary artery disease;
SARC	cis	rs1728785	0.901	rs11075688	chr16:68655924	A/G	cg02972257	chr16:68554789	NA	0.48	5.67	0.35	4.22e-8	Ulcerative colitis;
SARC	cis	rs10513788	0.665	rs6791143	chr3:181994798	T/C	cg05977900	chr3:182512126	ATP11B	0.49	5.09	0.32	7.48e-7	Cognitive function;
SARC	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg05793240	chr7:2802953	GNA12	-0.36	-5.21	-0.32	4.15e-7	Height;
SARC	trans	rs17685	0.753	rs6464999	chr7:75787315	T/C	cg19862616	chr7:65841803	NCRNA00174	0.63	7.95	0.46	8.05e-14	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs3768617	0.510	rs2093984	chr1:183094314	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.68	10.12	0.55	3.45e-20	Fuchs's corneal dystrophy;
SARC	cis	rs9303401	0.659	rs34913878	chr17:56897094	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.06	12.03	0.62	3.09e-26	Cognitive test performance;
SARC	cis	rs1059312	0.808	rs2170989	chr12:129291317	T/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	-0.5	-7.35	-0.43	3.37e-12	Systemic lupus erythematosus;
SARC	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg21724239	chr8:58056113	NA	0.6	5.85	0.36	1.69e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs763014	0.931	rs7199839	chr16:636126	T/C	cg00908189	chr16:619842	PIGQ	0.83	12.08	0.62	2.01e-26	Height;
SARC	cis	rs72792276	1.000	rs3805608	chr5:127480998	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.65	5.38	0.33	1.84e-7	Red cell distribution width;
SARC	cis	rs11098499	0.535	rs7671759	chr4:120248094	A/C	cg09307838	chr4:120376055	NA	0.81	10.49	0.57	2.4e-21	Corneal astigmatism;
SARC	cis	rs2576037	0.899	rs12955429	chr18:44585484	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.68	-9.4	-0.52	5.31e-18	Personality dimensions;
SARC	cis	rs5758659	0.652	rs133347	chr22:42423645	A/T	cg04733989	chr22:42467013	NAGA	0.54	7.13	0.42	1.27e-11	Cognitive function;
SARC	cis	rs9616064	0.531	rs17821649	chr22:47050387	G/A	cg05621596	chr22:47072043	GRAMD4	-0.6	-8.26	-0.48	1.13e-14	Urate levels in obese individuals;
SARC	cis	rs3771570	1.000	rs62193197	chr2:242294301	G/A	cg21155796	chr2:242212141	HDLBP	0.68	6.09	0.37	4.67e-9	Prostate cancer;
SARC	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg09455208	chr3:40491958	NA	0.37	5.34	0.33	2.25e-7	Renal cell carcinoma;
SARC	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg11890956	chr21:40555474	PSMG1	1.14	15.77	0.72	1.35e-38	Cognitive function;
SARC	cis	rs1707322	0.721	rs10890343	chr1:46157922	C/T	cg06784218	chr1:46089804	CCDC17	0.35	6.12	0.37	3.84e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6582630	0.555	rs10880624	chr12:38526316	C/T	cg13010199	chr12:38710504	ALG10B	0.76	10.65	0.57	7.95e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1707322	0.650	rs4553239	chr1:46150486	C/A	cg03146154	chr1:46216737	IPP	0.52	6.3	0.38	1.45e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs10752881	1.000	rs10752886	chr1:182987248	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.7	0.57	5.56e-22	Colorectal cancer;
SARC	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg06212747	chr3:49208901	KLHDC8B	0.88	13.7	0.67	1.02e-31	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs2594989	0.616	rs6442254	chr3:11474491	T/C	cg00170343	chr3:11313890	ATG7	0.58	5.61	0.35	5.67e-8	Circulating chemerin levels;
SARC	cis	rs72945132	0.882	rs7116191	chr11:70159781	G/A	cg00319359	chr11:70116639	PPFIA1	0.67	6.08	0.37	4.85e-9	Coronary artery disease;
SARC	cis	rs1549118	0.595	rs17106478	chr14:78328310	A/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.48	4.92	0.31	1.61e-6	Resting heart rate;
SARC	cis	rs864537	0.622	rs1214598	chr1:167426424	C/T	cg09179987	chr1:167433047	CD247	0.39	6.18	0.38	2.84e-9	Celiac disease or Rheumatoid arthritis;Celiac disease;
SARC	cis	rs11658309	1	rs11658309	chr17:17762247	T/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.44	-5.72	-0.35	3.18e-8	Strep throat;
SARC	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg22903471	chr2:27725779	GCKR	-0.46	-6.82	-0.41	7.89e-11	Menopause (age at onset);
SARC	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg08859206	chr1:53392774	SCP2	0.39	5.53	0.34	8.44e-8	Monocyte count;
SARC	cis	rs9398803	0.799	rs1538170	chr6:126752874	C/T	cg20229609	chr6:126660872	C6orf173	0.38	5.47	0.34	1.14e-7	Male-pattern baldness;
SARC	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg22168489	chr12:122356033	WDR66	0.63	9.11	0.51	3.82e-17	Mean corpuscular volume;
SARC	cis	rs17331151	0.541	rs1139106	chr3:52871101	G/A	cg04865290	chr3:52927548	TMEM110	-0.6	-5.75	-0.35	2.73e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.8	10.61	0.57	1.04e-21	Prudent dietary pattern;
SARC	trans	rs2727020	0.796	rs7131672	chr11:49274421	A/C	cg15704280	chr7:45808275	SEPT13	0.64	7.39	0.44	2.59e-12	Coronary artery disease;
SARC	cis	rs644799	1.000	rs586238	chr11:95560371	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	14.49	0.69	2.38e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs4718428	0.662	rs34577323	chr7:66310041	G/C	cg12165864	chr7:66369176	NA	-0.44	-4.84	-0.3	2.34e-6	Corneal structure;
SARC	cis	rs2230307	0.536	rs564938	chr1:100592901	T/C	cg24955406	chr1:100503596	HIAT1	-0.72	-7.13	-0.42	1.24e-11	Carotid intima media thickness;
SARC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg11494091	chr17:61959527	GH2	0.54	8.07	0.47	3.82e-14	Prudent dietary pattern;
SARC	cis	rs8141529	0.748	rs5997412	chr22:29276747	G/A	cg15103426	chr22:29168792	CCDC117	0.68	8.9	0.5	1.64e-16	Lymphocyte counts;
SARC	cis	rs3774749	0.565	rs2518795	chr3:50208819	C/T	cg24110177	chr3:50126178	RBM5	-0.37	-4.72	-0.3	4.08e-6	Intelligence (multi-trait analysis);
SARC	cis	rs459571	0.959	rs408307	chr9:136892523	A/G	cg13947528	chr9:136727132	VAV2	-0.34	-4.8	-0.3	2.88e-6	Platelet distribution width;
SARC	cis	rs644799	0.526	rs693172	chr11:95636618	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.74	9.69	0.54	7.31e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs765787	0.530	rs3759895	chr15:45543870	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.67e-7	Uric acid levels;
SARC	cis	rs11097912	0.603	rs12504721	chr4:107178254	C/T	cg09646026	chr4:107269030	AIMP1	0.47	4.82	0.3	2.58e-6	Airflow obstruction;
SARC	cis	rs9916302	0.861	rs9903363	chr17:37499604	C/G	cg20243544	chr17:37824526	PNMT	-0.53	-6.45	-0.39	6.43e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs9457247	1.000	rs9457247	chr6:167392174	C/T	cg07741184	chr6:167504864	NA	0.29	5.49	0.34	1.04e-7	Crohn's disease;
SARC	cis	rs2635047	0.638	rs2668758	chr18:44685679	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.51	6.72	0.4	1.35e-10	Educational attainment;
SARC	cis	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg07636037	chr3:49044803	WDR6	0.65	8.6	0.49	1.19e-15	Resting heart rate;
SARC	cis	rs11098499	0.779	rs7674500	chr4:120303593	C/T	cg09160332	chr4:120329925	NA	-0.33	-4.77	-0.3	3.27e-6	Corneal astigmatism;
SARC	cis	rs365132	0.846	rs812246	chr5:176327644	G/A	cg16309518	chr5:176445507	NA	-0.48	-6.22	-0.38	2.31e-9	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs73206853	0.841	rs59698293	chr12:111054455	C/G	cg10860002	chr12:110842031	ANAPC7	0.63	5.16	0.32	5.39e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs989128	0.600	rs8082568	chr17:48629312	G/C	cg20467136	chr17:48638190	CACNA1G	0.47	5.45	0.34	1.25e-7	Type 2 diabetes;
SARC	cis	rs950027	0.596	rs2467865	chr15:45638307	T/C	cg15395560	chr15:45543142	SLC28A2	-0.27	-5.17	-0.32	5.14e-7	Response to fenofibrate (adiponectin levels);
SARC	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg06969265	chr17:73775802	H3F3B	0.66	7.14	0.42	1.18e-11	Psoriasis;
SARC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg10150615	chr22:24372951	LOC391322	0.44	4.97	0.31	1.27e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9325144	0.647	rs12229104	chr12:39110811	T/A	cg26384229	chr12:38710491	ALG10B	-0.61	-7.8	-0.46	2.04e-13	Morning vs. evening chronotype;
SARC	cis	rs7662987	0.517	rs2851265	chr4:100029684	A/G	cg12011299	chr4:100065546	ADH4	0.34	5.7	0.35	3.53e-8	Smoking initiation;
SARC	cis	rs854765	0.583	rs4413022	chr17:17858280	G/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.43	5.52	0.34	9.04e-8	Total body bone mineral density;
SARC	cis	rs10463554	0.895	rs12656561	chr5:102325692	A/G	cg23492399	chr5:102201601	PAM	-0.43	-5.31	-0.33	2.55e-7	Parkinson's disease;
SARC	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg11764359	chr7:65958608	NA	-0.79	-9.42	-0.52	4.79e-18	Aortic root size;
SARC	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg06212747	chr3:49208901	KLHDC8B	0.66	8.8	0.5	3.19e-16	Parkinson's disease;
SARC	cis	rs7520050	0.898	rs785502	chr1:46581444	T/C	cg24296786	chr1:45957014	TESK2	0.38	4.82	0.3	2.56e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs7918232	0.800	rs7907981	chr10:27444329	T/C	cg14240646	chr10:27532245	ACBD5	-0.5	-4.99	-0.31	1.16e-6	Breast cancer;
SARC	cis	rs4423214	0.559	rs11234042	chr11:71239086	C/A	cg05163923	chr11:71159392	DHCR7	-0.51	-5.11	-0.32	6.81e-7	Vitamin D levels;
SARC	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg18876405	chr7:65276391	NA	-0.47	-5.27	-0.33	3.15e-7	Aortic root size;
SARC	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg24549020	chr5:56110836	MAP3K1	0.81	8.4	0.48	4.37e-15	Initial pursuit acceleration;
SARC	cis	rs554111	0.656	rs4654893	chr1:21305596	G/C	cg04902671	chr1:21058625	SH2D5	0.44	5.4	0.33	1.62e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs2153535	0.601	rs4960414	chr6:8438541	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs7959452	0.535	rs10878953	chr12:69674187	A/G	cg14784868	chr12:69753453	YEATS4	0.4	5.24	0.32	3.61e-7	Blood protein levels;
SARC	trans	rs9395865	0.501	rs2067833	chr6:53330356	A/G	cg24045482	chr1:876993	SAMD11	-0.53	-6.87	-0.41	5.92e-11	Electroencephalographic traits in alcoholism;
SARC	cis	rs876084	0.505	rs12546625	chr8:121155225	C/T	cg06265175	chr8:121136014	COL14A1	0.55	7.18	0.43	9.16e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	trans	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-10.59	-0.57	1.18e-21	Intelligence (multi-trait analysis);
SARC	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg17376030	chr22:41985996	PMM1	-0.64	-7.88	-0.46	1.21e-13	Vitiligo;
SARC	cis	rs3741151	1.000	rs76610873	chr11:73084387	C/T	cg17517138	chr11:73019481	ARHGEF17	0.85	6.41	0.39	8e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs72781680	0.821	rs12623521	chr2:24181670	C/T	cg06627628	chr2:24431161	ITSN2	-0.57	-6.07	-0.37	5.07e-9	Lymphocyte counts;
SARC	cis	rs1949733	1.000	rs2631740	chr4:8484106	C/A	cg11789530	chr4:8429930	ACOX3	-0.82	-11.21	-0.59	1.34e-23	Response to antineoplastic agents;
SARC	cis	rs6912958	1.000	rs6912958	chr6:88133315	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.65	-8.91	-0.5	1.49e-16	Monocyte percentage of white cells;
SARC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg04267008	chr7:1944627	MAD1L1	-0.59	-6.97	-0.42	3.18e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs9393692	0.846	rs9366651	chr6:26336696	G/T	cg05868516	chr6:26286170	HIST1H4H	0.52	6.63	0.4	2.38e-10	Educational attainment;
SARC	cis	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg03213289	chr20:61660250	NA	0.46	6.43	0.39	7.22e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs995000	0.931	rs61471917	chr1:63084030	G/A	cg06896770	chr1:63153194	DOCK7	0.89	13.21	0.65	4.23e-30	Triglyceride levels;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg24361620	chr11:45868787	CRY2	0.54	6.89	0.41	5.06e-11	Lung adenocarcinoma;
SARC	cis	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg18252515	chr7:66147081	NA	-0.96	-9.17	-0.51	2.57e-17	Diabetic kidney disease;
SARC	cis	rs9911578	1.000	rs304292	chr17:56824123	G/A	cg12560992	chr17:57184187	TRIM37	0.88	12.14	0.62	1.31e-26	Intelligence (multi-trait analysis);
SARC	cis	rs651907	0.514	rs34301719	chr3:101417993	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	6.48	0.39	5.53e-10	Colorectal cancer;
SARC	trans	rs56279505	0.629	rs11499828	chr4:100277558	T/C	cg18024358	chr1:3420815	MEGF6	-0.83	-6.4	-0.39	8.29e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs734999	0.588	rs6689711	chr1:2531467	T/C	cg00980319	chr1:2560884	MMEL1	0.35	4.95	0.31	1.42e-6	Ulcerative colitis;
SARC	cis	rs6910061	0.830	rs36021520	chr6:11106122	C/T	cg27233058	chr6:11094804	LOC221710	0.61	5.54	0.34	8.11e-8	Diabetic kidney disease;
SARC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.73	7.01	0.42	2.53e-11	Platelet count;
SARC	cis	rs9394841	0.667	rs9471667	chr6:41776681	T/C	cg08135965	chr6:41755394	TOMM6	0.61	6.46	0.39	6.11e-10	Mean corpuscular hemoglobin;Red cell distribution width;
SARC	cis	rs713587	0.563	rs7605335	chr2:25109317	G/A	cg04586622	chr2:25135609	ADCY3	0.32	5.62	0.35	5.44e-8	Body mass index in non-asthmatics;
SARC	cis	rs7552404	0.731	rs11161836	chr1:76354333	C/T	cg22875332	chr1:76189707	ACADM	0.41	5.06	0.31	8.69e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs10870270	1.000	rs4880246	chr10:133764064	C/T	cg26149184	chr10:133730230	NA	0.47	5.18	0.32	4.84e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg11890956	chr21:40555474	PSMG1	1.04	16.03	0.72	1.71e-39	Cognitive function;
SARC	cis	rs7264396	0.580	rs2064511	chr20:34448810	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.56	-5.41	-0.33	1.53e-7	Total cholesterol levels;
SARC	cis	rs9902453	0.904	rs55633288	chr17:28368196	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.16	-0.42	1.02e-11	Coffee consumption (cups per day);
SARC	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	27.41	0.87	7.3e-75	Chronic sinus infection;
SARC	cis	rs356220	0.632	rs356166	chr4:90649290	C/G	cg06632027	chr4:90757378	SNCA	0.41	5.15	0.32	5.51e-7	Parkinson's disease;
SARC	cis	rs208520	0.690	rs12204512	chr6:66710486	C/T	cg07460842	chr6:66804631	NA	1.06	14.43	0.69	3.63e-34	Exhaled nitric oxide output;
SARC	cis	rs9911578	0.935	rs34523895	chr17:57034095	T/C	cg12560992	chr17:57184187	TRIM37	0.68	8.66	0.49	7.95e-16	Intelligence (multi-trait analysis);
SARC	cis	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg25427524	chr10:38739819	LOC399744	-0.61	-9.71	-0.54	6.09e-19	Extrinsic epigenetic age acceleration;
SARC	cis	rs11190604	1.000	rs10883513	chr10:102316964	A/G	cg14256752	chr10:102295592	HIF1AN	0.52	5.15	0.32	5.53e-7	Palmitoleic acid (16:1n-7) levels;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg15786971	chr19:55795459	BRSK1	-0.62	-6.28	-0.38	1.66e-9	Lung cancer in ever smokers;
SARC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg04234412	chr22:24373322	LOC391322	0.54	6.24	0.38	2e-9	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.37	-4.73	-0.3	3.92e-6	Lymphocyte counts;
SARC	cis	rs6908034	0.607	rs73376657	chr6:19805960	C/T	cg02682789	chr6:19804855	NA	0.72	5.45	0.34	1.31e-7	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg05863683	chr7:1912471	MAD1L1	0.37	5.53	0.34	8.46e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs4319547	0.656	rs2173582	chr12:122824694	A/G	cg23029597	chr12:123009494	RSRC2	-0.42	-5.32	-0.33	2.43e-7	Body mass index;
SARC	cis	rs708547	0.830	rs1713983	chr4:57883084	A/G	cg14719990	chr4:57843890	C4orf14;POLR2B	0.42	4.79	0.3	2.94e-6	Response to bleomycin (chromatid breaks);
SARC	cis	rs7667	0.812	rs12042240	chr1:19768571	A/G	cg15311933	chr1:19638897	PQLC2;AKR7A2	-0.42	-4.87	-0.3	2.07e-6	Crohn's disease and psoriasis;
SARC	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	9.53	0.53	2.12e-18	Platelet count;
SARC	cis	rs2396545	0.680	rs35467761	chr11:571568	A/G	cg15790184	chr11:494944	RNH1	0.38	4.72	0.3	4.12e-6	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs72781680	1.000	rs56339200	chr2:24188194	C/A	cg06627628	chr2:24431161	ITSN2	-0.7	-6.71	-0.4	1.49e-10	Lymphocyte counts;
SARC	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg18252515	chr7:66147081	NA	0.45	4.91	0.31	1.68e-6	Aortic root size;
SARC	cis	rs8064299	0.597	rs9944506	chr17:72782726	C/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.79	10.59	0.57	1.17e-21	Monocyte count;
SARC	trans	rs9929218	0.551	rs2296405	chr16:68721470	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.89	-15.57	-0.71	6.03e-38	Colorectal cancer;
SARC	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg05368731	chr17:41323189	NBR1	0.73	8.7	0.5	6.12e-16	Menopause (age at onset);
SARC	cis	rs3126085	0.935	rs2184953	chr1:152280782	A/G	cg26876637	chr1:152193138	HRNR	-0.47	-5.31	-0.33	2.54e-7	Atopic dermatitis;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg16124546	chr10:74927855	ECD;FAM149B1	-0.48	-6.46	-0.39	5.9e-10	Schizophrenia;
SARC	cis	rs3857536	0.785	rs6455089	chr6:66944733	A/C	cg07460842	chr6:66804631	NA	-0.45	-5.19	-0.32	4.5e-7	Blood trace element (Cu levels);
SARC	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg03351412	chr1:154909251	PMVK	0.62	8.06	0.47	3.86e-14	Prostate cancer;
SARC	cis	rs7937682	1.000	rs11608122	chr11:111535105	C/T	cg22437258	chr11:111473054	SIK2	-0.71	-9.13	-0.51	3.37e-17	Primary sclerosing cholangitis;
SARC	cis	rs116095464	0.558	rs62346506	chr5:201594	T/C	cg22857025	chr5:266934	NA	-1.15	-10.78	-0.58	2.97e-22	Breast cancer;
SARC	cis	rs3761847	0.622	rs10818500	chr9:123810883	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.4	-5.0	-0.31	1.12e-6	Rheumatoid arthritis;
SARC	cis	rs10416265	0.502	rs7245411	chr19:33543029	A/T	cg27124370	chr19:33622961	WDR88	0.5	6.55	0.39	3.69e-10	Bone properties (heel);
SARC	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg18876405	chr7:65276391	NA	-0.46	-5.58	-0.34	6.58e-8	Aortic root size;
SARC	cis	rs34375054	0.715	rs35933435	chr12:125632116	G/A	cg25124228	chr12:125621409	AACS	-0.56	-5.79	-0.35	2.28e-8	Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs4588572	0.686	rs116246588	chr5:77683144	T/G	cg11547950	chr5:77652471	NA	0.4	4.87	0.3	2.11e-6	Triglycerides;
SARC	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg26335602	chr6:28129616	ZNF389	0.45	5.19	0.32	4.61e-7	Cardiac Troponin-T levels;
SARC	cis	rs2011503	0.882	rs10401714	chr19:19363630	G/A	cg03709012	chr19:19516395	GATAD2A	0.6	5.46	0.34	1.22e-7	Bipolar disorder;
SARC	trans	rs9650657	0.836	rs891556	chr8:10623633	G/C	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.63	-0.4	2.27e-10	Neuroticism;
SARC	cis	rs7524258	0.903	rs4908449	chr1:7292700	T/C	cg07173049	chr1:7289937	CAMTA1	0.41	7.97	0.46	7.07e-14	Tourette's syndrome or obsessive-compulsive disorder;
SARC	cis	rs9467773	0.620	rs4368798	chr6:26593471	A/G	cg11502198	chr6:26597334	ABT1	0.66	8.87	0.5	1.97e-16	Intelligence (multi-trait analysis);
SARC	cis	rs668210	0.793	rs507672	chr11:65767153	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.7	-7.35	-0.43	3.27e-12	Cerebrospinal fluid biomarker levels;
SARC	trans	rs9329221	0.683	rs688491	chr8:9884823	C/G	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.88	-0.41	5.39e-11	Neuroticism;
SARC	cis	rs6570726	0.902	rs4895678	chr6:145935510	C/T	cg05220968	chr6:146057943	EPM2A	-0.3	-5.08	-0.32	7.62e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7937682	0.921	rs688354	chr11:111438762	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.84	-12.56	-0.64	5.63e-28	Primary sclerosing cholangitis;
SARC	cis	rs34172651	0.876	rs2547033	chr16:24743657	C/T	cg00152838	chr16:24741724	TNRC6A	-0.4	-4.83	-0.3	2.47e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2594989	0.836	rs1546231	chr3:11513678	T/G	cg00170343	chr3:11313890	ATG7	0.52	5.14	0.32	5.85e-7	Circulating chemerin levels;
SARC	cis	rs3087591	0.919	rs2285892	chr17:29553485	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.47	-5.77	-0.35	2.52e-8	Hip circumference;
SARC	cis	rs7937682	0.632	rs4936800	chr11:111734097	T/A	cg09085632	chr11:111637200	PPP2R1B	0.78	10.33	0.56	7.51e-21	Primary sclerosing cholangitis;
SARC	cis	rs9916302	0.660	rs4795367	chr17:37608843	G/C	cg20243544	chr17:37824526	PNMT	0.53	5.61	0.34	5.71e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs72781680	0.756	rs2712059	chr2:24020539	T/C	cg08917208	chr2:24149416	ATAD2B	0.58	5.98	0.36	8.29e-9	Lymphocyte counts;
SARC	cis	rs4481887	0.927	rs4292985	chr1:248473692	T/A	cg01631408	chr1:248437212	OR2T33	-0.39	-5.04	-0.31	9.2e-7	Common traits (Other);
SARC	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg11890956	chr21:40555474	PSMG1	-0.68	-9.07	-0.51	5.03e-17	Menarche (age at onset);
SARC	cis	rs9325144	0.577	rs10876008	chr12:39126750	T/C	cg13010199	chr12:38710504	ALG10B	-0.49	-6.08	-0.37	4.82e-9	Morning vs. evening chronotype;
SARC	cis	rs11997175	0.545	rs4733457	chr8:33661236	G/A	ch.8.33884649F	chr8:33765107	NA	0.48	6.16	0.37	3.23e-9	Body mass index;
SARC	cis	rs9818758	0.607	rs35283189	chr3:49113668	T/C	cg07636037	chr3:49044803	WDR6	-0.78	-6.78	-0.41	9.86e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs35417517	1	rs35417517	chr7:91772730	CG/C	cg17063962	chr7:91808500	NA	0.98	17.35	0.75	7.27e-44	Breast cancer;
SARC	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg09455208	chr3:40491958	NA	0.35	5.35	0.33	2.1e-7	Renal cell carcinoma;
SARC	trans	rs1973993	0.967	rs2181375	chr1:96940119	A/G	cg10631902	chr5:14652156	NA	0.45	7.65	0.45	5.36e-13	Weight;
SARC	cis	rs372883	0.600	rs1236460	chr21:30615513	G/A	cg24692254	chr21:30365293	RNF160	-0.66	-8.44	-0.48	3.44e-15	Pancreatic cancer;
SARC	cis	rs763121	0.853	rs5757213	chr22:39053888	C/T	cg06022373	chr22:39101656	GTPBP1	0.9	11.56	0.6	9.96e-25	Menopause (age at onset);
SARC	cis	rs10876993	0.928	rs2640636	chr12:58077544	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.43	-5.36	-0.33	1.96e-7	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs2153535	0.580	rs1120392	chr6:8487053	C/A	cg21535247	chr6:8435926	SLC35B3	0.55	6.9	0.41	4.76e-11	Motion sickness;
SARC	cis	rs9399137	0.561	rs11753985	chr6:135280438	C/T	cg24558204	chr6:135376177	HBS1L	0.59	7.64	0.45	5.5e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs7624766	0.901	rs7633816	chr3:160461351	C/T	cg22637730	chr3:160473554	PPM1L	0.42	5.48	0.34	1.12e-7	Response to methotrexate in rheumatoid arthritis;
SARC	cis	rs7587476	0.682	rs13009646	chr2:215691259	T/A	cg04004882	chr2:215674386	BARD1	0.56	6.4	0.39	8.5e-10	Neuroblastoma;
SARC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.57	0.8	2.65e-54	Prudent dietary pattern;
SARC	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg12463550	chr7:65579703	CRCP	-0.5	-5.55	-0.34	7.9e-8	Aortic root size;
SARC	cis	rs2841277	0.676	rs10438247	chr14:105411781	G/A	cg21017887	chr14:105400489	NA	0.51	7.16	0.42	1.02e-11	Rheumatoid arthritis;
SARC	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.64	-7.64	-0.45	5.7e-13	Gut microbiome composition (summer);
SARC	cis	rs7524258	0.778	rs12028181	chr1:7315085	C/T	cg07173049	chr1:7289937	CAMTA1	-0.31	-5.97	-0.36	8.74e-9	Tourette's syndrome or obsessive-compulsive disorder;
SARC	cis	rs9916302	0.851	rs11078906	chr17:37662767	C/T	cg15445000	chr17:37608096	MED1	0.41	4.83	0.3	2.48e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs9435341	0.930	rs2232015	chr1:107599258	A/T	cg09367891	chr1:107599246	PRMT6	0.74	9.19	0.52	2.31e-17	Facial morphology (factor 21, depth of nasal alae);
SARC	cis	rs1832871	0.672	rs6933928	chr6:158747071	C/T	cg07165851	chr6:158734300	TULP4	0.58	6.77	0.41	1.05e-10	Height;
SARC	cis	rs9612	1.000	rs2074634	chr19:44238347	C/T	cg07522664	chr19:44259120	C19orf61	-0.48	-5.56	-0.34	7.38e-8	Exhaled nitric oxide output;
SARC	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg26681399	chr22:41777847	TEF	0.43	4.98	0.31	1.22e-6	Vitiligo;
SARC	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-15.3	-0.71	4.7e-37	Chronic sinus infection;
SARC	cis	rs9393692	0.905	rs6931391	chr6:26279235	G/C	cg00631329	chr6:26305371	NA	-0.62	-9.05	-0.51	5.82e-17	Educational attainment;
SARC	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg13126279	chr21:47581558	C21orf56	-0.45	-5.2	-0.32	4.39e-7	Testicular germ cell tumor;
SARC	cis	rs7633770	0.710	rs4683259	chr3:46698538	A/G	cg11219411	chr3:46661640	NA	-0.37	-5.67	-0.35	4.23e-8	Coronary artery disease;
SARC	cis	rs34311866	0.808	rs748483	chr4:952409	A/G	cg07828340	chr4:882639	GAK	0.73	5.49	0.34	1.05e-7	Parkinson's disease;
SARC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg08280861	chr8:58055591	NA	0.61	5.94	0.36	1.01e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6912958	0.781	rs9444504	chr6:88181046	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-5.63	-0.35	5.17e-8	Monocyte percentage of white cells;
SARC	cis	rs10504073	0.647	rs10957357	chr8:49988587	C/A	cg00325661	chr8:49890786	NA	0.52	6.97	0.42	3.19e-11	Blood metabolite ratios;
SARC	cis	rs17376456	0.825	rs28412976	chr5:93248377	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.57	0.34	6.9e-8	Diabetic retinopathy;
SARC	cis	rs875971	0.545	rs12673308	chr7:65631361	C/A	cg11764359	chr7:65958608	NA	0.67	6.65	0.4	2.03e-10	Aortic root size;
SARC	cis	rs8060686	0.545	rs3815173	chr16:68160289	T/G	cg09117114	chr16:67998030	SLC12A4	-0.49	-4.71	-0.3	4.2e-6	HDL cholesterol;Metabolic syndrome;
SARC	cis	rs644799	0.965	rs1944080	chr11:95503636	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	15.46	0.71	1.39e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs1712517	0.873	rs1163083	chr10:105038455	T/A	cg05636881	chr10:105038444	INA	0.33	4.87	0.3	2.03e-6	Migraine;
SARC	cis	rs10489202	0.608	rs7556350	chr1:168077797	C/T	cg24449463	chr1:168025552	DCAF6	-0.57	-7.26	-0.43	5.7e-12	Schizophrenia;
SARC	cis	rs7932354	0.528	rs11039074	chr11:47081732	C/T	cg03339077	chr11:47165057	C11orf49	-0.39	-5.23	-0.32	3.76e-7	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs6582630	0.599	rs1589392	chr12:38418535	G/C	cg26384229	chr12:38710491	ALG10B	-0.55	-6.89	-0.41	5.04e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs12911832	1.000	rs12911961	chr15:58985867	C/T	cg05156742	chr15:59063176	FAM63B	0.64	8.04	0.47	4.49e-14	Schizophrenia;
SARC	cis	rs897984	0.568	rs4889653	chr16:30895713	C/T	cg00531865	chr16:30841666	NA	0.48	5.09	0.32	7.34e-7	Dementia with Lewy bodies;
SARC	cis	rs854765	0.647	rs7406744	chr17:17981938	C/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.41	5.19	0.32	4.5e-7	Total body bone mineral density;
SARC	cis	rs7756236	0.521	rs11969445	chr6:36625382	C/T	cg08179530	chr6:36648295	CDKN1A	-0.54	-6.67	-0.4	1.89e-10	QRS duration;
SARC	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg05368731	chr17:41323189	NBR1	0.79	9.57	0.53	1.59e-18	Menopause (age at onset);
SARC	cis	rs6674176	0.628	rs4660759	chr1:44432500	C/G	cg13606994	chr1:44402422	ARTN	-0.33	-5.42	-0.33	1.48e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg06074448	chr4:187884817	NA	-0.37	-5.07	-0.32	8.2e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs995000	0.931	rs11207996	chr1:63055470	G/A	cg06896770	chr1:63153194	DOCK7	0.98	15.31	0.71	4.29e-37	Triglyceride levels;
SARC	cis	rs2204008	0.652	rs11520002	chr12:38022179	G/T	cg26384229	chr12:38710491	ALG10B	0.89	13.1	0.65	9.74e-30	Bladder cancer;
SARC	cis	rs11098499	0.908	rs1002152	chr4:120273387	C/A	cg24375607	chr4:120327624	NA	0.4	4.84	0.3	2.36e-6	Corneal astigmatism;
SARC	cis	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg05623727	chr3:50126028	RBM5	-0.32	-4.74	-0.3	3.76e-6	Body mass index;
SARC	cis	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.77	-0.41	1.02e-10	Joint mobility (Beighton score);
SARC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg11494091	chr17:61959527	GH2	0.53	7.96	0.46	7.52e-14	Prudent dietary pattern;
SARC	cis	rs6988636	1.000	rs11993411	chr8:124180537	T/C	cg23067535	chr8:124195133	FAM83A	-0.66	-4.84	-0.3	2.33e-6	Urinary uromodulin levels;
SARC	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg07343612	chr16:622815	PIGQ	-0.58	-8.15	-0.47	2.24e-14	Height;
SARC	cis	rs7959452	0.503	rs7300266	chr12:69654187	A/G	cg20891283	chr12:69753455	YEATS4	0.39	5.12	0.32	6.37e-7	Blood protein levels;
SARC	cis	rs78487399	0.808	rs6544669	chr2:43736171	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-4.94	-0.31	1.52e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs10504229	0.593	rs80174614	chr8:58024631	G/A	cg20607798	chr8:58055168	NA	0.62	5.51	0.34	9.38e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs28655083	0.956	rs11863953	chr16:77065710	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.46	-6.44	-0.39	6.74e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1949733	0.877	rs940133	chr4:8473614	T/C	cg11789530	chr4:8429930	ACOX3	0.81	9.84	0.54	2.42e-19	Response to antineoplastic agents;
SARC	trans	rs12310956	0.510	rs4931758	chr12:33871870	C/T	cg13010199	chr12:38710504	ALG10B	0.57	7.38	0.44	2.8e-12	Morning vs. evening chronotype;
SARC	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	11.05	0.59	4.24e-23	Platelet count;
SARC	cis	rs1843834	0.539	rs10177898	chr2:225437552	C/T	cg22455342	chr2:225449267	CUL3	0.67	8.46	0.48	3.07e-15	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.73	6.95	0.41	3.68e-11	Platelet count;
SARC	cis	rs748404	0.578	rs576557	chr15:43597737	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	6.82	0.41	7.9e-11	Lung cancer;
SARC	cis	rs9549367	0.789	rs9549365	chr13:113907391	C/T	cg18105134	chr13:113819100	PROZ	0.35	5.34	0.33	2.17e-7	Platelet distribution width;
SARC	cis	rs4481887	1.000	rs9660769	chr1:248484558	C/G	cg01631408	chr1:248437212	OR2T33	0.46	5.43	0.34	1.4e-7	Common traits (Other);
SARC	cis	rs73206853	0.764	rs7312139	chr12:110985442	C/A	cg10860002	chr12:110842031	ANAPC7	0.58	4.82	0.3	2.64e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs898097	0.607	rs2199111	chr17:80823203	A/G	cg20578329	chr17:80767326	TBCD	-0.35	-4.92	-0.31	1.63e-6	Breast cancer;
SARC	cis	rs943466	1.000	rs6940353	chr6:33752550	G/A	cg04676172	chr6:33757040	LEMD2	0.45	4.78	0.3	3.1e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
SARC	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg20891283	chr12:69753455	YEATS4	0.66	9.45	0.53	3.79e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs4803468	0.967	rs11083619	chr19:41913267	A/C	cg09537434	chr19:41945824	ATP5SL	-0.97	-16.94	-0.74	1.74e-42	Height;
SARC	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg17221315	chr6:27791827	HIST1H4J	0.46	4.84	0.3	2.35e-6	Depression;
SARC	cis	rs67133203	0.632	rs706802	chr12:51373742	C/T	cg13576200	chr12:52111417	SCN8A	0.33	4.87	0.3	2.06e-6	Urinary tract infection frequency;
SARC	cis	rs140244541	1	rs140244541	chr2:203808532	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.63	6.18	0.38	2.9e-9	LDL cholesterol;
SARC	cis	rs7666738	0.791	rs10022061	chr4:98926821	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9807989	0.507	rs1420096	chr2:103010912	C/T	cg03938978	chr2:103052716	IL18RAP	0.31	5.07	0.32	7.94e-7	Asthma;
SARC	cis	rs9682041	0.627	rs11924474	chr3:170091333	T/G	cg11886554	chr3:170076028	SKIL	0.67	6.54	0.39	3.8e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg11890956	chr21:40555474	PSMG1	-1.01	-14.85	-0.7	1.51e-35	Cognitive function;
SARC	cis	rs8078723	0.510	rs3859189	chr17:38137033	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.31	5.68	0.35	3.98e-8	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg09699651	chr6:150184138	LRP11	0.39	4.8	0.3	2.79e-6	Lung cancer;
SARC	trans	rs61931739	0.534	rs10844800	chr12:34230734	A/G	cg26384229	chr12:38710491	ALG10B	0.84	12.03	0.62	3.02e-26	Morning vs. evening chronotype;
SARC	cis	rs17376456	0.542	rs2084916	chr5:93194961	A/T	cg21475434	chr5:93447410	FAM172A	-0.64	-6.37	-0.39	9.72e-10	Diabetic retinopathy;
SARC	cis	rs2652834	1.000	rs2652835	chr15:63396408	T/C	cg05507819	chr15:63340323	TPM1	0.55	5.52	0.34	9.16e-8	HDL cholesterol;
SARC	cis	rs11122272	0.735	rs2474634	chr1:231487017	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-9.91	-0.54	1.5e-19	Hemoglobin concentration;
SARC	cis	rs644799	1.000	rs544119	chr11:95538624	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.7	9.55	0.53	1.87e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs1065656	0.553	rs344357	chr16:1836255	C/G	cg07870479	chr16:1813987	MAPK8IP3	0.49	5.99	0.37	8.1e-9	Insulin-like growth factors;
SARC	cis	rs7772486	0.790	rs2265917	chr6:146212285	A/G	cg23711669	chr6:146136114	FBXO30	0.8	12.59	0.64	4.55e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg05623727	chr3:50126028	RBM5	0.33	5.0	0.31	1.14e-6	Intelligence (multi-trait analysis);
SARC	cis	rs12579753	0.917	rs11610365	chr12:82218108	C/T	cg07988820	chr12:82153109	PPFIA2	-0.49	-5.45	-0.34	1.28e-7	Resting heart rate;
SARC	cis	rs2908197	0.765	rs2098205	chr7:75938888	A/G	cg22830091	chr7:75961684	YWHAG	-0.33	-4.84	-0.3	2.38e-6	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg23131131	chr22:24373011	LOC391322	0.44	5.08	0.32	7.67e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg11987759	chr7:65425863	GUSB	0.49	6.14	0.37	3.48e-9	Aortic root size;
SARC	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg13393036	chr8:95962371	TP53INP1	-0.36	-6.21	-0.38	2.38e-9	Type 2 diabetes;
SARC	cis	rs10958369	0.871	rs2126793	chr8:54399039	C/A	cg12485204	chr8:54507357	NA	0.36	5.25	0.33	3.43e-7	Response to antineoplastic agents;
SARC	cis	rs787274	1.000	rs7859175	chr9:115587160	G/A	cg13803584	chr9:115635662	SNX30	-0.83	-5.03	-0.31	9.96e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs9943753	0.508	rs5013021	chr12:109790752	C/A	cg19025524	chr12:109796872	NA	-0.4	-5.68	-0.35	4.07e-8	HDL cholesterol;
SARC	cis	rs3796352	1.000	rs114562844	chr3:52991584	C/T	cg15956490	chr3:53032818	SFMBT1	0.79	5.18	0.32	4.85e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs921968	0.541	rs485975	chr2:219374250	C/T	cg02176678	chr2:219576539	TTLL4	0.46	7.12	0.42	1.33e-11	Mean corpuscular hemoglobin concentration;
SARC	cis	rs2228479	0.541	rs12918575	chr16:89811151	A/G	cg00800038	chr16:89945340	TCF25	-0.66	-5.1	-0.32	7.1e-7	Skin colour saturation;
SARC	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg06028808	chr11:68637592	NA	0.43	5.46	0.34	1.2e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs1559088	0.947	rs10403238	chr19:33552405	A/G	cg17764715	chr19:33622953	WDR88	0.49	6.39	0.39	8.87e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs798554	0.607	rs1182151	chr7:2909225	C/G	cg04166393	chr7:2884313	GNA12	0.58	5.78	0.35	2.33e-8	Height;
SARC	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg04944784	chr2:26401820	FAM59B	-0.49	-6.31	-0.38	1.4e-9	Gut microbiome composition (summer);
SARC	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	20.88	0.81	2.75e-55	Chronic sinus infection;
SARC	cis	rs72627123	0.867	rs73303113	chr14:74481068	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.74	5.84	0.36	1.78e-8	Morning vs. evening chronotype;
SARC	cis	rs634534	0.562	rs661335	chr11:65754061	G/A	cg26695010	chr11:65641043	EFEMP2	-0.55	-7.08	-0.42	1.66e-11	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs7843479	0.930	rs4871903	chr8:21827833	C/T	cg17168535	chr8:21777572	XPO7	-0.6	-7.61	-0.45	6.74e-13	Mean corpuscular volume;
SARC	cis	rs6963495	0.818	rs711430	chr7:105167969	A/G	cg13798780	chr7:105162888	PUS7	0.47	4.74	0.3	3.7e-6	Bipolar disorder (body mass index interaction);
SARC	cis	rs9790314	0.747	rs1599378	chr3:160874511	A/C	cg04691961	chr3:161091175	C3orf57	-0.63	-8.21	-0.47	1.55e-14	Morning vs. evening chronotype;
SARC	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg05368731	chr17:41323189	NBR1	-0.72	-8.56	-0.49	1.59e-15	Menopause (age at onset);
SARC	trans	rs11098499	0.909	rs7681978	chr4:120383775	T/C	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	cis	rs796364	0.806	rs4673634	chr2:200863349	A/C	cg23649088	chr2:200775458	C2orf69	0.6	5.35	0.33	2.08e-7	Schizophrenia;
SARC	cis	rs12545912	0.863	rs10087749	chr8:9461815	T/C	cg21625330	chr8:9911636	MSRA	-0.52	-4.96	-0.31	1.38e-6	Multiple myeloma (hyperdiploidy);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg02657244	chr4:99183198	RAP1GDS1	-0.56	-6.25	-0.38	1.95e-9	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs2439831	1.000	rs2256764	chr15:43735763	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.78	7.02	0.42	2.4e-11	Lung cancer in ever smokers;
SARC	cis	rs6912958	0.754	rs10755484	chr6:88244648	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.51	-6.89	-0.41	5.24e-11	Monocyte percentage of white cells;
SARC	cis	rs12912251	0.947	rs7177621	chr15:38999394	C/G	cg01338139	chr15:38987640	C15orf53	-0.47	-5.04	-0.31	9.45e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
SARC	cis	rs6582630	0.502	rs10880388	chr12:38401341	A/T	cg26384229	chr12:38710491	ALG10B	0.85	12.08	0.62	2.08e-26	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg11062466	chr8:58055876	NA	0.54	5.53	0.34	8.37e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2153535	0.541	rs9379207	chr6:8458186	C/T	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.04e-14	Motion sickness;
SARC	cis	rs910316	0.967	rs11159116	chr14:75550584	G/T	cg06637938	chr14:75390232	RPS6KL1	0.53	7.65	0.45	5.29e-13	Height;
SARC	cis	rs12579753	1.000	rs17692461	chr12:82171755	C/G	cg07988820	chr12:82153109	PPFIA2	-0.63	-7.13	-0.42	1.25e-11	Resting heart rate;
SARC	cis	rs2180341	0.695	rs6569487	chr6:127726196	C/T	cg27446573	chr6:127587934	RNF146	-0.71	-9.51	-0.53	2.42e-18	Breast cancer;
SARC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.63	-0.4	2.28e-10	Total body bone mineral density;
SARC	cis	rs1153858	0.621	rs12913645	chr15:45555066	G/A	cg19305227	chr15:45544335	SLC28A2	0.29	5.18	0.32	4.83e-7	Homoarginine levels;
SARC	cis	rs4642101	0.737	rs6767504	chr3:12826667	C/T	cg12400702	chr3:12838781	CAND2	-0.26	-5.13	-0.32	6.01e-7	QRS complex (12-leadsum);
SARC	cis	rs67311347	0.955	rs11719205	chr3:40417258	G/A	cg09455208	chr3:40491958	NA	0.42	6.55	0.39	3.64e-10	Renal cell carcinoma;
SARC	cis	rs8077889	0.750	rs231533	chr17:41945588	A/G	cg26893861	chr17:41843967	DUSP3	-0.72	-7.04	-0.42	2.16e-11	Triglycerides;
SARC	cis	rs4417855	0.794	rs7633309	chr3:187427720	T/C	cg08969912	chr3:187456781	BCL6	-0.42	-5.0	-0.31	1.12e-6	Granulocyte percentage of myeloid white cells;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg26420824	chr1:28562883	ATPIF1	0.5	6.61	0.4	2.57e-10	Chemerin levels;
SARC	cis	rs4664308	1.000	rs6759924	chr2:160912747	G/A	cg03641300	chr2:160917029	PLA2R1	-0.66	-8.52	-0.49	1.95e-15	Idiopathic membranous nephropathy;
SARC	cis	rs6484504	0.553	rs7113880	chr11:31279557	A/G	cg02090638	chr11:31391270	DNAJC24;DCDC1	-0.43	-5.52	-0.34	9.01e-8	Red blood cell count;
SARC	cis	rs3733585	0.699	rs1079128	chr4:9951221	T/C	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.36	-0.33	1.95e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs4276643	0.531	rs2685409	chr8:27817747	G/A	cg25028855	chr8:28560486	EXTL3	0.33	4.91	0.31	1.71e-6	Low vWF levels;
SARC	cis	rs897080	0.515	rs1067356	chr2:44663072	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	5.79	0.35	2.29e-8	Height;
SARC	cis	rs7089973	0.604	rs55759483	chr10:116573423	T/C	cg03647239	chr10:116582469	FAM160B1	0.52	6.7	0.4	1.53e-10	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	5.06	0.31	8.4e-7	Personality dimensions;
SARC	cis	rs11122272	0.733	rs2749700	chr1:231522734	A/G	cg06096015	chr1:231504339	EGLN1	0.38	5.8	0.35	2.19e-8	Hemoglobin concentration;
SARC	cis	rs1348850	0.872	rs2084233	chr2:178331206	G/A	cg23306229	chr2:178417860	TTC30B	0.56	6.51	0.39	4.45e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg00933542	chr6:150070202	PCMT1	0.31	5.24	0.32	3.56e-7	Lung cancer;
SARC	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.37	0.39	9.96e-10	Height;
SARC	cis	rs9790314	0.502	rs2404342	chr3:161092562	C/T	cg17135325	chr3:160939158	NMD3	0.6	7.5	0.44	1.34e-12	Morning vs. evening chronotype;
SARC	cis	rs7312774	0.748	rs1861746	chr12:107301518	G/A	cg16260113	chr12:107380972	MTERFD3	0.76	6.62	0.4	2.41e-10	Severe influenza A (H1N1) infection;
SARC	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.98	9.98	0.55	9.48e-20	Platelet count;
SARC	cis	rs3923518	0.956	rs4320030	chr3:38928112	T/C	cg15678707	chr3:39149194	GORASP1;TTC21A	0.48	5.1	0.32	7.15e-7	Migraine;
SARC	cis	rs2204008	0.668	rs1619009	chr12:38120485	G/A	cg26384229	chr12:38710491	ALG10B	-0.66	-8.64	-0.49	9.24e-16	Bladder cancer;
SARC	cis	rs2153535	0.580	rs1414349	chr6:8472290	A/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs11098499	0.710	rs6851130	chr4:120133712	G/A	cg09307838	chr4:120376055	NA	-0.78	-10.49	-0.57	2.38e-21	Corneal astigmatism;
SARC	cis	rs10207060	0.771	rs4852124	chr2:240680022	C/T	cg20333904	chr2:240724165	NA	-0.28	-4.88	-0.3	1.99e-6	Obesity-related traits;
SARC	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg19748678	chr4:122722346	EXOSC9	0.78	9.75	0.54	4.8e-19	Type 2 diabetes;
SARC	cis	rs12421382	0.615	rs11607972	chr11:109392155	A/G	cg16359550	chr11:109292809	C11orf87	0.37	5.45	0.34	1.31e-7	Schizophrenia;
SARC	cis	rs9430161	0.644	rs34365965	chr1:11034442	G/A	cg02454025	chr1:11042201	C1orf127	0.87	12.31	0.63	3.73e-27	Ewing sarcoma;
SARC	cis	rs10883723	0.810	rs1056857	chr10:104240003	C/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.56	7.13	0.42	1.24e-11	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs1215050	0.740	rs783963	chr4:98989070	A/G	cg05340658	chr4:99064831	C4orf37	0.5	6.91	0.41	4.48e-11	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs4925386	0.840	rs6143034	chr20:60920545	T/C	cg24112000	chr20:60950667	NA	-0.35	-5.28	-0.33	2.96e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs10046574	0.656	rs17403326	chr7:135194440	T/G	cg27474649	chr7:135195673	CNOT4	0.86	7.94	0.46	8.42e-14	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs7582720	0.943	rs72936879	chr2:203792628	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg06558623	chr16:89946397	TCF25	0.88	5.83	0.36	1.84e-8	Skin colour saturation;
SARC	cis	rs7246657	0.943	rs10414904	chr19:37830088	G/A	cg23950597	chr19:37808831	NA	-0.54	-5.47	-0.34	1.15e-7	Coronary artery calcification;
SARC	cis	rs7726839	0.526	rs55647623	chr5:567747	T/C	cg09021430	chr5:549028	NA	-0.46	-6.24	-0.38	2.06e-9	Obesity-related traits;
SARC	cis	rs1355223	0.583	rs2941060	chr11:34879154	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.76	10.83	0.58	2.04e-22	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs787274	0.681	rs4978506	chr9:115600162	C/A	cg13803584	chr9:115635662	SNX30	-0.84	-5.11	-0.32	6.8e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs5757673	1	rs5757673	chr22:39837920	T/C	cg24399712	chr22:39784796	NA	-0.4	-4.99	-0.31	1.18e-6	Post bronchodilator FEV1;
SARC	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg22968622	chr17:43663579	NA	1.14	15.17	0.7	1.31e-36	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg18876405	chr7:65276391	NA	0.7	8.7	0.5	6.12e-16	Aortic root size;
SARC	cis	rs12586317	0.547	rs13379372	chr14:35483882	A/C	cg26967526	chr14:35346199	BAZ1A	-0.57	-5.71	-0.35	3.4e-8	Psoriasis;
SARC	cis	rs35110281	0.837	rs2838343	chr21:45078035	C/T	cg21573476	chr21:45109991	RRP1B	-0.49	-6.97	-0.42	3.3e-11	Mean corpuscular volume;
SARC	cis	rs6570726	0.935	rs369458	chr6:145812809	A/G	cg23711669	chr6:146136114	FBXO30	0.78	11.91	0.62	7.29e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs477692	1.000	rs530466	chr10:131427717	A/G	cg05714579	chr10:131428358	MGMT	0.57	7.56	0.44	9.25e-13	Response to temozolomide;
SARC	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg02891314	chr5:179741120	GFPT2	-0.52	-6.28	-0.38	1.67e-9	Height;
SARC	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg22968622	chr17:43663579	NA	0.83	10.46	0.57	3.08e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs753778	0.667	rs6578153	chr8:142209543	C/T	cg16341495	chr8:142228727	SLC45A4	-0.41	-5.72	-0.35	3.32e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs9325144	0.600	rs10880934	chr12:38730455	C/T	cg04568710	chr12:38710424	ALG10B	-0.38	-4.72	-0.3	4.02e-6	Morning vs. evening chronotype;
SARC	cis	rs11122272	0.735	rs2244986	chr1:231537452	C/T	cg06096015	chr1:231504339	EGLN1	0.35	5.1	0.32	7.04e-7	Hemoglobin concentration;
SARC	cis	rs870825	0.616	rs36022027	chr4:185639192	C/T	cg04058563	chr4:185651563	MLF1IP	0.81	11.3	0.6	6.58e-24	Blood protein levels;
SARC	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg13393036	chr8:95962371	TP53INP1	-0.37	-6.17	-0.37	2.92e-9	Type 2 diabetes;
SARC	cis	rs673253	0.662	rs61769611	chr1:44028913	G/A	cg10881128	chr1:44031826	PTPRF	0.38	4.95	0.31	1.41e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7772486	0.754	rs697055	chr6:146003790	C/G	cg23711669	chr6:146136114	FBXO30	0.87	14.76	0.7	2.88e-35	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7223966	1.000	rs112143304	chr17:61822401	T/A	cg00588841	chr17:61851480	DDX42;CCDC47	-0.68	-7.24	-0.43	6.42e-12	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1865760	0.713	rs2013063	chr6:25994098	C/T	cg17691542	chr6:26056736	HIST1H1C	0.51	6.57	0.4	3.2e-10	Height;
SARC	cis	rs6062509	0.630	rs6011058	chr20:62356627	C/T	cg27236539	chr20:62289627	RTEL1	0.52	5.72	0.35	3.32e-8	Prostate cancer;
SARC	cis	rs3096299	0.933	rs2965824	chr16:89455306	A/G	cg02034447	chr16:89574710	SPG7	0.39	4.93	0.31	1.54e-6	Multiple myeloma (IgH translocation);
SARC	trans	rs4883201	0.572	rs1805735	chr12:9086683	A/T	cg24352934	chr17:1053717	ABR	0.6	6.63	0.4	2.31e-10	Cholesterol, total;Total cholesterol levels;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg22026457	chr15:74045705	NA	0.51	6.62	0.4	2.51e-10	Lung adenocarcinoma;
SARC	cis	rs11098499	0.955	rs35434465	chr4:120169378	C/G	cg24375607	chr4:120327624	NA	0.39	4.82	0.3	2.6e-6	Corneal astigmatism;
SARC	trans	rs1814175	0.645	rs10839456	chr11:49964093	C/T	cg03929089	chr4:120376271	NA	-0.82	-11.84	-0.61	1.2e-25	Height;
SARC	cis	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg25427524	chr10:38739819	LOC399744	-0.63	-10.01	-0.55	7.62e-20	Extrinsic epigenetic age acceleration;
SARC	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.5	0.39	4.96e-10	Bipolar disorder;
SARC	cis	rs138880	0.542	rs9616371	chr22:50306338	G/A	cg03033257	chr22:50311977	ALG12;CRELD2	0.64	4.83	0.3	2.45e-6	Schizophrenia;
SARC	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg22920501	chr2:26401640	FAM59B	-0.55	-6.98	-0.42	2.99e-11	Gut microbiome composition (summer);
SARC	cis	rs1865760	0.516	rs9379818	chr6:26023206	G/T	cg16482183	chr6:26056742	HIST1H1C	0.46	5.96	0.36	9.36e-9	Height;
SARC	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg24209194	chr3:40518798	ZNF619	-0.69	-8.53	-0.49	1.85e-15	Renal cell carcinoma;
SARC	cis	rs4478037	0.732	rs12490111	chr3:33103007	G/A	cg19404215	chr3:33155277	CRTAP	0.81	6.12	0.37	3.92e-9	Major depressive disorder;
SARC	cis	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg26695010	chr11:65641043	EFEMP2	-0.54	-7.03	-0.42	2.3e-11	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs7624766	0.555	rs1378654	chr3:160527151	C/T	cg22637730	chr3:160473554	PPM1L	0.37	4.79	0.3	2.92e-6	Response to methotrexate in rheumatoid arthritis;
SARC	cis	rs7412746	0.658	rs12068264	chr1:150727329	C/T	cg13175981	chr1:150552382	MCL1	-0.46	-5.49	-0.34	1.06e-7	Melanoma;
SARC	cis	rs12479064	0.724	rs6748200	chr2:100080895	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.43	-4.83	-0.3	2.44e-6	Chronic sinus infection;
SARC	cis	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg12257692	chr3:49977190	RBM6	-0.27	-4.8	-0.3	2.89e-6	Body mass index;
SARC	cis	rs4720575	1.000	rs1074575	chr7:47090545	A/C	cg00036614	chr7:47093842	NA	-0.43	-6.05	-0.37	5.62e-9	Angiotensin-converting enzyme inhibitor intolerance;
SARC	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.67	-7.89	-0.46	1.21e-13	Gut microbiome composition (summer);
SARC	cis	rs9457247	0.663	rs2237274	chr6:167442995	C/G	cg07741184	chr6:167504864	NA	0.38	7.28	0.43	5.01e-12	Crohn's disease;
SARC	cis	rs36051895	0.664	rs3824433	chr9:5113577	C/T	cg02405213	chr9:5042618	JAK2	-0.42	-5.07	-0.32	8.02e-7	Pediatric autoimmune diseases;
SARC	cis	rs35110281	0.616	rs2236666	chr21:45109856	T/C	cg21573476	chr21:45109991	RRP1B	-0.61	-8.62	-0.49	1.01e-15	Mean corpuscular volume;
SARC	cis	rs6489785	0.525	rs6553	chr12:121202362	T/C	cg02403541	chr12:121454288	C12orf43	0.43	4.82	0.3	2.55e-6	Longevity;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs9303401	0.659	rs16943176	chr17:56769887	G/A	cg25039879	chr17:56429692	SUPT4H1	0.68	6.4	0.39	8.57e-10	Cognitive test performance;
SARC	cis	rs9325144	0.647	rs35138700	chr12:38804474	C/T	cg26384229	chr12:38710491	ALG10B	-0.58	-7.68	-0.45	4.38e-13	Morning vs. evening chronotype;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg18179145	chr15:45444627	DUOX1	0.52	6.87	0.41	5.69e-11	Schizophrenia;
SARC	cis	rs9393777	0.513	rs9379907	chr6:26654318	C/T	cg12826209	chr6:26865740	GUSBL1	0.66	5.87	0.36	1.47e-8	Intelligence (multi-trait analysis);
SARC	cis	rs734999	0.588	rs2843403	chr1:2529097	T/C	cg00980319	chr1:2560884	MMEL1	0.34	4.91	0.31	1.7e-6	Ulcerative colitis;
SARC	cis	rs2120019	0.567	rs8025170	chr15:75170983	A/G	cg17294928	chr15:75287854	SCAMP5	0.85	8.92	0.5	1.42e-16	Blood trace element (Zn levels);
SARC	cis	rs2073499	1.000	rs4141060	chr3:50300117	T/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.54	6.7	0.4	1.53e-10	Schizophrenia;
SARC	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg05313129	chr8:58192883	C8orf71	-0.51	-4.94	-0.31	1.49e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs34172651	0.917	rs200532	chr16:24756148	C/T	cg06028605	chr16:24865363	SLC5A11	-0.28	-5.1	-0.32	7.14e-7	Intelligence (multi-trait analysis);
SARC	cis	rs870825	0.616	rs28416641	chr4:185617999	C/T	cg04058563	chr4:185651563	MLF1IP	0.82	11.42	0.6	2.8e-24	Blood protein levels;
SARC	cis	rs787274	1.000	rs787286	chr9:115534336	T/C	cg13803584	chr9:115635662	SNX30	-0.83	-5.06	-0.31	8.49e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs870825	0.616	rs67409049	chr4:185623989	G/A	cg04058563	chr4:185651563	MLF1IP	0.82	11.42	0.6	2.8e-24	Blood protein levels;
SARC	trans	rs56279505	0.690	rs62307321	chr4:100279458	T/C	cg18024358	chr1:3420815	MEGF6	-0.82	-6.42	-0.39	7.63e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2153535	0.580	rs9406171	chr6:8515362	T/C	cg07606381	chr6:8435919	SLC35B3	0.77	10.9	0.58	1.28e-22	Motion sickness;
SARC	cis	rs6908034	0.607	rs74559916	chr6:19818717	G/T	cg02682789	chr6:19804855	NA	0.69	5.58	0.34	6.81e-8	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.35	4.75	0.3	3.51e-6	Personality dimensions;
SARC	cis	rs4742903	0.527	rs55909255	chr9:106871788	T/C	cg14250997	chr9:106856677	SMC2	0.5	6.29	0.38	1.57e-9	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs208520	0.690	rs207081	chr6:66773742	A/G	cg07460842	chr6:66804631	NA	-1.1	-15.03	-0.7	3.84e-36	Exhaled nitric oxide output;
SARC	cis	rs6570726	0.791	rs436156	chr6:145874873	A/G	cg05347473	chr6:146136440	FBXO30	0.54	7.44	0.44	1.97e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs15676	0.783	rs7033070	chr9:131586374	G/A	cg00228799	chr9:131580591	ENDOG	-0.65	-8.18	-0.47	1.83e-14	Blood metabolite levels;
SARC	cis	rs12586317	0.547	rs28569331	chr14:35473584	T/C	cg16230307	chr14:35515116	FAM177A1	1.02	11.85	0.61	1.18e-25	Psoriasis;
SARC	cis	rs2204008	0.837	rs11168334	chr12:37961768	A/G	cg26384229	chr12:38710491	ALG10B	0.89	13.29	0.66	2.2e-30	Bladder cancer;
SARC	cis	rs4253772	0.550	rs9615913	chr22:46668515	A/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.66	-6.67	-0.4	1.82e-10	LDL cholesterol;Cholesterol, total;
SARC	cis	rs1348850	0.567	rs1405714	chr2:178538584	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.48	-5.72	-0.35	3.17e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg04772025	chr11:68637568	NA	0.46	5.71	0.35	3.46e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg00933542	chr6:150070202	PCMT1	0.31	5.13	0.32	6.15e-7	Lung cancer;
SARC	cis	rs7937682	1.000	rs12363179	chr11:111568091	G/A	cg09085632	chr11:111637200	PPP2R1B	0.97	16.4	0.73	1.06e-40	Primary sclerosing cholangitis;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg23005295	chr11:104780795	NA	0.48	6.92	0.41	4.41e-11	Thyroid stimulating hormone;
SARC	cis	rs1559088	0.895	rs7259582	chr19:33593979	A/G	cg27124370	chr19:33622961	WDR88	0.44	5.86	0.36	1.6e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs3820928	0.874	rs10199655	chr2:227892428	T/C	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.68	-0.35	4.04e-8	Pulmonary function;
SARC	cis	rs6964587	0.782	rs13221571	chr7:91500236	C/T	cg17063962	chr7:91808500	NA	-0.92	-13.86	-0.67	2.91e-32	Breast cancer;
SARC	cis	rs2439831	0.850	rs12441861	chr15:44060883	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.75	7.34	0.43	3.62e-12	Lung cancer in ever smokers;
SARC	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg12564285	chr5:131593104	PDLIM4	0.42	6.16	0.37	3.24e-9	Acylcarnitine levels;
SARC	cis	rs7474896	0.616	rs1985260	chr10:38434090	C/T	cg00409905	chr10:38381863	ZNF37A	-0.54	-5.23	-0.32	3.86e-7	Obesity (extreme);
SARC	cis	rs1578862	0.966	rs11581163	chr1:247475532	A/G	cg22704608	chr1:247479546	ZNF496	-0.33	-4.72	-0.3	4.08e-6	Monocyte percentage of white cells;
SARC	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.34	-5.04	-0.31	9.51e-7	Total body bone mineral density;
SARC	cis	rs56330463	0.967	rs2400707	chr5:148205052	A/G	cg21580376	chr5:148206412	ADRB2	0.38	5.27	0.33	3.18e-7	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Monocyte percentage of white cells;Eosinophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;
SARC	cis	rs7255045	0.788	rs7250751	chr19:12962648	A/G	cg21491176	chr19:12958399	MAST1	-0.34	-4.72	-0.3	4.14e-6	Mean corpuscular volume;
SARC	cis	rs17376456	0.877	rs10476596	chr5:93367074	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.62	-5.53	-0.34	8.43e-8	Diabetic retinopathy;
SARC	cis	rs3782089	0.793	rs34789990	chr11:65252477	G/T	cg00206168	chr11:65308501	LTBP3	0.76	5.03	0.31	9.83e-7	Height;
SARC	cis	rs10078	0.571	rs2721028	chr5:443849	A/G	cg26072250	chr5:443457	EXOC3;C5orf55	0.69	5.73	0.35	3.1e-8	Fat distribution (HIV);
SARC	cis	rs9818758	0.607	rs35108630	chr3:49088356	T/A	cg00383909	chr3:49044727	WDR6	0.78	6.77	0.41	1.04e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs10911251	0.528	rs10911264	chr1:183115040	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.67	9.66	0.53	8.88e-19	Colorectal cancer;
SARC	cis	rs4073582	0.595	rs474005	chr11:66033301	C/T	cg14036092	chr11:66035641	RAB1B	0.62	8.92	0.5	1.41e-16	Gout;
SARC	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg03033257	chr22:50311977	ALG12;CRELD2	-0.54	-5.4	-0.33	1.68e-7	Schizophrenia;
SARC	cis	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg07777115	chr5:623756	CEP72	-0.56	-5.03	-0.31	9.96e-7	Lung disease severity in cystic fibrosis;
SARC	trans	rs7824557	0.547	rs2736287	chr8:11228006	G/A	cg06636001	chr8:8085503	FLJ10661	-0.61	-7.99	-0.46	6.24e-14	Retinal vascular caliber;
SARC	cis	rs7762018	0.770	rs3823466	chr6:170189926	C/T	cg13891659	chr6:170190454	C6orf122;C6orf208	0.58	5.28	0.33	2.92e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs7760949	0.963	rs9349840	chr6:13903809	G/A	cg27413430	chr6:13925136	RNF182	0.4	4.98	0.31	1.26e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg21573476	chr21:45109991	RRP1B	-0.56	-8.23	-0.47	1.36e-14	Mean corpuscular volume;
SARC	cis	rs2635047	0.601	rs2576058	chr18:44641397	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	6.39	0.39	8.84e-10	Educational attainment;
SARC	cis	rs12497850	0.931	rs11920534	chr3:48937761	G/T	cg06212747	chr3:49208901	KLHDC8B	0.71	9.56	0.53	1.79e-18	Parkinson's disease;
SARC	cis	rs7223966	0.921	rs3020612	chr17:61960878	C/T	cg00588841	chr17:61851480	DDX42;CCDC47	-0.58	-6.39	-0.39	8.85e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs240764	0.658	rs7746947	chr6:101188708	G/A	cg09795085	chr6:101329169	ASCC3	-0.49	-6.42	-0.39	7.54e-10	Neuroticism;
SARC	cis	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg00409905	chr10:38381863	ZNF37A	-0.5	-6.9	-0.41	4.93e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs9470366	0.848	rs66761782	chr6:36636080	T/C	cg08179530	chr6:36648295	CDKN1A	0.58	6.13	0.37	3.66e-9	QRS duration;
SARC	cis	rs8067354	0.645	rs1874548	chr17:57841357	A/G	cg13753209	chr17:57696993	CLTC	0.63	6.35	0.38	1.09e-9	Hemoglobin concentration;
SARC	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg26335602	chr6:28129616	ZNF389	0.53	5.93	0.36	1.1e-8	Depression;
SARC	trans	rs10838798	0.504	rs11039627	chr11:48293931	C/T	cg15704280	chr7:45808275	SEPT13	-0.47	-6.4	-0.39	8.3e-10	Height;
SARC	cis	rs1920116	0.778	rs12492588	chr3:169558711	T/A	cg08193579	chr3:169529701	LRRC34	0.39	4.8	0.3	2.85e-6	Glioma (high-grade);
SARC	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-8.4	-0.48	4.32e-15	Chronic sinus infection;
SARC	cis	rs7666738	0.791	rs2081621	chr4:98926753	C/A	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6580649	0.825	rs4760611	chr12:48421449	A/G	cg24011408	chr12:48396354	COL2A1	0.47	5.2	0.32	4.38e-7	Lung cancer;
SARC	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.56	7.25	0.43	6.03e-12	Menarche (age at onset);
SARC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg05863683	chr7:1912471	MAD1L1	-0.33	-4.95	-0.31	1.44e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs3762637	1.000	rs12633461	chr3:122135897	C/G	cg24169773	chr3:122142474	KPNA1	-0.55	-5.56	-0.34	7.29e-8	LDL cholesterol levels;
SARC	cis	rs10992471	0.598	rs7867300	chr9:95183107	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.42	5.0	0.31	1.14e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs4561483	0.801	rs33637	chr16:11989875	A/T	cg08843971	chr16:11963173	GSPT1	-0.41	-4.99	-0.31	1.15e-6	Testicular germ cell tumor;
SARC	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	11.84	0.61	1.28e-25	Alzheimer's disease;
SARC	cis	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg14541582	chr5:601475	NA	-0.39	-4.87	-0.3	2.05e-6	Obesity-related traits;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg16239628	chr13:46626330	ZC3H13	-0.5	-6.87	-0.41	5.8e-11	Chemerin levels;
SARC	cis	rs9807989	0.729	rs10170583	chr2:102974764	G/A	cg09003973	chr2:102972529	NA	0.41	5.64	0.35	4.85e-8	Asthma;
SARC	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg11764359	chr7:65958608	NA	-0.66	-7.91	-0.46	1.04e-13	Aortic root size;
SARC	trans	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg20587970	chr11:113659929	NA	-1.38	-13.71	-0.67	8.88e-32	Hip circumference adjusted for BMI;
SARC	cis	rs10911232	0.507	rs10752891	chr1:183023283	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.09	0.55	4.29e-20	Hypertriglyceridemia;
SARC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg24846343	chr22:24311635	DDTL	0.49	7.07	0.42	1.84e-11	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs826838	0.616	rs10880738	chr12:38617762	C/T	cg26384229	chr12:38710491	ALG10B	-0.59	-7.54	-0.44	1.04e-12	Heart rate;
SARC	cis	rs76419734	1.000	rs111248783	chr4:106770998	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.77	5.19	0.32	4.53e-7	Post bronchodilator FEV1;
SARC	cis	rs8067545	0.750	rs4570919	chr17:20000815	C/T	cg13482628	chr17:19912719	NA	0.5	6.59	0.4	2.96e-10	Schizophrenia;
SARC	cis	rs9303401	0.614	rs56284918	chr17:57178838	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.98	10.26	0.56	1.25e-20	Cognitive test performance;
SARC	cis	rs9902453	0.934	rs4427857	chr17:28457989	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	6.88	0.41	5.46e-11	Coffee consumption (cups per day);
SARC	cis	rs3126085	0.935	rs10749669	chr1:152177289	A/C	cg03465714	chr1:152285911	FLG	0.44	5.32	0.33	2.47e-7	Atopic dermatitis;
SARC	cis	rs9814567	1.000	rs4498009	chr3:134198008	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-7.08	-0.42	1.68e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	10.64	0.57	8.51e-22	Platelet count;
SARC	cis	rs9486719	0.947	rs9386648	chr6:97035656	T/C	cg06623918	chr6:96969491	KIAA0776	-0.79	-8.88	-0.5	1.86e-16	Migraine;Coronary artery disease;
SARC	cis	rs2236918	0.710	rs2526700	chr1:242019999	C/A	cg17736920	chr1:242011382	EXO1	0.65	8.87	0.5	1.91e-16	Menopause (age at onset);
SARC	cis	rs1008375	1.000	rs10011865	chr4:17645710	G/A	cg27347728	chr4:17578864	LAP3	0.47	5.9	0.36	1.28e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs6695352	0.802	rs12026786	chr1:214969949	C/T	cg21282452	chr22:42232160	SREBF2	0.46	6.47	0.39	5.69e-10	Migraine without aura;
SARC	trans	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg06677010	chr5:52405506	MOCS2	-0.66	-6.25	-0.38	1.99e-9	Cutaneous psoriasis;
SARC	cis	rs2412208	0.796	rs11588097	chr1:7071415	A/G	cg20434152	chr1:7120926	CAMTA1	-0.34	-4.91	-0.31	1.71e-6	Survival in sporadic amyotrophic lateral sclerosis;
SARC	cis	rs6088813	1.000	rs4911180	chr20:33972948	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	-0.44	-5.21	-0.32	4.21e-7	Height;
SARC	cis	rs7647973	0.626	rs1586827	chr3:49671224	T/C	cg03060546	chr3:49711283	APEH	0.66	7.12	0.42	1.34e-11	Menarche (age at onset);
SARC	cis	rs12600121	0.600	rs4788592	chr16:72022941	C/T	cg01557791	chr16:72042693	DHODH	0.42	5.29	0.33	2.82e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1943345	0.731	rs498292	chr11:82903283	C/T	cg07047830	chr11:82868014	PCF11	0.67	9.39	0.52	5.75e-18	Obesity-related traits;
SARC	cis	rs2635047	0.756	rs34939493	chr18:44795621	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	6.38	0.39	9.2e-10	Educational attainment;
SARC	cis	rs920590	0.684	rs7461774	chr8:19666645	G/A	cg01411142	chr8:19674711	INTS10	0.55	6.27	0.38	1.77e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs3820928	0.904	rs2396431	chr2:227765488	G/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-6.74	-0.4	1.21e-10	Pulmonary function;
SARC	cis	rs2439831	0.681	rs478104	chr15:43594900	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.77	8.56	0.49	1.51e-15	Lung cancer in ever smokers;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg24951396	chr12:125473687	DHX37	0.51	6.49	0.39	5.25e-10	Breast cancer;
SARC	cis	rs6963495	0.592	rs114793754	chr7:105152162	G/C	cg19920283	chr7:105172520	RINT1	0.62	5.15	0.32	5.67e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg21724239	chr8:58056113	NA	0.6	6.37	0.38	1.03e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6991838	0.670	rs869151	chr8:66638722	A/G	cg13398993	chr8:66546079	ARMC1	0.44	5.68	0.35	4.05e-8	Intelligence (multi-trait analysis);
SARC	cis	rs12155623	0.932	rs34236473	chr8:49828725	A/T	cg22283653	chr8:49824208	NA	0.39	5.59	0.34	6.35e-8	Sudden cardiac arrest;
SARC	cis	rs2251381	0.606	rs8129515	chr21:30520167	C/G	cg24692254	chr21:30365293	RNF160	0.8	10.95	0.58	8.87e-23	Selective IgA deficiency;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg18332146	chr11:88071004	CTSC	-0.57	-6.85	-0.41	6.41e-11	Fibrinogen levels;
SARC	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg18252515	chr7:66147081	NA	-1.37	-12.29	-0.63	4.33e-27	Diabetic kidney disease;
SARC	cis	rs1153858	0.943	rs7402632	chr15:45701913	A/T	cg26924012	chr15:45694286	SPATA5L1	0.79	10.58	0.57	1.31e-21	Homoarginine levels;
SARC	trans	rs1814175	0.717	rs11040450	chr11:49650638	G/A	cg03929089	chr4:120376271	NA	-0.84	-12.91	-0.65	4.14e-29	Height;
SARC	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.31	-4.83	-0.3	2.42e-6	Total body bone mineral density;
SARC	cis	rs854765	0.587	rs4077828	chr17:17833644	A/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.43	5.58	0.34	6.58e-8	Total body bone mineral density;
SARC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.42	-6.42	-0.39	7.6e-10	Total body bone mineral density;
SARC	cis	rs9393692	0.905	rs7761298	chr6:26278436	C/T	cg13736514	chr6:26305472	NA	-0.6	-8.38	-0.48	5.15e-15	Educational attainment;
SARC	cis	rs7843479	0.582	rs7009693	chr8:21775314	C/T	cg17168535	chr8:21777572	XPO7	0.85	12.08	0.62	2e-26	Mean corpuscular volume;
SARC	trans	rs11098499	0.863	rs3775849	chr4:120450908	G/C	cg25214090	chr10:38739885	LOC399744	0.57	7.35	0.43	3.31e-12	Corneal astigmatism;
SARC	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg18252515	chr7:66147081	NA	-1.33	-11.72	-0.61	3e-25	Diabetic kidney disease;
SARC	cis	rs8031584	0.958	rs61997076	chr15:31216225	C/T	cg08109568	chr15:31115862	NA	-0.44	-4.93	-0.31	1.57e-6	Huntington's disease progression;
SARC	cis	rs28374715	0.662	rs691907	chr15:41474657	C/G	cg18705301	chr15:41695430	NDUFAF1	0.95	13.92	0.67	1.89e-32	Ulcerative colitis;
SARC	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg17971929	chr21:40555470	PSMG1	0.99	13.88	0.67	2.43e-32	Cognitive function;
SARC	cis	rs4792901	0.959	rs12603053	chr17:41628292	A/G	cg22562494	chr17:41607896	ETV4	-0.33	-5.2	-0.32	4.33e-7	Dupuytren's disease;
SARC	cis	rs9303401	0.659	rs2072316	chr17:56604813	G/T	cg25039879	chr17:56429692	SUPT4H1	0.66	6.16	0.37	3.19e-9	Cognitive test performance;
SARC	cis	rs67311347	1.000	rs2887995	chr3:40409029	C/G	cg09455208	chr3:40491958	NA	0.4	6.31	0.38	1.36e-9	Renal cell carcinoma;
SARC	cis	rs7772486	0.558	rs2142978	chr6:146012061	T/C	cg23711669	chr6:146136114	FBXO30	-0.81	-11.87	-0.61	9.73e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg22875332	chr1:76189707	ACADM	0.46	6.25	0.38	1.9e-9	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9911578	0.839	rs7208505	chr17:57187729	C/T	cg05425664	chr17:57184151	TRIM37	-0.59	-7.54	-0.44	1.02e-12	Intelligence (multi-trait analysis);
SARC	cis	rs9815354	0.953	rs1613233	chr3:41945144	A/G	cg03022575	chr3:42003672	ULK4	-0.55	-5.21	-0.32	4.11e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs876084	0.505	rs4431629	chr8:121108668	C/T	cg06265175	chr8:121136014	COL14A1	0.58	7.56	0.44	9.46e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg14049380	chr3:52805078	NEK4	0.49	6.76	0.4	1.11e-10	Thyroid stimulating hormone;
SARC	cis	rs78487399	0.808	rs74600494	chr2:43743491	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-4.74	-0.3	3.73e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs10791323	0.582	rs2851120	chr11:133708065	A/G	cg06766960	chr11:133703094	NA	-0.31	-4.75	-0.3	3.49e-6	Childhood ear infection;
SARC	cis	rs7829975	0.782	rs6990746	chr8:8547811	A/G	cg06636001	chr8:8085503	FLJ10661	-0.64	-8.35	-0.48	6e-15	Mood instability;
SARC	cis	rs10752881	1.000	rs12126434	chr1:182988414	A/G	cg13390022	chr1:182993471	LAMC1	-0.32	-4.89	-0.31	1.86e-6	Colorectal cancer;
SARC	cis	rs2303759	0.709	rs7256363	chr19:49827804	C/T	cg22590775	chr19:49891494	CCDC155	0.47	5.22	0.32	3.89e-7	Multiple sclerosis;
SARC	cis	rs9291683	0.552	rs10939656	chr4:10014646	A/C	cg00071950	chr4:10020882	SLC2A9	0.41	6.47	0.39	5.6e-10	Bone mineral density;
SARC	cis	rs7223966	1.000	rs9903897	chr17:61716705	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.38	0.39	9.6e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2576037	0.796	rs6507718	chr18:44581284	G/C	cg15049968	chr18:44337910	ST8SIA5	0.33	5.38	0.33	1.79e-7	Personality dimensions;
SARC	cis	rs554111	0.891	rs531044	chr1:21057011	T/C	cg04902671	chr1:21058625	SH2D5	-0.45	-5.14	-0.32	5.79e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs896543	0.702	rs6715324	chr2:237495510	C/T	cg25295825	chr2:237489920	CXCR7	0.46	5.17	0.32	5.08e-7	Alcohol dependence (age at onset);
SARC	cis	rs4853036	1.000	rs11902295	chr2:70084599	C/T	cg02498382	chr2:70120550	SNRNP27	-0.42	-5.44	-0.34	1.34e-7	Colorectal or endometrial cancer;
SARC	cis	rs34779708	0.966	rs10827487	chr10:35406878	T/A	cg03585969	chr10:35415529	CREM	0.42	5.32	0.33	2.38e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs2486288	0.656	rs2413774	chr15:45549423	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.45	-5.57	-0.34	7.07e-8	Glomerular filtration rate;
SARC	cis	rs9788682	0.747	rs2656072	chr15:78744292	A/G	cg06917634	chr15:78832804	PSMA4	0.51	5.35	0.33	2.09e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg25894440	chr7:65020034	NA	-0.73	-5.48	-0.34	1.09e-7	Diabetic kidney disease;
SARC	cis	rs9831754	1.000	rs9822043	chr3:78352113	T/C	cg06138941	chr3:78371609	NA	-0.57	-6.6	-0.4	2.74e-10	Calcium levels;
SARC	cis	rs9322817	0.691	rs9377679	chr6:105345036	C/T	cg02098413	chr6:105308735	HACE1	0.4	6.15	0.37	3.3e-9	Thyroid stimulating hormone;
SARC	cis	rs870825	0.655	rs28661636	chr4:185634218	A/C	cg04058563	chr4:185651563	MLF1IP	0.83	11.16	0.59	1.91e-23	Blood protein levels;
SARC	cis	rs9828933	0.752	rs17069507	chr3:63924956	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.81	-6.02	-0.37	6.55e-9	Type 2 diabetes;
SARC	cis	rs11785400	0.762	rs4401833	chr8:143739731	A/T	cg10596483	chr8:143751796	JRK	0.55	7.01	0.42	2.59e-11	Schizophrenia;
SARC	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg20891283	chr12:69753455	YEATS4	0.55	7.55	0.44	9.74e-13	Blood protein levels;
SARC	cis	rs981844	1.000	rs72731670	chr4:154662471	C/T	cg14289246	chr4:154710475	SFRP2	0.59	6.74	0.4	1.25e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs13191362	1.000	rs13212608	chr6:163032128	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.55	5.32	0.33	2.48e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs7520050	0.966	rs6675726	chr1:46560643	A/G	cg06784218	chr1:46089804	CCDC17	-0.26	-4.82	-0.3	2.56e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs748404	0.690	rs2924369	chr15:43777985	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	-0.48	-5.22	-0.32	3.92e-7	Lung cancer;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06002975	chr2:86422967	IMMT	-0.53	-7.05	-0.42	1.98e-11	Smoking initiation;
SARC	cis	rs858239	0.539	rs6461695	chr7:23197784	C/A	cg23682824	chr7:23144976	KLHL7	0.67	8.51	0.49	2.15e-15	Cerebrospinal fluid biomarker levels;
SARC	cis	rs7223966	1.000	rs7223412	chr17:61808172	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	6.88	0.41	5.45e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs4689388	0.926	rs11725494	chr4:6293855	C/T	cg00701064	chr4:6280414	WFS1	0.57	9.55	0.53	1.82e-18	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs5753618	0.504	rs8142121	chr22:31882785	G/A	cg02404636	chr22:31891804	SFI1	0.53	5.61	0.34	5.79e-8	Colorectal cancer;
SARC	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg13385521	chr17:29058706	SUZ12P	-0.67	-6.96	-0.41	3.52e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs10089	1.000	rs883074	chr5:127445823	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.79	-9.63	-0.53	1.08e-18	Ileal carcinoids;
SARC	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.63	5.79	0.35	2.32e-8	Lung function (FEV1/FVC);
SARC	cis	rs6582630	0.555	rs34730221	chr12:38405140	C/T	cg14851346	chr12:38532713	NA	-0.41	-4.94	-0.31	1.52e-6	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9916302	0.904	rs588193	chr17:37440439	A/C	cg00129232	chr17:37814104	STARD3	0.58	7.31	0.43	4.23e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs11688816	1.000	rs11688816	chr2:63053048	G/A	cg17519650	chr2:63277830	OTX1	-0.39	-4.95	-0.31	1.43e-6	Body mass index;
SARC	cis	rs2841277	0.771	rs2819469	chr14:105394859	G/A	cg15352829	chr14:105391018	PLD4	0.35	6.54	0.39	3.85e-10	Rheumatoid arthritis;
SARC	cis	rs748404	0.560	rs2255663	chr15:43829008	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.45	-4.87	-0.3	2.08e-6	Lung cancer;
SARC	cis	rs7726839	0.578	rs112516582	chr5:584319	G/A	cg09021430	chr5:549028	NA	-0.57	-11.62	-0.61	6.4e-25	Obesity-related traits;
SARC	cis	rs7918232	0.882	rs6415983	chr10:27357211	A/G	cg14442939	chr10:27389572	ANKRD26	0.62	5.49	0.34	1.07e-7	Breast cancer;
SARC	cis	rs908922	0.676	rs11581947	chr1:152482587	G/A	cg09873164	chr1:152488093	CRCT1	0.63	8.25	0.48	1.19e-14	Hair morphology;
SARC	cis	rs11689667	0.617	rs17763853	chr2:85480715	A/G	cg00361467	chr2:85109344	C2orf89	0.4	4.82	0.3	2.58e-6	Pulse pressure;
SARC	cis	rs2304069	0.954	rs4705409	chr5:149414899	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.9	9.63	0.53	1.09e-18	HIV-1 control;
SARC	cis	rs6693567	0.565	rs1260374	chr1:150331593	G/A	cg09579323	chr1:150459698	TARS2	0.41	5.11	0.32	6.71e-7	Migraine;
SARC	cis	rs916888	0.610	rs199438	chr17:44791643	G/A	cg15921436	chr17:44337874	NA	0.48	5.45	0.34	1.29e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.95	11.92	0.62	6.96e-26	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs6493487	0.512	rs2414054	chr15:51129827	A/G	cg02338191	chr15:51200825	AP4E1	0.52	4.98	0.31	1.25e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs796364	0.806	rs79897806	chr2:201073968	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.61	-4.82	-0.3	2.64e-6	Schizophrenia;
SARC	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg11644478	chr21:40555479	PSMG1	-0.88	-11.37	-0.6	3.97e-24	Cognitive function;
SARC	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.74	10.04	0.55	6.13e-20	Menarche (age at onset);
SARC	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.74	10.75	0.58	3.63e-22	Personality dimensions;
SARC	cis	rs9868809	0.505	rs9882549	chr3:48749358	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.58	-5.36	-0.33	1.95e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg03185022	chr7:2884158	GNA12	0.43	4.74	0.3	3.66e-6	Height;
SARC	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.41	-6.93	-0.41	4.16e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs11264799	0.520	rs849816	chr1:157542074	A/C	cg18268488	chr1:157545234	FCRL4	0.32	5.75	0.35	2.73e-8	IgA nephropathy;
SARC	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg27541892	chr1:1571801	CDK11B	-0.41	-5.68	-0.35	4.09e-8	Body mass index;
SARC	cis	rs7824557	0.527	rs2572449	chr8:11239137	A/G	cg21775007	chr8:11205619	TDH	0.6	8.12	0.47	2.67e-14	Retinal vascular caliber;
SARC	cis	rs453301	0.522	rs2929309	chr8:9083771	C/A	cg08975724	chr8:8085496	FLJ10661	-0.48	-5.91	-0.36	1.21e-8	Joint mobility (Beighton score);
SARC	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg21782813	chr7:2030301	MAD1L1	0.35	5.58	0.34	6.74e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs453301	0.686	rs6601281	chr8:8911004	A/G	cg06636001	chr8:8085503	FLJ10661	-0.64	-8.63	-0.49	9.68e-16	Joint mobility (Beighton score);
SARC	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.42	5.35	0.33	2.12e-7	Lymphocyte counts;
SARC	cis	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg00409905	chr10:38381863	ZNF37A	-0.53	-7.31	-0.43	4.24e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs9325144	0.624	rs7309400	chr12:39150369	G/C	cg13010199	chr12:38710504	ALG10B	-0.5	-6.11	-0.37	4.15e-9	Morning vs. evening chronotype;
SARC	cis	rs3818285	0.632	rs536343	chr10:111632879	T/C	cg00817464	chr10:111662876	XPNPEP1	0.5	8.09	0.47	3.34e-14	Superior crus of antihelix expression;
SARC	cis	rs2455799	0.502	rs2470532	chr3:15696909	A/C	cg16303742	chr3:15540471	COLQ	0.37	5.58	0.34	6.79e-8	Mean platelet volume;
SARC	cis	rs2439831	0.867	rs2412778	chr15:43660982	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.77	7.95	0.46	7.92e-14	Lung cancer in ever smokers;
SARC	trans	rs629535	0.814	rs571682	chr8:70062793	A/G	cg21567404	chr3:27674614	NA	1.03	12.95	0.65	3e-29	Dupuytren's disease;
SARC	cis	rs7944584	0.552	rs12361415	chr11:47474146	T/G	cg10504702	chr11:47789108	FNBP4	0.68	8.17	0.47	1.95e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs2576037	0.796	rs2571033	chr18:44578552	C/T	cg19077165	chr18:44547161	KATNAL2	0.44	6.19	0.38	2.66e-9	Personality dimensions;
SARC	cis	rs1728785	0.818	rs11075684	chr16:68582365	C/T	cg02972257	chr16:68554789	NA	-0.43	-5.01	-0.31	1.08e-6	Ulcerative colitis;
SARC	cis	rs3008870	1.000	rs1925408	chr1:67365034	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.92	11.48	0.6	1.78e-24	Lymphocyte percentage of white cells;
SARC	cis	rs7756236	0.521	rs9462208	chr6:36627890	T/C	cg08179530	chr6:36648295	CDKN1A	0.51	6.26	0.38	1.86e-9	QRS duration;
SARC	cis	rs4481887	1.000	rs4489592	chr1:248470697	A/T	cg13385794	chr1:248469461	NA	0.36	5.46	0.34	1.19e-7	Common traits (Other);
SARC	cis	rs9790314	0.875	rs336580	chr3:161082982	A/T	cg03342759	chr3:160939853	NMD3	-0.63	-8.26	-0.48	1.09e-14	Morning vs. evening chronotype;
SARC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg15383120	chr6:291909	DUSP22	-0.61	-7.88	-0.46	1.25e-13	Menopause (age at onset);
SARC	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg22618164	chr12:122356400	WDR66	0.43	6.88	0.41	5.45e-11	Mean corpuscular volume;
SARC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg20607798	chr8:58055168	NA	0.58	5.55	0.34	7.69e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7772486	0.624	rs6930154	chr6:146025662	C/T	cg23711669	chr6:146136114	FBXO30	-0.79	-12.68	-0.64	2.27e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11723261	0.664	rs4627799	chr4:132389	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.39	5.33	0.33	2.36e-7	Immune response to smallpox vaccine (IL-6);
SARC	cis	rs5769765	0.954	rs910799	chr22:50278568	A/G	cg03033257	chr22:50311977	ALG12;CRELD2	-0.51	-5.05	-0.31	8.77e-7	Schizophrenia;
SARC	trans	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg01181084	chr8:43059863	NA	-0.44	-6.27	-0.38	1.73e-9	Immature fraction of reticulocytes;
SARC	cis	rs6840360	0.554	rs62329088	chr4:152471289	C/T	cg22705602	chr4:152727874	NA	-0.4	-6.25	-0.38	1.92e-9	Intelligence (multi-trait analysis);
SARC	cis	rs9640161	0.789	rs2373751	chr7:150021599	G/C	cg21361702	chr7:150065534	REPIN1	0.55	5.51	0.34	9.58e-8	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg13271783	chr10:134563150	INPP5A	-0.4	-5.13	-0.32	6.24e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg01181863	chr3:195395398	SDHAP2	-0.57	-6.4	-0.39	8.24e-10	Pancreatic cancer;
SARC	cis	rs9682041	0.660	rs13089256	chr3:170113601	G/A	cg11886554	chr3:170076028	SKIL	0.84	7.76	0.45	2.72e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg13622047	chr19:54693861	MBOAT7;TSEN34	-0.62	-6.5	-0.39	4.81e-10	Lung cancer in ever smokers;
SARC	cis	rs6088590	1.000	rs6120705	chr20:33313740	T/C	cg24642439	chr20:33292090	TP53INP2	0.89	12.73	0.64	1.54e-28	Coronary artery disease;
SARC	trans	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg06437703	chr8:37914619	EIF4EBP1	-0.6	-7.29	-0.43	4.85e-12	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9660992	0.762	rs1668871	chr1:205237137	T/C	cg21643547	chr1:205240462	TMCC2	-0.6	-8.02	-0.46	5.27e-14	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs2153535	0.580	rs9406162	chr6:8466196	C/T	cg07606381	chr6:8435919	SLC35B3	0.77	10.83	0.58	2.14e-22	Motion sickness;
SARC	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg11890956	chr21:40555474	PSMG1	-1.06	-15.63	-0.72	3.88e-38	Cognitive function;
SARC	cis	rs11785400	0.731	rs9720504	chr8:143725502	T/C	cg10596483	chr8:143751796	JRK	0.57	7.39	0.44	2.61e-12	Schizophrenia;
SARC	cis	rs2204008	0.537	rs28680519	chr12:38502946	C/T	cg26384229	chr12:38710491	ALG10B	0.85	12.31	0.63	3.83e-27	Bladder cancer;
SARC	cis	rs986417	1.000	rs10144805	chr14:60927652	T/C	cg27398547	chr14:60952738	C14orf39	1.02	9.54	0.53	2.06e-18	Gut microbiota (bacterial taxa);
SARC	cis	rs7772486	0.754	rs702323	chr6:146008274	A/G	cg23711669	chr6:146136114	FBXO30	-0.8	-12.88	-0.64	5.14e-29	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7089973	0.604	rs7895830	chr10:116625776	A/G	cg03647239	chr10:116582469	FAM160B1	0.54	7.03	0.42	2.32e-11	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs9902453	0.967	rs1906451	chr17:28515479	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	6.69	0.4	1.64e-10	Coffee consumption (cups per day);
SARC	cis	rs963731	0.649	rs78421201	chr2:39339424	C/A	cg04010122	chr2:39346883	SOS1	1.11	6.38	0.39	9.36e-10	Corticobasal degeneration;
SARC	cis	rs568617	1.000	rs687672	chr11:65649984	T/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.47	-5.46	-0.34	1.23e-7	Crohn's disease;
SARC	trans	rs4481887	0.830	rs4474289	chr1:248474972	T/A	cg12668902	chr6:7261808	NA	-0.53	-6.49	-0.39	5.22e-10	Common traits (Other);
SARC	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg00933542	chr6:150070202	PCMT1	0.31	5.36	0.33	2.04e-7	Lung cancer;
SARC	trans	rs6934651	0.708	rs56145052	chr6:85987469	G/T	cg04848555	chr14:53975804	NA	0.69	6.47	0.39	5.61e-10	Breast cancer;
SARC	cis	rs17023223	0.537	rs12064137	chr1:119709749	G/A	cg05756136	chr1:119680316	WARS2	-0.49	-5.62	-0.35	5.47e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs17376456	0.877	rs10076052	chr5:93317762	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.46	0.34	1.24e-7	Diabetic retinopathy;
SARC	cis	rs2153535	0.580	rs6597325	chr6:8461053	A/C	cg23788917	chr6:8435910	SLC35B3	0.62	8.19	0.47	1.77e-14	Motion sickness;
SARC	cis	rs9768139	0.733	rs34173461	chr7:158122175	C/G	cg25566285	chr7:158114605	PTPRN2	0.32	5.26	0.33	3.33e-7	Calcium levels;
SARC	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg25072359	chr17:41440525	NA	0.51	6.13	0.37	3.66e-9	Menopause (age at onset);
SARC	cis	rs921968	0.643	rs832802	chr2:219386899	C/T	cg02176678	chr2:219576539	TTLL4	0.36	5.59	0.34	6.18e-8	Mean corpuscular hemoglobin concentration;
SARC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg05165339	chr4:1420672	NA	-0.25	-5.39	-0.33	1.75e-7	Longevity;
SARC	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg22875332	chr1:76189707	ACADM	-0.5	-6.25	-0.38	1.95e-9	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9788682	0.706	rs2568493	chr15:78740233	G/A	cg24631222	chr15:78858424	CHRNA5	-0.75	-9.28	-0.52	1.25e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	trans	rs61931739	0.929	rs3912551	chr12:34076696	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.07	-0.42	1.84e-11	Morning vs. evening chronotype;
SARC	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg04267008	chr7:1944627	MAD1L1	-0.61	-7.1	-0.42	1.5e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs12153160	1.000	rs12515561	chr5:152955611	C/G	cg16532600	chr5:153857824	HAND1	0.55	5.09	0.32	7.34e-7	Middle childhood and early adolescence aggressive behavior;
SARC	cis	rs4713118	0.662	rs149900	chr6:28014597	C/T	cg16479474	chr6:28041457	NA	0.37	5.17	0.32	4.94e-7	Parkinson's disease;
SARC	cis	rs926392	1.000	rs2867898	chr20:37690952	G/A	cg16355469	chr20:37678765	NA	0.5	6.53	0.39	4.12e-10	Dialysis-related mortality;
SARC	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg08280861	chr8:58055591	NA	0.61	5.96	0.36	9.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2239547	0.522	rs9842974	chr3:53011050	C/A	cg11645453	chr3:52864694	ITIH4	0.34	5.32	0.33	2.46e-7	Schizophrenia;
SARC	cis	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg22496380	chr5:211416	CCDC127	-0.88	-9.35	-0.52	7.72e-18	Breast cancer;
SARC	cis	rs4319547	0.585	rs10846792	chr12:122882374	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.56	-6.36	-0.38	1.07e-9	Body mass index;
SARC	cis	rs9747201	0.862	rs11651738	chr17:80178691	A/T	cg17462356	chr17:80056334	FASN	-0.48	-5.05	-0.31	9.09e-7	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg12463550	chr7:65579703	CRCP	0.54	5.84	0.36	1.76e-8	Aortic root size;
SARC	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg18252515	chr7:66147081	NA	-0.47	-5.09	-0.32	7.32e-7	Aortic root size;
SARC	cis	rs4642101	0.561	rs7641959	chr3:12810755	G/C	cg05775895	chr3:12838266	CAND2	0.54	7.61	0.45	6.97e-13	QRS complex (12-leadsum);
SARC	cis	rs9300255	0.602	rs1716165	chr12:123648881	C/T	cg00376283	chr12:123451042	ABCB9	0.58	6.9	0.41	4.89e-11	Neutrophil percentage of white cells;
SARC	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg08859206	chr1:53392774	SCP2	-0.41	-5.8	-0.36	2.12e-8	Monocyte count;
SARC	cis	rs17401966	0.502	rs6541080	chr1:10236039	A/G	cg15208524	chr1:10270712	KIF1B	-0.4	-4.93	-0.31	1.53e-6	Hepatocellular carcinoma;
SARC	cis	rs6809651	0.524	rs6444105	chr3:185811301	C/T	cg00760338	chr3:185826511	ETV5	-0.84	-10.76	-0.58	3.58e-22	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
SARC	cis	rs861020	1.000	rs674433	chr1:209964875	A/C	cg05527609	chr1:210001259	C1orf107	-0.96	-11.02	-0.59	5.42e-23	Orofacial clefts;
SARC	cis	rs1707322	0.752	rs6703748	chr1:46095976	G/A	cg03146154	chr1:46216737	IPP	0.51	6.07	0.37	5.01e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg04123373	chr1:44411915	IPO13	-0.54	-6.78	-0.41	9.51e-11	Breast cancer;
SARC	cis	rs4555082	0.834	rs11849607	chr14:105745383	G/A	cg10792982	chr14:105748885	BRF1	0.54	8.01	0.46	5.58e-14	Mean platelet volume;Platelet distribution width;
SARC	trans	rs2018683	1.000	rs740252	chr7:28997765	C/G	cg19402173	chr7:128379420	CALU	-0.76	-10.51	-0.57	2.1e-21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg25894440	chr7:65020034	NA	-0.73	-5.54	-0.34	8.11e-8	Diabetic kidney disease;
SARC	trans	rs9929218	0.953	rs28608872	chr16:68802038	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.53	-6.72	-0.4	1.41e-10	Colorectal cancer;
SARC	cis	rs10911232	0.507	rs2151669	chr1:183055398	T/G	cg13390022	chr1:182993471	LAMC1	0.33	5.05	0.31	8.97e-7	Hypertriglyceridemia;
SARC	cis	rs9916302	0.706	rs2879259	chr17:37410892	C/G	cg07936489	chr17:37558343	FBXL20	-0.73	-8.77	-0.5	3.71e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg01316550	chr5:56110833	MAP3K1	0.52	4.91	0.31	1.75e-6	Initial pursuit acceleration;
SARC	cis	rs9814567	1.000	rs4309773	chr3:134277301	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.02	-0.42	2.47e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	trans	rs2727020	0.658	rs7120136	chr11:49384358	A/C	cg03929089	chr4:120376271	NA	-0.8	-11.96	-0.62	5.12e-26	Coronary artery disease;
SARC	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg00149659	chr3:10157352	C3orf10	0.64	5.91	0.36	1.22e-8	Alzheimer's disease;
SARC	cis	rs9467773	1.000	rs3736781	chr6:26505362	G/A	cg12292205	chr6:26970375	C6orf41	0.43	5.24	0.32	3.66e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg00933542	chr6:150070202	PCMT1	0.3	5.14	0.32	5.77e-7	Lung cancer;
SARC	cis	rs16976116	0.901	rs28714578	chr15:55491121	G/A	cg17854078	chr15:55489399	RSL24D1	0.66	6.46	0.39	6.14e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2075371	0.932	rs34664116	chr7:133984878	G/A	cg20476274	chr7:133979776	SLC35B4	0.58	7.57	0.44	8.59e-13	Mean platelet volume;
SARC	cis	rs3540	0.512	rs11633872	chr15:91080512	G/A	cg22089800	chr15:90895588	ZNF774	-0.61	-7.6	-0.45	7.4e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs7772486	0.754	rs4360151	chr6:146255079	A/C	cg23711669	chr6:146136114	FBXO30	-0.76	-11.76	-0.61	2.25e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg18404041	chr3:52824283	ITIH1	-0.33	-4.89	-0.3	1.92e-6	Electroencephalogram traits;
SARC	cis	rs1348850	0.846	rs4893962	chr2:178421106	A/G	cg23306229	chr2:178417860	TTC30B	0.57	6.72	0.4	1.4e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs60843830	0.964	rs62114538	chr2:256116	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.65	9.44	0.53	4.15e-18	Spherical equivalent (joint analysis main effects and education interaction);
SARC	cis	rs6963495	0.818	rs117845382	chr7:105152040	T/C	cg19920283	chr7:105172520	RINT1	0.63	5.3	0.33	2.75e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs1865760	1.000	rs56118523	chr6:25908975	A/G	cg16482183	chr6:26056742	HIST1H1C	0.5	6.22	0.38	2.27e-9	Height;
SARC	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg22903657	chr4:1355424	KIAA1530	-0.42	-5.65	-0.35	4.64e-8	Obesity-related traits;
SARC	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.48	5.92	0.36	1.17e-8	Tonsillectomy;
SARC	cis	rs6496667	1.000	rs3803538	chr15:90891771	A/G	cg22089800	chr15:90895588	ZNF774	0.52	4.89	0.31	1.89e-6	Rheumatoid arthritis;
SARC	cis	rs6728642	0.908	rs7588921	chr2:98021001	C/T	cg26665480	chr2:98280029	ACTR1B	-0.66	-6.11	-0.37	4.12e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs9503598	0.636	rs7766753	chr6:3467708	A/C	cg00476032	chr6:3446245	SLC22A23	0.39	6.1	0.37	4.37e-9	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
SARC	cis	rs6570726	0.791	rs398408	chr6:145801020	G/A	cg23711669	chr6:146136114	FBXO30	0.86	14.24	0.68	1.59e-33	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs71277158	0.688	rs16854875	chr3:169899667	T/G	cg04067573	chr3:169899625	PHC3	0.57	4.89	0.31	1.84e-6	Prostate cancer;
SARC	cis	rs72781680	0.799	rs17508218	chr2:23976536	C/T	cg06627628	chr2:24431161	ITSN2	-0.68	-6.43	-0.39	7.31e-10	Lymphocyte counts;
SARC	cis	rs6138458	1.000	rs6114980	chr20:24974288	A/G	cg26195577	chr20:24973756	C20orf3	0.91	9.89	0.54	1.77e-19	Blood protein levels;
SARC	cis	rs4481887	1.000	rs7513161	chr1:248453422	A/T	cg00666640	chr1:248458726	OR2T12	0.36	5.95	0.36	9.69e-9	Common traits (Other);
SARC	cis	rs79349575	0.783	rs12602746	chr17:47031741	A/C	cg16584676	chr17:46985605	UBE2Z	0.55	6.58	0.4	3.01e-10	Type 2 diabetes;
SARC	cis	rs8031584	1.000	rs11634216	chr15:31288670	G/A	cg19680485	chr15:31195859	MTMR15	-0.54	-5.84	-0.36	1.79e-8	Huntington's disease progression;
SARC	cis	rs8067545	0.750	rs6587215	chr17:19980779	G/T	cg13482628	chr17:19912719	NA	0.54	6.91	0.41	4.55e-11	Schizophrenia;
SARC	cis	rs4926611	0.698	rs12072004	chr1:54060991	C/A	cg08927728	chr1:54059983	GLIS1	0.3	4.95	0.31	1.4e-6	Hand grip strength;
SARC	cis	rs6582630	0.502	rs1607876	chr12:38355750	T/C	cg26384229	chr12:38710491	ALG10B	0.87	12.85	0.64	6.2e-29	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs4927850	0.752	rs7624460	chr3:195748530	C/T	cg00031303	chr3:195681400	NA	0.51	6.11	0.37	4.07e-9	Pancreatic cancer;
SARC	cis	rs950027	0.549	rs11636114	chr15:45601412	C/G	cg15395560	chr15:45543142	SLC28A2	-0.29	-5.31	-0.33	2.52e-7	Response to fenofibrate (adiponectin levels);
SARC	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg25894440	chr7:65020034	NA	-0.75	-5.67	-0.35	4.13e-8	Diabetic kidney disease;
SARC	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg03352830	chr11:487213	PTDSS2	0.5	4.83	0.3	2.44e-6	Body mass index;
SARC	trans	rs34421088	0.560	rs2248316	chr8:11397073	A/C	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.5	-0.39	4.96e-10	Neuroticism;
SARC	cis	rs1559088	0.948	rs10410778	chr19:33592301	C/A	cg27124370	chr19:33622961	WDR88	0.44	5.86	0.36	1.6e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs2228479	0.557	rs62056064	chr16:89903843	G/A	cg12064134	chr16:90016061	DEF8	-0.56	-4.79	-0.3	2.91e-6	Skin colour saturation;
SARC	trans	rs8073060	0.504	rs225271	chr17:33969836	C/T	cg19694781	chr19:47549865	TMEM160	-0.67	-6.74	-0.4	1.21e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg10065215	chr1:1613982	CDK11B;LOC728661	0.44	6.27	0.38	1.71e-9	Schizophrenia;
SARC	cis	rs11249608	0.548	rs17078991	chr5:178459426	A/C	cg21905437	chr5:178450457	ZNF879	0.56	7.41	0.44	2.27e-12	Pubertal anthropometrics;
SARC	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-6.24	-0.38	2.09e-9	Personality dimensions;
SARC	cis	rs6598955	0.670	rs10902734	chr1:26617923	G/T	cg21300267	chr1:26547059	NA	0.25	4.73	0.3	3.89e-6	Obesity-related traits;
SARC	cis	rs7568458	0.905	rs6739015	chr2:85755357	A/G	cg23752985	chr2:85803571	VAMP8	0.33	4.8	0.3	2.8e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg17971929	chr21:40555470	PSMG1	0.99	14.16	0.68	2.89e-33	Cognitive function;
SARC	cis	rs778371	0.676	rs2293780	chr2:233635213	T/C	cg20388707	chr2:233749442	NGEF	-0.34	-4.9	-0.31	1.79e-6	Schizophrenia;
SARC	cis	rs7829975	0.510	rs332037	chr8:8722675	C/T	cg15556689	chr8:8085844	FLJ10661	0.43	5.4	0.33	1.6e-7	Mood instability;
SARC	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg08280861	chr8:58055591	NA	0.61	5.96	0.36	9.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs722599	0.683	rs7145246	chr14:75242394	A/T	cg06637938	chr14:75390232	RPS6KL1	-0.41	-5.04	-0.31	9.28e-7	IgG glycosylation;
SARC	cis	rs11155671	0.530	rs9397420	chr6:150206781	C/T	cg09699651	chr6:150184138	LRP11	-0.52	-6.65	-0.4	2.03e-10	Testicular germ cell tumor;
SARC	cis	rs36051895	0.530	rs60768043	chr9:5224676	T/G	cg02405213	chr9:5042618	JAK2	-0.42	-4.91	-0.31	1.71e-6	Pediatric autoimmune diseases;
SARC	cis	rs1797081	0.811	rs1797076	chr10:16853076	A/G	cg23933602	chr10:16859644	RSU1	0.88	15.54	0.71	7.52e-38	Platelet distribution width;
SARC	cis	rs838147	0.733	rs8106205	chr19:49250197	T/C	cg13540341	chr19:49222985	MAMSTR	0.29	4.95	0.31	1.41e-6	Dietary macronutrient intake;
SARC	cis	rs9733	0.526	rs6587542	chr1:150907701	G/T	cg10589385	chr1:150898437	SETDB1	0.4	5.4	0.33	1.61e-7	Tonsillectomy;
SARC	cis	rs4128725	1.000	rs75906889	chr1:159403820	T/C	cg25076881	chr1:159409836	OR10J1	0.4	4.8	0.3	2.86e-6	Select biomarker traits;
SARC	cis	rs6835098	0.962	rs4377567	chr4:174083590	C/G	cg08422745	chr4:174089978	GALNT7	0.74	9.93	0.55	1.28e-19	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	trans	rs877282	0.898	rs36064821	chr10:760952	C/T	cg22713356	chr15:30763199	NA	0.96	9.66	0.53	8.72e-19	Uric acid levels;
SARC	cis	rs7264396	1.000	rs224424	chr20:34147998	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.46	-5.31	-0.33	2.52e-7	Total cholesterol levels;
SARC	cis	rs61332075	0.518	rs6749508	chr2:239456243	C/T	cg18131467	chr2:239335373	ASB1	-0.56	-5.2	-0.32	4.3e-7	Lung function (FEV1/FVC);
SARC	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.41	-6.89	-0.41	5.21e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs67311347	1.000	rs4128740	chr3:40519532	C/A	cg09455208	chr3:40491958	NA	0.39	5.73	0.35	3.13e-8	Renal cell carcinoma;
SARC	cis	rs67460515	0.563	rs35914913	chr3:160826561	A/G	cg17135325	chr3:160939158	NMD3	0.63	7.7	0.45	3.8e-13	Parkinson's disease;
SARC	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg04824913	chr4:887549	GAK	0.41	5.04	0.31	9.51e-7	Sjögren's syndrome;
SARC	cis	rs1153858	1.000	rs4625670	chr15:45652926	C/T	cg21132104	chr15:45694354	SPATA5L1	0.77	10.99	0.58	6.68e-23	Homoarginine levels;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg20725662	chr12:978764	HSN2;WNK1	0.51	7.05	0.42	1.99e-11	Thyroid stimulating hormone;
SARC	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg09455208	chr3:40491958	NA	-0.37	-5.57	-0.34	6.95e-8	Renal cell carcinoma;
SARC	cis	rs7945705	0.692	rs11042149	chr11:9010737	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-6.85	-0.41	6.39e-11	Hemoglobin concentration;
SARC	cis	rs7927771	1.000	rs4752856	chr11:47648042	C/T	cg05585544	chr11:47624801	NA	-0.4	-5.47	-0.34	1.17e-7	Subjective well-being;
SARC	cis	rs11235843	0.636	rs2140892	chr11:73422879	A/G	cg18195628	chr11:73498948	MRPL48	-0.57	-5.59	-0.34	6.18e-8	Hand grip strength;
SARC	cis	rs3018712	0.532	rs7932726	chr11:68414727	T/C	cg01657329	chr11:68192670	LRP5	0.58	5.23	0.32	3.69e-7	Total body bone mineral density;
SARC	cis	rs116095464	0.558	rs73029475	chr5:206969	T/C	cg22496380	chr5:211416	CCDC127	-0.9	-8.06	-0.47	3.98e-14	Breast cancer;
SARC	cis	rs365132	0.967	rs11740768	chr5:176339499	G/A	cg16309518	chr5:176445507	NA	-0.45	-5.85	-0.36	1.61e-8	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg13206674	chr6:150067644	NUP43	-0.48	-6.29	-0.38	1.57e-9	Lung cancer;
SARC	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg16606324	chr3:10149918	C3orf24	0.48	5.04	0.31	9.53e-7	Alzheimer's disease;
SARC	cis	rs7615952	0.546	rs2922197	chr3:125322032	G/A	cg05084668	chr3:125655381	ALG1L	-0.55	-4.89	-0.31	1.88e-6	Blood pressure (smoking interaction);
SARC	cis	rs6582630	0.502	rs11514371	chr12:38306306	G/C	cg13010199	chr12:38710504	ALG10B	0.78	10.77	0.58	3.34e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg13126279	chr21:47581558	C21orf56	0.51	6.15	0.37	3.39e-9	Testicular germ cell tumor;
SARC	cis	rs13217239	0.585	rs114919438	chr6:26963792	T/C	cg12292205	chr6:26970375	C6orf41	-0.43	-5.09	-0.32	7.24e-7	Schizophrenia;
SARC	cis	rs10078	0.515	rs890984	chr5:479540	A/G	cg08916839	chr5:415575	AHRR	0.82	7.9	0.46	1.08e-13	Fat distribution (HIV);
SARC	cis	rs7769051	0.522	rs6930703	chr6:133111266	C/T	cg22852734	chr6:133119734	C6orf192	1.14	7.27	0.43	5.3e-12	Type 2 diabetes nephropathy;
SARC	cis	rs11098499	0.955	rs7684942	chr4:120162201	C/T	cg09307838	chr4:120376055	NA	0.84	11.55	0.6	1.04e-24	Corneal astigmatism;
SARC	cis	rs34779708	0.931	rs7084196	chr10:35367161	T/C	cg03585969	chr10:35415529	CREM	0.39	4.97	0.31	1.32e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs3020736	0.500	rs6002601	chr22:42489058	A/T	cg15557168	chr22:42548783	NA	0.35	4.8	0.3	2.85e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.46	-5.46	-0.34	1.25e-7	Bipolar disorder;
SARC	cis	rs11871801	0.517	rs60929812	chr17:40759448	G/A	cg14558262	chr17:40713999	COASY	0.5	5.57	0.34	6.9e-8	Crohn's disease;
SARC	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg02725872	chr8:58115012	NA	-0.34	-5.37	-0.33	1.91e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6690583	1.000	rs6690583	chr1:85466337	A/G	cg22153463	chr1:85462885	MCOLN2	-0.62	-6.46	-0.39	6.04e-10	Serum sulfate level;
SARC	cis	rs8067354	0.645	rs2645467	chr17:57854783	C/T	cg13753209	chr17:57696993	CLTC	0.67	7.09	0.42	1.59e-11	Hemoglobin concentration;
SARC	cis	rs12142240	0.659	rs1984491	chr1:46858607	T/G	cg00530320	chr1:46809349	NSUN4	0.57	7.0	0.42	2.74e-11	Menopause (age at onset);
SARC	cis	rs981844	1.000	rs116588966	chr4:154664794	T/C	cg14289246	chr4:154710475	SFRP2	0.58	6.68	0.4	1.71e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs3796352	1.000	rs1346719	chr3:53077372	A/G	cg15956490	chr3:53032818	SFMBT1	0.64	5.16	0.32	5.26e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs7712401	0.691	rs62377436	chr5:122353702	C/G	cg19412675	chr5:122181750	SNX24	-0.45	-5.84	-0.36	1.75e-8	Mean platelet volume;
SARC	cis	rs7726839	0.718	rs6887972	chr5:597274	C/G	cg09021430	chr5:549028	NA	-0.47	-6.97	-0.42	3.2e-11	Obesity-related traits;
SARC	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg22535103	chr8:58192502	C8orf71	-0.81	-9.27	-0.52	1.26e-17	Developmental language disorder (linguistic errors);
SARC	cis	rs9715521	0.775	rs62301198	chr4:59848776	C/T	cg11281224	chr4:60001000	NA	-0.4	-5.11	-0.32	6.63e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs57994353	0.897	rs36101132	chr9:139367566	G/A	cg14169450	chr9:139327907	INPP5E	0.43	5.53	0.34	8.37e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	trans	rs61931739	0.533	rs7970871	chr12:33917301	G/A	cg26384229	chr12:38710491	ALG10B	0.55	7.14	0.42	1.21e-11	Morning vs. evening chronotype;
SARC	cis	rs4819052	0.788	rs35323494	chr21:46703739	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.66	7.76	0.45	2.73e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs11077998	0.967	rs4789786	chr17:80504352	A/G	cg10255544	chr17:80519551	FOXK2	-0.42	-6.21	-0.38	2.37e-9	Reticulocyte fraction of red cells;
SARC	cis	rs10463554	0.892	rs6872442	chr5:102266522	A/T	cg23492399	chr5:102201601	PAM	-0.45	-5.4	-0.33	1.67e-7	Parkinson's disease;
SARC	cis	rs9392653	1.000	rs9392653	chr6:5071492	C/T	cg00563771	chr6:5110810	LYRM4	-0.44	-4.9	-0.31	1.79e-6	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs2204008	0.777	rs2049130	chr12:38444837	G/A	cg26384229	chr12:38710491	ALG10B	0.82	10.96	0.58	7.9e-23	Bladder cancer;
SARC	trans	rs17685	0.712	rs9800948	chr7:75810473	A/G	cg19862616	chr7:65841803	NCRNA00174	0.57	7.18	0.43	9.27e-12	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs568617	0.716	rs17854357	chr11:65601560	G/C	cg04055107	chr11:65626734	MUS81;CFL1	0.63	6.16	0.37	3.08e-9	Crohn's disease;
SARC	cis	rs4642101	0.765	rs9871991	chr3:12827525	C/A	cg12400702	chr3:12838781	CAND2	-0.26	-5.14	-0.32	5.75e-7	QRS complex (12-leadsum);
SARC	cis	rs8017423	0.967	rs7160032	chr14:90708472	A/G	cg20276874	chr14:90721474	PSMC1	-0.37	-5.17	-0.32	5.12e-7	Mortality in heart failure;
SARC	cis	rs2742234	0.590	rs2435377	chr10:43683600	A/G	cg15436174	chr10:43711423	RASGEF1A	0.41	4.94	0.31	1.52e-6	Hirschsprung disease;
SARC	cis	rs8058578	0.945	rs8058961	chr16:30809063	G/A	cg00531865	chr16:30841666	NA	-0.47	-5.26	-0.33	3.26e-7	Multiple myeloma;
SARC	cis	rs6910061	0.830	rs6456869	chr6:11115348	G/A	cg27233058	chr6:11094804	LOC221710	0.59	5.38	0.33	1.81e-7	Diabetic kidney disease;
SARC	cis	rs1153858	1.000	rs11070456	chr15:45686835	G/A	cg21132104	chr15:45694354	SPATA5L1	0.78	10.56	0.57	1.54e-21	Homoarginine levels;
SARC	cis	rs11122272	0.735	rs2486728	chr1:231535883	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.08	-0.55	4.68e-20	Hemoglobin concentration;
SARC	cis	rs7927592	0.913	rs10896330	chr11:68254998	A/G	cg01657329	chr11:68192670	LRP5	-0.41	-5.11	-0.32	6.72e-7	Total body bone mineral density;
SARC	cis	rs72781680	0.716	rs2712050	chr2:24059408	A/C	cg08917208	chr2:24149416	ATAD2B	0.65	6.42	0.39	7.52e-10	Lymphocyte counts;
SARC	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg05368731	chr17:41323189	NBR1	0.73	8.73	0.5	5.08e-16	Menopause (age at onset);
SARC	cis	rs2011503	0.943	rs2965195	chr19:19463032	A/G	cg03709012	chr19:19516395	GATAD2A	-0.63	-5.7	-0.35	3.65e-8	Bipolar disorder;
SARC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg20102877	chr2:27665638	KRTCAP3	-0.35	-4.75	-0.3	3.6e-6	Total body bone mineral density;
SARC	cis	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg00409905	chr10:38381863	ZNF37A	-0.5	-6.79	-0.41	9.26e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs2153535	0.580	rs4140586	chr6:8503192	A/G	cg23788917	chr6:8435910	SLC35B3	0.64	8.23	0.47	1.32e-14	Motion sickness;
SARC	cis	rs11190604	1.000	rs12219789	chr10:102213778	A/G	cg07080220	chr10:102295463	HIF1AN	0.77	9.69	0.54	7.17e-19	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs9341808	0.667	rs2490251	chr6:80895164	A/G	cg08355045	chr6:80787529	NA	0.37	5.96	0.36	9.18e-9	Sitting height ratio;
SARC	cis	rs950776	0.518	rs28438420	chr15:78836288	A/T	cg22563815	chr15:78856949	CHRNA5	-0.37	-6.1	-0.37	4.29e-9	Sudden cardiac arrest;
SARC	cis	rs1348850	0.651	rs1901826	chr2:178225266	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	7.89	0.46	1.2e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs317865	0.737	rs55949632	chr4:16207072	T/C	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.63	4.83	0.3	2.46e-6	Kidney disease (early stage) in type 1 diabetes;
SARC	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg13206674	chr6:150067644	NUP43	0.44	5.78	0.35	2.37e-8	Lung cancer;
SARC	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.79	11.44	0.6	2.47e-24	Subjective well-being;
SARC	cis	rs709400	0.628	rs12879085	chr14:103874420	G/A	cg12935359	chr14:103987150	CKB	0.4	5.97	0.36	8.86e-9	Body mass index;
SARC	cis	rs10911232	0.507	rs4483371	chr1:182988352	G/A	cg13390022	chr1:182993471	LAMC1	0.35	5.24	0.32	3.63e-7	Hypertriglyceridemia;
SARC	cis	rs208520	0.661	rs4710566	chr6:66848538	G/A	cg07460842	chr6:66804631	NA	-1.06	-15.03	-0.7	3.85e-36	Exhaled nitric oxide output;
SARC	cis	rs644799	0.735	rs10831432	chr11:95516040	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.93	16.13	0.73	7.97e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs1113500	0.805	rs11185248	chr1:108611001	A/G	cg06207961	chr1:108661230	NA	-0.37	-4.83	-0.3	2.45e-6	Growth-regulated protein alpha levels;
SARC	cis	rs2562456	0.920	rs2650784	chr19:21666597	T/C	cg00806126	chr19:22604979	ZNF98	0.49	5.28	0.33	2.92e-7	Pain;
SARC	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg05368731	chr17:41323189	NBR1	0.81	9.93	0.55	1.35e-19	Menopause (age at onset);
SARC	trans	rs17685	0.753	rs869804	chr7:75688954	A/G	cg19862616	chr7:65841803	NCRNA00174	0.63	7.99	0.46	6.41e-14	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	9.6	0.53	1.31e-18	Platelet count;
SARC	cis	rs9473924	0.542	rs66834257	chr6:50809141	G/A	cg14470998	chr6:50812995	TFAP2B	0.66	5.86	0.36	1.57e-8	Body mass index;
SARC	cis	rs7592578	0.537	rs62180982	chr2:191264485	G/T	cg10560079	chr2:191398806	TMEM194B	-0.68	-7.35	-0.43	3.26e-12	Diastolic blood pressure;
SARC	cis	rs9430161	0.579	rs9659356	chr1:11034817	A/G	cg02454025	chr1:11042201	C1orf127	0.88	12.45	0.63	1.28e-27	Ewing sarcoma;
SARC	cis	rs9985766	0.916	rs57168672	chr4:151056499	A/T	cg05926478	chr4:151174724	DCLK2	-0.49	-4.76	-0.3	3.47e-6	Coronary artery disease;Myocardial infarction;
SARC	cis	rs1564271	0.553	rs2489583	chr10:26987698	A/G	cg13837822	chr10:26931731	LOC731789	0.38	5.35	0.33	2.09e-7	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
SARC	cis	rs3733585	0.673	rs4447861	chr4:9953940	C/T	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.39	-0.33	1.76e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs17209837	1.000	rs59934297	chr7:87116469	T/G	cg00919237	chr7:87102261	ABCB4	-0.45	-4.76	-0.3	3.48e-6	Gallbladder cancer;
SARC	cis	rs2425143	1.000	rs733609	chr20:34393074	A/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	5.15	0.32	5.6e-7	Blood protein levels;
SARC	cis	rs4713118	0.516	rs6931858	chr6:28078411	A/T	cg26335602	chr6:28129616	ZNF389	0.52	5.69	0.35	3.86e-8	Parkinson's disease;
SARC	cis	rs7005606	1.000	rs12543882	chr8:32410693	C/T	cg14488905	chr8:32406789	NRG1	0.45	6.23	0.38	2.21e-9	Hirschsprung disease;
SARC	cis	rs2380220	0.720	rs9398251	chr6:95984709	C/T	cg04719120	chr6:96025338	MANEA	0.55	6.24	0.38	2.09e-9	Behavioural disinhibition (generation interaction);
SARC	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg04267008	chr7:1944627	MAD1L1	-0.49	-5.5	-0.34	9.72e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg08975724	chr8:8085496	FLJ10661	-0.46	-5.88	-0.36	1.39e-8	Mood instability;
SARC	cis	rs172166	0.637	rs1233691	chr6:28153897	T/G	cg26335602	chr6:28129616	ZNF389	0.42	5.14	0.32	5.7e-7	Cardiac Troponin-T levels;
SARC	cis	rs950776	0.684	rs61012457	chr15:78865694	C/G	cg22563815	chr15:78856949	CHRNA5	0.35	5.55	0.34	7.72e-8	Sudden cardiac arrest;
SARC	cis	rs826838	1.000	rs826888	chr12:39104719	C/G	cg13010199	chr12:38710504	ALG10B	-0.64	-9.24	-0.52	1.61e-17	Heart rate;
SARC	cis	rs2070677	0.935	rs11812637	chr10:135413418	A/G	cg20169779	chr10:135381914	SYCE1	-0.51	-6.07	-0.37	5.16e-9	Gout;
SARC	cis	rs7766436	0.614	rs55663812	chr6:22562881	G/A	cg13666174	chr6:22585274	NA	-0.56	-5.86	-0.36	1.59e-8	Coronary artery disease;
SARC	cis	rs1707322	1.000	rs11211223	chr1:46380605	C/T	cg03146154	chr1:46216737	IPP	0.46	5.52	0.34	8.98e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg03060546	chr3:49711283	APEH	0.48	6.31	0.38	1.41e-9	Menarche (age at onset);
SARC	cis	rs7836436	0.686	rs7010457	chr8:120955012	A/G	cg21659575	chr8:120844832	TAF2	0.7	5.15	0.32	5.42e-7	HIV-1 viral setpoint;
SARC	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.46	-5.83	-0.36	1.83e-8	Personality dimensions;
SARC	cis	rs7523050	0.643	rs7519293	chr1:109399543	A/G	cg08274380	chr1:109419600	GPSM2	1.07	8.3	0.48	8.22e-15	Fat distribution (HIV);
SARC	cis	rs10888329	0.665	rs9662722	chr1:248385891	T/G	cg13385794	chr1:248469461	NA	0.37	4.96	0.31	1.37e-6	Autism spectrum disorder;
SARC	cis	rs10771431	0.817	rs10843149	chr12:9362067	G/A	cg08997352	chr12:9597637	DDX12	-0.64	-9.35	-0.52	7.44e-18	Breast size;
SARC	cis	rs2602836	0.600	rs6858148	chr4:100065917	T/C	cg12011299	chr4:100065546	ADH4	-0.33	-5.87	-0.36	1.47e-8	HDL cholesterol;HDL cholesterol levels;
SARC	trans	rs9836270	1.000	rs9836270	chr3:131916996	G/T	cg25381331	chr1:53556414	SLC1A7	0.53	7.29	0.43	4.83e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9911578	1.000	rs2333332	chr17:56631054	A/G	cg12560992	chr17:57184187	TRIM37	-0.82	-11.06	-0.59	4.08e-23	Intelligence (multi-trait analysis);
SARC	cis	rs9906944	0.707	rs3816272	chr17:47120467	A/G	cg16584676	chr17:46985605	UBE2Z	-0.44	-5.3	-0.33	2.67e-7	Intelligence (multi-trait analysis);Body fat percentage;
SARC	cis	rs57502260	0.704	rs60538784	chr11:68386735	G/A	cg01657329	chr11:68192670	LRP5	-0.57	-5.66	-0.35	4.37e-8	Total body bone mineral density (age 45-60);
SARC	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg25894440	chr7:65020034	NA	-0.76	-5.65	-0.35	4.7e-8	Diabetic kidney disease;
SARC	cis	rs9303280	0.806	rs11078928	chr17:38064469	T/C	cg00129232	chr17:37814104	STARD3	-0.37	-4.83	-0.3	2.51e-6	Self-reported allergy;
SARC	cis	rs2204008	0.571	rs1117803	chr12:38281007	C/G	cg26384229	chr12:38710491	ALG10B	-0.6	-7.63	-0.45	5.8e-13	Bladder cancer;
SARC	trans	rs17685	0.712	rs60721456	chr7:75743820	T/A	cg19862616	chr7:65841803	NCRNA00174	0.58	7.0	0.42	2.74e-11	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs950776	0.518	rs4886571	chr15:78833758	G/A	cg17108064	chr15:78857060	CHRNA5	-0.29	-4.98	-0.31	1.24e-6	Sudden cardiac arrest;
SARC	cis	rs765787	0.530	rs11636404	chr15:45535861	C/G	cg24006582	chr15:45444508	DUOX1	-0.56	-7.49	-0.44	1.4e-12	Uric acid levels;
SARC	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg07343612	chr16:622815	PIGQ	-0.53	-7.39	-0.44	2.67e-12	Height;
SARC	cis	rs1448094	0.967	rs6539934	chr12:86343973	G/A	cg02569458	chr12:86230093	RASSF9	0.41	5.92	0.36	1.15e-8	Major depressive disorder;
SARC	cis	rs11264799	0.539	rs11264775	chr1:157578884	A/G	cg18268488	chr1:157545234	FCRL4	0.3	5.41	0.33	1.57e-7	IgA nephropathy;
SARC	cis	rs6489785	0.525	rs584001	chr12:121228055	G/T	cg02403541	chr12:121454288	C12orf43	0.43	4.78	0.3	3.14e-6	Longevity;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs834603	0.547	rs1704966	chr7:47469948	G/A	cg23694490	chr7:47445681	TNS3	-0.32	-5.89	-0.36	1.33e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs9457247	1.000	rs398278	chr6:167388169	A/G	cg07741184	chr6:167504864	NA	0.3	5.61	0.35	5.61e-8	Crohn's disease;
SARC	cis	rs3784262	0.967	rs12910752	chr15:58314679	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.38	-5.74	-0.35	2.99e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg21782813	chr7:2030301	MAD1L1	0.39	6.14	0.37	3.56e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs4243830	0.510	rs7518459	chr1:6596678	C/G	cg04093404	chr1:6614507	TAS1R1;NOL9	0.56	4.95	0.31	1.41e-6	Body mass index;
SARC	cis	rs910316	0.967	rs35446981	chr14:75637351	A/T	cg11812906	chr14:75593930	NEK9	-0.82	-11.68	-0.61	4.09e-25	Height;
SARC	cis	rs12912251	0.591	rs2624272	chr15:39003409	A/G	cg01338139	chr15:38987640	C15orf53	0.49	4.81	0.3	2.67e-6	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
SARC	cis	rs9388451	0.839	rs11154331	chr6:126111429	A/T	cg06289844	chr6:126071538	HEY2	0.32	5.14	0.32	5.77e-7	Brugada syndrome;
SARC	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg02592271	chr2:27665507	KRTCAP3	-0.42	-6.42	-0.39	7.71e-10	Total body bone mineral density;
SARC	cis	rs66573146	0.831	rs6851488	chr4:6987412	C/T	cg15105060	chr4:7024189	TBC1D14	-0.69	-5.31	-0.33	2.62e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs1008375	1.000	rs28545485	chr4:17645376	C/T	cg02297831	chr4:17616191	MED28	0.5	6.47	0.39	5.82e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6580649	0.941	rs7296913	chr12:48488920	G/A	cg05342945	chr12:48394962	COL2A1	0.57	6.27	0.38	1.77e-9	Lung cancer;
SARC	cis	rs73195822	0.667	rs73194055	chr12:111216292	T/C	cg10860002	chr12:110842031	ANAPC7	0.58	4.98	0.31	1.24e-6	Itch intensity from mosquito bite;
SARC	cis	rs13088281	1.000	rs13088281	chr3:53147576	A/C	cg15956490	chr3:53032818	SFMBT1	-0.74	-5.1	-0.32	7.16e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	6.0	0.37	7.37e-9	Prudent dietary pattern;
SARC	cis	rs9291683	0.530	rs10939620	chr4:9946132	C/T	cg11266682	chr4:10021025	SLC2A9	-0.39	-7.1	-0.42	1.52e-11	Bone mineral density;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg17461271	chr1:172717683	NA	-0.79	-6.53	-0.39	3.98e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2230307	0.536	rs560659	chr1:100523536	A/G	cg24955406	chr1:100503596	HIAT1	-0.71	-7.04	-0.42	2.16e-11	Carotid intima media thickness;
SARC	cis	rs13040088	1.000	rs2273412	chr20:61553802	G/A	cg23096297	chr20:61557774	DIDO1	0.93	9.66	0.53	8.89e-19	Menopause (age at onset);
SARC	cis	rs7621025	0.500	rs9845460	chr3:136587117	A/G	cg15507776	chr3:136538369	TMEM22	0.93	10.68	0.57	6.21e-22	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg26476595	chr16:2284284	E4F1	-0.72	-6.24	-0.38	2.05e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs11574514	0.661	rs35356834	chr16:67696365	G/A	cg01866162	chr16:67596514	CTCF	1.13	6.68	0.4	1.7e-10	Crohn's disease;
SARC	cis	rs933688	1.000	rs12654787	chr5:90713259	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.02	12.84	0.64	6.81e-29	Smoking behavior;
SARC	cis	rs9905704	0.647	rs9901655	chr17:56987142	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.41	-4.92	-0.31	1.62e-6	Testicular germ cell tumor;
SARC	cis	rs10744422	1.000	rs4759355	chr12:123316566	A/G	cg25930673	chr12:123319894	HIP1R	-0.65	-5.03	-0.31	9.99e-7	Schizophrenia;
SARC	cis	rs2576037	0.899	rs12955429	chr18:44585484	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.37	-5.02	-0.31	1e-6	Personality dimensions;
SARC	cis	rs7998202	0.667	rs282578	chr13:113358584	A/G	cg02820901	chr13:113351484	ATP11A	0.52	4.92	0.31	1.65e-6	Glycated hemoglobin levels;
SARC	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg13206674	chr6:150067644	NUP43	0.41	5.36	0.33	2.01e-7	Lung cancer;
SARC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg14159672	chr1:205819179	PM20D1	0.94	17.2	0.75	2.33e-43	Menarche (age at onset);
SARC	cis	rs3733585	0.598	rs28677023	chr4:9958326	C/A	cg11266682	chr4:10021025	SLC2A9	-0.35	-6.03	-0.37	6.35e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs992157	0.560	rs1514132	chr2:219084082	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.59	-7.9	-0.46	1.1e-13	Colorectal cancer;
SARC	cis	rs9790314	0.846	rs6768818	chr3:160951648	A/G	cg03342759	chr3:160939853	NMD3	-0.73	-9.94	-0.55	1.26e-19	Morning vs. evening chronotype;
SARC	cis	rs3008870	1.000	rs4620509	chr1:67449941	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.89	-11.03	-0.59	4.76e-23	Lymphocyte percentage of white cells;
SARC	cis	rs8079658	0.951	rs114298253	chr17:63833653	C/G	cg03442606	chr17:63822778	CCDC46	-0.38	-4.82	-0.3	2.63e-6	Post bronchodilator FEV1;
SARC	cis	rs57506017	0.585	rs3173615	chr7:12269417	C/G	cg23422036	chr7:12250390	TMEM106B	0.45	5.87	0.36	1.49e-8	Neuroticism;
SARC	cis	rs3820928	0.874	rs6706802	chr2:227850776	A/G	cg11843606	chr2:227700838	RHBDD1	-0.56	-6.78	-0.41	9.86e-11	Pulmonary function;
SARC	cis	rs453301	0.657	rs36056437	chr8:8792865	T/G	cg15556689	chr8:8085844	FLJ10661	-0.39	-4.82	-0.3	2.62e-6	Joint mobility (Beighton score);
SARC	cis	rs10861342	1.000	rs7305712	chr12:105519188	A/T	cg23923672	chr12:105501055	KIAA1033	-0.78	-6.05	-0.37	5.66e-9	IgG glycosylation;
SARC	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.79	-8.47	-0.49	2.86e-15	Alzheimer's disease;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg07661849	chr4:146686236	ZNF827	-0.47	-6.24	-0.38	2.06e-9	Chemerin levels;
SARC	cis	rs7829975	0.560	rs4841013	chr8:8552013	A/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-5.58	-0.34	6.62e-8	Mood instability;
SARC	trans	rs9650657	0.711	rs35091929	chr8:10693492	T/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.1	-0.42	1.47e-11	Neuroticism;
SARC	cis	rs74417235	0.610	rs35212808	chr5:154057808	A/G	cg17344516	chr5:154026930	NA	0.52	5.25	0.33	3.39e-7	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
SARC	cis	rs8020289	0.560	rs8012119	chr14:77260702	G/T	cg23436960	chr14:77239540	VASH1	-0.32	-4.79	-0.3	2.91e-6	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);
SARC	cis	rs4820294	0.926	rs62236671	chr22:38069305	G/A	cg21798802	chr22:38057573	PDXP	0.38	5.71	0.35	3.35e-8	Fat distribution (HIV);
SARC	cis	rs2273669	0.831	rs11153152	chr6:109343340	A/T	cg05315195	chr6:109294784	ARMC2	-0.51	-5.23	-0.32	3.74e-7	Prostate cancer;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg06816055	chr11:122527360	UBASH3B	0.51	6.5	0.39	4.73e-10	Lung adenocarcinoma;
SARC	cis	rs9354308	0.771	rs2814100	chr6:66528107	A/G	cg07460842	chr6:66804631	NA	0.5	5.63	0.35	5.19e-8	Metabolite levels;
SARC	cis	rs888194	0.934	rs3742015	chr12:110017125	T/C	cg08884029	chr12:110012500	MVK;MMAB	-0.33	-4.94	-0.31	1.5e-6	Neuroticism;
SARC	cis	rs910316	0.789	rs175444	chr14:75601782	G/C	cg06637938	chr14:75390232	RPS6KL1	-0.46	-6.22	-0.38	2.28e-9	Height;
SARC	cis	rs17376456	0.504	rs7702649	chr5:93065149	C/A	cg25358565	chr5:93447407	FAM172A	0.95	10.58	0.57	1.29e-21	Diabetic retinopathy;
SARC	cis	rs751728	0.717	rs2281816	chr6:33772335	A/G	cg25922239	chr6:33757077	LEMD2	0.64	7.63	0.45	6.12e-13	Crohn's disease;
SARC	cis	rs9457247	0.934	rs2345571	chr6:167403400	T/G	cg07741184	chr6:167504864	NA	0.29	5.55	0.34	7.59e-8	Crohn's disease;
SARC	cis	rs13082711	0.911	rs923941	chr3:27458914	A/G	cg02860705	chr3:27208620	NA	0.46	5.98	0.36	8.17e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg18252515	chr7:66147081	NA	0.51	5.5	0.34	1.01e-7	Aortic root size;
SARC	cis	rs75920871	0.588	rs4938321	chr11:116852507	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.47	-4.94	-0.31	1.47e-6	Subjective well-being;
SARC	cis	rs526231	0.511	rs62362558	chr5:102368493	C/T	cg23492399	chr5:102201601	PAM	-0.51	-5.58	-0.34	6.63e-8	Primary biliary cholangitis;
SARC	cis	rs3768617	0.510	rs2296290	chr1:183079412	C/T	cg13390022	chr1:182993471	LAMC1	0.32	4.88	0.3	1.95e-6	Fuchs's corneal dystrophy;
SARC	cis	rs10979	0.651	rs9321921	chr6:143895053	C/T	cg25407410	chr6:143891975	LOC285740	-0.6	-7.5	-0.44	1.35e-12	Hypospadias;
SARC	cis	rs7552404	0.627	rs12127049	chr1:76353248	G/A	cg22875332	chr1:76189707	ACADM	0.41	5.17	0.32	5.04e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	trans	rs80052780	0.579	rs298465	chr4:139260860	C/G	cg09529783	chr8:1958930	NA	-0.61	-6.47	-0.39	5.75e-10	Response to paliperidone in schizophrenia (Multivariate);
SARC	cis	rs7592578	0.713	rs60915953	chr2:191331304	G/C	cg10560079	chr2:191398806	TMEM194B	-0.8	-8.38	-0.48	5e-15	Diastolic blood pressure;
SARC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg09436375	chr6:42928200	GNMT	-0.35	-5.25	-0.33	3.41e-7	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs17125944	0.686	rs2025634	chr14:53336017	C/T	cg00686598	chr14:53173677	PSMC6	-0.62	-4.77	-0.3	3.3e-6	Alzheimer's disease (late onset);
SARC	cis	rs2230307	0.764	rs17418475	chr1:100587146	T/C	cg24955406	chr1:100503596	HIAT1	0.71	4.86	0.3	2.11e-6	Carotid intima media thickness;
SARC	cis	rs2153535	0.580	rs6941771	chr6:8494452	T/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.44	0.6	2.41e-24	Motion sickness;
SARC	cis	rs77106637	0.929	rs1059000	chr11:72504972	G/C	cg03713592	chr11:72463424	ARAP1	1.04	9.91	0.54	1.56e-19	Type 2 diabetes;
SARC	cis	rs1865760	0.516	rs9393683	chr6:26066198	A/G	cg18357526	chr6:26021779	HIST1H4A	0.45	5.72	0.35	3.23e-8	Height;
SARC	cis	rs765787	0.530	rs11070451	chr15:45533541	T/C	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.81e-6	Uric acid levels;
SARC	cis	rs763121	0.819	rs5757169	chr22:39003495	G/A	cg21395723	chr22:39101663	GTPBP1	0.58	6.72	0.4	1.4e-10	Menopause (age at onset);
SARC	trans	rs11143230	1.000	rs11143230	chr9:74887703	G/T	cg14073058	chr2:99797500	MRPL30;MITD1	0.56	6.23	0.38	2.14e-9	Suicidal ideation;
SARC	cis	rs9323205	0.911	rs12587611	chr14:51641399	C/T	cg23942311	chr14:51606299	NA	-0.32	-4.97	-0.31	1.31e-6	Cancer;
SARC	cis	rs4880487	0.853	rs1876898	chr10:1249986	C/T	cg03183215	chr10:1252341	ADARB2	-0.32	-5.25	-0.33	3.46e-7	Migraine;
SARC	cis	rs9393692	0.645	rs6939048	chr6:26327953	G/A	cg05868516	chr6:26286170	HIST1H4H	0.48	5.48	0.34	1.08e-7	Educational attainment;
SARC	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.65	4.79	0.3	2.95e-6	Initial pursuit acceleration;
SARC	cis	rs1878931	0.580	rs7204571	chr16:3402444	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.87	12.67	0.64	2.46e-28	Body mass index (adult);
SARC	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg00450029	chr8:599525	NA	0.72	5.56	0.34	7.35e-8	IgG glycosylation;
SARC	cis	rs10779751	0.666	rs77270747	chr1:11214584	A/C	cg08854313	chr1:11322531	MTOR	-0.82	-11.38	-0.6	3.85e-24	Body mass index;
SARC	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg18876405	chr7:65276391	NA	0.48	5.47	0.34	1.14e-7	Aortic root size;
SARC	cis	rs2153535	0.580	rs7753192	chr6:8482637	G/A	cg07606381	chr6:8435919	SLC35B3	0.78	11.13	0.59	2.44e-23	Motion sickness;
SARC	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg18850127	chr7:39170497	POU6F2	0.46	5.9	0.36	1.27e-8	IgG glycosylation;
SARC	cis	rs7513165	1.000	rs11240695	chr1:204158132	C/A	cg23788856	chr1:204159729	KISS1	-0.32	-4.98	-0.31	1.24e-6	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
SARC	cis	rs10779751	0.881	rs2744815	chr1:11360957	C/T	cg08854313	chr1:11322531	MTOR	0.73	9.9	0.54	1.62e-19	Body mass index;
SARC	cis	rs11997175	0.574	rs4400340	chr8:33713343	C/T	ch.8.33884649F	chr8:33765107	NA	0.53	6.4	0.39	8.53e-10	Body mass index;
SARC	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg20607798	chr8:58055168	NA	0.58	5.57	0.34	6.9e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7662987	0.517	rs2602872	chr4:100038996	A/G	cg12011299	chr4:100065546	ADH4	0.32	5.36	0.33	2.02e-7	Smoking initiation;
SARC	cis	rs7223966	1.000	rs78172786	chr17:61847114	A/C	cg26338869	chr17:61819248	STRADA	0.48	5.05	0.31	9e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs933688	0.532	rs10072084	chr5:90539203	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.43	4.96	0.31	1.37e-6	Smoking behavior;
SARC	cis	rs9916302	0.752	rs12150047	chr17:37601755	A/G	cg07936489	chr17:37558343	FBXL20	-0.77	-9.06	-0.51	5.48e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs8084125	0.832	rs62105180	chr18:74951197	C/G	cg26065057	chr18:74961000	GALR1	0.47	4.89	0.31	1.89e-6	Obesity-related traits;
SARC	cis	rs11871801	0.517	rs6963	chr17:40731597	A/T	cg14558262	chr17:40713999	COASY	-0.52	-5.94	-0.36	1.05e-8	Crohn's disease;
SARC	cis	rs2760061	0.583	rs708113	chr1:228192753	T/A	cg01200585	chr1:228362443	C1orf69	0.44	5.74	0.35	3e-8	Diastolic blood pressure;
SARC	cis	rs13314892	0.764	rs61148813	chr3:69870033	C/A	cg17445875	chr3:69859618	MITF	-0.49	-5.12	-0.32	6.44e-7	QRS complex (12-leadsum);
SARC	cis	rs950776	0.616	rs6495307	chr15:78890321	C/T	cg22563815	chr15:78856949	CHRNA5	0.37	6.32	0.38	1.33e-9	Sudden cardiac arrest;
SARC	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg20120463	chr17:44301886	NA	0.32	5.03	0.31	9.89e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	trans	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.55	-7.09	-0.42	1.57e-11	Intelligence (multi-trait analysis);
SARC	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	5.28	0.33	2.93e-7	Tonsillectomy;
SARC	cis	rs11676348	0.818	rs7425447	chr2:218980183	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.5	-6.54	-0.39	3.81e-10	Ulcerative colitis;
SARC	cis	rs3749237	0.595	rs6797765	chr3:49423976	A/G	cg03060546	chr3:49711283	APEH	0.74	10.67	0.57	6.93e-22	Resting heart rate;
SARC	cis	rs2070997	0.607	rs7037741	chr9:133675110	C/A	cg11464064	chr9:133710261	ABL1	0.63	5.96	0.36	9.17e-9	Response to amphetamines;
SARC	cis	rs6121246	0.567	rs6060262	chr20:30193071	A/C	cg13852791	chr20:30311386	BCL2L1	0.66	5.92	0.36	1.15e-8	Mean corpuscular hemoglobin;
SARC	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	11.62	0.61	6.17e-25	Alzheimer's disease;
SARC	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg08280861	chr8:58055591	NA	0.72	6.19	0.38	2.62e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.57	8.94	0.51	1.24e-16	Eosinophil percentage of white cells;
SARC	cis	rs13191362	1.000	rs68045643	chr6:163029709	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.56	5.49	0.34	1.06e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs6912958	0.712	rs2307379	chr6:88366771	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.45	-5.9	-0.36	1.28e-8	Monocyte percentage of white cells;
SARC	cis	rs10916814	0.589	rs7416238	chr1:20897240	A/G	cg24502330	chr1:20914028	CDA	-0.29	-5.1	-0.32	7.19e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs9815354	1.000	rs7631057	chr3:41817951	C/T	cg03022575	chr3:42003672	ULK4	0.59	5.68	0.35	4.06e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg09359103	chr1:154839909	KCNN3	-0.45	-7.71	-0.45	3.66e-13	Prostate cancer;
SARC	cis	rs9894429	0.690	rs11869779	chr17:79570067	C/T	cg18240062	chr17:79603768	NPLOC4	-0.87	-13.58	-0.66	2.42e-31	Eye color traits;
SARC	cis	rs7582180	0.544	rs13026570	chr2:100939498	A/C	cg14675211	chr2:100938903	LONRF2	0.52	7.56	0.44	9.15e-13	Intelligence (multi-trait analysis);
SARC	cis	rs11098499	0.863	rs6835635	chr4:120458867	A/G	cg09307838	chr4:120376055	NA	0.92	12.32	0.63	3.39e-27	Corneal astigmatism;
SARC	cis	rs7681440	1.000	rs1471483	chr4:90754292	A/G	cg06632027	chr4:90757378	SNCA	0.44	6.28	0.38	1.63e-9	Dementia with Lewy bodies;
SARC	cis	rs9329221	0.527	rs34259385	chr8:10325456	C/T	cg21775007	chr8:11205619	TDH	-0.37	-4.74	-0.3	3.75e-6	Neuroticism;
SARC	trans	rs9650657	0.547	rs11250099	chr8:10818657	C/T	cg08975724	chr8:8085496	FLJ10661	0.54	7.05	0.42	2.05e-11	Neuroticism;
SARC	cis	rs8141529	0.956	rs132539	chr22:29304253	C/T	cg02153584	chr22:29168773	CCDC117	0.76	10.29	0.56	1.06e-20	Lymphocyte counts;
SARC	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg24503407	chr1:205819492	PM20D1	0.44	5.01	0.31	1.07e-6	Parkinson's disease;
SARC	cis	rs7296418	0.961	rs11608811	chr12:123529056	A/G	cg00376283	chr12:123451042	ABCB9	0.67	8.66	0.49	8.02e-16	Platelet count;
SARC	cis	rs7786877	0.521	rs2293767	chr7:100361675	A/G	cg20848291	chr7:100343083	ZAN	0.4	4.91	0.31	1.75e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg13188409	chr6:86303887	SNX14	0.63	6.43	0.39	7.1e-10	Lung cancer in ever smokers;
SARC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.56	6.33	0.38	1.27e-9	Prudent dietary pattern;
SARC	cis	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg24110177	chr3:50126178	RBM5	-0.4	-5.06	-0.31	8.7e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6918586	0.658	rs198828	chr6:26119459	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.45	-5.75	-0.35	2.77e-8	Schizophrenia;
SARC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.8	10.35	0.56	6.69e-21	Prudent dietary pattern;
SARC	cis	rs1355223	0.506	rs6484738	chr11:34860858	C/T	cg11622362	chr11:34938112	PDHX;APIP	0.39	4.94	0.31	1.52e-6	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs12142240	0.659	rs111723629	chr1:46853361	G/T	cg00530320	chr1:46809349	NSUN4	0.57	7.0	0.42	2.74e-11	Menopause (age at onset);
SARC	cis	rs734999	0.545	rs6698817	chr1:2564183	T/C	cg18854424	chr1:2615690	NA	-0.32	-5.11	-0.32	6.74e-7	Ulcerative colitis;
SARC	cis	rs10905065	0.965	rs7100576	chr10:5784649	G/A	cg09072322	chr10:5726702	C10orf18	-0.39	-4.99	-0.31	1.2e-6	Menopause (age at onset);
SARC	cis	rs11697848	1.000	rs77310132	chr20:48510630	A/G	cg17849948	chr20:48532315	SPATA2	0.86	5.17	0.32	4.97e-7	Systemic lupus erythematosus;
SARC	cis	rs13191362	1.000	rs7764785	chr6:163009967	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.56	5.35	0.33	2.07e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs6714710	0.603	rs116309486	chr2:98493359	A/G	cg26665480	chr2:98280029	ACTR1B	0.49	6.72	0.4	1.38e-10	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg16325326	chr1:53192061	ZYG11B	0.82	13.17	0.65	5.73e-30	Monocyte count;
SARC	cis	rs477692	0.673	rs1970197	chr10:131359588	C/T	cg05714579	chr10:131428358	MGMT	0.56	7.28	0.43	5.19e-12	Response to temozolomide;
SARC	cis	rs8014204	0.762	rs957345	chr14:75276079	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.5	-5.83	-0.36	1.85e-8	Caffeine consumption;
SARC	cis	rs7592578	0.771	rs4439990	chr2:191398353	A/C	cg10560079	chr2:191398806	TMEM194B	-0.78	-8.55	-0.49	1.61e-15	Diastolic blood pressure;
SARC	cis	rs8180040	0.739	rs11719306	chr3:47184182	G/A	cg02527881	chr3:46936655	PTH1R	-0.31	-4.8	-0.3	2.88e-6	Colorectal cancer;
SARC	cis	rs3796352	1.000	rs35507120	chr3:53053924	C/T	cg07884673	chr3:53033167	SFMBT1	0.91	5.89	0.36	1.37e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs67460515	0.892	rs73026976	chr3:160964271	G/A	cg03342759	chr3:160939853	NMD3	-0.71	-9.12	-0.51	3.55e-17	Parkinson's disease;
SARC	cis	rs9916302	0.706	rs584377	chr17:37460128	G/A	cg00129232	chr17:37814104	STARD3	0.54	5.76	0.35	2.7e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs2153535	0.580	rs1889715	chr6:8443475	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	7.37	0.43	2.94e-12	Motion sickness;
SARC	trans	rs1814175	0.618	rs1851843	chr11:50021846	T/C	cg03929089	chr4:120376271	NA	-0.82	-11.88	-0.61	9.03e-26	Height;
SARC	cis	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg06636001	chr8:8085503	FLJ10661	0.61	8.24	0.47	1.25e-14	Mood instability;
SARC	trans	rs1493916	0.777	rs1493910	chr18:31318376	A/G	cg27147174	chr7:100797783	AP1S1	-0.5	-6.25	-0.38	1.95e-9	Life satisfaction;
SARC	cis	rs4268898	0.896	rs2702042	chr2:24546542	C/T	cg06627628	chr2:24431161	ITSN2	-0.62	-8.72	-0.5	5.34e-16	Asthma;
SARC	cis	rs1023500	0.573	rs133382	chr22:42471774	C/T	cg04733989	chr22:42467013	NAGA	0.76	10.68	0.57	6.29e-22	Schizophrenia;
SARC	cis	rs1707322	1.000	rs785470	chr1:46519622	C/A	cg06784218	chr1:46089804	CCDC17	-0.39	-6.86	-0.41	6.02e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2303745	0.589	rs6512182	chr19:17399476	G/T	cg10664184	chr19:17420304	DDA1	0.48	4.89	0.3	1.91e-6	Systemic lupus erythematosus;
SARC	cis	rs6866344	0.570	rs1071881	chr5:178135917	C/T	cg10224037	chr5:178157518	ZNF354A	1.02	14.41	0.69	4.21e-34	Neutrophil percentage of white cells;
SARC	cis	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg25427524	chr10:38739819	LOC399744	-0.53	-8.46	-0.48	2.95e-15	Extrinsic epigenetic age acceleration;
SARC	cis	rs3815700	1.000	rs8109885	chr19:33095557	A/G	cg24916020	chr19:33096688	ANKRD27	0.55	5.32	0.33	2.4e-7	Eosinophilic esophagitis;
SARC	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg11987759	chr7:65425863	GUSB	-0.47	-6.25	-0.38	1.91e-9	Aortic root size;
SARC	cis	rs2425143	1.000	rs7261284	chr20:34244104	T/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.13	0.32	6.04e-7	Blood protein levels;
SARC	cis	rs6580649	0.941	rs72644841	chr12:48411987	A/G	cg05342945	chr12:48394962	COL2A1	0.54	5.64	0.35	4.85e-8	Lung cancer;
SARC	cis	rs3126085	0.935	rs4511113	chr1:152222192	G/A	cg26876637	chr1:152193138	HRNR	0.46	5.37	0.33	1.89e-7	Atopic dermatitis;
SARC	cis	rs9303401	0.659	rs11495824	chr17:56918882	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.07	12.11	0.62	1.62e-26	Cognitive test performance;
SARC	cis	rs4268898	0.662	rs714531	chr2:24399877	G/A	cg06627628	chr2:24431161	ITSN2	-0.8	-9.59	-0.53	1.46e-18	Asthma;
SARC	cis	rs2250402	0.510	rs2291621	chr15:40324837	C/T	cg01081584	chr15:40268610	EIF2AK4	-0.69	-5.97	-0.36	8.62e-9	Corneal curvature;
SARC	cis	rs8054556	0.787	rs12935701	chr16:30026748	C/T	cg06015834	chr16:30021696	DOC2A	-0.37	-5.0	-0.31	1.15e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg24846343	chr22:24311635	DDTL	0.54	7.75	0.45	2.9e-13	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2997447	0.846	rs61775417	chr1:26393347	C/G	cg19633962	chr1:26362018	EXTL1	-0.7	-5.51	-0.34	9.68e-8	QRS complex (12-leadsum);
SARC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg01238044	chr22:24384105	GSTT1	-0.58	-6.5	-0.39	4.85e-10	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg17971929	chr21:40555470	PSMG1	0.96	11.63	0.61	6.09e-25	Cognitive function;
SARC	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg03709012	chr19:19516395	GATAD2A	0.95	14.77	0.7	2.76e-35	Tonsillectomy;
SARC	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg10435706	chr6:150039699	LATS1	0.36	4.76	0.3	3.45e-6	Lung cancer;
SARC	cis	rs6121246	0.909	rs1887732	chr20:30413469	C/T	cg13852791	chr20:30311386	BCL2L1	0.86	8.26	0.48	1.07e-14	Mean corpuscular hemoglobin;
SARC	cis	rs921968	0.565	rs6436073	chr2:219618237	A/C	cg02176678	chr2:219576539	TTLL4	-0.32	-4.89	-0.31	1.85e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg21747090	chr2:27597821	SNX17	-0.56	-7.82	-0.46	1.77e-13	Total body bone mineral density;
SARC	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg22875332	chr1:76189707	ACADM	0.5	6.98	0.42	3.07e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg24846343	chr22:24311635	DDTL	-0.39	-4.9	-0.31	1.8e-6	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs7772486	0.754	rs702306	chr6:145991029	T/C	cg05347473	chr6:146136440	FBXO30	-0.54	-7.52	-0.44	1.14e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1707322	0.721	rs10890346	chr1:46223892	C/T	cg03146154	chr1:46216737	IPP	-0.5	-5.95	-0.36	9.52e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6964587	1.000	rs2188154	chr7:91595138	T/A	cg17063962	chr7:91808500	NA	0.95	15.95	0.72	3.15e-39	Breast cancer;
SARC	cis	rs8077889	0.956	rs61608877	chr17:41848713	A/C	cg26893861	chr17:41843967	DUSP3	0.79	9.11	0.51	3.8e-17	Triglycerides;
SARC	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg18225595	chr11:63971243	STIP1	0.41	4.9	0.31	1.8e-6	Mean platelet volume;
SARC	cis	rs2204008	0.837	rs11168387	chr12:37962818	G/A	cg13010199	chr12:38710504	ALG10B	-0.66	-8.87	-0.5	1.9e-16	Bladder cancer;
SARC	cis	rs4713675	0.565	rs3818530	chr6:33661222	C/G	cg15676125	chr6:33679581	C6orf125	0.5	6.22	0.38	2.33e-9	Plateletcrit;
SARC	cis	rs7727544	0.606	rs2631360	chr5:131707429	A/G	cg24060327	chr5:131705240	SLC22A5	-0.41	-4.91	-0.31	1.73e-6	Blood metabolite levels;
SARC	cis	rs7772486	0.686	rs857883	chr6:145969214	G/T	cg23711669	chr6:146136114	FBXO30	-0.86	-14.16	-0.68	3.03e-33	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1707322	1.000	rs6693336	chr1:46354595	C/T	cg06784218	chr1:46089804	CCDC17	0.35	6.06	0.37	5.3300000000000004e-09	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs16854884	0.609	rs9872126	chr3:143683851	G/A	cg06585982	chr3:143692056	C3orf58	0.5	6.68	0.4	1.76e-10	Economic and political preferences (feminism/equality);
SARC	cis	rs8141529	0.748	rs132533	chr22:29299571	A/G	cg02153584	chr22:29168773	CCDC117	-0.75	-10.83	-0.58	2.14e-22	Lymphocyte counts;
SARC	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg11861562	chr11:117069780	TAGLN	0.21	4.73	0.3	3.88e-6	Blood protein levels;
SARC	cis	rs6831352	0.879	rs29001212	chr4:100051877	T/C	cg12011299	chr4:100065546	ADH4	-0.34	-5.67	-0.35	4.13e-8	Alcohol dependence;
SARC	cis	rs7760949	0.889	rs9382688	chr6:13926746	A/T	cg27413430	chr6:13925136	RNF182	0.42	4.86	0.3	2.17e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs10883723	0.810	rs7094366	chr10:104274730	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	8.4	0.48	4.35e-15	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs41271473	0.526	rs2182202	chr1:228733959	G/C	cg10167378	chr1:228756711	NA	0.61	5.33	0.33	2.27e-7	Chronic lymphocytic leukemia;
SARC	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg18876405	chr7:65276391	NA	-0.47	-5.27	-0.33	3.15e-7	Aortic root size;
SARC	cis	rs11650494	0.516	rs117384420	chr17:47505383	G/C	cg08112188	chr17:47440006	ZNF652	0.69	6.63	0.4	2.25e-10	Prostate cancer;
SARC	cis	rs12545109	0.800	rs1467126	chr8:57418452	C/T	cg19413350	chr8:57351067	NA	-0.43	-5.4	-0.33	1.67e-7	Obesity-related traits;
SARC	cis	rs116095464	1.000	rs6873902	chr5:313337	C/G	cg22857025	chr5:266934	NA	-1.04	-8.51	-0.49	2.12e-15	Breast cancer;
SARC	cis	rs858239	0.570	rs10242166	chr7:23162799	A/G	cg23682824	chr7:23144976	KLHL7	0.74	10.17	0.55	2.37e-20	Cerebrospinal fluid biomarker levels;
SARC	cis	rs6665290	0.904	rs11578103	chr1:227189642	C/A	cg14016676	chr1:227182615	CDC42BPA	0.37	5.33	0.33	2.31e-7	Myeloid white cell count;
SARC	cis	rs6500395	0.925	rs9933148	chr16:48672099	C/T	cg04672837	chr16:48644449	N4BP1	0.46	6.03	0.37	6.28e-9	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs28475163	0.958	rs7395116	chr11:324880	C/G	cg03071500	chr11:325964	NA	0.52	6.44	0.39	6.92e-10	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
SARC	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg19680485	chr15:31195859	MTMR15	0.6	6.81	0.41	8.29e-11	Huntington's disease progression;
SARC	cis	rs1568889	0.938	rs7128045	chr11:28190180	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	10.16	0.55	2.62e-20	Bipolar disorder;
SARC	cis	rs7762018	0.769	rs4716385	chr6:170127608	G/T	cg13891659	chr6:170190454	C6orf122;C6orf208	0.62	5.35	0.33	2.1e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg00933542	chr6:150070202	PCMT1	0.31	5.05	0.31	8.78e-7	Lung cancer;
SARC	cis	rs861020	1.000	rs595918	chr1:209966843	A/G	cg05527609	chr1:210001259	C1orf107	0.95	10.51	0.57	2.1e-21	Orofacial clefts;
SARC	cis	rs72781680	0.950	rs72796402	chr2:24180104	A/G	cg06627628	chr2:24431161	ITSN2	-0.75	-7.03	-0.42	2.31e-11	Lymphocyte counts;
SARC	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.68	-8.88	-0.5	1.86e-16	Intelligence (multi-trait analysis);
SARC	cis	rs7084402	0.967	rs1658495	chr10:60280153	C/A	cg07615347	chr10:60278583	BICC1	-0.59	-8.54	-0.49	1.76e-15	Refractive error;
SARC	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg26924012	chr15:45694286	SPATA5L1	0.77	10.99	0.58	6.8e-23	Homoarginine levels;
SARC	cis	rs1865760	0.566	rs3752419	chr6:26027433	C/T	cg17691542	chr6:26056736	HIST1H1C	0.51	6.17	0.37	3.03e-9	Height;
SARC	cis	rs2013441	1.000	rs2703791	chr17:20163529	A/G	cg13482628	chr17:19912719	NA	-0.47	-6.18	-0.38	2.87e-9	Obesity-related traits;
SARC	cis	rs12908161	0.959	rs12906348	chr15:85329421	A/C	cg17507749	chr15:85114479	UBE2QP1	0.54	6.11	0.37	4.18e-9	Schizophrenia;
SARC	cis	rs6750795	0.502	rs11685196	chr2:232381298	A/G	cg19187155	chr2:232395269	NMUR1	0.72	10.85	0.58	1.77e-22	Height;
SARC	cis	rs66573146	0.634	rs55633489	chr4:6988745	C/A	cg15105060	chr4:7024189	TBC1D14	-0.69	-4.96	-0.31	1.35e-6	Granulocyte percentage of myeloid white cells;
SARC	cis	rs2204008	0.743	rs2127952	chr12:37995364	G/T	cg26384229	chr12:38710491	ALG10B	0.86	12.42	0.63	1.62e-27	Bladder cancer;
SARC	cis	rs9916302	0.904	rs602282	chr17:37433021	C/T	cg20243544	chr17:37824526	PNMT	0.56	6.87	0.41	5.87e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs3825932	0.778	rs1036938	chr15:79237247	C/G	cg25744700	chr15:79237217	CTSH	0.37	5.0	0.31	1.13e-6	Type 1 diabetes;
SARC	cis	rs62244186	0.520	rs9311361	chr3:44796132	T/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.57	7.49	0.44	1.44e-12	Depressive symptoms;
SARC	cis	rs148734725	1	rs148734725	chr3:49406708	G/A	cg03060546	chr3:49711283	APEH	-0.57	-7.14	-0.42	1.19e-11	Educational attainment (college completion);
SARC	cis	rs67478160	0.619	rs12885018	chr14:104273812	A/G	cg26031613	chr14:104095156	KLC1	-0.4	-4.79	-0.3	3e-6	Schizophrenia;
SARC	cis	rs995000	0.931	rs10889330	chr1:62939466	G/C	cg06896770	chr1:63153194	DOCK7	0.95	14.49	0.69	2.45e-34	Triglyceride levels;
SARC	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg15352829	chr14:105391018	PLD4	-0.33	-6.33	-0.38	1.24e-9	Rheumatoid arthritis;
SARC	cis	rs10504073	0.647	rs59064792	chr8:50018337	A/C	cg00325661	chr8:49890786	NA	0.53	7.35	0.43	3.36e-12	Blood metabolite ratios;
SARC	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg11987759	chr7:65425863	GUSB	0.57	7.53	0.44	1.14e-12	Aortic root size;
SARC	cis	rs3824867	0.959	rs4237544	chr11:47454271	G/T	cg20307385	chr11:47447363	PSMC3	-0.49	-5.36	-0.33	1.98e-7	Mean corpuscular hemoglobin;
SARC	cis	rs2777491	1.000	rs2730055	chr15:41735708	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.82	-12.19	-0.62	9.25e-27	Ulcerative colitis;
SARC	cis	rs6598955	0.502	rs6683157	chr1:26545865	G/A	cg04990556	chr1:26633338	UBXN11	0.76	7.67	0.45	4.53e-13	Obesity-related traits;
SARC	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.91	11.07	0.59	3.6e-23	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs79349575	0.716	rs46522	chr17:46988597	C/T	cg07967210	chr17:47022446	SNF8	0.4	4.96	0.31	1.34e-6	Type 2 diabetes;
SARC	cis	rs12681366	0.571	rs2919654	chr8:95476273	T/A	cg26464482	chr8:95565502	KIAA1429	0.42	5.18	0.32	4.71e-7	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs240764	0.746	rs151572	chr6:101110984	C/T	cg09795085	chr6:101329169	ASCC3	0.44	5.71	0.35	3.39e-8	Neuroticism;
SARC	cis	rs1568889	1.000	rs1464897	chr11:28034844	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	10.16	0.55	2.68e-20	Bipolar disorder;
SARC	cis	rs9527	0.590	rs7073323	chr10:104797423	A/C	cg04362960	chr10:104952993	NT5C2	0.43	4.89	0.3	1.91e-6	Arsenic metabolism;
SARC	cis	rs477692	1.000	rs558764	chr10:131426957	G/T	cg05714579	chr10:131428358	MGMT	-0.53	-6.67	-0.4	1.84e-10	Response to temozolomide;
SARC	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.91	11.07	0.59	3.6e-23	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg15847926	chr7:2749597	AMZ1	-0.29	-4.8	-0.3	2.81e-6	Height;
SARC	cis	rs67311347	1.000	rs13324109	chr3:40460767	T/C	cg09455208	chr3:40491958	NA	0.43	6.91	0.41	4.53e-11	Renal cell carcinoma;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg16283385	chr11:120958445	TBCEL	0.49	7.04	0.42	2.2e-11	Thyroid stimulating hormone;
SARC	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg24399712	chr22:39784796	NA	-0.42	-5.28	-0.33	2.9e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs2120019	0.938	rs8033925	chr15:75311959	A/G	cg12414181	chr15:75287860	SCAMP5	-0.48	-5.53	-0.34	8.36e-8	Blood trace element (Zn levels);
SARC	cis	rs694739	1.000	rs11231757	chr11:64106317	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.67	8.61	0.49	1.11e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs12586317	0.547	rs60152856	chr14:35421373	G/A	cg16230307	chr14:35515116	FAM177A1	1.05	11.56	0.6	9.61e-25	Psoriasis;
SARC	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg22484793	chr3:52261325	TLR9	0.29	4.73	0.3	3.83e-6	Bipolar disorder;
SARC	cis	rs66486766	1	rs66486766	chr15:84806060	G/A	cg17507749	chr15:85114479	UBE2QP1	0.75	8.75	0.5	4.29e-16	Bipolar disorder lithium response (categorical) or schizophrenia;
SARC	cis	rs11997175	0.646	rs61693382	chr8:33697255	A/C	ch.8.33884649F	chr8:33765107	NA	0.63	8.6	0.49	1.21e-15	Body mass index;
SARC	cis	rs9399137	0.507	rs13209780	chr6:135344795	G/C	cg24558204	chr6:135376177	HBS1L	0.62	8.02	0.47	5.03e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	trans	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg22501899	chr17:41133082	AARSD1;RUNDC1	-0.7	-6.81	-0.41	8.39e-11	Cutaneous psoriasis;
SARC	cis	rs3749237	0.595	rs17595772	chr3:49409704	G/A	cg06212747	chr3:49208901	KLHDC8B	0.51	6.24	0.38	1.99e-9	Resting heart rate;
SARC	cis	rs2562456	1.000	rs2562456	chr19:21666210	A/G	cg03331224	chr19:21860916	NA	-0.29	-4.82	-0.3	2.63e-6	Pain;
SARC	cis	rs1003719	0.788	rs4817844	chr21:38447064	A/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.69	-10.49	-0.57	2.49e-21	Eye color traits;
SARC	cis	rs7520050	0.808	rs11211195	chr1:46282295	T/C	cg06784218	chr1:46089804	CCDC17	-0.26	-4.74	-0.3	3.76e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs4243830	0.850	rs4908911	chr1:6599523	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.48	-4.8	-0.3	2.87e-6	Body mass index;
SARC	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	8.86	0.5	2.03e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg02725872	chr8:58115012	NA	-0.35	-5.39	-0.33	1.72e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs208520	1.000	rs72882102	chr6:66983408	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.83	9.35	0.52	7.46e-18	Exhaled nitric oxide output;
SARC	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg22920501	chr2:26401640	FAM59B	-0.55	-7.03	-0.42	2.29e-11	Gut microbiome composition (summer);
SARC	cis	rs35213789	0.878	rs7779308	chr7:69529374	A/T	cg10619644	chr7:69149951	AUTS2	0.41	5.09	0.32	7.28e-7	Childhood ear infection;
SARC	cis	rs7904368	0.659	rs3740169	chr10:16873547	C/T	cg14835575	chr10:16859367	RSU1	0.62	6.9	0.41	4.83e-11	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs7666738	0.830	rs11944855	chr4:99068258	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.71	0.5	5.54e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs17376456	0.877	rs12374488	chr5:93481407	A/G	cg21475434	chr5:93447410	FAM172A	0.89	7.4	0.44	2.4e-12	Diabetic retinopathy;
SARC	cis	rs112591243	0.614	rs78654337	chr21:47824372	A/G	cg10657630	chr21:48055338	PRMT2	0.76	4.78	0.3	3.11e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs644799	0.965	rs499076	chr11:95546341	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	15.35	0.71	3.21e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2908197	0.737	rs10230188	chr7:75980872	A/G	cg22830091	chr7:75961684	YWHAG	-0.35	-5.21	-0.32	4.09e-7	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs735539	0.521	rs2585902	chr13:21417636	A/C	cg16922012	chr13:21400325	XPO4	-0.44	-6.08	-0.37	4.98e-9	Dental caries;
SARC	cis	rs4427176	0.579	rs7821695	chr8:9656509	A/T	cg21625330	chr8:9911636	MSRA	0.64	5.19	0.32	4.6e-7	Mosquito bite size;
SARC	cis	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg05623727	chr3:50126028	RBM5	0.33	5.0	0.31	1.14e-6	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg08280861	chr8:58055591	NA	0.6	5.94	0.36	1.03e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs743757	1.000	rs2236979	chr3:50486895	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.51	4.85	0.3	2.29e-6	Diastolic blood pressure;
SARC	cis	rs2153535	0.580	rs6905242	chr6:8471799	A/C	cg23788917	chr6:8435910	SLC35B3	0.64	8.4	0.48	4.41e-15	Motion sickness;
SARC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg06873352	chr17:61820015	STRADA	0.53	6.88	0.41	5.62e-11	Prudent dietary pattern;
SARC	trans	rs3942852	0.568	rs7479361	chr11:48109793	C/T	cg03929089	chr4:120376271	NA	-0.56	-6.77	-0.41	1.04e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs6089584	0.830	rs6089309	chr20:60585687	T/C	cg23262073	chr20:60523788	NA	-0.45	-6.43	-0.39	7.25e-10	Body mass index;
SARC	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg10792982	chr14:105748885	BRF1	0.54	8.08	0.47	3.51e-14	Mean platelet volume;Platelet distribution width;
SARC	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg05368731	chr17:41323189	NBR1	0.81	9.93	0.55	1.35e-19	Menopause (age at onset);
SARC	cis	rs9787249	0.957	rs56064244	chr1:40213890	C/T	cg24920358	chr1:40204285	PPIE	0.43	5.25	0.33	3.45e-7	Blood protein levels;
SARC	cis	rs17376456	0.877	rs10052428	chr5:93476530	T/C	cg21475434	chr5:93447410	FAM172A	0.91	7.83	0.46	1.71e-13	Diabetic retinopathy;
SARC	cis	rs11630290	1.000	rs72750986	chr15:63996338	C/A	cg12036633	chr15:63758958	NA	-0.58	-5.52	-0.34	8.83e-8	Iris characteristics;
SARC	cis	rs7264396	0.635	rs6058358	chr20:34492560	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-7.65	-0.45	5.39e-13	Total cholesterol levels;
SARC	cis	rs73198271	0.751	rs617813	chr8:8635888	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.07	-0.37	5.25e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs2908197	0.737	rs6465096	chr7:75972872	T/G	cg24580635	chr7:76178542	LOC100133091	-0.42	-4.87	-0.3	2.08e-6	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs763121	0.853	rs6001175	chr22:39018334	T/C	cg21395723	chr22:39101663	GTPBP1	0.6	7.1	0.42	1.46e-11	Menopause (age at onset);
SARC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.35	0.48	6.12e-15	Prudent dietary pattern;
SARC	cis	rs6570726	0.935	rs397418	chr6:145842362	C/T	cg05220968	chr6:146057943	EPM2A	-0.31	-5.34	-0.33	2.23e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7766436	0.885	rs3734215	chr6:22571323	T/C	cg13666174	chr6:22585274	NA	-0.56	-6.97	-0.42	3.2e-11	Coronary artery disease;
SARC	cis	rs58688157	0.549	rs11246192	chr11:572473	T/C	cg16486109	chr11:613632	IRF7	0.35	4.94	0.31	1.52e-6	Systemic lupus erythematosus;
SARC	cis	rs6690583	0.623	rs6672362	chr1:85454881	C/G	cg22153463	chr1:85462885	MCOLN2	0.72	6.96	0.42	3.33e-11	Serum sulfate level;
SARC	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg12311346	chr5:56204834	C5orf35	-0.59	-6.13	-0.37	3.65e-9	Initial pursuit acceleration;
SARC	cis	rs6977660	0.562	rs2189566	chr7:19768960	G/A	cg07541023	chr7:19748670	TWISTNB	0.93	8.12	0.47	2.77e-14	Thyroid stimulating hormone;
SARC	cis	rs67311347	0.544	rs6762121	chr3:40355313	G/A	cg09455208	chr3:40491958	NA	0.3	4.93	0.31	1.56e-6	Renal cell carcinoma;
SARC	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg02018176	chr4:1364513	KIAA1530	-0.37	-5.24	-0.32	3.62e-7	Obesity-related traits;
SARC	cis	rs13161895	0.941	rs438050	chr5:179414645	T/C	cg04265672	chr5:179402240	RNF130	-0.53	-5.07	-0.32	8.22e-7	LDL cholesterol;
SARC	cis	rs136211	0.965	rs2899262	chr22:36768595	A/G	cg16924664	chr22:36878180	TXN2	0.42	5.13	0.32	6e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs7560272	0.538	rs7599453	chr2:73937901	T/G	cg20560298	chr2:73613845	ALMS1	0.42	5.6	0.34	6.15e-8	Schizophrenia;
SARC	cis	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg00745463	chr17:30367425	LRRC37B	-0.58	-4.98	-0.31	1.22e-6	Hip circumference adjusted for BMI;
SARC	cis	rs651907	0.557	rs7645391	chr3:101361506	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	6.4	0.39	8.31e-10	Colorectal cancer;
SARC	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg15595755	chr5:1867978	NA	0.46	6.33	0.38	1.22e-9	Cardiovascular disease risk factors;
SARC	cis	rs4720575	1.000	rs6463383	chr7:47091686	A/G	cg00036614	chr7:47093842	NA	0.41	5.89	0.36	1.32e-8	Angiotensin-converting enzyme inhibitor intolerance;
SARC	cis	rs7927592	0.763	rs10896326	chr11:68234571	T/C	cg01657329	chr11:68192670	LRP5	-0.36	-5.03	-0.31	9.95e-7	Total body bone mineral density;
SARC	cis	rs910316	0.967	rs175502	chr14:75533679	A/G	cg08847533	chr14:75593920	NEK9	-0.88	-13.98	-0.68	1.2e-32	Height;
SARC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg11494091	chr17:61959527	GH2	0.55	8.18	0.47	1.85e-14	Prudent dietary pattern;
SARC	cis	rs6545883	0.859	rs2600661	chr2:61543081	T/C	cg15711740	chr2:61764176	XPO1	0.4	4.94	0.31	1.51e-6	Tuberculosis;
SARC	cis	rs11583043	1.000	rs12750667	chr1:101498682	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.49	5.54	0.34	8.1e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg00933542	chr6:150070202	PCMT1	0.32	5.48	0.34	1.1e-7	Lung cancer;
SARC	cis	rs757110	0.834	rs1002226	chr11:17405617	C/T	cg15432903	chr11:17409602	KCNJ11	0.54	9.17	0.52	2.53e-17	Type 2 diabetes;
SARC	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg24675658	chr1:53192096	ZYG11B	0.67	9.85	0.54	2.29e-19	Monocyte count;
SARC	cis	rs7246657	0.943	rs7255785	chr19:37971683	C/T	cg23950597	chr19:37808831	NA	-0.55	-5.44	-0.34	1.34e-7	Coronary artery calcification;
SARC	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg08219700	chr8:58056026	NA	0.6	5.71	0.35	3.49e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2228479	0.850	rs17226980	chr16:89825065	G/A	cg26513180	chr16:89883248	FANCA	0.72	4.79	0.3	2.99e-6	Skin colour saturation;
SARC	cis	rs11098499	0.691	rs12502524	chr4:120271414	G/A	cg24375607	chr4:120327624	NA	0.37	4.73	0.3	3.87e-6	Corneal astigmatism;
SARC	cis	rs926392	0.692	rs6028259	chr20:37696977	T/A	cg16355469	chr20:37678765	NA	0.67	8.81	0.5	2.88e-16	Dialysis-related mortality;
SARC	cis	rs854765	0.547	rs2955377	chr17:17932818	G/A	cg05444541	chr17:17804740	TOM1L2	-0.3	-4.8	-0.3	2.82e-6	Total body bone mineral density;
SARC	cis	rs7296418	0.961	rs11613937	chr12:123520071	C/T	cg16085171	chr12:123569118	PITPNM2	-0.38	-4.87	-0.3	2.03e-6	Platelet count;
SARC	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg24633833	chr3:10029261	TMEM111	0.52	5.25	0.33	3.43e-7	Alzheimer's disease;
SARC	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg16479474	chr6:28041457	NA	0.37	5.39	0.33	1.73e-7	Depression;
SARC	cis	rs4742903	1.000	rs1026181	chr9:106893334	A/G	cg14250997	chr9:106856677	SMC2	0.53	7.04	0.42	2.13e-11	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs1008375	1.000	rs4698634	chr4:17630192	A/C	cg16339924	chr4:17578868	LAP3	-0.68	-8.74	-0.5	4.62e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2504916	0.830	rs2661846	chr6:160785060	A/T	cg20340146	chr6:160172821	WTAP	0.42	4.82	0.3	2.53e-6	Response to hepatitis C treatment;
SARC	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg27266027	chr21:40555129	PSMG1	0.49	5.36	0.33	2.02e-7	Cognitive function;
SARC	cis	rs78487399	0.908	rs12469695	chr2:43833258	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-5.15	-0.32	5.61e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs10191773	0.589	rs72831636	chr2:112948248	G/A	cg07905836	chr2:113190072	RGPD8;RGPD5	0.96	7.97	0.46	6.88e-14	Yeast infection;
SARC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg23696834	chr6:42928345	GNMT	-0.31	-4.75	-0.3	3.6e-6	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs2841233	0.558	rs10145270	chr14:105349891	G/A	cg16576083	chr14:105354267	KIAA0284	0.55	8.39	0.48	4.8e-15	IgG glycosylation;
SARC	cis	rs4595586	0.545	rs7973338	chr12:39380704	T/C	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	cis	rs6910061	1.000	rs13214666	chr6:11103537	C/A	cg27233058	chr6:11094804	LOC221710	0.56	5.35	0.33	2.05e-7	Diabetic kidney disease;
SARC	trans	rs459571	0.920	rs460154	chr9:136909309	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.61	-7.08	-0.42	1.64e-11	Platelet distribution width;
SARC	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg22549504	chr19:17448937	GTPBP3	-0.48	-4.99	-0.31	1.17e-6	Systemic lupus erythematosus;
SARC	trans	rs1853207	1.000	rs10509678	chr10:96576190	A/C	cg02737782	chr1:8014393	NA	-0.95	-6.37	-0.39	1.01e-9	Blood metabolite levels;
SARC	cis	rs4906332	0.966	rs7401563	chr14:103964425	G/A	cg26031613	chr14:104095156	KLC1	-0.49	-5.78	-0.35	2.41e-8	Coronary artery disease;
SARC	cis	rs3818285	0.544	rs7899805	chr10:111671177	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.53	-7.17	-0.43	9.8e-12	Superior crus of antihelix expression;
SARC	cis	rs2075371	1.000	rs1862047	chr7:133978078	G/C	cg00033643	chr7:134001901	SLC35B4	0.41	4.98	0.31	1.25e-6	Mean platelet volume;
SARC	cis	rs3092073	0.624	rs11696623	chr20:44580380	C/T	cg10662479	chr20:44420225	WFDC3;DNTTIP1	0.44	5.56	0.34	7.27e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2295359	0.892	rs10889657	chr1:67615487	A/G	cg11235152	chr1:67600687	NA	0.5	6.93	0.41	4.17e-11	Psoriasis;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg25655799	chr10:79397930	KCNMA1	0.52	6.5	0.39	4.85e-10	Breast cancer;
SARC	cis	rs7647973	0.626	rs7637711	chr3:49829653	A/G	cg13072238	chr3:49761600	GMPPB	0.52	5.26	0.33	3.27e-7	Menarche (age at onset);
SARC	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg26335602	chr6:28129616	ZNF389	0.52	5.69	0.35	3.74e-8	Depression;
SARC	cis	rs9902453	0.808	rs1986555	chr17:28014448	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	7.26	0.43	5.81e-12	Coffee consumption (cups per day);
SARC	cis	rs909674	0.775	rs4821896	chr22:39833437	T/C	cg24399712	chr22:39784796	NA	-0.44	-5.73	-0.35	3.1e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs3540	0.512	rs17263706	chr15:91078803	G/T	cg22089800	chr15:90895588	ZNF774	0.59	7.45	0.44	1.76e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	trans	rs61931739	0.517	rs11611190	chr12:34015697	G/A	cg26384229	chr12:38710491	ALG10B	0.85	12.24	0.63	6.08e-27	Morning vs. evening chronotype;
SARC	cis	rs7592578	0.581	rs59109438	chr2:191287683	A/G	cg10560079	chr2:191398806	TMEM194B	-0.71	-8.19	-0.47	1.73e-14	Diastolic blood pressure;
SARC	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg11764359	chr7:65958608	NA	-0.77	-9.12	-0.51	3.71e-17	Aortic root size;
SARC	cis	rs1348850	0.567	rs3770012	chr2:178538023	A/G	cg23306229	chr2:178417860	TTC30B	-0.43	-4.89	-0.3	1.92e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	5.69	0.35	3.71e-8	Bipolar disorder;
SARC	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg17971929	chr21:40555470	PSMG1	0.97	13.62	0.67	1.83e-31	Cognitive function;
SARC	cis	rs4555082	0.957	rs2816628	chr14:105736134	T/G	cg13114125	chr14:105738426	BRF1	-0.73	-10.94	-0.58	9.38e-23	Mean platelet volume;Platelet distribution width;
SARC	cis	rs992157	0.767	rs2014615	chr2:219171191	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.59	8.4	0.48	4.34e-15	Colorectal cancer;
SARC	cis	rs10463554	1.000	rs3776862	chr5:102331721	G/A	cg23492399	chr5:102201601	PAM	-0.48	-5.84	-0.36	1.79e-8	Parkinson's disease;
SARC	cis	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg00409905	chr10:38381863	ZNF37A	-0.52	-7.29	-0.43	4.69e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs6788895	1.000	rs7617507	chr3:150499595	C/T	cg09723797	chr3:150481914	SIAH2	-0.77	-5.1	-0.32	6.94e-7	Breast cancer;
SARC	cis	rs6570726	0.935	rs411641	chr6:145827532	G/A	cg05347473	chr6:146136440	FBXO30	0.5	6.62	0.4	2.44e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6696846	0.715	rs61822659	chr1:205142847	G/A	cg00857998	chr1:205179979	DSTYK	0.51	6.24	0.38	2.04e-9	Red blood cell count;
SARC	cis	rs2073300	0.609	rs3827085	chr20:23356985	A/T	cg12062639	chr20:23401060	NAPB	1.01	6.9	0.41	4.88e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs1559088	0.744	rs12462426	chr19:33536683	A/C	cg27124370	chr19:33622961	WDR88	0.39	4.72	0.3	4.13e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg00933542	chr6:150070202	PCMT1	0.33	5.63	0.35	5.13e-8	Lung cancer;
SARC	cis	rs7647973	0.710	rs11130207	chr3:49611666	T/G	cg03060546	chr3:49711283	APEH	0.72	6.71	0.4	1.44e-10	Menarche (age at onset);
SARC	cis	rs9486719	1.000	rs11152951	chr6:96894135	C/G	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.01	-0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs2153535	0.546	rs9378559	chr6:8539058	A/T	cg23788917	chr6:8435910	SLC35B3	0.62	8.06	0.47	4.07e-14	Motion sickness;
SARC	cis	rs870825	0.550	rs28525282	chr4:185631468	T/C	cg04058563	chr4:185651563	MLF1IP	0.82	11.01	0.58	5.81e-23	Blood protein levels;
SARC	cis	rs17376456	0.877	rs7734897	chr5:93305402	G/A	cg21475434	chr5:93447410	FAM172A	0.85	7.72	0.45	3.4e-13	Diabetic retinopathy;
SARC	cis	rs9818758	0.607	rs34566463	chr3:49245077	T/C	cg01304814	chr3:48885189	PRKAR2A	0.59	4.9	0.31	1.81e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs1467026	0.606	rs9814180	chr3:12818386	A/G	cg05775895	chr3:12838266	CAND2	0.8	13.66	0.67	1.3e-31	P wave duration;
SARC	cis	rs9640161	0.830	rs76741564	chr7:150059529	A/T	cg10018233	chr7:150070692	REPIN1	0.7	10.38	0.56	5.51e-21	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs2439831	0.867	rs8041132	chr15:43635136	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.04	10.9	0.58	1.25e-22	Lung cancer in ever smokers;
SARC	cis	rs12586317	0.531	rs57856432	chr14:35719708	G/T	cg16230307	chr14:35515116	FAM177A1	0.44	5.32	0.33	2.47e-7	Psoriasis;
SARC	cis	rs5769765	0.837	rs4824110	chr22:50271631	T/A	cg03033257	chr22:50311977	ALG12;CRELD2	-0.54	-5.64	-0.35	4.81e-8	Schizophrenia;
SARC	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg24531977	chr5:56204891	C5orf35	-0.51	-5.22	-0.32	3.89e-7	Initial pursuit acceleration;
SARC	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg09699651	chr6:150184138	LRP11	0.39	4.85	0.3	2.28e-6	Lung cancer;
SARC	cis	rs7647973	0.626	rs11720705	chr3:49753788	A/G	cg13072238	chr3:49761600	GMPPB	-0.61	-6.34	-0.38	1.19e-9	Menarche (age at onset);
SARC	cis	rs2153535	0.601	rs2327091	chr6:8540369	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	8.24	0.47	1.27e-14	Motion sickness;
SARC	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg00149659	chr3:10157352	C3orf10	0.7	6.58	0.4	3.15e-10	Alzheimer's disease;
SARC	cis	rs807669	0.777	rs9605972	chr22:19253274	C/T	cg02655711	chr22:19163373	SLC25A1	0.42	6.18	0.38	2.79e-9	Metabolite levels;
SARC	cis	rs569214	0.763	rs484377	chr8:27477509	C/T	cg04264299	chr8:27491209	SCARA3	-0.41	-4.71	-0.3	4.19e-6	Alzheimer's disease;
SARC	cis	rs617791	0.530	rs10791835	chr11:65750924	C/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.57	6.91	0.41	4.47e-11	Breast cancer;
SARC	cis	rs9814567	0.896	rs13089566	chr3:134349710	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.49	6.23	0.38	2.21e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs11992162	0.507	rs60902764	chr8:11784991	A/T	cg02127589	chr8:12458309	NA	-0.32	-4.78	-0.3	3.13e-6	Monocyte count;
SARC	cis	rs77633900	0.614	rs280028	chr15:77031466	A/G	cg21673338	chr15:77095150	SCAPER	-0.6	-5.1	-0.32	7.05e-7	Non-glioblastoma glioma;Glioma;
SARC	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg01570182	chr17:44337453	NA	-0.82	-9.75	-0.54	4.71e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs918629	0.530	rs7702674	chr5:95237365	A/C	cg16656078	chr5:95278638	ELL2	-0.56	-6.98	-0.42	3.06e-11	IgG glycosylation;
SARC	cis	rs13191362	1.000	rs34052221	chr6:163160803	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.72	6.11	0.37	4.25e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	trans	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg21775007	chr8:11205619	TDH	0.51	6.28	0.38	1.61e-9	Systolic blood pressure;
SARC	cis	rs55882075	0.808	rs6867806	chr5:179179585	C/G	cg14593053	chr5:179126677	CANX	0.4	5.11	0.32	6.71e-7	Monocyte percentage of white cells;
SARC	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg25952890	chr19:58913133	NA	0.36	5.09	0.32	7.25e-7	Uric acid clearance;
SARC	cis	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg06558623	chr16:89946397	TCF25	0.92	6.39	0.39	8.93e-10	Skin colour saturation;
SARC	cis	rs2072499	0.750	rs55910626	chr1:156159909	C/G	cg25208724	chr1:156163844	SLC25A44	0.86	9.9	0.54	1.67e-19	Testicular germ cell tumor;
SARC	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg03709012	chr19:19516395	GATAD2A	0.96	15.27	0.71	5.8e-37	Tonsillectomy;
SARC	trans	rs7824557	0.614	rs17741537	chr8:11213092	A/G	cg06636001	chr8:8085503	FLJ10661	0.53	6.53	0.39	4.1e-10	Retinal vascular caliber;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg19189965	chr12:123459820	ABCB9;OGFOD2	0.53	6.63	0.4	2.26e-10	Breast cancer;
SARC	cis	rs8060686	0.545	rs7199878	chr16:68186301	A/G	cg27539214	chr16:67997921	SLC12A4	-0.52	-4.89	-0.3	1.92e-6	HDL cholesterol;Metabolic syndrome;
SARC	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.04	0.37	6e-9	Prudent dietary pattern;
SARC	cis	rs73206853	0.764	rs73191812	chr12:110910279	G/A	cg10860002	chr12:110842031	ANAPC7	0.64	5.1	0.32	7.2e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs921968	0.643	rs545460	chr2:219392159	A/G	cg02176678	chr2:219576539	TTLL4	0.37	5.59	0.34	6.32e-8	Mean corpuscular hemoglobin concentration;
SARC	cis	rs1153858	0.621	rs1706824	chr15:45579948	C/T	cg26924012	chr15:45694286	SPATA5L1	0.71	9.02	0.51	6.9e-17	Homoarginine levels;
SARC	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg03060546	chr3:49711283	APEH	0.48	6.31	0.38	1.37e-9	Menarche (age at onset);
SARC	cis	rs2242116	0.761	rs6780601	chr3:46965856	A/G	cg27129171	chr3:47204927	SETD2	0.62	8.15	0.47	2.19e-14	Birth weight;
SARC	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg21724239	chr8:58056113	NA	-0.59	-6.25	-0.38	1.9e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs453301	0.686	rs4840389	chr8:8884503	G/C	cg15556689	chr8:8085844	FLJ10661	-0.53	-7.1	-0.42	1.5e-11	Joint mobility (Beighton score);
SARC	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg22618164	chr12:122356400	WDR66	0.4	6.03	0.37	6.21e-9	Mean corpuscular volume;
SARC	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg19680485	chr15:31195859	MTMR15	0.44	5.26	0.33	3.21e-7	Huntington's disease progression;
SARC	cis	rs12950390	0.853	rs55745341	chr17:45855778	G/C	cg24803719	chr17:45855879	NA	-0.48	-7.77	-0.45	2.51e-13	IgG glycosylation;
SARC	cis	rs7826238	0.594	rs2948285	chr8:8130538	A/T	cg11608241	chr8:8085544	FLJ10661	0.43	5.32	0.33	2.41e-7	Systolic blood pressure;
SARC	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg25072359	chr17:41440525	NA	0.49	5.72	0.35	3.19e-8	Menopause (age at onset);
SARC	cis	rs6809651	0.524	rs4686728	chr3:185795333	C/T	cg00760338	chr3:185826511	ETV5	0.75	9.67	0.54	8.02e-19	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
SARC	cis	rs721399	0.539	rs10088333	chr8:18267878	G/A	cg18736775	chr8:18248649	NAT2	-0.56	-5.42	-0.33	1.47e-7	Blood metabolite levels;
SARC	cis	rs710216	0.752	rs841848	chr1:43402545	G/A	cg03128534	chr1:43423976	SLC2A1	0.59	5.59	0.34	6.2e-8	Red cell distribution width;
SARC	cis	rs6964587	1.000	rs6465343	chr7:91618208	T/C	cg17063962	chr7:91808500	NA	0.96	16.55	0.74	3.24e-41	Breast cancer;
SARC	cis	rs568617	0.903	rs601863	chr11:65646557	C/A	cg26695010	chr11:65641043	EFEMP2	0.5	5.78	0.35	2.36e-8	Crohn's disease;
SARC	cis	rs11997175	0.545	rs7818001	chr8:33807682	G/T	ch.8.33884649F	chr8:33765107	NA	0.5	6.46	0.39	5.97e-10	Body mass index;
SARC	cis	rs9818758	0.607	rs11710247	chr3:49249800	G/T	cg07636037	chr3:49044803	WDR6	-0.77	-6.91	-0.41	4.67e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs870825	0.929	rs72689263	chr4:185590961	C/T	cg04058563	chr4:185651563	MLF1IP	0.79	8.8	0.5	3.22e-16	Blood protein levels;
SARC	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg06618935	chr21:46677482	NA	-0.4	-5.37	-0.33	1.88e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg09436375	chr6:42928200	GNMT	-0.34	-5.32	-0.33	2.46e-7	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs8141529	0.778	rs7287806	chr22:29213011	G/A	cg02153584	chr22:29168773	CCDC117	0.79	11.72	0.61	3.15e-25	Lymphocyte counts;
SARC	cis	rs3784262	0.669	rs4646626	chr15:58256127	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.35	-5.21	-0.32	4.06e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg04310824	chr1:53393297	SCP2	0.51	6.65	0.4	2.05e-10	Lung adenocarcinoma;
SARC	cis	rs7811142	1.000	rs6972167	chr7:100080013	G/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.64	-6.77	-0.41	1.06e-10	Platelet count;
SARC	cis	rs10056811	0.538	rs56174528	chr5:74400516	G/C	cg06933384	chr5:74808293	COL4A3BP;POLK	0.51	4.93	0.31	1.55e-6	Coronary artery disease;
SARC	cis	rs6450176	1.000	rs4311394	chr5:53300662	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.67	-7.7	-0.45	3.91e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg16414030	chr3:133502952	NA	-0.37	-4.75	-0.3	3.59e-6	Iron status biomarkers;
SARC	cis	rs7086627	0.515	rs10887905	chr10:82210855	A/T	cg01528321	chr10:82214614	TSPAN14	0.58	8.48	0.49	2.68e-15	Post bronchodilator FEV1;
SARC	cis	rs11719291	0.831	rs11715177	chr3:48763894	G/A	cg00383909	chr3:49044727	WDR6	0.66	6.02	0.37	6.61e-9	Cognitive function;
SARC	cis	rs3087591	0.960	rs2905883	chr17:29550141	G/A	cg24425628	chr17:29625626	OMG;NF1	0.48	5.92	0.36	1.17e-8	Hip circumference;
SARC	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg11987759	chr7:65425863	GUSB	-0.48	-5.87	-0.36	1.51e-8	Aortic root size;
SARC	cis	rs944802	0.929	rs10965271	chr9:22165269	T/C	cg00491127	chr9:22154101	NA	-0.53	-4.86	-0.3	2.19e-6	White blood cell count;
SARC	cis	rs35213789	0.887	rs1014382	chr7:69130121	C/A	cg10619644	chr7:69149951	AUTS2	-0.44	-5.89	-0.36	1.35e-8	Childhood ear infection;
SARC	cis	rs13191362	0.935	rs34035978	chr6:163165336	G/C	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.23	0.32	3.71e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs820218	0.926	rs820206	chr17:73641714	G/A	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.68	9.24	0.52	1.64e-17	Rotator cuff tears;
SARC	cis	rs7223966	1.000	rs8069687	chr17:61883023	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.45	-4.81	-0.3	2.69e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg00149659	chr3:10157352	C3orf10	0.64	6.01	0.37	7.21e-9	Alzheimer's disease;
SARC	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg13628971	chr7:2884303	GNA12	0.63	7.33	0.43	3.71e-12	Height;
SARC	cis	rs67311347	0.866	rs11712426	chr3:40330322	G/A	cg09455208	chr3:40491958	NA	0.38	6.05	0.37	5.72e-9	Renal cell carcinoma;
SARC	cis	rs9397240	0.789	rs10499303	chr6:155615239	G/A	cg07943832	chr6:155568918	TIAM2	-0.56	-5.43	-0.33	1.44e-7	Life satisfaction;
SARC	cis	rs2898681	0.770	rs10032190	chr4:53734940	C/A	cg00338735	chr4:53728038	RASL11B	0.4	5.14	0.32	5.78e-7	Optic nerve measurement (cup area);
SARC	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg16405210	chr4:1374714	KIAA1530	-0.47	-5.54	-0.34	8.28e-8	Obesity-related traits;
SARC	cis	rs7412746	0.611	rs4509581	chr1:150774465	A/G	cg15448220	chr1:150897856	SETDB1	0.49	6.36	0.38	1.07e-9	Melanoma;
SARC	cis	rs12477438	0.871	rs13396584	chr2:99611768	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.58	6.38	0.39	9.33e-10	Chronic sinus infection;
SARC	cis	rs13191362	1.000	rs13204013	chr6:163002480	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.57	5.38	0.33	1.85e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs12682352	0.650	rs13265731	chr8:8673320	T/C	cg08975724	chr8:8085496	FLJ10661	0.42	5.28	0.33	3e-7	Neuroticism;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14097577	chr3:25824924	NGLY1	-0.5	-6.38	-0.39	9.61e-10	Smoking initiation;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg02996796	chr17:6540502	KIAA0753	0.5	6.35	0.38	1.1e-9	Schizophrenia;
SARC	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.97	-15.7	-0.72	2.3e-38	Chronic sinus infection;
SARC	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-7.83	-0.46	1.71e-13	Alzheimer's disease;
SARC	cis	rs911555	0.755	rs7147664	chr14:103963420	G/A	cg24130564	chr14:104152367	KLC1	-0.5	-5.94	-0.36	1.01e-8	Intelligence (multi-trait analysis);
SARC	cis	rs4713675	0.584	rs7770465	chr6:33674156	G/C	cg15676125	chr6:33679581	C6orf125	0.52	6.23	0.38	2.16e-9	Plateletcrit;
SARC	cis	rs7296418	0.961	rs4148862	chr12:123568619	A/C	cg00376283	chr12:123451042	ABCB9	0.6	7.41	0.44	2.28e-12	Platelet count;
SARC	cis	rs4699052	0.963	rs11733615	chr4:104157164	C/T	cg16532752	chr4:104119610	CENPE	-0.45	-5.35	-0.33	2.07e-7	Testicular germ cell tumor;
SARC	cis	rs9894429	0.966	rs10871499	chr17:79589006	G/A	cg18240062	chr17:79603768	NPLOC4	0.72	9.85	0.54	2.38e-19	Eye color traits;
SARC	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg09359103	chr1:154839909	KCNN3	-0.41	-6.79	-0.41	9.43e-11	Prostate cancer;
SARC	cis	rs7223966	1.000	rs992416	chr17:61745905	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	6.35	0.38	1.1e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2070677	0.935	rs12255182	chr10:135404096	G/A	cg20169779	chr10:135381914	SYCE1	-0.55	-6.5	-0.39	4.75e-10	Gout;
SARC	cis	rs4243830	1.000	rs11809957	chr1:6584420	C/A	cg22792644	chr1:6614718	TAS1R1;NOL9	0.93	7.38	0.44	2.85e-12	Body mass index;
SARC	cis	rs7624766	0.743	rs13073659	chr3:160542087	A/T	cg22637730	chr3:160473554	PPM1L	0.43	5.6	0.34	5.89e-8	Response to methotrexate in rheumatoid arthritis;
SARC	cis	rs920590	0.600	rs4921678	chr8:19663449	A/G	cg03894339	chr8:19674705	INTS10	0.43	5.17	0.32	5.04e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs826838	1.000	rs1684395	chr12:39083161	T/G	cg26384229	chr12:38710491	ALG10B	-0.79	-12.33	-0.63	3.11e-27	Heart rate;
SARC	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg13126279	chr21:47581558	C21orf56	-0.5	-6.23	-0.38	2.13e-9	Testicular germ cell tumor;
SARC	cis	rs1448094	0.842	rs7309725	chr12:86440612	T/C	cg02569458	chr12:86230093	RASSF9	0.39	5.73	0.35	3.09e-8	Major depressive disorder;
SARC	cis	rs67460515	0.500	rs964533	chr3:160749019	C/A	cg03342759	chr3:160939853	NMD3	-0.49	-5.82	-0.36	1.98e-8	Parkinson's disease;
SARC	cis	rs4803468	1.000	rs10417311	chr19:41902038	G/A	cg14132834	chr19:41945861	ATP5SL	-0.55	-7.37	-0.43	2.88e-12	Height;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg02028540	chr16:67193883	TRADD;FBXL8	0.62	6.33	0.38	1.24e-9	Lung cancer in ever smokers;
SARC	trans	rs61931739	0.534	rs11053010	chr12:34093228	G/A	cg26384229	chr12:38710491	ALG10B	0.87	12.44	0.63	1.37e-27	Morning vs. evening chronotype;
SARC	cis	rs796364	0.806	rs34582889	chr2:201010527	A/G	cg23649088	chr2:200775458	C2orf69	-0.64	-6.49	-0.39	5.01e-10	Schizophrenia;
SARC	cis	rs34375054	0.660	rs57031290	chr12:125593053	A/G	cg25124228	chr12:125621409	AACS	-0.52	-5.54	-0.34	8.06e-8	Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs8523	0.697	rs57549068	chr6:11059210	T/C	cg13562911	chr6:11044106	ELOVL2	0.48	6.37	0.39	9.74e-10	Red blood cell fatty acid levels;
SARC	cis	rs921968	0.565	rs7573999	chr2:219601392	A/G	cg02176678	chr2:219576539	TTLL4	-0.34	-5.14	-0.32	5.84e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs6964587	0.967	rs7801058	chr7:91784381	C/T	cg17063962	chr7:91808500	NA	0.93	15.63	0.72	3.83e-38	Breast cancer;
SARC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg09373136	chr17:61933544	TCAM1	-0.45	-6.13	-0.37	3.66e-9	Prudent dietary pattern;
SARC	trans	rs3780486	1.000	rs10813957	chr9:33153527	G/T	cg04842962	chr6:43655489	MRPS18A	0.99	13.84	0.67	3.3e-32	IgG glycosylation;
SARC	cis	rs644799	1.000	rs505220	chr11:95563228	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.68	9.17	0.51	2.6e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs6831352	0.819	rs896992	chr4:100002372	C/T	cg13256891	chr4:100009986	ADH5	0.62	8.42	0.48	3.88e-15	Alcohol dependence;
SARC	cis	rs17376456	0.542	rs10476588	chr5:93208330	C/T	cg21475434	chr5:93447410	FAM172A	-0.66	-6.54	-0.39	3.76e-10	Diabetic retinopathy;
SARC	cis	rs2439831	0.850	rs28718261	chr15:44043793	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	8.57	0.49	1.44e-15	Lung cancer in ever smokers;
SARC	cis	rs72781680	0.898	rs56179550	chr2:23934867	C/T	cg08917208	chr2:24149416	ATAD2B	0.93	8.58	0.49	1.32e-15	Lymphocyte counts;
SARC	cis	rs858239	0.570	rs10235467	chr7:23148808	C/T	cg23682824	chr7:23144976	KLHL7	0.72	9.69	0.54	7.22e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs34172651	0.917	rs200532	chr16:24756148	C/T	cg00339695	chr16:24857497	SLC5A11	-0.28	-4.77	-0.3	3.26e-6	Intelligence (multi-trait analysis);
SARC	cis	rs1008375	0.966	rs7675735	chr4:17587137	T/A	cg27347728	chr4:17578864	LAP3	0.49	6.06	0.37	5.46e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg16405210	chr4:1374714	KIAA1530	-0.48	-5.69	-0.35	3.76e-8	Obesity-related traits;
SARC	cis	rs1371867	0.846	rs1660349	chr8:101319326	G/A	cg11906718	chr8:101322791	RNF19A	0.71	9.12	0.51	3.68e-17	Atrioventricular conduction;
SARC	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg02564969	chr6:151773285	C6orf211;RMND1	-0.61	-8.26	-0.48	1.09e-14	Menarche (age at onset);
SARC	cis	rs637571	0.584	rs659824	chr11:65636509	A/G	cg26695010	chr11:65641043	EFEMP2	0.76	11.89	0.61	8.45e-26	Eosinophil percentage of white cells;
SARC	cis	rs1699337	0.930	rs2921188	chr3:12412115	A/G	cg04748988	chr3:12329223	PPARG	-0.38	-5.04	-0.31	9.31e-7	Cholesterol, total;
SARC	cis	rs7666738	0.791	rs11730069	chr4:98945772	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6456156	0.692	rs9457270	chr6:167512928	A/G	cg07741184	chr6:167504864	NA	0.36	6.88	0.41	5.42e-11	Primary biliary cholangitis;
SARC	cis	rs34172651	0.876	rs2547033	chr16:24743657	C/T	cg04756594	chr16:24857601	SLC5A11	0.36	5.77	0.35	2.5e-8	Intelligence (multi-trait analysis);
SARC	cis	rs372883	0.613	rs1153290	chr21:30687404	G/T	cg08807101	chr21:30365312	RNF160	-0.58	-7.48	-0.44	1.49e-12	Pancreatic cancer;
SARC	cis	rs7712401	0.601	rs246328	chr5:122287628	G/A	cg19412675	chr5:122181750	SNX24	0.4	5.13	0.32	5.98e-7	Mean platelet volume;
SARC	cis	rs8013055	0.796	rs11628497	chr14:105970789	C/T	cg19700328	chr14:106028568	NA	-0.62	-8.61	-0.49	1.11e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
SARC	trans	rs9951602	0.512	rs8098115	chr18:76653986	G/T	cg02800362	chr5:177631904	HNRNPAB	0.7	8.91	0.5	1.49e-16	Obesity-related traits;
SARC	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg15049968	chr18:44337910	ST8SIA5	-0.37	-5.94	-0.36	1.05e-8	Personality dimensions;
SARC	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	5.92	0.36	1.14e-8	Electroencephalogram traits;
SARC	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg06028808	chr11:68637592	NA	0.42	5.21	0.32	4.22e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9303401	0.659	rs11495824	chr17:56918882	C/A	cg25039879	chr17:56429692	SUPT4H1	0.65	6.13	0.37	3.77e-9	Cognitive test performance;
SARC	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg11995313	chr8:8860691	ERI1	-0.44	-5.78	-0.35	2.33e-8	Mood instability;
SARC	cis	rs9790314	0.586	rs11710916	chr3:161130070	A/G	cg17135325	chr3:160939158	NMD3	0.53	6.52	0.39	4.37e-10	Morning vs. evening chronotype;
SARC	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg22920501	chr2:26401640	FAM59B	-0.6	-8.1	-0.47	3.11e-14	Gut microbiome composition (summer);
SARC	cis	rs644799	1.000	rs596277	chr11:95566886	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.89	13.95	0.67	1.5e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9462027	0.628	rs2477507	chr6:34703599	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.91	-0.36	1.19e-8	Systemic lupus erythematosus;
SARC	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg15049968	chr18:44337910	ST8SIA5	-0.35	-5.66	-0.35	4.52e-8	Personality dimensions;
SARC	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.93	-13.87	-0.67	2.78e-32	Gut microbiome composition (summer);
SARC	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg21433558	chr17:40837037	CNTNAP1	0.57	7.95	0.46	7.79e-14	Colorectal or endometrial cancer;
SARC	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg00684032	chr4:1343700	KIAA1530	-0.36	-5.27	-0.33	3.06e-7	Obesity-related traits;
SARC	cis	rs72781680	0.611	rs78861366	chr2:24354428	A/G	cg08917208	chr2:24149416	ATAD2B	0.62	6.14	0.37	3.47e-9	Lymphocyte counts;
SARC	cis	rs4664308	0.875	rs2124969	chr2:160989486	T/C	cg03641300	chr2:160917029	PLA2R1	-0.65	-8.6	-0.49	1.18e-15	Idiopathic membranous nephropathy;
SARC	cis	rs7223966	1.000	rs8073373	chr17:61703320	T/C	cg00588841	chr17:61851480	DDX42;CCDC47	-0.59	-6.87	-0.41	5.81e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs490234	0.588	rs34983978	chr9:128169170	G/A	cg14078157	chr9:128172775	NA	-0.36	-4.86	-0.3	2.16e-6	Mean arterial pressure;
SARC	cis	rs17384381	1.000	rs12758237	chr1:85870783	G/A	cg16011679	chr1:85725395	C1orf52	0.61	5.77	0.35	2.49e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs78456975	0.943	rs10470006	chr2:1580971	A/C	cg26248373	chr2:1572462	NA	-0.56	-5.8	-0.36	2.09e-8	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs10489202	1.000	rs1846416	chr1:167905411	G/A	cg24449463	chr1:168025552	DCAF6	-0.65	-7.18	-0.43	9.13e-12	Schizophrenia;
SARC	cis	rs9788721	0.836	rs7181486	chr15:78741618	C/T	cg18825076	chr15:78729989	IREB2	0.53	6.79	0.41	9.48e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	trans	rs7980799	0.682	rs7138529	chr12:33634855	T/C	cg26384229	chr12:38710491	ALG10B	-0.62	-7.65	-0.45	5.44e-13	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg18876405	chr7:65276391	NA	-0.72	-9.18	-0.52	2.4e-17	Aortic root size;
SARC	cis	rs7945705	0.747	rs1980428	chr11:9010497	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.48	6.87	0.41	5.69e-11	Hemoglobin concentration;
SARC	cis	rs7408868	1.000	rs10415431	chr19:15277027	G/A	cg14696996	chr19:15285081	NOTCH3	1.02	8.7	0.5	6e-16	Pulse pressure;
SARC	cis	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg18252515	chr7:66147081	NA	-1.26	-11.14	-0.59	2.14e-23	Diabetic kidney disease;
SARC	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg17279839	chr7:150038598	RARRES2	0.5	6.67	0.4	1.84e-10	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs9549367	0.774	rs9549696	chr13:113875062	C/T	cg18105134	chr13:113819100	PROZ	-0.43	-6.35	-0.38	1.13e-9	Platelet distribution width;
SARC	trans	rs208520	0.690	rs10455594	chr6:66737894	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	13.86	0.67	2.98e-32	Exhaled nitric oxide output;
SARC	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg06028605	chr16:24865363	SLC5A11	0.37	5.45	0.34	1.28e-7	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.520	rs55967509	chr8:57992448	A/G	cg22535103	chr8:58192502	C8orf71	-0.59	-5.59	-0.34	6.17e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg22920501	chr2:26401640	FAM59B	-0.55	-7.14	-0.42	1.18e-11	Gut microbiome composition (summer);
SARC	cis	rs6545883	0.929	rs7561229	chr2:61737990	A/T	cg15711740	chr2:61764176	XPO1	-0.42	-5.27	-0.33	3.03e-7	Tuberculosis;
SARC	cis	rs12995491	0.933	rs12995212	chr2:88527184	C/T	cg04511125	chr2:88470314	THNSL2	-0.37	-5.43	-0.34	1.4e-7	Response to metformin (IC50);
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg00275962	chr6:43484808	POLR1C;YIPF3	0.53	7.04	0.42	2.14e-11	Tetralogy of Fallot;
SARC	cis	rs7772486	0.754	rs6906258	chr6:146089356	A/G	cg05347473	chr6:146136440	FBXO30	-0.55	-7.64	-0.45	5.77e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs870825	0.616	rs7660064	chr4:185617529	T/C	cg04058563	chr4:185651563	MLF1IP	0.82	11.37	0.6	4.16e-24	Blood protein levels;
SARC	cis	rs9303401	0.614	rs66480139	chr17:57101538	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.98	10.07	0.55	4.9e-20	Cognitive test performance;
SARC	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg13206674	chr6:150067644	NUP43	0.46	6.1	0.37	4.29e-9	Lung cancer;
SARC	cis	rs826838	0.654	rs7977738	chr12:38722460	G/A	cg10518543	chr12:38710700	ALG10B	0.39	4.87	0.3	2.08e-6	Heart rate;
SARC	cis	rs6714710	0.535	rs13033383	chr2:98339513	C/T	cg26665480	chr2:98280029	ACTR1B	0.5	6.42	0.39	7.58e-10	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs11574514	1.000	rs118008021	chr16:67722328	T/A	cg01866162	chr16:67596514	CTCF	1.13	6.68	0.4	1.7e-10	Crohn's disease;
SARC	cis	rs950169	0.845	rs4502182	chr15:84923520	A/G	cg24253500	chr15:84953950	NA	0.36	5.23	0.32	3.85e-7	Schizophrenia;
SARC	cis	rs9399137	0.507	rs35571217	chr6:135290355	T/C	cg22676075	chr6:135203613	NA	0.39	4.97	0.31	1.32e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs9790314	0.586	rs11713185	chr3:161111357	C/G	cg04691961	chr3:161091175	C3orf57	-0.48	-5.99	-0.37	7.89e-9	Morning vs. evening chronotype;
SARC	cis	rs7223966	1.000	rs61360320	chr17:61800392	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-5.86	-0.36	1.6e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs10992471	0.528	rs4744133	chr9:95226702	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.42	-4.77	-0.3	3.24e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs6089584	0.566	rs6061963	chr20:60607480	C/G	cg23262073	chr20:60523788	NA	-0.34	-5.22	-0.32	3.96e-7	Body mass index;
SARC	cis	rs861020	0.771	rs661849	chr1:210001233	C/T	cg05527609	chr1:210001259	C1orf107	1.06	13.66	0.67	1.39e-31	Orofacial clefts;
SARC	cis	rs7666738	0.830	rs890470	chr4:98923435	A/C	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2204008	0.515	rs11495471	chr12:38027178	G/A	cg26384229	chr12:38710491	ALG10B	0.89	13.17	0.65	5.77e-30	Bladder cancer;
SARC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg09373136	chr17:61933544	TCAM1	-0.45	-6.23	-0.38	2.18e-9	Prudent dietary pattern;
SARC	cis	rs13191362	1.000	rs13202339	chr6:163081812	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.72	6.38	0.39	9.33e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg16606324	chr3:10149918	C3orf24	0.48	4.8	0.3	2.87e-6	Alzheimer's disease;
SARC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.54	7.02	0.42	2.37e-11	Lymphocyte counts;
SARC	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg04248312	chr19:17393744	ANKLE1	0.6	8.01	0.46	5.44e-14	Systemic lupus erythematosus;
SARC	cis	rs10739663	0.520	rs1566362	chr9:128163132	C/T	cg14078157	chr9:128172775	NA	0.34	4.77	0.3	3.21e-6	Resting heart rate;
SARC	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg15595755	chr5:1867978	NA	0.49	6.67	0.4	1.81e-10	Cardiovascular disease risk factors;
SARC	cis	rs1600249	0.562	rs17153419	chr8:11394233	C/T	cg21775007	chr8:11205619	TDH	-0.4	-4.88	-0.3	2.01e-6	Rheumatoid arthritis;
SARC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg20007245	chr22:24372913	LOC391322	0.67	8.77	0.5	3.94e-16	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2016266	0.859	rs10876433	chr12:53734114	G/A	cg26875137	chr12:53738046	NA	-0.4	-4.76	-0.3	3.47e-6	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg13126279	chr21:47581558	C21orf56	0.42	4.89	0.31	1.86e-6	Testicular germ cell tumor;
SARC	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg19223190	chr17:80058835	NA	-0.44	-6.04	-0.37	6.02e-9	Life satisfaction;
SARC	cis	rs751728	1.000	rs6920075	chr6:33731797	C/T	cg25922239	chr6:33757077	LEMD2	0.81	10.73	0.58	4.29e-22	Crohn's disease;
SARC	cis	rs854765	0.583	rs9912895	chr17:17826020	C/T	cg05444541	chr17:17804740	TOM1L2	0.29	4.72	0.3	4.05e-6	Total body bone mineral density;
SARC	cis	rs10463316	0.894	rs7723379	chr5:150765025	T/C	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.28	-0.33	2.89e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs933688	0.639	rs332530	chr5:90789810	G/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	12.38	0.63	2.19e-27	Smoking behavior;
SARC	cis	rs9611519	0.929	rs73174660	chr22:41437304	T/C	cg17376030	chr22:41985996	PMM1	0.49	6.06	0.37	5.3e-9	Neuroticism;
SARC	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.69	-9.01	-0.51	7.45e-17	Chronic sinus infection;
SARC	cis	rs9796	0.870	rs2925346	chr15:41315695	G/A	cg18705301	chr15:41695430	NDUFAF1	0.43	5.98	0.36	8.35e-9	Menopause (age at onset);
SARC	cis	rs1472147	1.000	rs3736609	chr7:128509319	G/A	cg00260937	chr7:128520193	KCP	0.42	4.92	0.31	1.62e-6	Calcium levels;
SARC	cis	rs6582630	0.622	rs11182004	chr12:38441254	G/A	cg14851346	chr12:38532713	NA	-0.47	-5.76	-0.35	2.6e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2236918	1.000	rs851782	chr1:242033783	A/G	cg17736920	chr1:242011382	EXO1	0.78	10.49	0.57	2.4e-21	Menopause (age at onset);
SARC	cis	rs9715521	0.775	rs67846233	chr4:59848576	G/A	cg11281224	chr4:60001000	NA	-0.4	-5.11	-0.32	6.63e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.41	-6.35	-0.38	1.14e-9	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs2120243	0.539	rs6441128	chr3:157121258	A/C	cg24825693	chr3:157122686	VEPH1	-0.46	-6.31	-0.38	1.39e-9	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs6120849	0.707	rs6088703	chr20:33676049	T/A	cg06115741	chr20:33292138	TP53INP2	0.54	5.09	0.32	7.33e-7	Protein C levels;
SARC	cis	rs6910061	0.783	rs72825145	chr6:11132285	T/C	cg27233058	chr6:11094804	LOC221710	0.63	5.63	0.35	5.03e-8	Diabetic kidney disease;
SARC	cis	rs7144547	0.803	rs8008602	chr14:81890171	T/A	cg02996355	chr14:81879375	NA	-0.66	-7.78	-0.45	2.32e-13	Prudent dietary pattern;
SARC	cis	rs7481584	0.624	rs412149	chr11:3069943	G/A	cg25174290	chr11:3078921	CARS	-0.58	-7.97	-0.46	6.84e-14	Calcium levels;
SARC	cis	rs17739167	0.550	rs11634233	chr15:42224563	G/A	cg20935245	chr15:42234343	EHD4	0.45	5.98	0.37	8.13e-9	Monocyte count;
SARC	cis	rs7647973	0.961	rs11130186	chr3:49275828	A/G	cg06212747	chr3:49208901	KLHDC8B	0.59	6.38	0.39	9.69e-10	Menarche (age at onset);
SARC	cis	rs9788721	0.836	rs17483686	chr15:78733390	A/T	cg06917634	chr15:78832804	PSMA4	-0.54	-5.98	-0.36	8.51e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs854765	0.547	rs2955383	chr17:17941364	A/G	cg04398451	chr17:18023971	MYO15A	-0.45	-6.45	-0.39	6.23e-10	Total body bone mineral density;
SARC	cis	rs1707322	1.000	rs6672115	chr1:46272879	T/C	cg03146154	chr1:46216737	IPP	0.5	6.0	0.37	7.38e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg25894440	chr7:65020034	NA	-0.73	-5.48	-0.34	1.09e-7	Diabetic kidney disease;
SARC	cis	rs7659604	1.000	rs7659943	chr4:122665560	C/T	cg20573242	chr4:122745356	CCNA2	0.42	5.31	0.33	2.57e-7	Type 2 diabetes;
SARC	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.62	7.45	0.44	1.8e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-6.28	-0.38	1.63e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg15049968	chr18:44337910	ST8SIA5	-0.33	-5.24	-0.32	3.58e-7	Personality dimensions;
SARC	cis	rs1662342	0.673	rs4325658	chr18:3286923	T/C	cg14211874	chr18:3262499	MYL12B	-0.64	-5.14	-0.32	5.8e-7	QRS duration;
SARC	cis	rs11122272	0.705	rs1416914	chr1:231533196	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-9.97	-0.55	1.03e-19	Hemoglobin concentration;
SARC	cis	rs3824867	0.920	rs7111873	chr11:47469439	A/G	cg20307385	chr11:47447363	PSMC3	0.48	5.24	0.32	3.68e-7	Mean corpuscular hemoglobin;
SARC	cis	rs9487051	1.000	rs6568569	chr6:109613196	C/A	cg01475377	chr6:109611718	NA	-0.41	-5.61	-0.34	5.72e-8	Reticulocyte fraction of red cells;
SARC	trans	rs7937682	0.961	rs4936682	chr11:111629743	T/G	cg18187862	chr3:45730750	SACM1L	-0.59	-7.16	-0.42	1.06e-11	Primary sclerosing cholangitis;
SARC	cis	rs1371867	0.875	rs1788168	chr8:101324960	G/T	cg11906718	chr8:101322791	RNF19A	0.66	8.62	0.49	1.01e-15	Atrioventricular conduction;
SARC	cis	rs7264396	0.563	rs1970577	chr20:34336737	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-6.71	-0.4	1.47e-10	Total cholesterol levels;
SARC	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg03060546	chr3:49711283	APEH	0.47	6.16	0.37	3.2e-9	Menarche (age at onset);
SARC	cis	rs10892173	0.566	rs2298649	chr11:117672225	A/G	cg21640587	chr11:117668038	DSCAML1	0.72	10.0	0.55	8.28e-20	Myopia;
SARC	cis	rs11098499	0.954	rs10008459	chr4:120394231	T/C	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	cis	rs3768617	0.510	rs4491025	chr1:183065183	C/T	cg13390022	chr1:182993471	LAMC1	0.33	4.94	0.31	1.49e-6	Fuchs's corneal dystrophy;
SARC	cis	rs8077889	0.917	rs9894873	chr17:41911832	A/G	cg26893861	chr17:41843967	DUSP3	0.86	10.77	0.58	3.2e-22	Triglycerides;
SARC	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.66	0.35	4.44e-8	Bipolar disorder;
SARC	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg15595755	chr5:1867978	NA	0.5	6.91	0.41	4.46e-11	Cardiovascular disease risk factors;
SARC	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg15921436	chr17:44337874	NA	0.48	4.92	0.31	1.62e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs12594515	0.506	rs74199860	chr15:45989190	C/T	cg14863074	chr15:45997064	NA	0.34	5.24	0.32	3.57e-7	Waist circumference;Weight;
SARC	cis	rs9300255	0.602	rs1616131	chr12:123619838	G/A	cg00376283	chr12:123451042	ABCB9	0.56	6.52	0.39	4.36e-10	Neutrophil percentage of white cells;
SARC	cis	rs6834538	0.964	rs2129407	chr4:113387928	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.47	5.75	0.35	2.81e-8	Free thyroxine concentration;
SARC	cis	rs2997447	0.846	rs3008419	chr1:26402820	A/C	cg19633962	chr1:26362018	EXTL1	-0.56	-5.25	-0.32	3.5e-7	QRS complex (12-leadsum);
SARC	cis	rs12048904	0.505	rs6577209	chr1:101255080	A/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.68	8.2	0.47	1.62e-14	Multiple sclerosis;
SARC	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg04756594	chr16:24857601	SLC5A11	0.46	6.32	0.38	1.34e-9	Intelligence (multi-trait analysis);
SARC	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg04166393	chr7:2884313	GNA12	0.63	7.41	0.44	2.25e-12	Height;
SARC	cis	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg14541582	chr5:601475	NA	-0.4	-4.8	-0.3	2.85e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg18252515	chr7:66147081	NA	0.6	6.3	0.38	1.44e-9	Aortic root size;
SARC	cis	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg03060546	chr3:49711283	APEH	0.73	6.76	0.4	1.11e-10	Menarche (age at onset);
SARC	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg17971929	chr21:40555470	PSMG1	-0.93	-12.97	-0.65	2.56e-29	Cognitive function;
SARC	cis	rs12478296	0.892	rs11893879	chr2:243010411	G/A	cg06360820	chr2:242988706	NA	-0.61	-5.68	-0.35	4.04e-8	Obesity-related traits;
SARC	cis	rs7223966	1.000	rs7220821	chr17:61704147	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.82	0.41	7.9e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6570726	0.935	rs384453	chr6:145815145	G/C	cg23711669	chr6:146136114	FBXO30	0.78	11.91	0.62	7.29e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1707322	0.752	rs11211173	chr1:46219376	C/T	cg03146154	chr1:46216737	IPP	0.52	6.29	0.38	1.56e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs11166927	0.548	rs9324514	chr8:140830241	A/G	cg16909799	chr8:140841666	TRAPPC9	0.38	5.26	0.33	3.34e-7	Pediatric non-alcoholic fatty liver disease activity score;
SARC	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg12756686	chr19:29218302	NA	0.68	8.99	0.51	8.55e-17	Methadone dose in opioid dependence;
SARC	cis	rs6964587	0.933	rs6465350	chr7:91768615	G/A	cg17063962	chr7:91808500	NA	0.96	16.39	0.73	1.11e-40	Breast cancer;
SARC	cis	rs10979	1.000	rs9390110	chr6:143893413	A/G	cg25407410	chr6:143891975	LOC285740	-0.65	-8.83	-0.5	2.62e-16	Hypospadias;
SARC	cis	rs9768139	0.733	rs13225172	chr7:158120334	G/A	cg25566285	chr7:158114605	PTPRN2	0.3	4.83	0.3	2.51e-6	Calcium levels;
SARC	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg11987759	chr7:65425863	GUSB	-0.47	-6.27	-0.38	1.7e-9	Aortic root size;
SARC	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg20965017	chr5:231967	SDHA	-0.55	-5.29	-0.33	2.82e-7	Breast cancer;
SARC	cis	rs151234	0.741	rs151230	chr16:28583215	G/A	cg01378222	chr16:28622494	SULT1A1	-0.5	-5.78	-0.35	2.36e-8	Platelet distribution width;
SARC	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg13939156	chr17:80058883	NA	-0.42	-6.48	-0.39	5.51e-10	Life satisfaction;
SARC	cis	rs4805272	0.512	rs4805279	chr19:29336966	A/G	cg04546413	chr19:29218101	NA	0.45	5.0	0.31	1.14e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg01238044	chr22:24384105	GSTT1	-0.51	-5.76	-0.35	2.7e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs17376456	0.569	rs7735009	chr5:93260865	T/C	cg21475434	chr5:93447410	FAM172A	-0.61	-6.56	-0.39	3.45e-10	Diabetic retinopathy;
SARC	cis	rs2859741	1.000	rs1773575	chr1:37505129	T/C	cg09363841	chr1:37513479	NA	-0.27	-4.79	-0.3	2.95e-6	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
SARC	cis	rs6486730	1.000	rs6486730	chr12:129275027	C/T	cg09035930	chr12:129282057	SLC15A4	0.38	4.95	0.31	1.45e-6	Systemic lupus erythematosus;
SARC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.08	18.15	0.77	1.83e-46	Prudent dietary pattern;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg07432643	chr22:50247581	ZBED4	0.46	6.39	0.39	8.77e-10	Thyroid stimulating hormone;
SARC	cis	rs3820928	0.874	rs4675131	chr2:227836742	T/G	cg11843606	chr2:227700838	RHBDD1	-0.57	-7.24	-0.43	6.33e-12	Pulmonary function;
SARC	cis	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg18252515	chr7:66147081	NA	-1.3	-11.63	-0.61	5.98e-25	Diabetic kidney disease;
SARC	cis	rs477692	0.699	rs576175	chr10:131386408	A/T	cg14263093	chr10:131365266	MGMT	0.36	5.13	0.32	5.96e-7	Response to temozolomide;
SARC	cis	rs7769051	0.522	rs60631157	chr6:133094817	G/A	cg07930552	chr6:133119739	C6orf192	0.95	5.96	0.36	9.13e-9	Type 2 diabetes nephropathy;
SARC	cis	rs765787	0.530	rs1706835	chr15:45517884	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.43	-5.28	-0.33	2.96e-7	Uric acid levels;
SARC	cis	rs7084402	0.967	rs1649062	chr10:60309326	G/A	cg07615347	chr10:60278583	BICC1	0.59	8.61	0.49	1.12e-15	Refractive error;
SARC	cis	rs11718455	0.960	rs13081767	chr3:44004468	T/C	cg08738300	chr3:44038990	NA	0.54	5.87	0.36	1.47e-8	Coronary artery disease;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg10724491	chr3:112738377	C3orf17	0.49	6.45	0.39	6.23e-10	Thyroid stimulating hormone;
SARC	cis	rs7208859	0.623	rs35916850	chr17:29011173	G/A	cg13385521	chr17:29058706	SUZ12P	0.81	6.15	0.37	3.27e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs739401	0.967	rs451041	chr11:3060725	C/T	cg25174290	chr11:3078921	CARS	0.56	8.03	0.47	4.91e-14	Longevity;
SARC	cis	rs9843304	0.529	rs4681512	chr3:149203441	C/T	cg08667024	chr3:149219783	TM4SF4	-0.4	-5.84	-0.36	1.72e-8	Gallstone disease;
SARC	cis	rs7412746	0.611	rs4509581	chr1:150774465	A/G	cg13175981	chr1:150552382	MCL1	-0.56	-6.87	-0.41	5.7e-11	Melanoma;
SARC	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg03709012	chr19:19516395	GATAD2A	0.95	14.76	0.7	2.9e-35	Tonsillectomy;
SARC	cis	rs41278232	0.557	rs817351	chr20:62610447	T/C	cg24354818	chr20:62328094	TNFRSF6B	0.35	4.96	0.31	1.34e-6	Tonsillectomy;
SARC	cis	rs67478160	0.634	rs2144080	chr14:104258761	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.36	-4.95	-0.31	1.42e-6	Schizophrenia;
SARC	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg00800038	chr16:89945340	TCF25	-0.72	-5.75	-0.35	2.8e-8	Skin colour saturation;
SARC	cis	rs193541	0.632	rs400207	chr5:122318497	C/T	cg19412675	chr5:122181750	SNX24	-0.49	-6.29	-0.38	1.57e-9	Glucose homeostasis traits;
SARC	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg13264159	chr8:625131	ERICH1	-0.65	-4.98	-0.31	1.26e-6	IgG glycosylation;
SARC	cis	rs2073499	1.000	rs79536844	chr3:50375066	C/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.51	4.73	0.3	3.83e-6	Schizophrenia;
SARC	cis	rs1153858	1.000	rs4625670	chr15:45652926	C/T	cg14582100	chr15:45693742	SPATA5L1	0.35	4.82	0.3	2.64e-6	Homoarginine levels;
SARC	cis	rs11155671	0.530	rs9383914	chr6:150207234	T/G	cg09699651	chr6:150184138	LRP11	0.51	6.55	0.39	3.7e-10	Testicular germ cell tumor;
SARC	cis	rs9818758	0.607	rs73084135	chr3:49272218	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.72	-6.15	-0.37	3.32e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs6665290	0.904	rs1045285	chr1:227179054	G/A	cg14016676	chr1:227182615	CDC42BPA	0.33	4.74	0.3	3.75e-6	Myeloid white cell count;
SARC	cis	rs17376456	0.877	rs10059230	chr5:93450347	A/G	cg21475434	chr5:93447410	FAM172A	0.88	8.11	0.47	2.81e-14	Diabetic retinopathy;
SARC	cis	rs2070488	0.775	rs6780349	chr3:38555178	C/T	cg27533700	chr3:38537683	EXOG	0.37	4.85	0.3	2.24e-6	Electrocardiographic conduction measures;
SARC	cis	rs765787	0.530	rs11636410	chr15:45535913	A/C	cg24006582	chr15:45444508	DUOX1	0.56	7.43	0.44	2.07e-12	Uric acid levels;
SARC	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg07636037	chr3:49044803	WDR6	1.02	18.01	0.76	5.08e-46	Parkinson's disease;
SARC	cis	rs36051895	0.664	rs10116560	chr9:5096433	A/G	cg02405213	chr9:5042618	JAK2	-0.48	-5.71	-0.35	3.36e-8	Pediatric autoimmune diseases;
SARC	cis	rs67460515	0.500	rs9832109	chr3:160723364	T/C	cg17135325	chr3:160939158	NMD3	0.51	6.28	0.38	1.64e-9	Parkinson's disease;
SARC	cis	rs3087591	0.920	rs11080150	chr17:29629326	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.52	-6.4	-0.39	8.39e-10	Hip circumference;
SARC	trans	rs61931739	0.517	rs860950	chr12:34104376	C/G	cg26384229	chr12:38710491	ALG10B	0.74	10.17	0.55	2.5e-20	Morning vs. evening chronotype;
SARC	cis	rs72781680	0.898	rs17763224	chr2:24213776	T/C	cg08917208	chr2:24149416	ATAD2B	0.79	7.65	0.45	5.14e-13	Lymphocyte counts;
SARC	cis	rs644799	0.965	rs11021305	chr11:95498269	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.86	13.39	0.66	1.09e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs8064299	0.967	rs880827	chr17:72767435	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.57	-7.27	-0.43	5.28e-12	Monocyte count;
SARC	cis	rs7827545	1.000	rs9644456	chr8:135568656	G/T	cg17885191	chr8:135476712	NA	0.44	4.91	0.31	1.74e-6	Hypertension (SNP x SNP interaction);
SARC	cis	rs12458462	0.892	rs35928863	chr18:77438956	A/G	cg11879182	chr18:77439856	CTDP1	0.87	12.82	0.64	7.84e-29	Monocyte count;
SARC	cis	rs9911578	1.000	rs6503887	chr17:56993320	T/C	cg12560992	chr17:57184187	TRIM37	0.85	11.57	0.6	9.08e-25	Intelligence (multi-trait analysis);
SARC	cis	rs35306767	0.903	rs12250937	chr10:900209	C/T	cg20503657	chr10:835505	NA	0.88	8.42	0.48	3.91e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs2075371	1.000	rs2241336	chr7:133979578	A/G	cg11752832	chr7:134001865	SLC35B4	0.56	7.39	0.44	2.64e-12	Mean platelet volume;
SARC	cis	rs9902453	0.838	rs9646436	chr17:28209059	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	7.05	0.42	2.07e-11	Coffee consumption (cups per day);
SARC	cis	rs10779751	0.770	rs11581010	chr1:11212458	A/G	cg08854313	chr1:11322531	MTOR	-0.84	-10.66	-0.57	7.4e-22	Body mass index;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg00511405	chr20:42219387	IFT52	-0.49	-6.49	-0.39	4.98e-10	Neuroticism;
SARC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg09373136	chr17:61933544	TCAM1	-0.43	-5.88	-0.36	1.42e-8	Prudent dietary pattern;
SARC	cis	rs4423214	0.918	rs11233789	chr11:71181085	A/G	cg05163923	chr11:71159392	DHCR7	0.68	9.55	0.53	1.9e-18	Vitamin D levels;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg25184481	chr7:19813001	TMEM196	-0.45	-6.23	-0.38	2.11e-9	Tetralogy of Fallot;
SARC	cis	rs2276314	0.802	rs4799838	chr18:33597530	T/C	cg05985134	chr18:33552581	C18orf21	0.66	6.75	0.4	1.14e-10	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs5753618	0.539	rs1034588	chr22:31616301	A/G	cg07713946	chr22:31675144	LIMK2	-0.39	-5.34	-0.33	2.24e-7	Colorectal cancer;
SARC	cis	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg07777115	chr5:623756	CEP72	-0.6	-5.43	-0.34	1.43e-7	Obesity-related traits;
SARC	cis	rs763121	0.853	rs10135	chr22:39082174	C/T	cg21395723	chr22:39101663	GTPBP1	-0.55	-6.5	-0.39	4.77e-10	Menopause (age at onset);
SARC	cis	rs7617773	0.817	rs13094727	chr3:48323489	G/A	cg11946769	chr3:48343235	NME6	0.7	9.03	0.51	6.89e-17	Coronary artery disease;
SARC	cis	rs79349575	0.749	rs318093	chr17:46989354	A/G	cg16584676	chr17:46985605	UBE2Z	0.53	6.42	0.39	7.58e-10	Type 2 diabetes;
SARC	cis	rs7106204	1.000	rs4244512	chr11:24217355	A/G	ch.11.24196551F	chr11:24239977	NA	-0.63	-6.3	-0.38	1.47e-9	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg06212747	chr3:49208901	KLHDC8B	0.65	8.64	0.49	9.19e-16	Parkinson's disease;
SARC	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg18252515	chr7:66147081	NA	0.56	6.02	0.37	6.73e-9	Aortic root size;
SARC	cis	rs6582630	0.555	rs7969922	chr12:38529491	C/T	cg13010199	chr12:38710504	ALG10B	0.76	10.56	0.57	1.47e-21	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1957429	0.520	rs72625642	chr14:65338884	G/T	cg23373153	chr14:65346875	NA	-0.84	-5.81	-0.36	2.04e-8	Pediatric areal bone mineral density (radius);
SARC	cis	rs73198271	0.599	rs10103169	chr8:8650698	T/A	cg06636001	chr8:8085503	FLJ10661	-0.48	-5.4	-0.33	1.65e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs7264396	0.790	rs6060526	chr20:34225302	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.71	7.71	0.45	3.55e-13	Total cholesterol levels;
SARC	cis	rs12216125	0.549	rs9358905	chr6:26077839	T/A	cg18357526	chr6:26021779	HIST1H4A	0.42	5.32	0.33	2.46e-7	Iron status biomarkers;
SARC	trans	rs208520	0.690	rs6929762	chr6:66709277	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	14.02	0.68	8.85e-33	Exhaled nitric oxide output;
SARC	cis	rs4243830	0.850	rs13513	chr1:6585804	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.78	-7.63	-0.45	5.93e-13	Body mass index;
SARC	cis	rs1046896	0.607	rs12449739	chr17:80683420	G/A	cg05255149	chr17:80675120	FN3KRP	0.47	5.12	0.32	6.54e-7	Glycated hemoglobin levels;
SARC	cis	rs79349575	0.756	rs937301	chr17:47046276	A/G	cg16584676	chr17:46985605	UBE2Z	-0.45	-5.39	-0.33	1.77e-7	Type 2 diabetes;
SARC	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg18252515	chr7:66147081	NA	-1.26	-11.14	-0.59	2.14e-23	Diabetic kidney disease;
SARC	cis	rs10504229	0.593	rs58647001	chr8:58025132	G/A	cg22535103	chr8:58192502	C8orf71	-0.57	-5.85	-0.36	1.68e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs933688	0.583	rs6882172	chr5:90576958	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.48	-4.87	-0.3	2.08e-6	Smoking behavior;
SARC	cis	rs6570726	0.846	rs439035	chr6:145887990	G/C	cg05347473	chr6:146136440	FBXO30	0.51	7.06	0.42	1.9e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6087990	0.568	rs853854	chr20:31420757	T/A	cg13636640	chr20:31349939	DNMT3B	0.67	9.37	0.52	6.75e-18	Ulcerative colitis;
SARC	cis	rs7582720	0.945	rs72936875	chr2:203791912	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs9517313	0.523	rs4772104	chr13:99235677	G/A	cg07423050	chr13:99094983	FARP1	-0.4	-5.16	-0.32	5.27e-7	Neuroticism;
SARC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg08280861	chr8:58055591	NA	0.61	5.94	0.36	1.01e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg17837792	chr4:83273357	NA	0.55	7.65	0.45	5.39e-13	Thyroid stimulating hormone;
SARC	cis	rs743757	0.938	rs2236981	chr3:50488845	A/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.51	4.85	0.3	2.29e-6	Diastolic blood pressure;
SARC	cis	rs7084402	0.523	rs10740730	chr10:60334939	T/C	cg07615347	chr10:60278583	BICC1	0.39	5.21	0.32	4.07e-7	Refractive error;
SARC	cis	rs367943	1.000	rs168365	chr5:112817984	G/A	cg12552261	chr5:112820674	MCC	-0.45	-5.21	-0.32	4.24e-7	Type 2 diabetes;
SARC	cis	rs8084125	0.832	rs62105173	chr18:74947147	A/G	cg07390210	chr18:74961196	GALR1	0.53	5.97	0.36	8.62e-9	Obesity-related traits;
SARC	cis	rs11651000	0.625	rs58067360	chr17:45819587	G/C	cg24803719	chr17:45855879	NA	-0.45	-7.27	-0.43	5.47e-12	IgG glycosylation;
SARC	cis	rs1348850	0.519	rs1544002	chr2:178529534	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.41	4.83	0.3	2.48e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg12311346	chr5:56204834	C5orf35	-0.58	-5.9	-0.36	1.28e-8	Initial pursuit acceleration;
SARC	cis	rs80282103	0.618	rs76068439	chr10:1121018	T/A	cg08668510	chr10:1095578	IDI1	0.84	5.02	0.31	1.01e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs9916302	0.784	rs34473775	chr17:37396201	G/T	cg20243544	chr17:37824526	PNMT	0.53	6.4	0.39	8.66e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs4948102	0.924	rs13241866	chr7:56090878	C/G	cg17215666	chr7:56131930	SUMF2	0.43	4.89	0.31	1.88e-6	Plasma homocysteine levels (post-methionine load test);
SARC	cis	rs752010	0.684	rs10789402	chr1:42084649	A/G	cg06885757	chr1:42089581	HIVEP3	0.42	6.46	0.39	5.99e-10	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs9902453	0.817	rs12941382	chr17:28410124	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.56	-7.21	-0.43	7.69e-12	Coffee consumption (cups per day);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	6.47	0.39	5.84e-10	Thyroid stimulating hormone;
SARC	cis	rs9815354	1.000	rs1716660	chr3:41929960	G/A	cg03022575	chr3:42003672	ULK4	-0.56	-5.38	-0.33	1.81e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg04166393	chr7:2884313	GNA12	0.52	5.75	0.35	2.82e-8	Height;
SARC	cis	rs796364	0.951	rs3098341	chr2:200792498	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.76	6.88	0.41	5.42e-11	Schizophrenia;
SARC	cis	rs12130219	0.500	rs4845743	chr1:152184149	A/G	cg26320663	chr1:152161521	NA	0.41	5.11	0.32	6.72e-7	Inflammatory skin disease;
SARC	cis	rs12048904	0.533	rs1590580	chr1:101292668	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.68	7.16	0.42	1.03e-11	Multiple sclerosis;
SARC	cis	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg03060546	chr3:49711283	APEH	0.74	10.7	0.57	5.32e-22	Resting heart rate;
SARC	cis	rs7084402	0.967	rs1649055	chr10:60320045	T/A	cg07615347	chr10:60278583	BICC1	0.58	8.33	0.48	7.16e-15	Refractive error;
SARC	trans	rs61931739	0.517	rs11513519	chr12:34075077	G/A	cg13010199	chr12:38710504	ALG10B	0.77	10.36	0.56	6.42e-21	Morning vs. evening chronotype;
SARC	cis	rs1707322	0.827	rs6694302	chr1:46245645	A/T	cg03146154	chr1:46216737	IPP	0.5	6.2	0.38	2.57e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs10992471	0.756	rs10123342	chr9:95087824	T/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-6.69	-0.4	1.67e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs4253772	0.591	rs6520010	chr22:46721223	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.75	7.47	0.44	1.62e-12	LDL cholesterol;Cholesterol, total;
SARC	cis	rs4713118	0.513	rs149972	chr6:27983227	C/T	cg26450541	chr6:28235208	ZNF187	0.46	4.9	0.31	1.79e-6	Parkinson's disease;
SARC	cis	rs643506	1.000	rs643506	chr11:111636627	T/G	cg09085632	chr11:111637200	PPP2R1B	0.51	5.78	0.35	2.42e-8	Breast cancer;
SARC	cis	rs78456975	1.000	rs6744743	chr2:1558161	C/T	cg26248373	chr2:1572462	NA	0.54	5.59	0.34	6.19e-8	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg21724239	chr8:58056113	NA	0.61	6.43	0.39	7.16e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9457247	0.602	rs9457262	chr6:167473685	A/G	cg23791538	chr6:167370224	RNASET2	-0.53	-7.01	-0.42	2.51e-11	Crohn's disease;
SARC	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg16414030	chr3:133502952	NA	-0.47	-6.29	-0.38	1.54e-9	Iron status biomarkers;
SARC	cis	rs5771242	0.518	rs6010216	chr22:50679471	C/T	cg16473166	chr22:50639996	SELO	0.54	5.77	0.35	2.54e-8	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
SARC	cis	rs7772486	0.754	rs4895682	chr6:146062861	G/A	cg23711669	chr6:146136114	FBXO30	-0.93	-16.35	-0.73	1.53e-40	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7592578	0.723	rs4371384	chr2:191430741	A/G	cg10560079	chr2:191398806	TMEM194B	0.83	9.48	0.53	3.11e-18	Diastolic blood pressure;
SARC	cis	rs4595586	0.545	rs6580893	chr12:39371885	G/T	cg13010199	chr12:38710504	ALG10B	0.4	4.75	0.3	3.57e-6	Morning vs. evening chronotype;
SARC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.58	7.49	0.44	1.43e-12	Lymphocyte counts;
SARC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg11494091	chr17:61959527	GH2	0.54	7.99	0.46	6.26e-14	Prudent dietary pattern;
SARC	cis	rs61935443	0.720	rs11107776	chr12:95294283	T/G	cg21533806	chr12:95267307	NA	0.68	8.17	0.47	1.93e-14	Schizophrenia;
SARC	cis	rs6088813	1.000	rs6142376	chr20:33992761	T/A	cg23207816	chr20:34252616	CPNE1;RBM12	-0.44	-5.29	-0.33	2.78e-7	Height;
SARC	cis	rs6088590	0.523	rs6058084	chr20:33183804	C/T	cg08999081	chr20:33150536	PIGU	0.45	6.82	0.41	7.77e-11	Coronary artery disease;
SARC	cis	rs9807989	0.811	rs4485585	chr2:102970759	T/C	cg09003973	chr2:102972529	NA	0.41	5.6	0.34	6.11e-8	Asthma;
SARC	cis	rs910316	1.000	rs12590452	chr14:75548756	T/C	cg23033748	chr14:75592666	NEK9	0.37	5.27	0.33	3.11e-7	Height;
SARC	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg03517284	chr6:25882590	NA	-0.35	-4.94	-0.31	1.51e-6	Blood metabolite levels;
SARC	cis	rs4853036	0.904	rs2278934	chr2:70121197	T/C	cg02498382	chr2:70120550	SNRNP27	-0.42	-5.91	-0.36	1.18e-8	Colorectal or endometrial cancer;
SARC	cis	rs7264396	0.512	rs2425072	chr20:34293686	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-7.32	-0.43	3.93e-12	Total cholesterol levels;
SARC	cis	rs7178572	0.568	rs4886850	chr15:77404160	G/C	cg22256960	chr15:77711686	NA	-0.52	-5.48	-0.34	1.08e-7	Type 2 diabetes;
SARC	cis	rs57506017	0.585	rs5011439	chr7:12268811	G/C	cg23422036	chr7:12250390	TMEM106B	0.45	5.87	0.36	1.46e-8	Neuroticism;
SARC	cis	rs9467773	1.000	rs6933176	chr6:26540178	G/A	cg12292205	chr6:26970375	C6orf41	0.45	5.42	0.33	1.45e-7	Intelligence (multi-trait analysis);
SARC	cis	rs12142240	0.698	rs66483119	chr1:46838389	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-5.56	-0.34	7.46e-8	Menopause (age at onset);
SARC	cis	rs7086627	0.515	rs10887894	chr10:82209952	A/G	cg01528321	chr10:82214614	TSPAN14	0.57	8.41	0.48	4.07e-15	Post bronchodilator FEV1;
SARC	cis	rs17572109	0.666	rs11696005	chr2:219229641	T/C	cg00012203	chr2:219082015	ARPC2	-0.54	-5.61	-0.34	5.74e-8	Platelet count;Platelet distribution width;Mean platelet volume;
SARC	cis	rs3768617	0.510	rs3768618	chr1:183092491	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.68	10.11	0.55	3.67e-20	Fuchs's corneal dystrophy;
SARC	cis	rs9916302	0.904	rs9944411	chr17:37483599	T/C	cg20243544	chr17:37824526	PNMT	-0.56	-6.92	-0.41	4.39e-11	Glomerular filtration rate (creatinine);
SARC	trans	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg21659725	chr3:3221576	CRBN	-0.55	-7.24	-0.43	6.29e-12	Intelligence (multi-trait analysis);
SARC	cis	rs1355223	0.583	rs1396880	chr11:34870552	C/T	cg18508148	chr11:34937573	PDHX;APIP	-0.45	-5.77	-0.35	2.56e-8	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs440932	0.798	rs330942	chr8:9020439	A/C	cg06636001	chr8:8085503	FLJ10661	0.41	4.94	0.31	1.48e-6	High light scatter reticulocyte percentage of red cells;
SARC	cis	rs7818345	1.000	rs12675717	chr8:19293177	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.39	5.32	0.33	2.45e-7	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs11711311	0.712	rs3773683	chr3:113341007	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	7.26	0.43	5.9e-12	IgG glycosylation;
SARC	cis	rs208515	0.525	rs10944869	chr6:66687576	G/T	cg07460842	chr6:66804631	NA	0.86	9.87	0.54	2.02e-19	Exhaled nitric oxide levels;
SARC	cis	rs12142240	0.698	rs66911505	chr1:46823298	A/G	cg10495392	chr1:46806563	NSUN4	0.65	6.8	0.41	8.89e-11	Menopause (age at onset);
SARC	cis	rs7520050	1.000	rs12410070	chr1:46358882	T/C	cg06784218	chr1:46089804	CCDC17	-0.26	-4.89	-0.31	1.85e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs4727027	0.866	rs3927307	chr7:148774869	C/T	cg23583168	chr7:148888333	NA	-0.72	-10.06	-0.55	5.31e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs963731	0.579	rs6544195	chr2:39288486	A/G	cg04010122	chr2:39346883	SOS1	-0.69	-4.77	-0.3	3.29e-6	Corticobasal degeneration;
SARC	cis	rs798554	0.704	rs2527684	chr7:2825922	G/T	cg13628971	chr7:2884303	GNA12	0.44	5.38	0.33	1.85e-7	Height;
SARC	cis	rs910316	0.783	rs11850751	chr14:75590113	A/T	cg11812906	chr14:75593930	NEK9	0.86	13.25	0.66	3.13e-30	Height;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg03631076	chr16:87985047	BANP	0.59	8.18	0.47	1.79e-14	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs11739663	0.574	rs67276442	chr5:583918	T/C	cg23206463	chr5:561769	NA	-0.43	-6.05	-0.37	5.87e-9	Ulcerative colitis;
SARC	cis	rs12142240	0.698	rs12385695	chr1:46819021	A/G	cg10495392	chr1:46806563	NSUN4	0.65	6.83	0.41	7.25e-11	Menopause (age at onset);
SARC	cis	rs751728	0.643	rs12173787	chr6:33735471	G/C	cg25922239	chr6:33757077	LEMD2	0.56	6.98	0.42	3.09e-11	Crohn's disease;
SARC	trans	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-7.53	-0.44	1.11e-12	Intelligence (multi-trait analysis);
SARC	cis	rs12791968	1.000	rs1552301	chr11:45002551	A/G	cg11846598	chr11:44996168	LOC221122	-0.36	-5.52	-0.34	9.04e-8	Inhibitory control;
SARC	cis	rs9325144	0.555	rs1973292	chr12:38679626	T/C	cg13010199	chr12:38710504	ALG10B	0.56	7.33	0.43	3.73e-12	Morning vs. evening chronotype;
SARC	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg19671926	chr4:122722719	EXOSC9	-0.52	-6.05	-0.37	5.62e-9	Type 2 diabetes;
SARC	cis	rs9815354	1.000	rs9818169	chr3:41860599	A/G	cg03022575	chr3:42003672	ULK4	0.58	5.41	0.33	1.59e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg24829409	chr8:58192753	C8orf71	-0.57	-4.8	-0.3	2.89e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs1878931	0.624	rs39728	chr16:3453076	A/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.71	8.22	0.47	1.46e-14	Body mass index (adult);
SARC	cis	rs7084402	0.967	rs1658483	chr10:60288933	C/T	cg07615347	chr10:60278583	BICC1	0.61	8.99	0.51	8.84e-17	Refractive error;
SARC	cis	rs3859192	0.599	rs2227321	chr17:38171294	G/C	cg17467752	chr17:38218738	THRA	-0.38	-4.76	-0.3	3.41e-6	White blood cell count;
SARC	cis	rs282587	0.597	rs438116	chr13:113392149	G/C	cg02820901	chr13:113351484	ATP11A	-0.5	-4.83	-0.3	2.51e-6	Glycated hemoglobin levels;
SARC	cis	rs854765	0.619	rs6502636	chr17:17983817	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.63	8.75	0.5	4.46e-16	Total body bone mineral density;
SARC	cis	rs9790314	0.905	rs4856739	chr3:160986710	A/C	cg04691961	chr3:161091175	C3orf57	-0.75	-10.85	-0.58	1.88e-22	Morning vs. evening chronotype;
SARC	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs11039798	0.588	rs1847640	chr11:49004025	C/T	cg15704280	chr7:45808275	SEPT13	0.72	7.0	0.42	2.66e-11	Axial length;
SARC	cis	rs7481584	1.000	rs756693	chr11:3027889	A/G	cg08508325	chr11:3079039	CARS	0.22	4.84	0.3	2.39e-6	Calcium levels;
SARC	cis	rs9790314	0.718	rs1599383	chr3:160829820	T/C	cg04691961	chr3:161091175	C3orf57	-0.62	-8.47	-0.49	2.77e-15	Morning vs. evening chronotype;
SARC	cis	rs11651000	0.654	rs12451801	chr17:45820975	T/C	cg24803719	chr17:45855879	NA	-0.47	-7.08	-0.42	1.7e-11	IgG glycosylation;
SARC	trans	rs1814175	0.645	rs11040703	chr11:50024961	C/T	cg03929089	chr4:120376271	NA	-0.82	-11.88	-0.61	9.03e-26	Height;
SARC	cis	rs7589728	1.000	rs75309929	chr2:88524377	T/C	cg04511125	chr2:88470314	THNSL2	0.65	5.68	0.35	4.09e-8	Plasma clusterin levels;
SARC	cis	rs55883249	1.000	rs76964971	chr2:9763904	C/A	cg23886495	chr2:9695866	ADAM17	0.66	6.68	0.4	1.72e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.21	0.52	2e-17	Prudent dietary pattern;
SARC	cis	rs9303401	0.612	rs2526370	chr17:56487636	G/C	cg05425664	chr17:57184151	TRIM37	-0.43	-5.14	-0.32	5.74e-7	Cognitive test performance;
SARC	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg24531977	chr5:56204891	C5orf35	-0.54	-5.45	-0.34	1.26e-7	Initial pursuit acceleration;
SARC	cis	rs9399137	0.507	rs7771310	chr6:135272535	G/A	cg22676075	chr6:135203613	NA	0.42	5.51	0.34	9.3e-8	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs820218	0.770	rs7226367	chr17:73614968	G/A	cg01592526	chr17:73663357	RECQL5;SAP30BP	-0.49	-6.15	-0.37	3.31e-9	Rotator cuff tears;
SARC	trans	rs66573146	1.000	rs6852613	chr4:7035637	G/A	cg07817883	chr1:32538562	TMEM39B	1.36	7.93	0.46	9.16e-14	Granulocyte percentage of myeloid white cells;
SARC	cis	rs2075371	0.830	rs2077671	chr7:133951204	C/T	cg11752832	chr7:134001865	SLC35B4	0.54	6.89	0.41	5.12e-11	Mean platelet volume;
SARC	cis	rs981844	0.961	rs6827685	chr4:154662227	C/T	cg14289246	chr4:154710475	SFRP2	0.56	6.51	0.39	4.55e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs9640161	0.789	rs2373751	chr7:150021599	G/C	cg17279839	chr7:150038598	RARRES2	0.49	6.61	0.4	2.6e-10	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs67460515	0.926	rs11715591	chr3:161043137	C/T	cg17135325	chr3:160939158	NMD3	0.63	7.93	0.46	9.23e-14	Parkinson's disease;
SARC	cis	rs9486719	0.948	rs2092095	chr6:96870864	T/G	cg06623918	chr6:96969491	KIAA0776	0.73	8.01	0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs4919087	0.590	rs793519	chr10:99030554	C/G	cg25902810	chr10:99078978	FRAT1	0.51	5.42	0.33	1.45e-7	Monocyte count;
SARC	cis	rs57994353	0.897	rs11999609	chr9:139363539	C/T	cg14169450	chr9:139327907	INPP5E	0.43	5.57	0.34	7.16e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	11.31	0.6	6.28e-24	Alzheimer's disease;
SARC	cis	rs2645694	0.626	rs2703151	chr4:77834095	A/G	cg06046430	chr4:77819534	ANKRD56	0.45	6.14	0.37	3.53e-9	Emphysema distribution in smoking;
SARC	cis	rs17376456	0.877	rs10213956	chr5:93460839	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.71	0.35	3.39e-8	Diabetic retinopathy;
SARC	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg01475735	chr3:40494733	NA	-0.49	-5.37	-0.33	1.95e-7	Renal cell carcinoma;
SARC	cis	rs6815814	0.898	rs5743592	chr4:38803063	A/G	cg06935464	chr4:38784597	TLR10	0.63	6.42	0.39	7.38e-10	Breast cancer;
SARC	cis	rs9462027	0.583	rs9469902	chr6:34793768	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-6.1	-0.37	4.32e-9	Systemic lupus erythematosus;
SARC	cis	rs55794721	0.509	rs12027135	chr1:25775733	A/T	cg02931644	chr1:25747376	RHCE	0.42	6.83	0.41	7.3e-11	Plateletcrit;Mean corpuscular volume;
SARC	cis	rs10848704	0.956	rs10848703	chr12:2882250	C/T	cg19995117	chr12:2880862	NA	0.3	4.9	0.31	1.78e-6	Quantitative traits;
SARC	cis	rs722599	0.748	rs2537824	chr14:75367349	T/C	cg08847533	chr14:75593920	NEK9	-0.42	-4.79	-0.3	3.02e-6	IgG glycosylation;
SARC	cis	rs12594515	0.967	rs8039088	chr15:45990178	T/C	cg14863074	chr15:45997064	NA	0.34	5.24	0.32	3.57e-7	Waist circumference;Weight;
SARC	cis	rs7980687	0.628	rs2851443	chr12:123694250	C/T	cg05973401	chr12:123451056	ABCB9	0.55	6.38	0.39	9.28e-10	Height;Educational attainment;Head circumference (infant);
SARC	cis	rs2531992	0.702	rs1045475	chr16:4015316	A/G	cg08098950	chr16:4033226	ADCY9	-0.32	-5.14	-0.32	5.89e-7	Waist circumference;
SARC	cis	rs7247513	0.701	rs8107642	chr19:12766370	C/T	cg23899408	chr19:12877188	HOOK2	0.45	5.73	0.35	3.11e-8	Bipolar disorder;
SARC	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg20891283	chr12:69753455	YEATS4	0.66	9.45	0.53	3.66e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs959260	0.528	rs4559942	chr17:73309269	G/A	cg14668889	chr17:73230827	NUP85	-0.54	-6.91	-0.41	4.68e-11	Systemic lupus erythematosus;
SARC	cis	rs1707322	1.000	rs4660906	chr1:46470860	C/T	cg03146154	chr1:46216737	IPP	0.46	5.54	0.34	8.13e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6831352	0.879	rs1984362	chr4:100070973	G/A	cg12011299	chr4:100065546	ADH4	-0.31	-5.03	-0.31	9.6e-7	Alcohol dependence;
SARC	cis	rs76878669	0.561	rs7117630	chr11:66154777	C/T	cg14036092	chr11:66035641	RAB1B	-0.4	-4.72	-0.3	4.03e-6	Educational attainment (years of education);
SARC	cis	rs12142240	0.667	rs55887761	chr1:46826587	C/A	cg00530320	chr1:46809349	NSUN4	0.57	6.79	0.41	9.05e-11	Menopause (age at onset);
SARC	cis	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg24110177	chr3:50126178	RBM5	-0.56	-7.72	-0.45	3.41e-13	Intelligence (multi-trait analysis);
SARC	cis	rs1559088	0.948	rs9304844	chr19:33579935	G/T	cg27124370	chr19:33622961	WDR88	0.43	5.65	0.35	4.58e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs12745968	0.685	rs2180976	chr1:93271332	G/A	cg17283838	chr1:93427260	FAM69A	-0.42	-4.84	-0.3	2.35e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs1348850	0.874	rs13013752	chr2:178456862	A/G	cg23306229	chr2:178417860	TTC30B	0.6	6.95	0.41	3.54e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs73198271	0.562	rs55657655	chr8:8675491	G/A	cg01851573	chr8:8652454	MFHAS1	0.45	5.46	0.34	1.19e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs600231	0.542	rs34527830	chr11:65240863	G/A	cg17120908	chr11:65337727	SSSCA1	-0.45	-4.99	-0.31	1.17e-6	Bone mineral density;
SARC	cis	rs9527	0.590	rs1926037	chr10:104878010	A/C	cg04362960	chr10:104952993	NT5C2	0.43	4.94	0.31	1.47e-6	Arsenic metabolism;
SARC	trans	rs9427116	0.502	rs12125166	chr1:154582129	A/G	cg13131908	chr15:81616310	STARD5	-0.5	-6.24	-0.38	2.08e-9	Blood protein levels;
SARC	cis	rs9790314	0.586	rs16832246	chr3:161109916	A/G	cg04691961	chr3:161091175	C3orf57	0.49	6.2	0.38	2.57e-9	Morning vs. evening chronotype;
SARC	cis	rs981844	0.816	rs56413502	chr4:154721784	T/A	cg14289246	chr4:154710475	SFRP2	0.57	6.27	0.38	1.78e-9	Response to statins (LDL cholesterol change);
SARC	cis	rs9894429	0.646	rs9905639	chr17:79614154	A/G	cg18240062	chr17:79603768	NPLOC4	0.6	7.55	0.44	9.95e-13	Eye color traits;
SARC	cis	rs10905065	0.965	rs10737019	chr10:5783733	G/A	cg09072322	chr10:5726702	C10orf18	-0.39	-5.06	-0.31	8.56e-7	Menopause (age at onset);
SARC	cis	rs34172651	0.874	rs200534	chr16:24752641	G/A	cg00339695	chr16:24857497	SLC5A11	-0.3	-4.88	-0.3	1.97e-6	Intelligence (multi-trait analysis);
SARC	cis	rs10140922	0.966	rs4982259	chr14:35821950	T/C	cg26967526	chr14:35346199	BAZ1A	-0.4	-4.89	-0.31	1.88e-6	Hip circumference adjusted for BMI;
SARC	cis	rs6088590	1.000	rs2378256	chr20:33292127	G/C	cg06115741	chr20:33292138	TP53INP2	0.54	6.47	0.39	5.68e-10	Coronary artery disease;
SARC	cis	rs73086581	1.000	rs34640283	chr20:3989576	T/A	cg02187196	chr20:3869020	PANK2	0.66	6.39	0.39	9.18e-10	Response to antidepressants in depression;
SARC	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg18225595	chr11:63971243	STIP1	0.44	5.27	0.33	3.12e-7	Mean platelet volume;
SARC	cis	rs2594989	0.779	rs61275424	chr3:11595585	G/C	cg00170343	chr3:11313890	ATG7	-0.53	-5.53	-0.34	8.55e-8	Circulating chemerin levels;
SARC	cis	rs600231	0.542	rs10896008	chr11:65245904	C/G	cg17120908	chr11:65337727	SSSCA1	-0.45	-4.93	-0.31	1.55e-6	Bone mineral density;
SARC	cis	rs9322817	0.691	rs6571207	chr6:105242161	A/C	cg02098413	chr6:105308735	HACE1	-0.39	-6.08	-0.37	4.85e-9	Thyroid stimulating hormone;
SARC	cis	rs9920	0.585	rs62469000	chr7:116149844	C/T	cg24770985	chr7:116166421	CAV1	0.87	5.67	0.35	4.26e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Immature fraction of reticulocytes;QT interval;
SARC	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg03433033	chr1:76189801	ACADM	0.53	7.72	0.45	3.49e-13	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2549003	0.966	rs2070730	chr5:131819800	G/A	cg21138405	chr5:131827807	IRF1	0.27	5.33	0.33	2.26e-7	Asthma (sex interaction);
SARC	cis	rs9436747	0.714	rs1171261	chr1:66001402	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.49	4.85	0.3	2.24e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg22875332	chr1:76189707	ACADM	0.48	6.56	0.39	3.45e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs1044826	0.597	rs1017468	chr3:139145778	A/G	cg15131784	chr3:139108705	COPB2	0.4	5.09	0.32	7.34e-7	Obesity-related traits;
SARC	cis	rs12042938	0.622	rs12030517	chr1:231808385	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.59	7.55	0.44	1e-12	Neuranatomic and neurocognitive phenotypes;
SARC	cis	rs4141404	0.851	rs5749222	chr22:31556759	C/G	cg02404636	chr22:31891804	SFI1	-0.46	-5.47	-0.34	1.16e-7	Paclitaxel-induced neuropathy;
SARC	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg25894440	chr7:65020034	NA	-0.79	-5.99	-0.37	8.04e-9	Diabetic kidney disease;
SARC	cis	rs3857536	0.904	rs4710578	chr6:66898163	A/G	cg07460842	chr6:66804631	NA	-0.44	-5.27	-0.33	3.08e-7	Blood trace element (Cu levels);
SARC	trans	rs11039798	0.588	rs11039782	chr11:48524785	A/G	cg15704280	chr7:45808275	SEPT13	0.64	6.57	0.4	3.34e-10	Axial length;
SARC	cis	rs2282335	0.507	rs2498421	chr9:71855357	A/G	cg14075627	chr9:71863002	TJP2	0.4	4.95	0.31	1.41e-6	Renal sinus fat;
SARC	cis	rs7833790	0.636	rs12544174	chr8:82731477	G/A	cg17211192	chr8:82754475	SNX16	-0.49	-6.21	-0.38	2.35e-9	Diastolic blood pressure;
SARC	cis	rs7833986	0.501	rs2667978	chr8:56897951	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.68	6.71	0.4	1.47e-10	Height;
SARC	cis	rs778371	0.723	rs6710294	chr2:233579634	T/C	cg16596103	chr2:233749413	NGEF	-0.38	-5.95	-0.36	9.78e-9	Schizophrenia;
SARC	cis	rs870825	0.616	rs6810635	chr4:185616859	T/C	cg04058563	chr4:185651563	MLF1IP	0.84	11.45	0.6	2.25e-24	Blood protein levels;
SARC	cis	rs7223966	1.000	rs7220821	chr17:61704147	G/A	cg26338869	chr17:61819248	STRADA	0.44	5.09	0.32	7.26e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs995000	0.931	rs6587980	chr1:63090858	C/T	cg06896770	chr1:63153194	DOCK7	0.93	13.73	0.67	8.15e-32	Triglyceride levels;
SARC	cis	rs4927850	0.958	rs2044599	chr3:195736740	G/A	cg00031303	chr3:195681400	NA	0.54	6.24	0.38	2.08e-9	Pancreatic cancer;
SARC	cis	rs62344088	1.000	rs28409618	chr5:160289	C/T	cg22857025	chr5:266934	NA	-0.75	-4.8	-0.3	2.84e-6	Asthma (childhood onset);
SARC	cis	rs6087990	0.899	rs4911262	chr20:31393352	G/A	cg13636640	chr20:31349939	DNMT3B	0.77	11.89	0.61	8.52e-26	Ulcerative colitis;
SARC	cis	rs995000	0.965	rs11485618	chr1:63094207	A/G	cg06896770	chr1:63153194	DOCK7	0.98	15.08	0.7	2.62e-36	Triglyceride levels;
SARC	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg11987759	chr7:65425863	GUSB	-0.48	-6.54	-0.39	3.9e-10	Aortic root size;
SARC	cis	rs13161895	1.000	rs27018	chr5:179405144	A/G	cg04265672	chr5:179402240	RNF130	-0.54	-5.17	-0.32	5.01e-7	LDL cholesterol;
SARC	trans	rs1814175	0.817	rs28544182	chr11:50049577	G/T	cg15704280	chr7:45808275	SEPT13	-0.98	-18.19	-0.77	1.31e-46	Height;
SARC	cis	rs2228479	1.000	rs4257207	chr16:89947861	T/A	cg00800038	chr16:89945340	TCF25	-0.75	-5.23	-0.32	3.82e-7	Skin colour saturation;
SARC	cis	rs7208859	0.673	rs73277967	chr17:29184166	T/A	cg13385521	chr17:29058706	SUZ12P	0.82	6.63	0.4	2.35e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs7474896	0.507	rs2474555	chr10:38465220	G/C	cg25427524	chr10:38739819	LOC399744	-0.53	-5.66	-0.35	4.53e-8	Obesity (extreme);
SARC	cis	rs4789693	0.872	rs28612648	chr17:80403386	G/A	cg23652146	chr17:80417115	NARF	0.43	4.75	0.3	3.48e-6	Glucocorticoid-induced osteonecrosis;
SARC	cis	rs617219	0.889	rs10942885	chr5:78436773	C/T	cg24856658	chr5:78533917	JMY	-0.32	-4.76	-0.3	3.41e-6	Betaine levels in individuals undergoing cardiac evaluation;
SARC	cis	rs1832871	0.655	rs4292552	chr6:158722888	G/A	cg07165851	chr6:158734300	TULP4	0.53	6.46	0.39	5.92e-10	Height;
SARC	cis	rs9611519	0.780	rs9611528	chr22:41648502	T/C	cg03806693	chr22:41940476	POLR3H	-0.68	-8.91	-0.5	1.5e-16	Neuroticism;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg22677180	chr15:57537929	TCF12	0.46	6.51	0.39	4.61e-10	Thyroid stimulating hormone;
SARC	cis	rs1044826	1.000	rs964227	chr3:139156093	C/A	cg15131784	chr3:139108705	COPB2	0.46	5.15	0.32	5.47e-7	Obesity-related traits;
SARC	cis	rs7927592	0.913	rs59056571	chr11:68272973	T/G	cg01657329	chr11:68192670	LRP5	-0.41	-5.01	-0.31	1.08e-6	Total body bone mineral density;
SARC	cis	rs4481887	0.893	rs7538645	chr1:248478137	C/T	cg13385794	chr1:248469461	NA	0.33	5.08	0.32	7.75e-7	Common traits (Other);
SARC	cis	rs17376456	0.877	rs10064520	chr5:93427358	T/C	cg25358565	chr5:93447407	FAM172A	1.32	14.75	0.69	3.21e-35	Diabetic retinopathy;
SARC	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg01341218	chr17:43662625	NA	1.01	11.61	0.61	6.64e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs644799	0.965	rs566877	chr11:95528045	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	14.15	0.68	3.08e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7762018	0.760	rs28660085	chr6:170101996	C/G	cg15038512	chr6:170123185	PHF10	0.65	7.41	0.44	2.26e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs78456975	0.941	rs11886649	chr2:1567757	A/G	cg01028140	chr2:1542097	TPO	-0.48	-5.09	-0.32	7.41e-7	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs1050631	1.000	rs1539822	chr18:33695943	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.42	5.06	0.31	8.67e-7	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs7617773	0.780	rs11714176	chr3:48360862	C/T	cg11946769	chr3:48343235	NME6	0.76	9.67	0.54	8.16e-19	Coronary artery disease;
SARC	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg22968622	chr17:43663579	NA	-0.8	-9.77	-0.54	4.17e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs8078723	1.000	rs4794824	chr17:38179290	G/A	cg17467752	chr17:38218738	THRA	0.48	6.22	0.38	2.28e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg10435706	chr6:150039699	LATS1	0.37	4.87	0.3	2.04e-6	Lung cancer;
SARC	cis	rs78545713	1.000	rs3734534	chr6:26240649	A/G	cg13736514	chr6:26305472	NA	0.63	5.22	0.32	3.97e-7	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs2742234	0.518	rs2505514	chr10:43633248	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.41	-4.94	-0.31	1.49e-6	Hirschsprung disease;
SARC	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg17971929	chr21:40555470	PSMG1	0.99	13.69	0.67	1.04e-31	Cognitive function;
SARC	trans	rs7819412	0.668	rs2409714	chr8:11010118	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.59	-0.4	2.98e-10	Triglycerides;
SARC	cis	rs796364	0.715	rs11688872	chr2:201052418	C/T	cg23649088	chr2:200775458	C2orf69	-0.63	-5.57	-0.34	6.87e-8	Schizophrenia;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg20932348	chr4:26862197	STIM2	0.5	6.28	0.38	1.67e-9	Lung adenocarcinoma;
SARC	cis	rs6582630	0.576	rs2387837	chr12:38403164	G/T	cg26384229	chr12:38710491	ALG10B	-0.57	-7.04	-0.42	2.19e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs546131	0.642	rs537873	chr11:34835121	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.41	4.72	0.3	3.99e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.3	-4.75	-0.3	3.51e-6	Total body bone mineral density;
SARC	cis	rs7666738	0.791	rs6532725	chr4:99061479	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.7	0.5	6.15e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.44	5.37	0.33	1.93e-7	Bipolar disorder;
SARC	cis	rs4888262	0.508	rs4544266	chr16:74660993	C/A	cg02853019	chr16:75273486	BCAR1	0.34	4.77	0.3	3.29e-6	Testicular germ cell tumor;
SARC	cis	rs4926611	0.762	rs11206175	chr1:54055318	T/C	cg08927728	chr1:54059983	GLIS1	0.3	4.82	0.3	2.6e-6	Hand grip strength;
SARC	cis	rs1865760	0.568	rs2032450	chr6:25993114	C/G	cg17691542	chr6:26056736	HIST1H1C	0.51	6.57	0.4	3.2e-10	Height;
SARC	cis	rs9916302	0.904	rs4794807	chr17:37531718	T/A	cg00129232	chr17:37814104	STARD3	0.61	7.58	0.44	7.99e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs1008375	0.966	rs11733730	chr4:17625209	G/C	cg16339924	chr4:17578868	LAP3	0.64	8.48	0.49	2.56e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg19223190	chr17:80058835	NA	-0.38	-5.2	-0.32	4.34e-7	Life satisfaction;
SARC	cis	rs77633900	0.614	rs280033	chr15:77023099	G/A	cg21673338	chr15:77095150	SCAPER	-0.61	-5.19	-0.32	4.68e-7	Non-glioblastoma glioma;Glioma;
SARC	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg10896456	chr17:42255109	ASB16;C17orf65	0.36	4.99	0.31	1.19e-6	Total body bone mineral density;
SARC	cis	rs56283067	0.887	rs10948172	chr6:44777691	A/G	cg18551225	chr6:44695536	NA	-0.36	-4.93	-0.31	1.54e-6	Total body bone mineral density;
SARC	cis	rs916888	0.647	rs199523	chr17:44848517	C/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.6	-6.6	-0.4	2.69e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs6121246	0.609	rs6089075	chr20:30392884	A/G	cg13852791	chr20:30311386	BCL2L1	0.81	9.9	0.54	1.62e-19	Mean corpuscular hemoglobin;
SARC	cis	rs12079745	0.590	rs79899534	chr1:169188861	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.87	-5.44	-0.34	1.35e-7	QT interval;
SARC	cis	rs13191362	1.000	rs35593345	chr6:163174981	G/C	cg18825119	chr6:163149453	PACRG;PARK2	0.43	5.28	0.33	2.99e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.42	-0.44	2.12e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs6759839	0.591	rs7605154	chr2:16694280	A/G	cg09580478	chr2:16689509	NA	-0.43	-5.77	-0.35	2.46e-8	Mean platelet volume;
SARC	cis	rs734999	0.588	rs6701238	chr1:2520500	G/A	cg20673091	chr1:2541236	MMEL1	0.33	5.05	0.31	8.72e-7	Ulcerative colitis;
SARC	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg05535760	chr7:792225	HEATR2	0.84	8.32	0.48	7.31e-15	Cerebrospinal P-tau181p levels;
SARC	cis	rs748404	0.631	rs11070399	chr15:43646347	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.39	4.76	0.3	3.43e-6	Lung cancer;
SARC	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.47	-5.89	-0.36	1.31e-8	Tonsillectomy;
SARC	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg15847926	chr7:2749597	AMZ1	-0.3	-4.92	-0.31	1.62e-6	Height;
SARC	cis	rs7666738	0.830	rs13138438	chr4:99050545	C/A	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4128725	1.000	rs78879802	chr1:159373275	T/A	cg25076881	chr1:159409836	OR10J1	0.4	4.77	0.3	3.31e-6	Select biomarker traits;
SARC	cis	rs2120243	0.539	rs2305622	chr3:157122504	C/T	cg24825693	chr3:157122686	VEPH1	-0.45	-6.35	-0.38	1.13e-9	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-8.89	-0.5	1.75e-16	Alzheimer's disease;
SARC	cis	rs7000551	0.642	rs2122880	chr8:22375042	C/A	cg12081754	chr8:22256438	SLC39A14	0.52	7.17	0.43	9.66e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs11718455	1.000	rs9858826	chr3:44031412	C/T	cg21419209	chr3:44054225	NA	0.41	5.08	0.32	7.92e-7	Coronary artery disease;
SARC	cis	rs765787	0.530	rs2413785	chr15:45530381	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.67e-7	Uric acid levels;
SARC	cis	rs67311347	1.000	rs73080165	chr3:40533062	G/T	cg01475735	chr3:40494733	NA	-0.42	-4.88	-0.3	1.99e-6	Renal cell carcinoma;
SARC	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg12463550	chr7:65579703	CRCP	-0.5	-5.48	-0.34	1.09e-7	Aortic root size;
SARC	cis	rs9914988	0.943	rs7215310	chr17:27088626	G/T	cg20469991	chr17:27169893	C17orf63	-0.5	-5.42	-0.33	1.49e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs6752107	0.935	rs10199278	chr2:234160669	C/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.47	6.19	0.38	2.7e-9	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs3815700	1.000	rs8104729	chr19:33093979	C/T	cg24916020	chr19:33096688	ANKRD27	0.56	5.41	0.33	1.59e-7	Eosinophilic esophagitis;
SARC	cis	rs1707322	1.000	rs785504	chr1:46595696	C/T	cg03146154	chr1:46216737	IPP	-0.46	-5.4	-0.33	1.67e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7681440	0.904	rs2301134	chr4:90758945	A/G	cg02192967	chr4:90758406	SNCA	0.36	5.16	0.32	5.23e-7	Dementia with Lewy bodies;
SARC	cis	rs4481887	0.927	rs4534422	chr1:248479482	A/G	cg13385794	chr1:248469461	NA	0.33	5.07	0.32	7.96e-7	Common traits (Other);
SARC	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.73	8.91	0.5	1.51e-16	Height;
SARC	cis	rs6570726	0.791	rs1509213	chr6:145783360	G/A	cg05347473	chr6:146136440	FBXO30	-0.51	-7.03	-0.42	2.28e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg07636037	chr3:49044803	WDR6	0.64	6.51	0.39	4.58e-10	Menarche (age at onset);
SARC	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.96	-10.84	-0.58	1.96e-22	Alzheimer's disease;
SARC	cis	rs9397240	0.789	rs9383746	chr6:155563435	C/T	cg07943832	chr6:155568918	TIAM2	-0.59	-5.53	-0.34	8.6e-8	Life satisfaction;
SARC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg14159672	chr1:205819179	PM20D1	0.87	14.61	0.69	9.67e-35	Menarche (age at onset);
SARC	cis	rs13401104	0.796	rs10929167	chr2:237115248	G/A	cg19324714	chr2:237145437	ASB18	0.55	5.61	0.35	5.63e-8	Educational attainment;
SARC	cis	rs2153535	0.601	rs9505472	chr6:8538765	T/C	cg21535247	chr6:8435926	SLC35B3	0.55	6.82	0.41	7.81e-11	Motion sickness;
SARC	cis	rs372883	0.648	rs11088117	chr21:30737816	G/C	cg08807101	chr21:30365312	RNF160	0.54	6.77	0.41	1.02e-10	Pancreatic cancer;
SARC	cis	rs9393692	0.645	rs6939048	chr6:26327953	G/A	cg13736514	chr6:26305472	NA	-0.72	-9.26	-0.52	1.38e-17	Educational attainment;
SARC	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg10253484	chr15:75165896	SCAMP2	0.4	4.93	0.31	1.59e-6	Breast cancer;
SARC	cis	rs8017423	0.967	rs55667096	chr14:90714798	C/T	cg20276874	chr14:90721474	PSMC1	-0.36	-5.0	-0.31	1.13e-6	Mortality in heart failure;
SARC	cis	rs7615952	0.866	rs1976459	chr3:125647486	A/T	cg05084668	chr3:125655381	ALG1L	-0.68	-6.76	-0.41	1.08e-10	Blood pressure (smoking interaction);
SARC	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg14784868	chr12:69753453	YEATS4	0.51	6.77	0.41	1.04e-10	Blood protein levels;
SARC	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg13395646	chr4:1353034	KIAA1530	-0.47	-5.69	-0.35	3.89e-8	Obesity-related traits;
SARC	cis	rs12142240	0.698	rs41294478	chr1:46818442	G/A	cg10495392	chr1:46806563	NSUN4	0.65	6.83	0.41	7.25e-11	Menopause (age at onset);
SARC	cis	rs9436747	0.641	rs4655528	chr1:66049489	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.48	4.97	0.31	1.29e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs644799	0.542	rs10831415	chr11:95466159	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.7	8.98	0.51	9.53e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg00933542	chr6:150070202	PCMT1	0.31	5.29	0.33	2.83e-7	Lung cancer;
SARC	cis	rs782590	0.620	rs4322879	chr2:55797033	G/T	cg18811423	chr2:55921094	PNPT1	-0.55	-6.67	-0.4	1.81e-10	Metabolic syndrome;
SARC	cis	rs4925386	1.000	rs4925386	chr20:60921044	C/T	cg22307297	chr20:60903441	LAMA5	0.31	4.78	0.3	3.14e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs10504229	0.679	rs2317991	chr8:58035080	C/T	cg08280861	chr8:58055591	NA	-0.55	-5.32	-0.33	2.43e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs17376456	0.877	rs10059230	chr5:93450347	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.79	0.35	2.3e-8	Diabetic retinopathy;
SARC	cis	rs11122272	0.735	rs2246645	chr1:231497393	T/G	cg06096015	chr1:231504339	EGLN1	0.37	5.56	0.34	7.48e-8	Hemoglobin concentration;
SARC	cis	rs7552404	0.924	rs1313071	chr1:76195542	C/G	cg03433033	chr1:76189801	ACADM	0.48	7.03	0.42	2.3e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs554111	0.963	rs601329	chr1:21044161	A/G	cg08890418	chr1:21044141	KIF17	0.52	7.07	0.42	1.82e-11	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs6693567	0.565	rs11205355	chr1:150252329	G/A	cg09579323	chr1:150459698	TARS2	-0.41	-4.91	-0.31	1.74e-6	Migraine;
SARC	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs35213789	0.768	rs12333974	chr7:69367000	C/T	cg10619644	chr7:69149951	AUTS2	0.39	4.79	0.3	2.96e-6	Childhood ear infection;
SARC	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg11764359	chr7:65958608	NA	0.55	6.4	0.39	8.33e-10	Aortic root size;
SARC	cis	rs6732160	0.809	rs6728959	chr2:73383327	C/T	cg01422370	chr2:73384389	NA	0.33	5.37	0.33	1.92e-7	Intelligence (multi-trait analysis);
SARC	cis	rs17376456	1.000	rs66978370	chr5:93553633	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.62	5.4	0.33	1.68e-7	Diabetic retinopathy;
SARC	cis	rs1153858	0.943	rs4774580	chr15:45652086	G/A	cg03999130	chr15:45571217	NA	0.38	4.95	0.31	1.43e-6	Homoarginine levels;
SARC	cis	rs9381040	0.610	rs6941090	chr6:41043465	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.43	-4.9	-0.31	1.78e-6	Alzheimer's disease (late onset);
SARC	cis	rs986417	1.000	rs1254324	chr14:60908551	C/T	cg27398547	chr14:60952738	C14orf39	-1.03	-9.75	-0.54	4.8e-19	Gut microbiota (bacterial taxa);
SARC	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg11878867	chr6:150167359	LRP11	-0.34	-4.77	-0.3	3.29e-6	Lung cancer;
SARC	cis	rs2479724	1.000	rs2479724	chr6:41890982	T/C	cg17623882	chr6:41773611	USP49	-0.5	-6.56	-0.39	3.39e-10	Menarche (age at onset);
SARC	cis	rs7666738	0.606	rs4699611	chr4:99097492	T/G	cg05340658	chr4:99064831	C4orf37	0.48	6.08	0.37	4.78e-9	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2948294	0.545	rs11776397	chr8:8115161	C/T	cg15556689	chr8:8085844	FLJ10661	0.43	4.78	0.3	3.17e-6	Red cell distribution width;
SARC	cis	rs796364	0.577	rs7574287	chr2:200680999	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.55	4.74	0.3	3.76e-6	Schizophrenia;
SARC	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg23758822	chr17:41437982	NA	0.9	11.33	0.6	5.44e-24	Menopause (age at onset);
SARC	cis	rs7647973	0.667	rs6446286	chr3:49681704	A/G	cg07636037	chr3:49044803	WDR6	0.64	6.51	0.39	4.58e-10	Menarche (age at onset);
SARC	cis	rs76419734	0.850	rs111813903	chr4:106779481	A/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	5.31	0.33	2.52e-7	Post bronchodilator FEV1;
SARC	cis	rs2758596	1.000	rs2842866	chr1:156159721	G/A	cg24450063	chr1:156163899	SLC25A44	0.86	5.6	0.34	5.91e-8	Paclitaxel disposition in epithelial ovarian cancer;
SARC	cis	rs2153535	0.580	rs4960411	chr6:8438231	C/G	cg21535247	chr6:8435926	SLC35B3	0.56	7.01	0.42	2.6e-11	Motion sickness;
SARC	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg02297831	chr4:17616191	MED28	0.51	6.63	0.4	2.36e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg20607798	chr8:58055168	NA	0.57	5.52	0.34	9.02e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2832270	0.562	rs8133819	chr21:30458754	T/C	cg08807101	chr21:30365312	RNF160	-0.57	-4.76	-0.3	3.44e-6	Response to mTOR inhibitor (everolimus);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg06856563	chr7:75623987	TMEM120A	0.54	6.92	0.41	4.27e-11	Breast cancer;
SARC	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg00149659	chr3:10157352	C3orf10	0.64	6.01	0.37	7.21e-9	Alzheimer's disease;
SARC	cis	rs370915	0.564	rs10027461	chr4:187837608	T/C	cg10295955	chr4:187884368	NA	-0.45	-5.36	-0.33	1.98e-7	Gout;
SARC	cis	rs10979	1.000	rs9496681	chr6:143896964	G/A	cg25407410	chr6:143891975	LOC285740	-0.64	-8.78	-0.5	3.67e-16	Hypospadias;
SARC	cis	rs2228479	0.702	rs78331410	chr16:89917775	C/T	cg12064134	chr16:90016061	DEF8	-0.56	-4.83	-0.3	2.47e-6	Skin colour saturation;
SARC	cis	rs2529049	0.527	rs2158063	chr7:24777871	A/G	cg17569154	chr7:24781545	DFNA5	0.51	7.26	0.43	5.78e-12	Urate levels in obese individuals;
SARC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	10.29	0.56	1.02e-20	Platelet count;
SARC	cis	rs7582180	0.676	rs1437969	chr2:100983482	A/C	cg14675211	chr2:100938903	LONRF2	0.51	7.6	0.45	7.25e-13	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg08219700	chr8:58056026	NA	0.59	6.27	0.38	1.76e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6484504	0.576	rs58702363	chr11:31246397	C/A	cg02090638	chr11:31391270	DNAJC24;DCDC1	-0.4	-5.06	-0.31	8.37e-7	Red blood cell count;
SARC	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg11987759	chr7:65425863	GUSB	-0.49	-6.21	-0.38	2.46e-9	Aortic root size;
SARC	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.68	-8.75	-0.5	4.34e-16	Chronic sinus infection;
SARC	cis	rs6963495	0.872	rs1569134	chr7:105158228	T/C	cg13798780	chr7:105162888	PUS7	0.6	5.45	0.34	1.31e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs7607369	0.536	rs12623007	chr2:219665335	T/C	cg02176678	chr2:219576539	TTLL4	-0.4	-6.17	-0.37	3.07e-9	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	trans	rs1814175	0.645	rs847635	chr11:49923323	G/A	cg03929089	chr4:120376271	NA	-0.81	-11.69	-0.61	3.89e-25	Height;
SARC	cis	rs136211	0.929	rs1883273	chr22:36769685	A/G	cg16924664	chr22:36878180	TXN2	-0.42	-5.22	-0.32	4e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs3762637	0.943	rs3817040	chr3:122254769	G/A	cg24169773	chr3:122142474	KPNA1	-0.56	-5.68	-0.35	4.05e-8	LDL cholesterol levels;
SARC	cis	rs7953249	0.935	rs7135337	chr12:121404155	A/C	cg02403541	chr12:121454288	C12orf43	-0.56	-7.11	-0.42	1.42e-11	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs17384381	0.953	rs11161599	chr1:85795965	A/G	cg16011679	chr1:85725395	C1orf52	-0.59	-5.62	-0.35	5.56e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11122272	0.735	rs2437150	chr1:231488524	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.65	9.76	0.54	4.47e-19	Hemoglobin concentration;
SARC	cis	rs7208859	0.623	rs7214570	chr17:29147164	A/G	cg13385521	chr17:29058706	SUZ12P	0.87	7.74	0.45	3.07e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs11098499	0.954	rs56270433	chr4:120406030	C/T	cg24375607	chr4:120327624	NA	0.42	4.97	0.31	1.28e-6	Corneal astigmatism;
SARC	cis	rs7317038	0.745	rs75590443	chr13:114015421	A/T	cg24344662	chr13:114018021	GRTP1	-0.47	-5.82	-0.36	1.92e-8	Mean platelet volume;
SARC	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg13393036	chr8:95962371	TP53INP1	-0.36	-6.21	-0.38	2.45e-9	Type 2 diabetes;
SARC	cis	rs735539	0.521	rs7997062	chr13:21368822	A/G	cg16922012	chr13:21400325	XPO4	-0.42	-5.72	-0.35	3.22e-8	Dental caries;
SARC	cis	rs8180040	0.966	rs56351005	chr3:47430186	G/T	cg27129171	chr3:47204927	SETD2	-0.68	-9.5	-0.53	2.68e-18	Colorectal cancer;
SARC	trans	rs3780486	0.505	rs1411609	chr9:33137303	C/T	cg20290983	chr6:43655470	MRPS18A	0.92	13.29	0.66	2.34e-30	IgG glycosylation;
SARC	cis	rs7927771	0.864	rs2868459	chr11:47454972	C/G	cg20307385	chr11:47447363	PSMC3	-0.6	-7.59	-0.45	7.64e-13	Subjective well-being;
SARC	cis	rs2180341	1.000	rs2038378	chr6:127590400	C/T	cg17762328	chr6:126965162	NA	-0.43	-4.86	-0.3	2.18e-6	Breast cancer;
SARC	cis	rs7223966	1.000	rs11658740	chr17:61751069	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.56	-5.99	-0.37	7.8e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2180341	0.960	rs9401953	chr6:127687574	G/A	cg24812749	chr6:127587940	RNF146	1.02	13.46	0.66	6.06e-31	Breast cancer;
SARC	cis	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg14343924	chr8:8086146	FLJ10661	0.41	4.99	0.31	1.19e-6	Joint mobility (Beighton score);
SARC	cis	rs9640161	0.789	rs2098053	chr7:150043205	G/A	cg21361702	chr7:150065534	REPIN1	0.49	4.95	0.31	1.45e-6	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs11734570	0.509	rs6823102	chr4:38568303	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.37	4.82	0.3	2.64e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs4423214	0.959	rs11606033	chr11:71154204	A/G	cg24826892	chr11:71159390	DHCR7	0.49	6.13	0.37	3.76e-9	Vitamin D levels;
SARC	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg13939156	chr17:80058883	NA	0.37	5.59	0.34	6.2e-8	Life satisfaction;
SARC	cis	rs6831352	0.840	rs29001223	chr4:100047433	C/T	cg12011299	chr4:100065546	ADH4	-0.34	-5.66	-0.35	4.44e-8	Alcohol dependence;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg09659697	chr5:54529994	CCNO	-0.46	-6.28	-0.38	1.67e-9	Chemerin levels;
SARC	cis	rs6693567	0.545	rs1260385	chr1:150316385	G/A	cg09579323	chr1:150459698	TARS2	0.41	5.11	0.32	6.8e-7	Migraine;
SARC	cis	rs10088262	0.629	rs6990565	chr8:124785645	C/A	cg15047889	chr8:124780837	FAM91A1	-0.65	-7.05	-0.42	2.02e-11	Pancreatic cancer;
SARC	cis	rs9457247	0.663	rs6456143	chr6:167415440	C/A	cg07741184	chr6:167504864	NA	0.32	6.31	0.38	1.41e-9	Crohn's disease;
SARC	cis	rs12893668	0.703	rs8017993	chr14:104047734	A/G	cg26031613	chr14:104095156	KLC1	-0.6	-6.73	-0.4	1.3e-10	Reticulocyte count;
SARC	cis	rs10504229	0.679	rs73681882	chr8:58030038	A/G	cg08280861	chr8:58055591	NA	0.57	5.19	0.32	4.66e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg05793240	chr7:2802953	GNA12	-0.35	-4.71	-0.3	4.19e-6	Height;
SARC	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg08280861	chr8:58055591	NA	0.7	5.74	0.35	2.91e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7223966	0.621	rs28571160	chr17:61638723	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.47	5.23	0.32	3.84e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg13206674	chr6:150067644	NUP43	0.42	5.53	0.34	8.42e-8	Lung cancer;
SARC	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg21017887	chr14:105400489	NA	0.54	7.41	0.44	2.26e-12	Rheumatoid arthritis;
SARC	cis	rs2731664	0.756	rs2545796	chr5:176864269	T/C	cg23176889	chr5:176863531	GRK6	-0.56	-8.25	-0.48	1.16e-14	Intelligence (multi-trait analysis);
SARC	cis	rs782590	0.643	rs13032503	chr2:55739093	C/T	cg18811423	chr2:55921094	PNPT1	-0.57	-7.03	-0.42	2.24e-11	Metabolic syndrome;
SARC	cis	rs7000551	0.556	rs12674913	chr8:22263617	G/C	cg12081754	chr8:22256438	SLC39A14	0.85	12.11	0.62	1.64e-26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs666930	0.519	rs477992	chr1:120257576	A/G	cg19096424	chr1:120255104	PHGDH	0.77	9.81	0.54	3.18e-19	Breast cancer;
SARC	cis	rs9549260	0.755	rs17061450	chr13:41183716	G/A	cg21288729	chr13:41239152	FOXO1	0.62	8.43	0.48	3.74e-15	Red blood cell count;
SARC	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg05313129	chr8:58192883	C8orf71	-0.55	-5.14	-0.32	5.74e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs9818941	0.744	rs13098886	chr3:157613783	C/T	cg21028463	chr17:74733682	MIR636;SFRS2;MFSD11	0.55	6.34	0.38	1.16e-9	Height;
SARC	cis	rs7020830	0.898	rs308495	chr9:37277603	G/T	cg14294708	chr9:37120828	ZCCHC7	1.08	19.31	0.78	2.86e-50	Schizophrenia;
SARC	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg13264159	chr8:625131	ERICH1	-0.68	-4.74	-0.3	3.7e-6	IgG glycosylation;
SARC	cis	rs1832871	0.643	rs9456282	chr6:158724743	A/G	cg07165851	chr6:158734300	TULP4	0.53	6.37	0.38	1.02e-9	Height;
SARC	cis	rs780096	0.526	rs11682621	chr2:27749669	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.34	-5.45	-0.34	1.3e-7	Total body bone mineral density;
SARC	cis	rs472402	0.580	rs10060745	chr5:6658003	T/C	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.45	-5.36	-0.33	1.99e-7	Response to amphetamines;
SARC	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg25072359	chr17:41440525	NA	0.52	6.11	0.37	4.12e-9	Menopause (age at onset);
SARC	cis	rs765787	0.530	rs4775834	chr15:45537511	C/T	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.81e-6	Uric acid levels;
SARC	cis	rs9291683	0.546	rs4529049	chr4:10045389	C/T	cg00071950	chr4:10020882	SLC2A9	0.33	4.98	0.31	1.26e-6	Bone mineral density;
SARC	cis	rs10754283	0.935	rs10801756	chr1:90101832	C/T	cg21401794	chr1:90099060	LRRC8C	0.6	8.42	0.48	3.81e-15	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs10416265	0.503	rs1981818	chr19:33615122	C/T	cg17764715	chr19:33622953	WDR88	-0.61	-8.14	-0.47	2.37e-14	Bone properties (heel);
SARC	cis	rs7666738	0.800	rs10008654	chr4:98820498	C/A	cg05340658	chr4:99064831	C4orf37	0.66	8.76	0.5	4.2e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9916302	0.629	rs9972882	chr17:37807698	A/C	cg00129232	chr17:37814104	STARD3	-0.74	-9.99	-0.55	8.51e-20	Glomerular filtration rate (creatinine);
SARC	cis	rs2295359	0.892	rs12401432	chr1:67656931	C/G	cg11235152	chr1:67600687	NA	0.51	7.2	0.43	8.09e-12	Psoriasis;
SARC	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg18876405	chr7:65276391	NA	-0.44	-5.0	-0.31	1.13e-6	Aortic root size;
SARC	cis	rs11608355	0.515	rs4766605	chr12:109895636	C/A	cg05360138	chr12:110035743	NA	0.92	9.61	0.53	1.27e-18	Neuroticism;
SARC	cis	rs965604	1.000	rs12903295	chr15:78778972	A/G	cg24631222	chr15:78858424	CHRNA5	-0.48	-6.09	-0.37	4.63e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs1707322	1.000	rs1707317	chr1:46510642	C/T	cg03146154	chr1:46216737	IPP	-0.48	-5.78	-0.35	2.34e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6696846	0.765	rs61822565	chr1:205077332	T/C	cg00857998	chr1:205179979	DSTYK	0.49	6.28	0.38	1.62e-9	Red blood cell count;
SARC	cis	rs7589342	0.660	rs7571132	chr2:106398913	C/T	cg16077055	chr2:106428750	NCK2	0.33	6.31	0.38	1.37e-9	Addiction;
SARC	cis	rs62432291	0.614	rs452112	chr6:159658028	A/G	cg14500486	chr6:159655392	FNDC1	-0.63	-6.19	-0.38	2.73e-9	Joint mobility (Beighton score);
SARC	cis	rs709400	0.628	rs12889639	chr14:103860206	G/A	cg26031613	chr14:104095156	KLC1	-0.75	-10.89	-0.58	1.39e-22	Body mass index;
SARC	cis	rs2204008	0.542	rs34770471	chr12:38009613	C/T	cg13010199	chr12:38710504	ALG10B	0.78	10.73	0.57	4.45e-22	Bladder cancer;
SARC	cis	rs9815354	0.951	rs7626217	chr3:41842415	A/G	cg03022575	chr3:42003672	ULK4	0.56	5.41	0.33	1.59e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg12463550	chr7:65579703	CRCP	0.7	5.31	0.33	2.6e-7	Diabetic kidney disease;
SARC	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg22857025	chr5:266934	NA	-1.06	-11.8	-0.61	1.74e-25	Breast cancer;
SARC	cis	rs11122272	0.735	rs2024878	chr1:231528415	A/C	cg06096015	chr1:231504339	EGLN1	-0.35	-5.08	-0.32	7.84e-7	Hemoglobin concentration;
SARC	cis	rs921968	0.565	rs7599945	chr2:219641528	G/T	cg02176678	chr2:219576539	TTLL4	-0.33	-5.03	-0.31	9.92e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs9381040	0.655	rs879491	chr6:41026953	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.42	-4.96	-0.31	1.36e-6	Alzheimer's disease (late onset);
SARC	cis	rs4713118	0.516	rs6931858	chr6:28078411	A/T	cg17221315	chr6:27791827	HIST1H4J	0.47	4.87	0.3	2.07e-6	Parkinson's disease;
SARC	cis	rs7712401	0.715	rs424247	chr5:122347993	G/A	cg19412675	chr5:122181750	SNX24	-0.41	-5.26	-0.33	3.18e-7	Mean platelet volume;
SARC	cis	rs59918340	0.738	rs7007986	chr8:142217115	G/A	cg16341495	chr8:142228727	SLC45A4	-0.35	-4.83	-0.3	2.43e-6	Immature fraction of reticulocytes;
SARC	cis	rs3845702	1.000	rs3768839	chr2:180835992	G/A	cg01881094	chr2:180872142	CWC22	-0.74	-6.83	-0.41	7.39e-11	Schizophrenia;
SARC	cis	rs7674212	0.539	rs6821617	chr4:104128410	G/A	cg16532752	chr4:104119610	CENPE	-0.48	-6.0	-0.37	7.55e-9	Type 2 diabetes;
SARC	cis	rs8072100	0.667	rs1912485	chr17:45515678	T/G	cg08085267	chr17:45401833	C17orf57	-0.43	-5.03	-0.31	9.66e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs6912958	0.512	rs910563	chr6:88058885	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.35	6.31	0.38	1.42e-9	Monocyte percentage of white cells;
SARC	cis	rs9372253	0.934	rs9320327	chr6:110715194	T/A	cg01119278	chr6:110721349	DDO	-0.38	-4.84	-0.3	2.33e-6	Platelet distribution width;
SARC	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg03264133	chr6:25882463	NA	0.5	6.59	0.4	2.98e-10	Blood metabolite levels;
SARC	cis	rs3749237	0.595	rs17595772	chr3:49409704	G/A	cg02487422	chr3:49467188	NICN1	0.5	6.51	0.39	4.57e-10	Resting heart rate;
SARC	cis	rs6089584	0.586	rs2296087	chr20:60584328	T/A	cg13770153	chr20:60521292	NA	-0.4	-5.85	-0.36	1.65e-8	Body mass index;
SARC	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg24675658	chr1:53192096	ZYG11B	0.57	8.08	0.47	3.54e-14	Monocyte count;
SARC	cis	rs6930083	0.605	rs3829964	chr6:36644498	T/C	cg08179530	chr6:36648295	CDKN1A	0.89	13.22	0.65	3.76e-30	Coronary artery disease;
SARC	trans	rs2727020	0.576	rs1917321	chr11:49377760	A/C	cg03929089	chr4:120376271	NA	-0.56	-7.57	-0.44	8.58e-13	Coronary artery disease;
SARC	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg26039829	chr8:22132926	PIWIL2	0.47	6.8	0.41	8.58e-11	Hypertriglyceridemia;
SARC	cis	rs28795989	0.830	rs1320074	chr4:7904111	T/G	cg18538662	chr4:7941764	AFAP1	-0.42	-5.27	-0.33	3.12e-7	Intraocular pressure;
SARC	cis	rs2929278	0.562	rs8033846	chr15:44035363	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.44	-4.83	-0.3	2.52e-6	Schizophrenia;
SARC	cis	rs569214	0.724	rs536332	chr8:27475767	G/A	cg04264299	chr8:27491209	SCARA3	-0.45	-5.15	-0.32	5.57e-7	Alzheimer's disease;
SARC	cis	rs1030877	0.557	rs2576752	chr2:105978761	A/G	cg02079111	chr2:105885981	TGFBRAP1	0.4	5.67	0.35	4.14e-8	Obesity-related traits;
SARC	cis	rs9487023	1	rs9487023	chr6:109590004	A/G	cg01475377	chr6:109611718	NA	-0.41	-5.77	-0.35	2.48e-8	Red blood cell count;Mean corpuscular hemoglobin concentration;Neutrophil percentage of white cells;Lymphocyte percentage of white cells;Mean corpuscular hemoglobin;High light scatter reticulocyte percentage of red cells;Mean corpuscular volume;
SARC	cis	rs6060717	0.654	rs8122716	chr20:34607001	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-4.73	-0.3	3.86e-6	Hip circumference adjusted for BMI;
SARC	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-5.96	-0.36	9.37e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7647973	1.000	rs11719762	chr3:49409002	G/C	cg07636037	chr3:49044803	WDR6	0.76	8.55	0.49	1.69e-15	Menarche (age at onset);
SARC	cis	rs3768617	0.510	rs10797839	chr1:183077797	A/G	cg13390022	chr1:182993471	LAMC1	0.33	4.9	0.31	1.8e-6	Fuchs's corneal dystrophy;
SARC	cis	rs2531992	0.686	rs933392	chr16:4032716	T/G	cg05927578	chr16:4029543	ADCY9	0.48	5.75	0.35	2.84e-8	Waist circumference;
SARC	cis	rs8068544	0.818	rs75771390	chr17:40194054	A/G	cg26502583	chr17:39992600	KLHL10;NT5C3L	-0.94	-6.75	-0.4	1.15e-10	Reticulocyte fraction of red cells;Reticulocyte count;
SARC	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg18305652	chr10:134549665	INPP5A	0.34	4.93	0.31	1.57e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs34330	0.562	rs11055025	chr12:12866619	A/T	cg04607235	chr12:12878440	APOLD1	-0.53	-5.2	-0.32	4.43e-7	Systemic lupus erythematosus;
SARC	cis	rs9790314	0.521	rs13084731	chr3:161086020	G/A	cg03342759	chr3:160939853	NMD3	-0.57	-7.11	-0.42	1.45e-11	Morning vs. evening chronotype;
SARC	cis	rs60752752	0.777	rs3014885	chr1:153352127	C/T	cg26882115	chr1:153603048	S100A1;S100A13	-0.63	-4.83	-0.3	2.49e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs2204008	0.837	rs11169157	chr12:37980047	T/C	cg13010199	chr12:38710504	ALG10B	0.73	9.85	0.54	2.32e-19	Bladder cancer;
SARC	cis	rs7829975	0.684	rs474892	chr8:8596731	G/T	cg15556689	chr8:8085844	FLJ10661	-0.48	-5.81	-0.36	2.07e-8	Mood instability;
SARC	cis	rs7666738	0.830	rs13145011	chr4:98993410	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9815354	0.812	rs113528686	chr3:41951547	T/C	cg03022575	chr3:42003672	ULK4	0.7	5.7	0.35	3.66e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs79149102	0.579	rs78664321	chr15:75339575	G/A	cg00629941	chr15:75287862	SCAMP5	-0.84	-5.96	-0.36	9.44e-9	Lung cancer;
SARC	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg13206674	chr6:150067644	NUP43	0.41	5.4	0.33	1.67e-7	Lung cancer;
SARC	cis	rs9916302	0.706	rs8075737	chr17:37727316	C/T	cg07936489	chr17:37558343	FBXL20	0.77	9.62	0.53	1.15e-18	Glomerular filtration rate (creatinine);
SARC	cis	rs1448094	0.512	rs6539932	chr12:86247497	T/C	cg02569458	chr12:86230093	RASSF9	0.38	5.39	0.33	1.71e-7	Major depressive disorder;
SARC	cis	rs965469	1.000	rs6051747	chr20:3307945	T/C	cg25506879	chr20:3388711	C20orf194	-0.47	-4.8	-0.3	2.89e-6	IFN-related cytopenia;
SARC	cis	rs10911251	0.546	rs2027084	chr1:183110801	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	9.89	0.54	1.74e-19	Colorectal cancer;
SARC	cis	rs6908034	0.607	rs79162793	chr6:19813065	A/G	cg02682789	chr6:19804855	NA	0.69	5.56	0.34	7.3900000000000007e-08	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs6570726	0.846	rs397311	chr6:145806701	C/T	cg05347473	chr6:146136440	FBXO30	-0.49	-6.81	-0.41	8.04e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2898681	0.561	rs58577680	chr4:53734294	C/T	cg00338735	chr4:53728038	RASL11B	0.49	5.46	0.34	1.24e-7	Optic nerve measurement (cup area);
SARC	trans	rs61931739	0.517	rs7960878	chr12:34055645	C/A	cg13010199	chr12:38710504	ALG10B	0.76	10.39	0.56	4.9e-21	Morning vs. evening chronotype;
SARC	cis	rs2916247	0.954	rs7845971	chr8:93022095	T/A	cg10183463	chr8:93005414	RUNX1T1	-0.58	-6.04	-0.37	5.91e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg03433033	chr1:76189801	ACADM	0.58	7.97	0.46	6.99e-14	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.69	-8.91	-0.5	1.46e-16	Chronic sinus infection;
SARC	cis	rs911555	0.570	rs11625397	chr14:104027557	A/G	cg12935359	chr14:103987150	CKB	0.34	5.15	0.32	5.65e-7	Intelligence (multi-trait analysis);
SARC	cis	rs13256369	1.000	rs12547721	chr8:8570671	C/T	cg18904891	chr8:8559673	CLDN23	0.5	5.85	0.36	1.62e-8	Obesity-related traits;
SARC	cis	rs1559088	0.847	rs10416265	chr19:33605300	A/G	cg17764715	chr19:33622953	WDR88	0.46	6.16	0.37	3.15e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.49	-5.4	-0.33	1.65e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs9902453	0.808	rs8069669	chr17:28239502	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	7.0	0.42	2.63e-11	Coffee consumption (cups per day);
SARC	cis	rs4595586	0.545	rs1156705	chr12:39372672	C/T	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	cis	rs240764	0.580	rs4839789	chr6:101233235	T/A	cg09795085	chr6:101329169	ASCC3	-0.44	-5.7	-0.35	3.54e-8	Neuroticism;
SARC	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg05313129	chr8:58192883	C8orf71	-0.62	-6.34	-0.38	1.18e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6952808	0.931	rs12537430	chr7:1868761	A/G	cg13880726	chr7:1868755	MAD1L1	-0.51	-6.01	-0.37	7.08e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs2204008	0.807	rs4123933	chr12:37973539	G/A	cg13010199	chr12:38710504	ALG10B	0.79	10.99	0.58	6.51e-23	Bladder cancer;
SARC	cis	rs6009824	0.891	rs6009822	chr22:50085731	C/T	cg27029450	chr22:50098074	NA	0.46	4.82	0.3	2.62e-6	Natriuretic peptide levels;
SARC	cis	rs9815354	1.000	rs9839399	chr3:41928044	G/A	cg03022575	chr3:42003672	ULK4	-0.56	-5.38	-0.33	1.81e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs7106204	0.686	rs12790317	chr11:24254405	T/C	ch.11.24196551F	chr11:24239977	NA	0.61	5.38	0.33	1.79e-7	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg11987759	chr7:65425863	GUSB	-0.59	-8.15	-0.47	2.26e-14	Aortic root size;
SARC	cis	rs9787249	0.957	rs7547787	chr1:40220806	C/T	cg02773041	chr1:40204384	PPIE	0.51	6.31	0.38	1.42e-9	Blood protein levels;
SARC	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg11987759	chr7:65425863	GUSB	-0.6	-7.96	-0.46	7.49e-14	Aortic root size;
SARC	cis	rs9309711	0.666	rs6767	chr2:3483205	C/T	cg08493051	chr2:3487164	NA	-0.4	-5.06	-0.31	8.4e-7	Neurofibrillary tangles;
SARC	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg22484793	chr3:52261325	TLR9	0.29	4.77	0.3	3.31e-6	Bipolar disorder;
SARC	cis	rs7829975	0.582	rs6982832	chr8:8792217	A/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.78	-0.41	9.74e-11	Mood instability;
SARC	cis	rs2836633	0.929	rs2836610	chr21:40044502	C/T	cg12884169	chr21:40033163	ERG	0.46	8.45	0.48	3.09e-15	Coronary artery disease;
SARC	cis	rs7044106	0.500	rs56725168	chr9:123492576	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	6.81	0.41	8.04e-11	Hip circumference adjusted for BMI;
SARC	cis	rs36051895	0.589	rs10491651	chr9:5200060	A/G	cg02405213	chr9:5042618	JAK2	-0.44	-5.04	-0.31	9.37e-7	Pediatric autoimmune diseases;
SARC	cis	rs8005677	1.000	rs8005677	chr14:23376678	T/C	cg01529538	chr14:23388837	RBM23	0.46	5.77	0.35	2.53e-8	Cognitive ability (multi-trait analysis);
SARC	cis	rs1982346	1.000	rs2553470	chr4:106713673	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	-0.68	-4.88	-0.3	1.99e-6	Lung function (FEV1);
SARC	cis	rs10513788	0.665	rs72622588	chr3:182003490	G/T	cg05977900	chr3:182512126	ATP11B	0.47	4.74	0.3	3.64e-6	Cognitive function;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg11031669	chr8:11188490	AMAC1L2	-0.38	-6.34	-0.38	1.19e-9	Chemerin levels;
SARC	cis	rs8044995	0.563	rs73613962	chr16:68361974	T/G	cg05110241	chr16:68378359	PRMT7	-0.66	-6.37	-0.39	9.96e-10	Schizophrenia;
SARC	cis	rs1003719	0.715	rs35199609	chr21:38510262	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-9.13	-0.51	3.35e-17	Eye color traits;
SARC	cis	rs752010	0.714	rs7513753	chr1:42079232	A/G	cg06885757	chr1:42089581	HIVEP3	0.41	6.14	0.37	3.52e-9	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs6879260	1.000	rs1035411	chr5:179729519	A/G	cg23221052	chr5:179740743	GFPT2	-0.54	-6.49	-0.39	5.06e-10	Height;
SARC	cis	rs9486719	0.857	rs4839833	chr6:96882069	T/C	cg18709589	chr6:96969512	KIAA0776	0.49	5.35	0.33	2.11e-7	Migraine;Coronary artery disease;
SARC	cis	rs11025559	0.685	rs10833341	chr11:20535247	C/G	cg04101203	chr11:20408940	PRMT3	-0.48	-5.33	-0.33	2.34e-7	Pursuit maintenance gain;
SARC	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg22920501	chr2:26401640	FAM59B	-0.55	-7.14	-0.42	1.18e-11	Gut microbiome composition (summer);
SARC	cis	rs944802	0.684	rs2065500	chr9:22145694	A/G	cg00491127	chr9:22154101	NA	-0.53	-5.79	-0.35	2.23e-8	White blood cell count;
SARC	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg01316550	chr5:56110833	MAP3K1	0.53	4.9	0.31	1.8e-6	Initial pursuit acceleration;
SARC	cis	rs7103648	0.966	rs1377416	chr11:47416746	C/T	cg20307385	chr11:47447363	PSMC3	0.85	13.68	0.67	1.15e-31	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg13206674	chr6:150067644	NUP43	0.48	6.36	0.38	1.07e-9	Lung cancer;
SARC	cis	rs950776	0.684	rs692780	chr15:78876505	C/G	cg06917634	chr15:78832804	PSMA4	-0.79	-10.62	-0.57	9.73e-22	Sudden cardiac arrest;
SARC	cis	rs9309711	0.506	rs9284794	chr2:3492052	G/A	cg15541040	chr2:3486749	NA	-0.44	-5.72	-0.35	3.33e-8	Neurofibrillary tangles;
SARC	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg06558623	chr16:89946397	TCF25	0.9	6.1	0.37	4.45e-9	Skin colour saturation;
SARC	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg16049864	chr8:95962084	TP53INP1	-0.47	-7.69	-0.45	4.07e-13	Type 2 diabetes;
SARC	cis	rs8031584	0.958	rs34909055	chr15:31284170	C/T	cg19680485	chr15:31195859	MTMR15	-0.52	-6.21	-0.38	2.46e-9	Huntington's disease progression;
SARC	cis	rs6732160	0.838	rs13411380	chr2:73382846	G/C	cg01422370	chr2:73384389	NA	0.33	5.37	0.33	1.92e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1707322	0.752	rs12024590	chr1:46127496	A/C	cg06784218	chr1:46089804	CCDC17	0.36	6.25	0.38	1.97e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6840360	0.571	rs7674244	chr4:152488302	T/C	cg22705602	chr4:152727874	NA	-0.41	-6.47	-0.39	5.71e-10	Intelligence (multi-trait analysis);
SARC	cis	rs9398803	0.865	rs9385400	chr6:126764190	G/T	cg20229609	chr6:126660872	C6orf173	-0.41	-5.94	-0.36	1.05e-8	Male-pattern baldness;
SARC	cis	rs9322817	0.691	rs2400071	chr6:105344075	C/T	cg02098413	chr6:105308735	HACE1	0.4	6.15	0.37	3.26e-9	Thyroid stimulating hormone;
SARC	cis	rs12586317	0.547	rs28569331	chr14:35473584	T/C	cg26967526	chr14:35346199	BAZ1A	-0.57	-5.71	-0.35	3.4e-8	Psoriasis;
SARC	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg24549020	chr5:56110836	MAP3K1	0.7	7.21	0.43	7.76e-12	Initial pursuit acceleration;
SARC	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg11890956	chr21:40555474	PSMG1	1.16	16.25	0.73	3.18e-40	Cognitive function;
SARC	cis	rs9467603	1.000	rs9467603	chr6:25803712	A/G	cg21479132	chr6:26055353	NA	0.77	5.1	0.32	7.06e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7084402	0.764	rs2033149	chr10:60264741	A/T	cg07615347	chr10:60278583	BICC1	0.49	6.72	0.4	1.4e-10	Refractive error;
SARC	cis	rs6500395	1.000	rs11859909	chr16:48668441	T/C	cg04672837	chr16:48644449	N4BP1	0.47	6.24	0.38	2.05e-9	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs282587	0.569	rs282594	chr13:113379640	A/G	cg02820901	chr13:113351484	ATP11A	-0.49	-4.79	-0.3	2.92e-6	Glycated hemoglobin levels;
SARC	cis	rs7044106	0.648	rs2031369	chr9:123360294	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	8.27	0.48	1.03e-14	Hip circumference adjusted for BMI;
SARC	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg16405210	chr4:1374714	KIAA1530	0.69	8.45	0.48	3.12e-15	Obesity-related traits;
SARC	cis	rs3857067	0.806	rs17302300	chr4:95109177	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.04	-0.31	9.48e-7	QT interval;
SARC	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg11062466	chr8:58055876	NA	0.58	5.61	0.35	5.65e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9399137	0.507	rs13214669	chr6:135299959	T/C	cg22676075	chr6:135203613	NA	0.4	5.1	0.32	6.97e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs616147	0.816	rs1768190	chr3:39509440	T/C	cg17944282	chr3:39448217	RPSA	0.47	4.99	0.31	1.18e-6	Amyotrophic lateral sclerosis;Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg10876282	chr6:28092338	ZSCAN16	0.48	4.72	0.3	4e-6	Parkinson's disease;
SARC	cis	rs9814567	1.000	rs7427492	chr3:134261654	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.08	-0.42	1.73e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs9916302	0.851	rs11078906	chr17:37662767	C/T	cg07936489	chr17:37558343	FBXL20	-0.69	-8.92	-0.5	1.4e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs2898290	0.617	rs13278965	chr8:11466745	A/T	cg21775007	chr8:11205619	TDH	0.43	5.41	0.33	1.52e-7	Systolic blood pressure;
SARC	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.56	-0.39	3.45e-10	Total body bone mineral density;
SARC	cis	rs888194	0.738	rs2241213	chr12:109938857	A/G	cg13986417	chr12:110012484	MVK;MMAB	-0.31	-4.77	-0.3	3.19e-6	Neuroticism;
SARC	cis	rs73086581	0.838	rs56401022	chr20:4024281	A/G	cg02187196	chr20:3869020	PANK2	0.51	5.0	0.31	1.13e-6	Response to antidepressants in depression;
SARC	cis	rs1008375	1.000	rs6854733	chr4:17640526	C/T	cg16339924	chr4:17578868	LAP3	0.67	8.96	0.51	1.05e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg18876405	chr7:65276391	NA	-0.44	-4.96	-0.31	1.33e-6	Aortic root size;
SARC	cis	rs2250402	0.510	rs2291621	chr15:40324837	C/T	cg09159619	chr15:40331526	SRP14	0.69	4.77	0.3	3.26e-6	Corneal curvature;
SARC	cis	rs1144333	0.510	rs1146652	chr1:76273708	A/G	cg03433033	chr1:76189801	ACADM	-0.58	-4.82	-0.3	2.59e-6	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs2120243	0.539	rs6801110	chr3:157084731	C/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.43	5.32	0.33	2.48e-7	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs11168351	0.927	rs7971880	chr12:48391055	C/T	cg24011408	chr12:48396354	COL2A1	0.43	5.31	0.33	2.59e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs9911578	0.692	rs411988	chr17:56709034	G/A	cg05425664	chr17:57184151	TRIM37	-0.53	-6.52	-0.39	4.26e-10	Intelligence (multi-trait analysis);
SARC	cis	rs2075371	0.933	rs1833474	chr7:133958240	A/G	cg11752832	chr7:134001865	SLC35B4	0.54	6.89	0.41	5.12e-11	Mean platelet volume;
SARC	cis	rs4478037	0.643	rs9875798	chr3:33120448	G/C	cg19404215	chr3:33155277	CRTAP	0.72	5.85	0.36	1.62e-8	Major depressive disorder;
SARC	cis	rs936229	0.705	rs936227	chr15:75131959	A/G	cg09165964	chr15:75287851	SCAMP5	0.41	5.04	0.31	9.47e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg20891283	chr12:69753455	YEATS4	0.54	7.5	0.44	1.29e-12	Blood protein levels;
SARC	cis	rs4423214	0.840	rs1792226	chr11:71176574	C/T	cg05163923	chr11:71159392	DHCR7	-0.61	-7.39	-0.44	2.64e-12	Vitamin D levels;
SARC	cis	rs832540	0.898	rs331497	chr5:56251660	G/T	cg14703610	chr5:56206110	C5orf35	-0.48	-5.85	-0.36	1.63e-8	Coronary artery disease;
SARC	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg26818010	chr10:134567672	INPP5A	-0.61	-6.35	-0.38	1.13e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	trans	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg00938859	chr5:1591904	SDHAP3	0.69	6.36	0.38	1.03e-9	Breast cancer;
SARC	cis	rs10484885	0.878	rs72921959	chr6:90591326	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.59	-4.94	-0.31	1.49e-6	QRS interval (sulfonylurea treatment interaction);
SARC	cis	rs7020830	0.571	rs7031314	chr9:37376122	A/T	cg14294708	chr9:37120828	ZCCHC7	-0.83	-9.44	-0.53	4e-18	Schizophrenia;
SARC	cis	rs1322639	0.614	rs6900964	chr6:169566763	A/G	cg03254818	chr6:169586852	NA	0.73	7.45	0.44	1.85e-12	Pulse pressure;
SARC	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	5.42	0.33	1.47e-7	Bipolar disorder;
SARC	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg15049968	chr18:44337910	ST8SIA5	0.36	5.8	0.36	2.1e-8	Personality dimensions;
SARC	cis	rs17270561	1.000	rs17270561	chr6:25820439	A/C	cg17691542	chr6:26056736	HIST1H1C	-0.68	-7.34	-0.43	3.46e-12	Iron status biomarkers;
SARC	cis	rs6570726	0.935	rs391820	chr6:145821284	C/T	cg05347473	chr6:146136440	FBXO30	0.49	6.54	0.39	3.91e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3857536	0.813	rs7770349	chr6:66946659	G/T	cg07460842	chr6:66804631	NA	-0.45	-5.19	-0.32	4.5e-7	Blood trace element (Cu levels);
SARC	cis	rs2153535	0.563	rs6942177	chr6:8534460	A/G	cg23788917	chr6:8435910	SLC35B3	-0.61	-7.98	-0.46	6.8e-14	Motion sickness;
SARC	cis	rs6728642	0.908	rs6731522	chr2:97647997	A/G	cg26665480	chr2:98280029	ACTR1B	-0.62	-6.11	-0.37	4.21e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs1044826	1.000	rs12695698	chr3:139175781	A/G	cg15131784	chr3:139108705	COPB2	-0.47	-5.37	-0.33	1.86e-7	Obesity-related traits;
SARC	cis	rs9291683	0.527	rs11727087	chr4:10096020	A/G	cg11266682	chr4:10021025	SLC2A9	0.45	7.86	0.46	1.39e-13	Bone mineral density;
SARC	cis	rs9858542	0.953	rs11719996	chr3:49525958	T/C	cg03060546	chr3:49711283	APEH	-0.58	-7.13	-0.42	1.28e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	trans	rs931812	0.825	rs6993937	chr8:101898707	A/G	cg20993868	chr7:22813445	NA	0.46	6.38	0.39	9.62e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs6831352	0.918	rs13112176	chr4:100055825	G/A	cg12011299	chr4:100065546	ADH4	-0.34	-5.74	-0.35	2.95e-8	Alcohol dependence;
SARC	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg22857025	chr5:266934	NA	-1.08	-11.86	-0.61	1.06e-25	Breast cancer;
SARC	cis	rs9457247	0.967	rs387733	chr6:167409771	C/T	cg07741184	chr6:167504864	NA	-0.31	-5.7	-0.35	3.52e-8	Crohn's disease;
SARC	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg12463550	chr7:65579703	CRCP	-0.5	-5.36	-0.33	2.05e-7	Aortic root size;
SARC	cis	rs7917772	0.599	rs2863717	chr10:104519829	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-6.43	-0.39	7.05e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg05368731	chr17:41323189	NBR1	0.79	9.6	0.53	1.34e-18	Menopause (age at onset);
SARC	cis	rs9646954	0.542	rs3828193	chr2:101031561	A/C	cg14675211	chr2:100938903	LONRF2	-0.54	-7.84	-0.46	1.63e-13	Intelligence (multi-trait analysis);
SARC	cis	rs2732480	0.557	rs2732441	chr12:48723324	C/G	cg24011408	chr12:48396354	COL2A1	0.43	5.07	0.32	8.25e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs941408	0.515	rs878893	chr19:2781325	A/G	cg00079169	chr19:2811669	THOP1	0.44	4.88	0.3	1.99e-6	Total cholesterol levels;
SARC	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg20607798	chr8:58055168	NA	0.67	5.66	0.35	4.42e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs3106136	0.903	rs67552174	chr4:95203097	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.38	-5.95	-0.36	9.94e-9	Capecitabine sensitivity;
SARC	cis	rs995000	1.000	rs995000	chr1:63107526	C/T	cg06896770	chr1:63153194	DOCK7	0.99	15.38	0.71	2.53e-37	Triglyceride levels;
SARC	cis	rs10089	0.953	rs1985268	chr5:127375931	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	10.19	0.56	2.04e-20	Ileal carcinoids;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg23517954	chr2:162168615	PSMD14	-0.57	-7.08	-0.42	1.67e-11	Alcohol dependence;
SARC	cis	rs9487051	0.714	rs13209277	chr6:109624963	T/A	cg01475377	chr6:109611718	NA	-0.39	-5.48	-0.34	1.1e-7	Reticulocyte fraction of red cells;
SARC	trans	rs9354352	0.818	rs9453548	chr6:66691885	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.61	-7.63	-0.45	5.99e-13	Initial pursuit acceleration in psychotic disorders;
SARC	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg09359103	chr1:154839909	KCNN3	-0.44	-7.34	-0.43	3.46e-12	Prostate cancer;
SARC	cis	rs7582720	0.943	rs72926798	chr2:203827675	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs9611519	0.565	rs8135524	chr22:41436442	T/C	cg03806693	chr22:41940476	POLR3H	-0.62	-8.33	-0.48	7.14e-15	Neuroticism;
SARC	cis	rs6539288	0.899	rs7956807	chr12:107300526	C/T	cg07730007	chr12:107377277	MTERFD3	0.38	4.79	0.3	2.91e-6	Total body bone mineral density;
SARC	cis	rs897080	0.515	rs786401	chr2:44712069	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	6.14	0.37	3.5e-9	Height;
SARC	cis	rs1707322	0.721	rs11211165	chr1:46157906	C/T	cg03146154	chr1:46216737	IPP	0.53	6.35	0.38	1.12e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	7.45	0.44	1.79e-12	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg19774624	chr17:42201019	HDAC5	-0.58	-8.36	-0.48	5.88e-15	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs7666738	0.830	rs2903154	chr4:99048151	A/G	cg05340658	chr4:99064831	C4orf37	0.64	8.6	0.49	1.18e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs3857536	0.740	rs7773577	chr6:66892124	G/A	cg07460842	chr6:66804631	NA	-0.6	-7.16	-0.42	1.04e-11	Blood trace element (Cu levels);
SARC	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg13206674	chr6:150067644	NUP43	0.46	5.95	0.36	9.77e-9	Lung cancer;
SARC	cis	rs7729447	0.804	rs116090595	chr5:32698148	T/G	cg16267343	chr5:32710456	NPR3	0.63	8.41	0.48	4.19e-15	Blood pressure;
SARC	cis	rs9486715	0.838	rs7452350	chr6:96883326	C/A	cg06623918	chr6:96969491	KIAA0776	0.88	12.7	0.64	1.95e-28	Headache;
SARC	cis	rs12908161	1.000	rs35726233	chr15:85337800	C/T	cg17507749	chr15:85114479	UBE2QP1	0.54	6.1	0.37	4.39e-9	Schizophrenia;
SARC	cis	rs580438	1.000	rs552525	chr3:13347755	A/G	cg05446471	chr3:13522740	HDAC11	-0.29	-4.71	-0.3	4.2e-6	Myringotomy;
SARC	cis	rs2061333	1.000	rs2061332	chr19:44613661	G/T	cg18700516	chr19:44507157	ZNF230	0.51	5.26	0.33	3.3e-7	Alzheimer's disease;
SARC	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg06618935	chr21:46677482	NA	-0.42	-5.54	-0.34	7.99e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs3733585	0.673	rs10018204	chr4:9964570	C/T	cg11266682	chr4:10021025	SLC2A9	-0.35	-6.03	-0.37	6.35e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7786808	0.782	rs7787923	chr7:158227312	A/G	cg09998033	chr7:158218633	PTPRN2	-0.37	-5.84	-0.36	1.71e-8	Obesity-related traits;
SARC	cis	rs6931421	1.000	rs6931421	chr6:80880138	A/C	cg08355045	chr6:80787529	NA	0.38	5.99	0.37	8.02e-9	Sitting height ratio;
SARC	cis	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg03060546	chr3:49711283	APEH	-0.66	-8.36	-0.48	5.63e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg16079958	chr5:71404742	MAP1B	0.5	6.99	0.42	2.83e-11	Tetralogy of Fallot;
SARC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg11494091	chr17:61959527	GH2	0.53	8.0	0.46	5.72e-14	Prudent dietary pattern;
SARC	cis	rs356220	0.656	rs6848708	chr4:90634828	G/T	cg06632027	chr4:90757378	SNCA	0.39	5.0	0.31	1.13e-6	Parkinson's disease;
SARC	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg07636037	chr3:49044803	WDR6	1.0	17.66	0.76	6.92e-45	Parkinson's disease;
SARC	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg16325326	chr1:53192061	ZYG11B	0.77	12.33	0.63	3.29e-27	Monocyte count;
SARC	cis	rs17401966	0.838	rs1556916	chr1:10403482	G/A	cg15208524	chr1:10270712	KIF1B	0.46	5.42	0.33	1.46e-7	Hepatocellular carcinoma;
SARC	cis	rs2235642	0.821	rs2281234	chr16:1602938	A/G	cg26528668	chr16:1614120	IFT140	0.36	4.77	0.3	3.28e-6	Coronary artery disease;
SARC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.33	4.9	0.31	1.81e-6	Electroencephalogram traits;
SARC	cis	rs12142240	0.698	rs6696777	chr1:46810970	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-5.48	-0.34	1.12e-7	Menopause (age at onset);
SARC	cis	rs9388451	0.839	rs9321054	chr6:126079968	A/G	cg05901451	chr6:126070800	HEY2	0.67	9.18	0.52	2.41e-17	Brugada syndrome;
SARC	cis	rs2421770	0.530	rs10836375	chr11:35353842	C/T	cg13971030	chr11:35366721	SLC1A2	-0.34	-4.92	-0.31	1.61e-6	Staphylococcus aureus nasal carriage (persistent);
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10027562	chr6:20402074	E2F3	0.5	6.29	0.38	1.51e-9	Smoking initiation;
SARC	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg24675658	chr1:53192096	ZYG11B	-0.56	-7.78	-0.45	2.32e-13	Monocyte count;
SARC	cis	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg03060546	chr3:49711283	APEH	-0.67	-8.31	-0.48	8e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs1451375	0.617	rs1807066	chr7:50543683	T/C	cg14593290	chr7:50529359	DDC	-0.46	-4.97	-0.31	1.31e-6	Malaria;
SARC	cis	rs7904368	0.951	rs7074647	chr10:16855455	T/C	cg14835575	chr10:16859367	RSU1	0.74	7.9	0.46	1.07e-13	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs16912285	0.892	rs80332091	chr11:24255248	T/A	ch.11.24196551F	chr11:24239977	NA	0.73	6.22	0.38	2.32e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg14930269	chr3:49142045	QARS	0.48	6.45	0.39	6.39e-10	Tetralogy of Fallot;
SARC	cis	rs2594989	0.832	rs13325556	chr3:11566961	T/G	cg00170343	chr3:11313890	ATG7	-0.59	-5.8	-0.36	2.18e-8	Circulating chemerin levels;
SARC	cis	rs9902453	1.000	rs9912741	chr17:28359511	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.53	-6.96	-0.41	3.47e-11	Coffee consumption (cups per day);
SARC	cis	rs1448094	0.512	rs7302741	chr12:86237127	C/T	cg00310523	chr12:86230176	RASSF9	0.33	5.27	0.33	3.04e-7	Major depressive disorder;
SARC	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg22974920	chr21:40686053	BRWD1	-0.43	-4.83	-0.3	2.47e-6	Cognitive function;
SARC	cis	rs921968	0.643	rs520095	chr2:219329485	C/T	cg02176678	chr2:219576539	TTLL4	0.37	5.49	0.34	1.03e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg20120463	chr17:44301886	NA	0.33	5.1	0.32	7.11e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg05313129	chr8:58192883	C8orf71	-0.62	-6.37	-0.39	9.92e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6141769	0.542	rs6087976	chr20:31316287	G/A	cg13636640	chr20:31349939	DNMT3B	-0.45	-4.78	-0.3	3.08e-6	Subjective well-being;
SARC	cis	rs8180040	0.764	rs4683324	chr3:47251284	T/C	cg27129171	chr3:47204927	SETD2	0.68	9.71	0.54	6.04e-19	Colorectal cancer;
SARC	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg06420487	chr17:61919686	SMARCD2	0.46	5.09	0.32	7.48e-7	Height;
SARC	cis	rs7000551	0.779	rs2443507	chr8:22373231	G/A	cg12081754	chr8:22256438	SLC39A14	0.58	8.08	0.47	3.47e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs10992471	0.603	rs10116813	chr9:95090360	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-5.46	-0.34	1.19e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg02725872	chr8:58115012	NA	-0.37	-6.47	-0.39	5.76e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs910316	0.875	rs12588099	chr14:75594462	A/T	cg23033748	chr14:75592666	NEK9	0.38	5.38	0.33	1.78e-7	Height;
SARC	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.59e-6	Depression;
SARC	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg06618935	chr21:46677482	NA	-0.42	-5.56	-0.34	7.26e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9325144	0.647	rs7487395	chr12:38865660	C/A	cg13010199	chr12:38710504	ALG10B	-0.46	-5.78	-0.35	2.38e-8	Morning vs. evening chronotype;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25015662	chr20:34742333	EPB41L1	-0.56	-6.74	-0.4	1.23e-10	Fibrinogen levels;
SARC	cis	rs7179456	0.545	rs605928	chr15:59046163	C/G	cg05156742	chr15:59063176	FAM63B	0.67	8.73	0.5	4.86e-16	Asperger disorder;
SARC	cis	rs6087990	0.842	rs4911105	chr20:31330413	G/A	cg13636640	chr20:31349939	DNMT3B	0.79	12.57	0.64	5.17e-28	Ulcerative colitis;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg09096067	chr10:15820266	FAM188A	0.45	6.66	0.4	1.91e-10	Thyroid stimulating hormone;
SARC	cis	rs7833986	1.000	rs4263734	chr8:57099931	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.6	5.33	0.33	2.36e-7	Height;
SARC	cis	rs4654899	0.897	rs710311	chr1:21062001	T/C	cg04902671	chr1:21058625	SH2D5	-0.4	-4.75	-0.3	3.49e-6	Superior frontal gyrus grey matter volume;
SARC	cis	rs1670533	0.818	rs6835141	chr4:1070140	G/T	cg27284194	chr4:1044797	NA	0.44	4.86	0.3	2.12e-6	Recombination rate (females);
SARC	cis	rs892961	0.899	rs66749226	chr17:75412826	G/A	cg05865280	chr17:75406074	SEPT9	0.55	8.17	0.47	1.99e-14	Airflow obstruction;
SARC	cis	rs7635838	0.523	rs9873503	chr3:11396100	T/C	cg00170343	chr3:11313890	ATG7	0.57	7.62	0.45	6.43e-13	HDL cholesterol;
SARC	cis	rs11690935	0.550	rs7584187	chr2:172866105	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.49	-6.26	-0.38	1.79e-9	Schizophrenia;
SARC	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg20891283	chr12:69753455	YEATS4	0.66	9.53	0.53	2.11e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg00800038	chr16:89945340	TCF25	-0.72	-5.75	-0.35	2.8e-8	Skin colour saturation;
SARC	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg03060546	chr3:49711283	APEH	0.4	5.08	0.32	7.86e-7	Parkinson's disease;
SARC	cis	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.75	-0.45	2.87e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs28655083	0.913	rs7190129	chr16:77071456	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.42	-6.06	-0.37	5.3e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3087591	0.922	rs9892839	chr17:29618990	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.52	-6.38	-0.39	9.69e-10	Hip circumference;
SARC	cis	rs3617	0.573	rs12638968	chr3:52919447	T/A	cg05564831	chr3:52568323	NT5DC2	-0.3	-5.1	-0.32	7.13e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs6582630	0.599	rs8175936	chr12:38426315	C/G	cg14851346	chr12:38532713	NA	-0.47	-5.66	-0.35	4.49e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs3741404	0.560	rs7938819	chr11:63910116	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.74	-9.75	-0.54	4.72e-19	Platelet count;
SARC	cis	rs6977660	0.714	rs4719587	chr7:19828174	C/G	cg07541023	chr7:19748670	TWISTNB	0.53	4.91	0.31	1.68e-6	Thyroid stimulating hormone;
SARC	trans	rs12310956	0.515	rs1872745	chr12:33985987	G/A	cg26384229	chr12:38710491	ALG10B	0.75	10.56	0.57	1.45e-21	Morning vs. evening chronotype;
SARC	cis	rs981844	0.816	rs74549610	chr4:154710464	C/G	cg14289246	chr4:154710475	SFRP2	0.66	7.04	0.42	2.1e-11	Response to statins (LDL cholesterol change);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg10578696	chr1:65532742	NA	0.55	6.26	0.38	1.86e-9	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs6831352	0.918	rs13127582	chr4:100058194	G/A	cg12011299	chr4:100065546	ADH4	-0.34	-5.74	-0.35	2.95e-8	Alcohol dependence;
SARC	cis	rs497273	0.552	rs1179939	chr12:121326876	G/C	cg02403541	chr12:121454288	C12orf43	-0.43	-5.09	-0.32	7.35e-7	Systemic lupus erythematosus;
SARC	cis	rs3087591	1.000	rs2012988	chr17:29547296	T/C	cg24425628	chr17:29625626	OMG;NF1	0.5	6.19	0.38	2.68e-9	Hip circumference;
SARC	cis	rs617219	0.889	rs12519500	chr5:78436905	C/A	cg24856658	chr5:78533917	JMY	-0.32	-4.75	-0.3	3.54e-6	Betaine levels in individuals undergoing cardiac evaluation;
SARC	cis	rs17376456	1.000	rs13181660	chr5:93533658	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	5.89	0.36	1.32e-8	Diabetic retinopathy;
SARC	cis	rs57143961	1	rs57143961	chr19:16533225	C/CT	cg10248733	chr19:16607483	C19orf44;CALR3	-0.77	-7.89	-0.46	1.18e-13	Lymphocyte percentage of white cells;
SARC	cis	rs6893807	1.000	rs13163173	chr5:87943620	C/A	cg09002922	chr5:87956389	LOC645323	-0.42	-4.83	-0.3	2.44e-6	Body mass index;
SARC	cis	rs6964587	1.000	rs12536529	chr7:91684086	C/T	cg17063962	chr7:91808500	NA	-0.98	-16.97	-0.74	1.39e-42	Breast cancer;
SARC	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg04944784	chr2:26401820	FAM59B	-0.6	-7.86	-0.46	1.46e-13	Gut microbiome composition (summer);
SARC	cis	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg14019146	chr3:50243930	SLC38A3	-0.31	-4.83	-0.3	2.42e-6	Body mass index;
SARC	cis	rs6540556	0.682	rs667681	chr1:209914449	A/G	cg05527609	chr1:210001259	C1orf107	0.7	6.65	0.4	2.12e-10	Red blood cell count;
SARC	cis	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg07274523	chr3:49395745	GPX1	0.49	5.5	0.34	9.87e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs1580019	0.587	rs7806113	chr7:32553084	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.53	6.91	0.41	4.63e-11	Cognitive ability;
SARC	cis	rs1256061	0.564	rs1256043	chr14:64734282	A/G	cg23250157	chr14:64679961	SYNE2	0.48	6.62	0.4	2.49e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.8	7.48	0.44	1.46e-12	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs7937682	0.883	rs631490	chr11:111452040	G/C	cg22437258	chr11:111473054	SIK2	0.7	9.41	0.52	4.9e-18	Primary sclerosing cholangitis;
SARC	cis	rs7666738	0.924	rs11097592	chr4:98927532	C/T	cg05340658	chr4:99064831	C4orf37	0.57	7.3	0.43	4.44e-12	Colonoscopy-negative controls vs population controls;
SARC	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	13.88	0.67	2.59e-32	Chronic sinus infection;
SARC	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg13939156	chr17:80058883	NA	-0.41	-6.37	-0.39	1.01e-9	Life satisfaction;
SARC	cis	rs6540556	0.723	rs1415542	chr1:209902110	T/C	cg23920097	chr1:209922102	NA	-0.52	-5.31	-0.33	2.59e-7	Red blood cell count;
SARC	cis	rs2559856	0.935	rs7970952	chr12:102081577	C/T	cg12924262	chr12:102091054	CHPT1	0.58	7.62	0.45	6.2800000000000005e-13	Blood protein levels;
SARC	cis	rs7113874	0.578	rs7924477	chr11:8538247	T/C	cg09828998	chr11:8703972	RPL27A	0.5	5.45	0.34	1.31e-7	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2120019	0.938	rs8040169	chr15:75370958	C/A	cg09165964	chr15:75287851	SCAMP5	-0.87	-13.08	-0.65	1.1e-29	Blood trace element (Zn levels);
SARC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg06873352	chr17:61820015	STRADA	0.53	6.9	0.41	4.95e-11	Prudent dietary pattern;
SARC	cis	rs11997175	0.511	rs4613957	chr8:33673130	C/T	ch.8.33884649F	chr8:33765107	NA	-0.49	-6.48	-0.39	5.25e-10	Body mass index;
SARC	cis	rs703842	1.000	rs10783848	chr12:58196528	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.78	11.38	0.6	3.68e-24	Multiple sclerosis;
SARC	cis	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg07777115	chr5:623756	CEP72	-0.63	-5.6	-0.34	6.08e-8	Obesity-related traits;
SARC	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.58	-7.56	-0.44	9.36e-13	Mean platelet volume;
SARC	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg25072359	chr17:41440525	NA	0.51	6.04	0.37	6.2e-9	Menopause (age at onset);
SARC	cis	rs858239	0.539	rs6955726	chr7:23186691	A/G	cg23682824	chr7:23144976	KLHL7	0.72	9.28	0.52	1.22e-17	Cerebrospinal fluid biomarker levels;
SARC	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg20607798	chr8:58055168	NA	0.71	6.1	0.37	4.4e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4711336	0.633	rs9469583	chr6:33717770	T/C	cg15676125	chr6:33679581	C6orf125	0.48	6.15	0.37	3.42e-9	Height;
SARC	cis	rs2938670	1	rs2938670	chr15:78740688	T/G	cg06917634	chr15:78832804	PSMA4	-0.49	-5.39	-0.33	1.7e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1 in COPD;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs2120243	0.539	rs1456108	chr3:157119054	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.39	4.96	0.31	1.37e-6	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs1008375	0.966	rs3775925	chr4:17588437	A/G	cg27347728	chr4:17578864	LAP3	0.49	6.04	0.37	5.95e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6430585	0.528	rs309165	chr2:136667301	T/C	cg07169764	chr2:136633963	MCM6	1.01	15.39	0.71	2.32e-37	Corneal structure;
SARC	trans	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg07211511	chr3:129823064	LOC729375	-0.62	-6.6	-0.4	2.72e-10	Blood pressure (smoking interaction);
SARC	cis	rs2153535	0.580	rs1414344	chr6:8471365	C/A	cg21535247	chr6:8435926	SLC35B3	0.56	7.09	0.42	1.55e-11	Motion sickness;
SARC	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg03060546	chr3:49711283	APEH	0.43	5.36	0.33	1.98e-7	Parkinson's disease;
SARC	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.39	-4.86	-0.3	2.17e-6	Lymphocyte counts;
SARC	cis	rs7647973	0.560	rs77473999	chr3:49777660	T/C	cg03060546	chr3:49711283	APEH	-0.58	-5.75	-0.35	2.79e-8	Menarche (age at onset);
SARC	cis	rs11255291	1.000	rs7917456	chr10:7732323	A/G	cg13340899	chr10:7670827	ITIH5	0.39	5.04	0.31	9.45e-7	Ovarian reserve;
SARC	cis	rs2976388	0.507	rs2572874	chr8:143837219	C/T	cg06565975	chr8:143823917	SLURP1	0.28	4.86	0.3	2.19e-6	Urinary tract infection frequency;
SARC	cis	rs910316	0.763	rs735452	chr14:75497984	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.52	-7.24	-0.43	6.51e-12	Height;
SARC	cis	rs2576037	0.899	rs12955429	chr18:44585484	C/T	cg15049968	chr18:44337910	ST8SIA5	0.33	5.23	0.32	3.84e-7	Personality dimensions;
SARC	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg23758822	chr17:41437982	NA	0.87	10.68	0.57	6.2e-22	Menopause (age at onset);
SARC	cis	rs2075371	0.764	rs1643034	chr7:134006176	A/G	cg20476274	chr7:133979776	SLC35B4	0.56	7.59	0.45	7.66e-13	Mean platelet volume;
SARC	cis	rs11098499	0.954	rs2389803	chr4:120393511	A/G	cg09307838	chr4:120376055	NA	-0.9	-12.72	-0.64	1.73e-28	Corneal astigmatism;
SARC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg09373136	chr17:61933544	TCAM1	-0.45	-6.2	-0.38	2.48e-9	Prudent dietary pattern;
SARC	cis	rs11190604	1.000	rs7100386	chr10:102301417	C/T	cg07080220	chr10:102295463	HIF1AN	0.83	9.82	0.54	2.9e-19	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.71	9.63	0.53	1.05e-18	Lymphocyte counts;
SARC	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg11987759	chr7:65425863	GUSB	0.5	6.07	0.37	5.27e-9	Aortic root size;
SARC	cis	rs3768617	0.510	rs7414273	chr1:183075017	T/C	cg13390022	chr1:182993471	LAMC1	0.32	4.78	0.3	3.07e-6	Fuchs's corneal dystrophy;
SARC	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg07153921	chr17:41440717	NA	-0.4	-4.86	-0.3	2.11e-6	Menopause (age at onset);
SARC	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg18252515	chr7:66147081	NA	0.45	4.85	0.3	2.27e-6	Aortic root size;
SARC	cis	rs6912958	0.703	rs9362427	chr6:88097634	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.35	6.01	0.37	6.94e-9	Monocyte percentage of white cells;
SARC	cis	rs11098499	0.739	rs9884728	chr4:120127079	C/T	cg09307838	chr4:120376055	NA	-0.78	-10.49	-0.57	2.38e-21	Corneal astigmatism;
SARC	cis	rs1355223	0.902	rs12802323	chr11:34747739	G/A	cg18508148	chr11:34937573	PDHX;APIP	-0.4	-5.13	-0.32	6.12e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs10463554	0.927	rs257314	chr5:102421095	T/C	cg23492399	chr5:102201601	PAM	-0.52	-5.75	-0.35	2.78e-8	Parkinson's disease;
SARC	cis	rs7766436	0.885	rs11759879	chr6:22587130	C/T	cg13666174	chr6:22585274	NA	-0.59	-7.41	-0.44	2.32e-12	Coronary artery disease;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg25756680	chr11:67771726	UNC93B1	-0.5	-6.49	-0.39	5.19e-10	Height;
SARC	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg04944784	chr2:26401820	FAM59B	0.6	7.95	0.46	8.14e-14	Gut microbiome composition (summer);
SARC	cis	rs11690935	0.550	rs55653103	chr2:172861816	T/C	cg13550731	chr2:172543902	DYNC1I2	0.51	6.42	0.39	7.67e-10	Schizophrenia;
SARC	cis	rs34638657	0.827	rs3829548	chr16:82206238	C/G	cg07918374	chr16:82182319	MPHOSPH6	-0.62	-6.01	-0.37	7.1e-9	Lung adenocarcinoma;
SARC	cis	rs7408868	1.000	rs10407320	chr19:15275716	G/C	cg14696996	chr19:15285081	NOTCH3	1.05	8.52	0.49	1.95e-15	Pulse pressure;
SARC	cis	rs10791097	0.694	rs7106973	chr11:130758113	G/A	cg12179176	chr11:130786555	SNX19	0.76	11.59	0.6	8.05e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs9875589	0.509	rs7651599	chr3:14010974	C/G	cg19554555	chr3:13937349	NA	-0.42	-5.48	-0.34	1.13e-7	Ovarian reserve;
SARC	cis	rs3820928	0.874	rs6717168	chr2:227901342	C/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-6.52	-0.39	4.29e-10	Pulmonary function;
SARC	cis	rs6504340	0.793	rs12946855	chr17:46608030	G/A	cg04904318	chr17:46607828	HOXB1	-0.46	-5.6	-0.34	5.9e-8	Primary tooth development (number of teeth);
SARC	cis	rs7011049	1.000	rs10958336	chr8:53841318	G/A	cg26025543	chr8:53854495	NA	0.6	5.39	0.33	1.73e-7	Systolic blood pressure;
SARC	cis	rs262150	0.659	rs2527237	chr7:158798494	A/G	cg09640425	chr7:158790006	NA	0.39	5.42	0.33	1.48e-7	Facial morphology (factor 20);
SARC	cis	rs2153535	0.580	rs718503	chr6:8527463	A/T	cg21535247	chr6:8435926	SLC35B3	0.52	6.53	0.39	4.11e-10	Motion sickness;
SARC	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs62432291	0.681	rs418859	chr6:159649695	A/T	cg14500486	chr6:159655392	FNDC1	0.62	6.09	0.37	4.52e-9	Joint mobility (Beighton score);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg19502972	chr1:12040413	MFN2	0.5	6.6	0.4	2.69e-10	Chemerin levels;
SARC	cis	rs7255045	0.742	rs6511841	chr19:12955149	G/T	cg21491176	chr19:12958399	MAST1	-0.34	-4.76	-0.3	3.38e-6	Mean corpuscular volume;
SARC	cis	rs4718428	0.705	rs62465692	chr7:66295745	T/C	cg12165864	chr7:66369176	NA	-0.43	-4.78	-0.3	3.14e-6	Corneal structure;
SARC	cis	rs7528419	0.895	rs583104	chr1:109821307	G/T	cg00908766	chr1:109817496	CELSR2	0.55	7.26	0.43	5.84e-12	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
SARC	cis	rs9467773	1.000	rs10946834	chr6:26533664	G/C	cg11502198	chr6:26597334	ABT1	0.46	5.53	0.34	8.38e-8	Intelligence (multi-trait analysis);
SARC	cis	rs11250464	0.833	rs4554799	chr10:1407728	C/T	cg26394196	chr10:1453818	ADARB2	-0.3	-4.97	-0.31	1.3e-6	Radiation response;
SARC	cis	rs2777491	1.000	rs11631770	chr15:41737059	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.78	-11.43	-0.6	2.63e-24	Ulcerative colitis;
SARC	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.86	10.22	0.56	1.74e-20	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs4072980	0.545	rs12120737	chr1:38422544	C/T	cg12658694	chr1:38397304	INPP5B	0.69	8.11	0.47	2.88e-14	Coronary artery disease;
SARC	cis	rs1448094	0.512	rs7309500	chr12:86249647	C/T	cg02569458	chr12:86230093	RASSF9	0.37	5.15	0.32	5.54e-7	Major depressive disorder;
SARC	cis	rs2204008	0.837	rs11183232	chr12:37941053	A/G	cg13010199	chr12:38710504	ALG10B	0.75	10.03	0.55	6.49e-20	Bladder cancer;
SARC	cis	rs2153535	0.580	rs7766852	chr6:8472417	C/T	cg07606381	chr6:8435919	SLC35B3	0.78	11.2	0.59	1.39e-23	Motion sickness;
SARC	cis	rs7666738	0.830	rs10005120	chr4:99038200	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.84	0.5	2.39e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-8.03	-0.47	4.67e-14	Chronic sinus infection;
SARC	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.35	-0.43	3.34e-12	Gut microbiome composition (summer);
SARC	cis	rs2965280	1.000	rs2910412	chr19:34921161	A/G	cg18377133	chr19:34977105	WTIP	0.6	4.81	0.3	2.69e-6	Colorectal cancer;
SARC	cis	rs908922	0.573	rs7544564	chr1:152527007	A/C	cg09873164	chr1:152488093	CRCT1	0.59	7.65	0.45	5.25e-13	Hair morphology;
SARC	cis	rs6940638	0.715	rs9348751	chr6:27067190	T/A	cg12826209	chr6:26865740	GUSBL1	0.54	5.95	0.36	1e-8	Intelligence (multi-trait analysis);
SARC	cis	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.73	10.11	0.55	3.7e-20	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs6860806	0.531	rs270607	chr5:131649186	A/G	cg24060327	chr5:131705240	SLC22A5	-0.66	-8.09	-0.47	3.37e-14	Breast cancer;
SARC	cis	rs73198271	0.632	rs477018	chr8:8600817	T/A	cg06636001	chr8:8085503	FLJ10661	-0.49	-5.34	-0.33	2.22e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs4969178	0.965	rs3817294	chr17:76396963	A/G	cg20026190	chr17:76395443	PGS1	0.4	5.37	0.33	1.94e-7	HDL cholesterol levels;
SARC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg27588902	chr6:42928151	GNMT	-0.33	-4.91	-0.31	1.72e-6	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs72781680	0.679	rs718138	chr2:23976324	G/A	cg08917208	chr2:24149416	ATAD2B	0.55	5.66	0.35	4.42e-8	Lymphocyte counts;
SARC	cis	rs9790314	0.628	rs4342141	chr3:160783922	T/C	cg04691961	chr3:161091175	C3orf57	-0.54	-7.04	-0.42	2.08e-11	Morning vs. evening chronotype;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12769138	chr2:168150203	NA	-0.48	-6.42	-0.39	7.53e-10	Smoking initiation;
SARC	cis	rs208520	0.690	rs1318604	chr6:66825278	A/C	cg07460842	chr6:66804631	NA	-1.06	-14.03	-0.68	8.04e-33	Exhaled nitric oxide output;
SARC	cis	rs703842	1.000	rs10877019	chr12:58172929	A/G	cg00599273	chr12:58146742	CDK4	-0.35	-4.79	-0.3	2.97e-6	Multiple sclerosis;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg11988203	chr2:198272801	SF3B1	-0.51	-6.34	-0.38	1.18e-9	Alcohol dependence;
SARC	cis	rs10513788	0.813	rs58615252	chr3:182037427	G/T	cg05977900	chr3:182512126	ATP11B	0.46	4.75	0.3	3.56e-6	Cognitive function;
SARC	cis	rs8060686	0.545	rs3815173	chr16:68160289	T/G	cg27539214	chr16:67997921	SLC12A4	-0.54	-5.03	-0.31	9.6e-7	HDL cholesterol;Metabolic syndrome;
SARC	cis	rs3857536	0.904	rs9345779	chr6:66900989	C/T	cg07460842	chr6:66804631	NA	-0.43	-5.09	-0.32	7.24e-7	Blood trace element (Cu levels);
SARC	cis	rs6088813	0.885	rs6142353	chr20:33942685	G/A	cg14752227	chr20:34000481	UQCC	-0.37	-4.85	-0.3	2.26e-6	Height;
SARC	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg12463550	chr7:65579703	CRCP	0.5	5.9	0.36	1.27e-8	Aortic root size;
SARC	cis	rs2011503	0.882	rs1064395	chr19:19361735	C/T	cg03709012	chr19:19516395	GATAD2A	0.59	5.5	0.34	9.9e-8	Bipolar disorder;
SARC	cis	rs2576037	1.000	rs2576037	chr18:44585420	C/T	cg15049968	chr18:44337910	ST8SIA5	0.32	5.09	0.32	7.4e-7	Personality dimensions;
SARC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg05165339	chr4:1420672	NA	0.25	5.49	0.34	1.07e-7	Longevity;
SARC	cis	rs6835098	1.000	rs28477433	chr4:174085820	T/C	cg08422745	chr4:174089978	GALNT7	-0.77	-10.28	-0.56	1.09e-20	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs4141404	0.577	rs2413045	chr22:31665862	A/G	cg07713946	chr22:31675144	LIMK2	-0.45	-4.72	-0.3	4.08e-6	Paclitaxel-induced neuropathy;
SARC	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg08219700	chr8:58056026	NA	0.58	5.65	0.35	4.7e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2736337	0.530	rs2003422	chr8:11303137	G/C	cg21775007	chr8:11205619	TDH	0.41	4.84	0.3	2.35e-6	Rheumatoid arthritis;
SARC	cis	rs7481584	0.624	rs375579	chr11:3065300	G/C	cg05729581	chr11:3078854	CARS	0.53	6.86	0.41	6.3e-11	Calcium levels;
SARC	cis	rs6815814	0.898	rs73236646	chr4:38871385	T/C	cg06935464	chr4:38784597	TLR10	0.53	5.13	0.32	5.97e-7	Breast cancer;
SARC	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg22535103	chr8:58192502	C8orf71	-0.84	-9.55	-0.53	1.91e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs6496667	0.510	rs16944405	chr15:90975517	A/G	cg22089800	chr15:90895588	ZNF774	0.42	4.87	0.3	2.02e-6	Rheumatoid arthritis;
SARC	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg01181863	chr3:195395398	SDHAP2	-0.59	-6.66	-0.4	1.97e-10	Pancreatic cancer;
SARC	cis	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg25894440	chr7:65020034	NA	-0.62	-4.88	-0.3	2e-6	Diabetic kidney disease;
SARC	cis	rs4690686	0.538	rs4690428	chr4:177263665	C/T	cg17059388	chr4:177262070	NA	0.36	4.78	0.3	3.09e-6	Essential tremor;
SARC	cis	rs6088590	1.000	rs6119516	chr20:33328024	C/T	cg24642439	chr20:33292090	TP53INP2	0.86	12.35	0.63	2.83e-27	Coronary artery disease;
SARC	cis	rs13256369	0.851	rs13255061	chr8:8563834	G/A	cg17143192	chr8:8559678	CLDN23	0.53	5.87	0.36	1.46e-8	Obesity-related traits;
SARC	cis	rs2197308	0.740	rs10880619	chr12:37922720	T/C	cg26384229	chr12:38710491	ALG10B	0.9	13.3	0.66	2.04e-30	Morning vs. evening chronotype;
SARC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg07414643	chr4:187882934	NA	0.51	7.58	0.44	8.37e-13	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs61931739	0.500	rs11836198	chr12:34552782	T/C	cg13010199	chr12:38710504	ALG10B	0.78	11.09	0.59	3.19e-23	Morning vs. evening chronotype;
SARC	cis	rs595982	0.559	rs117227130	chr19:49367959	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.65	-7.34	-0.43	3.65e-12	Red cell distribution width;
SARC	cis	rs10191773	0.535	rs11685514	chr2:113100014	C/T	cg07905836	chr2:113190072	RGPD8;RGPD5	0.92	8.95	0.51	1.18e-16	Yeast infection;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg22529541	chr3:149536976	RNF13	0.45	6.73	0.4	1.3100000000000001e-10	Thyroid stimulating hormone;
SARC	cis	rs1348850	0.668	rs6705405	chr2:178493713	A/G	cg23306229	chr2:178417860	TTC30B	0.6	6.59	0.4	2.94e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs10771431	0.597	rs3759275	chr12:9353828	A/T	cg08997352	chr12:9597637	DDX12	-0.55	-7.51	-0.44	1.29e-12	Breast size;
SARC	cis	rs2072499	0.750	rs2241109	chr1:156173082	C/T	cg24450063	chr1:156163899	SLC25A44	1.09	14.38	0.69	5.4400000000000004e-34	Testicular germ cell tumor;
SARC	cis	rs4148883	0.504	rs4585310	chr4:100120233	T/C	cg12011299	chr4:100065546	ADH4	-0.31	-5.76	-0.35	2.58e-8	Alcohol dependence;
SARC	cis	rs9325144	0.671	rs7485963	chr12:38768254	C/G	cg13010199	chr12:38710504	ALG10B	-0.5	-6.38	-0.39	9.31e-10	Morning vs. evening chronotype;
SARC	cis	rs7607369	0.536	rs13032993	chr2:219666377	T/C	cg02176678	chr2:219576539	TTLL4	-0.4	-6.12	-0.37	3.86e-9	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	20.2	0.8	4.16e-53	Prudent dietary pattern;
SARC	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg11890956	chr21:40555474	PSMG1	1.16	16.53	0.73	3.93e-41	Cognitive function;
SARC	cis	rs7552404	0.628	rs5745442	chr1:76342858	T/G	cg22875332	chr1:76189707	ACADM	0.45	5.39	0.33	1.74e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7769051	1.000	rs9493445	chr6:133125409	C/T	cg22852734	chr6:133119734	C6orf192	1.09	11.3	0.59	6.88e-24	Type 2 diabetes nephropathy;
SARC	trans	rs61931739	1.000	rs1852223	chr12:34013251	C/T	cg26384229	chr12:38710491	ALG10B	-0.57	-7.13	-0.42	1.23e-11	Morning vs. evening chronotype;
SARC	cis	rs796364	0.662	rs11687313	chr2:201146399	G/A	cg23649088	chr2:200775458	C2orf69	-0.64	-5.31	-0.33	2.58e-7	Schizophrenia;
SARC	cis	rs4268898	0.931	rs2111882	chr2:24434424	A/G	cg06627628	chr2:24431161	ITSN2	0.67	9.33	0.52	8.4e-18	Asthma;
SARC	cis	rs2486288	0.656	rs12911186	chr15:45551423	A/G	cg15395560	chr15:45543142	SLC28A2	0.29	5.63	0.35	5.17e-8	Glomerular filtration rate;
SARC	cis	rs7940866	0.804	rs3910267	chr11:130810282	C/T	cg12179176	chr11:130786555	SNX19	0.68	9.81	0.54	3.1e-19	Schizophrenia;
SARC	cis	rs7000551	0.751	rs2449329	chr8:22374794	G/T	cg12081754	chr8:22256438	SLC39A14	0.57	8.08	0.47	3.41e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs2439831	0.717	rs28495368	chr15:43895642	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.93	8.3	0.48	8.35e-15	Lung cancer in ever smokers;
SARC	cis	rs1395	0.744	rs11686131	chr2:27508710	C/T	cg22903471	chr2:27725779	GCKR	-0.39	-4.75	-0.3	3.51e-6	Blood metabolite levels;
SARC	cis	rs9875589	0.509	rs7614591	chr3:14061118	A/T	cg19554555	chr3:13937349	NA	-0.4	-5.14	-0.32	5.95e-7	Ovarian reserve;
SARC	cis	rs6582630	0.502	rs11520261	chr12:38332019	T/G	cg13010199	chr12:38710504	ALG10B	0.77	10.2	0.56	1.95e-20	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg09021430	chr5:549028	NA	-0.45	-5.77	-0.35	2.57e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg11494091	chr17:61959527	GH2	-0.48	-7.29	-0.43	4.76e-12	Prudent dietary pattern;
SARC	trans	rs61931739	0.749	rs11053093	chr12:34231095	A/G	cg26384229	chr12:38710491	ALG10B	0.58	7.84	0.46	1.6e-13	Morning vs. evening chronotype;
SARC	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg18876405	chr7:65276391	NA	-0.66	-8.21	-0.47	1.5e-14	Aortic root size;
SARC	cis	rs9457247	1.000	rs405553	chr6:167395058	A/G	cg07741184	chr6:167504864	NA	0.29	5.49	0.34	1.03e-7	Crohn's disease;
SARC	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg18876405	chr7:65276391	NA	0.68	8.27	0.48	1.05e-14	Aortic root size;
SARC	cis	rs2070488	1.000	rs2268753	chr3:38500189	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	14.64	0.69	7.76e-35	Electrocardiographic conduction measures;
SARC	cis	rs554111	0.571	rs4537519	chr1:21461370	T/C	cg08890418	chr1:21044141	KIF17	-0.38	-5.28	-0.33	2.89e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs72781680	1.000	rs72781667	chr2:24225667	A/G	cg06627628	chr2:24431161	ITSN2	-0.69	-6.64	-0.4	2.22e-10	Lymphocyte counts;
SARC	cis	rs7819412	0.505	rs17726209	chr8:11022185	C/T	cg21775007	chr8:11205619	TDH	0.45	5.77	0.35	2.47e-8	Triglycerides;
SARC	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	11.95	0.62	5.37e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs2295359	1.000	rs4655682	chr1:67610967	C/T	cg12940439	chr1:67600707	NA	0.43	6.83	0.41	7.14e-11	Psoriasis;
SARC	cis	rs7223966	1.000	rs12325866	chr17:61755974	G/A	cg00588841	chr17:61851480	DDX42;CCDC47	-0.62	-6.79	-0.41	9.03e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs3743392	0.665	rs4932449	chr15:89451511	A/G	cg09162909	chr1:10075991	RBP7	0.33	6.29	0.38	1.54e-9	Blood protein levels;
SARC	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg12463550	chr7:65579703	CRCP	0.48	5.23	0.32	3.76e-7	Aortic root size;
SARC	cis	rs2073300	0.609	rs6137939	chr20:23390206	C/T	cg16736954	chr20:23401023	NAPB	-0.79	-4.89	-0.31	1.85e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs2380220	0.720	rs9374178	chr6:95979974	G/T	cg23517279	chr6:96025343	MANEA	0.49	5.61	0.34	5.85e-8	Behavioural disinhibition (generation interaction);
SARC	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg11644478	chr21:40555479	PSMG1	-0.54	-6.57	-0.4	3.24e-10	Menarche (age at onset);
SARC	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg22974920	chr21:40686053	BRWD1	-0.43	-4.85	-0.3	2.22e-6	Cognitive function;
SARC	cis	rs477692	0.699	rs471357	chr10:131389373	C/G	cg14263093	chr10:131365266	MGMT	0.35	5.03	0.31	9.81e-7	Response to temozolomide;
SARC	cis	rs8031584	0.958	rs34909055	chr15:31284170	C/T	cg14829155	chr15:31115871	NA	-0.4	-5.13	-0.32	6.23e-7	Huntington's disease progression;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg21778900	chr17:79237360	SLC38A10	-0.46	-6.36	-0.38	1.06e-9	Chemerin levels;
SARC	cis	rs7824557	0.583	rs6601585	chr8:11233659	A/G	cg21775007	chr8:11205619	TDH	-0.63	-8.37	-0.48	5.21e-15	Retinal vascular caliber;
SARC	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg18404041	chr3:52824283	ITIH1	0.42	6.26	0.38	1.84e-9	Bipolar disorder;
SARC	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg11987759	chr7:65425863	GUSB	-0.47	-6.27	-0.38	1.7e-9	Aortic root size;
SARC	cis	rs10782582	0.609	rs5745430	chr1:76332994	C/T	cg10523679	chr1:76189770	ACADM	-0.42	-5.16	-0.32	5.41e-7	Daytime sleep phenotypes;
SARC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg07414643	chr4:187882934	NA	0.52	7.47	0.44	1.63e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9359856	0.564	rs6914142	chr6:90398903	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.58	-4.75	-0.3	3.52e-6	Bipolar disorder;
SARC	cis	rs1707322	0.752	rs11211171	chr1:46168642	A/G	cg06784218	chr1:46089804	CCDC17	0.36	6.24	0.38	2.03e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs3126085	0.935	rs10888473	chr1:152220235	G/A	cg03465714	chr1:152285911	FLG	-0.44	-5.26	-0.33	3.23e-7	Atopic dermatitis;
SARC	cis	rs13095912	1.000	rs10937226	chr3:185302885	G/A	cg11274856	chr3:185301563	NA	0.35	4.74	0.3	3.77e-6	Systolic blood pressure;
SARC	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.56	-7.26	-0.43	5.58e-12	Mean platelet volume;
SARC	cis	rs6484504	0.532	rs7117286	chr11:31283810	T/A	cg26647111	chr11:31128758	NA	-0.39	-5.12	-0.32	6.53e-7	Red blood cell count;
SARC	cis	rs11122272	0.735	rs11122281	chr1:231519842	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-9.7	-0.54	6.45e-19	Hemoglobin concentration;
SARC	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.5	-5.84	-0.36	1.77e-8	Calcium levels;
SARC	cis	rs7523050	0.908	rs72697202	chr1:109398704	A/G	cg08274380	chr1:109419600	GPSM2	0.79	6.61	0.4	2.55e-10	Fat distribution (HIV);
SARC	cis	rs13191362	1.000	rs35126854	chr6:163012443	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.54	5.29	0.33	2.82e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs1256061	0.646	rs1256056	chr14:64712626	A/G	cg23250157	chr14:64679961	SYNE2	0.49	6.91	0.41	4.53e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs10911232	0.507	rs10911230	chr1:183051118	A/C	cg13390022	chr1:182993471	LAMC1	0.33	5.06	0.31	8.41e-7	Hypertriglyceridemia;
SARC	cis	rs3784262	0.669	rs12905608	chr15:58314139	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.34	-5.14	-0.32	5.77e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs1790761	0.692	rs1269981	chr11:67334959	G/A	cg00290607	chr11:67383545	NA	0.39	5.24	0.32	3.56e-7	Mean corpuscular volume;
SARC	cis	rs644799	0.965	rs11021310	chr11:95502106	A/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	9.56	0.53	1.73e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs7819412	0.623	rs7833435	chr8:10801137	A/G	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.51	-0.39	4.52e-10	Triglycerides;
SARC	cis	rs13256369	0.826	rs7846050	chr8:8575669	A/G	cg17143192	chr8:8559678	CLDN23	0.41	4.81	0.3	2.76e-6	Obesity-related traits;
SARC	cis	rs11690935	0.531	rs62183800	chr2:172867273	C/T	cg13550731	chr2:172543902	DYNC1I2	0.52	6.63	0.4	2.27e-10	Schizophrenia;
SARC	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg00908189	chr16:619842	PIGQ	0.77	10.91	0.58	1.13e-22	Height;
SARC	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg05313129	chr8:58192883	C8orf71	-0.51	-4.81	-0.3	2.65e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs4481887	0.830	rs9662041	chr1:248484701	A/T	cg01631408	chr1:248437212	OR2T33	-0.38	-4.77	-0.3	3.23e-6	Common traits (Other);
SARC	cis	rs2204008	0.576	rs11519979	chr12:37999413	C/T	cg13010199	chr12:38710504	ALG10B	0.78	10.73	0.57	4.45e-22	Bladder cancer;
SARC	cis	rs7178572	0.633	rs12901130	chr15:77848806	C/T	cg22256960	chr15:77711686	NA	-0.45	-4.9	-0.31	1.83e-6	Type 2 diabetes;
SARC	cis	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg13072238	chr3:49761600	GMPPB	-0.64	-5.6	-0.34	5.9e-8	Menarche (age at onset);
SARC	trans	rs2727020	0.729	rs7924782	chr11:49267249	A/G	cg03929089	chr4:120376271	NA	-0.78	-11.18	-0.59	1.61e-23	Coronary artery disease;
SARC	cis	rs2486288	0.656	rs7171312	chr15:45570225	C/G	cg19305227	chr15:45544335	SLC28A2	0.31	5.75	0.35	2.86e-8	Glomerular filtration rate;
SARC	cis	rs3981351	0.797	rs12766891	chr10:115460714	G/A	cg24846397	chr10:115438155	CASP7	-0.37	-4.82	-0.3	2.55e-6	Obesity-related traits;
SARC	cis	rs9325144	0.555	rs2387855	chr12:38687964	T/G	cg13010199	chr12:38710504	ALG10B	0.55	7.22	0.43	7.12e-12	Morning vs. evening chronotype;
SARC	cis	rs9815354	0.812	rs73073233	chr3:42010550	A/G	cg03022575	chr3:42003672	ULK4	0.71	6.03	0.37	6.5e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg26681399	chr22:41777847	TEF	-0.49	-5.34	-0.33	2.16e-7	Vitiligo;
SARC	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg13385521	chr17:29058706	SUZ12P	0.73	5.99	0.37	7.83e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9486719	1.000	rs2499804	chr6:96861216	A/G	cg06623918	chr6:96969491	KIAA0776	0.74	7.81	0.46	1.96e-13	Migraine;Coronary artery disease;
SARC	cis	rs35306767	0.903	rs17159970	chr10:935601	T/C	cg26597838	chr10:835615	NA	0.81	8.33	0.48	6.99e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs9303401	0.659	rs17222523	chr17:56620501	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	12.28	0.63	4.56e-27	Cognitive test performance;
SARC	cis	rs73195822	0.614	rs73194056	chr12:111216325	A/G	cg10860002	chr12:110842031	ANAPC7	0.58	5.07	0.31	8.3e-7	Itch intensity from mosquito bite;
SARC	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg24060327	chr5:131705240	SLC22A5	-0.43	-5.21	-0.32	4.2e-7	Blood metabolite levels;
SARC	cis	rs6964587	0.967	rs6465341	chr7:91596121	G/C	cg17063962	chr7:91808500	NA	0.95	15.95	0.72	3.15e-39	Breast cancer;
SARC	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg10435706	chr6:150039699	LATS1	0.36	4.77	0.3	3.25e-6	Lung cancer;
SARC	cis	rs7029536	0.551	rs11791717	chr9:130173320	T/C	cg09445097	chr9:130186736	ZNF79	0.53	4.99	0.31	1.2e-6	Metabolite levels (HVA);
SARC	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg22968622	chr17:43663579	NA	1.26	17.39	0.75	5.49e-44	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs17376456	0.825	rs10061377	chr5:93174513	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.69	6.03	0.37	6.43e-9	Diabetic retinopathy;
SARC	cis	rs1008375	0.900	rs12650220	chr4:17595365	A/T	cg02297831	chr4:17616191	MED28	0.46	5.69	0.35	3.83e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs629535	0.814	rs72654071	chr8:70079484	A/G	cg21567404	chr3:27674614	NA	-1.06	-13.84	-0.67	3.53e-32	Dupuytren's disease;
SARC	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg08219700	chr8:58056026	NA	0.59	6.27	0.38	1.76e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs736408	0.924	rs2535629	chr3:52833219	C/T	cg18404041	chr3:52824283	ITIH1	-0.47	-6.9	-0.41	4.77e-11	Bipolar disorder;
SARC	cis	rs11676348	0.818	rs6436033	chr2:218983763	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.49	-6.37	-0.38	1.02e-9	Ulcerative colitis;
SARC	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg11987759	chr7:65425863	GUSB	0.46	6.08	0.37	4.9e-9	Aortic root size;
SARC	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg24549020	chr5:56110836	MAP3K1	0.68	6.08	0.37	4.94e-9	Type 2 diabetes;
SARC	cis	rs6429082	0.749	rs3819974	chr1:235601958	G/T	cg26050004	chr1:235667680	B3GALNT2	-0.59	-7.29	-0.43	4.84e-12	Adiposity;
SARC	cis	rs8014204	0.804	rs35769520	chr14:75255115	G/A	cg17347104	chr14:75034677	LTBP2	-0.43	-5.33	-0.33	2.33e-7	Caffeine consumption;
SARC	cis	rs13082711	0.911	rs6777272	chr3:27488310	T/G	cg02860705	chr3:27208620	NA	0.49	6.3	0.38	1.43e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs2694528	0.844	rs4699961	chr5:60073219	A/T	cg11474532	chr5:59995715	DEPDC1B	0.75	5.21	0.32	4.06e-7	Parkinson's disease;
SARC	cis	rs3617	0.625	rs6445541	chr3:52880128	G/T	cg18404041	chr3:52824283	ITIH1	-0.36	-5.33	-0.33	2.34e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs12134245	0.747	rs11164929	chr1:92012836	G/C	cg02896835	chr1:92012615	NA	-0.57	-7.89	-0.46	1.18e-13	Breast cancer;
SARC	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg12373951	chr3:133503437	NA	0.43	6.11	0.37	4.1e-9	Iron status biomarkers;
SARC	cis	rs3733346	0.553	rs2290403	chr4:942006	G/A	cg20916646	chr4:852691	GAK	0.48	6.59	0.4	2.94e-10	Sjögren's syndrome;
SARC	cis	rs2204008	0.570	rs1315664	chr12:38138274	A/G	cg13010199	chr12:38710504	ALG10B	-0.61	-7.68	-0.45	4.42e-13	Bladder cancer;
SARC	cis	rs6831352	0.959	rs6848050	chr4:100053733	T/C	cg12011299	chr4:100065546	ADH4	0.34	6.0	0.37	7.51e-9	Alcohol dependence;
SARC	trans	rs1814175	0.645	rs6486022	chr11:49776137	A/G	cg15704280	chr7:45808275	SEPT13	-0.88	-13.89	-0.67	2.29e-32	Height;
SARC	cis	rs17125944	0.505	rs75194546	chr14:53212069	A/C	cg13660082	chr14:53194042	PSMC6	-0.75	-4.76	-0.3	3.41e-6	Alzheimer's disease (late onset);
SARC	cis	rs6456156	0.586	rs2345753	chr6:167484344	T/A	cg23791538	chr6:167370224	RNASET2	-0.53	-6.99	-0.42	2.86e-11	Primary biliary cholangitis;
SARC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg07157834	chr1:205819609	PM20D1	0.71	11.0	0.58	6.18e-23	Menarche (age at onset);
SARC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg10862848	chr6:42927986	GNMT	-0.44	-7.33	-0.43	3.83e-12	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs2153535	0.580	rs9393016	chr6:8458573	T/A	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.04e-14	Motion sickness;
SARC	cis	rs929354	0.553	rs34498858	chr7:156931337	T/C	cg05182265	chr7:156933206	UBE3C	-0.33	-5.18	-0.32	4.76e-7	Body mass index;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg22913584	chr5:81046758	SSBP2	0.62	8.08	0.47	3.59e-14	Breast cancer;
SARC	trans	rs34421088	0.560	rs2248699	chr8:11393764	A/G	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.6	-0.4	2.81e-10	Neuroticism;
SARC	cis	rs9902453	0.808	rs56216220	chr17:28209182	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	7.05	0.42	2.07e-11	Coffee consumption (cups per day);
SARC	cis	rs2120019	0.505	rs77456790	chr15:75330095	G/T	cg17294928	chr15:75287854	SCAMP5	-1.16	-9.18	-0.52	2.38e-17	Blood trace element (Zn levels);
SARC	cis	rs11770686	0.766	rs10954317	chr7:75327352	A/C	cg17787366	chr7:75369077	HIP1	-0.42	-5.11	-0.32	6.68e-7	Essential tremor;
SARC	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.03	12.03	0.62	3.06e-26	Alzheimer's disease;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg12362369	chr4:140098382	NA	-0.53	-6.98	-0.42	3.07e-11	Electrocardiographic conduction measures;
SARC	cis	rs721399	0.539	rs2410561	chr8:18266774	G/A	cg18736775	chr8:18248649	NAT2	-0.57	-5.66	-0.35	4.39e-8	Blood metabolite levels;
SARC	cis	rs2180341	0.782	rs6924274	chr6:127721556	T/A	cg24812749	chr6:127587940	RNF146	0.72	9.64	0.53	1.02e-18	Breast cancer;
SARC	cis	rs4466137	1.000	rs4466137	chr5:82985739	A/C	cg16102102	chr5:83017553	HAPLN1	-0.75	-9.5	-0.53	2.66e-18	Prostate cancer;
SARC	cis	rs6582630	0.576	rs2222345	chr12:38356020	G/A	cg26384229	chr12:38710491	ALG10B	-0.58	-7.16	-0.42	1.08e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7584330	0.666	rs7600317	chr2:238353513	C/T	cg14458575	chr2:238380390	NA	0.53	6.11	0.37	4.09e-9	Prostate cancer;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg04005843	chr5:1462820	LPCAT1	-0.49	-6.47	-0.39	5.85e-10	Height;
SARC	cis	rs10465746	0.780	rs6703493	chr1:84435812	G/A	cg10977910	chr1:84465055	TTLL7	0.45	5.54	0.34	8.33e-8	Obesity-related traits;
SARC	cis	rs477692	0.563	rs12266634	chr10:131412659	G/C	cg05714579	chr10:131428358	MGMT	-0.71	-9.8	-0.54	3.19e-19	Response to temozolomide;
SARC	cis	rs7178572	0.568	rs11636554	chr15:77608747	C/T	cg22256960	chr15:77711686	NA	-0.5	-5.45	-0.34	1.26e-7	Type 2 diabetes;
SARC	cis	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg26513180	chr16:89883248	FANCA	0.72	4.79	0.3	2.99e-6	Skin colour saturation;
SARC	cis	rs2467099	1.000	rs2467099	chr17:73949045	C/T	cg06969265	chr17:73775802	H3F3B	0.65	6.83	0.41	7.51e-11	Systolic blood pressure;
SARC	cis	rs73242632	1.000	rs2227902	chr4:57797100	G/T	cg20415529	chr4:57845134	POLR2B;C4orf14	0.99	5.73	0.35	3.07e-8	Congenital heart disease (maternal effect);
SARC	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	10.82	0.58	2.26e-22	Platelet count;
SARC	cis	rs9910055	0.530	rs2269905	chr17:42294462	A/G	cg19774624	chr17:42201019	HDAC5	-0.49	-6.67	-0.4	1.84e-10	Total body bone mineral density;
SARC	cis	rs1729951	0.575	rs361241	chr3:136699561	C/A	cg15507776	chr3:136538369	TMEM22	0.49	5.34	0.33	2.24e-7	Neuroticism;
SARC	cis	rs7937682	0.883	rs11213941	chr11:111434094	T/C	cg09085632	chr11:111637200	PPP2R1B	0.88	12.68	0.64	2.22e-28	Primary sclerosing cholangitis;
SARC	cis	rs2529049	0.606	rs2721780	chr7:24728563	A/G	cg17569154	chr7:24781545	DFNA5	0.46	6.53	0.39	4.11e-10	Urate levels in obese individuals;
SARC	cis	rs9905704	0.647	rs12940492	chr17:56954655	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.4	-4.89	-0.3	1.89e-6	Testicular germ cell tumor;
SARC	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs35213789	0.708	rs2533431	chr7:69152022	T/A	cg10619644	chr7:69149951	AUTS2	-0.35	-4.82	-0.3	2.57e-6	Childhood ear infection;
SARC	cis	rs681343	1.000	rs681343	chr19:49206462	C/T	cg21064579	chr19:49206444	FUT2	0.35	4.94	0.31	1.51e-6	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
SARC	cis	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg02487422	chr3:49467188	NICN1	0.5	6.85	0.41	6.52e-11	Resting heart rate;
SARC	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs3796352	0.881	rs34238610	chr3:53026480	A/T	cg12962167	chr3:53033115	SFMBT1	0.82	5.4	0.33	1.61e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg01238044	chr22:24384105	GSTT1	0.59	6.67	0.4	1.87e-10	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs3857536	0.904	rs9345775	chr6:66885729	T/G	cg07460842	chr6:66804631	NA	-0.46	-5.35	-0.33	2.11e-7	Blood trace element (Cu levels);
SARC	cis	rs898097	0.801	rs68141193	chr17:80878816	C/T	cg15664640	chr17:80829946	TBCD	-0.49	-7.39	-0.44	2.64e-12	Breast cancer;
SARC	cis	rs11574514	1.000	rs62636658	chr16:67855107	C/T	cg01866162	chr16:67596514	CTCF	1.12	6.46	0.39	5.91e-10	Crohn's disease;
SARC	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs644799	1.000	rs534497	chr11:95562868	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.9	14.03	0.68	7.82e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2204008	0.536	rs12368354	chr12:38042798	G/A	cg26384229	chr12:38710491	ALG10B	0.89	13.1	0.65	9.74e-30	Bladder cancer;
SARC	cis	rs3126085	0.935	rs7534716	chr1:152198654	A/G	cg03465714	chr1:152285911	FLG	-0.44	-5.3	-0.33	2.67e-7	Atopic dermatitis;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg08166600	chr1:165083715	NA	-0.58	-6.65	-0.4	2.08e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs6426558	0.537	rs7523167	chr1:227365304	G/A	cg10327440	chr1:227177885	CDC42BPA	-0.41	-4.78	-0.3	3.09e-6	Neutrophil percentage of white cells;
SARC	cis	rs787274	0.764	rs787299	chr9:115542369	A/G	cg13803584	chr9:115635662	SNX30	-0.83	-5.06	-0.31	8.34e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs7395581	0.959	rs35879051	chr11:47275882	C/G	cg25783544	chr11:47291846	MADD	0.48	5.02	0.31	1.02e-6	HDL cholesterol;
SARC	cis	rs1707322	0.963	rs6429581	chr1:46319096	G/A	cg06784218	chr1:46089804	CCDC17	0.35	6.12	0.37	3.89e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs854765	0.583	rs9913724	chr17:17819101	A/G	cg04398451	chr17:18023971	MYO15A	-0.37	-5.29	-0.33	2.76e-7	Total body bone mineral density;
SARC	cis	rs1538970	0.816	rs9727262	chr1:45998579	T/G	cg05343316	chr1:45956843	TESK2	0.84	9.23	0.52	1.76e-17	Platelet count;
SARC	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2075371	0.835	rs1646724	chr7:134001875	T/G	cg20476274	chr7:133979776	SLC35B4	0.57	7.44	0.44	1.97e-12	Mean platelet volume;
SARC	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.62	7.52	0.44	1.14e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.62	-6.73	-0.4	1.29e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs497273	0.534	rs9431	chr12:121202664	A/C	cg02403541	chr12:121454288	C12orf43	0.44	5.3	0.33	2.62e-7	Systemic lupus erythematosus;
SARC	cis	rs17270561	0.609	rs7450798	chr6:25719280	T/A	cg17691542	chr6:26056736	HIST1H1C	0.59	7.21	0.43	7.66e-12	Iron status biomarkers;
SARC	cis	rs6693567	0.565	rs1260458	chr1:150347454	C/T	cg09579323	chr1:150459698	TARS2	0.45	5.83	0.36	1.83e-8	Migraine;
SARC	cis	rs60733400	0.818	rs10909839	chr1:2708430	G/A	cg18854424	chr1:2615690	NA	0.32	5.2	0.32	4.37e-7	Multiple sclerosis;
SARC	cis	rs4478037	0.822	rs9865342	chr3:33118631	G/A	cg19404215	chr3:33155277	CRTAP	0.72	5.86	0.36	1.6e-8	Major depressive disorder;
SARC	cis	rs7246760	0.867	rs59616842	chr19:9792245	G/A	cg16876255	chr19:9731953	ZNF561	0.82	5.05	0.31	8.72e-7	Pursuit maintenance gain;
SARC	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg20607798	chr8:58055168	NA	0.73	6.16	0.37	3.22e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2834188	0.924	rs2850015	chr21:34697264	T/C	cg04842828	chr21:34696676	IFNAR1	0.41	4.8	0.3	2.84e-6	Narcolepsy;
SARC	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg11764359	chr7:65958608	NA	0.78	9.86	0.54	2.14e-19	Aortic root size;
SARC	cis	rs317689	0.718	rs645026	chr12:69757931	G/A	cg20891283	chr12:69753455	YEATS4	0.49	5.62	0.35	5.33e-8	Response to diuretic therapy;
SARC	cis	rs7617773	0.501	rs12185901	chr3:48382919	G/T	cg11946769	chr3:48343235	NME6	0.55	6.76	0.4	1.11e-10	Coronary artery disease;
SARC	cis	rs9388451	0.626	rs9385383	chr6:126086290	G/T	cg06289844	chr6:126071538	HEY2	0.33	5.21	0.32	4.09e-7	Brugada syndrome;
SARC	cis	rs8114671	0.562	rs4911449	chr20:33512236	T/G	cg07148914	chr20:33460835	GGT7	0.43	5.32	0.33	2.48e-7	Height;
SARC	cis	rs10463554	0.963	rs26254	chr5:102556859	A/G	cg23492399	chr5:102201601	PAM	-0.47	-5.19	-0.32	4.55e-7	Parkinson's disease;
SARC	cis	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg13472882	chr9:72287821	APBA1	0.41	4.88	0.3	1.94e-6	Migraine with aura;
SARC	cis	rs12155623	0.619	rs870397	chr8:49861225	C/T	cg22283653	chr8:49824208	NA	0.35	5.02	0.31	1.05e-6	Sudden cardiac arrest;
SARC	trans	rs6934651	0.529	rs62420062	chr6:85936681	C/T	cg04848555	chr14:53975804	NA	0.65	6.33	0.38	1.25e-9	Breast cancer;
SARC	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.3	-0.38	1.47e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7712401	0.601	rs371604	chr5:122318432	C/T	cg19412675	chr5:122181750	SNX24	-0.43	-5.47	-0.34	1.15e-7	Mean platelet volume;
SARC	cis	rs9303401	0.659	rs7210432	chr17:56668170	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.09	12.25	0.63	5.64e-27	Cognitive test performance;
SARC	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg08280861	chr8:58055591	NA	0.57	5.47	0.34	1.14e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9513627	0.833	rs73556129	chr13:100113167	C/T	cg25919922	chr13:100150906	NA	-0.77	-5.25	-0.33	3.48e-7	Obesity-related traits;
SARC	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg17971929	chr21:40555470	PSMG1	-0.56	-7.07	-0.42	1.81e-11	Menarche (age at onset);
SARC	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg11764359	chr7:65958608	NA	-0.76	-8.84	-0.5	2.4e-16	Aortic root size;
SARC	cis	rs13191362	0.935	rs7769048	chr6:163010040	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.5	0.34	1.01e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs6580649	0.941	rs72644843	chr12:48465061	A/G	cg05342945	chr12:48394962	COL2A1	0.56	6.03	0.37	6.35e-9	Lung cancer;
SARC	cis	rs12364620	1	rs12364620	chr11:68252123	T/G	cg01657329	chr11:68192670	LRP5	-0.4	-4.83	-0.3	2.42e-6	Total body bone mineral density (age 0-15);
SARC	cis	rs2425143	1.000	rs1970357	chr20:34339200	A/G	cg01084648	chr20:34329383	RBM39	-0.62	-4.94	-0.31	1.47e-6	Blood protein levels;
SARC	trans	rs17685	0.712	rs28456330	chr7:75810542	A/G	cg19862616	chr7:65841803	NCRNA00174	0.62	7.65	0.45	5.44e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs858239	0.601	rs6461702	chr7:23249273	C/G	cg23682824	chr7:23144976	KLHL7	0.66	8.28	0.48	9.89e-15	Cerebrospinal fluid biomarker levels;
SARC	cis	rs854765	0.647	rs721669	chr17:18005073	A/G	cg04398451	chr17:18023971	MYO15A	-0.59	-8.54	-0.49	1.79e-15	Total body bone mineral density;
SARC	cis	rs888194	1.000	rs888194	chr12:109986918	C/G	cg08884029	chr12:110012500	MVK;MMAB	-0.32	-4.79	-0.3	2.98e-6	Neuroticism;
SARC	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg05861140	chr6:150128134	PCMT1	-0.37	-4.88	-0.3	2.01e-6	Lung cancer;
SARC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg06873352	chr17:61820015	STRADA	0.53	6.81	0.41	8.27e-11	Prudent dietary pattern;
SARC	cis	rs782590	0.774	rs782629	chr2:55900283	C/T	cg18811423	chr2:55921094	PNPT1	-0.66	-9.88	-0.54	1.92e-19	Metabolic syndrome;
SARC	cis	rs8031584	0.918	rs35396566	chr15:31263057	T/C	cg19680485	chr15:31195859	MTMR15	-0.52	-5.44	-0.34	1.34e-7	Huntington's disease progression;
SARC	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.45	-5.55	-0.34	7.8e-8	Systemic lupus erythematosus;
SARC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg09373136	chr17:61933544	TCAM1	-0.45	-6.12	-0.37	3.83e-9	Prudent dietary pattern;
SARC	cis	rs11971779	0.680	rs6961812	chr7:139043808	A/C	cg23387468	chr7:139079360	LUC7L2	0.33	4.71	0.3	4.2e-6	Diisocyanate-induced asthma;
SARC	cis	rs7103648	0.864	rs10742802	chr11:47432725	T/G	cg20307385	chr11:47447363	PSMC3	0.87	14.78	0.7	2.51e-35	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs1707322	0.752	rs4660880	chr1:46111040	C/T	cg03146154	chr1:46216737	IPP	0.56	6.78	0.41	9.75e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4509693	1.000	rs4917908	chr10:102502674	G/C	cg15234845	chr10:102496500	NA	0.32	4.86	0.3	2.13e-6	Alzheimer's disease;
SARC	cis	rs2797160	1.000	rs6904069	chr6:125995134	C/T	cg05901451	chr6:126070800	HEY2	-0.39	-4.73	-0.3	3.88e-6	Endometrial cancer;
SARC	cis	rs9435341	0.929	rs1730865	chr1:107605611	A/C	cg09367891	chr1:107599246	PRMT6	0.7	8.36	0.48	5.89e-15	Facial morphology (factor 21, depth of nasal alae);
SARC	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.69	-8.9	-0.5	1.61e-16	Chronic sinus infection;
SARC	cis	rs4846580	0.901	rs12134534	chr1:219926009	T/C	cg08034750	chr1:219919793	NA	0.34	4.94	0.31	1.51e-6	Total body bone mineral density;
SARC	cis	rs9788682	0.748	rs667282	chr15:78863472	T/C	cg06917634	chr15:78832804	PSMA4	-0.5	-5.61	-0.35	5.63e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs10484885	0.878	rs55750696	chr6:90552336	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.61	-5.23	-0.32	3.71e-7	QRS interval (sulfonylurea treatment interaction);
SARC	cis	rs13006833	0.668	rs291458	chr2:191181481	A/C	cg25963032	chr2:191064776	C2orf88	0.38	5.38	0.33	1.79e-7	Urinary metabolites;
SARC	cis	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg13072238	chr3:49761600	GMPPB	0.42	5.54	0.34	8.33e-8	Intelligence (multi-trait analysis);
SARC	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.75	9.98	0.55	9.05e-20	Chronic sinus infection;
SARC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg23034840	chr1:205782522	SLC41A1	0.6	7.47	0.44	1.58e-12	Menarche (age at onset);
SARC	cis	rs796364	0.806	rs79156935	chr2:200913822	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-6.62	-0.4	2.51e-10	Schizophrenia;
SARC	cis	rs826838	0.967	rs34496261	chr12:39023829	G/A	cg26384229	chr12:38710491	ALG10B	0.91	14.26	0.68	1.38e-33	Heart rate;
SARC	cis	rs9487051	0.676	rs9372208	chr6:109596168	A/G	cg01475377	chr6:109611718	NA	-0.35	-5.08	-0.32	7.8e-7	Reticulocyte fraction of red cells;
SARC	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg18876405	chr7:65276391	NA	-0.56	-6.99	-0.42	2.81e-11	Calcium levels;
SARC	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.35	4.85	0.3	2.28e-6	Total body bone mineral density;
SARC	cis	rs8014204	0.806	rs11159104	chr14:75293374	A/G	cg06637938	chr14:75390232	RPS6KL1	0.69	9.83	0.54	2.62e-19	Caffeine consumption;
SARC	cis	rs698833	0.828	rs2850298	chr2:44731590	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.68	8.27	0.48	1.02e-14	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs112591243	0.685	rs74671132	chr21:47963485	T/C	cg10657630	chr21:48055338	PRMT2	0.82	5.2	0.32	4.39e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs1023500	0.573	rs1807494	chr22:42474138	C/G	cg04733989	chr22:42467013	NAGA	-0.76	-10.7	-0.57	5.23e-22	Schizophrenia;
SARC	cis	rs1008375	1.000	rs10805357	chr4:17652352	G/A	cg27347728	chr4:17578864	LAP3	0.47	5.88	0.36	1.42e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs651907	0.557	rs13066768	chr3:101486920	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.51	-6.14	-0.37	3.57e-9	Colorectal cancer;
SARC	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg15556689	chr8:8085844	FLJ10661	-0.48	-5.91	-0.36	1.18e-8	Mood instability;
SARC	cis	rs10876993	0.928	rs1689596	chr12:58053029	T/C	cg18357645	chr12:58087776	OS9	0.51	6.77	0.41	1.06e-10	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs11585357	0.843	rs113593167	chr1:17613355	G/A	cg08277548	chr1:17600880	PADI3	-0.5	-5.52	-0.34	8.92e-8	Hair shape;
SARC	cis	rs2153535	0.526	rs1796689	chr6:8536433	A/C	cg23788917	chr6:8435910	SLC35B3	0.62	8.19	0.47	1.68e-14	Motion sickness;
SARC	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg00933542	chr6:150070202	PCMT1	0.34	5.53	0.34	8.56e-8	Lung cancer;
SARC	cis	rs897984	0.683	rs13337900	chr16:30822409	G/A	cg00531865	chr16:30841666	NA	-0.49	-5.76	-0.35	2.6e-8	Dementia with Lewy bodies;
SARC	cis	rs1113500	0.862	rs3853494	chr1:108637334	G/A	cg06207961	chr1:108661230	NA	0.44	5.9	0.36	1.29e-8	Growth-regulated protein alpha levels;
SARC	cis	rs6088590	0.965	rs6087619	chr20:33288511	C/G	cg06115741	chr20:33292138	TP53INP2	0.52	6.25	0.38	1.99e-9	Coronary artery disease;
SARC	cis	rs916888	0.610	rs199530	chr17:44836653	C/T	cg01570182	chr17:44337453	NA	-0.65	-7.86	-0.46	1.38e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg10560079	chr2:191398806	TMEM194B	0.65	9.53	0.53	2.16e-18	Pulse pressure;
SARC	cis	rs36051895	0.632	rs7029084	chr9:5174638	T/C	cg02405213	chr9:5042618	JAK2	-0.44	-5.28	-0.33	3.01e-7	Pediatric autoimmune diseases;
SARC	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg00933542	chr6:150070202	PCMT1	0.33	5.63	0.35	5.13e-8	Lung cancer;
SARC	cis	rs644799	1.000	rs586498	chr11:95537828	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	15.35	0.71	3.21e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9322193	0.566	rs9397070	chr6:150243209	T/C	cg11878867	chr6:150167359	LRP11	0.39	4.83	0.3	2.44e-6	Lung cancer;
SARC	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg19318889	chr4:1322082	MAEA	0.4	4.77	0.3	3.23e-6	Longevity;
SARC	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.98	11.33	0.6	5.52e-24	Platelet count;
SARC	trans	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg21659725	chr3:3221576	CRBN	-0.79	-11.96	-0.62	5.19e-26	Intelligence (multi-trait analysis);
SARC	cis	rs72781680	0.898	rs17762609	chr2:24114729	G/T	cg08917208	chr2:24149416	ATAD2B	0.79	7.73	0.45	3.15e-13	Lymphocyte counts;
SARC	cis	rs6964587	0.620	rs7808587	chr7:91620096	G/A	cg17063962	chr7:91808500	NA	0.84	12.82	0.64	8.13e-29	Breast cancer;
SARC	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg13939156	chr17:80058883	NA	-0.38	-5.85	-0.36	1.62e-8	Life satisfaction;
SARC	cis	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg24110177	chr3:50126178	RBM5	0.38	4.87	0.3	2.11e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7666738	0.830	rs10021044	chr4:99002488	A/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs933688	0.938	rs7708782	chr5:90718517	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.03	13.23	0.65	3.53e-30	Smoking behavior;
SARC	cis	rs2204008	0.818	rs7313608	chr12:38383428	C/A	cg13010199	chr12:38710504	ALG10B	-0.72	-9.94	-0.55	1.26e-19	Bladder cancer;
SARC	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg12257692	chr3:49977190	RBM6	0.28	4.98	0.31	1.23e-6	Body mass index;
SARC	cis	rs4280164	0.830	rs2144494	chr14:24773387	T/C	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.58	-5.46	-0.34	1.24e-7	Parent of origin effect on language impairment (paternal);
SARC	cis	rs8141529	0.748	rs5762882	chr22:29290680	C/A	cg02153584	chr22:29168773	CCDC117	0.76	10.97	0.58	7.54e-23	Lymphocyte counts;
SARC	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg11987759	chr7:65425863	GUSB	-0.5	-5.94	-0.36	1e-8	Aortic root size;
SARC	cis	rs72945132	0.562	rs7951959	chr11:70234272	A/G	cg00319359	chr11:70116639	PPFIA1	0.56	5.19	0.32	4.56e-7	Coronary artery disease;
SARC	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg11062466	chr8:58055876	NA	0.54	5.51	0.34	9.41e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7766436	0.621	rs2294825	chr6:22597820	G/T	cg13666174	chr6:22585274	NA	0.52	7.22	0.43	7.46e-12	Coronary artery disease;
SARC	cis	rs514406	0.505	rs427319	chr1:53178807	T/G	cg24675658	chr1:53192096	ZYG11B	-0.66	-9.69	-0.54	7.19e-19	Monocyte count;
SARC	cis	rs7666738	0.716	rs2865982	chr4:99031661	T/G	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg12667521	chr19:29218732	NA	0.4	5.36	0.33	1.95e-7	Methadone dose in opioid dependence;
SARC	cis	rs7546	0.501	rs12102426	chr16:4922450	T/G	cg08329684	chr16:4932620	PPL	0.38	5.99	0.37	7.77e-9	Cancer;
SARC	cis	rs9303401	0.625	rs34963822	chr17:56988424	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.07	12.11	0.62	1.62e-26	Cognitive test performance;
SARC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.69	0.54	7.32e-19	Prudent dietary pattern;
SARC	cis	rs9457247	1.000	rs421214	chr6:167396629	A/G	cg23791538	chr6:167370224	RNASET2	-0.63	-8.73	-0.5	4.86e-16	Crohn's disease;
SARC	cis	rs4660306	1.000	rs11211132	chr1:45990516	T/C	cg24296786	chr1:45957014	TESK2	0.58	6.79	0.41	9.22e-11	Homocysteine levels;
SARC	cis	rs6942407	0.543	rs739712	chr7:86746798	G/A	cg02420886	chr7:86849541	C7orf23	0.59	5.41	0.33	1.55e-7	Food allergy;
SARC	cis	rs6700896	0.931	rs4655584	chr1:66155515	T/G	cg04111102	chr1:66153794	NA	0.37	5.56	0.34	7.44e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	trans	rs11098499	0.955	rs13113112	chr4:120156040	C/T	cg25214090	chr10:38739885	LOC399744	0.53	6.97	0.42	3.18e-11	Corneal astigmatism;
SARC	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg18305652	chr10:134549665	INPP5A	0.36	5.24	0.32	3.66e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs1949733	0.656	rs2688243	chr4:8436286	A/G	cg13073564	chr4:8508604	NA	-0.37	-5.73	-0.35	3.05e-8	Response to antineoplastic agents;
SARC	cis	rs2290720	0.798	rs10778114	chr12:101745285	G/A	cg22051763	chr12:101673672	UTP20	-0.46	-5.55	-0.34	7.78e-8	Brain structure (hippocampal volume);
SARC	cis	rs4713118	0.513	rs149878	chr6:27878738	T/G	cg17221315	chr6:27791827	HIST1H4J	0.45	4.97	0.31	1.32e-6	Parkinson's disease;
SARC	cis	rs12545109	0.800	rs990301	chr8:57406021	G/C	cg21220214	chr8:57350948	NA	-0.41	-4.82	-0.3	2.63e-6	Obesity-related traits;
SARC	cis	rs2180341	0.521	rs12189967	chr6:127718058	G/A	cg27446573	chr6:127587934	RNF146	0.49	6.1	0.37	4.31e-9	Breast cancer;
SARC	cis	rs5757676	0.858	rs6001585	chr22:39812986	G/T	cg24399712	chr22:39784796	NA	-0.42	-5.16	-0.32	5.25e-7	IgG glycosylation;
SARC	cis	rs9457247	1.000	rs10946199	chr6:167404492	G/A	cg07741184	chr6:167504864	NA	0.29	5.55	0.34	7.72e-8	Crohn's disease;
SARC	cis	rs7940866	0.804	rs10894287	chr11:130808483	C/T	cg12179176	chr11:130786555	SNX19	0.65	9.21	0.52	1.99e-17	Schizophrenia;
SARC	cis	rs9788682	0.747	rs2568488	chr15:78736593	T/A	cg24631222	chr15:78858424	CHRNA5	-0.77	-9.54	-0.53	1.96e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs1881797	1.000	rs1881794	chr1:247682920	G/C	cg05639522	chr1:247681581	NA	-0.43	-4.83	-0.3	2.53e-6	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg18876405	chr7:65276391	NA	0.49	6.05	0.37	5.73e-9	Aortic root size;
SARC	cis	rs34172651	0.687	rs8044992	chr16:24811207	T/C	cg04756594	chr16:24857601	SLC5A11	0.38	6.0	0.37	7.67e-9	Intelligence (multi-trait analysis);
SARC	cis	rs1801251	0.963	rs35395584	chr2:233573698	G/C	cg25237894	chr2:233734115	C2orf82	0.36	4.73	0.3	3.97e-6	Coronary artery disease;
SARC	cis	rs7223966	0.883	rs2955250	chr17:61959740	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.47	5.04	0.31	9.25e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg06212747	chr3:49208901	KLHDC8B	0.72	9.88	0.54	1.89e-19	Parkinson's disease;
SARC	cis	rs2213920	0.749	rs7467654	chr9:118253677	C/T	cg13918206	chr9:118159781	DEC1	0.84	6.55	0.39	3.64e-10	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.45	-5.79	-0.35	2.25e-8	Personality dimensions;
SARC	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg16325326	chr1:53192061	ZYG11B	0.78	12.04	0.62	2.7e-26	Monocyte count;
SARC	cis	rs765787	0.530	rs2458224	chr15:45522130	T/C	cg24006582	chr15:45444508	DUOX1	-0.5	-6.41	-0.39	8.17e-10	Uric acid levels;
SARC	cis	rs2276314	0.857	rs28530656	chr18:33588700	C/T	cg05985134	chr18:33552581	C18orf21	-0.62	-6.75	-0.4	1.17e-10	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs4891159	0.548	rs11150952	chr18:74128188	T/C	cg24786174	chr18:74118243	ZNF516	0.72	12.17	0.62	1.09e-26	Longevity;
SARC	cis	rs698833	0.509	rs56202458	chr2:44765856	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.4	5.02	0.31	1.05e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.67	0.54	7.99e-19	Prudent dietary pattern;
SARC	cis	rs7980687	0.574	rs10744149	chr12:123708490	T/A	cg00376283	chr12:123451042	ABCB9	0.52	6.13	0.37	3.71e-9	Height;Educational attainment;Head circumference (infant);
SARC	cis	rs9467711	0.606	rs9358939	chr6:26416787	C/G	cg12826209	chr6:26865740	GUSBL1	0.8	4.92	0.31	1.62e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg22535103	chr8:58192502	C8orf71	-0.6	-6.33	-0.38	1.24e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9457247	0.646	rs4710160	chr6:167409241	T/A	cg23791538	chr6:167370224	RNASET2	-0.6	-8.22	-0.47	1.39e-14	Crohn's disease;
SARC	cis	rs7578035	0.500	rs17021941	chr2:99384299	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.45	-5.15	-0.32	5.56e-7	Bipolar disorder;
SARC	trans	rs7824557	0.583	rs6601585	chr8:11233659	A/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.68	-0.4	1.77e-10	Retinal vascular caliber;
SARC	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg23758822	chr17:41437982	NA	0.91	11.43	0.6	2.63e-24	Menopause (age at onset);
SARC	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg26335602	chr6:28129616	ZNF389	0.53	5.88	0.36	1.43e-8	Depression;
SARC	cis	rs3762637	0.941	rs9810999	chr3:122074391	G/A	cg24169773	chr3:122142474	KPNA1	-0.53	-5.13	-0.32	5.96e-7	LDL cholesterol levels;
SARC	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg11843238	chr5:131593191	PDLIM4	-0.42	-5.12	-0.32	6.4e-7	Breast cancer;
SARC	trans	rs11250097	0.549	rs11778177	chr8:11310362	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.66	-0.4	1.97e-10	Neuroticism;
SARC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.46	0.57	3.12e-21	Prudent dietary pattern;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg15202251	chr7:100183972	FBXO24;LRCH4	-0.49	-6.27	-0.38	1.77e-9	Chemerin levels;
SARC	cis	rs9399137	0.507	rs6940258	chr6:135366132	C/T	cg22676075	chr6:135203613	NA	0.39	4.96	0.31	1.34e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	trans	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.58	-0.44	8.27e-13	Neuroticism;
SARC	cis	rs7474896	0.515	rs2738208	chr10:38306128	A/G	cg25427524	chr10:38739819	LOC399744	0.44	5.45	0.34	1.28e-7	Obesity (extreme);
SARC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg13397359	chr6:42928475	GNMT	0.57	7.94	0.46	8.64e-14	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs11098499	0.754	rs1980027	chr4:120251577	C/T	cg09307838	chr4:120376055	NA	0.83	11.34	0.6	5.05e-24	Corneal astigmatism;
SARC	cis	rs11711311	0.955	rs7617313	chr3:113391740	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	8.19	0.47	1.72e-14	IgG glycosylation;
SARC	cis	rs3820928	1.000	rs3731593	chr2:227773924	A/G	cg11843606	chr2:227700838	RHBDD1	-0.56	-7.34	-0.43	3.47e-12	Pulmonary function;
SARC	cis	rs1983891	1.000	rs9381080	chr6:41527698	G/C	cg15051332	chr6:41514432	FOXP4	0.54	6.0	0.37	7.67e-9	Prostate cancer;
SARC	cis	rs4319547	0.697	rs7974262	chr12:122896385	C/T	cg23029597	chr12:123009494	RSRC2	0.42	5.21	0.32	4.18e-7	Body mass index;
SARC	cis	rs2011503	0.941	rs55762233	chr19:19367319	C/G	cg03709012	chr19:19516395	GATAD2A	0.59	5.33	0.33	2.33e-7	Bipolar disorder;
SARC	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg14895029	chr7:2775587	GNA12	0.37	4.8	0.3	2.78e-6	Height;
SARC	trans	rs7824557	0.564	rs7834572	chr8:11236685	C/T	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.72	-0.5	5.49e-16	Retinal vascular caliber;
SARC	cis	rs7833986	0.501	rs2667983	chr8:56894087	T/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.68	6.78	0.41	1e-10	Height;
SARC	cis	rs72627123	0.867	rs17094448	chr14:74440119	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.73	5.53	0.34	8.48e-8	Morning vs. evening chronotype;
SARC	trans	rs9354308	0.866	rs2814095	chr6:66535706	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.58	6.74	0.4	1.23e-10	Metabolite levels;
SARC	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.88e-8	Aortic root size;
SARC	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg00684032	chr4:1343700	KIAA1530	0.35	5.15	0.32	5.53e-7	Obesity-related traits;
SARC	cis	rs13314892	0.764	rs62252219	chr3:69882748	T/C	cg17445875	chr3:69859618	MITF	-0.49	-5.13	-0.32	6.2e-7	QRS complex (12-leadsum);
SARC	cis	rs6138458	1.000	rs11905625	chr20:24977065	A/C	cg26195577	chr20:24973756	C20orf3	0.91	9.89	0.54	1.77e-19	Blood protein levels;
SARC	cis	rs847851	0.617	rs9394265	chr6:34950274	T/G	cg13137465	chr6:34857473	ANKS1A	0.59	4.76	0.3	3.44e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7824557	0.564	rs13274106	chr8:11233958	A/G	cg21775007	chr8:11205619	TDH	-0.65	-8.63	-0.49	9.45e-16	Retinal vascular caliber;
SARC	cis	rs1865760	0.566	rs1800702	chr6:26086463	C/G	cg16482183	chr6:26056742	HIST1H1C	0.47	5.91	0.36	1.22e-8	Height;
SARC	trans	rs61931739	0.817	rs2636084	chr12:34130210	G/A	cg26384229	chr12:38710491	ALG10B	0.58	7.85	0.46	1.47e-13	Morning vs. evening chronotype;
SARC	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg13880726	chr7:1868755	MAD1L1	0.56	6.6	0.4	2.68e-10	Bipolar disorder and schizophrenia;
SARC	trans	rs11098499	0.909	rs71614422	chr4:120359340	G/A	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	cis	rs9309473	0.904	rs62149783	chr2:73821384	T/A	cg20560298	chr2:73613845	ALMS1	-0.47	-5.64	-0.35	4.9e-8	Metabolite levels;
SARC	cis	rs6912958	0.712	rs7772561	chr6:88331299	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.54	-0.34	8.34e-8	Monocyte percentage of white cells;
SARC	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg22800045	chr5:56110881	MAP3K1	0.72	7.82	0.46	1.83e-13	Initial pursuit acceleration;
SARC	cis	rs10892173	0.765	rs1892902	chr11:117669794	T/G	cg21640587	chr11:117668038	DSCAML1	0.48	6.76	0.4	1.13e-10	Myopia;
SARC	cis	rs12893668	0.572	rs12590968	chr14:104136633	G/C	cg26031613	chr14:104095156	KLC1	-0.53	-5.83	-0.36	1.82e-8	Reticulocyte count;
SARC	cis	rs2933343	1.000	rs876756	chr3:128627623	G/A	cg25356066	chr3:128598488	ACAD9	0.6	6.79	0.41	9.22e-11	IgG glycosylation;
SARC	cis	rs76693355	0.512	rs11217857	chr11:120270170	A/G	cg15690696	chr11:120217718	ARHGEF12	-0.38	-4.81	-0.3	2.72e-6	Intraocular pressure;
SARC	trans	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg07211511	chr3:129823064	LOC729375	-0.56	-6.43	-0.39	7.18e-10	Blood pressure (smoking interaction);
SARC	cis	rs7523050	0.908	rs67425757	chr1:109398656	T/G	cg08274380	chr1:109419600	GPSM2	0.79	6.61	0.4	2.55e-10	Fat distribution (HIV);
SARC	cis	rs12579753	0.833	rs12579530	chr12:82163930	A/C	cg07988820	chr12:82153109	PPFIA2	-0.58	-7.06	-0.42	1.89e-11	Resting heart rate;
SARC	cis	rs6450176	0.909	rs6866586	chr5:53295568	A/C	ch.5.1024479R	chr5:53302184	ARL15	-0.65	-7.38	-0.44	2.69e-12	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs7588746	0.571	rs4673891	chr2:201156362	C/G	cg23649088	chr2:200775458	C2orf69	-0.46	-5.59	-0.34	6.19e-8	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs208520	0.690	rs207094	chr6:66799009	G/A	cg07460842	chr6:66804631	NA	-1.08	-14.98	-0.7	5.37e-36	Exhaled nitric oxide output;
SARC	trans	rs360488	0.639	rs16861218	chr2:14266344	A/T	cg13543375	chr1:22470218	WNT4	0.59	6.56	0.39	3.36e-10	Emphysema imaging phenotypes;
SARC	cis	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg13072238	chr3:49761600	GMPPB	0.44	5.64	0.35	4.82e-8	Intelligence (multi-trait analysis);
SARC	cis	rs3761847	0.593	rs1468673	chr9:123809890	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	5.04	0.31	9.5e-7	Rheumatoid arthritis;
SARC	cis	rs9611565	0.921	rs2281332	chr22:41746212	T/C	cg03806693	chr22:41940476	POLR3H	-0.69	-9.47	-0.53	3.29e-18	Vitiligo;
SARC	cis	rs548181	0.536	rs503287	chr11:125461788	C/T	cg03464685	chr11:125439445	EI24	1.06	9.96	0.55	1.09e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg04267008	chr7:1944627	MAD1L1	-0.5	-5.73	-0.35	3.12e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs4803468	1.000	rs284663	chr19:41932612	C/T	cg14132834	chr19:41945861	ATP5SL	-0.57	-7.5	-0.44	1.3e-12	Height;
SARC	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs722599	0.748	rs59112602	chr14:75358817	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.44	-5.45	-0.34	1.26e-7	IgG glycosylation;
SARC	cis	rs2735413	0.918	rs11150037	chr16:78075774	A/G	cg04733911	chr16:78082701	NA	-0.31	-5.61	-0.34	5.78e-8	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs11668609	0.505	rs115627793	chr19:24062265	C/A	cg27517351	chr19:23941871	ZNF681	-0.54	-4.73	-0.3	3.86e-6	Response to taxane treatment (docetaxel);
SARC	cis	rs9381107	0.505	rs13208500	chr6:9479707	T/C	cg14735645	chr6:9486422	NA	-0.5	-5.86	-0.36	1.55e-8	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs3733585	0.638	rs6414766	chr4:9956474	G/A	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.95	-0.36	9.9e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg11301795	chr4:187892539	NA	-0.71	-10.14	-0.55	3.07e-20	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs239198	0.568	rs34555037	chr6:101327153	G/C	cg09795085	chr6:101329169	ASCC3	0.45	5.72	0.35	3.27e-8	Menarche (age at onset);
SARC	cis	rs2859741	0.528	rs6686296	chr1:37489380	G/T	cg09363841	chr1:37513479	NA	0.29	4.97	0.31	1.33e-6	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
SARC	cis	rs7847628	0.765	rs10985024	chr9:123516812	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	7.37	0.43	2.92e-12	Birth weight;
SARC	cis	rs7568458	0.905	rs59877521	chr2:85759494	C/T	cg23752985	chr2:85803571	VAMP8	0.34	4.88	0.3	2e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs1008375	0.966	rs4698619	chr4:17580955	G/A	cg16339924	chr4:17578868	LAP3	0.69	9.17	0.51	2.59e-17	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs13082711	0.871	rs7624790	chr3:27468601	C/A	cg02860705	chr3:27208620	NA	0.45	5.87	0.36	1.51e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs6449502	0.764	rs16878397	chr5:60065519	G/A	cg08904082	chr5:60457901	C5orf43	-0.61	-4.75	-0.3	3.61e-6	Mean platelet volume;
SARC	cis	rs941408	1.000	rs1640274	chr19:2807375	G/A	cg06609049	chr19:2785107	THOP1	0.84	10.49	0.57	2.5e-21	Total cholesterol levels;
SARC	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg17376030	chr22:41985996	PMM1	-0.73	-8.97	-0.51	1.01e-16	Vitiligo;
SARC	cis	rs17401966	0.800	rs12122029	chr1:10339822	G/A	cg15208524	chr1:10270712	KIF1B	0.46	5.53	0.34	8.69e-8	Hepatocellular carcinoma;
SARC	cis	rs6088580	0.543	rs13042351	chr20:33238573	G/A	cg08999081	chr20:33150536	PIGU	-0.34	-5.08	-0.32	7.69e-7	Glomerular filtration rate (creatinine);
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg17533847	chr17:77812622	CBX4	0.5	6.39	0.39	8.88e-10	Lung adenocarcinoma;
SARC	cis	rs9807989	0.507	rs13021177	chr2:103056493	A/G	cg03938978	chr2:103052716	IL18RAP	0.3	4.79	0.3	2.96e-6	Asthma;
SARC	cis	rs35306767	0.903	rs11253495	chr10:937064	C/T	cg20503657	chr10:835505	NA	0.81	7.85	0.46	1.53e-13	Eosinophil percentage of granulocytes;
SARC	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg13939156	chr17:80058883	NA	-0.35	-5.34	-0.33	2.22e-7	Life satisfaction;
SARC	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg23758822	chr17:41437982	NA	0.86	11.32	0.6	6e-24	Menopause (age at onset);
SARC	cis	rs9487051	0.676	rs7753705	chr6:109593302	A/C	cg01475377	chr6:109611718	NA	-0.35	-5.08	-0.32	7.66e-7	Reticulocyte fraction of red cells;
SARC	cis	rs4642101	0.640	rs12629398	chr3:12826799	A/G	cg24848339	chr3:12840334	CAND2	0.33	5.23	0.32	3.74e-7	QRS complex (12-leadsum);
SARC	cis	rs6991952	0.676	rs12676732	chr8:25690785	C/A	cg21775463	chr8:25538546	NA	0.27	4.73	0.3	3.89e-6	Inguinal hernia;
SARC	cis	rs4319547	0.656	rs2173582	chr12:122824694	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.58	-6.77	-0.41	1.04e-10	Body mass index;
SARC	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg16606324	chr3:10149918	C3orf24	0.49	4.82	0.3	2.56e-6	Alzheimer's disease;
SARC	cis	rs751728	1.000	rs747695	chr6:33736672	G/A	cg25922239	chr6:33757077	LEMD2	0.8	10.36	0.56	6.03e-21	Crohn's disease;
SARC	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg06221963	chr1:154839813	KCNN3	-0.45	-7.0	-0.42	2.64e-11	Prostate cancer;
SARC	cis	rs2425143	1.000	rs60646509	chr20:34303409	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.1	-0.37	4.39e-9	Blood protein levels;
SARC	cis	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg08045932	chr20:61659980	NA	0.5	6.84	0.41	7.06e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs4234284	0.556	rs9968173	chr3:126965437	G/A	cg27326032	chr3:127006922	NA	-0.52	-6.0	-0.37	7.58e-9	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
SARC	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg25036284	chr2:26402008	FAM59B	0.41	5.11	0.32	6.65e-7	Gut microbiome composition (summer);
SARC	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg13628971	chr7:2884303	GNA12	0.67	8.17	0.47	1.95e-14	Height;
SARC	cis	rs807669	0.933	rs712959	chr22:19159015	C/T	cg02655711	chr22:19163373	SLC25A1	0.44	6.36	0.38	1.06e-9	Metabolite levels;
SARC	cis	rs6991838	0.751	rs35553155	chr8:66463467	A/G	cg13398993	chr8:66546079	ARMC1	0.41	5.05	0.31	8.76e-7	Intelligence (multi-trait analysis);
SARC	cis	rs17376456	0.825	rs28645862	chr5:93233128	G/C	cg21475434	chr5:93447410	FAM172A	0.83	7.35	0.43	3.37e-12	Diabetic retinopathy;
SARC	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg15157837	chr2:97482059	CNNM3	-0.52	-6.6	-0.4	2.75e-10	Parental extreme longevity (95 years and older);
SARC	trans	rs2727020	0.675	rs1684258	chr11:49340020	G/A	cg15704280	chr7:45808275	SEPT13	0.67	7.44	0.44	1.97e-12	Coronary artery disease;
SARC	cis	rs7615952	0.800	rs11915699	chr3:125632684	A/G	cg05084668	chr3:125655381	ALG1L	-0.6	-6.02	-0.37	6.78e-9	Blood pressure (smoking interaction);
SARC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	4.82	0.3	2.56e-6	Cognitive function;
SARC	cis	rs7666738	0.830	rs1834647	chr4:98882915	G/A	cg05340658	chr4:99064831	C4orf37	0.64	8.51	0.49	2.14e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs13314892	0.764	rs1430604	chr3:69876319	G/T	cg17445875	chr3:69859618	MITF	-0.48	-5.12	-0.32	6.53e-7	QRS complex (12-leadsum);
SARC	cis	rs4750440	0.733	rs2446585	chr10:14028086	C/T	cg27542038	chr10:14027202	FRMD4A	-0.31	-4.88	-0.3	2e-6	Adiponectin levels;
SARC	cis	rs1941023	0.584	rs2241921	chr11:60164302	C/T	cg08716584	chr11:60157161	MS4A7	-0.39	-6.31	-0.38	1.36e-9	Congenital heart disease (maternal effect);
SARC	cis	rs9399135	0.660	rs9376072	chr6:135280519	G/C	cg24558204	chr6:135376177	HBS1L	0.46	6.3	0.38	1.47e-9	Red blood cell count;
SARC	cis	rs748404	0.723	rs573169	chr15:43550581	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.41	5.09	0.32	7.44e-7	Lung cancer;
SARC	cis	rs17376456	0.569	rs7736892	chr5:93205597	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.53	-5.53	-0.34	8.42e-8	Diabetic retinopathy;
SARC	cis	rs2531992	0.620	rs2041248	chr16:4032489	T/G	cg05927578	chr16:4029543	ADCY9	0.48	5.78	0.35	2.43e-8	Waist circumference;
SARC	cis	rs459571	0.959	rs465724	chr9:136910097	C/T	cg13789015	chr9:136890014	NCRNA00094	0.59	7.93	0.46	9e-14	Platelet distribution width;
SARC	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg00933542	chr6:150070202	PCMT1	0.31	5.36	0.33	2.04e-7	Lung cancer;
SARC	cis	rs7927771	1.000	rs11039255	chr11:47495746	G/T	cg20307385	chr11:47447363	PSMC3	-0.51	-6.29	-0.38	1.58e-9	Subjective well-being;
SARC	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg24549020	chr5:56110836	MAP3K1	-0.54	-4.99	-0.31	1.17e-6	Initial pursuit acceleration;
SARC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg06873352	chr17:61820015	STRADA	0.53	6.9	0.41	4.75e-11	Prudent dietary pattern;
SARC	cis	rs11190604	1.000	rs2489051	chr10:102351785	C/T	cg07080220	chr10:102295463	HIF1AN	-0.8	-8.76	-0.5	4.09e-16	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs9916302	0.800	rs11869259	chr17:37518141	C/A	cg07936489	chr17:37558343	FBXL20	0.69	9.14	0.51	3.18e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs733592	1.000	rs733592	chr12:48429776	C/T	cg24011408	chr12:48396354	COL2A1	-0.48	-6.46	-0.39	6.04e-10	Plateletcrit;
SARC	cis	rs3923518	0.956	rs4320030	chr3:38928112	T/C	cg26331595	chr3:39149181	GORASP1;TTC21A	0.45	4.74	0.3	3.76e-6	Migraine;
SARC	cis	rs4664308	0.935	rs877200	chr2:160903723	G/C	cg03641300	chr2:160917029	PLA2R1	-0.64	-8.55	-0.49	1.65e-15	Idiopathic membranous nephropathy;
SARC	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg24549020	chr5:56110836	MAP3K1	-0.56	-4.94	-0.31	1.46e-6	Initial pursuit acceleration;
SARC	cis	rs8067354	0.645	rs9910518	chr17:57812067	T/C	cg13753209	chr17:57696993	CLTC	0.67	7.24	0.43	6.46e-12	Hemoglobin concentration;
SARC	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7474896	0.583	rs12783272	chr10:38024885	T/G	cg25427524	chr10:38739819	LOC399744	-0.46	-5.16	-0.32	5.2e-7	Obesity (extreme);
SARC	cis	rs7223966	1.000	rs17549954	chr17:61707032	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-5.08	-0.32	7.59e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6089584	0.507	rs6061989	chr20:60627893	C/T	cg06108461	chr20:60628389	TAF4	-0.72	-9.38	-0.52	5.95e-18	Body mass index;
SARC	cis	rs2439831	0.867	rs2412779	chr15:43655927	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	8.32	0.48	7.2e-15	Lung cancer in ever smokers;
SARC	cis	rs13161895	1.000	rs4389651	chr5:179460968	T/A	cg02702477	chr5:179499311	RNF130	0.67	6.57	0.4	3.17e-10	LDL cholesterol;
SARC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg04845466	chr2:27665079	KRTCAP3;NRBP1	0.33	4.78	0.3	3.13e-6	Total body bone mineral density;
SARC	cis	rs7084402	0.934	rs1658455	chr10:60306089	G/C	cg07615347	chr10:60278583	BICC1	0.59	8.61	0.49	1.12e-15	Refractive error;
SARC	cis	rs78545713	0.649	rs11751062	chr6:26216165	C/T	cg00631329	chr6:26305371	NA	-0.71	-5.14	-0.32	5.85e-7	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs453301	0.686	rs3989373	chr8:8911308	G/T	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.68	-0.4	1.75e-10	Joint mobility (Beighton score);
SARC	cis	rs138249	0.902	rs138240	chr22:50564181	A/C	cg24864161	chr22:50528282	MOV10L1	-0.32	-5.11	-0.32	6.74e-7	Gestational age at birth in labor-initiated deliveries (child effect);
SARC	cis	rs981844	1.000	rs1116636	chr4:154657151	C/T	cg14289246	chr4:154710475	SFRP2	0.58	6.64	0.4	2.14e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs6840360	0.967	rs6535817	chr4:152641941	G/C	cg22705602	chr4:152727874	NA	-0.38	-6.6	-0.4	2.71e-10	Intelligence (multi-trait analysis);
SARC	cis	rs796364	0.901	rs13030683	chr2:201061535	C/T	cg05691004	chr2:201170426	SPATS2L	-0.46	-5.11	-0.32	6.8e-7	Schizophrenia;
SARC	cis	rs372883	0.648	rs382732	chr21:30719010	A/G	cg24692254	chr21:30365293	RNF160	0.62	7.7	0.45	3.91e-13	Pancreatic cancer;
SARC	cis	rs933688	0.532	rs2973477	chr5:90553722	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.48	-5.27	-0.33	3.14e-7	Smoking behavior;
SARC	cis	rs9436747	0.615	rs2105462	chr1:66047880	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.48	4.94	0.31	1.48e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs10463554	1.000	rs56372231	chr5:102321905	C/T	cg23492399	chr5:102201601	PAM	-0.51	-6.44	-0.39	6.84e-10	Parkinson's disease;
SARC	cis	rs7130144	0.686	rs10894216	chr11:130433733	A/G	cg26307797	chr11:130446613	NA	-0.57	-5.01	-0.31	1.07e-6	Urate levels in lean individuals;
SARC	trans	rs11634851	0.966	rs2627324	chr15:81021174	A/G	cg04669574	chr12:50297945	FAIM2	0.47	6.38	0.39	9.71e-10	Systolic blood pressure;
SARC	cis	rs6089584	1.000	rs3787425	chr20:60559256	C/T	cg13770153	chr20:60521292	NA	-0.55	-7.78	-0.45	2.37e-13	Body mass index;
SARC	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg18876405	chr7:65276391	NA	0.72	9.46	0.53	3.55e-18	Calcium levels;
SARC	cis	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg09021430	chr5:549028	NA	-0.45	-5.7	-0.35	3.69e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs2013441	1.000	rs9905493	chr17:20188581	C/G	cg13482628	chr17:19912719	NA	-0.5	-6.47	-0.39	5.83e-10	Obesity-related traits;
SARC	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.53	-5.25	-0.33	3.45e-7	Lung function (FEV1/FVC);
SARC	cis	rs501120	1.000	rs559580	chr10:44752078	C/T	cg09554077	chr10:44749378	NA	-0.42	-5.75	-0.35	2.72e-8	Coronary artery disease;Coronary heart disease;
SARC	cis	rs7582720	1.000	rs114393235	chr2:203795987	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs561341	1.000	rs560132	chr17:30320019	C/T	cg00745463	chr17:30367425	LRRC37B	-0.7	-5.51	-0.34	9.36e-8	Hip circumference adjusted for BMI;
SARC	cis	rs1153858	1.000	rs4775907	chr15:45638647	G/A	cg14582100	chr15:45693742	SPATA5L1	0.37	5.03	0.31	9.67e-7	Homoarginine levels;
SARC	cis	rs4689388	0.926	rs4343789	chr4:6285228	C/G	cg25554036	chr4:6271136	WFS1	0.43	7.05	0.42	1.97e-11	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs9290065	0.519	rs10513560	chr3:160710798	C/T	cg03342759	chr3:160939853	NMD3	-0.52	-6.44	-0.39	6.93e-10	Kawasaki disease;
SARC	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	7.88	0.46	1.28e-13	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs6988636	1.000	rs61422480	chr8:124188940	C/A	cg23067535	chr8:124195133	FAM83A	-0.69	-5.46	-0.34	1.24e-7	Urinary uromodulin levels;
SARC	cis	rs13256369	1.000	rs10098234	chr8:8576692	G/A	cg18904891	chr8:8559673	CLDN23	0.49	5.75	0.35	2.82e-8	Obesity-related traits;
SARC	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.5e-10	Life satisfaction;
SARC	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg09323728	chr8:95962352	TP53INP1	-0.29	-4.94	-0.31	1.52e-6	Type 2 diabetes;
SARC	cis	rs11608355	1.000	rs7969719	chr12:109883577	C/T	cg19025524	chr12:109796872	NA	-0.41	-5.23	-0.32	3.8e-7	Neuroticism;
SARC	cis	rs8141529	0.515	rs13056243	chr22:29349306	A/G	cg02153584	chr22:29168773	CCDC117	-0.63	-6.61	-0.4	2.56e-10	Lymphocyte counts;
SARC	cis	rs17376456	1.000	rs9968691	chr5:93509756	C/G	cg25358565	chr5:93447407	FAM172A	1.34	14.13	0.68	3.63e-33	Diabetic retinopathy;
SARC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg23034840	chr1:205782522	SLC41A1	0.62	7.95	0.46	8.08e-14	Menarche (age at onset);
SARC	cis	rs4144743	0.759	rs67972765	chr17:45318326	G/A	cg18085866	chr17:45331354	ITGB3	-0.73	-6.33	-0.38	1.22e-9	Body mass index;
SARC	cis	rs1348850	0.567	rs3821006	chr2:178537694	G/A	cg22681709	chr2:178499509	PDE11A	-0.37	-5.22	-0.32	3.98e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs11585357	0.895	rs4625336	chr1:17630964	G/T	cg08277548	chr1:17600880	PADI3	-0.41	-5.05	-0.31	8.75e-7	Hair shape;
SARC	cis	rs35146811	0.844	rs12705071	chr7:99682026	T/C	cg22004693	chr7:99632812	ZKSCAN1	-0.49	-5.18	-0.32	4.82e-7	Coronary artery disease;
SARC	cis	rs9596270	0.772	rs11842790	chr13:50924448	A/G	cg02621481	chr13:50931836	NA	-0.43	-5.94	-0.36	1e-8	Multiple sclerosis;
SARC	cis	rs2251381	0.778	rs2471947	chr21:30534219	G/T	cg24692254	chr21:30365293	RNF160	0.86	12.36	0.63	2.47e-27	Selective IgA deficiency;
SARC	cis	rs80130819	0.748	rs10747531	chr12:48632280	A/G	cg24011408	chr12:48396354	COL2A1	0.53	5.94	0.36	1.02e-8	Prostate cancer;
SARC	cis	rs240764	0.658	rs12174806	chr6:101219581	C/T	cg09795085	chr6:101329169	ASCC3	-0.41	-5.24	-0.32	3.59e-7	Neuroticism;
SARC	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg18876405	chr7:65276391	NA	-0.44	-4.92	-0.31	1.62e-6	Aortic root size;
SARC	cis	rs4901847	0.577	rs10782436	chr14:58574964	T/C	cg15908186	chr14:58618357	C14orf37	0.54	6.75	0.4	1.15e-10	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs1450679	0.843	rs1360176	chr9:106854716	A/C	cg21169611	chr9:106856078	SMC2	-0.55	-4.93	-0.31	1.54e-6	Response to cytadine analogues (cytosine arabinoside);
SARC	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	5.96	0.36	9.5e-9	Tonsillectomy;
SARC	cis	rs9303401	0.614	rs3803753	chr17:56540110	G/A	cg25039879	chr17:56429692	SUPT4H1	0.63	5.77	0.35	2.51e-8	Cognitive test performance;
SARC	cis	rs7666738	0.830	rs7659006	chr4:98934529	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg12463550	chr7:65579703	CRCP	-0.49	-5.79	-0.35	2.29e-8	Aortic root size;
SARC	cis	rs6568686	0.530	rs72938270	chr6:111951212	A/G	cg15721981	chr6:111408429	SLC16A10	0.65	4.76	0.3	3.38e-6	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs477692	0.935	rs568918	chr10:131414455	A/G	cg05714579	chr10:131428358	MGMT	0.58	7.77	0.45	2.43e-13	Response to temozolomide;
SARC	cis	rs910316	0.737	rs424120	chr14:75482828	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.45	-5.92	-0.36	1.12e-8	Height;
SARC	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg04518342	chr5:131593106	PDLIM4	0.42	5.39	0.33	1.76e-7	Breast cancer;
SARC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.52	6.48	0.39	5.3e-10	Lymphocyte counts;
SARC	cis	rs425277	1.000	rs262670	chr1:2082458	C/T	cg24578937	chr1:2090814	PRKCZ	0.31	5.85	0.36	1.63e-8	Height;
SARC	cis	rs6540556	0.723	rs12059226	chr1:209906675	A/G	cg05527609	chr1:210001259	C1orf107	-0.55	-5.46	-0.34	1.23e-7	Red blood cell count;
SARC	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg02725872	chr8:58115012	NA	-0.34	-5.38	-0.33	1.78e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9300255	0.602	rs1617434	chr12:123649486	A/G	cg05973401	chr12:123451056	ABCB9	0.57	5.46	0.34	1.2e-7	Neutrophil percentage of white cells;
SARC	cis	rs7829975	0.572	rs28730413	chr8:8795447	A/C	cg08975724	chr8:8085496	FLJ10661	-0.42	-5.15	-0.32	5.61e-7	Mood instability;
SARC	cis	rs1018836	0.631	rs9987133	chr8:91470730	T/C	cg16814680	chr8:91681699	NA	-0.68	-9.79	-0.54	3.5e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs7178572	0.568	rs1565757	chr15:77657682	C/T	cg22256960	chr15:77711686	NA	-0.54	-5.92	-0.36	1.16e-8	Type 2 diabetes;
SARC	cis	rs7264396	0.563	rs17092980	chr20:34289005	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-7.17	-0.43	9.99e-12	Total cholesterol levels;
SARC	trans	rs208520	0.874	rs208517	chr6:66947040	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.9	-10.42	-0.56	4.04e-21	Exhaled nitric oxide output;
SARC	cis	rs10875746	0.855	rs10875729	chr12:48426726	A/G	cg26205652	chr12:48591994	NA	0.51	5.52	0.34	8.94e-8	Longevity (90 years and older);
SARC	cis	rs6570726	0.935	rs413916	chr6:145831400	T/C	cg05347473	chr6:146136440	FBXO30	0.5	6.58	0.4	3.1e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9467711	0.606	rs9379900	chr6:26603811	A/C	cg12826209	chr6:26865740	GUSBL1	0.74	4.98	0.31	1.27e-6	Autism spectrum disorder or schizophrenia;
SARC	trans	rs17056278	0.841	rs17056318	chr5:158285953	A/G	cg08360457	chr5:132764399	MIR1289-2;FSTL4	0.6	6.42	0.39	7.51e-10	Hip circumference (psychosocial stress interaction);
SARC	cis	rs73206853	0.841	rs17625767	chr12:111102627	A/C	cg10860002	chr12:110842031	ANAPC7	0.62	5.08	0.32	7.57e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs3784262	0.669	rs6493981	chr15:58352923	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.33	-5.0	-0.31	1.15e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg11890956	chr21:40555474	PSMG1	-1.07	-15.71	-0.72	2.01e-38	Cognitive function;
SARC	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg08280861	chr8:58055591	NA	0.69	5.64	0.35	4.93e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs892961	0.836	rs35077273	chr17:75412415	T/C	cg05865280	chr17:75406074	SEPT9	0.57	8.47	0.48	2.87e-15	Airflow obstruction;
SARC	trans	rs6600671	0.967	rs11249347	chr1:121188347	G/T	cg00646200	chr1:148855367	NA	0.53	7.39	0.44	2.58e-12	Hip geometry;
SARC	cis	rs9916302	0.904	rs4795384	chr17:37716771	C/G	cg07936489	chr17:37558343	FBXL20	-0.68	-8.83	-0.5	2.63e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg25427524	chr10:38739819	LOC399744	-0.63	-10.05	-0.55	5.66e-20	Extrinsic epigenetic age acceleration;
SARC	cis	rs3768617	0.510	rs3818417	chr1:183079376	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.8e-21	Fuchs's corneal dystrophy;
SARC	cis	rs644799	0.635	rs10831428	chr11:95508404	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.94	16.0	0.72	2.32e-39	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs76419734	0.614	rs17035936	chr4:106525864	T/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.66	5.82	0.36	1.91e-8	Post bronchodilator FEV1;
SARC	cis	rs7264396	0.563	rs2425081	chr20:34299733	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-7.17	-0.43	9.99e-12	Total cholesterol levels;
SARC	cis	rs7945705	0.818	rs4929916	chr11:8824996	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.35	4.8	0.3	2.83e-6	Hemoglobin concentration;
SARC	cis	rs228769	0.673	rs228787	chr17:42099488	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.49	-5.37	-0.33	1.89e-7	Bone mineral density (hip);Bone mineral density (spine);
SARC	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg04944784	chr2:26401820	FAM59B	0.48	6.02	0.37	6.8e-9	Gut microbiome composition (summer);
SARC	cis	rs3008870	0.755	rs2815364	chr1:67498384	C/T	cg02640540	chr1:67518911	SLC35D1	0.45	5.15	0.32	5.51e-7	Lymphocyte percentage of white cells;
SARC	cis	rs2729354	0.903	rs1846568	chr11:57357714	A/C	cg02958346	chr11:57425731	CLP1	0.48	4.82	0.3	2.59e-6	Blood protein levels;
SARC	cis	rs400736	0.896	rs225126	chr1:8090615	A/G	cg25007680	chr1:8021821	PARK7	0.48	6.14	0.37	3.48e-9	Response to antidepressants and depression;
SARC	cis	rs7851660	0.527	rs7870540	chr9:100573925	T/C	cg13688889	chr9:100608707	NA	-0.45	-5.23	-0.32	3.85e-7	Strep throat;
SARC	cis	rs933688	1.000	rs6865495	chr5:90746424	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.96	12.39	0.63	2.01e-27	Smoking behavior;
SARC	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg22920501	chr2:26401640	FAM59B	0.61	7.98	0.46	6.5e-14	Gut microbiome composition (summer);
SARC	trans	rs61931739	0.500	rs7306053	chr12:34510848	T/G	cg26384229	chr12:38710491	ALG10B	0.83	12.41	0.63	1.78e-27	Morning vs. evening chronotype;
SARC	cis	rs6909279	0.678	rs9479056	chr6:151848899	C/A	cg10883421	chr6:151773342	RMND1;C6orf211	-0.49	-6.32	-0.38	1.29e-9	Bone mineral density;
SARC	cis	rs7043114	0.563	rs10820990	chr9:95323297	C/T	cg13798575	chr9:95087839	CENPP;NOL8	0.5	6.11	0.37	4.13e-9	Height;
SARC	cis	rs8114671	0.562	rs6120758	chr20:33492523	C/T	cg08999081	chr20:33150536	PIGU	0.33	4.89	0.3	1.9e-6	Height;
SARC	cis	rs2228479	0.850	rs117675822	chr16:89919081	C/A	cg12064134	chr16:90016061	DEF8	-0.56	-4.83	-0.3	2.47e-6	Skin colour saturation;
SARC	cis	rs8523	0.804	rs7752895	chr6:11064780	C/T	cg13562911	chr6:11044106	ELOVL2	0.48	6.5	0.39	4.83e-10	Red blood cell fatty acid levels;
SARC	cis	rs7385804	0.727	rs551238	chr7:100321528	G/T	cg20848291	chr7:100343083	ZAN	0.41	4.96	0.31	1.34e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
SARC	cis	rs9457247	0.740	rs13195812	chr6:167443902	C/T	cg23791538	chr6:167370224	RNASET2	-0.52	-6.82	-0.41	7.71e-11	Crohn's disease;
SARC	cis	rs11630290	0.592	rs1912049	chr15:64155606	G/T	cg12036633	chr15:63758958	NA	0.48	5.24	0.32	3.52e-7	Iris characteristics;
SARC	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.45	5.26	0.33	3.24e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9467773	0.620	rs2504565	chr6:26656890	G/A	cg12292205	chr6:26970375	C6orf41	0.39	4.77	0.3	3.24e-6	Intelligence (multi-trait analysis);
SARC	cis	rs3096299	0.606	rs8052103	chr16:89541243	A/T	cg08392591	chr16:89556376	ANKRD11	-0.51	-6.03	-0.37	6.44e-9	Multiple myeloma (IgH translocation);
SARC	cis	rs6690583	0.623	rs61769366	chr1:85534062	G/A	cg22153463	chr1:85462885	MCOLN2	0.68	5.05	0.31	8.78e-7	Serum sulfate level;
SARC	cis	rs9296092	0.517	rs11752179	chr6:33534713	G/T	cg13560919	chr6:33536144	NA	-0.53	-6.33	-0.38	1.23e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs910316	1.000	rs4899546	chr14:75594946	G/C	cg06637938	chr14:75390232	RPS6KL1	0.5	7.02	0.42	2.4e-11	Height;
SARC	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.78	-10.94	-0.58	9.57e-23	Total body bone mineral density;
SARC	cis	rs9300255	0.544	rs1716157	chr12:123670473	T/C	cg00376283	chr12:123451042	ABCB9	0.55	6.53	0.39	4.09e-10	Neutrophil percentage of white cells;
SARC	cis	rs9926296	0.715	rs467035	chr16:89740285	C/G	cg03605463	chr16:89740564	NA	-0.52	-6.6	-0.4	2.68e-10	Vitiligo;
SARC	cis	rs4660306	1.000	rs7536557	chr1:45992114	T/C	cg24296786	chr1:45957014	TESK2	0.56	6.59	0.4	2.92e-10	Homocysteine levels;
SARC	cis	rs1448094	0.512	rs7957170	chr12:86243282	A/G	cg02569458	chr12:86230093	RASSF9	0.39	5.44	0.34	1.34e-7	Major depressive disorder;
SARC	cis	rs2832191	0.791	rs2832181	chr21:30481371	G/T	cg24692254	chr21:30365293	RNF160	-0.92	-13.86	-0.67	2.95e-32	Dental caries;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg07605620	chr19:21512141	ZNF708	0.47	6.31	0.38	1.38e-9	Chemerin levels;
SARC	cis	rs6752107	1.000	rs6708373	chr2:234172846	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.5	6.4	0.39	8.49e-10	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs7582720	1.000	rs72936869	chr2:203788950	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs7089973	0.604	rs17095662	chr10:116596071	A/C	cg03647239	chr10:116582469	FAM160B1	0.5	6.55	0.39	3.6e-10	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg18110333	chr6:292329	DUSP22	-0.6	-7.73	-0.45	3.29e-13	Menopause (age at onset);
SARC	cis	rs1395	0.744	rs11126936	chr2:27483101	A/C	cg21747090	chr2:27597821	SNX17	0.47	5.8	0.36	2.16e-8	Blood metabolite levels;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg04562739	chr20:5107446	CDS2;PCNA	0.56	7.06	0.42	1.88e-11	Breast cancer;
SARC	cis	rs9398803	0.865	rs9388496	chr6:126785062	A/G	cg20229609	chr6:126660872	C6orf173	0.39	5.52	0.34	8.84e-8	Male-pattern baldness;
SARC	trans	rs208520	1.000	rs72884025	chr6:66994185	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	9.32	0.52	9.16e-18	Exhaled nitric oxide output;
SARC	cis	rs13392177	0.684	rs11695527	chr2:219068103	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.58	7.52	0.44	1.2e-12	Pyoderma gangrenosum in inflammatory bowel disease;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04128145	chr16:69373507	COG8;NIP7	-0.51	-6.41	-0.39	7.78e-10	Smoking initiation;
SARC	cis	rs911555	0.692	rs7145753	chr14:103866100	G/A	cg24130564	chr14:104152367	KLC1	0.46	5.3	0.33	2.67e-7	Intelligence (multi-trait analysis);
SARC	cis	rs67311347	0.956	rs12633446	chr3:40505661	G/A	cg01475735	chr3:40494733	NA	0.44	5.07	0.32	8.1e-7	Renal cell carcinoma;
SARC	cis	rs9316337	0.549	rs9509714	chr13:22016616	A/G	cg21080246	chr13:22033151	ZDHHC20	0.43	5.03	0.31	9.71e-7	Schizophrenia;
SARC	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg23370820	chr17:17987590	NA	0.26	5.0	0.31	1.12e-6	Total body bone mineral density;
SARC	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg27347728	chr4:17578864	LAP3	0.48	6.1	0.37	4.5e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.27	-4.87	-0.3	2.02e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg13072238	chr3:49761600	GMPPB	0.43	5.65	0.35	4.57e-8	Intelligence (multi-trait analysis);
SARC	cis	rs12142240	0.698	rs17357635	chr1:46808668	G/A	cg00530320	chr1:46809349	NSUN4	0.58	7.07	0.42	1.74e-11	Menopause (age at onset);
SARC	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg23758822	chr17:41437982	NA	0.86	10.52	0.57	1.97e-21	Menopause (age at onset);
SARC	cis	rs6570726	0.791	rs418701	chr6:145889992	C/T	cg23711669	chr6:146136114	FBXO30	0.83	13.84	0.67	3.41e-32	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg08219700	chr8:58056026	NA	0.47	5.19	0.32	4.64e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs3762637	0.943	rs7629285	chr3:122265739	A/G	cg24169773	chr3:122142474	KPNA1	0.52	5.28	0.33	2.91e-7	LDL cholesterol levels;
SARC	cis	rs3008870	1.000	rs58680688	chr1:67443751	C/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.89	-10.74	-0.58	3.95e-22	Lymphocyte percentage of white cells;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg24905370	chr5:74063138	NSA2;GFM2	-0.5	-6.33	-0.38	1.24e-9	Height;
SARC	cis	rs13256369	0.851	rs13258283	chr8:8563630	T/C	cg17143192	chr8:8559678	CLDN23	0.52	5.81	0.36	1.99e-8	Obesity-related traits;
SARC	cis	rs6060717	0.536	rs6060670	chr20:34481143	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-5.78	-0.35	2.42e-8	Hip circumference adjusted for BMI;
SARC	cis	rs6938	0.618	rs11072514	chr15:75221865	T/A	cg14664628	chr15:75095509	CSK	-0.42	-5.08	-0.32	7.59e-7	Breast cancer;
SARC	cis	rs2522056	0.932	rs2522064	chr5:131806488	G/A	cg24060327	chr5:131705240	SLC22A5	0.5	5.15	0.32	5.51e-7	Lymphocyte counts;Fibrinogen;
SARC	cis	rs1395	0.848	rs6716850	chr2:27525350	G/A	cg21747090	chr2:27597821	SNX17	-0.43	-5.13	-0.32	5.99e-7	Blood metabolite levels;
SARC	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg05313129	chr8:58192883	C8orf71	-0.55	-6.11	-0.37	4.06e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	10.0	0.55	8.26e-20	Platelet count;
SARC	cis	rs4975709	0.569	rs4975742	chr5:1858612	T/C	cg14773178	chr5:1868261	NA	0.37	5.7	0.35	3.61e-8	Cardiovascular disease risk factors;
SARC	cis	rs1971762	0.545	rs7485472	chr12:54044438	T/C	cg06632207	chr12:54070931	ATP5G2	0.59	8.01	0.46	5.43e-14	Height;
SARC	trans	rs2727020	0.521	rs7946190	chr11:49521964	T/A	cg03929089	chr4:120376271	NA	0.7	7.9	0.46	1.13e-13	Coronary artery disease;
SARC	cis	rs73198271	0.562	rs2048420	chr8:8667603	G/A	cg01851573	chr8:8652454	MFHAS1	0.43	5.24	0.32	3.57e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs910316	0.934	rs8016330	chr14:75657507	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.5	-6.94	-0.41	3.81e-11	Height;
SARC	cis	rs4478037	0.822	rs9827863	chr3:33118951	C/T	cg19404215	chr3:33155277	CRTAP	-0.74	-6.05	-0.37	5.88e-9	Major depressive disorder;
SARC	cis	rs9868809	0.772	rs9841602	chr3:48713570	A/G	cg07636037	chr3:49044803	WDR6	-0.69	-6.47	-0.39	5.77e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.51	4.75	0.3	3.55e-6	Lung function (FEV1/FVC);
SARC	cis	rs765787	0.530	rs4775836	chr15:45537664	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.67e-7	Uric acid levels;
SARC	cis	rs453301	0.686	rs7814328	chr8:8876229	T/C	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.87	-0.41	5.71e-11	Joint mobility (Beighton score);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg23116180	chr11:45167805	PRDM11	-0.51	-6.3	-0.38	1.51e-9	Breast cancer;
SARC	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg12373951	chr3:133503437	NA	0.36	5.25	0.33	3.38e-7	Iron status biomarkers;
SARC	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.05	15.99	0.72	2.41e-39	Height;
SARC	cis	rs11690935	0.549	rs2129475	chr2:172916772	A/G	cg13550731	chr2:172543902	DYNC1I2	0.61	8.43	0.48	3.53e-15	Schizophrenia;
SARC	cis	rs35995292	0.963	rs10242978	chr7:38898823	A/G	cg19327137	chr7:38886074	VPS41	0.36	5.09	0.32	7.43e-7	Subjective well-being (multi-trait analysis);
SARC	cis	rs926938	0.527	rs360666	chr1:115481290	C/T	cg12756093	chr1:115239321	AMPD1	0.39	4.87	0.3	2.05e-6	Autism;
SARC	cis	rs6793245	0.960	rs7373779	chr3:38593943	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.43	-5.22	-0.32	3.94e-7	QT interval;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg03903647	chr4:40058344	N4BP2;LOC344967	0.52	7.11	0.42	1.39e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs4132509	0.793	rs12037013	chr1:243784207	G/A	cg21452805	chr1:244014465	NA	0.54	5.18	0.32	4.69e-7	RR interval (heart rate);
SARC	cis	rs2153535	0.580	rs7743418	chr6:8438128	A/C	cg21535247	chr6:8435926	SLC35B3	0.57	7.07	0.42	1.77e-11	Motion sickness;
SARC	cis	rs13191362	1.000	rs66789102	chr6:163104432	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.74	6.34	0.38	1.18e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs6815814	0.851	rs11736207	chr4:38766285	G/A	cg09316306	chr4:38807337	TLR1	0.5	4.81	0.3	2.7e-6	Breast cancer;
SARC	cis	rs7829975	0.606	rs891570	chr8:8794454	G/A	cg14343924	chr8:8086146	FLJ10661	-0.4	-4.82	-0.3	2.61e-6	Mood instability;
SARC	cis	rs6840360	0.615	rs56319216	chr4:152463716	C/T	cg22705602	chr4:152727874	NA	-0.42	-6.55	-0.39	3.67e-10	Intelligence (multi-trait analysis);
SARC	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg16325326	chr1:53192061	ZYG11B	-0.9	-15.45	-0.71	1.53e-37	Monocyte count;
SARC	cis	rs9911578	1.000	rs8076121	chr17:57041699	G/A	cg12560992	chr17:57184187	TRIM37	0.85	11.74	0.61	2.67e-25	Intelligence (multi-trait analysis);
SARC	cis	rs9660992	0.573	rs1172159	chr1:205207512	T/C	cg21643547	chr1:205240462	TMCC2	-0.59	-7.62	-0.45	6.38e-13	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs7264396	0.790	rs6121015	chr20:34243017	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-8.2	-0.47	1.6e-14	Total cholesterol levels;
SARC	cis	rs864537	0.618	rs1214595	chr1:167427557	G/A	cg09179987	chr1:167433047	CD247	0.4	6.55	0.39	3.57e-10	Celiac disease or Rheumatoid arthritis;Celiac disease;
SARC	cis	rs9916302	0.904	rs8076546	chr17:37555403	G/A	cg20243544	chr17:37824526	PNMT	-0.57	-6.87	-0.41	5.64e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs1044826	0.956	rs2233811	chr3:139195860	C/G	cg15131784	chr3:139108705	COPB2	0.45	5.19	0.32	4.69e-7	Obesity-related traits;
SARC	cis	rs2011503	0.941	rs6511027	chr19:19391851	C/T	cg03709012	chr19:19516395	GATAD2A	0.61	5.68	0.35	3.94e-8	Bipolar disorder;
SARC	cis	rs11581859	0.613	rs12739340	chr1:99199742	G/A	cg20286094	chr1:99190917	SNX7	-0.42	-4.93	-0.31	1.55e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs4689388	0.926	rs4689394	chr4:6291003	C/G	cg25554036	chr4:6271136	WFS1	-0.39	-6.21	-0.38	2.36e-9	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	trans	rs208520	1.000	rs28773210	chr6:66993566	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	9.32	0.52	9.16e-18	Exhaled nitric oxide output;
SARC	cis	rs2777491	0.957	rs919961	chr15:41651721	A/G	cg01768344	chr15:41576519	LOC729082	0.45	5.04	0.31	9.39e-7	Ulcerative colitis;
SARC	cis	rs12754538	0.777	rs1000184	chr1:8640831	G/C	cg13785123	chr1:8931135	ENO1	-0.46	-5.14	-0.32	5.75e-7	Subjective well-being;
SARC	cis	rs644799	0.932	rs572015	chr11:95637416	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	14.1	0.68	4.73e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs12079745	0.590	rs12097682	chr1:169333438	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.94	-5.58	-0.34	6.71e-8	QT interval;
SARC	cis	rs910316	1.000	rs2300601	chr14:75639571	A/G	cg06637938	chr14:75390232	RPS6KL1	0.52	6.66	0.4	2e-10	Height;
SARC	cis	rs78456975	0.943	rs7602369	chr2:1574754	T/C	cg26248373	chr2:1572462	NA	-0.56	-5.85	-0.36	1.65e-8	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs7223966	1.000	rs9899491	chr17:61934384	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.5	5.16	0.32	5.28e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg15049968	chr18:44337910	ST8SIA5	-0.32	-5.07	-0.32	8.03e-7	Personality dimensions;
SARC	cis	rs4595586	0.525	rs12825567	chr12:39386621	C/T	cg13010199	chr12:38710504	ALG10B	0.4	4.72	0.3	4.06e-6	Morning vs. evening chronotype;
SARC	cis	rs7560272	0.723	rs1320374	chr2:73828310	T/C	cg20560298	chr2:73613845	ALMS1	0.52	7.05	0.42	2.03e-11	Schizophrenia;
SARC	cis	rs67460515	0.563	rs68166680	chr3:160829735	T/A	cg03342759	chr3:160939853	NMD3	-0.63	-7.65	-0.45	5.18e-13	Parkinson's disease;
SARC	cis	rs4253772	0.515	rs6008591	chr22:46703664	T/C	cg24881330	chr22:46731750	TRMU	0.68	5.77	0.35	2.45e-8	LDL cholesterol;Cholesterol, total;
SARC	cis	rs2486288	0.656	rs11632778	chr15:45551056	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.51	-6.44	-0.39	6.68e-10	Glomerular filtration rate;
SARC	cis	rs189798	0.738	rs330908	chr8:8995166	A/G	cg06636001	chr8:8085503	FLJ10661	0.39	4.72	0.3	4.12e-6	Myopia (pathological);
SARC	cis	rs3820928	0.839	rs4673174	chr2:227801316	A/T	cg05526886	chr2:227700861	RHBDD1	-0.54	-6.65	-0.4	2.04e-10	Pulmonary function;
SARC	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg26116260	chr4:7069785	GRPEL1	0.89	10.69	0.57	5.64e-22	Monocyte percentage of white cells;
SARC	cis	rs317689	0.718	rs645026	chr12:69757931	G/A	cg14784868	chr12:69753453	YEATS4	0.47	5.21	0.32	4.23e-7	Response to diuretic therapy;
SARC	cis	rs11264799	0.539	rs2779160	chr1:157550950	C/T	cg18268488	chr1:157545234	FCRL4	0.33	5.88	0.36	1.43e-8	IgA nephropathy;
SARC	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg24549020	chr5:56110836	MAP3K1	-0.52	-5.77	-0.35	2.5e-8	Initial pursuit acceleration;
SARC	cis	rs273218	1.000	rs156437	chr5:53376454	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.69	7.47	0.44	1.64e-12	Migraine;
SARC	cis	rs10791097	0.667	rs12363163	chr11:130744509	A/G	cg12179176	chr11:130786555	SNX19	0.74	11.09	0.59	3.11e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs941408	1.000	rs1640272	chr19:2800192	A/T	cg00079169	chr19:2811669	THOP1	0.5	5.53	0.34	8.73e-8	Total cholesterol levels;
SARC	cis	rs787274	0.867	rs6477959	chr9:115554296	G/A	cg13803584	chr9:115635662	SNX30	-0.83	-5.06	-0.31	8.34e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.48	0.34	1.1e-7	Bipolar disorder;
SARC	cis	rs8031584	0.505	rs2959036	chr15:31219742	T/G	cg08109568	chr15:31115862	NA	0.45	5.96	0.36	9.12e-9	Huntington's disease progression;
SARC	cis	rs7772486	0.686	rs9386131	chr6:146121608	G/A	cg05347473	chr6:146136440	FBXO30	0.51	7.16	0.42	1.03e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7474896	0.583	rs10740950	chr10:38003496	C/T	cg25427524	chr10:38739819	LOC399744	-0.49	-5.93	-0.36	1.11e-8	Obesity (extreme);
SARC	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg18876405	chr7:65276391	NA	0.7	8.37	0.48	5.48e-15	Aortic root size;
SARC	cis	rs820218	0.923	rs820157	chr17:73661411	A/G	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.58	6.94	0.41	3.85e-11	Rotator cuff tears;
SARC	cis	rs12545109	0.800	rs2118261	chr8:57393286	A/G	cg19413350	chr8:57351067	NA	0.41	4.74	0.3	3.69e-6	Obesity-related traits;
SARC	cis	rs155076	1.000	rs261430	chr13:21865242	C/T	cg06138931	chr13:21896616	NA	-0.4	-5.21	-0.32	4.15e-7	White matter hyperintensity burden;
SARC	cis	rs524281	0.861	rs10896090	chr11:65945186	A/G	cg14036092	chr11:66035641	RAB1B	-0.49	-5.11	-0.32	6.72e-7	Electroencephalogram traits;
SARC	cis	rs6580649	0.941	rs10492080	chr12:48501411	A/G	cg05342945	chr12:48394962	COL2A1	0.53	5.82	0.36	1.91e-8	Lung cancer;
SARC	cis	rs35110281	0.774	rs2838321	chr21:44995488	A/T	cg21573476	chr21:45109991	RRP1B	-0.47	-6.81	-0.41	8.35e-11	Mean corpuscular volume;
SARC	cis	rs2836950	0.545	rs2836949	chr21:40602456	C/A	cg11644478	chr21:40555479	PSMG1	-0.53	-6.16	-0.37	3.2e-9	Menarche (age at onset);
SARC	cis	rs4901847	0.562	rs11628678	chr14:58611623	A/C	cg15908186	chr14:58618357	C14orf37	0.59	7.64	0.45	5.67e-13	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs1865760	0.929	rs2876693	chr6:25954434	C/G	cg16482183	chr6:26056742	HIST1H1C	0.52	6.62	0.4	2.43e-10	Height;
SARC	cis	rs763121	0.849	rs12004	chr22:38877461	T/G	cg14440974	chr22:39074834	NA	-0.33	-4.76	-0.3	3.42e-6	Menopause (age at onset);
SARC	cis	rs9911578	1.000	rs7215808	chr17:56940742	G/C	cg05425664	chr17:57184151	TRIM37	-0.66	-8.16	-0.47	2.07e-14	Intelligence (multi-trait analysis);
SARC	trans	rs17453880	0.929	rs11948856	chr5:151983819	G/T	cg10447111	chr12:4647897	RAD51AP1;C12orf4	0.48	6.32	0.38	1.32e-9	Subjective well-being;
SARC	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.45	5.0	0.31	1.12e-6	Renal function-related traits (BUN);
SARC	cis	rs4713118	0.666	rs4140646	chr6:27738801	G/A	cg17221315	chr6:27791827	HIST1H4J	0.56	5.75	0.35	2.84e-8	Parkinson's disease;
SARC	cis	rs2342371	0.565	rs11185543	chr3:196215660	G/A	cg15048948	chr3:196158458	UBXN7	-0.41	-5.3	-0.33	2.75e-7	Fat distribution (HIV);
SARC	cis	rs546131	0.515	rs6484737	chr11:34857579	A/G	cg06937548	chr11:34938143	PDHX;APIP	-0.45	-4.82	-0.3	2.62e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs1355223	0.902	rs34875830	chr11:34722205	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.4	-5.02	-0.31	1.03e-6	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs11608355	0.545	rs35422737	chr12:109911456	A/G	cg05360138	chr12:110035743	NA	0.93	9.74	0.54	4.9e-19	Neuroticism;
SARC	trans	rs61931739	0.534	rs10844732	chr12:34037104	A/C	cg13010199	chr12:38710504	ALG10B	0.76	10.32	0.56	8.23e-21	Morning vs. evening chronotype;
SARC	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg14784868	chr12:69753453	YEATS4	0.5	6.67	0.4	1.88e-10	Blood protein levels;
SARC	cis	rs2250402	0.510	rs8031319	chr15:40323692	A/G	cg16127683	chr15:40268777	EIF2AK4	-0.59	-5.06	-0.31	8.39e-7	Corneal curvature;
SARC	cis	rs7216064	0.953	rs80135947	chr17:65836001	A/C	cg12091567	chr17:66097778	LOC651250	-0.69	-6.99	-0.42	2.89e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg09323728	chr8:95962352	TP53INP1	-0.3	-5.08	-0.32	7.86e-7	Type 2 diabetes;
SARC	cis	rs11669910	1	rs11669910	chr19:45741333	A/T	cg01416317	chr19:45737208	EXOC3L2	0.36	4.99	0.31	1.21e-6	Sum eosinophil basophil counts;
SARC	cis	rs950776	0.518	rs62008194	chr15:78813805	G/T	cg22563815	chr15:78856949	CHRNA5	0.42	6.95	0.41	3.72e-11	Sudden cardiac arrest;
SARC	cis	rs4595586	0.563	rs11169769	chr12:39233134	C/G	cg13010199	chr12:38710504	ALG10B	0.55	6.54	0.39	3.78e-10	Morning vs. evening chronotype;
SARC	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg22857025	chr5:266934	NA	-1.06	-11.8	-0.61	1.74e-25	Breast cancer;
SARC	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg16405210	chr4:1374714	KIAA1530	-0.5	-5.79	-0.35	2.29e-8	Obesity-related traits;
SARC	cis	rs67460515	0.859	rs7610800	chr3:161002582	C/T	cg03342759	chr3:160939853	NMD3	-0.71	-9.02	-0.51	7.27e-17	Parkinson's disease;
SARC	cis	rs7923609	0.811	rs7919685	chr10:65315800	G/T	cg01631684	chr10:65280961	REEP3	0.35	4.72	0.3	4.06e-6	Educational attainment;Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs593982	0.920	rs72922791	chr11:65567395	G/A	cg08755490	chr11:65554678	OVOL1	-0.87	-8.84	-0.5	2.34e-16	Atopic dermatitis;
SARC	cis	rs17030434	0.906	rs57446135	chr4:154679331	A/G	cg14289246	chr4:154710475	SFRP2	-0.71	-7.08	-0.42	1.68e-11	Electrocardiographic conduction measures;
SARC	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg00933542	chr6:150070202	PCMT1	0.33	5.5	0.34	9.75e-8	Lung cancer;
SARC	cis	rs4727027	0.933	rs62505074	chr7:148834780	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	5.58	0.34	6.5e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg16606324	chr3:10149918	C3orf24	0.49	5.08	0.32	7.9e-7	Alzheimer's disease;
SARC	cis	rs2933343	0.679	rs789229	chr3:128602526	C/T	cg25356066	chr3:128598488	ACAD9	0.73	9.65	0.53	9.44e-19	IgG glycosylation;
SARC	cis	rs79349575	0.783	rs62075839	chr17:46996434	G/C	cg16584676	chr17:46985605	UBE2Z	0.53	6.38	0.39	9.28e-10	Type 2 diabetes;
SARC	trans	rs6815916	1.000	rs6816783	chr4:182553207	G/A	cg13864546	chr1:2310327	MORN1	0.67	6.36	0.38	1.06e-9	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs6120849	0.754	rs6120793	chr20:33604407	T/C	cg24642439	chr20:33292090	TP53INP2	0.56	5.38	0.33	1.78e-7	Protein C levels;
SARC	cis	rs644799	0.965	rs598876	chr11:95560853	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.68	9.17	0.51	2.6e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs898097	0.812	rs55794221	chr17:80849003	G/A	cg15664640	chr17:80829946	TBCD	-0.55	-8.26	-0.48	1.11e-14	Breast cancer;
SARC	trans	rs9650657	0.506	rs7823296	chr8:10778546	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.11	-0.42	1.43e-11	Neuroticism;
SARC	cis	rs9549367	0.789	rs9549361	chr13:113898329	C/T	cg18105134	chr13:113819100	PROZ	0.38	5.63	0.35	5.26e-8	Platelet distribution width;
SARC	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	15.0	0.7	4.66e-36	Chronic sinus infection;
SARC	cis	rs60871478	0.945	rs62432254	chr7:804175	C/T	cg19087971	chr7:751233	PRKAR1B	-0.42	-4.85	-0.3	2.26e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs3741404	0.560	rs2875748	chr11:63915537	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.61	-7.87	-0.46	1.31e-13	Platelet count;
SARC	cis	rs7808935	0.581	rs6968704	chr7:27966984	C/T	cg05786569	chr7:27702416	HIBADH	0.42	4.74	0.3	3.72e-6	Prostate cancer;
SARC	cis	rs3126085	0.935	rs74129461	chr1:152285099	C/T	cg26876637	chr1:152193138	HRNR	-0.5	-5.47	-0.34	1.14e-7	Atopic dermatitis;
SARC	cis	rs4803468	0.905	rs284662	chr19:41932275	T/C	cg09537434	chr19:41945824	ATP5SL	-0.99	-17.33	-0.75	8.95e-44	Height;
SARC	cis	rs1348850	0.554	rs1374438	chr2:178376684	A/G	cg23306229	chr2:178417860	TTC30B	0.79	7.68	0.45	4.31e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9828933	0.832	rs2292662	chr3:63897215	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.71	-6.95	-0.41	3.72e-11	Type 2 diabetes;
SARC	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.54	0.44	1.06e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4319547	0.656	rs10846664	chr12:122823777	C/T	cg05707623	chr12:122985044	ZCCHC8	0.56	6.5	0.39	4.73e-10	Body mass index;
SARC	cis	rs11155671	0.530	rs6933882	chr6:150210802	A/G	cg05036130	chr6:150231994	NA	0.28	4.87	0.3	2.04e-6	Testicular germ cell tumor;
SARC	cis	rs1865760	0.827	rs9295681	chr6:25944117	T/G	cg17691542	chr6:26056736	HIST1H1C	0.57	7.18	0.43	9.29e-12	Height;
SARC	cis	rs3956705	0.830	rs7811609	chr7:32930597	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.43	-5.16	-0.32	5.34e-7	Red cell distribution width;
SARC	cis	rs763121	0.853	rs5750630	chr22:38985818	A/C	cg14440974	chr22:39074834	NA	-0.33	-4.94	-0.31	1.52e-6	Menopause (age at onset);
SARC	cis	rs911263	0.515	rs12889206	chr14:68769182	A/G	cg18825221	chr14:68749962	RAD51L1	0.44	6.04	0.37	6.18e-9	Primary biliary cholangitis;
SARC	cis	rs6493487	0.512	rs2899459	chr15:51130369	A/T	cg02338191	chr15:51200825	AP4E1	0.49	4.8	0.3	2.82e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs7020830	0.861	rs13289001	chr9:37311592	A/G	cg14294708	chr9:37120828	ZCCHC7	1.15	21.74	0.82	5.52e-58	Schizophrenia;
SARC	cis	rs7829975	0.711	rs1039916	chr8:8685854	A/G	cg15556689	chr8:8085844	FLJ10661	0.43	5.37	0.33	1.95e-7	Mood instability;
SARC	cis	rs10465746	0.780	rs11163867	chr1:84384847	C/T	cg10977910	chr1:84465055	TTLL7	0.41	4.88	0.3	1.95e-6	Obesity-related traits;
SARC	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg04277193	chr17:41438351	NA	0.44	4.78	0.3	3.04e-6	Menopause (age at onset);
SARC	cis	rs8141529	0.753	rs5752813	chr22:29226570	T/G	cg02153584	chr22:29168773	CCDC117	0.79	11.75	0.61	2.43e-25	Lymphocyte counts;
SARC	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg11764359	chr7:65958608	NA	-0.68	-7.98	-0.46	6.45e-14	Aortic root size;
SARC	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg06212747	chr3:49208901	KLHDC8B	0.66	8.79	0.5	3.35e-16	Parkinson's disease;
SARC	cis	rs8038465	0.622	rs62004587	chr15:73859016	A/C	cg15420318	chr15:73925796	NPTN	0.61	6.93	0.41	4.06e-11	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs244293	0.673	rs12944690	chr17:53029614	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.41	-4.98	-0.31	1.22e-6	Menarche (age at onset);
SARC	cis	rs9341808	0.519	rs4446525	chr6:81024053	C/T	cg08355045	chr6:80787529	NA	-0.37	-5.64	-0.35	4.8e-8	Sitting height ratio;
SARC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.42	-6.41	-0.39	8.13e-10	Total body bone mineral density;
SARC	cis	rs2797160	0.651	rs6569436	chr6:126032104	A/G	cg05901451	chr6:126070800	HEY2	0.46	5.61	0.34	5.71e-8	Endometrial cancer;
SARC	cis	rs9921222	0.521	rs11649255	chr16:357140	A/G	cg12437481	chr16:420112	MRPL28	-0.36	-4.98	-0.31	1.27e-6	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs637571	0.522	rs679581	chr11:65746653	A/G	cg26695010	chr11:65641043	EFEMP2	-0.53	-6.71	-0.4	1.5e-10	Eosinophil percentage of white cells;
SARC	cis	rs11792861	0.781	rs838835	chr9:111758590	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.75	-9.17	-0.51	2.64e-17	Menarche (age at onset);
SARC	cis	rs10992471	0.580	rs12341093	chr9:95234182	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.25	-0.33	3.37e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs9549367	0.713	rs3024764	chr13:113824314	A/G	cg18105134	chr13:113819100	PROZ	-0.49	-7.39	-0.44	2.54e-12	Platelet distribution width;
SARC	cis	rs2153535	0.580	rs1335636	chr6:8465047	T/C	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	cis	rs4702	0.611	rs1894401	chr15:91429042	C/T	cg05469396	chr15:91419421	FURIN	0.41	5.76	0.35	2.63e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs11902236	0.660	rs2163336	chr2:10110517	A/G	cg02698806	chr2:10522874	HPCAL1	0.3	4.72	0.3	4.09e-6	Prostate cancer;
SARC	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg13395646	chr4:1353034	KIAA1530	0.42	4.97	0.31	1.29e-6	Obesity-related traits;
SARC	cis	rs73198271	0.562	rs17631052	chr8:8663787	G/A	cg01851573	chr8:8652454	MFHAS1	0.42	5.14	0.32	5.88e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg14004477	chr1:27719043	GPR3	0.46	6.26	0.38	1.85e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs6912958	0.781	rs6454631	chr6:88225863	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-7.15	-0.42	1.08e-11	Monocyte percentage of white cells;
SARC	cis	rs1200821	0.535	rs1208789	chr10:37722472	A/G	cg00409905	chr10:38381863	ZNF37A	-0.43	-5.78	-0.35	2.39e-8	Hemostatic factors and hematological phenotypes;
SARC	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.61	-7.47	-0.44	1.58e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs11676348	0.741	rs12694425	chr2:218942313	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.4	5.09	0.32	7.23e-7	Ulcerative colitis;
SARC	cis	rs7772486	0.754	rs9373475	chr6:146126419	C/T	cg05347473	chr6:146136440	FBXO30	0.56	7.91	0.46	1.01e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2075371	0.501	rs1643051	chr7:134025372	A/G	cg00033643	chr7:134001901	SLC35B4	-0.49	-6.1	-0.37	4.36e-9	Mean platelet volume;
SARC	cis	rs1580019	0.885	rs4460270	chr7:32496450	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.73	9.78	0.54	3.93e-19	Cognitive ability;
SARC	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg11987759	chr7:65425863	GUSB	-0.47	-6.27	-0.38	1.7e-9	Aortic root size;
SARC	cis	rs11711311	0.955	rs1048892	chr3:113464859	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.69	8.78	0.5	3.47e-16	IgG glycosylation;
SARC	cis	rs4481887	0.604	rs6694598	chr1:248409490	A/G	cg13385794	chr1:248469461	NA	0.34	4.83	0.3	2.5e-6	Common traits (Other);
SARC	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.82	12.64	0.64	3.01e-28	Personality dimensions;
SARC	cis	rs2898681	0.642	rs62336790	chr4:53728000	T/C	cg00338735	chr4:53728038	RASL11B	0.38	4.85	0.3	2.26e-6	Optic nerve measurement (cup area);
SARC	cis	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg17331738	chr1:156647236	NES	0.39	5.02	0.31	1.01e-6	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	11.99	0.62	4.12e-26	Platelet count;
SARC	cis	rs6089584	0.526	rs6089619	chr20:60610916	C/T	cg13770153	chr20:60521292	NA	-0.4	-5.74	-0.35	2.88e-8	Body mass index;
SARC	cis	rs13006833	0.668	rs291453	chr2:191160196	G/A	cg25963032	chr2:191064776	C2orf88	0.35	4.75	0.3	3.51e-6	Urinary metabolites;
SARC	cis	rs1865760	0.713	rs2013063	chr6:25994098	C/T	cg16482183	chr6:26056742	HIST1H1C	0.5	6.68	0.4	1.75e-10	Height;
SARC	cis	rs12048904	0.505	rs10493936	chr1:101213335	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.64	-7.61	-0.45	6.78e-13	Multiple sclerosis;
SARC	cis	rs2276314	0.748	rs4799839	chr18:33597531	T/C	cg05985134	chr18:33552581	C18orf21	0.66	6.75	0.4	1.14e-10	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs2916247	1.000	rs7820440	chr8:93036627	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.59	-6.25	-0.38	1.94e-9	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg08219700	chr8:58056026	NA	0.6	5.82	0.36	1.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2576037	0.796	rs2576039	chr18:44582148	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.36	-5.02	-0.31	1.03e-6	Personality dimensions;
SARC	cis	rs7772486	0.790	rs1832362	chr6:146179955	C/T	cg23711669	chr6:146136114	FBXO30	0.79	13.1	0.65	9.2e-30	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05471465	chr5:146614536	STK32A	-0.54	-6.49	-0.39	5.23e-10	Fibrinogen levels;
SARC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg26338869	chr17:61819248	STRADA	0.79	10.62	0.57	9.65e-22	Prudent dietary pattern;
SARC	cis	rs10128251	0.746	rs9424194	chr10:5724073	A/G	cg09072322	chr10:5726702	C10orf18	0.47	5.14	0.32	5.81e-7	Childhood ear infection;
SARC	cis	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg25427524	chr10:38739819	LOC399744	-0.59	-9.72	-0.54	5.83e-19	Extrinsic epigenetic age acceleration;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg07847428	chr19:8478158	MARCH2	0.49	6.68	0.4	1.69e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs4820539	1.000	rs4822361	chr22:23482718	A/G	cg14186256	chr22:23484241	RTDR1	-0.86	-14.2	-0.68	2.11e-33	Bone mineral density;
SARC	cis	rs3087591	0.708	rs7505	chr17:29644852	G/A	cg24425628	chr17:29625626	OMG;NF1	0.42	5.36	0.33	1.98e-7	Hip circumference;
SARC	cis	rs1858740	0.509	rs196375	chr3:38422919	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.66	8.95	0.51	1.12e-16	Schizophrenia;
SARC	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg04944784	chr2:26401820	FAM59B	-0.59	-7.76	-0.45	2.57e-13	Gut microbiome composition (summer);
SARC	cis	rs16854884	0.586	rs6795008	chr3:143738421	A/G	cg06585982	chr3:143692056	C3orf58	0.7	9.83	0.54	2.77e-19	Economic and political preferences (feminism/equality);
SARC	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg22903657	chr4:1355424	KIAA1530	-0.36	-4.86	-0.3	2.14e-6	Obesity-related traits;
SARC	cis	rs8180040	0.620	rs9844122	chr3:47108330	C/T	cg27129171	chr3:47204927	SETD2	0.7	9.56	0.53	1.79e-18	Colorectal cancer;
SARC	cis	rs2404602	0.647	rs11072618	chr15:77019342	A/G	cg15268244	chr15:77196840	NA	0.46	5.34	0.33	2.2e-7	Blood metabolite levels;
SARC	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg24549020	chr5:56110836	MAP3K1	0.81	8.51	0.49	2.11e-15	Initial pursuit acceleration;
SARC	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.6	5.21	0.32	4.13e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2228479	0.867	rs62052168	chr16:89947203	G/A	cg00800038	chr16:89945340	TCF25	-0.75	-5.23	-0.32	3.82e-7	Skin colour saturation;
SARC	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg16405210	chr4:1374714	KIAA1530	-0.48	-5.72	-0.35	3.29e-8	Obesity-related traits;
SARC	cis	rs7681440	0.904	rs1442153	chr4:90775719	T/G	cg02192967	chr4:90758406	SNCA	0.37	5.26	0.33	3.25e-7	Dementia with Lewy bodies;
SARC	cis	rs72627123	0.867	rs59675549	chr14:74469480	A/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.79	5.97	0.36	8.97e-9	Morning vs. evening chronotype;
SARC	cis	rs7647973	0.626	rs7649428	chr3:49868876	A/T	cg03060546	chr3:49711283	APEH	-0.66	-6.85	-0.41	6.46e-11	Menarche (age at onset);
SARC	cis	rs910316	1.000	rs10142865	chr14:75555624	G/A	cg23033748	chr14:75592666	NEK9	0.37	5.27	0.33	3.12e-7	Height;
SARC	cis	rs477692	0.517	rs871026	chr10:131293145	A/G	cg05714579	chr10:131428358	MGMT	-0.56	-7.27	-0.43	5.57e-12	Response to temozolomide;
SARC	cis	rs3796352	1.000	rs3796352	chr3:52913279	C/T	cg12962167	chr3:53033115	SFMBT1	0.79	5.26	0.33	3.31e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs5758659	0.714	rs133373	chr22:42465788	G/A	cg04733989	chr22:42467013	NAGA	0.51	6.32	0.38	1.34e-9	Cognitive function;
SARC	cis	rs67311347	0.910	rs13089215	chr3:40495894	T/C	cg09455208	chr3:40491958	NA	-0.41	-6.23	-0.38	2.11e-9	Renal cell carcinoma;
SARC	cis	rs11098499	0.779	rs10011097	chr4:120310359	T/G	cg09307838	chr4:120376055	NA	0.91	12.88	0.65	4.9e-29	Corneal astigmatism;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg14037413	chr11:9482594	ZNF143	-0.58	-6.52	-0.39	4.24e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg08067268	chr2:26466485	HADHB;HADHA	0.46	5.77	0.35	2.54e-8	Gut microbiome composition (summer);
SARC	cis	rs3784262	0.669	rs4646580	chr15:58329211	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.33	-4.96	-0.31	1.38e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs34779708	0.733	rs11597184	chr10:35397396	G/A	cg03585969	chr10:35415529	CREM	0.42	5.11	0.32	6.77e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs6912958	0.728	rs7773906	chr6:88251869	T/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.38	-0.33	1.84e-7	Monocyte percentage of white cells;
SARC	cis	rs2204008	0.583	rs12307593	chr12:38317803	A/G	cg14851346	chr12:38532713	NA	0.43	5.05	0.31	9.04e-7	Bladder cancer;
SARC	cis	rs920590	0.560	rs3758061	chr8:19674033	C/T	cg17834443	chr8:19674713	INTS10	-0.56	-6.75	-0.4	1.13e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9486719	0.857	rs6568392	chr6:96861476	G/T	cg18709589	chr6:96969512	KIAA0776	0.52	5.6	0.34	6.16e-8	Migraine;Coronary artery disease;
SARC	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg11062466	chr8:58055876	NA	0.66	5.86	0.36	1.56e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs17270561	0.609	rs9358872	chr6:25727517	G/A	cg16482183	chr6:26056742	HIST1H1C	0.43	5.25	0.33	3.49e-7	Iron status biomarkers;
SARC	cis	rs1448094	0.621	rs10863091	chr12:86282240	T/C	cg00310523	chr12:86230176	RASSF9	0.31	4.79	0.3	3.01e-6	Major depressive disorder;
SARC	cis	rs7726839	0.555	rs7720419	chr5:589343	A/T	cg16447950	chr5:562315	NA	-0.52	-7.49	-0.44	1.39e-12	Obesity-related traits;
SARC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg26338869	chr17:61819248	STRADA	-0.79	-10.65	-0.57	7.96e-22	Prudent dietary pattern;
SARC	cis	rs6840360	0.615	rs113052419	chr4:152473008	T/C	cg22705602	chr4:152727874	NA	-0.41	-6.25	-0.38	1.98e-9	Intelligence (multi-trait analysis);
SARC	cis	rs943466	1.000	rs7755323	chr6:33761159	A/G	cg04676172	chr6:33757040	LEMD2	0.46	4.87	0.3	2.09e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
SARC	cis	rs9300255	0.569	rs1716170	chr12:123716513	C/T	cg05973401	chr12:123451056	ABCB9	0.47	5.29	0.33	2.84e-7	Neutrophil percentage of white cells;
SARC	cis	rs10463554	0.963	rs34772	chr5:102450512	C/A	cg23492399	chr5:102201601	PAM	-0.52	-5.72	-0.35	3.2e-8	Parkinson's disease;
SARC	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg04546413	chr19:29218101	NA	0.63	8.52	0.49	2.01e-15	Methadone dose in opioid dependence;
SARC	cis	rs9810259	0.586	rs17817276	chr3:12397392	A/G	cg04748988	chr3:12329223	PPARG	-0.39	-4.98	-0.31	1.22e-6	Platelet count;
SARC	cis	rs3733585	0.605	rs7656624	chr4:10121097	T/C	cg11266682	chr4:10021025	SLC2A9	-0.34	-5.55	-0.34	7.72e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs5758511	0.680	rs5758688	chr22:42662501	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.45	6.71	0.4	1.49e-10	Birth weight;
SARC	cis	rs7020830	0.931	rs3802422	chr9:37097172	G/A	cg14294708	chr9:37120828	ZCCHC7	1.14	21.9	0.82	1.75e-58	Schizophrenia;
SARC	cis	rs7937682	0.961	rs17113227	chr11:111620491	A/G	cg22437258	chr11:111473054	SIK2	0.67	8.83	0.5	2.49e-16	Primary sclerosing cholangitis;
SARC	cis	rs2228479	0.717	rs2286392	chr16:89809549	A/G	cg06558623	chr16:89946397	TCF25	0.87	6.94	0.41	3.78e-11	Skin colour saturation;
SARC	cis	rs7927771	0.832	rs7924485	chr11:47419129	A/G	cg20307385	chr11:47447363	PSMC3	0.6	7.65	0.45	5.11e-13	Subjective well-being;
SARC	trans	rs8073060	0.561	rs225260	chr17:33958422	T/C	cg19694781	chr19:47549865	TMEM160	-0.68	-6.87	-0.41	5.88e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg19723775	chr5:179050963	HNRNPH1	-0.46	-6.1	-0.37	4.49e-9	Lung cancer;
SARC	cis	rs7044106	0.791	rs10985000	chr9:123484115	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	6.27	0.38	1.72e-9	Hip circumference adjusted for BMI;
SARC	cis	rs6121246	0.567	rs6058189	chr20:30192389	A/G	cg21427119	chr20:30132790	HM13	-0.45	-4.98	-0.31	1.23e-6	Mean corpuscular hemoglobin;
SARC	cis	rs9457247	0.663	rs9459835	chr6:167417551	G/T	cg07741184	chr6:167504864	NA	0.33	6.26	0.38	1.84e-9	Crohn's disease;
SARC	cis	rs8180040	0.654	rs6766230	chr3:47196209	C/A	cg27129171	chr3:47204927	SETD2	0.69	9.4	0.52	5.41e-18	Colorectal cancer;
SARC	cis	rs858239	0.601	rs28673077	chr7:23250854	C/T	cg23682824	chr7:23144976	KLHL7	0.65	7.86	0.46	1.43e-13	Cerebrospinal fluid biomarker levels;
SARC	cis	rs11718455	0.960	rs3843373	chr3:44011053	C/T	cg08738300	chr3:44038990	NA	-0.57	-6.26	-0.38	1.85e-9	Coronary artery disease;
SARC	cis	rs7772486	0.790	rs6917482	chr6:146243581	C/T	cg05347473	chr6:146136440	FBXO30	-0.48	-6.52	-0.39	4.23e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs478304	0.934	rs610037	chr11:65546857	A/C	cg27068330	chr11:65405492	SIPA1	0.37	4.81	0.3	2.77e-6	Acne (severe);
SARC	cis	rs4808199	0.948	rs757001	chr19:19448808	G/A	cg03709012	chr19:19516395	GATAD2A	1.13	11.33	0.6	5.5e-24	Nonalcoholic fatty liver disease;
SARC	cis	rs2204008	0.745	rs8189516	chr12:38239084	C/T	cg26384229	chr12:38710491	ALG10B	0.92	13.78	0.67	5.45e-32	Bladder cancer;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg04438595	chr1:16176425	SPEN	-0.49	-6.78	-0.41	9.82e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs7568458	0.905	rs59877521	chr2:85759494	C/T	cg17127132	chr2:85788382	GGCX	0.43	5.69	0.35	3.85e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg05623727	chr3:50126028	RBM5	-0.33	-5.06	-0.31	8.68e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7945705	0.902	rs2016942	chr11:8938787	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.43	5.86	0.36	1.58e-8	Hemoglobin concentration;
SARC	cis	rs9581943	0.901	rs9554188	chr13:28462132	G/A	cg17352152	chr13:28491409	NA	0.4	5.28	0.33	2.9e-7	Pancreatic cancer;
SARC	cis	rs240764	0.578	rs6927598	chr6:101232729	T/C	cg09795085	chr6:101329169	ASCC3	0.45	5.66	0.35	4.42e-8	Neuroticism;
SARC	cis	rs2486288	0.656	rs2461705	chr15:45570241	A/G	cg15395560	chr15:45543142	SLC28A2	0.33	6.24	0.38	2.02e-9	Glomerular filtration rate;
SARC	cis	rs2043112	0.691	rs13154561	chr5:39078291	T/G	cg04869206	chr5:39074266	RICTOR	0.54	6.78	0.41	9.72e-11	Obesity-related traits;
SARC	cis	rs5753618	0.561	rs2283881	chr22:31638932	G/A	cg00478049	chr22:31556069	RNF185	0.44	4.75	0.3	3.55e-6	Colorectal cancer;
SARC	cis	rs7769051	0.808	rs1467403	chr6:133089952	T/A	cg07930552	chr6:133119739	C6orf192	0.89	8.12	0.47	2.63e-14	Type 2 diabetes nephropathy;
SARC	cis	rs838147	0.537	rs503279	chr19:49209010	C/T	cg07051648	chr19:49177693	NTN5;SEC1	0.4	5.19	0.32	4.62e-7	Dietary macronutrient intake;
SARC	cis	rs9309473	1.000	rs7586463	chr2:73798476	T/C	cg20560298	chr2:73613845	ALMS1	-0.48	-5.92	-0.36	1.14e-8	Metabolite levels;
SARC	cis	rs6840360	0.967	rs7684350	chr4:152672882	T/G	cg22705602	chr4:152727874	NA	-0.36	-6.32	-0.38	1.34e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7589342	0.660	rs1897169	chr2:106397624	C/T	cg16077055	chr2:106428750	NCK2	-0.32	-5.96	-0.36	9.02e-9	Addiction;
SARC	cis	rs55823223	0.648	rs11867582	chr17:73857306	A/G	cg06969265	chr17:73775802	H3F3B	0.58	6.12	0.37	3.94e-9	Psoriasis;
SARC	cis	rs7011049	0.778	rs118059348	chr8:53865777	C/T	cg26025543	chr8:53854495	NA	0.55	4.86	0.3	2.2e-6	Systolic blood pressure;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg24927001	chr1:111682055	CEPT1;DRAM2	-0.6	-6.45	-0.39	6.48e-10	Lung cancer in ever smokers;
SARC	cis	rs637571	0.780	rs677029	chr11:65683531	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.71	9.51	0.53	2.49e-18	Eosinophil percentage of white cells;
SARC	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg24250549	chr1:154909240	PMVK	0.79	11.29	0.59	7.22e-24	Prostate cancer;
SARC	cis	rs17376456	0.569	rs10050364	chr5:93064127	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.49	4.97	0.31	1.28e-6	Diabetic retinopathy;
SARC	cis	rs7568458	0.684	rs7593969	chr2:85809670	A/G	cg23752985	chr2:85803571	VAMP8	-0.48	-6.31	-0.38	1.38e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg11952622	chr19:58962976	ZNF324B	0.53	6.93	0.41	4.15e-11	Uric acid clearance;
SARC	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.47	5.81	0.36	2.01e-8	Tonsillectomy;
SARC	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg03351412	chr1:154909251	PMVK	0.62	7.87	0.46	1.37e-13	Prostate cancer;
SARC	cis	rs5769765	0.955	rs5770750	chr22:50276828	A/G	cg03033257	chr22:50311977	ALG12;CRELD2	-0.54	-5.64	-0.35	4.81e-8	Schizophrenia;
SARC	cis	rs73198271	0.563	rs3748143	chr8:8655237	A/G	cg15556689	chr8:8085844	FLJ10661	0.52	4.84	0.3	2.37e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs7589342	0.839	rs7589790	chr2:106433909	C/G	cg16077055	chr2:106428750	NCK2	-0.35	-5.95	-0.36	9.56e-9	Addiction;
SARC	cis	rs710216	0.752	rs841845	chr1:43404713	C/T	cg03128534	chr1:43423976	SLC2A1	-0.59	-5.8	-0.36	2.16e-8	Red cell distribution width;
SARC	cis	rs4148883	0.628	rs34195655	chr4:100073795	C/T	cg12011299	chr4:100065546	ADH4	0.37	7.04	0.42	2.19e-11	Alcohol dependence;
SARC	cis	rs2304069	0.954	rs6861548	chr5:149384680	A/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.68	6.57	0.4	3.3e-10	HIV-1 control;
SARC	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg12463550	chr7:65579703	CRCP	0.49	5.61	0.34	5.75e-8	Aortic root size;
SARC	cis	rs734999	0.588	rs3001837	chr1:2532506	G/A	cg20673091	chr1:2541236	MMEL1	-0.33	-5.13	-0.32	5.98e-7	Ulcerative colitis;
SARC	cis	rs6752107	0.967	rs6431661	chr2:234167421	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.48	6.22	0.38	2.22e-9	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs7659604	1.000	rs28532673	chr4:122664323	A/G	cg19748678	chr4:122722346	EXOSC9	-0.44	-5.48	-0.34	1.08e-7	Type 2 diabetes;
SARC	cis	rs9916302	0.706	rs649180	chr17:37464959	A/C	cg00129232	chr17:37814104	STARD3	0.52	5.48	0.34	1.09e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs965469	1.000	rs2236108	chr20:3286331	A/C	cg25506879	chr20:3388711	C20orf194	-0.47	-4.76	-0.3	3.42e-6	IFN-related cytopenia;
SARC	cis	rs2241193	0.649	rs9341191	chr2:217521648	A/G	cg23642078	chr2:216946473	TMEM169;PECR	0.7	5.24	0.32	3.67e-7	Visceral fat;
SARC	cis	rs9715521	0.935	rs62301184	chr4:59836168	A/G	cg11281224	chr4:60001000	NA	-0.39	-4.96	-0.31	1.34e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs501120	1.000	rs634963	chr10:44760033	T/C	cg09554077	chr10:44749378	NA	0.48	6.45	0.39	6.48e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg20007245	chr22:24372913	LOC391322	-0.72	-9.73	-0.54	5.43e-19	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2425143	1.000	rs12479473	chr20:34398628	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-5.84	-0.36	1.71e-8	Blood protein levels;
SARC	trans	rs877282	0.853	rs7079299	chr10:756455	A/G	cg22713356	chr15:30763199	NA	0.99	9.88	0.54	1.92e-19	Uric acid levels;
SARC	cis	rs9393692	0.905	rs9357004	chr6:26303319	A/G	cg05868516	chr6:26286170	HIST1H4H	0.59	7.6	0.45	7.28e-13	Educational attainment;
SARC	cis	rs3126085	0.935	rs4845740	chr1:152183310	G/A	cg26876637	chr1:152193138	HRNR	0.47	5.39	0.33	1.7e-7	Atopic dermatitis;
SARC	trans	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg03024183	chr8:37963317	ASH2L	0.44	6.25	0.38	1.94e-9	Immature fraction of reticulocytes;
SARC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.12	-20.63	-0.8	1.67e-54	Prudent dietary pattern;
SARC	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.72	8.23	0.47	1.3e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs8044868	1.000	rs8044868	chr16:72162102	C/T	cg16558253	chr16:72132732	DHX38	-0.37	-5.16	-0.32	5.2e-7	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
SARC	cis	rs796364	0.806	rs10445791	chr2:201078307	C/T	cg23649088	chr2:200775458	C2orf69	-0.64	-5.39	-0.33	1.7e-7	Schizophrenia;
SARC	cis	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg12257692	chr3:49977190	RBM6	-0.27	-4.83	-0.3	2.45e-6	Body mass index;
SARC	cis	rs6831352	1.000	rs6822348	chr4:100053894	A/T	cg12011299	chr4:100065546	ADH4	0.34	5.98	0.36	8.33e-9	Alcohol dependence;
SARC	cis	rs9788721	0.967	rs72740955	chr15:78849779	C/T	cg06917634	chr15:78832804	PSMA4	-0.51	-5.34	-0.33	2.21e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	trans	rs17685	0.725	rs7795291	chr7:75725206	C/A	cg19862616	chr7:65841803	NCRNA00174	0.61	7.48	0.44	1.47e-12	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg19774624	chr17:42201019	HDAC5	0.73	9.95	0.55	1.19e-19	Total body bone mineral density;
SARC	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg26335602	chr6:28129616	ZNF389	0.53	5.88	0.36	1.43e-8	Depression;
SARC	cis	rs7766436	0.767	rs13206434	chr6:22608883	A/G	cg13666174	chr6:22585274	NA	-0.5	-6.73	-0.4	1.33e-10	Coronary artery disease;
SARC	cis	rs477895	1.000	rs2276014	chr11:64081445	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	5.49	0.34	1.04e-7	Mean platelet volume;
SARC	cis	rs1475911	0.708	rs66994219	chr21:43521647	G/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.35	-4.77	-0.3	3.21e-6	IgG glycosylation;
SARC	cis	rs2204008	0.626	rs11520260	chr12:38330092	C/T	cg26384229	chr12:38710491	ALG10B	0.87	12.6	0.64	4.2e-28	Bladder cancer;
SARC	cis	rs6963495	0.818	rs9769403	chr7:105163091	G/A	cg13798780	chr7:105162888	PUS7	0.6	5.45	0.34	1.31e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs611744	0.967	rs702801	chr8:109211802	T/C	cg21045802	chr8:109455806	TTC35	0.46	5.41	0.33	1.57e-7	Dupuytren's disease;
SARC	cis	rs933688	1.000	rs12656350	chr5:90751343	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	12.47	0.63	1.09e-27	Smoking behavior;
SARC	cis	rs708547	0.874	rs1614251	chr4:57891386	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.69	8.07	0.47	3.75e-14	Response to bleomycin (chromatid breaks);
SARC	cis	rs6582630	0.555	rs10880544	chr12:38473464	G/C	cg26384229	chr12:38710491	ALG10B	0.84	12.0	0.62	3.64e-26	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9467711	0.591	rs9461222	chr6:25905111	G/A	cg21479132	chr6:26055353	NA	0.74	4.72	0.3	4.08e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs3126085	0.799	rs11589532	chr1:152176539	G/A	cg26876637	chr1:152193138	HRNR	-0.46	-5.08	-0.32	7.56e-7	Atopic dermatitis;
SARC	cis	rs11155671	0.530	rs7763849	chr6:150206380	C/T	cg05036130	chr6:150231994	NA	0.27	4.76	0.3	3.33e-6	Testicular germ cell tumor;
SARC	cis	rs5753618	0.561	rs9609264	chr22:31746719	C/G	cg02404636	chr22:31891804	SFI1	0.5	5.42	0.33	1.51e-7	Colorectal cancer;
SARC	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg05313129	chr8:58192883	C8orf71	-0.57	-6.43	-0.39	7.31e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6582630	0.519	rs9738104	chr12:38338459	A/C	cg26384229	chr12:38710491	ALG10B	0.92	13.31	0.66	1.98e-30	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg12463550	chr7:65579703	CRCP	0.66	5.07	0.32	8.09e-7	Diabetic kidney disease;
SARC	cis	rs7949030	0.754	rs36104523	chr11:62395740	A/T	cg13298116	chr11:62369859	EML3;MTA2	-0.42	-6.21	-0.38	2.38e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs1559088	0.803	rs10411529	chr19:33616256	A/C	cg17764715	chr19:33622953	WDR88	0.51	6.75	0.4	1.19e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs7582720	1.000	rs72928620	chr2:203840973	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs9467773	0.620	rs2494692	chr6:26615223	G/A	cg12292205	chr6:26970375	C6orf41	0.4	5.0	0.31	1.14e-6	Intelligence (multi-trait analysis);
SARC	cis	rs8114671	0.562	rs6088647	chr20:33505997	T/C	cg24642439	chr20:33292090	TP53INP2	0.47	5.61	0.35	5.66e-8	Height;
SARC	trans	rs11250098	0.541	rs6997997	chr8:10766082	T/C	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.54	-0.39	3.79e-10	Morning vs. evening chronotype;
SARC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg06873352	chr17:61820015	STRADA	0.53	6.92	0.41	4.3e-11	Prudent dietary pattern;
SARC	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	8.7	0.5	6.11e-16	Alzheimer's disease;
SARC	cis	rs2075371	0.501	rs1643051	chr7:134025372	A/G	cg11752832	chr7:134001865	SLC35B4	-0.48	-6.01	-0.37	7.07e-9	Mean platelet volume;
SARC	cis	rs7246657	0.882	rs8112610	chr19:37928730	C/A	cg23950597	chr19:37808831	NA	-0.57	-5.67	-0.35	4.24e-8	Coronary artery calcification;
SARC	cis	rs1008375	1.000	rs9291659	chr4:17662360	A/C	cg16339924	chr4:17578868	LAP3	0.62	8.03	0.47	4.8e-14	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg08048268	chr3:133502702	NA	-0.45	-6.13	-0.37	3.69e-9	Iron status biomarkers;
SARC	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg18404041	chr3:52824283	ITIH1	0.38	5.53	0.34	8.61e-8	Bipolar disorder;
SARC	cis	rs67311347	1.000	rs11714912	chr3:40494065	A/G	cg24209194	chr3:40518798	ZNF619	-0.66	-8.89	-0.5	1.66e-16	Renal cell carcinoma;
SARC	trans	rs11088226	0.681	rs1015048	chr21:33949306	T/C	cg09050820	chr6:167586206	TCP10L2	0.61	6.79	0.41	9.27e-11	Gastritis;
SARC	trans	rs11098499	0.954	rs4345162	chr4:120312959	G/A	cg25214090	chr10:38739885	LOC399744	0.55	7.14	0.42	1.15e-11	Corneal astigmatism;
SARC	cis	rs79149102	0.579	rs12593542	chr15:75282147	C/G	cg17294928	chr15:75287854	SCAMP5	-0.9	-8.61	-0.49	1.1e-15	Lung cancer;
SARC	cis	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg25894440	chr7:65020034	NA	-0.77	-5.9	-0.36	1.24e-8	Diabetic kidney disease;
SARC	cis	rs7520050	0.966	rs785494	chr1:46586626	C/A	cg06784218	chr1:46089804	CCDC17	-0.26	-4.82	-0.3	2.56e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs10875746	0.855	rs2269936	chr12:48425235	G/A	cg26205652	chr12:48591994	NA	0.53	5.68	0.35	3.97e-8	Longevity (90 years and older);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg12229505	chr15:80351983	ZFAND6	-0.85	-7.13	-0.42	1.25e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9790314	1.000	rs6775627	chr3:160953609	A/G	cg03342759	chr3:160939853	NMD3	-0.61	-7.73	-0.45	3.22e-13	Morning vs. evening chronotype;
SARC	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg13126279	chr21:47581558	C21orf56	-0.42	-4.85	-0.3	2.21e-6	Testicular germ cell tumor;
SARC	cis	rs9790314	0.582	rs11922752	chr3:160600599	G/C	cg04691961	chr3:161091175	C3orf57	0.55	7.59	0.45	7.64e-13	Morning vs. evening chronotype;
SARC	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg03709012	chr19:19516395	GATAD2A	0.97	15.18	0.71	1.17e-36	Tonsillectomy;
SARC	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg04944784	chr2:26401820	FAM59B	-0.5	-6.37	-0.39	1.01e-9	Gut microbiome composition (summer);
SARC	cis	rs12701220	0.689	rs12533004	chr7:1095410	C/T	cg02733842	chr7:1102375	C7orf50	-0.6	-7.01	-0.42	2.49e-11	Bronchopulmonary dysplasia;
SARC	cis	rs2425143	1.000	rs117010355	chr20:34343442	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-6.15	-0.37	3.35e-9	Blood protein levels;
SARC	cis	rs79149102	0.579	rs2304904	chr15:75315975	G/A	cg09165964	chr15:75287851	SCAMP5	-1.04	-8.66	-0.49	7.71e-16	Lung cancer;
SARC	cis	rs3018712	0.532	rs2513280	chr11:68416907	C/G	cg01657329	chr11:68192670	LRP5	0.59	5.38	0.33	1.81e-7	Total body bone mineral density;
SARC	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	cis	rs9914988	0.613	rs1806982	chr17:27266143	C/T	cg10538030	chr17:27276405	PHF12	-0.58	-4.93	-0.31	1.59e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg11644478	chr21:40555479	PSMG1	-0.59	-7.29	-0.43	4.67e-12	Menarche (age at onset);
SARC	cis	rs2180341	0.538	rs4392733	chr6:127712603	T/C	cg24812749	chr6:127587940	RNF146	0.46	5.55	0.34	7.64e-8	Breast cancer;
SARC	cis	rs7044106	0.537	rs10739573	chr9:123489818	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	8.29	0.48	8.81e-15	Hip circumference adjusted for BMI;
SARC	cis	rs6696846	0.515	rs11240364	chr1:205105917	C/G	cg21643547	chr1:205240462	TMCC2	-0.46	-5.73	-0.35	3.14e-8	Red blood cell count;
SARC	cis	rs9486715	0.830	rs2475023	chr6:96996833	G/A	cg18709589	chr6:96969512	KIAA0776	-0.62	-7.85	-0.46	1.55e-13	Headache;
SARC	cis	rs4332037	0.805	rs10278591	chr7:1921362	A/G	cg23422044	chr7:1970798	MAD1L1	0.48	6.19	0.38	2.62e-9	Bipolar disorder;
SARC	cis	rs116095464	0.558	rs10065584	chr5:253997	G/A	cg22857025	chr5:266934	NA	-1.11	-10.56	-0.57	1.45e-21	Breast cancer;
SARC	cis	rs668210	0.894	rs1786171	chr11:65769809	G/C	cg02202077	chr11:65769826	EIF1AD;BANF1	0.67	7.63	0.45	5.86e-13	Cerebrospinal fluid biomarker levels;
SARC	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	11.03	0.59	4.93e-23	Alzheimer's disease;
SARC	cis	rs1355223	0.902	rs11603774	chr11:34732891	G/T	cg18508148	chr11:34937573	PDHX;APIP	-0.38	-4.81	-0.3	2.68e-6	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg13206674	chr6:150067644	NUP43	0.47	6.15	0.37	3.41e-9	Lung cancer;
SARC	cis	rs2425143	1.000	rs73902908	chr20:34365112	G/T	cg01084648	chr20:34329383	RBM39	0.64	4.81	0.3	2.73e-6	Blood protein levels;
SARC	cis	rs9916302	0.904	rs7216086	chr17:37709422	G/A	cg07936489	chr17:37558343	FBXL20	-0.67	-8.63	-0.49	9.55e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg24549020	chr5:56110836	MAP3K1	0.81	8.4	0.48	4.37e-15	Initial pursuit acceleration;
SARC	cis	rs35213789	0.803	rs2851485	chr7:69074768	T/C	cg10619644	chr7:69149951	AUTS2	-0.45	-5.75	-0.35	2.85e-8	Childhood ear infection;
SARC	trans	rs1814175	0.817	rs10769598	chr11:49669326	C/G	cg03929089	chr4:120376271	NA	-0.88	-13.86	-0.67	3.03e-32	Height;
SARC	cis	rs6977660	0.714	rs10252597	chr7:19791171	G/T	cg05791153	chr7:19748676	TWISTNB	-0.72	-6.37	-0.39	9.74e-10	Thyroid stimulating hormone;
SARC	cis	rs3741404	0.537	rs1123251	chr11:63917601	G/T	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.37	-5.38	-0.33	1.77e-7	Platelet count;
SARC	cis	rs9815354	0.812	rs73073364	chr3:41843058	T/C	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg04277193	chr17:41438351	NA	0.47	5.04	0.31	9.3e-7	Menopause (age at onset);
SARC	cis	rs112591243	0.685	rs2839323	chr21:47978421	G/A	cg26904215	chr21:47823096	PCNT	-0.76	-5.14	-0.32	5.75e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs4917300	0.571	rs2029620	chr8:143111294	T/C	cg06573787	chr8:143070187	NA	0.35	4.72	0.3	4.06e-6	Amyotrophic lateral sclerosis;
SARC	cis	rs67311347	0.713	rs114569261	chr3:40314580	G/A	cg09455208	chr3:40491958	NA	0.35	5.42	0.33	1.47e-7	Renal cell carcinoma;
SARC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.54	6.16	0.37	3.12e-9	Prudent dietary pattern;
SARC	cis	rs7772486	0.686	rs857875	chr6:145980033	T/G	cg05347473	chr6:146136440	FBXO30	-0.5	-7.1	-0.42	1.48e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg08280861	chr8:58055591	NA	0.6	5.28	0.33	2.92e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9818758	0.556	rs9813813	chr3:49207093	T/A	cg06212747	chr3:49208901	KLHDC8B	-0.71	-6.16	-0.37	3.22e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs7647973	0.626	rs1463728	chr3:49647404	T/A	cg06212747	chr3:49208901	KLHDC8B	0.72	6.44	0.39	6.87e-10	Menarche (age at onset);
SARC	cis	rs9916302	0.851	rs11078907	chr17:37662954	C/T	cg20243544	chr17:37824526	PNMT	0.55	6.53	0.39	4.05e-10	Glomerular filtration rate (creatinine);
SARC	trans	rs656319	0.513	rs3885723	chr8:9991661	A/C	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.91	-0.46	1.01e-13	Myopia (pathological);
SARC	cis	rs7223966	1.000	rs8075521	chr17:61804954	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-5.86	-0.36	1.6e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6772849	0.930	rs9813197	chr3:128369104	G/A	cg08795948	chr3:128337044	NA	0.54	7.57	0.44	8.84e-13	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs1348850	0.567	rs3770009	chr2:178536544	C/T	cg22681709	chr2:178499509	PDE11A	-0.36	-5.14	-0.32	5.89e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg04944784	chr2:26401820	FAM59B	0.63	8.03	0.47	4.74e-14	Gut microbiome composition (summer);
SARC	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg06634786	chr22:41940651	POLR3H	0.5	6.16	0.37	3.11e-9	Vitiligo;
SARC	cis	rs6062302	0.545	rs2297430	chr20:62229244	T/C	cg09650180	chr20:62225654	GMEB2	-0.44	-5.4	-0.33	1.66e-7	Glioblastoma;
SARC	cis	rs3768617	0.510	rs723014	chr1:183076287	A/G	cg13390022	chr1:182993471	LAMC1	0.32	4.79	0.3	2.91e-6	Fuchs's corneal dystrophy;
SARC	cis	rs10875746	0.951	rs11168433	chr12:48558064	C/G	cg26205652	chr12:48591994	NA	0.54	6.01	0.37	7.01e-9	Longevity (90 years and older);
SARC	cis	rs9443189	0.530	rs614065	chr6:76315633	G/A	cg01950844	chr6:76311363	SENP6	0.86	8.23	0.47	1.31e-14	Prostate cancer;
SARC	cis	rs55794721	0.509	rs2982358	chr1:25745204	G/T	cg27572855	chr1:25598939	RHD	0.56	9.5	0.53	2.58e-18	Plateletcrit;Mean corpuscular volume;
SARC	cis	rs7520050	0.966	rs4545281	chr1:46360054	C/T	cg24296786	chr1:45957014	TESK2	0.38	4.82	0.3	2.58e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs4742903	0.875	rs7041529	chr9:106991539	G/A	cg14250997	chr9:106856677	SMC2	0.4	5.17	0.32	5.08e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg15844154	chr10:75173990	ANXA7	-0.52	-6.42	-0.39	7.65e-10	Height;
SARC	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg11764359	chr7:65958608	NA	-0.85	-12.29	-0.63	4.45e-27	Aortic root size;
SARC	cis	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg00031303	chr3:195681400	NA	0.51	6.11	0.37	4.07e-9	Pancreatic cancer;
SARC	trans	rs9325144	0.647	rs11169189	chr12:39097078	A/T	cg23762105	chr12:34175262	ALG10	0.5	6.23	0.38	2.14e-9	Morning vs. evening chronotype;
SARC	cis	rs36051895	0.632	rs10118789	chr9:5141178	G/A	cg02405213	chr9:5042618	JAK2	-0.43	-5.14	-0.32	5.83e-7	Pediatric autoimmune diseases;
SARC	cis	rs16976116	0.901	rs28591259	chr15:55498940	T/A	cg17854078	chr15:55489399	RSL24D1	0.66	6.53	0.39	4.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs796364	0.806	rs1106400	chr2:201004089	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.53	-4.87	-0.3	2.08e-6	Schizophrenia;
SARC	cis	rs3857536	0.904	rs9345776	chr6:66888552	A/G	cg07460842	chr6:66804631	NA	-0.45	-5.33	-0.33	2.28e-7	Blood trace element (Cu levels);
SARC	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg27266027	chr21:40555129	PSMG1	-0.41	-4.76	-0.3	3.4e-6	Menarche (age at onset);
SARC	cis	rs7937682	0.632	rs4935811	chr11:111679262	C/T	cg22437258	chr11:111473054	SIK2	-0.48	-5.6	-0.34	5.92e-8	Primary sclerosing cholangitis;
SARC	cis	rs11583043	0.667	rs873760	chr1:101540561	C/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.44	4.74	0.3	3.77e-6	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs67478160	0.643	rs8004408	chr14:104203938	G/A	cg26031613	chr14:104095156	KLC1	-0.39	-4.87	-0.3	2.11e-6	Schizophrenia;
SARC	trans	rs1853207	0.737	rs17878382	chr10:96610631	T/C	cg02737782	chr1:8014393	NA	-0.95	-6.37	-0.39	1.01e-9	Blood metabolite levels;
SARC	cis	rs10751667	0.961	rs10902263	chr11:992691	A/C	cg06064525	chr11:970664	AP2A2	0.24	5.37	0.33	1.93e-7	Alzheimer's disease (late onset);
SARC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg22105103	chr4:187893119	NA	0.51	6.91	0.41	4.69e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1401999	0.650	rs3792585	chr3:183646222	A/G	cg01324343	chr3:183735012	ABCC5	0.58	10.49	0.57	2.54e-21	Anterior chamber depth;
SARC	cis	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.56	8.62	0.49	1.07e-15	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs986417	1.000	rs3931460	chr14:60939101	A/C	cg27398547	chr14:60952738	C14orf39	0.97	8.68	0.49	7.1e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs7617773	0.817	rs17786132	chr3:48249420	C/G	cg11946769	chr3:48343235	NME6	0.72	9.36	0.52	7.22e-18	Coronary artery disease;
SARC	cis	rs3020736	0.500	rs4147641	chr22:42482502	C/G	cg15557168	chr22:42548783	NA	0.35	4.8	0.3	2.85e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1707322	0.964	rs785516	chr1:46564758	T/G	cg06784218	chr1:46089804	CCDC17	-0.36	-6.28	-0.38	1.61e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs710865	0.966	rs709683	chr1:19565344	C/G	cg13387374	chr1:19411106	UBR4	0.44	5.58	0.34	6.82e-8	Brain structure;
SARC	cis	rs10791323	0.593	rs2282604	chr11:133714672	A/G	cg14349672	chr11:133703707	NA	-0.36	-5.39	-0.33	1.76e-7	Childhood ear infection;
SARC	cis	rs2191566	0.747	rs4803667	chr19:44533604	T/C	cg20607764	chr19:44506953	ZNF230	-0.45	-4.97	-0.31	1.29e-6	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg22535103	chr8:58192502	C8orf71	-0.8	-7.85	-0.46	1.55e-13	Developmental language disorder (linguistic errors);
SARC	cis	rs7223966	1.000	rs9903903	chr17:61762044	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.48	-5.35	-0.33	2.07e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs701145	0.556	rs355756	chr3:154021063	G/A	cg16511985	chr3:153974050	SGEF	0.41	4.85	0.3	2.24e-6	Coronary artery disease;
SARC	cis	rs2013441	1.000	rs2526483	chr17:20112216	A/G	cg13482628	chr17:19912719	NA	-0.46	-5.98	-0.36	8.48e-9	Obesity-related traits;
SARC	cis	rs11098499	0.954	rs2892848	chr4:120381341	C/T	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	trans	rs3942852	0.568	rs4412719	chr11:48101660	T/A	cg03929089	chr4:120376271	NA	-0.56	-6.84	-0.41	7.02e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg24110177	chr3:50126178	RBM5	0.55	7.41	0.44	2.32e-12	Intelligence (multi-trait analysis);
SARC	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg18252515	chr7:66147081	NA	-1.29	-11.04	-0.59	4.48e-23	Diabetic kidney disease;
SARC	cis	rs763121	0.889	rs1837988	chr22:38901094	A/G	cg06022373	chr22:39101656	GTPBP1	0.91	11.49	0.6	1.65e-24	Menopause (age at onset);
SARC	cis	rs9660992	0.674	rs72745219	chr1:205262271	G/A	cg19090574	chr1:205240910	TMCC2	-0.4	-4.75	-0.3	3.49e-6	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs72945132	0.825	rs2277273	chr11:70223992	T/C	cg05964544	chr11:70165517	PPFIA1	-0.58	-5.74	-0.35	2.89e-8	Coronary artery disease;
SARC	cis	rs6088580	0.634	rs4911151	chr20:32932273	T/C	cg24642439	chr20:33292090	TP53INP2	-0.64	-8.23	-0.47	1.33e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs10992471	0.603	rs968040	chr9:95279985	C/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.38	-0.33	1.78e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs2075371	1.000	rs2058976	chr7:133981379	G/T	cg00033643	chr7:134001901	SLC35B4	0.4	4.83	0.3	2.47e-6	Mean platelet volume;
SARC	cis	rs611744	0.631	rs627392	chr8:109254677	C/T	cg21045802	chr8:109455806	TTC35	0.61	7.7	0.45	3.89e-13	Dupuytren's disease;
SARC	cis	rs7959452	0.535	rs10784771	chr12:69621264	A/G	cg14784868	chr12:69753453	YEATS4	0.4	5.14	0.32	5.85e-7	Blood protein levels;
SARC	cis	rs12410462	0.710	rs74140145	chr1:227423946	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.53	-5.09	-0.32	7.25e-7	Major depressive disorder;
SARC	trans	rs61931739	0.635	rs1825746	chr12:33939984	C/T	cg26384229	chr12:38710491	ALG10B	0.59	7.56	0.44	9.26e-13	Morning vs. evening chronotype;
SARC	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg27266027	chr21:40555129	PSMG1	0.46	4.84	0.3	2.36e-6	Cognitive function;
SARC	cis	rs7824557	0.591	rs2736282	chr8:11225480	C/T	cg21775007	chr8:11205619	TDH	0.63	8.5	0.49	2.27e-15	Retinal vascular caliber;
SARC	cis	rs9815354	1.000	rs6803560	chr3:41824480	A/G	cg03022575	chr3:42003672	ULK4	0.58	5.67	0.35	4.28e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs72627123	0.867	rs77320708	chr14:74478482	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.76	5.99	0.37	7.73e-9	Morning vs. evening chronotype;
SARC	trans	rs1994135	0.647	rs67243558	chr12:33695383	T/C	cg13010199	chr12:38710504	ALG10B	0.72	8.72	0.5	5.41e-16	Resting heart rate;
SARC	cis	rs7666738	0.830	rs62318472	chr4:98926030	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.73	0.5	5.13e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2439831	0.867	rs486301	chr15:43836949	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.78	7.78	0.45	2.37e-13	Lung cancer in ever smokers;
SARC	cis	rs9911578	0.967	rs72628392	chr17:56506160	A/G	cg05425664	chr17:57184151	TRIM37	0.59	7.06	0.42	1.85e-11	Intelligence (multi-trait analysis);
SARC	cis	rs7940866	0.834	rs10894302	chr11:130861994	C/T	cg12179176	chr11:130786555	SNX19	0.65	8.69	0.49	6.42e-16	Schizophrenia;
SARC	cis	rs2235642	0.750	rs1894649	chr16:1657284	C/G	cg09065629	chr16:1709722	CRAMP1L	0.36	5.0	0.31	1.12e-6	Coronary artery disease;
SARC	cis	rs11098499	0.865	rs28845498	chr4:120405186	G/A	cg24375607	chr4:120327624	NA	0.42	4.97	0.31	1.28e-6	Corneal astigmatism;
SARC	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg06420487	chr17:61919686	SMARCD2	0.48	5.47	0.34	1.16e-7	Height;
SARC	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg02951883	chr7:2050386	MAD1L1	-0.42	-5.31	-0.33	2.51e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg20887711	chr4:1340912	KIAA1530	-0.62	-7.28	-0.43	5.1e-12	Obesity-related traits;
SARC	cis	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg00031303	chr3:195681400	NA	0.66	7.51	0.44	1.25e-12	Pancreatic cancer;
SARC	cis	rs2072499	0.932	rs2540183	chr1:156164885	C/G	cg24450063	chr1:156163899	SLC25A44	1.17	17.8	0.76	2.48e-45	Testicular germ cell tumor;
SARC	cis	rs7584330	0.744	rs72620822	chr2:238379582	C/T	cg14458575	chr2:238380390	NA	0.58	6.39	0.39	8.96e-10	Prostate cancer;
SARC	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg12463550	chr7:65579703	CRCP	0.7	5.34	0.33	2.21e-7	Diabetic kidney disease;
SARC	cis	rs6540556	0.679	rs11808690	chr1:209891450	T/G	cg23920097	chr1:209922102	NA	-0.5	-5.1	-0.32	6.88e-7	Red blood cell count;
SARC	cis	rs834603	0.735	rs11764365	chr7:47447541	G/A	cg23694490	chr7:47445681	TNS3	0.35	6.46	0.39	5.95e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs765787	0.530	rs2433229	chr15:45515235	C/A	cg24006582	chr15:45444508	DUOX1	-0.49	-6.47	-0.39	5.7e-10	Uric acid levels;
SARC	cis	rs9920506	0.518	rs11072774	chr15:78952697	C/T	cg04896959	chr15:78267971	NA	-0.52	-5.27	-0.33	3.07e-7	Post bronchodilator FEV1;
SARC	cis	rs7666738	0.830	rs7662218	chr4:98983126	T/G	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg21747090	chr2:27597821	SNX17	-0.55	-7.81	-0.46	1.97e-13	Total body bone mineral density;
SARC	cis	rs9303401	0.659	rs9303399	chr17:56672309	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	12.42	0.63	1.63e-27	Cognitive test performance;
SARC	cis	rs2120243	0.592	rs4640513	chr3:157115950	A/G	cg24825693	chr3:157122686	VEPH1	-0.43	-6.0	-0.37	7.67e-9	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs2760061	0.784	rs708116	chr1:228198196	C/A	cg02753203	chr1:228287806	NA	0.58	7.99	0.46	6.05e-14	Diastolic blood pressure;
SARC	cis	rs7296418	0.699	rs11057219	chr12:123750073	T/C	cg00376283	chr12:123451042	ABCB9	0.56	6.84	0.41	6.77e-11	Platelet count;
SARC	cis	rs9326248	1.000	rs585849	chr11:117069061	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.49	5.63	0.35	5.12e-8	Blood protein levels;
SARC	trans	rs61931739	0.500	rs6488218	chr12:34452587	T/C	cg26384229	chr12:38710491	ALG10B	0.85	12.71	0.64	1.86e-28	Morning vs. evening chronotype;
SARC	cis	rs1355223	1.000	rs1396879	chr11:34766653	A/C	cg18508148	chr11:34937573	PDHX;APIP	-0.41	-5.42	-0.33	1.48e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs10088262	0.591	rs13270541	chr8:124794849	G/A	cg15047889	chr8:124780837	FAM91A1	-0.66	-7.3	-0.43	4.53e-12	Pancreatic cancer;
SARC	trans	rs3942852	0.696	rs4597030	chr11:48176573	G/A	cg15704280	chr7:45808275	SEPT13	-0.61	-7.11	-0.42	1.42e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs11578119	0.933	rs7511715	chr1:170432995	T/C	cg09767346	chr1:170501363	GORAB	0.45	5.25	0.33	3.42e-7	Male-pattern baldness;
SARC	cis	rs798554	1.000	rs798562	chr7:2757938	C/T	cg19346786	chr7:2764209	NA	-0.38	-5.74	-0.35	2.86e-8	Height;
SARC	cis	rs7223966	1.000	rs2854223	chr17:61939014	A/G	cg26338869	chr17:61819248	STRADA	0.46	5.16	0.32	5.27e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1707322	0.752	rs8179296	chr1:46143791	G/A	cg03146154	chr1:46216737	IPP	0.52	6.32	0.38	1.33e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9660992	0.539	rs113699533	chr1:205122895	G/A	cg21643547	chr1:205240462	TMCC2	-0.58	-8.01	-0.46	5.44e-14	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs820218	0.886	rs1093992	chr17:73614357	C/T	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.62	8.13	0.47	2.54e-14	Rotator cuff tears;
SARC	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg01448562	chr3:133502909	NA	-0.49	-7.54	-0.44	1.06e-12	Iron status biomarkers;
SARC	cis	rs2228479	0.850	rs17227057	chr16:89816333	C/T	cg06558623	chr16:89946397	TCF25	0.88	6.21	0.38	2.39e-9	Skin colour saturation;
SARC	cis	rs10927875	0.578	rs10927859	chr1:16141862	C/T	cg07117364	chr1:16154769	NA	-0.42	-4.85	-0.3	2.21e-6	Dilated cardiomyopathy;
SARC	cis	rs950169	1.000	rs1911155	chr15:84787635	A/G	cg24253500	chr15:84953950	NA	0.38	5.49	0.34	1.07e-7	Schizophrenia;
SARC	cis	rs6831352	0.589	rs1133483	chr4:100023923	G/C	cg12011299	chr4:100065546	ADH4	0.31	5.9	0.36	1.24e-8	Alcohol dependence;
SARC	cis	rs950776	0.518	rs1504545	chr15:78818471	C/G	cg24631222	chr15:78858424	CHRNA5	0.37	4.72	0.3	4.03e-6	Sudden cardiac arrest;
SARC	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg17221315	chr6:27791827	HIST1H4J	0.45	4.74	0.3	3.76e-6	Depression;
SARC	cis	rs7474896	0.537	rs2472149	chr10:38262196	A/C	cg25427524	chr10:38739819	LOC399744	0.45	5.48	0.34	1.08e-7	Obesity (extreme);
SARC	cis	rs3770081	1.000	rs12617717	chr2:86342303	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.81	-4.77	-0.3	3.26e-6	Facial emotion recognition (sad faces);
SARC	cis	rs911555	0.504	rs61995761	chr14:104075712	T/C	cg26031613	chr14:104095156	KLC1	0.61	7.99	0.46	6.39e-14	Intelligence (multi-trait analysis);
SARC	cis	rs7552404	0.731	rs2029683	chr1:76341643	T/G	cg22875332	chr1:76189707	ACADM	-0.45	-5.75	-0.35	2.8e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs4969178	0.895	rs2292640	chr17:76396610	G/A	cg02836325	chr17:76403955	PGS1	0.33	5.01	0.31	1.07e-6	HDL cholesterol levels;
SARC	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg06618935	chr21:46677482	NA	-0.38	-5.06	-0.31	8.36e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs57502260	0.704	rs17149179	chr11:68351722	C/T	cg20283391	chr11:68216788	NA	-0.56	-4.99	-0.31	1.17e-6	Total body bone mineral density (age 45-60);
SARC	cis	rs6598955	0.543	rs57564009	chr1:26557618	A/T	cg04990556	chr1:26633338	UBXN11	0.76	7.81	0.46	1.92e-13	Obesity-related traits;
SARC	cis	rs6540556	0.682	rs667681	chr1:209914449	A/G	cg23920097	chr1:209922102	NA	0.5	4.95	0.31	1.42e-6	Red blood cell count;
SARC	trans	rs3857536	0.740	rs7766407	chr6:66885658	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.6	-7.1	-0.42	1.48e-11	Blood trace element (Cu levels);
SARC	cis	rs2806561	0.734	rs2806564	chr1:23506685	T/C	cg12483005	chr1:23474871	LUZP1	0.44	5.73	0.35	3.05e-8	Height;
SARC	cis	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg08045932	chr20:61659980	NA	0.52	6.91	0.41	4.6e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs9787249	1.000	rs9787249	chr1:40212878	G/A	cg02773041	chr1:40204384	PPIE	0.53	6.46	0.39	6.11e-10	Blood protein levels;
SARC	cis	rs3741404	0.665	rs594461	chr11:63872543	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	9.07	0.51	5.25e-17	Platelet count;
SARC	cis	rs11098499	1.000	rs3749591	chr4:120214030	T/G	cg09307838	chr4:120376055	NA	0.86	11.88	0.61	9.08e-26	Corneal astigmatism;
SARC	cis	rs2834188	0.889	rs1467849	chr21:34682069	G/T	cg15382669	chr21:34697036	IFNAR1	0.42	4.81	0.3	2.71e-6	Narcolepsy;
SARC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg26338869	chr17:61819248	STRADA	0.81	10.86	0.58	1.68e-22	Prudent dietary pattern;
SARC	cis	rs12142240	0.698	rs1984490	chr1:46858734	C/T	cg14993813	chr1:46806288	NSUN4	0.54	5.72	0.35	3.24e-8	Menopause (age at onset);
SARC	cis	rs992157	0.764	rs4672886	chr2:219185545	C/T	cg00012203	chr2:219082015	ARPC2	-0.6	-7.71	-0.45	3.61e-13	Colorectal cancer;
SARC	cis	rs9868809	0.649	rs3733086	chr3:48699519	C/T	cg07636037	chr3:49044803	WDR6	-0.73	-6.37	-0.39	1.01e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs2070488	0.775	rs6599208	chr3:38558104	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.77	-11.41	-0.6	3.02e-24	Electrocardiographic conduction measures;
SARC	cis	rs62432291	0.681	rs431205	chr6:159662499	A/G	cg14500486	chr6:159655392	FNDC1	-0.57	-5.89	-0.36	1.36e-8	Joint mobility (Beighton score);
SARC	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.49	-5.96	-0.36	9.04e-9	Renal function-related traits (BUN);
SARC	cis	rs6456042	1.000	rs3099299	chr6:166526587	C/T	cg11088901	chr6:166572345	T	-0.34	-4.95	-0.31	1.39e-6	Asthma;
SARC	cis	rs739401	0.869	rs395188	chr11:3072631	A/G	cg25174290	chr11:3078921	CARS	-0.57	-8.17	-0.47	1.96e-14	Longevity;
SARC	cis	rs2074409	0.530	rs7224979	chr17:35953632	C/T	cg16670864	chr17:35848621	DUSP14	-0.43	-4.97	-0.31	1.29e-6	Response to angiotensin II receptor blocker therapy;
SARC	cis	rs41271473	1.000	rs6701241	chr1:228868477	C/G	cg10167378	chr1:228756711	NA	0.48	4.71	0.3	4.17e-6	Chronic lymphocytic leukemia;
SARC	cis	rs6991838	0.584	rs6994213	chr8:66513732	A/G	cg13398993	chr8:66546079	ARMC1	-0.61	-8.1	-0.47	3.16e-14	Intelligence (multi-trait analysis);
SARC	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	27.41	0.87	7.3e-75	Chronic sinus infection;
SARC	cis	rs11264799	0.603	rs7520627	chr1:157568371	A/T	cg18268488	chr1:157545234	FCRL4	0.33	5.66	0.35	4.52e-8	IgA nephropathy;
SARC	cis	rs7408868	1.000	rs7247906	chr19:15271135	T/G	cg14696996	chr19:15285081	NOTCH3	1.06	8.68	0.49	6.85e-16	Pulse pressure;
SARC	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg19346786	chr7:2764209	NA	-0.44	-6.8	-0.41	8.52e-11	Height;
SARC	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.75	8.86	0.5	2.11e-16	Height;
SARC	cis	rs7666738	0.830	rs7696686	chr4:98938445	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2841233	0.681	rs2582558	chr14:105347488	A/G	cg01147727	chr14:105363015	KIAA0284	0.34	5.57	0.34	7.05e-8	IgG glycosylation;
SARC	trans	rs12310956	0.510	rs11052882	chr12:33890017	T/C	cg26384229	chr12:38710491	ALG10B	0.61	8.04	0.47	4.53e-14	Morning vs. evening chronotype;
SARC	cis	rs16976116	0.901	rs73409853	chr15:55502681	A/T	cg11288833	chr15:55489084	RSL24D1	0.63	6.13	0.37	3.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs12079745	0.793	rs12067351	chr1:169279758	T/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.83	-5.12	-0.32	6.49e-7	QT interval;
SARC	cis	rs67460515	0.892	rs73026974	chr3:160963231	A/C	cg03342759	chr3:160939853	NMD3	-0.71	-9.12	-0.51	3.55e-17	Parkinson's disease;
SARC	cis	rs1549733	0.559	rs4674193	chr2:218444361	C/T	cg01830674	chr2:219433148	RQCD1;USP37	0.55	4.72	0.3	4.11e-6	Optic disc area;
SARC	cis	rs2115630	0.846	rs8024538	chr15:85368419	A/T	cg12501888	chr15:85177176	SCAND2	-0.47	-5.54	-0.34	8.15e-8	P wave terminal force;
SARC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg24846343	chr22:24311635	DDTL	0.51	7.23	0.43	6.93e-12	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg19729930	chr2:74357872	NA	0.76	10.85	0.58	1.76e-22	Gestational age at birth (maternal effect);
SARC	cis	rs57506017	0.565	rs2043539	chr7:12253880	G/A	cg23422036	chr7:12250390	TMEM106B	0.5	6.68	0.4	1.75e-10	Neuroticism;
SARC	cis	rs7264396	0.623	rs78949029	chr20:34384964	C/G	cg01084648	chr20:34329383	RBM39	0.67	5.3	0.33	2.69e-7	Total cholesterol levels;
SARC	cis	rs870825	0.929	rs10015218	chr4:185589789	T/C	cg04058563	chr4:185651563	MLF1IP	0.82	9.17	0.51	2.63e-17	Blood protein levels;
SARC	trans	rs11098499	1.000	rs7659194	chr4:120207147	T/G	cg25214090	chr10:38739885	LOC399744	0.53	7.0	0.42	2.63e-11	Corneal astigmatism;
SARC	cis	rs2985684	1.000	rs17121651	chr14:50097172	T/C	cg04989706	chr14:50066350	PPIL5	-0.53	-5.58	-0.34	6.5e-8	Carotid intima media thickness;
SARC	trans	rs11098499	0.863	rs3775854	chr4:120471971	C/T	cg25214090	chr10:38739885	LOC399744	0.57	7.25	0.43	6.27e-12	Corneal astigmatism;
SARC	cis	rs854765	0.552	rs11078407	chr17:17841083	T/C	cg05444541	chr17:17804740	TOM1L2	-0.29	-4.94	-0.31	1.49e-6	Total body bone mineral density;
SARC	cis	rs16976116	0.901	rs8027098	chr15:55492269	C/T	cg17854078	chr15:55489399	RSL24D1	0.65	6.43	0.39	7.12e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4689388	0.824	rs114669221	chr4:6301459	G/A	cg00701064	chr4:6280414	WFS1	0.54	8.55	0.49	1.67e-15	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs2952156	0.959	rs2517956	chr17:37843859	G/A	cg20243544	chr17:37824526	PNMT	0.5	6.01	0.37	6.93e-9	Asthma;
SARC	cis	rs9309473	0.950	rs6546847	chr2:73785358	A/G	cg20560298	chr2:73613845	ALMS1	-0.46	-5.55	-0.34	7.78e-8	Metabolite levels;
SARC	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg05025164	chr4:1340916	KIAA1530	-0.46	-5.41	-0.33	1.55e-7	Obesity-related traits;
SARC	cis	rs288326	0.561	rs77426227	chr2:183890678	A/T	cg09997497	chr2:183902928	NCKAP1	0.74	5.1	0.32	6.97e-7	Blood protein levels;
SARC	cis	rs820218	0.926	rs820199	chr17:73629007	C/T	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.66	8.84	0.5	2.34e-16	Rotator cuff tears;
SARC	trans	rs2727020	0.658	rs10839278	chr11:49450847	G/C	cg03929089	chr4:120376271	NA	-0.78	-11.42	-0.6	2.81e-24	Coronary artery disease;
SARC	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-9.69	-0.54	7.21e-19	Chronic sinus infection;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg15545021	chr2:30802226	LCLAT1	0.47	6.36	0.38	1.06e-9	Thyroid stimulating hormone;
SARC	trans	rs1814175	0.645	rs1851844	chr11:50021773	T/C	cg03929089	chr4:120376271	NA	-0.82	-11.88	-0.61	9.03e-26	Height;
SARC	cis	rs7617773	0.539	rs12486944	chr3:48390016	G/A	cg11946769	chr3:48343235	NME6	0.51	6.27	0.38	1.77e-9	Coronary artery disease;
SARC	cis	rs400736	0.729	rs9434949	chr1:8006083	C/G	cg25007680	chr1:8021821	PARK7	-0.43	-5.64	-0.35	4.88e-8	Response to antidepressants and depression;
SARC	cis	rs6963495	0.818	rs56177071	chr7:105165648	C/T	cg19920283	chr7:105172520	RINT1	0.66	5.62	0.35	5.45e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg03452623	chr4:187889614	NA	-0.78	-11.72	-0.61	2.97e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4664308	1.000	rs62175515	chr2:160909524	A/T	cg03641300	chr2:160917029	PLA2R1	-0.67	-8.98	-0.51	9.03e-17	Idiopathic membranous nephropathy;
SARC	cis	rs17376456	0.825	rs10054903	chr5:93281491	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	5.82	0.36	1.93e-8	Diabetic retinopathy;
SARC	cis	rs2644899	0.750	rs2249835	chr19:41269766	G/A	cg24958765	chr19:41283667	RAB4B	-0.6	-6.95	-0.41	3.67e-11	Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs9462027	0.583	rs7755982	chr6:34715297	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.4	-5.7	-0.35	3.67e-8	Systemic lupus erythematosus;
SARC	cis	rs7624766	0.709	rs1378656	chr3:160526864	A/T	cg22637730	chr3:160473554	PPM1L	0.43	5.58	0.34	6.58e-8	Response to methotrexate in rheumatoid arthritis;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23091255	chr6:64345855	NA	-0.55	-7.33	-0.43	3.7e-12	Smoking initiation;
SARC	trans	rs1814175	0.935	rs28586931	chr11:49693872	G/A	cg03929089	chr4:120376271	NA	-0.87	-13.82	-0.67	3.82e-32	Height;
SARC	cis	rs1003719	0.679	rs2835674	chr21:38581522	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-9.04	-0.51	6.39e-17	Eye color traits;
SARC	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg02524346	chr8:600233	NA	0.8	6.55	0.39	3.57e-10	IgG glycosylation;
SARC	cis	rs763121	0.853	rs2064088	chr22:39053382	A/G	cg21395723	chr22:39101663	GTPBP1	0.58	6.67	0.4	1.85e-10	Menopause (age at onset);
SARC	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	9.07	0.51	5.01e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg08219700	chr8:58056026	NA	0.71	6.61	0.4	2.61e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg24101359	chr6:42928495	GNMT	-0.44	-6.04	-0.37	6.09e-9	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg04317338	chr11:64019027	PLCB3	0.84	9.15	0.51	2.99e-17	Mean platelet volume;
SARC	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6424115	1.000	rs7519554	chr1:24154566	T/A	cg15997130	chr1:24165203	NA	-0.46	-6.21	-0.38	2.43e-9	Immature fraction of reticulocytes;
SARC	cis	rs9682041	0.569	rs11914970	chr3:170112307	T/G	cg11886554	chr3:170076028	SKIL	0.65	6.44	0.39	6.82e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs9790314	0.846	rs7627528	chr3:160990878	A/G	cg03342759	chr3:160939853	NMD3	-0.73	-9.84	-0.54	2.56e-19	Morning vs. evening chronotype;
SARC	cis	rs6701037	1.000	rs12747817	chr1:175118895	C/T	cg17845761	chr1:175162550	KIAA0040	-0.28	-4.79	-0.3	2.92e-6	Alcohol dependence;
SARC	cis	rs7119	0.717	rs11629652	chr15:77779951	C/A	cg17802220	chr15:77601643	NA	-0.43	-5.6	-0.34	5.92e-8	Type 2 diabetes;
SARC	cis	rs10752881	0.743	rs10737244	chr1:183098417	G/A	cg13390022	chr1:182993471	LAMC1	0.31	4.79	0.3	3.01e-6	Colorectal cancer;
SARC	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg06873352	chr17:61820015	STRADA	-0.43	-5.66	-0.35	4.49e-8	Prudent dietary pattern;
SARC	cis	rs17376456	0.877	rs12153501	chr5:93360866	T/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	6.12	0.37	3.99e-9	Diabetic retinopathy;
SARC	cis	rs7566780	0.630	rs6705856	chr2:16698235	C/T	cg09580478	chr2:16689509	NA	0.53	6.41	0.39	8.05e-10	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-9.57	-0.53	1.62e-18	Chronic sinus infection;
SARC	cis	rs4555082	0.834	rs28489970	chr14:105748862	T/C	cg13114125	chr14:105738426	BRF1	-0.79	-11.51	-0.6	1.41e-24	Mean platelet volume;Platelet distribution width;
SARC	cis	rs1215050	0.782	rs6532693	chr4:98655815	T/C	cg05340658	chr4:99064831	C4orf37	-0.43	-5.67	-0.35	4.27e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs6977660	0.714	rs12530537	chr7:19822641	A/G	cg07541023	chr7:19748670	TWISTNB	-0.52	-5.08	-0.32	7.69e-7	Thyroid stimulating hormone;
SARC	cis	rs6831352	0.765	rs35361391	chr4:100069281	A/T	cg12011299	chr4:100065546	ADH4	-0.32	-5.09	-0.32	7.33e-7	Alcohol dependence;
SARC	cis	rs7712401	0.645	rs154497	chr5:122221420	T/C	cg19412675	chr5:122181750	SNX24	0.41	5.22	0.32	3.87e-7	Mean platelet volume;
SARC	cis	rs9790314	0.586	rs73021449	chr3:161128941	G/A	cg17135325	chr3:160939158	NMD3	0.51	6.2	0.38	2.51e-9	Morning vs. evening chronotype;
SARC	cis	rs17253792	0.822	rs74051609	chr14:56171132	G/A	cg01858014	chr14:56050164	KTN1	-0.6	-4.72	-0.3	4.02e-6	Putamen volume;
SARC	cis	rs7552404	0.731	rs1770885	chr1:76402212	C/T	cg03433033	chr1:76189801	ACADM	-0.43	-5.43	-0.34	1.43e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs4851254	0.920	rs11123816	chr2:100783653	G/A	cg04109781	chr2:100722022	AFF3	0.34	4.81	0.3	2.77e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2425143	0.730	rs2095819	chr20:34353278	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	5.24	0.32	3.52e-7	Blood protein levels;
SARC	cis	rs7644634	0.688	rs9876767	chr3:105449793	T/G	cg23051926	chr3:105466016	CBLB	0.44	5.52	0.34	9.1e-8	Itch intensity from mosquito bite;
SARC	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg25036284	chr2:26402008	FAM59B	0.48	5.72	0.35	3.19e-8	Gut microbiome composition (summer);
SARC	cis	rs9796	0.870	rs72737704	chr15:41323575	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.42	-5.83	-0.36	1.85e-8	Menopause (age at onset);
SARC	cis	rs35995292	0.963	rs2240555	chr7:38949424	T/C	cg19327137	chr7:38886074	VPS41	0.36	5.16	0.32	5.29e-7	Subjective well-being (multi-trait analysis);
SARC	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.73	-0.5	5.15e-16	Alzheimer's disease;
SARC	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg24503407	chr1:205819492	PM20D1	0.54	6.19	0.38	2.65e-9	Prostate-specific antigen levels;
SARC	cis	rs1267303	0.637	rs1745371	chr1:46985192	C/T	cg25110126	chr1:46999211	NA	0.7	7.87	0.46	1.35e-13	Monobrow;
SARC	cis	rs16870629	0.564	rs326050	chr5:1002620	C/T	cg00278107	chr5:1061253	SLC12A7	0.64	8.28	0.48	9.65e-15	QT interval;
SARC	cis	rs9611519	0.589	rs8138917	chr22:41412425	T/C	cg17376030	chr22:41985996	PMM1	0.39	4.85	0.3	2.29e-6	Neuroticism;
SARC	cis	rs2236918	0.932	rs2488471	chr1:242019831	T/C	cg17736920	chr1:242011382	EXO1	0.77	10.68	0.57	6.15e-22	Menopause (age at onset);
SARC	cis	rs240764	0.782	rs12216199	chr6:101152723	C/A	cg09795085	chr6:101329169	ASCC3	-0.45	-5.91	-0.36	1.21e-8	Neuroticism;
SARC	cis	rs1008375	0.931	rs979823	chr4:17700176	G/A	cg02297831	chr4:17616191	MED28	0.38	4.75	0.3	3.52e-6	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs3109167	0.524	rs2713182	chr7:83097221	T/A	cg14519356	chr7:83097669	SEMA3E	0.38	5.1	0.32	7.19e-7	Blood protein levels;
SARC	cis	rs57994353	1.000	rs57994353	chr9:139356987	T/C	cg14169450	chr9:139327907	INPP5E	0.43	5.9	0.36	1.3e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs11098499	0.955	rs13113112	chr4:120156040	C/T	cg09307838	chr4:120376055	NA	0.86	11.66	0.61	4.64e-25	Corneal astigmatism;
SARC	cis	rs870825	0.698	rs2696046	chr4:185599972	G/A	cg04058563	chr4:185651563	MLF1IP	-0.75	-9.3	-0.52	1.07e-17	Blood protein levels;
SARC	cis	rs3126085	0.935	rs10888471	chr1:152200849	G/T	cg26876637	chr1:152193138	HRNR	-0.47	-5.91	-0.36	1.19e-8	Atopic dermatitis;
SARC	cis	rs2304069	0.954	rs2340463	chr5:149409294	C/T	cg12661370	chr5:149340060	SLC26A2	0.59	5.73	0.35	3.11e-8	HIV-1 control;
SARC	cis	rs35110281	0.748	rs4997353	chr21:45002329	A/C	cg21573476	chr21:45109991	RRP1B	-0.46	-6.72	-0.4	1.41e-10	Mean corpuscular volume;
SARC	cis	rs6540556	0.635	rs17389184	chr1:209916789	C/T	cg05527609	chr1:210001259	C1orf107	-0.62	-5.55	-0.34	7.69e-8	Red blood cell count;
SARC	cis	rs11583043	0.918	rs56402739	chr1:101397133	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.47	5.47	0.34	1.14e-7	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs11874712	0.899	rs56075249	chr18:43670863	T/C	cg25174615	chr18:43684699	ATP5A1;HAUS1	0.42	4.89	0.3	1.91e-6	Migraine - clinic-based;
SARC	trans	rs2727020	0.530	rs7113153	chr11:49457957	G/A	cg15704280	chr7:45808275	SEPT13	-0.71	-8.04	-0.47	4.56e-14	Coronary artery disease;
SARC	cis	rs72945132	0.882	rs60780459	chr11:70162468	A/G	cg05964544	chr11:70165517	PPFIA1	-0.61	-5.87	-0.36	1.5e-8	Coronary artery disease;
SARC	cis	rs735539	0.521	rs2147347	chr13:21410468	C/T	cg16922012	chr13:21400325	XPO4	-0.42	-5.58	-0.34	6.76e-8	Dental caries;
SARC	cis	rs11997175	0.655	rs72630922	chr8:33662401	G/A	ch.8.33884649F	chr8:33765107	NA	0.47	6.16	0.37	3.15e-9	Body mass index;
SARC	cis	rs1865760	0.566	rs1971509	chr6:26085777	T/C	cg16482183	chr6:26056742	HIST1H1C	0.47	5.91	0.36	1.22e-8	Height;
SARC	cis	rs854765	0.583	rs7207043	chr17:17819188	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.43	5.67	0.35	4.17e-8	Total body bone mineral density;
SARC	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg03806693	chr22:41940476	POLR3H	-0.94	-13.14	-0.65	7.11e-30	Vitiligo;
SARC	cis	rs2652834	0.851	rs1566660	chr15:63429258	C/G	cg02713581	chr15:63449717	RPS27L	0.48	4.84	0.3	2.42e-6	HDL cholesterol;
SARC	cis	rs7666738	0.715	rs61114099	chr4:98931270	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs634534	0.562	rs642293	chr11:65730217	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.58	9.2	0.52	2.1e-17	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs17345786	1.000	rs17345786	chr3:101318318	A/C	cg12386194	chr3:101231763	SENP7	-0.71	-8.41	-0.48	4.23e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs11792861	0.781	rs2151426	chr9:111743797	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.74	8.46	0.48	2.91e-15	Menarche (age at onset);
SARC	cis	rs72717009	0.825	rs11810143	chr1:161480649	A/G	cg23840854	chr1:161414152	NA	-0.54	-5.04	-0.31	9.44e-7	Rheumatoid arthritis;
SARC	cis	rs2180341	0.889	rs2000909	chr6:127711173	G/A	cg27446573	chr6:127587934	RNF146	0.77	10.05	0.55	5.8e-20	Breast cancer;
SARC	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	11.65	0.61	4.98e-25	Alzheimer's disease;
SARC	cis	rs4891159	0.548	rs690414	chr18:74117840	T/C	cg24786174	chr18:74118243	ZNF516	0.77	13.31	0.66	1.92e-30	Longevity;
SARC	cis	rs6665290	0.904	rs11586604	chr1:227183865	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.08	-24.47	-0.85	2.6e-66	Myeloid white cell count;
SARC	trans	rs1910358	0.554	rs10057796	chr5:23759746	C/T	cg19736286	chr2:48010117	MSH6	0.55	6.35	0.38	1.1e-9	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs11574514	1.000	rs117782866	chr16:68023169	G/A	cg01866162	chr16:67596514	CTCF	1.03	6.53	0.39	3.97e-10	Crohn's disease;
SARC	cis	rs2120243	0.533	rs1500921	chr3:157055427	C/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.42	5.54	0.34	8.13e-8	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg17971929	chr21:40555470	PSMG1	0.84	11.08	0.59	3.3e-23	Cognitive function;
SARC	cis	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg08564027	chr20:61660810	NA	0.76	11.8	0.61	1.69e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs796364	0.774	rs112564437	chr2:201074048	G/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.49	-5.09	-0.32	7.54e-7	Schizophrenia;
SARC	cis	rs2832191	0.740	rs2832168	chr21:30463695	G/A	cg08807101	chr21:30365312	RNF160	0.91	14.34	0.68	7.42e-34	Dental caries;
SARC	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg07701084	chr6:150067640	NUP43	0.41	5.39	0.33	1.75e-7	Lung cancer;
SARC	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.83	-8.92	-0.5	1.37e-16	Mean platelet volume;
SARC	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.39	-4.8	-0.3	2.83e-6	Lymphocyte counts;
SARC	cis	rs6500602	0.702	rs17761816	chr16:4548832	C/G	cg08645402	chr16:4508243	NA	0.44	6.0	0.37	7.64e-9	Schizophrenia;
SARC	cis	rs28374715	0.662	rs521890	chr15:41473143	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.96	-13.96	-0.67	1.38e-32	Ulcerative colitis;
SARC	cis	rs7106204	0.534	rs79475764	chr11:24278384	C/A	ch.11.24196551F	chr11:24239977	NA	0.65	4.85	0.3	2.29e-6	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs9916302	0.904	rs9905432	chr17:37555918	C/A	cg00129232	chr17:37814104	STARD3	0.62	7.61	0.45	6.89e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs9790314	0.582	rs11708813	chr3:160589852	G/A	cg04691961	chr3:161091175	C3orf57	0.58	7.85	0.46	1.53e-13	Morning vs. evening chronotype;
SARC	cis	rs4718428	0.705	rs4717331	chr7:66378886	C/T	cg12165864	chr7:66369176	NA	-0.48	-5.44	-0.34	1.31e-7	Corneal structure;
SARC	cis	rs6840360	0.550	rs6836343	chr4:152497564	A/G	cg22705602	chr4:152727874	NA	-0.41	-6.47	-0.39	5.71e-10	Intelligence (multi-trait analysis);
SARC	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.31	-4.95	-0.31	1.42e-6	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg10548277	chr1:43855471	MED8;C1orf84	0.5	6.47	0.39	5.81e-10	Lung adenocarcinoma;
SARC	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg02574844	chr11:5959923	NA	0.35	5.15	0.32	5.48e-7	DNA methylation (variation);
SARC	cis	rs1707322	0.964	rs6697830	chr1:46290477	C/A	cg03146154	chr1:46216737	IPP	0.47	5.62	0.35	5.38e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6484504	0.512	rs2761594	chr11:31318244	A/G	cg26647111	chr11:31128758	NA	0.39	4.98	0.31	1.25e-6	Red blood cell count;
SARC	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.46e-10	Life satisfaction;
SARC	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg10373733	chr6:25993375	NA	0.4	4.88	0.3	1.99e-6	Height;
SARC	cis	rs17384381	1.000	rs12743049	chr1:85897386	G/A	cg16011679	chr1:85725395	C1orf52	0.61	5.76	0.35	2.63e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1059312	0.522	rs3825181	chr12:129279264	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	-0.43	-5.54	-0.34	8.26e-8	Systemic lupus erythematosus;
SARC	cis	rs7681440	0.543	rs2619370	chr4:90736585	C/T	cg06632027	chr4:90757378	SNCA	-0.42	-5.22	-0.32	4.01e-7	Dementia with Lewy bodies;
SARC	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1215050	0.755	rs6851840	chr4:98776366	A/G	cg05340658	chr4:99064831	C4orf37	0.44	5.85	0.36	1.62e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	trans	rs877282	0.838	rs34778553	chr10:796865	T/C	cg22713356	chr15:30763199	NA	1.08	11.37	0.6	3.92e-24	Uric acid levels;
SARC	cis	rs9322817	0.691	rs2168394	chr6:105259152	C/T	cg02098413	chr6:105308735	HACE1	-0.38	-5.91	-0.36	1.18e-8	Thyroid stimulating hormone;
SARC	cis	rs5753618	0.561	rs714909	chr22:31741067	G/A	cg02404636	chr22:31891804	SFI1	0.49	5.31	0.33	2.49e-7	Colorectal cancer;
SARC	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg21782813	chr7:2030301	MAD1L1	0.37	5.71	0.35	3.47e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg09373136	chr17:61933544	TCAM1	-0.45	-6.2	-0.38	2.48e-9	Prudent dietary pattern;
SARC	cis	rs6815814	0.904	rs67712706	chr4:38820616	A/G	cg06935464	chr4:38784597	TLR10	0.48	4.77	0.3	3.29e-6	Breast cancer;
SARC	cis	rs1559088	0.901	rs7249983	chr19:33598851	C/A	cg17764715	chr19:33622953	WDR88	0.49	6.56	0.39	3.5e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs3008870	0.755	rs2815349	chr1:67472280	G/A	cg02640540	chr1:67518911	SLC35D1	0.46	5.26	0.33	3.34e-7	Lymphocyte percentage of white cells;
SARC	cis	rs10752881	0.839	rs6692207	chr1:183085304	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.11	0.55	3.69e-20	Colorectal cancer;
SARC	cis	rs7560272	0.723	rs1083919	chr2:73713863	C/G	cg20560298	chr2:73613845	ALMS1	0.56	7.58	0.44	7.94e-13	Schizophrenia;
SARC	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg24642844	chr7:1081250	C7orf50	-0.57	-6.05	-0.37	5.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs10504229	0.679	rs73681882	chr8:58030038	A/G	cg21724239	chr8:58056113	NA	0.62	6.34	0.38	1.18e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2916247	0.954	rs7461004	chr8:93088828	T/G	cg10183463	chr8:93005414	RUNX1T1	0.68	7.29	0.43	4.8e-12	Intelligence (multi-trait analysis);
SARC	cis	rs11098499	0.909	rs79026312	chr4:120440677	C/A	cg24375607	chr4:120327624	NA	0.42	4.94	0.31	1.47e-6	Corneal astigmatism;
SARC	cis	rs9916302	0.706	rs4332770	chr17:37704712	T/C	cg20243544	chr17:37824526	PNMT	0.53	5.46	0.34	1.23e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg10351095	chr21:47802916	PCNT	-0.41	-4.86	-0.3	2.13e-6	Testicular germ cell tumor;
SARC	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg08280861	chr8:58055591	NA	0.57	5.1	0.32	6.94e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7666738	0.830	rs34890015	chr4:99023769	A/T	cg05340658	chr4:99064831	C4orf37	0.65	8.88	0.5	1.84e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs3733585	0.699	rs6449158	chr4:9960459	T/C	cg11266682	chr4:10021025	SLC2A9	-0.38	-6.53	-0.39	4.12e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs12142240	0.698	rs7515284	chr1:46809419	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-5.45	-0.34	1.28e-7	Menopause (age at onset);
SARC	trans	rs17221829	0.733	rs11018668	chr11:89356178	C/T	cg23100493	chr13:53191537	HNRNPA1L2	0.51	7.06	0.42	1.9e-11	Anxiety in major depressive disorder;
SARC	cis	rs2180341	0.920	rs6906717	chr6:127596782	C/A	cg27446573	chr6:127587934	RNF146	1.01	14.18	0.68	2.45e-33	Breast cancer;
SARC	cis	rs17376456	1.000	rs9968691	chr5:93509756	C/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.26	0.33	3.27e-7	Diabetic retinopathy;
SARC	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	24.35	0.85	5.64e-66	Chronic sinus infection;
SARC	cis	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg00800038	chr16:89945340	TCF25	-0.74	-5.14	-0.32	5.79e-7	Skin colour saturation;
SARC	cis	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg25894440	chr7:65020034	NA	-0.75	-5.67	-0.35	4.23e-8	Diabetic kidney disease;
SARC	cis	rs6840360	0.571	rs62327271	chr4:152535916	A/G	cg22705602	chr4:152727874	NA	-0.42	-6.62	-0.4	2.46e-10	Intelligence (multi-trait analysis);
SARC	cis	rs1670533	1.000	rs1010342	chr4:1068819	C/T	cg27284194	chr4:1044797	NA	0.45	4.73	0.3	3.93e-6	Recombination rate (females);
SARC	cis	rs4642101	0.537	rs4997708	chr3:12839603	G/A	cg24848339	chr3:12840334	CAND2	0.38	5.68	0.35	4.01e-8	QRS complex (12-leadsum);
SARC	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg23758822	chr17:41437982	NA	0.88	11.19	0.59	1.55e-23	Menopause (age at onset);
SARC	cis	rs9660992	0.710	rs1172136	chr1:205247097	T/G	cg00857998	chr1:205179979	DSTYK	0.51	6.02	0.37	6.78e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs14978	1.000	rs6969722	chr7:12278437	C/T	cg23422036	chr7:12250390	TMEM106B	0.47	5.66	0.35	4.44e-8	Response to amphetamines;
SARC	cis	rs62064224	0.791	rs17806082	chr17:30705346	G/C	cg25809561	chr17:30822961	MYO1D	0.37	5.52	0.34	8.88e-8	Schizophrenia;
SARC	cis	rs6500395	0.962	rs9937568	chr16:48612361	C/T	cg04672837	chr16:48644449	N4BP1	-0.43	-5.8	-0.36	2.18e-8	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs11785400	1.000	rs13266249	chr8:143732433	A/C	cg10596483	chr8:143751796	JRK	0.63	8.37	0.48	5.33e-15	Schizophrenia;
SARC	cis	rs62432291	0.681	rs378339	chr6:159658852	C/T	cg14500486	chr6:159655392	FNDC1	-0.64	-6.37	-0.39	9.75e-10	Joint mobility (Beighton score);
SARC	cis	rs2916247	1.000	rs11990286	chr8:93061406	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.58	-5.95	-0.36	1e-8	Intelligence (multi-trait analysis);
SARC	cis	rs12497850	0.931	rs3774628	chr3:48801840	C/T	cg07636037	chr3:49044803	WDR6	0.96	16.52	0.73	4.15e-41	Parkinson's disease;
SARC	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg27170947	chr2:26402098	FAM59B	-0.37	-4.8	-0.3	2.79e-6	Gut microbiome composition (summer);
SARC	cis	rs7084402	0.565	rs1982173	chr10:60334002	G/T	cg07615347	chr10:60278583	BICC1	0.41	5.53	0.34	8.66e-8	Refractive error;
SARC	cis	rs3768617	0.510	rs10752904	chr1:183101038	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.66e-21	Fuchs's corneal dystrophy;
SARC	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg13206674	chr6:150067644	NUP43	0.44	5.58	0.34	6.63e-8	Lung cancer;
SARC	cis	rs16854884	0.657	rs35067746	chr3:143747147	T/A	cg06585982	chr3:143692056	C3orf58	0.67	9.14	0.51	3.13e-17	Economic and political preferences (feminism/equality);
SARC	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg08677398	chr8:58056175	NA	0.43	4.81	0.3	2.72e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs950776	0.518	rs1979907	chr15:78842239	T/C	cg17108064	chr15:78857060	CHRNA5	-0.29	-4.86	-0.3	2.13e-6	Sudden cardiac arrest;
SARC	cis	rs9399137	0.507	rs6904897	chr6:135382980	T/G	cg22676075	chr6:135203613	NA	0.41	5.2	0.32	4.28e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs67460515	0.892	rs34771618	chr3:161059795	A/C	cg03342759	chr3:160939853	NMD3	-0.67	-8.73	-0.5	4.99e-16	Parkinson's disease;
SARC	cis	rs10416265	0.516	rs1270252	chr19:33623604	G/A	cg27124370	chr19:33622961	WDR88	-0.46	-4.81	-0.3	2.71e-6	Bone properties (heel);
SARC	trans	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg21659725	chr3:3221576	CRBN	-0.81	-12.44	-0.63	1.38e-27	Intelligence (multi-trait analysis);
SARC	cis	rs7772486	0.790	rs7753696	chr6:146279098	G/T	cg23711669	chr6:146136114	FBXO30	-0.81	-12.83	-0.64	7.46e-29	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs5167	0.533	rs11083755	chr19:45490065	C/T	cg13119609	chr19:45449297	APOC2	0.39	5.53	0.34	8.77e-8	Blood protein levels;
SARC	cis	rs9790314	0.934	rs462413	chr3:161101587	T/C	cg03342759	chr3:160939853	NMD3	-0.55	-6.77	-0.41	1.01e-10	Morning vs. evening chronotype;
SARC	cis	rs742614	0.533	rs6059496	chr20:32446931	T/C	cg06304546	chr20:32448765	NA	-0.58	-7.67	-0.45	4.57e-13	Stearic acid (18:0) levels;
SARC	cis	rs7937682	0.575	rs1346180	chr11:111715570	G/C	cg09085632	chr11:111637200	PPP2R1B	0.8	10.59	0.57	1.16e-21	Primary sclerosing cholangitis;
SARC	cis	rs11874712	1.000	rs7244921	chr18:43667528	T/C	cg25174615	chr18:43684699	ATP5A1;HAUS1	0.4	4.75	0.3	3.52e-6	Migraine - clinic-based;
SARC	trans	rs7824557	0.564	rs12550129	chr8:11233917	C/T	cg06636001	chr8:8085503	FLJ10661	-0.64	-8.57	-0.49	1.42e-15	Retinal vascular caliber;
SARC	cis	rs62432291	0.681	rs2501176	chr6:159655383	A/G	cg14500486	chr6:159655392	FNDC1	-0.62	-6.03	-0.37	6.44e-9	Joint mobility (Beighton score);
SARC	cis	rs10905065	0.610	rs72774056	chr10:5737065	C/T	cg09072322	chr10:5726702	C10orf18	0.43	4.93	0.31	1.53e-6	Menopause (age at onset);
SARC	cis	rs12594515	1.000	rs12594515	chr15:45985071	C/G	cg14863074	chr15:45997064	NA	-0.35	-5.21	-0.32	4.22e-7	Waist circumference;Weight;
SARC	cis	rs7129727	1	rs7129727	chr11:57484660	G/A	cg23127183	chr11:57508653	C11orf31	-0.49	-5.72	-0.35	3.27e-8	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9486715	0.838	rs9386473	chr6:96873341	C/A	cg18709589	chr6:96969512	KIAA0776	0.58	7.33	0.43	3.86e-12	Headache;
SARC	cis	rs8180040	0.764	rs11712716	chr3:47193432	T/C	cg02527881	chr3:46936655	PTH1R	-0.32	-4.97	-0.31	1.28e-6	Colorectal cancer;
SARC	cis	rs10988449	0.891	rs7020510	chr9:132392356	C/T	cg18327994	chr9:132372705	NA	-0.5	-5.16	-0.32	5.39e-7	Response to anti-depressant treatment in major depressive disorder;
SARC	cis	rs13161895	1.000	rs34882290	chr5:179463836	C/A	cg06664874	chr5:179499304	RNF130	0.5	4.85	0.3	2.26e-6	LDL cholesterol;
SARC	trans	rs11165623	0.585	rs6698447	chr1:96999473	C/T	cg10631902	chr5:14652156	NA	-0.43	-6.54	-0.39	3.89e-10	Hip circumference;Waist circumference;
SARC	cis	rs7178572	0.524	rs12914128	chr15:77493875	T/C	cg22256960	chr15:77711686	NA	-0.5	-5.53	-0.34	8.67e-8	Type 2 diabetes;
SARC	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg21016266	chr12:122356598	WDR66	0.31	4.89	0.31	1.87e-6	Mean corpuscular volume;
SARC	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs7481584	0.581	rs515481	chr11:3047184	A/G	cg08508325	chr11:3079039	CARS	0.23	5.13	0.32	6.14e-7	Calcium levels;
SARC	cis	rs11025559	0.812	rs11025583	chr11:20513260	C/T	cg19653624	chr11:20408972	PRMT3	0.55	6.18	0.38	2.77e-9	Pursuit maintenance gain;
SARC	cis	rs17401966	0.931	rs12130563	chr1:10428452	G/A	cg15208524	chr1:10270712	KIF1B	0.5	5.99	0.37	7.88e-9	Hepatocellular carcinoma;
SARC	cis	rs6840360	0.762	rs62327352	chr4:152670780	C/A	cg22705602	chr4:152727874	NA	-0.38	-6.68	-0.4	1.76e-10	Intelligence (multi-trait analysis);
SARC	cis	rs9611519	1.000	rs9611519	chr22:41613188	C/T	cg03806693	chr22:41940476	POLR3H	-0.57	-6.86	-0.41	6.28e-11	Neuroticism;
SARC	cis	rs7647973	1.000	rs56127630	chr3:49438036	C/G	cg07636037	chr3:49044803	WDR6	-0.75	-8.18	-0.47	1.88e-14	Menarche (age at onset);
SARC	cis	rs4243830	0.850	rs4434862	chr1:6602241	C/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.87	-8.99	-0.51	8.48e-17	Body mass index;
SARC	cis	rs9303401	0.659	rs12946852	chr17:57013337	G/C	cg25039879	chr17:56429692	SUPT4H1	0.62	5.77	0.35	2.46e-8	Cognitive test performance;
SARC	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.46	-5.73	-0.35	3.11e-8	Gut microbiome composition (summer);
SARC	cis	rs11098499	0.731	rs6846966	chr4:120293208	A/G	cg09307838	chr4:120376055	NA	0.83	11.57	0.6	9.18e-25	Corneal astigmatism;
SARC	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-7.06	-0.42	1.9e-11	Gut microbiome composition (summer);
SARC	trans	rs208520	0.837	rs208498	chr6:66931560	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.87	-10.23	-0.56	1.57e-20	Exhaled nitric oxide output;
SARC	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg04317338	chr11:64019027	PLCB3	0.81	8.68	0.49	6.79e-16	Mean platelet volume;
SARC	cis	rs6815814	0.808	rs7653908	chr4:38782221	G/C	cg06935464	chr4:38784597	TLR10	0.61	6.32	0.38	1.31e-9	Breast cancer;
SARC	cis	rs1018836	0.923	rs6986001	chr8:91650205	T/C	cg16814680	chr8:91681699	NA	-0.81	-13.32	-0.66	1.73e-30	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs62432291	0.681	rs397476	chr6:159639284	A/G	cg14500486	chr6:159655392	FNDC1	-0.56	-5.62	-0.35	5.54e-8	Joint mobility (Beighton score);
SARC	cis	rs77880822	0.562	rs6078405	chr20:1247246	T/C	cg23117778	chr20:1206693	RAD21L1	0.59	4.9	0.31	1.82e-6	Angiotensin-converting enzyme inhibitor intolerance;
SARC	trans	rs561341	0.783	rs512698	chr17:30292507	G/T	cg20587970	chr11:113659929	NA	-1.35	-13.48	-0.66	5.32e-31	Hip circumference adjusted for BMI;
SARC	cis	rs6963495	0.769	rs73192134	chr7:105189338	T/C	cg13798780	chr7:105162888	PUS7	0.57	5.23	0.32	3.86e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs910316	0.737	rs175048	chr14:75479894	A/T	cg08847533	chr14:75593920	NEK9	-0.82	-12.23	-0.63	6.98e-27	Height;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg08885381	chr5:72116865	TNPO1	0.57	7.98	0.46	6.69e-14	Thyroid stimulating hormone;
SARC	cis	rs7666738	0.611	rs34982650	chr4:98819530	T/A	cg05340658	chr4:99064831	C4orf37	0.66	8.68	0.49	7.14e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6840360	0.554	rs6849111	chr4:152708874	T/C	cg22705602	chr4:152727874	NA	-0.48	-8.37	-0.48	5.34e-15	Intelligence (multi-trait analysis);
SARC	cis	rs11249608	0.548	rs7704565	chr5:178473923	G/C	cg21905437	chr5:178450457	ZNF879	0.54	6.72	0.4	1.37e-10	Pubertal anthropometrics;
SARC	cis	rs3733585	0.673	rs4519796	chr4:9955936	A/G	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.95	-0.36	9.9e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs2404618	0.587	rs6994849	chr8:1492839	G/T	cg13402656	chr8:1511478	DLGAP2	0.58	8.74	0.5	4.56e-16	Lung cancer;
SARC	cis	rs9354308	0.966	rs1909533	chr6:66565658	G/A	cg07460842	chr6:66804631	NA	0.48	5.45	0.34	1.3e-7	Metabolite levels;
SARC	cis	rs7681440	0.606	rs2619360	chr4:90756191	C/T	cg06632027	chr4:90757378	SNCA	-0.43	-5.36	-0.33	2e-7	Dementia with Lewy bodies;
SARC	cis	rs7264396	0.709	rs2425073	chr20:34293699	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.59	6.1	0.37	4.34e-9	Total cholesterol levels;
SARC	cis	rs6500395	1.000	rs1872654	chr16:48671050	C/T	cg04672837	chr16:48644449	N4BP1	0.47	6.24	0.38	2.05e-9	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs4737010	0.578	rs4466386	chr8:41679853	A/G	cg17182837	chr8:41585554	ANK1	-0.49	-5.89	-0.36	1.37e-8	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
SARC	cis	rs668210	0.947	rs610497	chr11:65765551	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.68	7.66	0.45	4.9e-13	Cerebrospinal fluid biomarker levels;
SARC	cis	rs2645694	0.626	rs2645684	chr4:77819892	A/C	cg18351406	chr4:77819688	ANKRD56	0.45	6.26	0.38	1.81e-9	Emphysema distribution in smoking;
SARC	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg03433033	chr1:76189801	ACADM	0.56	7.84	0.46	1.61e-13	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs17125944	0.506	rs1998776	chr14:53355590	T/A	cg00686598	chr14:53173677	PSMC6	-0.63	-4.87	-0.3	2.06e-6	Alzheimer's disease (late onset);
SARC	cis	rs875971	0.545	rs4718348	chr7:65906576	A/G	cg11764359	chr7:65958608	NA	0.67	6.31	0.38	1.36e-9	Aortic root size;
SARC	cis	rs11608355	0.545	rs4766473	chr12:109900596	C/T	cg05360138	chr12:110035743	NA	0.92	9.65	0.53	9.69e-19	Neuroticism;
SARC	cis	rs1348850	0.567	rs880899	chr2:178532416	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.42	4.89	0.31	1.88e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7296418	0.961	rs949143	chr12:123595163	G/A	cg00376283	chr12:123451042	ABCB9	0.67	8.76	0.5	4e-16	Platelet count;
SARC	cis	rs73242632	1.000	rs3775083	chr4:57868186	A/G	cg20415529	chr4:57845134	POLR2B;C4orf14	1.07	6.6	0.4	2.74e-10	Congenital heart disease (maternal effect);
SARC	cis	rs4642101	0.662	rs9874893	chr3:12833079	C/G	cg05775895	chr3:12838266	CAND2	0.84	15.66	0.72	2.97e-38	QRS complex (12-leadsum);
SARC	cis	rs79349575	0.721	rs9904645	chr17:46969665	A/T	cg16584676	chr17:46985605	UBE2Z	0.55	6.68	0.4	1.72e-10	Type 2 diabetes;
SARC	cis	rs7617773	0.539	rs1471217	chr3:48384895	A/C	cg11946769	chr3:48343235	NME6	0.56	6.78	0.41	9.53e-11	Coronary artery disease;
SARC	cis	rs10932679	0.901	rs13027512	chr2:217656764	C/G	cg05032264	chr2:217675019	NA	0.58	5.57	0.34	6.93e-8	Pulse pressure;
SARC	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg14784868	chr12:69753453	YEATS4	0.51	6.77	0.41	1.01e-10	Blood protein levels;
SARC	cis	rs526231	0.511	rs6881612	chr5:102377013	C/T	cg23492399	chr5:102201601	PAM	-0.52	-5.62	-0.35	5.32e-8	Primary biliary cholangitis;
SARC	cis	rs2075371	0.933	rs2544191	chr7:133954248	A/G	cg11752832	chr7:134001865	SLC35B4	0.54	6.89	0.41	5.12e-11	Mean platelet volume;
SARC	cis	rs6570726	0.791	rs6918814	chr6:145906028	G/A	cg05220968	chr6:146057943	EPM2A	-0.28	-4.93	-0.31	1.58e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg12756686	chr19:29218302	NA	0.68	8.99	0.51	8.55e-17	Methadone dose in opioid dependence;
SARC	cis	rs2075371	1.000	rs1862050	chr7:133980999	T/C	cg20476274	chr7:133979776	SLC35B4	0.62	8.48	0.49	2.54e-15	Mean platelet volume;
SARC	cis	rs2304069	0.954	rs10068537	chr5:149403193	G/A	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.7	7.06	0.42	1.9e-11	HIV-1 control;
SARC	cis	rs11723261	0.582	rs6830247	chr4:150683	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.39	4.94	0.31	1.51e-6	Immune response to smallpox vaccine (IL-6);
SARC	cis	rs17826219	0.500	rs28452421	chr17:29083980	G/A	cg13385521	chr17:29058706	SUZ12P	0.89	7.89	0.46	1.18e-13	Body mass index;
SARC	cis	rs11098499	0.955	rs35916640	chr4:120155852	T/C	cg09307838	chr4:120376055	NA	0.86	11.6	0.61	7.28e-25	Corneal astigmatism;
SARC	cis	rs12956009	0.518	rs11663852	chr18:44887542	G/A	cg15049968	chr18:44337910	ST8SIA5	-0.31	-4.74	-0.3	3.67e-6	Educational attainment (years of education);
SARC	cis	rs10489202	1.000	rs11587594	chr1:167989180	A/T	cg24449463	chr1:168025552	DCAF6	-0.64	-7.06	-0.42	1.94e-11	Schizophrenia;
SARC	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs35306767	0.903	rs7067865	chr10:908387	C/T	cg20503657	chr10:835505	NA	0.87	8.2	0.47	1.57e-14	Eosinophil percentage of granulocytes;
SARC	cis	rs1971762	0.545	rs3864905	chr12:54058324	C/T	cg06632207	chr12:54070931	ATP5G2	0.6	8.34	0.48	6.53e-15	Height;
SARC	cis	rs344364	0.511	rs1742395	chr16:1955965	G/A	cg26617929	chr16:1858877	NA	-0.66	-5.42	-0.33	1.45e-7	Glomerular filtration rate in chronic kidney disease;
SARC	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg04277193	chr17:41438351	NA	0.44	4.72	0.3	3.99e-6	Menopause (age at onset);
SARC	cis	rs67311347	0.524	rs11129869	chr3:40259738	G/A	cg24209194	chr3:40518798	ZNF619	0.46	5.51	0.34	9.62e-8	Renal cell carcinoma;
SARC	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.66	0.35	4.44e-8	Bipolar disorder;
SARC	trans	rs61931739	0.782	rs7969373	chr12:34249655	T/G	cg26384229	chr12:38710491	ALG10B	0.63	8.24	0.48	1.28e-14	Morning vs. evening chronotype;
SARC	cis	rs11098499	0.909	rs17046118	chr4:120387496	T/G	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	cis	rs79149102	0.649	rs2229730	chr15:75093389	C/T	cg17294928	chr15:75287854	SCAMP5	-0.93	-4.73	-0.3	3.82e-6	Lung cancer;
SARC	cis	rs6493487	0.512	rs17599974	chr15:51237349	C/T	cg02338191	chr15:51200825	AP4E1	-0.55	-5.04	-0.31	9.45e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs7700895	0.737	rs17085231	chr5:95222156	C/T	cg16656078	chr5:95278638	ELL2	-0.58	-7.01	-0.42	2.56e-11	IgG glycosylation;
SARC	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg13206674	chr6:150067644	NUP43	0.48	6.36	0.38	1.07e-9	Lung cancer;
SARC	cis	rs644799	0.622	rs1255167	chr11:95500213	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.72	9.94	0.55	1.26e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs6683419	0.604	rs12726742	chr1:19851031	A/G	cg12094543	chr1:19923282	C1orf151	0.6	6.63	0.4	2.28e-10	Serum thyroid-stimulating hormone levels;
SARC	cis	rs617791	0.678	rs551659	chr11:65749645	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.43	5.3	0.33	2.66e-7	Breast cancer;
SARC	cis	rs10861342	1.000	rs10861356	chr12:105526965	G/T	cg23923672	chr12:105501055	KIAA1033	0.76	5.88	0.36	1.39e-8	IgG glycosylation;
SARC	trans	rs17685	0.664	rs9801113	chr7:75792031	C/T	cg19862616	chr7:65841803	NCRNA00174	0.64	8.01	0.46	5.5e-14	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs8053891	0.906	rs28714527	chr16:71997862	C/G	cg16558253	chr16:72132732	DHX38	-0.41	-5.32	-0.33	2.44e-7	Coronary artery disease;
SARC	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg03213289	chr20:61660250	NA	0.46	6.43	0.39	7.22e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs12956009	0.583	rs1821446	chr18:44894422	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.58	7.49	0.44	1.44e-12	Educational attainment (years of education);
SARC	cis	rs7412746	0.658	rs11582281	chr1:150826831	T/C	cg10589385	chr1:150898437	SETDB1	0.42	5.6	0.34	6.13e-8	Melanoma;
SARC	cis	rs995000	0.965	rs11207981	chr1:63006087	C/A	cg06896770	chr1:63153194	DOCK7	-0.9	-13.49	-0.66	5.08e-31	Triglyceride levels;
SARC	cis	rs4481887	1.000	rs7513161	chr1:248453422	A/T	cg01631408	chr1:248437212	OR2T33	-0.43	-5.55	-0.34	7.73e-8	Common traits (Other);
SARC	cis	rs79149102	0.579	rs58645417	chr15:75325858	T/G	cg00629941	chr15:75287862	SCAMP5	-0.72	-5.51	-0.34	9.27e-8	Lung cancer;
SARC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg26338869	chr17:61819248	STRADA	0.8	10.69	0.57	5.79e-22	Prudent dietary pattern;
SARC	cis	rs10791097	0.694	rs10160281	chr11:130742788	T/C	cg12179176	chr11:130786555	SNX19	0.73	10.91	0.58	1.19e-22	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg03060546	chr3:49711283	APEH	0.77	11.26	0.59	8.94e-24	Resting heart rate;
SARC	trans	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.52	-0.39	4.21e-10	Triglycerides;
SARC	cis	rs6582630	0.621	rs10880656	chr12:38571220	A/C	cg14851346	chr12:38532713	NA	-0.44	-5.24	-0.32	3.53e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7089973	0.836	rs1966384	chr10:116627910	G/T	cg08188268	chr10:116634841	FAM160B1	0.37	5.91	0.36	1.19e-8	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg06873352	chr17:61820015	STRADA	0.53	6.89	0.41	5.28e-11	Prudent dietary pattern;
SARC	cis	rs3018712	0.532	rs10791988	chr11:68416051	A/T	cg01657329	chr11:68192670	LRP5	0.59	5.38	0.33	1.81e-7	Total body bone mineral density;
SARC	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg05368731	chr17:41323189	NBR1	0.78	9.51	0.53	2.46e-18	Menopause (age at onset);
SARC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	20.44	0.8	7e-54	Prudent dietary pattern;
SARC	cis	rs9467773	1.000	rs1884948	chr6:26567988	G/A	cg12292205	chr6:26970375	C6orf41	0.45	5.43	0.33	1.45e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg00409905	chr10:38381863	ZNF37A	-0.5	-6.65	-0.4	2.04e-10	Extrinsic epigenetic age acceleration;
SARC	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg13395646	chr4:1353034	KIAA1530	0.43	5.02	0.31	1.01e-6	Obesity-related traits;
SARC	cis	rs449789	0.857	rs10806706	chr6:159721945	G/T	cg14500486	chr6:159655392	FNDC1	0.43	4.96	0.31	1.38e-6	Pulse pressure;
SARC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg18402987	chr7:1209562	NA	0.41	5.35	0.33	2.08e-7	Longevity;Endometriosis;
SARC	cis	rs7086627	0.515	rs7077373	chr10:82211615	C/T	cg01528321	chr10:82214614	TSPAN14	0.58	8.48	0.49	2.68e-15	Post bronchodilator FEV1;
SARC	cis	rs1144333	0.655	rs17097837	chr1:76462166	G/A	cg03433033	chr1:76189801	ACADM	0.61	4.97	0.31	1.28e-6	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs9303280	0.806	rs2872507	chr17:38040763	C/T	cg17467752	chr17:38218738	THRA	-0.37	-4.74	-0.3	3.68e-6	Self-reported allergy;
SARC	cis	rs9457247	0.565	rs2239824	chr6:167511799	T/A	cg07741184	chr6:167504864	NA	0.38	7.14	0.42	1.15e-11	Crohn's disease;
SARC	cis	rs12134245	0.719	rs61798831	chr1:91996588	C/T	cg02896835	chr1:92012615	NA	-0.52	-7.19	-0.43	8.94e-12	Breast cancer;
SARC	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg03647317	chr4:187891568	NA	-0.35	-5.03	-0.31	1e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6570726	0.935	rs454614	chr6:145832633	C/T	cg05347473	chr6:146136440	FBXO30	0.48	6.42	0.39	7.51e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg04317338	chr11:64019027	PLCB3	0.81	8.68	0.49	6.79e-16	Mean platelet volume;
SARC	cis	rs7084402	0.967	rs1658479	chr10:60289398	C/A	cg07615347	chr10:60278583	BICC1	0.6	8.84	0.5	2.34e-16	Refractive error;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg23530064	chr21:30713266	BACH1	0.49	6.73	0.4	1.29e-10	Thyroid stimulating hormone;
SARC	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg22875332	chr1:76189707	ACADM	-0.47	-6.58	-0.4	3.09e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs28374715	0.662	rs113913466	chr15:41483100	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.0	-13.58	-0.66	2.57e-31	Ulcerative colitis;
SARC	cis	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg25427524	chr10:38739819	LOC399744	-0.57	-8.91	-0.5	1.45e-16	Extrinsic epigenetic age acceleration;
SARC	cis	rs9831754	0.756	rs12714468	chr3:78445878	A/T	cg06138941	chr3:78371609	NA	-0.53	-6.18	-0.38	2.86e-9	Calcium levels;
SARC	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.79	11.4	0.6	3.28e-24	Total body bone mineral density;
SARC	cis	rs765787	0.530	rs7167731	chr15:45510900	T/C	cg24006582	chr15:45444508	DUOX1	0.45	5.77	0.35	2.53e-8	Uric acid levels;
SARC	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg18876405	chr7:65276391	NA	0.45	5.08	0.32	7.82e-7	Aortic root size;
SARC	cis	rs8067545	0.641	rs4925060	chr17:19863258	C/G	cg04132472	chr17:19861366	AKAP10	0.38	5.02	0.31	1.04e-6	Schizophrenia;
SARC	cis	rs9733	0.818	rs4970926	chr1:150673684	T/C	cg15448220	chr1:150897856	SETDB1	-0.36	-4.72	-0.3	3.98e-6	Tonsillectomy;
SARC	cis	rs4481887	1.000	rs10888360	chr1:248479282	G/A	cg01631408	chr1:248437212	OR2T33	-0.43	-5.34	-0.33	2.23e-7	Common traits (Other);
SARC	cis	rs1707322	0.721	rs10890343	chr1:46157922	C/T	cg03146154	chr1:46216737	IPP	0.51	6.18	0.38	2.85e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg05368731	chr17:41323189	NBR1	0.78	9.2	0.52	2.1e-17	Menopause (age at onset);
SARC	cis	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg05084668	chr3:125655381	ALG1L	-0.48	-4.87	-0.3	2.02e-6	Blood pressure (smoking interaction);
SARC	cis	rs9309473	1.000	rs6546836	chr2:73677833	A/G	cg20560298	chr2:73613845	ALMS1	-0.51	-6.2	-0.38	2.57e-9	Metabolite levels;
SARC	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg11878867	chr6:150167359	LRP11	-0.36	-4.74	-0.3	3.77e-6	Lung cancer;
SARC	cis	rs986417	0.748	rs8019541	chr14:60929145	A/G	cg27398547	chr14:60952738	C14orf39	1.02	9.54	0.53	2.06e-18	Gut microbiota (bacterial taxa);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg25420070	chr6:52149649	MCM3	0.5	6.26	0.38	1.88e-9	Breast cancer;
SARC	cis	rs7589342	0.536	rs10173137	chr2:106388049	A/C	cg16077055	chr2:106428750	NCK2	0.31	6.07	0.37	5.12e-9	Addiction;
SARC	cis	rs9581857	0.579	rs3759433	chr13:27997999	C/T	cg22138327	chr13:27999177	GTF3A	0.61	5.82	0.36	1.94e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	cis	rs55871839	0.708	rs7000535	chr8:59804351	T/C	cg07426533	chr8:59803705	TOX	-0.45	-6.04	-0.37	5.97e-9	Pneumonia;
SARC	cis	rs8038465	0.622	rs56712926	chr15:73886849	G/T	cg15420318	chr15:73925796	NPTN	0.63	7.17	0.43	9.88e-12	Liver enzyme levels (gamma-glutamyl transferase);
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15059389	chr1:12079390	MIIP	0.64	8.81	0.5	3.02e-16	Smoking initiation;
SARC	cis	rs1451375	0.617	rs2060763	chr7:50542359	G/A	cg14593290	chr7:50529359	DDC	-0.47	-4.89	-0.3	1.92e-6	Malaria;
SARC	cis	rs7084402	0.967	rs2917949	chr10:60329166	G/A	cg07615347	chr10:60278583	BICC1	0.58	8.58	0.49	1.36e-15	Refractive error;
SARC	trans	rs208520	0.874	rs208512	chr6:66943869	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.87	-10.1	-0.55	3.99e-20	Exhaled nitric oxide output;
SARC	cis	rs9291683	0.588	rs17247314	chr4:10004743	C/G	cg11266682	chr4:10021025	SLC2A9	0.4	7.26	0.43	5.79e-12	Bone mineral density;
SARC	cis	rs6570726	0.764	rs4263604	chr6:145916697	A/G	cg23711669	chr6:146136114	FBXO30	0.83	13.24	0.66	3.17e-30	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs61931739	0.929	rs10844730	chr12:34026721	C/G	cg26384229	chr12:38710491	ALG10B	-0.6	-8.12	-0.47	2.65e-14	Morning vs. evening chronotype;
SARC	cis	rs11971779	0.680	rs11765421	chr7:139025094	G/A	cg23387468	chr7:139079360	LUC7L2	0.33	4.79	0.3	2.97e-6	Diisocyanate-induced asthma;
SARC	cis	rs9818758	0.607	rs9880088	chr3:49178990	G/A	cg00383909	chr3:49044727	WDR6	0.72	6.27	0.38	1.73e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs7584330	0.737	rs13397017	chr2:238361241	G/A	cg11271282	chr2:238384023	NA	0.44	5.04	0.31	9.36e-7	Prostate cancer;
SARC	cis	rs12142240	0.698	rs68012736	chr1:46839510	A/G	cg00530320	chr1:46809349	NSUN4	0.57	7.0	0.42	2.74e-11	Menopause (age at onset);
SARC	cis	rs981844	1.000	rs2263434	chr4:154658312	A/G	cg14289246	chr4:154710475	SFRP2	0.58	6.64	0.4	2.14e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs10875746	0.951	rs7485355	chr12:48548342	G/A	cg27446233	chr12:48516484	PFKM	-0.46	-5.22	-0.32	4.04e-7	Longevity (90 years and older);
SARC	cis	rs8031584	0.958	rs3512	chr15:31235005	G/C	cg14298792	chr15:30685198	CHRFAM7A	-0.45	-4.92	-0.31	1.64e-6	Huntington's disease progression;
SARC	trans	rs1814175	0.817	rs11040474	chr11:49708441	G/A	cg15704280	chr7:45808275	SEPT13	-0.97	-17.91	-0.76	1.06e-45	Height;
SARC	cis	rs80282103	0.867	rs17155821	chr10:1071701	A/G	cg08668510	chr10:1095578	IDI1	0.77	5.25	0.33	3.45e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs7327064	1.000	rs7327064	chr13:36771017	C/T	cg13455704	chr13:36871754	C13orf38	0.54	6.05	0.37	5.69e-9	Economic and political preferences;
SARC	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg27541892	chr1:1571801	CDK11B	0.4	5.38	0.33	1.85e-7	Body mass index;
SARC	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg05313129	chr8:58192883	C8orf71	-0.64	-6.68	-0.4	1.72e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs710216	1.000	rs710216	chr1:43428757	A/G	cg22176566	chr1:43424700	SLC2A1	0.53	5.15	0.32	5.61e-7	Red cell distribution width;
SARC	cis	rs9916302	0.571	rs28799952	chr17:37533056	C/T	cg15445000	chr17:37608096	MED1	-0.45	-4.85	-0.3	2.29e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs9914544	0.545	rs68046274	chr17:18785126	G/A	cg25390199	chr17:18761479	PRPSAP2	0.46	6.05	0.37	5.66e-9	Educational attainment (years of education);
SARC	cis	rs9291683	0.609	rs3796836	chr4:10011345	A/G	cg00071950	chr4:10020882	SLC2A9	0.41	6.43	0.39	6.98e-10	Bone mineral density;
SARC	cis	rs981844	0.775	rs62323976	chr4:154739032	A/G	cg14289246	chr4:154710475	SFRP2	0.57	6.1	0.37	4.47e-9	Response to statins (LDL cholesterol change);
SARC	cis	rs11711311	0.736	rs13320940	chr3:113400954	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	7.34	0.43	3.55e-12	IgG glycosylation;
SARC	cis	rs8017423	0.935	rs11624890	chr14:90738165	T/A	cg20276874	chr14:90721474	PSMC1	0.35	4.77	0.3	3.27e-6	Mortality in heart failure;
SARC	cis	rs9303401	0.625	rs66508449	chr17:56691034	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.11	12.59	0.64	4.36e-28	Cognitive test performance;
SARC	cis	rs637571	0.584	rs594689	chr11:65635559	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.39	4.96	0.31	1.37e-6	Eosinophil percentage of white cells;
SARC	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg02725872	chr8:58115012	NA	-0.37	-6.54	-0.39	3.81e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs8060686	0.591	rs255054	chr16:68017356	A/G	cg27539214	chr16:67997921	SLC12A4	-0.54	-5.51	-0.34	9.66e-8	HDL cholesterol;Metabolic syndrome;
SARC	cis	rs6450176	0.633	rs25858	chr5:53339518	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.62	-7.07	-0.42	1.79e-11	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg18252515	chr7:66147081	NA	0.59	6.27	0.38	1.74e-9	Aortic root size;
SARC	trans	rs7980799	0.716	rs1351683	chr12:33598563	G/A	cg26384229	chr12:38710491	ALG10B	-0.62	-7.65	-0.45	5.16e-13	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-9.15	-0.51	2.85e-17	Alzheimer's disease;
SARC	cis	rs7727544	0.735	rs272879	chr5:131670546	C/G	cg24060327	chr5:131705240	SLC22A5	-0.68	-8.78	-0.5	3.65e-16	Blood metabolite levels;
SARC	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs9733	0.687	rs11204735	chr1:150841667	T/C	cg13175981	chr1:150552382	MCL1	0.62	8.41	0.48	4.16e-15	Tonsillectomy;
SARC	cis	rs2180341	0.924	rs9285459	chr6:127631113	T/C	cg27446573	chr6:127587934	RNF146	1.02	14.46	0.69	2.89e-34	Breast cancer;
SARC	cis	rs73086581	1.000	rs17214621	chr20:3925924	T/C	cg02187196	chr20:3869020	PANK2	0.67	6.38	0.39	9.48e-10	Response to antidepressants in depression;
SARC	cis	rs72634258	0.554	rs12061787	chr1:7888730	G/C	cg26816564	chr1:7831052	VAMP3	0.54	4.99	0.31	1.2e-6	Inflammatory bowel disease;
SARC	cis	rs559928	0.556	rs734762	chr11:63912189	G/C	cg05555928	chr11:63887634	MACROD1	-0.51	-4.85	-0.3	2.26e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	trans	rs2727020	0.658	rs10839278	chr11:49450847	G/C	cg15704280	chr7:45808275	SEPT13	-0.86	-13.99	-0.68	1.06e-32	Coronary artery disease;
SARC	cis	rs7208859	0.673	rs78799101	chr17:29215160	A/T	cg13385521	chr17:29058706	SUZ12P	0.86	7.33	0.43	3.87e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs6088590	1.000	rs2295354	chr20:33356541	T/C	cg24642439	chr20:33292090	TP53INP2	0.88	12.29	0.63	4.16e-27	Coronary artery disease;
SARC	cis	rs9948	0.655	rs2314399	chr2:97442390	G/A	cg15007626	chr2:97405879	LMAN2L	0.73	4.86	0.3	2.14e-6	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs2242116	0.761	rs6780601	chr3:46965856	A/G	cg02527881	chr3:46936655	PTH1R	-0.39	-6.03	-0.37	6.49e-9	Birth weight;
SARC	cis	rs1904096	0.513	rs2632405	chr4:95152215	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.47	-7.07	-0.42	1.74e-11	Type 2 diabetes;
SARC	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg21724239	chr8:58056113	NA	0.57	6.14	0.37	3.54e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg18252515	chr7:66147081	NA	-0.57	-6.11	-0.37	4.17e-9	Aortic root size;
SARC	cis	rs4481887	0.893	rs4244186	chr1:248493319	A/G	cg00666640	chr1:248458726	OR2T12	0.34	5.68	0.35	4.08e-8	Common traits (Other);
SARC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9303401	0.659	rs72828726	chr17:56951217	C/G	cg25039879	chr17:56429692	SUPT4H1	0.63	5.93	0.36	1.06e-8	Cognitive test performance;
SARC	cis	rs9715521	0.775	rs62301193	chr4:59844120	C/T	cg11281224	chr4:60001000	NA	-0.4	-5.12	-0.32	6.5e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg19346786	chr7:2764209	NA	-0.34	-5.07	-0.31	8.26e-7	Height;
SARC	cis	rs9517320	0.534	rs9554477	chr13:99160379	C/T	cg07423050	chr13:99094983	FARP1	-0.42	-5.84	-0.36	1.7e-8	Longevity;
SARC	cis	rs6504663	0.558	rs7627	chr17:48552154	G/C	cg00901687	chr17:48585270	MYCBPAP	0.53	5.99	0.37	7.78e-9	Visceral fat;
SARC	cis	rs7412746	0.611	rs7556661	chr1:150892009	C/T	cg10589385	chr1:150898437	SETDB1	0.42	5.64	0.35	4.91e-8	Melanoma;
SARC	cis	rs526231	0.543	rs34832	chr5:102444595	T/C	cg23492399	chr5:102201601	PAM	-0.52	-5.62	-0.35	5.5e-8	Primary biliary cholangitis;
SARC	cis	rs9787249	0.957	rs10888958	chr1:40211737	T/C	cg24920358	chr1:40204285	PPIE	0.44	5.23	0.32	3.75e-7	Blood protein levels;
SARC	cis	rs9325144	0.554	rs1906264	chr12:38739490	A/G	cg26384229	chr12:38710491	ALG10B	0.61	8.06	0.47	4.09e-14	Morning vs. evening chronotype;
SARC	cis	rs7264396	0.635	rs6060709	chr20:34536022	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.52	5.27	0.33	3.18e-7	Total cholesterol levels;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg13268919	chr11:842945	TSPAN4;POLR2L	-0.5	-6.49	-0.39	5.01e-10	Electrocardiographic conduction measures;
SARC	cis	rs9398803	0.835	rs9321065	chr6:126744087	G/A	cg19875578	chr6:126661172	C6orf173	0.59	7.98	0.46	6.62e-14	Male-pattern baldness;
SARC	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg24829409	chr8:58192753	C8orf71	-0.56	-6.19	-0.38	2.62e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9790314	0.934	rs465985	chr3:161098552	T/C	cg04691961	chr3:161091175	C3orf57	-0.79	-11.76	-0.61	2.26e-25	Morning vs. evening chronotype;
SARC	cis	rs7659604	0.521	rs4240263	chr4:122683623	C/T	cg19671926	chr4:122722719	EXOSC9	0.57	7.3	0.43	4.52e-12	Type 2 diabetes;
SARC	cis	rs7429990	0.965	rs4858810	chr3:48043737	G/A	cg11946769	chr3:48343235	NME6	-0.47	-5.34	-0.33	2.2e-7	Educational attainment (years of education);
SARC	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg21782813	chr7:2030301	MAD1L1	0.4	6.28	0.38	1.62e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg18252515	chr7:66147081	NA	1.29	11.17	0.59	1.7e-23	Diabetic kidney disease;
SARC	cis	rs780096	0.814	rs780093	chr2:27742603	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.29	-4.87	-0.3	2.1e-6	Total body bone mineral density;
SARC	cis	rs9300255	0.602	rs1790126	chr12:123683563	C/T	cg00376283	chr12:123451042	ABCB9	0.55	6.53	0.39	4.09e-10	Neutrophil percentage of white cells;
SARC	cis	rs6738485	0.507	rs66569888	chr2:106886967	G/A	cg23109721	chr2:106886537	NA	-0.48	-5.13	-0.32	6.2e-7	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
SARC	cis	rs6807306	1.000	rs6764020	chr3:167451230	C/T	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.49	4.91	0.31	1.7e-6	Mean platelet volume;
SARC	cis	rs7520050	0.833	rs1085242	chr1:46544224	T/A	cg24296786	chr1:45957014	TESK2	0.38	4.82	0.3	2.56e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg27266027	chr21:40555129	PSMG1	0.48	5.15	0.32	5.5e-7	Cognitive function;
SARC	trans	rs1814175	0.645	rs1851857	chr11:49855589	A/C	cg03929089	chr4:120376271	NA	-0.83	-12.19	-0.62	8.89e-27	Height;
SARC	cis	rs2180341	0.597	rs11154397	chr6:127646649	G/C	cg24812749	chr6:127587940	RNF146	0.59	7.23	0.43	6.9e-12	Breast cancer;
SARC	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg09033563	chr22:24373618	LOC391322	0.47	5.41	0.33	1.56e-7	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs5758659	0.652	rs5758537	chr22:42397042	G/T	cg04733989	chr22:42467013	NAGA	0.5	6.73	0.4	1.29e-10	Cognitive function;
SARC	cis	rs7520050	0.966	rs11211241	chr1:46452683	T/A	cg24296786	chr1:45957014	TESK2	0.38	4.88	0.3	2.01e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs3008870	0.883	rs2755249	chr1:67493662	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.9	11.27	0.59	8.24e-24	Lymphocyte percentage of white cells;
SARC	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg22541963	chr20:60982533	CABLES2	-0.43	-4.8	-0.3	2.79e-6	Colorectal cancer;
SARC	cis	rs7223966	0.921	rs7225092	chr17:61864005	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.5	-5.09	-0.32	7.43e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs3942852	0.524	rs7118665	chr11:48078427	C/A	cg03929089	chr4:120376271	NA	0.55	6.59	0.4	2.89e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs2290159	0.752	rs5746182	chr3:12672550	A/G	cg23032965	chr3:12705835	RAF1	0.78	8.68	0.49	6.81e-16	Cholesterol, total;
SARC	cis	rs7546668	1.000	rs4646093	chr1:15821400	G/T	cg18192808	chr1:15853278	DNAJC16	0.46	5.79	0.35	2.22e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs12142240	0.698	rs72677585	chr1:46812374	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-5.48	-0.34	1.12e-7	Menopause (age at onset);
SARC	cis	rs9325144	0.600	rs61931871	chr12:38829889	G/A	cg26384229	chr12:38710491	ALG10B	-0.59	-7.66	-0.45	4.81e-13	Morning vs. evening chronotype;
SARC	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg19774624	chr17:42201019	HDAC5	-0.79	-11.38	-0.6	3.65e-24	Total body bone mineral density;
SARC	cis	rs672059	0.934	rs6703054	chr1:183155778	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.52	7.04	0.42	2.18e-11	Hypertriglyceridemia;
SARC	cis	rs918629	0.567	rs10069748	chr5:95241222	C/T	cg16656078	chr5:95278638	ELL2	0.53	6.82	0.41	7.74e-11	IgG glycosylation;
SARC	cis	rs7412746	0.552	rs4970980	chr1:150864992	A/C	cg13175981	chr1:150552382	MCL1	-0.51	-6.28	-0.38	1.64e-9	Melanoma;
SARC	cis	rs9300255	0.596	rs10734901	chr12:123743447	G/A	cg00376283	chr12:123451042	ABCB9	0.51	5.73	0.35	3.04e-8	Neutrophil percentage of white cells;
SARC	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg16434002	chr17:42200994	HDAC5	0.47	6.05	0.37	5.76e-9	Total body bone mineral density;
SARC	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.47	4.9	0.31	1.83e-6	Renal function-related traits (BUN);
SARC	cis	rs7845219	0.539	rs713113	chr8:95877787	C/T	cg16049864	chr8:95962084	TP53INP1	0.36	6.15	0.37	3.28e-9	Type 2 diabetes;
SARC	cis	rs4742903	0.875	rs10991141	chr9:106938280	T/C	cg14250997	chr9:106856677	SMC2	0.44	5.5	0.34	1.01e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs13082711	0.911	rs13100751	chr3:27454964	A/G	cg02860705	chr3:27208620	NA	0.48	6.09	0.37	4.52e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs6599192	1	rs6599192	chr3:41992408	G/A	cg03022575	chr3:42003672	ULK4	-0.58	-5.74	-0.35	2.88e-8	Multiple myeloma;
SARC	cis	rs6690583	0.562	rs11588919	chr1:85442813	A/T	cg22153463	chr1:85462885	MCOLN2	0.71	6.8	0.41	8.51e-11	Serum sulfate level;
SARC	cis	rs2980439	0.525	rs2945238	chr8:8170136	A/C	cg15556689	chr8:8085844	FLJ10661	0.49	6.05	0.37	5.75e-9	Neuroticism;
SARC	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	12.3	0.63	4.09e-27	Chronic sinus infection;
SARC	cis	rs9378357	0.850	rs6910086	chr6:3287118	T/C	cg08754725	chr6:3293098	SLC22A23	0.66	4.9	0.31	1.81e-6	Obesity-related traits;
SARC	cis	rs7208859	0.623	rs9896603	chr17:29078512	C/G	cg13385521	chr17:29058706	SUZ12P	0.88	7.75	0.45	2.9e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	trans	rs12486865	0.522	rs11719857	chr3:99920884	A/G	cg21934772	chr13:110198949	NA	0.51	7.0	0.42	2.7e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs12142240	0.698	rs6690075	chr1:46819848	G/A	cg00530320	chr1:46809349	NSUN4	0.57	6.92	0.41	4.4e-11	Menopause (age at onset);
SARC	cis	rs7927771	0.524	rs7122182	chr11:47843133	A/C	cg20307385	chr11:47447363	PSMC3	-0.49	-6.63	-0.4	2.36e-10	Subjective well-being;
SARC	cis	rs73001065	0.901	rs73004959	chr19:19711139	C/T	cg03709012	chr19:19516395	GATAD2A	0.81	5.23	0.32	3.78e-7	LDL cholesterol;
SARC	cis	rs12540874	0.500	rs12719030	chr7:50485073	T/C	cg18232548	chr7:50535776	DDC	-0.48	-5.98	-0.36	8.31e-9	Systemic sclerosis;
SARC	cis	rs6733011	0.578	rs1581250	chr2:99500750	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.43	-5.51	-0.34	9.34e-8	Bipolar disorder;
SARC	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg02951883	chr7:2050386	MAD1L1	-0.42	-5.31	-0.33	2.51e-7	Bipolar disorder and schizophrenia;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg04065742	chr10:34763442	PARD3	0.47	6.35	0.38	1.11e-9	Thyroid stimulating hormone;
SARC	cis	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg24110177	chr3:50126178	RBM5	-0.56	-7.53	-0.44	1.07e-12	Intelligence (multi-trait analysis);
SARC	cis	rs981844	1.000	rs2251900	chr4:154654145	C/T	cg14289246	chr4:154710475	SFRP2	0.51	5.56	0.34	7.3e-8	Response to statins (LDL cholesterol change);
SARC	cis	rs5762813	0.510	rs1222	chr22:29185113	G/T	cg02153584	chr22:29168773	CCDC117	-0.66	-6.44	-0.39	6.84e-10	Hematocrit;Hemoglobin concentration;
SARC	cis	rs8180040	1.000	rs4858888	chr3:47405305	C/T	cg27129171	chr3:47204927	SETD2	-0.71	-9.74	-0.54	5.07e-19	Colorectal cancer;
SARC	cis	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg25894440	chr7:65020034	NA	-0.77	-5.9	-0.36	1.24e-8	Diabetic kidney disease;
SARC	cis	rs7927771	0.800	rs55876153	chr11:47416636	G/A	cg20307385	chr11:47447363	PSMC3	-0.58	-7.35	-0.43	3.34e-12	Subjective well-being;
SARC	cis	rs6815814	0.950	rs66979032	chr4:38814700	A/G	cg09316306	chr4:38807337	TLR1	0.47	4.81	0.3	2.72e-6	Breast cancer;
SARC	cis	rs9486719	0.843	rs2499796	chr6:96848364	A/G	cg06623918	chr6:96969491	KIAA0776	0.75	7.35	0.43	3.27e-12	Migraine;Coronary artery disease;
SARC	cis	rs7524258	0.868	rs2412153	chr1:7272412	C/T	cg07173049	chr1:7289937	CAMTA1	0.36	7.04	0.42	2.08e-11	Tourette's syndrome or obsessive-compulsive disorder;
SARC	cis	rs3008870	0.959	rs2985808	chr1:67367741	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.9	10.78	0.58	2.98e-22	Lymphocyte percentage of white cells;
SARC	cis	rs910316	0.935	rs11159119	chr14:75636967	C/T	cg08847533	chr14:75593920	NEK9	-0.91	-14.16	-0.68	3e-33	Height;
SARC	cis	rs7084402	0.967	rs11006170	chr10:60276369	T/C	cg07615347	chr10:60278583	BICC1	-0.6	-8.82	-0.5	2.78e-16	Refractive error;
SARC	cis	rs9790314	1.000	rs464766	chr3:161087592	C/G	cg04691961	chr3:161091175	C3orf57	-0.82	-12.8	-0.64	9.45e-29	Morning vs. evening chronotype;
SARC	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg16339924	chr4:17578868	LAP3	0.68	9.02	0.51	7.12e-17	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs17376456	1.000	rs9968749	chr5:93509559	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.49	0.34	1.03e-7	Diabetic retinopathy;
SARC	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg11987759	chr7:65425863	GUSB	-0.6	-7.95	-0.46	7.8500000000000006e-14	Aortic root size;
SARC	cis	rs2415984	0.562	rs1389605	chr14:46964784	T/C	cg14871534	chr14:47121158	RPL10L	0.4	5.28	0.33	2.97e-7	Number of children ever born;
SARC	cis	rs2933343	0.621	rs4927921	chr3:128568868	A/G	cg24203234	chr3:128598194	ACAD9	-0.59	-7.23	-0.43	7.03e-12	IgG glycosylation;
SARC	cis	rs7833790	0.724	rs10958045	chr8:82722994	T/C	cg06027949	chr8:82754900	SNX16	-0.49	-6.21	-0.38	2.39e-9	Diastolic blood pressure;
SARC	cis	rs7089973	0.872	rs35622181	chr10:116631976	C/T	cg08188268	chr10:116634841	FAM160B1	0.35	5.66	0.35	4.34e-8	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs992157	0.835	rs7585702	chr2:219146607	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.69	-10.09	-0.55	4.32e-20	Colorectal cancer;
SARC	cis	rs763121	0.853	rs5750673	chr22:39110124	G/A	cg21395723	chr22:39101663	GTPBP1	0.54	6.04	0.37	5.94e-9	Menopause (age at onset);
SARC	cis	rs10949834	0.504	rs12539781	chr7:73568425	C/T	cg07137043	chr7:73588983	EIF4H	-0.47	-4.74	-0.3	3.71e-6	Verbal memory performance (residualized delayed recall change);
SARC	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg20102877	chr2:27665638	KRTCAP3	-0.39	-5.41	-0.33	1.54e-7	Total body bone mineral density;
SARC	trans	rs1814175	0.616	rs28417656	chr11:50040152	C/T	cg15704280	chr7:45808275	SEPT13	-0.91	-14.49	-0.69	2.43e-34	Height;
SARC	cis	rs7568458	0.660	rs6547623	chr2:85801964	T/A	cg02493740	chr2:85810744	VAMP5	-0.43	-5.82	-0.36	1.97e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg03647317	chr4:187891568	NA	-0.35	-4.95	-0.31	1.43e-6	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg00752806	chr2:220462673	STK11IP	-0.77	-6.29	-0.38	1.52e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs8180040	0.654	rs62246451	chr3:47211632	C/T	cg27129171	chr3:47204927	SETD2	-0.69	-9.43	-0.53	4.2e-18	Colorectal cancer;
SARC	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg23758822	chr17:41437982	NA	0.9	11.44	0.6	2.35e-24	Menopause (age at onset);
SARC	cis	rs12079745	0.793	rs79758658	chr1:169387286	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.81	-5.31	-0.33	2.62e-7	QT interval;
SARC	cis	rs2380220	0.606	rs4559095	chr6:95994154	A/C	cg23517279	chr6:96025343	MANEA	0.51	5.95	0.36	9.86e-9	Behavioural disinhibition (generation interaction);
SARC	trans	rs8073060	0.586	rs225256	chr17:33955756	C/T	cg19694781	chr19:47549865	TMEM160	-0.68	-6.84	-0.41	7.09e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs11098499	0.863	rs1552092	chr4:120488496	C/T	cg09307838	chr4:120376055	NA	0.91	12.25	0.63	5.66e-27	Corneal astigmatism;
SARC	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg12000995	chr2:27665139	KRTCAP3	-0.31	-4.75	-0.3	3.55e-6	Total body bone mineral density;
SARC	cis	rs1003719	0.591	rs1053966	chr21:38568009	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.57	-7.79	-0.45	2.22e-13	Eye color traits;
SARC	cis	rs8114671	0.836	rs6058154	chr20:33585834	C/T	cg24642439	chr20:33292090	TP53INP2	-0.52	-6.13	-0.37	3.64e-9	Height;
SARC	trans	rs3808502	0.549	rs4841564	chr8:11425809	T/G	cg06636001	chr8:8085503	FLJ10661	-0.64	-9.38	-0.52	5.94e-18	Neuroticism;
SARC	cis	rs672059	1.000	rs638781	chr1:183157358	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.51	6.93	0.41	4.1e-11	Hypertriglyceridemia;
SARC	cis	rs6840360	1.000	rs6833368	chr4:152603177	C/T	cg22705602	chr4:152727874	NA	0.38	6.62	0.4	2.38e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7208859	0.673	rs9894876	chr17:29182020	G/A	cg13385521	chr17:29058706	SUZ12P	0.86	7.34	0.43	3.54e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs7937682	0.889	rs3017767	chr11:111508098	A/G	cg22437258	chr11:111473054	SIK2	0.74	10.3	0.56	9.9e-21	Primary sclerosing cholangitis;
SARC	cis	rs710216	0.536	rs710222	chr1:43413653	A/G	cg03128534	chr1:43423976	SLC2A1	0.73	10.83	0.58	2.06e-22	Red cell distribution width;
SARC	cis	rs7824557	0.603	rs7016671	chr8:11182455	A/G	cg21775007	chr8:11205619	TDH	0.64	8.17	0.47	1.94e-14	Retinal vascular caliber;
SARC	cis	rs7712401	0.601	rs398142	chr5:122345576	C/T	cg19412675	chr5:122181750	SNX24	-0.43	-5.43	-0.34	1.41e-7	Mean platelet volume;
SARC	cis	rs9790314	0.580	rs10936227	chr3:161043869	A/C	cg04691961	chr3:161091175	C3orf57	-0.57	-7.49	-0.44	1.38e-12	Morning vs. evening chronotype;
SARC	cis	rs7149337	0.805	rs2999355	chr14:51607084	A/G	cg23942311	chr14:51606299	NA	0.3	5.48	0.34	1.1e-7	Cancer;
SARC	cis	rs9420	0.807	rs12807357	chr11:57656902	C/T	cg23127183	chr11:57508653	C11orf31	-0.6	-6.7	-0.4	1.57e-10	Schizophrenia;
SARC	cis	rs950776	0.518	rs12916483	chr15:78832397	G/A	cg22563815	chr15:78856949	CHRNA5	0.41	6.79	0.41	9.03e-11	Sudden cardiac arrest;
SARC	cis	rs11098499	0.863	rs1155576	chr4:120450159	A/C	cg24375607	chr4:120327624	NA	0.41	4.81	0.3	2.65e-6	Corneal astigmatism;
SARC	cis	rs9398803	0.835	rs9321065	chr6:126744087	G/A	cg20229609	chr6:126660872	C6orf173	0.41	5.89	0.36	1.36e-8	Male-pattern baldness;
SARC	trans	rs79976124	0.842	rs7760550	chr6:66628788	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	8.22	0.47	1.42e-14	Type 2 diabetes;
SARC	cis	rs9788682	0.747	rs3743078	chr15:78894759	C/G	cg06917634	chr15:78832804	PSMA4	0.46	5.33	0.33	2.31e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs10861342	1.000	rs73395802	chr12:105588718	T/C	cg23923672	chr12:105501055	KIAA1033	0.64	4.97	0.31	1.28e-6	IgG glycosylation;
SARC	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg11062466	chr8:58055876	NA	0.53	5.24	0.32	3.52e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs643506	1.000	rs612345	chr11:111639122	G/A	cg09085632	chr11:111637200	PPP2R1B	0.51	5.81	0.36	2.02e-8	Breast cancer;
SARC	cis	rs11651000	0.761	rs11079788	chr17:45820723	C/T	cg24803719	chr17:45855879	NA	-0.46	-6.98	-0.42	3.11e-11	IgG glycosylation;
SARC	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	5.42	0.33	1.46e-7	Bipolar disorder;
SARC	cis	rs1371867	0.875	rs1962901	chr8:101326428	A/G	cg11906718	chr8:101322791	RNF19A	0.66	8.62	0.49	1.01e-15	Atrioventricular conduction;
SARC	cis	rs2933343	0.700	rs789239	chr3:128633808	T/C	cg25356066	chr3:128598488	ACAD9	0.7	9.3	0.52	1.08e-17	IgG glycosylation;
SARC	cis	rs763121	0.886	rs1013339	chr22:38974680	C/T	cg21395723	chr22:39101663	GTPBP1	0.53	6.35	0.38	1.12e-9	Menopause (age at onset);
SARC	cis	rs3008870	0.727	rs2862729	chr1:67500828	T/C	cg02640540	chr1:67518911	SLC35D1	0.46	5.19	0.32	4.54e-7	Lymphocyte percentage of white cells;
SARC	cis	rs2228479	0.850	rs45567439	chr16:89814604	G/A	cg06558623	chr16:89946397	TCF25	0.88	6.22	0.38	2.27e-9	Skin colour saturation;
SARC	cis	rs1707322	1.000	rs10890355	chr1:46317348	G/A	cg03146154	chr1:46216737	IPP	0.47	5.65	0.35	4.76e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7000551	0.751	rs2469755	chr8:22360212	G/A	cg12081754	chr8:22256438	SLC39A14	0.54	7.7	0.45	3.95e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs9815354	0.812	rs77732985	chr3:41945872	G/A	cg03022575	chr3:42003672	ULK4	0.7	5.7	0.35	3.66e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs889312	0.500	rs33323	chr5:56175566	C/G	cg14703610	chr5:56206110	C5orf35	0.53	6.66	0.4	1.9e-10	Breast cancer;Breast cancer (early onset);
SARC	cis	rs2985684	0.748	rs2985686	chr14:50100683	C/G	cg04989706	chr14:50066350	PPIL5	-0.56	-5.88	-0.36	1.43e-8	Carotid intima media thickness;
SARC	cis	rs858239	0.738	rs13225593	chr7:23260307	A/G	cg23682824	chr7:23144976	KLHL7	0.6	7.63	0.45	5.99e-13	Cerebrospinal fluid biomarker levels;
SARC	cis	rs7659604	0.521	rs4833232	chr4:122684367	C/T	cg19671926	chr4:122722719	EXOSC9	0.58	7.45	0.44	1.82e-12	Type 2 diabetes;
SARC	cis	rs870825	0.616	rs2130394	chr4:185642577	C/A	cg04058563	chr4:185651563	MLF1IP	0.81	11.52	0.6	1.31e-24	Blood protein levels;
SARC	cis	rs5762813	0.515	rs5762822	chr22:29219601	A/G	cg02153584	chr22:29168773	CCDC117	0.65	6.65	0.4	2.02e-10	Hematocrit;Hemoglobin concentration;
SARC	cis	rs6991952	0.676	rs11135894	chr8:25691031	T/G	cg21775463	chr8:25538546	NA	0.28	4.85	0.3	2.3e-6	Inguinal hernia;
SARC	cis	rs622217	0.624	rs9364558	chr6:160929944	C/G	cg12345982	chr6:160389645	IGF2R	-0.32	-4.82	-0.3	2.53e-6	Type 2 diabetes;
SARC	cis	rs651907	0.557	rs11712748	chr3:101383562	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	6.21	0.38	2.36e-9	Colorectal cancer;
SARC	cis	rs7084402	0.967	rs7091440	chr10:60271372	T/A	cg07615347	chr10:60278583	BICC1	-0.58	-8.38	-0.48	5.08e-15	Refractive error;
SARC	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg11878867	chr6:150167359	LRP11	-0.34	-4.75	-0.3	3.56e-6	Lung cancer;
SARC	cis	rs4128725	0.925	rs12143656	chr1:159479148	A/G	cg25076881	chr1:159409836	OR10J1	0.46	5.49	0.34	1.04e-7	Select biomarker traits;
SARC	cis	rs3733585	0.578	rs6837224	chr4:9955255	G/T	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.95	-0.36	9.9e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg18404041	chr3:52824283	ITIH1	-0.43	-6.58	-0.4	3.15e-10	Bipolar disorder;
SARC	cis	rs4481887	1.000	rs7553333	chr1:248493956	C/G	cg00666640	chr1:248458726	OR2T12	0.4	6.64	0.4	2.15e-10	Common traits (Other);
SARC	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg11366901	chr6:160182831	ACAT2	1.05	11.02	0.59	5.16e-23	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg24829409	chr8:58192753	C8orf71	-0.58	-5.24	-0.32	3.55e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs11690462	0.963	rs7603413	chr2:26561117	C/A	cg26119090	chr2:26468346	HADHA;HADHB	0.39	4.97	0.31	1.31e-6	Coronary artery disease;
SARC	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.59e-6	Depression;
SARC	cis	rs10752881	0.809	rs3738829	chr1:183113862	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	9.86	0.54	2.11e-19	Colorectal cancer;
SARC	cis	rs7829975	0.511	rs2976906	chr8:8342415	A/T	cg06636001	chr8:8085503	FLJ10661	0.63	8.96	0.51	1.04e-16	Mood instability;
SARC	cis	rs17401966	0.838	rs4623	chr1:10366692	C/G	cg15208524	chr1:10270712	KIF1B	0.49	5.81	0.36	2.01e-8	Hepatocellular carcinoma;
SARC	cis	rs2559856	1.000	rs2695285	chr12:102089043	G/A	cg12924262	chr12:102091054	CHPT1	0.57	7.85	0.46	1.54e-13	Blood protein levels;
SARC	cis	rs3812111	0.510	rs17077755	chr6:116592033	C/T	cg18828861	chr6:116576566	TSPYL4	0.33	4.84	0.3	2.4e-6	Age-related macular degeneration;
SARC	cis	rs67460515	0.892	rs1478566	chr3:161030335	A/T	cg03342759	chr3:160939853	NMD3	-0.68	-8.7	-0.5	6.23e-16	Parkinson's disease;
SARC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg11301795	chr4:187892539	NA	-0.7	-10.38	-0.56	5.24e-21	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.63	7.72	0.45	3.51e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg16681246	chr2:65541310	SPRED2	0.47	6.83	0.41	7.18e-11	Thyroid stimulating hormone;
SARC	cis	rs710865	0.519	rs10753518	chr1:19483593	T/C	cg13387374	chr1:19411106	UBR4	0.54	7.52	0.44	1.15e-12	Brain structure;
SARC	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.23e-9	Life satisfaction;
SARC	cis	rs11690935	0.595	rs788166	chr2:172915489	G/C	cg13550731	chr2:172543902	DYNC1I2	0.67	9.44	0.53	4.02e-18	Schizophrenia;
SARC	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	5.97	0.36	8.74e-9	Bipolar disorder;
SARC	cis	rs7772486	0.754	rs702324	chr6:146008793	A/G	cg05347473	chr6:146136440	FBXO30	-0.51	-6.89	-0.41	5.05e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9787249	0.874	rs12094291	chr1:40226046	G/A	cg02773041	chr1:40204384	PPIE	0.49	6.01	0.37	7.08e-9	Blood protein levels;
SARC	trans	rs877282	0.898	rs11253356	chr10:768604	G/A	cg22713356	chr15:30763199	NA	0.91	9.01	0.51	7.47e-17	Uric acid levels;
SARC	cis	rs9393692	0.676	rs1543681	chr6:26187783	G/T	cg05868516	chr6:26286170	HIST1H4H	0.57	6.98	0.42	3.04e-11	Educational attainment;
SARC	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg11987759	chr7:65425863	GUSB	-0.46	-6.14	-0.37	3.49e-9	Aortic root size;
SARC	cis	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg24110177	chr3:50126178	RBM5	0.65	8.59	0.49	1.24e-15	Body mass index;
SARC	cis	rs1707322	1.000	rs3922887	chr1:46473802	A/G	cg06784218	chr1:46089804	CCDC17	0.34	5.94	0.36	1.03e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg00149659	chr3:10157352	C3orf10	0.68	6.38	0.39	9.46e-10	Alzheimer's disease;
SARC	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	9.01	0.51	7.42e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs11098499	0.739	rs10013032	chr4:120149419	C/T	cg09307838	chr4:120376055	NA	-0.77	-10.44	-0.56	3.42e-21	Corneal astigmatism;
SARC	cis	rs7762018	1.000	rs6912959	chr6:170126224	G/A	cg17545662	chr6:170176663	C6orf70	0.42	4.81	0.3	2.74e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs13191362	0.872	rs13213421	chr6:163203805	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.62	5.47	0.34	1.14e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg24209194	chr3:40518798	ZNF619	0.67	8.2	0.47	1.66e-14	Renal cell carcinoma;
SARC	cis	rs9420	0.961	rs1647405	chr11:57477889	C/T	cg23127183	chr11:57508653	C11orf31	-0.5	-5.83	-0.36	1.83e-8	Schizophrenia;
SARC	cis	rs910316	1.000	rs10136948	chr14:75511075	C/T	cg11812906	chr14:75593930	NEK9	0.88	13.32	0.66	1.74e-30	Height;
SARC	cis	rs10779751	0.734	rs910660	chr1:11130643	C/T	cg08854313	chr1:11322531	MTOR	-0.81	-11.21	-0.59	1.27e-23	Body mass index;
SARC	cis	rs2576037	0.899	rs2576035	chr18:44587654	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.54	7.05	0.42	2.07e-11	Personality dimensions;
SARC	cis	rs76419734	1.000	rs72673870	chr4:106779865	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	5.31	0.33	2.52e-7	Post bronchodilator FEV1;
SARC	cis	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg07636037	chr3:49044803	WDR6	0.49	5.67	0.35	4.24e-8	Resting heart rate;
SARC	cis	rs7712401	0.601	rs397731	chr5:122322959	A/G	cg19412675	chr5:122181750	SNX24	-0.43	-5.43	-0.34	1.41e-7	Mean platelet volume;
SARC	cis	rs2859741	1.000	rs2859741	chr1:37509352	C/T	cg09363841	chr1:37513479	NA	-0.27	-4.76	-0.3	3.41e-6	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
SARC	cis	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg00071950	chr4:10020882	SLC2A9	0.39	6.31	0.38	1.4e-9	Bone mineral density;
SARC	cis	rs854765	0.583	rs10048206	chr17:17866897	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	9.85	0.54	2.34e-19	Total body bone mineral density;
SARC	cis	rs477692	0.905	rs7905466	chr10:131438937	A/T	cg05714579	chr10:131428358	MGMT	-0.55	-7.38	-0.44	2.76e-12	Response to temozolomide;
SARC	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg18404041	chr3:52824283	ITIH1	-0.44	-6.69	-0.4	1.62e-10	Bipolar disorder;
SARC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg10295955	chr4:187884368	NA	-1.01	-18.02	-0.76	4.66e-46	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg12419862	chr22:24373484	LOC391322	-0.81	-11.42	-0.6	2.88e-24	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg24503407	chr1:205819492	PM20D1	-0.44	-5.6	-0.34	6.06e-8	Menarche (age at onset);
SARC	cis	rs397969	0.646	rs1638526	chr17:19848450	T/C	cg13482628	chr17:19912719	NA	0.43	4.88	0.3	1.96e-6	Platelet count;
SARC	cis	rs7223966	1.000	rs9747164	chr17:61864787	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.49	-4.85	-0.3	2.23e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1348850	0.914	rs6710575	chr2:178377311	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.72	9.13	0.51	3.49e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2228479	0.850	rs62054257	chr16:89900195	G/A	cg06558623	chr16:89946397	TCF25	0.93	6.63	0.4	2.29e-10	Skin colour saturation;
SARC	cis	rs3733585	0.579	rs4235356	chr4:10123106	G/C	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.65	-0.35	4.67e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs2070488	0.662	rs6599203	chr3:38487802	G/A	cg27533700	chr3:38537683	EXOG	-0.4	-5.07	-0.31	8.26e-7	Electrocardiographic conduction measures;
SARC	trans	rs17685	0.672	rs10952841	chr7:75778626	A/C	cg19862616	chr7:65841803	NCRNA00174	0.63	7.95	0.46	8.05e-14	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs3008870	1.000	rs1118393	chr1:67366668	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.9	10.79	0.58	2.74e-22	Lymphocyte percentage of white cells;
SARC	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg25036284	chr2:26402008	FAM59B	0.43	5.42	0.33	1.52e-7	Gut microbiome composition (summer);
SARC	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.31	5.04	0.31	9.23e-7	Schizophrenia;
SARC	cis	rs787274	1.000	rs787285	chr9:115536743	A/G	cg13803584	chr9:115635662	SNX30	-0.83	-5.06	-0.31	8.49e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs9359856	0.564	rs72913976	chr6:90390233	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.62	-4.88	-0.3	2.01e-6	Bipolar disorder;
SARC	cis	rs7940866	0.803	rs1865296	chr11:130882944	C/T	cg12179176	chr11:130786555	SNX19	-0.66	-9.06	-0.51	5.49e-17	Schizophrenia;
SARC	cis	rs838721	0.574	rs13014016	chr2:234257454	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.38	4.96	0.31	1.35e-6	Total body bone mineral density;
SARC	cis	rs7624766	0.555	rs1851378	chr3:160513520	G/T	cg22637730	chr3:160473554	PPM1L	-0.39	-5.07	-0.32	8.04e-7	Response to methotrexate in rheumatoid arthritis;
SARC	cis	rs73206853	0.841	rs73205085	chr12:110627912	C/G	cg10860002	chr12:110842031	ANAPC7	0.65	4.83	0.3	2.42e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs2916247	1.000	rs10441534	chr8:93056692	A/G	cg10183463	chr8:93005414	RUNX1T1	0.54	5.97	0.36	8.69e-9	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6088590	1.000	rs6120747	chr20:33449769	T/C	cg06115741	chr20:33292138	TP53INP2	0.57	6.98	0.42	3.05e-11	Coronary artery disease;
SARC	cis	rs1348850	0.598	rs1405717	chr2:178500101	G/T	cg22681709	chr2:178499509	PDE11A	-0.41	-5.58	-0.34	6.8e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg16325326	chr1:53192061	ZYG11B	-0.71	-9.62	-0.53	1.16e-18	Monocyte count;
SARC	cis	rs939574	1.000	rs79013471	chr2:220096122	C/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.64	5.11	0.32	6.85e-7	Platelet distribution width;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg08422181	chr19:4909468	UHRF1	-0.51	-6.43	-0.39	7.17e-10	Schizophrenia;
SARC	cis	rs4727027	0.704	rs12535154	chr7:148895304	G/A	cg23583168	chr7:148888333	NA	-0.83	-13.49	-0.66	4.93e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs6782228	0.628	rs7641584	chr3:128392630	G/C	cg08795948	chr3:128337044	NA	0.36	4.72	0.3	4.06e-6	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
SARC	cis	rs36051895	0.589	rs12682672	chr9:5187941	T/C	cg02405213	chr9:5042618	JAK2	-0.41	-4.73	-0.3	3.98e-6	Pediatric autoimmune diseases;
SARC	cis	rs3733585	0.638	rs17185835	chr4:9958180	T/G	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.82	-0.36	1.92e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7264396	0.561	rs6142470	chr20:34570579	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-5.76	-0.35	2.7e-8	Total cholesterol levels;
SARC	cis	rs7296418	0.961	rs949143	chr12:123595163	G/A	cg16085171	chr12:123569118	PITPNM2	-0.37	-4.83	-0.3	2.44e-6	Platelet count;
SARC	cis	rs11122272	0.735	rs2808585	chr1:231514218	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg11301795	chr4:187892539	NA	-0.77	-12.15	-0.62	1.26e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6693567	0.545	rs1566225	chr1:150415990	G/C	cg09579323	chr1:150459698	TARS2	0.44	5.58	0.34	6.5e-8	Migraine;
SARC	trans	rs7615952	0.515	rs7637246	chr3:125678706	A/G	cg07211511	chr3:129823064	LOC729375	-0.66	-6.73	-0.4	1.27e-10	Blood pressure (smoking interaction);
SARC	cis	rs2295359	0.892	rs4655687	chr1:67649946	C/T	cg11235152	chr1:67600687	NA	0.51	7.07	0.42	1.8e-11	Psoriasis;
SARC	cis	rs2732480	0.577	rs2634684	chr12:48730875	C/T	cg21466736	chr12:48725269	NA	0.32	5.04	0.31	9.47e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs9399137	0.507	rs4289677	chr6:135275485	A/G	cg22676075	chr6:135203613	NA	0.42	5.49	0.34	1.04e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs72945132	0.882	rs7937984	chr11:70144254	C/T	cg00319359	chr11:70116639	PPFIA1	0.67	6.08	0.37	4.85e-9	Coronary artery disease;
SARC	cis	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg13072238	chr3:49761600	GMPPB	0.45	5.77	0.35	2.54e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7647973	0.667	rs4241405	chr3:49642027	C/T	cg06212747	chr3:49208901	KLHDC8B	0.73	6.53	0.39	4.13e-10	Menarche (age at onset);
SARC	trans	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg06636001	chr8:8085503	FLJ10661	0.64	8.83	0.5	2.57e-16	Neuroticism;
SARC	cis	rs2120243	0.539	rs1869859	chr3:157107762	G/T	cg24825693	chr3:157122686	VEPH1	-0.47	-6.53	-0.39	4.08e-10	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg11764359	chr7:65958608	NA	-0.63	-7.54	-0.44	1.06e-12	Aortic root size;
SARC	cis	rs2153535	0.580	rs1319169	chr6:8464456	G/A	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg02364793	chr5:175964512	RNF44	-0.73	-6.31	-0.38	1.42e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs8014131	0.689	rs4904252	chr14:85985659	A/G	cg10406690	chr14:85995726	FLRT2	0.42	5.45	0.34	1.29e-7	Menarche (age at onset);
SARC	cis	rs9467711	0.651	rs2237228	chr6:26104630	C/T	cg21479132	chr6:26055353	NA	0.97	7.0	0.42	2.74e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs11864453	0.826	rs9941087	chr16:72118324	G/A	cg01557791	chr16:72042693	DHODH	-0.66	-9.07	-0.51	5.15e-17	Fibrinogen levels;
SARC	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg26335602	chr6:28129616	ZNF389	0.49	5.6	0.34	5.9e-8	Cardiac Troponin-T levels;
SARC	cis	rs5167	0.601	rs73047694	chr19:45497852	G/A	cg13119609	chr19:45449297	APOC2	0.39	5.55	0.34	7.65e-8	Blood protein levels;
SARC	cis	rs7633857	0.536	rs2889391	chr3:160696186	A/G	cg17135325	chr3:160939158	NMD3	0.39	4.74	0.3	3.75e-6	Educational attainment (years of education);
SARC	cis	rs763121	0.853	rs5757196	chr22:39039855	G/C	cg21395723	chr22:39101663	GTPBP1	0.58	6.67	0.4	1.85e-10	Menopause (age at onset);
SARC	cis	rs282587	0.569	rs282598	chr13:113384331	A/G	cg02820901	chr13:113351484	ATP11A	-0.49	-4.76	-0.3	3.35e-6	Glycated hemoglobin levels;
SARC	cis	rs3858526	0.959	rs11039723	chr11:5956002	G/C	cg02574844	chr11:5959923	NA	-0.39	-4.72	-0.3	4.05e-6	DNA methylation (variation);
SARC	cis	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg14541582	chr5:601475	NA	-0.38	-4.79	-0.3	2.96e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs4803468	1.000	rs4674	chr19:41930396	A/G	cg09537434	chr19:41945824	ATP5SL	-0.98	-17.28	-0.75	1.27e-43	Height;
SARC	cis	rs73086581	1.000	rs17214949	chr20:3940952	T/C	cg02187196	chr20:3869020	PANK2	0.67	6.4	0.39	8.3e-10	Response to antidepressants in depression;
SARC	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg21724239	chr8:58056113	NA	0.6	6.31	0.38	1.43e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs8067545	0.586	rs3850779	chr17:20171872	C/T	cg13482628	chr17:19912719	NA	-0.56	-7.43	-0.44	1.99e-12	Schizophrenia;
SARC	cis	rs2014572	0.967	rs8100154	chr19:57765432	A/G	cg24459738	chr19:57751996	ZNF805	-0.44	-5.06	-0.31	8.42e-7	Hyperactive-impulsive symptoms;
SARC	cis	rs7937682	0.924	rs495460	chr11:111504777	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.93	-15.22	-0.71	8.48e-37	Primary sclerosing cholangitis;
SARC	cis	rs8067545	0.693	rs8066150	chr17:19886948	G/A	cg13482628	chr17:19912719	NA	0.56	6.89	0.41	5.1e-11	Schizophrenia;
SARC	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg00149659	chr3:10157352	C3orf10	1.09	10.0	0.55	7.87e-20	Alzheimer's disease;
SARC	cis	rs7666738	0.830	rs1426665	chr4:99027764	C/T	cg05340658	chr4:99064831	C4orf37	0.64	8.6	0.49	1.18e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9811216	0.917	rs1317082	chr3:169497585	A/G	cg14222479	chr3:169487675	ARPM1	0.47	5.34	0.33	2.25e-7	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg14545253	chr6:56894280	NA	0.48	6.57	0.4	3.32e-10	Thyroid stimulating hormone;
SARC	cis	rs55794721	0.509	rs2982358	chr1:25745204	G/T	cg03650068	chr1:25596491	NA	0.33	5.03	0.31	9.92e-7	Plateletcrit;Mean corpuscular volume;
SARC	cis	rs7727544	0.661	rs273900	chr5:131694606	G/A	cg24060327	chr5:131705240	SLC22A5	-0.67	-8.46	-0.48	3.01e-15	Blood metabolite levels;
SARC	cis	rs2952156	0.959	rs2952151	chr17:37828496	T/C	cg07936489	chr17:37558343	FBXL20	-0.38	-4.74	-0.3	3.71e-6	Asthma;
SARC	cis	rs60871478	0.947	rs4074610	chr7:791755	G/A	cg19087971	chr7:751233	PRKAR1B	-0.42	-4.84	-0.3	2.41e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg22875332	chr1:76189707	ACADM	0.5	7.17	0.42	1.01e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.6	7.81	0.46	1.95e-13	Lymphocyte counts;
SARC	cis	rs10875746	0.951	rs58865997	chr12:48566873	G/A	cg27446233	chr12:48516484	PFKM	-0.41	-4.79	-0.3	2.97e-6	Longevity (90 years and older);
SARC	cis	rs4280164	0.945	rs2281472	chr14:24775846	C/T	cg16194253	chr14:24768981	DHRS1;C14orf21	0.59	5.79	0.35	2.26e-8	Parent of origin effect on language impairment (paternal);
SARC	cis	rs72781680	0.821	rs2339887	chr2:24198376	G/A	cg08917208	chr2:24149416	ATAD2B	0.58	6.03	0.37	6.48e-9	Lymphocyte counts;
SARC	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.89	11.41	0.6	2.92e-24	Multiple sclerosis;
SARC	cis	rs933688	0.877	rs1477349	chr5:90707773	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.01	12.94	0.65	3.09e-29	Smoking behavior;
SARC	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg22535103	chr8:58192502	C8orf71	-0.6	-6.33	-0.38	1.24e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg24675658	chr1:53192096	ZYG11B	0.74	11.28	0.59	7.93e-24	Monocyte count;
SARC	cis	rs505401	0.554	rs10408625	chr19:6076688	G/A	cg18109231	chr19:6110877	RFX2	0.81	5.61	0.35	5.65e-8	Mean platelet volume;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg00488691	chr2:25016078	CENPO;C2orf79	0.51	6.24	0.38	2.1e-9	Breast cancer;
SARC	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg19223190	chr17:80058835	NA	0.47	6.43	0.39	7.29e-10	Life satisfaction;
SARC	cis	rs2730245	1.000	rs2730241	chr7:158723014	T/C	cg00815399	chr7:158750607	NA	-0.36	-5.01	-0.31	1.08e-6	Height;
SARC	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg03352830	chr11:487213	PTDSS2	0.62	6.37	0.39	9.81e-10	Body mass index;
SARC	cis	rs6058796	1.000	rs35220493	chr20:31267831	G/A	cg13636640	chr20:31349939	DNMT3B	0.59	5.17	0.32	5.1e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs1707322	1.000	rs10890370	chr1:46389217	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.11	0.37	4.09e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs5753618	0.554	rs5753648	chr22:31879465	A/G	cg02404636	chr22:31891804	SFI1	0.54	5.63	0.35	5.05e-8	Colorectal cancer;
SARC	cis	rs8180040	0.593	rs10433549	chr3:47031433	C/T	cg27129171	chr3:47204927	SETD2	-0.7	-9.29	-0.52	1.16e-17	Colorectal cancer;
SARC	cis	rs2479724	0.636	rs2265139	chr6:41819407	C/G	cg17623882	chr6:41773611	USP49	-0.43	-5.01	-0.31	1.09e-6	Menarche (age at onset);
SARC	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg22535103	chr8:58192502	C8orf71	-0.83	-9.5	-0.53	2.68e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs2204008	0.837	rs12369089	chr12:38060263	G/A	cg13010199	chr12:38710504	ALG10B	0.78	10.66	0.57	7.37e-22	Bladder cancer;
SARC	cis	rs12579753	0.672	rs4509857	chr12:82268017	C/T	cg07988820	chr12:82153109	PPFIA2	-0.45	-5.47	-0.34	1.16e-7	Resting heart rate;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg21496518	chr3:15374154	SH3BP5	0.51	6.45	0.39	6.51e-10	Height;
SARC	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	12.23	0.63	6.97e-27	Chronic sinus infection;
SARC	trans	rs62103177	0.759	rs9956512	chr18:77607517	G/A	cg05926928	chr17:57297772	GDPD1	1.03	9.83	0.54	2.61e-19	Opioid sensitivity;
SARC	cis	rs6835098	0.923	rs7671278	chr4:174095769	A/G	cg08422745	chr4:174089978	GALNT7	-0.73	-9.4	-0.52	5.41e-18	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	12.47	0.63	1.11e-27	Personality dimensions;
SARC	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg24829409	chr8:58192753	C8orf71	-0.65	-6.15	-0.37	3.4e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg10435706	chr6:150039699	LATS1	0.37	4.83	0.3	2.42e-6	Lung cancer;
SARC	cis	rs1707322	1.000	rs6672115	chr1:46272879	T/C	cg06784218	chr1:46089804	CCDC17	0.35	6.08	0.37	4.88e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs10782582	0.609	rs1001160	chr1:76358591	A/C	cg10523679	chr1:76189770	ACADM	-0.4	-4.95	-0.31	1.42e-6	Daytime sleep phenotypes;
SARC	cis	rs7681440	0.583	rs2583958	chr4:90720365	T/C	cg06632027	chr4:90757378	SNCA	-0.47	-5.72	-0.35	3.23e-8	Dementia with Lewy bodies;
SARC	cis	rs17376456	0.825	rs6898842	chr5:93213221	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.69	6.11	0.37	4.06e-9	Diabetic retinopathy;
SARC	cis	rs9914988	0.832	rs11650788	chr17:27174523	T/A	cg20469991	chr17:27169893	C17orf63	-0.47	-4.72	-0.3	4.01e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	trans	rs3774749	0.565	rs2518795	chr3:50208819	C/T	cg21659725	chr3:3221576	CRBN	0.5	6.37	0.39	1.02e-9	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-7.83	-0.46	1.71e-13	Alzheimer's disease;
SARC	cis	rs1322639	0.574	rs9689193	chr6:169588074	A/G	cg04662567	chr6:169592167	NA	-0.5	-4.95	-0.31	1.4e-6	Pulse pressure;
SARC	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg16405210	chr4:1374714	KIAA1530	-0.48	-5.71	-0.35	3.38e-8	Obesity-related traits;
SARC	cis	rs4427176	0.505	rs62489420	chr8:9663177	T/G	cg21625330	chr8:9911636	MSRA	-0.67	-5.47	-0.34	1.16e-7	Mosquito bite size;
SARC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg21747090	chr2:27597821	SNX17	-0.55	-7.68	-0.45	4.44e-13	Total body bone mineral density;
SARC	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg10207240	chr12:122356781	WDR66	0.29	4.77	0.3	3.2e-6	Mean corpuscular volume;
SARC	cis	rs9790314	0.663	rs7630674	chr3:160813597	G/A	cg04691961	chr3:161091175	C3orf57	-0.58	-7.82	-0.46	1.85e-13	Morning vs. evening chronotype;
SARC	cis	rs6582630	0.500	rs35251810	chr12:38577666	T/C	cg13010199	chr12:38710504	ALG10B	-0.52	-6.48	-0.39	5.33e-10	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7666738	0.830	rs13102652	chr4:99006737	T/G	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs941408	0.515	rs12610096	chr19:2778129	C/T	cg00079169	chr19:2811669	THOP1	0.43	4.78	0.3	3.17e-6	Total cholesterol levels;
SARC	cis	rs2043112	0.964	rs10461997	chr5:38984149	C/T	cg04869206	chr5:39074266	RICTOR	0.51	6.2	0.38	2.58e-9	Obesity-related traits;
SARC	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg22800045	chr5:56110881	MAP3K1	0.42	5.08	0.32	7.85e-7	Coronary artery disease;
SARC	cis	rs11700980	0.636	rs11702742	chr21:30254022	T/C	cg24692254	chr21:30365293	RNF160	-0.65	-4.92	-0.31	1.61e-6	QRS complex (12-leadsum);
SARC	cis	rs6570726	0.791	rs1935612	chr6:145906090	T/A	cg23711669	chr6:146136114	FBXO30	0.79	12.75	0.64	1.35e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs35771425	0.626	rs11119744	chr1:211644575	C/T	cg10512769	chr1:211675356	NA	-0.34	-4.92	-0.31	1.66e-6	Educational attainment (years of education);
SARC	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg13628971	chr7:2884303	GNA12	0.57	6.49	0.39	5.11e-10	Height;
SARC	cis	rs67460515	0.892	rs13073147	chr3:161045237	T/C	cg04691961	chr3:161091175	C3orf57	-0.49	-6.15	-0.37	3.36e-9	Parkinson's disease;
SARC	cis	rs8141529	0.529	rs5762774	chr22:29149796	G/A	cg02153584	chr22:29168773	CCDC117	0.63	6.34	0.38	1.2e-9	Lymphocyte counts;
SARC	cis	rs9393692	0.846	rs7771202	chr6:26279907	A/G	cg05868516	chr6:26286170	HIST1H4H	0.57	7.66	0.45	5.08e-13	Educational attainment;
SARC	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	11.07	0.59	3.6e-23	Alzheimer's disease;
SARC	cis	rs6964587	0.626	rs2269810	chr7:91508837	T/C	cg17063962	chr7:91808500	NA	-0.79	-11.71	-0.61	3.39e-25	Breast cancer;
SARC	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg09699651	chr6:150184138	LRP11	0.4	4.83	0.3	2.44e-6	Lung cancer;
SARC	cis	rs826838	0.935	rs980571	chr12:39127532	C/G	cg13010199	chr12:38710504	ALG10B	-0.64	-8.99	-0.51	8.5e-17	Heart rate;
SARC	cis	rs9916302	0.706	rs12947506	chr17:37707592	A/G	cg07936489	chr17:37558343	FBXL20	-0.73	-8.44	-0.48	3.45e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs9486715	0.793	rs2499777	chr6:97013814	T/C	cg06623918	chr6:96969491	KIAA0776	-0.94	-14.49	-0.69	2.36e-34	Headache;
SARC	cis	rs959260	0.588	rs8079197	chr17:73316679	G/C	cg07104495	chr17:73266070	MIF4GD	-0.32	-4.92	-0.31	1.6e-6	Systemic lupus erythematosus;
SARC	cis	rs4423214	1.000	rs12808368	chr11:71170817	C/T	cg24826892	chr11:71159390	DHCR7	0.44	5.61	0.35	5.6e-8	Vitamin D levels;
SARC	cis	rs7633857	0.536	rs2889391	chr3:160696186	A/G	cg04691961	chr3:161091175	C3orf57	-0.49	-6.32	-0.38	1.35e-9	Educational attainment (years of education);
SARC	trans	rs1814175	0.817	rs12295885	chr11:50036762	T/G	cg03929089	chr4:120376271	NA	-0.9	-14.81	-0.7	2.1e-35	Height;
SARC	cis	rs1580019	0.844	rs1037322	chr7:32501857	C/T	cg07520158	chr7:32535189	LSM5;AVL9	0.43	5.01	0.31	1.08e-6	Cognitive ability;
SARC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.8	10.5	0.57	2.27e-21	Prudent dietary pattern;
SARC	cis	rs7624766	0.743	rs12637922	chr3:160537813	A/T	cg22637730	chr3:160473554	PPM1L	-0.43	-5.55	-0.34	7.82e-8	Response to methotrexate in rheumatoid arthritis;
SARC	cis	rs7647973	0.710	rs34890793	chr3:49619493	C/T	cg13072238	chr3:49761600	GMPPB	-0.66	-5.83	-0.36	1.81e-8	Menarche (age at onset);
SARC	cis	rs2731664	0.792	rs335452	chr5:176879671	C/T	cg23176889	chr5:176863531	GRK6	-0.56	-8.4	-0.48	4.42e-15	Intelligence (multi-trait analysis);
SARC	cis	rs6952809	0.532	rs10227362	chr7:2456799	A/G	cg05083358	chr7:2394359	EIF3B	-0.56	-5.38	-0.33	1.84e-7	Multiple sclerosis;
SARC	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg13866156	chr1:1669148	SLC35E2	0.63	8.25	0.48	1.15e-14	Body mass index;
SARC	cis	rs6459804	1.000	rs6459804	chr7:157510195	C/T	cg05731713	chr7:157510257	PTPRN2	0.3	5.92	0.36	1.14e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs2204008	0.744	rs11180504	chr12:38236313	C/T	cg13010199	chr12:38710504	ALG10B	0.81	11.19	0.59	1.48e-23	Bladder cancer;
SARC	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg13939156	chr17:80058883	NA	0.4	6.25	0.38	1.92e-9	Life satisfaction;
SARC	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg17971929	chr21:40555470	PSMG1	-0.86	-11.17	-0.59	1.72e-23	Cognitive function;
SARC	cis	rs9914988	0.887	rs11080072	chr17:27081160	G/T	cg20469991	chr17:27169893	C17orf63	-0.49	-5.07	-0.32	8.25e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs11190604	1.000	rs11190551	chr10:102204734	A/G	cg07080220	chr10:102295463	HIF1AN	0.77	9.5	0.53	2.71e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg06636001	chr8:8085503	FLJ10661	0.63	8.25	0.48	1.18e-14	Mood instability;
SARC	cis	rs2050392	0.767	rs2183175	chr10:30699336	A/G	cg25182066	chr10:30743637	MAP3K8	-0.45	-6.07	-0.37	5.04e-9	Inflammatory bowel disease;
SARC	cis	rs11122272	0.732	rs2808605	chr1:231540187	A/C	cg06096015	chr1:231504339	EGLN1	0.38	5.58	0.34	6.77e-8	Hemoglobin concentration;
SARC	cis	rs4689388	0.679	rs1046316	chr4:6304087	A/G	cg25554036	chr4:6271136	WFS1	0.41	5.99	0.37	7.92e-9	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg00933542	chr6:150070202	PCMT1	0.35	6.19	0.38	2.62e-9	Lung cancer;
SARC	cis	rs9790314	0.628	rs1599381	chr3:160867680	G/A	cg03342759	chr3:160939853	NMD3	-0.56	-7.09	-0.42	1.59e-11	Morning vs. evening chronotype;
SARC	cis	rs1538970	0.924	rs11211118	chr1:45930270	A/C	cg05343316	chr1:45956843	TESK2	0.77	8.64	0.49	9.03e-16	Platelet count;
SARC	trans	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg26309987	chr1:37940113	ZC3H12A	-0.68	-6.25	-0.38	1.98e-9	Cutaneous psoriasis;
SARC	cis	rs2479724	0.636	rs1192238	chr6:41803836	C/T	cg17623882	chr6:41773611	USP49	0.43	5.01	0.31	1.09e-6	Menarche (age at onset);
SARC	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg03452623	chr4:187889614	NA	-0.76	-11.77	-0.61	2.03e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3087591	0.919	rs2018624	chr17:29560777	T/G	cg24425628	chr17:29625626	OMG;NF1	-0.47	-5.65	-0.35	4.67e-8	Hip circumference;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg21483475	chr3:154042025	DHX36	-0.61	-6.99	-0.42	2.85e-11	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs3767633	0.800	rs2880055	chr1:161922365	C/T	cg09175582	chr1:161736000	ATF6	0.58	5.36	0.33	2.02e-7	IgG glycosylation;
SARC	cis	rs8008758	1.000	rs12432879	chr14:101688977	A/G	cg26224664	chr14:101693935	NA	0.4	6.71	0.4	1.5e-10	Body mass index (alcohol intake interaction);
SARC	cis	rs12893668	0.543	rs12147645	chr14:104100208	T/A	cg26031613	chr14:104095156	KLC1	-0.5	-5.52	-0.34	8.94e-8	Reticulocyte count;
SARC	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg13628971	chr7:2884303	GNA12	0.58	6.74	0.4	1.26e-10	Height;
SARC	cis	rs2985684	1.000	rs2985687	chr14:50100386	T/C	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.46	4.84	0.3	2.39e-6	Carotid intima media thickness;
SARC	cis	rs933688	0.532	rs997737	chr5:90567031	C/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.52	-5.72	-0.35	3.28e-8	Smoking behavior;
SARC	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg14664628	chr15:75095509	CSK	-0.41	-4.93	-0.31	1.54e-6	Breast cancer;
SARC	cis	rs2307121	0.512	rs2047066	chr5:64734172	T/C	cg11190754	chr5:64858552	CENPK;PPWD1	0.37	4.75	0.3	3.61e-6	Corneal structure;
SARC	cis	rs7103648	1.000	rs7103648	chr11:47461783	A/G	cg20307385	chr11:47447363	PSMC3	0.88	14.78	0.7	2.48e-35	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs2075371	0.932	rs1035328	chr7:133978419	T/C	cg20476274	chr7:133979776	SLC35B4	0.59	7.94	0.46	8.36e-14	Mean platelet volume;
SARC	cis	rs6570726	0.967	rs9403706	chr6:145795187	C/T	cg05347473	chr6:146136440	FBXO30	-0.45	-6.12	-0.37	3.99e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2180341	0.538	rs3756993	chr6:127651551	A/C	cg24812749	chr6:127587940	RNF146	0.59	7.28	0.43	5.17e-12	Breast cancer;
SARC	cis	rs8014204	0.762	rs7144654	chr14:75298637	A/G	cg06637938	chr14:75390232	RPS6KL1	0.55	7.9	0.46	1.11e-13	Caffeine consumption;
SARC	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.12	26.16	0.86	2.82e-71	Chronic sinus infection;
SARC	cis	rs3857536	0.874	rs979693	chr6:66896442	T/A	cg07460842	chr6:66804631	NA	-0.44	-5.21	-0.32	4.14e-7	Blood trace element (Cu levels);
SARC	cis	rs7264396	0.563	rs61191623	chr20:34219987	A/C	cg01084648	chr20:34329383	RBM39	0.64	5.14	0.32	5.91e-7	Total cholesterol levels;
SARC	cis	rs10992471	0.528	rs7031567	chr9:95241363	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.43	-4.84	-0.3	2.37e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs7020830	0.867	rs563132	chr9:37245476	A/T	cg14294708	chr9:37120828	ZCCHC7	1.12	20.42	0.8	7.93e-54	Schizophrenia;
SARC	cis	rs3818285	0.655	rs2475277	chr10:111639730	C/T	cg00817464	chr10:111662876	XPNPEP1	0.52	8.22	0.47	1.4e-14	Superior crus of antihelix expression;
SARC	cis	rs72634258	0.945	rs6577459	chr1:8100173	G/T	cg00042356	chr1:8021962	PARK7	0.91	8.4	0.48	4.38e-15	Inflammatory bowel disease;
SARC	cis	rs9486719	1.000	rs6923212	chr6:97061940	A/G	cg06623918	chr6:96969491	KIAA0776	-0.77	-8.35	-0.48	6.02e-15	Migraine;Coronary artery disease;
SARC	cis	rs920590	0.721	rs61180388	chr8:19670214	G/C	cg03894339	chr8:19674705	INTS10	0.58	6.81	0.41	8.22e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.61	-7.4	-0.44	2.42e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2153535	0.580	rs1115079	chr6:8449615	G/C	cg07606381	chr6:8435919	SLC35B3	0.77	11.07	0.59	3.77e-23	Motion sickness;
SARC	cis	rs9467773	1.000	rs9467782	chr6:26542773	G/A	cg12292205	chr6:26970375	C6orf41	0.45	5.42	0.33	1.45e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7937682	0.710	rs674230	chr11:111437887	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.87	-13.16	-0.65	5.86e-30	Primary sclerosing cholangitis;
SARC	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg16680214	chr1:154839983	KCNN3	-0.35	-5.47	-0.34	1.18e-7	Prostate cancer;
SARC	cis	rs477692	0.597	rs574831	chr10:131379190	C/T	cg14263093	chr10:131365266	MGMT	-0.33	-4.82	-0.3	2.64e-6	Response to temozolomide;
SARC	cis	rs9457247	0.967	rs1211447	chr6:167381979	C/T	cg07741184	chr6:167504864	NA	0.3	5.61	0.35	5.69e-8	Crohn's disease;
SARC	cis	rs9911578	0.935	rs302873	chr17:56769481	C/G	cg12560992	chr17:57184187	TRIM37	0.83	11.18	0.59	1.62e-23	Intelligence (multi-trait analysis);
SARC	cis	rs2832191	0.720	rs2832200	chr21:30499165	G/A	cg24692254	chr21:30365293	RNF160	-0.84	-11.9	-0.61	8.25e-26	Dental caries;
SARC	cis	rs1468333	0.619	rs191968	chr5:137461112	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.72	7.29	0.43	4.71e-12	Resting heart rate;
SARC	trans	rs61931739	0.635	rs7979207	chr12:33910566	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-7.14	-0.42	1.17e-11	Morning vs. evening chronotype;
SARC	cis	rs9611519	0.780	rs1535048	chr22:41684093	C/T	cg17376030	chr22:41985996	PMM1	0.56	7.13	0.42	1.26e-11	Neuroticism;
SARC	cis	rs950880	0.593	rs887971	chr2:103041167	T/C	cg03938978	chr2:103052716	IL18RAP	-0.34	-4.92	-0.31	1.64e-6	Serum protein levels (sST2);
SARC	cis	rs4690686	0.500	rs11723131	chr4:177268602	G/A	cg17059388	chr4:177262070	NA	0.37	4.86	0.3	2.13e-6	Essential tremor;
SARC	cis	rs3758785	0.510	rs486975	chr11:94069491	T/A	cg13023536	chr11:94226537	MRE11A;ANKRD49	-0.43	-5.51	-0.34	9.54e-8	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
SARC	cis	rs7043114	0.525	rs12353096	chr9:95031144	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.44	-5.3	-0.33	2.64e-7	Height;
SARC	cis	rs9467773	0.967	rs7753565	chr6:26560012	A/G	cg11502198	chr6:26597334	ABT1	0.5	6.11	0.37	4.16e-9	Intelligence (multi-trait analysis);
SARC	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg25072359	chr17:41440525	NA	0.51	6.21	0.38	2.35e-9	Menopause (age at onset);
SARC	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2645694	0.626	rs2645709	chr4:77824474	G/A	cg03477792	chr4:77819574	ANKRD56	0.49	7.57	0.44	8.9e-13	Emphysema distribution in smoking;
SARC	cis	rs72717009	0.825	rs12722986	chr1:161465420	A/G	cg23840854	chr1:161414152	NA	-0.54	-4.88	-0.3	1.97e-6	Rheumatoid arthritis;
SARC	cis	rs9322193	0.607	rs12209310	chr6:150226018	G/A	cg01145232	chr6:150245071	RAET1G	0.42	4.73	0.3	3.86e-6	Lung cancer;
SARC	cis	rs7633857	0.537	rs9813700	chr3:160683279	G/T	cg17135325	chr3:160939158	NMD3	0.41	4.83	0.3	2.45e-6	Educational attainment (years of education);
SARC	cis	rs6456156	0.792	rs4710178	chr6:167513532	G/A	cg07741184	chr6:167504864	NA	0.36	7.05	0.42	2.02e-11	Primary biliary cholangitis;
SARC	cis	rs8077889	0.703	rs72836567	chr17:41945776	G/A	cg26893861	chr17:41843967	DUSP3	0.73	6.93	0.41	4.2e-11	Triglycerides;
SARC	trans	rs1493916	0.777	rs1845385	chr18:31318336	T/C	cg27147174	chr7:100797783	AP1S1	-0.5	-6.25	-0.38	1.95e-9	Life satisfaction;
SARC	cis	rs832540	0.656	rs6862118	chr5:56106474	G/A	cg24549020	chr5:56110836	MAP3K1	0.43	5.09	0.32	7.48e-7	Coronary artery disease;
SARC	cis	rs73001065	0.591	rs57009615	chr19:19613622	A/G	cg03709012	chr19:19516395	GATAD2A	1.18	9.43	0.53	4.31e-18	LDL cholesterol;
SARC	cis	rs6991838	0.831	rs4394432	chr8:66473174	A/G	cg13398993	chr8:66546079	ARMC1	0.48	6.42	0.39	7.54e-10	Intelligence (multi-trait analysis);
SARC	cis	rs12142240	0.698	rs3991877	chr1:46853749	C/A	cg14993813	chr1:46806288	NSUN4	-0.52	-5.56	-0.34	7.46e-8	Menopause (age at onset);
SARC	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg16479474	chr6:28041457	NA	0.37	5.47	0.34	1.17e-7	Parkinson's disease;
SARC	cis	rs262150	0.672	rs2730230	chr7:158788529	A/G	cg19418458	chr7:158789849	NA	-0.38	-5.42	-0.33	1.47e-7	Facial morphology (factor 20);
SARC	cis	rs3087591	0.960	rs6505232	chr17:29611411	T/C	cg24425628	chr17:29625626	OMG;NF1	-0.56	-6.89	-0.41	5.17e-11	Hip circumference;
SARC	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.98	10.78	0.58	2.93e-22	Platelet count;
SARC	cis	rs6964587	0.967	rs28399886	chr7:91638451	A/G	cg17063962	chr7:91808500	NA	0.95	15.96	0.72	3.08e-39	Breast cancer;
SARC	trans	rs66573146	1.000	rs56350643	chr4:7017591	G/A	cg07817883	chr1:32538562	TMEM39B	1.54	8.97	0.51	9.8e-17	Granulocyte percentage of myeloid white cells;
SARC	cis	rs6963495	0.818	rs73192143	chr7:105202415	A/G	cg19920283	chr7:105172520	RINT1	0.67	5.72	0.35	3.33e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs2439831	0.867	rs2245715	chr15:43818052	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.81	7.89	0.46	1.17e-13	Lung cancer in ever smokers;
SARC	cis	rs12477438	1.000	rs12053372	chr2:99810055	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-7.15	-0.42	1.12e-11	Chronic sinus infection;
SARC	cis	rs9290065	0.519	rs7616249	chr3:160679422	T/C	cg17135325	chr3:160939158	NMD3	0.41	4.97	0.31	1.28e-6	Kawasaki disease;
SARC	cis	rs651907	0.557	rs13099674	chr3:101489629	G/A	cg12386194	chr3:101231763	SENP7	0.48	5.68	0.35	3.93e-8	Colorectal cancer;
SARC	cis	rs35306767	0.903	rs35567307	chr10:915804	G/C	cg26597838	chr10:835615	NA	0.84	8.42	0.48	3.86e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs1395	0.778	rs12465084	chr2:27414203	G/C	cg21747090	chr2:27597821	SNX17	-0.48	-5.77	-0.35	2.47e-8	Blood metabolite levels;
SARC	cis	rs2985684	0.948	rs6572592	chr14:50080871	G/A	cg04989706	chr14:50066350	PPIL5	-0.56	-6.02	-0.37	6.65e-9	Carotid intima media thickness;
SARC	cis	rs9362426	1.000	rs6930076	chr6:88088654	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.4	4.93	0.31	1.55e-6	Depressive episodes in bipolar disorder;
SARC	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.57	-6.84	-0.41	7.03e-11	Renal function-related traits (BUN);
SARC	cis	rs8064299	0.597	rs4789097	chr17:72781208	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.81	-11.23	-0.59	1.14e-23	Monocyte count;
SARC	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-8.56	-0.49	1.56e-15	Alzheimer's disease;
SARC	cis	rs9398803	0.763	rs576049	chr6:126730543	T/G	cg19875578	chr6:126661172	C6orf173	0.59	7.98	0.46	6.62e-14	Male-pattern baldness;
SARC	cis	rs12681288	0.676	rs6559208	chr8:1018833	A/G	cg15309053	chr8:964076	NA	0.4	6.58	0.4	3.12e-10	Schizophrenia;
SARC	cis	rs2832191	0.791	rs9983651	chr21:30491227	T/A	cg08807101	chr21:30365312	RNF160	-0.82	-11.26	-0.59	9.12e-24	Dental caries;
SARC	cis	rs6912958	0.781	rs2300906	chr6:88207155	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.26	-0.33	3.31e-7	Monocyte percentage of white cells;
SARC	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg26335602	chr6:28129616	ZNF389	0.53	6.02	0.37	6.68e-9	Depression;
SARC	cis	rs2425143	0.818	rs12481545	chr20:34407698	C/T	cg01084648	chr20:34329383	RBM39	0.7	4.74	0.3	3.76e-6	Blood protein levels;
SARC	cis	rs9291683	0.551	rs62295971	chr4:9978142	G/A	cg00071950	chr4:10020882	SLC2A9	0.4	6.37	0.39	9.82e-10	Bone mineral density;
SARC	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg27266027	chr21:40555129	PSMG1	0.5	5.43	0.33	1.43e-7	Cognitive function;
SARC	cis	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg12591125	chr7:1885375	MAD1L1	0.49	5.08	0.32	7.69e-7	Bipolar disorder;
SARC	cis	rs1865760	0.602	rs2157050	chr6:26020431	C/T	cg16482183	chr6:26056742	HIST1H1C	0.5	6.37	0.39	9.84e-10	Height;
SARC	cis	rs10513788	0.665	rs72622585	chr3:181992315	T/C	cg05977900	chr3:182512126	ATP11B	0.47	4.95	0.31	1.46e-6	Cognitive function;
SARC	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg18252515	chr7:66147081	NA	0.56	6.15	0.37	3.26e-9	Aortic root size;
SARC	cis	rs9815354	0.761	rs73083326	chr3:41927150	G/T	cg03022575	chr3:42003672	ULK4	0.69	5.65	0.35	4.69e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs7123876	0.587	rs61895588	chr11:72360986	A/G	cg03713592	chr11:72463424	ARAP1	0.57	5.11	0.32	6.58e-7	Body mass index;
SARC	cis	rs1707322	1.000	rs12133129	chr1:46373348	C/T	cg03146154	chr1:46216737	IPP	0.46	5.52	0.34	8.98e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1832871	0.655	rs4273715	chr6:158722847	T/C	cg07165851	chr6:158734300	TULP4	0.53	6.46	0.39	5.92e-10	Height;
SARC	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs4688759	0.719	rs73079018	chr3:49875327	T/C	cg01304814	chr3:48885189	PRKAR2A	0.63	5.03	0.31	9.95e-7	Blood protein levels;
SARC	cis	rs554111	0.613	rs10753510	chr1:21412248	G/A	cg04902671	chr1:21058625	SH2D5	0.43	5.31	0.33	2.57e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs6570726	0.935	rs388394	chr6:145852689	C/T	cg05347473	chr6:146136440	FBXO30	0.49	6.57	0.4	3.19e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10779751	1.000	rs12124983	chr1:11286178	C/T	cg08854313	chr1:11322531	MTOR	-0.89	-13.84	-0.67	3.29e-32	Body mass index;
SARC	cis	rs6456156	0.846	rs7749827	chr6:167515624	C/T	cg07741184	chr6:167504864	NA	-0.33	-6.13	-0.37	3.68e-9	Primary biliary cholangitis;
SARC	cis	rs11190604	0.767	rs7916904	chr10:102186778	C/G	cg07080220	chr10:102295463	HIF1AN	0.71	8.16	0.47	2.14e-14	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs9398803	0.687	rs4549631	chr6:126966308	A/G	cg20229609	chr6:126660872	C6orf173	0.38	5.47	0.34	1.17e-7	Male-pattern baldness;
SARC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.54	7.01	0.42	2.61e-11	Lymphocyte counts;
SARC	cis	rs4128725	0.925	rs4656237	chr1:159413824	T/C	cg25076881	chr1:159409836	OR10J1	0.4	4.81	0.3	2.67e-6	Select biomarker traits;
SARC	trans	rs61931739	0.517	rs12816252	chr12:34067693	G/A	cg13010199	chr12:38710504	ALG10B	0.77	10.36	0.56	6.42e-21	Morning vs. evening chronotype;
SARC	cis	rs9815354	1.000	rs1716688	chr3:41926546	G/A	cg03022575	chr3:42003672	ULK4	-0.56	-5.38	-0.33	1.79e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs666930	1.000	rs666930	chr1:120258970	A/G	cg19096424	chr1:120255104	PHGDH	0.54	7.46	0.44	1.7e-12	Breast cancer;
SARC	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg11764359	chr7:65958608	NA	0.83	11.09	0.59	3.09e-23	Aortic root size;
SARC	cis	rs12142240	0.698	rs72677592	chr1:46818288	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-5.39	-0.33	1.72e-7	Menopause (age at onset);
SARC	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg11062466	chr8:58055876	NA	0.6	5.71	0.35	3.44e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg21659725	chr3:3221576	CRBN	0.52	6.71	0.4	1.46e-10	Intelligence (multi-trait analysis);
SARC	cis	rs17376456	0.825	rs67328989	chr5:93243133	T/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	6.11	0.37	4.09e-9	Diabetic retinopathy;
SARC	trans	rs804280	0.543	rs13261205	chr8:11791216	A/G	cg06636001	chr8:8085503	FLJ10661	0.5	6.28	0.38	1.64e-9	Myopia (pathological);
SARC	trans	rs1635	0.655	rs59598126	chr6:28303600	A/C	cg08080395	chr15:65488966	CILP	0.66	6.47	0.39	5.71e-10	Schizophrenia;
SARC	cis	rs9392653	1.000	rs9392652	chr6:5071102	T/C	cg00563771	chr6:5110810	LYRM4	-0.49	-5.77	-0.35	2.49e-8	Venous thromboembolism (SNP x SNP interaction);
SARC	trans	rs11098499	0.863	rs10009626	chr4:120470005	T/C	cg25214090	chr10:38739885	LOC399744	0.57	7.25	0.43	6.27e-12	Corneal astigmatism;
SARC	trans	rs9650657	0.707	rs2005309	chr8:10652170	T/C	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.43	-0.39	7.11e-10	Neuroticism;
SARC	cis	rs3820928	0.904	rs60906902	chr2:227760034	C/T	cg05526886	chr2:227700861	RHBDD1	-0.5	-6.04	-0.37	6.08e-9	Pulmonary function;
SARC	cis	rs11785693	0.862	rs7009771	chr8:4990189	C/T	cg26367366	chr8:4980734	NA	0.68	6.11	0.37	4.07e-9	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs1023500	0.505	rs134887	chr22:42674239	A/G	cg04733989	chr22:42467013	NAGA	0.48	6.17	0.37	3.02e-9	Schizophrenia;
SARC	cis	rs2387326	1.000	rs12252465	chr10:129932395	G/A	cg16087940	chr10:129947807	NA	-0.49	-6.29	-0.38	1.59e-9	Select biomarker traits;
SARC	trans	rs3808502	0.526	rs11783065	chr8:11417257	A/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.5	-0.39	4.73e-10	Neuroticism;
SARC	cis	rs11719291	0.831	rs11715177	chr3:48763894	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.6	-5.32	-0.33	2.43e-7	Cognitive function;
SARC	cis	rs9393777	0.513	rs13215020	chr6:26656073	G/A	cg12826209	chr6:26865740	GUSBL1	0.66	5.87	0.36	1.47e-8	Intelligence (multi-trait analysis);
SARC	cis	rs6003958	1	rs6003958	chr22:24264089	T/G	cg25703541	chr22:24373054	LOC391322	0.78	9.02	0.51	7.06e-17	S-phenylmercapturic acid levels in smokers;
SARC	cis	rs7829975	0.511	rs2955578	chr8:8137083	T/C	cg08975724	chr8:8085496	FLJ10661	0.67	9.15	0.51	3.04e-17	Mood instability;
SARC	cis	rs11864453	0.826	rs2074627	chr16:72136769	C/T	cg01557791	chr16:72042693	DHODH	-0.65	-9.17	-0.51	2.6e-17	Fibrinogen levels;
SARC	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg05234568	chr11:5960015	NA	-0.43	-5.95	-0.36	9.97e-9	DNA methylation (variation);
SARC	cis	rs6570726	0.846	rs973856	chr6:145781916	C/T	cg05347473	chr6:146136440	FBXO30	-0.47	-6.46	-0.39	6e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg17178900	chr1:205818956	PM20D1	0.52	7.45	0.44	1.82e-12	Menarche (age at onset);
SARC	cis	rs2073300	0.609	rs6137919	chr20:23363163	T/C	cg12062639	chr20:23401060	NAPB	0.95	6.46	0.39	6.01e-10	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs1185460	0.904	rs1003081	chr11:118913993	A/G	cg23280166	chr11:118938394	VPS11	-0.54	-7.56	-0.44	9.02e-13	Coronary artery disease;
SARC	cis	rs10870270	1.000	rs10870292	chr10:133770782	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.48	-5.35	-0.33	2.13e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs9902453	0.967	rs9900911	chr17:28330280	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.52	-6.74	-0.4	1.25e-10	Coffee consumption (cups per day);
SARC	cis	rs12824058	0.831	rs7299065	chr12:130809661	A/T	cg23887609	chr12:130822674	PIWIL1	0.37	5.15	0.32	5.48e-7	Menopause (age at onset);
SARC	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg00149659	chr3:10157352	C3orf10	0.65	6.02	0.37	6.79e-9	Alzheimer's disease;
SARC	cis	rs10870270	0.913	rs4880326	chr10:133745547	C/A	cg08754478	chr10:133766260	PPP2R2D	-0.46	-5.44	-0.34	1.33e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs7568458	0.846	rs2028900	chr2:85767735	A/G	cg17127132	chr2:85788382	GGCX	-0.47	-6.33	-0.38	1.22e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg20891558	chr2:74357851	NA	0.64	8.96	0.51	1.04e-16	Gestational age at birth (maternal effect);
SARC	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg20120463	chr17:44301886	NA	-0.33	-4.98	-0.31	1.23e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg25703541	chr22:24373054	LOC391322	-0.77	-10.47	-0.57	2.88e-21	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs4319547	0.637	rs61244464	chr12:123090565	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.49	-6.26	-0.38	1.87e-9	Body mass index;
SARC	cis	rs910316	1.000	rs175512	chr14:75523382	T/C	cg23033748	chr14:75592666	NEK9	-0.36	-4.96	-0.31	1.39e-6	Height;
SARC	cis	rs17253792	0.822	rs17685053	chr14:56125771	T/A	cg01858014	chr14:56050164	KTN1	-0.7	-5.91	-0.36	1.2e-8	Putamen volume;
SARC	cis	rs6772849	0.896	rs61112519	chr3:128338176	T/A	cg01163369	chr3:128370232	RPN1	-0.34	-4.82	-0.3	2.56e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs6121246	0.567	rs6060263	chr20:30193110	T/C	cg21427119	chr20:30132790	HM13	-0.48	-5.29	-0.33	2.84e-7	Mean corpuscular hemoglobin;
SARC	cis	rs10875746	0.855	rs10875728	chr12:48426392	T/G	cg27446233	chr12:48516484	PFKM	-0.41	-4.93	-0.31	1.54e-6	Longevity (90 years and older);
SARC	cis	rs78320035	1.000	rs2294250	chr1:168165168	C/T	cg17113809	chr1:168148080	TIPRL	1.26	6.8	0.41	8.48e-11	Red cell distribution width;
SARC	cis	rs9840812	0.769	rs548288	chr3:135969755	C/T	cg15507776	chr3:136538369	TMEM22	-0.43	-4.88	-0.3	1.96e-6	Fibrinogen levels;
SARC	cis	rs449789	0.857	rs2501175	chr6:159714412	C/T	cg14500486	chr6:159655392	FNDC1	-0.44	-5.02	-0.31	1.01e-6	Pulse pressure;
SARC	cis	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg24110177	chr3:50126178	RBM5	0.38	4.87	0.3	2.11e-6	Intelligence (multi-trait analysis);
SARC	cis	rs644799	1.000	rs644799	chr11:95564259	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.9	13.86	0.67	2.83e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs950169	0.580	rs17598114	chr15:85171317	C/T	cg17507749	chr15:85114479	UBE2QP1	0.58	6.84	0.41	6.81e-11	Schizophrenia;
SARC	cis	rs7927771	0.542	rs7122217	chr11:47777920	G/C	cg20307385	chr11:47447363	PSMC3	-0.49	-6.63	-0.4	2.36e-10	Subjective well-being;
SARC	cis	rs7944584	0.551	rs12224672	chr11:47500400	C/T	cg10504702	chr11:47789108	FNBP4	0.66	8.08	0.47	3.53e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg19223190	chr17:80058835	NA	0.44	6.23	0.38	2.14e-9	Life satisfaction;
SARC	cis	rs2228479	0.681	rs10153055	chr16:89965842	C/T	cg00800038	chr16:89945340	TCF25	-0.63	-4.86	-0.3	2.15e-6	Skin colour saturation;
SARC	cis	rs7647973	1.000	rs1464569	chr3:49460350	A/G	cg06212747	chr3:49208901	KLHDC8B	0.57	6.19	0.38	2.71e-9	Menarche (age at onset);
SARC	cis	rs317689	0.684	rs315125	chr12:69758884	C/T	cg14784868	chr12:69753453	YEATS4	0.47	5.25	0.33	3.37e-7	Response to diuretic therapy;
SARC	cis	rs9467773	0.869	rs9295689	chr6:26455811	T/C	cg11502198	chr6:26597334	ABT1	0.48	5.62	0.35	5.54e-8	Intelligence (multi-trait analysis);
SARC	cis	rs477692	1.000	rs477692	chr10:131426022	T/C	cg05714579	chr10:131428358	MGMT	0.55	7.26	0.43	5.59e-12	Response to temozolomide;
SARC	cis	rs1062177	0.756	rs2964589	chr5:151118189	G/T	cg00977110	chr5:151150581	G3BP1	-0.54	-5.47	-0.34	1.18e-7	Preschool internalizing problems;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg03658009	chr20:20033184	C20orf26;CRNKL1	0.64	6.41	0.39	8.04e-10	Lung cancer in ever smokers;
SARC	cis	rs4132509	0.793	rs7538011	chr1:243703344	A/G	cg21452805	chr1:244014465	NA	0.59	5.69	0.35	3.86e-8	RR interval (heart rate);
SARC	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg24829409	chr8:58192753	C8orf71	-0.63	-5.96	-0.36	9.37e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1729951	0.575	rs361248	chr3:136709066	G/A	cg15507776	chr3:136538369	TMEM22	0.49	5.34	0.33	2.18e-7	Neuroticism;
SARC	cis	rs2594989	1.000	rs2594978	chr3:11383347	C/A	cg00170343	chr3:11313890	ATG7	0.54	5.23	0.32	3.85e-7	Circulating chemerin levels;
SARC	cis	rs1552244	0.554	rs6768339	chr3:10006079	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	0.42	5.1	0.32	6.94e-7	Alzheimer's disease;
SARC	cis	rs503734	0.502	rs348864	chr3:100910127	T/G	cg27318481	chr3:100970896	IMPG2	-0.51	-6.16	-0.37	3.23e-9	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.91	-13.85	-0.67	3.06e-32	Chronic sinus infection;
SARC	cis	rs9660992	0.762	rs1172129	chr1:205244972	T/A	cg00857998	chr1:205179979	DSTYK	0.47	5.74	0.35	2.96e-8	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg09699651	chr6:150184138	LRP11	0.4	4.94	0.31	1.49e-6	Lung cancer;
SARC	cis	rs504918	0.616	rs4289301	chr3:123982611	C/T	cg05766129	chr3:123988013	KALRN	0.32	5.29	0.33	2.78e-7	Schizophrenia;
SARC	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg06074448	chr4:187884817	NA	-0.41	-5.37	-0.33	1.87e-7	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs9395865	0.520	rs6903708	chr6:53332940	A/G	cg24837744	chr17:7620647	NA	-0.5	-6.39	-0.39	9.08e-10	Electroencephalographic traits in alcoholism;
SARC	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg09455208	chr3:40491958	NA	0.38	5.51	0.34	9.28e-8	Renal cell carcinoma;
SARC	cis	rs511515	1	rs511515	chr6:33541507	A/G	cg24505687	chr6:33548425	BAK1	0.36	4.9	0.31	1.81e-6	Eosinophil counts;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
SARC	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg24060327	chr5:131705240	SLC22A5	0.71	8.08	0.47	3.47e-14	Breast cancer;
SARC	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg06212747	chr3:49208901	KLHDC8B	0.59	7.95	0.46	8.13e-14	Menarche (age at onset);
SARC	cis	rs8077889	0.917	rs58283314	chr17:41905963	T/G	cg26893861	chr17:41843967	DUSP3	0.83	10.1	0.55	3.97e-20	Triglycerides;
SARC	cis	rs7044106	0.791	rs12554440	chr9:123485333	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	6.41	0.39	7.93e-10	Hip circumference adjusted for BMI;
SARC	cis	rs3093024	0.595	rs4412174	chr6:167476066	A/G	cg23791538	chr6:167370224	RNASET2	-0.53	-7.01	-0.42	2.51e-11	Rheumatoid arthritis;
SARC	cis	rs9296092	0.521	rs56332659	chr6:33537887	T/C	cg13560919	chr6:33536144	NA	-0.47	-5.23	-0.32	3.69e-7	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg17971929	chr21:40555470	PSMG1	0.96	13.39	0.66	1.04e-30	Cognitive function;
SARC	cis	rs2153535	0.580	rs2327064	chr6:8454052	C/T	cg21535247	chr6:8435926	SLC35B3	0.52	6.33	0.38	1.24e-9	Motion sickness;
SARC	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg24642844	chr7:1081250	C7orf50	-0.59	-6.05	-0.37	5.79e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg24675658	chr1:53192096	ZYG11B	-0.58	-7.96	-0.46	7.63e-14	Monocyte count;
SARC	cis	rs2228479	0.850	rs1108063	chr16:89893983	A/G	cg06558623	chr16:89946397	TCF25	0.93	6.62	0.4	2.48e-10	Skin colour saturation;
SARC	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs16866061	0.926	rs17479770	chr2:225335814	A/G	cg12698349	chr2:225449008	CUL3	0.68	9.49	0.53	2.83e-18	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	cis	rs8008758	1.000	rs12435364	chr14:101690209	G/A	cg26224664	chr14:101693935	NA	-0.38	-6.04	-0.37	5.99e-9	Body mass index (alcohol intake interaction);
SARC	cis	rs72945132	0.714	rs117232799	chr11:70157182	G/A	cg00319359	chr11:70116639	PPFIA1	0.68	6.01	0.37	7.17e-9	Coronary artery disease;
SARC	cis	rs10779751	0.770	rs12097293	chr1:11197467	A/G	cg08854313	chr1:11322531	MTOR	-0.82	-10.47	-0.57	2.76e-21	Body mass index;
SARC	cis	rs7223966	1.000	rs11542436	chr17:61778689	A/C	cg00588841	chr17:61851480	DDX42;CCDC47	-0.62	-6.89	-0.41	5.15e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs877282	0.898	rs71489279	chr10:760510	T/C	cg22713356	chr15:30763199	NA	0.96	9.76	0.54	4.28e-19	Uric acid levels;
SARC	cis	rs2832191	1.000	rs8131214	chr21:30483386	T/G	cg24692254	chr21:30365293	RNF160	-0.77	-10.73	-0.58	4.22e-22	Dental caries;
SARC	cis	rs9868809	0.505	rs11719291	chr3:48735706	A/G	cg07636037	chr3:49044803	WDR6	-0.74	-7.05	-0.42	1.98e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs2635047	0.638	rs12953864	chr18:44625245	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	6.39	0.39	9.16e-10	Educational attainment;
SARC	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg16606324	chr3:10149918	C3orf24	0.48	5.04	0.31	9.53e-7	Alzheimer's disease;
SARC	cis	rs4642101	0.611	rs6442331	chr3:12820636	T/G	cg12400702	chr3:12838781	CAND2	-0.26	-4.97	-0.31	1.28e-6	QRS complex (12-leadsum);
SARC	cis	rs9420	0.884	rs673344	chr11:57657141	G/A	cg19752551	chr11:57585705	CTNND1	0.5	6.57	0.4	3.22e-10	Schizophrenia;
SARC	cis	rs10493773	0.748	rs12758511	chr1:86165987	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.55	-8.54	-0.49	1.76e-15	Urate levels in overweight individuals;
SARC	cis	rs6860806	0.507	rs272854	chr5:131688017	C/T	cg04518342	chr5:131593106	PDLIM4	0.42	5.35	0.33	2.14e-7	Breast cancer;
SARC	cis	rs9910055	0.530	rs11656758	chr17:42301541	A/G	cg19774624	chr17:42201019	HDAC5	-0.49	-6.74	-0.4	1.25e-10	Total body bone mineral density;
SARC	trans	rs561341	0.943	rs508566	chr17:30289861	G/C	cg20587970	chr11:113659929	NA	-1.35	-13.24	-0.66	3.29e-30	Hip circumference adjusted for BMI;
SARC	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg05872129	chr22:39784769	NA	-0.43	-6.09	-0.37	4.62e-9	Intelligence (multi-trait analysis);
SARC	cis	rs737337	0.623	rs17699089	chr19:11343795	A/G	cg00586551	chr19:11347513	LOC55908;DOCK6	0.59	6.28	0.38	1.67e-9	HDL cholesterol;HDL cholesterol levels;
SARC	cis	rs10492096	0.947	rs11064231	chr12:6604415	T/G	cg13857086	chr12:6580257	VAMP1	0.69	6.85	0.41	6.6e-11	Hip geometry;
SARC	cis	rs763121	0.853	rs5750622	chr22:38956464	C/G	cg06022373	chr22:39101656	GTPBP1	0.88	11.33	0.6	5.33e-24	Menopause (age at onset);
SARC	cis	rs1920116	0.778	rs59800107	chr3:169556383	T/C	cg14222479	chr3:169487675	ARPM1	0.43	4.93	0.31	1.55e-6	Glioma (high-grade);
SARC	cis	rs9790314	0.628	rs1599381	chr3:160867680	G/A	cg04691961	chr3:161091175	C3orf57	-0.55	-7.34	-0.43	3.46e-12	Morning vs. evening chronotype;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg22938275	chr17:39968122	FKBP10;SC65	0.6	6.78	0.41	9.75e-11	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg23758822	chr17:41437982	NA	0.89	11.4	0.6	3.3e-24	Menopause (age at onset);
SARC	cis	rs6062302	0.534	rs1556456	chr20:62216289	T/C	cg09650180	chr20:62225654	GMEB2	-0.47	-5.62	-0.35	5.39e-8	Glioblastoma;
SARC	cis	rs2652822	0.571	rs62012880	chr15:63527162	A/G	cg02713581	chr15:63449717	RPS27L	0.49	5.42	0.33	1.51e-7	Metabolic traits;
SARC	cis	rs11122272	0.735	rs2486734	chr1:231531392	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.08	-0.55	4.68e-20	Hemoglobin concentration;
SARC	cis	rs9513627	0.915	rs9582298	chr13:100118707	T/C	cg25919922	chr13:100150906	NA	-0.75	-5.5	-0.34	1.01e-7	Obesity-related traits;
SARC	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg03517284	chr6:25882590	NA	-0.47	-6.17	-0.37	2.98e-9	Intelligence (multi-trait analysis);
SARC	cis	rs6500395	0.775	rs7198145	chr16:48666500	A/C	cg04672837	chr16:48644449	N4BP1	0.44	5.95	0.36	9.62e-9	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs7772486	0.719	rs7753770	chr6:146066161	G/A	cg23711669	chr6:146136114	FBXO30	-0.92	-16.54	-0.73	3.74e-41	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7027203	0.828	rs10821229	chr9:96595136	A/C	cg13679303	chr9:96623674	NA	-0.36	-5.25	-0.33	3.34e-7	DNA methylation (variation);
SARC	cis	rs365132	0.905	rs353463	chr5:176403170	A/C	cg16309518	chr5:176445507	NA	-0.48	-6.24	-0.38	2.06e-9	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs8114671	0.836	rs6060165	chr20:33619480	A/C	cg08999081	chr20:33150536	PIGU	-0.36	-5.17	-0.32	5.09e-7	Height;
SARC	cis	rs10916814	0.632	rs4655224	chr1:20902195	A/C	cg24502330	chr1:20914028	CDA	-0.29	-5.05	-0.31	8.71e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs7429990	0.932	rs34025851	chr3:47953733	C/A	cg11946769	chr3:48343235	NME6	0.46	5.26	0.33	3.26e-7	Educational attainment (years of education);
SARC	cis	rs13082711	0.522	rs574955	chr3:27351000	T/C	cg02860705	chr3:27208620	NA	0.42	5.54	0.34	8.26e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs6815814	0.950	rs73236617	chr4:38793860	C/G	cg02016764	chr4:38805732	TLR1	-0.41	-4.72	-0.3	4.06e-6	Breast cancer;
SARC	cis	rs36051895	0.632	rs10116823	chr9:5171944	T/A	cg02405213	chr9:5042618	JAK2	-0.43	-5.0	-0.31	1.12e-6	Pediatric autoimmune diseases;
SARC	cis	rs6679356	0.664	rs6672745	chr1:67788565	C/T	cg09018107	chr1:67798929	IL12RB2	0.5	5.23	0.32	3.7e-7	Primary biliary cholangitis;
SARC	cis	rs6964587	1.000	rs756647	chr7:91586389	A/G	cg17063962	chr7:91808500	NA	0.91	15.2	0.71	9.95e-37	Breast cancer;
SARC	cis	rs1050631	1.000	rs11081934	chr18:33705304	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.47	5.59	0.34	6.27e-8	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs17376456	0.778	rs72786662	chr5:93137630	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.7	6.42	0.39	7.41e-10	Diabetic retinopathy;
SARC	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg22433210	chr17:43662623	NA	1.03	12.67	0.64	2.48e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs12220238	0.915	rs11001020	chr10:76139217	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.61	6.06	0.37	5.57e-9	Soluble interleukin-2 receptor subunit alpha;
SARC	cis	rs4699052	1.000	rs7694190	chr4:104168017	A/G	cg16532752	chr4:104119610	CENPE	-0.44	-5.2	-0.32	4.32e-7	Testicular germ cell tumor;
SARC	cis	rs7772486	0.743	rs111332144	chr6:146056681	C/T	cg05220968	chr6:146057943	EPM2A	0.3	5.09	0.32	7.21e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4588572	0.643	rs10942857	chr5:77760241	A/G	cg11547950	chr5:77652471	NA	-0.41	-5.03	-0.31	9.75e-7	Triglycerides;
SARC	cis	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.41	5.11	0.32	6.78e-7	Eosinophil percentage of white cells;
SARC	cis	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg25427524	chr10:38739819	LOC399744	-0.56	-8.75	-0.5	4.28e-16	Extrinsic epigenetic age acceleration;
SARC	cis	rs9473924	0.542	rs2857501	chr6:50797286	A/G	cg14470998	chr6:50812995	TFAP2B	0.7	6.22	0.38	2.32e-9	Body mass index;
SARC	cis	rs992157	0.717	rs11692780	chr2:219149163	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.69	-10.03	-0.55	6.49e-20	Colorectal cancer;
SARC	cis	rs7772486	0.806	rs7740785	chr6:146171299	C/A	cg23711669	chr6:146136114	FBXO30	0.81	13.06	0.65	1.31e-29	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg20007245	chr22:24372913	LOC391322	-0.82	-11.68	-0.61	4.08e-25	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs34172651	0.917	rs11640931	chr16:24797919	A/G	cg00152838	chr16:24741724	TNRC6A	-0.42	-5.22	-0.32	3.97e-7	Intelligence (multi-trait analysis);
SARC	cis	rs616147	0.850	rs631312	chr3:39508968	A/G	cg17944282	chr3:39448217	RPSA	-0.5	-5.35	-0.33	2.06e-7	Amyotrophic lateral sclerosis;Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs2425143	1.000	rs4504072	chr20:34448773	G/C	cg01084648	chr20:34329383	RBM39	0.64	4.95	0.31	1.44e-6	Blood protein levels;
SARC	cis	rs13392177	0.684	rs6720449	chr2:219080978	G/A	cg00012203	chr2:219082015	ARPC2	-0.69	-9.47	-0.53	3.19e-18	Pyoderma gangrenosum in inflammatory bowel disease;
SARC	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg22920501	chr2:26401640	FAM59B	0.61	8.19	0.47	1.71e-14	Gut microbiome composition (summer);
SARC	cis	rs7647973	1.000	rs13088309	chr3:49368317	A/G	cg07636037	chr3:49044803	WDR6	0.72	8.2	0.47	1.66e-14	Menarche (age at onset);
SARC	cis	rs35146811	0.622	rs6946204	chr7:99589125	T/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.42	5.06	0.31	8.68e-7	Coronary artery disease;
SARC	cis	rs4481887	0.800	rs10888342	chr1:248441999	A/G	cg13385794	chr1:248469461	NA	0.31	4.75	0.3	3.53e-6	Common traits (Other);
SARC	cis	rs6495122	0.501	rs6495144	chr15:75343438	T/C	cg17294928	chr15:75287854	SCAMP5	-0.5	-6.49	-0.39	5.02e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	cis	rs2952156	0.920	rs12150298	chr17:37834541	T/C	cg07936489	chr17:37558343	FBXL20	-0.4	-5.28	-0.33	2.89e-7	Asthma;
SARC	cis	rs765787	0.530	rs1706834	chr15:45517854	G/A	cg24006582	chr15:45444508	DUOX1	-0.55	-7.36	-0.43	3.14e-12	Uric acid levels;
SARC	cis	rs748404	0.560	rs572837	chr15:43823813	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.48	5.22	0.32	3.87e-7	Lung cancer;
SARC	cis	rs172166	0.652	rs476167	chr6:28065888	T/C	cg26335602	chr6:28129616	ZNF389	0.47	5.43	0.34	1.42e-7	Cardiac Troponin-T levels;
SARC	cis	rs6424115	0.830	rs6680132	chr1:24198804	T/C	cg15997130	chr1:24165203	NA	0.41	5.48	0.34	1.09e-7	Immature fraction of reticulocytes;
SARC	cis	rs7772486	0.686	rs6933161	chr6:146081369	G/A	cg05347473	chr6:146136440	FBXO30	-0.51	-7.14	-0.42	1.15e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg02353165	chr6:42928485	GNMT	0.59	8.27	0.48	1.05e-14	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg05896524	chr21:47604654	C21orf56	0.42	4.95	0.31	1.4e-6	Testicular germ cell tumor;
SARC	cis	rs4705952	0.557	rs4588593	chr5:131845333	C/T	cg07395648	chr5:131743802	NA	-0.43	-4.74	-0.3	3.69e-6	C-reactive protein levels;
SARC	cis	rs7084402	0.935	rs1649068	chr10:60304864	A/C	cg07615347	chr10:60278583	BICC1	0.58	8.32	0.48	7.45e-15	Refractive error;
SARC	cis	rs4481887	0.927	rs4244185	chr1:248486913	A/G	cg01631408	chr1:248437212	OR2T33	-0.4	-5.01	-0.31	1.1e-6	Common traits (Other);
SARC	cis	rs79149102	0.579	rs7174129	chr15:75305040	A/G	cg00629941	chr15:75287862	SCAMP5	-0.66	-5.39	-0.33	1.7e-7	Lung cancer;
SARC	cis	rs2463822	0.920	rs72923207	chr11:62117959	A/G	cg06239285	chr11:62104954	ASRGL1	-0.85	-8.1	-0.47	3.09e-14	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs7447927	0.950	rs13153461	chr5:138852369	G/A	cg11459648	chr5:138714337	SLC23A1	0.44	5.92	0.36	1.12e-8	Esophageal squamous cell carcinoma;
SARC	cis	rs9911578	0.934	rs58092632	chr17:57111101	T/C	cg05425664	chr17:57184151	TRIM37	0.64	8.01	0.46	5.41e-14	Intelligence (multi-trait analysis);
SARC	cis	rs703842	1.000	rs11172349	chr12:58212528	G/A	cg00677455	chr12:58241039	CTDSP2	0.51	6.58	0.4	3.06e-10	Multiple sclerosis;
SARC	cis	rs9911578	1.000	rs11869828	chr17:56609525	G/A	cg12560992	chr17:57184187	TRIM37	-0.8	-10.77	-0.58	3.19e-22	Intelligence (multi-trait analysis);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg05174924	chr6:90062691	UBE2J1	-0.75	-6.26	-0.38	1.87e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7582720	1.000	rs72932780	chr2:203695826	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	7.4	0.44	2.48e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg04087434	chr1:1669123	SLC35E2	-0.37	-4.81	-0.3	2.67e-6	Body mass index;
SARC	cis	rs9896052	0.535	rs35615150	chr17:73433560	G/A	cg04121983	chr17:73511085	CASKIN2	0.42	5.02	0.31	1.03e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs473651	0.904	rs501333	chr2:239336045	G/A	cg00800569	chr2:239229395	TRAF3IP1	0.4	4.81	0.3	2.74e-6	Multiple system atrophy;
SARC	cis	rs13082711	0.522	rs594466	chr3:27362069	A/G	cg02860705	chr3:27208620	NA	-0.41	-5.53	-0.34	8.6e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs10876993	0.890	rs1689597	chr12:58051886	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.49	-6.12	-0.37	3.87e-9	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs7666738	0.822	rs979946	chr4:98921235	C/A	cg05340658	chr4:99064831	C4orf37	0.68	9.09	0.51	4.43e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg03433033	chr1:76189801	ACADM	-0.52	-7.37	-0.43	2.97e-12	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs11077998	0.935	rs11653926	chr17:80484953	G/A	cg10255544	chr17:80519551	FOXK2	0.44	6.37	0.39	9.92e-10	Reticulocyte fraction of red cells;
SARC	cis	rs2075671	0.855	rs11974395	chr7:100282538	G/A	cg20848291	chr7:100343083	ZAN	-0.66	-7.36	-0.43	3.2e-12	Other erythrocyte phenotypes;
SARC	cis	rs2439831	0.850	rs8023458	chr15:44080939	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.95	8.43	0.48	3.73e-15	Lung cancer in ever smokers;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg13994897	chr10:134162016	LRRC27	0.47	6.55	0.39	3.65e-10	Thyroid stimulating hormone;
SARC	cis	rs6430585	1.000	rs73958618	chr2:136500475	A/G	cg07169764	chr2:136633963	MCM6	0.79	10.63	0.57	8.94e-22	Corneal structure;
SARC	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.03	12.03	0.62	3.06e-26	Alzheimer's disease;
SARC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg06873352	chr17:61820015	STRADA	0.53	6.75	0.4	1.17e-10	Prudent dietary pattern;
SARC	cis	rs477692	0.967	rs496692	chr10:131429100	C/T	cg05714579	chr10:131428358	MGMT	0.57	7.39	0.44	2.61e-12	Response to temozolomide;
SARC	cis	rs9399137	0.507	rs4594969	chr6:135285586	A/T	cg22676075	chr6:135203613	NA	0.4	5.14	0.32	5.94e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs8078723	0.933	rs55846942	chr17:38164470	G/A	cg17467752	chr17:38218738	THRA	0.47	5.94	0.36	1.01e-8	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs2288912	0.807	rs10423208	chr19:45453656	G/A	cg20090143	chr19:45452003	APOC2	0.3	4.89	0.31	1.87e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg23982607	chr1:1823379	GNB1	-0.64	-10.63	-0.57	9.15e-22	Body mass index;
SARC	cis	rs7589342	0.536	rs10167046	chr2:106386764	A/G	cg16077055	chr2:106428750	NCK2	0.3	6.16	0.37	3.19e-9	Addiction;
SARC	cis	rs11122272	0.735	rs2739510	chr1:231526718	T/C	cg06096015	chr1:231504339	EGLN1	0.4	5.99	0.37	7.74e-9	Hemoglobin concentration;
SARC	cis	rs2730245	0.527	rs2709858	chr7:158675266	C/G	cg24397884	chr7:158709396	WDR60	1.17	10.57	0.57	1.39e-21	Height;
SARC	cis	rs2120243	0.533	rs1392798	chr3:157056287	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	-0.42	-5.47	-0.34	1.18e-7	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs1865760	0.566	rs2794720	chr6:26087202	G/C	cg10373733	chr6:25993375	NA	0.45	5.43	0.34	1.4e-7	Height;
SARC	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.45	5.1	0.32	7.1e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs13191362	0.507	rs2023036	chr6:163122736	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.49	5.33	0.33	2.29e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs7843479	0.601	rs4872209	chr8:21848832	A/T	cg17168535	chr8:21777572	XPO7	0.84	12.75	0.64	1.35e-28	Mean corpuscular volume;
SARC	cis	rs6540556	0.608	rs3817821	chr1:209918503	A/T	cg05527609	chr1:210001259	C1orf107	-0.49	-5.04	-0.31	9.19e-7	Red blood cell count;
SARC	cis	rs13427251	0.868	rs1901284	chr2:100146040	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.46	5.65	0.35	4.58e-8	Chronic sinus infection;
SARC	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg11301795	chr4:187892539	NA	-0.71	-10.58	-0.57	1.29e-21	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg18252515	chr7:66147081	NA	0.54	5.88	0.36	1.4e-8	Aortic root size;
SARC	cis	rs3126085	1.000	rs72696963	chr1:152181189	T/C	cg03465714	chr1:152285911	FLG	0.44	4.81	0.3	2.73e-6	Atopic dermatitis;
SARC	cis	rs3087591	0.887	rs12150521	chr17:29595108	C/T	cg24425628	chr17:29625626	OMG;NF1	0.56	6.95	0.41	3.66e-11	Hip circumference;
SARC	cis	rs4689388	0.581	rs1801212	chr4:6302519	C/T	cg25554036	chr4:6271136	WFS1	0.38	5.23	0.32	3.75e-7	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg14343924	chr8:8086146	FLJ10661	0.44	5.45	0.34	1.3e-7	Mood instability;
SARC	cis	rs9916302	0.706	rs9899069	chr17:37540772	A/G	cg20243544	chr17:37824526	PNMT	-0.55	-5.81	-0.36	2.08e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-6.23	-0.38	2.15e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7089973	0.624	rs10885614	chr10:116609098	C/T	cg03647239	chr10:116582469	FAM160B1	0.5	6.49	0.39	5.19e-10	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs1270639	0.778	rs2530404	chr7:157445995	C/T	cg13357408	chr7:157437802	PTPRN2	-0.44	-4.85	-0.3	2.3e-6	Colorectal cancer;
SARC	cis	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg14019146	chr3:50243930	SLC38A3	-0.31	-4.9	-0.31	1.77e-6	Body mass index;
SARC	cis	rs10504073	0.584	rs56074306	chr8:49940282	C/T	cg00325661	chr8:49890786	NA	0.51	6.81	0.41	8.3e-11	Blood metabolite ratios;
SARC	cis	rs6580649	0.831	rs4760620	chr12:48559642	A/G	cg24011408	chr12:48396354	COL2A1	0.45	5.16	0.32	5.35e-7	Lung cancer;
SARC	cis	rs7959452	0.901	rs1384	chr12:69747834	C/T	cg22834771	chr12:69754056	YEATS4	-0.43	-5.75	-0.35	2.77e-8	Blood protein levels;
SARC	cis	rs10771431	0.597	rs3759274	chr12:9353875	T/C	cg08997352	chr12:9597637	DDX12	-0.55	-7.51	-0.44	1.29e-12	Breast size;
SARC	cis	rs4820294	1.000	rs41280035	chr22:38054038	A/G	cg21798802	chr22:38057573	PDXP	0.34	5.06	0.31	8.5e-7	Fat distribution (HIV);
SARC	cis	rs10078	0.571	rs2561664	chr5:459793	T/C	cg07599136	chr5:415885	AHRR	0.67	5.93	0.36	1.08e-8	Fat distribution (HIV);
SARC	cis	rs3126085	0.800	rs55650366	chr1:152279920	A/G	cg26876637	chr1:152193138	HRNR	-0.5	-5.61	-0.34	5.74e-8	Atopic dermatitis;
SARC	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg11764359	chr7:65958608	NA	0.59	7.05	0.42	2.03e-11	Calcium levels;
SARC	cis	rs17030434	1.000	rs6853522	chr4:154706220	A/C	cg14289246	chr4:154710475	SFRP2	0.84	8.5	0.49	2.32e-15	Electrocardiographic conduction measures;
SARC	cis	rs796364	1.000	rs11694369	chr2:200741720	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.7	-5.85	-0.36	1.69e-8	Schizophrenia;
SARC	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg20818283	chr2:191399100	TMEM194B	-0.5	-6.24	-0.38	2.02e-9	Pulse pressure;
SARC	cis	rs607987	0.841	rs11031014	chr11:30281066	T/C	cg06241208	chr11:30344200	C11orf46	0.42	5.06	0.31	8.31e-7	Body mass index;
SARC	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg25894440	chr7:65020034	NA	0.79	5.95	0.36	9.65e-9	Diabetic kidney disease;
SARC	cis	rs7786877	0.723	rs73407376	chr7:100215200	C/T	cg16850897	chr7:100343110	ZAN	-0.57	-5.42	-0.33	1.51e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs7666738	0.830	rs6854919	chr4:98947326	C/T	cg05340658	chr4:99064831	C4orf37	0.69	9.36	0.52	6.88e-18	Colonoscopy-negative controls vs population controls;
SARC	cis	rs950776	0.518	rs56007453	chr15:78826239	T/C	cg17108064	chr15:78857060	CHRNA5	0.29	4.93	0.31	1.56e-6	Sudden cardiac arrest;
SARC	cis	rs6977660	0.607	rs10243965	chr7:19797893	G/A	cg07541023	chr7:19748670	TWISTNB	0.71	6.52	0.39	4.28e-10	Thyroid stimulating hormone;
SARC	cis	rs7666738	0.830	rs28810677	chr4:99043193	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs992157	0.804	rs7559525	chr2:219150307	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.69	-10.04	-0.55	6.05e-20	Colorectal cancer;
SARC	trans	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg07211511	chr3:129823064	LOC729375	-0.63	-6.72	-0.4	1.35e-10	Blood pressure (smoking interaction);
SARC	cis	rs4481887	0.830	rs10888341	chr1:248441995	T/C	cg01631408	chr1:248437212	OR2T33	-0.43	-5.39	-0.33	1.68e-7	Common traits (Other);
SARC	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.27	-4.87	-0.3	2.02e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs11645898	0.935	rs3812985	chr16:72187957	A/T	cg14768367	chr16:72042858	DHODH	-0.56	-5.52	-0.34	9.15e-8	Blood protein levels;
SARC	cis	rs920915	0.597	rs11071380	chr15:58710627	A/C	cg00344888	chr15:58699976	NA	0.4	5.34	0.33	2.25e-7	Age-related macular degeneration;
SARC	cis	rs1699337	0.770	rs709156	chr3:12461615	G/A	cg04748988	chr3:12329223	PPARG	-0.41	-5.21	-0.32	4.19e-7	Cholesterol, total;
SARC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg27588902	chr6:42928151	GNMT	-0.38	-5.8	-0.35	2.2e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs12711979	0.509	rs1031478	chr2:3827425	G/A	cg17052675	chr2:3827356	NA	-0.56	-8.35	-0.48	6.02e-15	Itch intensity from mosquito bite adjusted by bite size;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg25377468	chr2:27200226	MAPRE3	0.45	6.26	0.38	1.86e-9	Thyroid stimulating hormone;
SARC	cis	rs6831352	0.877	rs29001183	chr4:100056539	C/T	cg13256891	chr4:100009986	ADH5	-0.64	-8.0	-0.46	5.7e-14	Alcohol dependence;
SARC	cis	rs4589502	0.502	rs2169460	chr15:67197240	A/G	cg12317470	chr15:67143691	NA	-0.55	-6.11	-0.37	4.19e-9	Lung cancer (smoking interaction);
SARC	cis	rs34172651	0.917	rs12599643	chr16:24832693	C/T	cg00339695	chr16:24857497	SLC5A11	0.29	4.72	0.3	4.11e-6	Intelligence (multi-trait analysis);
SARC	cis	rs8067354	0.681	rs9907923	chr17:57824927	C/T	cg02344993	chr17:57696989	CLTC	0.65	6.69	0.4	1.61e-10	Hemoglobin concentration;
SARC	cis	rs734999	0.566	rs6664969	chr1:2534978	G/A	cg20673091	chr1:2541236	MMEL1	0.34	5.16	0.32	5.31e-7	Ulcerative colitis;
SARC	cis	rs5769765	0.955	rs5769761	chr22:50263641	G/T	cg03033257	chr22:50311977	ALG12;CRELD2	-0.54	-5.64	-0.35	4.81e-8	Schizophrenia;
SARC	trans	rs8020941	0.585	rs76985498	chr14:97499493	A/G	cg05136476	chr3:53190709	NA	-0.63	-6.39	-0.39	8.99e-10	Diabetic kidney disease;
SARC	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg04944784	chr2:26401820	FAM59B	-0.5	-6.38	-0.39	9.57e-10	Gut microbiome composition (summer);
SARC	cis	rs6696846	0.703	rs112653854	chr1:205079251	G/T	cg00857998	chr1:205179979	DSTYK	0.49	6.24	0.38	2.05e-9	Red blood cell count;
SARC	cis	rs6912958	0.559	rs183599	chr6:88061024	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.77	12.1	0.62	1.8e-26	Monocyte percentage of white cells;
SARC	cis	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg25894440	chr7:65020034	NA	0.64	4.96	0.31	1.35e-6	Diabetic kidney disease;
SARC	cis	rs11786130	1.000	rs10956401	chr8:129002419	G/A	cg17583432	chr8:129005567	PVT1	-0.38	-6.65	-0.4	2.11e-10	Eosinophil counts;Sum eosinophil basophil counts;
SARC	cis	rs13392177	0.684	rs11695527	chr2:219068103	A/G	cg00012203	chr2:219082015	ARPC2	0.68	9.34	0.52	8.31e-18	Pyoderma gangrenosum in inflammatory bowel disease;
SARC	cis	rs4268898	1.000	rs10195436	chr2:24436112	C/T	cg06627628	chr2:24431161	ITSN2	0.6	8.34	0.48	6.69e-15	Asthma;
SARC	cis	rs2180341	0.781	rs6913350	chr6:127570560	C/T	cg24812749	chr6:127587940	RNF146	0.85	11.28	0.59	7.97e-24	Breast cancer;
SARC	cis	rs1003719	0.582	rs2835634	chr21:38528270	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.27	-0.52	1.31e-17	Eye color traits;
SARC	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.67	6.46	0.39	6.09e-10	Platelet count;
SARC	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.52	6.19	0.38	2.72e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs11690935	0.550	rs62183769	chr2:172838074	A/C	cg13550731	chr2:172543902	DYNC1I2	0.55	7.26	0.43	5.91e-12	Schizophrenia;
SARC	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg00149659	chr3:10157352	C3orf10	1.09	10.0	0.55	7.87e-20	Alzheimer's disease;
SARC	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg22800045	chr5:56110881	MAP3K1	-0.65	-6.08	-0.37	4.95e-9	Initial pursuit acceleration;
SARC	cis	rs9948	0.655	rs17119564	chr2:97384728	G/A	cg01990225	chr2:97406019	LMAN2L	-0.99	-7.08	-0.42	1.72e-11	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg10435706	chr6:150039699	LATS1	0.37	4.87	0.3	2.04e-6	Lung cancer;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg23100841	chr14:74111439	DNAL1	0.49	6.29	0.38	1.56e-9	Lung adenocarcinoma;
SARC	cis	rs854765	0.583	rs11078404	chr17:17820487	A/T	cg05444541	chr17:17804740	TOM1L2	-0.3	-4.98	-0.31	1.21e-6	Total body bone mineral density;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg19440484	chr8:93977688	C8orf83	-0.47	-6.34	-0.38	1.16e-9	Neuroticism;
SARC	cis	rs4727027	0.635	rs12111923	chr7:148885877	G/A	cg23583168	chr7:148888333	NA	-0.75	-10.03	-0.55	6.47e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg22903471	chr2:27725779	GCKR	-0.49	-7.23	-0.43	6.91e-12	Total body bone mineral density;
SARC	cis	rs198851	0.915	rs72834643	chr6:26041986	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.41	-5.17	-0.32	4.94e-7	Red cell distribution width;High light scatter reticulocyte percentage of red cells;Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg09263875	chr16:632152	PIGQ	0.52	7.85	0.46	1.47e-13	Height;
SARC	cis	rs1050631	0.592	rs1789547	chr18:33725705	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.59	6.9	0.41	4.78e-11	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs1348850	0.632	rs11678875	chr2:178509068	A/G	cg22681709	chr2:178499509	PDE11A	-0.42	-5.8	-0.36	2.13e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg16405210	chr4:1374714	KIAA1530	-0.52	-6.01	-0.37	6.93e-9	Obesity-related traits;
SARC	cis	rs6582630	0.638	rs12423236	chr12:38548162	G/A	cg26384229	chr12:38710491	ALG10B	-0.59	-7.47	-0.44	1.64e-12	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1865760	0.566	rs7772312	chr6:26049616	G/C	cg17691542	chr6:26056736	HIST1H1C	0.54	6.71	0.4	1.48e-10	Height;
SARC	cis	rs7666738	0.791	rs13146909	chr4:98934198	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs12477438	1.000	rs73963398	chr2:99887025	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-8.29	-0.48	8.79e-15	Chronic sinus infection;
SARC	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.73	6.99	0.42	2.79e-11	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs79349575	0.594	rs1985785	chr17:46967788	T/C	cg07967210	chr17:47022446	SNF8	0.39	4.86	0.3	2.15e-6	Type 2 diabetes;
SARC	cis	rs1003719	0.715	rs2835653	chr21:38558636	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.29	-0.52	1.11e-17	Eye color traits;
SARC	cis	rs6089584	0.566	rs6061972	chr20:60610245	C/T	cg23262073	chr20:60523788	NA	-0.34	-5.33	-0.33	2.37e-7	Body mass index;
SARC	cis	rs67133203	0.634	rs7977104	chr12:51559511	A/G	cg15029631	chr12:52078762	SCN8A	-0.42	-4.81	-0.3	2.77e-6	Urinary tract infection frequency;
SARC	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg20607798	chr8:58055168	NA	0.55	5.07	0.32	7.93e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs11105298	0.891	rs11105325	chr12:89938590	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.55	-5.53	-0.34	8.4e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs1408799	0.720	rs13284898	chr9:12724560	C/T	cg05274944	chr9:12693694	TYRP1	0.35	5.2	0.32	4.32e-7	Eye color;Blue vs. green eyes;
SARC	cis	rs7914558	0.966	rs7096269	chr10:104736721	A/G	cg04362960	chr10:104952993	NT5C2	0.41	5.02	0.31	1.04e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg02398342	chr17:80708632	TBCD;FN3K	-0.51	-6.75	-0.4	1.14e-10	Glycated hemoglobin levels;
SARC	cis	rs4689388	0.853	rs1079214	chr4:6282157	T/C	cg14416269	chr4:6271139	WFS1	0.37	5.49	0.34	1.07e-7	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg25482607	chr13:111358552	CARS2	0.7	4.81	0.3	2.67e-6	Obesity-related traits;
SARC	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg08280861	chr8:58055591	NA	0.71	5.87	0.36	1.51e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9581943	0.967	rs4424773	chr13:28470544	C/G	cg25299895	chr13:28498091	PDX1	0.37	5.02	0.31	1.03e-6	Pancreatic cancer;
SARC	cis	rs5753618	0.539	rs4820962	chr22:31689951	A/G	cg02404636	chr22:31891804	SFI1	-0.5	-5.21	-0.32	4.23e-7	Colorectal cancer;
SARC	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg05234568	chr11:5960015	NA	-0.39	-5.31	-0.33	2.59e-7	DNA methylation (variation);
SARC	trans	rs61931739	0.635	rs6488185	chr12:33933127	G/C	cg13010199	chr12:38710504	ALG10B	0.5	6.35	0.38	1.11e-9	Morning vs. evening chronotype;
SARC	cis	rs908922	0.676	rs1856119	chr1:152512483	A/G	cg09873164	chr1:152488093	CRCT1	0.65	8.66	0.49	7.93e-16	Hair morphology;
SARC	cis	rs854765	0.583	rs9890341	chr17:17823175	G/C	cg05444541	chr17:17804740	TOM1L2	-0.29	-4.98	-0.31	1.22e-6	Total body bone mineral density;
SARC	cis	rs6545883	0.929	rs10190332	chr2:61619267	T/G	cg15711740	chr2:61764176	XPO1	0.42	5.09	0.32	7.51e-7	Tuberculosis;
SARC	cis	rs10089	0.552	rs58595196	chr5:127558338	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.57	5.82	0.36	1.93e-8	Ileal carcinoids;
SARC	cis	rs72627123	0.867	rs73303129	chr14:74489244	A/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.76	5.99	0.37	7.73e-9	Morning vs. evening chronotype;
SARC	cis	rs7438	0.528	rs4235024	chr4:170511551	T/G	cg07701716	chr4:170533879	NEK1	0.41	4.9	0.31	1.83e-6	Schizophrenia;
SARC	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg08859206	chr1:53392774	SCP2	0.39	5.65	0.35	4.74e-8	Monocyte count;
SARC	cis	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg12257692	chr3:49977190	RBM6	0.28	4.88	0.3	1.95e-6	Body mass index;
SARC	cis	rs10193935	0.901	rs7594010	chr2:42534896	C/T	cg27598129	chr2:42591480	NA	-0.36	-4.89	-0.31	1.87e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.43	0.44	2.1e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs478304	0.903	rs546202	chr11:65510024	C/T	cg27068330	chr11:65405492	SIPA1	-0.36	-4.82	-0.3	2.6e-6	Acne (severe);
SARC	cis	rs2832191	0.679	rs2705659	chr21:30363908	G/C	cg24692254	chr21:30365293	RNF160	1.03	19.06	0.78	1.97e-49	Dental caries;
SARC	cis	rs826838	0.616	rs10880754	chr12:38628154	C/T	cg26384229	chr12:38710491	ALG10B	-0.6	-7.64	-0.45	5.47e-13	Heart rate;
SARC	cis	rs6831352	0.734	rs2602856	chr4:100029145	C/A	cg12011299	chr4:100065546	ADH4	0.28	5.05	0.31	8.73e-7	Alcohol dependence;
SARC	cis	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg08564027	chr20:61660810	NA	0.76	11.75	0.61	2.4e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs7666738	0.830	rs9996098	chr4:98867740	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.59	0.49	1.24e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2153535	0.580	rs4960423	chr6:8477210	C/T	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	cis	rs2289583	0.503	rs12050494	chr15:75260896	G/A	cg10253484	chr15:75165896	SCAMP2	0.5	5.39	0.33	1.71e-7	Systemic lupus erythematosus;
SARC	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg13114125	chr14:105738426	BRF1	-0.79	-11.45	-0.6	2.26e-24	Mean platelet volume;Platelet distribution width;
SARC	cis	rs9399135	0.967	rs13199205	chr6:135286505	T/C	cg24558204	chr6:135376177	HBS1L	0.44	6.01	0.37	7.17e-9	Red blood cell count;
SARC	cis	rs1949733	0.523	rs62287455	chr4:8544994	A/T	cg11789530	chr4:8429930	ACOX3	-0.69	-7.73	-0.45	3.26e-13	Response to antineoplastic agents;
SARC	cis	rs473651	0.935	rs520765	chr2:239354712	C/T	cg18131467	chr2:239335373	ASB1	0.98	15.38	0.71	2.68e-37	Multiple system atrophy;
SARC	cis	rs9457247	0.905	rs453184	chr6:167387404	A/C	cg23791538	chr6:167370224	RNASET2	-0.62	-8.66	-0.49	8.17e-16	Crohn's disease;
SARC	cis	rs17376456	0.542	rs2084916	chr5:93194961	A/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.53	-5.53	-0.34	8.42e-8	Diabetic retinopathy;
SARC	cis	rs57502260	0.651	rs3781586	chr11:68199393	C/A	cg01657329	chr11:68192670	LRP5	-0.52	-5.3	-0.33	2.71e-7	Total body bone mineral density (age 45-60);
SARC	trans	rs453301	0.624	rs330058	chr8:9089809	G/A	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.89	-0.41	5.01e-11	Joint mobility (Beighton score);
SARC	cis	rs3796352	1.000	rs2336540	chr3:52974589	G/A	cg27565382	chr3:53032988	SFMBT1	0.83	5.57	0.34	7.16e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs9682041	0.627	rs3772172	chr3:170077713	C/T	cg11886554	chr3:170076028	SKIL	-0.7	-6.55	-0.39	3.6e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg26565578	chr12:10766330	MAGOHB	0.5	6.25	0.38	1.95e-9	Blood pressure;
SARC	cis	rs796364	0.951	rs11897245	chr2:201063644	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.49	4.87	0.3	2.06e-6	Schizophrenia;
SARC	cis	rs1018836	0.884	rs9643307	chr8:91625257	A/C	cg16814680	chr8:91681699	NA	-0.85	-13.99	-0.68	1.06e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs6952808	0.636	rs73048162	chr7:1949328	T/C	cg13880726	chr7:1868755	MAD1L1	0.43	4.97	0.31	1.28e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs6496667	0.509	rs2657948	chr15:90948617	G/A	cg22089800	chr15:90895588	ZNF774	0.43	4.94	0.31	1.49e-6	Rheumatoid arthritis;
SARC	cis	rs12586317	0.508	rs8015350	chr14:35635230	A/T	cg16230307	chr14:35515116	FAM177A1	0.48	6.05	0.37	5.62e-9	Psoriasis;
SARC	cis	rs829883	0.659	rs11109520	chr12:98928646	C/T	cg25150519	chr12:98850993	NA	0.59	7.34	0.43	3.46e-12	Colorectal adenoma (advanced);
SARC	cis	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg13647721	chr17:30228624	UTP6	0.61	4.92	0.31	1.65e-6	Hip circumference adjusted for BMI;
SARC	cis	rs7647973	0.626	rs11130217	chr3:49737323	A/G	cg03060546	chr3:49711283	APEH	0.63	6.63	0.4	2.32e-10	Menarche (age at onset);
SARC	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg11890956	chr21:40555474	PSMG1	1.17	16.63	0.74	1.78e-41	Cognitive function;
SARC	cis	rs34330	0.562	rs7486387	chr12:12866911	G/A	cg04607235	chr12:12878440	APOLD1	-0.57	-5.57	-0.34	7.16e-8	Systemic lupus erythematosus;
SARC	cis	rs7086627	0.515	rs10887905	chr10:82210855	A/T	cg00277334	chr10:82204260	NA	-0.57	-9.42	-0.53	4.63e-18	Post bronchodilator FEV1;
SARC	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg05332525	chr7:65337924	VKORC1L1	0.44	4.92	0.31	1.61e-6	Calcium levels;
SARC	cis	rs9943753	0.525	rs983307	chr12:109815103	T/G	cg19025524	chr12:109796872	NA	-0.38	-5.67	-0.35	4.16e-8	HDL cholesterol;
SARC	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	6.67	0.4	1.84e-10	Hip circumference adjusted for BMI;
SARC	cis	rs17376456	0.825	rs6865441	chr5:93284746	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.57	0.34	6.9e-8	Diabetic retinopathy;
SARC	trans	rs1994135	0.608	rs1482994	chr12:33713631	T/C	cg13010199	chr12:38710504	ALG10B	0.76	8.92	0.5	1.41e-16	Resting heart rate;
SARC	cis	rs9581943	0.967	rs9554193	chr13:28471366	G/A	cg25299895	chr13:28498091	PDX1	0.37	5.02	0.31	1.03e-6	Pancreatic cancer;
SARC	cis	rs3733585	0.673	rs4407505	chr4:9953367	T/G	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.94	-0.36	1.06e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs995000	0.965	rs11207980	chr1:62992749	T/C	cg06896770	chr1:63153194	DOCK7	0.97	14.27	0.68	1.28e-33	Triglyceride levels;
SARC	trans	rs61931739	0.500	rs11053272	chr12:34547020	C/G	cg13010199	chr12:38710504	ALG10B	0.83	11.73	0.61	2.89e-25	Morning vs. evening chronotype;
SARC	cis	rs2243480	0.522	rs1638736	chr7:66092308	A/T	cg18252515	chr7:66147081	NA	-1.07	-7.12	-0.42	1.3e-11	Diabetic kidney disease;
SARC	cis	rs1355223	0.545	rs7111695	chr11:34874906	T/G	cg11622362	chr11:34938112	PDHX;APIP	0.45	5.88	0.36	1.42e-8	Systemic lupus erythematosus and Systemic sclerosis;
SARC	trans	rs7815944	1.000	rs16902895	chr8:129425593	A/G	cg25487405	chr22:46473039	NA	0.64	6.35	0.38	1.09e-9	Atopic dermatitis;
SARC	cis	rs898097	0.841	rs9896263	chr17:80902741	A/G	cg15664640	chr17:80829946	TBCD	0.45	7.03	0.42	2.21e-11	Breast cancer;
SARC	cis	rs6690583	0.623	rs12037219	chr1:85505951	G/A	cg22153463	chr1:85462885	MCOLN2	0.74	6.05	0.37	5.67e-9	Serum sulfate level;
SARC	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	10.56	0.57	1.49e-21	Alzheimer's disease;
SARC	cis	rs9790314	1.000	rs460508	chr3:161091089	C/G	cg03342759	chr3:160939853	NMD3	0.55	6.59	0.4	2.92e-10	Morning vs. evening chronotype;
SARC	cis	rs7395581	0.918	rs12575456	chr11:47326073	G/A	cg25783544	chr11:47291846	MADD	0.5	5.64	0.35	4.82e-8	HDL cholesterol;
SARC	cis	rs992157	0.661	rs10171839	chr2:219051314	C/T	cg00012203	chr2:219082015	ARPC2	0.83	12.99	0.65	2.18e-29	Colorectal cancer;
SARC	cis	rs6088590	0.735	rs6060001	chr20:33294353	C/T	cg24642439	chr20:33292090	TP53INP2	-0.71	-9.93	-0.55	1.29e-19	Coronary artery disease;
SARC	cis	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.42	-5.19	-0.32	4.68e-7	Eosinophil percentage of white cells;
SARC	cis	rs7566780	0.565	rs1346751	chr2:16639566	C/T	cg09580478	chr2:16689509	NA	0.46	5.01	0.31	1.09e-6	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs12971120	0.838	rs3794950	chr18:72182965	G/A	cg26446133	chr18:72167187	CNDP2	-0.54	-7.09	-0.42	1.56e-11	Refractive error;
SARC	cis	rs826838	0.904	rs7973992	chr12:39168233	T/C	cg26384229	chr12:38710491	ALG10B	0.88	12.71	0.64	1.82e-28	Heart rate;
SARC	cis	rs8180040	1.000	rs8180040	chr3:47388947	A/T	cg27129171	chr3:47204927	SETD2	0.68	9.63	0.53	1.07e-18	Colorectal cancer;
SARC	cis	rs1318878	0.639	rs11056452	chr12:15515716	C/T	cg08258403	chr12:15378311	NA	0.47	6.58	0.4	3.15e-10	Intelligence (multi-trait analysis);
SARC	cis	rs957448	1.000	rs16916881	chr8:95566270	C/A	cg26464482	chr8:95565502	KIAA1429	0.42	4.72	0.3	4.16e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs9916302	0.847	rs7218670	chr17:37500424	G/A	cg07936489	chr17:37558343	FBXL20	0.69	9.14	0.51	3.18e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.48	0.44	1.5e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs10982256	0.782	rs1324631	chr9:117254731	G/C	cg21159778	chr9:117266918	DFNB31	0.36	4.9	0.31	1.77e-6	Bipolar disorder;
SARC	cis	rs9790314	1.000	rs3849524	chr3:161015589	C/T	cg04691961	chr3:161091175	C3orf57	-0.76	-11.2	-0.59	1.39e-23	Morning vs. evening chronotype;
SARC	cis	rs7481584	0.624	rs436580	chr11:3063961	T/G	cg20651018	chr11:3035856	CARS	0.39	5.8	0.36	2.13e-8	Calcium levels;
SARC	cis	rs3106136	0.967	rs767657	chr4:95227901	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.37	-5.69	-0.35	3.84e-8	Capecitabine sensitivity;
SARC	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg21724239	chr8:58056113	NA	0.59	5.55	0.34	7.85e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg22857025	chr5:266934	NA	-1.06	-11.63	-0.61	5.91e-25	Breast cancer;
SARC	cis	rs6964587	1.000	rs3753109	chr7:91630001	G/C	cg17063962	chr7:91808500	NA	0.94	15.6	0.71	4.79e-38	Breast cancer;
SARC	cis	rs3956705	0.762	rs13437980	chr7:32997749	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.5	6.26	0.38	1.79e-9	Red cell distribution width;
SARC	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg15352829	chr14:105391018	PLD4	-0.33	-6.33	-0.38	1.24e-9	Rheumatoid arthritis;
SARC	cis	rs3815700	1.000	rs7248845	chr19:33096718	T/C	cg24916020	chr19:33096688	ANKRD27	0.56	5.66	0.35	4.43e-8	Eosinophilic esophagitis;
SARC	cis	rs1904096	0.506	rs114312933	chr4:95216802	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.49	-7.4	-0.44	2.44e-12	Type 2 diabetes;
SARC	cis	rs6570726	0.764	rs367065	chr6:145882309	T/G	cg05347473	chr6:146136440	FBXO30	0.54	7.54	0.44	1.05e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4727027	0.800	rs10952796	chr7:148813138	G/C	cg23583168	chr7:148888333	NA	-0.74	-10.37	-0.56	5.62e-21	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs6582630	0.502	rs11610978	chr12:38356957	C/G	cg26384229	chr12:38710491	ALG10B	0.86	12.43	0.63	1.5e-27	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs950027	0.787	rs1547487	chr15:45723983	A/G	cg26924012	chr15:45694286	SPATA5L1	0.49	5.98	0.36	8.47e-9	Response to fenofibrate (adiponectin levels);
SARC	cis	rs3857536	0.813	rs7743965	chr6:66941346	C/G	cg07460842	chr6:66804631	NA	-0.51	-5.83	-0.36	1.86e-8	Blood trace element (Cu levels);
SARC	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg07701084	chr6:150067640	NUP43	0.41	5.37	0.33	1.87e-7	Lung cancer;
SARC	cis	rs288326	0.561	rs74564500	chr2:183786420	C/A	cg09997497	chr2:183902928	NCKAP1	0.75	5.13	0.32	6.18e-7	Blood protein levels;
SARC	cis	rs6693567	0.565	rs1260408	chr1:150307270	T/G	cg09579323	chr1:150459698	TARS2	0.43	5.4	0.33	1.61e-7	Migraine;
SARC	trans	rs61931739	0.857	rs999715	chr12:34143253	G/C	cg13010199	chr12:38710504	ALG10B	0.55	7.33	0.43	3.74e-12	Morning vs. evening chronotype;
SARC	cis	rs709400	0.628	rs11622356	chr14:103912195	C/T	cg26031613	chr14:104095156	KLC1	0.81	11.64	0.61	5.37e-25	Body mass index;
SARC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.42	0.53	4.71e-18	Prudent dietary pattern;
SARC	cis	rs8013055	0.796	rs8005568	chr14:105971794	A/G	cg19700328	chr14:106028568	NA	-0.58	-8.39	-0.48	4.58e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
SARC	cis	rs11676348	0.811	rs4674255	chr2:218987325	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.5	-6.51	-0.39	4.51e-10	Ulcerative colitis;
SARC	cis	rs9896052	0.580	rs7406977	chr17:73460417	T/G	cg04121983	chr17:73511085	CASKIN2	0.42	4.86	0.3	2.2e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs7647973	1.000	rs4241407	chr3:49600319	C/T	cg06212747	chr3:49208901	KLHDC8B	0.55	5.92	0.36	1.13e-8	Menarche (age at onset);
SARC	cis	rs748404	0.631	rs6493086	chr15:43655394	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	5.81	0.36	2.09e-8	Lung cancer;
SARC	cis	rs6500602	0.647	rs3747600	chr16:4586222	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.3	4.95	0.31	1.44e-6	Schizophrenia;
SARC	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.94	10.04	0.55	5.91e-20	Platelet count;
SARC	cis	rs9398803	0.965	rs6907898	chr6:126666416	C/T	cg19875578	chr6:126661172	C6orf173	0.6	8.17	0.47	1.96e-14	Male-pattern baldness;
SARC	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.72	-9.0	-0.51	7.94e-17	Prudent dietary pattern;
SARC	cis	rs2985684	0.894	rs8005990	chr14:50022248	G/A	cg04989706	chr14:50066350	PPIL5	-0.53	-5.93	-0.36	1.07e-8	Carotid intima media thickness;
SARC	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg26335602	chr6:28129616	ZNF389	0.53	5.92	0.36	1.12e-8	Depression;
SARC	cis	rs10463554	0.963	rs11955683	chr5:102326696	A/G	cg23492399	chr5:102201601	PAM	-0.47	-5.76	-0.35	2.71e-8	Parkinson's disease;
SARC	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7208859	0.573	rs56031503	chr17:29075665	T/C	cg13385521	chr17:29058706	SUZ12P	0.88	7.94	0.46	8.37e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs7044106	0.690	rs10739569	chr9:123361027	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	4.75	0.3	3.49e-6	Hip circumference adjusted for BMI;
SARC	cis	rs9911578	0.692	rs411988	chr17:56709034	G/A	cg12560992	chr17:57184187	TRIM37	0.64	8.32	0.48	7.29e-15	Intelligence (multi-trait analysis);
SARC	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg09455208	chr3:40491958	NA	-0.4	-6.15	-0.37	3.31e-9	Renal cell carcinoma;
SARC	cis	rs2834188	0.883	rs16997869	chr21:34696867	C/T	cg14352951	chr21:34696688	IFNAR1	-0.46	-5.64	-0.35	5.03e-8	Narcolepsy;
SARC	cis	rs1008375	0.966	rs3733576	chr4:17586703	T/C	cg16339924	chr4:17578868	LAP3	0.71	9.3	0.52	1.03e-17	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg04317338	chr11:64019027	PLCB3	0.79	7.81	0.46	1.96e-13	Mean platelet volume;
SARC	cis	rs35110281	0.667	rs2838354	chr21:45119857	T/C	cg21573476	chr21:45109991	RRP1B	-0.62	-8.99	-0.51	8.91e-17	Mean corpuscular volume;
SARC	cis	rs9457247	0.967	rs387733	chr6:167409771	C/T	cg23791538	chr6:167370224	RNASET2	0.62	8.28	0.48	9.8e-15	Crohn's disease;
SARC	cis	rs703842	1.000	rs3782130	chr12:58161898	G/C	cg00677455	chr12:58241039	CTDSP2	0.52	6.74	0.4	1.2e-10	Multiple sclerosis;
SARC	cis	rs8067545	0.616	rs203477	chr17:19831819	A/C	cg04132472	chr17:19861366	AKAP10	0.38	5.08	0.32	7.88e-7	Schizophrenia;
SARC	cis	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg18252515	chr7:66147081	NA	1.27	11.36	0.6	4.41e-24	Diabetic kidney disease;
SARC	cis	rs72634258	0.786	rs9434991	chr1:8178708	G/C	cg00042356	chr1:8021962	PARK7	0.61	5.61	0.35	5.67e-8	Inflammatory bowel disease;
SARC	cis	rs7940866	0.801	rs2113928	chr11:130835975	A/G	cg12179176	chr11:130786555	SNX19	0.65	8.64	0.49	9.27e-16	Schizophrenia;
SARC	cis	rs6570726	0.935	rs409725	chr6:145840340	G/A	cg05220968	chr6:146057943	EPM2A	-0.29	-4.99	-0.31	1.19e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs77633900	0.614	rs113557153	chr15:76994445	A/G	cg21673338	chr15:77095150	SCAPER	-0.74	-5.75	-0.35	2.86e-8	Non-glioblastoma glioma;Glioma;
SARC	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg17376030	chr22:41985996	PMM1	-0.73	-8.97	-0.51	1.01e-16	Vitiligo;
SARC	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg16606324	chr3:10149918	C3orf24	0.5	5.01	0.31	1.08e-6	Alzheimer's disease;
SARC	trans	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg06437703	chr8:37914619	EIF4EBP1	0.58	6.84	0.41	7.11e-11	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs57221529	0.600	rs11750269	chr5:666270	G/A	cg07777115	chr5:623756	CEP72	-0.58	-4.88	-0.3	2.01e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs7712401	0.601	rs418229	chr5:122341664	T/C	cg19412675	chr5:122181750	SNX24	-0.43	-5.43	-0.34	1.41e-7	Mean platelet volume;
SARC	cis	rs7666738	0.830	rs13119995	chr4:99026790	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs11252926	0.599	rs11252213	chr10:454694	C/T	cg16386425	chr10:429943	DIP2C	-0.41	-4.86	-0.3	2.19e-6	Psychosis in Alzheimer's disease;
SARC	cis	rs12824058	0.831	rs11616174	chr12:130814503	A/G	cg26677194	chr12:130822605	PIWIL1	0.55	7.58	0.44	8.33e-13	Menopause (age at onset);
SARC	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	15.58	0.71	5.4e-38	Chronic sinus infection;
SARC	cis	rs11997175	0.603	rs7008747	chr8:33834886	G/A	ch.8.33884649F	chr8:33765107	NA	0.43	5.34	0.33	2.19e-7	Body mass index;
SARC	cis	rs10493773	0.775	rs2069208	chr1:86117583	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.54	-8.42	-0.48	3.76e-15	Urate levels in overweight individuals;
SARC	cis	rs6840360	1.000	rs3749562	chr4:152596540	T/C	cg22705602	chr4:152727874	NA	-0.36	-6.14	-0.37	3.6e-9	Intelligence (multi-trait analysis);
SARC	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg02297831	chr4:17616191	MED28	0.51	6.63	0.4	2.36e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4808199	0.947	rs751858	chr19:19602821	G/C	cg03709012	chr19:19516395	GATAD2A	1.19	13.27	0.66	2.57e-30	Nonalcoholic fatty liver disease;
SARC	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg18225595	chr11:63971243	STIP1	0.58	8.69	0.49	6.43e-16	Platelet count;
SARC	cis	rs7714584	1.000	rs73282255	chr5:150223647	A/T	cg22134413	chr5:150180641	NA	0.78	6.56	0.39	3.42e-10	Crohn's disease;
SARC	cis	rs5750830	0.594	rs9611166	chr22:39775268	T/C	cg24399712	chr22:39784796	NA	-0.44	-6.11	-0.37	4.14e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7264396	0.836	rs6058282	chr20:34212590	T/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.56	5.54	0.34	8.31e-8	Total cholesterol levels;
SARC	cis	rs3204270	0.714	rs8074828	chr17:79657136	G/C	cg26965718	chr17:79658957	HGS	-0.63	-5.18	-0.32	4.71e-7	Dental caries;
SARC	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs12973672	1.000	rs10421599	chr19:35767933	G/A	cg12095397	chr19:35769544	USF2	0.38	4.89	0.31	1.88e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs36715	0.909	rs152906	chr5:127551840	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.57	6.31	0.38	1.43e-9	Breast cancer;
SARC	cis	rs796364	0.587	rs7588746	chr2:200986345	A/G	cg23649088	chr2:200775458	C2orf69	0.65	7.19	0.43	8.94e-12	Schizophrenia;
SARC	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.72	8.41	0.48	4.26e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg18404041	chr3:52824283	ITIH1	-0.36	-5.3	-0.33	2.66e-7	Bipolar disorder;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg23143603	chr11:82783581	RAB30	0.48	6.3	0.38	1.44e-9	Electrocardiographic conduction measures;
SARC	cis	rs2304069	0.913	rs3812009	chr5:149380159	G/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.91	9.54	0.53	2.08e-18	HIV-1 control;
SARC	cis	rs1707322	0.721	rs12037803	chr1:46156492	A/G	cg06784218	chr1:46089804	CCDC17	0.36	6.17	0.37	2.95e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2952156	0.920	rs2941506	chr17:37833035	A/G	cg07936489	chr17:37558343	FBXL20	-0.39	-5.17	-0.32	5.02e-7	Asthma;
SARC	cis	rs9818758	0.556	rs9814987	chr3:49207849	T/C	cg07636037	chr3:49044803	WDR6	-0.74	-6.74	-0.4	1.22e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs9818758	0.607	rs67831908	chr3:49313513	T/G	cg01304814	chr3:48885189	PRKAR2A	0.65	5.29	0.33	2.75e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs3796352	1.000	rs17052727	chr3:53070914	T/C	cg27565382	chr3:53032988	SFMBT1	0.78	6.0	0.37	7.36e-9	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs453301	0.686	rs11787026	chr8:8902371	A/T	cg11995313	chr8:8860691	ERI1	-0.44	-5.71	-0.35	3.41e-8	Joint mobility (Beighton score);
SARC	cis	rs7216064	0.953	rs1599859	chr17:65837193	C/G	cg12091567	chr17:66097778	LOC651250	-0.75	-8.23	-0.47	1.34e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs25645	0.771	rs11078936	chr17:38197914	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.38	7.03	0.42	2.26e-11	Myeloid white cell count;
SARC	cis	rs1559088	0.895	rs13345542	chr19:33586739	G/C	cg27124370	chr19:33622961	WDR88	0.44	5.86	0.36	1.6e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg01316550	chr5:56110833	MAP3K1	0.54	4.92	0.31	1.62e-6	Initial pursuit acceleration;
SARC	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.58	5.48	0.34	1.1e-7	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.39	-6.53	-0.39	4e-10	Total body bone mineral density;
SARC	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.45	5.49	0.34	1.04e-7	Gut microbiome composition (summer);
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg10208294	chr16:23464607	COG7	0.52	6.59	0.4	2.83e-10	Lung adenocarcinoma;
SARC	cis	rs6963495	0.585	rs1728653	chr7:105191335	A/G	cg19920283	chr7:105172520	RINT1	0.5	5.2	0.32	4.45e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs4481887	0.861	rs4486480	chr1:248449714	C/T	cg13385794	chr1:248469461	NA	0.33	4.97	0.31	1.31e-6	Common traits (Other);
SARC	cis	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg06636001	chr8:8085503	FLJ10661	0.64	8.45	0.48	3.28e-15	Mood instability;
SARC	cis	rs17001868	0.568	rs742140	chr22:40781586	G/A	cg07138101	chr22:40742427	ADSL	0.58	6.29	0.38	1.54e-9	Mammographic density (dense area);
SARC	cis	rs6674970	1.000	rs6676190	chr1:151079317	C/T	cg11822372	chr1:151115635	SEMA6C	0.43	5.21	0.32	4.07e-7	Childhood ear infection;
SARC	cis	rs8067354	0.645	rs1874548	chr17:57841357	A/G	cg02344993	chr17:57696989	CLTC	0.63	6.09	0.37	4.59e-9	Hemoglobin concentration;
SARC	cis	rs644799	1.000	rs3177463	chr11:95502128	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.89	13.99	0.68	1.11e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2952156	0.920	rs1565920	chr17:37831613	G/A	cg20243544	chr17:37824526	PNMT	0.54	7.12	0.42	1.29e-11	Asthma;
SARC	cis	rs6088580	0.634	rs6087579	chr20:32985155	A/G	cg08999081	chr20:33150536	PIGU	-0.42	-6.4	-0.39	8.53e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs6988636	1.000	rs6988636	chr8:124185970	A/G	cg23067535	chr8:124195133	FAM83A	-0.59	-5.02	-0.31	1.03e-6	Urinary uromodulin levels;
SARC	cis	rs11711311	1.000	rs62268168	chr3:113489447	A/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	8.6	0.49	1.15e-15	IgG glycosylation;
SARC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg11494091	chr17:61959527	GH2	0.54	8.06	0.47	4.05e-14	Prudent dietary pattern;
SARC	cis	rs6456156	0.586	rs12528689	chr6:167461746	A/G	cg23791538	chr6:167370224	RNASET2	-0.52	-6.79	-0.41	9.49e-11	Primary biliary cholangitis;
SARC	cis	rs8014204	0.935	rs4903267	chr14:75360419	G/T	cg17347104	chr14:75034677	LTBP2	0.4	4.94	0.31	1.5e-6	Caffeine consumption;
SARC	cis	rs7084402	0.967	rs1649015	chr10:60289031	A/G	cg07615347	chr10:60278583	BICC1	0.61	8.99	0.51	8.84e-17	Refractive error;
SARC	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg11494091	chr17:61959527	GH2	0.37	5.07	0.32	7.99e-7	Height;
SARC	cis	rs9815354	1.000	rs6805880	chr3:41865397	A/G	cg03022575	chr3:42003672	ULK4	0.56	5.02	0.31	1.05e-6	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2952156	0.920	rs732084	chr17:37834357	A/C	cg20243544	chr17:37824526	PNMT	0.56	7.44	0.44	1.94e-12	Asthma;
SARC	cis	rs9894429	1.000	rs12948099	chr17:79600799	C/G	cg10661904	chr17:79619235	PDE6G	-0.34	-4.76	-0.3	3.45e-6	Eye color traits;
SARC	cis	rs2204008	0.630	rs1283300	chr12:38150227	C/T	cg26384229	chr12:38710491	ALG10B	-0.66	-8.56	-0.49	1.54e-15	Bladder cancer;
SARC	cis	rs7762018	0.607	rs6907814	chr6:170058206	G/A	cg19338460	chr6:170058176	WDR27	-0.83	-6.03	-0.37	6.43e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs9457247	0.529	rs6907666	chr6:167523395	A/G	cg23791538	chr6:167370224	RNASET2	0.45	5.67	0.35	4.16e-8	Crohn's disease;
SARC	cis	rs7659604	1.000	rs7659604	chr4:122665514	A/G	cg19671926	chr4:122722719	EXOSC9	0.52	6.32	0.38	1.31e-9	Type 2 diabetes;
SARC	cis	rs2075371	1.000	rs1421484	chr7:133979795	T/C	cg11752832	chr7:134001865	SLC35B4	0.58	7.64	0.45	5.46e-13	Mean platelet volume;
SARC	cis	rs6912958	0.712	rs2754262	chr6:88405585	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.3	-4.82	-0.3	2.54e-6	Monocyte percentage of white cells;
SARC	cis	rs7582180	0.845	rs11683088	chr2:100920667	C/T	cg14675211	chr2:100938903	LONRF2	0.52	7.51	0.44	1.22e-12	Intelligence (multi-trait analysis);
SARC	cis	rs9322193	0.516	rs1999632	chr6:150187873	C/T	cg05036130	chr6:150231994	NA	0.33	4.72	0.3	4.06e-6	Lung cancer;
SARC	cis	rs7084402	0.935	rs1896246	chr10:60276068	A/G	cg07615347	chr10:60278583	BICC1	-0.6	-8.82	-0.5	2.78e-16	Refractive error;
SARC	cis	rs9902453	0.935	rs7220151	chr17:28334710	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.52	-6.82	-0.41	7.63e-11	Coffee consumption (cups per day);
SARC	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg16405210	chr4:1374714	KIAA1530	-0.48	-5.52	-0.34	9.17e-8	Obesity-related traits;
SARC	cis	rs7824557	0.545	rs2572450	chr8:11229638	C/T	cg12395012	chr8:11607386	GATA4	0.3	5.03	0.31	9.81e-7	Retinal vascular caliber;
SARC	cis	rs1707322	1.000	rs10789486	chr1:46408667	A/G	cg03146154	chr1:46216737	IPP	0.49	5.86	0.36	1.57e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1008375	0.932	rs6835077	chr4:17653285	A/T	cg27347728	chr4:17578864	LAP3	0.49	6.19	0.38	2.73e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs17376456	0.569	rs7701114	chr5:93096028	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.5	5.14	0.32	5.81e-7	Diabetic retinopathy;
SARC	cis	rs2268241	0.938	rs17879003	chr21:34778527	C/T	cg14850771	chr21:34775459	IFNGR2	0.96	8.91	0.5	1.46e-16	Obesity-related traits;
SARC	cis	rs7312774	0.748	rs10492214	chr12:107294758	T/C	cg16260113	chr12:107380972	MTERFD3	0.77	6.66	0.4	1.93e-10	Severe influenza A (H1N1) infection;
SARC	cis	rs9309711	0.772	rs9752251	chr2:3489869	C/T	cg10845886	chr2:3471009	TTC15	-0.54	-6.19	-0.38	2.73e-9	Neurofibrillary tangles;
SARC	cis	rs7474896	0.583	rs10827817	chr10:37997974	A/G	cg25427524	chr10:38739819	LOC399744	-0.46	-5.67	-0.35	4.1e-8	Obesity (extreme);
SARC	cis	rs8068544	0.606	rs77681389	chr17:40154419	T/C	cg26502583	chr17:39992600	KLHL10;NT5C3L	-0.87	-6.45	-0.39	6.54e-10	Reticulocyte fraction of red cells;Reticulocyte count;
SARC	trans	rs561341	0.941	rs2428336	chr17:30290577	T/C	cg20587970	chr11:113659929	NA	-1.26	-12.25	-0.63	5.62e-27	Hip circumference adjusted for BMI;
SARC	cis	rs12908161	0.960	rs17599989	chr15:85285536	A/G	cg17507749	chr15:85114479	UBE2QP1	0.55	6.33	0.38	1.21e-9	Schizophrenia;
SARC	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg07701084	chr6:150067640	NUP43	0.4	5.37	0.33	1.93e-7	Lung cancer;
SARC	cis	rs244899	0.967	rs2445785	chr5:167924928	A/G	cg06604206	chr5:167912465	RARS	0.33	4.79	0.3	2.94e-6	Response to platinum-based chemotherapy (carboplatin);
SARC	cis	rs11098499	0.954	rs9998585	chr4:120396802	T/A	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs11098499	0.691	rs12502524	chr4:120271414	G/A	cg09307838	chr4:120376055	NA	0.74	10.26	0.56	1.27e-20	Corneal astigmatism;
SARC	cis	rs7089973	0.604	rs7903663	chr10:116609904	G/A	cg03647239	chr10:116582469	FAM160B1	0.5	6.49	0.39	5.19e-10	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs3008870	0.755	rs2208577	chr1:67513574	A/C	cg02640540	chr1:67518911	SLC35D1	0.61	7.52	0.44	1.2e-12	Lymphocyte percentage of white cells;
SARC	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg11952622	chr19:58962976	ZNF324B	0.56	7.41	0.44	2.38e-12	Uric acid clearance;
SARC	cis	rs17376456	0.825	rs12716454	chr5:93272279	A/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.7	0.35	3.7e-8	Diabetic retinopathy;
SARC	trans	rs7980799	0.682	rs1580396	chr12:33615841	C/A	cg26384229	chr12:38710491	ALG10B	-0.63	-7.73	-0.45	3.26e-13	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.03	-0.37	6.4e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6450176	0.680	rs255756	chr5:53309364	A/G	ch.5.1024479R	chr5:53302184	ARL15	-1.1	-12.5	-0.63	9e-28	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs2273669	0.667	rs12374658	chr6:109345930	T/C	cg05315195	chr6:109294784	ARMC2	-0.63	-5.7	-0.35	3.6e-8	Prostate cancer;
SARC	cis	rs7937682	0.924	rs513425	chr11:111504861	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.93	-15.22	-0.71	8.48e-37	Primary sclerosing cholangitis;
SARC	cis	rs35110281	0.591	rs86138	chr21:44932398	G/A	cg01579765	chr21:45077557	HSF2BP	-0.32	-5.31	-0.33	2.5e-7	Mean corpuscular volume;
SARC	cis	rs6847149	0.929	rs6839680	chr4:110765496	A/G	cg07850274	chr4:110748770	RRH	-0.45	-5.23	-0.32	3.71e-7	Exercise treadmill test traits;
SARC	cis	rs2486288	0.656	rs11637920	chr15:45550905	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.51	-6.44	-0.39	6.68e-10	Glomerular filtration rate;
SARC	cis	rs7712401	0.601	rs246308	chr5:122270090	G/T	cg19412675	chr5:122181750	SNX24	0.41	5.21	0.32	4.23e-7	Mean platelet volume;
SARC	cis	rs7223966	1.000	rs16947042	chr17:61766457	T/G	cg00588841	chr17:61851480	DDX42;CCDC47	-0.59	-6.86	-0.41	6.03e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.8	8.61	0.49	1.13e-15	Alzheimer's disease;
SARC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg16405210	chr4:1374714	KIAA1530	-0.86	-11.29	-0.59	7.25e-24	Longevity;
SARC	cis	rs6964587	1.000	rs6970277	chr7:91680655	T/C	cg17063962	chr7:91808500	NA	0.96	15.51	0.71	9.27e-38	Breast cancer;
SARC	cis	rs709400	0.627	rs62007686	chr14:103899344	A/G	cg26031613	chr14:104095156	KLC1	0.81	11.51	0.6	1.47e-24	Body mass index;
SARC	cis	rs7819412	0.740	rs28633434	chr8:11053922	G/A	cg12395012	chr8:11607386	GATA4	0.3	5.02	0.31	1.04e-6	Triglycerides;
SARC	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg18876405	chr7:65276391	NA	0.49	6.05	0.37	5.7e-9	Aortic root size;
SARC	cis	rs7660520	0.524	rs114404677	chr4:183733832	G/A	cg04181038	chr4:183730758	NA	0.57	5.85	0.36	1.65e-8	Pediatric autoimmune diseases;
SARC	cis	rs7772486	0.790	rs9485024	chr6:146142487	A/G	cg23711669	chr6:146136114	FBXO30	-0.81	-13.02	-0.65	1.78e-29	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3768617	0.510	rs1886499	chr1:183095024	C/T	cg13390022	chr1:182993471	LAMC1	0.31	4.79	0.3	3.01e-6	Fuchs's corneal dystrophy;
SARC	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg00933542	chr6:150070202	PCMT1	0.33	5.63	0.35	5.13e-8	Lung cancer;
SARC	cis	rs7103648	0.669	rs7114011	chr11:47811309	A/C	cg10504702	chr11:47789108	FNBP4	0.76	9.98	0.55	9.12e-20	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs9660180	0.620	rs34298494	chr1:1663402	A/C	cg17990871	chr1:1677678	SLC35E2	-0.45	-5.28	-0.33	2.89e-7	Body mass index;
SARC	cis	rs6484504	0.625	rs10835766	chr11:31374329	C/A	cg26647111	chr11:31128758	NA	0.39	5.02	0.31	1.03e-6	Red blood cell count;
SARC	trans	rs1814175	0.712	rs9665784	chr11:50030617	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-18.31	-0.77	5.28e-47	Height;
SARC	cis	rs2916247	0.788	rs1973258	chr8:93121262	A/G	cg10183463	chr8:93005414	RUNX1T1	0.57	5.87	0.36	1.52e-8	Intelligence (multi-trait analysis);
SARC	cis	rs73206853	0.620	rs73194038	chr12:111172339	G/T	cg10860002	chr12:110842031	ANAPC7	0.6	4.99	0.31	1.2e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs2204008	0.775	rs11514369	chr12:38305411	C/T	cg13010199	chr12:38710504	ALG10B	0.78	10.82	0.58	2.18e-22	Bladder cancer;
SARC	cis	rs1018836	0.923	rs9694450	chr8:91618292	G/A	cg16814680	chr8:91681699	NA	-0.83	-13.29	-0.66	2.19e-30	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs4141404	0.818	rs5997897	chr22:31570436	G/A	cg02404636	chr22:31891804	SFI1	-0.56	-7.43	-0.44	2.04e-12	Paclitaxel-induced neuropathy;
SARC	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg02725872	chr8:58115012	NA	-0.35	-6.21	-0.38	2.46e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs12310956	0.532	rs6488187	chr12:33975029	C/T	cg13010199	chr12:38710504	ALG10B	0.66	8.58	0.49	1.33e-15	Morning vs. evening chronotype;
SARC	cis	rs11874712	0.966	rs8094902	chr18:43666774	T/C	cg25174615	chr18:43684699	ATP5A1;HAUS1	0.4	4.75	0.3	3.52e-6	Migraine - clinic-based;
SARC	cis	rs11785693	0.862	rs11778306	chr8:4988269	A/C	cg26367366	chr8:4980734	NA	0.68	6.33	0.38	1.25e-9	Neuroticism (multi-trait analysis);Neuroticism;
SARC	trans	rs9870680	0.505	rs1450097	chr3:7545521	C/T	cg01296532	chr3:157217187	VEPH1	-0.39	-6.23	-0.38	2.14e-9	Major depressive disorder (broad);
SARC	cis	rs7208859	0.524	rs11653098	chr17:29122501	C/T	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs11770686	0.659	rs2705797	chr7:75308923	T/C	cg17787366	chr7:75369077	HIP1	0.4	5.04	0.31	9.5e-7	Essential tremor;
SARC	cis	rs6762477	0.748	rs11717349	chr3:50223977	C/T	cg24110177	chr3:50126178	RBM5	0.47	6.13	0.37	3.66e-9	Menarche (age at onset);
SARC	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg11987759	chr7:65425863	GUSB	-0.59	-8.0	-0.46	5.91e-14	Calcium levels;
SARC	cis	rs3733585	0.674	rs7375643	chr4:9955239	A/G	cg11266682	chr4:10021025	SLC2A9	-0.39	-7.0	-0.42	2.7e-11	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs3857536	0.904	rs4710576	chr6:66897994	A/G	cg07460842	chr6:66804631	NA	-0.44	-5.27	-0.33	3.08e-7	Blood trace element (Cu levels);
SARC	cis	rs9457247	0.730	rs9459841	chr6:167431949	G/A	cg23791538	chr6:167370224	RNASET2	-0.49	-6.59	-0.4	2.97e-10	Crohn's disease;
SARC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.99	12.23	0.63	6.97e-27	Platelet count;
SARC	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg07701084	chr6:150067640	NUP43	0.41	5.39	0.33	1.68e-7	Lung cancer;
SARC	cis	rs17030434	1.000	rs10026531	chr4:154727070	C/T	cg14289246	chr4:154710475	SFRP2	-0.74	-7.35	-0.43	3.26e-12	Electrocardiographic conduction measures;
SARC	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg03433033	chr1:76189801	ACADM	0.54	7.65	0.45	5.14e-13	Blood metabolite levels;Acylcarnitine levels;
SARC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg24109975	chr19:59055787	TRIM28	0.48	6.34	0.38	1.19e-9	Colonoscopy-negative controls vs population controls;
SARC	cis	rs554111	0.963	rs666371	chr1:21041555	A/G	cg08890418	chr1:21044141	KIF17	0.56	7.8	0.46	2.05e-13	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg13628971	chr7:2884303	GNA12	0.6	7.15	0.42	1.12e-11	Height;
SARC	cis	rs9290065	0.519	rs7635796	chr3:160674689	G/C	cg04691961	chr3:161091175	C3orf57	-0.5	-6.48	-0.39	5.35e-10	Kawasaki disease;
SARC	cis	rs6964587	1.000	rs2282968	chr7:91580287	A/C	cg17063962	chr7:91808500	NA	-0.95	-14.91	-0.7	9.58e-36	Breast cancer;
SARC	cis	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg09021430	chr5:549028	NA	-0.44	-5.69	-0.35	3.87e-8	Obesity-related traits;
SARC	cis	rs7481584	0.624	rs421196	chr11:3048582	T/G	cg05729581	chr11:3078854	CARS	0.57	7.4	0.44	2.45e-12	Calcium levels;
SARC	cis	rs1790761	0.632	rs625978	chr11:67344664	C/T	cg00290607	chr11:67383545	NA	0.39	5.28	0.33	3.01e-7	Mean corpuscular volume;
SARC	cis	rs9399135	0.967	rs4896120	chr6:135293512	C/G	cg24558204	chr6:135376177	HBS1L	0.44	5.91	0.36	1.2e-8	Red blood cell count;
SARC	trans	rs9929218	0.551	rs2296406	chr16:68721340	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.87	15.54	0.71	7.71e-38	Colorectal cancer;
SARC	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.49	5.44	0.34	1.36e-7	Renal function-related traits (BUN);
SARC	cis	rs765787	0.530	rs1648285	chr15:45517505	C/G	cg25801113	chr15:45476975	SHF	0.29	4.73	0.3	3.85e-6	Uric acid levels;
SARC	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg08493051	chr2:3487164	NA	-0.42	-5.32	-0.33	2.42e-7	Neurofibrillary tangles;
SARC	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg08859206	chr1:53392774	SCP2	0.43	6.22	0.38	2.31e-9	Monocyte count;
SARC	cis	rs4242434	0.819	rs720745	chr8:22471147	G/T	cg03733263	chr8:22462867	KIAA1967	0.93	15.45	0.71	1.47e-37	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs6665290	0.835	rs7549465	chr1:227214399	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.03	-22.2	-0.82	2.07e-59	Myeloid white cell count;
SARC	trans	rs1853207	1.000	rs17110321	chr10:96639896	A/G	cg02737782	chr1:8014393	NA	-1.09	-6.59	-0.4	2.89e-10	Blood metabolite levels;
SARC	cis	rs17376456	0.569	rs35878747	chr5:93094070	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.56	5.82	0.36	1.96e-8	Diabetic retinopathy;
SARC	cis	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg09021430	chr5:549028	NA	-0.45	-5.77	-0.35	2.57e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg11890956	chr21:40555474	PSMG1	-0.68	-9.08	-0.51	4.76e-17	Menarche (age at onset);
SARC	cis	rs2635047	0.615	rs2576052	chr18:44690107	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.44	-5.4	-0.33	1.68e-7	Educational attainment;
SARC	cis	rs660899	0.578	rs61768408	chr1:44220747	G/A	cg19824710	chr1:43995379	PTPRF	0.44	4.86	0.3	2.17e-6	Hypertension risk in short sleep duration;
SARC	cis	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg06212747	chr3:49208901	KLHDC8B	0.53	6.56	0.39	3.41e-10	Resting heart rate;
SARC	cis	rs7829975	0.502	rs7820738	chr8:8702607	C/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.4	-0.44	2.41e-12	Mood instability;
SARC	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg11062466	chr8:58055876	NA	0.61	5.75	0.35	2.74e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs35123781	0.696	rs13154510	chr5:139071301	A/C	cg10513866	chr5:139070639	NA	0.35	4.79	0.3	2.94e-6	Schizophrenia;
SARC	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg19761014	chr17:28927070	LRRC37B2	0.55	4.95	0.31	1.39e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg03607946	chr20:34203965	SPAG4	-0.8	-6.48	-0.39	5.33e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1355223	0.902	rs1901831	chr11:34725175	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-5.31	-0.33	2.6e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg00071950	chr4:10020882	SLC2A9	0.38	6.23	0.38	2.2e-9	Bone mineral density;
SARC	cis	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg13072238	chr3:49761600	GMPPB	0.42	5.18	0.32	4.75e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7312933	0.612	rs10785334	chr12:42620377	A/G	cg19980929	chr12:42632907	YAF2	-0.43	-5.77	-0.35	2.48e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs733592	0.507	rs56129148	chr12:48485530	T/C	cg21466736	chr12:48725269	NA	0.31	5.5	0.34	1.01e-7	Plateletcrit;
SARC	trans	rs7016717	1.000	rs10504653	chr8:78405264	T/C	cg09446250	chr11:82430349	NA	0.97	6.23	0.38	2.15e-9	Resistance to antihypertensive treatment in hypertension;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg12577610	chr17:61920423	SMARCD2	0.77	6.41	0.39	7.95e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs3733585	0.699	rs28610447	chr4:9971517	T/C	cg00071950	chr4:10020882	SLC2A9	-0.37	-5.6	-0.34	6.11e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs1957429	0.561	rs92070	chr14:65239877	C/T	cg23373153	chr14:65346875	NA	-0.5	-4.92	-0.31	1.65e-6	Pediatric areal bone mineral density (radius);
SARC	cis	rs2204008	0.837	rs2387317	chr12:38235319	T/C	cg13010199	chr12:38710504	ALG10B	0.81	11.19	0.59	1.48e-23	Bladder cancer;
SARC	cis	rs3820928	1.000	rs10210763	chr2:227776029	G/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-6.81	-0.41	8.13e-11	Pulmonary function;
SARC	cis	rs7659604	0.840	rs6821305	chr4:122713863	A/C	cg20573242	chr4:122745356	CCNA2	0.55	7.06	0.42	1.91e-11	Type 2 diabetes;
SARC	cis	rs7312774	0.618	rs4964503	chr12:107335937	C/G	cg16260113	chr12:107380972	MTERFD3	-1.02	-8.15	-0.47	2.27e-14	Severe influenza A (H1N1) infection;
SARC	cis	rs10191773	0.589	rs6761440	chr2:112959193	G/A	cg07905836	chr2:113190072	RGPD8;RGPD5	0.88	7.54	0.44	1.07e-12	Yeast infection;
SARC	cis	rs340874	0.703	rs340835	chr1:214163675	C/T	cg24083324	chr1:214162604	PROX1	0.36	5.42	0.33	1.48e-7	Type 2 diabetes;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;Fasting blood glucose;
SARC	trans	rs61931739	0.534	rs1826144	chr12:34094272	A/G	cg13010199	chr12:38710504	ALG10B	0.77	10.37	0.56	5.83e-21	Morning vs. evening chronotype;
SARC	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg12042659	chr19:58951599	ZNF132	0.41	5.47	0.34	1.15e-7	Uric acid clearance;
SARC	cis	rs10752881	0.935	rs10797834	chr1:183048749	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.08	0.55	4.44e-20	Colorectal cancer;
SARC	cis	rs870825	0.698	rs7673203	chr4:185625397	T/C	cg04058563	chr4:185651563	MLF1IP	0.81	11.38	0.6	3.74e-24	Blood protein levels;
SARC	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg04166393	chr7:2884313	GNA12	0.48	5.59	0.34	6.26e-8	Height;
SARC	trans	rs2727020	0.595	rs7924311	chr11:49507573	G/A	cg15704280	chr7:45808275	SEPT13	-0.87	-14.33	-0.68	7.94e-34	Coronary artery disease;
SARC	cis	rs2046867	0.818	rs62249860	chr3:72866073	T/G	cg25664220	chr3:72788482	NA	-0.29	-4.83	-0.3	2.49e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
SARC	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg09455208	chr3:40491958	NA	0.4	5.85	0.36	1.66e-8	Renal cell carcinoma;
SARC	cis	rs34779708	0.931	rs12261654	chr10:35322024	G/A	cg03585969	chr10:35415529	CREM	0.39	4.99	0.31	1.16e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs2228479	0.557	rs62054639	chr16:89821489	C/T	cg06558623	chr16:89946397	TCF25	0.88	6.21	0.38	2.39e-9	Skin colour saturation;
SARC	trans	rs11098499	0.954	rs12502423	chr4:120424172	A/C	cg25214090	chr10:38739885	LOC399744	0.58	7.47	0.44	1.63e-12	Corneal astigmatism;
SARC	cis	rs7772486	0.790	rs9497424	chr6:146225271	C/A	cg23711669	chr6:146136114	FBXO30	-0.76	-11.9	-0.61	7.75e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg26681399	chr22:41777847	TEF	0.5	5.32	0.33	2.47e-7	Vitiligo;
SARC	cis	rs1018836	0.847	rs4735226	chr8:91569238	T/A	cg16814680	chr8:91681699	NA	-0.82	-12.94	-0.65	3.26e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs8067545	0.967	rs1034904	chr17:19927699	A/G	cg13482628	chr17:19912719	NA	-0.59	-8.48	-0.49	2.58e-15	Schizophrenia;
SARC	cis	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.41	5.17	0.32	5.06e-7	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs1707322	0.752	rs11211152	chr1:46114157	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.25	0.38	1.97e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9914544	0.545	rs4924944	chr17:18810002	C/T	cg25390199	chr17:18761479	PRPSAP2	0.44	5.81	0.36	2.05e-8	Educational attainment (years of education);
SARC	cis	rs35306767	0.623	rs56201968	chr10:1141666	A/G	cg18964960	chr10:1102726	WDR37	0.5	5.22	0.32	3.98e-7	Eosinophil percentage of granulocytes;
SARC	trans	rs7824557	0.527	rs10109537	chr8:11239640	C/T	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.72	-0.45	3.43e-13	Retinal vascular caliber;
SARC	cis	rs11098499	0.644	rs3806808	chr4:120551085	A/C	cg09307838	chr4:120376055	NA	0.75	10.21	0.56	1.84e-20	Corneal astigmatism;
SARC	cis	rs6815814	0.851	rs11466645	chr4:38778203	A/T	cg06935464	chr4:38784597	TLR10	0.63	5.98	0.36	8.46e-9	Breast cancer;
SARC	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg14893161	chr1:205819251	PM20D1	0.47	5.27	0.33	3.17e-7	Parkinson's disease;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20014441	chr20:42086101	SFRS6	-0.51	-6.65	-0.4	2.08e-10	Smoking initiation;
SARC	cis	rs1003719	0.788	rs2835595	chr21:38466203	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.63	9.05	0.51	5.67e-17	Eye color traits;
SARC	cis	rs28374715	0.681	rs59000092	chr15:41626148	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.96	-14.98	-0.7	5.42e-36	Ulcerative colitis;
SARC	cis	rs9291683	0.566	rs13115776	chr4:10040189	C/G	cg00071950	chr4:10020882	SLC2A9	0.34	5.05	0.31	8.92e-7	Bone mineral density;
SARC	cis	rs1594829	0.535	rs1434022	chr8:26153222	G/A	cg11498726	chr8:26250323	BNIP3L	-0.4	-5.27	-0.33	3.09e-7	Height;
SARC	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg13877915	chr19:58951672	ZNF132	0.65	9.47	0.53	3.33e-18	Uric acid clearance;
SARC	cis	rs2486288	0.656	rs8041702	chr15:45547093	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.56	-7.26	-0.43	5.83e-12	Glomerular filtration rate;
SARC	cis	rs12348691	0.503	rs7849497	chr9:100615660	G/C	cg13688889	chr9:100608707	NA	-0.47	-5.0	-0.31	1.15e-6	Alopecia areata;
SARC	trans	rs2727020	0.729	rs588458	chr11:49214048	C/A	cg03929089	chr4:120376271	NA	0.77	10.64	0.57	8.3e-22	Coronary artery disease;
SARC	cis	rs10089	0.552	rs59430737	chr5:127557568	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.58	5.97	0.36	8.94e-9	Ileal carcinoids;
SARC	cis	rs4268898	1.000	rs6707781	chr2:24441883	T/G	cg26838691	chr2:24397539	C2orf84	0.37	5.09	0.32	7.5e-7	Asthma;
SARC	cis	rs13256369	0.755	rs12550057	chr8:8562268	G/A	cg17143192	chr8:8559678	CLDN23	0.52	5.83	0.36	1.86e-8	Obesity-related traits;
SARC	cis	rs10276381	1.000	rs10280937	chr7:28182306	T/C	cg23620719	chr7:28220237	JAZF1	0.71	5.78	0.35	2.42e-8	Crohn's disease;
SARC	cis	rs3820928	0.874	rs2396452	chr2:227838040	T/G	cg05526886	chr2:227700861	RHBDD1	-0.56	-6.86	-0.41	6.12e-11	Pulmonary function;
SARC	cis	rs2439831	0.850	rs7168158	chr15:44050376	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	8.57	0.49	1.44e-15	Lung cancer in ever smokers;
SARC	cis	rs17384381	1.000	rs12123745	chr1:85884772	T/C	cg16011679	chr1:85725395	C1orf52	0.61	5.66	0.35	4.32e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs17125944	0.505	rs75296244	chr14:53233218	G/A	cg13660082	chr14:53194042	PSMC6	-0.75	-4.76	-0.3	3.41e-6	Alzheimer's disease (late onset);
SARC	cis	rs12586317	0.620	rs28870452	chr14:35536878	C/A	cg26967526	chr14:35346199	BAZ1A	-0.63	-6.66	-0.4	1.99e-10	Psoriasis;
SARC	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg26818010	chr10:134567672	INPP5A	-0.62	-6.49	-0.39	5.08e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs765787	0.530	rs12905246	chr15:45500841	C/T	cg26924012	chr15:45694286	SPATA5L1	0.42	5.05	0.31	9.06e-7	Uric acid levels;
SARC	cis	rs2832191	0.671	rs2832212	chr21:30511417	G/A	cg24692254	chr21:30365293	RNF160	-0.68	-8.19	-0.47	1.73e-14	Dental caries;
SARC	cis	rs1003719	0.788	rs13050757	chr21:38465345	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.63	9.05	0.51	5.67e-17	Eye color traits;
SARC	cis	rs1153858	0.723	rs4580098	chr15:45596909	T/A	cg26924012	chr15:45694286	SPATA5L1	0.74	9.47	0.53	3.27e-18	Homoarginine levels;
SARC	cis	rs7666738	0.800	rs7683737	chr4:99070880	A/T	cg05340658	chr4:99064831	C4orf37	0.65	8.71	0.5	5.79e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7246657	0.882	rs6508719	chr19:37877419	A/G	cg14683738	chr19:37701593	ZNF585B	0.49	4.76	0.3	3.47e-6	Coronary artery calcification;
SARC	cis	rs72781680	0.611	rs72797819	chr2:24351141	T/G	cg06627628	chr2:24431161	ITSN2	-0.5	-5.0	-0.31	1.14e-6	Lymphocyte counts;
SARC	cis	rs3768617	0.811	rs6424883	chr1:183037695	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	8.0	0.46	5.99e-14	Fuchs's corneal dystrophy;
SARC	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.94	-13.78	-0.67	5.54e-32	Gut microbiome composition (summer);
SARC	cis	rs1395	1.000	rs1275530	chr2:27432547	A/G	cg21747090	chr2:27597821	SNX17	0.38	4.72	0.3	4.03e-6	Blood metabolite levels;
SARC	cis	rs9807989	0.507	rs6706002	chr2:103006104	A/G	cg03938978	chr2:103052716	IL18RAP	0.32	5.16	0.32	5.28e-7	Asthma;
SARC	cis	rs6964587	0.967	rs7786031	chr7:91649001	T/G	cg17063962	chr7:91808500	NA	0.93	15.78	0.72	1.19e-38	Breast cancer;
SARC	cis	rs13256369	0.851	rs13255061	chr8:8563834	G/A	cg18904891	chr8:8559673	CLDN23	0.49	5.55	0.34	7.83e-8	Obesity-related traits;
SARC	cis	rs17401966	0.931	rs11587854	chr1:10447622	G/A	cg15208524	chr1:10270712	KIF1B	0.5	6.0	0.37	7.68e-9	Hepatocellular carcinoma;
SARC	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg06028808	chr11:68637592	NA	0.45	5.56	0.34	7.45e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg06634786	chr22:41940651	POLR3H	-0.58	-6.79	-0.41	9.11e-11	Vitiligo;
SARC	cis	rs11785400	0.793	rs2976399	chr8:143746050	C/T	cg10596483	chr8:143751796	JRK	0.56	7.11	0.42	1.39e-11	Schizophrenia;
SARC	cis	rs6669919	1.000	rs6669919	chr1:211674383	T/C	cg10512769	chr1:211675356	NA	-0.28	-4.72	-0.3	4.02e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg18252515	chr7:66147081	NA	1.29	11.12	0.59	2.48e-23	Diabetic kidney disease;
SARC	cis	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg07636037	chr3:49044803	WDR6	0.63	8.4	0.48	4.49e-15	Resting heart rate;
SARC	cis	rs11651000	0.857	rs57171311	chr17:45826168	A/G	cg03474202	chr17:45855739	NA	-0.44	-6.1	-0.37	4.36e-9	IgG glycosylation;
SARC	cis	rs6424115	1.000	rs974698	chr1:24132785	C/T	cg15997130	chr1:24165203	NA	0.48	6.66	0.4	1.94e-10	Immature fraction of reticulocytes;
SARC	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.65	-6.79	-0.41	9.33e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs72720396	0.789	rs10922910	chr1:91199862	G/T	cg24453699	chr1:91190891	NA	0.37	4.94	0.31	1.52e-6	Morning vs. evening chronotype;Chronotype;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg24424146	chr6:126070718	HEY2	-0.46	-6.26	-0.38	1.86e-9	Neuroticism;
SARC	trans	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-7.11	-0.42	1.4e-11	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg11987759	chr7:65425863	GUSB	0.5	6.22	0.38	2.29e-9	Aortic root size;
SARC	cis	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg11995313	chr8:8860691	ERI1	0.39	4.78	0.3	3.05e-6	Joint mobility (Beighton score);
SARC	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg16405210	chr4:1374714	KIAA1530	-0.49	-5.69	-0.35	3.78e-8	Obesity-related traits;
SARC	cis	rs11098499	0.754	rs2036857	chr4:120249240	T/C	cg09307838	chr4:120376055	NA	0.82	11.14	0.59	2.19e-23	Corneal astigmatism;
SARC	cis	rs4423214	0.592	rs10898186	chr11:71188800	G/A	cg05163923	chr11:71159392	DHCR7	-0.49	-4.96	-0.31	1.34e-6	Vitamin D levels;
SARC	trans	rs1814175	0.645	rs1851857	chr11:49855589	A/C	cg15704280	chr7:45808275	SEPT13	-0.87	-13.88	-0.67	2.59e-32	Height;
SARC	cis	rs992157	0.798	rs12053514	chr2:219167965	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.65	-9.15	-0.51	2.86e-17	Colorectal cancer;
SARC	cis	rs2273669	0.667	rs11755471	chr6:109342169	T/C	cg05315195	chr6:109294784	ARMC2	-0.63	-5.73	-0.35	3.16e-8	Prostate cancer;
SARC	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg13393036	chr8:95962371	TP53INP1	-0.32	-5.39	-0.33	1.69e-7	Type 2 diabetes;
SARC	cis	rs910316	0.763	rs13712	chr14:75483812	T/C	cg08847533	chr14:75593920	NEK9	0.86	12.86	0.64	5.95e-29	Height;
SARC	cis	rs826838	1.000	rs11514441	chr12:38775190	C/T	cg26384229	chr12:38710491	ALG10B	0.95	15.46	0.71	1.43e-37	Heart rate;
SARC	cis	rs7551222	0.752	rs10900599	chr1:204541943	T/C	cg20240347	chr1:204465584	NA	-0.33	-5.81	-0.36	2.09e-8	Schizophrenia;
SARC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.67	0.54	7.99e-19	Prudent dietary pattern;
SARC	cis	rs3126085	0.935	rs7537637	chr1:152223335	T/A	cg26876637	chr1:152193138	HRNR	0.45	5.34	0.33	2.24e-7	Atopic dermatitis;
SARC	cis	rs35164067	0.708	rs1051738	chr19:10577843	G/T	cg21868191	chr19:10515988	NA	-0.44	-5.57	-0.34	6.9e-8	Inflammatory bowel disease;
SARC	cis	rs6728642	1.000	rs60608738	chr2:97608085	G/A	cg26665480	chr2:98280029	ACTR1B	-0.56	-4.96	-0.31	1.38e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs911555	0.546	rs28798508	chr14:104068970	T/C	cg17925084	chr14:104152323	KLC1	0.39	5.45	0.34	1.27e-7	Intelligence (multi-trait analysis);
SARC	cis	rs76917914	0.954	rs3739672	chr9:100745902	A/G	cg03040243	chr9:100819229	NANS	0.6	6.27	0.38	1.75e-9	Immature fraction of reticulocytes;
SARC	cis	rs72945132	0.882	rs66627443	chr11:70199036	C/G	cg05964544	chr11:70165517	PPFIA1	-0.56	-5.37	-0.33	1.93e-7	Coronary artery disease;
SARC	cis	rs9640161	0.789	rs1464751	chr7:150021282	C/T	cg21361702	chr7:150065534	REPIN1	0.48	5.01	0.31	1.08e-6	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs57221529	0.608	rs11749927	chr5:668842	C/T	cg14541582	chr5:601475	NA	-0.37	-4.81	-0.3	2.66e-6	Lung disease severity in cystic fibrosis;
SARC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg07332563	chr6:291687	DUSP22	-0.59	-7.97	-0.46	6.84e-14	Menopause (age at onset);
SARC	cis	rs7937890	0.810	rs10734224	chr11:14424124	G/T	cg02886208	chr11:14281011	SPON1	-0.36	-4.85	-0.3	2.27e-6	Mitochondrial DNA levels;
SARC	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg08392591	chr16:89556376	ANKRD11	0.61	8.64	0.49	8.94e-16	Multiple myeloma (IgH translocation);
SARC	cis	rs3815700	1.000	rs8104726	chr19:33094675	G/A	cg24916020	chr19:33096688	ANKRD27	0.57	5.47	0.34	1.15e-7	Eosinophilic esophagitis;
SARC	cis	rs7666738	0.791	rs10005118	chr4:99038196	A/C	cg05340658	chr4:99064831	C4orf37	0.66	8.84	0.5	2.39e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg16405210	chr4:1374714	KIAA1530	-0.47	-5.61	-0.35	5.64e-8	Obesity-related traits;
SARC	cis	rs10463554	0.963	rs3776860	chr5:102349970	G/C	cg23492399	chr5:102201601	PAM	-0.47	-5.32	-0.33	2.43e-7	Parkinson's disease;
SARC	cis	rs735539	0.521	rs2763001	chr13:21378018	A/C	cg16922012	chr13:21400325	XPO4	-0.43	-5.78	-0.35	2.34e-8	Dental caries;
SARC	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg25811766	chr13:21894605	NA	0.69	9.24	0.52	1.64e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs9325144	0.647	rs35254764	chr12:39102928	T/C	cg13010199	chr12:38710504	ALG10B	-0.52	-6.47	-0.39	5.68e-10	Morning vs. evening chronotype;
SARC	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg13628971	chr7:2884303	GNA12	0.49	5.71	0.35	3.46e-8	Height;
SARC	cis	rs3820928	0.874	rs6740108	chr2:227889559	G/T	cg05526886	chr2:227700861	RHBDD1	0.45	5.21	0.32	4.19e-7	Pulmonary function;
SARC	cis	rs12754538	0.734	rs12568634	chr1:8815935	G/C	cg13785123	chr1:8931135	ENO1	-0.5	-5.94	-0.36	1.04e-8	Subjective well-being;
SARC	cis	rs7592578	0.882	rs61117285	chr2:191468986	G/C	cg27211696	chr2:191398769	TMEM194B	-0.52	-5.46	-0.34	1.25e-7	Diastolic blood pressure;
SARC	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	9.93	0.55	1.32e-19	Platelet count;
SARC	cis	rs2854207	0.505	rs2466957	chr17:61961230	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	6.53	0.39	4.06e-10	Height;
SARC	cis	rs7818345	0.967	rs4391454	chr8:19275653	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.41	5.57	0.34	7.15e-8	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs6831352	0.918	rs17218288	chr4:100058030	A/T	cg12011299	chr4:100065546	ADH4	-0.34	-5.68	-0.35	4.08e-8	Alcohol dependence;
SARC	cis	rs12681288	0.578	rs56702775	chr8:968860	G/A	cg04851639	chr8:1020857	NA	-0.29	-4.89	-0.3	1.91e-6	Schizophrenia;
SARC	cis	rs16912285	0.535	rs6484040	chr11:24309809	C/A	ch.11.24196551F	chr11:24239977	NA	0.59	6.0	0.37	7.36e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg13126279	chr21:47581558	C21orf56	0.42	4.91	0.31	1.71e-6	Testicular germ cell tumor;
SARC	cis	rs193541	0.632	rs1460040	chr5:122105232	A/G	cg19412675	chr5:122181750	SNX24	0.45	5.93	0.36	1.08e-8	Glucose homeostasis traits;
SARC	cis	rs9914544	0.564	rs7223173	chr17:18805887	A/G	cg25390199	chr17:18761479	PRPSAP2	0.45	5.94	0.36	1.03e-8	Educational attainment (years of education);
SARC	cis	rs2816062	0.775	rs2816048	chr1:18893763	T/C	cg10574377	chr1:18908098	NA	0.37	5.26	0.33	3.21e-7	Urate levels in lean individuals;
SARC	cis	rs4727027	0.933	rs6955564	chr7:148866173	A/G	cg23583168	chr7:148888333	NA	-0.63	-9.15	-0.51	2.99e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs16854884	0.586	rs13081286	chr3:143723757	A/T	cg06585982	chr3:143692056	C3orf58	0.7	9.84	0.54	2.42e-19	Economic and political preferences (feminism/equality);
SARC	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg04518342	chr5:131593106	PDLIM4	0.36	5.07	0.32	8.05e-7	Breast cancer;
SARC	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg07636037	chr3:49044803	WDR6	0.91	15.44	0.71	1.58e-37	Menarche (age at onset);
SARC	cis	rs9400467	0.506	rs12198556	chr6:111662338	C/T	cg15721981	chr6:111408429	SLC16A10	0.65	5.65	0.35	4.61e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs12052479	0.614	rs2290563	chr2:173433186	A/T	cg17679246	chr2:173420265	PDK1	0.46	4.77	0.3	3.28e-6	Blood protein levels;
SARC	cis	rs721399	1.000	rs4646249	chr8:18260431	T/G	cg18736775	chr8:18248649	NAT2	0.43	5.57	0.34	6.89e-8	Blood metabolite levels;
SARC	cis	rs7772486	0.869	rs2777473	chr6:146301494	G/A	cg23711669	chr6:146136114	FBXO30	0.74	11.21	0.59	1.31e-23	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6582630	0.615	rs11182380	chr12:38511735	G/T	cg26384229	chr12:38710491	ALG10B	-0.58	-7.34	-0.43	3.5e-12	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	7.07	0.42	1.81e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.74	-10.81	-0.58	2.44e-22	Intelligence (multi-trait analysis);
SARC	cis	rs7005380	0.581	rs2176750	chr8:120937700	T/C	cg21744203	chr8:120868354	DSCC1	0.45	5.29	0.33	2.75e-7	Interstitial lung disease;
SARC	cis	rs79149102	0.579	rs7172989	chr15:75295905	C/T	cg00629941	chr15:75287862	SCAMP5	-0.64	-5.11	-0.32	6.76e-7	Lung cancer;
SARC	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg00933542	chr6:150070202	PCMT1	0.32	5.4	0.33	1.68e-7	Lung cancer;
SARC	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg22004693	chr7:99632812	ZKSCAN1	0.54	5.48	0.34	1.08e-7	Lung function (FEV1/FVC);
SARC	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg04518342	chr5:131593106	PDLIM4	-0.47	-5.73	-0.35	3.02e-8	Breast cancer;
SARC	cis	rs9858542	0.953	rs3811699	chr3:49396360	T/C	cg03060546	chr3:49711283	APEH	-0.57	-7.14	-0.42	1.19e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs8028182	0.636	rs28432989	chr15:75768297	T/C	cg20655648	chr15:75932815	IMP3	0.63	7.52	0.44	1.19e-12	Sudden cardiac arrest;
SARC	cis	rs155076	1.000	rs2478824	chr13:21844144	G/C	cg06138931	chr13:21896616	NA	-0.39	-5.08	-0.32	7.88e-7	White matter hyperintensity burden;
SARC	trans	rs11039798	0.588	rs10838970	chr11:48606267	G/T	cg15704280	chr7:45808275	SEPT13	0.6	6.35	0.38	1.12e-9	Axial length;
SARC	cis	rs1707322	1.000	rs12097761	chr1:46291162	T/C	cg03146154	chr1:46216737	IPP	0.5	6.08	0.37	4.93e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs698813	0.789	rs2592195	chr2:44607707	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.63	7.58	0.44	8.01e-13	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs67460515	0.892	rs6780536	chr3:161058726	T/C	cg17135325	chr3:160939158	NMD3	0.61	7.77	0.45	2.42e-13	Parkinson's disease;
SARC	trans	rs698833	0.926	rs1067342	chr2:44622256	A/C	cg19364021	chr13:53776396	NA	0.45	6.27	0.38	1.72e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs6580649	0.941	rs17122612	chr12:48459488	C/G	cg05342945	chr12:48394962	COL2A1	0.58	6.22	0.38	2.23e-9	Lung cancer;
SARC	cis	rs17376456	0.825	rs13361613	chr5:93272176	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.67	6.14	0.37	3.48e-9	Diabetic retinopathy;
SARC	cis	rs317689	0.918	rs689415	chr12:69738139	A/G	cg20891283	chr12:69753455	YEATS4	-0.45	-5.04	-0.31	9.49e-7	Response to diuretic therapy;
SARC	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg11890956	chr21:40555474	PSMG1	-1.04	-14.82	-0.7	1.83e-35	Cognitive function;
SARC	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg08125733	chr17:73851984	WBP2	0.65	7.11	0.42	1.42e-11	Psoriasis;
SARC	cis	rs2153535	0.580	rs7767756	chr6:8453428	A/C	cg07606381	chr6:8435919	SLC35B3	0.78	11.13	0.59	2.34e-23	Motion sickness;
SARC	cis	rs1008375	1.000	rs28693609	chr4:17645233	C/T	cg02297831	chr4:17616191	MED28	0.51	6.48	0.39	5.37e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7005606	1.000	rs4733356	chr8:32407453	A/T	cg14488905	chr8:32406789	NRG1	0.45	6.31	0.38	1.42e-9	Hirschsprung disease;
SARC	cis	rs763121	0.853	rs3747174	chr22:39069181	T/C	cg06022373	chr22:39101656	GTPBP1	0.86	10.88	0.58	1.41e-22	Menopause (age at onset);
SARC	cis	rs4763879	0.752	rs10772083	chr12:9874898	T/C	cg27502298	chr12:9555721	NA	-0.44	-4.93	-0.31	1.56e-6	Type 1 diabetes;
SARC	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg11366901	chr6:160182831	ACAT2	1.03	10.98	0.58	7.22e-23	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs2204008	0.840	rs11181795	chr12:38401129	A/G	cg13010199	chr12:38710504	ALG10B	0.77	10.42	0.56	4.05e-21	Bladder cancer;
SARC	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg12550574	chr4:177240810	SPCS3	-0.46	-6.5	-0.39	4.88e-10	Cancer;
SARC	cis	rs2228479	0.681	rs10153196	chr16:89967397	A/C	cg06558623	chr16:89946397	TCF25	0.77	6.37	0.39	1e-9	Skin colour saturation;
SARC	cis	rs12908161	0.959	rs17598603	chr15:85200211	C/G	cg17507749	chr15:85114479	UBE2QP1	-0.49	-5.24	-0.32	3.62e-7	Schizophrenia;
SARC	cis	rs711245	0.573	rs3770796	chr2:36799515	T/C	cg09467607	chr2:36825704	FEZ2	0.57	7.78	0.45	2.38e-13	Height;
SARC	cis	rs12142240	0.698	rs41294456	chr1:46809782	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-5.45	-0.34	1.28e-7	Menopause (age at onset);
SARC	cis	rs8077889	0.750	rs231535	chr17:41944865	T/G	cg26893861	chr17:41843967	DUSP3	-0.73	-7.24	-0.43	6.46e-12	Triglycerides;
SARC	cis	rs7223966	1.000	rs55674647	chr17:61794195	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.46	4.73	0.3	3.89e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs11785400	0.731	rs4294163	chr8:143730830	G/T	cg24634471	chr8:143751801	JRK	0.6	7.74	0.45	2.98e-13	Schizophrenia;
SARC	cis	rs7772486	0.566	rs735536	chr6:146036832	A/C	cg05347473	chr6:146136440	FBXO30	-0.5	-6.91	-0.41	4.66e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg08859206	chr1:53392774	SCP2	0.39	5.53	0.34	8.44e-8	Monocyte count;
SARC	cis	rs6570726	0.791	rs405206	chr6:145836873	C/A	cg23711669	chr6:146136114	FBXO30	0.87	14.58	0.69	1.18e-34	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2011503	1.000	rs11669558	chr19:19655670	C/T	cg15839431	chr19:19639596	YJEFN3	-0.49	-4.92	-0.31	1.63e-6	Bipolar disorder;
SARC	cis	rs7481584	1.000	rs12804412	chr11:3020782	G/A	cg25174290	chr11:3078921	CARS	-0.51	-6.59	-0.4	2.98e-10	Calcium levels;
SARC	cis	rs34779708	0.931	rs34304999	chr10:35365705	C/T	cg03585969	chr10:35415529	CREM	0.38	4.78	0.3	3.13e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg09033563	chr22:24373618	LOC391322	-0.49	-6.03	-0.37	6.33e-9	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2439831	1.000	rs2439831	chr15:43784475	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	8.18	0.47	1.85e-14	Lung cancer in ever smokers;
SARC	trans	rs208520	0.690	rs851465	chr6:66840293	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-13.77	-0.67	5.95e-32	Exhaled nitric oxide output;
SARC	cis	rs7296418	0.885	rs1790104	chr12:123709409	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-5.27	-0.33	3.05e-7	Platelet count;
SARC	trans	rs12310956	0.510	rs10844694	chr12:33865682	A/C	cg26384229	chr12:38710491	ALG10B	0.61	8.03	0.47	4.97e-14	Morning vs. evening chronotype;
SARC	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg10523679	chr1:76189770	ACADM	0.42	5.26	0.33	3.26e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs751728	1.000	rs9380378	chr6:33765479	T/C	cg15252951	chr6:33757062	LEMD2	0.57	6.66	0.4	1.91e-10	Crohn's disease;
SARC	cis	rs7223966	1.000	rs9912904	chr17:61763534	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.53	-5.79	-0.35	2.31e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg17081801	chr17:57696709	CLTC	-0.5	-6.27	-0.38	1.7e-9	Schizophrenia;
SARC	cis	rs35110281	0.840	rs7276633	chr21:45078800	C/T	cg01579765	chr21:45077557	HSF2BP	-0.33	-5.41	-0.33	1.59e-7	Mean corpuscular volume;
SARC	cis	rs12579753	0.917	rs7138895	chr12:82203280	T/G	cg07988820	chr12:82153109	PPFIA2	-0.52	-6.11	-0.37	4.18e-9	Resting heart rate;
SARC	cis	rs2075371	0.829	rs35897242	chr7:134004041	G/A	cg00033643	chr7:134001901	SLC35B4	0.47	5.66	0.35	4.33e-8	Mean platelet volume;
SARC	cis	rs73086581	0.787	rs67202952	chr20:3869099	A/C	cg02187196	chr20:3869020	PANK2	0.67	5.88	0.36	1.38e-8	Response to antidepressants in depression;
SARC	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg08219700	chr8:58056026	NA	0.61	6.35	0.38	1.13e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1843834	0.539	rs12694643	chr2:225446603	A/G	cg22455342	chr2:225449267	CUL3	0.68	8.57	0.49	1.41e-15	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs4253772	0.678	rs9627281	chr22:46644168	A/G	cg24881330	chr22:46731750	TRMU	0.54	5.99	0.37	8.05e-9	LDL cholesterol;Cholesterol, total;
SARC	cis	rs992157	0.732	rs10932771	chr2:219170236	A/T	cg00012203	chr2:219082015	ARPC2	0.65	9.49	0.53	2.94e-18	Colorectal cancer;
SARC	cis	rs1153858	1.000	rs1890565	chr15:45663299	T/C	cg03999130	chr15:45571217	NA	0.39	5.04	0.31	9.27e-7	Homoarginine levels;
SARC	cis	rs6089829	0.692	rs6122349	chr20:61664096	T/C	cg08045932	chr20:61659980	NA	0.42	5.0	0.31	1.11e-6	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg26681399	chr22:41777847	TEF	-0.48	-5.24	-0.32	3.68e-7	Vitiligo;
SARC	cis	rs7762018	0.607	rs7759404	chr6:170135728	A/G	cg15038512	chr6:170123185	PHF10	0.53	4.93	0.31	1.58e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs870825	0.929	rs72689266	chr4:185591053	T/C	cg04058563	chr4:185651563	MLF1IP	0.79	8.8	0.5	3.22e-16	Blood protein levels;
SARC	cis	rs2760061	0.583	rs708110	chr1:228190805	T/A	cg01200585	chr1:228362443	C1orf69	0.46	5.69	0.35	3.75e-8	Diastolic blood pressure;
SARC	cis	rs870825	0.616	rs28445002	chr4:185648977	C/T	cg04058563	chr4:185651563	MLF1IP	0.8	11.35	0.6	4.56e-24	Blood protein levels;
SARC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.73	10.03	0.55	6.52e-20	Lymphocyte counts;
SARC	cis	rs710216	0.957	rs710215	chr1:43429105	T/C	cg03128534	chr1:43423976	SLC2A1	0.66	6.61	0.4	2.61e-10	Red cell distribution width;
SARC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg18110333	chr6:292329	DUSP22	-0.59	-7.51	-0.44	1.25e-12	Menopause (age at onset);
SARC	cis	rs644799	0.542	rs10831415	chr11:95466159	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.64	7.86	0.46	1.45e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs4268898	0.662	rs55661701	chr2:24400769	A/C	cg06627628	chr2:24431161	ITSN2	-0.8	-9.59	-0.53	1.46e-18	Asthma;
SARC	cis	rs7429990	0.965	rs4858887	chr3:48092017	G/T	cg11946769	chr3:48343235	NME6	-0.49	-5.26	-0.33	3.3e-7	Educational attainment (years of education);
SARC	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2228479	0.850	rs17233567	chr16:89813821	G/A	cg06558623	chr16:89946397	TCF25	0.91	6.4	0.39	8.49e-10	Skin colour saturation;
SARC	cis	rs752010	0.746	rs11210499	chr1:42089703	C/T	cg06885757	chr1:42089581	HIVEP3	-0.43	-6.63	-0.4	2.26e-10	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs10483809	0.659	rs911256	chr14:68773580	C/G	cg18825221	chr14:68749962	RAD51L1	-0.45	-4.96	-0.31	1.39e-6	Circulating chromogranin peptide levels;
SARC	cis	rs3733585	0.638	rs17185835	chr4:9958180	T/G	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.36	-0.33	1.96e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs501120	1.000	rs554568	chr10:44755446	C/T	cg09554077	chr10:44749378	NA	0.48	6.67	0.4	1.85e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg08219700	chr8:58056026	NA	0.6	5.82	0.36	1.97e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg02083989	chr12:65153459	GNS	-0.56	-6.24	-0.38	2.01e-9	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg18876405	chr7:65276391	NA	-0.47	-5.63	-0.35	5.19e-8	Aortic root size;
SARC	cis	rs4481887	0.927	rs10158431	chr1:248481253	A/G	cg01631408	chr1:248437212	OR2T33	-0.42	-5.25	-0.33	3.39e-7	Common traits (Other);
SARC	trans	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	7.04	0.42	2.12e-11	Intelligence (multi-trait analysis);
SARC	cis	rs7250872	0.647	rs2304613	chr19:1817943	G/C	cg05970437	chr19:1864622	KLF16	0.44	4.8	0.3	2.78e-6	Bipolar disorder;
SARC	cis	rs2153535	0.580	rs1335643	chr6:8488021	T/G	cg07606381	chr6:8435919	SLC35B3	0.78	11.09	0.59	3.13e-23	Motion sickness;
SARC	cis	rs9911578	0.967	rs4076229	chr17:56937256	C/T	cg12560992	chr17:57184187	TRIM37	0.86	11.93	0.62	6.56e-26	Intelligence (multi-trait analysis);
SARC	cis	rs8044995	0.563	rs56899435	chr16:68395675	G/A	cg09835421	chr16:68378352	PRMT7	-0.64	-5.81	-0.36	1.99e-8	Schizophrenia;
SARC	cis	rs12950390	0.548	rs7215477	chr17:45858117	A/C	cg03474202	chr17:45855739	NA	-0.39	-6.1	-0.37	4.39e-9	IgG glycosylation;
SARC	cis	rs2013441	1.000	rs2703821	chr17:20121526	C/T	cg13482628	chr17:19912719	NA	-0.45	-5.92	-0.36	1.16e-8	Obesity-related traits;
SARC	cis	rs3796352	0.764	rs11714902	chr3:53101544	G/C	cg07884673	chr3:53033167	SFMBT1	0.8	5.36	0.33	2.02e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs6493487	0.512	rs17599863	chr15:51219962	G/A	cg02338191	chr15:51200825	AP4E1	0.55	5.08	0.32	7.63e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs9291683	0.609	rs7678012	chr4:9993772	T/C	cg11266682	chr4:10021025	SLC2A9	0.41	7.34	0.43	3.53e-12	Bone mineral density;
SARC	cis	rs67311347	1.000	rs9829800	chr3:40443927	T/C	cg24209194	chr3:40518798	ZNF619	0.6	7.55	0.44	9.76e-13	Renal cell carcinoma;
SARC	cis	rs926938	0.618	rs3121506	chr1:115363207	T/G	cg12756093	chr1:115239321	AMPD1	0.39	5.11	0.32	6.67e-7	Autism;
SARC	cis	rs981844	0.712	rs4469056	chr4:154745796	A/T	cg14289246	chr4:154710475	SFRP2	0.46	5.52	0.34	9.07e-8	Response to statins (LDL cholesterol change);
SARC	cis	rs6860806	0.507	rs270615	chr5:131641573	G/C	cg04518342	chr5:131593106	PDLIM4	0.42	5.34	0.33	2.16e-7	Breast cancer;
SARC	cis	rs7624766	0.743	rs1378655	chr3:160527078	T/G	cg22637730	chr3:160473554	PPM1L	0.43	5.58	0.34	6.58e-8	Response to methotrexate in rheumatoid arthritis;
SARC	cis	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg08045932	chr20:61659980	NA	0.52	6.91	0.41	4.6e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs57994353	0.897	rs72775772	chr9:139356738	C/T	cg13611204	chr9:139324423	INPP5E	-0.28	-4.88	-0.3	1.93e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs2075371	0.933	rs2544191	chr7:133954248	A/G	cg20476274	chr7:133979776	SLC35B4	0.61	8.32	0.48	7.38e-15	Mean platelet volume;
SARC	cis	rs9611519	0.780	rs9611546	chr22:41698542	C/G	cg17376030	chr22:41985996	PMM1	0.58	7.15	0.42	1.11e-11	Neuroticism;
SARC	trans	rs208520	0.661	rs851466	chr6:66840476	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-13.77	-0.67	5.95e-32	Exhaled nitric oxide output;
SARC	cis	rs1832871	0.711	rs9457248	chr6:158681204	C/T	cg07165851	chr6:158734300	TULP4	0.55	6.67	0.4	1.8e-10	Height;
SARC	cis	rs11209002	0.956	rs2013772	chr1:67581445	A/T	cg02640540	chr1:67518911	SLC35D1	0.47	4.77	0.3	3.19e-6	Crohn's disease;
SARC	cis	rs2731664	0.792	rs2545795	chr5:176887106	A/C	cg23176889	chr5:176863531	GRK6	-0.54	-8.05	-0.47	4.24e-14	Intelligence (multi-trait analysis);
SARC	cis	rs929354	0.713	rs3802130	chr7:156965237	A/G	cg05182265	chr7:156933206	UBE3C	-0.33	-5.08	-0.32	7.67e-7	Body mass index;
SARC	cis	rs33912345	0.695	rs1268618	chr14:60897181	A/C	cg27398547	chr14:60952738	C14orf39	-0.39	-4.82	-0.3	2.62e-6	Glaucoma (high intraocular pressure);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg11293821	chr19:17186167	MYO9B;HAUS8	-0.79	-6.4	-0.39	8.52e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2463822	1.000	rs2463822	chr11:62103420	T/C	cg06239285	chr11:62104954	ASRGL1	0.87	8.8	0.5	3.03e-16	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs11122272	0.637	rs2808593	chr1:231524228	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	trans	rs877282	0.797	rs7079164	chr10:756363	A/G	cg22713356	chr15:30763199	NA	0.99	9.88	0.54	1.92e-19	Uric acid levels;
SARC	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg22903471	chr2:27725779	GCKR	-0.54	-8.03	-0.47	4.82e-14	Total body bone mineral density;
SARC	trans	rs11039798	0.588	rs11039781	chr11:48523085	T/G	cg15704280	chr7:45808275	SEPT13	0.64	6.57	0.4	3.34e-10	Axial length;
SARC	cis	rs881375	1.000	rs6478486	chr9:123655329	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.42	5.0	0.31	1.11e-6	Rheumatoid arthritis;
SARC	cis	rs8070624	0.574	rs11078408	chr17:17876011	A/G	cg04398451	chr17:18023971	MYO15A	-0.46	-6.24	-0.38	2e-9	Total body bone mineral density;
SARC	cis	rs1569175	1.000	rs3094761	chr2:200934490	T/G	cg23649088	chr2:200775458	C2orf69	-0.79	-5.56	-0.34	7.34e-8	Response to treatment for acute lymphoblastic leukemia;
SARC	cis	rs2204008	0.775	rs11514370	chr12:38305566	G/A	cg13010199	chr12:38710504	ALG10B	0.78	10.85	0.58	1.81e-22	Bladder cancer;
SARC	cis	rs3784262	0.647	rs2414529	chr15:58317094	G/T	cg12031962	chr15:58353849	ALDH1A2	-0.34	-5.12	-0.32	6.41e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	trans	rs2727020	0.656	rs7925524	chr11:49437542	G/A	cg15704280	chr7:45808275	SEPT13	-0.75	-9.93	-0.55	1.32e-19	Coronary artery disease;
SARC	trans	rs1814175	0.591	rs11040589	chr11:49862449	A/G	cg15704280	chr7:45808275	SEPT13	-0.87	-13.81	-0.67	4.37e-32	Height;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg18809122	chr2:191513153	NAB1	0.5	6.74	0.4	1.27e-10	Gallstone disease;
SARC	cis	rs921968	0.613	rs2912737	chr2:219545789	A/G	cg02176678	chr2:219576539	TTLL4	-0.35	-5.06	-0.31	8.59e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs7635838	0.859	rs9812885	chr3:11508326	G/C	cg00170343	chr3:11313890	ATG7	0.64	8.58	0.49	1.35e-15	HDL cholesterol;
SARC	cis	rs7829975	0.782	rs6990746	chr8:8547811	A/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-5.29	-0.33	2.76e-7	Mood instability;
SARC	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg23985595	chr17:80112537	CCDC57	-0.32	-4.85	-0.3	2.28e-6	Life satisfaction;
SARC	cis	rs72945132	0.882	rs67283107	chr11:70221204	C/T	cg00319359	chr11:70116639	PPFIA1	0.68	6.51	0.39	4.51e-10	Coronary artery disease;
SARC	cis	rs9398803	0.723	rs1262545	chr6:127074587	C/T	cg20229609	chr6:126660872	C6orf173	-0.34	-4.79	-0.3	3.02e-6	Male-pattern baldness;
SARC	cis	rs1059312	0.808	rs10847693	chr12:129292006	G/A	cg09035930	chr12:129282057	SLC15A4	0.56	8.04	0.47	4.57e-14	Systemic lupus erythematosus;
SARC	cis	rs16854884	0.657	rs35877644	chr3:143701755	A/G	cg06585982	chr3:143692056	C3orf58	0.68	9.21	0.52	1.9e-17	Economic and political preferences (feminism/equality);
SARC	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg16606324	chr3:10149918	C3orf24	0.48	4.75	0.3	3.56e-6	Alzheimer's disease;
SARC	cis	rs7829975	0.667	rs1877119	chr8:8707197	C/G	cg08975724	chr8:8085496	FLJ10661	0.43	5.33	0.33	2.35e-7	Mood instability;
SARC	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2594989	0.943	rs2606733	chr3:11412319	C/T	cg00170343	chr3:11313890	ATG7	0.56	5.29	0.33	2.81e-7	Circulating chemerin levels;
SARC	cis	rs11690935	0.959	rs4668412	chr2:172619770	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.0	-16.02	-0.72	1.9e-39	Schizophrenia;
SARC	cis	rs6121246	0.559	rs6060716	chr20:30274847	C/G	cg13852791	chr20:30311386	BCL2L1	0.87	10.56	0.57	1.47e-21	Mean corpuscular hemoglobin;
SARC	cis	rs7264396	0.635	rs6121102	chr20:34544274	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.52	5.17	0.32	4.98e-7	Total cholesterol levels;
SARC	cis	rs7712401	0.601	rs35847506	chr5:122327108	G/A	cg19412675	chr5:122181750	SNX24	-0.43	-5.43	-0.34	1.41e-7	Mean platelet volume;
SARC	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg02592271	chr2:27665507	KRTCAP3	0.4	6.28	0.38	1.66e-9	Total body bone mineral density;
SARC	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg14829155	chr15:31115871	NA	0.51	6.62	0.4	2.43e-10	Huntington's disease progression;
SARC	cis	rs344364	0.511	rs1742467	chr16:1950187	G/T	cg26617929	chr16:1858877	NA	-0.71	-6.06	-0.37	5.5e-9	Glomerular filtration rate in chronic kidney disease;
SARC	trans	rs12310956	0.532	rs1852226	chr12:33962940	G/A	cg26384229	chr12:38710491	ALG10B	0.73	10.1	0.55	4.11e-20	Morning vs. evening chronotype;
SARC	cis	rs41271473	1.000	rs4391638	chr1:228878481	A/C	cg16512390	chr1:228756714	NA	0.48	4.79	0.3	3.02e-6	Chronic lymphocytic leukemia;
SARC	cis	rs2066819	1.000	rs2066808	chr12:56737973	A/G	cg26316697	chr12:56727976	PAN2	0.9	6.37	0.39	9.89e-10	Psoriasis vulgaris;
SARC	cis	rs12421382	0.636	rs1371329	chr11:109382725	G/T	cg16359550	chr11:109292809	C11orf87	-0.37	-5.41	-0.33	1.53e-7	Schizophrenia;
SARC	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg02951883	chr7:2050386	MAD1L1	-0.41	-5.22	-0.32	4e-7	Schizophrenia;
SARC	cis	rs4568518	0.803	rs4721679	chr7:18039252	T/C	cg00911873	chr7:18067463	PRPS1L1	-0.33	-4.74	-0.3	3.64e-6	Measles;
SARC	cis	rs67311347	0.956	rs12633446	chr3:40505661	G/A	cg24209194	chr3:40518798	ZNF619	-0.66	-8.54	-0.49	1.74e-15	Renal cell carcinoma;
SARC	cis	rs763121	0.889	rs1837988	chr22:38901094	A/G	cg21395723	chr22:39101663	GTPBP1	0.61	6.92	0.41	4.42e-11	Menopause (age at onset);
SARC	cis	rs1570884	0.890	rs6561541	chr13:50127280	C/T	cg08779649	chr13:50194554	NA	0.33	5.27	0.33	3.05e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs763121	0.853	rs6001204	chr22:39100239	T/C	cg06022373	chr22:39101656	GTPBP1	0.9	12.43	0.63	1.53e-27	Menopause (age at onset);
SARC	trans	rs17038463	1.000	rs79879569	chr3:1401610	C/G	cg18003583	chr5:176819624	SLC34A1	0.99	6.31	0.38	1.38e-9	Neurocognitive impairment in HIV-1 infection (continuous);
SARC	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg01475735	chr3:40494733	NA	-0.48	-5.34	-0.33	2.2e-7	Renal cell carcinoma;
SARC	cis	rs6912958	0.500	rs4707352	chr6:87929705	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.37	-6.25	-0.38	1.97e-9	Monocyte percentage of white cells;
SARC	trans	rs11098499	0.821	rs10032151	chr4:120391628	C/T	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.47e-12	Corneal astigmatism;
SARC	cis	rs3771570	0.901	rs4675944	chr2:242430170	C/T	cg21155796	chr2:242212141	HDLBP	0.55	5.36	0.33	2.03e-7	Prostate cancer;
SARC	cis	rs6570726	0.902	rs973855	chr6:145781850	C/T	cg05220968	chr6:146057943	EPM2A	0.29	5.0	0.31	1.14e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4664308	0.935	rs17216980	chr2:160960932	G/A	cg03641300	chr2:160917029	PLA2R1	-0.69	-9.47	-0.53	3.29e-18	Idiopathic membranous nephropathy;
SARC	cis	rs992157	0.835	rs7585702	chr2:219146607	T/C	cg00012203	chr2:219082015	ARPC2	-0.64	-9.13	-0.51	3.49e-17	Colorectal cancer;
SARC	cis	rs10489202	0.632	rs203779	chr1:167877647	T/G	cg17859187	chr1:168147929	TIPRL	0.39	4.87	0.3	2.02e-6	Schizophrenia;
SARC	cis	rs6582630	0.537	rs1851124	chr12:38516404	G/A	cg13010199	chr12:38710504	ALG10B	0.75	10.44	0.56	3.49e-21	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7296418	0.961	rs4275659	chr12:123447928	C/T	cg00376283	chr12:123451042	ABCB9	-0.7	-9.15	-0.51	2.96e-17	Platelet count;
SARC	cis	rs57024841	0.819	rs11145948	chr9:139857912	C/T	cg00693599	chr9:139836323	FBXW5	-0.31	-5.15	-0.32	5.54e-7	Beta-trace protein levels;
SARC	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg16680214	chr1:154839983	KCNN3	-0.38	-5.98	-0.36	8.52e-9	Prostate cancer;
SARC	cis	rs2439831	0.850	rs7181039	chr15:44179112	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.75	0.45	2.85e-13	Lung cancer in ever smokers;
SARC	cis	rs1635	0.655	rs10484542	chr6:28309753	C/T	cg15743358	chr6:28303923	ZNF323	-0.61	-4.8	-0.3	2.78e-6	Schizophrenia;
SARC	cis	rs9457247	0.935	rs1187530	chr6:167376812	C/T	cg23791538	chr6:167370224	RNASET2	0.63	8.74	0.5	4.81e-16	Crohn's disease;
SARC	cis	rs11792861	0.926	rs1051474	chr9:111881856	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.67	7.67	0.45	4.75e-13	Menarche (age at onset);
SARC	cis	rs7113874	0.659	rs57757082	chr11:8528653	T/A	cg09828998	chr11:8703972	RPL27A	0.49	5.24	0.32	3.63e-7	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs920590	0.796	rs10888170	chr8:19635328	C/T	cg17834443	chr8:19674713	INTS10	0.46	5.57	0.34	6.84e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs2070677	0.542	rs7086127	chr10:135393731	T/C	cg20169779	chr10:135381914	SYCE1	-0.55	-6.67	-0.4	1.8e-10	Gout;
SARC	cis	rs1983170	0.735	rs963910	chr1:92014136	T/C	cg25838465	chr1:92012736	NA	-0.6	-7.02	-0.42	2.36e-11	Eosinophil percentage of white cells;
SARC	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg22974920	chr21:40686053	BRWD1	-0.43	-4.83	-0.3	2.47e-6	Cognitive function;
SARC	cis	rs7264396	0.690	rs2425175	chr20:34445563	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	5.52	0.34	8.89e-8	Total cholesterol levels;
SARC	cis	rs4803468	1.000	rs17318666	chr19:41940342	T/G	cg14132834	chr19:41945861	ATP5SL	0.58	7.71	0.45	3.67e-13	Height;
SARC	cis	rs2376015	1	rs2376015	chr1:66123774	A/G	cg04111102	chr1:66153794	NA	0.36	5.66	0.35	4.49e-8	Fibrinogen levels;
SARC	cis	rs6088580	0.660	rs6087592	chr20:33114503	A/G	cg08999081	chr20:33150536	PIGU	0.43	6.72	0.4	1.39e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg16680214	chr1:154839983	KCNN3	-0.36	-5.69	-0.35	3.7e-8	Prostate cancer;
SARC	cis	rs2652834	1.000	rs2729782	chr15:63403354	G/C	cg05507819	chr15:63340323	TPM1	0.55	5.44	0.34	1.38e-7	HDL cholesterol;
SARC	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg05313129	chr8:58192883	C8orf71	-0.62	-6.46	-0.39	5.92e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs754466	1.000	rs754466	chr10:79680434	A/T	cg17075019	chr10:79541650	NA	-0.61	-7.58	-0.44	8.22e-13	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9399135	1.000	rs4475342	chr6:135283348	T/C	cg24558204	chr6:135376177	HBS1L	0.45	6.06	0.37	5.42e-9	Red blood cell count;
SARC	cis	rs1707322	0.686	rs3014235	chr1:46091512	A/G	cg03146154	chr1:46216737	IPP	-0.51	-6.1	-0.37	4.4e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs7824557	0.545	rs2572380	chr8:11237477	A/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.8	-0.41	8.83e-11	Retinal vascular caliber;
SARC	cis	rs896854	0.530	rs10956934	chr8:95992473	C/A	cg13393036	chr8:95962371	TP53INP1	-0.34	-5.51	-0.34	9.35e-8	Type 2 diabetes;
SARC	cis	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg13072238	chr3:49761600	GMPPB	-0.43	-5.57	-0.34	6.87e-8	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9790314	0.875	rs55688744	chr3:160944222	G/A	cg03342759	chr3:160939853	NMD3	-0.73	-9.85	-0.54	2.36e-19	Morning vs. evening chronotype;
SARC	cis	rs12586317	0.728	rs2415288	chr14:35807508	T/C	cg16230307	chr14:35515116	FAM177A1	0.76	7.99	0.46	6.28e-14	Psoriasis;
SARC	cis	rs7432375	0.901	rs1681817	chr3:136473728	C/T	cg15507776	chr3:136538369	TMEM22	-0.44	-4.93	-0.31	1.56e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	cis	rs35995292	0.534	rs28460817	chr7:38921917	T/C	cg19327137	chr7:38886074	VPS41	0.52	7.79	0.45	2.19e-13	Subjective well-being (multi-trait analysis);
SARC	cis	rs986417	0.901	rs3759688	chr14:60975579	A/C	cg27398547	chr14:60952738	C14orf39	0.99	9.02	0.51	6.89e-17	Gut microbiota (bacterial taxa);
SARC	cis	rs2933343	0.649	rs789216	chr3:128594503	A/C	cg25356066	chr3:128598488	ACAD9	0.72	9.59	0.53	1.44e-18	IgG glycosylation;
SARC	cis	rs6963495	0.818	rs6973974	chr7:105170629	C/T	cg19920283	chr7:105172520	RINT1	0.67	5.76	0.35	2.59e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs2236918	1.000	rs1627006	chr1:242038004	C/T	cg17736920	chr1:242011382	EXO1	0.8	11.21	0.59	1.27e-23	Menopause (age at onset);
SARC	cis	rs6867032	1.000	rs2129472	chr5:2016247	G/A	cg26168224	chr5:2018326	NA	0.92	14.86	0.7	1.4e-35	Gut microbiome composition (winter);
SARC	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6871536	1.000	rs62383714	chr5:131909795	G/A	cg11797159	chr5:131991491	NA	0.38	4.9	0.31	1.75e-6	Asthma (childhood onset);
SARC	cis	rs4906332	0.966	rs12185021	chr14:103927805	A/G	cg26031613	chr14:104095156	KLC1	-0.49	-5.74	-0.35	2.88e-8	Coronary artery disease;
SARC	cis	rs2635047	0.542	rs2668772	chr18:44770621	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	5.37	0.33	1.86e-7	Educational attainment;
SARC	cis	rs55871839	0.708	rs4738730	chr8:59808935	A/T	cg07426533	chr8:59803705	TOX	-0.45	-5.98	-0.36	8.22e-9	Pneumonia;
SARC	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg05025164	chr4:1340916	KIAA1530	0.43	4.8	0.3	2.83e-6	Obesity-related traits;
SARC	cis	rs79149102	0.579	rs7182286	chr15:75293839	A/G	cg00629941	chr15:75287862	SCAMP5	-0.64	-5.11	-0.32	6.76e-7	Lung cancer;
SARC	cis	rs4280164	0.551	rs3212243	chr14:24810370	T/C	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.53	-5.41	-0.33	1.53e-7	Parent of origin effect on language impairment (paternal);
SARC	cis	rs3126085	0.696	rs41266112	chr1:152185762	C/G	cg09127314	chr1:152161683	NA	0.42	4.77	0.3	3.26e-6	Atopic dermatitis;
SARC	trans	rs9858542	1.000	rs9822268	chr3:49719729	G/A	cg21659725	chr3:3221576	CRBN	-0.55	-6.32	-0.38	1.3e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs7208859	0.673	rs3764420	chr17:29164154	A/G	cg13385521	chr17:29058706	SUZ12P	0.86	7.3	0.43	4.51e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs7481584	0.624	rs428726	chr11:3046201	G/A	cg20651018	chr11:3035856	CARS	0.4	5.96	0.36	9.21e-9	Calcium levels;
SARC	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg11843238	chr5:131593191	PDLIM4	0.43	5.82	0.36	1.93e-8	Acylcarnitine levels;
SARC	cis	rs4713675	0.584	rs4711339	chr6:33667199	A/G	cg15676125	chr6:33679581	C6orf125	0.5	6.0	0.37	7.53e-9	Plateletcrit;
SARC	cis	rs2304069	0.954	rs216125	chr5:149428395	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.85	9.18	0.52	2.48e-17	HIV-1 control;
SARC	cis	rs17376456	0.757	rs10066431	chr5:93198204	A/G	cg21475434	chr5:93447410	FAM172A	0.79	6.77	0.41	1.07e-10	Diabetic retinopathy;
SARC	cis	rs4319547	0.760	rs61954973	chr12:123074168	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.66	-7.98	-0.46	6.73e-14	Body mass index;
SARC	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg23758822	chr17:41437982	NA	0.9	11.58	0.6	8.5e-25	Menopause (age at onset);
SARC	cis	rs7959452	0.640	rs4761154	chr12:69705362	A/G	cg20891283	chr12:69753455	YEATS4	-0.45	-5.95	-0.36	9.58e-9	Blood protein levels;
SARC	cis	rs13256369	1.000	rs12550458	chr8:8567832	G/A	cg17143192	chr8:8559678	CLDN23	0.52	6.0	0.37	7.31e-9	Obesity-related traits;
SARC	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg06634786	chr22:41940651	POLR3H	-0.51	-6.26	-0.38	1.8e-9	Vitiligo;
SARC	cis	rs6120849	0.754	rs6120788	chr20:33583716	C/T	cg06115741	chr20:33292138	TP53INP2	0.56	5.4	0.33	1.63e-7	Protein C levels;
SARC	cis	rs9302635	0.513	rs7184169	chr16:72152933	C/T	cg16558253	chr16:72132732	DHX38	-0.54	-6.92	-0.41	4.24e-11	Blood protein levels;
SARC	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg26335602	chr6:28129616	ZNF389	0.53	5.95	0.36	9.59e-9	Depression;
SARC	cis	rs9660992	0.573	rs1318187	chr1:205206172	T/A	cg21643547	chr1:205240462	TMCC2	-0.6	-7.83	-0.46	1.76e-13	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg27170947	chr2:26402098	FAM59B	0.39	4.92	0.31	1.63e-6	Gut microbiome composition (summer);
SARC	cis	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg13072238	chr3:49761600	GMPPB	-0.42	-5.43	-0.34	1.4e-7	Intelligence (multi-trait analysis);
SARC	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.68	7.17	0.43	9.96e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs4889855	0.505	rs12952775	chr17:78607820	A/G	cg17956530	chr17:78667699	RPTOR	-0.47	-5.4	-0.33	1.65e-7	Fractional excretion of uric acid;
SARC	cis	rs11764590	0.694	rs7797112	chr7:2085165	T/C	cg21782813	chr7:2030301	MAD1L1	-0.31	-4.83	-0.3	2.48e-6	Neuroticism;
SARC	trans	rs11165623	0.792	rs6593599	chr1:96911468	C/T	cg10631902	chr5:14652156	NA	-0.46	-7.49	-0.44	1.46e-12	Hip circumference;Waist circumference;
SARC	cis	rs7572733	0.555	rs6745726	chr2:198934080	A/G	cg00792783	chr2:198669748	PLCL1	0.43	4.85	0.3	2.25e-6	Dermatomyositis;
SARC	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg19346786	chr7:2764209	NA	-0.35	-5.23	-0.32	3.82e-7	Height;
SARC	cis	rs7551222	0.716	rs12041075	chr1:204492153	C/G	cg20240347	chr1:204465584	NA	-0.34	-5.97	-0.36	8.62e-9	Schizophrenia;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg23539970	chr8:41788798	MYST3	0.48	6.48	0.39	5.37e-10	Thyroid stimulating hormone;
SARC	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg12310025	chr6:25882481	NA	-0.46	-5.67	-0.35	4.13e-8	Intelligence (multi-trait analysis);
SARC	trans	rs17685	0.753	rs1637037	chr7:75692927	C/T	cg19862616	chr7:65841803	NCRNA00174	0.61	7.65	0.45	5.19e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs7624766	0.743	rs2886909	chr3:160542117	G/A	cg22637730	chr3:160473554	PPM1L	0.43	5.59	0.34	6.35e-8	Response to methotrexate in rheumatoid arthritis;
SARC	cis	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg12257692	chr3:49977190	RBM6	0.28	4.8	0.3	2.8e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7666738	0.791	rs7684521	chr4:99071219	A/G	cg05340658	chr4:99064831	C4orf37	0.65	8.71	0.5	5.79e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1865760	0.865	rs2164485	chr6:25952106	G/A	cg17691542	chr6:26056736	HIST1H1C	0.58	7.28	0.43	5.17e-12	Height;
SARC	cis	rs4481887	1.000	rs10788782	chr1:248496132	C/A	cg01631408	chr1:248437212	OR2T33	-0.43	-5.4	-0.33	1.68e-7	Common traits (Other);
SARC	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg19223190	chr17:80058835	NA	0.44	6.16	0.37	3.17e-9	Life satisfaction;
SARC	cis	rs2019216	0.542	rs1987424	chr17:21874036	G/A	cg22648282	chr17:21454238	C17orf51	-0.3	-4.78	-0.3	3.08e-6	Pelvic organ prolapse;
SARC	cis	rs112591243	0.685	rs4819263	chr21:47950866	G/A	cg10657630	chr21:48055338	PRMT2	0.76	4.8	0.3	2.88e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg26338869	chr17:61819248	STRADA	0.81	10.92	0.58	1.13e-22	Prudent dietary pattern;
SARC	trans	rs1814175	0.645	rs28634872	chr11:50042175	T/A	cg15704280	chr7:45808275	SEPT13	-0.91	-14.49	-0.69	2.43e-34	Height;
SARC	cis	rs2204008	0.715	rs11514342	chr12:38236710	T/A	cg13010199	chr12:38710504	ALG10B	0.81	11.19	0.59	1.48e-23	Bladder cancer;
SARC	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.77	-11.57	-0.6	9.41e-25	Personality dimensions;
SARC	cis	rs3126085	0.932	rs72696991	chr1:152250235	T/C	cg03465714	chr1:152285911	FLG	0.46	4.84	0.3	2.31e-6	Atopic dermatitis;
SARC	cis	rs9816226	0.591	rs76880877	chr3:185802628	A/C	cg00760338	chr3:185826511	ETV5	-0.79	-7.81	-0.46	1.99e-13	Obesity;Body mass index;
SARC	cis	rs5997397	0.720	rs132549	chr22:29318724	C/T	cg15103426	chr22:29168792	CCDC117	-0.54	-6.92	-0.41	4.43e-11	Red cell distribution width;
SARC	cis	rs9467773	1.000	rs9461259	chr6:26504835	C/A	cg12292205	chr6:26970375	C6orf41	0.43	5.24	0.32	3.66e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9359856	0.564	rs41273329	chr6:90393483	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.62	-4.88	-0.3	2.01e-6	Bipolar disorder;
SARC	cis	rs2204008	0.837	rs2387317	chr12:38235319	T/C	cg26384229	chr12:38710491	ALG10B	0.92	13.59	0.66	2.33e-31	Bladder cancer;
SARC	cis	rs9291683	0.538	rs11727199	chr4:10036190	C/T	cg11266682	chr4:10021025	SLC2A9	0.4	7.15	0.42	1.1e-11	Bone mineral density;
SARC	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg22920501	chr2:26401640	FAM59B	-0.54	-7.04	-0.42	2.18e-11	Gut microbiome composition (summer);
SARC	cis	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg05084668	chr3:125655381	ALG1L	-0.48	-4.93	-0.31	1.54e-6	Blood pressure (smoking interaction);
SARC	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg21724239	chr8:58056113	NA	0.69	6.31	0.38	1.37e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7819412	0.765	rs17783634	chr8:11054097	C/A	cg03403963	chr8:11986501	LOC392196;FAM66D	-0.33	-4.84	-0.3	2.36e-6	Triglycerides;
SARC	cis	rs8114671	0.562	rs3818273	chr20:33509275	G/A	cg07148914	chr20:33460835	GGT7	0.42	5.1	0.32	6.98e-7	Height;
SARC	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.43	4.91	0.31	1.7e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7772486	0.790	rs9403756	chr6:146257761	C/G	cg23711669	chr6:146136114	FBXO30	-0.81	-13.04	-0.65	1.56e-29	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	11.57	0.6	9.53e-25	Platelet count;
SARC	cis	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg20965017	chr5:231967	SDHA	-0.54	-5.17	-0.32	5.11e-7	Breast cancer;
SARC	cis	rs818427	0.826	rs439456	chr5:112205207	G/C	cg07820702	chr5:112228657	REEP5	0.47	5.51	0.34	9.36e-8	Total body bone mineral density;
SARC	cis	rs796364	1.000	rs1658807	chr2:200767512	C/T	cg23649088	chr2:200775458	C2orf69	0.62	5.88	0.36	1.43e-8	Schizophrenia;
SARC	cis	rs611744	0.967	rs641721	chr8:109230140	G/A	cg21045802	chr8:109455806	TTC35	0.46	5.43	0.34	1.38e-7	Dupuytren's disease;
SARC	cis	rs6426558	0.537	rs12139758	chr1:227260519	A/G	cg10327440	chr1:227177885	CDC42BPA	0.41	4.89	0.31	1.84e-6	Neutrophil percentage of white cells;
SARC	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg19223190	chr17:80058835	NA	0.44	6.19	0.38	2.67e-9	Life satisfaction;
SARC	cis	rs922107	0.738	rs12410923	chr1:90035786	G/A	cg15422784	chr1:90023713	LRRC8B	-0.33	-4.86	-0.3	2.18e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
SARC	cis	rs1976403	0.659	rs10799700	chr1:21820968	G/C	cg17800788	chr1:21766015	NBPF3	0.29	4.81	0.3	2.67e-6	Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs7617773	0.817	rs3731513	chr3:48219537	A/G	cg11946769	chr3:48343235	NME6	0.72	9.33	0.52	8.61e-18	Coronary artery disease;
SARC	cis	rs7582720	0.943	rs72928610	chr2:203838961	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs2645694	0.626	rs2703143	chr4:77830441	A/G	cg10057126	chr4:77819792	ANKRD56	0.37	5.59	0.34	6.31e-8	Emphysema distribution in smoking;
SARC	trans	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.56	-7.41	-0.44	2.25e-12	Intelligence (multi-trait analysis);
SARC	cis	rs35110281	0.667	rs2155722	chr21:45096206	A/G	cg01579765	chr21:45077557	HSF2BP	0.35	5.68	0.35	3.91e-8	Mean corpuscular volume;
SARC	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg19729930	chr2:74357872	NA	0.73	10.98	0.58	6.86e-23	Gestational age at birth (maternal effect);
SARC	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg11890956	chr21:40555474	PSMG1	1.17	16.44	0.73	7.64e-41	Cognitive function;
SARC	cis	rs9815354	0.812	rs17218504	chr3:41987278	A/G	cg03022575	chr3:42003672	ULK4	0.72	6.26	0.38	1.79e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg09455208	chr3:40491958	NA	0.4	5.78	0.35	2.36e-8	Renal cell carcinoma;
SARC	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	12.54	0.63	6.36e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg12564285	chr5:131593104	PDLIM4	0.36	5.44	0.34	1.37e-7	Breast cancer;
SARC	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.82	9.32	0.52	8.98e-18	Alzheimer's disease;
SARC	cis	rs9303401	0.573	rs67378767	chr17:57194237	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.98	9.99	0.55	8.43e-20	Cognitive test performance;
SARC	cis	rs526231	0.578	rs17154825	chr5:102246069	T/C	cg23492399	chr5:102201601	PAM	-0.44	-5.21	-0.32	4.21e-7	Primary biliary cholangitis;
SARC	cis	rs11155671	0.530	rs4869764	chr6:150211828	T/C	cg05036130	chr6:150231994	NA	0.28	4.87	0.3	2.04e-6	Testicular germ cell tumor;
SARC	cis	rs16858210	0.520	rs12633858	chr3:183549395	C/T	cg03417191	chr3:183542750	MAP6D1	-0.56	-4.94	-0.31	1.46e-6	Menopause (age at onset);
SARC	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.74	8.74	0.5	4.58e-16	Height;
SARC	cis	rs6912958	0.559	rs242280	chr6:88048714	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	10.92	0.58	1.11e-22	Monocyte percentage of white cells;
SARC	cis	rs459571	1.000	rs2810489	chr9:136922700	C/T	cg13789015	chr9:136890014	NCRNA00094	0.6	8.24	0.47	1.26e-14	Platelet distribution width;
SARC	cis	rs2075371	0.933	rs1421481	chr7:133964380	A/C	cg11752832	chr7:134001865	SLC35B4	0.54	6.92	0.41	4.35e-11	Mean platelet volume;
SARC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg26338869	chr17:61819248	STRADA	0.8	10.72	0.57	4.8e-22	Prudent dietary pattern;
SARC	cis	rs7296418	0.922	rs12425009	chr12:123502044	C/T	cg00376283	chr12:123451042	ABCB9	0.67	8.64	0.49	9.3e-16	Platelet count;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01528762	chr19:8455291	RAB11B	-0.51	-6.42	-0.39	7.52e-10	Smoking initiation;
SARC	cis	rs67460515	0.500	rs1345156	chr3:160649272	G/T	cg04691961	chr3:161091175	C3orf57	0.43	4.97	0.31	1.29e-6	Parkinson's disease;
SARC	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg19748678	chr4:122722346	EXOSC9	0.78	9.85	0.54	2.3e-19	Type 2 diabetes;
SARC	cis	rs7589342	0.929	rs6719896	chr2:106428404	C/G	cg16077055	chr2:106428750	NCK2	-0.4	-7.66	-0.45	4.87e-13	Addiction;
SARC	cis	rs6981523	0.532	rs1987190	chr8:11053514	T/A	cg12395012	chr8:11607386	GATA4	0.33	5.62	0.35	5.38e-8	Neuroticism;
SARC	cis	rs9910055	0.509	rs9916444	chr17:42313512	C/G	cg19774624	chr17:42201019	HDAC5	-0.44	-5.84	-0.36	1.73e-8	Total body bone mineral density;
SARC	cis	rs734999	0.588	rs10910099	chr1:2533552	G/T	cg18854424	chr1:2615690	NA	-0.31	-4.93	-0.31	1.59e-6	Ulcerative colitis;
SARC	cis	rs1008375	0.800	rs28754811	chr4:17612312	C/T	cg16339924	chr4:17578868	LAP3	0.63	8.11	0.47	2.83e-14	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2760061	0.583	rs1636195	chr1:228211589	T/C	cg02753203	chr1:228287806	NA	0.83	11.38	0.6	3.88e-24	Diastolic blood pressure;
SARC	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg10374962	chr7:1011985	COX19	-0.45	-5.09	-0.32	7.38e-7	Bronchopulmonary dysplasia;
SARC	cis	rs7772486	0.686	rs9390347	chr6:146044747	G/T	cg23711669	chr6:146136114	FBXO30	-0.8	-12.65	-0.64	2.79e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1707322	0.716	rs10890342	chr1:46157087	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.24	0.38	2.03e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs950169	0.810	rs2879976	chr15:85109578	G/A	cg17507749	chr15:85114479	UBE2QP1	0.79	9.59	0.53	1.43e-18	Schizophrenia;
SARC	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg19901468	chr14:105411992	AHNAK2	-0.73	-10.79	-0.58	2.78e-22	Rheumatoid arthritis;
SARC	cis	rs526231	0.512	rs34797	chr5:102425727	T/C	cg23492399	chr5:102201601	PAM	-0.53	-5.73	-0.35	3.04e-8	Primary biliary cholangitis;
SARC	cis	rs1153858	0.621	rs12913645	chr15:45555066	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.68	-8.94	-0.51	1.26e-16	Homoarginine levels;
SARC	cis	rs6815814	0.904	rs3924113	chr4:38796255	G/T	cg06935464	chr4:38784597	TLR10	0.63	5.96	0.36	9.17e-9	Breast cancer;
SARC	cis	rs9467773	0.935	rs1056668	chr6:26510605	C/T	cg11502198	chr6:26597334	ABT1	0.42	4.92	0.31	1.6e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7223966	0.883	rs2955250	chr17:61959740	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.46	4.99	0.31	1.18e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg24399712	chr22:39784796	NA	0.44	5.78	0.35	2.42e-8	Intelligence (multi-trait analysis);
SARC	cis	rs13202913	0.518	rs13205543	chr6:151813779	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.76	6.4	0.39	8.56e-10	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs854765	0.583	rs8065970	chr17:17858771	A/G	cg04398451	chr17:18023971	MYO15A	-0.4	-5.51	-0.34	9.71e-8	Total body bone mineral density;
SARC	cis	rs9914544	0.545	rs8077775	chr17:18809543	A/G	cg25390199	chr17:18761479	PRPSAP2	0.45	5.86	0.36	1.53e-8	Educational attainment (years of education);
SARC	cis	rs193541	0.642	rs42538	chr5:122292352	A/T	cg19412675	chr5:122181750	SNX24	0.48	6.16	0.37	3.15e-9	Glucose homeostasis traits;
SARC	cis	rs546131	0.963	rs539044	chr11:34841542	G/T	cg06937548	chr11:34938143	PDHX;APIP	0.56	7.33	0.43	3.76e-12	Lung disease severity in cystic fibrosis;
SARC	cis	rs1448094	0.967	rs7974794	chr12:86323280	A/G	cg02569458	chr12:86230093	RASSF9	0.4	5.82	0.36	1.92e-8	Major depressive disorder;
SARC	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg13939156	chr17:80058883	NA	0.37	5.65	0.35	4.6e-8	Life satisfaction;
SARC	cis	rs950027	0.549	rs12909409	chr15:45608582	T/G	cg15395560	chr15:45543142	SLC28A2	0.3	5.7	0.35	3.55e-8	Response to fenofibrate (adiponectin levels);
SARC	cis	rs9462027	0.628	rs2814945	chr6:34647978	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.98	-0.36	8.35e-9	Systemic lupus erythematosus;
SARC	cis	rs796364	0.806	rs76112266	chr2:201087157	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.65	-5.34	-0.33	2.25e-7	Schizophrenia;
SARC	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.98	11.82	0.61	1.49e-25	Platelet count;
SARC	cis	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg12463550	chr7:65579703	CRCP	-0.61	-4.78	-0.3	3.14e-6	Diabetic kidney disease;
SARC	cis	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg06558623	chr16:89946397	TCF25	0.91	6.4	0.39	8.43e-10	Skin colour saturation;
SARC	cis	rs2120243	0.539	rs988588	chr3:157054016	C/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.4	4.97	0.31	1.3e-6	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs10504229	0.679	rs78941440	chr8:58052095	A/G	cg20607798	chr8:58055168	NA	0.59	5.43	0.34	1.4e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg07638871	chr5:56247860	MIER3	-0.72	-6.26	-0.38	1.87e-9	Autism spectrum disorder or schizophrenia;
SARC	trans	rs61931739	0.500	rs10844862	chr12:34531965	A/T	cg13010199	chr12:38710504	ALG10B	0.78	11.07	0.59	3.68e-23	Morning vs. evening chronotype;
SARC	cis	rs11190604	1.000	rs35106985	chr10:102307542	T/C	cg07080220	chr10:102295463	HIF1AN	0.83	9.85	0.54	2.4e-19	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs6570726	0.905	rs377143	chr6:145834220	C/T	cg05347473	chr6:146136440	FBXO30	0.47	6.39	0.39	8.82e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7385804	0.761	rs1617640	chr7:100317298	C/A	cg20848291	chr7:100343083	ZAN	0.4	4.92	0.31	1.66e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
SARC	cis	rs2712184	0.967	rs2541385	chr2:217669595	C/T	cg05032264	chr2:217675019	NA	-0.64	-8.73	-0.5	4.96e-16	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
SARC	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg04267008	chr7:1944627	MAD1L1	-0.5	-5.73	-0.35	3.12e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs5758659	0.714	rs2413668	chr22:42505841	G/A	cg15128208	chr22:42549153	NA	0.36	5.0	0.31	1.15e-6	Cognitive function;
SARC	cis	rs523522	0.962	rs11065154	chr12:120971417	T/C	cg27279351	chr12:120934652	DYNLL1	0.72	8.89	0.5	1.75e-16	High light scatter reticulocyte count;
SARC	cis	rs2834188	0.814	rs2843996	chr21:34711448	G/A	cg14352951	chr21:34696688	IFNAR1	0.47	5.53	0.34	8.62e-8	Narcolepsy;
SARC	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg12564285	chr5:131593104	PDLIM4	-0.46	-6.27	-0.38	1.71e-9	Breast cancer;
SARC	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg13770153	chr20:60521292	NA	-0.49	-6.89	-0.41	5.18e-11	Body mass index;
SARC	cis	rs7927771	1.000	rs11039426	chr11:47863119	G/A	cg20307385	chr11:47447363	PSMC3	-0.47	-5.59	-0.34	6.3e-8	Subjective well-being;
SARC	cis	rs986417	1.000	rs7160408	chr14:60977471	A/G	cg27398547	chr14:60952738	C14orf39	0.99	9.02	0.51	6.89e-17	Gut microbiota (bacterial taxa);
SARC	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.84	-11.91	-0.62	7.24e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs11583043	0.874	rs11578366	chr1:101396852	T/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.44	5.39	0.33	1.69e-7	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg24633833	chr3:10029261	TMEM111	0.52	5.25	0.33	3.43e-7	Alzheimer's disease;
SARC	cis	rs9640161	0.742	rs2108854	chr7:150017408	C/T	cg10018233	chr7:150070692	REPIN1	-0.68	-9.29	-0.52	1.17e-17	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs7246657	0.714	rs12972195	chr19:37752505	T/C	cg14683738	chr19:37701593	ZNF585B	0.58	5.4	0.33	1.68e-7	Coronary artery calcification;
SARC	cis	rs17270561	0.609	rs9348695	chr6:25763010	A/T	cg17691542	chr6:26056736	HIST1H1C	0.57	7.0	0.42	2.78e-11	Iron status biomarkers;
SARC	cis	rs796364	0.806	rs78527234	chr2:200913453	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-6.62	-0.4	2.51e-10	Schizophrenia;
SARC	cis	rs9354308	0.866	rs2814095	chr6:66535706	C/G	cg07460842	chr6:66804631	NA	0.49	5.56	0.34	7.26e-8	Metabolite levels;
SARC	cis	rs7666738	0.830	rs7657179	chr4:98948569	G/A	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs12451471	0.529	rs2278620	chr17:78083565	G/A	cg06718696	chr17:78121285	EIF4A3	0.88	10.13	0.55	3.31e-20	Plateletcrit;Mean corpuscular hemoglobin concentration;
SARC	cis	rs9815354	1.000	rs1717031	chr3:41905791	G/T	cg03022575	chr3:42003672	ULK4	0.56	5.29	0.33	2.81e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6500602	0.727	rs4786515	chr16:4578133	T/A	cg02719221	chr16:3613509	NLRC3	-0.25	-4.78	-0.3	3.13e-6	Schizophrenia;
SARC	cis	rs116248771	0.549	rs9825140	chr3:158435374	C/T	cg16708174	chr3:158430962	RARRES1	0.48	4.86	0.3	2.13e-6	diarrhoeal disease at age 2;
SARC	cis	rs7568458	0.905	rs6547620	chr2:85755928	C/T	cg02493740	chr2:85810744	VAMP5	-0.34	-5.0	-0.31	1.13e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg09373136	chr17:61933544	TCAM1	-0.46	-6.33	-0.38	1.28e-9	Prudent dietary pattern;
SARC	cis	rs6429082	0.715	rs2131924	chr1:235580928	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.62	-7.46	-0.44	1.71e-12	Adiposity;
SARC	cis	rs7937682	1.000	rs2186839	chr11:111534442	T/G	cg09085632	chr11:111637200	PPP2R1B	-0.99	-16.57	-0.74	2.84e-41	Primary sclerosing cholangitis;
SARC	cis	rs9517320	0.515	rs1107379	chr13:99198921	C/T	cg07423050	chr13:99094983	FARP1	-0.42	-5.55	-0.34	7.88e-8	Longevity;
SARC	cis	rs6582630	0.519	rs11495700	chr12:38288240	A/G	cg26384229	chr12:38710491	ALG10B	0.91	13.64	0.67	1.61e-31	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs986417	0.748	rs4400969	chr14:61013298	A/C	cg27398547	chr14:60952738	C14orf39	0.96	8.75	0.5	4.38e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs6121246	0.567	rs6120879	chr20:30202961	T/C	cg13852791	chr20:30311386	BCL2L1	0.66	5.6	0.34	6.08e-8	Mean corpuscular hemoglobin;
SARC	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.72	-7.24	-0.43	6.52e-12	Platelet count;
SARC	cis	rs12142240	0.698	rs6703374	chr1:46862332	C/G	cg00530320	chr1:46809349	NSUN4	0.57	7.0	0.42	2.74e-11	Menopause (age at onset);
SARC	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg25072359	chr17:41440525	NA	0.48	5.55	0.34	7.82e-8	Menopause (age at onset);
SARC	cis	rs9467711	0.651	rs2051539	chr6:25947259	G/C	cg21479132	chr6:26055353	NA	0.84	5.2	0.32	4.46e-7	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg10207240	chr12:122356781	WDR66	0.3	4.82	0.3	2.61e-6	Mean corpuscular volume;
SARC	cis	rs2658782	1.000	rs2608216	chr11:93149172	G/A	cg15737290	chr11:93063684	CCDC67	0.71	7.57	0.44	8.4e-13	Pulmonary function decline;
SARC	cis	rs2486288	0.586	rs12909625	chr15:45572053	C/A	cg21132104	chr15:45694354	SPATA5L1	-0.55	-6.86	-0.41	5.98e-11	Glomerular filtration rate;
SARC	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.32	-4.72	-0.3	3.99e-6	Electroencephalogram traits;
SARC	cis	rs17826219	0.706	rs28469200	chr17:29133572	T/A	cg13385521	chr17:29058706	SUZ12P	0.89	7.77	0.45	2.44e-13	Body mass index;
SARC	cis	rs1728785	1.000	rs1615609	chr16:68596401	C/A	cg02972257	chr16:68554789	NA	-0.45	-5.29	-0.33	2.82e-7	Ulcerative colitis;
SARC	cis	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg03213289	chr20:61660250	NA	0.47	6.51	0.39	4.69e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs7824557	0.872	rs1347410	chr8:11111242	G/A	cg21775007	chr8:11205619	TDH	-0.44	-5.24	-0.32	3.56e-7	Retinal vascular caliber;
SARC	cis	rs2635047	0.638	rs2668784	chr18:44711391	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	5.94	0.36	1.05e-8	Educational attainment;
SARC	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg05332525	chr7:65337924	VKORC1L1	0.44	4.89	0.3	1.92e-6	Calcium levels;
SARC	cis	rs17826219	0.636	rs79565452	chr17:29142841	T/C	cg13385521	chr17:29058706	SUZ12P	0.9	7.58	0.44	7.91e-13	Body mass index;
SARC	trans	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg12170299	chr20:33880195	FAM83C	0.48	6.34	0.38	1.15e-9	Colonoscopy-negative controls vs population controls;
SARC	cis	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg15556689	chr8:8085844	FLJ10661	-0.42	-5.39	-0.33	1.7e-7	Joint mobility (Beighton score);
SARC	cis	rs9902453	0.935	rs9905950	chr17:28431198	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	7.08	0.42	1.73e-11	Coffee consumption (cups per day);
SARC	cis	rs6088580	0.634	rs6059880	chr20:33088669	G/A	cg24642439	chr20:33292090	TP53INP2	0.66	8.58	0.49	1.39e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg11764359	chr7:65958608	NA	-0.77	-10.0	-0.55	7.89e-20	Aortic root size;
SARC	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.53	5.22	0.32	4.02e-7	Lung function (FEV1/FVC);
SARC	cis	rs9818758	0.607	rs11710247	chr3:49249800	G/T	cg01304814	chr3:48885189	PRKAR2A	0.6	4.99	0.31	1.19e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs6912958	0.703	rs12207825	chr6:88098292	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.35	6.01	0.37	6.94e-9	Monocyte percentage of white cells;
SARC	cis	rs12762955	0.608	rs7922760	chr10:1156815	G/C	cg18964960	chr10:1102726	WDR37	-0.71	-8.42	-0.48	3.87e-15	Response to angiotensin II receptor blocker therapy;
SARC	cis	rs616402	0.527	rs10779737	chr1:10580275	C/G	cg17425144	chr1:10567563	PEX14	0.46	7.48	0.44	1.5e-12	Breast size;
SARC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg22903471	chr2:27725779	GCKR	-0.49	-7.36	-0.43	3.15e-12	Total body bone mineral density;
SARC	cis	rs73206853	0.688	rs57530940	chr12:110597842	C/T	cg10860002	chr12:110842031	ANAPC7	0.67	5.29	0.33	2.82e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs12908161	1.000	rs35316992	chr15:85248133	A/G	cg17507749	chr15:85114479	UBE2QP1	0.58	6.63	0.4	2.31e-10	Schizophrenia;
SARC	cis	rs11690935	0.879	rs908671	chr2:172690265	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.98	-15.01	-0.7	4.5e-36	Schizophrenia;
SARC	cis	rs6908034	0.660	rs7750716	chr6:19804839	C/T	cg02682789	chr6:19804855	NA	0.86	7.59	0.45	7.44e-13	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	trans	rs61931739	0.500	rs7489130	chr12:34539674	C/A	cg26384229	chr12:38710491	ALG10B	0.91	13.78	0.67	5.4e-32	Morning vs. evening chronotype;
SARC	cis	rs9309473	1.000	rs11674602	chr2:73723185	A/T	cg20560298	chr2:73613845	ALMS1	-0.53	-6.28	-0.38	1.6e-9	Metabolite levels;
SARC	cis	rs11098499	0.865	rs9996417	chr4:120295862	T/C	cg09307838	chr4:120376055	NA	0.9	12.7	0.64	2.01e-28	Corneal astigmatism;
SARC	cis	rs11098499	1.000	rs1011054	chr4:120202387	A/G	cg24375607	chr4:120327624	NA	-0.41	-4.96	-0.31	1.38e-6	Corneal astigmatism;
SARC	cis	rs2832191	0.671	rs2832213	chr21:30512914	A/G	cg24692254	chr21:30365293	RNF160	-0.69	-8.37	-0.48	5.38e-15	Dental caries;
SARC	cis	rs5167	0.536	rs1882752	chr19:45461342	G/C	cg09555818	chr19:45449301	APOC2	0.4	5.31	0.33	2.54e-7	Blood protein levels;
SARC	cis	rs240764	0.697	rs239194	chr6:101131959	G/A	cg09795085	chr6:101329169	ASCC3	0.38	4.82	0.3	2.58e-6	Neuroticism;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg09724878	chr12:132195595	SFRS8	0.64	6.42	0.39	7.38e-10	Lung cancer in ever smokers;
SARC	cis	rs3845702	0.736	rs16867131	chr2:180848651	A/G	cg01881094	chr2:180872142	CWC22	-1.13	-9.68	-0.54	7.83e-19	Schizophrenia;
SARC	cis	rs1707322	0.927	rs11211194	chr1:46282084	C/T	cg06784218	chr1:46089804	CCDC17	0.33	5.76	0.35	2.66e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg00149659	chr3:10157352	C3orf10	0.64	5.91	0.36	1.22e-8	Alzheimer's disease;
SARC	cis	rs2153535	0.580	rs4960422	chr6:8459309	T/C	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.04e-14	Motion sickness;
SARC	trans	rs7819412	0.594	rs7460507	chr8:10969075	C/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.27	-0.43	5.28e-12	Triglycerides;
SARC	cis	rs2072499	0.966	rs6427307	chr1:156190083	A/G	cg25208724	chr1:156163844	SLC25A44	0.82	10.42	0.56	4.02e-21	Testicular germ cell tumor;
SARC	cis	rs9462027	0.651	rs1543559	chr6:34784104	G/T	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-6.04	-0.37	5.95e-9	Systemic lupus erythematosus;
SARC	cis	rs67311347	1.000	rs6599094	chr3:40399593	A/G	cg24209194	chr3:40518798	ZNF619	0.59	7.54	0.44	1.05e-12	Renal cell carcinoma;
SARC	cis	rs7666738	0.830	rs11097608	chr4:99011693	T/C	cg05340658	chr4:99064831	C4orf37	0.64	8.34	0.48	6.69e-15	Colonoscopy-negative controls vs population controls;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg10561472	chr19:4066818	ZBTB7A	-0.77	-6.3	-0.38	1.43e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9467773	0.620	rs2451731	chr6:26624822	A/C	cg12292205	chr6:26970375	C6orf41	0.41	5.11	0.32	6.57e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1468333	0.592	rs217272	chr5:137486426	A/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.71	7.43	0.44	2.04e-12	Resting heart rate;
SARC	cis	rs7260598	0.539	rs115199376	chr19:24064990	G/A	cg27517351	chr19:23941871	ZNF681	0.54	4.73	0.3	3.86e-6	Response to taxane treatment (placlitaxel);
SARC	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg12463550	chr7:65579703	CRCP	-0.49	-5.34	-0.33	2.21e-7	Aortic root size;
SARC	cis	rs17345786	0.817	rs11720560	chr3:101328484	C/T	cg12386194	chr3:101231763	SENP7	0.72	8.64	0.49	9.18e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4805272	0.512	rs17772319	chr19:29343064	T/A	cg14983838	chr19:29218262	NA	0.54	5.8	0.36	2.09e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg07777115	chr5:623756	CEP72	-0.56	-4.84	-0.3	2.34e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs1008375	0.966	rs12509962	chr4:17680292	G/A	cg16339924	chr4:17578868	LAP3	0.64	8.4	0.48	4.51e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs8067545	0.636	rs11204300	chr17:20195438	C/T	cg13482628	chr17:19912719	NA	-0.58	-7.7	-0.45	3.8e-13	Schizophrenia;
SARC	cis	rs155076	1.000	rs9509638	chr13:21860193	G/A	cg06138931	chr13:21896616	NA	-0.4	-5.2	-0.32	4.27e-7	White matter hyperintensity burden;
SARC	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg02725872	chr8:58115012	NA	-0.37	-6.37	-0.39	9.78e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6964587	1.000	rs13239875	chr7:91716104	G/A	cg17063962	chr7:91808500	NA	0.94	15.98	0.72	2.68e-39	Breast cancer;
SARC	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg07701084	chr6:150067640	NUP43	0.38	4.95	0.31	1.43e-6	Lung cancer;
SARC	cis	rs6964587	1.000	rs2299239	chr7:91654617	C/T	cg17063962	chr7:91808500	NA	0.95	16.01	0.72	2.09e-39	Breast cancer;
SARC	cis	rs870825	0.616	rs7681824	chr4:185617525	A/G	cg04058563	chr4:185651563	MLF1IP	0.83	11.52	0.6	1.33e-24	Blood protein levels;
SARC	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg22920501	chr2:26401640	FAM59B	0.61	8.19	0.47	1.71e-14	Gut microbiome composition (summer);
SARC	cis	rs3784262	0.740	rs4646582	chr15:58307381	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.34	-5.01	-0.31	1.08e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs11122272	0.701	rs743120	chr1:231531232	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.08	-0.55	4.68e-20	Hemoglobin concentration;
SARC	cis	rs933688	1.000	rs10073935	chr5:90742188	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.04	13.23	0.66	3.43e-30	Smoking behavior;
SARC	cis	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg25427524	chr10:38739819	LOC399744	-0.6	-9.59	-0.53	1.38e-18	Extrinsic epigenetic age acceleration;
SARC	cis	rs2594989	0.597	rs347593	chr3:11248957	C/G	cg00170343	chr3:11313890	ATG7	0.63	6.32	0.38	1.28e-9	Circulating chemerin levels;
SARC	cis	rs908922	1.000	rs908922	chr1:152454591	C/T	cg09873164	chr1:152488093	CRCT1	0.59	7.05	0.42	2e-11	Hair morphology;
SARC	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg07167872	chr1:205819463	PM20D1	0.41	4.77	0.3	3.31e-6	Parkinson's disease;
SARC	cis	rs79349575	0.783	rs2088139	chr17:47000110	C/T	cg16584676	chr17:46985605	UBE2Z	0.53	6.39	0.39	8.93e-10	Type 2 diabetes;
SARC	cis	rs9398803	0.830	rs9401885	chr6:126825837	C/G	cg20229609	chr6:126660872	C6orf173	0.4	5.79	0.35	2.23e-8	Male-pattern baldness;
SARC	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg03352830	chr11:487213	PTDSS2	0.51	4.91	0.31	1.69e-6	Body mass index;
SARC	cis	rs365132	0.934	rs251844	chr5:176476605	T/A	cg16309518	chr5:176445507	NA	-0.42	-5.48	-0.34	1.09e-7	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs938554	0.806	rs4447862	chr4:9931645	C/G	cg25986240	chr4:9926439	SLC2A9	0.3	4.9	0.31	1.76e-6	Blood metabolite levels;
SARC	cis	rs17023223	0.537	rs1325940	chr1:119586687	G/A	cg05756136	chr1:119680316	WARS2	-0.44	-5.35	-0.33	2.05e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs9297145	0.724	rs6958790	chr7:98774738	C/T	cg05967295	chr7:98741636	SMURF1	-0.72	-7.72	-0.45	3.5e-13	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
SARC	trans	rs9929218	1.000	rs28660361	chr16:68800838	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.53	-6.72	-0.4	1.41e-10	Colorectal cancer;
SARC	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg03575189	chr17:44344142	NA	0.61	5.89	0.36	1.38e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs11874712	1.000	rs7244921	chr18:43667528	T/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.46	5.5	0.34	1.02e-7	Migraine - clinic-based;
SARC	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	9.03	0.51	6.74e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs910316	1.000	rs10138183	chr14:75615227	T/C	cg08847533	chr14:75593920	NEK9	0.92	15.54	0.71	7.41e-38	Height;
SARC	cis	rs4268898	0.862	rs11125549	chr2:24576240	C/T	cg26838691	chr2:24397539	C2orf84	0.36	4.88	0.3	2.01e-6	Asthma;
SARC	trans	rs61931739	0.635	rs1405025	chr12:33908491	C/T	cg26384229	chr12:38710491	ALG10B	0.57	7.36	0.43	3.11e-12	Morning vs. evening chronotype;
SARC	cis	rs892961	0.932	rs3987885	chr17:75414990	A/G	cg05865280	chr17:75406074	SEPT9	0.53	7.72	0.45	3.32e-13	Airflow obstruction;
SARC	cis	rs12200560	0.505	rs984519	chr6:97076223	A/G	cg06623918	chr6:96969491	KIAA0776	-0.45	-5.18	-0.32	4.78e-7	Coronary heart disease;
SARC	cis	rs763121	0.853	rs138704	chr22:39133410	A/G	cg21395723	chr22:39101663	GTPBP1	0.57	7.1	0.42	1.5e-11	Menopause (age at onset);
SARC	trans	rs4848143	0.864	rs921089	chr2:121808766	C/G	cg11477977	chr8:29952662	LEPROTL1	0.47	6.29	0.38	1.58e-9	Capecitabine sensitivity;
SARC	cis	rs4563143	0.502	rs73029061	chr19:29283980	T/A	cg14983838	chr19:29218262	NA	0.75	9.94	0.55	1.26e-19	Methadone dose in opioid dependence;
SARC	cis	rs483180	0.511	rs496195	chr1:120207182	A/G	cg19096424	chr1:120255104	PHGDH	-0.51	-5.94	-0.36	1.04e-8	Macular telangiectasia type 2;
SARC	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.45	-5.79	-0.35	2.25e-8	Personality dimensions;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg10016835	chr1:29557393	MECR	0.53	6.7	0.4	1.54e-10	Lung adenocarcinoma;
SARC	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg04166393	chr7:2884313	GNA12	0.67	8.13	0.47	2.58e-14	Height;
SARC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.8	10.5	0.57	2.27e-21	Prudent dietary pattern;
SARC	cis	rs12367572	1.000	rs12367572	chr12:45290466	C/T	cg04608330	chr12:45269318	NELL2	0.4	4.98	0.31	1.25e-6	Gut microbiome composition (summer);
SARC	cis	rs9916302	0.904	rs57399933	chr17:37551189	A/G	cg15445000	chr17:37608096	MED1	-0.42	-5.02	-0.31	1.04e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs735396	0.770	rs1169301	chr12:121431300	C/T	cg15155738	chr12:121454335	C12orf43	0.52	6.39	0.39	8.97e-10	N-glycan levels;
SARC	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg25894440	chr7:65020034	NA	-0.76	-5.73	-0.35	3.11e-8	Diabetic kidney disease;
SARC	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg23758822	chr17:41437982	NA	0.89	11.46	0.6	2.09e-24	Menopause (age at onset);
SARC	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg06634786	chr22:41940651	POLR3H	-0.5	-6.17	-0.37	3.04e-9	Vitiligo;
SARC	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-7.06	-0.42	1.87e-11	Gut microbiome composition (summer);
SARC	cis	rs9296095	0.747	rs12206050	chr6:33564296	A/T	cg14003231	chr6:33640908	ITPR3	0.39	5.74	0.35	2.93e-8	Platelet count;
SARC	cis	rs35213789	0.887	rs12333508	chr7:69094426	T/C	cg10619644	chr7:69149951	AUTS2	-0.43	-5.77	-0.35	2.54e-8	Childhood ear infection;
SARC	cis	rs3733585	0.638	rs28715627	chr4:9958140	T/A	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.82	-0.36	1.92e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	trans	rs61931739	0.511	rs2035659	chr12:33826241	T/C	cg26384229	chr12:38710491	ALG10B	0.54	6.68	0.4	1.72e-10	Morning vs. evening chronotype;
SARC	cis	rs1003719	0.646	rs7276711	chr21:38578189	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-8.88	-0.5	1.88e-16	Eye color traits;
SARC	cis	rs6665290	0.935	rs6670924	chr1:227196048	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.09	-25.43	-0.86	3.74e-69	Myeloid white cell count;
SARC	cis	rs6424115	1.000	rs6697805	chr1:24151996	C/A	cg15997130	chr1:24165203	NA	-0.46	-6.14	-0.37	3.51e-9	Immature fraction of reticulocytes;
SARC	cis	rs7247513	0.701	rs8107642	chr19:12766370	C/T	cg01871581	chr19:12707946	ZNF490	-0.73	-10.49	-0.57	2.54e-21	Bipolar disorder;
SARC	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg22535103	chr8:58192502	C8orf71	-0.71	-6.66	-0.4	1.91e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs3733585	0.682	rs13124563	chr4:9927553	A/G	cg00071950	chr4:10020882	SLC2A9	0.42	6.67	0.4	1.84e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg11764359	chr7:65958608	NA	0.86	12.33	0.63	3.29e-27	Aortic root size;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg06661924	chr1:65613383	AK3L1	0.53	6.75	0.4	1.19e-10	Breast cancer;
SARC	cis	rs9399135	0.967	rs6902954	chr6:135313994	C/A	cg24558204	chr6:135376177	HBS1L	0.45	5.95	0.36	9.67e-9	Red blood cell count;
SARC	cis	rs67460515	0.563	rs4679672	chr3:160901020	G/A	cg17135325	chr3:160939158	NMD3	0.68	8.71	0.5	5.63e-16	Parkinson's disease;
SARC	cis	rs17079247	1.000	rs7322604	chr13:85773768	C/T	ch.13.84760847R	chr13:85862846	NA	-0.55	-5.13	-0.32	6.12e-7	Bipolar disorder (mania);
SARC	cis	rs11098499	0.542	rs10440343	chr4:120309787	G/C	cg09160332	chr4:120329925	NA	-0.33	-4.77	-0.3	3.27e-6	Corneal astigmatism;
SARC	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.59	0.34	6.34e-8	Bipolar disorder;
SARC	cis	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg12463550	chr7:65579703	CRCP	0.66	5.05	0.31	9.09e-7	Diabetic kidney disease;
SARC	cis	rs6430585	0.583	rs3769012	chr2:136556480	C/T	cg07169764	chr2:136633963	MCM6	1.09	17.1	0.75	5.08e-43	Corneal structure;
SARC	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg22920501	chr2:26401640	FAM59B	-0.5	-6.75	-0.4	1.17e-10	Gut microbiome composition (summer);
SARC	cis	rs12142240	0.698	rs6703374	chr1:46862332	C/G	cg10495392	chr1:46806563	NSUN4	0.65	6.88	0.41	5.6e-11	Menopause (age at onset);
SARC	cis	rs6570726	0.967	rs373527	chr6:145801861	C/T	cg05347473	chr6:146136440	FBXO30	0.45	6.12	0.37	3.99e-9	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs3929778	1.000	rs13045192	chr20:6463017	G/A	cg27502912	chr22:51017001	CPT1B;CHKB-CPT1B	0.61	6.45	0.39	6.27e-10	QRS complex (Cornell);
SARC	cis	rs7560272	0.564	rs4852939	chr2:73856769	C/G	cg20560298	chr2:73613845	ALMS1	-0.48	-6.52	-0.39	4.35e-10	Schizophrenia;
SARC	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg05793240	chr7:2802953	GNA12	-0.38	-5.42	-0.33	1.45e-7	Height;
SARC	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg22535103	chr8:58192502	C8orf71	-0.8	-9.15	-0.51	2.94e-17	Developmental language disorder (linguistic errors);
SARC	trans	rs11098499	0.909	rs73842633	chr4:120375464	G/A	cg25214090	chr10:38739885	LOC399744	0.56	7.16	0.42	1.06e-11	Corneal astigmatism;
SARC	cis	rs920590	0.717	rs62496675	chr8:19635733	A/T	cg03894339	chr8:19674705	INTS10	0.56	6.79	0.41	9.25e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs7937682	0.601	rs2187388	chr11:111387116	C/T	cg09085632	chr11:111637200	PPP2R1B	0.5	6.26	0.38	1.86e-9	Primary sclerosing cholangitis;
SARC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg26338869	chr17:61819248	STRADA	0.78	10.42	0.56	3.99e-21	Prudent dietary pattern;
SARC	cis	rs1678542	1.000	rs11172254	chr12:57968738	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.4	-5.12	-0.32	6.53e-7	Rheumatoid arthritis;
SARC	cis	rs763121	0.962	rs2071887	chr22:38879010	A/T	cg21395723	chr22:39101663	GTPBP1	0.46	5.36	0.33	2.03e-7	Menopause (age at onset);
SARC	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-6.51	-0.39	4.61e-10	Personality dimensions;
SARC	cis	rs4555082	0.915	rs79048296	chr14:105754944	G/A	cg10792982	chr14:105748885	BRF1	0.54	7.88	0.46	1.22e-13	Mean platelet volume;Platelet distribution width;
SARC	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg06634786	chr22:41940651	POLR3H	0.49	6.09	0.37	4.68e-9	Vitiligo;
SARC	cis	rs7312774	0.618	rs35435903	chr12:107346572	G/C	cg16260113	chr12:107380972	MTERFD3	0.95	7.85	0.46	1.49e-13	Severe influenza A (H1N1) infection;
SARC	cis	rs929596	0.785	rs34352510	chr2:234650562	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.37	-4.97	-0.31	1.28e-6	Total bilirubin levels in HIV-1 infection;
SARC	cis	rs8064299	0.967	rs7420	chr17:72765215	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	-0.54	-6.61	-0.4	2.65e-10	Monocyte count;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg13443997	chr9:139743586	PHPT1	0.48	6.38	0.39	9.39e-10	Chemerin levels;
SARC	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.08	22.41	0.83	4.65e-60	Chronic sinus infection;
SARC	trans	rs208520	0.802	rs208496	chr6:66930786	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-10.89	-0.58	1.37e-22	Exhaled nitric oxide output;
SARC	cis	rs7829975	0.514	rs2945873	chr8:8260445	C/T	cg15556689	chr8:8085844	FLJ10661	0.53	6.3	0.38	1.49e-9	Mood instability;
SARC	cis	rs1008375	1.000	rs917665	chr4:17668504	A/C	cg16339924	chr4:17578868	LAP3	-0.57	-7.24	-0.43	6.33e-12	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs12579753	0.917	rs11115032	chr12:82205073	T/C	cg07988820	chr12:82153109	PPFIA2	-0.52	-6.11	-0.37	4.18e-9	Resting heart rate;
SARC	cis	rs7223966	1.000	rs7220892	chr17:61908316	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	7.32	0.43	4.11e-12	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9303401	0.614	rs35308719	chr17:57163501	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.97	10.17	0.55	2.42e-20	Cognitive test performance;
SARC	cis	rs9462027	0.540	rs4282407	chr6:34830162	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-6.03	-0.37	6.23e-9	Systemic lupus erythematosus;
SARC	cis	rs12545912	0.863	rs4579533	chr8:9469028	A/G	cg21625330	chr8:9911636	MSRA	-0.5	-4.79	-0.3	2.94e-6	Multiple myeloma (hyperdiploidy);
SARC	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.41	-0.44	2.33e-12	Gut microbiome composition (summer);
SARC	cis	rs926392	0.965	rs6129168	chr20:37689360	T/C	cg16355469	chr20:37678765	NA	0.55	7.18	0.43	9.38e-12	Dialysis-related mortality;
SARC	cis	rs9790314	1.000	rs460508	chr3:161091089	C/G	cg04691961	chr3:161091175	C3orf57	0.82	11.74	0.61	2.63e-25	Morning vs. evening chronotype;
SARC	cis	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg12463550	chr7:65579703	CRCP	-0.66	-5.1	-0.32	7.2e-7	Diabetic kidney disease;
SARC	cis	rs9733	0.744	rs2039590	chr1:150813315	G/A	cg15448220	chr1:150897856	SETDB1	-0.38	-5.09	-0.32	7.44e-7	Tonsillectomy;
SARC	cis	rs6500602	0.727	rs4786516	chr16:4578641	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.32	5.24	0.32	3.68e-7	Schizophrenia;
SARC	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7937682	0.632	rs11608193	chr11:111732215	T/C	cg09085632	chr11:111637200	PPP2R1B	0.77	10.12	0.55	3.56e-20	Primary sclerosing cholangitis;
SARC	cis	rs72627509	0.904	rs17081935	chr4:57823476	C/T	cg26694713	chr4:57773883	REST	0.64	6.22	0.38	2.3e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs11583043	0.958	rs11583674	chr1:101396560	C/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.47	5.47	0.34	1.14e-7	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs896854	0.738	rs509594	chr8:95967156	C/G	cg13393036	chr8:95962371	TP53INP1	0.31	5.06	0.31	8.67e-7	Type 2 diabetes;
SARC	cis	rs7635838	0.819	rs4684072	chr3:11514860	A/G	cg00170343	chr3:11313890	ATG7	0.62	8.77	0.5	3.86e-16	HDL cholesterol;
SARC	cis	rs7566780	0.656	rs2340764	chr2:16676356	C/T	cg09580478	chr2:16689509	NA	0.45	6.06	0.37	5.48e-9	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs2735413	0.881	rs4888727	chr16:78077038	T/C	cg04733911	chr16:78082701	NA	-0.31	-5.61	-0.34	5.78e-8	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs763121	0.925	rs5757165	chr22:38994577	C/T	cg21395723	chr22:39101663	GTPBP1	0.53	6.15	0.37	3.36e-9	Menopause (age at onset);
SARC	cis	rs72772090	0.539	rs11739020	chr5:96113838	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.62	5.19	0.32	4.64e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs72781680	0.898	rs72796396	chr2:24178154	G/A	cg06627628	chr2:24431161	ITSN2	-0.7	-6.71	-0.4	1.49e-10	Lymphocyte counts;
SARC	cis	rs1008375	0.900	rs4698625	chr4:17599500	G/T	cg02297831	chr4:17616191	MED28	0.49	5.98	0.36	8.2e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs8078723	1.000	rs4795418	chr17:38164851	T/C	cg17467752	chr17:38218738	THRA	0.47	5.94	0.36	1.01e-8	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs7727544	0.581	rs10075801	chr5:131677642	A/G	cg24060327	chr5:131705240	SLC22A5	-0.42	-4.9	-0.31	1.75e-6	Blood metabolite levels;
SARC	cis	rs7777484	0.500	rs757787	chr7:2836355	G/A	cg19717773	chr7:2847554	GNA12	-0.38	-4.99	-0.31	1.16e-6	Height;
SARC	cis	rs6963495	0.818	rs73190133	chr7:105147821	G/C	cg19920283	chr7:105172520	RINT1	0.67	5.8	0.36	2.14e-8	Bipolar disorder (body mass index interaction);
SARC	trans	rs877282	0.898	rs12354872	chr10:763362	G/A	cg22713356	chr15:30763199	NA	1.03	9.99	0.55	8.97e-20	Uric acid levels;
SARC	cis	rs6674176	0.569	rs34830883	chr1:44405339	T/C	cg12908607	chr1:44402522	ARTN	-0.41	-7.12	-0.42	1.3e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs11122272	0.735	rs2808600	chr1:231534723	T/C	cg06096015	chr1:231504339	EGLN1	0.38	5.64	0.35	4.92e-8	Hemoglobin concentration;
SARC	cis	rs1345301	1.000	rs13431601	chr2:102873713	G/A	cg12451869	chr2:102867685	NA	0.39	5.5	0.34	1e-7	Waist circumference;
SARC	cis	rs7043114	0.525	rs10739927	chr9:95052081	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-5.47	-0.34	1.16e-7	Height;
SARC	cis	rs4851254	0.961	rs11677607	chr2:100751150	C/T	cg04109781	chr2:100722022	AFF3	0.33	4.81	0.3	2.68e-6	Intelligence (multi-trait analysis);
SARC	cis	rs12594515	1.000	rs58368732	chr15:45990531	G/C	cg14863074	chr15:45997064	NA	0.34	5.24	0.32	3.57e-7	Waist circumference;Weight;
SARC	cis	rs995000	0.868	rs880694	chr1:63173284	C/T	cg06896770	chr1:63153194	DOCK7	-0.85	-12.94	-0.65	3.09e-29	Triglyceride levels;
SARC	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg16325326	chr1:53192061	ZYG11B	-0.79	-12.2	-0.62	8.32e-27	Monocyte count;
SARC	cis	rs11690935	0.550	rs6746701	chr2:172869255	G/A	cg13550731	chr2:172543902	DYNC1I2	0.54	6.77	0.41	1.04e-10	Schizophrenia;
SARC	cis	rs2439831	1.000	rs2444250	chr15:43785051	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	8.42	0.48	3.97e-15	Lung cancer in ever smokers;
SARC	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg21747090	chr2:27597821	SNX17	-0.54	-7.59	-0.45	7.45e-13	Total body bone mineral density;
SARC	cis	rs796364	0.806	rs10931889	chr2:201101900	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.77	-6.58	-0.4	3.01e-10	Schizophrenia;
SARC	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg22903657	chr4:1355424	KIAA1530	-0.33	-4.8	-0.3	2.85e-6	Longevity;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg02290708	chr21:35747831	FAM165B	0.5	6.28	0.38	1.6e-9	Breast cancer;
SARC	cis	rs67311347	0.544	rs12633295	chr3:40335292	G/T	cg09455208	chr3:40491958	NA	-0.28	-4.77	-0.3	3.26e-6	Renal cell carcinoma;
SARC	cis	rs9790314	1.000	rs4370045	chr3:160943865	A/G	cg04691961	chr3:161091175	C3orf57	-0.77	-11.39	-0.6	3.39e-24	Morning vs. evening chronotype;
SARC	cis	rs9322817	0.540	rs2034823	chr6:105219573	A/T	cg02098413	chr6:105308735	HACE1	-0.39	-6.13	-0.37	3.8e-9	Thyroid stimulating hormone;
SARC	cis	rs9916302	0.904	rs7503705	chr17:37669704	A/G	cg00129232	chr17:37814104	STARD3	-0.65	-7.96	-0.46	7.56e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs66679842	1	rs66679842	chr6:88171407	AC/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-5.41	-0.33	1.53e-7	Itch intensity from mosquito bite adjusted by bite size;
SARC	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg11987759	chr7:65425863	GUSB	-0.48	-6.54	-0.39	3.9e-10	Aortic root size;
SARC	cis	rs4372836	0.658	rs11127189	chr2:28992020	T/G	cg09522027	chr2:28974177	PPP1CB	0.36	4.72	0.3	4.13e-6	Body mass index;
SARC	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg13628971	chr7:2884303	GNA12	0.63	7.4	0.44	2.52e-12	Height;
SARC	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg11987759	chr7:65425863	GUSB	0.47	5.64	0.35	4.91e-8	Aortic root size;
SARC	cis	rs72781680	0.898	rs72798041	chr2:23953076	T/C	cg06627628	chr2:24431161	ITSN2	-0.69	-6.42	-0.39	7.61e-10	Lymphocyte counts;
SARC	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg16606324	chr3:10149918	C3orf24	0.5	5.01	0.31	1.08e-6	Alzheimer's disease;
SARC	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg24829409	chr8:58192753	C8orf71	-0.65	-6.15	-0.37	3.28e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg08677398	chr8:58056175	NA	0.44	5.25	0.33	3.38e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7586879	0.681	rs6752483	chr2:25120086	C/T	cg04586622	chr2:25135609	ADCY3	0.33	5.68	0.35	3.94e-8	Body mass index;
SARC	cis	rs7208859	0.673	rs11649765	chr17:29233888	T/A	cg13385521	chr17:29058706	SUZ12P	0.85	7.23	0.43	7.08e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs1018836	0.663	rs56784954	chr8:91505094	C/T	cg16814680	chr8:91681699	NA	-0.75	-11.46	-0.6	2.16e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs4128725	0.850	rs79508328	chr1:159414113	A/G	cg25076881	chr1:159409836	OR10J1	0.4	4.79	0.3	2.95e-6	Select biomarker traits;
SARC	cis	rs9322193	0.607	rs915140	chr6:150220810	C/T	cg05036130	chr6:150231994	NA	0.31	4.89	0.31	1.88e-6	Lung cancer;
SARC	cis	rs7740797	0.905	rs1980602	chr6:155156221	G/A	cg02865717	chr6:155053990	RBM16	0.34	4.72	0.3	4.13e-6	Colorectal or endometrial cancer;
SARC	cis	rs7829975	0.682	rs7013471	chr8:8687325	A/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-5.46	-0.34	1.19e-7	Mood instability;
SARC	cis	rs7216064	1.000	rs62084248	chr17:65874541	C/T	cg12091567	chr17:66097778	LOC651250	-0.64	-6.45	-0.39	6.56e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	trans	rs61931739	0.517	rs1486882	chr12:34025896	A/G	cg13010199	chr12:38710504	ALG10B	0.77	10.41	0.56	4.29e-21	Morning vs. evening chronotype;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg18435900	chr10:44101962	ZNF485	0.51	6.3	0.38	1.48e-9	Breast cancer;
SARC	cis	rs7552404	0.731	rs10873787	chr1:76367797	G/A	cg03433033	chr1:76189801	ACADM	0.46	5.67	0.35	4.18e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	trans	rs7824557	0.767	rs10104728	chr8:11171300	A/G	cg06636001	chr8:8085503	FLJ10661	0.59	7.2	0.43	8.35e-12	Retinal vascular caliber;
SARC	cis	rs734999	0.545	rs10797441	chr1:2551660	T/G	cg20673091	chr1:2541236	MMEL1	0.32	4.86	0.3	2.13e-6	Ulcerative colitis;
SARC	cis	rs36051895	0.664	rs11793659	chr9:5109707	A/G	cg02405213	chr9:5042618	JAK2	-0.44	-5.1	-0.32	7.19e-7	Pediatric autoimmune diseases;
SARC	cis	rs6866344	0.697	rs62392833	chr5:178135452	T/A	cg10224037	chr5:178157518	ZNF354A	1.0	12.31	0.63	3.57e-27	Neutrophil percentage of white cells;
SARC	cis	rs13256369	1.000	rs12550458	chr8:8567832	G/A	cg18904891	chr8:8559673	CLDN23	0.48	5.54	0.34	8.31e-8	Obesity-related traits;
SARC	cis	rs4713118	0.662	rs149901	chr6:27965503	C/T	cg26335602	chr6:28129616	ZNF389	0.48	5.22	0.32	4.01e-7	Parkinson's disease;
SARC	cis	rs35306767	0.903	rs12244253	chr10:889320	G/T	cg26597838	chr10:835615	NA	0.81	8.34	0.48	6.54e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs1966248	0.543	rs4895992	chr6:134118263	T/A	cg25632230	chr6:134101081	NA	-0.55	-7.34	-0.43	3.63e-12	Coronary artery disease;
SARC	cis	rs1008375	0.966	rs11733730	chr4:17625209	G/C	cg02297831	chr4:17616191	MED28	0.5	6.48	0.39	5.32e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg15556689	chr8:8085844	FLJ10661	0.44	5.62	0.35	5.3e-8	Mood instability;
SARC	cis	rs4268898	0.662	rs9784114	chr2:24437517	C/T	cg06627628	chr2:24431161	ITSN2	-0.82	-9.95	-0.55	1.17e-19	Asthma;
SARC	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg25427524	chr10:38739819	LOC399744	-0.61	-9.92	-0.55	1.38e-19	Extrinsic epigenetic age acceleration;
SARC	cis	rs2439831	0.850	rs56909447	chr15:44137618	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	8.02	0.47	5.04e-14	Lung cancer in ever smokers;
SARC	cis	rs6912958	0.631	rs9450704	chr6:88182704	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.52	-6.77	-0.41	1.06e-10	Monocyte percentage of white cells;
SARC	cis	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg12257692	chr3:49977190	RBM6	-0.27	-4.83	-0.3	2.45e-6	Body mass index;
SARC	cis	rs473651	0.935	rs482775	chr2:239335403	G/C	cg18131467	chr2:239335373	ASB1	0.96	16.25	0.73	3.21e-40	Multiple system atrophy;
SARC	cis	rs2204008	0.729	rs2892365	chr12:38446760	G/C	cg26384229	chr12:38710491	ALG10B	-0.8	-11.57	-0.6	9.48e-25	Bladder cancer;
SARC	trans	rs12555078	0.710	rs7863833	chr9:75898254	T/C	cg13456470	chr9:98266766	PTCH1	0.79	6.34	0.38	1.2e-9	Obesity-related traits;
SARC	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg02297831	chr4:17616191	MED28	0.51	6.63	0.4	2.36e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs12347191	0.500	rs907582	chr9:100621926	T/C	cg13688889	chr9:100608707	NA	-0.48	-5.1	-0.32	7.11e-7	Orofacial clefts;
SARC	cis	rs6831352	0.918	rs17218288	chr4:100058030	A/T	cg13256891	chr4:100009986	ADH5	-0.64	-7.91	-0.46	1e-13	Alcohol dependence;
SARC	cis	rs12042938	0.507	rs2570408	chr1:231732934	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.87	-0.58	1.59e-22	Neuranatomic and neurocognitive phenotypes;
SARC	cis	rs4595586	0.545	rs3858554	chr12:39381460	C/T	cg13010199	chr12:38710504	ALG10B	0.4	4.82	0.3	2.55e-6	Morning vs. evening chronotype;
SARC	cis	rs7589342	0.929	rs1465640	chr2:106439103	C/T	cg14210321	chr2:106509881	NCK2	-0.44	-5.2	-0.32	4.38e-7	Addiction;
SARC	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg24829409	chr8:58192753	C8orf71	-0.63	-6.48	-0.39	5.37e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs13191362	1.000	rs35044651	chr6:163004142	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.49	0.34	1.04e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs1318878	0.565	rs12315037	chr12:15424108	G/A	cg08258403	chr12:15378311	NA	0.47	6.7	0.4	1.56e-10	Intelligence (multi-trait analysis);
SARC	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg03060546	chr3:49711283	APEH	0.42	5.24	0.32	3.51e-7	Parkinson's disease;
SARC	cis	rs2070997	0.607	rs10901283	chr9:133663242	G/A	cg11464064	chr9:133710261	ABL1	0.54	5.17	0.32	5.01e-7	Response to amphetamines;
SARC	cis	rs6570726	0.875	rs12524077	chr6:145866333	G/C	cg23711669	chr6:146136114	FBXO30	0.78	12.0	0.62	3.86e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7851660	0.870	rs55960649	chr9:100598695	C/A	cg13688889	chr9:100608707	NA	-0.37	-4.76	-0.3	3.37e-6	Strep throat;
SARC	cis	rs7589342	0.628	rs9646959	chr2:106412191	A/G	cg16077055	chr2:106428750	NCK2	-0.32	-5.52	-0.34	9.18e-8	Addiction;
SARC	cis	rs561341	0.739	rs6505267	chr17:30225950	A/C	cg13647721	chr17:30228624	UTP6	0.69	6.77	0.41	1.02e-10	Hip circumference adjusted for BMI;
SARC	cis	rs6840360	0.967	rs6823423	chr4:152604723	T/C	cg22705602	chr4:152727874	NA	-0.38	-6.45	-0.39	6.51e-10	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg12463550	chr7:65579703	CRCP	0.47	5.16	0.32	5.3e-7	Aortic root size;
SARC	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	8.64	0.49	9.15e-16	Mean platelet volume;
SARC	cis	rs10504229	0.679	rs10504217	chr8:58037522	A/G	cg08280861	chr8:58055591	NA	0.52	4.85	0.3	2.24e-6	Developmental language disorder (linguistic errors);
SARC	trans	rs34421088	0.560	rs2248316	chr8:11397073	A/C	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.98	-0.51	9.29e-17	Neuroticism;
SARC	cis	rs11608355	0.515	rs12833054	chr12:109890955	G/A	cg05360138	chr12:110035743	NA	0.89	8.79	0.5	3.25e-16	Neuroticism;
SARC	cis	rs17270561	0.609	rs7770037	chr6:25760591	G/A	cg16482183	chr6:26056742	HIST1H1C	0.48	5.95	0.36	9.58e-9	Iron status biomarkers;
SARC	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg25072359	chr17:41440525	NA	0.53	6.24	0.38	2.07e-9	Menopause (age at onset);
SARC	cis	rs7412746	0.611	rs7532045	chr1:150821847	G/A	cg10589385	chr1:150898437	SETDB1	0.42	5.61	0.34	5.73e-8	Melanoma;
SARC	cis	rs9395865	0.501	rs2067833	chr6:53330356	A/G	cg23554129	chr6:53413076	NA	-0.41	-4.86	-0.3	2.14e-6	Electroencephalographic traits in alcoholism;
SARC	cis	rs9325144	0.555	rs1973292	chr12:38679626	T/C	cg10518543	chr12:38710700	ALG10B	0.39	4.94	0.31	1.5e-6	Morning vs. evening chronotype;
SARC	cis	rs72945132	0.882	rs7942613	chr11:70210675	C/T	cg05964544	chr11:70165517	PPFIA1	-0.56	-5.48	-0.34	1.11e-7	Coronary artery disease;
SARC	cis	rs7552404	0.889	rs1250874	chr1:76190978	A/G	cg03433033	chr1:76189801	ACADM	0.49	7.24	0.43	6.65e-12	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs765787	0.530	rs2413780	chr15:45538866	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.67e-7	Uric acid levels;
SARC	cis	rs4820294	1.000	rs62236665	chr22:38059847	C/A	cg21798802	chr22:38057573	PDXP	0.34	5.09	0.32	7.39e-7	Fat distribution (HIV);
SARC	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg23982607	chr1:1823379	GNB1	-0.66	-11.14	-0.59	2.14e-23	Body mass index;
SARC	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg23221052	chr5:179740743	GFPT2	-0.5	-6.34	-0.38	1.17e-9	Height;
SARC	cis	rs17001868	0.568	rs9611316	chr22:40737027	A/G	cg07138101	chr22:40742427	ADSL	0.54	5.94	0.36	1.01e-8	Mammographic density (dense area);
SARC	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.76	9.64	0.53	9.91e-19	Height;
SARC	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg14517863	chr17:44321492	NA	0.41	5.93	0.36	1.1e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg08677398	chr8:58056175	NA	0.43	5.05	0.31	8.92e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs1612141	0.901	rs1367573	chr14:41791385	G/C	cg08384155	chr4:119948360	SYNPO2	0.44	6.32	0.38	1.3e-9	QT interval (drug interaction);
SARC	cis	rs2013441	1.000	rs2526480	chr17:20130074	A/G	cg13482628	chr17:19912719	NA	0.47	6.14	0.37	3.53e-9	Obesity-related traits;
SARC	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg08677398	chr8:58056175	NA	0.35	4.75	0.3	3.56e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs6456156	0.586	rs9459853	chr6:167465774	C/A	cg23791538	chr6:167370224	RNASET2	-0.51	-6.75	-0.4	1.16e-10	Primary biliary cholangitis;
SARC	cis	rs12545109	0.800	rs2670026	chr8:57424338	G/T	cg19413350	chr8:57351067	NA	-0.44	-5.61	-0.34	5.72e-8	Obesity-related traits;
SARC	cis	rs2204008	0.618	rs8186932	chr12:38338386	G/A	cg13010199	chr12:38710504	ALG10B	-0.49	-5.92	-0.36	1.17e-8	Bladder cancer;
SARC	cis	rs3020736	0.500	rs5996109	chr22:42493098	A/G	cg04733989	chr22:42467013	NAGA	-0.76	-10.7	-0.57	5.23e-22	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7940866	0.903	rs10791112	chr11:130870215	A/C	cg12179176	chr11:130786555	SNX19	-0.63	-8.52	-0.49	2.02e-15	Schizophrenia;
SARC	cis	rs10927875	0.541	rs1739842	chr1:16342848	T/G	cg21385522	chr1:16154831	NA	0.55	6.58	0.4	3.05e-10	Dilated cardiomyopathy;
SARC	cis	rs9948	0.655	rs62156232	chr2:97431161	C/A	cg15007626	chr2:97405879	LMAN2L	0.73	4.88	0.3	1.95e-6	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs11098499	0.909	rs1809406	chr4:120377122	G/A	cg09160332	chr4:120329925	NA	-0.33	-4.74	-0.3	3.75e-6	Corneal astigmatism;
SARC	cis	rs11235843	0.714	rs7128512	chr11:73372299	A/G	cg18195628	chr11:73498948	MRPL48	-0.56	-5.48	-0.34	1.11e-7	Hand grip strength;
SARC	cis	rs875971	0.545	rs316305	chr7:65617971	G/A	cg11764359	chr7:65958608	NA	-0.66	-6.5	-0.39	4.83e-10	Aortic root size;
SARC	cis	rs4481887	1.000	rs4244172	chr1:248466838	A/G	cg01631408	chr1:248437212	OR2T33	-0.44	-5.57	-0.34	6.92e-8	Common traits (Other);
SARC	cis	rs66573146	1.000	rs9942188	chr4:6984181	C/T	cg00086871	chr4:6988644	TBC1D14	0.99	5.28	0.33	2.99e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg22133161	chr19:49891603	CCDC155	0.44	4.86	0.3	2.12e-6	Multiple sclerosis;
SARC	cis	rs9875589	0.509	rs1601868	chr3:14065450	T/C	cg19554555	chr3:13937349	NA	-0.4	-5.14	-0.32	5.95e-7	Ovarian reserve;
SARC	cis	rs9372253	0.678	rs9487392	chr6:110708626	C/T	cg00083206	chr6:110721305	DDO	0.38	5.18	0.32	4.69e-7	Platelet distribution width;
SARC	cis	rs9788682	0.591	rs7170068	chr15:78912943	G/A	cg24631222	chr15:78858424	CHRNA5	0.65	8.07	0.47	3.81e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs10489202	1.000	rs17556487	chr1:167889094	T/A	cg24449463	chr1:168025552	DCAF6	-0.65	-7.18	-0.43	9.13e-12	Schizophrenia;
SARC	cis	rs4148883	0.737	rs13148577	chr4:100060836	G/A	cg13256891	chr4:100009986	ADH5	0.58	7.77	0.45	2.49e-13	Alcohol dependence;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg16116313	chr12:122255002	SETD1B	0.51	6.34	0.38	1.16e-9	Schizophrenia;
SARC	cis	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg15556689	chr8:8085844	FLJ10661	0.54	6.77	0.41	1.03e-10	Mood instability;
SARC	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg23221052	chr5:179740743	GFPT2	0.52	6.49	0.39	5.07e-10	Height;
SARC	trans	rs1814175	0.645	rs847630	chr11:49926360	C/T	cg03929089	chr4:120376271	NA	-0.81	-11.69	-0.61	3.89e-25	Height;
SARC	cis	rs644799	1.000	rs473155	chr11:95596873	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	14.28	0.68	1.22e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs5753618	0.561	rs2073857	chr22:31658281	A/G	cg00478049	chr22:31556069	RNF185	0.44	4.84	0.3	2.37e-6	Colorectal cancer;
SARC	cis	rs939574	0.676	rs12694457	chr2:220134010	A/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.48	-4.78	-0.3	3.13e-6	Platelet distribution width;
SARC	cis	rs694739	0.628	rs645078	chr11:64135298	A/C	cg02228329	chr11:64053129	BAD;GPR137	0.48	5.15	0.32	5.48e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	trans	rs208520	1.000	rs12193077	chr6:66989548	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	9.36	0.52	6.83e-18	Exhaled nitric oxide output;
SARC	cis	rs2011503	1.000	rs2965194	chr19:19460702	C/T	cg15839431	chr19:19639596	YJEFN3	0.49	4.77	0.3	3.18e-6	Bipolar disorder;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg23378609	chr5:178054312	CLK4	-0.51	-6.25	-0.38	1.89e-9	Schizophrenia;
SARC	cis	rs36051895	0.695	rs7043489	chr9:5023604	A/C	cg02405213	chr9:5042618	JAK2	-0.5	-5.67	-0.35	4.1e-8	Pediatric autoimmune diseases;
SARC	cis	rs9868809	0.772	rs9821797	chr3:48718253	T/A	cg07636037	chr3:49044803	WDR6	-0.71	-6.62	-0.4	2.39e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg27479400	chr22:42228998	SREBF2	-0.5	-6.36	-0.38	1.06e-9	Tetralogy of Fallot;
SARC	cis	rs965469	0.779	rs6037566	chr20:3331414	A/C	cg25506879	chr20:3388711	C20orf194	-0.46	-4.99	-0.31	1.17e-6	IFN-related cytopenia;
SARC	cis	rs796364	0.806	rs6435040	chr2:200861161	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.77	6.78	0.41	9.78e-11	Schizophrenia;
SARC	cis	rs4742903	0.875	rs7037174	chr9:106924871	C/T	cg14250997	chr9:106856677	SMC2	0.44	5.53	0.34	8.58e-8	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs17376456	0.877	rs17374627	chr5:93296306	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.59	5.35	0.33	2.15e-7	Diabetic retinopathy;
SARC	cis	rs71636778	0.631	rs76133297	chr1:27154470	G/A	cg04852280	chr1:26496234	ZNF593	0.57	5.02	0.31	1.01e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs2832191	0.671	rs2409332	chr21:30512779	G/A	cg08807101	chr21:30365312	RNF160	-0.69	-8.33	-0.48	7.02e-15	Dental caries;
SARC	cis	rs2562456	0.917	rs2562468	chr19:21714850	G/A	cg00806126	chr19:22604979	ZNF98	0.49	5.03	0.31	9.61e-7	Pain;
SARC	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg05025164	chr4:1340916	KIAA1530	0.48	5.73	0.35	3.05e-8	Longevity;
SARC	cis	rs73198271	0.632	rs570396	chr8:8593652	A/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-4.72	-0.3	4.07e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg12463550	chr7:65579703	CRCP	-0.71	-5.4	-0.33	1.61e-7	Diabetic kidney disease;
SARC	cis	rs7560272	0.695	rs10190002	chr2:73794054	C/T	cg20560298	chr2:73613845	ALMS1	-0.48	-6.43	-0.39	7.33e-10	Schizophrenia;
SARC	cis	rs758129	0.722	rs149234	chr15:89929607	T/C	cg03745604	chr15:89905304	NA	0.39	5.21	0.32	4.24e-7	Schizophrenia;
SARC	cis	rs4605213	0.686	rs8076111	chr17:49302782	C/G	cg00965052	chr17:49230932	NME1;NME1-NME2	-0.5	-5.15	-0.32	5.64e-7	Height;
SARC	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg11644478	chr21:40555479	PSMG1	-0.58	-7.15	-0.42	1.13e-11	Menarche (age at onset);
SARC	trans	rs35833281	1.000	rs71560899	chr6:55036760	C/A	cg19977494	chr7:128431264	CCDC136	-0.74	-7.05	-0.42	1.99e-11	Morning vs. evening chronotype;
SARC	cis	rs9397240	0.789	rs4870367	chr6:155604844	T/C	cg07943832	chr6:155568918	TIAM2	-0.6	-5.77	-0.35	2.54e-8	Life satisfaction;
SARC	cis	rs9894429	0.572	rs112417725	chr17:79578219	A/G	cg18240062	chr17:79603768	NPLOC4	-0.6	-7.33	-0.43	3.75e-12	Eye color traits;
SARC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg03452623	chr4:187889614	NA	-0.81	-12.96	-0.65	2.81e-29	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg11890956	chr21:40555474	PSMG1	-1.04	-15.95	-0.72	3.38e-39	Cognitive function;
SARC	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg17376030	chr22:41985996	PMM1	-0.65	-8.11	-0.47	2.97e-14	Vitiligo;
SARC	cis	rs11608355	0.515	rs3742018	chr12:109949134	C/T	cg05360138	chr12:110035743	NA	0.92	9.39	0.52	5.78e-18	Neuroticism;
SARC	cis	rs72781680	0.660	rs72780104	chr2:23983715	A/G	cg08917208	chr2:24149416	ATAD2B	0.76	7.16	0.42	1.08e-11	Lymphocyte counts;
SARC	cis	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.82	11.97	0.62	4.77e-26	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs10078	0.559	rs2037077	chr5:447226	A/G	cg07599136	chr5:415885	AHRR	0.65	5.78	0.35	2.41e-8	Fat distribution (HIV);
SARC	cis	rs6840360	0.571	rs875667	chr4:152525477	G/A	cg22705602	chr4:152727874	NA	-0.44	-6.8	-0.41	8.48e-11	Intelligence (multi-trait analysis);
SARC	cis	rs9303401	0.659	rs16943326	chr17:57050365	C/T	cg25039879	chr17:56429692	SUPT4H1	0.61	5.73	0.35	3.08e-8	Cognitive test performance;
SARC	cis	rs17270561	0.609	rs1165156	chr6:25792978	T/C	cg16482183	chr6:26056742	HIST1H1C	0.48	6.15	0.37	3.3e-9	Iron status biomarkers;
SARC	cis	rs7772486	0.782	rs7747576	chr6:146277827	C/T	cg23711669	chr6:146136114	FBXO30	-0.8	-12.46	-0.63	1.19e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9902453	0.817	rs9909128	chr17:28161482	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	7.19	0.43	8.98e-12	Coffee consumption (cups per day);
SARC	cis	rs35306767	0.714	rs10508206	chr10:1075777	A/C	cg18964960	chr10:1102726	WDR37	0.56	5.66	0.35	4.34e-8	Eosinophil percentage of granulocytes;
SARC	cis	rs4148883	0.615	rs2187483	chr4:100134103	G/T	cg12011299	chr4:100065546	ADH4	-0.3	-5.27	-0.33	3.12e-7	Alcohol dependence;
SARC	trans	rs3780486	0.801	rs56687083	chr9:33132134	A/G	cg20290983	chr6:43655470	MRPS18A	1.15	22.78	0.83	3.27e-61	IgG glycosylation;
SARC	cis	rs478304	0.619	rs10896028	chr11:65432187	A/T	cg27068330	chr11:65405492	SIPA1	-0.42	-4.96	-0.31	1.37e-6	Acne (severe);
SARC	cis	rs72781680	0.611	rs72797810	chr2:24336469	G/A	cg06627628	chr2:24431161	ITSN2	-0.5	-5.28	-0.33	2.98e-7	Lymphocyte counts;
SARC	trans	rs7824557	0.688	rs2572397	chr8:11176403	G/A	cg06636001	chr8:8085503	FLJ10661	0.69	9.4	0.52	5.21e-18	Retinal vascular caliber;
SARC	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg14893161	chr1:205819251	PM20D1	0.51	5.78	0.35	2.4e-8	Parkinson's disease;
SARC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.54	6.14	0.37	3.48e-9	Prudent dietary pattern;
SARC	cis	rs9309473	1.000	rs6711033	chr2:73746643	T/C	cg20560298	chr2:73613845	ALMS1	-0.5	-6.08	-0.37	4.9e-9	Metabolite levels;
SARC	cis	rs2710642	0.678	rs11125946	chr2:63298150	C/T	cg17519650	chr2:63277830	OTX1	-0.41	-5.2	-0.32	4.32e-7	LDL cholesterol levels;LDL cholesterol;
SARC	cis	rs2204008	0.745	rs12146863	chr12:38502346	G/A	cg26384229	chr12:38710491	ALG10B	0.83	11.98	0.62	4.5e-26	Bladder cancer;
SARC	cis	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg12257692	chr3:49977190	RBM6	-0.27	-4.8	-0.3	2.88e-6	Body mass index;
SARC	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg27266027	chr21:40555129	PSMG1	-0.5	-5.65	-0.35	4.75e-8	Cognitive function;
SARC	trans	rs637571	0.726	rs669371	chr11:65674153	G/T	cg17712092	chr4:129076599	LARP1B	-0.68	-7.98	-0.46	6.78e-14	Eosinophil percentage of white cells;
SARC	cis	rs10927875	0.541	rs1048334	chr1:16340761	T/C	cg21385522	chr1:16154831	NA	0.55	6.64	0.4	2.24e-10	Dilated cardiomyopathy;
SARC	cis	rs3857067	0.806	rs72665629	chr4:95112160	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.05	-0.31	8.98e-7	QT interval;
SARC	cis	rs9910055	0.529	rs615070	chr17:42176591	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.44	4.97	0.31	1.28e-6	Total body bone mineral density;
SARC	cis	rs13161895	1.000	rs6873994	chr5:179436696	T/G	cg02702477	chr5:179499311	RNF130	-0.65	-6.46	-0.39	5.92e-10	LDL cholesterol;
SARC	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg05863683	chr7:1912471	MAD1L1	0.36	5.32	0.33	2.4e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs76419734	0.850	rs72671855	chr4:106647299	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.84	5.41	0.33	1.59e-7	Post bronchodilator FEV1;
SARC	cis	rs11581859	0.536	rs1982703	chr1:99242849	A/G	cg20286094	chr1:99190917	SNX7	-0.43	-5.1	-0.32	7.18e-7	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg22433210	chr17:43662623	NA	0.68	7.91	0.46	1.02e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs11190604	1.000	rs75063298	chr10:102213600	C/A	cg07080220	chr10:102295463	HIF1AN	0.77	9.69	0.54	7.17e-19	Palmitoleic acid (16:1n-7) levels;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg07339812	chr16:25268887	ZKSCAN2	-0.51	-6.5	-0.39	4.81e-10	Gallstone disease;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg26001467	chr14:21979675	METTL3	0.48	6.36	0.38	1.08e-9	Lung adenocarcinoma;
SARC	cis	rs8141529	0.732	rs5997408	chr22:29207915	G/A	cg02153584	chr22:29168773	CCDC117	0.78	11.53	0.6	1.22e-24	Lymphocyte counts;
SARC	cis	rs4148883	0.713	rs3828541	chr4:100042262	A/G	cg13256891	chr4:100009986	ADH5	0.59	8.33	0.48	7.1e-15	Alcohol dependence;
SARC	cis	rs10078	0.571	rs2241597	chr5:480509	A/G	cg07599136	chr5:415885	AHRR	0.66	5.98	0.36	8.39e-9	Fat distribution (HIV);
SARC	cis	rs1707322	0.682	rs10890334	chr1:46100378	A/T	cg03146154	chr1:46216737	IPP	0.51	6.11	0.37	4.04e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs796364	0.525	rs10931895	chr2:201143242	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.51	5.08	0.32	7.66e-7	Schizophrenia;
SARC	cis	rs9303401	0.659	rs7224276	chr17:56897827	C/T	cg25039879	chr17:56429692	SUPT4H1	0.64	6.1	0.37	4.41e-9	Cognitive test performance;
SARC	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg12463550	chr7:65579703	CRCP	0.48	5.79	0.35	2.23e-8	Aortic root size;
SARC	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg05863683	chr7:1912471	MAD1L1	-0.33	-4.97	-0.31	1.28e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs1707322	1.000	rs7532204	chr1:46485075	C/G	cg06784218	chr1:46089804	CCDC17	-0.34	-6.0	-0.37	7.61e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg16325326	chr1:53192061	ZYG11B	0.7	10.35	0.56	6.8e-21	Monocyte count;
SARC	cis	rs9300255	0.739	rs2337934	chr12:123745359	A/G	cg00376283	chr12:123451042	ABCB9	0.48	5.44	0.34	1.38e-7	Neutrophil percentage of white cells;
SARC	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg21782813	chr7:2030301	MAD1L1	0.39	6.16	0.37	3.23e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg13175981	chr1:150552382	MCL1	-0.54	-6.84	-0.41	6.75e-11	Tonsillectomy;
SARC	cis	rs10254118	0.757	rs13241123	chr7:133135507	A/T	cg10665199	chr7:133106180	EXOC4	0.4	4.88	0.3	1.95e-6	Intelligence (multi-trait analysis);
SARC	trans	rs61931739	0.517	rs1843738	chr12:34056935	C/T	cg26384229	chr12:38710491	ALG10B	0.86	12.46	0.63	1.16e-27	Morning vs. evening chronotype;
SARC	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg23262073	chr20:60523788	NA	-0.57	-8.25	-0.48	1.14e-14	Obesity-related traits;
SARC	cis	rs9916302	0.706	rs3744349	chr17:37414842	C/T	cg07936489	chr17:37558343	FBXL20	-0.71	-8.52	-0.49	1.96e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs9814567	0.806	rs11927540	chr3:134319455	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.49	-6.41	-0.39	8.05e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg17079530	chr11:117014700	PAFAH1B2	0.5	6.38	0.39	9.59e-10	Lung adenocarcinoma;
SARC	trans	rs9395865	0.520	rs6903708	chr6:53332940	A/G	cg10582690	chr10:69644422	SIRT1	-0.49	-6.23	-0.38	2.16e-9	Electroencephalographic traits in alcoholism;
SARC	trans	rs61931739	0.927	rs1906135	chr12:34038103	C/A	cg26384229	chr12:38710491	ALG10B	-0.58	-7.27	-0.43	5.33e-12	Morning vs. evening chronotype;
SARC	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	11.07	0.59	3.59e-23	Alzheimer's disease;
SARC	cis	rs9300255	0.569	rs1727320	chr12:123700476	T/A	cg00376283	chr12:123451042	ABCB9	0.55	6.53	0.39	4.09e-10	Neutrophil percentage of white cells;
SARC	cis	rs17376456	0.569	rs7713956	chr5:93133185	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.56	-5.85	-0.36	1.65e-8	Diabetic retinopathy;
SARC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg04267008	chr7:1944627	MAD1L1	-0.6	-7.03	-0.42	2.23e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs7666738	0.830	rs10049627	chr4:99025272	A/C	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	trans	rs7980799	0.711	rs12319055	chr12:33626509	C/T	cg26384229	chr12:38710491	ALG10B	-0.63	-7.77	-0.45	2.52e-13	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs2153535	0.580	rs969422	chr6:8451780	A/T	cg07606381	chr6:8435919	SLC35B3	0.78	11.13	0.59	2.34e-23	Motion sickness;
SARC	cis	rs5753618	0.561	rs2413049	chr22:31686144	A/G	cg13145458	chr22:31556086	RNF185	0.48	5.11	0.32	6.69e-7	Colorectal cancer;
SARC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg27588902	chr6:42928151	GNMT	0.38	5.89	0.36	1.36e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs7953249	0.656	rs2243616	chr12:121406370	G/T	cg02403541	chr12:121454288	C12orf43	-0.75	-10.34	-0.56	7.06e-21	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.77	-11.1	-0.59	2.93e-23	Total body bone mineral density;
SARC	cis	rs10504229	0.636	rs114725691	chr8:58054292	C/T	cg08219700	chr8:58056026	NA	0.6	6.03	0.37	6.34e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs12586317	0.553	rs3809448	chr14:35515096	C/T	cg26967526	chr14:35346199	BAZ1A	-0.57	-5.68	-0.35	4.01e-8	Psoriasis;
SARC	cis	rs1580019	0.563	rs2392071	chr7:32572536	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.95	16.94	0.74	1.71e-42	Cognitive ability;
SARC	cis	rs17331151	0.573	rs13080929	chr3:52885112	A/C	cg04865290	chr3:52927548	TMEM110	-0.64	-5.77	-0.35	2.53e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs9733	0.566	rs11204675	chr1:150570985	A/C	cg17724175	chr1:150552817	MCL1	-0.4	-5.08	-0.32	7.74e-7	Tonsillectomy;
SARC	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.53	5.9	0.36	1.26e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	trans	rs61931739	0.591	rs10743834	chr12:33916129	A/C	cg26384229	chr12:38710491	ALG10B	0.55	7.14	0.42	1.21e-11	Morning vs. evening chronotype;
SARC	cis	rs1728785	1.000	rs1645938	chr16:68595197	G/A	cg02972257	chr16:68554789	NA	-0.45	-5.32	-0.33	2.48e-7	Ulcerative colitis;
SARC	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.72	10.32	0.56	8.38e-21	Menarche (age at onset);
SARC	cis	rs3762637	0.882	rs72958418	chr3:122160373	G/C	cg24169773	chr3:122142474	KPNA1	-0.56	-5.73	-0.35	3.07e-8	LDL cholesterol levels;
SARC	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	23.11	0.83	3.31e-62	Chronic sinus infection;
SARC	cis	rs1707322	0.691	rs12031182	chr1:46220999	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.22	0.38	2.26e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg11987759	chr7:65425863	GUSB	-0.58	-7.94	-0.46	8.47e-14	Calcium levels;
SARC	cis	rs911555	0.662	rs4906322	chr14:103879032	A/G	cg24130564	chr14:104152367	KLC1	0.47	5.46	0.34	1.2e-7	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg11062466	chr8:58055876	NA	0.54	5.56	0.34	7.55e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6570726	1.000	rs436066	chr6:145847127	C/T	cg05220968	chr6:146057943	EPM2A	-0.29	-5.05	-0.31	9.02e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6582630	0.519	rs11514372	chr12:38308613	T/G	cg26384229	chr12:38710491	ALG10B	0.87	12.74	0.64	1.45e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs3126085	0.935	rs11586114	chr1:152299767	G/A	cg26876637	chr1:152193138	HRNR	-0.52	-5.42	-0.33	1.45e-7	Atopic dermatitis;
SARC	cis	rs7223966	0.961	rs35844156	chr17:61837568	G/A	cg26338869	chr17:61819248	STRADA	0.48	5.02	0.31	1.01e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg08219700	chr8:58056026	NA	0.62	6.52	0.39	4.28e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7584330	0.744	rs58223447	chr2:238378644	G/C	cg11271282	chr2:238384023	NA	0.46	4.76	0.3	3.36e-6	Prostate cancer;
SARC	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg18252515	chr7:66147081	NA	-0.55	-6.08	-0.37	4.79e-9	Aortic root size;
SARC	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg12463550	chr7:65579703	CRCP	0.5	5.9	0.36	1.27e-8	Aortic root size;
SARC	cis	rs240764	0.687	rs7754085	chr6:101220806	T/A	cg09795085	chr6:101329169	ASCC3	-0.44	-5.64	-0.35	4.85e-8	Neuroticism;
SARC	cis	rs7937682	0.575	rs34888817	chr11:111756455	C/T	cg22437258	chr11:111473054	SIK2	-0.47	-5.38	-0.33	1.77e-7	Primary sclerosing cholangitis;
SARC	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg17554472	chr22:41940697	POLR3H	-0.48	-5.28	-0.33	2.92e-7	Vitiligo;
SARC	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg05861140	chr6:150128134	PCMT1	-0.4	-5.11	-0.32	6.71e-7	Lung cancer;
SARC	cis	rs1153858	1.000	rs12591058	chr15:45640172	T/C	cg21132104	chr15:45694354	SPATA5L1	0.78	10.82	0.58	2.33e-22	Homoarginine levels;
SARC	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg04944784	chr2:26401820	FAM59B	0.47	5.8	0.35	2.19e-8	Gut microbiome composition (summer);
SARC	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg23988827	chr10:69676715	SIRT1	0.59	8.49	0.49	2.38e-15	Thyroid stimulating hormone;
SARC	cis	rs9790314	0.586	rs35713426	chr3:161131271	A/G	cg17135325	chr3:160939158	NMD3	0.48	5.95	0.36	9.62e-9	Morning vs. evening chronotype;
SARC	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg18252515	chr7:66147081	NA	0.59	6.34	0.38	1.17e-9	Aortic root size;
SARC	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	8.84	0.5	2.44e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2228479	0.572	rs62054252	chr16:89896834	G/A	cg00800038	chr16:89945340	TCF25	-0.82	-5.9	-0.36	1.27e-8	Skin colour saturation;
SARC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.99	-16.03	-0.72	1.73e-39	Prudent dietary pattern;
SARC	cis	rs1062177	0.756	rs2915826	chr5:151119963	G/A	cg00977110	chr5:151150581	G3BP1	-0.55	-5.53	-0.34	8.58e-8	Preschool internalizing problems;
SARC	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg04944784	chr2:26401820	FAM59B	-0.47	-5.75	-0.35	2.81e-8	Gut microbiome composition (summer);
SARC	cis	rs6772849	0.896	rs4557179	chr3:128366726	A/C	cg08795948	chr3:128337044	NA	0.55	7.79	0.45	2.23e-13	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs554111	0.891	rs659046	chr1:21047725	C/T	cg04902671	chr1:21058625	SH2D5	0.42	4.88	0.3	1.95e-6	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs2204008	0.748	rs8186658	chr12:38301461	A/C	cg26384229	chr12:38710491	ALG10B	0.86	12.23	0.63	6.59e-27	Bladder cancer;
SARC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg26668828	chr6:292823	DUSP22	0.64	8.43	0.48	3.59e-15	Menopause (age at onset);
SARC	cis	rs8044995	0.563	rs3785113	chr16:68369213	T/C	cg05110241	chr16:68378359	PRMT7	-0.63	-5.88	-0.36	1.45e-8	Schizophrenia;
SARC	cis	rs6582630	0.533	rs4103689	chr12:38702980	A/C	cg10518543	chr12:38710700	ALG10B	0.38	4.88	0.3	2e-6	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9790314	0.747	rs6789244	chr3:160866230	A/C	cg04691961	chr3:161091175	C3orf57	-0.51	-6.73	-0.4	1.32e-10	Morning vs. evening chronotype;
SARC	cis	rs7647973	0.626	rs1352889	chr3:49652148	T/C	cg07636037	chr3:49044803	WDR6	0.65	6.58	0.4	3.01e-10	Menarche (age at onset);
SARC	cis	rs9916302	0.808	rs12943928	chr17:37611330	G/A	cg07936489	chr17:37558343	FBXL20	-0.69	-9.02	-0.51	7.32e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs10411936	0.712	rs10414751	chr19:16591695	G/A	cg10248733	chr19:16607483	C19orf44;CALR3	0.62	7.44	0.44	1.97e-12	White blood cell count;Multiple sclerosis;
SARC	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg05368731	chr17:41323189	NBR1	0.81	9.82	0.54	2.91e-19	Menopause (age at onset);
SARC	cis	rs8067545	0.604	rs55705283	chr17:20027138	G/A	cg13482628	chr17:19912719	NA	0.52	6.87	0.41	5.72e-11	Schizophrenia;
SARC	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg04151384	chr11:10315732	SBF2	0.5	6.31	0.38	1.39e-9	Height;
SARC	cis	rs10782582	0.593	rs6675076	chr1:76118503	A/C	cg10523679	chr1:76189770	ACADM	-0.4	-5.02	-0.31	1.02e-6	Daytime sleep phenotypes;
SARC	cis	rs2302729	0.625	rs1592573	chr12:2831556	A/T	cg19945202	chr12:2788847	CACNA1C	-0.49	-4.92	-0.31	1.65e-6	Sleep quality;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg09936566	chr1:163292020	NUF2	-0.5	-6.72	-0.4	1.37e-10	Neuroticism;
SARC	cis	rs7727544	0.684	rs270602	chr5:131656700	T/C	cg07395648	chr5:131743802	NA	-0.41	-4.78	-0.3	3.04e-6	Blood metabolite levels;
SARC	cis	rs912057	0.932	rs1294406	chr6:6737737	A/G	cg06612196	chr6:6737390	NA	0.65	9.84	0.54	2.45e-19	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs986417	0.901	rs10782440	chr14:61031648	G/C	cg27398547	chr14:60952738	C14orf39	0.97	9.13	0.51	3.34e-17	Gut microbiota (bacterial taxa);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg10922808	chr20:54978525	CSTF1	0.47	6.48	0.39	5.41e-10	Thyroid stimulating hormone;
SARC	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.46	0.39	6.13e-10	Bipolar disorder;
SARC	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.35	4.72	0.3	4.04e-6	Personality dimensions;
SARC	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg16680214	chr1:154839983	KCNN3	-0.37	-5.94	-0.36	1.01e-8	Prostate cancer;
SARC	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg09858108	chr8:58055024	NA	0.42	5.22	0.32	4.01e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg27266027	chr21:40555129	PSMG1	0.52	5.79	0.35	2.21e-8	Cognitive function;
SARC	cis	rs6120849	0.754	rs6088682	chr20:33615702	A/C	cg06115741	chr20:33292138	TP53INP2	0.54	5.16	0.32	5.3e-7	Protein C levels;
SARC	cis	rs735396	0.770	rs2257764	chr12:121446446	T/A	cg04422896	chr12:121454269	C12orf43	-0.41	-5.01	-0.31	1.07e-6	N-glycan levels;
SARC	cis	rs9487051	0.676	rs9398193	chr6:109593134	G/T	cg01475377	chr6:109611718	NA	-0.35	-5.08	-0.32	7.66e-7	Reticulocyte fraction of red cells;
SARC	cis	rs365132	1.000	rs353478	chr5:176370988	T/C	cg16309518	chr5:176445507	NA	-0.46	-6.01	-0.37	7.17e-9	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg25036284	chr2:26402008	FAM59B	-0.44	-5.41	-0.33	1.56e-7	Gut microbiome composition (summer);
SARC	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg01448562	chr3:133502909	NA	-0.48	-6.92	-0.41	4.35e-11	Iron status biomarkers;
SARC	cis	rs12216125	0.801	rs56107510	chr6:25987436	C/A	cg10373733	chr6:25993375	NA	0.47	5.35	0.33	2.07e-7	Iron status biomarkers;
SARC	cis	rs7605378	0.567	rs717915	chr2:200714766	C/T	cg17644776	chr2:200775616	C2orf69	0.54	6.76	0.4	1.13e-10	Osteoporosis;
SARC	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.59e-6	Depression;
SARC	cis	rs2635047	0.713	rs9304344	chr18:44758665	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.48	-6.2	-0.38	2.59e-9	Educational attainment;
SARC	trans	rs12546673	0.628	rs58959058	chr8:24277878	G/A	cg13641198	chr9:16044344	NA	-0.48	-6.37	-0.39	1.02e-9	Scarlet fever;
SARC	cis	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg25894440	chr7:65020034	NA	-0.74	-5.55	-0.34	7.85e-8	Diabetic kidney disease;
SARC	cis	rs7086627	0.515	rs11202963	chr10:82210392	A/G	cg01528321	chr10:82214614	TSPAN14	0.58	8.49	0.49	2.44e-15	Post bronchodilator FEV1;
SARC	cis	rs4253772	0.678	rs1053332	chr22:46640179	A/G	cg24881330	chr22:46731750	TRMU	0.55	6.04	0.37	6.1e-9	LDL cholesterol;Cholesterol, total;
SARC	cis	rs933688	0.938	rs1477348	chr5:90707823	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.01	12.94	0.65	3.09e-29	Smoking behavior;
SARC	trans	rs11722228	0.549	rs2241488	chr4:10101131	T/C	cg26043149	chr18:55253948	FECH	0.71	7.91	0.46	1e-13	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs57024841	0.819	rs11145949	chr9:139857958	A/G	cg00693599	chr9:139836323	FBXW5	-0.3	-4.85	-0.3	2.27e-6	Beta-trace protein levels;
SARC	cis	rs9790314	1.000	rs9850455	chr3:161017192	G/A	cg03342759	chr3:160939853	NMD3	-0.61	-7.69	-0.45	4.18e-13	Morning vs. evening chronotype;
SARC	cis	rs6570726	0.967	rs373704	chr6:145860618	C/A	cg23711669	chr6:146136114	FBXO30	0.73	10.86	0.58	1.65e-22	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs449789	0.857	rs592212	chr6:159711083	G/C	cg14500486	chr6:159655392	FNDC1	-0.44	-5.02	-0.31	1.01e-6	Pulse pressure;
SARC	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.5	5.96	0.36	9.48e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs892961	0.899	rs7222532	chr17:75413302	G/C	cg05865280	chr17:75406074	SEPT9	0.57	8.47	0.48	2.87e-15	Airflow obstruction;
SARC	cis	rs8523	0.901	rs1321536	chr6:11018812	A/C	cg13562911	chr6:11044106	ELOVL2	0.38	5.14	0.32	5.93e-7	Red blood cell fatty acid levels;
SARC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.78	10.01	0.55	7.48e-20	Prudent dietary pattern;
SARC	cis	rs2832077	0.527	rs1048546	chr21:30244877	G/T	cg08807101	chr21:30365312	RNF160	-0.48	-5.16	-0.32	5.4e-7	Cognitive test performance;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg18798572	chr1:52116301	OSBPL9	0.49	6.56	0.39	3.4e-10	Thyroid stimulating hormone;
SARC	cis	rs7662987	0.517	rs3018048	chr4:100005538	C/T	cg12011299	chr4:100065546	ADH4	0.32	5.26	0.33	3.25e-7	Smoking initiation;
SARC	cis	rs892961	0.932	rs7208336	chr17:75412932	T/C	cg05865280	chr17:75406074	SEPT9	0.57	8.47	0.48	2.87e-15	Airflow obstruction;
SARC	cis	rs7587476	0.784	rs34112702	chr2:215696002	A/G	cg11970703	chr2:215861251	ABCA12	-0.32	-4.96	-0.31	1.36e-6	Neuroblastoma;
SARC	cis	rs2361710	0.704	rs4889979	chr17:78121707	T/A	cg20811857	chr17:78079795	GAA	-0.33	-5.3	-0.33	2.69e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
SARC	cis	rs3733585	0.762	rs6449217	chr4:10009151	T/A	cg00071950	chr4:10020882	SLC2A9	0.35	5.34	0.33	2.26e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs9581857	0.547	rs76971629	chr13:28051031	C/T	cg01674679	chr13:27998804	GTF3A	-0.67	-5.13	-0.32	6.24e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	cis	rs2013441	1.000	rs8074047	chr17:20176703	G/A	cg13482628	chr17:19912719	NA	-0.47	-6.09	-0.37	4.52e-9	Obesity-related traits;
SARC	cis	rs11122272	0.735	rs2572252	chr1:231513653	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs1448094	0.935	rs11117119	chr12:86336432	A/T	cg02569458	chr12:86230093	RASSF9	0.4	5.85	0.36	1.64e-8	Major depressive disorder;
SARC	cis	rs2997447	0.846	rs3008430	chr1:26390328	A/G	cg19633962	chr1:26362018	EXTL1	-0.59	-4.88	-0.3	1.99e-6	QRS complex (12-leadsum);
SARC	cis	rs2832191	0.633	rs2832166	chr21:30462395	G/C	cg08807101	chr21:30365312	RNF160	0.91	14.32	0.68	8.4e-34	Dental caries;
SARC	cis	rs7584330	0.704	rs7598954	chr2:238364776	C/T	cg14458575	chr2:238380390	NA	0.56	6.26	0.38	1.82e-9	Prostate cancer;
SARC	cis	rs9398803	0.865	rs9375442	chr6:126803137	A/C	cg20229609	chr6:126660872	C6orf173	0.37	5.38	0.33	1.84e-7	Male-pattern baldness;
SARC	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg11764359	chr7:65958608	NA	0.65	7.6	0.45	7.08e-13	Aortic root size;
SARC	cis	rs2295359	0.824	rs11209003	chr1:67601132	G/T	cg08029281	chr1:67600428	NA	0.38	4.72	0.3	4.08e-6	Psoriasis;
SARC	cis	rs7644634	0.623	rs7646445	chr3:105422536	T/C	cg23051926	chr3:105466016	CBLB	0.44	5.52	0.34	9.08e-8	Itch intensity from mosquito bite;
SARC	cis	rs73206853	0.841	rs57216167	chr12:110940748	C/T	cg10860002	chr12:110842031	ANAPC7	0.6	4.82	0.3	2.65e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs6060717	0.529	rs6060535	chr20:34235522	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-5.58	-0.34	6.66e-8	Hip circumference adjusted for BMI;
SARC	cis	rs12479064	0.694	rs4341989	chr2:100046783	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.7	-9.05	-0.51	5.85e-17	Chronic sinus infection;
SARC	cis	rs7945705	0.935	rs2568062	chr11:8887945	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.46	-6.54	-0.39	3.82e-10	Hemoglobin concentration;
SARC	cis	rs3087591	0.708	rs964288	chr17:29679246	G/A	cg24425628	chr17:29625626	OMG;NF1	0.41	5.23	0.32	3.74e-7	Hip circumference;
SARC	cis	rs9894429	0.546	rs9906979	chr17:79608765	A/G	cg10661904	chr17:79619235	PDE6G	-0.41	-5.78	-0.35	2.44e-8	Eye color traits;
SARC	cis	rs2952156	0.920	rs2517959	chr17:37846512	A/T	cg00129232	chr17:37814104	STARD3	-0.69	-8.99	-0.51	8.97e-17	Asthma;
SARC	cis	rs1065852	0.906	rs9611734	chr22:42502070	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.42	6.26	0.38	1.8e-9	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
SARC	cis	rs9291683	0.595	rs35250962	chr4:10048271	C/T	cg00071950	chr4:10020882	SLC2A9	0.39	6.27	0.38	1.74e-9	Bone mineral density;
SARC	cis	rs4642101	0.686	rs13085726	chr3:12832672	A/C	cg05775895	chr3:12838266	CAND2	0.85	16.04	0.72	1.65e-39	QRS complex (12-leadsum);
SARC	cis	rs4253772	0.591	rs6007732	chr22:46652303	A/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.67	7.16	0.42	1.05e-11	LDL cholesterol;Cholesterol, total;
SARC	cis	rs5760092	0.755	rs11090298	chr22:24262061	G/A	cg20007245	chr22:24372913	LOC391322	0.67	7.43	0.44	1.99e-12	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs2303759	0.626	rs12982246	chr19:49801169	A/G	cg22307029	chr19:49891270	CCDC155	0.58	6.74	0.4	1.22e-10	Multiple sclerosis;
SARC	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg01475735	chr3:40494733	NA	-0.49	-5.37	-0.33	1.95e-7	Renal cell carcinoma;
SARC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg24503407	chr1:205819492	PM20D1	-0.75	-12.13	-0.62	1.39e-26	Monocyte percentage of white cells;
SARC	cis	rs4765905	0.610	rs4765670	chr12:2313126	A/G	cg10668781	chr12:2307325	CACNA1C	-0.31	-4.87	-0.3	2.08e-6	Schizophrenia;
SARC	cis	rs926392	0.666	rs56877916	chr20:37696192	A/T	cg16355469	chr20:37678765	NA	0.73	9.6	0.53	1.35e-18	Dialysis-related mortality;
SARC	cis	rs2289583	0.544	rs12050759	chr15:75265191	G/A	cg14664628	chr15:75095509	CSK	0.49	5.31	0.33	2.62e-7	Systemic lupus erythematosus;
SARC	cis	rs7084402	0.935	rs10826202	chr10:60359091	C/T	cg07615347	chr10:60278583	BICC1	0.61	8.83	0.5	2.57e-16	Refractive error;
SARC	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg07701084	chr6:150067640	NUP43	0.38	4.8	0.3	2.83e-6	Lung cancer;
SARC	cis	rs155076	1.000	rs12870992	chr13:21846019	A/G	cg11317459	chr13:21872234	NA	0.9	10.54	0.57	1.68e-21	White matter hyperintensity burden;
SARC	cis	rs9398803	0.830	rs1159619	chr6:126801144	C/A	cg20229609	chr6:126660872	C6orf173	0.4	5.82	0.36	1.96e-8	Male-pattern baldness;
SARC	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg24633833	chr3:10029261	TMEM111	0.52	5.25	0.33	3.43e-7	Alzheimer's disease;
SARC	cis	rs3092073	0.624	rs11696196	chr20:44574533	C/T	cg10662479	chr20:44420225	WFDC3;DNTTIP1	0.44	5.59	0.34	6.38e-8	Intelligence (multi-trait analysis);
SARC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	20.42	0.8	8.2e-54	Prudent dietary pattern;
SARC	cis	rs11697848	1.000	rs2284646	chr20:48526776	T/G	cg17849948	chr20:48532315	SPATA2	0.87	5.2	0.32	4.3e-7	Systemic lupus erythematosus;
SARC	cis	rs2479724	0.870	rs7766817	chr6:41918104	T/A	cg17623882	chr6:41773611	USP49	-0.45	-5.75	-0.35	2.72e-8	Menarche (age at onset);
SARC	cis	rs73194058	1	rs73194058	chr21:34764288	C/A	cg14850771	chr21:34775459	IFNGR2	0.78	6.15	0.37	3.25e-9	Rheumatoid arthritis;
SARC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg06873352	chr17:61820015	STRADA	0.53	6.79	0.41	9.36e-11	Prudent dietary pattern;
SARC	cis	rs7819412	0.740	rs7844536	chr8:11034028	A/G	cg12395012	chr8:11607386	GATA4	0.32	5.36	0.33	2.04e-7	Triglycerides;
SARC	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.63	7.56	0.44	9.42e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs67460515	0.563	rs13071892	chr3:160817877	A/C	cg03342759	chr3:160939853	NMD3	-0.66	-7.89	-0.46	1.2e-13	Parkinson's disease;
SARC	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg09165964	chr15:75287851	SCAMP5	0.53	7.03	0.42	2.31e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	cis	rs6696846	0.729	rs72757512	chr1:205079203	G/A	cg00857998	chr1:205179979	DSTYK	0.49	6.22	0.38	2.23e-9	Red blood cell count;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg21883765	chr7:127032075	ZNF800	-0.78	-6.38	-0.39	9.27e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs514406	0.505	rs6703127	chr1:53180565	C/T	cg24675658	chr1:53192096	ZYG11B	-0.64	-9.42	-0.53	4.62e-18	Monocyte count;
SARC	cis	rs2228479	0.850	rs11644526	chr16:89898660	C/T	cg00800038	chr16:89945340	TCF25	-0.82	-5.77	-0.35	2.46e-8	Skin colour saturation;
SARC	cis	rs9875589	0.509	rs6442423	chr3:14016062	G/A	cg19554555	chr3:13937349	NA	-0.4	-5.14	-0.32	5.95e-7	Ovarian reserve;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg11521436	chr4:40068229	N4BP2	0.46	6.57	0.4	3.32e-10	Breast cancer;
SARC	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg25072359	chr17:41440525	NA	0.58	7.18	0.43	9.36e-12	Menopause (age at onset);
SARC	cis	rs10892173	0.765	rs1892903	chr11:117669619	A/G	cg07621104	chr11:117668040	DSCAML1	0.36	4.77	0.3	3.22e-6	Myopia;
SARC	cis	rs12142240	0.659	rs72677602	chr1:46837487	G/A	cg00530320	chr1:46809349	NSUN4	0.58	6.84	0.41	7e-11	Menopause (age at onset);
SARC	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	13.85	0.67	3.04e-32	Chronic sinus infection;
SARC	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg10435706	chr6:150039699	LATS1	0.36	4.8	0.3	2.88e-6	Lung cancer;
SARC	cis	rs4803468	0.967	rs67047091	chr19:41938684	C/T	cg14132834	chr19:41945861	ATP5SL	0.58	7.71	0.45	3.67e-13	Height;
SARC	cis	rs7659604	0.605	rs1396080	chr4:122740454	T/G	cg06713675	chr4:122721982	EXOSC9	-0.39	-5.11	-0.32	6.64e-7	Type 2 diabetes;
SARC	cis	rs9818758	0.607	rs34343820	chr3:49309534	C/G	cg06212747	chr3:49208901	KLHDC8B	-0.7	-5.94	-0.36	1.05e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs6963495	0.745	rs73192150	chr7:105211610	A/C	cg13798780	chr7:105162888	PUS7	0.58	5.3	0.33	2.66e-7	Bipolar disorder (body mass index interaction);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg24877391	chr2:61244844	PEX13;PUS10	-0.47	-6.51	-0.39	4.44e-10	Thyroid stimulating hormone;
SARC	cis	rs7481584	0.962	rs12805426	chr11:3020580	C/T	cg08508325	chr11:3079039	CARS	0.22	4.87	0.3	2.02e-6	Calcium levels;
SARC	cis	rs1215050	0.791	rs13107606	chr4:98823187	C/A	cg05340658	chr4:99064831	C4orf37	0.43	5.85	0.36	1.66e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs6430585	0.583	rs1435577	chr2:136624947	C/G	cg07169764	chr2:136633963	MCM6	1.09	16.65	0.74	1.55e-41	Corneal structure;
SARC	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.93	13.87	0.67	2.78e-32	Gut microbiome composition (summer);
SARC	cis	rs9300255	0.512	rs2851436	chr12:123667354	G/T	cg05973401	chr12:123451056	ABCB9	0.52	5.89	0.36	1.34e-8	Neutrophil percentage of white cells;
SARC	cis	rs2688419	0.545	rs1849478	chr3:23067010	C/G	cg00327796	chr3:23032191	NA	-0.41	-5.8	-0.36	2.13e-8	Type 2 diabetes;
SARC	cis	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg24110177	chr3:50126178	RBM5	0.62	8.12	0.47	2.73e-14	Body mass index;
SARC	cis	rs9303401	0.659	rs12600349	chr17:57054245	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-1.05	-11.87	-0.61	1.03e-25	Cognitive test performance;
SARC	cis	rs17666538	1.000	rs57255985	chr8:574131	C/T	cg23958373	chr8:599963	NA	-0.94	-6.74	-0.4	1.27e-10	IgG glycosylation;
SARC	cis	rs3092073	0.617	rs3746513	chr20:44594228	G/A	cg00981651	chr20:44574847	PCIF1	-0.33	-5.23	-0.32	3.75e-7	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg18876405	chr7:65276391	NA	-0.44	-4.93	-0.31	1.56e-6	Aortic root size;
SARC	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg05368731	chr17:41323189	NBR1	0.79	9.83	0.54	2.62e-19	Menopause (age at onset);
SARC	cis	rs748404	0.723	rs11853991	chr15:43557549	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.49	5.33	0.33	2.27e-7	Lung cancer;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg22183057	chr5:162883763	NUDCD2	0.46	6.34	0.38	1.2e-9	Thyroid stimulating hormone;
SARC	cis	rs2842992	0.714	rs2475564	chr6:160123673	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.68	6.5	0.39	4.96e-10	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs7552404	0.696	rs67487205	chr1:76373756	T/C	cg03433033	chr1:76189801	ACADM	0.46	5.55	0.34	7.89e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg12463550	chr7:65579703	CRCP	0.65	5.03	0.31	9.96e-7	Diabetic kidney disease;
SARC	cis	rs73242632	1.000	rs2271807	chr4:57898729	A/G	cg20415529	chr4:57845134	POLR2B;C4orf14	1.01	6.42	0.39	7.44e-10	Congenital heart disease (maternal effect);
SARC	cis	rs2710642	0.962	rs2058567	chr2:63091426	T/C	cg17519650	chr2:63277830	OTX1	0.39	4.97	0.31	1.31e-6	LDL cholesterol levels;LDL cholesterol;
SARC	cis	rs3087591	0.683	rs17826544	chr17:29640225	A/G	cg24425628	chr17:29625626	OMG;NF1	0.44	5.61	0.35	5.64e-8	Hip circumference;
SARC	cis	rs7824557	0.527	rs57629785	chr8:11235150	C/A	cg21775007	chr8:11205619	TDH	-0.65	-8.61	-0.49	1.12e-15	Retinal vascular caliber;
SARC	cis	rs6582630	0.593	rs7299329	chr12:38447943	G/C	cg13010199	chr12:38710504	ALG10B	0.75	10.21	0.56	1.79e-20	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg12419862	chr22:24373484	LOC391322	0.85	12.14	0.62	1.33e-26	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7592578	0.679	rs62181018	chr2:191323295	C/T	cg25963032	chr2:191064776	C2orf88	-0.44	-5.07	-0.32	8.14e-7	Diastolic blood pressure;
SARC	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg01570182	chr17:44337453	NA	0.8	9.1	0.51	4.09e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg03060546	chr3:49711283	APEH	0.41	5.14	0.32	5.86e-7	Parkinson's disease;
SARC	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg07636037	chr3:49044803	WDR6	1.01	17.88	0.76	1.35e-45	Parkinson's disease;
SARC	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg02018176	chr4:1364513	KIAA1530	-0.36	-5.17	-0.32	4.96e-7	Obesity-related traits;
SARC	cis	rs9788721	0.802	rs56219465	chr15:78742579	A/G	cg06917634	chr15:78832804	PSMA4	-0.49	-5.24	-0.32	3.52e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs6088590	1.000	rs6088595	chr20:33358499	T/A	cg06115741	chr20:33292138	TP53INP2	0.51	5.82	0.36	1.97e-8	Coronary artery disease;
SARC	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg13395646	chr4:1353034	KIAA1530	-0.45	-5.25	-0.33	3.41e-7	Obesity-related traits;
SARC	cis	rs7264396	0.676	rs6058383	chr20:34556005	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	5.3	0.33	2.71e-7	Total cholesterol levels;
SARC	cis	rs11971779	0.616	rs6967932	chr7:139022381	C/T	cg23387468	chr7:139079360	LUC7L2	0.33	4.79	0.3	2.92e-6	Diisocyanate-induced asthma;
SARC	cis	rs6429082	0.818	rs453315	chr1:235680585	C/T	cg26050004	chr1:235667680	B3GALNT2	0.67	7.89	0.46	1.19e-13	Adiposity;
SARC	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg18404041	chr3:52824283	ITIH1	-0.43	-6.53	-0.39	4.04e-10	Bipolar disorder;
SARC	cis	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg12463550	chr7:65579703	CRCP	0.68	5.24	0.32	3.61e-7	Diabetic kidney disease;
SARC	cis	rs3892630	0.817	rs12609866	chr19:33184412	C/T	cg22980127	chr19:33182716	NUDT19	1.06	9.68	0.54	7.46e-19	Red blood cell traits;
SARC	cis	rs17376456	0.877	rs10040648	chr5:93490301	G/C	cg25358565	chr5:93447407	FAM172A	1.35	14.18	0.68	2.46e-33	Diabetic retinopathy;
SARC	cis	rs10078	0.571	rs890973	chr5:471494	T/C	cg24955955	chr5:415729	AHRR	0.73	6.66	0.4	1.93e-10	Fat distribution (HIV);
SARC	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg01316550	chr5:56110833	MAP3K1	0.52	4.74	0.3	3.78e-6	Initial pursuit acceleration;
SARC	cis	rs1153858	1.000	rs11858495	chr15:45637662	A/G	cg15395560	chr15:45543142	SLC28A2	0.26	4.86	0.3	2.18e-6	Homoarginine levels;
SARC	cis	rs1448094	0.621	rs10863090	chr12:86282211	C/T	cg02569458	chr12:86230093	RASSF9	0.4	5.46	0.34	1.22e-7	Major depressive disorder;
SARC	cis	rs8523	0.774	rs2147041	chr6:11050523	C/T	cg13562911	chr6:11044106	ELOVL2	-0.46	-6.52	-0.39	4.27e-10	Red blood cell fatty acid levels;
SARC	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg11168104	chr5:1857477	NA	-0.33	-4.74	-0.3	3.78e-6	Cardiovascular disease risk factors;
SARC	cis	rs910316	0.687	rs11627442	chr14:75669649	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.43	-5.81	-0.36	2.08e-8	Height;
SARC	cis	rs12701220	0.817	rs1058727	chr7:1087095	A/G	cg26769984	chr7:1090371	C7orf50	0.46	5.26	0.33	3.24e-7	Bronchopulmonary dysplasia;
SARC	cis	rs478304	0.651	rs12225620	chr11:65505448	T/C	cg26695010	chr11:65641043	EFEMP2	0.39	4.78	0.3	3.1e-6	Acne (severe);
SARC	cis	rs12586317	0.514	rs74590021	chr14:35490113	T/G	cg26967526	chr14:35346199	BAZ1A	-0.57	-5.71	-0.35	3.4e-8	Psoriasis;
SARC	cis	rs7980687	0.596	rs1727319	chr12:123701353	T/C	cg00376283	chr12:123451042	ABCB9	0.58	6.86	0.41	5.99e-11	Height;Educational attainment;Head circumference (infant);
SARC	cis	rs12220238	0.818	rs16931294	chr10:75999169	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.54	6.13	0.37	3.64e-9	Soluble interleukin-2 receptor subunit alpha;
SARC	cis	rs4243830	0.737	rs925744	chr1:6615695	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.87	-8.19	-0.47	1.68e-14	Body mass index;
SARC	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg18876405	chr7:65276391	NA	-0.44	-5.05	-0.31	8.78e-7	Aortic root size;
SARC	cis	rs8114671	0.935	rs633198	chr20:33778434	T/C	cg24642439	chr20:33292090	TP53INP2	-0.49	-5.48	-0.34	1.1e-7	Height;
SARC	cis	rs17666538	0.591	rs2878547	chr8:603416	G/A	cg23958373	chr8:599963	NA	0.71	6.09	0.37	4.67e-9	IgG glycosylation;
SARC	cis	rs60871478	1.000	rs6460801	chr7:810506	T/C	cg05535760	chr7:792225	HEATR2	0.79	8.17	0.47	1.91e-14	Cerebrospinal P-tau181p levels;
SARC	cis	rs8078723	0.668	rs4239225	chr17:38127112	G/A	cg17467752	chr17:38218738	THRA	0.43	5.47	0.34	1.17e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.41	-4.74	-0.3	3.77e-6	Prudent dietary pattern;
SARC	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg01017244	chr2:74357527	NA	0.56	6.88	0.41	5.35e-11	Gestational age at birth (maternal effect);
SARC	cis	rs8114671	0.967	rs1415774	chr20:33765616	C/T	cg24642439	chr20:33292090	TP53INP2	-0.51	-5.82	-0.36	1.93e-8	Height;
SARC	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg11301795	chr4:187892539	NA	-0.71	-10.14	-0.55	3.07e-20	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9392918	0.871	rs10793850	chr6:7715955	G/T	cg23089261	chr6:7723385	NA	0.39	5.19	0.32	4.52e-7	Height;
SARC	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg16405210	chr4:1374714	KIAA1530	-0.52	-6.01	-0.37	6.93e-9	Obesity-related traits;
SARC	cis	rs9660992	0.573	rs7531256	chr1:205191202	T/G	cg07972983	chr1:205091412	RBBP5	0.56	6.91	0.41	4.7e-11	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs72781680	0.898	rs12614616	chr2:23996501	T/G	cg06627628	chr2:24431161	ITSN2	-0.67	-6.35	-0.38	1.14e-9	Lymphocyte counts;
SARC	trans	rs10771431	0.935	rs1117735	chr12:9372728	G/A	cg27600084	chr12:12264075	NA	0.56	7.76	0.45	2.64e-13	Breast size;
SARC	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg11764359	chr7:65958608	NA	-0.88	-12.61	-0.64	3.94e-28	Aortic root size;
SARC	cis	rs924607	0.898	rs905193	chr5:635095	T/C	cg09021430	chr5:549028	NA	-0.31	-5.84	-0.36	1.77e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	trans	rs1493916	0.905	rs9956315	chr18:31405546	G/C	cg27147174	chr7:100797783	AP1S1	-0.54	-6.87	-0.41	5.69e-11	Life satisfaction;
SARC	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg25703541	chr22:24373054	LOC391322	0.7	8.69	0.49	6.32e-16	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg08219700	chr8:58056026	NA	0.47	5.19	0.32	4.64e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2153535	0.562	rs10458225	chr6:8386004	G/A	cg23788917	chr6:8435910	SLC35B3	-0.64	-8.28	-0.48	9.9e-15	Motion sickness;
SARC	cis	rs1538970	1.000	rs17395553	chr1:45864761	C/T	cg05343316	chr1:45956843	TESK2	0.72	8.64	0.49	8.86e-16	Platelet count;
SARC	cis	rs77372450	0.636	rs10057597	chr5:157012870	A/G	cg23851860	chr5:157002805	ADAM19	0.5	4.83	0.3	2.5e-6	Bipolar disorder (body mass index interaction);
SARC	cis	rs7647973	0.925	rs6446256	chr3:49224210	A/G	cg06212747	chr3:49208901	KLHDC8B	0.6	6.42	0.39	7.46e-10	Menarche (age at onset);
SARC	cis	rs834603	0.569	rs834602	chr7:47446215	A/C	cg23694490	chr7:47445681	TNS3	0.36	5.94	0.36	1.05e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs9399137	0.507	rs4451150	chr6:135279063	T/G	cg24558204	chr6:135376177	HBS1L	0.62	8.18	0.47	1.87e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs3820928	0.874	rs9288618	chr2:227872617	A/G	cg05526886	chr2:227700861	RHBDD1	-0.5	-6.15	-0.37	3.36e-9	Pulmonary function;
SARC	cis	rs854765	0.551	rs8070748	chr17:17859421	A/G	cg05444541	chr17:17804740	TOM1L2	-0.29	-4.82	-0.3	2.56e-6	Total body bone mineral density;
SARC	cis	rs12931792	0.712	rs4787495	chr16:30165725	C/T	cg17640201	chr16:30407289	ZNF48	-0.59	-7.72	-0.45	3.41e-13	Tonsillectomy;
SARC	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg06060754	chr5:176797920	RGS14	0.52	6.48	0.39	5.38e-10	Urinary electrolytes (magnesium/calcium ratio);
SARC	cis	rs7264396	0.563	rs6060566	chr20:34288226	T/C	cg01084648	chr20:34329383	RBM39	0.55	4.83	0.3	2.45e-6	Total cholesterol levels;
SARC	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg15320075	chr8:145703422	NA	0.6	8.1	0.47	3.01e-14	Age at first birth;
SARC	cis	rs6871536	1.000	rs12187537	chr5:131939904	A/C	cg11797159	chr5:131991491	NA	0.38	4.85	0.3	2.21e-6	Asthma (childhood onset);
SARC	cis	rs8017423	0.669	rs7153190	chr14:90703904	T/G	cg20276874	chr14:90721474	PSMC1	-0.39	-5.35	-0.33	2.09e-7	Mortality in heart failure;
SARC	cis	rs72792276	1.000	rs72794386	chr5:127479278	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	5.92	0.36	1.13e-8	Red cell distribution width;
SARC	cis	rs546131	0.928	rs552868	chr11:34830694	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.47	5.82	0.36	1.89e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs9393813	1.000	rs13220817	chr6:27356527	T/C	cg11502198	chr6:26597334	ABT1	0.41	4.93	0.31	1.54e-6	Bipolar disorder;
SARC	cis	rs2635047	0.806	rs9962602	chr18:44599057	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.39	-4.83	-0.3	2.46e-6	Educational attainment;
SARC	cis	rs7589342	0.517	rs6736701	chr2:106390440	G/T	cg16077055	chr2:106428750	NCK2	0.28	5.45	0.34	1.25e-7	Addiction;
SARC	cis	rs4668356	0.687	rs16859206	chr2:172043803	A/G	cg13882835	chr2:172017928	TLK1	0.63	5.19	0.32	4.65e-7	Cognitive performance;
SARC	cis	rs12142240	0.698	rs67276232	chr1:46825484	T/G	cg14993813	chr1:46806288	NSUN4	-0.51	-5.34	-0.33	2.19e-7	Menopause (age at onset);
SARC	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg13770153	chr20:60521292	NA	-0.48	-6.53	-0.39	3.98e-10	Body mass index;
SARC	cis	rs2841277	0.738	rs1036713	chr14:105396693	C/G	cg14403583	chr14:105418241	AHNAK2	0.45	5.8	0.36	2.15e-8	Rheumatoid arthritis;
SARC	cis	rs17270561	0.609	rs1179086	chr6:25791745	A/T	cg16482183	chr6:26056742	HIST1H1C	0.48	6.15	0.37	3.3e-9	Iron status biomarkers;
SARC	cis	rs5753618	0.539	rs2228619	chr22:31663842	C/G	cg02404636	chr22:31891804	SFI1	-0.49	-5.24	-0.32	3.53e-7	Colorectal cancer;
SARC	cis	rs9399135	1.000	rs11754265	chr6:135356216	C/G	cg24558204	chr6:135376177	HBS1L	0.46	6.26	0.38	1.87e-9	Red blood cell count;
SARC	trans	rs17685	0.593	rs56265719	chr7:75796269	C/T	cg19862616	chr7:65841803	NCRNA00174	0.6	7.43	0.44	2.09e-12	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg25894440	chr7:65020034	NA	0.75	5.67	0.35	4.23e-8	Diabetic kidney disease;
SARC	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.5	5.62	0.35	5.34e-8	Renal function-related traits (BUN);
SARC	cis	rs9790314	0.663	rs10513559	chr3:160667465	G/A	cg04691961	chr3:161091175	C3orf57	0.61	8.56	0.49	1.5e-15	Morning vs. evening chronotype;
SARC	cis	rs3780378	0.935	rs2230724	chr9:5081780	G/A	cg03508284	chr9:4985524	JAK2	-0.43	-5.2	-0.32	4.45e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
SARC	cis	rs13256369	1.000	rs12550762	chr8:8576535	T/A	cg18904891	chr8:8559673	CLDN23	0.5	6.08	0.37	4.95e-9	Obesity-related traits;
SARC	cis	rs9513627	1.000	rs9585075	chr13:100128634	G/A	cg25919922	chr13:100150906	NA	-0.64	-4.81	-0.3	2.66e-6	Obesity-related traits;
SARC	cis	rs4243830	0.850	rs4908915	chr1:6601607	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.9	-9.13	-0.51	3.37e-17	Body mass index;
SARC	cis	rs78320035	0.867	rs75786448	chr1:168097146	G/A	cg17113809	chr1:168148080	TIPRL	1.14	6.54	0.39	3.88e-10	Red cell distribution width;
SARC	cis	rs6840360	0.593	rs3805356	chr4:152680701	C/T	cg22705602	chr4:152727874	NA	0.49	8.48	0.49	2.55e-15	Intelligence (multi-trait analysis);
SARC	cis	rs2795502	1.000	rs3121323	chr10:43377166	A/G	cg20628663	chr10:43360327	NA	-0.43	-5.94	-0.36	1.05e-8	Blood protein levels;
SARC	cis	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg18252515	chr7:66147081	NA	-1.34	-11.93	-0.62	6.47e-26	Diabetic kidney disease;
SARC	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg06634786	chr22:41940651	POLR3H	-0.57	-6.77	-0.41	1.05e-10	Vitiligo;
SARC	trans	rs643955	0.637	rs4841271	chr8:9870137	T/A	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.54	-0.44	1.05e-12	Systemic lupus erythematosus;
SARC	cis	rs4930561	0.714	rs7950451	chr11:67962406	C/A	cg16338278	chr11:67432957	ALDH3B2	0.34	5.6	0.34	6.12e-8	Breast cancer in childhood cancer survivors;IgG glycosylation;
SARC	cis	rs2075371	1.000	rs1862047	chr7:133978078	G/C	cg20476274	chr7:133979776	SLC35B4	0.6	8.19	0.47	1.7e-14	Mean platelet volume;
SARC	cis	rs3796352	1.000	rs2336540	chr3:52974589	G/A	cg15956490	chr3:53032818	SFMBT1	0.79	5.18	0.32	4.85e-7	Immune reponse to smallpox (secreted IL-2);
SARC	trans	rs61931739	0.513	rs1463634	chr12:33899621	A/G	cg26384229	chr12:38710491	ALG10B	0.69	9.57	0.53	1.64e-18	Morning vs. evening chronotype;
SARC	cis	rs9457247	0.765	rs9457252	chr6:167433925	A/G	cg07741184	chr6:167504864	NA	-0.36	-7.12	-0.42	1.3e-11	Crohn's disease;
SARC	cis	rs826838	0.967	rs826870	chr12:39120250	G/A	cg26384229	chr12:38710491	ALG10B	-0.82	-12.53	-0.63	6.94e-28	Heart rate;
SARC	cis	rs8072100	0.738	rs9915222	chr17:45448615	G/T	cg08085267	chr17:45401833	C17orf57	-0.41	-4.73	-0.3	3.85e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-7.12	-0.42	1.37e-11	Alzheimer's disease;
SARC	cis	rs1707322	0.721	rs11211151	chr1:46112752	T/C	cg03146154	chr1:46216737	IPP	0.52	6.32	0.38	1.33e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg07777115	chr5:623756	CEP72	-0.61	-5.53	-0.34	8.61e-8	Obesity-related traits;
SARC	cis	rs12421382	0.593	rs1808842	chr11:109389454	C/T	cg16359550	chr11:109292809	C11orf87	0.34	5.14	0.32	5.73e-7	Schizophrenia;
SARC	cis	rs8014204	0.819	rs2003490	chr14:75377555	C/A	cg06637938	chr14:75390232	RPS6KL1	0.8	11.94	0.62	5.97e-26	Caffeine consumption;
SARC	cis	rs2882877	0.648	rs66883355	chr2:190397021	G/A	cg21926118	chr2:190387206	NA	-0.41	-5.14	-0.32	5.86e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs7520050	0.807	rs28647556	chr1:46206399	G/A	cg06784218	chr1:46089804	CCDC17	0.26	4.76	0.3	3.38e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs9325144	0.600	rs10748442	chr12:38732939	A/T	cg13010199	chr12:38710504	ALG10B	0.55	7.07	0.42	1.8e-11	Morning vs. evening chronotype;
SARC	cis	rs17125944	0.615	rs7151474	chr14:53313680	C/T	cg00686598	chr14:53173677	PSMC6	-0.67	-4.96	-0.31	1.36e-6	Alzheimer's disease (late onset);
SARC	cis	rs3796352	1.000	rs35174175	chr3:53041509	T/C	cg07884673	chr3:53033167	SFMBT1	0.9	5.87	0.36	1.49e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs9303280	0.685	rs9916765	chr17:38005595	T/C	cg20243544	chr17:37824526	PNMT	0.44	5.91	0.36	1.24e-8	Self-reported allergy;
SARC	cis	rs8180040	0.764	rs11708451	chr3:47198826	G/A	cg27129171	chr3:47204927	SETD2	0.67	9.52	0.53	2.32e-18	Colorectal cancer;
SARC	cis	rs7216064	1.000	rs8082512	chr17:65837059	T/C	cg12091567	chr17:66097778	LOC651250	-0.69	-6.99	-0.42	2.89e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs2075371	1.000	rs378358	chr7:133970628	A/G	cg00033643	chr7:134001901	SLC35B4	0.41	5.04	0.31	9.16e-7	Mean platelet volume;
SARC	cis	rs910316	0.874	rs61980828	chr14:75630378	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.51	-6.86	-0.41	6.16e-11	Height;
SARC	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg25072359	chr17:41440525	NA	0.5	5.84	0.36	1.71e-8	Menopause (age at onset);
SARC	cis	rs7429990	0.930	rs13072132	chr3:47866161	A/G	cg11946769	chr3:48343235	NME6	0.69	6.86	0.41	6.28e-11	Educational attainment (years of education);
SARC	cis	rs3126085	0.935	rs4421596	chr1:152181673	G/A	cg26876637	chr1:152193138	HRNR	0.49	5.61	0.35	5.67e-8	Atopic dermatitis;
SARC	cis	rs12477438	1.000	rs1922624	chr2:99909958	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-6.65	-0.4	2.08e-10	Chronic sinus infection;
SARC	cis	rs11758351	1.000	rs3757135	chr6:26200707	G/A	cg23601095	chr6:26197514	HIST1H3D	0.61	5.3	0.33	2.64e-7	Gout;Renal underexcretion gout;
SARC	cis	rs56390833	1	rs56390833	chr15:78877381	C/A	cg06917634	chr15:78832804	PSMA4	-0.53	-5.7	-0.35	3.57e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg04287289	chr16:89883240	FANCA	0.84	14.61	0.69	9.49e-35	Vitiligo;
SARC	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg20607798	chr8:58055168	NA	0.58	5.57	0.34	6.9e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs78487399	0.808	rs79955955	chr2:43686985	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-4.97	-0.31	1.31e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs7264396	0.563	rs6060569	chr20:34290731	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-7.17	-0.43	9.99e-12	Total cholesterol levels;
SARC	cis	rs79146658	0.736	rs6707222	chr2:179743923	C/T	cg17765952	chr2:179737173	CCDC141	-0.59	-5.2	-0.32	4.46e-7	Diastolic blood pressure;
SARC	cis	rs826838	1.000	rs11168218	chr12:38884466	A/G	cg13010199	chr12:38710504	ALG10B	0.77	10.7	0.57	5.42e-22	Heart rate;
SARC	cis	rs2200578	1.000	rs62153845	chr2:99887162	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.54	5.14	0.32	5.73e-7	IgG glycosylation;
SARC	cis	rs703842	1.000	rs11172335	chr12:58175201	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.78	11.25	0.59	9.62e-24	Multiple sclerosis;
SARC	cis	rs2075371	0.579	rs11766422	chr7:134018160	T/C	cg11752832	chr7:134001865	SLC35B4	0.5	6.22	0.38	2.3e-9	Mean platelet volume;
SARC	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg18404041	chr3:52824283	ITIH1	0.42	6.19	0.38	2.73e-9	Bipolar disorder;
SARC	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg04756594	chr16:24857601	SLC5A11	-0.45	-6.29	-0.38	1.52e-9	Intelligence (multi-trait analysis);
SARC	cis	rs11792861	0.926	rs7855282	chr9:111802614	T/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.68	7.72	0.45	3.51e-13	Menarche (age at onset);
SARC	cis	rs8141529	0.673	rs132548	chr22:29317559	C/G	cg15103426	chr22:29168792	CCDC117	-0.67	-8.71	-0.5	5.8e-16	Lymphocyte counts;
SARC	trans	rs1814175	0.935	rs11040465	chr11:49689323	C/T	cg03929089	chr4:120376271	NA	-0.87	-13.82	-0.67	4.11e-32	Height;
SARC	cis	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg12463550	chr7:65579703	CRCP	0.68	5.09	0.32	7.53e-7	Gout;
SARC	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	11.57	0.6	9.38e-25	Platelet count;
SARC	cis	rs6840360	0.550	rs6853955	chr4:152510806	G/A	cg22705602	chr4:152727874	NA	-0.44	-6.82	-0.41	7.54e-11	Intelligence (multi-trait analysis);
SARC	cis	rs910316	1.000	rs10142865	chr14:75555624	G/A	cg11812906	chr14:75593930	NEK9	0.89	14.1	0.68	4.63e-33	Height;
SARC	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg06634786	chr22:41940651	POLR3H	-0.63	-7.13	-0.42	1.24e-11	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs1003719	0.715	rs1981433	chr21:38542223	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.48	-0.53	3.11e-18	Eye color traits;
SARC	cis	rs17376456	0.877	rs12374470	chr5:93481046	A/G	cg21475434	chr5:93447410	FAM172A	0.89	7.46	0.44	1.7e-12	Diabetic retinopathy;
SARC	cis	rs2929278	0.589	rs11638972	chr15:44074691	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.45	-5.18	-0.32	4.73e-7	Schizophrenia;
SARC	cis	rs9815354	0.812	rs17215183	chr3:41812334	T/C	cg03022575	chr3:42003672	ULK4	0.72	5.99	0.37	7.83e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg11987759	chr7:65425863	GUSB	0.47	6.26	0.38	1.82e-9	Aortic root size;
SARC	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg24549020	chr5:56110836	MAP3K1	0.62	5.52	0.34	9.16e-8	Initial pursuit acceleration;
SARC	cis	rs7084402	0.967	rs12242287	chr10:60278340	A/G	cg07615347	chr10:60278583	BICC1	-0.6	-8.88	-0.5	1.84e-16	Refractive error;
SARC	cis	rs10504073	0.631	rs341813	chr8:50039916	T/C	cg00325661	chr8:49890786	NA	0.55	7.45	0.44	1.84e-12	Blood metabolite ratios;
SARC	cis	rs55692411	0.537	rs35375092	chr3:50065274	G/A	cg24110177	chr3:50126178	RBM5	-0.48	-5.31	-0.33	2.56e-7	Intelligence (multi-trait analysis);
SARC	cis	rs4919694	1.000	rs35159404	chr10:104805610	C/A	cg04362960	chr10:104952993	NT5C2	0.65	5.56	0.34	7.45e-8	Arsenic metabolism;
SARC	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.43	0.39	7.26e-10	Height;
SARC	cis	rs6580649	0.941	rs757556	chr12:48502493	C/T	cg24011408	chr12:48396354	COL2A1	-0.47	-5.28	-0.33	2.92e-7	Lung cancer;
SARC	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs17376456	0.542	rs6556833	chr5:93104707	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.53	5.69	0.35	3.76e-8	Diabetic retinopathy;
SARC	cis	rs9581943	0.901	rs9551414	chr13:28474237	C/T	cg17352152	chr13:28491409	NA	0.39	5.15	0.32	5.59e-7	Pancreatic cancer;
SARC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg26338869	chr17:61819248	STRADA	0.79	10.66	0.57	7e-22	Prudent dietary pattern;
SARC	cis	rs13096357	0.520	rs17080319	chr3:48732480	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.57	-5.28	-0.33	2.94e-7	Cognitive ability (multi-trait analysis);
SARC	cis	rs2645694	0.533	rs2645680	chr4:77820956	T/C	cg06046430	chr4:77819534	ANKRD56	0.54	7.78	0.45	2.35e-13	Emphysema distribution in smoking;
SARC	cis	rs722599	0.748	rs59112602	chr14:75358817	C/G	cg08847533	chr14:75593920	NEK9	-0.44	-5.09	-0.32	7.47e-7	IgG glycosylation;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg14311088	chr22:40573762	TNRC6B	0.5	6.37	0.39	1.03e-9	Electrocardiographic conduction measures;
SARC	cis	rs2153535	0.580	rs7741456	chr6:8452424	G/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.49	1.52e-15	Motion sickness;
SARC	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.93	-0.51	1.28e-16	Alzheimer's disease;
SARC	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg05313129	chr8:58192883	C8orf71	-0.62	-6.37	-0.39	9.92e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9300255	0.569	rs1727320	chr12:123700476	T/A	cg05973401	chr12:123451056	ABCB9	0.52	5.89	0.36	1.34e-8	Neutrophil percentage of white cells;
SARC	cis	rs2204008	0.837	rs11611861	chr12:38357459	A/G	cg13010199	chr12:38710504	ALG10B	0.78	10.77	0.58	3.24e-22	Bladder cancer;
SARC	cis	rs17376456	0.825	rs17314825	chr5:93234937	A/G	cg21475434	chr5:93447410	FAM172A	0.86	7.53	0.44	1.09e-12	Diabetic retinopathy;
SARC	cis	rs17666538	0.591	rs7818950	chr8:643831	C/T	cg07234876	chr8:600039	NA	0.79	6.75	0.4	1.17e-10	IgG glycosylation;
SARC	cis	rs2230307	0.536	rs640030	chr1:100574992	C/T	cg24955406	chr1:100503596	HIAT1	-0.71	-6.81	-0.41	8.3e-11	Carotid intima media thickness;
SARC	cis	rs933688	1.000	rs11948075	chr5:90680579	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.02	12.97	0.65	2.47e-29	Smoking behavior;
SARC	cis	rs2486288	0.656	rs11854365	chr15:45558083	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.46	-5.68	-0.35	4.03e-8	Glomerular filtration rate;
SARC	cis	rs3820928	0.874	rs10166736	chr2:227900419	C/T	cg11843606	chr2:227700838	RHBDD1	-0.56	-6.95	-0.41	3.67e-11	Pulmonary function;
SARC	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg15448220	chr1:150897856	SETDB1	0.47	6.25	0.38	1.94e-9	Urate levels;
SARC	cis	rs7647973	1.000	rs7619789	chr3:49476263	T/C	cg06212747	chr3:49208901	KLHDC8B	0.57	6.19	0.38	2.71e-9	Menarche (age at onset);
SARC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg06873352	chr17:61820015	STRADA	0.51	6.49	0.39	5.04e-10	Prudent dietary pattern;
SARC	trans	rs7819412	0.659	rs4073948	chr8:10772644	A/T	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.54	-0.44	1.06e-12	Triglycerides;
SARC	cis	rs4820539	1.000	rs916584	chr22:23469433	A/G	cg14186256	chr22:23484241	RTDR1	0.88	14.37	0.69	5.77e-34	Bone mineral density;
SARC	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg01276201	chr10:134613136	NA	0.33	6.06	0.37	5.48e-9	Migraine;
SARC	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg27266027	chr21:40555129	PSMG1	0.52	5.68	0.35	3.9e-8	Cognitive function;
SARC	cis	rs607987	0.871	rs689233	chr11:30270667	G/A	cg06241208	chr11:30344200	C11orf46	-0.41	-5.07	-0.32	8.23e-7	Body mass index;
SARC	cis	rs1448094	0.511	rs59858864	chr12:86166404	G/A	cg02569458	chr12:86230093	RASSF9	0.37	4.86	0.3	2.21e-6	Major depressive disorder;
SARC	cis	rs9462027	0.628	rs2764211	chr6:34704613	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.42	5.79	0.35	2.31e-8	Systemic lupus erythematosus;
SARC	cis	rs9733	0.621	rs12746899	chr1:150579678	A/T	cg13175981	chr1:150552382	MCL1	0.69	9.42	0.53	4.58e-18	Tonsillectomy;
SARC	cis	rs751837	0.518	rs17101146	chr14:103463599	A/G	cg02938407	chr14:103486904	CDC42BPB	-0.53	-4.81	-0.3	2.77e-6	Large B-cell lymphoma;
SARC	cis	rs9486719	0.947	rs9398072	chr6:96911304	T/C	cg06623918	chr6:96969491	KIAA0776	0.76	8.54	0.49	1.79e-15	Migraine;Coronary artery disease;
SARC	cis	rs10504229	0.679	rs16921683	chr8:58053270	T/C	cg20607798	chr8:58055168	NA	0.61	5.66	0.35	4.51e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs722599	0.599	rs8003660	chr14:75227098	T/C	cg06637938	chr14:75390232	RPS6KL1	0.41	5.03	0.31	9.95e-7	IgG glycosylation;
SARC	cis	rs7772486	0.790	rs10223507	chr6:146285204	C/A	cg23711669	chr6:146136114	FBXO30	-0.77	-11.99	-0.62	4.08e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.5	0.44	1.3e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4800452	0.826	rs7244739	chr18:20747874	C/T	cg13313047	chr18:20735648	CABLES1	-0.42	-5.09	-0.32	7.3e-7	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
SARC	cis	rs9733	0.593	rs10888384	chr1:150574256	C/T	cg13175981	chr1:150552382	MCL1	0.64	8.4	0.48	4.31e-15	Tonsillectomy;
SARC	cis	rs12681366	0.614	rs2919663	chr8:95470146	C/A	cg26464482	chr8:95565502	KIAA1429	0.42	5.25	0.33	3.39e-7	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs796364	0.774	rs112564437	chr2:201074048	G/C	cg23649088	chr2:200775458	C2orf69	-0.61	-6.93	-0.41	4.05e-11	Schizophrenia;
SARC	cis	rs6500602	0.789	rs2404546	chr16:4479734	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.33	5.4	0.33	1.63e-7	Schizophrenia;
SARC	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg18404041	chr3:52824283	ITIH1	-0.43	-6.43	-0.39	7.24e-10	Bipolar disorder;
SARC	cis	rs4268898	1.000	rs10165445	chr2:24441698	C/T	cg26838691	chr2:24397539	C2orf84	0.37	5.09	0.32	7.5e-7	Asthma;
SARC	trans	rs1814175	0.616	rs10769644	chr11:49987676	C/A	cg03929089	chr4:120376271	NA	-0.82	-11.88	-0.61	9.2e-26	Height;
SARC	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9916302	0.904	rs2168785	chr17:37407135	C/T	cg07936489	chr17:37558343	FBXL20	-0.69	-9.27	-0.52	1.32e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs3092073	0.624	rs11696623	chr20:44580380	C/T	cg00981651	chr20:44574847	PCIF1	0.3	4.88	0.3	1.93e-6	Intelligence (multi-trait analysis);
SARC	cis	rs3813567	0.702	rs7164665	chr15:78953919	T/C	cg04896959	chr15:78267971	NA	-0.51	-5.23	-0.32	3.74e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
SARC	cis	rs6598955	0.543	rs881578	chr1:26536141	G/A	cg04990556	chr1:26633338	UBXN11	0.76	7.72	0.45	3.49e-13	Obesity-related traits;
SARC	cis	rs9581943	0.967	rs7985481	chr13:28466090	A/C	cg25299895	chr13:28498091	PDX1	0.37	4.98	0.31	1.24e-6	Pancreatic cancer;
SARC	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg03806693	chr22:41940476	POLR3H	-0.98	-13.6	-0.67	2.18e-31	Vitiligo;
SARC	cis	rs11098499	0.954	rs12499324	chr4:120393786	C/T	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs950169	0.959	rs12902070	chr15:84793558	T/C	cg24253500	chr15:84953950	NA	0.36	5.23	0.32	3.77e-7	Schizophrenia;
SARC	cis	rs6570726	0.905	rs388728	chr6:145816419	T/C	cg05347473	chr6:146136440	FBXO30	0.49	6.48	0.39	5.27e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg16479474	chr6:28041457	NA	0.37	5.87	0.36	1.46e-8	Depression;
SARC	cis	rs8067545	0.611	rs2703807	chr17:20109189	C/T	cg13482628	chr17:19912719	NA	-0.52	-6.72	-0.4	1.37e-10	Schizophrenia;
SARC	cis	rs6991838	0.800	rs11786598	chr8:66472179	C/T	cg13398993	chr8:66546079	ARMC1	-0.44	-5.71	-0.35	3.47e-8	Intelligence (multi-trait analysis);
SARC	cis	rs734999	0.566	rs6664969	chr1:2534978	G/A	cg18854424	chr1:2615690	NA	0.31	4.99	0.31	1.2e-6	Ulcerative colitis;
SARC	cis	rs7568458	0.837	rs35215812	chr2:85792384	G/A	cg17127132	chr2:85788382	GGCX	0.43	5.57	0.34	7.11e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs9815354	1.000	rs6768542	chr3:41865474	G/A	cg03022575	chr3:42003672	ULK4	0.56	5.02	0.31	1.05e-6	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.13	0.8	7.01e-53	Prudent dietary pattern;
SARC	cis	rs138249	1.000	rs138252	chr22:50570873	G/T	cg24864161	chr22:50528282	MOV10L1	0.32	5.11	0.32	6.73e-7	Gestational age at birth in labor-initiated deliveries (child effect);
SARC	cis	rs9868809	0.772	rs9821797	chr3:48718253	T/A	cg12468774	chr3:49236860	CCDC36	0.45	4.83	0.3	2.45e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg22535103	chr8:58192502	C8orf71	-0.59	-6.21	-0.38	2.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9400467	0.537	rs17663278	chr6:111504881	A/C	cg15721981	chr6:111408429	SLC16A10	0.67	5.65	0.35	4.66e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs995000	0.965	rs11207977	chr1:62977307	C/T	cg06896770	chr1:63153194	DOCK7	1.0	15.03	0.7	3.79e-36	Triglyceride levels;
SARC	cis	rs920590	0.704	rs3866469	chr8:19658534	T/C	cg03894339	chr8:19674705	INTS10	0.44	5.46	0.34	1.2e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs12458462	0.859	rs35493271	chr18:77448793	G/T	cg23301140	chr18:77439876	CTDP1	0.62	8.08	0.47	3.48e-14	Monocyte count;
SARC	trans	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.07	-0.42	1.8e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs600231	0.542	rs11227199	chr11:65238121	G/A	cg17120908	chr11:65337727	SSSCA1	-0.45	-4.99	-0.31	1.17e-6	Bone mineral density;
SARC	cis	rs6088590	0.561	rs6087605	chr20:33180624	G/T	cg24642439	chr20:33292090	TP53INP2	0.66	8.51	0.49	2.12e-15	Coronary artery disease;
SARC	cis	rs1355223	1.000	rs1355221	chr11:34758609	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-5.99	-0.37	7.78e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs7681440	0.904	rs6816469	chr4:90772885	G/C	cg02192967	chr4:90758406	SNCA	0.37	5.25	0.33	3.5e-7	Dementia with Lewy bodies;
SARC	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	8.8	0.5	3.1e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2832191	0.626	rs2254796	chr21:30341891	A/G	cg24692254	chr21:30365293	RNF160	-0.99	-17.19	-0.75	2.56e-43	Dental caries;
SARC	trans	rs1814175	0.527	rs7110797	chr11:49644096	T/C	cg03929089	chr4:120376271	NA	-0.72	-8.19	-0.47	1.74e-14	Height;
SARC	cis	rs7824557	0.767	rs4559208	chr8:11153925	C/G	cg21775007	chr8:11205619	TDH	0.52	6.25	0.38	1.93e-9	Retinal vascular caliber;
SARC	cis	rs8016982	0.855	rs10149681	chr14:81686319	G/A	cg01989461	chr14:81687754	GTF2A1	0.58	7.22	0.43	7.09e-12	Schizophrenia;
SARC	cis	rs17376456	0.809	rs12152763	chr5:93405509	T/A	cg25358565	chr5:93447407	FAM172A	1.3	14.36	0.69	6.16e-34	Diabetic retinopathy;
SARC	cis	rs35110281	0.563	rs162371	chr21:44931489	G/T	cg21573476	chr21:45109991	RRP1B	-0.49	-7.3	-0.43	4.55e-12	Mean corpuscular volume;
SARC	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg13770153	chr20:60521292	NA	-0.54	-7.27	-0.43	5.53e-12	Body mass index;
SARC	cis	rs748404	0.560	rs529611	chr15:43805988	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	5.5	0.34	9.75e-8	Lung cancer;
SARC	cis	rs7586879	0.639	rs2384058	chr2:25100328	A/G	cg01884057	chr2:25150051	NA	0.29	4.8	0.3	2.81e-6	Body mass index;
SARC	cis	rs6141769	0.542	rs7360824	chr20:31315158	A/G	cg13636640	chr20:31349939	DNMT3B	-0.46	-4.87	-0.3	2.05e-6	Subjective well-being;
SARC	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg07701084	chr6:150067640	NUP43	0.44	5.56	0.34	7.19e-8	Lung cancer;
SARC	cis	rs3768617	0.510	rs3765522	chr1:183077618	C/T	cg13390022	chr1:182993471	LAMC1	0.32	4.88	0.3	1.95e-6	Fuchs's corneal dystrophy;
SARC	cis	rs9487051	0.872	rs1111866	chr6:109610846	A/C	cg01475377	chr6:109611718	NA	0.4	5.73	0.35	3.1e-8	Reticulocyte fraction of red cells;
SARC	cis	rs698813	0.604	rs58667148	chr2:44481443	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	5.97	0.36	8.64e-9	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs7027203	0.521	rs9299412	chr9:96523268	G/T	cg14598338	chr9:96623480	NA	-0.34	-4.76	-0.3	3.43e-6	DNA methylation (variation);
SARC	cis	rs9303280	0.901	rs1008723	chr17:38066267	G/T	cg00129232	chr17:37814104	STARD3	-0.36	-4.77	-0.3	3.2e-6	Self-reported allergy;
SARC	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg04277193	chr17:41438351	NA	0.45	4.84	0.3	2.4e-6	Menopause (age at onset);
SARC	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg20607798	chr8:58055168	NA	0.57	5.53	0.34	8.58e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7681440	0.904	rs6816736	chr4:90765746	G/A	cg06632027	chr4:90757378	SNCA	0.39	5.66	0.35	4.49e-8	Dementia with Lewy bodies;
SARC	cis	rs7568458	0.870	rs1562323	chr2:85809711	T/C	cg02493740	chr2:85810744	VAMP5	-0.33	-4.86	-0.3	2.19e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs7937682	0.889	rs487985	chr11:111517908	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.93	-15.22	-0.71	8.48e-37	Primary sclerosing cholangitis;
SARC	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg22535103	chr8:58192502	C8orf71	-0.57	-5.57	-0.34	6.91e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs881375	1.000	rs1953126	chr9:123640500	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.44	5.26	0.33	3.21e-7	Rheumatoid arthritis;
SARC	cis	rs7000551	0.715	rs2461477	chr8:22378314	A/G	cg12081754	chr8:22256438	SLC39A14	0.57	7.95	0.46	7.91e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs644799	1.000	rs651445	chr11:95539122	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.7	9.55	0.53	1.87e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs651907	0.557	rs3806654	chr3:101396529	G/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	6.69	0.4	1.68e-10	Colorectal cancer;
SARC	cis	rs208520	0.837	rs208467	chr6:66914837	T/C	cg07460842	chr6:66804631	NA	-1.0	-12.18	-0.62	9.65e-27	Exhaled nitric oxide output;
SARC	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg06713675	chr4:122721982	EXOSC9	-0.51	-6.63	-0.4	2.35e-10	Type 2 diabetes;
SARC	cis	rs8014204	0.747	rs2070598	chr14:75360906	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.53	-7.55	-0.44	9.99e-13	Caffeine consumption;
SARC	cis	rs9322193	0.566	rs3922947	chr6:150245992	G/A	cg11878867	chr6:150167359	LRP11	0.39	5.01	0.31	1.09e-6	Lung cancer;
SARC	cis	rs2075371	1.000	rs2241336	chr7:133979578	A/G	cg20476274	chr7:133979776	SLC35B4	0.61	8.46	0.48	2.89e-15	Mean platelet volume;
SARC	cis	rs9325144	0.534	rs4882283	chr12:38710249	C/T	cg26384229	chr12:38710491	ALG10B	0.63	8.61	0.49	1.13e-15	Morning vs. evening chronotype;
SARC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg25405998	chr7:65216604	CCT6P1	0.48	5.7	0.35	3.63e-8	Calcium levels;
SARC	cis	rs933688	0.532	rs13165085	chr5:90538448	G/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.47	-5.24	-0.32	3.52e-7	Smoking behavior;
SARC	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg13393036	chr8:95962371	TP53INP1	-0.36	-6.21	-0.38	2.38e-9	Type 2 diabetes;
SARC	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg02711726	chr17:80685570	FN3KRP	-0.54	-6.51	-0.39	4.55e-10	Glycated hemoglobin levels;
SARC	cis	rs17270561	0.609	rs3922699	chr6:25734969	A/G	cg17691542	chr6:26056736	HIST1H1C	0.58	7.09	0.42	1.6e-11	Iron status biomarkers;
SARC	cis	rs2387326	0.767	rs11016098	chr10:129942982	A/G	cg16087940	chr10:129947807	NA	-0.45	-5.53	-0.34	8.57e-8	Select biomarker traits;
SARC	cis	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg11995313	chr8:8860691	ERI1	-0.41	-5.19	-0.32	4.68e-7	Mood instability;
SARC	cis	rs7412746	0.658	rs12097963	chr1:150870450	T/C	cg13175981	chr1:150552382	MCL1	-0.48	-5.86	-0.36	1.57e-8	Melanoma;
SARC	cis	rs6430585	0.583	rs111837148	chr2:136612036	G/A	cg07169764	chr2:136633963	MCM6	1.09	16.66	0.74	1.44e-41	Corneal structure;
SARC	cis	rs9325144	0.560	rs11182952	chr12:38636278	C/A	cg13010199	chr12:38710504	ALG10B	-0.55	-6.83	-0.41	7.47e-11	Morning vs. evening chronotype;
SARC	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg13395646	chr4:1353034	KIAA1530	0.5	5.99	0.37	8.1e-9	Obesity-related traits;
SARC	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg24549020	chr5:56110836	MAP3K1	0.52	5.8	0.36	2.11e-8	Coronary artery disease;
SARC	cis	rs1568889	0.877	rs57202579	chr11:28221677	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	10.04	0.55	6.23e-20	Bipolar disorder;
SARC	cis	rs9815354	0.812	rs73073323	chr3:41834051	C/T	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg21724239	chr8:58056113	NA	0.66	6.2	0.38	2.51e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg22337509	chr1:204093899	SOX13	0.47	6.8	0.41	8.53e-11	Schizophrenia;
SARC	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg04267008	chr7:1944627	MAD1L1	-0.62	-7.23	-0.43	6.85e-12	Bipolar disorder and schizophrenia;
SARC	cis	rs9487051	0.837	rs932223	chr6:109586656	A/G	cg01475377	chr6:109611718	NA	-0.39	-5.61	-0.35	5.62e-8	Reticulocyte fraction of red cells;
SARC	cis	rs1348850	0.668	rs2365619	chr2:178497366	A/G	cg23306229	chr2:178417860	TTC30B	-0.59	-6.1	-0.37	4.5e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	trans	rs4481887	0.854	rs4534423	chr1:248474993	G/C	cg12668902	chr6:7261808	NA	-0.53	-6.49	-0.39	5.22e-10	Common traits (Other);
SARC	cis	rs1609391	0.543	rs9881139	chr3:136634040	A/G	cg15507776	chr3:136538369	TMEM22	0.86	11.7	0.61	3.48e-25	Neuroticism;
SARC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.44	-5.1	-0.32	7.17e-7	Prudent dietary pattern;
SARC	cis	rs36051895	0.695	rs60221565	chr9:5029077	T/G	cg02405213	chr9:5042618	JAK2	-0.49	-5.27	-0.33	3.12e-7	Pediatric autoimmune diseases;
SARC	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg03934478	chr11:495069	RNH1	0.56	5.3	0.33	2.73e-7	Body mass index;
SARC	cis	rs72781680	0.784	rs12616678	chr2:24181159	G/T	cg08917208	chr2:24149416	ATAD2B	0.58	6.0	0.37	7.32e-9	Lymphocyte counts;
SARC	cis	rs11098499	0.954	rs3890049	chr4:120326283	T/A	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	cis	rs965469	0.947	rs6051692	chr20:3244098	T/C	cg25506879	chr20:3388711	C20orf194	-0.56	-5.54	-0.34	8.35e-8	IFN-related cytopenia;
SARC	cis	rs911555	0.755	rs8010247	chr14:103933556	A/G	cg24130564	chr14:104152367	KLC1	0.49	5.77	0.35	2.48e-8	Intelligence (multi-trait analysis);
SARC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg06873352	chr17:61820015	STRADA	0.51	6.58	0.4	3.07e-10	Prudent dietary pattern;
SARC	cis	rs2645694	0.626	rs2703124	chr4:77820626	G/T	cg06046430	chr4:77819534	ANKRD56	0.54	7.78	0.45	2.35e-13	Emphysema distribution in smoking;
SARC	cis	rs11203032	0.831	rs11203011	chr10:90931178	A/C	cg16672925	chr10:90967113	CH25H	0.67	6.35	0.38	1.12e-9	Heart failure;
SARC	cis	rs644799	0.511	rs12791736	chr11:95475399	C/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	6.57	0.4	3.19e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs1814175	0.565	rs4881721	chr11:49761851	G/A	cg03929089	chr4:120376271	NA	-0.73	-10.8	-0.58	2.54e-22	Height;
SARC	cis	rs7659604	0.502	rs11098640	chr4:122675875	G/A	cg19671926	chr4:122722719	EXOSC9	0.55	6.99	0.42	2.87e-11	Type 2 diabetes;
SARC	cis	rs7617773	0.539	rs12486935	chr3:48390164	C/T	cg11946769	chr3:48343235	NME6	0.53	6.53	0.39	4.03e-10	Coronary artery disease;
SARC	cis	rs208520	0.690	rs10455594	chr6:66737894	C/G	cg07460842	chr6:66804631	NA	1.04	13.88	0.67	2.45e-32	Exhaled nitric oxide output;
SARC	cis	rs2729354	0.903	rs2729371	chr11:57321322	A/G	cg02958346	chr11:57425731	CLP1	0.54	5.37	0.33	1.93e-7	Blood protein levels;
SARC	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg18404041	chr3:52824283	ITIH1	-0.4	-6.07	-0.37	5.16e-9	Electroencephalogram traits;
SARC	cis	rs4969178	0.965	rs56658017	chr17:76396164	G/A	cg02836325	chr17:76403955	PGS1	0.32	4.86	0.3	2.15e-6	HDL cholesterol levels;
SARC	cis	rs112591243	0.685	rs115448966	chr21:47988420	G/A	cg26904215	chr21:47823096	PCNT	-0.75	-4.81	-0.3	2.75e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	trans	rs7819412	0.521	rs11777887	chr8:11036799	C/G	cg06636001	chr8:8085503	FLJ10661	0.51	6.59	0.4	2.88e-10	Triglycerides;
SARC	cis	rs1957429	0.634	rs7143541	chr14:65419777	G/T	cg23373153	chr14:65346875	NA	-0.95	-8.83	-0.5	2.59e-16	Pediatric areal bone mineral density (radius);
SARC	cis	rs7149337	0.837	rs4296182	chr14:51662167	A/C	cg23942311	chr14:51606299	NA	0.32	5.74	0.35	2.98e-8	Cancer;
SARC	cis	rs2304069	0.913	rs9324637	chr5:149390947	T/C	cg12661370	chr5:149340060	SLC26A2	0.59	5.62	0.35	5.47e-8	HIV-1 control;
SARC	cis	rs870825	0.616	rs35818632	chr4:185649661	G/T	cg04058563	chr4:185651563	MLF1IP	0.81	11.14	0.59	2.11e-23	Blood protein levels;
SARC	cis	rs1018836	0.886	rs4734246	chr8:91569028	A/C	cg16814680	chr8:91681699	NA	-0.82	-12.94	-0.65	3.26e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	trans	rs9929218	1.000	rs17772363	chr16:68788909	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.63	-8.11	-0.47	2.9e-14	Colorectal cancer;
SARC	cis	rs2304069	0.733	rs216138	chr5:149437190	C/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.5	5.04	0.31	9.49e-7	HIV-1 control;
SARC	cis	rs6570726	0.935	rs390252	chr6:145856896	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.58	0.4	3.04e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg00908189	chr16:619842	PIGQ	0.87	12.56	0.64	5.67e-28	Height;
SARC	cis	rs17666538	0.585	rs1037393	chr8:622634	G/C	cg07234876	chr8:600039	NA	0.77	6.51	0.39	4.6e-10	IgG glycosylation;
SARC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.46	-5.11	-0.32	6.83e-7	Longevity;Endometriosis;
SARC	cis	rs4319547	0.656	rs10773088	chr12:122828069	A/T	cg05707623	chr12:122985044	ZCCHC8	-0.57	-6.64	-0.4	2.14e-10	Body mass index;
SARC	cis	rs6733011	0.506	rs11123755	chr2:99507948	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.41	-5.27	-0.33	3.16e-7	Bipolar disorder;
SARC	cis	rs3812049	0.784	rs2568928	chr5:127487603	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.9	-10.08	-0.55	4.53e-20	Lymphocyte counts;Red cell distribution width;
SARC	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg03264133	chr6:25882463	NA	-0.66	-8.2	-0.47	1.59e-14	Intelligence (multi-trait analysis);
SARC	cis	rs8072100	0.713	rs3871595	chr17:45511388	C/T	cg08085267	chr17:45401833	C17orf57	-0.43	-4.98	-0.31	1.26e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg26681399	chr22:41777847	TEF	-0.5	-5.53	-0.34	8.77e-8	Vitiligo;
SARC	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg13866156	chr1:1669148	SLC35E2	0.54	8.03	0.47	4.75e-14	Body mass index;
SARC	cis	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg14019146	chr3:50243930	SLC38A3	0.32	4.94	0.31	1.49e-6	Intelligence (multi-trait analysis);
SARC	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg11987759	chr7:65425863	GUSB	-0.6	-7.96	-0.46	7.38e-14	Aortic root size;
SARC	cis	rs12477438	0.666	rs10179910	chr2:99658503	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-14.29	-0.68	1.08e-33	Chronic sinus infection;
SARC	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg11366901	chr6:160182831	ACAT2	1.05	10.89	0.58	1.33e-22	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs9325144	0.647	rs3759139	chr12:39087609	G/A	cg26384229	chr12:38710491	ALG10B	-0.63	-8.09	-0.47	3.38e-14	Morning vs. evening chronotype;
SARC	trans	rs11098499	0.954	rs28572238	chr4:120316686	T/G	cg25214090	chr10:38739885	LOC399744	0.55	7.14	0.42	1.15e-11	Corneal astigmatism;
SARC	cis	rs7086627	0.515	rs12245180	chr10:82211897	C/G	cg01528321	chr10:82214614	TSPAN14	0.58	8.48	0.49	2.68e-15	Post bronchodilator FEV1;
SARC	cis	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg12463550	chr7:65579703	CRCP	0.65	5.04	0.31	9.53e-7	Diabetic kidney disease;
SARC	trans	rs61931739	0.500	rs7308338	chr12:34553181	A/G	cg13010199	chr12:38710504	ALG10B	0.78	11.14	0.59	2.23e-23	Morning vs. evening chronotype;
SARC	cis	rs1981331	0.609	rs7282611	chr21:48043297	C/A	cg17243659	chr21:48055224	PRMT2	0.8	4.82	0.3	2.65e-6	Cerebrospinal fluid t-tau:AB1-42 ratio;
SARC	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg11764359	chr7:65958608	NA	-0.72	-8.42	-0.48	3.77e-15	Aortic root size;
SARC	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg22535103	chr8:58192502	C8orf71	-0.73	-7.24	-0.43	6.52e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs9303401	0.614	rs34683543	chr17:56520036	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.01	10.87	0.58	1.61e-22	Cognitive test performance;
SARC	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg05793240	chr7:2802953	GNA12	-0.34	-5.04	-0.31	9.38e-7	Height;
SARC	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.6	6.51	0.39	4.5e-10	Renal function-related traits (BUN);
SARC	cis	rs858239	0.632	rs1985769	chr7:23122506	T/G	cg23682824	chr7:23144976	KLHL7	0.71	9.57	0.53	1.68e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs5769765	0.542	rs5770725	chr22:50256309	C/T	cg03033257	chr22:50311977	ALG12;CRELD2	-0.55	-4.81	-0.3	2.68e-6	Schizophrenia;
SARC	cis	rs7465272	1.000	rs36050651	chr8:143681796	A/G	cg01509843	chr8:143695822	ARC	0.43	4.84	0.3	2.32e-6	Bipolar disorder and schizophrenia;
SARC	trans	rs61931739	0.926	rs1995966	chr12:34095420	G/A	cg13010199	chr12:38710504	ALG10B	-0.55	-6.73	-0.4	1.32e-10	Morning vs. evening chronotype;
SARC	cis	rs2180341	0.594	rs7738385	chr6:127777516	T/C	cg27446573	chr6:127587934	RNF146	0.64	7.55	0.44	1.01e-12	Breast cancer;
SARC	cis	rs17376456	1.000	rs6867042	chr5:93555761	C/T	cg25358565	chr5:93447407	FAM172A	1.35	14.06	0.68	6.12e-33	Diabetic retinopathy;
SARC	cis	rs6690583	0.623	rs55721024	chr1:85454447	A/C	cg22153463	chr1:85462885	MCOLN2	0.72	6.96	0.42	3.33e-11	Serum sulfate level;
SARC	cis	rs11098499	0.863	rs1480939	chr4:120456927	T/C	cg09307838	chr4:120376055	NA	0.91	12.31	0.63	3.63e-27	Corneal astigmatism;
SARC	cis	rs918629	0.530	rs1458019	chr5:95253489	A/G	cg16656078	chr5:95278638	ELL2	-0.57	-6.87	-0.41	5.72e-11	IgG glycosylation;
SARC	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg25894440	chr7:65020034	NA	-0.73	-5.54	-0.34	8.11e-8	Diabetic kidney disease;
SARC	cis	rs9660992	0.548	rs1172152	chr1:205220718	T/A	cg21545522	chr1:205238299	TMCC2	0.39	5.5	0.34	1.02e-7	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.59	-7.75	-0.45	2.87e-13	Mean platelet volume;
SARC	trans	rs1814175	0.817	rs4881623	chr11:49804991	C/T	cg03929089	chr4:120376271	NA	-0.9	-14.5	-0.69	2.17e-34	Height;
SARC	cis	rs709400	1.000	rs8018979	chr14:104109087	G/A	cg12935359	chr14:103987150	CKB	-0.34	-5.17	-0.32	4.98e-7	Body mass index;
SARC	cis	rs3741151	0.773	rs73544711	chr11:73164870	T/A	cg17517138	chr11:73019481	ARHGEF17	0.92	6.85	0.41	6.4e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	trans	rs453301	0.571	rs330057	chr8:9089793	C/T	cg06636001	chr8:8085503	FLJ10661	-0.69	-9.3	-0.52	1.08e-17	Joint mobility (Beighton score);
SARC	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg09263875	chr16:632152	PIGQ	0.54	8.34	0.48	6.32e-15	Height;
SARC	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg18876405	chr7:65276391	NA	0.46	5.47	0.34	1.16e-7	Aortic root size;
SARC	cis	rs11209002	0.911	rs2815346	chr1:67531646	G/A	cg02640540	chr1:67518911	SLC35D1	0.51	4.9	0.31	1.82e-6	Crohn's disease;
SARC	cis	rs12545109	0.959	rs12547974	chr8:57314785	G/T	cg19413350	chr8:57351067	NA	-0.41	-4.78	-0.3	3.14e-6	Obesity-related traits;
SARC	cis	rs12802200	0.535	rs35541591	chr11:570538	C/A	cg16486109	chr11:613632	IRF7	0.35	4.95	0.31	1.42e-6	Systemic lupus erythematosus;
SARC	cis	rs2115630	1.000	rs6496452	chr15:85372645	A/T	cg17507749	chr15:85114479	UBE2QP1	-0.45	-5.59	-0.34	6.44e-8	P wave terminal force;
SARC	cis	rs9462027	1.000	rs6457792	chr6:34764443	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.4	5.38	0.33	1.8e-7	Systemic lupus erythematosus;
SARC	cis	rs1420338	0.839	rs918036	chr7:34181859	A/G	cg01275685	chr7:34179230	BMPER	-0.44	-5.39	-0.33	1.74e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
SARC	cis	rs2115630	0.967	rs8027779	chr15:85255385	T/C	cg17507749	chr15:85114479	UBE2QP1	-0.47	-5.57	-0.34	6.98e-8	P wave terminal force;
SARC	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg22433210	chr17:43662623	NA	1.03	12.12	0.62	1.58e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs11077998	0.844	rs8064433	chr17:80501046	A/T	cg10255544	chr17:80519551	FOXK2	0.43	6.32	0.38	1.32e-9	Reticulocyte fraction of red cells;
SARC	cis	rs8078723	1.000	rs59925331	chr17:38169273	C/G	cg17467752	chr17:38218738	THRA	0.47	5.94	0.36	1.01e-8	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	trans	rs61931739	0.500	rs6488209	chr12:34319309	A/G	cg13010199	chr12:38710504	ALG10B	0.64	8.51	0.49	2.14e-15	Morning vs. evening chronotype;
SARC	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg17221315	chr6:27791827	HIST1H4J	0.45	4.74	0.3	3.76e-6	Depression;
SARC	cis	rs5022636	0.507	rs4971035	chr1:151324058	G/T	cg13175981	chr1:150552382	MCL1	0.56	5.66	0.35	4.35e-8	Gut microbiota (functional units);
SARC	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.46	5.87	0.36	1.53e-8	Gut microbiome composition (summer);
SARC	cis	rs142802669	1	rs142802669	chr3:41869427	A/C	cg03022575	chr3:42003672	ULK4	0.56	5.29	0.33	2.78e-7	Immunoglobulin light chain (AL) amyloidosis;
SARC	trans	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg17712092	chr4:129076599	LARP1B	-0.63	-8.3	-0.48	8.33e-15	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg05084668	chr3:125655381	ALG1L	-0.47	-4.8	-0.3	2.87e-6	Blood pressure (smoking interaction);
SARC	cis	rs7819412	1.000	rs2409722	chr8:11039816	T/G	cg21775007	chr8:11205619	TDH	-0.43	-5.15	-0.32	5.55e-7	Triglycerides;
SARC	cis	rs2228479	0.850	rs62052212	chr16:89981960	G/A	cg00800038	chr16:89945340	TCF25	-0.72	-4.72	-0.3	4.08e-6	Skin colour saturation;
SARC	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-5.56	-0.34	7.49e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs17079773	1.000	rs17079773	chr13:24598384	A/G	cg02336218	chr13:24462867	PCOTH;MIPEP	-0.52	-4.95	-0.31	1.45e-6	Inattentive symptoms;
SARC	cis	rs2075371	0.933	rs431306	chr7:133955974	A/T	cg11752832	chr7:134001865	SLC35B4	0.53	6.76	0.4	1.13e-10	Mean platelet volume;
SARC	cis	rs67460515	0.563	rs73023235	chr3:160864123	G/A	cg17135325	chr3:160939158	NMD3	0.64	7.92	0.46	9.62e-14	Parkinson's disease;
SARC	cis	rs7216064	1.000	rs4790908	chr17:65852907	T/G	cg12091567	chr17:66097778	LOC651250	-0.71	-7.76	-0.45	2.67e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg18404041	chr3:52824283	ITIH1	-0.4	-6.0	-0.37	7.68e-9	Electroencephalogram traits;
SARC	cis	rs28643277	0.671	rs13664	chr10:15556322	G/T	cg26519486	chr10:14996238	DCLRE1C	-0.43	-4.84	-0.3	2.32e-6	Periodontitis (CDC/AAP);
SARC	cis	rs861020	0.771	rs126280	chr1:210019824	A/G	cg05527609	chr1:210001259	C1orf107	0.96	12.31	0.63	3.78e-27	Orofacial clefts;
SARC	cis	rs6733011	0.628	rs4851163	chr2:99466664	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.4	-4.95	-0.31	1.44e-6	Bipolar disorder;
SARC	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.7	9.57	0.53	1.68e-18	Menarche (age at onset);
SARC	cis	rs2985684	0.740	rs2883438	chr14:50044392	T/C	cg04989706	chr14:50066350	PPIL5	-0.56	-6.14	-0.37	3.46e-9	Carotid intima media thickness;
SARC	cis	rs9916302	0.808	rs12947281	chr17:37652210	G/T	cg00129232	chr17:37814104	STARD3	-0.64	-7.8	-0.46	2.05e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs11687170	0.882	rs78146299	chr2:237057928	C/T	cg19324714	chr2:237145437	ASB18	0.49	4.89	0.31	1.89e-6	Educational attainment;Educational attainment (years of education);
SARC	trans	rs11039798	0.588	rs61932767	chr11:48704806	C/T	cg15704280	chr7:45808275	SEPT13	0.6	6.39	0.39	8.79e-10	Axial length;
SARC	cis	rs9660992	0.710	rs1668867	chr1:205240251	C/T	cg00857998	chr1:205179979	DSTYK	0.51	6.34	0.38	1.21e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg16479474	chr6:28041457	NA	0.36	5.45	0.34	1.25e-7	Parkinson's disease;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg11215015	chr1:197116161	ASPM	-0.44	-6.25	-0.38	1.91e-9	Tetralogy of Fallot;
SARC	cis	rs7772486	0.790	rs2253764	chr6:146199881	T/A	cg05347473	chr6:146136440	FBXO30	0.52	7.44	0.44	1.9e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9911578	0.900	rs8067264	chr17:57182793	G/C	cg05425664	chr17:57184151	TRIM37	-0.63	-7.9	-0.46	1.07e-13	Intelligence (multi-trait analysis);
SARC	cis	rs4481887	1.000	rs10888360	chr1:248479282	G/A	cg13385794	chr1:248469461	NA	0.37	5.51	0.34	9.38e-8	Common traits (Other);
SARC	cis	rs929354	0.742	rs7785227	chr7:156999297	C/T	cg05182265	chr7:156933206	UBE3C	-0.33	-5.02	-0.31	1.03e-6	Body mass index;
SARC	cis	rs1008375	0.900	rs12650220	chr4:17595365	A/T	cg16339924	chr4:17578868	LAP3	0.66	8.4	0.48	4.52e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg13206674	chr6:150067644	NUP43	0.49	6.36	0.38	1.04e-9	Lung cancer;
SARC	trans	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg21659725	chr3:3221576	CRBN	-0.55	-7.22	-0.43	7.19e-12	Intelligence (multi-trait analysis);
SARC	cis	rs4803468	1.000	rs2241709	chr19:41912250	C/T	cg14132834	chr19:41945861	ATP5SL	-0.55	-7.3	-0.43	4.56e-12	Height;
SARC	cis	rs57506017	0.540	rs7804736	chr7:12266867	G/T	cg23422036	chr7:12250390	TMEM106B	0.45	5.85	0.36	1.66e-8	Neuroticism;
SARC	trans	rs61931739	0.534	rs1608912	chr12:34008574	C/T	cg26384229	chr12:38710491	ALG10B	0.7	9.5	0.53	2.75e-18	Morning vs. evening chronotype;
SARC	cis	rs6964587	1.000	rs10488510	chr7:91660225	G/T	cg17063962	chr7:91808500	NA	0.96	16.54	0.73	3.73e-41	Breast cancer;
SARC	trans	rs7824557	0.527	rs2736298	chr8:11235136	C/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-6.99	-0.42	2.9e-11	Retinal vascular caliber;
SARC	cis	rs7408868	0.611	rs11671336	chr19:15294043	C/T	cg14696996	chr19:15285081	NOTCH3	0.57	5.9	0.36	1.3e-8	Pulse pressure;
SARC	cis	rs10861342	0.892	rs2044307	chr12:105531171	G/T	cg23923672	chr12:105501055	KIAA1033	0.72	5.23	0.32	3.73e-7	IgG glycosylation;
SARC	cis	rs9436747	0.641	rs11208679	chr1:66049738	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.49	5.08	0.32	7.66e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs2997447	0.761	rs60404932	chr1:26454881	C/T	cg19633962	chr1:26362018	EXTL1	-0.58	-5.08	-0.32	7.83e-7	QRS complex (12-leadsum);
SARC	cis	rs787274	1.000	rs4979148	chr9:115553399	C/T	cg13803584	chr9:115635662	SNX30	-0.77	-5.88	-0.36	1.38e-8	Age-related hearing impairment (SNP x SNP interaction);
SARC	trans	rs11088226	0.681	rs4547609	chr21:33953542	G/A	cg09050820	chr6:167586206	TCP10L2	0.61	6.8	0.41	8.49e-11	Gastritis;
SARC	cis	rs12594515	1.000	rs11070467	chr15:45985001	C/T	cg14863074	chr15:45997064	NA	-0.34	-5.18	-0.32	4.74e-7	Waist circumference;Weight;
SARC	trans	rs9329221	0.935	rs3750310	chr8:10283426	G/A	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.55	-0.49	1.64e-15	Neuroticism;
SARC	cis	rs3126085	0.867	rs12027899	chr1:152253954	C/A	cg03465714	chr1:152285911	FLG	-0.46	-5.46	-0.34	1.21e-7	Atopic dermatitis;
SARC	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg11644478	chr21:40555479	PSMG1	1.05	15.2	0.71	9.98e-37	Cognitive function;
SARC	cis	rs35213789	0.762	rs2851503	chr7:69112980	A/G	cg10619644	chr7:69149951	AUTS2	-0.36	-4.85	-0.3	2.25e-6	Childhood ear infection;
SARC	cis	rs9814567	1.000	rs9851441	chr3:134315091	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.53	-6.66	-0.4	1.99e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs12220238	1.000	rs9665468	chr10:75938838	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.52	5.16	0.32	5.39e-7	Soluble interleukin-2 receptor subunit alpha;
SARC	cis	rs1008375	0.933	rs4698637	chr4:17632843	A/T	cg27347728	chr4:17578864	LAP3	0.46	5.72	0.35	3.25e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs72945132	0.882	rs12282678	chr11:70152457	G/A	cg00319359	chr11:70116639	PPFIA1	0.67	6.08	0.37	4.85e-9	Coronary artery disease;
SARC	cis	rs6964587	0.869	rs10242792	chr7:91492103	A/C	cg17063962	chr7:91808500	NA	0.9	13.39	0.66	1.02e-30	Breast cancer;
SARC	cis	rs34375054	0.660	rs900411	chr12:125612839	C/T	cg25124228	chr12:125621409	AACS	-0.45	-4.94	-0.31	1.52e-6	Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs617219	0.726	rs2364596	chr5:78434291	C/T	cg24856658	chr5:78533917	JMY	-0.32	-4.92	-0.31	1.64e-6	Betaine levels in individuals undergoing cardiac evaluation;
SARC	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg25894440	chr7:65020034	NA	-0.73	-5.54	-0.34	8.11e-8	Diabetic kidney disease;
SARC	cis	rs1348850	0.958	rs4893941	chr2:178269531	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.71	8.9	0.5	1.65e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9430161	0.579	rs7542354	chr1:11040385	G/A	cg02454025	chr1:11042201	C1orf127	0.85	12.51	0.63	8.47e-28	Ewing sarcoma;
SARC	cis	rs6964587	0.967	rs13233496	chr7:91813035	T/C	cg17063962	chr7:91808500	NA	0.97	15.78	0.72	1.23e-38	Breast cancer;
SARC	cis	rs17376456	0.877	rs10055741	chr5:93297187	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.46	0.34	1.24e-7	Diabetic retinopathy;
SARC	cis	rs1322639	0.657	rs9355135	chr6:169573006	C/T	cg04662567	chr6:169592167	NA	-0.53	-5.28	-0.33	3e-7	Pulse pressure;
SARC	cis	rs7772486	0.686	rs2328708	chr6:146095739	G/A	cg23711669	chr6:146136114	FBXO30	-0.79	-12.69	-0.64	2.11e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg13175981	chr1:150552382	MCL1	-0.54	-6.82	-0.41	7.54e-11	Tonsillectomy;
SARC	cis	rs1832871	0.683	rs9459852	chr6:158687250	T/G	cg07165851	chr6:158734300	TULP4	0.55	6.67	0.4	1.8e-10	Height;
SARC	cis	rs262147	1.000	rs262147	chr7:158745142	A/G	cg24397884	chr7:158709396	WDR60	0.71	5.39	0.33	1.72e-7	Hippocampal volume;
SARC	cis	rs513349	1.000	rs513349	chr6:33541719	A/G	cg07679836	chr6:33548423	BAK1	0.33	4.8	0.3	2.83e-6	Platelet count;
SARC	cis	rs6963495	0.818	rs117845382	chr7:105152040	T/C	cg13798780	chr7:105162888	PUS7	0.58	5.28	0.33	2.95e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg15448220	chr1:150897856	SETDB1	0.51	6.52	0.39	4.3e-10	Melanoma;
SARC	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg27266027	chr21:40555129	PSMG1	-0.46	-5.17	-0.32	4.97e-7	Cognitive function;
SARC	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg06420487	chr17:61919686	SMARCD2	0.45	4.93	0.31	1.59e-6	Height;
SARC	cis	rs1059312	0.808	rs2306683	chr12:129299675	C/G	cg09035930	chr12:129282057	SLC15A4	0.56	7.99	0.46	6.14e-14	Systemic lupus erythematosus;
SARC	cis	rs3820928	1.000	rs11686072	chr2:227777493	A/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-6.88	-0.41	5.56e-11	Pulmonary function;
SARC	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg02018176	chr4:1364513	KIAA1530	-0.35	-5.0	-0.31	1.13e-6	Obesity-related traits;
SARC	cis	rs854765	0.654	rs9911281	chr17:17762457	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.66	-9.79	-0.54	3.47e-19	Total body bone mineral density;
SARC	cis	rs4888262	0.545	rs4072450	chr16:74666634	G/C	cg02853019	chr16:75273486	BCAR1	0.35	4.74	0.3	3.69e-6	Testicular germ cell tumor;
SARC	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg03806693	chr22:41940476	POLR3H	0.92	12.64	0.64	3.07e-28	Vitiligo;
SARC	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	12.43	0.63	1.51e-27	Platelet count;
SARC	cis	rs6429082	0.818	rs291344	chr1:235663860	C/G	cg26050004	chr1:235667680	B3GALNT2	-0.65	-7.58	-0.44	7.93e-13	Adiposity;
SARC	cis	rs11252926	0.673	rs10795161	chr10:497748	G/T	cg16386425	chr10:429943	DIP2C	-0.51	-6.02	-0.37	6.58e-9	Psychosis in Alzheimer's disease;
SARC	cis	rs8014204	0.566	rs9441	chr14:75128425	G/A	cg06637938	chr14:75390232	RPS6KL1	0.62	8.91	0.5	1.5e-16	Caffeine consumption;
SARC	cis	rs1318878	0.565	rs11056434	chr12:15498466	T/C	cg08258403	chr12:15378311	NA	0.49	6.94	0.41	3.97e-11	Intelligence (multi-trait analysis);
SARC	cis	rs861020	0.771	rs1962735	chr1:210012102	A/G	cg23166289	chr1:210001082	C1orf107	0.42	4.87	0.3	2.05e-6	Orofacial clefts;
SARC	cis	rs9916302	0.904	rs801420	chr17:37466103	C/G	cg15445000	chr17:37608096	MED1	-0.44	-5.31	-0.33	2.6e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs2439831	0.867	rs2260160	chr15:43895643	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	8.48	0.49	2.57e-15	Lung cancer in ever smokers;
SARC	cis	rs9303280	0.806	rs13380815	chr17:38027583	A/G	cg20243544	chr17:37824526	PNMT	0.43	5.64	0.35	4.95e-8	Self-reported allergy;
SARC	cis	rs11204677	1	rs11204677	chr1:150574695	C/G	cg17724175	chr1:150552817	MCL1	-0.38	-4.97	-0.31	1.3e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	trans	rs2396442	1.000	rs2256819	chr6:45418402	A/G	cg23224405	chr12:12715060	DUSP16	-0.55	-6.24	-0.38	2.09e-9	Left ventricle wall thickness;
SARC	cis	rs9920	0.901	rs56014347	chr7:116166400	C/T	cg24770985	chr7:116166421	CAV1	0.85	5.51	0.34	9.34e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Immature fraction of reticulocytes;QT interval;
SARC	cis	rs9462027	0.606	rs205258	chr6:34564243	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-6.02	-0.37	6.65e-9	Systemic lupus erythematosus;
SARC	cis	rs2304069	1.000	rs216126	chr5:149428424	G/C	cg12661370	chr5:149340060	SLC26A2	0.49	5.09	0.32	7.55e-7	HIV-1 control;
SARC	cis	rs74417235	0.673	rs6873342	chr5:154051835	A/G	cg08893839	chr5:154027129	NA	-0.54	-5.03	-0.31	9.85e-7	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
SARC	cis	rs4970966	0.951	rs6665912	chr1:150544093	T/C	cg13175981	chr1:150552382	MCL1	0.53	5.22	0.32	3.99e-7	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
SARC	cis	rs7560272	0.538	rs17350056	chr2:73922877	G/A	cg20560298	chr2:73613845	ALMS1	0.49	6.48	0.39	5.27e-10	Schizophrenia;
SARC	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg09455208	chr3:40491958	NA	0.39	5.74	0.35	2.97e-8	Renal cell carcinoma;
SARC	cis	rs748404	0.631	rs4296223	chr15:43645246	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	5.83	0.36	1.79e-8	Lung cancer;
SARC	cis	rs6582630	0.555	rs35186318	chr12:38295822	C/T	cg14851346	chr12:38532713	NA	-0.46	-5.39	-0.33	1.69e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg11987759	chr7:65425863	GUSB	0.36	4.73	0.3	3.98e-6	Calcium levels;
SARC	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg04277193	chr17:41438351	NA	0.47	5.02	0.31	1.02e-6	Menopause (age at onset);
SARC	cis	rs13256369	0.802	rs13256404	chr8:8562974	T/C	cg18904891	chr8:8559673	CLDN23	0.48	5.41	0.33	1.55e-7	Obesity-related traits;
SARC	cis	rs4481887	0.962	rs10788770	chr1:248457474	T/G	cg01631408	chr1:248437212	OR2T33	-0.43	-5.43	-0.34	1.39e-7	Common traits (Other);
SARC	cis	rs8084125	0.832	rs62105182	chr18:74951407	T/C	cg07390210	chr18:74961196	GALR1	0.56	6.39	0.39	8.73e-10	Obesity-related traits;
SARC	cis	rs921968	0.643	rs537520	chr2:219381852	A/G	cg02176678	chr2:219576539	TTLL4	0.35	5.41	0.33	1.53e-7	Mean corpuscular hemoglobin concentration;
SARC	trans	rs1973993	0.544	rs2800427	chr1:97002766	A/C	cg10631902	chr5:14652156	NA	0.44	7.16	0.42	1.03e-11	Weight;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg26270411	chr20:43514327	YWHAB	0.49	6.31	0.38	1.38e-9	Chemerin levels;
SARC	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.43	-5.4	-0.33	1.65e-7	Lymphocyte counts;
SARC	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	12.22	0.62	7.4e-27	Chronic sinus infection;
SARC	cis	rs12545109	0.571	rs4237014	chr8:57284479	C/A	cg19413350	chr8:57351067	NA	-0.4	-4.95	-0.31	1.45e-6	Obesity-related traits;
SARC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	6.0	0.37	7.37e-9	Prudent dietary pattern;
SARC	cis	rs950169	0.922	rs12906983	chr15:84931022	G/A	cg24253500	chr15:84953950	NA	0.36	5.2	0.32	4.41e-7	Schizophrenia;
SARC	cis	rs2467099	0.732	rs2168855	chr17:73943350	C/T	cg23806715	chr17:73775811	H3F3B	0.55	5.56	0.34	7.42e-8	Systolic blood pressure;
SARC	cis	rs9300255	0.568	rs1790090	chr12:123633424	G/A	cg05973401	chr12:123451056	ABCB9	0.53	5.99	0.37	8.08e-9	Neutrophil percentage of white cells;
SARC	cis	rs7296418	0.961	rs1790094	chr12:123586688	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.42	-5.72	-0.35	3.26e-8	Platelet count;
SARC	cis	rs17376456	1.000	rs58734583	chr5:93532155	C/T	cg21475434	chr5:93447410	FAM172A	0.93	8.14	0.47	2.44e-14	Diabetic retinopathy;
SARC	cis	rs6690583	0.623	rs61768852	chr1:85454613	T/C	cg22153463	chr1:85462885	MCOLN2	0.72	6.96	0.42	3.33e-11	Serum sulfate level;
SARC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.91	10.42	0.56	4.02e-21	Platelet count;
SARC	cis	rs796364	1.000	rs10178177	chr2:200829993	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.75	7.08	0.42	1.68e-11	Schizophrenia;
SARC	cis	rs9916302	0.706	rs439537	chr17:37734482	T/C	cg20243544	chr17:37824526	PNMT	0.54	5.62	0.35	5.48e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg13206674	chr6:150067644	NUP43	0.4	5.23	0.32	3.81e-7	Lung cancer;
SARC	cis	rs7644634	0.649	rs13083716	chr3:105381361	G/A	cg23051926	chr3:105466016	CBLB	0.47	5.93	0.36	1.08e-8	Itch intensity from mosquito bite;
SARC	cis	rs858239	0.539	rs6956828	chr7:23187347	A/G	cg23682824	chr7:23144976	KLHL7	0.72	9.28	0.52	1.22e-17	Cerebrospinal fluid biomarker levels;
SARC	cis	rs3106136	0.507	rs13134502	chr4:95304507	G/A	cg11021082	chr4:95130006	SMARCAD1	0.33	4.93	0.31	1.53e-6	Capecitabine sensitivity;
SARC	cis	rs7927771	0.832	rs56030824	chr11:47397353	G/A	cg20307385	chr11:47447363	PSMC3	-0.57	-7.05	-0.42	1.96e-11	Subjective well-being;
SARC	cis	rs9325144	0.723	rs1586373	chr12:39181582	G/A	cg26384229	chr12:38710491	ALG10B	-0.61	-7.58	-0.44	8.25e-13	Morning vs. evening chronotype;
SARC	cis	rs3796352	1.000	rs11713206	chr3:52999243	A/G	cg27565382	chr3:53032988	SFMBT1	0.94	6.03	0.37	6.33e-9	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs3796352	1.000	rs36090694	chr3:53010742	T/C	cg27565382	chr3:53032988	SFMBT1	0.96	6.46	0.39	6.2e-10	Immune reponse to smallpox (secreted IL-2);
SARC	trans	rs3808502	0.585	rs4549730	chr8:11239078	T/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.36	-0.38	1.08e-9	Neuroticism;
SARC	cis	rs6752107	0.901	rs2289477	chr2:234160345	T/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.46	6.11	0.37	4.23e-9	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs7216064	1.000	rs7210027	chr17:65977053	C/T	cg12091567	chr17:66097778	LOC651250	0.72	8.01	0.46	5.31e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs965469	1.000	rs6037556	chr20:3317890	G/C	cg25506879	chr20:3388711	C20orf194	-0.5	-5.18	-0.32	4.79e-7	IFN-related cytopenia;
SARC	cis	rs8077889	0.750	rs231539	chr17:41942109	T/C	cg26893861	chr17:41843967	DUSP3	-0.74	-7.15	-0.42	1.14e-11	Triglycerides;
SARC	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg03709012	chr19:19516395	GATAD2A	1.04	18.6	0.77	5.91e-48	Tonsillectomy;
SARC	cis	rs7552404	0.889	rs2211080	chr1:76243438	G/A	cg22875332	chr1:76189707	ACADM	0.43	5.89	0.36	1.31e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs763121	1.000	rs763121	chr22:38879940	C/T	cg06022373	chr22:39101656	GTPBP1	-0.63	-7.62	-0.45	6.53e-13	Menopause (age at onset);
SARC	cis	rs9926296	0.715	rs467035	chr16:89740285	C/G	cg26513180	chr16:89883248	FANCA	0.5	6.06	0.37	5.55e-9	Vitiligo;
SARC	cis	rs6484504	0.532	rs2774403	chr11:31320530	A/T	cg02090638	chr11:31391270	DNAJC24;DCDC1	0.39	5.01	0.31	1.07e-6	Red blood cell count;
SARC	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg04398451	chr17:18023971	MYO15A	-0.48	-6.6	-0.4	2.67e-10	Total body bone mineral density;
SARC	cis	rs34172651	0.917	rs200538	chr16:24735736	C/T	cg04756594	chr16:24857601	SLC5A11	-0.37	-6.02	-0.37	6.57e-9	Intelligence (multi-trait analysis);
SARC	cis	rs10189230	0.967	rs10498113	chr2:222352629	C/T	cg14652038	chr2:222343519	EPHA4	0.42	5.72	0.35	3.22e-8	Urate levels in lean individuals;
SARC	cis	rs929596	0.561	rs7564935	chr2:234645186	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.37	-5.42	-0.33	1.49e-7	Total bilirubin levels in HIV-1 infection;
SARC	cis	rs2282802	0.685	rs2337082	chr5:139649201	G/A	cg26211634	chr5:139558579	C5orf32	0.39	4.98	0.31	1.24e-6	Intelligence (multi-trait analysis);
SARC	cis	rs35213789	0.536	rs2865116	chr7:69042724	G/A	cg10619644	chr7:69149951	AUTS2	-0.36	-5.07	-0.32	8.07e-7	Childhood ear infection;
SARC	cis	rs1448094	0.511	rs58742237	chr12:86166444	C/T	cg02569458	chr12:86230093	RASSF9	0.37	4.86	0.3	2.21e-6	Major depressive disorder;
SARC	trans	rs629535	0.862	rs2472141	chr8:70054216	T/C	cg21567404	chr3:27674614	NA	1.04	13.82	0.67	3.98e-32	Dupuytren's disease;
SARC	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg08742575	chr21:47604166	C21orf56	0.46	5.83	0.36	1.88e-8	Testicular germ cell tumor;
SARC	cis	rs72781680	0.716	rs2675363	chr2:24080003	G/C	cg08917208	chr2:24149416	ATAD2B	0.58	6.04	0.37	6.18e-9	Lymphocyte counts;
SARC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg10150615	chr22:24372951	LOC391322	-0.42	-4.74	-0.3	3.7e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs708547	0.874	rs7674167	chr4:57721477	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.54	-5.73	-0.35	3.15e-8	Response to bleomycin (chromatid breaks);
SARC	cis	rs2952156	0.883	rs907089	chr17:37833600	C/T	cg00129232	chr17:37814104	STARD3	-0.71	-10.23	-0.56	1.61e-20	Asthma;
SARC	trans	rs7395662	0.591	rs10838972	chr11:48611400	A/G	cg15704280	chr7:45808275	SEPT13	-0.49	-6.49	-0.39	5.08e-10	HDL cholesterol;
SARC	cis	rs12421382	0.659	rs57978015	chr11:109385473	T/C	cg16359550	chr11:109292809	C11orf87	0.36	5.28	0.33	2.9e-7	Schizophrenia;
SARC	cis	rs8077889	1.000	rs2066725	chr17:41891473	A/G	cg26893861	chr17:41843967	DUSP3	0.88	10.98	0.58	6.99e-23	Triglycerides;
SARC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.6	7.82	0.46	1.77e-13	Lymphocyte counts;
SARC	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1185460	0.967	rs1784302	chr11:118940957	C/G	cg23280166	chr11:118938394	VPS11	0.81	12.08	0.62	2.1e-26	Coronary artery disease;
SARC	cis	rs7818345	1.000	rs4430112	chr8:19293365	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.39	5.32	0.33	2.45e-7	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs8031584	0.560	rs7171208	chr15:31198929	A/G	cg19680485	chr15:31195859	MTMR15	0.6	7.77	0.45	2.43e-13	Huntington's disease progression;
SARC	cis	rs6938	0.534	rs11854704	chr15:75221015	C/T	cg09165964	chr15:75287851	SCAMP5	0.51	6.86	0.41	6.04e-11	Breast cancer;
SARC	cis	rs9486719	1.000	rs2142652	chr6:96868504	A/C	cg06623918	chr6:96969491	KIAA0776	0.73	8.01	0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg07930192	chr7:1003750	NA	0.44	5.97	0.36	8.9e-9	Longevity;Endometriosis;
SARC	cis	rs8072100	0.688	rs8075843	chr17:45442363	C/T	cg08085267	chr17:45401833	C17orf57	-0.44	-5.14	-0.32	5.77e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs17270561	0.609	rs1937131	chr6:25744831	A/T	cg16482183	chr6:26056742	HIST1H1C	-0.42	-4.93	-0.31	1.55e-6	Iron status biomarkers;
SARC	cis	rs1472147	1.000	rs4323418	chr7:128506970	C/T	cg17511168	chr7:128516960	KCP	-0.31	-5.12	-0.32	6.38e-7	Calcium levels;
SARC	cis	rs1707322	0.929	rs785513	chr1:46538320	T/C	cg06784218	chr1:46089804	CCDC17	-0.38	-6.52	-0.39	4.37e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs3815700	0.920	rs10424732	chr19:33096487	C/T	cg02997394	chr19:33096574	ANKRD27	0.8	8.38	0.48	5.11e-15	Eosinophilic esophagitis;
SARC	cis	rs4481887	1.000	rs4244176	chr1:248468231	G/A	cg01631408	chr1:248437212	OR2T33	-0.42	-5.3	-0.33	2.68e-7	Common traits (Other);
SARC	trans	rs7615952	0.932	rs13065725	chr3:125632289	C/A	cg07211511	chr3:129823064	LOC729375	-0.97	-10.71	-0.57	4.89e-22	Blood pressure (smoking interaction);
SARC	trans	rs13325613	0.915	rs34005848	chr3:46263745	C/T	cg12387106	chr12:133178249	NA	0.84	6.58	0.4	3e-10	Monocyte count;
SARC	cis	rs4718428	0.672	rs12530806	chr7:66390724	A/G	cg18252515	chr7:66147081	NA	-0.56	-6.15	-0.37	3.43e-9	Corneal structure;
SARC	cis	rs7772486	0.790	rs7753092	chr6:146248863	C/T	cg05347473	chr6:146136440	FBXO30	-0.5	-6.79	-0.41	9.48e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg01181863	chr3:195395398	SDHAP2	-0.58	-6.57	-0.4	3.3e-10	Pancreatic cancer;
SARC	cis	rs995000	0.931	rs4915840	chr1:62999595	C/G	cg06896770	chr1:63153194	DOCK7	-0.9	-13.49	-0.66	5.08e-31	Triglyceride levels;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg19782173	chr5:76383047	LOC728723;ZBED3	0.48	6.47	0.39	5.7e-10	Breast cancer;
SARC	cis	rs11969893	0.850	rs9390697	chr6:101294431	G/A	cg12253828	chr6:101329408	ASCC3	1.25	7.83	0.46	1.76e-13	Economic and political preferences (immigration/crime);
SARC	cis	rs9814567	1.000	rs7611828	chr3:134250325	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.1	-0.42	1.49e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg21782813	chr7:2030301	MAD1L1	0.36	5.68	0.35	4e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs10752881	1.000	rs4233192	chr1:182970837	A/C	cg13390022	chr1:182993471	LAMC1	-0.33	-5.03	-0.31	9.87e-7	Colorectal cancer;
SARC	cis	rs11097912	0.632	rs12510058	chr4:107188835	T/C	cg09646026	chr4:107269030	AIMP1	-0.44	-4.74	-0.3	3.68e-6	Airflow obstruction;
SARC	cis	rs2425143	1.000	rs1056196	chr20:34327159	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-5.62	-0.35	5.31e-8	Blood protein levels;
SARC	cis	rs4253772	0.513	rs6008597	chr22:46703904	A/C	cg24881330	chr22:46731750	TRMU	0.65	5.55	0.34	7.82e-8	LDL cholesterol;Cholesterol, total;
SARC	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg16414030	chr3:133502952	NA	-0.41	-5.62	-0.35	5.37e-8	Iron status biomarkers;
SARC	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg07930192	chr7:1003750	NA	0.42	5.65	0.35	4.56e-8	Longevity;Endometriosis;
SARC	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg08677398	chr8:58056175	NA	0.43	5.13	0.32	6.07e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.09	-22.59	-0.83	1.31e-60	Chronic sinus infection;
SARC	cis	rs208520	0.526	rs7771233	chr6:66819784	A/G	cg07460842	chr6:66804631	NA	-1.08	-20.53	-0.8	3.63e-54	Exhaled nitric oxide output;
SARC	cis	rs1348850	0.632	rs4470372	chr2:178505857	G/A	cg23306229	chr2:178417860	TTC30B	0.49	5.49	0.34	1.07e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9796	0.870	rs3900905	chr15:41260801	G/A	cg18705301	chr15:41695430	NDUFAF1	0.43	5.92	0.36	1.13e-8	Menopause (age at onset);
SARC	cis	rs796364	0.625	rs4673837	chr2:201131159	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.55	5.18	0.32	4.85e-7	Schizophrenia;
SARC	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg25072359	chr17:41440525	NA	0.51	6.0	0.37	7.33e-9	Menopause (age at onset);
SARC	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7312774	0.618	rs11612483	chr12:107346884	A/G	cg16260113	chr12:107380972	MTERFD3	0.95	7.82	0.46	1.86e-13	Severe influenza A (H1N1) infection;
SARC	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg26513180	chr16:89883248	FANCA	0.89	16.31	0.73	2.1e-40	Vitiligo;
SARC	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg23758822	chr17:41437982	NA	0.88	11.24	0.59	1.04e-23	Menopause (age at onset);
SARC	cis	rs9296092	0.560	rs9469500	chr6:33526196	C/T	cg13560919	chr6:33536144	NA	-0.51	-6.03	-0.37	6.47e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.05	0.8	1.19e-52	Prudent dietary pattern;
SARC	cis	rs4141404	0.640	rs9606854	chr22:31930567	C/T	cg02404636	chr22:31891804	SFI1	0.51	5.09	0.32	7.35e-7	Paclitaxel-induced neuropathy;
SARC	cis	rs11098499	0.754	rs10213554	chr4:120260785	A/G	cg09307838	chr4:120376055	NA	-0.84	-11.6	-0.6	7.51e-25	Corneal astigmatism;
SARC	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg26850624	chr5:429559	AHRR	-0.33	-5.23	-0.32	3.7e-7	Cystic fibrosis severity;
SARC	cis	rs2292864	0.764	rs3892085	chr17:45340480	A/G	cg18085866	chr17:45331354	ITGB3	-0.76	-5.72	-0.35	3.31e-8	Left atrial antero-posterior diameter;
SARC	cis	rs739401	0.572	rs410820	chr11:3080102	G/A	cg05729581	chr11:3078854	CARS	-0.51	-6.75	-0.4	1.15e-10	Longevity;
SARC	cis	rs36051895	0.632	rs11793886	chr9:5125469	A/G	cg02405213	chr9:5042618	JAK2	-0.45	-5.3	-0.33	2.64e-7	Pediatric autoimmune diseases;
SARC	trans	rs208520	0.690	rs2208442	chr6:66867004	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-14.2	-0.68	2.26e-33	Exhaled nitric oxide output;
SARC	trans	rs79976124	0.800	rs10944857	chr6:66637078	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	7.98	0.46	6.52e-14	Type 2 diabetes;
SARC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg22105103	chr4:187893119	NA	0.5	6.84	0.41	6.8e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4906332	1.000	rs8012623	chr14:103937086	G/A	cg26031613	chr14:104095156	KLC1	-0.49	-5.76	-0.35	2.64e-8	Coronary artery disease;
SARC	cis	rs2832077	0.506	rs2832088	chr21:30158620	G/A	cg03476357	chr21:30257390	N6AMT1	-0.47	-5.07	-0.32	7.94e-7	Cognitive test performance;
SARC	trans	rs9329221	0.870	rs11777976	chr8:10255402	A/G	cg06636001	chr8:8085503	FLJ10661	-0.68	-9.26	-0.52	1.37e-17	Neuroticism;
SARC	cis	rs17270561	0.609	rs1185976	chr6:25822363	A/G	cg17691542	chr6:26056736	HIST1H1C	-0.49	-6.33	-0.38	1.25e-9	Iron status biomarkers;
SARC	cis	rs10911251	0.546	rs1547714	chr1:183114119	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	9.86	0.54	2.11e-19	Colorectal cancer;
SARC	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg00152838	chr16:24741724	TNRC6A	0.59	6.45	0.39	6.37e-10	Intelligence (multi-trait analysis);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg12188830	chr3:57741926	SLMAP	-0.62	-7.08	-0.42	1.66e-11	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs826838	0.935	rs1684406	chr12:39127265	A/G	cg26384229	chr12:38710491	ALG10B	-0.76	-11.59	-0.6	7.97e-25	Heart rate;
SARC	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.1	20.69	0.8	1.12e-54	Chronic sinus infection;
SARC	cis	rs9814567	0.752	rs9836401	chr3:134336897	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.51	-6.55	-0.39	3.55e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs3762637	0.941	rs9810996	chr3:122074387	G/A	cg24169773	chr3:122142474	KPNA1	-0.53	-5.13	-0.32	5.96e-7	LDL cholesterol levels;
SARC	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg11987759	chr7:65425863	GUSB	-0.61	-8.37	-0.48	5.22e-15	Calcium levels;
SARC	cis	rs812925	0.512	rs7558954	chr2:61384906	T/C	cg10580144	chr2:61372316	C2orf74	0.39	5.25	0.33	3.39e-7	Immature fraction of reticulocytes;
SARC	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.5	5.96	0.36	9.48e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs36051895	0.659	rs1159782	chr9:5078117	T/C	cg02405213	chr9:5042618	JAK2	-0.45	-5.22	-0.32	4.03e-7	Pediatric autoimmune diseases;
SARC	cis	rs770189	0.955	rs700593	chr5:88101150	C/T	cg18498987	chr5:88179539	MEF2C	0.38	4.85	0.3	2.25e-6	Tonometry;
SARC	cis	rs12142240	0.659	rs67547686	chr1:46832229	G/C	cg00530320	chr1:46809349	NSUN4	0.58	7.07	0.42	1.78e-11	Menopause (age at onset);
SARC	cis	rs1691799	0.867	rs1039056	chr12:66760391	C/T	cg16791601	chr12:66731901	HELB	-0.71	-10.78	-0.58	3.09e-22	White blood cell count (basophil);
SARC	cis	rs6991838	0.584	rs34226237	chr8:66513165	A/C	cg13398993	chr8:66546079	ARMC1	-0.61	-8.17	-0.47	2e-14	Intelligence (multi-trait analysis);
SARC	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg11890956	chr21:40555474	PSMG1	-1.04	-15.17	-0.7	1.26e-36	Cognitive function;
SARC	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg13264159	chr8:625131	ERICH1	-0.74	-5.3	-0.33	2.71e-7	IgG glycosylation;
SARC	cis	rs13191362	1.000	rs73035023	chr6:163000927	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.49	0.34	1.04e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs9300255	0.569	rs1716170	chr12:123716513	C/T	cg00376283	chr12:123451042	ABCB9	0.52	6.03	0.37	6.37e-9	Neutrophil percentage of white cells;
SARC	cis	rs2239547	0.522	rs2581805	chr3:52979050	T/C	cg11645453	chr3:52864694	ITIH4	-0.34	-5.23	-0.32	3.7e-7	Schizophrenia;
SARC	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg18252515	chr7:66147081	NA	0.55	5.82	0.36	1.89e-8	Aortic root size;
SARC	cis	rs3540	0.960	rs28539372	chr15:91021412	T/A	cg22089800	chr15:90895588	ZNF774	0.49	5.57	0.34	7.17e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs698833	0.926	rs1067399	chr2:44678648	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.61	7.58	0.44	8.19e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs11105298	0.891	rs10777163	chr12:89830720	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.52	-5.19	-0.32	4.51e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs4664308	0.967	rs62175559	chr2:160955833	G/A	cg03641300	chr2:160917029	PLA2R1	-0.7	-9.6	-0.53	1.33e-18	Idiopathic membranous nephropathy;
SARC	cis	rs9309473	0.519	rs13022145	chr2:73863473	G/A	cg20560298	chr2:73613845	ALMS1	0.48	6.47	0.39	5.87e-10	Metabolite levels;
SARC	cis	rs4430311	0.571	rs1379700	chr1:243909402	A/G	cg21452805	chr1:244014465	NA	-0.45	-5.98	-0.36	8.39e-9	Post-traumatic stress disorder (asjusted for relatedness);
SARC	cis	rs1008375	0.933	rs4698637	chr4:17632843	A/T	cg02297831	chr4:17616191	MED28	0.51	6.46	0.39	6.17e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs3126085	0.935	rs12144058	chr1:152170216	C/T	cg03465714	chr1:152285911	FLG	-0.47	-5.56	-0.34	7.45e-8	Atopic dermatitis;
SARC	cis	rs3812111	0.510	rs6930059	chr6:116577623	T/C	cg18828861	chr6:116576566	TSPYL4	0.33	4.85	0.3	2.21e-6	Age-related macular degeneration;
SARC	cis	rs56343172	0.832	rs73228550	chr3:111605354	A/G	cg19148281	chr3:111577973	PHLDB2	-0.56	-4.73	-0.3	3.97e-6	Thionamide-induced agranulocytosis in Graves' disease;
SARC	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg24399712	chr22:39784796	NA	-0.44	-5.85	-0.36	1.67e-8	Intelligence (multi-trait analysis);
SARC	cis	rs11105298	0.891	rs11105302	chr12:89891366	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	0.5	5.28	0.33	3.02e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs6782228	0.606	rs7627549	chr3:128353079	G/A	cg08795948	chr3:128337044	NA	0.37	5.1	0.32	6.98e-7	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
SARC	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	trans	rs6894249	1.000	rs6894249	chr5:131797547	A/G	cg06500355	chr6:111804104	REV3L	0.48	6.56	0.39	3.46e-10	Asthma;
SARC	cis	rs4690686	0.500	rs17062804	chr4:177262892	A/G	cg17059388	chr4:177262070	NA	0.36	4.78	0.3	3.09e-6	Essential tremor;
SARC	cis	rs4713118	0.824	rs7759217	chr6:27730463	A/G	cg17221315	chr6:27791827	HIST1H4J	0.51	5.56	0.34	7.36e-8	Parkinson's disease;
SARC	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg18876405	chr7:65276391	NA	0.45	5.08	0.32	7.82e-7	Aortic root size;
SARC	cis	rs2486288	0.656	rs6493145	chr15:45573862	G/T	cg21132104	chr15:45694354	SPATA5L1	-0.55	-6.86	-0.41	5.98e-11	Glomerular filtration rate;
SARC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg01773306	chr2:85555458	TGOLN2	-0.5	-6.24	-0.38	2.04e-9	HDL cholesterol;
SARC	cis	rs3087591	0.639	rs2342053	chr17:29722196	A/G	cg24425628	chr17:29625626	OMG;NF1	0.39	4.88	0.3	1.93e-6	Hip circumference;
SARC	cis	rs2073499	0.872	rs58051625	chr3:50278717	G/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.61	5.8	0.36	2.15e-8	Schizophrenia;
SARC	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-6.27	-0.38	1.75e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.35	0.38	1.13e-9	Bipolar disorder;
SARC	cis	rs787274	0.543	rs1324930	chr9:115634639	A/G	cg13803584	chr9:115635662	SNX30	0.81	6.96	0.41	3.47e-11	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg11987759	chr7:65425863	GUSB	0.62	8.25	0.48	1.17e-14	Aortic root size;
SARC	cis	rs7829975	0.510	rs2979160	chr8:8307666	A/G	cg06636001	chr8:8085503	FLJ10661	0.77	10.8	0.58	2.71e-22	Mood instability;
SARC	trans	rs12935229	1.000	rs17712956	chr16:77322254	A/G	cg26529044	chr13:43354767	C13orf30	-0.49	-6.44	-0.39	6.64e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
SARC	cis	rs7044106	0.708	rs10984992	chr9:123473416	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	5.94	0.36	1.01e-8	Hip circumference adjusted for BMI;
SARC	cis	rs908922	0.676	rs1001834	chr1:152495940	C/A	cg09873164	chr1:152488093	CRCT1	0.63	8.06	0.47	4.07e-14	Hair morphology;
SARC	cis	rs1707322	1.000	rs11211248	chr1:46476844	A/G	cg06784218	chr1:46089804	CCDC17	0.34	6.03	0.37	6.48e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7633770	0.841	rs11709020	chr3:46680063	A/G	cg11219411	chr3:46661640	NA	-0.48	-8.19	-0.47	1.75e-14	Coronary artery disease;
SARC	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	16.56	0.74	3.18e-41	Height;
SARC	cis	rs6700896	0.931	rs1938492	chr1:66117829	A/C	cg04111102	chr1:66153794	NA	0.35	5.55	0.34	7.6e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs1707322	0.964	rs1768802	chr1:46547868	A/G	cg06784218	chr1:46089804	CCDC17	-0.36	-6.21	-0.38	2.44e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs17001868	0.568	rs3788578	chr22:40742921	C/T	cg07138101	chr22:40742427	ADSL	0.55	6.07	0.37	5.15e-9	Mammographic density (dense area);
SARC	cis	rs4243830	0.737	rs11581831	chr1:6609958	C/T	cg04093404	chr1:6614507	TAS1R1;NOL9	0.62	5.23	0.32	3.76e-7	Body mass index;
SARC	cis	rs9400467	0.537	rs73530951	chr6:111484814	G/A	cg15721981	chr6:111408429	SLC16A10	0.66	5.67	0.35	4.24e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs34779708	1.000	rs12769189	chr10:35399668	A/G	cg03585969	chr10:35415529	CREM	0.42	5.17	0.32	5.03e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs2777491	0.957	rs316614	chr15:41746625	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.81	-12.13	-0.62	1.47e-26	Ulcerative colitis;
SARC	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg26335602	chr6:28129616	ZNF389	0.53	5.88	0.36	1.43e-8	Depression;
SARC	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg12292205	chr6:26970375	C6orf41	-0.56	-6.2	-0.38	2.6e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs4481887	1.000	rs6663817	chr1:248495613	A/G	cg13385794	chr1:248469461	NA	0.36	5.36	0.33	2.04e-7	Common traits (Other);
SARC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg06877462	chr1:205807181	PM20D1	0.33	4.78	0.3	3.07e-6	Menarche (age at onset);
SARC	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg18404041	chr3:52824283	ITIH1	-0.38	-5.73	-0.35	3.13e-8	Bipolar disorder;
SARC	cis	rs4865169	0.623	rs6838975	chr4:57739816	G/C	cg24291500	chr4:57773398	REST	-0.31	-4.72	-0.3	4.02e-6	Breast cancer;
SARC	cis	rs763121	0.744	rs5757140	chr22:38957013	T/C	cg21395723	chr22:39101663	GTPBP1	0.58	6.67	0.4	1.8e-10	Menopause (age at onset);
SARC	cis	rs34779708	0.966	rs11010102	chr10:35411066	T/A	cg03585969	chr10:35415529	CREM	0.42	5.37	0.33	1.91e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs1348850	0.789	rs2197611	chr2:178369036	G/C	cg23306229	chr2:178417860	TTC30B	0.55	6.32	0.38	1.35e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs11098499	0.697	rs4560394	chr4:120313435	T/G	cg09160332	chr4:120329925	NA	-0.33	-4.77	-0.3	3.27e-6	Corneal astigmatism;
SARC	cis	rs9916302	0.904	rs8070695	chr17:37478062	C/T	cg07936489	chr17:37558343	FBXL20	0.66	8.25	0.48	1.18e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs1008375	1.000	rs1121089	chr4:17676476	C/A	cg27347728	chr4:17578864	LAP3	0.44	5.42	0.33	1.46e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1801251	1.000	rs283480	chr2:233648742	G/A	cg25237894	chr2:233734115	C2orf82	0.38	4.82	0.3	2.56e-6	Coronary artery disease;
SARC	cis	rs2749592	0.550	rs12255038	chr10:37869332	T/C	cg25427524	chr10:38739819	LOC399744	0.44	6.33	0.38	1.27e-9	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs6058796	1.000	rs34311932	chr20:31260997	T/C	cg13636640	chr20:31349939	DNMT3B	0.56	4.94	0.31	1.48e-6	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs2153535	0.580	rs9505455	chr6:8478622	A/G	cg21535247	chr6:8435926	SLC35B3	0.55	6.97	0.42	3.17e-11	Motion sickness;
SARC	cis	rs3771570	0.792	rs4675970	chr2:242200406	G/A	cg21155796	chr2:242212141	HDLBP	0.56	5.19	0.32	4.51e-7	Prostate cancer;
SARC	cis	rs372883	0.648	rs15092	chr21:30718201	G/A	cg24692254	chr21:30365293	RNF160	-0.66	-8.47	-0.49	2.73e-15	Pancreatic cancer;
SARC	trans	rs12310956	0.532	rs10506119	chr12:33963684	A/G	cg13010199	chr12:38710504	ALG10B	0.73	9.9	0.54	1.69e-19	Morning vs. evening chronotype;
SARC	trans	rs9329221	0.662	rs11249996	chr8:10245463	G/T	cg06636001	chr8:8085503	FLJ10661	-0.62	-7.86	-0.46	1.4e-13	Neuroticism;
SARC	cis	rs10779751	1.000	rs7544489	chr1:11299511	A/G	cg08854313	chr1:11322531	MTOR	-0.88	-13.85	-0.67	3.18e-32	Body mass index;
SARC	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.51	6.32	0.38	1.34e-9	Gut microbiome composition (summer);
SARC	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg11987759	chr7:65425863	GUSB	0.45	6.03	0.37	6.22e-9	Aortic root size;
SARC	cis	rs16944613	0.541	rs10852135	chr15:91106412	T/C	cg26821196	chr15:91095069	CRTC3	0.55	5.61	0.35	5.59e-8	Colorectal cancer;
SARC	cis	rs6121246	0.909	rs1994251	chr20:30287328	T/G	cg13852791	chr20:30311386	BCL2L1	0.86	9.16	0.51	2.76e-17	Mean corpuscular hemoglobin;
SARC	trans	rs61931739	0.500	rs6416261	chr12:34540377	T/C	cg26384229	chr12:38710491	ALG10B	0.85	12.63	0.64	3.4e-28	Morning vs. evening chronotype;
SARC	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg12379764	chr21:47803548	PCNT	-0.55	-5.74	-0.35	2.95e-8	Testicular germ cell tumor;
SARC	cis	rs9916302	0.706	rs801418	chr17:37457982	G/C	cg15445000	chr17:37608096	MED1	-0.45	-4.92	-0.31	1.62e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs2404618	0.624	rs28439223	chr8:1476901	C/G	cg13402656	chr8:1511478	DLGAP2	-0.59	-8.78	-0.5	3.64e-16	Lung cancer;
SARC	cis	rs7255436	0.965	rs7351098	chr19:8451671	G/C	cg10174797	chr19:8464628	RAB11B	0.45	6.44	0.39	6.84e-10	HDL cholesterol;
SARC	cis	rs7843479	0.601	rs727693	chr8:21850116	A/G	cg17168535	chr8:21777572	XPO7	0.85	12.72	0.64	1.65e-28	Mean corpuscular volume;
SARC	cis	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg00031303	chr3:195681400	NA	-0.45	-5.44	-0.34	1.35e-7	Bronchopulmonary dysplasia;
SARC	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.42	-6.42	-0.39	7.71e-10	Total body bone mineral density;
SARC	cis	rs7917772	0.503	rs11191347	chr10:104351617	C/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.61	8.38	0.48	5.04e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs2439831	0.850	rs12101756	chr15:44053887	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	8.57	0.49	1.44e-15	Lung cancer in ever smokers;
SARC	cis	rs208515	0.525	rs9453538	chr6:66668508	G/A	cg07460842	chr6:66804631	NA	0.97	11.01	0.58	5.72e-23	Exhaled nitric oxide levels;
SARC	cis	rs4481887	1.000	rs7525344	chr1:248467565	C/T	cg01631408	chr1:248437212	OR2T33	0.43	5.43	0.34	1.39e-7	Common traits (Other);
SARC	cis	rs7666738	0.822	rs28367231	chr4:98845726	G/T	cg05340658	chr4:99064831	C4orf37	0.65	8.58	0.49	1.36e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9640161	0.789	rs1464752	chr7:150021284	C/T	cg21361702	chr7:150065534	REPIN1	0.49	5.09	0.32	7.52e-7	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs6540556	0.682	rs11119332	chr1:209892960	C/T	cg23920097	chr1:209922102	NA	-0.52	-5.29	-0.33	2.76e-7	Red blood cell count;
SARC	cis	rs6542838	0.641	rs6757098	chr2:99471399	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.38	-4.73	-0.3	3.88e-6	Fear of minor pain;
SARC	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg18252515	chr7:66147081	NA	0.53	5.6	0.34	5.91e-8	Aortic root size;
SARC	cis	rs55794721	0.509	rs2982358	chr1:25745204	G/T	cg02931644	chr1:25747376	RHCE	0.46	7.69	0.45	4.2e-13	Plateletcrit;Mean corpuscular volume;
SARC	cis	rs11599315	0.507	rs12218307	chr10:1341914	G/A	cg01270228	chr10:1369114	ADARB2	0.32	5.23	0.32	3.73e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs9611519	0.894	rs9611488	chr22:41462592	G/T	cg17376030	chr22:41985996	PMM1	0.52	6.38	0.39	9.61e-10	Neuroticism;
SARC	cis	rs7582180	0.663	rs4850929	chr2:100990707	A/C	cg14675211	chr2:100938903	LONRF2	0.54	7.89	0.46	1.21e-13	Intelligence (multi-trait analysis);
SARC	cis	rs9322817	0.691	rs2499666	chr6:105318576	A/G	cg02098413	chr6:105308735	HACE1	0.38	5.92	0.36	1.17e-8	Thyroid stimulating hormone;
SARC	cis	rs11630290	0.592	rs12232261	chr15:64153302	A/G	cg12036633	chr15:63758958	NA	0.47	4.9	0.31	1.77e-6	Iris characteristics;
SARC	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg20120463	chr17:44301886	NA	-0.36	-5.44	-0.34	1.31e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg24250549	chr1:154909240	PMVK	0.84	12.26	0.63	5.46e-27	Prostate cancer;
SARC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg24846343	chr22:24311635	DDTL	0.48	6.45	0.39	6.53e-10	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg13175981	chr1:150552382	MCL1	0.51	6.48	0.39	5.43e-10	Urate levels;
SARC	trans	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg00938859	chr5:1591904	SDHAP3	0.76	7.43	0.44	2.03e-12	Breast cancer;
SARC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg11494091	chr17:61959527	GH2	0.54	8.19	0.47	1.67e-14	Prudent dietary pattern;
SARC	cis	rs747650	0.892	rs1976143	chr11:47225534	G/A	cg03339077	chr11:47165057	C11orf49	-0.45	-6.35	-0.38	1.14e-9	Acne (severe);
SARC	cis	rs36051895	0.502	rs12347799	chr9:5215954	G/A	cg02405213	chr9:5042618	JAK2	-0.39	-4.79	-0.3	2.95e-6	Pediatric autoimmune diseases;
SARC	cis	rs12479064	0.724	rs62153852	chr2:99934713	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.56	-6.34	-0.38	1.19e-9	Chronic sinus infection;
SARC	cis	rs7113850	0.541	rs7102578	chr11:24244671	G/T	ch.11.24196551F	chr11:24239977	NA	0.72	5.32	0.33	2.46e-7	Bone fracture in osteoporosis;
SARC	cis	rs2273669	0.667	rs112319185	chr6:109305318	T/C	cg05315195	chr6:109294784	ARMC2	-0.57	-5.24	-0.32	3.62e-7	Prostate cancer;
SARC	cis	rs9467773	0.620	rs2498351	chr6:26659642	C/T	cg12292205	chr6:26970375	C6orf41	0.4	4.9	0.31	1.77e-6	Intelligence (multi-trait analysis);
SARC	cis	rs3815700	0.920	rs10426856	chr19:33096406	A/G	cg02997394	chr19:33096574	ANKRD27	0.77	8.46	0.48	3.04e-15	Eosinophilic esophagitis;
SARC	cis	rs13082711	0.911	rs2371065	chr3:27494589	A/C	cg02860705	chr3:27208620	NA	0.47	6.04	0.37	6.16e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs2645694	0.626	rs2703126	chr4:77819842	T/C	cg03477792	chr4:77819574	ANKRD56	0.49	7.34	0.43	3.48e-12	Emphysema distribution in smoking;
SARC	cis	rs936229	1.000	rs4886615	chr15:75131661	A/G	cg10253484	chr15:75165896	SCAMP2	-0.48	-4.95	-0.31	1.4e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs9828933	0.938	rs7617036	chr3:64002995	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	-0.64	-5.65	-0.35	4.59e-8	Type 2 diabetes;
SARC	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg12463550	chr7:65579703	CRCP	0.52	5.81	0.36	2.06e-8	Aortic root size;
SARC	cis	rs1185460	0.934	rs10892328	chr11:118942654	T/A	cg23280166	chr11:118938394	VPS11	0.76	10.64	0.57	8.12e-22	Coronary artery disease;
SARC	cis	rs7568458	0.870	rs1010	chr2:85808982	C/T	cg23752985	chr2:85803571	VAMP8	-0.35	-5.27	-0.33	3.07e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs7666738	0.830	rs9999200	chr4:99030690	A/C	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6991838	0.584	rs3765205	chr8:66517486	C/T	cg13398993	chr8:66546079	ARMC1	-0.61	-8.09	-0.47	3.21e-14	Intelligence (multi-trait analysis);
SARC	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.58	5.33	0.33	2.37e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	trans	rs61931739	0.782	rs451940	chr12:34196005	T/C	cg26384229	chr12:38710491	ALG10B	0.61	8.27	0.48	1.06e-14	Morning vs. evening chronotype;
SARC	cis	rs739401	0.611	rs2071104	chr11:3036933	G/T	cg05729581	chr11:3078854	CARS	-0.45	-5.69	-0.35	3.75e-8	Longevity;
SARC	cis	rs959260	0.537	rs8074355	chr17:73415816	A/T	cg00200289	chr17:73401734	GRB2	-0.54	-4.87	-0.3	2.02e-6	Systemic lupus erythematosus;
SARC	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.56	8.48	0.49	2.54e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs17384381	0.700	rs11161616	chr1:85907625	A/G	cg16011679	chr1:85725395	C1orf52	-0.53	-5.44	-0.34	1.33e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7727544	0.507	rs9791170	chr5:131569627	A/G	cg12564285	chr5:131593104	PDLIM4	0.36	5.27	0.33	3.1e-7	Blood metabolite levels;
SARC	cis	rs3796352	0.667	rs11720228	chr3:52877270	G/A	cg15956490	chr3:53032818	SFMBT1	0.81	5.21	0.32	4.13e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs17376456	0.757	rs10476591	chr5:93333723	G/C	cg25358565	chr5:93447407	FAM172A	1.29	14.41	0.69	4.52e-34	Diabetic retinopathy;
SARC	trans	rs12310956	0.532	rs1352210	chr12:33983187	A/G	cg13010199	chr12:38710504	ALG10B	0.65	8.81	0.5	3.02e-16	Morning vs. evening chronotype;
SARC	cis	rs933688	1.000	rs60513756	chr5:90727692	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.04	13.1	0.65	9.4e-30	Smoking behavior;
SARC	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg27266027	chr21:40555129	PSMG1	0.48	5.24	0.32	3.67e-7	Cognitive function;
SARC	cis	rs11098499	0.863	rs6858777	chr4:120475966	A/G	cg09307838	chr4:120376055	NA	0.91	12.25	0.63	5.66e-27	Corneal astigmatism;
SARC	cis	rs7666738	0.830	rs58696666	chr4:99006913	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7666738	0.830	rs11097605	chr4:98985167	T/C	cg05340658	chr4:99064831	C4orf37	0.64	8.67	0.49	7.4e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2439831	0.867	rs2255051	chr15:43846161	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	7.89	0.46	1.19e-13	Lung cancer in ever smokers;
SARC	cis	rs7940866	0.834	rs10894298	chr11:130840571	C/A	cg12179176	chr11:130786555	SNX19	0.66	8.79	0.5	3.43e-16	Schizophrenia;
SARC	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.39	5.21	0.32	4.09e-7	Personality dimensions;
SARC	cis	rs34779708	0.931	rs4934724	chr10:35393669	C/T	cg03585969	chr10:35415529	CREM	0.41	5.05	0.31	8.82e-7	Inflammatory bowel disease;Crohn's disease;
SARC	trans	rs61931739	0.517	rs11053063	chr12:34181011	C/T	cg26384229	chr12:38710491	ALG10B	0.85	12.17	0.62	1.07e-26	Morning vs. evening chronotype;
SARC	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg24642844	chr7:1081250	C7orf50	-0.59	-6.12	-0.37	3.89e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg08859206	chr1:53392774	SCP2	-0.41	-5.98	-0.36	8.53e-9	Monocyte count;
SARC	cis	rs3768617	0.510	rs3768619	chr1:183092404	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.68	10.11	0.55	3.67e-20	Fuchs's corneal dystrophy;
SARC	cis	rs6696846	0.765	rs2836	chr1:205111761	G/T	cg00857998	chr1:205179979	DSTYK	-0.51	-6.74	-0.4	1.22e-10	Red blood cell count;
SARC	cis	rs4742903	0.904	rs10121829	chr9:106993996	A/G	cg14250997	chr9:106856677	SMC2	0.4	5.1	0.32	6.89e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs4891159	0.513	rs35534021	chr18:74130523	G/A	cg24786174	chr18:74118243	ZNF516	0.73	11.99	0.62	3.96e-26	Longevity;
SARC	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg00933542	chr6:150070202	PCMT1	0.31	4.88	0.3	2e-6	Lung cancer;
SARC	cis	rs11190604	1.000	rs2489043	chr10:102334327	T/C	cg07510080	chr10:102295549	HIF1AN	0.45	4.89	0.31	1.86e-6	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs3087591	0.708	rs35109242	chr17:29649223	A/G	cg24425628	chr17:29625626	OMG;NF1	0.42	5.36	0.33	1.98e-7	Hip circumference;
SARC	cis	rs7647973	1.000	rs11928090	chr3:49604904	G/A	cg07636037	chr3:49044803	WDR6	0.78	8.85	0.5	2.22e-16	Menarche (age at onset);
SARC	cis	rs1881797	0.932	rs10925071	chr1:247686521	C/T	cg18198730	chr1:247681584	NA	-0.53	-6.01	-0.37	7.11e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs2576037	0.796	rs2576034	chr18:44588548	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.67	-9.69	-0.54	6.95e-19	Personality dimensions;
SARC	cis	rs554111	0.634	rs7551785	chr1:21524297	C/G	cg04902671	chr1:21058625	SH2D5	-0.42	-5.03	-0.31	9.71e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	trans	rs17453880	0.929	rs11948856	chr5:151983819	G/T	cg23699148	chr19:53087184	ZNF701	-0.5	-6.37	-0.39	9.93e-10	Subjective well-being;
SARC	cis	rs921968	0.509	rs3856548	chr2:219398164	C/T	cg02176678	chr2:219576539	TTLL4	-0.5	-7.63	-0.45	5.84e-13	Mean corpuscular hemoglobin concentration;
SARC	cis	rs73635312	0.850	rs80143905	chr10:8945788	C/T	cg24467326	chr10:9646929	NA	0.6	5.03	0.31	9.81e-7	Basal cell carcinoma;
SARC	trans	rs3857536	0.740	rs6455080	chr6:66887413	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.6	-7.1	-0.42	1.48e-11	Blood trace element (Cu levels);
SARC	cis	rs9470366	0.883	rs9462210	chr6:36628953	G/A	cg08179530	chr6:36648295	CDKN1A	0.56	5.89	0.36	1.36e-8	QRS duration;
SARC	cis	rs6918586	0.616	rs198836	chr6:26113616	T/A	cg18357526	chr6:26021779	HIST1H4A	-0.45	-5.76	-0.35	2.71e-8	Schizophrenia;
SARC	cis	rs9457247	1.000	rs9457247	chr6:167392174	C/T	cg23791538	chr6:167370224	RNASET2	-0.62	-8.66	-0.49	8.17e-16	Crohn's disease;
SARC	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg11764359	chr7:65958608	NA	-0.79	-9.75	-0.54	4.53e-19	Aortic root size;
SARC	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg08859206	chr1:53392774	SCP2	0.41	5.99	0.37	7.78e-9	Monocyte count;
SARC	cis	rs4253772	0.592	rs1807600	chr22:46644640	A/G	cg24881330	chr22:46731750	TRMU	0.56	6.06	0.37	5.3e-9	LDL cholesterol;Cholesterol, total;
SARC	cis	rs9581943	0.967	rs4424773	chr13:28470544	C/G	cg17352152	chr13:28491409	NA	0.39	5.18	0.32	4.71e-7	Pancreatic cancer;
SARC	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.27	-0.52	1.34e-17	Developmental language disorder (linguistic errors);
SARC	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg16482183	chr6:26056742	HIST1H1C	0.41	5.16	0.32	5.23e-7	Height;
SARC	cis	rs9436747	0.748	rs1171272	chr1:65999811	G/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.53	-5.19	-0.32	4.49e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg11774413	chr4:56412743	CLOCK	0.84	7.15	0.42	1.09e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg18876405	chr7:65276391	NA	-0.44	-4.83	-0.3	2.43e-6	Aortic root size;
SARC	trans	rs11098499	0.863	rs3775844	chr4:120428033	G/A	cg25214090	chr10:38739885	LOC399744	0.59	7.32	0.43	3.92e-12	Corneal astigmatism;
SARC	cis	rs9325144	0.560	rs7980358	chr12:38640396	C/G	cg13010199	chr12:38710504	ALG10B	0.56	6.95	0.41	3.65e-11	Morning vs. evening chronotype;
SARC	trans	rs656319	0.638	rs670044	chr8:9892529	G/T	cg06636001	chr8:8085503	FLJ10661	0.71	9.19	0.52	2.27e-17	Myopia (pathological);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg16362480	chr16:30077084	ALDOA	0.48	6.46	0.39	6.2e-10	Chemerin levels;
SARC	cis	rs9818758	0.607	rs34343820	chr3:49309534	C/G	cg01304814	chr3:48885189	PRKAR2A	0.65	5.29	0.33	2.75e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs11098499	0.908	rs9995234	chr4:120321827	A/G	cg24375607	chr4:120327624	NA	0.4	4.81	0.3	2.71e-6	Corneal astigmatism;
SARC	cis	rs950027	0.596	rs2467865	chr15:45638307	T/C	cg21132104	chr15:45694354	SPATA5L1	0.55	7.1	0.42	1.49e-11	Response to fenofibrate (adiponectin levels);
SARC	cis	rs9470366	0.527	rs4711456	chr6:36632482	C/T	cg08179530	chr6:36648295	CDKN1A	-0.66	-8.94	-0.51	1.2e-16	QRS duration;
SARC	cis	rs10463554	0.927	rs39666	chr5:102447127	C/T	cg23492399	chr5:102201601	PAM	-0.52	-5.72	-0.35	3.2e-8	Parkinson's disease;
SARC	cis	rs11209002	0.614	rs4655673	chr1:67555018	T/C	cg02640540	chr1:67518911	SLC35D1	0.55	6.37	0.39	9.94e-10	Crohn's disease;
SARC	cis	rs9858542	0.953	rs6997	chr3:49453834	C/T	cg07274523	chr3:49395745	GPX1	0.52	6.13	0.37	3.69e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs9457247	1.000	rs1819333	chr6:167373547	G/T	cg23791538	chr6:167370224	RNASET2	-0.64	-8.83	-0.5	2.54e-16	Crohn's disease;
SARC	cis	rs155076	1.000	rs261432	chr13:21865915	G/C	cg14456004	chr13:21872349	NA	-0.98	-12.27	-0.63	5.02e-27	White matter hyperintensity burden;
SARC	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg16482183	chr6:26056742	HIST1H1C	0.43	5.39	0.33	1.7e-7	Height;
SARC	cis	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg12463550	chr7:65579703	CRCP	0.66	5.08	0.32	7.67e-7	Diabetic kidney disease;
SARC	cis	rs9916302	0.904	rs7210488	chr17:37539819	T/G	cg07936489	chr17:37558343	FBXL20	0.69	9.32	0.52	9.49e-18	Glomerular filtration rate (creatinine);
SARC	cis	rs9911578	0.935	rs420878	chr17:56709077	A/G	cg12560992	chr17:57184187	TRIM37	0.83	11.32	0.6	5.91e-24	Intelligence (multi-trait analysis);
SARC	cis	rs9486715	0.659	rs9399930	chr6:96854444	G/T	cg06623918	chr6:96969491	KIAA0776	0.87	12.07	0.62	2.28e-26	Headache;
SARC	cis	rs9790314	0.521	rs1376122	chr3:161087857	A/G	cg17135325	chr3:160939158	NMD3	0.52	6.57	0.4	3.23e-10	Morning vs. evening chronotype;
SARC	cis	rs1008375	0.966	rs6449313	chr4:17588320	A/G	cg27347728	chr4:17578864	LAP3	0.49	6.14	0.37	3.45e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2439831	1.000	rs2245054	chr15:43751909	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.05	10.98	0.58	7.25e-23	Lung cancer in ever smokers;
SARC	cis	rs9341808	0.618	rs6916507	chr6:80862265	T/C	cg08355045	chr6:80787529	NA	0.35	5.58	0.34	6.55e-8	Sitting height ratio;
SARC	cis	rs240764	0.717	rs1039031	chr6:101161812	A/G	cg09795085	chr6:101329169	ASCC3	0.44	5.64	0.35	4.9e-8	Neuroticism;
SARC	cis	rs7412746	0.658	rs4970987	chr1:150949682	T/C	cg15448220	chr1:150897856	SETDB1	0.49	6.13	0.37	3.65e-9	Melanoma;
SARC	cis	rs6908034	0.607	rs113592672	chr6:19806063	G/C	cg02682789	chr6:19804855	NA	0.72	5.45	0.34	1.31e-7	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg09325174	chr14:50154983	POLE2	0.49	6.45	0.39	6.26e-10	Chemerin levels;
SARC	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg27572855	chr1:25598939	RHD	0.5	8.55	0.49	1.64e-15	Erythrocyte sedimentation rate;
SARC	cis	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg11266682	chr4:10021025	SLC2A9	0.41	7.29	0.43	4.75e-12	Bone mineral density;
SARC	cis	rs4319547	0.695	rs1803290	chr12:122865029	T/C	cg23029597	chr12:123009494	RSRC2	0.41	5.09	0.32	7.41e-7	Body mass index;
SARC	cis	rs4925386	0.959	rs6121989	chr20:60916713	A/T	cg24112000	chr20:60950667	NA	0.33	5.42	0.33	1.51e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs1707322	1.000	rs785465	chr1:46522577	G/T	cg06784218	chr1:46089804	CCDC17	0.38	6.67	0.4	1.82e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9300255	0.569	rs1790115	chr12:123620270	C/G	cg05973401	chr12:123451056	ABCB9	0.52	5.85	0.36	1.68e-8	Neutrophil percentage of white cells;
SARC	cis	rs4727027	0.933	rs34578816	chr7:148847606	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	5.53	0.34	8.68e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs7119	0.717	rs34194537	chr15:77795761	G/A	cg17802220	chr15:77601643	NA	-0.41	-5.19	-0.32	4.62e-7	Type 2 diabetes;
SARC	cis	rs921968	0.565	rs12612395	chr2:219621642	G/C	cg02176678	chr2:219576539	TTLL4	-0.32	-4.89	-0.31	1.85e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs834603	0.611	rs2470993	chr7:47440225	A/G	cg23694490	chr7:47445681	TNS3	-0.34	-5.99	-0.37	7.69e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs11722228	0.549	rs56146302	chr4:10081052	C/T	cg11266682	chr4:10021025	SLC2A9	0.32	4.73	0.3	3.97e-6	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs9400467	0.506	rs10457237	chr6:111606126	T/C	cg15721981	chr6:111408429	SLC16A10	0.66	5.5	0.34	1e-7	Blood metabolite levels;Amino acid levels;
SARC	cis	rs4481887	0.927	rs4390209	chr1:248472613	A/T	cg00666640	chr1:248458726	OR2T12	0.34	5.7	0.35	3.65e-8	Common traits (Other);
SARC	cis	rs11155671	0.530	rs7757984	chr6:150208651	A/G	cg05036130	chr6:150231994	NA	0.29	4.94	0.31	1.47e-6	Testicular germ cell tumor;
SARC	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.43	-5.19	-0.32	4.67e-7	Bipolar disorder;
SARC	cis	rs6570726	1.000	rs1935617	chr6:145943326	C/T	cg23711669	chr6:146136114	FBXO30	0.73	10.89	0.58	1.41e-22	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7223966	1.000	rs11657120	chr17:61857218	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-5.76	-0.35	2.6e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs73198271	0.563	rs3748143	chr8:8655237	A/G	cg06636001	chr8:8085503	FLJ10661	0.53	4.91	0.31	1.7e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs1008375	0.966	rs4698621	chr4:17587565	C/T	cg27347728	chr4:17578864	LAP3	0.49	6.06	0.37	5.46e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg25703541	chr22:24373054	LOC391322	-0.87	-12.89	-0.65	4.64e-29	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs875971	0.545	rs6961853	chr7:66002022	G/A	cg11764359	chr7:65958608	NA	0.64	6.39	0.39	8.77e-10	Aortic root size;
SARC	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg05025164	chr4:1340916	KIAA1530	0.54	6.39	0.39	8.69e-10	Obesity-related traits;
SARC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg02475777	chr4:1388615	CRIPAK	-0.61	-7.14	-0.42	1.21e-11	Longevity;
SARC	cis	rs1062177	0.724	rs2915828	chr5:151118121	G/A	cg00977110	chr5:151150581	G3BP1	-0.54	-5.4	-0.33	1.61e-7	Preschool internalizing problems;
SARC	cis	rs72781680	0.898	rs2339851	chr2:23938883	G/A	cg06627628	chr2:24431161	ITSN2	-0.66	-6.06	-0.37	5.51e-9	Lymphocyte counts;
SARC	cis	rs6674176	0.628	rs3828146	chr1:44428715	C/T	cg13606994	chr1:44402422	ARTN	-0.33	-5.36	-0.33	2.02e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg08859206	chr1:53392774	SCP2	-0.4	-5.75	-0.35	2.75e-8	Monocyte count;
SARC	cis	rs722599	0.748	rs2537824	chr14:75367349	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.38	-4.75	-0.3	3.52e-6	IgG glycosylation;
SARC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg26338869	chr17:61819248	STRADA	0.8	10.82	0.58	2.2e-22	Prudent dietary pattern;
SARC	cis	rs2816062	0.813	rs2816050	chr1:18894432	A/G	cg18795169	chr1:18902165	NA	-0.78	-12.27	-0.63	4.91e-27	Urate levels in lean individuals;
SARC	cis	rs3820928	0.874	rs7582251	chr2:227791703	G/T	cg11843606	chr2:227700838	RHBDD1	-0.56	-7.12	-0.42	1.33e-11	Pulmonary function;
SARC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-4.85	-0.3	2.26e-6	Total body bone mineral density;
SARC	trans	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg11693508	chr17:37793320	STARD3	0.73	6.66	0.4	1.92e-10	Bipolar disorder;
SARC	cis	rs11098499	1.000	rs10029750	chr4:120172543	A/G	cg24375607	chr4:120327624	NA	0.39	4.73	0.3	3.92e-6	Corneal astigmatism;
SARC	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg17376030	chr22:41985996	PMM1	-0.62	-7.44	-0.44	1.9e-12	Vitiligo;
SARC	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg11062466	chr8:58055876	NA	0.61	5.75	0.35	2.74e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7312774	0.618	rs3803122	chr12:107354680	G/A	cg16260113	chr12:107380972	MTERFD3	0.93	7.65	0.45	5.22e-13	Severe influenza A (H1N1) infection;
SARC	cis	rs870825	0.616	rs28450662	chr4:185638900	G/A	cg04058563	chr4:185651563	MLF1IP	0.81	11.26	0.59	9.09e-24	Blood protein levels;
SARC	cis	rs9462027	0.583	rs2814995	chr6:34621171	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-6.16	-0.37	3.12e-9	Systemic lupus erythematosus;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg16101101	chr1:153643504	ILF2	-0.52	-6.7	-0.4	1.57e-10	Gallstone disease;
SARC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg24503407	chr1:205819492	PM20D1	-0.8	-11.59	-0.6	8.17e-25	Menarche (age at onset);
SARC	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg01475735	chr3:40494733	NA	-0.47	-5.33	-0.33	2.27e-7	Renal cell carcinoma;
SARC	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg13393036	chr8:95962371	TP53INP1	-0.37	-6.35	-0.38	1.09e-9	Type 2 diabetes;
SARC	cis	rs10489202	0.657	rs201541	chr1:167992344	T/A	cg24449463	chr1:168025552	DCAF6	-0.66	-8.89	-0.5	1.69e-16	Schizophrenia;
SARC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg25703541	chr22:24373054	LOC391322	-0.73	-9.17	-0.51	2.66e-17	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs568617	0.953	rs1151519	chr11:65645831	G/C	cg26695010	chr11:65641043	EFEMP2	0.5	5.78	0.35	2.36e-8	Crohn's disease;
SARC	cis	rs5753618	0.561	rs9609264	chr22:31746719	C/G	cg00478049	chr22:31556069	RNF185	-0.44	-4.78	-0.3	3.12e-6	Colorectal cancer;
SARC	cis	rs11785400	1.000	rs3735994	chr8:143742683	C/T	cg24634471	chr8:143751801	JRK	0.68	9.17	0.52	2.5e-17	Schizophrenia;
SARC	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-5.96	-0.36	9.37e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg06618935	chr21:46677482	NA	0.39	5.14	0.32	5.93e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	7.04	0.42	2.08e-11	Intelligence (multi-trait analysis);
SARC	cis	rs11785400	0.762	rs7017931	chr8:143726728	A/G	cg10596483	chr8:143751796	JRK	0.57	7.39	0.44	2.61e-12	Schizophrenia;
SARC	cis	rs10504073	0.584	rs62507177	chr8:49937306	C/A	cg00325661	chr8:49890786	NA	0.52	6.89	0.41	5.2e-11	Blood metabolite ratios;
SARC	cis	rs76419734	1.000	rs72673866	chr4:106771155	A/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	5.31	0.33	2.52e-7	Post bronchodilator FEV1;
SARC	cis	rs397969	0.596	rs62066348	chr17:19899913	A/G	cg13482628	chr17:19912719	NA	0.43	4.73	0.3	3.97e-6	Platelet count;
SARC	cis	rs9660992	0.573	rs12140703	chr1:205182865	G/C	cg00857998	chr1:205179979	DSTYK	0.52	6.35	0.38	1.12e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs7178909	0.902	rs2043882	chr15:90439753	G/A	cg19708238	chr15:90437601	AP3S2	0.63	8.52	0.49	2.01e-15	Common traits (Other);
SARC	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.62	-6.38	-0.39	9.51e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs6424115	1.000	rs4237	chr1:24114129	C/T	cg09473613	chr1:24152604	HMGCL	0.33	4.73	0.3	3.94e-6	Immature fraction of reticulocytes;
SARC	cis	rs8114671	0.805	rs4616	chr20:33590358	C/T	cg24642439	chr20:33292090	TP53INP2	-0.53	-6.18	-0.38	2.87e-9	Height;
SARC	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg05234568	chr11:5960015	NA	-0.43	-5.81	-0.36	2e-8	DNA methylation (variation);
SARC	cis	rs6831352	1.000	rs1126671	chr4:100048414	T/C	cg12011299	chr4:100065546	ADH4	0.34	5.91	0.36	1.18e-8	Alcohol dependence;
SARC	cis	rs17270561	0.609	rs4712970	chr6:25770707	G/A	cg17691542	chr6:26056736	HIST1H1C	0.59	7.19	0.43	8.91e-12	Iron status biomarkers;
SARC	cis	rs3087591	0.636	rs736598	chr17:29720470	T/C	cg24425628	chr17:29625626	OMG;NF1	0.39	4.83	0.3	2.49e-6	Hip circumference;
SARC	cis	rs6088813	1.000	rs6087702	chr20:33995945	T/A	cg23207816	chr20:34252616	CPNE1;RBM12	-0.43	-5.23	-0.32	3.79e-7	Height;
SARC	cis	rs854765	0.565	rs4072738	chr17:17884547	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.68	9.72	0.54	5.9e-19	Total body bone mineral density;
SARC	cis	rs10088262	0.629	rs7828192	chr8:124804669	C/T	cg20713898	chr8:124780851	FAM91A1	-0.64	-7.14	-0.42	1.19e-11	Pancreatic cancer;
SARC	cis	rs8114671	0.552	rs2024635	chr20:33422614	G/A	cg07148914	chr20:33460835	GGT7	0.43	5.2	0.32	4.39e-7	Height;
SARC	cis	rs2635047	0.811	rs17723754	chr18:44771481	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	6.21	0.38	2.38e-9	Educational attainment;
SARC	cis	rs6815814	0.898	rs1106956	chr4:38889811	A/G	cg06935464	chr4:38784597	TLR10	0.53	5.27	0.33	3.08e-7	Breast cancer;
SARC	cis	rs1348850	0.526	rs10930797	chr2:178437553	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.65	6.27	0.38	1.73e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs950169	0.959	rs66801143	chr15:84736657	C/T	cg24253500	chr15:84953950	NA	0.35	5.04	0.31	9.53e-7	Schizophrenia;
SARC	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg00684032	chr4:1343700	KIAA1530	0.37	5.17	0.32	5.06e-7	Obesity-related traits;
SARC	cis	rs10876993	0.890	rs1585781	chr12:58056701	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.47	-5.93	-0.36	1.08e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg26818010	chr10:134567672	INPP5A	-0.52	-5.73	-0.35	3.14e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs4737010	0.501	rs55694640	chr8:41649439	T/G	cg17182837	chr8:41585554	ANK1	-0.46	-5.0	-0.31	1.13e-6	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
SARC	cis	rs876084	0.505	rs6469899	chr8:121102762	C/T	cg06265175	chr8:121136014	COL14A1	0.6	7.67	0.45	4.65e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.95	9.52	0.53	2.38e-18	Platelet count;
SARC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.76	9.54	0.53	1.96e-18	Prudent dietary pattern;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg13884470	chr9:86595151	HNRNPK;RMI1	0.61	6.32	0.38	1.32e-9	Lung cancer in ever smokers;
SARC	cis	rs9815354	0.670	rs73073238	chr3:42014325	G/C	cg03022575	chr3:42003672	ULK4	0.71	5.94	0.36	1.04e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9747201	1.000	rs56283054	chr17:80135326	C/T	cg09264619	chr17:80180166	NA	0.51	5.97	0.36	8.8e-9	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs3796352	0.892	rs58515094	chr3:52995575	C/T	cg12962167	chr3:53033115	SFMBT1	0.75	4.9	0.31	1.8e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs7829975	0.686	rs907180	chr8:8702827	A/G	cg15556689	chr8:8085844	FLJ10661	0.42	5.45	0.34	1.3e-7	Mood instability;
SARC	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg13264159	chr8:625131	ERICH1	-0.73	-5.17	-0.32	5.01e-7	IgG glycosylation;
SARC	cis	rs7089973	0.604	rs765174	chr10:116601888	C/T	cg03647239	chr10:116582469	FAM160B1	0.5	6.49	0.39	5.19e-10	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.9	-0.5	1.61e-16	Alzheimer's disease;
SARC	cis	rs12477438	0.765	rs6542846	chr2:99563654	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-14.98	-0.7	5.7e-36	Chronic sinus infection;
SARC	cis	rs96067	0.711	rs272827	chr1:36627191	C/T	cg24686825	chr1:36642396	MAP7D1	0.61	7.86	0.46	1.4e-13	Corneal structure;
SARC	cis	rs6669919	0.516	rs11577717	chr1:211668920	C/T	cg10512769	chr1:211675356	NA	-0.37	-5.87	-0.36	1.5e-8	Intelligence (multi-trait analysis);
SARC	cis	rs10791097	0.720	rs6590516	chr11:130733393	G/T	cg09137382	chr11:130731461	NA	0.31	4.96	0.31	1.34e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs832540	0.519	rs6895442	chr5:56260998	T/C	cg14703610	chr5:56206110	C5orf35	0.46	5.4	0.33	1.66e-7	Coronary artery disease;
SARC	trans	rs9427116	0.502	rs12125166	chr1:154582129	A/G	cg14243623	chr9:90341158	CTSL1	-0.52	-6.67	-0.4	1.81e-10	Blood protein levels;
SARC	cis	rs17376456	0.825	rs34967135	chr5:93221785	G/A	cg25358565	chr5:93447407	FAM172A	1.24	13.39	0.66	1.04e-30	Diabetic retinopathy;
SARC	cis	rs7727544	0.684	rs274546	chr5:131699867	A/G	cg24060327	chr5:131705240	SLC22A5	-0.7	-8.96	-0.51	1.08e-16	Blood metabolite levels;
SARC	cis	rs35213789	0.878	rs12698847	chr7:69552829	G/C	cg10619644	chr7:69149951	AUTS2	0.42	5.13	0.32	5.97e-7	Childhood ear infection;
SARC	cis	rs751728	0.965	rs9394165	chr6:33731408	G/A	cg15252951	chr6:33757062	LEMD2	0.58	6.72	0.4	1.35e-10	Crohn's disease;
SARC	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.53	-5.52	-0.34	8.87e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs870825	0.616	rs56232457	chr4:185628153	T/G	cg04058563	chr4:185651563	MLF1IP	0.81	11.33	0.6	5.35e-24	Blood protein levels;
SARC	cis	rs7011049	1.000	rs79536146	chr8:53853526	G/A	cg26025543	chr8:53854495	NA	0.6	5.46	0.34	1.24e-7	Systolic blood pressure;
SARC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.61	0.53	1.27e-18	Prudent dietary pattern;
SARC	cis	rs2276314	1.000	rs4799835	chr18:33571268	G/A	cg19628046	chr18:33552617	C18orf21	0.6	6.17	0.37	3.06e-9	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs1878931	0.559	rs1968055	chr16:3392053	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.74	9.92	0.55	1.4e-19	Body mass index (adult);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg27595100	chr20:37203500	RALGAPB	0.43	6.4	0.39	8.58e-10	Thyroid stimulating hormone;
SARC	cis	rs35110281	0.667	rs4818859	chr21:45117120	G/A	cg21573476	chr21:45109991	RRP1B	-0.61	-8.74	-0.5	4.54e-16	Mean corpuscular volume;
SARC	cis	rs9815354	1.000	rs1615243	chr3:41965234	C/T	cg03022575	chr3:42003672	ULK4	-0.55	-5.27	-0.33	3.16e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6582630	0.598	rs11182207	chr12:38477514	T/C	cg26384229	chr12:38710491	ALG10B	-0.57	-7.14	-0.42	1.2e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs3087591	0.960	rs4795593	chr17:29613600	G/C	cg24425628	chr17:29625626	OMG;NF1	-0.53	-6.48	-0.39	5.44e-10	Hip circumference;
SARC	cis	rs4555082	0.750	rs2816650	chr14:105708343	C/T	cg06808227	chr14:105710500	BRF1	-0.51	-6.51	-0.39	4.59e-10	Mean platelet volume;Platelet distribution width;
SARC	cis	rs9818758	0.607	rs13087930	chr3:48961726	A/G	cg01304814	chr3:48885189	PRKAR2A	0.62	5.12	0.32	6.46e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg03264133	chr6:25882463	NA	-0.5	-6.58	-0.4	3.06e-10	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg08219700	chr8:58056026	NA	0.6	5.71	0.35	3.49e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs61931739	0.517	rs4104182	chr12:34081343	G/A	cg26384229	chr12:38710491	ALG10B	0.84	12.02	0.62	3.35e-26	Morning vs. evening chronotype;
SARC	cis	rs13191362	1.000	rs67042566	chr6:163006541	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.57	5.38	0.33	1.85e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs6582630	0.555	rs11182429	chr12:38526679	A/C	cg13010199	chr12:38710504	ALG10B	0.75	10.44	0.56	3.64e-21	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs950776	0.518	rs4887062	chr15:78837801	G/A	cg06917634	chr15:78832804	PSMA4	-0.89	-13.75	-0.67	6.85e-32	Sudden cardiac arrest;
SARC	cis	rs1008375	1.000	rs13119927	chr4:17691640	G/A	cg02297831	chr4:17616191	MED28	-0.44	-5.41	-0.33	1.6e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10078	0.571	rs2721028	chr5:443849	A/G	cg08916839	chr5:415575	AHRR	0.8	7.42	0.44	2.18e-12	Fat distribution (HIV);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg13969321	chr5:6713231	POLS	0.54	7.25	0.43	6.11e-12	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs8141529	0.732	rs2269577	chr22:29196757	G/C	cg02153584	chr22:29168773	CCDC117	0.82	12.64	0.64	3.02e-28	Lymphocyte counts;
SARC	cis	rs4803468	1.000	rs17318666	chr19:41940342	T/G	cg08477640	chr19:41863820	B9D2	-0.43	-5.39	-0.33	1.71e-7	Height;
SARC	cis	rs9916302	0.861	rs11078913	chr17:37671714	G/T	cg07936489	chr17:37558343	FBXL20	-0.66	-8.46	-0.48	2.89e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs3845702	0.736	rs9288045	chr2:180814194	G/A	cg01881094	chr2:180872142	CWC22	-1.12	-9.33	-0.52	8.63e-18	Schizophrenia;
SARC	cis	rs3091242	0.809	rs660129	chr1:25727438	C/T	cg02931644	chr1:25747376	RHCE	0.47	7.82	0.46	1.77e-13	Erythrocyte sedimentation rate;
SARC	cis	rs17270561	0.609	rs9358876	chr6:25738956	A/G	cg17691542	chr6:26056736	HIST1H1C	0.58	7.09	0.42	1.6e-11	Iron status biomarkers;
SARC	cis	rs2477686	0.526	rs1998759	chr1:2397174	C/T	cg02275930	chr1:2372054	NA	-0.27	-4.9	-0.31	1.76e-6	Non-obstructive azoospermia;
SARC	cis	rs4664308	0.810	rs62175552	chr2:160937220	T/G	cg03641300	chr2:160917029	PLA2R1	-0.71	-9.54	-0.53	2.02e-18	Idiopathic membranous nephropathy;
SARC	cis	rs4595586	0.545	rs12819061	chr12:39386976	C/T	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	cis	rs8067545	0.611	rs77449863	chr17:20191860	C/G	cg13482628	chr17:19912719	NA	-0.58	-7.82	-0.46	1.78e-13	Schizophrenia;
SARC	cis	rs372883	0.613	rs1153274	chr21:30660026	T/C	cg24692254	chr21:30365293	RNF160	-0.63	-8.02	-0.47	5.11e-14	Pancreatic cancer;
SARC	cis	rs3820928	0.874	rs10189579	chr2:227864876	A/G	cg05526886	chr2:227700861	RHBDD1	-0.49	-5.87	-0.36	1.5e-8	Pulmonary function;
SARC	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9346455	1.000	rs9354986	chr6:71996205	G/C	cg27238071	chr6:71998145	OGFRL1	0.58	4.81	0.3	2.73e-6	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
SARC	cis	rs898097	0.625	rs898095	chr17:80890638	T/C	cg02711726	chr17:80685570	FN3KRP	-0.36	-4.97	-0.31	1.27e-6	Breast cancer;
SARC	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.8	12.0	0.62	3.85e-26	Total body bone mineral density;
SARC	cis	rs11581859	0.613	rs4548463	chr1:99190949	T/G	cg20286094	chr1:99190917	SNX7	-0.42	-4.99	-0.31	1.2e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs523522	0.962	rs2233676	chr12:120933607	G/A	cg27279351	chr12:120934652	DYNLL1	0.72	8.91	0.5	1.5e-16	High light scatter reticulocyte count;
SARC	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg13880726	chr7:1868755	MAD1L1	0.6	7.16	0.42	1.06e-11	Bipolar disorder and schizophrenia;
SARC	trans	rs11039798	0.588	rs6485891	chr11:48612024	T/A	cg15704280	chr7:45808275	SEPT13	0.62	6.58	0.4	3.08e-10	Axial length;
SARC	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg17971929	chr21:40555470	PSMG1	0.96	13.19	0.65	4.8e-30	Cognitive function;
SARC	cis	rs17376456	0.877	rs9314092	chr5:93326362	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.61	5.55	0.34	7.76e-8	Diabetic retinopathy;
SARC	cis	rs17030434	0.906	rs11099901	chr4:154671468	T/A	cg14289246	chr4:154710475	SFRP2	-0.71	-7.09	-0.42	1.63e-11	Electrocardiographic conduction measures;
SARC	cis	rs1059312	0.932	rs4760589	chr12:129284382	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.5	-6.13	-0.37	3.69e-9	Systemic lupus erythematosus;
SARC	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg06212747	chr3:49208901	KLHDC8B	0.64	8.4	0.48	4.55e-15	Parkinson's disease;
SARC	cis	rs17401966	0.838	rs12125535	chr1:10350849	T/A	cg15208524	chr1:10270712	KIF1B	0.45	5.31	0.33	2.53e-7	Hepatocellular carcinoma;
SARC	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg05368731	chr17:41323189	NBR1	0.8	9.77	0.54	3.97e-19	Menopause (age at onset);
SARC	cis	rs67460515	0.563	rs68166680	chr3:160829735	T/A	cg17135325	chr3:160939158	NMD3	0.63	7.74	0.45	3.01e-13	Parkinson's disease;
SARC	cis	rs7617773	0.780	rs36121690	chr3:48345511	C/T	cg11946769	chr3:48343235	NME6	0.76	9.7	0.54	6.55e-19	Coronary artery disease;
SARC	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg07414643	chr4:187882934	NA	0.51	7.79	0.45	2.17e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11785400	1.000	rs4557682	chr8:143738182	T/C	cg24634471	chr8:143751801	JRK	0.68	9.17	0.52	2.5e-17	Schizophrenia;
SARC	cis	rs13191362	0.872	rs13213421	chr6:163203805	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.39	5.05	0.31	9.11e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2228479	0.850	rs11649100	chr16:89798179	A/G	cg06558623	chr16:89946397	TCF25	0.85	5.77	0.35	2.46e-8	Skin colour saturation;
SARC	cis	rs600231	0.665	rs1784859	chr11:65220749	A/G	cg17120908	chr11:65337727	SSSCA1	0.44	5.71	0.35	3.38e-8	Bone mineral density;
SARC	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg01448562	chr3:133502909	NA	0.58	9.11	0.51	3.96e-17	Iron status biomarkers;
SARC	cis	rs926392	0.932	rs6513589	chr20:37686585	A/G	cg16355469	chr20:37678765	NA	0.56	7.33	0.43	3.87e-12	Dialysis-related mortality;
SARC	cis	rs9300255	0.537	rs1790101	chr12:123704844	T/C	cg05973401	chr12:123451056	ABCB9	0.52	5.89	0.36	1.34e-8	Neutrophil percentage of white cells;
SARC	cis	rs1008375	0.932	rs964012	chr4:17619184	A/G	cg16339924	chr4:17578868	LAP3	0.64	8.46	0.48	2.97e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6963495	0.818	rs73190202	chr7:105166510	A/G	cg19920283	chr7:105172520	RINT1	0.66	5.62	0.35	5.45e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.54	6.89	0.41	5.13e-11	Lymphocyte counts;
SARC	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.42	-5.38	-0.33	1.79e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg00149659	chr3:10157352	C3orf10	0.7	6.35	0.38	1.11e-9	Alzheimer's disease;
SARC	cis	rs9911578	1.000	rs4636974	chr17:56965373	C/G	cg05425664	chr17:57184151	TRIM37	-0.66	-8.16	-0.47	2.07e-14	Intelligence (multi-trait analysis);
SARC	cis	rs1008375	1.000	rs555	chr4:17625658	A/G	cg02297831	chr4:17616191	MED28	0.47	5.86	0.36	1.53e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg05893365	chr16:67260970	LRRC29;TMEM208	0.49	6.25	0.38	1.98e-9	Lung adenocarcinoma;
SARC	cis	rs9309473	0.500	rs4286298	chr2:73882108	T/A	cg20560298	chr2:73613845	ALMS1	0.52	7.25	0.43	6.11e-12	Metabolite levels;
SARC	cis	rs17376456	0.569	rs11948511	chr5:93286601	A/C	cg25358565	chr5:93447407	FAM172A	-0.81	-9.47	-0.53	3.31e-18	Diabetic retinopathy;
SARC	trans	rs8020941	0.585	rs80318300	chr14:97501244	G/T	cg05136476	chr3:53190709	NA	-0.64	-6.45	-0.39	6.29e-10	Diabetic kidney disease;
SARC	cis	rs36051895	0.632	rs12352285	chr9:5141476	C/G	cg02405213	chr9:5042618	JAK2	-0.45	-5.53	-0.34	8.71e-8	Pediatric autoimmune diseases;
SARC	trans	rs1994135	0.565	rs11052767	chr12:33731194	A/G	cg26384229	chr12:38710491	ALG10B	0.74	8.88	0.5	1.85e-16	Resting heart rate;
SARC	cis	rs6879260	1.000	rs1035411	chr5:179729519	A/G	cg13944838	chr5:179740914	GFPT2	-0.58	-7.11	-0.42	1.39e-11	Height;
SARC	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg11644478	chr21:40555479	PSMG1	1.03	14.32	0.68	8.7e-34	Cognitive function;
SARC	cis	rs3768617	0.565	rs4233194	chr1:183060917	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.66	9.45	0.53	3.7e-18	Fuchs's corneal dystrophy;
SARC	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg22508957	chr16:3507546	NAT15	0.37	5.36	0.33	2.03e-7	Tuberculosis;
SARC	cis	rs6500602	0.739	rs4786502	chr16:4537104	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.34	5.74	0.35	2.86e-8	Schizophrenia;
SARC	cis	rs644799	0.710	rs519511	chr11:95538270	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.95	16.03	0.72	1.74e-39	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9487051	0.837	rs2356817	chr6:109642675	G/A	cg01475377	chr6:109611718	NA	-0.45	-6.44	-0.39	6.9e-10	Reticulocyte fraction of red cells;
SARC	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg07701084	chr6:150067640	NUP43	0.41	5.39	0.33	1.68e-7	Lung cancer;
SARC	cis	rs9611519	0.929	rs9611465	chr22:41426139	G/A	cg03806693	chr22:41940476	POLR3H	-0.61	-7.56	-0.44	8.99e-13	Neuroticism;
SARC	cis	rs9291683	0.575	rs3756223	chr4:10105797	C/T	cg11266682	chr4:10021025	SLC2A9	0.38	6.55	0.39	3.6e-10	Bone mineral density;
SARC	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg15448220	chr1:150897856	SETDB1	0.48	6.38	0.39	9.29e-10	Tonsillectomy;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg21037006	chr7:134574965	CALD1	0.46	6.4	0.39	8.63e-10	Thyroid stimulating hormone;
SARC	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.47	5.2	0.32	4.27e-7	Renal function-related traits (BUN);
SARC	cis	rs826838	1.000	rs826889	chr12:39101076	G/A	cg13010199	chr12:38710504	ALG10B	-0.64	-9.24	-0.52	1.61e-17	Heart rate;
SARC	cis	rs9303401	0.614	rs35245220	chr17:56510305	G/A	cg25039879	chr17:56429692	SUPT4H1	0.64	5.65	0.35	4.71e-8	Cognitive test performance;
SARC	cis	rs10206020	0.885	rs6720797	chr2:1574340	T/C	cg26248373	chr2:1572462	NA	-0.6	-8.42	-0.48	3.76e-15	IgG glycosylation;
SARC	cis	rs7568458	0.870	rs1009	chr2:85808737	A/G	cg17127132	chr2:85788382	GGCX	0.42	5.59	0.34	6.23e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs13191362	1.000	rs13214516	chr6:163121583	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.73	6.44	0.39	6.66e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs7904368	0.806	rs3858182	chr10:16855094	C/T	cg23933602	chr10:16859644	RSU1	0.59	5.94	0.36	1.02e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs2235544	0.565	rs12758219	chr1:54466145	G/A	cg10336722	chr1:54665764	CYB5RL;MRPL37	-0.39	-4.8	-0.3	2.82e-6	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
SARC	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.95	-13.96	-0.67	1.32e-32	Gut microbiome composition (summer);
SARC	cis	rs9487051	0.807	rs7748641	chr6:109592381	C/T	cg01475377	chr6:109611718	NA	-0.4	-5.79	-0.35	2.25e-8	Reticulocyte fraction of red cells;
SARC	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg11764359	chr7:65958608	NA	0.63	7.29	0.43	4.8e-12	Aortic root size;
SARC	cis	rs240764	0.619	rs10872623	chr6:101165047	A/G	cg09795085	chr6:101329169	ASCC3	-0.39	-4.92	-0.31	1.67e-6	Neuroticism;
SARC	cis	rs16854884	0.609	rs2885197	chr3:143636616	A/T	cg06585982	chr3:143692056	C3orf58	-0.64	-8.61	-0.49	1.13e-15	Economic and political preferences (feminism/equality);
SARC	cis	rs11097912	0.632	rs76150963	chr4:107187152	C/T	cg09646026	chr4:107269030	AIMP1	-0.44	-4.73	-0.3	3.84e-6	Airflow obstruction;
SARC	cis	rs4689388	0.890	rs9993624	chr4:6286528	C/T	cg00701064	chr4:6280414	WFS1	0.58	9.41	0.52	4.94e-18	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs6088580	0.634	rs1205344	chr20:32918298	G/A	cg08999081	chr20:33150536	PIGU	-0.43	-6.59	-0.4	2.89e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs11608355	1.000	rs11611370	chr12:109870291	A/G	cg05360138	chr12:110035743	NA	-0.45	-5.12	-0.32	6.4e-7	Neuroticism;
SARC	cis	rs7551222	0.752	rs12741351	chr1:204528256	G/A	cg20240347	chr1:204465584	NA	-0.33	-5.77	-0.35	2.57e-8	Schizophrenia;
SARC	cis	rs3008870	1.000	rs2182143	chr1:67378936	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.93	11.27	0.59	8.55e-24	Lymphocyte percentage of white cells;
SARC	cis	rs11098499	0.863	rs3775854	chr4:120471971	C/T	cg24375607	chr4:120327624	NA	0.42	4.92	0.31	1.64e-6	Corneal astigmatism;
SARC	cis	rs5758659	0.714	rs2284087	chr22:42485671	T/C	cg04733989	chr22:42467013	NAGA	-0.5	-6.22	-0.38	2.27e-9	Cognitive function;
SARC	cis	rs763121	0.853	rs6001188	chr22:39062194	T/C	cg06022373	chr22:39101656	GTPBP1	0.91	11.44	0.6	2.4e-24	Menopause (age at onset);
SARC	cis	rs9467773	0.620	rs2494696	chr6:26620894	A/G	cg11502198	chr6:26597334	ABT1	0.62	8.48	0.49	2.55e-15	Intelligence (multi-trait analysis);
SARC	trans	rs7615952	0.673	rs7632557	chr3:125634881	G/C	cg07211511	chr3:129823064	LOC729375	-0.96	-10.53	-0.57	1.86e-21	Blood pressure (smoking interaction);
SARC	cis	rs12594515	1.000	rs8026221	chr15:45987910	G/T	cg14863074	chr15:45997064	NA	0.34	5.24	0.32	3.57e-7	Waist circumference;Weight;
SARC	cis	rs10046574	0.519	rs7799873	chr7:135214030	C/T	cg27474649	chr7:135195673	CNOT4	0.78	7.52	0.44	1.21e-12	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs7546	0.505	rs760118	chr16:4940994	A/G	cg08329684	chr16:4932620	PPL	-0.43	-6.9	-0.41	4.91e-11	Cancer;
SARC	cis	rs4132509	0.793	rs74379351	chr1:243779604	T/C	cg21452805	chr1:244014465	NA	0.57	5.5	0.34	9.91e-8	RR interval (heart rate);
SARC	cis	rs957448	0.904	rs56302978	chr8:95518111	G/A	cg26464482	chr8:95565502	KIAA1429	0.43	4.74	0.3	3.73e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs4919044	0.641	rs7905234	chr10:94719384	A/G	cg05127821	chr10:94822908	CYP26C1	-0.65	-5.46	-0.34	1.22e-7	Coronary artery disease;
SARC	cis	rs1878931	0.697	rs1044390	chr16:3432594	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	1.01	18.72	0.78	2.37e-48	Body mass index (adult);
SARC	cis	rs4253772	0.530	rs11090865	chr22:46731689	G/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.61	4.86	0.3	2.11e-6	LDL cholesterol;Cholesterol, total;
SARC	cis	rs735396	1.000	rs1169309	chr12:121439192	G/T	cg25281562	chr12:121454272	C12orf43	0.5	6.06	0.37	5.55e-9	N-glycan levels;
SARC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg24101359	chr6:42928495	GNMT	0.44	6.03	0.37	6.39e-9	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs910316	0.935	rs175076	chr14:75505486	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.58	-8.01	-0.46	5.48e-14	Height;
SARC	cis	rs7727544	0.684	rs274561	chr5:131719228	A/C	cg24060327	chr5:131705240	SLC22A5	-0.71	-9.26	-0.52	1.36e-17	Blood metabolite levels;
SARC	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg24209194	chr3:40518798	ZNF619	0.58	7.14	0.42	1.16e-11	Renal cell carcinoma;
SARC	cis	rs748404	0.697	rs513970	chr15:43579566	A/G	cg08831455	chr15:43942014	CATSPER2	-0.41	-4.75	-0.3	3.49e-6	Lung cancer;
SARC	cis	rs9393692	0.557	rs61324092	chr6:26297392	G/A	cg13736514	chr6:26305472	NA	-0.41	-5.01	-0.31	1.06e-6	Educational attainment;
SARC	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg22857025	chr5:266934	NA	-1.06	-11.8	-0.61	1.74e-25	Breast cancer;
SARC	cis	rs13191362	1.000	rs13206253	chr6:163166902	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.25	0.33	3.44e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2387326	0.717	rs10829340	chr10:129943941	G/T	cg16087940	chr10:129947807	NA	-0.45	-5.74	-0.35	2.98e-8	Select biomarker traits;
SARC	cis	rs9906944	0.707	rs9916472	chr17:47109998	C/T	cg16584676	chr17:46985605	UBE2Z	-0.42	-5.04	-0.31	9.27e-7	Intelligence (multi-trait analysis);Body fat percentage;
SARC	cis	rs1215050	0.791	rs649866	chr4:98738826	T/C	cg05340658	chr4:99064831	C4orf37	0.43	5.74	0.35	2.91e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg11247378	chr22:39784982	NA	-0.32	-5.15	-0.32	5.48e-7	Intelligence (multi-trait analysis);
SARC	cis	rs12579753	0.719	rs10862377	chr12:82270172	C/T	cg07988820	chr12:82153109	PPFIA2	-0.44	-5.36	-0.33	2.04e-7	Resting heart rate;
SARC	cis	rs2273669	0.585	rs11153159	chr6:109376647	C/G	cg05315195	chr6:109294784	ARMC2	-0.65	-5.17	-0.32	4.92e-7	Prostate cancer;
SARC	cis	rs10870270	1.000	rs6560694	chr10:133773448	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.48	-5.51	-0.34	9.46e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs3857536	0.904	rs9294685	chr6:66901684	C/T	cg07460842	chr6:66804631	NA	-0.41	-4.81	-0.3	2.75e-6	Blood trace element (Cu levels);
SARC	cis	rs7560272	0.538	rs2012574	chr2:73928366	G/C	cg20560298	chr2:73613845	ALMS1	0.47	6.32	0.38	1.31e-9	Schizophrenia;
SARC	cis	rs7931462	0.655	rs6483208	chr11:92705844	A/C	cg24302024	chr11:93468466	SNORA40	-0.61	-4.91	-0.31	1.75e-6	DNA methylation (parent-of-origin);
SARC	cis	rs11785400	0.731	rs4644221	chr8:143736984	C/T	cg24634471	chr8:143751801	JRK	-0.58	-7.56	-0.44	9.27e-13	Schizophrenia;
SARC	cis	rs4891159	1.000	rs4891159	chr18:74101941	A/G	cg24786174	chr18:74118243	ZNF516	0.58	8.95	0.51	1.18e-16	Longevity;
SARC	cis	rs6430585	0.528	rs309152	chr2:136657252	C/T	cg07169764	chr2:136633963	MCM6	-0.91	-11.25	-0.59	9.47e-24	Corneal structure;
SARC	cis	rs888194	0.966	rs1558804	chr12:109898732	A/G	cg13986417	chr12:110012484	MVK;MMAB	-0.35	-5.4	-0.33	1.61e-7	Neuroticism;
SARC	cis	rs7555523	0.779	rs2790049	chr1:165743523	A/G	cg24409356	chr1:165738333	TMCO1	0.76	6.46	0.39	6.06e-10	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg27185819	chr4:73434820	ADAMTS3	0.49	6.24	0.38	2e-9	Chemerin levels;
SARC	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg10523679	chr1:76189770	ACADM	0.49	6.63	0.4	2.26e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2120019	0.938	rs8040169	chr15:75370958	C/A	cg12414181	chr15:75287860	SCAMP5	-0.42	-4.89	-0.31	1.87e-6	Blood trace element (Zn levels);
SARC	cis	rs3820928	1.000	rs61067328	chr2:227761256	G/A	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.97	-0.36	8.55e-9	Pulmonary function;
SARC	cis	rs1003719	0.788	rs2835600	chr21:38468958	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.63	9.05	0.51	5.67e-17	Eye color traits;
SARC	cis	rs2486288	0.656	rs6493143	chr15:45570781	G/T	cg19305227	chr15:45544335	SLC28A2	0.31	5.75	0.35	2.86e-8	Glomerular filtration rate;
SARC	trans	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg00938859	chr5:1591904	SDHAP3	0.76	7.39	0.44	2.55e-12	Breast cancer;
SARC	cis	rs1371867	0.846	rs1613453	chr8:101244215	G/T	cg11906718	chr8:101322791	RNF19A	-0.69	-8.71	-0.5	5.81e-16	Atrioventricular conduction;
SARC	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg06618935	chr21:46677482	NA	-0.41	-5.36	-0.33	2.03e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs240764	0.764	rs10457800	chr6:100936628	C/T	cg21058520	chr6:100914733	NA	0.32	5.01	0.31	1.06e-6	Neuroticism;
SARC	cis	rs2204008	0.654	rs1733410	chr12:38132172	G/A	cg26384229	chr12:38710491	ALG10B	-0.66	-8.64	-0.49	9.24e-16	Bladder cancer;
SARC	cis	rs425277	0.917	rs78609670	chr1:2045886	G/T	cg24578937	chr1:2090814	PRKCZ	0.32	6.01	0.37	7.22e-9	Height;
SARC	cis	rs7395581	0.797	rs10742801	chr11:47342220	A/C	cg25783544	chr11:47291846	MADD	0.47	5.27	0.33	3.05e-7	HDL cholesterol;
SARC	cis	rs910316	1.000	rs7147118	chr14:75610170	G/C	cg11812906	chr14:75593930	NEK9	0.87	13.74	0.67	7.12e-32	Height;
SARC	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg02574844	chr11:5959923	NA	-0.38	-5.37	-0.33	1.94e-7	DNA methylation (variation);
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24718163	chr3:125314451	OSBPL11	-0.61	-7.43	-0.44	2.11e-12	Fibrinogen levels;
SARC	trans	rs7937682	0.889	rs12360825	chr11:111528786	A/T	cg18187862	chr3:45730750	SACM1L	0.55	6.86	0.41	6.12e-11	Primary sclerosing cholangitis;
SARC	cis	rs9322193	0.607	rs12527391	chr6:150203292	T/C	cg05036130	chr6:150231994	NA	0.34	5.1	0.32	6.93e-7	Lung cancer;
SARC	cis	rs147858478	1	rs147858478	chr5:131682785	CCTGAGTT/C	cg24060327	chr5:131705240	SLC22A5	-0.65	-8.01	-0.46	5.3e-14	High light scatter reticulocyte percentage of red cells;
SARC	cis	rs17376456	0.877	rs12716456	chr5:93397557	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.76	0.35	2.64e-8	Diabetic retinopathy;
SARC	cis	rs62064224	0.765	rs62065463	chr17:30732405	G/T	cg18200150	chr17:30822561	MYO1D	0.44	7.06	0.42	1.89e-11	Schizophrenia;
SARC	cis	rs2295359	1.000	rs963427	chr1:67609347	A/G	cg12940439	chr1:67600707	NA	0.43	6.75	0.4	1.15e-10	Psoriasis;
SARC	trans	rs208520	0.874	rs208456	chr6:66907942	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.93	-10.74	-0.58	4.13e-22	Exhaled nitric oxide output;
SARC	cis	rs9303401	0.614	rs12947982	chr17:57140301	A/G	cg25039879	chr17:56429692	SUPT4H1	0.56	4.98	0.31	1.22e-6	Cognitive test performance;
SARC	cis	rs4722166	0.645	rs1404006	chr7:22795077	T/C	cg26061582	chr7:22766209	IL6	0.47	5.27	0.33	3.09e-7	Lung cancer;
SARC	cis	rs7248779	0.532	rs10153475	chr19:2413961	G/C	cg22729335	chr19:2427816	TIMM13	1.06	17.35	0.75	7.67e-44	Cortisol levels (saliva);
SARC	cis	rs2832191	1.000	rs2832185	chr21:30483761	C/G	cg08807101	chr21:30365312	RNF160	-0.75	-10.39	-0.56	4.97e-21	Dental caries;
SARC	cis	rs73206853	0.841	rs73206847	chr12:110672353	G/A	cg08946844	chr12:110511112	NA	0.59	4.81	0.3	2.67e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs9911578	0.967	rs57869245	chr17:57106630	A/G	cg12560992	chr17:57184187	TRIM37	-0.8	-10.94	-0.58	9.39e-23	Intelligence (multi-trait analysis);
SARC	cis	rs2712184	0.756	rs2541388	chr2:217664284	A/G	cg05032264	chr2:217675019	NA	0.51	6.66	0.4	1.93e-10	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
SARC	cis	rs6489785	0.562	rs494632	chr12:121189116	C/T	cg02403541	chr12:121454288	C12orf43	0.42	5.01	0.31	1.09e-6	Longevity;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs9902453	0.715	rs2628176	chr17:28139292	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.54	-7.06	-0.42	1.85e-11	Coffee consumption (cups per day);
SARC	cis	rs12545109	0.876	rs1992120	chr8:57337112	G/A	cg19413350	chr8:57351067	NA	-0.45	-5.07	-0.32	8.12e-7	Obesity-related traits;
SARC	cis	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg13647721	chr17:30228624	UTP6	0.6	4.78	0.3	3.16e-6	Hip circumference adjusted for BMI;
SARC	trans	rs61931739	0.534	rs11053000	chr12:34079022	C/T	cg26384229	chr12:38710491	ALG10B	0.84	11.92	0.62	6.83e-26	Morning vs. evening chronotype;
SARC	cis	rs6696846	0.777	rs2369526	chr1:205054406	C/T	cg21545522	chr1:205238299	TMCC2	0.35	4.85	0.3	2.28e-6	Red blood cell count;
SARC	cis	rs1983170	0.736	rs4484968	chr1:92012005	C/A	cg25838465	chr1:92012736	NA	0.57	5.89	0.36	1.34e-8	Eosinophil percentage of white cells;
SARC	cis	rs4803468	1.000	rs284652	chr19:41928652	C/T	cg14132834	chr19:41945861	ATP5SL	-0.57	-7.49	-0.44	1.39e-12	Height;
SARC	cis	rs7103648	0.897	rs35032070	chr11:47408592	G/A	cg20307385	chr11:47447363	PSMC3	0.8	11.61	0.61	7.11e-25	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs4974559	0.790	rs2293631	chr4:1315917	C/A	cg02980000	chr4:1222292	CTBP1	0.58	5.47	0.34	1.17e-7	Systolic blood pressure;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg02750935	chr5:145214981	PRELID2	-0.58	-6.57	-0.4	3.24e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs13082711	0.911	rs7640929	chr3:27513944	C/A	cg02860705	chr3:27208620	NA	0.45	5.72	0.35	3.27e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs2718058	0.630	rs2722292	chr7:37824581	A/G	cg24998770	chr7:37888106	TXNDC3	0.38	5.39	0.33	1.68e-7	Alzheimer's disease (late onset);
SARC	cis	rs2073300	0.609	rs6137917	chr20:23360369	G/A	cg12062639	chr20:23401060	NAPB	0.95	6.46	0.39	6.01e-10	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs10782582	0.609	rs1628063	chr1:76391646	A/G	cg03433033	chr1:76189801	ACADM	-0.4	-5.14	-0.32	5.68e-7	Daytime sleep phenotypes;
SARC	cis	rs9300255	0.543	rs1617156	chr12:123590165	T/C	cg00376283	chr12:123451042	ABCB9	0.56	6.31	0.38	1.36e-9	Neutrophil percentage of white cells;
SARC	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg08859206	chr1:53392774	SCP2	0.43	5.94	0.36	1.02e-8	Monocyte count;
SARC	trans	rs656319	0.605	rs4840467	chr8:10079637	A/G	cg06636001	chr8:8085503	FLJ10661	0.58	7.73	0.45	3.2e-13	Myopia (pathological);
SARC	cis	rs826838	1.000	rs1843881	chr12:38733706	A/G	cg26384229	chr12:38710491	ALG10B	-0.97	-15.89	-0.72	5.23e-39	Heart rate;
SARC	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg13939156	chr17:80058883	NA	-0.42	-6.48	-0.39	5.51e-10	Life satisfaction;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg03477043	chr16:2812423	SRRM2	0.51	6.42	0.39	7.41e-10	Schizophrenia;
SARC	cis	rs35110281	0.807	rs2838326	chr21:45014315	C/T	cg21573476	chr21:45109991	RRP1B	-0.49	-7.39	-0.44	2.59e-12	Mean corpuscular volume;
SARC	cis	rs7647973	0.626	rs9824435	chr3:49674343	A/G	cg03060546	chr3:49711283	APEH	-0.62	-6.2	-0.38	2.52e-9	Menarche (age at onset);
SARC	cis	rs514024	0.700	rs538927	chr9:130488494	C/T	cg13643465	chr9:130375613	STXBP1	0.42	5.19	0.32	4.64e-7	Eating disorders (purging via substances);
SARC	cis	rs12586317	0.620	rs17103042	chr14:35575428	T/C	cg26967526	chr14:35346199	BAZ1A	-0.64	-6.96	-0.41	3.45e-11	Psoriasis;
SARC	cis	rs4566357	0.615	rs2272200	chr2:227912331	G/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.86	-0.36	1.53e-8	Coronary artery disease;
SARC	cis	rs11608355	1.000	rs7132057	chr12:109880279	A/C	cg19025524	chr12:109796872	NA	-0.4	-5.13	-0.32	6.17e-7	Neuroticism;
SARC	cis	rs826838	0.967	rs7963716	chr12:38876090	C/T	cg26384229	chr12:38710491	ALG10B	0.87	12.49	0.63	9.82e-28	Heart rate;
SARC	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg25036284	chr2:26402008	FAM59B	0.48	5.72	0.35	3.19e-8	Gut microbiome composition (summer);
SARC	cis	rs9457247	0.508	rs7760495	chr6:167506795	C/T	cg23791538	chr6:167370224	RNASET2	-0.39	-4.74	-0.3	3.65e-6	Crohn's disease;
SARC	cis	rs918629	0.761	rs17085333	chr5:95280848	A/T	cg16656078	chr5:95278638	ELL2	0.7	8.35	0.48	5.98e-15	IgG glycosylation;
SARC	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg24675658	chr1:53192096	ZYG11B	0.61	8.85	0.5	2.21e-16	Monocyte count;
SARC	cis	rs6500602	0.727	rs11076836	chr16:4569331	G/A	cg08645402	chr16:4508243	NA	0.45	5.98	0.36	8.53e-9	Schizophrenia;
SARC	trans	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg06437703	chr8:37914619	EIF4EBP1	0.68	7.72	0.45	3.31e-13	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	trans	rs7824557	0.564	rs12547100	chr8:11242632	G/A	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.35	-0.38	1.09e-9	Retinal vascular caliber;
SARC	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg27170947	chr2:26402098	FAM59B	-0.37	-4.8	-0.3	2.79e-6	Gut microbiome composition (summer);
SARC	cis	rs7666738	0.830	rs11731478	chr4:99001686	A/G	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7310409	0.544	rs1169292	chr12:121426478	C/T	cg25281562	chr12:121454272	C12orf43	0.52	6.35	0.38	1.12e-9	Liver enzyme levels (gamma-glutamyl transferase);C-reactive protein;Pancreatic cancer;
SARC	cis	rs936229	0.813	rs2301249	chr15:75092384	T/C	cg14664628	chr15:75095509	CSK	-1.05	-14.88	-0.7	1.19e-35	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs3733585	0.674	rs7375643	chr4:9955239	A/G	cg00071950	chr4:10020882	SLC2A9	-0.4	-6.4	-0.39	8.29e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg05861140	chr6:150128134	PCMT1	-0.41	-5.17	-0.32	4.94e-7	Lung cancer;
SARC	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg19748678	chr4:122722346	EXOSC9	0.77	10.16	0.55	2.59e-20	Type 2 diabetes;
SARC	cis	rs11249608	0.548	rs12152869	chr5:178462520	A/G	cg21905437	chr5:178450457	ZNF879	0.57	7.47	0.44	1.63e-12	Pubertal anthropometrics;
SARC	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.63e-10	Life satisfaction;
SARC	cis	rs7523050	0.643	rs7551142	chr1:109399710	G/T	cg08274380	chr1:109419600	GPSM2	1.07	8.3	0.48	8.22e-15	Fat distribution (HIV);
SARC	cis	rs12478296	0.901	rs73007142	chr2:243010852	T/C	cg06360820	chr2:242988706	NA	-0.8	-6.11	-0.37	4.25e-9	Obesity-related traits;
SARC	cis	rs12421382	0.614	rs12575538	chr11:109390966	C/A	cg16359550	chr11:109292809	C11orf87	0.34	5.1	0.32	7.05e-7	Schizophrenia;
SARC	cis	rs9393692	0.627	rs2179517	chr6:26198845	G/C	cg13736514	chr6:26305472	NA	-0.58	-7.7	-0.45	3.92e-13	Educational attainment;
SARC	cis	rs561341	1.000	rs757009	chr17:30243937	A/G	cg13647721	chr17:30228624	UTP6	0.63	5.62	0.35	5.35e-8	Hip circumference adjusted for BMI;
SARC	cis	rs72766638	0.848	rs11789898	chr9:136925663	A/C	cg13789015	chr9:136890014	NCRNA00094	-0.62	-7.01	-0.42	2.51e-11	Mosquito bite size;
SARC	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.97e-8	Aortic root size;
SARC	cis	rs524281	0.731	rs2276036	chr11:66033430	C/T	cg14036092	chr11:66035641	RAB1B	-0.59	-6.01	-0.37	7.02e-9	Electroencephalogram traits;
SARC	cis	rs11792861	0.816	rs744980	chr9:111690388	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.74	8.95	0.51	1.16e-16	Menarche (age at onset);
SARC	cis	rs2425143	1.000	rs11699044	chr20:34312713	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.72	6.8	0.41	8.85e-11	Blood protein levels;
SARC	cis	rs4748857	0.947	rs4603206	chr10:23607192	C/T	cg12804278	chr10:23633326	C10orf67	0.4	4.75	0.3	3.51e-6	Systemic lupus erythematosus;
SARC	cis	rs1476029	0.612	rs132646	chr22:36550067	T/C	cg23889684	chr22:36556813	APOL3	0.48	4.94	0.31	1.48e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
SARC	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg04944784	chr2:26401820	FAM59B	-0.6	-7.86	-0.46	1.41e-13	Gut microbiome composition (summer);
SARC	cis	rs9905704	0.647	rs2108435	chr17:57102133	T/C	cg12560992	chr17:57184187	TRIM37	-0.51	-6.18	-0.38	2.78e-9	Testicular germ cell tumor;
SARC	cis	rs3204955	0.802	rs12734646	chr1:116247050	A/T	cg20810993	chr1:116250018	CASQ2	-0.52	-5.21	-0.32	4.22e-7	Itch intensity from mosquito bite adjusted by bite size;
SARC	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg14664628	chr15:75095509	CSK	-0.46	-5.56	-0.34	7.32e-8	Breast cancer;
SARC	cis	rs372883	0.600	rs1153277	chr21:30666867	A/T	cg24692254	chr21:30365293	RNF160	-0.66	-8.44	-0.48	3.32e-15	Pancreatic cancer;
SARC	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg24060327	chr5:131705240	SLC22A5	-0.47	-5.63	-0.35	5.18e-8	Acylcarnitine levels;
SARC	cis	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg15556689	chr8:8085844	FLJ10661	0.48	6.05	0.37	5.8e-9	Mood instability;
SARC	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.54	5.82	0.36	1.94e-8	Renal function-related traits (BUN);
SARC	cis	rs17095355	1.000	rs11194920	chr10:111695412	G/T	cg00817464	chr10:111662876	XPNPEP1	-0.41	-4.74	-0.3	3.74e-6	Biliary atresia;
SARC	cis	rs2073300	0.609	rs6137950	chr20:23418722	T/A	cg16736954	chr20:23401023	NAPB	0.77	4.79	0.3	3.02e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs10782582	0.609	rs1498311	chr1:76254726	A/C	cg03433033	chr1:76189801	ACADM	0.4	5.11	0.32	6.73e-7	Daytime sleep phenotypes;
SARC	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg11987759	chr7:65425863	GUSB	-0.49	-6.36	-0.38	1.05e-9	Aortic root size;
SARC	cis	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg08975724	chr8:8085496	FLJ10661	0.56	7.15	0.42	1.11e-11	Neuroticism;
SARC	cis	rs9297145	0.724	rs62473013	chr7:98762418	G/T	cg05967295	chr7:98741636	SMURF1	0.76	7.8	0.46	2.04e-13	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
SARC	cis	rs4595586	0.545	rs7970307	chr12:39380760	A/C	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	cis	rs11578119	0.933	rs12120718	chr1:170394250	A/T	cg09767346	chr1:170501363	GORAB	0.42	4.92	0.31	1.63e-6	Male-pattern baldness;
SARC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg25703541	chr22:24373054	LOC391322	-0.8	-10.45	-0.56	3.23e-21	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs11098499	0.863	rs11736416	chr4:120431661	C/T	cg24375607	chr4:120327624	NA	0.42	4.9	0.31	1.77e-6	Corneal astigmatism;
SARC	cis	rs5753618	0.539	rs8135344	chr22:31671932	G/T	cg13145458	chr22:31556086	RNF185	0.47	5.06	0.31	8.47e-7	Colorectal cancer;
SARC	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg24829409	chr8:58192753	C8orf71	-0.63	-5.96	-0.36	9.37e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2354432	0.607	rs2353999	chr1:146830686	T/C	cg25205988	chr1:146714368	CHD1L	-0.95	-7.16	-0.42	1.03e-11	Mitochondrial DNA levels;
SARC	cis	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg11266682	chr4:10021025	SLC2A9	0.4	7.31	0.43	4.24e-12	Bone mineral density;
SARC	cis	rs30380	0.586	rs28119	chr5:96131733	G/A	cg16492584	chr5:96139282	ERAP1	-0.47	-5.35	-0.33	2.07e-7	Cerebrospinal fluid biomarker levels;
SARC	cis	rs6121246	0.821	rs6121209	chr20:30311258	G/C	cg13852791	chr20:30311386	BCL2L1	0.85	9.18	0.52	2.48e-17	Mean corpuscular hemoglobin;
SARC	cis	rs709400	0.628	rs11622356	chr14:103912195	C/T	cg12935359	chr14:103987150	CKB	-0.4	-5.88	-0.36	1.45e-8	Body mass index;
SARC	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg11987759	chr7:65425863	GUSB	-0.5	-6.19	-0.38	2.62e-9	Aortic root size;
SARC	cis	rs12291225	0.637	rs8570	chr11:14300759	C/G	cg19336497	chr11:14380999	RRAS2	-0.4	-6.76	-0.41	1.07e-10	Sense of smell;
SARC	cis	rs2732480	0.500	rs2450991	chr12:48651621	A/G	cg24011408	chr12:48396354	COL2A1	0.45	5.29	0.33	2.87e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs9911578	0.933	rs2531725	chr17:56517962	G/A	cg05425664	chr17:57184151	TRIM37	-0.58	-7.01	-0.42	2.53e-11	Intelligence (multi-trait analysis);
SARC	cis	rs7481584	0.624	rs412149	chr11:3069943	G/A	cg05729581	chr11:3078854	CARS	0.54	7.0	0.42	2.78e-11	Calcium levels;
SARC	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg00933542	chr6:150070202	PCMT1	0.3	5.14	0.32	5.77e-7	Lung cancer;
SARC	trans	rs6964833	1.000	rs17515241	chr7:74132014	C/T	cg07504079	chr7:72649617	NCF1B	0.56	6.3	0.38	1.46e-9	Menarche (age at onset);
SARC	cis	rs72949976	0.646	rs1441171	chr2:214033637	G/T	cg08319019	chr2:214017104	IKZF2	0.46	6.12	0.37	3.98e-9	Lung cancer;Squamous cell lung carcinoma;
SARC	cis	rs4664308	0.618	rs17830940	chr2:160891768	T/C	cg03641300	chr2:160917029	PLA2R1	-0.38	-4.97	-0.31	1.3e-6	Idiopathic membranous nephropathy;
SARC	cis	rs2153535	0.580	rs718502	chr6:8527400	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	6.53	0.39	4.11e-10	Motion sickness;
SARC	cis	rs67460515	0.563	rs1599375	chr3:160897771	C/T	cg04691961	chr3:161091175	C3orf57	0.46	5.62	0.35	5.44e-8	Parkinson's disease;
SARC	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg25894440	chr7:65020034	NA	-0.72	-5.46	-0.34	1.23e-7	Diabetic kidney disease;
SARC	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg24549020	chr5:56110836	MAP3K1	-0.51	-5.66	-0.35	4.38e-8	Initial pursuit acceleration;
SARC	cis	rs944802	0.639	rs7022662	chr9:22147715	C/G	cg00491127	chr9:22154101	NA	0.53	5.86	0.36	1.55e-8	White blood cell count;
SARC	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.95	9.55	0.53	1.93e-18	Platelet count;
SARC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.89	0.81	2.61e-55	Prudent dietary pattern;
SARC	cis	rs933688	0.532	rs28637141	chr5:90538743	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.47	-5.47	-0.34	1.15e-7	Smoking behavior;
SARC	cis	rs2288912	0.838	rs7251503	chr19:45455715	C/G	cg10169327	chr19:45448959	APOC2	0.31	5.11	0.32	6.85e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs10493773	0.928	rs12741600	chr1:86191172	A/C	cg17807903	chr1:86174739	ZNHIT6	-0.49	-7.25	-0.43	6.26e-12	Urate levels in overweight individuals;
SARC	cis	rs7178909	0.872	rs7179633	chr15:90434877	T/C	cg19708238	chr15:90437601	AP3S2	0.59	7.89	0.46	1.19e-13	Common traits (Other);
SARC	cis	rs870825	0.616	rs4616798	chr4:185634144	C/T	cg04058563	chr4:185651563	MLF1IP	-0.79	-10.55	-0.57	1.57e-21	Blood protein levels;
SARC	cis	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg25135259	chr10:115614956	NHLRC2;DCLRE1A	0.42	5.33	0.33	2.35e-7	Breast cancer;
SARC	cis	rs7647973	1.000	rs4241407	chr3:49600319	C/T	cg07636037	chr3:49044803	WDR6	0.75	8.75	0.5	4.3e-16	Menarche (age at onset);
SARC	cis	rs2985684	0.789	rs7161649	chr14:50064028	A/G	cg04989706	chr14:50066350	PPIL5	-0.56	-6.28	-0.38	1.65e-9	Carotid intima media thickness;
SARC	cis	rs7772486	0.686	rs857883	chr6:145969214	G/T	cg05347473	chr6:146136440	FBXO30	-0.54	-7.43	-0.44	2.02e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10927875	0.518	rs945416	chr1:16344402	G/A	cg21385522	chr1:16154831	NA	0.54	6.47	0.39	5.8e-10	Dilated cardiomyopathy;
SARC	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg24250549	chr1:154909240	PMVK	0.8	11.66	0.61	4.78e-25	Prostate cancer;
SARC	cis	rs17021463	0.966	rs1565062	chr4:95183000	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.49	-7.48	-0.44	1.47e-12	Testicular germ cell tumor;
SARC	cis	rs7712401	0.601	rs30038	chr5:122277362	A/C	cg19412675	chr5:122181750	SNX24	0.39	4.88	0.3	1.93e-6	Mean platelet volume;
SARC	cis	rs6448317	0.954	rs12186333	chr4:24919774	T/C	cg21108841	chr4:24914750	CCDC149	-0.56	-5.94	-0.36	1.02e-8	Heschl's gyrus morphology;
SARC	cis	rs1401999	0.510	rs2293001	chr3:183700211	C/T	cg01324343	chr3:183735012	ABCC5	0.48	8.37	0.48	5.38e-15	Anterior chamber depth;
SARC	cis	rs6912958	0.605	rs2754247	chr6:88383571	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.31	-0.33	2.55e-7	Monocyte percentage of white cells;
SARC	trans	rs61931739	0.500	rs11615231	chr12:34413330	T/C	cg13010199	chr12:38710504	ALG10B	0.81	11.39	0.6	3.58e-24	Morning vs. evening chronotype;
SARC	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg16325326	chr1:53192061	ZYG11B	0.78	12.14	0.62	1.29e-26	Monocyte count;
SARC	cis	rs2652834	0.904	rs2729826	chr15:63360446	C/G	cg05507819	chr15:63340323	TPM1	-0.55	-5.56	-0.34	7.18e-8	HDL cholesterol;
SARC	cis	rs7555523	0.887	rs4657471	chr1:165686873	T/C	cg19769164	chr1:165738335	TMCO1	0.64	5.04	0.31	9.4e-7	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	cis	rs73195822	0.614	rs17190144	chr12:111214767	A/G	cg10860002	chr12:110842031	ANAPC7	0.58	5.07	0.31	8.3e-7	Itch intensity from mosquito bite;
SARC	cis	rs13065560	0.534	rs4637231	chr3:38909115	T/C	cg26331595	chr3:39149181	GORASP1;TTC21A	0.38	4.74	0.3	3.78e-6	Interleukin-18 levels;
SARC	cis	rs72781680	0.898	rs12622290	chr2:23979894	C/G	cg06627628	chr2:24431161	ITSN2	-0.68	-6.49	-0.39	5.15e-10	Lymphocyte counts;
SARC	cis	rs7000551	0.725	rs2461489	chr8:22370253	G/A	cg12081754	chr8:22256438	SLC39A14	0.57	8.06	0.47	3.85e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg12463550	chr7:65579703	CRCP	0.48	5.58	0.34	6.58e-8	Aortic root size;
SARC	cis	rs6580649	0.941	rs57054831	chr12:48486892	C/T	cg05342945	chr12:48394962	COL2A1	0.56	6.2	0.38	2.59e-9	Lung cancer;
SARC	cis	rs9486719	1.000	rs12212614	chr6:97036466	T/G	cg06623918	chr6:96969491	KIAA0776	-0.79	-8.88	-0.5	1.86e-16	Migraine;Coronary artery disease;
SARC	cis	rs62064224	0.606	rs61390192	chr17:30837447	C/T	cg18200150	chr17:30822561	MYO1D	0.5	7.63	0.45	5.8e-13	Schizophrenia;
SARC	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	8.83	0.5	2.51e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs28374715	0.662	rs28827035	chr15:41492290	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.0	-13.62	-0.67	1.85e-31	Ulcerative colitis;
SARC	cis	rs523522	0.962	rs1050187	chr12:120902111	A/G	cg27279351	chr12:120934652	DYNLL1	-0.72	-8.65	-0.49	8.48e-16	High light scatter reticulocyte count;
SARC	cis	rs11731606	0.508	rs57403425	chr4:95312411	G/T	cg00507259	chr4:95128692	SMARCAD1	0.56	5.27	0.33	3.04e-7	Mean platelet volume;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg17846497	chr17:78290901	RNF213	-0.49	-6.54	-0.39	3.91e-10	Electrocardiographic conduction measures;
SARC	cis	rs6570726	0.967	rs439017	chr6:145806123	T/C	cg05220968	chr6:146057943	EPM2A	-0.28	-4.8	-0.3	2.9e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs554111	0.613	rs10753510	chr1:21412248	G/A	cg08890418	chr1:21044141	KIF17	-0.36	-5.11	-0.32	6.62e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs4243830	0.850	rs12744992	chr1:6601290	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.9	-9.26	-0.52	1.41e-17	Body mass index;
SARC	cis	rs748404	0.697	rs524547	chr15:43551023	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.41	5.09	0.32	7.44e-7	Lung cancer;
SARC	cis	rs2361718	0.500	rs8064429	chr17:78096187	A/C	cg23534315	chr17:78082725	GAA	0.42	5.58	0.34	6.64e-8	Yeast infection;
SARC	cis	rs897080	0.515	rs1067358	chr2:44662183	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	6.03	0.37	6.33e-9	Height;
SARC	trans	rs3780486	0.505	rs10758188	chr9:33123386	C/T	cg20290983	chr6:43655470	MRPS18A	-0.92	-14.13	-0.68	3.8e-33	IgG glycosylation;
SARC	cis	rs449789	0.502	rs529281	chr6:159708505	T/C	cg14500486	chr6:159655392	FNDC1	-0.44	-5.02	-0.31	1.01e-6	Pulse pressure;
SARC	cis	rs1044826	1.000	rs13074208	chr3:139207151	A/G	cg15131784	chr3:139108705	COPB2	0.46	5.16	0.32	5.24e-7	Obesity-related traits;
SARC	cis	rs7937682	0.889	rs558736	chr11:111500760	C/G	cg22437258	chr11:111473054	SIK2	0.75	10.38	0.56	5.41e-21	Primary sclerosing cholangitis;
SARC	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg13206674	chr6:150067644	NUP43	0.4	5.23	0.32	3.82e-7	Lung cancer;
SARC	cis	rs9790314	1.000	rs336585	chr3:161081670	A/G	cg03342759	chr3:160939853	NMD3	-0.58	-7.08	-0.42	1.72e-11	Morning vs. evening chronotype;
SARC	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg12311346	chr5:56204834	C5orf35	-0.58	-6.01	-0.37	7.24e-9	Initial pursuit acceleration;
SARC	cis	rs6061231	1.000	rs6061231	chr20:60956917	C/A	cg24112000	chr20:60950667	NA	-0.39	-6.07	-0.37	5.22e-9	Colorectal cancer;
SARC	cis	rs3820928	1.000	rs7561378	chr2:227772248	T/C	cg11843606	chr2:227700838	RHBDD1	-0.54	-6.81	-0.41	8.13e-11	Pulmonary function;
SARC	cis	rs2439831	0.764	rs12324584	chr15:43683446	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.76	7.87	0.46	1.3e-13	Lung cancer in ever smokers;
SARC	cis	rs367615	0.704	rs60538082	chr5:108829101	A/G	cg17395555	chr5:108820864	NA	0.47	6.63	0.4	2.34e-10	Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs7584330	0.738	rs13398506	chr2:238374824	A/G	cg11271282	chr2:238384023	NA	0.49	5.57	0.34	6.93e-8	Prostate cancer;
SARC	cis	rs4148883	0.645	rs2851287	chr4:100014548	G/A	cg12011299	chr4:100065546	ADH4	0.36	6.71	0.4	1.43e-10	Alcohol dependence;
SARC	cis	rs1559088	0.576	rs11084707	chr19:33612873	C/T	cg27124370	chr19:33622961	WDR88	0.54	7.23	0.43	6.9e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg05368731	chr17:41323189	NBR1	0.77	9.25	0.52	1.52e-17	Menopause (age at onset);
SARC	trans	rs3929778	0.959	rs13037119	chr20:6458525	C/T	cg00270625	chr22:51017019	CPT1B;CHKB-CPT1B	0.61	6.82	0.41	7.94e-11	QRS complex (Cornell);
SARC	cis	rs10979	0.562	rs9399446	chr6:143874639	G/C	cg25407410	chr6:143891975	LOC285740	-0.44	-5.36	-0.33	2.03e-7	Hypospadias;
SARC	cis	rs7666738	0.830	rs7679299	chr4:99057620	C/A	cg05340658	chr4:99064831	C4orf37	0.64	8.69	0.49	6.68e-16	Colonoscopy-negative controls vs population controls;
SARC	trans	rs6894249	1.000	rs6894249	chr5:131797547	A/G	cg01728682	chr2:25057480	ADCY3	-0.52	-6.93	-0.41	4.15e-11	Asthma;
SARC	cis	rs2635047	0.638	rs28718304	chr18:44632830	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	6.42	0.39	7.69e-10	Educational attainment;
SARC	cis	rs7766436	0.767	rs11754964	chr6:22604737	G/T	cg13666174	chr6:22585274	NA	-0.49	-6.8	-0.41	8.67e-11	Coronary artery disease;
SARC	cis	rs9398803	0.687	rs7738836	chr6:126936235	A/G	cg19875578	chr6:126661172	C6orf173	0.61	8.32	0.48	7.54e-15	Male-pattern baldness;
SARC	cis	rs6714710	0.580	rs6711101	chr2:98379813	G/A	cg26665480	chr2:98280029	ACTR1B	0.48	6.36	0.38	1.07e-9	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.59	4.95	0.31	1.43e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs262150	1.000	rs262149	chr7:158778256	A/G	cg04111992	chr7:158790115	NA	0.37	4.91	0.31	1.68e-6	Facial morphology (factor 20);
SARC	cis	rs3771570	0.579	rs62190373	chr2:242388685	G/A	cg21155796	chr2:242212141	HDLBP	0.68	6.08	0.37	4.81e-9	Prostate cancer;
SARC	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg13628971	chr7:2884303	GNA12	0.56	6.64	0.4	2.13e-10	Height;
SARC	cis	rs11792861	0.926	rs7470160	chr9:111844246	C/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.67	7.73	0.45	3.27e-13	Menarche (age at onset);
SARC	cis	rs854765	0.693	rs8079321	chr17:17760789	C/T	cg05444541	chr17:17804740	TOM1L2	-0.32	-5.31	-0.33	2.54e-7	Total body bone mineral density;
SARC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg07332563	chr6:291687	DUSP22	-0.58	-7.89	-0.46	1.14e-13	Menopause (age at onset);
SARC	cis	rs1971762	0.583	rs10876485	chr12:54087648	C/T	cg06632207	chr12:54070931	ATP5G2	-0.44	-5.71	-0.35	3.43e-8	Height;
SARC	cis	rs7829975	0.533	rs1039917	chr8:8718850	C/T	cg15556689	chr8:8085844	FLJ10661	0.45	5.32	0.33	2.45e-7	Mood instability;
SARC	cis	rs7561273	0.586	rs12477718	chr2:24330539	A/G	cg08917208	chr2:24149416	ATAD2B	0.45	4.93	0.31	1.55e-6	Quantitative traits;
SARC	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg26335602	chr6:28129616	ZNF389	0.52	5.78	0.35	2.41e-8	Parkinson's disease;
SARC	cis	rs1983891	0.673	rs9381083	chr6:41570250	T/A	cg15051332	chr6:41514432	FOXP4	0.51	5.62	0.35	5.41e-8	Prostate cancer;
SARC	cis	rs7681440	0.904	rs28415623	chr4:90767110	C/T	cg06632027	chr4:90757378	SNCA	0.39	5.66	0.35	4.49e-8	Dementia with Lewy bodies;
SARC	cis	rs7818345	0.935	rs6991212	chr8:19276522	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.42	5.7	0.35	3.64e-8	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg14298792	chr15:30685198	CHRFAM7A	0.46	5.46	0.34	1.22e-7	Huntington's disease progression;
SARC	cis	rs986417	1.000	rs9989167	chr14:60942374	T/C	cg27398547	chr14:60952738	C14orf39	1.03	9.89	0.54	1.74e-19	Gut microbiota (bacterial taxa);
SARC	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg11890956	chr21:40555474	PSMG1	-0.71	-9.23	-0.52	1.69e-17	Menarche (age at onset);
SARC	cis	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg07636037	chr3:49044803	WDR6	0.63	8.4	0.48	4.49e-15	Resting heart rate;
SARC	cis	rs933688	1.000	rs332529	chr5:90789470	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.97	11.11	0.59	2.64e-23	Smoking behavior;
SARC	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg23172400	chr8:95962367	TP53INP1	-0.33	-5.78	-0.35	2.4e-8	Type 2 diabetes;
SARC	cis	rs796364	0.589	rs6743217	chr2:201134914	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.53	-5.02	-0.31	1.04e-6	Schizophrenia;
SARC	cis	rs11792861	0.851	rs17552292	chr9:111891954	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.67	7.52	0.44	1.21e-12	Menarche (age at onset);
SARC	cis	rs2635047	0.967	rs1119005	chr18:44725605	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.53	7.11	0.42	1.41e-11	Educational attainment;
SARC	cis	rs875971	0.545	rs12671152	chr7:65776127	G/T	cg11764359	chr7:65958608	NA	0.65	6.21	0.38	2.39e-9	Aortic root size;
SARC	cis	rs11122272	0.735	rs2572251	chr1:231514243	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs995000	0.931	rs1168044	chr1:62977558	A/C	cg06896770	chr1:63153194	DOCK7	-0.89	-12.89	-0.65	4.52e-29	Triglyceride levels;
SARC	cis	rs6912958	0.525	rs586771	chr6:88064971	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.37	6.59	0.4	2.91e-10	Monocyte percentage of white cells;
SARC	trans	rs3942852	0.545	rs7395231	chr11:48091689	T/C	cg15704280	chr7:45808275	SEPT13	-0.66	-8.71	-0.5	5.74e-16	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs11098499	0.955	rs13114751	chr4:120156617	G/A	cg09307838	chr4:120376055	NA	0.86	11.6	0.61	7.28e-25	Corneal astigmatism;
SARC	cis	rs1355223	0.583	rs2956074	chr11:34864880	T/C	cg11058730	chr11:34937778	PDHX;APIP	0.76	11.05	0.59	4.39e-23	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs12477438	0.765	rs7605218	chr2:99593080	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-8.16	-0.47	2.11e-14	Chronic sinus infection;
SARC	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg10523679	chr1:76189770	ACADM	0.45	5.41	0.33	1.6e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9309473	1.000	rs60844734	chr2:73623205	T/A	cg20560298	chr2:73613845	ALMS1	-0.52	-6.26	-0.38	1.84e-9	Metabolite levels;
SARC	cis	rs1729951	0.575	rs10935213	chr3:136693459	A/G	cg15507776	chr3:136538369	TMEM22	0.5	5.6	0.34	6.04e-8	Neuroticism;
SARC	cis	rs11997175	0.549	rs4357253	chr8:33652458	G/A	ch.8.33884649F	chr8:33765107	NA	0.48	6.45	0.39	6.25e-10	Body mass index;
SARC	cis	rs73206853	0.841	rs28480627	chr12:110834659	T/C	cg10860002	chr12:110842031	ANAPC7	0.64	5.15	0.32	5.49e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs7647973	0.626	rs6809879	chr3:49834571	A/G	cg03060546	chr3:49711283	APEH	-0.69	-6.99	-0.42	2.9e-11	Menarche (age at onset);
SARC	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg05861140	chr6:150128134	PCMT1	-0.4	-5.23	-0.32	3.76e-7	Lung cancer;
SARC	cis	rs7617773	0.747	rs34076262	chr3:48370416	C/T	cg11946769	chr3:48343235	NME6	0.77	9.79	0.54	3.54e-19	Coronary artery disease;
SARC	cis	rs79149102	1.000	rs78940327	chr15:75152480	G/A	cg17294928	chr15:75287854	SCAMP5	-1.04	-5.9	-0.36	1.27e-8	Lung cancer;
SARC	cis	rs9393692	0.905	rs4412192	chr6:26290377	A/G	cg05868516	chr6:26286170	HIST1H4H	-0.57	-7.31	-0.43	4.13e-12	Educational attainment;
SARC	trans	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg11693508	chr17:37793320	STARD3	0.72	6.78	0.41	9.94e-11	Bipolar disorder;
SARC	cis	rs7712401	0.601	rs2126935	chr5:122313571	A/G	cg19412675	chr5:122181750	SNX24	-0.42	-5.23	-0.32	3.74e-7	Mean platelet volume;
SARC	cis	rs2425143	0.818	rs73902932	chr20:34489009	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-5.41	-0.33	1.53e-7	Blood protein levels;
SARC	cis	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg13072238	chr3:49761600	GMPPB	-0.43	-5.57	-0.34	6.87e-8	Blood protein levels;
SARC	cis	rs2221894	0.506	rs77261575	chr8:28894579	C/T	cg07962641	chr8:28805897	HMBOX1	-0.77	-7.61	-0.45	6.86e-13	Obesity-related traits;
SARC	cis	rs1707322	0.716	rs28370457	chr1:46172062	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.24	0.38	2.03e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2576037	0.901	rs6507719	chr18:44581310	A/T	cg15049968	chr18:44337910	ST8SIA5	0.32	5.13	0.32	6.05e-7	Personality dimensions;
SARC	cis	rs10499694	0.901	rs6975453	chr7:50585211	A/T	cg19499709	chr7:50660583	GRB10	-0.35	-4.75	-0.3	3.49e-6	Body mass index;
SARC	cis	rs17401966	1.000	rs12757820	chr1:10266671	A/T	cg15208524	chr1:10270712	KIF1B	0.56	6.43	0.39	7.18e-10	Hepatocellular carcinoma;
SARC	cis	rs7829975	0.774	rs1703982	chr8:8598388	A/T	cg06636001	chr8:8085503	FLJ10661	-0.69	-9.04	-0.51	6.22e-17	Mood instability;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg02622866	chr2:176032527	ATF2;MIR933	-0.49	-6.34	-0.38	1.15e-9	Thyroid stimulating hormone;
SARC	cis	rs74781061	0.585	rs750608	chr15:74734615	C/T	cg09165964	chr15:75287851	SCAMP5	-0.6	-4.87	-0.3	2.06e-6	Endometriosis;
SARC	cis	rs11574514	1.000	rs117436074	chr16:67752282	A/G	cg01866162	chr16:67596514	CTCF	1.13	6.68	0.4	1.7e-10	Crohn's disease;
SARC	cis	rs6912958	0.702	rs2300909	chr6:88212100	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.3	-5.17	-0.32	5.07e-7	Monocyte percentage of white cells;
SARC	cis	rs7772486	0.597	rs2485631	chr6:146190077	G/C	cg23711669	chr6:146136114	FBXO30	0.83	12.06	0.62	2.43e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1008375	0.966	rs3733581	chr4:17695206	C/G	cg16339924	chr4:17578868	LAP3	-0.57	-7.07	-0.42	1.84e-11	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg12395012	chr8:11607386	GATA4	0.33	5.6	0.34	5.94e-8	Triglycerides;
SARC	cis	rs9420	0.961	rs708228	chr11:57585662	C/T	cg23127183	chr11:57508653	C11orf31	-0.59	-6.7	-0.4	1.51e-10	Schizophrenia;
SARC	cis	rs12464559	0.649	rs4664496	chr2:152522556	T/C	cg01189475	chr2:152685088	ARL5A	-0.61	-4.95	-0.31	1.4e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs9291683	0.588	rs11732054	chr4:9999877	C/T	cg00071950	chr4:10020882	SLC2A9	0.39	6.11	0.37	4.06e-9	Bone mineral density;
SARC	cis	rs17376456	0.542	rs1982439	chr5:93160560	C/G	cg25358565	chr5:93447407	FAM172A	-0.95	-10.62	-0.57	9.51e-22	Diabetic retinopathy;
SARC	cis	rs34375054	0.660	rs57491100	chr12:125593010	C/T	cg25124228	chr12:125621409	AACS	-0.52	-5.54	-0.34	8.06e-8	Post bronchodilator FEV1/FVC ratio;
SARC	trans	rs921665	0.681	rs6548169	chr2:3183752	A/G	cg15506477	chr2:133426129	LYPD1	-0.82	-6.75	-0.4	1.18e-10	World class endurance athleticism;
SARC	cis	rs4900538	0.963	rs4906205	chr14:102932447	A/G	cg18135206	chr14:102964638	TECPR2	0.64	8.52	0.49	2.05e-15	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg11317459	chr13:21872234	NA	1.1	16.25	0.73	3.42e-40	White matter hyperintensity burden;
SARC	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg00149659	chr3:10157352	C3orf10	0.68	6.38	0.39	9.46e-10	Alzheimer's disease;
SARC	cis	rs7599312	0.553	rs6710653	chr2:213404893	A/G	cg20637307	chr2:213403960	ERBB4	0.8	12.5	0.63	8.9e-28	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs6088590	0.561	rs3891369	chr20:33161127	C/T	cg08999081	chr20:33150536	PIGU	0.44	6.78	0.41	9.96e-11	Coronary artery disease;
SARC	cis	rs765787	0.530	rs4775832	chr15:45534828	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.67e-7	Uric acid levels;
SARC	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg22920501	chr2:26401640	FAM59B	-0.53	-6.57	-0.4	3.17e-10	Gut microbiome composition (summer);
SARC	cis	rs2916247	0.954	rs10094140	chr8:93155798	G/C	cg10183463	chr8:93005414	RUNX1T1	0.48	5.34	0.33	2.24e-7	Intelligence (multi-trait analysis);
SARC	cis	rs12142240	0.698	rs57267378	chr1:46816644	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-5.46	-0.34	1.22e-7	Menopause (age at onset);
SARC	cis	rs751728	0.664	rs2395402	chr6:33753673	G/A	cg25922239	chr6:33757077	LEMD2	0.58	7.62	0.45	6.22e-13	Crohn's disease;
SARC	cis	rs829883	0.659	rs11109522	chr12:98930964	C/T	cg25150519	chr12:98850993	NA	-0.59	-7.3	-0.43	4.42e-12	Colorectal adenoma (advanced);
SARC	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/A	cg00383909	chr3:49044727	WDR6	0.66	6.22	0.38	2.32e-9	Parkinson's disease;
SARC	cis	rs6088590	0.965	rs6087639	chr20:33443866	G/A	cg06115741	chr20:33292138	TP53INP2	0.57	6.76	0.4	1.13e-10	Coronary artery disease;
SARC	cis	rs11902236	0.660	rs2116015	chr2:10110439	T/C	cg02698806	chr2:10522874	HPCAL1	0.3	4.72	0.3	4.09e-6	Prostate cancer;
SARC	cis	rs2032447	0.530	rs9356996	chr6:26008487	C/A	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.35	-4.84	-0.3	2.32e-6	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg08219700	chr8:58056026	NA	0.6	5.71	0.35	3.49e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7044106	0.708	rs10760113	chr9:123474050	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	5.94	0.36	1.01e-8	Hip circumference adjusted for BMI;
SARC	trans	rs61931739	0.534	rs11053016	chr12:34104372	C/T	cg26384229	chr12:38710491	ALG10B	0.87	12.44	0.63	1.37e-27	Morning vs. evening chronotype;
SARC	cis	rs2732480	0.577	rs2732486	chr12:48737834	G/A	cg24011408	chr12:48396354	COL2A1	0.43	5.11	0.32	6.81e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg11494091	chr17:61959527	GH2	0.54	8.12	0.47	2.64e-14	Prudent dietary pattern;
SARC	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg16132339	chr22:24313637	DDTL;DDT	0.38	5.11	0.32	6.78e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	trans	rs7824557	0.527	rs4631425	chr8:11239054	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.36	-0.38	1.08e-9	Retinal vascular caliber;
SARC	cis	rs6582630	0.577	rs12312748	chr12:38343326	T/C	cg14851346	chr12:38532713	NA	-0.45	-5.22	-0.32	3.88e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7633857	0.512	rs745707	chr3:160652672	G/T	cg03342759	chr3:160939853	NMD3	-0.5	-5.95	-0.36	9.71e-9	Educational attainment (years of education);
SARC	cis	rs9291683	0.692	rs1558489	chr4:10325489	T/A	cg11266682	chr4:10021025	SLC2A9	-0.33	-5.68	-0.35	4.08e-8	Bone mineral density;
SARC	cis	rs12134245	0.755	rs11164928	chr1:92012678	G/A	cg02896835	chr1:92012615	NA	-0.58	-7.88	-0.46	1.28e-13	Breast cancer;
SARC	cis	rs2721195	0.845	rs3757966	chr8:145744618	G/A	cg15320075	chr8:145703422	NA	0.62	8.28	0.48	9.62e-15	Age at first birth;
SARC	cis	rs907683	0.546	rs1058261	chr2:220285309	C/T	cg15015639	chr2:220282977	DES	-0.37	-5.85	-0.36	1.65e-8	Resting heart rate;
SARC	cis	rs67311347	1.000	rs9842564	chr3:40405810	A/G	cg24209194	chr3:40518798	ZNF619	-0.58	-7.48	-0.44	1.51e-12	Renal cell carcinoma;
SARC	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg06618935	chr21:46677482	NA	-0.39	-5.14	-0.32	5.72e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6735179	0.688	rs6745142	chr2:1763886	A/G	cg08534653	chr2:1747700	PXDN	0.38	4.77	0.3	3.24e-6	Response to antipsychotic treatment;
SARC	cis	rs854765	0.594	rs8066560	chr17:17728043	A/G	cg05444541	chr17:17804740	TOM1L2	0.28	4.71	0.3	4.17e-6	Total body bone mineral density;
SARC	cis	rs2011503	1.000	rs74950305	chr19:19639448	C/T	cg15839431	chr19:19639596	YJEFN3	-0.48	-4.77	-0.3	3.32e-6	Bipolar disorder;
SARC	cis	rs858239	0.539	rs28624974	chr7:23188936	T/C	cg23682824	chr7:23144976	KLHL7	0.71	9.28	0.52	1.23e-17	Cerebrospinal fluid biomarker levels;
SARC	cis	rs7260598	0.539	rs59175483	chr19:24065542	T/C	cg27517351	chr19:23941871	ZNF681	0.54	4.73	0.3	3.86e-6	Response to taxane treatment (placlitaxel);
SARC	cis	rs7408868	0.908	rs2074619	chr19:15276919	G/A	cg14696996	chr19:15285081	NOTCH3	1.02	8.7	0.5	6e-16	Pulse pressure;
SARC	cis	rs698833	0.612	rs698776	chr2:44739563	T/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	5.86	0.36	1.56e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs2239547	0.603	rs4687698	chr3:53097108	C/T	cg11645453	chr3:52864694	ITIH4	0.32	5.13	0.32	6.15e-7	Schizophrenia;
SARC	cis	rs11025559	0.812	rs10833338	chr11:20514709	A/G	cg04101203	chr11:20408940	PRMT3	-0.48	-5.19	-0.32	4.52e-7	Pursuit maintenance gain;
SARC	cis	rs4481887	0.861	rs10788776	chr1:248479177	T/C	cg13385794	chr1:248469461	NA	0.34	5.22	0.32	4e-7	Common traits (Other);
SARC	cis	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg20965017	chr5:231967	SDHA	-0.55	-5.29	-0.33	2.77e-7	Breast cancer;
SARC	cis	rs1008375	1.000	rs62295634	chr4:17685346	C/A	cg16339924	chr4:17578868	LAP3	0.63	8.08	0.47	3.4e-14	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs72945132	0.882	rs7128969	chr11:70205017	C/A	cg00319359	chr11:70116639	PPFIA1	0.67	6.21	0.38	2.36e-9	Coronary artery disease;
SARC	trans	rs1814175	0.615	rs10839378	chr11:49806943	C/T	cg03929089	chr4:120376271	NA	-0.84	-12.24	-0.63	6.34e-27	Height;
SARC	cis	rs739401	0.611	rs417957	chr11:3046231	A/G	cg08508325	chr11:3079039	CARS	-0.32	-8.05	-0.47	4.29e-14	Longevity;
SARC	cis	rs7818688	0.697	rs58282276	chr8:95985391	G/A	cg13393036	chr8:95962371	TP53INP1	0.4	4.85	0.3	2.23e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs751728	0.664	rs943474	chr6:33749834	G/C	cg25922239	chr6:33757077	LEMD2	0.58	7.6	0.45	7.1e-13	Crohn's disease;
SARC	cis	rs2228479	0.702	rs62056087	chr16:89920383	C/A	cg06558623	chr16:89946397	TCF25	0.93	6.61	0.4	2.59e-10	Skin colour saturation;
SARC	cis	rs9303401	0.659	rs62081315	chr17:56781468	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	11.87	0.61	9.72e-26	Cognitive test performance;
SARC	cis	rs6570726	0.935	rs379164	chr6:145829093	A/T	cg23711669	chr6:146136114	FBXO30	0.78	11.86	0.61	1.04e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9868809	0.505	rs11706983	chr3:48738678	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.58	-5.34	-0.33	2.25e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg19557623	chr17:40540543	STAT3	0.5	6.25	0.38	1.97e-9	Lung adenocarcinoma;
SARC	cis	rs9457247	0.935	rs1044059	chr6:167369897	C/A	cg07741184	chr6:167504864	NA	-0.3	-5.73	-0.35	3.02e-8	Crohn's disease;
SARC	cis	rs1865760	0.622	rs10946807	chr6:26079638	T/C	cg16482183	chr6:26056742	HIST1H1C	0.53	6.25	0.38	1.89e-9	Height;
SARC	cis	rs13343954	0.825	rs12461135	chr19:33534185	A/G	cg17764715	chr19:33622953	WDR88	0.49	5.43	0.34	1.38e-7	Colorectal cancer;
SARC	cis	rs12586317	0.547	rs78609489	chr14:35497285	T/C	cg16230307	chr14:35515116	FAM177A1	0.99	11.59	0.6	7.79e-25	Psoriasis;
SARC	cis	rs9640161	0.742	rs2159235	chr7:150017228	T/C	cg17279839	chr7:150038598	RARRES2	0.45	6.49	0.39	5.04e-10	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg24060327	chr5:131705240	SLC22A5	-0.49	-5.88	-0.36	1.43e-8	Acylcarnitine levels;
SARC	cis	rs9818758	0.607	rs13087930	chr3:48961726	A/G	cg00383909	chr3:49044727	WDR6	0.75	6.7	0.4	1.54e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs2290720	0.930	rs7301458	chr12:101747562	T/G	cg22051763	chr12:101673672	UTP20	-0.46	-5.48	-0.34	1.13e-7	Brain structure (hippocampal volume);
SARC	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg22535103	chr8:58192502	C8orf71	-0.66	-5.85	-0.36	1.65e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs735539	0.521	rs2818995	chr13:21420964	T/G	cg16922012	chr13:21400325	XPO4	-0.42	-5.55	-0.34	7.62e-8	Dental caries;
SARC	cis	rs7772486	0.654	rs702321	chr6:146006695	A/G	cg05347473	chr6:146136440	FBXO30	-0.52	-7.19	-0.43	8.59e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6430585	0.583	rs4988145	chr2:136632300	A/C	cg07169764	chr2:136633963	MCM6	1.15	16.62	0.74	2.02e-41	Corneal structure;
SARC	cis	rs10876993	0.928	rs1678530	chr12:58054076	A/C	cg18357645	chr12:58087776	OS9	0.46	5.91	0.36	1.2e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs10916814	0.632	rs7545313	chr1:20902728	C/T	cg24502330	chr1:20914028	CDA	-0.28	-4.83	-0.3	2.52e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs7769051	0.708	rs9483514	chr6:133228716	G/A	cg07930552	chr6:133119739	C6orf192	0.79	6.81	0.41	8.13e-11	Type 2 diabetes nephropathy;
SARC	cis	rs2191566	0.576	rs382255	chr19:44494156	T/C	cg20607764	chr19:44506953	ZNF230	0.41	4.72	0.3	4.03e-6	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs4853036	1.000	rs28362672	chr2:70056866	A/G	cg02498382	chr2:70120550	SNRNP27	-0.41	-5.4	-0.33	1.67e-7	Colorectal or endometrial cancer;
SARC	cis	rs11098499	0.954	rs7656252	chr4:120404268	T/C	cg24375607	chr4:120327624	NA	0.42	4.97	0.31	1.28e-6	Corneal astigmatism;
SARC	cis	rs9902453	0.765	rs2628185	chr17:28070107	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.24	-0.43	6.57e-12	Coffee consumption (cups per day);
SARC	cis	rs9549260	0.753	rs61963264	chr13:41154792	G/A	cg21288729	chr13:41239152	FOXO1	0.59	5.68	0.35	4e-8	Red blood cell count;
SARC	cis	rs10465746	0.747	rs10493741	chr1:84388118	G/C	cg10977910	chr1:84465055	TTLL7	0.44	5.21	0.32	4.14e-7	Obesity-related traits;
SARC	cis	rs2204008	0.505	rs11182550	chr12:38570061	A/T	cg26384229	chr12:38710491	ALG10B	0.61	7.9	0.46	1.09e-13	Bladder cancer;
SARC	cis	rs6604026	0.656	rs35367625	chr1:93399705	G/A	cg17283838	chr1:93427260	FAM69A	0.41	4.77	0.3	3.25e-6	Multiple sclerosis;
SARC	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg13206674	chr6:150067644	NUP43	0.49	6.36	0.38	1.04e-9	Lung cancer;
SARC	cis	rs2991971	0.967	rs10789465	chr1:45971759	T/C	cg24296786	chr1:45957014	TESK2	0.64	9.27	0.52	1.28e-17	High light scatter reticulocyte count;
SARC	cis	rs72945132	0.882	rs12278125	chr11:70134016	T/C	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.78	-0.35	2.39e-8	Coronary artery disease;
SARC	cis	rs72781680	0.716	rs2551343	chr2:24027002	C/G	cg08917208	chr2:24149416	ATAD2B	0.57	5.87	0.36	1.52e-8	Lymphocyte counts;
SARC	trans	rs1865760	0.929	rs9461224	chr6:25936402	G/T	cg06942064	chr1:208417143	PLXNA2	-0.53	-6.39	-0.39	9e-10	Height;
SARC	cis	rs9341808	0.718	rs3805922	chr6:80891989	A/G	cg08355045	chr6:80787529	NA	0.34	5.33	0.33	2.28e-7	Sitting height ratio;
SARC	cis	rs2075371	0.579	rs11766422	chr7:134018160	T/C	cg20476274	chr7:133979776	SLC35B4	0.38	4.72	0.3	4.03e-6	Mean platelet volume;
SARC	cis	rs10421328	0.784	rs11667828	chr19:19768474	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.42	-4.73	-0.3	3.81e-6	Parental longevity (combined parental age at death);
SARC	cis	rs829883	0.616	rs249832	chr12:98832387	C/T	cg25150519	chr12:98850993	NA	0.79	12.95	0.65	2.9e-29	Colorectal adenoma (advanced);
SARC	cis	rs9948	1.000	rs6576987	chr2:97512059	G/A	cg01990225	chr2:97406019	LMAN2L	-0.79	-5.69	-0.35	3.73e-8	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs7617773	0.817	rs6791930	chr3:48329900	A/G	cg11946769	chr3:48343235	NME6	0.73	9.65	0.53	9.55e-19	Coronary artery disease;
SARC	cis	rs17270561	0.636	rs9358880	chr6:25743161	C/T	cg16482183	chr6:26056742	HIST1H1C	0.43	5.08	0.32	7.76e-7	Iron status biomarkers;
SARC	cis	rs6665290	0.901	rs2104860	chr1:227208637	G/C	cg10327440	chr1:227177885	CDC42BPA	-1.05	-23.57	-0.84	1.33e-63	Myeloid white cell count;
SARC	cis	rs10416265	0.527	rs11084699	chr19:33538393	A/T	cg03563238	chr19:33554763	RHPN2	-0.27	-4.74	-0.3	3.64e-6	Bone properties (heel);
SARC	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-6.42	-0.39	7.37e-10	Bipolar disorder;
SARC	cis	rs7587476	0.784	rs36086595	chr2:215680293	A/G	cg04004882	chr2:215674386	BARD1	0.58	6.65	0.4	2.09e-10	Neuroblastoma;
SARC	cis	rs4481887	0.927	rs4345830	chr1:248474845	G/C	cg01631408	chr1:248437212	OR2T33	-0.39	-5.06	-0.31	8.56e-7	Common traits (Other);
SARC	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg24675658	chr1:53192096	ZYG11B	0.58	8.09	0.47	3.22e-14	Monocyte count;
SARC	cis	rs12545912	0.739	rs12541617	chr8:9539099	A/G	cg21625330	chr8:9911636	MSRA	0.45	4.74	0.3	3.64e-6	Multiple myeloma (hyperdiploidy);
SARC	cis	rs7666738	0.830	rs1120708	chr4:98931260	G/C	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg24250549	chr1:154909240	PMVK	0.82	11.89	0.61	8.9e-26	Prostate cancer;
SARC	cis	rs4481887	0.927	rs4916087	chr1:248493833	T/C	cg01631408	chr1:248437212	OR2T33	-0.39	-4.86	-0.3	2.15e-6	Common traits (Other);
SARC	cis	rs10791323	0.572	rs4353292	chr11:133742656	A/G	cg15485101	chr11:133734466	NA	0.31	5.0	0.31	1.15e-6	Childhood ear infection;
SARC	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.97	-15.56	-0.71	6.41e-38	Chronic sinus infection;
SARC	cis	rs10193935	1.000	rs10171023	chr2:42407093	G/C	cg27598129	chr2:42591480	NA	-0.35	-4.72	-0.3	4e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10493773	1.000	rs10493774	chr1:86137963	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.51	-7.28	-0.43	5e-12	Urate levels in overweight individuals;
SARC	cis	rs6901004	0.803	rs168522	chr6:111506628	A/G	cg15721981	chr6:111408429	SLC16A10	-0.45	-5.43	-0.34	1.43e-7	Blood metabolite levels;
SARC	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg06028808	chr11:68637592	NA	0.47	5.93	0.36	1.08e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg13958324	chr10:63845528	ARID5B	0.5	6.49	0.39	5.2e-10	Thyroid stimulating hormone;
SARC	cis	rs7681440	0.874	rs1372522	chr4:90765280	A/G	cg02192967	chr4:90758406	SNCA	0.36	5.13	0.32	6.11e-7	Dementia with Lewy bodies;
SARC	cis	rs936229	0.813	rs1378938	chr15:75096443	T/C	cg10253484	chr15:75165896	SCAMP2	-0.44	-4.72	-0.3	4.15e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs6696846	0.765	rs61822567	chr1:205078725	T/C	cg07972983	chr1:205091412	RBBP5	0.58	7.61	0.45	6.57e-13	Red blood cell count;
SARC	cis	rs72781680	1.000	rs56205282	chr2:24221317	C/T	cg06627628	chr2:24431161	ITSN2	-0.73	-6.93	-0.41	4.14e-11	Lymphocyte counts;
SARC	cis	rs7605378	0.658	rs4673507	chr2:200710167	G/C	cg17644776	chr2:200775616	C2orf69	0.55	6.96	0.42	3.34e-11	Osteoporosis;
SARC	cis	rs34172651	0.917	rs7202252	chr16:24741686	T/C	cg00152838	chr16:24741724	TNRC6A	0.48	5.76	0.35	2.66e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7568458	0.684	rs7593969	chr2:85809670	A/G	cg02493740	chr2:85810744	VAMP5	0.41	5.31	0.33	2.59e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs9916302	0.904	rs2024073	chr17:37471330	T/G	cg20243544	chr17:37824526	PNMT	-0.55	-6.64	-0.4	2.19e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs1568889	1.000	rs7933332	chr11:28036392	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	10.25	0.56	1.35e-20	Bipolar disorder;
SARC	cis	rs9309473	0.606	rs6759452	chr2:73878352	C/T	cg07208825	chr2:73871855	ALMS1P	0.38	5.01	0.31	1.08e-6	Metabolite levels;
SARC	cis	rs11687170	0.882	rs73131605	chr2:237055087	A/G	cg19324714	chr2:237145437	ASB18	0.49	4.89	0.31	1.89e-6	Educational attainment;Educational attainment (years of education);
SARC	cis	rs7647973	0.925	rs6446256	chr3:49224210	A/G	cg07636037	chr3:49044803	WDR6	0.8	9.13	0.51	3.38e-17	Menarche (age at onset);
SARC	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg00933542	chr6:150070202	PCMT1	0.33	5.49	0.34	1.06e-7	Lung cancer;
SARC	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg20090690	chr10:134436459	INPP5A	0.48	5.2	0.32	4.34e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs9902453	0.967	rs9913074	chr17:28481199	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	6.59	0.4	2.87e-10	Coffee consumption (cups per day);
SARC	cis	rs9611565	0.506	rs1984839	chr22:41685937	G/C	cg03806693	chr22:41940476	POLR3H	-0.71	-9.46	-0.53	3.62e-18	Vitiligo;
SARC	cis	rs7044106	0.762	rs10760110	chr9:123412563	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.4	-4.79	-0.3	3.03e-6	Hip circumference adjusted for BMI;
SARC	cis	rs9790314	0.586	rs67077657	chr3:161138521	A/G	cg04691961	chr3:161091175	C3orf57	-0.51	-6.38	-0.39	9.47e-10	Morning vs. evening chronotype;
SARC	cis	rs7089973	0.668	rs7077148	chr10:116644896	A/G	cg03647239	chr10:116582469	FAM160B1	0.39	4.87	0.3	2.08e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs11105298	0.891	rs10777162	chr12:89830523	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.51	-5.11	-0.32	6.82e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs17209837	1.000	rs7802783	chr7:87130397	A/G	cg00919237	chr7:87102261	ABCB4	0.48	4.77	0.3	3.3e-6	Gallbladder cancer;
SARC	cis	rs7927771	0.524	rs7124396	chr11:47787434	T/G	cg20307385	chr11:47447363	PSMC3	-0.49	-6.63	-0.4	2.36e-10	Subjective well-being;
SARC	cis	rs7818688	0.697	rs112411609	chr8:95980854	C/A	cg13393036	chr8:95962371	TP53INP1	0.4	4.85	0.3	2.27e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs6424115	0.867	rs10917431	chr1:24174093	T/G	cg15997130	chr1:24165203	NA	-0.43	-5.82	-0.36	1.95e-8	Immature fraction of reticulocytes;
SARC	cis	rs2839186	0.504	rs4347941	chr21:47938239	T/C	cg12379764	chr21:47803548	PCNT	0.65	8.25	0.48	1.19e-14	Testicular germ cell tumor;
SARC	cis	rs9810259	0.554	rs13088728	chr3:12338450	C/A	cg04748988	chr3:12329223	PPARG	-0.42	-5.31	-0.33	2.6e-7	Platelet count;
SARC	cis	rs7746199	0.668	rs34864796	chr6:27459923	G/A	cg12826209	chr6:26865740	GUSBL1	0.86	4.89	0.3	1.9e-6	Gait speed in old age;Autism spectrum disorder or schizophrenia;
SARC	cis	rs7551222	0.752	rs10793766	chr1:204549496	C/T	cg20240347	chr1:204465584	NA	-0.33	-5.88	-0.36	1.43e-8	Schizophrenia;
SARC	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg24250549	chr1:154909240	PMVK	0.77	10.81	0.58	2.46e-22	Prostate cancer;
SARC	cis	rs6580649	0.941	rs7963934	chr12:48477086	C/G	cg24011408	chr12:48396354	COL2A1	-0.48	-5.36	-0.33	2.04e-7	Lung cancer;
SARC	cis	rs6456156	0.586	rs2285148	chr6:167490999	G/T	cg23791538	chr6:167370224	RNASET2	-0.54	-6.97	-0.42	3.28e-11	Primary biliary cholangitis;
SARC	cis	rs763121	0.889	rs1043402	chr22:38879688	G/A	cg21395723	chr22:39101663	GTPBP1	0.6	6.81	0.41	8.19e-11	Menopause (age at onset);
SARC	cis	rs7312933	0.703	rs7957471	chr12:42545591	G/T	cg19980929	chr12:42632907	YAF2	0.43	5.81	0.36	2.05e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs796364	0.806	rs55985986	chr2:201120987	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.67	-5.28	-0.33	2.98e-7	Schizophrenia;
SARC	cis	rs7296418	0.922	rs1790134	chr12:123697898	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-5.25	-0.32	3.5e-7	Platelet count;
SARC	cis	rs9381040	0.655	rs2268187	chr6:41042993	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.49	-5.62	-0.35	5.4e-8	Alzheimer's disease (late onset);
SARC	cis	rs11758351	0.660	rs16891446	chr6:26226996	A/C	cg01420254	chr6:26195488	NA	0.55	4.75	0.3	3.49e-6	Gout;Renal underexcretion gout;
SARC	cis	rs7551222	0.613	rs10900592	chr1:204460681	T/C	cg20240347	chr1:204465584	NA	-0.28	-4.87	-0.3	2.08e-6	Schizophrenia;
SARC	cis	rs2075371	1.000	rs1421484	chr7:133979795	T/C	cg00033643	chr7:134001901	SLC35B4	0.41	5.01	0.31	1.05e-6	Mean platelet volume;
SARC	cis	rs950169	0.840	rs62019457	chr15:85102142	T/C	cg17507749	chr15:85114479	UBE2QP1	0.78	9.53	0.53	2.19e-18	Schizophrenia;
SARC	cis	rs9868809	0.505	rs56735597	chr3:48765168	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.65	-5.5	-0.34	1.01e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs6696846	0.777	rs6664397	chr1:205051871	C/T	cg21643547	chr1:205240462	TMCC2	-0.49	-6.5	-0.39	4.72e-10	Red blood cell count;
SARC	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.16	-0.37	3.13e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg24110177	chr3:50126178	RBM5	0.67	9.07	0.51	5.02e-17	Body mass index;
SARC	cis	rs17095355	0.892	rs1571617	chr10:111732025	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.43	-4.83	-0.3	2.46e-6	Biliary atresia;
SARC	cis	rs1865760	0.566	rs2032443	chr6:26046802	A/G	cg17691542	chr6:26056736	HIST1H1C	0.54	6.73	0.4	1.3e-10	Height;
SARC	cis	rs7223966	0.960	rs2854222	chr17:61939015	C/T	cg00588841	chr17:61851480	DDX42;CCDC47	-0.57	-6.38	-0.39	9.3e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg11644478	chr21:40555479	PSMG1	-0.59	-7.27	-0.43	5.48e-12	Menarche (age at onset);
SARC	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg03351412	chr1:154909251	PMVK	0.62	7.91	0.46	1.03e-13	Prostate cancer;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg14036868	chr2:38604442	ATL2	-0.58	-6.6	-0.4	2.72e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs526231	0.511	rs10515341	chr5:102317117	G/A	cg23492399	chr5:102201601	PAM	-0.52	-6.38	-0.39	9.62e-10	Primary biliary cholangitis;
SARC	trans	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.58	-0.4	3.03e-10	Triglycerides;
SARC	cis	rs778371	0.659	rs2289911	chr2:233704252	A/G	cg16596103	chr2:233749413	NGEF	0.33	5.0	0.31	1.12e-6	Schizophrenia;
SARC	cis	rs6570726	0.935	rs406343	chr6:145874388	A/G	cg23711669	chr6:146136114	FBXO30	0.78	11.97	0.62	4.89e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9611565	0.921	rs8137373	chr22:41729216	A/G	cg17376030	chr22:41985996	PMM1	-0.52	-6.35	-0.38	1.15e-9	Vitiligo;
SARC	cis	rs6864727	0.964	rs4574537	chr5:137419728	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.56	6.24	0.38	2e-9	Atrial fibrillation;
SARC	cis	rs11687170	0.882	rs11678829	chr2:237057426	C/T	cg19324714	chr2:237145437	ASB18	0.49	4.89	0.31	1.89e-6	Educational attainment;Educational attainment (years of education);
SARC	cis	rs9682041	0.561	rs6444928	chr3:170147875	A/G	cg11886554	chr3:170076028	SKIL	0.75	7.05	0.42	1.98e-11	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs7524258	0.868	rs4908607	chr1:7269323	A/G	cg07173049	chr1:7289937	CAMTA1	0.37	7.2	0.43	8.33e-12	Tourette's syndrome or obsessive-compulsive disorder;
SARC	cis	rs7727544	0.507	rs9791170	chr5:131569627	A/G	cg09877947	chr5:131593287	PDLIM4	0.42	5.03	0.31	9.58e-7	Blood metabolite levels;
SARC	cis	rs6570726	1.000	rs1935615	chr6:145921117	G/T	cg23711669	chr6:146136114	FBXO30	0.75	10.98	0.58	7.18e-23	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs73086581	1.000	rs6052209	chr20:3961747	G/A	cg02187196	chr20:3869020	PANK2	0.67	6.46	0.39	6.21e-10	Response to antidepressants in depression;
SARC	cis	rs6598955	0.670	rs3795688	chr1:26560481	C/A	cg04990556	chr1:26633338	UBXN11	-0.6	-8.39	-0.48	4.78e-15	Obesity-related traits;
SARC	cis	rs7566780	0.549	rs1430054	chr2:16680691	C/T	cg09580478	chr2:16689509	NA	-0.55	-6.89	-0.41	5.14e-11	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg14784868	chr12:69753453	YEATS4	0.51	6.77	0.41	1.04e-10	Blood protein levels;
SARC	cis	rs11785400	0.793	rs750530	chr8:143744931	G/A	cg24634471	chr8:143751801	JRK	0.59	7.45	0.44	1.83e-12	Schizophrenia;
SARC	cis	rs7727544	0.735	rs272842	chr5:131656517	A/G	cg24060327	chr5:131705240	SLC22A5	-0.69	-8.78	-0.5	3.7e-16	Blood metabolite levels;
SARC	cis	rs12682352	0.652	rs3789843	chr8:8724257	C/T	cg08975724	chr8:8085496	FLJ10661	0.43	5.35	0.33	2.12e-7	Neuroticism;
SARC	cis	rs2228479	0.702	rs11646374	chr16:89857935	G/A	cg00800038	chr16:89945340	TCF25	-0.76	-5.33	-0.33	2.27e-7	Skin colour saturation;
SARC	cis	rs7712401	0.601	rs30049	chr5:122306097	G/A	cg19412675	chr5:122181750	SNX24	0.4	5.13	0.32	5.98e-7	Mean platelet volume;
SARC	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg03647317	chr4:187891568	NA	-0.37	-5.08	-0.32	7.75e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3857067	0.550	rs113785667	chr4:94999566	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.32	-4.75	-0.3	3.56e-6	QT interval;
SARC	cis	rs6429082	0.755	rs291367	chr1:235690800	G/A	cg26050004	chr1:235667680	B3GALNT2	0.66	8.56	0.49	1.54e-15	Adiposity;
SARC	cis	rs1536827	0.698	rs10857736	chr10:135336514	A/G	cg22671611	chr10:135291010	NA	-0.45	-4.79	-0.3	3.03e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg24485466	chr1:200589999	KIF14	0.54	6.88	0.41	5.61e-11	Breast cancer;
SARC	cis	rs4906332	1.000	rs13987	chr14:103969909	A/G	cg26031613	chr14:104095156	KLC1	-0.51	-5.73	-0.35	3.07e-8	Coronary artery disease;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg27658321	chr15:81281915	MESDC2	0.54	6.61	0.4	2.63e-10	Breast cancer;
SARC	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-6.82	-0.41	7.86e-11	Personality dimensions;
SARC	cis	rs713477	0.935	rs4901567	chr14:55912698	C/T	cg13175173	chr14:55914753	NA	-0.31	-4.77	-0.3	3.31e-6	Pediatric bone mineral content (femoral neck);
SARC	cis	rs6484504	0.576	rs11031320	chr11:31242545	C/T	cg02090638	chr11:31391270	DNAJC24;DCDC1	-0.39	-4.95	-0.31	1.43e-6	Red blood cell count;
SARC	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg26335602	chr6:28129616	ZNF389	0.53	5.88	0.36	1.43e-8	Depression;
SARC	cis	rs3008870	0.755	rs3929738	chr1:67397865	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.59	7.5	0.44	1.32e-12	Lymphocyte percentage of white cells;
SARC	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.78	5.81	0.36	2.02e-8	Initial pursuit acceleration;
SARC	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg15049968	chr18:44337910	ST8SIA5	-0.35	-5.65	-0.35	4.75e-8	Personality dimensions;
SARC	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg22834771	chr12:69754056	YEATS4	0.42	5.48	0.34	1.09e-7	Cerebrospinal fluid biomarker levels;
SARC	cis	rs7178572	1.000	rs8024485	chr15:77718368	C/A	cg22256960	chr15:77711686	NA	-0.56	-6.61	-0.4	2.65e-10	Type 2 diabetes;
SARC	cis	rs2115536	0.935	rs11854390	chr15:80224817	C/T	cg00225070	chr15:80189496	MTHFS	0.64	8.55	0.49	1.7e-15	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
SARC	cis	rs1784581	0.588	rs6455790	chr6:162418447	C/T	cg17173639	chr6:162384350	PARK2	-0.53	-6.8	-0.41	8.92e-11	Itch intensity from mosquito bite;
SARC	cis	rs478304	0.903	rs546202	chr11:65510024	C/T	cg08755490	chr11:65554678	OVOL1	-0.35	-4.96	-0.31	1.33e-6	Acne (severe);
SARC	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	8.84	0.5	2.33e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg04234412	chr22:24373322	LOC391322	0.62	8.12	0.47	2.65e-14	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs595982	0.559	rs73061632	chr19:49361663	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.65	-6.88	-0.41	5.46e-11	Red cell distribution width;
SARC	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg11987759	chr7:65425863	GUSB	0.46	6.2	0.38	2.59e-9	Aortic root size;
SARC	cis	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg05623727	chr3:50126028	RBM5	-0.34	-5.19	-0.32	4.52e-7	Intelligence (multi-trait analysis);
SARC	cis	rs11190604	1.000	rs11190556	chr10:102209223	G/A	cg07080220	chr10:102295463	HIF1AN	0.78	9.58	0.53	1.56e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs921968	0.542	rs630858	chr2:219409689	C/A	cg02176678	chr2:219576539	TTLL4	0.47	7.16	0.42	1.07e-11	Mean corpuscular hemoglobin concentration;
SARC	cis	rs7662987	0.517	rs2851260	chr4:100033574	C/T	cg12011299	chr4:100065546	ADH4	0.33	5.53	0.34	8.55e-8	Smoking initiation;
SARC	cis	rs7474896	0.537	rs2749586	chr10:38270214	G/C	cg00409905	chr10:38381863	ZNF37A	0.42	4.72	0.3	4.14e-6	Obesity (extreme);
SARC	cis	rs2963155	0.518	rs258748	chr5:142656454	C/G	cg17617527	chr5:142782415	NR3C1	0.89	6.8	0.41	8.86e-11	Breast cancer;
SARC	cis	rs9303401	0.659	rs34468504	chr17:56648277	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	11.65	0.61	5.15e-25	Cognitive test performance;
SARC	cis	rs9486715	0.867	rs926277	chr6:96868837	T/A	cg06623918	chr6:96969491	KIAA0776	0.88	12.7	0.64	1.95e-28	Headache;
SARC	cis	rs6964587	1.000	rs2282970	chr7:91584281	A/G	cg17063962	chr7:91808500	NA	0.92	14.96	0.7	6.41e-36	Breast cancer;
SARC	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg10523679	chr1:76189770	ACADM	0.49	6.1	0.37	4.29e-9	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6665290	0.839	rs6699400	chr1:227190497	A/G	cg14016676	chr1:227182615	CDC42BPA	0.36	5.23	0.32	3.85e-7	Myeloid white cell count;
SARC	trans	rs637571	0.522	rs503524	chr11:65751764	C/T	cg17712092	chr4:129076599	LARP1B	0.7	9.51	0.53	2.55e-18	Eosinophil percentage of white cells;
SARC	cis	rs910187	0.641	rs6124966	chr20:45813099	T/G	cg27589058	chr20:45804311	EYA2	-0.31	-5.01	-0.31	1.05e-6	Migraine;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg26607248	chr1:202979751	TMEM183A;TMEM183B	0.45	6.31	0.38	1.4e-9	Thyroid stimulating hormone;
SARC	cis	rs12579753	0.917	rs12822036	chr12:82183009	C/T	cg07988820	chr12:82153109	PPFIA2	-0.54	-6.34	-0.38	1.16e-9	Resting heart rate;
SARC	cis	rs9879311	0.932	rs7427473	chr3:10413197	C/T	cg11030744	chr3:10328490	GHRL;GHRLOS	0.48	5.86	0.36	1.59e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	cis	rs6964587	0.967	rs55801687	chr7:91762629	C/A	cg17063962	chr7:91808500	NA	0.96	16.36	0.73	1.42e-40	Breast cancer;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg14937059	chr7:94248343	SGCE	0.49	6.5	0.39	4.94e-10	Thyroid stimulating hormone;
SARC	cis	rs6088590	1.000	rs6058111	chr20:33310999	T/C	cg06115741	chr20:33292138	TP53INP2	0.54	6.6	0.4	2.82e-10	Coronary artery disease;
SARC	cis	rs67311347	0.544	rs6769627	chr3:40327845	G/A	cg09455208	chr3:40491958	NA	0.31	5.06	0.31	8.57e-7	Renal cell carcinoma;
SARC	cis	rs929354	0.742	rs11980541	chr7:156988776	G/C	cg05182265	chr7:156933206	UBE3C	-0.33	-5.02	-0.31	1.03e-6	Body mass index;
SARC	cis	rs644799	0.710	rs522536	chr11:95528714	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.95	16.03	0.72	1.74e-39	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs4273100	0.646	rs6587216	chr17:19224397	G/C	cg25447019	chr17:19030144	GRAPL	0.39	5.69	0.35	3.86e-8	Schizophrenia;
SARC	cis	rs11581859	0.613	rs17388577	chr1:99211276	T/C	cg20286094	chr1:99190917	SNX7	-0.43	-5.21	-0.32	4.23e-7	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs546131	0.571	rs4351790	chr11:34856891	A/G	cg06937548	chr11:34938143	PDHX;APIP	-0.44	-4.73	-0.3	3.81e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg10560079	chr2:191398806	TMEM194B	0.64	9.21	0.52	1.91e-17	Pulse pressure;
SARC	cis	rs739401	0.527	rs418832	chr11:3072236	C/T	cg08508325	chr11:3079039	CARS	-0.31	-7.56	-0.44	9.21e-13	Longevity;
SARC	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg16606324	chr3:10149918	C3orf24	0.5	5.01	0.31	1.08e-6	Alzheimer's disease;
SARC	cis	rs992157	0.710	rs7569907	chr2:219070551	C/T	cg00012203	chr2:219082015	ARPC2	0.84	13.95	0.67	1.51e-32	Colorectal cancer;
SARC	cis	rs6963495	0.818	rs118134111	chr7:105161229	A/C	cg13798780	chr7:105162888	PUS7	0.6	5.45	0.34	1.31e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs9398803	0.865	rs9388496	chr6:126785062	A/G	cg19875578	chr6:126661172	C6orf173	0.62	8.45	0.48	3.2e-15	Male-pattern baldness;
SARC	cis	rs7560272	0.538	rs13006448	chr2:73924424	G/T	cg20560298	chr2:73613845	ALMS1	0.46	6.12	0.37	4e-9	Schizophrenia;
SARC	cis	rs11676348	0.846	rs7594532	chr2:219008000	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.51	-6.66	-0.4	1.9e-10	Ulcerative colitis;
SARC	cis	rs9788682	0.747	rs28511883	chr15:78783683	C/T	cg24631222	chr15:78858424	CHRNA5	0.73	8.78	0.5	3.49e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs2976388	0.565	rs2572905	chr8:143797104	C/T	cg06565975	chr8:143823917	SLURP1	0.31	5.32	0.33	2.47e-7	Urinary tract infection frequency;
SARC	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg03433033	chr1:76189801	ACADM	0.53	7.72	0.45	3.49e-13	Blood metabolite levels;Acylcarnitine levels;
SARC	trans	rs61931739	0.500	rs6488213	chr12:34393319	C/T	cg13010199	chr12:38710504	ALG10B	0.75	10.67	0.57	6.59e-22	Morning vs. evening chronotype;
SARC	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg18876405	chr7:65276391	NA	-0.43	-4.72	-0.3	4.13e-6	Aortic root size;
SARC	cis	rs908922	0.651	rs564107	chr1:152519295	C/T	cg09873164	chr1:152488093	CRCT1	0.62	8.04	0.47	4.46e-14	Hair morphology;
SARC	cis	rs4423214	0.879	rs1792284	chr11:71134966	A/G	cg05163923	chr11:71159392	DHCR7	0.54	6.13	0.37	3.71e-9	Vitamin D levels;
SARC	cis	rs548181	0.736	rs1941558	chr11:125425606	C/T	cg03464685	chr11:125439445	EI24	1.12	11.24	0.59	1.02e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs6840360	1.000	rs17360475	chr4:152671640	C/G	cg22705602	chr4:152727874	NA	0.35	6.16	0.37	3.22e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7605378	0.528	rs281787	chr2:200784238	C/T	cg17644776	chr2:200775616	C2orf69	-0.57	-7.27	-0.43	5.28e-12	Osteoporosis;
SARC	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg08219700	chr8:58056026	NA	0.59	6.27	0.38	1.76e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs710216	0.843	rs1385129	chr1:43408966	G/A	cg22176566	chr1:43424700	SLC2A1	0.54	5.51	0.34	9.32e-8	Red cell distribution width;
SARC	cis	rs2933343	0.859	rs789247	chr3:128580585	C/A	cg24203234	chr3:128598194	ACAD9	0.53	5.93	0.36	1.09e-8	IgG glycosylation;
SARC	cis	rs2070488	0.775	rs13072731	chr3:38533335	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.78	11.58	0.6	8.48e-25	Electrocardiographic conduction measures;
SARC	cis	rs6708331	1.000	rs10195155	chr2:70354475	G/T	cg16435808	chr2:70475954	TIA1	0.47	4.87	0.3	2.1e-6	Obesity-related traits;
SARC	cis	rs67311347	0.544	rs4974040	chr3:40331059	G/A	cg24209194	chr3:40518798	ZNF619	0.49	6.61	0.4	2.64e-10	Renal cell carcinoma;
SARC	cis	rs9807989	0.507	rs2310300	chr2:103049074	A/G	cg03938978	chr2:103052716	IL18RAP	0.32	5.18	0.32	4.71e-7	Asthma;
SARC	cis	rs9807841	0.670	rs2738039	chr19:10793749	A/G	cg17710535	chr19:10819994	QTRT1	0.43	4.91	0.31	1.74e-6	Inflammatory skin disease;
SARC	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4243830	0.737	rs7552172	chr1:6612269	C/T	cg04093404	chr1:6614507	TAS1R1;NOL9	0.62	5.23	0.32	3.76e-7	Body mass index;
SARC	cis	rs2292864	0.764	rs3785872	chr17:45372075	G/A	cg18085866	chr17:45331354	ITGB3	-0.8	-6.0	-0.37	7.3e-9	Left atrial antero-posterior diameter;
SARC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg06873352	chr17:61820015	STRADA	0.52	6.85	0.41	6.33e-11	Prudent dietary pattern;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg11140344	chr10:114878970	TCF7L2	0.49	6.57	0.4	3.21e-10	Thyroid stimulating hormone;
SARC	cis	rs6976053	0.541	rs314359	chr7:100411278	T/C	cg03098644	chr7:100410630	EPHB4	-0.52	-7.25	-0.43	6.25e-12	Plasminogen activator inhibitor type 1 levels (PAI-1);
SARC	cis	rs4688759	0.719	rs73079018	chr3:49875327	T/C	cg07636037	chr3:49044803	WDR6	-0.76	-6.39	-0.39	9.05e-10	Blood protein levels;
SARC	cis	rs2153535	0.580	rs4960413	chr6:8438466	C/T	cg07606381	chr6:8435919	SLC35B3	0.78	11.09	0.59	3.11e-23	Motion sickness;
SARC	cis	rs12130219	0.500	rs4845737	chr1:152177539	G/A	cg26320663	chr1:152161521	NA	0.44	5.39	0.33	1.76e-7	Inflammatory skin disease;
SARC	cis	rs10779751	0.770	rs11121695	chr1:11229515	G/A	cg08854313	chr1:11322531	MTOR	-0.82	-10.45	-0.57	3.17e-21	Body mass index;
SARC	cis	rs7208859	0.623	rs7220999	chr17:29149298	C/T	cg13385521	chr17:29058706	SUZ12P	0.9	7.36	0.43	3.12e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs28655083	0.828	rs11640648	chr16:77122494	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.46	6.46	0.39	6.06e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9902453	0.934	rs7213902	chr17:28322935	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	6.87	0.41	5.93e-11	Coffee consumption (cups per day);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg26593228	chr10:88610737	BMPR1A	0.52	7.0	0.42	2.78e-11	Thyroid stimulating hormone;
SARC	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	11.31	0.6	6.28e-24	Alzheimer's disease;
SARC	cis	rs9549367	0.789	rs12584813	chr13:113895443	C/G	cg18105134	chr13:113819100	PROZ	-0.35	-5.08	-0.32	7.63e-7	Platelet distribution width;
SARC	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg03806693	chr22:41940476	POLR3H	0.88	12.16	0.62	1.15e-26	Vitiligo;
SARC	cis	rs155076	0.938	rs485361	chr13:21845826	G/T	cg14456004	chr13:21872349	NA	-1.0	-12.77	-0.64	1.13e-28	White matter hyperintensity burden;
SARC	cis	rs2304206	0.614	rs12104272	chr19:50148052	A/G	cg03172226	chr19:50162898	IRF3	-0.31	-5.13	-0.32	6.09e-7	Vitiligo;
SARC	cis	rs637571	0.522	rs503524	chr11:65751764	C/T	cg26695010	chr11:65641043	EFEMP2	-0.53	-6.83	-0.41	7.2e-11	Eosinophil percentage of white cells;
SARC	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg15448220	chr1:150897856	SETDB1	0.47	6.22	0.38	2.24e-9	Tonsillectomy;
SARC	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.48	5.97	0.36	8.69e-9	Tonsillectomy;
SARC	cis	rs6690583	0.623	rs12042910	chr1:85452580	G/A	cg22153463	chr1:85462885	MCOLN2	0.72	6.96	0.42	3.33e-11	Serum sulfate level;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg19480152	chr11:74109674	PGM2L1	0.55	6.83	0.41	7.17e-11	Breast cancer;
SARC	cis	rs4481887	0.830	rs6686474	chr1:248477116	A/C	cg13385794	chr1:248469461	NA	0.33	5.08	0.32	7.75e-7	Common traits (Other);
SARC	cis	rs910316	0.726	rs61979167	chr14:75663610	C/T	cg08847533	chr14:75593920	NEK9	-0.77	-10.66	-0.57	7.07e-22	Height;
SARC	trans	rs10825741	0.825	rs56101313	chr10:57907010	G/T	cg12948920	chr4:8609706	CPZ	0.53	6.29	0.38	1.53e-9	Night sleep phenotypes;
SARC	cis	rs9457247	0.905	rs377232	chr6:167409638	C/A	cg23791538	chr6:167370224	RNASET2	-0.54	-7.32	-0.43	4.02e-12	Crohn's disease;
SARC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg26338869	chr17:61819248	STRADA	0.77	10.1	0.55	3.96e-20	Prudent dietary pattern;
SARC	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg17376030	chr22:41985996	PMM1	0.77	9.37	0.52	6.7e-18	Vitiligo;
SARC	cis	rs561341	1.000	rs564714	chr17:30318404	C/T	cg00745463	chr17:30367425	LRRC37B	-0.71	-5.58	-0.34	6.7e-8	Hip circumference adjusted for BMI;
SARC	cis	rs3892630	0.588	rs7260037	chr19:33242701	G/A	cg22980127	chr19:33182716	NUDT19	1.09	11.51	0.6	1.46e-24	Red blood cell traits;
SARC	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg22307029	chr19:49891270	CCDC155	0.58	6.66	0.4	1.93e-10	Multiple sclerosis;
SARC	cis	rs4906332	1.000	rs12896919	chr14:103956713	T/C	cg26031613	chr14:104095156	KLC1	-0.49	-5.76	-0.35	2.64e-8	Coronary artery disease;
SARC	cis	rs1865760	0.532	rs2794719	chr6:26088890	T/G	cg16482183	chr6:26056742	HIST1H1C	0.5	6.29	0.38	1.56e-9	Height;
SARC	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10782582	0.593	rs6675212	chr1:76230829	C/A	cg10523679	chr1:76189770	ACADM	-0.44	-5.35	-0.33	2.14e-7	Daytime sleep phenotypes;
SARC	cis	rs921968	0.565	rs7599568	chr2:219607819	A/G	cg02176678	chr2:219576539	TTLL4	-0.32	-4.94	-0.31	1.49e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs6665290	0.901	rs11580229	chr1:227210820	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.05	-23.12	-0.83	2.91e-62	Myeloid white cell count;
SARC	cis	rs11098499	0.954	rs6849171	chr4:120409549	G/A	cg24375607	chr4:120327624	NA	0.4	4.75	0.3	3.51e-6	Corneal astigmatism;
SARC	cis	rs9790314	0.586	rs1811483	chr3:161130900	A/G	cg17135325	chr3:160939158	NMD3	0.54	6.79	0.41	9.37e-11	Morning vs. evening chronotype;
SARC	cis	rs13191362	1.000	rs35383933	chr6:163002869	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.57	5.38	0.33	1.85e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs453301	0.686	rs4840389	chr8:8884503	G/C	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.41	-0.39	8.06e-10	Joint mobility (Beighton score);
SARC	cis	rs7264396	0.779	rs2425162	chr20:34429974	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-7.52	-0.44	1.14e-12	Total cholesterol levels;
SARC	cis	rs12134245	0.874	rs35115044	chr1:92021650	A/G	cg25838465	chr1:92012736	NA	-0.57	-7.89	-0.46	1.16e-13	Breast cancer;
SARC	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg08280861	chr8:58055591	NA	0.6	5.71	0.35	3.4e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs5753618	0.555	rs5749286	chr22:31900359	G/T	cg07713946	chr22:31675144	LIMK2	0.36	5.1	0.32	7.13e-7	Colorectal cancer;
SARC	cis	rs7772486	0.790	rs2485632	chr6:146193228	A/G	cg05347473	chr6:146136440	FBXO30	0.55	7.71	0.45	3.72e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2832191	0.791	rs8134407	chr21:30476586	G/A	cg24692254	chr21:30365293	RNF160	0.93	13.53	0.66	3.59e-31	Dental caries;
SARC	cis	rs10189230	0.935	rs3770145	chr2:222345147	T/C	cg14652038	chr2:222343519	EPHA4	0.45	5.84	0.36	1.74e-8	Urate levels in lean individuals;
SARC	cis	rs6089584	0.821	rs4925332	chr20:60604639	C/T	cg06108461	chr20:60628389	TAF4	-0.92	-12.45	-0.63	1.27e-27	Body mass index;
SARC	cis	rs11098499	0.863	rs10013305	chr4:120450424	G/A	cg24375607	chr4:120327624	NA	0.42	4.9	0.31	1.76e-6	Corneal astigmatism;
SARC	cis	rs4253772	0.637	rs9627295	chr22:46650100	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.64	6.81	0.41	8.27e-11	LDL cholesterol;Cholesterol, total;
SARC	cis	rs9814567	1.000	rs11708531	chr3:134224902	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-7.02	-0.42	2.38e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg13939156	chr17:80058883	NA	0.4	6.22	0.38	2.23e-9	Life satisfaction;
SARC	cis	rs453301	0.658	rs6986044	chr8:8874786	G/C	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.81	-0.41	8.13e-11	Joint mobility (Beighton score);
SARC	cis	rs112591243	0.685	rs4819263	chr21:47950866	G/A	cg26904215	chr21:47823096	PCNT	-0.76	-4.87	-0.3	2.07e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg14541582	chr5:601475	NA	-0.41	-5.15	-0.32	5.42e-7	Obesity-related traits;
SARC	cis	rs67460515	0.892	rs10513564	chr3:161059762	A/G	cg04691961	chr3:161091175	C3orf57	-0.48	-6.04	-0.37	5.94e-9	Parkinson's disease;
SARC	cis	rs7481584	0.646	rs434114	chr11:3050210	A/G	cg20651018	chr11:3035856	CARS	0.41	6.12	0.37	4.01e-9	Calcium levels;
SARC	cis	rs4689388	0.853	rs13103357	chr4:6294544	A/G	cg25554036	chr4:6271136	WFS1	0.39	6.42	0.39	7.48e-10	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg16405210	chr4:1374714	KIAA1530	0.52	6.19	0.38	2.66e-9	Obesity-related traits;
SARC	cis	rs9660992	0.542	rs17345153	chr1:205179997	A/G	cg21643547	chr1:205240462	TMCC2	-0.56	-7.15	-0.42	1.13e-11	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs79349575	0.783	rs62075852	chr17:47017176	T/C	cg07967210	chr17:47022446	SNF8	0.38	4.77	0.3	3.2e-6	Type 2 diabetes;
SARC	cis	rs16854884	0.632	rs1910691	chr3:143656905	G/A	cg06585982	chr3:143692056	C3orf58	0.69	9.46	0.53	3.63e-18	Economic and political preferences (feminism/equality);
SARC	cis	rs7824557	0.778	rs3808502	chr8:11179458	G/T	cg21775007	chr8:11205619	TDH	0.56	7.16	0.42	1.05e-11	Retinal vascular caliber;
SARC	cis	rs2645694	0.626	rs904050	chr4:77826089	T/G	cg18351406	chr4:77819688	ANKRD56	0.4	5.57	0.34	7.12e-8	Emphysema distribution in smoking;
SARC	cis	rs155076	0.702	rs482731	chr13:21846075	G/A	cg25811766	chr13:21894605	NA	-0.51	-5.5	-0.34	9.92e-8	White matter hyperintensity burden;
SARC	cis	rs11881751	0.868	rs33938520	chr19:4984588	A/G	cg04571196	chr19:4910051	UHRF1	-0.46	-4.88	-0.3	1.94e-6	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs2522056	1.000	rs2522062	chr5:131805416	A/G	cg24060327	chr5:131705240	SLC22A5	0.48	4.76	0.3	3.47e-6	Lymphocyte counts;Fibrinogen;
SARC	cis	rs7714584	1.000	rs80075680	chr5:150223737	C/T	cg22134413	chr5:150180641	NA	0.78	6.56	0.39	3.42e-10	Crohn's disease;
SARC	cis	rs910316	0.737	rs398896	chr14:75482827	C/A	cg11812906	chr14:75593930	NEK9	-0.75	-10.12	-0.55	3.54e-20	Height;
SARC	cis	rs7819412	0.502	rs4841499	chr8:10988138	A/C	cg21775007	chr8:11205619	TDH	-0.44	-5.14	-0.32	5.85e-7	Triglycerides;
SARC	cis	rs11676348	0.783	rs4674252	chr2:218984478	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.5	-6.42	-0.39	7.61e-10	Ulcerative colitis;
SARC	cis	rs7587476	0.784	rs34112702	chr2:215696002	A/G	cg04004882	chr2:215674386	BARD1	0.56	6.41	0.39	7.98e-10	Neuroblastoma;
SARC	cis	rs10504229	0.679	rs6474100	chr8:58031161	G/A	cg11062466	chr8:58055876	NA	0.51	5.02	0.31	1.03e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs17253792	0.822	rs10148122	chr14:56146694	G/T	cg01858014	chr14:56050164	KTN1	-0.71	-5.58	-0.34	6.78e-8	Putamen volume;
SARC	cis	rs2836633	0.929	rs62217517	chr21:40033177	T/A	cg12884169	chr21:40033163	ERG	0.48	8.79	0.5	3.33e-16	Coronary artery disease;
SARC	cis	rs736408	0.583	rs2710323	chr3:52815905	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.4	4.87	0.3	2.03e-6	Bipolar disorder;
SARC	cis	rs958025	1	rs958025	chr15:78759348	C/T	cg06917634	chr15:78832804	PSMA4	-0.53	-5.45	-0.34	1.27e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
SARC	cis	rs473651	1.000	rs473651	chr2:239335401	A/C	cg18131467	chr2:239335373	ASB1	0.96	16.17	0.73	6.31e-40	Multiple system atrophy;
SARC	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.27	-4.89	-0.3	1.9e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg11764359	chr7:65958608	NA	0.69	8.18	0.47	1.88e-14	Aortic root size;
SARC	cis	rs7582720	0.945	rs116773016	chr2:203811902	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs7772486	0.686	rs9390347	chr6:146044747	G/T	cg05347473	chr6:146136440	FBXO30	-0.5	-6.9	-0.41	4.85e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs526231	0.511	rs34823	chr5:102438291	C/T	cg23492399	chr5:102201601	PAM	0.52	5.57	0.34	6.91e-8	Primary biliary cholangitis;
SARC	cis	rs7223966	0.921	rs3020612	chr17:61960878	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-5.91	-0.36	1.23e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs13082711	0.911	rs34422761	chr3:27513366	C/A	cg02860705	chr3:27208620	NA	0.4	5.29	0.33	2.79e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs9457247	1.000	rs400837	chr6:167411008	T/C	cg07741184	chr6:167504864	NA	0.3	5.6	0.34	5.91e-8	Crohn's disease;
SARC	cis	rs8060686	0.591	rs255054	chr16:68017356	A/G	cg06378129	chr16:67998246	SLC12A4	-0.47	-4.73	-0.3	3.91e-6	HDL cholesterol;Metabolic syndrome;
SARC	cis	rs9467773	1.000	rs6932156	chr6:26571506	T/G	cg11502198	chr6:26597334	ABT1	0.53	6.46	0.39	6.05e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg15556689	chr8:8085844	FLJ10661	0.45	5.51	0.34	9.47e-8	Mood instability;
SARC	cis	rs6121246	0.529	rs6060118	chr20:30171209	T/C	cg21427119	chr20:30132790	HM13	-0.46	-5.07	-0.32	8.12e-7	Mean corpuscular hemoglobin;
SARC	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg13628971	chr7:2884303	GNA12	0.58	6.72	0.4	1.39e-10	Height;
SARC	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg08219700	chr8:58056026	NA	0.61	6.36	0.38	1.05e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs3087591	0.600	rs2905808	chr17:29493993	A/T	cg24425628	chr17:29625626	OMG;NF1	0.46	4.74	0.3	3.73e-6	Hip circumference;
SARC	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.02	0.37	6.64e-9	Height;
SARC	cis	rs546131	0.642	rs61881097	chr11:34821598	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-4.91	-0.31	1.71e-6	Lung disease severity in cystic fibrosis;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg13483431	chr3:124949647	ZNF148	0.5	7.04	0.42	2.15e-11	Thyroid stimulating hormone;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg20306180	chr22:32340197	C22orf24;YWHAH	-0.51	-6.51	-0.39	4.64e-10	Height;
SARC	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg16680214	chr1:154839983	KCNN3	-0.35	-5.26	-0.33	3.31e-7	Prostate cancer;
SARC	cis	rs7103648	0.966	rs10769263	chr11:47417183	A/C	cg20307385	chr11:47447363	PSMC3	0.86	13.8	0.67	4.48e-32	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs8028182	0.636	rs4451914	chr15:75739824	C/T	cg20655648	chr15:75932815	IMP3	0.64	7.58	0.44	8.28e-13	Sudden cardiac arrest;
SARC	cis	rs7666738	0.830	rs60007031	chr4:98824753	G/C	cg05340658	chr4:99064831	C4orf37	0.66	8.76	0.5	4.2e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg24531977	chr5:56204891	C5orf35	-0.52	-5.32	-0.33	2.46e-7	Initial pursuit acceleration;
SARC	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg00933542	chr6:150070202	PCMT1	0.34	5.89	0.36	1.34e-8	Lung cancer;
SARC	cis	rs7582180	0.629	rs74177696	chr2:100938481	C/G	cg14675211	chr2:100938903	LONRF2	0.51	7.59	0.45	7.54e-13	Intelligence (multi-trait analysis);
SARC	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	9.68	0.54	7.66e-19	Platelet count;
SARC	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg25036284	chr2:26402008	FAM59B	0.49	5.95	0.36	1e-8	Gut microbiome composition (summer);
SARC	cis	rs950776	0.518	rs1504545	chr15:78818471	C/G	cg22563815	chr15:78856949	CHRNA5	-0.4	-6.6	-0.4	2.75e-10	Sudden cardiac arrest;
SARC	cis	rs7223966	1.000	rs55674647	chr17:61794195	T/C	cg26338869	chr17:61819248	STRADA	0.47	4.9	0.31	1.81e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs8072100	0.738	rs9900123	chr17:45549055	T/C	cg08085267	chr17:45401833	C17orf57	-0.43	-5.13	-0.32	6.16e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs3931020	0.548	rs17618340	chr1:75247617	G/A	cg10128416	chr1:75198403	TYW3;CRYZ	0.42	5.32	0.33	2.41e-7	Resistin levels;
SARC	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-9.68	-0.54	7.76e-19	Chronic sinus infection;
SARC	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg06636001	chr8:8085503	FLJ10661	-0.81	-11.97	-0.62	4.67e-26	Neuroticism;
SARC	cis	rs4319547	0.774	rs10773394	chr12:123124778	C/A	cg05707623	chr12:122985044	ZCCHC8	-0.52	-5.99	-0.37	7.69e-9	Body mass index;
SARC	cis	rs9660992	0.548	rs1172152	chr1:205220718	T/A	cg21643547	chr1:205240462	TMCC2	-0.54	-7.18	-0.43	9.35e-12	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs8038465	0.592	rs899981	chr15:73935329	G/A	cg15420318	chr15:73925796	NPTN	0.66	7.63	0.45	5.95e-13	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs10504229	0.679	rs11783557	chr8:58030644	A/G	cg21724239	chr8:58056113	NA	0.61	6.37	0.38	1.02e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2153535	0.580	rs1932276	chr6:8442593	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs7932354	0.528	rs7947878	chr11:47028531	C/T	cg03339077	chr11:47165057	C11orf49	-0.4	-5.47	-0.34	1.16e-7	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs7589342	0.929	rs7590652	chr2:106440306	A/G	cg16077055	chr2:106428750	NCK2	0.4	7.56	0.44	9.11e-13	Addiction;
SARC	cis	rs1881797	1.000	rs12071797	chr1:247686871	A/G	cg18198730	chr1:247681584	NA	0.48	5.29	0.33	2.85e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs3796352	1.000	rs35507120	chr3:53053924	C/T	cg12962167	chr3:53033115	SFMBT1	0.82	5.39	0.33	1.71e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2280630	0.529	rs6599274	chr3:39013948	T/C	cg01426195	chr3:39028469	NA	-0.34	-4.8	-0.3	2.86e-6	Verbal declarative memory;
SARC	cis	rs9326248	0.813	rs4938350	chr11:117022276	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.59	5.89	0.36	1.36e-8	Blood protein levels;
SARC	cis	rs9527	0.568	rs1926036	chr10:104883812	C/T	cg04362960	chr10:104952993	NT5C2	0.43	4.94	0.31	1.47e-6	Arsenic metabolism;
SARC	cis	rs6500602	0.702	rs17761816	chr16:4548832	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.32	5.61	0.34	5.77e-8	Schizophrenia;
SARC	cis	rs6912958	0.781	rs9450739	chr6:88268271	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-6.82	-0.41	7.75e-11	Monocyte percentage of white cells;
SARC	cis	rs9790314	0.747	rs9848239	chr3:160823488	A/C	cg03342759	chr3:160939853	NMD3	-0.46	-5.67	-0.35	4.22e-8	Morning vs. evening chronotype;
SARC	cis	rs7927592	0.763	rs10896340	chr11:68312645	A/G	cg01657329	chr11:68192670	LRP5	0.37	5.0	0.31	1.11e-6	Total body bone mineral density;
SARC	cis	rs8192482	1	rs8192482	chr15:78886198	C/T	cg18825076	chr15:78729989	IREB2	-0.45	-5.11	-0.32	6.56e-7	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs1005277	0.522	rs289650	chr10:37975505	G/T	cg00409905	chr10:38381863	ZNF37A	-0.52	-7.39	-0.44	2.6e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs10489525	0.583	rs6660550	chr1:115650850	C/G	cg01522456	chr1:115632236	TSPAN2	0.7	8.28	0.48	9.48e-15	Autism;
SARC	cis	rs1468333	1.000	rs4835669	chr5:137473391	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.8	11.18	0.59	1.66e-23	Resting heart rate;
SARC	cis	rs7762018	0.607	rs78941587	chr6:170061157	G/C	cg19338460	chr6:170058176	WDR27	-0.83	-5.85	-0.36	1.68e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs992157	0.687	rs35271699	chr2:219117482	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.67	9.23	0.52	1.75e-17	Colorectal cancer;
SARC	cis	rs3020736	0.500	rs9620026	chr22:42498578	C/T	cg04733989	chr22:42467013	NAGA	-0.76	-10.7	-0.57	5.23e-22	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg22875332	chr1:76189707	ACADM	-0.46	-6.53	-0.39	3.99e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs17401966	0.931	rs2236678	chr1:10471789	A/T	cg15208524	chr1:10270712	KIF1B	0.43	4.96	0.31	1.39e-6	Hepatocellular carcinoma;
SARC	cis	rs908922	0.676	rs4845443	chr1:152507156	C/T	cg09873164	chr1:152488093	CRCT1	0.6	7.7	0.45	3.75e-13	Hair morphology;
SARC	trans	rs1814175	0.645	rs11040699	chr11:50023798	C/G	cg15704280	chr7:45808275	SEPT13	-0.9	-14.33	-0.68	7.84e-34	Height;
SARC	cis	rs644799	1.000	rs1784135	chr11:95531748	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.9	13.74	0.67	7.12e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs17376456	0.542	rs35672980	chr5:93284877	A/T	cg25358565	chr5:93447407	FAM172A	-0.81	-9.63	-0.53	1.06e-18	Diabetic retinopathy;
SARC	cis	rs4718428	0.672	rs4718412	chr7:66286867	C/T	cg12165864	chr7:66369176	NA	0.49	5.52	0.34	9.13e-8	Corneal structure;
SARC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg09373136	chr17:61933544	TCAM1	-0.45	-6.18	-0.38	2.87e-9	Prudent dietary pattern;
SARC	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg13393036	chr8:95962371	TP53INP1	-0.37	-6.25	-0.38	1.9e-9	Type 2 diabetes;
SARC	cis	rs2273669	0.667	rs2003315	chr6:109367169	C/T	cg05315195	chr6:109294784	ARMC2	-0.63	-5.7	-0.35	3.6e-8	Prostate cancer;
SARC	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg01276201	chr10:134613136	NA	0.32	5.34	0.33	2.25e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg03433033	chr1:76189801	ACADM	0.55	7.76	0.45	2.61e-13	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.63	-7.54	-0.44	1.01e-12	Gut microbiome composition (summer);
SARC	cis	rs17376456	0.877	rs17083455	chr5:93446380	A/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.79	0.35	2.3e-8	Diabetic retinopathy;
SARC	cis	rs4332037	0.539	rs34571717	chr7:2106855	T/C	cg21782813	chr7:2030301	MAD1L1	-0.33	-5.02	-0.31	1.04e-6	Bipolar disorder;
SARC	cis	rs2731664	0.792	rs335466	chr5:176889530	C/A	cg23176889	chr5:176863531	GRK6	-0.56	-8.37	-0.48	5.43e-15	Intelligence (multi-trait analysis);
SARC	cis	rs1580019	0.922	rs34545272	chr7:32460630	C/T	cg07520158	chr7:32535189	LSM5;AVL9	0.41	5.01	0.31	1.06e-6	Cognitive ability;
SARC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.77	-9.7	-0.54	6.64e-19	Prudent dietary pattern;
SARC	cis	rs9486719	0.690	rs2092094	chr6:96844123	G/C	cg06623918	chr6:96969491	KIAA0776	0.75	7.39	0.44	2.65e-12	Migraine;Coronary artery disease;
SARC	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-10.79	-0.58	2.85e-22	Chronic sinus infection;
SARC	cis	rs9581943	0.967	rs7985481	chr13:28466090	A/C	cg16302790	chr13:28498334	PDX1	0.55	8.29	0.48	8.79e-15	Pancreatic cancer;
SARC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.28	0.8	2.29e-53	Prudent dietary pattern;
SARC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.64	-0.4	2.16e-10	Total body bone mineral density;
SARC	cis	rs240764	0.764	rs6910391	chr6:100925774	T/C	cg21058520	chr6:100914733	NA	0.34	5.13	0.32	6.21e-7	Neuroticism;
SARC	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg14558262	chr17:40713999	COASY	0.79	11.9	0.61	7.87e-26	Colorectal or endometrial cancer;
SARC	cis	rs2921073	0.510	rs2976945	chr8:8270871	G/T	cg06636001	chr8:8085503	FLJ10661	0.65	8.01	0.46	5.41e-14	Parkinson's disease;
SARC	cis	rs4319547	0.506	rs2062488	chr12:122804256	C/T	cg05707623	chr12:122985044	ZCCHC8	0.46	5.25	0.33	3.45e-7	Body mass index;
SARC	cis	rs17345786	0.798	rs4257518	chr3:101281709	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.46	-5.47	-0.34	1.15e-7	Colonoscopy-negative controls vs population controls;
SARC	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg18252515	chr7:66147081	NA	-0.46	-5.08	-0.32	7.78e-7	Aortic root size;
SARC	cis	rs1318878	1.000	rs983798	chr12:15543931	A/G	cg08258403	chr12:15378311	NA	-0.46	-5.87	-0.36	1.48e-8	Intelligence (multi-trait analysis);
SARC	cis	rs36715	0.953	rs36700	chr5:127551273	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.6	6.55	0.39	3.62e-10	Breast cancer;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg25183890	chr8:94929275	PDP1	-0.52	-6.52	-0.39	4.37e-10	Schizophrenia;
SARC	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg06618935	chr21:46677482	NA	-0.39	-5.2	-0.32	4.34e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7223966	1.000	rs2874121	chr17:61731024	C/T	cg00588841	chr17:61851480	DDX42;CCDC47	-0.62	-6.75	-0.4	1.17e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg11062466	chr8:58055876	NA	0.59	5.72	0.35	3.33e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6570726	1.000	rs441477	chr6:145848243	C/T	cg05347473	chr6:146136440	FBXO30	0.48	6.48	0.39	5.45e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9300255	0.699	rs11057204	chr12:123725827	T/C	cg05973401	chr12:123451056	ABCB9	0.47	5.18	0.32	4.77e-7	Neutrophil percentage of white cells;
SARC	cis	rs7551222	0.681	rs2045623	chr1:204497413	A/G	cg20240347	chr1:204465584	NA	-0.35	-6.25	-0.38	1.98e-9	Schizophrenia;
SARC	trans	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg21659725	chr3:3221576	CRBN	-0.8	-12.22	-0.62	7.09e-27	Intelligence (multi-trait analysis);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg08201854	chr19:50922128	SPIB	0.49	6.39	0.39	9.12e-10	Breast cancer;
SARC	cis	rs8066384	1	rs8066384	chr17:78625756	T/C	cg17956530	chr17:78667699	RPTOR	-0.48	-5.47	-0.34	1.13e-7	Schizophrenia;
SARC	trans	rs61931739	0.534	rs11053020	chr12:34111092	C/G	cg13010199	chr12:38710504	ALG10B	0.77	10.36	0.56	6.18e-21	Morning vs. evening chronotype;
SARC	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg08975724	chr8:8085496	FLJ10661	0.64	8.63	0.49	9.39e-16	Systolic blood pressure;
SARC	cis	rs12893668	0.703	rs2403197	chr14:104053764	C/T	cg26031613	chr14:104095156	KLC1	-0.57	-6.37	-0.39	1e-9	Reticulocyte count;
SARC	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg11941060	chr3:133502564	NA	0.33	4.78	0.3	3.13e-6	Iron status biomarkers;
SARC	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.92	10.24	0.56	1.46e-20	Platelet count;
SARC	cis	rs698833	0.518	rs7562945	chr2:44552772	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.66	7.31	0.43	4.31e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs1865760	0.566	rs2032449	chr6:26026599	G/C	cg17691542	chr6:26056736	HIST1H1C	0.53	6.64	0.4	2.13e-10	Height;
SARC	cis	rs7539542	0.556	rs6692075	chr1:202881302	C/T	cg08940984	chr1:202857613	RABIF	0.4	5.4	0.33	1.67e-7	Mean platelet volume;
SARC	cis	rs79149102	0.579	rs6495135	chr15:75295030	T/C	cg09165964	chr15:75287851	SCAMP5	-0.95	-8.78	-0.5	3.63e-16	Lung cancer;
SARC	cis	rs7712401	0.601	rs257813	chr5:122217168	G/A	cg19412675	chr5:122181750	SNX24	0.41	5.24	0.32	3.51e-7	Mean platelet volume;
SARC	cis	rs2033732	0.706	rs1437512	chr8:85064763	T/G	cg05716166	chr8:85095498	RALYL	0.47	5.62	0.35	5.51e-8	Body mass index;
SARC	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg06618935	chr21:46677482	NA	-0.39	-5.32	-0.33	2.45e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2486288	0.554	rs1719235	chr15:45576108	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.51	-6.17	-0.37	3.07e-9	Glomerular filtration rate;
SARC	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg19500275	chr17:80737654	TBCD	0.44	5.13	0.32	5.98e-7	Glycated hemoglobin levels;
SARC	cis	rs9916302	0.904	rs2024073	chr17:37471330	T/G	cg07936489	chr17:37558343	FBXL20	0.68	9.06	0.51	5.39e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs9316337	0.843	rs61950006	chr13:21954033	G/A	cg21080246	chr13:22033151	ZDHHC20	0.4	4.97	0.31	1.33e-6	Schizophrenia;
SARC	cis	rs2735413	0.881	rs4888732	chr16:78080505	A/G	cg04733911	chr16:78082701	NA	-0.31	-5.51	-0.34	9.61e-8	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs911555	0.723	rs6575986	chr14:103886671	G/A	cg24130564	chr14:104152367	KLC1	-0.5	-5.8	-0.36	2.12e-8	Intelligence (multi-trait analysis);
SARC	cis	rs6598955	0.670	rs7531518	chr1:26539749	T/C	cg04990556	chr1:26633338	UBXN11	-0.6	-8.41	-0.48	4.25e-15	Obesity-related traits;
SARC	cis	rs7520050	0.966	rs785479	chr1:46492144	C/T	cg24296786	chr1:45957014	TESK2	0.38	4.86	0.3	2.2e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs6060717	0.654	rs6060686	chr20:34512606	C/G	cg12579300	chr20:34535607	PHF20	-0.47	-5.23	-0.32	3.86e-7	Hip circumference adjusted for BMI;
SARC	cis	rs3857536	0.904	rs7762308	chr6:66893552	A/G	cg07460842	chr6:66804631	NA	-0.44	-5.2	-0.32	4.31e-7	Blood trace element (Cu levels);
SARC	cis	rs7937682	0.737	rs542275	chr11:111431614	C/T	cg22437258	chr11:111473054	SIK2	0.56	7.28	0.43	5.08e-12	Primary sclerosing cholangitis;
SARC	cis	rs2070997	0.816	rs6597643	chr9:133725830	C/T	cg03924115	chr9:133768966	QRFP	-0.44	-4.82	-0.3	2.6e-6	Response to amphetamines;
SARC	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg11952622	chr19:58962976	ZNF324B	0.53	6.93	0.41	4.15e-11	Uric acid clearance;
SARC	cis	rs1552244	0.706	rs279545	chr3:9972493	A/G	cg16606324	chr3:10149918	C3orf24	0.46	5.1	0.32	6.89e-7	Alzheimer's disease;
SARC	cis	rs1468333	1.000	rs17171767	chr5:137493528	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	-0.78	-11.15	-0.59	1.99e-23	Resting heart rate;
SARC	cis	rs892961	0.932	rs66886702	chr17:75412714	G/A	cg05865280	chr17:75406074	SEPT9	0.57	8.47	0.48	2.87e-15	Airflow obstruction;
SARC	cis	rs16866061	0.515	rs3738951	chr2:225368321	A/G	cg12698349	chr2:225449008	CUL3	0.82	14.22	0.68	1.86e-33	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	cis	rs7481584	0.581	rs366422	chr11:3053873	C/T	cg20651018	chr11:3035856	CARS	0.41	6.02	0.37	6.85e-9	Calcium levels;
SARC	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg24829409	chr8:58192753	C8orf71	-0.57	-5.14	-0.32	5.91e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs425277	1.000	rs262672	chr1:2080813	G/T	cg21442419	chr1:2182373	SKI	-0.52	-6.68	-0.4	1.76e-10	Height;
SARC	cis	rs992157	0.710	rs13026485	chr2:219057984	C/T	cg00012203	chr2:219082015	ARPC2	-0.81	-12.86	-0.64	5.82e-29	Colorectal cancer;
SARC	cis	rs7264396	0.635	rs6058358	chr20:34492560	A/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	5.36	0.33	2.04e-7	Total cholesterol levels;
SARC	cis	rs7769051	0.803	rs12193474	chr6:133186168	T/C	cg22852734	chr6:133119734	C6orf192	0.98	7.92	0.46	9.8e-14	Type 2 diabetes nephropathy;
SARC	cis	rs2295359	1.000	rs736197	chr1:67607135	G/T	cg11235152	chr1:67600687	NA	0.47	7.24	0.43	6.31e-12	Psoriasis;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg03602886	chr2:48507243	NA	0.51	7.26	0.43	5.87e-12	Thyroid stimulating hormone;
SARC	cis	rs3820928	0.874	rs10178731	chr2:227874232	C/T	cg11843606	chr2:227700838	RHBDD1	-0.49	-5.99	-0.37	7.78e-9	Pulmonary function;
SARC	cis	rs7005380	0.581	rs4871795	chr8:120941665	C/T	cg21744203	chr8:120868354	DSCC1	0.44	5.14	0.32	5.95e-7	Interstitial lung disease;
SARC	cis	rs3771570	0.892	rs62186433	chr2:242257835	A/G	cg21155796	chr2:242212141	HDLBP	0.68	5.75	0.35	2.85e-8	Prostate cancer;
SARC	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.49	7.2	0.43	8.31e-12	Systemic lupus erythematosus;
SARC	cis	rs9300255	0.602	rs6488864	chr12:123618362	G/C	cg05973401	chr12:123451056	ABCB9	0.56	5.27	0.33	3.04e-7	Neutrophil percentage of white cells;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg06347499	chr1:9599419	SLC25A33	0.52	7.3	0.43	4.4e-12	Tetralogy of Fallot;
SARC	cis	rs6088580	0.609	rs2378205	chr20:33110803	C/G	cg08999081	chr20:33150536	PIGU	0.45	6.92	0.41	4.39e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs1448094	0.512	rs56082822	chr12:86255475	C/T	cg02569458	chr12:86230093	RASSF9	0.38	5.3	0.33	2.7e-7	Major depressive disorder;
SARC	cis	rs611744	0.625	rs6469168	chr8:109288399	G/T	cg21045802	chr8:109455806	TTC35	0.67	8.58	0.49	1.32e-15	Dupuytren's disease;
SARC	cis	rs4660306	0.633	rs1771549	chr1:45896779	G/A	cg24296786	chr1:45957014	TESK2	-0.48	-4.73	-0.3	3.84e-6	Homocysteine levels;
SARC	cis	rs9788682	1.000	rs7181447	chr15:78814567	A/G	cg06917634	chr15:78832804	PSMA4	-0.58	-6.68	-0.4	1.73e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs79149102	0.579	rs7173218	chr15:75315328	A/G	cg17294928	chr15:75287854	SCAMP5	-1.01	-9.39	-0.52	5.56e-18	Lung cancer;
SARC	cis	rs910316	1.000	rs175442	chr14:75603564	T/C	cg08847533	chr14:75593920	NEK9	-0.87	-14.02	-0.68	8.89e-33	Height;
SARC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg09033563	chr22:24373618	LOC391322	-0.43	-5.25	-0.33	3.34e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs3931020	0.688	rs277374	chr1:75200486	G/A	cg10128416	chr1:75198403	TYW3;CRYZ	-0.48	-5.01	-0.31	1.07e-6	Resistin levels;
SARC	cis	rs6815814	0.950	rs11725779	chr4:38811668	G/A	cg02016764	chr4:38805732	TLR1	-0.41	-4.86	-0.3	2.18e-6	Breast cancer;
SARC	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg13699009	chr12:122356056	WDR66	-0.59	-9.48	-0.53	2.99e-18	Mean corpuscular volume;
SARC	cis	rs910316	0.503	rs12894709	chr14:75441734	G/A	cg06637938	chr14:75390232	RPS6KL1	0.55	7.33	0.43	3.85e-12	Height;
SARC	cis	rs2477686	0.526	rs1998759	chr1:2397174	C/T	cg11214544	chr1:2391121	NA	-0.31	-4.85	-0.3	2.23e-6	Non-obstructive azoospermia;
SARC	cis	rs11155671	0.530	rs9397398	chr6:150193603	G/A	cg00933542	chr6:150070202	PCMT1	0.3	4.78	0.3	3.04e-6	Testicular germ cell tumor;
SARC	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10875746	0.556	rs4760619	chr12:48499931	A/T	cg26205652	chr12:48591994	NA	0.56	5.17	0.32	5.03e-7	Longevity (90 years and older);
SARC	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg13939156	chr17:80058883	NA	0.4	6.22	0.38	2.23e-9	Life satisfaction;
SARC	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg20965017	chr5:231967	SDHA	-0.55	-5.26	-0.33	3.23e-7	Breast cancer;
SARC	trans	rs1814175	0.817	rs4881623	chr11:49804991	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-17.99	-0.76	6.09e-46	Height;
SARC	cis	rs6426558	0.502	rs1929858	chr1:227220175	C/A	cg10327440	chr1:227177885	CDC42BPA	0.43	5.09	0.32	7.33e-7	Neutrophil percentage of white cells;
SARC	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	10.24	0.56	1.52e-20	Platelet count;
SARC	cis	rs3126085	0.877	rs3126055	chr1:152266364	G/A	cg03465714	chr1:152285911	FLG	0.46	5.51	0.34	9.56e-8	Atopic dermatitis;
SARC	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg02931644	chr1:25747376	RHCE	0.43	6.98	0.42	3.08e-11	Plateletcrit;Mean corpuscular volume;
SARC	cis	rs2228479	0.850	rs17233567	chr16:89813821	G/A	cg00800038	chr16:89945340	TCF25	-0.74	-5.1	-0.32	7.19e-7	Skin colour saturation;
SARC	cis	rs6991838	0.584	rs66467166	chr8:66486400	C/A	cg13398993	chr8:66546079	ARMC1	-0.62	-8.36	-0.48	5.88e-15	Intelligence (multi-trait analysis);
SARC	cis	rs1153858	1.000	rs11858495	chr15:45637662	A/G	cg03999130	chr15:45571217	NA	-0.44	-5.56	-0.34	7.27e-8	Homoarginine levels;
SARC	cis	rs2290159	0.747	rs6777175	chr3:12646255	A/T	cg23032965	chr3:12705835	RAF1	0.74	7.99	0.46	6.38e-14	Cholesterol, total;
SARC	cis	rs9303401	0.659	rs12150536	chr17:56640834	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	11.65	0.61	5.15e-25	Cognitive test performance;
SARC	trans	rs1853207	1.000	rs9332147	chr10:96722552	T/C	cg02737782	chr1:8014393	NA	-0.89	-6.4	-0.39	8.69e-10	Blood metabolite levels;
SARC	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg24209194	chr3:40518798	ZNF619	0.67	8.08	0.47	3.58e-14	Renal cell carcinoma;
SARC	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg15966229	chr18:44337664	ST8SIA5	-0.37	-4.86	-0.3	2.15e-6	Personality dimensions;
SARC	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg18135555	chr8:22132992	PIWIL2	0.4	6.12	0.37	3.86e-9	Hypertriglyceridemia;
SARC	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg27266027	chr21:40555129	PSMG1	-0.44	-4.87	-0.3	2.05e-6	Cognitive function;
SARC	cis	rs4664308	0.935	rs6731260	chr2:160977769	A/G	cg03641300	chr2:160917029	PLA2R1	-0.7	-9.49	-0.53	2.77e-18	Idiopathic membranous nephropathy;
SARC	cis	rs7512552	0.839	rs2867894	chr1:150452912	T/A	cg15654264	chr1:150340011	RPRD2	0.38	4.84	0.3	2.38e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs9290065	0.519	rs6763532	chr3:160701816	G/A	cg03342759	chr3:160939853	NMD3	-0.49	-5.94	-0.36	1.01e-8	Kawasaki disease;
SARC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg05552183	chr6:42928497	GNMT	0.59	7.93	0.46	8.88e-14	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs11098499	0.954	rs17006190	chr4:120418838	C/G	cg09307838	chr4:120376055	NA	0.93	12.73	0.64	1.6e-28	Corneal astigmatism;
SARC	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg18357526	chr6:26021779	HIST1H4A	0.6	6.86	0.41	6.11e-11	Intelligence (multi-trait analysis);
SARC	cis	rs11792861	0.926	rs7856626	chr9:111775502	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.67	7.72	0.45	3.46e-13	Menarche (age at onset);
SARC	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg19223190	chr17:80058835	NA	0.48	6.49	0.39	5.09e-10	Life satisfaction;
SARC	cis	rs611744	0.967	rs595266	chr8:109193784	A/G	cg21045802	chr8:109455806	TTC35	0.44	5.3	0.33	2.63e-7	Dupuytren's disease;
SARC	trans	rs1814175	0.676	rs1721999	chr11:49917372	A/G	cg03929089	chr4:120376271	NA	-0.81	-11.69	-0.61	3.89e-25	Height;
SARC	cis	rs524281	0.861	rs7124165	chr11:65901218	C/T	cg14036092	chr11:66035641	RAB1B	-0.51	-5.22	-0.32	3.99e-7	Electroencephalogram traits;
SARC	trans	rs61931739	0.749	rs7315233	chr12:34271975	G/T	cg26384229	chr12:38710491	ALG10B	0.6	7.92	0.46	9.95e-14	Morning vs. evening chronotype;
SARC	trans	rs7395662	0.570	rs11039737	chr11:48450200	G/A	cg15704280	chr7:45808275	SEPT13	-0.49	-6.62	-0.4	2.38e-10	HDL cholesterol;
SARC	cis	rs72781680	0.898	rs7569424	chr2:24036222	A/G	cg08917208	chr2:24149416	ATAD2B	0.78	7.32	0.43	3.96e-12	Lymphocyte counts;
SARC	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.53	8.15	0.47	2.22e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs2295359	1.000	rs4655682	chr1:67610967	C/T	cg03340356	chr1:67600835	NA	0.34	4.99	0.31	1.18e-6	Psoriasis;
SARC	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg00149659	chr3:10157352	C3orf10	0.69	6.58	0.4	3.1e-10	Alzheimer's disease;
SARC	cis	rs13256369	0.708	rs11783670	chr8:8559394	G/A	cg17143192	chr8:8559678	CLDN23	0.52	5.81	0.36	2.07e-8	Obesity-related traits;
SARC	cis	rs7681440	0.904	rs2870029	chr4:90772057	G/T	cg02192967	chr4:90758406	SNCA	0.37	5.26	0.33	3.22e-7	Dementia with Lewy bodies;
SARC	cis	rs16976116	0.901	rs7165491	chr15:55500455	A/C	cg11288833	chr15:55489084	RSL24D1	0.58	5.57	0.34	6.88e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1007738	0.542	rs11603373	chr11:47203245	C/T	cg03339077	chr11:47165057	C11orf49	0.42	5.03	0.31	9.64e-7	Bone mineral density (hip);
SARC	cis	rs9914544	0.545	rs4290526	chr17:18772967	T/C	cg25390199	chr17:18761479	PRPSAP2	0.43	5.67	0.35	4.11e-8	Educational attainment (years of education);
SARC	cis	rs7551222	0.752	rs4951407	chr1:204558070	G/T	cg20240347	chr1:204465584	NA	0.26	4.72	0.3	4.11e-6	Schizophrenia;
SARC	cis	rs9814567	1.000	rs7645295	chr3:134307734	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.05	-0.42	2.01e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs365132	1.000	rs1700490	chr5:176402401	G/A	cg16309518	chr5:176445507	NA	-0.45	-5.91	-0.36	1.2e-8	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg06221963	chr1:154839813	KCNN3	0.51	8.22	0.47	1.47e-14	Prostate cancer;
SARC	cis	rs9660992	0.710	rs1668869	chr1:205239779	G/C	cg00857998	chr1:205179979	DSTYK	0.52	6.33	0.38	1.28e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg24250549	chr1:154909240	PMVK	0.83	12.38	0.63	2.18e-27	Prostate cancer;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg22200633	chr11:6651263	DCHS1	0.5	6.28	0.38	1.66e-9	Schizophrenia;
SARC	cis	rs7587476	0.906	rs17487827	chr2:215644335	C/G	cg11970703	chr2:215861251	ABCA12	-0.36	-5.31	-0.33	2.62e-7	Neuroblastoma;
SARC	cis	rs7223966	0.881	rs3020608	chr17:61979993	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.5	-4.89	-0.31	1.89e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.13	0.37	3.78e-9	Prudent dietary pattern;
SARC	cis	rs9309473	0.861	rs6546857	chr2:73837955	A/G	cg20560298	chr2:73613845	ALMS1	-0.49	-5.91	-0.36	1.19e-8	Metabolite levels;
SARC	cis	rs17867775	0.623	rs11563761	chr7:126695508	A/G	cg02090654	chr7:126698344	MIR592;GRM8	0.57	4.82	0.3	2.59e-6	Anti-saccade response;
SARC	cis	rs7103648	0.669	rs10437655	chr11:47391948	G/A	cg20307385	chr11:47447363	PSMC3	0.84	13.07	0.65	1.18e-29	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs1670533	1.000	rs6599279	chr4:1058833	G/A	cg27284194	chr4:1044797	NA	0.48	5.03	0.31	9.65e-7	Recombination rate (females);
SARC	cis	rs1707322	0.648	rs4439382	chr1:46150805	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.25	0.38	1.89e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg16145915	chr7:1198662	ZFAND2A	-0.49	-8.13	-0.47	2.49e-14	Longevity;Endometriosis;
SARC	cis	rs501120	1.000	rs554565	chr10:44755448	G/A	cg09554077	chr10:44749378	NA	0.48	6.67	0.4	1.85e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs2043112	0.728	rs11750346	chr5:38968584	A/C	cg04869206	chr5:39074266	RICTOR	0.52	6.39	0.39	8.91e-10	Obesity-related traits;
SARC	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg05313129	chr8:58192883	C8orf71	-0.62	-6.34	-0.38	1.18e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.7	9.58	0.53	1.49e-18	Menarche (age at onset);
SARC	cis	rs8072100	0.640	rs3851808	chr17:45425144	C/T	cg08085267	chr17:45401833	C17orf57	-0.44	-5.14	-0.32	5.77e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs1580019	0.563	rs2392071	chr7:32572536	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.52	6.83	0.41	7.25e-11	Cognitive ability;
SARC	cis	rs17376456	1.000	rs66978370	chr5:93553633	G/A	cg25358565	chr5:93447407	FAM172A	1.35	14.25	0.68	1.48e-33	Diabetic retinopathy;
SARC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg11494091	chr17:61959527	GH2	0.54	8.19	0.47	1.67e-14	Prudent dietary pattern;
SARC	cis	rs9393692	0.840	rs9358915	chr6:26277268	G/A	cg00631329	chr6:26305371	NA	-0.58	-8.36	-0.48	5.54e-15	Educational attainment;
SARC	cis	rs765787	0.530	rs4775822	chr15:45527127	A/G	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.81e-6	Uric acid levels;
SARC	cis	rs7647973	0.593	rs1799844	chr3:49847642	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.61	-5.76	-0.35	2.68e-8	Menarche (age at onset);
SARC	cis	rs2760061	0.583	rs1774757	chr1:228211135	C/G	cg01200585	chr1:228362443	C1orf69	0.44	5.51	0.34	9.46e-8	Diastolic blood pressure;
SARC	cis	rs2075371	1.000	rs2598297	chr7:133993001	T/G	cg11752832	chr7:134001865	SLC35B4	0.58	7.44	0.44	1.91e-12	Mean platelet volume;
SARC	cis	rs7412746	0.658	rs4970982	chr1:150865084	G/C	cg10589385	chr1:150898437	SETDB1	0.42	5.64	0.35	4.91e-8	Melanoma;
SARC	cis	rs2033732	0.706	rs7826406	chr8:85061639	G/A	cg05716166	chr8:85095498	RALYL	0.47	5.62	0.35	5.51e-8	Body mass index;
SARC	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg22133161	chr19:49891603	CCDC155	0.43	4.81	0.3	2.67e-6	Multiple sclerosis;
SARC	cis	rs1371867	0.846	rs1660347	chr8:101314980	G/A	cg11906718	chr8:101322791	RNF19A	0.71	9.02	0.51	7.17e-17	Atrioventricular conduction;
SARC	cis	rs7666738	0.515	rs13434650	chr4:98889886	A/G	cg05340658	chr4:99064831	C4orf37	0.58	7.14	0.42	1.17e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9815354	1.000	rs9856088	chr3:41860482	G/T	cg03022575	chr3:42003672	ULK4	0.58	5.41	0.33	1.59e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs7552404	0.924	rs3818855	chr1:76198785	C/T	cg10523679	chr1:76189770	ACADM	0.5	6.96	0.41	3.48e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7647973	1.000	rs7648995	chr3:49438803	C/T	cg07636037	chr3:49044803	WDR6	-0.75	-8.18	-0.47	1.88e-14	Menarche (age at onset);
SARC	cis	rs10779751	0.770	rs11121691	chr1:11181327	C/T	cg08854313	chr1:11322531	MTOR	-0.77	-10.11	-0.55	3.67e-20	Body mass index;
SARC	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg11764359	chr7:65958608	NA	-0.78	-9.41	-0.52	4.86e-18	Aortic root size;
SARC	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg19223190	chr17:80058835	NA	-0.45	-6.19	-0.38	2.66e-9	Life satisfaction;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg08589981	chr10:22977154	PIP4K2A	0.57	8.11	0.47	2.87e-14	Thyroid stimulating hormone;
SARC	cis	rs17600642	0.672	rs17600546	chr10:72457933	T/G	cg18679544	chr10:72432482	ADAMTS14	0.46	4.86	0.3	2.14e-6	Bipolar disorder;
SARC	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg18252515	chr7:66147081	NA	-0.63	-6.76	-0.41	1.07e-10	Aortic root size;
SARC	cis	rs4253772	0.530	rs9615958	chr22:46751122	A/G	cg24881330	chr22:46731750	TRMU	0.69	5.15	0.32	5.66e-7	LDL cholesterol;Cholesterol, total;
SARC	cis	rs3862030	0.810	rs5870	chr10:104239100	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.46	-6.03	-0.37	6.38e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
SARC	cis	rs7582720	1.000	rs115654617	chr2:203893999	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	7.24	0.43	6.55e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg22920501	chr2:26401640	FAM59B	-0.55	-7.11	-0.42	1.43e-11	Gut microbiome composition (summer);
SARC	trans	rs61931739	0.500	rs11053211	chr12:34464334	T/C	cg26384229	chr12:38710491	ALG10B	0.84	12.43	0.63	1.46e-27	Morning vs. evening chronotype;
SARC	cis	rs1018836	0.892	rs4140680	chr8:91584157	G/A	cg16814680	chr8:91681699	NA	-0.75	-11.17	-0.59	1.8e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg06074448	chr4:187884817	NA	-0.38	-5.18	-0.32	4.83e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9341808	0.538	rs9443742	chr6:81016929	T/G	cg08355045	chr6:80787529	NA	-0.33	-5.01	-0.31	1.06e-6	Sitting height ratio;
SARC	cis	rs7937682	0.593	rs1944117	chr11:111351184	T/C	cg09085632	chr11:111637200	PPP2R1B	0.43	5.04	0.31	9.52e-7	Primary sclerosing cholangitis;
SARC	cis	rs6570726	0.791	rs401331	chr6:145831408	A/G	cg05347473	chr6:146136440	FBXO30	0.55	7.45	0.44	1.76e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3008870	1.000	rs2755256	chr1:67471692	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.91	11.08	0.59	3.49e-23	Lymphocyte percentage of white cells;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg25741567	chr21:35747810	FAM165B	0.53	6.37	0.39	1.01e-9	Blood pressure;
SARC	cis	rs734999	0.566	rs12748729	chr1:2558740	C/T	cg20673091	chr1:2541236	MMEL1	-0.32	-4.98	-0.31	1.23e-6	Ulcerative colitis;
SARC	cis	rs1008375	1.000	rs3733579	chr4:17694943	A/G	cg27347728	chr4:17578864	LAP3	0.44	5.42	0.33	1.48e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2816062	0.775	rs2816046	chr1:18893708	A/G	cg10574377	chr1:18908098	NA	0.35	5.01	0.31	1.09e-6	Urate levels in lean individuals;
SARC	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg09359103	chr1:154839909	KCNN3	-0.46	-7.73	-0.45	3.23e-13	Prostate cancer;
SARC	cis	rs3858526	0.883	rs11039584	chr11:5935251	C/G	cg13902645	chr11:5959945	NA	-0.45	-5.3	-0.33	2.66e-7	DNA methylation (variation);
SARC	cis	rs6005807	0.588	rs16986177	chr22:28629713	C/T	cg02153584	chr22:29168773	CCDC117	0.52	4.74	0.3	3.67e-6	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
SARC	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg16479474	chr6:28041457	NA	0.36	5.25	0.33	3.43e-7	Depression;
SARC	cis	rs8114671	0.836	rs13042358	chr20:33634479	G/A	cg24642439	chr20:33292090	TP53INP2	-0.51	-5.99	-0.37	8.05e-9	Height;
SARC	trans	rs2727020	0.573	rs7925419	chr11:49231859	C/T	cg15704280	chr7:45808275	SEPT13	-0.63	-8.7	-0.5	6.16e-16	Coronary artery disease;
SARC	cis	rs9815354	1.000	rs1125203	chr3:41760895	T/C	cg03022575	chr3:42003672	ULK4	0.55	5.23	0.32	3.75e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs7659604	0.540	rs10007956	chr4:122700669	A/T	cg19671926	chr4:122722719	EXOSC9	0.66	8.81	0.5	2.84e-16	Type 2 diabetes;
SARC	cis	rs56330463	0.967	rs11168068	chr5:148204121	C/T	cg21580376	chr5:148206412	ADRB2	0.4	5.52	0.34	8.83e-8	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Monocyte percentage of white cells;Eosinophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;
SARC	cis	rs4563143	0.514	rs73029079	chr19:29294903	A/G	cg04546413	chr19:29218101	NA	0.59	7.0	0.42	2.75e-11	Methadone dose in opioid dependence;
SARC	cis	rs9462027	0.583	rs11755420	chr6:34760956	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.85	-0.36	1.63e-8	Systemic lupus erythematosus;
SARC	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg16325326	chr1:53192061	ZYG11B	0.93	18.47	0.77	1.57e-47	Monocyte count;
SARC	cis	rs2228479	0.850	rs17226966	chr16:89825338	A/G	cg06558623	chr16:89946397	TCF25	0.89	6.23	0.38	2.14e-9	Skin colour saturation;
SARC	cis	rs1843834	0.624	rs2396110	chr2:225560219	A/G	cg22455342	chr2:225449267	CUL3	0.49	5.96	0.36	9.39e-9	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg24209194	chr3:40518798	ZNF619	0.65	7.97	0.46	7.13e-14	Renal cell carcinoma;
SARC	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg11062466	chr8:58055876	NA	0.52	5.39	0.33	1.74e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs722599	0.715	rs11851433	chr14:75339450	C/T	cg08847533	chr14:75593920	NEK9	0.42	4.89	0.31	1.88e-6	IgG glycosylation;
SARC	cis	rs13161895	1.000	rs4700853	chr5:179473328	G/A	cg02702477	chr5:179499311	RNF130	0.65	6.2	0.38	2.6e-9	LDL cholesterol;
SARC	cis	rs3796352	1.000	rs35737577	chr3:53002557	G/C	cg12962167	chr3:53033115	SFMBT1	0.73	4.82	0.3	2.55e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs17381785	1.000	rs17381785	chr4:14918968	T/C	cg18497811	chr4:14860861	NA	0.49	5.01	0.31	1.07e-6	Urate levels in overweight individuals;
SARC	cis	rs4865169	0.934	rs3796531	chr4:57850846	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.51	-6.48	-0.39	5.48e-10	Breast cancer;
SARC	cis	rs6831352	0.918	rs35784540	chr4:100061692	T/A	cg12011299	chr4:100065546	ADH4	-0.34	-5.67	-0.35	4.2e-8	Alcohol dependence;
SARC	cis	rs801193	0.742	rs9969300	chr7:65781646	G/A	cg11987759	chr7:65425863	GUSB	0.57	7.22	0.43	7.25e-12	Aortic root size;
SARC	cis	rs12142240	0.738	rs41293275	chr1:46806429	A/T	cg10495392	chr1:46806563	NSUN4	0.65	6.9	0.41	4.99e-11	Menopause (age at onset);
SARC	cis	rs73320584	0.518	rs1936614	chr10:92434957	C/T	cg14313238	chr10:92632228	RPP30	0.66	6.54	0.39	3.95e-10	Alzheimer disease and age of onset;
SARC	cis	rs60871478	0.947	rs62432866	chr7:809281	T/G	cg05535760	chr7:792225	HEATR2	0.79	8.17	0.47	1.91e-14	Cerebrospinal P-tau181p levels;
SARC	cis	rs9394841	0.667	rs3747749	chr6:41770604	G/A	cg08135965	chr6:41755394	TOMM6	0.62	6.55	0.39	3.7e-10	Mean corpuscular hemoglobin;Red cell distribution width;
SARC	cis	rs2635047	0.601	rs2576057	chr18:44644127	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	6.38	0.39	9.47e-10	Educational attainment;
SARC	cis	rs13082711	1.000	rs6791212	chr3:27507179	C/A	cg02860705	chr3:27208620	NA	0.46	5.85	0.36	1.64e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg13206674	chr6:150067644	NUP43	0.42	5.42	0.33	1.5e-7	Lung cancer;
SARC	cis	rs9362426	0.895	rs242292	chr6:88078074	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.4	4.84	0.3	2.4e-6	Depressive episodes in bipolar disorder;
SARC	cis	rs6570726	0.791	rs443628	chr6:145883484	T/C	cg05347473	chr6:146136440	FBXO30	0.54	7.48	0.44	1.48e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg05025164	chr4:1340916	KIAA1530	-0.45	-5.34	-0.33	2.2e-7	Obesity-related traits;
SARC	cis	rs2204008	0.837	rs7301679	chr12:37989629	T/C	cg13010199	chr12:38710504	ALG10B	-0.65	-8.71	-0.5	5.89e-16	Bladder cancer;
SARC	cis	rs9902453	0.808	rs78154346	chr17:28169493	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	7.16	0.42	1.07e-11	Coffee consumption (cups per day);
SARC	cis	rs7524258	0.835	rs75096060	chr1:7270248	G/C	cg07173049	chr1:7289937	CAMTA1	0.34	6.72	0.4	1.36e-10	Tourette's syndrome or obsessive-compulsive disorder;
SARC	cis	rs362296	0.698	rs3095081	chr4:3263776	C/T	cg06533319	chr4:3265114	C4orf44	0.36	5.75	0.35	2.83e-8	Parental longevity (mother's age at death);
SARC	cis	rs981844	1.000	rs17298985	chr4:154664261	C/T	cg14289246	chr4:154710475	SFRP2	0.57	6.32	0.38	1.31e-9	Response to statins (LDL cholesterol change);
SARC	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg18252515	chr7:66147081	NA	0.56	5.86	0.36	1.55e-8	Aortic root size;
SARC	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg00990874	chr7:1149470	C7orf50	-0.61	-6.43	-0.39	7.32e-10	Bronchopulmonary dysplasia;
SARC	cis	rs17270561	0.609	rs4712961	chr6:25727334	C/T	cg17691542	chr6:26056736	HIST1H1C	0.58	7.09	0.42	1.59e-11	Iron status biomarkers;
SARC	cis	rs7089973	0.628	rs11196953	chr10:116607707	A/G	cg03647239	chr10:116582469	FAM160B1	0.5	6.49	0.39	5.19e-10	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg06618935	chr21:46677482	NA	-0.38	-5.13	-0.32	6.19e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg14950044	chr20:49457327	BCAS4	-0.48	-6.3	-0.38	1.49e-9	Chemerin levels;
SARC	cis	rs7395581	0.918	rs61896050	chr11:47309063	T/C	cg25783544	chr11:47291846	MADD	0.49	5.54	0.34	8e-8	HDL cholesterol;
SARC	cis	rs1153858	1.000	rs1820518	chr15:45694579	C/T	cg15395560	chr15:45543142	SLC28A2	-0.27	-4.91	-0.31	1.74e-6	Homoarginine levels;
SARC	cis	rs13082711	0.596	rs683503	chr3:27348094	C/T	cg02860705	chr3:27208620	NA	0.51	6.74	0.4	1.2e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs3784262	0.771	rs4775005	chr15:58208165	C/T	cg12031962	chr15:58353849	ALDH1A2	0.38	5.55	0.34	7.71e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg06636001	chr8:8085503	FLJ10661	-0.6	-7.71	-0.45	3.64e-13	Mood instability;
SARC	cis	rs854765	0.647	rs854767	chr17:18018263	A/C	cg05444541	chr17:17804740	TOM1L2	0.32	5.3	0.33	2.73e-7	Total body bone mineral density;
SARC	cis	rs17376456	0.877	rs12374488	chr5:93481407	A/G	cg25358565	chr5:93447407	FAM172A	1.36	14.0	0.68	1.04e-32	Diabetic retinopathy;
SARC	cis	rs1568889	1.000	rs7102106	chr11:28343953	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.72	9.55	0.53	1.91e-18	Bipolar disorder;
SARC	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg06028605	chr16:24865363	SLC5A11	-0.35	-5.22	-0.32	3.88e-7	Intelligence (multi-trait analysis);
SARC	cis	rs950027	0.572	rs12910764	chr15:45609360	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.48	-5.85	-0.36	1.62e-8	Response to fenofibrate (adiponectin levels);
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg13279019	chr7:5266987	WIPI2	0.5	6.58	0.4	3.05e-10	Schizophrenia;
SARC	cis	rs986417	0.818	rs8005621	chr14:61106699	G/A	cg27398547	chr14:60952738	C14orf39	0.76	7.19	0.43	8.88e-12	Gut microbiota (bacterial taxa);
SARC	cis	rs651907	0.737	rs9844218	chr3:101584983	C/T	cg12386194	chr3:101231763	SENP7	-0.42	-4.81	-0.3	2.7e-6	Colorectal cancer;
SARC	cis	rs7528684	0.565	rs10908587	chr1:157643579	G/A	cg18268488	chr1:157545234	FCRL4	0.26	4.76	0.3	3.41e-6	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;
SARC	cis	rs3936840	1.000	rs3936840	chr14:102984274	G/C	cg18135206	chr14:102964638	TECPR2	0.52	6.69	0.4	1.67e-10	Plateletcrit;
SARC	cis	rs9640161	0.830	rs3735165	chr7:150068371	T/C	cg17279839	chr7:150038598	RARRES2	0.37	6.07	0.37	5.24e-9	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs4642101	0.793	rs13320486	chr3:12822069	C/A	cg05775895	chr3:12838266	CAND2	0.75	11.88	0.61	9.18e-26	QRS complex (12-leadsum);
SARC	cis	rs1878931	0.597	rs37814	chr16:3455247	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.68	-7.5	-0.44	1.34e-12	Body mass index (adult);
SARC	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	12.18	0.62	9.58e-27	Personality dimensions;
SARC	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg22920501	chr2:26401640	FAM59B	-0.55	-7.33	-0.43	3.78e-12	Gut microbiome composition (summer);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg05585810	chr3:152880101	RAP2B	-0.77	-6.37	-0.39	9.99e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg26335602	chr6:28129616	ZNF389	0.51	5.55	0.34	7.63e-8	Parkinson's disease;
SARC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.41	4.8	0.3	2.83e-6	Prudent dietary pattern;
SARC	cis	rs6087771	0.650	rs6060395	chr20:30219823	G/C	cg13852791	chr20:30311386	BCL2L1	0.7	6.99	0.42	2.79e-11	Subcortical brain region volumes;Putamen volume;
SARC	cis	rs2011503	1.000	rs75525243	chr19:19638218	G/A	cg15839431	chr19:19639596	YJEFN3	-0.48	-4.77	-0.3	3.32e-6	Bipolar disorder;
SARC	cis	rs73206853	0.698	rs1018134	chr12:111121119	G/A	cg10860002	chr12:110842031	ANAPC7	0.58	5.03	0.31	9.89e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs7647973	0.626	rs12715437	chr3:49751856	T/C	cg13072238	chr3:49761600	GMPPB	-0.61	-6.26	-0.38	1.81e-9	Menarche (age at onset);
SARC	cis	rs11098499	0.738	rs28687057	chr4:120280812	A/G	cg09307838	chr4:120376055	NA	0.83	11.82	0.61	1.46e-25	Corneal astigmatism;
SARC	cis	rs2404602	0.647	rs12910820	chr15:77022825	T/C	cg15268244	chr15:77196840	NA	0.43	4.99	0.31	1.19e-6	Blood metabolite levels;
SARC	cis	rs78487399	0.808	rs75126888	chr2:43664007	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.65	-5.79	-0.35	2.27e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs9581943	0.967	rs8000004	chr13:28477590	A/G	cg17352152	chr13:28491409	NA	0.37	5.02	0.31	1.03e-6	Pancreatic cancer;
SARC	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg19223190	chr17:80058835	NA	-0.43	-6.02	-0.37	6.57e-9	Life satisfaction;
SARC	cis	rs1707322	1.000	rs7526369	chr1:46390560	G/C	cg03146154	chr1:46216737	IPP	0.46	5.54	0.34	7.97e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2153535	0.541	rs6932434	chr6:8467679	G/A	cg07606381	chr6:8435919	SLC35B3	0.77	10.83	0.58	2.14e-22	Motion sickness;
SARC	trans	rs1814175	0.754	rs10839453	chr11:49955815	A/T	cg15704280	chr7:45808275	SEPT13	-0.98	-18.59	-0.77	6.51e-48	Height;
SARC	cis	rs2933343	0.649	rs1683786	chr3:128626952	T/C	cg24203234	chr3:128598194	ACAD9	0.65	8.37	0.48	5.51e-15	IgG glycosylation;
SARC	cis	rs11997175	0.574	rs872489	chr8:33646401	T/C	ch.8.33884649F	chr8:33765107	NA	0.5	6.62	0.4	2.44e-10	Body mass index;
SARC	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg18876405	chr7:65276391	NA	0.47	5.67	0.35	4.11e-8	Aortic root size;
SARC	cis	rs10504073	0.647	rs62507247	chr8:50013554	T/G	cg00325661	chr8:49890786	NA	0.54	7.3	0.43	4.46e-12	Blood metabolite ratios;
SARC	cis	rs10791323	0.582	rs2851120	chr11:133708065	A/G	cg14349672	chr11:133703707	NA	-0.37	-5.42	-0.33	1.47e-7	Childhood ear infection;
SARC	cis	rs2404602	0.716	rs67888330	chr15:76752483	A/G	cg22467129	chr15:76604101	ETFA	-0.37	-4.92	-0.31	1.6e-6	Blood metabolite levels;
SARC	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg25072359	chr17:41440525	NA	0.48	5.62	0.35	5.43e-8	Menopause (age at onset);
SARC	cis	rs1971762	0.563	rs7975862	chr12:54078427	A/C	cg06632207	chr12:54070931	ATP5G2	-0.46	-6.02	-0.37	6.67e-9	Height;
SARC	cis	rs4595586	0.525	rs6580891	chr12:39370127	C/T	cg26384229	chr12:38710491	ALG10B	0.51	6.25	0.38	1.9e-9	Morning vs. evening chronotype;
SARC	cis	rs17376456	0.877	rs34595581	chr5:93369422	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.68	0.35	3.93e-8	Diabetic retinopathy;
SARC	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.98	-16.12	-0.73	9.07e-40	Chronic sinus infection;
SARC	cis	rs9815354	1.000	rs9863915	chr3:41762002	G/A	cg03022575	chr3:42003672	ULK4	0.55	5.23	0.32	3.75e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg08348990	chr13:110425835	IRS2	0.69	5.21	0.32	4.08e-7	Obesity-related traits;
SARC	cis	rs4803468	1.000	rs4674	chr19:41930396	A/G	cg08477640	chr19:41863820	B9D2	0.44	5.53	0.34	8.62e-8	Height;
SARC	cis	rs6570726	1.000	rs404229	chr6:145868200	G/A	cg05347473	chr6:146136440	FBXO30	0.48	6.5	0.39	4.96e-10	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs747334	0.846	rs7897603	chr10:92708759	C/G	cg23486345	chr6:99797485	C6orf168	-0.47	-6.37	-0.39	1.02e-9	Fibroblast growth factor basic levels;
SARC	cis	rs11190604	0.767	rs7085426	chr10:102163640	T/C	cg07080220	chr10:102295463	HIF1AN	0.69	7.57	0.44	8.81e-13	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs2180341	1.000	rs13218061	chr6:127653758	G/A	cg24812749	chr6:127587940	RNF146	0.98	13.14	0.65	7.1e-30	Breast cancer;
SARC	cis	rs854765	0.547	rs7223696	chr17:17915791	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.64	9.45	0.53	3.79e-18	Total body bone mineral density;
SARC	cis	rs2425143	1.000	rs11696369	chr20:34378629	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	5.17	0.32	5.14e-7	Blood protein levels;
SARC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-4.93	-0.31	1.59e-6	Total body bone mineral density;
SARC	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg22875332	chr1:76189707	ACADM	0.63	10.19	0.56	2.14e-20	Blood metabolite levels;Acylcarnitine levels;
SARC	trans	rs10771431	0.817	rs10843149	chr12:9362067	G/A	cg27600084	chr12:12264075	NA	0.58	7.86	0.46	1.39e-13	Breast size;
SARC	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg15049968	chr18:44337910	ST8SIA5	-0.34	-5.24	-0.32	3.58e-7	Personality dimensions;
SARC	cis	rs7264396	0.635	rs6060660	chr20:34476649	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	5.5	0.34	9.86e-8	Total cholesterol levels;
SARC	cis	rs2806561	0.765	rs681395	chr1:23500314	G/A	cg12483005	chr1:23474871	LUZP1	0.42	5.52	0.34	9.12e-8	Height;
SARC	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg02725872	chr8:58115012	NA	-0.35	-6.23	-0.38	2.18e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs870825	0.616	rs12498890	chr4:185636096	C/G	cg04058563	chr4:185651563	MLF1IP	-0.82	-11.1	-0.59	2.88e-23	Blood protein levels;
SARC	cis	rs611744	0.901	rs639746	chr8:109234825	T/C	cg21045802	chr8:109455806	TTC35	0.46	5.43	0.34	1.38e-7	Dupuytren's disease;
SARC	cis	rs4803468	1.000	rs284651	chr19:41928336	T/C	cg14132834	chr19:41945861	ATP5SL	-0.57	-7.49	-0.44	1.45e-12	Height;
SARC	cis	rs9916302	0.904	rs4794814	chr17:37696852	G/A	cg00129232	chr17:37814104	STARD3	-0.64	-7.78	-0.45	2.37e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs35213789	0.762	rs55662212	chr7:69177428	A/G	cg10619644	chr7:69149951	AUTS2	-0.35	-4.78	-0.3	3.16e-6	Childhood ear infection;
SARC	cis	rs4727027	0.901	rs34201592	chr7:148842403	C/G	cg23583168	chr7:148888333	NA	-0.74	-10.98	-0.58	7.02e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs1707322	1.000	rs12124847	chr1:46380850	T/A	cg06784218	chr1:46089804	CCDC17	0.36	6.33	0.38	1.27e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs12908161	1.000	rs36033486	chr15:85319692	A/G	cg17507749	chr15:85114479	UBE2QP1	0.54	6.2	0.38	2.61e-9	Schizophrenia;
SARC	cis	rs7582720	0.943	rs72932559	chr2:203847382	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg19223190	chr17:80058835	NA	-0.45	-6.19	-0.38	2.66e-9	Life satisfaction;
SARC	cis	rs4808199	0.895	rs7252888	chr19:19628037	C/T	cg03709012	chr19:19516395	GATAD2A	1.21	14.04	0.68	7.53e-33	Nonalcoholic fatty liver disease;
SARC	trans	rs1814175	0.817	rs11518158	chr11:49985633	G/T	cg03929089	chr4:120376271	NA	-0.89	-14.59	-0.69	1.1e-34	Height;
SARC	trans	rs61931739	0.817	rs11053125	chr12:34265417	C/T	cg26384229	chr12:38710491	ALG10B	0.59	7.75	0.45	2.76e-13	Morning vs. evening chronotype;
SARC	cis	rs3617	0.573	rs4687682	chr3:52916939	T/C	cg05564831	chr3:52568323	NT5DC2	-0.29	-5.01	-0.31	1.07e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg25365783	chr7:108166722	PNPLA8	-0.57	-6.41	-0.39	7.99e-10	Brain volume in infants (cerebrospinal fluid);
SARC	trans	rs1814175	0.562	rs1794130	chr11:49903764	T/A	cg15704280	chr7:45808275	SEPT13	-0.88	-13.97	-0.68	1.24e-32	Height;
SARC	cis	rs2120019	1.000	rs7167285	chr15:75368769	A/G	cg17294928	chr15:75287854	SCAMP5	-0.9	-13.28	-0.66	2.39e-30	Blood trace element (Zn levels);
SARC	cis	rs6582630	0.512	rs11182667	chr12:38588392	C/A	cg14851346	chr12:38532713	NA	-0.44	-5.32	-0.33	2.43e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg11890956	chr21:40555474	PSMG1	-0.69	-9.11	-0.51	3.92e-17	Menarche (age at onset);
SARC	cis	rs16854884	1.000	rs58251824	chr3:143786258	T/C	cg06585982	chr3:143692056	C3orf58	0.57	7.16	0.42	1.08e-11	Economic and political preferences (feminism/equality);
SARC	cis	rs7772486	0.686	rs1292334	chr6:145968288	A/G	cg05347473	chr6:146136440	FBXO30	0.53	7.27	0.43	5.25e-12	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs12310956	0.510	rs1386936	chr12:33875369	G/A	cg13010199	chr12:38710504	ALG10B	0.57	7.5	0.44	1.32e-12	Morning vs. evening chronotype;
SARC	cis	rs11122272	0.735	rs2250749	chr1:231485763	C/G	cg06096015	chr1:231504339	EGLN1	0.36	5.43	0.34	1.39e-7	Hemoglobin concentration;
SARC	cis	rs9393692	1.000	rs2393593	chr6:26285683	T/C	cg00631329	chr6:26305371	NA	-0.65	-8.99	-0.51	8.84e-17	Educational attainment;
SARC	trans	rs1814175	0.645	rs11040535	chr11:49808669	C/T	cg03929089	chr4:120376271	NA	-0.84	-12.32	-0.63	3.43e-27	Height;
SARC	cis	rs6920965	0.507	rs9385388	chr6:126215296	C/T	cg05901451	chr6:126070800	HEY2	-0.49	-6.05	-0.37	5.61e-9	High light scatter reticulocyte count;
SARC	trans	rs561341	0.941	rs4625780	chr17:30249214	A/C	cg20587970	chr11:113659929	NA	-1.0	-9.86	-0.54	2.13e-19	Hip circumference adjusted for BMI;
SARC	cis	rs13191362	0.935	rs116735807	chr6:163010615	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.56	5.35	0.33	2.07e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	trans	rs61931739	0.500	rs4436630	chr12:34394200	C/T	cg26384229	chr12:38710491	ALG10B	0.84	12.77	0.64	1.2e-28	Morning vs. evening chronotype;
SARC	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg08859206	chr1:53392774	SCP2	0.39	5.57	0.34	7.13e-8	Monocyte count;
SARC	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg16405210	chr4:1374714	KIAA1530	0.71	8.7	0.5	6.13e-16	Obesity-related traits;
SARC	cis	rs4727027	0.933	rs12667123	chr7:148850621	G/A	cg23583168	chr7:148888333	NA	-0.74	-11.03	-0.59	4.73e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	trans	rs7615952	0.932	rs7630077	chr3:125649676	T/C	cg07211511	chr3:129823064	LOC729375	-0.94	-10.6	-0.57	1.13e-21	Blood pressure (smoking interaction);
SARC	cis	rs6500395	0.735	rs7204345	chr16:48666726	T/C	cg04672837	chr16:48644449	N4BP1	0.41	5.59	0.34	6.41e-8	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs9660992	0.710	rs1768586	chr1:205238275	A/G	cg00857998	chr1:205179979	DSTYK	0.5	6.21	0.38	2.35e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg08975724	chr8:8085496	FLJ10661	0.67	8.99	0.51	8.45e-17	Mood instability;
SARC	cis	rs9916302	0.904	rs2338798	chr17:37547269	T/C	cg07936489	chr17:37558343	FBXL20	0.67	8.89	0.5	1.69e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs9747201	0.832	rs4072580	chr17:80160337	A/C	cg17462356	chr17:80056334	FASN	-0.44	-4.94	-0.31	1.49e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	9.08	0.51	4.67e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs568617	1.000	rs687672	chr11:65649984	T/C	cg00576331	chr11:65640516	EFEMP2	0.47	5.46	0.34	1.22e-7	Crohn's disease;
SARC	cis	rs854765	0.663	rs4925120	chr17:17754633	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.6	-8.82	-0.5	2.74e-16	Total body bone mineral density;
SARC	cis	rs1008375	0.966	rs3733576	chr4:17586703	T/C	cg27347728	chr4:17578864	LAP3	0.53	6.47	0.39	5.62e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7216064	1.000	rs2128792	chr17:65857177	C/T	cg12091567	chr17:66097778	LOC651250	-0.64	-6.45	-0.39	6.56e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg26335602	chr6:28129616	ZNF389	0.53	5.88	0.36	1.43e-8	Depression;
SARC	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg18876405	chr7:65276391	NA	-0.74	-9.42	-0.53	4.63e-18	Aortic root size;
SARC	cis	rs4268898	0.722	rs10445893	chr2:24407128	A/G	cg06627628	chr2:24431161	ITSN2	0.54	7.21	0.43	7.9e-12	Asthma;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg03273382	chr1:205782342	SLC41A1	0.49	6.32	0.38	1.32e-9	Lung adenocarcinoma;
SARC	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg13628971	chr7:2884303	GNA12	0.48	5.3	0.33	2.66e-7	Height;
SARC	cis	rs12701220	0.894	rs10263252	chr7:1049949	G/A	cg02733842	chr7:1102375	C7orf50	-0.6	-7.14	-0.42	1.17e-11	Bronchopulmonary dysplasia;
SARC	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg06618935	chr21:46677482	NA	-0.37	-4.89	-0.31	1.85e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs526231	0.511	rs17155009	chr5:102374144	C/T	cg23492399	chr5:102201601	PAM	-0.52	-5.62	-0.35	5.55e-8	Primary biliary cholangitis;
SARC	cis	rs10162002	1.000	rs73449251	chr13:24042272	C/T	cg00158254	chr13:24040743	NA	0.51	4.89	0.31	1.86e-6	Hypothyroidism;
SARC	cis	rs796364	0.901	rs13030683	chr2:201061535	C/T	cg23649088	chr2:200775458	C2orf69	0.66	7.33	0.43	3.87e-12	Schizophrenia;
SARC	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.41	4.94	0.31	1.52e-6	Tonsillectomy;
SARC	cis	rs55823223	0.564	rs9894009	chr17:73850414	C/T	cg06969265	chr17:73775802	H3F3B	0.48	5.31	0.33	2.6e-7	Psoriasis;
SARC	cis	rs6964587	1.000	rs11981461	chr7:91692662	A/G	cg17063962	chr7:91808500	NA	0.96	16.21	0.73	4.33e-40	Breast cancer;
SARC	cis	rs1505368	0.567	rs972491	chr2:213316573	A/G	cg20637307	chr2:213403960	ERBB4	-0.5	-6.5	-0.39	4.86e-10	Symmetrical dimethylarginine levels;
SARC	cis	rs11673344	0.566	rs1545755	chr19:37981509	A/T	cg14683738	chr19:37701593	ZNF585B	-0.43	-5.08	-0.32	7.67e-7	Obesity-related traits;
SARC	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg11890956	chr21:40555474	PSMG1	-0.71	-9.26	-0.52	1.41e-17	Menarche (age at onset);
SARC	cis	rs2985684	0.894	rs10147029	chr14:50020232	G/T	cg04989706	chr14:50066350	PPIL5	0.49	5.48	0.34	1.1e-7	Carotid intima media thickness;
SARC	cis	rs2153535	0.601	rs7741024	chr6:8530313	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	10.6	0.57	1.12e-21	Motion sickness;
SARC	cis	rs13191362	1.000	rs35818596	chr6:163001874	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.57	5.38	0.33	1.85e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs61823972	0.510	rs11240351	chr1:205044339	C/T	cg21643547	chr1:205240462	TMCC2	-0.46	-6.01	-0.37	7.24e-9	Immature fraction of reticulocytes;Mean corpuscular volume;Mean corpuscular hemoglobin;Mean corpuscular hemoglobin concentration;High light scatter reticulocyte count;
SARC	trans	rs1853207	1.000	rs76110720	chr10:96641794	A/C	cg02737782	chr1:8014393	NA	-0.97	-6.42	-0.39	7.44e-10	Blood metabolite levels;
SARC	cis	rs2732480	0.557	rs2409004	chr12:48721451	T/C	cg21466736	chr12:48725269	NA	-0.31	-4.82	-0.3	2.63e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs11214589	0.651	rs12360992	chr11:113262900	A/C	cg14159747	chr11:113255604	NA	0.37	5.29	0.33	2.83e-7	Neuroticism;
SARC	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs9858542	0.953	rs10640	chr3:49454277	G/A	cg21659725	chr3:3221576	CRBN	-0.55	-6.29	-0.38	1.58e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs12421382	0.558	rs12422001	chr11:109391880	A/G	cg27471124	chr11:109292789	C11orf87	0.4	5.46	0.34	1.23e-7	Schizophrenia;
SARC	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg24531977	chr5:56204891	C5orf35	-0.54	-5.45	-0.34	1.26e-7	Initial pursuit acceleration;
SARC	cis	rs10425738	0.830	rs12459565	chr19:41427539	G/C	cg17435250	chr19:41386441	CYP2A7	-0.42	-4.8	-0.3	2.78e-6	nicotine metabolite ratio in current smokers;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
SARC	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg09323728	chr8:95962352	TP53INP1	-0.29	-4.92	-0.31	1.66e-6	Type 2 diabetes;
SARC	cis	rs2204008	0.623	rs1663281	chr12:38120936	A/G	cg14851346	chr12:38532713	NA	-0.44	-5.33	-0.33	2.32e-7	Bladder cancer;
SARC	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	12.03	0.62	3.06e-26	Chronic sinus infection;
SARC	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg25894440	chr7:65020034	NA	-0.73	-5.54	-0.34	8.11e-8	Diabetic kidney disease;
SARC	cis	rs3733585	0.631	rs7699671	chr4:10125874	C/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-6.87	-0.41	5.71e-11	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs6977660	0.507	rs28402966	chr7:19774469	A/C	cg07541023	chr7:19748670	TWISTNB	0.93	8.12	0.47	2.77e-14	Thyroid stimulating hormone;
SARC	trans	rs7922314	0.571	rs61865718	chr10:64740407	C/A	cg25304107	chr2:177017331	HOXD4	-0.86	-6.68	-0.4	1.71e-10	Cutaneous psoriasis;
SARC	cis	rs4243830	0.850	rs4434862	chr1:6602241	C/A	cg04093404	chr1:6614507	TAS1R1;NOL9	0.57	5.09	0.32	7.24e-7	Body mass index;
SARC	cis	rs708547	0.676	rs11133470	chr4:57864926	G/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.44	-5.44	-0.34	1.37e-7	Response to bleomycin (chromatid breaks);
SARC	cis	rs10504229	0.679	rs4737454	chr8:58033965	A/T	cg21724239	chr8:58056113	NA	0.61	6.37	0.38	1.02e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9733	0.650	rs12125672	chr1:150554470	A/T	cg18016565	chr1:150552671	MCL1	-0.4	-5.48	-0.34	1.12e-7	Tonsillectomy;
SARC	cis	rs10752881	1.000	rs6658501	chr1:182991417	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.68	-10.17	-0.55	2.41e-20	Colorectal cancer;
SARC	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg12311346	chr5:56204834	C5orf35	-0.58	-6.01	-0.37	7.24e-9	Initial pursuit acceleration;
SARC	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg11890956	chr21:40555474	PSMG1	-1.06	-16.1	-0.73	1.07e-39	Cognitive function;
SARC	cis	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg22857025	chr5:266934	NA	-1.07	-11.83	-0.61	1.32e-25	Breast cancer;
SARC	cis	rs7546668	0.640	rs4661635	chr1:15808702	C/T	cg21858823	chr1:15850916	CASP9	0.49	5.93	0.36	1.1e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs9436747	0.626	rs17412723	chr1:65952741	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	-0.46	-5.55	-0.34	7.78e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs7592578	0.679	rs62181019	chr2:191325414	A/G	cg25963032	chr2:191064776	C2orf88	-0.45	-5.2	-0.32	4.42e-7	Diastolic blood pressure;
SARC	cis	rs11697848	1.000	rs74928591	chr20:48521878	A/C	cg17849948	chr20:48532315	SPATA2	0.86	5.17	0.32	4.97e-7	Systemic lupus erythematosus;
SARC	cis	rs4780401	0.609	rs4781141	chr16:11808769	A/C	cg01061890	chr16:11836724	TXNDC11	-0.61	-8.7	-0.5	6.01e-16	Rheumatoid arthritis;
SARC	cis	rs1153858	1.000	rs7181167	chr15:45686236	C/G	cg26924012	chr15:45694286	SPATA5L1	0.78	10.65	0.57	7.65e-22	Homoarginine levels;
SARC	cis	rs79839061	0.610	rs34006051	chr4:847445	C/T	cg07828340	chr4:882639	GAK	0.74	5.52	0.34	9.1e-8	Intelligence (multi-trait analysis);
SARC	cis	rs10992471	0.702	rs10120915	chr9:95547725	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-5.89	-0.36	1.37e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs6725517	0.737	rs7576788	chr2:25083310	A/G	cg04586622	chr2:25135609	ADCY3	0.32	5.74	0.35	2.93e-8	Breast cancer;
SARC	cis	rs7945705	0.902	rs10769979	chr11:9010659	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.45	6.12	0.37	4.01e-9	Hemoglobin concentration;
SARC	cis	rs6752107	1.000	rs2289474	chr2:234181848	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.46	6.24	0.38	1.99e-9	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs796364	0.806	rs203765	chr2:200903020	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.66	-5.45	-0.34	1.27e-7	Schizophrenia;
SARC	trans	rs36093844	0.800	rs1445504	chr11:85584879	G/A	cg27065003	chr5:122429449	PRDM6	-0.55	-6.46	-0.39	5.9e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs11585357	0.947	rs11585119	chr1:17605792	C/A	cg08277548	chr1:17600880	PADI3	-0.5	-5.47	-0.34	1.18e-7	Hair shape;
SARC	cis	rs11098499	0.691	rs10010355	chr4:120261043	A/G	cg09307838	chr4:120376055	NA	0.75	10.4	0.56	4.7e-21	Corneal astigmatism;
SARC	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg04267008	chr7:1944627	MAD1L1	-0.52	-5.99	-0.37	8.09e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.95	13.96	0.67	1.32e-32	Gut microbiome composition (summer);
SARC	cis	rs6910061	0.830	rs9468435	chr6:11112486	G/A	cg27233058	chr6:11094804	LOC221710	0.59	5.38	0.33	1.81e-7	Diabetic kidney disease;
SARC	cis	rs1045902	0.574	rs1474298	chr2:73466592	C/T	cg06642617	chr2:73461528	CCT7;C2orf7	0.39	4.73	0.3	3.82e-6	Intelligence (multi-trait analysis);
SARC	trans	rs10519937	0.935	rs60153933	chr5:126739427	A/G	cg26526953	chr19:1921199	SCAMP4	0.6	6.26	0.38	1.79e-9	IgG glycosylation;
SARC	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg16405210	chr4:1374714	KIAA1530	-0.52	-6.01	-0.37	6.93e-9	Obesity-related traits;
SARC	trans	rs12967884	0.892	rs907284	chr18:76564163	A/G	cg10946435	chr1:154843044	KCNN3	0.57	6.31	0.38	1.38e-9	Subcutaneous adipose tissue;
SARC	trans	rs10506458	1.000	rs73127086	chr12:63415626	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.72	-6.63	-0.4	2.3e-10	Hemostatic factors and hematological phenotypes;
SARC	cis	rs6088590	1.000	rs1998028	chr20:33344595	A/T	cg06115741	chr20:33292138	TP53INP2	0.57	6.96	0.41	3.41e-11	Coronary artery disease;
SARC	cis	rs35306767	0.903	rs11253462	chr10:889323	T/G	cg20503657	chr10:835505	NA	0.8	7.94	0.46	8.64e-14	Eosinophil percentage of granulocytes;
SARC	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg10207240	chr12:122356781	WDR66	0.36	6.02	0.37	6.57e-9	Mean corpuscular volume;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg07875825	chr17:7210680	EIF5A	0.48	6.25	0.38	1.93e-9	Electrocardiographic conduction measures;
SARC	cis	rs71636778	0.543	rs113002196	chr1:27200156	T/C	cg04852280	chr1:26496234	ZNF593	0.53	4.89	0.3	1.91e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg16479474	chr6:28041457	NA	0.36	5.36	0.33	1.97e-7	Depression;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg01866022	chr22:29199247	NA	-0.47	-6.33	-0.38	1.24e-9	Electrocardiographic conduction measures;
SARC	cis	rs10089	1.000	rs4836370	chr5:127499224	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.79	9.74	0.54	5.03e-19	Ileal carcinoids;
SARC	cis	rs4141404	0.923	rs2413035	chr22:31600460	A/G	cg02404636	chr22:31891804	SFI1	-0.48	-5.02	-0.31	1.01e-6	Paclitaxel-induced neuropathy;
SARC	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg18252515	chr7:66147081	NA	0.52	5.53	0.34	8.49e-8	Aortic root size;
SARC	cis	rs11098499	0.908	rs2017057	chr4:120257711	A/G	cg09160332	chr4:120329925	NA	-0.34	-4.85	-0.3	2.21e-6	Corneal astigmatism;
SARC	cis	rs9790314	0.613	rs6799160	chr3:160634889	A/G	cg04691961	chr3:161091175	C3orf57	0.59	7.97	0.46	7.12e-14	Morning vs. evening chronotype;
SARC	cis	rs4919087	1.000	rs7076523	chr10:99089296	T/C	cg25902810	chr10:99078978	FRAT1	-0.46	-5.69	-0.35	3.71e-8	Monocyte count;
SARC	cis	rs918629	0.679	rs58921760	chr5:95270865	A/C	cg16656078	chr5:95278638	ELL2	-0.62	-7.45	-0.44	1.78e-12	IgG glycosylation;
SARC	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.68	8.61	0.49	1.09e-15	Gut microbiome composition (summer);
SARC	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg19223190	chr17:80058835	NA	-0.4	-5.45	-0.34	1.3e-7	Life satisfaction;
SARC	cis	rs4727027	0.870	rs11524138	chr7:148799125	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.47	5.61	0.35	5.67e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg20607798	chr8:58055168	NA	0.57	5.48	0.34	1.12e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1865760	0.929	rs9461224	chr6:25936402	G/T	cg03595861	chr6:26126282	NA	-0.46	-5.4	-0.33	1.66e-7	Height;
SARC	cis	rs10766496	1.000	rs4261259	chr11:18737952	A/C	cg10955973	chr11:19366714	NA	-0.42	-4.72	-0.3	3.98e-6	Diabetic kidney disease;
SARC	cis	rs1865760	0.964	rs1324084	chr6:25915134	C/T	cg16482183	chr6:26056742	HIST1H1C	0.5	6.15	0.37	3.38e-9	Height;
SARC	cis	rs6542838	0.641	rs4553869	chr2:99505940	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.39	-4.73	-0.3	3.81e-6	Fear of minor pain;
SARC	cis	rs12367572	1.000	rs10880704	chr12:45318430	C/T	cg04608330	chr12:45269318	NELL2	-0.46	-5.71	-0.35	3.5e-8	Gut microbiome composition (summer);
SARC	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs780094	0.585	rs7586601	chr2:27584666	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.32	-4.83	-0.3	2.47e-6	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs4819052	0.679	rs2838860	chr21:46684904	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.53	6.44	0.39	6.81e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs933688	0.532	rs10072084	chr5:90539203	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.46	5.22	0.32	3.96e-7	Smoking behavior;
SARC	cis	rs262150	0.567	rs2040897	chr7:158803848	C/T	cg19418458	chr7:158789849	NA	-0.46	-6.41	-0.39	8.09e-10	Facial morphology (factor 20);
SARC	cis	rs7412746	0.611	rs752376	chr1:150941381	C/T	cg13175981	chr1:150552382	MCL1	-0.53	-6.41	-0.39	7.98e-10	Melanoma;
SARC	cis	rs8064299	0.560	rs11077763	chr17:72786029	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.79	10.65	0.57	7.89e-22	Monocyte count;
SARC	cis	rs240764	0.658	rs7740006	chr6:101220432	T/C	cg09795085	chr6:101329169	ASCC3	-0.44	-5.64	-0.35	4.85e-8	Neuroticism;
SARC	trans	rs61931739	0.500	rs7312938	chr12:34378708	C/T	cg13010199	chr12:38710504	ALG10B	0.8	11.24	0.59	1.09e-23	Morning vs. evening chronotype;
SARC	cis	rs240764	0.853	rs10457808	chr6:100979506	A/T	cg09795085	chr6:101329169	ASCC3	-0.48	-6.32	-0.38	1.35e-9	Neuroticism;
SARC	cis	rs4619890	0.528	rs62289339	chr4:7878981	C/G	cg18538662	chr4:7941764	AFAP1	-0.37	-4.76	-0.3	3.39e-6	Glaucoma (primary open-angle);
SARC	trans	rs61931739	0.517	rs10844830	chr12:34308133	C/T	cg26384229	chr12:38710491	ALG10B	0.75	10.79	0.58	2.83e-22	Morning vs. evening chronotype;
SARC	cis	rs986417	0.818	rs1254325	chr14:60909689	A/G	cg27398547	chr14:60952738	C14orf39	-0.87	-8.51	-0.49	2.09e-15	Gut microbiota (bacterial taxa);
SARC	cis	rs9858542	0.953	rs3811697	chr3:49590770	C/T	cg03060546	chr3:49711283	APEH	-0.61	-7.78	-0.45	2.3e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs6831352	0.877	rs2602890	chr4:100043179	C/T	cg13256891	chr4:100009986	ADH5	0.66	8.34	0.48	6.55e-15	Alcohol dependence;
SARC	cis	rs3733585	0.657	rs62286568	chr4:10124889	C/T	cg11266682	chr4:10021025	SLC2A9	-0.38	-6.02	-0.37	6.58e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs6582630	0.638	rs35864536	chr12:38472255	T/A	cg14851346	chr12:38532713	NA	-0.46	-5.58	-0.34	6.64e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7208859	0.673	rs9891413	chr17:29208209	G/C	cg13385521	chr17:29058706	SUZ12P	0.86	7.34	0.43	3.54e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs10779751	0.734	rs2791647	chr1:11132801	G/A	cg08854313	chr1:11322531	MTOR	0.82	11.29	0.59	7.2e-24	Body mass index;
SARC	cis	rs57506017	0.585	rs12667950	chr7:12268468	G/T	cg23422036	chr7:12250390	TMEM106B	0.45	5.87	0.36	1.46e-8	Neuroticism;
SARC	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg26039829	chr8:22132926	PIWIL2	0.47	6.77	0.41	1.05e-10	Hypertriglyceridemia;
SARC	cis	rs7959452	0.503	rs7300266	chr12:69654187	A/G	cg22834771	chr12:69754056	YEATS4	-0.42	-5.68	-0.35	4.02e-8	Blood protein levels;
SARC	cis	rs9527	0.615	rs7917295	chr10:104701187	A/G	cg04362960	chr10:104952993	NT5C2	0.4	4.72	0.3	4.08e-6	Arsenic metabolism;
SARC	cis	rs644799	0.511	rs12791736	chr11:95475399	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	9.15	0.51	3.05e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs34421088	0.559	rs12386974	chr8:11400628	C/G	cg08975724	chr8:8085496	FLJ10661	0.56	7.54	0.44	1.03e-12	Neuroticism;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg03903647	chr4:40058344	N4BP2;LOC344967	0.51	6.93	0.41	4.11e-11	Thyroid stimulating hormone;
SARC	trans	rs3780486	0.846	rs7864705	chr9:33140352	A/C	cg20290983	chr6:43655470	MRPS18A	1.13	22.55	0.83	1.71e-60	IgG glycosylation;
SARC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	10.55	0.57	1.57e-21	Prudent dietary pattern;
SARC	cis	rs2153535	0.580	rs4960433	chr6:8523697	A/G	cg07606381	chr6:8435919	SLC35B3	0.76	11.05	0.59	4.36e-23	Motion sickness;
SARC	cis	rs734999	0.588	rs745368	chr1:2524205	C/T	cg00980319	chr1:2560884	MMEL1	-0.35	-4.95	-0.31	1.41e-6	Ulcerative colitis;
SARC	cis	rs6598955	0.670	rs6663950	chr1:26560131	T/C	cg04990556	chr1:26633338	UBXN11	-0.6	-8.39	-0.48	4.78e-15	Obesity-related traits;
SARC	cis	rs1008375	0.966	rs4698638	chr4:17632988	G/C	cg02297831	chr4:17616191	MED28	0.49	6.31	0.38	1.39e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6918586	0.658	rs198826	chr6:26121153	A/G	cg18357526	chr6:26021779	HIST1H4A	0.43	5.23	0.32	3.75e-7	Schizophrenia;
SARC	cis	rs7937682	0.558	rs7113067	chr11:111692182	G/A	cg22437258	chr11:111473054	SIK2	-0.49	-5.73	-0.35	3.11e-8	Primary sclerosing cholangitis;
SARC	cis	rs7264396	0.690	rs2425165	chr20:34438059	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.51	5.08	0.32	7.84e-7	Total cholesterol levels;
SARC	cis	rs66887589	0.967	rs1155577	chr4:120449810	C/T	cg09307838	chr4:120376055	NA	-0.51	-7.06	-0.42	1.93e-11	Diastolic blood pressure;
SARC	cis	rs7959452	0.535	rs1350166	chr12:69636314	G/T	cg20891283	chr12:69753455	YEATS4	0.4	5.26	0.33	3.2e-7	Blood protein levels;
SARC	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	10.7	0.57	5.58e-22	Platelet count;
SARC	cis	rs10493773	0.609	rs10873716	chr1:86178347	G/T	cg17807903	chr1:86174739	ZNHIT6	-0.61	-9.96	-0.55	1.1e-19	Urate levels in overweight individuals;
SARC	cis	rs739401	0.572	rs739400	chr11:3016520	G/A	cg05729581	chr11:3078854	CARS	-0.52	-6.92	-0.41	4.44e-11	Longevity;
SARC	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.43	-5.38	-0.33	1.82e-7	Lymphocyte counts;
SARC	cis	rs1691799	0.867	rs1168311	chr12:66725912	A/C	cg16791601	chr12:66731901	HELB	0.73	11.06	0.59	3.83e-23	White blood cell count (basophil);
SARC	cis	rs501120	0.929	rs605425	chr10:44750669	T/C	cg09554077	chr10:44749378	NA	0.46	6.42	0.39	7.38e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg22903657	chr4:1355424	KIAA1530	-0.35	-4.96	-0.31	1.36e-6	Longevity;
SARC	cis	rs55883249	1.000	rs17453752	chr2:9766171	C/T	cg23886495	chr2:9695866	ADAM17	-0.67	-6.91	-0.41	4.56e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs3768617	0.510	rs4651143	chr1:183097398	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.2	0.56	1.95e-20	Fuchs's corneal dystrophy;
SARC	cis	rs10911363	0.549	rs2794619	chr1:183459670	G/A	cg09173681	chr1:183549694	NCF2	0.31	4.99	0.31	1.17e-6	Systemic lupus erythematosus;
SARC	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg07701084	chr6:150067640	NUP43	0.41	5.29	0.33	2.81e-7	Lung cancer;
SARC	cis	rs17021463	0.902	rs62320439	chr4:95248721	G/C	cg11021082	chr4:95130006	SMARCAD1	0.42	6.29	0.38	1.55e-9	Testicular germ cell tumor;
SARC	cis	rs9341808	0.667	rs2505944	chr6:80888410	T/C	cg08355045	chr6:80787529	NA	0.37	5.91	0.36	1.18e-8	Sitting height ratio;
SARC	cis	rs2073499	0.872	rs2282751	chr3:50291785	A/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	-0.52	-6.8	-0.41	8.71e-11	Schizophrenia;
SARC	cis	rs2652822	0.530	rs7165016	chr15:63439590	T/A	cg02713581	chr15:63449717	RPS27L	0.49	5.49	0.34	1.03e-7	Metabolic traits;
SARC	cis	rs644799	0.511	rs10831420	chr11:95478209	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.57	6.91	0.41	4.7e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs3812831	0.629	rs7318527	chr13:114946956	C/T	cg08824895	chr13:115047677	UPF3A	0.56	7.65	0.45	5.12e-13	Schizophrenia;
SARC	cis	rs7772486	0.738	rs2246334	chr6:146183635	G/A	cg23711669	chr6:146136114	FBXO30	0.85	14.48	0.69	2.64e-34	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs763121	0.853	rs2267395	chr22:39113903	C/T	cg21395723	chr22:39101663	GTPBP1	0.56	6.77	0.41	1.03e-10	Menopause (age at onset);
SARC	cis	rs13191362	1.000	rs35723993	chr6:163008197	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.56	5.35	0.33	2.07e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg19223190	chr17:80058835	NA	-0.43	-6.02	-0.37	6.57e-9	Life satisfaction;
SARC	cis	rs7615952	0.599	rs12486459	chr3:125741465	T/G	cg15145296	chr3:125709740	NA	-0.5	-4.97	-0.31	1.28e-6	Blood pressure (smoking interaction);
SARC	cis	rs6867913	1.000	rs12519447	chr5:141457161	G/A	cg15672022	chr5:141805772	NA	-0.35	-5.02	-0.31	1.03e-6	Asthma;
SARC	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg12064134	chr16:90016061	DEF8	-0.57	-4.76	-0.3	3.38e-6	Skin colour saturation;
SARC	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg07701084	chr6:150067640	NUP43	0.41	5.44	0.34	1.32e-7	Lung cancer;
SARC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg05064044	chr6:292385	DUSP22	-0.55	-7.06	-0.42	1.87e-11	Menopause (age at onset);
SARC	cis	rs2075371	0.829	rs35897155	chr7:134002711	G/A	cg11752832	chr7:134001865	SLC35B4	0.56	6.88	0.41	5.48e-11	Mean platelet volume;
SARC	cis	rs8014204	0.541	rs35591392	chr14:75157713	G/T	cg06637938	chr14:75390232	RPS6KL1	0.57	8.17	0.47	1.95e-14	Caffeine consumption;
SARC	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg18357526	chr6:26021779	HIST1H4A	0.45	5.71	0.35	3.49e-8	Blood metabolite levels;
SARC	cis	rs2991971	0.967	rs12133294	chr1:45988764	C/T	cg24296786	chr1:45957014	TESK2	0.64	9.17	0.51	2.57e-17	High light scatter reticulocyte count;
SARC	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg08859206	chr1:53392774	SCP2	-0.43	-6.03	-0.37	6.23e-9	Monocyte count;
SARC	cis	rs7208859	0.573	rs8078656	chr17:29080971	A/T	cg13385521	chr17:29058706	SUZ12P	0.88	7.75	0.45	2.9e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg08677398	chr8:58056175	NA	0.42	5.07	0.32	8.07e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs17030434	0.784	rs8180349	chr4:154657038	T/C	cg14289246	chr4:154710475	SFRP2	-0.52	-5.96	-0.36	9.18e-9	Electrocardiographic conduction measures;
SARC	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg18404041	chr3:52824283	ITIH1	-0.38	-5.68	-0.35	3.93e-8	Bipolar disorder;
SARC	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg25072359	chr17:41440525	NA	0.51	6.13	0.37	3.66e-9	Menopause (age at onset);
SARC	cis	rs796364	0.951	rs36086821	chr2:201067436	G/A	cg05691004	chr2:201170426	SPATS2L	-0.46	-5.12	-0.32	6.37e-7	Schizophrenia;
SARC	cis	rs796364	1.000	rs11694369	chr2:200741720	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-5.98	-0.37	8.13e-9	Schizophrenia;
SARC	cis	rs10791323	0.593	rs2282604	chr11:133714672	A/G	cg15485101	chr11:133734466	NA	0.32	5.07	0.32	7.99e-7	Childhood ear infection;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg18803079	chr1:64014643	EFCAB7;DLEU2L	-0.76	-6.25	-0.38	1.93e-9	Autism spectrum disorder or schizophrenia;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg23936098	chr10:103911881	NOLC1	0.5	6.54	0.39	3.94e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs11792861	0.926	rs72607174	chr9:111899132	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.68	7.62	0.45	6.51e-13	Menarche (age at onset);
SARC	cis	rs2013441	1.000	rs2526490	chr17:20097526	A/G	cg13482628	chr17:19912719	NA	-0.48	-6.16	-0.37	3.1e-9	Obesity-related traits;
SARC	cis	rs7712401	0.601	rs187405	chr5:122294995	G/A	cg19412675	chr5:122181750	SNX24	0.4	5.13	0.32	5.98e-7	Mean platelet volume;
SARC	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg08859206	chr1:53392774	SCP2	-0.42	-6.22	-0.38	2.33e-9	Monocyte count;
SARC	cis	rs7223966	1.000	rs7217982	chr17:61832150	C/T	cg00588841	chr17:61851480	DDX42;CCDC47	-0.68	-7.59	-0.45	7.54e-13	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1790761	0.520	rs1551884	chr11:67399601	C/G	cg23188684	chr11:67383651	NA	-0.43	-5.72	-0.35	3.29e-8	Mean corpuscular volume;
SARC	cis	rs55728055	0.661	rs73162106	chr22:32034875	A/G	cg01338084	chr22:32026380	PISD	1.01	6.07	0.37	5.2e-9	Age-related hearing impairment;
SARC	cis	rs9814567	0.702	rs9871226	chr3:134331466	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.51	-6.61	-0.4	2.53e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs9911578	0.692	rs412000	chr17:56709058	G/C	cg05425664	chr17:57184151	TRIM37	-0.53	-6.52	-0.39	4.26e-10	Intelligence (multi-trait analysis);
SARC	cis	rs9486715	1.000	rs7752277	chr6:97065131	C/T	cg18709589	chr6:96969512	KIAA0776	-0.56	-7.0	-0.42	2.76e-11	Headache;
SARC	cis	rs9896052	0.591	rs7212620	chr17:73461930	A/T	cg14668889	chr17:73230827	NUP85	-0.39	-5.0	-0.31	1.11e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs6728642	0.519	rs62152905	chr2:97572222	C/T	cg26665480	chr2:98280029	ACTR1B	-0.64	-5.46	-0.34	1.19e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg13206674	chr6:150067644	NUP43	0.52	6.71	0.4	1.49e-10	Lung cancer;
SARC	cis	rs9790314	1.000	rs6765269	chr3:160948542	T/C	cg03342759	chr3:160939853	NMD3	-0.61	-7.76	-0.45	2.65e-13	Morning vs. evening chronotype;
SARC	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg11764359	chr7:65958608	NA	-0.74	-9.41	-0.52	4.85e-18	Aortic root size;
SARC	cis	rs15676	0.812	rs10819447	chr9:131576416	T/G	cg00228799	chr9:131580591	ENDOG	0.59	7.33	0.43	3.82e-12	Blood metabolite levels;
SARC	cis	rs7829975	0.582	rs6983150	chr8:8792426	A/G	cg08975724	chr8:8085496	FLJ10661	-0.41	-4.93	-0.31	1.6e-6	Mood instability;
SARC	cis	rs3733585	0.699	rs6449171	chr4:9965998	C/T	cg11266682	chr4:10021025	SLC2A9	0.37	6.2	0.38	2.56e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs6991838	0.557	rs4737222	chr8:66500113	G/T	cg13398993	chr8:66546079	ARMC1	-0.62	-8.31	-0.48	7.89e-15	Intelligence (multi-trait analysis);
SARC	cis	rs634534	0.622	rs552130	chr11:65732800	T/C	cg04055107	chr11:65626734	MUS81;CFL1	0.44	5.63	0.35	5.16e-8	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs9858542	0.953	rs9859556	chr3:49455986	G/T	cg07274523	chr3:49395745	GPX1	0.51	5.93	0.36	1.07e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs929354	0.742	rs886677	chr7:157003782	T/A	cg05182265	chr7:156933206	UBE3C	-0.31	-4.84	-0.3	2.41e-6	Body mass index;
SARC	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg20607798	chr8:58055168	NA	0.59	5.58	0.34	6.82e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6963495	0.818	rs73192120	chr7:105171156	C/T	cg19920283	chr7:105172520	RINT1	0.67	5.76	0.35	2.59e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs10504229	0.679	rs1442125	chr8:58036258	A/C	cg22535103	chr8:58192502	C8orf71	0.53	5.2	0.32	4.36e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg24360745	chr7:105112740	PUS7	0.46	6.26	0.38	1.88e-9	Thyroid stimulating hormone;
SARC	cis	rs6693567	0.545	rs1932934	chr1:150449195	G/A	cg09579323	chr1:150459698	TARS2	0.45	5.78	0.35	2.38e-8	Migraine;
SARC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg13397359	chr6:42928475	GNMT	0.56	7.8	0.46	2.06e-13	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs4481887	0.927	rs4244173	chr1:248466899	G/C	cg13385794	chr1:248469461	NA	0.34	5.08	0.32	7.66e-7	Common traits (Other);
SARC	cis	rs858239	0.539	rs4365988	chr7:23190871	T/C	cg23682824	chr7:23144976	KLHL7	0.74	9.66	0.53	8.86e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs7772486	0.790	rs9376970	chr6:146241472	A/C	cg05347473	chr6:146136440	FBXO30	-0.5	-6.78	-0.41	9.82e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs60752752	0.852	rs4845541	chr1:153360678	A/T	cg26882115	chr1:153603048	S100A1;S100A13	-0.66	-5.0	-0.31	1.15e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs6840360	0.533	rs13121190	chr4:152729072	T/G	cg22705602	chr4:152727874	NA	0.48	8.55	0.49	1.68e-15	Intelligence (multi-trait analysis);
SARC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.0	12.26	0.63	5.27e-27	Platelet count;
SARC	cis	rs7951870	0.560	rs3136505	chr11:46759571	A/G	cg03339077	chr11:47165057	C11orf49	0.4	5.09	0.32	7.23e-7	Schizophrenia;
SARC	cis	rs6912958	0.630	rs4707377	chr6:88280332	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.43	-0.34	1.42e-7	Monocyte percentage of white cells;
SARC	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-10.53	-0.57	1.88e-21	Chronic sinus infection;
SARC	trans	rs3780486	0.813	rs3780488	chr9:33133812	T/C	cg04842962	chr6:43655489	MRPS18A	1.1	19.86	0.79	5.07e-52	IgG glycosylation;
SARC	trans	rs1814175	0.935	rs7479914	chr11:49661351	T/C	cg15704280	chr7:45808275	SEPT13	-0.92	-16.3	-0.73	2.2e-40	Height;
SARC	cis	rs1003719	0.715	rs2835649	chr21:38552230	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.66	9.35	0.52	7.64e-18	Eye color traits;
SARC	cis	rs45430	0.928	rs398206	chr21:42742036	C/A	cg22778903	chr21:42741698	MX2	0.37	5.0	0.31	1.13e-6	Melanoma;
SARC	cis	rs7312774	0.618	rs12316476	chr12:107343326	C/G	cg16260113	chr12:107380972	MTERFD3	0.93	7.65	0.45	5.22e-13	Severe influenza A (H1N1) infection;
SARC	cis	rs6570726	0.846	rs426874	chr6:145880630	A/C	cg05347473	chr6:146136440	FBXO30	0.51	7.21	0.43	7.86e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs8031584	0.958	rs34294266	chr15:31246840	A/G	cg19680485	chr15:31195859	MTMR15	-0.53	-6.1	-0.37	4.28e-9	Huntington's disease progression;
SARC	cis	rs35110281	0.806	rs1454649	chr21:45032982	C/T	cg01579765	chr21:45077557	HSF2BP	-0.37	-6.3	-0.38	1.45e-9	Mean corpuscular volume;
SARC	cis	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg13072238	chr3:49761600	GMPPB	-0.43	-5.57	-0.34	6.88e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2153535	0.541	rs5026687	chr6:8473957	A/T	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	cis	rs2997447	0.633	rs11247848	chr1:26357667	G/A	cg19633962	chr1:26362018	EXTL1	-0.8	-7.9	-0.46	1.08e-13	QRS complex (12-leadsum);
SARC	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg18876405	chr7:65276391	NA	0.48	5.47	0.34	1.14e-7	Aortic root size;
SARC	cis	rs9788721	0.836	rs72738736	chr15:78765122	G/T	cg18825076	chr15:78729989	IREB2	-0.51	-6.33	-0.38	1.28e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-8.27	-0.48	1.05e-14	Chronic sinus infection;
SARC	cis	rs2197308	0.765	rs12230545	chr12:37927114	C/T	cg13010199	chr12:38710504	ALG10B	-0.68	-9.18	-0.52	2.43e-17	Morning vs. evening chronotype;
SARC	cis	rs12908161	1.000	rs4643294	chr15:85250253	C/T	cg17507749	chr15:85114479	UBE2QP1	0.58	6.68	0.4	1.77e-10	Schizophrenia;
SARC	cis	rs7766436	0.885	rs12111204	chr6:22578227	C/T	cg13666174	chr6:22585274	NA	-0.59	-7.54	-0.44	1.02e-12	Coronary artery disease;
SARC	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg04267008	chr7:1944627	MAD1L1	-0.64	-7.38	-0.44	2.79e-12	Bipolar disorder and schizophrenia;
SARC	cis	rs11731606	0.508	rs7677981	chr4:95299736	C/T	cg20625393	chr4:95128694	SMARCAD1	0.55	5.39	0.33	1.71e-7	Mean platelet volume;
SARC	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg17376030	chr22:41985996	PMM1	0.71	8.34	0.48	6.6e-15	Vitiligo;
SARC	cis	rs3093024	0.839	rs968334	chr6:167526096	T/C	cg07741184	chr6:167504864	NA	-0.33	-6.25	-0.38	1.98e-9	Rheumatoid arthritis;
SARC	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.47	5.38	0.33	1.82e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs4891159	0.570	rs690132	chr18:74117261	T/C	cg24786174	chr18:74118243	ZNF516	0.77	13.31	0.66	1.92e-30	Longevity;
SARC	cis	rs6933660	0.512	rs13202634	chr6:151800630	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.72	6.18	0.38	2.82e-9	Menarche (age at onset);
SARC	cis	rs897080	0.552	rs1067389	chr2:44642290	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.58	6.71	0.4	1.45e-10	Height;
SARC	trans	rs8020941	0.585	rs17094884	chr14:97517208	A/T	cg05136476	chr3:53190709	NA	-0.7	-7.01	-0.42	2.58e-11	Diabetic kidney disease;
SARC	cis	rs9486719	0.857	rs6568392	chr6:96861476	G/T	cg06623918	chr6:96969491	KIAA0776	0.72	8.19	0.47	1.77e-14	Migraine;Coronary artery disease;
SARC	cis	rs7792596	1.000	rs6952539	chr7:93994003	A/G	cg20814616	chr7:94014465	NA	-0.44	-5.43	-0.34	1.43e-7	Intelligence;
SARC	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.6	-6.31	-0.38	1.42e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs17376456	0.935	rs10036891	chr5:93171738	T/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.69	5.53	0.34	8.75e-8	Diabetic retinopathy;
SARC	cis	rs9916302	0.904	rs612194	chr17:37442707	T/A	cg20243544	chr17:37824526	PNMT	-0.56	-6.87	-0.41	5.87e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs6582630	0.502	rs11614397	chr12:38328163	C/T	cg13010199	chr12:38710504	ALG10B	0.77	10.47	0.57	2.87e-21	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1448094	0.511	rs2405621	chr12:86149336	A/T	cg00310523	chr12:86230176	RASSF9	-0.3	-4.71	-0.3	4.18e-6	Major depressive disorder;
SARC	cis	rs57506017	0.606	rs12699324	chr7:12253372	T/C	cg23422036	chr7:12250390	TMEM106B	0.51	6.88	0.41	5.42e-11	Neuroticism;
SARC	cis	rs7223966	0.961	rs112709843	chr17:61836936	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.52	-5.52	-0.34	8.97e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs13096760	1	rs13096760	chr3:49476806	T/C	cg03060546	chr3:49711283	APEH	0.75	11.19	0.59	1.56e-23	Intelligence (multi-trait analysis);
SARC	cis	rs7904368	0.568	rs7075036	chr10:16864810	C/T	cg23933602	chr10:16859644	RSU1	0.75	9.53	0.53	2.15e-18	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs1568889	0.877	rs34351528	chr11:28304293	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	9.43	0.53	4.25e-18	Bipolar disorder;
SARC	cis	rs9894429	0.634	rs9709130	chr17:79583948	C/T	cg18240062	chr17:79603768	NPLOC4	0.6	7.36	0.43	3.18e-12	Eye color traits;
SARC	cis	rs4927850	1.000	rs4927704	chr3:195738228	C/T	cg01181863	chr3:195395398	SDHAP2	-0.63	-7.27	-0.43	5.39e-12	Pancreatic cancer;
SARC	cis	rs4481887	0.893	rs4576683	chr1:248472390	T/C	cg13385794	chr1:248469461	NA	0.35	5.45	0.34	1.29e-7	Common traits (Other);
SARC	cis	rs6545883	0.895	rs796597	chr2:61681060	A/G	cg15711740	chr2:61764176	XPO1	-0.44	-5.2	-0.32	4.31e-7	Tuberculosis;
SARC	cis	rs1957429	0.901	rs17102320	chr14:65384693	T/C	cg23373153	chr14:65346875	NA	-1.01	-10.28	-0.56	1.07e-20	Pediatric areal bone mineral density (radius);
SARC	cis	rs7246657	0.943	rs1035479	chr19:37893300	G/T	cg14683738	chr19:37701593	ZNF585B	-0.51	-4.98	-0.31	1.22e-6	Coronary artery calcification;
SARC	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg19223190	chr17:80058835	NA	0.45	6.31	0.38	1.37e-9	Life satisfaction;
SARC	cis	rs11785400	1.000	rs13266249	chr8:143732433	A/C	cg24634471	chr8:143751801	JRK	0.66	8.72	0.5	5.18e-16	Schizophrenia;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg05174924	chr6:90062691	UBE2J1	0.5	6.37	0.39	1.01e-9	Breast cancer;
SARC	cis	rs7520050	1.000	rs12143096	chr1:46469763	G/A	cg24296786	chr1:45957014	TESK2	0.39	4.92	0.31	1.62e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs6449957	0.832	rs11742365	chr5:67470244	C/G	cg23036683	chr5:67512108	NA	0.57	6.58	0.4	3.07e-10	Cleft lip with or without cleft palate;
SARC	cis	rs12478296	1.000	rs73007129	chr2:243000555	T/C	cg06360820	chr2:242988706	NA	-0.81	-6.11	-0.37	4.09e-9	Obesity-related traits;
SARC	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg12667521	chr19:29218732	NA	0.39	5.26	0.33	3.27e-7	Methadone dose in opioid dependence;
SARC	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg23172400	chr8:95962367	TP53INP1	-0.35	-5.96	-0.36	9.47e-9	Type 2 diabetes;
SARC	cis	rs2228479	0.850	rs62054601	chr16:89811751	C/G	cg06558623	chr16:89946397	TCF25	0.91	6.37	0.38	1.03e-9	Skin colour saturation;
SARC	cis	rs2304069	0.507	rs4705407	chr5:149404983	G/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.45	5.26	0.33	3.26e-7	HIV-1 control;
SARC	trans	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg06636001	chr8:8085503	FLJ10661	0.59	7.93	0.46	9.29e-14	Retinal vascular caliber;
SARC	cis	rs2594989	0.943	rs62245870	chr3:11439838	G/A	cg00170343	chr3:11313890	ATG7	0.63	6.3	0.38	1.51e-9	Circulating chemerin levels;
SARC	cis	rs6964587	1.000	rs12704635	chr7:91737324	T/G	cg17063962	chr7:91808500	NA	0.95	16.04	0.72	1.66e-39	Breast cancer;
SARC	cis	rs995000	0.931	rs10889343	chr1:63026429	T/G	cg06896770	chr1:63153194	DOCK7	-0.9	-13.26	-0.66	2.87e-30	Triglyceride levels;
SARC	cis	rs9902453	0.868	rs11080118	chr17:28475379	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.52	-6.72	-0.4	1.41e-10	Coffee consumption (cups per day);
SARC	cis	rs4555082	0.874	rs2816606	chr14:105716034	C/T	cg13114125	chr14:105738426	BRF1	-0.82	-11.88	-0.61	9.23e-26	Mean platelet volume;Platelet distribution width;
SARC	cis	rs7590720	0.819	rs6435931	chr2:216892754	C/G	cg12620499	chr2:216877984	MREG	0.69	10.31	0.56	9.08e-21	Alcohol dependence;
SARC	cis	rs826838	0.935	rs7301104	chr12:39182821	C/T	cg26384229	chr12:38710491	ALG10B	0.88	12.52	0.63	7.62e-28	Heart rate;
SARC	cis	rs2806561	0.765	rs668234	chr1:23515467	G/A	cg12483005	chr1:23474871	LUZP1	0.44	5.86	0.36	1.61e-8	Height;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg13495574	chr1:173793781	CENPL;DARS2	0.5	6.69	0.4	1.67e-10	Chemerin levels;
SARC	cis	rs4242434	0.927	rs3736147	chr8:22471824	A/G	cg03733263	chr8:22462867	KIAA1967	-1.01	-16.55	-0.74	3.27e-41	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs13376709	0.636	rs12723537	chr1:243812680	G/A	cg21452805	chr1:244014465	NA	-0.39	-4.9	-0.31	1.77e-6	Schizophrenia;
SARC	cis	rs6582630	0.598	rs10880614	chr12:38509766	G/A	cg14851346	chr12:38532713	NA	-0.42	-5.03	-0.31	9.87e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2304069	0.526	rs6863283	chr5:149402448	C/A	cg12661370	chr5:149340060	SLC26A2	0.57	6.7	0.4	1.53e-10	HIV-1 control;
SARC	cis	rs7833986	0.501	rs2719233	chr8:56886156	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.57	5.19	0.32	4.67e-7	Height;
SARC	cis	rs12291225	0.535	rs10832248	chr11:14413087	G/A	cg19336497	chr11:14380999	RRAS2	-0.35	-5.98	-0.36	8.42e-9	Sense of smell;
SARC	trans	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.6	-8.0	-0.46	5.97e-14	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1610096	0.538	rs2279796	chr19:1059004	A/G	cg18950617	chr19:1066959	HMHA1	-0.47	-6.17	-0.37	3e-9	Neutrophil percentage of granulocytes;
SARC	cis	rs6910061	1.000	rs28860023	chr6:11106765	G/A	cg27233058	chr6:11094804	LOC221710	0.56	5.32	0.33	2.43e-7	Diabetic kidney disease;
SARC	cis	rs9786986	0.831	rs12563639	chr1:235667130	G/A	cg26050004	chr1:235667680	B3GALNT2	0.61	5.11	0.32	6.58e-7	Body mass index;
SARC	cis	rs1865063	1.000	rs1865063	chr19:11341029	C/T	cg00586551	chr19:11347513	LOC55908;DOCK6	0.73	7.35	0.43	3.26e-12	HDL cholesterol levels;
SARC	cis	rs9457247	0.663	rs12526548	chr6:167431147	C/T	cg07741184	chr6:167504864	NA	0.34	6.57	0.4	3.28e-10	Crohn's disease;
SARC	cis	rs72781680	1.000	rs72798417	chr2:24188656	C/T	cg06627628	chr2:24431161	ITSN2	-0.7	-6.71	-0.4	1.49e-10	Lymphocyte counts;
SARC	cis	rs7712401	0.692	rs6881135	chr5:122080371	A/T	cg19412675	chr5:122181750	SNX24	-0.42	-5.8	-0.36	2.15e-8	Mean platelet volume;
SARC	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg11987759	chr7:65425863	GUSB	-0.5	-6.19	-0.38	2.62e-9	Aortic root size;
SARC	cis	rs9902453	0.933	rs1532042	chr17:28504389	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	6.66	0.4	1.98e-10	Coffee consumption (cups per day);
SARC	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	5.88	0.36	1.39e-8	Bipolar disorder;
SARC	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg22535103	chr8:58192502	C8orf71	-0.6	-6.15	-0.37	3.42e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7246657	0.943	rs4801803	chr19:37966923	A/G	cg23950597	chr19:37808831	NA	0.64	6.14	0.37	3.52e-9	Coronary artery calcification;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg02178630	chr2:218678534	TNS1	0.47	6.27	0.38	1.7e-9	Thyroid stimulating hormone;
SARC	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.8	7.48	0.44	1.46e-12	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs995000	0.931	rs10889350	chr1:63085266	C/T	cg06896770	chr1:63153194	DOCK7	0.89	13.21	0.65	4.23e-30	Triglyceride levels;
SARC	cis	rs12477438	0.520	rs11695751	chr2:99708247	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.12	26.49	0.87	3.08e-72	Chronic sinus infection;
SARC	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg13877915	chr19:58951672	ZNF132	-0.63	-9.18	-0.52	2.37e-17	Uric acid clearance;
SARC	cis	rs17095355	1.000	rs12571674	chr10:111717608	C/T	cg00817464	chr10:111662876	XPNPEP1	0.48	5.02	0.31	1.04e-6	Biliary atresia;
SARC	cis	rs7312774	0.618	rs9651926	chr12:107356820	G/A	cg16260113	chr12:107380972	MTERFD3	1.11	8.76	0.5	4.13e-16	Severe influenza A (H1N1) infection;
SARC	cis	rs11098499	0.865	rs10032158	chr4:120391632	C/T	cg24375607	chr4:120327624	NA	0.4	4.76	0.3	3.36e-6	Corneal astigmatism;
SARC	cis	rs151234	0.676	rs554206	chr16:28576369	G/A	cg01378222	chr16:28622494	SULT1A1	-0.5	-5.78	-0.35	2.36e-8	Platelet distribution width;
SARC	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg05313129	chr8:58192883	C8orf71	-0.55	-4.71	-0.3	4.18e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs6912958	0.559	rs6921504	chr6:88058972	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.35	6.31	0.38	1.42e-9	Monocyte percentage of white cells;
SARC	cis	rs4742903	0.967	rs7871759	chr9:106865438	A/G	cg21169611	chr9:106856078	SMC2	0.39	4.74	0.3	3.76e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs17253792	0.822	rs8006705	chr14:56171283	C/T	cg01858014	chr14:56050164	KTN1	-0.6	-4.72	-0.3	4.02e-6	Putamen volume;
SARC	cis	rs10892173	0.566	rs12364667	chr11:117675286	A/C	cg07621104	chr11:117668040	DSCAML1	0.6	7.66	0.45	4.97e-13	Myopia;
SARC	cis	rs11122272	0.675	rs1416913	chr1:231533206	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.28	-0.56	1.11e-20	Hemoglobin concentration;
SARC	cis	rs10883723	0.810	rs12162	chr10:104240498	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.58	6.17	0.37	3.06e-9	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs2594989	0.677	rs7631716	chr3:11576689	T/C	cg00170343	chr3:11313890	ATG7	-0.57	-6.31	-0.38	1.4e-9	Circulating chemerin levels;
SARC	cis	rs7568458	0.870	rs6757263	chr2:85803542	A/G	cg02493740	chr2:85810744	VAMP5	-0.34	-4.92	-0.31	1.63e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.46	5.77	0.35	2.54e-8	Gut microbiome composition (summer);
SARC	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg03433033	chr1:76189801	ACADM	0.43	5.64	0.35	5.02e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs1371867	0.846	rs924057	chr8:101266157	A/G	cg11906718	chr8:101322791	RNF19A	-0.68	-9.07	-0.51	5.09e-17	Atrioventricular conduction;
SARC	cis	rs2153535	0.601	rs9328487	chr6:8529378	G/C	cg07606381	chr6:8435919	SLC35B3	0.74	10.59	0.57	1.15e-21	Motion sickness;
SARC	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg13206674	chr6:150067644	NUP43	0.46	6.01	0.37	6.92e-9	Lung cancer;
SARC	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-8.86	-0.5	2.06e-16	Alzheimer's disease;
SARC	cis	rs4268898	0.662	rs9917315	chr2:24431501	C/A	cg26838691	chr2:24397539	C2orf84	-0.54	-6.2	-0.38	2.54e-9	Asthma;
SARC	cis	rs7249142	0.573	rs2238668	chr19:19282597	A/G	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.23	4.85	0.3	2.23e-6	IgG glycosylation;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg14313443	chr15:66995985	SMAD6	0.52	6.93	0.41	4.2e-11	Breast cancer;
SARC	cis	rs9486719	0.947	rs11153071	chr6:97039741	G/A	cg06623918	chr6:96969491	KIAA0776	-0.79	-8.88	-0.5	1.86e-16	Migraine;Coronary artery disease;
SARC	cis	rs8072100	1.000	rs4375701	chr17:45712218	C/T	cg08085267	chr17:45401833	C17orf57	-0.42	-4.75	-0.3	3.56e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs6912958	0.559	rs2985039	chr6:88041757	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.76	11.3	0.59	6.84e-24	Monocyte percentage of white cells;
SARC	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg16405210	chr4:1374714	KIAA1530	0.71	8.7	0.5	6.13e-16	Obesity-related traits;
SARC	cis	rs6088580	0.660	rs6059893	chr20:33105897	T/G	cg08999081	chr20:33150536	PIGU	0.43	6.64	0.4	2.18e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs11509153	0.500	rs4721055	chr7:12242363	C/G	cg23422036	chr7:12250390	TMEM106B	0.42	5.31	0.33	2.56e-7	Residual cognition;
SARC	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg22535103	chr8:58192502	C8orf71	-0.65	-6.1	-0.37	4.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	-0.38	-4.74	-0.3	3.77e-6	Tonsillectomy;
SARC	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg05368731	chr17:41323189	NBR1	0.77	9.18	0.52	2.34e-17	Menopause (age at onset);
SARC	cis	rs7937682	0.774	rs59921976	chr11:111473088	G/A	cg22437258	chr11:111473054	SIK2	0.76	10.57	0.57	1.42e-21	Primary sclerosing cholangitis;
SARC	cis	rs875971	0.545	rs67397473	chr7:65633305	A/G	cg25894440	chr7:65020034	NA	0.51	4.76	0.3	3.33e-6	Aortic root size;
SARC	cis	rs4595586	0.545	rs7310463	chr12:39368927	T/C	cg13010199	chr12:38710504	ALG10B	0.4	4.75	0.3	3.57e-6	Morning vs. evening chronotype;
SARC	cis	rs9916302	0.847	rs7218670	chr17:37500424	G/A	cg00129232	chr17:37814104	STARD3	0.6	7.36	0.43	3.15e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg07308232	chr7:1071921	C7orf50	-0.66	-8.45	-0.48	3.2e-15	Longevity;Endometriosis;
SARC	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg09455208	chr3:40491958	NA	0.39	5.75	0.35	2.82e-8	Renal cell carcinoma;
SARC	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg07157834	chr1:205819609	PM20D1	0.43	5.1	0.32	7.07e-7	Parkinson's disease;
SARC	cis	rs7927592	0.763	rs7120876	chr11:68261398	C/G	cg01657329	chr11:68192670	LRP5	-0.37	-5.17	-0.32	4.96e-7	Total body bone mineral density;
SARC	cis	rs9393692	0.905	rs1124999	chr6:26287043	G/T	cg05868516	chr6:26286170	HIST1H4H	0.56	7.37	0.43	2.99e-12	Educational attainment;
SARC	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg11764359	chr7:65958608	NA	-0.77	-9.36	-0.52	6.84e-18	Aortic root size;
SARC	cis	rs7465272	1.000	rs7017842	chr8:143685116	G/A	cg10596483	chr8:143751796	JRK	0.55	5.85	0.36	1.64e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs4819052	0.565	rs35776291	chr21:46706142	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.61	7.56	0.44	9.43e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg23087877	chr10:22022646	MLLT10	0.54	7.71	0.45	3.72e-13	Thyroid stimulating hormone;
SARC	cis	rs6952808	0.964	rs10950407	chr7:1895666	T/G	cg21782813	chr7:2030301	MAD1L1	0.4	6.19	0.38	2.68e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs9611519	0.964	rs20551	chr22:41548008	A/G	cg03806693	chr22:41940476	POLR3H	-0.54	-6.11	-0.37	4.13e-9	Neuroticism;
SARC	cis	rs6546550	0.935	rs3214007	chr2:70098808	A/G	cg02498382	chr2:70120550	SNRNP27	-0.38	-6.33	-0.38	1.24e-9	Prevalent atrial fibrillation;
SARC	cis	rs11203032	0.831	rs12219735	chr10:90922890	C/T	cg16672925	chr10:90967113	CH25H	0.71	6.9	0.41	4.79e-11	Heart failure;
SARC	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg08677398	chr8:58056175	NA	0.44	5.22	0.32	4e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs834603	0.687	rs17544073	chr7:47451572	C/T	cg23694490	chr7:47445681	TNS3	0.35	6.28	0.38	1.68e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs4917300	0.606	rs13261328	chr8:143096137	T/C	cg06573787	chr8:143070187	NA	0.38	5.32	0.33	2.41e-7	Amyotrophic lateral sclerosis;
SARC	trans	rs61931739	0.782	rs1197569	chr12:34186733	A/T	cg13010199	chr12:38710504	ALG10B	0.58	7.68	0.45	4.49e-13	Morning vs. evening chronotype;
SARC	cis	rs1707322	1.000	rs785467	chr1:46521559	A/T	cg03146154	chr1:46216737	IPP	-0.47	-5.59	-0.34	6.32e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6580649	0.941	rs58046797	chr12:48487619	T/C	cg05342945	chr12:48394962	COL2A1	0.57	6.27	0.38	1.77e-9	Lung cancer;
SARC	cis	rs7635838	0.892	rs9310381	chr3:11458466	A/G	cg00170343	chr3:11313890	ATG7	0.62	8.45	0.48	3.24e-15	HDL cholesterol;
SARC	cis	rs2153535	0.521	rs6939827	chr6:8461360	C/G	cg23788917	chr6:8435910	SLC35B3	0.64	8.55	0.49	1.6e-15	Motion sickness;
SARC	cis	rs13191362	1.000	rs60719662	chr6:163006643	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.57	5.51	0.34	9.61e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg13012494	chr21:47604986	C21orf56	0.46	5.24	0.32	3.53e-7	Testicular germ cell tumor;
SARC	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg21724239	chr8:58056113	NA	0.61	5.93	0.36	1.1e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg13175981	chr1:150552382	MCL1	0.53	6.77	0.41	1.02e-10	Tonsillectomy;
SARC	cis	rs7714584	1.000	rs11746807	chr5:150300419	G/A	cg22134413	chr5:150180641	NA	0.8	6.59	0.4	2.97e-10	Crohn's disease;
SARC	cis	rs11792861	0.855	rs116127510	chr9:111868344	G/A	cg13535736	chr9:111863775	C9orf5	-0.4	-4.89	-0.31	1.87e-6	Menarche (age at onset);
SARC	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg19346786	chr7:2764209	NA	-0.34	-5.16	-0.32	5.39e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
SARC	cis	rs6831352	0.703	rs4235435	chr4:100039578	C/T	cg12011299	chr4:100065546	ADH4	0.28	4.8	0.3	2.86e-6	Alcohol dependence;
SARC	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	5.74	0.35	2.92e-8	Bipolar disorder;
SARC	cis	rs4742903	1.000	rs4742905	chr9:106856972	G/C	cg14250997	chr9:106856677	SMC2	0.52	6.86	0.41	6.13e-11	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs11673344	0.544	rs6508721	chr19:37910021	G/T	cg14683738	chr19:37701593	ZNF585B	0.45	5.34	0.33	2.18e-7	Obesity-related traits;
SARC	cis	rs11651753	0.561	rs17616603	chr17:45959620	T/C	cg02219949	chr17:45927392	SP6	0.35	4.82	0.3	2.63e-6	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	cis	rs722599	0.639	rs2193596	chr14:75234101	A/C	cg06637938	chr14:75390232	RPS6KL1	0.43	5.05	0.31	8.78e-7	IgG glycosylation;
SARC	cis	rs6088580	0.634	rs1205345	chr20:32914699	A/G	cg24642439	chr20:33292090	TP53INP2	-0.67	-8.61	-0.49	1.09e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs12545109	0.800	rs2576592	chr8:57419357	A/C	cg19413350	chr8:57351067	NA	-0.43	-5.4	-0.33	1.67e-7	Obesity-related traits;
SARC	cis	rs2652822	0.550	rs72747098	chr15:63525249	G/A	cg02713581	chr15:63449717	RPS27L	0.55	6.42	0.39	7.52e-10	Metabolic traits;
SARC	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	9.15	0.51	3.02e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs36093844	0.706	rs75334800	chr11:85586581	A/G	cg15359163	chr5:122429178	PRDM6	-0.54	-6.44	-0.39	6.72e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs2933343	0.621	rs883843	chr3:128567383	C/T	cg25356066	chr3:128598488	ACAD9	-0.68	-8.93	-0.51	1.28e-16	IgG glycosylation;
SARC	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg26513180	chr16:89883248	FANCA	0.91	16.21	0.73	4.48e-40	Vitiligo;
SARC	cis	rs4808199	0.842	rs11085259	chr19:19445856	C/T	cg03709012	chr19:19516395	GATAD2A	1.13	11.33	0.6	5.5e-24	Nonalcoholic fatty liver disease;
SARC	cis	rs3824867	0.920	rs7101772	chr11:47449378	A/G	cg20307385	chr11:47447363	PSMC3	-0.47	-5.14	-0.32	5.92e-7	Mean corpuscular hemoglobin;
SARC	cis	rs2295359	0.824	rs11209003	chr1:67601132	G/T	cg12940439	chr1:67600707	NA	0.49	6.66	0.4	1.9e-10	Psoriasis;
SARC	cis	rs9858542	0.953	rs9827021	chr3:49514764	C/A	cg07274523	chr3:49395745	GPX1	0.53	6.13	0.37	3.82e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs2204008	0.694	rs10880262	chr12:38328696	C/T	cg26384229	chr12:38710491	ALG10B	0.71	9.12	0.51	3.54e-17	Bladder cancer;
SARC	cis	rs7208859	0.623	rs9891166	chr17:29111902	G/A	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs10463316	0.894	rs869198	chr5:150745893	G/T	cg03212797	chr5:150827313	SLC36A1	0.49	5.94	0.36	1.01e-8	Metabolite levels (Pyroglutamine);
SARC	cis	rs9435341	0.965	rs1335053	chr1:107622823	C/T	cg09367891	chr1:107599246	PRMT6	-0.73	-8.68	-0.49	6.86e-16	Facial morphology (factor 21, depth of nasal alae);
SARC	cis	rs796364	0.715	rs78988795	chr2:201095739	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.65	-4.81	-0.3	2.7e-6	Schizophrenia;
SARC	cis	rs7762018	0.607	rs61740334	chr6:170047902	T/A	cg13891659	chr6:170190454	C6orf122;C6orf208	0.76	4.99	0.31	1.17e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs4919694	0.572	rs7080935	chr10:104929113	C/A	cg04362960	chr10:104952993	NT5C2	0.58	5.37	0.33	1.91e-7	Arsenic metabolism;
SARC	trans	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg21659725	chr3:3221576	CRBN	0.78	11.73	0.61	2.72e-25	Intelligence (multi-trait analysis);
SARC	cis	rs698833	0.886	rs6721675	chr2:44566027	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.69	9.03	0.51	6.67e-17	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs67460515	0.563	rs4679672	chr3:160901020	G/A	cg03342759	chr3:160939853	NMD3	-0.65	-8.04	-0.47	4.55e-14	Parkinson's disease;
SARC	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg03517284	chr6:25882590	NA	-0.47	-5.96	-0.36	9.04e-9	Intelligence (multi-trait analysis);
SARC	cis	rs208520	0.661	rs207099	chr6:66796373	A/C	cg07460842	chr6:66804631	NA	-1.08	-14.98	-0.7	5.37e-36	Exhaled nitric oxide output;
SARC	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.51	6.32	0.38	1.34e-9	Gut microbiome composition (summer);
SARC	cis	rs9398803	0.687	rs9491653	chr6:126943630	A/G	cg19875578	chr6:126661172	C6orf173	0.63	8.72	0.5	5.29e-16	Male-pattern baldness;
SARC	trans	rs4076764	0.958	rs6688181	chr1:163384193	C/T	cg13981223	chr11:31391216	DNAJC24;DCDC1	0.51	6.55	0.39	3.65e-10	Motion sickness;
SARC	cis	rs78487399	0.808	rs78108161	chr2:43663848	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.53	-0.34	8.42e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs6831352	1.000	rs1126673	chr4:100045616	C/T	cg12011299	chr4:100065546	ADH4	0.33	5.74	0.35	2.87e-8	Alcohol dependence;
SARC	cis	rs3892630	0.529	rs35300319	chr19:33409948	G/A	cg22980127	chr19:33182716	NUDT19	0.53	5.3	0.33	2.68e-7	Red blood cell traits;
SARC	cis	rs9467711	0.651	rs13206443	chr6:26119245	C/T	cg21479132	chr6:26055353	NA	0.97	6.77	0.41	1.06e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs3087591	0.960	rs1013947	chr17:29530362	C/T	cg24425628	chr17:29625626	OMG;NF1	0.49	6.1	0.37	4.48e-9	Hip circumference;
SARC	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg03999130	chr15:45571217	NA	0.39	5.09	0.32	7.55e-7	Homoarginine levels;
SARC	cis	rs9372253	1.000	rs9372253	chr6:110716136	C/T	cg19196401	chr6:110721138	DDO	-0.41	-5.38	-0.33	1.82e-7	Platelet distribution width;
SARC	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg00684032	chr4:1343700	KIAA1530	0.38	5.51	0.34	9.43e-8	Obesity-related traits;
SARC	cis	rs7712401	0.601	rs246268	chr5:122256342	C/T	cg19412675	chr5:122181750	SNX24	0.4	5.17	0.32	5.13e-7	Mean platelet volume;
SARC	cis	rs6580649	0.941	rs4760618	chr12:48434767	G/A	cg24011408	chr12:48396354	COL2A1	-0.5	-5.37	-0.33	1.9e-7	Lung cancer;
SARC	cis	rs9296092	0.517	rs113111213	chr6:33520790	A/G	cg13560919	chr6:33536144	NA	-0.5	-6.31	-0.38	1.38e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs7959452	0.640	rs10878957	chr12:69699638	G/C	cg22834771	chr12:69754056	YEATS4	-0.41	-5.49	-0.34	1.06e-7	Blood protein levels;
SARC	cis	rs1055129	0.560	rs56248937	chr17:73915153	T/A	cg14829360	chr17:73884958	NA	-0.56	-8.25	-0.48	1.17e-14	White matter hyperintensity burden;
SARC	cis	rs607987	0.871	rs1222218	chr11:30344761	A/G	cg06241208	chr11:30344200	C11orf46	-0.39	-4.76	-0.3	3.42e-6	Body mass index;
SARC	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg14893161	chr1:205819251	PM20D1	0.51	5.87	0.36	1.52e-8	Parkinson's disease;
SARC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg05863683	chr7:1912471	MAD1L1	-0.32	-4.91	-0.31	1.74e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg25036284	chr2:26402008	FAM59B	0.48	5.94	0.36	1.04e-8	Gut microbiome composition (summer);
SARC	cis	rs11785400	0.793	rs4467920	chr8:143736846	C/T	cg10596483	chr8:143751796	JRK	0.56	7.2	0.43	8.42e-12	Schizophrenia;
SARC	cis	rs2735413	0.709	rs9938043	chr16:78091426	A/G	cg04733911	chr16:78082701	NA	-0.31	-5.13	-0.32	6.06e-7	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg25072359	chr17:41440525	NA	0.53	6.45	0.39	6.24e-10	Menopause (age at onset);
SARC	cis	rs10916814	0.632	rs4439331	chr1:20897091	T/C	cg24502330	chr1:20914028	CDA	-0.29	-5.1	-0.32	7.19e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs599083	0.793	rs314750	chr11:68182028	G/A	cg01657329	chr11:68192670	LRP5	0.42	5.86	0.36	1.6e-8	Bone mineral density (spine);
SARC	cis	rs6539288	0.933	rs10861673	chr12:107300071	A/G	cg07730007	chr12:107377277	MTERFD3	0.38	4.79	0.3	2.91e-6	Total body bone mineral density;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg12692753	chr10:89265684	MINPP1	-0.48	-6.74	-0.4	1.23e-10	Thyroid stimulating hormone;
SARC	cis	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg18252515	chr7:66147081	NA	-1.41	-12.93	-0.65	3.5e-29	Diabetic kidney disease;
SARC	trans	rs607987	0.967	rs7925930	chr11:30220739	A/T	cg16771474	chr7:7776115	NA	0.49	6.53	0.39	4.02e-10	Body mass index;
SARC	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg04756594	chr16:24857601	SLC5A11	0.45	6.39	0.39	8.86e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7539409	0.651	rs970457	chr1:84296540	C/T	cg10977910	chr1:84465055	TTLL7	0.51	4.79	0.3	2.96e-6	Alzheimer's disease;
SARC	cis	rs240110	0.515	rs12530388	chr6:101329173	A/C	cg09795085	chr6:101329169	ASCC3	0.6	8.28	0.48	9.51e-15	Neuroticism;
SARC	cis	rs13314892	0.764	rs62251029	chr3:69864732	T/C	cg17445875	chr3:69859618	MITF	-0.48	-5.08	-0.32	7.89e-7	QRS complex (12-leadsum);
SARC	cis	rs11098499	0.865	rs11722183	chr4:120280597	A/C	cg09307838	chr4:120376055	NA	0.89	12.72	0.64	1.67e-28	Corneal astigmatism;
SARC	cis	rs8042680	0.522	rs1867225	chr15:91563829	A/G	cg08919649	chr15:91565780	VPS33B	0.42	5.17	0.32	4.95e-7	Type 2 diabetes;
SARC	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg12463550	chr7:65579703	CRCP	0.5	5.9	0.36	1.27e-8	Aortic root size;
SARC	cis	rs2562456	0.917	rs2650804	chr19:21680184	A/G	cg00806126	chr19:22604979	ZNF98	-0.5	-5.29	-0.33	2.84e-7	Pain;
SARC	cis	rs362272	0.524	rs2749781	chr4:3346617	T/C	cg08741688	chr4:3415352	RGS12	-0.5	-6.35	-0.38	1.12e-9	Serum sulfate level;
SARC	cis	rs10779751	0.632	rs2748876	chr1:11134157	T/G	cg08854313	chr1:11322531	MTOR	0.76	9.59	0.53	1.46e-18	Body mass index;
SARC	cis	rs10463316	0.894	rs7729438	chr5:150762197	G/A	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.28	-0.33	2.89e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs11785400	0.701	rs9297968	chr8:143723009	A/G	cg24634471	chr8:143751801	JRK	0.6	7.85	0.46	1.51e-13	Schizophrenia;
SARC	cis	rs1832871	0.711	rs12527510	chr6:158657299	T/G	cg07165851	chr6:158734300	TULP4	0.56	6.77	0.41	1.03e-10	Height;
SARC	cis	rs1559088	0.901	rs7249983	chr19:33598851	C/A	cg27124370	chr19:33622961	WDR88	0.42	5.48	0.34	1.09e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs12478296	0.792	rs3924263	chr2:243005167	A/C	cg06360820	chr2:242988706	NA	-0.7	-6.45	-0.39	6.25e-10	Obesity-related traits;
SARC	trans	rs1814175	0.587	rs7937757	chr11:49978342	G/A	cg03929089	chr4:120376271	NA	-0.82	-11.88	-0.61	9.2e-26	Height;
SARC	trans	rs208520	1.000	rs12191598	chr6:66983962	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.83	9.35	0.52	7.46e-18	Exhaled nitric oxide output;
SARC	trans	rs3780486	0.505	rs10758194	chr9:33157419	G/T	cg20290983	chr6:43655470	MRPS18A	0.94	13.66	0.67	1.34e-31	IgG glycosylation;
SARC	cis	rs6912958	0.712	rs2787927	chr6:88412786	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.4	-4.92	-0.31	1.61e-6	Monocyte percentage of white cells;
SARC	cis	rs7560272	0.723	rs4346412	chr2:73843571	A/G	cg20560298	chr2:73613845	ALMS1	-0.49	-6.67	-0.4	1.83e-10	Schizophrenia;
SARC	cis	rs7568458	0.870	rs6733913	chr2:85757379	T/C	cg23752985	chr2:85803571	VAMP8	0.34	4.93	0.31	1.57e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs858239	0.600	rs7341483	chr7:23127657	G/T	cg23682824	chr7:23144976	KLHL7	-0.69	-9.3	-0.52	1.08e-17	Cerebrospinal fluid biomarker levels;
SARC	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg05340658	chr4:99064831	C4orf37	0.58	7.23	0.43	6.76e-12	Colonoscopy-negative controls vs population controls;
SARC	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg26335602	chr6:28129616	ZNF389	0.53	5.88	0.36	1.43e-8	Depression;
SARC	cis	rs7412746	0.658	rs11204750	chr1:150939744	C/A	cg10589385	chr1:150898437	SETDB1	0.41	5.46	0.34	1.2e-7	Melanoma;
SARC	cis	rs76419734	1.000	rs114256679	chr4:106636598	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.84	5.41	0.33	1.59e-7	Post bronchodilator FEV1;
SARC	cis	rs6687840	0.563	rs11265204	chr1:159439913	A/G	cg07417683	chr1:159440267	NA	0.31	5.04	0.31	9.45e-7	Chemerin levels;
SARC	cis	rs2304069	0.954	rs4705408	chr5:149412545	A/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	-0.71	-7.28	-0.43	5.24e-12	HIV-1 control;
SARC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.51	5.81	0.36	2.02e-8	Renal function-related traits (BUN);
SARC	cis	rs3764021	0.870	rs7970116	chr12:9880114	C/T	cg27502298	chr12:9555721	NA	0.41	4.84	0.3	2.36e-6	Type 1 diabetes;
SARC	cis	rs11711311	1.000	rs6792447	chr3:113508335	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	8.58	0.49	1.31e-15	IgG glycosylation;
SARC	cis	rs9987353	0.589	rs1053036	chr8:9060077	A/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-5.33	-0.33	2.36e-7	Recombination measurement;
SARC	cis	rs1552244	0.554	rs6768339	chr3:10006079	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.43	-5.19	-0.32	4.67e-7	Alzheimer's disease;
SARC	cis	rs75064307	0.834	rs7636575	chr3:108115862	C/T	cg03329597	chr3:108125523	MYH15	-0.47	-4.93	-0.31	1.56e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg10523679	chr1:76189770	ACADM	-0.46	-4.8	-0.3	2.89e-6	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs617219	0.698	rs12189248	chr5:78517143	A/G	cg24856658	chr5:78533917	JMY	0.31	4.98	0.31	1.23e-6	Betaine levels in individuals undergoing cardiac evaluation;
SARC	cis	rs4074493	1.000	rs4460622	chr1:231173033	C/T	cg22172038	chr1:231176991	FAM89A	0.33	4.78	0.3	3.16e-6	Carotid plaque burden (smoking interaction);
SARC	cis	rs9916302	0.706	rs597069	chr17:37458512	G/T	cg00129232	chr17:37814104	STARD3	0.52	5.48	0.34	1.09e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs8014204	0.836	rs12588415	chr14:75278211	G/A	cg17347104	chr14:75034677	LTBP2	-0.41	-4.97	-0.31	1.29e-6	Caffeine consumption;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg21627574	chr3:53164588	RFT1	-0.48	-6.3	-0.38	1.51e-9	Neuroticism;
SARC	cis	rs6424115	0.830	rs3123554	chr1:24196401	C/T	cg09473613	chr1:24152604	HMGCL	-0.33	-4.77	-0.3	3.18e-6	Immature fraction of reticulocytes;
SARC	cis	rs6570726	0.791	rs379040	chr6:145889035	T/C	cg23711669	chr6:146136114	FBXO30	0.79	12.64	0.64	3.15e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg03575189	chr17:44344142	NA	-0.52	-5.07	-0.32	7.99e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg27588902	chr6:42928151	GNMT	-0.36	-5.36	-0.33	2.01e-7	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs11785400	0.793	rs35985277	chr8:143736137	C/T	cg24634471	chr8:143751801	JRK	0.59	7.62	0.45	6.46e-13	Schizophrenia;
SARC	cis	rs9303280	0.806	rs9909593	chr17:37970149	C/T	cg20243544	chr17:37824526	PNMT	-0.41	-5.35	-0.33	2.08e-7	Self-reported allergy;
SARC	cis	rs477692	0.699	rs557311	chr10:131389484	A/G	cg05714579	chr10:131428358	MGMT	0.55	7.2	0.43	8.07e-12	Response to temozolomide;
SARC	cis	rs9916302	0.808	rs12947281	chr17:37652210	G/T	cg15445000	chr17:37608096	MED1	0.42	5.01	0.31	1.08e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg03351412	chr1:154909251	PMVK	-0.43	-5.23	-0.32	3.8e-7	Schizophrenia;
SARC	cis	rs2153535	0.580	rs2184586	chr6:8474182	A/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.23	0.47	1.35e-14	Motion sickness;
SARC	cis	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg05623727	chr3:50126028	RBM5	0.35	5.11	0.32	6.72e-7	Body mass index;
SARC	cis	rs9815354	1.000	rs2371623	chr3:41761083	T/C	cg03022575	chr3:42003672	ULK4	0.55	5.21	0.32	4.11e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9948	0.655	rs62156232	chr2:97431161	C/A	cg01990225	chr2:97406019	LMAN2L	-0.96	-6.8	-0.41	8.7e-11	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs11644362	1.000	rs12934970	chr16:12988077	G/C	cg06890432	chr16:12997467	SHISA9	-0.55	-7.34	-0.43	3.46e-12	Positive affect;Subjective well-being;
SARC	cis	rs7582180	0.764	rs11682748	chr2:100925934	C/A	cg14675211	chr2:100938903	LONRF2	0.54	7.84	0.46	1.61e-13	Intelligence (multi-trait analysis);
SARC	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg18252515	chr7:66147081	NA	-1.29	-11.04	-0.59	4.48e-23	Diabetic kidney disease;
SARC	cis	rs17270561	0.609	rs1317510	chr6:25778924	T/C	cg17691542	chr6:26056736	HIST1H1C	0.58	6.98	0.42	3.05e-11	Iron status biomarkers;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg14249877	chr10:32322959	KIF5B	-0.55	-6.75	-0.4	1.19e-10	Alcohol dependence;
SARC	cis	rs6835098	0.608	rs2332668	chr4:174163360	A/G	cg08422745	chr4:174089978	GALNT7	-0.67	-8.83	-0.5	2.54e-16	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs7149337	0.809	rs10134478	chr14:51693708	G/C	cg23942311	chr14:51606299	NA	0.32	5.63	0.35	5.28e-8	Cancer;
SARC	cis	rs10911363	0.592	rs2702180	chr1:183517971	T/C	cg09173681	chr1:183549694	NCF2	0.31	5.03	0.31	9.8e-7	Systemic lupus erythematosus;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg23939166	chr14:55032812	NA	-0.86	-7.14	-0.42	1.21e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1707322	0.721	rs6665808	chr1:46162283	C/T	cg03146154	chr1:46216737	IPP	0.5	6.04	0.37	6.1e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg11890956	chr21:40555474	PSMG1	-0.71	-9.29	-0.52	1.12e-17	Menarche (age at onset);
SARC	cis	rs9914988	0.943	rs7215000	chr17:27088436	C/T	cg20469991	chr17:27169893	C17orf63	-0.5	-5.32	-0.33	2.38e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs2658782	0.738	rs2605628	chr11:93261560	C/A	cg15737290	chr11:93063684	CCDC67	0.72	8.14	0.47	2.41e-14	Pulmonary function decline;
SARC	cis	rs11785693	0.819	rs6994891	chr8:4989856	T/A	cg26367366	chr8:4980734	NA	0.72	6.43	0.39	7.25e-10	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs828999	0.583	rs10494090	chr1:108693336	A/G	cg06207961	chr1:108661230	NA	0.35	4.81	0.3	2.7e-6	Monocyte percentage of white cells;
SARC	cis	rs798554	0.524	rs2283784	chr7:2855337	T/C	cg13628971	chr7:2884303	GNA12	0.48	5.95	0.36	9.6e-9	Height;
SARC	cis	rs7027203	1.000	rs7864114	chr9:96551954	A/G	cg13679303	chr9:96623674	NA	0.35	4.83	0.3	2.45e-6	DNA methylation (variation);
SARC	cis	rs11583043	0.667	rs4617425	chr1:101543205	C/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.45	4.84	0.3	2.34e-6	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs1707322	0.650	rs4660879	chr1:46105401	C/A	cg03146154	chr1:46216737	IPP	0.49	5.82	0.36	1.9e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9399135	0.517	rs1883354	chr6:135457541	C/T	cg03340261	chr6:135375900	HBS1L	0.38	4.77	0.3	3.32e-6	Red blood cell count;
SARC	cis	rs2153535	0.580	rs2327067	chr6:8518482	C/G	cg23788917	chr6:8435910	SLC35B3	0.63	8.28	0.48	9.37e-15	Motion sickness;
SARC	cis	rs453301	0.658	rs6983877	chr8:8904639	T/C	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.24	-0.38	2.07e-9	Joint mobility (Beighton score);
SARC	trans	rs629535	0.699	rs539956	chr8:70033647	G/A	cg21567404	chr3:27674614	NA	1.04	13.82	0.67	3.98e-32	Dupuytren's disease;
SARC	cis	rs7029536	0.551	rs7873847	chr9:130174444	G/C	cg09445097	chr9:130186736	ZNF79	0.53	4.99	0.31	1.2e-6	Metabolite levels (HVA);
SARC	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	12.5	0.63	9.02e-28	Chronic sinus infection;
SARC	cis	rs1728785	0.901	rs1631910	chr16:68603335	G/A	cg02972257	chr16:68554789	NA	-0.46	-5.53	-0.34	8.75e-8	Ulcerative colitis;
SARC	cis	rs2153535	0.580	rs6905237	chr6:8471790	A/T	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.85e-22	Motion sickness;
SARC	cis	rs1448094	0.785	rs7955173	chr12:86447214	G/A	cg02569458	chr12:86230093	RASSF9	-0.41	-6.13	-0.37	3.68e-9	Major depressive disorder;
SARC	cis	rs10046574	0.831	rs76054058	chr7:135093486	G/C	cg27474649	chr7:135195673	CNOT4	0.87	6.97	0.42	3.25e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs7666738	0.830	rs10031190	chr4:98908683	C/A	cg05340658	chr4:99064831	C4orf37	0.65	8.64	0.49	9.2e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs11785693	0.862	rs11783719	chr8:4991311	G/T	cg26367366	chr8:4980734	NA	0.71	6.26	0.38	1.81e-9	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs9911578	1.000	rs2531732	chr17:56548420	T/A	cg12560992	chr17:57184187	TRIM37	-0.81	-10.75	-0.58	3.84e-22	Intelligence (multi-trait analysis);
SARC	trans	rs2727020	0.634	rs11040331	chr11:49345726	T/C	cg15704280	chr7:45808275	SEPT13	-0.67	-7.46	-0.44	1.66e-12	Coronary artery disease;
SARC	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg04317338	chr11:64019027	PLCB3	0.84	8.98	0.51	9.05e-17	Mean platelet volume;
SARC	cis	rs6545883	0.894	rs7572603	chr2:61552145	C/G	cg15711740	chr2:61764176	XPO1	0.4	4.76	0.3	3.33e-6	Tuberculosis;
SARC	cis	rs9443189	0.763	rs2748952	chr6:76444360	G/A	cg01950844	chr6:76311363	SENP6	-0.72	-6.72	-0.4	1.42e-10	Prostate cancer;
SARC	trans	rs208520	0.690	rs207082	chr6:66773796	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.06	-14.31	-0.68	9.38e-34	Exhaled nitric oxide output;
SARC	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg16606324	chr3:10149918	C3orf24	0.51	4.94	0.31	1.48e-6	Alzheimer's disease;
SARC	cis	rs4906332	0.811	rs2296487	chr14:103996205	T/C	cg09185829	chr14:104603440	NA	0.48	4.79	0.3	2.96e-6	Coronary artery disease;
SARC	cis	rs4969178	0.965	rs12450500	chr17:76395750	C/T	cg20026190	chr17:76395443	PGS1	0.4	5.37	0.33	1.94e-7	HDL cholesterol levels;
SARC	cis	rs2011503	1.000	rs75453386	chr19:19637781	C/T	cg03709012	chr19:19516395	GATAD2A	0.6	5.29	0.33	2.8e-7	Bipolar disorder;
SARC	cis	rs4722166	0.630	rs12700390	chr7:22777129	G/T	cg26061582	chr7:22766209	IL6	0.57	6.19	0.38	2.73e-9	Lung cancer;
SARC	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2014572	0.510	rs8111661	chr19:57752326	C/G	cg24459738	chr19:57751996	ZNF805	0.51	5.94	0.36	1.05e-8	Hyperactive-impulsive symptoms;
SARC	cis	rs12600121	0.579	rs7184140	chr16:72025899	T/G	cg01557791	chr16:72042693	DHODH	0.42	5.23	0.32	3.71e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2180341	0.961	rs7775493	chr6:127615000	C/A	cg17762328	chr6:126965162	NA	-0.46	-5.24	-0.32	3.55e-7	Breast cancer;
SARC	cis	rs7216064	1.000	rs4791299	chr17:65930937	A/G	cg12091567	chr17:66097778	LOC651250	-0.75	-8.29	-0.48	9.02e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs2204008	0.539	rs1283295	chr12:38146014	A/C	cg26384229	chr12:38710491	ALG10B	-0.68	-8.82	-0.5	2.75e-16	Bladder cancer;
SARC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg03452623	chr4:187889614	NA	-0.78	-11.81	-0.61	1.53e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs708547	0.836	rs1625691	chr4:57845740	T/C	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.5	-5.87	-0.36	1.48e-8	Response to bleomycin (chromatid breaks);
SARC	cis	rs1707322	1.000	rs6687301	chr1:46382852	T/C	cg06784218	chr1:46089804	CCDC17	0.34	5.94	0.36	1.03e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs3767633	0.800	rs6685369	chr1:161754834	T/C	cg09175582	chr1:161736000	ATF6	0.72	6.18	0.38	2.83e-9	IgG glycosylation;
SARC	cis	rs7000551	0.689	rs2122878	chr8:22311916	T/C	cg12081754	chr8:22256438	SLC39A14	0.6	8.5	0.49	2.29e-15	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs208520	0.526	rs2881644	chr6:66803535	A/C	cg07460842	chr6:66804631	NA	1.11	22.15	0.82	2.96e-59	Exhaled nitric oxide output;
SARC	cis	rs12142240	0.698	rs6667861	chr1:46815749	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-5.46	-0.34	1.22e-7	Menopause (age at onset);
SARC	cis	rs9790314	1.000	rs336569	chr3:161072346	T/G	cg03342759	chr3:160939853	NMD3	-0.59	-7.53	-0.44	1.13e-12	Morning vs. evening chronotype;
SARC	cis	rs735396	0.965	rs2257962	chr12:121445808	T/C	cg15155738	chr12:121454335	C12orf43	0.5	6.22	0.38	2.29e-9	N-glycan levels;
SARC	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg18252515	chr7:66147081	NA	0.48	5.14	0.32	5.88e-7	Aortic root size;
SARC	cis	rs611744	0.967	rs678387	chr8:109242730	G/C	cg21045802	chr8:109455806	TTC35	0.45	5.37	0.33	1.87e-7	Dupuytren's disease;
SARC	cis	rs2629540	0.889	rs10901808	chr10:126399159	A/C	cg08799069	chr10:126477246	METTL10	0.61	6.6	0.4	2.77e-10	Cocaine dependence;
SARC	cis	rs10089	1.000	rs10478803	chr5:127488855	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.8	9.98	0.55	9.61e-20	Ileal carcinoids;
SARC	cis	rs4481887	0.893	rs10736379	chr1:248455876	A/T	cg00666640	chr1:248458726	OR2T12	0.35	5.72	0.35	3.2e-8	Common traits (Other);
SARC	cis	rs7000551	0.581	rs11136030	chr8:22254235	C/T	cg12081754	chr8:22256438	SLC39A14	0.83	11.54	0.6	1.16e-24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs6912958	0.559	rs242280	chr6:88048714	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.34	5.91	0.36	1.2e-8	Monocyte percentage of white cells;
SARC	cis	rs9790314	1.000	rs7653233	chr3:160992033	G/A	cg04691961	chr3:161091175	C3orf57	-0.75	-10.8	-0.58	2.59e-22	Morning vs. evening chronotype;
SARC	cis	rs854765	0.547	rs2955370	chr17:17966945	C/T	cg04398451	chr17:18023971	MYO15A	0.47	6.56	0.39	3.41e-10	Total body bone mineral density;
SARC	cis	rs7560272	0.501	rs12713790	chr2:73945611	C/T	cg20560298	chr2:73613845	ALMS1	0.44	5.89	0.36	1.33e-8	Schizophrenia;
SARC	trans	rs2727020	0.521	rs2088526	chr11:49531968	G/A	cg15704280	chr7:45808275	SEPT13	0.7	8.14	0.47	2.31e-14	Coronary artery disease;
SARC	cis	rs8028182	0.636	rs4545784	chr15:75755651	A/G	cg20655648	chr15:75932815	IMP3	0.64	7.68	0.45	4.46e-13	Sudden cardiac arrest;
SARC	cis	rs708547	0.647	rs1718839	chr4:57827206	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.41	-4.86	-0.3	2.18e-6	Response to bleomycin (chromatid breaks);
SARC	cis	rs763121	0.853	rs138713	chr22:39142615	T/C	cg21395723	chr22:39101663	GTPBP1	0.55	6.4	0.39	8.59e-10	Menopause (age at onset);
SARC	cis	rs7927592	0.731	rs488381	chr11:68291693	G/A	cg01657329	chr11:68192670	LRP5	0.37	5.15	0.32	5.43e-7	Total body bone mineral density;
SARC	cis	rs11583043	0.918	rs6693456	chr1:101424561	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.46	5.91	0.36	1.23e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs12477438	0.834	rs1563108	chr2:99701153	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.0	-0.46	5.75e-14	Chronic sinus infection;
SARC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg16132339	chr22:24313637	DDTL;DDT	0.41	5.52	0.34	9.23e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6539267	0.516	rs17218455	chr12:106716441	C/T	cg00173435	chr12:106696525	TCP11L2	0.63	5.55	0.34	7.88e-8	Tourette syndrome;
SARC	cis	rs2153535	0.580	rs7341206	chr6:8470489	T/G	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	cis	rs9814567	0.727	rs9809344	chr3:134342758	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.48	-6.19	-0.38	2.76e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs5753618	0.583	rs34545960	chr22:31812462	G/A	cg07713946	chr22:31675144	LIMK2	0.35	4.88	0.3	1.94e-6	Colorectal cancer;
SARC	cis	rs11191193	0.710	rs11191170	chr10:103749743	C/T	cg15320455	chr10:103880129	LDB1	-0.59	-6.21	-0.38	2.47e-9	Educational attainment;
SARC	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg18370025	chr7:2749541	AMZ1	-0.3	-4.73	-0.3	3.95e-6	Height;
SARC	trans	rs11098499	0.954	rs6848389	chr4:120402622	A/G	cg25214090	chr10:38739885	LOC399744	0.57	7.33	0.43	3.75e-12	Corneal astigmatism;
SARC	cis	rs9815354	1.000	rs9866759	chr3:41758418	T/C	cg03022575	chr3:42003672	ULK4	0.56	5.32	0.33	2.43e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs589448	0.538	rs622656	chr12:69753595	C/T	cg20891283	chr12:69753455	YEATS4	0.52	6.33	0.38	1.22e-9	Cerebrospinal fluid biomarker levels;
SARC	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	trans	rs2347867	0.771	rs9479142	chr6:152244787	T/C	cg12042060	chr8:4846849	CSMD1	-0.4	-6.3	-0.38	1.49e-9	Age at first birth;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg14675516	chr12:95044311	TMCC3	-0.52	-6.43	-0.39	7.25e-10	Schizophrenia;
SARC	cis	rs11098499	0.697	rs6832410	chr4:120296800	A/G	cg09307838	chr4:120376055	NA	0.91	12.88	0.65	4.9e-29	Corneal astigmatism;
SARC	cis	rs5758659	0.967	rs5751250	chr22:42639645	T/G	cg15557168	chr22:42548783	NA	-0.35	-4.85	-0.3	2.29e-6	Cognitive function;
SARC	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg16479474	chr6:28041457	NA	0.4	5.58	0.34	6.66e-8	Parkinson's disease;
SARC	cis	rs9818758	0.556	rs9835439	chr3:49220330	G/C	cg07636037	chr3:49044803	WDR6	-0.78	-6.85	-0.41	6.54e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs76419734	1.000	rs72671849	chr4:106643818	T/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.84	5.42	0.33	1.51e-7	Post bronchodilator FEV1;
SARC	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg08219700	chr8:58056026	NA	0.56	5.31	0.33	2.52e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1707322	1.000	rs12124847	chr1:46380850	T/A	cg03146154	chr1:46216737	IPP	0.5	6.04	0.37	5.89e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs3106136	0.527	rs4693376	chr4:95157240	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.45	-6.57	-0.4	3.24e-10	Capecitabine sensitivity;
SARC	cis	rs55871839	0.708	rs10112089	chr8:59813429	C/T	cg07426533	chr8:59803705	TOX	-0.43	-5.77	-0.35	2.51e-8	Pneumonia;
SARC	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.46	-5.83	-0.36	1.83e-8	Personality dimensions;
SARC	cis	rs1008375	1.000	rs13119927	chr4:17691640	G/A	cg16339924	chr4:17578868	LAP3	-0.61	-7.69	-0.45	4.23e-13	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4689388	0.889	rs13128674	chr4:6294517	C/T	cg00701064	chr4:6280414	WFS1	0.54	8.58	0.49	1.38e-15	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs9790314	0.846	rs1478568	chr3:161014276	C/T	cg04691961	chr3:161091175	C3orf57	-0.67	-9.17	-0.52	2.52e-17	Morning vs. evening chronotype;
SARC	cis	rs9640161	0.659	rs77354576	chr7:150013300	A/C	cg10018233	chr7:150070692	REPIN1	0.62	8.63	0.49	9.43e-16	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs694739	0.734	rs663743	chr11:64107735	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.71	9.25	0.52	1.47e-17	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs72781680	1.000	rs6751655	chr2:24155478	A/G	cg06627628	chr2:24431161	ITSN2	-0.72	-6.76	-0.4	1.09e-10	Lymphocyte counts;
SARC	cis	rs7582180	0.614	rs4149518	chr2:101013649	A/G	cg14675211	chr2:100938903	LONRF2	0.52	7.77	0.45	2.48e-13	Intelligence (multi-trait analysis);
SARC	trans	rs61931739	0.635	rs1825746	chr12:33939984	C/T	cg13010199	chr12:38710504	ALG10B	0.53	6.64	0.4	2.18e-10	Morning vs. evening chronotype;
SARC	cis	rs6815814	0.950	rs45588337	chr4:38807328	A/G	cg06935464	chr4:38784597	TLR10	0.63	6.31	0.38	1.41e-9	Breast cancer;
SARC	cis	rs4689388	0.926	rs5018647	chr4:6292799	A/C	cg00701064	chr4:6280414	WFS1	0.53	8.46	0.48	2.95e-15	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs11969893	0.850	rs9498418	chr6:101331838	A/T	cg12253828	chr6:101329408	ASCC3	1.11	7.39	0.44	2.6e-12	Economic and political preferences (immigration/crime);
SARC	cis	rs2204008	0.837	rs11168387	chr12:37962818	G/A	cg26384229	chr12:38710491	ALG10B	-0.78	-11.27	-0.59	8.73e-24	Bladder cancer;
SARC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.32	-4.73	-0.3	3.84e-6	Longevity;Endometriosis;
SARC	cis	rs920590	0.684	rs3899017	chr8:19669198	A/T	cg01411142	chr8:19674711	INTS10	0.53	6.0	0.37	7.45e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs929354	0.772	rs10228145	chr7:157007337	A/G	cg13976544	chr7:156755178	NOM1	0.41	4.88	0.3	1.93e-6	Body mass index;
SARC	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg17971929	chr21:40555470	PSMG1	-0.57	-7.15	-0.42	1.1e-11	Menarche (age at onset);
SARC	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg21017887	chr14:105400489	NA	0.5	7.07	0.42	1.8e-11	Rheumatoid arthritis;
SARC	cis	rs7582180	0.629	rs4851297	chr2:100949571	G/A	cg14675211	chr2:100938903	LONRF2	0.51	7.61	0.45	6.56e-13	Intelligence (multi-trait analysis);
SARC	cis	rs7762018	0.769	rs7766146	chr6:170070135	A/T	cg13891659	chr6:170190454	C6orf122;C6orf208	0.62	5.02	0.31	1e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs1707322	1.000	rs11211236	chr1:46443767	C/A	cg03146154	chr1:46216737	IPP	0.45	5.41	0.33	1.57e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg08859206	chr1:53392774	SCP2	0.39	5.68	0.35	3.9e-8	Monocyte count;
SARC	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg13175981	chr1:150552382	MCL1	0.53	6.79	0.41	9.12e-11	Tonsillectomy;
SARC	cis	rs4834770	0.765	rs1511016	chr4:120170355	A/T	cg09307838	chr4:120376055	NA	0.44	4.76	0.3	3.45e-6	Blood protein levels;
SARC	cis	rs17854409	1.000	rs66634465	chr20:61482306	C/T	cg07645718	chr20:61493192	TCFL5	0.77	4.97	0.31	1.32e-6	Obesity-related traits;
SARC	cis	rs9467773	1.000	rs2224380	chr6:26553943	G/A	cg11502198	chr6:26597334	ABT1	0.5	6.09	0.37	4.53e-9	Intelligence (multi-trait analysis);
SARC	cis	rs3812831	0.543	rs389108	chr13:114925389	A/G	cg08824895	chr13:115047677	UPF3A	0.52	6.72	0.4	1.39e-10	Schizophrenia;
SARC	cis	rs911555	0.504	rs745079	chr14:104073551	G/A	cg24130564	chr14:104152367	KLC1	-0.72	-10.25	-0.56	1.41e-20	Intelligence (multi-trait analysis);
SARC	cis	rs7005380	0.581	rs4871786	chr8:120936411	C/T	cg21744203	chr8:120868354	DSCC1	0.45	5.29	0.33	2.75e-7	Interstitial lung disease;
SARC	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg18876405	chr7:65276391	NA	0.47	5.45	0.34	1.27e-7	Aortic root size;
SARC	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg05861140	chr6:150128134	PCMT1	-0.41	-5.34	-0.33	2.19e-7	Lung cancer;
SARC	cis	rs8180040	0.966	rs6800271	chr3:47470787	A/T	cg27129171	chr3:47204927	SETD2	-0.66	-9.53	-0.53	2.22e-18	Colorectal cancer;
SARC	cis	rs12545912	0.909	rs12682247	chr8:9479599	A/G	cg21625330	chr8:9911636	MSRA	0.5	4.8	0.3	2.79e-6	Multiple myeloma (hyperdiploidy);
SARC	cis	rs7539409	0.651	rs6576953	chr1:84316946	A/G	cg10977910	chr1:84465055	TTLL7	0.64	6.06	0.37	5.43e-9	Alzheimer's disease;
SARC	cis	rs4727027	0.704	rs10952805	chr7:148907849	G/A	cg23583168	chr7:148888333	NA	-0.81	-12.16	-0.62	1.12e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs12142240	0.698	rs17361950	chr1:46864150	C/T	cg10495392	chr1:46806563	NSUN4	0.67	6.83	0.41	7.24e-11	Menopause (age at onset);
SARC	cis	rs6772849	0.930	rs4467479	chr3:128369055	C/G	cg01163369	chr3:128370232	RPN1	-0.34	-4.96	-0.31	1.34e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs826838	0.935	rs7301104	chr12:39182821	C/T	cg13010199	chr12:38710504	ALG10B	0.75	9.9	0.54	1.67e-19	Heart rate;
SARC	cis	rs7474896	0.537	rs598857	chr10:38302926	A/G	cg25427524	chr10:38739819	LOC399744	0.44	5.45	0.34	1.28e-7	Obesity (extreme);
SARC	cis	rs73001065	0.591	rs11668386	chr19:19531910	A/G	cg03709012	chr19:19516395	GATAD2A	1.03	7.12	0.42	1.32e-11	LDL cholesterol;
SARC	cis	rs1008375	1.000	rs3846357	chr4:17635887	A/T	cg02297831	chr4:17616191	MED28	0.49	6.31	0.38	1.39e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs751728	0.717	rs3763260	chr6:33774070	C/T	cg25922239	chr6:33757077	LEMD2	0.64	7.5	0.44	1.3e-12	Crohn's disease;
SARC	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg01448562	chr3:133502909	NA	-0.44	-6.53	-0.39	4.13e-10	Iron status biomarkers;
SARC	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg23172400	chr8:95962367	TP53INP1	-0.32	-5.53	-0.34	8.63e-8	Type 2 diabetes;
SARC	cis	rs7626444	0.625	rs7648479	chr3:196477213	G/C	cg12930392	chr3:196481615	PAK2	0.24	4.74	0.3	3.73e-6	Monocyte count;
SARC	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg24531977	chr5:56204891	C5orf35	-0.63	-5.93	-0.36	1.07e-8	Initial pursuit acceleration;
SARC	trans	rs9329221	0.525	rs4394398	chr8:10084394	C/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.35	-0.43	3.36e-12	Neuroticism;
SARC	cis	rs7089973	0.604	rs17663387	chr10:116588060	C/G	cg03647239	chr10:116582469	FAM160B1	0.54	6.98	0.42	3.03e-11	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg09664259	chr3:156544070	LEKR1	0.52	6.45	0.39	6.43e-10	Myopia (pathological);
SARC	cis	rs6964587	0.869	rs10256780	chr7:91527176	T/A	cg17063962	chr7:91808500	NA	-0.91	-14.0	-0.68	9.98e-33	Breast cancer;
SARC	cis	rs4664308	1.000	rs62175517	chr2:160911575	C/T	cg03641300	chr2:160917029	PLA2R1	-0.68	-9.15	-0.51	3.05e-17	Idiopathic membranous nephropathy;
SARC	cis	rs7633857	0.512	rs2376477	chr3:160700699	G/T	cg04691961	chr3:161091175	C3orf57	-0.46	-5.88	-0.36	1.43e-8	Educational attainment (years of education);
SARC	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.7	6.33	0.38	1.22e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs13082711	0.911	rs11717669	chr3:27458484	C/T	cg02860705	chr3:27208620	NA	0.48	6.09	0.37	4.52e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs2549003	1.000	rs3846732	chr5:131816087	T/C	cg21138405	chr5:131827807	IRF1	0.27	5.44	0.34	1.32e-7	Asthma (sex interaction);
SARC	cis	rs453301	0.658	rs9650616	chr8:8869199	T/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.55	-0.39	3.73e-10	Joint mobility (Beighton score);
SARC	cis	rs2481665	0.772	rs6668421	chr1:62536619	C/G	cg18591186	chr1:62594603	INADL	-0.57	-7.98	-0.46	6.7e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs4268898	0.662	rs2303297	chr2:24432937	C/T	cg06627628	chr2:24431161	ITSN2	-0.84	-10.12	-0.55	3.39e-20	Asthma;
SARC	cis	rs7264396	0.635	rs6060673	chr20:34482396	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.67	7.44	0.44	1.9e-12	Total cholesterol levels;
SARC	cis	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg12463550	chr7:65579703	CRCP	0.69	5.29	0.33	2.86e-7	Diabetic kidney disease;
SARC	cis	rs9896052	0.580	rs8065142	chr17:73441060	G/A	cg25649188	chr17:73499917	CASKIN2	0.35	5.06	0.31	8.46e-7	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg16414030	chr3:133502952	NA	-0.47	-6.21	-0.38	2.4e-9	Iron status biomarkers;
SARC	cis	rs7408868	1.000	rs757472	chr19:15273221	T/C	cg14696996	chr19:15285081	NOTCH3	0.94	8.14	0.47	2.44e-14	Pulse pressure;
SARC	cis	rs16976116	0.532	rs6493754	chr15:55435798	G/A	cg17854078	chr15:55489399	RSL24D1	-0.6	-5.17	-0.32	5.03e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs72781680	1.000	rs72796339	chr2:24143063	T/C	cg06627628	chr2:24431161	ITSN2	-0.68	-6.44	-0.39	6.58e-10	Lymphocyte counts;
SARC	cis	rs9303280	0.806	rs12709365	chr17:38027400	A/G	cg20243544	chr17:37824526	PNMT	0.43	5.64	0.35	4.95e-8	Self-reported allergy;
SARC	cis	rs2011503	1.000	rs78010159	chr19:19615905	C/T	cg15839431	chr19:19639596	YJEFN3	-0.48	-4.78	-0.3	3.15e-6	Bipolar disorder;
SARC	cis	rs910316	1.000	rs10873275	chr14:75531460	A/T	cg08847533	chr14:75593920	NEK9	0.94	16.01	0.72	2.1e-39	Height;
SARC	trans	rs61931739	0.500	rs7137392	chr12:34447074	T/C	cg13010199	chr12:38710504	ALG10B	0.76	10.71	0.57	5.2e-22	Morning vs. evening chronotype;
SARC	cis	rs151234	0.741	rs151227	chr16:28549508	C/T	cg01378222	chr16:28622494	SULT1A1	-0.45	-5.7	-0.35	3.61e-8	Platelet distribution width;
SARC	cis	rs611744	0.550	rs57045491	chr8:109279120	A/C	cg21045802	chr8:109455806	TTC35	0.61	7.58	0.44	8.25e-13	Dupuytren's disease;
SARC	cis	rs2486288	0.656	rs11854325	chr15:45548959	T/C	cg15395560	chr15:45543142	SLC28A2	0.29	5.59	0.34	6.44e-8	Glomerular filtration rate;
SARC	cis	rs1408799	0.523	rs10960762	chr9:12726054	G/T	cg05274944	chr9:12693694	TYRP1	0.33	4.86	0.3	2.12e-6	Eye color;Blue vs. green eyes;
SARC	cis	rs16986825	0.570	rs5762879	chr22:29286180	C/T	cg15103426	chr22:29168792	CCDC117	0.6	6.67	0.4	1.8e-10	Pancreatic cancer;
SARC	cis	rs55871839	0.559	rs1448549	chr8:59836138	C/T	cg07426533	chr8:59803705	TOX	0.47	5.24	0.32	3.58e-7	Pneumonia;
SARC	trans	rs2268365	0.500	rs9789747	chr2:170037070	A/G	cg08373610	chr2:198540621	RFTN2	0.47	6.27	0.38	1.74e-9	Blood pressure (smoking interaction);
SARC	cis	rs9911578	1.000	rs12453049	chr17:56611372	C/T	cg12560992	chr17:57184187	TRIM37	-0.8	-10.77	-0.58	3.19e-22	Intelligence (multi-trait analysis);
SARC	cis	rs3931020	0.688	rs525487	chr1:75217420	A/G	cg10128416	chr1:75198403	TYW3;CRYZ	-0.48	-4.94	-0.31	1.5e-6	Resistin levels;
SARC	cis	rs865483	0.929	rs9906140	chr17:35857151	A/G	cg06561646	chr17:35873369	DUSP14	0.47	6.36	0.38	1.08e-9	Monocyte count;
SARC	cis	rs13191362	0.507	rs2849527	chr6:163117932	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.47	5.21	0.32	4.13e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg00149659	chr3:10157352	C3orf10	0.64	6.07	0.37	5.22e-9	Alzheimer's disease;
SARC	cis	rs2070488	0.965	rs6599206	chr3:38545349	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.81	-12.87	-0.64	5.59e-29	Electrocardiographic conduction measures;
SARC	cis	rs6088590	0.561	rs3891369	chr20:33161127	C/T	cg24642439	chr20:33292090	TP53INP2	0.66	8.51	0.49	2.12e-15	Coronary artery disease;
SARC	cis	rs9457247	0.602	rs12208359	chr6:167458455	G/A	cg07741184	chr6:167504864	NA	0.37	7.05	0.42	2.04e-11	Crohn's disease;
SARC	cis	rs72781680	1.000	rs72796316	chr2:24132272	T/C	cg06627628	chr2:24431161	ITSN2	-0.7	-6.55	-0.39	3.71e-10	Lymphocyte counts;
SARC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.11	0.37	4.11e-9	Prudent dietary pattern;
SARC	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg21724239	chr8:58056113	NA	0.61	5.93	0.36	1.1e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4566357	0.615	rs2272204	chr2:227915601	G/T	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.93	-0.36	1.1e-8	Coronary artery disease;
SARC	cis	rs11190604	0.767	rs11190534	chr10:102190930	G/A	cg07080220	chr10:102295463	HIF1AN	0.71	8.15	0.47	2.29e-14	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs8016982	0.651	rs9806027	chr14:81668707	G/C	cg01989461	chr14:81687754	GTF2A1	0.76	11.04	0.59	4.46e-23	Schizophrenia;
SARC	cis	rs116095464	1.000	rs3777237	chr5:307641	C/T	cg22857025	chr5:266934	NA	-1.06	-6.91	-0.41	4.53e-11	Breast cancer;
SARC	cis	rs55794721	0.543	rs1293260	chr1:25709104	C/G	cg23205692	chr1:25664452	TMEM50A	0.41	4.94	0.31	1.49e-6	Plateletcrit;Mean corpuscular volume;
SARC	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg19077165	chr18:44547161	KATNAL2	-0.52	-7.13	-0.42	1.25e-11	Personality dimensions;
SARC	cis	rs7264396	0.790	rs2425115	chr20:34322418	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	6.01	0.37	7.06e-9	Total cholesterol levels;
SARC	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg08219700	chr8:58056026	NA	0.59	6.27	0.38	1.76e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs35833281	1.000	rs66476116	chr6:55041396	C/A	cg19977494	chr7:128431264	CCDC136	-0.71	-6.52	-0.39	4.38e-10	Morning vs. evening chronotype;
SARC	cis	rs2273669	0.667	rs12215736	chr6:109330367	A/G	cg05315195	chr6:109294784	ARMC2	-0.63	-5.7	-0.35	3.6e-8	Prostate cancer;
SARC	trans	rs61931739	0.635	rs1352208	chr12:33932543	T/C	cg26384229	chr12:38710491	ALG10B	0.55	7.13	0.42	1.26e-11	Morning vs. evening chronotype;
SARC	cis	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg18252515	chr7:66147081	NA	1.34	11.75	0.61	2.48e-25	Diabetic kidney disease;
SARC	cis	rs1153858	1.000	rs7164602	chr15:45671325	A/G	cg03999130	chr15:45571217	NA	0.39	4.98	0.31	1.25e-6	Homoarginine levels;
SARC	cis	rs1580019	0.568	rs2122633	chr7:32523870	G/T	cg07520158	chr7:32535189	LSM5;AVL9	0.55	7.11	0.42	1.39e-11	Cognitive ability;
SARC	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.51	0.34	9.64e-8	Bipolar disorder;
SARC	cis	rs1348850	0.567	rs7605493	chr2:178534983	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.4	4.74	0.3	3.7e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs911263	0.603	rs2180769	chr14:68799102	A/T	cg18825221	chr14:68749962	RAD51L1	0.4	6.98	0.42	3.09e-11	Primary biliary cholangitis;
SARC	cis	rs8180040	1.000	rs811115	chr3:47322133	C/T	cg27129171	chr3:47204927	SETD2	0.67	9.24	0.52	1.54e-17	Colorectal cancer;
SARC	cis	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg00409905	chr10:38381863	ZNF37A	0.53	6.84	0.41	6.9e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs1046896	0.553	rs8073413	chr17:80836005	G/A	cg19500275	chr17:80737654	TBCD	0.43	5.15	0.32	5.65e-7	Glycated hemoglobin levels;
SARC	cis	rs981844	0.775	rs55986083	chr4:154765640	A/C	cg14289246	chr4:154710475	SFRP2	0.62	7.05	0.42	2.05e-11	Response to statins (LDL cholesterol change);
SARC	cis	rs892961	0.932	rs6501954	chr17:75414398	G/C	cg05865280	chr17:75406074	SEPT9	0.56	8.25	0.48	1.18e-14	Airflow obstruction;
SARC	cis	rs509477	1.000	rs11660848	chr18:32574010	T/C	cg23791764	chr18:32556832	MAPRE2	-0.56	-6.62	-0.4	2.39e-10	Cerebrospinal fluid AB1-42 levels;
SARC	cis	rs15676	0.853	rs2259043	chr9:131607921	A/G	cg00228799	chr9:131580591	ENDOG	0.56	6.85	0.41	6.53e-11	Blood metabolite levels;
SARC	cis	rs76419734	0.558	rs7698817	chr4:106532500	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.63	6.03	0.37	6.22e-9	Post bronchodilator FEV1;
SARC	cis	rs7178909	0.835	rs8035374	chr15:90395198	G/A	cg19708238	chr15:90437601	AP3S2	0.6	7.66	0.45	5.1e-13	Common traits (Other);
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01209943	chr14:54863601	CDKN3	-0.52	-6.54	-0.39	3.79e-10	Smoking initiation;
SARC	cis	rs2439831	0.717	rs10518820	chr15:43888976	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.85	7.73	0.45	3.23e-13	Lung cancer in ever smokers;
SARC	cis	rs9316337	0.872	rs9580094	chr13:21951162	C/A	cg21080246	chr13:22033151	ZDHHC20	0.38	4.74	0.3	3.79e-6	Schizophrenia;
SARC	cis	rs2997447	0.637	rs2000403	chr1:26410161	A/G	cg19633962	chr1:26362018	EXTL1	-0.67	-5.78	-0.35	2.43e-8	QRS complex (12-leadsum);
SARC	trans	rs10771431	0.597	rs3759274	chr12:9353875	T/C	cg27600084	chr12:12264075	NA	0.52	6.87	0.41	5.96e-11	Breast size;
SARC	cis	rs2073300	0.536	rs6137947	chr20:23414630	C/A	cg16736954	chr20:23401023	NAPB	0.77	4.79	0.3	3.02e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs2228479	0.702	rs2074903	chr16:89811663	T/C	cg00800038	chr16:89945340	TCF25	-0.74	-5.1	-0.32	7.08e-7	Skin colour saturation;
SARC	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.46	5.39	0.33	1.72e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg09021430	chr5:549028	NA	-0.42	-5.46	-0.34	1.19e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs7216064	0.953	rs75231441	chr17:65885485	A/G	cg12091567	chr17:66097778	LOC651250	-0.64	-6.45	-0.39	6.56e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs9457247	1.000	rs2149085	chr6:167371110	T/C	cg07741184	chr6:167504864	NA	-0.3	-5.6	-0.34	5.89e-8	Crohn's disease;
SARC	cis	rs10779751	0.922	rs2746638	chr1:11278125	T/C	cg08854313	chr1:11322531	MTOR	0.79	11.2	0.59	1.41e-23	Body mass index;
SARC	cis	rs3126085	1.000	rs55957623	chr1:152223196	T/A	cg26876637	chr1:152193138	HRNR	-0.49	-5.02	-0.31	1.02e-6	Atopic dermatitis;
SARC	cis	rs5758511	0.680	rs5758662	chr22:42628088	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.46	6.9	0.41	4.87e-11	Birth weight;
SARC	cis	rs9902453	1.000	rs4465650	chr17:28396721	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	6.45	0.39	6.54e-10	Coffee consumption (cups per day);
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27574066	chr17:26687382	TMEM199	0.52	6.36	0.38	1.07e-9	Smoking initiation;
SARC	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg11764359	chr7:65958608	NA	-0.79	-9.42	-0.52	4.79e-18	Aortic root size;
SARC	cis	rs698833	0.828	rs1067341	chr2:44623687	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.66	8.37	0.48	5.47e-15	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg07636037	chr3:49044803	WDR6	0.96	16.44	0.73	7.69e-41	Menarche (age at onset);
SARC	cis	rs34779708	0.966	rs113170867	chr10:35450147	C/T	cg03585969	chr10:35415529	CREM	0.39	4.79	0.3	2.91e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs10089	0.953	rs6875982	chr5:127529197	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.79	9.84	0.54	2.43e-19	Ileal carcinoids;
SARC	cis	rs2075371	0.830	rs12669960	chr7:133931782	A/G	cg11752832	chr7:134001865	SLC35B4	0.48	5.76	0.35	2.69e-8	Mean platelet volume;
SARC	cis	rs950169	1.000	rs1818950	chr15:84722521	A/G	cg24253500	chr15:84953950	NA	0.36	5.16	0.32	5.17e-7	Schizophrenia;
SARC	cis	rs4891159	0.548	rs2554830	chr18:74127702	A/G	cg24786174	chr18:74118243	ZNF516	0.72	12.18	0.62	9.65e-27	Longevity;
SARC	cis	rs3741151	0.686	rs11544310	chr11:73107592	A/G	cg17517138	chr11:73019481	ARHGEF17	0.7	5.53	0.34	8.58e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs73635312	0.850	rs77481341	chr10:8968306	T/C	cg24467326	chr10:9646929	NA	0.56	4.85	0.3	2.28e-6	Basal cell carcinoma;
SARC	cis	rs477692	0.597	rs574831	chr10:131379190	C/T	cg05714579	chr10:131428358	MGMT	-0.51	-6.67	-0.4	1.84e-10	Response to temozolomide;
SARC	cis	rs34172651	0.917	rs1465422	chr16:24772486	C/T	cg04756594	chr16:24857601	SLC5A11	0.35	5.77	0.35	2.45e-8	Intelligence (multi-trait analysis);
SARC	cis	rs17030434	0.954	rs79908936	chr4:154749305	C/T	cg14289246	chr4:154710475	SFRP2	-0.73	-7.57	-0.44	8.58e-13	Electrocardiographic conduction measures;
SARC	cis	rs3008870	1.000	rs2815371	chr1:67504313	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.9	11.21	0.59	1.34e-23	Lymphocyte percentage of white cells;
SARC	cis	rs1008375	0.931	rs1860592	chr4:17577028	C/G	cg02297831	chr4:17616191	MED28	0.49	6.22	0.38	2.31e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg22105103	chr4:187893119	NA	0.51	6.91	0.41	4.69e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4742903	0.904	rs966390	chr9:106944031	A/G	cg14250997	chr9:106856677	SMC2	0.43	5.42	0.33	1.47e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg02841227	chr6:26021843	HIST1H4A	0.56	6.93	0.41	4.18e-11	Intelligence (multi-trait analysis);
SARC	trans	rs1945213	0.694	rs67394518	chr11:55855303	G/A	cg15704280	chr7:45808275	SEPT13	0.67	6.68	0.4	1.76e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs992157	0.835	rs13031757	chr2:219151926	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.69	-10.04	-0.55	6.05e-20	Colorectal cancer;
SARC	cis	rs3218477	1.000	rs3218455	chr7:152360416	A/G	cg06618968	chr7:152373420	XRCC2	-0.76	-4.73	-0.3	3.81e-6	Mean platelet volume;
SARC	trans	rs1910358	0.554	rs10057796	chr5:23759746	C/T	cg12048552	chr3:141457385	RNF7	0.56	6.52	0.39	4.38e-10	Venous thromboembolism (SNP x SNP interaction);
SARC	trans	rs2727020	0.553	rs3907576	chr11:49536639	A/C	cg15704280	chr7:45808275	SEPT13	-0.81	-13.02	-0.65	1.8e-29	Coronary artery disease;
SARC	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg06618935	chr21:46677482	NA	-0.38	-5.01	-0.31	1.05e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg11764359	chr7:65958608	NA	0.86	12.33	0.63	3.29e-27	Aortic root size;
SARC	cis	rs17376456	0.877	rs28637444	chr5:93495548	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.61	5.12	0.32	6.49e-7	Diabetic retinopathy;
SARC	cis	rs2153535	0.563	rs1796687	chr6:8536118	C/G	cg07606381	chr6:8435919	SLC35B3	0.75	9.93	0.55	1.34e-19	Motion sickness;
SARC	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg11764359	chr7:65958608	NA	0.79	9.88	0.54	1.93e-19	Aortic root size;
SARC	cis	rs4642101	0.793	rs12714880	chr3:12832101	G/A	cg05775895	chr3:12838266	CAND2	0.73	11.54	0.6	1.18e-24	QRS complex (12-leadsum);
SARC	cis	rs2834188	0.924	rs2007849	chr21:34681116	G/A	cg14352951	chr21:34696688	IFNAR1	0.45	5.56	0.34	7.26e-8	Narcolepsy;
SARC	cis	rs739401	0.572	rs7111857	chr11:3068106	A/G	cg25174290	chr11:3078921	CARS	-0.6	-8.53	-0.49	1.87e-15	Longevity;
SARC	cis	rs673253	0.662	rs11586016	chr1:44031793	G/C	cg10881128	chr1:44031826	PTPRF	0.36	5.0	0.31	1.13e-6	Intelligence (multi-trait analysis);
SARC	trans	rs2727020	0.701	rs7949044	chr11:49597334	C/T	cg15704280	chr7:45808275	SEPT13	-0.8	-11.15	-0.59	2.0500000000000001e-23	Coronary artery disease;
SARC	trans	rs9929218	0.906	rs9933844	chr16:68747001	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.65	-8.33	-0.48	6.83e-15	Colorectal cancer;
SARC	cis	rs2658782	0.654	rs2605617	chr11:93243333	T/C	cg15737290	chr11:93063684	CCDC67	0.77	8.85	0.5	2.29e-16	Pulmonary function decline;
SARC	cis	rs6500602	0.702	rs4786493	chr16:4500122	C/T	cg09269891	chr16:3843415	CREBBP	-0.41	-4.97	-0.31	1.33e-6	Schizophrenia;
SARC	cis	rs7568458	0.905	rs17026396	chr2:85759127	C/T	cg17127132	chr2:85788382	GGCX	-0.42	-5.63	-0.35	5.25e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs7592578	0.640	rs56127319	chr2:191296429	G/A	cg25963032	chr2:191064776	C2orf88	-0.49	-5.7	-0.35	3.59e-8	Diastolic blood pressure;
SARC	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg26818010	chr10:134567672	INPP5A	-0.65	-6.92	-0.41	4.21e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs7647973	0.593	rs55997059	chr3:49858661	A/T	cg13072238	chr3:49761600	GMPPB	0.6	6.08	0.37	4.8e-9	Menarche (age at onset);
SARC	cis	rs2952156	1.000	rs1565923	chr17:37858678	A/G	cg00129232	chr17:37814104	STARD3	-0.68	-8.8	-0.5	3.08e-16	Asthma;
SARC	cis	rs4803455	0.565	rs11083616	chr19:41865643	A/G	cg09537434	chr19:41945824	ATP5SL	0.64	8.56	0.49	1.54e-15	Migraine;Coronary artery disease;
SARC	cis	rs9457247	0.935	rs2149093	chr6:167373045	T/C	cg23791538	chr6:167370224	RNASET2	0.62	8.55	0.49	1.63e-15	Crohn's disease;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15291235	chr17:48172663	PDK2	0.51	6.47	0.39	5.63e-10	Smoking initiation;
SARC	cis	rs2013441	1.000	rs2526484	chr17:20103760	A/G	cg13482628	chr17:19912719	NA	-0.46	-5.85	-0.36	1.61e-8	Obesity-related traits;
SARC	cis	rs1707322	0.721	rs4415615	chr1:46132109	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.25	0.38	1.97e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9902453	0.900	rs12451122	chr17:28486376	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	6.52	0.39	4.25e-10	Coffee consumption (cups per day);
SARC	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg11878867	chr6:150167359	LRP11	-0.36	-4.85	-0.3	2.23e-6	Lung cancer;
SARC	cis	rs644799	1.000	rs680134	chr11:95559517	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.68	9.17	0.51	2.6e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg09699651	chr6:150184138	LRP11	0.39	4.87	0.3	2.04e-6	Lung cancer;
SARC	cis	rs9715521	0.677	rs67500083	chr4:59862419	C/T	cg11281224	chr4:60001000	NA	-0.5	-6.21	-0.38	2.41e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs6866344	0.570	rs1079487	chr5:178136005	G/A	cg10224037	chr5:178157518	ZNF354A	1.02	14.41	0.69	4.21e-34	Neutrophil percentage of white cells;
SARC	cis	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg05623727	chr3:50126028	RBM5	-0.33	-4.98	-0.31	1.26e-6	Intelligence (multi-trait analysis);
SARC	trans	rs7937682	0.961	rs11601674	chr11:111634354	C/T	cg18187862	chr3:45730750	SACM1L	0.6	7.38	0.44	2.75e-12	Primary sclerosing cholangitis;
SARC	cis	rs3768617	0.510	rs1413389	chr1:183096668	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.82e-21	Fuchs's corneal dystrophy;
SARC	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg18252515	chr7:66147081	NA	-1.3	-11.62	-0.61	6.33e-25	Diabetic kidney disease;
SARC	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg15448220	chr1:150897856	SETDB1	0.46	6.02	0.37	6.66e-9	Tonsillectomy;
SARC	cis	rs2075371	0.932	rs11766132	chr7:133993062	T/C	cg11752832	chr7:134001865	SLC35B4	0.51	6.34	0.38	1.2e-9	Mean platelet volume;
SARC	cis	rs4803468	1.000	rs284663	chr19:41932612	C/T	cg09537434	chr19:41945824	ATP5SL	-0.98	-17.29	-0.75	1.15e-43	Height;
SARC	trans	rs2727020	0.521	rs7101761	chr11:49598178	G/A	cg03929089	chr4:120376271	NA	-0.69	-7.39	-0.44	2.61e-12	Coronary artery disease;
SARC	cis	rs576982	1	rs576982	chr15:78870803	C/T	cg24631222	chr15:78858424	CHRNA5	0.74	9.99	0.55	8.43e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs17270561	0.609	rs4711101	chr6:25741970	A/G	cg16482183	chr6:26056742	HIST1H1C	0.43	5.08	0.32	7.76e-7	Iron status biomarkers;
SARC	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg18876405	chr7:65276391	NA	-0.46	-5.32	-0.33	2.38e-7	Aortic root size;
SARC	cis	rs8114671	0.836	rs2425012	chr20:33581955	G/A	cg08999081	chr20:33150536	PIGU	-0.33	-4.79	-0.3	2.92e-6	Height;
SARC	cis	rs56114371	0.530	rs9357045	chr6:27688927	G/A	cg17221315	chr6:27791827	HIST1H4J	0.51	4.76	0.3	3.38e-6	Breast cancer;
SARC	cis	rs4555082	0.957	rs10140586	chr14:105749582	A/G	cg06808227	chr14:105710500	BRF1	-0.54	-7.41	-0.44	2.37e-12	Mean platelet volume;Platelet distribution width;
SARC	cis	rs7647973	0.769	rs6772452	chr3:49040462	A/G	cg07636037	chr3:49044803	WDR6	0.92	10.97	0.58	7.65e-23	Menarche (age at onset);
SARC	cis	rs12079745	0.793	rs76254504	chr1:169182779	T/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.78	-5.14	-0.32	5.81e-7	QT interval;
SARC	cis	rs12142240	0.698	rs6703374	chr1:46862332	C/G	cg14993813	chr1:46806288	NSUN4	-0.52	-5.56	-0.34	7.46e-8	Menopause (age at onset);
SARC	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg08219700	chr8:58056026	NA	0.59	6.29	0.38	1.55e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs910316	1.000	rs12588240	chr14:75612083	C/A	cg06637938	chr14:75390232	RPS6KL1	0.49	6.98	0.42	3.13e-11	Height;
SARC	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6866344	0.570	rs56236920	chr5:178144617	C/T	cg10224037	chr5:178157518	ZNF354A	0.98	13.54	0.66	3.42e-31	Neutrophil percentage of white cells;
SARC	cis	rs2250402	1.000	rs2250402	chr15:40322552	G/T	cg01081584	chr15:40268610	EIF2AK4	-0.63	-4.9	-0.31	1.82e-6	Corneal curvature;
SARC	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg00684032	chr4:1343700	KIAA1530	0.37	5.34	0.33	2.24e-7	Obesity-related traits;
SARC	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.58	-7.56	-0.44	9.36e-13	Mean platelet volume;
SARC	cis	rs11098499	0.691	rs9307471	chr4:120261262	G/A	cg09307838	chr4:120376055	NA	0.75	10.4	0.56	4.7e-21	Corneal astigmatism;
SARC	cis	rs10463554	0.927	rs158245	chr5:102409505	G/T	cg23492399	chr5:102201601	PAM	-0.52	-5.7	-0.35	3.63e-8	Parkinson's disease;
SARC	cis	rs12545109	0.800	rs2576599	chr8:57388410	G/A	cg19413350	chr8:57351067	NA	-0.43	-4.78	-0.3	3.07e-6	Obesity-related traits;
SARC	cis	rs4727027	0.754	rs917124	chr7:148851213	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	5.37	0.33	1.88e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs6450176	0.556	rs111423662	chr5:53288661	T/C	ch.5.1024479R	chr5:53302184	ARL15	-1.07	-10.91	-0.58	1.14e-22	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	11.14	0.59	2.19e-23	Platelet count;
SARC	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg11987759	chr7:65425863	GUSB	-0.5	-6.19	-0.38	2.62e-9	Aortic root size;
SARC	cis	rs10870270	1.000	rs10870232	chr10:133738537	T/G	cg26149184	chr10:133730230	NA	0.47	5.39	0.33	1.68e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs1865721	0.771	rs6566092	chr18:73136496	C/T	cg26385618	chr18:73139727	C18orf62	-0.4	-5.53	-0.34	8.56e-8	Intelligence;
SARC	trans	rs2018683	0.834	rs2012754	chr7:29026257	G/A	cg19402173	chr7:128379420	CALU	-0.71	-9.48	-0.53	3.15e-18	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	7.77	0.45	2.56e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9527	0.590	rs7092029	chr10:104823909	A/T	cg04362960	chr10:104952993	NT5C2	0.43	5.0	0.31	1.11e-6	Arsenic metabolism;
SARC	cis	rs4803468	1.000	rs3213861	chr19:41919944	A/C	cg14132834	chr19:41945861	ATP5SL	-0.55	-7.19	-0.43	8.79e-12	Height;
SARC	cis	rs12709013	0.591	rs30840	chr16:58744069	C/T	cg04273148	chr16:57808038	KIFC3	0.4	5.39	0.33	1.69e-7	Blood metabolite ratios;
SARC	cis	rs7772486	0.720	rs7752286	chr6:146072662	C/T	cg23711669	chr6:146136114	FBXO30	-0.89	-15.33	-0.71	3.72e-37	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12540874	0.529	rs732215	chr7:50544063	A/C	cg18232548	chr7:50535776	DDC	-0.42	-5.06	-0.31	8.37e-7	Systemic sclerosis;
SARC	cis	rs7084402	0.905	rs7098329	chr10:60276915	C/T	cg07615347	chr10:60278583	BICC1	-0.6	-8.8	-0.5	3.04e-16	Refractive error;
SARC	cis	rs1707322	1.000	rs785465	chr1:46522577	G/T	cg03146154	chr1:46216737	IPP	0.47	5.6	0.34	6.02e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7659604	1.000	rs34952897	chr4:122664409	C/T	cg19748678	chr4:122722346	EXOSC9	0.43	5.28	0.33	2.89e-7	Type 2 diabetes;
SARC	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg22920501	chr2:26401640	FAM59B	-0.56	-7.32	-0.43	4.02e-12	Gut microbiome composition (summer);
SARC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg09436375	chr6:42928200	GNMT	-0.36	-5.66	-0.35	4.41e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs6952809	0.532	rs6461361	chr7:2432167	A/G	cg05083358	chr7:2394359	EIF3B	-0.58	-5.38	-0.33	1.83e-7	Multiple sclerosis;
SARC	cis	rs17381785	0.531	rs34479500	chr4:14939389	G/A	cg12377275	chr4:15005593	CPEB2	0.48	4.96	0.31	1.36e-6	Urate levels in overweight individuals;
SARC	cis	rs7681440	0.904	rs6532192	chr4:90764131	G/A	cg06632027	chr4:90757378	SNCA	0.41	5.88	0.36	1.38e-8	Dementia with Lewy bodies;
SARC	cis	rs9398803	0.865	rs1907067	chr6:126837663	A/C	cg20229609	chr6:126660872	C6orf173	0.4	5.74	0.35	2.98e-8	Male-pattern baldness;
SARC	cis	rs9303401	0.659	rs62081314	chr17:56778328	A/G	cg25039879	chr17:56429692	SUPT4H1	0.68	6.36	0.38	1.03e-9	Cognitive test performance;
SARC	cis	rs7615952	0.932	rs1976458	chr3:125647512	T/G	cg05084668	chr3:125655381	ALG1L	-0.68	-6.71	-0.4	1.43e-10	Blood pressure (smoking interaction);
SARC	cis	rs9549367	0.789	rs9549718	chr13:113909822	A/G	cg18105134	chr13:113819100	PROZ	-0.46	-6.69	-0.4	1.62e-10	Platelet distribution width;
SARC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.34	-5.18	-0.32	4.86e-7	Longevity;Endometriosis;
SARC	cis	rs478304	0.654	rs7934036	chr11:65451020	G/T	cg27068330	chr11:65405492	SIPA1	-0.39	-4.75	-0.3	3.56e-6	Acne (severe);
SARC	cis	rs12079745	0.793	rs12094791	chr1:169387911	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.81	-5.31	-0.33	2.62e-7	QT interval;
SARC	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.97	-15.37	-0.71	2.85e-37	Chronic sinus infection;
SARC	cis	rs73206853	0.764	rs55887805	chr12:110597246	T/C	cg10860002	chr12:110842031	ANAPC7	0.65	5.28	0.33	2.93e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg24829409	chr8:58192753	C8orf71	-0.62	-6.41	-0.39	7.8e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs10465746	0.747	rs34155960	chr1:84447539	T/G	cg10977910	chr1:84465055	TTLL7	0.4	4.91	0.31	1.71e-6	Obesity-related traits;
SARC	cis	rs751728	1.000	rs2395449	chr6:33728755	T/A	cg25922239	chr6:33757077	LEMD2	0.8	10.44	0.56	3.49e-21	Crohn's disease;
SARC	cis	rs858239	0.932	rs1728313	chr7:23271031	A/C	cg23682824	chr7:23144976	KLHL7	0.62	7.73	0.45	3.11e-13	Cerebrospinal fluid biomarker levels;
SARC	cis	rs2731664	0.792	rs1130857	chr5:176863519	G/C	cg23176889	chr5:176863531	GRK6	-0.57	-8.32	-0.48	7.42e-15	Intelligence (multi-trait analysis);
SARC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.7	-7.1	-0.42	1.45e-11	Platelet count;
SARC	cis	rs4481887	1.000	rs11204626	chr1:248458974	T/A	cg00666640	chr1:248458726	OR2T12	0.33	5.5	0.34	9.82e-8	Common traits (Other);
SARC	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg22968622	chr17:43663579	NA	1.17	15.59	0.71	5.32e-38	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg17971929	chr21:40555470	PSMG1	-0.58	-7.34	-0.43	3.58e-12	Menarche (age at onset);
SARC	cis	rs6121246	0.609	rs2376998	chr20:30340663	T/C	cg13852791	chr20:30311386	BCL2L1	0.81	9.97	0.55	9.89e-20	Mean corpuscular hemoglobin;
SARC	cis	rs2735413	0.918	rs12931394	chr16:78081629	G/A	cg04733911	chr16:78082701	NA	-0.3	-5.47	-0.34	1.17e-7	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs796364	0.951	rs281769	chr2:200809709	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.78	7.15	0.42	1.12e-11	Schizophrenia;
SARC	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.78	-8.32	-0.48	7.3e-15	Alzheimer's disease;
SARC	cis	rs1153858	1.000	rs4271549	chr15:45652730	G/A	cg14582100	chr15:45693742	SPATA5L1	0.35	4.82	0.3	2.64e-6	Homoarginine levels;
SARC	cis	rs13191362	1.000	rs35911566	chr6:162994154	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.57	5.49	0.34	1.03e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs10493773	0.630	rs3753790	chr1:86174772	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.62	-10.01	-0.55	7.27e-20	Urate levels in overweight individuals;
SARC	trans	rs61931739	0.534	rs7138522	chr12:34039762	G/A	cg13010199	chr12:38710504	ALG10B	0.76	10.32	0.56	8.23e-21	Morning vs. evening chronotype;
SARC	cis	rs11718455	1.000	rs17076273	chr3:44020113	A/G	cg21419209	chr3:44054225	NA	-0.41	-5.0	-0.31	1.1e-6	Coronary artery disease;
SARC	cis	rs9392918	0.600	rs7770372	chr6:7700065	C/T	cg23089261	chr6:7723385	NA	0.53	6.76	0.4	1.11e-10	Height;
SARC	cis	rs4848143	0.864	rs921089	chr2:121808766	C/G	cg17169613	chr2:121010068	RALB	0.41	5.47	0.34	1.16e-7	Capecitabine sensitivity;
SARC	cis	rs11190604	1.000	rs11190557	chr10:102209369	G/A	cg07080220	chr10:102295463	HIF1AN	0.78	9.58	0.53	1.56e-18	Palmitoleic acid (16:1n-7) levels;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg16015205	chr1:26606912	SH3BGRL3	0.53	7.76	0.45	2.64e-13	Chemerin levels;
SARC	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg26335602	chr6:28129616	ZNF389	0.53	5.88	0.36	1.43e-8	Depression;
SARC	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.71	-9.68	-0.54	7.58e-19	Gut microbiome composition (summer);
SARC	cis	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg13072238	chr3:49761600	GMPPB	-0.41	-5.34	-0.33	2.25e-7	Intelligence (multi-trait analysis);
SARC	cis	rs10791097	1.000	rs10791098	chr11:130718711	T/G	cg12179176	chr11:130786555	SNX19	0.61	8.51	0.49	2.08e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs3812831	0.695	rs8000778	chr13:114944310	T/C	cg08824895	chr13:115047677	UPF3A	0.53	7.02	0.42	2.35e-11	Schizophrenia;
SARC	cis	rs798554	0.660	rs2644275	chr7:2854010	G/A	cg04166393	chr7:2884313	GNA12	0.42	5.19	0.32	4.53e-7	Height;
SARC	cis	rs7044106	0.762	rs1324473	chr9:123404610	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.46	-5.53	-0.34	8.52e-8	Hip circumference adjusted for BMI;
SARC	cis	rs763121	0.819	rs5750629	chr22:38985065	T/C	cg06022373	chr22:39101656	GTPBP1	0.9	12.24	0.63	6.39e-27	Menopause (age at onset);
SARC	trans	rs877282	0.838	rs34912955	chr10:772222	T/C	cg22713356	chr15:30763199	NA	1.04	10.03	0.55	6.55e-20	Uric acid levels;
SARC	cis	rs1113500	0.933	rs10881497	chr1:108634515	A/G	cg06207961	chr1:108661230	NA	-0.46	-6.01	-0.37	7.28e-9	Growth-regulated protein alpha levels;
SARC	cis	rs796364	0.806	rs11679658	chr2:200923081	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.66	-5.57	-0.34	7.12e-8	Schizophrenia;
SARC	cis	rs12681366	0.614	rs935052	chr8:95461946	T/C	cg26464482	chr8:95565502	KIAA1429	0.43	5.23	0.32	3.76e-7	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg08280861	chr8:58055591	NA	0.6	5.83	0.36	1.8e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg18225595	chr11:63971243	STIP1	0.44	5.4	0.33	1.65e-7	Mean platelet volume;
SARC	cis	rs9660992	0.590	rs1779411	chr1:205238530	C/T	cg21545522	chr1:205238299	TMCC2	0.49	6.8	0.41	8.94e-11	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs76878669	0.606	rs2282531	chr11:66099494	C/T	cg14036092	chr11:66035641	RAB1B	-0.42	-4.98	-0.31	1.24e-6	Educational attainment (years of education);
SARC	cis	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg06212747	chr3:49208901	KLHDC8B	0.51	6.48	0.39	5.37e-10	Resting heart rate;
SARC	cis	rs1030877	0.515	rs2576741	chr2:105897964	T/C	cg02079111	chr2:105885981	TGFBRAP1	0.55	6.38	0.39	9.7e-10	Obesity-related traits;
SARC	cis	rs11718455	0.960	rs13060222	chr3:44005046	A/T	cg21419209	chr3:44054225	NA	-0.41	-4.97	-0.31	1.31e-6	Coronary artery disease;
SARC	cis	rs11874712	0.899	rs11872954	chr18:43686450	A/G	cg25174615	chr18:43684699	ATP5A1;HAUS1	0.42	4.91	0.31	1.68e-6	Migraine - clinic-based;
SARC	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg13628971	chr7:2884303	GNA12	-0.54	-6.33	-0.38	1.22e-9	Height;
SARC	cis	rs73206853	0.841	rs73191851	chr12:111032305	G/A	cg10860002	chr12:110842031	ANAPC7	0.61	5.2	0.32	4.34e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs2952156	0.920	rs2517955	chr17:37843681	C/T	cg07936489	chr17:37558343	FBXL20	-0.44	-5.66	-0.35	4.38e-8	Asthma;
SARC	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg15049968	chr18:44337910	ST8SIA5	-0.38	-6.12	-0.37	3.84e-9	Personality dimensions;
SARC	cis	rs57506017	0.540	rs12699323	chr7:12253362	T/C	cg23422036	chr7:12250390	TMEM106B	0.5	6.74	0.4	1.25e-10	Neuroticism;
SARC	cis	rs9660992	0.710	rs1172136	chr1:205247097	T/G	cg21643547	chr1:205240462	TMCC2	-0.63	-8.04	-0.47	4.5e-14	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs2197308	0.765	rs68029712	chr12:37906585	T/G	cg13010199	chr12:38710504	ALG10B	0.8	11.02	0.59	5.3e-23	Morning vs. evening chronotype;
SARC	cis	rs2832191	1.000	rs2832189	chr21:30487414	C/T	cg08807101	chr21:30365312	RNF160	-0.76	-10.6	-0.57	1.09e-21	Dental caries;
SARC	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg19077165	chr18:44547161	KATNAL2	0.53	7.26	0.43	5.89e-12	Personality dimensions;
SARC	cis	rs546131	1.000	rs546131	chr11:34851760	G/C	cg06937548	chr11:34938143	PDHX;APIP	0.52	6.74	0.4	1.24e-10	Lung disease severity in cystic fibrosis;
SARC	cis	rs7918232	0.627	rs10829165	chr10:27319465	A/G	cg14442939	chr10:27389572	ANKRD26	0.47	5.13	0.32	6.01e-7	Breast cancer;
SARC	cis	rs2153535	0.580	rs718503	chr6:8527463	A/T	cg23788917	chr6:8435910	SLC35B3	0.62	8.31	0.48	8.11e-15	Motion sickness;
SARC	cis	rs9911578	0.935	rs7218105	chr17:57041119	A/G	cg12560992	chr17:57184187	TRIM37	0.85	11.74	0.61	2.67e-25	Intelligence (multi-trait analysis);
SARC	cis	rs17125944	0.615	rs2025632	chr14:53294319	T/C	cg00686598	chr14:53173677	PSMC6	-0.74	-5.68	-0.35	4.03e-8	Alzheimer's disease (late onset);
SARC	cis	rs76419734	1.000	rs112654776	chr4:106765058	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	5.31	0.33	2.52e-7	Post bronchodilator FEV1;
SARC	cis	rs734999	0.588	rs2764848	chr1:2530694	G/A	cg00980319	chr1:2560884	MMEL1	0.35	4.95	0.31	1.44e-6	Ulcerative colitis;
SARC	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg16606324	chr3:10149918	C3orf24	0.49	5.04	0.31	9.35e-7	Alzheimer's disease;
SARC	cis	rs1008375	1.000	rs10440301	chr4:17663199	G/A	cg16339924	chr4:17578868	LAP3	0.68	8.81	0.5	2.88e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9393692	0.676	rs806977	chr6:26189615	A/G	cg14598143	chr6:26205244	HIST1H4E	0.41	4.72	0.3	4.01e-6	Educational attainment;
SARC	cis	rs2836974	0.583	rs2776306	chr21:40713754	A/G	cg11644478	chr21:40555479	PSMG1	0.66	8.47	0.49	2.71e-15	Cognitive function;
SARC	cis	rs11098499	0.618	rs6858383	chr4:120296772	T/C	cg09307838	chr4:120376055	NA	0.91	12.88	0.65	4.9e-29	Corneal astigmatism;
SARC	cis	rs9902453	0.780	rs57037139	chr17:28173283	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	7.22	0.43	7.39e-12	Coffee consumption (cups per day);
SARC	cis	rs3733585	0.699	rs4408959	chr4:9948868	C/T	cg11266682	chr4:10021025	SLC2A9	-0.37	-6.46	-0.39	6.11e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7408868	0.908	rs45591935	chr19:15277006	T/C	cg14696996	chr19:15285081	NOTCH3	0.99	8.54	0.49	1.76e-15	Pulse pressure;
SARC	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg08109568	chr15:31115862	NA	-0.52	-6.71	-0.4	1.46e-10	Huntington's disease progression;
SARC	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg24642844	chr7:1081250	C7orf50	-0.53	-5.9	-0.36	1.27e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs477692	0.870	rs512655	chr10:131424547	T/A	cg05714579	chr10:131428358	MGMT	0.57	7.69	0.45	4.14e-13	Response to temozolomide;
SARC	cis	rs67311347	0.866	rs3214006	chr3:40352134	C/T	cg09455208	chr3:40491958	NA	0.39	6.1	0.37	4.32e-9	Renal cell carcinoma;
SARC	cis	rs4911259	0.552	rs13038017	chr20:31467551	T/C	cg13636640	chr20:31349939	DNMT3B	-0.67	-9.22	-0.52	1.84e-17	Inflammatory bowel disease;
SARC	trans	rs2727020	0.658	rs4980440	chr11:49386017	C/T	cg03929089	chr4:120376271	NA	-0.8	-11.95	-0.62	5.47e-26	Coronary artery disease;
SARC	cis	rs9322193	0.607	rs9322229	chr6:150230085	A/G	cg01145232	chr6:150245071	RAET1G	0.41	4.8	0.3	2.86e-6	Lung cancer;
SARC	cis	rs9858542	0.953	rs67216675	chr3:49493151	G/T	cg03060546	chr3:49711283	APEH	-0.58	-7.13	-0.42	1.28e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs897080	0.515	rs1067349	chr2:44670369	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	5.83	0.36	1.84e-8	Height;
SARC	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs3820928	0.934	rs66959645	chr2:227761582	C/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-6.9	-0.41	4.77e-11	Pulmonary function;
SARC	cis	rs7092929	0.941	rs575738	chr10:3579283	C/A	cg14308648	chr10:3568949	NA	0.5	5.05	0.31	9.08e-7	Coronary artery calcification;
SARC	cis	rs12893668	0.703	rs4906337	chr14:104040414	C/A	cg26031613	chr14:104095156	KLC1	-0.57	-6.31	-0.38	1.38e-9	Reticulocyte count;
SARC	cis	rs477895	1.000	rs7947143	chr11:64090422	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	5.77	0.35	2.47e-8	Mean platelet volume;
SARC	cis	rs1018836	0.923	rs6986088	chr8:91538474	A/C	cg16814680	chr8:91681699	NA	-0.8	-12.93	-0.65	3.53e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs7681440	0.904	rs28750169	chr4:90774303	A/G	cg06632027	chr4:90757378	SNCA	0.4	5.68	0.35	3.9e-8	Dementia with Lewy bodies;
SARC	cis	rs6449957	0.639	rs251397	chr5:67508511	A/G	cg23036683	chr5:67512108	NA	0.39	4.77	0.3	3.27e-6	Cleft lip with or without cleft palate;
SARC	cis	rs8141529	0.529	rs5762812	chr22:29200117	T/C	cg02153584	chr22:29168773	CCDC117	0.66	6.58	0.4	3.11e-10	Lymphocyte counts;
SARC	cis	rs3087591	0.708	rs2107359	chr17:29697223	A/T	cg24425628	chr17:29625626	OMG;NF1	0.42	5.29	0.33	2.78e-7	Hip circumference;
SARC	cis	rs11676348	0.772	rs12471105	chr2:218950209	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-5.86	-0.36	1.61e-8	Ulcerative colitis;
SARC	trans	rs9325144	0.555	rs7955128	chr12:38684121	A/T	cg23762105	chr12:34175262	ALG10	-0.53	-7.09	-0.42	1.64e-11	Morning vs. evening chronotype;
SARC	cis	rs7027203	0.828	rs10122041	chr9:96615517	A/G	cg14598338	chr9:96623480	NA	-0.53	-7.64	-0.45	5.61e-13	DNA methylation (variation);
SARC	cis	rs7824557	0.627	rs7838897	chr8:11207326	C/A	cg21775007	chr8:11205619	TDH	0.67	8.68	0.49	6.75e-16	Retinal vascular caliber;
SARC	cis	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg05623727	chr3:50126028	RBM5	-0.33	-5.04	-0.31	9.21e-7	Intelligence (multi-trait analysis);
SARC	cis	rs11711311	1.000	rs7649590	chr3:113447267	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	8.14	0.47	2.31e-14	IgG glycosylation;
SARC	cis	rs698833	0.548	rs6721421	chr2:44535686	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.65	7.32	0.43	4.07e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg21132104	chr15:45694354	SPATA5L1	0.77	10.98	0.58	6.87e-23	Metabolite levels (small molecules and protein measures);
SARC	cis	rs5753618	0.583	rs5749268	chr22:31809152	G/A	cg07713946	chr22:31675144	LIMK2	0.35	4.88	0.3	1.94e-6	Colorectal cancer;
SARC	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg19223190	chr17:80058835	NA	0.44	6.19	0.38	2.67e-9	Life satisfaction;
SARC	trans	rs10838801	1	rs10838801	chr11:48098280	G/A	cg15704280	chr7:45808275	SEPT13	-0.67	-8.73	-0.5	4.86e-16	Height;
SARC	cis	rs2404602	0.716	rs4079681	chr15:76695230	G/A	cg22467129	chr15:76604101	ETFA	-0.36	-4.87	-0.3	2.09e-6	Blood metabolite levels;
SARC	trans	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg21659725	chr3:3221576	CRBN	0.53	6.83	0.41	7.25e-11	Intelligence (multi-trait analysis);
SARC	cis	rs892961	0.806	rs312910	chr17:75413961	A/C	cg05865280	chr17:75406074	SEPT9	0.57	8.6	0.49	1.2e-15	Airflow obstruction;
SARC	cis	rs6788895	0.661	rs60259684	chr3:150494951	A/G	cg09723797	chr3:150481914	SIAH2	0.78	5.13	0.32	6.09e-7	Breast cancer;
SARC	cis	rs6807306	1.000	rs9829009	chr3:167364471	C/T	cg24249075	chr3:167452484	PDCD10;SERPINI1	-0.55	-5.53	-0.34	8.53e-8	Mean platelet volume;
SARC	cis	rs7582180	0.629	rs11682557	chr2:100948008	C/A	cg14675211	chr2:100938903	LONRF2	0.51	7.62	0.45	6.43e-13	Intelligence (multi-trait analysis);
SARC	cis	rs7584330	0.666	rs72620819	chr2:238354982	C/T	cg14458575	chr2:238380390	NA	0.6	6.58	0.4	3.16e-10	Prostate cancer;
SARC	cis	rs1707322	1.000	rs4606257	chr1:46307268	G/A	cg06784218	chr1:46089804	CCDC17	0.35	6.15	0.37	3.32e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs5743618	0.537	rs7694115	chr4:38779094	A/G	cg06935464	chr4:38784597	TLR10	0.38	4.79	0.3	2.96e-6	Asthma;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs13202913	0.709	rs11965449	chr6:151830598	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	-0.62	-6.06	-0.37	5.44e-9	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs12912251	0.894	rs7183893	chr15:38996981	A/C	cg01338139	chr15:38987640	C15orf53	-0.46	-5.28	-0.33	3e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
SARC	cis	rs6484504	0.600	rs2616815	chr11:31327316	C/T	cg02090638	chr11:31391270	DNAJC24;DCDC1	0.41	5.06	0.31	8.51e-7	Red blood cell count;
SARC	cis	rs752010	0.631	rs1073197	chr1:42059822	C/T	cg06885757	chr1:42089581	HIVEP3	-0.49	-6.8	-0.41	8.63e-11	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs4481887	0.927	rs4409694	chr1:248485498	C/T	cg00666640	chr1:248458726	OR2T12	0.35	5.78	0.35	2.45e-8	Common traits (Other);
SARC	cis	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg08975724	chr8:8085496	FLJ10661	0.46	5.57	0.34	6.97e-8	Mood instability;
SARC	cis	rs6120849	0.754	rs6088691	chr20:33633758	C/T	cg24642439	chr20:33292090	TP53INP2	0.57	5.48	0.34	1.1e-7	Protein C levels;
SARC	cis	rs11169225	0.906	rs3782319	chr12:50345079	G/A	cg04450003	chr12:50355995	AQP5	0.6	8.51	0.49	2.18e-15	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs7113850	0.541	rs75893426	chr11:24210429	T/C	ch.11.24196551F	chr11:24239977	NA	0.78	6.06	0.37	5.36e-9	Bone fracture in osteoporosis;
SARC	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.97	10.28	0.56	1.11e-20	Platelet count;
SARC	cis	rs7223966	1.000	rs72848797	chr17:61934664	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	7.59	0.45	7.54e-13	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs34172651	0.583	rs4787649	chr16:24700215	C/T	cg04756594	chr16:24857601	SLC5A11	-0.38	-5.0	-0.31	1.15e-6	Intelligence (multi-trait analysis);
SARC	cis	rs10791097	0.694	rs2236711	chr11:130739284	G/A	cg12179176	chr11:130786555	SNX19	0.73	10.91	0.58	1.19e-22	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg11965913	chr1:205819406	PM20D1	-0.9	-13.47	-0.66	5.62e-31	Menarche (age at onset);
SARC	cis	rs6580649	0.882	rs7133249	chr12:48456823	C/T	cg24011408	chr12:48396354	COL2A1	-0.48	-5.31	-0.33	2.56e-7	Lung cancer;
SARC	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	11.6	0.61	7.26e-25	Alzheimer's disease;
SARC	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg19077165	chr18:44547161	KATNAL2	-0.55	-7.6	-0.45	7.25e-13	Personality dimensions;
SARC	cis	rs950027	0.620	rs1153855	chr15:45660758	C/G	cg15395560	chr15:45543142	SLC28A2	-0.27	-5.26	-0.33	3.29e-7	Response to fenofibrate (adiponectin levels);
SARC	cis	rs1949733	0.636	rs16842498	chr4:8539529	C/T	cg11789530	chr4:8429930	ACOX3	-0.62	-6.9	-0.41	5e-11	Response to antineoplastic agents;
SARC	cis	rs7296418	0.754	rs1619283	chr12:123717362	A/G	cg05973401	chr12:123451056	ABCB9	0.55	6.42	0.39	7.37e-10	Platelet count;
SARC	cis	rs12134245	1.000	rs12134245	chr1:92021464	C/T	cg25838465	chr1:92012736	NA	-0.67	-9.73	-0.54	5.4e-19	Breast cancer;
SARC	cis	rs17600642	0.694	rs72814533	chr10:72444918	G/C	cg19779893	chr10:72451501	ADAMTS14	-0.35	-5.5	-0.34	1.02e-7	Bipolar disorder;
SARC	cis	rs11098499	0.954	rs11729521	chr4:120416788	T/C	cg09307838	chr4:120376055	NA	0.93	12.38	0.63	2.24e-27	Corneal astigmatism;
SARC	cis	rs12311304	0.901	rs12296735	chr12:15412945	A/G	cg08258403	chr12:15378311	NA	0.43	6.68	0.4	1.76e-10	Behavioural disinhibition (generation interaction);
SARC	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	11.55	0.6	1.06e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.94	10.04	0.55	5.91e-20	Platelet count;
SARC	cis	rs1865760	0.566	rs9467672	chr6:26083904	C/T	cg16482183	chr6:26056742	HIST1H1C	0.47	5.91	0.36	1.22e-8	Height;
SARC	cis	rs6840360	0.554	rs4643789	chr4:152726691	C/T	cg22705602	chr4:152727874	NA	-0.47	-8.09	-0.47	3.22e-14	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg18252515	chr7:66147081	NA	0.59	6.34	0.38	1.16e-9	Aortic root size;
SARC	trans	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg20271681	chr21:44299600	WDR4	-0.66	-6.32	-0.38	1.29e-9	Cutaneous psoriasis;
SARC	trans	rs9650657	0.504	rs10108347	chr8:11033517	G/C	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.67	-0.45	4.6e-13	Neuroticism;
SARC	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg16479474	chr6:28041457	NA	0.36	5.25	0.33	3.43e-7	Depression;
SARC	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg26874164	chr19:58962979	ZNF324B	0.52	6.85	0.41	6.65e-11	Uric acid clearance;
SARC	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg00629941	chr15:75287862	SCAMP5	0.42	5.04	0.31	9.4e-7	Breast cancer;
SARC	cis	rs10979	0.965	rs9496679	chr6:143896741	G/T	cg25407410	chr6:143891975	LOC285740	-0.64	-8.78	-0.5	3.67e-16	Hypospadias;
SARC	cis	rs1318878	0.565	rs73057240	chr12:15501860	T/G	cg08258403	chr12:15378311	NA	0.51	7.0	0.42	2.68e-11	Intelligence (multi-trait analysis);
SARC	cis	rs826838	1.000	rs11183747	chr12:38822595	A/G	cg26384229	chr12:38710491	ALG10B	-0.92	-14.98	-0.7	5.51e-36	Heart rate;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08881067	chr5:74062846	NSA2;GFM2	-0.51	-6.66	-0.4	1.95e-10	Smoking initiation;
SARC	cis	rs9788682	0.747	rs7174190	chr15:78763617	C/T	cg06917634	chr15:78832804	PSMA4	-0.53	-5.5	-0.34	1.02e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs765787	0.530	rs1706831	chr15:45516230	T/C	cg25801113	chr15:45476975	SHF	0.28	4.72	0.3	4.06e-6	Uric acid levels;
SARC	cis	rs710216	0.917	rs900836	chr1:43412727	T/C	cg22176566	chr1:43424700	SLC2A1	-0.53	-5.39	-0.33	1.75e-7	Red cell distribution width;
SARC	cis	rs6912958	0.967	rs6905947	chr6:88161949	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.36	-6.01	-0.37	7.05e-9	Monocyte percentage of white cells;
SARC	cis	rs2204008	0.744	rs11519905	chr12:38222959	G/A	cg26384229	chr12:38710491	ALG10B	0.88	12.94	0.65	3.26e-29	Bladder cancer;
SARC	cis	rs10781543	0.845	rs10781540	chr9:139321836	G/A	cg14169450	chr9:139327907	INPP5E	0.45	6.18	0.38	2.77e-9	Monocyte percentage of white cells;
SARC	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg13939156	chr17:80058883	NA	-0.42	-6.48	-0.39	5.51e-10	Life satisfaction;
SARC	cis	rs568617	1.000	rs568617	chr11:65653242	C/T	cg26695010	chr11:65641043	EFEMP2	-0.49	-5.75	-0.35	2.82e-8	Crohn's disease;
SARC	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg20102877	chr2:27665638	KRTCAP3	-0.35	-4.77	-0.3	3.2e-6	Total body bone mineral density;
SARC	cis	rs735539	0.521	rs693814	chr13:21422910	A/T	cg16922012	chr13:21400325	XPO4	-0.42	-5.55	-0.34	7.62e-8	Dental caries;
SARC	cis	rs7772486	0.654	rs1011597	chr6:146075672	A/C	cg05347473	chr6:146136440	FBXO30	-0.52	-7.24	-0.43	6.61e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7552404	0.727	rs2172508	chr1:76320215	A/G	cg10523679	chr1:76189770	ACADM	0.47	5.47	0.34	1.15e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs698833	0.620	rs1067354	chr2:44663675	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	5.96	0.36	9.39e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg22535103	chr8:58192502	C8orf71	-0.7	-6.26	-0.38	1.79e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.39	4.82	0.3	2.59e-6	Tonsillectomy;
SARC	cis	rs7647973	0.626	rs7649428	chr3:49868876	A/T	cg13072238	chr3:49761600	GMPPB	0.58	5.79	0.35	2.25e-8	Menarche (age at onset);
SARC	cis	rs2120019	1.000	rs2415253	chr15:75375699	A/G	cg09165964	chr15:75287851	SCAMP5	-0.87	-13.24	-0.66	3.19e-30	Blood trace element (Zn levels);
SARC	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg12463550	chr7:65579703	CRCP	-0.49	-5.34	-0.33	2.21e-7	Aortic root size;
SARC	cis	rs6762477	0.748	rs2073726	chr3:50223593	T/A	cg24110177	chr3:50126178	RBM5	0.47	6.15	0.37	3.4e-9	Menarche (age at onset);
SARC	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.67	8.58	0.49	1.37e-15	Gut microbiome composition (summer);
SARC	cis	rs3126085	0.867	rs12748016	chr1:152197235	T/C	cg26876637	chr1:152193138	HRNR	-0.5	-5.66	-0.35	4.37e-8	Atopic dermatitis;
SARC	cis	rs3218477	1.000	rs77381421	chr7:152375537	G/C	cg06618968	chr7:152373420	XRCC2	-0.76	-4.99	-0.31	1.19e-6	Mean platelet volume;
SARC	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg06108461	chr20:60628389	TAF4	-0.92	-12.75	-0.64	1.33e-28	Body mass index;
SARC	cis	rs1144333	0.655	rs76992868	chr1:76418916	G/A	cg03433033	chr1:76189801	ACADM	0.62	5.09	0.32	7.45e-7	Attention function in attention deficit hyperactive disorder;
SARC	trans	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg06437703	chr8:37914619	EIF4EBP1	0.58	7.1	0.42	1.48e-11	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs981844	1.000	rs2606329	chr4:154654643	A/C	cg14289246	chr4:154710475	SFRP2	0.58	6.69	0.4	1.68e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs453301	0.624	rs2288671	chr8:8860894	T/C	cg06636001	chr8:8085503	FLJ10661	0.37	4.85	0.3	2.23e-6	Joint mobility (Beighton score);
SARC	cis	rs1801251	1.000	rs7606090	chr2:233606740	T/C	cg25237894	chr2:233734115	C2orf82	0.37	4.87	0.3	2.03e-6	Coronary artery disease;
SARC	cis	rs41264869	0.628	rs3795556	chr1:205112911	T/C	cg21643547	chr1:205240462	TMCC2	0.47	5.1	0.32	7.16e-7	Blood protein levels;
SARC	cis	rs9818758	0.607	rs35060561	chr3:49255503	T/C	cg07636037	chr3:49044803	WDR6	-0.79	-6.94	-0.41	3.85e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs523522	0.892	rs4767916	chr12:121024032	T/C	cg12219531	chr12:120966889	COQ5	0.82	10.7	0.57	5.52e-22	High light scatter reticulocyte count;
SARC	cis	rs7626444	0.625	rs9877495	chr3:196483280	G/A	cg12930392	chr3:196481615	PAK2	0.25	4.9	0.31	1.79e-6	Monocyte count;
SARC	cis	rs6089584	0.546	rs6061980	chr20:60618877	G/A	cg23262073	chr20:60523788	NA	-0.34	-5.22	-0.32	3.91e-7	Body mass index;
SARC	cis	rs76419734	1.000	rs17036129	chr4:106624529	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.81	4.9	0.31	1.76e-6	Post bronchodilator FEV1;
SARC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg27588902	chr6:42928151	GNMT	-0.37	-5.53	-0.34	8.38e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	trans	rs2018683	0.707	rs1874974	chr7:28967647	G/C	cg19402173	chr7:128379420	CALU	-0.54	-6.92	-0.41	4.23e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs616402	0.527	rs604369	chr1:10567208	C/A	cg07384165	chr1:10488281	NA	-0.41	-5.38	-0.33	1.83e-7	Breast size;
SARC	cis	rs4803468	1.000	rs10413735	chr19:41921071	C/T	cg09537434	chr19:41945824	ATP5SL	-0.98	-17.39	-0.75	5.41e-44	Height;
SARC	cis	rs10493773	1.000	rs2274738	chr1:86119898	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.48	-6.96	-0.41	3.51e-11	Urate levels in overweight individuals;
SARC	cis	rs1185460	0.565	rs538478	chr11:118925341	C/T	cg23280166	chr11:118938394	VPS11	-0.51	-6.55	-0.39	3.74e-10	Coronary artery disease;
SARC	cis	rs7566780	0.632	rs7580701	chr2:16678130	A/G	cg09580478	chr2:16689509	NA	0.45	6.06	0.37	5.34e-9	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs1003719	0.715	rs6579	chr21:38568308	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-8.99	-0.51	8.94e-17	Eye color traits;
SARC	cis	rs3820928	0.845	rs13415319	chr2:227878936	G/C	cg11843606	chr2:227700838	RHBDD1	-0.53	-6.58	-0.4	2.99e-10	Pulmonary function;
SARC	trans	rs7824557	0.778	rs3808502	chr8:11179458	G/T	cg15556689	chr8:8085844	FLJ10661	0.5	6.36	0.38	1.04e-9	Retinal vascular caliber;
SARC	cis	rs2204008	0.774	rs11520273	chr12:38354075	A/T	cg26384229	chr12:38710491	ALG10B	0.87	12.85	0.64	6.2e-29	Bladder cancer;
SARC	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg26039829	chr8:22132926	PIWIL2	0.43	5.97	0.36	8.65e-9	Hypertriglyceridemia;
SARC	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg18252515	chr7:66147081	NA	0.48	5.14	0.32	5.72e-7	Aortic root size;
SARC	cis	rs870825	0.616	rs4263438	chr4:185624238	C/T	cg04058563	chr4:185651563	MLF1IP	0.82	11.42	0.6	2.8e-24	Blood protein levels;
SARC	cis	rs17384381	0.859	rs12130591	chr1:85904985	C/T	cg16011679	chr1:85725395	C1orf52	0.54	5.56	0.34	7.21e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.49	0.57	2.47e-21	Prudent dietary pattern;
SARC	cis	rs9291683	0.552	rs17187075	chr4:9990328	G/C	cg00071950	chr4:10020882	SLC2A9	0.41	6.53	0.39	4.18e-10	Bone mineral density;
SARC	cis	rs2354432	0.607	rs1530336	chr1:146685121	G/A	cg25205988	chr1:146714368	CHD1L	1.06	8.87	0.5	2.02e-16	Mitochondrial DNA levels;
SARC	cis	rs2425143	1.000	rs11699793	chr20:34271574	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.15	0.32	5.46e-7	Blood protein levels;
SARC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg03452623	chr4:187889614	NA	-0.76	-11.73	-0.61	2.83e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2486288	0.656	rs2413771	chr15:45553140	A/G	cg19305227	chr15:45544335	SLC28A2	0.29	5.54	0.34	8.07e-8	Glomerular filtration rate;
SARC	cis	rs4660306	0.961	rs4660862	chr1:45955056	C/T	cg24296786	chr1:45957014	TESK2	0.58	6.72	0.4	1.35e-10	Homocysteine levels;
SARC	cis	rs7829975	0.557	rs7816427	chr8:8545884	T/C	cg06636001	chr8:8085503	FLJ10661	-0.48	-5.63	-0.35	5.11e-8	Mood instability;
SARC	cis	rs9814567	1.000	rs2370641	chr3:134222161	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-6.8	-0.41	8.7e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs8180040	0.764	rs4682852	chr3:47177772	C/T	cg02527881	chr3:46936655	PTH1R	-0.3	-4.75	-0.3	3.54e-6	Colorectal cancer;
SARC	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg04277193	chr17:41438351	NA	0.45	4.88	0.3	1.95e-6	Menopause (age at onset);
SARC	cis	rs6991838	0.584	rs57042777	chr8:66489090	T/A	cg13398993	chr8:66546079	ARMC1	-0.62	-8.36	-0.48	5.88e-15	Intelligence (multi-trait analysis);
SARC	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg18876405	chr7:65276391	NA	0.47	5.72	0.35	3.21e-8	Aortic root size;
SARC	cis	rs2239547	0.603	rs34230854	chr3:53078590	C/A	cg11645453	chr3:52864694	ITIH4	0.32	4.89	0.3	1.9e-6	Schizophrenia;
SARC	cis	rs2408955	0.541	rs11168428	chr12:48547128	A/G	cg24011408	chr12:48396354	COL2A1	-0.41	-5.1	-0.32	6.99e-7	Glycated hemoglobin levels;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg25737003	chr12:54488364	FLJ12825	0.35	6.33	0.38	1.25e-9	Breast cancer;
SARC	cis	rs910316	0.673	rs2012627	chr14:75443103	C/T	cg11812906	chr14:75593930	NEK9	0.75	9.99	0.55	8.96e-20	Height;
SARC	cis	rs12477438	1.000	rs57846982	chr2:99921574	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-8.06	-0.47	3.88e-14	Chronic sinus infection;
SARC	cis	rs965469	0.779	rs3746630	chr20:3320902	C/T	cg25506879	chr20:3388711	C20orf194	-0.45	-4.93	-0.31	1.54e-6	IFN-related cytopenia;
SARC	cis	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg18252515	chr7:66147081	NA	-1.34	-12.05	-0.62	2.51e-26	Diabetic kidney disease;
SARC	cis	rs3126085	0.935	rs4845750	chr1:152201217	A/G	cg26876637	chr1:152193138	HRNR	0.5	5.71	0.35	3.46e-8	Atopic dermatitis;
SARC	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg22857025	chr5:266934	NA	-1.06	-11.8	-0.61	1.74e-25	Breast cancer;
SARC	trans	rs61931739	0.500	rs12829125	chr12:34314789	A/G	cg26384229	chr12:38710491	ALG10B	0.84	11.85	0.61	1.13e-25	Morning vs. evening chronotype;
SARC	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg09455208	chr3:40491958	NA	0.4	5.89	0.36	1.36e-8	Renal cell carcinoma;
SARC	cis	rs9916302	0.904	rs57399933	chr17:37551189	A/G	cg07936489	chr17:37558343	FBXL20	0.69	9.1	0.51	4.07e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs7179456	0.515	rs602602	chr15:59057023	T/A	cg05156742	chr15:59063176	FAM63B	0.6	7.28	0.43	5e-12	Asperger disorder;
SARC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	18.95	0.78	4.43e-49	Prudent dietary pattern;
SARC	cis	rs4253772	0.530	rs9615990	chr22:46804154	G/A	cg18190219	chr22:46762943	CELSR1	-0.59	-5.13	-0.32	6.05e-7	LDL cholesterol;Cholesterol, total;
SARC	cis	rs7100689	0.577	rs2185427	chr10:82056667	G/T	cg01528321	chr10:82214614	TSPAN14	-0.67	-8.95	-0.51	1.11e-16	Post bronchodilator FEV1;
SARC	cis	rs12478296	0.792	rs6740738	chr2:243007368	A/C	cg06360820	chr2:242988706	NA	-0.61	-5.94	-0.36	1.04e-8	Obesity-related traits;
SARC	cis	rs35146811	0.883	rs4134903	chr7:99711040	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.4	4.8	0.3	2.9e-6	Coronary artery disease;
SARC	cis	rs721399	0.568	rs35942058	chr8:18274398	G/A	cg18736775	chr8:18248649	NAT2	-0.54	-5.89	-0.36	1.34e-8	Blood metabolite levels;
SARC	cis	rs9902453	0.808	rs4595850	chr17:28206326	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	7.17	0.43	9.74e-12	Coffee consumption (cups per day);
SARC	cis	rs3768617	0.510	rs3768624	chr1:183079252	C/T	cg13390022	chr1:182993471	LAMC1	0.32	4.88	0.3	1.95e-6	Fuchs's corneal dystrophy;
SARC	cis	rs7818345	1.000	rs13278459	chr8:19297583	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.38	5.17	0.32	4.93e-7	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs12135062	0.851	rs2651925	chr1:3101863	C/G	cg21609526	chr1:3105151	PRDM16	0.41	6.91	0.41	4.61e-11	Migraine;
SARC	cis	rs644799	0.672	rs11021347	chr11:95653494	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	12.69	0.64	2.07e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	10.97	0.58	7.58e-23	Alzheimer's disease;
SARC	cis	rs2439831	0.681	rs11858152	chr15:43634196	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.06	11.53	0.6	1.2e-24	Lung cancer in ever smokers;
SARC	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg12463550	chr7:65579703	CRCP	-0.49	-5.3	-0.33	2.65e-7	Aortic root size;
SARC	cis	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg03213289	chr20:61660250	NA	0.45	6.16	0.37	3.11e-9	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs9910055	0.571	rs10208	chr17:42300278	C/T	cg13607699	chr17:42295918	UBTF	0.91	14.42	0.69	4.09e-34	Total body bone mineral density;
SARC	cis	rs9436747	0.748	rs1171271	chr1:65998790	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.53	-5.19	-0.32	4.49e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs921968	0.643	rs2556386	chr2:219534530	C/T	cg02176678	chr2:219576539	TTLL4	-0.36	-5.34	-0.33	2.16e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg02725872	chr8:58115012	NA	-0.34	-5.37	-0.33	1.91e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs561341	0.783	rs512698	chr17:30292507	G/T	cg00745463	chr17:30367425	LRRC37B	-0.68	-5.23	-0.32	3.82e-7	Hip circumference adjusted for BMI;
SARC	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg21171335	chr12:122356390	WDR66	0.39	6.39	0.39	9.06e-10	Mean corpuscular volume;
SARC	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg04511125	chr2:88470314	THNSL2	0.81	7.27	0.43	5.44e-12	Plasma clusterin levels;
SARC	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2832191	0.511	rs7278227	chr21:30482707	C/T	cg24692254	chr21:30365293	RNF160	-0.64	-7.36	-0.43	3.17e-12	Dental caries;
SARC	cis	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg06212747	chr3:49208901	KLHDC8B	0.51	6.48	0.39	5.37e-10	Resting heart rate;
SARC	cis	rs9916302	0.904	rs4794813	chr17:37670994	A/T	cg00129232	chr17:37814104	STARD3	-0.64	-7.93	-0.46	8.88e-14	Glomerular filtration rate (creatinine);
SARC	trans	rs1994135	0.630	rs11052760	chr12:33724949	A/T	cg13010199	chr12:38710504	ALG10B	0.76	8.92	0.5	1.41e-16	Resting heart rate;
SARC	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg08859206	chr1:53392774	SCP2	0.38	5.43	0.34	1.43e-7	Monocyte count;
SARC	cis	rs12142240	0.698	rs1057535	chr1:46815898	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-5.46	-0.34	1.22e-7	Menopause (age at onset);
SARC	cis	rs7772486	0.651	rs1292338	chr6:145967471	A/C	cg23711669	chr6:146136114	FBXO30	-0.78	-12.58	-0.64	4.88e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9354308	0.868	rs9345696	chr6:66557641	C/T	cg07460842	chr6:66804631	NA	-0.41	-4.72	-0.3	4.05e-6	Metabolite levels;
SARC	cis	rs7824557	0.734	rs2293856	chr8:11177447	C/T	cg21775007	chr8:11205619	TDH	0.55	6.7	0.4	1.53e-10	Retinal vascular caliber;
SARC	cis	rs72949976	0.584	rs12471471	chr2:214023052	C/T	cg08319019	chr2:214017104	IKZF2	-0.48	-6.49	-0.39	5.02e-10	Lung cancer;Squamous cell lung carcinoma;
SARC	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg07636037	chr3:49044803	WDR6	-0.61	-7.99	-0.46	6.06e-14	Resting heart rate;
SARC	cis	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg07777115	chr5:623756	CEP72	-0.62	-5.24	-0.32	3.64e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs2153535	0.580	rs9393033	chr6:8521446	G/A	cg21535247	chr6:8435926	SLC35B3	0.54	6.92	0.41	4.29e-11	Motion sickness;
SARC	trans	rs561341	0.505	rs28708703	chr17:30386845	C/G	cg20587970	chr11:113659929	NA	-0.98	-9.65	-0.53	9.23e-19	Hip circumference adjusted for BMI;
SARC	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg06618935	chr21:46677482	NA	-0.42	-5.65	-0.35	4.7e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs703842	0.892	rs1021469	chr12:58208164	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.62	8.4	0.48	4.35e-15	Multiple sclerosis;
SARC	cis	rs1153858	0.887	rs7164139	chr15:45670851	G/A	cg21132104	chr15:45694354	SPATA5L1	0.78	11.01	0.59	5.55e-23	Homoarginine levels;
SARC	trans	rs2727020	0.567	rs1164687	chr11:49290669	G/A	cg03929089	chr4:120376271	NA	0.77	10.12	0.55	3.45e-20	Coronary artery disease;
SARC	cis	rs644799	0.544	rs499637	chr11:95569183	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.74	9.8	0.54	3.23e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg17971929	chr21:40555470	PSMG1	-0.86	-11.3	-0.6	6.67e-24	Cognitive function;
SARC	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.32	-4.85	-0.3	2.23e-6	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs1538970	0.962	rs9429075	chr1:45818421	G/A	cg05343316	chr1:45956843	TESK2	0.68	7.82	0.46	1.83e-13	Platelet count;
SARC	cis	rs734999	0.545	rs10752748	chr1:2544640	G/A	cg20673091	chr1:2541236	MMEL1	0.34	5.15	0.32	5.43e-7	Ulcerative colitis;
SARC	cis	rs4988958	0.565	rs12712146	chr2:103008714	C/T	cg03938978	chr2:103052716	IL18RAP	0.32	5.24	0.32	3.68e-7	Asthma (childhood onset);
SARC	cis	rs9640161	0.789	rs28439010	chr7:150046276	C/T	cg21361702	chr7:150065534	REPIN1	0.51	5.6	0.34	5.93e-8	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs12478296	1.000	rs73007140	chr2:243010756	T/C	cg06360820	chr2:242988706	NA	-0.6	-5.55	-0.34	7.56e-8	Obesity-related traits;
SARC	cis	rs12950390	0.893	rs4239166	chr17:45847329	A/G	cg03474202	chr17:45855739	NA	-0.46	-7.29	-0.43	4.86e-12	IgG glycosylation;
SARC	cis	rs4727027	0.901	rs11760293	chr7:148811725	A/G	cg23583168	chr7:148888333	NA	-0.75	-11.09	-0.59	3.26e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs2916247	0.954	rs13273012	chr8:93092337	G/A	cg10183463	chr8:93005414	RUNX1T1	0.66	6.9	0.41	4.81e-11	Intelligence (multi-trait analysis);
SARC	cis	rs11874712	1.000	rs11872985	chr18:43686578	A/G	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.52	6.22	0.38	2.3e-9	Migraine - clinic-based;
SARC	cis	rs7666738	0.830	rs17484890	chr4:99013778	T/C	cg05340658	chr4:99064831	C4orf37	0.64	8.59	0.49	1.22e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg00409905	chr10:38381863	ZNF37A	0.55	7.57	0.44	8.85e-13	Extrinsic epigenetic age acceleration;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg08113639	chr17:17061915	MPRIP	0.5	6.45	0.39	6.4e-10	Schizophrenia;
SARC	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg18252515	chr7:66147081	NA	-1.31	-11.71	-0.61	3.25e-25	Diabetic kidney disease;
SARC	trans	rs36093844	0.706	rs116940726	chr11:85584052	A/C	cg27065003	chr5:122429449	PRDM6	-0.55	-6.46	-0.39	5.9e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs7578035	0.622	rs10178956	chr2:99511774	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.41	-4.77	-0.3	3.27e-6	Bipolar disorder;
SARC	cis	rs4423214	0.959	rs11606033	chr11:71154204	A/G	cg05163923	chr11:71159392	DHCR7	0.67	9.16	0.51	2.73e-17	Vitamin D levels;
SARC	cis	rs7710178	0.816	rs467530	chr5:156123672	G/C	cg26439139	chr5:155924786	SGCD	-0.48	-4.8	-0.3	2.79e-6	Airway responsiveness in chronic obstructive pulmonary disease;
SARC	cis	rs3771570	1.000	rs73004354	chr2:242356239	G/T	cg21155796	chr2:242212141	HDLBP	0.7	6.27	0.38	1.74e-9	Prostate cancer;
SARC	cis	rs854765	0.547	rs2955383	chr17:17941364	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.46	6.03	0.37	6.53e-9	Total body bone mineral density;
SARC	cis	rs12824058	0.737	rs11060829	chr12:130814996	G/T	cg26677194	chr12:130822605	PIWIL1	0.55	7.57	0.44	8.59e-13	Menopause (age at onset);
SARC	cis	rs9513627	1.000	rs7338335	chr13:100125296	G/C	cg25919922	chr13:100150906	NA	-0.71	-5.29	-0.33	2.78e-7	Obesity-related traits;
SARC	cis	rs854765	0.587	rs4077828	chr17:17833644	A/T	cg04398451	chr17:18023971	MYO15A	-0.39	-5.56	-0.34	7.34e-8	Total body bone mineral density;
SARC	cis	rs10782582	0.593	rs11579752	chr1:76178694	C/T	cg03433033	chr1:76189801	ACADM	-0.39	-5.02	-0.31	1.05e-6	Daytime sleep phenotypes;
SARC	cis	rs1007738	0.542	rs2279438	chr11:47204175	A/T	cg03339077	chr11:47165057	C11orf49	-0.41	-5.04	-0.31	9.29e-7	Bone mineral density (hip);
SARC	trans	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-10.55	-0.57	1.63e-21	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs11098499	0.955	rs13113112	chr4:120156040	C/T	cg24375607	chr4:120327624	NA	0.39	4.75	0.3	3.61e-6	Corneal astigmatism;
SARC	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	16.12	0.73	8.93e-40	Chronic sinus infection;
SARC	cis	rs2153535	0.580	rs9392223	chr6:8468650	G/A	cg23788917	chr6:8435910	SLC35B3	0.61	7.97	0.46	7e-14	Motion sickness;
SARC	trans	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg06636001	chr8:8085503	FLJ10661	-0.73	-10.25	-0.56	1.42e-20	Retinal vascular caliber;
SARC	cis	rs2204008	0.870	rs12369578	chr12:38444227	C/T	cg26384229	chr12:38710491	ALG10B	0.82	10.95	0.58	9.1e-23	Bladder cancer;
SARC	cis	rs1971256	0.500	rs1971255	chr6:151816094	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	-0.56	-4.8	-0.3	2.89e-6	Endometriosis;
SARC	cis	rs15676	0.947	rs2997922	chr9:131580744	C/T	cg00228799	chr9:131580591	ENDOG	0.6	7.54	0.44	1.06e-12	Blood metabolite levels;
SARC	cis	rs2439831	1.000	rs2467736	chr15:43784917	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.05	10.85	0.58	1.78e-22	Lung cancer in ever smokers;
SARC	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-8.76	-0.5	4.15e-16	Alzheimer's disease;
SARC	cis	rs7772486	0.743	rs9376955	chr6:145949404	T/A	cg23711669	chr6:146136114	FBXO30	0.79	12.42	0.63	1.6e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2075371	0.501	rs1613152	chr7:134019837	A/G	cg11752832	chr7:134001865	SLC35B4	0.47	5.91	0.36	1.24e-8	Mean platelet volume;
SARC	trans	rs11039798	0.582	rs1304193	chr11:48688588	C/T	cg15704280	chr7:45808275	SEPT13	0.64	6.41	0.39	8.11e-10	Axial length;
SARC	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg12064134	chr16:90016061	DEF8	-0.49	-5.16	-0.32	5.36e-7	Skin colour saturation;
SARC	cis	rs11509153	0.687	rs2098363	chr7:12279198	G/A	cg23422036	chr7:12250390	TMEM106B	0.47	6.03	0.37	6.23e-9	Residual cognition;
SARC	cis	rs17209837	1.000	rs4148808	chr7:87105795	T/C	cg00919237	chr7:87102261	ABCB4	-0.47	-4.87	-0.3	2.07e-6	Gallbladder cancer;
SARC	cis	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg07777115	chr5:623756	CEP72	-0.62	-5.58	-0.34	6.66e-8	Obesity-related traits;
SARC	cis	rs733592	0.507	rs3825403	chr12:48457159	G/A	cg21466736	chr12:48725269	NA	0.31	5.43	0.34	1.4e-7	Plateletcrit;
SARC	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg04317338	chr11:64019027	PLCB3	0.81	8.46	0.48	2.93e-15	Mean platelet volume;
SARC	cis	rs72781680	1.000	rs7588286	chr2:24071427	A/G	cg06627628	chr2:24431161	ITSN2	-0.68	-6.55	-0.39	3.56e-10	Lymphocyte counts;
SARC	cis	rs12579753	0.879	rs1922552	chr12:82158093	G/T	cg07988820	chr12:82153109	PPFIA2	-0.59	-7.06	-0.42	1.87e-11	Resting heart rate;
SARC	cis	rs8072100	0.840	rs9893901	chr17:45506682	T/G	cg08085267	chr17:45401833	C17orf57	-0.41	-4.88	-0.3	2.01e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs2718058	0.630	rs2722359	chr7:37839764	T/C	cg24998770	chr7:37888106	TXNDC3	0.36	5.19	0.32	4.54e-7	Alzheimer's disease (late onset);
SARC	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg19346786	chr7:2764209	NA	-0.42	-6.28	-0.38	1.62e-9	Height;
SARC	cis	rs861020	0.771	rs654470	chr1:210014093	A/T	cg05527609	chr1:210001259	C1orf107	1.07	12.96	0.65	2.73e-29	Orofacial clefts;
SARC	cis	rs9943753	0.508	rs11066422	chr12:109807153	A/G	cg19025524	chr12:109796872	NA	-0.39	-5.71	-0.35	3.42e-8	HDL cholesterol;
SARC	cis	rs35110281	0.641	rs9978858	chr21:45085552	A/G	cg21573476	chr21:45109991	RRP1B	-0.59	-7.91	-0.46	1e-13	Mean corpuscular volume;
SARC	cis	rs2354432	0.607	rs6683243	chr1:146733422	A/T	cg25205988	chr1:146714368	CHD1L	-1.0	-7.56	-0.44	9.4e-13	Mitochondrial DNA levels;
SARC	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg22862634	chr11:62369728	EML3;MTA2	0.47	6.16	0.37	3.25e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg22903657	chr4:1355424	KIAA1530	-0.36	-4.89	-0.31	1.84e-6	Obesity-related traits;
SARC	cis	rs2439831	0.681	rs528517	chr15:43612925	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	8.76	0.5	4.02e-16	Lung cancer in ever smokers;
SARC	cis	rs59918340	0.764	rs10101692	chr8:142230823	C/T	cg16341495	chr8:142228727	SLC45A4	-0.34	-4.87	-0.3	2.1e-6	Immature fraction of reticulocytes;
SARC	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg07167872	chr1:205819463	PM20D1	-0.41	-4.81	-0.3	2.66e-6	Parkinson's disease;
SARC	cis	rs6840360	0.571	rs7695866	chr4:152488110	G/A	cg22705602	chr4:152727874	NA	-0.42	-6.51	-0.39	4.64e-10	Intelligence (multi-trait analysis);
SARC	cis	rs10752881	1.000	rs6424880	chr1:182986679	C/T	cg13390022	chr1:182993471	LAMC1	0.35	5.24	0.32	3.63e-7	Colorectal cancer;
SARC	cis	rs3815700	1.000	rs7248845	chr19:33096718	T/C	cg02997394	chr19:33096574	ANKRD27	0.79	8.55	0.49	1.67e-15	Eosinophilic esophagitis;
SARC	cis	rs4713675	0.604	rs791902	chr6:33702617	G/A	cg15676125	chr6:33679581	C6orf125	-0.52	-6.17	-0.37	3.07e-9	Plateletcrit;
SARC	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg12463550	chr7:65579703	CRCP	-0.48	-5.46	-0.34	1.23e-7	Aortic root size;
SARC	cis	rs9322193	0.567	rs7742692	chr6:150213499	A/G	cg05036130	chr6:150231994	NA	0.29	4.94	0.31	1.48e-6	Lung cancer;
SARC	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg19223190	chr17:80058835	NA	-0.43	-6.02	-0.37	6.57e-9	Life satisfaction;
SARC	cis	rs3845702	0.668	rs12693215	chr2:180826007	A/C	cg01881094	chr2:180872142	CWC22	-1.12	-9.33	-0.52	8.63e-18	Schizophrenia;
SARC	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.76	9.5	0.53	2.75e-18	Height;
SARC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg01504836	chr11:94706833	KDM4D;CWC15	-0.53	-6.81	-0.41	8.37e-11	Gut microbiota (bacterial taxa);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg00040047	chr2:162021002	TANK	0.51	7.14	0.42	1.21e-11	Thyroid stimulating hormone;
SARC	cis	rs6426558	0.537	rs10799381	chr1:227239746	G/T	cg10327440	chr1:227177885	CDC42BPA	0.4	4.78	0.3	3.13e-6	Neutrophil percentage of white cells;
SARC	cis	rs2481665	0.765	rs2481679	chr1:62634303	T/A	cg18591186	chr1:62594603	INADL	-0.54	-7.3	-0.43	4.59e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs7937682	0.889	rs567859	chr11:111486738	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.89	-14.18	-0.68	2.61e-33	Primary sclerosing cholangitis;
SARC	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg17971929	chr21:40555470	PSMG1	0.95	11.6	0.61	7.27e-25	Cognitive function;
SARC	cis	rs7829975	0.684	rs488904	chr8:8587571	T/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-5.67	-0.35	4.28e-8	Mood instability;
SARC	cis	rs9886651	0.935	rs4404878	chr8:128798394	T/C	cg24514600	chr8:128805414	PVT1	-0.43	-5.68	-0.35	4.05e-8	Epithelial ovarian cancer;Serous invasive ovarian cancer;
SARC	cis	rs897984	0.520	rs4889534	chr16:30865440	T/C	cg00531865	chr16:30841666	NA	0.46	4.94	0.31	1.51e-6	Dementia with Lewy bodies;
SARC	cis	rs8141529	0.843	rs1065497	chr22:29279991	C/T	cg02153584	chr22:29168773	CCDC117	0.77	10.95	0.58	8.8e-23	Lymphocyte counts;
SARC	trans	rs9951602	0.512	rs6506872	chr18:76649695	T/C	cg02800362	chr5:177631904	HNRNPAB	0.72	9.13	0.51	3.28e-17	Obesity-related traits;
SARC	cis	rs6088590	1.000	rs6087625	chr20:33342477	A/G	cg08999081	chr20:33150536	PIGU	-0.35	-4.97	-0.31	1.32e-6	Coronary artery disease;
SARC	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg11941060	chr3:133502564	NA	-0.41	-5.81	-0.36	2.08e-8	Iron status biomarkers;
SARC	cis	rs72781680	0.716	rs2551325	chr2:23979729	C/T	cg08917208	chr2:24149416	ATAD2B	0.54	5.64	0.35	4.96e-8	Lymphocyte counts;
SARC	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg09839136	chr7:766187	HEATR2;PRKAR1B	0.59	5.08	0.32	7.6e-7	Cerebrospinal P-tau181p levels;
SARC	cis	rs57994353	0.667	rs34985258	chr9:139327154	C/T	cg14169450	chr9:139327907	INPP5E	0.41	5.25	0.33	3.48e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg25072359	chr17:41440525	NA	0.56	6.86	0.41	6.23e-11	Menopause (age at onset);
SARC	cis	rs3204270	0.639	rs7216239	chr17:79660187	C/T	cg26965718	chr17:79658957	HGS	-0.61	-5.02	-0.31	1.04e-6	Dental caries;
SARC	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg06221963	chr1:154839813	KCNN3	-0.53	-8.57	-0.49	1.44e-15	Prostate cancer;
SARC	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-5.64	-0.35	4.97e-8	Bipolar disorder;
SARC	cis	rs6991838	0.778	rs11779601	chr8:66462476	T/C	cg13398993	chr8:66546079	ARMC1	0.39	4.73	0.3	3.83e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7552404	0.727	rs5745390	chr1:76306591	A/C	cg22875332	chr1:76189707	ACADM	0.45	5.52	0.34	8.96e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg08975724	chr8:8085496	FLJ10661	0.48	6.02	0.37	6.86e-9	Mood instability;
SARC	cis	rs957448	1.000	rs16916874	chr8:95549977	T/C	cg26464482	chr8:95565502	KIAA1429	0.43	4.74	0.3	3.73e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs1559088	0.522	rs7254912	chr19:33554151	A/G	cg17764715	chr19:33622953	WDR88	0.58	7.87	0.46	1.3e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs763121	0.785	rs6001203	chr22:39099602	T/C	cg06022373	chr22:39101656	GTPBP1	0.9	12.42	0.63	1.68e-27	Menopause (age at onset);
SARC	cis	rs3099143	1.000	rs3106380	chr15:77104377	G/A	cg21673338	chr15:77095150	SCAPER	-0.76	-6.25	-0.38	1.93e-9	Recalcitrant atopic dermatitis;
SARC	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg20120463	chr17:44301886	NA	-0.33	-4.98	-0.31	1.23e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs826838	0.967	rs11168299	chr12:38902028	G/T	cg13010199	chr12:38710504	ALG10B	0.78	10.86	0.58	1.6400000000000001e-22	Heart rate;
SARC	cis	rs3791556	0.504	rs1001285	chr2:240107814	A/G	cg27074582	chr2:240114406	HDAC4	0.35	5.26	0.33	3.27e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs995000	0.509	rs912540	chr1:63135127	A/G	cg06896770	chr1:63153194	DOCK7	-0.75	-8.16	-0.47	2.07e-14	Triglyceride levels;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg20974482	chr6:37321680	RNF8	0.49	6.27	0.38	1.78e-9	Chemerin levels;
SARC	cis	rs1569175	0.826	rs769951	chr2:200731990	C/G	cg23649088	chr2:200775458	C2orf69	-0.92	-4.92	-0.31	1.62e-6	Response to treatment for acute lymphoblastic leukemia;
SARC	cis	rs6991838	0.733	rs13281090	chr8:66590479	C/A	cg13398993	chr8:66546079	ARMC1	0.39	4.86	0.3	2.17e-6	Intelligence (multi-trait analysis);
SARC	cis	rs11025559	0.812	rs10833336	chr11:20514288	C/G	cg04101203	chr11:20408940	PRMT3	-0.48	-5.19	-0.32	4.52e-7	Pursuit maintenance gain;
SARC	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	cis	rs7927592	0.913	rs7106339	chr11:68240241	C/T	cg01657329	chr11:68192670	LRP5	-0.41	-4.96	-0.31	1.37e-6	Total body bone mineral density;
SARC	cis	rs2204008	0.606	rs6582502	chr12:38543352	C/T	cg26384229	chr12:38710491	ALG10B	-0.59	-7.46	-0.44	1.7e-12	Bladder cancer;
SARC	cis	rs9326248	0.530	rs10732856	chr11:116907113	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.56	4.75	0.3	3.48e-6	Blood protein levels;
SARC	cis	rs11105298	0.891	rs10858890	chr12:89907166	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.51	-5.19	-0.32	4.66e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs2204008	0.538	rs61931093	chr12:38242911	C/T	cg14851346	chr12:38532713	NA	-0.48	-5.83	-0.36	1.8e-8	Bladder cancer;
SARC	cis	rs4642101	0.737	rs6767504	chr3:12826667	C/T	cg24848339	chr3:12840334	CAND2	0.33	4.98	0.31	1.22e-6	QRS complex (12-leadsum);
SARC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg14893161	chr1:205819251	PM20D1	1.06	22.05	0.82	5.89e-59	Menarche (age at onset);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg05241157	chr5:17354674	NA	0.54	6.3	0.38	1.49e-9	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg22535103	chr8:58192502	C8orf71	-0.7	-7.06	-0.42	1.93e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs1707322	0.963	rs12145287	chr1:46325002	C/G	cg03146154	chr1:46216737	IPP	0.51	6.19	0.38	2.66e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg18876405	chr7:65276391	NA	0.46	5.25	0.33	3.41e-7	Aortic root size;
SARC	cis	rs3820928	0.874	rs6718057	chr2:227834349	T/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-6.73	-0.4	1.27e-10	Pulmonary function;
SARC	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg19223190	chr17:80058835	NA	-0.43	-6.02	-0.37	6.57e-9	Life satisfaction;
SARC	cis	rs6463523	0.815	rs66886645	chr7:763853	C/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.81	11.88	0.61	8.97e-26	Subjective well-being;
SARC	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg11987759	chr7:65425863	GUSB	-0.64	-8.32	-0.48	7.33e-15	Aortic root size;
SARC	cis	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg06212747	chr3:49208901	KLHDC8B	0.51	6.48	0.39	5.37e-10	Resting heart rate;
SARC	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg08219700	chr8:58056026	NA	0.63	6.41	0.39	7.94e-10	Developmental language disorder (linguistic errors);
SARC	trans	rs9325144	0.647	rs61931899	chr12:38892422	A/G	cg23762105	chr12:34175262	ALG10	0.49	6.35	0.38	1.12e-9	Morning vs. evening chronotype;
SARC	cis	rs918629	0.761	rs3777165	chr5:95291425	A/G	cg16656078	chr5:95278638	ELL2	0.71	8.2	0.47	1.57e-14	IgG glycosylation;
SARC	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	9.01	0.51	7.74e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1401999	1.000	rs3805108	chr3:183691650	T/C	cg01324343	chr3:183735012	ABCC5	0.66	13.23	0.65	3.66e-30	Anterior chamber depth;
SARC	cis	rs10504229	0.679	rs11783557	chr8:58030644	A/G	cg08219700	chr8:58056026	NA	0.6	6.12	0.37	3.98e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs17401966	0.838	rs35257796	chr1:10267390	T/A	cg15208524	chr1:10270712	KIF1B	0.47	5.59	0.34	6.37e-8	Hepatocellular carcinoma;
SARC	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-15.39	-0.71	2.48e-37	Chronic sinus infection;
SARC	cis	rs36051895	0.559	rs72701680	chr9:5207294	A/T	cg02405213	chr9:5042618	JAK2	-0.42	-4.92	-0.31	1.66e-6	Pediatric autoimmune diseases;
SARC	cis	rs62244186	0.593	rs9814298	chr3:44871899	T/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.57	7.61	0.45	6.96e-13	Depressive symptoms;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg22121237	chr7:119915258	KCND2	0.45	6.31	0.38	1.42e-9	Schizophrenia;
SARC	cis	rs7113850	0.541	rs7101719	chr11:24234947	T/C	ch.11.24196551F	chr11:24239977	NA	0.66	4.97	0.31	1.29e-6	Bone fracture in osteoporosis;
SARC	cis	rs2486288	0.656	rs11631021	chr15:45556829	A/G	cg19305227	chr15:45544335	SLC28A2	0.3	5.69	0.35	3.73e-8	Glomerular filtration rate;
SARC	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.44	4.95	0.31	1.46e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs1355223	0.506	rs7947848	chr11:34866220	T/C	cg18508148	chr11:34937573	PDHX;APIP	-0.37	-4.74	-0.3	3.74e-6	Systemic lupus erythematosus and Systemic sclerosis;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg06119275	chr12:133384736	GOLGA3	-0.73	-6.4	-0.39	8.56e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.95	-13.96	-0.67	1.32e-32	Gut microbiome composition (summer);
SARC	cis	rs6582630	0.519	rs11495373	chr12:38275470	T/C	cg26384229	chr12:38710491	ALG10B	0.9	13.45	0.66	6.44e-31	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6459804	1.000	rs73163880	chr7:157508755	C/T	cg05731713	chr7:157510257	PTPRN2	0.29	5.67	0.35	4.17e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs3126085	0.935	rs4511113	chr1:152222192	G/A	cg03465714	chr1:152285911	FLG	-0.44	-5.26	-0.33	3.23e-7	Atopic dermatitis;
SARC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-4.91	-0.31	1.71e-6	Total body bone mineral density;
SARC	cis	rs6500602	0.627	rs863501	chr16:4588394	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.35	-5.77	-0.35	2.47e-8	Schizophrenia;
SARC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg27588902	chr6:42928151	GNMT	-0.37	-5.7	-0.35	3.59e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs4268898	0.717	rs2543662	chr2:24443271	G/T	cg06627628	chr2:24431161	ITSN2	0.66	7.78	0.45	2.3e-13	Asthma;
SARC	cis	rs9398803	0.687	rs9491652	chr6:126943620	G/C	cg20229609	chr6:126660872	C6orf173	0.37	5.38	0.33	1.79e-7	Male-pattern baldness;
SARC	cis	rs17666538	0.901	rs73177064	chr8:585293	C/G	cg23958373	chr8:599963	NA	-0.99	-7.45	-0.44	1.79e-12	IgG glycosylation;
SARC	cis	rs7270101	0.749	rs117398381	chr20:3168977	G/A	cg25506879	chr20:3388711	C20orf194	-0.61	-4.72	-0.3	4.04e-6	Chronic hepatitis C infection;
SARC	trans	rs453301	0.624	rs330060	chr8:9090902	A/G	cg21775007	chr8:11205619	TDH	-0.51	-6.5	-0.39	4.88e-10	Joint mobility (Beighton score);
SARC	cis	rs1113500	0.933	rs12132785	chr1:108633083	A/T	cg06207961	chr1:108661230	NA	0.44	5.82	0.36	1.93e-8	Growth-regulated protein alpha levels;
SARC	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg05861140	chr6:150128134	PCMT1	-0.37	-4.77	-0.3	3.22e-6	Lung cancer;
SARC	cis	rs10504229	0.593	rs113184543	chr8:58042950	A/G	cg08219700	chr8:58056026	NA	0.6	6.08	0.37	4.88e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7766436	0.885	rs13209127	chr6:22597625	A/G	cg13666174	chr6:22585274	NA	0.59	7.71	0.45	3.7e-13	Coronary artery disease;
SARC	cis	rs6570726	0.905	rs452770	chr6:145847162	T/C	cg05220968	chr6:146057943	EPM2A	-0.29	-5.04	-0.31	9.48e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg08280861	chr8:58055591	NA	0.68	5.89	0.36	1.31e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4919087	0.884	rs4917762	chr10:98976471	G/T	cg25902810	chr10:99078978	FRAT1	0.47	5.65	0.35	4.7e-8	Monocyte count;
SARC	cis	rs7824557	0.527	rs2572448	chr8:11239352	G/A	cg21775007	chr8:11205619	TDH	-0.57	-7.65	-0.45	5.19e-13	Retinal vascular caliber;
SARC	cis	rs861020	1.000	rs861020	chr1:209977111	A/G	cg05527609	chr1:210001259	C1orf107	0.97	10.97	0.58	7.64e-23	Orofacial clefts;
SARC	cis	rs12142240	0.698	rs17357711	chr1:46829013	A/G	cg14993813	chr1:46806288	NSUN4	-0.53	-5.62	-0.35	5.48e-8	Menopause (age at onset);
SARC	cis	rs7666738	0.830	rs28522896	chr4:99008243	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg05277466	chr16:88082055	BANP	-0.8	-6.93	-0.41	4.13e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs13256369	0.951	rs10503394	chr8:8565775	A/G	cg18904891	chr8:8559673	CLDN23	0.49	5.45	0.34	1.27e-7	Obesity-related traits;
SARC	cis	rs6088580	0.634	rs62212172	chr20:32987705	G/A	cg24642439	chr20:33292090	TP53INP2	-0.66	-8.58	-0.49	1.36e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg00149659	chr3:10157352	C3orf10	1.09	10.0	0.55	7.87e-20	Alzheimer's disease;
SARC	cis	rs2153535	0.580	rs9379210	chr6:8461928	C/G	cg07606381	chr6:8435919	SLC35B3	0.75	10.69	0.57	5.96e-22	Motion sickness;
SARC	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg18876405	chr7:65276391	NA	-0.47	-5.29	-0.33	2.84e-7	Aortic root size;
SARC	cis	rs75804782	0.641	rs72987327	chr2:239359833	T/G	cg21699342	chr2:239360505	ASB1	-0.58	-4.86	-0.3	2.2e-6	Morning vs. evening chronotype;Chronotype;
SARC	cis	rs11190604	1.000	rs2489049	chr10:102350732	G/A	cg07080220	chr10:102295463	HIF1AN	0.76	8.66	0.49	8.22e-16	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs2370759	1.000	rs11008865	chr10:32574842	C/T	cg01819863	chr10:32635814	EPC1	1.01	9.89	0.54	1.71e-19	Sexual dysfunction (female);
SARC	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg22535103	chr8:58192502	C8orf71	-0.66	-5.85	-0.36	1.65e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs11785400	1.000	rs6995314	chr8:143749718	A/G	cg24634471	chr8:143751801	JRK	-0.66	-8.82	-0.5	2.75e-16	Schizophrenia;
SARC	cis	rs2760061	0.583	rs1774757	chr1:228211135	C/G	cg02753203	chr1:228287806	NA	0.79	11.09	0.59	3.23e-23	Diastolic blood pressure;
SARC	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg18876405	chr7:65276391	NA	0.7	8.84	0.5	2.4e-16	Aortic root size;
SARC	cis	rs13191362	1.000	rs13213408	chr6:162998049	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.57	5.6	0.34	6.01e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg02980000	chr4:1222292	CTBP1	-0.41	-4.98	-0.31	1.23e-6	Obesity-related traits;
SARC	cis	rs2916247	0.908	rs7005983	chr8:93167589	G/A	cg10183463	chr8:93005414	RUNX1T1	0.46	4.94	0.31	1.47e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2153535	0.580	rs2184583	chr6:8447808	A/G	cg07606381	chr6:8435919	SLC35B3	0.77	11.03	0.59	5.01e-23	Motion sickness;
SARC	cis	rs908922	0.924	rs6669608	chr1:152475233	A/G	cg09873164	chr1:152488093	CRCT1	0.67	7.51	0.44	1.22e-12	Hair morphology;
SARC	cis	rs9291683	0.632	rs12508991	chr4:10041104	C/T	cg11266682	chr4:10021025	SLC2A9	0.4	7.21	0.43	7.8e-12	Bone mineral density;
SARC	cis	rs9487051	0.714	rs9487058	chr6:109631060	A/C	cg01475377	chr6:109611718	NA	-0.37	-5.29	-0.33	2.82e-7	Reticulocyte fraction of red cells;
SARC	cis	rs1865760	0.566	rs9358904	chr6:26068566	C/T	cg18357526	chr6:26021779	HIST1H4A	0.43	5.32	0.33	2.43e-7	Height;
SARC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.63	-6.57	-0.4	3.29e-10	Platelet count;
SARC	cis	rs9302635	0.678	rs8054585	chr16:72225314	G/A	cg01557791	chr16:72042693	DHODH	-0.51	-5.51	-0.34	9.67e-8	Blood protein levels;
SARC	cis	rs11025559	0.631	rs11025571	chr11:20482801	C/G	cg04101203	chr11:20408940	PRMT3	0.62	5.96	0.36	9.06e-9	Pursuit maintenance gain;
SARC	cis	rs1790761	0.520	rs7124513	chr11:67395714	C/T	cg00864171	chr11:67383662	NA	-0.45	-5.88	-0.36	1.41e-8	Mean corpuscular volume;
SARC	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	8.55	0.49	1.67e-15	Mean platelet volume;
SARC	cis	rs9517313	0.591	rs9554480	chr13:99221138	T/A	cg07423050	chr13:99094983	FARP1	-0.42	-5.24	-0.32	3.52e-7	Neuroticism;
SARC	cis	rs8017423	0.845	rs8005870	chr14:90723172	A/C	cg20276874	chr14:90721474	PSMC1	-0.39	-5.49	-0.34	1.06e-7	Mortality in heart failure;
SARC	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg24209194	chr3:40518798	ZNF619	0.65	7.99	0.46	6.28e-14	Renal cell carcinoma;
SARC	cis	rs561341	1.000	rs497479	chr17:30328605	C/T	cg00745463	chr17:30367425	LRRC37B	-0.67	-5.2	-0.32	4.26e-7	Hip circumference adjusted for BMI;
SARC	cis	rs2228479	0.702	rs17233868	chr16:89803629	C/T	cg00800038	chr16:89945340	TCF25	-0.71	-4.75	-0.3	3.5e-6	Skin colour saturation;
SARC	cis	rs698833	0.547	rs1067348	chr2:44671409	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.48	0.34	1.1e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs11105298	0.891	rs10858865	chr12:89846476	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.49	-4.93	-0.31	1.57e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs2011503	1.000	rs58074958	chr19:19570555	G/C	cg03709012	chr19:19516395	GATAD2A	0.65	5.73	0.35	3.16e-8	Bipolar disorder;
SARC	cis	rs11583043	0.918	rs58029001	chr1:101393409	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.44	5.39	0.33	1.69e-7	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	12.83	0.64	7.44e-29	Platelet count;
SARC	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.41	-6.6	-0.4	2.75e-10	Total body bone mineral density;
SARC	cis	rs1153858	1.000	rs4627277	chr15:45652768	C/A	cg26924012	chr15:45694286	SPATA5L1	0.78	11.14	0.59	2.18e-23	Homoarginine levels;
SARC	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.46	5.85	0.36	1.64e-8	Tonsillectomy;
SARC	cis	rs721399	0.752	rs4921915	chr8:18272466	G/A	cg18736775	chr8:18248649	NAT2	0.42	5.23	0.32	3.86e-7	Blood metabolite levels;
SARC	cis	rs12311304	0.965	rs12307666	chr12:15388204	A/G	cg08258403	chr12:15378311	NA	0.46	7.19	0.43	8.94e-12	Behavioural disinhibition (generation interaction);
SARC	trans	rs3780486	0.834	rs75443249	chr9:33149207	A/G	cg20290983	chr6:43655470	MRPS18A	1.01	14.38	0.69	5.45e-34	IgG glycosylation;
SARC	cis	rs763121	0.853	rs6519120	chr22:38991393	A/C	cg06022373	chr22:39101656	GTPBP1	-0.87	-10.49	-0.57	2.5e-21	Menopause (age at onset);
SARC	trans	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg00938859	chr5:1591904	SDHAP3	0.78	7.47	0.44	1.57e-12	Breast cancer;
SARC	cis	rs12048904	0.541	rs6699536	chr1:101276544	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.8	10.1	0.55	4.03e-20	Multiple sclerosis;
SARC	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg12463550	chr7:65579703	CRCP	0.67	5.08	0.32	7.66e-7	Diabetic kidney disease;
SARC	cis	rs7429990	0.896	rs7427648	chr3:48158239	C/T	cg11946769	chr3:48343235	NME6	-0.46	-5.42	-0.33	1.46e-7	Educational attainment (years of education);
SARC	trans	rs9811216	0.651	rs13097028	chr3:169464942	A/G	cg02552189	chr2:223891284	NA	-0.51	-6.75	-0.4	1.15e-10	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs6089584	0.546	rs4925337	chr20:60637637	T/C	cg13770153	chr20:60521292	NA	-0.38	-5.37	-0.33	1.87e-7	Body mass index;
SARC	cis	rs763121	0.819	rs138700	chr22:39129999	A/G	cg06022373	chr22:39101656	GTPBP1	0.87	11.76	0.61	2.26e-25	Menopause (age at onset);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg10010376	chr1:144932311	PDE4DIP	0.55	6.78	0.41	9.82e-11	Breast cancer;
SARC	cis	rs4595586	0.679	rs1878228	chr12:39355595	T/C	cg26384229	chr12:38710491	ALG10B	0.43	5.36	0.33	2.01e-7	Morning vs. evening chronotype;
SARC	cis	rs7208859	0.623	rs12103440	chr17:29086657	A/G	cg13385521	chr17:29058706	SUZ12P	0.9	7.81	0.46	1.96e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs7412746	0.658	rs12097963	chr1:150870450	T/C	cg10589385	chr1:150898437	SETDB1	0.42	5.64	0.35	4.91e-8	Melanoma;
SARC	cis	rs11122272	0.735	rs2808583	chr1:231512587	G/C	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs453301	0.686	rs10217044	chr8:8894752	A/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.76	-0.4	1.09e-10	Joint mobility (Beighton score);
SARC	cis	rs7044106	0.708	rs10760113	chr9:123474050	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.18	0.52	2.34e-17	Hip circumference adjusted for BMI;
SARC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg26354017	chr1:205819088	PM20D1	-0.67	-10.42	-0.56	4.1e-21	Monocyte percentage of white cells;
SARC	cis	rs8077889	0.826	rs60085355	chr17:41847415	T/C	cg26893861	chr17:41843967	DUSP3	0.79	9.11	0.51	3.8e-17	Triglycerides;
SARC	cis	rs13033859	0.794	rs6707786	chr2:166224	G/T	cg12623918	chr2:306882	NA	-0.29	-4.8	-0.3	2.86e-6	Mitochondrial DNA levels;
SARC	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg00149659	chr3:10157352	C3orf10	0.69	6.44	0.39	6.6e-10	Alzheimer's disease;
SARC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg04234412	chr22:24373322	LOC391322	0.73	10.45	0.57	3.17e-21	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs16976116	0.855	rs7172289	chr15:55501705	A/G	cg11288833	chr15:55489084	RSL24D1	0.63	6.13	0.37	3.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs240764	0.817	rs12216304	chr6:101174161	A/G	cg09795085	chr6:101329169	ASCC3	-0.5	-6.45	-0.39	6.46e-10	Neuroticism;
SARC	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg25072359	chr17:41440525	NA	-0.54	-6.76	-0.4	1.12e-10	Menopause (age at onset);
SARC	cis	rs6142102	0.778	rs6059581	chr20:32528388	C/A	cg24642439	chr20:33292090	TP53INP2	0.44	4.76	0.3	3.36e-6	Skin pigmentation;
SARC	cis	rs1568889	1.000	rs12797712	chr11:28290890	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.72	9.5	0.53	2.58e-18	Bipolar disorder;
SARC	cis	rs10861342	1.000	rs703683	chr12:105567135	T/C	cg23923672	chr12:105501055	KIAA1033	0.66	5.0	0.31	1.1e-6	IgG glycosylation;
SARC	cis	rs6484504	0.532	rs2150212	chr11:31255935	G/A	cg02090638	chr11:31391270	DNAJC24;DCDC1	-0.42	-5.29	-0.33	2.83e-7	Red blood cell count;
SARC	cis	rs2153535	0.580	rs1119689	chr6:8460754	C/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.14	0.47	2.37e-14	Motion sickness;
SARC	cis	rs870825	0.616	rs4615214	chr4:185624129	G/C	cg04058563	chr4:185651563	MLF1IP	0.82	11.42	0.6	2.8e-24	Blood protein levels;
SARC	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.66	6.15	0.37	3.26e-9	Platelet count;
SARC	cis	rs763121	0.853	rs11704021	chr22:39074716	G/A	cg06022373	chr22:39101656	GTPBP1	0.84	10.39	0.56	4.96e-21	Menopause (age at onset);
SARC	cis	rs2760061	0.626	rs634106	chr1:228121548	C/T	cg02753203	chr1:228287806	NA	-0.57	-8.16	-0.47	2.05e-14	Diastolic blood pressure;
SARC	cis	rs3741151	1.000	rs57893472	chr11:73042826	C/T	cg17517138	chr11:73019481	ARHGEF17	0.85	7.01	0.42	2.51e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs910187	0.605	rs6063080	chr20:45805091	G/A	cg27589058	chr20:45804311	EYA2	-0.3	-4.96	-0.31	1.36e-6	Migraine;
SARC	cis	rs7659604	0.728	rs3924987	chr4:122689784	G/T	cg20573242	chr4:122745356	CCNA2	0.56	7.15	0.42	1.13e-11	Type 2 diabetes;
SARC	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg06618935	chr21:46677482	NA	-0.4	-4.81	-0.3	2.66e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2898681	0.521	rs115874483	chr4:53728272	G/A	cg00338735	chr4:53728038	RASL11B	0.49	5.41	0.33	1.59e-7	Optic nerve measurement (cup area);
SARC	trans	rs7819412	0.775	rs4545055	chr8:10935366	T/C	cg15556689	chr8:8085844	FLJ10661	-0.54	-7.03	-0.42	2.3e-11	Triglycerides;
SARC	cis	rs6121246	0.909	rs6088962	chr20:30268184	C/T	cg13852791	chr20:30311386	BCL2L1	0.86	8.53	0.49	1.85e-15	Mean corpuscular hemoglobin;
SARC	cis	rs3857536	0.706	rs1418854	chr6:66893284	C/T	cg07460842	chr6:66804631	NA	-0.61	-7.16	-0.42	1.05e-11	Blood trace element (Cu levels);
SARC	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg08677398	chr8:58056175	NA	0.44	5.25	0.33	3.38e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs36051895	0.664	rs3780371	chr9:5095191	T/A	cg02405213	chr9:5042618	JAK2	-0.47	-5.56	-0.34	7.29e-8	Pediatric autoimmune diseases;
SARC	cis	rs4319547	0.656	rs4997380	chr12:122838956	A/G	cg23029597	chr12:123009494	RSRC2	-0.43	-5.5	-0.34	9.77e-8	Body mass index;
SARC	cis	rs5760092	0.755	rs11090298	chr22:24262061	G/A	cg25703541	chr22:24373054	LOC391322	0.77	8.86	0.5	2.16e-16	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs6570726	0.837	rs419991	chr6:145864212	C/T	cg23711669	chr6:146136114	FBXO30	0.78	12.0	0.62	3.86e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4481887	0.508	rs4390207	chr1:248400174	C/T	cg13385794	chr1:248469461	NA	0.37	4.97	0.31	1.33e-6	Common traits (Other);
SARC	cis	rs9325144	0.555	rs7968322	chr12:38792348	T/C	cg13010199	chr12:38710504	ALG10B	-0.49	-6.32	-0.38	1.35e-9	Morning vs. evening chronotype;
SARC	cis	rs7937682	0.632	rs10789850	chr11:111750829	C/T	cg22437258	chr11:111473054	SIK2	-0.47	-5.47	-0.34	1.17e-7	Primary sclerosing cholangitis;
SARC	cis	rs8141529	0.636	rs5762799	chr22:29187380	G/T	cg02153584	chr22:29168773	CCDC117	0.72	8.7	0.5	5.92e-16	Lymphocyte counts;
SARC	cis	rs1670533	1.000	rs11724371	chr4:1052125	T/C	cg27284194	chr4:1044797	NA	0.49	4.95	0.31	1.42e-6	Recombination rate (females);
SARC	cis	rs9486715	0.867	rs4839828	chr6:96863326	G/A	cg18709589	chr6:96969512	KIAA0776	0.58	7.27	0.43	5.5e-12	Headache;
SARC	cis	rs76419734	1.000	rs72673817	chr4:106713490	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.8	5.35	0.33	2.13e-7	Post bronchodilator FEV1;
SARC	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg27347728	chr4:17578864	LAP3	0.48	6.1	0.37	4.5e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg08677398	chr8:58056175	NA	0.44	5.25	0.33	3.38e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6088580	0.609	rs6058029	chr20:32969643	T/C	cg24642439	chr20:33292090	TP53INP2	-0.68	-8.73	-0.5	4.96e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg00339695	chr16:24857497	SLC5A11	-0.43	-5.93	-0.36	1.1e-8	Intelligence (multi-trait analysis);
SARC	cis	rs4144743	1.000	rs4144746	chr17:45323355	C/G	cg18085866	chr17:45331354	ITGB3	-0.71	-7.35	-0.43	3.36e-12	Body mass index;
SARC	cis	rs11676348	0.818	rs6436033	chr2:218983763	A/G	cg00012203	chr2:219082015	ARPC2	-0.55	-7.32	-0.43	4.05e-12	Ulcerative colitis;
SARC	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg07636037	chr3:49044803	WDR6	-0.89	-14.91	-0.7	9.69e-36	Menarche (age at onset);
SARC	cis	rs11122272	0.668	rs2790874	chr1:231537988	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.09	-0.55	4.24e-20	Hemoglobin concentration;
SARC	cis	rs10752881	1.000	rs10797812	chr1:182984597	A/G	cg13390022	chr1:182993471	LAMC1	-0.34	-5.18	-0.32	4.89e-7	Colorectal cancer;
SARC	trans	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg16568036	chr11:2398531	CD81	0.46	6.51	0.39	4.49e-10	Immature fraction of reticulocytes;
SARC	cis	rs1008375	0.966	rs1860599	chr4:17638900	T/C	cg02297831	chr4:17616191	MED28	0.5	6.47	0.39	5.62e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	6.83	0.41	7.18e-11	Platelet count;
SARC	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.4	4.86	0.3	2.17e-6	Lymphocyte counts;
SARC	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg02725872	chr8:58115012	NA	-0.33	-5.33	-0.33	2.33e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9902453	0.845	rs7218113	chr17:28372130	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.16	-0.42	1.02e-11	Coffee consumption (cups per day);
SARC	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg04518342	chr5:131593106	PDLIM4	0.43	5.55	0.34	7.88e-8	Acylcarnitine levels;
SARC	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg04277193	chr17:41438351	NA	0.45	4.93	0.31	1.59e-6	Menopause (age at onset);
SARC	cis	rs13314892	0.764	rs6805306	chr3:69862153	T/G	cg17445875	chr3:69859618	MITF	-0.49	-5.1	-0.32	6.98e-7	QRS complex (12-leadsum);
SARC	cis	rs870825	0.587	rs35845099	chr4:185639762	A/G	cg04058563	chr4:185651563	MLF1IP	0.79	11.24	0.59	1.03e-23	Blood protein levels;
SARC	cis	rs4689388	0.853	rs6817447	chr4:6286847	G/T	cg14416269	chr4:6271139	WFS1	0.35	5.29	0.33	2.8e-7	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs4742903	0.967	rs10820605	chr9:106881402	C/T	cg14250997	chr9:106856677	SMC2	0.54	7.29	0.43	4.85e-12	High-grade serous ovarian cancer;Breast cancer;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg08417687	chr6:108582627	SNX3	-0.48	-6.55	-0.39	3.71e-10	Neuroticism;
SARC	cis	rs9815354	0.951	rs9864331	chr3:41762217	G/A	cg03022575	chr3:42003672	ULK4	0.63	5.35	0.33	2.05e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6772849	0.768	rs9820741	chr3:128416080	G/A	cg08795948	chr3:128337044	NA	0.54	7.28	0.43	5.12e-12	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs9462027	0.628	rs6942040	chr6:34761809	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.85	-0.36	1.63e-8	Systemic lupus erythematosus;
SARC	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.53	8.15	0.47	2.22e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs1691799	0.899	rs1168292	chr12:66732660	C/T	cg16791601	chr12:66731901	HELB	-0.72	-10.75	-0.58	3.75e-22	White blood cell count (basophil);
SARC	cis	rs738322	0.967	rs133018	chr22:38572761	G/A	cg25457927	chr22:38595422	NA	-0.29	-5.95	-0.36	9.7e-9	Cutaneous nevi;
SARC	cis	rs12802200	0.561	rs7937217	chr11:571967	T/C	cg16486109	chr11:613632	IRF7	0.35	4.96	0.31	1.38e-6	Systemic lupus erythematosus;
SARC	cis	rs2795502	1.000	rs2473119	chr10:43339038	A/T	cg20628663	chr10:43360327	NA	-0.47	-6.27	-0.38	1.77e-9	Blood protein levels;
SARC	cis	rs1163251	0.902	rs839605	chr1:120217524	C/A	cg19096424	chr1:120255104	PHGDH	0.53	6.2	0.38	2.56e-9	Blood metabolite levels;
SARC	cis	rs2952156	0.920	rs2247862	chr17:37829129	A/G	cg00129232	chr17:37814104	STARD3	-0.67	-9.04	-0.51	6.14e-17	Asthma;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg18415444	chr3:32932484	TRIM71	-0.33	-6.23	-0.38	2.15e-9	Electrocardiographic conduction measures;
SARC	cis	rs6495122	0.699	rs1378942	chr15:75077367	A/C	cg14664628	chr15:75095509	CSK	0.8	10.75	0.58	3.75e-22	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	cis	rs8062405	0.824	rs4788085	chr16:28535003	A/G	cg08761264	chr16:28874980	SH2B1	-0.42	-4.76	-0.3	3.33e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs992157	0.798	rs4674284	chr2:219161241	C/T	cg13835894	chr2:219148914	PNKD;TMBIM1	-0.29	-4.76	-0.3	3.38e-6	Colorectal cancer;
SARC	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg00933542	chr6:150070202	PCMT1	0.31	5.27	0.33	3.05e-7	Lung cancer;
SARC	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg06634786	chr22:41940651	POLR3H	0.49	6.09	0.37	4.68e-9	Vitiligo;
SARC	cis	rs7020830	0.830	rs17487601	chr9:37213641	G/A	cg14294708	chr9:37120828	ZCCHC7	1.13	19.44	0.79	1.11e-50	Schizophrenia;
SARC	cis	rs7824557	0.564	rs13260727	chr8:11232860	A/G	cg07291889	chr8:11471712	NA	-0.33	-4.89	-0.31	1.85e-6	Retinal vascular caliber;
SARC	cis	rs3087591	0.960	rs2285812	chr17:29533871	A/G	cg24425628	chr17:29625626	OMG;NF1	0.49	6.01	0.37	6.95e-9	Hip circumference;
SARC	cis	rs2204008	0.745	rs12146863	chr12:38502346	G/A	cg13010199	chr12:38710504	ALG10B	0.74	10.18	0.56	2.18e-20	Bladder cancer;
SARC	cis	rs4689388	0.890	rs4688989	chr4:6290594	T/C	cg00701064	chr4:6280414	WFS1	0.55	8.79	0.5	3.45e-16	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs2070488	0.965	rs7640050	chr3:38525864	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	13.67	0.67	1.21e-31	Electrocardiographic conduction measures;
SARC	cis	rs509477	0.887	rs595309	chr18:32562402	A/G	cg23791764	chr18:32556832	MAPRE2	0.67	7.18	0.43	9.23e-12	Cerebrospinal fluid AB1-42 levels;
SARC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg11494091	chr17:61959527	GH2	0.56	8.5	0.49	2.22e-15	Prudent dietary pattern;
SARC	cis	rs17401966	1.000	rs11121533	chr1:10292888	G/C	cg15208524	chr1:10270712	KIF1B	0.6	6.91	0.41	4.59e-11	Hepatocellular carcinoma;
SARC	cis	rs11785400	0.753	rs9773415	chr8:143731170	G/A	cg10596483	chr8:143751796	JRK	0.57	7.38	0.44	2.81e-12	Schizophrenia;
SARC	cis	rs11711311	1.000	rs11719303	chr3:113494524	A/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	8.64	0.49	9.34e-16	IgG glycosylation;
SARC	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg20965017	chr5:231967	SDHA	-0.57	-5.43	-0.34	1.38e-7	Breast cancer;
SARC	cis	rs6540556	0.954	rs10863786	chr1:209937764	A/G	cg05527609	chr1:210001259	C1orf107	-0.56	-6.09	-0.37	4.57e-9	Red blood cell count;
SARC	cis	rs3741151	1.000	rs112840535	chr11:73066771	G/A	cg17517138	chr11:73019481	ARHGEF17	0.97	6.83	0.41	7.16e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs1349547	0.510	rs3864654	chr8:39497122	A/C	cg12140000	chr8:38554703	NA	0.31	4.74	0.3	3.71e-6	HIV-1 susceptibility;
SARC	cis	rs883565	0.569	rs1274971	chr3:39161464	G/A	cg26331595	chr3:39149181	GORASP1;TTC21A	0.43	5.04	0.31	9.47e-7	Handedness;
SARC	cis	rs2204008	0.571	rs8175738	chr12:38311234	C/T	cg14851346	chr12:38532713	NA	-0.47	-5.64	-0.35	4.96e-8	Bladder cancer;
SARC	cis	rs7681440	0.583	rs2619373	chr4:90722433	G/A	cg06632027	chr4:90757378	SNCA	-0.47	-5.72	-0.35	3.23e-8	Dementia with Lewy bodies;
SARC	cis	rs8077889	0.672	rs2106764	chr17:41852717	T/A	cg26893861	chr17:41843967	DUSP3	0.98	15.59	0.71	5.36e-38	Triglycerides;
SARC	cis	rs67311347	0.594	rs12629111	chr3:40285351	T/C	cg24209194	chr3:40518798	ZNF619	0.42	5.3	0.33	2.64e-7	Renal cell carcinoma;
SARC	cis	rs1564271	0.528	rs1980756	chr10:26979371	G/C	cg13837822	chr10:26931731	LOC731789	0.41	5.98	0.37	8.12e-9	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
SARC	cis	rs2832191	0.550	rs66484040	chr21:30511691	G/A	cg08807101	chr21:30365312	RNF160	-0.7	-8.54	-0.49	1.76e-15	Dental caries;
SARC	cis	rs72949976	0.646	rs13029384	chr2:214029164	G/A	cg08319019	chr2:214017104	IKZF2	0.47	6.31	0.38	1.39e-9	Lung cancer;Squamous cell lung carcinoma;
SARC	cis	rs12791968	1.000	rs12791968	chr11:45001490	C/T	cg11846598	chr11:44996168	LOC221122	0.37	5.82	0.36	1.92e-8	Inhibitory control;
SARC	cis	rs11098499	0.731	rs9995026	chr4:120490499	T/A	cg09307838	chr4:120376055	NA	0.91	12.25	0.63	5.66e-27	Corneal astigmatism;
SARC	cis	rs9354308	1.000	rs9360161	chr6:66565457	C/T	cg07460842	chr6:66804631	NA	0.46	5.4	0.33	1.6e-7	Metabolite levels;
SARC	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg12463550	chr7:65579703	CRCP	0.52	5.81	0.36	2.06e-8	Aortic root size;
SARC	cis	rs6570726	0.935	rs406343	chr6:145874388	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.56	0.39	3.48e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs17270561	0.609	rs6924794	chr6:25735874	A/G	cg17691542	chr6:26056736	HIST1H1C	0.58	7.09	0.42	1.6e-11	Iron status biomarkers;
SARC	trans	rs13325613	0.915	rs34414382	chr3:46265190	C/T	cg12387106	chr12:133178249	NA	0.84	6.57	0.4	3.25e-10	Monocyte count;
SARC	cis	rs73198271	0.773	rs66618176	chr8:8646974	G/C	cg06636001	chr8:8085503	FLJ10661	-0.47	-5.0	-0.31	1.15e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs6912958	0.559	rs173333	chr6:88047754	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	10.96	0.58	8.44e-23	Monocyte percentage of white cells;
SARC	cis	rs1153858	1.000	rs1346268	chr15:45673029	T/C	cg03999130	chr15:45571217	NA	0.39	4.98	0.31	1.25e-6	Homoarginine levels;
SARC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.03	0.37	6.27e-9	Prudent dietary pattern;
SARC	cis	rs3857536	0.566	rs208463	chr6:66913962	T/A	cg07460842	chr6:66804631	NA	-0.75	-8.63	-0.49	9.86e-16	Blood trace element (Cu levels);
SARC	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg23758822	chr17:41437982	NA	0.86	10.56	0.57	1.52e-21	Menopause (age at onset);
SARC	cis	rs9303401	0.614	rs2007993	chr17:56590643	T/C	cg25039879	chr17:56429692	SUPT4H1	0.64	5.96	0.36	9.19e-9	Cognitive test performance;
SARC	cis	rs41271473	0.526	rs72765760	chr1:228743222	G/A	cg16512390	chr1:228756714	NA	0.67	6.76	0.4	1.11e-10	Chronic lymphocytic leukemia;
SARC	cis	rs501120	1.000	rs487465	chr10:44758197	A/C	cg09554077	chr10:44749378	NA	0.48	6.49	0.39	5.12e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs9359856	0.623	rs7742602	chr6:90327385	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.52	-4.98	-0.31	1.26e-6	Bipolar disorder;
SARC	cis	rs12188164	0.543	rs2434694	chr5:462734	C/T	cg16584290	chr5:462447	EXOC3	0.43	6.67	0.4	1.81e-10	Cystic fibrosis severity;
SARC	cis	rs1448094	0.842	rs7301280	chr12:86455752	G/T	cg02569458	chr12:86230093	RASSF9	-0.39	-5.71	-0.35	3.39e-8	Major depressive disorder;
SARC	cis	rs7932354	0.666	rs6485696	chr11:46842045	C/T	cg03339077	chr11:47165057	C11orf49	-0.37	-4.91	-0.31	1.7e-6	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs10754283	0.967	rs1934044	chr1:90107501	C/T	cg21401794	chr1:90099060	LRRC8C	-0.58	-7.91	-0.46	1.05e-13	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs10751667	0.580	rs7395515	chr11:1005160	C/T	cg20946044	chr11:1010712	AP2A2	-0.38	-5.73	-0.35	3.04e-8	Alzheimer's disease (late onset);
SARC	cis	rs6121246	0.954	rs6060992	chr20:30431255	G/T	cg13852791	chr20:30311386	BCL2L1	0.85	9.16	0.51	2.77e-17	Mean corpuscular hemoglobin;
SARC	cis	rs1983170	1.000	rs483532	chr1:91980447	A/G	cg25838465	chr1:92012736	NA	-0.53	-5.64	-0.35	5e-8	Eosinophil percentage of white cells;
SARC	cis	rs17376456	0.542	rs10061069	chr5:93071630	G/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.54	5.87	0.36	1.5e-8	Diabetic retinopathy;
SARC	cis	rs9398803	0.686	rs3861458	chr6:126912162	G/A	cg20229609	chr6:126660872	C6orf173	0.37	5.39	0.33	1.74e-7	Male-pattern baldness;
SARC	cis	rs9309473	0.950	rs6745480	chr2:73840055	C/T	cg20560298	chr2:73613845	ALMS1	-0.44	-5.21	-0.32	4.11e-7	Metabolite levels;
SARC	cis	rs9916302	0.706	rs4287601	chr17:37513852	T/C	cg00129232	chr17:37814104	STARD3	0.53	5.7	0.35	3.69e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs2463822	0.925	rs1528730	chr11:62081181	A/C	cg06239285	chr11:62104954	ASRGL1	0.79	8.1	0.47	3.04e-14	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs9640161	0.789	rs10952250	chr7:150025966	T/C	cg17279839	chr7:150038598	RARRES2	0.49	7.43	0.44	2.07e-12	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg18876405	chr7:65276391	NA	0.7	9.09	0.51	4.42e-17	Aortic root size;
SARC	cis	rs17270561	0.609	rs9358877	chr6:25739228	A/G	cg16482183	chr6:26056742	HIST1H1C	0.43	5.22	0.32	3.92e-7	Iron status biomarkers;
SARC	cis	rs897080	0.831	rs7583741	chr2:44775055	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.44	4.98	0.31	1.26e-6	Height;
SARC	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg22920501	chr2:26401640	FAM59B	-0.56	-7.4	-0.44	2.5e-12	Gut microbiome composition (summer);
SARC	cis	rs11864453	1.000	rs7185407	chr16:72034957	A/T	cg01557791	chr16:72042693	DHODH	0.71	8.7	0.5	6.2e-16	Fibrinogen levels;
SARC	cis	rs9462027	0.628	rs2814969	chr6:34713399	C/A	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.85	-0.36	1.64e-8	Systemic lupus erythematosus;
SARC	cis	rs12541335	0.639	rs68063696	chr8:22153236	A/G	cg26039829	chr8:22132926	PIWIL2	0.46	6.49	0.39	5.11e-10	Hypertriglyceridemia;
SARC	cis	rs7681440	0.835	rs7668531	chr4:90791819	G/T	cg06632027	chr4:90757378	SNCA	0.41	5.79	0.35	2.27e-8	Dementia with Lewy bodies;
SARC	cis	rs1865760	0.865	rs9467641	chr6:25947236	T/C	cg17691542	chr6:26056736	HIST1H1C	0.58	7.3	0.43	4.62e-12	Height;
SARC	trans	rs11098499	0.909	rs17046118	chr4:120387496	T/G	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	cis	rs61935443	0.666	rs73218073	chr12:95314346	A/G	cg21533806	chr12:95267307	NA	0.66	7.38	0.44	2.73e-12	Schizophrenia;
SARC	trans	rs11039571	0.588	rs61917001	chr11:48233667	G/C	cg15704280	chr7:45808275	SEPT13	0.63	6.5	0.39	4.82e-10	D-dimer levels;
SARC	cis	rs11190604	1.000	rs2495739	chr10:102335507	C/T	cg07080220	chr10:102295463	HIF1AN	0.77	8.92	0.5	1.35e-16	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs34172651	0.917	rs12599643	chr16:24832693	C/T	cg04756594	chr16:24857601	SLC5A11	0.34	5.43	0.34	1.39e-7	Intelligence (multi-trait analysis);
SARC	cis	rs12709013	0.591	rs30838	chr16:58745417	T/C	cg04273148	chr16:57808038	KIFC3	0.37	5.22	0.32	4.01e-7	Blood metabolite ratios;
SARC	cis	rs4711336	0.664	rs4713662	chr6:33674188	A/G	cg15676125	chr6:33679581	C6orf125	0.52	6.23	0.38	2.16e-9	Height;
SARC	cis	rs568617	0.953	rs658938	chr11:65651830	A/G	cg26695010	chr11:65641043	EFEMP2	0.49	5.75	0.35	2.82e-8	Crohn's disease;
SARC	cis	rs7904368	0.754	rs12253908	chr10:16853358	T/C	cg23933602	chr10:16859644	RSU1	0.61	6.12	0.37	3.85e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	trans	rs7239883	1.000	rs7239883	chr18:40147671	A/G	cg26101560	chr11:118889209	TRAPPC4;RPS25	-0.55	-6.28	-0.38	1.64e-9	Waist circumference;Body mass index;
SARC	cis	rs1559088	0.948	rs12610266	chr19:33581237	C/G	cg03563238	chr19:33554763	RHPN2	0.27	4.95	0.31	1.43e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg06558623	chr16:89946397	TCF25	0.92	6.39	0.39	8.93e-10	Skin colour saturation;
SARC	cis	rs7020830	0.898	rs2047010	chr9:37077947	A/G	cg14294708	chr9:37120828	ZCCHC7	1.14	21.54	0.82	2.29e-57	Schizophrenia;
SARC	cis	rs763121	0.853	rs138702	chr22:39132601	A/T	cg06022373	chr22:39101656	GTPBP1	-0.86	-12.01	-0.62	3.55e-26	Menopause (age at onset);
SARC	cis	rs13392177	0.660	rs12988046	chr2:219073804	A/G	cg00012203	chr2:219082015	ARPC2	-0.7	-9.57	-0.53	1.67e-18	Pyoderma gangrenosum in inflammatory bowel disease;
SARC	cis	rs11785400	1.000	rs754957	chr8:143746416	A/G	cg10596483	chr8:143751796	JRK	0.64	8.5	0.49	2.36e-15	Schizophrenia;
SARC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.42	0.53	4.71e-18	Prudent dietary pattern;
SARC	trans	rs6601450	0.522	rs7837979	chr8:10198534	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	7.06	0.42	1.89e-11	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs12545109	0.800	rs1437278	chr8:57357024	T/C	cg19413350	chr8:57351067	NA	-0.45	-4.92	-0.31	1.61e-6	Obesity-related traits;
SARC	cis	rs820218	0.847	rs10808	chr17:73616853	G/C	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.57	7.16	0.42	1.06e-11	Rotator cuff tears;
SARC	cis	rs7953249	0.722	rs2255531	chr12:121414915	G/A	cg02403541	chr12:121454288	C12orf43	0.7	9.8	0.54	3.2e-19	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs7666738	0.800	rs2839836	chr4:98970512	A/G	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs11697848	1.000	rs13433386	chr20:48507912	A/G	cg17849948	chr20:48532315	SPATA2	0.86	5.15	0.32	5.59e-7	Systemic lupus erythematosus;
SARC	cis	rs7937682	0.961	rs11828343	chr11:111491322	A/G	cg09085632	chr11:111637200	PPP2R1B	0.96	15.33	0.71	3.79e-37	Primary sclerosing cholangitis;
SARC	cis	rs6835098	0.692	rs7657374	chr4:174065756	A/T	cg08422745	chr4:174089978	GALNT7	-0.59	-7.33	-0.43	3.81e-12	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg03806693	chr22:41940476	POLR3H	-0.92	-12.38	-0.63	2.2e-27	Vitiligo;
SARC	cis	rs3770081	0.536	rs7562837	chr2:86306251	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.74	-6.07	-0.37	5.04e-9	Facial emotion recognition (sad faces);
SARC	cis	rs17376456	0.825	rs17374166	chr5:93238655	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.7	0.35	3.54e-8	Diabetic retinopathy;
SARC	cis	rs9467711	0.591	rs9467621	chr6:25851338	G/A	cg21479132	chr6:26055353	NA	0.78	5.0	0.31	1.1e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs3820928	1.000	rs4675116	chr2:227769607	A/C	cg11843606	chr2:227700838	RHBDD1	-0.53	-6.66	-0.4	1.95e-10	Pulmonary function;
SARC	cis	rs1971762	0.602	rs4759283	chr12:54079243	C/T	cg06632207	chr12:54070931	ATP5G2	0.43	5.65	0.35	4.76e-8	Height;
SARC	cis	rs35306767	0.903	rs12264711	chr10:929525	T/C	cg20503657	chr10:835505	NA	0.88	8.48	0.49	2.57e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg12564285	chr5:131593104	PDLIM4	0.41	6.01	0.37	6.96e-9	Acylcarnitine levels;
SARC	cis	rs9796	0.870	rs11854472	chr15:41357687	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.43	-5.91	-0.36	1.2e-8	Menopause (age at onset);
SARC	cis	rs13343954	0.756	rs2042190	chr19:33532716	T/C	cg17764715	chr19:33622953	WDR88	0.48	5.2	0.32	4.29e-7	Colorectal cancer;
SARC	cis	rs288326	0.561	rs77227040	chr2:183894166	T/C	cg09997497	chr2:183902928	NCKAP1	0.74	5.1	0.32	6.97e-7	Blood protein levels;
SARC	cis	rs3091242	0.967	rs3093614	chr1:25677844	T/A	cg27572855	chr1:25598939	RHD	-0.57	-9.93	-0.55	1.34e-19	Erythrocyte sedimentation rate;
SARC	cis	rs3771570	0.901	rs4675964	chr2:242324760	A/C	cg21155796	chr2:242212141	HDLBP	0.53	5.11	0.32	6.73e-7	Prostate cancer;
SARC	cis	rs10411696	0.872	rs3752243	chr19:1054060	C/T	cg18950617	chr19:1066959	HMHA1	0.49	6.45	0.39	6.27e-10	Eosinophil percentage of white cells;
SARC	cis	rs4714291	0.928	rs761799	chr6:39990050	T/A	cg09256477	chr6:40556568	LRFN2	0.26	4.72	0.3	3.99e-6	Strep throat;
SARC	cis	rs8031584	1.000	rs35607976	chr15:31277788	T/C	cg08109568	chr15:31115862	NA	-0.45	-5.13	-0.32	6.2e-7	Huntington's disease progression;
SARC	trans	rs1814175	0.817	rs7483795	chr11:49704930	G/A	cg03929089	chr4:120376271	NA	-0.9	-14.95	-0.7	6.77e-36	Height;
SARC	cis	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg16664915	chr8:10907788	XKR6	0.36	4.87	0.3	2.1e-6	Triglycerides;
SARC	cis	rs4718428	0.705	rs68168107	chr7:66255238	G/A	cg12165864	chr7:66369176	NA	-0.43	-4.75	-0.3	3.51e-6	Corneal structure;
SARC	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.85	8.89	0.5	1.74e-16	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs9291683	0.526	rs7695555	chr4:10001656	T/C	cg11266682	chr4:10021025	SLC2A9	0.36	6.09	0.37	4.72e-9	Bone mineral density;
SARC	cis	rs78545713	0.649	rs41266811	chr6:26216656	T/C	cg00631329	chr6:26305371	NA	-0.71	-5.14	-0.32	5.85e-7	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs4803468	1.000	rs2569754	chr19:41936734	A/G	cg09537434	chr19:41945824	ATP5SL	-0.96	-16.49	-0.73	5.31e-41	Height;
SARC	trans	rs9325144	0.647	rs34963631	chr12:38912260	T/A	cg23762105	chr12:34175262	ALG10	0.48	6.26	0.38	1.83e-9	Morning vs. evening chronotype;
SARC	cis	rs2857078	0.720	rs9901595	chr17:42305699	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	0.43	5.75	0.35	2.77e-8	Red cell distribution width;Reticulocyte count;
SARC	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg06212747	chr3:49208901	KLHDC8B	0.66	8.71	0.5	5.89e-16	Parkinson's disease;
SARC	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg13175981	chr1:150552382	MCL1	-0.48	-5.91	-0.36	1.23e-8	Tonsillectomy;
SARC	cis	rs1371867	0.846	rs1660312	chr8:101330634	C/G	cg11906718	chr8:101322791	RNF19A	0.7	9.03	0.51	6.61e-17	Atrioventricular conduction;
SARC	cis	rs7766436	0.614	rs60412116	chr6:22563741	G/T	cg13666174	chr6:22585274	NA	-0.56	-5.86	-0.36	1.59e-8	Coronary artery disease;
SARC	cis	rs3106136	0.967	rs2664892	chr4:95154186	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.39	-6.01	-0.37	7.17e-9	Capecitabine sensitivity;
SARC	cis	rs9462027	0.606	rs412392	chr6:34549699	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-6.08	-0.37	4.78e-9	Systemic lupus erythematosus;
SARC	cis	rs9290065	0.622	rs6797798	chr3:160646598	G/A	cg04691961	chr3:161091175	C3orf57	0.5	6.66	0.4	1.94e-10	Kawasaki disease;
SARC	cis	rs7223966	1.000	rs2854218	chr17:61942940	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	7.68	0.45	4.33e-13	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg13939156	chr17:80058883	NA	-0.42	-6.48	-0.39	5.51e-10	Life satisfaction;
SARC	cis	rs6807306	0.913	rs6444447	chr3:167349004	C/T	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.51	4.9	0.31	1.79e-6	Mean platelet volume;
SARC	cis	rs72945132	0.619	rs61887436	chr11:70243337	C/T	cg05226335	chr11:70253499	CTTN	-0.53	-4.97	-0.31	1.3e-6	Coronary artery disease;
SARC	cis	rs7647973	0.626	rs4855849	chr3:49653378	A/G	cg07636037	chr3:49044803	WDR6	0.63	6.42	0.39	7.57e-10	Menarche (age at onset);
SARC	cis	rs10758161	1.000	rs10758161	chr9:32755028	A/G	cg12762715	chr9:33025796	DNAJA1	0.6	5.03	0.31	9.94e-7	Immune response to anthrax vaccine;
SARC	cis	rs703842	1.000	rs3825079	chr12:58203354	C/T	cg00677455	chr12:58241039	CTDSP2	0.51	6.64	0.4	2.24e-10	Multiple sclerosis;
SARC	cis	rs3008870	0.755	rs2815380	chr1:67510857	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.42	-5.25	-0.33	3.4e-7	Lymphocyte percentage of white cells;
SARC	cis	rs12291225	0.639	rs61883858	chr11:14294708	C/T	cg19336497	chr11:14380999	RRAS2	-0.41	-6.81	-0.41	8.46e-11	Sense of smell;
SARC	cis	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.44	-0.44	1.95e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs933688	0.938	rs7705465	chr5:90680949	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.02	12.97	0.65	2.47e-29	Smoking behavior;
SARC	cis	rs2645694	0.626	rs2703122	chr4:77821418	A/C	cg06046430	chr4:77819534	ANKRD56	0.54	7.78	0.45	2.35e-13	Emphysema distribution in smoking;
SARC	cis	rs7223966	1.000	rs8074771	chr17:61735865	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.34	0.38	1.19e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs3780486	1.000	rs3780486	chr9:33139453	C/T	cg20290983	chr6:43655470	MRPS18A	1.01	14.4	0.69	4.57e-34	IgG glycosylation;
SARC	cis	rs10504229	0.813	rs6999878	chr8:58197243	C/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.38	-0.33	1.82e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs12579753	0.917	rs76240969	chr12:82195236	C/A	cg07988820	chr12:82153109	PPFIA2	-0.52	-6.11	-0.37	4.18e-9	Resting heart rate;
SARC	cis	rs2290159	0.948	rs7956	chr3:12624763	C/T	cg23032965	chr3:12705835	RAF1	-0.63	-7.02	-0.42	2.38e-11	Cholesterol, total;
SARC	cis	rs7927592	0.956	rs10896337	chr11:68284236	T/C	cg01657329	chr11:68192670	LRP5	-0.41	-5.13	-0.32	6.01e-7	Total body bone mineral density;
SARC	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg22508957	chr16:3507546	NAT15	-0.39	-5.83	-0.36	1.84e-8	Tuberculosis;
SARC	cis	rs2273669	0.915	rs11970599	chr6:109314350	C/T	cg01304950	chr6:109416612	SESN1;C6orf182	-0.55	-5.08	-0.32	7.61e-7	Prostate cancer;
SARC	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.41	4.96	0.31	1.39e-6	Electroencephalogram traits;
SARC	cis	rs2933343	0.649	rs789219	chr3:128592520	G/A	cg25356066	chr3:128598488	ACAD9	0.7	9.35	0.52	7.52e-18	IgG glycosylation;
SARC	cis	rs8067354	0.645	rs7215180	chr17:57822354	A/G	cg13753209	chr17:57696993	CLTC	0.67	7.24	0.43	6.46e-12	Hemoglobin concentration;
SARC	cis	rs751728	0.571	rs4713691	chr6:33790415	A/G	cg25922239	chr6:33757077	LEMD2	-0.57	-6.69	-0.4	1.65e-10	Crohn's disease;
SARC	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg04277193	chr17:41438351	NA	0.44	4.73	0.3	3.83e-6	Menopause (age at onset);
SARC	cis	rs644799	0.540	rs10831419	chr11:95478037	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.76	10.25	0.56	1.38e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs67311347	0.955	rs6599100	chr3:40447362	C/T	cg24209194	chr3:40518798	ZNF619	0.6	7.66	0.45	4.97e-13	Renal cell carcinoma;
SARC	cis	rs6690583	0.697	rs10782537	chr1:85484473	C/T	cg11262906	chr1:85462892	MCOLN2	-0.51	-5.48	-0.34	1.13e-7	Serum sulfate level;
SARC	cis	rs11997175	0.655	rs4380889	chr8:33663381	C/T	ch.8.33884649F	chr8:33765107	NA	0.46	6.04	0.37	6.04e-9	Body mass index;
SARC	trans	rs3780486	0.718	rs10971418	chr9:33122024	A/C	cg20290983	chr6:43655470	MRPS18A	-0.89	-10.79	-0.58	2.78e-22	IgG glycosylation;
SARC	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg10523679	chr1:76189770	ACADM	0.5	6.45	0.39	6.24e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	trans	rs3780486	0.801	rs6476398	chr9:33119241	C/T	cg20290983	chr6:43655470	MRPS18A	1.14	23.4	0.84	4.2e-63	IgG glycosylation;
SARC	cis	rs2303745	0.544	rs6512180	chr19:17399153	C/T	cg22549504	chr19:17448937	GTPBP3	0.52	5.23	0.32	3.77e-7	Systemic lupus erythematosus;
SARC	cis	rs735396	1.000	rs1169310	chr12:121439433	G/A	cg02403541	chr12:121454288	C12orf43	0.72	9.48	0.53	2.97e-18	N-glycan levels;
SARC	cis	rs9467711	0.606	rs9348726	chr6:26605206	G/A	cg12826209	chr6:26865740	GUSBL1	0.72	4.85	0.3	2.25e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg09307838	chr4:120376055	NA	0.87	12.22	0.63	7.13e-27	Corneal astigmatism;
SARC	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg25036284	chr2:26402008	FAM59B	0.46	5.7	0.35	3.59e-8	Gut microbiome composition (summer);
SARC	cis	rs986417	1.000	rs1951115	chr14:60922006	G/C	cg27398547	chr14:60952738	C14orf39	-1.02	-9.54	-0.53	2.06e-18	Gut microbiota (bacterial taxa);
SARC	cis	rs713477	0.935	rs7147968	chr14:55909040	G/A	cg13175173	chr14:55914753	NA	-0.3	-4.75	-0.3	3.63e-6	Pediatric bone mineral content (femoral neck);
SARC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.51	5.93	0.36	1.09e-8	Prudent dietary pattern;
SARC	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg19901468	chr14:105411992	AHNAK2	-0.72	-10.55	-0.57	1.6e-21	Rheumatoid arthritis;
SARC	cis	rs561341	0.941	rs7215147	chr17:30266711	G/A	cg13647721	chr17:30228624	UTP6	0.59	5.22	0.32	4.02e-7	Hip circumference adjusted for BMI;
SARC	cis	rs752010	0.644	rs6700390	chr1:42112554	A/G	cg06885757	chr1:42089581	HIVEP3	0.39	5.98	0.36	8.23e-9	Lupus nephritis in systemic lupus erythematosus;
SARC	trans	rs1814175	0.904	rs7924371	chr11:49620595	C/T	cg03929089	chr4:120376271	NA	-0.85	-13.28	-0.66	2.49e-30	Height;
SARC	trans	rs208520	0.706	rs851601	chr6:66893853	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-12.56	-0.64	5.74e-28	Exhaled nitric oxide output;
SARC	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg13607699	chr17:42295918	UBTF	0.56	6.63	0.4	2.29e-10	Total body bone mineral density;
SARC	cis	rs7412746	0.611	rs4319334	chr1:150766822	G/A	cg10589385	chr1:150898437	SETDB1	0.4	5.26	0.33	3.2e-7	Melanoma;
SARC	cis	rs2529049	0.537	rs1053962	chr7:24703298	G/A	cg17569154	chr7:24781545	DFNA5	0.5	7.16	0.42	1.05e-11	Urate levels in obese individuals;
SARC	cis	rs2204008	0.837	rs7315255	chr12:37949279	G/A	cg26384229	chr12:38710491	ALG10B	0.89	13.31	0.66	1.93e-30	Bladder cancer;
SARC	cis	rs2070997	0.756	rs7872328	chr9:133727453	T/A	cg03924115	chr9:133768966	QRFP	0.46	5.24	0.32	3.6e-7	Response to amphetamines;
SARC	cis	rs10779751	0.734	rs2791657	chr1:11128001	A/G	cg08854313	chr1:11322531	MTOR	0.82	11.32	0.6	5.86e-24	Body mass index;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10886005	chr2:98612331	TMEM131	-0.5	-6.27	-0.38	1.72e-9	Smoking initiation;
SARC	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg09323728	chr8:95962352	TP53INP1	-0.33	-5.41	-0.33	1.59e-7	Type 2 diabetes;
SARC	cis	rs3126085	0.935	rs6670717	chr1:152249956	T/C	cg26876637	chr1:152193138	HRNR	-0.5	-5.46	-0.34	1.22e-7	Atopic dermatitis;
SARC	cis	rs7481584	0.624	rs693687	chr11:3052494	A/G	cg08508325	chr11:3079039	CARS	0.23	5.13	0.32	5.98e-7	Calcium levels;
SARC	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg04317338	chr11:64019027	PLCB3	0.84	8.94	0.51	1.19e-16	Mean platelet volume;
SARC	cis	rs9896052	0.533	rs7406173	chr17:73454563	G/A	cg25649188	chr17:73499917	CASKIN2	0.38	5.39	0.33	1.69e-7	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs1055129	0.655	rs8067076	chr17:73837142	G/T	cg14829360	chr17:73884958	NA	0.42	5.76	0.35	2.65e-8	White matter hyperintensity burden;
SARC	cis	rs1949733	1.000	rs2631745	chr4:8490530	T/C	cg11789530	chr4:8429930	ACOX3	-0.82	-11.09	-0.59	3.06e-23	Response to antineoplastic agents;
SARC	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.31	-0.56	9.06e-21	Chronic sinus infection;
SARC	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg26335602	chr6:28129616	ZNF389	0.52	5.89	0.36	1.34e-8	Depression;
SARC	cis	rs4642101	0.765	rs3901665	chr3:12824610	C/A	cg24848339	chr3:12840334	CAND2	0.32	4.94	0.31	1.48e-6	QRS complex (12-leadsum);
SARC	cis	rs11098499	0.955	rs13129661	chr4:120152909	C/G	cg09307838	chr4:120376055	NA	0.86	11.55	0.6	1.05e-24	Corneal astigmatism;
SARC	cis	rs11098499	0.954	rs7437420	chr4:120312903	A/G	cg09307838	chr4:120376055	NA	0.91	12.88	0.65	4.9e-29	Corneal astigmatism;
SARC	cis	rs910316	0.967	rs12890371	chr14:75593839	T/C	cg06637938	chr14:75390232	RPS6KL1	0.5	7.15	0.42	1.09e-11	Height;
SARC	cis	rs7615952	0.866	rs13063119	chr3:125643847	G/A	cg05084668	chr3:125655381	ALG1L	-0.64	-6.45	-0.39	6.55e-10	Blood pressure (smoking interaction);
SARC	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg24549020	chr5:56110836	MAP3K1	0.74	7.51	0.44	1.23e-12	Initial pursuit acceleration;
SARC	cis	rs12477438	0.765	rs7591992	chr2:99668954	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-15.46	-0.71	1.39e-37	Chronic sinus infection;
SARC	cis	rs694739	0.628	rs617051	chr11:64133638	C/A	cg23796481	chr11:64053134	BAD;GPR137	0.66	7.57	0.44	8.82e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs9487051	0.714	rs7744284	chr6:109616218	C/T	cg01475377	chr6:109611718	NA	-0.4	-5.71	-0.35	3.41e-8	Reticulocyte fraction of red cells;
SARC	cis	rs4243830	0.850	rs7552196	chr1:6590502	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.81	-7.78	-0.45	2.31e-13	Body mass index;
SARC	trans	rs66573146	0.831	rs67315413	chr4:6987910	T/C	cg07817883	chr1:32538562	TMEM39B	1.26	8.27	0.48	1.04e-14	Granulocyte percentage of myeloid white cells;
SARC	cis	rs2486288	0.656	rs12910009	chr15:45572408	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.53	-6.65	-0.4	2.03e-10	Glomerular filtration rate;
SARC	cis	rs6450176	0.909	rs6898870	chr5:53293107	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.65	-7.35	-0.43	3.24e-12	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs27434	0.529	rs42443	chr5:96156224	G/A	cg16492584	chr5:96139282	ERAP1	-0.56	-7.02	-0.42	2.43e-11	Ankylosing spondylitis;
SARC	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg18404041	chr3:52824283	ITIH1	-0.41	-6.09	-0.37	4.67e-9	Bipolar disorder;
SARC	cis	rs2735413	0.846	rs12923290	chr16:78079956	A/G	cg04733911	chr16:78082701	NA	-0.29	-5.32	-0.33	2.48e-7	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg02841227	chr6:26021843	HIST1H4A	-0.63	-7.6	-0.45	7.34e-13	Intelligence (multi-trait analysis);
SARC	cis	rs1949733	0.523	rs56053534	chr4:8542876	G/A	cg11789530	chr4:8429930	ACOX3	-0.71	-8.05	-0.47	4.31e-14	Response to antineoplastic agents;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg07996345	chr11:47600851	KBTBD4;NDUFS3	0.48	6.32	0.38	1.29e-9	Chemerin levels;
SARC	cis	rs8051517	1.000	rs11862550	chr16:68419831	A/G	cg01866162	chr16:67596514	CTCF	0.9	4.87	0.3	2.1e-6	Blood protein levels;
SARC	cis	rs10504073	0.647	rs11785310	chr8:50025035	G/A	cg00325661	chr8:49890786	NA	0.54	7.39	0.44	2.67e-12	Blood metabolite ratios;
SARC	cis	rs7592578	0.882	rs2192010	chr2:191462133	C/T	cg27211696	chr2:191398769	TMEM194B	-0.54	-5.75	-0.35	2.77e-8	Diastolic blood pressure;
SARC	cis	rs911555	0.755	rs34411783	chr14:103900639	G/A	cg24130564	chr14:104152367	KLC1	0.5	5.73	0.35	3.07e-8	Intelligence (multi-trait analysis);
SARC	cis	rs4803468	1.000	rs10409485	chr19:41920765	C/T	cg09537434	chr19:41945824	ATP5SL	0.91	15.2	0.71	9.93e-37	Height;
SARC	cis	rs8017423	0.967	rs2277517	chr14:90722778	G/A	cg20276874	chr14:90721474	PSMC1	-0.39	-5.49	-0.34	1.06e-7	Mortality in heart failure;
SARC	trans	rs6762477	0.748	rs9831967	chr3:50217234	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.51	-6.4	-0.39	8.55e-10	Menarche (age at onset);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg05791779	chr3:126452023	CHCHD6	0.52	6.55	0.39	3.59e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg13939156	chr17:80058883	NA	0.4	6.25	0.38	1.92e-9	Life satisfaction;
SARC	cis	rs2439831	1.000	rs689596	chr15:43761717	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.04	11.03	0.59	4.93e-23	Lung cancer in ever smokers;
SARC	cis	rs5753618	0.561	rs9609254	chr22:31705942	G/A	cg13145458	chr22:31556086	RNF185	-0.46	-4.94	-0.31	1.51e-6	Colorectal cancer;
SARC	cis	rs11574514	1.000	rs1123072	chr16:67898797	G/A	cg01866162	chr16:67596514	CTCF	0.93	5.67	0.35	4.2e-8	Crohn's disease;
SARC	cis	rs7246657	0.943	rs10409204	chr19:37917692	G/A	cg23950597	chr19:37808831	NA	-0.64	-6.16	-0.37	3.21e-9	Coronary artery calcification;
SARC	cis	rs12477438	0.765	rs10181422	chr2:99558970	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-14.93	-0.7	8.25e-36	Chronic sinus infection;
SARC	cis	rs9902453	0.967	rs17825877	chr17:28515188	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	6.82	0.41	7.95e-11	Coffee consumption (cups per day);
SARC	cis	rs3741404	0.620	rs11231722	chr11:63967770	C/G	cg18225595	chr11:63971243	STIP1	0.47	7.35	0.43	3.26e-12	Platelet count;
SARC	cis	rs17401966	0.931	rs746881	chr1:10346810	C/T	cg15208524	chr1:10270712	KIF1B	-0.47	-5.27	-0.33	3.06e-7	Hepatocellular carcinoma;
SARC	cis	rs17023223	0.537	rs10923759	chr1:119692194	A/G	cg05756136	chr1:119680316	WARS2	0.48	5.54	0.34	8.08e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg23758822	chr17:41437982	NA	0.89	11.4	0.6	3.2e-24	Menopause (age at onset);
SARC	cis	rs2153535	0.601	rs9328487	chr6:8529378	G/C	cg23788917	chr6:8435910	SLC35B3	0.61	8.19	0.47	1.75e-14	Motion sickness;
SARC	cis	rs2276314	1.000	rs9304154	chr18:33562227	C/T	cg19628046	chr18:33552617	C18orf21	0.57	5.96	0.36	9.43e-9	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs2594989	0.887	rs2437684	chr3:11593261	C/T	cg00170343	chr3:11313890	ATG7	-0.54	-5.85	-0.36	1.63e-8	Circulating chemerin levels;
SARC	cis	rs72653721	0.838	rs3756962	chr6:11006861	C/T	cg13562911	chr6:11044106	ELOVL2	0.54	6.27	0.38	1.73e-9	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	cis	rs9400467	0.537	rs12199840	chr6:111428865	A/G	cg15721981	chr6:111408429	SLC16A10	0.68	5.86	0.36	1.56e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs2153535	0.580	rs9379206	chr6:8458021	C/A	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.04e-14	Motion sickness;
SARC	cis	rs7633857	0.537	rs1580253	chr3:160767150	T/C	cg04691961	chr3:161091175	C3orf57	-0.49	-6.09	-0.37	4.58e-9	Educational attainment (years of education);
SARC	cis	rs72945132	0.882	rs4567496	chr11:70193208	A/T	cg00319359	chr11:70116639	PPFIA1	0.69	6.25	0.38	1.92e-9	Coronary artery disease;
SARC	cis	rs818427	0.795	rs454968	chr5:112188456	T/C	cg07820702	chr5:112228657	REEP5	0.5	5.83	0.36	1.8e-8	Total body bone mineral density;
SARC	cis	rs9911578	0.803	rs8069033	chr17:57131581	T/A	cg05425664	chr17:57184151	TRIM37	0.64	8.01	0.46	5.41e-14	Intelligence (multi-trait analysis);
SARC	cis	rs9309473	0.950	rs6546847	chr2:73785358	A/G	cg07208825	chr2:73871855	ALMS1P	0.32	4.78	0.3	3.16e-6	Metabolite levels;
SARC	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.7	7.93	0.46	9.07e-14	Multiple sclerosis;
SARC	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6835098	0.509	rs2332655	chr4:174093002	A/G	cg08422745	chr4:174089978	GALNT7	0.55	7.48	0.44	1.46e-12	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs757081	0.667	rs17641418	chr11:17161341	T/C	cg15432903	chr11:17409602	KCNJ11	-0.36	-4.72	-0.3	4.01e-6	Systolic blood pressure;
SARC	cis	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.42	-5.15	-0.32	5.58e-7	Eosinophil percentage of white cells;
SARC	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg24829409	chr8:58192753	C8orf71	-0.55	-4.77	-0.3	3.29e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg05863683	chr7:1912471	MAD1L1	0.33	4.99	0.31	1.19e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg00339695	chr16:24857497	SLC5A11	-0.39	-5.41	-0.33	1.56e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7772486	0.754	rs702324	chr6:146008793	A/G	cg23711669	chr6:146136114	FBXO30	-0.84	-13.31	-0.66	1.91e-30	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs8060686	0.591	rs255054	chr16:68017356	A/G	cg04539111	chr16:67997858	SLC12A4	-0.48	-4.72	-0.3	4.11e-6	HDL cholesterol;Metabolic syndrome;
SARC	cis	rs6456156	0.586	rs1358883	chr6:167467433	C/G	cg23791538	chr6:167370224	RNASET2	0.5	6.5	0.39	4.72e-10	Primary biliary cholangitis;
SARC	cis	rs6931421	0.800	rs12662365	chr6:80905389	T/A	cg08355045	chr6:80787529	NA	0.39	6.04	0.37	6.09e-9	Sitting height ratio;
SARC	cis	rs10992471	0.603	rs10761155	chr9:95153729	C/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.21	-0.32	4.15e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs478304	0.593	rs4645933	chr11:65485120	C/T	cg27068330	chr11:65405492	SIPA1	-0.48	-5.64	-0.35	4.83e-8	Acne (severe);
SARC	cis	rs7587476	0.862	rs13001462	chr2:215678346	G/A	cg04004882	chr2:215674386	BARD1	0.58	6.64	0.4	2.18e-10	Neuroblastoma;
SARC	cis	rs72781680	0.756	rs2551337	chr2:24006886	C/T	cg08917208	chr2:24149416	ATAD2B	0.61	6.14	0.37	3.55e-9	Lymphocyte counts;
SARC	cis	rs4803468	1.000	rs284658	chr19:41929988	G/A	cg09537434	chr19:41945824	ATP5SL	-0.98	-17.24	-0.75	1.73e-43	Height;
SARC	trans	rs11098499	0.955	rs13129661	chr4:120152909	C/G	cg25214090	chr10:38739885	LOC399744	0.54	6.91	0.41	4.52e-11	Corneal astigmatism;
SARC	cis	rs7712401	0.601	rs35699701	chr5:122333756	G/T	cg19412675	chr5:122181750	SNX24	-0.43	-5.43	-0.34	1.41e-7	Mean platelet volume;
SARC	cis	rs6831352	0.918	rs34071486	chr4:100051087	A/G	cg13256891	chr4:100009986	ADH5	-0.65	-8.11	-0.47	2.83e-14	Alcohol dependence;
SARC	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.45	5.14	0.32	5.82e-7	Renal function-related traits (BUN);
SARC	cis	rs7927771	0.524	rs10838774	chr11:47856114	A/G	cg10504702	chr11:47789108	FNBP4	0.48	6.17	0.37	2.99e-9	Subjective well-being;
SARC	cis	rs2153535	0.580	rs6920779	chr6:8437624	C/T	cg21535247	chr6:8435926	SLC35B3	0.56	6.91	0.41	4.7e-11	Motion sickness;
SARC	cis	rs9467773	1.000	rs4871	chr6:26545632	G/A	cg12292205	chr6:26970375	C6orf41	0.45	5.42	0.33	1.45e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6450176	0.953	rs3776724	chr5:53292270	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.64	-7.22	-0.43	7.11e-12	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs1580019	0.883	rs6945294	chr7:32472099	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.44	5.32	0.33	2.39e-7	Cognitive ability;
SARC	cis	rs2243480	0.666	rs1880311	chr7:65276752	G/C	cg12463550	chr7:65579703	CRCP	-0.66	-4.74	-0.3	3.67e-6	Diabetic kidney disease;
SARC	cis	rs8031584	0.918	rs34693097	chr15:31253984	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.44	-4.83	-0.3	2.5e-6	Huntington's disease progression;
SARC	cis	rs8044995	0.517	rs2863973	chr16:68409435	A/C	cg09835421	chr16:68378352	PRMT7	-0.44	-4.88	-0.3	1.97e-6	Schizophrenia;
SARC	trans	rs11098499	0.730	rs12505735	chr4:120532956	G/T	cg25214090	chr10:38739885	LOC399744	0.51	6.64	0.4	2.14e-10	Corneal astigmatism;
SARC	cis	rs6121246	0.567	rs6087700	chr20:30217560	A/G	cg13852791	chr20:30311386	BCL2L1	0.64	5.64	0.35	4.79e-8	Mean corpuscular hemoglobin;
SARC	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg12288994	chr5:1860383	NA	0.37	6.06	0.37	5.47e-9	Cardiovascular disease risk factors;
SARC	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg18252515	chr7:66147081	NA	-0.57	-6.11	-0.37	4.17e-9	Aortic root size;
SARC	cis	rs546131	0.642	rs1039841	chr11:34833139	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-4.83	-0.3	2.52e-6	Lung disease severity in cystic fibrosis;
SARC	trans	rs3780486	0.846	rs913214	chr9:33135085	G/A	cg04842962	chr6:43655489	MRPS18A	1.07	19.19	0.78	7.22e-50	IgG glycosylation;
SARC	cis	rs7520050	0.966	rs1707336	chr1:46493460	T/G	cg24296786	chr1:45957014	TESK2	0.38	4.86	0.3	2.2e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg24642844	chr7:1081250	C7orf50	-0.57	-6.05	-0.37	5.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs1318878	0.565	rs11833467	chr12:15491164	A/G	cg08258403	chr12:15378311	NA	-0.48	-6.79	-0.41	9.13e-11	Intelligence (multi-trait analysis);
SARC	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	11.6	0.61	7.26e-25	Alzheimer's disease;
SARC	cis	rs1707322	0.717	rs3014246	chr1:46086077	C/T	cg03146154	chr1:46216737	IPP	-0.51	-6.14	-0.37	3.43e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9916302	0.800	rs8069451	chr17:37504933	C/T	cg15445000	chr17:37608096	MED1	0.42	5.07	0.32	8.01e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg16414030	chr3:133502952	NA	-0.41	-5.54	-0.34	8e-8	Iron status biomarkers;
SARC	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	13.96	0.67	1.39e-32	Chronic sinus infection;
SARC	cis	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg15556689	chr8:8085844	FLJ10661	-0.41	-4.8	-0.3	2.89e-6	Mood instability;
SARC	cis	rs7937682	0.564	rs10891277	chr11:111373103	A/G	cg09085632	chr11:111637200	PPP2R1B	0.5	6.2	0.38	2.58e-9	Primary sclerosing cholangitis;
SARC	cis	rs6500602	0.702	rs4786493	chr16:4500122	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.35	5.75	0.35	2.81e-8	Schizophrenia;
SARC	cis	rs1018836	0.632	rs6988302	chr8:91477660	C/T	cg16814680	chr8:91681699	NA	-0.71	-10.56	-0.57	1.48e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs4906332	1.000	rs35224956	chr14:103900481	A/G	cg26031613	chr14:104095156	KLC1	-0.5	-5.83	-0.36	1.81e-8	Coronary artery disease;
SARC	cis	rs17030434	1.000	rs732680	chr4:154725211	G/A	cg14289246	chr4:154710475	SFRP2	-0.78	-7.5	-0.44	1.34e-12	Electrocardiographic conduction measures;
SARC	cis	rs7106204	0.534	rs75423384	chr11:24273691	A/T	ch.11.24196551F	chr11:24239977	NA	0.65	4.8	0.3	2.88e-6	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs2658782	0.724	rs2248020	chr11:93259965	A/C	cg15737290	chr11:93063684	CCDC67	0.64	7.52	0.44	1.18e-12	Pulmonary function decline;
SARC	cis	rs67311347	1.000	rs67311347	chr3:40533243	G/A	cg01475735	chr3:40494733	NA	-0.44	-5.14	-0.32	5.75e-7	Renal cell carcinoma;
SARC	cis	rs1008375	1.000	rs6811887	chr4:17640858	C/T	cg27347728	chr4:17578864	LAP3	0.47	5.94	0.36	1.01e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1568889	1.000	rs34140872	chr11:28335872	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.72	9.49	0.53	2.79e-18	Bipolar disorder;
SARC	cis	rs7709909	0.720	rs6868774	chr5:79985963	T/C	cg04186980	chr5:79953697	MSH3	0.35	4.72	0.3	4.12e-6	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
SARC	cis	rs4664308	1.000	rs17831161	chr2:160909360	A/G	cg03641300	chr2:160917029	PLA2R1	-0.67	-8.98	-0.51	9.03e-17	Idiopathic membranous nephropathy;
SARC	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg26818010	chr10:134567672	INPP5A	0.64	7.17	0.43	9.78e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs7582180	0.675	rs4851313	chr2:101029002	A/G	cg14675211	chr2:100938903	LONRF2	-0.52	-7.55	-0.44	9.98e-13	Intelligence (multi-trait analysis);
SARC	trans	rs7615952	0.673	rs35955861	chr3:125626201	T/C	cg07211511	chr3:129823064	LOC729375	-0.84	-7.72	-0.45	3.42e-13	Blood pressure (smoking interaction);
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14592474	chr7:79082531	MAGI2	0.52	6.36	0.38	1.06e-9	Fibrinogen levels;
SARC	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.63	-7.6	-0.45	6.99e-13	Gut microbiome composition (summer);
SARC	cis	rs56114371	0.568	rs200468	chr6:27757855	C/G	cg17221315	chr6:27791827	HIST1H4J	0.49	4.74	0.3	3.8e-6	Breast cancer;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg18769103	chr1:236445447	ERO1LB	0.49	6.54	0.39	3.83e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs17376456	0.877	rs17374627	chr5:93296306	C/T	cg25358565	chr5:93447407	FAM172A	1.28	14.37	0.69	5.98e-34	Diabetic retinopathy;
SARC	cis	rs35110281	0.627	rs7283362	chr21:44973667	C/G	cg21573476	chr21:45109991	RRP1B	-0.38	-5.51	-0.34	9.46e-8	Mean corpuscular volume;
SARC	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg05313129	chr8:58192883	C8orf71	-0.62	-6.34	-0.38	1.18e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2576037	0.763	rs2060418	chr18:44576535	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.66	-9.53	-0.53	2.24e-18	Personality dimensions;
SARC	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg07308232	chr7:1071921	C7orf50	-0.65	-7.96	-0.46	7.4e-14	Longevity;Endometriosis;
SARC	cis	rs12458462	0.509	rs3786241	chr18:77494328	A/C	cg11879182	chr18:77439856	CTDP1	0.54	6.77	0.41	1.06e-10	Monocyte count;
SARC	cis	rs826838	1.000	rs9795768	chr12:39012479	T/C	cg26384229	chr12:38710491	ALG10B	0.92	14.28	0.68	1.22e-33	Heart rate;
SARC	cis	rs2481665	0.772	rs6668600	chr1:62536683	C/G	cg18591186	chr1:62594603	INADL	0.52	7.12	0.42	1.34e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2204008	0.591	rs11495396	chr12:38380182	C/T	cg13010199	chr12:38710504	ALG10B	0.78	10.77	0.58	3.24e-22	Bladder cancer;
SARC	cis	rs9916302	0.904	rs588193	chr17:37440439	A/C	cg07936489	chr17:37558343	FBXL20	0.68	9.23	0.52	1.73e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg22920501	chr2:26401640	FAM59B	-0.55	-7.14	-0.42	1.18e-11	Gut microbiome composition (summer);
SARC	cis	rs7766436	0.885	rs13210010	chr6:22585075	C/T	cg13666174	chr6:22585274	NA	-0.6	-7.74	-0.45	3.04e-13	Coronary artery disease;
SARC	cis	rs9341808	0.530	rs3805877	chr6:81031529	T/A	cg08355045	chr6:80787529	NA	0.32	4.94	0.31	1.52e-6	Sitting height ratio;
SARC	cis	rs2242663	0.531	rs2511225	chr11:66248431	A/C	cg25197388	chr11:66278006	BBS1	0.35	5.16	0.32	5.38e-7	Bipolar disorder;
SARC	cis	rs3857536	0.776	rs9342535	chr6:66932963	C/T	cg07460842	chr6:66804631	NA	-0.51	-5.8	-0.36	2.14e-8	Blood trace element (Cu levels);
SARC	cis	rs11098499	0.863	rs3822192	chr4:120445720	A/C	cg09307838	chr4:120376055	NA	0.93	12.64	0.64	3.01e-28	Corneal astigmatism;
SARC	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg02475777	chr4:1388615	CRIPAK	0.65	7.43	0.44	2.02e-12	Longevity;
SARC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg01238044	chr22:24384105	GSTT1	-0.49	-5.35	-0.33	2.11e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	trans	rs1814175	0.645	rs1851869	chr11:49960552	T/C	cg03929089	chr4:120376271	NA	-0.82	-11.88	-0.61	9.2e-26	Height;
SARC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg07167872	chr1:205819463	PM20D1	0.86	14.81	0.7	2.08e-35	Menarche (age at onset);
SARC	cis	rs73206853	0.841	rs28404862	chr12:110850241	C/G	cg10860002	chr12:110842031	ANAPC7	0.62	4.95	0.31	1.4e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs3820928	0.874	rs1917122	chr2:227835681	C/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-6.73	-0.4	1.27e-10	Pulmonary function;
SARC	cis	rs6963495	0.799	rs73190201	chr7:105165891	A/C	cg19920283	chr7:105172520	RINT1	0.66	5.62	0.35	5.45e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg11764359	chr7:65958608	NA	0.78	9.86	0.54	2.14e-19	Aortic root size;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg27164762	chr5:175815688	HIGD2A;NOP16	0.56	7.36	0.43	3.22e-12	Lung adenocarcinoma;
SARC	cis	rs17125944	0.505	rs77949716	chr14:53204234	G/A	cg00686598	chr14:53173677	PSMC6	1.33	9.06	0.51	5.6e-17	Alzheimer's disease (late onset);
SARC	cis	rs7326068	0.510	rs4432108	chr13:21342151	G/A	cg16922012	chr13:21400325	XPO4	-0.46	-6.25	-0.38	1.88e-9	Schizophrenia, bipolar disorder and depression (combined);
SARC	cis	rs11785693	0.862	rs11784262	chr8:4996942	G/A	cg26367366	chr8:4980734	NA	0.76	6.99	0.42	2.95e-11	Neuroticism (multi-trait analysis);Neuroticism;
SARC	trans	rs61931739	0.517	rs7975714	chr12:34055611	T/C	cg13010199	chr12:38710504	ALG10B	0.76	10.39	0.56	4.9e-21	Morning vs. evening chronotype;
SARC	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg17971929	chr21:40555470	PSMG1	-0.87	-11.25	-0.59	9.59e-24	Cognitive function;
SARC	cis	rs6952809	0.561	rs1548598	chr7:2438912	T/C	cg05083358	chr7:2394359	EIF3B	-0.54	-5.03	-0.31	9.75e-7	Multiple sclerosis;
SARC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.62	-7.62	-0.45	6.22e-13	Longevity;Endometriosis;
SARC	cis	rs6847149	0.929	rs4698752	chr4:110780964	A/G	cg07850274	chr4:110748770	RRH	0.48	5.27	0.33	3.15e-7	Exercise treadmill test traits;
SARC	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg12000995	chr2:27665139	KRTCAP3	-0.31	-4.83	-0.3	2.49e-6	Total body bone mineral density;
SARC	cis	rs9420	0.961	rs7117205	chr11:57641883	A/G	cg19752551	chr11:57585705	CTNND1	-0.54	-7.27	-0.43	5.48e-12	Schizophrenia;
SARC	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg16325326	chr1:53192061	ZYG11B	-0.82	-13.46	-0.66	6.13e-31	Monocyte count;
SARC	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg04234412	chr22:24373322	LOC391322	-0.52	-6.2	-0.38	2.58e-9	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs981844	1.000	rs2606328	chr4:154653864	C/T	cg14289246	chr4:154710475	SFRP2	0.51	5.99	0.37	8.02e-9	Response to statins (LDL cholesterol change);
SARC	cis	rs950776	0.518	rs55690619	chr15:78833612	A/G	cg22563815	chr15:78856949	CHRNA5	-0.4	-6.75	-0.4	1.15e-10	Sudden cardiac arrest;
SARC	cis	rs11676348	0.774	rs13397673	chr2:219047782	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.43	-5.51	-0.34	9.69e-8	Ulcerative colitis;
SARC	cis	rs9398803	0.865	rs9401883	chr6:126797111	A/G	cg20229609	chr6:126660872	C6orf173	0.4	5.82	0.36	1.96e-8	Male-pattern baldness;
SARC	cis	rs72945132	0.882	rs17853270	chr11:70200529	C/T	cg00319359	chr11:70116639	PPFIA1	0.68	6.1	0.37	4.34e-9	Coronary artery disease;
SARC	cis	rs3859192	0.599	rs34933056	chr17:38162983	G/A	cg17467752	chr17:38218738	THRA	-0.38	-4.77	-0.3	3.31e-6	White blood cell count;
SARC	cis	rs2011503	0.943	rs79370636	chr19:19614289	G/A	cg03709012	chr19:19516395	GATAD2A	0.61	5.36	0.33	1.95e-7	Bipolar disorder;
SARC	cis	rs10463554	0.892	rs34816	chr5:102434645	T/G	cg23492399	chr5:102201601	PAM	-0.53	-5.87	-0.36	1.47e-8	Parkinson's disease;
SARC	cis	rs73206853	0.841	rs73191836	chr12:110966177	G/T	cg10860002	chr12:110842031	ANAPC7	0.63	4.86	0.3	2.12e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs7818688	0.697	rs74861094	chr8:95981385	A/G	cg13393036	chr8:95962371	TP53INP1	0.4	4.85	0.3	2.27e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs6912958	0.559	rs395358	chr6:88057924	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.36	6.37	0.39	9.71e-10	Monocyte percentage of white cells;
SARC	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg24642844	chr7:1081250	C7orf50	-0.57	-6.05	-0.37	5.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs2486288	0.656	rs8039153	chr15:45579813	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.54	-6.52	-0.39	4.28e-10	Glomerular filtration rate;
SARC	cis	rs9902453	0.967	rs12602258	chr17:28317657	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	6.86	0.41	6.08e-11	Coffee consumption (cups per day);
SARC	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg11987759	chr7:65425863	GUSB	0.47	5.71	0.35	3.48e-8	Aortic root size;
SARC	cis	rs1976403	0.633	rs1697422	chr1:21821897	T/C	cg21906605	chr1:21766650	NBPF3	0.46	6.07	0.37	5.09e-9	Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs10789491	1.000	rs4553120	chr1:47165729	C/T	cg15501359	chr1:47185051	KIAA0494	0.76	8.15	0.47	2.25e-14	Response to hepatitis C treatment;
SARC	cis	rs9660992	0.573	rs12140422	chr1:205187981	G/A	cg21643547	chr1:205240462	TMCC2	-0.6	-7.74	-0.45	2.95e-13	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg21442419	chr1:2182373	SKI	-0.49	-6.29	-0.38	1.56e-9	Height;
SARC	cis	rs9303542	0.559	rs35621842	chr17:46606222	C/T	cg04904318	chr17:46607828	HOXB1	-0.45	-5.05	-0.31	9.05e-7	Ovarian cancer;Epithelial ovarian cancer;
SARC	trans	rs61931739	0.500	rs11053249	chr12:34518834	A/T	cg13010199	chr12:38710504	ALG10B	0.77	10.58	0.57	1.32e-21	Morning vs. evening chronotype;
SARC	trans	rs7819412	0.749	rs11991118	chr8:10939273	A/C	cg08975724	chr8:8085496	FLJ10661	0.51	6.83	0.41	7.48e-11	Triglycerides;
SARC	cis	rs17401966	0.838	rs1538557	chr1:10297230	T/C	cg15208524	chr1:10270712	KIF1B	0.47	5.42	0.33	1.5e-7	Hepatocellular carcinoma;
SARC	cis	rs7666738	0.830	rs6532723	chr4:99052147	A/T	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.42	5.24	0.32	3.51e-7	Tonsillectomy;
SARC	cis	rs7937682	0.824	rs577044	chr11:111490420	G/T	cg09085632	chr11:111637200	PPP2R1B	-0.93	-15.25	-0.71	7.22e-37	Primary sclerosing cholangitis;
SARC	cis	rs6088580	0.634	rs6088502	chr20:33037644	A/T	cg08999081	chr20:33150536	PIGU	0.43	6.58	0.4	3.06e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs7084402	0.934	rs1649051	chr10:60321997	A/G	cg07615347	chr10:60278583	BICC1	0.64	9.01	0.51	7.61e-17	Refractive error;
SARC	cis	rs832540	0.519	rs10036895	chr5:56273693	G/A	cg14703610	chr5:56206110	C5orf35	0.47	5.48	0.34	1.12e-7	Coronary artery disease;
SARC	cis	rs36051895	0.589	rs7848312	chr9:5237442	T/C	cg02405213	chr9:5042618	JAK2	-0.42	-4.78	-0.3	3.13e-6	Pediatric autoimmune diseases;
SARC	cis	rs2072438	0.503	rs1323474	chr9:123852859	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.39	4.94	0.31	1.5e-6	Rheumatoid arthritis;
SARC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.33	-4.74	-0.3	3.7e-6	Lymphocyte counts;
SARC	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg22857025	chr5:266934	NA	-1.08	-11.86	-0.61	1.06e-25	Breast cancer;
SARC	cis	rs2204008	0.627	rs1851117	chr12:38398987	G/T	cg13010199	chr12:38710504	ALG10B	0.77	10.26	0.56	1.27e-20	Bladder cancer;
SARC	cis	rs67460515	0.892	rs11711695	chr3:161057593	A/G	cg03342759	chr3:160939853	NMD3	-0.69	-8.91	-0.5	1.54e-16	Parkinson's disease;
SARC	cis	rs79149102	0.579	rs12591175	chr15:75356073	C/T	cg00629941	chr15:75287862	SCAMP5	-0.7	-5.17	-0.32	5e-7	Lung cancer;
SARC	cis	rs9916302	0.904	rs8079303	chr17:37530755	G/C	cg20243544	chr17:37824526	PNMT	-0.55	-6.63	-0.4	2.36e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs2594989	0.943	rs9878389	chr3:11457099	T/G	cg00170343	chr3:11313890	ATG7	0.62	5.97	0.36	8.85e-9	Circulating chemerin levels;
SARC	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	7.73	0.45	3.1400000000000003e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7520050	1.000	rs785473	chr1:46516863	T/C	cg24296786	chr1:45957014	TESK2	0.37	4.75	0.3	3.61e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs7144547	0.950	rs8004137	chr14:81884857	A/G	cg02996355	chr14:81879375	NA	-0.67	-8.11	-0.47	2.87e-14	Prudent dietary pattern;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg22548015	chr20:30539544	PDRG1	0.47	6.38	0.39	9.25e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg17554472	chr22:41940697	POLR3H	-0.46	-5.15	-0.32	5.48e-7	Vitiligo;
SARC	cis	rs798554	0.660	rs2527694	chr7:2858240	T/C	cg04166393	chr7:2884313	GNA12	0.43	5.31	0.33	2.51e-7	Height;
SARC	cis	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg24110177	chr3:50126178	RBM5	-0.54	-7.18	-0.43	9.52e-12	Intelligence (multi-trait analysis);
SARC	trans	rs17685	0.753	rs2868203	chr7:75680026	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.62	-7.88	-0.46	1.22e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg01604348	chr19:54663591	LENG1	0.51	6.29	0.38	1.58e-9	Breast cancer;
SARC	cis	rs4555082	0.874	rs2142190	chr14:105719306	G/A	cg10792982	chr14:105748885	BRF1	0.53	7.66	0.45	4.97e-13	Mean platelet volume;Platelet distribution width;
SARC	cis	rs4713118	0.581	rs200504	chr6:27785820	T/C	cg17221315	chr6:27791827	HIST1H4J	0.56	5.35	0.33	2.13e-7	Parkinson's disease;
SARC	cis	rs1957429	0.614	rs66883381	chr14:65334773	C/T	cg23373153	chr14:65346875	NA	-0.79	-6.36	-0.38	1.03e-9	Pediatric areal bone mineral density (radius);
SARC	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg02725872	chr8:58115012	NA	-0.32	-4.89	-0.31	1.89e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs1497406	0.744	rs12057175	chr1:16508375	A/G	cg06365898	chr1:16533907	ARHGEF19	0.43	5.65	0.35	4.63e-8	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs875971	0.545	rs6950988	chr7:65976415	C/T	cg11764359	chr7:65958608	NA	0.65	6.46	0.39	6.16e-10	Aortic root size;
SARC	cis	rs7592578	0.508	rs55919641	chr2:191265414	G/A	cg10560079	chr2:191398806	TMEM194B	-0.63	-7.13	-0.42	1.26e-11	Diastolic blood pressure;
SARC	cis	rs6570726	0.818	rs437978	chr6:145809134	A/G	cg05347473	chr6:146136440	FBXO30	0.5	6.79	0.41	9.16e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg04267008	chr7:1944627	MAD1L1	-0.48	-5.47	-0.34	1.17e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg27347728	chr4:17578864	LAP3	0.47	5.89	0.36	1.31e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs61931739	1.000	rs12427279	chr12:34025898	T/G	cg26384229	chr12:38710491	ALG10B	-0.58	-7.34	-0.43	3.52e-12	Morning vs. evening chronotype;
SARC	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg19723775	chr5:179050963	HNRNPH1	0.41	5.21	0.32	4.21e-7	Lung cancer;
SARC	cis	rs2228479	0.702	rs62056092	chr16:89930426	A/G	cg06558623	chr16:89946397	TCF25	0.87	6.41	0.39	7.81e-10	Skin colour saturation;
SARC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg20102877	chr2:27665638	KRTCAP3	-0.37	-5.25	-0.33	3.44e-7	Total body bone mineral density;
SARC	cis	rs9462027	0.606	rs2235569	chr6:34570070	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-6.17	-0.37	3.07e-9	Systemic lupus erythematosus;
SARC	cis	rs1801251	1.000	rs13035829	chr2:233604487	A/T	cg25237894	chr2:233734115	C2orf82	0.37	4.87	0.3	2.03e-6	Coronary artery disease;
SARC	cis	rs2635047	0.648	rs4986203	chr18:44597092	A/G	cg19077165	chr18:44547161	KATNAL2	-0.39	-5.26	-0.33	3.32e-7	Educational attainment;
SARC	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.67	-8.01	-0.46	5.58e-14	Gut microbiome composition (summer);
SARC	cis	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg00409905	chr10:38381863	ZNF37A	0.57	8.29	0.48	9.23e-15	Extrinsic epigenetic age acceleration;
SARC	cis	rs79387448	0.745	rs1880000	chr2:103099953	T/C	cg09003973	chr2:102972529	NA	0.61	5.94	0.36	1.02e-8	Gut microbiota (bacterial taxa);
SARC	cis	rs651907	0.557	rs13077925	chr3:101488181	T/A	cg12386194	chr3:101231763	SENP7	0.48	5.73	0.35	3.06e-8	Colorectal cancer;
SARC	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg17376030	chr22:41985996	PMM1	0.7	8.45	0.48	3.23e-15	Vitiligo;
SARC	cis	rs2075371	0.863	rs9641966	chr7:133961205	G/A	cg11752832	chr7:134001865	SLC35B4	0.48	5.85	0.36	1.66e-8	Mean platelet volume;
SARC	cis	rs4481887	0.893	rs1339991	chr1:248509363	C/T	cg01631408	chr1:248437212	OR2T33	-0.43	-5.87	-0.36	1.46e-8	Common traits (Other);
SARC	cis	rs11792861	0.926	rs118011482	chr9:111770626	G/C	cg13535736	chr9:111863775	C9orf5	-0.39	-4.76	-0.3	3.36e-6	Menarche (age at onset);
SARC	cis	rs6088580	0.524	rs6087612	chr20:33230822	T/G	cg08999081	chr20:33150536	PIGU	-0.35	-5.12	-0.32	6.32e-7	Glomerular filtration rate (creatinine);
SARC	trans	rs3942852	0.568	rs6485807	chr11:48102867	G/A	cg03929089	chr4:120376271	NA	-0.56	-6.81	-0.41	8.26e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs754466	0.606	rs7084705	chr10:79596675	A/G	cg17075019	chr10:79541650	NA	-0.81	-12.86	-0.64	5.7e-29	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.7	7.99	0.46	6.18e-14	Multiple sclerosis;
SARC	cis	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg14541582	chr5:601475	NA	-0.39	-4.76	-0.3	3.39e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs62432291	0.681	rs420054	chr6:159655084	C/G	cg14500486	chr6:159655392	FNDC1	-0.62	-6.02	-0.37	6.68e-9	Joint mobility (Beighton score);
SARC	cis	rs2204008	0.687	rs2320523	chr12:38251397	T/C	cg26384229	chr12:38710491	ALG10B	0.89	13.06	0.65	1.31e-29	Bladder cancer;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg05619116	chr3:27754569	NA	-0.58	-6.59	-0.4	2.91e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs41278232	0.557	rs1093457	chr20:62604816	T/C	cg07620230	chr20:62328084	TNFRSF6B	0.33	4.72	0.3	4.13e-6	Tonsillectomy;
SARC	cis	rs708547	0.792	rs7667084	chr4:57727435	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.56	-5.92	-0.36	1.16e-8	Response to bleomycin (chromatid breaks);
SARC	cis	rs1318878	0.565	rs11056429	chr12:15474823	A/C	cg08258403	chr12:15378311	NA	0.49	6.77	0.41	1.02e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg20573242	chr4:122745356	CCNA2	0.56	7.18	0.43	9.1e-12	Type 2 diabetes;
SARC	trans	rs3779273	1.000	rs3779272	chr7:77828991	A/T	cg05596911	chr5:118502651	DMXL1	-0.55	-7.06	-0.42	1.91e-11	Body mass index;
SARC	cis	rs1707322	0.721	rs4330955	chr1:46217485	G/C	cg03146154	chr1:46216737	IPP	0.53	6.37	0.39	1.01e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs72627123	0.867	rs75754154	chr14:74473578	C/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.79	5.88	0.36	1.38e-8	Morning vs. evening chronotype;
SARC	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg12648201	chr2:27665141	KRTCAP3	-0.32	-4.84	-0.3	2.36e-6	Total body bone mineral density;
SARC	cis	rs9303401	0.659	rs3809724	chr17:57061238	G/A	cg25039879	chr17:56429692	SUPT4H1	0.65	5.7	0.35	3.57e-8	Cognitive test performance;
SARC	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg19077165	chr18:44547161	KATNAL2	-0.48	-6.48	-0.39	5.36e-10	Personality dimensions;
SARC	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg18876405	chr7:65276391	NA	-0.72	-9.0	-0.51	8.24e-17	Aortic root size;
SARC	cis	rs116979167	0.575	rs1728649	chr7:105170570	A/G	cg19920283	chr7:105172520	RINT1	0.55	5.7	0.35	3.62e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	11.39	0.6	3.59e-24	Platelet count;
SARC	cis	rs9325144	0.555	rs2387843	chr12:38711203	T/C	cg13010199	chr12:38710504	ALG10B	0.56	7.38	0.44	2.77e-12	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg11062466	chr8:58055876	NA	-0.59	-5.44	-0.34	1.32e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs782590	0.935	rs782649	chr2:55860308	T/C	cg18811423	chr2:55921094	PNPT1	0.69	10.42	0.56	3.93e-21	Metabolic syndrome;
SARC	cis	rs1971762	0.545	rs9788134	chr12:54046067	A/T	cg06632207	chr12:54070931	ATP5G2	0.6	8.24	0.48	1.25e-14	Height;
SARC	cis	rs651907	0.535	rs2290859	chr3:101525625	C/T	cg12386194	chr3:101231763	SENP7	0.51	5.91	0.36	1.22e-8	Colorectal cancer;
SARC	cis	rs11697848	1.000	rs56230511	chr20:48468621	G/A	cg17849948	chr20:48532315	SPATA2	0.8	4.86	0.3	2.15e-6	Systemic lupus erythematosus;
SARC	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg23758822	chr17:41437982	NA	0.91	12.27	0.63	4.87e-27	Menopause (age at onset);
SARC	cis	rs858239	0.899	rs28635122	chr7:23310181	C/T	cg23682824	chr7:23144976	KLHL7	0.57	7.06	0.42	1.93e-11	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	5.9	0.36	1.24e-8	Electroencephalogram traits;
SARC	cis	rs3737883	1.000	rs871298	chr1:203039602	C/G	cg03900565	chr1:203031815	PPFIA4	0.37	5.69	0.35	3.7e-8	Early onset atrial fibrillation;
SARC	cis	rs858239	0.601	rs11984129	chr7:23152677	A/G	cg23682824	chr7:23144976	KLHL7	0.71	9.46	0.53	3.41e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg11062466	chr8:58055876	NA	0.52	5.4	0.33	1.64e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2180341	0.961	rs7774468	chr6:127592501	G/C	cg17762328	chr6:126965162	NA	-0.46	-5.23	-0.32	3.82e-7	Breast cancer;
SARC	cis	rs2439831	0.681	rs498837	chr15:43608024	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.78	8.73	0.5	5.04e-16	Lung cancer in ever smokers;
SARC	cis	rs12451471	0.637	rs7567	chr17:78093549	G/T	cg06718696	chr17:78121285	EIF4A3	0.95	10.89	0.58	1.38e-22	Plateletcrit;Mean corpuscular hemoglobin concentration;
SARC	cis	rs854765	0.547	rs6502633	chr17:17941037	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	9.76	0.54	4.36e-19	Total body bone mineral density;
SARC	cis	rs7043114	0.563	rs987554	chr9:95298738	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.51	-6.28	-0.38	1.65e-9	Height;
SARC	cis	rs4481887	0.893	rs4529743	chr1:248473683	G/C	cg00666640	chr1:248458726	OR2T12	0.34	5.67	0.35	4.19e-8	Common traits (Other);
SARC	cis	rs11864453	0.826	rs12708928	chr16:72137227	C/A	cg16558253	chr16:72132732	DHX38	-0.56	-8.9	-0.5	1.55e-16	Fibrinogen levels;
SARC	trans	rs61931739	0.517	rs12815556	chr12:34319670	G/A	cg13010199	chr12:38710504	ALG10B	0.75	10.02	0.55	7.16e-20	Morning vs. evening chronotype;
SARC	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.38	-5.78	-0.35	2.35e-8	Total body bone mineral density;
SARC	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg24250549	chr1:154909240	PMVK	0.83	11.96	0.62	4.97e-26	Prostate cancer;
SARC	cis	rs6570726	0.791	rs9373463	chr6:145894762	C/T	cg05347473	chr6:146136440	FBXO30	0.51	7.17	0.43	9.59e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs62344088	0.590	rs73016637	chr5:172462	G/A	cg22496380	chr5:211416	CCDC127	-0.84	-5.39	-0.33	1.68e-7	Asthma (childhood onset);
SARC	cis	rs6964587	1.000	rs9690208	chr7:91735613	T/A	cg17063962	chr7:91808500	NA	0.93	15.65	0.72	3.24e-38	Breast cancer;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg26877631	chr10:21823297	MLLT10	-0.82	-6.83	-0.41	7.5e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs11509153	0.687	rs3800842	chr7:12271452	A/G	cg23422036	chr7:12250390	TMEM106B	0.45	5.79	0.35	2.21e-8	Residual cognition;
SARC	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg02018176	chr4:1364513	KIAA1530	0.61	9.3	0.52	1.05e-17	Longevity;
SARC	cis	rs116095464	0.558	rs10068203	chr5:206618	C/T	cg22496380	chr5:211416	CCDC127	-0.9	-8.06	-0.47	3.98e-14	Breast cancer;
SARC	cis	rs2046867	0.908	rs62251634	chr3:72788705	A/C	cg25664220	chr3:72788482	NA	-0.29	-4.89	-0.3	1.9e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
SARC	cis	rs9914988	0.673	rs12325788	chr17:27080049	G/A	cg20469991	chr17:27169893	C17orf63	-0.5	-5.3	-0.33	2.75e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs2153904	0.793	rs12118655	chr1:205663478	A/G	cg17178900	chr1:205818956	PM20D1	-0.57	-4.94	-0.31	1.48e-6	Prostate-specific antigen levels;
SARC	cis	rs72781680	0.716	rs78332127	chr2:24150163	C/G	cg06627628	chr2:24431161	ITSN2	-0.57	-5.91	-0.36	1.21e-8	Lymphocyte counts;
SARC	cis	rs7617773	0.709	rs4404473	chr3:48353626	A/G	cg11946769	chr3:48343235	NME6	0.74	9.26	0.52	1.42e-17	Coronary artery disease;
SARC	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg02725872	chr8:58115012	NA	-0.37	-6.52	-0.39	4.21e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs11690935	0.885	rs7602037	chr2:172817794	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.94	-14.12	-0.68	4.06e-33	Schizophrenia;
SARC	cis	rs1153858	0.945	rs1974981	chr15:45729123	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.69	-8.86	-0.5	2.11e-16	Homoarginine levels;
SARC	cis	rs9612	0.664	rs164069	chr19:44260199	T/C	cg08581076	chr19:44259116	C19orf61	0.59	7.38	0.44	2.7e-12	Exhaled nitric oxide output;
SARC	cis	rs26232	0.526	rs61654927	chr5:102382725	C/A	cg23492399	chr5:102201601	PAM	-0.52	-5.65	-0.35	4.66e-8	Rheumatoid arthritis;
SARC	cis	rs1008375	0.897	rs3733577	chr4:17649233	T/G	cg27347728	chr4:17578864	LAP3	0.47	5.86	0.36	1.57e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7582720	0.778	rs6719001	chr2:203777903	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs17376456	0.877	rs2085960	chr5:93399934	A/G	cg25358565	chr5:93447407	FAM172A	1.3	14.56	0.69	1.43e-34	Diabetic retinopathy;
SARC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg07414643	chr4:187882934	NA	0.51	7.73	0.45	3.26e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6570726	1.000	rs404229	chr6:145868200	G/A	cg05220968	chr6:146057943	EPM2A	-0.29	-4.91	-0.31	1.73e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg22920501	chr2:26401640	FAM59B	0.62	8.22	0.47	1.46e-14	Gut microbiome composition (summer);
SARC	cis	rs4555082	0.718	rs75139030	chr14:105710853	A/AG	cg13114125	chr14:105738426	BRF1	-0.81	-12.07	-0.62	2.19e-26	Mean platelet volume;Platelet distribution width;
SARC	cis	rs17376456	1.000	rs58734583	chr5:93532155	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.19	0.32	4.5e-7	Diabetic retinopathy;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg08849330	chr6:166797222	BRP44L	0.78	6.42	0.39	7.44e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6582630	0.555	rs1829583	chr12:38423161	T/C	cg26384229	chr12:38710491	ALG10B	-0.8	-11.57	-0.6	9.48e-25	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg18876405	chr7:65276391	NA	0.69	9.06	0.51	5.41e-17	Aortic root size;
SARC	cis	rs7710178	0.557	rs32085	chr5:156128122	G/T	cg26439139	chr5:155924786	SGCD	-0.42	-4.86	-0.3	2.2e-6	Airway responsiveness in chronic obstructive pulmonary disease;
SARC	cis	rs367615	0.513	rs11741087	chr5:108807760	G/A	cg17395555	chr5:108820864	NA	0.51	7.45	0.44	1.84e-12	Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs8114671	0.904	rs6060197	chr20:33654315	C/T	cg08999081	chr20:33150536	PIGU	-0.34	-4.84	-0.3	2.38e-6	Height;
SARC	cis	rs1707322	1.000	rs785498	chr1:46592414	C/T	cg03146154	chr1:46216737	IPP	-0.47	-5.48	-0.34	1.09e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1570884	0.516	rs2094108	chr13:50171550	G/A	cg08779649	chr13:50194554	NA	0.37	6.38	0.39	9.41e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs9818758	0.607	rs56004653	chr3:49072228	T/C	cg01304814	chr3:48885189	PRKAR2A	0.84	6.56	0.39	3.38e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	trans	rs61931739	0.500	rs11053280	chr12:34559297	G/T	cg26384229	chr12:38710491	ALG10B	0.92	13.82	0.67	4.07e-32	Morning vs. evening chronotype;
SARC	cis	rs9467773	0.620	rs2451741	chr6:26629404	A/G	cg12292205	chr6:26970375	C6orf41	0.41	5.12	0.32	6.5e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg22800045	chr5:56110881	MAP3K1	0.74	7.83	0.46	1.74e-13	Initial pursuit acceleration;
SARC	cis	rs6831352	0.725	rs2602846	chr4:100025151	T/A	cg12011299	chr4:100065546	ADH4	0.32	5.26	0.33	3.23e-7	Alcohol dependence;
SARC	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg06212747	chr3:49208901	KLHDC8B	0.76	11.07	0.59	3.64e-23	Menarche (age at onset);
SARC	cis	rs6665290	0.904	rs1045290	chr1:227178700	A/G	cg14016676	chr1:227182615	CDC42BPA	0.34	5.03	0.31	1e-6	Myeloid white cell count;
SARC	cis	rs7113850	0.541	rs11826483	chr11:24237730	C/T	ch.11.24196551F	chr11:24239977	NA	0.74	5.62	0.35	5.48e-8	Bone fracture in osteoporosis;
SARC	cis	rs7247513	0.701	rs8107642	chr19:12766370	C/T	cg06417478	chr19:12876846	HOOK2	0.42	5.26	0.33	3.24e-7	Bipolar disorder;
SARC	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg18252515	chr7:66147081	NA	1.29	11.12	0.59	2.48e-23	Diabetic kidney disease;
SARC	cis	rs7264396	0.673	rs2425163	chr20:34432670	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.07	-0.42	1.78e-11	Total cholesterol levels;
SARC	cis	rs7274811	0.711	rs291669	chr20:31945364	C/T	cg21523528	chr20:32077966	CBFA2T2	-0.41	-4.93	-0.31	1.54e-6	Height;
SARC	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg13866156	chr1:1669148	SLC35E2	-0.63	-9.61	-0.53	1.21e-18	Body mass index;
SARC	cis	rs17376456	0.569	rs10076965	chr5:93094972	G/A	cg25358565	chr5:93447407	FAM172A	0.94	10.43	0.56	3.7e-21	Diabetic retinopathy;
SARC	cis	rs6910061	0.830	rs13214911	chr6:11103690	C/A	cg27233058	chr6:11094804	LOC221710	0.61	5.54	0.34	8.11e-8	Diabetic kidney disease;
SARC	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg27286337	chr10:134555280	INPP5A	0.71	7.95	0.46	8.13e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs11658309	1	rs11658309	chr17:17762247	T/G	cg16928487	chr17:17741425	SREBF1	0.22	4.71	0.3	4.17e-6	Strep throat;
SARC	cis	rs909674	0.818	rs8136980	chr22:39844574	G/A	cg24399712	chr22:39784796	NA	-0.46	-5.92	-0.36	1.17e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs765787	0.530	rs11855435	chr15:45522117	G/A	cg24006582	chr15:45444508	DUOX1	-0.5	-6.41	-0.39	8.17e-10	Uric acid levels;
SARC	trans	rs17685	0.753	rs1639609	chr7:75683581	T/C	cg19862616	chr7:65841803	NCRNA00174	0.59	7.35	0.43	3.26e-12	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg13628971	chr7:2884303	GNA12	0.56	6.67	0.4	1.79e-10	Height;
SARC	trans	rs208520	0.690	rs10944872	chr6:66708239	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	14.26	0.68	1.42e-33	Exhaled nitric oxide output;
SARC	cis	rs9790314	0.589	rs4679662	chr3:160603024	T/C	cg04691961	chr3:161091175	C3orf57	0.52	7.1	0.42	1.48e-11	Morning vs. evening chronotype;
SARC	trans	rs11722228	0.522	rs77691548	chr4:10136115	T/G	cg26043149	chr18:55253948	FECH	0.76	9.33	0.52	8.67e-18	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg27347728	chr4:17578864	LAP3	0.48	6.1	0.37	4.5e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9457247	1.000	rs2013815	chr6:167373812	T/A	cg07741184	chr6:167504864	NA	-0.3	-5.61	-0.35	5.69e-8	Crohn's disease;
SARC	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg05861140	chr6:150128134	PCMT1	-0.42	-5.22	-0.32	3.92e-7	Lung cancer;
SARC	cis	rs4319547	0.661	rs10773172	chr12:122939655	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.54	-6.22	-0.38	2.23e-9	Body mass index;
SARC	cis	rs765787	0.530	rs1706832	chr15:45517173	C/T	cg25801113	chr15:45476975	SHF	0.28	4.75	0.3	3.5e-6	Uric acid levels;
SARC	cis	rs10979	1.000	rs9484769	chr6:143896719	A/G	cg25407410	chr6:143891975	LOC285740	-0.64	-8.78	-0.5	3.67e-16	Hypospadias;
SARC	cis	rs11264799	0.520	rs849819	chr1:157541674	A/C	cg18268488	chr1:157545234	FCRL4	0.32	5.85	0.36	1.62e-8	IgA nephropathy;
SARC	cis	rs7575873	1	rs7575873	chr2:23962647	A/G	cg06627628	chr2:24431161	ITSN2	-0.67	-6.16	-0.37	3.14e-9	Birth weight;
SARC	cis	rs35110281	0.782	rs1454650	chr21:45012353	C/T	cg21573476	chr21:45109991	RRP1B	-0.54	-7.92	-0.46	9.39e-14	Mean corpuscular volume;
SARC	cis	rs4319547	0.915	rs7314638	chr12:122983460	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.67	-7.88	-0.46	1.24e-13	Body mass index;
SARC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.64	-0.4	2.16e-10	Total body bone mineral density;
SARC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg17178900	chr1:205818956	PM20D1	0.75	11.95	0.62	5.42e-26	Menarche (age at onset);
SARC	cis	rs10876993	0.855	rs1678520	chr12:58049319	C/G	cg18357645	chr12:58087776	OS9	0.45	5.75	0.35	2.74e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg22903471	chr2:27725779	GCKR	-0.49	-7.42	-0.44	2.21e-12	Total body bone mineral density;
SARC	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg27170947	chr2:26402098	FAM59B	0.37	4.8	0.3	2.79e-6	Gut microbiome composition (summer);
SARC	cis	rs9843304	0.501	rs34540967	chr3:149204381	T/C	cg08667024	chr3:149219783	TM4SF4	-0.38	-5.49	-0.34	1.05e-7	Gallstone disease;
SARC	cis	rs6807306	1.000	rs9861088	chr3:167451117	A/G	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.49	4.84	0.3	2.37e-6	Mean platelet volume;
SARC	cis	rs28655083	1.000	rs7197078	chr16:77072735	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.42	-6.01	-0.37	7.05e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1153858	1.000	rs1365610	chr15:45694610	C/T	cg26924012	chr15:45694286	SPATA5L1	0.79	10.8	0.58	2.58e-22	Homoarginine levels;
SARC	cis	rs7412746	0.611	rs10888394	chr1:150749913	C/T	cg13175981	chr1:150552382	MCL1	-0.54	-6.57	-0.4	3.32e-10	Melanoma;
SARC	cis	rs7106204	0.614	rs117122818	chr11:24245880	C/T	ch.11.24196551F	chr11:24239977	NA	0.74	5.42	0.33	1.51e-7	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs3809863	0.646	rs9899121	chr17:45395144	C/T	cg08085267	chr17:45401833	C17orf57	-0.55	-6.7	-0.4	1.59e-10	Glaucoma (primary open-angle);
SARC	cis	rs3796352	1.000	rs10510761	chr3:52965255	A/G	cg15956490	chr3:53032818	SFMBT1	-0.8	-5.7	-0.35	3.61e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg20887711	chr4:1340912	KIAA1530	0.4	4.87	0.3	2.1e-6	Longevity;
SARC	trans	rs8073060	0.586	rs188959	chr17:34021307	C/A	cg19694781	chr19:47549865	TMEM160	-0.71	-6.94	-0.41	3.88e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs1371867	0.846	rs2919469	chr8:101233896	C/T	cg11906718	chr8:101322791	RNF19A	0.68	8.73	0.5	4.86e-16	Atrioventricular conduction;
SARC	cis	rs11098499	0.954	rs71629403	chr4:120372567	C/T	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs9906944	0.707	rs9912906	chr17:47104432	A/T	cg16584676	chr17:46985605	UBE2Z	-0.42	-5.17	-0.32	5.09e-7	Intelligence (multi-trait analysis);Body fat percentage;
SARC	cis	rs11874712	1.000	rs56181324	chr18:43678024	G/A	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	6.34	0.38	1.21e-9	Migraine - clinic-based;
SARC	cis	rs2694528	0.844	rs2409823	chr5:60080374	A/G	cg11474532	chr5:59995715	DEPDC1B	0.77	5.31	0.33	2.54e-7	Parkinson's disease;
SARC	cis	rs9868809	0.881	rs13063312	chr3:48661985	G/A	cg07636037	chr3:49044803	WDR6	-0.7	-6.49	-0.39	5.01e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4737010	0.511	rs7006871	chr8:41670952	A/G	cg08923054	chr8:41654455	ANK1	0.66	7.63	0.45	5.9e-13	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
SARC	cis	rs9341808	0.727	rs9361599	chr6:81025242	C/G	cg08355045	chr6:80787529	NA	0.37	6.0	0.37	7.65e-9	Sitting height ratio;
SARC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.69	8.63	0.49	9.96e-16	Prudent dietary pattern;
SARC	cis	rs7712401	0.658	rs4836203	chr5:122077077	A/T	cg19412675	chr5:122181750	SNX24	0.41	5.77	0.35	2.49e-8	Mean platelet volume;
SARC	cis	rs155076	1.000	rs58519241	chr13:21845006	C/A	cg11317459	chr13:21872234	NA	-0.98	-12.36	-0.63	2.52e-27	White matter hyperintensity burden;
SARC	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg18252515	chr7:66147081	NA	-0.52	-6.24	-0.38	2e-9	Aortic root size;
SARC	cis	rs7296418	0.663	rs4553407	chr12:123750748	G/C	cg05973401	chr12:123451056	ABCB9	0.48	5.6	0.34	6.14e-8	Platelet count;
SARC	cis	rs67311347	0.713	rs73073505	chr3:40310693	C/T	cg24209194	chr3:40518798	ZNF619	0.57	6.86	0.41	6.02e-11	Renal cell carcinoma;
SARC	cis	rs3087591	0.683	rs2040792	chr17:29628549	G/T	cg24425628	chr17:29625626	OMG;NF1	0.46	5.98	0.36	8.46e-9	Hip circumference;
SARC	cis	rs7666738	0.753	rs35194639	chr4:99053819	G/C	cg05340658	chr4:99064831	C4orf37	0.65	8.85	0.5	2.24e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs79349575	0.811	rs80032154	chr17:47014992	C/A	cg07967210	chr17:47022446	SNF8	0.38	4.85	0.3	2.27e-6	Type 2 diabetes;
SARC	cis	rs2075371	1.000	rs8134	chr7:133974519	A/G	cg11752832	chr7:134001865	SLC35B4	0.57	7.45	0.44	1.83e-12	Mean platelet volume;
SARC	cis	rs7945705	0.776	rs11042069	chr11:8817315	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.43	5.64	0.35	4.82e-8	Hemoglobin concentration;
SARC	cis	rs36051895	0.625	rs12340344	chr9:5176281	C/A	cg02405213	chr9:5042618	JAK2	-0.45	-5.3	-0.33	2.62e-7	Pediatric autoimmune diseases;
SARC	cis	rs3020736	0.500	rs6002605	chr22:42494335	A/G	cg04733989	chr22:42467013	NAGA	-0.77	-10.92	-0.58	1.11e-22	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg12419862	chr22:24373484	LOC391322	-0.78	-10.55	-0.57	1.61e-21	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs155076	0.938	rs536209	chr13:21847714	C/T	cg11317459	chr13:21872234	NA	-0.98	-12.36	-0.63	2.52e-27	White matter hyperintensity burden;
SARC	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg24549020	chr5:56110836	MAP3K1	-0.51	-5.58	-0.34	6.82e-8	Initial pursuit acceleration;
SARC	cis	rs736408	0.812	rs2071507	chr3:52826707	G/A	cg18404041	chr3:52824283	ITIH1	-0.46	-6.64	-0.4	2.25e-10	Bipolar disorder;
SARC	cis	rs4077515	0.504	rs10870164	chr9:139315682	C/T	cg14169450	chr9:139327907	INPP5E	-0.38	-5.26	-0.33	3.29e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs10513788	0.617	rs3943132	chr3:181983157	A/G	cg05977900	chr3:182512126	ATP11B	0.49	4.94	0.31	1.47e-6	Cognitive function;
SARC	cis	rs524281	0.861	rs7929909	chr11:65951698	C/T	cg14036092	chr11:66035641	RAB1B	-0.51	-5.52	-0.34	9.19e-8	Electroencephalogram traits;
SARC	cis	rs7666738	0.830	rs11944107	chr4:98931638	G/C	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9303401	0.614	rs62084384	chr17:57126842	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.0	10.12	0.55	3.43e-20	Cognitive test performance;
SARC	cis	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg07777115	chr5:623756	CEP72	-0.57	-5.11	-0.32	6.69e-7	Obesity-related traits;
SARC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg09033563	chr22:24373618	LOC391322	-0.42	-4.85	-0.3	2.21e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs12048904	0.505	rs6577209	chr1:101255080	A/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.53	5.68	0.35	3.96e-8	Multiple sclerosis;
SARC	cis	rs7860634	1.000	rs7860634	chr9:139089679	C/T	cg04455058	chr9:139085579	NA	0.64	9.19	0.52	2.25e-17	Thyroid hormone levels;
SARC	cis	rs2012796	0.743	rs12435764	chr14:81836866	A/C	cg02996355	chr14:81879375	NA	0.5	5.62	0.35	5.55e-8	Night sleep phenotypes;
SARC	cis	rs2439831	1.000	rs101094	chr15:43787322	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	8.42	0.48	3.97e-15	Lung cancer in ever smokers;
SARC	cis	rs2380220	1.000	rs9632496	chr6:95976450	C/G	cg04719120	chr6:96025338	MANEA	0.65	6.75	0.4	1.15e-10	Behavioural disinhibition (generation interaction);
SARC	cis	rs6493487	0.512	rs8024689	chr15:51129127	C/T	cg02338191	chr15:51200825	AP4E1	0.52	4.98	0.31	1.25e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.23e-9	Life satisfaction;
SARC	cis	rs9810259	0.614	rs1822535	chr3:12299957	G/T	cg04748988	chr3:12329223	PPARG	-0.37	-4.74	-0.3	3.74e-6	Platelet count;
SARC	cis	rs3758785	0.537	rs694262	chr11:94071167	A/G	cg13023536	chr11:94226537	MRE11A;ANKRD49	-0.42	-5.02	-0.31	1.05e-6	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
SARC	cis	rs2153535	0.580	rs9328484	chr6:8524843	A/T	cg21535247	chr6:8435926	SLC35B3	0.54	6.93	0.41	4.13e-11	Motion sickness;
SARC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg11494091	chr17:61959527	GH2	0.54	7.99	0.46	6.26e-14	Prudent dietary pattern;
SARC	trans	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-10.55	-0.57	1.63e-21	Intelligence (multi-trait analysis);
SARC	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg07636037	chr3:49044803	WDR6	-0.63	-8.35	-0.48	5.92e-15	Resting heart rate;
SARC	cis	rs6815814	0.731	rs4513579	chr4:38773816	T/C	cg06935464	chr4:38784597	TLR10	0.5	5.19	0.32	4.66e-7	Breast cancer;
SARC	cis	rs10979	0.965	rs9390111	chr6:143894272	T/C	cg25407410	chr6:143891975	LOC285740	-0.64	-8.78	-0.5	3.67e-16	Hypospadias;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg07708937	chr12:57914306	DDIT3	0.48	6.41	0.39	7.95e-10	Tetralogy of Fallot;
SARC	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg18357526	chr6:26021779	HIST1H4A	0.88	11.67	0.61	4.32e-25	Intelligence (multi-trait analysis);
SARC	trans	rs61931739	0.534	rs73103090	chr12:34098801	C/T	cg13010199	chr12:38710504	ALG10B	0.76	10.14	0.55	2.99e-20	Morning vs. evening chronotype;
SARC	cis	rs6570726	0.791	rs10872577	chr6:145900560	G/T	cg05347473	chr6:146136440	FBXO30	0.51	7.2	0.43	8.39e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.77	-0.45	2.5e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs9790314	1.000	rs336570	chr3:161072054	A/G	cg03342759	chr3:160939853	NMD3	0.59	7.32	0.43	3.93e-12	Morning vs. evening chronotype;
SARC	cis	rs2304069	0.954	rs4705408	chr5:149412545	A/G	cg12661370	chr5:149340060	SLC26A2	-0.6	-6.05	-0.37	5.75e-9	HIV-1 control;
SARC	cis	rs1950500	0.509	rs12888965	chr14:24834291	C/T	cg16194253	chr14:24768981	DHRS1;C14orf21	0.6	7.47	0.44	1.64e-12	Height;
SARC	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg26116260	chr4:7069785	GRPEL1	0.93	11.55	0.6	1.07e-24	Monocyte percentage of white cells;
SARC	cis	rs858239	0.669	rs6461687	chr7:23116580	A/G	cg23682824	chr7:23144976	KLHL7	0.58	7.23	0.43	6.76e-12	Cerebrospinal fluid biomarker levels;
SARC	cis	rs992157	0.866	rs2292554	chr2:219146868	T/C	cg00012203	chr2:219082015	ARPC2	-0.64	-9.12	-0.51	3.65e-17	Colorectal cancer;
SARC	cis	rs9398803	0.636	rs1262542	chr6:127032008	T/A	cg20229609	chr6:126660872	C6orf173	-0.33	-4.75	-0.3	3.48e-6	Male-pattern baldness;
SARC	cis	rs76419734	0.850	rs72671863	chr4:106650116	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.84	5.41	0.33	1.59e-7	Post bronchodilator FEV1;
SARC	cis	rs3808502	0.526	rs7843987	chr8:11422130	T/C	cg21775007	chr8:11205619	TDH	-0.47	-5.98	-0.36	8.36e-9	Neuroticism;
SARC	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg10523679	chr1:76189770	ACADM	0.51	6.81	0.41	8.23e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7264396	0.790	rs6058290	chr20:34247702	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-8.17	-0.47	2.02e-14	Total cholesterol levels;
SARC	cis	rs9399137	0.507	rs7745289	chr6:135380327	A/G	cg22676075	chr6:135203613	NA	0.4	5.01	0.31	1.09e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs11997175	0.646	rs6993892	chr8:33729200	T/C	ch.8.33884649F	chr8:33765107	NA	0.64	8.84	0.5	2.43e-16	Body mass index;
SARC	cis	rs11155671	0.530	rs6935829	chr6:150217811	C/T	cg05036130	chr6:150231994	NA	0.29	5.09	0.32	7.23e-7	Testicular germ cell tumor;
SARC	cis	rs2645694	0.626	rs2703115	chr4:77824442	C/T	cg03477792	chr4:77819574	ANKRD56	0.48	7.39	0.44	2.62e-12	Emphysema distribution in smoking;
SARC	cis	rs7917772	0.636	rs4418737	chr10:104525123	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-6.38	-0.39	9.19e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs7666738	0.830	rs13124904	chr4:98856973	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.59	0.49	1.24e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg11764359	chr7:65958608	NA	0.78	9.86	0.54	2.14e-19	Aortic root size;
SARC	cis	rs9398803	0.687	rs7738836	chr6:126936235	A/G	cg20229609	chr6:126660872	C6orf173	0.37	5.28	0.33	2.99e-7	Male-pattern baldness;
SARC	cis	rs7223966	0.883	rs2727317	chr17:61961302	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.45	-4.74	-0.3	3.69e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs965469	0.779	rs6037571	chr20:3334322	C/T	cg25506879	chr20:3388711	C20orf194	-0.46	-4.99	-0.31	1.17e-6	IFN-related cytopenia;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg22562194	chr17:72209580	TTYH2;MGC16275	-0.62	-8.14	-0.47	2.33e-14	Gallstone disease;
SARC	cis	rs7589728	0.925	rs80065975	chr2:88502758	G/A	cg04511125	chr2:88470314	THNSL2	0.69	6.2	0.38	2.61e-9	Plasma clusterin levels;
SARC	cis	rs2249694	0.572	rs9418984	chr10:135322356	C/G	cg20169779	chr10:135381914	SYCE1	-0.34	-4.71	-0.3	4.2e-6	Obesity-related traits;
SARC	cis	rs11711311	0.736	rs2278941	chr3:113350508	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	7.14	0.42	1.17e-11	IgG glycosylation;
SARC	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg24675658	chr1:53192096	ZYG11B	0.67	9.57	0.53	1.65e-18	Monocyte count;
SARC	cis	rs13191362	1.000	rs7769686	chr6:163199467	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.4	5.17	0.32	5.11e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs1008375	1.000	rs10939750	chr4:17692422	C/G	cg16339924	chr4:17578868	LAP3	0.54	6.83	0.41	7.51e-11	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10206020	0.885	rs6720923	chr2:1574197	T/C	cg12573674	chr2:1569213	NA	-0.46	-5.33	-0.33	2.27e-7	IgG glycosylation;
SARC	cis	rs734999	0.550	rs2985855	chr1:2531372	A/C	cg18854424	chr1:2615690	NA	-0.32	-5.04	-0.31	9.17e-7	Ulcerative colitis;
SARC	cis	rs12586317	0.547	rs2254990	chr14:35465565	T/C	cg26967526	chr14:35346199	BAZ1A	-0.57	-5.71	-0.35	3.4e-8	Psoriasis;
SARC	cis	rs11997175	0.545	rs66783231	chr8:33811467	A/T	ch.8.33884649F	chr8:33765107	NA	0.5	6.43	0.39	7.21e-10	Body mass index;
SARC	cis	rs2282526	0.615	rs162377	chr21:44926001	A/G	cg21573476	chr21:45109991	RRP1B	-0.46	-6.31	-0.38	1.36e-9	Mean corpuscular hemoglobin;
SARC	cis	rs79839061	0.520	rs2279187	chr4:875529	C/T	cg07828340	chr4:882639	GAK	0.72	5.02	0.31	1.04e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9399135	0.967	rs1041480	chr6:135373076	G/T	cg24558204	chr6:135376177	HBS1L	0.46	6.24	0.38	2.09e-9	Red blood cell count;
SARC	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg19223190	chr17:80058835	NA	0.44	6.19	0.38	2.67e-9	Life satisfaction;
SARC	trans	rs3942852	0.774	rs10838814	chr11:48187178	G/A	cg15704280	chr7:45808275	SEPT13	-0.62	-7.2	-0.43	8.05e-12	Acute lymphoblastic leukemia (childhood);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg17866680	chr15:82338403	MEX3B	-0.78	-6.43	-0.39	7.04e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7520050	0.966	rs4545281	chr1:46360054	C/T	cg06784218	chr1:46089804	CCDC17	-0.26	-4.75	-0.3	3.55e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs916888	0.610	rs199436	chr17:44789285	C/T	cg01570182	chr17:44337453	NA	-0.61	-7.29	-0.43	4.75e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs2153535	0.580	rs9406165	chr6:8488837	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	8.19	0.47	1.7e-14	Motion sickness;
SARC	cis	rs710216	0.571	rs11210772	chr1:43448499	A/G	cg03128534	chr1:43423976	SLC2A1	-0.54	-6.12	-0.37	3.84e-9	Red cell distribution width;
SARC	cis	rs644799	0.544	rs1150360	chr11:95512060	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	9.76	0.54	4.35e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7220711	0.934	rs1983490	chr17:41782957	C/T	cg26893861	chr17:41843967	DUSP3	0.38	4.83	0.3	2.52e-6	Bone mineral density (spine);Bone mineral density (hip);
SARC	cis	rs12142240	0.698	rs17357759	chr1:46832534	A/G	cg00530320	chr1:46809349	NSUN4	0.54	6.48	0.39	5.28e-10	Menopause (age at onset);
SARC	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg00149659	chr3:10157352	C3orf10	0.7	6.89	0.41	5.14e-11	Alzheimer's disease;
SARC	cis	rs473651	0.935	rs559579	chr2:239339501	G/C	cg18131467	chr2:239335373	ASB1	0.98	12.45	0.63	1.28e-27	Multiple system atrophy;
SARC	cis	rs4253772	0.786	rs4253765	chr22:46622888	C/T	cg24881330	chr22:46731750	TRMU	0.46	5.09	0.32	7.26e-7	LDL cholesterol;Cholesterol, total;
SARC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg09373136	chr17:61933544	TCAM1	-0.44	-6.09	-0.37	4.59e-9	Prudent dietary pattern;
SARC	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg27286337	chr10:134555280	INPP5A	0.71	8.16	0.47	2.03e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.6	-6.31	-0.38	1.42e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg06112779	chr12:54982626	PPP1R1A	-0.51	-6.29	-0.38	1.58e-9	Blood pressure;
SARC	cis	rs9815354	1.000	rs9866092	chr3:41895967	A/C	cg03022575	chr3:42003672	ULK4	0.56	5.29	0.33	2.81e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs1707322	1.000	rs1768801	chr1:46549137	C/G	cg06784218	chr1:46089804	CCDC17	-0.36	-6.21	-0.38	2.44e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs11792861	0.926	rs12686736	chr9:111888739	A/G	cg13535736	chr9:111863775	C9orf5	-0.39	-4.85	-0.3	2.26e-6	Menarche (age at onset);
SARC	cis	rs1448094	0.872	rs4919777	chr12:86358491	C/T	cg02569458	chr12:86230093	RASSF9	0.4	6.0	0.37	7.62e-9	Major depressive disorder;
SARC	cis	rs1023500	0.573	rs133381	chr22:42470608	C/G	cg15557168	chr22:42548783	NA	-0.37	-4.96	-0.31	1.36e-6	Schizophrenia;
SARC	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg10523679	chr1:76189770	ACADM	-0.5	-5.9	-0.36	1.3e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs4481887	0.861	rs1339989	chr1:248511624	C/G	cg01631408	chr1:248437212	OR2T33	-0.42	-5.59	-0.34	6.43e-8	Common traits (Other);
SARC	trans	rs1814175	0.645	rs28454367	chr11:50045708	G/A	cg03929089	chr4:120376271	NA	-0.81	-11.64	-0.61	5.33e-25	Height;
SARC	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg03709012	chr19:19516395	GATAD2A	-1.02	-17.65	-0.76	7.68e-45	Tonsillectomy;
SARC	cis	rs8114671	0.742	rs6058161	chr20:33620026	C/T	cg08999081	chr20:33150536	PIGU	-0.34	-4.89	-0.31	1.86e-6	Height;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg09920145	chr3:69100714	TMF1	-0.47	-6.23	-0.38	2.11e-9	Chemerin levels;
SARC	cis	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg09021430	chr5:549028	NA	-0.43	-5.68	-0.35	3.92e-8	Lung disease severity in cystic fibrosis;
SARC	trans	rs1493916	0.748	rs34501189	chr18:31314196	A/G	cg27147174	chr7:100797783	AP1S1	-0.51	-6.3	-0.38	1.48e-9	Life satisfaction;
SARC	cis	rs9790314	1.000	rs336589	chr3:161080358	C/T	cg04691961	chr3:161091175	C3orf57	-0.81	-12.47	-0.63	1.11e-27	Morning vs. evening chronotype;
SARC	cis	rs62283056	0.512	rs4568307	chr4:6284965	A/G	cg25554036	chr4:6271136	WFS1	0.38	5.59	0.34	6.38e-8	Cisplatin-induced ototoxicity;
SARC	cis	rs262150	0.579	rs4909110	chr7:158787332	C/T	cg19418458	chr7:158789849	NA	0.46	5.03	0.31	9.61e-7	Facial morphology (factor 20);
SARC	cis	rs7429990	1.000	rs7429990	chr3:47901803	C/A	cg11946769	chr3:48343235	NME6	0.62	6.73	0.4	1.34e-10	Educational attainment (years of education);
SARC	cis	rs10463316	0.894	rs7709994	chr5:150753597	A/T	cg03212797	chr5:150827313	SLC36A1	-0.52	-6.32	-0.38	1.3e-9	Metabolite levels (Pyroglutamine);
SARC	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.5	5.96	0.36	9.48e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs6088813	0.961	rs6060371	chr20:33913322	G/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.43	5.24	0.32	3.53e-7	Height;
SARC	cis	rs7429990	0.932	rs7630685	chr3:48131170	G/C	cg11946769	chr3:48343235	NME6	-0.47	-5.15	-0.32	5.65e-7	Educational attainment (years of education);
SARC	cis	rs123509	0.687	rs73075297	chr3:42832466	A/G	cg12982090	chr3:42733453	KBTBD5	-0.53	-5.95	-0.36	9.96e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs10911363	0.592	rs2702178	chr1:183452545	G/A	cg09173681	chr1:183549694	NCF2	0.31	4.97	0.31	1.27e-6	Systemic lupus erythematosus;
SARC	cis	rs2404602	0.692	rs35557205	chr15:77130711	T/G	cg22467129	chr15:76604101	ETFA	-0.39	-4.95	-0.31	1.41e-6	Blood metabolite levels;
SARC	cis	rs7626444	0.625	rs843541	chr3:196475750	A/G	cg12930392	chr3:196481615	PAK2	0.25	5.02	0.31	1.02e-6	Monocyte count;
SARC	cis	rs6696239	0.531	rs10799423	chr1:227737384	C/G	cg26340147	chr1:227730820	NA	0.33	4.73	0.3	3.95e-6	Height;
SARC	cis	rs533581	0.816	rs1559446	chr16:88975332	A/G	cg05579598	chr16:88989069	CBFA2T3	0.34	5.06	0.31	8.45e-7	Social autistic-like traits;
SARC	cis	rs11190604	0.767	rs79106148	chr10:102184732	G/A	cg07080220	chr10:102295463	HIF1AN	0.72	8.27	0.48	1.05e-14	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs17023223	0.537	rs2361269	chr1:119602215	A/G	cg05756136	chr1:119680316	WARS2	-0.43	-5.03	-0.31	9.81e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs9916302	0.706	rs597069	chr17:37458512	G/T	cg15445000	chr17:37608096	MED1	-0.45	-4.76	-0.3	3.42e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs67311347	1.000	rs9874006	chr3:40471596	G/A	cg09455208	chr3:40491958	NA	0.42	6.69	0.4	1.63e-10	Renal cell carcinoma;
SARC	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg16405210	chr4:1374714	KIAA1530	0.54	6.44	0.39	6.84e-10	Obesity-related traits;
SARC	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg20607798	chr8:58055168	NA	0.72	6.04	0.37	5.95e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg18876405	chr7:65276391	NA	-0.67	-8.3	-0.48	8.63e-15	Aortic root size;
SARC	cis	rs820218	0.926	rs820209	chr17:73649954	C/G	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.68	9.34	0.52	8.15e-18	Rotator cuff tears;
SARC	cis	rs2594989	0.831	rs7356051	chr3:11566288	A/C	cg00170343	chr3:11313890	ATG7	-0.57	-5.96	-0.36	9.21e-9	Circulating chemerin levels;
SARC	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg24549020	chr5:56110836	MAP3K1	-0.51	-5.58	-0.34	6.82e-8	Initial pursuit acceleration;
SARC	cis	rs2997447	0.706	rs61776574	chr1:26429492	C/T	cg19633962	chr1:26362018	EXTL1	-0.67	-5.65	-0.35	4.72e-8	QRS complex (12-leadsum);
SARC	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg14983838	chr19:29218262	NA	0.77	10.53	0.57	1.83e-21	Methadone dose in opioid dependence;
SARC	cis	rs7998202	0.667	rs188166	chr13:113355498	T/C	cg02820901	chr13:113351484	ATP11A	0.56	5.06	0.31	8.58e-7	Glycated hemoglobin levels;
SARC	cis	rs6500602	0.727	rs11644481	chr16:4581002	T/G	cg08645402	chr16:4508243	NA	0.41	5.29	0.33	2.82e-7	Schizophrenia;
SARC	cis	rs9341808	0.718	rs9443735	chr6:80820474	G/T	cg08355045	chr6:80787529	NA	0.34	5.48	0.34	1.09e-7	Sitting height ratio;
SARC	cis	rs3092073	0.624	rs3848719	chr20:44596545	G/A	cg27529037	chr20:44575021	PCIF1	0.39	6.09	0.37	4.67e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7555523	0.778	rs2790052	chr1:165738463	G/C	cg24409356	chr1:165738333	TMCO1	0.81	6.72	0.4	1.35e-10	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg13880726	chr7:1868755	MAD1L1	0.43	4.98	0.31	1.23e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs2303745	0.589	rs6512182	chr19:17399476	G/T	cg22549504	chr19:17448937	GTPBP3	0.52	5.23	0.32	3.77e-7	Systemic lupus erythematosus;
SARC	cis	rs7084402	0.967	rs1619284	chr10:60302515	C/T	cg07615347	chr10:60278583	BICC1	0.57	8.44	0.48	3.5e-15	Refractive error;
SARC	cis	rs2869548	1	rs2869548	chr15:78922638	G/A	cg06917634	chr15:78832804	PSMA4	-0.5	-5.42	-0.33	1.49e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg13395646	chr4:1353034	KIAA1530	-0.56	-6.69	-0.4	1.66e-10	Obesity-related traits;
SARC	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg22800045	chr5:56110881	MAP3K1	0.77	8.18	0.47	1.82e-14	Type 2 diabetes;
SARC	cis	rs9513627	1.000	rs7317126	chr13:100119739	T/A	cg25919922	chr13:100150906	NA	-0.66	-5.01	-0.31	1.07e-6	Obesity-related traits;
SARC	trans	rs10506458	0.915	rs60094497	chr12:63394838	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.74	-6.26	-0.38	1.81e-9	Hemostatic factors and hematological phenotypes;
SARC	cis	rs4919694	1.000	rs7100592	chr10:104769098	T/G	cg04362960	chr10:104952993	NT5C2	0.65	5.48	0.34	1.09e-7	Arsenic metabolism;
SARC	cis	rs11718455	0.960	rs1852037	chr3:44003720	G/T	cg21419209	chr3:44054225	NA	0.41	4.92	0.31	1.65e-6	Coronary artery disease;
SARC	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg16479474	chr6:28041457	NA	-0.36	-5.36	-0.33	1.96e-7	Depression;
SARC	cis	rs2011503	1.000	rs11085264	chr19:19621780	A/G	cg03709012	chr19:19516395	GATAD2A	0.6	5.29	0.33	2.8e-7	Bipolar disorder;
SARC	cis	rs17125944	0.505	rs2274275	chr14:53235728	G/T	cg00686598	chr14:53173677	PSMC6	1.32	9.07	0.51	4.94e-17	Alzheimer's disease (late onset);
SARC	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg13206674	chr6:150067644	NUP43	0.48	6.36	0.38	1.07e-9	Lung cancer;
SARC	cis	rs6088580	0.524	rs2378251	chr20:33276750	C/T	cg08999081	chr20:33150536	PIGU	-0.35	-5.05	-0.31	9.07e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs9916302	0.904	rs6503506	chr17:37524653	C/A	cg15445000	chr17:37608096	MED1	-0.43	-5.13	-0.32	6.23e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs6582630	0.519	rs11495700	chr12:38288240	A/G	cg13010199	chr12:38710504	ALG10B	0.81	11.31	0.6	6.33e-24	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs17376456	0.825	rs55947981	chr5:93278104	G/T	cg25358565	chr5:93447407	FAM172A	1.3	14.32	0.68	8.73e-34	Diabetic retinopathy;
SARC	cis	rs1348850	0.914	rs3813259	chr2:178257214	G/A	cg23306229	chr2:178417860	TTC30B	0.55	6.4	0.39	8.43e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg16479474	chr6:28041457	NA	0.33	5.47	0.34	1.13e-7	Cardiac Troponin-T levels;
SARC	cis	rs7904368	0.806	rs7099178	chr10:16862578	C/G	cg14835575	chr10:16859367	RSU1	0.81	8.28	0.48	9.59e-15	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs911555	0.504	rs8021368	chr14:104074810	G/A	cg26031613	chr14:104095156	KLC1	0.61	8.05	0.47	4.33e-14	Intelligence (multi-trait analysis);
SARC	cis	rs870825	0.655	rs1527870	chr4:185616631	T/C	cg04058563	chr4:185651563	MLF1IP	0.82	11.18	0.59	1.58e-23	Blood protein levels;
SARC	cis	rs72781680	1.000	rs72781675	chr2:24232092	G/A	cg08917208	chr2:24149416	ATAD2B	0.94	9.2	0.52	2.17e-17	Lymphocyte counts;
SARC	cis	rs3099143	1.000	rs3106378	chr15:77110524	A/C	cg21673338	chr15:77095150	SCAPER	-0.76	-6.25	-0.38	1.93e-9	Recalcitrant atopic dermatitis;
SARC	cis	rs8078723	0.510	rs9898547	chr17:38136026	G/T	cg17344932	chr17:38183730	MED24;SNORD124	0.3	5.49	0.34	1.07e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs2204008	0.545	rs1663283	chr12:38132039	G/A	cg26384229	chr12:38710491	ALG10B	-0.66	-8.64	-0.49	9.24e-16	Bladder cancer;
SARC	cis	rs62244186	0.659	rs6441844	chr3:44503579	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.46	5.8	0.36	2.13e-8	Depressive symptoms;
SARC	cis	rs6011002	0.810	rs6010988	chr20:62278210	G/A	cg23957118	chr20:62200850	PRIC285	0.64	4.84	0.3	2.41e-6	Dental caries;
SARC	cis	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg00409905	chr10:38381863	ZNF37A	0.51	7.18	0.43	9.24e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs13191362	1.000	rs73008453	chr6:163013384	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.57	5.47	0.34	1.16e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2730245	0.527	rs2527194	chr7:158732959	G/A	cg24397884	chr7:158709396	WDR60	-1.22	-11.91	-0.62	7.13e-26	Height;
SARC	cis	rs950776	0.695	rs1878399	chr15:78912003	G/C	cg17108064	chr15:78857060	CHRNA5	-0.28	-4.76	-0.3	3.36e-6	Sudden cardiac arrest;
SARC	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg14983838	chr19:29218262	NA	0.77	10.52	0.57	2e-21	Methadone dose in opioid dependence;
SARC	cis	rs7326068	0.610	rs7990231	chr13:21337838	C/T	cg16922012	chr13:21400325	XPO4	-0.45	-6.21	-0.38	2.4e-9	Schizophrenia, bipolar disorder and depression (combined);
SARC	cis	rs9814567	0.964	rs4974480	chr3:134178562	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.49	-6.18	-0.38	2.76e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs883565	0.655	rs4645092	chr3:39051718	G/A	cg01426195	chr3:39028469	NA	-0.36	-5.26	-0.33	3.29e-7	Handedness;
SARC	cis	rs6693567	0.565	rs35784258	chr1:150405882	T/C	cg09579323	chr1:150459698	TARS2	0.44	5.66	0.35	4.4e-8	Migraine;
SARC	cis	rs9914988	0.943	rs9303621	chr17:27161138	A/G	cg20469991	chr17:27169893	C17orf63	-0.5	-5.1	-0.32	7.08e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs2304069	0.545	rs11167492	chr5:149403101	G/A	cg12661370	chr5:149340060	SLC26A2	0.56	6.67	0.4	1.82e-10	HIV-1 control;
SARC	cis	rs1580019	0.587	rs1597555	chr7:32546118	T/G	cg06627557	chr7:32535165	LSM5;AVL9	0.98	17.41	0.75	4.7e-44	Cognitive ability;
SARC	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg27266027	chr21:40555129	PSMG1	0.51	5.57	0.34	6.84e-8	Cognitive function;
SARC	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg01448562	chr3:133502909	NA	0.52	8.16	0.47	2.14e-14	Iron status biomarkers;
SARC	cis	rs9392653	1.000	rs13340416	chr6:5071438	T/G	cg00563771	chr6:5110810	LYRM4	-0.5	-5.87	-0.36	1.52e-8	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg08280861	chr8:58055591	NA	0.61	5.96	0.36	9.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg24675658	chr1:53192096	ZYG11B	-0.58	-7.9	-0.46	1.09e-13	Monocyte count;
SARC	cis	rs372883	0.648	rs4817279	chr21:30638285	T/C	cg24692254	chr21:30365293	RNF160	-0.63	-8.08	-0.47	3.5e-14	Pancreatic cancer;
SARC	cis	rs651907	0.535	rs11714444	chr3:101513682	G/A	cg12386194	chr3:101231763	SENP7	0.47	5.38	0.33	1.77e-7	Colorectal cancer;
SARC	cis	rs2797160	0.651	rs6569436	chr6:126032104	A/G	cg06289844	chr6:126071538	HEY2	-0.31	-4.88	-0.3	1.96e-6	Endometrial cancer;
SARC	cis	rs9462027	0.628	rs34141614	chr6:34777031	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.86	-0.36	1.54e-8	Systemic lupus erythematosus;
SARC	cis	rs2576037	0.796	rs2576043	chr18:44573476	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.47	6.22	0.38	2.25e-9	Personality dimensions;
SARC	cis	rs7927592	0.871	rs12360903	chr11:68236314	C/A	cg01657329	chr11:68192670	LRP5	-0.41	-4.99	-0.31	1.18e-6	Total body bone mineral density;
SARC	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg00933542	chr6:150070202	PCMT1	0.31	5.27	0.33	3.05e-7	Lung cancer;
SARC	cis	rs11866815	0.817	rs9935993	chr16:401209	C/T	cg26913058	chr16:419975	MRPL28	0.31	4.96	0.31	1.38e-6	Body mass index;
SARC	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg04518342	chr5:131593106	PDLIM4	-0.41	-5.7	-0.35	3.64e-8	Acylcarnitine levels;
SARC	cis	rs523522	0.923	rs10774553	chr12:120954984	T/C	cg12219531	chr12:120966889	COQ5	0.84	11.23	0.59	1.1e-23	High light scatter reticulocyte count;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg18308252	chr10:5855585	GDI2	0.57	7.78	0.45	2.28e-13	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs11608355	0.545	rs55902232	chr12:109902305	G/A	cg05360138	chr12:110035743	NA	0.92	9.65	0.53	9.69e-19	Neuroticism;
SARC	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9790314	0.632	rs62280333	chr3:160689060	G/A	cg04691961	chr3:161091175	C3orf57	0.58	7.88	0.46	1.27e-13	Morning vs. evening chronotype;
SARC	cis	rs2295359	1.000	rs10889664	chr1:67635475	C/T	cg03340356	chr1:67600835	NA	0.33	4.76	0.3	3.34e-6	Psoriasis;
SARC	cis	rs3126085	0.935	rs11586114	chr1:152299767	G/A	cg03465714	chr1:152285911	FLG	0.44	4.71	0.3	4.18e-6	Atopic dermatitis;
SARC	cis	rs11997175	0.503	rs7013967	chr8:33826107	T/G	ch.8.33884649F	chr8:33765107	NA	0.46	5.93	0.36	1.1e-8	Body mass index;
SARC	cis	rs13401104	0.796	rs72620805	chr2:237113711	G/C	cg19324714	chr2:237145437	ASB18	0.57	5.91	0.36	1.22e-8	Educational attainment;
SARC	cis	rs751728	1.000	rs9394166	chr6:33751122	G/C	cg25922239	chr6:33757077	LEMD2	0.78	10.34	0.56	7.07e-21	Crohn's disease;
SARC	cis	rs208520	0.954	rs1468153	chr6:67009054	A/C	cg07460842	chr6:66804631	NA	0.79	8.19	0.47	1.69e-14	Exhaled nitric oxide output;
SARC	cis	rs1801251	1.000	rs13003675	chr2:233584109	C/T	cg25237894	chr2:233734115	C2orf82	0.39	5.06	0.31	8.68e-7	Coronary artery disease;
SARC	cis	rs6456156	0.792	rs4710181	chr6:167513998	T/C	cg07741184	chr6:167504864	NA	0.37	7.32	0.43	4.11e-12	Primary biliary cholangitis;
SARC	cis	rs7833790	0.926	rs72686467	chr8:82758929	T/G	cg17211192	chr8:82754475	SNX16	0.59	6.43	0.39	7.2e-10	Diastolic blood pressure;
SARC	cis	rs17376456	0.877	rs28418572	chr5:93144161	A/C	cg21475434	chr5:93447410	FAM172A	0.78	6.65	0.4	2.02e-10	Diabetic retinopathy;
SARC	cis	rs742614	0.576	rs2747537	chr20:32405217	A/G	cg06304546	chr20:32448765	NA	-0.52	-6.5	-0.39	4.94e-10	Stearic acid (18:0) levels;
SARC	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	5.44	0.34	1.32e-7	Bipolar disorder;
SARC	cis	rs3820928	0.648	rs1997484	chr2:227898962	T/A	cg11843606	chr2:227700838	RHBDD1	-0.55	-6.87	-0.41	5.92e-11	Pulmonary function;
SARC	cis	rs1881797	1.000	rs66845073	chr1:247688010	C/T	cg11166453	chr1:247681781	NA	0.46	5.18	0.32	4.74e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs17376456	1.000	rs66978370	chr5:93553633	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.17	0.32	5e-7	Diabetic retinopathy;
SARC	trans	rs7824557	0.806	rs10503418	chr8:11118983	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.31	-0.38	1.43e-9	Retinal vascular caliber;
SARC	cis	rs4711350	0.954	rs1536501	chr6:33727885	C/T	cg07979401	chr6:33739406	LEMD2	0.41	4.76	0.3	3.38e-6	Schizophrenia;
SARC	cis	rs796364	0.755	rs203762	chr2:200905136	C/A	cg23649088	chr2:200775458	C2orf69	-0.64	-5.54	-0.34	8.17e-8	Schizophrenia;
SARC	cis	rs9467773	1.000	rs6910899	chr6:26524339	A/G	cg12292205	chr6:26970375	C6orf41	0.44	5.46	0.34	1.24e-7	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg21724239	chr8:58056113	NA	0.71	6.41	0.39	8.1e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg03709012	chr19:19516395	GATAD2A	0.97	15.48	0.71	1.19e-37	Tonsillectomy;
SARC	cis	rs6539288	0.933	rs6539289	chr12:107309316	A/C	cg07730007	chr12:107377277	MTERFD3	-0.39	-4.99	-0.31	1.16e-6	Total body bone mineral density;
SARC	cis	rs10504229	0.593	rs113184543	chr8:58042950	A/G	cg22535103	chr8:58192502	C8orf71	-0.53	-5.24	-0.32	3.56e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs11122272	0.670	rs2474632	chr1:231484361	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.19	-0.56	2.14e-20	Hemoglobin concentration;
SARC	cis	rs9818758	0.607	rs11706052	chr3:49064110	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.68	-5.76	-0.35	2.62e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs9303401	0.614	rs68100606	chr17:56500898	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.0	10.33	0.56	7.47e-21	Cognitive test performance;
SARC	cis	rs7953249	0.935	rs7135337	chr12:121404155	A/C	cg25281562	chr12:121454272	C12orf43	-0.39	-4.79	-0.3	3.01e-6	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs9457247	0.602	rs2157388	chr6:167481912	G/A	cg07741184	chr6:167504864	NA	0.38	7.36	0.43	3.15e-12	Crohn's disease;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg03157633	chr12:13154475	HTR7P;HEBP1	0.5	6.75	0.4	1.2e-10	Tetralogy of Fallot;
SARC	cis	rs1949733	1.000	rs2140337	chr4:8502112	A/G	cg13073564	chr4:8508604	NA	-0.48	-7.9	-0.46	1.1e-13	Response to antineoplastic agents;
SARC	cis	rs9916302	0.904	rs7503705	chr17:37669704	A/G	cg07936489	chr17:37558343	FBXL20	-0.69	-8.9	-0.5	1.63e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs17666538	0.585	rs1037393	chr8:622634	G/C	cg23958373	chr8:599963	NA	0.72	6.01	0.37	7.05e-9	IgG glycosylation;
SARC	cis	rs12477438	0.765	rs6722164	chr2:99561527	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-9.84	-0.54	2.47e-19	Chronic sinus infection;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg03988675	chr1:14075428	PRDM2	0.5	6.5	0.39	4.77e-10	Lung adenocarcinoma;
SARC	cis	rs722599	0.562	rs2193597	chr14:75234329	G/A	cg08847533	chr14:75593920	NEK9	0.43	4.89	0.31	1.88e-6	IgG glycosylation;
SARC	cis	rs9916302	0.851	rs6503502	chr17:37501855	A/G	cg20243544	chr17:37824526	PNMT	-0.53	-6.37	-0.39	9.76e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs7586879	0.575	rs6744205	chr2:25133148	T/C	cg04586622	chr2:25135609	ADCY3	0.31	5.1	0.32	6.98e-7	Body mass index;
SARC	cis	rs2204008	0.774	rs11520237	chr12:38266978	G/A	cg13010199	chr12:38710504	ALG10B	0.81	11.31	0.6	6.15e-24	Bladder cancer;
SARC	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg22484793	chr3:52261325	TLR9	0.29	4.73	0.3	3.83e-6	Bipolar disorder;
SARC	cis	rs1448094	0.512	rs12297441	chr12:86233980	C/T	cg00310523	chr12:86230176	RASSF9	0.31	4.88	0.3	2e-6	Major depressive disorder;
SARC	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg20607798	chr8:58055168	NA	0.5	4.76	0.3	3.38e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs27434	0.607	rs34750	chr5:96142806	G/C	cg16492584	chr5:96139282	ERAP1	-0.6	-7.78	-0.45	2.36e-13	Ankylosing spondylitis;
SARC	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg14159672	chr1:205819179	PM20D1	0.45	5.17	0.32	5.16e-7	Parkinson's disease;
SARC	cis	rs2710642	0.815	rs6545971	chr2:63074986	A/T	cg17519650	chr2:63277830	OTX1	0.41	5.3	0.33	2.63e-7	LDL cholesterol levels;LDL cholesterol;
SARC	cis	rs11718455	0.960	rs11917885	chr3:44008013	A/G	cg21419209	chr3:44054225	NA	0.42	5.16	0.32	5.37e-7	Coronary artery disease;
SARC	cis	rs11122272	0.701	rs11122273	chr1:231476789	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-9.94	-0.55	1.19e-19	Hemoglobin concentration;
SARC	cis	rs9399137	0.507	rs7768278	chr6:135274957	T/C	cg24558204	chr6:135376177	HBS1L	0.6	7.84	0.46	1.58e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9875589	0.509	rs1488379	chr3:14014719	A/G	cg19554555	chr3:13937349	NA	-0.4	-5.12	-0.32	6.3e-7	Ovarian reserve;
SARC	cis	rs2180341	0.574	rs13192350	chr6:127677762	G/T	cg27446573	chr6:127587934	RNF146	0.68	8.62	0.49	1.07e-15	Breast cancer;
SARC	cis	rs6570726	0.846	rs870491	chr6:145933390	T/G	cg05347473	chr6:146136440	FBXO30	0.51	7.12	0.42	1.35e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg21782813	chr7:2030301	MAD1L1	0.43	6.97	0.42	3.16e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs453301	0.686	rs13252797	chr8:8861430	A/G	cg15556689	chr8:8085844	FLJ10661	0.48	6.05	0.37	5.68e-9	Joint mobility (Beighton score);
SARC	cis	rs11168187	0.891	rs726588	chr12:48124151	A/C	cg12761788	chr12:48120090	P11	0.41	5.23	0.32	3.83e-7	Vertical cup-disc ratio;
SARC	cis	rs911555	0.504	rs61995761	chr14:104075712	T/C	cg24130564	chr14:104152367	KLC1	-0.7	-9.92	-0.54	1.47e-19	Intelligence (multi-trait analysis);
SARC	cis	rs79149102	0.579	rs8031545	chr15:75290496	T/C	cg00629941	chr15:75287862	SCAMP5	-0.64	-5.11	-0.32	6.76e-7	Lung cancer;
SARC	cis	rs7647973	0.922	rs57273516	chr3:49483074	A/G	cg07636037	chr3:49044803	WDR6	0.8	9.36	0.52	6.83e-18	Menarche (age at onset);
SARC	cis	rs6831352	0.703	rs3133152	chr4:100031721	C/G	cg13256891	chr4:100009986	ADH5	0.6	7.9	0.46	1.09e-13	Alcohol dependence;
SARC	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg24399712	chr22:39784796	NA	-0.45	-5.8	-0.36	2.16e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs12701220	0.542	rs6957866	chr7:1111674	G/A	cg02733842	chr7:1102375	C7orf50	-0.58	-6.75	-0.4	1.18e-10	Bronchopulmonary dysplasia;
SARC	cis	rs7659604	0.517	rs6856996	chr4:122671271	C/T	cg06713675	chr4:122721982	EXOSC9	-0.51	-6.54	-0.39	3.96e-10	Type 2 diabetes;
SARC	cis	rs478304	0.651	rs11227279	chr11:65495211	G/A	cg26695010	chr11:65641043	EFEMP2	0.39	4.75	0.3	3.59e-6	Acne (severe);
SARC	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg01341218	chr17:43662625	NA	0.95	11.08	0.59	3.29e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs748404	0.697	rs546722	chr15:43580819	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	6.56	0.4	3.36e-10	Lung cancer;
SARC	cis	rs7666738	0.791	rs7665273	chr4:98997413	C/A	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg12000995	chr2:27665139	KRTCAP3	-0.3	-4.72	-0.3	4.08e-6	Total body bone mineral density;
SARC	cis	rs933688	0.938	rs10063683	chr5:90714595	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.03	13.23	0.65	3.53e-30	Smoking behavior;
SARC	cis	rs13226913	0.967	rs2881756	chr7:7256440	C/T	cg19603390	chr7:7222222	C1GALT1	0.4	5.01	0.31	1.1e-6	Serum galactose-deficient IgA1 levels;
SARC	cis	rs807669	0.548	rs885979	chr22:19198375	T/C	cg02655711	chr22:19163373	SLC25A1	0.49	6.97	0.42	3.22e-11	Metabolite levels;
SARC	cis	rs2952156	0.920	rs12940986	chr17:37836581	A/G	cg20243544	chr17:37824526	PNMT	-0.54	-7.11	-0.42	1.38e-11	Asthma;
SARC	cis	rs9916302	0.904	rs801420	chr17:37466103	C/G	cg07936489	chr17:37558343	FBXL20	0.68	9.06	0.51	5.39e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg01842473	chr11:617407	IRF7;MUPCDH	-0.49	-5.77	-0.35	2.48e-8	Systemic lupus erythematosus;
SARC	cis	rs8028182	0.549	rs3809547	chr15:75628841	C/G	cg20655648	chr15:75932815	IMP3	-0.63	-7.01	-0.42	2.57e-11	Sudden cardiac arrest;
SARC	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg18225595	chr11:63971243	STIP1	0.56	8.49	0.49	2.45e-15	Platelet count;
SARC	cis	rs4148883	0.545	rs17595102	chr4:99986316	C/G	cg12011299	chr4:100065546	ADH4	0.39	7.12	0.42	1.34e-11	Alcohol dependence;
SARC	cis	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg10591111	chr5:226296	SDHA	-0.52	-4.79	-0.3	2.93e-6	Breast cancer;
SARC	cis	rs9354308	0.774	rs10155672	chr6:66538447	A/G	cg07460842	chr6:66804631	NA	-0.45	-5.21	-0.32	4.09e-7	Metabolite levels;
SARC	cis	rs12477438	0.765	rs12612688	chr2:99613091	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-7.36	-0.43	3.1e-12	Chronic sinus infection;
SARC	cis	rs9790314	0.663	rs5004752	chr3:160748380	A/T	cg04691961	chr3:161091175	C3orf57	-0.59	-8.13	-0.47	2.6e-14	Morning vs. evening chronotype;
SARC	cis	rs7552404	0.924	rs12136754	chr1:76230232	C/A	cg22875332	chr1:76189707	ACADM	0.45	6.34	0.38	1.21e-9	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs3087591	0.960	rs2269855	chr17:29482878	G/A	cg24425628	chr17:29625626	OMG;NF1	0.52	6.47	0.39	5.57e-10	Hip circumference;
SARC	cis	rs858239	0.600	rs6961131	chr7:23134790	A/G	cg23682824	chr7:23144976	KLHL7	0.71	9.6	0.53	1.34e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs7772486	0.875	rs7767660	chr6:146436550	T/C	cg23711669	chr6:146136114	FBXO30	0.71	10.58	0.57	1.33e-21	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg08677398	chr8:58056175	NA	0.44	5.19	0.32	4.6e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7587476	0.906	rs3768713	chr2:215637505	G/A	cg04004882	chr2:215674386	BARD1	0.57	6.1	0.37	4.45e-9	Neuroblastoma;
SARC	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg04267008	chr7:1944627	MAD1L1	-0.5	-5.69	-0.35	3.85e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs77372450	0.551	rs73814843	chr5:157063058	A/C	cg05585991	chr5:157099197	C5orf52	0.54	5.38	0.33	1.85e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs13082711	0.911	rs6775176	chr3:27432475	G/A	cg02860705	chr3:27208620	NA	0.47	6.19	0.38	2.7e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg20007245	chr22:24372913	LOC391322	-0.72	-9.73	-0.54	5.29e-19	Liver enzyme levels (gamma-glutamyl transferase);
SARC	trans	rs208520	0.802	rs4710314	chr6:66883656	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.03	-12.94	-0.65	3.22e-29	Exhaled nitric oxide output;
SARC	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg17971929	chr21:40555470	PSMG1	0.99	14.22	0.68	1.86e-33	Cognitive function;
SARC	cis	rs6450176	1.000	rs7707547	chr5:53295737	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.65	-7.38	-0.44	2.69e-12	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs10490913	0.806	rs11198392	chr10:120168787	A/G	cg23160142	chr10:120154512	NA	-0.39	-5.79	-0.35	2.31e-8	Cancer;
SARC	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg11843238	chr5:131593191	PDLIM4	-0.42	-5.14	-0.32	5.92e-7	Breast cancer;
SARC	cis	rs835154	0.900	rs835153	chr5:14877474	A/G	cg18064842	chr5:14874549	NA	-0.47	-6.54	-0.39	3.86e-10	Blood metabolite levels;
SARC	cis	rs854765	0.583	rs66531105	chr17:17809001	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.43	5.58	0.34	6.79e-8	Total body bone mineral density;
SARC	cis	rs9513627	0.915	rs4539436	chr13:100122802	C/G	cg25919922	chr13:100150906	NA	-0.69	-5.17	-0.32	4.94e-7	Obesity-related traits;
SARC	cis	rs7666738	0.791	rs17549003	chr4:98969132	A/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs11997175	0.713	rs4733454	chr8:33651253	C/A	ch.8.33884649F	chr8:33765107	NA	0.5	6.57	0.4	3.27e-10	Body mass index;
SARC	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9660992	0.508	rs113817010	chr1:205104581	C/A	cg00857998	chr1:205179979	DSTYK	0.49	6.23	0.38	2.14e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs9393692	0.572	rs4145878	chr6:26198046	A/T	cg00631329	chr6:26305371	NA	-0.53	-7.03	-0.42	2.29e-11	Educational attainment;
SARC	cis	rs9818758	0.607	rs34566463	chr3:49245077	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.73	-6.45	-0.39	6.26e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg11995313	chr8:8860691	ERI1	-0.38	-4.79	-0.3	3.03e-6	Joint mobility (Beighton score);
SARC	trans	rs9650657	0.769	rs1115866	chr8:10638333	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.66	-0.4	1.92e-10	Neuroticism;
SARC	cis	rs6701037	0.555	rs10912899	chr1:175120715	C/T	cg08873628	chr1:175162347	KIAA0040	0.36	4.88	0.3	1.96e-6	Alcohol dependence;
SARC	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg12463550	chr7:65579703	CRCP	0.5	5.9	0.36	1.27e-8	Aortic root size;
SARC	cis	rs10504073	0.584	rs55838473	chr8:49948281	C/A	cg00325661	chr8:49890786	NA	0.52	6.87	0.41	5.66e-11	Blood metabolite ratios;
SARC	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg19223190	chr17:80058835	NA	0.44	6.16	0.37	3.2e-9	Life satisfaction;
SARC	cis	rs854765	0.583	rs6502622	chr17:17834691	A/G	cg05444541	chr17:17804740	TOM1L2	-0.3	-5.07	-0.31	8.28e-7	Total body bone mineral density;
SARC	trans	rs9929218	0.953	rs12930910	chr16:68762520	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.64	-8.05	-0.47	4.17e-14	Colorectal cancer;
SARC	cis	rs9322817	0.691	rs9486015	chr6:105254000	C/T	cg02098413	chr6:105308735	HACE1	-0.38	-5.91	-0.36	1.18e-8	Thyroid stimulating hormone;
SARC	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg07636037	chr3:49044803	WDR6	0.99	17.23	0.75	1.85e-43	Parkinson's disease;
SARC	cis	rs367615	0.661	rs9326773	chr5:108833523	C/T	cg17395555	chr5:108820864	NA	0.48	6.96	0.41	3.43e-11	Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs9487051	0.676	rs6928622	chr6:109595112	C/T	cg01475377	chr6:109611718	NA	-0.35	-5.08	-0.32	7.8e-7	Reticulocyte fraction of red cells;
SARC	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg00149659	chr3:10157352	C3orf10	0.68	6.38	0.39	9.46e-10	Alzheimer's disease;
SARC	cis	rs7644634	0.559	rs2305035	chr3:105439026	G/A	cg23051926	chr3:105466016	CBLB	0.47	5.27	0.33	3.18e-7	Itch intensity from mosquito bite;
SARC	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.5	0.39	4.96e-10	Bipolar disorder;
SARC	cis	rs3733585	0.578	rs6837224	chr4:9955255	G/T	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.39	-0.33	1.73e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7084402	0.967	rs1427199	chr10:60274941	C/T	cg07615347	chr10:60278583	BICC1	-0.57	-8.4	-0.48	4.36e-15	Refractive error;
SARC	cis	rs9796	0.870	rs12905926	chr15:41283408	G/A	cg18705301	chr15:41695430	NDUFAF1	0.42	5.71	0.35	3.44e-8	Menopause (age at onset);
SARC	trans	rs3136441	0.786	rs10838612	chr11:46701728	G/T	cg08109568	chr15:31115862	NA	0.77	6.34	0.38	1.21e-9	HDL cholesterol;
SARC	cis	rs76917914	0.780	rs6478556	chr9:100842005	A/G	cg03040243	chr9:100819229	NANS	-0.66	-7.07	-0.42	1.74e-11	Immature fraction of reticulocytes;
SARC	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg02592271	chr2:27665507	KRTCAP3	-0.42	-6.32	-0.38	1.31e-9	Total body bone mineral density;
SARC	cis	rs1707322	1.000	rs4660889	chr1:46297331	C/T	cg06784218	chr1:46089804	CCDC17	0.33	5.77	0.35	2.45e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2180341	1.000	rs9285460	chr6:127640190	A/G	cg27446573	chr6:127587934	RNF146	1.03	14.54	0.69	1.56e-34	Breast cancer;
SARC	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1865760	0.602	rs9467662	chr6:26021327	G/A	cg18357526	chr6:26021779	HIST1H4A	0.46	5.74	0.35	3e-8	Height;
SARC	cis	rs2153535	0.541	rs5026687	chr6:8473957	A/T	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs1348850	0.958	rs12471741	chr2:178448196	A/G	cg23306229	chr2:178417860	TTC30B	0.59	7.09	0.42	1.57e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg16049864	chr8:95962084	TP53INP1	-0.47	-7.85	-0.46	1.5e-13	Type 2 diabetes;
SARC	cis	rs9399137	0.507	rs11757723	chr6:135291293	C/T	cg22676075	chr6:135203613	NA	0.39	4.9	0.31	1.78e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs1153858	1.000	rs4271549	chr15:45652730	G/A	cg03999130	chr15:45571217	NA	0.39	4.97	0.31	1.27e-6	Homoarginine levels;
SARC	cis	rs9875589	0.509	rs2731337	chr3:14091440	G/C	cg19554555	chr3:13937349	NA	-0.39	-4.91	-0.31	1.73e-6	Ovarian reserve;
SARC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg15242686	chr22:24348715	GSTTP1	-0.46	-5.56	-0.34	7.46e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs17376456	0.825	rs10064368	chr5:93266396	C/A	cg21475434	chr5:93447410	FAM172A	0.86	7.72	0.45	3.37e-13	Diabetic retinopathy;
SARC	cis	rs6977660	0.714	rs17141884	chr7:19790280	A/G	cg07541023	chr7:19748670	TWISTNB	-0.74	-6.73	-0.4	1.28e-10	Thyroid stimulating hormone;
SARC	cis	rs17666538	0.901	rs73177064	chr8:585293	C/G	cg07234876	chr8:600039	NA	-1.0	-7.44	-0.44	1.88e-12	IgG glycosylation;
SARC	cis	rs554111	0.634	rs1453265	chr1:21277711	C/T	cg04902671	chr1:21058625	SH2D5	0.44	5.38	0.33	1.85e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg22496380	chr5:211416	CCDC127	-0.88	-9.35	-0.52	7.72e-18	Breast cancer;
SARC	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg20607798	chr8:58055168	NA	0.67	5.56	0.34	7.23e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.38	-4.97	-0.31	1.29e-6	Bronchopulmonary dysplasia;
SARC	cis	rs2228479	0.850	rs11647174	chr16:89958538	G/A	cg12064134	chr16:90016061	DEF8	-0.55	-4.75	-0.3	3.59e-6	Skin colour saturation;
SARC	cis	rs12311304	1.000	rs12317636	chr12:15420288	A/G	cg08258403	chr12:15378311	NA	-0.47	-7.19	-0.43	8.61e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs4268898	0.931	rs7603997	chr2:24524958	C/T	cg26838691	chr2:24397539	C2orf84	-0.4	-5.4	-0.33	1.64e-7	Asthma;
SARC	cis	rs12893668	0.673	rs2296482	chr14:104029819	T/G	cg26031613	chr14:104095156	KLC1	-0.51	-5.42	-0.33	1.48e-7	Reticulocyte count;
SARC	cis	rs1059312	0.808	rs2306683	chr12:129299675	C/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.46	-5.61	-0.34	5.75e-8	Systemic lupus erythematosus;
SARC	cis	rs9303280	0.747	rs1453559	chr17:38020419	T/C	cg20243544	chr17:37824526	PNMT	0.44	5.91	0.36	1.24e-8	Self-reported allergy;
SARC	cis	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg00071950	chr4:10020882	SLC2A9	0.41	6.53	0.39	4.14e-10	Bone mineral density;
SARC	cis	rs7223966	0.961	rs17631394	chr17:61646000	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.58	-5.81	-0.36	2.02e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6840360	0.615	rs1962910	chr4:152479392	T/A	cg22705602	chr4:152727874	NA	-0.4	-6.25	-0.38	1.92e-9	Intelligence (multi-trait analysis);
SARC	cis	rs4568518	0.803	rs12699947	chr7:18040239	G/T	cg00911873	chr7:18067463	PRPS1L1	-0.35	-5.12	-0.32	6.52e-7	Measles;
SARC	cis	rs317689	0.684	rs315125	chr12:69758884	C/T	cg20891283	chr12:69753455	YEATS4	0.5	5.67	0.35	4.17e-8	Response to diuretic therapy;
SARC	cis	rs6120849	0.615	rs11167248	chr20:33538721	G/T	cg06115741	chr20:33292138	TP53INP2	0.55	5.42	0.33	1.51e-7	Protein C levels;
SARC	cis	rs3771570	0.901	rs35496488	chr2:242434316	G/A	cg21155796	chr2:242212141	HDLBP	0.61	5.45	0.34	1.28e-7	Prostate cancer;
SARC	cis	rs4481887	0.927	rs4282853	chr1:248475127	A/G	cg00666640	chr1:248458726	OR2T12	0.32	5.45	0.34	1.25e-7	Common traits (Other);
SARC	cis	rs922107	0.738	rs12116782	chr1:90032047	G/A	cg15422784	chr1:90023713	LRRC8B	-0.32	-4.75	-0.3	3.56e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
SARC	cis	rs17376456	0.877	rs28633397	chr5:93447048	A/G	cg21475434	chr5:93447410	FAM172A	0.88	8.11	0.47	2.81e-14	Diabetic retinopathy;
SARC	cis	rs11190604	1.000	rs74650218	chr10:102293830	C/T	cg07080220	chr10:102295463	HIF1AN	0.8	9.57	0.53	1.65e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs9291683	0.509	rs6849717	chr4:9958719	T/C	cg11266682	chr4:10021025	SLC2A9	-0.39	-6.98	-0.42	2.99e-11	Bone mineral density;
SARC	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.76	7.56	0.44	8.94e-13	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs3820928	0.874	rs3752895	chr2:227886773	A/G	cg11843606	chr2:227700838	RHBDD1	-0.55	-6.95	-0.41	3.58e-11	Pulmonary function;
SARC	cis	rs12142240	0.698	rs72886907	chr1:46814265	C/T	cg00530320	chr1:46809349	NSUN4	0.56	6.79	0.41	9.42e-11	Menopause (age at onset);
SARC	cis	rs35306767	0.903	rs12240651	chr10:943656	A/G	cg26597838	chr10:835615	NA	0.74	7.61	0.45	6.58e-13	Eosinophil percentage of granulocytes;
SARC	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9436747	0.641	rs3790424	chr1:66044013	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.47	4.88	0.3	1.92e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs950776	0.714	rs3743074	chr15:78909480	G/A	cg22563815	chr15:78856949	CHRNA5	-0.31	-4.84	-0.3	2.35e-6	Sudden cardiac arrest;
SARC	cis	rs2204008	0.626	rs11520260	chr12:38330092	C/T	cg13010199	chr12:38710504	ALG10B	0.79	10.83	0.58	2.12e-22	Bladder cancer;
SARC	cis	rs9517313	0.592	rs11069311	chr13:99202101	G/T	cg07423050	chr13:99094983	FARP1	-0.42	-5.49	-0.34	1.05e-7	Neuroticism;
SARC	trans	rs208520	0.526	rs4710310	chr6:66802808	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-21.46	-0.81	4.2e-57	Exhaled nitric oxide output;
SARC	cis	rs607987	0.836	rs1933347	chr11:30279609	T/C	cg06241208	chr11:30344200	C11orf46	0.41	4.9	0.31	1.79e-6	Body mass index;
SARC	trans	rs7937682	0.889	rs484013	chr11:111495779	G/A	cg18187862	chr3:45730750	SACM1L	0.55	6.98	0.42	3.11e-11	Primary sclerosing cholangitis;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg00688330	chr2:234748185	HJURP	-0.46	-6.55	-0.39	3.65e-10	Breast cancer;
SARC	cis	rs9911578	1.000	rs2531729	chr17:56539890	C/T	cg12560992	chr17:57184187	TRIM37	0.81	10.75	0.58	3.84e-22	Intelligence (multi-trait analysis);
SARC	cis	rs2576037	0.901	rs2571021	chr18:44583498	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.7	-10.29	-0.56	9.97e-21	Personality dimensions;
SARC	cis	rs4974559	0.947	rs28437782	chr4:1355062	A/G	cg09010372	chr4:1323433	MAEA	-0.48	-4.84	-0.3	2.31e-6	Systolic blood pressure;
SARC	cis	rs1920116	0.778	rs12494201	chr3:169559856	T/C	cg14222479	chr3:169487675	ARPM1	0.44	5.14	0.32	5.7e-7	Glioma (high-grade);
SARC	cis	rs10883723	0.668	rs12414407	chr10:104387019	A/G	ch.10.2196322F	chr10:104248062	ACTR1A	-0.48	-6.43	-0.39	7.29e-10	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs77372450	0.551	rs7728747	chr5:157083635	C/T	cg05585991	chr5:157099197	C5orf52	0.51	5.06	0.31	8.47e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs6565189	0.865	rs4350585	chr16:30505513	A/G	cg17640201	chr16:30407289	ZNF48	0.51	5.49	0.34	1.05e-7	Tonsillectomy;
SARC	cis	rs3099143	1.000	rs2629034	chr15:77042240	G/A	cg21673338	chr15:77095150	SCAPER	-0.6	-5.01	-0.31	1.07e-6	Recalcitrant atopic dermatitis;
SARC	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg13206674	chr6:150067644	NUP43	0.44	5.61	0.34	5.74e-8	Lung cancer;
SARC	cis	rs2730245	1.000	rs2730245	chr7:158724789	G/C	cg00815399	chr7:158750607	NA	-0.35	-4.9	-0.31	1.8e-6	Height;
SARC	trans	rs3780486	0.846	rs3780487	chr9:33139237	T/C	cg04842962	chr6:43655489	MRPS18A	1.09	20.5	0.8	4.53e-54	IgG glycosylation;
SARC	cis	rs7666738	0.830	rs13138059	chr4:99050430	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg24675658	chr1:53192096	ZYG11B	-0.59	-8.15	-0.47	2.16e-14	Monocyte count;
SARC	trans	rs208520	0.909	rs9354411	chr6:67019930	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.82	8.32	0.48	7.56e-15	Exhaled nitric oxide output;
SARC	cis	rs13256369	0.802	rs11781257	chr8:8559663	A/T	cg18904891	chr8:8559673	CLDN23	0.48	5.38	0.33	1.79e-7	Obesity-related traits;
SARC	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs10754283	0.967	rs4658308	chr1:90122931	C/G	cg21401794	chr1:90099060	LRRC8C	0.58	7.85	0.46	1.54e-13	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs3008870	1.000	rs2985825	chr1:67412822	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.92	11.4	0.6	3.22e-24	Lymphocyte percentage of white cells;
SARC	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg11764359	chr7:65958608	NA	-0.84	-12.27	-0.63	5.04e-27	Aortic root size;
SARC	cis	rs5995756	0.554	rs4522708	chr22:39985283	G/A	cg10455938	chr22:40058150	CACNA1I	0.39	4.8	0.3	2.84e-6	Autism spectrum disorder or schizophrenia;
SARC	trans	rs61931739	0.817	rs1705772	chr12:34174756	G/A	cg26384229	chr12:38710491	ALG10B	0.61	8.09	0.47	3.2e-14	Morning vs. evening chronotype;
SARC	cis	rs875971	0.867	rs13227219	chr7:65844062	T/A	cg12463550	chr7:65579703	CRCP	0.47	5.43	0.34	1.4e-7	Aortic root size;
SARC	cis	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg05084668	chr3:125655381	ALG1L	-0.5	-5.61	-0.35	5.57e-8	Blood pressure (smoking interaction);
SARC	cis	rs13108904	0.517	rs7671242	chr4:1339875	G/A	cg13395646	chr4:1353034	KIAA1530	-0.58	-6.79	-0.41	9.39e-11	Obesity-related traits;
SARC	cis	rs6860806	0.507	rs2631372	chr5:131703578	C/G	cg04518342	chr5:131593106	PDLIM4	0.44	5.18	0.32	4.77e-7	Breast cancer;
SARC	cis	rs7927771	0.864	rs3781625	chr11:47443080	T/C	cg05585544	chr11:47624801	NA	-0.36	-4.84	-0.3	2.41e-6	Subjective well-being;
SARC	cis	rs918629	0.567	rs1841010	chr5:95251911	G/C	cg16656078	chr5:95278638	ELL2	-0.54	-6.77	-0.41	1.04e-10	IgG glycosylation;
SARC	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg13699009	chr12:122356056	WDR66	-0.58	-9.4	-0.52	5.31e-18	Mean corpuscular volume;
SARC	cis	rs9398803	0.687	rs6569469	chr6:127008431	C/T	cg20229609	chr6:126660872	C6orf173	-0.36	-5.18	-0.32	4.74e-7	Male-pattern baldness;
SARC	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg05313129	chr8:58192883	C8orf71	-0.6	-6.65	-0.4	2.1e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7551222	0.749	rs2887429	chr1:204565012	G/T	cg20240347	chr1:204465584	NA	-0.27	-4.93	-0.31	1.58e-6	Schizophrenia;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg17753496	chr6:108881018	FOXO3	-0.78	-6.5	-0.39	4.82e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6963495	0.510	rs73192157	chr7:105225862	A/T	cg19920283	chr7:105172520	RINT1	0.58	4.77	0.3	3.27e-6	Bipolar disorder (body mass index interaction);
SARC	cis	rs240764	0.782	rs395521	chr6:101054999	C/T	cg09795085	chr6:101329169	ASCC3	0.44	5.7	0.35	3.59e-8	Neuroticism;
SARC	cis	rs4242434	0.854	rs3735893	chr8:22452704	A/G	cg03733263	chr8:22462867	KIAA1967	0.9	14.17	0.68	2.66e-33	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs7520050	0.966	rs4134386	chr1:46395089	G/A	cg24296786	chr1:45957014	TESK2	0.39	4.9	0.31	1.77e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs11105298	0.891	rs11105309	chr12:89909850	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.53	-5.34	-0.33	2.19e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs9894429	0.527	rs7405469	chr17:79566596	G/C	cg02159489	chr17:79459563	NA	0.35	5.02	0.31	1.04e-6	Eye color traits;
SARC	cis	rs4642101	0.640	rs9877049	chr3:12821231	A/G	cg24848339	chr3:12840334	CAND2	0.38	6.13	0.37	3.66e-9	QRS complex (12-leadsum);
SARC	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg11987759	chr7:65425863	GUSB	0.48	6.29	0.38	1.59e-9	Aortic root size;
SARC	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg05313129	chr8:58192883	C8orf71	-0.57	-6.56	-0.39	3.39e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg27266027	chr21:40555129	PSMG1	-0.5	-5.65	-0.35	4.75e-8	Cognitive function;
SARC	cis	rs2011503	1.000	rs75582668	chr19:19569023	C/T	cg03709012	chr19:19516395	GATAD2A	0.64	5.69	0.35	3.77e-8	Bipolar disorder;
SARC	cis	rs6918586	0.615	rs198824	chr6:26122783	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.46	-5.89	-0.36	1.33e-8	Schizophrenia;
SARC	trans	rs6964833	1.000	rs13227433	chr7:74094721	T/G	cg07504079	chr7:72649617	NCF1B	-0.59	-6.44	-0.39	6.68e-10	Menarche (age at onset);
SARC	cis	rs1113500	0.862	rs2336128	chr1:108640739	G/T	cg06207961	chr1:108661230	NA	0.46	6.15	0.37	3.3e-9	Growth-regulated protein alpha levels;
SARC	trans	rs11250098	0.600	rs4240671	chr8:10767748	A/G	cg06636001	chr8:8085503	FLJ10661	0.52	6.65	0.4	2.08e-10	Morning vs. evening chronotype;
SARC	cis	rs16976116	0.901	rs73409853	chr15:55502681	A/T	cg17854078	chr15:55489399	RSL24D1	0.66	6.53	0.39	4.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs995000	0.899	rs12136083	chr1:63163073	T/C	cg06896770	chr1:63153194	DOCK7	0.93	14.05	0.68	7.05e-33	Triglyceride levels;
SARC	cis	rs992157	0.560	rs12987130	chr2:219104990	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.6	-7.99	-0.46	6.24e-14	Colorectal cancer;
SARC	cis	rs1865760	0.533	rs1408270	chr6:25873184	A/G	cg17691542	chr6:26056736	HIST1H1C	0.65	8.08	0.47	3.54e-14	Height;
SARC	cis	rs3106136	0.967	rs11722476	chr4:95170839	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.39	-6.05	-0.37	5.83e-9	Capecitabine sensitivity;
SARC	cis	rs7551222	0.749	rs11240764	chr1:204569376	A/G	cg07972458	chr1:204535000	NA	0.35	4.82	0.3	2.54e-6	Schizophrenia;
SARC	cis	rs7712401	0.580	rs10066632	chr5:122364683	C/A	cg19412675	chr5:122181750	SNX24	0.49	6.16	0.37	3.12e-9	Mean platelet volume;
SARC	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg03709012	chr19:19516395	GATAD2A	0.97	15.48	0.71	1.19e-37	Tonsillectomy;
SARC	trans	rs7824557	0.767	rs11775635	chr8:11164865	G/A	cg06636001	chr8:8085503	FLJ10661	0.57	6.98	0.42	3.02e-11	Retinal vascular caliber;
SARC	cis	rs6088580	0.668	rs1205340	chr20:32923871	G/A	cg24642439	chr20:33292090	TP53INP2	-0.65	-8.52	-0.49	1.96e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs9640161	0.830	rs35635199	chr7:150063342	C/T	cg10018233	chr7:150070692	REPIN1	0.71	10.09	0.55	4.38e-20	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs999943	0.846	rs10947422	chr6:33611351	G/A	cg14003231	chr6:33640908	ITPR3	0.54	8.79	0.5	3.29e-16	Obesity (extreme);
SARC	cis	rs2075371	0.796	rs7780583	chr7:133960716	C/G	cg11752832	chr7:134001865	SLC35B4	0.48	5.85	0.36	1.66e-8	Mean platelet volume;
SARC	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg08219700	chr8:58056026	NA	0.62	6.52	0.39	4.28e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7727544	1.000	rs10076701	chr5:131596419	A/G	cg24060327	chr5:131705240	SLC22A5	-0.42	-5.13	-0.32	6.24e-7	Blood metabolite levels;
SARC	cis	rs2153535	0.541	rs1414352	chr6:8485547	A/C	cg23788917	chr6:8435910	SLC35B3	0.62	8.05	0.47	4.27e-14	Motion sickness;
SARC	cis	rs870825	0.929	rs871253	chr4:185589234	G/A	cg04058563	chr4:185651563	MLF1IP	0.82	9.01	0.51	7.75e-17	Blood protein levels;
SARC	cis	rs16937	0.711	rs6675633	chr1:205100480	G/A	cg00857998	chr1:205179979	DSTYK	0.4	4.74	0.3	3.76e-6	Schizophrenia;
SARC	cis	rs4689388	0.926	rs3821940	chr4:6286711	C/A	cg25554036	chr4:6271136	WFS1	0.43	7.01	0.42	2.57e-11	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs6570726	0.846	rs9376954	chr6:145943737	T/A	cg05347473	chr6:146136440	FBXO30	0.51	7.13	0.42	1.25e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4148883	0.651	rs2851301	chr4:100010127	C/T	cg12011299	chr4:100065546	ADH4	0.38	7.06	0.42	1.9e-11	Alcohol dependence;
SARC	cis	rs16976116	0.855	rs11856010	chr15:55495008	A/G	cg11288833	chr15:55489084	RSL24D1	0.63	6.13	0.37	3.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6580649	0.941	rs4760677	chr12:48449163	C/T	cg24011408	chr12:48396354	COL2A1	-0.48	-5.31	-0.33	2.56e-7	Lung cancer;
SARC	cis	rs1008375	0.966	rs758483	chr4:17703614	G/T	cg16339924	chr4:17578868	LAP3	-0.57	-7.37	-0.43	2.98e-12	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs3923518	1.000	rs13079538	chr3:38906903	T/C	cg26331595	chr3:39149181	GORASP1;TTC21A	0.47	5.01	0.31	1.09e-6	Migraine;
SARC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg15242686	chr22:24348715	GSTTP1	0.42	5.4	0.33	1.62e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg16405210	chr4:1374714	KIAA1530	-0.86	-11.34	-0.6	5.23e-24	Longevity;
SARC	cis	rs3126085	0.935	rs6666382	chr1:152217226	C/G	cg09127314	chr1:152161683	NA	-0.44	-5.04	-0.31	9.32e-7	Atopic dermatitis;
SARC	cis	rs4478037	0.822	rs4320035	chr3:33113697	C/G	cg19404215	chr3:33155277	CRTAP	-0.78	-6.22	-0.38	2.25e-9	Major depressive disorder;
SARC	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-10.81	-0.58	2.36e-22	Chronic sinus infection;
SARC	cis	rs1843834	0.505	rs940317	chr2:225358118	C/T	cg22509189	chr2:225307070	NA	-0.71	-9.03	-0.51	6.52e-17	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs6952809	0.561	rs1548598	chr7:2438912	T/C	cg23289794	chr7:2394357	EIF3B	-0.65	-6.29	-0.38	1.57e-9	Multiple sclerosis;
SARC	cis	rs710216	0.957	rs841563	chr1:43429520	C/T	cg07803811	chr1:43423981	SLC2A1	0.52	5.09	0.32	7.41e-7	Red cell distribution width;
SARC	cis	rs6860806	0.507	rs273901	chr5:131694360	G/T	cg11843238	chr5:131593191	PDLIM4	0.4	4.97	0.31	1.29e-6	Breast cancer;
SARC	cis	rs12142240	0.698	rs67487250	chr1:46811333	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-5.48	-0.34	1.12e-7	Menopause (age at onset);
SARC	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg05665937	chr4:1216051	CTBP1	0.35	5.04	0.31	9.52e-7	Obesity-related traits;
SARC	cis	rs3820928	0.874	rs4423583	chr2:227874957	A/G	cg05526886	chr2:227700861	RHBDD1	0.5	6.08	0.37	4.97e-9	Pulmonary function;
SARC	cis	rs10875746	0.951	rs10875747	chr12:48525861	A/G	cg27446233	chr12:48516484	PFKM	-0.41	-4.72	-0.3	3.99e-6	Longevity (90 years and older);
SARC	trans	rs66573146	0.831	rs68111914	chr4:6986677	C/T	cg07817883	chr1:32538562	TMEM39B	1.26	8.27	0.48	1.04e-14	Granulocyte percentage of myeloid white cells;
SARC	cis	rs4144743	1.000	rs7218524	chr17:45326565	A/G	cg18085866	chr17:45331354	ITGB3	-0.73	-7.41	-0.44	2.29e-12	Body mass index;
SARC	cis	rs3820928	0.618	rs2141828	chr2:227922470	T/C	cg11843606	chr2:227700838	RHBDD1	-0.53	-6.07	-0.37	5.13e-9	Pulmonary function;
SARC	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg20573242	chr4:122745356	CCNA2	0.58	7.52	0.44	1.2e-12	Type 2 diabetes;
SARC	trans	rs17685	0.753	rs10952840	chr7:75772878	C/T	cg19862616	chr7:65841803	NCRNA00174	0.63	7.95	0.46	8.05e-14	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg13147721	chr7:65941812	NA	-0.52	-4.8	-0.3	2.88e-6	Diabetic kidney disease;
SARC	cis	rs11716531	0.574	rs7624067	chr3:27267853	G/A	cg02860705	chr3:27208620	NA	0.56	7.18	0.43	9.49e-12	Diastolic blood pressure;
SARC	cis	rs2933343	1.000	rs1683776	chr3:128622760	G/T	cg24203234	chr3:128598194	ACAD9	0.54	5.99	0.37	8e-9	IgG glycosylation;
SARC	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg12463550	chr7:65579703	CRCP	-0.49	-5.83	-0.36	1.79e-8	Aortic root size;
SARC	cis	rs9443189	0.813	rs2748956	chr6:76465003	G/C	cg01950844	chr6:76311363	SENP6	-0.68	-6.38	-0.39	9.33e-10	Prostate cancer;
SARC	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg09323728	chr8:95962352	TP53INP1	-0.32	-5.47	-0.34	1.18e-7	Type 2 diabetes;
SARC	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg12463550	chr7:65579703	CRCP	0.66	5.08	0.32	7.79e-7	Diabetic kidney disease;
SARC	cis	rs9916302	0.706	rs667239	chr17:37442241	A/G	cg20243544	chr17:37824526	PNMT	-0.51	-5.48	-0.34	1.09e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs2839186	0.585	rs2839154	chr21:47637760	C/T	cg11766577	chr21:47581405	C21orf56	0.4	4.83	0.3	2.53e-6	Testicular germ cell tumor;
SARC	cis	rs763121	1.000	rs138457	chr22:38898051	T/C	cg21395723	chr22:39101663	GTPBP1	-0.51	-6.19	-0.38	2.62e-9	Menopause (age at onset);
SARC	cis	rs1707322	0.721	rs12069121	chr1:46231984	G/A	cg03146154	chr1:46216737	IPP	0.5	5.91	0.36	1.19e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9840812	0.592	rs35418151	chr3:136162621	A/C	cg15507776	chr3:136538369	TMEM22	0.48	5.54	0.34	8.01e-8	Fibrinogen levels;
SARC	cis	rs477692	0.673	rs579952	chr10:131356084	A/T	cg05714579	chr10:131428358	MGMT	-0.55	-7.18	-0.43	9.07e-12	Response to temozolomide;
SARC	cis	rs76419734	1.000	rs11736859	chr4:106708785	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.8	5.36	0.33	2.02e-7	Post bronchodilator FEV1;
SARC	cis	rs9420	0.961	rs77993055	chr11:57522840	C/T	cg19752551	chr11:57585705	CTNND1	-0.52	-7.19	-0.43	8.7e-12	Schizophrenia;
SARC	cis	rs981844	0.735	rs17371573	chr4:154765216	G/A	cg14289246	chr4:154710475	SFRP2	0.62	7.05	0.42	2.05e-11	Response to statins (LDL cholesterol change);
SARC	cis	rs2486288	0.656	rs12915314	chr15:45551491	C/G	cg15395560	chr15:45543142	SLC28A2	0.29	5.63	0.35	5.17e-8	Glomerular filtration rate;
SARC	cis	rs73195822	0.614	rs56259130	chr12:111225650	C/T	cg10860002	chr12:110842031	ANAPC7	0.58	5.05	0.31	8.84e-7	Itch intensity from mosquito bite;
SARC	cis	rs4423214	0.802	rs4616066	chr11:71183846	G/A	cg05163923	chr11:71159392	DHCR7	-0.6	-7.21	-0.43	7.58e-12	Vitamin D levels;
SARC	cis	rs4430311	0.688	rs4658590	chr1:243908796	A/T	cg21452805	chr1:244014465	NA	-0.41	-5.46	-0.34	1.2e-7	Post-traumatic stress disorder (asjusted for relatedness);
SARC	cis	rs7613875	0.654	rs3774751	chr3:50209053	G/T	cg24110177	chr3:50126178	RBM5	0.42	5.37	0.33	1.91e-7	Body mass index;
SARC	cis	rs861020	1.000	rs680923	chr1:209986672	T/C	cg05527609	chr1:210001259	C1orf107	0.96	11.13	0.59	2.38e-23	Orofacial clefts;
SARC	cis	rs11792861	0.566	rs67780641	chr9:111850710	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.44	5.45	0.34	1.28e-7	Menarche (age at onset);
SARC	cis	rs9911578	0.835	rs1990008	chr17:56459408	C/G	cg05425664	chr17:57184151	TRIM37	0.68	8.4	0.48	4.38e-15	Intelligence (multi-trait analysis);
SARC	cis	rs12971120	0.891	rs12605820	chr18:72167802	G/A	cg26446133	chr18:72167187	CNDP2	-0.51	-7.27	-0.43	5.35e-12	Refractive error;
SARC	cis	rs11209002	0.524	rs2815386	chr1:67541996	A/G	cg02640540	chr1:67518911	SLC35D1	0.59	6.66	0.4	1.99e-10	Crohn's disease;
SARC	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg03806693	chr22:41940476	POLR3H	-0.95	-13.28	-0.66	2.49e-30	Vitiligo;
SARC	cis	rs7659604	0.540	rs34445121	chr4:122710889	G/A	cg19671926	chr4:122722719	EXOSC9	0.67	8.6	0.49	1.22e-15	Type 2 diabetes;
SARC	cis	rs17854409	0.881	rs68091818	chr20:61479882	A/C	cg07645718	chr20:61493192	TCFL5	0.72	4.93	0.31	1.57e-6	Obesity-related traits;
SARC	cis	rs17376456	1.000	rs34854140	chr5:93538169	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.45	0.34	1.27e-7	Diabetic retinopathy;
SARC	cis	rs7568458	0.837	rs6547624	chr2:85802134	A/T	cg17127132	chr2:85788382	GGCX	0.44	5.81	0.36	2.02e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs9399135	0.967	rs9389261	chr6:135371148	C/G	cg22676075	chr6:135203613	NA	0.34	4.75	0.3	3.59e-6	Red blood cell count;
SARC	trans	rs11098499	0.866	rs3756156	chr4:120524841	G/A	cg25214090	chr10:38739885	LOC399744	0.51	6.69	0.4	1.61e-10	Corneal astigmatism;
SARC	cis	rs6964587	0.839	rs6952459	chr7:91435820	T/A	cg17063962	chr7:91808500	NA	0.82	11.52	0.6	1.38e-24	Breast cancer;
SARC	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg22920501	chr2:26401640	FAM59B	-0.61	-8.19	-0.47	1.71e-14	Gut microbiome composition (summer);
SARC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg11494091	chr17:61959527	GH2	0.53	7.87	0.46	1.34e-13	Prudent dietary pattern;
SARC	cis	rs7589342	0.894	rs7557976	chr2:106435061	C/A	cg14210321	chr2:106509881	NCK2	-0.46	-5.36	-0.33	2e-7	Addiction;
SARC	cis	rs17376456	1.000	rs34756085	chr5:93556294	A/G	cg21475434	chr5:93447410	FAM172A	0.92	7.81	0.46	1.91e-13	Diabetic retinopathy;
SARC	cis	rs6901004	0.803	rs354545	chr6:111531412	G/A	cg15721981	chr6:111408429	SLC16A10	-0.45	-5.47	-0.34	1.17e-7	Blood metabolite levels;
SARC	cis	rs6142102	0.812	rs6059578	chr20:32527706	G/C	cg24642439	chr20:33292090	TP53INP2	0.45	4.85	0.3	2.27e-6	Skin pigmentation;
SARC	cis	rs208520	0.634	rs3909071	chr6:66836947	T/C	cg07460842	chr6:66804631	NA	-1.05	-14.45	-0.69	3.33e-34	Exhaled nitric oxide output;
SARC	cis	rs17539620	0.624	rs62432736	chr6:154834401	A/G	cg20019720	chr6:154832845	CNKSR3	0.42	4.9	0.31	1.83e-6	Lipoprotein (a) levels;
SARC	cis	rs3796352	0.892	rs9756317	chr3:53088815	T/C	cg27565382	chr3:53032988	SFMBT1	-0.73	-5.68	-0.35	4.04e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs9309473	1.000	rs11893881	chr2:73824373	T/A	cg20560298	chr2:73613845	ALMS1	-0.49	-5.89	-0.36	1.31e-8	Metabolite levels;
SARC	trans	rs7824557	0.872	rs2572431	chr8:11105077	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.28	-0.38	1.62e-9	Retinal vascular caliber;
SARC	cis	rs36051895	0.659	rs3780367	chr9:5068755	T/G	cg02405213	chr9:5042618	JAK2	-0.46	-5.29	-0.33	2.76e-7	Pediatric autoimmune diseases;
SARC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg05165339	chr4:1420672	NA	-0.25	-5.4	-0.33	1.65e-7	Longevity;
SARC	cis	rs2204008	0.682	rs2320517	chr12:38259239	A/T	cg26384229	chr12:38710491	ALG10B	0.91	13.64	0.67	1.61e-31	Bladder cancer;
SARC	cis	rs11711311	0.955	rs9851812	chr3:113412362	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	8.25	0.48	1.17e-14	IgG glycosylation;
SARC	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg16414030	chr3:133502952	NA	-0.47	-6.32	-0.38	1.28e-9	Iron status biomarkers;
SARC	trans	rs360488	0.607	rs11890305	chr2:14263148	A/G	cg13543375	chr1:22470218	WNT4	0.59	6.45	0.39	6.24e-10	Emphysema imaging phenotypes;
SARC	cis	rs11676348	0.772	rs11687200	chr2:218944615	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.42	-5.36	-0.33	2.02e-7	Ulcerative colitis;
SARC	cis	rs7959452	0.868	rs10784774	chr12:69737879	C/T	cg22834771	chr12:69754056	YEATS4	0.41	5.4	0.33	1.66e-7	Blood protein levels;
SARC	trans	rs1945213	0.694	rs1384088	chr11:55848713	G/C	cg15704280	chr7:45808275	SEPT13	-0.64	-6.71	-0.4	1.5e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs739401	0.611	rs391188	chr11:3047634	G/A	cg20651018	chr11:3035856	CARS	-0.49	-7.76	-0.45	2.7e-13	Longevity;
SARC	cis	rs2120019	0.935	rs8043181	chr15:75380424	T/C	cg00629941	chr15:75287862	SCAMP5	-0.59	-7.07	-0.42	1.84e-11	Blood trace element (Zn levels);
SARC	cis	rs7647973	0.925	rs6808036	chr3:49236439	T/G	cg07636037	chr3:49044803	WDR6	0.8	9.19	0.52	2.19e-17	Menarche (age at onset);
SARC	cis	rs3733585	0.699	rs6449174	chr4:9966422	C/T	cg00071950	chr4:10020882	SLC2A9	-0.38	-5.91	-0.36	1.19e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs11098499	0.954	rs6834796	chr4:120414693	A/C	cg24375607	chr4:120327624	NA	0.41	4.86	0.3	2.12e-6	Corneal astigmatism;
SARC	cis	rs12973672	1.000	rs10414846	chr19:35772471	A/G	cg12095397	chr19:35769544	USF2	-0.38	-4.86	-0.3	2.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9790314	1.000	rs4370045	chr3:160943865	A/G	cg03342759	chr3:160939853	NMD3	-0.61	-7.78	-0.45	2.38e-13	Morning vs. evening chronotype;
SARC	cis	rs2120243	0.592	rs28638274	chr3:157124479	C/T	cg24825693	chr3:157122686	VEPH1	-0.43	-5.86	-0.36	1.57e-8	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs734999	0.588	rs745367	chr1:2524457	T/C	cg18854424	chr1:2615690	NA	0.33	5.22	0.32	3.88e-7	Ulcerative colitis;
SARC	trans	rs1994135	0.715	rs10844625	chr12:33693006	C/T	cg26384229	chr12:38710491	ALG10B	0.68	8.17	0.47	2e-14	Resting heart rate;
SARC	cis	rs6582630	0.539	rs35114325	chr12:38320886	G/T	cg14851346	chr12:38532713	NA	-0.48	-5.65	-0.35	4.71e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs473651	0.935	rs541128	chr2:239336449	A/G	cg21699342	chr2:239360505	ASB1	0.48	6.94	0.41	3.85e-11	Multiple system atrophy;
SARC	cis	rs412050	1.000	rs412050	chr22:22307519	C/G	cg17089214	chr22:22089827	YPEL1	0.55	5.34	0.33	2.19e-7	Attention deficit hyperactivity disorder;
SARC	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg12463550	chr7:65579703	CRCP	-0.47	-5.03	-0.31	9.64e-7	Aortic root size;
SARC	cis	rs11587400	0.532	rs2268700	chr1:115228879	T/G	cg12756093	chr1:115239321	AMPD1	-0.39	-4.91	-0.31	1.71e-6	Autism;
SARC	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.59e-6	Depression;
SARC	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg13939156	chr17:80058883	NA	-0.4	-6.27	-0.38	1.77e-9	Life satisfaction;
SARC	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg05025164	chr4:1340916	KIAA1530	-0.74	-9.0	-0.51	7.99e-17	Longevity;
SARC	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg19552044	chr7:124570047	POT1	-0.52	-6.5	-0.39	4.96e-10	Parental extreme longevity (95 years and older);
SARC	cis	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg23404562	chr10:115615082	NHLRC2;DCLRE1A	0.39	4.79	0.3	2.96e-6	Breast cancer;
SARC	cis	rs2859741	1.000	rs4653239	chr1:37509872	C/G	cg09363841	chr1:37513479	NA	0.27	4.76	0.3	3.41e-6	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
SARC	cis	rs11874712	1.000	rs7244950	chr18:43676523	G/C	cg25174615	chr18:43684699	ATP5A1;HAUS1	0.4	4.77	0.3	3.31e-6	Migraine - clinic-based;
SARC	cis	rs931127	0.505	rs2306362	chr11:65405510	G/T	cg27068330	chr11:65405492	SIPA1	-0.5	-5.89	-0.36	1.33e-8	Systemic lupus erythematosus;
SARC	cis	rs6466055	0.748	rs9640686	chr7:104867330	T/G	cg04380332	chr7:105027541	SRPK2	0.4	4.73	0.3	3.92e-6	Schizophrenia;
SARC	cis	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg22857025	chr5:266934	NA	-1.06	-11.8	-0.61	1.74e-25	Breast cancer;
SARC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg06873352	chr17:61820015	STRADA	0.53	6.93	0.41	3.99e-11	Prudent dietary pattern;
SARC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg06873352	chr17:61820015	STRADA	0.52	6.76	0.41	1.09e-10	Prudent dietary pattern;
SARC	trans	rs9395865	0.520	rs6903708	chr6:53332940	A/G	cg18706864	chr14:51134552	SAV1	-0.5	-6.32	-0.38	1.32e-9	Electroencephalographic traits in alcoholism;
SARC	cis	rs7481584	0.624	rs2106229	chr11:3041195	G/A	cg20651018	chr11:3035856	CARS	0.41	5.92	0.36	1.16e-8	Calcium levels;
SARC	cis	rs763014	0.898	rs2017567	chr16:637212	T/C	cg00908189	chr16:619842	PIGQ	0.84	12.18	0.62	1.02e-26	Height;
SARC	cis	rs17023223	0.537	rs12086686	chr1:119689084	T/A	cg05756136	chr1:119680316	WARS2	-0.48	-5.55	-0.34	7.84e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg18402987	chr7:1209562	NA	0.41	5.15	0.32	5.57e-7	Longevity;Endometriosis;
SARC	cis	rs13191362	1.000	rs13207671	chr6:162979056	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.56	5.37	0.33	1.89e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs9875589	0.509	rs6778884	chr3:14044681	A/G	cg19554555	chr3:13937349	NA	-0.41	-5.4	-0.33	1.64e-7	Ovarian reserve;
SARC	cis	rs1035144	0.510	rs12432357	chr14:81299468	A/G	cg06600135	chr14:81408086	NA	-0.53	-6.12	-0.37	3.85e-9	Male sexual orientation;
SARC	cis	rs6964587	0.869	rs4729010	chr7:91486751	G/A	cg17063962	chr7:91808500	NA	-0.89	-13.51	-0.66	4.14e-31	Breast cancer;
SARC	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg21724239	chr8:58056113	NA	0.6	6.37	0.38	1.03e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs2727020	0.755	rs652655	chr11:49251293	G/A	cg03929089	chr4:120376271	NA	0.77	11.39	0.6	3.47e-24	Coronary artery disease;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg13658921	chr2:136499517	UBXN4	0.48	6.47	0.39	5.87e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs6582630	0.555	rs11610015	chr12:38508856	A/G	cg13010199	chr12:38710504	ALG10B	0.74	10.24	0.56	1.43e-20	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs11122272	0.735	rs2808586	chr1:231515559	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs7429990	0.727	rs319695	chr3:47884239	T/C	cg27129171	chr3:47204927	SETD2	0.42	4.8	0.3	2.87e-6	Educational attainment (years of education);
SARC	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg25072359	chr17:41440525	NA	0.51	6.11	0.37	4.18e-9	Menopause (age at onset);
SARC	cis	rs7520050	0.931	rs7526678	chr1:46374159	A/G	cg06784218	chr1:46089804	CCDC17	-0.26	-4.79	-0.3	2.97e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs3768617	0.510	rs10752900	chr1:183086238	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.11	0.55	3.69e-20	Fuchs's corneal dystrophy;
SARC	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.62	-7.67	-0.45	4.56e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	9.33	0.52	8.41e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs907683	0.584	rs1058284	chr2:220286142	G/A	cg15015639	chr2:220282977	DES	-0.37	-5.85	-0.36	1.65e-8	Resting heart rate;
SARC	cis	rs2916247	0.954	rs4458918	chr8:93076553	C/T	cg10183463	chr8:93005414	RUNX1T1	0.65	6.77	0.41	1.02e-10	Intelligence (multi-trait analysis);
SARC	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg11764359	chr7:65958608	NA	0.61	7.18	0.43	9.56e-12	Aortic root size;
SARC	cis	rs6831352	0.918	rs1042364	chr4:100045574	T/C	cg12011299	chr4:100065546	ADH4	0.34	5.64	0.35	4.82e-8	Alcohol dependence;
SARC	cis	rs7772486	0.754	rs9390358	chr6:146145678	C/T	cg23711669	chr6:146136114	FBXO30	0.85	14.38	0.69	5.7e-34	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12311304	0.932	rs961176	chr12:15375619	A/C	cg08258403	chr12:15378311	NA	0.5	7.37	0.43	2.94e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs705471	0.966	rs705469	chr10:3658919	T/C	cg14308648	chr10:3568949	NA	0.51	6.69	0.4	1.67e-10	Capecitabine sensitivity;
SARC	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg05368731	chr17:41323189	NBR1	0.8	9.67	0.54	8.15e-19	Menopause (age at onset);
SARC	cis	rs807669	0.835	rs1780639	chr22:19174603	T/C	cg02655711	chr22:19163373	SLC25A1	0.55	7.49	0.44	1.44e-12	Metabolite levels;
SARC	cis	rs61826828	1	rs61826828	chr1:174015261	A/G	cg00981945	chr1:173977793	NA	-0.41	-5.13	-0.32	6.13e-7	Schizophrenia;
SARC	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg12463550	chr7:65579703	CRCP	0.5	5.93	0.36	1.09e-8	Aortic root size;
SARC	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.39	-4.86	-0.3	2.17e-6	Lymphocyte counts;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg25757737	chr3:47423140	PTPN23	0.53	6.48	0.39	5.44e-10	Breast cancer;
SARC	cis	rs2016266	0.859	rs7953656	chr12:53738433	G/T	cg26875137	chr12:53738046	NA	0.42	5.13	0.32	6.2e-7	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs2908197	0.699	rs2908191	chr7:75962322	A/G	cg24580635	chr7:76178542	LOC100133091	-0.41	-4.85	-0.3	2.22e-6	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg05025164	chr4:1340916	KIAA1530	-0.45	-5.23	-0.32	3.69e-7	Obesity-related traits;
SARC	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg11062466	chr8:58055876	NA	0.61	5.75	0.35	2.74e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9325144	0.560	rs6582539	chr12:38630097	C/T	cg13010199	chr12:38710504	ALG10B	-0.57	-7.31	-0.43	4.38e-12	Morning vs. evening chronotype;
SARC	trans	rs10209086	0.736	rs1584436	chr2:138298878	A/G	cg02099053	chr1:110880516	RBM15	-0.45	-6.26	-0.38	1.83e-9	Multiple system atrophy;
SARC	cis	rs6568686	0.730	rs56300817	chr6:111785030	A/T	cg15721981	chr6:111408429	SLC16A10	0.65	5.64	0.35	4.87e-8	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs7566780	0.568	rs6531130	chr2:16629415	C/T	cg09580478	chr2:16689509	NA	-0.46	-4.99	-0.31	1.17e-6	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs11168351	0.517	rs10875754	chr12:48557922	G/C	cg24011408	chr12:48396354	COL2A1	0.46	6.41	0.39	8.18e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs9916302	0.904	rs11867312	chr17:37597748	C/T	cg00129232	chr17:37814104	STARD3	-0.62	-7.65	-0.45	5.14e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs3008870	0.755	rs2815349	chr1:67472280	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.59	7.6	0.45	7e-13	Lymphocyte percentage of white cells;
SARC	cis	rs2832191	0.647	rs11170	chr21:30378090	C/T	cg24692254	chr21:30365293	RNF160	0.99	16.92	0.74	1.97e-42	Dental caries;
SARC	cis	rs13082711	0.863	rs35998108	chr3:27423427	G/A	cg02860705	chr3:27208620	NA	0.46	6.13	0.37	3.76e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs9733	0.596	rs7412396	chr1:150666797	C/T	cg15448220	chr1:150897856	SETDB1	0.46	5.16	0.32	5.33e-7	Tonsillectomy;
SARC	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg17971929	chr21:40555470	PSMG1	-0.86	-11.56	-0.6	9.68e-25	Cognitive function;
SARC	cis	rs9467773	1.000	rs9393728	chr6:26509330	C/G	cg11502198	chr6:26597334	ABT1	0.48	5.98	0.36	8.37e-9	Intelligence (multi-trait analysis);
SARC	trans	rs459571	0.959	rs456205	chr9:136911146	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.62	-7.11	-0.42	1.44e-11	Platelet distribution width;
SARC	trans	rs12310956	0.510	rs1565026	chr12:33887499	A/G	cg26384229	chr12:38710491	ALG10B	0.62	8.19	0.47	1.68e-14	Morning vs. evening chronotype;
SARC	cis	rs911263	0.603	rs1956528	chr14:68788968	C/T	cg18825221	chr14:68749962	RAD51L1	-0.43	-7.6	-0.45	6.99e-13	Primary biliary cholangitis;
SARC	cis	rs10876993	0.928	rs1689594	chr12:58057156	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.47	-5.93	-0.36	1.08e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs4555082	0.834	rs2816607	chr14:105718385	A/T	cg06808227	chr14:105710500	BRF1	-0.51	-6.41	-0.39	8.22e-10	Mean platelet volume;Platelet distribution width;
SARC	cis	rs2854207	0.505	rs2466957	chr17:61961230	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.53	-5.61	-0.35	5.63e-8	Height;
SARC	cis	rs477895	1.000	rs477895	chr11:64048912	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.61	-5.69	-0.35	3.85e-8	Mean platelet volume;
SARC	cis	rs992157	0.710	rs6719789	chr2:219057810	G/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.64	-9.27	-0.52	1.31e-17	Colorectal cancer;
SARC	cis	rs760805	0.965	rs11249203	chr1:25258585	G/C	cg22509179	chr1:25234806	RUNX3	-0.5	-6.96	-0.42	3.36e-11	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs9486719	1.000	rs12197411	chr6:97039621	G/A	cg06623918	chr6:96969491	KIAA0776	-0.79	-8.88	-0.5	1.86e-16	Migraine;Coronary artery disease;
SARC	cis	rs3768617	0.510	rs2296291	chr1:183079509	C/T	cg13390022	chr1:182993471	LAMC1	0.32	4.88	0.3	1.95e-6	Fuchs's corneal dystrophy;
SARC	cis	rs9341808	0.905	rs3805903	chr6:80975829	T/C	cg08355045	chr6:80787529	NA	0.36	6.02	0.37	6.58e-9	Sitting height ratio;
SARC	cis	rs57994353	0.598	rs72775768	chr9:139324574	C/T	cg14169450	chr9:139327907	INPP5E	0.47	6.06	0.37	5.4e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs5769765	1.000	rs5770741	chr22:50270215	A/G	cg03033257	chr22:50311977	ALG12;CRELD2	-0.54	-5.64	-0.35	4.81e-8	Schizophrenia;
SARC	cis	rs4689388	0.782	rs4262051	chr4:6281775	G/A	cg00701064	chr4:6280414	WFS1	0.56	8.61	0.49	1.1e-15	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	trans	rs2727020	0.556	rs2866365	chr11:49390731	A/G	cg03929089	chr4:120376271	NA	-0.7	-7.6	-0.45	7.29e-13	Coronary artery disease;
SARC	cis	rs6866344	0.569	rs56070635	chr5:178150169	A/C	cg03877680	chr5:178157825	ZNF354A	1.1	14.63	0.69	8.3e-35	Neutrophil percentage of white cells;
SARC	cis	rs763014	0.838	rs4984670	chr16:641044	A/G	cg00908189	chr16:619842	PIGQ	0.83	12.0	0.62	3.89e-26	Height;
SARC	cis	rs2370759	1.000	rs79806114	chr10:32618022	T/C	cg05361325	chr10:32636312	EPC1	-0.77	-6.85	-0.41	6.33e-11	Sexual dysfunction (female);
SARC	cis	rs11583043	1.000	rs7541397	chr1:101322866	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.45	-5.5	-0.34	1e-7	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs8054556	0.787	rs35105141	chr16:30057148	C/T	cg06015834	chr16:30021696	DOC2A	-0.37	-4.96	-0.31	1.36e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs523522	0.962	rs2233676	chr12:120933607	G/A	cg12219531	chr12:120966889	COQ5	0.83	11.18	0.59	1.61e-23	High light scatter reticulocyte count;
SARC	trans	rs1814175	0.791	rs10769593	chr11:49616217	T/C	cg15704280	chr7:45808275	SEPT13	-0.94	-16.44	-0.73	7.97e-41	Height;
SARC	cis	rs8017423	0.935	rs11621820	chr14:90727154	C/T	cg20276874	chr14:90721474	PSMC1	-0.39	-5.4	-0.33	1.64e-7	Mortality in heart failure;
SARC	cis	rs6138458	1.000	rs227630	chr20:24913584	A/G	cg26195577	chr20:24973756	C20orf3	0.88	9.9	0.54	1.69e-19	Blood protein levels;
SARC	cis	rs986417	0.792	rs4901990	chr14:61015474	C/T	cg27398547	chr14:60952738	C14orf39	-0.98	-7.88	-0.46	1.22e-13	Gut microbiota (bacterial taxa);
SARC	cis	rs7666738	0.657	rs13102002	chr4:98617794	T/C	cg05340658	chr4:99064831	C4orf37	0.5	5.3	0.33	2.69e-7	Colonoscopy-negative controls vs population controls;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg27517446	chr7:112506990	C7orf60	0.44	6.28	0.38	1.66e-9	Thyroid stimulating hormone;
SARC	cis	rs7666738	0.830	rs60391193	chr4:98933912	T/G	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs3213545	0.659	rs2259693	chr12:121457995	G/A	cg25281562	chr12:121454272	C12orf43	0.5	6.29	0.38	1.56e-9	Subjective well-being;Cardiovascular disease risk factors;
SARC	cis	rs9581857	0.547	rs75800999	chr13:28055293	A/G	cg01674679	chr13:27998804	GTF3A	-0.66	-5.0	-0.31	1.11e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	cis	rs6580649	0.941	rs1793933	chr12:48396450	G/T	cg24011408	chr12:48396354	COL2A1	0.65	7.23	0.43	6.92e-12	Lung cancer;
SARC	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg11764359	chr7:65958608	NA	0.63	7.22	0.43	7.29e-12	Aortic root size;
SARC	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg00933542	chr6:150070202	PCMT1	0.33	5.7	0.35	3.7e-8	Lung cancer;
SARC	cis	rs1594829	0.535	rs11784209	chr8:26170246	T/C	cg11498726	chr8:26250323	BNIP3L	-0.42	-5.5	-0.34	9.75e-8	Height;
SARC	cis	rs3796352	1.000	rs11713290	chr3:52971579	G/A	cg12962167	chr3:53033115	SFMBT1	0.75	4.9	0.31	1.8e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs9400467	0.506	rs76110409	chr6:111603132	C/A	cg15721981	chr6:111408429	SLC16A10	0.68	5.84	0.36	1.71e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs1008375	1.000	rs2872958	chr4:17665032	A/G	cg16339924	chr4:17578868	LAP3	0.63	8.21	0.47	1.51e-14	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.79	-8.47	-0.49	2.86e-15	Alzheimer's disease;
SARC	cis	rs7647973	0.626	rs11709734	chr3:49745235	G/A	cg13072238	chr3:49761600	GMPPB	-0.61	-6.34	-0.38	1.19e-9	Menarche (age at onset);
SARC	cis	rs478304	0.654	rs10896035	chr11:65461160	G/A	cg27068330	chr11:65405492	SIPA1	-0.41	-4.76	-0.3	3.47e-6	Acne (severe);
SARC	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	5.45	0.34	1.3e-7	Bipolar disorder;
SARC	cis	rs35110281	0.693	rs11089093	chr21:45121161	C/T	cg21573476	chr21:45109991	RRP1B	-0.58	-8.22	-0.47	1.46e-14	Mean corpuscular volume;
SARC	cis	rs9291683	0.679	rs2278122	chr4:10096241	T/A	cg00071950	chr4:10020882	SLC2A9	-0.32	-4.86	-0.3	2.2e-6	Bone mineral density;
SARC	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	14.89	0.7	1.14e-35	Chronic sinus infection;
SARC	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg13012494	chr21:47604986	C21orf56	0.46	5.32	0.33	2.47e-7	Testicular germ cell tumor;
SARC	cis	rs2486288	0.656	rs11632419	chr15:45557456	C/A	cg21132104	chr15:45694354	SPATA5L1	-0.49	-6.21	-0.38	2.45e-9	Glomerular filtration rate;
SARC	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg16680214	chr1:154839983	KCNN3	0.36	5.67	0.35	4.11e-8	Prostate cancer;
SARC	cis	rs6089584	0.927	rs6089593	chr20:60572312	G/A	cg13770153	chr20:60521292	NA	-0.54	-7.59	-0.45	7.83e-13	Body mass index;
SARC	cis	rs9527	0.615	rs4917991	chr10:104783833	T/C	cg04362960	chr10:104952993	NT5C2	0.45	5.39	0.33	1.72e-7	Arsenic metabolism;
SARC	trans	rs208515	0.525	rs1351866	chr6:66696969	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.99	11.49	0.6	1.62e-24	Exhaled nitric oxide levels;
SARC	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg18876405	chr7:65276391	NA	-0.43	-4.72	-0.3	4.07e-6	Aortic root size;
SARC	cis	rs9398803	0.678	rs1155938	chr6:126866472	C/A	cg20229609	chr6:126660872	C6orf173	0.39	5.52	0.34	8.82e-8	Male-pattern baldness;
SARC	cis	rs1559088	1.000	rs7260051	chr19:33550111	C/A	cg17764715	chr19:33622953	WDR88	0.48	6.25	0.38	1.95e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs4481887	0.927	rs12042598	chr1:248482016	C/T	cg13385794	chr1:248469461	NA	0.35	5.29	0.33	2.83e-7	Common traits (Other);
SARC	cis	rs6835098	0.924	rs7672108	chr4:174165126	A/G	cg08422745	chr4:174089978	GALNT7	0.62	8.31	0.48	8.01e-15	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs10191773	0.535	rs72833432	chr2:113102746	T/C	cg07905836	chr2:113190072	RGPD8;RGPD5	0.92	8.62	0.49	1.01e-15	Yeast infection;
SARC	cis	rs6582630	0.519	rs80226845	chr12:38528231	C/A	cg13010199	chr12:38710504	ALG10B	0.76	10.6	0.57	1.08e-21	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs8014204	0.836	rs7153700	chr14:75268544	C/T	cg06637938	chr14:75390232	RPS6KL1	0.69	9.91	0.54	1.54e-19	Caffeine consumption;
SARC	cis	rs6690583	0.623	rs898036	chr1:85521904	A/T	cg22153463	chr1:85462885	MCOLN2	0.68	5.05	0.31	9.03e-7	Serum sulfate level;
SARC	cis	rs8067545	0.641	rs203458	chr17:19816898	A/C	cg04132472	chr17:19861366	AKAP10	0.38	4.99	0.31	1.17e-6	Schizophrenia;
SARC	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg03351412	chr1:154909251	PMVK	0.59	7.27	0.43	5.26e-12	Prostate cancer;
SARC	cis	rs6977660	0.714	rs12700075	chr7:19791476	G/T	cg07541023	chr7:19748670	TWISTNB	0.75	6.97	0.42	3.32e-11	Thyroid stimulating hormone;
SARC	trans	rs1814175	0.791	rs1722011	chr11:49899340	G/C	cg03929089	chr4:120376271	NA	-0.88	-13.98	-0.68	1.18e-32	Height;
SARC	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg11764359	chr7:65958608	NA	-0.79	-9.74	-0.54	5.08e-19	Aortic root size;
SARC	cis	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg20965017	chr5:231967	SDHA	-0.57	-5.86	-0.36	1.6e-8	Breast cancer;
SARC	cis	rs6540556	0.682	rs932335	chr1:209905734	G/C	cg05527609	chr1:210001259	C1orf107	-0.63	-5.84	-0.36	1.7e-8	Red blood cell count;
SARC	cis	rs7523050	0.643	rs35662800	chr1:109400816	C/A	cg08274380	chr1:109419600	GPSM2	1.07	8.3	0.48	8.22e-15	Fat distribution (HIV);
SARC	cis	rs7179456	0.654	rs10162914	chr15:59253792	T/C	cg05156742	chr15:59063176	FAM63B	-0.57	-7.31	-0.43	4.12e-12	Asperger disorder;
SARC	cis	rs77633900	0.614	rs2468122	chr15:76918686	A/C	cg21673338	chr15:77095150	SCAPER	-0.74	-6.22	-0.38	2.25e-9	Non-glioblastoma glioma;Glioma;
SARC	cis	rs7216064	1.000	rs9913471	chr17:65874495	C/T	cg12091567	chr17:66097778	LOC651250	-0.7	-7.64	-0.45	5.5e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg17260001	chr11:65627869	MUS81	0.5	6.41	0.39	7.86e-10	Electrocardiographic conduction measures;
SARC	trans	rs61931739	0.500	rs7313094	chr12:34457508	T/C	cg26384229	chr12:38710491	ALG10B	0.84	12.51	0.63	8.09e-28	Morning vs. evening chronotype;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg26705425	chr19:54024076	ZNF331	-0.51	-6.68	-0.4	1.71e-10	Tetralogy of Fallot;
SARC	trans	rs2727020	0.658	rs1851992	chr11:49438110	C/T	cg03929089	chr4:120376271	NA	-0.79	-11.77	-0.61	2.09e-25	Coronary artery disease;
SARC	cis	rs7666738	0.830	rs10017201	chr4:98983561	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7937682	0.921	rs11213940	chr11:111433927	C/A	cg22437258	chr11:111473054	SIK2	-0.7	-9.03	-0.51	6.68e-17	Primary sclerosing cholangitis;
SARC	cis	rs2072499	0.750	rs2241109	chr1:156173082	C/T	cg25208724	chr1:156163844	SLC25A44	0.86	9.9	0.54	1.64e-19	Testicular germ cell tumor;
SARC	cis	rs1355223	0.506	rs7130678	chr11:34869181	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.49	-6.32	-0.38	1.3e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs3126085	0.825	rs7535078	chr1:152222915	T/C	cg03465714	chr1:152285911	FLG	-0.45	-5.51	-0.34	9.51e-8	Atopic dermatitis;
SARC	cis	rs77372450	0.636	rs6556089	chr5:157000854	C/G	cg23851860	chr5:157002805	ADAM19	0.51	4.85	0.3	2.24e-6	Bipolar disorder (body mass index interaction);
SARC	cis	rs6570726	0.791	rs383841	chr6:145888329	G/T	cg23711669	chr6:146136114	FBXO30	-0.87	-14.04	-0.68	7.3e-33	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1050631	0.592	rs1785909	chr18:33731173	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.55	6.41	0.39	8.08e-10	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs240764	0.621	rs9404052	chr6:101249718	T/C	cg09795085	chr6:101329169	ASCC3	-0.44	-5.67	-0.35	4.21e-8	Neuroticism;
SARC	trans	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg00938859	chr5:1591904	SDHAP3	0.79	7.59	0.45	7.5e-13	Breast cancer;
SARC	cis	rs9911578	1.000	rs4398153	chr17:56968181	T/C	cg05425664	chr17:57184151	TRIM37	0.68	8.48	0.49	2.54e-15	Intelligence (multi-trait analysis);
SARC	cis	rs2191566	0.614	rs396497	chr19:44494430	A/T	cg20607764	chr19:44506953	ZNF230	-0.51	-6.01	-0.37	7.18e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs11792861	0.816	rs11790105	chr9:111731785	T/C	cg13535736	chr9:111863775	C9orf5	-0.38	-4.78	-0.3	3.14e-6	Menarche (age at onset);
SARC	cis	rs7598759	0.712	rs12991636	chr2:232333666	T/C	cg19187155	chr2:232395269	NMUR1	0.58	8.23	0.47	1.33e-14	Noise-induced hearing loss;
SARC	cis	rs2011503	1.000	rs78883953	chr19:19630002	G/A	cg15839431	chr19:19639596	YJEFN3	-0.48	-4.77	-0.3	3.32e-6	Bipolar disorder;
SARC	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.98	13.7	0.67	9.81e-32	Platelet count;
SARC	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg11764359	chr7:65958608	NA	-0.79	-9.79	-0.54	3.48e-19	Aortic root size;
SARC	cis	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.85	12.92	0.65	3.75e-29	Eosinophil percentage of white cells;
SARC	cis	rs7932354	0.528	rs11039107	chr11:47157866	G/A	cg03339077	chr11:47165057	C11orf49	0.41	5.66	0.35	4.37e-8	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs2084898	0.550	rs470411	chr11:120012390	G/C	cg07435449	chr11:120005650	TRIM29	0.45	6.58	0.4	3.08e-10	Stroke (pediatric);
SARC	cis	rs738322	0.555	rs731821	chr22:38559448	C/A	cg25457927	chr22:38595422	NA	-0.27	-5.13	-0.32	6e-7	Cutaneous nevi;
SARC	cis	rs11690935	0.959	rs67204065	chr2:172672624	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.95	-14.41	-0.69	4.52e-34	Schizophrenia;
SARC	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-5.94	-0.36	1.04e-8	Personality dimensions;
SARC	cis	rs2230307	0.656	rs12146139	chr1:100458417	G/A	cg24955406	chr1:100503596	HIAT1	0.68	5.68	0.35	3.94e-8	Carotid intima media thickness;
SARC	cis	rs12477438	0.871	rs62156364	chr2:99695097	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-8.48	-0.49	2.63e-15	Chronic sinus infection;
SARC	cis	rs72634258	0.554	rs4908704	chr1:7918904	A/G	cg00042356	chr1:8021962	PARK7	0.65	5.36	0.33	2.02e-7	Inflammatory bowel disease;
SARC	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.62	7.51	0.44	1.26e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs9532669	0.963	rs9532662	chr13:41500351	A/C	cg07169535	chr18:34408654	KIAA1328;C18orf10	0.5	6.54	0.39	3.75e-10	Cervical cancer;
SARC	cis	rs763121	0.849	rs12004	chr22:38877461	T/G	cg06022373	chr22:39101656	GTPBP1	0.91	11.51	0.6	1.43e-24	Menopause (age at onset);
SARC	cis	rs2204008	0.714	rs11520135	chr12:38114863	C/T	cg13010199	chr12:38710504	ALG10B	0.8	10.95	0.58	8.58e-23	Bladder cancer;
SARC	cis	rs16912285	0.688	rs11827298	chr11:24324000	G/A	ch.11.24196551F	chr11:24239977	NA	0.5	4.76	0.3	3.42e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs3857536	0.707	rs9345793	chr6:66929807	G/C	cg07460842	chr6:66804631	NA	-0.52	-5.88	-0.36	1.42e-8	Blood trace element (Cu levels);
SARC	cis	rs2916247	0.908	rs9657006	chr8:93178242	A/C	cg10183463	chr8:93005414	RUNX1T1	0.53	5.51	0.34	9.52e-8	Intelligence (multi-trait analysis);
SARC	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg16325326	chr1:53192061	ZYG11B	-0.71	-9.6	-0.53	1.38e-18	Monocyte count;
SARC	cis	rs1801251	1.000	rs283476	chr2:233650168	A/G	cg25237894	chr2:233734115	C2orf82	0.37	4.79	0.3	3e-6	Coronary artery disease;
SARC	cis	rs1008375	0.966	rs11737844	chr4:17697421	A/C	cg27347728	chr4:17578864	LAP3	0.44	5.67	0.35	4.13e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6831352	0.918	rs2851249	chr4:100044822	T/C	cg13256891	chr4:100009986	ADH5	0.66	8.38	0.48	4.94e-15	Alcohol dependence;
SARC	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg05368731	chr17:41323189	NBR1	0.8	9.58	0.53	1.58e-18	Menopause (age at onset);
SARC	cis	rs10911232	0.507	rs10911199	chr1:182998036	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.67	0.57	6.63e-22	Hypertriglyceridemia;
SARC	cis	rs2439831	0.867	rs2412778	chr15:43660982	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	10.73	0.58	4.29e-22	Lung cancer in ever smokers;
SARC	cis	rs7700895	0.737	rs6879652	chr5:95227462	T/C	cg16656078	chr5:95278638	ELL2	-0.54	-6.79	-0.41	9.14e-11	IgG glycosylation;
SARC	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg03264133	chr6:25882463	NA	0.51	6.67	0.4	1.83e-10	Blood metabolite levels;
SARC	cis	rs9640161	0.663	rs1916932	chr7:150021644	T/C	cg17279839	chr7:150038598	RARRES2	0.49	7.39	0.44	2.64e-12	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	10.84	0.58	2.01e-22	Alzheimer's disease;
SARC	cis	rs2806561	0.765	rs682766	chr1:23516397	C/G	cg12483005	chr1:23474871	LUZP1	0.45	5.9	0.36	1.3e-8	Height;
SARC	cis	rs943466	0.955	rs1887340	chr6:33730095	C/T	cg04676172	chr6:33757040	LEMD2	0.46	4.89	0.31	1.84e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
SARC	cis	rs965604	1.000	rs4887057	chr15:78760918	G/A	cg24631222	chr15:78858424	CHRNA5	0.46	5.96	0.36	9.31e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg27248073	chr17:6347727	FAM64A	0.47	6.24	0.38	2.04e-9	Chemerin levels;
SARC	cis	rs1468333	1.000	rs4835671	chr5:137511801	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.77	10.24	0.56	1.5e-20	Resting heart rate;
SARC	cis	rs2213920	0.679	rs6478168	chr9:118225951	A/T	cg13918206	chr9:118159781	DEC1	0.75	5.79	0.35	2.31e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg25036284	chr2:26402008	FAM59B	0.48	5.9	0.36	1.24e-8	Gut microbiome composition (summer);
SARC	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs11997175	0.545	rs5005657	chr8:33668913	C/G	ch.8.33884649F	chr8:33765107	NA	0.48	6.07	0.37	5.27e-9	Body mass index;
SARC	cis	rs9611519	1.000	rs4820433	chr22:41607065	C/G	cg17376030	chr22:41985996	PMM1	0.47	5.93	0.36	1.06e-8	Neuroticism;
SARC	cis	rs2153535	0.580	rs915350	chr6:8443486	A/G	cg07606381	chr6:8435919	SLC35B3	0.78	11.09	0.59	3.11e-23	Motion sickness;
SARC	cis	rs3768617	0.510	rs6424885	chr1:183066254	T/G	cg13390022	chr1:182993471	LAMC1	0.33	4.94	0.31	1.47e-6	Fuchs's corneal dystrophy;
SARC	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg12463550	chr7:65579703	CRCP	0.66	5.06	0.31	8.64e-7	Diabetic kidney disease;
SARC	cis	rs3126085	0.877	rs57597406	chr1:152246619	C/G	cg26876637	chr1:152193138	HRNR	0.45	5.21	0.32	4.07e-7	Atopic dermatitis;
SARC	cis	rs2933343	0.533	rs11915889	chr3:128700866	A/C	cg25356066	chr3:128598488	ACAD9	0.62	7.63	0.45	6.12e-13	IgG glycosylation;
SARC	cis	rs7666738	0.830	rs6819047	chr4:98866902	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.59	0.49	1.24e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6439153	0.933	rs900381	chr3:128713455	C/G	cg25356066	chr3:128598488	ACAD9	0.47	5.55	0.34	7.64e-8	Pneumococcal bacteremia;
SARC	cis	rs8141529	0.748	rs132528	chr22:29295898	C/T	cg02153584	chr22:29168773	CCDC117	-0.78	-11.26	-0.59	9.4e-24	Lymphocyte counts;
SARC	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.59e-6	Depression;
SARC	cis	rs1801251	0.778	rs2675957	chr2:233754364	C/T	cg25237894	chr2:233734115	C2orf82	-0.35	-4.99	-0.31	1.19e-6	Coronary artery disease;
SARC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg11965913	chr1:205819406	PM20D1	0.74	11.46	0.6	2.03e-24	Menarche (age at onset);
SARC	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg07636037	chr3:49044803	WDR6	0.99	17.47	0.75	3.09e-44	Parkinson's disease;
SARC	cis	rs459571	0.959	rs392134	chr9:136909008	G/A	cg01294253	chr9:136912663	BRD3	0.44	5.7	0.35	3.52e-8	Platelet distribution width;
SARC	cis	rs2011503	0.882	rs72999030	chr19:19364240	A/T	cg03709012	chr19:19516395	GATAD2A	0.59	5.4	0.33	1.63e-7	Bipolar disorder;
SARC	cis	rs9790314	1.000	rs7647327	chr3:161016421	T/C	cg04691961	chr3:161091175	C3orf57	-0.78	-11.34	-0.6	5.15e-24	Morning vs. evening chronotype;
SARC	cis	rs6121246	0.567	rs6058187	chr20:30190923	T/C	cg13852791	chr20:30311386	BCL2L1	0.68	5.91	0.36	1.2e-8	Mean corpuscular hemoglobin;
SARC	cis	rs9987353	0.566	rs6998368	chr8:9070288	G/C	cg06636001	chr8:8085503	FLJ10661	-0.6	-7.62	-0.45	6.5e-13	Recombination measurement;
SARC	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg13395646	chr4:1353034	KIAA1530	-0.56	-6.8	-0.41	8.58e-11	Obesity-related traits;
SARC	cis	rs8017423	0.935	rs8012299	chr14:90715822	G/T	cg20276874	chr14:90721474	PSMC1	-0.37	-5.09	-0.32	7.21e-7	Mortality in heart failure;
SARC	trans	rs61931739	0.534	rs11053073	chr12:34202412	C/T	cg26384229	chr12:38710491	ALG10B	0.84	12.1	0.62	1.76e-26	Morning vs. evening chronotype;
SARC	cis	rs9811216	1.000	rs9866776	chr3:169487651	C/A	cg14222479	chr3:169487675	ARPM1	0.44	5.29	0.33	2.86e-7	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg15049968	chr18:44337910	ST8SIA5	-0.35	-5.65	-0.35	4.75e-8	Personality dimensions;
SARC	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-7.47	-0.44	1.58e-12	Alzheimer's disease;
SARC	cis	rs9868809	0.772	rs2286651	chr3:48694147	G/A	cg07636037	chr3:49044803	WDR6	-0.72	-6.43	-0.39	7.21e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs1322639	0.614	rs7751131	chr6:169578710	G/A	cg03254818	chr6:169586852	NA	0.72	7.2	0.43	8.21e-12	Pulse pressure;
SARC	cis	rs3741404	0.560	rs7938819	chr11:63910116	G/A	cg04317338	chr11:64019027	PLCB3	-0.46	-5.52	-0.34	9.07e-8	Platelet count;
SARC	cis	rs6594499	0.872	rs7732974	chr5:110455381	T/C	cg04022379	chr5:110408740	TSLP	0.47	6.03	0.37	6.36e-9	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.39	5.34	0.33	2.2e-7	Personality dimensions;
SARC	cis	rs7481584	0.646	rs434114	chr11:3050210	A/G	cg05729581	chr11:3078854	CARS	0.57	7.4	0.44	2.45e-12	Calcium levels;
SARC	trans	rs7615952	0.932	rs9841157	chr3:125635655	C/A	cg07211511	chr3:129823064	LOC729375	-0.96	-10.53	-0.57	1.86e-21	Blood pressure (smoking interaction);
SARC	cis	rs6964587	0.626	rs10266424	chr7:91503228	C/T	cg17063962	chr7:91808500	NA	-0.77	-11.27	-0.59	8.67e-24	Breast cancer;
SARC	cis	rs9640161	0.702	rs11765692	chr7:150026567	C/T	cg10018233	chr7:150070692	REPIN1	0.69	9.35	0.52	7.41e-18	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs1983170	0.808	rs4658229	chr1:92019171	G/A	cg25838465	chr1:92012736	NA	0.44	5.29	0.33	2.86e-7	Eosinophil percentage of white cells;
SARC	cis	rs736408	0.608	rs4687657	chr3:52852538	G/T	cg18404041	chr3:52824283	ITIH1	-0.47	-6.0	-0.37	7.4e-9	Bipolar disorder;
SARC	cis	rs2120019	0.938	rs2120020	chr15:75316845	T/C	cg17294928	chr15:75287854	SCAMP5	-1.01	-15.23	-0.71	7.88e-37	Blood trace element (Zn levels);
SARC	cis	rs9302635	0.513	rs9923575	chr16:72230112	C/T	cg16558253	chr16:72132732	DHX38	-0.55	-6.38	-0.39	9.31e-10	Blood protein levels;
SARC	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	16.12	0.73	8.93e-40	Chronic sinus infection;
SARC	trans	rs208520	0.633	rs7738469	chr6:66807446	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.06	-14.37	-0.69	6.07e-34	Exhaled nitric oxide output;
SARC	cis	rs41278232	0.557	rs817343	chr20:62607160	C/T	cg07620230	chr20:62328084	TNFRSF6B	0.34	4.78	0.3	3.09e-6	Tonsillectomy;
SARC	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg11644478	chr21:40555479	PSMG1	-0.58	-7.06	-0.42	1.85e-11	Menarche (age at onset);
SARC	cis	rs7595412	1.000	rs7595412	chr2:198962243	C/T	cg00208931	chr2:198669586	PLCL1	-0.78	-5.95	-0.36	9.62e-9	Hip bone size;
SARC	cis	rs3008870	0.816	rs1118392	chr1:67366549	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.74	-9.89	-0.54	1.8e-19	Lymphocyte percentage of white cells;
SARC	trans	rs61931739	0.500	rs7306334	chr12:34482900	A/G	cg13010199	chr12:38710504	ALG10B	-0.81	-11.48	-0.6	1.8e-24	Morning vs. evening chronotype;
SARC	cis	rs67460515	0.506	rs935497	chr3:160600563	A/G	cg04691961	chr3:161091175	C3orf57	-0.43	-4.74	-0.3	3.73e-6	Parkinson's disease;
SARC	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg04166393	chr7:2884313	GNA12	0.67	8.33	0.48	6.83e-15	Height;
SARC	cis	rs9549367	0.713	rs11620600	chr13:113829090	G/A	cg18105134	chr13:113819100	PROZ	-0.49	-7.0	-0.42	2.72e-11	Platelet distribution width;
SARC	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg12463550	chr7:65579703	CRCP	0.5	5.9	0.36	1.27e-8	Aortic root size;
SARC	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg04772025	chr11:68637568	NA	0.55	7.0	0.42	2.72e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs8017423	0.967	rs6575120	chr14:90725094	C/T	cg20276874	chr14:90721474	PSMC1	-0.37	-5.14	-0.32	5.73e-7	Mortality in heart failure;
SARC	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg16680214	chr1:154839983	KCNN3	-0.37	-5.9	-0.36	1.27e-8	Prostate cancer;
SARC	cis	rs1865760	0.827	rs9461227	chr6:25960815	C/T	cg16482183	chr6:26056742	HIST1H1C	0.51	6.65	0.4	2.04e-10	Height;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg14430007	chr14:88851995	SPATA7	0.56	6.96	0.41	3.42e-11	Breast cancer;
SARC	cis	rs3762637	1.000	rs11932	chr3:122141135	A/G	cg24169773	chr3:122142474	KPNA1	0.58	6.14	0.37	3.62e-9	LDL cholesterol levels;
SARC	cis	rs6500602	0.647	rs4786501	chr16:4536165	G/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.32	-5.53	-0.34	8.72e-8	Schizophrenia;
SARC	cis	rs76419734	1.000	rs72671852	chr4:106646349	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.84	5.64	0.35	4.94e-8	Post bronchodilator FEV1;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg13660082	chr14:53194042	PSMC6	-0.52	-6.25	-0.38	1.98e-9	Alcohol dependence;
SARC	cis	rs611744	0.659	rs669584	chr8:109138107	G/A	cg21045802	chr8:109455806	TTC35	0.4	4.75	0.3	3.5e-6	Dupuytren's disease;
SARC	cis	rs3733585	0.753	rs12500805	chr4:10017979	C/T	cg11266682	chr4:10021025	SLC2A9	0.39	6.76	0.4	1.09e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs2404618	0.506	rs12156177	chr8:1493684	C/T	cg13402656	chr8:1511478	DLGAP2	-0.51	-7.31	-0.43	4.12e-12	Lung cancer;
SARC	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg03806693	chr22:41940476	POLR3H	-0.87	-11.95	-0.62	5.34e-26	Vitiligo;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg07439056	chr5:97912653	NA	0.5	6.48	0.39	5.51e-10	Breast cancer;
SARC	cis	rs2124969	0.522	rs6432608	chr2:161034991	C/T	cg03641300	chr2:160917029	PLA2R1	-0.44	-6.17	-0.37	3.05e-9	Waist circumference adjusted for body mass index;
SARC	cis	rs922107	0.688	rs10922661	chr1:90024094	T/C	cg15422784	chr1:90023713	LRRC8B	-0.32	-4.73	-0.3	3.9e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
SARC	cis	rs8114671	0.904	rs6060197	chr20:33654315	C/T	cg24642439	chr20:33292090	TP53INP2	-0.51	-5.96	-0.36	9.12e-9	Height;
SARC	trans	rs61931739	0.534	rs10844840	chr12:34364517	C/T	cg26384229	chr12:38710491	ALG10B	0.9	13.26	0.66	2.92e-30	Morning vs. evening chronotype;
SARC	cis	rs981844	1.000	rs2606341	chr4:154658702	T/C	cg14289246	chr4:154710475	SFRP2	0.58	6.64	0.4	2.14e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs995000	0.931	rs1168047	chr1:62983751	C/T	cg06896770	chr1:63153194	DOCK7	-0.89	-12.89	-0.65	4.52e-29	Triglyceride levels;
SARC	cis	rs2304069	1.000	rs7737689	chr5:149396159	C/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.75	8.44	0.48	3.45e-15	HIV-1 control;
SARC	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.42	5.22	0.32	3.89e-7	Electroencephalogram traits;
SARC	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-4.86	-0.3	2.17e-6	Total body bone mineral density;
SARC	cis	rs9462027	0.628	rs1543558	chr6:34784371	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-6.04	-0.37	6.01e-9	Systemic lupus erythematosus;
SARC	cis	rs751728	0.585	rs9380381	chr6:33771070	C/T	cg15252951	chr6:33757062	LEMD2	0.44	4.79	0.3	2.98e-6	Crohn's disease;
SARC	trans	rs9329221	0.712	rs1962073	chr8:10260553	A/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.3	-0.43	4.49e-12	Neuroticism;
SARC	cis	rs7246657	0.525	rs997516	chr19:37474264	T/C	cg14683738	chr19:37701593	ZNF585B	0.55	4.86	0.3	2.13e-6	Coronary artery calcification;
SARC	cis	rs4689388	0.926	rs10937717	chr4:6295087	T/A	cg14416269	chr4:6271139	WFS1	0.33	5.13	0.32	6.07e-7	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs4268898	0.636	rs76172309	chr2:24458911	G/C	cg26838691	chr2:24397539	C2orf84	-0.51	-5.87	-0.36	1.51e-8	Asthma;
SARC	cis	rs1953600	0.870	rs2789690	chr10:81938204	G/T	cg00277334	chr10:82204260	NA	0.36	5.31	0.33	2.55e-7	Sarcoidosis;
SARC	cis	rs1707322	0.963	rs1768815	chr1:46528603	G/A	cg03146154	chr1:46216737	IPP	-0.47	-5.61	-0.34	5.83e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs561341	0.739	rs1978116	chr17:30220978	A/C	cg13647721	chr17:30228624	UTP6	0.7	7.2	0.43	8.46e-12	Hip circumference adjusted for BMI;
SARC	cis	rs12022452	0.591	rs12049435	chr1:40990560	C/T	cg25568243	chr1:40974465	DEM1	0.52	4.8	0.3	2.79e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs7566780	0.602	rs6742067	chr2:16685148	C/G	cg09580478	chr2:16689509	NA	-0.59	-7.19	-0.43	8.64e-12	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	trans	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg20587970	chr11:113659929	NA	-0.88	-9.31	-0.52	9.74e-18	Hip circumference adjusted for BMI;
SARC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg13015440	chr7:42971910	MRPL32;PSMA2	-0.58	-6.26	-0.38	1.88e-9	Hepatitis;
SARC	cis	rs17376456	0.825	rs12188163	chr5:93250608	A/G	cg25358565	chr5:93447407	FAM172A	-1.3	-14.32	-0.68	8.73e-34	Diabetic retinopathy;
SARC	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg03433033	chr1:76189801	ACADM	0.53	7.72	0.45	3.49e-13	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9467773	0.620	rs2451732	chr6:26622904	A/T	cg11502198	chr6:26597334	ABT1	-0.57	-7.67	-0.45	4.69e-13	Intelligence (multi-trait analysis);
SARC	cis	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg09021430	chr5:549028	NA	-0.48	-6.35	-0.38	1.12e-9	Obesity-related traits;
SARC	cis	rs2066819	1.000	rs2695789	chr12:56694261	C/A	cg26316697	chr12:56727976	PAN2	-0.9	-6.37	-0.39	9.89e-10	Psoriasis vulgaris;
SARC	cis	rs116095464	1.000	rs7736	chr5:314935	T/C	cg22496380	chr5:211416	CCDC127	-0.81	-6.4	-0.39	8.48e-10	Breast cancer;
SARC	cis	rs9381040	0.610	rs6919961	chr6:41020361	T/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.41	-4.79	-0.3	2.95e-6	Alzheimer's disease (late onset);
SARC	cis	rs9300255	0.602	rs1727314	chr12:123640664	C/A	cg05973401	chr12:123451056	ABCB9	0.53	6.14	0.37	3.6e-9	Neutrophil percentage of white cells;
SARC	cis	rs9790314	1.000	rs336570	chr3:161072054	A/G	cg04691961	chr3:161091175	C3orf57	0.79	11.38	0.6	3.78e-24	Morning vs. evening chronotype;
SARC	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-6.5	-0.39	4.79e-10	Personality dimensions;
SARC	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	27.41	0.87	7.3e-75	Chronic sinus infection;
SARC	cis	rs6487679	0.526	rs7972426	chr12:9381254	C/T	cg08997352	chr12:9597637	DDX12	-0.44	-5.48	-0.34	1.08e-7	Non-alcoholic fatty liver disease histology (AST);
SARC	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg27266027	chr21:40555129	PSMG1	0.48	5.14	0.32	5.69e-7	Cognitive function;
SARC	cis	rs854765	0.583	rs9890341	chr17:17823175	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	9.82	0.54	2.79e-19	Total body bone mineral density;
SARC	cis	rs6500602	0.610	rs1659499	chr16:4595269	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.31	-5.12	-0.32	6.5e-7	Schizophrenia;
SARC	cis	rs4319547	0.695	rs12314643	chr12:122917423	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.51	-5.9	-0.36	1.27e-8	Body mass index;
SARC	cis	rs7647973	1.000	rs974495	chr3:49400482	T/C	cg06212747	chr3:49208901	KLHDC8B	0.58	6.05	0.37	5.65e-9	Menarche (age at onset);
SARC	cis	rs11697848	1.000	rs77146093	chr20:48482352	C/T	cg17849948	chr20:48532315	SPATA2	0.8	4.86	0.3	2.15e-6	Systemic lupus erythematosus;
SARC	cis	rs507506	0.771	rs929229	chr17:7105399	C/T	cg25256661	chr17:7137939	DVL2	0.51	6.75	0.4	1.17e-10	Adiponectin levels;
SARC	trans	rs2727020	0.590	rs7949936	chr11:49378902	G/A	cg15704280	chr7:45808275	SEPT13	-0.7	-7.66	-0.45	5e-13	Coronary artery disease;
SARC	cis	rs526231	0.543	rs26819	chr5:102529401	G/A	cg23492399	chr5:102201601	PAM	-0.53	-5.61	-0.34	5.75e-8	Primary biliary cholangitis;
SARC	cis	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg13072238	chr3:49761600	GMPPB	-0.43	-5.5	-0.34	9.92e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg23982607	chr1:1823379	GNB1	-0.44	-6.65	-0.4	2.1e-10	Body mass index;
SARC	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg25036284	chr2:26402008	FAM59B	0.44	5.46	0.34	1.22e-7	Gut microbiome composition (summer);
SARC	cis	rs478304	0.651	rs11227279	chr11:65495211	G/A	cg27068330	chr11:65405492	SIPA1	-0.39	-4.79	-0.3	3e-6	Acne (severe);
SARC	cis	rs7561149	0.714	rs12464215	chr2:179690968	G/T	cg17765952	chr2:179737173	CCDC141	-0.35	-4.75	-0.3	3.58e-6	QT interval;
SARC	cis	rs4555082	0.834	rs11849607	chr14:105745383	G/A	cg13114125	chr14:105738426	BRF1	-0.8	-11.72	-0.61	3.04e-25	Mean platelet volume;Platelet distribution width;
SARC	cis	rs7635838	0.785	rs2594972	chr3:11397417	A/G	cg00170343	chr3:11313890	ATG7	0.56	7.58	0.44	8.03e-13	HDL cholesterol;
SARC	cis	rs11055008	0.935	rs10845601	chr12:12820134	A/G	cg09462578	chr12:12878428	APOLD1	0.53	6.47	0.39	5.8e-10	Pulse pressure;
SARC	trans	rs9951602	0.512	rs12607938	chr18:76651887	A/C	cg02800362	chr5:177631904	HNRNPAB	0.7	8.89	0.5	1.73e-16	Obesity-related traits;
SARC	cis	rs9487051	0.714	rs6903695	chr6:109631422	C/G	cg01475377	chr6:109611718	NA	0.37	5.37	0.33	1.88e-7	Reticulocyte fraction of red cells;
SARC	cis	rs1401999	0.864	rs4148563	chr3:183725999	T/C	cg01324343	chr3:183735012	ABCC5	0.65	13.16	0.65	6.23e-30	Anterior chamber depth;
SARC	cis	rs6429082	0.967	rs834143	chr1:235626406	C/T	cg26050004	chr1:235667680	B3GALNT2	0.42	5.5	0.34	9.92e-8	Adiposity;
SARC	cis	rs2576037	0.796	rs2576039	chr18:44582148	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.68	-9.85	-0.54	2.35e-19	Personality dimensions;
SARC	cis	rs1008375	0.932	rs13109475	chr4:17677565	C/G	cg27347728	chr4:17578864	LAP3	-0.46	-5.61	-0.34	5.78e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs116095464	0.558	rs34629844	chr5:200829	A/G	cg22496380	chr5:211416	CCDC127	-0.91	-8.14	-0.47	2.41e-14	Breast cancer;
SARC	cis	rs5753618	0.583	rs5753601	chr22:31798259	G/T	cg02404636	chr22:31891804	SFI1	0.49	5.17	0.32	4.93e-7	Colorectal cancer;
SARC	cis	rs4713118	0.868	rs10484401	chr6:27746590	A/T	cg17221315	chr6:27791827	HIST1H4J	-0.52	-4.99	-0.31	1.16e-6	Parkinson's disease;
SARC	cis	rs9392918	0.600	rs911748	chr6:7698828	A/T	cg23089261	chr6:7723385	NA	0.53	6.76	0.4	1.11e-10	Height;
SARC	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg13395646	chr4:1353034	KIAA1530	-0.47	-5.46	-0.34	1.23e-7	Obesity-related traits;
SARC	cis	rs7512552	0.698	rs12028001	chr1:150407820	C/T	cg15654264	chr1:150340011	RPRD2	0.4	5.16	0.32	5.32e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs2228479	0.850	rs62054611	chr16:89817017	T/C	cg06558623	chr16:89946397	TCF25	0.88	6.21	0.38	2.39e-9	Skin colour saturation;
SARC	cis	rs9916302	0.851	rs677888	chr17:37461018	T/G	cg20243544	chr17:37824526	PNMT	-0.54	-6.25	-0.38	1.89e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs4742903	0.967	rs10820601	chr9:106861281	G/A	cg14250997	chr9:106856677	SMC2	0.52	6.85	0.41	6.65e-11	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs17331151	0.573	rs2240916	chr3:52859212	T/A	cg04865290	chr3:52927548	TMEM110	-0.54	-5.09	-0.32	7.34e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs6570726	0.935	rs419850	chr6:145827281	A/G	cg05220968	chr6:146057943	EPM2A	-0.29	-4.83	-0.3	2.44e-6	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg07191189	chr2:37193690	STRN	-0.5	-6.26	-0.38	1.87e-9	Schizophrenia;
SARC	cis	rs787274	1.000	rs700122	chr9:115551847	A/G	cg13803584	chr9:115635662	SNX30	-0.83	-5.06	-0.31	8.34e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs12554020	0.786	rs12551314	chr9:96379797	C/A	cg21184699	chr9:96277131	FAM120A	-0.51	-4.89	-0.31	1.86e-6	Schizophrenia;
SARC	cis	rs6121246	0.559	rs6060962	chr20:30397847	A/G	cg13852791	chr20:30311386	BCL2L1	0.87	10.91	0.58	1.14e-22	Mean corpuscular hemoglobin;
SARC	cis	rs3800461	0.509	rs73407707	chr6:34476644	T/G	cg17674042	chr6:34482479	PACSIN1	-0.58	-5.05	-0.31	8.71e-7	Chronic lymphocytic leukemia;
SARC	cis	rs826838	1.000	rs10880826	chr12:38672787	G/C	cg13010199	chr12:38710504	ALG10B	0.81	11.59	0.6	8.06e-25	Heart rate;
SARC	cis	rs6598955	0.670	rs4659366	chr1:26542572	G/A	cg04990556	chr1:26633338	UBXN11	-0.63	-8.78	-0.5	3.65e-16	Obesity-related traits;
SARC	cis	rs58688157	0.549	rs11246192	chr11:572473	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.39	-4.77	-0.3	3.28e-6	Systemic lupus erythematosus;
SARC	cis	rs7264396	0.635	rs6060682	chr20:34506331	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	5.4	0.33	1.68e-7	Total cholesterol levels;
SARC	cis	rs503734	0.521	rs348884	chr3:100975293	C/G	cg27318481	chr3:100970896	IMPG2	-0.46	-5.53	-0.34	8.5e-8	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg06028808	chr11:68637592	NA	0.47	5.96	0.36	9.37e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs1390897	0.692	rs7198249	chr16:77063846	A/C	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.36	-4.9	-0.31	1.78e-6	beta-nerve growth factor levels;
SARC	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg03060546	chr3:49711283	APEH	0.43	5.33	0.33	2.31e-7	Parkinson's disease;
SARC	cis	rs909341	0.537	rs11696871	chr20:62387417	C/T	cg14758556	chr20:62440591	NA	0.53	5.32	0.33	2.41e-7	Atopic dermatitis;
SARC	trans	rs1814175	0.935	rs7482690	chr11:49648814	C/T	cg03929089	chr4:120376271	NA	-0.81	-12.14	-0.62	1.33e-26	Height;
SARC	cis	rs11792861	0.532	rs10979659	chr9:111788975	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.5	6.18	0.38	2.78e-9	Menarche (age at onset);
SARC	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg24829409	chr8:58192753	C8orf71	-0.6	-6.6	-0.4	2.74e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg00684032	chr4:1343700	KIAA1530	-0.35	-4.93	-0.31	1.58e-6	Obesity-related traits;
SARC	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg05313129	chr8:58192883	C8orf71	-0.57	-6.37	-0.39	9.94e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs782590	0.967	rs782586	chr2:55836165	A/C	cg18811423	chr2:55921094	PNPT1	0.68	10.42	0.56	3.98e-21	Metabolic syndrome;
SARC	cis	rs2153535	0.580	rs4404802	chr6:8442052	A/G	cg21535247	chr6:8435926	SLC35B3	0.56	7.01	0.42	2.6e-11	Motion sickness;
SARC	cis	rs9399135	1.000	rs1014021	chr6:135334600	C/T	cg24558204	chr6:135376177	HBS1L	-0.47	-6.39	-0.39	8.73e-10	Red blood cell count;
SARC	cis	rs7949030	0.590	rs12225213	chr11:62350248	T/A	cg11742103	chr11:62369870	EML3;MTA2	0.42	6.26	0.38	1.79e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs8141529	0.702	rs469992	chr22:29314899	T/C	cg02153584	chr22:29168773	CCDC117	-0.79	-11.52	-0.6	1.33e-24	Lymphocyte counts;
SARC	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg23758822	chr17:41437982	NA	0.91	11.54	0.6	1.12e-24	Menopause (age at onset);
SARC	cis	rs986417	0.818	rs6573319	chr14:61091913	C/G	cg27398547	chr14:60952738	C14orf39	0.73	6.71	0.4	1.49e-10	Gut microbiota (bacterial taxa);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg04770025	chr11:108172798	ATM	0.46	6.45	0.39	6.55e-10	Thyroid stimulating hormone;
SARC	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-4.75	-0.3	3.56e-6	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs829883	0.639	rs829898	chr12:98857675	A/C	cg25150519	chr12:98850993	NA	0.84	13.52	0.66	4.05e-31	Colorectal adenoma (advanced);
SARC	cis	rs8016982	0.633	rs7160342	chr14:81713427	G/C	cg01989461	chr14:81687754	GTF2A1	0.73	10.87	0.58	1.57e-22	Schizophrenia;
SARC	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-9.15	-0.51	2.85e-17	Alzheimer's disease;
SARC	cis	rs6430585	0.583	rs61253125	chr2:136618178	T/C	cg07169764	chr2:136633963	MCM6	1.09	16.65	0.74	1.55e-41	Corneal structure;
SARC	cis	rs344364	0.511	rs1742463	chr16:1946110	A/G	cg26617929	chr16:1858877	NA	-0.71	-6.06	-0.37	5.5e-9	Glomerular filtration rate in chronic kidney disease;
SARC	cis	rs7584330	0.704	rs72620821	chr2:238362615	C/A	cg14458575	chr2:238380390	NA	0.56	6.26	0.38	1.82e-9	Prostate cancer;
SARC	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg08859206	chr1:53392774	SCP2	-0.37	-5.3	-0.33	2.64e-7	Monocyte count;
SARC	trans	rs2727020	0.587	rs1164658	chr11:49298551	C/A	cg03929089	chr4:120376271	NA	0.77	11.53	0.6	1.22e-24	Coronary artery disease;
SARC	cis	rs13161895	1.000	rs3719	chr5:179435118	T/C	cg04265672	chr5:179402240	RNF130	0.52	5.15	0.32	5.48e-7	LDL cholesterol;
SARC	cis	rs9457247	1.000	rs2769354	chr6:167379771	G/T	cg07741184	chr6:167504864	NA	-0.3	-5.61	-0.35	5.69e-8	Crohn's disease;
SARC	cis	rs6582630	0.519	rs12578283	chr12:38325349	A/T	cg13010199	chr12:38710504	ALG10B	0.78	10.63	0.57	8.73e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7772486	0.686	rs2179323	chr6:145982786	T/G	cg05347473	chr6:146136440	FBXO30	-0.5	-6.95	-0.41	3.74e-11	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs9427116	0.502	rs12125166	chr1:154582129	A/G	cg06329143	chr18:48556512	SMAD4	-0.53	-6.64	-0.4	2.12e-10	Blood protein levels;
SARC	cis	rs7264396	0.563	rs2425084	chr20:34301871	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	5.87	0.36	1.48e-8	Total cholesterol levels;
SARC	cis	rs3761847	0.622	rs10435888	chr9:123819603	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.41	5.13	0.32	6e-7	Rheumatoid arthritis;
SARC	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg21747090	chr2:27597821	SNX17	-0.54	-7.53	-0.44	1.12e-12	Total body bone mineral density;
SARC	cis	rs12451471	0.559	rs12452263	chr17:78079310	T/C	cg06718696	chr17:78121285	EIF4A3	0.89	10.32	0.56	8.35e-21	Plateletcrit;Mean corpuscular hemoglobin concentration;
SARC	cis	rs12545109	0.800	rs2670053	chr8:57421998	A/T	cg09654669	chr8:57350985	NA	-0.39	-4.98	-0.31	1.26e-6	Obesity-related traits;
SARC	cis	rs1371867	0.846	rs1788199	chr8:101292854	A/G	cg11906718	chr8:101322791	RNF19A	0.69	8.92	0.5	1.36e-16	Atrioventricular conduction;
SARC	cis	rs8031584	0.958	rs11629793	chr15:31238423	G/A	cg19680485	chr15:31195859	MTMR15	-0.51	-5.92	-0.36	1.16e-8	Huntington's disease progression;
SARC	cis	rs67311347	0.544	rs9821440	chr3:40342347	T/C	cg24209194	chr3:40518798	ZNF619	0.47	6.36	0.38	1.03e-9	Renal cell carcinoma;
SARC	cis	rs524281	0.861	rs7946917	chr11:65956577	A/G	cg14036092	chr11:66035641	RAB1B	-0.5	-5.37	-0.33	1.89e-7	Electroencephalogram traits;
SARC	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg13880726	chr7:1868755	MAD1L1	0.49	5.76	0.35	2.65e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs2011503	1.000	rs4808205	chr19:19645493	T/G	cg03709012	chr19:19516395	GATAD2A	0.6	5.29	0.33	2.8e-7	Bipolar disorder;
SARC	cis	rs10982256	0.817	rs2297815	chr9:117266965	C/T	cg21159778	chr9:117266918	DFNB31	0.39	5.51	0.34	9.57e-8	Bipolar disorder;
SARC	cis	rs6570726	0.791	rs11155432	chr6:145898761	T/C	cg05347473	chr6:146136440	FBXO30	0.51	7.2	0.43	8.39e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg02841227	chr6:26021843	HIST1H4A	0.63	7.44	0.44	1.92e-12	Intelligence (multi-trait analysis);
SARC	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.52	6.33	0.38	1.26e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7615952	0.599	rs2279821	chr3:125734308	G/A	cg05084668	chr3:125655381	ALG1L	-0.5	-5.33	-0.33	2.37e-7	Blood pressure (smoking interaction);
SARC	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg18876405	chr7:65276391	NA	-0.65	-8.11	-0.47	2.97e-14	Aortic root size;
SARC	cis	rs12950390	0.853	rs11655336	chr17:45858836	A/G	cg24803719	chr17:45855879	NA	0.45	7.33	0.43	3.73e-12	IgG glycosylation;
SARC	cis	rs6693567	0.565	rs6684939	chr1:150440563	G/A	cg09579323	chr1:150459698	TARS2	-0.44	-5.63	-0.35	5.05e-8	Migraine;
SARC	cis	rs9894429	0.608	rs7406219	chr17:79609410	G/T	cg10661904	chr17:79619235	PDE6G	-0.44	-6.23	-0.38	2.21e-9	Eye color traits;
SARC	cis	rs1729951	0.546	rs835632	chr3:136676525	A/T	cg15507776	chr3:136538369	TMEM22	0.5	5.4	0.33	1.68e-7	Neuroticism;
SARC	cis	rs9916302	0.680	rs2271308	chr17:37817482	T/C	cg20243544	chr17:37824526	PNMT	0.59	7.74	0.45	3.05e-13	Glomerular filtration rate (creatinine);
SARC	trans	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg16141378	chr3:129829833	LOC729375	-0.55	-6.48	-0.39	5.26e-10	Neuroticism;
SARC	cis	rs2559856	1.000	rs2695296	chr12:102085487	T/C	cg12924262	chr12:102091054	CHPT1	0.58	7.69	0.45	4.23e-13	Blood protein levels;
SARC	cis	rs2652834	1.000	rs11637852	chr15:63397151	G/A	cg05507819	chr15:63340323	TPM1	0.54	5.36	0.33	2e-7	HDL cholesterol;
SARC	cis	rs4481887	1.000	rs4474293	chr1:248470438	T/C	cg00666640	chr1:248458726	OR2T12	0.38	6.42	0.39	7.43e-10	Common traits (Other);
SARC	cis	rs1878931	0.582	rs9635562	chr16:3416689	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.68	7.77	0.45	2.43e-13	Body mass index (adult);
SARC	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg23172400	chr8:95962367	TP53INP1	-0.3	-5.2	-0.32	4.44e-7	Type 2 diabetes;
SARC	cis	rs3796352	1.000	rs35576914	chr3:53092270	G/A	cg27565382	chr3:53032988	SFMBT1	0.98	6.93	0.41	4.19e-11	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg23758822	chr17:41437982	NA	0.87	10.68	0.57	6.32e-22	Menopause (age at onset);
SARC	cis	rs9398803	0.805	rs1591805	chr6:126717064	A/G	cg19875578	chr6:126661172	C6orf173	0.59	7.86	0.46	1.43e-13	Male-pattern baldness;
SARC	trans	rs1814175	0.817	rs1621090	chr11:49895868	C/A	cg15704280	chr7:45808275	SEPT13	-0.97	-18.17	-0.77	1.53e-46	Height;
SARC	cis	rs4268898	0.608	rs72793980	chr2:24428859	T/C	cg06627628	chr2:24431161	ITSN2	-0.66	-7.95	-0.46	8.13e-14	Asthma;
SARC	cis	rs829661	0.512	rs11676852	chr2:30792898	A/C	cg17749961	chr2:30669863	LCLAT1	-0.42	-5.05	-0.31	8.81e-7	Midgestational circulating levels of PBDEs (fetal genetic effect);
SARC	cis	rs1322639	0.614	rs7768154	chr6:169565470	A/G	cg03254818	chr6:169586852	NA	0.73	7.63	0.45	6.07e-13	Pulse pressure;
SARC	cis	rs4927850	1.000	rs4927848	chr3:195738406	A/G	cg12923728	chr3:195709715	SDHAP1	-0.69	-8.37	-0.48	5.31e-15	Pancreatic cancer;
SARC	cis	rs765787	0.530	rs1706831	chr15:45516230	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.43	-5.39	-0.33	1.73e-7	Uric acid levels;
SARC	cis	rs4742903	0.868	rs4743684	chr9:106852385	A/C	cg14250997	chr9:106856677	SMC2	0.57	7.53	0.44	1.12e-12	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs2816062	0.760	rs2244192	chr1:18890939	A/T	cg10574377	chr1:18908098	NA	0.36	5.13	0.32	6e-7	Urate levels in lean individuals;
SARC	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg18357526	chr6:26021779	HIST1H4A	0.82	10.4	0.56	4.8e-21	Intelligence (multi-trait analysis);
SARC	cis	rs4803468	1.000	rs2241706	chr19:41912807	A/G	cg14132834	chr19:41945861	ATP5SL	-0.56	-7.32	-0.43	4.06e-12	Height;
SARC	cis	rs2304069	0.644	rs216131	chr5:149431223	C/T	cg12661370	chr5:149340060	SLC26A2	0.52	5.0	0.31	1.11e-6	HIV-1 control;
SARC	cis	rs7552404	0.924	rs2153126	chr1:76199345	C/G	cg03433033	chr1:76189801	ACADM	0.51	7.52	0.44	1.16e-12	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg22903657	chr4:1355424	KIAA1530	-0.42	-5.55	-0.34	7.75e-8	Obesity-related traits;
SARC	cis	rs4727027	0.704	rs12704070	chr7:148902789	G/A	cg23583168	chr7:148888333	NA	-0.82	-13.28	-0.66	2.37e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs10752881	1.000	rs10797808	chr1:182979623	T/C	cg13390022	chr1:182993471	LAMC1	0.33	5.06	0.31	8.36e-7	Colorectal cancer;
SARC	cis	rs34779708	0.931	rs4934693	chr10:35271844	G/A	cg03585969	chr10:35415529	CREM	0.4	5.01	0.31	1.07e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs4927850	0.829	rs6768483	chr3:195745963	C/G	cg12923728	chr3:195709715	SDHAP1	-0.7	-7.79	-0.45	2.18e-13	Pancreatic cancer;
SARC	cis	rs2066819	1.000	rs2371494	chr12:56728000	G/A	cg26316697	chr12:56727976	PAN2	0.9	6.37	0.39	9.89e-10	Psoriasis vulgaris;
SARC	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.63e-10	Life satisfaction;
SARC	cis	rs4481887	1.000	rs6671789	chr1:248482931	G/A	cg00666640	chr1:248458726	OR2T12	0.39	6.37	0.39	9.89e-10	Common traits (Other);
SARC	cis	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg22496380	chr5:211416	CCDC127	-0.89	-9.18	-0.52	2.44e-17	Breast cancer;
SARC	cis	rs739401	0.572	rs7111857	chr11:3068106	A/G	cg05729581	chr11:3078854	CARS	0.5	6.41	0.39	7.97e-10	Longevity;
SARC	cis	rs796364	0.806	rs10931890	chr2:201102055	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.66	-5.35	-0.33	2.08e-7	Schizophrenia;
SARC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg04267008	chr7:1944627	MAD1L1	-0.49	-5.48	-0.34	1.08e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs6570726	0.935	rs430561	chr6:145813140	C/T	cg05347473	chr6:146136440	FBXO30	0.52	7.05	0.42	2.03e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg21724239	chr8:58056113	NA	0.57	6.08	0.37	4.82e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs634534	0.561	rs613924	chr11:65769295	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.84	12.52	0.63	7.68e-28	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg11062466	chr8:58055876	NA	0.66	6.12	0.37	3.97e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg24642844	chr7:1081250	C7orf50	-0.59	-6.12	-0.37	3.89e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs13314892	0.764	rs17638538	chr3:69880673	A/T	cg17445875	chr3:69859618	MITF	0.5	5.32	0.33	2.39e-7	QRS complex (12-leadsum);
SARC	cis	rs113835537	0.935	rs1127145	chr11:66373305	G/A	cg24851651	chr11:66362959	CCS	0.48	5.1	0.32	7.05e-7	Airway imaging phenotypes;
SARC	cis	rs2658782	0.789	rs3019206	chr11:93111073	A/G	cg15737290	chr11:93063684	CCDC67	0.72	7.76	0.45	2.74e-13	Pulmonary function decline;
SARC	cis	rs7617773	0.817	rs4131361	chr3:48328812	T/C	cg11946769	chr3:48343235	NME6	0.73	9.65	0.53	9.55e-19	Coronary artery disease;
SARC	cis	rs1865760	0.532	rs2794719	chr6:26088890	T/G	cg18357526	chr6:26021779	HIST1H4A	0.43	5.3	0.33	2.64e-7	Height;
SARC	cis	rs9467773	0.869	rs1796520	chr6:26410800	C/T	cg11502198	chr6:26597334	ABT1	-0.49	-5.85	-0.36	1.65e-8	Intelligence (multi-trait analysis);
SARC	cis	rs3820928	0.874	rs1917125	chr2:227798981	G/A	cg05526886	chr2:227700861	RHBDD1	-0.54	-6.65	-0.4	2.04e-10	Pulmonary function;
SARC	cis	rs3762637	0.943	rs9289199	chr3:122277172	G/A	cg24169773	chr3:122142474	KPNA1	-0.55	-5.58	-0.34	6.82e-8	LDL cholesterol levels;
SARC	cis	rs67366981	0.925	rs56753733	chr14:77713930	A/C	cg06779847	chr14:77687015	TMEM63C	-0.46	-5.32	-0.33	2.42e-7	Obsessive-compulsive symptoms;
SARC	cis	rs921968	0.542	rs588182	chr2:219412335	C/A	cg02176678	chr2:219576539	TTLL4	0.45	6.82	0.41	7.94e-11	Mean corpuscular hemoglobin concentration;
SARC	cis	rs1570884	0.516	rs2094108	chr13:50171550	G/A	cg03651054	chr13:50194643	NA	0.32	5.2	0.32	4.26e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs16912285	0.688	rs12276587	chr11:24280656	C/G	ch.11.24196551F	chr11:24239977	NA	-0.58	-6.15	-0.37	3.38e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg16774013	chr18:77160150	NFATC1	-0.51	-6.51	-0.39	4.69e-10	Gallstone disease;
SARC	cis	rs11690935	0.550	rs4280427	chr2:172813218	G/A	cg13550731	chr2:172543902	DYNC1I2	0.55	7.22	0.43	7.52e-12	Schizophrenia;
SARC	cis	rs644799	0.687	rs3748252	chr11:95519195	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.91	-15.37	-0.71	2.81e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs11792861	0.589	rs75742991	chr9:111929624	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	6.74	0.4	1.26e-10	Menarche (age at onset);
SARC	cis	rs10489202	0.913	rs380753	chr1:168035273	G/T	cg24449463	chr1:168025552	DCAF6	-0.64	-7.65	-0.45	5.15e-13	Schizophrenia;
SARC	cis	rs12142240	0.698	rs1135459	chr1:46815930	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-5.46	-0.34	1.22e-7	Menopause (age at onset);
SARC	cis	rs67460515	0.563	rs11720263	chr3:160848293	T/C	cg03342759	chr3:160939853	NMD3	-0.63	-7.65	-0.45	5.2e-13	Parkinson's disease;
SARC	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg20607798	chr8:58055168	NA	0.66	5.7	0.35	3.62e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1355223	0.506	rs1509660	chr11:34865017	A/G	cg18508148	chr11:34937573	PDHX;APIP	-0.37	-4.74	-0.3	3.74e-6	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs6582630	0.519	rs11181526	chr12:38360230	A/G	cg13010199	chr12:38710504	ALG10B	0.78	10.79	0.58	2.78e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2153535	0.623	rs2327055	chr6:8443145	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	7.31	0.43	4.24e-12	Motion sickness;
SARC	cis	rs240764	0.782	rs7748644	chr6:101166809	T/G	cg09795085	chr6:101329169	ASCC3	-0.48	-6.03	-0.37	6.45e-9	Neuroticism;
SARC	cis	rs2095921	1	rs2095921	chr1:11033322	C/G	cg02454025	chr1:11042201	C1orf127	0.87	12.08	0.62	2.04e-26	Male-pattern baldness;
SARC	cis	rs79149102	0.737	rs75128970	chr15:75181397	C/T	cg17294928	chr15:75287854	SCAMP5	-0.94	-5.78	-0.35	2.34e-8	Lung cancer;
SARC	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg24675658	chr1:53192096	ZYG11B	-0.66	-9.87	-0.54	2e-19	Monocyte count;
SARC	cis	rs6558174	0.802	rs6558170	chr8:22487388	C/G	cg03733263	chr8:22462867	KIAA1967	0.52	6.05	0.37	5.8e-9	Breast cancer;
SARC	cis	rs1865760	0.566	rs9379821	chr6:26054268	A/C	cg16482183	chr6:26056742	HIST1H1C	0.49	6.29	0.38	1.6e-9	Height;
SARC	cis	rs4975616	0.869	rs421284	chr5:1325590	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.57	-8.48	-0.49	2.6e-15	Lung cancer;
SARC	cis	rs6912958	0.535	rs242283	chr6:88030931	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.78	11.7	0.61	3.65e-25	Monocyte percentage of white cells;
SARC	cis	rs6728642	0.519	rs59131346	chr2:97566768	C/T	cg26665480	chr2:98280029	ACTR1B	-0.58	-5.28	-0.33	3.01e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs317689	0.513	rs529268	chr12:69687051	G/A	cg20891283	chr12:69753455	YEATS4	0.4	4.96	0.31	1.34e-6	Response to diuretic therapy;
SARC	cis	rs9815354	0.812	rs17218441	chr3:41987044	A/G	cg03022575	chr3:42003672	ULK4	0.72	6.26	0.38	1.79e-9	Pulse pressure;Diastolic blood pressure;
SARC	trans	rs1814175	0.715	rs10839409	chr11:49884647	G/T	cg03929089	chr4:120376271	NA	-0.89	-14.53	-0.69	1.73e-34	Height;
SARC	cis	rs12145833	1.000	rs10926986	chr1:243467611	A/C	cg02356786	chr1:243265016	LOC731275	-0.67	-5.72	-0.35	3.33e-8	Obesity (early onset extreme);
SARC	cis	rs4481887	0.708	rs6688853	chr1:248548006	G/A	cg00666640	chr1:248458726	OR2T12	0.32	5.64	0.35	4.9e-8	Common traits (Other);
SARC	cis	rs950776	0.518	rs4887063	chr15:78839715	C/T	cg06917634	chr15:78832804	PSMA4	-0.88	-12.42	-0.63	1.57e-27	Sudden cardiac arrest;
SARC	cis	rs6446731	0.517	rs2157093	chr4:3270913	C/G	cg06533319	chr4:3265114	C4orf44	0.31	4.88	0.3	1.97e-6	Mean platelet volume;
SARC	cis	rs6831352	0.918	rs2851249	chr4:100044822	T/C	cg12011299	chr4:100065546	ADH4	0.34	5.68	0.35	4e-8	Alcohol dependence;
SARC	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg11366901	chr6:160182831	ACAT2	0.97	9.87	0.54	2.03e-19	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs7766436	0.885	rs13199041	chr6:22577718	A/G	cg13666174	chr6:22585274	NA	-0.59	-7.66	-0.45	5.07e-13	Coronary artery disease;
SARC	cis	rs12950390	0.512	rs59396604	chr17:45837777	G/A	cg03474202	chr17:45855739	NA	-0.42	-5.12	-0.32	6.27e-7	IgG glycosylation;
SARC	cis	rs3817198	0.927	rs112907808	chr11:1907610	T/C	cg27474957	chr11:1567578	HCCA2	-0.34	-4.82	-0.3	2.63e-6	Breast cancer;Mammographic density (dense area);
SARC	cis	rs17270561	0.585	rs9393663	chr6:25741033	A/T	cg17691542	chr6:26056736	HIST1H1C	0.6	7.22	0.43	7.22e-12	Iron status biomarkers;
SARC	cis	rs920590	0.876	rs3907478	chr8:19657753	G/T	cg17834443	chr8:19674713	INTS10	0.5	6.33	0.38	1.28e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg05861140	chr6:150128134	PCMT1	-0.41	-5.34	-0.33	2.19e-7	Lung cancer;
SARC	cis	rs2153535	0.601	rs330105	chr6:8543981	A/C	cg07606381	chr6:8435919	SLC35B3	0.79	11.34	0.6	5.02e-24	Motion sickness;
SARC	cis	rs941764	0.965	rs8018155	chr14:91842978	G/C	cg10511902	chr14:91842949	CCDC88C	0.34	5.65	0.35	4.57e-8	Breast cancer;
SARC	cis	rs829883	1.000	rs1347956	chr12:98889564	A/G	cg25150519	chr12:98850993	NA	0.7	9.57	0.53	1.59e-18	Colorectal adenoma (advanced);
SARC	cis	rs6570726	0.935	rs386823	chr6:145841365	C/T	cg23711669	chr6:146136114	FBXO30	0.78	11.86	0.61	1.04e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9916302	0.904	rs35335692	chr17:37710006	A/G	cg15445000	chr17:37608096	MED1	0.42	4.9	0.31	1.77e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs2529049	0.537	rs767421	chr7:24692331	C/G	cg17569154	chr7:24781545	DFNA5	0.5	7.22	0.43	7.32e-12	Urate levels in obese individuals;
SARC	trans	rs13098911	0.540	rs71327014	chr3:46101466	C/T	cg03842258	chr15:67135396	NA	0.78	6.27	0.38	1.74e-9	Celiac disease;
SARC	cis	rs2304069	0.779	rs245080	chr5:149354805	A/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	-0.46	-4.72	-0.3	4.08e-6	HIV-1 control;
SARC	cis	rs1153858	0.943	rs67045941	chr15:45677011	A/G	cg21132104	chr15:45694354	SPATA5L1	0.78	11.01	0.59	5.55e-23	Homoarginine levels;
SARC	cis	rs2439831	0.850	rs3097773	chr15:43893072	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.82	-8.4	-0.48	4.3e-15	Lung cancer in ever smokers;
SARC	cis	rs113835537	0.627	rs11227534	chr11:66336171	C/A	cg24851651	chr11:66362959	CCS	0.39	4.8	0.3	2.83e-6	Airway imaging phenotypes;
SARC	cis	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg21775007	chr8:11205619	TDH	0.49	6.27	0.38	1.73e-9	Retinal vascular caliber;
SARC	cis	rs11155671	0.530	rs7768626	chr6:150207962	G/T	cg05036130	chr6:150231994	NA	0.29	5.05	0.31	8.9e-7	Testicular germ cell tumor;
SARC	cis	rs6772849	0.896	rs35535737	chr3:128383406	G/A	cg01163369	chr3:128370232	RPN1	-0.34	-4.95	-0.31	1.42e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs6062509	0.895	rs6062497	chr20:62336258	C/T	cg27236539	chr20:62289627	RTEL1	0.5	5.44	0.34	1.36e-7	Prostate cancer;
SARC	cis	rs1568889	0.667	rs16917914	chr11:28459909	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.65	7.93	0.46	9.18e-14	Bipolar disorder;
SARC	cis	rs10782582	0.593	rs12129523	chr1:76129223	C/A	cg03433033	chr1:76189801	ACADM	-0.41	-5.41	-0.33	1.56e-7	Daytime sleep phenotypes;
SARC	cis	rs1580019	0.563	rs34201720	chr7:32568935	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.61	8.24	0.47	1.26e-14	Cognitive ability;
SARC	cis	rs4132509	0.948	rs12032342	chr1:243834360	G/A	cg21452805	chr1:244014465	NA	0.53	5.3	0.33	2.67e-7	RR interval (heart rate);
SARC	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg21724239	chr8:58056113	NA	0.57	6.07	0.37	5.07e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs79149102	0.649	rs1531163	chr15:75113083	A/G	cg17294928	chr15:75287854	SCAMP5	-0.81	-5.15	-0.32	5.45e-7	Lung cancer;
SARC	cis	rs11688816	0.904	rs2539984	chr2:63133584	G/C	cg17519650	chr2:63277830	OTX1	0.41	5.11	0.32	6.63e-7	Body mass index;
SARC	cis	rs1865760	0.613	rs9379805	chr6:25938764	T/A	cg17691542	chr6:26056736	HIST1H1C	0.57	7.11	0.42	1.42e-11	Height;
SARC	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg07636037	chr3:49044803	WDR6	-1.02	-18.42	-0.77	2.31e-47	Parkinson's disease;
SARC	cis	rs6807306	1.000	rs6444467	chr3:167367774	C/T	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.5	4.8	0.3	2.86e-6	Mean platelet volume;
SARC	cis	rs11638352	0.661	rs2706490	chr15:44422238	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.76	-5.91	-0.36	1.23e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	trans	rs9951602	0.512	rs8089247	chr18:76651467	C/A	cg02800362	chr5:177631904	HNRNPAB	0.71	9.0	0.51	8.26e-17	Obesity-related traits;
SARC	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.4	-4.91	-0.31	1.75e-6	Lymphocyte counts;
SARC	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg09699651	chr6:150184138	LRP11	0.39	4.87	0.3	2.07e-6	Lung cancer;
SARC	cis	rs6918586	0.658	rs198854	chr6:26104057	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.45	-5.81	-0.36	2.08e-8	Schizophrenia;
SARC	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg03806693	chr22:41940476	POLR3H	-0.99	-13.51	-0.66	4.33e-31	Vitiligo;
SARC	cis	rs1278769	0.735	rs9577395	chr13:113534984	C/G	cg01161842	chr13:113518337	ATP11A	0.42	4.94	0.31	1.48e-6	Interstitial lung disease;
SARC	cis	rs2658782	0.789	rs2605580	chr11:93147054	C/T	cg15737290	chr11:93063684	CCDC67	0.62	6.76	0.4	1.1e-10	Pulmonary function decline;
SARC	cis	rs9513627	0.512	rs9517759	chr13:100180108	T/G	cg25919922	chr13:100150906	NA	0.61	5.66	0.35	4.53e-8	Obesity-related traits;
SARC	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg12310025	chr6:25882481	NA	-0.51	-6.52	-0.39	4.39e-10	Intelligence (multi-trait analysis);
SARC	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg16049864	chr8:95962084	TP53INP1	-0.48	-7.82	-0.46	1.77e-13	Type 2 diabetes;
SARC	cis	rs921968	0.591	rs6717107	chr2:219588697	A/G	cg02176678	chr2:219576539	TTLL4	-0.33	-5.07	-0.32	8.2e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs7474896	0.559	rs1735641	chr10:38184852	C/A	cg00409905	chr10:38381863	ZNF37A	0.46	4.94	0.31	1.49e-6	Obesity (extreme);
SARC	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg21747090	chr2:27597821	SNX17	-0.54	-7.52	-0.44	1.16e-12	Total body bone mineral density;
SARC	cis	rs1707322	0.721	rs12043945	chr1:46106922	T/A	cg06784218	chr1:46089804	CCDC17	0.36	6.2	0.38	2.59e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs672059	1.000	rs652753	chr1:183156569	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.51	6.93	0.41	4.1e-11	Hypertriglyceridemia;
SARC	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg05368731	chr17:41323189	NBR1	0.76	9.01	0.51	7.77e-17	Menopause (age at onset);
SARC	cis	rs9300255	0.596	rs4460848	chr12:123677810	A/G	cg00376283	chr12:123451042	ABCB9	0.57	6.86	0.41	6.06e-11	Neutrophil percentage of white cells;
SARC	cis	rs5758659	0.652	rs133349	chr22:42428727	A/T	cg04733989	chr22:42467013	NAGA	0.54	7.13	0.42	1.27e-11	Cognitive function;
SARC	cis	rs712039	0.652	rs1616371	chr17:35773799	A/G	cg16670864	chr17:35848621	DUSP14	0.46	5.22	0.32	3.92e-7	Tuberculosis;
SARC	trans	rs7615952	0.608	rs35668111	chr3:125544635	C/T	cg07211511	chr3:129823064	LOC729375	-0.75	-8.65	-0.49	8.6e-16	Blood pressure (smoking interaction);
SARC	cis	rs7296418	0.738	rs10846489	chr12:123743927	A/G	cg05973401	chr12:123451056	ABCB9	-0.51	-5.92	-0.36	1.17e-8	Platelet count;
SARC	cis	rs523522	0.926	rs10774555	chr12:120971978	G/A	cg27279351	chr12:120934652	DYNLL1	0.72	8.89	0.5	1.75e-16	High light scatter reticulocyte count;
SARC	cis	rs7617773	0.539	rs35460860	chr3:48392085	A/T	cg11946769	chr3:48343235	NME6	0.55	6.64	0.4	2.12e-10	Coronary artery disease;
SARC	cis	rs929354	0.772	rs3802126	chr7:156970281	G/A	cg05182265	chr7:156933206	UBE3C	-0.33	-5.08	-0.32	7.67e-7	Body mass index;
SARC	cis	rs5753037	0.702	rs36576	chr22:30206291	C/A	cg01021169	chr22:30184971	ASCC2	-0.45	-6.08	-0.37	4.8e-9	Type 1 diabetes;
SARC	cis	rs9911578	0.765	rs66954617	chr17:56999427	A/G	cg05425664	chr17:57184151	TRIM37	-0.67	-8.32	-0.48	7.53e-15	Intelligence (multi-trait analysis);
SARC	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.38	-4.8	-0.3	2.86e-6	Lymphocyte counts;
SARC	cis	rs3749237	0.595	rs1568661	chr3:49520958	A/G	cg03060546	chr3:49711283	APEH	0.75	10.81	0.58	2.35e-22	Resting heart rate;
SARC	cis	rs1003719	0.680	rs2257091	chr21:38522618	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-9.01	-0.51	7.85e-17	Eye color traits;
SARC	cis	rs12477438	0.765	rs12470471	chr2:99689141	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.89	14.44	0.69	3.37e-34	Chronic sinus infection;
SARC	cis	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg09021430	chr5:549028	NA	-0.44	-5.6	-0.34	6.06e-8	Obesity-related traits;
SARC	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs11676348	0.791	rs4133195	chr2:218951245	A/G	cg00012203	chr2:219082015	ARPC2	0.5	6.76	0.4	1.11e-10	Ulcerative colitis;
SARC	cis	rs3768617	0.510	rs10752903	chr1:183100863	A/G	cg13390022	chr1:182993471	LAMC1	0.31	4.79	0.3	3.01e-6	Fuchs's corneal dystrophy;
SARC	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7582180	0.606	rs12618908	chr2:100947026	A/T	cg14675211	chr2:100938903	LONRF2	0.51	7.63	0.45	6.1e-13	Intelligence (multi-trait analysis);
SARC	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg17221315	chr6:27791827	HIST1H4J	0.51	5.28	0.33	2.97e-7	Parkinson's disease;
SARC	cis	rs721399	0.539	rs7460653	chr8:18266983	G/C	cg18736775	chr8:18248649	NAT2	-0.57	-5.73	-0.35	3.13e-8	Blood metabolite levels;
SARC	cis	rs8031584	0.958	rs11293	chr15:31234981	G/A	cg14298792	chr15:30685198	CHRFAM7A	-0.45	-4.95	-0.31	1.45e-6	Huntington's disease progression;
SARC	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.42	-5.11	-0.32	6.63e-7	Tonsillectomy;
SARC	cis	rs112591243	0.685	rs78443123	chr21:47953331	G/T	cg26904215	chr21:47823096	PCNT	-0.74	-4.77	-0.3	3.3e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs4481887	0.927	rs12044126	chr1:248481952	T/C	cg13385794	chr1:248469461	NA	0.33	5.09	0.32	7.48e-7	Common traits (Other);
SARC	cis	rs2929282	1	rs2929282	chr15:44245931	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.68	4.96	0.31	1.33e-6	Triglycerides;Triglyceride levels;
SARC	cis	rs78545713	0.649	rs79308455	chr6:26224377	A/G	cg00631329	chr6:26305371	NA	-0.71	-5.14	-0.32	5.85e-7	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg14298792	chr15:30685198	CHRFAM7A	0.49	5.59	0.34	6.42e-8	Huntington's disease progression;
SARC	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg22535103	chr8:58192502	C8orf71	-0.58	-6.22	-0.38	2.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9715521	0.588	rs11731207	chr4:59852246	G/A	cg11281224	chr4:60001000	NA	-0.46	-5.89	-0.36	1.32e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs2204008	0.597	rs4002591	chr12:38133841	A/G	cg26384229	chr12:38710491	ALG10B	0.89	13.09	0.65	1.02e-29	Bladder cancer;
SARC	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.1	20.49	0.8	5e-54	Chronic sinus infection;
SARC	cis	rs7428	0.545	rs2366404	chr2:85551779	G/A	cg03728395	chr2:85555865	TGOLN2	-0.47	-6.48	-0.39	5.55e-10	Ear protrusion;
SARC	cis	rs7520050	0.808	rs11211196	chr1:46282296	A/T	cg06784218	chr1:46089804	CCDC17	-0.26	-4.74	-0.3	3.76e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs9486715	1.000	rs6899647	chr6:97065661	A/G	cg06623918	chr6:96969491	KIAA0776	-0.81	-11.12	-0.59	2.56e-23	Headache;
SARC	cis	rs9916302	0.706	rs6503521	chr17:37715551	A/C	cg20243544	chr17:37824526	PNMT	-0.51	-4.96	-0.31	1.37e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs7264396	0.563	rs6060558	chr20:34271092	C/G	cg01084648	chr20:34329383	RBM39	0.63	5.25	0.33	3.41e-7	Total cholesterol levels;
SARC	cis	rs16854884	0.545	rs7650459	chr3:143658934	C/G	cg06585982	chr3:143692056	C3orf58	0.54	7.0	0.42	2.77e-11	Economic and political preferences (feminism/equality);
SARC	cis	rs4713118	0.629	rs149899	chr6:28019979	C/T	cg17221315	chr6:27791827	HIST1H4J	0.52	5.27	0.33	3.1e-7	Parkinson's disease;
SARC	cis	rs8064299	1.000	rs8064299	chr17:72762646	C/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.55	6.74	0.4	1.26e-10	Monocyte count;
SARC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg01516881	chr6:292596	DUSP22	-0.63	-7.87	-0.46	1.29e-13	Menopause (age at onset);
SARC	cis	rs72945132	0.882	rs12295111	chr11:70131882	C/A	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.78	-0.35	2.39e-8	Coronary artery disease;
SARC	cis	rs17023223	0.537	rs7532510	chr1:119594236	A/G	cg05756136	chr1:119680316	WARS2	-0.48	-5.55	-0.34	7.82e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg20891283	chr12:69753455	YEATS4	0.68	9.8	0.54	3.26e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9325144	0.560	rs13377717	chr12:38639474	T/A	cg13010199	chr12:38710504	ALG10B	-0.57	-7.53	-0.44	1.1e-12	Morning vs. evening chronotype;
SARC	cis	rs2204008	0.837	rs4312131	chr12:38181087	G/T	cg26384229	chr12:38710491	ALG10B	0.88	12.94	0.65	3.26e-29	Bladder cancer;
SARC	cis	rs11724804	0.532	rs73207782	chr4:848764	G/C	cg23939001	chr4:940644	TMEM175	0.4	4.85	0.3	2.29e-6	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg06700871	chr2:84686330	SUCLG1	0.73	7.72	0.45	3.31e-13	Lung cancer in ever smokers;
SARC	cis	rs9303401	0.527	rs7224468	chr17:56749943	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	11.45	0.6	2.21e-24	Cognitive test performance;
SARC	cis	rs757081	0.667	rs60173525	chr11:17259967	A/G	cg15432903	chr11:17409602	KCNJ11	-0.37	-4.79	-0.3	3.01e-6	Systolic blood pressure;
SARC	cis	rs2153535	0.580	rs4451187	chr6:8473910	C/T	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs9325144	0.752	rs12300353	chr12:39154492	G/C	cg13010199	chr12:38710504	ALG10B	-0.5	-6.06	-0.37	5.35e-9	Morning vs. evening chronotype;
SARC	cis	rs7833790	0.963	rs7836040	chr8:82698328	G/A	cg17211192	chr8:82754475	SNX16	-0.58	-6.22	-0.38	2.23e-9	Diastolic blood pressure;
SARC	cis	rs1062177	0.826	rs2915822	chr5:151130901	G/T	cg00977110	chr5:151150581	G3BP1	-0.57	-5.88	-0.36	1.38e-8	Preschool internalizing problems;
SARC	cis	rs1003719	0.788	rs2835576	chr21:38457393	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.65	9.46	0.53	3.43e-18	Eye color traits;
SARC	cis	rs2153535	0.580	rs1414350	chr6:8472331	C/T	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg27158341	chr6:52959510	FBXO9	0.47	6.76	0.4	1.1e-10	Thyroid stimulating hormone;
SARC	cis	rs9467603	0.925	rs28412066	chr6:25775570	T/A	cg21479132	chr6:26055353	NA	-0.75	-4.75	-0.3	3.55e-6	Intelligence (multi-trait analysis);
SARC	cis	rs10089	0.953	rs10045113	chr5:127386631	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.83	9.67	0.54	8.06e-19	Ileal carcinoids;
SARC	cis	rs67460515	0.892	rs4856703	chr3:161047720	G/T	cg03342759	chr3:160939853	NMD3	-0.68	-8.66	-0.49	8.12e-16	Parkinson's disease;
SARC	cis	rs9329289	0.632	rs2452187	chr10:2551147	C/G	cg15501526	chr10:2543763	NA	0.5	7.19	0.43	8.69e-12	Age-related hearing impairment;
SARC	cis	rs6062302	0.522	rs2236503	chr20:62224595	G/A	cg09650180	chr20:62225654	GMEB2	-0.47	-5.74	-0.35	2.92e-8	Glioblastoma;
SARC	cis	rs763121	0.853	rs5750649	chr22:39036769	T/C	cg06022373	chr22:39101656	GTPBP1	0.92	12.73	0.64	1.6e-28	Menopause (age at onset);
SARC	trans	rs1814175	0.935	rs7482690	chr11:49648814	C/T	cg15704280	chr7:45808275	SEPT13	-0.9	-15.16	-0.7	1.41e-36	Height;
SARC	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	12.08	0.62	2.03e-26	Platelet count;
SARC	cis	rs12477438	1.000	rs17760953	chr2:99859863	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.7	-7.94	-0.46	8.32e-14	Chronic sinus infection;
SARC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg03647317	chr4:187891568	NA	-0.35	-4.81	-0.3	2.74e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7561273	0.561	rs35268318	chr2:24352824	A/T	cg07265300	chr2:24346000	PFN4;LOC375190	-0.42	-4.72	-0.3	4.01e-6	Quantitative traits;
SARC	cis	rs9788721	0.806	rs4887056	chr15:78734585	A/G	cg18825076	chr15:78729989	IREB2	-0.52	-6.45	-0.39	6.47e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs2865126	0.743	rs10502403	chr18:10749140	T/C	cg21165219	chr18:10698044	FAM38B	-0.47	-4.74	-0.3	3.71e-6	Metabolite levels (5-HIAA/ MHPG Ratio);
SARC	cis	rs1185460	0.967	rs1784459	chr11:118938388	C/A	cg23280166	chr11:118938394	VPS11	0.81	12.33	0.63	3.08e-27	Coronary artery disease;
SARC	cis	rs7729447	0.566	rs3828589	chr5:32713327	T/C	cg16267343	chr5:32710456	NPR3	0.61	7.97	0.46	7.26e-14	Blood pressure;
SARC	cis	rs6582630	0.519	rs11181294	chr12:38312787	C/T	cg26384229	chr12:38710491	ALG10B	0.85	12.48	0.63	1.01e-27	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg13880726	chr7:1868755	MAD1L1	0.43	5.0	0.31	1.14e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs2276314	1.000	rs4573997	chr18:33552568	C/T	cg05985134	chr18:33552581	C18orf21	0.74	7.88	0.46	1.28e-13	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs3820928	0.845	rs13415319	chr2:227878936	G/C	cg05526886	chr2:227700861	RHBDD1	-0.49	-5.79	-0.35	2.31e-8	Pulmonary function;
SARC	cis	rs7568458	0.684	rs67988001	chr2:85787123	C/T	cg02493740	chr2:85810744	VAMP5	-0.41	-5.16	-0.32	5.37e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs7474896	0.515	rs688608	chr10:38331624	G/A	cg25427524	chr10:38739819	LOC399744	0.45	5.06	0.31	8.48e-7	Obesity (extreme);
SARC	trans	rs2727020	0.729	rs685789	chr11:49241228	G/A	cg03929089	chr4:120376271	NA	0.74	10.18	0.55	2.23e-20	Coronary artery disease;
SARC	cis	rs449789	0.711	rs7765794	chr6:159704925	T/C	cg14500486	chr6:159655392	FNDC1	-0.44	-5.02	-0.31	1.01e-6	Pulse pressure;
SARC	cis	rs12950390	0.530	rs16947058	chr17:45825186	A/G	cg24803719	chr17:45855879	NA	0.46	7.77	0.45	2.52e-13	IgG glycosylation;
SARC	cis	rs9815354	1.000	rs6789260	chr3:41776350	G/C	cg03022575	chr3:42003672	ULK4	0.67	5.75	0.35	2.78e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9788721	0.902	rs114205691	chr15:78901113	C/T	cg18825076	chr15:78729989	IREB2	-0.43	-5.11	-0.32	6.81e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs1920116	0.778	rs11928433	chr3:169563450	T/C	cg14222479	chr3:169487675	ARPM1	0.44	5.1	0.32	7e-7	Glioma (high-grade);
SARC	cis	rs11969893	0.850	rs12664068	chr6:101362098	G/T	cg12253828	chr6:101329408	ASCC3	1.22	7.25	0.43	6.2e-12	Economic and political preferences (immigration/crime);
SARC	cis	rs5753037	0.630	rs140111	chr22:30131570	A/G	cg01021169	chr22:30184971	ASCC2	-0.44	-6.18	-0.38	2.86e-9	Type 1 diabetes;
SARC	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg09699651	chr6:150184138	LRP11	0.49	5.93	0.36	1.06e-8	Lung cancer;
SARC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg16132339	chr22:24313637	DDTL;DDT	0.41	5.22	0.32	4.02e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs959260	0.557	rs4788887	chr17:73323876	C/G	cg07104495	chr17:73266070	MIF4GD	-0.33	-4.95	-0.31	1.4e-6	Systemic lupus erythematosus;
SARC	cis	rs4481887	1.000	rs4554750	chr1:248496530	C/G	cg01631408	chr1:248437212	OR2T33	-0.42	-5.26	-0.33	3.32e-7	Common traits (Other);
SARC	cis	rs1832871	0.672	rs12525675	chr6:158708749	A/T	cg07165851	chr6:158734300	TULP4	0.54	6.56	0.39	3.5e-10	Height;
SARC	trans	rs629535	0.911	rs688612	chr8:70011887	C/T	cg21567404	chr3:27674614	NA	-1.06	-14.12	-0.68	4.15e-33	Dupuytren's disease;
SARC	cis	rs11599315	0.507	rs12217329	chr10:1341897	A/G	cg09624528	chr10:1369823	ADARB2	0.43	6.79	0.41	9.47e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs7617773	0.925	rs35942721	chr3:48173069	C/T	cg11946769	chr3:48343235	NME6	0.65	7.28	0.43	5.06e-12	Coronary artery disease;
SARC	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg24549020	chr5:56110836	MAP3K1	0.81	8.46	0.48	3.01e-15	Initial pursuit acceleration;
SARC	cis	rs7662987	0.517	rs2602873	chr4:100039032	G/C	cg12011299	chr4:100065546	ADH4	0.33	5.47	0.34	1.13e-7	Smoking initiation;
SARC	cis	rs6693567	0.565	rs834242	chr1:150379858	G/A	cg09579323	chr1:150459698	TARS2	0.45	5.84	0.36	1.74e-8	Migraine;
SARC	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg04944784	chr2:26401820	FAM59B	0.6	7.95	0.46	8.14e-14	Gut microbiome composition (summer);
SARC	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg25703541	chr22:24373054	LOC391322	0.83	10.87	0.58	1.55e-22	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.99	11.73	0.61	2.89e-25	Platelet count;
SARC	cis	rs950027	0.620	rs1145084	chr15:45675440	G/A	cg15395560	chr15:45543142	SLC28A2	-0.27	-5.25	-0.33	3.36e-7	Response to fenofibrate (adiponectin levels);
SARC	cis	rs10861342	1.000	rs10861357	chr12:105544254	C/T	cg23923672	chr12:105501055	KIAA1033	0.7	5.37	0.33	1.95e-7	IgG glycosylation;
SARC	cis	rs72945132	0.882	rs11235755	chr11:70136323	A/G	cg00319359	chr11:70116639	PPFIA1	0.68	6.32	0.38	1.32e-9	Coronary artery disease;
SARC	cis	rs6696846	0.765	rs11576867	chr1:205064676	C/T	cg00857998	chr1:205179979	DSTYK	0.5	6.58	0.4	3.03e-10	Red blood cell count;
SARC	cis	rs11249608	0.548	rs6894076	chr5:178449813	T/C	cg21905437	chr5:178450457	ZNF879	0.57	7.48	0.44	1.46e-12	Pubertal anthropometrics;
SARC	cis	rs8141529	0.529	rs66471734	chr22:29215803	G/A	cg02153584	chr22:29168773	CCDC117	0.65	6.65	0.4	2.02e-10	Lymphocyte counts;
SARC	cis	rs3892630	0.824	rs35700505	chr19:33325006	C/T	cg22980127	chr19:33182716	NUDT19	0.89	7.93	0.46	8.81e-14	Red blood cell traits;
SARC	cis	rs9788721	0.836	rs2009746	chr15:78754102	A/G	cg18825076	chr15:78729989	IREB2	-0.52	-6.41	-0.39	7.86e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	11.6	0.61	7.26e-25	Alzheimer's disease;
SARC	cis	rs559928	0.606	rs56311067	chr11:63931607	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	5.12	0.32	6.44e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs9788682	0.668	rs2036529	chr15:78726272	A/T	cg24631222	chr15:78858424	CHRNA5	-0.73	-8.39	-0.48	4.57e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg12311346	chr5:56204834	C5orf35	-0.58	-5.99	-0.37	8.02e-9	Initial pursuit acceleration;
SARC	cis	rs9790314	0.875	rs459515	chr3:161092351	T/C	cg04691961	chr3:161091175	C3orf57	-0.76	-11.31	-0.6	6.12e-24	Morning vs. evening chronotype;
SARC	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg07701084	chr6:150067640	NUP43	0.41	5.41	0.33	1.59e-7	Lung cancer;
SARC	cis	rs9914988	0.943	rs2242345	chr17:27185827	C/T	cg20469991	chr17:27169893	C17orf63	0.52	5.31	0.33	2.53e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.52	-5.2	-0.32	4.35e-7	Lung function (FEV1/FVC);
SARC	cis	rs3126085	0.935	rs3126062	chr1:152272352	G/A	cg03465714	chr1:152285911	FLG	0.47	5.58	0.34	6.82e-8	Atopic dermatitis;
SARC	cis	rs6840360	0.615	rs28659854	chr4:152607442	T/C	cg22705602	chr4:152727874	NA	-0.48	-8.42	-0.48	3.83e-15	Intelligence (multi-trait analysis);
SARC	cis	rs4853036	0.672	rs3771542	chr2:70029310	A/G	cg02498382	chr2:70120550	SNRNP27	-0.36	-4.97	-0.31	1.28e-6	Colorectal or endometrial cancer;
SARC	cis	rs9435341	1.000	rs9435341	chr1:107616641	T/C	cg09367891	chr1:107599246	PRMT6	-0.64	-7.91	-0.46	1.06e-13	Facial morphology (factor 21, depth of nasal alae);
SARC	cis	rs12586317	0.513	rs11156871	chr14:35481196	G/A	cg26967526	chr14:35346199	BAZ1A	-0.57	-5.71	-0.35	3.4e-8	Psoriasis;
SARC	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg12311346	chr5:56204834	C5orf35	-0.58	-6.01	-0.37	7.24e-9	Initial pursuit acceleration;
SARC	cis	rs56390833	1	rs56390833	chr15:78877381	C/A	cg18825076	chr15:78729989	IREB2	-0.43	-5.16	-0.32	5.28e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs6580649	0.883	rs7967762	chr12:48420214	C/T	cg05342945	chr12:48394962	COL2A1	0.57	6.18	0.38	2.79e-9	Lung cancer;
SARC	cis	rs3091242	0.933	rs3093584	chr1:25668714	T/C	cg03650068	chr1:25596491	NA	-0.35	-5.42	-0.33	1.46e-7	Erythrocyte sedimentation rate;
SARC	cis	rs8077889	1.000	rs4793035	chr17:41887753	C/T	cg26893861	chr17:41843967	DUSP3	0.93	11.15	0.59	1.97e-23	Triglycerides;
SARC	cis	rs17376456	1.000	rs13163610	chr5:93548877	A/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.17	0.32	5e-7	Diabetic retinopathy;
SARC	cis	rs6016377	0.798	rs6016381	chr20:39180436	T/C	cg06424997	chr20:39929561	ZHX3	0.38	4.96	0.31	1.38e-6	Birth weight;
SARC	cis	rs644799	1.000	rs557079	chr11:95530125	C/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.7	9.55	0.53	1.87e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg22105103	chr4:187893119	NA	0.5	6.79	0.41	9.33e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs908922	0.676	rs10888491	chr1:152492622	A/G	cg09873164	chr1:152488093	CRCT1	0.62	7.96	0.46	7.55e-14	Hair morphology;
SARC	cis	rs2361718	0.900	rs8081698	chr17:78104212	G/A	cg14949292	chr17:78079608	GAA	-0.29	-4.75	-0.3	3.6e-6	Yeast infection;
SARC	cis	rs765787	0.530	rs4775832	chr15:45534828	A/G	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.81e-6	Uric acid levels;
SARC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg06873352	chr17:61820015	STRADA	0.54	7.1	0.42	1.49e-11	Prudent dietary pattern;
SARC	cis	rs3087591	0.922	rs757383	chr17:29596045	C/G	cg24425628	chr17:29625626	OMG;NF1	0.53	6.64	0.4	2.19e-10	Hip circumference;
SARC	cis	rs9807989	0.507	rs2287033	chr2:103011237	C/T	cg03938978	chr2:103052716	IL18RAP	-0.31	-4.96	-0.31	1.35e-6	Asthma;
SARC	cis	rs2455601	0.608	rs16906256	chr11:8887097	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.4	-4.86	-0.3	2.19e-6	Schizophrenia;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg21803754	chr20:60718392	PSMA7;SS18L1	0.51	6.98	0.42	2.97e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs17376456	0.877	rs9314093	chr5:93333347	G/A	cg25358565	chr5:93447407	FAM172A	1.3	14.42	0.69	3.97e-34	Diabetic retinopathy;
SARC	cis	rs4774830	0.744	rs62046383	chr15:56303623	C/T	cg24530489	chr15:56299380	NA	-0.84	-4.97	-0.31	1.28e-6	Delta-5 desaturase activity;
SARC	cis	rs453301	0.686	rs13252797	chr8:8861430	A/G	cg11995313	chr8:8860691	ERI1	-0.46	-5.86	-0.36	1.57e-8	Joint mobility (Beighton score);
SARC	cis	rs7216064	0.765	rs6504550	chr17:65894542	A/G	cg12091567	chr17:66097778	LOC651250	-0.61	-7.21	-0.43	7.7e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs7666738	0.830	rs34212748	chr4:99068708	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.71	0.5	5.54e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9300255	0.543	rs1260294	chr12:123560289	T/C	cg05973401	chr12:123451056	ABCB9	-0.52	-4.8	-0.3	2.88e-6	Neutrophil percentage of white cells;
SARC	cis	rs7208859	0.673	rs11656845	chr17:29206164	G/T	cg13385521	chr17:29058706	SUZ12P	0.83	6.68	0.4	1.72e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs57506017	0.585	rs5011438	chr7:12268798	C/T	cg23422036	chr7:12250390	TMEM106B	0.45	5.87	0.36	1.46e-8	Neuroticism;
SARC	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg08677398	chr8:58056175	NA	0.42	5.12	0.32	6.32e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6142102	0.812	rs6059558	chr20:32516830	G/C	cg24642439	chr20:33292090	TP53INP2	0.45	4.81	0.3	2.75e-6	Skin pigmentation;
SARC	cis	rs9811216	0.917	rs3772190	chr3:169500487	G/A	cg14222479	chr3:169487675	ARPM1	0.47	5.34	0.33	2.25e-7	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg18252515	chr7:66147081	NA	0.48	5.14	0.32	5.72e-7	Aortic root size;
SARC	cis	rs4332037	0.901	rs11767040	chr7:1945468	C/T	cg23422044	chr7:1970798	MAD1L1	-0.46	-4.88	-0.3	1.96e-6	Bipolar disorder;
SARC	trans	rs459571	0.920	rs455073	chr9:136909141	G/C	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.6	-6.66	-0.4	1.95e-10	Platelet distribution width;
SARC	cis	rs4481887	0.927	rs4292985	chr1:248473692	T/A	cg00666640	chr1:248458726	OR2T12	0.34	5.67	0.35	4.19e-8	Common traits (Other);
SARC	cis	rs7762018	0.607	rs75521584	chr6:170051595	T/C	cg19338460	chr6:170058176	WDR27	-0.75	-5.04	-0.31	9.33e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs12421382	0.593	rs1808842	chr11:109389454	C/T	cg27471124	chr11:109292789	C11orf87	0.36	5.18	0.32	4.89e-7	Schizophrenia;
SARC	cis	rs6696846	0.765	rs61822567	chr1:205078725	T/C	cg00857998	chr1:205179979	DSTYK	0.49	6.29	0.38	1.59e-9	Red blood cell count;
SARC	cis	rs3936840	0.964	rs10150698	chr14:102977876	A/G	cg18135206	chr14:102964638	TECPR2	0.52	6.41	0.39	8e-10	Plateletcrit;
SARC	cis	rs9916302	0.861	rs593480	chr17:37453780	A/C	cg20243544	chr17:37824526	PNMT	-0.55	-6.56	-0.39	3.52e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs3767633	0.925	rs4233380	chr1:161892483	A/C	cg09175582	chr1:161736000	ATF6	0.73	6.33	0.38	1.23e-9	IgG glycosylation;
SARC	cis	rs9660992	0.710	rs1668867	chr1:205240251	C/T	cg21643547	chr1:205240462	TMCC2	-0.67	-8.97	-0.51	1.01e-16	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs6964587	0.900	rs4279	chr7:91764128	C/A	cg17063962	chr7:91808500	NA	0.96	16.36	0.73	1.37e-40	Breast cancer;
SARC	cis	rs7824557	0.767	rs1897951	chr8:11169854	C/T	cg21775007	chr8:11205619	TDH	0.51	6.01	0.37	7.21e-9	Retinal vascular caliber;
SARC	cis	rs6964587	0.692	rs4729021	chr7:91758422	C/A	cg17063962	chr7:91808500	NA	0.79	12.03	0.62	2.97e-26	Breast cancer;
SARC	cis	rs17376456	0.825	rs66564678	chr5:93165894	C/T	cg21475434	chr5:93447410	FAM172A	0.8	6.72	0.4	1.4e-10	Diabetic retinopathy;
SARC	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg06634786	chr22:41940651	POLR3H	-0.57	-6.77	-0.41	1.05e-10	Vitiligo;
SARC	cis	rs910316	0.967	rs7146523	chr14:75659880	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.47	-6.5	-0.39	4.84e-10	Height;
SARC	cis	rs3809566	1.000	rs10851721	chr15:63332383	T/C	cg05507819	chr15:63340323	TPM1	0.53	5.79	0.35	2.25e-8	Platelet count;
SARC	cis	rs7584330	0.955	rs7581882	chr2:238390745	T/C	cg11271282	chr2:238384023	NA	0.46	5.48	0.34	1.12e-7	Prostate cancer;
SARC	cis	rs4423214	0.592	rs79634040	chr11:71230169	G/C	cg05163923	chr11:71159392	DHCR7	-0.55	-5.41	-0.33	1.54e-7	Vitamin D levels;
SARC	cis	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg00409905	chr10:38381863	ZNF37A	-0.55	-7.58	-0.44	8.22e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs2712184	0.756	rs2024489	chr2:217661530	A/G	cg05032264	chr2:217675019	NA	-0.5	-6.54	-0.39	3.85e-10	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
SARC	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.32	-4.99	-0.31	1.19e-6	Total body bone mineral density;
SARC	cis	rs2070488	0.965	rs1870915	chr3:38494228	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	14.57	0.69	1.31e-34	Electrocardiographic conduction measures;
SARC	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg08280861	chr8:58055591	NA	0.6	5.83	0.36	1.8e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs3768617	0.528	rs3736888	chr1:183084607	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.11	0.55	3.69e-20	Fuchs's corneal dystrophy;
SARC	trans	rs61931739	0.500	rs7488438	chr12:34531359	G/T	cg13010199	chr12:38710504	ALG10B	0.83	11.64	0.61	5.5e-25	Morning vs. evening chronotype;
SARC	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.7	-7.98	-0.46	6.59e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.23e-9	Life satisfaction;
SARC	cis	rs6570726	0.764	rs448258	chr6:145869145	C/A	cg23711669	chr6:146136114	FBXO30	0.87	14.71	0.69	4.26e-35	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2204008	0.744	rs66474616	chr12:38461564	G/A	cg26384229	chr12:38710491	ALG10B	0.87	12.52	0.63	7.68e-28	Bladder cancer;
SARC	cis	rs7005606	1.000	rs17719705	chr8:32414332	A/T	cg14488905	chr8:32406789	NRG1	0.46	6.54	0.39	3.9e-10	Hirschsprung disease;
SARC	cis	rs7582720	1.000	rs72936830	chr2:203769803	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.31	0.43	4.24e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs1961456	0.542	rs75501607	chr8:18244753	C/T	cg18736775	chr8:18248649	NAT2	-0.59	-6.73	-0.4	1.28e-10	Total cholesterol levels;
SARC	cis	rs12950390	0.853	rs8078052	chr17:45859434	A/G	cg03474202	chr17:45855739	NA	-0.43	-6.71	-0.4	1.44e-10	IgG glycosylation;
SARC	cis	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.84	12.36	0.63	2.64e-27	Eosinophil percentage of white cells;
SARC	cis	rs950776	1.000	rs950776	chr15:78926018	A/G	cg06917634	chr15:78832804	PSMA4	0.66	8.59	0.49	1.23e-15	Sudden cardiac arrest;
SARC	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.74	10.08	0.55	4.46e-20	Menarche (age at onset);
SARC	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg25894440	chr7:65020034	NA	-0.75	-5.59	-0.34	6.48e-8	Diabetic kidney disease;
SARC	cis	rs11190604	0.767	rs11190509	chr10:102156208	G/A	cg07080220	chr10:102295463	HIF1AN	0.7	7.66	0.45	5.04e-13	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs3733585	0.699	rs7437120	chr4:9967683	T/A	cg00071950	chr4:10020882	SLC2A9	-0.38	-6.01	-0.37	7.25e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg17971929	chr21:40555470	PSMG1	-0.59	-7.5	-0.44	1.36e-12	Menarche (age at onset);
SARC	trans	rs9650657	0.707	rs11250076	chr8:10647823	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.94	-0.41	3.76e-11	Neuroticism;
SARC	cis	rs6120849	0.901	rs13037296	chr20:33749228	T/A	cg24642439	chr20:33292090	TP53INP2	0.48	4.74	0.3	3.78e-6	Protein C levels;
SARC	cis	rs910316	0.789	rs175457	chr14:75584507	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.48	-6.5	-0.39	4.92e-10	Height;
SARC	cis	rs2529049	0.560	rs2711128	chr7:24656208	A/G	cg17569154	chr7:24781545	DFNA5	0.5	7.19	0.43	9.01e-12	Urate levels in obese individuals;
SARC	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg22535103	chr8:58192502	C8orf71	-0.82	-9.22	-0.52	1.89e-17	Developmental language disorder (linguistic errors);
SARC	cis	rs76419734	1.000	rs74398423	chr4:106720966	C/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.76	5.13	0.32	6.17e-7	Post bronchodilator FEV1;
SARC	cis	rs611744	0.538	rs59930666	chr8:109262296	T/C	cg21045802	chr8:109455806	TTC35	0.61	8.02	0.47	5.03e-14	Dupuytren's disease;
SARC	cis	rs9788721	0.592	rs28564957	chr15:78906107	C/A	cg22563815	chr15:78856949	CHRNA5	-0.37	-6.08	-0.37	4.83e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs7937682	0.855	rs7934922	chr11:111500026	T/C	cg22437258	chr11:111473054	SIK2	0.74	10.03	0.55	6.36e-20	Primary sclerosing cholangitis;
SARC	cis	rs1865760	0.532	rs2006736	chr6:26086017	C/T	cg17691542	chr6:26056736	HIST1H1C	0.52	6.41	0.39	8.05e-10	Height;
SARC	cis	rs2882877	0.648	rs726093	chr2:190396659	T/C	cg21926118	chr2:190387206	NA	-0.41	-5.1	-0.32	6.88e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg23262073	chr20:60523788	NA	-0.39	-5.63	-0.35	5.17e-8	Body mass index;
SARC	cis	rs9300255	0.639	rs1716171	chr12:123716376	C/T	cg05973401	chr12:123451056	ABCB9	0.47	5.29	0.33	2.84e-7	Neutrophil percentage of white cells;
SARC	cis	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg07274523	chr3:49395745	GPX1	0.49	5.61	0.35	5.68e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs9457247	0.935	rs2149093	chr6:167373045	T/C	cg07741184	chr6:167504864	NA	-0.3	-5.74	-0.35	2.93e-8	Crohn's disease;
SARC	cis	rs9393777	0.623	rs9358945	chr6:26472114	C/T	cg12826209	chr6:26865740	GUSBL1	-0.81	-7.68	-0.45	4.45e-13	Intelligence (multi-trait analysis);
SARC	cis	rs8017423	0.967	rs55962513	chr14:90729460	C/G	cg20276874	chr14:90721474	PSMC1	-0.38	-5.25	-0.33	3.39e-7	Mortality in heart failure;
SARC	cis	rs7914558	0.966	rs1591915	chr10:104646849	C/T	cg15744005	chr10:104629667	AS3MT	-0.27	-4.89	-0.3	1.91e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg17971929	chr21:40555470	PSMG1	0.96	11.74	0.61	2.72e-25	Cognitive function;
SARC	cis	rs4481887	0.893	rs11204632	chr1:248479532	G/A	cg00666640	chr1:248458726	OR2T12	0.34	5.56	0.34	7.45e-8	Common traits (Other);
SARC	cis	rs1018697	0.518	rs2482506	chr10:104563743	C/G	cg04362960	chr10:104952993	NT5C2	-0.48	-5.02	-0.31	1.01e-6	Colorectal adenoma (advanced);
SARC	trans	rs634534	0.622	rs531612	chr11:65705432	C/T	cg17712092	chr4:129076599	LARP1B	-0.66	-8.69	-0.49	6.65e-16	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.64	-7.96	-0.46	7.53e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7843479	0.932	rs68023663	chr8:21794379	T/C	cg17168535	chr8:21777572	XPO7	0.65	8.32	0.48	7.22e-15	Mean corpuscular volume;
SARC	cis	rs9309473	0.851	rs6546850	chr2:73831147	A/T	cg20560298	chr2:73613845	ALMS1	-0.46	-5.4	-0.33	1.64e-7	Metabolite levels;
SARC	cis	rs7769051	0.522	rs7762248	chr6:133105303	A/C	cg22852734	chr6:133119734	C6orf192	1.15	7.34	0.43	3.57e-12	Type 2 diabetes nephropathy;
SARC	cis	rs637571	0.522	rs528736	chr11:65705108	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.58	8.92	0.5	1.4e-16	Eosinophil percentage of white cells;
SARC	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-4.91	-0.31	1.71e-6	Total body bone mineral density;
SARC	cis	rs12130219	0.500	rs4845737	chr1:152177539	G/A	cg25272121	chr1:152190972	HRNR	-0.41	-5.44	-0.34	1.35e-7	Inflammatory skin disease;
SARC	cis	rs13191362	0.938	rs13192618	chr6:163132822	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.52	5.34	0.33	2.23e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs1348850	0.958	rs11689550	chr2:178456298	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.64	7.7	0.45	3.93e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.73	9.72	0.54	5.83e-19	Lymphocyte counts;
SARC	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg18876405	chr7:65276391	NA	0.72	9.37	0.52	6.5e-18	Aortic root size;
SARC	cis	rs400736	0.671	rs2131630	chr1:7990367	G/A	cg25007680	chr1:8021821	PARK7	-0.41	-5.35	-0.33	2.09e-7	Response to antidepressants and depression;
SARC	cis	rs1050631	0.592	rs1631346	chr18:33709664	T/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.57	6.76	0.4	1.09e-10	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs898097	0.783	rs11650335	chr17:80835111	A/G	cg20578329	chr17:80767326	TBCD	-0.51	-6.77	-0.41	1.05e-10	Breast cancer;
SARC	trans	rs11250098	0.574	rs4554431	chr8:10771638	T/A	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.41	-0.39	8.09e-10	Morning vs. evening chronotype;
SARC	cis	rs3768617	0.528	rs2027082	chr1:183084608	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.11	0.55	3.69e-20	Fuchs's corneal dystrophy;
SARC	cis	rs79349575	0.783	rs1994970	chr17:47014127	C/T	cg16584676	chr17:46985605	UBE2Z	-0.58	-6.82	-0.41	7.85e-11	Type 2 diabetes;
SARC	trans	rs1994135	0.715	rs10844624	chr12:33691010	A/G	cg13010199	chr12:38710504	ALG10B	0.7	8.55	0.49	1.62e-15	Resting heart rate;
SARC	cis	rs244731	0.959	rs11740250	chr5:176721272	G/C	cg16006841	chr5:176797999	RGS14	0.56	6.6	0.4	2.79e-10	Urate levels in lean individuals;
SARC	cis	rs2153535	0.580	rs9328486	chr6:8528008	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	6.53	0.39	4.11e-10	Motion sickness;
SARC	cis	rs17376456	0.877	rs10213956	chr5:93460839	C/T	cg25358565	chr5:93447407	FAM172A	1.32	14.94	0.7	7.42e-36	Diabetic retinopathy;
SARC	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg06212747	chr3:49208901	KLHDC8B	0.67	8.89	0.5	1.7e-16	Parkinson's disease;
SARC	cis	rs4689388	0.819	rs12649341	chr4:6294759	G/A	cg25554036	chr4:6271136	WFS1	0.39	6.42	0.39	7.48e-10	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg11941060	chr3:133502564	NA	0.4	5.64	0.35	4.93e-8	Iron status biomarkers;
SARC	cis	rs9914544	0.545	rs4393623	chr17:18775900	A/G	cg25390199	chr17:18761479	PRPSAP2	0.46	6.06	0.37	5.3e-9	Educational attainment (years of education);
SARC	cis	rs2439831	1.000	rs2253708	chr15:43797273	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	8.12	0.47	2.67e-14	Lung cancer in ever smokers;
SARC	cis	rs72634258	0.554	rs12723500	chr1:7857374	G/C	cg05338066	chr1:7812865	CAMTA1	0.65	5.35	0.33	2.05e-7	Inflammatory bowel disease;
SARC	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg11764359	chr7:65958608	NA	0.78	10.12	0.55	3.55e-20	Aortic root size;
SARC	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg01238044	chr22:24384105	GSTT1	0.61	7.09	0.42	1.58e-11	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs67311347	1.000	rs4973898	chr3:40459532	A/G	cg24209194	chr3:40518798	ZNF619	-0.64	-8.28	-0.48	9.84e-15	Renal cell carcinoma;
SARC	cis	rs9487051	0.714	rs7755970	chr6:109602359	A/G	cg01475377	chr6:109611718	NA	-0.35	-5.03	-0.31	9.63e-7	Reticulocyte fraction of red cells;
SARC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg06873352	chr17:61820015	STRADA	0.51	6.6	0.4	2.72e-10	Prudent dietary pattern;
SARC	cis	rs2204008	0.540	rs3908193	chr12:38410907	G/T	cg26384229	chr12:38710491	ALG10B	-0.56	-6.9	-0.41	4.73e-11	Bladder cancer;
SARC	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg03806693	chr22:41940476	POLR3H	0.9	11.92	0.62	6.71e-26	Vitiligo;
SARC	cis	rs7084783	0.622	rs61606504	chr10:105348767	A/G	cg00126946	chr10:105363258	SH3PXD2A	0.29	4.91	0.31	1.69e-6	Fear of pain;
SARC	cis	rs787274	1.000	rs787271	chr9:115549463	C/T	cg13803584	chr9:115635662	SNX30	-0.75	-5.88	-0.36	1.42e-8	Age-related hearing impairment (SNP x SNP interaction);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg09145256	chr2:48757694	NA	0.52	6.88	0.41	5.53e-11	Chemerin levels;
SARC	cis	rs7937682	0.855	rs539553	chr11:111477333	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.89	-13.96	-0.67	1.34e-32	Primary sclerosing cholangitis;
SARC	cis	rs6835098	1.000	rs2332654	chr4:174088399	C/T	cg08422745	chr4:174089978	GALNT7	-0.78	-10.44	-0.56	3.41e-21	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs6815814	0.861	rs6531663	chr4:38792340	T/C	cg06935464	chr4:38784597	TLR10	0.51	5.67	0.35	4.18e-8	Breast cancer;
SARC	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg13264159	chr8:625131	ERICH1	-0.72	-5.42	-0.33	1.5e-7	IgG glycosylation;
SARC	cis	rs950776	0.642	rs34694149	chr15:78965917	C/T	cg06917634	chr15:78832804	PSMA4	0.45	4.98	0.31	1.26e-6	Sudden cardiac arrest;
SARC	cis	rs4702	0.611	rs2071382	chr15:91428197	T/C	cg05469396	chr15:91419421	FURIN	0.43	5.9	0.36	1.26e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg04772025	chr11:68637568	NA	0.51	6.64	0.4	2.23e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg08280861	chr8:58055591	NA	0.59	5.22	0.32	4.02e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs11621710	0.557	rs799474	chr14:35516099	C/G	cg16230307	chr14:35515116	FAM177A1	0.48	6.02	0.37	6.63e-9	Granulocyte percentage of myeloid white cells;
SARC	cis	rs6815814	0.950	rs56357984	chr4:38806462	G/A	cg02016764	chr4:38805732	TLR1	-0.43	-4.98	-0.31	1.26e-6	Breast cancer;
SARC	cis	rs3126085	0.877	rs11204968	chr1:152250211	A/T	cg03465714	chr1:152285911	FLG	-0.45	-5.45	-0.34	1.25e-7	Atopic dermatitis;
SARC	cis	rs72781680	0.611	rs55983206	chr2:24333995	A/C	cg06627628	chr2:24431161	ITSN2	-0.55	-5.77	-0.35	2.5e-8	Lymphocyte counts;
SARC	cis	rs427394	0.802	rs274721	chr5:6719164	C/T	cg10857441	chr5:6722123	POLS	-0.33	-5.04	-0.31	9.56e-7	Menopause (age at onset);
SARC	cis	rs1348850	0.793	rs6734528	chr2:178493731	G/A	cg23306229	chr2:178417860	TTC30B	0.51	5.66	0.35	4.46e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1707322	0.717	rs2275086	chr1:46085879	C/G	cg06784218	chr1:46089804	CCDC17	-0.37	-6.46	-0.39	6.06e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.62	7.34	0.43	3.53e-12	Gut microbiome composition (summer);
SARC	cis	rs9303542	0.625	rs17703660	chr17:46567134	T/C	cg04904318	chr17:46607828	HOXB1	-0.47	-5.46	-0.34	1.23e-7	Ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs5753618	0.509	rs4820951	chr22:31586248	G/A	cg00478049	chr22:31556069	RNF185	0.44	4.74	0.3	3.65e-6	Colorectal cancer;
SARC	cis	rs282587	0.569	rs373653	chr13:113406699	A/G	cg09142119	chr13:113884190	CUL4A	-0.46	-4.91	-0.31	1.75e-6	Glycated hemoglobin levels;
SARC	cis	rs1003719	0.788	rs2835586	chr21:38461326	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.65	9.38	0.52	6.15e-18	Eye color traits;
SARC	cis	rs9611565	0.506	rs2024567	chr22:41699206	G/C	cg17376030	chr22:41985996	PMM1	0.58	7.22	0.43	7.42e-12	Vitiligo;
SARC	cis	rs7909074	0.898	rs10793565	chr10:45388231	G/C	cg04218760	chr10:45406644	TMEM72	-0.26	-5.17	-0.32	4.98e-7	Mean corpuscular volume;
SARC	cis	rs17401966	0.931	rs4846213	chr1:10399178	A/G	cg15208524	chr1:10270712	KIF1B	0.5	5.98	0.36	8.28e-9	Hepatocellular carcinoma;
SARC	cis	rs2153535	0.580	rs9379213	chr6:8474945	G/A	cg21535247	chr6:8435926	SLC35B3	0.54	6.79	0.41	9.19e-11	Motion sickness;
SARC	trans	rs643955	0.637	rs4841271	chr8:9870137	T/A	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.51	-0.39	4.57e-10	Systemic lupus erythematosus;
SARC	cis	rs10411936	0.712	rs9305079	chr19:16591464	C/T	cg10248733	chr19:16607483	C19orf44;CALR3	0.61	7.44	0.44	1.93e-12	White blood cell count;Multiple sclerosis;
SARC	cis	rs11731606	0.508	rs12108275	chr4:95298847	T/G	cg20625393	chr4:95128694	SMARCAD1	0.57	5.55	0.34	7.71e-8	Mean platelet volume;
SARC	cis	rs6864727	1.000	rs6864727	chr5:137247940	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	-0.53	-5.99	-0.37	7.71e-9	Atrial fibrillation;
SARC	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg13880726	chr7:1868755	MAD1L1	0.51	6.14	0.37	3.51e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg11878867	chr6:150167359	LRP11	-0.35	-4.81	-0.3	2.76e-6	Lung cancer;
SARC	cis	rs2594989	0.779	rs13353407	chr3:11585299	C/T	cg00170343	chr3:11313890	ATG7	-0.55	-5.8	-0.36	2.1e-8	Circulating chemerin levels;
SARC	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg26681399	chr22:41777847	TEF	-0.43	-4.77	-0.3	3.28e-6	Vitiligo;
SARC	cis	rs9902453	0.765	rs2628167	chr17:28064498	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.54	-7.14	-0.42	1.19e-11	Coffee consumption (cups per day);
SARC	cis	rs7149242	0.662	rs4905998	chr14:101181781	A/G	cg18089426	chr14:101175970	NA	-0.42	-5.86	-0.36	1.58e-8	Platelet count;
SARC	trans	rs61931739	0.500	rs10844846	chr12:34394611	C/G	cg13010199	chr12:38710504	ALG10B	0.75	10.67	0.57	6.59e-22	Morning vs. evening chronotype;
SARC	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg16325326	chr1:53192061	ZYG11B	-0.82	-12.99	-0.65	2.22e-29	Monocyte count;
SARC	cis	rs1018836	0.527	rs13268721	chr8:91481549	G/A	cg16814680	chr8:91681699	NA	-0.76	-11.57	-0.6	9.06e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs929354	0.742	rs6459734	chr7:156935454	A/G	cg05182265	chr7:156933206	UBE3C	-0.34	-5.19	-0.32	4.49e-7	Body mass index;
SARC	cis	rs12200560	0.505	rs211167	chr6:97069087	T/A	cg06623918	chr6:96969491	KIAA0776	0.45	5.09	0.32	7.28e-7	Coronary heart disease;
SARC	cis	rs1881797	0.872	rs2141544	chr1:247690800	A/G	cg05639522	chr1:247681581	NA	0.49	5.9	0.36	1.29e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9325144	0.600	rs7965877	chr12:38743697	G/T	cg13010199	chr12:38710504	ALG10B	0.55	7.07	0.42	1.76e-11	Morning vs. evening chronotype;
SARC	trans	rs7819412	0.505	rs17782536	chr8:11021682	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.2	-0.43	8.4e-12	Triglycerides;
SARC	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg09177884	chr7:1199841	ZFAND2A	-0.41	-4.8	-0.3	2.78e-6	Longevity;Endometriosis;
SARC	cis	rs6674176	0.932	rs12410334	chr1:44442521	A/C	cg12908607	chr1:44402522	ARTN	-0.36	-5.85	-0.36	1.64e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs9486719	0.948	rs2472881	chr6:96862562	C/T	cg06623918	chr6:96969491	KIAA0776	0.73	8.01	0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg12463550	chr7:65579703	CRCP	0.5	5.9	0.36	1.27e-8	Aortic root size;
SARC	cis	rs6088580	0.601	rs6059872	chr20:33082775	C/A	cg24642439	chr20:33292090	TP53INP2	0.7	9.05	0.51	5.63e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs7223966	1.000	rs11658329	chr17:61763031	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.42	-4.76	-0.3	3.44e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg06074448	chr4:187884817	NA	-0.36	-4.72	-0.3	4.03e-6	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg03132702	chr1:61547632	NFIA	-0.5	-6.7	-0.4	1.59e-10	Thyroid stimulating hormone;
SARC	cis	rs8054556	0.787	rs12325400	chr16:30023786	C/G	cg06015834	chr16:30021696	DOC2A	-0.37	-5.0	-0.31	1.15e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs67460515	0.596	rs35589595	chr3:160930984	G/A	cg03342759	chr3:160939853	NMD3	-0.66	-8.19	-0.47	1.78e-14	Parkinson's disease;
SARC	cis	rs826838	0.967	rs4768329	chr12:39129394	T/C	cg26384229	chr12:38710491	ALG10B	-0.76	-11.59	-0.6	7.97e-25	Heart rate;
SARC	cis	rs9818758	0.607	rs9837237	chr3:49215583	G/T	cg00383909	chr3:49044727	WDR6	0.7	6.03	0.37	6.31e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs1949733	0.523	rs16842563	chr4:8545146	C/T	cg05004818	chr4:8539015	NA	0.39	5.14	0.32	5.79e-7	Response to antineoplastic agents;
SARC	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg22004693	chr7:99632812	ZKSCAN1	0.51	5.15	0.32	5.64e-7	Lung function (FEV1/FVC);
SARC	cis	rs9790314	0.875	rs336580	chr3:161082982	A/T	cg04691961	chr3:161091175	C3orf57	-0.76	-11.31	-0.6	6.12e-24	Morning vs. evening chronotype;
SARC	cis	rs7917772	0.502	rs2296583	chr10:104244322	T/G	ch.10.2196322F	chr10:104248062	ACTR1A	0.56	7.31	0.43	4.14e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg23758822	chr17:41437982	NA	0.87	11.97	0.62	4.71e-26	Menopause (age at onset);
SARC	cis	rs2016266	0.964	rs61754164	chr12:53684619	A/G	cg26875137	chr12:53738046	NA	-0.38	-5.02	-0.31	1e-6	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs888194	0.934	rs12314392	chr12:110010866	A/G	cg08884029	chr12:110012500	MVK;MMAB	-0.34	-4.99	-0.31	1.21e-6	Neuroticism;
SARC	cis	rs9788721	0.934	rs1051730	chr15:78894339	G/A	cg06917634	chr15:78832804	PSMA4	-0.58	-6.11	-0.37	4.11e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs8051517	1.000	rs34859996	chr16:68401085	G/A	cg01866162	chr16:67596514	CTCF	1.08	6.23	0.38	2.12e-9	Blood protein levels;
SARC	cis	rs2153535	0.580	rs9328478	chr6:8519183	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	7.25	0.43	6.2e-12	Motion sickness;
SARC	cis	rs4660306	1.000	rs6429569	chr1:46001330	A/C	cg24296786	chr1:45957014	TESK2	0.52	6.17	0.37	3.05e-9	Homocysteine levels;
SARC	cis	rs9486719	0.857	rs11759769	chr6:97065212	G/A	cg06623918	chr6:96969491	KIAA0776	-0.69	-7.52	-0.44	1.15e-12	Migraine;Coronary artery disease;
SARC	cis	rs9397240	0.789	rs4869851	chr6:155613906	A/G	cg07943832	chr6:155568918	TIAM2	-0.56	-5.05	-0.31	8.9e-7	Life satisfaction;
SARC	cis	rs870825	0.616	rs2310108	chr4:185639475	C/T	cg04058563	chr4:185651563	MLF1IP	0.81	11.3	0.6	6.58e-24	Blood protein levels;
SARC	cis	rs1707322	1.000	rs4660896	chr1:46372416	A/G	cg06784218	chr1:46089804	CCDC17	0.34	5.94	0.36	1.03e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs10099921	0.743	rs34421889	chr8:41636251	T/C	cg08923054	chr8:41654455	ANK1	-0.45	-5.27	-0.33	3.04e-7	Neutrophil percentage of white cells;
SARC	cis	rs9747201	0.962	rs35051180	chr17:80135046	G/A	cg09264619	chr17:80180166	NA	0.51	5.97	0.36	8.64e-9	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs10883723	0.810	rs2296582	chr10:104244139	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	8.34	0.48	6.64e-15	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs7714584	1.000	rs10058821	chr5:150226385	A/G	cg22134413	chr5:150180641	NA	0.78	6.56	0.39	3.42e-10	Crohn's disease;
SARC	cis	rs10046574	0.519	rs112479683	chr7:135203288	G/A	cg27474649	chr7:135195673	CNOT4	0.81	7.79	0.45	2.25e-13	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs672059	1.000	rs3120034	chr1:183167051	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.47	6.29	0.38	1.56e-9	Hypertriglyceridemia;
SARC	cis	rs9435341	0.965	rs2335077	chr1:107573565	A/G	cg09367891	chr1:107599246	PRMT6	0.67	8.48	0.49	2.54e-15	Facial morphology (factor 21, depth of nasal alae);
SARC	cis	rs765787	0.530	rs2899381	chr15:45529630	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.67e-7	Uric acid levels;
SARC	cis	rs1562975	0.609	rs11932691	chr4:109431283	C/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.47	6.14	0.37	3.56e-9	Height;
SARC	cis	rs2933343	0.859	rs789245	chr3:128583580	C/A	cg25356066	chr3:128598488	ACAD9	0.57	6.3	0.38	1.5e-9	IgG glycosylation;
SARC	cis	rs2635047	0.684	rs7236105	chr18:44757226	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	6.29	0.38	1.59e-9	Educational attainment;
SARC	cis	rs743757	0.878	rs9867588	chr3:50526880	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.56	5.09	0.32	7.21e-7	Diastolic blood pressure;
SARC	cis	rs2985684	0.948	rs7143010	chr14:50081803	T/C	cg23336454	chr14:50234671	KLHDC2	-0.48	-4.98	-0.31	1.25e-6	Carotid intima media thickness;
SARC	cis	rs7336332	0.598	rs75439483	chr13:28010512	A/G	cg01674679	chr13:27998804	GTF3A	-0.55	-5.13	-0.32	5.96e-7	Weight;
SARC	cis	rs7539542	0.556	rs10753926	chr1:202876085	C/T	cg08940984	chr1:202857613	RABIF	0.39	5.28	0.33	3.01e-7	Mean platelet volume;
SARC	cis	rs929354	0.772	rs6967764	chr7:156994964	C/T	cg05182265	chr7:156933206	UBE3C	-0.33	-5.02	-0.31	1.03e-6	Body mass index;
SARC	cis	rs3087591	0.960	rs7212264	chr17:29454766	C/T	cg24425628	chr17:29625626	OMG;NF1	0.55	6.91	0.41	4.59e-11	Hip circumference;
SARC	cis	rs950169	0.922	rs62029585	chr15:84951874	C/G	cg17507749	chr15:85114479	UBE2QP1	0.74	8.55	0.49	1.67e-15	Schizophrenia;
SARC	cis	rs9831754	1.000	rs3946823	chr3:78353052	G/A	cg06138941	chr3:78371609	NA	-0.56	-6.63	-0.4	2.37e-10	Calcium levels;
SARC	cis	rs6582630	0.519	rs7294300	chr12:38277359	C/A	cg26384229	chr12:38710491	ALG10B	0.91	13.64	0.67	1.61e-31	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg20573242	chr4:122745356	CCNA2	0.58	7.54	0.44	1.03e-12	Type 2 diabetes;
SARC	cis	rs9397240	0.789	rs9371876	chr6:155591404	G/A	cg07943832	chr6:155568918	TIAM2	-0.61	-5.78	-0.35	2.43e-8	Life satisfaction;
SARC	cis	rs9868809	0.505	rs28793701	chr3:48762683	C/G	cg06212747	chr3:49208901	KLHDC8B	-0.6	-5.4	-0.33	1.66e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.63e-10	Life satisfaction;
SARC	cis	rs8067545	0.611	rs2526466	chr17:20165251	C/T	cg13482628	chr17:19912719	NA	-0.57	-7.52	-0.44	1.21e-12	Schizophrenia;
SARC	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg21782813	chr7:2030301	MAD1L1	0.45	7.08	0.42	1.68e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs13256369	0.951	rs13270852	chr8:8566853	A/G	cg18904891	chr8:8559673	CLDN23	0.5	5.75	0.35	2.8e-8	Obesity-related traits;
SARC	cis	rs854765	0.551	rs12600546	chr17:17867614	A/G	cg05444541	chr17:17804740	TOM1L2	-0.31	-5.01	-0.31	1.08e-6	Total body bone mineral density;
SARC	cis	rs8016982	0.593	rs7160569	chr14:81713686	C/T	cg01989461	chr14:81687754	GTF2A1	0.73	10.87	0.58	1.57e-22	Schizophrenia;
SARC	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	11.13	0.59	2.42e-23	Platelet count;
SARC	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg24060327	chr5:131705240	SLC22A5	-0.72	-8.88	-0.5	1.82e-16	Breast cancer;
SARC	cis	rs7089973	0.584	rs7908665	chr10:116611337	G/A	cg03647239	chr10:116582469	FAM160B1	0.55	7.31	0.43	4.17e-12	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg08219700	chr8:58056026	NA	0.78	7.03	0.42	2.21e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs55823223	0.646	rs74410877	chr17:73832384	C/T	cg08125733	chr17:73851984	WBP2	0.59	4.82	0.3	2.63e-6	Psoriasis;
SARC	cis	rs9916302	0.861	rs752314	chr17:37410700	C/T	cg15445000	chr17:37608096	MED1	0.41	5.06	0.31	8.45e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg07234876	chr8:600039	NA	0.78	5.78	0.35	2.32e-8	IgG glycosylation;
SARC	cis	rs78487399	0.665	rs17031016	chr2:43764442	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-4.9	-0.31	1.83e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs2153535	0.580	rs9328479	chr6:8519646	A/G	cg21535247	chr6:8435926	SLC35B3	0.57	7.21	0.43	7.67e-12	Motion sickness;
SARC	cis	rs73086581	0.617	rs2300213	chr20:3986723	T/C	cg02187196	chr20:3869020	PANK2	-0.5	-5.6	-0.34	5.99e-8	Response to antidepressants in depression;
SARC	cis	rs6963495	0.818	rs73192120	chr7:105171156	C/T	cg13798780	chr7:105162888	PUS7	0.6	5.55	0.34	7.84e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs2180341	0.814	rs9321085	chr6:127735361	T/C	cg24812749	chr6:127587940	RNF146	0.78	9.92	0.55	1.39e-19	Breast cancer;
SARC	cis	rs9398803	0.763	rs576049	chr6:126730543	T/G	cg20229609	chr6:126660872	C6orf173	0.41	5.89	0.36	1.36e-8	Male-pattern baldness;
SARC	cis	rs7772486	0.754	rs9497401	chr6:146051271	T/C	cg05347473	chr6:146136440	FBXO30	-0.55	-7.59	-0.45	7.58e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg27266027	chr21:40555129	PSMG1	0.51	5.14	0.32	5.74e-7	Cognitive function;
SARC	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	9.68	0.54	7.66e-19	Platelet count;
SARC	cis	rs1059312	1.000	rs7135854	chr12:129279988	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.48	-5.86	-0.36	1.56e-8	Systemic lupus erythematosus;
SARC	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg12463550	chr7:65579703	CRCP	0.53	5.76	0.35	2.7e-8	Aortic root size;
SARC	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg22683308	chr4:1340831	KIAA1530	0.44	5.26	0.33	3.31e-7	Longevity;
SARC	cis	rs2486288	0.656	rs2413768	chr15:45561984	A/G	cg15395560	chr15:45543142	SLC28A2	0.28	5.37	0.33	1.91e-7	Glomerular filtration rate;
SARC	cis	rs765787	0.530	rs4775836	chr15:45537664	T/C	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.81e-6	Uric acid levels;
SARC	cis	rs1971762	0.521	rs5009146	chr12:54089297	A/C	cg06632207	chr12:54070931	ATP5G2	0.44	5.69	0.35	3.73e-8	Height;
SARC	cis	rs6088590	1.000	rs6119530	chr20:33403930	A/G	cg06115741	chr20:33292138	TP53INP2	0.57	6.92	0.41	4.26e-11	Coronary artery disease;
SARC	cis	rs72792276	1.000	rs72794379	chr5:127464965	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	6.19	0.38	2.7e-9	Red cell distribution width;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg25418748	chr5:178977236	RUFY1	-0.6	-6.85	-0.41	6.68e-11	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs2644899	0.750	rs2607424	chr19:41275147	C/T	cg24958765	chr19:41283667	RAB4B	-0.57	-6.4	-0.39	8.68e-10	Post bronchodilator FEV1/FVC ratio;
SARC	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg17878204	chr1:145611075	RNF115;POLR3C	-0.51	-6.66	-0.4	1.91e-10	Parental extreme longevity (95 years and older);
SARC	cis	rs76419734	0.702	rs72671862	chr4:106650038	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.84	5.41	0.33	1.59e-7	Post bronchodilator FEV1;
SARC	cis	rs11770686	0.935	rs6467388	chr7:75330422	A/G	cg17787366	chr7:75369077	HIP1	0.43	5.32	0.33	2.48e-7	Essential tremor;
SARC	cis	rs763121	0.853	rs6001182	chr22:39047443	A/G	cg21395723	chr22:39101663	GTPBP1	0.58	6.67	0.4	1.85e-10	Menopause (age at onset);
SARC	cis	rs9905704	0.647	rs11659035	chr17:56966052	C/T	cg12560992	chr17:57184187	TRIM37	0.4	4.79	0.3	2.97e-6	Testicular germ cell tumor;
SARC	cis	rs17826219	0.568	rs9898097	chr17:29072672	T/G	cg13385521	chr17:29058706	SUZ12P	0.88	7.94	0.46	8.37e-14	Body mass index;
SARC	trans	rs12486865	0.500	rs79147820	chr3:99924320	T/C	cg21934772	chr13:110198949	NA	0.51	6.94	0.41	3.81e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs9818758	0.607	rs34580506	chr3:49113713	C/A	cg06212747	chr3:49208901	KLHDC8B	-0.69	-5.82	-0.36	1.98e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs41264869	0.628	rs7529665	chr1:205124871	G/A	cg21643547	chr1:205240462	TMCC2	0.43	4.75	0.3	3.61e-6	Blood protein levels;
SARC	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	10.47	0.57	2.77e-21	Platelet count;
SARC	cis	rs6456156	0.819	rs7765739	chr6:167518472	C/T	cg07741184	chr6:167504864	NA	0.33	6.32	0.38	1.31e-9	Primary biliary cholangitis;
SARC	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg04267008	chr7:1944627	MAD1L1	-0.49	-5.23	-0.32	3.75e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs78487399	0.808	rs6737882	chr2:43731908	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-4.84	-0.3	2.37e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs4555082	0.957	rs2816608	chr14:105718407	A/G	cg13114125	chr14:105738426	BRF1	0.74	10.83	0.58	2.07e-22	Mean platelet volume;Platelet distribution width;
SARC	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg25036284	chr2:26402008	FAM59B	-0.46	-5.7	-0.35	3.59e-8	Gut microbiome composition (summer);
SARC	cis	rs898097	0.812	rs56274787	chr17:80862682	C/T	cg15664640	chr17:80829946	TBCD	-0.56	-8.3	-0.48	8.28e-15	Breast cancer;
SARC	cis	rs10791323	0.569	rs2187450	chr11:133743792	A/G	cg15485101	chr11:133734466	NA	0.32	5.14	0.32	5.92e-7	Childhood ear infection;
SARC	cis	rs8111500	0.793	rs10412111	chr19:49155256	G/A	cg07051648	chr19:49177693	NTN5;SEC1	0.45	4.83	0.3	2.43e-6	Elevated serum carcinoembryonic antigen levels;
SARC	cis	rs12142240	0.698	rs72677600	chr1:46834449	G/A	cg14993813	chr1:46806288	NSUN4	-0.51	-5.2	-0.32	4.45e-7	Menopause (age at onset);
SARC	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg14784868	chr12:69753453	YEATS4	0.65	9.03	0.51	6.82e-17	Cerebrospinal fluid biomarker levels;
SARC	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.59e-6	Depression;
SARC	cis	rs9911578	1.000	rs7342903	chr17:56914588	C/G	cg05425664	chr17:57184151	TRIM37	-0.64	-7.98	-0.46	6.52e-14	Intelligence (multi-trait analysis);
SARC	cis	rs3858526	0.883	rs1453429	chr11:5933478	C/T	cg02574844	chr11:5959923	NA	-0.41	-5.12	-0.32	6.54e-7	DNA methylation (variation);
SARC	cis	rs7178572	0.889	rs7171448	chr15:77832316	C/G	cg22256960	chr15:77711686	NA	-0.51	-5.95	-0.36	9.92e-9	Type 2 diabetes;
SARC	cis	rs9467711	0.591	rs35902160	chr6:26128538	C/G	cg21479132	chr6:26055353	NA	0.95	6.8	0.41	8.86e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.54	7.04	0.42	2.15e-11	Lymphocyte counts;
SARC	cis	rs7635838	0.617	rs346075	chr3:11294027	T/G	cg00170343	chr3:11313890	ATG7	0.76	10.33	0.56	7.91e-21	HDL cholesterol;
SARC	cis	rs2072499	0.900	rs2248080	chr1:156195971	T/A	cg25208724	chr1:156163844	SLC25A44	0.8	9.49	0.53	2.82e-18	Testicular germ cell tumor;
SARC	cis	rs2404618	0.504	rs2906567	chr8:1494118	C/T	cg13402656	chr8:1511478	DLGAP2	-0.58	-8.62	-0.49	1.01e-15	Lung cancer;
SARC	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg16479474	chr6:28041457	NA	0.35	4.97	0.31	1.3e-6	Parkinson's disease;
SARC	cis	rs6700896	0.931	rs1805096	chr1:66102257	C/T	cg04111102	chr1:66153794	NA	0.36	5.63	0.35	5.03e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6570726	0.935	rs110289	chr6:145865176	C/G	cg05220968	chr6:146057943	EPM2A	-0.3	-5.08	-0.32	7.76e-7	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs11098499	0.954	rs878373	chr4:120237484	A/T	cg25214090	chr10:38739885	LOC399744	0.55	7.17	0.43	9.85e-12	Corneal astigmatism;
SARC	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg01475735	chr3:40494733	NA	-0.47	-5.43	-0.34	1.4e-7	Renal cell carcinoma;
SARC	trans	rs61931739	0.513	rs10844698	chr12:33890158	C/T	cg13010199	chr12:38710504	ALG10B	0.56	7.31	0.43	4.33e-12	Morning vs. evening chronotype;
SARC	cis	rs3096299	0.869	rs748941	chr16:89440754	T/A	cg02187348	chr16:89574699	SPG7	0.42	5.35	0.33	2.08e-7	Multiple myeloma (IgH translocation);
SARC	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg26335602	chr6:28129616	ZNF389	0.53	5.88	0.36	1.43e-8	Depression;
SARC	cis	rs1185460	0.967	rs1784461	chr11:118937985	G/A	cg23280166	chr11:118938394	VPS11	0.81	12.37	0.63	2.28e-27	Coronary artery disease;
SARC	cis	rs854765	0.583	rs7207043	chr17:17819188	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.66	10.0	0.55	7.86e-20	Total body bone mineral density;
SARC	cis	rs2075371	0.966	rs1901204	chr7:133985896	A/G	cg00033643	chr7:134001901	SLC35B4	0.41	5.02	0.31	1.01e-6	Mean platelet volume;
SARC	cis	rs2075371	0.897	rs1643033	chr7:134004662	T/C	cg11752832	chr7:134001865	SLC35B4	0.63	8.31	0.48	7.8e-15	Mean platelet volume;
SARC	cis	rs11785400	0.928	rs10100287	chr8:143734836	C/T	cg10596483	chr8:143751796	JRK	0.63	8.4	0.48	4.42e-15	Schizophrenia;
SARC	trans	rs1814175	0.817	rs28502006	chr11:50049930	T/C	cg15704280	chr7:45808275	SEPT13	-0.97	-18.68	-0.77	3.33e-48	Height;
SARC	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg22903657	chr4:1355424	KIAA1530	-0.36	-4.9	-0.31	1.78e-6	Obesity-related traits;
SARC	cis	rs10870270	1.000	rs4880263	chr10:133787629	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.44	-4.78	-0.3	3.17e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs2354432	0.714	rs7531962	chr1:146746023	G/A	cg25205988	chr1:146714368	CHD1L	-1.08	-11.4	-0.6	3.33e-24	Mitochondrial DNA levels;
SARC	cis	rs4423214	1.000	rs4944957	chr11:71168035	C/T	cg24826892	chr11:71159390	DHCR7	-0.48	-6.14	-0.37	3.45e-9	Vitamin D levels;
SARC	cis	rs9875589	0.509	rs9824910	chr3:14040136	C/T	cg19554555	chr3:13937349	NA	-0.4	-5.14	-0.32	5.95e-7	Ovarian reserve;
SARC	cis	rs6991838	0.557	rs7812390	chr8:66506217	A/G	cg13398993	chr8:66546079	ARMC1	-0.62	-8.37	-0.48	5.33e-15	Intelligence (multi-trait analysis);
SARC	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg14829155	chr15:31115871	NA	0.43	5.64	0.35	4.88e-8	Huntington's disease progression;
SARC	cis	rs7223966	1.000	rs7214312	chr17:61870863	A/G	cg00588841	chr17:61851480	DDX42;CCDC47	-0.64	-6.93	-0.41	4.06e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs11997175	0.740	rs6991071	chr8:33814103	G/A	ch.8.33884649F	chr8:33765107	NA	0.48	6.28	0.38	1.68e-9	Body mass index;
SARC	trans	rs9929218	0.953	rs9927329	chr16:68750331	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.65	-8.41	-0.48	4.11e-15	Colorectal cancer;
SARC	cis	rs1008375	1.000	rs10939744	chr4:17664473	G/T	cg16339924	chr4:17578868	LAP3	0.64	8.33	0.48	6.81e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7223966	1.000	rs9908044	chr17:61747032	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.57	-6.67	-0.4	1.87e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg08045932	chr20:61659980	NA	-0.52	-6.97	-0.42	3.23e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs3796352	1.000	rs13074524	chr3:52974184	A/G	cg12962167	chr3:53033115	SFMBT1	0.75	4.9	0.31	1.8e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.45	-5.0	-0.31	1.11e-6	Longevity;Endometriosis;
SARC	cis	rs1707322	1.000	rs10890380	chr1:46449469	A/G	cg06784218	chr1:46089804	CCDC17	0.34	5.95	0.36	9.76e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9814567	0.964	rs9833753	chr3:134213665	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-7.03	-0.42	2.3e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs2243480	1.000	rs316315	chr7:65591205	C/T	cg25894440	chr7:65020034	NA	0.53	4.85	0.3	2.29e-6	Diabetic kidney disease;
SARC	cis	rs61989804	0.826	rs61987800	chr14:65709777	G/A	cg15999311	chr14:65749247	NA	0.52	5.03	0.31	9.78e-7	Midgestational circulating levels of PCBs (fetal genetic effect);
SARC	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg24675658	chr1:53192096	ZYG11B	-0.58	-8.24	-0.48	1.24e-14	Monocyte count;
SARC	cis	rs36051895	0.664	rs10117565	chr9:5094461	G/A	cg02405213	chr9:5042618	JAK2	-0.47	-5.61	-0.35	5.6e-8	Pediatric autoimmune diseases;
SARC	cis	rs7264396	0.790	rs10211771	chr20:34219994	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.56	5.63	0.35	5.28e-8	Total cholesterol levels;
SARC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg20007245	chr22:24372913	LOC391322	-0.62	-7.38	-0.44	2.79e-12	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs11612508	0.660	rs10772569	chr12:12615237	C/T	cg12403778	chr12:11804115	ETV6	0.35	4.96	0.31	1.34e-6	Inflammatory bowel disease;
SARC	cis	rs6991838	0.584	rs4449837	chr8:66488152	C/T	cg13398993	chr8:66546079	ARMC1	-0.62	-8.36	-0.48	5.88e-15	Intelligence (multi-trait analysis);
SARC	cis	rs8133932	0.701	rs7276114	chr21:47301187	C/T	cg11214348	chr21:47283868	PCBP3	-0.37	-4.8	-0.3	2.86e-6	Schizophrenia;
SARC	cis	rs4481887	0.927	rs4517383	chr1:248426484	C/T	cg00666640	chr1:248458726	OR2T12	0.38	6.35	0.38	1.14e-9	Common traits (Other);
SARC	cis	rs911555	0.755	rs12432803	chr14:103930032	C/T	cg12935359	chr14:103987150	CKB	0.38	5.25	0.33	3.39e-7	Intelligence (multi-trait analysis);
SARC	cis	rs449789	0.857	rs9355713	chr6:159722548	C/T	cg14500486	chr6:159655392	FNDC1	-0.44	-5.03	-0.31	9.92e-7	Pulse pressure;
SARC	cis	rs2228479	0.619	rs78001663	chr16:89896331	C/A	cg12064134	chr16:90016061	DEF8	-0.56	-4.9	-0.31	1.77e-6	Skin colour saturation;
SARC	trans	rs61931739	0.929	rs7955240	chr12:34066388	G/A	cg13010199	chr12:38710504	ALG10B	-0.5	-6.73	-0.4	1.27e-10	Morning vs. evening chronotype;
SARC	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg15448220	chr1:150897856	SETDB1	0.47	6.25	0.38	1.94e-9	Tonsillectomy;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg26297968	chr2:211035960	C2orf67	-0.5	-6.67	-0.4	1.8e-10	Electrocardiographic conduction measures;
SARC	cis	rs7959452	0.868	rs10878967	chr12:69740869	T/C	cg22834771	chr12:69754056	YEATS4	-0.43	-5.74	-0.35	2.93e-8	Blood protein levels;
SARC	cis	rs6424115	1.000	rs12116511	chr1:24162662	A/G	cg15997130	chr1:24165203	NA	-0.48	-6.34	-0.38	1.19e-9	Immature fraction of reticulocytes;
SARC	cis	rs12908161	1.000	rs62021219	chr15:85256159	C/T	cg17507749	chr15:85114479	UBE2QP1	0.58	6.68	0.4	1.77e-10	Schizophrenia;
SARC	cis	rs7792596	1.000	rs10263858	chr7:93995226	T/C	cg20814616	chr7:94014465	NA	-0.43	-5.35	-0.33	2.12e-7	Intelligence;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg01862523	chr6:71123290	FAM135A	-0.85	-7.29	-0.43	4.93e-12	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg08975724	chr8:8085496	FLJ10661	0.46	5.75	0.35	2.8e-8	Mood instability;
SARC	cis	rs8044995	0.563	rs73615919	chr16:68398862	C/T	cg05110241	chr16:68378359	PRMT7	-0.64	-6.19	-0.38	2.64e-9	Schizophrenia;
SARC	cis	rs796364	0.806	rs6435041	chr2:200867144	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.71	6.07	0.37	5.18e-9	Schizophrenia;
SARC	cis	rs7904368	0.806	rs7087360	chr10:16872337	C/A	cg14835575	chr10:16859367	RSU1	0.82	8.43	0.48	3.6e-15	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg18404041	chr3:52824283	ITIH1	-0.38	-5.59	-0.34	6.45e-8	Electroencephalogram traits;
SARC	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg13939156	chr17:80058883	NA	-0.41	-6.27	-0.38	1.7e-9	Life satisfaction;
SARC	trans	rs11098499	0.863	rs58452170	chr4:120459674	A/T	cg25214090	chr10:38739885	LOC399744	0.59	7.45	0.44	1.85e-12	Corneal astigmatism;
SARC	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg14840502	chr6:22623897	NA	0.4	6.26	0.38	1.87e-9	Thyroid stimulating hormone;
SARC	cis	rs6456156	0.792	rs10946212	chr6:167515947	C/G	cg23791538	chr6:167370224	RNASET2	-0.43	-5.39	-0.33	1.73e-7	Primary biliary cholangitis;
SARC	trans	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg20587970	chr11:113659929	NA	1.0	9.39	0.52	5.65e-18	Hip circumference adjusted for BMI;
SARC	cis	rs9902453	1.000	rs11080114	chr17:28407287	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.53	-6.93	-0.41	4.11e-11	Coffee consumption (cups per day);
SARC	cis	rs7937682	0.883	rs568038	chr11:111432161	A/C	cg09085632	chr11:111637200	PPP2R1B	0.9	12.37	0.63	2.37e-27	Primary sclerosing cholangitis;
SARC	cis	rs950169	0.881	rs72750843	chr15:85135783	C/T	cg24253500	chr15:84953950	NA	0.35	5.01	0.31	1.1e-6	Schizophrenia;
SARC	cis	rs12711979	0.765	rs10208316	chr2:3827630	T/C	cg17052675	chr2:3827356	NA	-0.32	-4.85	-0.3	2.22e-6	Itch intensity from mosquito bite adjusted by bite size;
SARC	cis	rs5753618	0.539	rs737888	chr22:31611549	A/G	cg00478049	chr22:31556069	RNF185	0.44	4.75	0.3	3.57e-6	Colorectal cancer;
SARC	cis	rs796364	0.760	rs1569178	chr2:201024512	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-6.1	-0.37	4.37e-9	Schizophrenia;
SARC	cis	rs8114671	0.562	rs4911164	chr20:33479488	G/C	cg24642439	chr20:33292090	TP53INP2	0.47	5.62	0.35	5.53e-8	Height;
SARC	trans	rs11039798	0.588	rs1814768	chr11:48987455	T/C	cg15704280	chr7:45808275	SEPT13	0.64	6.65	0.4	2.07e-10	Axial length;
SARC	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg11987759	chr7:65425863	GUSB	-0.58	-7.55	-0.44	9.82e-13	Aortic root size;
SARC	cis	rs12893668	0.543	rs1799796	chr14:104165927	T/C	cg26031613	chr14:104095156	KLC1	-0.53	-5.74	-0.35	2.95e-8	Reticulocyte count;
SARC	cis	rs910316	1.000	rs7156328	chr14:75532941	T/C	cg08847533	chr14:75593920	NEK9	0.94	15.76	0.72	1.37e-38	Height;
SARC	cis	rs9303401	0.659	rs17222691	chr17:56771096	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.09	11.7	0.61	3.6e-25	Cognitive test performance;
SARC	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg08677398	chr8:58056175	NA	0.43	5.13	0.32	6.07e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg21782813	chr7:2030301	MAD1L1	0.42	6.81	0.41	8.31e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs3106136	0.807	rs28716591	chr4:95274832	A/G	cg11021082	chr4:95130006	SMARCAD1	0.36	5.51	0.34	9.64e-8	Capecitabine sensitivity;
SARC	cis	rs4642101	0.639	rs9870433	chr3:12853566	T/C	cg05775895	chr3:12838266	CAND2	0.68	9.78	0.54	3.7e-19	QRS complex (12-leadsum);
SARC	cis	rs6963495	0.818	rs55922564	chr7:105155890	G/A	cg13798780	chr7:105162888	PUS7	0.6	5.45	0.34	1.31e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs11235843	0.929	rs11235844	chr11:73379075	G/T	cg18195628	chr11:73498948	MRPL48	0.6	4.79	0.3	3.03e-6	Hand grip strength;
SARC	cis	rs3870371	0.955	rs920455	chr8:122700197	A/G	cg21781600	chr8:122651575	HAS2;HAS2AS	0.5	5.48	0.34	1.12e-7	Periodontal disease-related phenotypes;
SARC	cis	rs763121	0.853	rs6001185	chr22:39052155	G/A	cg21395723	chr22:39101663	GTPBP1	0.58	6.67	0.4	1.85e-10	Menopause (age at onset);
SARC	cis	rs2486288	0.656	rs11632724	chr15:45550791	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.51	-6.44	-0.39	6.68e-10	Glomerular filtration rate;
SARC	cis	rs7092929	0.883	rs835960	chr10:3586532	G/C	cg14308648	chr10:3568949	NA	0.51	5.13	0.32	6.16e-7	Coronary artery calcification;
SARC	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-9.57	-0.53	1.65e-18	Chronic sinus infection;
SARC	cis	rs10876993	0.890	rs2640630	chr12:58067267	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.48	-6.12	-0.37	3.95e-9	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs9815354	0.812	rs116393551	chr3:41865476	G/A	cg03022575	chr3:42003672	ULK4	0.7	5.47	0.34	1.16e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs1322639	0.614	rs4708414	chr6:169574144	C/G	cg04662567	chr6:169592167	NA	-0.38	-5.07	-0.32	8.1e-7	Pulse pressure;
SARC	cis	rs13082711	0.911	rs4973772	chr3:27450234	G/T	cg02860705	chr3:27208620	NA	0.46	5.8	0.36	2.12e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs763121	0.853	rs2294296	chr22:39053049	T/C	cg06022373	chr22:39101656	GTPBP1	0.9	11.44	0.6	2.44e-24	Menopause (age at onset);
SARC	cis	rs77106637	1.000	rs11600585	chr11:72727840	A/G	cg03713592	chr11:72463424	ARAP1	0.87	8.17	0.47	1.92e-14	Type 2 diabetes;
SARC	cis	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg24110177	chr3:50126178	RBM5	-0.62	-8.13	-0.47	2.61e-14	Body mass index;
SARC	cis	rs7566780	0.597	rs4389335	chr2:16688159	G/T	cg09580478	chr2:16689509	NA	-0.53	-6.33	-0.38	1.26e-9	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs3213545	0.700	rs2260445	chr12:121468863	C/A	cg02403541	chr12:121454288	C12orf43	0.74	10.54	0.57	1.69e-21	Subjective well-being;Cardiovascular disease risk factors;
SARC	cis	rs3126085	0.935	rs4845423	chr1:152184950	T/G	cg26876637	chr1:152193138	HRNR	0.48	5.62	0.35	5.42e-8	Atopic dermatitis;
SARC	cis	rs765787	0.505	rs4439707	chr15:45524216	G/A	cg21132104	chr15:45694354	SPATA5L1	0.42	4.86	0.3	2.13e-6	Uric acid levels;
SARC	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg22920501	chr2:26401640	FAM59B	0.61	8.19	0.47	1.71e-14	Gut microbiome composition (summer);
SARC	cis	rs9393692	0.645	rs11756673	chr6:26323505	A/G	cg05868516	chr6:26286170	HIST1H4H	0.48	5.56	0.34	7.31e-8	Educational attainment;
SARC	cis	rs9807841	0.592	rs10415961	chr19:10759981	G/C	cg17710535	chr19:10819994	QTRT1	0.41	4.88	0.3	1.99e-6	Inflammatory skin disease;
SARC	cis	rs796364	0.951	rs7608668	chr2:201000017	T/C	cg23649088	chr2:200775458	C2orf69	-0.62	-6.8	-0.41	8.54e-11	Schizophrenia;
SARC	cis	rs7666738	0.830	rs1593572	chr4:98979322	A/G	cg05340658	chr4:99064831	C4orf37	-0.67	-9.28	-0.52	1.18e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg26752003	chr8:145688521	CYHR1	-0.61	-8.64	-0.49	9.08e-16	Age at first birth;
SARC	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs73086581	1.000	rs73084575	chr20:3906768	G/T	cg02187196	chr20:3869020	PANK2	0.65	5.78	0.35	2.38e-8	Response to antidepressants in depression;
SARC	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg09359103	chr1:154839909	KCNN3	-0.48	-8.35	-0.48	6.23e-15	Prostate cancer;
SARC	cis	rs846111	1.000	rs846111	chr1:6279370	G/C	cg15892785	chr1:6309343	GPR153	-0.59	-7.62	-0.45	6.3e-13	QT interval;
SARC	cis	rs7582180	0.629	rs13010911	chr2:100953390	G/C	cg14675211	chr2:100938903	LONRF2	0.51	7.63	0.45	5.86e-13	Intelligence (multi-trait analysis);
SARC	cis	rs4706831	0.647	rs9350847	chr6:80889017	C/T	cg08355045	chr6:80787529	NA	0.3	4.71	0.3	4.19e-6	Joint mobility (Beighton score);
SARC	cis	rs2997447	0.633	rs6665062	chr1:26362001	C/T	cg19633962	chr1:26362018	EXTL1	-0.84	-8.25	-0.48	1.21e-14	QRS complex (12-leadsum);
SARC	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs782590	0.683	rs782633	chr2:55898203	A/G	cg18811423	chr2:55921094	PNPT1	0.7	10.7	0.57	5.47e-22	Metabolic syndrome;
SARC	cis	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg14019146	chr3:50243930	SLC38A3	-0.32	-5.12	-0.32	6.54e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9914988	0.943	rs1035989	chr17:27143810	T/G	cg20469991	chr17:27169893	C17orf63	-0.52	-5.39	-0.33	1.74e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs897080	0.515	rs1065784	chr2:44660777	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	5.99	0.37	7.98e-9	Height;
SARC	cis	rs765787	0.530	rs4444275	chr15:45535347	T/C	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.81e-6	Uric acid levels;
SARC	cis	rs6088580	0.634	rs2424992	chr20:33012060	C/T	cg24642439	chr20:33292090	TP53INP2	0.67	8.57	0.49	1.48e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs1018836	0.923	rs1476427	chr8:91552791	A/G	cg16814680	chr8:91681699	NA	0.81	12.2	0.62	8.18e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg27532560	chr4:187881888	NA	-0.36	-4.95	-0.31	1.42e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7223966	1.000	rs8066719	chr17:61825764	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.45	4.76	0.3	3.39e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs13256369	0.802	rs12681326	chr8:8566389	G/A	cg18904891	chr8:8559673	CLDN23	0.48	5.4	0.33	1.65e-7	Obesity-related traits;
SARC	cis	rs1483890	0.723	rs900670	chr3:69406781	G/A	cg22125112	chr3:69402811	FRMD4B	0.3	4.99	0.31	1.21e-6	Resting heart rate;
SARC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg12419862	chr22:24373484	LOC391322	-0.73	-8.94	-0.51	1.23e-16	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs13314892	0.764	rs62251019	chr3:69859651	A/G	cg17445875	chr3:69859618	MITF	-0.49	-5.14	-0.32	5.68e-7	QRS complex (12-leadsum);
SARC	cis	rs6570726	0.526	rs4895674	chr6:145735860	T/G	cg23711669	chr6:146136114	FBXO30	-0.64	-8.29	-0.48	9.27e-15	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11997175	0.545	rs7839592	chr8:33666662	T/C	ch.8.33884649F	chr8:33765107	NA	0.49	6.17	0.37	2.95e-9	Body mass index;
SARC	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.39	-4.88	-0.3	1.95e-6	Lymphocyte counts;
SARC	cis	rs2011503	1.000	rs34067609	chr19:19653524	G/A	cg03709012	chr19:19516395	GATAD2A	0.6	5.29	0.33	2.8e-7	Bipolar disorder;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg04717373	chr6:111306256	RPF2	0.44	6.5	0.39	4.88e-10	Thyroid stimulating hormone;
SARC	cis	rs2718058	0.606	rs1349393	chr7:37869525	C/T	cg24998770	chr7:37888106	TXNDC3	0.35	5.12	0.32	6.53e-7	Alzheimer's disease (late onset);
SARC	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg12564285	chr5:131593104	PDLIM4	-0.43	-5.79	-0.35	2.27e-8	Breast cancer;
SARC	cis	rs9815354	0.812	rs78342280	chr3:41948810	G/A	cg03022575	chr3:42003672	ULK4	0.7	5.7	0.35	3.66e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg04267008	chr7:1944627	MAD1L1	-0.48	-5.42	-0.33	1.49e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	5.4	0.33	1.67e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7552404	0.731	rs11161857	chr1:76370228	G/C	cg03433033	chr1:76189801	ACADM	0.47	5.6	0.34	5.92e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs4130590	1.000	rs4130590	chr9:130107964	C/T	cg13736810	chr9:130213283	LRSAM1;RPL12	-0.46	-5.67	-0.35	4.22e-8	Bipolar disorder;
SARC	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg22968622	chr17:43663579	NA	1.22	16.42	0.73	8.72e-41	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs34779708	0.898	rs11595898	chr10:35326263	T/C	cg03585969	chr10:35415529	CREM	0.4	5.02	0.31	1.03e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-9.16	-0.51	2.76e-17	Alzheimer's disease;
SARC	cis	rs6580649	0.941	rs4760677	chr12:48449163	C/T	cg05342945	chr12:48394962	COL2A1	0.57	6.15	0.37	3.42e-9	Lung cancer;
SARC	cis	rs208520	0.690	rs12209753	chr6:66703951	A/G	cg07460842	chr6:66804631	NA	1.06	14.43	0.69	3.63e-34	Exhaled nitric oxide output;
SARC	cis	rs2370759	1.000	rs16933225	chr10:32599464	C/T	cg05361325	chr10:32636312	EPC1	-0.66	-6.08	-0.37	4.78e-9	Sexual dysfunction (female);
SARC	cis	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg13072238	chr3:49761600	GMPPB	0.43	5.57	0.34	6.87e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2832191	0.692	rs2245517	chr21:30357968	C/T	cg24692254	chr21:30365293	RNF160	1.04	19.13	0.78	1.1e-49	Dental caries;
SARC	cis	rs9682041	0.932	rs9841852	chr3:170067049	C/G	cg11886554	chr3:170076028	SKIL	0.74	6.46	0.39	6.05e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	trans	rs7819412	0.775	rs34094119	chr8:10935898	A/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.99	-0.42	2.84e-11	Triglycerides;
SARC	cis	rs6120849	0.754	rs6120819	chr20:33653038	T/C	cg06115741	chr20:33292138	TP53INP2	0.56	5.31	0.33	2.59e-7	Protein C levels;
SARC	cis	rs6570726	0.526	rs4896805	chr6:145735429	C/A	cg05347473	chr6:146136440	FBXO30	-0.44	-5.5	-0.34	1.02e-7	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs61931739	0.534	rs11052960	chr12:33997754	A/T	cg13010199	chr12:38710504	ALG10B	0.76	10.28	0.56	1.07e-20	Morning vs. evening chronotype;
SARC	cis	rs7647973	1.000	rs73088137	chr3:49448423	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.58	-5.59	-0.34	6.39e-8	Menarche (age at onset);
SARC	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg14159672	chr1:205819179	PM20D1	0.49	6.52	0.39	4.36e-10	Menarche (age at onset);
SARC	cis	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg14541582	chr5:601475	NA	-0.39	-4.87	-0.3	2.05e-6	Obesity-related traits;
SARC	cis	rs9914988	0.943	rs7224870	chr17:27102620	A/G	cg20469991	chr17:27169893	C17orf63	-0.49	-5.09	-0.32	7.48e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs5167	0.506	rs7257916	chr19:45482884	T/C	cg13119609	chr19:45449297	APOC2	-0.53	-9.01	-0.51	7.88e-17	Blood protein levels;
SARC	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg05025164	chr4:1340916	KIAA1530	-0.74	-9.0	-0.51	7.99e-17	Longevity;
SARC	cis	rs9916302	0.706	rs9646419	chr17:37597185	A/G	cg20243544	chr17:37824526	PNMT	0.54	5.61	0.35	5.69e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9902453	0.904	rs12939344	chr17:28328819	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.54	-6.87	-0.41	5.72e-11	Coffee consumption (cups per day);
SARC	cis	rs36051895	0.695	rs11794708	chr9:5023441	G/A	cg02405213	chr9:5042618	JAK2	-0.51	-5.41	-0.33	1.54e-7	Pediatric autoimmune diseases;
SARC	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	cis	rs12586317	0.547	rs10134907	chr14:35499211	A/C	cg16230307	chr14:35515116	FAM177A1	1.02	11.85	0.61	1.18e-25	Psoriasis;
SARC	cis	rs2120243	0.510	rs7623173	chr3:157119949	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.39	4.96	0.31	1.37e-6	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg11764359	chr7:65958608	NA	0.75	8.47	0.49	2.79e-15	Aortic root size;
SARC	cis	rs2486288	0.656	rs11637838	chr15:45550657	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.51	-6.33	-0.38	1.22e-9	Glomerular filtration rate;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg21944138	chr2:3448742	TTC15	0.44	6.26	0.38	1.84e-9	Thyroid stimulating hormone;
SARC	cis	rs76419734	1.000	rs72673832	chr4:106738760	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	5.2	0.32	4.29e-7	Post bronchodilator FEV1;
SARC	cis	rs908922	0.676	rs4845780	chr1:152488846	T/G	cg09873164	chr1:152488093	CRCT1	0.65	8.35	0.48	6.25e-15	Hair morphology;
SARC	cis	rs643506	1.000	rs647080	chr11:111609174	A/G	cg09085632	chr11:111637200	PPP2R1B	0.46	5.24	0.32	3.55e-7	Breast cancer;
SARC	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg13939156	chr17:80058883	NA	-0.42	-6.48	-0.39	5.51e-10	Life satisfaction;
SARC	cis	rs13095912	1.000	rs2034344	chr3:185337788	T/C	cg11274856	chr3:185301563	NA	0.35	4.84	0.3	2.34e-6	Systolic blood pressure;
SARC	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-4.73	-0.3	3.89e-6	Menopause (age at onset);
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg27524515	chr8:38239417	WHSC1L1	0.62	6.61	0.4	2.58e-10	Lung cancer in ever smokers;
SARC	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.66	0.35	4.44e-8	Bipolar disorder;
SARC	cis	rs5750830	0.594	rs5757648	chr22:39775156	G/A	cg05872129	chr22:39784769	NA	-0.46	-6.67	-0.4	1.81e-10	Intelligence (multi-trait analysis);
SARC	cis	rs6570726	0.516	rs9376932	chr6:145729490	T/C	cg23711669	chr6:146136114	FBXO30	0.55	7.33	0.43	3.74e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg00800038	chr16:89945340	TCF25	-0.74	-5.08	-0.32	7.86e-7	Skin colour saturation;
SARC	cis	rs3796352	1.000	rs13072457	chr3:53102389	G/A	cg27565382	chr3:53032988	SFMBT1	1.0	6.88	0.41	5.55e-11	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs920590	0.560	rs10090638	chr8:19673750	T/G	cg17834443	chr8:19674713	INTS10	-0.52	-6.29	-0.38	1.53e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs12701220	0.503	rs13222294	chr7:1172969	G/A	cg01324507	chr7:1177794	C7orf50	0.49	4.81	0.3	2.68e-6	Bronchopulmonary dysplasia;
SARC	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg22433210	chr17:43662623	NA	-0.7	-8.23	-0.47	1.34e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs2153904	0.793	rs12118655	chr1:205663478	A/G	cg11965913	chr1:205819406	PM20D1	-0.6	-5.06	-0.31	8.58e-7	Prostate-specific antigen levels;
SARC	cis	rs12311304	0.965	rs11056400	chr12:15365558	A/G	cg08258403	chr12:15378311	NA	-0.49	-7.7	-0.45	3.85e-13	Behavioural disinhibition (generation interaction);
SARC	cis	rs1113500	0.933	rs11185259	chr1:108635062	A/G	cg06207961	chr1:108661230	NA	-0.44	-5.95	-0.36	9.53e-9	Growth-regulated protein alpha levels;
SARC	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg02524346	chr8:600233	NA	0.7	5.86	0.36	1.61e-8	IgG glycosylation;
SARC	cis	rs4819052	0.679	rs2838860	chr21:46684904	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.62	7.72	0.45	3.4e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg26338869	chr17:61819248	STRADA	0.78	10.39	0.56	5.04e-21	Prudent dietary pattern;
SARC	trans	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg00938859	chr5:1591904	SDHAP3	0.79	7.66	0.45	5.1e-13	Breast cancer;
SARC	cis	rs11758351	1.000	rs1341759	chr6:26195502	G/A	cg23601095	chr6:26197514	HIST1H3D	0.62	5.39	0.33	1.68e-7	Gout;Renal underexcretion gout;
SARC	cis	rs7412746	0.658	rs10305714	chr1:150800655	C/T	cg13175981	chr1:150552382	MCL1	0.47	5.71	0.35	3.4e-8	Melanoma;
SARC	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg01475735	chr3:40494733	NA	0.49	5.64	0.35	4.78e-8	Renal cell carcinoma;
SARC	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.48	7.35	0.43	3.33e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs7044106	0.762	rs10984972	chr9:123409864	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.71	9.09	0.51	4.42e-17	Hip circumference adjusted for BMI;
SARC	cis	rs72781680	0.898	rs113027486	chr2:24098371	G/A	cg06627628	chr2:24431161	ITSN2	-0.65	-6.37	-0.39	9.72e-10	Lymphocyte counts;
SARC	cis	rs57502260	0.704	rs55975204	chr11:68249124	C/T	cg01657329	chr11:68192670	LRP5	-0.49	-5.12	-0.32	6.39e-7	Total body bone mineral density (age 45-60);
SARC	cis	rs6867032	0.687	rs4998338	chr5:2015910	A/G	cg26168224	chr5:2018326	NA	0.92	14.86	0.7	1.4e-35	Gut microbiome composition (winter);
SARC	cis	rs7264396	0.635	rs6121102	chr20:34544274	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-7.43	-0.44	2.06e-12	Total cholesterol levels;
SARC	cis	rs4319547	0.695	rs10846746	chr12:122868696	C/T	cg05707623	chr12:122985044	ZCCHC8	0.57	6.41	0.39	7.89e-10	Body mass index;
SARC	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg13866156	chr1:1669148	SLC35E2	-0.63	-9.54	-0.53	2.05e-18	Body mass index;
SARC	cis	rs76419734	1.000	rs35808787	chr4:106681179	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.8	5.36	0.33	2.02e-7	Post bronchodilator FEV1;
SARC	cis	rs2180341	1.000	rs6569486	chr6:127708424	A/C	cg17762328	chr6:126965162	NA	-0.44	-4.86	-0.3	2.13e-6	Breast cancer;
SARC	cis	rs7586879	0.575	rs6706316	chr2:25128351	C/G	cg04586622	chr2:25135609	ADCY3	0.31	5.29	0.33	2.8e-7	Body mass index;
SARC	cis	rs10256972	0.630	rs10282584	chr7:1081442	C/T	cg00431813	chr7:1051703	C7orf50	-0.38	-5.91	-0.36	1.2e-8	Longevity;Endometriosis;
SARC	cis	rs796364	1.000	rs281794	chr2:200846666	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.78	7.37	0.43	2.97e-12	Schizophrenia;
SARC	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg15383120	chr6:291909	DUSP22	-0.53	-6.99	-0.42	2.94e-11	Menopause (age at onset);
SARC	cis	rs2933343	0.951	rs789218	chr3:128592670	G/A	cg24203234	chr3:128598194	ACAD9	0.52	5.71	0.35	3.49e-8	IgG glycosylation;
SARC	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-8.88	-0.5	1.8e-16	Alzheimer's disease;
SARC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg09373136	chr17:61933544	TCAM1	-0.45	-6.19	-0.38	2.75e-9	Prudent dietary pattern;
SARC	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg18876405	chr7:65276391	NA	-0.45	-5.31	-0.33	2.51e-7	Aortic root size;
SARC	cis	rs593982	1.000	rs74638829	chr11:65495571	C/T	cg08755490	chr11:65554678	OVOL1	-0.92	-9.79	-0.54	3.46e-19	Atopic dermatitis;
SARC	cis	rs708547	0.874	rs1315006	chr4:57858193	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.46	-4.94	-0.31	1.46e-6	Response to bleomycin (chromatid breaks);
SARC	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg20120463	chr17:44301886	NA	0.32	5.03	0.31	9.89e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs959260	0.765	rs12945469	chr17:73372243	G/A	cg14668889	chr17:73230827	NUP85	-0.42	-4.72	-0.3	4.03e-6	Systemic lupus erythematosus;
SARC	cis	rs55780018	0.645	rs12998817	chr2:208500945	A/G	cg19956940	chr2:208394514	CREB1	0.39	4.84	0.3	2.41e-6	Systolic blood pressure;
SARC	cis	rs9788682	1.000	rs57064725	chr15:78833036	C/A	cg06917634	chr15:78832804	PSMA4	-0.57	-6.5	-0.39	4.91e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs6088580	0.601	rs6059827	chr20:33016358	C/T	cg24642439	chr20:33292090	TP53INP2	0.66	8.55	0.49	1.63e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs17376456	1.000	rs10514382	chr5:93566534	G/A	cg21475434	chr5:93447410	FAM172A	0.93	8.04	0.47	4.41e-14	Diabetic retinopathy;
SARC	cis	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg18252515	chr7:66147081	NA	-1.22	-10.67	-0.57	6.88e-22	Diabetic kidney disease;
SARC	cis	rs9948	0.655	rs62156212	chr2:97399096	C/T	cg01990225	chr2:97406019	LMAN2L	-0.94	-6.38	-0.39	9.49e-10	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs2011503	1.000	rs7256028	chr19:19628240	C/T	cg03709012	chr19:19516395	GATAD2A	0.6	5.49	0.34	1.05e-7	Bipolar disorder;
SARC	cis	rs2204008	0.774	rs4534658	chr12:38246783	G/A	cg26384229	chr12:38710491	ALG10B	0.91	13.8	0.67	4.77e-32	Bladder cancer;
SARC	cis	rs12044355	0.927	rs66909551	chr1:231834942	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.6	8.02	0.47	5e-14	Alzheimer's disease;
SARC	cis	rs11718455	1.000	rs11917515	chr3:44020237	A/G	cg08738300	chr3:44038990	NA	0.51	5.7	0.35	3.56e-8	Coronary artery disease;
SARC	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.43	6.4	0.39	8.27e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs10089	0.909	rs7732599	chr5:127370421	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.87	10.36	0.56	6.04e-21	Ileal carcinoids;
SARC	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg06028605	chr16:24865363	SLC5A11	0.36	5.53	0.34	8.49e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7552404	0.924	rs1146574	chr1:76202671	A/G	cg10523679	chr1:76189770	ACADM	0.45	6.2	0.38	2.53e-9	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs4853036	0.951	rs7575302	chr2:70055236	T/C	cg02498382	chr2:70120550	SNRNP27	-0.41	-5.42	-0.33	1.49e-7	Colorectal or endometrial cancer;
SARC	cis	rs11122272	0.735	rs2790877	chr1:231535427	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.08	-0.55	4.68e-20	Hemoglobin concentration;
SARC	cis	rs36051895	0.659	rs12337134	chr9:5061578	G/A	cg02405213	chr9:5042618	JAK2	-0.45	-5.09	-0.32	7.22e-7	Pediatric autoimmune diseases;
SARC	cis	rs7772486	0.686	rs702314	chr6:146003510	G/A	cg23711669	chr6:146136114	FBXO30	-0.79	-12.76	-0.64	1.22e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7264396	0.676	rs6058380	chr20:34552900	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-6.92	-0.41	4.41e-11	Total cholesterol levels;
SARC	cis	rs7312933	0.703	rs2406567	chr12:42551479	G/C	cg17420585	chr12:42539391	GXYLT1	-0.34	-4.73	-0.3	3.93e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs11098499	0.866	rs11098506	chr4:120284971	A/G	cg09307838	chr4:120376055	NA	0.83	11.47	0.6	1.95e-24	Corneal astigmatism;
SARC	cis	rs6831352	0.879	rs29001208	chr4:100052539	A/C	cg12011299	chr4:100065546	ADH4	-0.34	-5.68	-0.35	4.05e-8	Alcohol dependence;
SARC	cis	rs10791323	0.660	rs10791332	chr11:133732150	A/G	cg14349672	chr11:133703707	NA	-0.33	-5.12	-0.32	6.44e-7	Childhood ear infection;
SARC	trans	rs11722228	0.508	rs3822246	chr4:10094698	G/A	cg26043149	chr18:55253948	FECH	0.67	7.57	0.44	8.58e-13	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs7312933	0.510	rs10880223	chr12:42413443	G/A	cg17420585	chr12:42539391	GXYLT1	-0.45	-6.96	-0.41	3.48e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs9660992	0.736	rs72745207	chr1:205251991	C/G	cg00857998	chr1:205179979	DSTYK	0.5	5.98	0.36	8.28e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs2290405	1.000	rs2290405	chr4:946974	A/G	cg04824913	chr4:887549	GAK	-0.42	-5.58	-0.34	6.71e-8	Systemic sclerosis;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg19332102	chr11:124588484	NA	-0.51	-6.57	-0.4	3.24e-10	Height;
SARC	cis	rs9815354	1.000	rs9824731	chr3:41889698	G/T	cg03022575	chr3:42003672	ULK4	0.67	5.73	0.35	3.13e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9398803	0.687	rs6911485	chr6:126975115	A/G	cg20229609	chr6:126660872	C6orf173	0.37	5.39	0.33	1.74e-7	Male-pattern baldness;
SARC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.79	9.9	0.54	1.6e-19	Prudent dietary pattern;
SARC	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg01475735	chr3:40494733	NA	0.46	5.2	0.32	4.46e-7	Renal cell carcinoma;
SARC	trans	rs1814175	0.645	rs7952104	chr11:49964180	C/T	cg15704280	chr7:45808275	SEPT13	-0.88	-14.06	-0.68	6.36e-33	Height;
SARC	cis	rs9916302	0.851	rs2338795	chr17:37399364	T/G	cg20243544	chr17:37824526	PNMT	0.53	6.4	0.39	8.66e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs8180040	0.764	rs11708451	chr3:47198826	G/A	cg02527881	chr3:46936655	PTH1R	-0.32	-4.97	-0.31	1.28e-6	Colorectal cancer;
SARC	cis	rs9611519	0.580	rs8138349	chr22:41412723	C/T	cg06634786	chr22:41940651	POLR3H	-0.38	-4.9	-0.31	1.8e-6	Neuroticism;
SARC	cis	rs9911578	1.000	rs1472288	chr17:56910720	G/A	cg12560992	chr17:57184187	TRIM37	0.86	12.1	0.62	1.84e-26	Intelligence (multi-trait analysis);
SARC	cis	rs7044106	0.762	rs1470307	chr9:123433039	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	5.43	0.34	1.41e-7	Hip circumference adjusted for BMI;
SARC	trans	rs7618501	0.966	rs2246832	chr3:49881134	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.73	10.16	0.55	2.63e-20	Intelligence (multi-trait analysis);
SARC	cis	rs739401	0.595	rs2237903	chr11:2967901	C/T	cg20651018	chr11:3035856	CARS	-0.42	-6.42	-0.39	7.57e-10	Longevity;
SARC	trans	rs61931739	0.517	rs10844727	chr12:34017435	C/T	cg26384229	chr12:38710491	ALG10B	0.75	10.64	0.57	8.3e-22	Morning vs. evening chronotype;
SARC	cis	rs3733585	0.673	rs4312757	chr4:9956145	T/A	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.39	-0.33	1.73e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7246865	0.510	rs1130222	chr19:17170885	C/T	cg16202187	chr19:17186497	HAUS8;MYO9B	0.39	4.78	0.3	3.15e-6	Reticulocyte fraction of red cells;
SARC	cis	rs3820928	0.874	rs4234063	chr2:227828335	A/T	cg05526886	chr2:227700861	RHBDD1	0.53	6.43	0.39	7.34e-10	Pulmonary function;
SARC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	15.91	0.72	4.56e-39	Prudent dietary pattern;
SARC	cis	rs733592	0.507	rs7304428	chr12:48494275	T/G	cg21466736	chr12:48725269	NA	0.33	5.78	0.35	2.33e-8	Plateletcrit;
SARC	trans	rs7824557	0.527	rs2736305	chr8:11237773	T/C	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.46	-0.39	6.12e-10	Retinal vascular caliber;
SARC	cis	rs2153535	0.584	rs9502721	chr6:8541379	G/A	cg23788917	chr6:8435910	SLC35B3	0.64	8.35	0.48	6.23e-15	Motion sickness;
SARC	cis	rs7326068	0.610	rs8000601	chr13:21339384	G/A	cg16922012	chr13:21400325	XPO4	-0.46	-6.25	-0.38	1.88e-9	Schizophrenia, bipolar disorder and depression (combined);
SARC	cis	rs9400467	0.506	rs77097930	chr6:111615479	G/A	cg15721981	chr6:111408429	SLC16A10	0.69	5.85	0.36	1.67e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs9303401	1.000	rs6503877	chr17:56841948	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.67	7.91	0.46	1.04e-13	Cognitive test performance;
SARC	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.36	5.05	0.31	8.95e-7	Obesity-related traits;
SARC	cis	rs9457247	0.765	rs9457251	chr6:167426707	T/C	cg07741184	chr6:167504864	NA	0.34	6.55	0.39	3.64e-10	Crohn's disease;
SARC	cis	rs561341	0.609	rs739800	chr17:30190083	T/A	cg13647721	chr17:30228624	UTP6	-0.73	-7.08	-0.42	1.73e-11	Hip circumference adjusted for BMI;
SARC	cis	rs875971	1.000	rs1167612	chr7:65567976	C/A	cg18876405	chr7:65276391	NA	-0.46	-5.51	-0.34	9.4e-8	Aortic root size;
SARC	cis	rs2290720	0.930	rs7298507	chr12:101715728	G/T	cg22051763	chr12:101673672	UTP20	-0.43	-5.06	-0.31	8.32e-7	Brain structure (hippocampal volume);
SARC	cis	rs4664308	0.935	rs4665148	chr2:160917901	A/G	cg03641300	chr2:160917029	PLA2R1	-0.67	-9.03	-0.51	6.88e-17	Idiopathic membranous nephropathy;
SARC	cis	rs208520	0.661	rs207079	chr6:66770462	C/T	cg07460842	chr6:66804631	NA	-1.07	-14.58	-0.69	1.21e-34	Exhaled nitric oxide output;
SARC	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg19087971	chr7:751233	PRKAR1B	-0.44	-4.79	-0.3	3.01e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs4889855	0.530	rs8080678	chr17:78544003	G/T	cg17956530	chr17:78667699	RPTOR	0.4	4.77	0.3	3.31e-6	Fractional excretion of uric acid;
SARC	cis	rs753778	0.667	rs6578153	chr8:142209543	C/T	cg18755752	chr8:142205143	DENND3	-0.53	-7.71	-0.45	3.66e-13	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	trans	rs9929218	1.000	rs13333528	chr16:68790502	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.63	-7.92	-0.46	9.75e-14	Colorectal cancer;
SARC	cis	rs796364	1.000	rs1509835	chr2:200814809	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.77	7.06	0.42	1.86e-11	Schizophrenia;
SARC	cis	rs6866344	0.697	rs11739893	chr5:178127837	G/A	cg03877680	chr5:178157825	ZNF354A	1.02	12.35	0.63	2.74e-27	Neutrophil percentage of white cells;
SARC	cis	rs7927771	0.965	rs4752881	chr11:47898535	A/G	cg05585544	chr11:47624801	NA	-0.38	-4.98	-0.31	1.22e-6	Subjective well-being;
SARC	cis	rs2153535	0.580	rs1932284	chr6:8477694	A/T	cg07606381	chr6:8435919	SLC35B3	0.76	10.74	0.58	4.06e-22	Motion sickness;
SARC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	6.0	0.37	7.37e-9	Prudent dietary pattern;
SARC	cis	rs1707322	1.000	rs10890381	chr1:46451771	T/G	cg03146154	chr1:46216737	IPP	0.49	5.84	0.36	1.71e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7937682	0.632	rs11214015	chr11:111719417	A/T	cg22437258	chr11:111473054	SIK2	0.49	5.7	0.35	3.62e-8	Primary sclerosing cholangitis;
SARC	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg22535103	chr8:58192502	C8orf71	-0.59	-6.21	-0.38	2.35e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs72781680	0.898	rs72786277	chr2:24062818	T/G	cg06627628	chr2:24431161	ITSN2	-0.68	-6.5	-0.39	4.88e-10	Lymphocyte counts;
SARC	cis	rs7100689	0.577	rs1340385	chr10:82058851	G/A	cg01528321	chr10:82214614	TSPAN14	0.69	9.1	0.51	4.21e-17	Post bronchodilator FEV1;
SARC	cis	rs9309473	0.687	rs6706409	chr2:73606508	G/T	cg20560298	chr2:73613845	ALMS1	0.54	6.82	0.41	7.57e-11	Metabolite levels;
SARC	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg22535103	chr8:58192502	C8orf71	-0.73	-7.24	-0.43	6.52e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs9325144	0.647	rs11168819	chr12:39011082	C/A	cg13010199	chr12:38710504	ALG10B	-0.53	-6.69	-0.4	1.67e-10	Morning vs. evening chronotype;
SARC	cis	rs7326068	0.595	rs2477164	chr13:21402388	A/C	cg16922012	chr13:21400325	XPO4	-0.4	-5.38	-0.33	1.82e-7	Schizophrenia, bipolar disorder and depression (combined);
SARC	cis	rs1144333	0.510	rs1250882	chr1:76287314	C/A	cg03433033	chr1:76189801	ACADM	-0.61	-5.0	-0.31	1.11e-6	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs10870270	0.956	rs10781555	chr10:133745720	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.46	-5.44	-0.34	1.33e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs1055129	0.560	rs9891076	chr17:73911715	C/T	cg14829360	chr17:73884958	NA	-0.55	-8.03	-0.47	4.88e-14	White matter hyperintensity burden;
SARC	cis	rs6912958	0.935	rs2179844	chr6:88165773	C/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.56	-0.34	7.35e-8	Monocyte percentage of white cells;
SARC	cis	rs5753037	0.547	rs140134	chr22:30163332	G/A	cg01021169	chr22:30184971	ASCC2	-0.53	-7.37	-0.43	2.94e-12	Type 1 diabetes;
SARC	cis	rs7319311	1.000	rs7319311	chr13:111030578	A/G	cg06243866	chr13:111019493	COL4A2	0.38	4.81	0.3	2.74e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs17376456	0.569	rs35878747	chr5:93094070	C/A	cg25358565	chr5:93447407	FAM172A	0.94	10.43	0.56	3.7e-21	Diabetic retinopathy;
SARC	cis	rs2228479	0.850	rs74251568	chr16:89903416	A/C	cg06558623	chr16:89946397	TCF25	0.93	6.63	0.4	2.29e-10	Skin colour saturation;
SARC	cis	rs3106136	0.546	rs2664881	chr4:95143484	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.47	-7.05	-0.42	2.06e-11	Capecitabine sensitivity;
SARC	cis	rs1707322	1.000	rs11211190	chr1:46266255	C/T	cg03146154	chr1:46216737	IPP	0.47	5.62	0.35	5.38e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1552244	0.700	rs9833566	chr3:9981671	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	8.71	0.5	5.81e-16	Alzheimer's disease;
SARC	cis	rs6121246	0.909	rs6058460	chr20:30363071	G/A	cg13852791	chr20:30311386	BCL2L1	0.86	9.18	0.52	2.36e-17	Mean corpuscular hemoglobin;
SARC	trans	rs3010562	1.000	rs3010562	chr6:167765251	A/G	cg13679164	chr6:161258479	NA	-0.49	-6.72	-0.4	1.41e-10	Gut microbiome composition (summer and winter);
SARC	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg11062466	chr8:58055876	NA	0.6	5.71	0.35	3.41e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg21724239	chr8:58056113	NA	0.68	6.39	0.39	8.82e-10	Developmental language disorder (linguistic errors);
SARC	trans	rs1814175	0.645	rs1721995	chr11:49915488	A/G	cg03929089	chr4:120376271	NA	-0.82	-11.67	-0.61	4.51e-25	Height;
SARC	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg13175981	chr1:150552382	MCL1	-0.54	-6.9	-0.41	4.97e-11	Tonsillectomy;
SARC	cis	rs1008375	0.931	rs10008337	chr4:17593849	G/C	cg02297831	chr4:17616191	MED28	0.51	6.39	0.39	8.91e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs208520	0.837	rs208486	chr6:66926255	A/T	cg07460842	chr6:66804631	NA	-1.01	-12.24	-0.63	6.35e-27	Exhaled nitric oxide output;
SARC	cis	rs208520	1.000	rs12190316	chr6:66973365	T/C	cg07460842	chr6:66804631	NA	0.79	8.87	0.5	2e-16	Exhaled nitric oxide output;
SARC	cis	rs2153535	0.601	rs4140585	chr6:8503298	T/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.09	0.59	3.11e-23	Motion sickness;
SARC	cis	rs11997175	0.574	rs4370495	chr8:33654819	G/A	ch.8.33884649F	chr8:33765107	NA	0.48	6.45	0.39	6.25e-10	Body mass index;
SARC	cis	rs782590	0.967	rs35504023	chr2:55806503	C/T	cg18811423	chr2:55921094	PNPT1	-0.68	-10.39	-0.56	4.89e-21	Metabolic syndrome;
SARC	cis	rs5167	0.504	rs8100120	chr19:45466058	T/C	cg13119609	chr19:45449297	APOC2	0.52	9.08	0.51	4.79e-17	Blood protein levels;
SARC	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg24531977	chr5:56204891	C5orf35	-0.52	-5.3	-0.33	2.73e-7	Initial pursuit acceleration;
SARC	cis	rs2836633	0.894	rs55955614	chr21:40037330	T/G	cg12884169	chr21:40033163	ERG	0.49	9.02	0.51	7.18e-17	Coronary artery disease;
SARC	cis	rs9291683	0.632	rs11734786	chr4:10041499	A/C	cg00071950	chr4:10020882	SLC2A9	0.39	6.22	0.38	2.26e-9	Bone mineral density;
SARC	cis	rs10088262	0.629	rs12541177	chr8:124800273	G/T	cg02993010	chr8:124780839	FAM91A1	-0.79	-9.28	-0.52	1.24e-17	Pancreatic cancer;
SARC	cis	rs11252926	0.527	rs10904093	chr10:436848	A/G	cg16386425	chr10:429943	DIP2C	0.41	4.71	0.3	4.19e-6	Psychosis in Alzheimer's disease;
SARC	cis	rs10754283	0.934	rs7529653	chr1:90111851	G/A	cg21401794	chr1:90099060	LRRC8C	0.59	8.09	0.47	3.24e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg06361531	chr16:68057779	DUS2L;DDX28	-0.6	-6.86	-0.41	6.05e-11	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs13082711	0.911	rs13078798	chr3:27445971	A/G	cg02860705	chr3:27208620	NA	-0.43	-5.59	-0.34	6.28e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs600231	0.651	rs2846862	chr11:65219790	A/G	cg17120908	chr11:65337727	SSSCA1	-0.42	-5.38	-0.33	1.79e-7	Bone mineral density;
SARC	cis	rs4727027	1.000	rs4727027	chr7:148869277	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	5.78	0.35	2.35e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs6740322	0.748	rs6720087	chr2:43468745	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.53	6.2	0.38	2.61e-9	Coronary artery disease;
SARC	cis	rs76419734	0.850	rs115962916	chr4:106801715	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.89	4.91	0.31	1.7e-6	Post bronchodilator FEV1;
SARC	cis	rs9818758	0.556	rs9813813	chr3:49207093	T/A	cg07636037	chr3:49044803	WDR6	-0.77	-6.84	-0.41	6.93e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	trans	rs7070797	0.735	rs72831358	chr10:63534978	C/T	cg06731886	chr7:73284078	NA	-0.51	-6.47	-0.39	5.86e-10	Takotsubo syndrome;
SARC	cis	rs17030434	0.784	rs17370965	chr4:154650948	C/T	cg14289246	chr4:154710475	SFRP2	-0.49	-5.58	-0.34	6.58e-8	Electrocardiographic conduction measures;
SARC	cis	rs2652834	0.904	rs2937859	chr15:63366282	C/T	cg05507819	chr15:63340323	TPM1	0.6	6.24	0.38	2.06e-9	HDL cholesterol;
SARC	cis	rs459482	0.504	rs467773	chr21:42818106	C/T	cg14166395	chr21:42792516	MX1	-0.42	-4.86	-0.3	2.18e-6	IgG glycosylation;
SARC	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg11764359	chr7:65958608	NA	-0.79	-9.5	-0.53	2.66e-18	Aortic root size;
SARC	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg18252515	chr7:66147081	NA	-1.3	-11.62	-0.61	6.33e-25	Diabetic kidney disease;
SARC	cis	rs12200560	0.505	rs211176	chr6:97073821	G/A	cg06623918	chr6:96969491	KIAA0776	0.45	5.11	0.32	6.85e-7	Coronary heart disease;
SARC	cis	rs472402	0.623	rs8192131	chr5:6636465	C/T	cg27314116	chr5:6583850	LOC255167	0.31	4.9	0.31	1.81e-6	Response to amphetamines;
SARC	trans	rs1821002	1	rs1821002	chr8:10640065	C/G	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.31	-0.38	1.43e-9	Systolic blood pressure;
SARC	cis	rs6772849	0.930	rs9868579	chr3:128351054	C/T	cg01163369	chr3:128370232	RPN1	0.34	4.92	0.31	1.66e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs9911578	0.835	rs10853006	chr17:56489076	G/A	cg05425664	chr17:57184151	TRIM37	0.62	7.31	0.43	4.27e-12	Intelligence (multi-trait analysis);
SARC	cis	rs1881797	1.000	rs1881797	chr1:247689532	A/G	cg11166453	chr1:247681781	NA	0.53	6.05	0.37	5.76e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs72653721	1.000	rs72653721	chr6:10971886	C/T	cg13562911	chr6:11044106	ELOVL2	0.57	6.03	0.37	6.53e-9	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	cis	rs7808935	0.628	rs72598552	chr7:27939961	G/A	cg05786569	chr7:27702416	HIBADH	0.74	7.94	0.46	8.63e-14	Prostate cancer;
SARC	cis	rs8014204	0.901	rs4899536	chr14:75316614	A/G	cg17347104	chr14:75034677	LTBP2	0.4	4.87	0.3	2.07e-6	Caffeine consumption;
SARC	cis	rs4848768	1.000	rs4848768	chr2:123141545	A/G	cg09809242	chr2:122494874	MKI67IP	-0.5	-4.74	-0.3	3.72e-6	Lentiform nucleus volume;
SARC	cis	rs7937682	0.921	rs12806479	chr11:111443192	G/C	cg09085632	chr11:111637200	PPP2R1B	0.87	12.55	0.64	5.89e-28	Primary sclerosing cholangitis;
SARC	cis	rs17376456	0.877	rs10476599	chr5:93383423	A/G	cg21475434	chr5:93447410	FAM172A	0.85	7.56	0.44	9.4e-13	Diabetic retinopathy;
SARC	cis	rs1865760	0.602	rs9467662	chr6:26021327	G/A	cg02841227	chr6:26021843	HIST1H4A	0.4	4.85	0.3	2.24e-6	Height;
SARC	cis	rs10849893	0.595	rs7980819	chr12:121887194	A/G	cg01154721	chr12:121881891	KDM2B	-0.38	-5.41	-0.33	1.56e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs9388451	0.839	rs980014	chr6:126068001	T/G	cg06289844	chr6:126071538	HEY2	0.38	6.19	0.38	2.64e-9	Brugada syndrome;
SARC	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	6.98	0.42	3.08e-11	Platelet count;
SARC	cis	rs2120019	1.000	rs7168680	chr15:75369212	G/A	cg00629941	chr15:75287862	SCAMP5	-0.6	-7.27	-0.43	5.46e-12	Blood trace element (Zn levels);
SARC	trans	rs11039798	0.582	rs60764175	chr11:48775856	T/G	cg15704280	chr7:45808275	SEPT13	0.64	6.41	0.39	8.11e-10	Axial length;
SARC	cis	rs1008375	0.932	rs4698627	chr4:17605959	T/C	cg27347728	chr4:17578864	LAP3	0.45	5.52	0.34	9.09e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7084402	0.967	rs1658489	chr10:60285924	A/G	cg07615347	chr10:60278583	BICC1	0.6	8.82	0.5	2.75e-16	Refractive error;
SARC	trans	rs1814175	0.817	rs7950856	chr11:49976394	C/T	cg15704280	chr7:45808275	SEPT13	-0.98	-18.59	-0.77	6.51e-48	Height;
SARC	cis	rs4481887	0.927	rs4603165	chr1:248473799	T/A	cg00666640	chr1:248458726	OR2T12	0.32	5.45	0.34	1.25e-7	Common traits (Other);
SARC	cis	rs782590	0.729	rs706548	chr2:55850106	C/G	cg18811423	chr2:55921094	PNPT1	0.66	9.39	0.52	5.82e-18	Metabolic syndrome;
SARC	cis	rs6918586	0.658	rs198814	chr6:26127759	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.44	-5.53	-0.34	8.42e-8	Schizophrenia;
SARC	cis	rs908922	0.676	rs486283	chr1:152525957	A/G	cg09873164	chr1:152488093	CRCT1	0.61	7.89	0.46	1.18e-13	Hair morphology;
SARC	cis	rs12950390	0.893	rs11079789	chr17:45849715	A/G	cg24803719	chr17:45855879	NA	-0.48	-7.98	-0.46	6.75e-14	IgG glycosylation;
SARC	cis	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg08975724	chr8:8085496	FLJ10661	-0.46	-5.45	-0.34	1.31e-7	Mood instability;
SARC	cis	rs1865721	0.771	rs6566093	chr18:73136682	T/C	cg26385618	chr18:73139727	C18orf62	-0.4	-5.53	-0.34	8.56e-8	Intelligence;
SARC	cis	rs34172651	0.917	rs200533	chr16:24754771	C/T	cg04756594	chr16:24857601	SLC5A11	-0.36	-5.99	-0.37	7.78e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg24110177	chr3:50126178	RBM5	0.57	7.8	0.45	2.12e-13	Intelligence (multi-trait analysis);
SARC	cis	rs734999	0.549	rs6670198	chr1:2520527	T/C	cg20673091	chr1:2541236	MMEL1	0.33	5.05	0.31	8.72e-7	Ulcerative colitis;
SARC	cis	rs7666738	0.753	rs35146453	chr4:98902278	A/G	cg05340658	chr4:99064831	C4orf37	0.64	8.46	0.48	3.06e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg02951883	chr7:2050386	MAD1L1	-0.42	-5.42	-0.33	1.49e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs10791097	0.739	rs11222358	chr11:130730497	G/A	cg12179176	chr11:130786555	SNX19	0.64	8.85	0.5	2.21e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs1348850	0.914	rs4341974	chr2:178324879	A/C	cg23306229	chr2:178417860	TTC30B	0.52	6.16	0.37	3.11e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9399137	0.507	rs12663447	chr6:135317026	A/C	cg22676075	chr6:135203613	NA	0.38	4.84	0.3	2.32e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs12541335	0.615	rs4872464	chr8:22153381	G/A	cg02788857	chr8:22132959	PIWIL2	0.35	4.95	0.31	1.44e-6	Hypertriglyceridemia;
SARC	cis	rs12586317	0.883	rs4982254	chr14:35755737	C/T	cg16230307	chr14:35515116	FAM177A1	0.78	8.7	0.5	6.18e-16	Psoriasis;
SARC	cis	rs1878931	0.535	rs55732163	chr16:3411518	A/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.63	-6.98	-0.42	3.05e-11	Body mass index (adult);
SARC	cis	rs11190604	1.000	rs2295779	chr10:102296061	A/G	cg07080220	chr10:102295463	HIF1AN	0.82	10.13	0.55	3.29e-20	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs7647973	1.000	rs11710434	chr3:49346130	T/C	cg07636037	chr3:49044803	WDR6	0.72	8.41	0.48	4.12e-15	Menarche (age at onset);
SARC	cis	rs62244186	0.659	rs4431151	chr3:44510906	G/C	cg15225532	chr3:44803084	KIF15;KIAA1143	0.46	5.77	0.35	2.53e-8	Depressive symptoms;
SARC	cis	rs6138458	1.000	rs6707	chr20:24944166	C/T	cg26195577	chr20:24973756	C20orf3	0.87	9.23	0.52	1.72e-17	Blood protein levels;
SARC	cis	rs1153858	1.000	rs60476496	chr15:45713801	C/T	cg15395560	chr15:45543142	SLC28A2	-0.27	-4.87	-0.3	2.05e-6	Homoarginine levels;
SARC	cis	rs3796352	1.000	rs35163227	chr3:53127876	A/G	cg07884673	chr3:53033167	SFMBT1	0.76	4.76	0.3	3.34e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs356220	0.642	rs356171	chr4:90632023	C/T	cg06632027	chr4:90757378	SNCA	0.41	5.44	0.34	1.37e-7	Parkinson's disease;
SARC	cis	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg18252515	chr7:66147081	NA	-1.26	-11.14	-0.59	2.14e-23	Diabetic kidney disease;
SARC	cis	rs7264396	0.563	rs2425130	chr20:34335059	A/G	cg01084648	chr20:34329383	RBM39	0.57	5.0	0.31	1.13e-6	Total cholesterol levels;
SARC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.42	0.53	4.71e-18	Prudent dietary pattern;
SARC	cis	rs3091242	1.000	rs646867	chr1:25709258	A/C	cg27572855	chr1:25598939	RHD	0.55	9.47	0.53	3.23e-18	Erythrocyte sedimentation rate;
SARC	cis	rs365302	0.628	rs409096	chr6:159610904	T/C	cg14500486	chr6:159655392	FNDC1	0.39	4.75	0.3	3.49e-6	Coronary heart disease;
SARC	cis	rs7582720	1.000	rs72936872	chr2:203790889	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs826838	0.967	rs11183577	chr12:38781887	A/G	cg26384229	chr12:38710491	ALG10B	0.95	15.46	0.71	1.43e-37	Heart rate;
SARC	cis	rs2180341	0.920	rs6916990	chr6:127698759	G/A	cg17762328	chr6:126965162	NA	-0.44	-4.86	-0.3	2.13e-6	Breast cancer;
SARC	cis	rs9436747	0.653	rs1751479	chr1:66016205	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	-0.44	-5.06	-0.31	8.51e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs7264396	0.690	rs2425183	chr20:34450621	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.53	-0.44	1.09e-12	Total cholesterol levels;
SARC	cis	rs4727027	0.933	rs4727028	chr7:148874666	A/G	cg23583168	chr7:148888333	NA	0.71	11.0	0.58	5.99e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs72627509	0.904	rs3796529	chr4:57797414	C/T	cg26694713	chr4:57773883	REST	0.65	6.78	0.41	9.73e-11	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg07701084	chr6:150067640	NUP43	0.39	5.16	0.32	5.38e-7	Lung cancer;
SARC	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg11941060	chr3:133502564	NA	0.36	5.17	0.32	4.96e-7	Iron status biomarkers;
SARC	cis	rs7904368	0.806	rs12242261	chr10:16872929	T/C	cg14835575	chr10:16859367	RSU1	0.77	7.47	0.44	1.57e-12	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	trans	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.11	-0.42	1.43e-11	Extrinsic epigenetic age acceleration;
SARC	trans	rs5417	0.689	rs55868524	chr17:7170665	G/A	cg15655154	chr3:113604241	GRAMD1C	-0.51	-7.15	-0.42	1.13e-11	Diastolic blood pressure;
SARC	cis	rs7659604	0.502	rs13106764	chr4:122699630	C/G	cg19671926	chr4:122722719	EXOSC9	0.65	8.55	0.49	1.68e-15	Type 2 diabetes;
SARC	cis	rs6918586	0.658	rs1572982	chr6:26094367	G/A	cg18357526	chr6:26021779	HIST1H4A	0.45	5.81	0.36	2.07e-8	Schizophrenia;
SARC	cis	rs79387448	0.638	rs7600961	chr2:103035455	G/A	cg09003973	chr2:102972529	NA	0.77	7.48	0.44	1.5e-12	Gut microbiota (bacterial taxa);
SARC	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg24829409	chr8:58192753	C8orf71	-0.65	-6.15	-0.37	3.28e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2016266	0.784	rs7308162	chr12:53654956	G/A	cg26875137	chr12:53738046	NA	0.4	5.19	0.32	4.49e-7	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs1448094	0.512	rs7299285	chr12:86244959	A/T	cg02569458	chr12:86230093	RASSF9	0.38	5.4	0.33	1.64e-7	Major depressive disorder;
SARC	cis	rs4792901	0.918	rs2271959	chr17:41622740	G/T	cg22562494	chr17:41607896	ETV4	-0.33	-5.3	-0.33	2.63e-7	Dupuytren's disease;
SARC	cis	rs12971120	0.838	rs3794950	chr18:72182965	G/A	cg25817165	chr18:72167213	CNDP2	-0.56	-7.4	-0.44	2.45e-12	Refractive error;
SARC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg07414643	chr4:187882934	NA	0.46	6.57	0.4	3.28e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs8014204	0.935	rs10141438	chr14:75354600	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.78	-11.9	-0.61	7.78e-26	Caffeine consumption;
SARC	cis	rs10782582	0.593	rs11576534	chr1:76112751	C/T	cg10523679	chr1:76189770	ACADM	-0.4	-5.03	-0.31	9.7e-7	Daytime sleep phenotypes;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg03055737	chr13:111365026	ING1	0.49	6.35	0.38	1.13e-9	Tetralogy of Fallot;
SARC	cis	rs9916302	0.851	rs4390625	chr17:37620347	A/G	cg07936489	chr17:37558343	FBXL20	-0.69	-9.02	-0.51	7.32e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs10861342	1.000	rs10861358	chr12:105559563	G/A	cg23923672	chr12:105501055	KIAA1033	0.76	6.2	0.38	2.56e-9	IgG glycosylation;
SARC	cis	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg13647721	chr17:30228624	UTP6	-0.69	-5.88	-0.36	1.4e-8	Hip circumference adjusted for BMI;
SARC	cis	rs1878931	0.507	rs35214904	chr16:3410017	C/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.6	-6.37	-0.38	1.01e-9	Body mass index (adult);
SARC	cis	rs10782582	0.593	rs11164042	chr1:76178440	G/A	cg03433033	chr1:76189801	ACADM	-0.42	-5.43	-0.34	1.42e-7	Daytime sleep phenotypes;
SARC	trans	rs11088226	0.681	rs2833912	chr21:33949822	G/A	cg09050820	chr6:167586206	TCP10L2	0.6	6.73	0.4	1.33e-10	Gastritis;
SARC	cis	rs6089584	0.606	rs6089599	chr20:60576992	A/G	cg13770153	chr20:60521292	NA	0.41	6.07	0.37	5.17e-9	Body mass index;
SARC	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg00800038	chr16:89945340	TCF25	-0.76	-5.35	-0.33	2.12e-7	Skin colour saturation;
SARC	cis	rs1008375	0.966	rs4698642	chr4:17679174	A/T	cg02297831	chr4:17616191	MED28	0.43	5.45	0.34	1.26e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg18404041	chr3:52824283	ITIH1	-0.48	-7.35	-0.43	3.36e-12	Bipolar disorder;
SARC	cis	rs847851	0.617	rs73403805	chr6:34964724	C/T	cg13137465	chr6:34857473	ANKS1A	0.6	4.83	0.3	2.48e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2230307	0.536	rs575971	chr1:100546591	T/C	cg24955406	chr1:100503596	HIAT1	0.73	7.2	0.43	8.43e-12	Carotid intima media thickness;
SARC	cis	rs9486719	1.000	rs12529248	chr6:96895377	T/G	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.01	-0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs10791097	0.694	rs6590520	chr11:130747386	C/G	cg12179176	chr11:130786555	SNX19	0.76	11.59	0.6	7.95e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs7666738	0.546	rs62320963	chr4:98839297	A/G	cg05340658	chr4:99064831	C4orf37	0.59	7.16	0.42	1.04e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg20607798	chr8:58055168	NA	0.66	5.6	0.34	6.09e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs17666538	0.591	rs1669716	chr8:593707	C/T	cg07234876	chr8:600039	NA	0.64	5.59	0.34	6.37e-8	IgG glycosylation;
SARC	cis	rs865483	0.929	rs853214	chr17:35860964	T/C	cg06561646	chr17:35873369	DUSP14	-0.48	-6.46	-0.39	6.12e-10	Monocyte count;
SARC	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	10.98	0.58	6.89e-23	Platelet count;
SARC	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg18825119	chr6:163149453	PACRG;PARK2	0.39	4.84	0.3	2.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2204008	0.805	rs3863360	chr12:37966432	C/T	cg26384229	chr12:38710491	ALG10B	0.86	12.42	0.63	1.57e-27	Bladder cancer;
SARC	cis	rs9303280	0.936	rs907091	chr17:37921742	A/G	cg00129232	chr17:37814104	STARD3	-0.38	-4.89	-0.31	1.87e-6	Self-reported allergy;
SARC	cis	rs11583043	0.793	rs3903905	chr1:101420957	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.48	5.88	0.36	1.38e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg25894440	chr7:65020034	NA	-0.73	-5.5	-0.34	9.8e-8	Diabetic kidney disease;
SARC	trans	rs1814175	0.615	rs12417290	chr11:49876951	G/A	cg15704280	chr7:45808275	SEPT13	-0.87	-13.81	-0.67	4.37e-32	Height;
SARC	cis	rs2273669	0.667	rs16822	chr6:109307710	G/A	cg05315195	chr6:109294784	ARMC2	-0.58	-5.22	-0.32	3.94e-7	Prostate cancer;
SARC	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg10435706	chr6:150039699	LATS1	0.36	4.72	0.3	4.14e-6	Lung cancer;
SARC	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg04944784	chr2:26401820	FAM59B	-0.51	-6.18	-0.38	2.82e-9	Gut microbiome composition (summer);
SARC	cis	rs2836974	0.565	rs2836939	chr21:40578546	C/T	cg11890956	chr21:40555474	PSMG1	0.85	7.72	0.45	3.38e-13	Cognitive function;
SARC	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg23958373	chr8:599963	NA	1.04	7.93	0.46	8.84e-14	IgG glycosylation;
SARC	cis	rs6121246	0.559	rs6060922	chr20:30333909	C/T	cg13852791	chr20:30311386	BCL2L1	0.88	10.96	0.58	8.39e-23	Mean corpuscular hemoglobin;
SARC	cis	rs74181299	0.712	rs2241161	chr2:65290842	A/C	cg20592124	chr2:65290738	CEP68	-0.57	-8.8	-0.5	3.09e-16	Pulse pressure;
SARC	cis	rs3018712	0.508	rs4930582	chr11:68411104	C/T	cg01657329	chr11:68192670	LRP5	0.57	5.25	0.33	3.35e-7	Total body bone mineral density;
SARC	cis	rs9916302	0.706	rs1054488	chr17:37687968	A/G	cg00129232	chr17:37814104	STARD3	-0.57	-6.04	-0.37	6.17e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs8017423	0.967	rs2277516	chr14:90722824	G/C	cg20276874	chr14:90721474	PSMC1	-0.39	-5.49	-0.34	1.06e-7	Mortality in heart failure;
SARC	cis	rs56235845	0.694	rs12055081	chr5:176757191	C/T	cg16006841	chr5:176797999	RGS14	0.52	6.98	0.42	2.96e-11	Hemoglobin concentration;Hematocrit;
SARC	trans	rs61931739	0.500	rs11053210	chr12:34461771	A/G	cg26384229	chr12:38710491	ALG10B	-0.85	-11.1	-0.59	2.86e-23	Morning vs. evening chronotype;
SARC	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.86	-11.43	-0.6	2.68e-24	Intelligence (multi-trait analysis);
SARC	trans	rs2727020	0.729	rs10839268	chr11:49380328	G/A	cg15704280	chr7:45808275	SEPT13	-0.82	-13.25	-0.66	3.01e-30	Coronary artery disease;
SARC	cis	rs11122272	0.735	rs2739506	chr1:231529183	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.14	-0.55	2.99e-20	Hemoglobin concentration;
SARC	trans	rs643955	0.637	rs4841271	chr8:9870137	T/A	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.28	-0.38	1.65e-9	Systemic lupus erythematosus;
SARC	cis	rs16854884	0.657	rs2099543	chr3:143742164	C/T	cg06585982	chr3:143692056	C3orf58	0.67	9.14	0.51	3.13e-17	Economic and political preferences (feminism/equality);
SARC	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg22535103	chr8:58192502	C8orf71	-0.82	-9.34	-0.52	8.22e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs55692411	0.517	rs62262106	chr3:49991427	A/G	cg14019146	chr3:50243930	SLC38A3	-0.38	-5.41	-0.33	1.53e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2239547	0.522	rs4519686	chr3:52997871	C/T	cg07507251	chr3:52567010	NT5DC2	0.37	4.88	0.3	1.95e-6	Schizophrenia;
SARC	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	9.15	0.51	3.02e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs950169	1.000	rs12915234	chr15:84758301	G/A	cg24253500	chr15:84953950	NA	0.36	5.28	0.33	2.99e-7	Schizophrenia;
SARC	cis	rs7712401	0.601	rs2910140	chr5:122264395	T/A	cg19412675	chr5:122181750	SNX24	0.41	5.24	0.32	3.56e-7	Mean platelet volume;
SARC	cis	rs2075371	1.000	rs447266	chr7:133989543	A/G	cg00033643	chr7:134001901	SLC35B4	0.41	5.02	0.31	1.01e-6	Mean platelet volume;
SARC	cis	rs4481887	1.000	rs11204636	chr1:248492409	A/C	cg13385794	chr1:248469461	NA	-0.37	-5.44	-0.34	1.35e-7	Common traits (Other);
SARC	cis	rs8114671	0.836	rs3746432	chr20:33592763	C/T	cg24642439	chr20:33292090	TP53INP2	-0.51	-6.06	-0.37	5.3e-9	Height;
SARC	cis	rs13256369	0.802	rs12680019	chr8:8561698	A/G	cg17143192	chr8:8559678	CLDN23	0.5	5.43	0.34	1.4e-7	Obesity-related traits;
SARC	cis	rs7086627	0.515	rs10887896	chr10:82210144	A/C	cg01528321	chr10:82214614	TSPAN14	0.57	8.21	0.47	1.55e-14	Post bronchodilator FEV1;
SARC	cis	rs2235642	0.893	rs2076445	chr16:1592266	A/T	cg09025071	chr16:1593152	IFT140;TMEM204	0.34	5.03	0.31	9.62e-7	Coronary artery disease;
SARC	trans	rs3780486	0.718	rs10971418	chr9:33122024	A/C	cg04842962	chr6:43655489	MRPS18A	-0.85	-10.09	-0.55	4.37e-20	IgG glycosylation;
SARC	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg17691542	chr6:26056736	HIST1H1C	-0.42	-4.96	-0.31	1.37e-6	Blood metabolite levels;
SARC	trans	rs61931739	0.517	rs11513519	chr12:34075077	G/A	cg26384229	chr12:38710491	ALG10B	0.87	12.36	0.63	2.53e-27	Morning vs. evening chronotype;
SARC	cis	rs1008375	0.932	rs10029173	chr4:17659598	C/T	cg16339924	chr4:17578868	LAP3	-0.65	-8.66	-0.49	7.84e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6831352	0.819	rs1154401	chr4:100009738	G/C	cg13256891	chr4:100009986	ADH5	0.61	8.43	0.48	3.58e-15	Alcohol dependence;
SARC	cis	rs9911578	1.000	rs2055779	chr17:57030561	A/G	cg12560992	chr17:57184187	TRIM37	0.85	11.72	0.61	3.03e-25	Intelligence (multi-trait analysis);
SARC	cis	rs7223966	1.000	rs8075422	chr17:61804686	G/A	cg26338869	chr17:61819248	STRADA	0.43	4.84	0.3	2.31e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs12815613	0.621	rs11065360	chr12:121386532	A/G	cg02403541	chr12:121454288	C12orf43	-0.54	-6.44	-0.39	6.78e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs3741798	1.000	rs73277486	chr12:12494761	T/C	cg08615371	chr12:12503544	MANSC1	0.69	5.5	0.34	9.79e-8	Cerebrospinal fluid biomarker levels;
SARC	cis	rs6430585	0.527	rs6753232	chr2:136436317	C/T	cg07169764	chr2:136633963	MCM6	-0.72	-9.06	-0.51	5.57e-17	Corneal structure;
SARC	cis	rs11578119	0.898	rs10919405	chr1:170417755	A/G	cg09767346	chr1:170501363	GORAB	0.41	4.84	0.3	2.41e-6	Male-pattern baldness;
SARC	cis	rs239198	0.568	rs979122	chr6:101332215	C/T	cg09795085	chr6:101329169	ASCC3	-0.42	-5.24	-0.32	3.58e-7	Menarche (age at onset);
SARC	cis	rs10791097	0.694	rs1054869	chr11:130742630	G/A	cg09137382	chr11:130731461	NA	0.31	4.78	0.3	3.15e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs7811142	1.000	rs6953107	chr7:100095664	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	12.45	0.63	1.28e-27	Platelet count;
SARC	cis	rs11209002	0.571	rs7531772	chr1:67555516	T/C	cg02640540	chr1:67518911	SLC35D1	0.54	6.34	0.38	1.19e-9	Crohn's disease;
SARC	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg03650068	chr1:25596491	NA	0.33	5.13	0.32	5.96e-7	Erythrocyte sedimentation rate;
SARC	cis	rs6952808	0.707	rs13244345	chr7:1973004	A/G	cg03354898	chr7:1950403	MAD1L1	-0.37	-4.87	-0.3	2.1e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs6696846	0.791	rs11240352	chr1:205051711	C/G	cg00857998	chr1:205179979	DSTYK	-0.47	-6.14	-0.37	3.62e-9	Red blood cell count;
SARC	cis	rs3845702	0.736	rs72962575	chr2:180862133	C/G	cg01881094	chr2:180872142	CWC22	1.04	8.14	0.47	2.43e-14	Schizophrenia;
SARC	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg04944784	chr2:26401820	FAM59B	0.64	8.27	0.48	1.03e-14	Gut microbiome composition (summer);
SARC	cis	rs11676348	0.772	rs11676275	chr2:218944808	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.43	-5.49	-0.34	1.03e-7	Ulcerative colitis;
SARC	cis	rs7709377	0.595	rs253952	chr5:115633670	A/G	cg23108291	chr5:115420582	COMMD10	-0.43	-4.75	-0.3	3.55e-6	Metabolite levels  (X-11787);
SARC	cis	rs6964587	0.967	rs7781221	chr7:91664645	A/G	cg17063962	chr7:91808500	NA	0.95	16.02	0.72	1.87e-39	Breast cancer;
SARC	cis	rs854765	0.654	rs11078400	chr17:17757728	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.43	-5.57	-0.34	7.15e-8	Total body bone mineral density;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg25294185	chr11:65487814	RNASEH2C	-0.53	-6.25	-0.38	1.89e-9	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs2228479	0.717	rs34027607	chr16:89808939	T/C	cg06558623	chr16:89946397	TCF25	0.87	6.94	0.41	3.78e-11	Skin colour saturation;
SARC	cis	rs4319547	0.774	rs10773394	chr12:123124778	C/A	cg23029597	chr12:123009494	RSRC2	-0.43	-5.54	-0.34	8.16e-8	Body mass index;
SARC	cis	rs854765	0.547	rs9912096	chr17:17896673	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	9.57	0.53	1.65e-18	Total body bone mineral density;
SARC	cis	rs1348850	0.914	rs1374437	chr2:178363423	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.64	8.24	0.48	1.24e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs79149102	0.579	rs78664321	chr15:75339575	G/A	cg17294928	chr15:75287854	SCAMP5	-1.16	-9.08	-0.51	4.67e-17	Lung cancer;
SARC	cis	rs644799	0.965	rs10831426	chr11:95505888	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	9.45	0.53	3.74e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs35306767	0.714	rs7072554	chr10:1090988	C/T	cg18964960	chr10:1102726	WDR37	0.48	4.93	0.31	1.53e-6	Eosinophil percentage of granulocytes;
SARC	cis	rs651907	0.557	rs11917569	chr3:101355063	G/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	6.29	0.38	1.57e-9	Colorectal cancer;
SARC	cis	rs9916302	0.904	rs7208274	chr17:37513796	C/T	cg00129232	chr17:37814104	STARD3	0.59	7.31	0.43	4.18e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs3796352	1.000	rs113995589	chr3:53132372	A/T	cg15956490	chr3:53032818	SFMBT1	0.77	5.29	0.33	2.88e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2777491	0.915	rs8036498	chr15:41603276	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.75	-11.02	-0.59	5.42e-23	Ulcerative colitis;
SARC	cis	rs1920116	0.778	rs35510081	chr3:169549774	A/T	cg14222479	chr3:169487675	ARPM1	0.47	5.21	0.32	4.08e-7	Glioma (high-grade);
SARC	trans	rs3942852	0.712	rs2174129	chr11:48108557	A/C	cg15704280	chr7:45808275	SEPT13	-0.58	-6.75	-0.4	1.15e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs2650000	0.798	rs2701175	chr12:121391671	C/A	cg02403541	chr12:121454288	C12orf43	-0.73	-9.69	-0.54	6.88e-19	Metabolic traits;LDL cholesterol;
SARC	cis	rs11166927	0.967	rs56343024	chr8:140803580	G/A	cg16909799	chr8:140841666	TRAPPC9	0.36	4.9	0.31	1.79e-6	Pediatric non-alcoholic fatty liver disease activity score;
SARC	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg03161606	chr19:29218774	NA	0.39	4.96	0.31	1.33e-6	Methadone dose in opioid dependence;
SARC	cis	rs861020	0.606	rs627459	chr1:210004682	C/G	cg23166289	chr1:210001082	C1orf107	0.39	4.74	0.3	3.66e-6	Orofacial clefts;
SARC	cis	rs8031584	0.541	rs2955777	chr15:31219788	A/C	cg14829155	chr15:31115871	NA	0.42	5.74	0.35	2.93e-8	Huntington's disease progression;
SARC	cis	rs3858526	0.883	rs10769333	chr11:5939685	A/T	cg13902645	chr11:5959945	NA	-0.43	-4.92	-0.31	1.65e-6	DNA methylation (variation);
SARC	cis	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg08975724	chr8:8085496	FLJ10661	0.55	7.12	0.42	1.31e-11	Mood instability;
SARC	cis	rs9916302	0.904	rs10432031	chr17:37397852	G/A	cg20243544	chr17:37824526	PNMT	0.53	6.4	0.39	8.66e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg03806693	chr22:41940476	POLR3H	0.88	11.67	0.61	4.34e-25	Vitiligo;
SARC	cis	rs2153535	0.563	rs1796687	chr6:8536118	C/G	cg23788917	chr6:8435910	SLC35B3	0.59	7.27	0.43	5.45e-12	Motion sickness;
SARC	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg22875332	chr1:76189707	ACADM	-0.46	-6.51	-0.39	4.57e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2985684	0.802	rs8015368	chr14:50020510	G/A	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.47	5.23	0.32	3.83e-7	Carotid intima media thickness;
SARC	cis	rs6690583	0.562	rs6665436	chr1:85532894	T/C	cg22153463	chr1:85462885	MCOLN2	0.68	5.24	0.32	3.55e-7	Serum sulfate level;
SARC	cis	rs1387259	0.570	rs12368659	chr12:48562299	C/A	cg24011408	chr12:48396354	COL2A1	0.42	5.15	0.32	5.56e-7	Obstructive sleep apnea trait (apnea hypopnea index);
SARC	cis	rs11190604	1.000	rs7477246	chr10:102261538	C/T	cg07080220	chr10:102295463	HIF1AN	0.79	9.72	0.54	5.61e-19	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs2043112	0.867	rs357278	chr5:38932466	A/C	cg04869206	chr5:39074266	RICTOR	0.53	6.69	0.4	1.65e-10	Obesity-related traits;
SARC	cis	rs11764590	0.694	rs60626033	chr7:2099719	A/G	cg21782813	chr7:2030301	MAD1L1	-0.32	-4.9	-0.31	1.76e-6	Neuroticism;
SARC	cis	rs9300255	0.602	rs1727314	chr12:123640664	C/A	cg00376283	chr12:123451042	ABCB9	0.57	6.85	0.41	6.39e-11	Neutrophil percentage of white cells;
SARC	cis	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg08975724	chr8:8085496	FLJ10661	-0.49	-5.78	-0.35	2.41e-8	Mood instability;
SARC	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg04277193	chr17:41438351	NA	0.45	4.75	0.3	3.56e-6	Menopause (age at onset);
SARC	cis	rs9660992	0.542	rs17345153	chr1:205179997	A/G	cg00857998	chr1:205179979	DSTYK	0.53	6.5	0.39	4.96e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg11764359	chr7:65958608	NA	-0.78	-9.41	-0.52	4.93e-18	Aortic root size;
SARC	cis	rs6964587	0.839	rs6949700	chr7:91467435	A/G	cg17063962	chr7:91808500	NA	0.78	10.93	0.58	1.04e-22	Breast cancer;
SARC	cis	rs9896052	0.533	rs7406173	chr17:73454563	G/A	cg27037648	chr17:73511087	CASKIN2	0.41	4.78	0.3	3.13e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg06634786	chr22:41940651	POLR3H	0.55	6.45	0.39	6.23e-10	Vitiligo;
SARC	cis	rs4865169	0.783	rs7668814	chr4:57825190	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.42	-5.06	-0.31	8.51e-7	Breast cancer;
SARC	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg11062466	chr8:58055876	NA	0.63	5.36	0.33	1.99e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs5769765	1.000	rs4597652	chr22:50270570	A/G	cg03033257	chr22:50311977	ALG12;CRELD2	-0.54	-5.64	-0.35	4.81e-8	Schizophrenia;
SARC	cis	rs3733585	0.673	rs9994266	chr4:9954450	C/T	cg11266682	chr4:10021025	SLC2A9	-0.34	-5.63	-0.35	5.27e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs721399	1.000	rs4646250	chr8:18260598	G/A	cg18736775	chr8:18248649	NAT2	0.43	5.57	0.34	6.89e-8	Blood metabolite levels;
SARC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.73	7.01	0.42	2.53e-11	Platelet count;
SARC	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg10523679	chr1:76189770	ACADM	0.45	5.59	0.34	6.47e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg25072359	chr17:41440525	NA	0.51	6.13	0.37	3.66e-9	Menopause (age at onset);
SARC	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg16325326	chr1:53192061	ZYG11B	0.77	12.08	0.62	2.12e-26	Monocyte count;
SARC	cis	rs9400467	0.506	rs12192718	chr6:111569151	T/A	cg15721981	chr6:111408429	SLC16A10	0.66	5.44	0.34	1.35e-7	Blood metabolite levels;Amino acid levels;
SARC	cis	rs11190604	1.000	rs7099965	chr10:102301165	A/G	cg07080220	chr10:102295463	HIF1AN	0.83	9.82	0.54	2.9e-19	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs290268	1.000	rs290268	chr9:93552450	A/G	cg02608019	chr9:93564028	SYK	0.35	4.91	0.31	1.75e-6	Platelet count;
SARC	cis	rs1153858	1.000	rs2467863	chr15:45641880	G/A	cg14582100	chr15:45693742	SPATA5L1	0.37	5.02	0.31	1.01e-6	Homoarginine levels;
SARC	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg25072359	chr17:41440525	NA	0.53	6.24	0.38	2.07e-9	Menopause (age at onset);
SARC	cis	rs6991838	0.806	rs17302392	chr8:66463308	C/T	cg13398993	chr8:66546079	ARMC1	0.42	5.2	0.32	4.31e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7607369	0.536	rs12990447	chr2:219667413	T/C	cg02176678	chr2:219576539	TTLL4	-0.38	-5.67	-0.35	4.2e-8	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs933688	1.000	rs2059207	chr5:90731931	C/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.93	12.27	0.63	4.92e-27	Smoking behavior;
SARC	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg11644478	chr21:40555479	PSMG1	1.02	12.74	0.64	1.43e-28	Cognitive function;
SARC	cis	rs1476104	1	rs1476104	chr7:69567317	G/A	cg10619644	chr7:69149951	AUTS2	0.41	5.07	0.32	8.07e-7	Childhood ear infection;
SARC	cis	rs523522	0.962	rs10849757	chr12:120964014	G/A	cg12219531	chr12:120966889	COQ5	0.84	11.36	0.6	4.3e-24	High light scatter reticulocyte count;
SARC	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg24531977	chr5:56204891	C5orf35	-0.54	-5.45	-0.34	1.26e-7	Initial pursuit acceleration;
SARC	cis	rs7937682	0.855	rs521947	chr11:111492616	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.89	-14.18	-0.68	2.61e-33	Primary sclerosing cholangitis;
SARC	cis	rs1153858	1.000	rs3759899	chr15:45655903	T/C	cg26924012	chr15:45694286	SPATA5L1	0.79	11.29	0.59	7.41e-24	Homoarginine levels;
SARC	cis	rs875971	0.651	rs313829	chr7:65552497	A/G	cg11764359	chr7:65958608	NA	-0.7	-7.69	-0.45	4.2e-13	Aortic root size;
SARC	cis	rs9462027	0.651	rs4259246	chr6:34803947	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-6.09	-0.37	4.63e-9	Systemic lupus erythematosus;
SARC	cis	rs3741151	0.881	rs12099129	chr11:73091318	T/G	cg17517138	chr11:73019481	ARHGEF17	0.79	5.57	0.34	6.92e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs116095464	1.000	rs6555159	chr5:311562	G/A	cg20965017	chr5:231967	SDHA	-0.74	-5.52	-0.34	9.04e-8	Breast cancer;
SARC	cis	rs3768617	0.510	rs2027076	chr1:183073407	C/A	cg13390022	chr1:182993471	LAMC1	0.32	4.79	0.3	2.91e-6	Fuchs's corneal dystrophy;
SARC	cis	rs2204008	0.627	rs10878486	chr12:38148601	T/G	cg13010199	chr12:38710504	ALG10B	0.77	10.31	0.56	9.05e-21	Bladder cancer;
SARC	trans	rs9329221	0.513	rs4841296	chr8:10105447	C/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.94	-0.46	8.75e-14	Neuroticism;
SARC	cis	rs7208859	0.623	rs11657369	chr17:29136468	G/A	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs787274	0.850	rs10759604	chr9:115639748	G/A	cg13803584	chr9:115635662	SNX30	-0.88	-6.09	-0.37	4.52e-9	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.95	-8.65	-0.49	8.61e-16	Alzheimer's disease;
SARC	cis	rs804280	1.000	rs804280	chr8:11612698	G/T	cg00262122	chr8:11665843	FDFT1	0.39	4.72	0.3	4.1e-6	Myopia (pathological);
SARC	cis	rs9894429	0.671	rs6565616	chr17:79612161	C/T	cg10661904	chr17:79619235	PDE6G	-0.45	-6.37	-0.39	9.77e-10	Eye color traits;
SARC	cis	rs7481584	0.581	rs399565	chr11:3061780	C/T	cg25174290	chr11:3078921	CARS	-0.58	-8.03	-0.47	4.79e-14	Calcium levels;
SARC	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg21017887	chr14:105400489	NA	0.52	7.49	0.44	1.38e-12	Rheumatoid arthritis;
SARC	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg22508957	chr16:3507546	NAT15	0.39	5.77	0.35	2.46e-8	Tuberculosis;
SARC	cis	rs2306786	0.558	rs113150902	chr15:59501858	G/A	cg23054309	chr15:59226205	SLTM	0.75	4.87	0.3	2.09e-6	Metabolite levels;
SARC	cis	rs9902453	0.765	rs3102562	chr17:28040403	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	6.99	0.42	2.94e-11	Coffee consumption (cups per day);
SARC	cis	rs7568458	0.684	rs7579147	chr2:85805654	G/A	cg23752985	chr2:85803571	VAMP8	0.47	6.04	0.37	6e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs7937682	0.883	rs510388	chr11:111451869	G/T	cg22437258	chr11:111473054	SIK2	-0.66	-8.86	-0.5	2.16e-16	Primary sclerosing cholangitis;
SARC	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg03452623	chr4:187889614	NA	-0.79	-11.64	-0.61	5.36e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs61472021	1	rs61472021	chr6:26090025	T/C	cg21479132	chr6:26055353	NA	0.69	5.42	0.33	1.46e-7	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9354308	0.838	rs9445595	chr6:66537559	C/G	cg07460842	chr6:66804631	NA	-0.45	-5.22	-0.32	3.95e-7	Metabolite levels;
SARC	cis	rs8016982	0.633	rs8015423	chr14:81719357	C/T	cg01989461	chr14:81687754	GTF2A1	0.72	10.83	0.58	2.1e-22	Schizophrenia;
SARC	cis	rs995000	0.931	rs1168097	chr1:63120371	C/T	cg06896770	chr1:63153194	DOCK7	-0.89	-13.52	-0.66	4.03e-31	Triglyceride levels;
SARC	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg12288994	chr5:1860383	NA	0.41	6.53	0.39	4.03e-10	Cardiovascular disease risk factors;
SARC	trans	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg00938859	chr5:1591904	SDHAP3	0.78	7.58	0.44	8.08e-13	Breast cancer;
SARC	cis	rs72781680	0.898	rs72796152	chr2:23933626	G/A	cg06627628	chr2:24431161	ITSN2	-0.64	-5.82	-0.36	1.89e-8	Lymphocyte counts;
SARC	cis	rs11690935	0.877	rs13024846	chr2:172835803	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.0	-15.53	-0.71	8.15e-38	Schizophrenia;
SARC	cis	rs67460515	0.563	rs13085336	chr3:160880599	G/A	cg17135325	chr3:160939158	NMD3	0.64	8.07	0.47	3.76e-14	Parkinson's disease;
SARC	cis	rs7000551	0.725	rs7430	chr8:22398414	C/G	cg12081754	chr8:22256438	SLC39A14	0.55	7.73	0.45	3.24e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs2635047	0.967	rs2576030	chr18:44659166	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.58	7.93	0.46	9.38e-14	Educational attainment;
SARC	cis	rs910316	0.967	rs11624893	chr14:75660124	A/G	cg11812906	chr14:75593930	NEK9	-0.81	-11.83	-0.61	1.3e-25	Height;
SARC	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg26681399	chr22:41777847	TEF	0.47	5.14	0.32	5.91e-7	Vitiligo;
SARC	cis	rs748404	0.578	rs512628	chr15:43618734	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.55	6.69	0.4	1.65e-10	Lung cancer;
SARC	cis	rs7208859	0.623	rs60890550	chr17:29030861	A/G	cg13385521	chr17:29058706	SUZ12P	0.85	6.94	0.41	3.86e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs76419734	1.000	rs72671895	chr4:106685633	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.81	5.48	0.34	1.08e-7	Post bronchodilator FEV1;
SARC	cis	rs4141404	0.604	rs2103853	chr22:31855475	T/C	cg02404636	chr22:31891804	SFI1	0.43	5.38	0.33	1.78e-7	Paclitaxel-induced neuropathy;
SARC	cis	rs6088590	0.561	rs6087600	chr20:33157217	T/C	cg08999081	chr20:33150536	PIGU	0.44	6.78	0.41	9.96e-11	Coronary artery disease;
SARC	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg16325326	chr1:53192061	ZYG11B	0.71	10.45	0.56	3.25e-21	Monocyte count;
SARC	cis	rs17376456	0.877	rs12109629	chr5:93359702	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	6.12	0.37	3.99e-9	Diabetic retinopathy;
SARC	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg15966229	chr18:44337664	ST8SIA5	-0.37	-4.86	-0.3	2.15e-6	Personality dimensions;
SARC	cis	rs6690583	0.524	rs6680422	chr1:85451945	C/T	cg22153463	chr1:85462885	MCOLN2	0.72	6.96	0.42	3.33e-11	Serum sulfate level;
SARC	cis	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg25894440	chr7:65020034	NA	0.51	4.78	0.3	3.06e-6	Aortic root size;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg15708219	chr10:22621481	NA	0.5	6.75	0.4	1.16e-10	Thyroid stimulating hormone;
SARC	cis	rs6121246	0.567	rs6058189	chr20:30192389	A/G	cg13852791	chr20:30311386	BCL2L1	0.66	5.92	0.36	1.15e-8	Mean corpuscular hemoglobin;
SARC	cis	rs793571	0.502	rs395601	chr15:59063196	G/C	cg05156742	chr15:59063176	FAM63B	0.82	12.5	0.63	8.69e-28	Schizophrenia;
SARC	cis	rs7560272	0.538	rs7370393	chr2:73925636	A/C	cg20560298	chr2:73613845	ALMS1	0.47	6.23	0.38	2.21e-9	Schizophrenia;
SARC	cis	rs55871839	0.684	rs6988143	chr8:59810572	C/T	cg07426533	chr8:59803705	TOX	-0.43	-5.73	-0.35	3.09e-8	Pneumonia;
SARC	cis	rs7712401	0.601	rs246321	chr5:122308299	A/G	cg19412675	chr5:122181750	SNX24	0.4	5.13	0.32	5.98e-7	Mean platelet volume;
SARC	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg08280861	chr8:58055591	NA	0.61	5.81	0.36	2.02e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7223966	1.000	rs73337598	chr17:61732576	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.56	-6.32	-0.38	1.3e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg22875332	chr1:76189707	ACADM	-0.43	-5.57	-0.34	6.88e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs8180040	0.768	rs11915074	chr3:47309757	A/T	cg27129171	chr3:47204927	SETD2	-0.72	-9.48	-0.53	3.02e-18	Colorectal cancer;
SARC	cis	rs2180341	0.920	rs4472373	chr6:127705983	G/A	cg17762328	chr6:126965162	NA	-0.44	-4.86	-0.3	2.13e-6	Breast cancer;
SARC	cis	rs2916247	1.000	rs7833370	chr8:93066653	C/G	cg10183463	chr8:93005414	RUNX1T1	-0.58	-5.95	-0.36	1e-8	Intelligence (multi-trait analysis);
SARC	cis	rs858239	0.899	rs5850	chr7:23314547	C/T	cg23682824	chr7:23144976	KLHL7	0.56	7.14	0.42	1.15e-11	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9300255	0.602	rs949142	chr12:123634043	T/C	cg05973401	chr12:123451056	ABCB9	0.53	5.99	0.37	8.08e-9	Neutrophil percentage of white cells;
SARC	cis	rs4803455	0.565	rs11083616	chr19:41865643	A/G	cg08477640	chr19:41863820	B9D2	-0.64	-8.74	-0.5	4.63e-16	Migraine;Coronary artery disease;
SARC	cis	rs986417	1.000	rs8021348	chr14:60952777	G/T	cg27398547	chr14:60952738	C14orf39	1.02	9.7	0.54	6.72e-19	Gut microbiota (bacterial taxa);
SARC	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg02018176	chr4:1364513	KIAA1530	-0.38	-5.46	-0.34	1.21e-7	Obesity-related traits;
SARC	cis	rs6570726	0.818	rs399516	chr6:145810849	C/A	cg23711669	chr6:146136114	FBXO30	0.79	12.3	0.63	4.01e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg08219700	chr8:58056026	NA	0.62	6.52	0.39	4.28e-10	Developmental language disorder (linguistic errors);
SARC	trans	rs3942852	0.545	rs7395231	chr11:48091689	T/C	cg03929089	chr4:120376271	NA	-0.56	-6.87	-0.41	5.73e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs6570726	0.526	rs4895674	chr6:145735860	T/G	cg05347473	chr6:146136440	FBXO30	-0.45	-5.61	-0.34	5.82e-8	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg12867312	chr7:140454740	BRAF	0.54	7.63	0.45	6.14e-13	Thyroid stimulating hormone;
SARC	cis	rs73206853	0.841	rs56117211	chr12:111123485	T/G	cg10860002	chr12:110842031	ANAPC7	0.63	5.22	0.32	4.02e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs3087591	1.000	rs2854332	chr17:29712378	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.52	-6.4	-0.39	8.27e-10	Hip circumference;
SARC	cis	rs10779751	0.734	rs2261217	chr1:11127764	C/A	cg08854313	chr1:11322531	MTOR	0.82	11.26	0.59	8.86e-24	Body mass index;
SARC	cis	rs7772486	0.754	rs697053	chr6:145989807	T/C	cg23711669	chr6:146136114	FBXO30	-0.89	-15.38	-0.71	2.63e-37	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7824557	0.614	rs2293860	chr8:11219386	G/T	cg21775007	chr8:11205619	TDH	0.68	8.94	0.51	1.22e-16	Retinal vascular caliber;
SARC	trans	rs7465272	0.957	rs11994668	chr8:143687392	G/T	cg16922340	chr20:33873526	FAM83C;EIF6	0.47	6.23	0.38	2.14e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs3741404	0.560	rs12362602	chr11:63908660	G/A	cg04317338	chr11:64019027	PLCB3	-0.42	-5.09	-0.32	7.38e-7	Platelet count;
SARC	cis	rs763121	0.853	rs1013338	chr22:38974154	C/A	cg06022373	chr22:39101656	GTPBP1	0.89	12.23	0.63	6.89e-27	Menopause (age at onset);
SARC	cis	rs4481887	0.861	rs10788778	chr1:248481551	T/C	cg00666640	chr1:248458726	OR2T12	0.39	6.51	0.39	4.66e-10	Common traits (Other);
SARC	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg08219700	chr8:58056026	NA	0.76	6.94	0.41	3.82e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg11766577	chr21:47581405	C21orf56	-0.5	-6.12	-0.37	3.93e-9	Testicular germ cell tumor;
SARC	cis	rs1371867	0.846	rs1788205	chr8:101306546	G/C	cg11906718	chr8:101322791	RNF19A	0.7	8.98	0.51	9.31e-17	Atrioventricular conduction;
SARC	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg05234568	chr11:5960015	NA	-0.43	-5.61	-0.34	5.77e-8	DNA methylation (variation);
SARC	trans	rs2727020	0.619	rs1164665	chr11:49295630	T/C	cg03929089	chr4:120376271	NA	0.69	7.94	0.46	8.27e-14	Coronary artery disease;
SARC	cis	rs6568686	0.627	rs12207339	chr6:111767012	C/T	cg15721981	chr6:111408429	SLC16A10	0.65	5.67	0.35	4.31e-8	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs858239	0.600	rs1115941	chr7:23137188	C/T	cg23682824	chr7:23144976	KLHL7	0.71	9.68	0.54	7.67e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg20607798	chr8:58055168	NA	0.56	5.42	0.33	1.52e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6570726	0.791	rs448939	chr6:145808320	T/C	cg23711669	chr6:146136114	FBXO30	0.76	12.06	0.62	2.38e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7312774	0.618	rs7975954	chr12:107345750	C/T	cg16260113	chr12:107380972	MTERFD3	0.93	7.65	0.45	5.22e-13	Severe influenza A (H1N1) infection;
SARC	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg27266027	chr21:40555129	PSMG1	-0.5	-5.7	-0.35	3.66e-8	Cognitive function;
SARC	cis	rs4268898	0.686	rs2042468	chr2:24398446	A/T	cg26838691	chr2:24397539	C2orf84	0.42	5.6	0.34	5.99e-8	Asthma;
SARC	cis	rs754466	0.651	rs7895188	chr10:79623378	C/G	cg17075019	chr10:79541650	NA	0.8	12.62	0.64	3.46e-28	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg22535103	chr8:58192502	C8orf71	-0.6	-6.38	-0.39	9.22e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg07157834	chr1:205819609	PM20D1	-0.71	-10.3	-0.56	9.87e-21	Menarche (age at onset);
SARC	cis	rs4132509	0.739	rs79367267	chr1:243689543	C/A	cg21452805	chr1:244014465	NA	0.59	5.64	0.35	5.01e-8	RR interval (heart rate);
SARC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg08677398	chr8:58056175	NA	0.44	5.27	0.33	3.14e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs12477438	0.765	rs7591992	chr2:99668954	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-7.97	-0.46	7.21e-14	Chronic sinus infection;
SARC	cis	rs77372450	0.551	rs62390780	chr5:157056474	G/C	cg05585991	chr5:157099197	C5orf52	0.54	5.38	0.33	1.85e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg02733842	chr7:1102375	C7orf50	-0.48	-6.42	-0.39	7.6e-10	Bronchopulmonary dysplasia;
SARC	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg27266027	chr21:40555129	PSMG1	0.49	5.26	0.33	3.23e-7	Cognitive function;
SARC	cis	rs1983891	0.706	rs745548	chr6:41557117	G/T	cg15051332	chr6:41514432	FOXP4	-0.53	-5.47	-0.34	1.15e-7	Prostate cancer;
SARC	cis	rs6424115	0.729	rs1737362	chr1:24054800	T/C	cg15997130	chr1:24165203	NA	0.39	4.95	0.31	1.4e-6	Immature fraction of reticulocytes;
SARC	cis	rs6782228	0.606	rs2811490	chr3:128351755	C/T	cg08795948	chr3:128337044	NA	0.36	4.96	0.31	1.35e-6	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
SARC	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg22875332	chr1:76189707	ACADM	-0.44	-5.62	-0.35	5.51e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2594989	0.831	rs66488222	chr3:11576289	C/T	cg00170343	chr3:11313890	ATG7	-0.55	-5.64	-0.35	5.02e-8	Circulating chemerin levels;
SARC	cis	rs861020	0.630	rs616544	chr1:210007368	T/C	cg05527609	chr1:210001259	C1orf107	0.78	10.12	0.55	3.37e-20	Orofacial clefts;
SARC	cis	rs3796352	1.000	rs34979715	chr3:53048960	G/A	cg07884673	chr3:53033167	SFMBT1	0.9	5.85	0.36	1.66e-8	Immune reponse to smallpox (secreted IL-2);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg00762326	chr19:18682511	UBA52	0.47	6.26	0.38	1.8e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.48	5.92	0.36	1.17e-8	Tonsillectomy;
SARC	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg22535103	chr8:58192502	C8orf71	-0.69	-8.14	-0.47	2.39e-14	Developmental language disorder (linguistic errors);
SARC	cis	rs4595586	0.545	rs2388175	chr12:39389217	A/G	cg26384229	chr12:38710491	ALG10B	0.51	6.21	0.38	2.43e-9	Morning vs. evening chronotype;
SARC	cis	rs35362007	0.530	rs11621250	chr14:96011442	C/T	cg02940042	chr14:96000874	GLRX5;SNHG10;SCARNA13	0.62	5.36	0.33	1.99e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg22535103	chr8:58192502	C8orf71	-0.6	-6.33	-0.38	1.24e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs6582630	0.634	rs10748443	chr12:38734062	G/T	cg23762105	chr12:34175262	ALG10	-0.55	-7.21	-0.43	7.78e-12	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9906944	0.707	rs11655950	chr17:47129121	C/T	cg16584676	chr17:46985605	UBE2Z	-0.42	-5.06	-0.31	8.7e-7	Intelligence (multi-trait analysis);Body fat percentage;
SARC	cis	rs7542091	0.813	rs2049999	chr1:210031331	A/G	cg05527609	chr1:210001259	C1orf107	-0.46	-5.87	-0.36	1.48e-8	Monobrow;
SARC	cis	rs72945132	0.882	rs17160777	chr11:70163723	T/C	cg00319359	chr11:70116639	PPFIA1	0.67	6.08	0.37	4.85e-9	Coronary artery disease;
SARC	cis	rs722599	0.683	rs2058918	chr14:75288518	A/G	cg06637938	chr14:75390232	RPS6KL1	0.41	5.03	0.31	9.58e-7	IgG glycosylation;
SARC	cis	rs76419734	0.558	rs17035939	chr4:106526544	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.65	5.87	0.36	1.48e-8	Post bronchodilator FEV1;
SARC	trans	rs7819412	0.765	rs17783634	chr8:11054097	C/A	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.64	-0.45	5.68e-13	Triglycerides;
SARC	cis	rs1018836	0.631	rs61276517	chr8:91474406	A/G	cg16814680	chr8:91681699	NA	-0.65	-9.18	-0.52	2.42e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg20102877	chr2:27665638	KRTCAP3	-0.37	-5.36	-0.33	1.99e-7	Total body bone mineral density;
SARC	cis	rs11614333	0.839	rs1544687	chr12:15030704	C/T	cg19759883	chr12:14956454	WBP11;C12orf60	0.39	4.82	0.3	2.6e-6	Hand grip strength;
SARC	cis	rs2425143	1.000	rs6060591	chr20:34351476	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	5.21	0.32	4.08e-7	Blood protein levels;
SARC	trans	rs11098499	0.954	rs3733519	chr4:120423448	A/G	cg25214090	chr10:38739885	LOC399744	0.58	7.47	0.44	1.63e-12	Corneal astigmatism;
SARC	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg00409905	chr10:38381863	ZNF37A	-0.49	-6.55	-0.39	3.62e-10	Extrinsic epigenetic age acceleration;
SARC	cis	rs11785693	0.862	rs73189843	chr8:5000915	C/T	cg26367366	chr8:4980734	NA	0.68	6.09	0.37	4.65e-9	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs2985684	0.901	rs2354448	chr14:50098296	G/A	cg04989706	chr14:50066350	PPIL5	-0.53	-5.58	-0.34	6.5e-8	Carotid intima media thickness;
SARC	cis	rs3768617	0.510	rs4651145	chr1:183098900	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.66e-21	Fuchs's corneal dystrophy;
SARC	cis	rs11758351	0.587	rs10484436	chr6:26237155	C/T	cg01420254	chr6:26195488	NA	0.56	4.75	0.3	3.53e-6	Gout;Renal underexcretion gout;
SARC	trans	rs1941687	0.563	rs9947894	chr18:31328720	G/T	cg27147174	chr7:100797783	AP1S1	0.52	6.6	0.4	2.74e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
SARC	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg11890956	chr21:40555474	PSMG1	1.04	15.49	0.71	1.12e-37	Cognitive function;
SARC	cis	rs9660992	0.674	rs1151784	chr1:205232447	C/T	cg21545522	chr1:205238299	TMCC2	0.49	6.8	0.41	8.94e-11	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs2228479	0.618	rs72477006	chr16:89950299	G/C	cg00800038	chr16:89945340	TCF25	-0.72	-5.72	-0.35	3.18e-8	Skin colour saturation;
SARC	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg03185022	chr7:2884158	GNA12	0.45	4.88	0.3	1.99e-6	Height;
SARC	cis	rs9814567	0.806	rs4519744	chr3:134321523	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.51	-6.63	-0.4	2.36e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	trans	rs10209086	0.736	rs1584436	chr2:138298878	A/G	cg06212135	chr7:130131826	MEST;MESTIT1	-0.48	-6.29	-0.38	1.6e-9	Multiple system atrophy;
SARC	cis	rs4713118	0.662	rs175954	chr6:28011585	A/G	cg16479474	chr6:28041457	NA	0.33	4.73	0.3	3.96e-6	Parkinson's disease;
SARC	cis	rs2361718	0.933	rs8077849	chr17:78104137	C/T	cg27427491	chr17:78079615	GAA	-0.32	-5.24	-0.32	3.62e-7	Yeast infection;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg02466933	chr2:9770529	YWHAQ	0.5	6.33	0.38	1.23e-9	Height;
SARC	cis	rs208515	0.518	rs12209790	chr6:66662965	T/C	cg07460842	chr6:66804631	NA	0.98	11.11	0.59	2.72e-23	Exhaled nitric oxide levels;
SARC	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg24531977	chr5:56204891	C5orf35	-0.5	-5.01	-0.31	1.08e-6	Initial pursuit acceleration;
SARC	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg11062466	chr8:58055876	NA	0.6	5.71	0.35	3.44e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7020830	0.825	rs13297152	chr9:37075623	C/T	cg14294708	chr9:37120828	ZCCHC7	1.13	19.89	0.79	3.95e-52	Schizophrenia;
SARC	cis	rs7937682	0.575	rs7930208	chr11:111741463	T/C	cg22437258	chr11:111473054	SIK2	-0.48	-5.53	-0.34	8.7e-8	Primary sclerosing cholangitis;
SARC	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg06221963	chr1:154839813	KCNN3	-0.53	-8.66	-0.49	8.2e-16	Prostate cancer;
SARC	cis	rs11758351	0.518	rs79922979	chr6:26224975	A/G	cg01420254	chr6:26195488	NA	0.55	4.75	0.3	3.49e-6	Gout;Renal underexcretion gout;
SARC	cis	rs2120243	0.539	rs2168431	chr3:157120029	A/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.39	4.96	0.31	1.37e-6	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs12142240	0.698	rs6684274	chr1:46810842	A/G	cg00530320	chr1:46809349	NSUN4	-0.58	-7.4	-0.44	2.43e-12	Menopause (age at onset);
SARC	cis	rs1348850	0.632	rs12471621	chr2:178502353	T/C	cg22681709	chr2:178499509	PDE11A	-0.41	-5.6	-0.34	6.1e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg17971929	chr21:40555470	PSMG1	-0.53	-6.68	-0.4	1.76e-10	Menarche (age at onset);
SARC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.55	-7.24	-0.43	6.67e-12	Lymphocyte counts;
SARC	cis	rs3091242	0.866	rs11249249	chr1:25758134	A/G	cg27572855	chr1:25598939	RHD	0.55	9.22	0.52	1.8e-17	Erythrocyte sedimentation rate;
SARC	cis	rs55962025	0.883	rs362273	chr4:3227419	A/G	cg06533319	chr4:3265114	C4orf44	0.34	5.15	0.32	5.48e-7	Parental longevity (mother's age at death);
SARC	cis	rs5753618	0.561	rs5753543	chr22:31685458	G/A	cg13145458	chr22:31556086	RNF185	0.48	5.11	0.32	6.69e-7	Colorectal cancer;
SARC	trans	rs11227306	0.902	rs625652	chr11:65641931	T/A	cg17712092	chr4:129076599	LARP1B	-0.51	-6.34	-0.38	1.18e-9	DNA methylation (variation);
SARC	cis	rs17376456	0.877	rs7736620	chr5:93305762	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.54	0.34	8.17e-8	Diabetic retinopathy;
SARC	cis	rs933688	1.000	rs6867091	chr5:90734333	C/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.02	13.6	0.67	2.2e-31	Smoking behavior;
SARC	cis	rs6901004	0.803	rs402014	chr6:111527696	C/T	cg15721981	chr6:111408429	SLC16A10	-0.44	-5.24	-0.32	3.58e-7	Blood metabolite levels;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg05167782	chr15:74392505	NA	0.5	6.32	0.38	1.33e-9	Breast cancer;
SARC	cis	rs9660992	0.674	rs72745221	chr1:205262337	G/A	cg21545522	chr1:205238299	TMCC2	0.46	6.07	0.37	5.05e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg22535103	chr8:58192502	C8orf71	-0.6	-6.38	-0.39	9.22e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7084402	0.967	rs11815274	chr10:60328891	A/G	cg07615347	chr10:60278583	BICC1	-0.56	-8.31	-0.48	8.07e-15	Refractive error;
SARC	cis	rs372883	0.613	rs1153274	chr21:30660026	T/C	cg08807101	chr21:30365312	RNF160	-0.59	-7.43	-0.44	2.08e-12	Pancreatic cancer;
SARC	cis	rs3733585	0.699	rs6449157	chr4:9960442	G/A	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.47	-0.34	1.18e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg27286337	chr10:134555280	INPP5A	0.7	8.13	0.47	2.59e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs7635838	0.654	rs346086	chr3:11272932	G/T	cg00170343	chr3:11313890	ATG7	0.63	8.14	0.47	2.45e-14	HDL cholesterol;
SARC	cis	rs244731	0.959	rs7721671	chr5:176630984	A/G	cg06060754	chr5:176797920	RGS14	-0.45	-5.22	-0.32	3.91e-7	Urate levels in lean individuals;
SARC	cis	rs2180341	0.883	rs7760748	chr6:127690062	C/T	cg27446573	chr6:127587934	RNF146	1.06	14.81	0.7	2.04e-35	Breast cancer;
SARC	cis	rs6963495	0.745	rs73190169	chr7:105160500	A/G	cg19920283	chr7:105172520	RINT1	0.65	5.48	0.34	1.09e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs10465746	0.780	rs7551787	chr1:84419297	A/G	cg10977910	chr1:84465055	TTLL7	0.43	5.16	0.32	5.35e-7	Obesity-related traits;
SARC	cis	rs62064224	0.720	rs8078837	chr17:30763537	A/G	cg18200150	chr17:30822561	MYO1D	0.38	5.92	0.36	1.15e-8	Schizophrenia;
SARC	cis	rs10791097	0.694	rs2155752	chr11:130755998	C/T	cg09137382	chr11:130731461	NA	0.31	4.73	0.3	3.97e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs11792861	0.816	rs28361111	chr9:111761012	A/C	cg13535736	chr9:111863775	C9orf5	-0.38	-4.71	-0.3	4.2e-6	Menarche (age at onset);
SARC	cis	rs7555523	0.887	rs7518099	chr1:165736880	C/T	cg24409356	chr1:165738333	TMCO1	0.83	6.85	0.41	6.44e-11	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	cis	rs4595586	0.545	rs6580894	chr12:39371951	A/G	cg26384229	chr12:38710491	ALG10B	0.53	6.61	0.4	2.66e-10	Morning vs. evening chronotype;
SARC	cis	rs6570726	0.818	rs952405	chr6:145925952	T/C	cg23711669	chr6:146136114	FBXO30	0.78	12.12	0.62	1.53e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6456156	0.586	rs7746628	chr6:167483235	A/G	cg07741184	chr6:167504864	NA	0.36	6.99	0.42	2.83e-11	Primary biliary cholangitis;
SARC	cis	rs554111	0.660	rs667687	chr1:21072577	A/G	cg08890418	chr1:21044141	KIF17	0.44	6.21	0.38	2.38e-9	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg00149659	chr3:10157352	C3orf10	0.78	7.21	0.43	7.64e-12	Alzheimer's disease;
SARC	cis	rs4926611	0.863	rs2177957	chr1:54082487	C/T	cg08927728	chr1:54059983	GLIS1	0.3	5.03	0.31	9.84e-7	Hand grip strength;
SARC	cis	rs763121	0.815	rs4821799	chr22:39021326	T/G	cg06022373	chr22:39101656	GTPBP1	0.81	10.56	0.57	1.54e-21	Menopause (age at onset);
SARC	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg11764359	chr7:65958608	NA	0.77	9.41	0.52	5.12e-18	Aortic root size;
SARC	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg27266027	chr21:40555129	PSMG1	0.51	5.59	0.34	6.36e-8	Cognitive function;
SARC	cis	rs10463554	0.927	rs34831	chr5:102444089	C/T	cg23492399	chr5:102201601	PAM	-0.51	-5.59	-0.34	6.19e-8	Parkinson's disease;
SARC	cis	rs13256369	0.708	rs11783670	chr8:8559394	G/A	cg18904891	chr8:8559673	CLDN23	0.48	5.38	0.33	1.79e-7	Obesity-related traits;
SARC	cis	rs8028182	0.636	rs11637068	chr15:75743002	G/A	cg20655648	chr15:75932815	IMP3	0.66	7.75	0.45	2.85e-13	Sudden cardiac arrest;
SARC	cis	rs17376456	0.877	rs28575883	chr5:93346035	T/C	cg21475434	chr5:93447410	FAM172A	0.85	7.57	0.44	8.88e-13	Diabetic retinopathy;
SARC	cis	rs11249608	0.548	rs62393074	chr5:178450476	G/C	cg21905437	chr5:178450457	ZNF879	0.59	7.89	0.46	1.2e-13	Pubertal anthropometrics;
SARC	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.5	-4.98	-0.31	1.25e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs9916302	0.861	rs12150493	chr17:37586154	T/C	cg00129232	chr17:37814104	STARD3	-0.62	-7.61	-0.45	6.89e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs1707322	0.721	rs7519900	chr1:46234947	C/T	cg03146154	chr1:46216737	IPP	0.51	6.13	0.37	3.77e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1832871	0.672	rs56326208	chr6:158762944	C/T	cg07165851	chr6:158734300	TULP4	0.58	6.78	0.41	9.7e-11	Height;
SARC	cis	rs1559088	0.600	rs10423965	chr19:33600319	T/G	cg17764715	chr19:33622953	WDR88	0.57	7.8	0.46	2.02e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg12373951	chr3:133503437	NA	-0.4	-5.73	-0.35	3.06e-8	Iron status biomarkers;
SARC	cis	rs9902453	0.868	rs8066602	chr17:28523085	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	6.8	0.41	8.66e-11	Coffee consumption (cups per day);
SARC	cis	rs950027	0.584	rs1145086	chr15:45654327	A/G	cg26924012	chr15:45694286	SPATA5L1	0.53	6.78	0.41	9.59e-11	Response to fenofibrate (adiponectin levels);
SARC	cis	rs35306767	0.903	rs11253492	chr10:936873	T/C	cg20503657	chr10:835505	NA	0.82	7.81	0.46	1.89e-13	Eosinophil percentage of granulocytes;
SARC	cis	rs7264396	0.790	rs11697903	chr20:34272224	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-8.23	-0.47	1.36e-14	Total cholesterol levels;
SARC	cis	rs8141529	0.515	rs16986861	chr22:29343188	G/C	cg02153584	chr22:29168773	CCDC117	0.65	6.82	0.41	7.55e-11	Lymphocyte counts;
SARC	cis	rs1008375	0.932	rs2302394	chr4:17641188	A/G	cg27347728	chr4:17578864	LAP3	0.5	6.3	0.38	1.46e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs17376456	0.825	rs10064368	chr5:93266396	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	5.84	0.36	1.75e-8	Diabetic retinopathy;
SARC	trans	rs3780486	0.846	rs3824458	chr9:33144809	C/T	cg04842962	chr6:43655489	MRPS18A	1.05	18.35	0.77	3.8e-47	IgG glycosylation;
SARC	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg11987759	chr7:65425863	GUSB	-0.48	-6.54	-0.39	3.9e-10	Aortic root size;
SARC	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg22903657	chr4:1355424	KIAA1530	-0.36	-4.85	-0.3	2.24e-6	Obesity-related traits;
SARC	cis	rs72945132	0.882	rs12279046	chr11:70130388	A/G	cg05964544	chr11:70165517	PPFIA1	-0.6	-5.85	-0.36	1.66e-8	Coronary artery disease;
SARC	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg24209194	chr3:40518798	ZNF619	0.64	7.77	0.45	2.56e-13	Renal cell carcinoma;
SARC	cis	rs17376456	0.825	rs55724660	chr5:93276636	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	5.77	0.35	2.56e-8	Diabetic retinopathy;
SARC	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg11301795	chr4:187892539	NA	-0.7	-10.49	-0.57	2.5e-21	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg13012494	chr21:47604986	C21orf56	0.45	5.25	0.33	3.38e-7	Testicular germ cell tumor;
SARC	cis	rs763121	0.853	rs2413546	chr22:39107001	G/A	cg06022373	chr22:39101656	GTPBP1	0.85	10.6	0.57	1.12e-21	Menopause (age at onset);
SARC	cis	rs4891159	0.790	rs660029	chr18:74149668	A/G	cg24786174	chr18:74118243	ZNF516	0.71	11.54	0.6	1.12e-24	Longevity;
SARC	cis	rs6542838	0.588	rs4851174	chr2:99530113	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-6.24	-0.38	2.05e-9	Fear of minor pain;
SARC	cis	rs67311347	0.544	rs9833640	chr3:40354941	T/A	cg24209194	chr3:40518798	ZNF619	0.49	6.46	0.39	6.11e-10	Renal cell carcinoma;
SARC	cis	rs8523	0.774	rs1321535	chr6:11076026	A/C	cg13562911	chr6:11044106	ELOVL2	0.45	5.96	0.36	9.42e-9	Red blood cell fatty acid levels;
SARC	cis	rs7937682	0.889	rs564086	chr11:111501079	C/G	cg22437258	chr11:111473054	SIK2	0.74	10.3	0.56	9.9e-21	Primary sclerosing cholangitis;
SARC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg05165339	chr4:1420672	NA	-0.22	-4.91	-0.31	1.7e-6	Longevity;
SARC	cis	rs910316	1.000	rs7303	chr14:75520065	T/C	cg11812906	chr14:75593930	NEK9	0.9	13.91	0.67	2.06e-32	Height;
SARC	cis	rs9303401	0.614	rs12950028	chr17:56510140	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.03	10.8	0.58	2.53e-22	Cognitive test performance;
SARC	cis	rs3857067	0.776	rs6858265	chr4:95112565	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.05	-0.31	8.98e-7	QT interval;
SARC	cis	rs7772486	0.806	rs4075695	chr6:146250959	A/G	cg23711669	chr6:146136114	FBXO30	-0.76	-11.63	-0.61	6.02e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg25072359	chr17:41440525	NA	0.52	6.18	0.38	2.83e-9	Menopause (age at onset);
SARC	cis	rs9300255	0.739	rs4759417	chr12:123746510	C/T	cg00376283	chr12:123451042	ABCB9	0.49	5.55	0.34	7.72e-8	Neutrophil percentage of white cells;
SARC	cis	rs2504916	0.784	rs3004077	chr6:160767443	T/C	cg20340146	chr6:160172821	WTAP	-0.51	-4.99	-0.31	1.18e-6	Response to hepatitis C treatment;
SARC	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg12000995	chr2:27665139	KRTCAP3	0.31	4.84	0.3	2.38e-6	Total body bone mineral density;
SARC	cis	rs11997175	0.603	rs7386384	chr8:33782471	C/T	ch.8.33884649F	chr8:33765107	NA	0.44	5.64	0.35	4.97e-8	Body mass index;
SARC	trans	rs1459104	0.759	rs7939392	chr11:55257285	C/T	cg15704280	chr7:45808275	SEPT13	0.63	6.76	0.4	1.11e-10	Body mass index;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg22468803	chr18:9136381	ANKRD12	-0.49	-6.53	-0.39	4.07e-10	Neuroticism;
SARC	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg24829409	chr8:58192753	C8orf71	-0.59	-5.28	-0.33	2.96e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7621025	0.599	rs13063987	chr3:136445397	C/G	cg15507776	chr3:136538369	TMEM22	-0.5	-5.37	-0.33	1.94e-7	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
SARC	cis	rs17376456	1.000	rs67150649	chr5:93292377	A/G	cg21475434	chr5:93447410	FAM172A	0.87	7.78	0.45	2.39e-13	Diabetic retinopathy;
SARC	trans	rs561341	0.609	rs4795659	chr17:30187139	C/G	cg20587970	chr11:113659929	NA	0.68	6.54	0.39	3.95e-10	Hip circumference adjusted for BMI;
SARC	cis	rs6087771	0.890	rs6089056	chr20:30325773	A/G	cg13852791	chr20:30311386	BCL2L1	0.88	10.96	0.58	8.39e-23	Subcortical brain region volumes;Putamen volume;
SARC	cis	rs911263	0.603	rs7146850	chr14:68787881	A/C	cg18825221	chr14:68749962	RAD51L1	0.4	7.2	0.43	8.43e-12	Primary biliary cholangitis;
SARC	cis	rs2816062	0.813	rs2745318	chr1:18895844	C/T	cg18795169	chr1:18902165	NA	0.79	13.22	0.65	3.96e-30	Urate levels in lean individuals;
SARC	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg11494091	chr17:61959527	GH2	0.36	5.14	0.32	5.83e-7	Height;
SARC	cis	rs6582630	0.622	rs11831595	chr12:38511489	C/A	cg14851346	chr12:38532713	NA	-0.46	-5.69	-0.35	3.8e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2282802	0.660	rs4463213	chr5:139545748	G/A	cg26211634	chr5:139558579	C5orf32	-0.38	-4.82	-0.3	2.59e-6	Intelligence (multi-trait analysis);
SARC	cis	rs62432291	0.681	rs429339	chr6:159660148	C/T	cg14500486	chr6:159655392	FNDC1	-0.64	-6.37	-0.39	9.75e-10	Joint mobility (Beighton score);
SARC	cis	rs17376456	0.757	rs10476591	chr5:93333723	G/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	6.11	0.37	4.06e-9	Diabetic retinopathy;
SARC	cis	rs10463316	0.862	rs11740475	chr5:150777997	A/G	cg03212797	chr5:150827313	SLC36A1	-0.46	-5.47	-0.34	1.18e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs6831352	0.801	rs2602897	chr4:100046293	A/T	cg12011299	chr4:100065546	ADH4	0.34	5.64	0.35	4.82e-8	Alcohol dependence;
SARC	cis	rs644799	0.544	rs1622515	chr11:95523433	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.74	9.89	0.54	1.73e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs10782582	0.617	rs1846233	chr1:76159354	C/T	cg10523679	chr1:76189770	ACADM	-0.42	-5.18	-0.32	4.75e-7	Daytime sleep phenotypes;
SARC	cis	rs995000	0.931	rs626787	chr1:62901243	C/G	cg06896770	chr1:63153194	DOCK7	0.65	7.8	0.46	2.06e-13	Triglyceride levels;
SARC	cis	rs11605924	0.901	rs7112505	chr11:45840939	A/T	ch.11.939596F	chr11:45881766	CRY2	-0.47	-5.55	-0.34	7.76e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs56161922	1.000	rs74692669	chr1:207818120	G/C	cg11752769	chr1:207818423	CR1L	-0.58	-4.96	-0.31	1.39e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
SARC	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.27	-0.52	1.34e-17	Developmental language disorder (linguistic errors);
SARC	cis	rs2153535	0.580	rs9378551	chr6:8463744	A/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.23	0.47	1.34e-14	Motion sickness;
SARC	cis	rs155076	1.000	rs261431	chr13:21865738	A/G	cg06138931	chr13:21896616	NA	0.36	4.83	0.3	2.49e-6	White matter hyperintensity burden;
SARC	cis	rs7617773	0.780	rs34589064	chr3:48339549	G/A	cg11946769	chr3:48343235	NME6	0.76	9.72	0.54	5.94e-19	Coronary artery disease;
SARC	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.32	-4.84	-0.3	2.36e-6	Total body bone mineral density;
SARC	cis	rs9486715	1.000	rs9398148	chr6:97063555	A/G	cg18709589	chr6:96969512	KIAA0776	-0.58	-7.29	-0.43	4.75e-12	Headache;
SARC	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9788721	0.836	rs11858836	chr15:78783277	G/A	cg06917634	chr15:78832804	PSMA4	-0.49	-5.06	-0.31	8.6e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs11997175	0.603	rs12234894	chr8:33699275	G/C	ch.8.33884649F	chr8:33765107	NA	0.63	8.6	0.49	1.21e-15	Body mass index;
SARC	cis	rs3733585	0.673	rs4467563	chr4:9953460	A/T	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.39	-0.33	1.76e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs4148883	0.713	rs3828541	chr4:100042262	A/G	cg12011299	chr4:100065546	ADH4	0.34	6.36	0.38	1.06e-9	Alcohol dependence;
SARC	cis	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg03060546	chr3:49711283	APEH	0.6	7.43	0.44	2e-12	Resting heart rate;
SARC	cis	rs7516138	1.000	rs4240896	chr1:9713500	A/G	cg26573321	chr1:9711663	PIK3CD	-0.45	-5.9	-0.36	1.27e-8	Monocyte count;
SARC	cis	rs10782582	0.609	rs5745485	chr1:76349534	C/G	cg10523679	chr1:76189770	ACADM	-0.4	-4.93	-0.31	1.57e-6	Daytime sleep phenotypes;
SARC	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg04267008	chr7:1944627	MAD1L1	-0.48	-5.07	-0.32	8.11e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs6570726	0.791	rs6570695	chr6:145911286	C/A	cg23711669	chr6:146136114	FBXO30	0.84	14.12	0.68	3.87e-33	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs9929218	0.551	rs2274240	chr16:68725486	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.86	14.93	0.7	8.33e-36	Colorectal cancer;
SARC	cis	rs8180040	0.726	rs1869871	chr3:47023948	C/T	cg27129171	chr3:47204927	SETD2	0.62	8.22	0.47	1.45e-14	Colorectal cancer;
SARC	cis	rs733592	0.524	rs10875727	chr12:48426143	T/C	cg21466736	chr12:48725269	NA	0.31	5.5	0.34	1.01e-7	Plateletcrit;
SARC	cis	rs17376456	0.597	rs1031423	chr5:93276883	A/G	cg21475434	chr5:93447410	FAM172A	-0.61	-6.55	-0.39	3.71e-10	Diabetic retinopathy;
SARC	cis	rs7208859	0.573	rs11656121	chr17:29214043	A/G	cg13385521	chr17:29058706	SUZ12P	0.86	7.34	0.43	3.54e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg09699651	chr6:150184138	LRP11	0.39	4.87	0.3	2.04e-6	Lung cancer;
SARC	cis	rs9393777	0.513	rs3999471	chr6:26650306	T/C	cg12826209	chr6:26865740	GUSBL1	0.66	5.87	0.36	1.47e-8	Intelligence (multi-trait analysis);
SARC	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg16325326	chr1:53192061	ZYG11B	0.81	12.74	0.64	1.44e-28	Monocyte count;
SARC	cis	rs9436747	0.641	rs1343981	chr1:66045328	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.47	4.88	0.3	1.92e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs7681440	0.904	rs6816736	chr4:90765746	G/A	cg02192967	chr4:90758406	SNCA	0.36	5.13	0.32	6.11e-7	Dementia with Lewy bodies;
SARC	cis	rs2213920	0.679	rs7047851	chr9:118220718	A/G	cg13918206	chr9:118159781	DEC1	-0.75	-6.13	-0.37	3.7e-9	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs9359856	0.600	rs1179899	chr6:90320258	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.57	-5.1	-0.32	7.13e-7	Bipolar disorder;
SARC	cis	rs1691799	0.899	rs2951656	chr12:66732273	T/G	cg16791601	chr12:66731901	HELB	-0.72	-10.72	-0.57	4.65e-22	White blood cell count (basophil);
SARC	cis	rs2832077	0.527	rs9980449	chr21:30224889	G/C	cg08807101	chr21:30365312	RNF160	-0.55	-6.29	-0.38	1.53e-9	Cognitive test performance;
SARC	cis	rs2635047	0.577	rs1025563	chr18:44740003	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	5.18	0.32	4.88e-7	Educational attainment;
SARC	cis	rs73198271	0.740	rs10094270	chr8:8646633	G/A	cg06636001	chr8:8085503	FLJ10661	-0.47	-5.03	-0.31	1e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs7927771	1.000	rs11039390	chr11:47796295	C/G	cg20307385	chr11:47447363	PSMC3	-0.47	-5.59	-0.34	6.3e-8	Subjective well-being;
SARC	cis	rs11097912	0.632	rs55710349	chr4:107206902	G/A	cg09646026	chr4:107269030	AIMP1	-0.45	-4.86	-0.3	2.2e-6	Airflow obstruction;
SARC	cis	rs6484504	0.576	rs208103	chr11:31167400	A/G	cg26647111	chr11:31128758	NA	-0.38	-5.1	-0.32	6.98e-7	Red blood cell count;
SARC	cis	rs9303401	0.592	rs12936771	chr17:56725052	T/C	cg25039879	chr17:56429692	SUPT4H1	0.69	6.55	0.39	3.71e-10	Cognitive test performance;
SARC	cis	rs6964587	0.967	rs2188153	chr7:91595117	G/T	cg17063962	chr7:91808500	NA	0.91	15.2	0.71	9.95e-37	Breast cancer;
SARC	cis	rs11690935	0.959	rs1113389	chr2:172635365	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.0	-16.0	-0.72	2.3e-39	Schizophrenia;
SARC	trans	rs10506458	0.915	rs17687426	chr12:63397900	G/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.77	-6.73	-0.4	1.3100000000000001e-10	Hemostatic factors and hematological phenotypes;
SARC	cis	rs1801251	0.778	rs2592115	chr2:233736349	C/T	cg25237894	chr2:233734115	C2orf82	-0.34	-4.84	-0.3	2.32e-6	Coronary artery disease;
SARC	cis	rs1007738	0.542	rs10838662	chr11:47184117	T/G	cg03339077	chr11:47165057	C11orf49	0.41	4.78	0.3	3.14e-6	Bone mineral density (hip);
SARC	cis	rs854765	0.547	rs9897761	chr17:17912011	A/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.46	5.99	0.37	7.81e-9	Total body bone mineral density;
SARC	cis	rs7223966	1.000	rs7223672	chr17:61720565	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.53	-5.63	-0.35	5.04e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2742234	0.541	rs4648313	chr10:43716739	G/A	cg15436174	chr10:43711423	RASGEF1A	0.43	5.01	0.31	1.08e-6	Hirschsprung disease;
SARC	cis	rs9303401	0.614	rs28651036	chr17:57080471	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.99	10.43	0.56	3.73e-21	Cognitive test performance;
SARC	cis	rs11190604	1.000	rs11190599	chr10:102295420	C/T	cg07080220	chr10:102295463	HIF1AN	0.81	9.96	0.55	1.07e-19	Palmitoleic acid (16:1n-7) levels;
SARC	trans	rs561341	0.941	rs2428338	chr17:30299629	T/C	cg20587970	chr11:113659929	NA	-1.21	-11.65	-0.61	5.2e-25	Hip circumference adjusted for BMI;
SARC	cis	rs2997447	0.655	rs2275950	chr1:26385003	T/C	cg19633962	chr1:26362018	EXTL1	-0.8	-8.03	-0.47	4.79e-14	QRS complex (12-leadsum);
SARC	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg00933542	chr6:150070202	PCMT1	0.33	5.5	0.34	9.75e-8	Lung cancer;
SARC	cis	rs6752107	1.000	rs35300242	chr2:234168790	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.49	6.34	0.38	1.17e-9	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs6088580	0.634	rs4911423	chr20:32999386	T/A	cg24642439	chr20:33292090	TP53INP2	-0.65	-8.43	-0.48	3.57e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs11098499	0.909	rs1546502	chr4:120235898	A/G	cg09160332	chr4:120329925	NA	-0.35	-4.91	-0.31	1.72e-6	Corneal astigmatism;
SARC	cis	rs7772486	0.686	rs6570705	chr6:145961201	C/T	cg23711669	chr6:146136114	FBXO30	0.77	12.2	0.62	8.53e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs637571	0.780	rs677029	chr11:65683531	A/G	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.4	-4.95	-0.31	1.42e-6	Eosinophil percentage of white cells;
SARC	cis	rs9309473	0.583	rs11899517	chr2:73573261	A/G	cg20560298	chr2:73613845	ALMS1	-0.53	-6.68	-0.4	1.69e-10	Metabolite levels;
SARC	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg16405210	chr4:1374714	KIAA1530	-0.51	-5.98	-0.36	8.4e-9	Obesity-related traits;
SARC	cis	rs7666738	0.830	rs6854703	chr4:98977586	A/T	cg05340658	chr4:99064831	C4orf37	0.64	8.6	0.49	1.18e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	12.12	0.62	1.52e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs796364	0.568	rs11890894	chr2:201072055	C/T	cg23649088	chr2:200775458	C2orf69	0.62	7.46	0.44	1.65e-12	Schizophrenia;
SARC	cis	rs10754283	0.967	rs1953821	chr1:90107098	C/G	cg21401794	chr1:90099060	LRRC8C	0.53	6.95	0.41	3.73e-11	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs314370	0.951	rs13226502	chr7:100506381	C/T	cg10426581	chr7:100472382	SRRT	0.58	6.23	0.38	2.16e-9	Resting heart rate;
SARC	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg10295955	chr4:187884368	NA	-1.06	-18.56	-0.77	7.79e-48	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1448094	0.556	rs17345522	chr12:86169929	T/C	cg02569458	chr12:86230093	RASSF9	0.38	5.09	0.32	7.38e-7	Major depressive disorder;
SARC	cis	rs4423214	1.000	rs7935125	chr11:71184190	C/A	cg24826892	chr11:71159390	DHCR7	0.45	5.73	0.35	3.04e-8	Vitamin D levels;
SARC	cis	rs7246657	0.943	rs10404602	chr19:37825633	A/T	cg23950597	chr19:37808831	NA	-0.6	-5.85	-0.36	1.67e-8	Coronary artery calcification;
SARC	cis	rs11190604	1.000	rs4919465	chr10:102221703	C/T	cg07080220	chr10:102295463	HIF1AN	0.76	9.5	0.53	2.59e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs6003958	1	rs6003958	chr22:24264089	T/G	cg09033563	chr22:24373618	LOC391322	0.53	5.62	0.35	5.39e-8	S-phenylmercapturic acid levels in smokers;
SARC	cis	rs2439831	0.867	rs486301	chr15:43836949	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	8.96	0.51	1.06e-16	Lung cancer in ever smokers;
SARC	cis	rs5753618	0.561	rs714909	chr22:31741067	G/A	cg13145458	chr22:31556086	RNF185	-0.49	-5.29	-0.33	2.89e-7	Colorectal cancer;
SARC	cis	rs6582630	0.574	rs12146797	chr12:38436499	T/C	cg26384229	chr12:38710491	ALG10B	0.84	12.04	0.62	2.79e-26	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs17376456	1.000	rs35184505	chr5:93561535	A/G	cg21475434	chr5:93447410	FAM172A	0.91	8.2	0.47	1.65e-14	Diabetic retinopathy;
SARC	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.57	-7.43	-0.44	2.1e-12	Mean platelet volume;
SARC	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.41	-6.22	-0.38	2.33e-9	Total body bone mineral density;
SARC	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg06873352	chr17:61820015	STRADA	-0.51	-6.36	-0.38	1.06e-9	Prudent dietary pattern;
SARC	cis	rs8141529	0.748	rs5752826	chr22:29269808	A/G	cg02153584	chr22:29168773	CCDC117	0.76	11.25	0.59	1e-23	Lymphocyte counts;
SARC	cis	rs3820928	1.000	rs61067328	chr2:227761256	G/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.09	-0.42	1.56e-11	Pulmonary function;
SARC	cis	rs7246760	0.867	rs55914342	chr19:9824447	A/T	cg16876255	chr19:9731953	ZNF561	0.79	4.88	0.3	1.96e-6	Pursuit maintenance gain;
SARC	cis	rs6088813	1.000	rs62211529	chr20:33959315	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	-0.45	-5.39	-0.33	1.75e-7	Height;
SARC	cis	rs6496667	0.542	rs58182460	chr15:90897309	A/T	cg22089800	chr15:90895588	ZNF774	0.51	4.75	0.3	3.53e-6	Rheumatoid arthritis;
SARC	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.46	-4.84	-0.3	2.38e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs6807306	1.000	rs59953438	chr3:167437049	A/C	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.5	4.86	0.3	2.19e-6	Mean platelet volume;
SARC	trans	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg00938859	chr5:1591904	SDHAP3	0.78	7.58	0.44	8.08e-13	Breast cancer;
SARC	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg11890956	chr21:40555474	PSMG1	1.16	19.13	0.78	1.1e-49	Cognitive function;
SARC	cis	rs1832871	0.672	rs9457363	chr6:158777515	C/T	cg07165851	chr6:158734300	TULP4	0.5	5.84	0.36	1.77e-8	Height;
SARC	cis	rs17539620	0.624	rs74551216	chr6:154840524	T/C	cg17771515	chr6:154831774	CNKSR3	0.52	4.97	0.31	1.3e-6	Lipoprotein (a) levels;
SARC	cis	rs30380	0.632	rs27045	chr5:96138861	C/T	cg16492584	chr5:96139282	ERAP1	-0.48	-5.47	-0.34	1.18e-7	Cerebrospinal fluid biomarker levels;
SARC	cis	rs950027	0.595	rs2486288	chr15:45712339	T/C	cg15395560	chr15:45543142	SLC28A2	-0.28	-5.37	-0.33	1.89e-7	Response to fenofibrate (adiponectin levels);
SARC	cis	rs858239	0.600	rs2072368	chr7:23146112	C/T	cg23682824	chr7:23144976	KLHL7	0.72	9.73	0.54	5.43e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs10782582	0.593	rs11163967	chr1:76154185	T/C	cg10523679	chr1:76189770	ACADM	-0.42	-5.14	-0.32	5.74e-7	Daytime sleep phenotypes;
SARC	cis	rs6912958	0.781	rs7757636	chr6:88256092	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-7.04	-0.42	2.16e-11	Monocyte percentage of white cells;
SARC	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-15.46	-0.71	1.39e-37	Chronic sinus infection;
SARC	cis	rs240764	0.764	rs6903206	chr6:100929516	A/G	cg21058520	chr6:100914733	NA	-0.31	-4.75	-0.3	3.49e-6	Neuroticism;
SARC	cis	rs9291683	0.552	rs3796832	chr4:10015865	C/T	cg11266682	chr4:10021025	SLC2A9	0.4	7.12	0.42	1.37e-11	Bone mineral density;
SARC	cis	rs870825	0.616	rs9631783	chr4:185626511	C/T	cg04058563	chr4:185651563	MLF1IP	0.81	11.25	0.59	9.68e-24	Blood protein levels;
SARC	cis	rs546131	0.928	rs483976	chr11:34840167	C/G	cg11058730	chr11:34937778	PDHX;APIP	0.42	5.19	0.32	4.48e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs2012796	0.704	rs57670850	chr14:81841577	C/T	cg02996355	chr14:81879375	NA	0.53	5.8	0.36	2.16e-8	Night sleep phenotypes;
SARC	cis	rs950169	0.845	rs4106951	chr15:84833394	C/G	cg24253500	chr15:84953950	NA	0.35	4.93	0.31	1.6e-6	Schizophrenia;
SARC	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg03060546	chr3:49711283	APEH	0.46	5.78	0.35	2.42e-8	Parkinson's disease;
SARC	cis	rs3741151	0.773	rs57673166	chr11:73232557	T/A	cg17517138	chr11:73019481	ARHGEF17	0.92	6.86	0.41	6.15e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs7208859	0.623	rs73269916	chr17:29096326	A/G	cg13385521	chr17:29058706	SUZ12P	0.9	7.89	0.46	1.18e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs11711311	0.955	rs9860642	chr3:113419211	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	8.52	0.49	1.95e-15	IgG glycosylation;
SARC	cis	rs2239547	0.563	rs6797399	chr3:52905917	G/A	cg11645453	chr3:52864694	ITIH4	0.32	4.77	0.3	3.22e-6	Schizophrenia;
SARC	cis	rs4268898	0.795	rs12470303	chr2:24619883	C/T	cg26838691	chr2:24397539	C2orf84	-0.41	-5.69	-0.35	3.86e-8	Asthma;
SARC	cis	rs8012145	0.542	rs12881380	chr14:55171622	A/C	cg19913537	chr14:55186044	SAMD4A	0.44	4.72	0.3	4.04e-6	Plateletcrit;
SARC	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg27266027	chr21:40555129	PSMG1	0.5	4.95	0.31	1.42e-6	Cognitive function;
SARC	trans	rs9354352	0.967	rs6455062	chr6:66694131	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.59	7.69	0.45	4.15e-13	Initial pursuit acceleration in psychotic disorders;
SARC	cis	rs77106637	0.932	rs2886599	chr11:72721271	C/A	cg03713592	chr11:72463424	ARAP1	0.95	8.74	0.5	4.71e-16	Type 2 diabetes;
SARC	cis	rs1728785	0.901	rs1728797	chr16:68570989	A/T	cg02972257	chr16:68554789	NA	-0.44	-5.15	-0.32	5.43e-7	Ulcerative colitis;
SARC	cis	rs12142240	0.698	rs6703669	chr1:46862555	C/T	cg10495392	chr1:46806563	NSUN4	0.65	6.88	0.41	5.6e-11	Menopause (age at onset);
SARC	cis	rs7428	0.545	rs9248	chr2:85537312	G/A	cg03728395	chr2:85555865	TGOLN2	-0.45	-6.24	-0.38	2.04e-9	Ear protrusion;
SARC	cis	rs8141529	0.515	rs16986861	chr22:29343188	G/C	cg15103426	chr22:29168792	CCDC117	0.58	5.81	0.36	2.01e-8	Lymphocyte counts;
SARC	cis	rs72781680	0.716	rs72788206	chr2:24084989	T/C	cg06627628	chr2:24431161	ITSN2	-0.54	-5.85	-0.36	1.64e-8	Lymphocyte counts;
SARC	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg10435706	chr6:150039699	LATS1	0.36	4.77	0.3	3.25e-6	Lung cancer;
SARC	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg27211696	chr2:191398769	TMEM194B	0.49	6.84	0.41	7.1e-11	Pulse pressure;
SARC	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg11987759	chr7:65425863	GUSB	-0.52	-6.65	-0.4	2.03e-10	Aortic root size;
SARC	trans	rs61931739	0.500	rs7311302	chr12:34557211	T/C	cg26384229	chr12:38710491	ALG10B	0.85	12.64	0.64	3.01e-28	Morning vs. evening chronotype;
SARC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.44	0.53	3.96e-18	Prudent dietary pattern;
SARC	cis	rs9467773	0.967	rs1535276	chr6:26520941	T/C	cg12292205	chr6:26970375	C6orf41	0.44	5.46	0.34	1.24e-7	Intelligence (multi-trait analysis);
SARC	trans	rs17685	0.712	rs6954569	chr7:75738885	T/A	cg19862616	chr7:65841803	NCRNA00174	0.61	7.48	0.44	1.47e-12	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs950776	0.518	rs3813571	chr15:78832792	G/T	cg17108064	chr15:78857060	CHRNA5	0.29	4.99	0.31	1.17e-6	Sudden cardiac arrest;
SARC	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.41	-6.39	-0.39	9.12e-10	Total body bone mineral density;
SARC	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg05368731	chr17:41323189	NBR1	0.8	9.59	0.53	1.43e-18	Menopause (age at onset);
SARC	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg11987759	chr7:65425863	GUSB	-0.49	-6.21	-0.38	2.46e-9	Aortic root size;
SARC	cis	rs17270561	0.636	rs1185977	chr6:25829054	A/G	cg17691542	chr6:26056736	HIST1H1C	0.5	6.3	0.38	1.5e-9	Iron status biomarkers;
SARC	cis	rs4713675	0.565	rs4713670	chr6:33699882	C/T	cg15676125	chr6:33679581	C6orf125	-0.51	-6.25	-0.38	1.93e-9	Plateletcrit;
SARC	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg16339924	chr4:17578868	LAP3	0.65	8.64	0.49	8.83e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2112347	0.502	rs34342	chr5:74934213	A/C	cg06933384	chr5:74808293	COL4A3BP;POLK	-0.61	-5.99	-0.37	8.11e-9	Body mass index (joint analysis main effects and smoking interaction);Waist circumference;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Hip circumference;Body mass index;Body mass index in physically active individuals;Obesity;
SARC	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg05861140	chr6:150128134	PCMT1	-0.38	-4.85	-0.3	2.22e-6	Lung cancer;
SARC	cis	rs9916302	0.904	rs35335692	chr17:37710006	A/G	cg00129232	chr17:37814104	STARD3	-0.65	-7.87	-0.46	1.3e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs7617773	0.817	rs34728236	chr3:48259108	A/G	cg11946769	chr3:48343235	NME6	0.72	9.31	0.52	9.97e-18	Coronary artery disease;
SARC	cis	rs34330	0.562	rs11055024	chr12:12858969	A/G	cg04607235	chr12:12878440	APOLD1	-0.57	-5.54	-0.34	8.19e-8	Systemic lupus erythematosus;
SARC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg18402987	chr7:1209562	NA	0.4	5.09	0.32	7.48e-7	Longevity;Endometriosis;
SARC	cis	rs11711311	0.955	rs12636240	chr3:113391282	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	8.19	0.47	1.67e-14	IgG glycosylation;
SARC	cis	rs6429082	0.818	rs291341	chr1:235663174	G/T	cg26050004	chr1:235667680	B3GALNT2	0.66	7.7	0.45	3.79e-13	Adiposity;
SARC	trans	rs1814175	0.817	rs7932683	chr11:49983640	G/A	cg03929089	chr4:120376271	NA	-0.88	-14.05	-0.68	6.62e-33	Height;
SARC	cis	rs9322817	0.691	rs7743022	chr6:105170381	G/T	cg02098413	chr6:105308735	HACE1	-0.39	-6.1	-0.37	4.44e-9	Thyroid stimulating hormone;
SARC	cis	rs4555082	0.834	rs2816631	chr14:105739477	G/A	cg06808227	chr14:105710500	BRF1	-0.52	-6.64	-0.4	2.22e-10	Mean platelet volume;Platelet distribution width;
SARC	cis	rs6665290	0.669	rs34267809	chr1:227176162	C/G	cg14016676	chr1:227182615	CDC42BPA	0.34	4.91	0.31	1.69e-6	Myeloid white cell count;
SARC	cis	rs12295403	0.723	rs12787397	chr11:18687025	C/T	cg14332346	chr11:18548210	TSG101	-0.49	-5.01	-0.31	1.06e-6	Ovarian reserve;
SARC	cis	rs12824058	0.831	rs4759452	chr12:130812799	G/A	cg26677194	chr12:130822605	PIWIL1	0.54	7.41	0.44	2.25e-12	Menopause (age at onset);
SARC	trans	rs12310956	0.515	rs1405031	chr12:33958931	A/C	cg13010199	chr12:38710504	ALG10B	0.65	8.61	0.49	1.11e-15	Morning vs. evening chronotype;
SARC	cis	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg14019146	chr3:50243930	SLC38A3	-0.31	-4.83	-0.3	2.42e-6	Body mass index;
SARC	cis	rs6121246	0.559	rs6060857	chr20:30300222	A/G	cg13852791	chr20:30311386	BCL2L1	0.88	10.86	0.58	1.7e-22	Mean corpuscular hemoglobin;
SARC	cis	rs3771570	0.901	rs28433352	chr2:242339656	A/G	cg21155796	chr2:242212141	HDLBP	0.53	5.19	0.32	4.57e-7	Prostate cancer;
SARC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg20887711	chr4:1340912	KIAA1530	-0.75	-9.5	-0.53	2.59e-18	Longevity;
SARC	cis	rs722599	0.628	rs12896360	chr14:75278181	A/C	cg06637938	chr14:75390232	RPS6KL1	0.41	5.01	0.31	1.07e-6	IgG glycosylation;
SARC	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg25427524	chr10:38739819	LOC399744	-0.56	-8.73	-0.5	5.08e-16	Extrinsic epigenetic age acceleration;
SARC	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg04772025	chr11:68637568	NA	0.55	7.0	0.42	2.72e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg20102877	chr2:27665638	KRTCAP3	0.37	5.31	0.33	2.55e-7	Total body bone mineral density;
SARC	cis	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg06636001	chr8:8085503	FLJ10661	-0.7	-9.54	-0.53	2.07e-18	Joint mobility (Beighton score);
SARC	cis	rs9894429	0.505	rs35570626	chr17:79611084	A/G	cg10661904	chr17:79619235	PDE6G	-0.44	-6.26	-0.38	1.84e-9	Eye color traits;
SARC	cis	rs11776272	0.927	rs11135789	chr8:21878607	C/T	cg17168535	chr8:21777572	XPO7	-0.55	-6.63	-0.4	2.34e-10	Obesity-related traits;
SARC	cis	rs274567	0.599	rs11242110	chr5:131743777	A/C	cg24060327	chr5:131705240	SLC22A5	0.52	6.44	0.39	6.87e-10	Blood metabolite levels;
SARC	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-9.15	-0.51	2.85e-17	Alzheimer's disease;
SARC	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg01341218	chr17:43662625	NA	-0.85	-9.63	-0.53	1.11e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs79149102	0.579	rs7174129	chr15:75305040	A/G	cg17294928	chr15:75287854	SCAMP5	-1.01	-9.29	-0.52	1.13e-17	Lung cancer;
SARC	cis	rs67311347	0.544	rs4974040	chr3:40331059	G/A	cg09455208	chr3:40491958	NA	0.3	5.02	0.31	1.03e-6	Renal cell carcinoma;
SARC	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg22920501	chr2:26401640	FAM59B	0.53	6.45	0.39	6.38e-10	Gut microbiome composition (summer);
SARC	trans	rs1814175	0.817	rs12290508	chr11:49621037	C/T	cg03929089	chr4:120376271	NA	-0.9	-14.65	-0.69	6.79e-35	Height;
SARC	cis	rs7833790	0.724	rs1054078	chr8:82712153	A/G	cg17211192	chr8:82754475	SNX16	-0.51	-6.32	-0.38	1.29e-9	Diastolic blood pressure;
SARC	cis	rs7084402	0.967	rs1649022	chr10:60285867	A/G	cg07615347	chr10:60278583	BICC1	0.6	8.82	0.5	2.75e-16	Refractive error;
SARC	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg07636037	chr3:49044803	WDR6	0.99	17.51	0.75	2.23e-44	Parkinson's disease;
SARC	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg19077165	chr18:44547161	KATNAL2	-0.53	-7.34	-0.43	3.63e-12	Personality dimensions;
SARC	cis	rs4988958	0.565	rs3771154	chr2:103039360	C/T	cg03938978	chr2:103052716	IL18RAP	0.32	5.12	0.32	6.53e-7	Asthma (childhood onset);
SARC	cis	rs6582630	0.638	rs10880620	chr12:38517467	A/G	cg04568710	chr12:38710424	ALG10B	-0.41	-4.94	-0.31	1.5e-6	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2153535	0.542	rs915354	chr6:8440357	T/C	cg07606381	chr6:8435919	SLC35B3	0.79	10.79	0.58	2.92e-22	Motion sickness;
SARC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg21747090	chr2:27597821	SNX17	-0.55	-7.81	-0.46	1.97e-13	Total body bone mineral density;
SARC	cis	rs9291683	0.595	rs11722930	chr4:10035454	G/A	cg00071950	chr4:10020882	SLC2A9	0.4	6.29	0.38	1.54e-9	Bone mineral density;
SARC	cis	rs9303401	0.527	rs2116450	chr17:56745561	C/T	cg25039879	chr17:56429692	SUPT4H1	0.67	6.06	0.37	5.48e-9	Cognitive test performance;
SARC	cis	rs16976116	0.901	rs73409851	chr15:55502516	G/A	cg17854078	chr15:55489399	RSL24D1	0.66	6.53	0.39	4.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg18876405	chr7:65276391	NA	0.71	9.35	0.52	7.69e-18	Aortic root size;
SARC	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg01276201	chr10:134613136	NA	0.31	5.31	0.33	2.57e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs6543140	0.601	rs6543135	chr2:103062406	C/T	cg09003973	chr2:102972529	NA	0.51	5.77	0.35	2.46e-8	Blood protein levels;
SARC	cis	rs9611519	1.000	rs6002271	chr22:41566595	C/T	cg03806693	chr22:41940476	POLR3H	-0.55	-6.15	-0.37	3.42e-9	Neuroticism;
SARC	cis	rs1046896	0.594	rs67813226	chr17:80851134	G/A	cg22027946	chr17:80790580	TBCD;ZNF750	0.4	4.97	0.31	1.27e-6	Glycated hemoglobin levels;
SARC	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg16479474	chr6:28041457	NA	0.37	5.44	0.34	1.37e-7	Depression;
SARC	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg11987759	chr7:65425863	GUSB	0.56	7.53	0.44	1.08e-12	Aortic root size;
SARC	cis	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.5	-4.87	-0.3	2.09e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs6991838	0.584	rs34494846	chr8:66514632	T/C	cg13398993	chr8:66546079	ARMC1	-0.62	-8.3	-0.48	8.62e-15	Intelligence (multi-trait analysis);
SARC	cis	rs4737010	0.570	rs7823138	chr8:41644861	C/T	cg17182837	chr8:41585554	ANK1	0.45	5.11	0.32	6.83e-7	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
SARC	cis	rs705471	0.966	rs12573508	chr10:3656268	C/T	cg14308648	chr10:3568949	NA	0.59	7.48	0.44	1.47e-12	Capecitabine sensitivity;
SARC	cis	rs7917772	0.636	rs4418737	chr10:104525123	A/G	ch.10.2196322F	chr10:104248062	ACTR1A	-0.46	-5.4	-0.33	1.61e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs698813	0.674	rs3738985	chr2:44502788	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	6.35	0.38	1.09e-9	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs6582630	0.638	rs4882309	chr12:38448595	A/G	cg13010199	chr12:38710504	ALG10B	-0.46	-5.68	-0.35	4e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7582720	1.000	rs77230711	chr2:203805552	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs7044106	0.734	rs1981020	chr9:123388464	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	5.52	0.34	9.03e-8	Hip circumference adjusted for BMI;
SARC	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg17376030	chr22:41985996	PMM1	-0.72	-8.9	-0.5	1.6e-16	Vitiligo;
SARC	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg05368731	chr17:41323189	NBR1	0.77	9.17	0.52	2.53e-17	Menopause (age at onset);
SARC	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg02725872	chr8:58115012	NA	-0.35	-6.27	-0.38	1.71e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9300255	0.602	rs1790098	chr12:123655481	A/C	cg05973401	chr12:123451056	ABCB9	0.54	5.78	0.35	2.44e-8	Neutrophil percentage of white cells;
SARC	cis	rs4765905	0.610	rs12422554	chr12:2312620	A/C	cg10668781	chr12:2307325	CACNA1C	-0.3	-4.74	-0.3	3.72e-6	Schizophrenia;
SARC	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg08219700	chr8:58056026	NA	0.68	6.44	0.39	6.92e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9309473	0.607	rs7567017	chr2:73596270	C/T	cg20560298	chr2:73613845	ALMS1	-0.57	-7.26	-0.43	5.84e-12	Metabolite levels;
SARC	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg13628971	chr7:2884303	GNA12	0.64	7.51	0.44	1.25e-12	Height;
SARC	cis	rs858239	0.539	rs10279194	chr7:23191083	T/C	cg23682824	chr7:23144976	KLHL7	0.74	9.66	0.53	8.86e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs910316	0.763	rs735452	chr14:75497984	A/G	cg08847533	chr14:75593920	NEK9	-0.86	-13.25	-0.66	3.14e-30	Height;
SARC	cis	rs2797160	1.000	rs1832979	chr6:125997436	A/G	cg05901451	chr6:126070800	HEY2	-0.41	-4.88	-0.3	1.94e-6	Endometrial cancer;
SARC	cis	rs7762018	0.607	rs75964125	chr6:170054290	T/A	cg19338460	chr6:170058176	WDR27	-0.82	-6.0	-0.37	7.59e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg17178900	chr1:205818956	PM20D1	0.66	10.26	0.56	1.28e-20	Monocyte percentage of white cells;
SARC	cis	rs832540	0.902	rs194059	chr5:56197416	G/A	cg14703610	chr5:56206110	C5orf35	0.55	6.93	0.41	3.98e-11	Coronary artery disease;
SARC	cis	rs11785400	0.701	rs9721143	chr8:143727511	A/T	cg10596483	chr8:143751796	JRK	0.57	7.39	0.44	2.61e-12	Schizophrenia;
SARC	cis	rs9596270	0.772	rs11842790	chr13:50924448	A/G	cg10393508	chr13:50950265	NA	-0.49	-5.16	-0.32	5.31e-7	Multiple sclerosis;
SARC	cis	rs11722228	0.549	rs73212828	chr4:10078756	C/T	cg11266682	chr4:10021025	SLC2A9	0.32	4.73	0.3	3.97e-6	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs7395581	0.918	rs10501321	chr11:47294626	A/G	cg25783544	chr11:47291846	MADD	0.46	5.26	0.33	3.27e-7	HDL cholesterol;
SARC	trans	rs2727020	0.521	rs7107178	chr11:49526668	G/A	cg15704280	chr7:45808275	SEPT13	0.7	8.13	0.47	2.52e-14	Coronary artery disease;
SARC	trans	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg17830980	chr10:43048298	ZNF37B	-0.51	-7.02	-0.42	2.42e-11	Extrinsic epigenetic age acceleration;
SARC	trans	rs877282	0.583	rs10904562	chr10:819058	T/C	cg22713356	chr15:30763199	NA	0.92	8.68	0.49	6.81e-16	Uric acid levels;
SARC	cis	rs4423214	0.798	rs12224205	chr11:71180992	A/G	cg05163923	chr11:71159392	DHCR7	-0.61	-7.42	-0.44	2.17e-12	Vitamin D levels;
SARC	cis	rs72781680	0.846	rs72780108	chr2:23986780	G/A	cg08917208	chr2:24149416	ATAD2B	0.77	7.29	0.43	4.79e-12	Lymphocyte counts;
SARC	cis	rs36051895	0.658	rs10974910	chr9:5010091	G/A	cg02405213	chr9:5042618	JAK2	-0.51	-5.64	-0.35	5.03e-8	Pediatric autoimmune diseases;
SARC	cis	rs7843479	0.601	rs2002941	chr8:21834366	A/C	cg17168535	chr8:21777572	XPO7	0.85	13.53	0.66	3.53e-31	Mean corpuscular volume;
SARC	cis	rs1144333	0.655	rs946164	chr1:76383286	A/T	cg03433033	chr1:76189801	ACADM	0.64	5.23	0.32	3.73e-7	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.66	-6.78	-0.41	9.94e-11	Platelet count;
SARC	cis	rs1008375	0.966	rs6832414	chr4:17696866	C/G	cg27347728	chr4:17578864	LAP3	0.44	5.67	0.35	4.13e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs12311304	1.000	rs17347323	chr12:15383037	C/T	cg08258403	chr12:15378311	NA	0.48	7.24	0.43	6.45e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs6570726	0.870	rs370653	chr6:145823642	G/A	cg05220968	chr6:146057943	EPM2A	-0.29	-4.99	-0.31	1.19e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4423214	1.000	rs7944926	chr11:71165625	A/G	cg24826892	chr11:71159390	DHCR7	0.42	5.14	0.32	5.88e-7	Vitamin D levels;
SARC	cis	rs5167	0.601	rs73047694	chr19:45497852	G/A	cg10169327	chr19:45448959	APOC2	0.33	5.0	0.31	1.15e-6	Blood protein levels;
SARC	cis	rs5167	0.533	rs55778858	chr19:45485465	G/A	cg09555818	chr19:45449301	APOC2	0.39	5.17	0.32	5.11e-7	Blood protein levels;
SARC	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg03517284	chr6:25882590	NA	-0.44	-6.1	-0.37	4.45e-9	Intelligence (multi-trait analysis);
SARC	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.64	-7.54	-0.44	1.02e-12	Gut microbiome composition (summer);
SARC	cis	rs17376456	0.569	rs7713956	chr5:93133185	T/C	cg25358565	chr5:93447407	FAM172A	-0.94	-10.67	-0.57	6.51e-22	Diabetic retinopathy;
SARC	cis	rs9325144	0.534	rs1973293	chr12:38679575	C/T	cg26384229	chr12:38710491	ALG10B	0.62	8.44	0.48	3.4e-15	Morning vs. evening chronotype;
SARC	cis	rs4919087	0.561	rs61861844	chr10:99064171	G/A	cg25902810	chr10:99078978	FRAT1	-0.56	-5.93	-0.36	1.07e-8	Monocyte count;
SARC	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg06212747	chr3:49208901	KLHDC8B	0.68	8.89	0.5	1.7e-16	Parkinson's disease;
SARC	cis	rs2806561	0.704	rs2806570	chr1:23527005	C/T	cg12483005	chr1:23474871	LUZP1	-0.46	-6.05	-0.37	5.78e-9	Height;
SARC	cis	rs55986470	0.763	rs11888775	chr2:239424876	C/T	cg21699342	chr2:239360505	ASB1	0.47	5.07	0.31	8.29e-7	Chronotype;
SARC	cis	rs4280164	0.945	rs11158632	chr14:24769663	A/C	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.51	-4.88	-0.3	2.01e-6	Parent of origin effect on language impairment (paternal);
SARC	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg04277193	chr17:41438351	NA	0.44	4.76	0.3	3.35e-6	Menopause (age at onset);
SARC	cis	rs7647973	1.000	rs6805609	chr3:49471522	C/G	cg07636037	chr3:49044803	WDR6	-0.75	-7.53	-0.44	1.13e-12	Menarche (age at onset);
SARC	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg24060327	chr5:131705240	SLC22A5	0.74	8.97	0.51	9.94e-17	Breast cancer;
SARC	trans	rs9888736	0.501	rs1561044	chr15:47907348	A/G	cg01357263	chr12:122459509	BCL7A	-0.5	-6.28	-0.38	1.68e-9	Body mass index;
SARC	cis	rs9858542	0.953	rs6446264	chr3:49417243	C/A	cg03060546	chr3:49711283	APEH	-0.58	-7.24	-0.43	6.34e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg27266027	chr21:40555129	PSMG1	0.49	5.39	0.33	1.7e-7	Cognitive function;
SARC	cis	rs8072100	0.701	rs8075566	chr17:45771037	G/A	cg08085267	chr17:45401833	C17orf57	-0.42	-4.9	-0.31	1.76e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs7481584	0.961	rs12797969	chr11:3019216	C/T	cg05729581	chr11:3078854	CARS	0.47	5.78	0.35	2.44e-8	Calcium levels;
SARC	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg12463550	chr7:65579703	CRCP	-0.47	-5.15	-0.32	5.53e-7	Aortic root size;
SARC	cis	rs3126085	0.935	rs11204937	chr1:152193851	C/T	cg03465714	chr1:152285911	FLG	-0.48	-5.81	-0.36	2.07e-8	Atopic dermatitis;
SARC	cis	rs67311347	0.544	rs6762121	chr3:40355313	G/A	cg24209194	chr3:40518798	ZNF619	0.49	6.46	0.39	6.11e-10	Renal cell carcinoma;
SARC	trans	rs877282	0.891	rs34652870	chr10:772218	T/C	cg22713356	chr15:30763199	NA	1.04	10.03	0.55	6.55e-20	Uric acid levels;
SARC	cis	rs2916247	0.954	rs7011377	chr8:93020588	A/C	cg10183463	chr8:93005414	RUNX1T1	0.58	6.28	0.38	1.6e-9	Intelligence (multi-trait analysis);
SARC	cis	rs5753618	0.504	rs7284622	chr22:31907985	G/A	cg07713946	chr22:31675144	LIMK2	0.36	5.11	0.32	6.61e-7	Colorectal cancer;
SARC	cis	rs3768617	0.510	rs1413389	chr1:183096668	C/T	cg13390022	chr1:182993471	LAMC1	0.31	4.79	0.3	3.01e-6	Fuchs's corneal dystrophy;
SARC	cis	rs888194	0.686	rs11067376	chr12:110027795	A/G	cg05360138	chr12:110035743	NA	0.41	4.81	0.3	2.7e-6	Neuroticism;
SARC	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.49	-6.12	-0.37	3.97e-9	Lymphocyte counts;
SARC	trans	rs7980799	0.682	rs1384599	chr12:33624579	G/A	cg26384229	chr12:38710491	ALG10B	-0.63	-7.84	-0.46	1.59e-13	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg04277193	chr17:41438351	NA	0.44	4.73	0.3	3.83e-6	Menopause (age at onset);
SARC	cis	rs7474896	0.537	rs1208591	chr10:38212502	A/T	cg25427524	chr10:38739819	LOC399744	-0.42	-5.16	-0.32	5.28e-7	Obesity (extreme);
SARC	cis	rs372883	0.648	rs15092	chr21:30718201	G/A	cg08807101	chr21:30365312	RNF160	-0.6	-7.62	-0.45	6.47e-13	Pancreatic cancer;
SARC	cis	rs548181	0.611	rs2849225	chr11:125415936	A/G	cg03464685	chr11:125439445	EI24	1.3	13.33	0.66	1.71e-30	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg15556689	chr8:8085844	FLJ10661	0.52	6.52	0.39	4.37e-10	Mood instability;
SARC	cis	rs240764	0.555	rs4840150	chr6:101183774	T/C	cg09795085	chr6:101329169	ASCC3	0.5	6.42	0.39	7.41e-10	Neuroticism;
SARC	cis	rs870825	0.616	rs28636679	chr4:185627481	C/T	cg04058563	chr4:185651563	MLF1IP	0.83	11.45	0.6	2.27e-24	Blood protein levels;
SARC	cis	rs6060717	0.528	rs73905955	chr20:34332938	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-6.06	-0.37	5.49e-9	Hip circumference adjusted for BMI;
SARC	cis	rs2153535	0.580	rs7767926	chr6:8453557	A/G	cg07606381	chr6:8435919	SLC35B3	0.77	11.05	0.59	4.35e-23	Motion sickness;
SARC	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg08048268	chr3:133502702	NA	-0.43	-5.79	-0.35	2.32e-8	Iron status biomarkers;
SARC	cis	rs10911232	0.507	rs4575047	chr1:182976028	A/G	cg13390022	chr1:182993471	LAMC1	0.33	5.06	0.31	8.36e-7	Hypertriglyceridemia;
SARC	cis	rs1728785	0.901	rs1183956	chr16:68606726	G/A	cg02972257	chr16:68554789	NA	-0.47	-5.56	-0.34	7.2e-8	Ulcerative colitis;
SARC	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg03033257	chr22:50311977	ALG12;CRELD2	0.62	5.92	0.36	1.16e-8	Schizophrenia;
SARC	cis	rs832540	1.000	rs252913	chr5:56195846	C/T	cg14703610	chr5:56206110	C5orf35	-0.57	-7.03	-0.42	2.25e-11	Coronary artery disease;
SARC	cis	rs6540556	0.723	rs1415542	chr1:209902110	T/C	cg05527609	chr1:210001259	C1orf107	-0.62	-5.87	-0.36	1.46e-8	Red blood cell count;
SARC	cis	rs2439831	0.850	rs524417	chr15:43772374	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.06	10.31	0.56	8.86e-21	Lung cancer in ever smokers;
SARC	cis	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.3	-0.43	4.54e-12	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg08859206	chr1:53392774	SCP2	-0.4	-5.75	-0.35	2.75e-8	Monocyte count;
SARC	trans	rs1865760	0.929	rs9461224	chr6:25936402	G/T	cg03073851	chr15:89787445	FANCI	-0.53	-6.33	-0.38	1.21e-9	Height;
SARC	cis	rs9473924	0.505	rs9463663	chr6:50902266	G/A	cg14470998	chr6:50812995	TFAP2B	0.76	7.13	0.42	1.27e-11	Body mass index;
SARC	cis	rs10504073	0.647	rs4348510	chr8:50016027	C/A	cg00325661	chr8:49890786	NA	0.51	6.9	0.41	4.99e-11	Blood metabolite ratios;
SARC	cis	rs9309473	1.000	rs10186501	chr2:73697844	C/T	cg20560298	chr2:73613845	ALMS1	-0.51	-6.12	-0.37	3.98e-9	Metabolite levels;
SARC	cis	rs854765	0.583	rs8065416	chr17:17851162	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	9.85	0.54	2.34e-19	Total body bone mineral density;
SARC	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg14298792	chr15:30685198	CHRFAM7A	-0.46	-5.06	-0.31	8.44e-7	Huntington's disease progression;
SARC	cis	rs965469	0.895	rs6051840	chr20:3391483	C/T	cg25506879	chr20:3388711	C20orf194	0.62	6.48	0.39	5.33e-10	IFN-related cytopenia;
SARC	cis	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg25427524	chr10:38739819	LOC399744	0.54	8.5	0.49	2.24e-15	Extrinsic epigenetic age acceleration;
SARC	cis	rs6942407	0.546	rs2074757	chr7:86794121	G/A	cg02420886	chr7:86849541	C7orf23	0.72	6.32	0.38	1.3e-9	Food allergy;
SARC	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg22535103	chr8:58192502	C8orf71	-0.69	-8.36	-0.48	5.81e-15	Developmental language disorder (linguistic errors);
SARC	cis	rs8064024	0.538	rs12596053	chr16:4946794	A/C	cg08329684	chr16:4932620	PPL	-0.39	-6.05	-0.37	5.76e-9	Cancer;
SARC	cis	rs72781680	0.898	rs2879640	chr2:24043573	T/C	cg08917208	chr2:24149416	ATAD2B	0.79	7.43	0.44	2e-12	Lymphocyte counts;
SARC	cis	rs739401	0.611	rs10833048	chr11:3020040	A/G	cg05729581	chr11:3078854	CARS	-0.49	-6.33	-0.38	1.22e-9	Longevity;
SARC	cis	rs6088590	0.561	rs2295444	chr20:33173883	C/T	cg08999081	chr20:33150536	PIGU	0.44	6.78	0.41	1e-10	Coronary artery disease;
SARC	cis	rs9916302	0.851	rs7220650	chr17:37487168	A/G	cg00129232	chr17:37814104	STARD3	0.6	7.49	0.44	1.41e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg00933542	chr6:150070202	PCMT1	0.31	5.36	0.33	2.04e-7	Lung cancer;
SARC	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9818758	0.607	rs11719220	chr3:49245201	A/G	cg00383909	chr3:49044727	WDR6	0.7	6.19	0.38	2.75e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs7772486	0.806	rs4243478	chr6:146284560	A/G	cg05347473	chr6:146136440	FBXO30	-0.44	-5.89	-0.36	1.31e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs910316	1.000	rs12879542	chr14:75507525	C/T	cg06637938	chr14:75390232	RPS6KL1	0.56	7.84	0.46	1.56e-13	Height;
SARC	cis	rs2380220	0.872	rs2613528	chr6:95939437	C/G	cg23517279	chr6:96025343	MANEA	-0.55	-5.19	-0.32	4.55e-7	Behavioural disinhibition (generation interaction);
SARC	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.63	-7.52	-0.44	1.16e-12	Longevity;Endometriosis;
SARC	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	-0.53	-5.11	-0.32	6.71e-7	Lung function (FEV1/FVC);
SARC	trans	rs61931739	0.517	rs11053224	chr12:34484919	G/A	cg26384229	chr12:38710491	ALG10B	0.89	12.98	0.65	2.32e-29	Morning vs. evening chronotype;
SARC	cis	rs6882046	0.513	rs194225	chr5:88001186	A/G	cg22951263	chr5:87985283	NA	-0.36	-4.8	-0.3	2.88e-6	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
SARC	cis	rs274567	0.501	rs272856	chr5:131687081	G/C	cg24060327	chr5:131705240	SLC22A5	-0.69	-8.12	-0.47	2.63e-14	Blood metabolite levels;
SARC	cis	rs12142240	0.698	rs66847432	chr1:46832013	G/A	cg14993813	chr1:46806288	NSUN4	-0.53	-5.62	-0.35	5.48e-8	Menopause (age at onset);
SARC	cis	rs992157	1.000	rs2168704	chr2:219142492	G/A	cg00012203	chr2:219082015	ARPC2	0.73	11.25	0.59	9.89e-24	Colorectal cancer;
SARC	cis	rs6484504	0.576	rs286653	chr11:31227824	C/T	cg26647111	chr11:31128758	NA	-0.39	-5.15	-0.32	5.58e-7	Red blood cell count;
SARC	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg07636037	chr3:49044803	WDR6	0.99	17.87	0.76	1.44e-45	Parkinson's disease;
SARC	cis	rs820218	0.798	rs9912282	chr17:73673796	G/A	cg01592526	chr17:73663357	RECQL5;SAP30BP	-0.6	-7.9	-0.46	1.1e-13	Rotator cuff tears;
SARC	cis	rs6089584	0.566	rs2146852	chr20:60616492	T/G	cg23262073	chr20:60523788	NA	-0.34	-5.18	-0.32	4.78e-7	Body mass index;
SARC	cis	rs1448094	0.845	rs7966131	chr12:86350633	T/G	cg02569458	chr12:86230093	RASSF9	0.42	6.08	0.37	4.98e-9	Major depressive disorder;
SARC	cis	rs1153858	0.943	rs67045941	chr15:45677011	A/G	cg03999130	chr15:45571217	NA	0.39	4.98	0.31	1.25e-6	Homoarginine levels;
SARC	cis	rs1920116	0.961	rs11919269	chr3:169574465	T/G	cg14222479	chr3:169487675	ARPM1	0.43	5.17	0.32	4.97e-7	Glioma (high-grade);
SARC	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg16606324	chr3:10149918	C3orf24	0.49	4.76	0.3	3.37e-6	Alzheimer's disease;
SARC	cis	rs2594989	0.733	rs9861286	chr3:11568144	C/T	cg00170343	chr3:11313890	ATG7	-0.56	-6.44	-0.39	6.82e-10	Circulating chemerin levels;
SARC	cis	rs2486288	0.656	rs11637364	chr15:45579238	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.53	-6.52	-0.39	4.36e-10	Glomerular filtration rate;
SARC	cis	rs1401999	0.898	rs4148564	chr3:183725982	C/T	cg01324343	chr3:183735012	ABCC5	0.66	13.24	0.66	3.18e-30	Anterior chamber depth;
SARC	cis	rs7589342	0.792	rs13426321	chr2:106500280	G/A	cg14210321	chr2:106509881	NCK2	-0.52	-6.02	-0.37	6.88e-9	Addiction;
SARC	cis	rs1707322	1.000	rs4660328	chr1:46444831	G/T	cg06784218	chr1:46089804	CCDC17	0.34	5.95	0.36	9.76e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9304742	0.646	rs10408610	chr19:53463913	G/A	cg24044776	chr19:53454761	ZNF816A	-0.39	-5.4	-0.33	1.64e-7	Psoriasis;
SARC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg21280719	chr6:42927975	GNMT	0.43	7.56	0.44	9.11e-13	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg06618935	chr21:46677482	NA	-0.39	-5.2	-0.32	4.34e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg26695010	chr11:65641043	EFEMP2	-0.52	-6.72	-0.4	1.4e-10	Eosinophil percentage of white cells;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg24542046	chr7:102782124	NAPEPLD;RPL19P12	0.48	6.37	0.39	9.9e-10	Blood pressure;
SARC	cis	rs4805272	0.539	rs7256211	chr19:29333063	C/G	cg04546413	chr19:29218101	NA	0.51	6.05	0.37	5.65e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs9398803	0.865	rs4418209	chr6:126819699	T/G	cg19875578	chr6:126661172	C6orf173	0.63	8.53	0.49	1.82e-15	Male-pattern baldness;
SARC	cis	rs11997175	0.766	rs56803376	chr8:33687676	T/C	ch.8.33884649F	chr8:33765107	NA	0.56	7.55	0.44	9.51e-13	Body mass index;
SARC	cis	rs1003719	0.762	rs2835598	chr21:38466669	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.63	9.05	0.51	5.67e-17	Eye color traits;
SARC	cis	rs4555082	0.834	rs2735822	chr14:105712734	C/T	cg10792982	chr14:105748885	BRF1	0.55	8.22	0.47	1.46e-14	Mean platelet volume;Platelet distribution width;
SARC	cis	rs35110281	0.713	rs1378079	chr21:45011187	A/G	cg21573476	chr21:45109991	RRP1B	-0.48	-7.03	-0.42	2.32e-11	Mean corpuscular volume;
SARC	cis	rs6570726	0.935	rs421690	chr6:145834594	A/C	cg05220968	chr6:146057943	EPM2A	-0.29	-4.99	-0.31	1.19e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs897080	0.515	rs786417	chr2:44688766	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.6	6.46	0.39	6.03e-10	Height;
SARC	cis	rs6912958	1.000	rs9294380	chr6:88152667	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.38	-0.33	1.79e-7	Monocyte percentage of white cells;
SARC	cis	rs1468333	0.964	rs2967786	chr5:137547675	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.81	11.44	0.6	2.47e-24	Resting heart rate;
SARC	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg11987759	chr7:65425863	GUSB	-0.49	-6.04	-0.37	5.89e-9	Aortic root size;
SARC	cis	rs765787	0.530	rs12904331	chr15:45518293	C/T	cg26924012	chr15:45694286	SPATA5L1	0.41	4.94	0.31	1.53e-6	Uric acid levels;
SARC	cis	rs763121	0.819	rs5757133	chr22:38947835	A/G	cg21395723	chr22:39101663	GTPBP1	-0.51	-5.93	-0.36	1.06e-8	Menopause (age at onset);
SARC	cis	rs17401966	0.858	rs61778404	chr1:10432879	A/G	cg15208524	chr1:10270712	KIF1B	0.5	5.99	0.37	7.88e-9	Hepatocellular carcinoma;
SARC	cis	rs72945132	1.000	rs7938912	chr11:70114885	C/T	cg05964544	chr11:70165517	PPFIA1	-0.54	-5.26	-0.33	3.31e-7	Coronary artery disease;
SARC	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	0.36	5.39	0.33	1.76e-7	Total body bone mineral density;
SARC	cis	rs8180040	0.620	rs6767907	chr3:47162661	C/T	cg27129171	chr3:47204927	SETD2	-0.67	-9.29	-0.52	1.14e-17	Colorectal cancer;
SARC	cis	rs6582630	0.576	rs4882375	chr12:38371939	G/T	cg13010199	chr12:38710504	ALG10B	-0.5	-6.05	-0.37	5.82e-9	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs240764	0.817	rs239237	chr6:101094940	A/G	cg09795085	chr6:101329169	ASCC3	0.44	5.71	0.35	3.39e-8	Neuroticism;
SARC	cis	rs7769051	1.000	rs3813347	chr6:133119778	G/A	cg22852734	chr6:133119734	C6orf192	1.06	10.38	0.56	5.41e-21	Type 2 diabetes nephropathy;
SARC	cis	rs7659604	0.643	rs6839375	chr4:122663610	G/C	cg19748678	chr4:122722346	EXOSC9	0.44	4.97	0.31	1.28e-6	Type 2 diabetes;
SARC	cis	rs5753618	0.561	rs737887	chr22:31696615	A/G	cg02404636	chr22:31891804	SFI1	-0.49	-5.2	-0.32	4.27e-7	Colorectal cancer;
SARC	cis	rs698833	0.886	rs17580226	chr2:44570776	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.7	9.17	0.51	2.6e-17	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs4664308	0.905	rs62175518	chr2:160915149	C/T	cg03641300	chr2:160917029	PLA2R1	-0.64	-8.78	-0.5	3.59e-16	Idiopathic membranous nephropathy;
SARC	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg22875332	chr1:76189707	ACADM	0.41	5.36	0.33	1.98e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2153535	0.580	rs1932280	chr6:8473654	G/A	cg07606381	chr6:8435919	SLC35B3	0.76	10.88	0.58	1.42e-22	Motion sickness;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg03325406	chr16:74641227	GLG1	0.48	6.33	0.38	1.28e-9	Chemerin levels;
SARC	cis	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg15145296	chr3:125709740	NA	-0.51	-4.95	-0.31	1.44e-6	Blood pressure (smoking interaction);
SARC	cis	rs9487051	0.639	rs2884012	chr6:109598221	C/T	cg01475377	chr6:109611718	NA	-0.35	-5.08	-0.32	7.8e-7	Reticulocyte fraction of red cells;
SARC	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg02461776	chr11:598696	PHRF1	0.48	5.24	0.32	3.61e-7	Systemic lupus erythematosus;
SARC	cis	rs34779708	0.931	rs2384283	chr10:35326789	G/A	cg03585969	chr10:35415529	CREM	0.41	5.11	0.32	6.57e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs5850	0.557	rs10270788	chr7:23189000	T/C	cg23682824	chr7:23144976	KLHL7	0.71	9.28	0.52	1.23e-17	Blood protein levels;
SARC	cis	rs210138	1.000	rs210144	chr6:33547430	G/A	cg24505687	chr6:33548425	BAK1	0.44	5.14	0.32	5.94e-7	Testicular germ cell tumor;
SARC	cis	rs7552404	0.889	rs2211080	chr1:76243438	G/A	cg10523679	chr1:76189770	ACADM	0.47	6.13	0.37	3.67e-9	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.12	26.16	0.86	2.82e-71	Chronic sinus infection;
SARC	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg00339695	chr16:24857497	SLC5A11	0.41	5.84	0.36	1.77e-8	Intelligence (multi-trait analysis);
SARC	cis	rs1371867	0.846	rs1660353	chr8:101250907	C/T	cg11906718	chr8:101322791	RNF19A	-0.66	-8.59	-0.49	1.26e-15	Atrioventricular conduction;
SARC	cis	rs2070488	1.000	rs3792528	chr3:38493303	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.88	14.52	0.69	1.91e-34	Electrocardiographic conduction measures;
SARC	cis	rs2425143	1.000	rs6060524	chr20:34221155	G/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.06	0.31	8.38e-7	Blood protein levels;
SARC	trans	rs1814175	0.645	rs10128731	chr11:50023554	G/T	cg15704280	chr7:45808275	SEPT13	-0.91	-14.68	-0.69	5.63e-35	Height;
SARC	cis	rs6696846	0.749	rs11578293	chr1:205070178	T/C	cg07972983	chr1:205091412	RBBP5	0.57	7.14	0.42	1.18e-11	Red blood cell count;
SARC	cis	rs10883723	0.810	rs2296581	chr10:104242886	G/A	ch.10.2196322F	chr10:104248062	ACTR1A	0.56	7.27	0.43	5.41e-12	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs4971059	0.654	rs4971078	chr1:155129023	A/G	cg22049894	chr1:155113146	DPM3	0.4	4.99	0.31	1.18e-6	Breast cancer;
SARC	cis	rs7714584	1.000	rs61270113	chr5:150226263	G/A	cg22134413	chr5:150180641	NA	0.78	6.56	0.39	3.42e-10	Crohn's disease;
SARC	cis	rs595982	0.702	rs638050	chr19:49375676	A/G	cg03707168	chr19:49379127	PPP1R15A	0.45	6.07	0.37	5.18e-9	Red cell distribution width;
SARC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg06873352	chr17:61820015	STRADA	0.46	5.87	0.36	1.46e-8	Prudent dietary pattern;
SARC	cis	rs11764590	0.694	rs6461115	chr7:2103668	A/G	cg21782813	chr7:2030301	MAD1L1	-0.37	-5.36	-0.33	2.05e-7	Neuroticism;
SARC	cis	rs7786808	0.707	rs11770299	chr7:158228822	G/A	cg01191920	chr7:158217561	PTPRN2	-0.42	-7.95	-0.46	8.22e-14	Obesity-related traits;
SARC	trans	rs11098499	0.863	rs13140409	chr4:120503460	A/G	cg25214090	chr10:38739885	LOC399744	0.57	7.25	0.43	6.27e-12	Corneal astigmatism;
SARC	cis	rs5753618	0.504	rs5753671	chr22:31910734	T/C	cg02404636	chr22:31891804	SFI1	0.54	5.94	0.36	1.04e-8	Colorectal cancer;
SARC	cis	rs11997175	0.545	rs67960786	chr8:33668770	G/A	ch.8.33884649F	chr8:33765107	NA	0.48	6.07	0.37	5.27e-9	Body mass index;
SARC	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg15556689	chr8:8085844	FLJ10661	-0.41	-5.17	-0.32	5.07e-7	Mood instability;
SARC	cis	rs9513627	0.915	rs73556174	chr13:100121797	T/C	cg25919922	chr13:100150906	NA	-0.7	-5.26	-0.33	3.26e-7	Obesity-related traits;
SARC	cis	rs11625487	0.505	rs10145609	chr14:77957377	G/A	cg16049707	chr14:77965284	ISM2	-0.48	-6.32	-0.38	1.28e-9	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
SARC	cis	rs6912958	0.559	rs499373	chr6:88042062	A/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.76	11.3	0.59	6.84e-24	Monocyte percentage of white cells;
SARC	cis	rs703842	0.642	rs10876994	chr12:58064737	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.75	8.74	0.5	4.72e-16	Multiple sclerosis;
SARC	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg18357526	chr6:26021779	HIST1H4A	0.48	6.07	0.37	5.22e-9	Blood metabolite levels;
SARC	cis	rs2153535	0.580	rs7755284	chr6:8457479	T/C	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.04e-14	Motion sickness;
SARC	cis	rs9815354	1.000	rs9830469	chr3:41762535	A/G	cg03022575	chr3:42003672	ULK4	0.56	5.25	0.33	3.41e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs826838	1.000	rs826851	chr12:39112639	A/G	cg13010199	chr12:38710504	ALG10B	-0.68	-9.42	-0.53	4.58e-18	Heart rate;
SARC	cis	rs5769765	0.865	rs4824108	chr22:50271428	A/G	cg03033257	chr22:50311977	ALG12;CRELD2	-0.54	-5.64	-0.35	4.81e-8	Schizophrenia;
SARC	cis	rs4970966	1.000	rs4970966	chr1:150584103	A/C	cg13175981	chr1:150552382	MCL1	-0.49	-5.08	-0.32	7.8e-7	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
SARC	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg17971929	chr21:40555470	PSMG1	1.0	14.01	0.68	9.02e-33	Cognitive function;
SARC	cis	rs3136441	1.000	rs7941964	chr11:46805575	G/A	cg25783544	chr11:47291846	MADD	-0.57	-4.79	-0.3	3e-6	HDL cholesterol;
SARC	trans	rs9650657	0.707	rs4593498	chr8:10655470	C/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.41	-0.39	7.99e-10	Neuroticism;
SARC	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg02951883	chr7:2050386	MAD1L1	-0.46	-5.83	-0.36	1.82e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg10862848	chr6:42927986	GNMT	-0.4	-6.47	-0.39	5.74e-10	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg06221963	chr1:154839813	KCNN3	-0.48	-7.52	-0.44	1.19e-12	Prostate cancer;
SARC	cis	rs4925166	1	rs4925166	chr17:18210810	T/G	cg04261877	chr17:18218829	SMCR8;TOP3A	0.38	4.93	0.31	1.55e-6	Multiple sclerosis;
SARC	cis	rs933688	1.000	rs985434	chr5:90744509	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	12.57	0.64	5.35e-28	Smoking behavior;
SARC	cis	rs546131	0.928	rs499183	chr11:34836678	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.42	5.19	0.32	4.48e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg03060546	chr3:49711283	APEH	0.68	7.26	0.43	5.89e-12	Menarche (age at onset);
SARC	cis	rs12971120	0.891	rs12968731	chr18:72169708	G/T	cg26446133	chr18:72167187	CNDP2	-0.5	-7.12	-0.42	1.36e-11	Refractive error;
SARC	cis	rs818427	1.000	rs151977	chr5:112234549	A/T	cg07820702	chr5:112228657	REEP5	-0.47	-5.26	-0.33	3.2e-7	Total body bone mineral density;
SARC	cis	rs7555523	0.830	rs6426936	chr1:165684707	C/T	cg24409356	chr1:165738333	TMCO1	-0.83	-5.63	-0.35	5.08e-8	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	cis	rs6429082	0.791	rs291394	chr1:235651682	A/G	cg26050004	chr1:235667680	B3GALNT2	0.64	7.41	0.44	2.26e-12	Adiposity;
SARC	cis	rs7659604	0.605	rs1396080	chr4:122740454	T/G	cg19671926	chr4:122722719	EXOSC9	-0.65	-7.66	-0.45	4.95e-13	Type 2 diabetes;
SARC	cis	rs6450176	0.633	rs617777	chr5:53330440	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.56	-6.43	-0.39	6.98e-10	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs67460515	0.563	rs16831981	chr3:160897780	T/C	cg04691961	chr3:161091175	C3orf57	-0.42	-5.13	-0.32	6.13e-7	Parkinson's disease;
SARC	cis	rs950027	0.549	rs9920634	chr15:45596546	G/T	cg15395560	chr15:45543142	SLC28A2	0.3	5.43	0.33	1.43e-7	Response to fenofibrate (adiponectin levels);
SARC	cis	rs3733585	0.577	rs5014939	chr4:9953253	T/A	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.94	-0.36	1.06e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg06618935	chr21:46677482	NA	0.38	4.95	0.31	1.42e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs10779751	0.734	rs2259886	chr1:11137778	C/T	cg04508216	chr1:11107452	MASP2	0.34	4.83	0.3	2.45e-6	Body mass index;
SARC	cis	rs9326248	0.773	rs1060211	chr11:117039797	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.55	5.44	0.34	1.35e-7	Blood protein levels;
SARC	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg10523679	chr1:76189770	ACADM	-0.43	-5.28	-0.33	2.94e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.45	5.21	0.32	4.15e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs3820928	1.000	rs4675119	chr2:227774635	A/C	cg05526886	chr2:227700861	RHBDD1	-0.5	-6.14	-0.37	3.62e-9	Pulmonary function;
SARC	cis	rs10782582	0.609	rs1630587	chr1:76399787	T/C	cg10523679	chr1:76189770	ACADM	-0.41	-5.12	-0.32	6.51e-7	Daytime sleep phenotypes;
SARC	cis	rs2115630	1.000	rs2115630	chr15:85364516	C/T	cg12501888	chr15:85177176	SCAND2	-0.48	-6.05	-0.37	5.59e-9	P wave terminal force;
SARC	cis	rs6772849	1.000	rs2712373	chr3:128308055	T/C	cg08795948	chr3:128337044	NA	0.37	4.88	0.3	1.96e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs8141529	0.702	rs5762870	chr22:29261159	C/T	cg02153584	chr22:29168773	CCDC117	0.78	11.54	0.6	1.15e-24	Lymphocyte counts;
SARC	cis	rs2795502	0.630	rs1271547	chr10:43507665	C/T	cg08461752	chr10:43522343	NA	-0.43	-4.78	-0.3	3.08e-6	Blood protein levels;
SARC	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg19223190	chr17:80058835	NA	0.45	6.32	0.38	1.33e-9	Life satisfaction;
SARC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg11494091	chr17:61959527	GH2	0.54	8.07	0.47	3.81e-14	Prudent dietary pattern;
SARC	cis	rs6963495	0.818	rs115609508	chr7:105163716	C/A	cg19920283	chr7:105172520	RINT1	0.65	5.48	0.34	1.09e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs7191439	0.657	rs3826076	chr16:88780518	C/T	cg27087555	chr16:88793112	FAM38A	0.82	6.67	0.4	1.82e-10	Plateletcrit;
SARC	cis	rs72720396	0.789	rs12048450	chr1:91199660	G/A	cg13456504	chr1:91191583	NA	0.35	5.13	0.32	6.14e-7	Morning vs. evening chronotype;Chronotype;
SARC	cis	rs920590	0.560	rs3758061	chr8:19674033	C/T	cg03894339	chr8:19674705	INTS10	-0.48	-5.6	-0.34	6.03e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs4919694	1.000	rs12241091	chr10:104808997	G/A	cg04362960	chr10:104952993	NT5C2	0.65	5.56	0.34	7.45e-8	Arsenic metabolism;
SARC	cis	rs7208859	0.673	rs2269916	chr17:29233763	A/G	cg13385521	chr17:29058706	SUZ12P	0.85	7.23	0.43	7.08e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9303401	0.659	rs1864754	chr17:56688789	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	-1.05	-11.76	-0.61	2.22e-25	Cognitive test performance;
SARC	cis	rs2832191	0.716	rs1543652	chr21:30448000	G/C	cg08807101	chr21:30365312	RNF160	0.89	13.3	0.66	2.15e-30	Dental caries;
SARC	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg22535103	chr8:58192502	C8orf71	-0.59	-6.21	-0.38	2.35e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs9395865	0.520	rs6903708	chr6:53332940	A/G	cg23811540	chr1:11741690	MAD2L2	-0.49	-6.27	-0.38	1.72e-9	Electroencephalographic traits in alcoholism;
SARC	cis	rs17270561	0.609	rs12529272	chr6:25731342	A/G	cg17691542	chr6:26056736	HIST1H1C	0.57	7.04	0.42	2.14e-11	Iron status biomarkers;
SARC	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg09699651	chr6:150184138	LRP11	0.39	4.86	0.3	2.13e-6	Lung cancer;
SARC	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg24829409	chr8:58192753	C8orf71	-0.64	-6.14	-0.37	3.5e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7524258	0.868	rs2157499	chr1:7271472	C/T	cg07173049	chr1:7289937	CAMTA1	0.35	6.8	0.41	8.52e-11	Tourette's syndrome or obsessive-compulsive disorder;
SARC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg06873352	chr17:61820015	STRADA	0.53	6.83	0.41	7.23e-11	Prudent dietary pattern;
SARC	cis	rs7647973	0.580	rs12637576	chr3:49237334	C/T	cg06212747	chr3:49208901	KLHDC8B	0.73	10.34	0.56	7.38e-21	Menarche (age at onset);
SARC	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg11987759	chr7:65425863	GUSB	-0.43	-5.26	-0.33	3.32e-7	Aortic root size;
SARC	cis	rs1865760	0.566	rs2794720	chr6:26087202	G/C	cg18357526	chr6:26021779	HIST1H4A	0.41	4.98	0.31	1.23e-6	Height;
SARC	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg16325326	chr1:53192061	ZYG11B	-0.8	-12.67	-0.64	2.5e-28	Monocyte count;
SARC	cis	rs6963495	0.818	rs1721500	chr7:105219233	T/G	cg19920283	chr7:105172520	RINT1	0.66	5.77	0.35	2.52e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.56	-0.39	3.45e-10	Menopause (age at onset);
SARC	cis	rs4144743	0.759	rs4289057	chr17:45321030	G/A	cg18085866	chr17:45331354	ITGB3	-0.77	-6.89	-0.41	5.08e-11	Body mass index;
SARC	cis	rs9868809	0.505	rs28793701	chr3:48762683	C/G	cg00383909	chr3:49044727	WDR6	0.69	6.44	0.39	6.82e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	trans	rs1488902	0.796	rs12786451	chr11:89275028	C/T	cg18477666	chr7:43210461	HECW1	0.41	6.43	0.39	7.06e-10	Amyotrophic lateral sclerosis;
SARC	cis	rs3820928	0.605	rs6748311	chr2:227792530	T/A	cg11843606	chr2:227700838	RHBDD1	-0.55	-7.37	-0.43	2.96e-12	Pulmonary function;
SARC	cis	rs708547	0.533	rs3806746	chr4:57773330	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.52	-5.86	-0.36	1.54e-8	Response to bleomycin (chromatid breaks);
SARC	cis	rs7520050	0.807	rs3013595	chr1:46153203	G/A	cg06784218	chr1:46089804	CCDC17	0.26	4.76	0.3	3.42e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs9640161	0.702	rs3735175	chr7:150020457	C/T	cg21361702	chr7:150065534	REPIN1	0.5	5.14	0.32	5.95e-7	Blood protein levels;Circulating chemerin levels;
SARC	trans	rs643955	0.609	rs13259465	chr8:9982953	C/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.27	-0.43	5.29e-12	Systemic lupus erythematosus;
SARC	cis	rs4974559	0.948	rs3856982	chr4:1328863	C/T	cg02980000	chr4:1222292	CTBP1	-0.6	-6.03	-0.37	6.22e-9	Systolic blood pressure;
SARC	cis	rs9747201	0.894	rs4503854	chr17:80178696	A/T	cg09264619	chr17:80180166	NA	-0.57	-6.29	-0.38	1.52e-9	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs9815354	0.953	rs1717034	chr3:41955913	A/G	cg03022575	chr3:42003672	ULK4	-0.55	-5.27	-0.33	3.16e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2315504	0.626	rs757272	chr17:39003217	A/G	cg05063374	chr17:38953512	KRT28	0.27	4.9	0.31	1.83e-6	Height;
SARC	cis	rs10870270	0.913	rs115236491	chr10:133766855	T/G	cg08754478	chr10:133766260	PPP2R2D	-0.48	-5.51	-0.34	9.46e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs4919694	0.572	rs12255989	chr10:104867206	C/T	cg04362960	chr10:104952993	NT5C2	0.55	4.98	0.31	1.26e-6	Arsenic metabolism;
SARC	cis	rs12421382	0.659	rs35527696	chr11:109379944	T/A	cg27471124	chr11:109292789	C11orf87	0.36	5.04	0.31	9.21e-7	Schizophrenia;
SARC	cis	rs2180341	1.000	rs6569482	chr6:127631371	C/T	cg24812749	chr6:127587940	RNF146	0.97	12.89	0.65	4.63e-29	Breast cancer;
SARC	cis	rs6121246	0.559	rs6121038	chr20:30254773	T/G	cg13852791	chr20:30311386	BCL2L1	0.87	10.9	0.58	1.3e-22	Mean corpuscular hemoglobin;
SARC	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg25072359	chr17:41440525	NA	0.51	6.13	0.37	3.72e-9	Menopause (age at onset);
SARC	cis	rs4765905	0.610	rs4765669	chr12:2313111	A/G	cg10668781	chr12:2307325	CACNA1C	-0.31	-4.87	-0.3	2.08e-6	Schizophrenia;
SARC	cis	rs34172651	0.617	rs9922436	chr16:24704490	C/G	cg00339695	chr16:24857497	SLC5A11	0.43	5.96	0.36	9.17e-9	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg12463550	chr7:65579703	CRCP	0.65	4.92	0.31	1.65e-6	Diabetic kidney disease;
SARC	cis	rs6570726	0.846	rs1935616	chr6:145943512	C/T	cg05347473	chr6:146136440	FBXO30	0.51	7.13	0.42	1.25e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs72781680	1.000	rs72788280	chr2:24095907	A/G	cg08917208	chr2:24149416	ATAD2B	0.76	7.49	0.44	1.42e-12	Lymphocyte counts;
SARC	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg12310025	chr6:25882481	NA	-0.63	-7.71	-0.45	3.7e-13	Intelligence (multi-trait analysis);
SARC	trans	rs6671200	0.667	rs79658099	chr1:95417389	T/C	cg26944562	chr10:38070165	NA	0.73	6.33	0.38	1.25e-9	Stearic acid (18:0) levels;
SARC	cis	rs1712790	0.729	rs7123330	chr11:114615037	C/T	cg01161204	chr11:115530932	NA	-0.33	-5.03	-0.31	9.74e-7	Urinary albumin excretion;
SARC	cis	rs7264396	0.623	rs11698601	chr20:34205035	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	5.39	0.33	1.74e-7	Total cholesterol levels;
SARC	cis	rs9815354	0.812	rs111277902	chr3:41950312	C/T	cg03022575	chr3:42003672	ULK4	0.7	5.7	0.35	3.66e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs11155671	0.530	rs2342767	chr6:150209717	C/G	cg00933542	chr6:150070202	PCMT1	0.29	4.81	0.3	2.77e-6	Testicular germ cell tumor;
SARC	cis	rs950776	0.518	rs12906951	chr15:78825562	C/T	cg17108064	chr15:78857060	CHRNA5	0.29	4.93	0.31	1.56e-6	Sudden cardiac arrest;
SARC	cis	rs9929218	0.817	rs3114402	chr16:68719607	C/T	cg02972257	chr16:68554789	NA	0.41	4.78	0.3	3.1e-6	Colorectal cancer;
SARC	cis	rs60871478	1.000	rs4720930	chr7:808073	G/A	cg05535760	chr7:792225	HEATR2	0.79	8.17	0.47	1.91e-14	Cerebrospinal P-tau181p levels;
SARC	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg05313129	chr8:58192883	C8orf71	-0.62	-6.34	-0.38	1.18e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2070488	0.965	rs2366123	chr3:38493153	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	14.64	0.69	7.76e-35	Electrocardiographic conduction measures;
SARC	cis	rs7264396	0.580	rs6060648	chr20:34456704	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.55	5.24	0.32	3.64e-7	Total cholesterol levels;
SARC	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg06074448	chr4:187884817	NA	0.43	5.76	0.35	2.65e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs80282103	0.867	rs12241632	chr10:1069070	A/T	cg08668510	chr10:1095578	IDI1	0.91	7.12	0.42	1.31e-11	Glomerular filtration rate (creatinine);
SARC	trans	rs66573146	1.000	rs7686186	chr4:6986094	C/T	cg07817883	chr1:32538562	TMEM39B	1.52	9.1	0.51	4.22e-17	Granulocyte percentage of myeloid white cells;
SARC	cis	rs2120019	1.000	rs7175720	chr15:75348962	C/G	cg00629941	chr15:75287862	SCAMP5	0.62	7.32	0.43	4.11e-12	Blood trace element (Zn levels);
SARC	cis	rs9902453	0.765	rs2264302	chr17:28057095	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.54	-7.09	-0.42	1.61e-11	Coffee consumption (cups per day);
SARC	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg02725872	chr8:58115012	NA	-0.34	-5.37	-0.33	1.91e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10193935	0.901	rs2088281	chr2:42672731	A/G	cg27598129	chr2:42591480	NA	0.38	5.25	0.33	3.42e-7	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6831352	0.918	rs7689753	chr4:100055575	A/G	cg13256891	chr4:100009986	ADH5	-0.64	-8.0	-0.46	5.7e-14	Alcohol dependence;
SARC	cis	rs6456156	0.586	rs2001114	chr6:167486578	A/G	cg23791538	chr6:167370224	RNASET2	-0.56	-7.3	-0.43	4.38e-12	Primary biliary cholangitis;
SARC	cis	rs1707322	0.721	rs10789470	chr1:46158331	T/G	cg06784218	chr1:46089804	CCDC17	0.36	6.17	0.37	2.95e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs875971	0.830	rs427973	chr7:65526648	C/A	cg12463550	chr7:65579703	CRCP	0.42	4.89	0.31	1.86e-6	Aortic root size;
SARC	cis	rs7208859	0.623	rs9895785	chr17:29107708	C/T	cg13385521	chr17:29058706	SUZ12P	-0.92	-7.51	-0.44	1.29e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs910316	0.726	rs175040	chr14:75469555	A/G	cg08847533	chr14:75593920	NEK9	-0.86	-13.01	-0.65	1.82e-29	Height;
SARC	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg02733842	chr7:1102375	C7orf50	-0.62	-7.21	-0.43	7.71e-12	Bronchopulmonary dysplasia;
SARC	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg18876405	chr7:65276391	NA	-0.71	-9.01	-0.51	7.47e-17	Aortic root size;
SARC	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg20607798	chr8:58055168	NA	0.59	5.33	0.33	2.27e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7474896	0.616	rs2505239	chr10:38440765	A/G	cg00409905	chr10:38381863	ZNF37A	-0.54	-5.25	-0.33	3.46e-7	Obesity (extreme);
SARC	cis	rs4642101	0.737	rs6767504	chr3:12826667	C/T	cg05775895	chr3:12838266	CAND2	0.76	12.23	0.63	6.53e-27	QRS complex (12-leadsum);
SARC	cis	rs7100689	0.577	rs2236569	chr10:82043576	G/A	cg01528321	chr10:82214614	TSPAN14	0.64	8.03	0.47	4.71e-14	Post bronchodilator FEV1;
SARC	cis	rs8067354	0.645	rs56236317	chr17:57822125	C/T	cg02344993	chr17:57696989	CLTC	0.65	6.69	0.4	1.61e-10	Hemoglobin concentration;
SARC	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg05896524	chr21:47604654	C21orf56	-0.54	-6.49	-0.39	5.2400000000000005e-10	Testicular germ cell tumor;
SARC	cis	rs7582180	0.629	rs2164847	chr2:100958715	C/T	cg14675211	chr2:100938903	LONRF2	0.51	7.51	0.44	1.24e-12	Intelligence (multi-trait analysis);
SARC	cis	rs6570726	0.967	rs1396648	chr6:145785248	C/A	cg23711669	chr6:146136114	FBXO30	-0.71	-10.61	-0.57	1.07e-21	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs5997397	0.720	rs132549	chr22:29318724	C/T	cg02153584	chr22:29168773	CCDC117	-0.58	-7.79	-0.45	2.16e-13	Red cell distribution width;
SARC	cis	rs2439831	0.717	rs9806227	chr15:43680115	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.78	8.26	0.48	1.12e-14	Lung cancer in ever smokers;
SARC	cis	rs6582630	0.502	rs10880450	chr12:38440294	G/C	cg26384229	chr12:38710491	ALG10B	0.83	11.1	0.59	2.93e-23	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs4742903	0.935	rs975253	chr9:106928260	G/C	cg14250997	chr9:106856677	SMC2	0.44	5.47	0.34	1.17e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs2180341	0.814	rs9385424	chr6:127726796	A/G	cg27446573	chr6:127587934	RNF146	0.8	10.39	0.56	4.87e-21	Breast cancer;
SARC	cis	rs9868809	0.505	rs11706203	chr3:48746239	T/A	cg06212747	chr3:49208901	KLHDC8B	-0.55	-5.05	-0.31	8.91e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs9326248	0.689	rs4516002	chr11:116999059	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.58	5.57	0.34	6.88e-8	Blood protein levels;
SARC	cis	rs11792861	0.591	rs7044275	chr9:111717138	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.78	9.98	0.55	9.48e-20	Menarche (age at onset);
SARC	cis	rs2295359	1.000	rs11209007	chr1:67619345	C/G	cg12940439	chr1:67600707	NA	0.43	6.65	0.4	2.04e-10	Psoriasis;
SARC	cis	rs8064024	0.513	rs1049207	chr16:4934564	C/G	cg08329684	chr16:4932620	PPL	-0.45	-7.12	-0.42	1.36e-11	Cancer;
SARC	cis	rs11724804	0.532	rs7657611	chr4:880558	G/C	cg20916646	chr4:852691	GAK	0.55	6.96	0.42	3.33e-11	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
SARC	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg00825309	chr19:58991885	ZNF446	-0.57	-8.08	-0.47	3.6e-14	Uric acid clearance;
SARC	cis	rs10782582	0.609	rs1770882	chr1:76411549	G/A	cg10523679	chr1:76189770	ACADM	-0.44	-5.38	-0.33	1.79e-7	Daytime sleep phenotypes;
SARC	cis	rs6964587	1.000	rs7784248	chr7:91758111	A/G	cg17063962	chr7:91808500	NA	0.94	15.71	0.72	2.1e-38	Breast cancer;
SARC	cis	rs12369179	1.000	rs12369179	chr12:122963550	C/T	cg18578876	chr12:123200353	GPR109B	-0.89	-6.56	-0.39	3.41e-10	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;
SARC	cis	rs861020	0.606	rs627459	chr1:210004682	C/G	cg05527609	chr1:210001259	C1orf107	0.78	10.12	0.55	3.37e-20	Orofacial clefts;
SARC	cis	rs709400	0.604	rs7158144	chr14:103887615	A/G	cg12935359	chr14:103987150	CKB	-0.4	-5.88	-0.36	1.4e-8	Body mass index;
SARC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg14159672	chr1:205819179	PM20D1	0.86	14.62	0.69	8.7e-35	Menarche (age at onset);
SARC	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.51	6.63	0.4	2.25e-10	Personality dimensions;
SARC	cis	rs4595586	0.525	rs2892450	chr12:39363678	G/A	cg26384229	chr12:38710491	ALG10B	0.51	6.25	0.38	1.93e-9	Morning vs. evening chronotype;
SARC	cis	rs6087990	0.735	rs6058892	chr20:31388461	C/T	cg13636640	chr20:31349939	DNMT3B	0.76	11.72	0.61	3.07e-25	Ulcerative colitis;
SARC	cis	rs1949733	0.523	rs4619877	chr4:8543235	G/A	cg11789530	chr4:8429930	ACOX3	-0.71	-8.05	-0.47	4.31e-14	Response to antineoplastic agents;
SARC	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg21171335	chr12:122356390	WDR66	0.48	7.58	0.44	8.32e-13	Mean corpuscular volume;
SARC	cis	rs7011049	0.915	rs11997706	chr8:53833202	T/G	cg26025543	chr8:53854495	NA	0.61	5.6	0.34	5.94e-8	Systolic blood pressure;
SARC	cis	rs7481584	0.624	rs412842	chr11:3047448	A/G	cg05729581	chr11:3078854	CARS	0.57	7.42	0.44	2.13e-12	Calcium levels;
SARC	cis	rs9788721	1.000	rs8031948	chr15:78816057	G/T	cg18825076	chr15:78729989	IREB2	-0.4	-4.76	-0.3	3.35e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs6570726	0.935	rs367612	chr6:145828987	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.47	0.39	5.7e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10911232	0.560	rs6697320	chr1:183037377	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.64	8.83	0.5	2.64e-16	Hypertriglyceridemia;
SARC	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	12.08	0.62	2.03e-26	Platelet count;
SARC	cis	rs854765	0.520	rs9899355	chr17:17898243	C/T	cg04398451	chr17:18023971	MYO15A	-0.46	-6.34	-0.38	1.16e-9	Total body bone mineral density;
SARC	cis	rs9486719	1.000	rs2273622	chr6:97058567	A/G	cg06623918	chr6:96969491	KIAA0776	-0.75	-7.95	-0.46	7.94e-14	Migraine;Coronary artery disease;
SARC	cis	rs4481887	0.927	rs4517383	chr1:248426484	C/T	cg01631408	chr1:248437212	OR2T33	-0.42	-5.3	-0.33	2.74e-7	Common traits (Other);
SARC	cis	rs11874712	0.899	rs11664764	chr18:43675364	T/C	cg25174615	chr18:43684699	ATP5A1;HAUS1	0.4	4.77	0.3	3.31e-6	Migraine - clinic-based;
SARC	cis	rs10911232	0.507	rs10911206	chr1:183012423	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.44	0.56	3.45e-21	Hypertriglyceridemia;
SARC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	11.99	0.62	3.96e-26	Platelet count;
SARC	cis	rs7914558	0.966	rs10786724	chr10:104668942	A/G	cg04362960	chr10:104952993	NT5C2	0.41	4.91	0.31	1.73e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs7520050	0.966	rs4660910	chr1:46548402	G/T	cg24296786	chr1:45957014	TESK2	0.38	4.82	0.3	2.56e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs6840360	1.000	rs1366909	chr4:152588421	A/C	cg22705602	chr4:152727874	NA	-0.36	-6.21	-0.38	2.45e-9	Intelligence (multi-trait analysis);
SARC	cis	rs751728	1.000	rs4711351	chr6:33754592	G/A	cg25922239	chr6:33757077	LEMD2	0.77	10.25	0.56	1.35e-20	Crohn's disease;
SARC	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg12463550	chr7:65579703	CRCP	0.51	5.74	0.35	2.94e-8	Aortic root size;
SARC	cis	rs4443100	0.958	rs5996459	chr22:23391131	G/A	cg14186256	chr22:23484241	RTDR1	0.47	5.12	0.32	6.42e-7	Serum parathyroid hormone levels;
SARC	trans	rs11098499	1.000	rs58601355	chr4:120186367	T/C	cg25214090	chr10:38739885	LOC399744	0.54	7.02	0.42	2.45e-11	Corneal astigmatism;
SARC	cis	rs796364	0.755	rs203762	chr2:200905136	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.69	-5.65	-0.35	4.63e-8	Schizophrenia;
SARC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.04	0.37	6.05e-9	Prudent dietary pattern;
SARC	cis	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg00071950	chr4:10020882	SLC2A9	0.39	6.31	0.38	1.4e-9	Bone mineral density;
SARC	cis	rs765787	0.530	rs4270107	chr15:45535350	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.67e-7	Uric acid levels;
SARC	cis	rs6964587	1.000	rs2097739	chr7:91711466	C/T	cg17063962	chr7:91808500	NA	0.96	16.21	0.73	4.33e-40	Breast cancer;
SARC	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg19748678	chr4:122722346	EXOSC9	0.76	9.69	0.54	7.21e-19	Type 2 diabetes;
SARC	cis	rs9733	0.596	rs12089989	chr1:150715782	G/A	cg15448220	chr1:150897856	SETDB1	0.48	6.42	0.39	7.68e-10	Tonsillectomy;
SARC	cis	rs12586317	0.508	rs10134914	chr14:35425012	T/G	cg26967526	chr14:35346199	BAZ1A	-0.64	-7.51	-0.44	1.23e-12	Psoriasis;
SARC	cis	rs17376456	0.825	rs28645862	chr5:93233128	G/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.7	0.35	3.54e-8	Diabetic retinopathy;
SARC	cis	rs6429082	0.623	rs7547849	chr1:235564254	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.59	-7.94	-0.46	8.33e-14	Adiposity;
SARC	cis	rs858239	0.539	rs4294098	chr7:23185995	G/A	cg23682824	chr7:23144976	KLHL7	0.72	9.31	0.52	9.94e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.59	5.18	0.32	4.85e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs1707322	1.000	rs785469	chr1:46521091	C/T	cg06784218	chr1:46089804	CCDC17	-0.37	-6.57	-0.4	3.18e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.69	0.54	6.99e-19	Prudent dietary pattern;
SARC	cis	rs1549118	0.560	rs11848126	chr14:78318268	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	-0.48	-4.98	-0.31	1.23e-6	Resting heart rate;
SARC	cis	rs1865760	0.713	rs6928951	chr6:25995554	C/T	cg17691542	chr6:26056736	HIST1H1C	0.51	6.57	0.4	3.2e-10	Height;
SARC	cis	rs7624766	0.709	rs7642371	chr3:160493607	C/G	cg22637730	chr3:160473554	PPM1L	0.44	5.76	0.35	2.63e-8	Response to methotrexate in rheumatoid arthritis;
SARC	cis	rs854765	0.552	rs6502624	chr17:17847936	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	9.48	0.53	3.03e-18	Total body bone mineral density;
SARC	cis	rs708547	0.874	rs73242624	chr4:57847420	C/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.45	-4.94	-0.31	1.49e-6	Response to bleomycin (chromatid breaks);
SARC	cis	rs6580649	0.941	rs11609399	chr12:48501161	A/T	cg05342945	chr12:48394962	COL2A1	0.53	5.82	0.36	1.91e-8	Lung cancer;
SARC	trans	rs2018683	0.834	rs733485	chr7:29026685	C/A	cg19402173	chr7:128379420	CALU	-0.69	-9.15	-0.51	2.87e-17	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs73198271	0.641	rs34473848	chr8:8649837	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-5.58	-0.34	6.53e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs796364	1.000	rs796364	chr2:200716119	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.33	0.38	1.24e-9	Schizophrenia;
SARC	cis	rs13191362	0.872	rs73017702	chr6:163257695	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.63	6.05	0.37	5.69e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs344364	0.511	rs1657144	chr16:1963989	C/A	cg26617929	chr16:1858877	NA	-0.59	-4.91	-0.31	1.69e-6	Glomerular filtration rate in chronic kidney disease;
SARC	trans	rs7819412	0.502	rs4841499	chr8:10988138	A/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-6.77	-0.41	1.01e-10	Triglycerides;
SARC	trans	rs1635	0.655	rs2159275	chr6:28308446	G/A	cg08080395	chr15:65488966	CILP	0.63	6.3	0.38	1.48e-9	Schizophrenia;
SARC	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg11764359	chr7:65958608	NA	0.88	12.58	0.64	4.89e-28	Aortic root size;
SARC	cis	rs17376456	0.542	rs10070350	chr5:93103753	C/G	cg21475434	chr5:93447410	FAM172A	0.6	5.87	0.36	1.48e-8	Diabetic retinopathy;
SARC	cis	rs34779708	0.931	rs12776390	chr10:35391535	T/G	cg03585969	chr10:35415529	CREM	0.41	5.2	0.32	4.33e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs2153535	0.580	rs6902001	chr6:8477055	T/G	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg02463440	chr8:22132932	PIWIL2	0.45	6.44	0.39	6.81e-10	Hypertriglyceridemia;
SARC	trans	rs17038463	0.826	rs79646224	chr3:1402622	T/C	cg18003583	chr5:176819624	SLC34A1	0.99	6.29	0.38	1.56e-9	Neurocognitive impairment in HIV-1 infection (continuous);
SARC	cis	rs2425143	1.000	rs117010355	chr20:34343442	A/G	cg01084648	chr20:34329383	RBM39	0.63	4.94	0.31	1.49e-6	Blood protein levels;
SARC	cis	rs8114671	0.562	rs725521	chr20:33516071	T/C	cg08999081	chr20:33150536	PIGU	0.33	4.92	0.31	1.61e-6	Height;
SARC	cis	rs7566780	0.631	rs6531163	chr2:16674592	T/A	cg09580478	chr2:16689509	NA	0.45	6.06	0.37	5.48e-9	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg12463550	chr7:65579703	CRCP	-0.52	-5.56	-0.34	7.34e-8	Aortic root size;
SARC	cis	rs8044995	0.517	rs61593058	chr16:68384496	T/C	cg05110241	chr16:68378359	PRMT7	-0.43	-5.02	-0.31	1.04e-6	Schizophrenia;
SARC	cis	rs7044106	0.791	rs10985001	chr9:123484232	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	9.68	0.54	7.82e-19	Hip circumference adjusted for BMI;
SARC	cis	rs4919694	1.000	rs11191545	chr10:104829793	C/T	cg04362960	chr10:104952993	NT5C2	0.64	5.4	0.33	1.61e-7	Arsenic metabolism;
SARC	cis	rs1008375	1.000	rs60178264	chr4:17685308	G/T	cg27347728	chr4:17578864	LAP3	0.45	5.54	0.34	8.14e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs57046232	0.502	rs17794544	chr20:6460319	A/T	cg00270625	chr22:51017019	CPT1B;CHKB-CPT1B	0.6	6.59	0.4	2.86e-10	Colorectal cancer;
SARC	cis	rs7395581	0.877	rs10838691	chr11:47341729	T/C	cg25783544	chr11:47291846	MADD	0.47	5.27	0.33	3.05e-7	HDL cholesterol;
SARC	cis	rs2228479	0.850	rs62054638	chr16:89821131	G/C	cg26513180	chr16:89883248	FANCA	0.72	4.79	0.3	2.99e-6	Skin colour saturation;
SARC	cis	rs6866344	0.697	rs58549512	chr5:178133204	C/T	cg03877680	chr5:178157825	ZNF354A	1.03	12.73	0.64	1.59e-28	Neutrophil percentage of white cells;
SARC	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg24209194	chr3:40518798	ZNF619	0.67	8.08	0.47	3.58e-14	Renal cell carcinoma;
SARC	cis	rs6540556	0.954	rs10489342	chr1:209935778	A/G	cg23920097	chr1:209922102	NA	-0.62	-7.2	-0.43	8.36e-12	Red blood cell count;
SARC	cis	rs2288073	0.965	rs6545340	chr2:24422269	C/G	cg06627628	chr2:24431161	ITSN2	-0.65	-7.91	-0.46	1.03e-13	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs8114671	0.562	rs3818273	chr20:33509275	G/A	cg08999081	chr20:33150536	PIGU	0.33	4.91	0.31	1.72e-6	Height;
SARC	cis	rs4481887	0.741	rs28589987	chr1:248564785	T/C	cg13385794	chr1:248469461	NA	0.33	5.36	0.33	2.01e-7	Common traits (Other);
SARC	cis	rs6709815	0.841	rs12694442	chr2:219663599	T/C	cg02176678	chr2:219576539	TTLL4	-0.37	-5.62	-0.35	5.46e-8	Reticulocyte count;High light scatter reticulocyte count;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16132219	chr10:105992041	C10orf79	-0.56	-6.73	-0.4	1.32e-10	Fibrinogen levels;
SARC	cis	rs78487399	0.808	rs76851696	chr2:43746062	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.58	-4.78	-0.3	3.14e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg27211696	chr2:191398769	TMEM194B	0.51	7.06	0.42	1.95e-11	Pulse pressure;
SARC	cis	rs453301	0.571	rs2929456	chr8:9083416	G/A	cg06636001	chr8:8085503	FLJ10661	-0.7	-9.65	-0.53	9.73e-19	Joint mobility (Beighton score);
SARC	trans	rs61931739	0.963	rs1817759	chr12:34101521	G/A	cg26384229	chr12:38710491	ALG10B	-0.56	-6.81	-0.41	8.14e-11	Morning vs. evening chronotype;
SARC	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.5	5.96	0.36	9.48e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg23172400	chr8:95962367	TP53INP1	-0.34	-6.0	-0.37	7.62e-9	Type 2 diabetes;
SARC	trans	rs9329221	0.662	rs11249996	chr8:10245463	G/T	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.23	-0.38	2.15e-9	Neuroticism;
SARC	cis	rs11605924	0.692	rs877412	chr11:45897651	A/C	ch.11.939596F	chr11:45881766	CRY2	0.66	8.02	0.47	5e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs3818285	0.556	rs2084607	chr10:111681411	C/T	cg00817464	chr10:111662876	XPNPEP1	0.55	7.74	0.45	3.07e-13	Superior crus of antihelix expression;
SARC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.19	0.8	4.45e-53	Prudent dietary pattern;
SARC	cis	rs4423214	0.650	rs7940244	chr11:71221574	C/T	cg05163923	chr11:71159392	DHCR7	-0.62	-7.46	-0.44	1.68e-12	Vitamin D levels;
SARC	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg08392591	chr16:89556376	ANKRD11	-0.51	-7.17	-0.43	9.63e-12	Multiple myeloma (IgH translocation);
SARC	cis	rs7772486	0.875	rs56181683	chr6:146286620	A/G	cg05347473	chr6:146136440	FBXO30	-0.42	-5.72	-0.35	3.2e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs667920	0.500	rs34738913	chr3:136437884	T/A	cg15507776	chr3:136538369	TMEM22	-0.99	-8.4	-0.48	4.53e-15	Coronary artery disease;
SARC	cis	rs2834188	0.924	rs2409487	chr21:34684958	C/T	cg04842828	chr21:34696676	IFNAR1	0.42	5.07	0.32	8.05e-7	Narcolepsy;
SARC	cis	rs7959452	0.535	rs11615712	chr12:69619736	A/T	cg20891283	chr12:69753455	YEATS4	-0.37	-4.87	-0.3	2.07e-6	Blood protein levels;
SARC	cis	rs7312933	0.670	rs10880258	chr12:42547531	C/T	cg19980929	chr12:42632907	YAF2	0.44	5.99	0.37	7.71e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs2013441	1.000	rs2703792	chr17:20166950	G/A	cg13482628	chr17:19912719	NA	-0.47	-6.15	-0.37	3.29e-9	Obesity-related traits;
SARC	cis	rs2976388	0.609	rs2376491	chr8:143790934	G/A	cg06565975	chr8:143823917	SLURP1	0.32	5.54	0.34	7.97e-8	Urinary tract infection frequency;
SARC	cis	rs2153535	0.541	rs7774752	chr6:8468978	C/T	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs870825	0.616	rs3184982	chr4:185615768	T/G	cg04058563	chr4:185651563	MLF1IP	0.82	11.18	0.59	1.58e-23	Blood protein levels;
SARC	trans	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg08975724	chr8:8085496	FLJ10661	-0.54	-7.19	-0.43	8.86e-12	Neuroticism;
SARC	cis	rs4742903	0.935	rs3818626	chr9:106856633	C/T	cg14250997	chr9:106856677	SMC2	0.53	7.1	0.42	1.51e-11	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs9325144	0.560	rs2387923	chr12:38662677	G/A	cg13010199	chr12:38710504	ALG10B	-0.57	-7.44	-0.44	1.87e-12	Morning vs. evening chronotype;
SARC	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg12463550	chr7:65579703	CRCP	-0.46	-4.92	-0.31	1.63e-6	Aortic root size;
SARC	trans	rs1814175	0.645	rs4598671	chr11:50003191	C/A	cg03929089	chr4:120376271	NA	-0.82	-11.88	-0.61	9.03e-26	Height;
SARC	cis	rs986417	0.818	rs8014133	chr14:61104738	A/G	cg27398547	chr14:60952738	C14orf39	0.74	6.95	0.41	3.55e-11	Gut microbiota (bacterial taxa);
SARC	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg14829155	chr15:31115871	NA	0.48	5.87	0.36	1.46e-8	Huntington's disease progression;
SARC	cis	rs3772130	0.564	rs9817555	chr3:121406327	G/A	cg20356878	chr3:121714668	ILDR1	0.39	6.11	0.37	4.15e-9	Cognitive performance;
SARC	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	10.61	0.57	1.02e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9354308	0.868	rs4392709	chr6:66547178	G/A	cg07460842	chr6:66804631	NA	-0.45	-5.23	-0.32	3.77e-7	Metabolite levels;
SARC	cis	rs2834188	0.924	rs2834177	chr21:34676806	T/C	cg14352951	chr21:34696688	IFNAR1	0.44	5.4	0.33	1.61e-7	Narcolepsy;
SARC	cis	rs3820928	0.804	rs4675125	chr2:227802499	T/C	cg05526886	chr2:227700861	RHBDD1	-0.54	-6.65	-0.4	2.04e-10	Pulmonary function;
SARC	cis	rs9487051	0.714	rs6927569	chr6:109621494	T/C	cg01475377	chr6:109611718	NA	-0.38	-5.44	-0.34	1.34e-7	Reticulocyte fraction of red cells;
SARC	cis	rs7829975	0.667	rs1877119	chr8:8707197	C/G	cg15556689	chr8:8085844	FLJ10661	0.4	4.88	0.3	1.93e-6	Mood instability;
SARC	cis	rs870825	0.616	rs2310110	chr4:185647902	G/A	cg04058563	chr4:185651563	MLF1IP	0.8	11.35	0.6	4.56e-24	Blood protein levels;
SARC	cis	rs3087591	0.960	rs12949230	chr17:29461899	G/A	cg24425628	chr17:29625626	OMG;NF1	0.54	6.9	0.41	4.8e-11	Hip circumference;
SARC	cis	rs910316	0.967	rs4903285	chr14:75609268	A/T	cg06637938	chr14:75390232	RPS6KL1	0.5	7.14	0.42	1.17e-11	Height;
SARC	cis	rs6964587	1.000	rs6969536	chr7:91689351	C/G	cg17063962	chr7:91808500	NA	0.96	16.21	0.73	4.33e-40	Breast cancer;
SARC	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg24675658	chr1:53192096	ZYG11B	-0.56	-7.88	-0.46	1.27e-13	Monocyte count;
SARC	cis	rs2425143	0.908	rs75331436	chr20:34391052	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-6.37	-0.39	9.75e-10	Blood protein levels;
SARC	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.68	-8.46	-0.48	3.06e-15	Prudent dietary pattern;
SARC	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg08219700	chr8:58056026	NA	0.74	6.83	0.41	7.42e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs2354432	0.607	rs68080346	chr1:146708484	T/C	cg25205988	chr1:146714368	CHD1L	-1.03	-7.37	-0.43	2.92e-12	Mitochondrial DNA levels;
SARC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.13	0.37	3.73e-9	Prudent dietary pattern;
SARC	cis	rs28830936	0.625	rs8038764	chr15:41907905	A/C	cg17847044	chr15:42102381	MAPKBP1	0.47	7.43	0.44	2.02e-12	Diastolic blood pressure;
SARC	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg22535103	chr8:58192502	C8orf71	-0.7	-8.51	-0.49	2.18e-15	Developmental language disorder (linguistic errors);
SARC	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg05861140	chr6:150128134	PCMT1	-0.41	-5.41	-0.33	1.55e-7	Lung cancer;
SARC	cis	rs7178909	0.872	rs3784387	chr15:90437370	G/A	cg19708238	chr15:90437601	AP3S2	0.62	8.47	0.49	2.73e-15	Common traits (Other);
SARC	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg11644478	chr21:40555479	PSMG1	1.04	14.89	0.7	1.11e-35	Cognitive function;
SARC	cis	rs2952156	0.920	rs907090	chr17:37833632	T/C	cg20243544	chr17:37824526	PNMT	0.56	7.44	0.44	1.94e-12	Asthma;
SARC	cis	rs13256369	0.802	rs13281933	chr8:8562665	C/A	cg18904891	chr8:8559673	CLDN23	0.48	5.44	0.34	1.36e-7	Obesity-related traits;
SARC	cis	rs10464366	0.746	rs6945547	chr7:39145389	C/G	cg15212455	chr7:39170539	POU6F2	0.4	4.91	0.31	1.71e-6	IgG glycosylation;
SARC	trans	rs7395662	0.571	rs12421145	chr11:48624725	C/A	cg15704280	chr7:45808275	SEPT13	-0.49	-6.49	-0.39	5.08e-10	HDL cholesterol;
SARC	cis	rs7216064	1.000	rs12600941	chr17:65918807	A/G	cg12091567	chr17:66097778	LOC651250	-0.71	-7.25	-0.43	6.16e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs5753618	0.504	rs9606847	chr22:31901789	G/C	cg02404636	chr22:31891804	SFI1	0.53	5.91	0.36	1.2e-8	Colorectal cancer;
SARC	cis	rs3741404	0.609	rs641378	chr11:63869493	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	9.03	0.51	6.46e-17	Platelet count;
SARC	cis	rs9916302	0.904	rs8066704	chr17:37477218	C/T	cg15445000	chr17:37608096	MED1	-0.45	-5.5	-0.34	1.02e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs35110281	0.501	rs162381	chr21:44920915	A/G	cg21573476	chr21:45109991	RRP1B	0.38	5.24	0.32	3.63e-7	Mean corpuscular volume;
SARC	cis	rs41271473	1.000	rs11580020	chr1:228880466	A/G	cg16512390	chr1:228756714	NA	-0.51	-5.33	-0.33	2.3e-7	Chronic lymphocytic leukemia;
SARC	cis	rs12464559	0.522	rs13016166	chr2:152624144	G/A	cg01189475	chr2:152685088	ARL5A	0.59	4.9	0.31	1.78e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs7084402	0.967	rs1658443	chr10:60316926	G/T	cg07615347	chr10:60278583	BICC1	0.59	8.65	0.49	8.56e-16	Refractive error;
SARC	cis	rs10752881	0.901	rs10911201	chr1:183001622	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.36	0.56	6.3e-21	Colorectal cancer;
SARC	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg22920501	chr2:26401640	FAM59B	-0.57	-7.44	-0.44	1.92e-12	Gut microbiome composition (summer);
SARC	cis	rs9309473	0.579	rs1852644	chr2:73597718	A/G	cg20560298	chr2:73613845	ALMS1	-0.54	-6.87	-0.41	5.76e-11	Metabolite levels;
SARC	cis	rs793571	0.500	rs2555356	chr15:59016431	T/G	cg05156742	chr15:59063176	FAM63B	0.7	9.75	0.54	4.79e-19	Schizophrenia;
SARC	cis	rs1448094	0.791	rs7303256	chr12:86333217	C/T	cg02569458	chr12:86230093	RASSF9	-0.4	-5.59	-0.34	6.29e-8	Major depressive disorder;
SARC	cis	rs854765	0.547	rs2955355	chr17:17948475	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.45	-5.91	-0.36	1.24e-8	Total body bone mineral density;
SARC	cis	rs5758659	0.714	rs133376	chr22:42466905	C/T	cg15128208	chr22:42549153	NA	-0.37	-5.21	-0.32	4.22e-7	Cognitive function;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg07953307	chr16:29000920	LAT	-0.61	-6.39	-0.39	8.79e-10	Lung cancer in ever smokers;
SARC	cis	rs66716358	0.773	rs2054029	chr11:44325700	T/G	cg16977035	chr11:44330474	ALX4	0.26	4.75	0.3	3.54e-6	Monobrow;
SARC	cis	rs875971	0.793	rs460678	chr7:65527200	C/G	cg18876405	chr7:65276391	NA	0.5	6.23	0.38	2.17e-9	Aortic root size;
SARC	cis	rs2228479	0.702	rs62053701	chr16:89860584	G/A	cg06558623	chr16:89946397	TCF25	0.94	6.6	0.4	2.67e-10	Skin colour saturation;
SARC	cis	rs5769765	0.908	rs2319464	chr22:50265777	A/G	cg03033257	chr22:50311977	ALG12;CRELD2	-0.54	-5.61	-0.34	5.7e-8	Schizophrenia;
SARC	cis	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg12463550	chr7:65579703	CRCP	0.67	4.97	0.31	1.29e-6	Gout;
SARC	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg18876405	chr7:65276391	NA	0.7	9.04	0.51	6.05e-17	Aortic root size;
SARC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg25703541	chr22:24373054	LOC391322	-0.82	-10.55	-0.57	1.55e-21	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg24675658	chr1:53192096	ZYG11B	-0.82	-12.39	-0.63	2.08e-27	Monocyte count;
SARC	cis	rs6088590	0.930	rs6087618	chr20:33288407	C/T	cg24642439	chr20:33292090	TP53INP2	0.9	13.25	0.66	3.09e-30	Coronary artery disease;
SARC	cis	rs910316	1.000	rs28626045	chr14:75589195	G/C	cg08847533	chr14:75593920	NEK9	0.92	15.73	0.72	1.77e-38	Height;
SARC	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg11247378	chr22:39784982	NA	-0.3	-5.0	-0.31	1.11e-6	Intelligence (multi-trait analysis);
SARC	cis	rs13256369	1.000	rs7843488	chr8:8576217	C/T	cg18904891	chr8:8559673	CLDN23	0.48	5.29	0.33	2.88e-7	Obesity-related traits;
SARC	cis	rs35213789	0.878	rs12698838	chr7:69493670	A/G	cg10619644	chr7:69149951	AUTS2	0.41	5.09	0.32	7.26e-7	Childhood ear infection;
SARC	cis	rs7860634	0.872	rs7847312	chr9:139089718	A/C	cg04455058	chr9:139085579	NA	0.66	9.3	0.52	1.04e-17	Thyroid hormone levels;
SARC	cis	rs4595586	0.525	rs35046524	chr12:39414535	A/G	cg26384229	chr12:38710491	ALG10B	0.55	6.09	0.37	4.74e-9	Morning vs. evening chronotype;
SARC	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	10.25	0.56	1.33e-20	Platelet count;
SARC	cis	rs12142240	0.698	rs66972124	chr1:46807445	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-5.58	-0.34	6.8e-8	Menopause (age at onset);
SARC	cis	rs7312933	0.703	rs10459290	chr12:42613290	T/G	cg17420585	chr12:42539391	GXYLT1	-0.35	-4.78	-0.3	3.16e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs735396	0.694	rs2264750	chr12:121450165	C/T	cg04422896	chr12:121454269	C12orf43	0.41	5.06	0.31	8.68e-7	N-glycan levels;
SARC	cis	rs6964587	1.000	rs6944591	chr7:91642714	T/C	cg17063962	chr7:91808500	NA	0.93	15.73	0.72	1.7e-38	Breast cancer;
SARC	cis	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg13072238	chr3:49761600	GMPPB	-0.42	-5.54	-0.34	8.33e-8	Intelligence (multi-trait analysis);
SARC	cis	rs459571	0.883	rs2520096	chr9:136919416	A/G	cg01294253	chr9:136912663	BRD3	0.42	5.54	0.34	8.21e-8	Platelet distribution width;
SARC	cis	rs1549118	0.595	rs7160485	chr14:78332734	C/G	cg23188588	chr14:78226832	SNW1;C14orf178	-0.49	-5.05	-0.31	8.8e-7	Resting heart rate;
SARC	cis	rs10870270	0.957	rs9971084	chr10:133788747	G/C	cg26149184	chr10:133730230	NA	0.45	4.82	0.3	2.63e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs910316	1.000	rs12889472	chr14:75543979	A/G	cg11812906	chr14:75593930	NEK9	0.87	13.32	0.66	1.73e-30	Height;
SARC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg10295955	chr4:187884368	NA	-1.09	-21.05	-0.81	7.91e-56	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2153535	0.580	rs1928184	chr6:8532108	T/A	cg21535247	chr6:8435926	SLC35B3	0.54	6.95	0.41	3.68e-11	Motion sickness;
SARC	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg26119090	chr2:26468346	HADHA;HADHB	0.6	7.08	0.42	1.74e-11	Gut microbiome composition (summer);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg17409876	chr11:66436470	RBM4B	0.47	6.52	0.39	4.22e-10	Thyroid stimulating hormone;
SARC	cis	rs9354308	0.868	rs2882754	chr6:66537341	A/G	cg07460842	chr6:66804631	NA	0.42	4.82	0.3	2.54e-6	Metabolite levels;
SARC	cis	rs4481887	1.000	rs6663817	chr1:248495613	A/G	cg01631408	chr1:248437212	OR2T33	-0.43	-5.37	-0.33	1.88e-7	Common traits (Other);
SARC	cis	rs6738485	0.507	rs72819611	chr2:106845912	G/A	cg23109721	chr2:106886537	NA	-0.53	-5.36	-0.33	2.02e-7	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
SARC	cis	rs6570726	0.935	rs384519	chr6:145846017	C/A	cg05220968	chr6:146057943	EPM2A	-0.29	-5.04	-0.31	9.48e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg13902645	chr11:5959945	NA	-0.44	-5.92	-0.36	1.16e-8	DNA methylation (variation);
SARC	trans	rs11098499	0.863	rs11933966	chr4:120476715	G/A	cg25214090	chr10:38739885	LOC399744	0.57	7.25	0.43	6.27e-12	Corneal astigmatism;
SARC	cis	rs6088590	0.965	rs910869	chr20:33292777	C/T	cg08999081	chr20:33150536	PIGU	0.35	5.06	0.31	8.66e-7	Coronary artery disease;
SARC	cis	rs4919694	1.000	rs7083328	chr10:104769268	G/A	cg04362960	chr10:104952993	NT5C2	0.65	5.48	0.34	1.09e-7	Arsenic metabolism;
SARC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg11965913	chr1:205819406	PM20D1	-0.88	-14.56	-0.69	1.38e-34	Menarche (age at onset);
SARC	cis	rs2387326	0.951	rs7919668	chr10:129931541	A/C	cg16087940	chr10:129947807	NA	-0.45	-5.89	-0.36	1.34e-8	Select biomarker traits;
SARC	cis	rs4148883	0.689	rs1311621	chr4:100014018	T/C	cg12011299	chr4:100065546	ADH4	0.36	6.75	0.4	1.16e-10	Alcohol dependence;
SARC	cis	rs763121	0.853	rs5750621	chr22:38956166	C/T	cg21395723	chr22:39101663	GTPBP1	0.58	6.67	0.4	1.8e-10	Menopause (age at onset);
SARC	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg13939156	chr17:80058883	NA	0.4	6.2	0.38	2.57e-9	Life satisfaction;
SARC	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg24675658	chr1:53192096	ZYG11B	0.66	9.79	0.54	3.58e-19	Monocyte count;
SARC	cis	rs9400467	0.506	rs76813116	chr6:111690733	T/G	cg15721981	chr6:111408429	SLC16A10	0.65	5.65	0.35	4.61e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs78320035	0.867	rs77208718	chr1:168102600	G/A	cg17113809	chr1:168148080	TIPRL	1.15	6.69	0.4	1.61e-10	Red cell distribution width;
SARC	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg08677398	chr8:58056175	NA	0.42	4.99	0.31	1.2e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs2276314	0.857	rs6507157	chr18:33631703	A/C	cg05985134	chr18:33552581	C18orf21	0.66	6.71	0.4	1.44e-10	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs2153535	0.580	rs6913100	chr6:8456855	A/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.16	0.47	2.16e-14	Motion sickness;
SARC	cis	rs965604	1.000	rs8042238	chr15:78774271	C/T	cg24631222	chr15:78858424	CHRNA5	-0.47	-6.04	-0.37	6.2e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs9818758	0.545	rs55921200	chr3:49189316	T/C	cg01304814	chr3:48885189	PRKAR2A	0.82	6.32	0.38	1.34e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.79	9.87	0.54	1.96e-19	Prudent dietary pattern;
SARC	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg22105103	chr4:187893119	NA	0.5	6.83	0.41	7.49e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1113500	0.933	rs10881500	chr1:108638895	C/T	cg06207961	chr1:108661230	NA	0.43	5.77	0.35	2.55e-8	Growth-regulated protein alpha levels;
SARC	cis	rs7264396	0.635	rs3827030	chr20:34474947	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	-0.51	-5.06	-0.31	8.51e-7	Total cholesterol levels;
SARC	cis	rs9733	0.635	rs486836	chr1:150875967	A/T	cg13175981	chr1:150552382	MCL1	0.58	7.89	0.46	1.19e-13	Tonsillectomy;
SARC	cis	rs12545109	0.836	rs2196586	chr8:57347126	C/T	cg19413350	chr8:57351067	NA	0.41	4.78	0.3	3.04e-6	Obesity-related traits;
SARC	cis	rs6598955	0.543	rs12125620	chr1:26552238	G/A	cg04990556	chr1:26633338	UBXN11	0.75	7.68	0.45	4.48e-13	Obesity-related traits;
SARC	cis	rs7617773	0.539	rs11130165	chr3:48384721	G/T	cg11946769	chr3:48343235	NME6	0.56	6.78	0.41	9.53e-11	Coronary artery disease;
SARC	cis	rs2933343	0.729	rs789231	chr3:128602847	A/G	cg25356066	chr3:128598488	ACAD9	0.74	9.81	0.54	3.15e-19	IgG glycosylation;
SARC	cis	rs12291225	0.545	rs11023187	chr11:14345559	T/G	cg19336497	chr11:14380999	RRAS2	-0.45	-8.13	-0.47	2.6e-14	Sense of smell;
SARC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg19318889	chr4:1322082	MAEA	0.44	5.18	0.32	4.71e-7	Longevity;
SARC	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg22903471	chr2:27725779	GCKR	-0.54	-8.25	-0.48	1.21e-14	Total body bone mineral density;
SARC	cis	rs67460515	0.500	rs1868105	chr3:160645335	A/G	cg17135325	chr3:160939158	NMD3	0.53	5.78	0.35	2.35e-8	Parkinson's disease;
SARC	cis	rs9303401	0.614	rs34843288	chr17:57103140	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.04	10.17	0.55	2.41e-20	Cognitive test performance;
SARC	cis	rs787274	0.867	rs4978507	chr9:115609376	G/A	cg13803584	chr9:115635662	SNX30	-0.82	-4.94	-0.31	1.48e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs9906944	0.707	rs4794020	chr17:47111399	C/T	cg16584676	chr17:46985605	UBE2Z	-0.43	-5.27	-0.33	3.07e-7	Intelligence (multi-trait analysis);Body fat percentage;
SARC	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg03575189	chr17:44344142	NA	0.61	5.78	0.35	2.32e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs72781680	0.821	rs2176265	chr2:24158638	C/G	cg06627628	chr2:24431161	ITSN2	-0.56	-5.89	-0.36	1.35e-8	Lymphocyte counts;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg22159557	chr15:65067668	RBPMS2	-0.52	-6.39	-0.39	8.77e-10	Schizophrenia;
SARC	cis	rs155076	0.711	rs4770131	chr13:21897468	A/G	cg25811766	chr13:21894605	NA	0.72	8.1	0.47	3.06e-14	White matter hyperintensity burden;
SARC	cis	rs477692	1.000	rs531572	chr10:131427569	A/G	cg05714579	chr10:131428358	MGMT	-0.54	-6.99	-0.42	2.8e-11	Response to temozolomide;
SARC	cis	rs17572109	0.666	rs4674297	chr2:219229147	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.56	5.69	0.35	3.72e-8	Platelet count;Platelet distribution width;Mean platelet volume;
SARC	cis	rs57024841	0.819	rs908839	chr9:139856639	C/G	cg00693599	chr9:139836323	FBXW5	-0.31	-5.1	-0.32	7.14e-7	Beta-trace protein levels;
SARC	cis	rs7904368	0.806	rs12242261	chr10:16872929	T/C	cg23933602	chr10:16859644	RSU1	0.55	5.29	0.33	2.86e-7	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg16308101	chr1:67895914	SERBP1	0.46	6.45	0.39	6.5e-10	Gallstone disease;
SARC	cis	rs4713118	0.911	rs2394000	chr6:27686991	A/G	cg17221315	chr6:27791827	HIST1H4J	0.5	5.03	0.31	9.57e-7	Parkinson's disease;
SARC	trans	rs61931739	0.500	rs11053203	chr12:34456593	C/T	cg13010199	chr12:38710504	ALG10B	0.81	11.29	0.59	7.09e-24	Morning vs. evening chronotype;
SARC	cis	rs2295359	0.892	rs10789224	chr1:67605134	C/T	cg11235152	chr1:67600687	NA	-0.54	-7.73	-0.45	3.26e-13	Psoriasis;
SARC	cis	rs9818758	0.607	rs73074866	chr3:49626666	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.66	-5.3	-0.33	2.64e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs8180040	0.715	rs6772670	chr3:47191349	G/A	cg27129171	chr3:47204927	SETD2	0.67	9.52	0.53	2.32e-18	Colorectal cancer;
SARC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg09373136	chr17:61933544	TCAM1	-0.45	-6.17	-0.37	2.95e-9	Prudent dietary pattern;
SARC	trans	rs79976124	0.800	rs12194767	chr6:66639599	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.68	7.91	0.46	1.04e-13	Type 2 diabetes;
SARC	cis	rs9394841	0.667	rs3827633	chr6:41759846	A/C	cg08135965	chr6:41755394	TOMM6	0.62	6.55	0.39	3.7e-10	Mean corpuscular hemoglobin;Red cell distribution width;
SARC	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg18252515	chr7:66147081	NA	-1.3	-11.62	-0.61	6.33e-25	Diabetic kidney disease;
SARC	trans	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg21659725	chr3:3221576	CRBN	0.79	11.8	0.61	1.72e-25	Intelligence (multi-trait analysis);
SARC	cis	rs524281	0.861	rs11227409	chr11:65870938	A/G	cg14036092	chr11:66035641	RAB1B	-0.51	-5.34	-0.33	2.16e-7	Electroencephalogram traits;
SARC	cis	rs9640161	0.830	rs1051760	chr7:150070630	A/G	cg10018233	chr7:150070692	REPIN1	0.71	12.06	0.62	2.34e-26	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs9303401	0.646	rs9303403	chr17:57219300	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.59	-7.18	-0.43	9.47e-12	Cognitive test performance;
SARC	cis	rs2120019	0.938	rs3850093	chr15:75318482	A/G	cg00629941	chr15:75287862	SCAMP5	0.67	7.36	0.43	3.1e-12	Blood trace element (Zn levels);
SARC	cis	rs2814982	0.605	rs77579349	chr6:34480473	C/A	cg14254433	chr6:34482411	PACSIN1	-0.5	-4.72	-0.3	4e-6	Cholesterol, total;Total cholesterol levels;
SARC	cis	rs13191362	0.938	rs28360532	chr6:162997477	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.49	0.34	1.04e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	trans	rs2727020	0.521	rs10839296	chr11:49537617	T/C	cg03929089	chr4:120376271	NA	0.7	7.91	0.46	1.01e-13	Coronary artery disease;
SARC	cis	rs9672608	0.687	rs5019044	chr15:78796282	T/A	cg24631222	chr15:78858424	CHRNA5	0.76	9.1	0.51	4.16e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs12155623	0.578	rs13277226	chr8:49883029	G/T	cg22283653	chr8:49824208	NA	-0.36	-5.17	-0.32	5.07e-7	Sudden cardiac arrest;
SARC	cis	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg12463550	chr7:65579703	CRCP	0.71	5.72	0.35	3.21e-8	Diabetic kidney disease;
SARC	cis	rs9527	0.590	rs10883818	chr10:104759586	A/G	cg04362960	chr10:104952993	NT5C2	0.45	5.4	0.33	1.63e-7	Arsenic metabolism;
SARC	cis	rs1949733	0.598	rs4696838	chr4:8540349	A/G	cg11789530	chr4:8429930	ACOX3	-0.62	-6.9	-0.41	5e-11	Response to antineoplastic agents;
SARC	cis	rs13191362	1.000	rs34177053	chr6:163007772	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.57	5.51	0.34	9.61e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs16976116	0.643	rs7181237	chr15:55517231	C/G	cg17854078	chr15:55489399	RSL24D1	0.52	5.29	0.33	2.78e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9910055	0.529	rs408282	chr17:42182267	A/G	cg19774624	chr17:42201019	HDAC5	0.56	6.82	0.41	7.78e-11	Total body bone mineral density;
SARC	cis	rs4481887	0.927	rs7519334	chr1:248472076	C/T	cg00666640	chr1:248458726	OR2T12	0.33	5.64	0.35	4.89e-8	Common traits (Other);
SARC	cis	rs1348850	0.872	rs4893959	chr2:178400204	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	7.59	0.45	7.8e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg12463550	chr7:65579703	CRCP	0.5	5.9	0.36	1.27e-8	Aortic root size;
SARC	cis	rs17666538	1.000	rs61122136	chr8:585027	G/C	cg00450029	chr8:599525	NA	-0.78	-5.81	-0.36	2.05e-8	IgG glycosylation;
SARC	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-4.81	-0.3	2.7e-6	Total body bone mineral density;
SARC	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg00684032	chr4:1343700	KIAA1530	0.42	6.17	0.37	2.93e-9	Obesity-related traits;
SARC	cis	rs11098499	0.863	rs12502389	chr4:120454191	A/G	cg24375607	chr4:120327624	NA	0.42	4.9	0.31	1.76e-6	Corneal astigmatism;
SARC	cis	rs6840258	0.941	rs72667757	chr4:87946994	C/A	cg11209507	chr4:87813803	C4orf36	0.44	4.72	0.3	3.98e-6	Mean corpuscular volume;Basophil percentage of granulocytes;
SARC	cis	rs1448094	0.872	rs7314272	chr12:86401005	T/C	cg02569458	chr12:86230093	RASSF9	0.38	5.63	0.35	5.04e-8	Major depressive disorder;
SARC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg17330251	chr7:94953956	PON1	-0.42	-5.97	-0.36	8.85e-9	Paraoxonase activity;
SARC	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg12419862	chr22:24373484	LOC391322	-0.7	-8.32	-0.48	7.59e-15	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg27588902	chr6:42928151	GNMT	0.37	5.65	0.35	4.6e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg06108461	chr20:60628389	TAF4	-0.92	-12.69	-0.64	2.14e-28	Body mass index;
SARC	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg05332525	chr7:65337924	VKORC1L1	0.43	4.83	0.3	2.44e-6	Calcium levels;
SARC	cis	rs11673344	0.583	rs10425719	chr19:37950798	C/G	cg14683738	chr19:37701593	ZNF585B	0.47	5.61	0.34	5.85e-8	Obesity-related traits;
SARC	cis	rs9814567	1.000	rs4417907	chr3:134291363	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.01	-0.42	2.54e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg25464034	chr11:450264	PTDSS2	-0.52	-6.94	-0.41	3.76e-11	Electrocardiographic conduction measures;
SARC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.34	-5.11	-0.32	6.77e-7	Total body bone mineral density;
SARC	cis	rs17023223	0.537	rs3934789	chr1:119683063	G/A	cg05756136	chr1:119680316	WARS2	-0.46	-5.19	-0.32	4.63e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs71007656	1	rs71007656	chr10:37970845	CGGCTG/C	cg25427524	chr10:38739819	LOC399744	-0.54	-8.24	-0.47	1.27e-14	Extrinsic epigenetic age acceleration;
SARC	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.31	-4.89	-0.3	1.9e-6	Total body bone mineral density;
SARC	cis	rs9650657	0.615	rs4840519	chr8:10693113	T/C	cg21775007	chr8:11205619	TDH	-0.39	-4.88	-0.3	1.94e-6	Neuroticism;
SARC	cis	rs9467773	0.549	rs9461273	chr6:26584526	A/G	cg11502198	chr6:26597334	ABT1	-0.62	-8.32	-0.48	7.28e-15	Intelligence (multi-trait analysis);
SARC	cis	rs9747201	1.000	rs9747201	chr17:80177852	A/C	cg17462356	chr17:80056334	FASN	-0.48	-5.28	-0.33	2.97e-7	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs10463554	1.000	rs11949145	chr5:102330256	G/T	cg23492399	chr5:102201601	PAM	-0.48	-5.84	-0.36	1.79e-8	Parkinson's disease;
SARC	cis	rs17030434	0.954	rs11724154	chr4:154753108	G/T	cg14289246	chr4:154710475	SFRP2	-0.73	-7.54	-0.44	1.05e-12	Electrocardiographic conduction measures;
SARC	cis	rs60733400	0.817	rs4648657	chr1:2560735	A/G	cg18854424	chr1:2615690	NA	-0.31	-4.85	-0.3	2.3e-6	Multiple sclerosis;
SARC	cis	rs12594515	1.000	rs11854554	chr15:45994546	C/G	cg14863074	chr15:45997064	NA	0.34	5.18	0.32	4.84e-7	Waist circumference;Weight;
SARC	cis	rs6540556	0.608	rs7548781	chr1:209915795	A/G	cg05527609	chr1:210001259	C1orf107	0.54	5.5	0.34	1.01e-7	Red blood cell count;
SARC	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg21782813	chr7:2030301	MAD1L1	0.4	6.22	0.38	2.26e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg12064134	chr16:90016061	DEF8	-0.59	-5.06	-0.31	8.56e-7	Skin colour saturation;
SARC	trans	rs61931739	0.500	rs11053269	chr12:34545307	A/G	cg13010199	chr12:38710504	ALG10B	0.78	11.07	0.59	3.68e-23	Morning vs. evening chronotype;
SARC	cis	rs6141769	0.518	rs28510728	chr20:31287891	G/A	cg17884169	chr20:31446444	EFCAB8	-0.45	-4.87	-0.3	2.1e-6	Subjective well-being;
SARC	cis	rs2295359	0.643	rs1569923	chr1:67665210	A/G	cg12940439	chr1:67600707	NA	0.33	5.0	0.31	1.14e-6	Psoriasis;
SARC	cis	rs60752752	0.852	rs11205279	chr1:153358685	C/T	cg26882115	chr1:153603048	S100A1;S100A13	-0.67	-5.2	-0.32	4.3e-7	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs8072100	0.790	rs6505048	chr17:45674998	G/A	cg08085267	chr17:45401833	C17orf57	0.42	5.0	0.31	1.12e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs240764	0.658	rs4839792	chr6:101253788	A/T	cg09795085	chr6:101329169	ASCC3	-0.42	-5.38	-0.33	1.77e-7	Neuroticism;
SARC	cis	rs7726839	0.540	rs7434	chr5:660804	A/G	cg14541582	chr5:601475	NA	0.38	4.79	0.3	2.92e-6	Obesity-related traits;
SARC	cis	rs10504073	0.669	rs818559	chr8:50035806	C/T	cg00325661	chr8:49890786	NA	0.54	7.38	0.44	2.7e-12	Blood metabolite ratios;
SARC	cis	rs9303280	0.806	rs10445308	chr17:37938047	C/T	cg20243544	chr17:37824526	PNMT	0.41	5.46	0.34	1.21e-7	Self-reported allergy;
SARC	cis	rs10752881	0.967	rs8179361	chr1:182974572	T/C	cg13390022	chr1:182993471	LAMC1	0.33	5.06	0.31	8.36e-7	Colorectal cancer;
SARC	cis	rs12079745	0.793	rs3766052	chr1:169126031	A/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.93	-5.91	-0.36	1.18e-8	QT interval;
SARC	cis	rs11122272	0.705	rs2808599	chr1:231533482	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.28	-0.56	1.11e-20	Hemoglobin concentration;
SARC	cis	rs11098499	0.629	rs28369518	chr4:120271630	T/C	cg24375607	chr4:120327624	NA	0.37	4.74	0.3	3.74e-6	Corneal astigmatism;
SARC	cis	rs2153535	0.541	rs9505456	chr6:8479001	T/C	cg21535247	chr6:8435926	SLC35B3	0.58	7.33	0.43	3.7e-12	Motion sickness;
SARC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg23131131	chr22:24373011	LOC391322	-0.48	-5.27	-0.33	3.11e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	trans	rs208520	1.000	rs12199876	chr6:66989469	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	9.39	0.52	5.68e-18	Exhaled nitric oxide output;
SARC	cis	rs2414059	0.518	rs11070776	chr15:50735488	G/A	cg05456662	chr15:50716270	USP8	0.44	5.38	0.33	1.78e-7	QT interval;
SARC	cis	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg12463550	chr7:65579703	CRCP	0.65	5.03	0.31	9.96e-7	Diabetic kidney disease;
SARC	cis	rs7086627	0.515	rs7078254	chr10:82212193	C/T	cg00277334	chr10:82204260	NA	-0.58	-9.51	-0.53	2.53e-18	Post bronchodilator FEV1;
SARC	cis	rs1707322	1.000	rs6687301	chr1:46382852	T/C	cg03146154	chr1:46216737	IPP	0.46	5.52	0.34	8.98e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg06873352	chr17:61820015	STRADA	-0.41	-5.35	-0.33	2.06e-7	Prudent dietary pattern;
SARC	cis	rs995000	0.535	rs12239736	chr1:63085997	T/A	cg06896770	chr1:63153194	DOCK7	0.93	13.92	0.67	1.8e-32	Triglyceride levels;
SARC	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg20102877	chr2:27665638	KRTCAP3	-0.34	-4.75	-0.3	3.62e-6	Menopause (age at onset);
SARC	cis	rs17376456	0.877	rs12153506	chr5:93360953	T/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.76	0.35	2.64e-8	Diabetic retinopathy;
SARC	cis	rs2832191	0.740	rs13048618	chr21:30458684	A/G	cg08807101	chr21:30365312	RNF160	0.89	13.71	0.67	9.27e-32	Dental caries;
SARC	cis	rs4128725	1.000	rs4290055	chr1:159352971	C/T	cg25076881	chr1:159409836	OR10J1	0.4	4.78	0.3	3.04e-6	Select biomarker traits;
SARC	cis	rs11608355	0.515	rs2287192	chr12:109931594	C/T	cg05360138	chr12:110035743	NA	0.89	9.17	0.52	2.49e-17	Neuroticism;
SARC	cis	rs131805	0.794	rs131813	chr22:50961169	A/G	cg12969734	chr22:50962224	SCO2	0.45	4.94	0.31	1.48e-6	Granulocyte percentage of myeloid white cells;
SARC	cis	rs8078723	0.510	rs3087852	chr17:38137364	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.31	5.68	0.35	3.98e-8	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg13072238	chr3:49761600	GMPPB	0.42	5.52	0.34	8.89e-8	Intelligence (multi-trait analysis);
SARC	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.1	20.49	0.8	5e-54	Chronic sinus infection;
SARC	cis	rs79349575	0.715	rs62075844	chr17:47002389	G/A	cg16584676	chr17:46985605	UBE2Z	0.53	6.37	0.39	9.89e-10	Type 2 diabetes;
SARC	cis	rs4319547	0.695	rs4758643	chr12:122924819	A/T	cg05707623	chr12:122985044	ZCCHC8	-0.59	-6.6	-0.4	2.68e-10	Body mass index;
SARC	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg13393036	chr8:95962371	TP53INP1	-0.39	-6.69	-0.4	1.6e-10	Type 2 diabetes;
SARC	cis	rs67460515	0.531	rs13315565	chr3:160754626	G/C	cg03342759	chr3:160939853	NMD3	-0.6	-6.96	-0.41	3.45e-11	Parkinson's disease;
SARC	cis	rs3741151	0.773	rs6592526	chr11:73208911	C/T	cg17517138	chr11:73019481	ARHGEF17	0.96	7.52	0.44	1.16e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs929354	0.742	rs10274687	chr7:156933181	T/G	cg05182265	chr7:156933206	UBE3C	-0.34	-5.19	-0.32	4.49e-7	Body mass index;
SARC	cis	rs6088590	0.965	rs910869	chr20:33292777	C/T	cg06115741	chr20:33292138	TP53INP2	0.54	6.47	0.39	5.68e-10	Coronary artery disease;
SARC	cis	rs72634258	0.842	rs6577463	chr1:8169485	T/G	cg00042356	chr1:8021962	PARK7	-0.64	-5.9	-0.36	1.29e-8	Inflammatory bowel disease;
SARC	cis	rs240764	0.658	rs9485410	chr6:101261007	A/G	cg09795085	chr6:101329169	ASCC3	0.44	5.79	0.35	2.3e-8	Neuroticism;
SARC	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.31	-4.86	-0.3	2.17e-6	Total body bone mineral density;
SARC	cis	rs35306767	0.903	rs11253467	chr10:901244	A/G	cg26597838	chr10:835615	NA	0.83	8.49	0.49	2.51e-15	Eosinophil percentage of granulocytes;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg20034091	chr18:31158527	ASXL3	-0.74	-6.34	-0.38	1.15e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs986417	1.000	rs11158293	chr14:61109020	G/C	cg27398547	chr14:60952738	C14orf39	0.85	7.5	0.44	1.34e-12	Gut microbiota (bacterial taxa);
SARC	cis	rs4820294	0.961	rs62236664	chr22:38059427	T/C	cg21798802	chr22:38057573	PDXP	0.34	5.08	0.32	7.72e-7	Fat distribution (HIV);
SARC	cis	rs10791097	0.694	rs4456262	chr11:130755813	C/T	cg12179176	chr11:130786555	SNX19	-0.76	-11.53	-0.6	1.25e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs36051895	0.588	rs12340895	chr9:5076691	C/G	cg02405213	chr9:5042618	JAK2	0.43	4.89	0.31	1.88e-6	Pediatric autoimmune diseases;
SARC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.44	0.56	3.48e-21	Prudent dietary pattern;
SARC	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg19748678	chr4:122722346	EXOSC9	0.77	9.7	0.54	6.58e-19	Type 2 diabetes;
SARC	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg24503407	chr1:205819492	PM20D1	0.44	5.1	0.32	7.07e-7	Parkinson's disease;
SARC	cis	rs910316	0.967	rs175451	chr14:75589729	C/T	cg08847533	chr14:75593920	NEK9	-0.85	-13.35	-0.66	1.38e-30	Height;
SARC	cis	rs1568889	0.838	rs7943538	chr11:28288955	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.88	14.15	0.68	3.25e-33	Bipolar disorder;
SARC	cis	rs11676348	0.846	rs7607437	chr2:219008392	A/G	cg00012203	chr2:219082015	ARPC2	-0.51	-6.76	-0.41	1.08e-10	Ulcerative colitis;
SARC	trans	rs561341	1.000	rs550923	chr17:30327013	G/C	cg20587970	chr11:113659929	NA	-1.34	-13.79	-0.67	4.87e-32	Hip circumference adjusted for BMI;
SARC	cis	rs2916247	1.000	rs11775644	chr8:93042425	C/A	cg10183463	chr8:93005414	RUNX1T1	-0.65	-6.46	-0.39	5.97e-10	Intelligence (multi-trait analysis);
SARC	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg24675658	chr1:53192096	ZYG11B	-0.58	-8.3	-0.48	8.36e-15	Monocyte count;
SARC	cis	rs7336332	0.600	rs9579083	chr13:28017270	G/C	cg01674679	chr13:27998804	GTF3A	-0.5	-4.95	-0.31	1.43e-6	Weight;
SARC	cis	rs7551222	0.716	rs4951078	chr1:204491802	A/G	cg20240347	chr1:204465584	NA	-0.35	-6.22	-0.38	2.26e-9	Schizophrenia;
SARC	cis	rs2288073	0.965	rs10199334	chr2:24392618	T/C	cg26838691	chr2:24397539	C2orf84	-0.57	-6.9	-0.41	4.73e-11	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs9768139	0.708	rs11769028	chr7:158113881	G/A	cg06219351	chr7:158114137	PTPRN2	-0.29	-4.86	-0.3	2.2e-6	Calcium levels;
SARC	cis	rs7760949	0.889	rs9396262	chr6:13927418	C/T	cg27413430	chr6:13925136	RNF182	0.42	4.88	0.3	1.97e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg04944784	chr2:26401820	FAM59B	-0.52	-6.45	-0.39	6.42e-10	Gut microbiome composition (summer);
SARC	cis	rs2839186	0.585	rs2839154	chr21:47637760	C/T	cg13126279	chr21:47581558	C21orf56	0.38	4.71	0.3	4.17e-6	Testicular germ cell tumor;
SARC	cis	rs4919087	0.683	rs11189121	chr10:99072036	T/C	cg25902810	chr10:99078978	FRAT1	-0.55	-6.56	-0.39	3.4e-10	Monocyte count;
SARC	cis	rs761746	0.960	rs738656	chr22:31935347	G/A	cg15823100	chr22:32027580	PISD	0.36	5.0	0.31	1.12e-6	Intelligence;
SARC	cis	rs4889855	0.556	rs61096326	chr17:78543796	G/C	cg17956530	chr17:78667699	RPTOR	0.42	4.78	0.3	3.13e-6	Fractional excretion of uric acid;
SARC	cis	rs2050392	0.789	rs303438	chr10:30733493	C/T	cg25182066	chr10:30743637	MAP3K8	-0.36	-5.07	-0.31	8.27e-7	Inflammatory bowel disease;
SARC	trans	rs9325144	0.555	rs2387855	chr12:38687964	T/G	cg23762105	chr12:34175262	ALG10	-0.52	-6.97	-0.42	3.32e-11	Morning vs. evening chronotype;
SARC	cis	rs2016266	0.819	rs7398228	chr12:53660285	T/C	cg26875137	chr12:53738046	NA	0.42	5.57	0.34	7.08e-8	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs12451471	0.559	rs34746710	chr17:78079224	G/A	cg24585782	chr17:78113791	EIF4A3	-0.52	-5.77	-0.35	2.53e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
SARC	cis	rs7666738	0.830	rs4392515	chr4:98957431	A/G	cg05340658	chr4:99064831	C4orf37	0.66	9.0	0.51	8.07e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1580019	0.563	rs4723169	chr7:32567577	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.98	18.1	0.76	2.61e-46	Cognitive ability;
SARC	cis	rs4917833	0.779	rs4917832	chr10:100217739	G/C	cg19043522	chr10:100227446	HPSE2	0.38	4.81	0.3	2.66e-6	Pediatric bone mineral density (femoral neck);
SARC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg20007245	chr22:24372913	LOC391322	-0.7	-8.6	-0.49	1.21e-15	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs818427	1.000	rs2545167	chr5:112213071	G/T	cg07820702	chr5:112228657	REEP5	0.43	4.77	0.3	3.32e-6	Total body bone mineral density;
SARC	cis	rs796364	0.951	rs13029537	chr2:200998950	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.62	-5.83	-0.36	1.8e-8	Schizophrenia;
SARC	cis	rs9916302	0.904	rs3744348	chr17:37417575	C/G	cg15445000	chr17:37608096	MED1	0.42	5.14	0.32	5.74e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs9430161	0.611	rs12081197	chr1:11034239	T/C	cg02454025	chr1:11042201	C1orf127	0.87	12.08	0.62	2.04e-26	Ewing sarcoma;
SARC	cis	rs10484885	0.715	rs2585013	chr6:90553402	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.69	-7.39	-0.44	2.65e-12	QRS interval (sulfonylurea treatment interaction);
SARC	cis	rs240764	0.658	rs12213201	chr6:101176285	C/A	cg09795085	chr6:101329169	ASCC3	-0.51	-6.69	-0.4	1.61e-10	Neuroticism;
SARC	cis	rs10464366	0.746	rs4723822	chr7:39141613	C/T	cg18850127	chr7:39170497	POU6F2	0.44	5.4	0.33	1.64e-7	IgG glycosylation;
SARC	trans	rs12554020	0.686	rs77734990	chr9:96324152	G/A	cg26442883	chr16:49686662	ZNF423	0.61	6.58	0.4	3.01e-10	Schizophrenia;
SARC	cis	rs2011503	1.000	rs111406321	chr19:19637437	G/A	cg15839431	chr19:19639596	YJEFN3	-0.48	-4.77	-0.3	3.32e-6	Bipolar disorder;
SARC	cis	rs505401	0.505	rs28449972	chr19:6073790	G/C	cg18109231	chr19:6110877	RFX2	0.75	5.23	0.32	3.77e-7	Mean platelet volume;
SARC	trans	rs9951602	0.512	rs1599635	chr18:76643819	G/A	cg02800362	chr5:177631904	HNRNPAB	0.68	8.61	0.49	1.13e-15	Obesity-related traits;
SARC	cis	rs6952809	0.532	rs2023969	chr7:2449980	T/C	cg05083358	chr7:2394359	EIF3B	-0.52	-4.79	-0.3	2.91e-6	Multiple sclerosis;
SARC	cis	rs1008375	1.000	rs55939327	chr4:17642937	T/A	cg16339924	chr4:17578868	LAP3	0.67	8.96	0.51	1.05e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7264396	0.635	rs6058355	chr20:34491343	A/G	cg12579300	chr20:34535607	PHF20	-0.41	-4.86	-0.3	2.18e-6	Total cholesterol levels;
SARC	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg13175981	chr1:150552382	MCL1	-0.54	-6.82	-0.41	7.54e-11	Urate levels;
SARC	trans	rs9929218	0.581	rs7203337	chr16:68774800	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.78	12.76	0.64	1.29e-28	Colorectal cancer;
SARC	cis	rs7772486	0.686	rs702305	chr6:145973840	A/G	cg05347473	chr6:146136440	FBXO30	-0.5	-7.1	-0.42	1.48e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9462027	0.628	rs2492860	chr6:34705530	C/A	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.88	-0.36	1.39e-8	Systemic lupus erythematosus;
SARC	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg14983838	chr19:29218262	NA	0.77	10.53	0.57	1.83e-21	Methadone dose in opioid dependence;
SARC	cis	rs4727027	0.866	rs1358062	chr7:148783743	T/C	cg23583168	chr7:148888333	NA	-0.73	-10.51	-0.57	2.19e-21	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs17401966	1.000	rs58549151	chr1:10314657	A/C	cg15208524	chr1:10270712	KIF1B	0.58	6.52	0.39	4.26e-10	Hepatocellular carcinoma;
SARC	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg21747090	chr2:27597821	SNX17	-0.54	-7.47	-0.44	1.6e-12	Total body bone mineral density;
SARC	cis	rs57083693	0.551	rs10860709	chr12:101723363	G/T	cg22051763	chr12:101673672	UTP20	-0.44	-5.19	-0.32	4.68e-7	Alcohol dependence (age at onset);
SARC	cis	rs1865760	0.566	rs9467663	chr6:26021456	C/G	cg02841227	chr6:26021843	HIST1H4A	0.4	4.93	0.31	1.59e-6	Height;
SARC	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg18876405	chr7:65276391	NA	0.47	5.45	0.34	1.27e-7	Aortic root size;
SARC	cis	rs10911232	0.507	rs10797833	chr1:183044067	C/T	cg13390022	chr1:182993471	LAMC1	0.34	5.08	0.32	7.69e-7	Hypertriglyceridemia;
SARC	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.35	4.81	0.3	2.73e-6	Personality dimensions;
SARC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.67	0.54	8.17e-19	Prudent dietary pattern;
SARC	cis	rs3796352	1.000	rs11720191	chr3:53013839	T/C	cg12962167	chr3:53033115	SFMBT1	0.73	4.8	0.3	2.82e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs6942407	0.592	rs1981536	chr7:86747889	C/T	cg02420886	chr7:86849541	C7orf23	0.59	5.41	0.33	1.55e-7	Food allergy;
SARC	cis	rs611744	0.934	rs673356	chr8:109185159	A/T	cg21045802	chr8:109455806	TTC35	0.44	5.3	0.33	2.64e-7	Dupuytren's disease;
SARC	cis	rs709400	0.827	rs2274269	chr14:104029246	G/A	cg17925084	chr14:104152323	KLC1	0.34	4.8	0.3	2.86e-6	Body mass index;
SARC	cis	rs9611565	0.506	rs2024566	chr22:41697338	A/G	cg17376030	chr22:41985996	PMM1	0.57	7.09	0.42	1.58e-11	Vitiligo;
SARC	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.5	5.88	0.36	1.39e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs10791097	0.694	rs10894273	chr11:130742155	G/T	cg09137382	chr11:130731461	NA	0.31	4.78	0.3	3.15e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg00745463	chr17:30367425	LRRC37B	-0.63	-5.03	-0.31	9.84e-7	Hip circumference adjusted for BMI;
SARC	cis	rs17253792	0.822	rs74824071	chr14:56095142	T/G	cg01858014	chr14:56050164	KTN1	-0.68	-5.37	-0.33	1.86e-7	Putamen volume;
SARC	cis	rs13256369	0.802	rs4840350	chr8:8561442	A/G	cg17143192	chr8:8559678	CLDN23	0.52	5.74	0.35	2.9e-8	Obesity-related traits;
SARC	cis	rs3768617	0.510	rs2093985	chr1:183094322	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.67	9.87	0.54	1.95e-19	Fuchs's corneal dystrophy;
SARC	cis	rs6815814	0.898	rs73236616	chr4:38789675	G/A	cg06935464	chr4:38784597	TLR10	0.62	6.12	0.37	3.93e-9	Breast cancer;
SARC	cis	rs13256369	1.000	rs10103769	chr8:8573036	G/T	cg17143192	chr8:8559678	CLDN23	0.54	6.13	0.37	3.79e-9	Obesity-related traits;
SARC	cis	rs17401966	1.000	rs11121532	chr1:10277898	G/T	cg15208524	chr1:10270712	KIF1B	0.58	6.63	0.4	2.29e-10	Hepatocellular carcinoma;
SARC	cis	rs4972806	0.814	rs2113560	chr2:177030986	T/C	cg13092806	chr2:177043255	NA	0.39	5.02	0.31	1.03e-6	IgG glycosylation;
SARC	cis	rs986417	0.818	rs10148116	chr14:61101089	C/T	cg27398547	chr14:60952738	C14orf39	0.74	7.01	0.42	2.56e-11	Gut microbiota (bacterial taxa);
SARC	cis	rs9457247	0.602	rs6456152	chr6:167472062	A/G	cg23791538	chr6:167370224	RNASET2	-0.53	-7.01	-0.42	2.51e-11	Crohn's disease;
SARC	cis	rs8064024	0.538	rs11076854	chr16:4929269	A/G	cg08329684	chr16:4932620	PPL	-0.44	-6.91	-0.41	4.66e-11	Cancer;
SARC	cis	rs12479064	0.724	rs3792143	chr2:100057020	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.56	-6.46	-0.39	6.12e-10	Chronic sinus infection;
SARC	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg17971929	chr21:40555470	PSMG1	0.98	13.57	0.66	2.65e-31	Cognitive function;
SARC	cis	rs9788721	0.836	rs2656052	chr15:78740932	A/C	cg06917634	chr15:78832804	PSMA4	-0.49	-5.39	-0.33	1.7e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs6696846	0.791	rs7520752	chr1:205054114	C/T	cg21545522	chr1:205238299	TMCC2	-0.35	-4.91	-0.31	1.68e-6	Red blood cell count;
SARC	cis	rs67311347	0.544	rs9868700	chr3:40345408	G/A	cg24209194	chr3:40518798	ZNF619	0.47	6.38	0.39	9.19e-10	Renal cell carcinoma;
SARC	cis	rs1345301	0.518	rs12468355	chr2:102861250	T/G	cg12451869	chr2:102867685	NA	0.4	5.45	0.34	1.3e-7	Waist circumference;
SARC	cis	rs896543	0.702	rs12692189	chr2:237496112	A/G	cg25295825	chr2:237489920	CXCR7	-0.41	-4.97	-0.31	1.29e-6	Alcohol dependence (age at onset);
SARC	trans	rs11098499	0.955	rs1511018	chr4:120161580	G/T	cg25214090	chr10:38739885	LOC399744	0.52	6.88	0.41	5.62e-11	Corneal astigmatism;
SARC	cis	rs10848704	0.637	rs11062351	chr12:2881763	C/T	cg19945202	chr12:2788847	CACNA1C	-0.4	-5.29	-0.33	2.8e-7	Quantitative traits;
SARC	cis	rs9916302	0.706	rs6503521	chr17:37715551	A/C	cg00129232	chr17:37814104	STARD3	0.6	6.0	0.37	7.6e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs116095464	1.000	rs7723693	chr5:306032	G/A	cg22496380	chr5:211416	CCDC127	-0.86	-6.83	-0.41	7.48e-11	Breast cancer;
SARC	cis	rs9916302	0.904	rs34363096	chr17:37594294	G/A	cg00129232	chr17:37814104	STARD3	-0.62	-7.65	-0.45	5.14e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs73206853	0.563	rs16940950	chr12:111136459	A/G	cg10860002	chr12:110842031	ANAPC7	0.61	5.19	0.32	4.67e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs6963495	0.818	rs115609508	chr7:105163716	C/A	cg13798780	chr7:105162888	PUS7	0.6	5.45	0.34	1.31e-7	Bipolar disorder (body mass index interaction);
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg18915170	chr5:102548823	NA	0.46	6.28	0.38	1.6e-9	Tetralogy of Fallot;
SARC	cis	rs2120019	0.938	rs3850093	chr15:75318482	A/G	cg09165964	chr15:75287851	SCAMP5	1.02	14.71	0.69	4.23e-35	Blood trace element (Zn levels);
SARC	cis	rs78545713	1.000	rs78545713	chr6:26248840	A/G	cg13736514	chr6:26305472	NA	-0.59	-4.83	-0.3	2.43e-6	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs9303280	0.776	rs9910826	chr17:38035648	A/G	cg17467752	chr17:38218738	THRA	-0.37	-4.76	-0.3	3.34e-6	Self-reported allergy;
SARC	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg18252515	chr7:66147081	NA	0.47	5.05	0.31	8.83e-7	Aortic root size;
SARC	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg05896524	chr21:47604654	C21orf56	0.42	5.04	0.31	9.35e-7	Testicular germ cell tumor;
SARC	cis	rs60752752	0.852	rs3795391	chr1:153363105	T/C	cg26882115	chr1:153603048	S100A1;S100A13	-0.62	-4.87	-0.3	2.06e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs300774	1.000	rs300777	chr2:112026	T/C	cg06380356	chr2:467891	NA	-0.35	-4.82	-0.3	2.61e-6	Suicide attempts in bipolar disorder;
SARC	cis	rs79149102	0.579	rs7172989	chr15:75295905	C/T	cg17294928	chr15:75287854	SCAMP5	-0.99	-8.87	-0.5	1.91e-16	Lung cancer;
SARC	cis	rs2197308	0.626	rs6581156	chr12:37858731	C/A	cg13010199	chr12:38710504	ALG10B	-0.73	-10.07	-0.55	5.04e-20	Morning vs. evening chronotype;
SARC	cis	rs908922	0.651	rs548252	chr1:152489742	A/G	cg09873164	chr1:152488093	CRCT1	-0.61	-7.86	-0.46	1.42e-13	Hair morphology;
SARC	cis	rs72634258	0.796	rs4369247	chr1:8168993	C/T	cg00042356	chr1:8021962	PARK7	-0.63	-5.98	-0.36	8.53e-9	Inflammatory bowel disease;
SARC	cis	rs9470366	0.545	rs4713999	chr6:36633069	A/G	cg08179530	chr6:36648295	CDKN1A	-0.63	-8.37	-0.48	5.5e-15	QRS duration;
SARC	cis	rs7770848	1	rs7770848	chr6:44769237	A/C	cg10832949	chr6:45390783	RUNX2	0.6	5.24	0.32	3.62e-7	Asthma (childhood onset);
SARC	cis	rs9660992	0.649	rs72745216	chr1:205261016	G/A	cg21643547	chr1:205240462	TMCC2	-0.58	-7.18	-0.43	9.34e-12	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs9325144	0.560	rs10876005	chr12:39126149	C/G	cg13010199	chr12:38710504	ALG10B	-0.54	-7.12	-0.42	1.33e-11	Morning vs. evening chronotype;
SARC	cis	rs2916247	1.000	rs2028652	chr8:92990029	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.63	-6.12	-0.37	3.94e-9	Intelligence (multi-trait analysis);
SARC	cis	rs9916302	0.752	rs9901219	chr17:37558369	T/G	cg20243544	chr17:37824526	PNMT	-0.55	-6.23	-0.38	2.16e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg24250549	chr1:154909240	PMVK	0.6	7.9	0.46	1.08e-13	Prostate cancer;
SARC	cis	rs9549260	0.755	rs2721067	chr13:41156708	C/T	cg21288729	chr13:41239152	FOXO1	0.65	8.48	0.49	2.55e-15	Red blood cell count;
SARC	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.22	0.38	2.3e-9	Intelligence (multi-trait analysis);
SARC	cis	rs6866344	0.697	rs17184281	chr5:178127563	G/A	cg03877680	chr5:178157825	ZNF354A	1.02	12.27	0.63	4.82e-27	Neutrophil percentage of white cells;
SARC	cis	rs6580649	0.943	rs1859444	chr12:48399403	T/C	cg05342945	chr12:48394962	COL2A1	-0.59	-6.44	-0.39	6.66e-10	Lung cancer;
SARC	cis	rs9916302	0.904	rs8076546	chr17:37555403	G/A	cg00129232	chr17:37814104	STARD3	0.62	7.7	0.45	3.76e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs2952156	0.652	rs11869286	chr17:37813856	C/G	cg07936489	chr17:37558343	FBXL20	-0.44	-5.61	-0.34	5.83e-8	Asthma;
SARC	cis	rs10979	1.000	rs1054752	chr6:143890097	G/A	cg25407410	chr6:143891975	LOC285740	-0.64	-8.68	-0.49	6.88e-16	Hypospadias;
SARC	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	-0.97	-10.65	-0.57	8.01e-22	Platelet count;
SARC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.53	-6.17	-0.37	3.06e-9	Prudent dietary pattern;
SARC	cis	rs4234798	0.546	rs4689667	chr4:7249188	A/T	cg05206762	chr4:8160379	ABLIM2	0.43	4.98	0.31	1.24e-6	Insulin-like growth factors;
SARC	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg09323728	chr8:95962352	TP53INP1	-0.29	-4.84	-0.3	2.35e-6	Type 2 diabetes;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00222982	chr11:125439225	EI24	-0.52	-6.25	-0.38	1.94e-9	Fibrinogen levels;
SARC	cis	rs4588572	0.537	rs7705718	chr5:77730349	T/C	cg18281939	chr5:77783895	LHFPL2	0.34	4.71	0.3	4.17e-6	Triglycerides;
SARC	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg05313129	chr8:58192883	C8orf71	-0.51	-5.92	-0.36	1.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2075671	0.855	rs62483567	chr7:100286435	G/A	cg03098644	chr7:100410630	EPHB4	0.46	5.1	0.32	7.04e-7	Other erythrocyte phenotypes;
SARC	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg26924012	chr15:45694286	SPATA5L1	0.75	10.57	0.57	1.39e-21	Homoarginine levels;
SARC	cis	rs6594499	0.872	rs10045255	chr5:110438357	C/T	cg04022379	chr5:110408740	TSLP	-0.44	-5.57	-0.34	7.03e-8	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs875971	1.000	rs1144894	chr7:65542894	A/G	cg12463550	chr7:65579703	CRCP	-0.48	-5.67	-0.35	4.28e-8	Aortic root size;
SARC	cis	rs7584330	0.737	rs7595979	chr2:238364492	G/T	cg14458575	chr2:238380390	NA	0.43	5.13	0.32	6.07e-7	Prostate cancer;
SARC	cis	rs3106136	0.967	rs282449	chr4:95141228	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.97	-0.36	8.92e-9	Capecitabine sensitivity;
SARC	cis	rs2204008	0.654	rs1733410	chr12:38132172	G/A	cg13010199	chr12:38710504	ALG10B	-0.59	-7.53	-0.44	1.12e-12	Bladder cancer;
SARC	cis	rs1023500	0.551	rs133371	chr22:42465574	G/A	cg15557168	chr22:42548783	NA	-0.35	-4.87	-0.3	2.09e-6	Schizophrenia;
SARC	cis	rs4563143	0.592	rs12151001	chr19:29283386	C/G	cg04546413	chr19:29218101	NA	0.64	8.53	0.49	1.85e-15	Methadone dose in opioid dependence;
SARC	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg13395646	chr4:1353034	KIAA1530	-0.52	-6.12	-0.37	3.92e-9	Obesity-related traits;
SARC	cis	rs2658782	0.654	rs2248524	chr11:93255715	G/A	cg15737290	chr11:93063684	CCDC67	0.69	8.35	0.48	6.06e-15	Pulmonary function decline;
SARC	cis	rs10461617	0.541	rs7715822	chr5:56043600	G/T	cg24549020	chr5:56110836	MAP3K1	0.72	6.46	0.39	6.12e-10	Type 2 diabetes;
SARC	cis	rs1215050	0.765	rs783925	chr4:98969881	T/C	cg05340658	chr4:99064831	C4orf37	-0.47	-6.47	-0.39	5.84e-10	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg13395646	chr4:1353034	KIAA1530	-0.44	-5.55	-0.34	7.62e-8	Longevity;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg09163998	chr19:48103707	NA	0.52	6.24	0.38	2.02e-9	Breast cancer;
SARC	cis	rs611744	0.870	rs634216	chr8:109174803	A/G	cg21045802	chr8:109455806	TTC35	0.47	5.85	0.36	1.62e-8	Dupuytren's disease;
SARC	cis	rs3762637	0.943	rs9822345	chr3:122245598	A/G	cg24169773	chr3:122142474	KPNA1	-0.58	-5.83	-0.36	1.84e-8	LDL cholesterol levels;
SARC	cis	rs12142240	0.621	rs66828173	chr1:46818166	G/A	cg00530320	chr1:46809349	NSUN4	0.57	6.92	0.41	4.4e-11	Menopause (age at onset);
SARC	cis	rs753778	0.748	rs56767156	chr8:142216476	G/C	cg16341495	chr8:142228727	SLC45A4	-0.43	-5.9	-0.36	1.31e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs9916302	0.851	rs12947620	chr17:37605364	T/C	cg15445000	chr17:37608096	MED1	0.41	4.91	0.31	1.68e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs17539620	0.565	rs61383594	chr6:154841632	A/T	cg17771515	chr6:154831774	CNKSR3	0.53	4.96	0.31	1.39e-6	Lipoprotein (a) levels;
SARC	cis	rs644799	1.000	rs481630	chr11:95582447	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	15.2	0.71	1.05e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs67460515	0.563	rs7618924	chr3:160855599	A/G	cg17135325	chr3:160939158	NMD3	0.64	7.8	0.46	2.02e-13	Parkinson's disease;
SARC	trans	rs9329221	0.725	rs11250001	chr8:10255901	G/A	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.55	-0.39	3.61e-10	Neuroticism;
SARC	cis	rs4803468	1.000	rs4803465	chr19:41918158	A/G	cg08477640	chr19:41863820	B9D2	-0.4	-5.17	-0.32	4.92e-7	Height;
SARC	trans	rs9929218	0.581	rs12185157	chr16:68784587	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.78	12.31	0.63	3.65e-27	Colorectal cancer;
SARC	cis	rs12044355	0.927	rs61835382	chr1:231833225	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.57	7.61	0.45	6.96e-13	Alzheimer's disease;
SARC	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.44	5.34	0.33	2.17e-7	Bipolar disorder;
SARC	cis	rs9790314	0.905	rs4518145	chr3:160950030	T/C	cg04691961	chr3:161091175	C3orf57	-0.75	-10.85	-0.58	1.88e-22	Morning vs. evening chronotype;
SARC	cis	rs2153535	0.580	rs7453115	chr6:8447261	A/G	cg21535247	chr6:8435926	SLC35B3	0.57	7.24	0.43	6.41e-12	Motion sickness;
SARC	cis	rs705471	0.966	rs536226	chr10:3658172	G/A	cg14308648	chr10:3568949	NA	0.5	6.37	0.39	1.01e-9	Capecitabine sensitivity;
SARC	cis	rs7561149	0.768	rs17362581	chr2:179717131	C/T	cg17765952	chr2:179737173	CCDC141	0.5	6.48	0.39	5.36e-10	QT interval;
SARC	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	12.02	0.62	3.2e-26	Chronic sinus infection;
SARC	cis	rs11644362	0.966	rs36056252	chr16:12994672	T/G	cg06890432	chr16:12997467	SHISA9	-0.51	-6.52	-0.39	4.25e-10	Positive affect;Subjective well-being;
SARC	cis	rs7178909	0.800	rs3825866	chr15:90437638	A/T	cg19708238	chr15:90437601	AP3S2	0.62	8.47	0.49	2.73e-15	Common traits (Other);
SARC	cis	rs4253772	0.591	rs73886791	chr22:46687212	A/G	cg24881330	chr22:46731750	TRMU	0.73	7.78	0.45	2.28e-13	LDL cholesterol;Cholesterol, total;
SARC	cis	rs12594515	1.000	rs8027000	chr15:45987795	T/C	cg14863074	chr15:45997064	NA	0.34	5.24	0.32	3.57e-7	Waist circumference;Weight;
SARC	cis	rs9467773	0.620	rs2494716	chr6:26662736	T/C	cg12292205	chr6:26970375	C6orf41	0.4	4.9	0.31	1.77e-6	Intelligence (multi-trait analysis);
SARC	cis	rs35213789	0.960	rs9332399	chr7:69285977	A/G	cg10619644	chr7:69149951	AUTS2	0.36	4.73	0.3	3.83e-6	Childhood ear infection;
SARC	cis	rs986417	0.901	rs1955696	chr14:61028271	A/G	cg27398547	chr14:60952738	C14orf39	0.84	7.94	0.46	8.46e-14	Gut microbiota (bacterial taxa);
SARC	cis	rs2730245	0.505	rs1188956	chr7:158690576	G/A	cg24397884	chr7:158709396	WDR60	0.81	10.57	0.57	1.36e-21	Height;
SARC	cis	rs12956009	0.583	rs11663646	chr18:44862895	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.59	-7.77	-0.45	2.49e-13	Educational attainment (years of education);
SARC	cis	rs2559856	1.000	rs2251187	chr12:102081889	G/A	cg12924262	chr12:102091054	CHPT1	0.58	7.73	0.45	3.2e-13	Blood protein levels;
SARC	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg13699009	chr12:122356056	WDR66	0.6	9.95	0.55	1.18e-19	Mean corpuscular volume;
SARC	cis	rs13392177	0.684	rs6720105	chr2:219080718	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.56	-7.17	-0.43	9.82e-12	Pyoderma gangrenosum in inflammatory bowel disease;
SARC	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg25894440	chr7:65020034	NA	-0.73	-5.48	-0.34	1.09e-7	Diabetic kidney disease;
SARC	cis	rs9467773	1.000	rs9467773	chr6:26498426	A/G	cg11502198	chr6:26597334	ABT1	0.49	6.0	0.37	7.6e-9	Intelligence (multi-trait analysis);
SARC	cis	rs6138458	1.000	rs6114984	chr20:24976610	A/G	cg26195577	chr20:24973756	C20orf3	0.91	9.89	0.54	1.77e-19	Blood protein levels;
SARC	cis	rs916888	0.610	rs199454	chr17:44800110	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.57	-6.53	-0.39	4.19e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9314323	0.798	rs2019239	chr8:26217354	G/A	cg11498726	chr8:26250323	BNIP3L	-0.58	-7.48	-0.44	1.55e-12	Red cell distribution width;
SARC	cis	rs7766436	0.885	rs13200219	chr6:22595428	C/T	cg13666174	chr6:22585274	NA	-0.6	-7.54	-0.44	1.06e-12	Coronary artery disease;
SARC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg06074448	chr4:187884817	NA	-0.38	-5.18	-0.32	4.69e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12971120	0.891	rs11151961	chr18:72177340	C/T	cg26446133	chr18:72167187	CNDP2	-0.47	-6.34	-0.38	1.18e-9	Refractive error;
SARC	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7220401	0.512	rs2289629	chr17:27959903	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.48	5.29	0.33	2.8e-7	Coronary artery disease;
SARC	cis	rs428668	0.523	rs10060607	chr5:150679304	A/C	cg11125805	chr5:150678162	SLC36A3	0.35	4.73	0.3	3.87e-6	Skin aging (microtopography measurement);
SARC	cis	rs763121	0.853	rs2281021	chr22:39064667	T/C	cg14440974	chr22:39074834	NA	-0.34	-5.07	-0.32	8.19e-7	Menopause (age at onset);
SARC	cis	rs7666738	0.830	rs7662948	chr4:99020132	G/C	cg05340658	chr4:99064831	C4orf37	0.65	8.92	0.5	1.4e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg08219700	chr8:58056026	NA	0.74	6.8	0.41	8.57e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs2836950	0.545	rs11700813	chr21:40517469	T/G	cg11644478	chr21:40555479	PSMG1	-0.57	-6.83	-0.41	7.13e-11	Menarche (age at onset);
SARC	cis	rs2721195	0.845	rs3757966	chr8:145744618	G/A	cg17328964	chr8:145687451	CYHR1	-0.43	-5.76	-0.35	2.63e-8	Age at first birth;
SARC	cis	rs10876993	0.890	rs812304	chr12:58074853	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.46	-5.88	-0.36	1.39e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs17376456	1.000	rs34013242	chr5:93507947	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.26	0.33	3.27e-7	Diabetic retinopathy;
SARC	cis	rs3812049	0.784	rs2250127	chr5:127388844	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.86	-9.39	-0.52	5.71e-18	Lymphocyte counts;Red cell distribution width;
SARC	cis	rs8058578	1.000	rs6565201	chr16:30747191	C/T	cg00531865	chr16:30841666	NA	-0.52	-5.94	-0.36	1.04e-8	Multiple myeloma;
SARC	cis	rs7552404	0.627	rs12127049	chr1:76353248	G/A	cg10523679	chr1:76189770	ACADM	0.44	5.28	0.33	2.9e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	trans	rs208520	0.770	rs2153941	chr6:66885521	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.03	-12.94	-0.65	3.28e-29	Exhaled nitric oxide output;
SARC	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs12541335	0.536	rs4266653	chr8:22169087	A/G	cg10298898	chr8:22132678	PIWIL2	0.37	4.87	0.3	2.07e-6	Hypertriglyceridemia;
SARC	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg11987759	chr7:65425863	GUSB	-0.5	-5.93	-0.36	1.06e-8	Aortic root size;
SARC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.35	5.2	0.32	4.3e-7	Electroencephalogram traits;
SARC	cis	rs17376456	0.569	rs6881815	chr5:93105666	A/G	cg25358565	chr5:93447407	FAM172A	0.94	10.54	0.57	1.68e-21	Diabetic retinopathy;
SARC	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg16606324	chr3:10149918	C3orf24	0.52	5.27	0.33	3.08e-7	Alzheimer's disease;
SARC	cis	rs911263	0.590	rs6573834	chr14:68808398	T/C	cg18825221	chr14:68749962	RAD51L1	0.45	6.28	0.38	1.67e-9	Primary biliary cholangitis;
SARC	cis	rs870825	0.616	rs55685500	chr4:185614810	G/A	cg04058563	chr4:185651563	MLF1IP	0.85	11.33	0.6	5.52e-24	Blood protein levels;
SARC	cis	rs986417	1.000	rs10151958	chr14:60977275	T/C	cg27398547	chr14:60952738	C14orf39	1.03	9.89	0.54	1.74e-19	Gut microbiota (bacterial taxa);
SARC	cis	rs2153535	0.580	rs7769020	chr6:8457724	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	6.55	0.39	3.66e-10	Motion sickness;
SARC	cis	rs12579753	0.827	rs7958100	chr12:82200782	G/A	cg07988820	chr12:82153109	PPFIA2	-0.52	-6.0	-0.37	7.53e-9	Resting heart rate;
SARC	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg15448220	chr1:150897856	SETDB1	0.47	6.22	0.38	2.24e-9	Tonsillectomy;
SARC	cis	rs9814567	0.727	rs4543053	chr3:134351724	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.49	-6.33	-0.38	1.22e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs7762018	0.769	rs4716339	chr6:170063210	C/T	cg13891659	chr6:170190454	C6orf122;C6orf208	0.64	5.33	0.33	2.32e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	trans	rs656319	0.580	rs13252589	chr8:10005526	A/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-7.78	-0.45	2.37e-13	Myopia (pathological);
SARC	cis	rs9398803	0.865	rs9385400	chr6:126764190	G/T	cg19875578	chr6:126661172	C6orf173	-0.61	-8.3	-0.48	8.46e-15	Male-pattern baldness;
SARC	cis	rs17401966	1.000	rs11578788	chr1:10422958	A/G	cg15208524	chr1:10270712	KIF1B	0.6	6.61	0.4	2.52e-10	Hepatocellular carcinoma;
SARC	cis	rs2486288	0.656	rs11639420	chr15:45559268	A/C	cg15395560	chr15:45543142	SLC28A2	0.28	5.42	0.33	1.48e-7	Glomerular filtration rate;
SARC	cis	rs17023223	0.537	rs1343723	chr1:119605054	A/T	cg05756136	chr1:119680316	WARS2	-0.43	-5.13	-0.32	6.03e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.83	8.49	0.49	2.52e-15	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs116095464	1.000	rs6555160	chr5:311669	A/G	cg20965017	chr5:231967	SDHA	0.76	6.22	0.38	2.27e-9	Breast cancer;
SARC	cis	rs9660992	0.700	rs1172125	chr1:205258442	A/T	cg07972983	chr1:205091412	RBBP5	0.52	6.62	0.4	2.42e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs2342371	0.641	rs4916427	chr3:196094213	C/T	cg15048948	chr3:196158458	UBXN7	0.65	7.88	0.46	1.26e-13	Fat distribution (HIV);
SARC	cis	rs9436747	0.641	rs1343982	chr1:66045251	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.47	4.88	0.3	1.92e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs9309473	0.606	rs77962988	chr2:73886090	T/C	cg20560298	chr2:73613845	ALMS1	-0.47	-4.91	-0.31	1.68e-6	Metabolite levels;
SARC	cis	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.7	-0.45	3.77e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs72781680	0.800	rs6718635	chr2:24066183	A/C	cg08917208	chr2:24149416	ATAD2B	0.94	9.1	0.51	4.1e-17	Lymphocyte counts;
SARC	cis	rs933688	0.532	rs2973478	chr5:90553428	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.44	-4.94	-0.31	1.5e-6	Smoking behavior;
SARC	cis	rs35213789	0.887	rs2533449	chr7:69147703	A/C	cg10619644	chr7:69149951	AUTS2	-0.38	-5.07	-0.32	8.16e-7	Childhood ear infection;
SARC	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg12463550	chr7:65579703	CRCP	0.68	5.1	0.32	7.05e-7	Diabetic kidney disease;
SARC	cis	rs483180	0.512	rs594400	chr1:120214275	G/T	cg19096424	chr1:120255104	PHGDH	-0.51	-6.02	-0.37	6.57e-9	Macular telangiectasia type 2;
SARC	cis	rs611744	0.870	rs633794	chr8:109174702	A/G	cg21045802	chr8:109455806	TTC35	0.5	6.14	0.37	3.45e-9	Dupuytren's disease;
SARC	cis	rs8051517	1.000	rs115604426	chr16:68357030	A/G	cg01866162	chr16:67596514	CTCF	1.0	5.72	0.35	3.23e-8	Blood protein levels;
SARC	cis	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg18252515	chr7:66147081	NA	-1.41	-12.93	-0.65	3.5e-29	Diabetic kidney disease;
SARC	cis	rs4891159	0.790	rs72973773	chr18:74115176	T/C	cg24786174	chr18:74118243	ZNF516	-0.68	-9.89	-0.54	1.79e-19	Longevity;
SARC	cis	rs155076	0.938	rs485361	chr13:21845826	G/T	cg06138931	chr13:21896616	NA	-0.39	-5.08	-0.32	7.88e-7	White matter hyperintensity burden;
SARC	cis	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg24110177	chr3:50126178	RBM5	-0.55	-7.3	-0.43	4.64e-12	Intelligence (multi-trait analysis);
SARC	cis	rs12586317	0.547	rs112510746	chr14:35491833	T/G	cg16230307	chr14:35515116	FAM177A1	1.02	11.85	0.61	1.18e-25	Psoriasis;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg02339418	chr12:123717776	C12orf65	0.51	6.43	0.39	7.05e-10	Breast cancer;
SARC	cis	rs2997447	0.761	rs61776616	chr1:26455812	C/T	cg19633962	chr1:26362018	EXTL1	-0.57	-4.93	-0.31	1.54e-6	QRS complex (12-leadsum);
SARC	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg16479474	chr6:28041457	NA	0.36	5.84	0.36	1.7e-8	Depression;
SARC	cis	rs7220711	0.902	rs4793018	chr17:41781069	A/G	cg26893861	chr17:41843967	DUSP3	-0.4	-5.13	-0.32	6.05e-7	Bone mineral density (spine);Bone mineral density (hip);
SARC	cis	rs926392	0.965	rs6028258	chr20:37692844	T/A	cg16355469	chr20:37678765	NA	0.49	6.42	0.39	7.58e-10	Dialysis-related mortality;
SARC	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg12373951	chr3:133503437	NA	-0.36	-4.97	-0.31	1.33e-6	Iron status biomarkers;
SARC	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg18252515	chr7:66147081	NA	-1.29	-11.31	-0.6	6.31e-24	Diabetic kidney disease;
SARC	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.66	-6.78	-0.41	9.94e-11	Platelet count;
SARC	cis	rs965469	1.000	rs6037532	chr20:3267911	T/C	cg25506879	chr20:3388711	C20orf194	-0.47	-4.76	-0.3	3.42e-6	IFN-related cytopenia;
SARC	cis	rs918629	0.798	rs7705279	chr5:95324375	C/T	cg16656078	chr5:95278638	ELL2	-0.54	-6.5	-0.39	4.9e-10	IgG glycosylation;
SARC	cis	rs9341808	0.644	rs59371711	chr6:80942027	G/T	cg08355045	chr6:80787529	NA	-0.35	-5.72	-0.35	3.27e-8	Sitting height ratio;
SARC	cis	rs3126085	0.935	rs4845429	chr1:152225376	G/C	cg26876637	chr1:152193138	HRNR	0.45	5.28	0.33	2.97e-7	Atopic dermatitis;
SARC	cis	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg07636037	chr3:49044803	WDR6	0.63	8.4	0.48	4.49e-15	Resting heart rate;
SARC	cis	rs950776	0.593	rs680244	chr15:78871288	T/C	cg24631222	chr15:78858424	CHRNA5	0.37	4.87	0.3	2.04e-6	Sudden cardiac arrest;
SARC	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg05368731	chr17:41323189	NBR1	0.79	9.83	0.54	2.62e-19	Menopause (age at onset);
SARC	cis	rs9467773	1.000	rs6940188	chr6:26562029	G/C	cg11502198	chr6:26597334	ABT1	0.5	6.11	0.37	4.1e-9	Intelligence (multi-trait analysis);
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg10860527	chr2:109403091	CCDC138	-0.51	-6.26	-0.38	1.88e-9	Schizophrenia;
SARC	trans	rs1973993	0.745	rs6593602	chr1:96951281	G/A	cg10631902	chr5:14652156	NA	-0.44	-7.11	-0.42	1.39e-11	Weight;
SARC	cis	rs920590	0.796	rs7820520	chr8:19634864	A/G	cg03894339	chr8:19674705	INTS10	-0.6	-7.32	-0.43	4.03e-12	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs73206853	0.841	rs73194013	chr12:111100677	T/C	cg10860002	chr12:110842031	ANAPC7	0.57	4.78	0.3	3.06e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg19346786	chr7:2764209	NA	-0.37	-5.38	-0.33	1.82e-7	Height;
SARC	cis	rs3780378	0.935	rs7875908	chr9:5081334	C/T	cg03508284	chr9:4985524	JAK2	-0.43	-5.19	-0.32	4.67e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
SARC	cis	rs9381040	0.610	rs6941090	chr6:41043465	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.46	-5.27	-0.33	3.05e-7	Alzheimer's disease (late onset);
SARC	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg22974920	chr21:40686053	BRWD1	-0.44	-4.87	-0.3	2.06e-6	Cognitive function;
SARC	cis	rs739401	0.572	rs739400	chr11:3016520	G/A	cg08508325	chr11:3079039	CARS	-0.34	-8.39	-0.48	4.58e-15	Longevity;
SARC	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg18876405	chr7:65276391	NA	0.72	9.42	0.53	4.61e-18	Aortic root size;
SARC	cis	rs1044826	0.913	rs12488939	chr3:139050831	C/T	cg15131784	chr3:139108705	COPB2	0.46	5.13	0.32	6.02e-7	Obesity-related traits;
SARC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.31	-4.72	-0.3	4.07e-6	Total body bone mineral density;
SARC	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg22590775	chr19:49891494	CCDC155	0.49	5.6	0.34	5.98e-8	Multiple sclerosis;
SARC	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.31	-0.52	9.56e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs41278232	0.557	rs817347	chr20:62609394	G/A	cg24354818	chr20:62328094	TNFRSF6B	0.35	4.93	0.31	1.54e-6	Tonsillectomy;
SARC	cis	rs7824557	0.603	rs6995404	chr8:11182148	C/G	cg21775007	chr8:11205619	TDH	0.63	8.16	0.47	2.05e-14	Retinal vascular caliber;
SARC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg10862848	chr6:42927986	GNMT	0.45	7.4	0.44	2.4e-12	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg26335602	chr6:28129616	ZNF389	0.46	5.12	0.32	6.47e-7	Cardiac Troponin-T levels;
SARC	cis	rs796364	0.507	rs13035874	chr2:201109553	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.42	-4.84	-0.3	2.35e-6	Schizophrenia;
SARC	cis	rs3126085	0.877	rs10888472	chr1:152206896	C/G	cg03465714	chr1:152285911	FLG	0.51	5.86	0.36	1.58e-8	Atopic dermatitis;
SARC	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg18404041	chr3:52824283	ITIH1	0.45	6.69	0.4	1.61e-10	Bipolar disorder;
SARC	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg16405210	chr4:1374714	KIAA1530	-0.47	-5.46	-0.34	1.21e-7	Obesity-related traits;
SARC	cis	rs10876993	0.890	rs12302350	chr12:58062589	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.48	-6.12	-0.37	4.02e-9	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs7264396	0.747	rs2425112	chr20:34319775	A/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	6.01	0.37	7.06e-9	Total cholesterol levels;
SARC	cis	rs7914558	1.000	rs943036	chr10:104836047	T/C	cg04362960	chr10:104952993	NT5C2	0.4	4.85	0.3	2.27e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs8051517	1.000	rs12925682	chr16:68372702	A/G	cg01866162	chr16:67596514	CTCF	0.85	5.31	0.33	2.56e-7	Blood protein levels;
SARC	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	15.01	0.7	4.27e-36	Chronic sinus infection;
SARC	cis	rs2908197	0.737	rs6465097	chr7:75972914	T/C	cg07849177	chr7:76178544	LOC100133091	-0.43	-4.92	-0.31	1.66e-6	3-hydroxypropylmercapturic acid levels in smokers;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg22888751	chr2:175584400	NA	0.49	6.99	0.42	2.79e-11	Thyroid stimulating hormone;
SARC	cis	rs25645	0.760	rs11870683	chr17:38129841	T/A	cg17344932	chr17:38183730	MED24;SNORD124	0.4	7.0	0.42	2.65e-11	Myeloid white cell count;
SARC	cis	rs2749592	0.550	rs10764135	chr10:37866845	C/T	cg00409905	chr10:38381863	ZNF37A	0.54	7.21	0.43	7.55e-12	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.46	5.87	0.36	1.53e-8	Gut microbiome composition (summer);
SARC	cis	rs3771570	1.000	rs3771564	chr2:242355701	G/A	cg21155796	chr2:242212141	HDLBP	0.64	5.91	0.36	1.22e-8	Prostate cancer;
SARC	cis	rs17021463	0.934	rs28403447	chr4:95257753	G/A	cg11021082	chr4:95130006	SMARCAD1	0.45	6.83	0.41	7.22e-11	Testicular germ cell tumor;
SARC	cis	rs9354308	0.903	rs1938064	chr6:66559172	T/C	cg07460842	chr6:66804631	NA	-0.45	-5.19	-0.32	4.6e-7	Metabolite levels;
SARC	cis	rs10782582	0.586	rs12130324	chr1:76370012	A/G	cg03433033	chr1:76189801	ACADM	-0.4	-5.11	-0.32	6.71e-7	Daytime sleep phenotypes;
SARC	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg26335602	chr6:28129616	ZNF389	0.52	5.88	0.36	1.44e-8	Depression;
SARC	cis	rs7712401	0.525	rs2910150	chr5:122296745	G/T	cg19412675	chr5:122181750	SNX24	0.4	5.13	0.32	5.98e-7	Mean platelet volume;
SARC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg13397359	chr6:42928475	GNMT	0.58	8.05	0.47	4.25e-14	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs3087591	0.960	rs2018634	chr17:29560678	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.48	-5.86	-0.36	1.57e-8	Hip circumference;
SARC	cis	rs6735179	0.729	rs2382561	chr2:1763501	C/T	cg08534653	chr2:1747700	PXDN	0.38	4.72	0.3	4.01e-6	Response to antipsychotic treatment;
SARC	cis	rs9611519	0.780	rs9611528	chr22:41648502	T/C	cg17376030	chr22:41985996	PMM1	0.56	7.1	0.42	1.47e-11	Neuroticism;
SARC	cis	rs288326	0.561	rs79908577	chr2:183712172	T/G	cg09997497	chr2:183902928	NCKAP1	0.69	4.81	0.3	2.67e-6	Blood protein levels;
SARC	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg12463550	chr7:65579703	CRCP	0.68	5.15	0.32	5.48e-7	Diabetic kidney disease;
SARC	cis	rs11723261	0.582	rs4582104	chr4:136942	A/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.35	4.88	0.3	2.01e-6	Immune response to smallpox vaccine (IL-6);
SARC	cis	rs6088580	0.634	rs6141471	chr20:33006730	A/G	cg24642439	chr20:33292090	TP53INP2	-0.65	-8.43	-0.48	3.57e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs7529073	0.740	rs340883	chr1:214145706	A/G	cg24083324	chr1:214162604	PROX1	-0.38	-5.34	-0.33	2.23e-7	Schizophrenia;
SARC	cis	rs2645694	0.603	rs2703123	chr4:77821154	C/T	cg18351406	chr4:77819688	ANKRD56	0.45	6.31	0.38	1.37e-9	Emphysema distribution in smoking;
SARC	cis	rs753778	0.962	rs2043422	chr8:142236337	C/T	cg18755752	chr8:142205143	DENND3	-0.43	-5.31	-0.33	2.62e-7	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs6430585	0.583	rs79176913	chr2:136638113	C/A	cg07169764	chr2:136633963	MCM6	1.13	16.65	0.74	1.5e-41	Corneal structure;
SARC	cis	rs10089	1.000	rs7703634	chr5:127509223	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	9.01	0.51	7.68e-17	Ileal carcinoids;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg19721680	chr1:244816665	PPPDE1	-0.48	-6.4	-0.39	8.42e-10	Electrocardiographic conduction measures;
SARC	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg13699009	chr12:122356056	WDR66	0.59	9.58	0.53	1.51e-18	Mean corpuscular volume;
SARC	cis	rs7937682	0.632	rs12785809	chr11:111776055	T/A	cg09085632	chr11:111637200	PPP2R1B	0.8	10.64	0.57	8.05e-22	Primary sclerosing cholangitis;
SARC	cis	rs77372450	0.636	rs11465226	chr5:157003651	G/T	cg23851860	chr5:157002805	ADAM19	-0.52	-4.86	-0.3	2.18e-6	Bipolar disorder (body mass index interaction);
SARC	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg20102877	chr2:27665638	KRTCAP3	-0.36	-4.99	-0.31	1.21e-6	Total body bone mineral density;
SARC	cis	rs3733585	0.699	rs6449172	chr4:9966036	A/T	cg11266682	chr4:10021025	SLC2A9	-0.36	-6.23	-0.38	2.2e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg12564285	chr5:131593104	PDLIM4	0.35	5.27	0.33	3.15e-7	Breast cancer;
SARC	cis	rs782590	0.774	rs782632	chr2:55898290	C/G	cg18811423	chr2:55921094	PNPT1	0.69	10.52	0.57	1.94e-21	Metabolic syndrome;
SARC	cis	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg12463550	chr7:65579703	CRCP	0.69	5.24	0.32	3.57e-7	Diabetic kidney disease;
SARC	trans	rs1814175	0.817	rs1851858	chr11:49855638	G/A	cg15704280	chr7:45808275	SEPT13	-0.97	-18.17	-0.77	1.56e-46	Height;
SARC	cis	rs11098499	0.863	rs7678400	chr4:120461957	G/A	cg09160332	chr4:120329925	NA	-0.35	-4.77	-0.3	3.19e-6	Corneal astigmatism;
SARC	cis	rs7589342	0.566	rs11895542	chr2:106390429	G/A	cg16077055	chr2:106428750	NCK2	0.32	6.27	0.38	1.71e-9	Addiction;
SARC	cis	rs2120019	0.567	rs72625793	chr15:75207083	A/G	cg17294928	chr15:75287854	SCAMP5	-0.9	-9.36	-0.52	6.9e-18	Blood trace element (Zn levels);
SARC	cis	rs2273669	0.588	rs114414265	chr6:109306489	C/A	cg05315195	chr6:109294784	ARMC2	-0.57	-5.11	-0.32	6.79e-7	Prostate cancer;
SARC	cis	rs113507773	1	rs113507773	chr6:26255739	G/A	cg00631329	chr6:26305371	NA	-0.74	-6.56	-0.39	3.47e-10	Iron status biomarkers (transferrin saturation);Iron status biomarkers (iron levels);
SARC	cis	rs4642101	0.628	rs1003080	chr3:12811628	C/T	cg05775895	chr3:12838266	CAND2	-0.6	-8.83	-0.5	2.52e-16	QRS complex (12-leadsum);
SARC	cis	rs477692	1.000	rs516704	chr10:131419879	G/A	cg05714579	chr10:131428358	MGMT	0.56	7.28	0.43	5.02e-12	Response to temozolomide;
SARC	cis	rs9911578	1.000	rs4793952	chr17:56608465	C/T	cg12560992	chr17:57184187	TRIM37	-0.81	-10.77	-0.58	3.18e-22	Intelligence (multi-trait analysis);
SARC	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg11766577	chr21:47581405	C21orf56	-0.45	-5.47	-0.34	1.17e-7	Testicular germ cell tumor;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg11075937	chr13:46626275	ZC3H13	-0.46	-6.47	-0.39	5.67e-10	Thyroid stimulating hormone;
SARC	cis	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg03060546	chr3:49711283	APEH	0.73	10.57	0.57	1.34e-21	Resting heart rate;
SARC	cis	rs600231	0.508	rs35292734	chr11:65227700	C/T	cg17120908	chr11:65337727	SSSCA1	-0.46	-5.06	-0.31	8.36e-7	Bone mineral density;
SARC	cis	rs6580649	1.000	rs9805048	chr12:48403692	C/T	cg24011408	chr12:48396354	COL2A1	0.54	6.38	0.39	9.53e-10	Lung cancer;
SARC	cis	rs4713675	0.584	rs6457739	chr6:33673831	A/G	cg15676125	chr6:33679581	C6orf125	0.52	6.36	0.38	1.03e-9	Plateletcrit;
SARC	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg02725872	chr8:58115012	NA	-0.34	-5.37	-0.33	1.91e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.16	-0.37	3.13e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg06636001	chr8:8085503	FLJ10661	0.58	7.79	0.45	2.24e-13	Retinal vascular caliber;
SARC	cis	rs2836950	0.762	rs8134638	chr21:40644170	T/C	cg17971929	chr21:40555470	PSMG1	-0.41	-4.84	-0.3	2.37e-6	Menarche (age at onset);
SARC	cis	rs7582180	0.764	rs1946799	chr2:100921136	C/A	cg14675211	chr2:100938903	LONRF2	0.51	7.53	0.44	1.1e-12	Intelligence (multi-trait analysis);
SARC	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg04756594	chr16:24857601	SLC5A11	-0.48	-6.16	-0.37	3.08e-9	Intelligence (multi-trait analysis);
SARC	cis	rs2070488	0.965	rs3762791	chr3:38568828	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.81	-12.96	-0.65	2.79e-29	Electrocardiographic conduction measures;
SARC	cis	rs2276314	1.000	rs56050783	chr18:33553791	A/G	cg05985134	chr18:33552581	C18orf21	0.74	8.03	0.47	4.88e-14	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs2273669	0.667	rs11153155	chr6:109359963	G/A	cg05315195	chr6:109294784	ARMC2	-0.63	-5.7	-0.35	3.6e-8	Prostate cancer;
SARC	cis	rs2463822	0.614	rs117699706	chr11:62161659	T/C	cg06239285	chr11:62104954	ASRGL1	-0.85	-8.05	-0.47	4.25e-14	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs763121	0.853	rs3788545	chr22:39065172	A/G	cg21395723	chr22:39101663	GTPBP1	0.51	5.59	0.34	6.29e-8	Menopause (age at onset);
SARC	cis	rs10782582	0.609	rs1159215	chr1:76317869	A/T	cg03433033	chr1:76189801	ACADM	-0.38	-5.11	-0.32	6.62e-7	Daytime sleep phenotypes;
SARC	cis	rs1153858	1.000	rs66528868	chr15:45668547	A/C	cg26924012	chr15:45694286	SPATA5L1	0.79	11.28	0.59	7.91e-24	Homoarginine levels;
SARC	cis	rs185538822	1	rs185538822	chr4:106803682	A/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.89	4.91	0.31	1.7e-6	Post bronchodilator FEV1;
SARC	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg18876405	chr7:65276391	NA	0.49	6.05	0.37	5.69e-9	Aortic root size;
SARC	cis	rs1865721	1.000	rs7236756	chr18:73175689	T/C	cg26385618	chr18:73139727	C18orf62	-0.35	-4.73	-0.3	3.87e-6	Intelligence;
SARC	cis	rs6964587	1.000	rs1859114	chr7:91682848	T/C	cg17063962	chr7:91808500	NA	0.96	16.21	0.73	4.33e-40	Breast cancer;
SARC	cis	rs1348850	0.793	rs6734528	chr2:178493731	G/A	cg22681709	chr2:178499509	PDE11A	-0.37	-4.9	-0.31	1.8e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs10911232	0.507	rs4442336	chr1:182982538	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.72	10.87	0.58	1.6e-22	Hypertriglyceridemia;
SARC	cis	rs9911578	0.967	rs8182277	chr17:57144367	C/T	cg12560992	chr17:57184187	TRIM37	0.87	12.54	0.63	6.5e-28	Intelligence (multi-trait analysis);
SARC	cis	rs1003719	0.788	rs1543749	chr21:38446621	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.67	9.98	0.55	9.49e-20	Eye color traits;
SARC	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg11644478	chr21:40555479	PSMG1	1.03	14.57	0.69	1.33e-34	Cognitive function;
SARC	cis	rs2735413	0.781	rs11649473	chr16:78077238	C/T	cg04733911	chr16:78082701	NA	-0.31	-5.61	-0.34	5.78e-8	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs7659604	0.502	rs10013916	chr4:122702179	T/G	cg19671926	chr4:122722719	EXOSC9	0.66	8.81	0.5	2.84e-16	Type 2 diabetes;
SARC	cis	rs2594989	0.565	rs9848960	chr3:11601360	C/T	cg00170343	chr3:11313890	ATG7	-0.52	-5.54	-0.34	8.33e-8	Circulating chemerin levels;
SARC	cis	rs7615952	0.551	rs6438945	chr3:125634473	G/A	cg05084668	chr3:125655381	ALG1L	-0.66	-6.41	-0.39	8.14e-10	Blood pressure (smoking interaction);
SARC	cis	rs722599	0.748	rs3742783	chr14:75377008	C/T	cg08847533	chr14:75593920	NEK9	-0.42	-4.84	-0.3	2.4e-6	IgG glycosylation;
SARC	cis	rs10779751	0.734	rs1034528	chr1:11249132	G/C	cg08854313	chr1:11322531	MTOR	-0.85	-12.0	-0.62	3.76e-26	Body mass index;
SARC	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg20120463	chr17:44301886	NA	-0.35	-5.54	-0.34	8.02e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs6910061	1.000	rs6938867	chr6:11095303	A/G	cg27233058	chr6:11094804	LOC221710	0.57	5.5	0.34	1.02e-7	Diabetic kidney disease;
SARC	cis	rs524281	0.773	rs2298468	chr11:66042962	G/A	cg14036092	chr11:66035641	RAB1B	-0.59	-5.93	-0.36	1.11e-8	Electroencephalogram traits;
SARC	cis	rs1355223	0.506	rs7131272	chr11:34869548	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.46	5.76	0.35	2.67e-8	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs896854	0.738	rs527234	chr8:95963798	C/G	cg13393036	chr8:95962371	TP53INP1	0.3	5.01	0.31	1.07e-6	Type 2 diabetes;
SARC	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg22683308	chr4:1340831	KIAA1530	0.44	5.28	0.33	2.94e-7	Longevity;
SARC	cis	rs16976116	0.901	rs28535372	chr15:55500602	T/C	cg17854078	chr15:55489399	RSL24D1	0.66	6.53	0.39	4.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs11608355	0.532	rs7968387	chr12:109788019	A/C	cg19025524	chr12:109796872	NA	-0.4	-5.53	-0.34	8.78e-8	Neuroticism;
SARC	cis	rs4906332	0.811	rs2021965	chr14:103997248	C/A	cg09185829	chr14:104603440	NA	-0.48	-4.75	-0.3	3.55e-6	Coronary artery disease;
SARC	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg05890377	chr2:74357713	NA	0.55	6.94	0.41	3.92e-11	Gestational age at birth (maternal effect);
SARC	cis	rs6964587	0.626	rs7807765	chr7:91531974	C/A	cg17063962	chr7:91808500	NA	-0.77	-11.37	-0.6	4.16e-24	Breast cancer;
SARC	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-5.73	-0.35	3.13e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs7264396	0.563	rs61191623	chr20:34219987	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	5.11	0.32	6.63e-7	Total cholesterol levels;
SARC	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg02951883	chr7:2050386	MAD1L1	-0.48	-6.29	-0.38	1.55e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg21724239	chr8:58056113	NA	0.63	5.99	0.37	7.96e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7589342	0.862	rs12613864	chr2:106515869	G/A	cg16077055	chr2:106428750	NCK2	0.38	6.94	0.41	3.95e-11	Addiction;
SARC	cis	rs1568889	0.712	rs4567438	chr11:28380051	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.68	8.14	0.47	2.45e-14	Bipolar disorder;
SARC	cis	rs908922	0.676	rs10888492	chr1:152499908	G/C	cg09873164	chr1:152488093	CRCT1	0.65	8.42	0.48	3.76e-15	Hair morphology;
SARC	trans	rs17221829	0.733	rs11018668	chr11:89356178	C/T	cg17951613	chr5:131705445	SLC22A5	-0.46	-6.24	-0.38	2.02e-9	Anxiety in major depressive disorder;
SARC	cis	rs7726839	0.561	rs72703046	chr5:580129	T/C	cg07777115	chr5:623756	CEP72	-0.61	-5.53	-0.34	8.61e-8	Obesity-related traits;
SARC	cis	rs2295359	0.824	rs11209003	chr1:67601132	G/T	cg03340356	chr1:67600835	NA	0.38	4.89	0.31	1.85e-6	Psoriasis;
SARC	cis	rs1167827	0.710	rs1167836	chr7:75168900	T/A	cg09988129	chr7:74988866	PMS2L2;STAG3L1	0.59	6.98	0.42	3.03e-11	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs4268898	0.697	rs10445892	chr2:24406958	T/C	cg26838691	chr2:24397539	C2orf84	0.42	5.71	0.35	3.44e-8	Asthma;
SARC	cis	rs6484504	0.625	rs6484501	chr11:31373100	G/T	cg26647111	chr11:31128758	NA	0.39	4.98	0.31	1.23e-6	Red blood cell count;
SARC	cis	rs8064024	0.680	rs2063101	chr16:4916348	A/G	cg08329684	chr16:4932620	PPL	0.36	5.58	0.34	6.81e-8	Cancer;
SARC	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-6.09	-0.37	4.54e-9	Personality dimensions;
SARC	cis	rs910316	1.000	rs11159117	chr14:75584867	C/T	cg23033748	chr14:75592666	NEK9	0.38	5.3	0.33	2.66e-7	Height;
SARC	cis	rs16937	0.574	rs10900455	chr1:205123534	T/C	cg21643547	chr1:205240462	TMCC2	-0.43	-5.3	-0.33	2.67e-7	Schizophrenia;
SARC	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg18876405	chr7:65276391	NA	-0.46	-5.55	-0.34	7.69e-8	Aortic root size;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg17041101	chr6:105259926	HACE1	-0.56	-7.11	-0.42	1.38e-11	Alcohol dependence;
SARC	cis	rs6693567	0.565	rs578353	chr1:150287884	C/G	cg09579323	chr1:150459698	TARS2	0.39	5.02	0.31	1.01e-6	Migraine;
SARC	trans	rs1814175	0.817	rs7947526	chr11:49983654	T/C	cg15704280	chr7:45808275	SEPT13	-0.97	-18.35	-0.77	4.06e-47	Height;
SARC	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg03264133	chr6:25882463	NA	-0.53	-6.99	-0.42	2.89e-11	Intelligence (multi-trait analysis);
SARC	cis	rs1865760	0.566	rs7772312	chr6:26049616	G/C	cg10373733	chr6:25993375	NA	0.41	5.01	0.31	1.1e-6	Height;
SARC	cis	rs1005277	0.638	rs1005278	chr10:38218748	G/A	cg14184794	chr10:39023095	NA	0.32	4.94	0.31	1.53e-6	Extrinsic epigenetic age acceleration;
SARC	cis	rs3733346	0.529	rs6842493	chr4:914638	T/C	cg20916646	chr4:852691	GAK	0.45	6.13	0.37	3.76e-9	Sjögren's syndrome;
SARC	cis	rs10463316	0.894	rs4099168	chr5:150766467	A/G	cg03212797	chr5:150827313	SLC36A1	-0.44	-5.26	-0.33	3.34e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg16991341	chr13:111554054	ANKRD10	0.9	7.13	0.42	1.28e-11	Obesity-related traits;
SARC	trans	rs208520	0.821	rs9363572	chr6:67012231	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.82	8.32	0.48	7.56e-15	Exhaled nitric oxide output;
SARC	cis	rs1971762	0.545	rs10747676	chr12:54049930	T/C	cg06632207	chr12:54070931	ATP5G2	0.61	8.43	0.48	3.63e-15	Height;
SARC	cis	rs7647973	0.961	rs10154992	chr3:49276077	C/T	cg06212747	chr3:49208901	KLHDC8B	0.59	6.39	0.39	8.87e-10	Menarche (age at onset);
SARC	cis	rs13191362	1.000	rs66594243	chr6:163169024	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.43	5.3	0.33	2.71e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs11687170	0.882	rs11680082	chr2:237057668	C/T	cg19324714	chr2:237145437	ASB18	0.49	4.89	0.31	1.89e-6	Educational attainment;Educational attainment (years of education);
SARC	cis	rs883115	0.791	rs10799589	chr1:224819278	C/T	cg01808320	chr1:224927238	CNIH3	0.35	5.49	0.34	1.05e-7	Cancer;
SARC	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg25427524	chr10:38739819	LOC399744	-0.61	-9.92	-0.54	1.41e-19	Extrinsic epigenetic age acceleration;
SARC	cis	rs8013055	0.898	rs8014913	chr14:105977313	T/C	cg19700328	chr14:106028568	NA	-0.6	-8.51	-0.49	2.19e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
SARC	cis	rs2304069	0.954	rs1469691	chr5:149386716	G/A	cg12661370	chr5:149340060	SLC26A2	0.59	5.61	0.34	5.73e-8	HIV-1 control;
SARC	cis	rs425277	1.000	rs74877653	chr1:2065949	C/T	cg21442419	chr1:2182373	SKI	-0.52	-6.5	-0.39	4.9e-10	Height;
SARC	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg18876405	chr7:65276391	NA	0.47	5.67	0.35	4.11e-8	Aortic root size;
SARC	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg14773178	chr5:1868261	NA	0.34	5.3	0.33	2.64e-7	Cardiovascular disease risk factors;
SARC	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg17376030	chr22:41985996	PMM1	-0.68	-8.73	-0.5	5.08e-16	Vitiligo;
SARC	cis	rs11098499	0.954	rs28429722	chr4:120300093	G/A	cg09307838	chr4:120376055	NA	0.91	12.88	0.65	4.9e-29	Corneal astigmatism;
SARC	trans	rs1814175	0.791	rs11040472	chr11:49703116	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-17.89	-0.76	1.3e-45	Height;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg14807549	chr2:179315948	PRKRA;MIR548N;DFNB59	0.52	6.92	0.41	4.31e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs75064307	0.834	rs4855561	chr3:108116331	T/C	cg03329597	chr3:108125523	MYH15	0.47	4.81	0.3	2.73e-6	Intelligence (multi-trait analysis);
SARC	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg02018176	chr4:1364513	KIAA1530	-0.36	-5.16	-0.32	5.18e-7	Obesity-related traits;
SARC	cis	rs9916302	0.904	rs4795356	chr17:37535631	C/T	cg20243544	chr17:37824526	PNMT	-0.55	-6.66	-0.4	1.93e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs12369635	1.000	rs73159540	chr12:129559421	C/T	cg01909103	chr12:129572610	TMEM132D	-0.67	-6.27	-0.38	1.78e-9	Schizophrenia (inflammation and infection response interaction);
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22992573	chr12:95611779	VEZT;FGD6	0.54	6.78	0.41	9.54e-11	Smoking initiation;
SARC	cis	rs11997175	0.740	rs4733462	chr8:33679904	A/G	ch.8.33884649F	chr8:33765107	NA	0.55	7.43	0.44	2.04e-12	Body mass index;
SARC	cis	rs752092	0.925	rs8032007	chr15:101790817	C/T	cg25114630	chr15:101792522	CHSY1	-0.43	-5.03	-0.31	9.72e-7	Corneal structure;
SARC	cis	rs11608355	0.515	rs2287191	chr12:109931741	C/T	cg05360138	chr12:110035743	NA	0.92	9.39	0.52	5.78e-18	Neuroticism;
SARC	cis	rs2043112	1.000	rs7318	chr5:38935682	C/T	cg04869206	chr5:39074266	RICTOR	0.5	6.17	0.37	3.07e-9	Obesity-related traits;
SARC	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg12463550	chr7:65579703	CRCP	-0.5	-5.59	-0.34	6.32e-8	Aortic root size;
SARC	cis	rs1536827	0.620	rs10857735	chr10:135336230	A/C	cg22671611	chr10:135291010	NA	0.47	4.72	0.3	4.08e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs4555082	0.874	rs78923231	chr14:105754033	C/T	cg06808227	chr14:105710500	BRF1	-0.5	-6.28	-0.38	1.63e-9	Mean platelet volume;Platelet distribution width;
SARC	cis	rs796364	0.806	rs12619136	chr2:200910347	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.69	-5.65	-0.35	4.63e-8	Schizophrenia;
SARC	cis	rs7666738	0.753	rs9991512	chr4:99007205	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1153858	0.945	rs7182300	chr15:45634928	G/A	cg03999130	chr15:45571217	NA	0.4	5.21	0.32	4.21e-7	Homoarginine levels;
SARC	cis	rs9309473	0.718	rs6546829	chr2:73613789	C/G	cg20560298	chr2:73613845	ALMS1	-0.53	-6.74	-0.4	1.25e-10	Metabolite levels;
SARC	cis	rs73242632	1.000	rs73242622	chr4:57818564	C/T	cg20415529	chr4:57845134	POLR2B;C4orf14	0.99	5.73	0.35	3.07e-8	Congenital heart disease (maternal effect);
SARC	cis	rs4742903	0.904	rs1507510	chr9:106985153	T/A	cg14250997	chr9:106856677	SMC2	0.4	4.98	0.31	1.23e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs5753618	0.504	rs9609329	chr22:31966313	A/C	cg02404636	chr22:31891804	SFI1	0.52	5.72	0.35	3.34e-8	Colorectal cancer;
SARC	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg15049968	chr18:44337910	ST8SIA5	-0.36	-5.74	-0.35	2.95e-8	Personality dimensions;
SARC	cis	rs11098499	0.954	rs11729521	chr4:120416788	T/C	cg24375607	chr4:120327624	NA	0.42	4.92	0.31	1.65e-6	Corneal astigmatism;
SARC	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	cis	rs6831352	0.879	rs1984364	chr4:100070783	A/C	cg12011299	chr4:100065546	ADH4	-0.32	-5.09	-0.32	7.33e-7	Alcohol dependence;
SARC	cis	rs9788682	0.747	rs2915695	chr15:78739471	T/C	cg24631222	chr15:78858424	CHRNA5	-0.77	-9.54	-0.53	1.96e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs16976116	0.901	rs28526269	chr15:55499190	A/G	cg17854078	chr15:55489399	RSL24D1	0.66	6.53	0.39	4.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7666738	0.791	rs13125277	chr4:99009922	T/G	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2997447	0.637	rs3008413	chr1:26407063	G/A	cg19633962	chr1:26362018	EXTL1	-0.61	-5.59	-0.34	6.3e-8	QRS complex (12-leadsum);
SARC	cis	rs9916302	0.561	rs12453198	chr17:37741879	T/C	cg00129232	chr17:37814104	STARD3	-0.66	-7.08	-0.42	1.67e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs870825	0.616	rs28579226	chr4:185650458	A/C	cg04058563	chr4:185651563	MLF1IP	0.8	11.37	0.6	3.9e-24	Blood protein levels;
SARC	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.9	11.72	0.61	3.13e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs708547	0.874	rs1713978	chr4:57875879	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.69	8.26	0.48	1.08e-14	Response to bleomycin (chromatid breaks);
SARC	cis	rs8067545	0.750	rs9897653	chr17:19987924	G/A	cg13482628	chr17:19912719	NA	0.53	7.02	0.42	2.47e-11	Schizophrenia;
SARC	cis	rs763121	0.853	rs3747170	chr22:39067331	G/A	cg06022373	chr22:39101656	GTPBP1	0.86	10.71	0.57	4.88e-22	Menopause (age at onset);
SARC	cis	rs9818758	0.607	rs73082362	chr3:49113729	C/T	cg00383909	chr3:49044727	WDR6	0.78	6.16	0.37	3.16e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg24542046	chr7:102782124	NAPEPLD;RPL19P12	-0.49	-6.8	-0.41	8.91e-11	Height;
SARC	cis	rs1215050	0.740	rs185468	chr4:98756242	C/T	cg05340658	chr4:99064831	C4orf37	0.44	5.85	0.36	1.65e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs2180341	0.961	rs7774468	chr6:127592501	G/C	cg27446573	chr6:127587934	RNF146	1.01	14.15	0.68	3.29e-33	Breast cancer;
SARC	cis	rs6580649	0.941	rs7963934	chr12:48477086	C/G	cg05342945	chr12:48394962	COL2A1	0.55	5.91	0.36	1.22e-8	Lung cancer;
SARC	cis	rs10513788	1.000	rs115329674	chr3:182067083	C/T	cg05977900	chr3:182512126	ATP11B	0.48	4.72	0.3	4.08e-6	Cognitive function;
SARC	cis	rs73206853	0.764	rs56127909	chr12:110833763	G/A	cg10860002	chr12:110842031	ANAPC7	0.63	5.03	0.31	9.95e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs7178572	0.568	rs7176302	chr15:77671216	C/G	cg22256960	chr15:77711686	NA	-0.53	-5.88	-0.36	1.39e-8	Type 2 diabetes;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg06009432	chr2:178483847	TTC30A	-0.48	-6.25	-0.38	1.91e-9	Neuroticism;
SARC	cis	rs8523	0.779	rs67580629	chr6:11006026	A/G	cg13562911	chr6:11044106	ELOVL2	0.47	6.32	0.38	1.29e-9	Red blood cell fatty acid levels;
SARC	cis	rs11676348	0.818	rs6436031	chr2:218979259	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.5	-6.4	-0.39	8.53e-10	Ulcerative colitis;
SARC	cis	rs9818758	0.607	rs56004653	chr3:49072228	T/C	cg00383909	chr3:49044727	WDR6	0.8	6.5	0.39	4.75e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs6701037	1.000	rs6681020	chr1:175125264	G/A	cg00321850	chr1:175162397	KIAA0040	-0.34	-5.02	-0.31	1.03e-6	Alcohol dependence;
SARC	cis	rs765787	0.530	rs7165889	chr15:45531640	T/C	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.51e-10	Uric acid levels;
SARC	cis	rs651907	0.513	rs34963630	chr3:101504817	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.49	5.76	0.35	2.58e-8	Colorectal cancer;
SARC	cis	rs7566780	0.523	rs2879849	chr2:16640514	G/A	cg09580478	chr2:16689509	NA	0.47	5.95	0.36	9.62e-9	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs7681440	0.874	rs1372522	chr4:90765280	A/G	cg06632027	chr4:90757378	SNCA	0.39	5.66	0.35	4.49e-8	Dementia with Lewy bodies;
SARC	cis	rs10791097	0.668	rs10791102	chr11:130744977	G/A	cg12179176	chr11:130786555	SNX19	0.74	11.09	0.59	3.11e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg13012494	chr21:47604986	C21orf56	0.43	5.03	0.31	9.62e-7	Testicular germ cell tumor;
SARC	cis	rs2425143	1.000	rs78877130	chr20:34344947	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-5.43	-0.34	1.4e-7	Blood protein levels;
SARC	cis	rs10463554	0.727	rs34768	chr5:102491502	A/G	cg23492399	chr5:102201601	PAM	-0.54	-5.76	-0.35	2.69e-8	Parkinson's disease;
SARC	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg23262073	chr20:60523788	NA	-0.44	-6.09	-0.37	4.61e-9	Body mass index;
SARC	cis	rs9916302	0.904	rs6503506	chr17:37524653	C/A	cg07936489	chr17:37558343	FBXL20	0.67	8.84	0.5	2.36e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs950776	0.518	rs55690619	chr15:78833612	A/G	cg17108064	chr15:78857060	CHRNA5	-0.29	-4.98	-0.31	1.24e-6	Sudden cardiac arrest;
SARC	cis	rs9486719	0.895	rs11152960	chr6:96900398	A/G	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.01	-0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs67460515	0.892	rs73026976	chr3:160964271	G/A	cg17135325	chr3:160939158	NMD3	0.63	7.94	0.46	8.51e-14	Parkinson's disease;
SARC	cis	rs10046574	0.561	rs7781454	chr7:135205422	A/G	cg27474649	chr7:135195673	CNOT4	0.82	7.94	0.46	8.8e-14	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs13256369	0.950	rs13248096	chr8:8577476	C/T	cg17143192	chr8:8559678	CLDN23	0.53	5.85	0.36	1.63e-8	Obesity-related traits;
SARC	cis	rs910316	0.967	rs175479	chr14:75561871	A/C	cg11812906	chr14:75593930	NEK9	-0.83	-12.55	-0.64	5.99e-28	Height;
SARC	cis	rs10752881	1.000	rs4233193	chr1:182970865	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.88	0.58	1.46e-22	Colorectal cancer;
SARC	cis	rs7584330	0.910	rs66509917	chr2:238395394	T/G	cg11271282	chr2:238384023	NA	0.44	5.27	0.33	3.15e-7	Prostate cancer;
SARC	cis	rs6831352	0.918	rs17218162	chr4:100056060	G/A	cg13256891	chr4:100009986	ADH5	-0.64	-7.95	-0.46	7.96e-14	Alcohol dependence;
SARC	cis	rs2204008	0.694	rs1672436	chr12:38132547	G/T	cg14851346	chr12:38532713	NA	-0.45	-5.32	-0.33	2.45e-7	Bladder cancer;
SARC	cis	rs9325144	0.678	rs7315271	chr12:39164731	A/G	cg13010199	chr12:38710504	ALG10B	-0.5	-6.05	-0.37	5.66e-9	Morning vs. evening chronotype;
SARC	cis	rs986417	1.000	rs1956549	chr14:60928201	G/A	cg27398547	chr14:60952738	C14orf39	1.02	9.54	0.53	2.06e-18	Gut microbiota (bacterial taxa);
SARC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg02353165	chr6:42928485	GNMT	0.65	8.9	0.5	1.57e-16	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs9828933	0.938	rs3816157	chr3:63999322	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	-0.7	-6.02	-0.37	6.72e-9	Type 2 diabetes;
SARC	cis	rs644799	0.930	rs3802764	chr11:95514599	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.87	13.82	0.67	4.02e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs62244186	0.659	rs12108134	chr3:44543030	A/G	cg15225532	chr3:44803084	KIF15;KIAA1143	-0.46	-5.77	-0.35	2.47e-8	Depressive symptoms;
SARC	cis	rs1983891	1.000	rs9381082	chr6:41542214	T/C	cg20194872	chr6:41519635	FOXP4	0.35	4.73	0.3	3.91e-6	Prostate cancer;
SARC	cis	rs2414059	0.518	rs3098176	chr15:50781963	T/A	cg05456662	chr15:50716270	USP8	0.39	4.86	0.3	2.19e-6	QT interval;
SARC	trans	rs11098499	0.954	rs1480931	chr4:120395809	G/T	cg25214090	chr10:38739885	LOC399744	0.57	7.47	0.44	1.64e-12	Corneal astigmatism;
SARC	trans	rs61931739	0.534	rs11052984	chr12:34045904	T/C	cg13010199	chr12:38710504	ALG10B	0.67	9.1	0.51	4.09e-17	Morning vs. evening chronotype;
SARC	cis	rs11098499	0.532	rs4504231	chr4:120586891	G/A	cg09307838	chr4:120376055	NA	0.77	10.62	0.57	9.48e-22	Corneal astigmatism;
SARC	cis	rs11583043	0.918	rs6693456	chr1:101424561	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.48	5.85	0.36	1.66e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs7402982	0.934	rs6598539	chr15:99204483	T/C	cg03437748	chr15:99193247	IGF1R	0.88	12.35	0.63	2.64e-27	Birth weight;
SARC	cis	rs7615952	0.599	rs2279821	chr3:125734308	G/A	cg15145296	chr3:125709740	NA	-0.49	-4.89	-0.31	1.85e-6	Blood pressure (smoking interaction);
SARC	cis	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg05623727	chr3:50126028	RBM5	-0.34	-5.19	-0.32	4.56e-7	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg05313129	chr8:58192883	C8orf71	-0.62	-6.46	-0.39	6.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg03060546	chr3:49711283	APEH	0.56	6.62	0.4	2.48e-10	Resting heart rate;
SARC	cis	rs3859192	0.561	rs34453912	chr17:38180352	T/A	cg17344932	chr17:38183730	MED24;SNORD124	0.41	7.56	0.44	9.07e-13	White blood cell count;
SARC	cis	rs10489202	0.608	rs10800334	chr1:168075613	T/C	cg24449463	chr1:168025552	DCAF6	-0.58	-7.25	-0.43	5.93e-12	Schizophrenia;
SARC	cis	rs1153858	0.723	rs4580098	chr15:45596909	T/A	cg21132104	chr15:45694354	SPATA5L1	0.77	10.0	0.55	8.12e-20	Homoarginine levels;
SARC	cis	rs698833	0.819	rs12053381	chr2:44570804	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.74	9.65	0.53	9.09e-19	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs17270561	0.609	rs1892246	chr6:25764408	C/T	cg10373733	chr6:25993375	NA	0.4	4.75	0.3	3.6e-6	Iron status biomarkers;
SARC	cis	rs7528419	0.591	rs4970837	chr1:109822008	G/T	cg00908766	chr1:109817496	CELSR2	0.48	6.8	0.41	8.93e-11	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
SARC	cis	rs2658782	0.789	rs3020076	chr11:93141058	C/T	cg15737290	chr11:93063684	CCDC67	0.67	7.23	0.43	6.96e-12	Pulmonary function decline;
SARC	cis	rs5753037	0.676	rs6006267	chr22:30216982	C/A	cg01021169	chr22:30184971	ASCC2	-0.39	-5.19	-0.32	4.61e-7	Type 1 diabetes;
SARC	cis	rs12701220	0.595	rs12532837	chr7:1122851	T/A	cg10374962	chr7:1011985	COX19	-0.43	-4.73	-0.3	3.91e-6	Bronchopulmonary dysplasia;
SARC	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg08045932	chr20:61659980	NA	0.5	6.84	0.41	7.06e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs7617773	0.780	rs13082859	chr3:48344675	C/T	cg11946769	chr3:48343235	NME6	0.76	9.7	0.54	6.55e-19	Coronary artery disease;
SARC	cis	rs599083	0.530	rs2472415	chr11:68185616	T/C	cg01657329	chr11:68192670	LRP5	0.47	6.36	0.38	1.07e-9	Bone mineral density (spine);
SARC	cis	rs2522056	1.000	rs2706379	chr5:131805735	C/T	cg24060327	chr5:131705240	SLC22A5	0.48	4.76	0.3	3.47e-6	Lymphocyte counts;Fibrinogen;
SARC	cis	rs3741404	0.620	rs12787945	chr11:63977546	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	9.88	0.54	1.85e-19	Platelet count;
SARC	cis	rs3741151	0.686	rs7941359	chr11:73158119	A/G	cg17517138	chr11:73019481	ARHGEF17	0.67	5.14	0.32	5.68e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs208515	0.556	rs10455193	chr6:66691456	G/A	cg07460842	chr6:66804631	NA	0.96	11.03	0.59	4.77e-23	Exhaled nitric oxide levels;
SARC	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.61	7.4	0.44	2.43e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2075371	0.796	rs1978504	chr7:134006933	C/T	cg00033643	chr7:134001901	SLC35B4	-0.45	-5.51	-0.34	9.64e-8	Mean platelet volume;
SARC	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg13393036	chr8:95962371	TP53INP1	-0.4	-6.73	-0.4	1.28e-10	Type 2 diabetes;
SARC	cis	rs56104184	0.830	rs55966626	chr19:49342396	G/T	cg15549821	chr19:49342101	PLEKHA4	-0.93	-9.68	-0.54	7.61e-19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs240764	0.717	rs239236	chr6:101099217	A/G	cg09795085	chr6:101329169	ASCC3	0.43	5.44	0.34	1.34e-7	Neuroticism;
SARC	cis	rs941408	0.515	rs759067	chr19:2775668	C/T	cg06609049	chr19:2785107	THOP1	0.98	15.15	0.7	1.5e-36	Total cholesterol levels;
SARC	cis	rs6570726	0.935	rs442254	chr6:145849118	T/C	cg23711669	chr6:146136114	FBXO30	0.78	12.08	0.62	2.13e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs477692	0.673	rs10764889	chr10:131341521	G/A	cg05714579	chr10:131428358	MGMT	0.56	7.19	0.43	8.6e-12	Response to temozolomide;
SARC	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg24675658	chr1:53192096	ZYG11B	0.55	7.62	0.45	6.22e-13	Monocyte count;
SARC	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg25072359	chr17:41440525	NA	0.42	5.06	0.31	8.57e-7	Menopause (age at onset);
SARC	cis	rs2204008	0.677	rs1581356	chr12:38391467	T/C	cg13010199	chr12:38710504	ALG10B	0.81	10.9	0.58	1.29e-22	Bladder cancer;
SARC	cis	rs7520050	0.966	rs4660319	chr1:46341623	C/T	cg24296786	chr1:45957014	TESK2	0.39	4.92	0.31	1.63e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs1707322	0.752	rs3811435	chr1:46125790	C/A	cg06784218	chr1:46089804	CCDC17	0.36	6.25	0.38	1.93e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9902453	0.967	rs8072664	chr17:28333385	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.52	-6.82	-0.41	7.67e-11	Coffee consumption (cups per day);
SARC	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg06558623	chr16:89946397	TCF25	0.91	6.43	0.39	7.15e-10	Skin colour saturation;
SARC	cis	rs2180341	1.000	rs3798850	chr6:127613966	C/T	cg17762328	chr6:126965162	NA	-0.46	-5.24	-0.32	3.55e-7	Breast cancer;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg19620752	chr15:99192520	IGF1R	-0.46	-6.27	-0.38	1.76e-9	Neuroticism;
SARC	cis	rs910316	0.737	rs28687415	chr14:75495482	T/C	cg08847533	chr14:75593920	NEK9	0.82	11.75	0.61	2.39e-25	Height;
SARC	cis	rs34172651	0.917	rs200533	chr16:24754771	C/T	cg00152838	chr16:24741724	TNRC6A	0.4	5.0	0.31	1.14e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg12463550	chr7:65579703	CRCP	0.65	5.03	0.31	9.96e-7	Diabetic kidney disease;
SARC	cis	rs4927850	0.958	rs2044599	chr3:195736740	G/A	cg12923728	chr3:195709715	SDHAP1	-0.69	-8.37	-0.48	5.31e-15	Pancreatic cancer;
SARC	cis	rs6570726	0.818	rs437978	chr6:145809134	A/G	cg23711669	chr6:146136114	FBXO30	0.79	12.34	0.63	2.92e-27	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg06872435	chr12:43031000	NA	-0.84	-6.84	-0.41	7.09e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg08048268	chr3:133502702	NA	0.46	6.26	0.38	1.84e-9	Iron status biomarkers;
SARC	cis	rs17401966	1.000	rs1536263	chr1:10378914	T/C	cg15208524	chr1:10270712	KIF1B	0.63	7.02	0.42	2.42e-11	Hepatocellular carcinoma;
SARC	cis	rs290268	0.874	rs290995	chr9:93559477	C/A	cg02608019	chr9:93564028	SYK	0.35	5.07	0.32	7.92e-7	Platelet count;
SARC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.7	9.53	0.53	2.1e-18	Lymphocyte counts;
SARC	cis	rs2120019	0.935	rs12591119	chr15:75355944	A/G	cg17294928	chr15:75287854	SCAMP5	-0.96	-13.78	-0.67	5.52e-32	Blood trace element (Zn levels);
SARC	cis	rs7429990	0.932	rs12486714	chr3:48148700	C/G	cg11946769	chr3:48343235	NME6	-0.46	-5.42	-0.33	1.46e-7	Educational attainment (years of education);
SARC	cis	rs1448094	0.512	rs11503595	chr12:86244075	T/A	cg02569458	chr12:86230093	RASSF9	0.39	5.44	0.34	1.34e-7	Major depressive disorder;
SARC	cis	rs763121	0.853	rs5750662	chr22:39072472	G/A	cg14440974	chr22:39074834	NA	-0.32	-4.73	-0.3	3.86e-6	Menopause (age at onset);
SARC	cis	rs898097	0.607	rs2199111	chr17:80823203	A/G	cg15369054	chr17:80825471	TBCD	0.36	5.18	0.32	4.75e-7	Breast cancer;
SARC	cis	rs9303401	0.538	rs10515155	chr17:56481944	A/G	cg25039879	chr17:56429692	SUPT4H1	0.68	6.19	0.38	2.64e-9	Cognitive test performance;
SARC	cis	rs9611519	1.000	rs3818003	chr22:41609690	C/T	cg17376030	chr22:41985996	PMM1	0.47	5.93	0.36	1.06e-8	Neuroticism;
SARC	cis	rs2832077	0.506	rs2832093	chr21:30164855	C/T	cg03476357	chr21:30257390	N6AMT1	-0.45	-4.76	-0.3	3.41e-6	Cognitive test performance;
SARC	trans	rs1814175	0.616	rs1722001	chr11:49894427	A/G	cg03929089	chr4:120376271	NA	-0.83	-12.27	-0.63	5.13e-27	Height;
SARC	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg13206674	chr6:150067644	NUP43	0.52	6.65	0.4	2.05e-10	Lung cancer;
SARC	cis	rs2276314	0.857	rs6507158	chr18:33636066	A/C	cg05985134	chr18:33552581	C18orf21	0.67	7.78	0.45	2.32e-13	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs9911578	0.835	rs1990008	chr17:56459408	C/G	cg12560992	chr17:57184187	TRIM37	-0.76	-9.65	-0.53	9.09e-19	Intelligence (multi-trait analysis);
SARC	cis	rs13191362	0.935	rs34709632	chr6:163048380	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.63	5.41	0.33	1.54e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs7246657	0.524	rs28542490	chr19:37456584	C/A	cg23950597	chr19:37808831	NA	-0.54	-4.98	-0.31	1.23e-6	Coronary artery calcification;
SARC	cis	rs9916302	0.904	rs9904334	chr17:37468336	G/A	cg20243544	chr17:37824526	PNMT	-0.55	-6.64	-0.4	2.19e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs554111	0.593	rs9426660	chr1:21520449	A/G	cg04902671	chr1:21058625	SH2D5	-0.41	-4.9	-0.31	1.82e-6	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs7246657	0.943	rs10417844	chr19:37837587	C/T	cg14683738	chr19:37701593	ZNF585B	0.51	4.99	0.31	1.16e-6	Coronary artery calcification;
SARC	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg25072359	chr17:41440525	NA	0.48	5.62	0.35	5.43e-8	Menopause (age at onset);
SARC	cis	rs9303401	0.659	rs61291849	chr17:56909867	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	11.58	0.6	8.42e-25	Cognitive test performance;
SARC	cis	rs240764	0.604	rs9377234	chr6:101263035	C/T	cg09795085	chr6:101329169	ASCC3	0.44	5.52	0.34	8.93e-8	Neuroticism;
SARC	cis	rs965469	1.000	rs6037535	chr20:3270621	C/T	cg25506879	chr20:3388711	C20orf194	-0.5	-5.04	-0.31	9.37e-7	IFN-related cytopenia;
SARC	cis	rs910316	1.000	rs10140851	chr14:75512612	G/A	cg11812906	chr14:75593930	NEK9	0.88	13.44	0.66	7.35e-31	Height;
SARC	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg08280861	chr8:58055591	NA	0.61	5.96	0.36	9.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1395	0.778	rs2580759	chr2:27432500	G/T	cg21747090	chr2:27597821	SNX17	0.45	5.51	0.34	9.51e-8	Blood metabolite levels;
SARC	cis	rs7681440	0.835	rs1899389	chr4:90802998	G/A	cg06632027	chr4:90757378	SNCA	0.41	5.73	0.35	3.07e-8	Dementia with Lewy bodies;
SARC	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg23758822	chr17:41437982	NA	0.91	11.48	0.6	1.86e-24	Menopause (age at onset);
SARC	cis	rs17384381	1.000	rs12133722	chr1:85873237	C/T	cg16011679	chr1:85725395	C1orf52	0.61	5.72	0.35	3.28e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1153858	1.000	rs10519021	chr15:45631795	G/A	cg21132104	chr15:45694354	SPATA5L1	0.8	11.2	0.59	1.46e-23	Homoarginine levels;
SARC	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg20102877	chr2:27665638	KRTCAP3	-0.34	-4.75	-0.3	3.62e-6	Total body bone mineral density;
SARC	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg18225595	chr11:63971243	STIP1	0.43	5.19	0.32	4.65e-7	Mean platelet volume;
SARC	cis	rs76419734	1.000	rs72673828	chr4:106730342	C/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	5.33	0.33	2.37e-7	Post bronchodilator FEV1;
SARC	cis	rs826838	0.616	rs2387921	chr12:38624767	T/C	cg14851346	chr12:38532713	NA	-0.44	-5.32	-0.33	2.39e-7	Heart rate;
SARC	cis	rs703842	1.000	rs10431505	chr12:58178589	A/G	cg00677455	chr12:58241039	CTDSP2	0.52	6.82	0.41	7.65e-11	Multiple sclerosis;
SARC	cis	rs9814567	1.000	rs9990351	chr3:134239191	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.54	6.71	0.4	1.48e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.76	8.85	0.5	2.23e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs472402	0.580	rs3822430	chr5:6651970	A/G	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.43	-5.18	-0.32	4.84e-7	Response to amphetamines;
SARC	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg16434002	chr17:42200994	HDAC5	-0.44	-5.16	-0.32	5.27e-7	Total body bone mineral density;
SARC	cis	rs9790314	0.521	rs13084746	chr3:161086038	G/A	cg17135325	chr3:160939158	NMD3	0.52	6.57	0.4	3.23e-10	Morning vs. evening chronotype;
SARC	cis	rs60871478	1.000	rs34260834	chr7:822958	A/G	cg19087971	chr7:751233	PRKAR1B	-0.42	-4.73	-0.3	3.89e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs9640161	0.663	rs1916932	chr7:150021644	T/C	cg10018233	chr7:150070692	REPIN1	0.7	9.92	0.54	1.46e-19	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs72781680	0.665	rs2953028	chr2:24068126	T/C	cg06627628	chr2:24431161	ITSN2	-0.56	-5.8	-0.36	2.13e-8	Lymphocyte counts;
SARC	cis	rs950776	0.506	rs12915366	chr15:78831753	G/A	cg22563815	chr15:78856949	CHRNA5	0.41	6.82	0.41	7.96e-11	Sudden cardiac arrest;
SARC	cis	rs6088580	0.634	rs6142157	chr20:32984172	C/G	cg24642439	chr20:33292090	TP53INP2	-0.66	-8.58	-0.49	1.36e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs6570726	0.905	rs396492	chr6:145816180	C/G	cg05347473	chr6:146136440	FBXO30	0.48	6.46	0.39	6.14e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	5.94	0.36	1.02e-8	Bipolar disorder;
SARC	cis	rs36051895	0.695	rs4527935	chr9:5016455	A/T	cg02405213	chr9:5042618	JAK2	-0.49	-5.32	-0.33	2.42e-7	Pediatric autoimmune diseases;
SARC	cis	rs412000	0.553	rs2680702	chr17:56431549	A/G	cg25039879	chr17:56429692	SUPT4H1	0.58	6.7	0.4	1.58e-10	Primary tooth development (time to first tooth eruption);
SARC	cis	rs9527	0.590	rs726010	chr10:104841977	C/T	cg04362960	chr10:104952993	NT5C2	0.44	5.22	0.32	3.97e-7	Arsenic metabolism;
SARC	cis	rs7595412	1.000	rs12476075	chr2:199034949	C/T	cg00208931	chr2:198669586	PLCL1	-0.69	-5.34	-0.33	2.16e-7	Hip bone size;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg11373429	chr19:10400751	ICAM5	0.49	6.32	0.38	1.3e-9	Height;
SARC	cis	rs9398803	0.830	rs1337735	chr6:126771024	T/A	cg20229609	chr6:126660872	C6orf173	0.4	5.81	0.36	2.09e-8	Male-pattern baldness;
SARC	cis	rs10911232	0.507	rs3935384	chr1:183028970	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.49	0.57	2.41e-21	Hypertriglyceridemia;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg11084020	chr7:27779567	TAX1BP1	-0.58	-6.65	-0.4	2.12e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs35146811	1.000	rs35146811	chr7:99720994	A/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.4	4.86	0.3	2.17e-6	Coronary artery disease;
SARC	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg20965017	chr5:231967	SDHA	-0.56	-5.3	-0.33	2.71e-7	Breast cancer;
SARC	trans	rs61931739	0.500	rs7971957	chr12:34477558	C/T	cg13010199	chr12:38710504	ALG10B	0.76	10.81	0.58	2.49e-22	Morning vs. evening chronotype;
SARC	cis	rs11122272	0.735	rs2247132	chr1:231493359	G/A	cg06096015	chr1:231504339	EGLN1	0.37	5.46	0.34	1.2e-7	Hemoglobin concentration;
SARC	cis	rs66887589	0.967	rs3775842	chr4:120427732	G/A	cg09307838	chr4:120376055	NA	0.51	6.88	0.41	5.53e-11	Diastolic blood pressure;
SARC	cis	rs9457247	0.579	rs2181059	chr6:167441624	T/C	cg23791538	chr6:167370224	RNASET2	-0.52	-7.03	-0.42	2.23e-11	Crohn's disease;
SARC	cis	rs2120019	1.000	rs12185102	chr15:75352201	G/A	cg09165964	chr15:75287851	SCAMP5	-0.92	-13.88	-0.67	2.59e-32	Blood trace element (Zn levels);
SARC	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg24503407	chr1:205819492	PM20D1	-0.43	-5.42	-0.33	1.49e-7	Menarche (age at onset);
SARC	cis	rs4588572	0.643	rs1560196	chr5:77701982	G/C	cg11547950	chr5:77652471	NA	0.4	4.91	0.31	1.71e-6	Triglycerides;
SARC	cis	rs11098499	0.954	rs2892848	chr4:120381341	C/T	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs10782582	0.569	rs2131557	chr1:76388589	A/C	cg03433033	chr1:76189801	ACADM	0.39	5.11	0.32	6.63e-7	Daytime sleep phenotypes;
SARC	trans	rs61931739	0.500	rs11053208	chr12:34460029	A/G	cg26384229	chr12:38710491	ALG10B	0.83	12.17	0.62	1.06e-26	Morning vs. evening chronotype;
SARC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg09373136	chr17:61933544	TCAM1	0.44	6.1	0.37	4.27e-9	Prudent dietary pattern;
SARC	cis	rs6138458	0.961	rs227625	chr20:24911618	T/C	cg26195577	chr20:24973756	C20orf3	0.88	9.75	0.54	4.69e-19	Blood protein levels;
SARC	cis	rs11574514	1.000	rs1113232	chr16:67879827	C/A	cg01866162	chr16:67596514	CTCF	1.11	6.4	0.39	8.22e-10	Crohn's disease;
SARC	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg09359103	chr1:154839909	KCNN3	-0.47	-8.09	-0.47	3.37e-14	Prostate cancer;
SARC	cis	rs2120243	0.539	rs2168431	chr3:157120029	A/T	cg24825693	chr3:157122686	VEPH1	-0.46	-6.42	-0.39	7.36e-10	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs865483	0.895	rs853208	chr17:35826456	C/A	cg06561646	chr17:35873369	DUSP14	-0.49	-6.55	-0.39	3.6e-10	Monocyte count;
SARC	cis	rs854765	0.594	rs8066560	chr17:17728043	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.57	-8.05	-0.47	4.18e-14	Total body bone mineral density;
SARC	cis	rs7666738	0.719	rs4699323	chr4:98967484	G/A	cg05340658	chr4:99064831	C4orf37	0.48	5.26	0.33	3.18e-7	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9420	0.961	rs7949841	chr11:57524700	G/C	cg23127183	chr11:57508653	C11orf31	-0.58	-6.74	-0.4	1.23e-10	Schizophrenia;
SARC	cis	rs13256369	0.901	rs13251887	chr8:8568678	G/A	cg17143192	chr8:8559678	CLDN23	0.52	6.0	0.37	7.31e-9	Obesity-related traits;
SARC	cis	rs10876993	0.855	rs1689585	chr12:58080140	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.41	5.11	0.32	6.81e-7	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs4141404	0.640	rs9606854	chr22:31930567	C/T	cg07713946	chr22:31675144	LIMK2	0.37	4.8	0.3	2.79e-6	Paclitaxel-induced neuropathy;
SARC	cis	rs4803468	0.935	rs12602	chr19:41889748	T/C	cg09537434	chr19:41945824	ATP5SL	-0.94	-16.21	-0.73	4.43e-40	Height;
SARC	trans	rs3780486	1.000	rs10813957	chr9:33153527	G/T	cg20290983	chr6:43655470	MRPS18A	1.03	14.89	0.7	1.07e-35	IgG glycosylation;
SARC	cis	rs7766436	0.848	rs66989470	chr6:22598707	G/C	cg13666174	chr6:22585274	NA	-0.6	-7.65	-0.45	5.41e-13	Coronary artery disease;
SARC	cis	rs6831352	0.734	rs12502237	chr4:100015675	G/A	cg13256891	chr4:100009986	ADH5	0.58	7.68	0.45	4.26e-13	Alcohol dependence;
SARC	trans	rs61931739	0.500	rs34703942	chr12:34583776	T/C	cg26384229	chr12:38710491	ALG10B	-0.85	-12.8	-0.64	9.59e-29	Morning vs. evening chronotype;
SARC	cis	rs1044826	0.957	rs9882014	chr3:139176535	C/T	cg15131784	chr3:139108705	COPB2	0.45	5.19	0.32	4.65e-7	Obesity-related traits;
SARC	cis	rs9796	0.505	rs28665387	chr15:41532869	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.54	-7.58	-0.44	8.18e-13	Menopause (age at onset);
SARC	cis	rs11583043	0.918	rs56402739	chr1:101397133	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.44	5.39	0.33	1.69e-7	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs2898681	0.519	rs6554057	chr4:53730147	A/T	cg00338735	chr4:53728038	RASL11B	0.49	5.41	0.33	1.57e-7	Optic nerve measurement (cup area);
SARC	cis	rs7843479	1.000	rs66824050	chr8:21815425	T/G	cg17168535	chr8:21777572	XPO7	0.61	7.82	0.46	1.84e-13	Mean corpuscular volume;
SARC	cis	rs858239	1.000	rs156407	chr7:23315639	G/A	cg23682824	chr7:23144976	KLHL7	0.63	8.02	0.46	5.23e-14	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9790314	0.690	rs7633857	chr3:160844942	C/G	cg03342759	chr3:160939853	NMD3	-0.57	-7.22	-0.43	7.36e-12	Morning vs. evening chronotype;
SARC	cis	rs4930561	0.765	rs1894204	chr11:67929671	C/T	cg16338278	chr11:67432957	ALDH3B2	0.32	5.14	0.32	5.76e-7	Breast cancer in childhood cancer survivors;IgG glycosylation;
SARC	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg18402987	chr7:1209562	NA	0.57	4.96	0.31	1.34e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs6580649	0.882	rs7133249	chr12:48456823	C/T	cg05342945	chr12:48394962	COL2A1	0.57	6.15	0.37	3.42e-9	Lung cancer;
SARC	cis	rs9325144	0.624	rs7979541	chr12:39129679	T/C	cg26384229	chr12:38710491	ALG10B	-0.57	-7.29	-0.43	4.8e-12	Morning vs. evening chronotype;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg09397319	chr2:64250606	NA	0.48	7.0	0.42	2.77e-11	Thyroid stimulating hormone;
SARC	cis	rs4423214	1.000	rs12791871	chr11:71164544	A/C	cg05163923	chr11:71159392	DHCR7	0.65	8.57	0.49	1.4e-15	Vitamin D levels;
SARC	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.43	-5.12	-0.32	6.33e-7	Bipolar disorder;
SARC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.7	9.5	0.53	2.65e-18	Lymphocyte counts;
SARC	cis	rs2204008	0.563	rs2320512	chr12:38266913	G/A	cg13010199	chr12:38710504	ALG10B	-0.56	-6.8	-0.41	8.92e-11	Bladder cancer;
SARC	cis	rs6088590	1.000	rs6087632	chr20:33407704	A/C	cg24642439	chr20:33292090	TP53INP2	0.85	11.82	0.61	1.48e-25	Coronary artery disease;
SARC	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg08048268	chr3:133502702	NA	0.45	6.11	0.37	4.24e-9	Iron status biomarkers;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg02738677	chr3:133265129	NA	-0.51	-6.35	-0.38	1.11e-9	Height;
SARC	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg20607798	chr8:58055168	NA	0.63	5.75	0.35	2.8e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4713675	0.565	rs4713659	chr6:33667839	A/G	cg15676125	chr6:33679581	C6orf125	0.49	6.12	0.37	4.02e-9	Plateletcrit;
SARC	cis	rs4713118	0.869	rs9468214	chr6:27713299	G/C	cg17221315	chr6:27791827	HIST1H4J	0.49	5.36	0.33	1.99e-7	Parkinson's disease;
SARC	cis	rs3126085	0.825	rs10788830	chr1:152206898	A/C	cg03465714	chr1:152285911	FLG	-0.46	-5.64	-0.35	4.94e-8	Atopic dermatitis;
SARC	cis	rs131777	0.575	rs963980	chr22:51022117	C/A	cg02245810	chr22:51017432	CPT1B;CHKB;CHKB-CPT1B	0.31	5.0	0.31	1.12e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs7647973	0.710	rs11130208	chr3:49615624	G/T	cg06212747	chr3:49208901	KLHDC8B	0.73	6.49	0.39	5.02e-10	Menarche (age at onset);
SARC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	20.44	0.8	7e-54	Prudent dietary pattern;
SARC	trans	rs12310956	0.532	rs1352211	chr12:33983132	G/A	cg13010199	chr12:38710504	ALG10B	0.65	8.68	0.49	7.12e-16	Morning vs. evening chronotype;
SARC	cis	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg14541582	chr5:601475	NA	-0.4	-4.93	-0.31	1.54e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg00149659	chr3:10157352	C3orf10	1.02	8.46	0.48	2.92e-15	Alzheimer's disease;
SARC	cis	rs910316	0.967	rs4899545	chr14:75568138	A/G	cg23033748	chr14:75592666	NEK9	0.37	5.28	0.33	2.89e-7	Height;
SARC	cis	rs2200578	1.000	rs72961173	chr2:99886868	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.62	5.9	0.36	1.28e-8	IgG glycosylation;
SARC	cis	rs820218	0.515	rs34598265	chr17:73725301	C/T	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.61	6.92	0.41	4.43e-11	Rotator cuff tears;
SARC	cis	rs3008870	0.583	rs11208985	chr1:67464666	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.83	-8.83	-0.5	2.64e-16	Lymphocyte percentage of white cells;
SARC	trans	rs12310956	0.510	rs7301767	chr12:33886529	A/T	cg26384229	chr12:38710491	ALG10B	0.61	8.16	0.47	2.04e-14	Morning vs. evening chronotype;
SARC	cis	rs7100689	0.646	rs10788562	chr10:82072310	C/T	cg01528321	chr10:82214614	TSPAN14	-0.64	-8.54	-0.49	1.71e-15	Post bronchodilator FEV1;
SARC	cis	rs2832191	0.791	rs2832186	chr21:30484151	A/C	cg08807101	chr21:30365312	RNF160	-0.84	-11.99	-0.62	4.09e-26	Dental caries;
SARC	cis	rs10512697	0.685	rs11747698	chr5:3577008	A/G	cg19473799	chr5:3511975	NA	0.67	4.89	0.31	1.89e-6	Immune response to smallpox vaccine (IL-6);
SARC	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg27286337	chr10:134555280	INPP5A	0.62	7.29	0.43	4.91e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs708547	0.723	rs35982175	chr4:57841365	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.53	6.72	0.4	1.42e-10	Response to bleomycin (chromatid breaks);
SARC	cis	rs4253772	0.513	rs9306512	chr22:46716603	T/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.75	7.38	0.44	2.79e-12	LDL cholesterol;Cholesterol, total;
SARC	cis	rs7829975	0.514	rs2920983	chr8:8268063	G/C	cg08975724	chr8:8085496	FLJ10661	0.54	6.54	0.39	3.77e-10	Mood instability;
SARC	cis	rs9291683	0.530	rs13115193	chr4:9982191	C/T	cg00071950	chr4:10020882	SLC2A9	0.4	6.45	0.39	6.39e-10	Bone mineral density;
SARC	cis	rs208515	0.556	rs1872309	chr6:66660432	A/C	cg07460842	chr6:66804631	NA	0.88	9.52	0.53	2.38e-18	Exhaled nitric oxide levels;
SARC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg21782813	chr7:2030301	MAD1L1	0.43	6.84	0.41	6.8e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs981844	0.725	rs872453	chr4:154727131	T/C	cg14289246	chr4:154710475	SFRP2	0.6	7.01	0.42	2.56e-11	Response to statins (LDL cholesterol change);
SARC	cis	rs9943753	0.525	rs7957928	chr12:109835975	C/G	cg19025524	chr12:109796872	NA	-0.39	-5.78	-0.35	2.35e-8	HDL cholesterol;
SARC	cis	rs9398803	0.865	rs7738135	chr6:126829981	G/A	cg20229609	chr6:126660872	C6orf173	0.4	5.79	0.35	2.23e-8	Male-pattern baldness;
SARC	trans	rs9395865	0.520	rs6903708	chr6:53332940	A/G	cg17260383	chr8:22298246	PPP3CC	-0.51	-6.25	-0.38	1.97e-9	Electroencephalographic traits in alcoholism;
SARC	cis	rs1267303	0.642	rs116078607	chr1:46999238	G/A	cg25110126	chr1:46999211	NA	0.92	9.94	0.55	1.22e-19	Monobrow;
SARC	cis	rs7937682	0.883	rs2212520	chr11:111462096	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.93	-14.06	-0.68	6.32e-33	Primary sclerosing cholangitis;
SARC	cis	rs854765	0.583	rs11078406	chr17:17840823	G/T	cg05444541	chr17:17804740	TOM1L2	-0.32	-5.3	-0.33	2.74e-7	Total body bone mineral density;
SARC	cis	rs854765	0.547	rs6502632	chr17:17913057	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.66	9.75	0.54	4.75e-19	Total body bone mineral density;
SARC	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.62	5.44	0.34	1.33e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs12824058	0.831	rs12310049	chr12:130811260	C/G	cg26677194	chr12:130822605	PIWIL1	0.54	7.4	0.44	2.4e-12	Menopause (age at onset);
SARC	cis	rs924607	0.966	rs1621827	chr5:635074	A/G	cg09021430	chr5:549028	NA	-0.31	-5.84	-0.36	1.77e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.73	7.01	0.42	2.53e-11	Platelet count;
SARC	cis	rs853679	0.760	rs11967137	chr6:28199764	A/G	cg17221315	chr6:27791827	HIST1H4J	0.5	4.74	0.3	3.65e-6	Depression;
SARC	cis	rs10754283	0.901	rs10047070	chr1:90098715	G/C	cg21401794	chr1:90099060	LRRC8C	0.6	8.35	0.48	6.28e-15	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs3784262	0.867	rs8036453	chr15:58371635	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.33	-4.78	-0.3	3.11e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs7561149	0.902	rs3769858	chr2:179667806	C/T	cg17765952	chr2:179737173	CCDC141	-0.37	-4.79	-0.3	3.01e-6	QT interval;
SARC	cis	rs2735413	0.918	rs4888725	chr16:78076761	C/T	cg04733911	chr16:78082701	NA	-0.31	-5.61	-0.34	5.78e-8	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg07636037	chr3:49044803	WDR6	0.63	8.4	0.48	4.49e-15	Resting heart rate;
SARC	cis	rs9660992	0.710	rs1172136	chr1:205247097	T/G	cg07972983	chr1:205091412	RBBP5	0.55	6.56	0.39	3.53e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.75	-0.45	2.87e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs644799	0.965	rs11021313	chr11:95506907	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	9.43	0.53	4.29e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2439831	0.867	rs2255042	chr15:43834318	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.78	-7.91	-0.46	1.04e-13	Lung cancer in ever smokers;
SARC	cis	rs6570726	0.764	rs1912023	chr6:145824278	C/A	cg05347473	chr6:146136440	FBXO30	0.53	7.29	0.43	4.79e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs34172651	0.917	rs8043962	chr16:24781372	A/G	cg06028605	chr16:24865363	SLC5A11	0.27	4.85	0.3	2.22e-6	Intelligence (multi-trait analysis);
SARC	cis	rs763121	0.719	rs9610995	chr22:39057763	C/T	cg21395723	chr22:39101663	GTPBP1	0.58	6.43	0.39	7.23e-10	Menopause (age at onset);
SARC	cis	rs4711336	0.638	rs4713664	chr6:33674198	A/G	cg15676125	chr6:33679581	C6orf125	0.51	6.17	0.37	2.99e-9	Height;
SARC	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg02931644	chr1:25747376	RHCE	0.42	7.1	0.42	1.46e-11	Erythrocyte sedimentation rate;
SARC	cis	rs7412746	0.611	rs72704679	chr1:150897477	C/T	cg15448220	chr1:150897856	SETDB1	0.52	6.89	0.41	5.25e-11	Melanoma;
SARC	trans	rs931812	0.825	rs13271753	chr8:101895491	T/C	cg20993868	chr7:22813445	NA	0.46	6.33	0.38	1.25e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs346785	0.692	rs2279056	chr17:74309474	C/T	cg03550965	chr17:75254321	NA	0.35	4.85	0.3	2.21e-6	White matter hyperintensities in ischemic stroke;
SARC	cis	rs9831754	0.756	rs2872626	chr3:78435049	A/T	cg06138941	chr3:78371609	NA	-0.53	-6.37	-0.39	1e-9	Calcium levels;
SARC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg22903471	chr2:27725779	GCKR	-0.49	-7.42	-0.44	2.21e-12	Total body bone mineral density;
SARC	cis	rs2652834	0.851	rs2652820	chr15:63430901	T/C	cg02713581	chr15:63449717	RPS27L	0.48	4.82	0.3	2.54e-6	HDL cholesterol;
SARC	trans	rs7615952	0.866	rs6438949	chr3:125650064	G/C	cg07211511	chr3:129823064	LOC729375	-0.93	-10.7	-0.57	5.34e-22	Blood pressure (smoking interaction);
SARC	cis	rs611744	0.517	rs62537573	chr8:109269281	C/T	cg21045802	chr8:109455806	TTC35	0.59	7.76	0.45	2.71e-13	Dupuytren's disease;
SARC	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg01570182	chr17:44337453	NA	-0.81	-9.33	-0.52	8.33e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs79149102	0.579	rs76900720	chr15:75348895	A/T	cg17294928	chr15:75287854	SCAMP5	-1.1	-9.35	-0.52	7.35e-18	Lung cancer;
SARC	cis	rs11792861	0.851	rs4542004	chr9:111814478	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.67	7.98	0.46	6.81e-14	Menarche (age at onset);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg12639763	chr10:97321104	SORBS1	0.47	6.85	0.41	6.39e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs10490913	0.806	rs1986910	chr10:120164826	T/G	cg23160142	chr10:120154512	NA	0.36	5.45	0.34	1.28e-7	Cancer;
SARC	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg18876405	chr7:65276391	NA	0.46	5.25	0.33	3.41e-7	Aortic root size;
SARC	cis	rs2749592	0.513	rs9417249	chr10:37837155	C/T	cg00409905	chr10:38381863	ZNF37A	0.45	6.19	0.38	2.67e-9	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs2463822	0.925	rs74692811	chr11:62156572	G/A	cg06239285	chr11:62104954	ASRGL1	-0.89	-9.16	-0.51	2.79e-17	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs708547	0.599	rs1718864	chr4:57887471	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.56	6.81	0.41	8.03e-11	Response to bleomycin (chromatid breaks);
SARC	cis	rs911555	0.755	rs8018400	chr14:103901085	A/G	cg24130564	chr14:104152367	KLC1	0.5	5.75	0.35	2.82e-8	Intelligence (multi-trait analysis);
SARC	cis	rs57244997	1.000	rs57244997	chr6:162397506	G/A	cg17173639	chr6:162384350	PARK2	-0.64	-5.94	-0.36	1.03e-8	Mosquito bite size;
SARC	cis	rs8031584	0.918	rs61997140	chr15:31277312	A/G	cg19680485	chr15:31195859	MTMR15	-0.52	-6.11	-0.37	4.2e-9	Huntington's disease progression;
SARC	cis	rs2243480	0.706	rs6460257	chr7:65196780	C/T	cg25894440	chr7:65020034	NA	-0.63	-5.48	-0.34	1.11e-7	Diabetic kidney disease;
SARC	cis	rs12980942	0.810	rs35812313	chr19:41789178	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.59	4.74	0.3	3.67e-6	Coronary artery disease;
SARC	cis	rs943466	1.000	rs12524768	chr6:33760478	G/A	cg04676172	chr6:33757040	LEMD2	0.46	4.87	0.3	2.09e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
SARC	cis	rs17253792	0.822	rs28681420	chr14:56088403	G/T	cg01858014	chr14:56050164	KTN1	-0.67	-5.11	-0.32	6.86e-7	Putamen volume;
SARC	cis	rs2273669	0.588	rs111353760	chr6:109306493	T/G	cg05315195	chr6:109294784	ARMC2	-0.57	-5.11	-0.32	6.79e-7	Prostate cancer;
SARC	cis	rs7296418	0.630	rs28419092	chr12:123812629	G/C	cg00376283	chr12:123451042	ABCB9	0.57	6.95	0.41	3.55e-11	Platelet count;
SARC	cis	rs7005380	0.581	rs4871793	chr8:120941528	A/G	cg21744203	chr8:120868354	DSCC1	-0.41	-4.83	-0.3	2.43e-6	Interstitial lung disease;
SARC	cis	rs708547	0.647	rs1718839	chr4:57827206	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.5	6.06	0.37	5.46e-9	Response to bleomycin (chromatid breaks);
SARC	cis	rs3812831	0.695	rs422149	chr13:114931086	T/G	cg08824895	chr13:115047677	UPF3A	0.51	6.61	0.4	2.6200000000000003e-10	Schizophrenia;
SARC	cis	rs4820539	0.934	rs3788348	chr22:23467946	G/C	cg14186256	chr22:23484241	RTDR1	0.88	13.98	0.68	1.16e-32	Bone mineral density;
SARC	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.93	13.87	0.67	2.78e-32	Gut microbiome composition (summer);
SARC	cis	rs4268898	0.931	rs2111882	chr2:24434424	A/G	cg26838691	chr2:24397539	C2orf84	0.42	5.68	0.35	4.02e-8	Asthma;
SARC	cis	rs67460515	0.892	rs35100811	chr3:161084046	A/C	cg04691961	chr3:161091175	C3orf57	-0.52	-6.56	-0.39	3.5e-10	Parkinson's disease;
SARC	cis	rs1348850	0.632	rs13008857	chr2:178514468	G/A	cg23306229	chr2:178417860	TTC30B	0.48	5.45	0.34	1.28e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs372883	0.530	rs2832302	chr21:30749793	G/T	cg24692254	chr21:30365293	RNF160	-0.54	-6.79	-0.41	9.44e-11	Pancreatic cancer;
SARC	cis	rs11098499	0.863	rs11947234	chr4:120474859	A/G	cg24375607	chr4:120327624	NA	0.42	4.92	0.31	1.64e-6	Corneal astigmatism;
SARC	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg21724239	chr8:58056113	NA	0.46	4.73	0.3	3.89e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs262150	0.714	rs2657397	chr7:158785095	C/T	cg07977927	chr7:158815555	LOC154822	0.29	5.45	0.34	1.27e-7	Facial morphology (factor 20);
SARC	cis	rs2681735	0.624	rs1520332	chr14:72802666	A/G	cg17922283	chr14:72799938	RGS6	-0.3	-4.81	-0.3	2.66e-6	Antibody status in Tripanosoma cruzi seropositivity;
SARC	cis	rs1003719	0.715	rs2156078	chr21:38546473	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.48	-0.53	3.11e-18	Eye color traits;
SARC	cis	rs12478296	0.581	rs4973645	chr2:242993577	T/C	cg06360820	chr2:242988706	NA	-0.9	-7.54	-0.44	1.03e-12	Obesity-related traits;
SARC	cis	rs73086581	0.947	rs73084531	chr20:3878429	G/A	cg02187196	chr20:3869020	PANK2	0.65	5.79	0.35	2.3e-8	Response to antidepressants in depression;
SARC	cis	rs986417	0.748	rs4381505	chr14:61035968	C/T	cg27398547	chr14:60952738	C14orf39	0.76	7.57	0.44	8.71e-13	Gut microbiota (bacterial taxa);
SARC	cis	rs9910055	0.529	rs368328	chr17:42170289	G/A	cg19774624	chr17:42201019	HDAC5	0.55	6.55	0.39	3.64e-10	Total body bone mineral density;
SARC	cis	rs10979	0.557	rs9285501	chr6:143915121	G/C	cg25407410	chr6:143891975	LOC285740	-0.5	-5.68	-0.35	4.07e-8	Hypospadias;
SARC	cis	rs2153535	0.580	rs9405391	chr6:8466548	C/T	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg25192651	chr12:69632957	CPSF6	0.48	6.36	0.38	1.03e-9	Lung adenocarcinoma;
SARC	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	11.12	0.59	2.48e-23	Alzheimer's disease;
SARC	cis	rs13077101	0.772	rs1505701	chr3:120492579	A/C	cg24332942	chr3:120408071	RABL3	-0.37	-4.9	-0.31	1.78e-6	Obesity-related traits;
SARC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg06873352	chr17:61820015	STRADA	0.53	6.92	0.41	4.3e-11	Prudent dietary pattern;
SARC	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg12463550	chr7:65579703	CRCP	0.47	5.12	0.32	6.26e-7	Aortic root size;
SARC	trans	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg06636001	chr8:8085503	FLJ10661	0.68	9.34	0.52	7.92e-18	Retinal vascular caliber;
SARC	cis	rs2014572	1.000	rs3746231	chr19:57760057	G/A	cg24459738	chr19:57751996	ZNF805	-0.45	-5.2	-0.32	4.3e-7	Hyperactive-impulsive symptoms;
SARC	cis	rs1153858	0.887	rs7171163	chr15:45636395	A/C	cg21132104	chr15:45694354	SPATA5L1	0.78	11.03	0.59	4.99e-23	Homoarginine levels;
SARC	cis	rs4803468	1.000	rs284648	chr19:41926790	T/C	cg09537434	chr19:41945824	ATP5SL	-0.98	-17.13	-0.75	3.95e-43	Height;
SARC	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg24690094	chr11:67383802	NA	0.37	5.48	0.34	1.09e-7	Mean corpuscular volume;
SARC	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.48	-6.12	-0.37	4.02e-9	Lymphocyte counts;
SARC	cis	rs35110281	0.591	rs86139	chr21:44932802	G/A	cg21573476	chr21:45109991	RRP1B	-0.5	-7.43	-0.44	2.01e-12	Mean corpuscular volume;
SARC	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg21782813	chr7:2030301	MAD1L1	0.39	6.18	0.38	2.81e-9	Bipolar disorder and schizophrenia;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg13558061	chr22:22090124	YPEL1	-0.53	-6.27	-0.38	1.77e-9	Blood pressure;
SARC	cis	rs9549367	0.713	rs4907598	chr13:113861385	C/T	cg18105134	chr13:113819100	PROZ	0.41	6.02	0.37	6.72e-9	Platelet distribution width;
SARC	cis	rs11574514	1.000	rs117571960	chr16:68271261	C/G	cg01866162	chr16:67596514	CTCF	1.15	6.5	0.39	4.93e-10	Crohn's disease;
SARC	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg22535103	chr8:58192502	C8orf71	-0.73	-7.31	-0.43	4.37e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs8014204	0.604	rs11159109	chr14:75389074	G/A	cg08847533	chr14:75593920	NEK9	0.5	5.8	0.36	2.15e-8	Caffeine consumption;
SARC	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	trans	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg15556689	chr8:8085844	FLJ10661	0.52	6.67	0.4	1.89e-10	Retinal vascular caliber;
SARC	cis	rs4481887	0.741	rs28444488	chr1:248531776	C/A	cg00666640	chr1:248458726	OR2T12	0.36	6.2	0.38	2.58e-9	Common traits (Other);
SARC	cis	rs62344088	0.590	rs6882234	chr5:177389	C/G	cg20965017	chr5:231967	SDHA	-0.71	-5.36	-0.33	1.95e-7	Asthma (childhood onset);
SARC	cis	rs9910055	0.571	rs10208	chr17:42300278	C/T	cg19774624	chr17:42201019	HDAC5	-0.46	-5.93	-0.36	1.08e-8	Total body bone mineral density;
SARC	cis	rs2933343	0.729	rs6790091	chr3:128608751	G/C	cg24203234	chr3:128598194	ACAD9	0.62	7.77	0.45	2.49e-13	IgG glycosylation;
SARC	cis	rs7178572	0.625	rs12904553	chr15:77845959	G/A	cg22256960	chr15:77711686	NA	-0.46	-5.72	-0.35	3.24e-8	Type 2 diabetes;
SARC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	13.51	0.66	4.16e-31	Chronic sinus infection;
SARC	cis	rs11578119	0.933	rs10919423	chr1:170480531	C/T	cg09767346	chr1:170501363	GORAB	0.4	4.73	0.3	3.91e-6	Male-pattern baldness;
SARC	cis	rs208520	0.874	rs208485	chr6:66925654	T/C	cg07460842	chr6:66804631	NA	-1.0	-11.89	-0.61	8.86e-26	Exhaled nitric oxide output;
SARC	cis	rs2370759	1.000	rs11594459	chr10:32561858	A/C	cg01819863	chr10:32635814	EPC1	1.03	9.98	0.55	9.04e-20	Sexual dysfunction (female);
SARC	cis	rs116095464	0.558	rs10055993	chr5:264296	A/C	cg22496380	chr5:211416	CCDC127	-0.91	-8.19	-0.47	1.71e-14	Breast cancer;
SARC	cis	rs6089829	0.962	rs1116450	chr20:61658210	T/C	cg08045932	chr20:61659980	NA	0.52	6.9	0.41	5e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg17376030	chr22:41985996	PMM1	-0.79	-9.86	-0.54	2.19e-19	Vitiligo;
SARC	cis	rs6701037	0.566	rs1883102	chr1:175136793	T/A	cg00321850	chr1:175162397	KIAA0040	0.38	5.92	0.36	1.13e-8	Alcohol dependence;
SARC	cis	rs6456156	0.586	rs13195158	chr6:167481392	G/A	cg23791538	chr6:167370224	RNASET2	-0.53	-6.99	-0.42	2.86e-11	Primary biliary cholangitis;
SARC	cis	rs7520050	0.966	rs785488	chr1:46576095	G/A	cg24296786	chr1:45957014	TESK2	0.38	4.82	0.3	2.56e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs79349575	0.783	rs56046215	chr17:47008757	A/T	cg07967210	chr17:47022446	SNF8	0.38	4.89	0.31	1.89e-6	Type 2 diabetes;
SARC	cis	rs2559856	1.000	rs2559858	chr12:102089300	A/G	cg12924262	chr12:102091054	CHPT1	0.57	7.84	0.46	1.6e-13	Blood protein levels;
SARC	cis	rs826838	1.000	rs1719830	chr12:39096992	T/G	cg26384229	chr12:38710491	ALG10B	-0.76	-11.72	-0.61	3.04e-25	Heart rate;
SARC	cis	rs4727027	0.901	rs4727017	chr7:148822062	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	5.35	0.33	2.1e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs2908197	0.653	rs2961034	chr7:75961550	T/C	cg24580635	chr7:76178542	LOC100133091	-0.42	-4.87	-0.3	2.08e-6	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs778371	0.723	rs1973675	chr2:233636450	C/T	cg16596103	chr2:233749413	NGEF	0.36	5.79	0.35	2.27e-8	Schizophrenia;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg15010184	chr1:23543591	NA	-0.51	-6.43	-0.39	7.07e-10	Schizophrenia;
SARC	cis	rs9398803	0.687	rs853987	chr6:127024775	A/G	cg20229609	chr6:126660872	C6orf173	-0.35	-5.05	-0.31	8.85e-7	Male-pattern baldness;
SARC	cis	rs9300255	0.602	rs1716167	chr12:123651162	C/T	cg00376283	chr12:123451042	ABCB9	-0.53	-6.22	-0.38	2.27e-9	Neutrophil percentage of white cells;
SARC	cis	rs7927771	1.000	rs11039412	chr11:47841581	G/A	cg20307385	chr11:47447363	PSMC3	-0.47	-5.59	-0.34	6.3e-8	Subjective well-being;
SARC	cis	rs6840360	0.967	rs6841204	chr4:152598603	C/T	cg22705602	chr4:152727874	NA	-0.38	-6.51	-0.39	4.49e-10	Intelligence (multi-trait analysis);
SARC	cis	rs637571	0.522	rs503524	chr11:65751764	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.41	-5.07	-0.32	8.06e-7	Eosinophil percentage of white cells;
SARC	cis	rs1476670	0.710	rs4660763	chr1:44503576	T/C	cg09470012	chr1:44509516	NA	0.45	5.69	0.35	3.77e-8	Eotaxin levels;
SARC	cis	rs2153535	0.580	rs9393019	chr6:8462091	G/A	cg07606381	chr6:8435919	SLC35B3	0.77	11.07	0.59	3.68e-23	Motion sickness;
SARC	cis	rs2916247	1.000	rs2920463	chr8:93008292	A/G	cg10183463	chr8:93005414	RUNX1T1	0.62	6.63	0.4	2.32e-10	Intelligence (multi-trait analysis);
SARC	cis	rs1559088	1.000	rs7245404	chr19:33550589	C/T	cg17764715	chr19:33622953	WDR88	0.48	6.25	0.38	1.95e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs2916247	1.000	rs4415366	chr8:93052634	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.59	-5.97	-0.36	8.97e-9	Intelligence (multi-trait analysis);
SARC	trans	rs1941687	0.505	rs1389534	chr18:31311161	C/G	cg27147174	chr7:100797783	AP1S1	0.58	7.27	0.43	5.45e-12	Subjective well-being (multi-trait analysis);Subjective well-being;
SARC	cis	rs11112613	0.775	rs10778413	chr12:105962118	G/A	cg03607813	chr12:105948248	NA	0.55	7.42	0.44	2.18e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg10435706	chr6:150039699	LATS1	0.37	4.87	0.3	2.04e-6	Lung cancer;
SARC	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg17971929	chr21:40555470	PSMG1	1.0	13.95	0.67	1.42e-32	Cognitive function;
SARC	cis	rs950169	0.881	rs72750843	chr15:85135783	C/T	cg17507749	chr15:85114479	UBE2QP1	0.78	9.37	0.52	6.48e-18	Schizophrenia;
SARC	cis	rs6963495	0.818	rs6957192	chr7:105150255	A/C	cg13798780	chr7:105162888	PUS7	-0.63	-6.06	-0.37	5.34e-9	Bipolar disorder (body mass index interaction);
SARC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.45	0.56	3.22e-21	Prudent dietary pattern;
SARC	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg06618935	chr21:46677482	NA	-0.41	-5.46	-0.34	1.24e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9302635	0.745	rs35909200	chr16:72156666	T/G	cg01557791	chr16:72042693	DHODH	-0.56	-4.76	-0.3	3.37e-6	Blood protein levels;
SARC	cis	rs710216	0.957	rs3738514	chr1:43426591	A/G	cg07803811	chr1:43423981	SLC2A1	-0.5	-4.98	-0.31	1.25e-6	Red cell distribution width;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg12508534	chr6:34855789	TAF11;ANKS1A	0.52	6.73	0.4	1.32e-10	Height;
SARC	cis	rs9902453	0.817	rs4794861	chr17:28183174	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	7.08	0.42	1.68e-11	Coffee consumption (cups per day);
SARC	cis	rs9420	0.961	rs7121169	chr11:57452543	G/A	cg19752551	chr11:57585705	CTNND1	-0.5	-6.74	-0.4	1.24e-10	Schizophrenia;
SARC	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg13902645	chr11:5959945	NA	-0.44	-5.53	-0.34	8.52e-8	DNA methylation (variation);
SARC	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg12463550	chr7:65579703	CRCP	-0.44	-5.05	-0.31	8.91e-7	Aortic root size;
SARC	cis	rs35110281	0.837	rs2838340	chr21:45076373	A/G	cg01579765	chr21:45077557	HSF2BP	-0.28	-4.75	-0.3	3.62e-6	Mean corpuscular volume;
SARC	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg11764359	chr7:65958608	NA	-0.78	-9.49	-0.53	2.76e-18	Aortic root size;
SARC	trans	rs1600249	0.562	rs17153419	chr8:11394233	C/T	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.63	-0.49	9.97e-16	Rheumatoid arthritis;
SARC	cis	rs6121246	0.559	rs1062794	chr20:30381758	G/C	cg13852791	chr20:30311386	BCL2L1	0.87	10.86	0.58	1.69e-22	Mean corpuscular hemoglobin;
SARC	cis	rs7246657	1.000	rs1823061	chr19:37800626	G/A	cg23950597	chr19:37808831	NA	-0.51	-4.71	-0.3	4.19e-6	Coronary artery calcification;
SARC	cis	rs2408955	0.521	rs10875753	chr12:48557141	C/T	cg24011408	chr12:48396354	COL2A1	0.41	5.01	0.31	1.09e-6	Glycated hemoglobin levels;
SARC	cis	rs2506889	0.553	rs7548453	chr1:10589836	A/G	cg17425144	chr1:10567563	PEX14	0.43	7.1	0.42	1.49e-11	Breast cancer;
SARC	trans	rs61931739	0.500	rs10844734	chr12:34043083	G/A	cg26384229	chr12:38710491	ALG10B	0.75	10.62	0.57	9.96e-22	Morning vs. evening chronotype;
SARC	cis	rs11997175	0.574	rs4538830	chr8:33653741	C/G	ch.8.33884649F	chr8:33765107	NA	0.48	6.45	0.39	6.25e-10	Body mass index;
SARC	cis	rs6910061	0.830	rs13203123	chr6:11103491	T/C	cg27233058	chr6:11094804	LOC221710	0.61	5.54	0.34	8.11e-8	Diabetic kidney disease;
SARC	cis	rs1949733	1.000	rs2688233	chr4:8491885	T/C	cg11789530	chr4:8429930	ACOX3	0.82	11.05	0.59	4.38e-23	Response to antineoplastic agents;
SARC	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	5.37	0.33	1.89e-7	Personality dimensions;
SARC	cis	rs11112613	0.775	rs12305225	chr12:105963266	G/C	cg03607813	chr12:105948248	NA	0.5	6.84	0.41	6.96e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg22535103	chr8:58192502	C8orf71	-0.57	-5.57	-0.34	6.91e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs12586317	0.620	rs12588810	chr14:35554484	C/T	cg26967526	chr14:35346199	BAZ1A	-0.62	-6.36	-0.38	1.06e-9	Psoriasis;
SARC	cis	rs2576037	0.899	rs2571034	chr18:44578565	A/G	cg19077165	chr18:44547161	KATNAL2	0.49	6.8	0.41	8.96e-11	Personality dimensions;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg08611491	chr20:10654282	JAG1	0.5	6.31	0.38	1.37e-9	Breast cancer;
SARC	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg27266027	chr21:40555129	PSMG1	0.5	5.43	0.33	1.43e-7	Cognitive function;
SARC	cis	rs8017423	0.967	rs2277515	chr14:90723000	A/G	cg20276874	chr14:90721474	PSMC1	-0.39	-5.49	-0.34	1.06e-7	Mortality in heart failure;
SARC	cis	rs9457247	0.579	rs2181059	chr6:167441624	T/C	cg07741184	chr6:167504864	NA	0.35	6.99	0.42	2.9e-11	Crohn's disease;
SARC	cis	rs2213920	0.920	rs9408871	chr9:118263618	C/T	cg13918206	chr9:118159781	DEC1	0.65	5.33	0.33	2.33e-7	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs9911578	0.967	rs302842	chr17:56728102	C/G	cg12560992	chr17:57184187	TRIM37	0.83	11.32	0.6	5.91e-24	Intelligence (multi-trait analysis);
SARC	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg24209194	chr3:40518798	ZNF619	-0.66	-8.45	-0.48	3.12e-15	Renal cell carcinoma;
SARC	cis	rs6867032	0.527	rs4371796	chr5:1977785	C/T	cg26168224	chr5:2018326	NA	-0.55	-6.09	-0.37	4.68e-9	Gut microbiome composition (winter);
SARC	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg08859206	chr1:53392774	SCP2	-0.39	-5.58	-0.34	6.65e-8	Monocyte count;
SARC	cis	rs1200821	0.529	rs4934856	chr10:37807847	T/C	cg00409905	chr10:38381863	ZNF37A	0.47	6.4	0.39	8.45e-10	Hemostatic factors and hematological phenotypes;
SARC	cis	rs9910055	0.529	rs850851	chr17:42177674	C/T	cg19774624	chr17:42201019	HDAC5	0.55	6.68	0.4	1.79e-10	Total body bone mineral density;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg07823935	chr2:183902842	NCKAP1	-0.51	-6.38	-0.39	9.49e-10	Height;
SARC	cis	rs9291683	0.507	rs6849273	chr4:10021595	C/T	cg00071950	chr4:10020882	SLC2A9	0.33	4.99	0.31	1.2e-6	Bone mineral density;
SARC	cis	rs6088580	0.634	rs6087587	chr20:33058628	G/T	cg24642439	chr20:33292090	TP53INP2	0.69	8.85	0.5	2.17e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs921968	0.643	rs832801	chr2:219488698	G/A	cg02176678	chr2:219576539	TTLL4	0.4	6.05	0.37	5.79e-9	Mean corpuscular hemoglobin concentration;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg15834993	chr8:49826049	NA	0.46	6.62	0.4	2.43e-10	Thyroid stimulating hormone;
SARC	cis	rs2236918	0.901	rs1776132	chr1:242024473	C/G	cg17736920	chr1:242011382	EXO1	0.76	10.67	0.57	6.79e-22	Menopause (age at onset);
SARC	cis	rs1059312	1.000	rs12814773	chr12:129280786	C/T	cg09035930	chr12:129282057	SLC15A4	0.61	8.74	0.5	4.7e-16	Systemic lupus erythematosus;
SARC	trans	rs9354308	0.933	rs12194424	chr6:66574007	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.58	6.82	0.41	7.77e-11	Metabolite levels;
SARC	cis	rs734999	0.588	rs2985859	chr1:2532416	T/C	cg00980319	chr1:2560884	MMEL1	0.35	4.95	0.31	1.44e-6	Ulcerative colitis;
SARC	cis	rs4566357	0.787	rs12475134	chr2:227880511	C/T	cg11843606	chr2:227700838	RHBDD1	-0.46	-5.68	-0.35	3.92e-8	Coronary artery disease;
SARC	cis	rs7520050	0.966	rs7515491	chr1:46355079	A/G	cg24296786	chr1:45957014	TESK2	0.38	4.83	0.3	2.47e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs6690583	1.000	rs6690464	chr1:85466369	A/G	cg22153463	chr1:85462885	MCOLN2	-0.69	-7.27	-0.43	5.32e-12	Serum sulfate level;
SARC	cis	rs1348850	0.914	rs12693120	chr2:178283288	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.65	8.24	0.47	1.28e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs10870270	0.956	rs4131689	chr10:133744328	A/C	cg08754478	chr10:133766260	PPP2R2D	0.44	5.32	0.33	2.4e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs911263	0.561	rs2064912	chr14:68807132	C/T	cg18825221	chr14:68749962	RAD51L1	-0.42	-7.2	-0.43	8.36e-12	Primary biliary cholangitis;
SARC	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg05313129	chr8:58192883	C8orf71	-0.62	-6.34	-0.38	1.18e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs34864796	0.547	rs200476	chr6:27768348	A/T	cg17221315	chr6:27791827	HIST1H4J	0.52	4.92	0.31	1.64e-6	Lung function (FEV1);Lung function (FEV1/FVC);Lung function (FVC);
SARC	cis	rs11098499	0.739	rs4833612	chr4:120147596	A/C	cg09307838	chr4:120376055	NA	-0.77	-10.44	-0.56	3.42e-21	Corneal astigmatism;
SARC	cis	rs2120243	0.533	rs62278578	chr3:157055867	C/T	cg24825693	chr3:157122686	VEPH1	-0.4	-5.65	-0.35	4.73e-8	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg18357526	chr6:26021779	HIST1H4A	0.43	5.43	0.34	1.41e-7	Blood metabolite levels;
SARC	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg11890956	chr21:40555474	PSMG1	1.17	19.56	0.79	4.67e-51	Cognitive function;
SARC	cis	rs12142240	0.698	rs56049453	chr1:46835468	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-5.56	-0.34	7.46e-8	Menopause (age at onset);
SARC	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg08219700	chr8:58056026	NA	0.62	6.45	0.39	6.49e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg17221315	chr6:27791827	HIST1H4J	0.47	4.84	0.3	2.37e-6	Depression;
SARC	cis	rs2228479	0.717	rs2074904	chr16:89811546	A/G	cg06558623	chr16:89946397	TCF25	0.91	6.37	0.38	1.03e-9	Skin colour saturation;
SARC	cis	rs6088580	0.634	rs2424992	chr20:33012060	C/T	cg08999081	chr20:33150536	PIGU	0.44	6.59	0.4	2.93e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg18252515	chr7:66147081	NA	-1.31	-11.04	-0.59	4.58e-23	Diabetic kidney disease;
SARC	trans	rs79976124	0.837	rs10944858	chr6:66646039	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	7.86	0.46	1.41e-13	Type 2 diabetes;
SARC	cis	rs703842	0.642	rs11536137	chr12:58056426	C/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.74	8.66	0.49	7.91e-16	Multiple sclerosis;
SARC	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg20607798	chr8:58055168	NA	0.61	5.41	0.33	1.57e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs911263	0.887	rs8015139	chr14:68739301	G/T	cg18825221	chr14:68749962	RAD51L1	-0.49	-8.55	-0.49	1.61e-15	Primary biliary cholangitis;
SARC	cis	rs7520050	0.807	rs4468203	chr1:46113272	T/C	cg24296786	chr1:45957014	TESK2	-0.43	-5.56	-0.34	7.18e-8	Red blood cell count;Reticulocyte count;
SARC	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg18252515	chr7:66147081	NA	-1.3	-11.62	-0.61	6.33e-25	Diabetic kidney disease;
SARC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg07167872	chr1:205819463	PM20D1	0.82	13.46	0.66	6.35e-31	Menarche (age at onset);
SARC	cis	rs3820928	0.874	rs4234064	chr2:227857497	G/T	cg11843606	chr2:227700838	RHBDD1	-0.52	-6.38	-0.39	9.58e-10	Pulmonary function;
SARC	cis	rs6121246	0.559	rs6060952	chr20:30382108	T/G	cg13852791	chr20:30311386	BCL2L1	0.8	9.88	0.54	1.93e-19	Mean corpuscular hemoglobin;
SARC	cis	rs6813479	0.524	rs2612113	chr4:137745583	C/G	cg16185213	chr4:137733633	NA	0.39	5.31	0.33	2.54e-7	Longevity;
SARC	trans	rs9325144	0.647	rs12830095	chr12:38864199	C/T	cg23762105	chr12:34175262	ALG10	0.5	6.56	0.39	3.35e-10	Morning vs. evening chronotype;
SARC	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg19223190	chr17:80058835	NA	0.41	5.67	0.35	4.12e-8	Life satisfaction;
SARC	cis	rs7674212	0.570	rs6810571	chr4:104086787	G/T	cg16532752	chr4:104119610	CENPE	-0.47	-5.87	-0.36	1.47e-8	Type 2 diabetes;
SARC	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg16325326	chr1:53192061	ZYG11B	0.92	17.25	0.75	1.58e-43	Monocyte count;
SARC	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg08280861	chr8:58055591	NA	0.57	4.89	0.31	1.84e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs12458462	0.892	rs35928863	chr18:77438956	A/G	cg23301140	chr18:77439876	CTDP1	0.6	7.73	0.45	3.3e-13	Monocyte count;
SARC	cis	rs6430585	0.528	rs12464050	chr2:136663110	G/T	cg07169764	chr2:136633963	MCM6	1.04	13.34	0.66	1.5e-30	Corneal structure;
SARC	cis	rs113601626	1	rs113601626	chr2:24239189	T/TCCTGGC	cg06627628	chr2:24431161	ITSN2	-0.74	-7.11	-0.42	1.39e-11	Lymphocyte percentage of white cells;
SARC	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg26335602	chr6:28129616	ZNF389	0.52	5.94	0.36	1.04e-8	Depression;
SARC	cis	rs4919694	1.000	rs11191439	chr10:104638723	C/T	cg04362960	chr10:104952993	NT5C2	-0.65	-5.49	-0.34	1.07e-7	Arsenic metabolism;
SARC	cis	rs9910055	0.509	rs9916444	chr17:42313512	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.43	5.75	0.35	2.77e-8	Total body bone mineral density;
SARC	cis	rs793571	0.744	rs4775097	chr15:59140801	C/T	cg05156742	chr15:59063176	FAM63B	-0.5	-5.08	-0.32	7.56e-7	Schizophrenia;
SARC	cis	rs7666738	0.519	rs28539191	chr4:98821552	C/T	cg05340658	chr4:99064831	C4orf37	0.59	7.17	0.43	9.71e-12	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10463554	0.963	rs26253	chr5:102556967	T/C	cg23492399	chr5:102201601	PAM	-0.46	-5.09	-0.32	7.52e-7	Parkinson's disease;
SARC	cis	rs11871801	0.517	rs6963	chr17:40731597	A/T	cg20126647	chr17:40714003	COASY	-0.53	-5.87	-0.36	1.47e-8	Crohn's disease;
SARC	cis	rs986417	0.748	rs10133403	chr14:60945298	C/T	cg27398547	chr14:60952738	C14orf39	1.03	9.89	0.54	1.74e-19	Gut microbiota (bacterial taxa);
SARC	cis	rs2425143	1.000	rs73902908	chr20:34365112	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-5.91	-0.36	1.2e-8	Blood protein levels;
SARC	cis	rs7666738	0.791	rs34437628	chr4:99029232	C/G	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9470366	0.509	rs4714001	chr6:36638175	G/A	cg08179530	chr6:36648295	CDKN1A	-0.66	-8.92	-0.5	1.41e-16	QRS duration;
SARC	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg11987759	chr7:65425863	GUSB	-0.58	-7.64	-0.45	5.63e-13	Aortic root size;
SARC	cis	rs7000551	0.663	rs11778831	chr8:22335088	C/T	cg12081754	chr8:22256438	SLC39A14	0.62	8.78	0.5	3.48e-16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs7412746	0.611	rs2256355	chr1:150811794	A/G	cg15448220	chr1:150897856	SETDB1	0.5	6.55	0.39	3.57e-10	Melanoma;
SARC	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.5	0.39	4.96e-10	Electroencephalogram traits;
SARC	cis	rs4792901	0.797	rs117711821	chr17:41626145	C/G	cg22562494	chr17:41607896	ETV4	-0.33	-5.3	-0.33	2.63e-7	Dupuytren's disease;
SARC	cis	rs1691799	0.867	rs1168316	chr12:66746239	A/G	cg16791601	chr12:66731901	HELB	-0.71	-10.85	-0.58	1.89e-22	White blood cell count (basophil);
SARC	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs2916247	1.000	rs1814032	chr8:93005447	G/T	cg10183463	chr8:93005414	RUNX1T1	-0.58	-6.28	-0.38	1.61e-9	Intelligence (multi-trait analysis);
SARC	cis	rs9916302	0.904	rs9898170	chr17:37510092	T/C	cg20243544	chr17:37824526	PNMT	-0.56	-6.92	-0.41	4.39e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs939574	1.000	rs11552796	chr2:220108300	T/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.63	5.32	0.33	2.46e-7	Platelet distribution width;
SARC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg03647317	chr4:187891568	NA	0.4	5.89	0.36	1.34e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9814567	1.000	rs13059720	chr3:134242021	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.58	7.11	0.42	1.39e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs9611519	0.964	rs2092563	chr22:41592677	G/A	cg03806693	chr22:41940476	POLR3H	-0.6	-7.14	-0.42	1.21e-11	Neuroticism;
SARC	cis	rs910316	0.737	rs175424	chr14:75626257	T/C	cg08847533	chr14:75593920	NEK9	-0.76	-10.31	-0.56	8.72e-21	Height;
SARC	cis	rs11644362	0.966	rs1433747	chr16:12992147	C/A	cg06890432	chr16:12997467	SHISA9	-0.51	-6.66	-0.4	1.99e-10	Positive affect;Subjective well-being;
SARC	cis	rs9682041	0.696	rs11917147	chr3:170088448	C/T	cg11886554	chr3:170076028	SKIL	0.83	7.75	0.45	2.91e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs7772486	0.686	rs1415744	chr6:146022531	C/T	cg23711669	chr6:146136114	FBXO30	0.8	12.77	0.64	1.19e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg18252515	chr7:66147081	NA	-1.43	-12.98	-0.65	2.35e-29	Gout;
SARC	cis	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg26695010	chr11:65641043	EFEMP2	0.61	8.14	0.47	2.31e-14	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs1754541	0.957	rs10783155	chr1:101655670	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.43	-4.79	-0.3	2.93e-6	Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;
SARC	cis	rs12908161	1.000	rs12899981	chr15:85302373	G/A	cg17507749	chr15:85114479	UBE2QP1	0.55	6.22	0.38	2.33e-9	Schizophrenia;
SARC	cis	rs9788682	0.748	rs667282	chr15:78863472	T/C	cg24631222	chr15:78858424	CHRNA5	0.74	9.99	0.55	8.43e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs782590	0.967	rs58003472	chr2:55797507	T/C	cg18811423	chr2:55921094	PNPT1	0.67	10.37	0.56	5.95e-21	Metabolic syndrome;
SARC	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg17971929	chr21:40555470	PSMG1	-0.86	-11.45	-0.6	2.17e-24	Cognitive function;
SARC	cis	rs2273669	0.667	rs78550764	chr6:109312239	C/T	cg05315195	chr6:109294784	ARMC2	-0.59	-5.45	-0.34	1.28e-7	Prostate cancer;
SARC	cis	rs8067545	0.720	rs11204420	chr17:19889020	A/C	cg13482628	chr17:19912719	NA	0.56	6.89	0.41	5.1e-11	Schizophrenia;
SARC	cis	rs2916247	1.000	rs7832917	chr8:93036318	A/G	cg10183463	chr8:93005414	RUNX1T1	0.64	6.74	0.4	1.22e-10	Intelligence (multi-trait analysis);
SARC	cis	rs4423214	0.569	rs12806918	chr11:71119018	G/T	cg05163923	chr11:71159392	DHCR7	0.46	6.49	0.39	5.09e-10	Vitamin D levels;
SARC	cis	rs6570726	0.557	rs403956	chr6:145829956	T/C	cg05347473	chr6:146136440	FBXO30	0.72	9.91	0.54	1.52e-19	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6815814	0.808	rs4833093	chr4:38789740	G/T	cg06935464	chr4:38784597	TLR10	0.52	5.8	0.36	2.16e-8	Breast cancer;
SARC	cis	rs7927592	0.731	rs11228275	chr11:68303980	G/A	cg01657329	chr11:68192670	LRP5	0.38	5.31	0.33	2.5e-7	Total body bone mineral density;
SARC	cis	rs4642101	0.561	rs4560285	chr3:12809066	G/A	cg05775895	chr3:12838266	CAND2	0.56	7.92	0.46	9.52e-14	QRS complex (12-leadsum);
SARC	cis	rs7584330	0.910	rs12465081	chr2:238401784	A/G	cg11271282	chr2:238384023	NA	0.44	5.04	0.31	9.16e-7	Prostate cancer;
SARC	cis	rs6964587	1.000	rs9785013	chr7:91674302	G/A	cg17063962	chr7:91808500	NA	0.96	16.6	0.74	2.21e-41	Breast cancer;
SARC	cis	rs7560272	0.501	rs13003035	chr2:73957227	T/A	cg20560298	chr2:73613845	ALMS1	0.45	5.96	0.36	9.16e-9	Schizophrenia;
SARC	trans	rs11039798	0.588	rs113800184	chr11:48756855	G/A	cg15704280	chr7:45808275	SEPT13	0.65	6.44	0.39	6.73e-10	Axial length;
SARC	cis	rs17125944	0.615	rs1998777	chr14:53295706	C/T	cg00686598	chr14:53173677	PSMC6	-0.67	-5.05	-0.31	9e-7	Alzheimer's disease (late onset);
SARC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg26338869	chr17:61819248	STRADA	0.8	10.8	0.58	2.62e-22	Prudent dietary pattern;
SARC	cis	rs12681288	0.748	rs7000148	chr8:1016383	G/C	cg15309053	chr8:964076	NA	0.42	7.05	0.42	2.04e-11	Schizophrenia;
SARC	cis	rs7252505	1.000	rs7256513	chr19:33588266	C/T	cg17764715	chr19:33622953	WDR88	0.57	4.82	0.3	2.55e-6	Colorectal cancer;
SARC	cis	rs8070128	0.597	rs4635395	chr17:17882087	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	8.48	0.49	2.65e-15	Total body bone mineral density;
SARC	cis	rs2228479	0.850	rs74251570	chr16:89910068	C/A	cg12064134	chr16:90016061	DEF8	-0.56	-4.83	-0.3	2.47e-6	Skin colour saturation;
SARC	cis	rs2836633	0.895	rs2836597	chr21:40024424	A/G	cg12884169	chr21:40033163	ERG	0.47	8.41	0.48	4.23e-15	Coronary artery disease;
SARC	cis	rs2243480	0.706	rs6460257	chr7:65196780	C/T	cg11764359	chr7:65958608	NA	0.61	5.35	0.33	2.14e-7	Diabetic kidney disease;
SARC	cis	rs57506017	0.606	rs2302634	chr7:12270770	T/A	cg23422036	chr7:12250390	TMEM106B	0.45	5.87	0.36	1.49e-8	Neuroticism;
SARC	trans	rs61931739	0.612	rs2004961	chr12:33994599	A/G	cg26384229	chr12:38710491	ALG10B	0.58	7.52	0.44	1.18e-12	Morning vs. evening chronotype;
SARC	cis	rs4660306	0.961	rs945179	chr1:45992460	A/G	cg24296786	chr1:45957014	TESK2	-0.58	-6.83	-0.41	7.52e-11	Homocysteine levels;
SARC	cis	rs9457247	0.765	rs9457249	chr6:167426438	A/G	cg07741184	chr6:167504864	NA	0.34	6.55	0.39	3.64e-10	Crohn's disease;
SARC	cis	rs9815354	0.812	rs76966288	chr3:41825055	G/A	cg03022575	chr3:42003672	ULK4	0.71	5.89	0.36	1.34e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg24250549	chr1:154909240	PMVK	0.81	12.08	0.62	2.08e-26	Prostate cancer;
SARC	cis	rs7927592	0.913	rs12294029	chr11:68257059	A/C	cg01657329	chr11:68192670	LRP5	-0.39	-4.92	-0.31	1.64e-6	Total body bone mineral density;
SARC	cis	rs861020	0.630	rs657861	chr1:210006884	C/G	cg05527609	chr1:210001259	C1orf107	0.78	10.12	0.55	3.37e-20	Orofacial clefts;
SARC	cis	rs453301	0.686	rs28482034	chr8:8869664	G/A	cg08975724	chr8:8085496	FLJ10661	-0.44	-5.48	-0.34	1.07e-7	Joint mobility (Beighton score);
SARC	cis	rs9486719	1.000	rs72931061	chr6:96880285	G/A	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.01	-0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs3741151	0.773	rs73548688	chr11:73279544	C/T	cg17517138	chr11:73019481	ARHGEF17	0.93	6.88	0.41	5.4e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs9916302	0.904	rs801419	chr17:37466327	A/G	cg00129232	chr17:37814104	STARD3	0.59	7.27	0.43	5.47e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs60012524	1	rs60012524	chr2:99559117	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-10.27	-0.56	1.23e-20	Chronic sinus infection;
SARC	cis	rs9640161	0.673	rs11773351	chr7:150030963	T/C	cg17279839	chr7:150038598	RARRES2	0.49	6.4	0.39	8.22e-10	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs9309473	1.000	rs13421462	chr2:73719875	A/C	cg20560298	chr2:73613845	ALMS1	-0.53	-6.25	-0.38	1.91e-9	Metabolite levels;
SARC	cis	rs2370759	1.000	rs79442609	chr10:32608749	C/T	cg05361325	chr10:32636312	EPC1	-0.76	-6.82	-0.41	7.67e-11	Sexual dysfunction (female);
SARC	cis	rs2153535	0.580	rs6929206	chr6:8447961	A/G	cg07606381	chr6:8435919	SLC35B3	0.78	11.06	0.59	4.04e-23	Motion sickness;
SARC	trans	rs61931739	0.500	rs11053066	chr12:34185318	G/A	cg13010199	chr12:38710504	ALG10B	0.73	9.71	0.54	6.21e-19	Morning vs. evening chronotype;
SARC	cis	rs1008375	0.966	rs28441502	chr4:17598384	G/A	cg16339924	chr4:17578868	LAP3	0.68	8.64	0.49	8.95e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg13939156	chr17:80058883	NA	0.4	6.25	0.38	1.92e-9	Life satisfaction;
SARC	cis	rs9818758	0.607	rs13068038	chr3:49294250	C/A	cg01304814	chr3:48885189	PRKAR2A	0.63	5.14	0.32	5.72e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs9300255	0.507	rs1727302	chr12:123632930	G/A	cg05973401	chr12:123451056	ABCB9	0.57	6.53	0.39	3.98e-10	Neutrophil percentage of white cells;
SARC	cis	rs9300255	0.602	rs1727306	chr12:123665695	A/G	cg05973401	chr12:123451056	ABCB9	0.52	5.89	0.36	1.34e-8	Neutrophil percentage of white cells;
SARC	cis	rs9660992	0.590	rs1779411	chr1:205238530	C/T	cg21643547	chr1:205240462	TMCC2	-0.64	-8.25	-0.48	1.2e-14	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs1707322	1.000	rs11211243	chr1:46455433	G/C	cg03146154	chr1:46216737	IPP	0.46	5.59	0.34	6.25e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs8067545	0.750	rs4925081	chr17:19991993	A/G	cg13482628	chr17:19912719	NA	-0.53	-7.09	-0.42	1.58e-11	Schizophrenia;
SARC	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.74	10.64	0.57	8.48e-22	Personality dimensions;
SARC	cis	rs172166	0.637	rs1233708	chr6:28173219	C/T	cg26335602	chr6:28129616	ZNF389	0.42	5.24	0.32	3.6e-7	Cardiac Troponin-T levels;
SARC	cis	rs6912958	1.000	rs6912958	chr6:88133315	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.36	-6.12	-0.37	4.02e-9	Monocyte percentage of white cells;
SARC	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg24633833	chr3:10029261	TMEM111	0.5	4.89	0.3	1.9e-6	Alzheimer's disease;
SARC	cis	rs2342371	1.000	rs2342371	chr3:196187608	G/A	cg15048948	chr3:196158458	UBXN7	-0.48	-5.86	-0.36	1.6e-8	Fat distribution (HIV);
SARC	trans	rs6894249	1.000	rs6894249	chr5:131797547	A/G	cg06080712	chr22:32435515	NA	-0.44	-6.41	-0.39	7.83e-10	Asthma;
SARC	cis	rs7582720	0.943	rs115130739	chr2:203725677	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.76	7.4	0.44	2.38e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs854765	0.522	rs63721860	chr17:17829576	T/C	cg05444541	chr17:17804740	TOM1L2	-0.3	-5.09	-0.32	7.53e-7	Total body bone mineral density;
SARC	cis	rs2075371	0.865	rs2544172	chr7:133931338	T/C	cg11752832	chr7:134001865	SLC35B4	0.51	6.44	0.39	6.63e-10	Mean platelet volume;
SARC	cis	rs6840360	0.615	rs7669465	chr4:152609289	C/T	cg22705602	chr4:152727874	NA	-0.48	-8.26	-0.48	1.13e-14	Intelligence (multi-trait analysis);
SARC	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg07648498	chr16:89883185	FANCA	-0.4	-5.27	-0.33	3.05e-7	Vitiligo;
SARC	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg27266027	chr21:40555129	PSMG1	0.49	5.4	0.33	1.62e-7	Cognitive function;
SARC	cis	rs240764	0.782	rs151637	chr6:101104191	C/T	cg09795085	chr6:101329169	ASCC3	0.44	5.71	0.35	3.39e-8	Neuroticism;
SARC	trans	rs3942852	0.774	rs10838813	chr11:48186969	C/A	cg15704280	chr7:45808275	SEPT13	-0.62	-7.2	-0.43	8.05e-12	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs6570726	0.791	rs12205752	chr6:145896118	A/G	cg23711669	chr6:146136114	FBXO30	0.84	13.98	0.68	1.14e-32	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg04944784	chr2:26401820	FAM59B	0.51	5.92	0.36	1.15e-8	Gut microbiome composition (summer);
SARC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.63	-8.37	-0.48	5.43e-15	Lymphocyte counts;
SARC	cis	rs9322817	0.691	rs56075147	chr6:105337494	T/A	cg02098413	chr6:105308735	HACE1	0.39	6.06	0.37	5.5e-9	Thyroid stimulating hormone;
SARC	cis	rs4919087	0.590	rs78376466	chr10:99034835	G/A	cg25902810	chr10:99078978	FRAT1	-0.54	-6.03	-0.37	6.27e-9	Monocyte count;
SARC	cis	rs17376456	0.877	rs13173952	chr5:93307557	A/T	cg21475434	chr5:93447410	FAM172A	0.85	7.72	0.45	3.4e-13	Diabetic retinopathy;
SARC	cis	rs9398803	0.931	rs9375435	chr6:126661858	C/T	cg19875578	chr6:126661172	C6orf173	0.62	8.29	0.48	9.22e-15	Male-pattern baldness;
SARC	cis	rs2239547	0.563	rs6445547	chr3:52908577	T/C	cg07507251	chr3:52567010	NT5DC2	0.38	4.8	0.3	2.78e-6	Schizophrenia;
SARC	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg19346786	chr7:2764209	NA	-0.35	-5.32	-0.33	2.48e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
SARC	cis	rs12421382	0.593	rs2357793	chr11:109389353	A/T	cg27471124	chr11:109292789	C11orf87	0.36	5.18	0.32	4.89e-7	Schizophrenia;
SARC	cis	rs9948	0.655	rs56913233	chr2:97405896	A/G	cg01990225	chr2:97406019	LMAN2L	-0.94	-6.38	-0.39	9.49e-10	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs10078	0.571	rs2561664	chr5:459793	T/C	cg24955955	chr5:415729	AHRR	0.73	6.66	0.4	1.93e-10	Fat distribution (HIV);
SARC	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.5	6.53	0.39	4.14e-10	Personality dimensions;
SARC	cis	rs965469	0.779	rs6051683	chr20:3237822	G/C	cg25506879	chr20:3388711	C20orf194	-0.47	-4.94	-0.31	1.49e-6	IFN-related cytopenia;
SARC	cis	rs6912958	0.781	rs2268993	chr6:88184111	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.29	-4.97	-0.31	1.32e-6	Monocyte percentage of white cells;
SARC	trans	rs1910358	0.554	rs10057796	chr5:23759746	C/T	cg19344870	chr20:43595019	STK4	0.55	6.33	0.38	1.23e-9	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs2832191	0.740	rs2832175	chr21:30475606	A/G	cg24692254	chr21:30365293	RNF160	-1.05	-19.14	-0.78	1.06e-49	Dental caries;
SARC	cis	rs1044826	0.957	rs4683799	chr3:139210258	G/C	cg15131784	chr3:139108705	COPB2	0.42	5.12	0.32	6.49e-7	Obesity-related traits;
SARC	cis	rs804280	0.564	rs4639	chr8:11644751	A/G	cg00262122	chr8:11665843	FDFT1	0.48	6.13	0.37	3.62e-9	Myopia (pathological);
SARC	cis	rs908922	0.676	rs4845789	chr1:152528100	A/G	cg09873164	chr1:152488093	CRCT1	0.61	7.89	0.46	1.18e-13	Hair morphology;
SARC	cis	rs1953600	0.870	rs2573356	chr10:81949363	C/T	cg00277334	chr10:82204260	NA	0.36	5.29	0.33	2.85e-7	Sarcoidosis;
SARC	cis	rs3812049	0.826	rs6860245	chr5:127367998	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.88	-9.79	-0.54	3.49e-19	Lymphocyte counts;Red cell distribution width;
SARC	cis	rs12545109	0.800	rs1348082	chr8:57415016	A/G	cg19413350	chr8:57351067	NA	-0.43	-5.32	-0.33	2.38e-7	Obesity-related traits;
SARC	cis	rs7829975	0.660	rs10093926	chr8:8549020	A/C	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.23	-0.47	1.3e-14	Mood instability;
SARC	cis	rs2635047	0.638	rs2571010	chr18:44652130	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	6.48	0.39	5.46e-10	Educational attainment;
SARC	cis	rs7582180	0.629	rs6736576	chr2:100950854	C/T	cg14675211	chr2:100938903	LONRF2	0.47	7.0	0.42	2.67e-11	Intelligence (multi-trait analysis);
SARC	cis	rs7621025	0.630	rs1681816	chr3:136474762	C/G	cg15507776	chr3:136538369	TMEM22	-0.5	-5.6	-0.34	6.03e-8	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
SARC	cis	rs6835098	1.000	rs1054496	chr4:174089080	A/G	cg08422745	chr4:174089978	GALNT7	-0.7	-9.09	-0.51	4.41e-17	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs1008375	0.900	rs6851783	chr4:17578469	A/G	cg02297831	chr4:17616191	MED28	0.46	5.64	0.35	4.89e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs748404	0.697	rs574065	chr15:43550655	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.4	-5.08	-0.32	7.57e-7	Lung cancer;
SARC	cis	rs6772849	0.896	rs4557179	chr3:128366726	A/C	cg01163369	chr3:128370232	RPN1	-0.33	-4.82	-0.3	2.56e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs9354308	0.899	rs2814153	chr6:66557611	T/A	cg07460842	chr6:66804631	NA	0.47	5.34	0.33	2.15e-7	Metabolite levels;
SARC	cis	rs2013441	1.000	rs3850781	chr17:20181939	T/G	cg13482628	chr17:19912719	NA	-0.48	-6.33	-0.38	1.24e-9	Obesity-related traits;
SARC	cis	rs2439831	0.850	rs10438303	chr15:44016417	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.01	8.43	0.48	3.63e-15	Lung cancer in ever smokers;
SARC	cis	rs6484504	0.576	rs208091	chr11:31190099	G/C	cg26647111	chr11:31128758	NA	-0.39	-5.19	-0.32	4.67e-7	Red blood cell count;
SARC	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg15049968	chr18:44337910	ST8SIA5	0.36	5.71	0.35	3.41e-8	Personality dimensions;
SARC	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg15448220	chr1:150897856	SETDB1	0.48	6.3	0.38	1.5e-9	Melanoma;
SARC	cis	rs651907	0.557	rs11711079	chr3:101386918	G/A	cg12386194	chr3:101231763	SENP7	0.49	5.85	0.36	1.61e-8	Colorectal cancer;
SARC	cis	rs10870270	1.000	rs10870271	chr10:133754807	A/G	cg08754478	chr10:133766260	PPP2R2D	0.5	5.96	0.36	9.35e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg05861140	chr6:150128134	PCMT1	-0.42	-5.44	-0.34	1.32e-7	Lung cancer;
SARC	cis	rs7465272	1.000	rs36050651	chr8:143681796	A/G	cg10596483	chr8:143751796	JRK	0.56	6.31	0.38	1.42e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs73086581	1.000	rs6116130	chr20:3947026	A/T	cg02187196	chr20:3869020	PANK2	0.67	6.46	0.39	6.21e-10	Response to antidepressants in depression;
SARC	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg25894440	chr7:65020034	NA	-0.75	-5.65	-0.35	4.61e-8	Diabetic kidney disease;
SARC	cis	rs7465272	0.515	rs34087536	chr8:143720876	G/A	cg10596483	chr8:143751796	JRK	0.58	7.49	0.44	1.42e-12	Bipolar disorder and schizophrenia;
SARC	cis	rs10465746	0.809	rs2389617	chr1:84437652	A/T	cg10977910	chr1:84465055	TTLL7	0.43	5.26	0.33	3.26e-7	Obesity-related traits;
SARC	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg24209194	chr3:40518798	ZNF619	-0.66	-8.45	-0.48	3.12e-15	Renal cell carcinoma;
SARC	cis	rs9309473	1.000	rs13383871	chr2:73631779	T/C	cg20560298	chr2:73613845	ALMS1	-0.51	-6.07	-0.37	5.19e-9	Metabolite levels;
SARC	cis	rs2173063	1.000	rs76386586	chr15:93138375	C/A	cg20143492	chr15:92396574	SLCO3A1	-0.94	-4.8	-0.3	2.79e-6	Subcutaneous adipose tissue;
SARC	cis	rs1008375	0.932	rs13134570	chr4:17692863	C/T	cg16339924	chr4:17578868	LAP3	-0.6	-7.44	-0.44	1.89e-12	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2290159	0.800	rs5746187	chr3:12659419	A/G	cg23032965	chr3:12705835	RAF1	0.77	8.46	0.48	2.96e-15	Cholesterol, total;
SARC	cis	rs72653721	0.689	rs4711170	chr6:11070434	C/A	cg13562911	chr6:11044106	ELOVL2	0.58	6.5	0.39	4.77e-10	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	cis	rs12421382	0.614	rs11213102	chr11:109385853	G/A	cg16359550	chr11:109292809	C11orf87	0.33	4.8	0.3	2.86e-6	Schizophrenia;
SARC	cis	rs6446731	0.593	rs6446726	chr4:3274214	T/C	cg06533319	chr4:3265114	C4orf44	-0.3	-4.89	-0.31	1.86e-6	Mean platelet volume;
SARC	cis	rs7638909	0.512	rs7645178	chr3:38597558	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.41	-4.9	-0.31	1.79e-6	Electrocardiographic conduction measures;
SARC	cis	rs12477438	1.000	rs6542873	chr2:99824965	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-6.29	-0.38	1.54e-9	Chronic sinus infection;
SARC	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.52	0.44	1.17e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.77	7.64	0.45	5.59e-13	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs10911232	0.507	rs3934578	chr1:183027216	T/C	cg13390022	chr1:182993471	LAMC1	0.35	5.29	0.33	2.8e-7	Hypertriglyceridemia;
SARC	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg00149659	chr3:10157352	C3orf10	0.68	6.87	0.41	5.66e-11	Alzheimer's disease;
SARC	cis	rs5753618	0.504	rs9609296	chr22:31891784	T/G	cg02404636	chr22:31891804	SFI1	0.53	5.47	0.34	1.14e-7	Colorectal cancer;
SARC	cis	rs763121	0.752	rs6001190	chr22:39073811	T/C	cg06022373	chr22:39101656	GTPBP1	0.84	10.34	0.56	6.99e-21	Menopause (age at onset);
SARC	cis	rs7811142	1.000	rs6953107	chr7:100095664	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.97	11.52	0.6	1.32e-24	Platelet count;
SARC	cis	rs11785693	0.862	rs11781233	chr8:4993653	C/G	cg26367366	chr8:4980734	NA	-0.73	-6.71	-0.4	1.49e-10	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs7537052	0.564	rs6669395	chr1:36653717	A/G	cg24686825	chr1:36642396	MAP7D1	-0.65	-8.64	-0.49	9.05e-16	Schizophrenia;
SARC	cis	rs897080	0.515	rs698763	chr2:44573624	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.64	7.59	0.45	7.58e-13	Height;
SARC	cis	rs9300255	0.543	rs520088	chr12:123522150	C/G	cg05973401	chr12:123451056	ABCB9	0.49	5.26	0.33	3.29e-7	Neutrophil percentage of white cells;
SARC	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg05861140	chr6:150128134	PCMT1	-0.37	-4.87	-0.3	2.08e-6	Lung cancer;
SARC	cis	rs2859741	0.528	rs59729868	chr1:37493710	G/A	cg09363841	chr1:37513479	NA	-0.29	-5.01	-0.31	1.07e-6	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
SARC	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg20573242	chr4:122745356	CCNA2	0.67	8.48	0.49	2.68e-15	Type 2 diabetes;
SARC	cis	rs2011503	0.769	rs72999059	chr19:19378245	A/C	cg03709012	chr19:19516395	GATAD2A	0.62	5.34	0.33	2.17e-7	Bipolar disorder;
SARC	cis	rs10463554	0.927	rs34802	chr5:102427005	T/C	cg23492399	chr5:102201601	PAM	-0.54	-5.91	-0.36	1.23e-8	Parkinson's disease;
SARC	cis	rs2721811	0.535	rs2721805	chr7:24780316	C/T	cg17569154	chr7:24781545	DFNA5	0.37	4.95	0.31	1.41e-6	Depressive symptoms (multi-trait analysis);
SARC	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg01341218	chr17:43662625	NA	0.91	10.49	0.57	2.53e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	trans	rs61931739	0.890	rs1197560	chr12:34121447	G/C	cg26384229	chr12:38710491	ALG10B	0.58	7.85	0.46	1.47e-13	Morning vs. evening chronotype;
SARC	cis	rs7043114	0.525	rs7853859	chr9:95151377	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-5.68	-0.35	3.91e-8	Height;
SARC	cis	rs644799	1.000	rs494829	chr11:95571750	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.66	8.88	0.5	1.8e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs796364	1.000	rs35220450	chr2:200780737	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.68	-5.71	-0.35	3.45e-8	Schizophrenia;
SARC	cis	rs6752107	1.000	rs13009506	chr2:234175706	A/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	-0.49	-6.43	-0.39	7.22e-10	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs1865760	0.686	rs12210098	chr6:25963966	C/T	cg16482183	chr6:26056742	HIST1H1C	0.44	5.25	0.32	3.51e-7	Height;
SARC	cis	rs1044826	1.000	rs12494806	chr3:139067595	G/A	cg15131784	chr3:139108705	COPB2	0.42	4.93	0.31	1.57e-6	Obesity-related traits;
SARC	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg24675658	chr1:53192096	ZYG11B	0.67	9.85	0.54	2.29e-19	Monocyte count;
SARC	cis	rs9640161	0.830	rs17173703	chr7:150068620	C/T	cg10018233	chr7:150070692	REPIN1	0.7	9.5	0.53	2.67e-18	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs9761603	0.812	rs13112145	chr4:138413244	C/T	cg12033966	chr4:138453416	PCDH18	-0.56	-7.49	-0.44	1.38e-12	Diastolic blood pressure;
SARC	cis	rs11098499	0.954	rs10006706	chr4:120409152	A/G	cg24375607	chr4:120327624	NA	0.42	5.01	0.31	1.06e-6	Corneal astigmatism;
SARC	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg03213289	chr20:61660250	NA	0.46	6.43	0.39	7.22e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs8141529	1.000	rs8141529	chr22:29269692	A/G	cg02153584	chr22:29168773	CCDC117	0.76	10.5	0.57	2.28e-21	Lymphocyte counts;
SARC	cis	rs9304742	1.000	rs9304742	chr19:53451291	A/G	cg24044776	chr19:53454761	ZNF816A	-0.37	-5.14	-0.32	5.8e-7	Psoriasis;
SARC	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg24642844	chr7:1081250	C7orf50	-0.38	-5.25	-0.33	3.48e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	5.88	0.36	1.42e-8	Bipolar disorder;
SARC	cis	rs228437	1.000	rs4896083	chr6:134932535	G/A	cg24504307	chr6:134963096	NA	0.54	6.3	0.38	1.47e-9	Melanoma;
SARC	cis	rs986417	1.000	rs761555	chr14:61109543	T/C	cg27398547	chr14:60952738	C14orf39	0.94	8.06	0.47	3.93e-14	Gut microbiota (bacterial taxa);
SARC	cis	rs9948	0.655	rs2314399	chr2:97442390	G/A	cg01990225	chr2:97406019	LMAN2L	-0.96	-6.75	-0.4	1.15e-10	Erectile dysfunction and prostate cancer treatment;
SARC	trans	rs1814175	0.684	rs1827015	chr11:49585241	A/G	cg15704280	chr7:45808275	SEPT13	-0.72	-10.21	-0.56	1.76e-20	Height;
SARC	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg22618164	chr12:122356400	WDR66	0.51	8.26	0.48	1.12e-14	Mean corpuscular volume;
SARC	cis	rs9322193	0.504	rs7771014	chr6:150205446	T/A	cg00933542	chr6:150070202	PCMT1	0.3	4.81	0.3	2.72e-6	Lung cancer;
SARC	cis	rs6991952	0.676	rs12677889	chr8:25698666	C/T	cg21775463	chr8:25538546	NA	0.28	4.92	0.31	1.65e-6	Inguinal hernia;
SARC	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg11168104	chr5:1857477	NA	-0.34	-4.91	-0.31	1.68e-6	Cardiovascular disease risk factors;
SARC	cis	rs9788721	0.934	rs55676755	chr15:78898932	C/G	cg18825076	chr15:78729989	IREB2	-0.45	-5.31	-0.33	2.59e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs568617	0.953	rs658524	chr11:65647260	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.47	-5.47	-0.34	1.15e-7	Crohn's disease;
SARC	cis	rs2470135	1	rs2470135	chr15:43995789	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.48	5.18	0.32	4.79e-7	Diastolic blood pressure;
SARC	trans	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg21659725	chr3:3221576	CRBN	-0.54	-7.03	-0.42	2.3e-11	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg22535103	chr8:58192502	C8orf71	-0.79	-9.5	-0.53	2.61e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs9527	0.545	rs12784384	chr10:104957594	G/C	cg04362960	chr10:104952993	NT5C2	0.43	5.06	0.31	8.57e-7	Arsenic metabolism;
SARC	cis	rs34172651	0.917	rs2059134	chr16:24816492	C/T	cg04756594	chr16:24857601	SLC5A11	-0.38	-5.92	-0.36	1.14e-8	Intelligence (multi-trait analysis);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg11055358	chr19:4581552	NA	0.48	6.74	0.4	1.23e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs8051517	1.000	rs78318620	chr16:68356247	C/T	cg01866162	chr16:67596514	CTCF	0.77	4.85	0.3	2.29e-6	Blood protein levels;
SARC	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-8.57	-0.49	1.44e-15	Chronic sinus infection;
SARC	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg24846343	chr22:24311635	DDTL	-0.4	-5.2	-0.32	4.26e-7	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	7.28	0.43	4.94e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs11190604	1.000	rs7099913	chr10:102314777	T/C	cg07080220	chr10:102295463	HIF1AN	0.81	9.18	0.52	2.48e-17	Palmitoleic acid (16:1n-7) levels;
SARC	trans	rs61931739	0.500	rs7310576	chr12:34474735	T/C	cg13010199	chr12:38710504	ALG10B	0.73	10.16	0.55	2.53e-20	Morning vs. evening chronotype;
SARC	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.43	0.44	2.1e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6696846	0.777	rs2369526	chr1:205054406	C/T	cg07972983	chr1:205091412	RBBP5	0.51	6.35	0.38	1.09e-9	Red blood cell count;
SARC	cis	rs360798	0.656	rs4671446	chr2:62865488	G/C	cg16915676	chr2:62734870	TMEM17	0.45	5.53	0.34	8.55e-8	Coronary artery disease;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17880622	chr18:31158831	ASXL3	-0.5	-7.24	-0.43	6.61e-12	Smoking initiation;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg02715140	chr11:65625717	CFL1	0.5	6.47	0.39	5.74e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs995000	0.826	rs7555577	chr1:63034363	A/C	cg06896770	chr1:63153194	DOCK7	-0.89	-12.98	-0.65	2.35e-29	Triglyceride levels;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg07513446	chr7:45128474	NACAD	0.46	6.36	0.38	1.04e-9	Chemerin levels;
SARC	cis	rs6831352	0.918	rs2851246	chr4:100046104	A/G	cg13256891	chr4:100009986	ADH5	0.67	8.47	0.49	2.72e-15	Alcohol dependence;
SARC	cis	rs9309711	0.560	rs6548164	chr2:3472665	C/T	cg15506890	chr2:3487001	NA	0.41	5.35	0.33	2.12e-7	Neurofibrillary tangles;
SARC	cis	rs3762637	1.000	rs9836309	chr3:122135195	G/A	cg24169773	chr3:122142474	KPNA1	-0.55	-5.56	-0.34	7.29e-8	LDL cholesterol levels;
SARC	cis	rs1348850	0.574	rs2365617	chr2:178421934	C/A	cg23306229	chr2:178417860	TTC30B	0.82	7.99	0.46	6.1e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2933343	0.700	rs1683787	chr3:128627021	C/T	cg25356066	chr3:128598488	ACAD9	-0.67	-8.74	-0.5	4.64e-16	IgG glycosylation;
SARC	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg22433210	chr17:43662623	NA	1.06	12.49	0.63	9.7e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg13939156	chr17:80058883	NA	-0.41	-6.39	-0.39	8.7e-10	Life satisfaction;
SARC	cis	rs796364	1.000	rs166845	chr2:200823360	T/A	cg23649088	chr2:200775458	C2orf69	0.61	5.93	0.36	1.07e-8	Schizophrenia;
SARC	cis	rs7772486	0.764	rs7762562	chr6:146158994	T/C	cg05347473	chr6:146136440	FBXO30	0.5	7.02	0.42	2.42e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2425143	1.000	rs56052651	chr20:34344084	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-5.98	-0.36	8.39e-9	Blood protein levels;
SARC	cis	rs13082711	0.911	rs13082777	chr3:27421942	A/G	cg02860705	chr3:27208620	NA	0.47	6.27	0.38	1.78e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs6963495	0.818	rs73192105	chr7:105167945	T/C	cg13798780	chr7:105162888	PUS7	0.6	5.54	0.34	8.27e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs9768139	0.733	rs12698208	chr7:158117575	C/T	cg25566285	chr7:158114605	PTPRN2	0.3	4.96	0.31	1.34e-6	Calcium levels;
SARC	cis	rs10754283	0.557	rs1215511	chr1:90087543	C/A	cg21401794	chr1:90099060	LRRC8C	0.41	5.17	0.32	4.94e-7	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs918629	0.798	rs3777162	chr5:95293412	G/A	cg16656078	chr5:95278638	ELL2	-0.64	-7.69	-0.45	4.21e-13	IgG glycosylation;
SARC	cis	rs7833790	0.724	rs1054078	chr8:82712153	A/G	cg27398817	chr8:82754497	SNX16	-0.44	-5.58	-0.34	6.8e-8	Diastolic blood pressure;
SARC	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg03433033	chr1:76189801	ACADM	0.51	6.11	0.37	4.21e-9	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs12600856	1	rs12600856	chr17:38163295	T/C	cg17467752	chr17:38218738	THRA	0.46	5.86	0.36	1.55e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs5758511	0.514	rs3985938	chr22:42511727	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.42	6.04	0.37	6.11e-9	Birth weight;
SARC	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg09699651	chr6:150184138	LRP11	0.43	5.28	0.33	2.94e-7	Lung cancer;
SARC	cis	rs2327429	0.858	rs12207772	chr6:134189834	T/C	cg25632230	chr6:134101081	NA	-0.47	-5.7	-0.35	3.59e-8	Coronary artery disease;
SARC	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg04317338	chr11:64019027	PLCB3	0.78	8.08	0.47	3.53e-14	Mean platelet volume;
SARC	cis	rs1008375	0.966	rs6839660	chr4:17667987	C/T	cg16339924	chr4:17578868	LAP3	0.61	7.89	0.46	1.14e-13	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.85	8.56	0.49	1.57e-15	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs854765	0.583	rs4925125	chr17:17794444	T/C	cg04398451	chr17:18023971	MYO15A	0.41	5.83	0.36	1.81e-8	Total body bone mineral density;
SARC	cis	rs6570726	0.693	rs450921	chr6:145864260	C/T	cg05347473	chr6:146136440	FBXO30	0.54	7.45	0.44	1.82e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6840360	0.571	rs17275598	chr4:152568478	C/A	cg22705602	chr4:152727874	NA	-0.44	-6.79	-0.41	9.21e-11	Intelligence (multi-trait analysis);
SARC	cis	rs3741151	0.773	rs17310374	chr11:73274874	T/C	cg17517138	chr11:73019481	ARHGEF17	0.93	6.88	0.41	5.4e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs6831352	0.918	rs17218602	chr4:100061073	A/G	cg13256891	chr4:100009986	ADH5	-0.66	-8.16	-0.47	2.08e-14	Alcohol dependence;
SARC	cis	rs9612	1.000	rs8105041	chr19:44258458	A/G	cg08581076	chr19:44259116	C19orf61	0.65	7.93	0.46	9.08e-14	Exhaled nitric oxide output;
SARC	cis	rs9291683	0.588	rs11732054	chr4:9999877	C/T	cg11266682	chr4:10021025	SLC2A9	0.42	7.52	0.44	1.19e-12	Bone mineral density;
SARC	cis	rs9326248	0.648	rs11216257	chr11:116932561	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.55	5.47	0.34	1.15e-7	Blood protein levels;
SARC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg03647317	chr4:187891568	NA	-0.4	-5.72	-0.35	3.28e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.95	14.48	0.69	2.51e-34	Chronic sinus infection;
SARC	cis	rs7666738	0.830	rs7674095	chr4:99048158	T/A	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg09547170	chr10:105726688	SLK	0.58	7.27	0.43	5.4e-12	Breast cancer;
SARC	cis	rs6815814	0.950	rs66819621	chr4:38819403	A/G	cg09316306	chr4:38807337	TLR1	0.46	4.79	0.3	3e-6	Breast cancer;
SARC	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg20887711	chr4:1340912	KIAA1530	0.42	4.82	0.3	2.53e-6	Obesity-related traits;
SARC	cis	rs7607369	0.791	rs72965151	chr2:219344165	G/T	cg02176678	chr2:219576539	TTLL4	-0.53	-8.12	-0.47	2.62e-14	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs13191362	1.000	rs34344906	chr6:162993378	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.59	0.34	6.28e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs72634258	0.945	rs161800	chr1:8042402	A/T	cg00042356	chr1:8021962	PARK7	0.57	5.57	0.34	6.94e-8	Inflammatory bowel disease;
SARC	cis	rs734999	0.549	rs2764845	chr1:2528999	G/T	cg20673091	chr1:2541236	MMEL1	-0.33	-5.07	-0.32	8.06e-7	Ulcerative colitis;
SARC	cis	rs17376456	0.825	rs10214278	chr5:93237679	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.58	-5.38	-0.33	1.8e-7	Diabetic retinopathy;
SARC	cis	rs3091242	0.728	rs706845	chr1:25730713	G/A	cg03650068	chr1:25596491	NA	0.34	5.24	0.32	3.62e-7	Erythrocyte sedimentation rate;
SARC	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg25072359	chr17:41440525	NA	0.49	5.8	0.36	2.15e-8	Menopause (age at onset);
SARC	cis	rs12711979	0.584	rs11694096	chr2:3868113	G/A	cg17052675	chr2:3827356	NA	-0.44	-6.69	-0.4	1.61e-10	Itch intensity from mosquito bite adjusted by bite size;
SARC	cis	rs2486288	0.656	rs1706768	chr15:45569443	T/C	cg15395560	chr15:45543142	SLC28A2	0.33	6.35	0.38	1.09e-9	Glomerular filtration rate;
SARC	cis	rs6088580	0.634	rs6142164	chr20:33006597	C/T	cg08999081	chr20:33150536	PIGU	-0.43	-6.58	-0.4	3.15e-10	Glomerular filtration rate (creatinine);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg10073696	chr12:19660393	AEBP2	0.51	7.36	0.43	3.04e-12	Thyroid stimulating hormone;
SARC	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg04267008	chr7:1944627	MAD1L1	-0.53	-6.13	-0.37	3.72e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs709400	1.000	rs57218990	chr14:104128007	T/A	cg26031613	chr14:104095156	KLC1	0.98	17.72	0.76	4.68e-45	Body mass index;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg24651824	chr4:104117048	CENPE	0.47	6.7	0.4	1.55e-10	Thyroid stimulating hormone;
SARC	cis	rs35110281	0.627	rs1595167	chr21:44965874	T/G	cg21573476	chr21:45109991	RRP1B	-0.41	-5.87	-0.36	1.48e-8	Mean corpuscular volume;
SARC	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg12463550	chr7:65579703	CRCP	0.48	5.21	0.32	4.06e-7	Aortic root size;
SARC	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg03351412	chr1:154909251	PMVK	0.65	8.4	0.48	4.47e-15	Prostate cancer;
SARC	cis	rs4642101	0.669	rs1467026	chr3:12830775	G/A	cg12400702	chr3:12838781	CAND2	-0.27	-5.23	-0.32	3.81e-7	QRS complex (12-leadsum);
SARC	cis	rs6674176	0.628	rs4660758	chr1:44424879	A/C	cg12908607	chr1:44402522	ARTN	-0.37	-6.26	-0.38	1.84e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs9341808	0.754	rs3805885	chr6:80996751	C/G	cg08355045	chr6:80787529	NA	-0.31	-4.84	-0.3	2.39e-6	Sitting height ratio;
SARC	cis	rs2529049	0.545	rs2237322	chr7:24770740	C/G	cg17569154	chr7:24781545	DFNA5	0.47	6.58	0.4	2.99e-10	Urate levels in obese individuals;
SARC	cis	rs3092073	0.624	rs11906879	chr20:44591324	C/T	cg10662479	chr20:44420225	WFDC3;DNTTIP1	-0.44	-5.64	-0.35	4.8e-8	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg12463550	chr7:65579703	CRCP	-0.5	-5.55	-0.34	7.9e-8	Aortic root size;
SARC	cis	rs2602836	0.600	rs6858148	chr4:100065917	T/C	cg13256891	chr4:100009986	ADH5	-0.69	-9.45	-0.53	3.68e-18	HDL cholesterol;HDL cholesterol levels;
SARC	cis	rs9527	0.615	rs1556960	chr10:104726673	A/G	cg04362960	chr10:104952993	NT5C2	0.42	4.89	0.31	1.86e-6	Arsenic metabolism;
SARC	cis	rs2204008	0.774	rs12810027	chr12:38212165	A/G	cg13010199	chr12:38710504	ALG10B	0.78	10.64	0.57	8.61e-22	Bladder cancer;
SARC	cis	rs12893668	0.572	rs11540512	chr14:104147377	C/T	cg26031613	chr14:104095156	KLC1	-0.53	-5.82	-0.36	1.98e-8	Reticulocyte count;
SARC	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg05313129	chr8:58192883	C8orf71	-0.66	-6.81	-0.41	8.08e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs6570726	0.791	rs6570693	chr6:145910841	C/T	cg05347473	chr6:146136440	FBXO30	0.51	7.13	0.42	1.29e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9814567	0.712	rs9838621	chr3:134332319	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.51	-6.61	-0.4	2.53e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.98	10.78	0.58	3.03e-22	Platelet count;
SARC	cis	rs644799	1.000	rs557079	chr11:95530125	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	15.35	0.71	3.21e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs11758351	0.778	rs41266801	chr6:26197493	C/A	cg23601095	chr6:26197514	HIST1H3D	0.61	5.37	0.33	1.93e-7	Gout;Renal underexcretion gout;
SARC	cis	rs57506017	0.585	rs1054168	chr7:12273413	C/T	cg23422036	chr7:12250390	TMEM106B	0.46	5.96	0.36	9.38e-9	Neuroticism;
SARC	cis	rs10782582	0.593	rs12142247	chr1:76235746	C/T	cg03433033	chr1:76189801	ACADM	-0.43	-5.39	-0.33	1.76e-7	Daytime sleep phenotypes;
SARC	cis	rs2816062	0.735	rs2816045	chr1:18892999	A/G	cg18795169	chr1:18902165	NA	-0.77	-12.2	-0.62	8.68e-27	Urate levels in lean individuals;
SARC	cis	rs6502050	0.787	rs59251877	chr17:80056498	G/A	cg13939156	chr17:80058883	NA	0.37	5.65	0.35	4.62e-8	Life satisfaction;
SARC	cis	rs9815354	0.812	rs7639859	chr3:42001987	C/T	cg03022575	chr3:42003672	ULK4	0.68	5.86	0.36	1.56e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs4901847	0.868	rs8008786	chr14:58546110	C/A	cg15908186	chr14:58618357	C14orf37	0.48	5.54	0.34	7.96e-8	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs78545713	0.649	rs79988778	chr6:26210621	G/T	cg00631329	chr6:26305371	NA	-0.71	-5.14	-0.32	5.85e-7	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs9300255	0.568	rs1790108	chr12:123636841	A/G	cg00376283	chr12:123451042	ABCB9	0.58	6.88	0.41	5.39e-11	Neutrophil percentage of white cells;
SARC	cis	rs748404	0.646	rs2253268	chr15:43800968	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	5.5	0.34	1e-7	Lung cancer;
SARC	cis	rs12134245	1.000	rs12134245	chr1:92021464	C/T	cg21854759	chr1:92012499	NA	-0.35	-4.84	-0.3	2.37e-6	Breast cancer;
SARC	cis	rs533581	0.873	rs579740	chr16:88973937	A/G	cg16701003	chr16:89028210	CBFA2T3	-0.47	-7.13	-0.42	1.28e-11	Social autistic-like traits;
SARC	cis	rs1448094	0.544	rs56330110	chr12:86166666	A/G	cg02569458	chr12:86230093	RASSF9	0.37	4.97	0.31	1.28e-6	Major depressive disorder;
SARC	cis	rs634534	0.563	rs470192	chr11:65724291	C/T	cg26695010	chr11:65641043	EFEMP2	-0.55	-7.19	-0.43	8.91e-12	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs2439831	1.000	rs565007	chr15:43716641	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	8.09	0.47	3.35e-14	Lung cancer in ever smokers;
SARC	cis	rs73198271	0.562	rs17154743	chr8:8650787	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-4.83	-0.3	2.51e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs12540874	0.698	rs12718574	chr7:50573848	G/C	cg18232548	chr7:50535776	DDC	-0.42	-4.93	-0.31	1.53e-6	Systemic sclerosis;
SARC	trans	rs72809865	0.530	rs57409290	chr10:83254826	T/G	cg01169021	chr5:140792918	PCDHGA4;PCDHGA6;PCDHGA9;PCDHGA1;PCDHGA8;PCDHGA5;PCDHGB1;PCDHGA10;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGB6;PCDHGA7;PCDHGB2;PCDHGB5;PCDHGB3	-0.86	-6.32	-0.38	1.29e-9	Kidney disease (early and late stages) in type 1 diabetes;
SARC	cis	rs2342371	0.545	rs4393941	chr3:196206743	A/G	cg15048948	chr3:196158458	UBXN7	-0.42	-5.33	-0.33	2.32e-7	Fat distribution (HIV);
SARC	cis	rs2153535	0.547	rs9502720	chr6:8541362	C/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.57	0.49	1.42e-15	Motion sickness;
SARC	cis	rs6665290	0.901	rs12410103	chr1:227197408	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.09	-25.55	-0.86	1.65e-69	Myeloid white cell count;
SARC	cis	rs6840360	0.571	rs7664663	chr4:152508014	G/C	cg22705602	chr4:152727874	NA	-0.43	-6.66	-0.4	1.91e-10	Intelligence (multi-trait analysis);
SARC	cis	rs694739	1.000	rs499425	chr11:64105929	A/G	cg23796481	chr11:64053134	BAD;GPR137	-0.77	-10.67	-0.57	6.92e-22	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs72781680	0.898	rs72798049	chr2:23958002	C/G	cg06627628	chr2:24431161	ITSN2	-0.63	-6.18	-0.38	2.86e-9	Lymphocyte counts;
SARC	cis	rs4808199	0.948	rs8108647	chr19:19427623	A/G	cg03709012	chr19:19516395	GATAD2A	1.14	11.67	0.61	4.36e-25	Nonalcoholic fatty liver disease;
SARC	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg22484793	chr3:52261325	TLR9	0.3	4.8	0.3	2.79e-6	Bipolar disorder;
SARC	cis	rs3857536	0.904	rs10806525	chr6:66900488	A/C	cg07460842	chr6:66804631	NA	-0.46	-5.45	-0.34	1.26e-7	Blood trace element (Cu levels);
SARC	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg18357526	chr6:26021779	HIST1H4A	0.74	8.21	0.47	1.49e-14	Intelligence (multi-trait analysis);
SARC	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg18404041	chr3:52824283	ITIH1	-0.37	-5.47	-0.34	1.18e-7	Bipolar disorder;
SARC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.0	0.79	1.72e-52	Prudent dietary pattern;
SARC	cis	rs2486288	0.656	rs12908818	chr15:45571668	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.54	-6.7	-0.4	1.59e-10	Glomerular filtration rate;
SARC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.42	0.53	4.71e-18	Prudent dietary pattern;
SARC	cis	rs10504229	0.813	rs6999878	chr8:58197243	C/G	cg05313129	chr8:58192883	C8orf71	-0.53	-5.5	-0.34	9.93e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7084402	0.902	rs1658484	chr10:60288543	G/A	cg07615347	chr10:60278583	BICC1	0.6	8.86	0.5	2.16e-16	Refractive error;
SARC	cis	rs3733585	0.673	rs4467563	chr4:9953460	A/T	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.94	-0.36	1.06e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs2908197	0.662	rs917423	chr7:75984717	A/G	cg22830091	chr7:75961684	YWHAG	-0.35	-5.21	-0.32	4.09e-7	3-hydroxypropylmercapturic acid levels in smokers;
SARC	trans	rs1493916	0.967	rs9953765	chr18:31399464	A/G	cg27147174	chr7:100797783	AP1S1	-0.58	-7.49	-0.44	1.45e-12	Life satisfaction;
SARC	cis	rs28386778	0.700	rs12452767	chr17:62010503	G/A	cg26338869	chr17:61819248	STRADA	-0.67	-8.38	-0.48	4.92e-15	Prudent dietary pattern;
SARC	cis	rs73242632	1.000	rs73242621	chr4:57818081	A/G	cg20415529	chr4:57845134	POLR2B;C4orf14	0.99	5.73	0.35	3.07e-8	Congenital heart disease (maternal effect);
SARC	trans	rs1814175	0.502	rs12365889	chr11:49623034	G/A	cg15704280	chr7:45808275	SEPT13	-0.75	-9.26	-0.52	1.41e-17	Height;
SARC	cis	rs6496667	1.000	rs8026533	chr15:90893228	A/C	cg22089800	chr15:90895588	ZNF774	0.51	4.86	0.3	2.16e-6	Rheumatoid arthritis;
SARC	cis	rs13191362	1.000	rs35424047	chr6:163029715	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.57	5.48	0.34	1.09e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs4319547	0.656	rs10773088	chr12:122828069	A/T	cg23029597	chr12:123009494	RSRC2	-0.42	-5.35	-0.33	2.13e-7	Body mass index;
SARC	trans	rs11098499	0.863	rs10013305	chr4:120450424	G/A	cg25214090	chr10:38739885	LOC399744	0.57	7.35	0.43	3.31e-12	Corneal astigmatism;
SARC	cis	rs7412746	0.646	rs1972060	chr1:150937594	T/C	cg13175981	chr1:150552382	MCL1	-0.53	-6.41	-0.39	7.97e-10	Melanoma;
SARC	cis	rs17376456	0.877	rs12374470	chr5:93481046	A/G	cg25358565	chr5:93447407	FAM172A	1.36	14.18	0.68	2.63e-33	Diabetic retinopathy;
SARC	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg18252515	chr7:66147081	NA	-1.33	-11.96	-0.62	5.03e-26	Diabetic kidney disease;
SARC	cis	rs2304069	1.000	rs216126	chr5:149428424	G/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.73	8.05	0.47	4.33e-14	HIV-1 control;
SARC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.03	12.46	0.63	1.18e-27	Platelet count;
SARC	cis	rs2688608	0.620	rs7080350	chr10:75577843	A/G	cg13887666	chr10:75432598	NA	0.32	4.79	0.3	2.92e-6	Inflammatory bowel disease;
SARC	cis	rs7223966	0.691	rs9893518	chr17:62006997	A/G	cg00588841	chr17:61851480	DDX42;CCDC47	-0.64	-6.74	-0.4	1.23e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs35110281	0.805	rs2838317	chr21:44991791	A/C	cg21573476	chr21:45109991	RRP1B	-0.47	-6.85	-0.41	6.49e-11	Mean corpuscular volume;
SARC	cis	rs11097912	0.632	rs3737497	chr4:107257975	A/T	cg09646026	chr4:107269030	AIMP1	0.45	4.92	0.31	1.61e-6	Airflow obstruction;
SARC	cis	rs921968	0.528	rs13382651	chr2:219628191	A/G	cg02176678	chr2:219576539	TTLL4	-0.32	-4.95	-0.31	1.41e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs12586317	0.620	rs79832710	chr14:35547434	G/T	cg16230307	chr14:35515116	FAM177A1	1.0	11.55	0.6	1.08e-24	Psoriasis;
SARC	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg23982607	chr1:1823379	GNB1	-0.66	-11.32	-0.6	6e-24	Body mass index;
SARC	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg04944784	chr2:26401820	FAM59B	-0.47	-6.16	-0.37	3.11e-9	Gut microbiome composition (summer);
SARC	cis	rs13427251	0.868	rs1901284	chr2:100146040	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.64	8.51	0.49	2.09e-15	Chronic sinus infection;
SARC	cis	rs2228479	0.850	rs2286393	chr16:89809548	C/A	cg00800038	chr16:89945340	TCF25	-0.74	-5.15	-0.32	5.57e-7	Skin colour saturation;
SARC	cis	rs7412746	0.658	rs12090215	chr1:150893660	C/A	cg13175981	chr1:150552382	MCL1	-0.48	-5.86	-0.36	1.57e-8	Melanoma;
SARC	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg01316550	chr5:56110833	MAP3K1	0.52	4.82	0.3	2.54e-6	Initial pursuit acceleration;
SARC	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg14829155	chr15:31115871	NA	0.5	6.45	0.39	6.22e-10	Huntington's disease progression;
SARC	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg24060327	chr5:131705240	SLC22A5	-0.72	-8.74	-0.5	4.67e-16	Breast cancer;
SARC	cis	rs6456156	0.967	rs150108	chr6:167513153	C/T	cg07741184	chr6:167504864	NA	0.3	5.34	0.33	2.21e-7	Primary biliary cholangitis;
SARC	cis	rs78487399	0.710	rs75330033	chr2:43697723	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-4.93	-0.31	1.59e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs698813	0.573	rs6544750	chr2:44490780	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	6.16	0.37	3.21e-9	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg15049968	chr18:44337910	ST8SIA5	-0.35	-5.49	-0.34	1.07e-7	Personality dimensions;
SARC	cis	rs11997175	0.603	rs12156112	chr8:33791598	T/C	ch.8.33884649F	chr8:33765107	NA	0.44	5.6	0.34	6.1e-8	Body mass index;
SARC	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg11987759	chr7:65425863	GUSB	-0.48	-6.54	-0.39	3.9e-10	Aortic root size;
SARC	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg11764359	chr7:65958608	NA	0.66	7.62	0.45	6.53e-13	Aortic root size;
SARC	cis	rs992157	0.835	rs12987219	chr2:219144149	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.7	-10.24	-0.56	1.43e-20	Colorectal cancer;
SARC	cis	rs7568458	0.846	rs6705839	chr2:85761279	A/T	cg17127132	chr2:85788382	GGCX	0.46	6.19	0.38	2.64e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs9381040	0.610	rs2235679	chr6:41020577	G/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.41	-4.88	-0.3	1.95e-6	Alzheimer's disease (late onset);
SARC	cis	rs9807989	0.839	rs10204837	chr2:102977730	C/A	cg09003973	chr2:102972529	NA	0.41	5.64	0.35	4.86e-8	Asthma;
SARC	cis	rs11249608	0.548	rs7733072	chr5:178456007	A/G	cg01312482	chr5:178451176	ZNF879	-0.35	-4.75	-0.3	3.49e-6	Pubertal anthropometrics;
SARC	cis	rs5167	0.505	rs7257468	chr19:45453144	C/T	cg20090143	chr19:45452003	APOC2	0.3	4.89	0.31	1.86e-6	Blood protein levels;
SARC	cis	rs1318878	0.519	rs73057238	chr12:15501693	C/G	cg08258403	chr12:15378311	NA	0.51	7.08	0.42	1.68e-11	Intelligence (multi-trait analysis);
SARC	cis	rs820218	0.743	rs820233	chr17:73697391	C/T	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.6	7.6	0.45	7.19e-13	Rotator cuff tears;
SARC	cis	rs4969178	0.930	rs2292644	chr17:76394449	C/T	cg02836325	chr17:76403955	PGS1	0.32	4.99	0.31	1.17e-6	HDL cholesterol levels;
SARC	cis	rs9790314	0.663	rs55888276	chr3:160651406	A/G	cg04691961	chr3:161091175	C3orf57	0.6	8.41	0.48	4.19e-15	Morning vs. evening chronotype;
SARC	cis	rs3008870	1.000	rs3008854	chr1:67385951	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.93	11.49	0.6	1.62e-24	Lymphocyte percentage of white cells;
SARC	cis	rs526231	0.543	rs34808	chr5:102429188	T/A	cg23492399	chr5:102201601	PAM	-0.52	-5.65	-0.35	4.76e-8	Primary biliary cholangitis;
SARC	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg26039829	chr8:22132926	PIWIL2	0.46	6.55	0.39	3.56e-10	Hypertriglyceridemia;
SARC	cis	rs7270101	0.665	rs58439054	chr20:3170939	G/C	cg25506879	chr20:3388711	C20orf194	-0.67	-5.11	-0.32	6.69e-7	Chronic hepatitis C infection;
SARC	cis	rs453301	0.686	rs3895823	chr8:8873646	T/C	cg08975724	chr8:8085496	FLJ10661	-0.45	-5.63	-0.35	5.14e-8	Joint mobility (Beighton score);
SARC	cis	rs703842	0.963	rs923829	chr12:58174306	T/C	cg00677455	chr12:58241039	CTDSP2	0.52	6.82	0.41	7.65e-11	Multiple sclerosis;
SARC	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg06558623	chr16:89946397	TCF25	0.91	6.43	0.39	7.15e-10	Skin colour saturation;
SARC	cis	rs1448094	0.512	rs7133591	chr12:86239752	G/C	cg02569458	chr12:86230093	RASSF9	0.39	5.45	0.34	1.26e-7	Major depressive disorder;
SARC	cis	rs561341	0.941	rs501773	chr17:30314435	T/G	cg00745463	chr17:30367425	LRRC37B	-0.6	-4.78	-0.3	3.08e-6	Hip circumference adjusted for BMI;
SARC	cis	rs7296418	0.922	rs12425009	chr12:123502044	C/T	cg05973401	chr12:123451056	ABCB9	0.59	7.04	0.42	2.11e-11	Platelet count;
SARC	cis	rs7945705	0.934	rs1988709	chr11:8882890	A/T	cg21881798	chr11:8931708	C11orf17;ST5	0.41	5.68	0.35	3.98e-8	Hemoglobin concentration;
SARC	cis	rs4423214	0.650	rs4245442	chr11:71220909	T/C	cg24826892	chr11:71159390	DHCR7	0.45	5.14	0.32	5.84e-7	Vitamin D levels;
SARC	cis	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg07777115	chr5:623756	CEP72	-0.62	-5.55	-0.34	7.72e-8	Obesity-related traits;
SARC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.53	-5.66	-0.35	4.37e-8	Platelet count;
SARC	cis	rs9393777	0.528	rs34843552	chr6:27241915	A/G	cg12826209	chr6:26865740	GUSBL1	0.55	5.14	0.32	5.81e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2070488	0.766	rs6808093	chr3:38498160	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.81	12.58	0.64	4.69e-28	Electrocardiographic conduction measures;
SARC	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.85	-13.46	-0.66	6.28e-31	Personality dimensions;
SARC	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-6.96	-0.41	3.46e-11	Gut microbiome composition (summer);
SARC	cis	rs7560272	0.501	rs2272178	chr2:73977609	C/T	cg20560298	chr2:73613845	ALMS1	0.42	5.64	0.35	5e-8	Schizophrenia;
SARC	cis	rs3749237	0.557	rs7631908	chr3:49425707	T/G	cg06212747	chr3:49208901	KLHDC8B	0.51	6.24	0.38	1.99e-9	Resting heart rate;
SARC	cis	rs72634258	0.732	rs6577464	chr1:8171302	T/C	cg00042356	chr1:8021962	PARK7	-0.64	-5.95	-0.36	9.68e-9	Inflammatory bowel disease;
SARC	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9814567	0.896	rs6799110	chr3:134206749	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-7.02	-0.42	2.34e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs1008375	0.966	rs3775924	chr4:17585984	T/C	cg02297831	chr4:17616191	MED28	0.49	6.22	0.38	2.31e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1707322	1.000	rs10890360	chr1:46338444	C/T	cg06784218	chr1:46089804	CCDC17	0.33	5.78	0.35	2.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2908197	0.737	rs59755579	chr7:75992444	C/G	cg22830091	chr7:75961684	YWHAG	-0.37	-5.54	-0.34	8.18e-8	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs3857067	0.806	rs7669168	chr4:95104881	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.08	-0.32	7.69e-7	QT interval;
SARC	cis	rs3741404	0.609	rs651855	chr11:63870810	T/C	cg18225595	chr11:63971243	STIP1	0.39	5.55	0.34	7.79e-8	Platelet count;
SARC	cis	rs17023223	0.537	rs10923766	chr1:119726932	G/A	cg05756136	chr1:119680316	WARS2	-0.49	-5.62	-0.35	5.47e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs9420	0.890	rs547891	chr11:57499065	C/T	cg23127183	chr11:57508653	C11orf31	0.5	5.77	0.35	2.48e-8	Schizophrenia;
SARC	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg02725872	chr8:58115012	NA	-0.36	-6.12	-0.37	3.91e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs950169	0.526	rs698620	chr15:85177208	G/A	cg12501888	chr15:85177176	SCAND2	-0.51	-6.22	-0.38	2.25e-9	Schizophrenia;
SARC	cis	rs7727544	0.660	rs2631361	chr5:131707380	C/A	cg07395648	chr5:131743802	NA	0.42	4.92	0.31	1.61e-6	Blood metabolite levels;
SARC	trans	rs73036520	1.000	rs11666251	chr19:45741609	T/C	cg23345151	chr18:77292947	NA	0.43	6.43	0.39	7.03e-10	Monocyte percentage of white cells;
SARC	cis	rs9611519	0.929	rs71327107	chr22:41418229	T/G	cg17376030	chr22:41985996	PMM1	0.47	5.39	0.33	1.72e-7	Neuroticism;
SARC	cis	rs1008375	0.966	rs3775923	chr4:17585625	T/C	cg16339924	chr4:17578868	LAP3	0.71	9.3	0.52	1.03e-17	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1448094	0.690	rs7132879	chr12:86289864	A/G	cg02569458	chr12:86230093	RASSF9	0.39	5.14	0.32	5.8e-7	Major depressive disorder;
SARC	cis	rs9894429	0.809	rs9889642	chr17:79591762	T/C	cg18240062	chr17:79603768	NPLOC4	0.72	9.91	0.54	1.51e-19	Eye color traits;
SARC	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg27170947	chr2:26402098	FAM59B	-0.37	-4.8	-0.3	2.79e-6	Gut microbiome composition (summer);
SARC	cis	rs17739167	0.550	rs4924589	chr15:42229632	C/T	cg20935245	chr15:42234343	EHD4	0.48	6.36	0.38	1.08e-9	Monocyte count;
SARC	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg12463550	chr7:65579703	CRCP	-0.7	-5.31	-0.33	2.51e-7	Diabetic kidney disease;
SARC	cis	rs7659604	0.502	rs4516738	chr4:122669177	T/C	cg19671926	chr4:122722719	EXOSC9	0.53	6.63	0.4	2.33e-10	Type 2 diabetes;
SARC	cis	rs807669	0.903	rs762527	chr22:19183470	A/G	cg02655711	chr22:19163373	SLC25A1	0.55	7.51	0.44	1.27e-12	Metabolite levels;
SARC	cis	rs11722228	0.964	rs10939614	chr4:9926613	T/C	cg25986240	chr4:9926439	SLC2A9	0.3	5.0	0.31	1.12e-6	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg06212747	chr3:49208901	KLHDC8B	0.52	6.42	0.39	7.41e-10	Resting heart rate;
SARC	trans	rs4834272	0.662	rs2106993	chr4:113304342	A/G	cg04861380	chr7:150497663	TMEM176B;TMEM176A	-0.45	-6.31	-0.38	1.38e-9	Body mass index;
SARC	cis	rs12579753	1.000	rs11115017	chr12:82176914	C/A	cg07988820	chr12:82153109	PPFIA2	-0.59	-6.93	-0.41	4.09e-11	Resting heart rate;
SARC	trans	rs208520	0.690	rs12201156	chr6:66720874	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	14.23	0.68	1.69e-33	Exhaled nitric oxide output;
SARC	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg18370025	chr7:2749541	AMZ1	-0.29	-4.71	-0.3	4.18e-6	Height;
SARC	cis	rs12579753	1.000	rs34894912	chr12:82228721	A/G	cg07988820	chr12:82153109	PPFIA2	-0.52	-6.07	-0.37	5.24e-9	Resting heart rate;
SARC	cis	rs12887734	0.546	rs4906376	chr14:104272165	A/C	cg26031613	chr14:104095156	KLC1	-0.54	-6.08	-0.37	4.78e-9	Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	cis	rs7647973	0.731	rs13084037	chr3:49214066	G/A	cg07636037	chr3:49044803	WDR6	0.83	8.12	0.47	2.68e-14	Menarche (age at onset);
SARC	cis	rs2153535	0.601	rs9502715	chr6:8455709	C/T	cg21535247	chr6:8435926	SLC35B3	0.52	6.55	0.39	3.66e-10	Motion sickness;
SARC	cis	rs897080	0.515	rs1067409	chr2:44673057	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.08	0.37	4.76e-9	Height;
SARC	cis	rs9341808	0.683	rs9359409	chr6:80826897	C/G	cg08355045	chr6:80787529	NA	0.34	5.5	0.34	1.02e-7	Sitting height ratio;
SARC	cis	rs763014	0.898	rs8060585	chr16:635794	C/G	cg00908189	chr16:619842	PIGQ	0.83	12.08	0.62	2.01e-26	Height;
SARC	trans	rs1814175	0.645	rs7123448	chr11:49764865	T/G	cg03929089	chr4:120376271	NA	-0.84	-12.43	-0.63	1.47e-27	Height;
SARC	cis	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg13647721	chr17:30228624	UTP6	0.69	6.29	0.38	1.59e-9	Hip circumference adjusted for BMI;
SARC	cis	rs11697848	1.000	rs74597310	chr20:48462727	T/C	cg17849948	chr20:48532315	SPATA2	0.8	4.86	0.3	2.15e-6	Systemic lupus erythematosus;
SARC	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg11987759	chr7:65425863	GUSB	-0.57	-7.87	-0.46	1.36e-13	Calcium levels;
SARC	cis	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg13647721	chr17:30228624	UTP6	0.68	5.53	0.34	8.48e-8	Hip circumference adjusted for BMI;
SARC	cis	rs7529073	0.815	rs1431984	chr1:214148628	A/G	cg24083324	chr1:214162604	PROX1	-0.43	-6.31	-0.38	1.4e-9	Schizophrenia;
SARC	cis	rs11758351	0.660	rs11753131	chr6:26219384	G/A	cg01420254	chr6:26195488	NA	0.55	4.75	0.3	3.49e-6	Gout;Renal underexcretion gout;
SARC	cis	rs1443512	0.796	rs1822437	chr12:54340077	A/G	cg17410650	chr12:54324560	NA	0.32	4.95	0.31	1.45e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
SARC	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg21724239	chr8:58056113	NA	0.61	5.93	0.36	1.1e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1015213	0.609	rs117144627	chr8:52823157	A/C	cg18264719	chr8:53508979	NA	0.66	5.1	0.32	7.01e-7	Glaucoma (primary angle closure);
SARC	cis	rs708547	0.836	rs1277287	chr4:57853147	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.78	9.89	0.54	1.71e-19	Response to bleomycin (chromatid breaks);
SARC	cis	rs11098499	0.954	rs12508504	chr4:120410607	A/C	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.68e-6	Corneal astigmatism;
SARC	cis	rs9393692	0.905	rs7761298	chr6:26278436	C/T	cg00631329	chr6:26305371	NA	-0.58	-8.36	-0.48	5.54e-15	Educational attainment;
SARC	cis	rs1865760	0.516	rs10807007	chr6:26048931	A/C	cg16482183	chr6:26056742	HIST1H1C	0.47	6.11	0.37	4.23e-9	Height;
SARC	cis	rs17376456	0.569	rs7721668	chr5:93290995	G/A	cg21475434	chr5:93447410	FAM172A	-0.6	-6.51	-0.39	4.54e-10	Diabetic retinopathy;
SARC	cis	rs736408	0.648	rs2268023	chr3:52819327	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.3	0.33	2.68e-7	Bipolar disorder;
SARC	cis	rs3749237	0.964	rs2352975	chr3:49891885	T/C	cg03060546	chr3:49711283	APEH	0.55	6.2	0.38	2.56e-9	Resting heart rate;
SARC	cis	rs4919087	0.651	rs12240590	chr10:99072066	C/G	cg25902810	chr10:99078978	FRAT1	-0.55	-6.46	-0.39	5.97e-10	Monocyte count;
SARC	cis	rs950776	0.518	rs8053	chr15:78841220	T/C	cg22563815	chr15:78856949	CHRNA5	-0.4	-6.63	-0.4	2.26e-10	Sudden cardiac arrest;
SARC	trans	rs330048	0.545	rs11774353	chr8:9153127	C/T	cg06636001	chr8:8085503	FLJ10661	0.56	6.97	0.42	3.2e-11	Systemic lupus erythematosus;
SARC	cis	rs8067545	0.611	rs2703812	chr17:20114803	A/G	cg13482628	chr17:19912719	NA	-0.55	-7.3	-0.43	4.61e-12	Schizophrenia;
SARC	cis	rs6901004	0.803	rs2757571	chr6:111511124	T/G	cg15721981	chr6:111408429	SLC16A10	-0.44	-5.36	-0.33	1.96e-7	Blood metabolite levels;
SARC	cis	rs9790314	0.718	rs9847866	chr3:160758275	A/G	cg04691961	chr3:161091175	C3orf57	-0.6	-8.18	-0.47	1.89e-14	Morning vs. evening chronotype;
SARC	cis	rs2043112	0.867	rs1239344	chr5:38933749	C/T	cg04869206	chr5:39074266	RICTOR	0.49	5.95	0.36	9.69e-9	Obesity-related traits;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg26737766	chr1:24127303	GALE	-0.81	-6.9	-0.41	4.89e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2153535	0.580	rs1414348	chr6:8471940	A/G	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	cis	rs11098499	0.697	rs10016448	chr4:120298845	A/G	cg09307838	chr4:120376055	NA	0.91	12.88	0.65	4.9e-29	Corneal astigmatism;
SARC	trans	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg17830980	chr10:43048298	ZNF37B	-0.52	-6.82	-0.41	7.73e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs10752881	1.000	rs6673559	chr1:182983197	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.72	10.87	0.58	1.56e-22	Colorectal cancer;
SARC	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	7.72	0.45	3.42e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg26338869	chr17:61819248	STRADA	0.78	10.39	0.56	5.04e-21	Prudent dietary pattern;
SARC	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg15049968	chr18:44337910	ST8SIA5	0.33	5.13	0.32	6.23e-7	Personality dimensions;
SARC	cis	rs7551222	0.752	rs10900594	chr1:204470129	C/G	cg20240347	chr1:204465584	NA	-0.28	-4.94	-0.31	1.5e-6	Schizophrenia;
SARC	trans	rs7937682	0.889	rs1784787	chr11:111486125	T/A	cg18187862	chr3:45730750	SACM1L	0.55	6.99	0.42	2.93e-11	Primary sclerosing cholangitis;
SARC	cis	rs981844	0.712	rs878911	chr4:154755615	A/G	cg14289246	chr4:154710475	SFRP2	-0.47	-5.49	-0.34	1.04e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg17971929	chr21:40555470	PSMG1	0.98	13.69	0.67	1.06e-31	Cognitive function;
SARC	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg15541040	chr2:3486749	NA	-0.44	-5.87	-0.36	1.51e-8	Neurofibrillary tangles;
SARC	cis	rs344364	0.511	rs911391	chr16:1947016	C/A	cg26617929	chr16:1858877	NA	-0.71	-6.06	-0.37	5.5e-9	Glomerular filtration rate in chronic kidney disease;
SARC	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10046574	0.831	rs10243569	chr7:135063466	G/A	cg27474649	chr7:135195673	CNOT4	0.89	7.28	0.43	5.14e-12	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs7551222	0.749	rs4951409	chr1:204560990	A/T	cg20240347	chr1:204465584	NA	-0.28	-5.17	-0.32	5.09e-7	Schizophrenia;
SARC	cis	rs9527	0.590	rs3781282	chr10:104852419	C/T	cg04362960	chr10:104952993	NT5C2	-0.44	-5.3	-0.33	2.71e-7	Arsenic metabolism;
SARC	cis	rs1348850	0.632	rs13008857	chr2:178514468	G/A	cg22681709	chr2:178499509	PDE11A	-0.42	-5.8	-0.36	2.11e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs16922576	0.623	rs2104166	chr9:5230447	T/C	cg02405213	chr9:5042618	JAK2	-0.43	-5.17	-0.32	5.1e-7	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs7953249	0.656	rs2243616	chr12:121406370	G/T	cg15155738	chr12:121454335	C12orf43	-0.46	-5.74	-0.35	2.95e-8	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs1008375	1.000	rs10939756	chr4:17693867	C/T	cg27347728	chr4:17578864	LAP3	0.46	5.74	0.35	2.94e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg16325326	chr1:53192061	ZYG11B	-0.82	-12.99	-0.65	2.19e-29	Monocyte count;
SARC	cis	rs55986470	0.670	rs56313033	chr2:239346202	C/T	cg21699342	chr2:239360505	ASB1	-0.61	-5.1	-0.32	7.04e-7	Chronotype;
SARC	cis	rs17384381	0.861	rs34561661	chr1:85777250	C/T	cg16011679	chr1:85725395	C1orf52	0.71	6.34	0.38	1.2e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11098499	0.697	rs4560394	chr4:120313435	T/G	cg09307838	chr4:120376055	NA	0.91	12.88	0.65	4.9e-29	Corneal astigmatism;
SARC	cis	rs875971	0.545	rs1267814	chr7:66044409	G/A	cg11764359	chr7:65958608	NA	-0.63	-6.12	-0.37	3.83e-9	Aortic root size;
SARC	cis	rs17376456	0.877	rs9885329	chr5:93380278	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.7	0.35	3.55e-8	Diabetic retinopathy;
SARC	cis	rs611744	0.839	rs672552	chr8:109164223	A/G	cg21045802	chr8:109455806	TTC35	0.51	6.27	0.38	1.69e-9	Dupuytren's disease;
SARC	cis	rs3106136	0.872	rs28408371	chr4:95275182	T/C	cg11021082	chr4:95130006	SMARCAD1	0.35	5.43	0.34	1.38e-7	Capecitabine sensitivity;
SARC	cis	rs787274	0.543	rs10739377	chr9:115631598	A/G	cg13803584	chr9:115635662	SNX30	0.83	7.09	0.42	1.59e-11	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs3812049	0.784	rs7734927	chr5:127453735	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.87	9.55	0.53	1.93e-18	Lymphocyte counts;Red cell distribution width;
SARC	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg16325326	chr1:53192061	ZYG11B	0.91	16.76	0.74	6.72e-42	Monocyte count;
SARC	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg16606324	chr3:10149918	C3orf24	0.51	4.95	0.31	1.39e-6	Alzheimer's disease;
SARC	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg13175981	chr1:150552382	MCL1	0.49	5.91	0.36	1.2e-8	Urate levels;
SARC	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg07701084	chr6:150067640	NUP43	0.37	4.9	0.31	1.82e-6	Lung cancer;
SARC	cis	rs2153535	0.580	rs4960422	chr6:8459309	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	6.55	0.39	3.66e-10	Motion sickness;
SARC	cis	rs1395	0.778	rs60631624	chr2:27497815	T/G	cg21747090	chr2:27597821	SNX17	-0.54	-6.28	-0.38	1.61e-9	Blood metabolite levels;
SARC	cis	rs600231	0.708	rs3132767	chr11:65234860	C/T	cg17120908	chr11:65337727	SSSCA1	-0.41	-5.27	-0.33	3.07e-7	Bone mineral density;
SARC	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	11.76	0.61	2.34e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs6546550	0.933	rs1454498	chr2:70149225	C/A	cg02498382	chr2:70120550	SNRNP27	-0.33	-5.36	-0.33	1.99e-7	Prevalent atrial fibrillation;
SARC	cis	rs6087990	0.966	rs2377667	chr20:31346925	A/G	cg13636640	chr20:31349939	DNMT3B	0.81	12.8	0.64	9.27e-29	Ulcerative colitis;
SARC	cis	rs950027	0.620	rs1049518	chr15:45653367	G/A	cg21132104	chr15:45694354	SPATA5L1	0.55	7.09	0.42	1.59e-11	Response to fenofibrate (adiponectin levels);
SARC	cis	rs10791097	0.720	rs6590517	chr11:130733505	C/T	cg12179176	chr11:130786555	SNX19	0.71	10.62	0.57	9.41e-22	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs897080	0.589	rs1085448	chr2:44663805	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	6.0	0.37	7.32e-9	Height;
SARC	cis	rs9911578	1.000	rs3744108	chr17:56585872	G/C	cg05425664	chr17:57184151	TRIM37	0.64	7.97	0.46	7e-14	Intelligence (multi-trait analysis);
SARC	trans	rs11098499	0.955	rs4145951	chr4:120155817	A/G	cg25214090	chr10:38739885	LOC399744	0.54	6.95	0.41	3.66e-11	Corneal astigmatism;
SARC	cis	rs7223966	1.000	rs9901507	chr17:61765524	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.57	-6.67	-0.4	1.87e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9815354	0.767	rs73077375	chr3:41853058	C/T	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	trans	rs1853207	0.867	rs78264032	chr10:96694861	G/A	cg02737782	chr1:8014393	NA	-0.91	-6.52	-0.39	4.4e-10	Blood metabolite levels;
SARC	cis	rs2425143	0.841	rs4911519	chr20:34362326	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.74	6.35	0.38	1.1e-9	Blood protein levels;
SARC	trans	rs17685	0.753	rs1104878	chr7:75685593	G/T	cg19862616	chr7:65841803	NCRNA00174	0.61	7.65	0.45	5.19e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs11945232	0.790	rs6816224	chr4:88346510	G/A	cg23841344	chr4:88312519	HSD17B11	-0.54	-7.08	-0.42	1.73e-11	Intelligence (multi-trait analysis);
SARC	cis	rs12709013	0.569	rs30837	chr16:58745846	T/C	cg04273148	chr16:57808038	KIFC3	0.4	5.45	0.34	1.26e-7	Blood metabolite ratios;
SARC	cis	rs1371867	0.846	rs1660338	chr8:101242757	C/G	cg11906718	chr8:101322791	RNF19A	0.64	8.5	0.49	2.27e-15	Atrioventricular conduction;
SARC	cis	rs17270561	0.609	rs9393662	chr6:25739670	T/C	cg16482183	chr6:26056742	HIST1H1C	0.43	5.22	0.32	3.92e-7	Iron status biomarkers;
SARC	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg12016809	chr21:47604291	C21orf56	0.46	5.64	0.35	4.78e-8	Testicular germ cell tumor;
SARC	cis	rs12458462	0.859	rs2242177	chr18:77477379	G/A	cg23301140	chr18:77439876	CTDP1	0.61	7.98	0.46	6.7e-14	Monocyte count;
SARC	cis	rs9325144	0.534	rs6582538	chr12:38629997	A/C	cg26384229	chr12:38710491	ALG10B	-0.64	-8.64	-0.49	9.27e-16	Morning vs. evening chronotype;
SARC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg26338869	chr17:61819248	STRADA	0.81	10.79	0.58	2.72e-22	Prudent dietary pattern;
SARC	cis	rs7712401	0.562	rs377316	chr5:122259875	G/C	cg19412675	chr5:122181750	SNX24	0.41	5.24	0.32	3.56e-7	Mean platelet volume;
SARC	cis	rs2204008	0.715	rs11495369	chr12:38238673	T/C	cg26384229	chr12:38710491	ALG10B	0.92	13.59	0.66	2.32e-31	Bladder cancer;
SARC	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg22535103	chr8:58192502	C8orf71	-0.67	-5.75	-0.35	2.72e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg15242686	chr22:24348715	GSTTP1	-0.45	-5.45	-0.34	1.31e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7772486	0.790	rs2250387	chr6:146205233	C/T	cg23711669	chr6:146136114	FBXO30	0.81	12.91	0.65	3.92e-29	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs965469	1.000	rs2236106	chr20:3278410	A/C	cg25506879	chr20:3388711	C20orf194	-0.47	-4.76	-0.3	3.42e-6	IFN-related cytopenia;
SARC	cis	rs9788682	0.747	rs16969894	chr15:78776456	C/T	cg06917634	chr15:78832804	PSMA4	-0.53	-5.49	-0.34	1.03e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs9467773	0.583	rs1021373	chr6:26632457	G/A	cg11502198	chr6:26597334	ABT1	0.63	8.63	0.49	9.91e-16	Intelligence (multi-trait analysis);
SARC	cis	rs9398803	0.865	rs9398808	chr6:126758791	G/T	cg19875578	chr6:126661172	C6orf173	0.63	8.6	0.49	1.17e-15	Male-pattern baldness;
SARC	cis	rs7582180	0.652	rs11687865	chr2:100947000	T/A	cg14675211	chr2:100938903	LONRF2	0.51	7.63	0.45	6.1e-13	Intelligence (multi-trait analysis);
SARC	cis	rs9325144	0.510	rs7952795	chr12:38720686	C/T	cg26384229	chr12:38710491	ALG10B	0.62	8.15	0.47	2.25e-14	Morning vs. evening chronotype;
SARC	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.61	-6.27	-0.38	1.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs748404	0.650	rs556851	chr15:43571219	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	6.53	0.39	4.02e-10	Lung cancer;
SARC	cis	rs881375	0.967	rs1014529	chr9:123684943	C/G	cg00246817	chr9:123691163	NA	-0.37	-4.72	-0.3	4.08e-6	Rheumatoid arthritis;
SARC	cis	rs10870270	0.956	rs10870281	chr10:133762642	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.84	-10.49	-0.57	2.48e-21	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs9902453	0.967	rs12602065	chr17:28482488	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	6.68	0.4	1.75e-10	Coffee consumption (cups per day);
SARC	cis	rs7264396	0.635	rs6058378	chr20:34546658	G/A	cg12579300	chr20:34535607	PHF20	-0.43	-4.94	-0.31	1.49e-6	Total cholesterol levels;
SARC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg07362569	chr17:61921086	SMARCD2	0.37	4.83	0.3	2.47e-6	Prudent dietary pattern;
SARC	cis	rs9472414	0.546	rs4590263	chr6:45291381	A/G	cg11115867	chr6:45345767	RUNX2;SUPT3H	-0.57	-5.31	-0.33	2.52e-7	Height;
SARC	cis	rs2233152	0.656	rs2287691	chr19:41286163	C/G	cg07297178	chr19:42193084	CEACAM7	0.35	4.74	0.3	3.7e-6	Kawasaki disease;
SARC	cis	rs2295359	0.892	rs11209004	chr1:67613932	G/A	cg12940439	chr1:67600707	NA	0.47	6.67	0.4	1.87e-10	Psoriasis;
SARC	trans	rs61931739	0.500	rs12829125	chr12:34314789	A/G	cg13010199	chr12:38710504	ALG10B	0.74	9.98	0.55	9.15e-20	Morning vs. evening chronotype;
SARC	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6495122	0.501	rs12148488	chr15:75382542	G/T	cg17294928	chr15:75287854	SCAMP5	-0.52	-6.72	-0.4	1.36e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	trans	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg11199642	chr14:100405934	EML1	0.49	6.37	0.39	9.9e-10	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg17376030	chr22:41985996	PMM1	0.72	8.83	0.5	2.64e-16	Vitiligo;
SARC	cis	rs6762477	0.505	rs17304079	chr3:50085153	A/G	cg24110177	chr3:50126178	RBM5	-0.48	-5.35	-0.33	2.08e-7	Menarche (age at onset);
SARC	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	9.01	0.51	7.42e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg03351412	chr1:154909251	PMVK	0.58	7.47	0.44	1.56e-12	Prostate cancer;
SARC	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg11764359	chr7:65958608	NA	0.66	7.81	0.46	1.93e-13	Aortic root size;
SARC	cis	rs11098499	0.954	rs17005535	chr4:120411562	C/T	cg24375607	chr4:120327624	NA	0.41	4.86	0.3	2.12e-6	Corneal astigmatism;
SARC	cis	rs735396	0.595	rs2258287	chr12:121454313	G/T	cg25281562	chr12:121454272	C12orf43	0.56	7.33	0.43	3.74e-12	N-glycan levels;
SARC	cis	rs9747201	0.925	rs8072670	chr17:80159566	T/C	cg09264619	chr17:80180166	NA	-0.52	-6.06	-0.37	5.5e-9	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs9810259	0.614	rs67216730	chr3:12364377	T/C	cg23514324	chr3:12329213	PPARG	-0.39	-5.0	-0.31	1.15e-6	Platelet count;
SARC	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg18135555	chr8:22132992	PIWIL2	0.41	6.32	0.38	1.31e-9	Hypertriglyceridemia;
SARC	trans	rs61931739	0.513	rs7956626	chr12:33901640	C/T	cg13010199	chr12:38710504	ALG10B	0.58	7.62	0.45	6.41e-13	Morning vs. evening chronotype;
SARC	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg16325326	chr1:53192061	ZYG11B	0.95	17.64	0.76	8.42e-45	Monocyte count;
SARC	cis	rs2075371	0.863	rs2075370	chr7:133967812	A/G	cg20476274	chr7:133979776	SLC35B4	0.6	8.13	0.47	2.46e-14	Mean platelet volume;
SARC	cis	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg18252515	chr7:66147081	NA	1.18	10.14	0.55	2.98e-20	Diabetic kidney disease;
SARC	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg23958373	chr8:599963	NA	0.73	5.46	0.34	1.19e-7	IgG glycosylation;
SARC	trans	rs6600671	0.934	rs12060031	chr1:121243450	A/G	cg00646200	chr1:148855367	NA	-0.5	-6.77	-0.41	1.01e-10	Hip geometry;
SARC	cis	rs9911578	1.000	rs304299	chr17:56838472	C/G	cg12560992	chr17:57184187	TRIM37	0.88	12.06	0.62	2.46e-26	Intelligence (multi-trait analysis);
SARC	trans	rs8073060	0.544	rs225246	chr17:33944773	T/C	cg19694781	chr19:47549865	TMEM160	-0.64	-6.41	-0.39	7.95e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs1008375	1.000	rs11727312	chr4:17669185	C/T	cg16339924	chr4:17578868	LAP3	0.6	7.76	0.45	2.74e-13	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9916302	0.752	rs12150047	chr17:37601755	A/G	cg15445000	chr17:37608096	MED1	0.46	4.89	0.3	1.91e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs4319547	0.956	rs10847179	chr12:123040985	T/C	cg23029597	chr12:123009494	RSRC2	-0.42	-5.27	-0.33	3.13e-7	Body mass index;
SARC	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg22618164	chr12:122356400	WDR66	0.43	6.98	0.42	2.96e-11	Mean corpuscular volume;
SARC	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg18305652	chr10:134549665	INPP5A	0.33	5.02	0.31	1.01e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs9309473	0.861	rs6546856	chr2:73837751	T/C	cg07208825	chr2:73871855	ALMS1P	0.33	4.88	0.3	1.96e-6	Metabolite levels;
SARC	cis	rs9916302	0.706	rs597069	chr17:37458512	G/T	cg07936489	chr17:37558343	FBXL20	0.76	8.91	0.5	1.48e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs9858542	0.537	rs9863142	chr3:49366741	C/G	cg00383909	chr3:49044727	WDR6	0.46	4.94	0.31	1.48e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg13271783	chr10:134563150	INPP5A	-0.41	-5.17	-0.32	5.1e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg02931644	chr1:25747376	RHCE	0.47	7.86	0.46	1.45e-13	Erythrocyte sedimentation rate;
SARC	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.5	-6.32	-0.38	1.35e-9	Lymphocyte counts;
SARC	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg23248424	chr5:179741104	GFPT2	-0.49	-6.0	-0.37	7.59e-9	Height;
SARC	trans	rs78901727	0.614	rs76876306	chr2:194366006	T/A	cg02889647	chr1:152879586	IVL	0.83	6.32	0.38	1.33e-9	Schizophrenia;
SARC	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg05368731	chr17:41323189	NBR1	0.78	9.53	0.53	2.2e-18	Menopause (age at onset);
SARC	cis	rs2228479	0.850	rs117880578	chr16:89910230	C/G	cg12064134	chr16:90016061	DEF8	-0.56	-4.83	-0.3	2.47e-6	Skin colour saturation;
SARC	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg13395646	chr4:1353034	KIAA1530	-0.48	-5.87	-0.36	1.5e-8	Obesity-related traits;
SARC	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.98	11.11	0.59	2.76e-23	Platelet count;
SARC	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg02951883	chr7:2050386	MAD1L1	-0.5	-6.41	-0.39	7.98e-10	Schizophrenia;
SARC	cis	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg15556689	chr8:8085844	FLJ10661	0.42	5.19	0.32	4.66e-7	Mood instability;
SARC	cis	rs8058578	0.832	rs7500719	chr16:30840877	C/T	cg00531865	chr16:30841666	NA	-0.47	-5.29	-0.33	2.87e-7	Multiple myeloma;
SARC	cis	rs66573146	0.634	rs55633489	chr4:6988745	C/A	cg00086871	chr4:6988644	TBC1D14	0.9	5.39	0.33	1.72e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg25894440	chr7:65020034	NA	-0.73	-5.46	-0.34	1.25e-7	Diabetic kidney disease;
SARC	cis	rs4642101	0.611	rs6442331	chr3:12820636	T/G	cg24848339	chr3:12840334	CAND2	0.39	5.81	0.36	2.05e-8	QRS complex (12-leadsum);
SARC	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	9.15	0.51	3.02e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6570726	0.516	rs10457779	chr6:145736663	C/T	cg23711669	chr6:146136114	FBXO30	0.57	7.7	0.45	3.82e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3750965	1.000	rs3750965	chr11:68840160	A/G	cg06818126	chr11:68850279	TPCN2	-0.42	-4.8	-0.3	2.86e-6	Hair color;
SARC	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg14664628	chr15:75095509	CSK	-0.45	-5.43	-0.33	1.45e-7	Breast cancer;
SARC	cis	rs10484885	0.878	rs72921955	chr6:90588789	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.6	-4.98	-0.31	1.22e-6	QRS interval (sulfonylurea treatment interaction);
SARC	cis	rs1008375	0.932	rs6814465	chr4:17659034	C/T	cg27347728	chr4:17578864	LAP3	0.49	6.19	0.38	2.73e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs847851	0.617	rs11970238	chr6:34945143	T/C	cg13137465	chr6:34857473	ANKS1A	0.59	4.8	0.3	2.89e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6963495	0.818	rs114865717	chr7:105158526	C/T	cg19920283	chr7:105172520	RINT1	0.65	5.48	0.34	1.09e-7	Bipolar disorder (body mass index interaction);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg13722419	chr2:160088036	TANC1	0.58	8.14	0.47	2.31e-14	Thyroid stimulating hormone;
SARC	cis	rs1784581	1.000	rs1618170	chr6:162400337	C/T	cg17173639	chr6:162384350	PARK2	-0.8	-11.03	-0.59	4.75e-23	Itch intensity from mosquito bite;
SARC	cis	rs10988449	0.891	rs10988454	chr9:132390131	C/G	cg18327994	chr9:132372705	NA	0.5	5.23	0.32	3.85e-7	Response to anti-depressant treatment in major depressive disorder;
SARC	cis	rs1322639	0.614	rs7768154	chr6:169565470	A/G	cg04662567	chr6:169592167	NA	-0.47	-4.84	-0.3	2.42e-6	Pulse pressure;
SARC	cis	rs11992162	0.573	rs61468577	chr8:11784925	A/C	cg02127589	chr8:12458309	NA	-0.32	-4.78	-0.3	3.13e-6	Monocyte count;
SARC	cis	rs17376456	0.825	rs10036024	chr5:93074804	C/A	cg25358565	chr5:93447407	FAM172A	1.15	10.42	0.56	3.93e-21	Diabetic retinopathy;
SARC	cis	rs2115630	0.645	rs4842978	chr15:85197253	T/C	cg12501888	chr15:85177176	SCAND2	-0.53	-6.37	-0.39	1e-9	P wave terminal force;
SARC	cis	rs1570884	0.516	rs9535268	chr13:50175478	C/A	cg03651054	chr13:50194643	NA	0.3	4.77	0.3	3.21e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs910316	0.967	rs4384542	chr14:75658013	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.47	-6.55	-0.39	3.62e-10	Height;
SARC	cis	rs35213789	1.000	rs35213789	chr7:69268012	C/T	cg10619644	chr7:69149951	AUTS2	0.45	5.68	0.35	4.1e-8	Childhood ear infection;
SARC	cis	rs10782582	0.569	rs4549990	chr1:76125075	A/G	cg03433033	chr1:76189801	ACADM	-0.4	-5.23	-0.32	3.85e-7	Daytime sleep phenotypes;
SARC	cis	rs4727027	0.901	rs6944781	chr7:148829566	A/G	cg23583168	chr7:148888333	NA	-0.73	-10.69	-0.57	5.97e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs2295359	1.000	rs11465753	chr1:67631423	T/C	cg12940439	chr1:67600707	NA	0.43	6.55	0.39	3.56e-10	Psoriasis;
SARC	cis	rs992157	0.735	rs12990082	chr2:219102332	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.67	9.25	0.52	1.54e-17	Colorectal cancer;
SARC	cis	rs9399137	0.507	rs12663810	chr6:135289782	G/C	cg22676075	chr6:135203613	NA	0.41	5.29	0.33	2.85e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs2013441	1.000	rs2703789	chr17:20162923	G/A	cg13482628	chr17:19912719	NA	-0.47	-6.18	-0.38	2.87e-9	Obesity-related traits;
SARC	cis	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg05623727	chr3:50126028	RBM5	0.33	4.99	0.31	1.21e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9457247	0.765	rs9295385	chr6:167448181	A/G	cg07741184	chr6:167504864	NA	0.32	5.73	0.35	3.07e-8	Crohn's disease;
SARC	cis	rs829661	0.532	rs11127276	chr2:30794215	C/T	cg12454169	chr2:30669597	LCLAT1	-0.44	-5.66	-0.35	4.47e-8	Midgestational circulating levels of PBDEs (fetal genetic effect);
SARC	cis	rs738322	1.000	rs738320	chr22:38568715	G/T	cg25457927	chr22:38595422	NA	-0.27	-5.61	-0.35	5.61e-8	Cutaneous nevi;
SARC	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg17221315	chr6:27791827	HIST1H4J	0.45	4.74	0.3	3.76e-6	Depression;
SARC	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg19729930	chr2:74357872	NA	0.71	10.24	0.56	1.52e-20	Gestational age at birth (maternal effect);
SARC	cis	rs72634258	0.842	rs4908727	chr1:8163122	C/T	cg00042356	chr1:8021962	PARK7	0.64	5.9	0.36	1.24e-8	Inflammatory bowel disease;
SARC	trans	rs9329221	0.572	rs4841295	chr8:10105115	C/T	cg06636001	chr8:8085503	FLJ10661	0.53	7.26	0.43	5.84e-12	Neuroticism;
SARC	cis	rs6582630	0.524	rs10785494	chr12:38532431	C/G	cg14851346	chr12:38532713	NA	-0.47	-5.85	-0.36	1.67e-8	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg01446983	chr17:47754976	SPOP	0.48	6.47	0.39	5.7e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs12134245	0.776	rs12122066	chr1:92005140	C/T	cg25838465	chr1:92012736	NA	-0.69	-9.82	-0.54	2.93e-19	Breast cancer;
SARC	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg18252515	chr7:66147081	NA	-1.33	-11.84	-0.61	1.22e-25	Diabetic kidney disease;
SARC	cis	rs80130819	0.748	rs2732487	chr12:48686741	T/C	cg24011408	chr12:48396354	COL2A1	0.54	6.0	0.37	7.5e-9	Prostate cancer;
SARC	trans	rs7819412	0.811	rs2409691	chr8:10943276	C/T	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.65	-0.4	2.01e-10	Triglycerides;
SARC	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg14784868	chr12:69753453	YEATS4	0.51	6.77	0.41	1.04e-10	Blood protein levels;
SARC	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg14298792	chr15:30685198	CHRFAM7A	-0.48	-5.48	-0.34	1.11e-7	Huntington's disease progression;
SARC	cis	rs9462027	1.000	rs9296133	chr6:34777533	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.4	-5.43	-0.34	1.38e-7	Systemic lupus erythematosus;
SARC	cis	rs12586317	0.513	rs74564132	chr14:35472882	C/T	cg16230307	chr14:35515116	FAM177A1	1.02	11.85	0.61	1.18e-25	Psoriasis;
SARC	cis	rs667920	0.573	rs9682783	chr3:136539689	T/C	cg15507776	chr3:136538369	TMEM22	0.95	10.72	0.57	4.82e-22	Coronary artery disease;
SARC	cis	rs12600121	0.538	rs4788594	chr16:72023078	C/G	cg01557791	chr16:72042693	DHODH	0.41	5.12	0.32	6.51e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9309473	1.000	rs6546837	chr2:73677898	G/C	cg20560298	chr2:73613845	ALMS1	-0.51	-6.12	-0.37	3.98e-9	Metabolite levels;
SARC	cis	rs611744	0.967	rs635219	chr8:109229243	C/T	cg21045802	chr8:109455806	TTC35	0.45	5.39	0.33	1.69e-7	Dupuytren's disease;
SARC	cis	rs992157	0.710	rs7569907	chr2:219070551	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.65	9.12	0.51	3.63e-17	Colorectal cancer;
SARC	cis	rs9462027	0.628	rs9469917	chr6:34831369	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-6.08	-0.37	4.87e-9	Systemic lupus erythematosus;
SARC	cis	rs2286885	1.000	rs2286886	chr9:129246177	T/C	cg14319473	chr9:129242481	FAM125B	0.38	4.78	0.3	3.12e-6	Intraocular pressure;
SARC	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg16680214	chr1:154839983	KCNN3	0.34	5.42	0.33	1.49e-7	Prostate cancer;
SARC	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg07701084	chr6:150067640	NUP43	0.4	5.37	0.33	1.91e-7	Lung cancer;
SARC	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg17971929	chr21:40555470	PSMG1	0.99	14.22	0.68	1.86e-33	Cognitive function;
SARC	cis	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg21775007	chr8:11205619	TDH	-0.47	-6.19	-0.38	2.7e-9	Neuroticism;
SARC	cis	rs8068544	0.818	rs78333491	chr17:40163138	A/G	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.06	-8.41	-0.48	4.15e-15	Reticulocyte fraction of red cells;Reticulocyte count;
SARC	cis	rs2213920	0.516	rs71505548	chr9:118169753	G/A	cg13918206	chr9:118159781	DEC1	-0.83	-6.48	-0.39	5.31e-10	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg13271783	chr10:134563150	INPP5A	-0.4	-4.94	-0.31	1.5e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs11203032	0.831	rs7091822	chr10:90957403	G/T	cg16672925	chr10:90967113	CH25H	0.54	6.03	0.37	6.38e-9	Heart failure;
SARC	trans	rs7618501	0.519	rs3774749	chr3:50207227	C/T	cg21659725	chr3:3221576	CRBN	-0.5	-6.42	-0.39	7.43e-10	Intelligence (multi-trait analysis);
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg22532736	chr15:64126641	HERC1	-0.51	-6.59	-0.4	2.86e-10	Blood pressure;
SARC	cis	rs1348850	0.914	rs7573763	chr2:178249808	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.72	9.23	0.52	1.72e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg11965913	chr1:205819406	PM20D1	0.89	14.36	0.69	6.47e-34	Menarche (age at onset);
SARC	cis	rs7666738	0.830	rs28465658	chr4:99035866	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2180341	0.618	rs4502958	chr6:127593113	G/A	cg27446573	chr6:127587934	RNF146	0.66	8.66	0.49	7.81e-16	Breast cancer;
SARC	cis	rs7712401	0.678	rs401535	chr5:122358685	A/G	cg19412675	chr5:122181750	SNX24	-0.42	-5.3	-0.33	2.65e-7	Mean platelet volume;
SARC	trans	rs360488	0.549	rs6751610	chr2:14237327	A/C	cg13543375	chr1:22470218	WNT4	0.58	6.58	0.4	3.09e-10	Emphysema imaging phenotypes;
SARC	trans	rs9329221	0.683	rs814359	chr8:9883132	T/G	cg06636001	chr8:8085503	FLJ10661	-0.68	-9.67	-0.54	8.14e-19	Neuroticism;
SARC	cis	rs62056376	0.736	rs885691	chr17:32641225	C/T	cg16693818	chr17:32640541	NA	0.43	4.77	0.3	3.28e-6	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
SARC	cis	rs763121	0.853	rs2281019	chr22:39064378	T/A	cg06022373	chr22:39101656	GTPBP1	0.87	10.87	0.58	1.61e-22	Menopause (age at onset);
SARC	cis	rs16854884	0.690	rs35885310	chr3:143771333	A/G	cg06585982	chr3:143692056	C3orf58	0.66	9.09	0.51	4.54e-17	Economic and political preferences (feminism/equality);
SARC	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg03351412	chr1:154909251	PMVK	0.62	7.9	0.46	1.08e-13	Prostate cancer;
SARC	cis	rs11719291	0.915	rs9834996	chr3:48754877	G/T	cg00383909	chr3:49044727	WDR6	0.69	6.45	0.39	6.38e-10	Cognitive function;
SARC	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg07061783	chr6:25882402	NA	-0.56	-6.65	-0.4	2.02e-10	Urate levels;
SARC	cis	rs2708377	0.656	rs73066852	chr12:11276541	A/G	cg27345534	chr12:11509583	PRB1	0.5	4.75	0.3	3.59e-6	Bitter taste perception;
SARC	cis	rs3096299	0.586	rs4572400	chr16:89533516	T/A	cg02034447	chr16:89574710	SPG7	0.52	7.01	0.42	2.56e-11	Multiple myeloma (IgH translocation);
SARC	cis	rs10982256	0.789	rs10817629	chr9:117261987	C/T	cg21159778	chr9:117266918	DFNB31	0.37	5.07	0.32	7.97e-7	Bipolar disorder;
SARC	cis	rs2075371	1.000	rs2544221	chr7:133993014	G/C	cg00033643	chr7:134001901	SLC35B4	0.44	5.32	0.33	2.42e-7	Mean platelet volume;
SARC	cis	rs1448094	0.836	rs7484454	chr12:86425576	A/G	cg02569458	chr12:86230093	RASSF9	0.39	5.71	0.35	3.51e-8	Major depressive disorder;
SARC	trans	rs7615952	0.611	rs7632305	chr3:125634767	C/T	cg07211511	chr3:129823064	LOC729375	-0.82	-7.49	-0.44	1.41e-12	Blood pressure (smoking interaction);
SARC	cis	rs7762018	0.556	rs75659875	chr6:170054800	A/C	cg13015042	chr6:170102002	WDR27;C6orf120	0.7	5.09	0.32	7.46e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs76419734	0.558	rs72669984	chr4:106544702	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.65	6.25	0.38	1.95e-9	Post bronchodilator FEV1;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg07612045	chr7:144533234	TPK1	-0.61	-6.25	-0.38	1.89e-9	Lung cancer in ever smokers;
SARC	cis	rs3796352	1.000	rs34943350	chr3:53012888	C/T	cg12962167	chr3:53033115	SFMBT1	0.83	5.29	0.33	2.79e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2985684	0.894	rs4581611	chr14:50043520	A/T	cg04989706	chr14:50066350	PPIL5	-0.52	-5.8	-0.36	2.18e-8	Carotid intima media thickness;
SARC	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg24642844	chr7:1081250	C7orf50	-0.59	-6.11	-0.37	4.26e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs793571	0.544	rs383902	chr15:59034174	C/T	cg05156742	chr15:59063176	FAM63B	0.72	10.28	0.56	1.14e-20	Schizophrenia;
SARC	cis	rs4792901	0.918	rs67063813	chr17:41626728	T/C	cg22562494	chr17:41607896	ETV4	-0.31	-5.03	-0.31	9.8e-7	Dupuytren's disease;
SARC	cis	rs2115630	0.967	rs10438428	chr15:85330745	C/T	cg12501888	chr15:85177176	SCAND2	-0.46	-5.53	-0.34	8.43e-8	P wave terminal force;
SARC	trans	rs12310956	0.532	rs10844707	chr12:33936089	T/C	cg26384229	chr12:38710491	ALG10B	0.83	11.95	0.62	5.37e-26	Morning vs. evening chronotype;
SARC	cis	rs7681440	0.804	rs1442135	chr4:90819093	C/T	cg06632027	chr4:90757378	SNCA	-0.4	-5.55	-0.34	7.73e-8	Dementia with Lewy bodies;
SARC	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg06634786	chr22:41940651	POLR3H	0.57	6.69	0.4	1.64e-10	Vitiligo;
SARC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg06333435	chr8:22102724	POLR3D;MIR320A	0.51	6.29	0.38	1.58e-9	Myopia (pathological);
SARC	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg15320075	chr8:145703422	NA	0.57	7.81	0.46	1.99e-13	Age at first birth;
SARC	cis	rs60871478	1.000	rs62432861	chr7:807649	G/A	cg05535760	chr7:792225	HEATR2	0.78	8.07	0.47	3.77e-14	Cerebrospinal P-tau181p levels;
SARC	cis	rs2624839	0.704	rs2526384	chr3:50181136	C/T	cg14019146	chr3:50243930	SLC38A3	-0.35	-5.4	-0.33	1.66e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1949733	0.635	rs4358384	chr4:8536913	C/T	cg11789530	chr4:8429930	ACOX3	-0.58	-6.51	-0.39	4.48e-10	Response to antineoplastic agents;
SARC	cis	rs1008375	1.000	rs11722037	chr4:17683811	G/A	cg02297831	chr4:17616191	MED28	0.44	5.61	0.34	5.8e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4689388	0.926	rs5018648	chr4:6292818	C/G	cg00701064	chr4:6280414	WFS1	-0.54	-8.76	-0.5	4.21e-16	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	trans	rs61931739	0.635	rs7979207	chr12:33910566	C/T	cg13010199	chr12:38710504	ALG10B	-0.49	-6.26	-0.38	1.88e-9	Morning vs. evening chronotype;
SARC	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg13939156	chr17:80058883	NA	0.38	5.93	0.36	1.1e-8	Life satisfaction;
SARC	cis	rs6448317	1.000	rs11934149	chr4:24938953	T/C	cg21108841	chr4:24914750	CCDC149	-0.53	-5.47	-0.34	1.15e-7	Heschl's gyrus morphology;
SARC	cis	rs2933343	0.729	rs789228	chr3:128601050	A/G	cg25356066	chr3:128598488	ACAD9	0.73	9.65	0.53	9.44e-19	IgG glycosylation;
SARC	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg13939156	chr17:80058883	NA	-0.45	-6.95	-0.41	3.55e-11	Life satisfaction;
SARC	cis	rs11098499	0.780	rs12504773	chr4:120562149	G/C	cg24375607	chr4:120327624	NA	0.4	4.77	0.3	3.27e-6	Corneal astigmatism;
SARC	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.44	5.14	0.32	5.89e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs2832191	0.716	rs7509628	chr21:30454252	C/T	cg08807101	chr21:30365312	RNF160	0.9	13.72	0.67	8.61e-32	Dental caries;
SARC	cis	rs9790314	0.936	rs466399	chr3:161091194	G/T	cg04691961	chr3:161091175	C3orf57	-0.83	-13.33	-0.66	1.71e-30	Morning vs. evening chronotype;
SARC	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg14298792	chr15:30685198	CHRFAM7A	0.49	5.59	0.34	6.42e-8	Huntington's disease progression;
SARC	cis	rs6582630	0.519	rs11182457	chr12:38538331	G/A	cg26384229	chr12:38710491	ALG10B	0.9	13.51	0.66	4.18e-31	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9815354	0.556	rs56201224	chr3:42004427	A/C	cg03022575	chr3:42003672	ULK4	0.65	5.61	0.34	5.72e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.81	-0.46	1.92e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs6570726	1.000	rs405622	chr6:145871897	G/T	cg23711669	chr6:146136114	FBXO30	0.74	11.07	0.59	3.76e-23	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs473651	0.935	rs1103770	chr2:239339281	G/C	cg18131467	chr2:239335373	ASB1	0.98	12.45	0.63	1.28e-27	Multiple system atrophy;
SARC	trans	rs11098499	0.954	rs4577559	chr4:120404043	T/G	cg25214090	chr10:38739885	LOC399744	0.57	7.33	0.43	3.83e-12	Corneal astigmatism;
SARC	cis	rs4144743	1.000	rs4144744	chr17:45323262	A/G	cg18085866	chr17:45331354	ITGB3	-0.71	-7.35	-0.43	3.36e-12	Body mass index;
SARC	cis	rs6733011	0.578	rs4851170	chr2:99504323	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.43	5.45	0.34	1.25e-7	Bipolar disorder;
SARC	trans	rs7615952	0.673	rs3811677	chr3:125648080	G/A	cg07211511	chr3:129823064	LOC729375	-0.96	-10.77	-0.58	3.15e-22	Blood pressure (smoking interaction);
SARC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg11494091	chr17:61959527	GH2	0.53	7.98	0.46	6.66e-14	Prudent dietary pattern;
SARC	cis	rs524281	0.773	rs2155031	chr11:66030927	C/T	cg14036092	chr11:66035641	RAB1B	-0.59	-6.01	-0.37	7.02e-9	Electroencephalogram traits;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg20064231	chr18:74608296	ZNF236	0.52	6.41	0.39	8.11e-10	Schizophrenia;
SARC	cis	rs240764	0.817	rs240143	chr6:101080621	G/A	cg09795085	chr6:101329169	ASCC3	0.45	5.77	0.35	2.55e-8	Neuroticism;
SARC	cis	rs11098499	0.645	rs72676059	chr4:120290828	C/G	cg09307838	chr4:120376055	NA	0.83	11.82	0.61	1.46e-25	Corneal astigmatism;
SARC	cis	rs2731664	0.792	rs335468	chr5:176892349	A/G	cg23176889	chr5:176863531	GRK6	0.55	8.26	0.48	1.06e-14	Intelligence (multi-trait analysis);
SARC	cis	rs13161895	1.000	rs34027780	chr5:179478891	C/A	cg04265672	chr5:179402240	RNF130	-0.52	-5.02	-0.31	1.04e-6	LDL cholesterol;
SARC	cis	rs7224737	1.000	rs12603330	chr17:40290589	T/A	cg20291162	chr17:40259547	DHX58	-0.33	-4.85	-0.3	2.24e-6	Fibrinogen levels;
SARC	trans	rs2727020	0.538	rs61885230	chr11:49128958	T/C	cg15704280	chr7:45808275	SEPT13	-0.61	-8.33	-0.48	7.16e-15	Coronary artery disease;
SARC	cis	rs34779708	0.966	rs10508816	chr10:35459976	G/A	cg03585969	chr10:35415529	CREM	0.38	4.78	0.3	3.14e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg11366901	chr6:160182831	ACAT2	0.96	9.65	0.53	9.65e-19	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.59	7.32	0.43	4.02e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg05084668	chr3:125655381	ALG1L	-0.5	-5.28	-0.33	2.92e-7	Blood pressure (smoking interaction);
SARC	cis	rs1215050	0.874	rs17545594	chr4:98652689	A/G	cg05340658	chr4:99064831	C4orf37	-0.4	-5.12	-0.32	6.44e-7	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg22168489	chr12:122356033	WDR66	-0.62	-9.52	-0.53	2.37e-18	Mean corpuscular volume;
SARC	cis	rs78545713	0.536	rs78653353	chr6:26208917	A/G	cg00631329	chr6:26305371	NA	-0.73	-5.26	-0.33	3.25e-7	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs41271473	0.950	rs72751907	chr1:228867648	C/T	cg10167378	chr1:228756711	NA	0.49	4.73	0.3	3.94e-6	Chronic lymphocytic leukemia;
SARC	cis	rs7264396	0.570	rs6060717	chr20:34544647	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-7.43	-0.44	2.06e-12	Total cholesterol levels;
SARC	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7429990	0.965	rs777015	chr3:47937072	A/G	cg11946769	chr3:48343235	NME6	0.42	4.81	0.3	2.72e-6	Educational attainment (years of education);
SARC	cis	rs950169	0.922	rs12915832	chr15:85111457	C/T	cg17507749	chr15:85114479	UBE2QP1	0.79	9.47	0.53	3.2e-18	Schizophrenia;
SARC	cis	rs9400467	0.506	rs17510381	chr6:111794658	C/G	cg15721981	chr6:111408429	SLC16A10	0.65	5.71	0.35	3.5e-8	Blood metabolite levels;Amino acid levels;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg03523835	chr1:207223119	YOD1	-0.46	-6.33	-0.38	1.23e-9	Breast cancer;
SARC	cis	rs761746	0.882	rs4820978	chr22:31912119	G/A	cg15162869	chr22:32027605	PISD	0.39	5.29	0.33	2.81e-7	Intelligence;
SARC	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg12463550	chr7:65579703	CRCP	-0.49	-5.3	-0.33	2.64e-7	Aortic root size;
SARC	cis	rs8177253	0.632	rs6782523	chr3:133438917	C/T	cg01448562	chr3:133502909	NA	-0.43	-6.4	-0.39	8.67e-10	Iron status biomarkers;
SARC	cis	rs4803468	1.000	rs4803463	chr19:41911040	C/G	cg14132834	chr19:41945861	ATP5SL	-0.57	-7.45	-0.44	1.76e-12	Height;
SARC	cis	rs9309711	0.772	rs9309715	chr2:3492318	C/G	cg10845886	chr2:3471009	TTC15	0.58	6.91	0.41	4.47e-11	Neurofibrillary tangles;
SARC	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg19680485	chr15:31195859	MTMR15	-0.58	-6.88	-0.41	5.42e-11	Huntington's disease progression;
SARC	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg18252515	chr7:66147081	NA	-1.29	-11.12	-0.59	2.48e-23	Diabetic kidney disease;
SARC	cis	rs6700896	0.931	rs17127849	chr1:66105512	A/G	cg04111102	chr1:66153794	NA	0.35	5.49	0.34	1.05e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs611744	0.967	rs603571	chr8:109213893	A/C	cg21045802	chr8:109455806	TTC35	0.44	5.23	0.32	3.81e-7	Dupuytren's disease;
SARC	trans	rs2727020	0.554	rs7111711	chr11:49557880	G/A	cg03929089	chr4:120376271	NA	-0.7	-7.93	-0.46	9.2e-14	Coronary artery disease;
SARC	cis	rs763121	0.888	rs2235229	chr22:39124912	A/G	cg21395723	chr22:39101663	GTPBP1	0.47	5.81	0.36	2.08e-8	Menopause (age at onset);
SARC	cis	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg26695010	chr11:65641043	EFEMP2	-0.56	-7.4	-0.44	2.41e-12	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs9467773	0.620	rs9295701	chr6:26627508	T/C	cg11502198	chr6:26597334	ABT1	0.63	8.63	0.49	9.91e-16	Intelligence (multi-trait analysis);
SARC	cis	rs41264869	0.657	rs3183297	chr1:205113833	A/G	cg21643547	chr1:205240462	TMCC2	0.47	5.1	0.32	7.16e-7	Blood protein levels;
SARC	cis	rs1949733	1.000	rs3103071	chr4:8508579	C/G	cg13073564	chr4:8508604	NA	0.47	7.84	0.46	1.58e-13	Response to antineoplastic agents;
SARC	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg24675658	chr1:53192096	ZYG11B	0.57	8.04	0.47	4.48e-14	Monocyte count;
SARC	cis	rs933688	0.583	rs6882172	chr5:90576958	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.49	-5.06	-0.31	8.69e-7	Smoking behavior;
SARC	cis	rs2011503	1.000	rs11085264	chr19:19621780	A/G	cg15839431	chr19:19639596	YJEFN3	-0.48	-4.77	-0.3	3.32e-6	Bipolar disorder;
SARC	cis	rs12701220	0.503	rs13222294	chr7:1172969	G/A	cg02733842	chr7:1102375	C7orf50	-0.39	-4.72	-0.3	4.08e-6	Bronchopulmonary dysplasia;
SARC	cis	rs2327429	0.858	rs2105092	chr6:134184972	G/A	cg25632230	chr6:134101081	NA	-0.44	-5.3	-0.33	2.72e-7	Coronary artery disease;
SARC	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg05896524	chr21:47604654	C21orf56	0.42	5.08	0.32	7.71e-7	Testicular germ cell tumor;
SARC	cis	rs798554	0.610	rs2644297	chr7:2858906	A/C	cg13628971	chr7:2884303	GNA12	0.48	5.97	0.36	8.58e-9	Height;
SARC	cis	rs7712401	0.601	rs246273	chr5:122280975	G/A	cg19412675	chr5:122181750	SNX24	0.39	4.95	0.31	1.45e-6	Mean platelet volume;
SARC	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4595586	0.505	rs76485055	chr12:39358294	A/G	cg26384229	chr12:38710491	ALG10B	0.51	6.25	0.38	1.9e-9	Morning vs. evening chronotype;
SARC	cis	rs7607369	0.559	rs13002060	chr2:219660394	G/T	cg02176678	chr2:219576539	TTLL4	-0.37	-5.73	-0.35	3.02e-8	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg14019146	chr3:50243930	SLC38A3	0.31	4.85	0.3	2.3e-6	Body mass index;
SARC	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg22004693	chr7:99632812	ZKSCAN1	0.55	5.59	0.34	6.28e-8	Lung function (FEV1/FVC);
SARC	cis	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg02487422	chr3:49467188	NICN1	0.5	6.79	0.41	9.04e-11	Resting heart rate;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg11987090	chr1:22778442	ZBTB40	0.53	6.31	0.38	1.38e-9	Blood pressure;
SARC	cis	rs1008375	1.000	rs7688682	chr4:17693794	A/G	cg27347728	chr4:17578864	LAP3	-0.47	-5.79	-0.35	2.22e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs7824557	0.564	rs7834572	chr8:11236685	C/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.0	-0.42	2.66e-11	Retinal vascular caliber;
SARC	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9457247	0.663	rs9457258	chr6:167444254	T/C	cg07741184	chr6:167504864	NA	0.35	6.99	0.42	2.9e-11	Crohn's disease;
SARC	cis	rs9399135	0.967	rs6929661	chr6:135328792	G/A	cg24558204	chr6:135376177	HBS1L	0.45	6.04	0.37	6.18e-9	Red blood cell count;
SARC	cis	rs7681440	0.835	rs1899389	chr4:90802998	G/A	cg02192967	chr4:90758406	SNCA	0.35	4.88	0.3	1.95e-6	Dementia with Lewy bodies;
SARC	cis	rs7666738	0.606	rs4637413	chr4:99088151	A/G	cg05340658	chr4:99064831	C4orf37	0.47	5.95	0.36	9.8e-9	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7932354	0.528	rs12796744	chr11:47132724	A/T	cg03339077	chr11:47165057	C11orf49	0.46	6.46	0.39	5.97e-10	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg06028808	chr11:68637592	NA	0.44	5.45	0.34	1.3e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs3617	0.573	rs2336667	chr3:52916363	C/T	cg18404041	chr3:52824283	ITIH1	0.33	4.82	0.3	2.65e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs1062177	1.000	rs17741826	chr5:151149262	C/T	cg00977110	chr5:151150581	G3BP1	-0.6	-6.1	-0.37	4.31e-9	Preschool internalizing problems;
SARC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg09373136	chr17:61933544	TCAM1	-0.45	-6.12	-0.37	3.83e-9	Prudent dietary pattern;
SARC	cis	rs4803468	1.000	rs2241710	chr19:41912092	G/C	cg08477640	chr19:41863820	B9D2	0.46	5.85	0.36	1.64e-8	Height;
SARC	cis	rs11122272	0.735	rs2790877	chr1:231535427	A/G	cg06096015	chr1:231504339	EGLN1	0.38	5.7	0.35	3.54e-8	Hemoglobin concentration;
SARC	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg11644478	chr21:40555479	PSMG1	1.03	14.57	0.69	1.33e-34	Cognitive function;
SARC	cis	rs2228479	0.557	rs2293584	chr16:89888686	C/G	cg06558623	chr16:89946397	TCF25	0.91	6.49	0.39	5.16e-10	Skin colour saturation;
SARC	trans	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg00938859	chr5:1591904	SDHAP3	0.79	7.62	0.45	6.21e-13	Breast cancer;
SARC	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg13175981	chr1:150552382	MCL1	-0.54	-6.84	-0.41	6.75e-11	Tonsillectomy;
SARC	cis	rs763121	0.853	rs5757213	chr22:39053888	C/T	cg21395723	chr22:39101663	GTPBP1	0.58	6.67	0.4	1.85e-10	Menopause (age at onset);
SARC	cis	rs2282526	0.615	rs463738	chr21:44921166	G/A	cg21573476	chr21:45109991	RRP1B	0.46	6.15	0.37	3.32e-9	Mean corpuscular hemoglobin;
SARC	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg22968622	chr17:43663579	NA	1.21	16.18	0.73	5.59e-40	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9291683	0.679	rs2278122	chr4:10096241	T/A	cg11266682	chr4:10021025	SLC2A9	-0.43	-7.67	-0.45	4.53e-13	Bone mineral density;
SARC	cis	rs8060686	0.545	rs3826164	chr16:68280317	A/G	cg27539214	chr16:67997921	SLC12A4	0.52	4.78	0.3	3.15e-6	HDL cholesterol;Metabolic syndrome;
SARC	cis	rs10493773	1.000	rs55654440	chr1:86176158	G/C	cg17807903	chr1:86174739	ZNHIT6	-0.5	-7.09	-0.42	1.56e-11	Urate levels in overweight individuals;
SARC	cis	rs116095464	1.000	rs28416084	chr5:217640	G/A	cg22496380	chr5:211416	CCDC127	-0.89	-7.97	-0.46	7.24e-14	Breast cancer;
SARC	cis	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg25427524	chr10:38739819	LOC399744	-0.52	-8.06	-0.47	4.09e-14	Extrinsic epigenetic age acceleration;
SARC	cis	rs7828089	0.935	rs896375	chr8:22262098	A/G	cg12081754	chr8:22256438	SLC39A14	0.44	5.76	0.35	2.64e-8	Verbal declarative memory;
SARC	cis	rs1707322	1.000	rs4660903	chr1:46457601	A/G	cg06784218	chr1:46089804	CCDC17	0.35	6.07	0.37	5.11e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs10489202	0.608	rs3753934	chr1:168074677	C/T	cg24449463	chr1:168025552	DCAF6	-0.6	-7.85	-0.46	1.52e-13	Schizophrenia;
SARC	cis	rs12545109	0.800	rs1467124	chr8:57418862	T/G	cg09654669	chr8:57350985	NA	-0.39	-4.98	-0.31	1.26e-6	Obesity-related traits;
SARC	cis	rs11626933	0.959	rs2149649	chr14:90774974	A/G	cg14092571	chr14:90743983	NA	0.59	8.45	0.48	3.23e-15	Gut microbiota (bacterial taxa);
SARC	cis	rs1003719	0.751	rs55992706	chr21:38542749	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.38	-0.52	5.99e-18	Eye color traits;
SARC	cis	rs12780845	0.505	rs11598987	chr10:17250230	C/G	cg11116878	chr10:17243438	TRDMT1	0.4	4.98	0.31	1.23e-6	Homocysteine levels;
SARC	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg05872129	chr22:39784769	NA	0.42	5.87	0.36	1.49e-8	IgG glycosylation;
SARC	cis	rs9896052	0.614	rs11077791	chr17:73474629	T/G	cg25649188	chr17:73499917	CASKIN2	0.4	5.67	0.35	4.25e-8	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs13082711	0.911	rs17682751	chr3:27497027	C/T	cg02860705	chr3:27208620	NA	-0.46	-5.87	-0.36	1.47e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs288326	0.561	rs78528869	chr2:183815502	C/T	cg09997497	chr2:183902928	NCKAP1	0.74	5.1	0.32	6.97e-7	Blood protein levels;
SARC	cis	rs17030434	0.871	rs74380369	chr4:154730273	C/T	cg14289246	chr4:154710475	SFRP2	-0.6	-6.85	-0.41	6.65e-11	Electrocardiographic conduction measures;
SARC	cis	rs2839627	0.598	rs9975526	chr21:44266573	T/A	cg03543861	chr21:44258195	NA	0.45	5.02	0.31	1.02e-6	Information processing speed;
SARC	cis	rs7824557	0.527	rs2572447	chr8:11239510	G/A	cg21775007	chr8:11205619	TDH	-0.57	-7.65	-0.45	5.19e-13	Retinal vascular caliber;
SARC	cis	rs778371	0.748	rs2675953	chr2:233749565	G/C	cg20388707	chr2:233749442	NGEF	0.34	4.72	0.3	4.01e-6	Schizophrenia;
SARC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg20007245	chr22:24372913	LOC391322	-0.82	-11.47	-0.6	1.88e-24	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	8.53	0.49	1.89e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs61931739	0.890	rs814663	chr12:34106338	C/T	cg26384229	chr12:38710491	ALG10B	0.59	7.85	0.46	1.47e-13	Morning vs. evening chronotype;
SARC	cis	rs9309473	0.519	rs2178154	chr2:73661738	C/T	cg20560298	chr2:73613845	ALMS1	0.54	7.48	0.44	1.52e-12	Metabolite levels;
SARC	cis	rs1153858	1.000	rs12909158	chr15:45621174	A/G	cg14582100	chr15:45693742	SPATA5L1	0.34	4.72	0.3	4.05e-6	Homoarginine levels;
SARC	cis	rs9911578	0.692	rs412000	chr17:56709058	G/C	cg12560992	chr17:57184187	TRIM37	0.64	8.32	0.48	7.29e-15	Intelligence (multi-trait analysis);
SARC	cis	rs995000	0.868	rs1168002	chr1:62934308	A/G	cg06896770	chr1:63153194	DOCK7	-0.91	-13.92	-0.67	1.87e-32	Triglyceride levels;
SARC	cis	rs1348850	0.757	rs4893969	chr2:178478476	T/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.53	5.97	0.36	8.7e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs554111	0.634	rs34740989	chr1:21316782	C/T	cg04902671	chr1:21058625	SH2D5	0.44	5.37	0.33	1.94e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs7582720	1.000	rs72934732	chr2:203739856	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.28	0.43	5.16e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg11764359	chr7:65958608	NA	-0.77	-9.47	-0.53	3.31e-18	Aortic root size;
SARC	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg21724239	chr8:58056113	NA	0.47	4.85	0.3	2.3e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs9303401	1.000	rs1390006	chr17:56890663	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.66	-7.73	-0.45	3.17e-13	Cognitive test performance;
SARC	cis	rs72945132	0.882	rs7945389	chr11:70158876	C/A	cg05964544	chr11:70165517	PPFIA1	-0.61	-5.87	-0.36	1.5e-8	Coronary artery disease;
SARC	cis	rs8102137	0.962	rs62104480	chr19:30298800	A/G	cg27475126	chr19:30303651	CCNE1	-0.42	-5.91	-0.36	1.23e-8	Bladder cancer;
SARC	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg04267008	chr7:1944627	MAD1L1	-0.56	-6.44	-0.39	6.59e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs3772130	0.527	rs2141614	chr3:121590173	G/A	cg20356878	chr3:121714668	ILDR1	0.4	6.28	0.38	1.63e-9	Cognitive performance;
SARC	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg02951883	chr7:2050386	MAD1L1	-0.4	-5.17	-0.32	4.96e-7	Schizophrenia;
SARC	cis	rs4481887	1.000	rs7525344	chr1:248467565	C/T	cg00666640	chr1:248458726	OR2T12	-0.38	-6.31	-0.38	1.39e-9	Common traits (Other);
SARC	cis	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg25427524	chr10:38739819	LOC399744	-0.52	-8.25	-0.48	1.17e-14	Extrinsic epigenetic age acceleration;
SARC	cis	rs2120019	0.567	rs8037152	chr15:75156996	A/T	cg00629941	chr15:75287862	SCAMP5	-0.62	-5.86	-0.36	1.59e-8	Blood trace element (Zn levels);
SARC	trans	rs7824557	0.545	rs2736303	chr8:11236850	C/T	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.72	-0.5	5.49e-16	Retinal vascular caliber;
SARC	cis	rs6500602	0.727	rs4786509	chr16:4568769	C/G	cg08645402	chr16:4508243	NA	-0.44	-5.77	-0.35	2.47e-8	Schizophrenia;
SARC	cis	rs35362007	0.530	rs10484053	chr14:96011645	C/T	cg13511115	chr14:96000878	GLRX5;SNHG10;SCARNA13	0.66	5.79	0.35	2.3e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs926938	0.584	rs360606	chr1:115391769	C/T	cg12756093	chr1:115239321	AMPD1	0.4	5.37	0.33	1.92e-7	Autism;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg06363569	chr10:27793008	RAB18	0.53	6.32	0.38	1.31e-9	Blood pressure;
SARC	cis	rs734999	0.588	rs3748818	chr1:2525660	G/A	cg18854424	chr1:2615690	NA	0.33	5.19	0.32	4.66e-7	Ulcerative colitis;
SARC	cis	rs9911578	1.000	rs11870671	chr17:56605360	A/G	cg05425664	chr17:57184151	TRIM37	0.65	8.02	0.46	5.23e-14	Intelligence (multi-trait analysis);
SARC	cis	rs7824557	0.564	rs11781637	chr8:11214972	C/T	cg21775007	chr8:11205619	TDH	-0.65	-8.64	-0.49	9.12e-16	Retinal vascular caliber;
SARC	cis	rs1594829	0.553	rs6996531	chr8:26153455	C/A	cg11498726	chr8:26250323	BNIP3L	-0.4	-5.27	-0.33	3.09e-7	Height;
SARC	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg25072359	chr17:41440525	NA	0.53	6.28	0.38	1.61e-9	Menopause (age at onset);
SARC	cis	rs17376456	0.825	rs10051878	chr5:93064164	T/G	cg25358565	chr5:93447407	FAM172A	1.17	12.3	0.63	3.88e-27	Diabetic retinopathy;
SARC	cis	rs2933343	0.729	rs789228	chr3:128601050	A/G	cg24203234	chr3:128598194	ACAD9	0.62	7.77	0.45	2.49e-13	IgG glycosylation;
SARC	cis	rs9462027	0.628	rs9380455	chr6:34690778	C/A	cg07306190	chr6:34760872	UHRF1BP1	0.43	6.05	0.37	5.66e-9	Systemic lupus erythematosus;
SARC	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg22800045	chr5:56110881	MAP3K1	0.42	4.8	0.3	2.85e-6	Initial pursuit acceleration;
SARC	cis	rs2439831	0.850	rs28590651	chr15:44113016	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	8.09	0.47	3.22e-14	Lung cancer in ever smokers;
SARC	cis	rs9911578	0.805	rs12601867	chr17:56455260	C/G	cg12560992	chr17:57184187	TRIM37	-0.73	-9.65	-0.53	9.66e-19	Intelligence (multi-trait analysis);
SARC	cis	rs698833	0.527	rs10170837	chr2:44771535	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	6.34	0.38	1.2e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs7219014	1	rs7219014	chr17:37624790	A/G	cg07936489	chr17:37558343	FBXL20	-0.69	-9.12	-0.51	3.72e-17	Urinary metabolites;
SARC	cis	rs17023223	0.537	rs2794310	chr1:119561930	C/G	cg05756136	chr1:119680316	WARS2	-0.49	-5.8	-0.36	2.17e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg17294928	chr15:75287854	SCAMP5	0.49	6.21	0.38	2.4e-9	Breast cancer;
SARC	cis	rs7524258	0.835	rs7543228	chr1:7306538	G/C	cg07173049	chr1:7289937	CAMTA1	0.34	6.59	0.4	2.95e-10	Tourette's syndrome or obsessive-compulsive disorder;
SARC	cis	rs7178572	0.889	rs59153558	chr15:77806770	A/G	cg22256960	chr15:77711686	NA	-0.5	-5.63	-0.35	5.12e-8	Type 2 diabetes;
SARC	cis	rs6121246	0.567	rs6087700	chr20:30217560	A/G	cg21427119	chr20:30132790	HM13	-0.46	-5.05	-0.31	8.92e-7	Mean corpuscular hemoglobin;
SARC	cis	rs4144743	1.000	rs34492688	chr17:45321622	C/A	cg18085866	chr17:45331354	ITGB3	-0.73	-7.46	-0.44	1.66e-12	Body mass index;
SARC	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg04944784	chr2:26401820	FAM59B	-0.54	-6.89	-0.41	5.19e-11	Gut microbiome composition (summer);
SARC	cis	rs7520050	0.931	rs1707333	chr1:46547035	C/G	cg24296786	chr1:45957014	TESK2	0.38	4.82	0.3	2.56e-6	Red blood cell count;Reticulocyte count;
SARC	trans	rs656319	0.647	rs13264668	chr8:9884877	C/T	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.46	-0.44	1.69e-12	Myopia (pathological);
SARC	cis	rs7615952	0.688	rs12638240	chr3:125541238	G/A	cg05084668	chr3:125655381	ALG1L	-0.5	-5.3	-0.33	2.68e-7	Blood pressure (smoking interaction);
SARC	cis	rs3617	0.625	rs56019197	chr3:52874753	T/C	cg04865290	chr3:52927548	TMEM110	0.34	5.0	0.31	1.13e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs8017423	0.967	rs11621364	chr14:90709115	A/G	cg20276874	chr14:90721474	PSMC1	-0.36	-5.02	-0.31	1.04e-6	Mortality in heart failure;
SARC	cis	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg00071950	chr4:10020882	SLC2A9	0.4	6.38	0.39	9.57e-10	Bone mineral density;
SARC	cis	rs9436747	0.641	rs1938487	chr1:66047267	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.48	4.94	0.31	1.48e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08826460	chr19:11201433	LDLR	-0.53	-6.37	-0.39	9.77e-10	Fibrinogen levels;
SARC	cis	rs4253772	0.513	rs9615345	chr22:46713631	C/T	cg24881330	chr22:46731750	TRMU	0.83	8.47	0.49	2.79e-15	LDL cholesterol;Cholesterol, total;
SARC	cis	rs9303280	0.836	rs12453507	chr17:38053207	C/G	cg20243544	chr17:37824526	PNMT	0.42	5.71	0.35	3.4e-8	Self-reported allergy;
SARC	cis	rs9788682	0.947	rs7169584	chr15:78822660	A/T	cg06917634	chr15:78832804	PSMA4	-0.58	-6.59	-0.4	2.95e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs6693567	0.565	rs1776276	chr1:150293078	A/C	cg09579323	chr1:150459698	TARS2	0.42	5.33	0.33	2.27e-7	Migraine;
SARC	cis	rs67311347	0.866	rs11712426	chr3:40330322	G/A	cg24209194	chr3:40518798	ZNF619	0.55	7.09	0.42	1.62e-11	Renal cell carcinoma;
SARC	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg12463550	chr7:65579703	CRCP	0.5	5.9	0.36	1.27e-8	Aortic root size;
SARC	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg13866156	chr1:1669148	SLC35E2	-0.62	-9.23	-0.52	1.66e-17	Body mass index;
SARC	trans	rs7937682	0.889	rs487985	chr11:111517908	G/A	cg18187862	chr3:45730750	SACM1L	0.55	6.96	0.41	3.46e-11	Primary sclerosing cholangitis;
SARC	cis	rs2268241	0.938	rs9978166	chr21:34770516	A/G	cg14850771	chr21:34775459	IFNGR2	0.92	9.09	0.51	4.29e-17	Obesity-related traits;
SARC	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.35	-0.52	7.44e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs2153535	0.601	rs9379224	chr6:8538413	A/G	cg07606381	chr6:8435919	SLC35B3	0.78	10.85	0.58	1.84e-22	Motion sickness;
SARC	cis	rs78456975	0.943	rs13391932	chr2:1577679	T/C	cg26248373	chr2:1572462	NA	-0.58	-5.98	-0.36	8.14e-9	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs72781680	0.898	rs55846516	chr2:24158003	T/C	cg08917208	chr2:24149416	ATAD2B	0.77	7.19	0.43	8.94e-12	Lymphocyte counts;
SARC	cis	rs7681440	0.845	rs6843084	chr4:90766230	T/C	cg06632027	chr4:90757378	SNCA	0.39	5.66	0.35	4.49e-8	Dementia with Lewy bodies;
SARC	cis	rs9894429	0.550	rs6565617	chr17:79612333	G/A	cg10661904	chr17:79619235	PDE6G	-0.44	-6.26	-0.38	1.84e-9	Eye color traits;
SARC	cis	rs8067354	0.872	rs1295925	chr17:57910263	T/C	cg13753209	chr17:57696993	CLTC	-0.53	-6.65	-0.4	2.12e-10	Hemoglobin concentration;
SARC	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg22920501	chr2:26401640	FAM59B	-0.55	-7.24	-0.43	6.63e-12	Gut microbiome composition (summer);
SARC	cis	rs950169	0.800	rs4842847	chr15:84931199	G/A	cg17507749	chr15:85114479	UBE2QP1	0.79	9.66	0.53	8.73e-19	Schizophrenia;
SARC	cis	rs12142240	0.698	rs17361791	chr1:46812519	A/G	cg10495392	chr1:46806563	NSUN4	0.65	6.8	0.41	8.47e-11	Menopause (age at onset);
SARC	cis	rs4820539	1.000	rs1051875	chr22:23466031	G/A	cg14186256	chr22:23484241	RTDR1	0.89	13.77	0.67	5.97e-32	Bone mineral density;
SARC	cis	rs4742903	0.935	rs6479225	chr9:106940330	T/C	cg14250997	chr9:106856677	SMC2	0.44	5.49	0.34	1.02e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs1971762	0.545	rs10876466	chr12:53981426	G/C	cg06632207	chr12:54070931	ATP5G2	0.57	7.69	0.45	4.14e-13	Height;
SARC	cis	rs3087591	1.000	rs4795577	chr17:29456879	T/G	cg24425628	chr17:29625626	OMG;NF1	0.56	7.08	0.42	1.68e-11	Hip circumference;
SARC	cis	rs9831754	1.000	rs112170848	chr3:78359996	G/A	cg06138941	chr3:78371609	NA	-0.55	-6.52	-0.39	4.32e-10	Calcium levels;
SARC	cis	rs13191362	1.000	rs73008453	chr6:163013384	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.55	5.25	0.33	3.46e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs13006833	0.668	rs291461	chr2:191181644	T/G	cg25963032	chr2:191064776	C2orf88	0.36	4.99	0.31	1.16e-6	Urinary metabolites;
SARC	cis	rs447735	0.587	rs11647958	chr16:89720909	A/T	cg03605463	chr16:89740564	NA	0.38	5.17	0.32	5.04e-7	Hemoglobin concentration;
SARC	cis	rs1707322	1.000	rs4074225	chr1:46392364	G/C	cg06784218	chr1:46089804	CCDC17	0.36	6.36	0.38	1.07e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9322817	0.691	rs2486138	chr6:105290223	G/A	cg02098413	chr6:105308735	HACE1	0.38	5.91	0.36	1.18e-8	Thyroid stimulating hormone;
SARC	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg02725872	chr8:58115012	NA	-0.37	-6.54	-0.39	3.81e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-15.46	-0.71	1.39e-37	Chronic sinus infection;
SARC	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg15595755	chr5:1867978	NA	0.45	6.0	0.37	7.38e-9	Cardiovascular disease risk factors;
SARC	cis	rs2228479	0.850	rs11639788	chr16:89807543	G/A	cg06558623	chr16:89946397	TCF25	0.91	6.37	0.39	9.81e-10	Skin colour saturation;
SARC	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg13770153	chr20:60521292	NA	-0.45	-6.31	-0.38	1.39e-9	Body mass index;
SARC	cis	rs6580649	0.783	rs7969749	chr12:48550755	C/T	cg05342945	chr12:48394962	COL2A1	-0.51	-5.52	-0.34	8.85e-8	Lung cancer;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg24391471	chr3:44974926	ZDHHC3	0.51	6.34	0.38	1.16e-9	Blood pressure;
SARC	cis	rs7236492	0.683	rs78250476	chr18:77198934	G/A	cg15644404	chr18:77186268	NFATC1	-0.66	-6.68	-0.4	1.77e-10	Inflammatory bowel disease;Crohn's disease;
SARC	trans	rs1814175	0.645	rs11040671	chr11:49958776	G/A	cg15704280	chr7:45808275	SEPT13	-0.89	-14.17	-0.68	2.8e-33	Height;
SARC	cis	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg24110177	chr3:50126178	RBM5	0.57	7.84	0.46	1.63e-13	Intelligence (multi-trait analysis);
SARC	cis	rs4803468	1.000	rs284650	chr19:41927129	A/G	cg14132834	chr19:41945861	ATP5SL	-0.57	-7.49	-0.44	1.39e-12	Height;
SARC	cis	rs12311304	0.965	rs1382803	chr12:15372662	A/G	cg08258403	chr12:15378311	NA	0.48	7.45	0.44	1.85e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg27532560	chr4:187881888	NA	-0.38	-5.11	-0.32	6.6e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	0.679	rs7840100	chr8:58036662	T/G	cg20607798	chr8:58055168	NA	0.56	5.3	0.33	2.74e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg14343924	chr8:8086146	FLJ10661	0.41	5.04	0.31	9.49e-7	Mood instability;
SARC	trans	rs2727020	0.576	rs11040223	chr11:49034633	G/T	cg00717180	chr2:96193071	NA	-0.4	-6.83	-0.41	7.32e-11	Coronary artery disease;
SARC	cis	rs9815354	0.857	rs73830583	chr3:41996948	C/T	cg03022575	chr3:42003672	ULK4	0.71	6.03	0.37	6.5e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2295359	0.892	rs4655686	chr1:67638004	T/A	cg12940439	chr1:67600707	NA	0.47	6.72	0.4	1.41e-10	Psoriasis;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg20795500	chr2:174970644	OLA1	0.48	6.46	0.39	6.1e-10	Tetralogy of Fallot;
SARC	cis	rs1153858	1.000	rs59889118	chr15:45618730	G/A	cg21132104	chr15:45694354	SPATA5L1	0.8	11.08	0.59	3.5e-23	Homoarginine levels;
SARC	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg26335602	chr6:28129616	ZNF389	0.51	5.62	0.35	5.41e-8	Depression;
SARC	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-8.89	-0.5	1.75e-16	Alzheimer's disease;
SARC	cis	rs131777	0.547	rs131753	chr22:51022862	A/G	cg02245810	chr22:51017432	CPT1B;CHKB;CHKB-CPT1B	0.32	5.15	0.32	5.41e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs796364	0.906	rs6740981	chr2:201060216	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.49	4.9	0.31	1.77e-6	Schizophrenia;
SARC	cis	rs2276314	0.857	rs72883058	chr18:33612917	G/A	cg19628046	chr18:33552617	C18orf21	0.6	6.23	0.38	2.11e-9	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg21433313	chr16:3507492	NAT15	0.33	4.73	0.3	3.88e-6	Tuberculosis;
SARC	cis	rs7582720	1.000	rs115400054	chr2:203676105	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.7	6.82	0.41	7.55e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg07636037	chr3:49044803	WDR6	0.5	5.95	0.36	9.92e-9	Resting heart rate;
SARC	cis	rs7084402	0.935	rs2393449	chr10:60343030	A/G	cg07615347	chr10:60278583	BICC1	0.6	8.7	0.5	6.13e-16	Refractive error;
SARC	cis	rs208520	0.802	rs208499	chr6:66932146	C/T	cg07460842	chr6:66804631	NA	-0.9	-10.66	-0.57	7.23e-22	Exhaled nitric oxide output;
SARC	cis	rs2061333	0.557	rs10420143	chr19:44608082	A/G	cg18700516	chr19:44507157	ZNF230	-0.53	-4.98	-0.31	1.23e-6	Alzheimer's disease;
SARC	cis	rs1448094	0.654	rs7133797	chr12:86294184	G/C	cg02569458	chr12:86230093	RASSF9	0.36	4.79	0.3	2.92e-6	Major depressive disorder;
SARC	cis	rs9815354	1.000	rs1716692	chr3:41983786	G/A	cg03022575	chr3:42003672	ULK4	-0.55	-5.15	-0.32	5.6e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9911578	0.835	rs9904993	chr17:56468569	G/T	cg05425664	chr17:57184151	TRIM37	0.67	8.3	0.48	8.64e-15	Intelligence (multi-trait analysis);
SARC	trans	rs11098499	0.908	rs2017057	chr4:120257711	A/G	cg25214090	chr10:38739885	LOC399744	0.55	7.15	0.42	1.13e-11	Corneal astigmatism;
SARC	cis	rs11997175	0.603	rs7464072	chr8:33776973	G/A	ch.8.33884649F	chr8:33765107	NA	0.52	6.98	0.42	3.13e-11	Body mass index;
SARC	cis	rs7633770	0.786	rs6808214	chr3:46682746	T/C	cg11219411	chr3:46661640	NA	0.43	7.06	0.42	1.85e-11	Coronary artery disease;
SARC	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg22857025	chr5:266934	NA	-1.06	-11.8	-0.61	1.74e-25	Breast cancer;
SARC	cis	rs8077889	0.645	rs1230393	chr17:41842592	A/G	cg26893861	chr17:41843967	DUSP3	-1.04	-17.15	-0.75	3.37e-43	Triglycerides;
SARC	cis	rs2635047	0.542	rs1512235	chr18:44781569	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	5.17	0.32	5.02e-7	Educational attainment;
SARC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg26338869	chr17:61819248	STRADA	0.81	10.52	0.57	1.98e-21	Prudent dietary pattern;
SARC	cis	rs1348850	0.561	rs1838890	chr2:178410938	C/A	cg23306229	chr2:178417860	TTC30B	0.84	8.21	0.47	1.53e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9815354	1.000	rs28702390	chr3:41889920	C/A	cg03022575	chr3:42003672	ULK4	0.67	5.73	0.35	3.13e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg08677398	chr8:58056175	NA	0.43	5.05	0.31	8.92e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10911232	0.507	rs10732271	chr1:183025898	C/T	cg13390022	chr1:182993471	LAMC1	0.36	5.42	0.33	1.46e-7	Hypertriglyceridemia;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg08161947	chr12:19592900	AEBP2	-0.51	-6.6	-0.4	2.8e-10	Schizophrenia;
SARC	cis	rs62244186	0.659	rs9850129	chr3:44532047	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.47	5.68	0.35	3.9e-8	Depressive symptoms;
SARC	cis	rs7607369	0.618	rs62193298	chr2:219655211	T/G	cg02176678	chr2:219576539	TTLL4	-0.51	-8.24	-0.47	1.27e-14	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs965469	0.671	rs6139076	chr20:3305210	T/C	cg25506879	chr20:3388711	C20orf194	-0.45	-4.96	-0.31	1.37e-6	IFN-related cytopenia;
SARC	cis	rs13256369	1.000	rs12545771	chr8:8567977	C/G	cg18904891	chr8:8559673	CLDN23	0.48	5.54	0.34	8.31e-8	Obesity-related traits;
SARC	cis	rs1401999	1.000	rs4148575	chr3:183702275	A/G	cg01324343	chr3:183735012	ABCC5	0.66	13.04	0.65	1.51e-29	Anterior chamber depth;
SARC	cis	rs7953249	0.656	rs2251468	chr12:121405126	A/C	cg02403541	chr12:121454288	C12orf43	0.75	10.69	0.57	5.95e-22	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg15966229	chr18:44337664	ST8SIA5	-0.37	-4.86	-0.3	2.15e-6	Personality dimensions;
SARC	cis	rs7528419	1.000	rs629301	chr1:109818306	G/T	cg00908766	chr1:109817496	CELSR2	0.59	7.57	0.44	8.56e-13	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
SARC	cis	rs9828933	0.577	rs832193	chr3:63854445	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.9	8.3	0.48	8.7e-15	Type 2 diabetes;
SARC	cis	rs4423214	1.000	rs1981412	chr11:71138710	T/C	cg05163923	chr11:71159392	DHCR7	0.66	8.69	0.49	6.41e-16	Vitamin D levels;
SARC	cis	rs16854884	0.770	rs1530477	chr3:143819506	A/G	cg06585982	chr3:143692056	C3orf58	-0.63	-8.71	-0.5	5.78e-16	Economic and political preferences (feminism/equality);
SARC	cis	rs7582720	1.000	rs72934710	chr2:203709776	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	7.55	0.44	1e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs7296418	0.961	rs10773921	chr12:123541606	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.42	-5.75	-0.35	2.79e-8	Platelet count;
SARC	cis	rs10463316	0.823	rs7700340	chr5:150776320	C/T	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.37	-0.33	1.86e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs644799	0.710	rs666398	chr11:95551136	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	13.52	0.66	3.99e-31	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs908922	0.651	rs4240885	chr1:152529850	G/C	cg09873164	chr1:152488093	CRCT1	0.6	7.89	0.46	1.16e-13	Hair morphology;
SARC	cis	rs9303280	0.806	rs10852935	chr17:38031674	C/T	cg20243544	chr17:37824526	PNMT	0.42	5.52	0.34	9.01e-8	Self-reported allergy;
SARC	cis	rs1468333	0.691	rs35839251	chr5:137584080	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.8	10.73	0.58	4.33e-22	Resting heart rate;
SARC	trans	rs208520	0.954	rs12190073	chr6:66983740	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.83	9.35	0.52	7.46e-18	Exhaled nitric oxide output;
SARC	cis	rs9630089	0.622	rs7906782	chr10:98961596	C/T	cg25902810	chr10:99078978	FRAT1	0.42	5.09	0.32	7.53e-7	Neutrophil percentage of white cells;
SARC	trans	rs1961637	0.603	rs1550423	chr2:223885812	C/T	cg00674415	chr16:1859330	HAGH	0.45	6.46	0.39	6.19e-10	Oropharynx cancer;
SARC	cis	rs7542091	1.000	rs7542091	chr1:210031948	G/C	cg05527609	chr1:210001259	C1orf107	-0.49	-6.31	-0.38	1.35e-9	Monobrow;
SARC	cis	rs4690686	0.500	rs12501181	chr4:177264851	G/A	cg17059388	chr4:177262070	NA	0.37	4.81	0.3	2.76e-6	Essential tremor;
SARC	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg10523679	chr1:76189770	ACADM	0.54	7.38	0.44	2.73e-12	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6840360	0.615	rs1561917	chr4:152479233	G/A	cg22705602	chr4:152727874	NA	-0.42	-6.51	-0.39	4.59e-10	Intelligence (multi-trait analysis);
SARC	cis	rs2439831	0.717	rs28495368	chr15:43895642	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	7.48	0.44	1.54e-12	Lung cancer in ever smokers;
SARC	cis	rs9911578	1.000	rs9904879	chr17:56864422	G/A	cg05425664	chr17:57184151	TRIM37	-0.65	-8.03	-0.47	4.77e-14	Intelligence (multi-trait analysis);
SARC	cis	rs981844	0.890	rs62325115	chr4:154694847	A/G	cg14289246	chr4:154710475	SFRP2	0.64	7.11	0.42	1.4e-11	Response to statins (LDL cholesterol change);
SARC	cis	rs72634258	0.786	rs7523335	chr1:8180210	G/A	cg00042356	chr1:8021962	PARK7	0.59	5.52	0.34	9.08e-8	Inflammatory bowel disease;
SARC	cis	rs644799	1.000	rs488246	chr11:95560473	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.68	9.17	0.51	2.6e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg26828218	chr2:219264796	CTDSP1	0.48	6.28	0.38	1.65e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs10779751	1.000	rs1064261	chr1:11288758	C/T	cg08854313	chr1:11322531	MTOR	0.79	11.41	0.6	3.12e-24	Body mass index;
SARC	cis	rs17253792	1.000	rs28616134	chr14:56178802	G/A	cg01858014	chr14:56050164	KTN1	-0.62	-4.86	-0.3	2.19e-6	Putamen volume;
SARC	cis	rs6912958	0.559	rs451465	chr6:88043372	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.73	-11.02	-0.59	5.36e-23	Monocyte percentage of white cells;
SARC	cis	rs7412746	0.552	rs4970980	chr1:150864992	A/C	cg15448220	chr1:150897856	SETDB1	0.52	6.87	0.41	5.67e-11	Melanoma;
SARC	cis	rs9354308	0.868	rs6907911	chr6:66555683	A/G	cg07460842	chr6:66804631	NA	-0.45	-5.17	-0.32	4.92e-7	Metabolite levels;
SARC	cis	rs9457247	0.967	rs428805	chr6:167403132	C/A	cg23791538	chr6:167370224	RNASET2	-0.63	-8.73	-0.5	4.84e-16	Crohn's disease;
SARC	cis	rs1865760	1.000	rs6910174	chr6:25904414	C/T	cg16482183	chr6:26056742	HIST1H1C	0.49	6.13	0.37	3.78e-9	Height;
SARC	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg23758822	chr17:41437982	NA	0.9	11.44	0.6	2.35e-24	Menopause (age at onset);
SARC	cis	rs1580019	0.961	rs4460271	chr7:32496503	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.73	9.78	0.54	3.93e-19	Cognitive ability;
SARC	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg20965017	chr5:231967	SDHA	-0.58	-5.57	-0.34	7.03e-8	Breast cancer;
SARC	cis	rs11190604	1.000	rs2495741	chr10:102331795	A/G	cg07080220	chr10:102295463	HIF1AN	0.81	10.24	0.56	1.43e-20	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs9467160	0.559	rs2753911	chr6:24442288	C/T	cg20631270	chr6:24437470	GPLD1	0.41	5.34	0.33	2.23e-7	Liver enzyme levels;
SARC	cis	rs3857536	0.813	rs6904511	chr6:66939102	A/C	cg07460842	chr6:66804631	NA	-0.51	-5.83	-0.36	1.86e-8	Blood trace element (Cu levels);
SARC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.64	0.53	1.01e-18	Prudent dietary pattern;
SARC	trans	rs2727020	0.595	rs11040416	chr11:49566429	C/T	cg03929089	chr4:120376271	NA	-0.79	-12.01	-0.62	3.54e-26	Coronary artery disease;
SARC	cis	rs9393777	0.623	rs16891717	chr6:26477143	T/A	cg12826209	chr6:26865740	GUSBL1	0.81	7.39	0.44	2.59e-12	Intelligence (multi-trait analysis);
SARC	cis	rs7607369	0.580	rs17573724	chr2:219652141	T/A	cg02176678	chr2:219576539	TTLL4	-0.51	-8.32	-0.48	7.33e-15	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg26681399	chr22:41777847	TEF	0.47	5.06	0.31	8.62e-7	Vitiligo;
SARC	cis	rs7766436	0.848	rs2294828	chr6:22598018	G/A	cg13666174	chr6:22585274	NA	-0.62	-8.12	-0.47	2.65e-14	Coronary artery disease;
SARC	cis	rs3784262	1.000	rs7170896	chr15:58252393	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.39	-5.75	-0.35	2.81e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs9788682	0.747	rs2656071	chr15:78745343	A/T	cg06917634	chr15:78832804	PSMA4	0.5	5.2	0.32	4.27e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs13191362	1.000	rs66594243	chr6:163169024	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.72	6.11	0.37	4.25e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg11987759	chr7:65425863	GUSB	0.48	5.94	0.36	1.06e-8	Aortic root size;
SARC	cis	rs7937682	0.921	rs4616071	chr11:111440865	C/G	cg22437258	chr11:111473054	SIK2	-0.65	-8.21	-0.47	1.56e-14	Primary sclerosing cholangitis;
SARC	cis	rs7647973	0.588	rs62262675	chr3:49673662	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.57	-5.0	-0.31	1.12e-6	Menarche (age at onset);
SARC	cis	rs6964587	0.967	rs12671991	chr7:91559481	T/C	cg17063962	chr7:91808500	NA	-0.93	-14.77	-0.7	2.86e-35	Breast cancer;
SARC	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg05368731	chr17:41323189	NBR1	0.75	9.07	0.51	4.91e-17	Menopause (age at onset);
SARC	cis	rs9487051	0.872	rs6924776	chr6:109612276	A/G	cg01475377	chr6:109611718	NA	-0.41	-5.88	-0.36	1.39e-8	Reticulocyte fraction of red cells;
SARC	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.78	11.83	0.61	1.32e-25	Personality dimensions;
SARC	cis	rs67460515	0.892	rs11929238	chr3:161045937	A/T	cg17135325	chr3:160939158	NMD3	0.62	7.9	0.46	1.08e-13	Parkinson's disease;
SARC	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg07701084	chr6:150067640	NUP43	0.41	5.45	0.34	1.29e-7	Lung cancer;
SARC	cis	rs73206853	0.841	rs73191840	chr12:110970457	A/G	cg10860002	chr12:110842031	ANAPC7	0.61	5.07	0.31	8.28e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	trans	rs9325144	0.555	rs7977200	chr12:38713745	C/T	cg23762105	chr12:34175262	ALG10	-0.53	-7.0	-0.42	2.68e-11	Morning vs. evening chronotype;
SARC	cis	rs240768	0.511	rs61289570	chr6:101403098	C/T	cg12253828	chr6:101329408	ASCC3	0.91	6.2	0.38	2.55e-9	Economic and political preferences (immigration/crime);
SARC	cis	rs7522061	0.546	rs2785663	chr1:157620758	G/T	cg18268488	chr1:157545234	FCRL4	-0.26	-4.75	-0.3	3.51e-6	Blood protein levels;
SARC	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg25894440	chr7:65020034	NA	-0.75	-5.59	-0.34	6.48e-8	Diabetic kidney disease;
SARC	trans	rs8020941	0.585	rs78182503	chr14:97498920	T/C	cg05136476	chr3:53190709	NA	-0.63	-6.39	-0.39	8.99e-10	Diabetic kidney disease;
SARC	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg08280861	chr8:58055591	NA	0.69	5.42	0.33	1.45e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2976388	0.609	rs2572904	chr8:143792193	A/C	cg06565975	chr8:143823917	SLURP1	0.3	5.24	0.32	3.65e-7	Urinary tract infection frequency;
SARC	cis	rs883565	0.582	rs811969	chr3:39180162	A/C	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.44	-4.9	-0.31	1.79e-6	Handedness;
SARC	cis	rs7909074	0.831	rs11239271	chr10:45376294	A/G	cg04218760	chr10:45406644	TMEM72	-0.26	-5.21	-0.32	4.17e-7	Mean corpuscular volume;
SARC	cis	rs9394169	0.709	rs6919321	chr6:33724004	G/A	cg15676125	chr6:33679581	C6orf125	0.46	5.57	0.34	6.83e-8	Essential tremor;
SARC	cis	rs66887589	0.774	rs9307477	chr4:120421809	G/A	cg09307838	chr4:120376055	NA	0.54	7.39	0.44	2.63e-12	Diastolic blood pressure;
SARC	cis	rs12220238	1.000	rs11000909	chr10:75944828	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.6	5.91	0.36	1.2e-8	Soluble interleukin-2 receptor subunit alpha;
SARC	cis	rs10771431	0.935	rs1988852	chr12:9372862	G/A	cg08997352	chr12:9597637	DDX12	-0.54	-7.69	-0.45	4.06e-13	Breast size;
SARC	cis	rs9660992	0.710	rs4951184	chr1:205240659	A/T	cg21545522	chr1:205238299	TMCC2	0.41	5.78	0.35	2.36e-8	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs763121	0.853	rs5757181	chr22:39013522	G/A	cg21395723	chr22:39101663	GTPBP1	0.58	6.46	0.39	6.18e-10	Menopause (age at onset);
SARC	cis	rs17376456	1.000	rs59472588	chr5:93511981	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	5.51	0.34	9.64e-8	Diabetic retinopathy;
SARC	cis	rs2075371	1.000	rs2241335	chr7:133979368	C/T	cg00033643	chr7:134001901	SLC35B4	0.4	4.9	0.31	1.8e-6	Mean platelet volume;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg09288320	chr2:210994670	C2orf67	0.54	8.05	0.47	4.36e-14	Thyroid stimulating hormone;
SARC	cis	rs1707322	0.721	rs10890337	chr1:46124527	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.25	0.38	1.93e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2599510	0.783	rs2710630	chr2:32765997	A/C	cg02381751	chr2:32503542	YIPF4	-0.49	-5.72	-0.35	3.29e-8	Interleukin-18 levels;
SARC	cis	rs2730245	0.527	rs62476462	chr7:158686619	A/G	cg24397884	chr7:158709396	WDR60	1.14	10.19	0.56	2.12e-20	Height;
SARC	cis	rs10744422	0.925	rs2880678	chr12:123317099	C/T	cg25930673	chr12:123319894	HIP1R	-0.65	-5.03	-0.31	9.99e-7	Schizophrenia;
SARC	cis	rs778371	0.676	rs7560115	chr2:233709465	T/G	cg16596103	chr2:233749413	NGEF	0.32	4.74	0.3	3.79e-6	Schizophrenia;
SARC	cis	rs6964587	1.000	rs10234071	chr7:91645152	C/G	cg17063962	chr7:91808500	NA	-0.98	-16.76	-0.74	6.68e-42	Breast cancer;
SARC	cis	rs2916247	0.954	rs66579130	chr8:93054332	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.57	-5.92	-0.36	1.14e-8	Intelligence (multi-trait analysis);
SARC	trans	rs208520	0.661	rs4710566	chr6:66848538	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-14.09	-0.68	5.2e-33	Exhaled nitric oxide output;
SARC	cis	rs12079745	1.000	rs1138486	chr1:169101935	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.69	-4.94	-0.31	1.46e-6	QT interval;
SARC	cis	rs7552404	0.924	rs1146580	chr1:76209935	T/C	cg03433033	chr1:76189801	ACADM	0.47	6.94	0.41	3.75e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg24250549	chr1:154909240	PMVK	-0.73	-10.27	-0.56	1.17e-20	Prostate cancer;
SARC	cis	rs17209837	0.915	rs17149637	chr7:87085209	G/A	cg00919237	chr7:87102261	ABCB4	-0.5	-5.47	-0.34	1.14e-7	Gallbladder cancer;
SARC	cis	rs2652834	0.808	rs28583444	chr15:63357852	T/G	cg05507819	chr15:63340323	TPM1	0.64	6.62	0.4	2.51e-10	HDL cholesterol;
SARC	cis	rs7633770	0.805	rs11130098	chr3:46661926	A/G	cg11219411	chr3:46661640	NA	-0.49	-8.55	-0.49	1.62e-15	Coronary artery disease;
SARC	cis	rs8078723	0.714	rs2241244	chr17:38153554	G/C	cg17467752	chr17:38218738	THRA	-0.38	-4.84	-0.3	2.36e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg18357526	chr6:26021779	HIST1H4A	0.44	5.54	0.34	8.35e-8	Blood metabolite levels;
SARC	cis	rs6088813	1.000	rs1540927	chr20:33931344	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.44	-5.35	-0.33	2.07e-7	Height;
SARC	cis	rs6089584	0.507	rs6061990	chr20:60628429	T/G	cg13770153	chr20:60521292	NA	-0.37	-5.27	-0.33	3.15e-7	Body mass index;
SARC	cis	rs10979	0.571	rs9386039	chr6:143916992	A/T	cg25407410	chr6:143891975	LOC285740	0.53	5.88	0.36	1.4e-8	Hypospadias;
SARC	cis	rs9381040	0.655	rs2268188	chr6:41042590	T/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.42	-4.79	-0.3	2.96e-6	Alzheimer's disease (late onset);
SARC	cis	rs9916302	0.808	rs12948906	chr17:37644854	C/T	cg07936489	chr17:37558343	FBXL20	-0.7	-8.99	-0.51	8.63e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs9487051	1.000	rs11757567	chr6:109614713	G/A	cg01475377	chr6:109611718	NA	-0.41	-5.69	-0.35	3.7e-8	Reticulocyte fraction of red cells;
SARC	cis	rs34330	0.562	rs10845615	chr12:12863470	C/T	cg04607235	chr12:12878440	APOLD1	-0.56	-5.39	-0.33	1.73e-7	Systemic lupus erythematosus;
SARC	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg13939156	chr17:80058883	NA	0.4	6.22	0.38	2.23e-9	Life satisfaction;
SARC	cis	rs554111	0.891	rs604645	chr1:21043926	T/C	cg08890418	chr1:21044141	KIF17	0.54	7.34	0.43	3.48e-12	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs10504229	0.679	rs72649131	chr8:58054288	G/T	cg22535103	chr8:58192502	C8orf71	-0.6	-6.02	-0.37	6.68e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg00684032	chr4:1343700	KIAA1530	0.48	7.26	0.43	5.61e-12	Obesity-related traits;
SARC	cis	rs7223966	1.000	rs11658175	chr17:61923838	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.51	-5.3	-0.33	2.64e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs4689388	0.890	rs4689397	chr4:6299387	G/A	cg00701064	chr4:6280414	WFS1	0.55	8.85	0.5	2.25e-16	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs9818758	0.607	rs13077498	chr3:49313978	C/T	cg01304814	chr3:48885189	PRKAR2A	0.65	5.29	0.33	2.75e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.03	12.36	0.63	2.47e-27	Platelet count;
SARC	cis	rs4805272	0.512	rs17772319	chr19:29343064	T/A	cg04546413	chr19:29218101	NA	0.44	4.85	0.3	2.28e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs1568889	1.000	rs2354427	chr11:28049623	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	10.33	0.56	7.9e-21	Bipolar disorder;
SARC	cis	rs6582630	0.599	rs1851114	chr12:38424671	C/T	cg13010199	chr12:38710504	ALG10B	-0.46	-5.6	-0.34	6.11e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2295359	0.892	rs4655686	chr1:67638004	T/A	cg11235152	chr1:67600687	NA	0.51	7.05	0.42	2.04e-11	Psoriasis;
SARC	cis	rs9326248	0.652	rs7128382	chr11:117023487	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.59	5.93	0.36	1.06e-8	Blood protein levels;
SARC	cis	rs1559088	0.600	rs58173463	chr19:33596749	C/T	cg17764715	chr19:33622953	WDR88	0.6	8.43	0.48	3.71e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs67460515	0.567	rs34691229	chr3:160876897	G/T	cg17135325	chr3:160939158	NMD3	0.65	8.19	0.47	1.72e-14	Parkinson's disease;
SARC	cis	rs6500602	0.929	rs9926114	chr16:4478322	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.34	5.51	0.34	9.46e-8	Schizophrenia;
SARC	trans	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.21	-0.43	7.82e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs3782089	1.000	rs3782089	chr11:65336819	C/T	cg00206168	chr11:65308501	LTBP3	0.68	4.77	0.3	3.32e-6	Height;
SARC	cis	rs4742903	0.935	rs4587392	chr9:106972508	G/A	cg14250997	chr9:106856677	SMC2	0.42	5.3	0.33	2.74e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs9290065	0.519	rs1447608	chr3:160682019	G/T	cg17135325	chr3:160939158	NMD3	0.41	4.83	0.3	2.45e-6	Kawasaki disease;
SARC	cis	rs2838344	0.776	rs2298561	chr21:45085234	A/G	cg04455712	chr21:45112962	RRP1B	0.35	4.94	0.31	1.5e-6	Coronary artery disease;
SARC	trans	rs2727020	0.757	rs7924526	chr11:49267043	G/A	cg15704280	chr7:45808275	SEPT13	0.76	10.2	0.56	1.97e-20	Coronary artery disease;
SARC	cis	rs1707322	1.000	rs11211228	chr1:46399840	G/A	cg03146154	chr1:46216737	IPP	0.46	5.53	0.34	8.66e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.88	11.79	0.61	1.76e-25	Multiple sclerosis;
SARC	cis	rs854765	0.647	rs7406744	chr17:17981938	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.61	8.7	0.49	6.28e-16	Total body bone mineral density;
SARC	cis	rs1023500	0.505	rs134891	chr22:42675882	T/C	cg15557168	chr22:42548783	NA	-0.38	-5.4	-0.33	1.66e-7	Schizophrenia;
SARC	cis	rs6700896	0.522	rs4655583	chr1:66155407	C/A	cg04111102	chr1:66153794	NA	0.45	4.75	0.3	3.52e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs7792596	0.565	rs10487252	chr7:93981089	C/T	cg20814616	chr7:94014465	NA	0.47	5.12	0.32	6.52e-7	Intelligence;
SARC	cis	rs8079658	1.000	rs17695630	chr17:63801593	G/C	cg03442606	chr17:63822778	CCDC46	-0.39	-4.86	-0.3	2.13e-6	Post bronchodilator FEV1;
SARC	cis	rs2073300	0.609	rs2277765	chr20:23425163	C/T	cg12062639	chr20:23401060	NAPB	0.95	6.38	0.39	9.62e-10	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg26116260	chr4:7069785	GRPEL1	-0.84	-8.98	-0.51	9.26e-17	Monocyte percentage of white cells;
SARC	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg16434002	chr17:42200994	HDAC5	-0.42	-5.3	-0.33	2.65e-7	Total body bone mineral density;
SARC	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg02951883	chr7:2050386	MAD1L1	0.42	5.36	0.33	1.96e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs9399135	0.967	rs13218642	chr6:135309940	A/G	cg24558204	chr6:135376177	HBS1L	0.45	6.07	0.37	5.02e-9	Red blood cell count;
SARC	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg13395646	chr4:1353034	KIAA1530	-0.46	-5.44	-0.34	1.34e-7	Obesity-related traits;
SARC	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg06713675	chr4:122721982	EXOSC9	-0.51	-6.69	-0.4	1.6e-10	Type 2 diabetes;
SARC	cis	rs17376456	0.877	rs7736620	chr5:93305762	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.65	6.1	0.37	4.49e-9	Diabetic retinopathy;
SARC	cis	rs4268898	0.552	rs35331966	chr2:24367828	C/T	cg26838691	chr2:24397539	C2orf84	0.38	5.05	0.31	9.11e-7	Asthma;
SARC	trans	rs208520	0.874	rs208485	chr6:66925654	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-10.9	-0.58	1.24e-22	Exhaled nitric oxide output;
SARC	cis	rs2011503	1.000	rs8111093	chr19:19505548	C/T	cg15839431	chr19:19639596	YJEFN3	-0.5	-4.9	-0.31	1.78e-6	Bipolar disorder;
SARC	cis	rs12142240	0.660	rs112560929	chr1:46822297	A/G	cg00530320	chr1:46809349	NSUN4	0.57	6.79	0.41	9.05e-11	Menopause (age at onset);
SARC	cis	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg07777115	chr5:623756	CEP72	-0.62	-5.53	-0.34	8.61e-8	Obesity-related traits;
SARC	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg02725872	chr8:58115012	NA	-0.35	-6.03	-0.37	6.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs35306767	0.859	rs11817793	chr10:878895	C/T	cg26597838	chr10:835615	NA	0.71	7.23	0.43	6.96e-12	Eosinophil percentage of granulocytes;
SARC	cis	rs11578119	0.933	rs12124354	chr1:170415362	G/C	cg09767346	chr1:170501363	GORAB	0.41	4.84	0.3	2.41e-6	Male-pattern baldness;
SARC	cis	rs198851	0.915	rs72834627	chr6:26019411	G/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.38	-4.86	-0.3	2.2e-6	Red cell distribution width;High light scatter reticulocyte percentage of red cells;Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs2463822	0.583	rs72919462	chr11:62035663	G/A	cg06239285	chr11:62104954	ASRGL1	-0.87	-7.92	-0.46	9.4e-14	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg26335602	chr6:28129616	ZNF389	0.5	5.56	0.34	7.55e-8	Depression;
SARC	cis	rs1784581	0.588	rs7453474	chr6:162421736	C/T	cg17173639	chr6:162384350	PARK2	0.51	6.48	0.39	5.48e-10	Itch intensity from mosquito bite;
SARC	cis	rs2908197	0.843	rs2908193	chr7:75945945	A/G	cg24580635	chr7:76178542	LOC100133091	-0.42	-4.79	-0.3	2.93e-6	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs11190604	1.000	rs3750633	chr10:102308214	C/T	cg07080220	chr10:102295463	HIF1AN	0.8	9.98	0.55	9.42e-20	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs2439831	0.681	rs1095386	chr15:43609509	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	9.07	0.51	5.09e-17	Lung cancer in ever smokers;
SARC	cis	rs11235843	0.602	rs7106773	chr11:73383174	C/G	cg18195628	chr11:73498948	MRPL48	-0.56	-5.72	-0.35	3.19e-8	Hand grip strength;
SARC	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-8.76	-0.5	4.15e-16	Alzheimer's disease;
SARC	cis	rs66887589	0.807	rs13134517	chr4:120405262	G/A	cg09307838	chr4:120376055	NA	0.55	7.46	0.44	1.65e-12	Diastolic blood pressure;
SARC	cis	rs9329289	0.510	rs12356215	chr10:2545390	C/G	cg15501526	chr10:2543763	NA	0.38	5.78	0.35	2.41e-8	Age-related hearing impairment;
SARC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg04234412	chr22:24373322	LOC391322	-0.54	-7.05	-0.42	2.06e-11	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs11874712	0.965	rs11661945	chr18:43672194	T/A	cg25174615	chr18:43684699	ATP5A1;HAUS1	0.42	4.91	0.31	1.7e-6	Migraine - clinic-based;
SARC	cis	rs2204008	0.806	rs3922574	chr12:38329069	C/T	cg13010199	chr12:38710504	ALG10B	0.79	10.7	0.57	5.52e-22	Bladder cancer;
SARC	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg19223190	chr17:80058835	NA	0.49	6.57	0.4	3.24e-10	Life satisfaction;
SARC	cis	rs11122272	0.764	rs4486439	chr1:231477470	C/T	cg06096015	chr1:231504339	EGLN1	0.38	5.73	0.35	3.08e-8	Hemoglobin concentration;
SARC	cis	rs614226	0.935	rs7137953	chr12:120894685	C/T	cg01236616	chr12:121019343	POP5	-1.15	-16.1	-0.73	1.02e-39	Type 1 diabetes nephropathy;
SARC	cis	rs17376456	0.690	rs6892055	chr5:93113023	A/T	cg21475434	chr5:93447410	FAM172A	0.72	6.15	0.37	3.39e-9	Diabetic retinopathy;
SARC	cis	rs7786808	0.705	rs1377373	chr7:158215549	A/C	cg01191920	chr7:158217561	PTPRN2	0.32	5.56	0.34	7.26e-8	Obesity-related traits;
SARC	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-8.76	-0.5	4.15e-16	Alzheimer's disease;
SARC	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg03806693	chr22:41940476	POLR3H	0.92	12.37	0.63	2.4e-27	Vitiligo;
SARC	cis	rs6582630	0.576	rs3900594	chr12:38272429	C/T	cg14851346	chr12:38532713	NA	-0.47	-5.62	-0.35	5.45e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs3774749	0.565	rs2518795	chr3:50208819	C/T	cg14019146	chr3:50243930	SLC38A3	-0.33	-5.55	-0.34	7.65e-8	Intelligence (multi-trait analysis);
SARC	cis	rs8014131	0.615	rs7160149	chr14:85987475	G/A	cg10406690	chr14:85995726	FLRT2	0.4	5.14	0.32	5.68e-7	Menarche (age at onset);
SARC	cis	rs6088580	0.634	rs6119497	chr20:33012529	T/A	cg24642439	chr20:33292090	TP53INP2	0.67	8.57	0.49	1.48e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs2153535	0.580	rs6597322	chr6:8449952	T/G	cg21535247	chr6:8435926	SLC35B3	0.55	6.87	0.41	5.72e-11	Motion sickness;
SARC	cis	rs1448094	0.512	rs6539924	chr12:86236935	T/C	cg00310523	chr12:86230176	RASSF9	0.3	4.89	0.3	1.92e-6	Major depressive disorder;
SARC	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg16414030	chr3:133502952	NA	0.4	5.45	0.34	1.25e-7	Iron status biomarkers;
SARC	cis	rs2635047	0.806	rs9962602	chr18:44599057	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.64	8.68	0.49	7.1e-16	Educational attainment;
SARC	cis	rs936229	0.656	rs12898397	chr15:75130093	T/C	cg17294928	chr15:75287854	SCAMP5	0.41	4.73	0.3	3.92e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.8	10.35	0.56	6.76e-21	Prudent dietary pattern;
SARC	cis	rs908922	0.605	rs3753448	chr1:152486407	A/C	cg09873164	chr1:152488093	CRCT1	0.63	8.3	0.48	8.3e-15	Hair morphology;
SARC	cis	rs870825	0.587	rs6826883	chr4:185616167	A/C	cg04058563	chr4:185651563	MLF1IP	0.82	11.24	0.59	1.05e-23	Blood protein levels;
SARC	cis	rs2749592	0.531	rs994804	chr10:37900140	A/C	cg25427524	chr10:38739819	LOC399744	0.46	6.75	0.4	1.19e-10	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs79149102	0.579	rs6495140	chr15:75306041	T/C	cg00629941	chr15:75287862	SCAMP5	-0.66	-5.39	-0.33	1.7e-7	Lung cancer;
SARC	cis	rs10927875	0.619	rs7537101	chr1:16150384	T/C	cg22431228	chr1:16359049	CLCNKA	0.3	4.81	0.3	2.7e-6	Dilated cardiomyopathy;
SARC	cis	rs11098499	0.697	rs4373140	chr4:120307698	A/G	cg09307838	chr4:120376055	NA	0.91	12.88	0.65	4.9e-29	Corneal astigmatism;
SARC	cis	rs710216	0.843	rs1385129	chr1:43408966	G/A	cg03128534	chr1:43423976	SLC2A1	0.66	6.93	0.41	4.18e-11	Red cell distribution width;
SARC	cis	rs10754283	0.967	rs10801757	chr1:90103080	A/G	cg21401794	chr1:90099060	LRRC8C	0.59	8.21	0.47	1.52e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs11874712	0.966	rs8093880	chr18:43666786	C/T	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.46	5.5	0.34	1.02e-7	Migraine - clinic-based;
SARC	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg25036284	chr2:26402008	FAM59B	-0.46	-5.7	-0.35	3.59e-8	Gut microbiome composition (summer);
SARC	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.23e-9	Life satisfaction;
SARC	cis	rs644799	0.623	rs17207890	chr11:95490754	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.59	7.17	0.43	1e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs3858526	0.833	rs4758184	chr11:5926719	A/G	cg02574844	chr11:5959923	NA	-0.42	-5.09	-0.32	7.22e-7	DNA methylation (variation);
SARC	cis	rs9314323	0.557	rs3779916	chr8:26250906	C/A	cg11498726	chr8:26250323	BNIP3L	-0.5	-6.85	-0.41	6.58e-11	Red cell distribution width;
SARC	cis	rs6582630	0.560	rs4882325	chr12:38510037	C/T	cg26384229	chr12:38710491	ALG10B	-0.57	-7.3	-0.43	4.41e-12	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6991838	0.584	rs4320587	chr8:66499226	G/A	cg13398993	chr8:66546079	ARMC1	-0.62	-8.31	-0.48	7.89e-15	Intelligence (multi-trait analysis);
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg07817810	chr3:47205858	SETD2	0.49	6.7	0.4	1.58e-10	Lung adenocarcinoma;
SARC	cis	rs12142240	0.698	rs68012736	chr1:46839510	A/G	cg10495392	chr1:46806563	NSUN4	0.65	6.88	0.41	5.6e-11	Menopause (age at onset);
SARC	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg11644478	chr21:40555479	PSMG1	1.04	14.54	0.69	1.63e-34	Cognitive function;
SARC	cis	rs7429990	0.965	rs4858881	chr3:48123796	C/G	cg11946769	chr3:48343235	NME6	-0.46	-5.29	-0.33	2.76e-7	Educational attainment (years of education);
SARC	cis	rs3091242	0.933	rs11249250	chr1:25767609	G/A	cg02931644	chr1:25747376	RHCE	0.44	7.44	0.44	1.89e-12	Erythrocyte sedimentation rate;
SARC	trans	rs2727020	0.729	rs685789	chr11:49241228	G/A	cg15704280	chr7:45808275	SEPT13	0.83	12.71	0.64	1.83e-28	Coronary artery disease;
SARC	cis	rs11809207	0.568	rs1892494	chr1:26497626	C/G	cg00300879	chr1:26503847	CNKSR1	0.31	4.86	0.3	2.16e-6	Height;
SARC	cis	rs10782582	0.564	rs17647711	chr1:76241710	C/G	cg03433033	chr1:76189801	ACADM	-0.39	-4.86	-0.3	2.13e-6	Daytime sleep phenotypes;
SARC	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg03213289	chr20:61660250	NA	0.46	6.43	0.39	7.22e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs7432375	0.610	rs56695781	chr3:136510601	G/T	cg15507776	chr3:136538369	TMEM22	0.62	7.7	0.45	3.89e-13	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg08677398	chr8:58056175	NA	0.44	5.25	0.33	3.38e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9527	0.590	rs3781281	chr10:104852648	A/G	cg04362960	chr10:104952993	NT5C2	-0.47	-5.57	-0.34	7.15e-8	Arsenic metabolism;
SARC	cis	rs3796352	1.000	rs35720014	chr3:52982110	A/C	cg15956490	chr3:53032818	SFMBT1	0.89	5.7	0.35	3.59e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	12.42	0.63	1.59e-27	Personality dimensions;
SARC	cis	rs8180040	0.764	rs2132173	chr3:47247060	C/T	cg27129171	chr3:47204927	SETD2	-0.59	-7.94	-0.46	8.61e-14	Colorectal cancer;
SARC	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg04518342	chr5:131593106	PDLIM4	0.37	5.21	0.32	4.2e-7	Breast cancer;
SARC	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg05025164	chr4:1340916	KIAA1530	0.84	11.15	0.59	2.03e-23	Longevity;
SARC	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.46	0.39	6.12e-10	Bipolar disorder;
SARC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.31	4.77	0.3	3.24e-6	Bipolar disorder;
SARC	cis	rs72781680	0.898	rs7589440	chr2:24038595	G/A	cg06627628	chr2:24431161	ITSN2	-0.67	-6.31	-0.38	1.39e-9	Lymphocyte counts;
SARC	cis	rs1153858	1.000	rs8042786	chr15:45703539	T/C	cg26924012	chr15:45694286	SPATA5L1	0.78	10.67	0.57	6.94e-22	Homoarginine levels;
SARC	cis	rs644799	1.000	rs474252	chr11:95619292	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	13.79	0.67	5.05e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.45	5.07	0.32	8.2e-7	Renal function-related traits (BUN);
SARC	cis	rs1355223	0.966	rs11602318	chr11:34766983	C/T	cg18508148	chr11:34937573	PDHX;APIP	0.41	5.17	0.32	5.09e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg11742103	chr11:62369870	EML3;MTA2	0.42	6.21	0.38	2.35e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs9300255	0.596	rs1568427	chr12:123738678	A/G	cg00376283	chr12:123451042	ABCB9	0.55	6.25	0.38	1.89e-9	Neutrophil percentage of white cells;
SARC	cis	rs4969178	0.930	rs12452576	chr17:76386037	A/C	cg02836325	chr17:76403955	PGS1	0.32	4.87	0.3	2.07e-6	HDL cholesterol levels;
SARC	cis	rs2921073	0.509	rs2976931	chr8:8257317	C/A	cg08975724	chr8:8085496	FLJ10661	0.55	6.54	0.39	3.82e-10	Parkinson's disease;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg16424138	chr5:14581771	FAM105A	0.49	6.51	0.39	4.54e-10	Chemerin levels;
SARC	trans	rs1814175	0.645	rs847627	chr11:49927177	G/A	cg15704280	chr7:45808275	SEPT13	-0.88	-14.0	-0.68	1.02e-32	Height;
SARC	cis	rs7123876	0.587	rs11601122	chr11:72362718	A/G	cg03713592	chr11:72463424	ARAP1	0.56	4.93	0.31	1.59e-6	Body mass index;
SARC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg07167872	chr1:205819463	PM20D1	0.86	15.4	0.71	2.19e-37	Menarche (age at onset);
SARC	trans	rs637571	0.522	rs542332	chr11:65744421	C/T	cg17712092	chr4:129076599	LARP1B	0.68	9.23	0.52	1.76e-17	Eosinophil percentage of white cells;
SARC	cis	rs753778	0.559	rs2288997	chr8:142200731	A/G	cg18755752	chr8:142205143	DENND3	0.46	5.4	0.33	1.67e-7	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs1023500	0.573	rs2269524	chr22:42475703	T/G	cg04733989	chr22:42467013	NAGA	-0.77	-10.92	-0.58	1.11e-22	Schizophrenia;
SARC	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg19077165	chr18:44547161	KATNAL2	-0.48	-6.46	-0.39	6.03e-10	Personality dimensions;
SARC	cis	rs651907	0.557	rs36002990	chr3:101437862	G/A	cg12386194	chr3:101231763	SENP7	0.48	5.74	0.35	2.96e-8	Colorectal cancer;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg10939746	chr2:128238578	IWS1	0.47	6.35	0.38	1.09e-9	Thyroid stimulating hormone;
SARC	cis	rs67460515	0.563	rs9876142	chr3:160780968	A/G	cg03342759	chr3:160939853	NMD3	0.62	7.02	0.42	2.34e-11	Parkinson's disease;
SARC	cis	rs6942407	0.592	rs886318	chr7:86746500	C/G	cg02420886	chr7:86849541	C7orf23	0.58	5.48	0.34	1.1e-7	Food allergy;
SARC	cis	rs992157	0.835	rs2292555	chr2:219146882	G/C	cg00012203	chr2:219082015	ARPC2	-0.64	-9.12	-0.51	3.56e-17	Colorectal cancer;
SARC	cis	rs2635047	0.600	rs2635056	chr18:44710568	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	5.94	0.36	1.05e-8	Educational attainment;
SARC	cis	rs713477	1.000	rs8014621	chr14:55906849	A/C	cg13175173	chr14:55914753	NA	-0.35	-5.28	-0.33	2.98e-7	Pediatric bone mineral content (femoral neck);
SARC	trans	rs61931739	0.929	rs1490110	chr12:34091605	A/G	cg13010199	chr12:38710504	ALG10B	-0.52	-6.89	-0.41	5.04e-11	Morning vs. evening chronotype;
SARC	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg13206674	chr6:150067644	NUP43	0.47	6.04	0.37	6.14e-9	Lung cancer;
SARC	cis	rs898097	0.756	rs56249965	chr17:80806603	C/G	cg15369054	chr17:80825471	TBCD	0.54	7.41	0.44	2.27e-12	Breast cancer;
SARC	cis	rs698833	0.506	rs4952705	chr2:44499867	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.38	0.39	9.35e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.34	4.76	0.3	3.4e-6	Obesity-related traits;
SARC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	19.75	0.79	1.09e-51	Prudent dietary pattern;
SARC	cis	rs668210	0.793	rs534201	chr11:65776728	A/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.54	5.35	0.33	2.1e-7	Cerebrospinal fluid biomarker levels;
SARC	cis	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg05623727	chr3:50126028	RBM5	0.33	4.91	0.31	1.69e-6	Intelligence (multi-trait analysis);
SARC	cis	rs11098499	0.954	rs17006190	chr4:120418838	C/G	cg24375607	chr4:120327624	NA	0.41	4.86	0.3	2.12e-6	Corneal astigmatism;
SARC	cis	rs826838	0.620	rs11614695	chr12:39331847	C/T	cg13010199	chr12:38710504	ALG10B	0.63	7.82	0.46	1.78e-13	Heart rate;
SARC	cis	rs7674212	0.570	rs2711899	chr4:104062414	T/C	cg16532752	chr4:104119610	CENPE	-0.51	-6.2	-0.38	2.59e-9	Type 2 diabetes;
SARC	cis	rs10791097	0.694	rs2155751	chr11:130755240	G/A	cg09137382	chr11:130731461	NA	0.32	4.99	0.31	1.17e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs4555082	0.834	rs2735822	chr14:105712734	C/T	cg06808227	chr14:105710500	BRF1	-0.51	-6.51	-0.39	4.46e-10	Mean platelet volume;Platelet distribution width;
SARC	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg12756686	chr19:29218302	NA	0.68	8.99	0.51	8.47e-17	Methadone dose in opioid dependence;
SARC	cis	rs9527	0.640	rs35195396	chr10:104928770	T/A	cg04362960	chr10:104952993	NT5C2	0.43	5.12	0.32	6.5e-7	Arsenic metabolism;
SARC	cis	rs9303401	0.614	rs35057477	chr17:57097064	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	10.42	0.56	4.09e-21	Cognitive test performance;
SARC	cis	rs2404602	0.716	rs1588961	chr15:76752698	A/G	cg22467129	chr15:76604101	ETFA	-0.36	-4.75	-0.3	3.52e-6	Blood metabolite levels;
SARC	cis	rs921968	0.541	rs490483	chr2:219429052	A/T	cg02176678	chr2:219576539	TTLL4	0.47	7.21	0.43	7.58e-12	Mean corpuscular hemoglobin concentration;
SARC	cis	rs7635838	0.687	rs9849485	chr3:11395741	G/A	cg00170343	chr3:11313890	ATG7	0.65	9.11	0.51	3.95e-17	HDL cholesterol;
SARC	cis	rs7178572	0.625	rs907372	chr15:77844516	G/T	cg22256960	chr15:77711686	NA	-0.46	-5.72	-0.35	3.24e-8	Type 2 diabetes;
SARC	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.85	12.13	0.62	1.43e-26	Chronic sinus infection;
SARC	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg07701084	chr6:150067640	NUP43	0.42	5.28	0.33	2.91e-7	Lung cancer;
SARC	cis	rs9911578	0.817	rs304264	chr17:56749628	A/G	cg05425664	chr17:57184151	TRIM37	-0.64	-7.92	-0.46	9.84e-14	Intelligence (multi-trait analysis);
SARC	cis	rs2014572	0.875	rs10405008	chr19:57753643	C/G	cg24459738	chr19:57751996	ZNF805	0.43	5.12	0.32	6.39e-7	Hyperactive-impulsive symptoms;
SARC	cis	rs7829975	0.514	rs2979139	chr8:8268313	A/G	cg06636001	chr8:8085503	FLJ10661	0.62	7.7	0.45	3.78e-13	Mood instability;
SARC	trans	rs9523762	0.577	rs9516124	chr13:93354797	A/G	cg24487656	chr1:11986728	KIAA2013	0.43	6.27	0.38	1.72e-9	Multiple sclerosis;
SARC	cis	rs17600642	0.724	rs56375614	chr10:72444177	G/A	cg19779893	chr10:72451501	ADAMTS14	-0.37	-5.84	-0.36	1.71e-8	Bipolar disorder;
SARC	cis	rs12824058	0.831	rs7310433	chr12:130809289	C/T	cg23887609	chr12:130822674	PIWIL1	0.37	5.15	0.32	5.48e-7	Menopause (age at onset);
SARC	cis	rs7927771	0.826	rs7925389	chr11:47466790	A/T	cg05585544	chr11:47624801	NA	-0.36	-4.84	-0.3	2.36e-6	Subjective well-being;
SARC	trans	rs2727020	0.729	rs4315497	chr11:49214499	G/A	cg15704280	chr7:45808275	SEPT13	0.87	13.44	0.66	7.46e-31	Coronary artery disease;
SARC	cis	rs7246657	0.943	rs7408563	chr19:37808585	G/C	cg23950597	chr19:37808831	NA	-0.59	-5.82	-0.36	1.9e-8	Coronary artery calcification;
SARC	cis	rs2075371	0.796	rs1643040	chr7:134011703	G/C	cg00033643	chr7:134001901	SLC35B4	0.52	6.43	0.39	7.05e-10	Mean platelet volume;
SARC	cis	rs4423214	0.840	rs1792229	chr11:71179395	A/G	cg05163923	chr11:71159392	DHCR7	-0.6	-7.28	-0.43	5e-12	Vitamin D levels;
SARC	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg03735888	chr19:58951602	ZNF132	0.39	5.21	0.32	4.17e-7	Uric acid clearance;
SARC	cis	rs16854884	0.584	rs34372603	chr3:143738249	T/C	cg06585982	chr3:143692056	C3orf58	0.67	9.14	0.51	3.13e-17	Economic and political preferences (feminism/equality);
SARC	cis	rs41264869	0.723	rs4950978	chr1:205024573	C/T	cg21643547	chr1:205240462	TMCC2	0.49	5.28	0.33	2.94e-7	Blood protein levels;
SARC	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg11987759	chr7:65425863	GUSB	-0.47	-6.27	-0.38	1.7e-9	Aortic root size;
SARC	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg11987759	chr7:65425863	GUSB	0.49	6.06	0.37	5.48e-9	Aortic root size;
SARC	cis	rs11190604	1.000	rs2495759	chr10:102320363	C/T	cg07080220	chr10:102295463	HIF1AN	0.81	8.62	0.49	1.05e-15	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs1401999	0.650	rs3749445	chr3:183638506	C/T	cg01324343	chr3:183735012	ABCC5	0.58	10.47	0.57	2.92e-21	Anterior chamber depth;
SARC	cis	rs67311347	0.955	rs6773383	chr3:40377412	A/T	cg24209194	chr3:40518798	ZNF619	0.59	7.55	0.44	1e-12	Renal cell carcinoma;
SARC	cis	rs3106136	0.527	rs2664872	chr4:95146952	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.47	-7.05	-0.42	2.06e-11	Capecitabine sensitivity;
SARC	cis	rs9818758	0.545	rs9853352	chr3:49813258	C/T	cg06212747	chr3:49208901	KLHDC8B	0.66	5.89	0.36	1.37e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs7582180	0.701	rs11693044	chr2:100922313	T/C	cg14675211	chr2:100938903	LONRF2	0.54	7.85	0.46	1.55e-13	Intelligence (multi-trait analysis);
SARC	cis	rs11711311	1.000	rs1073040	chr3:113522123	C/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	8.36	0.48	5.58e-15	IgG glycosylation;
SARC	cis	rs9372253	1.000	rs2235989	chr6:110714584	A/T	cg01119278	chr6:110721349	DDO	-0.39	-5.15	-0.32	5.44e-7	Platelet distribution width;
SARC	cis	rs13161895	0.702	rs12652904	chr5:179496422	C/T	cg02702477	chr5:179499311	RNF130	0.78	7.17	0.43	9.63e-12	LDL cholesterol;
SARC	cis	rs9902453	0.791	rs28492945	chr17:28223982	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	7.04	0.42	2.09e-11	Coffee consumption (cups per day);
SARC	cis	rs4803468	1.000	rs284649	chr19:41926838	C/T	cg08477640	chr19:41863820	B9D2	0.44	5.56	0.34	7.43e-8	Height;
SARC	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg14343924	chr8:8086146	FLJ10661	0.46	5.65	0.35	4.75e-8	Mood instability;
SARC	cis	rs7000551	0.715	rs2469745	chr8:22343464	C/T	cg12081754	chr8:22256438	SLC39A14	0.58	8.17	0.47	2.01e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg22535103	chr8:58192502	C8orf71	-0.75	-6.81	-0.41	8.14e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs6831352	0.918	rs29001214	chr4:100051733	A/G	cg13256891	chr4:100009986	ADH5	-0.65	-8.09	-0.47	3.18e-14	Alcohol dependence;
SARC	cis	rs8079658	1.000	rs58176400	chr17:63816098	T/G	cg03442606	chr17:63822778	CCDC46	-0.38	-4.82	-0.3	2.63e-6	Post bronchodilator FEV1;
SARC	cis	rs1538970	0.962	rs2153609	chr1:45814058	A/G	cg05343316	chr1:45956843	TESK2	0.63	7.59	0.45	7.55e-13	Platelet count;
SARC	cis	rs9467773	1.000	rs9467783	chr6:26542894	C/T	cg12292205	chr6:26970375	C6orf41	0.43	5.29	0.33	2.79e-7	Intelligence (multi-trait analysis);
SARC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg06873352	chr17:61820015	STRADA	0.53	6.88	0.41	5.32e-11	Prudent dietary pattern;
SARC	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg03806693	chr22:41940476	POLR3H	-0.93	-12.97	-0.65	2.53e-29	Vitiligo;
SARC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg26338869	chr17:61819248	STRADA	0.78	10.39	0.56	5.05e-21	Prudent dietary pattern;
SARC	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	5.69	0.35	3.71e-8	Bipolar disorder;
SARC	cis	rs4561483	0.771	rs12924398	chr16:11972948	T/A	cg08843971	chr16:11963173	GSPT1	-0.42	-4.84	-0.3	2.39e-6	Testicular germ cell tumor;
SARC	cis	rs2769264	0.602	rs11204777	chr1:151072049	G/A	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.59	-5.39	-0.33	1.75e-7	Blood trace element (Cu levels);
SARC	cis	rs9831754	0.756	rs13084140	chr3:78426004	G/A	cg06138941	chr3:78371609	NA	-0.57	-6.86	-0.41	6.04e-11	Calcium levels;
SARC	cis	rs34375054	0.623	rs2297478	chr12:125591844	C/T	cg25124228	chr12:125621409	AACS	-0.49	-5.26	-0.33	3.31e-7	Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs7927771	0.524	rs4539273	chr11:47694699	C/T	cg10504702	chr11:47789108	FNBP4	-0.4	-5.21	-0.32	4.17e-7	Subjective well-being;
SARC	cis	rs13256369	0.950	rs13255655	chr8:8577736	C/T	cg17143192	chr8:8559678	CLDN23	0.54	5.78	0.35	2.44e-8	Obesity-related traits;
SARC	cis	rs897984	0.520	rs4889536	chr16:30871755	G/T	cg00531865	chr16:30841666	NA	0.45	4.76	0.3	3.47e-6	Dementia with Lewy bodies;
SARC	cis	rs870825	0.616	rs7694899	chr4:185625390	C/T	cg04058563	chr4:185651563	MLF1IP	0.82	11.59	0.6	8.07e-25	Blood protein levels;
SARC	cis	rs2404602	0.716	rs12437627	chr15:76845050	T/C	cg22467129	chr15:76604101	ETFA	-0.36	-4.78	-0.3	3.11e-6	Blood metabolite levels;
SARC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg26338869	chr17:61819248	STRADA	0.8	10.72	0.57	4.8e-22	Prudent dietary pattern;
SARC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg07092213	chr7:1199455	ZFAND2A	-0.44	-5.7	-0.35	3.52e-8	Longevity;Endometriosis;
SARC	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.97	-15.37	-0.71	2.85e-37	Chronic sinus infection;
SARC	cis	rs12908161	0.959	rs34784022	chr15:85231906	T/C	cg17507749	chr15:85114479	UBE2QP1	0.58	6.68	0.4	1.77e-10	Schizophrenia;
SARC	cis	rs2444240	0.967	rs470370	chr11:120013984	C/T	cg07435449	chr11:120005650	TRIM29	-0.28	-4.88	-0.3	1.94e-6	Corneal curvature;
SARC	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg22105103	chr4:187893119	NA	0.5	6.64	0.4	2.16e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs17209837	1.000	rs17149640	chr7:87086039	A/C	cg00919237	chr7:87102261	ABCB4	-0.5	-5.47	-0.34	1.14e-7	Gallbladder cancer;
SARC	cis	rs79349575	0.594	rs1985785	chr17:46967788	T/C	cg16584676	chr17:46985605	UBE2Z	0.54	6.45	0.39	6.25e-10	Type 2 diabetes;
SARC	cis	rs798554	0.660	rs2644295	chr7:2860217	A/C	cg04166393	chr7:2884313	GNA12	0.41	5.0	0.31	1.15e-6	Height;
SARC	cis	rs7681440	0.904	rs6817001	chr4:90766019	C/T	cg02192967	chr4:90758406	SNCA	0.36	5.13	0.32	6.11e-7	Dementia with Lewy bodies;
SARC	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.56	-7.2	-0.43	8.42e-12	Mean platelet volume;
SARC	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg11878867	chr6:150167359	LRP11	-0.34	-4.74	-0.3	3.72e-6	Lung cancer;
SARC	cis	rs995000	0.899	rs1168032	chr1:62967747	A/G	cg06896770	chr1:63153194	DOCK7	-0.89	-12.99	-0.65	2.12e-29	Triglyceride levels;
SARC	cis	rs7552404	0.924	rs1146588	chr1:76229787	C/G	cg22875332	chr1:76189707	ACADM	0.38	5.38	0.33	1.85e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg22535103	chr8:58192502	C8orf71	-0.59	-6.21	-0.38	2.35e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs12421382	0.593	rs2118973	chr11:109389231	G/A	cg16359550	chr11:109292809	C11orf87	0.34	5.14	0.32	5.73e-7	Schizophrenia;
SARC	cis	rs6964587	0.967	rs10248102	chr7:91699779	G/A	cg17063962	chr7:91808500	NA	0.96	16.21	0.73	4.33e-40	Breast cancer;
SARC	cis	rs13082711	0.522	rs646577	chr3:27352225	A/G	cg02860705	chr3:27208620	NA	0.44	5.88	0.36	1.4e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs78456975	0.943	rs13421238	chr2:1576879	G/A	cg12573674	chr2:1569213	NA	-0.57	-5.17	-0.32	4.92e-7	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs17376456	0.757	rs10066431	chr5:93198204	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.7	6.34	0.38	1.19e-9	Diabetic retinopathy;
SARC	cis	rs3096299	0.586	rs4572400	chr16:89533516	T/A	cg16743903	chr16:89593216	SPG7	-0.43	-5.9	-0.36	1.26e-8	Multiple myeloma (IgH translocation);
SARC	cis	rs1568889	0.838	rs11030187	chr11:28044391	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	14.72	0.69	4.15e-35	Bipolar disorder;
SARC	cis	rs76419734	1.000	rs11735851	chr4:106697254	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.8	5.33	0.33	2.27e-7	Post bronchodilator FEV1;
SARC	cis	rs1865760	1.000	rs9348698	chr6:25929689	T/A	cg16482183	chr6:26056742	HIST1H1C	0.52	6.38	0.39	9.52e-10	Height;
SARC	cis	rs3008870	1.000	rs3008853	chr1:67385488	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.93	11.5	0.6	1.61e-24	Lymphocyte percentage of white cells;
SARC	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg16405210	chr4:1374714	KIAA1530	0.51	6.18	0.38	2.85e-9	Obesity-related traits;
SARC	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-10.53	-0.57	1.88e-21	Chronic sinus infection;
SARC	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg19729930	chr2:74357872	NA	0.7	10.19	0.56	2.1e-20	Gestational age at birth (maternal effect);
SARC	cis	rs6696846	0.777	rs2369526	chr1:205054406	C/T	cg00857998	chr1:205179979	DSTYK	0.4	4.8	0.3	2.9e-6	Red blood cell count;
SARC	cis	rs9303401	0.580	rs34076823	chr17:57114497	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.98	9.95	0.55	1.16e-19	Cognitive test performance;
SARC	cis	rs7582720	1.000	rs6723704	chr2:203738664	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.19	0.43	8.82e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs9916302	0.861	rs33933929	chr17:37426441	A/C	cg20243544	chr17:37824526	PNMT	0.56	6.87	0.41	5.87e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs793571	0.666	rs544282	chr15:59022102	G/A	cg05156742	chr15:59063176	FAM63B	0.53	5.44	0.34	1.35e-7	Schizophrenia;
SARC	cis	rs6582630	0.555	rs11182148	chr12:38464883	A/C	cg13010199	chr12:38710504	ALG10B	0.74	10.06	0.55	5.41e-20	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg16049864	chr8:95962084	TP53INP1	-0.5	-8.19	-0.47	1.68e-14	Type 2 diabetes;
SARC	cis	rs1468333	0.724	rs12514307	chr5:137612143	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.77	10.34	0.56	7.12e-21	Resting heart rate;
SARC	cis	rs1008375	1.000	rs28693609	chr4:17645233	C/T	cg16339924	chr4:17578868	LAP3	0.69	9.26	0.52	1.4e-17	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg02725872	chr8:58115012	NA	-0.32	-4.73	-0.3	3.91e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs9400467	0.537	rs56272203	chr6:111492436	C/A	cg15721981	chr6:111408429	SLC16A10	0.69	5.89	0.36	1.34e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg22920501	chr2:26401640	FAM59B	-0.61	-8.19	-0.47	1.71e-14	Gut microbiome composition (summer);
SARC	cis	rs2153535	0.580	rs1335636	chr6:8465047	T/C	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs7647973	0.769	rs6772452	chr3:49040462	A/G	cg06212747	chr3:49208901	KLHDC8B	0.5	5.05	0.31	8.72e-7	Menarche (age at onset);
SARC	cis	rs7592578	0.640	rs56127319	chr2:191296429	G/A	cg27211696	chr2:191398769	TMEM194B	-0.48	-5.22	-0.32	4.01e-7	Diastolic blood pressure;
SARC	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg16405210	chr4:1374714	KIAA1530	-0.49	-5.69	-0.35	3.78e-8	Obesity-related traits;
SARC	cis	rs7647973	1.000	rs1982861	chr3:49577665	A/G	cg07636037	chr3:49044803	WDR6	0.75	8.41	0.48	4.23e-15	Menarche (age at onset);
SARC	cis	rs763121	0.853	rs2235230	chr22:39124467	A/G	cg21395723	chr22:39101663	GTPBP1	-0.53	-5.67	-0.35	4.3e-8	Menopause (age at onset);
SARC	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg11764359	chr7:65958608	NA	0.66	7.83	0.46	1.7e-13	Aortic root size;
SARC	cis	rs9486719	1.000	rs2064947	chr6:97052754	C/T	cg18709589	chr6:96969512	KIAA0776	-0.54	-5.63	-0.35	5.09e-8	Migraine;Coronary artery disease;
SARC	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg18876405	chr7:65276391	NA	0.49	6.04	0.37	6e-9	Aortic root size;
SARC	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg16414030	chr3:133502952	NA	-0.4	-5.46	-0.34	1.23e-7	Iron status biomarkers;
SARC	cis	rs6568686	0.627	rs113922733	chr6:111779448	T/C	cg15721981	chr6:111408429	SLC16A10	0.65	5.67	0.35	4.31e-8	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs453301	0.652	rs2043129	chr8:8825504	C/G	cg11995313	chr8:8860691	ERI1	-0.45	-5.39	-0.33	1.75e-7	Joint mobility (Beighton score);
SARC	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-6.01	-0.37	7.13e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg11317343	chr5:177580912	NHP2	0.53	6.8	0.41	8.58e-11	Lung adenocarcinoma;
SARC	cis	rs10870270	1.000	rs11146354	chr10:133774757	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.48	-5.41	-0.33	1.56e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs8031584	0.541	rs2959037	chr15:31218164	T/C	cg19680485	chr15:31195859	MTMR15	0.56	7.11	0.42	1.44e-11	Huntington's disease progression;
SARC	cis	rs6121246	0.542	rs75694362	chr20:30450708	T/C	cg09796376	chr20:30640595	HCK	0.62	5.3	0.33	2.69e-7	Mean corpuscular hemoglobin;
SARC	cis	rs9790314	0.645	rs10936224	chr3:160902531	G/A	cg04691961	chr3:161091175	C3orf57	-0.58	-7.56	-0.44	9.25e-13	Morning vs. evening chronotype;
SARC	cis	rs7130144	0.541	rs1921573	chr11:130461493	A/T	cg26307797	chr11:130446613	NA	-0.68	-5.72	-0.35	3.31e-8	Urate levels in lean individuals;
SARC	cis	rs4481887	0.962	rs4369256	chr1:248492274	G/A	cg13385794	chr1:248469461	NA	0.36	5.39	0.33	1.74e-7	Common traits (Other);
SARC	cis	rs1729951	0.575	rs835641	chr3:136703474	G/T	cg15507776	chr3:136538369	TMEM22	0.49	5.34	0.33	2.18e-7	Neuroticism;
SARC	cis	rs6558174	0.714	rs17674754	chr8:22533388	A/G	cg03733263	chr8:22462867	KIAA1967	0.63	6.37	0.39	9.84e-10	Breast cancer;
SARC	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg04772025	chr11:68637568	NA	0.55	7.0	0.42	2.72e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	trans	rs3808502	0.563	rs10098664	chr8:11417493	T/C	cg08975724	chr8:8085496	FLJ10661	0.49	6.29	0.38	1.54e-9	Neuroticism;
SARC	cis	rs2130392	0.926	rs10428357	chr4:185636217	T/A	cg21366198	chr4:185655624	MLF1IP	-0.38	-4.75	-0.3	3.51e-6	Kawasaki disease;
SARC	cis	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg07636037	chr3:49044803	WDR6	0.62	8.07	0.47	3.68e-14	Resting heart rate;
SARC	cis	rs6964587	0.758	rs35963176	chr7:91617115	C/T	cg17063962	chr7:91808500	NA	0.69	8.65	0.49	8.57e-16	Breast cancer;
SARC	cis	rs1270639	0.778	rs1796272	chr7:157437832	C/T	cg13357408	chr7:157437802	PTPRN2	-0.5	-5.31	-0.33	2.62e-7	Colorectal cancer;
SARC	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg22875332	chr1:76189707	ACADM	0.46	5.87	0.36	1.5e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	trans	rs9951602	0.512	rs12455591	chr18:76656028	A/G	cg02800362	chr5:177631904	HNRNPAB	0.71	9.02	0.51	7.01e-17	Obesity-related traits;
SARC	cis	rs11719291	0.504	rs34571182	chr3:49209057	T/A	cg07636037	chr3:49044803	WDR6	-0.75	-6.75	-0.4	1.16e-10	Cognitive function;
SARC	cis	rs6831352	0.918	rs17218108	chr4:100055755	T/C	cg12011299	chr4:100065546	ADH4	-0.34	-5.74	-0.35	2.95e-8	Alcohol dependence;
SARC	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg00684032	chr4:1343700	KIAA1530	0.4	5.85	0.36	1.65e-8	Obesity-related traits;
SARC	cis	rs2120019	0.567	rs68036747	chr15:75203200	A/C	cg00629941	chr15:75287862	SCAMP5	-0.59	-5.43	-0.34	1.38e-7	Blood trace element (Zn levels);
SARC	cis	rs2635047	0.682	rs7242976	chr18:44797159	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	6.37	0.39	9.75e-10	Educational attainment;
SARC	cis	rs6011674	1.000	rs45469101	chr20:61875007	C/T	cg06763829	chr20:61885236	FLJ16779;NKAIN4	0.72	5.29	0.33	2.78e-7	Response to cytadine analogues (cytosine arabinoside);
SARC	cis	rs1448094	0.580	rs11615323	chr12:86282171	T/C	cg02569458	chr12:86230093	RASSF9	0.43	5.83	0.36	1.84e-8	Major depressive disorder;
SARC	cis	rs4927850	1.000	rs4927848	chr3:195738406	A/G	cg00031303	chr3:195681400	NA	0.54	6.24	0.38	2.08e-9	Pancreatic cancer;
SARC	cis	rs9916302	0.904	rs4795356	chr17:37535631	C/T	cg15445000	chr17:37608096	MED1	-0.43	-5.16	-0.32	5.29e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs9911578	1.000	rs9915935	chr17:56843048	A/G	cg05425664	chr17:57184151	TRIM37	-0.65	-7.98	-0.46	6.82e-14	Intelligence (multi-trait analysis);
SARC	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.76	9.64	0.53	9.91e-19	Height;
SARC	cis	rs28386778	0.700	rs12452767	chr17:62010503	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.66	-7.82	-0.46	1.78e-13	Prudent dietary pattern;
SARC	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg12463550	chr7:65579703	CRCP	0.42	4.94	0.31	1.48e-6	Aortic root size;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg11417598	chr3:170714485	SLC2A2	0.48	6.52	0.39	4.37e-10	Thyroid stimulating hormone;
SARC	cis	rs2645694	0.626	rs2703120	chr4:77822470	G/A	cg03477792	chr4:77819574	ANKRD56	0.5	7.49	0.44	1.41e-12	Emphysema distribution in smoking;
SARC	cis	rs12681366	0.636	rs2921388	chr8:95452759	C/T	cg26464482	chr8:95565502	KIAA1429	0.44	5.34	0.33	2.2e-7	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs854765	0.693	rs8080061	chr17:17776389	C/T	cg04398451	chr17:18023971	MYO15A	0.44	6.37	0.39	9.82e-10	Total body bone mineral density;
SARC	cis	rs7647973	0.961	rs4955443	chr3:49286618	T/G	cg06212747	chr3:49208901	KLHDC8B	0.6	6.57	0.4	3.2e-10	Menarche (age at onset);
SARC	cis	rs11098499	0.530	rs114866537	chr4:120258608	A/T	cg09307838	chr4:120376055	NA	0.75	10.4	0.56	4.7e-21	Corneal astigmatism;
SARC	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg21747090	chr2:27597821	SNX17	-0.55	-7.73	-0.45	3.19e-13	Total body bone mineral density;
SARC	cis	rs17079773	1.000	rs17079773	chr13:24598384	A/G	cg25927529	chr13:24734778	SPATA13	-0.55	-5.11	-0.32	6.56e-7	Inattentive symptoms;
SARC	cis	rs8038465	0.638	rs12591473	chr15:73967485	A/T	cg15420318	chr15:73925796	NPTN	0.47	5.52	0.34	8.86e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9420	0.961	rs7116341	chr11:57481155	G/A	cg23127183	chr11:57508653	C11orf31	-0.55	-6.22	-0.38	2.3e-9	Schizophrenia;
SARC	cis	rs888194	0.690	rs877710	chr12:109993976	C/G	cg13986417	chr12:110012484	MVK;MMAB	-0.32	-4.78	-0.3	3.04e-6	Neuroticism;
SARC	cis	rs7408868	1.000	rs4809029	chr19:15273248	A/C	cg14696996	chr19:15285081	NOTCH3	1.06	8.68	0.49	6.85e-16	Pulse pressure;
SARC	cis	rs36051895	0.632	rs12337480	chr9:5134567	T/A	cg02405213	chr9:5042618	JAK2	-0.47	-5.78	-0.35	2.42e-8	Pediatric autoimmune diseases;
SARC	cis	rs7412746	0.611	rs11204748	chr1:150927369	G/T	cg15448220	chr1:150897856	SETDB1	0.52	6.76	0.4	1.1e-10	Melanoma;
SARC	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.72	8.45	0.48	3.21e-15	Height;
SARC	cis	rs365132	0.905	rs10068703	chr5:176377069	T/A	cg16309518	chr5:176445507	NA	-0.46	-5.98	-0.36	8.3e-9	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.69	-9.22	-0.52	1.83e-17	Chronic sinus infection;
SARC	cis	rs1215050	0.740	rs783929	chr4:98972495	T/A	cg05340658	chr4:99064831	C4orf37	-0.47	-6.47	-0.39	5.85e-10	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs6502050	0.761	rs11653003	chr17:80058795	G/T	cg19223190	chr17:80058835	NA	-0.46	-6.63	-0.4	2.28e-10	Life satisfaction;
SARC	trans	rs9325144	0.555	rs28738714	chr12:38706912	G/A	cg23762105	chr12:34175262	ALG10	0.48	6.24	0.38	2.02e-9	Morning vs. evening chronotype;
SARC	cis	rs959260	1.000	rs12604003	chr17:73399598	G/A	cg14668889	chr17:73230827	NUP85	-0.43	-4.83	-0.3	2.48e-6	Systemic lupus erythematosus;
SARC	cis	rs9325144	0.555	rs7977200	chr12:38713745	C/T	cg26384229	chr12:38710491	ALG10B	0.62	8.27	0.48	1.03e-14	Morning vs. evening chronotype;
SARC	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg11764359	chr7:65958608	NA	0.81	11.08	0.59	3.31e-23	Aortic root size;
SARC	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg12310025	chr6:25882481	NA	-0.46	-5.78	-0.35	2.38e-8	Intelligence (multi-trait analysis);
SARC	cis	rs1448094	0.935	rs4919775	chr12:86339985	T/C	cg02569458	chr12:86230093	RASSF9	0.4	5.84	0.36	1.75e-8	Major depressive disorder;
SARC	cis	rs6540556	0.723	rs6672256	chr1:209894043	A/T	cg23920097	chr1:209922102	NA	0.48	5.07	0.32	8.17e-7	Red blood cell count;
SARC	cis	rs2916247	0.954	rs7006836	chr8:93167342	C/T	cg10183463	chr8:93005414	RUNX1T1	0.46	4.95	0.31	1.42e-6	Intelligence (multi-trait analysis);
SARC	cis	rs10464366	0.544	rs953874	chr7:39147916	G/A	cg18850127	chr7:39170497	POU6F2	0.42	5.46	0.34	1.22e-7	IgG glycosylation;
SARC	cis	rs9896052	0.608	rs61264861	chr17:73459278	T/C	cg25649188	chr17:73499917	CASKIN2	0.36	5.04	0.31	9.14e-7	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg07636037	chr3:49044803	WDR6	1.01	17.84	0.76	1.85e-45	Parkinson's disease;
SARC	cis	rs11191193	0.710	rs35205878	chr10:103743133	G/A	cg15320455	chr10:103880129	LDB1	0.58	6.0	0.37	7.36e-9	Educational attainment;
SARC	trans	rs10829156	0.732	rs7100884	chr10:18812697	A/G	cg21448875	chr7:44104584	PGAM2	0.43	6.35	0.38	1.1e-9	Sudden cardiac arrest;
SARC	cis	rs2387326	0.671	rs10829346	chr10:129946104	C/T	cg16087940	chr10:129947807	NA	-0.46	-5.83	-0.36	1.88e-8	Select biomarker traits;
SARC	cis	rs3540	0.533	rs2352601	chr15:91053125	G/A	cg22089800	chr15:90895588	ZNF774	-0.61	-7.87	-0.46	1.3e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs9326248	0.813	rs7115562	chr11:117020470	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.59	5.9	0.36	1.27e-8	Blood protein levels;
SARC	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	11.69	0.61	3.92e-25	Alzheimer's disease;
SARC	cis	rs6546550	0.835	rs13002091	chr2:70118388	C/T	cg02498382	chr2:70120550	SNRNP27	-0.35	-5.64	-0.35	4.88e-8	Prevalent atrial fibrillation;
SARC	cis	rs2404602	0.684	rs57682236	chr15:76868478	G/A	cg15268244	chr15:77196840	NA	0.42	4.86	0.3	2.15e-6	Blood metabolite levels;
SARC	cis	rs56011263	0.687	rs11734460	chr4:705074	C/T	cg14024328	chr4:719362	PCGF3	-0.42	-5.69	-0.35	3.88e-8	White blood cell count;
SARC	trans	rs61931739	0.500	rs28624237	chr12:34457171	G/T	cg13010199	chr12:38710504	ALG10B	0.81	11.29	0.59	7.09e-24	Morning vs. evening chronotype;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg06117184	chr2:113522207	CKAP2L	-0.59	-6.68	-0.4	1.72e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs6088580	0.634	rs6088484	chr20:32985961	T/C	cg08999081	chr20:33150536	PIGU	-0.42	-6.39	-0.39	9.1e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg05368731	chr17:41323189	NBR1	0.78	9.52	0.53	2.33e-18	Menopause (age at onset);
SARC	cis	rs4713118	0.629	rs203887	chr6:28021269	C/T	cg26335602	chr6:28129616	ZNF389	0.6	5.93	0.36	1.08e-8	Parkinson's disease;
SARC	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg19223190	chr17:80058835	NA	-0.43	-6.02	-0.37	6.57e-9	Life satisfaction;
SARC	cis	rs4660306	0.961	rs4660864	chr1:45966582	C/T	cg24296786	chr1:45957014	TESK2	0.54	6.34	0.38	1.16e-9	Homocysteine levels;
SARC	cis	rs367943	0.965	rs644154	chr5:112799080	G/T	cg12552261	chr5:112820674	MCC	-0.49	-5.61	-0.35	5.63e-8	Type 2 diabetes;
SARC	cis	rs72781680	1.000	rs12614452	chr2:24194608	C/T	cg08917208	chr2:24149416	ATAD2B	0.79	7.55	0.44	9.78e-13	Lymphocyte counts;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg12424548	chr11:2591932	KCNQ1	0.47	6.65	0.4	2.02e-10	Schizophrenia;
SARC	cis	rs9911578	0.902	rs12948746	chr17:57071892	A/G	cg12560992	chr17:57184187	TRIM37	0.89	12.66	0.64	2.75e-28	Intelligence (multi-trait analysis);
SARC	cis	rs7264396	0.563	rs6060558	chr20:34271092	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.67	0.35	4.26e-8	Total cholesterol levels;
SARC	cis	rs35306767	0.903	rs12250937	chr10:900209	C/T	cg26597838	chr10:835615	NA	0.83	8.54	0.49	1.78e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs72949976	0.678	rs7573232	chr2:214040425	C/T	cg08319019	chr2:214017104	IKZF2	-0.43	-5.15	-0.32	5.61e-7	Lung cancer;Squamous cell lung carcinoma;
SARC	cis	rs8014204	0.533	rs12889955	chr14:75172999	G/A	cg17347104	chr14:75034677	LTBP2	-0.5	-6.75	-0.4	1.14e-10	Caffeine consumption;
SARC	cis	rs9303401	0.659	rs35797125	chr17:56736547	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	11.6	0.6	7.63e-25	Cognitive test performance;
SARC	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg17971929	chr21:40555470	PSMG1	-0.6	-7.67	-0.45	4.52e-13	Menarche (age at onset);
SARC	cis	rs668210	0.793	rs1151514	chr11:65758854	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	5.49	0.34	1.06e-7	Cerebrospinal fluid biomarker levels;
SARC	cis	rs28655083	0.828	rs11640648	chr16:77122494	T/C	cg01504555	chr16:77246968	SYCE1L	0.39	5.03	0.31	9.95e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7826238	0.594	rs2948285	chr8:8130538	A/T	cg15556689	chr8:8085844	FLJ10661	0.56	7.13	0.42	1.22e-11	Systolic blood pressure;
SARC	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg13939156	chr17:80058883	NA	-0.41	-6.39	-0.39	8.7e-10	Life satisfaction;
SARC	cis	rs6831352	0.918	rs13110764	chr4:100062466	C/T	cg13256891	chr4:100009986	ADH5	-0.63	-7.93	-0.46	8.97e-14	Alcohol dependence;
SARC	cis	rs4555082	1.000	rs4277291	chr14:105759009	A/G	cg06808227	chr14:105710500	BRF1	-0.45	-5.59	-0.34	6.45e-8	Mean platelet volume;Platelet distribution width;
SARC	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg05368731	chr17:41323189	NBR1	0.81	9.9	0.54	1.66e-19	Menopause (age at onset);
SARC	cis	rs13082711	0.863	rs35797268	chr3:27418862	T/C	cg02860705	chr3:27208620	NA	0.49	6.3	0.38	1.46e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	23.01	0.83	6.44e-62	Chronic sinus infection;
SARC	trans	rs7615952	0.932	rs1976458	chr3:125647512	T/G	cg07211511	chr3:129823064	LOC729375	-0.98	-10.96	-0.58	8.38e-23	Blood pressure (smoking interaction);
SARC	cis	rs6570726	0.791	rs6902410	chr6:145905261	G/A	cg05347473	chr6:146136440	FBXO30	0.52	7.31	0.43	4.32e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg05623727	chr3:50126028	RBM5	-0.34	-5.27	-0.33	3.18e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.41	-5.27	-0.33	3.07e-7	Lymphocyte counts;
SARC	cis	rs950169	0.960	rs12905475	chr15:84800495	G/A	cg24253500	chr15:84953950	NA	0.39	5.51	0.34	9.52e-8	Schizophrenia;
SARC	trans	rs61931739	0.517	rs7313663	chr12:34417058	T/C	cg13010199	chr12:38710504	ALG10B	0.75	10.66	0.57	7.34e-22	Morning vs. evening chronotype;
SARC	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg03188948	chr7:1209495	NA	0.57	5.14	0.32	5.88e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs9902453	0.904	rs12936302	chr17:28349476	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.54	-7.02	-0.42	2.35e-11	Coffee consumption (cups per day);
SARC	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg26924012	chr15:45694286	SPATA5L1	0.77	10.99	0.58	6.8e-23	Homoarginine levels;
SARC	cis	rs965469	1.000	rs3310	chr20:3237232	C/T	cg25506879	chr20:3388711	C20orf194	-0.56	-5.48	-0.34	1.12e-7	IFN-related cytopenia;
SARC	cis	rs2370759	1.000	rs2769241	chr10:32556229	T/C	cg18270830	chr10:32634957	EPC1	-0.59	-5.14	-0.32	5.76e-7	Sexual dysfunction (female);
SARC	cis	rs501120	0.733	rs587375	chr10:44745808	T/C	cg09554077	chr10:44749378	NA	0.47	6.48	0.39	5.32e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg21724239	chr8:58056113	NA	0.6	6.37	0.38	1.03e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg00684032	chr4:1343700	KIAA1530	0.36	5.26	0.33	3.21e-7	Obesity-related traits;
SARC	cis	rs908922	0.636	rs474086	chr1:152513431	C/T	cg09873164	chr1:152488093	CRCT1	0.66	8.74	0.5	4.81e-16	Hair morphology;
SARC	cis	rs78456975	0.943	rs13385274	chr2:1576791	A/T	cg26248373	chr2:1572462	NA	-0.58	-5.98	-0.36	8.14e-9	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs7027203	0.538	rs10125195	chr9:96523224	T/C	cg14598338	chr9:96623480	NA	-0.34	-4.76	-0.3	3.43e-6	DNA methylation (variation);
SARC	trans	rs7239883	1.000	rs7239883	chr18:40147671	A/G	cg23679141	chr4:165118930	MARCH1;ANP32C	-0.48	-6.32	-0.38	1.32e-9	Waist circumference;Body mass index;
SARC	cis	rs137699	0.959	rs5757633	chr22:39756270	A/G	cg24399712	chr22:39784796	NA	-0.35	-5.1	-0.32	6.99e-7	IgG glycosylation;
SARC	cis	rs228769	1.000	rs12937692	chr17:42256430	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	0.72	8.91	0.5	1.46e-16	Bone mineral density (hip);Bone mineral density (spine);
SARC	cis	rs826838	0.935	rs11168761	chr12:38997211	C/A	cg13010199	chr12:38710504	ALG10B	0.77	10.85	0.58	1.82e-22	Heart rate;
SARC	cis	rs13343954	0.825	rs7254716	chr19:33532128	T/C	cg24009623	chr19:33667908	NA	0.45	4.84	0.3	2.36e-6	Colorectal cancer;
SARC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg02018176	chr4:1364513	KIAA1530	-0.59	-8.98	-0.51	9.22e-17	Longevity;
SARC	cis	rs4851254	0.695	rs12712069	chr2:100766354	C/G	cg17356467	chr2:100759845	AFF3	0.29	4.8	0.3	2.8e-6	Intelligence (multi-trait analysis);
SARC	cis	rs67311347	1.000	rs9332450	chr3:40458041	C/T	cg24209194	chr3:40518798	ZNF619	-0.66	-8.73	-0.5	5.02e-16	Renal cell carcinoma;
SARC	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg18305652	chr10:134549665	INPP5A	0.34	4.98	0.31	1.21e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg23069120	chr6:71559905	SMAP1	-0.52	-6.34	-0.38	1.17e-9	Alcohol dependence;
SARC	cis	rs3106136	0.527	rs10030586	chr4:95150805	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.47	-7.05	-0.42	2.06e-11	Capecitabine sensitivity;
SARC	cis	rs66573146	1.000	rs55672215	chr4:6970529	T/C	cg00086871	chr4:6988644	TBC1D14	0.89	5.2	0.32	4.46e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg19223190	chr17:80058835	NA	-0.43	-5.93	-0.36	1.06e-8	Life satisfaction;
SARC	cis	rs7582180	0.629	rs12612809	chr2:100951616	G/T	cg14675211	chr2:100938903	LONRF2	0.51	7.63	0.45	6.1e-13	Intelligence (multi-trait analysis);
SARC	cis	rs6088590	0.561	rs6059934	chr20:33178324	G/T	cg08999081	chr20:33150536	PIGU	0.45	6.82	0.41	7.78e-11	Coronary artery disease;
SARC	cis	rs918629	0.530	rs11738768	chr5:95237780	C/A	cg16656078	chr5:95278638	ELL2	-0.58	-6.94	-0.41	3.89e-11	IgG glycosylation;
SARC	cis	rs11098499	0.863	rs7657849	chr4:120455494	T/C	cg24375607	chr4:120327624	NA	0.42	4.9	0.31	1.76e-6	Corneal astigmatism;
SARC	cis	rs372883	0.648	rs1153288	chr21:30686091	A/G	cg24692254	chr21:30365293	RNF160	0.65	8.17	0.47	2.01e-14	Pancreatic cancer;
SARC	cis	rs9911578	1.000	rs302848	chr17:56686454	C/T	cg05425664	chr17:57184151	TRIM37	-0.68	-8.43	-0.48	3.68e-15	Intelligence (multi-trait analysis);
SARC	trans	rs7824557	0.527	rs11785394	chr8:11238029	C/T	cg06636001	chr8:8085503	FLJ10661	-0.61	-8.05	-0.47	4.2e-14	Retinal vascular caliber;
SARC	cis	rs2180341	0.960	rs7773484	chr6:127670779	T/C	cg27446573	chr6:127587934	RNF146	1.05	14.53	0.69	1.75e-34	Breast cancer;
SARC	cis	rs554111	0.656	rs10753514	chr1:21492531	T/C	cg04902671	chr1:21058625	SH2D5	0.44	5.42	0.33	1.48e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.72	8.42	0.48	3.8e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2304069	0.954	rs1433010	chr5:149383954	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.9	-9.61	-0.53	1.26e-18	HIV-1 control;
SARC	cis	rs875971	0.965	rs697968	chr7:65535033	G/A	cg11987759	chr7:65425863	GUSB	0.43	5.69	0.35	3.81e-8	Aortic root size;
SARC	cis	rs3218477	1.000	rs3218477	chr7:152357059	C/T	cg06618968	chr7:152373420	XRCC2	-0.71	-4.72	-0.3	4.13e-6	Mean platelet volume;
SARC	cis	rs10782582	0.586	rs1856791	chr1:76308942	C/T	cg03433033	chr1:76189801	ACADM	-0.39	-4.98	-0.31	1.24e-6	Daytime sleep phenotypes;
SARC	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg11987759	chr7:65425863	GUSB	-0.48	-6.21	-0.38	2.36e-9	Aortic root size;
SARC	cis	rs1008375	0.800	rs62296338	chr4:17613425	G/T	cg16339924	chr4:17578868	LAP3	0.65	8.5	0.49	2.27e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs11638352	0.661	rs2706486	chr15:44428982	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.66	-5.49	-0.34	1.05e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg03517284	chr6:25882590	NA	-0.41	-5.36	-0.33	2.02e-7	Intelligence (multi-trait analysis);
SARC	trans	rs2727020	0.612	rs603672	chr11:49234566	T/A	cg03929089	chr4:120376271	NA	0.73	10.23	0.56	1.61e-20	Coronary artery disease;
SARC	cis	rs3106136	0.843	rs6840479	chr4:95275842	A/G	cg11021082	chr4:95130006	SMARCAD1	0.35	5.43	0.33	1.45e-7	Capecitabine sensitivity;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg03758918	chr6:45389877	RUNX2	0.53	6.64	0.4	2.13e-10	Lung adenocarcinoma;
SARC	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg27266027	chr21:40555129	PSMG1	0.5	5.44	0.34	1.31e-7	Cognitive function;
SARC	cis	rs3008870	0.920	rs2755253	chr1:67470843	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.69	8.19	0.47	1.76e-14	Lymphocyte percentage of white cells;
SARC	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg00990874	chr7:1149470	C7orf50	-0.62	-6.49	-0.39	5.1e-10	Bronchopulmonary dysplasia;
SARC	cis	rs7914558	1.000	rs4917994	chr10:104811699	C/T	cg04362960	chr10:104952993	NT5C2	0.42	5.08	0.32	7.7300000000000005e-07	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	trans	rs3733589	0.744	rs3775939	chr4:10025296	C/G	cg13168698	chr15:77481069	SGK269	0.77	6.34	0.38	1.17e-9	Renal overload gout;
SARC	cis	rs2479724	0.846	rs2254474	chr6:41843044	T/G	cg17623882	chr6:41773611	USP49	-0.46	-5.56	-0.34	7.45e-8	Menarche (age at onset);
SARC	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg00684032	chr4:1343700	KIAA1530	0.34	4.85	0.3	2.3e-6	Obesity-related traits;
SARC	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg21724239	chr8:58056113	NA	0.63	6.04	0.37	6.05e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7614311	0.731	rs1053338	chr3:63967900	A/G	cg22134162	chr3:63841271	THOC7	-0.47	-5.11	-0.32	6.75e-7	Lung function (FVC);Lung function (FEV1);
SARC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg11494091	chr17:61959527	GH2	0.54	8.07	0.47	3.81e-14	Prudent dietary pattern;
SARC	cis	rs748404	0.660	rs690367	chr15:43748304	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.5	-5.72	-0.35	3.32e-8	Lung cancer;
SARC	cis	rs1401999	1.000	rs6804242	chr3:183659463	A/T	cg01324343	chr3:183735012	ABCC5	0.67	13.44	0.66	7.1e-31	Anterior chamber depth;
SARC	cis	rs6582630	0.537	rs11520294	chr12:38402705	C/A	cg13010199	chr12:38710504	ALG10B	0.78	10.51	0.57	2.15e-21	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg06221963	chr1:154839813	KCNN3	-0.53	-8.66	-0.49	8.2e-16	Prostate cancer;
SARC	cis	rs11599315	0.507	rs12220554	chr10:1341852	C/T	cg09624528	chr10:1369823	ADARB2	0.43	6.79	0.41	9.47e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs6772849	0.930	rs68090762	chr3:128343907	C/T	cg08795948	chr3:128337044	NA	0.55	7.78	0.45	2.41e-13	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs7607369	0.648	rs55983650	chr2:219654932	T/C	cg02176678	chr2:219576539	TTLL4	-0.52	-8.35	-0.48	6.11e-15	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs7089973	0.604	rs10885618	chr10:116617718	A/G	cg03647239	chr10:116582469	FAM160B1	0.54	7.03	0.42	2.32e-11	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs7949030	1.000	rs10897289	chr11:62400016	T/C	cg13298116	chr11:62369859	EML3;MTA2	0.42	6.14	0.37	3.6e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs425277	0.958	rs262652	chr1:2090816	T/C	cg24578937	chr1:2090814	PRKCZ	0.32	5.97	0.36	8.76e-9	Height;
SARC	cis	rs2933343	1.000	rs789237	chr3:128636961	A/C	cg25356066	chr3:128598488	ACAD9	0.6	6.92	0.41	4.4e-11	IgG glycosylation;
SARC	cis	rs4268898	0.571	rs1986478	chr2:24468545	G/A	cg26838691	chr2:24397539	C2orf84	-0.5	-5.68	-0.35	3.96e-8	Asthma;
SARC	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg06634786	chr22:41940651	POLR3H	0.57	6.72	0.4	1.41e-10	Vitiligo;
SARC	cis	rs698833	0.892	rs2603257	chr2:44731588	T/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.68	8.27	0.48	1.02e-14	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs9911578	0.835	rs1476596	chr17:56485358	C/T	cg12560992	chr17:57184187	TRIM37	0.78	9.97	0.55	1.01e-19	Intelligence (multi-trait analysis);
SARC	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.69	-9.22	-0.52	1.83e-17	Chronic sinus infection;
SARC	cis	rs60871478	1.000	rs62432224	chr7:788284	G/A	cg19087971	chr7:751233	PRKAR1B	-0.44	-5.0	-0.31	1.11e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs6570726	0.791	rs11759979	chr6:145918881	C/T	cg23711669	chr6:146136114	FBXO30	0.85	13.62	0.67	1.83e-31	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4742903	0.509	rs1450674	chr9:106948674	T/C	cg14250997	chr9:106856677	SMC2	0.39	4.83	0.3	2.5e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs8114671	0.528	rs6119542	chr20:33484545	G/T	cg08999081	chr20:33150536	PIGU	0.33	4.89	0.3	1.9e-6	Height;
SARC	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg22535103	chr8:58192502	C8orf71	-0.66	-5.85	-0.36	1.65e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs17376456	0.877	rs9314099	chr5:93447375	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.79	0.35	2.3e-8	Diabetic retinopathy;
SARC	cis	rs319690	1	rs319690	chr3:47927484	T/C	cg11946769	chr3:48343235	NME6	0.45	5.16	0.32	5.26e-7	Blood pressure;Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs7568458	0.663	rs699664	chr2:85780536	A/G	cg02493740	chr2:85810744	VAMP5	0.39	5.16	0.32	5.25e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs2952156	0.920	rs2517951	chr17:37853097	C/T	cg00129232	chr17:37814104	STARD3	-0.69	-9.47	-0.53	3.25e-18	Asthma;
SARC	cis	rs79149102	0.649	rs8039046	chr15:75096352	A/G	cg09165964	chr15:75287851	SCAMP5	-0.88	-5.05	-0.31	9.08e-7	Lung cancer;
SARC	cis	rs2976388	0.609	rs2572899	chr8:143785549	A/G	cg06565975	chr8:143823917	SLURP1	0.31	5.45	0.34	1.27e-7	Urinary tract infection frequency;
SARC	cis	rs7945705	0.846	rs4929912	chr11:8816695	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.4	-5.22	-0.32	3.89e-7	Hemoglobin concentration;
SARC	cis	rs911555	0.755	rs8018400	chr14:103901085	A/G	cg12935359	chr14:103987150	CKB	0.41	5.6	0.34	6.08e-8	Intelligence (multi-trait analysis);
SARC	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg18758796	chr5:131593413	PDLIM4	0.36	4.83	0.3	2.45e-6	Breast cancer;
SARC	cis	rs2425143	0.730	rs6579259	chr20:34462550	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-5.78	-0.35	2.42e-8	Blood protein levels;
SARC	cis	rs11700980	0.636	rs115245768	chr21:30256118	T/G	cg24692254	chr21:30365293	RNF160	-0.65	-4.92	-0.31	1.61e-6	QRS complex (12-leadsum);
SARC	cis	rs9788682	0.747	rs2568488	chr15:78736593	T/A	cg06917634	chr15:78832804	PSMA4	0.52	5.41	0.33	1.55e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs9388451	0.872	rs2008027	chr6:126052359	A/G	cg06289844	chr6:126071538	HEY2	0.38	6.24	0.38	2.05e-9	Brugada syndrome;
SARC	cis	rs2070488	0.965	rs13079145	chr3:38517992	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	14.13	0.68	3.79e-33	Electrocardiographic conduction measures;
SARC	cis	rs7659604	1.000	rs28640980	chr4:122664284	T/C	cg20573242	chr4:122745356	CCNA2	0.44	5.81	0.36	2.08e-8	Type 2 diabetes;
SARC	cis	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg02487422	chr3:49467188	NICN1	0.52	6.94	0.41	3.82e-11	Resting heart rate;
SARC	cis	rs9398803	0.965	rs9388486	chr6:126661154	C/T	cg20229609	chr6:126660872	C6orf173	-0.38	-5.45	-0.34	1.29e-7	Male-pattern baldness;
SARC	cis	rs7095944	0.582	rs10901823	chr10:126488660	C/T	cg08799069	chr10:126477246	METTL10	-0.37	-4.83	-0.3	2.47e-6	Asthma;
SARC	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg13175981	chr1:150552382	MCL1	-0.54	-6.9	-0.41	4.97e-11	Tonsillectomy;
SARC	cis	rs9796	0.870	rs2412572	chr15:41264426	G/C	cg18705301	chr15:41695430	NDUFAF1	0.42	5.77	0.35	2.53e-8	Menopause (age at onset);
SARC	cis	rs6120849	0.754	rs1885117	chr20:33600740	C/T	cg06115741	chr20:33292138	TP53INP2	0.55	5.21	0.32	4.16e-7	Protein C levels;
SARC	cis	rs6732160	0.774	rs1367291	chr2:73374865	A/T	cg01422370	chr2:73384389	NA	0.32	5.3	0.33	2.7e-7	Intelligence (multi-trait analysis);
SARC	cis	rs10875746	0.951	rs10875748	chr12:48526360	A/G	cg27446233	chr12:48516484	PFKM	-0.41	-4.72	-0.3	3.99e-6	Longevity (90 years and older);
SARC	cis	rs55883249	1.000	rs75139639	chr2:9763905	A/T	cg23886495	chr2:9695866	ADAM17	0.66	6.68	0.4	1.72e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg22903657	chr4:1355424	KIAA1530	-0.36	-4.86	-0.3	2.14e-6	Obesity-related traits;
SARC	cis	rs9660992	0.674	rs1151784	chr1:205232447	C/T	cg07972983	chr1:205091412	RBBP5	0.56	6.69	0.4	1.6e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs2576037	0.899	rs2060417	chr18:44576486	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.66	-9.22	-0.52	1.78e-17	Personality dimensions;
SARC	cis	rs9486719	0.948	rs2472906	chr6:96875318	G/T	cg06623918	chr6:96969491	KIAA0776	0.73	8.01	0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs2735413	0.918	rs4888728	chr16:78077199	C/G	cg04733911	chr16:78082701	NA	-0.31	-5.61	-0.34	5.78e-8	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.08	22.63	0.83	9.78e-61	Chronic sinus infection;
SARC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg07414643	chr4:187882934	NA	0.52	7.86	0.46	1.42e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3812831	0.695	rs7998546	chr13:114939914	C/G	cg08824895	chr13:115047677	UPF3A	0.55	6.85	0.41	6.56e-11	Schizophrenia;
SARC	cis	rs1008375	0.931	rs3796814	chr4:17602033	G/C	cg02297831	chr4:17616191	MED28	0.5	6.36	0.38	1.07e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9325144	0.554	rs7960616	chr12:39096664	T/A	cg26384229	chr12:38710491	ALG10B	-0.59	-7.56	-0.44	9.46e-13	Morning vs. evening chronotype;
SARC	cis	rs2688419	0.527	rs2171030	chr3:23083720	A/G	cg00327796	chr3:23032191	NA	-0.4	-5.67	-0.35	4.15e-8	Type 2 diabetes;
SARC	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg19748678	chr4:122722346	EXOSC9	0.78	9.78	0.54	3.92e-19	Type 2 diabetes;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg02372393	chr17:45973417	SP2	0.59	7.66	0.45	4.98e-13	Lung adenocarcinoma;
SARC	cis	rs56235845	0.694	rs11738681	chr5:176761535	A/G	cg17509989	chr5:176798049	RGS14	0.55	7.59	0.45	7.56e-13	Hemoglobin concentration;Hematocrit;
SARC	cis	rs950169	0.526	rs698620	chr15:85177208	G/A	cg17507749	chr15:85114479	UBE2QP1	-0.5	-5.9	-0.36	1.29e-8	Schizophrenia;
SARC	cis	rs7044106	0.762	rs3903886	chr9:123383646	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.44	-5.6	-0.34	6.16e-8	Hip circumference adjusted for BMI;
SARC	cis	rs10463554	0.857	rs3776871	chr5:102292211	C/T	cg23492399	chr5:102201601	PAM	-0.46	-5.59	-0.34	6.35e-8	Parkinson's disease;
SARC	trans	rs79976124	0.876	rs17511913	chr6:66644361	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.67	7.61	0.45	6.85e-13	Type 2 diabetes;
SARC	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-8.45	-0.48	3.14e-15	Chronic sinus infection;
SARC	cis	rs7696431	0.575	rs17542688	chr4:169689516	A/G	cg07840446	chr4:169690674	PALLD	-0.32	-4.73	-0.3	3.92e-6	Coronary artery disease;
SARC	cis	rs2836974	0.565	rs34304022	chr21:40579619	G/A	cg11890956	chr21:40555474	PSMG1	0.87	7.77	0.45	2.57e-13	Cognitive function;
SARC	cis	rs12142240	0.698	rs55971480	chr1:46823206	G/T	cg14993813	chr1:46806288	NSUN4	-0.51	-5.34	-0.33	2.19e-7	Menopause (age at onset);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg11789864	chr1:229694784	ABCB10	0.48	6.28	0.38	1.6e-9	Thyroid stimulating hormone;
SARC	cis	rs4689388	0.926	rs4688986	chr4:6285797	C/A	cg25554036	chr4:6271136	WFS1	0.44	7.3	0.43	4.53e-12	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs10988449	0.891	rs7025011	chr9:132393271	G/T	cg18327994	chr9:132372705	NA	-0.5	-5.05	-0.31	9e-7	Response to anti-depressant treatment in major depressive disorder;
SARC	cis	rs9640161	0.783	rs1132261	chr7:150059987	G/A	cg21361702	chr7:150065534	REPIN1	0.59	6.85	0.41	6.36e-11	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs1881797	1.000	rs7527856	chr1:247688139	C/T	cg11166453	chr1:247681781	NA	0.46	5.16	0.32	5.31e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs637571	0.522	rs606978	chr11:65711517	A/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.55	8.52	0.49	2.07e-15	Eosinophil percentage of white cells;
SARC	cis	rs13031619	0.650	rs6542617	chr2:3694932	C/T	cg19052272	chr2:3704530	ALLC	0.33	4.75	0.3	3.54e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
SARC	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.93	-13.87	-0.67	2.78e-32	Gut microbiome composition (summer);
SARC	cis	rs6088580	0.634	rs6059875	chr20:33086090	T/G	cg24642439	chr20:33292090	TP53INP2	0.66	8.68	0.49	6.79e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg15145296	chr3:125709740	NA	-0.45	-4.78	-0.3	3.06e-6	Blood pressure (smoking interaction);
SARC	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg20607798	chr8:58055168	NA	0.57	5.45	0.34	1.3e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs11098499	0.909	rs10002083	chr4:120311152	C/T	cg09160332	chr4:120329925	NA	-0.33	-4.77	-0.3	3.27e-6	Corneal astigmatism;
SARC	cis	rs634534	0.561	rs655744	chr11:65776585	G/T	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.81	-11.86	-0.61	1.05e-25	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs2153535	0.580	rs6938071	chr6:8464845	A/T	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	cis	rs17401966	0.838	rs946501	chr1:10309580	C/G	cg15208524	chr1:10270712	KIF1B	0.45	5.29	0.33	2.79e-7	Hepatocellular carcinoma;
SARC	cis	rs7666738	0.830	rs1527517	chr4:98931907	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs11190604	1.000	rs2489047	chr10:102347028	A/G	cg07080220	chr10:102295463	HIF1AN	0.73	8.49	0.49	2.44e-15	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs2549003	1.000	rs2070724	chr5:131822072	A/G	cg21138405	chr5:131827807	IRF1	0.27	5.32	0.33	2.4e-7	Asthma (sex interaction);
SARC	cis	rs73086581	0.898	rs11906452	chr20:3981559	A/G	cg02187196	chr20:3869020	PANK2	0.53	5.04	0.31	9.17e-7	Response to antidepressants in depression;
SARC	cis	rs7089973	0.604	rs10490909	chr10:116593532	C/T	cg03647239	chr10:116582469	FAM160B1	0.5	6.49	0.39	5.09e-10	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg02018176	chr4:1364513	KIAA1530	0.6	9.34	0.52	8.09e-18	Longevity;
SARC	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg22509189	chr2:225307070	NA	0.68	8.33	0.48	6.78e-15	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs8016982	0.633	rs4363794	chr14:81674327	C/A	cg01989461	chr14:81687754	GTF2A1	0.74	10.87	0.58	1.55e-22	Schizophrenia;
SARC	cis	rs2976388	0.669	rs2976391	chr8:143762724	C/A	cg06565975	chr8:143823917	SLURP1	0.29	4.96	0.31	1.33e-6	Urinary tract infection frequency;
SARC	cis	rs9868809	0.656	rs73078362	chr3:48703917	G/C	cg12468774	chr3:49236860	CCDC36	0.59	4.99	0.31	1.16e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg06028808	chr11:68637592	NA	0.43	5.44	0.34	1.32e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg07701084	chr6:150067640	NUP43	0.41	5.45	0.34	1.29e-7	Lung cancer;
SARC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg11905131	chr22:24372483	LOC391322	-0.54	-6.21	-0.38	2.37e-9	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs3126085	0.935	rs7537637	chr1:152223335	T/A	cg03465714	chr1:152285911	FLG	-0.44	-5.34	-0.33	2.26e-7	Atopic dermatitis;
SARC	cis	rs12477438	0.677	rs12475034	chr2:99699464	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-8.21	-0.47	1.5e-14	Chronic sinus infection;
SARC	cis	rs524281	0.861	rs10750778	chr11:65948648	T/C	cg14036092	chr11:66035641	RAB1B	-0.5	-5.46	-0.34	1.23e-7	Electroencephalogram traits;
SARC	cis	rs568617	0.953	rs1151519	chr11:65645831	G/C	cg00576331	chr11:65640516	EFEMP2	0.47	5.45	0.34	1.27e-7	Crohn's disease;
SARC	cis	rs9467773	0.967	rs6456732	chr6:26514445	T/C	cg11502198	chr6:26597334	ABT1	0.47	5.93	0.36	1.1e-8	Intelligence (multi-trait analysis);
SARC	cis	rs526231	0.543	rs60633061	chr5:102330049	C/T	cg23492399	chr5:102201601	PAM	-0.52	-6.36	-0.38	1.03e-9	Primary biliary cholangitis;
SARC	trans	rs877282	0.898	rs35743076	chr10:758991	C/T	cg22713356	chr15:30763199	NA	0.95	9.75	0.54	4.53e-19	Uric acid levels;
SARC	cis	rs6910061	0.956	rs61185321	chr6:11103103	T/G	cg27233058	chr6:11094804	LOC221710	0.58	5.59	0.34	6.22e-8	Diabetic kidney disease;
SARC	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg26354017	chr1:205819088	PM20D1	0.43	4.79	0.3	2.94e-6	Parkinson's disease;
SARC	cis	rs10504229	0.679	rs1596142	chr8:58032406	G/A	cg11062466	chr8:58055876	NA	0.51	5.02	0.31	1.03e-6	Developmental language disorder (linguistic errors);
SARC	trans	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg07211511	chr3:129823064	LOC729375	-0.63	-6.9	-0.41	4.82e-11	Blood pressure (smoking interaction);
SARC	cis	rs10992471	0.528	rs10514815	chr9:95256695	C/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.42	-4.75	-0.3	3.6e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs17270561	0.609	rs4711103	chr6:25742224	C/T	cg17691542	chr6:26056736	HIST1H1C	0.61	7.36	0.43	3.06e-12	Iron status biomarkers;
SARC	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.68	6.53	0.39	4.09e-10	Platelet count;
SARC	cis	rs2486288	0.656	rs8024620	chr15:45574329	C/T	cg19305227	chr15:45544335	SLC28A2	0.3	5.63	0.35	5.06e-8	Glomerular filtration rate;
SARC	cis	rs892961	1.000	rs11077907	chr17:75400706	G/A	cg05865280	chr17:75406074	SEPT9	0.5	6.8	0.41	8.87e-11	Airflow obstruction;
SARC	cis	rs9486715	0.830	rs4425602	chr6:96893906	G/A	cg18709589	chr6:96969512	KIAA0776	0.59	7.33	0.43	3.8e-12	Headache;
SARC	cis	rs2635047	0.967	rs2571016	chr18:44639175	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.59	-8.11	-0.47	2.82e-14	Educational attainment;
SARC	cis	rs7560272	0.723	rs1052161	chr2:73828538	A/G	cg20560298	chr2:73613845	ALMS1	-0.52	-7.01	-0.42	2.59e-11	Schizophrenia;
SARC	cis	rs7811528	0.656	rs58091069	chr7:2705879	C/T	cg11411865	chr7:2701802	TTYH3	0.63	5.86	0.36	1.54e-8	Schizophrenia;
SARC	cis	rs861020	0.630	rs655712	chr1:210006437	G/A	cg23166289	chr1:210001082	C1orf107	0.39	4.74	0.3	3.66e-6	Orofacial clefts;
SARC	cis	rs921968	0.509	rs10932782	chr2:219353195	C/T	cg02176678	chr2:219576539	TTLL4	0.46	7.12	0.42	1.33e-11	Mean corpuscular hemoglobin concentration;
SARC	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg23758822	chr17:41437982	NA	0.88	11.24	0.59	1.04e-23	Menopause (age at onset);
SARC	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg09359103	chr1:154839909	KCNN3	-0.46	-7.7	-0.45	3.87e-13	Prostate cancer;
SARC	cis	rs2204008	0.515	rs11495471	chr12:38027178	G/A	cg13010199	chr12:38710504	ALG10B	0.78	10.65	0.57	7.8e-22	Bladder cancer;
SARC	cis	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg21144161	chr5:423903	AHRR	0.31	4.84	0.3	2.39e-6	Cystic fibrosis severity;
SARC	cis	rs9858542	0.953	rs7633271	chr3:49555963	T/C	cg03060546	chr3:49711283	APEH	-0.58	-7.35	-0.43	3.35e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs918629	0.761	rs7705720	chr5:95280033	T/C	cg16656078	chr5:95278638	ELL2	-0.69	-8.14	-0.47	2.38e-14	IgG glycosylation;
SARC	cis	rs7681440	0.933	rs10005233	chr4:90743331	C/T	cg02192967	chr4:90758406	SNCA	0.34	4.75	0.3	3.53e-6	Dementia with Lewy bodies;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg13279858	chr6:4135753	PECI	-0.78	-6.41	-0.39	7.84e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7043114	0.525	rs7869742	chr9:95256174	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-5.47	-0.34	1.13e-7	Height;
SARC	cis	rs7766436	0.614	rs16886454	chr6:22562975	T/A	cg13666174	chr6:22585274	NA	-0.56	-5.86	-0.36	1.59e-8	Coronary artery disease;
SARC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg03452623	chr4:187889614	NA	-0.75	-11.79	-0.61	1.83e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs829661	0.532	rs7602714	chr2:30789607	C/G	cg12454169	chr2:30669597	LCLAT1	-0.41	-5.13	-0.32	5.96e-7	Midgestational circulating levels of PBDEs (fetal genetic effect);
SARC	cis	rs8067354	0.645	rs28516945	chr17:57816578	T/C	cg13753209	chr17:57696993	CLTC	0.67	7.24	0.43	6.46e-12	Hemoglobin concentration;
SARC	cis	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.63	-0.45	5.88e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs13256369	0.901	rs13251887	chr8:8568678	G/A	cg18904891	chr8:8559673	CLDN23	0.48	5.54	0.34	8.31e-8	Obesity-related traits;
SARC	cis	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg18252515	chr7:66147081	NA	-1.29	-11.49	-0.6	1.7e-24	Diabetic kidney disease;
SARC	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg04287289	chr16:89883240	FANCA	-0.8	-11.17	-0.59	1.7e-23	Vitiligo;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg20064231	chr18:74608296	ZNF236	-0.53	-6.69	-0.4	1.62e-10	Height;
SARC	cis	rs950776	0.616	rs12901300	chr15:78892952	G/A	cg17108064	chr15:78857060	CHRNA5	0.31	5.36	0.33	2.04e-7	Sudden cardiac arrest;
SARC	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg13206674	chr6:150067644	NUP43	-0.46	-5.91	-0.36	1.18e-8	Lung cancer;
SARC	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg23758822	chr17:41437982	NA	0.89	11.4	0.6	3.2e-24	Menopause (age at onset);
SARC	cis	rs782590	0.783	rs7594279	chr2:55812073	T/G	cg18811423	chr2:55921094	PNPT1	0.68	10.38	0.56	5.37e-21	Metabolic syndrome;
SARC	cis	rs1983891	0.955	rs4714479	chr6:41518807	A/G	cg15051332	chr6:41514432	FOXP4	0.56	6.14	0.37	3.49e-9	Prostate cancer;
SARC	cis	rs7474896	0.537	rs2749589	chr10:38266870	C/T	cg25427524	chr10:38739819	LOC399744	0.48	6.02	0.37	6.81e-9	Obesity (extreme);
SARC	cis	rs193541	0.530	rs2045626	chr5:122081253	A/C	cg19412675	chr5:122181750	SNX24	0.48	6.54	0.39	3.9e-10	Glucose homeostasis traits;
SARC	cis	rs76419734	0.510	rs2553446	chr4:106696476	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	-0.71	-7.32	-0.43	3.95e-12	Post bronchodilator FEV1;
SARC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg06873352	chr17:61820015	STRADA	0.53	6.92	0.41	4.3e-11	Prudent dietary pattern;
SARC	cis	rs4148883	0.629	rs2602899	chr4:100010128	C/T	cg12011299	chr4:100065546	ADH4	0.38	7.06	0.42	1.9e-11	Alcohol dependence;
SARC	cis	rs10504073	0.647	rs9643394	chr8:50014427	A/G	cg00325661	chr8:49890786	NA	0.53	7.33	0.43	3.72e-12	Blood metabolite ratios;
SARC	cis	rs262150	0.501	rs2730206	chr7:158815173	G/C	cg09640425	chr7:158790006	NA	-0.39	-5.67	-0.35	4.2e-8	Facial morphology (factor 20);
SARC	cis	rs7264396	0.635	rs6060696	chr20:34522060	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.52	5.27	0.33	3.18e-7	Total cholesterol levels;
SARC	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg06636001	chr8:8085503	FLJ10661	0.79	11.36	0.6	4.24e-24	Neuroticism;
SARC	cis	rs2439831	0.681	rs956391	chr15:43617493	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-1.07	-11.65	-0.61	4.97e-25	Lung cancer in ever smokers;
SARC	cis	rs72634258	0.554	rs4908694	chr1:7850898	C/T	cg26816564	chr1:7831052	VAMP3	0.54	5.08	0.32	7.85e-7	Inflammatory bowel disease;
SARC	cis	rs854765	0.583	rs9913724	chr17:17819101	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.66	10.0	0.55	7.86e-20	Total body bone mineral density;
SARC	cis	rs5758659	0.519	rs133307	chr22:42396568	C/A	cg04733989	chr22:42467013	NAGA	0.5	6.74	0.4	1.23e-10	Cognitive function;
SARC	cis	rs2304069	0.545	rs13168011	chr5:149392377	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.59	6.94	0.41	3.86e-11	HIV-1 control;
SARC	cis	rs2290720	0.813	rs1979269	chr12:101755380	C/G	cg22051763	chr12:101673672	UTP20	-0.39	-4.76	-0.3	3.44e-6	Brain structure (hippocampal volume);
SARC	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg07701084	chr6:150067640	NUP43	0.4	5.29	0.33	2.84e-7	Lung cancer;
SARC	cis	rs1865760	0.566	rs2032445	chr6:26044812	T/A	cg18357526	chr6:26021779	HIST1H4A	0.42	5.29	0.33	2.85e-7	Height;
SARC	cis	rs4065321	0.522	rs34648856	chr17:38149411	G/A	cg17467752	chr17:38218738	THRA	-0.38	-4.84	-0.3	2.35e-6	White blood cell count (basophil);White blood cell count;
SARC	cis	rs9399135	0.967	rs9402676	chr6:135355507	C/T	cg24558204	chr6:135376177	HBS1L	0.46	6.2	0.38	2.56e-9	Red blood cell count;
SARC	cis	rs9399137	0.507	rs7748708	chr6:135275142	G/A	cg22676075	chr6:135203613	NA	0.4	5.16	0.32	5.17e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs27524	0.537	rs57889668	chr5:96080934	C/T	cg16492584	chr5:96139282	ERAP1	0.46	4.9	0.31	1.81e-6	Psoriasis;Hodgkin's lymphoma;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg12205742	chr18:68097929	NA	-0.73	-6.41	-0.39	7.85e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7264396	0.580	rs6060648	chr20:34456704	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-6.98	-0.42	3.12e-11	Total cholesterol levels;
SARC	cis	rs933688	1.000	rs10474353	chr5:90732285	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.1	13.88	0.67	2.47e-32	Smoking behavior;
SARC	cis	rs11997175	0.583	rs67830367	chr8:33833788	G/C	ch.8.33884649F	chr8:33765107	NA	0.49	6.34	0.38	1.16e-9	Body mass index;
SARC	cis	rs79349575	0.783	rs4793992	chr17:47008207	A/G	cg16584676	chr17:46985605	UBE2Z	0.52	6.24	0.38	2.08e-9	Type 2 diabetes;
SARC	cis	rs3857536	0.776	rs4710583	chr6:66940101	A/C	cg07460842	chr6:66804631	NA	-0.51	-5.83	-0.36	1.86e-8	Blood trace element (Cu levels);
SARC	cis	rs17023223	0.537	rs7525871	chr1:119621894	T/C	cg05756136	chr1:119680316	WARS2	-0.46	-5.22	-0.32	4e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs453301	0.686	rs6601280	chr8:8909236	A/T	cg08975724	chr8:8085496	FLJ10661	0.38	4.76	0.3	3.37e-6	Joint mobility (Beighton score);
SARC	cis	rs6429082	0.818	rs291391	chr1:235649955	A/G	cg26050004	chr1:235667680	B3GALNT2	0.65	7.72	0.45	3.46e-13	Adiposity;
SARC	cis	rs72781680	0.716	rs2675363	chr2:24080003	G/C	cg06627628	chr2:24431161	ITSN2	-0.53	-5.61	-0.34	5.82e-8	Lymphocyte counts;
SARC	cis	rs2933343	1.000	rs6785869	chr3:128643144	G/A	cg24203234	chr3:128598194	ACAD9	0.55	6.04	0.37	6.17e-9	IgG glycosylation;
SARC	cis	rs7236492	0.515	rs8086051	chr18:77173158	C/T	cg15644404	chr18:77186268	NFATC1	-0.65	-5.12	-0.32	6.31e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs72781680	0.768	rs112139157	chr2:24150783	A/C	cg06627628	chr2:24431161	ITSN2	-0.57	-5.91	-0.36	1.21e-8	Lymphocyte counts;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg16632280	chr11:65325623	LTBP3	0.59	6.25	0.38	1.92e-9	Lung cancer in ever smokers;
SARC	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg24829409	chr8:58192753	C8orf71	-0.63	-5.96	-0.36	9.37e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs12153160	1.000	rs12515622	chr5:152956050	C/T	cg16532600	chr5:153857824	HAND1	0.51	4.8	0.3	2.85e-6	Middle childhood and early adolescence aggressive behavior;
SARC	cis	rs12048904	0.619	rs10875347	chr1:101333737	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.89	11.59	0.6	7.98e-25	Multiple sclerosis;
SARC	trans	rs11165623	0.792	rs12132069	chr1:96918809	A/C	cg10631902	chr5:14652156	NA	-0.48	-7.82	-0.46	1.83e-13	Hip circumference;Waist circumference;
SARC	cis	rs400736	0.930	rs442862	chr1:8079494	T/C	cg25007680	chr1:8021821	PARK7	0.5	6.54	0.39	3.84e-10	Response to antidepressants and depression;
SARC	cis	rs1707322	0.717	rs28396194	chr1:46213227	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.37	0.38	1.03e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs3796352	1.000	rs13072818	chr3:53074263	C/T	cg27565382	chr3:53032988	SFMBT1	0.86	6.3	0.38	1.49e-9	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs9807989	0.773	rs5010059	chr2:102968826	C/G	cg09003973	chr2:102972529	NA	0.41	5.6	0.34	6.11e-8	Asthma;
SARC	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg22920501	chr2:26401640	FAM59B	0.59	7.7	0.45	3.9e-13	Gut microbiome composition (summer);
SARC	cis	rs2250402	0.510	rs7535	chr15:40328575	G/C	cg10636054	chr15:40330586	SRP14	0.91	6.83	0.41	7.32e-11	Corneal curvature;
SARC	trans	rs931812	0.895	rs4734013	chr8:101908687	A/C	cg20993868	chr7:22813445	NA	0.49	6.58	0.4	3.11e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs7027203	0.576	rs4509402	chr9:96543377	C/T	cg14598338	chr9:96623480	NA	0.34	4.76	0.3	3.35e-6	DNA methylation (variation);
SARC	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-8.85	-0.5	2.28e-16	Alzheimer's disease;
SARC	cis	rs4891159	0.548	rs12454625	chr18:74128751	A/G	cg24786174	chr18:74118243	ZNF516	0.72	12.17	0.62	1.09e-26	Longevity;
SARC	cis	rs13064447	0.967	rs9873195	chr3:12767936	A/G	cg05775895	chr3:12838266	CAND2	-0.38	-5.06	-0.31	8.57e-7	Major depression and alcohol dependence;
SARC	cis	rs3768617	0.510	rs10797837	chr1:183075121	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.17	0.55	2.42e-20	Fuchs's corneal dystrophy;
SARC	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg11764359	chr7:65958608	NA	-0.67	-7.97	-0.46	7.24e-14	Aortic root size;
SARC	cis	rs4938330	0.608	rs4938358	chr11:117084091	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.52	-5.45	-0.34	1.31e-7	Blood protein levels;
SARC	cis	rs796364	0.951	rs12463436	chr2:201061962	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.48	4.74	0.3	3.74e-6	Schizophrenia;
SARC	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg22903471	chr2:27725779	GCKR	-0.54	-8.22	-0.47	1.47e-14	Total body bone mineral density;
SARC	cis	rs4481887	0.800	rs4278391	chr1:248450495	C/T	cg13385794	chr1:248469461	NA	0.32	4.78	0.3	3.16e-6	Common traits (Other);
SARC	cis	rs2288073	0.965	rs10173173	chr2:24415461	G/T	cg06627628	chr2:24431161	ITSN2	0.65	7.93	0.46	8.85e-14	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs3820928	0.874	rs2229812	chr2:227896886	C/T	cg05526886	chr2:227700861	RHBDD1	-0.5	-5.92	-0.36	1.12e-8	Pulmonary function;
SARC	cis	rs17376456	0.825	rs17314797	chr5:93234845	T/A	cg21475434	chr5:93447410	FAM172A	0.83	7.35	0.43	3.37e-12	Diabetic retinopathy;
SARC	cis	rs17023223	0.537	rs1057990	chr1:119575232	T/C	cg05756136	chr1:119680316	WARS2	-0.45	-5.44	-0.34	1.35e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs7824557	0.767	rs1897950	chr8:11169551	C/A	cg21775007	chr8:11205619	TDH	0.5	5.96	0.36	9.26e-9	Retinal vascular caliber;
SARC	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg17376030	chr22:41985996	PMM1	-0.64	-7.78	-0.45	2.35e-13	Vitiligo;
SARC	cis	rs1957429	0.731	rs10144554	chr14:65321514	T/G	cg23373153	chr14:65346875	NA	0.86	9.05	0.51	5.88e-17	Pediatric areal bone mineral density (radius);
SARC	cis	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg17933148	chr7:20122468	NA	0.41	5.34	0.33	2.22e-7	Thyroid stimulating hormone;
SARC	cis	rs12824058	0.831	rs12300308	chr12:130813825	G/A	cg26677194	chr12:130822605	PIWIL1	0.54	7.47	0.44	1.6e-12	Menopause (age at onset);
SARC	cis	rs829883	0.724	rs1439774	chr12:98907692	C/T	cg25150519	chr12:98850993	NA	-0.67	-8.36	-0.48	5.6e-15	Colorectal adenoma (advanced);
SARC	cis	rs7412746	0.611	rs2271076	chr1:150916657	C/T	cg13175981	chr1:150552382	MCL1	-0.52	-6.43	-0.39	7.28e-10	Melanoma;
SARC	cis	rs1549118	0.595	rs17106478	chr14:78328310	A/G	cg21497246	chr14:78225524	SNW1;C14orf178	-0.51	-5.28	-0.33	2.93e-7	Resting heart rate;
SARC	cis	rs950169	0.922	rs4842946	chr15:84942331	G/A	cg17507749	chr15:85114479	UBE2QP1	0.79	9.66	0.53	8.73e-19	Schizophrenia;
SARC	cis	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg24110177	chr3:50126178	RBM5	-0.4	-5.07	-0.32	7.98e-7	Intelligence (multi-trait analysis);
SARC	cis	rs995000	0.895	rs1472257	chr1:63042126	A/G	cg06896770	chr1:63153194	DOCK7	-0.9	-13.26	-0.66	2.87e-30	Triglyceride levels;
SARC	cis	rs155076	1.000	rs564685	chr13:21846879	A/G	cg14456004	chr13:21872349	NA	-1.0	-12.77	-0.64	1.13e-28	White matter hyperintensity burden;
SARC	cis	rs10131894	0.611	rs175001	chr14:75436452	A/C	cg06637938	chr14:75390232	RPS6KL1	0.55	7.36	0.43	3.2e-12	Coronary artery disease;
SARC	cis	rs908922	0.676	rs7547628	chr1:152527738	T/C	cg09873164	chr1:152488093	CRCT1	0.62	7.95	0.46	8.19e-14	Hair morphology;
SARC	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg05313129	chr8:58192883	C8orf71	-0.6	-7.05	-0.42	2.05e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs6088580	0.634	rs6059829	chr20:33017074	G/A	cg08999081	chr20:33150536	PIGU	0.44	6.59	0.4	2.97e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg11764359	chr7:65958608	NA	0.55	6.52	0.39	4.22e-10	Aortic root size;
SARC	cis	rs7113850	0.541	rs75850541	chr11:24211467	C/G	ch.11.24196551F	chr11:24239977	NA	0.78	6.06	0.37	5.36e-9	Bone fracture in osteoporosis;
SARC	cis	rs6499188	0.522	rs10153230	chr16:68671741	C/G	cg02972257	chr16:68554789	NA	-0.43	-5.08	-0.32	7.74e-7	Ulcerative colitis;
SARC	cis	rs2921036	0.529	rs2979192	chr8:8338147	C/T	cg08975724	chr8:8085496	FLJ10661	0.52	6.19	0.38	2.67e-9	Neuroticism;
SARC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.41	-6.26	-0.38	1.81e-9	Longevity;Endometriosis;
SARC	cis	rs2180341	0.804	rs6902233	chr6:127555963	A/G	cg27446573	chr6:127587934	RNF146	1.02	12.08	0.62	2.06e-26	Breast cancer;
SARC	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.39	-6.53	-0.39	4.01e-10	Total body bone mineral density;
SARC	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg22903657	chr4:1355424	KIAA1530	-0.36	-4.83	-0.3	2.44e-6	Obesity-related traits;
SARC	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4319547	1.000	rs6489071	chr12:123025576	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.61	-7.27	-0.43	5.39e-12	Body mass index;
SARC	cis	rs62244186	0.715	rs10212378	chr3:44667286	C/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.44	5.5	0.34	1.02e-7	Depressive symptoms;
SARC	cis	rs13166103	0.657	rs4700283	chr5:57704465	C/G	cg10487770	chr5:57879443	RAB3C	0.52	5.73	0.35	3.01e-8	Type 2 diabetes (age of onset);
SARC	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg11764359	chr7:65958608	NA	-0.8	-9.67	-0.54	8.2e-19	Aortic root size;
SARC	cis	rs17376456	0.825	rs10058331	chr5:93279115	T/G	cg21475434	chr5:93447410	FAM172A	0.85	7.47	0.44	1.61e-12	Diabetic retinopathy;
SARC	cis	rs7833790	1.000	rs7834808	chr8:82704996	A/G	cg27398817	chr8:82754497	SNX16	-0.51	-5.55	-0.34	7.79e-8	Diastolic blood pressure;
SARC	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg02951883	chr7:2050386	MAD1L1	-0.37	-4.73	-0.3	3.94e-6	Schizophrenia;
SARC	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg14983838	chr19:29218262	NA	-0.6	-6.66	-0.4	1.94e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs17539620	0.534	rs11541339	chr6:154831643	G/C	cg20019720	chr6:154832845	CNKSR3	0.43	5.13	0.32	6.09e-7	Lipoprotein (a) levels;
SARC	cis	rs1949733	0.917	rs10461079	chr4:8392724	G/A	cg11789530	chr4:8429930	ACOX3	-0.93	-12.29	-0.63	4.46e-27	Response to antineoplastic agents;
SARC	cis	rs77972916	0.611	rs6709988	chr2:43601317	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-6.18	-0.38	2.84e-9	Granulocyte percentage of myeloid white cells;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg17878141	chr5:81521184	ATG10	0.48	6.75	0.4	1.14e-10	Thyroid stimulating hormone;
SARC	cis	rs7223966	1.000	rs8064261	chr17:61705212	G/A	cg26338869	chr17:61819248	STRADA	0.45	4.92	0.31	1.63e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs35110281	0.667	rs2070533	chr21:45122753	G/A	cg21573476	chr21:45109991	RRP1B	-0.59	-8.36	-0.48	5.62e-15	Mean corpuscular volume;
SARC	cis	rs2933343	0.649	rs789219	chr3:128592520	G/A	cg24203234	chr3:128598194	ACAD9	0.62	7.99	0.46	6.04e-14	IgG glycosylation;
SARC	cis	rs6087990	0.899	rs6058893	chr20:31392777	C/T	cg13636640	chr20:31349939	DNMT3B	0.74	11.74	0.61	2.71e-25	Ulcerative colitis;
SARC	cis	rs910316	0.737	rs175510	chr14:75524839	G/A	cg11812906	chr14:75593930	NEK9	-0.79	-11.0	-0.58	6.09e-23	Height;
SARC	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg11987759	chr7:65425863	GUSB	-0.46	-6.15	-0.37	3.36e-9	Aortic root size;
SARC	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg03452623	chr4:187889614	NA	-0.83	-13.98	-0.68	1.16e-32	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7937682	0.663	rs3867466	chr11:111668256	A/C	cg09085632	chr11:111637200	PPP2R1B	0.81	10.89	0.58	1.33e-22	Primary sclerosing cholangitis;
SARC	cis	rs933688	1.000	rs10474353	chr5:90732285	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.04	13.29	0.66	2.27e-30	Smoking behavior;
SARC	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg14983838	chr19:29218262	NA	0.76	10.52	0.57	2.03e-21	Methadone dose in opioid dependence;
SARC	cis	rs751728	0.588	rs7774620	chr6:33736285	T/A	cg25922239	chr6:33757077	LEMD2	0.59	7.47	0.44	1.6e-12	Crohn's disease;
SARC	trans	rs11722228	0.522	rs73212808	chr4:10055439	G/C	cg26043149	chr18:55253948	FECH	0.73	8.4	0.48	4.54e-15	Gout;Urate levels;Serum uric acid levels;
SARC	trans	rs208520	0.690	rs207077	chr6:66769855	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-13.51	-0.66	4.11e-31	Exhaled nitric oxide output;
SARC	cis	rs8141529	0.719	rs132561	chr22:29351179	C/T	cg02153584	chr22:29168773	CCDC117	-0.76	-10.49	-0.57	2.49e-21	Lymphocyte counts;
SARC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.06	0.37	5.34e-9	Prudent dietary pattern;
SARC	cis	rs1707322	0.686	rs1250	chr1:46094027	A/G	cg03146154	chr1:46216737	IPP	0.52	6.06	0.37	5.45e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg12463550	chr7:65579703	CRCP	0.48	5.58	0.34	6.58e-8	Aortic root size;
SARC	cis	rs9916302	0.706	rs8075737	chr17:37727316	C/T	cg15445000	chr17:37608096	MED1	-0.45	-4.94	-0.31	1.46e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs738322	0.967	rs133017	chr22:38572637	A/C	cg25457927	chr22:38595422	NA	-0.29	-5.95	-0.36	9.7e-9	Cutaneous nevi;
SARC	cis	rs7772486	0.790	rs80050589	chr6:146230454	T/C	cg05347473	chr6:146136440	FBXO30	-0.49	-6.63	-0.4	2.33e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3784262	0.679	rs11071365	chr15:58334126	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.36	-5.28	-0.33	3.01e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs2898290	0.506	rs2736311	chr8:11252170	C/T	cg21775007	chr8:11205619	TDH	-0.57	-7.53	-0.44	1.08e-12	Systolic blood pressure;
SARC	cis	rs9325144	0.554	rs1906264	chr12:38739490	A/G	cg13010199	chr12:38710504	ALG10B	0.55	7.14	0.42	1.19e-11	Morning vs. evening chronotype;
SARC	cis	rs7937682	0.961	rs552387	chr11:111490047	T/G	cg22437258	chr11:111473054	SIK2	0.72	9.91	0.54	1.54e-19	Primary sclerosing cholangitis;
SARC	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg12437481	chr16:420112	MRPL28	0.41	6.29	0.38	1.54e-9	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-4.82	-0.3	2.59e-6	Menopause (age at onset);
SARC	cis	rs6580649	0.943	rs1859444	chr12:48399403	T/C	cg24011408	chr12:48396354	COL2A1	0.53	6.01	0.37	6.97e-9	Lung cancer;
SARC	cis	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg08564027	chr20:61660810	NA	0.76	11.8	0.61	1.69e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs4423214	0.840	rs1792315	chr11:71165547	C/T	cg05163923	chr11:71159392	DHCR7	-0.6	-6.78	-0.41	9.82e-11	Vitamin D levels;
SARC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.34	-4.79	-0.3	3e-6	Lymphocyte counts;
SARC	cis	rs6582630	0.538	rs8189550	chr12:38333058	T/G	cg14851346	chr12:38532713	NA	-0.47	-5.48	-0.34	1.09e-7	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg16709874	chr1:211433282	RCOR3	-0.48	-6.74	-0.4	1.21e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs6963495	0.818	rs73190163	chr7:105157294	G/T	cg13798780	chr7:105162888	PUS7	0.6	5.45	0.34	1.31e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg09359103	chr1:154839909	KCNN3	-0.39	-6.07	-0.37	5.14e-9	Prostate cancer;
SARC	cis	rs1559088	0.847	rs10423531	chr19:33600140	T/C	cg27124370	chr19:33622961	WDR88	0.44	5.87	0.36	1.49e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs9611519	0.929	rs4820425	chr22:41431342	C/A	cg03806693	chr22:41940476	POLR3H	-0.6	-7.42	-0.44	2.12e-12	Neuroticism;
SARC	cis	rs8017423	0.967	rs4904656	chr14:90721442	G/T	cg20276874	chr14:90721474	PSMC1	-0.38	-5.32	-0.33	2.41e-7	Mortality in heart failure;
SARC	cis	rs910316	0.737	rs108621	chr14:75480637	T/C	cg23033748	chr14:75592666	NEK9	-0.36	-4.75	-0.3	3.51e-6	Height;
SARC	cis	rs957448	1.000	rs1992370	chr8:95558694	C/T	cg26464482	chr8:95565502	KIAA1429	0.43	4.74	0.3	3.73e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs4711336	0.935	rs3818529	chr6:33661106	T/C	cg15676125	chr6:33679581	C6orf125	0.54	6.68	0.4	1.71e-10	Height;
SARC	cis	rs7647973	0.560	rs77473999	chr3:49777660	T/C	cg13072238	chr3:49761600	GMPPB	0.67	6.58	0.4	3.03e-10	Menarche (age at onset);
SARC	cis	rs41307935	0.596	rs34204245	chr1:27204183	T/C	cg04852280	chr1:26496234	ZNF593	0.56	5.05	0.31	8.94e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1729951	0.575	rs1682333	chr3:136688618	G/A	cg15507776	chr3:136538369	TMEM22	0.5	5.6	0.34	6.04e-8	Neuroticism;
SARC	cis	rs708547	0.624	rs1718886	chr4:57849251	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.64	8.56	0.49	1.59e-15	Response to bleomycin (chromatid breaks);
SARC	cis	rs6570726	0.935	rs7757387	chr6:145816726	G/T	cg05347473	chr6:146136440	FBXO30	0.48	6.46	0.39	6.14e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg12564285	chr5:131593104	PDLIM4	0.36	5.4	0.33	1.67e-7	Breast cancer;
SARC	cis	rs1008375	1.000	rs10939743	chr4:17662731	G/A	cg16339924	chr4:17578868	LAP3	0.63	8.13	0.47	2.54e-14	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs644799	0.544	rs1727165	chr11:95521648	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	6.24	0.38	2.03e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9640161	0.750	rs1983440	chr7:150023941	G/C	cg21361702	chr7:150065534	REPIN1	0.49	5.09	0.32	7.52e-7	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg04166393	chr7:2884313	GNA12	0.51	6.05	0.37	5.74e-9	Height;
SARC	cis	rs2997447	0.846	rs72886619	chr1:26452604	G/A	cg19633962	chr1:26362018	EXTL1	-0.61	-5.27	-0.33	3.05e-7	QRS complex (12-leadsum);
SARC	cis	rs9843304	0.529	rs4681511	chr3:149201579	C/T	cg08667024	chr3:149219783	TM4SF4	-0.4	-5.91	-0.36	1.21e-8	Gallstone disease;
SARC	cis	rs2204008	0.728	rs11495375	chr12:38282631	G/A	cg13010199	chr12:38710504	ALG10B	0.81	11.31	0.6	6.33e-24	Bladder cancer;
SARC	cis	rs13191362	1.000	rs34443622	chr6:163208214	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.65	5.68	0.35	4.05e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs60843830	0.964	rs62114538	chr2:256116	G/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.62	8.93	0.51	1.28e-16	Spherical equivalent (joint analysis main effects and education interaction);
SARC	cis	rs7769051	1.000	rs12204027	chr6:133122831	A/G	cg07930552	chr6:133119739	C6orf192	0.87	7.85	0.46	1.47e-13	Type 2 diabetes nephropathy;
SARC	cis	rs2735413	0.881	rs12927515	chr16:78080141	T/G	cg04733911	chr16:78082701	NA	-0.3	-5.45	-0.34	1.29e-7	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs12754538	0.739	rs12735554	chr1:8695395	C/G	cg13785123	chr1:8931135	ENO1	-0.46	-4.98	-0.31	1.26e-6	Subjective well-being;
SARC	cis	rs6121246	0.865	rs6089055	chr20:30324045	C/T	cg13852791	chr20:30311386	BCL2L1	0.85	8.56	0.49	1.58e-15	Mean corpuscular hemoglobin;
SARC	cis	rs1707322	0.717	rs28396194	chr1:46213227	C/T	cg03146154	chr1:46216737	IPP	0.52	6.29	0.38	1.56e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs72945132	0.882	rs7114200	chr11:70186099	C/A	cg00319359	chr11:70116639	PPFIA1	0.69	6.25	0.38	1.92e-9	Coronary artery disease;
SARC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg13012494	chr21:47604986	C21orf56	-0.58	-6.88	-0.41	5.41e-11	Testicular germ cell tumor;
SARC	cis	rs3760982	0.585	rs8109812	chr19:44298494	C/A	cg11993925	chr19:44307056	LYPD5	0.31	4.82	0.3	2.63e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
SARC	trans	rs17685	0.702	rs6960598	chr7:75772991	T/C	cg19862616	chr7:65841803	NCRNA00174	0.6	7.38	0.44	2.77e-12	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs13161895	0.818	rs78282770	chr5:179483686	T/A	cg02702477	chr5:179499311	RNF130	0.76	6.94	0.41	3.86e-11	LDL cholesterol;
SARC	cis	rs11155671	0.530	rs6557133	chr6:150195384	G/T	cg05036130	chr6:150231994	NA	0.3	5.03	0.31	9.74e-7	Testicular germ cell tumor;
SARC	cis	rs8060686	0.641	rs79577483	chr16:68036939	A/G	cg27539214	chr16:67997921	SLC12A4	-0.54	-5.13	-0.32	5.98e-7	HDL cholesterol;Metabolic syndrome;
SARC	cis	rs7208859	0.573	rs11654035	chr17:29136426	T/C	cg13385521	chr17:29058706	SUZ12P	0.84	6.97	0.42	3.18e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs367943	0.965	rs458044	chr5:112797779	A/G	cg12552261	chr5:112820674	MCC	-0.48	-5.55	-0.34	7.86e-8	Type 2 diabetes;
SARC	cis	rs909341	0.909	rs1151623	chr20:62368606	T/C	cg27236539	chr20:62289627	RTEL1	0.47	4.84	0.3	2.41e-6	Atopic dermatitis;
SARC	cis	rs10499694	0.933	rs11575356	chr7:50594821	T/C	cg19499709	chr7:50660583	GRB10	-0.35	-4.79	-0.3	3.01e-6	Body mass index;
SARC	cis	rs12311304	1.000	rs28410854	chr12:15411810	A/G	cg08258403	chr12:15378311	NA	0.49	7.3	0.43	4.5e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs1387259	0.929	rs11168484	chr12:48633589	A/C	cg24011408	chr12:48396354	COL2A1	0.46	5.3	0.33	2.66e-7	Obstructive sleep apnea trait (apnea hypopnea index);
SARC	cis	rs12709013	0.636	rs8054414	chr16:58783676	T/C	cg04273148	chr16:57808038	KIFC3	0.32	4.72	0.3	4.08e-6	Blood metabolite ratios;
SARC	cis	rs3087591	0.708	rs2525569	chr17:29675971	T/A	cg24425628	chr17:29625626	OMG;NF1	0.42	5.33	0.33	2.36e-7	Hip circumference;
SARC	cis	rs514024	0.700	rs555022	chr9:130491726	T/C	cg13643465	chr9:130375613	STXBP1	0.45	5.5	0.34	9.72e-8	Eating disorders (purging via substances);
SARC	cis	rs2288884	0.505	rs12460506	chr19:52483593	G/C	cg24732339	chr19:52471368	ZNF350	-0.61	-5.31	-0.33	2.55e-7	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
SARC	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg02891314	chr5:179741120	GFPT2	-0.48	-5.97	-0.36	8.65e-9	Height;
SARC	cis	rs11098499	0.863	rs11723090	chr4:120490592	T/C	cg24375607	chr4:120327624	NA	0.42	4.92	0.31	1.64e-6	Corneal astigmatism;
SARC	cis	rs5760092	0.755	rs6003959	chr22:24264395	C/T	cg24846343	chr22:24311635	DDTL	-0.41	-4.98	-0.31	1.21e-6	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs8067545	0.750	rs9915758	chr17:19964775	A/G	cg13482628	chr17:19912719	NA	0.54	7.18	0.43	9.23e-12	Schizophrenia;
SARC	cis	rs1215050	0.704	rs783915	chr4:99023151	C/G	cg05340658	chr4:99064831	C4orf37	0.47	6.36	0.38	1.05e-9	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs7246657	0.943	rs4803460	chr19:37885228	T/C	cg14683738	chr19:37701593	ZNF585B	0.51	4.88	0.3	1.94e-6	Coronary artery calcification;
SARC	cis	rs13256369	0.708	rs11249886	chr8:8562021	T/A	cg18904891	chr8:8559673	CLDN23	0.49	5.53	0.34	8.66e-8	Obesity-related traits;
SARC	cis	rs9486715	0.659	rs9399930	chr6:96854444	G/T	cg18709589	chr6:96969512	KIAA0776	0.57	6.9	0.41	4.78e-11	Headache;
SARC	cis	rs76917914	0.589	rs55972150	chr9:100863941	G/T	cg03040243	chr9:100819229	NANS	0.54	5.81	0.36	2.05e-8	Immature fraction of reticulocytes;
SARC	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg03351412	chr1:154909251	PMVK	0.62	7.93	0.46	9.27e-14	Prostate cancer;
SARC	cis	rs12474201	0.572	rs7596521	chr2:46918665	A/G	cg09399716	chr2:46890238	NA	-0.28	-5.38	-0.33	1.78e-7	Height;
SARC	cis	rs2273669	0.667	rs11754955	chr6:109287459	A/G	cg05315195	chr6:109294784	ARMC2	-0.57	-5.15	-0.32	5.66e-7	Prostate cancer;
SARC	trans	rs9650657	0.675	rs2409658	chr8:10668965	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.69	-0.4	1.67e-10	Neuroticism;
SARC	cis	rs2028299	0.920	rs1866476	chr15:90428543	T/C	cg19708238	chr15:90437601	AP3S2	0.44	4.93	0.31	1.6e-6	Type 2 diabetes;
SARC	cis	rs9486715	0.867	rs9372106	chr6:96875058	T/C	cg18709589	chr6:96969512	KIAA0776	0.58	7.33	0.43	3.86e-12	Headache;
SARC	cis	rs66569888	0.632	rs6728600	chr2:106898653	G/T	cg16099169	chr2:106886729	NA	-0.59	-6.34	-0.38	1.17e-9	Facial morphology (factor 23);
SARC	cis	rs36051895	0.587	rs7871070	chr9:5040786	T/A	cg02405213	chr9:5042618	JAK2	-0.56	-6.64	-0.4	2.23e-10	Pediatric autoimmune diseases;
SARC	cis	rs1707322	1.000	rs4660335	chr1:46474718	C/T	cg03146154	chr1:46216737	IPP	0.5	6.01	0.37	6.98e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg20127207	chr2:160625571	CD302	-0.52	-6.64	-0.4	2.17e-10	Alcohol dependence;
SARC	cis	rs1976403	0.659	rs10799701	chr1:21820990	A/G	cg21906605	chr1:21766650	NBPF3	0.46	6.21	0.38	2.45e-9	Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg01448562	chr3:133502909	NA	-0.45	-6.58	-0.4	3.06e-10	Iron status biomarkers;
SARC	cis	rs911555	0.546	rs28798508	chr14:104068970	T/C	cg12935359	chr14:103987150	CKB	-0.34	-4.9	-0.31	1.78e-6	Intelligence (multi-trait analysis);
SARC	cis	rs796364	0.760	rs1569178	chr2:201024512	T/C	cg23649088	chr2:200775458	C2orf69	-0.64	-5.6	-0.34	6.01e-8	Schizophrenia;
SARC	cis	rs826838	0.616	rs11182893	chr12:38627715	C/G	cg13010199	chr12:38710504	ALG10B	-0.52	-6.43	-0.39	7.18e-10	Heart rate;
SARC	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg03517284	chr6:25882590	NA	-0.42	-5.42	-0.33	1.47e-7	Intelligence (multi-trait analysis);
SARC	cis	rs208520	0.690	rs1776365	chr6:66834474	G/T	cg07460842	chr6:66804631	NA	-1.04	-14.45	-0.69	3.19e-34	Exhaled nitric oxide output;
SARC	cis	rs1941023	0.503	rs7952244	chr11:60132164	G/A	cg08716584	chr11:60157161	MS4A7	-0.4	-6.76	-0.4	1.11e-10	Congenital heart disease (maternal effect);
SARC	cis	rs6840360	1.000	rs6535814	chr4:152609694	A/G	cg22705602	chr4:152727874	NA	-0.39	-6.81	-0.41	8.35e-11	Intelligence (multi-trait analysis);
SARC	cis	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg06636001	chr8:8085503	FLJ10661	0.7	9.66	0.53	9.07e-19	Mood instability;
SARC	trans	rs3808502	0.526	rs11783065	chr8:11417257	A/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-9.13	-0.51	3.45e-17	Neuroticism;
SARC	cis	rs1345301	0.552	rs1558626	chr2:102862070	T/A	cg12451869	chr2:102867685	NA	0.4	5.45	0.34	1.3e-7	Waist circumference;
SARC	cis	rs10513788	0.665	rs4300996	chr3:181988985	G/C	cg05977900	chr3:182512126	ATP11B	0.48	5.07	0.32	7.96e-7	Cognitive function;
SARC	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg12463550	chr7:65579703	CRCP	0.51	5.74	0.35	2.94e-8	Aortic root size;
SARC	cis	rs4718428	0.705	rs4717328	chr7:66352665	T/C	cg18252515	chr7:66147081	NA	-0.6	-6.52	-0.39	4.33e-10	Corneal structure;
SARC	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg16325326	chr1:53192061	ZYG11B	0.79	11.9	0.61	7.84e-26	Monocyte count;
SARC	cis	rs10256972	0.626	rs62433138	chr7:1050877	T/C	cg00431813	chr7:1051703	C7orf50	-0.33	-4.99	-0.31	1.2e-6	Longevity;Endometriosis;
SARC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg09373136	chr17:61933544	TCAM1	-0.44	-6.11	-0.37	4.1e-9	Prudent dietary pattern;
SARC	cis	rs4642101	0.793	rs56082700	chr3:12833833	T/C	cg12400702	chr3:12838781	CAND2	-0.26	-5.16	-0.32	5.17e-7	QRS complex (12-leadsum);
SARC	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg02592271	chr2:27665507	KRTCAP3	-0.4	-6.13	-0.37	3.79e-9	Total body bone mineral density;
SARC	cis	rs10754283	0.967	rs10922685	chr1:90118320	A/G	cg21401794	chr1:90099060	LRRC8C	0.59	8.23	0.47	1.32e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs6429082	0.744	rs903347	chr1:235586613	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.57	-7.47	-0.44	1.61e-12	Adiposity;
SARC	cis	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg21573476	chr21:45109991	RRP1B	-0.55	-8.3	-0.48	8.51e-15	Mean corpuscular volume;
SARC	cis	rs453301	0.574	rs10081437	chr8:8948979	T/C	cg08975724	chr8:8085496	FLJ10661	-0.44	-5.45	-0.34	1.25e-7	Joint mobility (Beighton score);
SARC	trans	rs61931739	0.500	rs12371415	chr12:34521362	C/T	cg13010199	chr12:38710504	ALG10B	0.84	11.64	0.61	5.48e-25	Morning vs. evening chronotype;
SARC	cis	rs2559856	0.903	rs10128996	chr12:102081498	G/A	cg12924262	chr12:102091054	CHPT1	0.58	7.62	0.45	6.2800000000000005e-13	Blood protein levels;
SARC	cis	rs1707322	0.686	rs2991986	chr1:46081282	A/G	cg06784218	chr1:46089804	CCDC17	-0.39	-6.85	-0.41	6.7e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs60871478	0.898	rs62432225	chr7:789433	G/A	cg05535760	chr7:792225	HEATR2	0.84	8.31	0.48	7.79e-15	Cerebrospinal P-tau181p levels;
SARC	cis	rs2836633	0.895	rs62217513	chr21:40024416	A/T	cg12884169	chr21:40033163	ERG	0.48	8.54	0.49	1.78e-15	Coronary artery disease;
SARC	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg21782813	chr7:2030301	MAD1L1	0.37	5.73	0.35	3.14e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs11711311	1.000	rs2242108	chr3:113433903	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.69	8.82	0.5	2.73e-16	IgG glycosylation;
SARC	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg16325326	chr1:53192061	ZYG11B	0.63	8.92	0.5	1.39e-16	Monocyte count;
SARC	cis	rs12995491	0.731	rs17435433	chr2:88509616	A/G	cg04511125	chr2:88470314	THNSL2	-0.41	-6.18	-0.38	2.89e-9	Response to metformin (IC50);
SARC	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg13393036	chr8:95962371	TP53INP1	0.3	5.29	0.33	2.86e-7	Type 2 diabetes;
SARC	cis	rs4481887	0.927	rs4244187	chr1:248493511	T/C	cg13385794	chr1:248469461	NA	0.32	4.8	0.3	2.81e-6	Common traits (Other);
SARC	cis	rs634534	0.622	rs501353	chr11:65739549	T/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.56	8.5	0.49	2.28e-15	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs11122272	0.735	rs2739510	chr1:231526718	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.95	-0.55	1.17e-19	Hemoglobin concentration;
SARC	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg11764359	chr7:65958608	NA	0.82	10.91	0.58	1.19e-22	Aortic root size;
SARC	trans	rs61931739	0.517	rs10844830	chr12:34308133	C/T	cg13010199	chr12:38710504	ALG10B	0.64	8.75	0.5	4.44e-16	Morning vs. evening chronotype;
SARC	cis	rs9309473	0.948	rs7603647	chr2:73817238	G/A	cg20560298	chr2:73613845	ALMS1	-0.47	-5.71	-0.35	3.42e-8	Metabolite levels;
SARC	cis	rs12579753	1.000	rs10862368	chr12:82244514	C/T	cg07988820	chr12:82153109	PPFIA2	-0.52	-6.07	-0.37	5.24e-9	Resting heart rate;
SARC	cis	rs72634258	0.519	rs4908708	chr1:7938113	G/C	cg00042356	chr1:8021962	PARK7	0.54	4.98	0.31	1.22e-6	Inflammatory bowel disease;
SARC	cis	rs6912958	1.000	rs6933587	chr6:88175577	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.61	-8.29	-0.48	8.82e-15	Monocyte percentage of white cells;
SARC	cis	rs3784262	0.669	rs4646642	chr15:58246916	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.32	-4.84	-0.3	2.4e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs6088813	1.000	rs56306402	chr20:33937704	G/A	cg14752227	chr20:34000481	UQCC	-0.37	-4.85	-0.3	2.26e-6	Height;
SARC	cis	rs698833	0.828	rs6748528	chr2:44517752	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.61	7.93	0.46	9.26e-14	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs11690935	0.851	rs9808259	chr2:172648974	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.99	-16.22	-0.73	4.16e-40	Schizophrenia;
SARC	cis	rs4555082	0.834	rs2816652	chr14:105712493	C/T	cg06808227	chr14:105710500	BRF1	-0.51	-6.51	-0.39	4.46e-10	Mean platelet volume;Platelet distribution width;
SARC	cis	rs3096299	0.582	rs12935119	chr16:89542874	A/T	cg16743903	chr16:89593216	SPG7	-0.37	-4.91	-0.31	1.7e-6	Multiple myeloma (IgH translocation);
SARC	cis	rs10781543	0.839	rs1127152	chr9:139335599	A/G	cg14169450	chr9:139327907	INPP5E	0.45	6.31	0.38	1.42e-9	Monocyte percentage of white cells;
SARC	cis	rs11574514	1.000	rs7195415	chr16:67689057	G/A	cg01866162	chr16:67596514	CTCF	0.82	5.15	0.32	5.46e-7	Crohn's disease;
SARC	cis	rs7666738	0.830	rs7664051	chr4:98766970	C/G	cg05340658	chr4:99064831	C4orf37	0.65	8.54	0.49	1.74e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs3087591	0.664	rs2854308	chr17:29666539	A/G	cg24425628	chr17:29625626	OMG;NF1	0.41	5.3	0.33	2.66e-7	Hip circumference;
SARC	cis	rs27434	0.561	rs151910	chr5:96156956	C/A	cg16492584	chr5:96139282	ERAP1	-0.57	-7.08	-0.42	1.65e-11	Ankylosing spondylitis;
SARC	cis	rs6964587	1.000	rs2282975	chr7:91761638	A/G	cg17063962	chr7:91808500	NA	0.94	15.96	0.72	2.96e-39	Breast cancer;
SARC	cis	rs28795989	0.931	rs7686202	chr4:7898577	C/T	cg18538662	chr4:7941764	AFAP1	-0.39	-5.0	-0.31	1.11e-6	Intraocular pressure;
SARC	cis	rs6867032	1.000	rs10462750	chr5:2012963	A/G	cg26168224	chr5:2018326	NA	0.93	15.26	0.71	6.34e-37	Gut microbiome composition (winter);
SARC	cis	rs17376456	0.877	rs17315943	chr5:93442830	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.71	0.35	3.39e-8	Diabetic retinopathy;
SARC	cis	rs1401999	0.690	rs6768149	chr3:183636195	T/C	cg01324343	chr3:183735012	ABCC5	0.58	10.47	0.57	2.92e-21	Anterior chamber depth;
SARC	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.43	-4.84	-0.3	2.35e-6	Prudent dietary pattern;
SARC	cis	rs826838	0.967	rs6580726	chr12:39108623	T/C	cg26384229	chr12:38710491	ALG10B	-0.78	-12.13	-0.62	1.45e-26	Heart rate;
SARC	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg02725872	chr8:58115012	NA	-0.32	-4.89	-0.31	1.89e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs1371867	0.846	rs1788180	chr8:101333368	A/G	cg11906718	chr8:101322791	RNF19A	0.66	8.65	0.49	8.33e-16	Atrioventricular conduction;
SARC	cis	rs1562975	0.567	rs7655031	chr4:109407640	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.4	4.81	0.3	2.71e-6	Height;
SARC	cis	rs748404	0.697	rs554001	chr15:43551919	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	5.63	0.35	5.04e-8	Lung cancer;
SARC	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg12463550	chr7:65579703	CRCP	-0.51	-5.53	-0.34	8.73e-8	Aortic root size;
SARC	cis	rs10911232	0.507	rs6664995	chr1:183017345	T/C	cg13390022	chr1:182993471	LAMC1	0.36	5.46	0.34	1.23e-7	Hypertriglyceridemia;
SARC	cis	rs9303401	0.703	rs8077052	chr17:57208921	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.69	8.18	0.47	1.87e-14	Cognitive test performance;
SARC	cis	rs34172651	0.917	rs2343606	chr16:24793741	C/T	cg04756594	chr16:24857601	SLC5A11	0.37	5.83	0.36	1.82e-8	Intelligence (multi-trait analysis);
SARC	cis	rs6933660	0.512	rs9383905	chr6:151804296	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.65	5.59	0.34	6.36e-8	Menarche (age at onset);
SARC	cis	rs17376456	0.825	rs35496867	chr5:93220400	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.68	0.35	3.91e-8	Diabetic retinopathy;
SARC	cis	rs10791097	0.720	rs4936121	chr11:130733878	A/G	cg09137382	chr11:130731461	NA	0.31	4.77	0.3	3.18e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs2130392	0.962	rs13132498	chr4:185611454	T/C	cg04058563	chr4:185651563	MLF1IP	-0.35	-5.01	-0.31	1.09e-6	Kawasaki disease;
SARC	cis	rs8114671	0.562	rs6087643	chr20:33474462	C/T	cg08999081	chr20:33150536	PIGU	0.33	4.94	0.31	1.51e-6	Height;
SARC	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg16606324	chr3:10149918	C3orf24	0.57	5.35	0.33	2.1e-7	Alzheimer's disease;
SARC	cis	rs8177253	0.696	rs4459901	chr3:133465699	T/C	cg16414030	chr3:133502952	NA	-0.38	-5.1	-0.32	7.09e-7	Iron status biomarkers;
SARC	cis	rs876084	0.505	rs66488706	chr8:121132894	C/T	cg06265175	chr8:121136014	COL14A1	0.57	7.34	0.43	3.52e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs11718455	1.000	rs4682928	chr3:44037192	T/C	cg08738300	chr3:44038990	NA	0.52	5.67	0.35	4.18e-8	Coronary artery disease;
SARC	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.59e-6	Depression;
SARC	cis	rs4819052	0.679	rs4819053	chr21:46711357	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.49	-6.0	-0.37	7.41e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg05025164	chr4:1340916	KIAA1530	0.48	5.72	0.35	3.23e-8	Longevity;
SARC	cis	rs9372253	1.000	rs9372253	chr6:110716136	C/T	cg01119278	chr6:110721349	DDO	-0.38	-4.89	-0.31	1.85e-6	Platelet distribution width;
SARC	cis	rs9911578	0.967	rs57869245	chr17:57106630	A/G	cg05425664	chr17:57184151	TRIM37	0.6	7.43	0.44	2.08e-12	Intelligence (multi-trait analysis);
SARC	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg26335602	chr6:28129616	ZNF389	0.53	5.92	0.36	1.12e-8	Depression;
SARC	cis	rs6580649	0.941	rs7957764	chr12:48429701	C/T	cg05342945	chr12:48394962	COL2A1	0.57	5.91	0.36	1.21e-8	Lung cancer;
SARC	cis	rs916888	0.610	rs199444	chr17:44818276	T/C	cg01570182	chr17:44337453	NA	0.63	7.71	0.45	3.7e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	trans	rs11039798	0.588	rs7108164	chr11:48626363	A/C	cg15704280	chr7:45808275	SEPT13	0.6	6.34	0.38	1.19e-9	Axial length;
SARC	cis	rs6088580	0.524	rs6087616	chr20:33263033	T/C	cg24642439	chr20:33292090	TP53INP2	-0.55	-6.74	-0.4	1.22e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs9858542	0.953	rs11926781	chr3:49603289	C/T	cg03060546	chr3:49711283	APEH	-0.62	-7.88	-0.46	1.28e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs74181299	0.892	rs2249105	chr2:65287896	C/T	cg20592124	chr2:65290738	CEP68	-0.49	-7.28	-0.43	4.95e-12	Pulse pressure;
SARC	cis	rs1580019	0.961	rs2392056	chr7:32498953	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.74	9.92	0.55	1.38e-19	Cognitive ability;
SARC	cis	rs138544659	1	rs138544659	chr15:78900701	T/G	cg18825076	chr15:78729989	IREB2	-0.43	-5.11	-0.32	6.81e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs644799	0.562	rs669973	chr11:95571839	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.74	9.79	0.54	3.43e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg12026095	chr19:49468461	FTL	-0.48	-6.4	-0.39	8.53e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg06481639	chr22:41940642	POLR3H	-0.45	-4.74	-0.3	3.71e-6	Vitiligo;
SARC	cis	rs9894429	0.646	rs7406825	chr17:79619188	C/T	cg18240062	chr17:79603768	NPLOC4	0.57	6.89	0.41	5.25e-11	Eye color traits;
SARC	cis	rs2576037	0.526	rs6507714	chr18:44519574	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	5.37	0.33	1.94e-7	Personality dimensions;
SARC	cis	rs8067545	0.611	rs9898080	chr17:20035257	A/G	cg13482628	chr17:19912719	NA	0.53	7.08	0.42	1.7e-11	Schizophrenia;
SARC	trans	rs7824557	0.564	rs34389419	chr8:11229319	C/G	cg06636001	chr8:8085503	FLJ10661	-0.6	-7.9	-0.46	1.09e-13	Retinal vascular caliber;
SARC	cis	rs826838	1.000	rs10875717	chr12:38911174	T/C	cg26384229	chr12:38710491	ALG10B	0.92	14.25	0.68	1.53e-33	Heart rate;
SARC	cis	rs34172651	0.917	rs11074651	chr16:24778409	A/G	cg04756594	chr16:24857601	SLC5A11	0.34	5.57	0.34	6.96e-8	Intelligence (multi-trait analysis);
SARC	cis	rs35110281	0.720	rs162376	chr21:44926759	G/T	cg01579765	chr21:45077557	HSF2BP	0.36	6.01	0.37	7.02e-9	Mean corpuscular volume;
SARC	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg08280861	chr8:58055591	NA	0.6	5.28	0.33	2.92e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs72781680	0.768	rs56339558	chr2:24125234	G/A	cg06627628	chr2:24431161	ITSN2	-0.54	-5.74	-0.35	2.9e-8	Lymphocyte counts;
SARC	cis	rs3796352	1.000	rs11710292	chr3:53117798	T/C	cg07884673	chr3:53033167	SFMBT1	0.78	4.94	0.31	1.47e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs10504229	0.593	rs113184543	chr8:58042950	A/G	cg11062466	chr8:58055876	NA	0.51	4.99	0.31	1.17e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg22535103	chr8:58192502	C8orf71	-0.73	-7.3	-0.43	4.61e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs9896052	0.614	rs34042490	chr17:73452956	T/C	cg25649188	chr17:73499917	CASKIN2	0.38	5.35	0.33	2.13e-7	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs4689388	0.890	rs9993624	chr4:6286528	C/T	cg25554036	chr4:6271136	WFS1	0.44	7.27	0.43	5.5e-12	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs1865760	0.929	rs9467646	chr6:25957408	A/G	cg17691542	chr6:26056736	HIST1H1C	0.59	7.48	0.44	1.5e-12	Height;
SARC	cis	rs1345301	1.000	rs10200410	chr2:102870871	G/A	cg12451869	chr2:102867685	NA	0.39	5.52	0.34	9.24e-8	Waist circumference;
SARC	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg18876405	chr7:65276391	NA	-0.43	-5.32	-0.33	2.39e-7	Aortic root size;
SARC	cis	rs34172651	0.917	rs7204281	chr16:24784475	C/T	cg06028605	chr16:24865363	SLC5A11	0.27	4.76	0.3	3.36e-6	Intelligence (multi-trait analysis);
SARC	cis	rs72945132	0.882	rs17853270	chr11:70200529	C/T	cg05964544	chr11:70165517	PPFIA1	-0.57	-5.36	-0.33	2.04e-7	Coronary artery disease;
SARC	cis	rs751728	1.000	rs6904991	chr6:33732262	T/G	cg15252951	chr6:33757062	LEMD2	0.58	6.76	0.4	1.11e-10	Crohn's disease;
SARC	cis	rs8067354	0.645	rs2645491	chr17:57877049	C/T	cg13753209	chr17:57696993	CLTC	0.68	7.55	0.44	9.66e-13	Hemoglobin concentration;
SARC	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.72	9.74	0.54	4.99e-19	Personality dimensions;
SARC	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg18357526	chr6:26021779	HIST1H4A	0.44	5.42	0.33	1.45e-7	Blood metabolite levels;
SARC	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg16479474	chr6:28041457	NA	0.37	5.44	0.34	1.37e-7	Depression;
SARC	cis	rs1801251	1.000	rs2044449	chr2:233718808	G/A	cg25237894	chr2:233734115	C2orf82	-0.36	-4.73	-0.3	3.81e-6	Coronary artery disease;
SARC	cis	rs7762018	0.607	rs75999653	chr6:170066927	A/G	cg19338460	chr6:170058176	WDR27	-0.78	-5.24	-0.32	3.6e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs13191362	1.000	rs7769686	chr6:163199467	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.65	5.75	0.35	2.72e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs9341808	0.538	rs7747327	chr6:81035774	G/T	cg08355045	chr6:80787529	NA	-0.34	-5.02	-0.31	1.03e-6	Sitting height ratio;
SARC	cis	rs7659604	0.967	rs10008348	chr4:122666987	A/C	cg19748678	chr4:122722346	EXOSC9	0.4	4.88	0.3	1.98e-6	Type 2 diabetes;
SARC	cis	rs12044355	1.000	rs12044355	chr1:231844347	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.52	6.91	0.41	4.64e-11	Alzheimer's disease;
SARC	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg11062466	chr8:58055876	NA	0.66	5.58	0.34	6.52e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9300255	0.537	rs2682429	chr12:123642955	C/G	cg00376283	chr12:123451042	ABCB9	0.58	6.9	0.41	4.89e-11	Neutrophil percentage of white cells;
SARC	cis	rs10416265	0.528	rs3826906	chr19:33620897	C/T	cg27124370	chr19:33622961	WDR88	0.46	4.82	0.3	2.62e-6	Bone properties (heel);
SARC	cis	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg10822447	chr10:70748436	KIAA1279	0.44	5.27	0.33	3.17e-7	Schizophrenia;
SARC	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg27170947	chr2:26402098	FAM59B	0.37	4.79	0.3	2.91e-6	Gut microbiome composition (summer);
SARC	cis	rs2072499	0.778	rs41265025	chr1:156163906	C/T	cg24450063	chr1:156163899	SLC25A44	1.1	14.42	0.69	3.93e-34	Testicular germ cell tumor;
SARC	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.5	0.39	4.88e-10	Bipolar disorder;
SARC	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg24675658	chr1:53192096	ZYG11B	0.67	10.01	0.55	7.31e-20	Monocyte count;
SARC	cis	rs8028182	0.636	rs7166737	chr15:75682513	A/G	cg20655648	chr15:75932815	IMP3	0.62	7.29	0.43	4.69e-12	Sudden cardiac arrest;
SARC	cis	rs6504663	0.525	rs557	chr17:48563234	C/T	cg03168497	chr17:48586147	MYCBPAP	0.45	4.98	0.31	1.23e-6	Visceral fat;
SARC	cis	rs11971779	0.680	rs6962637	chr7:139051350	G/A	cg23387468	chr7:139079360	LUC7L2	0.33	4.71	0.3	4.2e-6	Diisocyanate-induced asthma;
SARC	cis	rs4925386	1.000	rs6089351	chr20:60916153	G/A	cg24112000	chr20:60950667	NA	0.33	5.4	0.33	1.62e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg03433033	chr1:76189801	ACADM	0.48	5.94	0.36	1.02e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs637571	0.522	rs542332	chr11:65744421	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.4	4.99	0.31	1.19e-6	Eosinophil percentage of white cells;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg13191172	chr4:186064250	SLC25A4	0.51	6.49	0.39	5.06e-10	Lung adenocarcinoma;
SARC	cis	rs11225247	0.881	rs79796684	chr11:102257170	T/C	cg11690896	chr11:102217788	BIRC2	0.77	5.37	0.33	1.93e-7	Vein graft stenosis in coronary artery bypass grafting;
SARC	cis	rs7769051	0.711	rs7758531	chr6:133085302	T/C	cg22852734	chr6:133119734	C6orf192	1.11	10.28	0.56	1.07e-20	Type 2 diabetes nephropathy;
SARC	cis	rs12950390	0.853	rs12450729	chr17:45855363	A/G	cg03474202	chr17:45855739	NA	-0.43	-6.72	-0.4	1.4e-10	IgG glycosylation;
SARC	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg06634786	chr22:41940651	POLR3H	-0.56	-6.67	-0.4	1.85e-10	Vitiligo;
SARC	trans	rs66573146	1.000	rs59683609	chr4:6964910	C/G	cg07817883	chr1:32538562	TMEM39B	1.45	9.08	0.51	4.59e-17	Granulocyte percentage of myeloid white cells;
SARC	cis	rs13191362	0.507	rs2849520	chr6:163132038	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.46	-4.97	-0.31	1.29e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs56011263	0.687	rs73221103	chr4:706740	T/C	cg14024328	chr4:719362	PCGF3	-0.42	-5.69	-0.35	3.78e-8	White blood cell count;
SARC	cis	rs6545883	0.929	rs1186700	chr2:61663372	A/C	cg15711740	chr2:61764176	XPO1	-0.43	-5.15	-0.32	5.48e-7	Tuberculosis;
SARC	cis	rs3008870	0.651	rs2815376	chr1:67508531	G/A	cg02640540	chr1:67518911	SLC35D1	0.63	8.27	0.48	1.04e-14	Lymphocyte percentage of white cells;
SARC	cis	rs2439831	0.867	rs8041132	chr15:43635136	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.76	7.92	0.46	9.46e-14	Lung cancer in ever smokers;
SARC	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg04166393	chr7:2884313	GNA12	0.48	5.53	0.34	8.39e-8	Height;
SARC	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg00149659	chr3:10157352	C3orf10	-0.77	-7.28	-0.43	5.17e-12	Alzheimer's disease;
SARC	cis	rs79149102	0.522	rs79811537	chr15:74871815	A/G	cg09165964	chr15:75287851	SCAMP5	-0.66	-5.14	-0.32	5.74e-7	Lung cancer;
SARC	cis	rs7084402	0.967	rs7087528	chr10:60301294	A/T	cg07615347	chr10:60278583	BICC1	-0.54	-7.95	-0.46	7.78e-14	Refractive error;
SARC	cis	rs1003719	0.715	rs58008706	chr21:38540506	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-9.22	-0.52	1.79e-17	Eye color traits;
SARC	cis	rs4713118	0.696	rs2394002	chr6:27748015	G/A	cg17221315	chr6:27791827	HIST1H4J	0.47	5.08	0.32	7.87e-7	Parkinson's disease;
SARC	cis	rs2242116	0.796	rs7623898	chr3:46974172	C/T	cg27129171	chr3:47204927	SETD2	-0.62	-8.12	-0.47	2.75e-14	Birth weight;
SARC	cis	rs3617	0.625	rs2336558	chr3:52886240	C/T	cg18404041	chr3:52824283	ITIH1	0.37	5.38	0.33	1.83e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg17158414	chr2:27665306	KRTCAP3	-0.41	-6.68	-0.4	1.72e-10	Total body bone mineral density;
SARC	cis	rs6088813	0.883	rs2425055	chr20:33903636	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.43	5.07	0.32	8.14e-7	Height;
SARC	cis	rs2816062	0.813	rs2816050	chr1:18894432	A/G	cg10574377	chr1:18908098	NA	0.35	4.94	0.31	1.51e-6	Urate levels in lean individuals;
SARC	cis	rs9291683	0.704	rs11726271	chr4:10098192	G/A	cg11266682	chr4:10021025	SLC2A9	-0.47	-8.54	-0.49	1.78e-15	Bone mineral density;
SARC	cis	rs6831352	0.918	rs34805407	chr4:100050786	C/A	cg13256891	chr4:100009986	ADH5	-0.65	-8.11	-0.47	2.83e-14	Alcohol dependence;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg04719420	chr1:183441464	SMG7	-0.8	-6.88	-0.41	5.4e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg06221963	chr1:154839813	KCNN3	-0.52	-8.26	-0.48	1.1e-14	Prostate cancer;
SARC	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg22683308	chr4:1340831	KIAA1530	0.44	5.18	0.32	4.9e-7	Longevity;
SARC	cis	rs7843479	0.601	rs4422769	chr8:21844265	A/G	cg17168535	chr8:21777572	XPO7	0.85	13.32	0.66	1.78e-30	Mean corpuscular volume;
SARC	cis	rs1801251	1.000	rs4517962	chr2:233578337	T/C	cg25237894	chr2:233734115	C2orf82	0.36	4.82	0.3	2.53e-6	Coronary artery disease;
SARC	cis	rs3741151	0.773	rs7931767	chr11:73239207	A/G	cg17517138	chr11:73019481	ARHGEF17	0.92	6.86	0.41	6.15e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs3020736	0.500	rs8138678	chr22:42516229	A/G	cg04733989	chr22:42467013	NAGA	-0.76	-10.6	-0.57	1.15e-21	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg21782813	chr7:2030301	MAD1L1	0.48	7.75	0.45	2.91e-13	Bipolar disorder and schizophrenia;
SARC	trans	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg21659725	chr3:3221576	CRBN	0.8	12.22	0.62	7.09e-27	Intelligence (multi-trait analysis);
SARC	cis	rs9814567	0.752	rs4634170	chr3:134335471	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.52	-6.62	-0.4	2.39e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg18252515	chr7:66147081	NA	0.46	5.05	0.31	8.83e-7	Aortic root size;
SARC	cis	rs9640161	0.783	rs35435439	chr7:150063534	C/T	cg21361702	chr7:150065534	REPIN1	0.6	6.72	0.4	1.38e-10	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs10504073	0.584	rs1511365	chr8:49975321	A/T	cg00325661	chr8:49890786	NA	0.51	6.71	0.4	1.49e-10	Blood metabolite ratios;
SARC	cis	rs2288912	0.872	rs9304646	chr19:45450408	T/C	cg13119609	chr19:45449297	APOC2	0.52	8.55	0.49	1.61e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs9914988	0.943	rs4262997	chr17:27129562	A/G	cg20469991	chr17:27169893	C17orf63	-0.5	-5.25	-0.33	3.36e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs9513627	1.000	rs4584676	chr13:100160560	A/G	cg25919922	chr13:100150906	NA	0.62	4.78	0.3	3.09e-6	Obesity-related traits;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg20430861	chr10:89435113	PAPSS2	0.46	6.4	0.39	8.68e-10	Thyroid stimulating hormone;
SARC	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg08280861	chr8:58055591	NA	0.6	5.28	0.33	2.92e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9549367	0.713	rs9549357	chr13:113860121	C/T	cg18105134	chr13:113819100	PROZ	-0.42	-5.98	-0.36	8.5e-9	Platelet distribution width;
SARC	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg22920501	chr2:26401640	FAM59B	0.6	8.03	0.47	4.76e-14	Gut microbiome composition (summer);
SARC	cis	rs710216	0.917	rs1681859	chr1:43411829	G/A	cg03128534	chr1:43423976	SLC2A1	0.66	6.61	0.4	2.6e-10	Red cell distribution width;
SARC	cis	rs6570726	0.764	rs376257	chr6:145862949	G/A	cg05347473	chr6:146136440	FBXO30	0.54	7.45	0.44	1.82e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7005380	0.538	rs2056305	chr8:120929105	C/T	cg21744203	chr8:120868354	DSCC1	-0.45	-5.22	-0.32	3.98e-7	Interstitial lung disease;
SARC	cis	rs7617773	0.817	rs3937	chr3:48312402	T/C	cg11946769	chr3:48343235	NME6	0.68	8.99	0.51	8.62e-17	Coronary artery disease;
SARC	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg13939156	chr17:80058883	NA	0.4	6.22	0.38	2.24e-9	Life satisfaction;
SARC	cis	rs2594989	0.887	rs2447604	chr3:11574297	G/A	cg00170343	chr3:11313890	ATG7	-0.59	-5.26	-0.33	3.32e-7	Circulating chemerin levels;
SARC	cis	rs6582630	0.555	rs7965311	chr12:38513307	G/A	cg26384229	chr12:38710491	ALG10B	-0.8	-11.9	-0.61	7.82e-26	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs13161895	1.000	rs34882290	chr5:179463836	C/A	cg02702477	chr5:179499311	RNF130	0.67	6.57	0.4	3.17e-10	LDL cholesterol;
SARC	cis	rs4356932	1.000	rs11097212	chr4:76952879	A/G	cg24176760	chr4:76958061	ART3;CXCL11	-0.29	-4.85	-0.3	2.24e-6	Blood protein levels;
SARC	cis	rs7959452	0.535	rs1350166	chr12:69636314	G/T	cg14784868	chr12:69753453	YEATS4	0.4	5.28	0.33	3.01e-7	Blood protein levels;
SARC	cis	rs6120849	0.754	rs6088686	chr20:33623437	C/T	cg06115741	chr20:33292138	TP53INP2	0.54	5.17	0.32	5.03e-7	Protein C levels;
SARC	trans	rs2727020	0.857	rs1917324	chr11:49371759	G/C	cg03929089	chr4:120376271	NA	-0.72	-9.07	-0.51	4.97e-17	Coronary artery disease;
SARC	cis	rs9840812	0.591	rs1291921	chr3:136036226	A/G	cg15507776	chr3:136538369	TMEM22	0.49	5.42	0.33	1.52e-7	Fibrinogen levels;
SARC	cis	rs3824344	0.507	rs10814501	chr9:37019304	C/T	cg14294708	chr9:37120828	ZCCHC7	0.42	5.01	0.31	1.08e-6	Intelligence;
SARC	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg11890956	chr21:40555474	PSMG1	1.17	19.37	0.79	1.93e-50	Cognitive function;
SARC	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg20891558	chr2:74357851	NA	0.7	9.69	0.54	7.1e-19	Gestational age at birth (maternal effect);
SARC	cis	rs12754538	0.739	rs6577518	chr1:8748923	T/C	cg13785123	chr1:8931135	ENO1	-0.46	-5.14	-0.32	5.73e-7	Subjective well-being;
SARC	cis	rs9420	0.961	rs11607056	chr11:57496820	C/T	cg23127183	chr11:57508653	C11orf31	-0.55	-6.28	-0.38	1.61e-9	Schizophrenia;
SARC	cis	rs13256369	1.000	rs7004438	chr8:8574379	C/T	cg18904891	chr8:8559673	CLDN23	0.48	5.53	0.34	8.72e-8	Obesity-related traits;
SARC	cis	rs4481887	0.927	rs4282853	chr1:248475127	A/G	cg13385794	chr1:248469461	NA	0.34	5.32	0.33	2.46e-7	Common traits (Other);
SARC	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg18252515	chr7:66147081	NA	0.46	5.05	0.31	8.81e-7	Aortic root size;
SARC	trans	rs3808502	0.503	rs34190028	chr8:11417150	G/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.7	-0.4	1.58e-10	Neuroticism;
SARC	cis	rs7020830	0.823	rs13285624	chr9:37129496	T/G	cg14294708	chr9:37120828	ZCCHC7	1.14	19.96	0.79	2.32e-52	Schizophrenia;
SARC	cis	rs6546324	0.625	rs2902025	chr2:67842424	A/G	cg18237512	chr2:67827392	NA	-0.52	-6.22	-0.38	2.3e-9	Endometriosis;
SARC	cis	rs6582630	0.519	rs7305545	chr12:38349223	G/A	cg13010199	chr12:38710504	ALG10B	0.78	10.77	0.58	3.24e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs427394	0.659	rs175594	chr5:6729885	T/G	cg10857441	chr5:6722123	POLS	-0.33	-4.85	-0.3	2.29e-6	Menopause (age at onset);
SARC	cis	rs643506	0.934	rs4936690	chr11:111646915	T/A	cg09085632	chr11:111637200	PPP2R1B	0.49	5.57	0.34	7.11e-8	Breast cancer;
SARC	cis	rs244731	0.959	rs10037110	chr5:176658066	A/T	cg06060754	chr5:176797920	RGS14	-0.43	-5.04	-0.31	9.37e-7	Urate levels in lean individuals;
SARC	cis	rs2463822	0.925	rs12292586	chr11:62156312	C/T	cg06239285	chr11:62104954	ASRGL1	-0.86	-8.36	-0.48	5.71e-15	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs6910061	1.000	rs2327335	chr6:11119047	A/G	cg27233058	chr6:11094804	LOC221710	-0.58	-5.87	-0.36	1.49e-8	Diabetic kidney disease;
SARC	cis	rs6120849	0.754	rs36003887	chr20:33589107	G/A	cg06115741	chr20:33292138	TP53INP2	0.54	5.24	0.32	3.64e-7	Protein C levels;
SARC	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg08219700	chr8:58056026	NA	0.77	6.99	0.42	2.82e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs6908034	0.660	rs7746588	chr6:19804640	C/T	cg02682789	chr6:19804855	NA	0.86	7.59	0.45	7.44e-13	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg15017007	chr7:132984180	EXOC4	0.47	6.61	0.4	2.64e-10	Thyroid stimulating hormone;
SARC	cis	rs1050631	0.592	rs1789548	chr18:33724296	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.56	6.51	0.39	4.5e-10	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs7937682	0.961	rs4935790	chr11:111633014	T/C	cg09085632	chr11:111637200	PPP2R1B	1.08	19.87	0.79	4.72e-52	Primary sclerosing cholangitis;
SARC	cis	rs3796352	0.667	rs34860124	chr3:52857778	T/A	cg27565382	chr3:53032988	SFMBT1	0.79	5.38	0.33	1.8e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs62344088	0.590	rs6882234	chr5:177389	C/G	cg22496380	chr5:211416	CCDC127	-0.73	-5.48	-0.34	1.08e-7	Asthma (childhood onset);
SARC	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.79	12.13	0.62	1.45e-26	Personality dimensions;
SARC	cis	rs5758659	0.653	rs133383	chr22:42473603	C/T	cg04692870	chr22:42525206	CYP2D6	0.35	4.72	0.3	4.08e-6	Cognitive function;
SARC	cis	rs2832191	0.716	rs1984012	chr21:30392472	T/C	cg08807101	chr21:30365312	RNF160	0.89	14.13	0.68	3.83e-33	Dental caries;
SARC	cis	rs477692	0.569	rs10764884	chr10:131308370	G/C	cg05714579	chr10:131428358	MGMT	0.56	7.53	0.44	1.08e-12	Response to temozolomide;
SARC	cis	rs4555082	0.834	rs4412909	chr14:105759226	T/C	cg06808227	chr14:105710500	BRF1	-0.5	-6.1	-0.37	4.33e-9	Mean platelet volume;Platelet distribution width;
SARC	cis	rs11650776	1	rs11650776	chr17:37641402	G/A	cg20243544	chr17:37824526	PNMT	0.57	6.7	0.4	1.57e-10	Lung function (FEV1);
SARC	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.39	-4.85	-0.3	2.26e-6	Lymphocyte counts;
SARC	cis	rs5167	0.781	rs11672748	chr19:45490192	A/G	cg10169327	chr19:45448959	APOC2	0.31	4.92	0.31	1.61e-6	Blood protein levels;
SARC	cis	rs918629	0.567	rs11741590	chr5:95241127	A/G	cg16656078	chr5:95278638	ELL2	0.52	6.7	0.4	1.52e-10	IgG glycosylation;
SARC	cis	rs910316	1.000	rs28626045	chr14:75589195	G/C	cg23033748	chr14:75592666	NEK9	0.37	5.3	0.33	2.73e-7	Height;
SARC	cis	rs9303280	0.773	rs11078925	chr17:38025208	T/C	cg20243544	chr17:37824526	PNMT	0.43	5.59	0.34	6.33e-8	Self-reported allergy;
SARC	cis	rs7223966	0.921	rs34699959	chr17:61960720	T/G	cg00588841	chr17:61851480	DDX42;CCDC47	-0.58	-6.39	-0.39	8.85e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs12479064	0.694	rs11896520	chr2:99995517	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.43	-4.83	-0.3	2.44e-6	Chronic sinus infection;
SARC	cis	rs79149102	0.579	rs8039433	chr15:75367367	T/C	cg17294928	chr15:75287854	SCAMP5	-0.95	-8.39	-0.48	4.62e-15	Lung cancer;
SARC	cis	rs644799	0.965	rs10831426	chr11:95505888	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.88	13.79	0.67	5.12e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs5758659	0.714	rs5758578	chr22:42490292	A/C	cg15128208	chr22:42549153	NA	0.36	5.13	0.32	6.21e-7	Cognitive function;
SARC	cis	rs9486715	0.867	rs9386500	chr6:96889845	A/C	cg18709589	chr6:96969512	KIAA0776	0.54	6.66	0.4	1.95e-10	Headache;
SARC	cis	rs2153535	0.580	rs6910742	chr6:8448328	G/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.75	0.5	4.47e-16	Motion sickness;
SARC	cis	rs4427176	0.522	rs62489416	chr8:9660058	G/C	cg21625330	chr8:9911636	MSRA	-0.66	-5.34	-0.33	2.18e-7	Mosquito bite size;
SARC	cis	rs11718455	0.921	rs11130020	chr3:44009459	C/T	cg08738300	chr3:44038990	NA	0.56	6.17	0.38	2.92e-9	Coronary artery disease;
SARC	cis	rs7551222	0.721	rs1460036	chr1:204527379	A/G	cg20240347	chr1:204465584	NA	-0.33	-5.81	-0.36	2.06e-8	Schizophrenia;
SARC	cis	rs8017423	0.967	rs11626011	chr14:90693572	A/G	cg20276874	chr14:90721474	PSMC1	-0.34	-4.72	-0.3	4.12e-6	Mortality in heart failure;
SARC	trans	rs11098499	0.954	rs17046116	chr4:120387259	G/A	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	cis	rs721399	0.539	rs10087857	chr8:18267461	G/C	cg18736775	chr8:18248649	NAT2	-0.57	-5.67	-0.35	4.25e-8	Blood metabolite levels;
SARC	cis	rs9303401	0.659	rs35928756	chr17:56702652	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	12.63	0.64	3.28e-28	Cognitive test performance;
SARC	cis	rs1153858	1.000	rs7402650	chr15:45701895	C/T	cg15395560	chr15:45543142	SLC28A2	-0.27	-4.87	-0.3	2.05e-6	Homoarginine levels;
SARC	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg11764359	chr7:65958608	NA	-0.74	-9.41	-0.52	4.85e-18	Aortic root size;
SARC	cis	rs9858542	0.953	rs6766131	chr3:49538932	T/C	cg03060546	chr3:49711283	APEH	-0.57	-7.03	-0.42	2.31e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs28830936	0.510	rs11070349	chr15:42085017	A/C	cg17847044	chr15:42102381	MAPKBP1	-0.48	-7.63	-0.45	5.91e-13	Diastolic blood pressure;
SARC	trans	rs208515	0.525	rs12204452	chr6:66680325	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.99	11.54	0.6	1.13e-24	Exhaled nitric oxide levels;
SARC	cis	rs7481584	0.624	rs516443	chr11:3047294	A/G	cg08508325	chr11:3079039	CARS	0.23	5.13	0.32	6.14e-7	Calcium levels;
SARC	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg12698349	chr2:225449008	CUL3	0.6	7.72	0.45	3.34e-13	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg20007245	chr22:24372913	LOC391322	-0.7	-8.9	-0.5	1.6e-16	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-8.98	-0.51	9.19e-17	Alzheimer's disease;
SARC	cis	rs7937682	0.575	rs11604704	chr11:111764396	G/A	cg09085632	chr11:111637200	PPP2R1B	0.83	11.28	0.59	8.12e-24	Primary sclerosing cholangitis;
SARC	trans	rs61931739	0.817	rs11833948	chr12:34276942	G/T	cg13010199	chr12:38710504	ALG10B	0.57	7.38	0.44	2.79e-12	Morning vs. evening chronotype;
SARC	cis	rs9322193	0.607	rs12527391	chr6:150203292	T/C	cg11878867	chr6:150167359	LRP11	-0.41	-4.83	-0.3	2.53e-6	Lung cancer;
SARC	cis	rs2250402	0.510	rs2898984	chr15:40324075	G/C	cg10636054	chr15:40330586	SRP14	0.96	7.31	0.43	4.28e-12	Corneal curvature;
SARC	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-5.72	-0.35	3.23e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2952156	0.684	rs11658786	chr17:37815899	G/A	cg07936489	chr17:37558343	FBXL20	-0.43	-5.45	-0.34	1.27e-7	Asthma;
SARC	cis	rs10911232	0.507	rs4652762	chr1:182993960	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.67	0.57	6.63e-22	Hypertriglyceridemia;
SARC	cis	rs9300255	0.620	rs1727311	chr12:123660716	T/G	cg00376283	chr12:123451042	ABCB9	0.58	5.65	0.35	4.71e-8	Neutrophil percentage of white cells;
SARC	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9900497	0.604	rs12949049	chr17:19653310	A/G	cg27329371	chr17:19651940	ALDH3A1	0.31	4.89	0.31	1.85e-6	Response to paliperidone in schizophrenia (CGI-S score);
SARC	cis	rs910316	0.737	rs175045	chr14:75475275	A/C	cg11812906	chr14:75593930	NEK9	-0.66	-8.0	-0.46	5.87e-14	Height;
SARC	cis	rs523522	0.962	rs4767902	chr12:120910004	C/T	cg12219531	chr12:120966889	COQ5	0.81	10.4	0.56	4.74e-21	High light scatter reticulocyte count;
SARC	cis	rs6599636	1	rs6599636	chr10:124677899	T/G	cg05252487	chr10:124670562	FAM24A	-0.32	-4.89	-0.31	1.89e-6	Red cell distribution width;
SARC	cis	rs2645694	0.626	rs2703129	chr4:77818548	T/C	cg18351406	chr4:77819688	ANKRD56	0.45	6.26	0.38	1.87e-9	Emphysema distribution in smoking;
SARC	cis	rs3106136	0.814	rs6532482	chr4:95277414	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.39	-0.33	1.7e-7	Capecitabine sensitivity;
SARC	cis	rs3768617	0.745	rs4546885	chr1:183025555	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.62	8.31	0.48	7.83e-15	Fuchs's corneal dystrophy;
SARC	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg03709012	chr19:19516395	GATAD2A	-1.04	-17.97	-0.76	6.96e-46	Tonsillectomy;
SARC	cis	rs11097912	0.632	rs76869000	chr4:107200819	A/G	cg09646026	chr4:107269030	AIMP1	-0.45	-4.86	-0.3	2.2e-6	Airflow obstruction;
SARC	cis	rs921968	0.541	rs667251	chr2:219384384	C/G	cg02176678	chr2:219576539	TTLL4	0.47	7.22	0.43	7.38e-12	Mean corpuscular hemoglobin concentration;
SARC	cis	rs748404	0.723	rs560134	chr15:43555699	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	5.63	0.35	5.04e-8	Lung cancer;
SARC	cis	rs6088580	0.634	rs4911423	chr20:32999386	T/A	cg08999081	chr20:33150536	PIGU	-0.42	-6.39	-0.39	9.12e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs6540556	0.679	rs11808690	chr1:209891450	T/G	cg05527609	chr1:210001259	C1orf107	-0.58	-5.41	-0.33	1.59e-7	Red blood cell count;
SARC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	11.3	0.6	6.55e-24	Platelet count;
SARC	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg13206674	chr6:150067644	NUP43	0.42	5.53	0.34	8.42e-8	Lung cancer;
SARC	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.98	11.82	0.61	1.49e-25	Platelet count;
SARC	cis	rs2282802	0.711	rs3777095	chr5:139660916	G/A	cg26211634	chr5:139558579	C5orf32	0.37	4.81	0.3	2.75e-6	Intelligence (multi-trait analysis);
SARC	cis	rs6570726	0.935	rs419850	chr6:145827281	A/G	cg23711669	chr6:146136114	FBXO30	0.79	12.01	0.62	3.49e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs8072100	0.875	rs12451409	chr17:45544856	A/G	cg08085267	chr17:45401833	C17orf57	-0.45	-5.47	-0.34	1.15e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs11098499	0.863	rs58452170	chr4:120459674	A/T	cg24375607	chr4:120327624	NA	0.42	4.94	0.31	1.52e-6	Corneal astigmatism;
SARC	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg22496380	chr5:211416	CCDC127	-0.88	-9.59	-0.53	1.47e-18	Breast cancer;
SARC	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg17376030	chr22:41985996	PMM1	0.73	8.85	0.5	2.29e-16	Vitiligo;
SARC	cis	rs6696846	0.749	rs7553876	chr1:205079915	A/G	cg21643547	chr1:205240462	TMCC2	-0.55	-7.01	-0.42	2.49e-11	Red blood cell count;
SARC	cis	rs7584330	0.666	rs937386	chr2:238364039	C/T	cg14458575	chr2:238380390	NA	0.56	6.26	0.38	1.83e-9	Prostate cancer;
SARC	cis	rs1144333	0.655	rs1938321	chr1:76464302	T/C	cg03433033	chr1:76189801	ACADM	0.63	5.15	0.32	5.47e-7	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg22484793	chr3:52261325	TLR9	0.3	4.97	0.31	1.28e-6	Bipolar disorder;
SARC	cis	rs1707322	1.000	rs10789485	chr1:46407308	C/T	cg03146154	chr1:46216737	IPP	0.5	6.05	0.37	5.66e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6674176	0.660	rs6801	chr1:44396646	C/G	cg12908607	chr1:44402522	ARTN	0.41	7.07	0.42	1.83e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs986417	0.818	rs7156317	chr14:61087740	G/A	cg27398547	chr14:60952738	C14orf39	0.76	7.17	0.43	9.77e-12	Gut microbiota (bacterial taxa);
SARC	cis	rs6815814	0.851	rs4129009	chr4:38774889	T/C	cg06935464	chr4:38784597	TLR10	0.58	5.28	0.33	2.99e-7	Breast cancer;
SARC	cis	rs761746	0.920	rs5753662	chr22:31901432	G/A	cg15162869	chr22:32027605	PISD	0.45	6.14	0.37	3.43e-9	Intelligence;
SARC	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg25894440	chr7:65020034	NA	0.78	5.89	0.36	1.34e-8	Diabetic kidney disease;
SARC	cis	rs6728642	0.519	rs7589232	chr2:97566148	C/T	cg26665480	chr2:98280029	ACTR1B	-0.54	-4.99	-0.31	1.18e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg07701084	chr6:150067640	NUP43	0.39	5.15	0.32	5.67e-7	Lung cancer;
SARC	cis	rs67311347	0.713	rs4974018	chr3:40307419	G/A	cg09455208	chr3:40491958	NA	0.34	5.23	0.32	3.75e-7	Renal cell carcinoma;
SARC	cis	rs1371867	0.641	rs1788209	chr8:101337056	C/T	cg11906718	chr8:101322791	RNF19A	0.69	8.94	0.51	1.22e-16	Atrioventricular conduction;
SARC	cis	rs9902453	0.933	rs7216494	chr17:28502651	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	6.66	0.4	1.98e-10	Coffee consumption (cups per day);
SARC	cis	rs17376456	0.825	rs10075217	chr5:93176774	C/G	cg25358565	chr5:93447407	FAM172A	1.22	11.66	0.61	4.67e-25	Diabetic retinopathy;
SARC	cis	rs17376456	0.569	rs13186432	chr5:93336940	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.47	-5.07	-0.32	8.09e-7	Diabetic retinopathy;
SARC	cis	rs9916302	0.904	rs6503507	chr17:37525274	C/T	cg07936489	chr17:37558343	FBXL20	0.69	9.2	0.52	2.12e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs1050631	0.623	rs7242481	chr18:33709217	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.6	6.93	0.41	4.13e-11	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs2230307	0.656	rs2274569	chr1:100435079	T/C	cg24955406	chr1:100503596	HIAT1	0.68	5.67	0.35	4.27e-8	Carotid intima media thickness;
SARC	cis	rs4268898	0.931	rs55642516	chr2:24502305	A/G	cg26838691	chr2:24397539	C2orf84	-0.39	-5.17	-0.32	5e-7	Asthma;
SARC	trans	rs1814175	0.519	rs10839291	chr11:49514321	G/A	cg15704280	chr7:45808275	SEPT13	0.7	8.11	0.47	2.96e-14	Height;
SARC	trans	rs3942852	0.568	rs2904315	chr11:48109948	C/T	cg03929089	chr4:120376271	NA	0.55	6.73	0.4	1.3100000000000001e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs6693567	0.565	rs471657	chr1:150276461	G/A	cg09579323	chr1:150459698	TARS2	-0.43	-5.49	-0.34	1.05e-7	Migraine;
SARC	cis	rs2180341	1.000	rs6569478	chr6:127598619	G/A	cg24812749	chr6:127587940	RNF146	0.97	12.76	0.64	1.23e-28	Breast cancer;
SARC	cis	rs7524258	0.903	rs6577424	chr1:7292417	C/T	cg07173049	chr1:7289937	CAMTA1	-0.4	-7.79	-0.45	2.14e-13	Tourette's syndrome or obsessive-compulsive disorder;
SARC	cis	rs10992471	0.575	rs2147060	chr9:95160477	T/C	cg13798575	chr9:95087839	CENPP;NOL8	0.41	4.99	0.31	1.19e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs7520050	0.778	rs2991985	chr1:46080530	T/C	cg24296786	chr1:45957014	TESK2	0.42	5.45	0.34	1.31e-7	Red blood cell count;Reticulocyte count;
SARC	cis	rs858239	0.600	rs10256524	chr7:23144947	T/C	cg23682824	chr7:23144976	KLHL7	0.7	9.72	0.54	5.93e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs2816062	0.813	rs2745318	chr1:18895844	C/T	cg10574377	chr1:18908098	NA	-0.34	-4.95	-0.31	1.41e-6	Urate levels in lean individuals;
SARC	cis	rs27434	0.583	rs34761	chr5:96153624	C/T	cg16492584	chr5:96139282	ERAP1	-0.56	-6.95	-0.41	3.53e-11	Ankylosing spondylitis;
SARC	cis	rs4919694	1.000	rs17727391	chr10:104836101	C/A	cg04362960	chr10:104952993	NT5C2	0.66	5.4	0.33	1.66e-7	Arsenic metabolism;
SARC	cis	rs9297145	0.585	rs13235218	chr7:98785080	C/T	cg05967295	chr7:98741636	SMURF1	-0.49	-5.82	-0.36	1.97e-8	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg15324756	chr13:110961142	COL4A2	0.61	4.81	0.3	2.68e-6	Obesity-related traits;
SARC	cis	rs9399135	0.935	rs4273704	chr6:135297520	G/T	cg24558204	chr6:135376177	HBS1L	0.45	6.01	0.37	7.01e-9	Red blood cell count;
SARC	cis	rs7113850	0.541	rs7129839	chr11:24208606	C/T	ch.11.24196551F	chr11:24239977	NA	0.77	6.01	0.37	7.03e-9	Bone fracture in osteoporosis;
SARC	cis	rs4595586	0.545	rs3914595	chr12:39388530	G/T	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	cis	rs6545883	0.895	rs6545871	chr2:61692203	G/T	cg15711740	chr2:61764176	XPO1	-0.43	-5.17	-0.32	5.12e-7	Tuberculosis;
SARC	cis	rs876084	0.505	rs62526984	chr8:121128068	A/G	cg06265175	chr8:121136014	COL14A1	0.57	7.43	0.44	2.08e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg06873352	chr17:61820015	STRADA	0.54	7.0	0.42	2.74e-11	Prudent dietary pattern;
SARC	cis	rs3020736	0.500	rs7364293	chr22:42506370	C/T	cg15557168	chr22:42548783	NA	0.36	4.94	0.31	1.51e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs754466	0.606	rs3740250	chr10:79580101	C/T	cg17075019	chr10:79541650	NA	-0.8	-12.12	-0.62	1.54e-26	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7552404	0.727	rs11161626	chr1:76260837	C/T	cg22875332	chr1:76189707	ACADM	0.44	5.56	0.34	7.24e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs17376456	0.825	rs10476590	chr5:93244884	A/T	cg21475434	chr5:93447410	FAM172A	0.85	7.53	0.44	1.13e-12	Diabetic retinopathy;
SARC	cis	rs12142240	0.698	rs72885198	chr1:46812888	C/T	cg10495392	chr1:46806563	NSUN4	0.64	6.73	0.4	1.28e-10	Menopause (age at onset);
SARC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg09033563	chr22:24373618	LOC391322	-0.51	-6.2	-0.38	2.56e-9	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9902453	0.967	rs34323226	chr17:28517454	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	6.78	0.41	9.61e-11	Coffee consumption (cups per day);
SARC	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg08280861	chr8:58055591	NA	0.67	5.25	0.33	3.4e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2153535	0.542	rs4440510	chr6:8471818	C/T	cg21535247	chr6:8435926	SLC35B3	0.53	6.7	0.4	1.55e-10	Motion sickness;
SARC	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg21132104	chr15:45694354	SPATA5L1	0.77	10.98	0.58	6.87e-23	Homoarginine levels;
SARC	cis	rs9818758	0.607	rs34580506	chr3:49113713	C/A	cg00383909	chr3:49044727	WDR6	0.77	6.75	0.4	1.16e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs7412746	0.658	rs11204739	chr1:150865760	A/G	cg15448220	chr1:150897856	SETDB1	0.51	6.65	0.4	2.02e-10	Melanoma;
SARC	cis	rs9948	1.000	rs1320146	chr2:97507727	T/C	cg01990225	chr2:97406019	LMAN2L	-0.64	-5.06	-0.31	8.4e-7	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs738322	0.839	rs133015	chr22:38572526	C/G	cg25457927	chr22:38595422	NA	-0.29	-6.18	-0.38	2.83e-9	Cutaneous nevi;
SARC	cis	rs1008375	0.898	rs2079892	chr4:17577163	G/A	cg16339924	chr4:17578868	LAP3	0.69	9.17	0.51	2.59e-17	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs459571	0.883	rs2520096	chr9:136919416	A/G	cg13789015	chr9:136890014	NCRNA00094	0.61	8.5	0.49	2.29e-15	Platelet distribution width;
SARC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg26338869	chr17:61819248	STRADA	0.79	10.63	0.57	8.77e-22	Prudent dietary pattern;
SARC	cis	rs9303280	0.840	rs12939457	chr17:38032188	T/C	cg20243544	chr17:37824526	PNMT	0.42	5.63	0.35	5.11e-8	Self-reported allergy;
SARC	cis	rs7927592	0.913	rs12272917	chr11:68263370	T/C	cg01657329	chr11:68192670	LRP5	-0.41	-5.07	-0.32	7.93e-7	Total body bone mineral density;
SARC	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg13012494	chr21:47604986	C21orf56	0.55	6.31	0.38	1.38e-9	Testicular germ cell tumor;
SARC	cis	rs7429990	0.965	rs6791834	chr3:48115088	C/A	cg11946769	chr3:48343235	NME6	-0.46	-5.32	-0.33	2.46e-7	Educational attainment (years of education);
SARC	cis	rs116095464	0.558	rs56298907	chr5:283280	C/A	cg22496380	chr5:211416	CCDC127	-0.96	-8.83	-0.5	2.59e-16	Breast cancer;
SARC	cis	rs9911578	1.000	rs12940681	chr17:56933622	T/C	cg05425664	chr17:57184151	TRIM37	-0.64	-7.98	-0.46	6.52e-14	Intelligence (multi-trait analysis);
SARC	cis	rs524281	0.692	rs2302884	chr11:65824084	C/T	cg14036092	chr11:66035641	RAB1B	-0.61	-7.02	-0.42	2.41e-11	Electroencephalogram traits;
SARC	cis	rs6815814	0.950	rs11727978	chr4:38811051	T/A	cg02016764	chr4:38805732	TLR1	-0.41	-4.86	-0.3	2.18e-6	Breast cancer;
SARC	cis	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg26513180	chr16:89883248	FANCA	0.72	4.79	0.3	2.94e-6	Skin colour saturation;
SARC	cis	rs7635838	0.892	rs4684773	chr3:11418508	C/T	cg00170343	chr3:11313890	ATG7	0.63	8.4	0.48	4.32e-15	HDL cholesterol;
SARC	cis	rs753778	0.629	rs2278447	chr8:142206905	G/C	cg16341495	chr8:142228727	SLC45A4	-0.4	-5.57	-0.34	7.18e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg13939156	chr17:80058883	NA	-0.43	-6.56	-0.39	3.44e-10	Life satisfaction;
SARC	cis	rs607987	0.871	rs1933346	chr11:30279354	C/T	cg06241208	chr11:30344200	C11orf46	0.41	4.96	0.31	1.34e-6	Body mass index;
SARC	cis	rs6570726	0.791	rs4332001	chr6:145934841	T/C	cg23711669	chr6:146136114	FBXO30	0.77	12.16	0.62	1.17e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9486715	0.867	rs4839834	chr6:96882109	C/A	cg18709589	chr6:96969512	KIAA0776	0.54	6.66	0.4	1.95e-10	Headache;
SARC	cis	rs3820928	0.967	rs16822905	chr2:227770727	G/C	cg05526886	chr2:227700861	RHBDD1	-0.53	-6.33	-0.38	1.22e-9	Pulmonary function;
SARC	cis	rs9457247	1.000	rs413232	chr6:167400972	G/A	cg23791538	chr6:167370224	RNASET2	-0.63	-8.73	-0.5	4.84e-16	Crohn's disease;
SARC	cis	rs36051895	0.632	rs1571438	chr9:5140313	A/C	cg02405213	chr9:5042618	JAK2	-0.44	-5.43	-0.33	1.43e-7	Pediatric autoimmune diseases;
SARC	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg16479474	chr6:28041457	NA	0.37	5.35	0.33	2.08e-7	Parkinson's disease;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg26174628	chr8:80864316	MRPS28	0.47	6.46	0.39	6e-10	Thyroid stimulating hormone;
SARC	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg16325326	chr1:53192061	ZYG11B	-0.81	-12.97	-0.65	2.49e-29	Monocyte count;
SARC	cis	rs3087591	0.960	rs9303642	chr17:29578360	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.55	-6.89	-0.41	5.07e-11	Hip circumference;
SARC	cis	rs4660306	0.614	rs11211116	chr1:45930038	A/G	cg24296786	chr1:45957014	TESK2	-0.51	-4.96	-0.31	1.35e-6	Homocysteine levels;
SARC	trans	rs10506458	0.915	rs17738485	chr12:63394932	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.74	-6.26	-0.38	1.81e-9	Hemostatic factors and hematological phenotypes;
SARC	cis	rs2228479	0.702	rs62052710	chr16:89854893	C/T	cg00800038	chr16:89945340	TCF25	-0.79	-5.47	-0.34	1.19e-7	Skin colour saturation;
SARC	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.5	0.39	4.96e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7681440	0.904	rs28734152	chr4:90767359	C/T	cg06632027	chr4:90757378	SNCA	0.39	5.66	0.35	4.49e-8	Dementia with Lewy bodies;
SARC	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.72	8.69	0.49	6.62e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6570726	0.791	rs6902404	chr6:145905254	G/A	cg05347473	chr6:146136440	FBXO30	0.51	7.09	0.42	1.56e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3956705	0.798	rs1045477	chr7:32908704	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.47	5.66	0.35	4.36e-8	Red cell distribution width;
SARC	cis	rs8180040	0.676	rs1108301	chr3:47029426	G/A	cg27129171	chr3:47204927	SETD2	-0.63	-8.37	-0.48	5.45e-15	Colorectal cancer;
SARC	cis	rs73206853	0.841	rs28772589	chr12:110845040	C/T	cg10860002	chr12:110842031	ANAPC7	0.62	4.91	0.31	1.72e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs10892173	0.765	rs7125693	chr11:117670651	C/T	cg21640587	chr11:117668038	DSCAML1	0.48	6.73	0.4	1.27e-10	Myopia;
SARC	cis	rs1865760	0.865	rs9393678	chr6:25945819	C/T	cg16482183	chr6:26056742	HIST1H1C	0.51	6.49	0.39	4.98e-10	Height;
SARC	cis	rs7412746	0.658	rs11204723	chr1:150731618	T/C	cg13175981	chr1:150552382	MCL1	-0.46	-5.51	-0.34	9.58e-8	Melanoma;
SARC	cis	rs3820928	0.874	rs4461255	chr2:227846524	C/T	cg05526886	chr2:227700861	RHBDD1	0.57	6.73	0.4	1.3e-10	Pulmonary function;
SARC	cis	rs9381040	0.655	rs2268192	chr6:41024626	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-4.92	-0.31	1.64e-6	Alzheimer's disease (late onset);
SARC	cis	rs262150	0.544	rs2428780	chr7:158812471	T/A	cg19418458	chr7:158789849	NA	-0.41	-5.74	-0.35	2.96e-8	Facial morphology (factor 20);
SARC	cis	rs9581943	0.901	rs9554188	chr13:28462132	G/A	cg16302790	chr13:28498334	PDX1	0.56	8.37	0.48	5.41e-15	Pancreatic cancer;
SARC	cis	rs4481887	0.927	rs4390208	chr1:248472211	C/T	cg13385794	chr1:248469461	NA	0.33	5.19	0.32	4.68e-7	Common traits (Other);
SARC	cis	rs992157	0.687	rs10206984	chr2:219066980	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.65	9.12	0.51	3.63e-17	Colorectal cancer;
SARC	cis	rs2204008	0.840	rs7136347	chr12:38453531	G/A	cg26384229	chr12:38710491	ALG10B	0.87	12.52	0.63	7.68e-28	Bladder cancer;
SARC	cis	rs2635047	0.615	rs2684833	chr18:44719428	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.45	-5.4	-0.33	1.62e-7	Educational attainment;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg23373966	chr6:20668719	CDKAL1	0.5	6.82	0.41	7.88e-11	Thyroid stimulating hormone;
SARC	cis	rs3845702	0.866	rs818659	chr2:180870893	G/A	cg01881094	chr2:180872142	CWC22	0.62	5.64	0.35	4.99e-8	Schizophrenia;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg25141894	chr1:115164619	DENND2C	0.49	6.81	0.41	8.07e-11	Tetralogy of Fallot;
SARC	cis	rs9818758	0.607	rs34343820	chr3:49309534	C/G	cg00383909	chr3:49044727	WDR6	0.72	6.24	0.38	2.04e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs76419734	1.000	rs72671870	chr4:106659345	C/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.84	5.41	0.33	1.59e-7	Post bronchodilator FEV1;
SARC	cis	rs7635838	0.596	rs347599	chr3:11258191	C/T	cg00170343	chr3:11313890	ATG7	-0.65	-8.93	-0.51	1.27e-16	HDL cholesterol;
SARC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg20102877	chr2:27665638	KRTCAP3	-0.37	-5.25	-0.33	3.44e-7	Total body bone mineral density;
SARC	cis	rs2228479	0.850	rs62052212	chr16:89981960	G/A	cg06558623	chr16:89946397	TCF25	0.88	5.83	0.36	1.84e-8	Skin colour saturation;
SARC	trans	rs7395662	0.591	rs4882138	chr11:48619321	A/G	cg15704280	chr7:45808275	SEPT13	-0.49	-6.49	-0.39	5.08e-10	HDL cholesterol;
SARC	cis	rs554111	0.613	rs3816455	chr1:21191430	A/G	cg08890418	chr1:21044141	KIF17	-0.36	-4.99	-0.31	1.17e-6	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs986417	0.901	rs1950312	chr14:60989784	A/G	cg27398547	chr14:60952738	C14orf39	-1.03	-9.33	-0.52	8.69e-18	Gut microbiota (bacterial taxa);
SARC	cis	rs6714710	0.603	rs11680321	chr2:98379267	C/T	cg26665480	chr2:98280029	ACTR1B	0.48	6.36	0.38	1.07e-9	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs3820928	0.874	rs2177593	chr2:227833869	G/A	cg05526886	chr2:227700861	RHBDD1	-0.56	-6.76	-0.4	1.09e-10	Pulmonary function;
SARC	cis	rs7103648	0.897	rs3758675	chr11:47400602	G/A	cg20307385	chr11:47447363	PSMC3	0.79	11.26	0.59	8.83e-24	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs3008870	1.000	rs2985821	chr1:67403787	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.91	11.38	0.6	3.78e-24	Lymphocyte percentage of white cells;
SARC	trans	rs11722228	0.522	rs7681250	chr4:10133013	G/T	cg26043149	chr18:55253948	FECH	0.75	8.9	0.5	1.65e-16	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs9788721	0.836	rs1504550	chr15:78766250	A/G	cg18825076	chr15:78729989	IREB2	-0.53	-6.41	-0.39	7.93e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg13264159	chr8:625131	ERICH1	-0.65	-5.08	-0.32	7.74e-7	IgG glycosylation;
SARC	cis	rs9393777	0.528	rs34843552	chr6:27241915	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.31	-4.8	-0.3	2.8e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2130392	0.886	rs3806796	chr4:185652147	G/A	cg04058563	chr4:185651563	MLF1IP	-0.36	-5.02	-0.31	1.03e-6	Kawasaki disease;
SARC	cis	rs77633900	0.614	rs2459360	chr15:76868664	C/T	cg21673338	chr15:77095150	SCAPER	-0.75	-6.2	-0.38	2.55e-9	Non-glioblastoma glioma;Glioma;
SARC	cis	rs13191362	1.000	rs13210412	chr6:163019478	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.56	5.49	0.34	1.06e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg03700308	chr20:49575492	MOCS3;DPM1	-0.52	-7.13	-0.42	1.25e-11	Neuroticism;
SARC	cis	rs870825	0.616	rs7682557	chr4:185640773	A/G	cg04058563	chr4:185651563	MLF1IP	0.81	11.48	0.6	1.8e-24	Blood protein levels;
SARC	cis	rs116095464	1.000	rs2015774	chr5:312958	G/T	cg22496380	chr5:211416	CCDC127	-0.86	-7.03	-0.42	2.24e-11	Breast cancer;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg17468841	chr3:105588020	CBLB	-0.83	-6.88	-0.41	5.49e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2235544	0.565	rs928444	chr1:54473548	C/G	cg10336722	chr1:54665764	CYB5RL;MRPL37	-0.39	-4.8	-0.3	2.79e-6	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
SARC	cis	rs2153535	0.580	rs7745043	chr6:8513507	T/C	cg07606381	chr6:8435919	SLC35B3	0.78	10.93	0.58	9.84e-23	Motion sickness;
SARC	cis	rs2425143	0.841	rs4911519	chr20:34362326	A/T	cg23207816	chr20:34252616	CPNE1;RBM12	-0.64	-5.23	-0.32	3.83e-7	Blood protein levels;
SARC	cis	rs8114671	0.562	rs6087649	chr20:33510662	A/G	cg07148914	chr20:33460835	GGT7	0.43	5.35	0.33	2.13e-7	Height;
SARC	cis	rs778371	0.723	rs10210953	chr2:233698830	G/A	cg20388707	chr2:233749442	NGEF	0.32	4.81	0.3	2.74e-6	Schizophrenia;
SARC	cis	rs7084402	1.000	rs12250013	chr10:60265957	C/A	cg07615347	chr10:60278583	BICC1	-0.6	-8.61	-0.49	1.1e-15	Refractive error;
SARC	trans	rs10085978	0.604	rs11167128	chr8:143225883	A/G	cg03095825	chr17:18163865	SMCR7	-0.46	-6.34	-0.38	1.16e-9	Mosquito bite size;
SARC	cis	rs921968	0.541	rs593888	chr2:219427597	A/G	cg02176678	chr2:219576539	TTLL4	0.46	7.07	0.42	1.83e-11	Mean corpuscular hemoglobin concentration;
SARC	cis	rs7726839	0.540	rs72707016	chr5:665148	A/G	cg07777115	chr5:623756	CEP72	-0.56	-4.75	-0.3	3.6e-6	Obesity-related traits;
SARC	cis	rs11608355	0.810	rs12424599	chr12:109866615	A/G	cg05360138	chr12:110035743	NA	0.62	6.4	0.39	8.56e-10	Neuroticism;
SARC	trans	rs9329221	0.683	rs3105738	chr8:9889914	A/T	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.9	-0.41	4.98e-11	Neuroticism;
SARC	cis	rs847577	0.715	rs12665986	chr7:97719676	A/G	cg13397024	chr7:97797637	LMTK2	0.38	4.74	0.3	3.74e-6	Breast cancer;
SARC	cis	rs10892173	0.566	rs12364667	chr11:117675286	A/C	cg21014159	chr11:117668035	DSCAML1	0.41	5.31	0.33	2.59e-7	Myopia;
SARC	cis	rs10504229	0.679	rs4737454	chr8:58033965	A/T	cg20607798	chr8:58055168	NA	0.55	5.1	0.32	7.12e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2180341	1.000	rs2326567	chr6:127606160	G/A	cg17762328	chr6:126965162	NA	-0.46	-5.22	-0.32	3.95e-7	Breast cancer;
SARC	cis	rs6450176	0.859	rs3776719	chr5:53298684	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.66	-7.62	-0.45	6.2800000000000005e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg03433033	chr1:76189801	ACADM	0.72	12.2	0.62	8.23e-27	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs4481887	0.861	rs4309013	chr1:248480768	C/T	cg00666640	chr1:248458726	OR2T12	0.33	5.54	0.34	7.95e-8	Common traits (Other);
SARC	cis	rs13343954	0.825	rs2216595	chr19:33533292	C/T	cg17764715	chr19:33622953	WDR88	0.5	5.44	0.34	1.37e-7	Colorectal cancer;
SARC	cis	rs9790314	0.967	rs7623206	chr3:160971518	G/A	cg04691961	chr3:161091175	C3orf57	-0.79	-11.72	-0.61	3.09e-25	Morning vs. evening chronotype;
SARC	cis	rs7772486	0.686	rs6570701	chr6:145954090	A/G	cg23711669	chr6:146136114	FBXO30	0.78	12.61	0.64	3.75e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11264799	0.539	rs849825	chr1:157546762	C/T	cg18268488	chr1:157545234	FCRL4	0.32	5.75	0.35	2.73e-8	IgA nephropathy;
SARC	cis	rs2412208	0.816	rs2186090	chr1:7062426	C/T	cg20434152	chr1:7120926	CAMTA1	-0.34	-5.19	-0.32	4.64e-7	Survival in sporadic amyotrophic lateral sclerosis;
SARC	cis	rs981844	0.712	rs1037649	chr4:154737796	G/A	cg14289246	chr4:154710475	SFRP2	-0.45	-5.17	-0.32	5.14e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg11764359	chr7:65958608	NA	-0.83	-11.2	-0.59	1.46e-23	Aortic root size;
SARC	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg11764359	chr7:65958608	NA	-0.67	-7.97	-0.46	7.24e-14	Aortic root size;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	ch.16.1296828R	chr16:58587691	CNOT1	-0.47	-6.26	-0.38	1.86e-9	Thyroid stimulating hormone;
SARC	cis	rs992157	0.835	rs4674283	chr2:219144254	G/A	cg00012203	chr2:219082015	ARPC2	-0.63	-9.14	-0.51	3.16e-17	Colorectal cancer;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg01314691	chr13:111367171	ING1	-0.75	-5.59	-0.34	6.2e-8	Obesity-related traits;
SARC	cis	rs7772486	0.686	rs9390348	chr6:146044748	C/T	cg05347473	chr6:146136440	FBXO30	-0.5	-6.9	-0.41	4.85e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1008375	0.966	rs3796812	chr4:17582051	G/A	cg16339924	chr4:17578868	LAP3	0.67	8.67	0.49	7.21e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs10506458	0.834	rs12426860	chr12:63387948	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.74	-6.29	-0.38	1.52e-9	Hemostatic factors and hematological phenotypes;
SARC	cis	rs28655083	1.000	rs1843455	chr16:77072343	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.43	-6.16	-0.37	3.11e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7681440	0.715	rs17016305	chr4:90791381	A/G	cg01966878	chr4:90757139	SNCA	-0.38	-4.74	-0.3	3.68e-6	Dementia with Lewy bodies;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg07148914	chr20:33460835	GGT7	0.51	6.51	0.39	4.48e-10	Breast cancer;
SARC	cis	rs2898681	0.739	rs8287	chr4:53732586	T/C	cg00338735	chr4:53728038	RASL11B	0.39	4.91	0.31	1.68e-6	Optic nerve measurement (cup area);
SARC	cis	rs12458462	0.892	rs3786228	chr18:77464170	C/T	cg23301140	chr18:77439876	CTDP1	-0.58	-7.37	-0.43	3.02e-12	Monocyte count;
SARC	cis	rs9527	0.590	rs11191544	chr10:104827198	C/G	cg04362960	chr10:104952993	NT5C2	0.42	4.94	0.31	1.48e-6	Arsenic metabolism;
SARC	cis	rs9436747	0.546	rs10749753	chr1:65998467	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	-0.42	-5.3	-0.33	2.7e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs1008375	0.966	rs3775925	chr4:17588437	A/G	cg02297831	chr4:17616191	MED28	0.49	6.24	0.38	2.06e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg12527284	chr5:75013342	C5orf37	-0.54	-7.31	-0.43	4.15e-12	Neuroticism;
SARC	cis	rs1008375	1.000	rs1008375	chr4:17682834	T/C	cg16339924	chr4:17578868	LAP3	0.61	7.99	0.46	6.17e-14	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg07153921	chr17:41440717	NA	0.4	4.8	0.3	2.87e-6	Menopause (age at onset);
SARC	cis	rs6088580	0.634	rs2184836	chr20:32963369	A/G	cg24642439	chr20:33292090	TP53INP2	-0.68	-8.73	-0.5	4.96e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg11987759	chr7:65425863	GUSB	-0.6	-7.96	-0.46	7.38e-14	Aortic root size;
SARC	cis	rs514024	0.668	rs1573178	chr9:130372487	A/G	cg13643465	chr9:130375613	STXBP1	0.43	5.38	0.33	1.85e-7	Eating disorders (purging via substances);
SARC	cis	rs7937682	0.814	rs1784788	chr11:111486136	T/G	cg22437258	chr11:111473054	SIK2	0.75	10.27	0.56	1.2e-20	Primary sclerosing cholangitis;
SARC	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg11987759	chr7:65425863	GUSB	-0.57	-7.71	-0.45	3.6e-13	Aortic root size;
SARC	cis	rs7223966	1.000	rs9912201	chr17:61763208	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.49	-5.01	-0.31	1.1e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs950776	0.616	rs56276142	chr15:78889795	T/C	cg24631222	chr15:78858424	CHRNA5	-0.36	-4.75	-0.3	3.58e-6	Sudden cardiac arrest;
SARC	cis	rs9316337	0.902	rs12430301	chr13:21970729	C/T	cg21080246	chr13:22033151	ZDHHC20	0.42	5.32	0.33	2.38e-7	Schizophrenia;
SARC	cis	rs3820928	0.904	rs60906902	chr2:227760034	C/T	cg11843606	chr2:227700838	RHBDD1	-0.53	-6.58	-0.4	3.08e-10	Pulmonary function;
SARC	cis	rs71636778	0.722	rs34502618	chr1:27094156	A/G	cg04852280	chr1:26496234	ZNF593	0.57	5.15	0.32	5.63e-7	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs9341808	0.718	rs10943699	chr6:80940541	G/A	cg08355045	chr6:80787529	NA	0.32	5.2	0.32	4.45e-7	Sitting height ratio;
SARC	cis	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg25427524	chr10:38739819	LOC399744	-0.6	-9.67	-0.54	8.06e-19	Extrinsic epigenetic age acceleration;
SARC	cis	rs4660261	0.526	rs3094954	chr1:44320919	C/T	cg12908607	chr1:44402522	ARTN	-0.33	-5.83	-0.36	1.88e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2290416	0.892	rs3793372	chr8:144664233	A/C	cg10810860	chr8:144639591	GSDMD	-0.71	-4.92	-0.31	1.6e-6	Attention deficit hyperactivity disorder;
SARC	cis	rs6582630	0.623	rs12299293	chr12:38436288	G/A	cg13010199	chr12:38710504	ALG10B	-0.49	-5.99	-0.37	8.06e-9	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7149337	0.805	rs2999357	chr14:51606001	C/G	cg23942311	chr14:51606299	NA	0.31	5.78	0.35	2.42e-8	Cancer;
SARC	trans	rs61931739	1.000	rs12305700	chr12:34036332	T/C	cg26384229	chr12:38710491	ALG10B	-0.57	-7.19	-0.43	8.49e-12	Morning vs. evening chronotype;
SARC	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg22903657	chr4:1355424	KIAA1530	-0.36	-4.84	-0.3	2.41e-6	Obesity-related traits;
SARC	cis	rs2304069	0.545	rs4705404	chr5:149381952	A/C	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.43	4.77	0.3	3.31e-6	HIV-1 control;
SARC	cis	rs995000	0.899	rs1781212	chr1:62977419	G/A	cg06896770	chr1:63153194	DOCK7	-0.89	-12.89	-0.65	4.52e-29	Triglyceride levels;
SARC	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg11764359	chr7:65958608	NA	0.59	6.98	0.42	3.1e-11	Aortic root size;
SARC	cis	rs116248771	0.549	rs9849301	chr3:158444860	C/T	cg16708174	chr3:158430962	RARRES1	0.49	4.86	0.3	2.14e-6	diarrhoeal disease at age 2;
SARC	cis	rs72945132	0.882	rs7932431	chr11:70166059	A/T	cg00319359	chr11:70116639	PPFIA1	0.67	6.08	0.37	4.85e-9	Coronary artery disease;
SARC	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg11644478	chr21:40555479	PSMG1	1.04	14.48	0.69	2.48e-34	Cognitive function;
SARC	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg16414030	chr3:133502952	NA	-0.36	-4.82	-0.3	2.56e-6	Iron status biomarkers;
SARC	cis	rs2204008	0.748	rs11514352	chr12:38246954	C/T	cg13010199	chr12:38710504	ALG10B	0.81	11.31	0.6	6.33e-24	Bladder cancer;
SARC	cis	rs6942407	0.546	rs6465093	chr7:86764877	G/A	cg02420886	chr7:86849541	C7orf23	0.64	5.47	0.34	1.18e-7	Food allergy;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg18881776	chr1:28052146	FAM76A	-0.57	-6.42	-0.39	7.7e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg17376030	chr22:41985996	PMM1	-0.8	-10.14	-0.55	2.93e-20	Vitiligo;
SARC	cis	rs12311304	1.000	rs56232194	chr12:15383683	G/C	cg08258403	chr12:15378311	NA	0.47	7.35	0.43	3.35e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg19223190	chr17:80058835	NA	0.45	6.29	0.38	1.52e-9	Life satisfaction;
SARC	cis	rs888194	0.738	rs7956788	chr12:109960962	T/C	cg13986417	chr12:110012484	MVK;MMAB	-0.31	-4.77	-0.3	3.19e-6	Neuroticism;
SARC	cis	rs7223966	1.000	rs11542436	chr17:61778689	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.51	-5.36	-0.33	2.02e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.62	-6.6	-0.4	2.8e-10	Platelet count;
SARC	cis	rs11122272	0.735	rs2486735	chr1:231521778	C/T	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs2816062	0.786	rs2745316	chr1:18896830	G/A	cg10574377	chr1:18908098	NA	0.35	5.03	0.31	9.77e-7	Urate levels in lean individuals;
SARC	cis	rs7020830	0.894	rs13300951	chr9:37146627	A/G	cg14294708	chr9:37120828	ZCCHC7	1.13	20.48	0.8	5.19e-54	Schizophrenia;
SARC	cis	rs1059312	0.966	rs35907548	chr12:129282180	T/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.48	6.77	0.41	1.03e-10	Systemic lupus erythematosus;
SARC	cis	rs7666738	0.830	rs6851253	chr4:99029980	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs57994353	0.578	rs10448340	chr9:139320069	A/C	cg13611204	chr9:139324423	INPP5E	-0.27	-4.73	-0.3	3.87e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	trans	rs56279505	0.690	rs56009681	chr4:100285772	A/T	cg21156590	chr1:3420848	MEGF6	-0.78	-6.26	-0.38	1.79e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs2727020	0.576	rs61885308	chr11:49343363	G/A	cg03929089	chr4:120376271	NA	-0.56	-7.5	-0.44	1.31e-12	Coronary artery disease;
SARC	cis	rs12950390	0.814	rs11659069	chr17:45834275	G/T	cg03474202	chr17:45855739	NA	-0.46	-7.26	-0.43	5.71e-12	IgG glycosylation;
SARC	cis	rs10791097	0.967	rs4366492	chr11:130717256	T/C	cg12179176	chr11:130786555	SNX19	0.62	8.63	0.49	9.87e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs11098499	0.863	rs6853998	chr4:120475860	C/A	cg09307838	chr4:120376055	NA	0.91	12.25	0.63	5.66e-27	Corneal astigmatism;
SARC	cis	rs11711311	0.822	rs9850256	chr3:113408382	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	7.74	0.45	3.04e-13	IgG glycosylation;
SARC	trans	rs9650657	0.775	rs10100265	chr8:10633159	A/C	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.31	-0.38	1.36e-9	Neuroticism;
SARC	cis	rs7106204	0.748	rs7946633	chr11:24237411	C/T	ch.11.24196551F	chr11:24239977	NA	0.55	5.69	0.35	3.81e-8	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs995000	0.931	rs28641195	chr1:63128081	C/T	cg06896770	chr1:63153194	DOCK7	-0.89	-13.48	-0.66	5.3e-31	Triglyceride levels;
SARC	cis	rs526231	0.543	rs34807	chr5:102428522	T/C	cg23492399	chr5:102201601	PAM	-0.53	-5.79	-0.35	2.28e-8	Primary biliary cholangitis;
SARC	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg11764359	chr7:65958608	NA	0.77	9.96	0.55	1.06e-19	Aortic root size;
SARC	cis	rs8067545	0.967	rs4924801	chr17:19921070	T/C	cg13482628	chr17:19912719	NA	0.7	10.0	0.55	7.86e-20	Schizophrenia;
SARC	cis	rs5753618	0.561	rs737684	chr22:31659827	C/G	cg00478049	chr22:31556069	RNF185	0.44	4.84	0.3	2.37e-6	Colorectal cancer;
SARC	cis	rs1707322	1.000	rs3922887	chr1:46473802	A/G	cg03146154	chr1:46216737	IPP	0.46	5.54	0.34	8.13e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4466137	0.953	rs1585153	chr5:83000385	A/T	cg16102102	chr5:83017553	HAPLN1	-0.75	-9.37	-0.52	6.72e-18	Prostate cancer;
SARC	cis	rs66887589	0.616	rs11098498	chr4:120187119	T/C	cg09307838	chr4:120376055	NA	0.61	8.06	0.47	3.97e-14	Diastolic blood pressure;
SARC	cis	rs12802200	0.535	rs35541591	chr11:570538	C/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.39	-4.79	-0.3	2.9e-6	Systemic lupus erythematosus;
SARC	cis	rs6933660	0.800	rs3800273	chr6:151759035	G/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.72	9.78	0.54	3.69e-19	Menarche (age at onset);
SARC	cis	rs7786808	0.552	rs896762	chr7:158182029	A/G	cg01191920	chr7:158217561	PTPRN2	0.28	4.75	0.3	3.49e-6	Obesity-related traits;
SARC	cis	rs5167	0.566	rs2075620	chr19:45480037	C/T	cg10169327	chr19:45448959	APOC2	-0.32	-4.87	-0.3	2.07e-6	Blood protein levels;
SARC	cis	rs2153219	1.000	rs760897	chr6:149755726	G/A	cg18043157	chr6:150390308	ULBP3	-0.49	-4.73	-0.3	3.98e-6	Coronary artery disease;
SARC	cis	rs4737010	0.570	rs10112594	chr8:41645565	C/T	cg17182837	chr8:41585554	ANK1	-0.44	-4.77	-0.3	3.19e-6	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
SARC	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg12310025	chr6:25882481	NA	-0.51	-6.42	-0.39	7.44e-10	Intelligence (multi-trait analysis);
SARC	cis	rs9398803	0.589	rs853965	chr6:127036174	C/T	cg20229609	chr6:126660872	C6orf173	-0.35	-5.08	-0.32	7.74e-7	Male-pattern baldness;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg22411068	chr5:10442103	ROPN1L	-0.95	-8.31	-0.48	8.07e-15	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1018836	0.631	rs2205157	chr8:91472384	C/T	cg16814680	chr8:91681699	NA	-0.68	-9.79	-0.54	3.5e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs72945132	0.882	rs12099016	chr11:70195161	C/G	cg00319359	chr11:70116639	PPFIA1	0.67	6.17	0.37	2.95e-9	Coronary artery disease;
SARC	cis	rs12479064	0.724	rs3087403	chr2:100058870	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.49	-5.34	-0.33	2.21e-7	Chronic sinus infection;
SARC	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg11987759	chr7:65425863	GUSB	-0.49	-6.59	-0.4	2.96e-10	Aortic root size;
SARC	cis	rs9875589	0.509	rs2733556	chr3:14100172	A/T	cg19554555	chr3:13937349	NA	-0.38	-4.74	-0.3	3.73e-6	Ovarian reserve;
SARC	cis	rs35160687	0.901	rs7571424	chr2:86539160	A/G	cg10973622	chr2:86423274	IMMT	0.38	4.97	0.31	1.3e-6	Night sleep phenotypes;
SARC	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg03806693	chr22:41940476	POLR3H	0.92	12.37	0.63	2.4e-27	Vitiligo;
SARC	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg03060546	chr3:49711283	APEH	0.48	6.31	0.38	1.37e-9	Menarche (age at onset);
SARC	cis	rs13191362	1.000	rs34138336	chr6:163144929	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.43	5.3	0.33	2.71e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs8114671	0.967	rs6060285	chr20:33770487	G/T	cg24642439	chr20:33292090	TP53INP2	0.51	5.88	0.36	1.4e-8	Height;
SARC	cis	rs36051895	0.632	rs10121316	chr9:5147539	C/T	cg02405213	chr9:5042618	JAK2	0.46	5.67	0.35	4.2e-8	Pediatric autoimmune diseases;
SARC	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.45	-5.26	-0.33	3.32e-7	Bipolar disorder;
SARC	cis	rs17376456	0.877	rs28637444	chr5:93495548	C/T	cg25358565	chr5:93447407	FAM172A	1.36	14.0	0.68	1.04e-32	Diabetic retinopathy;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg23952644	chr13:27131780	WASF3	0.49	6.56	0.39	3.42e-10	Breast cancer;
SARC	cis	rs7246657	0.525	rs1667357	chr19:37484352	T/C	cg23950597	chr19:37808831	NA	-0.56	-5.16	-0.32	5.31e-7	Coronary artery calcification;
SARC	cis	rs11098499	0.863	rs3822194	chr4:120471648	A/G	cg24375607	chr4:120327624	NA	0.42	4.92	0.31	1.64e-6	Corneal astigmatism;
SARC	cis	rs6540556	0.643	rs2282739	chr1:209883001	C/T	cg05527609	chr1:210001259	C1orf107	-0.48	-4.97	-0.31	1.31e-6	Red blood cell count;
SARC	cis	rs7481584	0.624	rs693687	chr11:3052494	A/G	cg25174290	chr11:3078921	CARS	-0.6	-8.32	-0.48	7.35e-15	Calcium levels;
SARC	cis	rs3923518	1.000	rs4371451	chr3:38906037	A/C	cg26331595	chr3:39149181	GORASP1;TTC21A	0.46	4.81	0.3	2.72e-6	Migraine;
SARC	trans	rs1493916	1.000	rs9964702	chr18:31390427	A/C	cg27147174	chr7:100797783	AP1S1	-0.59	-7.76	-0.45	2.57e-13	Life satisfaction;
SARC	cis	rs35110281	0.782	rs6518309	chr21:45047992	C/A	cg01579765	chr21:45077557	HSF2BP	-0.41	-6.63	-0.4	2.31e-10	Mean corpuscular volume;
SARC	cis	rs4481887	0.720	rs4543835	chr1:248468608	A/T	cg13385794	chr1:248469461	NA	0.36	5.54	0.34	8.15e-8	Common traits (Other);
SARC	cis	rs11098499	0.754	rs12510269	chr4:120241646	A/G	cg09307838	chr4:120376055	NA	0.82	11.28	0.59	7.99e-24	Corneal astigmatism;
SARC	cis	rs148803332	1	rs148803332	chr17:65958250	CAAAAGAAA/C	cg12091567	chr17:66097778	LOC651250	0.76	8.48	0.49	2.58e-15	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;
SARC	cis	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg24110177	chr3:50126178	RBM5	0.54	7.28	0.43	5.15e-12	Intelligence (multi-trait analysis);
SARC	cis	rs2354432	0.546	rs11240030	chr1:146882616	G/A	cg25205988	chr1:146714368	CHD1L	0.88	8.73	0.5	5.1e-16	Mitochondrial DNA levels;
SARC	cis	rs7937682	0.663	rs7116280	chr11:111659111	T/C	cg09085632	chr11:111637200	PPP2R1B	0.81	10.94	0.58	9.56e-23	Primary sclerosing cholangitis;
SARC	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg00933542	chr6:150070202	PCMT1	0.33	5.46	0.34	1.22e-7	Lung cancer;
SARC	cis	rs1691799	0.867	rs1495497	chr12:66770020	A/T	cg16791601	chr12:66731901	HELB	-0.69	-10.17	-0.55	2.42e-20	White blood cell count (basophil);
SARC	cis	rs7666738	0.710	rs7674407	chr4:98838522	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.76	0.5	4.2e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6582630	0.638	rs10880644	chr12:38554959	G/A	cg13010199	chr12:38710504	ALG10B	0.49	6.15	0.37	3.43e-9	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs4742903	0.527	rs2417498	chr9:106952065	T/C	cg14250997	chr9:106856677	SMC2	0.39	4.85	0.3	2.3e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg00684032	chr4:1343700	KIAA1530	0.36	5.13	0.32	6.2e-7	Obesity-related traits;
SARC	cis	rs3018712	0.547	rs4930237	chr11:68414038	C/G	cg01657329	chr11:68192670	LRP5	0.57	5.22	0.32	3.88e-7	Total body bone mineral density;
SARC	cis	rs10504229	0.593	rs16921589	chr8:58024387	C/A	cg21724239	chr8:58056113	NA	0.67	6.68	0.4	1.76e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs4319547	0.695	rs7969429	chr12:122875606	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.57	-6.41	-0.39	7.89e-10	Body mass index;
SARC	cis	rs9393692	1.000	rs3999544	chr6:26285867	C/T	cg05868516	chr6:26286170	HIST1H4H	0.49	5.91	0.36	1.18e-8	Educational attainment;
SARC	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg27266027	chr21:40555129	PSMG1	0.51	5.53	0.34	8.41e-8	Cognitive function;
SARC	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg13012494	chr21:47604986	C21orf56	-0.42	-4.88	-0.3	1.95e-6	Testicular germ cell tumor;
SARC	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg03351412	chr1:154909251	PMVK	0.58	7.33	0.43	3.81e-12	Prostate cancer;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg05978187	chr14:69864930	ERH;SLC39A9	0.76	6.65	0.4	2.1e-10	Autism spectrum disorder or schizophrenia;
SARC	trans	rs629535	0.783	rs510632	chr8:70034570	A/G	cg21567404	chr3:27674614	NA	1.04	13.82	0.67	3.98e-32	Dupuytren's disease;
SARC	cis	rs17376456	0.825	rs13155452	chr5:93164449	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.68	-6.03	-0.37	6.31e-9	Diabetic retinopathy;
SARC	cis	rs7666738	0.830	rs6853266	chr4:99047528	G/T	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4430311	0.759	rs12691548	chr1:243820128	A/G	cg21452805	chr1:244014465	NA	-0.4	-4.94	-0.31	1.52e-6	Post-traumatic stress disorder (asjusted for relatedness);
SARC	cis	rs9768139	0.935	rs7809076	chr7:158118438	C/T	cg25566285	chr7:158114605	PTPRN2	-0.31	-5.44	-0.34	1.37e-7	Calcium levels;
SARC	cis	rs7264396	0.635	rs6060675	chr20:34493614	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	5.36	0.33	2.04e-7	Total cholesterol levels;
SARC	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg01206211	chr2:36825736	FEZ2	0.35	4.86	0.3	2.16e-6	Height;
SARC	cis	rs55728055	0.661	rs16989334	chr22:32016092	A/G	cg01338084	chr22:32026380	PISD	1.05	6.18	0.38	2.78e-9	Age-related hearing impairment;
SARC	cis	rs6429082	0.764	rs291377	chr1:235695186	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.66	-7.89	-0.46	1.2e-13	Adiposity;
SARC	trans	rs3942852	0.568	rs10769314	chr11:48097620	C/T	cg03929089	chr4:120376271	NA	-0.56	-6.84	-0.41	7.02e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs2594989	0.943	rs2252601	chr3:11481234	A/G	cg00170343	chr3:11313890	ATG7	0.58	5.69	0.35	3.77e-8	Circulating chemerin levels;
SARC	cis	rs17376456	0.877	rs7701011	chr5:93311456	G/A	cg25358565	chr5:93447407	FAM172A	1.29	14.58	0.69	1.2e-34	Diabetic retinopathy;
SARC	cis	rs9300255	0.602	rs1790116	chr12:123618544	G/T	cg00376283	chr12:123451042	ABCB9	0.56	6.65	0.4	2.09e-10	Neutrophil percentage of white cells;
SARC	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg19723775	chr5:179050963	HNRNPH1	0.47	6.16	0.37	3.13e-9	Lung cancer;
SARC	cis	rs7843479	1.000	rs13276082	chr8:21823184	A/G	cg17168535	chr8:21777572	XPO7	0.62	7.87	0.46	1.37e-13	Mean corpuscular volume;
SARC	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs921968	0.541	rs514356	chr2:219375018	C/T	cg02176678	chr2:219576539	TTLL4	0.46	7.12	0.42	1.33e-11	Mean corpuscular hemoglobin concentration;
SARC	cis	rs6484504	0.625	rs10835766	chr11:31374329	C/A	cg02090638	chr11:31391270	DNAJC24;DCDC1	0.41	5.23	0.32	3.73e-7	Red blood cell count;
SARC	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.97e-8	Aortic root size;
SARC	cis	rs7223966	0.655	rs9906924	chr17:61634538	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.5	-4.88	-0.3	1.97e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs3617	0.573	rs6795646	chr3:52922621	C/T	cg05564831	chr3:52568323	NT5DC2	-0.28	-4.98	-0.31	1.26e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs76419734	1.000	rs11727189	chr4:106619140	G/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.82	5.06	0.31	8.65e-7	Post bronchodilator FEV1;
SARC	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg20607798	chr8:58055168	NA	0.71	6.18	0.38	2.87e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7236492	0.532	rs3786184	chr18:77195885	A/C	cg15644404	chr18:77186268	NFATC1	-0.49	-5.57	-0.34	6.84e-8	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg22168489	chr12:122356033	WDR66	0.68	10.2	0.56	2.01e-20	Mean corpuscular volume;
SARC	cis	rs78487399	0.808	rs75386849	chr2:43723283	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.65	-4.77	-0.3	3.26e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs875971	1.000	rs1167612	chr7:65567976	C/A	cg11764359	chr7:65958608	NA	-0.86	-12.18	-0.62	9.99e-27	Aortic root size;
SARC	cis	rs9462027	0.959	rs205262	chr6:34563164	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-5.97	-0.36	8.84e-9	Systemic lupus erythematosus;
SARC	cis	rs17345786	0.511	rs13061565	chr3:101392270	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	6.43	0.39	6.98e-10	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6540556	0.723	rs3766618	chr1:209895437	G/T	cg05527609	chr1:210001259	C1orf107	-0.61	-5.29	-0.33	2.78e-7	Red blood cell count;
SARC	cis	rs6141769	0.542	rs6057628	chr20:31308684	C/T	cg13636640	chr20:31349939	DNMT3B	-0.44	-4.82	-0.3	2.53e-6	Subjective well-being;
SARC	cis	rs1707322	0.963	rs6690652	chr1:46376692	G/T	cg03146154	chr1:46216737	IPP	0.46	5.52	0.34	8.98e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs501120	1.000	rs579058	chr10:44755104	A/G	cg09554077	chr10:44749378	NA	0.48	6.67	0.4	1.85e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs7264396	0.511	rs2425102	chr20:34312303	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	5.75	0.35	2.8e-8	Total cholesterol levels;
SARC	cis	rs832540	0.866	rs832579	chr5:56164943	A/G	cg14703610	chr5:56206110	C5orf35	0.54	6.77	0.41	1.04e-10	Coronary artery disease;
SARC	cis	rs1865760	0.865	rs9467648	chr6:25957933	T/A	cg17691542	chr6:26056736	HIST1H1C	0.58	7.36	0.43	3.14e-12	Height;
SARC	cis	rs11700980	0.636	rs73190119	chr21:30303685	C/A	cg24692254	chr21:30365293	RNF160	-0.65	-5.51	-0.34	9.48e-8	QRS complex (12-leadsum);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg27158084	chr6:149813350	NA	0.51	6.37	0.39	9.84e-10	Breast cancer;
SARC	cis	rs9640161	0.742	rs11767726	chr7:150018096	A/C	cg10018233	chr7:150070692	REPIN1	-0.68	-9.41	-0.52	5.13e-18	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs698813	0.604	rs1596010	chr2:44491804	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.65	0.35	4.73e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs7582180	0.739	rs4851292	chr2:100924761	A/G	cg14675211	chr2:100938903	LONRF2	0.54	7.84	0.46	1.61e-13	Intelligence (multi-trait analysis);
SARC	cis	rs651907	0.535	rs11714444	chr3:101513682	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	5.8	0.36	2.13e-8	Colorectal cancer;
SARC	cis	rs1256061	0.603	rs1256041	chr14:64738029	A/G	cg23250157	chr14:64679961	SYNE2	0.48	6.62	0.4	2.49e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs2278491	0.557	rs4876679	chr8:117763873	A/G	cg23513447	chr8:117778558	UTP23	-0.47	-5.09	-0.32	7.27e-7	Body mass index;
SARC	cis	rs7555523	0.887	rs7518099	chr1:165736880	C/T	cg19769164	chr1:165738335	TMCO1	0.61	4.94	0.31	1.51e-6	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	cis	rs9858542	0.953	rs9837027	chr3:49597013	C/T	cg07274523	chr3:49395745	GPX1	0.51	6.0	0.37	7.32e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs6752107	1.000	rs10165561	chr2:234172915	G/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.5	6.4	0.39	8.49e-10	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs79839061	0.518	rs3755960	chr4:895060	G/T	cg07828340	chr4:882639	GAK	0.79	5.94	0.36	1.06e-8	Intelligence (multi-trait analysis);
SARC	cis	rs8114671	0.527	rs3736802	chr20:33604042	T/C	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.86	-0.36	1.59e-8	Height;
SARC	cis	rs1707322	0.752	rs6703748	chr1:46095976	G/A	cg06784218	chr1:46089804	CCDC17	0.37	6.39	0.39	8.81e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2180341	0.782	rs6569490	chr6:127729615	C/T	cg27446573	chr6:127587934	RNF146	0.79	10.27	0.56	1.21e-20	Breast cancer;
SARC	trans	rs61931739	0.500	rs11524949	chr12:34435551	C/T	cg13010199	chr12:38710504	ALG10B	0.81	11.19	0.59	1.47e-23	Morning vs. evening chronotype;
SARC	cis	rs7666738	0.830	rs35433756	chr4:99070555	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.71	0.5	5.79e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg00800038	chr16:89945340	TCF25	-0.72	-5.75	-0.35	2.8e-8	Skin colour saturation;
SARC	cis	rs10791323	0.559	rs10750549	chr11:133730820	A/G	cg13461336	chr11:133711254	SPATA19	-0.27	-4.75	-0.3	3.63e-6	Childhood ear infection;
SARC	cis	rs12478296	1.000	rs113129906	chr2:243004253	C/T	cg18898632	chr2:242989856	NA	-0.62	-4.89	-0.3	1.9e-6	Obesity-related traits;
SARC	cis	rs17270561	0.553	rs9379784	chr6:25725506	A/G	cg17691542	chr6:26056736	HIST1H1C	0.56	6.76	0.4	1.11e-10	Iron status biomarkers;
SARC	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg00031303	chr3:195681400	NA	0.52	5.94	0.36	1.03e-8	Pancreatic cancer;
SARC	cis	rs9788721	0.836	rs17483721	chr15:78733731	C/T	cg18825076	chr15:78729989	IREB2	0.51	6.48	0.39	5.27e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg26313233	chr2:114415511	NA	0.56	6.96	0.41	3.36e-11	Breast cancer;
SARC	cis	rs6088580	0.634	rs6088483	chr20:32984714	T/A	cg08999081	chr20:33150536	PIGU	-0.42	-6.39	-0.39	9.12e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs739401	0.572	rs384490	chr11:3078885	A/C	cg25174290	chr11:3078921	CARS	0.59	8.4	0.48	4.35e-15	Longevity;
SARC	cis	rs208520	0.690	rs12201219	chr6:66748862	A/T	cg07460842	chr6:66804631	NA	1.04	13.8	0.67	4.75e-32	Exhaled nitric oxide output;
SARC	cis	rs9325144	0.647	rs11168104	chr12:38857616	G/T	cg26384229	chr12:38710491	ALG10B	-0.55	-7.13	-0.42	1.25e-11	Morning vs. evening chronotype;
SARC	cis	rs1467026	0.719	rs17037220	chr3:12818103	A/G	cg24848339	chr3:12840334	CAND2	0.38	6.15	0.37	3.41e-9	P wave duration;
SARC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg04234412	chr22:24373322	LOC391322	-0.53	-6.15	-0.37	3.33e-9	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs4423214	0.650	rs2186777	chr11:71219803	C/A	cg05163923	chr11:71159392	DHCR7	0.57	6.76	0.41	1.07e-10	Vitamin D levels;
SARC	cis	rs7044106	0.762	rs10760112	chr9:123467570	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	8.93	0.5	1.34e-16	Hip circumference adjusted for BMI;
SARC	cis	rs2276314	0.947	rs3898595	chr18:33565885	T/A	cg19628046	chr18:33552617	C18orf21	0.56	5.92	0.36	1.16e-8	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs12048904	0.505	rs4517368	chr1:101255052	C/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.44	-4.76	-0.3	3.36e-6	Multiple sclerosis;
SARC	cis	rs1153858	0.621	rs12913645	chr15:45555066	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.39	-5.41	-0.33	1.55e-7	Homoarginine levels;
SARC	cis	rs2694528	0.844	rs2169256	chr5:60062668	C/T	cg11474532	chr5:59995715	DEPDC1B	0.74	5.23	0.32	3.77e-7	Parkinson's disease;
SARC	cis	rs3099143	1.000	rs3102710	chr15:77061148	T/C	cg21673338	chr15:77095150	SCAPER	-0.6	-5.06	-0.31	8.57e-7	Recalcitrant atopic dermatitis;
SARC	cis	rs61409971	0.881	rs67641625	chr14:93016079	C/T	cg04718702	chr14:93020195	RIN3	-0.36	-4.77	-0.3	3.29e-6	Lymphocyte percentage of white cells;
SARC	cis	rs2749592	0.918	rs1208653	chr10:38253826	C/G	cg25427524	chr10:38739819	LOC399744	0.44	5.42	0.33	1.51e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs9436747	0.667	rs11208674	chr1:66039317	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.47	-4.97	-0.31	1.31e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg07701084	chr6:150067640	NUP43	0.41	5.41	0.33	1.6e-7	Lung cancer;
SARC	cis	rs2043112	0.691	rs10042314	chr5:39088981	A/G	cg04869206	chr5:39074266	RICTOR	0.51	6.36	0.38	1.06e-9	Obesity-related traits;
SARC	cis	rs9486715	0.830	rs4425602	chr6:96893906	G/A	cg06623918	chr6:96969491	KIAA0776	0.88	12.74	0.64	1.51e-28	Headache;
SARC	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	14.03	0.68	8.15e-33	Chronic sinus infection;
SARC	cis	rs2425143	0.818	rs35448195	chr20:34542365	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-5.3	-0.33	2.74e-7	Blood protein levels;
SARC	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg16405210	chr4:1374714	KIAA1530	-0.51	-6.45	-0.39	6.25e-10	Obesity-related traits;
SARC	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg00684032	chr4:1343700	KIAA1530	0.47	6.79	0.41	9.32e-11	Obesity-related traits;
SARC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg11905131	chr22:24372483	LOC391322	0.48	5.12	0.32	6.47e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs3126085	0.932	rs11204949	chr1:152219797	A/C	cg03465714	chr1:152285911	FLG	0.46	4.86	0.3	2.16e-6	Atopic dermatitis;
SARC	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg26769984	chr7:1090371	C7orf50	-0.47	-4.97	-0.31	1.3e-6	Bronchopulmonary dysplasia;
SARC	cis	rs66887589	0.627	rs3872807	chr4:120360251	T/A	cg09307838	chr4:120376055	NA	0.54	7.39	0.44	2.63e-12	Diastolic blood pressure;
SARC	cis	rs274567	0.711	rs404771	chr5:131635092	A/T	cg24060327	chr5:131705240	SLC22A5	-0.72	-8.76	-0.5	4.14e-16	Blood metabolite levels;
SARC	cis	rs9911578	1.000	rs1057068	chr17:56598439	T/C	cg05425664	chr17:57184151	TRIM37	0.63	7.81	0.46	1.95e-13	Intelligence (multi-trait analysis);
SARC	trans	rs61931739	0.534	rs1486886	chr12:34043619	C/T	cg26384229	chr12:38710491	ALG10B	0.75	10.62	0.57	9.96e-22	Morning vs. evening chronotype;
SARC	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.6	5.67	0.35	4.16e-8	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs240764	0.817	rs6938440	chr6:101152009	T/C	cg09795085	chr6:101329169	ASCC3	-0.46	-5.94	-0.36	1.01e-8	Neuroticism;
SARC	cis	rs6840360	0.571	rs17360385	chr4:152587970	C/A	cg22705602	chr4:152727874	NA	-0.44	-6.82	-0.41	7.59e-11	Intelligence (multi-trait analysis);
SARC	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.54	7.16	0.42	1.07e-11	Menarche (age at onset);
SARC	cis	rs2354432	0.607	rs6694347	chr1:146751140	T/C	cg25205988	chr1:146714368	CHD1L	-1.0	-7.56	-0.44	9.4e-13	Mitochondrial DNA levels;
SARC	cis	rs9581857	0.685	rs9319371	chr13:28042564	A/G	cg01674679	chr13:27998804	GTF3A	-0.64	-4.86	-0.3	2.19e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	trans	rs2727020	0.688	rs11040338	chr11:49360601	A/G	cg03929089	chr4:120376271	NA	0.72	10.28	0.56	1.12e-20	Coronary artery disease;
SARC	cis	rs6120849	0.707	rs6120826	chr20:33671831	G/A	cg06115741	chr20:33292138	TP53INP2	0.56	5.28	0.33	2.9e-7	Protein C levels;
SARC	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-8.99	-0.51	8.97e-17	Alzheimer's disease;
SARC	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg18252515	chr7:66147081	NA	-1.3	-11.5	-0.6	1.59e-24	Diabetic kidney disease;
SARC	cis	rs9914988	0.509	rs17794628	chr17:27260145	C/T	cg10538030	chr17:27276405	PHF12	-0.58	-4.72	-0.3	3.98e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	trans	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg06437703	chr8:37914619	EIF4EBP1	-0.64	-7.97	-0.46	6.88e-14	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.94	10.1	0.55	4.12e-20	Platelet count;
SARC	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg11890956	chr21:40555474	PSMG1	-0.7	-9.34	-0.52	7.91e-18	Menarche (age at onset);
SARC	cis	rs910316	1.000	rs10149880	chr14:75633008	A/G	cg11812906	chr14:75593930	NEK9	-0.87	-12.59	-0.64	4.67e-28	Height;
SARC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg10150615	chr22:24372951	LOC391322	-0.48	-5.41	-0.33	1.59e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs933688	1.000	rs332544	chr5:90778848	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.91	11.72	0.61	2.94e-25	Smoking behavior;
SARC	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg23758822	chr17:41437982	NA	0.86	11.14	0.59	2.16e-23	Menopause (age at onset);
SARC	cis	rs6866344	0.598	rs11742156	chr5:178147833	C/T	cg10224037	chr5:178157518	ZNF354A	0.96	12.54	0.63	6.34e-28	Neutrophil percentage of white cells;
SARC	cis	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg05623727	chr3:50126028	RBM5	-0.33	-4.99	-0.31	1.21e-6	Intelligence (multi-trait analysis);
SARC	cis	rs3796352	1.000	rs61172708	chr3:52996052	T/G	cg27565382	chr3:53032988	SFMBT1	0.83	5.57	0.34	7.16e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs4319547	0.620	rs12372756	chr12:122815130	A/G	cg23029597	chr12:123009494	RSRC2	-0.4	-5.03	-0.31	9.93e-7	Body mass index;
SARC	trans	rs208520	0.789	rs9351549	chr6:66871851	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-14.41	-0.69	4.39e-34	Exhaled nitric oxide output;
SARC	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg08219700	chr8:58056026	NA	0.46	4.79	0.3	2.94e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg03576123	chr11:487126	PTDSS2	-1.15	-11.66	-0.61	4.87e-25	Body mass index;
SARC	cis	rs2153535	0.601	rs330105	chr6:8543981	A/C	cg21535247	chr6:8435926	SLC35B3	0.57	7.15	0.42	1.11e-11	Motion sickness;
SARC	cis	rs10782582	0.593	rs114421765	chr1:76141802	C/T	cg10523679	chr1:76189770	ACADM	-0.42	-5.05	-0.31	9.06e-7	Daytime sleep phenotypes;
SARC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	6.02	0.37	6.63e-9	Prudent dietary pattern;
SARC	trans	rs1973993	0.967	rs1555543	chr1:96944797	A/C	cg10631902	chr5:14652156	NA	0.48	8.42	0.48	4e-15	Weight;
SARC	trans	rs61931739	0.534	rs1211286	chr12:34135581	T/C	cg26384229	chr12:38710491	ALG10B	0.77	11.06	0.59	4.04e-23	Morning vs. evening chronotype;
SARC	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg09699651	chr6:150184138	LRP11	0.39	4.98	0.31	1.27e-6	Lung cancer;
SARC	cis	rs57506017	0.585	rs1468802	chr7:12276011	G/A	cg23422036	chr7:12250390	TMEM106B	0.47	6.07	0.37	5.1e-9	Neuroticism;
SARC	cis	rs7412746	0.658	rs72704685	chr1:150897687	C/G	cg13175981	chr1:150552382	MCL1	-0.48	-5.86	-0.36	1.57e-8	Melanoma;
SARC	cis	rs3126085	0.935	rs12063165	chr1:152176357	C/T	cg03465714	chr1:152285911	FLG	-0.47	-5.59	-0.34	6.31e-8	Atopic dermatitis;
SARC	cis	rs9354308	0.838	rs9363453	chr6:66544051	G/A	cg07460842	chr6:66804631	NA	-0.45	-5.23	-0.32	3.77e-7	Metabolite levels;
SARC	cis	rs1865760	0.532	rs1061482	chr6:26086699	G/T	cg17691542	chr6:26056736	HIST1H1C	0.5	6.05	0.37	5.58e-9	Height;
SARC	cis	rs1348850	0.632	rs1358328	chr2:178517532	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.45	5.23	0.32	3.72e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs12155623	0.803	rs6987879	chr8:49808062	T/C	cg06076277	chr8:49783056	NA	-0.29	-4.77	-0.3	3.22e-6	Sudden cardiac arrest;
SARC	cis	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg23422044	chr7:1970798	MAD1L1	-0.47	-5.2	-0.32	4.34e-7	Bipolar disorder;
SARC	cis	rs10448080	0.879	rs240946	chr8:28568905	A/G	cg25374552	chr8:27950443	ELP3	0.39	5.14	0.32	5.76e-7	Height;
SARC	cis	rs11225247	0.772	rs12270109	chr11:102229310	G/C	cg11690896	chr11:102217788	BIRC2	0.72	5.21	0.32	4.23e-7	Vein graft stenosis in coronary artery bypass grafting;
SARC	cis	rs17401966	0.894	rs12141201	chr1:10454714	G/A	cg15208524	chr1:10270712	KIF1B	0.48	5.72	0.35	3.31e-8	Hepatocellular carcinoma;
SARC	cis	rs1008375	0.932	rs13109475	chr4:17677565	C/G	cg16339924	chr4:17578868	LAP3	-0.64	-8.22	-0.47	1.45e-14	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.59	0.34	6.37e-8	Bipolar disorder;
SARC	trans	rs9325144	0.624	rs12231544	chr12:38901956	C/T	cg23762105	chr12:34175262	ALG10	0.48	6.26	0.38	1.83e-9	Morning vs. evening chronotype;
SARC	cis	rs6831352	0.879	rs4699717	chr4:100066137	C/T	cg13256891	chr4:100009986	ADH5	-0.65	-7.8	-0.45	2.07e-13	Alcohol dependence;
SARC	cis	rs9911578	0.967	rs12603238	chr17:57130785	C/T	cg12560992	chr17:57184187	TRIM37	-0.87	-12.38	-0.63	2.23e-27	Intelligence (multi-trait analysis);
SARC	cis	rs986417	1.000	rs1254332	chr14:60916587	T/C	cg27398547	chr14:60952738	C14orf39	-1.04	-9.78	-0.54	3.77e-19	Gut microbiota (bacterial taxa);
SARC	cis	rs9879311	0.966	rs4684684	chr3:10411344	C/T	cg11030744	chr3:10328490	GHRL;GHRLOS	0.43	5.31	0.33	2.61e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	cis	rs6456042	0.893	rs3127440	chr6:166558950	C/T	cg11088901	chr6:166572345	T	-0.34	-4.87	-0.3	2.03e-6	Asthma;
SARC	cis	rs7945705	0.870	rs4929922	chr11:8975776	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.39	-5.18	-0.32	4.72e-7	Hemoglobin concentration;
SARC	trans	rs11098499	0.863	rs12502389	chr4:120454191	A/G	cg25214090	chr10:38739885	LOC399744	0.57	7.35	0.43	3.31e-12	Corneal astigmatism;
SARC	cis	rs7474896	0.559	rs2738185	chr10:38247736	G/A	cg25427524	chr10:38739819	LOC399744	0.46	5.77	0.35	2.51e-8	Obesity (extreme);
SARC	cis	rs826838	1.000	rs11183469	chr12:38752311	G/A	cg26384229	chr12:38710491	ALG10B	0.96	15.61	0.71	4.51e-38	Heart rate;
SARC	cis	rs6424115	0.737	rs10917430	chr1:24170458	C/T	cg15997130	chr1:24165203	NA	-0.43	-5.15	-0.32	5.59e-7	Immature fraction of reticulocytes;
SARC	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg17971929	chr21:40555470	PSMG1	-0.57	-7.11	-0.42	1.38e-11	Menarche (age at onset);
SARC	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.08	22.31	0.83	9.34e-60	Chronic sinus infection;
SARC	cis	rs35306767	0.903	rs12240651	chr10:943656	A/G	cg20503657	chr10:835505	NA	0.8	7.58	0.44	8.17e-13	Eosinophil percentage of granulocytes;
SARC	cis	rs367615	0.704	rs17161885	chr5:108852642	A/G	cg17395555	chr5:108820864	NA	0.47	6.73	0.4	1.3100000000000001e-10	Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs2073300	0.609	rs6137945	chr20:23406136	C/T	cg16736954	chr20:23401023	NAPB	0.77	4.76	0.3	3.39e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs2204008	0.807	rs8186948	chr12:38325101	C/G	cg13010199	chr12:38710504	ALG10B	0.78	10.65	0.57	7.99e-22	Bladder cancer;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg01518977	chr19:41768456	HNRNPUL1	0.5	6.51	0.39	4.6e-10	Chemerin levels;
SARC	cis	rs818427	0.963	rs153545	chr5:112238882	T/C	cg07820702	chr5:112228657	REEP5	-0.46	-4.85	-0.3	2.21e-6	Total body bone mineral density;
SARC	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg04277193	chr17:41438351	NA	0.46	5.0	0.31	1.1e-6	Menopause (age at onset);
SARC	cis	rs12142240	0.698	rs6667861	chr1:46815749	T/C	cg00530320	chr1:46809349	NSUN4	0.57	6.92	0.41	4.4e-11	Menopause (age at onset);
SARC	cis	rs3741151	0.773	rs7951072	chr11:73221721	G/A	cg17517138	chr11:73019481	ARHGEF17	0.97	7.67	0.45	4.69e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs4555082	0.834	rs28846738	chr14:105745781	A/G	cg06808227	chr14:105710500	BRF1	-0.58	-7.92	-0.46	9.54e-14	Mean platelet volume;Platelet distribution width;
SARC	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg09455208	chr3:40491958	NA	0.4	5.76	0.35	2.7e-8	Renal cell carcinoma;
SARC	trans	rs7615952	0.558	rs17334039	chr3:125540308	A/G	cg07211511	chr3:129823064	LOC729375	-0.74	-8.57	-0.49	1.41e-15	Blood pressure (smoking interaction);
SARC	cis	rs7020830	0.867	rs1472169	chr9:37209396	C/T	cg14294708	chr9:37120828	ZCCHC7	1.09	19.53	0.79	5.85e-51	Schizophrenia;
SARC	trans	rs10435719	0.780	rs9692662	chr8:11789863	C/T	cg06636001	chr8:8085503	FLJ10661	0.5	6.3	0.38	1.48e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
SARC	cis	rs2204008	0.571	rs1117803	chr12:38281007	C/G	cg13010199	chr12:38710504	ALG10B	-0.52	-6.44	-0.39	6.73e-10	Bladder cancer;
SARC	cis	rs76419734	0.850	rs113325481	chr4:106675104	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.76	4.98	0.31	1.23e-6	Post bronchodilator FEV1;
SARC	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.94	13.16	0.65	5.86e-30	Gut microbiome composition (summer);
SARC	cis	rs6582630	0.531	rs3850000	chr12:38483752	T/C	cg13010199	chr12:38710504	ALG10B	0.75	10.21	0.56	1.79e-20	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs4689388	0.926	rs9998835	chr4:6293237	C/G	cg00701064	chr4:6280414	WFS1	0.54	8.58	0.49	1.38e-15	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg16479474	chr6:28041457	NA	0.37	5.44	0.34	1.37e-7	Depression;
SARC	cis	rs708547	1.000	rs2412770	chr4:57794660	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.63	6.57	0.4	3.32e-10	Response to bleomycin (chromatid breaks);
SARC	cis	rs9868809	0.505	rs13063223	chr3:48750340	G/A	cg03060546	chr3:49711283	APEH	-0.51	-4.75	-0.3	3.52e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg23982607	chr1:1823379	GNB1	-0.64	-10.63	-0.57	9.15e-22	Body mass index;
SARC	cis	rs1008375	0.931	rs3775926	chr4:17599837	G/A	cg02297831	chr4:17616191	MED28	0.44	5.41	0.33	1.55e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs112591243	0.685	rs74671132	chr21:47963485	T/C	cg26904215	chr21:47823096	PCNT	-0.82	-5.33	-0.33	2.26e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs831571	1.000	rs166230	chr3:64053207	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	0.52	4.73	0.3	3.92e-6	Type 2 diabetes;
SARC	cis	rs8031584	0.541	rs2955797	chr15:31210981	A/G	cg14829155	chr15:31115871	NA	0.4	5.49	0.34	1.06e-7	Huntington's disease progression;
SARC	cis	rs875971	0.545	rs17138149	chr7:65693180	A/G	cg11764359	chr7:65958608	NA	0.68	7.01	0.42	2.6e-11	Aortic root size;
SARC	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg04772025	chr11:68637568	NA	0.5	6.41	0.39	7.87e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	7.62	0.45	6.29e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs362272	0.545	rs3135145	chr4:3299504	T/C	cg08741688	chr4:3415352	RGS12	-0.47	-5.82	-0.36	1.94e-8	Serum sulfate level;
SARC	trans	rs62103177	0.810	rs62103195	chr18:77629693	T/C	cg05926928	chr17:57297772	GDPD1	1.14	9.58	0.53	1.57e-18	Opioid sensitivity;
SARC	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg13770153	chr20:60521292	NA	-0.45	-6.31	-0.38	1.39e-9	Body mass index;
SARC	cis	rs7246760	0.867	rs66943818	chr19:9746367	G/A	cg16876255	chr19:9731953	ZNF561	0.82	5.05	0.31	9.08e-7	Pursuit maintenance gain;
SARC	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg00152838	chr16:24741724	TNRC6A	-0.6	-6.43	-0.39	7.21e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs5753618	0.583	rs7293171	chr22:31802324	T/C	cg02404636	chr22:31891804	SFI1	0.49	5.16	0.32	5.33e-7	Colorectal cancer;
SARC	cis	rs6540556	0.608	rs2064148	chr1:209909385	C/T	cg05527609	chr1:210001259	C1orf107	0.52	5.44	0.34	1.31e-7	Red blood cell count;
SARC	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	5.42	0.33	1.47e-7	Bipolar disorder;
SARC	cis	rs9326248	0.559	rs12808524	chr11:116890993	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.65	8.03	0.47	4.66e-14	Blood protein levels;
SARC	cis	rs738322	0.934	rs133016	chr22:38572582	C/T	cg25457927	chr22:38595422	NA	-0.29	-5.95	-0.36	9.7e-9	Cutaneous nevi;
SARC	cis	rs524281	0.861	rs12226649	chr11:65842047	T/C	cg14036092	chr11:66035641	RAB1B	-0.52	-5.37	-0.33	1.95e-7	Electroencephalogram traits;
SARC	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg21782813	chr7:2030301	MAD1L1	0.39	6.19	0.38	2.65e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs2204008	0.837	rs2892296	chr12:37969785	C/T	cg13010199	chr12:38710504	ALG10B	-0.66	-8.91	-0.5	1.52e-16	Bladder cancer;
SARC	cis	rs9527	0.545	rs7915816	chr10:104881750	A/G	cg04362960	chr10:104952993	NT5C2	0.43	4.94	0.31	1.47e-6	Arsenic metabolism;
SARC	cis	rs11864453	0.647	rs10492813	chr16:72122463	A/G	cg01557791	chr16:72042693	DHODH	0.47	6.35	0.38	1.1e-9	Fibrinogen levels;
SARC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.45	5.38	0.33	1.83e-7	Calcium levels;
SARC	cis	rs12200782	0.530	rs6929908	chr6:26555289	C/A	cg11502198	chr6:26597334	ABT1	0.72	7.57	0.44	8.57e-13	Small cell lung carcinoma;
SARC	cis	rs3767633	0.925	rs4579731	chr1:161766859	G/A	cg09175582	chr1:161736000	ATF6	0.72	6.18	0.38	2.83e-9	IgG glycosylation;
SARC	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg16606324	chr3:10149918	C3orf24	0.48	4.75	0.3	3.54e-6	Alzheimer's disease;
SARC	cis	rs2439831	0.850	rs3736180	chr15:44106624	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.95	8.35	0.48	5.93e-15	Lung cancer in ever smokers;
SARC	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg24060327	chr5:131705240	SLC22A5	0.48	5.71	0.35	3.45e-8	Acylcarnitine levels;
SARC	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg21132104	chr15:45694354	SPATA5L1	0.77	10.98	0.58	6.87e-23	Homoarginine levels;
SARC	cis	rs11785400	1.000	rs6997771	chr8:143747752	T/G	cg24634471	chr8:143751801	JRK	0.68	8.96	0.51	1.04e-16	Schizophrenia;
SARC	cis	rs1348850	0.567	rs12994392	chr2:178536640	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.43	5.02	0.31	1.02e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg03806693	chr22:41940476	POLR3H	0.86	11.91	0.62	7.51e-26	Vitiligo;
SARC	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg17376030	chr22:41985996	PMM1	0.7	8.38	0.48	5.11e-15	Vitiligo;
SARC	cis	rs7635838	0.750	rs7625680	chr3:11378069	G/A	cg00170343	chr3:11313890	ATG7	0.64	8.81	0.5	2.97e-16	HDL cholesterol;
SARC	cis	rs12079745	0.793	rs78266198	chr1:169346615	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.92	-5.9	-0.36	1.29e-8	QT interval;
SARC	cis	rs734999	0.588	rs876938	chr1:2523212	G/C	cg20673091	chr1:2541236	MMEL1	0.34	5.17	0.32	5.07e-7	Ulcerative colitis;
SARC	trans	rs9951602	0.541	rs56882694	chr18:76647010	C/T	cg02800362	chr5:177631904	HNRNPAB	0.68	8.56	0.49	1.56e-15	Obesity-related traits;
SARC	cis	rs1348850	0.567	rs3770005	chr2:178528874	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.43	5.01	0.31	1.09e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9443189	0.813	rs2748948	chr6:76437994	T/A	cg01950844	chr6:76311363	SENP6	-0.72	-6.72	-0.4	1.42e-10	Prostate cancer;
SARC	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg06636001	chr8:8085503	FLJ10661	-0.67	-8.88	-0.5	1.79e-16	Mood instability;
SARC	cis	rs240764	0.658	rs9399694	chr6:101257877	A/G	cg09795085	chr6:101329169	ASCC3	-0.42	-5.38	-0.33	1.84e-7	Neuroticism;
SARC	cis	rs7681440	0.874	rs1372523	chr4:90775923	G/A	cg06632027	chr4:90757378	SNCA	0.4	5.68	0.35	3.91e-8	Dementia with Lewy bodies;
SARC	cis	rs7592578	0.723	rs4371384	chr2:191430741	A/G	cg27211696	chr2:191398769	TMEM194B	0.57	6.09	0.37	4.71e-9	Diastolic blood pressure;
SARC	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg17691542	chr6:26056736	HIST1H1C	0.44	5.08	0.32	7.6e-7	Intelligence (multi-trait analysis);
SARC	cis	rs8044868	1.000	rs6499562	chr16:72162855	G/A	cg16558253	chr16:72132732	DHX38	-0.36	-5.11	-0.32	6.63e-7	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
SARC	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg11608241	chr8:8085544	FLJ10661	0.38	4.86	0.3	2.13e-6	Mood instability;
SARC	cis	rs1008375	0.606	rs6828925	chr4:17561139	C/T	cg16339924	chr4:17578868	LAP3	0.57	6.97	0.42	3.28e-11	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9815354	0.767	rs17281609	chr3:41833432	G/A	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg16510485	chr5:111506044	EPB41L4A	0.46	6.37	0.39	9.91e-10	Thyroid stimulating hormone;
SARC	cis	rs4900538	0.892	rs4906208	chr14:102956489	G/C	cg18135206	chr14:102964638	TECPR2	0.67	9.03	0.51	6.65e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs5753618	0.561	rs4820043	chr22:31647094	A/G	cg00478049	chr22:31556069	RNF185	0.45	4.78	0.3	3.05e-6	Colorectal cancer;
SARC	cis	rs7624766	0.714	rs897494	chr3:160529290	T/C	cg22637730	chr3:160473554	PPM1L	0.43	5.58	0.34	6.58e-8	Response to methotrexate in rheumatoid arthritis;
SARC	cis	rs9296092	0.538	rs9469487	chr6:33516943	G/T	cg13560919	chr6:33536144	NA	-0.5	-6.12	-0.37	3.89e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs72781680	1.000	rs72798411	chr2:24184343	A/G	cg06627628	chr2:24431161	ITSN2	-0.75	-7.03	-0.42	2.31e-11	Lymphocyte counts;
SARC	cis	rs765787	0.530	rs55920042	chr15:45541577	G/A	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.51e-10	Uric acid levels;
SARC	cis	rs7208859	0.673	rs12949860	chr17:29223032	A/G	cg13385521	chr17:29058706	SUZ12P	0.85	7.23	0.43	7.08e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs950776	0.518	rs62008194	chr15:78813805	G/T	cg17108064	chr15:78857060	CHRNA5	0.28	4.81	0.3	2.73e-6	Sudden cardiac arrest;
SARC	cis	rs7523050	0.643	rs35907086	chr1:109406625	A/G	cg08274380	chr1:109419600	GPSM2	1.06	8.0	0.46	5.67e-14	Fat distribution (HIV);
SARC	trans	rs9354352	0.935	rs9354354	chr6:66699333	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.59	-7.84	-0.46	1.56e-13	Initial pursuit acceleration in psychotic disorders;
SARC	cis	rs3796352	1.000	rs35849389	chr3:53005235	A/G	cg15956490	chr3:53032818	SFMBT1	0.75	4.99	0.31	1.2e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs11690935	0.788	rs10201053	chr2:172889558	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.73	-9.69	-0.54	7.37e-19	Schizophrenia;
SARC	trans	rs2018683	0.707	rs4722878	chr7:28973031	C/T	cg19402173	chr7:128379420	CALU	-0.5	-6.37	-0.39	1.02e-9	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs9486719	0.843	rs2499789	chr6:96844510	T/C	cg06623918	chr6:96969491	KIAA0776	0.75	7.39	0.44	2.65e-12	Migraine;Coronary artery disease;
SARC	cis	rs13166103	0.657	rs11745514	chr5:57712444	C/T	cg10487770	chr5:57879443	RAB3C	0.52	5.46	0.34	1.19e-7	Type 2 diabetes (age of onset);
SARC	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg16479474	chr6:28041457	NA	0.37	5.48	0.34	1.11e-7	Parkinson's disease;
SARC	cis	rs858239	0.601	rs4440529	chr7:23168751	G/C	cg23682824	chr7:23144976	KLHL7	0.72	9.45	0.53	3.86e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs72781680	0.948	rs72796319	chr2:24133027	T/C	cg08917208	chr2:24149416	ATAD2B	0.79	7.64	0.45	5.66e-13	Lymphocyte counts;
SARC	cis	rs12478296	0.901	rs67423532	chr2:243004719	A/G	cg06360820	chr2:242988706	NA	-0.7	-6.64	-0.4	2.21e-10	Obesity-related traits;
SARC	cis	rs10504229	0.679	rs12679920	chr8:58051710	G/T	cg08219700	chr8:58056026	NA	0.6	6.0	0.37	7.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg18252515	chr7:66147081	NA	0.48	5.11	0.32	6.62e-7	Aortic root size;
SARC	cis	rs4417855	0.762	rs4686904	chr3:187438522	C/T	cg08969912	chr3:187456781	BCL6	-0.47	-5.4	-0.33	1.61e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs1018836	0.608	rs12679836	chr8:91465287	A/G	cg16814680	chr8:91681699	NA	-0.65	-9.31	-0.52	9.93e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs2304069	0.954	rs2276983	chr5:149424966	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.75	7.76	0.45	2.73e-13	HIV-1 control;
SARC	cis	rs35110281	0.715	rs8129601	chr21:45119104	A/G	cg21573476	chr21:45109991	RRP1B	-0.57	-8.3	-0.48	8.47e-15	Mean corpuscular volume;
SARC	cis	rs60871478	0.945	rs4719279	chr7:813618	T/C	cg05535760	chr7:792225	HEATR2	0.76	7.77	0.45	2.46e-13	Cerebrospinal P-tau181p levels;
SARC	cis	rs17780086	0.529	rs7406406	chr17:30220153	T/G	cg12000587	chr17:30186630	C17orf79	-0.33	-5.11	-0.32	6.65e-7	Height;
SARC	cis	rs36051895	0.632	rs7850484	chr9:5147817	C/T	cg02405213	chr9:5042618	JAK2	-0.54	-6.22	-0.38	2.27e-9	Pediatric autoimmune diseases;
SARC	cis	rs7223966	1.000	rs8073373	chr17:61703320	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.45	5.05	0.31	8.71e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	7.36	0.43	3.19e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg22939043	chr6:170059563	WDR27	-0.51	-6.32	-0.38	1.29e-9	Migraine with aura;
SARC	cis	rs7000551	0.715	rs7828610	chr8:22307326	C/T	cg12081754	chr8:22256438	SLC39A14	0.6	8.35	0.48	6.22e-15	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs41271473	0.526	rs28593014	chr1:228743576	G/A	cg10167378	chr1:228756711	NA	0.61	5.38	0.33	1.8e-7	Chronic lymphocytic leukemia;
SARC	cis	rs593982	1.000	rs665191	chr11:65493658	G/A	cg08755490	chr11:65554678	OVOL1	0.86	8.62	0.49	1.05e-15	Atopic dermatitis;
SARC	cis	rs3768617	0.510	rs3768629	chr1:183074582	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.68	9.93	0.55	1.31e-19	Fuchs's corneal dystrophy;
SARC	cis	rs6840360	1.000	rs751014	chr4:152601902	G/A	cg22705602	chr4:152727874	NA	-0.38	-6.54	-0.39	3.91e-10	Intelligence (multi-trait analysis);
SARC	cis	rs2075371	0.933	rs2544201	chr7:133963561	C/G	cg11752832	chr7:134001865	SLC35B4	0.56	7.13	0.42	1.25e-11	Mean platelet volume;
SARC	cis	rs4711350	0.765	rs943473	chr6:33743651	G/C	cg07979401	chr6:33739406	LEMD2	-0.38	-4.74	-0.3	3.8e-6	Schizophrenia;
SARC	cis	rs12142240	0.698	rs56909107	chr1:46808224	A/C	cg10495392	chr1:46806563	NSUN4	0.64	6.76	0.4	1.09e-10	Menopause (age at onset);
SARC	cis	rs9381040	0.610	rs2268191	chr6:41027653	G/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.41	-4.72	-0.3	4.14e-6	Alzheimer's disease (late onset);
SARC	cis	rs2204008	0.744	rs11519905	chr12:38222959	G/A	cg13010199	chr12:38710504	ALG10B	0.78	10.64	0.57	8.61e-22	Bladder cancer;
SARC	cis	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg00071950	chr4:10020882	SLC2A9	0.39	6.31	0.38	1.4e-9	Bone mineral density;
SARC	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg18758796	chr5:131593413	PDLIM4	0.38	4.93	0.31	1.55e-6	Acylcarnitine levels;
SARC	cis	rs240764	0.658	rs9322181	chr6:101221630	C/A	cg09795085	chr6:101329169	ASCC3	-0.44	-5.64	-0.35	4.85e-8	Neuroticism;
SARC	cis	rs1691799	0.899	rs1168306	chr12:66738900	A/G	cg16791601	chr12:66731901	HELB	-0.72	-10.76	-0.58	3.44e-22	White blood cell count (basophil);
SARC	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.97	-15.37	-0.71	2.85e-37	Chronic sinus infection;
SARC	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.97e-8	Aortic root size;
SARC	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg18404041	chr3:52824283	ITIH1	-0.42	-6.29	-0.38	1.56e-9	Bipolar disorder;
SARC	cis	rs9398803	0.624	rs9372837	chr6:126638124	G/A	cg19875578	chr6:126661172	C6orf173	0.45	6.16	0.37	3.21e-9	Male-pattern baldness;
SARC	cis	rs9325144	0.600	rs1825807	chr12:38737007	T/C	cg04568710	chr12:38710424	ALG10B	0.4	4.9	0.31	1.76e-6	Morning vs. evening chronotype;
SARC	trans	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.53	6.85	0.41	6.38e-11	Intelligence (multi-trait analysis);
SARC	cis	rs9549367	0.713	rs3024745	chr13:113821598	A/G	cg18105134	chr13:113819100	PROZ	-0.46	-6.53	-0.39	4.19e-10	Platelet distribution width;
SARC	cis	rs1055129	0.560	rs2608880	chr17:73938957	C/T	cg06969265	chr17:73775802	H3F3B	0.45	5.54	0.34	8.04e-8	White matter hyperintensity burden;
SARC	cis	rs11650776	1	rs11650776	chr17:37641402	G/A	cg07936489	chr17:37558343	FBXL20	-0.7	-9.0	-0.51	7.96e-17	Lung function (FEV1);
SARC	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg20607798	chr8:58055168	NA	0.61	5.41	0.33	1.57e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs56307353	0.652	rs4807191	chr19:1990309	C/T	cg11709110	chr19:1989583	BTBD2	0.32	4.81	0.3	2.77e-6	Coronary artery disease;
SARC	cis	rs10916814	0.546	rs1890006	chr1:20898841	G/T	cg24502330	chr1:20914028	CDA	-0.3	-5.27	-0.33	3.16e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs11264799	0.520	rs849826	chr1:157546346	A/T	cg18268488	chr1:157545234	FCRL4	0.32	5.83	0.36	1.8e-8	IgA nephropathy;
SARC	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg13395646	chr4:1353034	KIAA1530	-0.46	-5.42	-0.33	1.51e-7	Obesity-related traits;
SARC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg11235426	chr6:292522	DUSP22	-0.6	-7.71	-0.45	3.61e-13	Menopause (age at onset);
SARC	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg24060327	chr5:131705240	SLC22A5	-0.48	-5.95	-0.36	9.84e-9	Blood metabolite levels;
SARC	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg04772025	chr11:68637568	NA	0.5	6.31	0.38	1.38e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9948	0.786	rs62156234	chr2:97436292	C/G	cg01990225	chr2:97406019	LMAN2L	-0.96	-6.95	-0.41	3.73e-11	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs7818345	0.904	rs11780388	chr8:19271554	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.41	5.51	0.34	9.59e-8	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs4689388	0.890	rs4501291	chr4:6298582	C/T	cg00701064	chr4:6280414	WFS1	0.55	8.88	0.5	1.78e-16	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs709400	0.628	rs12889639	chr14:103860206	G/A	cg12935359	chr14:103987150	CKB	0.38	5.73	0.35	3.15e-8	Body mass index;
SARC	cis	rs9547692	1.000	rs11619849	chr13:37468238	A/G	cg01493522	chr13:37497338	NA	-0.43	-4.81	-0.3	2.68e-6	Coronary artery disease;
SARC	cis	rs9910055	0.509	rs9916444	chr17:42313512	C/G	cg13607699	chr17:42295918	UBTF	0.86	13.55	0.66	3.21e-31	Total body bone mineral density;
SARC	cis	rs7927771	0.965	rs34958982	chr11:47547046	T/C	cg05585544	chr11:47624801	NA	-0.36	-4.88	-0.3	2e-6	Subjective well-being;
SARC	cis	rs17376456	0.877	rs13173952	chr5:93307557	A/T	cg25358565	chr5:93447407	FAM172A	1.28	14.54	0.69	1.6e-34	Diabetic retinopathy;
SARC	trans	rs561341	0.556	rs542244	chr17:30307242	T/C	cg20587970	chr11:113659929	NA	-1.33	-13.84	-0.67	3.43e-32	Hip circumference adjusted for BMI;
SARC	cis	rs73206853	0.841	rs60013768	chr12:110576095	A/G	cg10860002	chr12:110842031	ANAPC7	0.67	5.29	0.33	2.82e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs763121	0.853	rs1043441	chr22:39130964	C/T	cg06022373	chr22:39101656	GTPBP1	0.88	11.65	0.61	5.08e-25	Menopause (age at onset);
SARC	cis	rs7712401	0.580	rs383262	chr5:122345684	C/T	cg19412675	chr5:122181750	SNX24	-0.43	-5.43	-0.34	1.41e-7	Mean platelet volume;
SARC	trans	rs7824557	0.614	rs4394351	chr8:11212875	G/C	cg06636001	chr8:8085503	FLJ10661	0.53	6.44	0.39	6.81e-10	Retinal vascular caliber;
SARC	cis	rs16976116	0.851	rs28784096	chr15:55503312	C/T	cg11288833	chr15:55489084	RSL24D1	0.63	6.08	0.37	4.81e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg05872129	chr22:39784769	NA	-0.43	-6.09	-0.37	4.62e-9	Intelligence (multi-trait analysis);
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg11923054	chr4:4250051	TMEM128	0.5	6.27	0.38	1.72e-9	Lung adenocarcinoma;
SARC	cis	rs7624766	0.508	rs9833075	chr3:160527846	T/G	cg22637730	chr3:160473554	PPM1L	0.37	4.74	0.3	3.77e-6	Response to methotrexate in rheumatoid arthritis;
SARC	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg06618935	chr21:46677482	NA	-0.41	-5.58	-0.34	6.79e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7264396	0.790	rs6058283	chr20:34216276	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-7.35	-0.43	3.4e-12	Total cholesterol levels;
SARC	cis	rs17376456	1.000	rs13154249	chr5:93550508	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.62	5.4	0.33	1.68e-7	Diabetic retinopathy;
SARC	cis	rs72717009	0.756	rs10494359	chr1:161463876	G/C	cg23840854	chr1:161414152	NA	-0.54	-5.02	-0.31	1.04e-6	Rheumatoid arthritis;
SARC	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg04944784	chr2:26401820	FAM59B	-0.55	-7.51	-0.44	1.22e-12	Gut microbiome composition (summer);
SARC	cis	rs2043112	1.000	rs12515328	chr5:39019550	C/G	cg04869206	chr5:39074266	RICTOR	0.49	5.94	0.36	1.02e-8	Obesity-related traits;
SARC	cis	rs1043515	0.748	rs11657530	chr17:36942814	T/C	cg09592244	chr17:37024020	NA	0.39	5.01	0.31	1.07e-6	Height;
SARC	cis	rs12928939	0.517	rs10852507	chr16:71971900	G/A	cg03805757	chr16:71968109	PKD1L3	-0.4	-4.72	-0.3	4.08e-6	Post bronchodilator FEV1;
SARC	cis	rs611744	0.934	rs604698	chr8:109238721	G/A	cg21045802	chr8:109455806	TTC35	0.46	5.43	0.34	1.38e-7	Dupuytren's disease;
SARC	cis	rs12532878	0.652	rs62482223	chr7:100198878	C/A	cg20848291	chr7:100343083	ZAN	-0.53	-5.26	-0.33	3.19e-7	Mean corpuscular hemoglobin;
SARC	cis	rs2180341	0.814	rs6905553	chr6:127727407	A/G	cg24812749	chr6:127587940	RNF146	0.78	9.92	0.55	1.39e-19	Breast cancer;
SARC	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg11764359	chr7:65958608	NA	-0.78	-9.67	-0.54	8.24e-19	Aortic root size;
SARC	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg11494091	chr17:61959527	GH2	0.37	5.23	0.32	3.8e-7	Height;
SARC	cis	rs2120243	0.539	rs1456097	chr3:157098630	T/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.38	4.84	0.3	2.38e-6	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs4919087	0.748	rs701816	chr10:98977250	C/T	cg25902810	chr10:99078978	FRAT1	-0.54	-6.0	-0.37	7.53e-9	Monocyte count;
SARC	cis	rs7772486	0.686	rs4895684	chr6:146114023	A/C	cg23711669	chr6:146136114	FBXO30	-0.79	-12.69	-0.64	2.16e-28	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs61931739	0.534	rs12372557	chr12:34363843	C/T	cg26384229	chr12:38710491	ALG10B	0.9	13.26	0.66	2.92e-30	Morning vs. evening chronotype;
SARC	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg11764359	chr7:65958608	NA	0.68	8.07	0.47	3.63e-14	Aortic root size;
SARC	trans	rs1493916	1.000	rs7238717	chr18:31395186	C/T	cg27147174	chr7:100797783	AP1S1	-0.59	-7.67	-0.45	4.76e-13	Life satisfaction;
SARC	cis	rs965469	1.000	rs6139064	chr20:3277050	G/T	cg25506879	chr20:3388711	C20orf194	-0.47	-4.76	-0.3	3.42e-6	IFN-related cytopenia;
SARC	cis	rs3126085	0.935	rs1552995	chr1:152171427	A/G	cg09127314	chr1:152161683	NA	0.42	4.79	0.3	3.03e-6	Atopic dermatitis;
SARC	cis	rs6089584	0.893	rs2281735	chr20:60582540	T/A	cg23262073	chr20:60523788	NA	-0.42	-6.17	-0.37	3.07e-9	Body mass index;
SARC	cis	rs1185460	0.967	rs1786684	chr11:118938435	G/A	cg23280166	chr11:118938394	VPS11	0.81	12.33	0.63	3.08e-27	Coronary artery disease;
SARC	cis	rs12950390	0.853	rs56363619	chr17:45854621	T/C	cg03474202	chr17:45855739	NA	-0.44	-7.06	-0.42	1.88e-11	IgG glycosylation;
SARC	cis	rs17376456	0.932	rs3940842	chr5:93534858	C/A	cg21475434	chr5:93447410	FAM172A	0.92	7.81	0.46	1.91e-13	Diabetic retinopathy;
SARC	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2033732	0.673	rs1437510	chr8:85065019	A/G	cg05716166	chr8:85095498	RALYL	0.47	5.62	0.35	5.51e-8	Body mass index;
SARC	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg12648201	chr2:27665141	KRTCAP3	-0.32	-4.78	-0.3	3.17e-6	Total body bone mineral density;
SARC	cis	rs2522056	1.000	rs2706383	chr5:131792402	G/A	cg24060327	chr5:131705240	SLC22A5	0.49	4.96	0.31	1.39e-6	Lymphocyte counts;Fibrinogen;
SARC	cis	rs17030434	0.784	rs67664355	chr4:154660229	A/G	cg14289246	chr4:154710475	SFRP2	-0.49	-5.67	-0.35	4.3e-8	Electrocardiographic conduction measures;
SARC	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg19077165	chr18:44547161	KATNAL2	-0.53	-7.42	-0.44	2.13e-12	Personality dimensions;
SARC	trans	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg00938859	chr5:1591904	SDHAP3	0.74	7.18	0.43	9.17e-12	Breast cancer;
SARC	cis	rs561341	0.941	rs2470236	chr17:30304940	G/C	cg00745463	chr17:30367425	LRRC37B	-0.6	-4.78	-0.3	3.08e-6	Hip circumference adjusted for BMI;
SARC	cis	rs10782582	0.593	rs1412717	chr1:76125471	C/T	cg10523679	chr1:76189770	ACADM	-0.41	-5.1	-0.32	6.96e-7	Daytime sleep phenotypes;
SARC	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	11.31	0.6	6.28e-24	Alzheimer's disease;
SARC	cis	rs9911578	1.000	rs7215808	chr17:56940742	G/C	cg12560992	chr17:57184187	TRIM37	0.86	11.75	0.61	2.37e-25	Intelligence (multi-trait analysis);
SARC	cis	rs6840360	1.000	rs6838966	chr4:152603475	C/T	cg22705602	chr4:152727874	NA	-0.37	-6.3	-0.38	1.46e-9	Intelligence (multi-trait analysis);
SARC	cis	rs9457247	1.000	rs436707	chr6:167388843	T/C	cg23791538	chr6:167370224	RNASET2	-0.62	-8.66	-0.49	8.17e-16	Crohn's disease;
SARC	cis	rs3780378	0.875	rs7032785	chr9:5042046	C/T	cg02405213	chr9:5042618	JAK2	-0.44	-5.39	-0.33	1.75e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
SARC	cis	rs3126085	0.825	rs868303	chr1:152178563	C/A	cg26876637	chr1:152193138	HRNR	0.49	5.61	0.35	5.67e-8	Atopic dermatitis;
SARC	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg09455208	chr3:40491958	NA	0.41	6.29	0.38	1.53e-9	Renal cell carcinoma;
SARC	cis	rs989128	0.600	rs2240218	chr17:48630580	A/T	cg20467136	chr17:48638190	CACNA1G	0.46	5.36	0.33	2e-7	Type 2 diabetes;
SARC	cis	rs554111	1.000	rs554111	chr1:21042300	C/G	cg08890418	chr1:21044141	KIF17	0.56	7.76	0.45	2.66e-13	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs920590	0.549	rs11204077	chr8:19653739	C/G	cg03894339	chr8:19674705	INTS10	0.39	4.78	0.3	3.06e-6	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs8141529	0.702	rs469992	chr22:29314899	T/C	cg15103426	chr22:29168792	CCDC117	-0.68	-8.91	-0.5	1.5e-16	Lymphocyte counts;
SARC	cis	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg18252515	chr7:66147081	NA	-1.43	-12.98	-0.65	2.35e-29	Gout;
SARC	cis	rs2594989	0.780	rs2454477	chr3:11555842	G/A	cg00170343	chr3:11313890	ATG7	0.57	5.36	0.33	1.96e-7	Circulating chemerin levels;
SARC	cis	rs2153535	0.541	rs1414347	chr6:8471831	T/C	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.01e-14	Motion sickness;
SARC	cis	rs11252926	0.528	rs11252090	chr10:436547	C/T	cg16386425	chr10:429943	DIP2C	0.41	4.83	0.3	2.44e-6	Psychosis in Alzheimer's disease;
SARC	cis	rs8014204	0.935	rs2300596	chr14:75353855	C/T	cg17347104	chr14:75034677	LTBP2	-0.41	-5.13	-0.32	6.1e-7	Caffeine consumption;
SARC	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg04267008	chr7:1944627	MAD1L1	-0.52	-5.98	-0.36	8.4e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs7247513	1.000	rs2042947	chr19:12693103	A/G	cg01871581	chr19:12707946	ZNF490	-0.81	-11.39	-0.6	3.57e-24	Bipolar disorder;
SARC	cis	rs28386778	0.700	rs4968672	chr17:62011352	G/A	cg09373136	chr17:61933544	TCAM1	0.44	5.87	0.36	1.47e-8	Prudent dietary pattern;
SARC	cis	rs1538970	0.962	rs3219463	chr1:45806432	C/T	cg16078521	chr1:45672383	ZSWIM5	0.48	4.82	0.3	2.62e-6	Platelet count;
SARC	cis	rs9457247	1.000	rs430477	chr6:167389851	T/C	cg07741184	chr6:167504864	NA	0.29	5.49	0.34	1.04e-7	Crohn's disease;
SARC	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.7	-9.96	-0.55	1.07e-19	Menarche (age at onset);
SARC	trans	rs1973993	0.651	rs60776572	chr1:96960121	C/T	cg10631902	chr5:14652156	NA	-0.42	-6.88	-0.41	5.46e-11	Weight;
SARC	cis	rs8053891	0.507	rs34150651	chr16:72028112	G/A	cg01557791	chr16:72042693	DHODH	-0.43	-5.12	-0.32	6.4e-7	Coronary artery disease;
SARC	cis	rs854765	0.551	rs12600546	chr17:17867614	A/G	cg04398451	chr17:18023971	MYO15A	-0.41	-5.68	-0.35	4.05e-8	Total body bone mineral density;
SARC	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg25894440	chr7:65020034	NA	0.75	5.66	0.35	4.46e-8	Diabetic kidney disease;
SARC	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg20120463	chr17:44301886	NA	-0.32	-5.03	-0.31	9.66e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs8017423	0.967	rs7155315	chr14:90700787	G/A	cg20276874	chr14:90721474	PSMC1	-0.36	-5.01	-0.31	1.09e-6	Mortality in heart failure;
SARC	cis	rs1003719	0.788	rs2835577	chr21:38457457	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.65	9.46	0.53	3.43e-18	Eye color traits;
SARC	cis	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg12257692	chr3:49977190	RBM6	-0.27	-4.83	-0.3	2.45e-6	Body mass index;
SARC	cis	rs67311347	0.544	rs1454492	chr3:40352884	C/T	cg24209194	chr3:40518798	ZNF619	0.5	6.61	0.4	2.59e-10	Renal cell carcinoma;
SARC	cis	rs9486719	1.000	rs12214469	chr6:97019471	G/T	cg06623918	chr6:96969491	KIAA0776	-0.79	-8.83	-0.5	2.51e-16	Migraine;Coronary artery disease;
SARC	cis	rs1797081	0.934	rs1797077	chr10:16853252	C/T	cg23933602	chr10:16859644	RSU1	0.91	16.24	0.73	3.66e-40	Platelet distribution width;
SARC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg12000995	chr2:27665139	KRTCAP3	-0.31	-4.86	-0.3	2.11e-6	Total body bone mineral density;
SARC	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.3	4.9	0.31	1.77e-6	Schizophrenia;
SARC	cis	rs11249608	0.636	rs13359549	chr5:178449178	T/A	cg21905437	chr5:178450457	ZNF879	0.57	7.66	0.45	5.07e-13	Pubertal anthropometrics;
SARC	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg01570182	chr17:44337453	NA	-0.81	-9.89	-0.54	1.74e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs1008375	0.966	rs12509962	chr4:17680292	G/A	cg02297831	chr4:17616191	MED28	0.42	5.36	0.33	2.03e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05727155	chr2:208394989	CREB1	0.54	6.63	0.4	2.32e-10	Fibrinogen levels;
SARC	cis	rs34172651	0.876	rs7186893	chr16:24806420	G/T	cg00152838	chr16:24741724	TNRC6A	-0.5	-6.01	-0.37	7e-9	Intelligence (multi-trait analysis);
SARC	cis	rs6920965	0.507	rs9401853	chr6:126215197	A/T	cg05901451	chr6:126070800	HEY2	-0.5	-6.01	-0.37	7.21e-9	High light scatter reticulocyte count;
SARC	cis	rs2075371	0.644	rs1643041	chr7:134012211	C/T	cg11752832	chr7:134001865	SLC35B4	0.46	5.71	0.35	3.5e-8	Mean platelet volume;
SARC	cis	rs9372253	0.678	rs9487392	chr6:110708626	C/T	cg01119278	chr6:110721349	DDO	0.37	4.99	0.31	1.17e-6	Platelet distribution width;
SARC	cis	rs9303401	0.614	rs12950028	chr17:56510140	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.0	10.5	0.57	2.35e-21	Cognitive test performance;
SARC	cis	rs644799	1.000	rs473155	chr11:95596873	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.68	8.79	0.5	3.41e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg13393036	chr8:95962371	TP53INP1	-0.36	-6.21	-0.38	2.35e-9	Type 2 diabetes;
SARC	cis	rs9303401	0.659	rs12944971	chr17:56988801	A/T	cg25039879	chr17:56429692	SUPT4H1	0.71	6.49	0.39	5.05e-10	Cognitive test performance;
SARC	cis	rs2916247	0.954	rs7015301	chr8:93173941	C/T	cg10183463	chr8:93005414	RUNX1T1	0.53	5.57	0.34	6.83e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9581857	0.556	rs9581863	chr13:28040171	A/G	cg22138327	chr13:27999177	GTF3A	0.55	5.65	0.35	4.56e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	cis	rs10028773	0.700	rs7671797	chr4:120248157	A/G	cg09307838	chr4:120376055	NA	0.81	10.98	0.58	6.97e-23	Educational attainment;
SARC	cis	rs11122272	0.735	rs2808583	chr1:231512587	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs9911578	1.000	rs8071280	chr17:57010225	T/C	cg05425664	chr17:57184151	TRIM37	-0.67	-8.32	-0.48	7.53e-15	Intelligence (multi-trait analysis);
SARC	cis	rs2576037	0.796	rs2247221	chr18:44580082	C/T	cg15049968	chr18:44337910	ST8SIA5	0.34	5.5	0.34	9.77e-8	Personality dimensions;
SARC	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg07157834	chr1:205819609	PM20D1	-0.42	-5.47	-0.34	1.13e-7	Menarche (age at onset);
SARC	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg20607798	chr8:58055168	NA	0.57	5.53	0.34	8.58e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6598163	0.517	rs10902453	chr12:132297091	G/T	cg07389463	chr12:132296394	NA	-0.47	-7.41	-0.44	2.36e-12	Migraine;
SARC	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg18305652	chr10:134549665	INPP5A	0.36	5.15	0.32	5.46e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs1832871	0.711	rs7770047	chr6:158685696	A/G	cg07165851	chr6:158734300	TULP4	0.55	6.67	0.4	1.8e-10	Height;
SARC	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.66	6.24	0.38	1.99e-9	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs2278491	0.557	rs10283129	chr8:117778673	G/A	cg23513447	chr8:117778558	UTP23	-0.47	-5.16	-0.32	5.28e-7	Body mass index;
SARC	cis	rs6060960	0.537	rs75351461	chr20:30458612	C/T	cg13852791	chr20:30311386	BCL2L1	0.63	5.68	0.35	4.08e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
SARC	cis	rs36051895	0.623	rs6476957	chr9:5261324	A/G	cg02405213	chr9:5042618	JAK2	-0.41	-4.82	-0.3	2.6e-6	Pediatric autoimmune diseases;
SARC	cis	rs6060717	0.536	rs6060664	chr20:34478884	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-5.78	-0.35	2.42e-8	Hip circumference adjusted for BMI;
SARC	cis	rs1355223	0.583	rs2941058	chr11:34880245	C/G	cg18508148	chr11:34937573	PDHX;APIP	0.56	6.92	0.41	4.44e-11	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs921968	0.643	rs559722	chr2:219398159	A/G	cg02176678	chr2:219576539	TTLL4	0.36	5.61	0.34	5.83e-8	Mean corpuscular hemoglobin concentration;
SARC	cis	rs7223966	0.515	rs2727315	chr17:61961458	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.5	-5.22	-0.32	4.01e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs72717009	0.825	rs867624	chr1:161467837	A/T	cg23840854	chr1:161414152	NA	-0.52	-4.92	-0.31	1.65e-6	Rheumatoid arthritis;
SARC	cis	rs16922576	0.640	rs12343727	chr9:5215926	A/G	cg02405213	chr9:5042618	JAK2	-0.39	-4.79	-0.3	2.95e-6	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs7312933	0.865	rs1920687	chr12:42398275	T/C	cg19980929	chr12:42632907	YAF2	0.34	4.78	0.3	3.07e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs9611519	0.602	rs8138520	chr22:41412928	A/G	cg03806693	chr22:41940476	POLR3H	-0.59	-7.95	-0.46	8.04e-14	Neuroticism;
SARC	cis	rs12142240	0.698	rs6679898	chr1:46820589	A/C	cg14993813	chr1:46806288	NSUN4	-0.51	-5.34	-0.33	2.19e-7	Menopause (age at onset);
SARC	cis	rs6570726	0.764	rs9403726	chr6:145901686	G/T	cg05347473	chr6:146136440	FBXO30	0.52	7.33	0.43	3.74e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg03060546	chr3:49711283	APEH	0.6	7.49	0.44	1.41e-12	Resting heart rate;
SARC	cis	rs735539	0.521	rs2031353	chr13:21380474	C/A	cg16922012	chr13:21400325	XPO4	-0.42	-5.68	-0.35	4.09e-8	Dental caries;
SARC	cis	rs75920871	0.588	rs1871756	chr11:116953645	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-5.11	-0.32	6.63e-7	Subjective well-being;
SARC	cis	rs861020	0.630	rs656566	chr1:210006603	C/T	cg23166289	chr1:210001082	C1orf107	0.39	4.74	0.3	3.66e-6	Orofacial clefts;
SARC	cis	rs4689388	0.890	rs4342257	chr4:6290037	G/C	cg14416269	chr4:6271139	WFS1	0.34	5.33	0.33	2.27e-7	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs10227331	1.000	rs11979293	chr7:157293586	C/T	cg04156418	chr7:157293606	NA	0.48	8.2	0.47	1.58e-14	Inattentive symptoms;
SARC	trans	rs61931739	0.929	rs3912551	chr12:34076696	C/T	cg13010199	chr12:38710504	ALG10B	-0.5	-6.74	-0.4	1.26e-10	Morning vs. evening chronotype;
SARC	cis	rs2439831	0.867	rs2412780	chr15:43655794	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.08	11.58	0.6	8.71e-25	Lung cancer in ever smokers;
SARC	cis	rs6998277	1.000	rs62523306	chr8:103640752	C/A	cg10187029	chr8:103597600	NA	0.73	7.06	0.42	1.85e-11	Migraine;
SARC	cis	rs10791323	0.628	rs2851118	chr11:133705995	A/C	cg13461336	chr11:133711254	SPATA19	-0.28	-4.81	-0.3	2.74e-6	Childhood ear infection;
SARC	cis	rs96067	0.772	rs1033891	chr1:36608402	A/G	cg24686825	chr1:36642396	MAP7D1	-0.54	-6.13	-0.37	3.65e-9	Corneal structure;
SARC	cis	rs787274	1.000	rs786961	chr9:115471346	T/C	cg13803584	chr9:115635662	SNX30	0.87	5.32	0.33	2.45e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs76419734	1.000	rs10516526	chr4:106688904	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.81	5.48	0.34	1.08e-7	Post bronchodilator FEV1;
SARC	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg09699651	chr6:150184138	LRP11	0.39	4.87	0.3	2.04e-6	Lung cancer;
SARC	cis	rs11574514	1.000	rs78575122	chr16:67869541	G/A	cg01866162	chr16:67596514	CTCF	1.11	6.4	0.39	8.22e-10	Crohn's disease;
SARC	cis	rs72781680	0.898	rs12612492	chr2:24093756	C/T	cg06627628	chr2:24431161	ITSN2	-0.68	-6.6	-0.4	2.75e-10	Lymphocyte counts;
SARC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg11965913	chr1:205819406	PM20D1	0.96	16.84	0.74	3.75e-42	Menarche (age at onset);
SARC	cis	rs826838	1.000	rs11183160	chr12:38676702	T/C	cg26384229	chr12:38710491	ALG10B	0.95	15.09	0.7	2.38e-36	Heart rate;
SARC	trans	rs9329221	0.683	rs658385	chr8:9892177	C/T	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.95	-0.41	3.68e-11	Neuroticism;
SARC	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.72	8.47	0.49	2.82e-15	Height;
SARC	cis	rs2361718	0.900	rs8081698	chr17:78104212	G/A	cg06718696	chr17:78121285	EIF4A3	0.49	5.67	0.35	4.3e-8	Yeast infection;
SARC	cis	rs1355223	0.545	rs7106831	chr11:34879542	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.49	-6.24	-0.38	2.05e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs6840360	1.000	rs749982	chr4:152601353	A/G	cg22705602	chr4:152727874	NA	-0.38	-6.54	-0.39	3.91e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7208859	0.562	rs8078897	chr17:29106257	T/G	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs6831352	0.734	rs2602857	chr4:100030318	G/A	cg12011299	chr4:100065546	ADH4	0.29	4.94	0.31	1.52e-6	Alcohol dependence;
SARC	cis	rs1790761	0.658	rs666328	chr11:67335538	G/A	cg00290607	chr11:67383545	NA	0.39	5.24	0.32	3.56e-7	Mean corpuscular volume;
SARC	cis	rs73206853	0.841	rs56076213	chr12:110572913	G/A	cg10860002	chr12:110842031	ANAPC7	0.67	5.29	0.33	2.82e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs372883	0.554	rs10154065	chr21:30749480	G/C	cg24692254	chr21:30365293	RNF160	0.57	7.33	0.43	3.68e-12	Pancreatic cancer;
SARC	cis	rs796364	0.865	rs769948	chr2:200728475	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.58	0.4	3.11e-10	Schizophrenia;
SARC	cis	rs6540556	0.859	rs11119341	chr1:209940675	A/G	cg05527609	chr1:210001259	C1orf107	0.6	6.07	0.37	5.28e-9	Red blood cell count;
SARC	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.53	-6.38	-0.39	9.52e-10	Renal function-related traits (BUN);
SARC	cis	rs10463554	0.963	rs34380	chr5:102396949	A/G	cg23492399	chr5:102201601	PAM	-0.51	-5.65	-0.35	4.78e-8	Parkinson's disease;
SARC	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg05861140	chr6:150128134	PCMT1	-0.38	-4.91	-0.31	1.75e-6	Lung cancer;
SARC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg10150615	chr22:24372951	LOC391322	-0.42	-4.9	-0.31	1.83e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg21144161	chr5:423903	AHRR	0.31	4.84	0.3	2.39e-6	Cystic fibrosis severity;
SARC	cis	rs2070677	0.935	rs4350328	chr10:135414948	G/A	cg20169779	chr10:135381914	SYCE1	-0.55	-6.49	-0.39	5.16e-10	Gout;
SARC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg23131131	chr22:24373011	LOC391322	0.45	4.78	0.3	3.15e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs12922317	0.556	rs8062691	chr16:12091829	A/G	cg09319797	chr16:12061715	TNFRSF17	-0.33	-4.85	-0.3	2.23e-6	Schizophrenia;
SARC	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg19077165	chr18:44547161	KATNAL2	0.56	7.92	0.46	9.92e-14	Personality dimensions;
SARC	cis	rs9486715	0.867	rs4131519	chr6:96964939	G/A	cg18709589	chr6:96969512	KIAA0776	0.6	7.48	0.44	1.54e-12	Headache;
SARC	cis	rs1008375	0.932	rs7677212	chr4:17675932	A/G	cg27347728	chr4:17578864	LAP3	-0.46	-5.59	-0.34	6.34e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs514406	0.505	rs269289	chr1:53167151	A/C	cg24675658	chr1:53192096	ZYG11B	-0.66	-10.03	-0.55	6.36e-20	Monocyte count;
SARC	cis	rs710865	0.516	rs12062540	chr1:19529204	A/G	cg13387374	chr1:19411106	UBR4	0.52	6.86	0.41	6.24e-11	Brain structure;
SARC	cis	rs6088580	0.609	rs945674	chr20:32964247	G/C	cg24642439	chr20:33292090	TP53INP2	-0.68	-8.73	-0.5	4.96e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs12579753	0.871	rs12822050	chr12:82183041	C/T	cg07988820	chr12:82153109	PPFIA2	-0.53	-6.3	-0.38	1.44e-9	Resting heart rate;
SARC	cis	rs981844	0.857	rs62325139	chr4:154712213	C/T	cg14289246	chr4:154710475	SFRP2	0.66	6.98	0.42	3.05e-11	Response to statins (LDL cholesterol change);
SARC	cis	rs4820539	0.932	rs3788349	chr22:23467950	A/G	cg14186256	chr22:23484241	RTDR1	0.88	13.98	0.68	1.16e-32	Bone mineral density;
SARC	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg17971929	chr21:40555470	PSMG1	-0.86	-11.17	-0.59	1.72e-23	Cognitive function;
SARC	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg24209194	chr3:40518798	ZNF619	-0.66	-8.45	-0.48	3.12e-15	Renal cell carcinoma;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg22781236	chr13:30424171	UBL3	0.48	6.73	0.4	1.3100000000000001e-10	Lung adenocarcinoma;
SARC	cis	rs7512552	0.839	rs12042229	chr1:150447398	A/G	cg15654264	chr1:150340011	RPRD2	0.38	4.81	0.3	2.7e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg24110177	chr3:50126178	RBM5	0.39	5.03	0.31	9.97e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7937682	0.889	rs1940529	chr11:111498523	G/C	cg22437258	chr11:111473054	SIK2	0.74	10.03	0.55	6.36e-20	Primary sclerosing cholangitis;
SARC	cis	rs9911578	0.835	rs9303398	chr17:56484257	T/C	cg05425664	chr17:57184151	TRIM37	0.65	7.94	0.46	8.29e-14	Intelligence (multi-trait analysis);
SARC	cis	rs6570726	0.935	rs12663205	chr6:145818378	G/A	cg05347473	chr6:146136440	FBXO30	0.49	6.48	0.39	5.27e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg23758822	chr17:41437982	NA	0.87	10.64	0.57	8.54e-22	Menopause (age at onset);
SARC	cis	rs7647973	1.000	rs11130190	chr3:49402137	T/C	cg07636037	chr3:49044803	WDR6	0.75	8.18	0.47	1.88e-14	Menarche (age at onset);
SARC	cis	rs17253792	0.822	rs17747083	chr14:56110594	T/C	cg01858014	chr14:56050164	KTN1	-0.69	-5.45	-0.34	1.26e-7	Putamen volume;
SARC	cis	rs2425143	1.000	rs11167275	chr20:34340275	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-6.07	-0.37	5.17e-9	Blood protein levels;
SARC	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg11764359	chr7:65958608	NA	-0.75	-9.18	-0.52	2.35e-17	Aortic root size;
SARC	cis	rs1448094	1.000	rs4919776	chr12:86353763	T/C	cg02569458	chr12:86230093	RASSF9	0.41	5.92	0.36	1.12e-8	Major depressive disorder;
SARC	cis	rs35110281	0.591	rs230642	chr21:44915533	A/C	cg21573476	chr21:45109991	RRP1B	0.49	7.21	0.43	7.59e-12	Mean corpuscular volume;
SARC	cis	rs698833	0.926	rs698835	chr2:44737089	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.66	8.24	0.47	1.28e-14	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs7246657	0.941	rs7259618	chr19:37750719	G/A	cg14683738	chr19:37701593	ZNF585B	0.61	5.45	0.34	1.31e-7	Coronary artery calcification;
SARC	cis	rs12479064	0.724	rs28369945	chr2:100080928	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.67	-7.94	-0.46	8.62e-14	Chronic sinus infection;
SARC	cis	rs7246865	0.510	rs1551551	chr19:17170541	G/T	cg16202187	chr19:17186497	HAUS8;MYO9B	0.39	4.78	0.3	3.15e-6	Reticulocyte fraction of red cells;
SARC	cis	rs78487399	0.808	rs113373412	chr2:43762987	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-5.11	-0.32	6.6e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg08219700	chr8:58056026	NA	0.6	6.36	0.38	1.04e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs2727020	0.553	rs10839295	chr11:49527345	A/C	cg03929089	chr4:120376271	NA	-0.75	-10.92	-0.58	1.13e-22	Coronary artery disease;
SARC	cis	rs11098499	0.863	rs9884402	chr4:120489982	A/G	cg09307838	chr4:120376055	NA	0.91	12.25	0.63	5.66e-27	Corneal astigmatism;
SARC	cis	rs950027	0.620	rs1145089	chr15:45652054	G/C	cg15395560	chr15:45543142	SLC28A2	-0.27	-5.21	-0.32	4.23e-7	Response to fenofibrate (adiponectin levels);
SARC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg09373136	chr17:61933544	TCAM1	-0.45	-6.17	-0.37	2.98e-9	Prudent dietary pattern;
SARC	cis	rs1865760	0.566	rs10807006	chr6:26048752	C/A	cg17691542	chr6:26056736	HIST1H1C	0.54	6.71	0.4	1.48e-10	Height;
SARC	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg12042659	chr19:58951599	ZNF132	0.64	7.96	0.46	7.3e-14	Mean platelet volume;
SARC	cis	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg18904891	chr8:8559673	CLDN23	0.51	6.21	0.38	2.38e-9	Obesity-related traits;
SARC	cis	rs6674176	0.597	rs4660262	chr1:44382524	G/A	cg13606994	chr1:44402422	ARTN	-0.34	-5.65	-0.35	4.6e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs9473924	0.580	rs58105163	chr6:50832730	C/T	cg14470998	chr6:50812995	TFAP2B	0.69	6.41	0.39	7.9e-10	Body mass index;
SARC	trans	rs656319	0.580	rs13279701	chr8:9969450	C/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.48	-0.44	1.47e-12	Myopia (pathological);
SARC	cis	rs12950390	0.893	rs12325760	chr17:45840886	C/T	cg24803719	chr17:45855879	NA	-0.49	-7.98	-0.46	6.41e-14	IgG glycosylation;
SARC	cis	rs9911578	1.000	rs12602346	chr17:56901713	T/C	cg05425664	chr17:57184151	TRIM37	-0.64	-7.98	-0.46	6.52e-14	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg02725872	chr8:58115012	NA	-0.34	-5.38	-0.33	1.78e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs57506017	0.540	rs4721061	chr7:12267559	G/C	cg23422036	chr7:12250390	TMEM106B	0.44	5.64	0.35	4.85e-8	Neuroticism;
SARC	cis	rs7824557	0.564	rs2736288	chr8:11228100	G/A	cg12395012	chr8:11607386	GATA4	0.3	5.03	0.31	9.94e-7	Retinal vascular caliber;
SARC	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg24675658	chr1:53192096	ZYG11B	-0.69	-9.99	-0.55	8.62e-20	Monocyte count;
SARC	cis	rs733592	0.504	rs2261608	chr12:48721634	A/T	cg24011408	chr12:48396354	COL2A1	0.47	6.41	0.39	8.06e-10	Plateletcrit;
SARC	cis	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg08564027	chr20:61660810	NA	0.77	11.74	0.61	2.68e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg11987759	chr7:65425863	GUSB	0.57	7.45	0.44	1.86e-12	Aortic root size;
SARC	cis	rs1345301	0.905	rs2310243	chr2:102877560	A/G	cg12451869	chr2:102867685	NA	0.38	5.29	0.33	2.78e-7	Waist circumference;
SARC	cis	rs787274	0.867	rs1711746	chr9:115452656	A/G	cg13803584	chr9:115635662	SNX30	0.75	4.92	0.31	1.65e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg18876405	chr7:65276391	NA	-0.45	-5.58	-0.34	6.61e-8	Aortic root size;
SARC	cis	rs2073300	0.609	rs6137915	chr20:23358509	A/G	cg16736954	chr20:23401023	NAPB	-0.75	-4.86	-0.3	2.19e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs4555082	0.834	rs2735826	chr14:105710866	G/A	cg10792982	chr14:105748885	BRF1	0.54	8.14	0.47	2.36e-14	Mean platelet volume;Platelet distribution width;
SARC	cis	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg25427524	chr10:38739819	LOC399744	-0.57	-8.85	-0.5	2.29e-16	Extrinsic epigenetic age acceleration;
SARC	cis	rs79149102	0.649	rs76516943	chr15:75127539	C/A	cg09165964	chr15:75287851	SCAMP5	-1.12	-6.71	-0.4	1.47e-10	Lung cancer;
SARC	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg05890377	chr2:74357713	NA	0.59	7.19	0.43	8.94e-12	Gestational age at birth (maternal effect);
SARC	cis	rs96067	0.711	rs7521145	chr1:36622903	A/G	cg24686825	chr1:36642396	MAP7D1	-0.56	-6.95	-0.41	3.68e-11	Corneal structure;
SARC	cis	rs9581857	0.547	rs17753121	chr13:28052613	T/C	cg01674679	chr13:27998804	GTF3A	-0.66	-5.0	-0.31	1.11e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	cis	rs2387326	0.868	rs769005	chr10:129920241	C/T	cg16087940	chr10:129947807	NA	-0.42	-5.16	-0.32	5.36e-7	Select biomarker traits;
SARC	cis	rs9325144	0.647	rs11169258	chr12:39113040	C/T	cg13010199	chr12:38710504	ALG10B	-0.5	-6.15	-0.37	3.4e-9	Morning vs. evening chronotype;
SARC	cis	rs8114671	0.585	rs2236271	chr20:33523840	G/T	cg24642439	chr20:33292090	TP53INP2	-0.46	-5.36	-0.33	1.98e-7	Height;
SARC	cis	rs7084402	0.967	rs1649058	chr10:60317087	G/A	cg07615347	chr10:60278583	BICC1	0.59	8.65	0.49	8.56e-16	Refractive error;
SARC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.58	0.53	1.52e-18	Prudent dietary pattern;
SARC	cis	rs1152591	0.967	rs1152589	chr14:64683926	A/T	cg23250157	chr14:64679961	SYNE2	-0.52	-7.88	-0.46	1.22e-13	Atrial fibrillation;
SARC	cis	rs12702595	0.936	rs6960832	chr7:7267787	G/T	cg04827551	chr7:7268805	C1GALT1	0.44	5.51	0.34	9.5e-8	Serum dimethylarginine levels (asymmetric/symetric ratio);Symmetrical dimethylarginine levels;
SARC	cis	rs6964587	0.626	rs4729014	chr7:91550707	A/G	cg17063962	chr7:91808500	NA	-0.76	-10.93	-0.58	1.04e-22	Breast cancer;
SARC	cis	rs2997447	0.723	rs2802336	chr1:26473758	A/C	cg19633962	chr1:26362018	EXTL1	-0.55	-4.76	-0.3	3.44e-6	QRS complex (12-leadsum);
SARC	cis	rs6570726	0.935	rs380433	chr6:145859601	A/T	cg05347473	chr6:146136440	FBXO30	0.49	6.58	0.4	3.04e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6604026	0.656	rs9651257	chr1:93385136	A/G	cg17283838	chr1:93427260	FAM69A	0.43	4.87	0.3	2.05e-6	Multiple sclerosis;
SARC	cis	rs7927771	0.929	rs12787646	chr11:47669665	T/C	cg05585544	chr11:47624801	NA	-0.4	-5.41	-0.33	1.57e-7	Subjective well-being;
SARC	cis	rs6912958	0.781	rs13193380	chr6:88297057	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-6.8	-0.41	8.58e-11	Monocyte percentage of white cells;
SARC	cis	rs6733011	0.578	rs12712039	chr2:99497980	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.38	-4.78	-0.3	3.16e-6	Bipolar disorder;
SARC	cis	rs228437	1.000	rs985121	chr6:134930893	C/T	cg24504307	chr6:134963096	NA	0.54	6.3	0.38	1.47e-9	Melanoma;
SARC	cis	rs7481584	0.624	rs377765	chr11:3046298	C/T	cg08508325	chr11:3079039	CARS	0.23	5.12	0.32	6.36e-7	Calcium levels;
SARC	cis	rs4295623	0.816	rs35558975	chr8:11584476	C/G	cg00262122	chr8:11665843	FDFT1	-0.44	-5.01	-0.31	1.08e-6	Morning vs. evening chronotype;
SARC	cis	rs4561483	0.767	rs33633	chr16:11994857	A/C	cg08843971	chr16:11963173	GSPT1	-0.42	-5.02	-0.31	1.03e-6	Testicular germ cell tumor;
SARC	cis	rs7847628	0.587	rs1060817	chr9:123583192	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.92	14.17	0.68	2.84e-33	Birth weight;
SARC	cis	rs4481887	0.927	rs4279879	chr1:248486475	A/G	cg13385794	chr1:248469461	NA	0.33	4.96	0.31	1.35e-6	Common traits (Other);
SARC	cis	rs34779708	0.966	rs4934725	chr10:35398236	T/C	cg03585969	chr10:35415529	CREM	0.42	5.17	0.32	5.03e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg18876405	chr7:65276391	NA	-0.46	-5.15	-0.32	5.63e-7	Aortic root size;
SARC	cis	rs2180341	0.883	rs6904630	chr6:127696869	A/G	cg17762328	chr6:126965162	NA	-0.44	-4.79	-0.3	2.98e-6	Breast cancer;
SARC	cis	rs7607369	0.714	rs4674334	chr2:219622811	T/C	cg02176678	chr2:219576539	TTLL4	-0.48	-7.55	-0.44	1.01e-12	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs1355223	0.545	rs12278318	chr11:34876507	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.5	-6.36	-0.38	1.06e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs2594989	1.000	rs2594989	chr3:11316143	C/T	cg00170343	chr3:11313890	ATG7	0.55	5.39	0.33	1.74e-7	Circulating chemerin levels;
SARC	cis	rs9653442	0.835	rs7565967	chr2:100744683	G/T	cg22139774	chr2:100720529	AFF3	-0.29	-4.97	-0.31	1.29e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
SARC	trans	rs10506458	1.000	rs73128794	chr12:63445313	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.79	-6.92	-0.41	4.24e-11	Hemostatic factors and hematological phenotypes;
SARC	cis	rs921968	0.643	rs532475	chr2:219434208	C/T	cg02176678	chr2:219576539	TTLL4	0.36	5.52	0.34	9.16e-8	Mean corpuscular hemoglobin concentration;
SARC	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg00031303	chr3:195681400	NA	0.49	5.57	0.34	7.12e-8	Pancreatic cancer;
SARC	cis	rs12188164	0.762	rs11745923	chr5:475408	T/G	cg15813090	chr5:442598	EXOC3;C5orf55	0.39	4.75	0.3	3.63e-6	Cystic fibrosis severity;
SARC	cis	rs11583043	1.000	rs6660290	chr1:101483512	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.5	-5.73	-0.35	3.08e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs4268898	0.552	rs11125444	chr2:24367205	G/T	cg06627628	chr2:24431161	ITSN2	0.48	6.22	0.38	2.29e-9	Asthma;
SARC	cis	rs9595973	0.571	rs6561478	chr13:49316146	A/G	cg26391794	chr13:49323899	NA	-0.49	-4.87	-0.3	2.03e-6	Systemic juvenile idiopathic arthritis;
SARC	cis	rs7429990	0.965	rs5012971	chr3:48074547	C/T	cg11946769	chr3:48343235	NME6	-0.45	-5.24	-0.32	3.64e-7	Educational attainment (years of education);
SARC	cis	rs3008870	0.755	rs2755243	chr1:67482783	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.59	7.6	0.45	7e-13	Lymphocyte percentage of white cells;
SARC	cis	rs10870270	1.000	rs4880263	chr10:133787629	C/T	cg26149184	chr10:133730230	NA	0.46	4.94	0.31	1.48e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs17666538	1.000	rs17666538	chr8:566207	T/C	cg00450029	chr8:599525	NA	-0.71	-5.0	-0.31	1.11e-6	IgG glycosylation;
SARC	cis	rs10504073	0.647	rs10808744	chr8:49988984	A/G	cg00325661	chr8:49890786	NA	0.52	7.09	0.42	1.59e-11	Blood metabolite ratios;
SARC	cis	rs2153535	0.580	rs1932275	chr6:8442333	T/A	cg23788917	chr6:8435910	SLC35B3	0.63	8.07	0.47	3.7e-14	Motion sickness;
SARC	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.41	-5.23	-0.32	3.79e-7	Lymphocyte counts;
SARC	trans	rs35833281	0.951	rs11751491	chr6:55044012	A/G	cg19977494	chr7:128431264	CCDC136	-0.71	-6.65	-0.4	2.12e-10	Morning vs. evening chronotype;
SARC	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg05872129	chr22:39784769	NA	-0.37	-5.04	-0.31	9.23e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs4642101	0.640	rs3901666	chr3:12824363	G/T	cg12400702	chr3:12838781	CAND2	0.25	4.89	0.31	1.87e-6	QRS complex (12-leadsum);
SARC	cis	rs77633900	0.614	rs157757	chr15:76855927	G/C	cg21673338	chr15:77095150	SCAPER	-0.79	-5.95	-0.36	9.62e-9	Non-glioblastoma glioma;Glioma;
SARC	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg13939156	chr17:80058883	NA	-0.42	-6.48	-0.39	5.51e-10	Life satisfaction;
SARC	cis	rs694739	1.000	rs1783521	chr11:64106291	T/C	cg23796481	chr11:64053134	BAD;GPR137	0.76	10.32	0.56	8.42e-21	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg05901451	chr6:126070800	HEY2	-0.67	-9.24	-0.52	1.55e-17	Brugada syndrome;
SARC	cis	rs9285223	1.000	rs7331264	chr13:23136836	C/T	cg08083251	chr13:23309930	NA	0.46	4.9	0.31	1.81e-6	Idiopathic osteonecrosis of the femoral head;
SARC	cis	rs2594989	1.000	rs2606752	chr3:11360170	A/G	cg00170343	chr3:11313890	ATG7	0.54	5.22	0.32	4.05e-7	Circulating chemerin levels;
SARC	cis	rs2732480	0.500	rs12828309	chr12:48641160	C/T	cg24011408	chr12:48396354	COL2A1	0.46	5.35	0.33	2.08e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg02878486	chr11:65746383	SART1	0.42	6.39	0.39	8.76e-10	Schizophrenia;
SARC	cis	rs3806933	0.522	rs34962120	chr5:110446091	G/A	cg04022379	chr5:110408740	TSLP	0.7	8.75	0.5	4.27e-16	Eosinophilic esophagitis;
SARC	cis	rs9733	0.596	rs7418501	chr1:150711896	A/T	cg15448220	chr1:150897856	SETDB1	0.41	5.53	0.34	8.75e-8	Tonsillectomy;
SARC	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg04234412	chr22:24373322	LOC391322	0.57	6.57	0.4	3.32e-10	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs4481887	1.000	rs4244179	chr1:248470984	T/A	cg01631408	chr1:248437212	OR2T33	-0.41	-5.13	-0.32	6.07e-7	Common traits (Other);
SARC	cis	rs11105298	0.891	rs10858903	chr12:89927972	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.55	-5.54	-0.34	8.05e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs35306767	0.903	rs12244253	chr10:889320	G/T	cg20503657	chr10:835505	NA	0.86	8.14	0.47	2.39e-14	Eosinophil percentage of granulocytes;
SARC	cis	rs7592578	0.771	rs4258824	chr2:191395027	C/T	cg25963032	chr2:191064776	C2orf88	-0.43	-4.91	-0.31	1.73e-6	Diastolic blood pressure;
SARC	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg15049968	chr18:44337910	ST8SIA5	0.34	5.23	0.32	3.81e-7	Personality dimensions;
SARC	cis	rs3741151	0.773	rs73548693	chr11:73286637	G/A	cg17517138	chr11:73019481	ARHGEF17	0.9	6.41	0.39	8.1e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg11080062	chr12:53615449	RARG	0.49	6.52	0.39	4.38e-10	Chemerin levels;
SARC	cis	rs7833986	0.501	rs2953898	chr8:56980803	C/T	cg26371346	chr8:56986568	SNORD54;RPS20	0.72	7.24	0.43	6.48e-12	Height;
SARC	cis	rs11264799	0.581	rs849815	chr1:157542162	A/G	cg18268488	chr1:157545234	FCRL4	0.29	4.78	0.3	3.05e-6	IgA nephropathy;
SARC	cis	rs4957048	0.891	rs11960196	chr5:568857	C/A	cg09021430	chr5:549028	NA	-0.46	-6.21	-0.38	2.36e-9	Ulcerative colitis;
SARC	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	trans	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg21659725	chr3:3221576	CRBN	-0.81	-12.46	-0.63	1.2e-27	Blood protein levels;
SARC	cis	rs1691799	0.867	rs1168342	chr12:66758734	A/T	cg16791601	chr12:66731901	HELB	-0.72	-10.83	-0.58	2.06e-22	White blood cell count (basophil);
SARC	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg20102877	chr2:27665638	KRTCAP3	-0.38	-5.17	-0.32	5.07e-7	Total body bone mineral density;
SARC	cis	rs9326248	0.520	rs74830	chr11:117090558	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.73	-9.96	-0.55	1.06e-19	Blood protein levels;
SARC	trans	rs641862	1	rs641862	chr13:110790232	C/T	cg23875597	chr13:113683971	MCF2L	-0.88	-6.64	-0.4	2.17e-10	Obesity-related traits;
SARC	cis	rs1318878	0.679	rs10161193	chr12:15520003	A/T	cg08258403	chr12:15378311	NA	0.52	6.89	0.41	5.27e-11	Intelligence (multi-trait analysis);
SARC	cis	rs10779751	1.000	rs4845854	chr1:11261929	T/C	cg08854313	chr1:11322531	MTOR	0.86	13.21	0.65	4.12e-30	Body mass index;
SARC	cis	rs8078723	0.714	rs3859187	chr17:38150613	C/A	cg17467752	chr17:38218738	THRA	-0.38	-4.89	-0.3	1.92e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs6089584	0.586	rs4925216	chr20:60599923	G/A	cg06108461	chr20:60628389	TAF4	-0.65	-8.14	-0.47	2.44e-14	Body mass index;
SARC	cis	rs4423214	0.840	rs1790339	chr11:71182761	C/A	cg05163923	chr11:71159392	DHCR7	-0.6	-7.21	-0.43	7.58e-12	Vitamin D levels;
SARC	cis	rs854765	0.551	rs8070748	chr17:17859421	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	9.85	0.54	2.34e-19	Total body bone mineral density;
SARC	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	8.64	0.49	9.15e-16	Attention deficit hyperactivity disorder;
SARC	cis	rs748404	0.697	rs473554	chr15:43568207	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.53	6.29	0.38	1.53e-9	Lung cancer;
SARC	cis	rs5995756	0.666	rs3788566	chr22:40006024	G/T	cg10455938	chr22:40058150	CACNA1I	0.43	5.09	0.32	7.42e-7	Autism spectrum disorder or schizophrenia;
SARC	cis	rs910316	1.000	rs11845639	chr14:75570293	C/T	cg06637938	chr14:75390232	RPS6KL1	0.5	6.97	0.42	3.21e-11	Height;
SARC	cis	rs918629	0.567	rs13361341	chr5:95250273	A/T	cg16656078	chr5:95278638	ELL2	-0.51	-6.38	-0.39	9.23e-10	IgG glycosylation;
SARC	cis	rs10197940	0.662	rs6735771	chr2:152273503	G/A	cg19508488	chr2:152266495	RIF1	-0.47	-5.19	-0.32	4.48e-7	Lung cancer;
SARC	cis	rs1559088	0.649	rs4528686	chr19:33556074	A/G	cg27124370	chr19:33622961	WDR88	0.43	5.42	0.33	1.49e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs559928	0.606	rs7941773	chr11:63952759	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.67	5.05	0.31	9.08e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs9322193	0.607	rs12204653	chr6:150213021	C/G	cg05036130	chr6:150231994	NA	0.32	4.82	0.3	2.55e-6	Lung cancer;
SARC	cis	rs9303401	0.659	rs34275691	chr17:56736640	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	11.6	0.6	7.63e-25	Cognitive test performance;
SARC	cis	rs910316	0.789	rs175457	chr14:75584507	C/T	cg08847533	chr14:75593920	NEK9	-0.8	-11.78	-0.61	1.9e-25	Height;
SARC	trans	rs17221829	0.733	rs11018668	chr11:89356178	C/T	cg18332146	chr11:88071004	CTSC	-0.48	-6.45	-0.39	6.47e-10	Anxiety in major depressive disorder;
SARC	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg21782813	chr7:2030301	MAD1L1	0.47	7.49	0.44	1.4e-12	Bipolar disorder and schizophrenia;
SARC	cis	rs2842992	0.747	rs4709379	chr6:160227530	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.8	7.41	0.44	2.26e-12	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg12463550	chr7:65579703	CRCP	0.71	5.38	0.33	1.77e-7	Diabetic kidney disease;
SARC	cis	rs9457247	0.508	rs2285147	chr6:167505548	G/A	cg07741184	chr6:167504864	NA	0.33	6.1	0.37	4.38e-9	Crohn's disease;
SARC	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.76	7.36	0.43	3.06e-12	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs3008870	0.755	rs4655660	chr1:67402953	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.59	7.54	0.44	1.07e-12	Lymphocyte percentage of white cells;
SARC	cis	rs2070677	0.935	rs12245318	chr10:135419483	A/G	cg20169779	chr10:135381914	SYCE1	-0.52	-6.46	-0.39	6e-10	Gout;
SARC	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg16680214	chr1:154839983	KCNN3	-0.35	-5.33	-0.33	2.26e-7	Prostate cancer;
SARC	trans	rs1814175	0.646	rs1722010	chr11:49897958	A/G	cg15704280	chr7:45808275	SEPT13	-0.88	-13.99	-0.68	1.12e-32	Height;
SARC	cis	rs2242116	1.000	rs2168443	chr3:46947087	A/T	cg02527881	chr3:46936655	PTH1R	0.39	6.17	0.37	2.94e-9	Birth weight;
SARC	cis	rs28374715	0.528	rs28492932	chr15:41624397	G/C	cg18705301	chr15:41695430	NDUFAF1	-1.17	-19.16	-0.78	8.85e-50	Ulcerative colitis;
SARC	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg21017887	chr14:105400489	NA	0.53	7.5	0.44	1.3e-12	Rheumatoid arthritis;
SARC	cis	rs7474896	0.609	rs11011336	chr10:37985316	A/G	cg25427524	chr10:38739819	LOC399744	-0.42	-4.93	-0.31	1.57e-6	Obesity (extreme);
SARC	cis	rs8017423	0.904	rs4603489	chr14:90760607	A/G	cg20276874	chr14:90721474	PSMC1	0.38	5.03	0.31	9.96e-7	Mortality in heart failure;
SARC	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg25072359	chr17:41440525	NA	0.48	5.56	0.34	7.48e-8	Menopause (age at onset);
SARC	cis	rs881375	0.967	rs2416806	chr9:123690292	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	5.37	0.33	1.94e-7	Rheumatoid arthritis;
SARC	cis	rs1451375	0.642	rs6963996	chr7:50559300	T/C	cg14593290	chr7:50529359	DDC	-0.43	-4.73	-0.3	3.87e-6	Malaria;
SARC	cis	rs12908161	1.000	rs11637142	chr15:85295927	A/G	cg17507749	chr15:85114479	UBE2QP1	0.55	6.22	0.38	2.33e-9	Schizophrenia;
SARC	cis	rs13392177	0.672	rs1877715	chr2:219052546	C/T	cg00012203	chr2:219082015	ARPC2	0.7	9.83	0.54	2.62e-19	Pyoderma gangrenosum in inflammatory bowel disease;
SARC	cis	rs13082711	0.680	rs7647818	chr3:27418896	T/C	cg02860705	chr3:27208620	NA	0.45	6.01	0.37	7.16e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs3782089	0.744	rs11545200	chr11:65319751	G/A	cg00206168	chr11:65308501	LTBP3	0.94	5.77	0.35	2.55e-8	Height;
SARC	cis	rs2354432	0.556	rs34602039	chr1:146850972	G/A	cg25205988	chr1:146714368	CHD1L	-0.95	-6.95	-0.41	3.58e-11	Mitochondrial DNA levels;
SARC	cis	rs4690686	0.500	rs35703625	chr4:177263286	G/A	cg17059388	chr4:177262070	NA	0.36	4.78	0.3	3.09e-6	Essential tremor;
SARC	cis	rs2075371	0.966	rs2544225	chr7:133995838	A/C	cg20476274	chr7:133979776	SLC35B4	0.62	8.43	0.48	3.74e-15	Mean platelet volume;
SARC	cis	rs9886651	0.935	rs28660151	chr8:128803578	A/T	cg24514600	chr8:128805414	PVT1	-0.44	-5.79	-0.35	2.32e-8	Epithelial ovarian cancer;Serous invasive ovarian cancer;
SARC	cis	rs76419734	0.510	rs2553461	chr4:106731410	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	-0.75	-7.74	-0.45	3.04e-13	Post bronchodilator FEV1;
SARC	cis	rs10464366	0.519	rs6974609	chr7:39219149	C/T	cg15212455	chr7:39170539	POU6F2	0.44	5.39	0.33	1.76e-7	IgG glycosylation;
SARC	cis	rs9815354	0.680	rs114478966	chr3:42007050	T/C	cg03022575	chr3:42003672	ULK4	0.65	5.61	0.34	5.72e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs4242434	0.672	rs7830206	chr8:22485375	C/T	cg03733263	chr8:22462867	KIAA1967	0.86	12.9	0.65	4.48e-29	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs10513788	0.578	rs72622586	chr3:181994804	A/G	cg05977900	chr3:182512126	ATP11B	0.47	4.88	0.3	1.99e-6	Cognitive function;
SARC	cis	rs12142240	0.698	rs56130131	chr1:46861306	A/C	cg14993813	chr1:46806288	NSUN4	-0.52	-5.53	-0.34	8.45e-8	Menopause (age at onset);
SARC	trans	rs6964833	0.786	rs35633336	chr7:74058292	G/T	cg07504079	chr7:72649617	NCF1B	-0.6	-6.51	-0.39	4.51e-10	Menarche (age at onset);
SARC	cis	rs2070488	0.931	rs7630012	chr3:38552250	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.8	-12.9	-0.65	4.23e-29	Electrocardiographic conduction measures;
SARC	cis	rs1215050	0.755	rs6843393	chr4:98822619	C/G	cg05340658	chr4:99064831	C4orf37	0.43	5.71	0.35	3.37e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg14343924	chr8:8086146	FLJ10661	0.45	5.62	0.35	5.43e-8	Mood instability;
SARC	trans	rs7615952	0.546	rs2976733	chr3:125414138	T/C	cg07211511	chr3:129823064	LOC729375	-0.57	-6.32	-0.38	1.32e-9	Blood pressure (smoking interaction);
SARC	cis	rs7561273	0.586	rs11892283	chr2:24317850	T/C	cg08917208	chr2:24149416	ATAD2B	0.45	4.93	0.31	1.55e-6	Quantitative traits;
SARC	cis	rs35306767	0.903	rs17159970	chr10:935601	T/C	cg20503657	chr10:835505	NA	0.86	8.3	0.48	8.21e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs9733	0.536	rs10888385	chr1:150574302	T/C	cg17724175	chr1:150552817	MCL1	-0.39	-4.94	-0.31	1.5e-6	Tonsillectomy;
SARC	cis	rs6545883	0.895	rs4430924	chr2:61703856	A/G	cg15711740	chr2:61764176	XPO1	-0.43	-5.08	-0.32	7.83e-7	Tuberculosis;
SARC	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg14829155	chr15:31115871	NA	0.49	6.02	0.37	6.88e-9	Huntington's disease progression;
SARC	cis	rs7296418	0.961	rs4148863	chr12:123569375	A/G	cg00376283	chr12:123451042	ABCB9	0.66	8.55	0.49	1.61e-15	Platelet count;
SARC	cis	rs10992471	0.603	rs7864575	chr9:95304647	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.42	-0.33	1.48e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg12463550	chr7:65579703	CRCP	0.68	5.18	0.32	4.78e-7	Diabetic kidney disease;
SARC	cis	rs2276314	0.857	rs28651028	chr18:33638910	G/A	cg05985134	chr18:33552581	C18orf21	0.67	7.24	0.43	6.4e-12	Endometriosis;Drug-induced torsades de pointes;
SARC	trans	rs1814175	0.592	rs1794161	chr11:49898825	A/C	cg03929089	chr4:120376271	NA	-0.82	-11.77	-0.61	2.09e-25	Height;
SARC	cis	rs9303401	0.659	rs66514313	chr17:56714057	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	12.09	0.62	2e-26	Cognitive test performance;
SARC	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg02931644	chr1:25747376	RHCE	-0.44	-7.32	-0.43	3.92e-12	Erythrocyte sedimentation rate;
SARC	cis	rs61409971	0.961	rs7157029	chr14:93017566	G/A	cg04718702	chr14:93020195	RIN3	-0.36	-4.77	-0.3	3.2e-6	Lymphocyte percentage of white cells;
SARC	cis	rs7937682	0.883	rs553632	chr11:111462897	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.93	-14.06	-0.68	6.32e-33	Primary sclerosing cholangitis;
SARC	cis	rs1707322	1.000	rs6676982	chr1:46275401	A/T	cg03146154	chr1:46216737	IPP	0.47	5.62	0.35	5.38e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6138458	0.701	rs6050255	chr20:25007089	A/G	cg26195577	chr20:24973756	C20orf3	0.72	8.47	0.49	2.71e-15	Blood protein levels;
SARC	cis	rs736801	0.780	rs12521868	chr5:131784393	A/C	cg07395648	chr5:131743802	NA	0.44	4.87	0.3	2.09e-6	Breast cancer;Mosquito bite size;
SARC	cis	rs735539	0.555	rs4608189	chr13:21343209	C/T	cg16922012	chr13:21400325	XPO4	-0.4	-5.43	-0.33	1.44e-7	Dental caries;
SARC	cis	rs7779181	0.556	rs11981007	chr7:32354307	C/G	cg16719466	chr7:32338569	NA	0.65	5.28	0.33	3.02e-7	Body mass index;
SARC	cis	rs7223966	0.881	rs3020608	chr17:61979993	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	6.62	0.4	2.51e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg06070421	chr8:100026087	VPS13B	-0.51	-6.64	-0.4	2.14e-10	Tetralogy of Fallot;
SARC	cis	rs7647973	0.593	rs1799844	chr3:49847642	G/A	cg13072238	chr3:49761600	GMPPB	0.66	6.32	0.38	1.34e-9	Menarche (age at onset);
SARC	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg16606324	chr3:10149918	C3orf24	0.49	4.86	0.3	2.13e-6	Alzheimer's disease;
SARC	cis	rs2153535	0.541	rs6938688	chr6:8521629	G/T	cg21535247	chr6:8435926	SLC35B3	0.54	6.92	0.41	4.29e-11	Motion sickness;
SARC	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg24675658	chr1:53192096	ZYG11B	0.61	8.55	0.49	1.64e-15	Monocyte count;
SARC	cis	rs7089973	0.604	rs2181563	chr10:116604344	T/C	cg03647239	chr10:116582469	FAM160B1	0.55	7.3	0.43	4.56e-12	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs6570726	0.791	rs387376	chr6:145822565	T/C	cg23711669	chr6:146136114	FBXO30	0.87	14.62	0.69	8.73e-35	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2916247	0.954	rs6981723	chr8:93175044	G/A	cg10183463	chr8:93005414	RUNX1T1	0.53	5.58	0.34	6.82e-8	Intelligence (multi-trait analysis);
SARC	cis	rs11122272	0.735	rs2808604	chr1:231538916	T/C	cg06096015	chr1:231504339	EGLN1	0.38	5.58	0.34	6.77e-8	Hemoglobin concentration;
SARC	cis	rs34779708	0.931	rs4934700	chr10:35310842	A/G	cg03585969	chr10:35415529	CREM	0.41	5.11	0.32	6.57e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs72781680	0.898	rs72786286	chr2:24074659	T/A	cg08917208	chr2:24149416	ATAD2B	0.78	7.43	0.44	2.09e-12	Lymphocyte counts;
SARC	cis	rs6690583	0.512	rs7547224	chr1:85456902	T/C	cg22488158	chr1:85528044	WDR63	0.62	5.16	0.32	5.16e-7	Serum sulfate level;
SARC	cis	rs6582630	0.555	rs2004152	chr12:38478951	C/T	cg13010199	chr12:38710504	ALG10B	0.77	10.35	0.56	6.77e-21	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg17971929	chr21:40555470	PSMG1	1.0	14.01	0.68	9.02e-33	Cognitive function;
SARC	cis	rs6582630	0.555	rs10880612	chr12:38509427	A/G	cg26384229	chr12:38710491	ALG10B	0.85	12.35	0.63	2.74e-27	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6964587	0.967	rs6973896	chr7:91778465	A/G	cg17063962	chr7:91808500	NA	0.98	17.34	0.75	7.95e-44	Breast cancer;
SARC	cis	rs9815354	0.767	rs60943892	chr3:41852307	T/C	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs4805272	0.626	rs12608533	chr19:29331405	C/G	cg04546413	chr19:29218101	NA	0.5	6.19	0.38	2.74e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs6665290	0.870	rs17600725	chr1:227204231	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.05	-23.58	-0.84	1.22e-63	Myeloid white cell count;
SARC	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg18252515	chr7:66147081	NA	-1.35	-12.01	-0.62	3.48e-26	Diabetic kidney disease;
SARC	trans	rs9929218	0.953	rs16260	chr16:68771034	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.63	-8.32	-0.48	7.27e-15	Colorectal cancer;
SARC	cis	rs41278232	0.557	rs843850	chr20:62607659	G/T	cg24354818	chr20:62328094	TNFRSF6B	0.35	4.93	0.31	1.54e-6	Tonsillectomy;
SARC	cis	rs910316	0.699	rs175039	chr14:75468950	G/C	cg06637938	chr14:75390232	RPS6KL1	-0.46	-6.04	-0.37	5.96e-9	Height;
SARC	cis	rs2730245	0.527	rs2036582	chr7:158701708	A/T	cg24397884	chr7:158709396	WDR60	1.02	9.35	0.52	7.39e-18	Height;
SARC	cis	rs9400467	0.537	rs17606481	chr6:111542388	A/G	cg15721981	chr6:111408429	SLC16A10	0.68	5.72	0.35	3.24e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs11676348	0.791	rs6726126	chr2:218952233	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.49	-6.44	-0.39	6.62e-10	Ulcerative colitis;
SARC	cis	rs10089	1.000	rs4836361	chr5:127459991	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	10.26	0.56	1.31e-20	Ileal carcinoids;
SARC	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg26681399	chr22:41777847	TEF	-0.46	-4.99	-0.31	1.21e-6	Vitiligo;
SARC	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg17971929	chr21:40555470	PSMG1	-0.59	-7.44	-0.44	1.88e-12	Menarche (age at onset);
SARC	cis	rs4901847	0.609	rs11158198	chr14:58576320	G/T	cg15908186	chr14:58618357	C14orf37	-0.55	-6.88	-0.41	5.4e-11	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg07701084	chr6:150067640	NUP43	0.41	5.29	0.33	2.81e-7	Lung cancer;
SARC	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg26681399	chr22:41777847	TEF	0.43	4.85	0.3	2.24e-6	Vitiligo;
SARC	cis	rs7552404	0.920	rs2788654	chr1:76219569	C/T	cg22875332	chr1:76189707	ACADM	0.39	5.43	0.34	1.41e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs1712517	1.000	rs3123794	chr10:105033742	A/G	cg05636881	chr10:105038444	INA	0.34	4.91	0.31	1.69e-6	Migraine;
SARC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg11494091	chr17:61959527	GH2	0.53	7.96	0.46	7.52e-14	Prudent dietary pattern;
SARC	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	13.06	0.65	1.26e-29	Chronic sinus infection;
SARC	cis	rs8017423	0.967	rs8022531	chr14:90729931	T/C	cg20276874	chr14:90721474	PSMC1	-0.38	-5.25	-0.33	3.39e-7	Mortality in heart failure;
SARC	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg00149659	chr3:10157352	C3orf10	0.69	6.44	0.39	6.6e-10	Alzheimer's disease;
SARC	trans	rs8073060	0.586	rs226090	chr17:34034059	C/T	cg19694781	chr19:47549865	TMEM160	-0.71	-6.9	-0.41	4.87e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs6456156	0.586	rs1407315	chr6:167468659	A/G	cg23791538	chr6:167370224	RNASET2	-0.52	-6.81	-0.41	8.22e-11	Primary biliary cholangitis;
SARC	cis	rs12079745	0.623	rs12091133	chr1:169387826	T/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.9	-5.72	-0.35	3.26e-8	QT interval;
SARC	cis	rs7833790	0.660	rs1451995	chr8:82746123	G/C	cg17211192	chr8:82754475	SNX16	0.49	6.21	0.38	2.35e-9	Diastolic blood pressure;
SARC	cis	rs453301	0.624	rs4841083	chr8:8870428	A/G	cg11995313	chr8:8860691	ERI1	-0.43	-5.61	-0.35	5.64e-8	Joint mobility (Beighton score);
SARC	cis	rs9910055	0.529	rs228757	chr17:42164885	G/C	cg09913183	chr17:42254507	C17orf65;ASB16	-0.47	-5.48	-0.34	1.12e-7	Total body bone mineral density;
SARC	cis	rs6088580	0.634	rs6087579	chr20:32985155	A/G	cg24642439	chr20:33292090	TP53INP2	-0.65	-8.41	-0.48	4.08e-15	Glomerular filtration rate (creatinine);
SARC	trans	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg21775007	chr8:11205619	TDH	-0.52	-6.48	-0.39	5.55e-10	Joint mobility (Beighton score);
SARC	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs748404	0.660	rs690472	chr15:43764368	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	5.58	0.34	6.68e-8	Lung cancer;
SARC	trans	rs2018683	0.683	rs12538606	chr7:28969408	T/C	cg19402173	chr7:128379420	CALU	-0.5	-6.44	-0.39	6.9e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs72945132	0.714	rs66542029	chr11:70196302	A/T	cg05964544	chr11:70165517	PPFIA1	-0.56	-5.36	-0.33	1.96e-7	Coronary artery disease;
SARC	cis	rs365132	1.000	rs353493	chr5:176432585	T/C	cg16309518	chr5:176445507	NA	-0.47	-6.07	-0.37	5.09e-9	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs7829975	0.606	rs6422352	chr8:8794193	A/G	cg15556689	chr8:8085844	FLJ10661	-0.41	-5.04	-0.31	9.16e-7	Mood instability;
SARC	cis	rs526231	0.543	rs34809	chr5:102430117	C/A	cg23492399	chr5:102201601	PAM	-0.52	-5.65	-0.35	4.76e-8	Primary biliary cholangitis;
SARC	cis	rs3008870	0.755	rs2755271	chr1:67474977	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.61	7.8	0.46	2.03e-13	Lymphocyte percentage of white cells;
SARC	cis	rs7246657	0.882	rs59224125	chr19:37963205	T/C	cg23950597	chr19:37808831	NA	-0.56	-5.59	-0.34	6.27e-8	Coronary artery calcification;
SARC	cis	rs826838	0.967	rs11168299	chr12:38902028	G/T	cg26384229	chr12:38710491	ALG10B	0.92	14.4	0.69	4.73e-34	Heart rate;
SARC	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg18404041	chr3:52824283	ITIH1	-0.41	-6.13	-0.37	3.81e-9	Bipolar disorder;
SARC	cis	rs2439831	0.571	rs689883	chr15:43812596	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	7.98	0.46	6.53e-14	Lung cancer in ever smokers;
SARC	cis	rs8077889	0.917	rs1859048	chr17:41892039	A/C	cg26893861	chr17:41843967	DUSP3	-0.84	-10.45	-0.56	3.39e-21	Triglycerides;
SARC	cis	rs668210	0.793	rs540584	chr11:65765866	C/G	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.5	-4.83	-0.3	2.48e-6	Cerebrospinal fluid biomarker levels;
SARC	cis	rs8077889	0.957	rs17742929	chr17:41891437	C/T	cg26893861	chr17:41843967	DUSP3	0.87	10.48	0.57	2.69e-21	Triglycerides;
SARC	cis	rs11098499	0.955	rs35434465	chr4:120169378	C/G	cg09307838	chr4:120376055	NA	0.85	11.69	0.61	3.9e-25	Corneal astigmatism;
SARC	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg09359103	chr1:154839909	KCNN3	-0.47	-8.05	-0.47	4.29e-14	Prostate cancer;
SARC	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9858542	0.953	rs9811982	chr3:49624377	A/C	cg07274523	chr3:49395745	GPX1	0.5	5.91	0.36	1.19e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs4727027	0.522	rs6956736	chr7:148893472	G/C	cg23583168	chr7:148888333	NA	-0.69	-8.42	-0.48	3.88e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg22433210	chr17:43662623	NA	0.69	8.29	0.48	8.77e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs3956705	0.798	rs35443929	chr7:32935434	C/A	cg06627557	chr7:32535165	LSM5;AVL9	0.45	5.48	0.34	1.12e-7	Red cell distribution width;
SARC	cis	rs10463316	0.894	rs12652733	chr5:150753999	G/A	cg03212797	chr5:150827313	SLC36A1	-0.44	-5.28	-0.33	2.9e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg17143192	chr8:8559678	CLDN23	0.5	5.97	0.36	8.95e-9	Obesity-related traits;
SARC	cis	rs7829975	0.517	rs12542733	chr8:8824858	G/T	cg14343924	chr8:8086146	FLJ10661	-0.39	-4.96	-0.31	1.34e-6	Mood instability;
SARC	cis	rs2153535	0.580	rs9505467	chr6:8520219	G/A	cg21535247	chr6:8435926	SLC35B3	0.54	6.92	0.41	4.29e-11	Motion sickness;
SARC	cis	rs9916302	0.610	rs11078902	chr17:37631883	C/G	cg15445000	chr17:37608096	MED1	0.41	4.78	0.3	3.14e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs4938330	0.608	rs3882897	chr11:117091227	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.52	-5.51	-0.34	9.61e-8	Blood protein levels;
SARC	cis	rs10883723	0.810	rs7094366	chr10:104274730	C/G	ch.10.2196322F	chr10:104248062	ACTR1A	0.54	7.15	0.42	1.14e-11	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs12682352	0.602	rs6993494	chr8:8667444	C/T	cg06636001	chr8:8085503	FLJ10661	0.53	6.72	0.4	1.35e-10	Neuroticism;
SARC	cis	rs3771570	1.000	rs4346380	chr2:242263223	G/A	cg21155796	chr2:242212141	HDLBP	0.68	5.89	0.36	1.32e-8	Prostate cancer;
SARC	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg18357526	chr6:26021779	HIST1H4A	0.46	5.85	0.36	1.64e-8	Blood metabolite levels;
SARC	cis	rs10046574	0.561	rs56014861	chr7:135203027	A/T	cg27474649	chr7:135195673	CNOT4	0.85	7.96	0.46	7.32e-14	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs6493487	0.512	rs2306333	chr15:51217674	A/G	cg02338191	chr15:51200825	AP4E1	0.55	5.09	0.32	7.27e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg22857025	chr5:266934	NA	-1.06	-11.63	-0.61	5.91e-25	Breast cancer;
SARC	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.03	12.03	0.62	3.06e-26	Alzheimer's disease;
SARC	cis	rs7666738	0.830	rs113999196	chr4:99041961	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1003719	0.523	rs1063949	chr21:38574675	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-8.97	-0.51	9.93e-17	Eye color traits;
SARC	cis	rs8060686	0.545	rs10500543	chr16:68281311	T/C	cg09117114	chr16:67998030	SLC12A4	-0.47	-4.72	-0.3	4.15e-6	HDL cholesterol;Metabolic syndrome;
SARC	cis	rs2549003	0.966	rs2706385	chr5:131831766	T/G	cg21138405	chr5:131827807	IRF1	-0.29	-5.82	-0.36	1.93e-8	Asthma (sex interaction);
SARC	cis	rs9660992	0.649	rs12128229	chr1:205268014	C/A	cg19090574	chr1:205240910	TMCC2	-0.4	-4.86	-0.3	2.19e-6	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs9790314	0.543	rs1349352	chr3:161118486	C/T	cg04691961	chr3:161091175	C3orf57	-0.47	-5.87	-0.36	1.46e-8	Morning vs. evening chronotype;
SARC	cis	rs6690583	0.623	rs893618	chr1:85513770	C/T	cg22153463	chr1:85462885	MCOLN2	0.69	5.32	0.33	2.44e-7	Serum sulfate level;
SARC	cis	rs1957429	0.808	rs6573581	chr14:65331955	G/A	cg23373153	chr14:65346875	NA	0.91	9.62	0.53	1.15e-18	Pediatric areal bone mineral density (radius);
SARC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg05552183	chr6:42928497	GNMT	0.46	6.33	0.38	1.28e-9	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs11770686	0.967	rs6964389	chr7:75328213	A/G	cg17787366	chr7:75369077	HIP1	0.43	5.32	0.33	2.48e-7	Essential tremor;
SARC	cis	rs7429990	0.965	rs319686	chr3:47930420	C/G	cg11946769	chr3:48343235	NME6	0.42	4.74	0.3	3.77e-6	Educational attainment (years of education);
SARC	cis	rs709400	0.633	rs10141433	chr14:103962559	A/G	cg26031613	chr14:104095156	KLC1	0.81	11.68	0.61	4.18e-25	Body mass index;
SARC	cis	rs11792861	0.926	rs11788904	chr9:111865052	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.69	7.9	0.46	1.08e-13	Menarche (age at onset);
SARC	cis	rs897984	0.646	rs9938088	chr16:30830004	G/A	cg00531865	chr16:30841666	NA	-0.48	-5.65	-0.35	4.69e-8	Dementia with Lewy bodies;
SARC	cis	rs761746	0.739	rs5753691	chr22:31952045	A/G	cg15823100	chr22:32027580	PISD	-0.36	-4.72	-0.3	4.1e-6	Intelligence;
SARC	cis	rs459571	0.876	rs2520095	chr9:136919568	A/G	cg01294253	chr9:136912663	BRD3	0.44	5.79	0.35	2.2e-8	Platelet distribution width;
SARC	cis	rs12681288	0.823	rs2701909	chr8:1003057	A/G	cg15309053	chr8:964076	NA	0.4	6.78	0.41	1e-10	Schizophrenia;
SARC	cis	rs36051895	0.623	rs7847811	chr9:5237081	T/C	cg02405213	chr9:5042618	JAK2	-0.42	-4.78	-0.3	3.13e-6	Pediatric autoimmune diseases;
SARC	cis	rs876084	0.505	rs10108373	chr8:121126109	T/C	cg06265175	chr8:121136014	COL14A1	0.55	7.26	0.43	5.73e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs6088813	0.961	rs745931	chr20:33956004	A/T	cg23207816	chr20:34252616	CPNE1;RBM12	-0.44	-5.33	-0.33	2.29e-7	Height;
SARC	cis	rs5769765	0.874	rs4624	chr22:50281917	A/G	cg03033257	chr22:50311977	ALG12;CRELD2	-0.54	-5.64	-0.35	4.81e-8	Schizophrenia;
SARC	cis	rs10788972	0.508	rs6691549	chr1:54480903	A/G	cg10336722	chr1:54665764	CYB5RL;MRPL37	0.41	5.01	0.31	1.07e-6	Parkinson disease and lewy body pathology;
SARC	cis	rs425277	0.917	rs78609670	chr1:2045886	G/T	cg21442419	chr1:2182373	SKI	-0.48	-5.8	-0.36	2.09e-8	Height;
SARC	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	-1.02	-11.58	-0.6	8.78e-25	Alzheimer's disease;
SARC	cis	rs765787	0.530	rs28396110	chr15:45536909	A/G	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.81e-6	Uric acid levels;
SARC	cis	rs1538970	0.924	rs1826691	chr1:45881262	A/G	cg05343316	chr1:45956843	TESK2	-0.72	-8.32	-0.48	7.45e-15	Platelet count;
SARC	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg02891314	chr5:179741120	GFPT2	-0.5	-6.29	-0.38	1.53e-9	Height;
SARC	cis	rs11190604	0.767	rs10883491	chr10:102196071	G/T	cg07080220	chr10:102295463	HIF1AN	0.71	8.15	0.47	2.29e-14	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg06713675	chr4:122721982	EXOSC9	-0.51	-6.72	-0.4	1.39e-10	Type 2 diabetes;
SARC	cis	rs72781680	0.898	rs6712524	chr2:24083925	T/C	cg08917208	chr2:24149416	ATAD2B	0.76	7.5	0.44	1.3e-12	Lymphocyte counts;
SARC	trans	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.21	-0.43	7.82e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs11112613	0.713	rs68053161	chr12:105950035	G/C	cg03607813	chr12:105948248	NA	0.56	7.54	0.44	1.06e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg03351412	chr1:154909251	PMVK	0.58	7.14	0.42	1.15e-11	Prostate cancer;
SARC	cis	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg05084668	chr3:125655381	ALG1L	-0.47	-4.89	-0.31	1.88e-6	Blood pressure (smoking interaction);
SARC	cis	rs1467026	0.606	rs9814180	chr3:12818386	A/G	cg24848339	chr3:12840334	CAND2	0.39	6.24	0.38	2.09e-9	P wave duration;
SARC	cis	rs9397240	0.740	rs1984028	chr6:155572712	T/G	cg07943832	chr6:155568918	TIAM2	-0.59	-5.63	-0.35	5.23e-8	Life satisfaction;
SARC	cis	rs922107	0.713	rs10922669	chr1:90043240	A/G	cg15422784	chr1:90023713	LRRC8B	-0.33	-4.89	-0.3	1.92e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
SARC	cis	rs7762018	0.891	rs7764839	chr6:170146351	C/A	cg13891659	chr6:170190454	C6orf122;C6orf208	0.55	4.88	0.3	2e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs6570726	0.818	rs398812	chr6:145817271	T/C	cg05220968	chr6:146057943	EPM2A	-0.29	-4.83	-0.3	2.44e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9611519	0.808	rs5751074	chr22:41665722	G/A	cg17376030	chr22:41985996	PMM1	0.53	6.7	0.4	1.51e-10	Neuroticism;
SARC	cis	rs8077889	0.750	rs80053172	chr17:41936843	C/T	cg26893861	chr17:41843967	DUSP3	0.75	7.18	0.43	9.48e-12	Triglycerides;
SARC	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	7.84	0.46	1.59e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs72634258	0.554	rs4908694	chr1:7850898	C/T	cg05338066	chr1:7812865	CAMTA1	0.61	5.38	0.33	1.8e-7	Inflammatory bowel disease;
SARC	cis	rs6964587	0.869	rs2013334	chr7:91549657	G/A	cg17063962	chr7:91808500	NA	-0.9	-13.48	-0.66	5.48e-31	Breast cancer;
SARC	cis	rs13161895	0.702	rs74507840	chr5:179487430	G/A	cg06664874	chr5:179499304	RNF130	0.64	5.85	0.36	1.63e-8	LDL cholesterol;
SARC	cis	rs921968	0.544	rs58827325	chr2:219415166	A/T	cg02176678	chr2:219576539	TTLL4	0.45	6.82	0.41	7.94e-11	Mean corpuscular hemoglobin concentration;
SARC	cis	rs412050	0.502	rs17759796	chr22:22190163	A/C	cg17089214	chr22:22089827	YPEL1	-0.74	-6.44	-0.39	6.82e-10	Attention deficit hyperactivity disorder;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg11839334	chr14:21152763	RNASE4;ANG	0.54	6.83	0.41	7.15e-11	Breast cancer;
SARC	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	5.14	0.32	5.68e-7	Personality dimensions;
SARC	cis	rs17253792	0.908	rs9972177	chr14:56073206	G/A	cg01858014	chr14:56050164	KTN1	-0.71	-5.63	-0.35	5.25e-8	Putamen volume;
SARC	cis	rs4803468	0.934	rs11880674	chr19:41889423	A/T	cg14132834	chr19:41945861	ATP5SL	-0.56	-7.54	-0.44	1.04e-12	Height;
SARC	cis	rs9549367	0.756	rs3861723	chr13:113910926	A/G	cg18105134	chr13:113819100	PROZ	-0.41	-6.14	-0.37	3.49e-9	Platelet distribution width;
SARC	cis	rs7223966	0.960	rs113155878	chr17:61706560	C/A	cg00588841	chr17:61851480	DDX42;CCDC47	-0.66	-6.98	-0.42	2.97e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6918586	0.658	rs198829	chr6:26118893	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.45	-5.75	-0.35	2.77e-8	Schizophrenia;
SARC	trans	rs7647973	0.593	rs55997059	chr3:49858661	A/T	cg21659725	chr3:3221576	CRBN	0.64	6.31	0.38	1.36e-9	Menarche (age at onset);
SARC	cis	rs10088262	0.629	rs7833650	chr8:124822969	C/T	cg02993010	chr8:124780839	FAM91A1	-0.78	-9.23	-0.52	1.71e-17	Pancreatic cancer;
SARC	trans	rs9329221	0.662	rs35472251	chr8:10246669	A/G	cg06636001	chr8:8085503	FLJ10661	0.58	7.18	0.43	9.18e-12	Neuroticism;
SARC	cis	rs7084402	0.967	rs1365741	chr10:60277489	C/T	cg07615347	chr10:60278583	BICC1	-0.6	-8.82	-0.5	2.78e-16	Refractive error;
SARC	trans	rs208520	0.690	rs207081	chr6:66773742	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-14.54	-0.69	1.63e-34	Exhaled nitric oxide output;
SARC	cis	rs9916302	0.904	rs11867312	chr17:37597748	C/T	cg07936489	chr17:37558343	FBXL20	-0.7	-9.25	-0.52	1.5e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs897984	0.644	rs73524556	chr16:30823162	G/A	cg00531865	chr16:30841666	NA	-0.48	-5.71	-0.35	3.36e-8	Dementia with Lewy bodies;
SARC	cis	rs752010	0.806	rs6696511	chr1:42110888	T/C	cg06885757	chr1:42089581	HIVEP3	0.48	7.16	0.42	1.03e-11	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs614226	0.935	rs7956998	chr12:120994932	G/A	cg01236616	chr12:121019343	POP5	1.26	18.96	0.78	4.17e-49	Type 1 diabetes nephropathy;
SARC	cis	rs698833	0.819	rs2340810	chr2:44536546	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.7	-9.36	-0.52	7.08e-18	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs10851411	0.518	rs17767264	chr15:42886656	C/T	cg21293051	chr15:42870591	STARD9	0.5	5.14	0.32	5.73e-7	Glucose homeostasis traits;
SARC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.69	9.42	0.53	4.49e-18	Lymphocyte counts;
SARC	cis	rs4664304	0.739	rs66814375	chr2:160716059	C/T	cg02280532	chr2:160761244	LY75	-0.31	-4.76	-0.3	3.45e-6	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs193541	0.632	rs6595413	chr5:122156949	G/A	cg19412675	chr5:122181750	SNX24	0.48	6.34	0.38	1.17e-9	Glucose homeostasis traits;
SARC	trans	rs7824557	0.767	rs3808509	chr8:11163256	G/T	cg06636001	chr8:8085503	FLJ10661	0.57	7.01	0.42	2.62e-11	Retinal vascular caliber;
SARC	cis	rs9914988	0.943	rs9913801	chr17:27132105	G/A	cg20469991	chr17:27169893	C17orf63	-0.5	-5.25	-0.33	3.36e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.32	-4.86	-0.3	2.18e-6	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs2273669	0.504	rs77107907	chr6:109436345	C/A	cg05315195	chr6:109294784	ARMC2	-0.6	-5.02	-0.31	1.01e-6	Prostate cancer;
SARC	cis	rs763121	0.853	rs5750671	chr22:39094619	A/C	cg06022373	chr22:39101656	GTPBP1	0.9	12.42	0.63	1.68e-27	Menopause (age at onset);
SARC	cis	rs916888	0.610	rs199529	chr17:44837217	A/C	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.64	7.08	0.42	1.69e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	14.21	0.68	2.01e-33	Chronic sinus infection;
SARC	cis	rs7937682	1.000	rs505372	chr11:111507189	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.97	-16.46	-0.73	6.54e-41	Primary sclerosing cholangitis;
SARC	cis	rs8017423	0.967	rs11628812	chr14:90713720	G/T	cg20276874	chr14:90721474	PSMC1	0.39	5.36	0.33	1.98e-7	Mortality in heart failure;
SARC	trans	rs11098499	1.000	rs6837898	chr4:120179154	C/T	cg25214090	chr10:38739885	LOC399744	0.52	6.88	0.41	5.62e-11	Corneal astigmatism;
SARC	trans	rs9325144	0.600	rs1817648	chr12:38733424	C/T	cg23762105	chr12:34175262	ALG10	0.56	7.38	0.44	2.85e-12	Morning vs. evening chronotype;
SARC	cis	rs5750854	0.503	rs5750862	chr22:40026309	G/A	cg10455938	chr22:40058150	CACNA1I	0.46	5.48	0.34	1.08e-7	Intelligence (multi-trait analysis);
SARC	cis	rs870825	0.655	rs10033035	chr4:185630880	T/C	cg04058563	chr4:185651563	MLF1IP	0.82	11.01	0.58	5.81e-23	Blood protein levels;
SARC	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg18252515	chr7:66147081	NA	0.44	4.75	0.3	3.5e-6	Aortic root size;
SARC	cis	rs770189	1.000	rs770189	chr5:88088439	G/C	cg18498987	chr5:88179539	MEF2C	-0.38	-4.72	-0.3	4.01e-6	Tonometry;
SARC	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg06558623	chr16:89946397	TCF25	0.9	6.1	0.37	4.45e-9	Skin colour saturation;
SARC	cis	rs13082711	0.595	rs13075389	chr3:27339586	C/T	cg02860705	chr3:27208620	NA	0.67	8.04	0.47	4.64e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs72781680	0.716	rs72788284	chr2:24097539	A/G	cg08917208	chr2:24149416	ATAD2B	0.59	6.26	0.38	1.81e-9	Lymphocyte counts;
SARC	cis	rs7084402	1.000	rs1346301	chr10:60267310	G/A	cg07615347	chr10:60278583	BICC1	-0.6	-8.5	-0.49	2.31e-15	Refractive error;
SARC	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg01475735	chr3:40494733	NA	0.49	5.64	0.35	4.98e-8	Renal cell carcinoma;
SARC	cis	rs2916247	0.954	rs7004515	chr8:93119689	G/A	cg10183463	chr8:93005414	RUNX1T1	0.53	5.66	0.35	4.49e-8	Intelligence (multi-trait analysis);
SARC	trans	rs1853207	1.000	rs3862009	chr10:96619025	C/T	cg02737782	chr1:8014393	NA	-0.97	-6.43	-0.39	7.21e-10	Blood metabolite levels;
SARC	cis	rs9914988	0.887	rs12947735	chr17:27156866	A/T	cg20469991	chr17:27169893	C17orf63	-0.52	-5.4	-0.33	1.62e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs881375	0.702	rs3761847	chr9:123690239	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	6.29	0.38	1.58e-9	Rheumatoid arthritis;
SARC	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg21171335	chr12:122356390	WDR66	0.42	6.64	0.4	2.21e-10	Mean corpuscular volume;
SARC	trans	rs7824557	0.614	rs2060459	chr8:11212599	C/T	cg06636001	chr8:8085503	FLJ10661	0.52	6.33	0.38	1.22e-9	Retinal vascular caliber;
SARC	cis	rs6696846	0.765	rs11240360	chr1:205083865	T/C	cg07972983	chr1:205091412	RBBP5	0.57	7.37	0.43	3.03e-12	Red blood cell count;
SARC	cis	rs4481887	0.927	rs28524655	chr1:248474331	C/T	cg00666640	chr1:248458726	OR2T12	0.34	5.7	0.35	3.65e-8	Common traits (Other);
SARC	cis	rs11574514	1.000	rs11574514	chr16:67971380	C/T	cg01866162	chr16:67596514	CTCF	0.98	5.83	0.36	1.82e-8	Crohn's disease;
SARC	trans	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg11693508	chr17:37793320	STARD3	0.72	6.85	0.41	6.36e-11	Bipolar disorder;
SARC	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg21698718	chr17:80085957	CCDC57	0.35	5.58	0.34	6.55e-8	Life satisfaction;
SARC	cis	rs12681288	0.676	rs1562925	chr8:1010894	A/G	cg04851639	chr8:1020857	NA	-0.29	-4.91	-0.31	1.72e-6	Schizophrenia;
SARC	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg17971929	chr21:40555470	PSMG1	0.98	13.6	0.67	2.2e-31	Cognitive function;
SARC	trans	rs11098499	0.954	rs10006525	chr4:120408931	T/G	cg25214090	chr10:38739885	LOC399744	0.57	7.29	0.43	4.92e-12	Corneal astigmatism;
SARC	cis	rs9894429	0.646	rs7406828	chr17:79619226	A/G	cg10661904	chr17:79619235	PDE6G	0.46	6.4	0.39	8.28e-10	Eye color traits;
SARC	cis	rs2463822	0.669	rs72919484	chr11:62043430	T/C	cg06239285	chr11:62104954	ASRGL1	-0.9	-8.24	-0.48	1.22e-14	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs4727027	0.835	rs6959224	chr7:148784495	A/G	cg23583168	chr7:148888333	NA	-0.77	-10.65	-0.57	7.56e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs818427	1.000	rs2545166	chr5:112213805	C/G	cg07820702	chr5:112228657	REEP5	0.43	4.78	0.3	3.06e-6	Total body bone mineral density;
SARC	cis	rs910316	1.000	rs7145159	chr14:75583268	A/G	cg23033748	chr14:75592666	NEK9	0.36	5.05	0.31	8.81e-7	Height;
SARC	cis	rs17376456	1.000	rs13185608	chr5:93509688	T/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.62	5.25	0.33	3.43e-7	Diabetic retinopathy;
SARC	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.6	6.5	0.39	4.92e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs1034435	0.755	rs5768681	chr22:48894501	C/T	cg05992904	chr22:48892994	FAM19A5	-0.48	-7.09	-0.42	1.61e-11	Late-onset Alzheimer's disease;
SARC	cis	rs9768139	0.733	rs56205111	chr7:158121055	T/C	cg25566285	chr7:158114605	PTPRN2	0.31	5.19	0.32	4.66e-7	Calcium levels;
SARC	cis	rs2235642	0.893	rs2143285	chr16:1593171	A/G	cg09065629	chr16:1709722	CRAMP1L	0.35	4.87	0.3	2.1e-6	Coronary artery disease;
SARC	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg13939156	chr17:80058883	NA	0.41	6.26	0.38	1.82e-9	Life satisfaction;
SARC	trans	rs877282	0.583	rs11595057	chr10:819203	A/C	cg22713356	chr15:30763199	NA	0.9	8.73	0.5	5.16e-16	Uric acid levels;
SARC	cis	rs7223966	0.655	rs9896476	chr17:61629692	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.52	-5.31	-0.33	2.59e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs330048	0.509	rs36111783	chr8:9145588	A/G	cg06636001	chr8:8085503	FLJ10661	0.56	6.58	0.4	3.03e-10	Systemic lupus erythematosus;
SARC	cis	rs11098499	0.738	rs10026493	chr4:120384194	C/G	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs1046896	0.503	rs12947062	chr17:80686370	A/G	cg02711726	chr17:80685570	FN3KRP	0.66	8.44	0.48	3.49e-15	Glycated hemoglobin levels;
SARC	cis	rs4319547	0.695	rs4758645	chr12:122946487	G/A	cg23029597	chr12:123009494	RSRC2	-0.38	-4.84	-0.3	2.35e-6	Body mass index;
SARC	cis	rs7223966	1.000	rs2854218	chr17:61942940	A/G	cg00588841	chr17:61851480	DDX42;CCDC47	-0.6	-6.26	-0.38	1.82e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg17971929	chr21:40555470	PSMG1	-0.57	-7.28	-0.43	5.06e-12	Menarche (age at onset);
SARC	cis	rs7672847	0.547	rs10023181	chr4:170328804	A/G	cg00846720	chr4:170533756	NEK1	-0.62	-4.79	-0.3	2.97e-6	Subjective well-being;
SARC	cis	rs55794721	0.509	rs4649085	chr1:25778832	G/A	cg02931644	chr1:25747376	RHCE	0.43	6.98	0.42	3.08e-11	Plateletcrit;Mean corpuscular volume;
SARC	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg16325326	chr1:53192061	ZYG11B	0.81	12.75	0.64	1.31e-28	Monocyte count;
SARC	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg01475735	chr3:40494733	NA	-0.47	-5.18	-0.32	4.77e-7	Renal cell carcinoma;
SARC	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg11987759	chr7:65425863	GUSB	-0.51	-6.28	-0.38	1.6e-9	Aortic root size;
SARC	cis	rs9796	0.558	rs8043253	chr15:41503730	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.57	-8.4	-0.48	4.4e-15	Menopause (age at onset);
SARC	cis	rs6604026	0.656	rs10493863	chr1:93399694	T/C	cg17283838	chr1:93427260	FAM69A	0.41	4.77	0.3	3.25e-6	Multiple sclerosis;
SARC	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	8.82	0.5	2.77e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs752010	0.967	rs10890153	chr1:42102060	C/A	cg06885757	chr1:42089581	HIVEP3	0.35	5.57	0.34	6.85e-8	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs6424115	0.729	rs561733	chr1:24049595	T/G	cg15997130	chr1:24165203	NA	0.38	4.79	0.3	2.95e-6	Immature fraction of reticulocytes;
SARC	cis	rs7666738	0.830	rs28456179	chr4:98991439	A/G	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg11764359	chr7:65958608	NA	0.65	7.79	0.45	2.16e-13	Aortic root size;
SARC	cis	rs453301	0.658	rs6986044	chr8:8874786	G/C	cg11995313	chr8:8860691	ERI1	0.47	6.06	0.37	5.46e-9	Joint mobility (Beighton score);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg27002185	chr11:2907067	CDKN1C	-0.79	-6.58	-0.4	3e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs10911232	0.507	rs10911234	chr1:183053001	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.35	0.56	6.82e-21	Hypertriglyceridemia;
SARC	cis	rs116095464	0.558	rs9654453	chr5:299621	T/C	cg22857025	chr5:266934	NA	-1.07	-9.85	-0.54	2.29e-19	Breast cancer;
SARC	cis	rs4595586	0.566	rs11615585	chr12:39409351	C/T	cg26384229	chr12:38710491	ALG10B	0.49	5.91	0.36	1.19e-8	Morning vs. evening chronotype;
SARC	trans	rs561341	0.556	rs118032208	chr17:30395634	T/C	cg20587970	chr11:113659929	NA	-1.12	-9.76	-0.54	4.29e-19	Hip circumference adjusted for BMI;
SARC	cis	rs8038734	0.591	rs11072379	chr15:72892916	G/A	cg10943348	chr15:72668568	HEXA;C15orf34	0.66	5.13	0.32	6.24e-7	Posterior cortical atrophy and Alzheimer's disease;
SARC	trans	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg00938859	chr5:1591904	SDHAP3	0.79	7.66	0.45	5.1e-13	Breast cancer;
SARC	cis	rs7917772	0.502	rs4919670	chr10:104515799	C/A	ch.10.2196322F	chr10:104248062	ACTR1A	-0.47	-5.59	-0.34	6.38e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg21724239	chr8:58056113	NA	0.61	6.35	0.38	1.13e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9457247	0.588	rs35171809	chr6:167432766	A/G	cg07741184	chr6:167504864	NA	0.34	6.66	0.4	1.91e-10	Crohn's disease;
SARC	cis	rs8103278	0.826	rs11669442	chr19:46374557	A/G	cg14061069	chr19:46274453	DMPK	-0.33	-4.76	-0.3	3.48e-6	Coronary artery disease;
SARC	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg11987759	chr7:65425863	GUSB	0.47	5.77	0.35	2.51e-8	Aortic root size;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg05818854	chr2:71295273	NAGK	0.53	6.69	0.4	1.63e-10	Lung adenocarcinoma;
SARC	cis	rs9790314	1.000	rs336590	chr3:161079583	G/A	cg03342759	chr3:160939853	NMD3	-0.6	-7.45	-0.44	1.83e-12	Morning vs. evening chronotype;
SARC	cis	rs9790314	0.875	rs462514	chr3:161092809	C/T	cg04691961	chr3:161091175	C3orf57	-0.74	-10.91	-0.58	1.15e-22	Morning vs. evening chronotype;
SARC	cis	rs4595586	0.545	rs3858553	chr12:39381291	A/C	cg26384229	chr12:38710491	ALG10B	0.52	6.21	0.38	2.4e-9	Morning vs. evening chronotype;
SARC	cis	rs4588572	0.601	rs10070202	chr5:77792462	A/C	cg11547950	chr5:77652471	NA	-0.41	-5.11	-0.32	6.67e-7	Triglycerides;
SARC	cis	rs58365910	1	rs58365910	chr15:78849034	T/C	cg06917634	chr15:78832804	PSMA4	-0.52	-5.68	-0.35	4.09e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs8523	0.774	rs6456810	chr6:11052418	C/A	cg13562911	chr6:11044106	ELOVL2	0.48	6.5	0.39	4.93e-10	Red blood cell fatty acid levels;
SARC	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg27170947	chr2:26402098	FAM59B	0.36	4.75	0.3	3.59e-6	Gut microbiome composition (summer);
SARC	cis	rs2718058	0.583	rs2722248	chr7:37845286	G/T	cg24998770	chr7:37888106	TXNDC3	0.35	5.09	0.32	7.46e-7	Alzheimer's disease (late onset);
SARC	cis	rs1062177	0.756	rs2915827	chr5:151119705	T/A	cg00977110	chr5:151150581	G3BP1	-0.55	-5.53	-0.34	8.58e-8	Preschool internalizing problems;
SARC	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg08048268	chr3:133502702	NA	-0.45	-6.16	-0.37	3.15e-9	Iron status biomarkers;
SARC	cis	rs1594829	0.553	rs7003030	chr8:26172699	G/T	cg11498726	chr8:26250323	BNIP3L	-0.43	-5.62	-0.35	5.46e-8	Height;
SARC	cis	rs7927592	0.913	rs2282563	chr11:68333200	C/T	cg01657329	chr11:68192670	LRP5	-0.43	-5.17	-0.32	4.94e-7	Total body bone mineral density;
SARC	cis	rs7914558	0.966	rs10786745	chr10:104956827	A/G	cg04362960	chr10:104952993	NT5C2	0.39	4.74	0.3	3.75e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.71	6.81	0.41	8.16e-11	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg11987759	chr7:65425863	GUSB	-0.63	-8.24	-0.48	1.22e-14	Aortic root size;
SARC	cis	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg25894440	chr7:65020034	NA	-0.73	-5.46	-0.34	1.2e-7	Diabetic kidney disease;
SARC	cis	rs2997447	0.748	rs2802346	chr1:26434354	G/A	cg19633962	chr1:26362018	EXTL1	-0.59	-5.26	-0.33	3.22e-7	QRS complex (12-leadsum);
SARC	cis	rs1983170	0.935	rs578155	chr1:91976541	G/A	cg25838465	chr1:92012736	NA	-0.53	-5.58	-0.34	6.58e-8	Eosinophil percentage of white cells;
SARC	cis	rs7819412	0.775	rs4841490	chr8:10936891	T/C	cg21775007	chr8:11205619	TDH	-0.45	-5.73	-0.35	3.02e-8	Triglycerides;
SARC	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg05863683	chr7:1912471	MAD1L1	0.34	5.1	0.32	7.03e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.32	-4.89	-0.31	1.89e-6	Menopause (age at onset);
SARC	cis	rs7412746	0.611	rs11204747	chr1:150927152	A/G	cg10589385	chr1:150898437	SETDB1	-0.41	-5.36	-0.33	2.01e-7	Melanoma;
SARC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg11301795	chr4:187892539	NA	-0.67	-9.83	-0.54	2.63e-19	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg12463550	chr7:65579703	CRCP	-0.47	-5.15	-0.32	5.53e-7	Aortic root size;
SARC	cis	rs2242194	0.844	rs11264295	chr1:154987526	C/T	cg09359103	chr1:154839909	KCNN3	-0.34	-5.37	-0.33	1.94e-7	Schizophrenia;
SARC	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg12667521	chr19:29218732	NA	0.38	5.01	0.31	1.06e-6	Methadone dose in opioid dependence;
SARC	cis	rs1707322	0.963	rs4630155	chr1:46257110	G/C	cg03146154	chr1:46216737	IPP	0.5	5.99	0.37	7.86e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg25036284	chr2:26402008	FAM59B	0.46	5.7	0.35	3.59e-8	Gut microbiome composition (summer);
SARC	cis	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg24110177	chr3:50126178	RBM5	0.61	8.14	0.47	2.45e-14	Body mass index;
SARC	cis	rs11630290	0.566	rs4777395	chr15:64161693	T/G	cg12036633	chr15:63758958	NA	0.48	4.94	0.31	1.52e-6	Iris characteristics;
SARC	cis	rs8067545	0.641	rs860335	chr17:19837679	A/G	cg04132472	chr17:19861366	AKAP10	0.4	5.25	0.32	3.5e-7	Schizophrenia;
SARC	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg24209194	chr3:40518798	ZNF619	0.65	7.99	0.46	6.21e-14	Renal cell carcinoma;
SARC	cis	rs710216	0.718	rs841852	chr1:43401499	C/T	cg03128534	chr1:43423976	SLC2A1	0.59	5.66	0.35	4.35e-8	Red cell distribution width;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg19006628	chr11:116827516	SIK3	0.45	6.39	0.39	9.12e-10	Thyroid stimulating hormone;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg23052793	chr1:84547955	PRKACB	0.54	7.82	0.46	1.85e-13	Thyroid stimulating hormone;
SARC	cis	rs11105298	0.891	rs10858896	chr12:89920184	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-5.43	-0.34	1.39e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs2933343	0.679	rs1091938	chr3:128637025	T/C	cg24203234	chr3:128598194	ACAD9	0.62	7.66	0.45	5e-13	IgG glycosylation;
SARC	cis	rs2115630	0.936	rs6496318	chr15:85215229	C/T	cg12501888	chr15:85177176	SCAND2	-0.46	-5.55	-0.34	7.7e-8	P wave terminal force;
SARC	cis	rs9393692	0.645	rs9467703	chr6:26318903	A/G	cg13736514	chr6:26305472	NA	-0.65	-8.15	-0.47	2.16e-14	Educational attainment;
SARC	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg20965017	chr5:231967	SDHA	-0.58	-5.73	-0.35	3.14e-8	Breast cancer;
SARC	cis	rs796364	0.951	rs971232	chr2:200792881	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.78	7.15	0.42	1.12e-11	Schizophrenia;
SARC	cis	rs17270561	0.609	rs9393665	chr6:25744284	G/A	cg17691542	chr6:26056736	HIST1H1C	0.61	7.36	0.43	3.06e-12	Iron status biomarkers;
SARC	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg18357526	chr6:26021779	HIST1H4A	0.43	5.48	0.34	1.11e-7	Blood metabolite levels;
SARC	cis	rs8523	0.548	rs7773173	chr6:10956703	G/C	cg13562911	chr6:11044106	ELOVL2	0.4	5.48	0.34	1.09e-7	Red blood cell fatty acid levels;
SARC	cis	rs10875746	0.951	rs10875748	chr12:48526360	A/G	cg26205652	chr12:48591994	NA	0.55	6.11	0.37	4.11e-9	Longevity (90 years and older);
SARC	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg16606324	chr3:10149918	C3orf24	0.49	5.14	0.32	5.78e-7	Alzheimer's disease;
SARC	cis	rs3820928	0.874	rs55959848	chr2:227805426	C/A	cg11843606	chr2:227700838	RHBDD1	-0.56	-7.12	-0.42	1.33e-11	Pulmonary function;
SARC	cis	rs887829	0.570	rs6759892	chr2:234601669	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.31	4.79	0.3	3.02e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
SARC	cis	rs870825	0.860	rs62339895	chr4:185598681	A/G	cg04058563	chr4:185651563	MLF1IP	-0.73	-9.08	-0.51	4.69e-17	Blood protein levels;
SARC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg11203670	chr7:100026453	MEPCE;ZCWPW1	0.49	4.83	0.3	2.48e-6	Platelet count;
SARC	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg23172400	chr8:95962367	TP53INP1	-0.31	-5.3	-0.33	2.65e-7	Type 2 diabetes;
SARC	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	12.74	0.64	1.44e-28	Platelet count;
SARC	cis	rs7582180	0.629	rs2309798	chr2:100956949	G/A	cg14675211	chr2:100938903	LONRF2	0.47	7.0	0.42	2.66e-11	Intelligence (multi-trait analysis);
SARC	cis	rs709400	0.633	rs10143247	chr14:103920927	G/A	cg26031613	chr14:104095156	KLC1	0.82	11.92	0.62	6.67e-26	Body mass index;
SARC	cis	rs7582720	1.000	rs116678869	chr2:203819471	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs7223966	1.000	rs1877316	chr17:61766880	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.53	-5.72	-0.35	3.24e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2404602	0.647	rs35710279	chr15:77082234	T/A	cg15268244	chr15:77196840	NA	0.45	5.17	0.32	5.05e-7	Blood metabolite levels;
SARC	cis	rs11673344	0.566	rs185368	chr19:37872729	T/C	cg14683738	chr19:37701593	ZNF585B	0.45	5.44	0.34	1.35e-7	Obesity-related traits;
SARC	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.36	0.43	3.08e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg25936770	chr7:122321411	CADPS2	0.51	6.56	0.39	3.48e-10	Schizophrenia;
SARC	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg24549020	chr5:56110836	MAP3K1	0.71	6.35	0.38	1.12e-9	Type 2 diabetes;
SARC	cis	rs4713118	0.513	rs149897	chr6:28006650	A/G	cg26450541	chr6:28235208	ZNF187	0.49	5.12	0.32	6.54e-7	Parkinson's disease;
SARC	cis	rs1966248	0.537	rs1414670	chr6:134114096	C/T	cg25632230	chr6:134101081	NA	-0.53	-7.05	-0.42	1.98e-11	Coronary artery disease;
SARC	cis	rs9303401	0.659	rs7210700	chr17:56668186	G/A	cg25039879	chr17:56429692	SUPT4H1	0.67	6.21	0.38	2.4e-9	Cognitive test performance;
SARC	cis	rs1707322	1.000	rs4660906	chr1:46470860	C/T	cg06784218	chr1:46089804	CCDC17	0.34	5.94	0.36	1.03e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2070997	0.667	rs72765063	chr9:133717391	G/A	cg11464064	chr9:133710261	ABL1	0.63	6.1	0.37	4.44e-9	Response to amphetamines;
SARC	trans	rs877282	0.583	rs7072970	chr10:822757	G/A	cg22713356	chr15:30763199	NA	0.93	8.8	0.5	3.09e-16	Uric acid levels;
SARC	cis	rs524281	0.861	rs10791854	chr11:65963543	A/T	cg14036092	chr11:66035641	RAB1B	-0.5	-5.33	-0.33	2.26e-7	Electroencephalogram traits;
SARC	cis	rs3091242	0.933	rs10903130	chr1:25769221	A/T	cg02931644	chr1:25747376	RHCE	0.43	7.27	0.43	5.36e-12	Erythrocyte sedimentation rate;
SARC	cis	rs77372450	0.636	rs6875939	chr5:156994466	A/G	cg23851860	chr5:157002805	ADAM19	0.51	4.9	0.31	1.83e-6	Bipolar disorder (body mass index interaction);
SARC	cis	rs796364	0.951	rs12620298	chr2:201047184	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.62	-6.35	-0.38	1.15e-9	Schizophrenia;
SARC	trans	rs3734266	0.697	rs67895864	chr6:34742773	G/A	cg08157914	chr7:2646478	IQCE	0.52	6.24	0.38	2.1e-9	Systemic lupus erythematosus;
SARC	cis	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.41	5.16	0.32	5.36e-7	Eosinophil percentage of white cells;
SARC	cis	rs7772486	0.701	rs697056	chr6:146003897	C/T	cg05347473	chr6:146136440	FBXO30	-0.56	-7.8	-0.46	2.07e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9322817	0.583	rs7746856	chr6:105146360	A/C	cg02098413	chr6:105308735	HACE1	0.35	5.25	0.33	3.37e-7	Thyroid stimulating hormone;
SARC	cis	rs1348850	0.651	rs4893935	chr2:178240601	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.55	6.94	0.41	3.8e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs941408	1.000	rs1736183	chr19:2809672	A/G	cg00079169	chr19:2811669	THOP1	0.44	5.0	0.31	1.13e-6	Total cholesterol levels;
SARC	cis	rs826838	1.000	rs11169031	chr12:39056738	T/C	cg26384229	chr12:38710491	ALG10B	0.9	14.09	0.68	5e-33	Heart rate;
SARC	cis	rs9398803	0.687	rs4629706	chr6:126888331	A/T	cg20229609	chr6:126660872	C6orf173	0.37	5.4	0.33	1.66e-7	Male-pattern baldness;
SARC	cis	rs239198	0.534	rs1813223	chr6:101331909	C/T	cg09795085	chr6:101329169	ASCC3	0.45	5.68	0.35	4.07e-8	Menarche (age at onset);
SARC	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.43	-5.43	-0.34	1.43e-7	Intelligence (multi-trait analysis);
SARC	cis	rs4481887	1.000	rs7527822	chr1:248467301	A/G	cg01631408	chr1:248437212	OR2T33	-0.44	-5.67	-0.35	4.26e-8	Common traits (Other);
SARC	cis	rs765787	0.530	rs2413776	chr15:45544170	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.41	-5.04	-0.31	9.29e-7	Uric acid levels;
SARC	trans	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg06636001	chr8:8085503	FLJ10661	-0.7	-9.93	-0.55	1.29e-19	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs10411936	0.692	rs62118141	chr19:16602808	T/C	cg10248733	chr19:16607483	C19orf44;CALR3	0.58	6.82	0.41	7.86e-11	White blood cell count;Multiple sclerosis;
SARC	cis	rs6570726	0.935	rs7757387	chr6:145816726	G/T	cg23711669	chr6:146136114	FBXO30	0.76	11.39	0.6	3.59e-24	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12142240	0.698	rs17357759	chr1:46832534	A/G	cg14993813	chr1:46806288	NSUN4	-0.56	-5.99	-0.37	7.89e-9	Menopause (age at onset);
SARC	cis	rs6484504	0.576	rs208093	chr11:31184400	C/T	cg26647111	chr11:31128758	NA	0.41	5.41	0.33	1.59e-7	Red blood cell count;
SARC	cis	rs74181299	0.684	rs6741255	chr2:65306905	C/T	cg20592124	chr2:65290738	CEP68	-0.35	-4.78	-0.3	3.17e-6	Pulse pressure;
SARC	cis	rs208520	0.690	rs1885100	chr6:66871047	C/G	cg07460842	chr6:66804631	NA	-1.09	-15.3	-0.71	4.9e-37	Exhaled nitric oxide output;
SARC	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg08219700	chr8:58056026	NA	0.62	6.52	0.39	4.28e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9868809	0.505	rs11706983	chr3:48738678	A/G	cg07636037	chr3:49044803	WDR6	-0.7	-6.64	-0.4	2.13e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs4917300	0.606	rs13250335	chr8:143096061	G/C	cg06573787	chr8:143070187	NA	0.38	5.32	0.33	2.41e-7	Amyotrophic lateral sclerosis;
SARC	cis	rs11122272	0.735	rs2486746	chr1:231497324	C/T	cg06096015	chr1:231504339	EGLN1	0.36	5.46	0.34	1.19e-7	Hemoglobin concentration;
SARC	cis	rs4713675	0.565	rs2281829	chr6:33675642	A/G	cg15676125	chr6:33679581	C6orf125	0.52	6.37	0.39	9.94e-10	Plateletcrit;
SARC	cis	rs2153535	0.601	rs1737581	chr6:8539138	A/G	cg07606381	chr6:8435919	SLC35B3	0.76	10.67	0.57	6.88e-22	Motion sickness;
SARC	trans	rs629535	0.814	rs654452	chr8:70074344	C/G	cg21567404	chr3:27674614	NA	1.05	13.16	0.65	6.03e-30	Dupuytren's disease;
SARC	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg20607798	chr8:58055168	NA	0.61	5.45	0.34	1.3e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs888194	0.587	rs6606711	chr12:109849297	A/G	cg19025524	chr12:109796872	NA	-0.33	-4.73	-0.3	3.86e-6	Neuroticism;
SARC	cis	rs6963495	0.745	rs73192153	chr7:105212418	A/T	cg19920283	chr7:105172520	RINT1	0.68	5.77	0.35	2.46e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg19223190	chr17:80058835	NA	0.44	6.12	0.37	3.88e-9	Life satisfaction;
SARC	cis	rs72781680	1.000	rs72781689	chr2:24256349	C/T	cg06627628	chr2:24431161	ITSN2	-0.7	-6.47	-0.39	5.6e-10	Lymphocyte counts;
SARC	cis	rs523522	0.962	rs3759394	chr12:120933173	C/A	cg12219531	chr12:120966889	COQ5	0.83	11.18	0.59	1.61e-23	High light scatter reticulocyte count;
SARC	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg06028605	chr16:24865363	SLC5A11	0.36	5.35	0.33	2.06e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	trans	rs11098499	0.866	rs72676074	chr4:120359841	A/C	cg25214090	chr10:38739885	LOC399744	0.54	7.03	0.42	2.21e-11	Corneal astigmatism;
SARC	cis	rs6570726	0.875	rs1883407	chr6:145823432	T/C	cg05347473	chr6:146136440	FBXO30	0.49	6.47	0.39	5.7e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7666738	0.830	rs1349757	chr4:99058763	C/G	cg05340658	chr4:99064831	C4orf37	0.63	8.37	0.48	5.34e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2297440	0.530	rs34533955	chr20:62233020	A/C	cg09650180	chr20:62225654	GMEB2	-0.47	-5.69	-0.35	3.72e-8	Glioma;Non-glioblastoma glioma;Glioblastoma;
SARC	cis	rs2153535	0.542	rs6905925	chr6:8440030	C/T	cg07606381	chr6:8435919	SLC35B3	0.78	11.09	0.59	3.11e-23	Motion sickness;
SARC	cis	rs7507204	0.530	rs4807469	chr19:3443382	G/C	cg08380311	chr19:3435252	NFIC	0.44	5.32	0.33	2.47e-7	Height;
SARC	trans	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.75	-10.78	-0.58	3.03e-22	Intelligence (multi-trait analysis);
SARC	cis	rs7937682	0.889	rs521155	chr11:111492563	G/A	cg22437258	chr11:111473054	SIK2	0.74	10.24	0.56	1.44e-20	Primary sclerosing cholangitis;
SARC	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg05368731	chr17:41323189	NBR1	0.8	9.59	0.53	1.43e-18	Menopause (age at onset);
SARC	cis	rs78545713	0.892	rs79262959	chr6:26259578	A/T	cg00631329	chr6:26305371	NA	-0.77	-6.87	-0.41	5.9e-11	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs8067354	0.645	rs2645487	chr17:57886125	T/G	cg02344993	chr17:57696989	CLTC	0.65	6.69	0.4	1.66e-10	Hemoglobin concentration;
SARC	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg11764359	chr7:65958608	NA	0.66	7.57	0.44	8.83e-13	Aortic root size;
SARC	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg11764359	chr7:65958608	NA	0.88	12.58	0.64	4.89e-28	Aortic root size;
SARC	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg15448220	chr1:150897856	SETDB1	0.47	6.24	0.38	2.06e-9	Tonsillectomy;
SARC	cis	rs7786877	0.723	rs62482239	chr7:100217810	C/T	cg16850897	chr7:100343110	ZAN	-0.6	-5.39	-0.33	1.72e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg19223190	chr17:80058835	NA	-0.42	-5.73	-0.35	3.09e-8	Life satisfaction;
SARC	cis	rs950880	0.710	rs17027060	chr2:103007567	T/C	cg03938978	chr2:103052716	IL18RAP	-0.34	-4.84	-0.3	2.36e-6	Serum protein levels (sST2);
SARC	cis	rs11599315	0.507	rs12220555	chr10:1341858	C/T	cg01270228	chr10:1369114	ADARB2	0.32	5.23	0.32	3.73e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs6752107	1.000	rs2289472	chr2:234182240	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.51	6.66	0.4	1.95e-10	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs10808265	0.567	rs7803585	chr7:132262702	C/G	cg05950570	chr7:132261418	PLXNA4	0.39	4.84	0.3	2.34e-6	Pulmonary function decline;
SARC	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.08	20.94	0.81	1.8e-55	Chronic sinus infection;
SARC	cis	rs9818758	0.607	rs11552724	chr3:49156473	C/G	cg01304814	chr3:48885189	PRKAR2A	0.62	5.01	0.31	1.07e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs11792861	0.926	rs72607170	chr9:111836941	G/A	cg13535736	chr9:111863775	C9orf5	-0.41	-5.07	-0.32	8.04e-7	Menarche (age at onset);
SARC	cis	rs1707322	0.752	rs28890893	chr1:46186576	T/G	cg06784218	chr1:46089804	CCDC17	0.36	6.24	0.38	2.03e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs12950390	0.853	rs56387656	chr17:45860189	C/G	cg03474202	chr17:45855739	NA	-0.43	-6.71	-0.4	1.44e-10	IgG glycosylation;
SARC	cis	rs8072100	0.651	rs1912484	chr17:45443664	C/G	cg08085267	chr17:45401833	C17orf57	-0.44	-5.14	-0.32	5.77e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.54	5.08	0.32	7.77e-7	Lung function (FEV1/FVC);
SARC	cis	rs7617773	0.851	rs7647817	chr3:48236507	G/A	cg11946769	chr3:48343235	NME6	0.72	9.33	0.52	8.45e-18	Coronary artery disease;
SARC	cis	rs6088580	0.634	rs6087580	chr20:32992592	A/G	cg08999081	chr20:33150536	PIGU	-0.42	-6.21	-0.38	2.42e-9	Glomerular filtration rate (creatinine);
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg15592541	chr3:197519021	LRCH3	-0.55	-7.17	-0.43	9.65e-12	Gallstone disease;
SARC	cis	rs4144743	1.000	rs10438781	chr17:45323819	A/G	cg18085866	chr17:45331354	ITGB3	-0.71	-7.35	-0.43	3.36e-12	Body mass index;
SARC	cis	rs936229	0.651	rs12908814	chr15:75132490	C/G	cg14664628	chr15:75095509	CSK	-0.66	-8.32	-0.48	7.39e-15	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs1355223	0.583	rs1396881	chr11:34870506	G/T	cg18508148	chr11:34937573	PDHX;APIP	0.49	6.36	0.38	1.08e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs9457247	1.000	rs364451	chr6:167384756	G/A	cg23791538	chr6:167370224	RNASET2	-0.62	-8.55	-0.49	1.63e-15	Crohn's disease;
SARC	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg07636037	chr3:49044803	WDR6	1.0	17.59	0.76	1.26e-44	Parkinson's disease;
SARC	cis	rs12142240	0.698	rs10158572	chr1:46822440	G/T	cg00530320	chr1:46809349	NSUN4	0.57	6.79	0.41	9.05e-11	Menopause (age at onset);
SARC	cis	rs2276314	0.857	rs72883058	chr18:33612917	G/A	cg05985134	chr18:33552581	C18orf21	0.68	7.17	0.43	9.87e-12	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs4742903	0.904	rs7038714	chr9:106992930	T/G	cg14250997	chr9:106856677	SMC2	0.39	4.95	0.31	1.41e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs9462027	0.651	rs9469885	chr6:34758716	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.79	-0.35	2.31e-8	Systemic lupus erythematosus;
SARC	cis	rs8017423	0.791	rs7146250	chr14:90711703	A/G	cg20276874	chr14:90721474	PSMC1	-0.39	-5.48	-0.34	1.08e-7	Mortality in heart failure;
SARC	trans	rs11929834	0.876	rs1351998	chr4:114068927	C/G	cg01843506	chr3:32993165	CCR4	0.29	6.26	0.38	1.81e-9	Parental longevity (combined parental age at death);
SARC	cis	rs8070624	0.543	rs11078409	chr17:17876296	C/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.39	4.73	0.3	3.89e-6	Total body bone mineral density;
SARC	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg18876405	chr7:65276391	NA	0.49	6.04	0.37	6e-9	Aortic root size;
SARC	cis	rs9902453	0.874	rs4474741	chr17:28148117	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.57	-7.35	-0.43	3.26e-12	Coffee consumption (cups per day);
SARC	cis	rs9916302	0.706	rs9944459	chr17:37484185	T/C	cg00129232	chr17:37814104	STARD3	0.53	5.69	0.35	3.85e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs317689	0.718	rs315130	chr12:69761444	T/C	cg20891283	chr12:69753455	YEATS4	0.5	5.72	0.35	3.23e-8	Response to diuretic therapy;
SARC	cis	rs7740797	0.791	rs2351847	chr6:155138810	G/A	cg02865717	chr6:155053990	RBM16	-0.33	-4.92	-0.31	1.65e-6	Colorectal or endometrial cancer;
SARC	cis	rs933688	1.000	rs11950530	chr5:90688740	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.02	12.78	0.64	1.09e-28	Smoking behavior;
SARC	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg19223190	chr17:80058835	NA	0.44	6.04	0.37	6.02e-9	Life satisfaction;
SARC	cis	rs865483	0.895	rs72828253	chr17:35783416	A/G	cg06561646	chr17:35873369	DUSP14	0.48	6.18	0.38	2.89e-9	Monocyte count;
SARC	cis	rs317689	0.513	rs317678	chr12:69692166	C/G	cg20891283	chr12:69753455	YEATS4	0.38	4.73	0.3	3.95e-6	Response to diuretic therapy;
SARC	cis	rs7512552	0.839	rs834232	chr1:150354682	T/C	cg15654264	chr1:150340011	RPRD2	0.38	4.81	0.3	2.7e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs1008375	0.900	rs3822235	chr4:17694916	C/T	cg27347728	chr4:17578864	LAP3	-0.44	-5.47	-0.34	1.16e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs17376456	1.000	rs17376456	chr5:93557702	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.61	-5.29	-0.33	2.87e-7	Diabetic retinopathy;
SARC	cis	rs11945232	1.000	rs28372775	chr4:88343704	G/A	cg23841344	chr4:88312519	HSD17B11	-0.6	-7.91	-0.46	1.02e-13	Intelligence (multi-trait analysis);
SARC	cis	rs9611519	0.929	rs13055800	chr22:41440424	G/A	cg17376030	chr22:41985996	PMM1	0.49	6.06	0.37	5.3e-9	Neuroticism;
SARC	cis	rs67311347	1.000	rs2276868	chr3:40498845	C/T	cg24209194	chr3:40518798	ZNF619	-0.65	-8.33	-0.48	7.07e-15	Renal cell carcinoma;
SARC	cis	rs5753618	0.509	rs5997912	chr22:31593861	A/G	cg00478049	chr22:31556069	RNF185	0.44	4.74	0.3	3.65e-6	Colorectal cancer;
SARC	cis	rs1941023	0.584	rs2014121	chr11:60156297	T/C	cg08716584	chr11:60157161	MS4A7	-0.39	-6.29	-0.38	1.52e-9	Congenital heart disease (maternal effect);
SARC	cis	rs9435341	0.826	rs1730858	chr1:107619244	T/C	cg09367891	chr1:107599246	PRMT6	-0.7	-8.18	-0.47	1.88e-14	Facial morphology (factor 21, depth of nasal alae);
SARC	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg18252515	chr7:66147081	NA	-1.34	-12.05	-0.62	2.51e-26	Diabetic kidney disease;
SARC	cis	rs911555	0.723	rs7149767	chr14:103863545	G/A	cg24130564	chr14:104152367	KLC1	0.47	5.55	0.34	7.81e-8	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.21	-0.52	1.91e-17	Developmental language disorder (linguistic errors);
SARC	cis	rs72945132	0.882	rs10466703	chr11:70218548	C/T	cg00319359	chr11:70116639	PPFIA1	0.69	6.65	0.4	2.05e-10	Coronary artery disease;
SARC	cis	rs9840812	0.769	rs483465	chr3:136047977	A/G	cg15507776	chr3:136538369	TMEM22	0.47	5.15	0.32	5.56e-7	Fibrinogen levels;
SARC	cis	rs5769765	0.913	rs2319462	chr22:50263370	C/T	cg03033257	chr22:50311977	ALG12;CRELD2	-0.54	-5.64	-0.35	4.81e-8	Schizophrenia;
SARC	cis	rs7662987	0.517	rs2602882	chr4:100040765	C/T	cg12011299	chr4:100065546	ADH4	0.33	5.51	0.34	9.41e-8	Smoking initiation;
SARC	cis	rs3126085	0.935	rs12738889	chr1:152257688	G/A	cg03465714	chr1:152285911	FLG	0.45	5.45	0.34	1.25e-7	Atopic dermatitis;
SARC	cis	rs597539	0.552	rs10792006	chr11:68722306	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.51	-6.52	-0.39	4.36e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs2370759	1.000	rs16933177	chr10:32565705	G/A	cg01819863	chr10:32635814	EPC1	1.01	9.94	0.55	1.26e-19	Sexual dysfunction (female);
SARC	cis	rs770189	0.955	rs244757	chr5:88098120	A/G	cg18498987	chr5:88179539	MEF2C	0.38	4.71	0.3	4.19e-6	Tonometry;
SARC	cis	rs2559856	1.000	rs10745921	chr12:102087193	A/G	cg12924262	chr12:102091054	CHPT1	0.56	7.7	0.45	3.94e-13	Blood protein levels;
SARC	cis	rs7208487	0.684	rs12449852	chr17:37632088	A/G	cg15445000	chr17:37608096	MED1	0.46	4.73	0.3	3.84e-6	Primary biliary cholangitis;Glomerular filtration rate in non diabetics (creatinine);
SARC	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.48	5.87	0.36	1.52e-8	Tonsillectomy;
SARC	cis	rs1865760	1.000	rs56118523	chr6:25908975	A/G	cg10373733	chr6:25993375	NA	0.46	5.54	0.34	8.23e-8	Height;
SARC	cis	rs9472414	0.546	rs4401652	chr6:45288088	C/A	cg11115867	chr6:45345767	RUNX2;SUPT3H	0.52	4.82	0.3	2.6e-6	Height;
SARC	cis	rs694739	0.628	rs508168	chr11:64135435	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.52	5.66	0.35	4.51e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs11785400	0.762	rs9694556	chr8:143727841	A/G	cg10596483	chr8:143751796	JRK	0.56	7.3	0.43	4.57e-12	Schizophrenia;
SARC	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg22875332	chr1:76189707	ACADM	0.41	5.36	0.33	1.98e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg22433210	chr17:43662623	NA	-0.95	-11.34	-0.6	4.92e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs3820928	0.967	rs4675114	chr2:227768362	C/T	cg11843606	chr2:227700838	RHBDD1	-0.53	-6.66	-0.4	1.95e-10	Pulmonary function;
SARC	cis	rs831571	0.519	rs13059603	chr3:63827381	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.8	8.6	0.49	1.2e-15	Type 2 diabetes;
SARC	cis	rs748404	0.660	rs2439845	chr15:43722610	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.4	4.78	0.3	3.13e-6	Lung cancer;
SARC	cis	rs4742903	0.818	rs1857981	chr9:106992584	T/G	cg14250997	chr9:106856677	SMC2	0.39	4.95	0.31	1.41e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs2073499	0.935	rs74398439	chr3:50331927	C/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.55	5.17	0.32	4.93e-7	Schizophrenia;
SARC	cis	rs4423214	1.000	rs1981412	chr11:71138710	T/C	cg24826892	chr11:71159390	DHCR7	0.45	5.39	0.33	1.7e-7	Vitamin D levels;
SARC	cis	rs17401966	1.000	rs7520935	chr1:10354271	G/T	cg15208524	chr1:10270712	KIF1B	0.56	6.41	0.39	8.22e-10	Hepatocellular carcinoma;
SARC	cis	rs6500395	0.584	rs1420698	chr16:48740708	C/G	cg04672837	chr16:48644449	N4BP1	0.42	4.91	0.31	1.71e-6	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg22857025	chr5:266934	NA	-1.06	-11.8	-0.61	1.74e-25	Breast cancer;
SARC	cis	rs826838	0.967	rs1684414	chr12:39129553	A/G	cg13010199	chr12:38710504	ALG10B	-0.63	-8.88	-0.5	1.87e-16	Heart rate;
SARC	cis	rs7568458	0.875	rs2044474	chr2:85758790	G/A	cg23752985	chr2:85803571	VAMP8	0.34	5.0	0.31	1.15e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs763121	0.925	rs9835	chr22:39130971	A/G	cg21395723	chr22:39101663	GTPBP1	0.48	5.71	0.35	3.4e-8	Menopause (age at onset);
SARC	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg18357526	chr6:26021779	HIST1H4A	0.8	11.27	0.59	8.47e-24	Intelligence (multi-trait analysis);
SARC	trans	rs629535	0.814	rs56301437	chr8:70108518	C/T	cg21567404	chr3:27674614	NA	-1.08	-14.03	-0.68	8.18e-33	Dupuytren's disease;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg23898951	chr10:4511903	NA	0.48	6.59	0.4	2.86e-10	Thyroid stimulating hormone;
SARC	cis	rs7236492	0.572	rs7242868	chr18:77179564	G/A	cg15644404	chr18:77186268	NFATC1	-0.63	-4.92	-0.31	1.64e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg02725872	chr8:58115012	NA	-0.37	-6.47	-0.39	5.76e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs72781680	0.611	rs7596060	chr2:24334361	A/G	cg08917208	chr2:24149416	ATAD2B	-0.57	-6.06	-0.37	5.31e-9	Lymphocyte counts;
SARC	cis	rs933688	1.000	rs12656350	chr5:90751343	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.98	11.83	0.61	1.39e-25	Smoking behavior;
SARC	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg17971929	chr21:40555470	PSMG1	1.0	14.22	0.68	1.89e-33	Cognitive function;
SARC	cis	rs7927771	1.000	rs10838757	chr11:47763016	T/C	cg05585544	chr11:47624801	NA	-0.37	-4.99	-0.31	1.19e-6	Subjective well-being;
SARC	trans	rs36093844	0.800	rs17817326	chr11:85595213	C/T	cg15359163	chr5:122429178	PRDM6	-0.55	-6.78	-0.41	9.54e-11	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs2295359	1.000	rs4655684	chr1:67611772	A/G	cg11235152	chr1:67600687	NA	-0.48	-7.33	-0.43	3.86e-12	Psoriasis;
SARC	cis	rs7828089	0.934	rs12544427	chr8:22263115	C/T	cg12081754	chr8:22256438	SLC39A14	-0.49	-6.35	-0.38	1.11e-9	Verbal declarative memory;
SARC	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg20607798	chr8:58055168	NA	0.49	4.83	0.3	2.43e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs4664308	0.967	rs7563607	chr2:160910215	C/G	cg03641300	chr2:160917029	PLA2R1	-0.68	-9.15	-0.51	3.05e-17	Idiopathic membranous nephropathy;
SARC	cis	rs7523050	0.643	rs34572569	chr1:109401856	A/T	cg08274380	chr1:109419600	GPSM2	1.03	7.67	0.45	4.7e-13	Fat distribution (HIV);
SARC	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg19901468	chr14:105411992	AHNAK2	-0.73	-10.79	-0.58	2.78e-22	Rheumatoid arthritis;
SARC	cis	rs11719291	0.504	rs71324924	chr3:48865444	G/A	cg01304814	chr3:48885189	PRKAR2A	0.63	5.21	0.32	4.2e-7	Cognitive function;
SARC	cis	rs748404	0.660	rs693510	chr15:43714625	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.4	4.78	0.3	3.13e-6	Lung cancer;
SARC	cis	rs7647973	0.626	rs62262722	chr3:49769419	G/C	cg06212747	chr3:49208901	KLHDC8B	-0.57	-5.07	-0.32	8.1e-7	Menarche (age at onset);
SARC	cis	rs3758785	0.501	rs1792620	chr11:94072467	G/A	cg13023536	chr11:94226537	MRE11A;ANKRD49	-0.47	-5.94	-0.36	1.03e-8	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
SARC	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg18876405	chr7:65276391	NA	0.49	6.04	0.37	6e-9	Aortic root size;
SARC	cis	rs9911578	0.935	rs302873	chr17:56769481	C/G	cg05425664	chr17:57184151	TRIM37	-0.66	-8.19	-0.47	1.73e-14	Intelligence (multi-trait analysis);
SARC	cis	rs4927850	1.000	rs4927704	chr3:195738228	C/T	cg12923728	chr3:195709715	SDHAP1	-0.69	-8.37	-0.48	5.31e-15	Pancreatic cancer;
SARC	cis	rs6831352	0.918	rs13138294	chr4:100062675	T/G	cg13256891	chr4:100009986	ADH5	-0.66	-8.16	-0.47	2.08e-14	Alcohol dependence;
SARC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.42	-6.56	-0.39	3.45e-10	Total body bone mineral density;
SARC	cis	rs36051895	0.626	rs3780368	chr9:5093188	G/C	cg02405213	chr9:5042618	JAK2	-0.46	-5.44	-0.34	1.35e-7	Pediatric autoimmune diseases;
SARC	cis	rs7179456	0.654	rs8037673	chr15:59249584	G/A	cg05156742	chr15:59063176	FAM63B	0.57	7.31	0.43	4.31e-12	Asperger disorder;
SARC	trans	rs7819412	0.540	rs2409726	chr8:11043138	T/C	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.31	-0.38	1.41e-9	Triglycerides;
SARC	trans	rs1814175	0.817	rs7929173	chr11:49944007	T/C	cg03929089	chr4:120376271	NA	-0.87	-13.61	-0.67	1.93e-31	Height;
SARC	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg08742575	chr21:47604166	C21orf56	0.42	5.42	0.33	1.46e-7	Testicular germ cell tumor;
SARC	cis	rs7481584	0.624	rs369461	chr11:3061992	A/G	cg08508325	chr11:3079039	CARS	0.21	4.76	0.3	3.34e-6	Calcium levels;
SARC	cis	rs6686643	0.630	rs7554034	chr1:165610464	G/A	cg19407955	chr1:165599744	MGST3	-0.66	-6.51	-0.39	4.57e-10	Total ventricular volume;
SARC	cis	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg01579765	chr21:45077557	HSF2BP	-0.38	-6.46	-0.39	5.92e-10	Mean corpuscular volume;
SARC	cis	rs13314892	0.728	rs1367370	chr3:69887656	A/G	cg17445875	chr3:69859618	MITF	-0.48	-4.95	-0.31	1.45e-6	QRS complex (12-leadsum);
SARC	cis	rs9747201	1.000	rs3922470	chr17:80110159	C/T	cg09264619	chr17:80180166	NA	0.49	5.76	0.35	2.64e-8	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs9916302	0.851	rs6503502	chr17:37501855	A/G	cg00129232	chr17:37814104	STARD3	0.6	7.36	0.43	3.15e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs12497850	0.644	rs11928552	chr3:48739883	T/C	cg03060546	chr3:49711283	APEH	0.39	4.86	0.3	2.17e-6	Parkinson's disease;
SARC	cis	rs1023500	0.573	rs133374	chr22:42465941	G/A	cg04733989	chr22:42467013	NAGA	0.76	10.78	0.58	2.96e-22	Schizophrenia;
SARC	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg19748678	chr4:122722346	EXOSC9	0.77	9.7	0.54	6.58e-19	Type 2 diabetes;
SARC	cis	rs9815354	0.767	rs75651509	chr3:41953564	A/G	cg03022575	chr3:42003672	ULK4	0.7	5.7	0.35	3.66e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs4319547	0.695	rs4758666	chr12:122902840	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.5	-5.76	-0.35	2.71e-8	Body mass index;
SARC	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg18305652	chr10:134549665	INPP5A	0.34	5.26	0.33	3.23e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs34172651	0.917	rs11074651	chr16:24778409	A/G	cg00152838	chr16:24741724	TNRC6A	-0.44	-5.57	-0.34	7.02e-8	Intelligence (multi-trait analysis);
SARC	cis	rs13256369	0.802	rs35382339	chr8:8559255	G/A	cg17143192	chr8:8559678	CLDN23	0.52	5.81	0.36	2.07e-8	Obesity-related traits;
SARC	cis	rs2735413	0.709	rs8051521	chr16:78088156	G/C	cg04733911	chr16:78082701	NA	0.33	5.45	0.34	1.28e-7	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg23262073	chr20:60523788	NA	-0.39	-5.71	-0.35	3.43e-8	Body mass index;
SARC	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg08219700	chr8:58056026	NA	-0.49	-4.92	-0.31	1.61e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs6545883	0.929	rs2421203	chr2:61669248	C/A	cg15711740	chr2:61764176	XPO1	-0.41	-5.05	-0.31	8.9e-7	Tuberculosis;
SARC	cis	rs4128725	1.000	rs11265186	chr1:159375903	A/G	cg25076881	chr1:159409836	OR10J1	-0.4	-4.78	-0.3	3.16e-6	Select biomarker traits;
SARC	cis	rs4566357	0.539	rs10933164	chr2:227860671	A/G	cg11843606	chr2:227700838	RHBDD1	-0.68	-8.25	-0.48	1.19e-14	Coronary artery disease;
SARC	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg21724239	chr8:58056113	NA	0.62	5.81	0.36	2.09e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10979	1.000	rs12191231	chr6:143891114	A/C	cg25407410	chr6:143891975	LOC285740	-0.64	-8.68	-0.49	6.88e-16	Hypospadias;
SARC	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg07061783	chr6:25882402	NA	-0.4	-4.78	-0.3	3.04e-6	Blood metabolite levels;
SARC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	6.97	0.42	3.19e-11	Prudent dietary pattern;
SARC	cis	rs67311347	0.824	rs73073561	chr3:40357298	G/T	cg24209194	chr3:40518798	ZNF619	0.55	6.83	0.41	7.46e-11	Renal cell carcinoma;
SARC	cis	rs2115630	0.967	rs12595786	chr15:85336670	T/C	cg12501888	chr15:85177176	SCAND2	-0.46	-5.63	-0.35	5.27e-8	P wave terminal force;
SARC	cis	rs9640161	0.742	rs11767726	chr7:150018096	A/C	cg21361702	chr7:150065534	REPIN1	-0.48	-5.34	-0.33	2.21e-7	Blood protein levels;Circulating chemerin levels;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg01931797	chr11:77899910	KCTD21;USP35	0.49	6.52	0.39	4.3e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs9916302	0.861	rs593480	chr17:37453780	A/C	cg07936489	chr17:37558343	FBXL20	0.68	8.95	0.51	1.13e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs9916302	0.706	rs4287601	chr17:37513852	T/C	cg20243544	chr17:37824526	PNMT	-0.54	-5.76	-0.35	2.67e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs2742234	0.503	rs1254968	chr10:43691691	C/T	cg15436174	chr10:43711423	RASGEF1A	0.4	4.74	0.3	3.67e-6	Hirschsprung disease;
SARC	trans	rs3857536	0.740	rs9354392	chr6:66894555	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.6	-7.1	-0.42	1.51e-11	Blood trace element (Cu levels);
SARC	cis	rs796364	0.951	rs36086821	chr2:201067436	G/A	cg23649088	chr2:200775458	C2orf69	0.66	7.25	0.43	6.02e-12	Schizophrenia;
SARC	cis	rs9300255	0.602	rs1790098	chr12:123655481	A/C	cg00376283	chr12:123451042	ABCB9	0.6	6.79	0.41	9.43e-11	Neutrophil percentage of white cells;
SARC	cis	rs7246865	0.510	rs2305757	chr19:17169758	G/C	cg16202187	chr19:17186497	HAUS8;MYO9B	0.4	4.81	0.3	2.69e-6	Reticulocyte fraction of red cells;
SARC	cis	rs889312	0.500	rs865570	chr5:56161975	C/T	cg14703610	chr5:56206110	C5orf35	0.55	6.87	0.41	5.69e-11	Breast cancer;Breast cancer (early onset);
SARC	cis	rs2019216	0.502	rs1842113	chr17:21872137	G/A	cg22648282	chr17:21454238	C17orf51	-0.31	-4.92	-0.31	1.62e-6	Pelvic organ prolapse;
SARC	cis	rs9388451	0.626	rs1268074	chr6:126107791	G/C	cg06289844	chr6:126071538	HEY2	0.32	5.16	0.32	5.34e-7	Brugada syndrome;
SARC	cis	rs835154	1.000	rs835154	chr5:14876569	A/G	cg18064842	chr5:14874549	NA	0.5	6.43	0.39	7.27e-10	Blood metabolite levels;
SARC	cis	rs9894429	0.789	rs7502346	chr17:79603741	T/C	cg18240062	chr17:79603768	NPLOC4	0.88	13.72	0.67	8.26e-32	Eye color traits;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg03554702	chr20:43595206	STK4	0.48	6.3	0.38	1.5e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs62244186	0.715	rs13321717	chr3:44667455	C/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.45	5.65	0.35	4.6e-8	Depressive symptoms;
SARC	cis	rs210142	1.000	rs210142	chr6:33546837	T/C	cg07679836	chr6:33548423	BAK1	0.39	5.37	0.33	1.88e-7	Platelet count;Plateletcrit;Chronic lymphocytic leukemia;
SARC	cis	rs12545109	0.800	rs1467124	chr8:57418862	T/G	cg21220214	chr8:57350948	NA	-0.4	-4.84	-0.3	2.37e-6	Obesity-related traits;
SARC	cis	rs4563143	0.592	rs12151001	chr19:29283386	C/G	cg14983838	chr19:29218262	NA	0.75	9.94	0.55	1.26e-19	Methadone dose in opioid dependence;
SARC	trans	rs7937682	1.000	rs7937682	chr11:111579939	C/G	cg18187862	chr3:45730750	SACM1L	0.55	6.85	0.41	6.69e-11	Primary sclerosing cholangitis;
SARC	cis	rs244731	0.959	rs7724098	chr5:176659570	G/A	cg17509989	chr5:176798049	RGS14	-0.68	-8.47	-0.49	2.85e-15	Urate levels in lean individuals;
SARC	cis	rs76419734	1.000	rs72671826	chr4:106624502	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.81	4.9	0.31	1.76e-6	Post bronchodilator FEV1;
SARC	cis	rs10752881	0.775	rs2147585	chr1:183074875	C/T	cg13390022	chr1:182993471	LAMC1	0.32	4.78	0.3	3.07e-6	Colorectal cancer;
SARC	cis	rs3812831	0.630	rs9562129	chr13:114917152	A/G	cg06611532	chr13:114900021	NA	0.34	5.78	0.35	2.44e-8	Schizophrenia;
SARC	cis	rs1008375	1.000	rs2109522	chr4:17658645	T/A	cg16339924	chr4:17578868	LAP3	0.66	8.83	0.5	2.57e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7829975	0.500	rs7841082	chr8:8168987	C/T	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.32	-0.43	4.06e-12	Mood instability;
SARC	cis	rs10861342	0.892	rs74971338	chr12:105499757	C/A	cg23923672	chr12:105501055	KIAA1033	0.77	5.3	0.33	2.64e-7	IgG glycosylation;
SARC	cis	rs651907	0.557	rs7651406	chr3:101393296	C/T	cg12386194	chr3:101231763	SENP7	0.49	5.85	0.36	1.63e-8	Colorectal cancer;
SARC	cis	rs2991971	0.967	rs60608374	chr1:46008913	G/A	cg24296786	chr1:45957014	TESK2	0.64	9.19	0.52	2.24e-17	High light scatter reticulocyte count;
SARC	cis	rs1904096	0.506	rs4558832	chr4:95148042	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.47	-7.05	-0.42	2.06e-11	Type 2 diabetes;
SARC	trans	rs62103177	0.713	rs62103186	chr18:77627574	G/C	cg05926928	chr17:57297772	GDPD1	1.09	9.19	0.52	2.24e-17	Opioid sensitivity;
SARC	cis	rs9916302	0.706	rs2338799	chr17:37513941	G/A	cg00129232	chr17:37814104	STARD3	0.53	5.7	0.35	3.69e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs7011049	1.000	rs72643590	chr8:53849595	A/G	cg26025543	chr8:53854495	NA	0.6	5.43	0.34	1.42e-7	Systolic blood pressure;
SARC	cis	rs7223966	0.881	rs3020608	chr17:61979993	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.47	4.8	0.3	2.86e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9790314	0.663	rs778648	chr3:160708943	A/G	cg04691961	chr3:161091175	C3orf57	-0.57	-7.9	-0.46	1.11e-13	Morning vs. evening chronotype;
SARC	cis	rs151317012	1	rs151317012	chr4:106806194	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.89	4.91	0.31	1.7e-6	Post bronchodilator FEV1;
SARC	cis	rs1865760	1.000	rs12209482	chr6:25909229	T/G	cg16482183	chr6:26056742	HIST1H1C	0.5	6.22	0.38	2.27e-9	Height;
SARC	cis	rs10845606	1.000	rs11055013	chr12:12829037	T/C	cg04607235	chr12:12878440	APOLD1	-0.54	-5.46	-0.34	1.19e-7	Systemic lupus erythematosus;
SARC	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg12463550	chr7:65579703	CRCP	0.5	5.9	0.36	1.27e-8	Aortic root size;
SARC	cis	rs8180040	0.701	rs11130111	chr3:47009805	C/T	cg02527881	chr3:46936655	PTH1R	-0.31	-4.78	-0.3	3.07e-6	Colorectal cancer;
SARC	cis	rs3008870	0.755	rs3736905	chr1:67392614	A/G	cg02640540	chr1:67518911	SLC35D1	0.44	5.04	0.31	9.14e-7	Lymphocyte percentage of white cells;
SARC	cis	rs2180341	0.618	rs12199451	chr6:127597780	C/G	cg27446573	chr6:127587934	RNF146	0.62	7.71	0.45	3.68e-13	Breast cancer;
SARC	cis	rs2204008	0.689	rs1581357	chr12:38391479	C/G	cg13010199	chr12:38710504	ALG10B	0.82	11.04	0.59	4.51e-23	Bladder cancer;
SARC	cis	rs698833	0.962	rs1067387	chr2:44642797	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.71	9.44	0.53	4.14e-18	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg16010370	chr3:53290200	TKT	-0.5	-6.65	-0.4	2.07e-10	Chemerin levels;
SARC	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg13628971	chr7:2884303	GNA12	0.56	6.42	0.39	7.41e-10	Height;
SARC	cis	rs7617480	0.648	rs7653408	chr3:48972351	A/C	cg07636037	chr3:49044803	WDR6	0.84	9.03	0.51	6.49e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs6088590	1.000	rs2378256	chr20:33292127	G/C	cg08999081	chr20:33150536	PIGU	0.35	5.06	0.31	8.66e-7	Coronary artery disease;
SARC	trans	rs11098499	0.909	rs6842762	chr4:120398236	A/T	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	cis	rs2153535	0.580	rs7755284	chr6:8457479	T/C	cg07606381	chr6:8435919	SLC35B3	0.75	10.66	0.57	7.43e-22	Motion sickness;
SARC	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs12479064	0.724	rs11885942	chr2:100004165	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.55	-6.31	-0.38	1.36e-9	Chronic sinus infection;
SARC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg08677398	chr8:58056175	NA	0.44	5.27	0.33	3.14e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	trans	rs10825741	0.825	rs11005238	chr10:57925677	G/A	cg12948920	chr4:8609706	CPZ	0.53	6.28	0.38	1.67e-9	Night sleep phenotypes;
SARC	cis	rs9640161	0.636	rs56190213	chr7:150025720	T/C	cg17279839	chr7:150038598	RARRES2	0.49	6.61	0.4	2.57e-10	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs7786808	0.649	rs6459879	chr7:158211792	C/G	cg01191920	chr7:158217561	PTPRN2	-0.34	-5.6	-0.34	5.97e-8	Obesity-related traits;
SARC	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg02951883	chr7:2050386	MAD1L1	0.38	4.76	0.3	3.36e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs9815354	0.716	rs73087368	chr3:41930379	A/G	cg03022575	chr3:42003672	ULK4	0.69	5.65	0.35	4.69e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs208520	0.874	rs208456	chr6:66907942	A/G	cg07460842	chr6:66804631	NA	-0.96	-11.34	-0.6	5.21e-24	Exhaled nitric oxide output;
SARC	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg26335602	chr6:28129616	ZNF389	0.47	5.34	0.33	2.26e-7	Cardiac Troponin-T levels;
SARC	cis	rs9815354	0.723	rs79741604	chr3:41947321	C/T	cg03022575	chr3:42003672	ULK4	0.7	5.7	0.35	3.66e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg11764359	chr7:65958608	NA	0.73	8.72	0.5	5.25e-16	Aortic root size;
SARC	cis	rs6570726	0.967	rs9497316	chr6:145792387	G/T	cg23711669	chr6:146136114	FBXO30	-0.71	-10.61	-0.57	1.07e-21	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs13161895	1.000	rs13161895	chr5:179471201	C/T	cg02702477	chr5:179499311	RNF130	0.65	6.2	0.38	2.6e-9	LDL cholesterol;
SARC	cis	rs9916302	0.784	rs4795382	chr17:37700860	A/G	cg07936489	chr17:37558343	FBXL20	-0.68	-8.81	-0.5	2.97e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs7635838	0.892	rs2880897	chr3:11494544	A/G	cg00170343	chr3:11313890	ATG7	0.62	8.3	0.48	8.39e-15	HDL cholesterol;
SARC	cis	rs920590	0.684	rs57462676	chr8:19670848	G/C	cg01411142	chr8:19674711	INTS10	0.54	6.06	0.37	5.54e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs2033711	0.503	rs7254299	chr19:58884965	A/G	cg13877915	chr19:58951672	ZNF132	0.4	5.1	0.32	6.96e-7	Uric acid clearance;
SARC	cis	rs7250872	0.568	rs749109	chr19:1819736	G/A	cg18850929	chr19:1828978	REXO1	0.42	5.02	0.31	1.01e-6	Bipolar disorder;
SARC	cis	rs9290065	0.519	rs10936216	chr3:160698314	G/C	cg04691961	chr3:161091175	C3orf57	-0.49	-6.37	-0.39	9.99e-10	Kawasaki disease;
SARC	cis	rs72634258	0.503	rs71637401	chr1:7837012	G/A	cg26816564	chr1:7831052	VAMP3	0.56	4.91	0.31	1.75e-6	Inflammatory bowel disease;
SARC	cis	rs11105298	0.891	rs10506972	chr12:89861529	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.49	-5.0	-0.31	1.11e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs478304	0.651	rs11604462	chr11:65551648	G/A	cg26695010	chr11:65641043	EFEMP2	0.41	4.82	0.3	2.59e-6	Acne (severe);
SARC	cis	rs6429082	1.000	rs6429082	chr1:235600129	C/T	cg26050004	chr1:235667680	B3GALNT2	0.41	5.3	0.33	2.68e-7	Adiposity;
SARC	cis	rs9300255	0.602	rs1716165	chr12:123648881	C/T	cg05973401	chr12:123451056	ABCB9	0.53	6.13	0.37	3.64e-9	Neutrophil percentage of white cells;
SARC	cis	rs9398803	0.678	rs3861456	chr6:126898660	A/G	cg20229609	chr6:126660872	C6orf173	0.37	5.39	0.33	1.74e-7	Male-pattern baldness;
SARC	cis	rs4423214	0.650	rs4245442	chr11:71220909	T/C	cg05163923	chr11:71159392	DHCR7	0.62	7.49	0.44	1.41e-12	Vitamin D levels;
SARC	cis	rs2304069	0.954	rs6579767	chr5:149406271	C/T	cg12661370	chr5:149340060	SLC26A2	0.59	5.92	0.36	1.17e-8	HIV-1 control;
SARC	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg13939156	chr17:80058883	NA	-0.42	-6.48	-0.39	5.51e-10	Life satisfaction;
SARC	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg08742575	chr21:47604166	C21orf56	0.47	6.07	0.37	5.19e-9	Testicular germ cell tumor;
SARC	cis	rs7662987	0.517	rs2602880	chr4:100040653	C/T	cg13256891	chr4:100009986	ADH5	0.68	8.6	0.49	1.18e-15	Smoking initiation;
SARC	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg23262073	chr20:60523788	NA	-0.39	-5.71	-0.35	3.43e-8	Body mass index;
SARC	cis	rs7520050	0.931	rs11211213	chr1:46342517	G/A	cg06784218	chr1:46089804	CCDC17	-0.26	-4.79	-0.3	2.98e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs2204008	0.774	rs12810027	chr12:38212165	A/G	cg26384229	chr12:38710491	ALG10B	0.88	12.94	0.65	3.26e-29	Bladder cancer;
SARC	cis	rs9300255	0.679	rs58809476	chr12:123724880	C/T	cg00376283	chr12:123451042	ABCB9	-0.5	-4.85	-0.3	2.25e-6	Neutrophil percentage of white cells;
SARC	cis	rs11097912	0.632	rs1988695	chr4:107202263	A/G	cg09646026	chr4:107269030	AIMP1	-0.45	-4.86	-0.3	2.2e-6	Airflow obstruction;
SARC	cis	rs763121	0.853	rs2267395	chr22:39113903	C/T	cg06022373	chr22:39101656	GTPBP1	0.89	12.31	0.63	3.73e-27	Menopause (age at onset);
SARC	cis	rs8102137	1.000	rs8102137	chr19:30296853	T/C	cg27475126	chr19:30303651	CCNE1	-0.39	-5.26	-0.33	3.24e-7	Bladder cancer;
SARC	cis	rs9790314	0.715	rs980976	chr3:160771668	T/G	cg04691961	chr3:161091175	C3orf57	-0.6	-8.18	-0.47	1.82e-14	Morning vs. evening chronotype;
SARC	cis	rs826838	0.616	rs10880751	chr12:38627485	C/T	cg26384229	chr12:38710491	ALG10B	0.58	7.46	0.44	1.66e-12	Heart rate;
SARC	cis	rs911555	0.723	rs11160751	chr14:103925740	T/C	cg12935359	chr14:103987150	CKB	-0.38	-5.25	-0.33	3.49e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7084402	0.967	rs1658486	chr10:60288081	A/T	cg07615347	chr10:60278583	BICC1	0.61	8.99	0.51	8.84e-17	Refractive error;
SARC	cis	rs17125944	0.686	rs77650471	chr14:53364307	C/T	cg00686598	chr14:53173677	PSMC6	0.82	5.63	0.35	5.06e-8	Alzheimer's disease (late onset);
SARC	cis	rs950776	0.745	rs3743075	chr15:78909452	T/C	cg06917634	chr15:78832804	PSMA4	-0.71	-9.33	-0.52	8.61e-18	Sudden cardiac arrest;
SARC	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg07701084	chr6:150067640	NUP43	0.41	5.42	0.33	1.48e-7	Lung cancer;
SARC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg09177884	chr7:1199841	ZFAND2A	-0.52	-5.72	-0.35	3.21e-8	Longevity;Endometriosis;
SARC	cis	rs9291683	0.655	rs2278121	chr4:10096134	G/A	cg11266682	chr4:10021025	SLC2A9	-0.4	-7.05	-0.42	1.97e-11	Bone mineral density;
SARC	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg11608241	chr8:8085544	FLJ10661	-0.46	-5.72	-0.35	3.22e-8	Neuroticism;
SARC	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg18252515	chr7:66147081	NA	-0.57	-6.2	-0.38	2.51e-9	Aortic root size;
SARC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.54	6.15	0.37	3.35e-9	Prudent dietary pattern;
SARC	cis	rs11971779	0.680	rs6965212	chr7:139026465	G/T	cg23387468	chr7:139079360	LUC7L2	0.34	4.91	0.31	1.73e-6	Diisocyanate-induced asthma;
SARC	cis	rs7584330	0.744	rs10929234	chr2:238380034	C/G	cg11271282	chr2:238384023	NA	-0.5	-5.12	-0.32	6.42e-7	Prostate cancer;
SARC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg20607798	chr8:58055168	NA	0.58	5.55	0.34	7.69e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2916247	0.954	rs13267490	chr8:93137598	A/G	cg10183463	chr8:93005414	RUNX1T1	0.54	5.7	0.35	3.55e-8	Intelligence (multi-trait analysis);
SARC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.46	-5.11	-0.32	6.83e-7	Longevity;Endometriosis;
SARC	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.47	0.39	5.8e-10	Bipolar disorder;
SARC	trans	rs3942852	0.703	rs11039513	chr11:48107204	C/T	cg15704280	chr7:45808275	SEPT13	0.59	6.89	0.41	5.15e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs2882877	0.648	rs13018571	chr2:190395126	A/T	cg21926118	chr2:190387206	NA	-0.39	-4.86	-0.3	2.12e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs8141529	0.529	rs2269578	chr22:29196843	G/C	cg15103426	chr22:29168792	CCDC117	0.6	5.68	0.35	4.06e-8	Lymphocyte counts;
SARC	trans	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg06437703	chr8:37914619	EIF4EBP1	-0.6	-7.29	-0.43	4.85e-12	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7666738	0.830	rs10031751	chr4:98939134	G/A	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6121246	0.567	rs2811	chr20:30194248	A/G	cg21427119	chr20:30132790	HM13	-0.48	-5.29	-0.33	2.84e-7	Mean corpuscular hemoglobin;
SARC	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg19346786	chr7:2764209	NA	-0.41	-6.15	-0.37	3.4e-9	Height;
SARC	cis	rs67311347	0.605	rs1880762	chr3:40283215	A/G	cg24209194	chr3:40518798	ZNF619	0.48	5.67	0.35	4.26e-8	Renal cell carcinoma;
SARC	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg08219700	chr8:58056026	NA	0.62	6.52	0.39	4.28e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg12463550	chr7:65579703	CRCP	0.7	5.31	0.33	2.6e-7	Diabetic kidney disease;
SARC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg11494091	chr17:61959527	GH2	0.53	7.96	0.46	7.75e-14	Prudent dietary pattern;
SARC	cis	rs6871536	1.000	rs59568225	chr5:131945745	T/G	cg11797159	chr5:131991491	NA	0.38	4.76	0.3	3.43e-6	Asthma (childhood onset);
SARC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg05165339	chr4:1420672	NA	-0.26	-5.66	-0.35	4.38e-8	Longevity;
SARC	cis	rs10979	1.000	rs9496673	chr6:143885393	C/G	cg25407410	chr6:143891975	LOC285740	-0.61	-8.01	-0.46	5.34e-14	Hypospadias;
SARC	cis	rs240764	0.817	rs240147	chr6:101078300	G/A	cg09795085	chr6:101329169	ASCC3	0.45	5.77	0.35	2.55e-8	Neuroticism;
SARC	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg06212747	chr3:49208901	KLHDC8B	0.68	8.99	0.51	8.6e-17	Parkinson's disease;
SARC	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg05861140	chr6:150128134	PCMT1	-0.4	-5.23	-0.32	3.75e-7	Lung cancer;
SARC	cis	rs16976116	0.951	rs3759862	chr15:55483104	C/A	cg17854078	chr15:55489399	RSL24D1	0.66	6.52	0.39	4.27e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2243480	1.000	rs160643	chr7:65558222	C/T	cg18252515	chr7:66147081	NA	-1.24	-10.92	-0.58	1.1e-22	Diabetic kidney disease;
SARC	trans	rs4848143	0.864	rs921089	chr2:121808766	C/G	cg26633120	chr2:105654408	MRPS9	0.49	6.28	0.38	1.62e-9	Capecitabine sensitivity;
SARC	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.54	6.97	0.42	3.19e-11	Personality dimensions;
SARC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg09373136	chr17:61933544	TCAM1	-0.43	-5.89	-0.36	1.36e-8	Prudent dietary pattern;
SARC	cis	rs35995292	1.000	rs9638944	chr7:38947417	T/C	cg19327137	chr7:38886074	VPS41	0.36	5.23	0.32	3.76e-7	Subjective well-being (multi-trait analysis);
SARC	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg03806693	chr22:41940476	POLR3H	-0.88	-11.81	-0.61	1.59e-25	Vitiligo;
SARC	cis	rs6456042	0.965	rs3127411	chr6:166534776	A/G	cg11088901	chr6:166572345	T	-0.34	-4.94	-0.31	1.51e-6	Asthma;
SARC	cis	rs11809207	0.523	rs2783626	chr1:26501044	C/T	cg23602478	chr1:26503979	CNKSR1	-0.28	-5.1	-0.32	6.91e-7	Height;
SARC	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-5.05	-0.31	8.87e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6088580	0.634	rs6059866	chr20:33075810	A/C	cg08999081	chr20:33150536	PIGU	0.42	6.18	0.38	2.77e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs2204008	0.630	rs12306932	chr12:38242029	C/T	cg14851346	chr12:38532713	NA	-0.45	-5.39	-0.33	1.71e-7	Bladder cancer;
SARC	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg13393036	chr8:95962371	TP53INP1	-0.39	-6.55	-0.39	3.61e-10	Type 2 diabetes;
SARC	cis	rs2345546	1	rs2345546	chr16:25427472	C/T	cg08360281	chr16:25269390	ZKSCAN2	0.9	8.15	0.47	2.26e-14	Major depression and alcohol dependence;
SARC	cis	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg05623727	chr3:50126028	RBM5	-0.34	-5.27	-0.33	3.18e-7	Intelligence (multi-trait analysis);
SARC	cis	rs4689388	0.853	rs6817447	chr4:6286847	G/T	cg00701064	chr4:6280414	WFS1	0.54	8.57	0.49	1.45e-15	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs9790314	0.967	rs10804790	chr3:161039300	T/A	cg04691961	chr3:161091175	C3orf57	-0.8	-11.8	-0.61	1.66e-25	Morning vs. evening chronotype;
SARC	cis	rs6598955	0.724	rs12068388	chr1:26621596	G/A	cg04990556	chr1:26633338	UBXN11	-0.59	-8.15	-0.47	2.27e-14	Obesity-related traits;
SARC	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg24829409	chr8:58192753	C8orf71	-0.58	-5.05	-0.31	8.87e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2070433	0.539	rs1008548	chr21:47959692	G/A	cg12379764	chr21:47803548	PCNT	0.56	6.06	0.37	5.52e-9	Lymphocyte counts;
SARC	cis	rs11700980	0.636	rs11701464	chr21:30285392	C/T	cg24692254	chr21:30365293	RNF160	0.66	5.65	0.35	4.62e-8	QRS complex (12-leadsum);
SARC	cis	rs12477438	0.765	rs12612688	chr2:99613091	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.9	-14.32	-0.68	8.47e-34	Chronic sinus infection;
SARC	cis	rs72781680	0.898	rs55841168	chr2:24007926	T/C	cg06627628	chr2:24431161	ITSN2	-0.66	-6.26	-0.38	1.83e-9	Lymphocyte counts;
SARC	cis	rs7614311	0.681	rs57766205	chr3:63895303	G/C	cg22134162	chr3:63841271	THOC7	-0.43	-4.89	-0.31	1.89e-6	Lung function (FVC);Lung function (FEV1);
SARC	cis	rs2645694	0.626	rs2645704	chr4:77830805	T/C	cg18351406	chr4:77819688	ANKRD56	0.37	5.18	0.32	4.74e-7	Emphysema distribution in smoking;
SARC	cis	rs9341808	0.538	rs7756067	chr6:81019794	C/T	cg08355045	chr6:80787529	NA	-0.33	-4.93	-0.31	1.57e-6	Sitting height ratio;
SARC	cis	rs11585357	0.843	rs72646796	chr1:17612503	T/C	cg08277548	chr1:17600880	PADI3	-0.49	-5.45	-0.34	1.27e-7	Hair shape;
SARC	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg11987759	chr7:65425863	GUSB	-0.64	-8.38	-0.48	5.05e-15	Aortic root size;
SARC	cis	rs9486715	1.000	rs6899647	chr6:97065661	A/G	cg18709589	chr6:96969512	KIAA0776	-0.59	-7.34	-0.43	3.61e-12	Headache;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg13075278	chr1:28655393	MED18	-0.63	-6.5	-0.39	4.78e-10	Lung cancer in ever smokers;
SARC	cis	rs7927592	0.513	rs689075	chr11:68194432	A/C	cg01657329	chr11:68192670	LRP5	-0.4	-5.44	-0.34	1.32e-7	Total body bone mineral density;
SARC	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg18876405	chr7:65276391	NA	-0.45	-5.15	-0.32	5.46e-7	Aortic root size;
SARC	cis	rs2239547	0.618	rs4687658	chr3:52860366	C/G	cg18404041	chr3:52824283	ITIH1	-0.42	-5.01	-0.31	1.05e-6	Schizophrenia;
SARC	cis	rs2011503	1.000	rs113527843	chr19:19643343	A/T	cg03709012	chr19:19516395	GATAD2A	0.6	5.29	0.33	2.8e-7	Bipolar disorder;
SARC	cis	rs2645694	0.533	rs2703125	chr4:77819900	T/C	cg10057126	chr4:77819792	ANKRD56	0.43	6.47	0.39	5.85e-10	Emphysema distribution in smoking;
SARC	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-9.08	-0.51	4.64e-17	Alzheimer's disease;
SARC	cis	rs3126085	0.935	rs11204934	chr1:152176848	C/A	cg26876637	chr1:152193138	HRNR	-0.46	-5.08	-0.32	7.56e-7	Atopic dermatitis;
SARC	cis	rs17826219	0.562	rs719600	chr17:28731262	G/A	cg13385521	chr17:29058706	SUZ12P	-0.57	-4.84	-0.3	2.35e-6	Body mass index;
SARC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg09373136	chr17:61933544	TCAM1	-0.45	-6.15	-0.37	3.36e-9	Prudent dietary pattern;
SARC	cis	rs10493773	0.649	rs17398321	chr1:86084493	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.46	-6.11	-0.37	4.2e-9	Urate levels in overweight individuals;
SARC	cis	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg05623727	chr3:50126028	RBM5	-0.35	-5.14	-0.32	5.92e-7	Body mass index;
SARC	trans	rs11098499	0.779	rs28495013	chr4:120375831	A/C	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	cis	rs10504229	0.593	rs16921589	chr8:58024387	C/A	cg22535103	chr8:58192502	C8orf71	-0.6	-5.76	-0.35	2.61e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs13191362	0.507	rs2023037	chr6:163120385	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.5	5.36	0.33	2.01e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs926392	0.640	rs7268716	chr20:37693214	C/T	cg16355469	chr20:37678765	NA	0.76	9.87	0.54	1.96e-19	Dialysis-related mortality;
SARC	cis	rs2933343	0.679	rs789229	chr3:128602526	C/T	cg24203234	chr3:128598194	ACAD9	0.62	7.77	0.45	2.49e-13	IgG glycosylation;
SARC	cis	rs11098499	0.863	rs6534141	chr4:120485223	A/T	cg09307838	chr4:120376055	NA	0.91	12.58	0.64	4.84e-28	Corneal astigmatism;
SARC	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.39	4.84	0.3	2.33e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg11987759	chr7:65425863	GUSB	0.5	6.07	0.37	5.27e-9	Aortic root size;
SARC	cis	rs2404602	0.563	rs12914005	chr15:76765667	A/G	cg22467129	chr15:76604101	ETFA	-0.37	-4.89	-0.31	1.87e-6	Blood metabolite levels;
SARC	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg18404041	chr3:52824283	ITIH1	-0.44	-6.58	-0.4	3.05e-10	Bipolar disorder;
SARC	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.57	6.13	0.37	3.73e-9	Renal function-related traits (BUN);
SARC	cis	rs4900538	0.963	rs1885708	chr14:102960164	A/G	cg18135206	chr14:102964638	TECPR2	0.67	9.02	0.51	7.16e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs2467099	0.786	rs1463486	chr17:73943942	G/A	cg06969265	chr17:73775802	H3F3B	0.64	6.73	0.4	1.34e-10	Systolic blood pressure;
SARC	cis	rs3008870	1.000	rs1925411	chr1:67370292	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.9	10.88	0.58	1.43e-22	Lymphocyte percentage of white cells;
SARC	cis	rs922107	0.738	rs12140018	chr1:90025689	G/A	cg15422784	chr1:90023713	LRRC8B	-0.32	-4.75	-0.3	3.56e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
SARC	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg13206674	chr6:150067644	NUP43	0.5	6.14	0.37	3.54e-9	Lung cancer;
SARC	cis	rs6840360	0.615	rs12641438	chr4:152607586	A/G	cg22705602	chr4:152727874	NA	-0.49	-8.47	-0.49	2.76e-15	Intelligence (multi-trait analysis);
SARC	cis	rs3812831	0.669	rs382913	chr13:114928255	G/T	cg06611532	chr13:114900021	NA	0.33	5.46	0.34	1.19e-7	Schizophrenia;
SARC	cis	rs11122272	0.735	rs722302	chr1:231480152	A/C	cg06096015	chr1:231504339	EGLN1	0.38	5.61	0.34	5.71e-8	Hemoglobin concentration;
SARC	cis	rs7937682	0.632	rs11603779	chr11:111781047	A/C	cg22437258	chr11:111473054	SIK2	-0.49	-5.66	-0.35	4.48e-8	Primary sclerosing cholangitis;
SARC	cis	rs2836974	0.897	rs2776308	chr21:40715175	A/G	cg11644478	chr21:40555479	PSMG1	0.99	13.45	0.66	6.9e-31	Cognitive function;
SARC	cis	rs2732480	0.557	rs2732484	chr12:48737245	A/C	cg24011408	chr12:48396354	COL2A1	0.43	5.11	0.32	6.81e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs1801251	0.778	rs2592116	chr2:233735709	G/A	cg25237894	chr2:233734115	C2orf82	-0.34	-4.82	-0.3	2.57e-6	Coronary artery disease;
SARC	cis	rs5753618	0.509	rs5997912	chr22:31593861	A/G	cg02404636	chr22:31891804	SFI1	-0.48	-5.05	-0.31	8.88e-7	Colorectal cancer;
SARC	cis	rs11583043	1.000	rs6682873	chr1:101470906	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	5.68	0.35	4.01e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs12791968	0.917	rs11038238	chr11:45002010	A/G	cg11846598	chr11:44996168	LOC221122	-0.36	-5.72	-0.35	3.3e-8	Inhibitory control;
SARC	cis	rs7250872	0.647	rs2304612	chr19:1817866	A/G	cg05970437	chr19:1864622	KLF16	-0.45	-4.97	-0.31	1.31e-6	Bipolar disorder;
SARC	cis	rs17376456	0.877	rs2085960	chr5:93399934	A/G	cg21475434	chr5:93447410	FAM172A	0.85	7.56	0.44	9.4e-13	Diabetic retinopathy;
SARC	cis	rs6540556	0.859	rs12131636	chr1:209942435	G/C	cg23920097	chr1:209922102	NA	-0.56	-5.39	-0.33	1.68e-7	Red blood cell count;
SARC	trans	rs453301	0.571	rs330054	chr8:9088291	G/A	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.43	-0.39	6.98e-10	Joint mobility (Beighton score);
SARC	cis	rs453301	0.686	rs6748	chr8:8890802	C/T	cg08975724	chr8:8085496	FLJ10661	-0.47	-6.08	-0.37	4.86e-9	Joint mobility (Beighton score);
SARC	cis	rs2836974	0.604	rs2854727	chr21:40713787	A/G	cg11644478	chr21:40555479	PSMG1	0.66	8.52	0.49	1.96e-15	Cognitive function;
SARC	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.58	5.44	0.34	1.34e-7	Lung function (FEV1/FVC);
SARC	cis	rs2075371	1.000	rs1862051	chr7:133981021	G/A	cg20476274	chr7:133979776	SLC35B4	0.62	8.57	0.49	1.47e-15	Mean platelet volume;
SARC	cis	rs11770686	0.666	rs2705801	chr7:75308071	G/A	cg17787366	chr7:75369077	HIP1	0.4	5.13	0.32	6.06e-7	Essential tremor;
SARC	cis	rs950776	0.714	rs17408276	chr15:78881618	T/C	cg22563815	chr15:78856949	CHRNA5	0.36	5.67	0.35	4.3e-8	Sudden cardiac arrest;
SARC	cis	rs12142240	0.698	rs72677593	chr1:46824363	T/C	cg10495392	chr1:46806563	NSUN4	0.65	6.8	0.41	8.89e-11	Menopause (age at onset);
SARC	cis	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg00071950	chr4:10020882	SLC2A9	0.39	6.31	0.38	1.4e-9	Bone mineral density;
SARC	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg16743903	chr16:89593216	SPG7	0.39	5.41	0.33	1.56e-7	Multiple myeloma (IgH translocation);
SARC	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg16479474	chr6:28041457	NA	0.36	5.27	0.33	3.04e-7	Depression;
SARC	cis	rs9303401	0.659	rs35539277	chr17:56853833	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	11.31	0.6	6.11e-24	Cognitive test performance;
SARC	cis	rs62064224	0.593	rs916663	chr17:30835833	A/C	cg25809561	chr17:30822961	MYO1D	-0.41	-6.06	-0.37	5.45e-9	Schizophrenia;
SARC	cis	rs7638909	0.512	rs6799868	chr3:38601556	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.42	-4.83	-0.3	2.48e-6	Electrocardiographic conduction measures;
SARC	cis	rs34779708	0.966	rs34605125	chr10:35411246	A/G	cg03585969	chr10:35415529	CREM	0.43	5.24	0.32	3.63e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs10752881	1.000	rs12753817	chr1:182970337	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.65	9.77	0.54	4.14e-19	Colorectal cancer;
SARC	cis	rs76419734	0.850	rs17036327	chr4:106761416	C/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.77	5.19	0.32	4.53e-7	Post bronchodilator FEV1;
SARC	cis	rs5167	0.504	rs3760629	chr19:45458146	A/C	cg13119609	chr19:45449297	APOC2	0.48	7.93	0.46	8.86e-14	Blood protein levels;
SARC	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg22168489	chr12:122356033	WDR66	-0.61	-9.45	-0.53	3.82e-18	Mean corpuscular volume;
SARC	cis	rs10512697	0.803	rs13172911	chr5:3578242	T/C	cg19473799	chr5:3511975	NA	-0.68	-4.86	-0.3	2.11e-6	Immune response to smallpox vaccine (IL-6);
SARC	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg10018233	chr7:150070692	REPIN1	-0.66	-8.79	-0.5	3.29e-16	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs918629	1.000	rs60482707	chr5:95307696	T/C	cg16656078	chr5:95278638	ELL2	-0.51	-6.37	-0.39	1.01e-9	IgG glycosylation;
SARC	cis	rs11785693	0.862	rs1156861	chr8:4984434	G/C	cg26367366	chr8:4980734	NA	0.68	6.08	0.37	4.98e-9	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs7084402	0.555	rs7069916	chr10:60271824	A/G	cg07615347	chr10:60278583	BICC1	0.42	5.62	0.35	5.38e-8	Refractive error;
SARC	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg18876405	chr7:65276391	NA	-0.44	-4.91	-0.31	1.75e-6	Aortic root size;
SARC	cis	rs8016982	0.674	rs1951615	chr14:81671762	G/A	cg01989461	chr14:81687754	GTF2A1	0.75	11.5	0.6	1.57e-24	Schizophrenia;
SARC	cis	rs6908034	0.556	rs113071446	chr6:19810835	A/C	cg02682789	chr6:19804855	NA	0.69	5.6	0.34	5.9e-8	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg01570182	chr17:44337453	NA	0.88	9.91	0.54	1.52e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs477692	0.673	rs1970197	chr10:131359588	C/T	cg14263093	chr10:131365266	MGMT	0.34	4.72	0.3	4.01e-6	Response to temozolomide;
SARC	cis	rs881375	0.902	rs2900180	chr9:123706382	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	5.5	0.34	1.01e-7	Rheumatoid arthritis;
SARC	cis	rs3008870	0.755	rs4486425	chr1:67460791	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.59	-7.48	-0.44	1.54e-12	Lymphocyte percentage of white cells;
SARC	cis	rs10197940	0.624	rs10497081	chr2:152353395	T/G	cg19508488	chr2:152266495	RIF1	0.51	5.55	0.34	7.75e-8	Lung cancer;
SARC	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg11366901	chr6:160182831	ACAT2	1.02	10.79	0.58	2.78e-22	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs854765	0.693	rs8079321	chr17:17760789	C/T	cg16928487	chr17:17741425	SREBF1	-0.25	-5.3	-0.33	2.73e-7	Total body bone mineral density;
SARC	cis	rs453301	0.658	rs12114954	chr8:8904862	T/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.24	-0.38	2.07e-9	Joint mobility (Beighton score);
SARC	cis	rs4803468	0.934	rs2317131	chr19:41885151	C/T	cg14132834	chr19:41945861	ATP5SL	-0.56	-7.61	-0.45	6.64e-13	Height;
SARC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg20887711	chr4:1340912	KIAA1530	0.8	10.02	0.55	7.09e-20	Longevity;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg24024426	chr20:4982196	SLC23A2	0.49	6.44	0.39	6.58e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs9815354	0.680	rs73830596	chr3:42028223	G/A	cg03022575	chr3:42003672	ULK4	0.59	4.75	0.3	3.49e-6	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs17401966	0.898	rs12757288	chr1:10323921	T/C	cg15208524	chr1:10270712	KIF1B	0.46	5.37	0.33	1.86e-7	Hepatocellular carcinoma;
SARC	cis	rs3749237	1.000	rs2291542	chr3:49751585	C/T	cg03060546	chr3:49711283	APEH	0.59	7.41	0.44	2.32e-12	Resting heart rate;
SARC	trans	rs208520	0.754	rs7753158	chr6:66875633	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-11.96	-0.62	4.93e-26	Exhaled nitric oxide output;
SARC	cis	rs2380220	0.574	rs9400526	chr6:95998441	T/C	cg15832292	chr6:96025679	MANEA	0.5	5.55	0.34	7.71e-8	Behavioural disinhibition (generation interaction);
SARC	cis	rs35306767	0.903	rs7077278	chr10:911291	A/G	cg20503657	chr10:835505	NA	-0.88	-8.05	-0.47	4.21e-14	Eosinophil percentage of granulocytes;
SARC	cis	rs10992471	0.605	rs7872375	chr9:95064843	C/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-5.47	-0.34	1.16e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs9796	0.870	rs28501589	chr15:41282534	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.42	-5.73	-0.35	3.1e-8	Menopause (age at onset);
SARC	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg06636001	chr8:8085503	FLJ10661	0.67	9.09	0.51	4.44e-17	Mood instability;
SARC	cis	rs9436747	0.605	rs61779815	chr1:65943197	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	-0.43	-5.37	-0.33	1.92e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs748404	0.697	rs579651	chr15:43558376	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.53	6.25	0.38	1.96e-9	Lung cancer;
SARC	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg18758796	chr5:131593413	PDLIM4	0.39	5.18	0.32	4.7e-7	Blood metabolite levels;
SARC	cis	rs11602339	1	rs11602339	chr11:47761471	C/T	cg05585544	chr11:47624801	NA	-0.37	-4.89	-0.31	1.87e-6	Body mass index;
SARC	trans	rs17221829	0.733	rs11018668	chr11:89356178	C/T	cg19354023	chr10:89577882	ATAD1;CFLP1	0.46	6.32	0.38	1.29e-9	Anxiety in major depressive disorder;
SARC	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg03806693	chr22:41940476	POLR3H	-0.96	-13.38	-0.66	1.11e-30	Vitiligo;
SARC	cis	rs7681440	0.606	rs2737013	chr4:90745503	C/T	cg06632027	chr4:90757378	SNCA	-0.44	-5.44	-0.34	1.36e-7	Dementia with Lewy bodies;
SARC	cis	rs12142240	0.698	rs17357621	chr1:46807697	C/T	cg10495392	chr1:46806563	NSUN4	0.64	6.76	0.4	1.09e-10	Menopause (age at onset);
SARC	cis	rs7927592	1.000	rs7927592	chr11:68369960	G/A	cg01657329	chr11:68192670	LRP5	-0.4	-4.87	-0.3	2.02e-6	Total body bone mineral density;
SARC	cis	rs2153535	0.580	rs9405391	chr6:8466548	C/T	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	cis	rs10791097	0.694	rs2236711	chr11:130739284	G/A	cg09137382	chr11:130731461	NA	0.31	4.78	0.3	3.15e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs13174863	1.000	rs13174863	chr5:139080745	C/T	cg10513866	chr5:139070639	NA	-0.41	-4.76	-0.3	3.34e-6	Body mass index;
SARC	cis	rs7560272	0.501	rs4852978	chr2:73943110	G/A	cg20560298	chr2:73613845	ALMS1	0.44	5.89	0.36	1.33e-8	Schizophrenia;
SARC	trans	rs61931739	0.534	rs35056575	chr12:34142914	A/T	cg26384229	chr12:38710491	ALG10B	0.85	12.16	0.62	1.14e-26	Morning vs. evening chronotype;
SARC	cis	rs6582630	0.519	rs11514056	chr12:38284001	G/T	cg13010199	chr12:38710504	ALG10B	0.78	10.65	0.57	7.82e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg26818010	chr10:134567672	INPP5A	-0.53	-5.98	-0.36	8.39e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs11690935	0.959	rs77280952	chr2:172620151	G/C	cg13550731	chr2:172543902	DYNC1I2	-0.99	-14.79	-0.7	2.39e-35	Schizophrenia;
SARC	cis	rs73635312	0.850	rs74319752	chr10:8954450	T/C	cg24467326	chr10:9646929	NA	0.62	5.1	0.32	6.99e-7	Basal cell carcinoma;
SARC	cis	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg25427524	chr10:38739819	LOC399744	-0.52	-8.25	-0.48	1.17e-14	Extrinsic epigenetic age acceleration;
SARC	cis	rs9309473	1.000	rs11903916	chr2:73815328	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-5.54	-0.34	7.95e-8	Metabolite levels;
SARC	cis	rs4423214	1.000	rs7928249	chr11:71161063	A/G	cg24826892	chr11:71159390	DHCR7	0.47	5.89	0.36	1.31e-8	Vitamin D levels;
SARC	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg00149659	chr3:10157352	C3orf10	0.69	6.76	0.4	1.1e-10	Alzheimer's disease;
SARC	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg24531977	chr5:56204891	C5orf35	-0.6	-5.47	-0.34	1.13e-7	Initial pursuit acceleration;
SARC	cis	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg05623727	chr3:50126028	RBM5	-0.33	-5.06	-0.31	8.7e-7	Intelligence (multi-trait analysis);
SARC	cis	rs995000	0.931	rs11207969	chr1:62911751	A/G	cg06896770	chr1:63153194	DOCK7	0.95	14.77	0.7	2.83e-35	Triglyceride levels;
SARC	cis	rs921968	0.541	rs55996799	chr2:219558193	C/G	cg02176678	chr2:219576539	TTLL4	-0.51	-7.8	-0.45	2.12e-13	Mean corpuscular hemoglobin concentration;
SARC	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg05863683	chr7:1912471	MAD1L1	-0.33	-5.0	-0.31	1.13e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg02487422	chr3:49467188	NICN1	0.48	6.44	0.39	6.94e-10	Resting heart rate;
SARC	cis	rs916888	0.779	rs199498	chr17:44865603	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.46	5.09	0.32	7.44e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs787274	1.000	rs4979155	chr9:115560134	G/A	cg13803584	chr9:115635662	SNX30	-0.83	-4.97	-0.31	1.28e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs1843834	0.539	rs10177898	chr2:225437552	C/T	cg22509189	chr2:225307070	NA	-0.68	-8.56	-0.49	1.52e-15	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs7520050	0.807	rs6429576	chr1:46216575	T/C	cg24296786	chr1:45957014	TESK2	-0.44	-5.68	-0.35	4.09e-8	Red blood cell count;Reticulocyte count;
SARC	cis	rs12586317	0.547	rs77780729	chr14:35496176	C/A	cg16230307	chr14:35515116	FAM177A1	1.02	11.85	0.61	1.17e-25	Psoriasis;
SARC	cis	rs7264396	0.563	rs2425138	chr20:34345710	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-6.3	-0.38	1.45e-9	Total cholesterol levels;
SARC	cis	rs6912958	0.582	rs242285	chr6:88070743	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.39	6.67	0.4	1.81e-10	Monocyte percentage of white cells;
SARC	cis	rs2153535	0.580	rs1120392	chr6:8487053	C/A	cg07606381	chr6:8435919	SLC35B3	0.78	11.09	0.59	3.13e-23	Motion sickness;
SARC	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg13206674	chr6:150067644	NUP43	0.41	5.35	0.33	2.08e-7	Lung cancer;
SARC	cis	rs2370759	1.000	rs16933243	chr10:32615135	T/C	cg01819863	chr10:32635814	EPC1	1.01	10.12	0.55	3.35e-20	Sexual dysfunction (female);
SARC	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg05872129	chr22:39784769	NA	-0.39	-5.29	-0.33	2.78e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs2361718	0.500	rs8068856	chr17:78100731	A/G	cg23534315	chr17:78082725	GAA	0.41	5.06	0.31	8.48e-7	Yeast infection;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg22122098	chr2:170934512	UBR3	0.48	6.72	0.4	1.38e-10	Thyroid stimulating hormone;
SARC	cis	rs8031584	0.958	rs8034856	chr15:31240957	T/C	cg08109568	chr15:31115862	NA	-0.46	-5.75	-0.35	2.78e-8	Huntington's disease progression;
SARC	cis	rs1215050	0.791	rs10856931	chr4:98819306	C/T	cg05340658	chr4:99064831	C4orf37	0.43	5.85	0.36	1.66e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	trans	rs1502172	0.550	rs77111836	chr3:135242169	G/A	cg17077762	chr15:64996104	OAZ2	0.49	6.34	0.38	1.15e-9	Visceral adipose tissue adjusted for BMI;
SARC	cis	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg15556689	chr8:8085844	FLJ10661	0.45	5.72	0.35	3.18e-8	Joint mobility (Beighton score);
SARC	cis	rs7666738	0.800	rs1559858	chr4:99024075	A/G	cg05340658	chr4:99064831	C4orf37	0.64	8.55	0.49	1.63e-15	Colonoscopy-negative controls vs population controls;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg22913584	chr5:81046758	SSBP2	-0.85	-7.11	-0.42	1.42e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs826838	0.616	rs10880751	chr12:38627485	C/T	cg14851346	chr12:38532713	NA	0.43	5.29	0.33	2.88e-7	Heart rate;
SARC	cis	rs55665837	0.559	rs11023210	chr11:14422762	A/G	cg19336497	chr11:14380999	RRAS2	0.33	5.5	0.34	9.89e-8	Vitamin D levels;
SARC	cis	rs240764	0.817	rs6907240	chr6:101153782	T/C	cg09795085	chr6:101329169	ASCC3	-0.45	-5.85	-0.36	1.65e-8	Neuroticism;
SARC	cis	rs77861329	1.000	rs28452586	chr3:52176007	A/G	cg08692210	chr3:52188851	WDR51A	0.7	4.72	0.3	4.13e-6	Macrophage inflammatory protein 1b levels;
SARC	cis	rs4803468	0.763	rs17318596	chr19:41937095	A/G	cg08477640	chr19:41863820	B9D2	0.39	4.84	0.3	2.34e-6	Height;
SARC	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg26335602	chr6:28129616	ZNF389	0.5	5.56	0.34	7.55e-8	Depression;
SARC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg26338869	chr17:61819248	STRADA	0.8	10.82	0.58	2.2e-22	Prudent dietary pattern;
SARC	cis	rs2061333	1.000	rs2061333	chr19:44614208	A/G	cg18700516	chr19:44507157	ZNF230	0.55	5.92	0.36	1.16e-8	Alzheimer's disease;
SARC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg02018176	chr4:1364513	KIAA1530	0.65	10.04	0.55	6.14e-20	Longevity;
SARC	cis	rs7084402	0.935	rs7474570	chr10:60343085	C/G	cg07615347	chr10:60278583	BICC1	0.6	8.7	0.5	6.13e-16	Refractive error;
SARC	cis	rs910316	1.000	rs10140851	chr14:75512612	G/A	cg08847533	chr14:75593920	NEK9	0.93	15.17	0.71	1.25e-36	Height;
SARC	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg11644478	chr21:40555479	PSMG1	-0.57	-7.1	-0.42	1.54e-11	Menarche (age at onset);
SARC	cis	rs11718455	0.767	rs9861276	chr3:43989595	C/T	cg08738300	chr3:44038990	NA	0.52	5.72	0.35	3.25e-8	Coronary artery disease;
SARC	cis	rs262150	0.851	rs2730249	chr7:158767628	A/G	cg19418458	chr7:158789849	NA	0.47	6.32	0.38	1.31e-9	Facial morphology (factor 20);
SARC	cis	rs912057	0.833	rs1024245	chr6:6743319	A/G	cg06612196	chr6:6737390	NA	0.64	9.32	0.52	9.03e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs9486719	1.000	rs4343922	chr6:96876903	C/T	cg18709589	chr6:96969512	KIAA0776	0.47	4.99	0.31	1.16e-6	Migraine;Coronary artery disease;
SARC	cis	rs2997447	0.846	rs3008418	chr1:26403098	G/A	cg19633962	chr1:26362018	EXTL1	-0.55	-5.17	-0.32	4.97e-7	QRS complex (12-leadsum);
SARC	cis	rs7666738	0.830	rs1869897	chr4:98730997	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.54	0.49	1.74e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs644799	0.622	rs1255167	chr11:95500213	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	6.54	0.39	3.8e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs10988449	0.891	rs3088095	chr9:132397239	T/C	cg18327994	chr9:132372705	NA	-0.5	-5.05	-0.31	8.79e-7	Response to anti-depressant treatment in major depressive disorder;
SARC	cis	rs9916302	0.706	rs439537	chr17:37734482	T/C	cg00129232	chr17:37814104	STARD3	-0.59	-6.15	-0.37	3.28e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs7582180	0.663	rs6542944	chr2:100988038	T/C	cg14675211	chr2:100938903	LONRF2	0.57	8.32	0.48	7.43e-15	Intelligence (multi-trait analysis);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg04041942	chr8:28747613	INTS9;HMBOX1	-0.64	-7.47	-0.44	1.6e-12	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs6964587	1.000	rs1859037	chr7:91568272	A/G	cg17063962	chr7:91808500	NA	-0.93	-14.77	-0.7	2.86e-35	Breast cancer;
SARC	cis	rs9911578	1.000	rs7216680	chr17:56988243	G/C	cg05425664	chr17:57184151	TRIM37	-0.67	-8.33	-0.48	7.15e-15	Intelligence (multi-trait analysis);
SARC	cis	rs11190604	0.767	rs12360395	chr10:102194074	A/T	cg07080220	chr10:102295463	HIF1AN	0.71	8.15	0.47	2.29e-14	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs1707322	0.752	rs8179296	chr1:46143791	G/A	cg06784218	chr1:46089804	CCDC17	0.36	6.25	0.38	1.93e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6456156	0.792	rs10946214	chr6:167516122	G/A	cg23791538	chr6:167370224	RNASET2	-0.41	-5.2	-0.32	4.3e-7	Primary biliary cholangitis;
SARC	cis	rs6670533	0.571	rs16829805	chr1:24860590	C/T	cg07475527	chr1:24864545	NA	-1.0	-5.65	-0.35	4.76e-8	Fasting blood insulin (BMI interaction);
SARC	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg13395646	chr4:1353034	KIAA1530	-0.5	-6.0	-0.37	7.57e-9	Obesity-related traits;
SARC	cis	rs57994353	0.861	rs34302850	chr9:139327064	A/G	cg14169450	chr9:139327907	INPP5E	0.42	5.61	0.35	5.6e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs453301	0.686	rs3895823	chr8:8873646	T/C	cg11995313	chr8:8860691	ERI1	0.47	5.93	0.36	1.07e-8	Joint mobility (Beighton score);
SARC	cis	rs11792861	0.926	rs3750451	chr9:111822866	C/T	cg13535736	chr9:111863775	C9orf5	-0.4	-5.01	-0.31	1.09e-6	Menarche (age at onset);
SARC	cis	rs910316	0.934	rs7141705	chr14:75655352	G/C	cg08847533	chr14:75593920	NEK9	-0.87	-13.66	-0.67	1.3e-31	Height;
SARC	cis	rs2742234	0.590	rs1254965	chr10:43689853	C/T	cg15436174	chr10:43711423	RASGEF1A	0.4	4.74	0.3	3.67e-6	Hirschsprung disease;
SARC	cis	rs6840360	0.615	rs12647465	chr4:152607318	C/A	cg22705602	chr4:152727874	NA	-0.48	-8.21	-0.47	1.56e-14	Intelligence (multi-trait analysis);
SARC	cis	rs9393692	0.905	rs6931391	chr6:26279235	G/C	cg13736514	chr6:26305472	NA	-0.61	-8.57	-0.49	1.42e-15	Educational attainment;
SARC	cis	rs698833	0.892	rs1067363	chr2:44658401	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.67	8.76	0.5	4.22e-16	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg16405210	chr4:1374714	KIAA1530	-0.6	-7.31	-0.43	4.25e-12	Longevity;
SARC	cis	rs897080	0.793	rs7557961	chr2:44769962	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.43	4.87	0.3	2.1e-6	Height;
SARC	cis	rs36051895	0.632	rs10815167	chr9:5150058	A/G	cg02405213	chr9:5042618	JAK2	-0.47	-5.62	-0.35	5.56e-8	Pediatric autoimmune diseases;
SARC	cis	rs2153535	0.580	rs7743995	chr6:8496212	A/G	cg07606381	chr6:8435919	SLC35B3	0.8	11.33	0.6	5.29e-24	Motion sickness;
SARC	cis	rs453301	0.686	rs11785819	chr8:8870378	T/G	cg11608241	chr8:8085544	FLJ10661	-0.44	-5.48	-0.34	1.08e-7	Joint mobility (Beighton score);
SARC	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg18876405	chr7:65276391	NA	-0.71	-8.8	-0.5	3.03e-16	Aortic root size;
SARC	cis	rs9513627	1.000	rs9582302	chr13:100125985	A/T	cg25919922	chr13:100150906	NA	-0.66	-5.0	-0.31	1.14e-6	Obesity-related traits;
SARC	cis	rs3820928	0.874	rs2272198	chr2:227893017	A/G	cg11843606	chr2:227700838	RHBDD1	0.55	6.46	0.39	6.09e-10	Pulmonary function;
SARC	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg09359103	chr1:154839909	KCNN3	-0.46	-7.8	-0.45	2.1e-13	Prostate cancer;
SARC	cis	rs2652822	0.550	rs12593078	chr15:63517347	A/G	cg02713581	chr15:63449717	RPS27L	0.52	6.16	0.37	3.25e-9	Metabolic traits;
SARC	cis	rs4803468	0.967	rs3745290	chr19:41890003	C/T	cg09537434	chr19:41945824	ATP5SL	-0.93	-16.21	-0.73	4.56e-40	Height;
SARC	cis	rs1662342	1.000	rs12606445	chr18:3255700	C/T	cg14211874	chr18:3262499	MYL12B	-0.73	-5.46	-0.34	1.23e-7	QRS duration;
SARC	cis	rs8027181	0.839	rs2277598	chr15:73027478	T/C	cg25996835	chr15:72978165	BBS4;HIGD2B	0.45	6.0	0.37	7.46e-9	Triglyceride levels;
SARC	cis	rs7264396	0.563	rs2425109	chr20:34316218	A/G	cg01084648	chr20:34329383	RBM39	0.57	4.97	0.31	1.29e-6	Total cholesterol levels;
SARC	cis	rs477895	1.000	rs11600990	chr11:64082807	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	5.49	0.34	1.04e-7	Mean platelet volume;
SARC	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg10523679	chr1:76189770	ACADM	0.53	6.04	0.37	6.18e-9	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9326248	0.798	rs10892079	chr11:117016824	T/G	cg10130564	chr11:117069849	TAGLN	0.22	4.83	0.3	2.5e-6	Blood protein levels;
SARC	cis	rs11098499	0.954	rs9685777	chr4:120365965	C/A	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg04944784	chr2:26401820	FAM59B	0.63	8.21	0.47	1.49e-14	Gut microbiome composition (summer);
SARC	cis	rs34779708	0.966	rs2505639	chr10:35474421	A/G	cg03585969	chr10:35415529	CREM	-0.43	-5.5	-0.34	9.76e-8	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg12463550	chr7:65579703	CRCP	0.48	5.79	0.35	2.23e-8	Aortic root size;
SARC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg11203670	chr7:100026453	MEPCE;ZCWPW1	0.48	4.83	0.3	2.47e-6	Platelet count;
SARC	cis	rs7044106	0.708	rs2416760	chr9:123374639	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	5.6	0.34	5.95e-8	Hip circumference adjusted for BMI;
SARC	cis	rs6840360	1.000	rs6823002	chr4:152604467	T/G	cg22705602	chr4:152727874	NA	-0.38	-6.53	-0.39	4.17e-10	Intelligence (multi-trait analysis);
SARC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg18404041	chr3:52824283	ITIH1	0.31	4.72	0.3	4.08e-6	Electroencephalogram traits;
SARC	cis	rs7786808	0.615	rs4909212	chr7:158197037	G/T	cg01191920	chr7:158217561	PTPRN2	-0.33	-5.71	-0.35	3.38e-8	Obesity-related traits;
SARC	cis	rs950776	0.720	rs11637890	chr15:78935419	C/G	cg06917634	chr15:78832804	PSMA4	-0.59	-7.54	-0.44	1.07e-12	Sudden cardiac arrest;
SARC	cis	rs6998277	1.000	rs4281092	chr8:103647956	A/G	cg10187029	chr8:103597600	NA	-0.63	-6.65	-0.4	2.03e-10	Migraine;
SARC	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg08067268	chr2:26466485	HADHB;HADHA	0.52	6.51	0.39	4.56e-10	Gut microbiome composition (summer);
SARC	cis	rs834603	0.575	rs1799370	chr7:47467864	C/T	cg23694490	chr7:47445681	TNS3	-0.32	-5.89	-0.36	1.36e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg17221315	chr6:27791827	HIST1H4J	0.51	5.27	0.33	3.11e-7	Parkinson's disease;
SARC	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	21.47	0.82	3.89e-57	Chronic sinus infection;
SARC	cis	rs9790314	0.663	rs12639128	chr3:160639645	A/G	cg04691961	chr3:161091175	C3orf57	0.6	8.31	0.48	8.1e-15	Morning vs. evening chronotype;
SARC	cis	rs4132509	1.000	rs10927043	chr1:243762208	C/T	cg21452805	chr1:244014465	NA	0.49	5.4	0.33	1.62e-7	RR interval (heart rate);
SARC	cis	rs35213789	0.802	rs35696945	chr7:69403462	T/G	cg10619644	chr7:69149951	AUTS2	0.37	4.84	0.3	2.37e-6	Childhood ear infection;
SARC	cis	rs73635312	0.850	rs78539108	chr10:8939198	A/T	cg24467326	chr10:9646929	NA	0.74	5.92	0.36	1.17e-8	Basal cell carcinoma;
SARC	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.31	-4.88	-0.3	1.94e-6	Total body bone mineral density;
SARC	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg25072359	chr17:41440525	NA	0.47	5.49	0.34	1.02e-7	Menopause (age at onset);
SARC	cis	rs57502260	0.704	rs17149179	chr11:68351722	C/T	cg01657329	chr11:68192670	LRP5	-0.57	-5.64	-0.35	4.98e-8	Total body bone mineral density (age 45-60);
SARC	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg02524346	chr8:600233	NA	0.91	7.09	0.42	1.59e-11	IgG glycosylation;
SARC	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg25894440	chr7:65020034	NA	-0.71	-5.4	-0.33	1.62e-7	Diabetic kidney disease;
SARC	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg23758822	chr17:41437982	NA	0.86	10.56	0.57	1.52e-21	Menopause (age at onset);
SARC	cis	rs9297145	0.509	rs13222381	chr7:98785024	T/G	cg05967295	chr7:98741636	SMURF1	-0.5	-5.92	-0.36	1.15e-8	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
SARC	cis	rs951366	0.553	rs10900522	chr1:205684067	T/C	cg11965913	chr1:205819406	PM20D1	-0.45	-5.15	-0.32	5.66e-7	Menarche (age at onset);
SARC	cis	rs995000	0.931	rs12062275	chr1:62991905	T/C	cg06896770	chr1:63153194	DOCK7	-0.88	-12.57	-0.64	5.16e-28	Triglyceride levels;
SARC	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.93	-13.87	-0.67	2.78e-32	Gut microbiome composition (summer);
SARC	cis	rs33912345	0.695	rs1254314	chr14:60896434	G/C	cg27398547	chr14:60952738	C14orf39	-0.39	-4.82	-0.3	2.62e-6	Glaucoma (high intraocular pressure);
SARC	cis	rs9325144	0.671	rs7486919	chr12:38767997	A/G	cg26384229	chr12:38710491	ALG10B	-0.59	-7.74	-0.45	2.92e-13	Morning vs. evening chronotype;
SARC	cis	rs6940638	0.688	rs9295730	chr6:27128806	T/C	cg12826209	chr6:26865740	GUSBL1	0.55	6.0	0.37	7.47e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7520050	0.966	rs6668284	chr1:46354510	G/A	cg24296786	chr1:45957014	TESK2	0.39	4.96	0.31	1.33e-6	Red blood cell count;Reticulocyte count;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg05725452	chr22:21996709	SDF2L1	-0.77	-6.28	-0.38	1.68e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg00149659	chr3:10157352	C3orf10	0.7	6.89	0.41	5.14e-11	Alzheimer's disease;
SARC	cis	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg09021430	chr5:549028	NA	-0.45	-5.55	-0.34	7.66e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs7512552	0.839	rs1498308	chr1:150295131	G/T	cg15654264	chr1:150340011	RPRD2	0.37	4.73	0.3	3.95e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs6060717	0.536	rs11696912	chr20:34497660	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.68	5.83	0.36	1.81e-8	Hip circumference adjusted for BMI;
SARC	cis	rs926392	0.572	rs6129159	chr20:37675011	A/T	cg16355469	chr20:37678765	NA	0.76	9.79	0.54	3.53e-19	Dialysis-related mortality;
SARC	cis	rs55883249	0.957	rs62119431	chr2:9750461	G/A	cg23886495	chr2:9695866	ADAM17	0.69	6.79	0.41	9.29e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs2288073	0.965	rs10185445	chr2:24410976	A/C	cg26838691	chr2:24397539	C2orf84	0.55	6.79	0.41	9.37e-11	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs11785400	1.000	rs4297023	chr8:143733307	C/A	cg24634471	chr8:143751801	JRK	0.67	9.05	0.51	5.93e-17	Schizophrenia;
SARC	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg11247378	chr22:39784982	NA	-0.32	-5.14	-0.32	5.95e-7	Intelligence (multi-trait analysis);
SARC	cis	rs4481887	0.861	rs4575112	chr1:248473534	A/G	cg13385794	chr1:248469461	NA	0.35	5.45	0.34	1.29e-7	Common traits (Other);
SARC	cis	rs478304	0.651	rs11532071	chr11:65500198	C/A	cg26695010	chr11:65641043	EFEMP2	0.39	4.78	0.3	3.1e-6	Acne (severe);
SARC	cis	rs6908034	0.505	rs76709285	chr6:19804330	C/G	cg02682789	chr6:19804855	NA	0.72	5.23	0.32	3.82e-7	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs7264396	0.580	rs2425173	chr20:34445142	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-6.42	-0.39	7.51e-10	Total cholesterol levels;
SARC	cis	rs8084125	0.832	rs62105179	chr18:74950858	A/G	cg07390210	chr18:74961196	GALR1	0.56	6.39	0.39	8.73e-10	Obesity-related traits;
SARC	cis	rs6991838	0.584	rs6991731	chr8:66555467	A/G	cg13398993	chr8:66546079	ARMC1	0.6	7.71	0.45	3.62e-13	Intelligence (multi-trait analysis);
SARC	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg04277193	chr17:41438351	NA	0.44	4.78	0.3	3.04e-6	Menopause (age at onset);
SARC	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg07701084	chr6:150067640	NUP43	0.42	5.56	0.34	7.54e-8	Lung cancer;
SARC	cis	rs3540	0.574	rs2657947	chr15:90968977	C/T	cg22089800	chr15:90895588	ZNF774	-0.63	-8.06	-0.47	4.08e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg22496380	chr5:211416	CCDC127	-0.84	-8.6	-0.49	1.19e-15	Breast cancer;
SARC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg14893161	chr1:205819251	PM20D1	1.03	21.32	0.81	1.16e-56	Menarche (age at onset);
SARC	cis	rs7089973	0.604	rs58587374	chr10:116597572	A/G	cg03647239	chr10:116582469	FAM160B1	0.5	6.48	0.39	5.49e-10	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.41	-6.76	-0.4	1.1e-10	Total body bone mineral density;
SARC	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg03351412	chr1:154909251	PMVK	0.65	8.47	0.48	2.88e-15	Prostate cancer;
SARC	cis	rs7223966	1.000	rs8067064	chr17:61825984	A/C	cg26338869	chr17:61819248	STRADA	0.47	5.0	0.31	1.13e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs12497850	1.000	rs1352420	chr3:48757291	A/G	cg03060546	chr3:49711283	APEH	0.41	5.14	0.32	5.75e-7	Parkinson's disease;
SARC	cis	rs2498796	0.752	rs34802997	chr14:105198822	C/T	cg07523784	chr14:105186699	NA	-0.33	-4.76	-0.3	3.42e-6	Endometrial cancer;Endometrial endometrioid carcinoma;
SARC	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg12463550	chr7:65579703	CRCP	-0.49	-5.24	-0.32	3.63e-7	Aortic root size;
SARC	cis	rs9398803	0.805	rs1591805	chr6:126717064	A/G	cg20229609	chr6:126660872	C6orf173	0.4	5.83	0.36	1.79e-8	Male-pattern baldness;
SARC	cis	rs13082711	0.648	rs13085782	chr3:27404390	C/G	cg02860705	chr3:27208620	NA	0.73	8.64	0.49	8.94e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs72781680	0.821	rs72796325	chr2:24134537	G/A	cg06627628	chr2:24431161	ITSN2	-0.58	-6.2	-0.38	2.52e-9	Lymphocyte counts;
SARC	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg13206674	chr6:150067644	NUP43	0.46	6.02	0.37	6.62e-9	Lung cancer;
SARC	cis	rs6540556	0.723	rs11487866	chr1:209892046	G/A	cg05527609	chr1:210001259	C1orf107	-0.57	-5.38	-0.33	1.82e-7	Red blood cell count;
SARC	cis	rs9914988	0.943	rs11652272	chr17:27167973	C/G	cg20469991	chr17:27169893	C17orf63	-0.5	-4.73	-0.3	3.92e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs9354308	0.809	rs9363461	chr6:66557574	A/G	cg07460842	chr6:66804631	NA	-0.45	-5.18	-0.32	4.78e-7	Metabolite levels;
SARC	cis	rs595982	0.546	rs10401443	chr19:49402059	C/A	cg03707168	chr19:49379127	PPP1R15A	0.47	6.31	0.38	1.42e-9	Red cell distribution width;
SARC	cis	rs889312	0.500	rs3099460	chr5:56133748	G/C	cg14703610	chr5:56206110	C5orf35	0.52	6.49	0.39	5.01e-10	Breast cancer;Breast cancer (early onset);
SARC	cis	rs7917772	0.582	rs10883736	chr10:104320029	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.5	6.86	0.41	6.17e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs6963495	0.818	rs6973263	chr7:105170293	A/G	cg19920283	chr7:105172520	RINT1	0.67	5.76	0.35	2.59e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs2280630	0.898	rs1828679	chr3:39195507	C/T	cg26331595	chr3:39149181	GORASP1;TTC21A	0.44	4.96	0.31	1.36e-6	Verbal declarative memory;
SARC	cis	rs7208859	0.673	rs11654914	chr17:29229424	C/G	cg13385521	chr17:29058706	SUZ12P	0.85	7.23	0.43	7.08e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs4727027	0.899	rs4727025	chr7:148862863	A/G	cg23583168	chr7:148888333	NA	-0.73	-11.03	-0.59	4.91e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs17376456	1.000	rs12188453	chr5:93560807	G/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.59	-5.25	-0.33	3.44e-7	Diabetic retinopathy;
SARC	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg22168489	chr12:122356033	WDR66	0.66	10.11	0.55	3.64e-20	Mean corpuscular volume;
SARC	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg09359103	chr1:154839909	KCNN3	-0.46	-7.63	-0.45	5.94e-13	Prostate cancer;
SARC	cis	rs2153535	0.580	rs1577466	chr6:8444192	T/C	cg07606381	chr6:8435919	SLC35B3	0.79	11.13	0.59	2.34e-23	Motion sickness;
SARC	cis	rs9392918	0.934	rs1575290	chr6:7715689	C/T	cg23089261	chr6:7723385	NA	0.39	5.19	0.32	4.52e-7	Height;
SARC	cis	rs7847628	0.765	rs7026635	chr9:123550027	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.65	-6.9	-0.41	5e-11	Birth weight;
SARC	cis	rs6815814	0.950	rs11722813	chr4:38810769	C/T	cg06935464	chr4:38784597	TLR10	0.63	6.41	0.39	8.04e-10	Breast cancer;
SARC	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-9.18	-0.52	2.35e-17	Alzheimer's disease;
SARC	trans	rs11722228	0.522	rs881641	chr4:10133747	G/A	cg26043149	chr18:55253948	FECH	0.79	9.68	0.54	7.45e-19	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg23758822	chr17:41437982	NA	0.9	11.47	0.6	1.98e-24	Menopause (age at onset);
SARC	cis	rs7666738	0.830	rs10012003	chr4:99064881	A/G	cg05340658	chr4:99064831	C4orf37	0.65	8.7	0.5	6.15e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9788682	0.747	rs11072766	chr15:78771546	C/T	cg06917634	chr15:78832804	PSMA4	-0.53	-5.5	-0.34	1.02e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs6942407	0.546	rs7780698	chr7:86835731	T/G	cg02420886	chr7:86849541	C7orf23	0.71	5.96	0.36	9.37e-9	Food allergy;
SARC	cis	rs17345786	0.906	rs11708616	chr3:101231731	C/T	cg12386194	chr3:101231763	SENP7	0.81	9.85	0.54	2.29e-19	Colonoscopy-negative controls vs population controls;
SARC	cis	rs17376456	0.778	rs10440717	chr5:93424852	C/A	cg25358565	chr5:93447407	FAM172A	1.31	15.17	0.7	1.33e-36	Diabetic retinopathy;
SARC	cis	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg05623727	chr3:50126028	RBM5	0.33	4.92	0.31	1.63e-6	Intelligence (multi-trait analysis);
SARC	cis	rs1448094	0.511	rs17345975	chr12:86202318	T/A	cg02569458	chr12:86230093	RASSF9	0.39	5.4	0.33	1.63e-7	Major depressive disorder;
SARC	cis	rs1904096	0.506	rs4693378	chr4:95168552	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.47	-7.07	-0.42	1.74e-11	Type 2 diabetes;
SARC	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg04772025	chr11:68637568	NA	0.53	6.5	0.39	4.7e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	trans	rs79976124	0.879	rs12214239	chr6:66636059	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	7.73	0.45	3.16e-13	Type 2 diabetes;
SARC	cis	rs6582630	0.599	rs8189525	chr12:38424982	A/C	cg13010199	chr12:38710504	ALG10B	0.47	5.76	0.35	2.67e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9303280	0.806	rs34189114	chr17:38032460	C/T	cg20243544	chr17:37824526	PNMT	0.42	5.52	0.34	9.01e-8	Self-reported allergy;
SARC	cis	rs12478296	0.581	rs4973645	chr2:242993577	T/C	cg18898632	chr2:242989856	NA	-0.58	-4.81	-0.3	2.67e-6	Obesity-related traits;
SARC	trans	rs7824557	0.578	rs2060458	chr8:11212811	C/A	cg06636001	chr8:8085503	FLJ10661	0.55	6.72	0.4	1.39e-10	Retinal vascular caliber;
SARC	cis	rs9436747	0.641	rs3790425	chr1:66043112	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.49	-5.12	-0.32	6.51e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs453301	0.658	rs3855900	chr8:8901921	A/G	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.43	-0.39	7.11e-10	Joint mobility (Beighton score);
SARC	cis	rs4722166	0.630	rs12700391	chr7:22777327	C/A	cg26061582	chr7:22766209	IL6	0.57	6.19	0.38	2.73e-9	Lung cancer;
SARC	cis	rs3820928	0.904	rs4414671	chr2:227816200	T/A	cg11843606	chr2:227700838	RHBDD1	-0.57	-7.27	-0.43	5.32e-12	Pulmonary function;
SARC	cis	rs11098499	0.954	rs3890049	chr4:120326283	T/A	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg22920501	chr2:26401640	FAM59B	0.61	7.99	0.46	6.18e-14	Mean corpuscular hemoglobin;
SARC	cis	rs9790314	0.871	rs339114	chr3:161109220	C/T	cg03342759	chr3:160939853	NMD3	0.58	7.27	0.43	5.49e-12	Morning vs. evening chronotype;
SARC	cis	rs854765	0.552	rs11078407	chr17:17841083	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.43	5.61	0.35	5.66e-8	Total body bone mineral density;
SARC	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg08219700	chr8:58056026	NA	0.7	6.57	0.4	3.22e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs4481887	1.000	rs7553333	chr1:248493956	C/G	cg13385794	chr1:248469461	NA	0.36	5.39	0.33	1.74e-7	Common traits (Other);
SARC	cis	rs9916302	0.904	rs12452880	chr17:37591149	G/C	cg20243544	chr17:37824526	PNMT	0.55	6.56	0.39	3.39e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs12472274	0.646	rs11688732	chr2:239096622	G/T	cg17459225	chr2:239074497	NA	0.6	6.17	0.37	2.93e-9	Phospholipid levels (plasma);
SARC	cis	rs2594989	0.943	rs2594970	chr3:11400877	C/T	cg00170343	chr3:11313890	ATG7	0.58	5.53	0.34	8.4e-8	Circulating chemerin levels;
SARC	cis	rs2197308	0.692	rs7488528	chr12:37912971	G/A	cg26384229	chr12:38710491	ALG10B	0.9	13.34	0.66	1.53e-30	Morning vs. evening chronotype;
SARC	trans	rs3804024	0.881	rs55918548	chr21:41983938	A/G	cg03228353	chr1:161520094	FCGR3A	0.57	7.05	0.42	2.03e-11	Obesity-related traits;
SARC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.09	0.8	9.09e-53	Prudent dietary pattern;
SARC	cis	rs6882046	0.513	rs254779	chr5:88019629	T/C	cg22951263	chr5:87985283	NA	-0.36	-4.78	-0.3	3.16e-6	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
SARC	trans	rs2727020	0.553	rs11040400	chr11:49518296	C/A	cg15704280	chr7:45808275	SEPT13	-0.82	-12.97	-0.65	2.62e-29	Coronary artery disease;
SARC	cis	rs12134245	0.742	rs17501381	chr1:92003919	A/G	cg02896835	chr1:92012615	NA	-0.53	-7.25	-0.43	6.01e-12	Breast cancer;
SARC	trans	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg00938859	chr5:1591904	SDHAP3	0.76	7.34	0.43	3.49e-12	Breast cancer;
SARC	cis	rs9398803	0.687	rs4243491	chr6:126938536	T/C	cg19875578	chr6:126661172	C6orf173	0.63	8.7	0.5	5.9e-16	Male-pattern baldness;
SARC	trans	rs2727020	0.637	rs1164673	chr11:49328356	C/G	cg15704280	chr7:45808275	SEPT13	0.64	8.88	0.5	1.83e-16	Coronary artery disease;
SARC	cis	rs12681366	0.571	rs2930959	chr8:95474158	C/T	cg26464482	chr8:95565502	KIAA1429	0.42	5.24	0.32	3.64e-7	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.47	-5.82	-0.36	1.93e-8	Tonsillectomy;
SARC	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg18876405	chr7:65276391	NA	-0.68	-8.88	-0.5	1.89e-16	Corneal structure;
SARC	cis	rs7546	0.504	rs2075637	chr16:4938280	T/C	cg08329684	chr16:4932620	PPL	-0.43	-6.82	-0.41	7.67e-11	Cancer;
SARC	cis	rs137603	0.623	rs137657	chr22:39733242	G/T	cg01093212	chr22:39715156	SNORD43;RPL3	-0.58	-6.98	-0.42	3.03e-11	Primary biliary cholangitis;
SARC	cis	rs7829975	0.623	rs7010753	chr8:8373956	A/G	cg08975724	chr8:8085496	FLJ10661	0.45	5.5	0.34	1.02e-7	Mood instability;
SARC	cis	rs9788682	0.747	rs2656072	chr15:78744292	A/G	cg24631222	chr15:78858424	CHRNA5	-0.75	-9.33	-0.52	8.73e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs2439831	0.867	rs28461955	chr15:43661459	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	8.36	0.48	5.82e-15	Lung cancer in ever smokers;
SARC	cis	rs9479482	0.967	rs61730071	chr6:150342232	G/A	cg03788504	chr6:150331562	NA	-0.33	-5.44	-0.34	1.34e-7	Alopecia areata;
SARC	trans	rs61931739	0.500	rs11053273	chr12:34547255	C/T	cg13010199	chr12:38710504	ALG10B	0.83	11.73	0.61	2.89e-25	Morning vs. evening chronotype;
SARC	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg15847926	chr7:2749597	AMZ1	-0.31	-4.89	-0.31	1.87e-6	Height;
SARC	cis	rs3814113	0.586	rs10962662	chr9:16889937	C/A	cg13173848	chr9:16870893	BNC2	-0.42	-5.09	-0.32	7.51e-7	Epithelial ovarian cancer;Ovarian cancer in BRCA1 mutation carriers;Ovarian cancer;
SARC	cis	rs1322639	0.571	rs13204417	chr6:169575355	G/A	cg04662567	chr6:169592167	NA	0.39	5.14	0.32	5.68e-7	Pulse pressure;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg20861091	chr8:144881744	SCRIB	-0.72	-6.24	-0.38	2.04e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1152591	0.543	rs1152592	chr14:64676098	A/G	cg23250157	chr14:64679961	SYNE2	0.45	6.26	0.38	1.82e-9	Atrial fibrillation;
SARC	cis	rs2075371	0.830	rs1421478	chr7:133922793	T/A	cg20476274	chr7:133979776	SLC35B4	0.53	6.78	0.41	9.88e-11	Mean platelet volume;
SARC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg08677398	chr8:58056175	NA	0.44	5.27	0.33	3.14e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6912958	0.559	rs242281	chr6:88048916	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.34	5.91	0.36	1.2e-8	Monocyte percentage of white cells;
SARC	cis	rs72781680	0.846	rs72782114	chr2:24025740	G/A	cg06627628	chr2:24431161	ITSN2	-0.66	-6.27	-0.38	1.69e-9	Lymphocyte counts;
SARC	cis	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg21573476	chr21:45109991	RRP1B	-0.55	-7.99	-0.46	6.23e-14	Mean corpuscular volume;
SARC	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.57	7.08	0.42	1.69e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg09021430	chr5:549028	NA	-0.45	-5.69	-0.35	3.74e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs3870371	0.868	rs11774882	chr8:122702067	T/C	cg21781600	chr8:122651575	HAS2;HAS2AS	0.48	5.45	0.34	1.3e-7	Periodontal disease-related phenotypes;
SARC	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg04277193	chr17:41438351	NA	0.46	4.98	0.31	1.23e-6	Menopause (age at onset);
SARC	cis	rs734999	0.588	rs3748818	chr1:2525660	G/A	cg20673091	chr1:2541236	MMEL1	0.33	5.1	0.32	7.12e-7	Ulcerative colitis;
SARC	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg07701084	chr6:150067640	NUP43	0.41	5.4	0.33	1.63e-7	Lung cancer;
SARC	cis	rs9420	0.961	rs527528	chr11:57433327	C/T	cg19752551	chr11:57585705	CTNND1	-0.4	-5.5	-0.34	9.99e-8	Schizophrenia;
SARC	cis	rs870825	0.616	rs7700216	chr4:185648510	G/T	cg04058563	chr4:185651563	MLF1IP	0.8	11.35	0.6	4.56e-24	Blood protein levels;
SARC	cis	rs831571	0.668	rs17069879	chr3:64083417	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	0.57	4.9	0.31	1.78e-6	Type 2 diabetes;
SARC	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg02951883	chr7:2050386	MAD1L1	-0.48	-6.11	-0.37	4.1e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs3126085	0.935	rs1496049	chr1:152161949	C/T	cg26876637	chr1:152193138	HRNR	-0.49	-5.52	-0.34	9.02e-8	Atopic dermatitis;
SARC	cis	rs11785400	0.793	rs7000765	chr8:143722457	G/A	cg10596483	chr8:143751796	JRK	0.59	7.62	0.45	6.25e-13	Schizophrenia;
SARC	cis	rs8014204	0.566	rs9441	chr14:75128425	G/A	cg17347104	chr14:75034677	LTBP2	-0.53	-7.03	-0.42	2.27e-11	Caffeine consumption;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg10314295	chr10:75936245	ADK	0.52	6.55	0.39	3.6e-10	Lung adenocarcinoma;
SARC	cis	rs3820928	0.967	rs4675113	chr2:227766339	G/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-6.68	-0.4	1.72e-10	Pulmonary function;
SARC	cis	rs9457247	0.765	rs9457256	chr6:167436461	T/C	cg23791538	chr6:167370224	RNASET2	-0.52	-6.8	-0.41	8.54e-11	Crohn's disease;
SARC	cis	rs11105298	0.891	rs4842661	chr12:89930399	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.55	-5.56	-0.34	7.43e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg12463550	chr7:65579703	CRCP	-0.49	-5.36	-0.33	1.98e-7	Aortic root size;
SARC	cis	rs7681440	0.835	rs7656954	chr4:90784670	G/A	cg06632027	chr4:90757378	SNCA	0.4	5.58	0.34	6.52e-8	Dementia with Lewy bodies;
SARC	cis	rs55823223	0.648	rs11869977	chr17:73857382	C/G	cg06969265	chr17:73775802	H3F3B	0.58	6.12	0.37	3.94e-9	Psoriasis;
SARC	cis	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg08975724	chr8:8085496	FLJ10661	0.51	6.56	0.4	3.35e-10	Mood instability;
SARC	cis	rs4727027	0.754	rs917124	chr7:148851213	C/T	cg23583168	chr7:148888333	NA	-0.75	-10.73	-0.58	4.2e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg18252515	chr7:66147081	NA	0.53	5.6	0.34	5.91e-8	Aortic root size;
SARC	cis	rs4699052	1.000	rs6533060	chr4:104139996	T/C	cg16532752	chr4:104119610	CENPE	-0.41	-4.86	-0.3	2.2e-6	Testicular germ cell tumor;
SARC	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg11764359	chr7:65958608	NA	-0.83	-11.1	-0.59	2.96e-23	Aortic root size;
SARC	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg06028808	chr11:68637592	NA	0.42	5.4	0.33	1.62e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs1562975	0.609	rs55707402	chr4:109418264	T/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.47	6.11	0.37	4.16e-9	Height;
SARC	cis	rs9393692	0.627	rs1059486	chr6:26200083	A/G	cg00631329	chr6:26305371	NA	-0.56	-7.6	-0.45	7.3e-13	Educational attainment;
SARC	cis	rs6604026	0.656	rs12745968	chr1:93401837	C/T	cg17283838	chr1:93427260	FAM69A	-0.42	-4.98	-0.31	1.21e-6	Multiple sclerosis;
SARC	cis	rs875971	0.545	rs73142233	chr7:65686280	T/A	cg11764359	chr7:65958608	NA	0.67	6.58	0.4	3.01e-10	Aortic root size;
SARC	cis	rs62432291	0.681	rs385438	chr6:159656213	A/G	cg14500486	chr6:159655392	FNDC1	-0.62	-6.23	-0.38	2.17e-9	Joint mobility (Beighton score);
SARC	cis	rs787274	1.000	rs1418410	chr9:115465282	A/G	cg13803584	chr9:115635662	SNX30	0.7	5.4	0.33	1.65e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs35213789	0.878	rs12698851	chr7:69577279	A/G	cg10619644	chr7:69149951	AUTS2	0.42	5.16	0.32	5.37e-7	Childhood ear infection;
SARC	cis	rs637571	0.522	rs566590	chr11:65754062	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.59	9.16	0.51	2.73e-17	Eosinophil percentage of white cells;
SARC	cis	rs6570726	0.935	rs585292	chr6:145862228	T/C	cg05347473	chr6:146136440	FBXO30	0.49	6.58	0.4	3.04e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs514406	0.505	rs405208	chr1:53176674	C/T	cg24675658	chr1:53192096	ZYG11B	-0.65	-9.47	-0.53	3.39e-18	Monocyte count;
SARC	cis	rs11651753	0.561	rs61422354	chr17:45969809	A/G	cg02219949	chr17:45927392	SP6	0.36	4.95	0.31	1.45e-6	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg11987759	chr7:65425863	GUSB	-0.48	-6.54	-0.39	3.93e-10	Aortic root size;
SARC	cis	rs1691799	0.863	rs1168291	chr12:66732488	T/C	cg16791601	chr12:66731901	HELB	-0.71	-10.66	-0.57	7.26e-22	White blood cell count (basophil);
SARC	cis	rs9443189	0.526	rs10943250	chr6:76208445	C/G	cg01950844	chr6:76311363	SENP6	0.88	7.2	0.43	8.13e-12	Prostate cancer;
SARC	cis	rs72720396	0.694	rs6689362	chr1:91203251	T/A	cg24453699	chr1:91190891	NA	-0.34	-4.73	-0.3	3.82e-6	Morning vs. evening chronotype;Chronotype;
SARC	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg23262073	chr20:60523788	NA	-0.39	-5.68	-0.35	3.92e-8	Body mass index;
SARC	cis	rs3087591	0.960	rs2905878	chr17:29511199	T/C	cg24425628	chr17:29625626	OMG;NF1	0.5	6.19	0.38	2.68e-9	Hip circumference;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg20564764	chr5:146833171	DPYSL3	0.52	6.51	0.39	4.66e-10	Breast cancer;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12832630	chr3:43732303	ABHD5	0.53	6.49	0.39	5.25e-10	Fibrinogen levels;
SARC	cis	rs981844	0.736	rs1036614	chr4:154639105	G/A	cg14289246	chr4:154710475	SFRP2	0.51	5.26	0.33	3.19e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs10992471	0.651	rs10124058	chr9:95522882	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.42	-4.84	-0.3	2.33e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg21548813	chr6:291882	DUSP22	-0.64	-8.35	-0.48	6.28e-15	Menopause (age at onset);
SARC	cis	rs6901004	0.688	rs34151782	chr6:111574537	T/A	cg15721981	chr6:111408429	SLC16A10	0.46	5.52	0.34	8.88e-8	Blood metabolite levels;
SARC	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg22862634	chr11:62369728	EML3;MTA2	-0.46	-6.27	-0.38	1.74e-9	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs12477438	0.715	rs7586608	chr2:99558017	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-9.7	-0.54	6.71e-19	Chronic sinus infection;
SARC	cis	rs57994353	0.793	rs35531907	chr9:139327143	C/T	cg13611204	chr9:139324423	INPP5E	-0.3	-5.21	-0.32	4.06e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg17971929	chr21:40555470	PSMG1	-0.56	-7.07	-0.42	1.79e-11	Menarche (age at onset);
SARC	cis	rs11098499	0.780	rs7680914	chr4:120563053	A/G	cg09307838	chr4:120376055	NA	0.87	11.94	0.62	6.05e-26	Corneal astigmatism;
SARC	cis	rs921968	0.545	rs2433738	chr2:219551036	T/A	cg02176678	chr2:219576539	TTLL4	-0.33	-4.85	-0.3	2.28e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg11890956	chr21:40555474	PSMG1	1.16	19.13	0.78	1.1e-49	Cognitive function;
SARC	cis	rs79149102	0.579	rs8033125	chr15:75374970	G/C	cg09165964	chr15:75287851	SCAMP5	-0.9	-8.5	-0.49	2.23e-15	Lung cancer;
SARC	cis	rs796364	0.760	rs74993507	chr2:201068684	C/A	cg23649088	chr2:200775458	C2orf69	-0.64	-5.41	-0.33	1.53e-7	Schizophrenia;
SARC	cis	rs6693567	0.565	rs8006	chr1:150280801	G/C	cg09579323	chr1:150459698	TARS2	-0.41	-5.26	-0.33	3.34e-7	Migraine;
SARC	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.9	-0.5	1.61e-16	Alzheimer's disease;
SARC	cis	rs11718455	0.767	rs6771202	chr3:43990087	A/T	cg08738300	chr3:44038990	NA	0.52	5.72	0.35	3.25e-8	Coronary artery disease;
SARC	cis	rs6484504	0.532	rs10835757	chr11:31281902	C/T	cg26647111	chr11:31128758	NA	-0.38	-4.91	-0.31	1.72e-6	Red blood cell count;
SARC	trans	rs62103177	0.810	rs62103187	chr18:77627633	G/C	cg05926928	chr17:57297772	GDPD1	1.09	9.19	0.52	2.24e-17	Opioid sensitivity;
SARC	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg21160192	chr5:180229544	MGAT1	-0.53	-6.55	-0.39	3.69e-10	Migraine with aura;
SARC	cis	rs6912958	0.559	rs107689	chr6:88069333	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.78	12.12	0.62	1.51e-26	Monocyte percentage of white cells;
SARC	cis	rs11690935	1.000	rs6721680	chr2:172543913	G/T	cg13550731	chr2:172543902	DYNC1I2	1.0	15.32	0.71	4.08e-37	Schizophrenia;
SARC	cis	rs4481887	0.927	rs7524700	chr1:248472816	A/G	cg13385794	chr1:248469461	NA	0.34	5.32	0.33	2.46e-7	Common traits (Other);
SARC	trans	rs1814175	0.746	rs10839429	chr11:49906845	G/A	cg03929089	chr4:120376271	NA	-0.88	-13.97	-0.68	1.25e-32	Height;
SARC	cis	rs13082711	0.522	rs514668	chr3:27330972	A/G	cg02860705	chr3:27208620	NA	0.47	6.26	0.38	1.86e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs1003719	0.715	rs2835644	chr21:38545610	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.48	-0.53	3.11e-18	Eye color traits;
SARC	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg17971929	chr21:40555470	PSMG1	-0.86	-11.56	-0.6	9.68e-25	Cognitive function;
SARC	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg21442419	chr1:2182373	SKI	-0.48	-6.31	-0.38	1.36e-9	Height;
SARC	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-5.72	-0.35	3.23e-8	Electroencephalogram traits;
SARC	cis	rs524281	0.861	rs2293121	chr11:65961347	T/G	cg14036092	chr11:66035641	RAB1B	-0.49	-5.18	-0.32	4.9e-7	Electroencephalogram traits;
SARC	cis	rs9916302	0.904	rs3744348	chr17:37417575	C/G	cg00129232	chr17:37814104	STARD3	-0.59	-7.39	-0.44	2.61e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs6964587	0.904	rs6465339	chr7:91570790	T/A	cg17063962	chr7:91808500	NA	-0.92	-14.57	-0.69	1.25e-34	Breast cancer;
SARC	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	7.38	0.44	2.79e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs11969893	0.850	rs9404058	chr6:101323078	T/C	cg12253828	chr6:101329408	ASCC3	1.25	7.85	0.46	1.55e-13	Economic and political preferences (immigration/crime);
SARC	cis	rs6088580	0.567	rs6088520	chr20:33132364	A/G	cg08999081	chr20:33150536	PIGU	-0.37	-5.34	-0.33	2.26e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs6835098	1.000	rs10011724	chr4:174088865	A/G	cg08422745	chr4:174089978	GALNT7	-0.77	-10.37	-0.56	5.62e-21	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs643472	0.540	rs79127334	chr8:29042069	T/C	cg07962641	chr8:28805897	HMBOX1	-0.68	-6.37	-0.39	9.81e-10	Corticobasal degeneration;
SARC	cis	rs1421811	0.606	rs10057069	chr5:32716589	A/G	cg16267343	chr5:32710456	NPR3	0.87	11.62	0.61	6.21e-25	Blood pressure;
SARC	cis	rs11785400	0.793	rs9297972	chr8:143723660	C/T	cg10596483	chr8:143751796	JRK	0.57	7.39	0.44	2.61e-12	Schizophrenia;
SARC	cis	rs7815944	1.000	rs72609869	chr8:129457834	T/C	cg08588859	chr8:128903227	PVT1	0.75	4.78	0.3	3.08e-6	Atopic dermatitis;
SARC	cis	rs11718455	0.960	rs34241796	chr3:44000394	A/T	cg08738300	chr3:44038990	NA	0.54	6.12	0.37	3.93e-9	Coronary artery disease;
SARC	cis	rs9790314	0.690	rs6799130	chr3:160847801	C/G	cg03342759	chr3:160939853	NMD3	-0.57	-7.3	-0.43	4.47e-12	Morning vs. evening chronotype;
SARC	cis	rs12479064	0.694	rs4341989	chr2:100046783	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.5	-5.93	-0.36	1.1e-8	Chronic sinus infection;
SARC	cis	rs708547	0.624	rs1277284	chr4:57855361	T/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.63	8.66	0.49	7.95e-16	Response to bleomycin (chromatid breaks);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg24713789	chr21:45285448	AGPAT3	0.53	7.17	0.43	9.79e-12	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs2380220	0.872	rs2613529	chr6:95945036	C/T	cg04719120	chr6:96025338	MANEA	-0.64	-6.4	-0.39	8.45e-10	Behavioural disinhibition (generation interaction);
SARC	cis	rs12701220	0.894	rs2141274	chr7:1034717	G/A	cg02733842	chr7:1102375	C7orf50	-0.58	-6.98	-0.42	2.98e-11	Bronchopulmonary dysplasia;
SARC	cis	rs10979	1.000	rs6905264	chr6:143894378	A/G	cg25407410	chr6:143891975	LOC285740	-0.64	-8.78	-0.5	3.67e-16	Hypospadias;
SARC	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg03354898	chr7:1950403	MAD1L1	-0.38	-5.18	-0.32	4.72e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg25072359	chr17:41440525	NA	0.51	6.13	0.37	3.66e-9	Menopause (age at onset);
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg01341170	chr16:12996338	SHISA9	-0.55	-7.41	-0.44	2.33e-12	Electrocardiographic conduction measures;
SARC	cis	rs858239	0.539	rs57864591	chr7:23184424	T/A	cg23682824	chr7:23144976	KLHL7	0.72	9.36	0.52	7.22e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg11644478	chr21:40555479	PSMG1	1.05	15.19	0.71	1.11e-36	Cognitive function;
SARC	cis	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg00800038	chr16:89945340	TCF25	-0.78	-5.4	-0.33	1.6e-7	Skin colour saturation;
SARC	cis	rs7223966	1.000	rs28463311	chr17:61919643	C/T	cg26338869	chr17:61819248	STRADA	0.52	5.44	0.34	1.37e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2377585	0.653	rs6487333	chr12:8848929	A/T	cg03761649	chr12:8850719	RIMKLB	-0.42	-4.76	-0.3	3.41e-6	Reticulocyte fraction of red cells;
SARC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg21548813	chr6:291882	DUSP22	-0.6	-7.84	-0.46	1.59e-13	Menopause (age at onset);
SARC	cis	rs6728642	1.000	rs6728642	chr2:97607071	A/G	cg26665480	chr2:98280029	ACTR1B	-0.56	-4.96	-0.31	1.38e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg23758822	chr17:41437982	NA	0.82	9.03	0.51	6.59e-17	Menopause (age at onset);
SARC	cis	rs4789939	0.528	rs2377003	chr17:76878902	T/C	cg19944656	chr17:76876040	TIMP2	-0.66	-4.83	-0.3	2.46e-6	Dupuytren's disease;
SARC	cis	rs9807989	0.507	rs4851577	chr2:103028921	T/C	cg03938978	chr2:103052716	IL18RAP	0.31	4.96	0.31	1.34e-6	Asthma;
SARC	cis	rs559928	0.593	rs112275221	chr11:63936994	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	5.12	0.32	6.44e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs6088580	0.713	rs1884669	chr20:33171287	G/A	cg08999081	chr20:33150536	PIGU	0.44	6.78	0.41	1e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs4925386	1.000	rs2151512	chr20:60913495	T/C	cg22633769	chr20:60982531	CABLES2	-0.45	-4.96	-0.31	1.39e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs11651000	0.625	rs2074190	chr17:45811210	A/G	cg03474202	chr17:45855739	NA	-0.39	-5.84	-0.36	1.75e-8	IgG glycosylation;
SARC	cis	rs2120019	0.567	rs8037152	chr15:75156996	A/T	cg09165964	chr15:75287851	SCAMP5	-0.94	-10.7	-0.57	5.33e-22	Blood trace element (Zn levels);
SARC	cis	rs734999	0.545	rs6666430	chr1:2698950	G/A	cg00980319	chr1:2560884	MMEL1	-0.34	-4.92	-0.31	1.66e-6	Ulcerative colitis;
SARC	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg13264159	chr8:625131	ERICH1	-0.74	-5.34	-0.33	2.22e-7	IgG glycosylation;
SARC	cis	rs1964356	0.967	rs17701675	chr8:8850633	A/G	cg06636001	chr8:8085503	FLJ10661	-0.48	-5.93	-0.36	1.07e-8	Mean corpuscular volume;
SARC	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg13939156	chr17:80058883	NA	-0.42	-6.48	-0.39	5.51e-10	Blood metabolite levels;
SARC	cis	rs7000551	0.581	rs2293145	chr8:22262654	A/T	cg12081754	chr8:22256438	SLC39A14	0.86	12.55	0.64	6.07e-28	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg27266027	chr21:40555129	PSMG1	0.45	4.8	0.3	2.82e-6	Cognitive function;
SARC	cis	rs9910055	0.529	rs228765	chr17:42186422	C/T	cg19774624	chr17:42201019	HDAC5	0.56	6.81	0.41	8.17e-11	Total body bone mineral density;
SARC	trans	rs1994135	0.692	rs7297538	chr12:33693438	T/C	cg13010199	chr12:38710504	ALG10B	0.75	8.86	0.5	2.11e-16	Resting heart rate;
SARC	cis	rs72627123	0.867	rs8020310	chr14:74494437	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.76	5.99	0.37	7.73e-9	Morning vs. evening chronotype;
SARC	cis	rs4319547	0.774	rs7295105	chr12:123124225	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.54	-6.35	-0.38	1.12e-9	Body mass index;
SARC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.91	10.78	0.58	3e-22	Platelet count;
SARC	cis	rs9303401	0.659	rs35564417	chr17:56718286	G/T	cg25039879	chr17:56429692	SUPT4H1	0.68	6.5	0.39	4.9e-10	Cognitive test performance;
SARC	cis	rs7296418	0.599	rs2277343	chr12:123794450	A/T	cg00376283	chr12:123451042	ABCB9	0.53	6.51	0.39	4.46e-10	Platelet count;
SARC	cis	rs28669119	0.841	rs10044342	chr5:88178683	C/T	cg18498987	chr5:88179539	MEF2C	-0.58	-5.51	-0.34	9.51e-8	Schizophrenia;
SARC	cis	rs1018836	0.669	rs6471243	chr8:91656967	C/T	cg16814680	chr8:91681699	NA	0.97	18.54	0.77	9.43e-48	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg04944784	chr2:26401820	FAM59B	0.6	7.95	0.46	8.14e-14	Gut microbiome composition (summer);
SARC	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg16479474	chr6:28041457	NA	0.37	5.35	0.33	2.08e-7	Parkinson's disease;
SARC	cis	rs4808199	0.948	rs1859287	chr19:19422187	T/C	cg03709012	chr19:19516395	GATAD2A	1.06	11.03	0.59	4.91e-23	Nonalcoholic fatty liver disease;
SARC	cis	rs9300255	0.596	rs1727331	chr12:123718879	C/G	cg00376283	chr12:123451042	ABCB9	-0.55	-6.52	-0.39	4.43e-10	Neutrophil percentage of white cells;
SARC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.68	6.92	0.41	4.4e-11	Platelet count;
SARC	cis	rs12971120	0.891	rs3794955	chr18:72174827	C/T	cg25817165	chr18:72167213	CNDP2	-0.51	-6.93	-0.41	3.97e-11	Refractive error;
SARC	cis	rs7587476	0.784	rs13032278	chr2:215698034	G/A	cg04530015	chr2:215796436	ABCA12	-0.41	-6.71	-0.4	1.44e-10	Neuroblastoma;
SARC	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg03264133	chr6:25882463	NA	-0.74	-10.15	-0.55	2.84e-20	Urate levels;
SARC	cis	rs2204008	0.805	rs12146846	chr12:37985847	C/T	cg26384229	chr12:38710491	ALG10B	0.89	13.14	0.65	6.99e-30	Bladder cancer;
SARC	cis	rs3733585	0.699	rs12498956	chr4:9950705	G/T	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.56	-0.34	7.32e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs11098499	0.774	rs11098505	chr4:120284627	C/T	cg09307838	chr4:120376055	NA	0.83	11.82	0.61	1.46e-25	Corneal astigmatism;
SARC	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg26818010	chr10:134567672	INPP5A	-0.62	-6.71	-0.4	1.49e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg11764359	chr7:65958608	NA	0.76	8.77	0.5	3.89e-16	Aortic root size;
SARC	cis	rs526231	0.511	rs27896	chr5:102488571	T/C	cg23492399	chr5:102201601	PAM	-0.54	-5.79	-0.35	2.24e-8	Primary biliary cholangitis;
SARC	cis	rs782590	0.967	rs10496050	chr2:55806313	C/T	cg18811423	chr2:55921094	PNPT1	0.68	10.34	0.56	7.14e-21	Metabolic syndrome;
SARC	cis	rs4664308	1.000	rs6707458	chr2:160914540	G/T	cg03641300	chr2:160917029	PLA2R1	-0.67	-8.79	-0.5	3.45e-16	Idiopathic membranous nephropathy;
SARC	cis	rs2204008	0.837	rs11180482	chr12:38235950	G/A	cg13010199	chr12:38710504	ALG10B	0.81	11.19	0.59	1.48e-23	Bladder cancer;
SARC	cis	rs9807989	0.839	rs4988958	chr2:102968285	T/C	cg09003973	chr2:102972529	NA	0.41	5.6	0.34	6.11e-8	Asthma;
SARC	cis	rs6964587	0.934	rs7798973	chr7:91588360	G/A	cg17063962	chr7:91808500	NA	0.95	15.95	0.72	3.15e-39	Breast cancer;
SARC	cis	rs4713118	0.539	rs200988	chr6:27819353	A/C	cg17221315	chr6:27791827	HIST1H4J	0.48	5.49	0.34	1.06e-7	Parkinson's disease;
SARC	cis	rs4243830	0.850	rs908273	chr1:6588604	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.79	-7.95	-0.46	7.84e-14	Body mass index;
SARC	cis	rs1670533	1.000	rs6837145	chr4:1071067	T/C	cg27284194	chr4:1044797	NA	0.44	4.8	0.3	2.8e-6	Recombination rate (females);
SARC	cis	rs17023223	0.537	rs2645301	chr1:119590420	C/T	cg05756136	chr1:119680316	WARS2	-0.45	-5.38	-0.33	1.83e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs1443512	0.812	rs1561987	chr12:54335268	C/T	cg17410650	chr12:54324560	NA	-0.34	-5.34	-0.33	2.17e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
SARC	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg22535103	chr8:58192502	C8orf71	-0.71	-6.82	-0.41	7.73e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg06028808	chr11:68637592	NA	0.48	6.23	0.38	2.15e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7666738	0.830	rs1896154	chr4:99021161	T/C	cg05340658	chr4:99064831	C4orf37	0.66	9.04	0.51	6.35e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs644799	0.965	rs3016295	chr11:95554311	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.9	14.03	0.68	7.73e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2354432	0.607	rs6593751	chr1:146726023	A/G	cg25205988	chr1:146714368	CHD1L	-1.02	-7.73	-0.45	3.15e-13	Mitochondrial DNA levels;
SARC	cis	rs7043114	0.525	rs7023004	chr9:95098712	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.81	-0.36	2.02e-8	Height;
SARC	cis	rs9790314	0.521	rs60625846	chr3:161084525	G/T	cg03342759	chr3:160939853	NMD3	-0.57	-7.11	-0.42	1.45e-11	Morning vs. evening chronotype;
SARC	cis	rs11690935	0.571	rs1008151	chr2:172912098	G/A	cg13550731	chr2:172543902	DYNC1I2	0.57	7.68	0.45	4.46e-13	Schizophrenia;
SARC	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.59	0.34	6.34e-8	Bipolar disorder;
SARC	cis	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg08975724	chr8:8085496	FLJ10661	0.6	7.93	0.46	8.87e-14	Mood instability;
SARC	trans	rs11098499	0.865	rs28634456	chr4:120375778	A/G	cg25214090	chr10:38739885	LOC399744	0.56	7.31	0.43	4.14e-12	Corneal astigmatism;
SARC	trans	rs61931739	0.500	rs7303318	chr12:34467789	T/C	cg26384229	chr12:38710491	ALG10B	0.84	12.43	0.63	1.46e-27	Morning vs. evening chronotype;
SARC	cis	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg25894440	chr7:65020034	NA	-0.74	-5.42	-0.33	1.47e-7	Diabetic kidney disease;
SARC	cis	rs6570726	0.935	rs400968	chr6:145819718	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.54	0.39	3.91e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg18357526	chr6:26021779	HIST1H4A	0.45	5.63	0.35	5.27e-8	Blood metabolite levels;
SARC	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg22875332	chr1:76189707	ACADM	0.5	7.17	0.42	1.01e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9790314	0.580	rs10936227	chr3:161043869	A/C	cg03342759	chr3:160939853	NMD3	-0.51	-6.16	-0.37	3.16e-9	Morning vs. evening chronotype;
SARC	cis	rs62244186	0.714	rs2293600	chr3:44599103	G/T	cg15225532	chr3:44803084	KIF15;KIAA1143	-0.43	-5.42	-0.33	1.48e-7	Depressive symptoms;
SARC	cis	rs959260	0.588	rs12938183	chr17:73320433	G/C	cg14668889	chr17:73230827	NUP85	-0.57	-7.24	-0.43	6.48e-12	Systemic lupus erythematosus;
SARC	trans	rs17221829	0.733	rs11018668	chr11:89356178	C/T	cg02718654	chr19:40971802	SPTBN4;BLVRB	0.53	7.54	0.44	1.03e-12	Anxiety in major depressive disorder;
SARC	cis	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg07777115	chr5:623756	CEP72	-0.56	-4.83	-0.3	2.49e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs6815814	0.950	rs5743571	chr4:38805489	C/T	cg09316306	chr4:38807337	TLR1	0.5	5.16	0.32	5.23e-7	Breast cancer;
SARC	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg14517863	chr17:44321492	NA	0.34	5.05	0.31	8.91e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2072499	0.966	rs6427307	chr1:156190083	A/G	cg24450063	chr1:156163899	SLC25A44	1.12	18.46	0.77	1.76e-47	Testicular germ cell tumor;
SARC	cis	rs17376456	0.877	rs35075119	chr5:93385457	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.76	0.35	2.64e-8	Diabetic retinopathy;
SARC	cis	rs2213920	0.679	rs4979533	chr9:118210764	C/T	cg13918206	chr9:118159781	DEC1	0.8	6.38	0.39	9.55e-10	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9902453	0.934	rs8079028	chr17:28484234	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	7.0	0.42	2.73e-11	Coffee consumption (cups per day);
SARC	cis	rs2295359	1.000	rs10889661	chr1:67625309	T/A	cg11235152	chr1:67600687	NA	0.46	6.85	0.41	6.52e-11	Psoriasis;
SARC	cis	rs1881797	1.000	rs1881797	chr1:247689532	A/G	cg18198730	chr1:247681584	NA	0.56	6.22	0.38	2.32e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs4742903	0.509	rs10991161	chr9:106963159	G/A	cg14250997	chr9:106856677	SMC2	0.39	4.8	0.3	2.77e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg25072359	chr17:41440525	NA	0.5	5.97	0.36	8.94e-9	Menopause (age at onset);
SARC	cis	rs7523050	0.730	rs12734623	chr1:109442654	A/G	cg08274380	chr1:109419600	GPSM2	1.08	8.3	0.48	8.49e-15	Fat distribution (HIV);
SARC	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg18876405	chr7:65276391	NA	-0.66	-8.11	-0.47	2.96e-14	Aortic root size;
SARC	cis	rs11608355	0.515	rs7976796	chr12:109928013	C/T	cg05360138	chr12:110035743	NA	0.93	9.49	0.53	2.87e-18	Neuroticism;
SARC	cis	rs7208859	0.623	rs3752019	chr17:29151705	C/T	cg13385521	chr17:29058706	SUZ12P	0.86	7.61	0.45	6.79e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs3018066	0.518	rs7696747	chr4:107296413	A/C	cg09646026	chr4:107269030	AIMP1	-0.44	-4.78	-0.3	3.15e-6	Cancer;
SARC	cis	rs7408868	0.908	rs10416865	chr19:15277601	T/C	cg14696996	chr19:15285081	NOTCH3	1.01	8.93	0.5	1.32e-16	Pulse pressure;
SARC	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg03650068	chr1:25596491	NA	0.34	5.3	0.33	2.7e-7	Erythrocyte sedimentation rate;
SARC	cis	rs3858526	0.959	rs4758219	chr11:5951846	G/C	cg05234568	chr11:5960015	NA	-0.42	-4.99	-0.31	1.2e-6	DNA methylation (variation);
SARC	cis	rs2649	0.518	rs4556742	chr15:63864433	C/T	cg22599514	chr15:63798201	USP3	0.4	4.75	0.3	3.54e-6	Aortic root size;
SARC	cis	rs72717009	0.825	rs9427398	chr1:161476205	A/G	cg23840854	chr1:161414152	NA	-0.51	-4.87	-0.3	2.04e-6	Rheumatoid arthritis;
SARC	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg03060546	chr3:49711283	APEH	0.43	5.33	0.33	2.31e-7	Parkinson's disease;
SARC	cis	rs10752881	1.000	rs8179282	chr1:182974598	C/G	cg13390022	chr1:182993471	LAMC1	0.33	5.06	0.31	8.36e-7	Colorectal cancer;
SARC	cis	rs6860806	0.531	rs270612	chr5:131637338	G/A	cg12564285	chr5:131593104	PDLIM4	0.44	5.93	0.36	1.06e-8	Breast cancer;
SARC	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg22800045	chr5:56110881	MAP3K1	0.68	7.22	0.43	7.19e-12	Initial pursuit acceleration;
SARC	cis	rs11608355	0.545	rs7969313	chr12:109907303	A/G	cg05360138	chr12:110035743	NA	0.93	9.71	0.54	6.21e-19	Neuroticism;
SARC	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.69	-8.9	-0.5	1.61e-16	Chronic sinus infection;
SARC	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg22903657	chr4:1355424	KIAA1530	-0.33	-4.81	-0.3	2.69e-6	Longevity;
SARC	cis	rs13166103	0.628	rs7718063	chr5:57654954	C/T	cg10487770	chr5:57879443	RAB3C	0.56	5.96	0.36	9.21e-9	Type 2 diabetes (age of onset);
SARC	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg24829409	chr8:58192753	C8orf71	-0.55	-4.92	-0.31	1.61e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs11673344	0.566	rs1968251	chr19:37947907	A/G	cg14683738	chr19:37701593	ZNF585B	0.46	5.47	0.34	1.17e-7	Obesity-related traits;
SARC	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg24549020	chr5:56110836	MAP3K1	0.81	8.46	0.48	3.01e-15	Initial pursuit acceleration;
SARC	cis	rs10979	1.000	rs12203151	chr6:143884856	C/T	cg25407410	chr6:143891975	LOC285740	-0.61	-8.01	-0.46	5.52e-14	Hypospadias;
SARC	trans	rs56279505	0.629	rs17586023	chr4:100272950	A/G	cg21156590	chr1:3420848	MEGF6	-0.83	-6.41	-0.39	8.04e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6582630	0.502	rs11181230	chr12:38300085	A/G	cg13010199	chr12:38710504	ALG10B	0.78	10.82	0.58	2.18e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6088590	0.710	rs6059992	chr20:33282275	T/C	cg08999081	chr20:33150536	PIGU	0.38	5.75	0.35	2.78e-8	Coronary artery disease;
SARC	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-8.89	-0.5	1.75e-16	Alzheimer's disease;
SARC	cis	rs9467711	0.651	rs13220395	chr6:26055368	A/G	cg21479132	chr6:26055353	NA	-0.86	-5.75	-0.35	2.77e-8	Autism spectrum disorder or schizophrenia;
SARC	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg11764359	chr7:65958608	NA	0.74	8.43	0.48	3.59e-15	Aortic root size;
SARC	trans	rs61931739	0.534	rs10844725	chr12:34009504	C/A	cg26384229	chr12:38710491	ALG10B	0.85	12.17	0.62	1.1e-26	Morning vs. evening chronotype;
SARC	cis	rs35849525	0.633	rs62263602	chr3:50152491	C/T	cg14019146	chr3:50243930	SLC38A3	-0.34	-4.74	-0.3	3.76e-6	Intelligence (multi-trait analysis);
SARC	cis	rs4481887	0.708	rs6587463	chr1:248544452	G/C	cg00666640	chr1:248458726	OR2T12	0.34	5.92	0.36	1.12e-8	Common traits (Other);
SARC	cis	rs10752881	1.000	rs10737236	chr1:182988608	C/T	cg13390022	chr1:182993471	LAMC1	-0.34	-5.11	-0.32	6.64e-7	Colorectal cancer;
SARC	cis	rs6580649	1.000	rs10783227	chr12:48400617	C/T	cg05342945	chr12:48394962	COL2A1	-0.59	-6.44	-0.39	6.66e-10	Lung cancer;
SARC	cis	rs35110281	0.720	rs230647	chr21:44919654	C/T	cg01579765	chr21:45077557	HSF2BP	0.41	6.51	0.39	4.48e-10	Mean corpuscular volume;
SARC	cis	rs6582630	0.555	rs34145279	chr12:38405588	T/C	cg26384229	chr12:38710491	ALG10B	0.89	12.72	0.64	1.75e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.42	-6.42	-0.39	7.71e-10	Total body bone mineral density;
SARC	cis	rs10089	1.000	rs4836363	chr5:127462737	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	10.26	0.56	1.31e-20	Ileal carcinoids;
SARC	cis	rs2760061	0.583	rs3094911	chr1:228210179	A/G	cg01200585	chr1:228362443	C1orf69	0.44	5.83	0.36	1.8e-8	Diastolic blood pressure;
SARC	cis	rs372883	0.648	rs1153288	chr21:30686091	A/G	cg08807101	chr21:30365312	RNF160	0.61	7.59	0.45	7.72e-13	Pancreatic cancer;
SARC	cis	rs738322	1.000	rs4379	chr22:38569171	T/C	cg25457927	chr22:38595422	NA	-0.28	-5.78	-0.35	2.4e-8	Cutaneous nevi;
SARC	cis	rs7647973	1.000	rs974495	chr3:49400482	T/C	cg07636037	chr3:49044803	WDR6	0.76	8.55	0.49	1.69e-15	Menarche (age at onset);
SARC	cis	rs6500395	1.000	rs1224	chr16:48572817	G/A	cg04672837	chr16:48644449	N4BP1	0.48	6.4	0.39	8.43e-10	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs7772486	0.875	rs56181683	chr6:146286620	A/G	cg23711669	chr6:146136114	FBXO30	-0.69	-10.31	-0.56	9.1e-21	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2916247	0.954	rs991872	chr8:93164442	G/A	cg10183463	chr8:93005414	RUNX1T1	0.46	4.94	0.31	1.47e-6	Intelligence (multi-trait analysis);
SARC	cis	rs17030434	0.834	rs6535958	chr4:154760834	C/G	cg14289246	chr4:154710475	SFRP2	0.66	7.48	0.44	1.51e-12	Electrocardiographic conduction measures;
SARC	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg11764359	chr7:65958608	NA	0.79	9.82	0.54	2.94e-19	Aortic root size;
SARC	cis	rs6952809	0.532	rs6952152	chr7:2440912	G/A	cg23289794	chr7:2394357	EIF3B	-0.72	-6.83	-0.41	7.23e-11	Multiple sclerosis;
SARC	trans	rs208520	0.837	rs208467	chr6:66914837	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-11.15	-0.59	2.01e-23	Exhaled nitric oxide output;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg03533979	chr22:47097306	CERK	0.48	6.46	0.39	6.03e-10	Schizophrenia;
SARC	cis	rs9443189	0.570	rs529383	chr6:76297847	T/G	cg01950844	chr6:76311363	SENP6	0.81	6.86	0.41	6.3e-11	Prostate cancer;
SARC	cis	rs10870270	1.000	rs11146324	chr10:133767445	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.82	-10.25	-0.56	1.38e-20	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs10504229	0.679	rs10504217	chr8:58037522	A/G	cg21724239	chr8:58056113	NA	0.58	6.11	0.37	4.11e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2072499	0.750	rs55910626	chr1:156159909	C/G	cg24450063	chr1:156163899	SLC25A44	1.09	14.4	0.69	4.79e-34	Testicular germ cell tumor;
SARC	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg21724239	chr8:58056113	NA	0.6	5.85	0.36	1.64e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs950169	1.000	rs12903820	chr15:84723820	A/G	cg17507749	chr15:85114479	UBE2QP1	0.76	9.16	0.51	2.76e-17	Schizophrenia;
SARC	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg11987759	chr7:65425863	GUSB	0.48	5.76	0.35	2.66e-8	Aortic root size;
SARC	cis	rs9818758	0.607	rs67060340	chr3:48915321	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.64	-5.46	-0.34	1.22e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs7647973	0.626	rs62262672	chr3:49655927	T/A	cg06212747	chr3:49208901	KLHDC8B	-0.6	-5.6	-0.34	5.97e-8	Menarche (age at onset);
SARC	trans	rs11098499	0.909	rs1546502	chr4:120235898	A/G	cg25214090	chr10:38739885	LOC399744	0.55	7.12	0.42	1.29e-11	Corneal astigmatism;
SARC	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg02592271	chr2:27665507	KRTCAP3	-0.41	-6.39	-0.39	9.12e-10	Total body bone mineral density;
SARC	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg09699651	chr6:150184138	LRP11	0.43	5.29	0.33	2.8e-7	Lung cancer;
SARC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg16448223	chr20:44035136	DBNDD2;SYS1-DBNDD2	0.56	7.59	0.45	7.69e-13	Myopia (pathological);
SARC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.87	9.26	0.52	1.38e-17	Platelet count;
SARC	cis	rs3820928	0.934	rs16822890	chr2:227761477	G/A	cg11843606	chr2:227700838	RHBDD1	-0.52	-6.53	-0.39	4.09e-10	Pulmonary function;
SARC	cis	rs7027203	0.828	rs3996239	chr9:96611290	T/A	cg13679303	chr9:96623674	NA	-0.37	-5.36	-0.33	2.02e-7	DNA methylation (variation);
SARC	cis	rs733592	0.507	rs7138917	chr12:48455255	G/A	cg21466736	chr12:48725269	NA	0.32	5.66	0.35	4.5e-8	Plateletcrit;
SARC	trans	rs12714314	0.560	rs11694545	chr2:1939208	C/T	cg17695351	chr2:26467313	HADHB;HADHA	0.57	6.57	0.4	3.21e-10	Type 2 diabetes (age of onset);
SARC	cis	rs9325144	0.723	rs11169482	chr12:39164327	A/T	cg13010199	chr12:38710504	ALG10B	0.51	6.13	0.37	3.69e-9	Morning vs. evening chronotype;
SARC	cis	rs921968	0.509	rs556468	chr2:219355794	G/A	cg02176678	chr2:219576539	TTLL4	0.46	7.12	0.42	1.33e-11	Mean corpuscular hemoglobin concentration;
SARC	cis	rs1953600	0.837	rs3098105	chr10:81953266	C/T	cg00277334	chr10:82204260	NA	0.36	5.29	0.33	2.85e-7	Sarcoidosis;
SARC	cis	rs769267	0.792	rs4808961	chr19:19577215	C/G	cg03709012	chr19:19516395	GATAD2A	0.99	16.0	0.72	2.3e-39	Tonsillectomy;
SARC	cis	rs11585357	0.895	rs34324150	chr1:17632464	C/G	cg08277548	chr1:17600880	PADI3	-0.44	-5.25	-0.33	3.47e-7	Hair shape;
SARC	cis	rs2908197	0.663	rs7802264	chr7:75985782	T/C	cg22830091	chr7:75961684	YWHAG	-0.35	-5.21	-0.32	4.09e-7	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs4713118	0.539	rs510987	chr6:27847517	G/A	cg17221315	chr6:27791827	HIST1H4J	0.45	5.06	0.31	8.4e-7	Parkinson's disease;
SARC	cis	rs7044106	0.791	rs10984998	chr9:123481516	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.52	0.53	2.39e-18	Hip circumference adjusted for BMI;
SARC	cis	rs854765	0.583	rs6502622	chr17:17834691	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.66	9.93	0.55	1.32e-19	Total body bone mineral density;
SARC	cis	rs6120849	0.754	rs6088686	chr20:33623437	C/T	cg24642439	chr20:33292090	TP53INP2	0.58	5.56	0.34	7.36e-8	Protein C levels;
SARC	cis	rs2916247	0.954	rs35983766	chr8:93056882	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.57	-6.04	-0.37	6.18e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7727544	0.735	rs274558	chr5:131721174	A/G	cg24060327	chr5:131705240	SLC22A5	0.69	8.96	0.51	1.06e-16	Blood metabolite levels;
SARC	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg03161606	chr19:29218774	NA	0.47	6.76	0.4	1.09e-10	Methadone dose in opioid dependence;
SARC	cis	rs7819412	0.668	rs4841507	chr8:11046394	C/G	cg12395012	chr8:11607386	GATA4	0.31	5.28	0.33	2.89e-7	Triglycerides;
SARC	cis	rs208520	0.779	rs208451	chr6:66906155	G/A	cg07460842	chr6:66804631	NA	-0.96	-11.34	-0.6	5.21e-24	Exhaled nitric oxide output;
SARC	cis	rs7666738	0.830	rs114722517	chr4:99042061	G/A	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs698833	0.886	rs4953086	chr2:44561532	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.75	9.7	0.54	6.46e-19	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs9486715	0.867	rs4839687	chr6:96951732	C/A	cg18709589	chr6:96969512	KIAA0776	0.59	7.33	0.43	3.65e-12	Headache;
SARC	cis	rs4664308	0.691	rs1877196	chr2:160915150	G/T	cg03641300	chr2:160917029	PLA2R1	-0.64	-8.78	-0.5	3.59e-16	Idiopathic membranous nephropathy;
SARC	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg27266027	chr21:40555129	PSMG1	0.5	5.51	0.34	9.46e-8	Cognitive function;
SARC	cis	rs4742903	0.509	rs10820611	chr9:106910264	A/G	cg14250997	chr9:106856677	SMC2	0.44	5.51	0.34	9.66e-8	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs17384381	0.953	rs12139958	chr1:85842112	A/G	cg16011679	chr1:85725395	C1orf52	0.64	5.93	0.36	1.06e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg00101154	chr16:420108	MRPL28	0.42	6.34	0.38	1.16e-9	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs12893668	0.703	rs12894729	chr14:104035292	G/A	cg26031613	chr14:104095156	KLC1	-0.51	-5.42	-0.33	1.48e-7	Reticulocyte count;
SARC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.08	0.37	4.93e-9	Prudent dietary pattern;
SARC	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg06028605	chr16:24865363	SLC5A11	-0.36	-5.16	-0.32	5.36e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6570726	0.791	rs448939	chr6:145808320	T/C	cg05220968	chr6:146057943	EPM2A	-0.28	-4.94	-0.31	1.48e-6	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg03861593	chr6:108881876	FOXO3	-0.8	-6.61	-0.4	2.61e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2531992	0.686	rs12922685	chr16:4028621	G/C	cg05927578	chr16:4029543	ADCY9	-0.51	-5.84	-0.36	1.73e-8	Waist circumference;
SARC	trans	rs61931739	0.500	rs9919726	chr12:34510783	A/G	cg26384229	chr12:38710491	ALG10B	0.83	12.41	0.63	1.78e-27	Morning vs. evening chronotype;
SARC	cis	rs8062405	0.824	rs62034324	chr16:28536762	T/C	cg08761264	chr16:28874980	SH2B1	-0.43	-4.81	-0.3	2.7e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs6456156	0.565	rs7750209	chr6:167482895	T/G	cg23791538	chr6:167370224	RNASET2	-0.53	-6.99	-0.42	2.86e-11	Primary biliary cholangitis;
SARC	cis	rs9359856	0.636	rs4706345	chr6:90301565	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.56	-4.97	-0.31	1.28e-6	Bipolar disorder;
SARC	cis	rs6546550	0.901	rs6546559	chr2:70145833	G/A	cg02498382	chr2:70120550	SNRNP27	-0.32	-5.13	-0.32	6.22e-7	Prevalent atrial fibrillation;
SARC	cis	rs17376456	0.569	rs1026279	chr5:93209581	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.5	-5.02	-0.31	1.02e-6	Diabetic retinopathy;
SARC	cis	rs8067354	0.645	rs72838857	chr17:57836767	A/G	cg02344993	chr17:57696989	CLTC	0.63	6.09	0.37	4.59e-9	Hemoglobin concentration;
SARC	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.89	-13.31	-0.66	1.88e-30	Prudent dietary pattern;
SARC	cis	rs554111	0.509	rs495522	chr1:21105994	C/T	cg08890418	chr1:21044141	KIF17	0.46	6.17	0.37	3.06e-9	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg26335602	chr6:28129616	ZNF389	0.48	5.7	0.35	3.57e-8	Depression;
SARC	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg03433033	chr1:76189801	ACADM	0.43	5.59	0.34	6.37e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs910316	0.967	rs175432	chr14:75615246	C/G	cg23033748	chr14:75592666	NEK9	-0.35	-4.74	-0.3	3.64e-6	Height;
SARC	cis	rs67460515	0.563	rs1599375	chr3:160897771	C/T	cg03342759	chr3:160939853	NMD3	0.59	7.24	0.43	6.32e-12	Parkinson's disease;
SARC	cis	rs9303401	0.659	rs34556735	chr17:56694447	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.08	11.8	0.61	1.72e-25	Cognitive test performance;
SARC	cis	rs80130819	0.688	rs2732475	chr12:48700754	G/C	cg05342945	chr12:48394962	COL2A1	-0.54	-5.9	-0.36	1.3e-8	Prostate cancer;
SARC	cis	rs12421382	0.511	rs2212430	chr11:109289538	C/T	cg15948088	chr11:109293068	C11orf87	0.39	5.35	0.33	2.06e-7	Schizophrenia;
SARC	cis	rs17253792	0.915	rs78089630	chr14:56178584	G/C	cg01858014	chr14:56050164	KTN1	-0.62	-4.86	-0.3	2.19e-6	Putamen volume;
SARC	cis	rs9436747	0.585	rs6662904	chr1:65997740	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.43	5.35	0.33	2.11e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs7618501	0.966	rs13085679	chr3:49869631	G/A	cg24110177	chr3:50126178	RBM5	-0.4	-5.08	-0.32	7.7e-7	Intelligence (multi-trait analysis);
SARC	cis	rs3784262	0.669	rs4646597	chr15:58300768	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.34	-5.21	-0.32	4.21e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs1401999	1.000	rs939336	chr3:183685534	A/G	cg01324343	chr3:183735012	ABCC5	0.67	13.43	0.66	7.75e-31	Anterior chamber depth;
SARC	cis	rs1707322	0.721	rs10157795	chr1:46228192	G/A	cg06784218	chr1:46089804	CCDC17	0.4	6.99	0.42	2.84e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg26681399	chr22:41777847	TEF	-0.45	-4.9	-0.31	1.81e-6	Vitiligo;
SARC	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.35	4.76	0.3	3.35e-6	Personality dimensions;
SARC	cis	rs660899	0.647	rs56319043	chr1:44171211	C/T	cg19824710	chr1:43995379	PTPRF	0.45	4.87	0.3	2.02e-6	Hypertension risk in short sleep duration;
SARC	cis	rs700651	0.624	rs12105927	chr2:198937258	G/A	cg00792783	chr2:198669748	PLCL1	0.43	4.85	0.3	2.25e-6	Intracranial aneurysm;
SARC	cis	rs10088262	0.629	rs1367829	chr8:124797135	A/G	cg15047889	chr8:124780837	FAM91A1	-0.65	-7.22	-0.43	7.24e-12	Pancreatic cancer;
SARC	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.58	-6.81	-0.41	8.19e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.49	-6.12	-0.37	3.97e-9	Lymphocyte counts;
SARC	cis	rs7592578	0.713	rs60915953	chr2:191331304	G/C	cg27211696	chr2:191398769	TMEM194B	-0.52	-5.21	-0.32	4.18e-7	Diastolic blood pressure;
SARC	cis	rs1468333	1.000	rs2864	chr5:137523430	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.79	10.68	0.57	6.18e-22	Resting heart rate;
SARC	cis	rs4595586	0.655	rs4142847	chr12:39395128	C/T	cg26384229	chr12:38710491	ALG10B	0.43	5.42	0.33	1.46e-7	Morning vs. evening chronotype;
SARC	cis	rs2718058	0.692	rs2718041	chr7:37783944	A/G	cg24998770	chr7:37888106	TXNDC3	0.31	4.87	0.3	2.05e-6	Alzheimer's disease (late onset);
SARC	cis	rs1865760	0.964	rs3799373	chr6:25929173	A/C	cg10373733	chr6:25993375	NA	0.41	4.85	0.3	2.22e-6	Height;
SARC	cis	rs698833	0.548	rs1372079	chr2:44543317	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.64	7.55	0.44	1e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs1419980	0.673	rs10845432	chr12:7728131	T/C	cg10578777	chr12:7781093	NA	0.66	6.79	0.41	9.34e-11	HDL cholesterol levels;
SARC	cis	rs4713118	0.955	rs9468203	chr6:27688667	A/G	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.65e-6	Parkinson's disease;
SARC	trans	rs1814175	0.538	rs1684260	chr11:49224231	G/A	cg15704280	chr7:45808275	SEPT13	0.83	12.74	0.64	1.45e-28	Height;
SARC	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg27121462	chr16:89883253	FANCA	0.71	11.39	0.6	3.59e-24	Vitiligo;
SARC	cis	rs2836974	0.544	rs8128919	chr21:40711862	C/T	cg17971929	chr21:40555470	PSMG1	0.64	8.33	0.48	6.75e-15	Cognitive function;
SARC	cis	rs35146811	0.807	rs6465761	chr7:99620277	G/C	cg22004693	chr7:99632812	ZKSCAN1	-0.45	-4.88	-0.3	1.96e-6	Coronary artery disease;
SARC	cis	rs2276314	1.000	rs1789513	chr18:33545630	A/G	cg19628046	chr18:33552617	C18orf21	-0.56	-5.83	-0.36	1.85e-8	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs2073300	0.609	rs6137950	chr20:23418722	T/A	cg12062639	chr20:23401060	NAPB	0.98	6.65	0.4	2.03e-10	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs2180341	0.618	rs6683	chr6:127610021	G/A	cg24812749	chr6:127587940	RNF146	0.57	7.16	0.42	1.04e-11	Breast cancer;
SARC	cis	rs11122272	0.735	rs2250704	chr1:231486647	A/G	cg06096015	chr1:231504339	EGLN1	0.37	5.6	0.34	6.04e-8	Hemoglobin concentration;
SARC	cis	rs2832191	0.740	rs6516890	chr21:30476812	T/A	cg08807101	chr21:30365312	RNF160	0.83	11.57	0.6	9.22e-25	Dental caries;
SARC	cis	rs2832191	0.791	rs7283853	chr21:30498515	G/A	cg24692254	chr21:30365293	RNF160	-0.84	-11.89	-0.61	8.3e-26	Dental caries;
SARC	cis	rs7248779	0.512	rs12610522	chr19:2413228	C/T	cg22729335	chr19:2427816	TIMM13	1.1	18.53	0.77	9.85e-48	Cortisol levels (saliva);
SARC	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg16479474	chr6:28041457	NA	0.33	5.09	0.32	7.48e-7	Cardiac Troponin-T levels;
SARC	cis	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg05623727	chr3:50126028	RBM5	-0.34	-5.27	-0.33	3.18e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6582630	0.555	rs61932279	chr12:38349096	C/T	cg13010199	chr12:38710504	ALG10B	-0.52	-6.22	-0.38	2.29e-9	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg18305652	chr10:134549665	INPP5A	0.36	5.1	0.32	7.09e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs2075371	1.000	rs2598291	chr7:133988313	C/G	cg11752832	chr7:134001865	SLC35B4	0.58	7.44	0.44	1.96e-12	Mean platelet volume;
SARC	cis	rs734999	0.545	rs12752515	chr1:2564465	T/C	cg00980319	chr1:2560884	MMEL1	0.33	4.77	0.3	3.19e-6	Ulcerative colitis;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg22964146	chr10:74767376	P4HA1	0.46	6.26	0.38	1.79e-9	Thyroid stimulating hormone;
SARC	cis	rs11785400	0.793	rs4430070	chr8:143729184	G/C	cg10596483	chr8:143751796	JRK	0.57	7.39	0.44	2.61e-12	Schizophrenia;
SARC	cis	rs11122272	0.735	rs2572263	chr1:231509408	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	trans	rs66573146	1.000	rs67405518	chr4:6965930	C/T	cg07817883	chr1:32538562	TMEM39B	1.45	9.08	0.51	4.59e-17	Granulocyte percentage of myeloid white cells;
SARC	cis	rs2841277	0.738	rs1036713	chr14:105396693	C/G	cg15352829	chr14:105391018	PLD4	0.3	5.73	0.35	3.1e-8	Rheumatoid arthritis;
SARC	cis	rs736408	1.000	rs736408	chr3:52835354	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.35	0.33	2.1e-7	Bipolar disorder;
SARC	cis	rs4481887	0.893	rs10888348	chr1:248448610	C/G	cg01631408	chr1:248437212	OR2T33	-0.42	-5.35	-0.33	2.08e-7	Common traits (Other);
SARC	cis	rs3136441	1.000	rs2306033	chr11:46897446	G/A	cg25783544	chr11:47291846	MADD	0.62	4.82	0.3	2.59e-6	HDL cholesterol;
SARC	cis	rs4689388	0.926	rs4308429	chr4:6294001	A/G	cg14416269	chr4:6271139	WFS1	0.32	4.92	0.31	1.61e-6	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	trans	rs9329221	0.527	rs4841352	chr8:10327590	A/C	cg06636001	chr8:8085503	FLJ10661	0.58	8.26	0.48	1.12e-14	Neuroticism;
SARC	cis	rs9486719	1.000	rs2499809	chr6:96870110	C/T	cg06623918	chr6:96969491	KIAA0776	0.73	8.01	0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs6942407	0.592	rs739711	chr7:86746741	G/C	cg02420886	chr7:86849541	C7orf23	0.59	5.41	0.33	1.55e-7	Food allergy;
SARC	cis	rs2070677	0.935	rs4335491	chr10:135422460	T/G	cg20169779	chr10:135381914	SYCE1	-0.56	-6.9	-0.41	4.74e-11	Gout;
SARC	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.6	5.67	0.35	4.16e-8	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs7429990	0.932	rs2361684	chr3:48152618	G/C	cg11946769	chr3:48343235	NME6	-0.46	-5.42	-0.33	1.46e-7	Educational attainment (years of education);
SARC	cis	rs79149102	0.579	rs3910748	chr15:75318652	A/G	cg09165964	chr15:75287851	SCAMP5	-1.02	-9.12	-0.51	3.52e-17	Lung cancer;
SARC	cis	rs7412746	0.611	rs36008098	chr1:150856806	G/A	cg13175981	chr1:150552382	MCL1	-0.53	-6.51	-0.39	4.58e-10	Melanoma;
SARC	cis	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg12257692	chr3:49977190	RBM6	0.28	4.91	0.31	1.7e-6	Intelligence (multi-trait analysis);
SARC	cis	rs10089	0.953	rs6595807	chr5:127531603	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.8	9.56	0.53	1.74e-18	Ileal carcinoids;
SARC	cis	rs73086581	1.000	rs73086588	chr20:3982224	A/T	cg02187196	chr20:3869020	PANK2	0.63	5.82	0.36	1.97e-8	Response to antidepressants in depression;
SARC	cis	rs9398803	0.865	rs4559102	chr6:126773580	G/A	cg19875578	chr6:126661172	C6orf173	0.62	8.51	0.49	2.2e-15	Male-pattern baldness;
SARC	cis	rs2204008	0.547	rs12318267	chr12:38250905	T/G	cg04568710	chr12:38710424	ALG10B	-0.4	-4.77	-0.3	3.21e-6	Bladder cancer;
SARC	trans	rs3857536	0.566	rs208463	chr6:66913962	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.71	-8.03	-0.47	4.8e-14	Blood trace element (Cu levels);
SARC	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg04166393	chr7:2884313	GNA12	0.55	6.28	0.38	1.6e-9	Height;
SARC	cis	rs9549367	0.713	rs3024769	chr13:113825601	A/C	cg18105134	chr13:113819100	PROZ	0.49	7.42	0.44	2.22e-12	Platelet distribution width;
SARC	cis	rs7568458	0.660	rs6722691	chr2:85758352	C/T	cg23752985	chr2:85803571	VAMP8	0.41	5.46	0.34	1.22e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs1008375	0.966	rs1476836	chr4:17585014	G/C	cg27347728	chr4:17578864	LAP3	0.49	6.06	0.37	5.46e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg19223190	chr17:80058835	NA	0.45	6.31	0.38	1.4e-9	Life satisfaction;
SARC	cis	rs546131	0.928	rs550313	chr11:34830919	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.51	6.68	0.4	1.72e-10	Lung disease severity in cystic fibrosis;
SARC	cis	rs6693567	0.565	rs834238	chr1:150366469	G/T	cg09579323	chr1:150459698	TARS2	0.45	5.73	0.35	3.02e-8	Migraine;
SARC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.0	11.78	0.61	1.93e-25	Platelet count;
SARC	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg05863683	chr7:1912471	MAD1L1	0.34	5.1	0.32	7.17e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs16854884	0.837	rs4380409	chr3:143800896	A/G	cg06585982	chr3:143692056	C3orf58	0.6	7.9	0.46	1.13e-13	Economic and political preferences (feminism/equality);
SARC	cis	rs4268898	0.717	rs3731626	chr2:24427864	G/A	cg06627628	chr2:24431161	ITSN2	-0.67	-8.26	-0.48	1.11e-14	Asthma;
SARC	cis	rs2251381	0.750	rs8129616	chr21:30520085	C/T	cg24692254	chr21:30365293	RNF160	-0.89	-12.33	-0.63	3.31e-27	Selective IgA deficiency;
SARC	cis	rs11690935	0.632	rs11690807	chr2:172628120	G/A	cg13550731	chr2:172543902	DYNC1I2	0.66	9.48	0.53	3.02e-18	Schizophrenia;
SARC	cis	rs1008375	1.000	rs10939740	chr4:17617490	T/C	cg16339924	chr4:17578868	LAP3	0.69	9.29	0.52	1.11e-17	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg12419862	chr22:24373484	LOC391322	1.0	17.1	0.75	5.03e-43	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9916302	0.707	rs11078903	chr17:37631924	G/A	cg20243544	chr17:37824526	PNMT	0.57	6.58	0.4	3.07e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs1018836	1.000	rs1018836	chr8:91570362	A/G	cg16814680	chr8:91681699	NA	-0.76	-11.48	-0.6	1.78e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs705471	0.931	rs705470	chr10:3666993	G/A	cg14308648	chr10:3568949	NA	0.5	6.34	0.38	1.19e-9	Capecitabine sensitivity;
SARC	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg16479474	chr6:28041457	NA	0.36	5.27	0.33	3.04e-7	Depression;
SARC	cis	rs17376456	0.569	rs6556839	chr5:93206292	T/C	cg25358565	chr5:93447407	FAM172A	-0.95	-10.7	-0.57	5.21e-22	Diabetic retinopathy;
SARC	cis	rs9894429	0.621	rs7502337	chr17:79588470	T/C	cg10661904	chr17:79619235	PDE6G	-0.45	-6.28	-0.38	1.66e-9	Eye color traits;
SARC	cis	rs72792276	1.000	rs10519971	chr5:127379216	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.71	-5.86	-0.36	1.58e-8	Red cell distribution width;
SARC	cis	rs7626444	0.626	rs5021325	chr3:196477629	A/T	cg12930392	chr3:196481615	PAK2	0.25	4.91	0.31	1.74e-6	Monocyte count;
SARC	cis	rs9902453	0.967	rs1042173	chr17:28525011	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	6.91	0.41	4.65e-11	Coffee consumption (cups per day);
SARC	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.44	4.72	0.3	4.11e-6	Renal function-related traits (BUN);
SARC	cis	rs7666738	0.830	rs7694889	chr4:98855596	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.59	0.49	1.24e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs3796352	0.892	rs11718388	chr3:53076415	G/A	cg27565382	chr3:53032988	SFMBT1	0.86	6.3	0.38	1.49e-9	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs7223966	1.000	rs11079511	chr17:61858537	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.5	5.15	0.32	5.58e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7027203	0.797	rs57882762	chr9:96580825	T/G	cg13679303	chr9:96623674	NA	-0.34	-4.91	-0.31	1.73e-6	DNA methylation (variation);
SARC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg09436375	chr6:42928200	GNMT	-0.36	-5.5	-0.34	1e-7	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs12995491	0.763	rs1914735	chr2:88511953	A/T	cg04511125	chr2:88470314	THNSL2	-0.39	-5.8	-0.36	2.15e-8	Response to metformin (IC50);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg10135682	chr10:20023014	NA	0.45	6.39	0.39	8.76e-10	Thyroid stimulating hormone;
SARC	cis	rs7605378	0.658	rs4673507	chr2:200710167	G/C	cg23649088	chr2:200775458	C2orf69	0.72	9.6	0.53	1.29e-18	Osteoporosis;
SARC	cis	rs7520050	0.931	rs785472	chr1:46518288	T/A	cg06784218	chr1:46089804	CCDC17	-0.28	-5.08	-0.32	7.58e-7	Red blood cell count;Reticulocyte count;
SARC	cis	rs73157695	1.000	rs8133858	chr21:47360338	C/T	cg00682050	chr21:47343716	PCBP3	-0.45	-5.24	-0.32	3.54e-7	Myopia;
SARC	cis	rs4805272	0.512	rs12373558	chr19:29337692	A/G	cg12756686	chr19:29218302	NA	0.48	5.09	0.32	7.34e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs66561647	0.895	rs9649959	chr8:128972721	C/T	cg05480350	chr8:128972681	MIR1205;PVT1	-0.45	-5.71	-0.35	3.51e-8	Hemoglobin concentration;
SARC	cis	rs1348850	0.526	rs7607073	chr2:178375065	C/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.69	6.26	0.38	1.81e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs6546324	0.559	rs11126134	chr2:67781064	G/T	cg18237512	chr2:67827392	NA	0.52	5.87	0.36	1.47e-8	Endometriosis;
SARC	cis	rs11098499	0.954	rs12510138	chr4:120423935	C/G	cg09307838	chr4:120376055	NA	0.89	12.4	0.63	1.9e-27	Corneal astigmatism;
SARC	cis	rs796364	0.906	rs281789	chr2:200780698	T/G	cg23649088	chr2:200775458	C2orf69	0.62	5.94	0.36	1.06e-8	Schizophrenia;
SARC	cis	rs7520050	0.966	rs61102033	chr1:46382441	G/T	cg24296786	chr1:45957014	TESK2	0.39	4.9	0.31	1.78e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs7264396	0.515	rs2425134	chr20:34339439	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-6.69	-0.4	1.68e-10	Total cholesterol levels;
SARC	cis	rs8180040	1.000	rs295461	chr3:47368010	T/C	cg27129171	chr3:47204927	SETD2	0.68	9.56	0.53	1.72e-18	Colorectal cancer;
SARC	cis	rs5167	0.504	rs7248162	chr19:45454686	T/C	cg10169327	chr19:45448959	APOC2	0.31	5.11	0.32	6.85e-7	Blood protein levels;
SARC	cis	rs2439831	1.000	rs2439850	chr15:43784854	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	8.42	0.48	3.97e-15	Lung cancer in ever smokers;
SARC	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg07701084	chr6:150067640	NUP43	0.4	5.37	0.33	1.91e-7	Lung cancer;
SARC	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg08742575	chr21:47604166	C21orf56	0.4	4.78	0.3	3.05e-6	Testicular germ cell tumor;
SARC	cis	rs6089584	0.893	rs2281735	chr20:60582540	T/A	cg13770153	chr20:60521292	NA	-0.5	-6.96	-0.41	3.53e-11	Body mass index;
SARC	cis	rs9392918	0.934	rs11243203	chr6:7720756	A/G	cg23089261	chr6:7723385	NA	0.37	4.94	0.31	1.47e-6	Height;
SARC	cis	rs1707322	0.827	rs6683274	chr1:46241638	T/G	cg06784218	chr1:46089804	CCDC17	0.37	6.46	0.39	6.21e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs10463316	0.963	rs4958450	chr5:150739932	A/C	cg03212797	chr5:150827313	SLC36A1	-0.44	-5.21	-0.32	4.25e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs12367572	0.965	rs7952764	chr12:45246211	C/A	cg04608330	chr12:45269318	NELL2	-0.49	-6.04	-0.37	6.07e-9	Gut microbiome composition (summer);
SARC	cis	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg21775007	chr8:11205619	TDH	0.45	5.7	0.35	3.67e-8	Neuroticism;
SARC	cis	rs7666738	0.791	rs13149968	chr4:99070262	G/T	cg05340658	chr4:99064831	C4orf37	0.65	8.71	0.5	5.79e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2295359	0.892	rs6688383	chr1:67655954	C/T	cg12940439	chr1:67600707	NA	-0.44	-6.23	-0.38	2.12e-9	Psoriasis;
SARC	cis	rs6582630	0.502	rs1915395	chr12:38420726	A/G	cg13010199	chr12:38710504	ALG10B	0.77	10.39	0.56	5.04e-21	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9914544	0.583	rs11078422	chr17:18804413	C/T	cg25390199	chr17:18761479	PRPSAP2	0.44	5.81	0.36	2.01e-8	Educational attainment (years of education);
SARC	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg25072359	chr17:41440525	NA	0.52	6.27	0.38	1.71e-9	Menopause (age at onset);
SARC	cis	rs2952156	0.959	rs2941503	chr17:37828745	A/G	cg07936489	chr17:37558343	FBXL20	-0.38	-4.79	-0.3	2.91e-6	Asthma;
SARC	cis	rs6121246	0.821	rs3181073	chr20:30307199	A/C	cg13852791	chr20:30311386	BCL2L1	-0.81	-8.82	-0.5	2.74e-16	Mean corpuscular hemoglobin;
SARC	cis	rs9914988	0.887	rs11652710	chr17:27145075	C/T	cg20469991	chr17:27169893	C17orf63	-0.52	-5.39	-0.33	1.74e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs1707322	0.686	rs3014242	chr1:46087577	G/A	cg03146154	chr1:46216737	IPP	-0.51	-6.17	-0.37	3.06e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2652834	0.950	rs2729787	chr15:63401493	G/T	cg05507819	chr15:63340323	TPM1	0.55	5.48	0.34	1.13e-7	HDL cholesterol;
SARC	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg13206674	chr6:150067644	NUP43	0.41	5.37	0.33	1.95e-7	Lung cancer;
SARC	cis	rs9818758	0.607	rs9837625	chr3:49215966	C/T	cg03060546	chr3:49711283	APEH	-0.56	-4.86	-0.3	2.17e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs2479724	0.811	rs8393	chr6:41757836	C/A	cg17623882	chr6:41773611	USP49	0.42	5.28	0.33	2.91e-7	Menarche (age at onset);
SARC	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg05368731	chr17:41323189	NBR1	-0.69	-8.39	-0.48	4.62e-15	Menopause (age at onset);
SARC	cis	rs854765	0.693	rs8079321	chr17:17760789	C/T	cg04398451	chr17:18023971	MYO15A	-0.46	-6.49	-0.39	4.99e-10	Total body bone mineral density;
SARC	cis	rs9473924	0.542	rs13195969	chr6:50814627	C/A	cg14470998	chr6:50812995	TFAP2B	0.7	6.19	0.38	2.66e-9	Body mass index;
SARC	cis	rs10916814	0.610	rs1890004	chr1:20899066	T/C	cg24502330	chr1:20914028	CDA	-0.3	-5.27	-0.33	3.16e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs1949733	1.000	rs2631740	chr4:8484106	C/A	cg13073564	chr4:8508604	NA	0.47	7.76	0.45	2.67e-13	Response to antineoplastic agents;
SARC	cis	rs6088590	0.648	rs6058105	chr20:33271719	C/T	cg08999081	chr20:33150536	PIGU	0.42	6.38	0.39	9.51e-10	Coronary artery disease;
SARC	cis	rs7644634	0.688	rs34896116	chr3:105450301	T/A	cg23051926	chr3:105466016	CBLB	0.44	5.52	0.34	9.1e-8	Itch intensity from mosquito bite;
SARC	cis	rs1163251	0.902	rs640195	chr1:120217650	T/A	cg19096424	chr1:120255104	PHGDH	0.53	6.2	0.38	2.56e-9	Blood metabolite levels;
SARC	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg07701084	chr6:150067640	NUP43	0.41	5.39	0.33	1.75e-7	Lung cancer;
SARC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg07167872	chr1:205819463	PM20D1	0.85	14.02	0.68	8.87e-33	Menarche (age at onset);
SARC	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.97	-15.7	-0.72	2.3e-38	Chronic sinus infection;
SARC	cis	rs2370759	1.000	rs11594963	chr10:32625736	G/A	cg01819863	chr10:32635814	EPC1	1.01	10.08	0.55	4.59e-20	Sexual dysfunction (female);
SARC	cis	rs2230307	0.536	rs482466	chr1:100488177	C/T	cg24955406	chr1:100503596	HIAT1	0.64	6.25	0.38	1.93e-9	Carotid intima media thickness;
SARC	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg03999130	chr15:45571217	NA	0.41	5.24	0.32	3.67e-7	Homoarginine levels;
SARC	cis	rs12148488	0.816	rs4886655	chr15:75385568	C/T	cg17294928	chr15:75287854	SCAMP5	0.5	6.41	0.39	8.06e-10	Caffeine consumption;
SARC	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg06634786	chr22:41940651	POLR3H	0.51	6.2	0.38	2.51e-9	Vitiligo;
SARC	cis	rs7927771	1.000	rs11039426	chr11:47863119	G/A	cg05585544	chr11:47624801	NA	-0.36	-4.82	-0.3	2.59e-6	Subjective well-being;
SARC	cis	rs950776	0.616	rs647041	chr15:78880481	T/C	cg06917634	chr15:78832804	PSMA4	-0.84	-12.39	-0.63	1.97e-27	Sudden cardiac arrest;
SARC	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg27572855	chr1:25598939	RHD	0.57	9.71	0.54	6.04e-19	Erythrocyte sedimentation rate;
SARC	cis	rs1662342	0.800	rs7239576	chr18:3269893	T/C	cg14211874	chr18:3262499	MYL12B	-0.62	-5.08	-0.32	7.82e-7	QRS duration;
SARC	cis	rs4660261	0.526	rs2040950	chr1:44315113	G/C	cg13606994	chr1:44402422	ARTN	-0.29	-4.73	-0.3	3.81e-6	Intelligence (multi-trait analysis);
SARC	cis	rs1865760	0.963	rs1540273	chr6:25924158	T/C	cg16482183	chr6:26056742	HIST1H1C	0.5	6.21	0.38	2.37e-9	Height;
SARC	cis	rs9896052	0.591	rs7212620	chr17:73461930	A/T	cg27037648	chr17:73511087	CASKIN2	0.38	5.06	0.31	8.62e-7	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg21782813	chr7:2030301	MAD1L1	0.36	5.75	0.35	2.84e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs7824557	0.638	rs4413734	chr8:11212778	C/T	cg21775007	chr8:11205619	TDH	0.73	9.67	0.54	8.24e-19	Retinal vascular caliber;
SARC	cis	rs7264396	0.561	rs6060750	chr20:34596371	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-5.95	-0.36	9.52e-9	Total cholesterol levels;
SARC	cis	rs240764	0.658	rs11155637	chr6:101203592	A/G	cg09795085	chr6:101329169	ASCC3	-0.5	-6.68	-0.4	1.74e-10	Neuroticism;
SARC	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg27286337	chr10:134555280	INPP5A	0.71	8.16	0.47	2.03e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs7762018	1.000	rs6942332	chr6:170131934	A/G	cg00262263	chr6:170184901	NA	0.39	4.81	0.3	2.73e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	0.36	5.28	0.33	2.98e-7	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs5167	0.504	rs3760629	chr19:45458146	A/C	cg20090143	chr19:45452003	APOC2	0.3	4.77	0.3	3.23e-6	Blood protein levels;
SARC	cis	rs6089584	0.830	rs6089309	chr20:60585687	T/C	cg13770153	chr20:60521292	NA	-0.52	-7.26	-0.43	5.81e-12	Body mass index;
SARC	cis	rs995000	0.868	rs1168114	chr1:63156043	C/T	cg06896770	chr1:63153194	DOCK7	0.83	12.26	0.63	5.58e-27	Triglyceride levels;
SARC	cis	rs35213789	0.887	rs2533446	chr7:69093418	G/A	cg10619644	chr7:69149951	AUTS2	-0.43	-5.77	-0.35	2.54e-8	Childhood ear infection;
SARC	cis	rs208520	1.000	rs12194996	chr6:66973366	G/C	cg07460842	chr6:66804631	NA	0.79	8.87	0.5	2e-16	Exhaled nitric oxide output;
SARC	cis	rs74417235	0.684	rs7723610	chr5:154053349	A/C	cg08754654	chr5:154026448	NA	0.47	4.79	0.3	2.97e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
SARC	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg24829409	chr8:58192753	C8orf71	0.64	5.9	0.36	1.27e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9921192	1.000	rs2892165	chr16:4324293	A/T	cg07945448	chr16:4304224	NA	0.54	6.96	0.41	3.49e-11	Prostate-specific antigen levels;
SARC	cis	rs6772849	0.775	rs9828414	chr3:128412717	C/T	cg08795948	chr3:128337044	NA	0.52	6.78	0.41	9.85e-11	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg21724239	chr8:58056113	NA	0.6	6.31	0.38	1.43e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1949733	0.656	rs2688243	chr4:8436286	A/G	cg11789530	chr4:8429930	ACOX3	0.8	10.28	0.56	1.13e-20	Response to antineoplastic agents;
SARC	cis	rs7772486	0.686	rs4896827	chr6:145953338	T/A	cg23711669	chr6:146136114	FBXO30	0.78	12.61	0.64	3.75e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs66887589	0.777	rs4643791	chr4:120265619	A/G	cg09307838	chr4:120376055	NA	-0.53	-7.04	-0.42	2.19e-11	Diastolic blood pressure;
SARC	cis	rs509477	0.690	rs273354	chr18:32598235	T/C	cg23791764	chr18:32556832	MAPRE2	0.43	5.28	0.33	2.93e-7	Cerebrospinal fluid AB1-42 levels;
SARC	cis	rs1669338	0.588	rs7629889	chr3:3187643	C/T	cg16797762	chr3:3221439	CRBN	-0.89	-9.13	-0.51	3.48e-17	White matter integrity;
SARC	cis	rs9394841	0.692	rs9369312	chr6:41841535	A/T	cg08135965	chr6:41755394	TOMM6	0.62	6.62	0.4	2.46e-10	Mean corpuscular hemoglobin;Red cell distribution width;
SARC	cis	rs79349575	0.783	rs12602933	chr17:47029280	G/C	cg07967210	chr17:47022446	SNF8	0.37	4.71	0.3	4.19e-6	Type 2 diabetes;
SARC	cis	rs9393777	0.588	rs6456727	chr6:26471155	T/C	cg12826209	chr6:26865740	GUSBL1	0.82	8.32	0.48	7.49e-15	Intelligence (multi-trait analysis);
SARC	cis	rs12621445	1	rs12621445	chr2:24154964	C/T	cg06627628	chr2:24431161	ITSN2	-0.75	-6.81	-0.41	7.99e-11	Immature fraction of reticulocytes;
SARC	cis	rs10193935	0.901	rs10201586	chr2:42622594	C/G	cg27598129	chr2:42591480	NA	-0.37	-5.21	-0.32	4.14e-7	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7808935	1.000	rs7808935	chr7:27977363	T/C	cg05786569	chr7:27702416	HIBADH	0.48	5.25	0.33	3.41e-7	Prostate cancer;
SARC	cis	rs7312933	0.510	rs61942483	chr12:42499538	T/A	cg01256987	chr12:42539512	GXYLT1	-0.42	-6.32	-0.38	1.34e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs3825932	0.744	rs11072818	chr15:79236933	A/G	cg25744700	chr15:79237217	CTSH	0.37	5.0	0.31	1.13e-6	Type 1 diabetes;
SARC	cis	rs77303550	1.000	rs217181	chr16:72114002	A/G	cg01557791	chr16:72042693	DHODH	-0.47	-4.93	-0.31	1.58e-6	Metabolite levels (small molecules and protein measures);
SARC	cis	rs9354308	0.867	rs2802051	chr6:66536403	C/T	cg07460842	chr6:66804631	NA	0.49	5.56	0.34	7.26e-8	Metabolite levels;
SARC	cis	rs9303401	0.659	rs62083368	chr17:56878062	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	11.56	0.6	9.91e-25	Cognitive test performance;
SARC	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg22433210	chr17:43662623	NA	1.07	13.07	0.65	1.24e-29	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7589728	1.000	rs7425670	chr2:88522028	C/T	cg04511125	chr2:88470314	THNSL2	0.69	6.14	0.37	3.47e-9	Plasma clusterin levels;
SARC	cis	rs17270561	0.609	rs4712960	chr6:25727265	C/T	cg16482183	chr6:26056742	HIST1H1C	0.43	5.25	0.33	3.49e-7	Iron status biomarkers;
SARC	cis	rs1182196	0.502	rs757786	chr7:2836019	C/T	cg19717773	chr7:2847554	GNA12	-0.39	-5.11	-0.32	6.57e-7	Plateletcrit;
SARC	cis	rs3106136	0.903	rs35361491	chr4:95202492	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.39	-6.09	-0.37	4.5e-9	Capecitabine sensitivity;
SARC	cis	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg24110177	chr3:50126178	RBM5	-0.39	-5.01	-0.31	1.07e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9843304	0.837	rs9857970	chr3:149210443	T/C	cg08667024	chr3:149219783	TM4SF4	0.37	5.82	0.36	1.94e-8	Gallstone disease;
SARC	cis	rs950776	0.518	rs11632604	chr15:78821914	T/C	cg06917634	chr15:78832804	PSMA4	0.91	14.24	0.68	1.6e-33	Sudden cardiac arrest;
SARC	trans	rs360488	0.639	rs6720754	chr2:14274175	C/T	cg13543375	chr1:22470218	WNT4	0.58	6.47	0.39	5.58e-10	Emphysema imaging phenotypes;
SARC	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	27.41	0.87	7.3e-75	Chronic sinus infection;
SARC	cis	rs8044995	0.563	rs56220628	chr16:68384837	G/A	cg05110241	chr16:68378359	PRMT7	-0.65	-6.34	-0.38	1.15e-9	Schizophrenia;
SARC	cis	rs1865760	0.566	rs9467663	chr6:26021456	C/G	cg17691542	chr6:26056736	HIST1H1C	0.52	6.44	0.39	6.72e-10	Height;
SARC	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	10.7	0.57	5.58e-22	Platelet count;
SARC	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg05368731	chr17:41323189	NBR1	0.81	9.9	0.54	1.66e-19	Menopause (age at onset);
SARC	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg10876282	chr6:28092338	ZSCAN16	-0.48	-4.73	-0.3	3.96e-6	Parkinson's disease;
SARC	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg03033257	chr22:50311977	ALG12;CRELD2	0.61	5.8	0.36	2.1e-8	Schizophrenia;
SARC	cis	rs933688	0.527	rs6898622	chr5:90578292	G/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.54	-4.86	-0.3	2.2e-6	Smoking behavior;
SARC	trans	rs61931739	0.500	rs34997501	chr12:34549828	C/G	cg26384229	chr12:38710491	ALG10B	0.92	13.82	0.67	4.07e-32	Morning vs. evening chronotype;
SARC	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	11.46	0.6	2.1e-24	Platelet count;
SARC	cis	rs10463554	0.892	rs257305	chr5:102417237	C/T	cg23492399	chr5:102201601	PAM	-0.52	-5.7	-0.35	3.63e-8	Parkinson's disease;
SARC	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg08677398	chr8:58056175	NA	0.42	4.99	0.31	1.2e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg26681399	chr22:41777847	TEF	0.47	5.1	0.32	6.98e-7	Vitiligo;
SARC	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg16325326	chr1:53192061	ZYG11B	-0.94	-17.86	-0.76	1.62e-45	Monocyte count;
SARC	cis	rs11225247	0.881	rs11225236	chr11:102250098	C/T	cg11690896	chr11:102217788	BIRC2	0.77	5.37	0.33	1.93e-7	Vein graft stenosis in coronary artery bypass grafting;
SARC	trans	rs66573146	0.808	rs73202120	chr4:7005588	A/G	cg07817883	chr1:32538562	TMEM39B	1.09	7.46	0.44	1.7e-12	Granulocyte percentage of myeloid white cells;
SARC	trans	rs61931739	0.517	rs12367881	chr12:34175508	T/C	cg13010199	chr12:38710504	ALG10B	0.72	9.61	0.53	1.27e-18	Morning vs. evening chronotype;
SARC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg18402987	chr7:1209562	NA	0.46	6.09	0.37	4.73e-9	Longevity;Endometriosis;
SARC	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg23758822	chr17:41437982	NA	0.89	11.2	0.59	1.38e-23	Menopause (age at onset);
SARC	cis	rs981844	0.712	rs4571310	chr4:154746832	T/C	cg14289246	chr4:154710475	SFRP2	-0.45	-5.36	-0.33	1.96e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg11764359	chr7:65958608	NA	0.78	9.86	0.54	2.14e-19	Aortic root size;
SARC	cis	rs6088590	0.931	rs6088617	chr20:33408036	G/A	cg24642439	chr20:33292090	TP53INP2	0.85	11.82	0.61	1.48e-25	Coronary artery disease;
SARC	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg13393036	chr8:95962371	TP53INP1	-0.36	-6.21	-0.38	2.38e-9	Type 2 diabetes;
SARC	cis	rs6831352	0.879	rs1984364	chr4:100070783	A/C	cg13256891	chr4:100009986	ADH5	-0.65	-7.8	-0.45	2.07e-13	Alcohol dependence;
SARC	cis	rs7582720	1.000	rs72932789	chr2:203699379	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	7.5	0.44	1.36e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs9916302	0.904	rs4239222	chr17:37696235	A/C	cg00129232	chr17:37814104	STARD3	0.62	7.6	0.45	7.28e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs7223966	0.960	rs11659013	chr17:61869559	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	7.19	0.43	8.86e-12	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs67311347	0.910	rs13089215	chr3:40495894	T/C	cg24209194	chr3:40518798	ZNF619	-0.62	-7.61	-0.45	6.86e-13	Renal cell carcinoma;
SARC	cis	rs72945132	0.882	rs6592552	chr11:70223831	A/T	cg00319359	chr11:70116639	PPFIA1	0.72	6.71	0.4	1.5e-10	Coronary artery disease;
SARC	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg22800045	chr5:56110881	MAP3K1	0.68	6.34	0.38	1.17e-9	Initial pursuit acceleration;
SARC	cis	rs6456156	0.565	rs12525345	chr6:167478875	T/C	cg23791538	chr6:167370224	RNASET2	-0.52	-6.81	-0.41	8.22e-11	Primary biliary cholangitis;
SARC	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg11987759	chr7:65425863	GUSB	0.48	5.81	0.36	1.99e-8	Aortic root size;
SARC	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg05863683	chr7:1912471	MAD1L1	0.36	5.45	0.34	1.25e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs72781680	0.898	rs6545127	chr2:24060670	C/T	cg06627628	chr2:24431161	ITSN2	-0.67	-6.5	-0.39	4.79e-10	Lymphocyte counts;
SARC	cis	rs240764	0.604	rs705586	chr6:101268046	C/G	cg09795085	chr6:101329169	ASCC3	0.42	5.18	0.32	4.8e-7	Neuroticism;
SARC	cis	rs4481887	1.000	rs4589143	chr1:248470446	A/G	cg01631408	chr1:248437212	OR2T33	-0.41	-5.13	-0.32	6.07e-7	Common traits (Other);
SARC	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg11987759	chr7:65425863	GUSB	-0.48	-6.04	-0.37	5.99e-9	Aortic root size;
SARC	cis	rs2387326	0.761	rs10764749	chr10:129901747	C/T	cg16087940	chr10:129947807	NA	-0.47	-6.16	-0.37	3.14e-9	Select biomarker traits;
SARC	cis	rs1008375	0.900	rs12650220	chr4:17595365	A/T	cg27347728	chr4:17578864	LAP3	0.45	5.42	0.33	1.45e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg07167872	chr1:205819463	PM20D1	-0.79	-11.74	-0.61	2.59e-25	Menarche (age at onset);
SARC	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg23758822	chr17:41437982	NA	0.76	9.49	0.53	2.77e-18	Menopause (age at onset);
SARC	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg18252515	chr7:66147081	NA	0.59	6.34	0.38	1.17e-9	Aortic root size;
SARC	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.48	5.85	0.36	1.65e-8	Tonsillectomy;
SARC	cis	rs2439831	0.850	rs28595038	chr15:44044859	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	8.57	0.49	1.44e-15	Lung cancer in ever smokers;
SARC	cis	rs8058578	0.943	rs7197770	chr16:30715908	T/C	cg00531865	chr16:30841666	NA	-0.51	-5.79	-0.35	2.24e-8	Multiple myeloma;
SARC	cis	rs72781680	0.665	rs72788298	chr2:24104293	T/C	cg08917208	chr2:24149416	ATAD2B	0.64	6.8	0.41	8.72e-11	Lymphocyte counts;
SARC	cis	rs1865760	0.566	rs9358904	chr6:26068566	C/T	cg17691542	chr6:26056736	HIST1H1C	0.51	6.34	0.38	1.2e-9	Height;
SARC	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg27572855	chr1:25598939	RHD	0.54	9.4	0.52	5.29e-18	Erythrocyte sedimentation rate;
SARC	cis	rs6088580	0.634	rs4911422	chr20:32999345	T/C	cg24642439	chr20:33292090	TP53INP2	-0.68	-8.73	-0.5	4.96e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs7429990	0.965	rs34507589	chr3:47874042	C/G	cg11946769	chr3:48343235	NME6	0.69	6.86	0.41	6.28e-11	Educational attainment (years of education);
SARC	cis	rs7000551	0.751	rs896379	chr8:22374200	C/T	cg12081754	chr8:22256438	SLC39A14	0.53	7.42	0.44	2.16e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg16606324	chr3:10149918	C3orf24	0.48	5.04	0.31	9.53e-7	Alzheimer's disease;
SARC	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.59	0.34	6.34e-8	Bipolar disorder;
SARC	cis	rs7511006	1.000	rs7364173	chr22:50681029	C/T	cg16473166	chr22:50639996	SELO	-0.46	-5.07	-0.32	8.14e-7	Obesity-related traits;
SARC	cis	rs7264396	0.790	rs6121018	chr20:34249060	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-8.22	-0.47	1.46e-14	Total cholesterol levels;
SARC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg18110333	chr6:292329	DUSP22	-0.59	-7.55	-0.44	9.52e-13	Menopause (age at onset);
SARC	cis	rs11122272	0.735	rs2486745	chr1:231505717	T/C	cg06096015	chr1:231504339	EGLN1	0.4	5.98	0.36	8.28e-9	Hemoglobin concentration;
SARC	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg06074448	chr4:187884817	NA	-0.41	-5.44	-0.34	1.38e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2070433	0.800	rs11702190	chr21:47877367	C/T	cg12379764	chr21:47803548	PCNT	0.56	5.06	0.31	8.55e-7	Lymphocyte counts;
SARC	cis	rs933688	0.938	rs6866923	chr5:90669352	A/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.05	13.43	0.66	7.67e-31	Smoking behavior;
SARC	trans	rs2727020	0.576	rs1917321	chr11:49377760	A/C	cg15704280	chr7:45808275	SEPT13	-0.65	-9.44	-0.53	4e-18	Coronary artery disease;
SARC	cis	rs568617	1.000	rs694994	chr11:65653309	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.47	5.45	0.34	1.31e-7	Crohn's disease;
SARC	cis	rs1008375	0.931	rs10939733	chr4:17570658	T/C	cg27347728	chr4:17578864	LAP3	0.45	5.46	0.34	1.23e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7327064	0.960	rs9546679	chr13:36783233	A/T	cg13455704	chr13:36871754	C13orf38	-0.48	-5.52	-0.34	9.05e-8	Economic and political preferences;
SARC	trans	rs7819412	0.522	rs11776603	chr8:11020313	G/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.03	-0.42	2.27e-11	Triglycerides;
SARC	trans	rs61931739	0.534	rs4365131	chr12:34053308	T/C	cg26384229	chr12:38710491	ALG10B	0.73	10.36	0.56	6.1e-21	Morning vs. evening chronotype;
SARC	trans	rs877282	0.853	rs10904544	chr10:756966	A/G	cg22713356	chr15:30763199	NA	0.98	9.74	0.54	5.03e-19	Uric acid levels;
SARC	cis	rs6539288	0.933	rs1444581	chr12:107314251	A/G	cg07730007	chr12:107377277	MTERFD3	0.39	4.8	0.3	2.9e-6	Total body bone mineral density;
SARC	cis	rs526231	0.511	rs1826673	chr5:102345916	G/A	cg23492399	chr5:102201601	PAM	-0.51	-5.77	-0.35	2.47e-8	Primary biliary cholangitis;
SARC	cis	rs7481584	0.624	rs511990	chr11:3052936	A/G	cg25174290	chr11:3078921	CARS	-0.6	-8.32	-0.48	7.35e-15	Calcium levels;
SARC	trans	rs8065311	0.701	rs6505044	chr17:54258240	G/T	cg24221648	chr13:79170283	NA	0.42	6.25	0.38	1.94e-9	Cannabis dependence;
SARC	cis	rs17376456	0.825	rs13165400	chr5:93091427	G/A	cg25358565	chr5:93447407	FAM172A	1.2	12.05	0.62	2.67e-26	Diabetic retinopathy;
SARC	cis	rs17125944	0.686	rs6572868	chr14:53325090	C/T	cg00686598	chr14:53173677	PSMC6	-0.7	-5.29	-0.33	2.84e-7	Alzheimer's disease (late onset);
SARC	cis	rs8067354	0.645	rs2173119	chr17:57859705	C/T	cg02344993	chr17:57696989	CLTC	0.62	6.0	0.37	7.47e-9	Hemoglobin concentration;
SARC	cis	rs7264396	0.836	rs6120995	chr20:34185726	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.54	-5.78	-0.35	2.38e-8	Total cholesterol levels;
SARC	cis	rs9303401	0.659	rs17822837	chr17:56737838	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.94	10.43	0.56	3.77e-21	Cognitive test performance;
SARC	cis	rs4253772	0.591	rs6007748	chr22:46657798	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.64	7.09	0.42	1.61e-11	LDL cholesterol;Cholesterol, total;
SARC	cis	rs9790314	0.521	rs1376122	chr3:161087857	A/G	cg03342759	chr3:160939853	NMD3	-0.57	-7.11	-0.42	1.45e-11	Morning vs. evening chronotype;
SARC	cis	rs12311304	1.000	rs56269213	chr12:15383650	A/C	cg08258403	chr12:15378311	NA	0.48	7.24	0.43	6.45e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs6568686	0.627	rs403667	chr6:111910604	T/C	cg15721981	chr6:111408429	SLC16A10	0.59	5.08	0.32	7.6e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs2191566	0.959	rs7255623	chr19:44510906	G/C	cg20607764	chr19:44506953	ZNF230	-0.44	-5.0	-0.31	1.11e-6	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs4430311	0.723	rs2220276	chr1:243717592	A/T	cg21452805	chr1:244014465	NA	-0.38	-4.78	-0.3	3.11e-6	Post-traumatic stress disorder (asjusted for relatedness);
SARC	cis	rs17376456	0.877	rs10514380	chr5:93409370	C/T	cg25358565	chr5:93447407	FAM172A	1.3	14.78	0.7	2.47e-35	Diabetic retinopathy;
SARC	cis	rs1878931	0.582	rs27238	chr16:3441223	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.65	-7.1	-0.42	1.46e-11	Body mass index (adult);
SARC	cis	rs7582720	1.000	rs72934563	chr2:203995405	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.76	7.84	0.46	1.65e-13	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs13256369	0.851	rs11786125	chr8:8564570	T/G	cg18904891	chr8:8559673	CLDN23	0.49	5.49	0.34	1.04e-7	Obesity-related traits;
SARC	cis	rs883565	0.569	rs784489	chr3:39173426	T/C	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.45	-5.33	-0.33	2.29e-7	Handedness;
SARC	cis	rs7402982	0.525	rs11247361	chr15:99207392	C/G	cg03437748	chr15:99193247	IGF1R	-0.59	-7.14	-0.42	1.21e-11	Birth weight;
SARC	cis	rs11711311	1.000	rs4362695	chr3:113534856	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	8.07	0.47	3.62e-14	IgG glycosylation;
SARC	cis	rs1559088	0.600	rs58173463	chr19:33596749	C/T	cg27124370	chr19:33622961	WDR88	0.51	6.91	0.41	4.52e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs10046574	0.831	rs113826521	chr7:135167999	T/C	cg27474649	chr7:135195673	CNOT4	0.87	7.13	0.42	1.27e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs2204008	0.641	rs66876045	chr12:38205713	G/A	cg13010199	chr12:38710504	ALG10B	0.78	10.64	0.57	8.11e-22	Bladder cancer;
SARC	trans	rs9650657	0.801	rs7018334	chr8:10612075	G/A	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.83	-0.41	7.37e-11	Neuroticism;
SARC	trans	rs57046232	0.502	rs13036588	chr20:6462428	T/C	cg27502912	chr22:51017001	CPT1B;CHKB-CPT1B	0.61	6.45	0.39	6.27e-10	Colorectal cancer;
SARC	cis	rs6088590	0.542	rs6059956	chr20:33220070	A/G	cg24642439	chr20:33292090	TP53INP2	0.67	8.76	0.5	4.09e-16	Coronary artery disease;
SARC	trans	rs61931739	0.500	rs7979769	chr12:34509522	C/T	cg13010199	chr12:38710504	ALG10B	0.82	11.58	0.6	8.37e-25	Morning vs. evening chronotype;
SARC	cis	rs7246760	0.867	rs1820114	chr19:9805692	G/A	cg16876255	chr19:9731953	ZNF561	0.79	4.88	0.3	1.95e-6	Pursuit maintenance gain;
SARC	cis	rs7586879	0.616	rs6545814	chr2:25131316	A/G	cg01884057	chr2:25150051	NA	0.29	4.79	0.3	3e-6	Body mass index;
SARC	cis	rs9462027	0.628	rs9469914	chr6:34827693	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.4	-5.74	-0.35	2.91e-8	Systemic lupus erythematosus;
SARC	cis	rs4711336	1.000	rs764754	chr6:33658310	C/T	cg15676125	chr6:33679581	C6orf125	0.57	6.81	0.41	8.1e-11	Height;
SARC	cis	rs2273669	0.915	rs4992384	chr6:109292806	A/G	cg01304950	chr6:109416612	SESN1;C6orf182	0.54	4.81	0.3	2.77e-6	Prostate cancer;
SARC	cis	rs2180341	0.924	rs877661	chr6:127587915	T/G	cg17762328	chr6:126965162	NA	-0.42	-4.8	-0.3	2.78e-6	Breast cancer;
SARC	cis	rs6570726	1.000	rs373778	chr6:145873252	C/T	cg05220968	chr6:146057943	EPM2A	-0.29	-4.92	-0.31	1.67e-6	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs62103177	0.810	rs62103192	chr18:77629050	A/T	cg05926928	chr17:57297772	GDPD1	1.09	9.19	0.52	2.24e-17	Opioid sensitivity;
SARC	cis	rs6908034	0.546	rs73376662	chr6:19806340	G/A	cg02682789	chr6:19804855	NA	0.72	5.45	0.34	1.31e-7	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs244731	0.959	rs10037110	chr5:176658066	A/T	cg16006841	chr5:176797999	RGS14	-0.57	-6.81	-0.41	8.34e-11	Urate levels in lean individuals;
SARC	cis	rs17376456	0.741	rs12374432	chr5:93481348	C/A	cg25358565	chr5:93447407	FAM172A	1.36	14.41	0.69	4.32e-34	Diabetic retinopathy;
SARC	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg25894440	chr7:65020034	NA	0.78	5.89	0.36	1.34e-8	Diabetic kidney disease;
SARC	cis	rs2013441	1.000	rs3850783	chr17:20184501	C/T	cg13482628	chr17:19912719	NA	0.47	6.07	0.37	5.22e-9	Obesity-related traits;
SARC	cis	rs34172651	0.917	rs17771137	chr16:24792242	G/A	cg00339695	chr16:24857497	SLC5A11	0.31	4.88	0.3	1.93e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9916302	0.555	rs12940193	chr17:37652178	T/G	cg00129232	chr17:37814104	STARD3	-0.64	-7.8	-0.46	2.05e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs9486719	0.741	rs976356	chr6:96849437	T/A	cg06623918	chr6:96969491	KIAA0776	0.74	7.29	0.43	4.77e-12	Migraine;Coronary artery disease;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg08717396	chr6:27100775	HIST1H2BJ;HIST1H2AG	-0.57	-6.47	-0.39	5.56e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg08109568	chr15:31115862	NA	0.52	6.27	0.38	1.71e-9	Huntington's disease progression;
SARC	cis	rs7785360	0.800	rs6978919	chr7:69735671	T/C	cg10619644	chr7:69149951	AUTS2	0.42	4.91	0.31	1.7e-6	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
SARC	cis	rs3733585	0.605	rs4697708	chr4:10121189	A/G	cg11266682	chr4:10021025	SLC2A9	-0.37	-6.06	-0.37	5.35e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs290268	0.874	rs290997	chr9:93559351	G/A	cg02608019	chr9:93564028	SYK	0.35	5.12	0.32	6.27e-7	Platelet count;
SARC	trans	rs61931739	0.635	rs1852224	chr12:33963080	A/C	cg13010199	chr12:38710504	ALG10B	0.5	6.42	0.39	7.45e-10	Morning vs. evening chronotype;
SARC	cis	rs35110281	0.693	rs4819290	chr21:45122713	C/T	cg01579765	chr21:45077557	HSF2BP	-0.34	-5.47	-0.34	1.18e-7	Mean corpuscular volume;
SARC	cis	rs1707322	1.000	rs785468	chr1:46521517	G/A	cg03146154	chr1:46216737	IPP	-0.48	-5.73	-0.35	3.14e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs55823223	0.648	rs11867582	chr17:73857306	A/G	cg23806715	chr17:73775811	H3F3B	0.56	5.81	0.36	2.02e-8	Psoriasis;
SARC	trans	rs9329221	0.623	rs7825778	chr8:10261010	C/T	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.44	-0.44	1.94e-12	Neuroticism;
SARC	cis	rs1580019	0.563	rs764483	chr7:32578150	A/T	cg07520158	chr7:32535189	LSM5;AVL9	0.57	7.34	0.43	3.63e-12	Cognitive ability;
SARC	cis	rs7264396	0.580	rs2425181	chr20:34447709	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-6.86	-0.41	6.24e-11	Total cholesterol levels;
SARC	cis	rs2777491	0.915	rs7178634	chr15:41634587	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.74	-10.99	-0.58	6.61e-23	Ulcerative colitis;
SARC	cis	rs751728	1.000	rs755496	chr6:33734376	C/G	cg15252951	chr6:33757062	LEMD2	0.58	6.82	0.41	7.84e-11	Crohn's disease;
SARC	cis	rs28374715	0.681	rs77187862	chr15:41619276	A/T	cg18705301	chr15:41695430	NDUFAF1	-0.96	-13.98	-0.68	1.19e-32	Ulcerative colitis;
SARC	cis	rs2120243	0.539	rs1456105	chr3:157123461	A/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.39	5.07	0.32	8e-7	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs12586317	0.534	rs1568200	chr14:35419592	C/T	cg26967526	chr14:35346199	BAZ1A	-0.64	-7.57	-0.44	8.55e-13	Psoriasis;
SARC	cis	rs7762018	0.655	rs11966349	chr6:170162537	A/G	cg13891659	chr6:170190454	C6orf122;C6orf208	-0.63	-5.44	-0.34	1.32e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs9790314	0.846	rs4470535	chr3:160974468	G/A	cg03342759	chr3:160939853	NMD3	-0.71	-9.51	-0.53	2.54e-18	Morning vs. evening chronotype;
SARC	cis	rs4481887	1.000	rs4244180	chr1:248471033	A/G	cg13385794	chr1:248469461	NA	0.36	5.46	0.34	1.19e-7	Common traits (Other);
SARC	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg08859206	chr1:53392774	SCP2	-0.4	-5.76	-0.35	2.69e-8	Monocyte count;
SARC	cis	rs897984	0.683	rs8046001	chr16:30833321	C/T	cg00531865	chr16:30841666	NA	-0.51	-6.03	-0.37	6.23e-9	Dementia with Lewy bodies;
SARC	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg05861140	chr6:150128134	PCMT1	-0.39	-5.05	-0.31	8.96e-7	Lung cancer;
SARC	cis	rs3733585	0.699	rs6449159	chr4:9960498	G/A	cg11266682	chr4:10021025	SLC2A9	-0.37	-6.25	-0.38	1.96e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg16479474	chr6:28041457	NA	0.37	5.39	0.33	1.73e-7	Depression;
SARC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg09373136	chr17:61933544	TCAM1	-0.44	-6.0	-0.37	7.57e-9	Prudent dietary pattern;
SARC	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg11062466	chr8:58055876	NA	0.67	6.2	0.38	2.57e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9660992	0.512	rs12142402	chr1:205128215	A/T	cg21545522	chr1:205238299	TMCC2	0.36	5.06	0.31	8.63e-7	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs9435341	0.965	rs56111229	chr1:107566689	T/A	cg09367891	chr1:107599246	PRMT6	0.71	9.09	0.51	4.43e-17	Facial morphology (factor 21, depth of nasal alae);
SARC	cis	rs2073300	0.609	rs34648279	chr20:23402935	T/G	cg12062639	chr20:23401060	NAPB	0.99	6.67	0.4	1.81e-10	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs9788682	1.000	rs7164594	chr15:78803057	C/T	cg24631222	chr15:78858424	CHRNA5	0.71	9.36	0.52	6.92e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs17270561	0.666	rs12209856	chr6:25793673	G/A	cg17691542	chr6:26056736	HIST1H1C	0.54	6.67	0.4	1.83e-10	Iron status biomarkers;
SARC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg11494091	chr17:61959527	GH2	0.53	7.86	0.46	1.4e-13	Prudent dietary pattern;
SARC	cis	rs72945132	0.882	rs7118156	chr11:70142922	T/C	cg05964544	chr11:70165517	PPFIA1	-0.61	-5.87	-0.36	1.5e-8	Coronary artery disease;
SARC	cis	rs73635312	0.850	rs77476954	chr10:8938561	A/G	cg24467326	chr10:9646929	NA	0.74	5.92	0.36	1.17e-8	Basal cell carcinoma;
SARC	cis	rs3020736	0.500	rs6002603	chr22:42492362	C/G	cg04733989	chr22:42467013	NAGA	-0.76	-10.61	-0.57	1.04e-21	Autism spectrum disorder or schizophrenia;
SARC	cis	rs921968	0.510	rs620887	chr2:219465594	C/A	cg02176678	chr2:219576539	TTLL4	0.47	7.11	0.42	1.43e-11	Mean corpuscular hemoglobin concentration;
SARC	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg03264133	chr6:25882463	NA	0.55	7.23	0.43	6.97e-12	Blood metabolite levels;
SARC	cis	rs4689388	0.926	rs4343789	chr4:6285228	C/G	cg14416269	chr4:6271139	WFS1	0.36	5.49	0.34	1.03e-7	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	trans	rs9650657	0.737	rs2409669	chr8:10623969	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.67	-0.4	1.88e-10	Neuroticism;
SARC	cis	rs2797160	1.000	rs1935774	chr6:125996661	A/G	cg05901451	chr6:126070800	HEY2	0.41	4.89	0.3	1.9e-6	Endometrial cancer;
SARC	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.95	11.92	0.62	6.96e-26	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs2295359	1.000	rs2295359	chr1:67635950	G/A	cg03340356	chr1:67600835	NA	0.33	4.81	0.3	2.71e-6	Psoriasis;
SARC	cis	rs16944613	0.541	rs4566137	chr15:91097964	A/G	cg26821196	chr15:91095069	CRTC3	0.58	5.92	0.36	1.12e-8	Colorectal cancer;
SARC	cis	rs2304069	0.913	rs7734382	chr5:149383241	A/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.67	6.6	0.4	2.76e-10	HIV-1 control;
SARC	cis	rs11785400	1.000	rs4736365	chr8:143742197	A/G	cg24634471	chr8:143751801	JRK	0.68	9.17	0.52	2.5e-17	Schizophrenia;
SARC	cis	rs35306767	0.903	rs11253460	chr10:887382	C/G	cg20503657	chr10:835505	NA	0.86	8.14	0.47	2.39e-14	Eosinophil percentage of granulocytes;
SARC	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg06221963	chr1:154839813	KCNN3	-0.51	-8.12	-0.47	2.74e-14	Prostate cancer;
SARC	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg11987759	chr7:65425863	GUSB	0.59	7.68	0.45	4.47e-13	Aortic root size;
SARC	cis	rs801193	0.613	rs2016325	chr7:66323500	T/C	cg11764359	chr7:65958608	NA	-0.46	-5.33	-0.33	2.31e-7	Aortic root size;
SARC	cis	rs17376456	0.569	rs68122392	chr5:93077807	A/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.56	5.76	0.35	2.58e-8	Diabetic retinopathy;
SARC	cis	rs67460515	0.892	rs35100811	chr3:161084046	A/C	cg03342759	chr3:160939853	NMD3	-0.63	-7.88	-0.46	1.25e-13	Parkinson's disease;
SARC	cis	rs7824557	0.544	rs1865521	chr8:11231249	T/C	cg21775007	chr8:11205619	TDH	0.63	8.26	0.48	1.08e-14	Retinal vascular caliber;
SARC	cis	rs7666738	0.830	rs10022389	chr4:99022229	T/C	cg05340658	chr4:99064831	C4orf37	0.66	9.04	0.51	6.35e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg16606324	chr3:10149918	C3orf24	0.49	4.86	0.3	2.13e-6	Alzheimer's disease;
SARC	cis	rs1865760	0.865	rs9393677	chr6:25945815	G/A	cg18357526	chr6:26021779	HIST1H4A	0.38	4.72	0.3	3.99e-6	Height;
SARC	cis	rs1153858	1.000	rs12437887	chr15:45669094	G/A	cg03999130	chr15:45571217	NA	0.39	4.98	0.31	1.25e-6	Homoarginine levels;
SARC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg05552183	chr6:42928497	GNMT	0.52	7.08	0.42	1.7e-11	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs9467711	0.651	rs66790453	chr6:26107088	C/T	cg21479132	chr6:26055353	NA	0.93	7.0	0.42	2.7e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs72792276	1.000	rs56657382	chr5:127387338	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	5.43	0.34	1.41e-7	Red cell distribution width;
SARC	cis	rs7717697	0.704	rs9293338	chr5:82728981	T/A	cg19814134	chr5:82768288	VCAN	0.43	4.99	0.31	1.16e-6	Vertical cup-disc ratio;
SARC	cis	rs1008375	1.000	rs56308330	chr4:17643050	G/A	cg16339924	chr4:17578868	LAP3	0.69	9.23	0.52	1.66e-17	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs8020941	0.585	rs76692665	chr14:97497406	G/A	cg05136476	chr3:53190709	NA	-0.63	-6.39	-0.39	8.99e-10	Diabetic kidney disease;
SARC	cis	rs36051895	0.695	rs2183137	chr9:5026293	A/G	cg02405213	chr9:5042618	JAK2	-0.5	-5.49	-0.34	1.07e-7	Pediatric autoimmune diseases;
SARC	cis	rs523522	0.962	rs12371550	chr12:120987643	C/T	cg27279351	chr12:120934652	DYNLL1	0.72	8.84	0.5	2.42e-16	High light scatter reticulocyte count;
SARC	cis	rs7555523	0.887	rs6696454	chr1:165707923	T/C	cg19769164	chr1:165738335	TMCO1	0.59	4.91	0.31	1.7e-6	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	cis	rs8008758	1.000	rs915379	chr14:101689392	T/C	cg26224664	chr14:101693935	NA	-0.4	-6.26	-0.38	1.84e-9	Body mass index (alcohol intake interaction);
SARC	cis	rs7607369	0.637	rs3888879	chr2:219290676	C/T	cg02176678	chr2:219576539	TTLL4	-0.49	-7.11	-0.42	1.42e-11	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs782590	0.967	rs2627759	chr2:55853341	T/C	cg18811423	chr2:55921094	PNPT1	0.69	10.56	0.57	1.51e-21	Metabolic syndrome;
SARC	cis	rs72945132	0.882	rs7943840	chr11:70228615	C/A	cg00319359	chr11:70116639	PPFIA1	0.68	6.46	0.39	6.04e-10	Coronary artery disease;
SARC	cis	rs2742234	0.590	rs2565201	chr10:43618484	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.42	-5.04	-0.31	9.52e-7	Hirschsprung disease;
SARC	cis	rs7953249	0.807	rs7310409	chr12:121424861	A/G	cg25281562	chr12:121454272	C12orf43	-0.41	-4.86	-0.3	2.18e-6	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs7223966	0.921	rs2854207	chr17:61947107	C/G	cg26338869	chr17:61819248	STRADA	0.49	5.28	0.33	2.9e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05036013	chr14:102391830	PPP2R5C	-0.71	-6.61	-0.4	2.6200000000000003e-10	Pancreatic cancer;
SARC	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.68	7.44	0.44	1.97e-12	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs1728785	1.000	rs1728764	chr16:68572292	G/C	cg02972257	chr16:68554789	NA	-0.44	-5.15	-0.32	5.43e-7	Ulcerative colitis;
SARC	cis	rs9398803	0.613	rs6918725	chr6:126990392	T/G	cg20229609	chr6:126660872	C6orf173	0.35	4.8	0.3	2.82e-6	Male-pattern baldness;
SARC	cis	rs9549367	0.826	rs9549710	chr13:113898064	A/C	cg18105134	chr13:113819100	PROZ	-0.39	-5.68	-0.35	3.93e-8	Platelet distribution width;
SARC	cis	rs10416265	0.528	rs28654374	chr19:33613610	G/A	cg17764715	chr19:33622953	WDR88	0.48	5.03	0.31	9.81e-7	Bone properties (heel);
SARC	cis	rs2290402	0.536	rs2061846	chr4:852484	A/G	cg00846425	chr4:957561	DGKQ	-0.42	-4.92	-0.31	1.61e-6	Type 2 diabetes;
SARC	cis	rs16976116	0.901	rs62020114	chr15:55501116	T/C	cg11288833	chr15:55489084	RSL24D1	0.63	6.13	0.37	3.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs11874712	0.931	rs8095031	chr18:43666861	T/C	cg25174615	chr18:43684699	ATP5A1;HAUS1	0.4	4.75	0.3	3.52e-6	Migraine - clinic-based;
SARC	cis	rs4718428	0.607	rs66954441	chr7:66369209	T/C	cg18252515	chr7:66147081	NA	-0.56	-6.11	-0.37	4.06e-9	Corneal structure;
SARC	cis	rs4689388	0.824	rs6446482	chr4:6295693	C/G	cg00701064	chr4:6280414	WFS1	0.53	8.37	0.48	5.39e-15	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs1348850	0.914	rs2364854	chr2:178378452	T/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	7.72	0.45	3.48e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9303280	0.806	rs36095411	chr17:38031865	T/G	cg20243544	chr17:37824526	PNMT	0.42	5.45	0.34	1.27e-7	Self-reported allergy;
SARC	cis	rs2230307	0.505	rs641458	chr1:100578672	G/C	cg24955406	chr1:100503596	HIAT1	-0.72	-7.13	-0.42	1.24e-11	Carotid intima media thickness;
SARC	trans	rs61931739	0.857	rs419112	chr12:34130528	A/G	cg26384229	chr12:38710491	ALG10B	0.58	7.84	0.46	1.65e-13	Morning vs. evening chronotype;
SARC	cis	rs6834538	0.931	rs6854311	chr4:113545454	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.48	5.66	0.35	4.39e-8	Free thyroxine concentration;
SARC	cis	rs2070997	0.756	rs2987903	chr9:133711263	G/A	cg03924115	chr9:133768966	QRFP	0.49	4.84	0.3	2.33e-6	Response to amphetamines;
SARC	cis	rs2120019	0.938	rs5020842	chr15:75322310	T/C	cg17294928	chr15:75287854	SCAMP5	-0.99	-14.94	-0.7	7.52e-36	Blood trace element (Zn levels);
SARC	cis	rs67311347	1.000	rs977652	chr3:40479169	A/G	cg01475735	chr3:40494733	NA	-0.41	-4.74	-0.3	3.72e-6	Renal cell carcinoma;
SARC	cis	rs8102137	1.000	rs79576418	chr19:30290890	A/G	cg27475126	chr19:30303651	CCNE1	-0.35	-4.73	-0.3	3.97e-6	Bladder cancer;
SARC	cis	rs10046574	0.831	rs7780345	chr7:135137731	T/C	cg27474649	chr7:135195673	CNOT4	0.88	7.17	0.43	9.89e-12	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs11098499	0.874	rs13139045	chr4:120168588	T/C	cg24375607	chr4:120327624	NA	0.37	4.75	0.3	3.5e-6	Corneal astigmatism;
SARC	cis	rs6991838	0.584	rs10957361	chr8:66531861	C/G	cg13398993	chr8:66546079	ARMC1	0.62	8.25	0.48	1.21e-14	Intelligence (multi-trait analysis);
SARC	cis	rs2760061	0.626	rs2527615	chr1:228119283	A/G	cg02753203	chr1:228287806	NA	-0.54	-7.6	-0.45	7.24e-13	Diastolic blood pressure;
SARC	cis	rs78487399	0.808	rs13413856	chr2:43764825	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-5.19	-0.32	4.54e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs7474896	0.583	rs1208770	chr10:38044683	C/T	cg00409905	chr10:38381863	ZNF37A	-0.45	-4.92	-0.31	1.6e-6	Obesity (extreme);
SARC	trans	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.21	-0.43	7.82e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs497273	0.512	rs1177585	chr12:121325321	C/T	cg02403541	chr12:121454288	C12orf43	-0.43	-5.09	-0.32	7.35e-7	Systemic lupus erythematosus;
SARC	cis	rs6912958	0.781	rs2207146	chr6:88180641	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.57	-0.4	3.27e-10	Monocyte percentage of white cells;
SARC	cis	rs11785400	0.793	rs3735993	chr8:143741170	G/A	cg24634471	chr8:143751801	JRK	0.6	7.67	0.45	4.63e-13	Schizophrenia;
SARC	trans	rs8073060	0.544	rs225268	chr17:33966224	A/C	cg19694781	chr19:47549865	TMEM160	-0.68	-6.84	-0.41	7.09e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs6570726	0.935	rs392014	chr6:145843691	A/C	cg05220968	chr6:146057943	EPM2A	-0.3	-5.21	-0.32	4.11e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6570726	0.935	rs384453	chr6:145815145	G/C	cg05220968	chr6:146057943	EPM2A	-0.29	-4.83	-0.3	2.44e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6840360	1.000	rs6535819	chr4:152651503	A/G	cg22705602	chr4:152727874	NA	-0.38	-6.42	-0.39	7.53e-10	Intelligence (multi-trait analysis);
SARC	cis	rs754466	0.580	rs10430529	chr10:79582623	C/A	cg17075019	chr10:79541650	NA	-0.79	-12.1	-0.62	1.74e-26	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2153535	0.580	rs6597326	chr6:8482019	A/C	cg07606381	chr6:8435919	SLC35B3	0.79	11.49	0.6	1.71e-24	Motion sickness;
SARC	cis	rs6815814	0.808	rs11721824	chr4:38767749	G/A	cg09316306	chr4:38807337	TLR1	0.49	4.77	0.3	3.22e-6	Breast cancer;
SARC	trans	rs2727020	0.595	rs10839281	chr11:49483373	A/C	cg15704280	chr7:45808275	SEPT13	-0.87	-14.41	-0.69	4.46e-34	Coronary artery disease;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg23952754	chr17:28431834	EFCAB5	-0.46	-6.31	-0.38	1.42e-9	Neuroticism;
SARC	cis	rs7296418	0.961	rs1727307	chr12:123575742	A/G	cg16085171	chr12:123569118	PITPNM2	-0.38	-4.82	-0.3	2.57e-6	Platelet count;
SARC	cis	rs7264396	0.563	rs11698796	chr20:34248134	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-6.37	-0.39	9.93e-10	Total cholesterol levels;
SARC	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg24846343	chr22:24311635	DDTL	-0.4	-4.84	-0.3	2.32e-6	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg04166393	chr7:2884313	GNA12	0.57	6.75	0.4	1.15e-10	Height;
SARC	cis	rs10895987	1.000	rs72932837	chr11:64876740	C/T	cg21152694	chr11:64885413	ZNHIT2	-0.46	-4.96	-0.31	1.37e-6	Blood protein levels;
SARC	cis	rs981844	0.683	rs1563462	chr4:154755051	G/A	cg14289246	chr4:154710475	SFRP2	-0.48	-5.67	-0.35	4.11e-8	Response to statins (LDL cholesterol change);
SARC	cis	rs896854	0.738	rs481887	chr8:95967838	A/G	cg16049864	chr8:95962084	TP53INP1	0.4	6.28	0.38	1.68e-9	Type 2 diabetes;
SARC	trans	rs453301	0.571	rs330057	chr8:9089793	C/T	cg21775007	chr8:11205619	TDH	-0.51	-6.32	-0.38	1.34e-9	Joint mobility (Beighton score);
SARC	cis	rs8114671	0.562	rs4911449	chr20:33512236	T/G	cg08999081	chr20:33150536	PIGU	0.32	4.73	0.3	3.83e-6	Height;
SARC	cis	rs2635047	0.811	rs17785419	chr18:44765469	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.49	-6.49	-0.39	5.16e-10	Educational attainment;
SARC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg24503407	chr1:205819492	PM20D1	0.53	7.07	0.42	1.78e-11	Menarche (age at onset);
SARC	cis	rs9486715	0.867	rs4839842	chr6:96955387	A/T	cg18709589	chr6:96969512	KIAA0776	0.59	7.33	0.43	3.65e-12	Headache;
SARC	cis	rs7666738	0.830	rs36047842	chr4:99004902	C/A	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6840360	0.967	rs4696105	chr4:152606702	T/G	cg22705602	chr4:152727874	NA	-0.37	-6.34	-0.38	1.18e-9	Intelligence (multi-trait analysis);
SARC	cis	rs11077998	0.967	rs4789782	chr17:80489323	G/T	cg10255544	chr17:80519551	FOXK2	-0.43	-6.39	-0.39	8.74e-10	Reticulocyte fraction of red cells;
SARC	cis	rs2688419	0.527	rs1355740	chr3:23070957	C/T	cg00327796	chr3:23032191	NA	0.4	5.69	0.35	3.81e-8	Type 2 diabetes;
SARC	cis	rs3820928	1.000	rs12615988	chr2:227769000	A/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-6.81	-0.41	7.98e-11	Pulmonary function;
SARC	trans	rs7944735	0.507	rs7396592	chr11:48100837	T/C	cg15704280	chr7:45808275	SEPT13	-0.58	-6.66	-0.4	1.92e-10	Intraocular pressure;
SARC	cis	rs11792861	0.890	rs57387569	chr9:111920392	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.71	8.01	0.46	5.43e-14	Menarche (age at onset);
SARC	cis	rs11785400	0.642	rs4256574	chr8:143725705	C/T	cg10596483	chr8:143751796	JRK	0.57	7.39	0.44	2.61e-12	Schizophrenia;
SARC	cis	rs7027203	0.663	rs4428726	chr9:96623559	T/G	cg14598338	chr9:96623480	NA	-0.56	-8.29	-0.48	9.09e-15	DNA methylation (variation);
SARC	cis	rs3767633	1.000	rs3767633	chr1:161826615	T/A	cg09175582	chr1:161736000	ATF6	0.68	5.88	0.36	1.38e-8	IgG glycosylation;
SARC	cis	rs4595586	0.545	rs7952765	chr12:39375325	C/G	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	cis	rs7940866	0.834	rs10791105	chr11:130839161	A/G	cg12179176	chr11:130786555	SNX19	0.66	8.73	0.5	4.89e-16	Schizophrenia;
SARC	cis	rs7937682	0.883	rs529529	chr11:111461128	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.93	-14.06	-0.68	6.32e-33	Primary sclerosing cholangitis;
SARC	cis	rs9346455	1.000	rs9346455	chr6:71991816	A/C	cg27238071	chr6:71998145	OGFRL1	0.63	5.09	0.32	7.41e-7	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
SARC	cis	rs7769051	0.522	rs57176306	chr6:133142168	C/T	cg22852734	chr6:133119734	C6orf192	1.2	7.69	0.45	4.24e-13	Type 2 diabetes nephropathy;
SARC	cis	rs2204008	0.657	rs8186888	chr12:38334260	T/G	cg26384229	chr12:38710491	ALG10B	0.7	8.73	0.5	4.95e-16	Bladder cancer;
SARC	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg18404041	chr3:52824283	ITIH1	-0.42	-6.35	-0.38	1.12e-9	Bipolar disorder;
SARC	cis	rs9398803	0.865	rs1538171	chr6:126752884	C/G	cg19875578	chr6:126661172	C6orf173	0.58	7.72	0.45	3.51e-13	Male-pattern baldness;
SARC	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-5.95	-0.36	9.94e-9	Mood instability;
SARC	cis	rs3008870	0.755	rs2815366	chr1:67499930	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.6	7.71	0.45	3.55e-13	Lymphocyte percentage of white cells;
SARC	cis	rs1448094	0.511	rs34656916	chr12:86154658	G/C	cg02569458	chr12:86230093	RASSF9	0.36	4.78	0.3	3.06e-6	Major depressive disorder;
SARC	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg18357526	chr6:26021779	HIST1H4A	0.86	11.22	0.59	1.2e-23	Intelligence (multi-trait analysis);
SARC	cis	rs9314323	0.964	rs3808579	chr8:26250682	C/T	cg11498726	chr8:26250323	BNIP3L	-0.62	-8.21	-0.47	1.53e-14	Red cell distribution width;
SARC	cis	rs4803468	1.000	rs10417997	chr19:41902361	G/A	cg09537434	chr19:41945824	ATP5SL	-0.95	-16.52	-0.73	4.11e-41	Height;
SARC	cis	rs4588572	0.601	rs10942855	chr5:77737529	G/A	cg11547950	chr5:77652471	NA	-0.41	-5.12	-0.32	6.45e-7	Triglycerides;
SARC	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg00149659	chr3:10157352	C3orf10	0.69	6.44	0.39	6.85e-10	Alzheimer's disease;
SARC	cis	rs9733	0.715	rs12402006	chr1:150869829	G/A	cg15448220	chr1:150897856	SETDB1	-0.43	-5.81	-0.36	1.99e-8	Tonsillectomy;
SARC	trans	rs3780486	0.846	rs10113903	chr9:33122645	C/G	cg20290983	chr6:43655470	MRPS18A	-1.08	-20.13	-0.8	6.73e-53	IgG glycosylation;
SARC	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg13206674	chr6:150067644	NUP43	0.47	6.1	0.37	4.45e-9	Lung cancer;
SARC	cis	rs72781680	0.898	rs111460347	chr2:24018833	G/A	cg06627628	chr2:24431161	ITSN2	-0.66	-6.27	-0.38	1.69e-9	Lymphocyte counts;
SARC	cis	rs2230307	0.536	rs580678	chr1:100483009	C/A	cg24955406	chr1:100503596	HIAT1	0.69	6.73	0.4	1.27e-10	Carotid intima media thickness;
SARC	cis	rs11122272	0.668	rs2749712	chr1:231537751	T/A	cg06096015	chr1:231504339	EGLN1	0.39	5.73	0.35	3.13e-8	Hemoglobin concentration;
SARC	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg20891283	chr12:69753455	YEATS4	-0.66	-9.51	-0.53	2.47e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs1801251	0.711	rs778339	chr2:233739678	T/C	cg25237894	chr2:233734115	C2orf82	-0.34	-4.94	-0.31	1.52e-6	Coronary artery disease;
SARC	cis	rs7833986	0.501	rs72653986	chr8:57035048	T/C	cg26371346	chr8:56986568	SNORD54;RPS20	0.74	7.53	0.44	1.13e-12	Height;
SARC	cis	rs763121	0.853	rs926299	chr22:39095698	C/G	cg06022373	chr22:39101656	GTPBP1	0.9	12.42	0.63	1.68e-27	Menopause (age at onset);
SARC	cis	rs4972806	0.849	rs2113561	chr2:177030925	G/A	cg14324370	chr2:177042789	NA	0.55	7.45	0.44	1.86e-12	IgG glycosylation;
SARC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg09033563	chr22:24373618	LOC391322	0.46	5.15	0.32	5.54e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-15.51	-0.71	9.76e-38	Chronic sinus infection;
SARC	cis	rs6430585	0.591	rs3098103	chr2:136656094	T/C	cg07169764	chr2:136633963	MCM6	1.02	13.35	0.66	1.39e-30	Corneal structure;
SARC	cis	rs941408	1.000	rs941406	chr19:2803623	A/G	cg06609049	chr19:2785107	THOP1	0.76	9.67	0.54	8.12e-19	Total cholesterol levels;
SARC	cis	rs13161895	1.000	rs6873781	chr5:179436734	A/C	cg06664874	chr5:179499304	RNF130	-0.49	-4.78	-0.3	3.14e-6	LDL cholesterol;
SARC	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg17691542	chr6:26056736	HIST1H1C	0.51	6.37	0.39	9.72e-10	Height;
SARC	trans	rs208520	0.690	rs4386800	chr6:66755242	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.01	13.61	0.67	2e-31	Exhaled nitric oxide output;
SARC	trans	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg00938859	chr5:1591904	SDHAP3	0.79	7.61	0.45	6.69e-13	Breast cancer;
SARC	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg06618935	chr21:46677482	NA	-0.42	-5.56	-0.34	7.22e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs7615952	0.673	rs34209763	chr3:125599595	G/A	cg07211511	chr3:129823064	LOC729375	-0.81	-8.09	-0.47	3.24e-14	Blood pressure (smoking interaction);
SARC	cis	rs3126085	0.935	rs10888468	chr1:152181539	C/T	cg09127314	chr1:152161683	NA	0.41	4.76	0.3	3.39e-6	Atopic dermatitis;
SARC	cis	rs17125944	0.686	rs7160582	chr14:53341445	G/T	cg00686598	chr14:53173677	PSMC6	0.75	5.05	0.31	9.04e-7	Alzheimer's disease (late onset);
SARC	cis	rs62344088	0.590	rs6872820	chr5:178900	G/A	cg20965017	chr5:231967	SDHA	-0.71	-5.33	-0.33	2.35e-7	Asthma (childhood onset);
SARC	cis	rs7647973	1.000	rs6805609	chr3:49471522	C/G	cg06212747	chr3:49208901	KLHDC8B	-0.57	-5.39	-0.33	1.69e-7	Menarche (age at onset);
SARC	cis	rs9815354	1.000	rs57479675	chr3:41798038	C/T	cg03022575	chr3:42003672	ULK4	0.59	5.68	0.35	4.02e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9660992	0.573	rs1172161	chr1:205206495	C/T	cg21643547	chr1:205240462	TMCC2	-0.6	-7.83	-0.46	1.76e-13	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs9916302	0.706	rs9899069	chr17:37540772	A/G	cg15445000	chr17:37608096	MED1	-0.45	-4.89	-0.31	1.86e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg21132104	chr15:45694354	SPATA5L1	-0.77	-10.91	-0.58	1.19e-22	Homoarginine levels;
SARC	cis	rs854765	0.647	rs8066764	chr17:17974668	C/T	cg04398451	chr17:18023971	MYO15A	-0.59	-8.6	-0.49	1.19e-15	Total body bone mineral density;
SARC	trans	rs2898290	0.617	rs13278965	chr8:11466745	A/T	cg06636001	chr8:8085503	FLJ10661	0.62	8.42	0.48	3.92e-15	Systolic blood pressure;
SARC	cis	rs698813	0.851	rs698812	chr2:44703714	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	5.54	0.34	8e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs9457247	0.566	rs10946207	chr6:167456036	C/T	cg23791538	chr6:167370224	RNASET2	-0.52	-6.75	-0.4	1.15e-10	Crohn's disease;
SARC	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg00149659	chr3:10157352	C3orf10	0.69	6.9	0.41	4.76e-11	Alzheimer's disease;
SARC	cis	rs11155671	0.530	rs9322228	chr6:150209309	C/G	cg00933542	chr6:150070202	PCMT1	0.29	4.81	0.3	2.77e-6	Testicular germ cell tumor;
SARC	cis	rs6546550	0.803	rs10165883	chr2:70117015	C/T	cg02498382	chr2:70120550	SNRNP27	-0.37	-6.0	-0.37	7.51e-9	Prevalent atrial fibrillation;
SARC	cis	rs13343954	0.518	rs8106293	chr19:33536376	C/T	cg27124370	chr19:33622961	WDR88	0.42	5.46	0.34	1.22e-7	Colorectal cancer;
SARC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg01238044	chr22:24384105	GSTT1	-0.57	-6.44	-0.39	6.66e-10	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs12142240	0.698	rs41293285	chr1:46808426	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-5.45	-0.34	1.28e-7	Menopause (age at onset);
SARC	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg19223190	chr17:80058835	NA	-0.43	-6.02	-0.37	6.57e-9	Life satisfaction;
SARC	cis	rs13191362	0.935	rs13212137	chr6:163010261	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.56	5.35	0.33	2.07e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2933343	0.951	rs789220	chr3:128592135	A/G	cg24203234	chr3:128598194	ACAD9	-0.51	-5.69	-0.35	3.76e-8	IgG glycosylation;
SARC	cis	rs7726839	0.794	rs10053310	chr5:595661	C/G	cg09021430	chr5:549028	NA	-0.47	-6.97	-0.42	3.2e-11	Obesity-related traits;
SARC	cis	rs4253772	0.591	rs7286155	chr22:46714735	A/G	cg24881330	chr22:46731750	TRMU	0.73	5.96	0.36	9.42e-9	LDL cholesterol;Cholesterol, total;
SARC	trans	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg07211511	chr3:129823064	LOC729375	-0.61	-6.58	-0.4	3.12e-10	Blood pressure (smoking interaction);
SARC	cis	rs943466	1.000	rs11754690	chr6:33744157	G/A	cg04676172	chr6:33757040	LEMD2	0.48	5.05	0.31	8.99e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
SARC	cis	rs9916302	0.904	rs6503507	chr17:37525274	C/T	cg00129232	chr17:37814104	STARD3	0.61	7.48	0.44	1.54e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs9902453	0.904	rs4598962	chr17:28293948	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	6.44	0.39	6.84e-10	Coffee consumption (cups per day);
SARC	trans	rs61931739	0.658	rs4476006	chr12:34237154	A/C	cg26384229	chr12:38710491	ALG10B	0.58	7.83	0.46	1.66e-13	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg22535103	chr8:58192502	C8orf71	-0.82	-9.34	-0.52	8.22e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs6700896	0.866	rs6588158	chr1:66160621	T/C	cg04111102	chr1:66153794	NA	-0.36	-5.55	-0.34	7.77e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs9875589	0.509	rs56071023	chr3:14075920	A/G	cg19554555	chr3:13937349	NA	-0.39	-5.02	-0.31	1.01e-6	Ovarian reserve;
SARC	cis	rs748404	0.631	rs28702649	chr15:43648629	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.49	5.6	0.34	5.88e-8	Lung cancer;
SARC	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs11758351	1.000	rs3734530	chr6:26195408	G/C	cg23601095	chr6:26197514	HIST1H3D	0.62	5.39	0.33	1.68e-7	Gout;Renal underexcretion gout;
SARC	cis	rs4727027	0.870	rs11525060	chr7:148801091	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	5.88	0.36	1.43e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs72781680	0.898	rs113522526	chr2:24018476	C/T	cg06627628	chr2:24431161	ITSN2	-0.65	-6.11	-0.37	4.18e-9	Lymphocyte counts;
SARC	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg03264133	chr6:25882463	NA	0.5	6.59	0.4	2.98e-10	Blood metabolite levels;
SARC	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-4.91	-0.31	1.71e-6	Total body bone mineral density;
SARC	cis	rs7824557	0.510	rs2736297	chr8:11234885	C/G	cg21775007	chr8:11205619	TDH	-0.65	-8.67	-0.49	7.44e-16	Retinal vascular caliber;
SARC	cis	rs1865760	0.534	rs72834629	chr6:26023032	C/T	cg17691542	chr6:26056736	HIST1H1C	0.63	7.21	0.43	7.81e-12	Height;
SARC	cis	rs34172651	0.917	rs11646987	chr16:24832408	G/T	cg00339695	chr16:24857497	SLC5A11	0.29	4.78	0.3	3.07e-6	Intelligence (multi-trait analysis);
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg26476595	chr16:2284284	E4F1	0.51	6.77	0.41	1.03e-10	Schizophrenia;
SARC	cis	rs9291683	0.609	rs7678012	chr4:9993772	T/C	cg00071950	chr4:10020882	SLC2A9	0.41	6.54	0.39	3.79e-10	Bone mineral density;
SARC	cis	rs1008375	0.966	rs6449329	chr4:17703677	T/C	cg27347728	chr4:17578864	LAP3	0.46	5.78	0.35	2.4e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7116495	0.529	rs575871	chr11:71778822	A/G	cg26138937	chr11:71823887	C11orf51	-0.84	-5.28	-0.33	2.96e-7	Severe influenza A (H1N1) infection;
SARC	cis	rs7539542	0.556	rs4950889	chr1:202874786	T/C	cg08940984	chr1:202857613	RABIF	0.39	5.28	0.33	3.01e-7	Mean platelet volume;
SARC	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg17509989	chr5:176798049	RGS14	0.68	8.91	0.5	1.48e-16	Urinary electrolytes (magnesium/calcium ratio);
SARC	cis	rs896854	0.608	rs7004862	chr8:95876963	T/G	cg16049864	chr8:95962084	TP53INP1	-0.41	-6.64	-0.4	2.17e-10	Type 2 diabetes;
SARC	cis	rs449789	0.817	rs534519	chr6:159711929	A/C	cg14500486	chr6:159655392	FNDC1	-0.44	-5.02	-0.31	1.01e-6	Pulse pressure;
SARC	cis	rs7179456	0.654	rs11637118	chr15:59248836	A/G	cg05156742	chr15:59063176	FAM63B	0.58	7.39	0.44	2.62e-12	Asperger disorder;
SARC	cis	rs9467711	0.651	rs35378061	chr6:26059157	C/A	cg21479132	chr6:26055353	NA	0.89	6.12	0.37	4.02e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg03806693	chr22:41940476	POLR3H	-0.89	-11.74	-0.61	2.55e-25	Vitiligo;
SARC	cis	rs4713118	0.662	rs149961	chr6:28015569	A/C	cg17221315	chr6:27791827	HIST1H4J	0.52	5.31	0.33	2.49e-7	Parkinson's disease;
SARC	cis	rs778371	0.723	rs283470	chr2:233656918	G/A	cg16596103	chr2:233749413	NGEF	-0.39	-6.15	-0.37	3.35e-9	Schizophrenia;
SARC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg01129886	chr20:31072675	C20orf112	-0.46	-6.28	-0.38	1.65e-9	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9362426	1.000	rs9450662	chr6:88088593	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.4	4.9	0.31	1.8e-6	Depressive episodes in bipolar disorder;
SARC	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg06634786	chr22:41940651	POLR3H	-0.58	-7.01	-0.42	2.48e-11	Vitiligo;
SARC	cis	rs9790314	0.846	rs4560315	chr3:160982132	G/T	cg04691961	chr3:161091175	C3orf57	-0.64	-8.7	-0.5	5.91e-16	Morning vs. evening chronotype;
SARC	trans	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.53	6.85	0.41	6.38e-11	Intelligence (multi-trait analysis);
SARC	trans	rs9325144	0.534	rs1843887	chr12:38692380	T/C	cg23762105	chr12:34175262	ALG10	-0.52	-6.97	-0.42	3.32e-11	Morning vs. evening chronotype;
SARC	cis	rs4595586	0.545	rs12828001	chr12:39392208	G/A	cg26384229	chr12:38710491	ALG10B	0.5	6.12	0.37	3.98e-9	Morning vs. evening chronotype;
SARC	cis	rs7223966	0.960	rs11659013	chr17:61869559	C/G	cg26338869	chr17:61819248	STRADA	0.47	5.08	0.32	7.71e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2204008	0.840	rs7957966	chr12:37953629	A/G	cg13010199	chr12:38710504	ALG10B	-0.68	-9.08	-0.51	4.74e-17	Bladder cancer;
SARC	trans	rs800082	0.671	rs800099	chr3:144398547	A/T	cg24215973	chr2:240111563	HDAC4	-0.53	-6.25	-0.38	1.96e-9	Smoking behavior;
SARC	cis	rs1580019	0.844	rs1584615	chr7:32503258	G/C	cg14728415	chr7:32535168	LSM5;AVL9	0.47	5.63	0.35	5.11e-8	Cognitive ability;
SARC	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg16479474	chr6:28041457	NA	0.34	5.09	0.32	7.34e-7	Cardiac Troponin-T levels;
SARC	cis	rs7772486	0.806	rs2247317	chr6:146217570	C/T	cg05347473	chr6:146136440	FBXO30	0.46	6.25	0.38	1.92e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs239198	0.578	rs13193416	chr6:101299602	A/T	cg09795085	chr6:101329169	ASCC3	0.47	6.0	0.37	7.54e-9	Menarche (age at onset);
SARC	cis	rs4742903	0.935	rs10820618	chr9:106960503	T/A	cg14250997	chr9:106856677	SMC2	0.43	5.42	0.33	1.47e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs72781680	0.752	rs72780185	chr2:24003967	G/A	cg08917208	chr2:24149416	ATAD2B	0.75	7.09	0.42	1.56e-11	Lymphocyte counts;
SARC	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg05313129	chr8:58192883	C8orf71	-0.52	-5.96	-0.36	9.41e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs523522	0.962	rs12309824	chr12:120990582	A/C	cg12219531	chr12:120966889	COQ5	0.83	11.21	0.59	1.28e-23	High light scatter reticulocyte count;
SARC	cis	rs2997447	0.846	rs3008232	chr1:26402621	A/G	cg19633962	chr1:26362018	EXTL1	-0.57	-5.17	-0.32	5.07e-7	QRS complex (12-leadsum);
SARC	cis	rs7647973	0.925	rs9881860	chr3:49352522	A/T	cg07636037	chr3:49044803	WDR6	0.69	7.52	0.44	1.16e-12	Menarche (age at onset);
SARC	cis	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg07777115	chr5:623756	CEP72	-0.56	-5.03	-0.31	9.96e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg10792982	chr14:105748885	BRF1	0.5	7.64	0.45	5.53e-13	Mean platelet volume;Platelet distribution width;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg10578696	chr1:65532742	NA	0.5	6.26	0.38	1.85e-9	Breast cancer;
SARC	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg00149659	chr3:10157352	C3orf10	0.65	6.21	0.38	2.38e-9	Alzheimer's disease;
SARC	cis	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg13072238	chr3:49761600	GMPPB	0.42	5.52	0.34	8.99e-8	Intelligence (multi-trait analysis);
SARC	cis	rs6570726	0.935	rs429306	chr6:145827016	T/C	cg05220968	chr6:146057943	EPM2A	-0.29	-4.99	-0.31	1.19e-6	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg18314121	chr1:225726360	ENAH	0.45	6.41	0.39	7.88e-10	Thyroid stimulating hormone;
SARC	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg12463550	chr7:65579703	CRCP	0.7	5.31	0.33	2.6e-7	Diabetic kidney disease;
SARC	cis	rs2153535	0.601	rs7741024	chr6:8530313	T/C	cg23788917	chr6:8435910	SLC35B3	0.62	8.31	0.48	8.11e-15	Motion sickness;
SARC	cis	rs9875589	0.509	rs2731330	chr3:14111588	C/G	cg19554555	chr3:13937349	NA	-0.4	-5.08	-0.32	7.65e-7	Ovarian reserve;
SARC	cis	rs9322193	0.607	rs6557165	chr6:150228019	C/G	cg05036130	chr6:150231994	NA	-0.31	-4.82	-0.3	2.54e-6	Lung cancer;
SARC	cis	rs6568686	0.527	rs174408	chr6:111932349	G/A	cg15721981	chr6:111408429	SLC16A10	0.71	5.98	0.36	8.21e-9	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs4566357	0.576	rs10187255	chr2:227913442	T/A	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.86	-0.36	1.61e-8	Coronary artery disease;
SARC	cis	rs11509153	0.664	rs6460903	chr7:12257728	T/C	cg23422036	chr7:12250390	TMEM106B	0.47	6.06	0.37	5.42e-9	Residual cognition;
SARC	cis	rs3892630	0.878	rs1559177	chr19:33210646	A/G	cg22980127	chr19:33182716	NUDT19	1.02	8.82	0.5	2.78e-16	Red blood cell traits;
SARC	cis	rs30380	0.666	rs26512	chr5:96128400	G/T	cg16492584	chr5:96139282	ERAP1	-0.48	-5.52	-0.34	8.89e-8	Cerebrospinal fluid biomarker levels;
SARC	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg09359103	chr1:154839909	KCNN3	-0.48	-8.05	-0.47	4.18e-14	Prostate cancer;
SARC	cis	rs2916247	1.000	rs2976505	chr8:92994972	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.57	-5.83	-0.36	1.86e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7223966	1.000	rs112143304	chr17:61822401	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.51	-5.22	-0.32	4.01e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9392918	0.934	rs3812163	chr6:7725760	A/T	cg23089261	chr6:7723385	NA	0.41	5.38	0.33	1.85e-7	Height;
SARC	cis	rs1008375	0.966	rs3796812	chr4:17582051	G/A	cg02297831	chr4:17616191	MED28	0.45	5.49	0.34	1.03e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs62344088	1.000	rs7710931	chr5:152286	C/T	cg22496380	chr5:211416	CCDC127	-0.87	-5.02	-0.31	1.02e-6	Asthma (childhood onset);
SARC	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg03576123	chr11:487126	PTDSS2	-1.12	-11.3	-0.6	6.74e-24	Body mass index;
SARC	cis	rs703842	1.000	rs11172333	chr12:58170335	A/G	cg00677455	chr12:58241039	CTDSP2	0.49	6.43	0.39	7.16e-10	Multiple sclerosis;
SARC	cis	rs703842	0.560	rs11533604	chr12:58047713	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.73	8.53	0.49	1.88e-15	Multiple sclerosis;
SARC	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9300255	0.544	rs10772995	chr12:123671761	T/C	cg00376283	chr12:123451042	ABCB9	0.55	6.33	0.38	1.26e-9	Neutrophil percentage of white cells;
SARC	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg20607798	chr8:58055168	NA	0.67	5.86	0.36	1.54e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10463316	0.963	rs10463315	chr5:150745615	T/A	cg03212797	chr5:150827313	SLC36A1	-0.44	-5.23	-0.32	3.73e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs1580019	0.547	rs56981934	chr7:32535202	C/G	cg14728415	chr7:32535168	LSM5;AVL9	0.53	6.81	0.41	8.21e-11	Cognitive ability;
SARC	cis	rs7408868	0.572	rs2074616	chr19:15294991	C/T	cg14696996	chr19:15285081	NOTCH3	0.55	5.47	0.34	1.13e-7	Pulse pressure;
SARC	cis	rs6991838	0.765	rs10957358	chr8:66502302	T/G	cg13398993	chr8:66546079	ARMC1	0.41	5.3	0.33	2.73e-7	Intelligence (multi-trait analysis);
SARC	cis	rs10992471	0.603	rs10114932	chr9:95307901	C/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.45	-0.34	1.25e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs854765	0.547	rs9896837	chr17:17924868	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.66	9.31	0.52	9.7e-18	Total body bone mineral density;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg22402853	chr12:50478901	SMARCD1	0.49	6.55	0.39	3.6e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs963731	0.649	rs1869514	chr2:39205796	C/T	cg04010122	chr2:39346883	SOS1	-0.83	-5.62	-0.35	5.55e-8	Corticobasal degeneration;
SARC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg17178900	chr1:205818956	PM20D1	0.78	12.49	0.63	9.33e-28	Menarche (age at onset);
SARC	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.7	5.79	0.35	2.26e-8	Initial pursuit acceleration;
SARC	cis	rs7264396	0.790	rs2425097	chr20:34308926	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	6.0	0.37	7.38e-9	Total cholesterol levels;
SARC	cis	rs7092929	0.941	rs705477	chr10:3582161	A/G	cg14308648	chr10:3568949	NA	0.51	5.09	0.32	7.28e-7	Coronary artery calcification;
SARC	cis	rs9807989	0.507	rs6743516	chr2:103036335	A/G	cg03938978	chr2:103052716	IL18RAP	0.32	5.12	0.32	6.49e-7	Asthma;
SARC	cis	rs72901758	0.810	rs61740716	chr17:76244648	G/A	cg23302638	chr17:76210176	BIRC5	0.47	4.88	0.3	1.97e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
SARC	cis	rs1865760	0.929	rs1816546	chr6:25938252	C/T	cg16482183	chr6:26056742	HIST1H1C	0.54	6.84	0.41	6.74e-11	Height;
SARC	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg01316550	chr5:56110833	MAP3K1	0.54	4.95	0.31	1.39e-6	Initial pursuit acceleration;
SARC	cis	rs965469	0.895	rs6051729	chr20:3290615	A/G	cg25506879	chr20:3388711	C20orf194	-0.49	-5.06	-0.31	8.49e-7	IFN-related cytopenia;
SARC	cis	rs8058578	0.943	rs3747486	chr16:30786927	C/T	cg00531865	chr16:30841666	NA	-0.55	-6.3	-0.38	1.49e-9	Multiple myeloma;
SARC	cis	rs7914558	0.966	rs10786727	chr10:104698523	G/A	cg04362960	chr10:104952993	NT5C2	0.41	4.95	0.31	1.43e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg27574168	chr18:54318782	WDR7	-0.55	-6.32	-0.38	1.3e-9	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs6546550	0.867	rs6738174	chr2:70150215	A/C	cg02498382	chr2:70120550	SNRNP27	-0.33	-5.36	-0.33	1.99e-7	Prevalent atrial fibrillation;
SARC	cis	rs3923518	0.824	rs13099670	chr3:38936829	G/A	cg15678707	chr3:39149194	GORASP1;TTC21A	0.45	4.8	0.3	2.83e-6	Migraine;
SARC	cis	rs4975616	0.869	rs467095	chr5:1336221	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.56	-7.51	-0.44	1.25e-12	Lung cancer;
SARC	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg07701084	chr6:150067640	NUP43	0.41	5.37	0.33	1.87e-7	Lung cancer;
SARC	cis	rs4253772	0.591	rs6007748	chr22:46657798	A/G	cg24881330	chr22:46731750	TRMU	0.62	6.86	0.41	6.14e-11	LDL cholesterol;Cholesterol, total;
SARC	trans	rs11098499	0.779	rs80242894	chr4:120375752	G/A	cg25214090	chr10:38739885	LOC399744	0.56	7.36	0.43	3.18e-12	Corneal astigmatism;
SARC	cis	rs10779751	0.770	rs2486922	chr1:11124885	T/C	cg08854313	chr1:11322531	MTOR	0.82	11.26	0.59	8.86e-24	Body mass index;
SARC	cis	rs1448094	0.692	rs7958438	chr12:86326141	A/T	cg02569458	chr12:86230093	RASSF9	0.42	5.96	0.36	9.16e-9	Major depressive disorder;
SARC	cis	rs754466	1.000	rs12220328	chr10:79681482	G/C	cg17075019	chr10:79541650	NA	-0.64	-7.56	-0.44	9.11e-13	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg21442419	chr1:2182373	SKI	0.46	6.06	0.37	5.5e-9	Height;
SARC	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg03351412	chr1:154909251	PMVK	0.58	7.48	0.44	1.53e-12	Prostate cancer;
SARC	cis	rs72627123	0.656	rs6574169	chr14:74637178	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	-0.74	-5.83	-0.36	1.87e-8	Morning vs. evening chronotype;
SARC	cis	rs6570726	0.870	rs370653	chr6:145823642	G/A	cg05347473	chr6:146136440	FBXO30	0.48	6.42	0.39	7.51e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg13939156	chr17:80058883	NA	0.4	6.25	0.38	1.92e-9	Life satisfaction;
SARC	cis	rs820218	0.886	rs820158	chr17:73660179	A/G	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.69	9.3	0.52	1.09e-17	Rotator cuff tears;
SARC	cis	rs3796352	0.881	rs13100714	chr3:53074824	T/G	cg27565382	chr3:53032988	SFMBT1	0.86	6.27	0.38	1.74e-9	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs6088580	0.634	rs6059890	chr20:33101653	G/C	cg08999081	chr20:33150536	PIGU	0.43	6.64	0.4	2.18e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg18876405	chr7:65276391	NA	-0.46	-5.18	-0.32	4.74e-7	Aortic root size;
SARC	cis	rs7927771	0.965	rs35985502	chr11:47847428	G/A	cg20307385	chr11:47447363	PSMC3	-0.47	-5.59	-0.34	6.3e-8	Subjective well-being;
SARC	cis	rs9640161	0.789	rs28439010	chr7:150046276	C/T	cg10018233	chr7:150070692	REPIN1	0.62	8.41	0.48	4.17e-15	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg12463550	chr7:65579703	CRCP	0.43	5.02	0.31	1.01e-6	Aortic root size;
SARC	cis	rs9303401	0.612	rs2526370	chr17:56487636	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.14	0.32	5.87e-7	Cognitive test performance;
SARC	cis	rs509477	0.718	rs273356	chr18:32597462	A/T	cg23791764	chr18:32556832	MAPRE2	0.42	5.18	0.32	4.89e-7	Cerebrospinal fluid AB1-42 levels;
SARC	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg19223190	chr17:80058835	NA	0.45	6.35	0.38	1.13e-9	Life satisfaction;
SARC	cis	rs2952156	0.920	rs2247862	chr17:37829129	A/G	cg20243544	chr17:37824526	PNMT	0.49	6.14	0.37	3.46e-9	Asthma;
SARC	cis	rs4595586	0.545	rs2388177	chr12:39364403	T/C	cg13010199	chr12:38710504	ALG10B	0.4	4.75	0.3	3.57e-6	Morning vs. evening chronotype;
SARC	cis	rs11098499	0.909	rs7681978	chr4:120383775	T/C	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	cis	rs71636778	0.722	rs116491347	chr1:27172684	C/T	cg04852280	chr1:26496234	ZNF593	0.55	5.16	0.32	5.19e-7	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs9457247	1.000	rs394522	chr6:167398071	A/C	cg07741184	chr6:167504864	NA	0.29	5.55	0.34	7.59e-8	Crohn's disease;
SARC	cis	rs2276314	0.857	rs16967327	chr18:33587036	C/T	cg05985134	chr18:33552581	C18orf21	0.7	7.4	0.44	2.42e-12	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs9309473	0.500	rs11126402	chr2:73776582	G/C	cg20560298	chr2:73613845	ALMS1	-0.5	-6.72	-0.4	1.39e-10	Metabolite levels;
SARC	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	9.14	0.51	3.15e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7312933	0.703	rs12371615	chr12:42563989	C/G	cg19980929	chr12:42632907	YAF2	0.43	5.83	0.36	1.79e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs78456975	1.000	rs11891809	chr2:1566001	A/G	cg01028140	chr2:1542097	TPO	-0.48	-4.94	-0.31	1.46e-6	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs6456156	0.586	rs12528323	chr6:167461645	A/G	cg23791538	chr6:167370224	RNASET2	-0.52	-6.79	-0.41	9.49e-11	Primary biliary cholangitis;
SARC	cis	rs8114671	0.562	rs6088653	chr20:33520321	T/C	cg24642439	chr20:33292090	TP53INP2	0.49	5.99	0.37	7.85e-9	Height;
SARC	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.58	-7.07	-0.42	1.82e-11	Prudent dietary pattern;
SARC	cis	rs11792861	0.566	rs11792635	chr9:111848819	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.44	5.45	0.34	1.28e-7	Menarche (age at onset);
SARC	cis	rs4460629	0.521	rs12039316	chr1:155073221	C/T	cg22049894	chr1:155113146	DPM3	0.41	5.21	0.32	4.21e-7	Serum magnesium levels;
SARC	cis	rs12579753	0.917	rs10862360	chr12:82187411	A/G	cg07988820	chr12:82153109	PPFIA2	-0.51	-6.19	-0.38	2.75e-9	Resting heart rate;
SARC	cis	rs1153858	1.000	rs7169587	chr15:45640379	A/G	cg14582100	chr15:45693742	SPATA5L1	0.37	5.06	0.31	8.45e-7	Homoarginine levels;
SARC	cis	rs2997447	0.653	rs56134135	chr1:26440718	A/T	cg19633962	chr1:26362018	EXTL1	-0.58	-5.18	-0.32	4.87e-7	QRS complex (12-leadsum);
SARC	cis	rs6991838	0.550	rs7817112	chr8:66537120	C/A	cg13398993	chr8:66546079	ARMC1	0.62	8.19	0.47	1.72e-14	Intelligence (multi-trait analysis);
SARC	cis	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg10591475	chr6:28109693	ZNF192	-0.4	-4.9	-0.31	1.76e-6	Schizophrenia;
SARC	trans	rs3808502	0.563	rs10098664	chr8:11417493	T/C	cg06636001	chr8:8085503	FLJ10661	0.63	8.53	0.49	1.84e-15	Neuroticism;
SARC	cis	rs7522061	0.546	rs10796981	chr1:157642082	A/G	cg18268488	chr1:157545234	FCRL4	0.26	4.79	0.3	2.9e-6	Blood protein levels;
SARC	cis	rs4642101	0.883	rs11718898	chr3:12848822	T/C	cg24848339	chr3:12840334	CAND2	0.33	4.74	0.3	3.71e-6	QRS complex (12-leadsum);
SARC	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg26354017	chr1:205819088	PM20D1	-0.47	-5.87	-0.36	1.47e-8	Menarche (age at onset);
SARC	cis	rs60695258	1.000	rs2035403	chr4:88018991	A/G	cg11209507	chr4:87813803	C4orf36	0.38	5.02	0.31	1.03e-6	Hematocrit;
SARC	cis	rs9660992	0.573	rs7368327	chr1:205214792	C/T	cg21643547	chr1:205240462	TMCC2	-0.56	-7.3	-0.43	4.44e-12	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg23262073	chr20:60523788	NA	-0.43	-6.23	-0.38	2.22e-9	Body mass index;
SARC	cis	rs950776	0.684	rs61012457	chr15:78865694	C/G	cg06917634	chr15:78832804	PSMA4	0.79	10.7	0.57	5.32e-22	Sudden cardiac arrest;
SARC	cis	rs2180341	0.960	rs7756884	chr6:127684018	A/G	cg17762328	chr6:126965162	NA	-0.45	-4.96	-0.31	1.33e-6	Breast cancer;
SARC	cis	rs7772486	0.754	rs9386133	chr6:146141213	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.69	0.4	1.63e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs607987	0.871	rs34487664	chr11:30275351	T/C	cg06241208	chr11:30344200	C11orf46	0.42	5.06	0.31	8.31e-7	Body mass index;
SARC	cis	rs4589502	0.841	rs55855162	chr15:67140523	C/A	cg12317470	chr15:67143691	NA	0.73	5.31	0.33	2.61e-7	Lung cancer (smoking interaction);
SARC	cis	rs3796352	0.571	rs71301816	chr3:53142071	G/A	cg12962167	chr3:53033115	SFMBT1	0.77	4.83	0.3	2.47e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	5.52	0.34	9.21e-8	Personality dimensions;
SARC	cis	rs10463554	0.963	rs27970	chr5:102486723	G/C	cg23492399	chr5:102201601	PAM	-0.48	-5.24	-0.32	3.67e-7	Parkinson's disease;
SARC	cis	rs9325144	0.600	rs11183505	chr12:38759110	G/T	cg13010199	chr12:38710504	ALG10B	-0.51	-6.47	-0.39	5.79e-10	Morning vs. evening chronotype;
SARC	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg05368731	chr17:41323189	NBR1	0.76	9.01	0.51	7.77e-17	Menopause (age at onset);
SARC	cis	rs7666738	0.830	rs1813972	chr4:98886828	C/A	cg05340658	chr4:99064831	C4orf37	0.65	8.56	0.49	1.54e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9894429	0.646	rs9904137	chr17:79613925	C/T	cg10661904	chr17:79619235	PDE6G	-0.44	-6.25	-0.38	1.91e-9	Eye color traits;
SARC	cis	rs55794721	0.543	rs1293260	chr1:25709104	C/G	cg03650068	chr1:25596491	NA	0.33	5.02	0.31	1.05e-6	Plateletcrit;Mean corpuscular volume;
SARC	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg26335602	chr6:28129616	ZNF389	0.52	5.69	0.35	3.74e-8	Depression;
SARC	trans	rs11098499	0.955	rs1511015	chr4:120170473	A/C	cg25214090	chr10:38739885	LOC399744	0.52	6.89	0.41	5.07e-11	Corneal astigmatism;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg00130309	chr20:25677623	ZNF337	-0.52	-6.59	-0.4	2.83e-10	Gallstone disease;
SARC	cis	rs6594499	0.872	rs6859041	chr5:110435231	G/A	cg04022379	chr5:110408740	TSLP	0.43	5.32	0.33	2.48e-7	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg26681399	chr22:41777847	TEF	-0.45	-4.86	-0.3	2.17e-6	Vitiligo;
SARC	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg11062466	chr8:58055876	NA	0.56	5.69	0.35	3.79e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs793571	0.566	rs1648532	chr15:59076778	G/C	cg05156742	chr15:59063176	FAM63B	0.76	10.61	0.57	1.06e-21	Schizophrenia;
SARC	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg19223190	chr17:80058835	NA	0.45	6.18	0.38	2.83e-9	Life satisfaction;
SARC	cis	rs9462027	0.628	rs7752060	chr6:34760325	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.85	-0.36	1.64e-8	Systemic lupus erythematosus;
SARC	cis	rs9916302	0.904	rs12452509	chr17:37574722	G/A	cg20243544	chr17:37824526	PNMT	0.56	6.64	0.4	2.19e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs3733585	0.648	rs13125029	chr4:9982029	A/G	cg00071950	chr4:10020882	SLC2A9	0.35	5.24	0.32	3.51e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg03060546	chr3:49711283	APEH	0.48	6.24	0.38	2e-9	Menarche (age at onset);
SARC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg11301795	chr4:187892539	NA	-0.75	-11.3	-0.59	6.84e-24	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg24531977	chr5:56204891	C5orf35	-0.54	-5.45	-0.34	1.26e-7	Initial pursuit acceleration;
SARC	cis	rs933688	1.000	rs1035477	chr5:90743325	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	12.57	0.64	5.35e-28	Smoking behavior;
SARC	cis	rs6540556	0.859	rs12079960	chr1:209937168	A/C	cg05527609	chr1:210001259	C1orf107	-0.56	-6.18	-0.38	2.82e-9	Red blood cell count;
SARC	cis	rs7666738	0.830	rs7662596	chr4:99019962	G/T	cg05340658	chr4:99064831	C4orf37	0.66	9.04	0.51	6.35e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	cis	rs2832077	0.527	rs2738953	chr21:30238363	G/C	cg08807101	chr21:30365312	RNF160	0.51	5.56	0.34	7.38e-8	Cognitive test performance;
SARC	cis	rs17376456	0.935	rs13156002	chr5:93508931	G/A	cg21475434	chr5:93447410	FAM172A	0.92	7.93	0.46	9.34e-14	Diabetic retinopathy;
SARC	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg10523679	chr1:76189770	ACADM	-0.51	-6.9	-0.41	5e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs3796352	1.000	rs35163227	chr3:53127876	A/G	cg12962167	chr3:53033115	SFMBT1	0.8	5.17	0.32	4.96e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg10207240	chr12:122356781	WDR66	0.29	5.06	0.31	8.7e-7	Mean corpuscular volume;
SARC	cis	rs910316	1.000	rs2300601	chr14:75639571	A/G	cg08847533	chr14:75593920	NEK9	0.92	13.34	0.66	1.49e-30	Height;
SARC	cis	rs9911578	0.902	rs12948746	chr17:57071892	A/G	cg05425664	chr17:57184151	TRIM37	-0.63	-7.81	-0.46	1.99e-13	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg21724239	chr8:58056113	NA	0.6	6.31	0.38	1.43e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs986417	1.000	rs1262174	chr14:60887194	C/T	cg27398547	chr14:60952738	C14orf39	0.76	7.17	0.43	9.58e-12	Gut microbiota (bacterial taxa);
SARC	cis	rs2486288	0.656	rs2413773	chr15:45549442	C/A	cg21132104	chr15:45694354	SPATA5L1	-0.51	-6.44	-0.39	6.68e-10	Glomerular filtration rate;
SARC	cis	rs9291683	0.566	rs13115776	chr4:10040189	C/G	cg11266682	chr4:10021025	SLC2A9	0.4	6.87	0.41	5.83e-11	Bone mineral density;
SARC	cis	rs13191362	1.000	rs34052221	chr6:163160803	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.43	5.3	0.33	2.71e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs12545109	0.800	rs1530217	chr8:57408097	C/T	cg19413350	chr8:57351067	NA	-0.43	-4.82	-0.3	2.57e-6	Obesity-related traits;
SARC	cis	rs796364	0.806	rs74771155	chr2:200913743	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.68	-5.72	-0.35	3.32e-8	Schizophrenia;
SARC	cis	rs3956705	0.966	rs1037324	chr7:32981161	A/C	cg06627557	chr7:32535165	LSM5;AVL9	0.42	4.84	0.3	2.36e-6	Red cell distribution width;
SARC	cis	rs6504663	1.000	rs6504661	chr17:48580126	A/T	cg03611598	chr17:48586076	MYCBPAP	-0.49	-6.19	-0.38	2.71e-9	Visceral fat;
SARC	cis	rs1707322	1.000	rs785480	chr1:46492164	C/G	cg03146154	chr1:46216737	IPP	0.43	4.96	0.31	1.37e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs17376456	0.569	rs68122392	chr5:93077807	A/T	cg21475434	chr5:93447410	FAM172A	0.62	6.01	0.37	7.07e-9	Diabetic retinopathy;
SARC	cis	rs920590	0.717	rs62496675	chr8:19635733	A/T	cg01411142	chr8:19674711	INTS10	0.41	4.8	0.3	2.81e-6	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs3008870	0.755	rs3929738	chr1:67397865	T/C	cg02640540	chr1:67518911	SLC35D1	0.45	5.16	0.32	5.34e-7	Lymphocyte percentage of white cells;
SARC	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg24642844	chr7:1081250	C7orf50	-0.57	-6.05	-0.37	5.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs4595586	0.545	rs12811619	chr12:39392196	T/C	cg26384229	chr12:38710491	ALG10B	0.5	6.12	0.37	3.98e-9	Morning vs. evening chronotype;
SARC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.31	-4.84	-0.3	2.34e-6	Total body bone mineral density;
SARC	cis	rs858239	0.601	rs10255228	chr7:23158863	G/T	cg23682824	chr7:23144976	KLHL7	0.72	9.81	0.54	3.17e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg11644478	chr21:40555479	PSMG1	-0.58	-7.27	-0.43	5.33e-12	Menarche (age at onset);
SARC	cis	rs9399135	0.967	rs7741626	chr6:135314182	C/T	cg24558204	chr6:135376177	HBS1L	0.45	6.11	0.37	4.14e-9	Red blood cell count;
SARC	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg04944784	chr2:26401820	FAM59B	-0.48	-5.8	-0.36	2.14e-8	Gut microbiome composition (summer);
SARC	trans	rs61931739	0.534	rs12831685	chr12:34038392	C/T	cg26384229	chr12:38710491	ALG10B	0.75	10.54	0.57	1.75e-21	Morning vs. evening chronotype;
SARC	cis	rs79149102	0.579	rs7172715	chr15:75287375	C/G	cg00629941	chr15:75287862	SCAMP5	-0.74	-5.48	-0.34	1.11e-7	Lung cancer;
SARC	cis	rs2404602	0.672	rs35374222	chr15:77071394	G/T	cg15268244	chr15:77196840	NA	0.45	5.16	0.32	5.25e-7	Blood metabolite levels;
SARC	cis	rs4820539	1.000	rs916583	chr22:23469267	C/T	cg14186256	chr22:23484241	RTDR1	0.88	14.41	0.69	4.24e-34	Bone mineral density;
SARC	cis	rs4664308	0.967	rs56293836	chr2:160910958	T/C	cg03641300	chr2:160917029	PLA2R1	-0.68	-9.15	-0.51	3.05e-17	Idiopathic membranous nephropathy;
SARC	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg11965913	chr1:205819406	PM20D1	0.61	6.98	0.42	3.02e-11	Prostate-specific antigen levels;
SARC	cis	rs1559088	0.739	rs9304845	chr19:33592794	A/G	cg17764715	chr19:33622953	WDR88	0.49	6.72	0.4	1.4e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs8523	0.901	rs1225737	chr6:10982652	C/T	cg13562911	chr6:11044106	ELOVL2	0.48	6.5	0.39	4.87e-10	Red blood cell fatty acid levels;
SARC	cis	rs11190604	1.000	rs4604805	chr10:102261409	C/G	cg14256752	chr10:102295592	HIF1AN	0.47	5.22	0.32	3.88e-7	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs7772486	0.776	rs4316025	chr6:146238032	C/T	cg05347473	chr6:146136440	FBXO30	-0.46	-6.14	-0.37	3.61e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6568686	0.576	rs12201640	chr6:111618318	G/A	cg15721981	chr6:111408429	SLC16A10	0.69	5.85	0.36	1.67e-8	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs1707322	1.000	rs6695421	chr1:46380207	T/C	cg03146154	chr1:46216737	IPP	0.46	5.52	0.34	8.98e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg18404041	chr3:52824283	ITIH1	-0.39	-5.93	-0.36	1.06e-8	Bipolar disorder;
SARC	cis	rs1865760	0.865	rs1541987	chr6:25950397	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.39	-4.86	-0.3	2.14e-6	Height;
SARC	cis	rs72653721	0.689	rs61669862	chr6:11068598	T/C	cg13562911	chr6:11044106	ELOVL2	0.53	5.96	0.36	9.39e-9	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	cis	rs16954776	1	rs16954776	chr13:98700617	C/T	cg21719626	chr13:99047355	FARP1	-0.64	-4.85	-0.3	2.29e-6	Smooth-surface caries;
SARC	trans	rs7819412	0.595	rs4841500	chr8:10988275	A/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.72	-0.45	3.31e-13	Triglycerides;
SARC	cis	rs123509	0.687	rs73077208	chr3:42835205	G/A	cg12982090	chr3:42733453	KBTBD5	-0.53	-5.95	-0.36	9.96e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs62244186	0.566	rs55852922	chr3:44826188	A/G	cg15687855	chr3:44754131	ZNF502	-0.34	-5.12	-0.32	6.44e-7	Depressive symptoms;
SARC	cis	rs1348850	0.526	rs6723063	chr2:178491398	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.54	4.79	0.3	3.01e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs6704644	0.932	rs11676524	chr2:234460968	A/T	cg27060346	chr2:234359958	DGKD	0.58	5.0	0.31	1.14e-6	Bilirubin levels;
SARC	cis	rs7086627	0.515	rs10887894	chr10:82209952	A/G	cg00277334	chr10:82204260	NA	-0.56	-9.34	-0.52	7.82e-18	Post bronchodilator FEV1;
SARC	cis	rs7582720	1.000	rs72934518	chr2:203937908	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	7.78	0.45	2.39e-13	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	trans	rs7395662	0.591	rs4882233	chr11:48739653	A/G	cg00717180	chr2:96193071	NA	-0.38	-6.36	-0.38	1.07e-9	HDL cholesterol;
SARC	cis	rs11673344	0.566	rs10419281	chr19:37950253	C/T	cg14683738	chr19:37701593	ZNF585B	0.45	5.39	0.33	1.69e-7	Obesity-related traits;
SARC	cis	rs11578119	0.933	rs12123065	chr1:170396098	C/T	cg09767346	chr1:170501363	GORAB	0.42	4.85	0.3	2.21e-6	Male-pattern baldness;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg23248324	chr6:80714171	TTK	-0.8	-6.78	-0.41	9.73e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.73	10.4	0.56	4.58e-21	Menarche (age at onset);
SARC	cis	rs733592	0.524	rs10875741	chr12:48492922	A/C	cg24011408	chr12:48396354	COL2A1	-0.51	-7.03	-0.42	2.32e-11	Plateletcrit;
SARC	cis	rs2635047	0.638	rs16954921	chr18:44610526	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	5.98	0.36	8.45e-9	Educational attainment;
SARC	cis	rs2760061	0.598	rs590657	chr1:228117581	A/C	cg02753203	chr1:228287806	NA	-0.54	-7.45	-0.44	1.79e-12	Diastolic blood pressure;
SARC	trans	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg17830980	chr10:43048298	ZNF37B	-0.48	-6.27	-0.38	1.74e-9	Extrinsic epigenetic age acceleration;
SARC	trans	rs11098499	0.955	rs35434465	chr4:120169378	C/G	cg25214090	chr10:38739885	LOC399744	0.52	6.84	0.41	7.08e-11	Corneal astigmatism;
SARC	cis	rs1865760	1.000	rs7757666	chr6:25902626	T/C	cg17691542	chr6:26056736	HIST1H1C	0.57	7.05	0.42	1.98e-11	Height;
SARC	trans	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg17830980	chr10:43048298	ZNF37B	0.55	7.53	0.44	1.08e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs6087771	0.781	rs6089067	chr20:30358894	G/C	cg13852791	chr20:30311386	BCL2L1	0.83	10.23	0.56	1.55e-20	Subcortical brain region volumes;Putamen volume;
SARC	cis	rs8180040	0.701	rs7625067	chr3:47095305	T/C	cg27129171	chr3:47204927	SETD2	0.66	9.19	0.52	2.23e-17	Colorectal cancer;
SARC	cis	rs7588746	0.621	rs4672726	chr2:201149413	C/T	cg23649088	chr2:200775458	C2orf69	-0.49	-5.67	-0.35	4.16e-8	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs897080	0.515	rs1085488	chr2:44618004	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	6.5	0.39	4.85e-10	Height;
SARC	trans	rs9354308	0.840	rs17508021	chr6:66569748	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.58	6.82	0.41	7.77e-11	Metabolite levels;
SARC	cis	rs2228479	0.850	rs1800331	chr16:89858417	C/A	cg06558623	chr16:89946397	TCF25	0.92	6.57	0.4	3.34e-10	Skin colour saturation;
SARC	cis	rs7474896	0.559	rs1208560	chr10:38221618	A/T	cg25427524	chr10:38739819	LOC399744	0.46	5.77	0.35	2.51e-8	Obesity (extreme);
SARC	cis	rs6815814	0.950	rs5743580	chr4:38804405	C/T	cg09316306	chr4:38807337	TLR1	0.5	5.16	0.32	5.23e-7	Breast cancer;
SARC	cis	rs4642101	0.662	rs1969154	chr3:12829156	A/G	cg12400702	chr3:12838781	CAND2	-0.27	-5.37	-0.33	1.93e-7	QRS complex (12-leadsum);
SARC	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg16931447	chr4:875861	GAK	-0.49	-5.13	-0.32	6.17e-7	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
SARC	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg11644478	chr21:40555479	PSMG1	1.01	12.2	0.62	8.33e-27	Cognitive function;
SARC	cis	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg04055107	chr11:65626734	MUS81;CFL1	0.41	5.2	0.32	4.46e-7	Eosinophil percentage of white cells;
SARC	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs6088580	0.634	rs6059892	chr20:33105766	A/G	cg24642439	chr20:33292090	TP53INP2	0.68	8.88	0.5	1.87e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs11098499	0.657	rs4463052	chr4:120313258	T/C	cg09160332	chr4:120329925	NA	-0.33	-4.77	-0.3	3.27e-6	Corneal astigmatism;
SARC	cis	rs6674176	0.593	rs3791120	chr1:44431715	T/C	cg13606994	chr1:44402422	ARTN	-0.33	-5.42	-0.33	1.48e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs818427	1.000	rs372492	chr5:112198015	A/G	cg07820702	chr5:112228657	REEP5	0.44	4.88	0.3	1.97e-6	Total body bone mineral density;
SARC	cis	rs17376456	0.825	rs6898842	chr5:93213221	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.69	6.18	0.38	2.82e-9	Diabetic retinopathy;
SARC	cis	rs2479724	0.870	rs6902650	chr6:41764080	G/A	cg17623882	chr6:41773611	USP49	0.46	5.75	0.35	2.74e-8	Menarche (age at onset);
SARC	cis	rs7666738	0.791	rs1426661	chr4:98874303	C/G	cg05340658	chr4:99064831	C4orf37	0.65	8.59	0.49	1.24e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg23205692	chr1:25664452	TMEM50A	0.44	5.42	0.33	1.48e-7	Erythrocyte sedimentation rate;
SARC	cis	rs9322193	0.639	rs4869756	chr6:150207496	G/A	cg05036130	chr6:150231994	NA	0.33	4.92	0.31	1.62e-6	Lung cancer;
SARC	cis	rs921968	0.643	rs552882	chr2:219401726	G/A	cg02176678	chr2:219576539	TTLL4	0.35	5.5	0.34	1e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs9393692	0.905	rs2393592	chr6:26285560	A/G	cg05868516	chr6:26286170	HIST1H4H	0.56	7.45	0.44	1.79e-12	Educational attainment;
SARC	cis	rs796364	0.755	rs203762	chr2:200905136	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-6.47	-0.39	5.62e-10	Schizophrenia;
SARC	cis	rs10911232	0.524	rs4652773	chr1:183054827	A/G	cg13390022	chr1:182993471	LAMC1	0.33	5.05	0.31	8.97e-7	Hypertriglyceridemia;
SARC	cis	rs2997447	0.846	rs3008414	chr1:26404747	G/A	cg19633962	chr1:26362018	EXTL1	-0.63	-5.54	-0.34	8.3e-8	QRS complex (12-leadsum);
SARC	cis	rs7513165	0.935	rs12097666	chr1:204162212	A/G	cg23788856	chr1:204159729	KISS1	-0.35	-5.56	-0.34	7.55e-8	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
SARC	cis	rs5758659	0.967	rs5758670	chr22:42636687	T/C	cg15557168	chr22:42548783	NA	-0.34	-4.74	-0.3	3.79e-6	Cognitive function;
SARC	cis	rs3741404	0.583	rs640999	chr11:63869425	C/A	cg04317338	chr11:64019027	PLCB3	0.48	5.52	0.34	8.86e-8	Platelet count;
SARC	cis	rs2624839	0.602	rs2526390	chr3:50192760	C/T	cg14019146	chr3:50243930	SLC38A3	-0.38	-5.9	-0.36	1.29e-8	Intelligence (multi-trait analysis);
SARC	cis	rs12079745	1.000	rs12086104	chr1:169115821	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.7	-4.89	-0.31	1.88e-6	QT interval;
SARC	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg12463550	chr7:65579703	CRCP	0.7	5.32	0.33	2.48e-7	Diabetic kidney disease;
SARC	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	10.63	0.57	9.15e-22	Platelet count;
SARC	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg02711726	chr17:80685570	FN3KRP	-0.55	-6.86	-0.41	6.22e-11	Glycated hemoglobin levels;
SARC	cis	rs2288073	0.965	rs10469924	chr2:24416230	G/A	cg26838691	chr2:24397539	C2orf84	-0.54	-6.75	-0.4	1.19e-10	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs2115630	1.000	rs11854291	chr15:85363708	T/C	cg17507749	chr15:85114479	UBE2QP1	-0.46	-5.56	-0.34	7.29e-8	P wave terminal force;
SARC	cis	rs933688	0.532	rs28693622	chr5:90538722	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.43	-4.8	-0.3	2.81e-6	Smoking behavior;
SARC	cis	rs9291683	0.566	rs13122689	chr4:10044648	A/G	cg11266682	chr4:10021025	SLC2A9	0.4	6.91	0.41	4.53e-11	Bone mineral density;
SARC	cis	rs4427176	0.660	rs35468013	chr8:9578208	G/T	cg21625330	chr8:9911636	MSRA	-0.55	-4.71	-0.3	4.19e-6	Mosquito bite size;
SARC	cis	rs17666538	1.000	rs17666538	chr8:566207	T/C	cg07234876	chr8:600039	NA	-0.95	-6.63	-0.4	2.37e-10	IgG glycosylation;
SARC	cis	rs9398803	0.698	rs1262553	chr6:127078785	T/C	cg19875578	chr6:126661172	C6orf173	-0.62	-8.6	-0.49	1.17e-15	Male-pattern baldness;
SARC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg11301795	chr4:187892539	NA	-0.69	-10.22	-0.56	1.69e-20	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.97	-15.37	-0.71	2.85e-37	Chronic sinus infection;
SARC	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg22800045	chr5:56110881	MAP3K1	0.66	7.01	0.42	2.62e-11	Initial pursuit acceleration;
SARC	cis	rs2486288	0.656	rs2413774	chr15:45549423	C/T	cg15395560	chr15:45543142	SLC28A2	0.29	5.63	0.35	5.17e-8	Glomerular filtration rate;
SARC	cis	rs36051895	0.664	rs3780374	chr9:5099677	G/A	cg02405213	chr9:5042618	JAK2	-0.47	-5.54	-0.34	8.2e-8	Pediatric autoimmune diseases;
SARC	cis	rs7264396	0.635	rs6060681	chr20:34506147	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.55	5.61	0.35	5.57e-8	Total cholesterol levels;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg21302120	chr4:24585281	DHX15	-0.63	-7.25	-0.43	6.06e-12	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg22307029	chr19:49891270	CCDC155	0.53	6.05	0.37	5.78e-9	Multiple sclerosis;
SARC	trans	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg20587970	chr11:113659929	NA	-1.38	-13.77	-0.67	5.89e-32	Hip circumference adjusted for BMI;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg10214058	chr5:154238169	CNOT8	0.52	6.92	0.41	4.26e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs9916302	0.752	rs9901219	chr17:37558369	T/G	cg07936489	chr17:37558343	FBXL20	0.78	10.03	0.55	6.56e-20	Glomerular filtration rate (creatinine);
SARC	cis	rs11223996	1.000	rs11223996	chr11:134626887	C/T	cg16258018	chr11:134025732	NCAPD3	-0.49	-5.06	-0.31	8.7e-7	Myopia (pathological);
SARC	cis	rs9916302	0.904	rs8079560	chr17:37497661	C/T	cg00129232	chr17:37814104	STARD3	0.59	7.31	0.43	4.18e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs2304069	0.913	rs7734382	chr5:149383241	A/T	cg12661370	chr5:149340060	SLC26A2	0.6	5.87	0.36	1.47e-8	HIV-1 control;
SARC	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg22875332	chr1:76189707	ACADM	0.48	6.99	0.42	2.9e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs72781680	0.679	rs718138	chr2:23976324	G/A	cg06627628	chr2:24431161	ITSN2	-0.52	-5.51	-0.34	9.31e-8	Lymphocyte counts;
SARC	cis	rs7412746	0.646	rs1972060	chr1:150937594	T/C	cg15448220	chr1:150897856	SETDB1	0.52	6.81	0.41	8.35e-11	Melanoma;
SARC	cis	rs6570726	1.000	rs951143	chr6:145932576	C/T	cg05220968	chr6:146057943	EPM2A	-0.3	-5.13	-0.32	6.14e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs703842	1.000	rs11172343	chr12:58188157	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.77	11.14	0.59	2.16e-23	Multiple sclerosis;
SARC	cis	rs8114671	0.527	rs6060068	chr20:33415820	T/A	cg24642439	chr20:33292090	TP53INP2	0.55	6.72	0.4	1.37e-10	Height;
SARC	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.62	7.72	0.45	3.45e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1949733	1.000	rs2631745	chr4:8490530	T/C	cg13073564	chr4:8508604	NA	0.47	7.76	0.45	2.61e-13	Response to antineoplastic agents;
SARC	cis	rs9911578	0.933	rs11868348	chr17:57179238	C/T	cg12560992	chr17:57184187	TRIM37	0.87	12.41	0.63	1.71e-27	Intelligence (multi-trait analysis);
SARC	cis	rs9916302	0.851	rs9904919	chr17:37556431	G/C	cg15445000	chr17:37608096	MED1	-0.4	-4.8	-0.3	2.88e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs9894429	0.646	rs7210026	chr17:79612382	T/C	cg10661904	chr17:79619235	PDE6G	-0.44	-6.26	-0.38	1.84e-9	Eye color traits;
SARC	cis	rs9818758	0.607	rs13077498	chr3:49313978	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.7	-5.94	-0.36	1.05e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs721399	0.568	rs13254811	chr8:18273018	A/G	cg18736775	chr8:18248649	NAT2	-0.56	-5.95	-0.36	1e-8	Blood metabolite levels;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg00683961	chr1:109940786	SORT1	-0.47	-6.77	-0.41	1.06e-10	Neuroticism;
SARC	cis	rs4466137	0.953	rs6869030	chr5:83007311	C/T	cg16102102	chr5:83017553	HAPLN1	-0.74	-9.11	-0.51	3.89e-17	Prostate cancer;
SARC	cis	rs11098499	0.954	rs67265404	chr4:120359270	C/T	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.43	4.89	0.31	1.86e-6	Renal function-related traits (BUN);
SARC	cis	rs17401966	0.931	rs3748579	chr1:10420937	C/T	cg15208524	chr1:10270712	KIF1B	0.5	5.99	0.37	7.88e-9	Hepatocellular carcinoma;
SARC	cis	rs13161895	0.818	rs116463976	chr5:179484519	G/C	cg02702477	chr5:179499311	RNF130	0.75	6.89	0.41	5.23e-11	LDL cholesterol;
SARC	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.76	-9.39	-0.52	5.85e-18	Prudent dietary pattern;
SARC	cis	rs6714710	0.603	rs11681535	chr2:98488949	G/C	cg26665480	chr2:98280029	ACTR1B	0.51	6.91	0.41	4.69e-11	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs1784581	0.588	rs9295179	chr6:162420546	G/A	cg17173639	chr6:162384350	PARK2	0.5	6.36	0.38	1.07e-9	Itch intensity from mosquito bite;
SARC	cis	rs6083	0.571	rs41294813	chr15:58847807	T/C	cg05156742	chr15:59063176	FAM63B	-0.63	-8.16	-0.47	2.14e-14	Schizophrenia;
SARC	cis	rs8031584	0.958	rs11637469	chr15:31238783	T/C	cg14298792	chr15:30685198	CHRFAM7A	-0.45	-4.99	-0.31	1.17e-6	Huntington's disease progression;
SARC	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg22974920	chr21:40686053	BRWD1	0.44	4.73	0.3	3.82e-6	Cognitive function;
SARC	cis	rs9916302	0.861	rs9903363	chr17:37499604	C/G	cg15445000	chr17:37608096	MED1	-0.44	-5.39	-0.33	1.71e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs523522	0.962	rs687873	chr12:121019634	G/A	cg27279351	chr12:120934652	DYNLL1	0.71	8.75	0.5	4.4e-16	High light scatter reticulocyte count;
SARC	trans	rs208520	0.690	rs1580430	chr6:66715162	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	14.03	0.68	7.86e-33	Exhaled nitric oxide output;
SARC	cis	rs76419734	1.000	rs72671808	chr4:106605720	A/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.82	4.96	0.31	1.37e-6	Post bronchodilator FEV1;
SARC	cis	rs73242632	1.000	rs10023009	chr4:57884338	G/C	cg20415529	chr4:57845134	POLR2B;C4orf14	1.03	5.94	0.36	1.02e-8	Congenital heart disease (maternal effect);
SARC	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg12292205	chr6:26970375	C6orf41	0.43	5.33	0.33	2.31e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6540556	0.723	rs6540551	chr1:209925295	C/T	cg05527609	chr1:210001259	C1orf107	-0.55	-5.55	-0.34	7.59e-8	Red blood cell count;
SARC	cis	rs3733585	0.624	rs7376154	chr4:9952587	C/A	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.94	-0.36	1.06e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.34	-5.03	-0.31	9.8e-7	Total body bone mineral density;
SARC	cis	rs898097	0.625	rs2125479	chr17:80890262	A/G	cg10494973	chr17:80897199	TBCD	0.38	4.88	0.3	1.97e-6	Breast cancer;
SARC	cis	rs4132509	0.947	rs10927041	chr1:243731890	T/C	cg21452805	chr1:244014465	NA	0.49	5.36	0.33	1.98e-7	RR interval (heart rate);
SARC	cis	rs2290159	0.800	rs59821954	chr3:12687613	T/C	cg23032965	chr3:12705835	RAF1	0.78	8.62	0.49	1.02e-15	Cholesterol, total;
SARC	cis	rs17376456	0.542	rs2043979	chr5:93120782	T/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.52	-5.6	-0.34	6.03e-8	Diabetic retinopathy;
SARC	cis	rs738322	0.555	rs6001027	chr22:38545619	A/G	cg25457927	chr22:38595422	NA	-0.25	-4.8	-0.3	2.87e-6	Cutaneous nevi;
SARC	cis	rs6998277	1.000	rs16869658	chr8:103633762	C/T	cg10187029	chr8:103597600	NA	0.66	6.7	0.4	1.58e-10	Migraine;
SARC	cis	rs73242632	0.881	rs7654665	chr4:57923774	C/T	cg20415529	chr4:57845134	POLR2B;C4orf14	0.88	5.31	0.33	2.5e-7	Congenital heart disease (maternal effect);
SARC	cis	rs3126085	0.935	rs12405678	chr1:152195308	C/G	cg03465714	chr1:152285911	FLG	0.45	4.86	0.3	2.2e-6	Atopic dermatitis;
SARC	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg13770153	chr20:60521292	NA	-0.46	-6.44	-0.39	6.66e-10	Body mass index;
SARC	trans	rs1814175	0.645	rs11040702	chr11:50024827	C/T	cg15704280	chr7:45808275	SEPT13	-0.9	-14.33	-0.68	7.84e-34	Height;
SARC	cis	rs244731	0.959	rs4976677	chr5:176629546	G/A	cg16006841	chr5:176797999	RGS14	-0.57	-6.8	-0.41	8.92e-11	Urate levels in lean individuals;
SARC	cis	rs2354432	0.607	rs7523812	chr1:146673489	A/G	cg25205988	chr1:146714368	CHD1L	-1.04	-8.94	-0.51	1.2e-16	Mitochondrial DNA levels;
SARC	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg24549020	chr5:56110836	MAP3K1	0.69	6.06	0.37	5.31e-9	Initial pursuit acceleration;
SARC	cis	rs9398803	0.661	rs853985	chr6:127020173	C/T	cg20229609	chr6:126660872	C6orf173	-0.35	-5.09	-0.32	7.54e-7	Male-pattern baldness;
SARC	cis	rs4430311	0.723	rs971285	chr1:243919773	C/T	cg21452805	chr1:244014465	NA	-0.39	-4.9	-0.31	1.79e-6	Post-traumatic stress disorder (asjusted for relatedness);
SARC	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg08280861	chr8:58055591	NA	0.68	5.82	0.36	1.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg17376030	chr22:41985996	PMM1	0.69	8.31	0.48	8.05e-15	Vitiligo;
SARC	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg17221315	chr6:27791827	HIST1H4J	0.46	4.83	0.3	2.53e-6	Depression;
SARC	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs7123876	0.553	rs12099027	chr11:72433920	A/G	cg03713592	chr11:72463424	ARAP1	0.47	5.57	0.34	7.11e-8	Body mass index;
SARC	cis	rs2236918	0.710	rs2797603	chr1:242029027	T/G	cg17736920	chr1:242011382	EXO1	0.64	8.69	0.49	6.61e-16	Menopause (age at onset);
SARC	cis	rs787274	1.000	rs2185769	chr9:115462594	A/G	cg13803584	chr9:115635662	SNX30	0.73	4.95	0.31	1.4e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs362296	0.698	rs3095072	chr4:3263325	G/A	cg06533319	chr4:3265114	C4orf44	0.36	5.68	0.35	4.07e-8	Parental longevity (mother's age at death);
SARC	cis	rs11112613	0.713	rs11112588	chr12:105943801	A/C	cg03607813	chr12:105948248	NA	0.54	7.11	0.42	1.39e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs9790314	0.663	rs1599379	chr3:160860665	A/G	cg04691961	chr3:161091175	C3orf57	-0.54	-7.25	-0.43	6.11e-12	Morning vs. evening chronotype;
SARC	cis	rs8017423	0.967	rs60548738	chr14:90724399	G/A	cg20276874	chr14:90721474	PSMC1	-0.39	-5.49	-0.34	1.06e-7	Mortality in heart failure;
SARC	cis	rs17270561	0.636	rs4145218	chr6:25746083	G/A	cg16482183	chr6:26056742	HIST1H1C	0.43	5.08	0.32	7.76e-7	Iron status biomarkers;
SARC	cis	rs950776	0.518	rs3813572	chr15:78832588	T/C	cg17108064	chr15:78857060	CHRNA5	0.29	4.93	0.31	1.56e-6	Sudden cardiac arrest;
SARC	cis	rs3106136	0.934	rs17376404	chr4:95224046	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.39	-6.05	-0.37	5.71e-9	Capecitabine sensitivity;
SARC	cis	rs2070488	0.662	rs7372545	chr3:38507570	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.64	8.24	0.48	1.22e-14	Electrocardiographic conduction measures;
SARC	trans	rs11098499	0.954	rs1546505	chr4:120241224	A/G	cg25214090	chr10:38739885	LOC399744	0.53	6.92	0.41	4.26e-11	Corneal astigmatism;
SARC	cis	rs9300255	0.537	rs10772993	chr12:123644714	A/G	cg00376283	chr12:123451042	ABCB9	0.59	5.91	0.36	1.22e-8	Neutrophil percentage of white cells;
SARC	cis	rs35110281	0.622	rs9977258	chr21:44976485	G/T	cg01579765	chr21:45077557	HSF2BP	-0.29	-4.88	-0.3	1.94e-6	Mean corpuscular volume;
SARC	cis	rs6121246	0.567	rs2811	chr20:30194248	A/G	cg13852791	chr20:30311386	BCL2L1	0.68	5.91	0.36	1.2e-8	Mean corpuscular hemoglobin;
SARC	cis	rs6991838	0.584	rs7463649	chr8:66485995	C/T	cg13398993	chr8:66546079	ARMC1	-0.62	-8.36	-0.48	5.88e-15	Intelligence (multi-trait analysis);
SARC	cis	rs13191362	0.808	rs13217502	chr6:163231414	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.62	5.96	0.36	9.15e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs854765	0.551	rs8070748	chr17:17859421	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.43	5.52	0.34	9.04e-8	Total body bone mineral density;
SARC	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg02018176	chr4:1364513	KIAA1530	-0.44	-6.1	-0.37	4.42e-9	Obesity-related traits;
SARC	cis	rs6088590	0.735	rs6060003	chr20:33294945	T/C	cg08999081	chr20:33150536	PIGU	0.37	5.69	0.35	3.8e-8	Coronary artery disease;
SARC	cis	rs7512552	0.839	rs834231	chr1:150389392	A/T	cg15654264	chr1:150340011	RPRD2	-0.39	-5.03	-0.31	9.92e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs763121	0.853	rs5757232	chr22:39071677	C/T	cg14440974	chr22:39074834	NA	-0.32	-4.73	-0.3	3.86e-6	Menopause (age at onset);
SARC	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg12696929	chr3:195401817	SDHAP2	0.39	5.18	0.32	4.78e-7	Pancreatic cancer;
SARC	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg12564285	chr5:131593104	PDLIM4	0.45	6.08	0.37	4.82e-9	Breast cancer;
SARC	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg04518342	chr5:131593106	PDLIM4	-0.36	-4.93	-0.31	1.53e-6	Acylcarnitine levels;
SARC	cis	rs8114671	0.527	rs6060068	chr20:33415820	T/A	cg07148914	chr20:33460835	GGT7	0.43	5.17	0.32	5.02e-7	Height;
SARC	cis	rs2013441	1.000	rs2013576	chr17:20167692	G/C	cg13482628	chr17:19912719	NA	-0.47	-6.18	-0.38	2.87e-9	Obesity-related traits;
SARC	cis	rs62064224	0.765	rs62065463	chr17:30732405	G/T	cg09324608	chr17:30823087	MYO1D	0.32	4.86	0.3	2.11e-6	Schizophrenia;
SARC	cis	rs6964587	1.000	rs10236397	chr7:91691601	C/T	cg17063962	chr7:91808500	NA	0.96	16.21	0.73	4.33e-40	Breast cancer;
SARC	cis	rs7635838	0.892	rs9838141	chr3:11488639	C/T	cg00170343	chr3:11313890	ATG7	0.63	8.43	0.48	3.53e-15	HDL cholesterol;
SARC	cis	rs6964587	1.000	rs35317449	chr7:91637010	G/A	cg17063962	chr7:91808500	NA	0.93	15.72	0.72	1.97e-38	Breast cancer;
SARC	cis	rs898097	1.000	rs898097	chr17:80904310	C/T	cg15369054	chr17:80825471	TBCD	-0.47	-6.71	-0.4	1.48e-10	Breast cancer;
SARC	cis	rs9902453	0.838	rs7217638	chr17:28336772	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.52	-6.82	-0.41	7.63e-11	Coffee consumption (cups per day);
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg20335185	chr1:155715152	MSTO2P	-0.58	-6.36	-0.38	1.05e-9	Lung cancer in ever smokers;
SARC	cis	rs7568458	0.837	rs6547624	chr2:85802134	A/T	cg02493740	chr2:85810744	VAMP5	-0.34	-5.02	-0.31	1.04e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs2070997	0.667	rs7869508	chr9:133716802	T/C	cg11464064	chr9:133710261	ABL1	0.62	5.99	0.37	7.99e-9	Response to amphetamines;
SARC	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg22683308	chr4:1340831	KIAA1530	0.45	5.47	0.34	1.16e-7	Longevity;
SARC	cis	rs7824557	0.527	rs2572376	chr8:11237756	C/A	cg21775007	chr8:11205619	TDH	-0.56	-7.27	-0.43	5.37e-12	Retinal vascular caliber;
SARC	cis	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg08564027	chr20:61660810	NA	0.76	11.8	0.61	1.69e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs9807989	0.501	rs11903946	chr2:103005330	A/G	cg03938978	chr2:103052716	IL18RAP	0.32	5.16	0.32	5.28e-7	Asthma;
SARC	cis	rs910316	0.967	rs7146523	chr14:75659880	T/C	cg11812906	chr14:75593930	NEK9	-0.83	-12.17	-0.62	1.03e-26	Height;
SARC	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg11905131	chr22:24372483	LOC391322	-0.52	-5.99	-0.37	7.88e-9	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9296092	0.538	rs9461882	chr6:33520221	A/C	cg13560919	chr6:33536144	NA	-0.49	-5.95	-0.36	9.74e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs7113850	0.541	rs76166238	chr11:24235418	G/A	ch.11.24196551F	chr11:24239977	NA	0.72	5.44	0.34	1.36e-7	Bone fracture in osteoporosis;
SARC	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg03185022	chr7:2884158	GNA12	0.45	4.88	0.3	1.99e-6	Height;
SARC	cis	rs3820928	0.874	rs10199655	chr2:227892428	T/C	cg11843606	chr2:227700838	RHBDD1	-0.56	-6.92	-0.41	4.39e-11	Pulmonary function;
SARC	trans	rs1973993	1.000	rs1973993	chr1:96943994	A/G	cg10631902	chr5:14652156	NA	0.44	7.42	0.44	2.14e-12	Weight;
SARC	cis	rs7208859	0.673	rs9911989	chr17:29237702	A/C	cg13385521	chr17:29058706	SUZ12P	-0.91	-7.54	-0.44	1.03e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	trans	rs3942852	0.568	rs1039484	chr11:48097948	A/G	cg03929089	chr4:120376271	NA	-0.56	-6.84	-0.41	7.02e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs11605924	0.901	rs11607883	chr11:45839709	G/A	ch.11.939596F	chr11:45881766	CRY2	-0.46	-5.5	-0.34	1.02e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs2766692	1.000	rs2766690	chr14:100682154	A/G	cg14866419	chr14:100704911	YY1	-0.55	-6.2	-0.38	2.55e-9	Electroencephalographic traits in alcoholism;
SARC	cis	rs9397240	0.789	rs12214833	chr6:155590518	C/T	cg07943832	chr6:155568918	TIAM2	-0.61	-5.89	-0.36	1.38e-8	Life satisfaction;
SARC	cis	rs12887734	0.524	rs12888002	chr14:104238647	T/C	cg26031613	chr14:104095156	KLC1	-0.46	-5.14	-0.32	5.81e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	cis	rs10927875	0.929	rs4661674	chr1:16296039	A/G	cg21385522	chr1:16154831	NA	-0.76	-9.77	-0.54	4.06e-19	Dilated cardiomyopathy;
SARC	cis	rs8031584	0.958	rs8034856	chr15:31240957	T/C	cg14829155	chr15:31115871	NA	-0.42	-5.28	-0.33	2.91e-7	Huntington's disease progression;
SARC	cis	rs6774721	1.000	rs6774721	chr3:49381898	G/A	cg19401529	chr3:49056140	DALRD3	0.69	5.92	0.36	1.16e-8	Intelligence (multi-trait analysis);
SARC	cis	rs10876993	0.928	rs2928053	chr12:58063475	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.46	-5.79	-0.35	2.3e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs1559088	0.948	rs12460195	chr19:33584479	G/A	cg27124370	chr19:33622961	WDR88	0.44	5.86	0.36	1.6e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs2836974	0.653	rs8130556	chr21:40516872	C/T	cg11890956	chr21:40555474	PSMG1	1.16	18.12	0.76	2.23e-46	Cognitive function;
SARC	cis	rs4803468	1.000	rs284656	chr19:41929251	T/C	cg09537434	chr19:41945824	ATP5SL	-0.98	-17.28	-0.75	1.27e-43	Height;
SARC	cis	rs17867775	0.623	rs12670241	chr7:126692465	G/A	cg02090654	chr7:126698344	MIR592;GRM8	0.57	4.82	0.3	2.59e-6	Anti-saccade response;
SARC	cis	rs933688	1.000	rs6866191	chr5:90746852	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	12.55	0.64	6e-28	Smoking behavior;
SARC	cis	rs9325144	0.505	rs826893	chr12:39100536	A/G	cg26384229	chr12:38710491	ALG10B	-0.73	-10.9	-0.58	1.24e-22	Morning vs. evening chronotype;
SARC	cis	rs3733585	0.699	rs10017674	chr4:9967053	T/C	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.65	-0.35	4.69e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg16132339	chr22:24313637	DDTL;DDT	-0.42	-5.67	-0.35	4.29e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6908034	0.607	rs12525152	chr6:19809424	A/T	cg02682789	chr6:19804855	NA	0.67	5.75	0.35	2.85e-8	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg12564285	chr5:131593104	PDLIM4	-0.47	-6.38	-0.39	9.59e-10	Blood metabolite levels;
SARC	cis	rs7772486	0.692	rs1577916	chr6:146069789	G/A	cg05347473	chr6:146136440	FBXO30	-0.55	-7.7	-0.45	3.77e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2180341	1.000	rs9388561	chr6:127634921	C/T	cg24812749	chr6:127587940	RNF146	0.97	12.95	0.65	2.97e-29	Breast cancer;
SARC	cis	rs11190604	0.767	rs11190531	chr10:102187310	T/A	cg07080220	chr10:102295463	HIF1AN	0.72	8.28	0.48	9.7e-15	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs4141404	0.737	rs5998067	chr22:32043630	C/T	cg07713946	chr22:31675144	LIMK2	-0.34	-4.79	-0.3	3.01e-6	Paclitaxel-induced neuropathy;
SARC	cis	rs17376456	0.825	rs6874766	chr5:93213807	C/G	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.66	-5.49	-0.34	1.03e-7	Diabetic retinopathy;
SARC	cis	rs7429990	0.932	rs11720151	chr3:48140634	G/A	cg11946769	chr3:48343235	NME6	-0.48	-5.6	-0.34	6.08e-8	Educational attainment (years of education);
SARC	cis	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg05623727	chr3:50126028	RBM5	0.36	5.48	0.34	1.11e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2842992	0.714	rs2475564	chr6:160123673	A/G	cg11366901	chr6:160182831	ACAT2	0.94	9.34	0.52	7.79e-18	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs1215050	0.791	rs260890	chr4:98741698	A/G	cg05340658	chr4:99064831	C4orf37	0.45	6.07	0.37	5.05e-9	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs12477438	0.953	rs3851334	chr2:99794704	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.76	-8.15	-0.47	2.24e-14	Chronic sinus infection;
SARC	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg14983838	chr19:29218262	NA	0.78	10.59	0.57	1.2e-21	Methadone dose in opioid dependence;
SARC	cis	rs13191362	0.938	rs35760705	chr6:163020637	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.57	5.5	0.34	1e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg17971929	chr21:40555470	PSMG1	0.55	7.05	0.42	2.04e-11	Menarche (age at onset);
SARC	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7043114	0.507	rs7037075	chr9:95216613	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.75	-0.35	2.72e-8	Height;
SARC	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg21171335	chr12:122356390	WDR66	0.41	6.5	0.39	4.95e-10	Mean corpuscular volume;
SARC	cis	rs3892630	0.619	rs61062732	chr19:33304717	T/C	cg22980127	chr19:33182716	NUDT19	1.0	10.76	0.58	3.52e-22	Red blood cell traits;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg15155672	chr3:14220327	LSM3;XPC	0.53	6.96	0.41	3.39e-11	Lung adenocarcinoma;
SARC	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-9.69	-0.54	6.94e-19	Chronic sinus infection;
SARC	trans	rs61931739	0.500	rs7312938	chr12:34378708	C/T	cg26384229	chr12:38710491	ALG10B	0.91	13.59	0.66	2.38e-31	Morning vs. evening chronotype;
SARC	trans	rs11098499	0.863	rs9884402	chr4:120489982	A/G	cg25214090	chr10:38739885	LOC399744	0.57	7.25	0.43	6.27e-12	Corneal astigmatism;
SARC	cis	rs12950390	0.853	rs56137679	chr17:45862112	C/G	cg24803719	chr17:45855879	NA	-0.46	-7.5	-0.44	1.34e-12	IgG glycosylation;
SARC	cis	rs2288912	0.807	rs7251501	chr19:45455706	C/T	cg13119609	chr19:45449297	APOC2	0.5	8.44	0.48	3.42e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs2439831	0.571	rs2470121	chr15:43937618	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.93	8.34	0.48	6.57e-15	Lung cancer in ever smokers;
SARC	cis	rs6912958	0.500	rs2025486	chr6:87796886	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-5.44	-0.34	1.33e-7	Monocyte percentage of white cells;
SARC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg23034840	chr1:205782522	SLC41A1	0.59	7.37	0.43	3.02e-12	Menarche (age at onset);
SARC	cis	rs910316	1.000	rs7156105	chr14:75541954	C/A	cg08847533	chr14:75593920	NEK9	0.94	16.16	0.73	6.4e-40	Height;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg15819780	chr17:53038915	COX11;TOM1L1	0.43	6.83	0.41	7.5e-11	Thyroid stimulating hormone;
SARC	cis	rs1050631	0.592	rs1785933	chr18:33719191	T/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.56	6.5	0.39	4.8e-10	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg21724239	chr8:58056113	NA	0.6	6.37	0.38	1.03e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg06558623	chr16:89946397	TCF25	0.91	6.17	0.37	3.02e-9	Skin colour saturation;
SARC	cis	rs7208859	0.524	rs60114476	chr17:29097667	A/T	cg13385521	chr17:29058706	SUZ12P	0.9	7.81	0.46	1.93e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg23758822	chr17:41437982	NA	0.88	11.31	0.6	6.44e-24	Menopause (age at onset);
SARC	cis	rs9660992	0.649	rs12128254	chr1:205268097	C/T	cg07972983	chr1:205091412	RBBP5	0.51	5.97	0.36	8.74e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs1580019	0.587	rs7804457	chr7:32557981	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.54	6.96	0.41	3.39e-11	Cognitive ability;
SARC	cis	rs8523	0.774	rs4713165	chr6:11074302	A/G	cg13562911	chr6:11044106	ELOVL2	0.45	5.86	0.36	1.59e-8	Red blood cell fatty acid levels;
SARC	cis	rs7428	0.527	rs4832164	chr2:85546932	A/C	cg03728395	chr2:85555865	TGOLN2	-0.49	-6.93	-0.41	4.2e-11	Ear protrusion;
SARC	cis	rs13095912	0.889	rs34765114	chr3:185335156	T/A	cg11274856	chr3:185301563	NA	0.36	5.0	0.31	1.13e-6	Systolic blood pressure;
SARC	cis	rs7223966	1.000	rs6504173	chr17:61735056	T/C	cg26338869	chr17:61819248	STRADA	0.43	4.86	0.3	2.18e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/C	cg07636037	chr3:49044803	WDR6	0.92	14.69	0.69	5.13e-35	Parkinson's disease;
SARC	trans	rs801193	0.613	rs2016325	chr7:66323500	T/C	cg18876405	chr7:65276391	NA	-0.52	-6.45	-0.39	6.51e-10	Aortic root size;
SARC	cis	rs1784581	0.802	rs6455787	chr6:162411378	G/A	cg17173639	chr6:162384350	PARK2	0.64	8.7	0.49	6.27e-16	Itch intensity from mosquito bite;
SARC	cis	rs6088590	0.965	rs6087639	chr20:33443866	G/A	cg24642439	chr20:33292090	TP53INP2	0.83	11.15	0.59	2e-23	Coronary artery disease;
SARC	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.23e-9	Life satisfaction;
SARC	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg17691542	chr6:26056736	HIST1H1C	0.44	5.05	0.31	8.91e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7223966	1.000	rs7214312	chr17:61870863	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.45	4.82	0.3	2.6e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs35110281	0.659	rs73367822	chr21:45024252	C/T	cg01579765	chr21:45077557	HSF2BP	-0.33	-5.61	-0.34	5.8e-8	Mean corpuscular volume;
SARC	cis	rs9486719	1.000	rs6921291	chr6:97066242	C/T	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.31	-0.33	2.57e-7	Migraine;Coronary artery disease;
SARC	cis	rs2439831	0.681	rs825739	chr15:43592428	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.77	8.51	0.49	2.21e-15	Lung cancer in ever smokers;
SARC	cis	rs6976053	0.518	rs314353	chr7:100406144	A/G	cg03098644	chr7:100410630	EPHB4	-0.45	-6.41	-0.39	8.18e-10	Plasminogen activator inhibitor type 1 levels (PAI-1);
SARC	cis	rs735396	1.000	rs1169306	chr12:121438311	C/T	cg25281562	chr12:121454272	C12orf43	0.49	5.77	0.35	2.57e-8	N-glycan levels;
SARC	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg25703541	chr22:24373054	LOC391322	-0.57	-6.81	-0.41	8.26e-11	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs3784262	1.000	rs12907038	chr15:58244032	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.43	-6.5	-0.39	4.82e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs10504229	0.679	rs60869047	chr8:58053221	G/A	cg22535103	chr8:58192502	C8orf71	-0.59	-5.94	-0.36	1.02e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs8014204	0.868	rs2230237	chr14:75359670	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.78	-11.92	-0.62	7.02e-26	Caffeine consumption;
SARC	cis	rs6429082	0.714	rs704719	chr1:235667170	G/A	cg26050004	chr1:235667680	B3GALNT2	0.66	7.72	0.45	3.45e-13	Adiposity;
SARC	cis	rs12971120	1.000	rs2278161	chr18:72176083	T/C	cg25817165	chr18:72167213	CNDP2	-0.51	-7.56	-0.44	9.11e-13	Refractive error;
SARC	cis	rs7712401	0.715	rs434789	chr5:122357310	C/T	cg19412675	chr5:122181750	SNX24	-0.42	-5.3	-0.33	2.65e-7	Mean platelet volume;
SARC	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg22618164	chr12:122356400	WDR66	0.41	6.56	0.39	3.45e-10	Mean corpuscular volume;
SARC	cis	rs883565	0.792	rs784498	chr3:39180099	A/G	cg01426195	chr3:39028469	NA	0.4	5.19	0.32	4.62e-7	Handedness;
SARC	cis	rs1966248	0.656	rs4895387	chr6:134123317	A/T	cg25632230	chr6:134101081	NA	-0.53	-7.07	-0.42	1.78e-11	Coronary artery disease;
SARC	cis	rs9420	0.961	rs12146541	chr11:57508678	G/C	cg19752551	chr11:57585705	CTNND1	-0.5	-6.92	-0.41	4.45e-11	Schizophrenia;
SARC	cis	rs9393692	0.905	rs9357004	chr6:26303319	A/G	cg00631329	chr6:26305371	NA	-0.66	-9.61	-0.53	1.27e-18	Educational attainment;
SARC	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg25072359	chr17:41440525	NA	0.5	5.94	0.36	1.04e-8	Menopause (age at onset);
SARC	cis	rs1580019	0.713	rs2167274	chr7:32524844	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.9	14.84	0.7	1.66e-35	Cognitive ability;
SARC	cis	rs7959452	0.640	rs4761233	chr12:69722880	T/C	cg22834771	chr12:69754056	YEATS4	-0.4	-5.25	-0.33	3.49e-7	Blood protein levels;
SARC	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg24324837	chr19:49891574	CCDC155	0.46	5.77	0.35	2.54e-8	Multiple sclerosis;
SARC	cis	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg03060546	chr3:49711283	APEH	-0.57	-7.34	-0.43	3.55e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs950776	0.518	rs12910100	chr15:78822667	C/T	cg22563815	chr15:78856949	CHRNA5	0.41	6.82	0.41	7.56e-11	Sudden cardiac arrest;
SARC	cis	rs7312933	0.703	rs11181378	chr12:42600658	T/C	cg19980929	chr12:42632907	YAF2	0.44	6.04	0.37	6.04e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs2239815	0.515	rs5762839	chr22:29231447	C/T	cg02153584	chr22:29168773	CCDC117	0.68	7.56	0.44	9.45e-13	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
SARC	cis	rs6138458	1.000	rs227629	chr20:24913551	G/T	cg26195577	chr20:24973756	C20orf3	0.88	9.9	0.54	1.69e-19	Blood protein levels;
SARC	cis	rs9467711	0.591	rs35249036	chr6:26026163	C/G	cg21479132	chr6:26055353	NA	0.97	7.03	0.42	2.29e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7264396	0.676	rs58372200	chr20:34555445	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-6.92	-0.41	4.41e-11	Total cholesterol levels;
SARC	cis	rs2204008	0.840	rs11181795	chr12:38401129	A/G	cg26384229	chr12:38710491	ALG10B	0.85	12.08	0.62	2.08e-26	Bladder cancer;
SARC	cis	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg22857025	chr5:266934	NA	-1.03	-11.25	-0.59	9.84e-24	Breast cancer;
SARC	cis	rs7937682	0.562	rs519850	chr11:111376888	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.56	-7.29	-0.43	4.66e-12	Primary sclerosing cholangitis;
SARC	cis	rs1964356	0.967	rs17701675	chr8:8850633	A/G	cg15556689	chr8:8085844	FLJ10661	-0.42	-5.08	-0.32	7.87e-7	Mean corpuscular volume;
SARC	cis	rs8031584	0.918	rs35784593	chr15:31254588	G/A	cg14829155	chr15:31115871	NA	-0.43	-5.44	-0.34	1.32e-7	Huntington's disease progression;
SARC	cis	rs10931896	0.531	rs296801	chr2:201142812	C/T	cg23649088	chr2:200775458	C2orf69	0.57	8.22	0.47	1.45e-14	Systolic blood pressure;
SARC	cis	rs6964587	0.934	rs4512319	chr7:91733829	G/A	cg17063962	chr7:91808500	NA	0.92	13.92	0.67	1.89e-32	Breast cancer;
SARC	cis	rs7833986	1.000	rs36088882	chr8:57092914	T/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.6	5.33	0.33	2.36e-7	Height;
SARC	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.48	-5.9	-0.36	1.24e-8	Bipolar disorder;
SARC	cis	rs7666738	0.830	rs4699598	chr4:99019158	C/T	cg05340658	chr4:99064831	C4orf37	0.66	9.04	0.51	6.35e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg13939156	chr17:80058883	NA	0.4	6.25	0.38	1.92e-9	Life satisfaction;
SARC	cis	rs12579753	0.917	rs10778834	chr12:82199742	A/C	cg07988820	chr12:82153109	PPFIA2	-0.5	-5.75	-0.35	2.77e-8	Resting heart rate;
SARC	cis	rs1707322	0.963	rs4508055	chr1:46257731	A/T	cg03146154	chr1:46216737	IPP	0.5	5.99	0.37	7.86e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs12458462	0.812	rs34583578	chr18:77491070	C/T	cg11879182	chr18:77439856	CTDP1	0.87	12.3	0.63	3.99e-27	Monocyte count;
SARC	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg00149659	chr3:10157352	C3orf10	-0.65	-6.42	-0.39	7.53e-10	Alzheimer's disease;
SARC	cis	rs3784262	0.669	rs3742959	chr15:58249113	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.33	-4.93	-0.31	1.53e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs10493773	0.609	rs6689168	chr1:86174232	G/T	cg17807903	chr1:86174739	ZNHIT6	-0.62	-10.13	-0.55	3.3e-20	Urate levels in overweight individuals;
SARC	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-7.97	-0.46	7.21e-14	Chronic sinus infection;
SARC	cis	rs4253772	0.614	rs11090859	chr22:46687460	T/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.72	7.48	0.44	1.55e-12	LDL cholesterol;Cholesterol, total;
SARC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.43	0.56	3.8e-21	Prudent dietary pattern;
SARC	cis	rs3820928	0.874	rs12614648	chr2:227785535	G/A	cg05526886	chr2:227700861	RHBDD1	-0.53	-6.51	-0.39	4.67e-10	Pulmonary function;
SARC	cis	rs6424115	0.790	rs72874118	chr1:24177800	A/G	cg15997130	chr1:24165203	NA	-0.39	-5.27	-0.33	3.13e-7	Immature fraction of reticulocytes;
SARC	cis	rs17401966	0.898	rs12122107	chr1:10251449	C/T	cg15208524	chr1:10270712	KIF1B	0.49	5.22	0.32	4.03e-7	Hepatocellular carcinoma;
SARC	cis	rs2153535	0.580	rs1577470	chr6:8462426	G/A	cg07606381	chr6:8435919	SLC35B3	0.76	10.71	0.57	4.89e-22	Motion sickness;
SARC	cis	rs9326248	0.861	rs4938343	chr11:117003528	G/C	cg01368799	chr11:117014884	PAFAH1B2	0.58	5.78	0.35	2.36e-8	Blood protein levels;
SARC	cis	rs7932354	0.528	rs7479189	chr11:47057009	T/A	cg03339077	chr11:47165057	C11orf49	-0.4	-5.44	-0.34	1.36e-7	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs1707322	0.964	rs785509	chr1:46527300	G/A	cg06784218	chr1:46089804	CCDC17	-0.37	-6.39	-0.39	8.76e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg01877644	chr19:5804248	NA	-0.5	-6.65	-0.4	2.05e-10	Thyroid cancer;
SARC	cis	rs11025559	0.773	rs16906274	chr11:20470142	T/C	cg19653624	chr11:20408972	PRMT3	-0.57	-6.26	-0.38	1.86e-9	Pursuit maintenance gain;
SARC	cis	rs4742903	0.935	rs4743694	chr9:106933163	C/G	cg14250997	chr9:106856677	SMC2	0.44	5.47	0.34	1.17e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs2014572	0.967	rs10427146	chr19:57755998	T/C	cg24459738	chr19:57751996	ZNF805	-0.47	-5.58	-0.34	6.62e-8	Hyperactive-impulsive symptoms;
SARC	cis	rs7762018	0.607	rs75521584	chr6:170051595	T/C	cg13891659	chr6:170190454	C6orf122;C6orf208	0.73	4.83	0.3	2.52e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs4642101	0.765	rs9872103	chr3:12827452	G/T	cg05775895	chr3:12838266	CAND2	0.76	12.26	0.63	5.21e-27	QRS complex (12-leadsum);
SARC	cis	rs9473924	0.542	rs2245173	chr6:50810540	T/C	cg14470998	chr6:50812995	TFAP2B	0.68	6.02	0.37	6.63e-9	Body mass index;
SARC	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs11098499	0.818	rs7688802	chr4:120451668	G/A	cg09307838	chr4:120376055	NA	0.91	12.31	0.63	3.63e-27	Corneal astigmatism;
SARC	cis	rs240764	0.658	rs11155666	chr6:101234841	G/C	cg09795085	chr6:101329169	ASCC3	-0.5	-6.57	-0.4	3.28e-10	Neuroticism;
SARC	cis	rs690037	0.673	rs690573	chr3:16376440	G/T	cg23474789	chr3:16306055	DPH3;OXNAD1	-0.49	-5.5	-0.34	9.74e-8	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);
SARC	trans	rs7591996	0.835	rs7585700	chr2:6504784	A/T	cg05000987	chr1:87379871	SEP15;HS2ST1	-0.49	-6.26	-0.38	1.88e-9	Osteosarcoma;
SARC	cis	rs6005807	0.543	rs6005868	chr22:29165766	T/C	cg02153584	chr22:29168773	CCDC117	0.66	5.17	0.32	5.08e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
SARC	cis	rs9815354	0.812	rs73069390	chr3:41785513	C/T	cg03022575	chr3:42003672	ULK4	0.7	5.89	0.36	1.35e-8	Pulse pressure;Diastolic blood pressure;
SARC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg06967118	chr6:108879610	FOXO3	-0.56	-6.23	-0.38	2.1e-9	Hepatitis;
SARC	cis	rs13082711	0.911	rs67104968	chr3:27510304	A/G	cg02860705	chr3:27208620	NA	0.4	5.26	0.33	3.22e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs637571	0.522	rs649000	chr11:65742933	T/C	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.4	-4.85	-0.3	2.25e-6	Eosinophil percentage of white cells;
SARC	cis	rs4689388	0.926	rs10010131	chr4:6292915	A/G	cg14416269	chr4:6271139	WFS1	0.32	4.92	0.31	1.61e-6	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs7100689	0.577	rs9421464	chr10:82043426	C/T	cg01528321	chr10:82214614	TSPAN14	0.66	8.61	0.49	1.13e-15	Post bronchodilator FEV1;
SARC	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg06969265	chr17:73775802	H3F3B	0.66	7.13	0.42	1.23e-11	Psoriasis;
SARC	cis	rs2120019	0.508	rs8030528	chr15:75171825	C/T	cg17294928	chr15:75287854	SCAMP5	-0.86	-8.99	-0.51	8.53e-17	Blood trace element (Zn levels);
SARC	trans	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg21659725	chr3:3221576	CRBN	0.54	6.99	0.42	2.83e-11	Intelligence (multi-trait analysis);
SARC	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.29	0.38	1.55e-9	Bipolar disorder;
SARC	trans	rs11098499	0.954	rs4309825	chr4:120314881	C/T	cg25214090	chr10:38739885	LOC399744	-0.57	-7.28	-0.43	5.18e-12	Corneal astigmatism;
SARC	cis	rs9914544	0.505	rs7503678	chr17:18776020	A/T	cg25390199	chr17:18761479	PRPSAP2	0.47	6.14	0.37	3.58e-9	Educational attainment (years of education);
SARC	cis	rs8053891	0.813	rs16973520	chr16:71996291	T/G	cg16558253	chr16:72132732	DHX38	-0.41	-5.37	-0.33	1.94e-7	Coronary artery disease;
SARC	cis	rs3617	0.503	rs9866243	chr3:52915219	C/T	cg18404041	chr3:52824283	ITIH1	0.34	4.94	0.31	1.48e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs7264396	0.563	rs2425117	chr20:34323776	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.87	-0.41	5.85e-11	Total cholesterol levels;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg08434594	chr19:14640333	TECR;MIR639	-0.52	-6.58	-0.4	3.15e-10	Schizophrenia;
SARC	cis	rs2370759	1.000	rs79578760	chr10:32611264	C/A	cg01819863	chr10:32635814	EPC1	1.02	10.16	0.55	2.67e-20	Sexual dysfunction (female);
SARC	cis	rs8014204	0.836	rs12888998	chr14:75292662	G/T	cg06637938	chr14:75390232	RPS6KL1	0.69	9.9	0.54	1.67e-19	Caffeine consumption;
SARC	cis	rs7826238	0.601	rs2979206	chr8:8345581	G/C	cg06636001	chr8:8085503	FLJ10661	0.62	8.72	0.5	5.45e-16	Systolic blood pressure;
SARC	cis	rs1559088	0.600	rs7246566	chr19:33589618	A/T	cg17764715	chr19:33622953	WDR88	0.57	7.97	0.46	7.22e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs9303401	0.659	rs7216648	chr17:56790858	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	11.87	0.61	9.72e-26	Cognitive test performance;
SARC	cis	rs1153858	0.887	rs7171163	chr15:45636395	A/C	cg26924012	chr15:45694286	SPATA5L1	0.76	10.58	0.57	1.3e-21	Homoarginine levels;
SARC	cis	rs4722166	0.604	rs2390715	chr7:22783878	A/C	cg26061582	chr7:22766209	IL6	0.55	6.11	0.37	4.09e-9	Lung cancer;
SARC	cis	rs2635047	0.811	rs12962421	chr18:44787498	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.51	6.55	0.39	3.58e-10	Educational attainment;
SARC	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg09455208	chr3:40491958	NA	0.41	5.93	0.36	1.07e-8	Renal cell carcinoma;
SARC	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs3091242	0.933	rs11249251	chr1:25770188	C/G	cg02931644	chr1:25747376	RHCE	0.43	7.27	0.43	5.36e-12	Erythrocyte sedimentation rate;
SARC	cis	rs908922	0.523	rs4845786	chr1:152510144	A/G	cg09873164	chr1:152488093	CRCT1	0.64	8.42	0.48	3.8e-15	Hair morphology;
SARC	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg06634786	chr22:41940651	POLR3H	0.51	6.17	0.37	3.07e-9	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs733592	0.507	rs10875739	chr12:48480919	C/T	cg21466736	chr12:48725269	NA	-0.32	-5.25	-0.33	3.41e-7	Plateletcrit;
SARC	cis	rs10489525	0.599	rs7516121	chr1:115604317	A/G	cg01522456	chr1:115632236	TSPAN2	0.46	5.46	0.34	1.24e-7	Autism;
SARC	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg22857025	chr5:266934	NA	-1.05	-11.51	-0.6	1.44e-24	Breast cancer;
SARC	cis	rs10489202	0.657	rs201540	chr1:167992883	G/A	cg24449463	chr1:168025552	DCAF6	-0.67	-9.13	-0.51	3.45e-17	Schizophrenia;
SARC	cis	rs9341808	0.718	rs9352801	chr6:80817468	G/T	cg08355045	chr6:80787529	NA	0.34	5.48	0.34	1.09e-7	Sitting height ratio;
SARC	cis	rs36051895	0.632	rs10118930	chr9:5148278	C/T	cg02405213	chr9:5042618	JAK2	-0.45	-5.35	-0.33	2.06e-7	Pediatric autoimmune diseases;
SARC	cis	rs7772486	0.658	rs9403737	chr6:145962193	G/T	cg05347473	chr6:146136440	FBXO30	0.54	7.43	0.44	2.02e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6912958	0.754	rs7762864	chr6:88236213	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-7.19	-0.43	9.01e-12	Monocyte percentage of white cells;
SARC	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg16606324	chr3:10149918	C3orf24	0.51	4.95	0.31	1.39e-6	Alzheimer's disease;
SARC	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg19500275	chr17:80737654	TBCD	0.41	4.79	0.3	3e-6	Glycated hemoglobin levels;
SARC	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg02931644	chr1:25747376	RHCE	0.45	7.6	0.45	7.18e-13	Plateletcrit;Mean corpuscular volume;
SARC	trans	rs57046232	0.502	rs13041415	chr20:6463095	T/C	cg27502912	chr22:51017001	CPT1B;CHKB-CPT1B	0.61	6.45	0.39	6.27e-10	Colorectal cancer;
SARC	cis	rs787274	0.867	rs786969	chr9:115449556	C/G	cg13803584	chr9:115635662	SNX30	0.74	5.14	0.32	5.89e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs9611519	0.589	rs8138917	chr22:41412425	T/C	cg06634786	chr22:41940651	POLR3H	-0.38	-4.9	-0.31	1.8e-6	Neuroticism;
SARC	cis	rs9291683	0.546	rs4575994	chr4:9997979	G/A	cg11266682	chr4:10021025	SLC2A9	0.4	6.86	0.41	6.13e-11	Bone mineral density;
SARC	cis	rs28374715	0.532	rs11854820	chr15:41676526	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.17	-18.76	-0.78	1.76e-48	Ulcerative colitis;
SARC	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg13877915	chr19:58951672	ZNF132	0.66	9.91	0.54	1.49e-19	Uric acid clearance;
SARC	cis	rs4481887	0.861	rs4486480	chr1:248449714	C/T	cg00666640	chr1:248458726	OR2T12	0.34	5.59	0.34	6.18e-8	Common traits (Other);
SARC	cis	rs8114671	0.562	rs6087644	chr20:33480917	G/C	cg24642439	chr20:33292090	TP53INP2	0.47	5.47	0.34	1.18e-7	Height;
SARC	trans	rs34421088	0.560	rs2245357	chr8:11399484	A/T	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.97	-0.51	9.92e-17	Neuroticism;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12950624	chr19:46000154	RTN2	0.5	6.47	0.39	5.78e-10	Smoking initiation;
SARC	cis	rs826838	0.967	rs12823908	chr12:38845686	T/C	cg26384229	chr12:38710491	ALG10B	0.93	14.91	0.7	9.31e-36	Heart rate;
SARC	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg18252515	chr7:66147081	NA	1.35	12.11	0.62	1.7e-26	Diabetic kidney disease;
SARC	cis	rs8067354	0.789	rs4622571	chr17:57884397	T/A	cg02344993	chr17:57696989	CLTC	0.44	5.08	0.32	7.85e-7	Hemoglobin concentration;
SARC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg06873352	chr17:61820015	STRADA	0.53	6.92	0.41	4.3e-11	Prudent dietary pattern;
SARC	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg04944784	chr2:26401820	FAM59B	-0.6	-7.86	-0.46	1.46e-13	Gut microbiome composition (summer);
SARC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.5	0.57	2.22e-21	Prudent dietary pattern;
SARC	cis	rs7666738	0.830	rs6855393	chr4:99056534	T/C	cg05340658	chr4:99064831	C4orf37	0.64	8.68	0.49	7.17e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs3540	0.574	rs2256388	chr15:90969335	A/C	cg22089800	chr15:90895588	ZNF774	-0.67	-8.64	-0.49	9.19e-16	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg26956754	chr6:158902233	TULP4	-0.48	-6.29	-0.38	1.59e-9	Height;
SARC	cis	rs7681440	0.904	rs3806789	chr4:90759556	C/T	cg02192967	chr4:90758406	SNCA	0.36	5.12	0.32	6.4e-7	Dementia with Lewy bodies;
SARC	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg11317459	chr13:21872234	NA	0.45	5.31	0.33	2.6e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.44	-5.64	-0.35	4.93e-8	Blood metabolite levels;
SARC	cis	rs9858542	0.953	rs9818590	chr3:49525096	A/G	cg07274523	chr3:49395745	GPX1	0.53	6.13	0.37	3.82e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs11122272	0.735	rs2486727	chr1:231539245	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.97	-0.55	1e-19	Hemoglobin concentration;
SARC	trans	rs11722228	0.522	rs73212817	chr4:10064011	T/C	cg26043149	chr18:55253948	FECH	0.7	7.8	0.46	2.04e-13	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg24549020	chr5:56110836	MAP3K1	0.81	8.4	0.48	4.37e-15	Initial pursuit acceleration;
SARC	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg22920501	chr2:26401640	FAM59B	-0.5	-6.56	-0.4	3.36e-10	Gut microbiome composition (summer);
SARC	trans	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-7.59	-0.45	7.48e-13	Intelligence (multi-trait analysis);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg22508569	chr3:127771381	SEC61A1	0.48	6.37	0.39	9.9e-10	Chemerin levels;
SARC	cis	rs7772486	0.754	rs6915718	chr6:146100676	A/G	cg05347473	chr6:146136440	FBXO30	-0.55	-7.64	-0.45	5.77e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7714584	1.000	rs75071288	chr5:150224379	C/T	cg22134413	chr5:150180641	NA	0.78	6.56	0.39	3.42e-10	Crohn's disease;
SARC	cis	rs6540556	0.859	rs12079960	chr1:209937168	A/C	cg23920097	chr1:209922102	NA	-0.46	-5.4	-0.33	1.63e-7	Red blood cell count;
SARC	trans	rs3780486	0.846	rs10738905	chr9:33123627	A/G	cg04842962	chr6:43655489	MRPS18A	1.08	20.73	0.81	8.36e-55	IgG glycosylation;
SARC	cis	rs9473924	0.505	rs2223869	chr6:50904239	C/T	cg14470998	chr6:50812995	TFAP2B	0.75	7.03	0.42	2.26e-11	Body mass index;
SARC	cis	rs4481887	0.893	rs10788774	chr1:248471712	T/C	cg13385794	chr1:248469461	NA	0.36	5.43	0.34	1.41e-7	Common traits (Other);
SARC	cis	rs11583043	1.000	rs12750667	chr1:101498682	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.49	5.8	0.36	2.12e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg04111992	chr7:158790115	NA	-0.35	-4.89	-0.3	1.91e-6	Facial morphology (factor 20);
SARC	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg01475735	chr3:40494733	NA	-0.48	-5.29	-0.33	2.86e-7	Renal cell carcinoma;
SARC	cis	rs8180040	0.966	rs9683033	chr3:47489820	C/T	cg27129171	chr3:47204927	SETD2	0.67	9.32	0.52	9.19e-18	Colorectal cancer;
SARC	cis	rs17345786	0.906	rs58835747	chr3:101243634	T/C	cg12386194	chr3:101231763	SENP7	0.82	9.88	0.54	1.88e-19	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10992471	0.603	rs7865019	chr9:95325631	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.45	-0.34	1.25e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs2354432	0.556	rs59180647	chr1:146772062	C/T	cg25205988	chr1:146714368	CHD1L	-1.02	-7.73	-0.45	3.15e-13	Mitochondrial DNA levels;
SARC	cis	rs6686643	1.000	rs957644	chr1:165616157	C/T	cg19407955	chr1:165599744	MGST3	-0.56	-5.79	-0.35	2.27e-8	Total ventricular volume;
SARC	cis	rs4971059	0.617	rs10908458	chr1:155126948	T/C	cg22049894	chr1:155113146	DPM3	0.41	5.05	0.31	8.92e-7	Breast cancer;
SARC	cis	rs447735	0.507	rs11645271	chr16:89729125	G/T	cg03605463	chr16:89740564	NA	-0.41	-5.61	-0.35	5.66e-8	Hemoglobin concentration;
SARC	cis	rs6908034	0.607	rs113894708	chr6:19806066	G/T	cg02682789	chr6:19804855	NA	0.72	5.45	0.34	1.31e-7	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs9660992	0.674	rs72745219	chr1:205262271	G/A	cg07972983	chr1:205091412	RBBP5	0.51	5.95	0.36	9.86e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg12463550	chr7:65579703	CRCP	-0.48	-5.27	-0.33	3.11e-7	Aortic root size;
SARC	cis	rs1005277	0.522	rs7072977	chr10:37940440	C/A	cg25427524	chr10:38739819	LOC399744	-0.51	-7.66	-0.45	4.89e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs453301	0.522	rs2929309	chr8:9083771	C/A	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.54	-0.49	1.81e-15	Joint mobility (Beighton score);
SARC	cis	rs11731606	0.567	rs17377951	chr4:95321099	C/T	cg00507259	chr4:95128692	SMARCAD1	0.55	5.07	0.32	8.09e-7	Mean platelet volume;
SARC	cis	rs6831352	0.918	rs3919370	chr4:100064326	A/T	cg13256891	chr4:100009986	ADH5	-0.66	-8.03	-0.47	4.84e-14	Alcohol dependence;
SARC	cis	rs427394	0.796	rs274683	chr5:6747950	T/A	cg10857441	chr5:6722123	POLS	-0.32	-4.73	-0.3	3.82e-6	Menopause (age at onset);
SARC	cis	rs11608355	0.545	rs7316375	chr12:109906998	G/C	cg05360138	chr12:110035743	NA	0.93	9.71	0.54	6.14e-19	Neuroticism;
SARC	cis	rs8013055	0.898	rs8004007	chr14:105971435	G/C	cg19700328	chr14:106028568	NA	-0.62	-8.61	-0.49	1.12e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
SARC	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg13628971	chr7:2884303	GNA12	0.58	6.77	0.41	1.06e-10	Height;
SARC	cis	rs12579753	1.000	rs11115030	chr12:82203021	A/T	cg07988820	chr12:82153109	PPFIA2	-0.57	-6.6	-0.4	2.67e-10	Resting heart rate;
SARC	cis	rs936229	0.511	rs12591513	chr15:75102714	G/A	cg14664628	chr15:75095509	CSK	-0.8	-10.49	-0.57	2.42e-21	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs6083	0.571	rs17190678	chr15:58847372	C/G	cg05156742	chr15:59063176	FAM63B	-0.63	-8.16	-0.47	2.12e-14	Schizophrenia;
SARC	trans	rs6500957	0.920	rs17648524	chr16:7459683	C/G	cg10175719	chr10:28592238	NA	-0.47	-6.42	-0.39	7.72e-10	Spherical equivalent (joint analysis main effects and education interaction);
SARC	cis	rs7937682	1.000	rs7121011	chr11:111568681	C/T	cg22437258	chr11:111473054	SIK2	-0.67	-8.71	-0.5	5.73e-16	Primary sclerosing cholangitis;
SARC	cis	rs477895	1.000	rs41294396	chr11:64078581	G/A	cg04317338	chr11:64019027	PLCB3	0.63	5.15	0.32	5.45e-7	Mean platelet volume;
SARC	trans	rs11722228	0.549	rs55848383	chr4:10081117	C/A	cg26043149	chr18:55253948	FECH	0.68	7.6	0.45	7.08e-13	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg20102877	chr2:27665638	KRTCAP3	-0.36	-5.15	-0.32	5.52e-7	Total body bone mineral density;
SARC	cis	rs3857067	0.680	rs1509946	chr4:95109078	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.32	-4.84	-0.3	2.39e-6	QT interval;
SARC	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg04277193	chr17:41438351	NA	0.45	4.74	0.3	3.7e-6	Menopause (age at onset);
SARC	cis	rs11252926	0.550	rs10904148	chr10:454551	G/T	cg16386425	chr10:429943	DIP2C	-0.43	-5.02	-0.31	1.03e-6	Psychosis in Alzheimer's disease;
SARC	cis	rs9457247	0.935	rs401260	chr6:167405888	T/C	cg23791538	chr6:167370224	RNASET2	-0.63	-8.74	-0.5	4.69e-16	Crohn's disease;
SARC	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg10591111	chr5:226296	SDHA	-0.55	-4.97	-0.31	1.31e-6	Breast cancer;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg22083815	chr1:32666378	CCDC28B	0.55	7.53	0.44	1.09e-12	Tetralogy of Fallot;
SARC	cis	rs858239	0.600	rs10266123	chr7:23136487	G/C	cg23682824	chr7:23144976	KLHL7	0.66	8.63	0.49	9.64e-16	Cerebrospinal fluid biomarker levels;
SARC	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg11987759	chr7:65425863	GUSB	-0.47	-6.27	-0.38	1.7e-9	Aortic root size;
SARC	cis	rs1707322	1.000	rs34444543	chr1:46358862	G/A	cg03146154	chr1:46216737	IPP	0.47	5.64	0.35	4.94e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs10085978	0.604	rs11167128	chr8:143225883	A/G	cg08692348	chr19:37642883	ZNF585A	0.46	6.3	0.38	1.51e-9	Mosquito bite size;
SARC	cis	rs1395	0.778	rs34618115	chr2:27418289	G/A	cg21747090	chr2:27597821	SNX17	-0.49	-5.79	-0.35	2.29e-8	Blood metabolite levels;
SARC	trans	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg03929089	chr4:120376271	NA	-0.79	-9.63	-0.53	1.1e-18	Height;
SARC	cis	rs72627123	0.656	rs11159064	chr14:74614743	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	-0.76	-5.79	-0.35	2.26e-8	Morning vs. evening chronotype;
SARC	cis	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg26513180	chr16:89883248	FANCA	0.72	4.79	0.3	2.94e-6	Skin colour saturation;
SARC	cis	rs7772486	0.686	rs857877	chr6:145976230	A/C	cg05347473	chr6:146136440	FBXO30	-0.54	-7.43	-0.44	2.02e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3796352	1.000	rs35174175	chr3:53041509	T/C	cg15956490	chr3:53032818	SFMBT1	0.87	5.73	0.35	3.14e-8	Immune reponse to smallpox (secreted IL-2);
SARC	trans	rs61931739	0.635	rs10772123	chr12:33975557	C/T	cg26384229	chr12:38710491	ALG10B	0.62	8.09	0.47	3.34e-14	Morning vs. evening chronotype;
SARC	cis	rs13191362	0.872	rs73017702	chr6:163257695	C/A	cg18825119	chr6:163149453	PACRG;PARK2	0.37	5.11	0.32	6.74e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg06212747	chr3:49208901	KLHDC8B	0.52	6.42	0.39	7.41e-10	Resting heart rate;
SARC	cis	rs8180040	0.691	rs12489211	chr3:47221451	T/A	cg27129171	chr3:47204927	SETD2	0.67	9.52	0.53	2.31e-18	Colorectal cancer;
SARC	cis	rs9916302	0.706	rs4794808	chr17:37531916	C/T	cg00129232	chr17:37814104	STARD3	0.54	5.78	0.35	2.34e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs7408868	1.000	rs2074618	chr19:15276143	C/T	cg14696996	chr19:15285081	NOTCH3	1.05	8.52	0.49	1.95e-15	Pulse pressure;
SARC	cis	rs950776	0.752	rs2869546	chr15:78907345	C/T	cg24631222	chr15:78858424	CHRNA5	0.39	5.0	0.31	1.14e-6	Sudden cardiac arrest;
SARC	cis	rs10791097	0.720	rs7119425	chr11:130733185	C/T	cg09137382	chr11:130731461	NA	0.31	4.87	0.3	2.1e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg03517284	chr6:25882590	NA	-0.34	-4.85	-0.3	2.23e-6	Blood metabolite levels;
SARC	cis	rs72848980	0.512	rs61151381	chr10:105370496	C/G	cg00126946	chr10:105363258	SH3PXD2A	0.5	7.29	0.43	4.77e-12	White matter hyperintensity burden;
SARC	cis	rs6772849	0.930	rs4857912	chr3:128329224	G/A	cg01163369	chr3:128370232	RPN1	-0.35	-5.07	-0.32	8.23e-7	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs4803468	1.000	rs10853751	chr19:41903220	G/A	cg09537434	chr19:41945824	ATP5SL	-0.94	-16.3	-0.73	2.27e-40	Height;
SARC	cis	rs651907	0.557	rs11917682	chr3:101355427	G/A	cg12386194	chr3:101231763	SENP7	0.5	5.95	0.36	9.98e-9	Colorectal cancer;
SARC	cis	rs17376456	0.877	rs28575883	chr5:93346035	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.49	0.34	1.06e-7	Diabetic retinopathy;
SARC	cis	rs4718428	0.672	rs12530806	chr7:66390724	A/G	cg12165864	chr7:66369176	NA	-0.47	-5.27	-0.33	3.17e-7	Corneal structure;
SARC	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg08280861	chr8:58055591	NA	0.6	5.83	0.36	1.8e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9902453	0.619	rs2255489	chr17:28084974	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.24	-0.43	6.33e-12	Coffee consumption (cups per day);
SARC	cis	rs11687170	0.882	rs56221553	chr2:237056787	A/G	cg19324714	chr2:237145437	ASB18	0.49	4.89	0.31	1.89e-6	Educational attainment;Educational attainment (years of education);
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg20138264	chr17:48585640	MYCBPAP	-0.63	-6.68	-0.4	1.74e-10	Lung cancer in ever smokers;
SARC	cis	rs1971762	0.527	rs784568	chr12:53927554	C/A	cg06632207	chr12:54070931	ATP5G2	-0.59	-8.07	-0.47	3.67e-14	Height;
SARC	cis	rs9815354	0.716	rs73828280	chr3:41833907	A/T	cg03022575	chr3:42003672	ULK4	0.58	5.41	0.33	1.58e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg06212747	chr3:49208901	KLHDC8B	0.51	6.3	0.38	1.46e-9	Resting heart rate;
SARC	cis	rs9290065	0.686	rs1839021	chr3:160623669	T/G	cg04691961	chr3:161091175	C3orf57	0.52	6.95	0.41	3.72e-11	Kawasaki disease;
SARC	cis	rs826838	1.000	rs11183214	chr12:38692938	C/T	cg26384229	chr12:38710491	ALG10B	0.96	15.74	0.72	1.65e-38	Heart rate;
SARC	cis	rs473651	0.935	rs541128	chr2:239336449	A/G	cg18131467	chr2:239335373	ASB1	0.95	15.58	0.71	5.57e-38	Multiple system atrophy;
SARC	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg11644478	chr21:40555479	PSMG1	1.02	13.93	0.67	1.78e-32	Cognitive function;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg18429434	chr2:203499731	FAM117B	0.48	6.32	0.38	1.35e-9	Tetralogy of Fallot;
SARC	cis	rs2304069	0.954	rs2340462	chr5:149415219	G/A	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.61	6.27	0.38	1.75e-9	HIV-1 control;
SARC	cis	rs9486715	0.929	rs2025044	chr6:97067028	A/G	cg18709589	chr6:96969512	KIAA0776	-0.59	-7.33	-0.43	3.76e-12	Headache;
SARC	cis	rs9886651	0.776	rs12155669	chr8:128779931	A/G	cg24514600	chr8:128805414	PVT1	0.39	5.03	0.31	9.7e-7	Epithelial ovarian cancer;Serous invasive ovarian cancer;
SARC	cis	rs8014204	0.935	rs2853779	chr14:75368508	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.74	-11.01	-0.59	5.57e-23	Caffeine consumption;
SARC	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg00290607	chr11:67383545	NA	0.39	5.34	0.33	2.15e-7	Mean corpuscular volume;
SARC	cis	rs2120019	0.938	rs8036573	chr15:75308690	C/T	cg12414181	chr15:75287860	SCAMP5	-0.52	-5.8	-0.36	2.13e-8	Blood trace element (Zn levels);
SARC	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg13939156	chr17:80058883	NA	-0.42	-6.48	-0.39	5.51e-10	Life satisfaction;
SARC	cis	rs965604	0.965	rs12899351	chr15:78792398	T/C	cg24631222	chr15:78858424	CHRNA5	-0.45	-5.78	-0.35	2.33e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs2276314	0.857	rs28651028	chr18:33638910	G/A	cg19628046	chr18:33552617	C18orf21	0.54	5.8	0.36	2.18e-8	Endometriosis;Drug-induced torsades de pointes;
SARC	trans	rs61931739	0.963	rs12298565	chr12:34036188	C/T	cg26384229	chr12:38710491	ALG10B	-0.58	-7.27	-0.43	5.33e-12	Morning vs. evening chronotype;
SARC	cis	rs986417	0.901	rs7160405	chr14:60970004	G/C	cg27398547	chr14:60952738	C14orf39	1.02	9.63	0.53	1.06e-18	Gut microbiota (bacterial taxa);
SARC	cis	rs9910055	0.529	rs228749	chr17:42174570	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.44	-5.16	-0.32	5.31e-7	Total body bone mineral density;
SARC	cis	rs2273669	0.915	rs6929070	chr6:109294322	G/T	cg05315195	chr6:109294784	ARMC2	-0.49	-4.82	-0.3	2.57e-6	Prostate cancer;
SARC	cis	rs13191362	1.000	rs13195226	chr6:163006421	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.57	5.51	0.34	9.61e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg02574844	chr11:5959923	NA	-0.39	-5.23	-0.32	3.7e-7	DNA methylation (variation);
SARC	cis	rs7208859	0.623	rs7223209	chr17:29107220	C/A	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs3768617	0.528	rs10737241	chr1:183098208	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.66e-21	Fuchs's corneal dystrophy;
SARC	cis	rs79149102	0.579	rs28394281	chr15:75326754	C/G	cg17294928	chr15:75287854	SCAMP5	-1.1	-9.52	-0.53	2.31e-18	Lung cancer;
SARC	cis	rs12079745	0.793	rs3766094	chr1:169288264	T/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.87	-5.18	-0.32	4.79e-7	QT interval;
SARC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.09	0.37	4.62e-9	Prudent dietary pattern;
SARC	cis	rs9300255	0.602	rs10744147	chr12:123643729	A/G	cg05973401	chr12:123451056	ABCB9	0.57	5.47	0.34	1.17e-7	Neutrophil percentage of white cells;
SARC	cis	rs4689388	0.926	rs4689394	chr4:6291003	C/G	cg00701064	chr4:6280414	WFS1	-0.57	-9.21	-0.52	1.94e-17	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs4481887	0.927	rs4347240	chr1:248475403	C/G	cg01631408	chr1:248437212	OR2T33	-0.38	-4.92	-0.31	1.67e-6	Common traits (Other);
SARC	cis	rs2439831	0.867	rs16957632	chr15:43642897	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.76	7.92	0.46	9.46e-14	Lung cancer in ever smokers;
SARC	cis	rs17376456	0.877	rs10476526	chr5:93461916	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.79	0.35	2.3e-8	Diabetic retinopathy;
SARC	cis	rs634534	0.622	rs624273	chr11:65712413	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	6.51	0.39	4.5e-10	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs2204008	0.905	rs8189449	chr12:38437377	C/A	cg26384229	chr12:38710491	ALG10B	0.82	10.96	0.58	7.9e-23	Bladder cancer;
SARC	cis	rs11608355	0.960	rs10774691	chr12:109859830	C/T	cg05360138	chr12:110035743	NA	0.43	4.8	0.3	2.86e-6	Neuroticism;
SARC	cis	rs11605924	0.901	rs7105751	chr11:45856973	G/A	ch.11.939596F	chr11:45881766	CRY2	-0.47	-5.62	-0.35	5.45e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs2439831	0.850	rs7183809	chr15:44120868	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	8.07	0.47	3.66e-14	Lung cancer in ever smokers;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg01644979	chr6:43543852	XPO5;POLH	0.61	6.91	0.41	4.71e-11	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs7727544	0.684	rs611084	chr5:131709739	A/C	cg24060327	chr5:131705240	SLC22A5	0.71	9.11	0.51	3.77e-17	Blood metabolite levels;
SARC	cis	rs7662987	0.517	rs3018048	chr4:100005538	C/T	cg13256891	chr4:100009986	ADH5	0.66	8.34	0.48	6.58e-15	Smoking initiation;
SARC	cis	rs2652834	0.950	rs4774474	chr15:63405580	C/G	cg05507819	chr15:63340323	TPM1	0.55	5.37	0.33	1.86e-7	HDL cholesterol;
SARC	cis	rs995000	0.931	rs598253	chr1:62911341	T/C	cg06896770	chr1:63153194	DOCK7	0.89	13.58	0.66	2.52e-31	Triglyceride levels;
SARC	cis	rs60752752	0.852	rs2916216	chr1:153353360	G/A	cg26882115	chr1:153603048	S100A1;S100A13	-0.66	-5.0	-0.31	1.13e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs9309473	0.519	rs7606947	chr2:73909818	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-6.22	-0.38	2.29e-9	Metabolite levels;
SARC	cis	rs6121246	0.529	rs6120862	chr20:30199459	T/C	cg13852791	chr20:30311386	BCL2L1	0.67	5.81	0.36	2.01e-8	Mean corpuscular hemoglobin;
SARC	cis	rs1215050	0.740	rs13134479	chr4:99067723	G/A	cg05340658	chr4:99064831	C4orf37	0.47	6.26	0.38	1.79e-9	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs6831352	0.569	rs4148883	chr4:100066332	T/C	cg12011299	chr4:100065546	ADH4	0.31	5.59	0.34	6.38e-8	Alcohol dependence;
SARC	cis	rs240764	0.658	rs9390685	chr6:101224725	A/T	cg09795085	chr6:101329169	ASCC3	0.42	5.47	0.34	1.14e-7	Neuroticism;
SARC	trans	rs11634851	0.966	rs7174250	chr15:81018587	C/T	cg04669574	chr12:50297945	FAIM2	0.47	6.25	0.38	1.96e-9	Systolic blood pressure;
SARC	trans	rs634534	0.561	rs14157	chr11:65769780	T/G	cg17712092	chr4:129076599	LARP1B	0.7	9.54	0.53	2.07e-18	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg10523679	chr1:76189770	ACADM	0.45	5.41	0.33	1.6e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs4727027	0.745	rs10952801	chr7:148864757	T/C	cg23583168	chr7:148888333	NA	-0.73	-10.97	-0.58	7.75e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg16479474	chr6:28041457	NA	0.36	5.41	0.33	1.52e-7	Depression;
SARC	cis	rs9467773	0.620	rs2494694	chr6:26619328	A/T	cg11502198	chr6:26597334	ABT1	0.62	8.48	0.49	2.55e-15	Intelligence (multi-trait analysis);
SARC	cis	rs372883	0.530	rs2832226	chr21:30532986	A/G	cg24692254	chr21:30365293	RNF160	-0.42	-5.19	-0.32	4.54e-7	Pancreatic cancer;
SARC	cis	rs11792861	0.926	rs72607171	chr9:111837776	T/C	cg13535736	chr9:111863775	C9orf5	-0.41	-5.07	-0.32	8.04e-7	Menarche (age at onset);
SARC	cis	rs7829975	0.509	rs7838674	chr8:8797073	A/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.93	-0.41	4.14e-11	Mood instability;
SARC	cis	rs6696846	1.000	rs6696846	chr1:205041952	C/T	cg00857998	chr1:205179979	DSTYK	0.39	4.82	0.3	2.59e-6	Red blood cell count;
SARC	cis	rs9513593	0.892	rs7320298	chr13:99875666	G/T	cg21788972	chr13:99853209	UBAC2	0.51	4.84	0.3	2.33e-6	Psoriasis;
SARC	cis	rs1536827	0.698	rs8192766	chr10:135339385	T/G	cg22671611	chr10:135291010	NA	-0.46	-4.75	-0.3	3.58e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs7824557	0.628	rs7841394	chr8:11185671	G/T	cg21775007	chr8:11205619	TDH	0.65	8.44	0.48	3.49e-15	Retinal vascular caliber;
SARC	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg03264133	chr6:25882463	NA	-0.65	-8.37	-0.48	5.38e-15	Intelligence (multi-trait analysis);
SARC	cis	rs8180040	0.966	rs11711824	chr3:47468261	C/T	cg27129171	chr3:47204927	SETD2	0.66	9.19	0.52	2.21e-17	Colorectal cancer;
SARC	trans	rs7824557	0.564	rs1435275	chr8:11235735	T/C	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.72	-0.5	5.36e-16	Retinal vascular caliber;
SARC	cis	rs9840812	0.535	rs695983	chr3:136064547	C/T	cg15507776	chr3:136538369	TMEM22	0.51	5.77	0.35	2.5e-8	Fibrinogen levels;
SARC	cis	rs56330463	0.874	rs9325120	chr5:148200958	C/A	cg21580376	chr5:148206412	ADRB2	0.41	5.65	0.35	4.58e-8	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Monocyte percentage of white cells;Eosinophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;
SARC	trans	rs2727020	0.521	rs10839285	chr11:49496852	T/G	cg15704280	chr7:45808275	SEPT13	0.71	8.53	0.49	1.91e-15	Coronary artery disease;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg06361108	chr16:2478781	CCNF	0.49	6.44	0.39	6.86e-10	Breast cancer;
SARC	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg14893161	chr1:205819251	PM20D1	-0.46	-5.23	-0.32	3.83e-7	Parkinson's disease;
SARC	cis	rs7824557	0.620	rs6996368	chr8:11182704	G/A	cg21775007	chr8:11205619	TDH	0.65	8.41	0.48	4.01e-15	Retinal vascular caliber;
SARC	cis	rs3091242	0.933	rs9645452	chr1:25668326	C/T	cg03650068	chr1:25596491	NA	-0.34	-5.31	-0.33	2.54e-7	Erythrocyte sedimentation rate;
SARC	cis	rs10276381	1.000	rs10281214	chr7:28185544	G/C	cg23620719	chr7:28220237	JAZF1	0.71	5.89	0.36	1.31e-8	Crohn's disease;
SARC	cis	rs10782582	0.593	rs6704444	chr1:76205108	T/C	cg03433033	chr1:76189801	ACADM	-0.42	-5.47	-0.34	1.15e-7	Daytime sleep phenotypes;
SARC	cis	rs965469	0.779	rs6051771	chr20:3328271	A/G	cg25506879	chr20:3388711	C20orf194	-0.46	-4.99	-0.31	1.17e-6	IFN-related cytopenia;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg02594498	chr15:22893147	CYFIP1	-0.65	-7.72	-0.45	3.38e-13	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs72781680	1.000	rs72781654	chr2:24218099	T/C	cg06627628	chr2:24431161	ITSN2	-0.53	-5.7	-0.35	3.56e-8	Lymphocyte counts;
SARC	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg04518342	chr5:131593106	PDLIM4	0.43	5.55	0.34	7.88e-8	Breast cancer;
SARC	cis	rs7524258	0.903	rs763197	chr1:7289959	A/G	cg07173049	chr1:7289937	CAMTA1	0.4	7.89	0.46	1.17e-13	Tourette's syndrome or obsessive-compulsive disorder;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg03586839	chr1:150601711	ENSA	-0.53	-6.62	-0.4	2.39e-10	Height;
SARC	cis	rs4742903	0.935	rs1507515	chr9:106989653	A/G	cg14250997	chr9:106856677	SMC2	-0.44	-5.65	-0.35	4.67e-8	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs6456042	1.000	rs9459577	chr6:166534389	C/A	cg11088901	chr6:166572345	T	-0.32	-4.74	-0.3	3.8e-6	Asthma;
SARC	cis	rs865483	0.895	rs1112173	chr17:35760056	C/T	cg06561646	chr17:35873369	DUSP14	0.48	6.12	0.37	3.98e-9	Monocyte count;
SARC	cis	rs13144136	0.687	rs13143538	chr4:10656897	T/C	cg10242279	chr4:10666415	CLNK	-0.42	-6.91	-0.41	4.71e-11	Resistance to antihypertensive treatment in hypertension;
SARC	cis	rs7621025	0.505	rs13063893	chr3:136387638	C/T	cg15507776	chr3:136538369	TMEM22	-0.98	-8.29	-0.48	9.03e-15	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
SARC	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg15331097	chr6:90539609	CASP8AP2	-0.5	-6.66	-0.4	2e-10	Thyroid cancer;
SARC	cis	rs858239	0.539	rs28716381	chr7:23189015	G/A	cg23682824	chr7:23144976	KLHL7	0.71	9.28	0.52	1.23e-17	Cerebrospinal fluid biomarker levels;
SARC	cis	rs11098499	0.909	rs78332141	chr4:120375782	C/T	cg09307838	chr4:120376055	NA	0.9	12.3	0.63	4.14e-27	Corneal astigmatism;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg14922279	chr10:62538201	CDK1;CDC2	0.52	6.39	0.39	8.72e-10	Breast cancer;
SARC	cis	rs10876993	0.928	rs2640637	chr12:58077586	G/A	cg18357645	chr12:58087776	OS9	0.52	6.89	0.41	5.14e-11	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg20887711	chr4:1340912	KIAA1530	0.78	9.75	0.54	4.75e-19	Longevity;
SARC	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.6	-6.31	-0.38	1.42e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs11583043	1.000	rs3861734	chr1:101489461	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.49	5.45	0.34	1.25e-7	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs3784262	0.904	rs12901462	chr15:58316487	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.38	-5.75	-0.35	2.77e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs8014131	0.689	rs4904253	chr14:85985712	T/C	cg10406690	chr14:85995726	FLRT2	0.42	5.45	0.34	1.29e-7	Menarche (age at onset);
SARC	trans	rs7819412	0.539	rs11250131	chr8:11251175	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.35	-0.38	1.11e-9	Triglycerides;
SARC	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg17554472	chr22:41940697	POLR3H	-0.48	-5.34	-0.33	2.22e-7	Vitiligo;
SARC	cis	rs2439831	0.867	rs6493082	chr15:43634808	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.76	7.92	0.46	9.46e-14	Lung cancer in ever smokers;
SARC	cis	rs274567	0.501	rs272855	chr5:131687175	C/T	cg11843238	chr5:131593191	PDLIM4	0.39	4.78	0.3	3.07e-6	Blood metabolite levels;
SARC	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-5.46	-0.34	1.24e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	trans	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.56	7.56	0.44	9.19e-13	Intelligence (multi-trait analysis);
SARC	cis	rs941408	0.515	rs7253128	chr19:2776982	C/T	cg00079169	chr19:2811669	THOP1	0.43	4.72	0.3	3.99e-6	Total cholesterol levels;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg05414026	chr15:72410489	MYO9A;SENP8	-0.54	-6.96	-0.41	3.42e-11	Gallstone disease;
SARC	cis	rs526231	0.511	rs28062	chr5:102540201	A/G	cg23492399	chr5:102201601	PAM	-0.52	-5.66	-0.35	4.32e-8	Primary biliary cholangitis;
SARC	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	7.72	0.45	3.42e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6138458	0.816	rs2151463	chr20:24911819	A/C	cg26195577	chr20:24973756	C20orf3	0.88	9.75	0.54	4.69e-19	Blood protein levels;
SARC	cis	rs9300255	0.566	rs10744150	chr12:123721614	A/C	cg05973401	chr12:123451056	ABCB9	0.52	5.89	0.36	1.37e-8	Neutrophil percentage of white cells;
SARC	cis	rs35306767	0.903	rs7074642	chr10:878359	A/G	cg20503657	chr10:835505	NA	0.85	8.16	0.47	2.09e-14	Eosinophil percentage of granulocytes;
SARC	cis	rs16854884	0.657	rs62269895	chr3:143749085	C/G	cg06585982	chr3:143692056	C3orf58	0.67	9.12	0.51	3.53e-17	Economic and political preferences (feminism/equality);
SARC	cis	rs10870270	0.956	rs7894	chr10:133769482	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.84	-10.4	-0.56	4.62e-21	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs644799	1.000	rs680134	chr11:95559517	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.9	14.03	0.68	7.82e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs4481887	1.000	rs6683717	chr1:248476792	A/G	cg13385794	chr1:248469461	NA	0.36	5.37	0.33	1.87e-7	Common traits (Other);
SARC	cis	rs703842	1.000	rs11172344	chr12:58193448	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.78	11.38	0.6	3.68e-24	Multiple sclerosis;
SARC	cis	rs72945132	0.825	rs947811	chr11:70209142	A/T	cg05964544	chr11:70165517	PPFIA1	-0.56	-5.37	-0.33	1.93e-7	Coronary artery disease;
SARC	cis	rs9473924	0.542	rs9473954	chr6:50928547	G/A	cg14470998	chr6:50812995	TFAP2B	0.76	6.79	0.41	9e-11	Body mass index;
SARC	cis	rs2295359	1.000	rs10889664	chr1:67635475	C/T	cg11235152	chr1:67600687	NA	0.48	7.14	0.42	1.17e-11	Psoriasis;
SARC	cis	rs17376456	0.825	rs66564678	chr5:93165894	C/T	cg25358565	chr5:93447407	FAM172A	1.23	12.32	0.63	3.36e-27	Diabetic retinopathy;
SARC	cis	rs8044995	0.563	rs61602448	chr16:68377520	C/T	cg05110241	chr16:68378359	PRMT7	-0.68	-6.6	-0.4	2.8e-10	Schizophrenia;
SARC	cis	rs8005677	1.000	rs1956881	chr14:23394069	A/C	cg01529538	chr14:23388837	RBM23	0.47	5.71	0.35	3.4e-8	Cognitive ability (multi-trait analysis);
SARC	cis	rs2282802	0.685	rs12188849	chr5:139621570	G/A	cg26211634	chr5:139558579	C5orf32	0.38	4.89	0.3	1.91e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg04234412	chr22:24373322	LOC391322	-0.49	-5.86	-0.36	1.6e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7818345	0.967	rs7015440	chr8:19276991	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.42	5.7	0.35	3.64e-8	Language performance in older adults (adjusted for episodic memory);
SARC	trans	rs11098499	0.604	rs10022185	chr4:120571765	C/G	cg25214090	chr10:38739885	LOC399744	0.51	6.61	0.4	2.56e-10	Corneal astigmatism;
SARC	cis	rs8014204	0.533	rs12434646	chr14:75178693	C/T	cg17347104	chr14:75034677	LTBP2	-0.48	-6.37	-0.39	1.01e-9	Caffeine consumption;
SARC	cis	rs865483	0.860	rs860468	chr17:35793286	G/C	cg06561646	chr17:35873369	DUSP14	-0.48	-6.22	-0.38	2.33e-9	Monocyte count;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg11940219	chr16:30935557	FBXL19;NCRNA00095	-0.45	-6.29	-0.38	1.57e-9	Neuroticism;
SARC	cis	rs10870270	0.956	rs67378218	chr10:133752420	A/C	cg26149184	chr10:133730230	NA	0.44	4.85	0.3	2.27e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs59112743	0.506	rs6913257	chr6:15684484	G/A	cg06375068	chr6:15849678	NA	0.5	4.75	0.3	3.5e-6	Multiple keratinocyte cancers;
SARC	cis	rs4141404	0.737	rs5998058	chr22:32006408	C/T	cg02404636	chr22:31891804	SFI1	0.52	5.36	0.33	1.97e-7	Paclitaxel-induced neuropathy;
SARC	cis	rs6121246	0.512	rs6060938	chr20:30363645	T/C	cg13852791	chr20:30311386	BCL2L1	0.88	11.05	0.59	4.19e-23	Mean corpuscular hemoglobin;
SARC	cis	rs2153535	0.580	rs2143355	chr6:8517856	T/A	cg21535247	chr6:8435926	SLC35B3	0.57	7.21	0.43	7.67e-12	Motion sickness;
SARC	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg17971929	chr21:40555470	PSMG1	-0.56	-7.11	-0.42	1.37e-11	Menarche (age at onset);
SARC	cis	rs35306767	0.903	rs12249828	chr10:894838	C/T	cg20503657	chr10:835505	NA	0.81	7.89	0.46	1.14e-13	Eosinophil percentage of granulocytes;
SARC	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg12463550	chr7:65579703	CRCP	-0.7	-5.31	-0.33	2.51e-7	Diabetic kidney disease;
SARC	cis	rs965469	0.779	rs6051746	chr20:3307290	C/G	cg25506879	chr20:3388711	C20orf194	-0.47	-5.11	-0.32	6.73e-7	IFN-related cytopenia;
SARC	cis	rs9790314	0.740	rs4856767	chr3:161004379	C/T	cg03342759	chr3:160939853	NMD3	-0.74	-9.94	-0.55	1.25e-19	Morning vs. evening chronotype;
SARC	cis	rs1401999	0.898	rs4148561	chr3:183726379	A/G	cg01324343	chr3:183735012	ABCC5	0.65	13.16	0.65	6.23e-30	Anterior chamber depth;
SARC	cis	rs7364180	0.582	rs139568	chr22:42210985	C/T	cg17376030	chr22:41985996	PMM1	-0.4	-5.22	-0.32	3.96e-7	Alzheimer's disease biomarkers;
SARC	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg16405210	chr4:1374714	KIAA1530	-0.5	-5.79	-0.35	2.29e-8	Obesity-related traits;
SARC	cis	rs17376456	0.569	rs35878747	chr5:93094070	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.5	5.05	0.31	8.86e-7	Diabetic retinopathy;
SARC	cis	rs66569888	0.632	rs6728600	chr2:106898653	G/T	cg15412446	chr2:106886593	NA	-0.56	-5.84	-0.36	1.71e-8	Facial morphology (factor 23);
SARC	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.5	-5.81	-0.36	2.07e-8	Blood metabolite levels;
SARC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.55	6.14	0.37	3.49e-9	Prudent dietary pattern;
SARC	cis	rs9300255	0.544	rs1790123	chr12:123659542	C/T	cg00376283	chr12:123451042	ABCB9	0.58	5.75	0.35	2.82e-8	Neutrophil percentage of white cells;
SARC	cis	rs1784581	0.588	rs1784606	chr6:162405992	A/T	cg17173639	chr6:162384350	PARK2	-0.46	-5.9	-0.36	1.28e-8	Itch intensity from mosquito bite;
SARC	cis	rs6912958	0.781	rs9444524	chr6:88311260	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.66	-0.4	1.96e-10	Monocyte percentage of white cells;
SARC	trans	rs656319	0.513	rs1484641	chr8:9986524	A/C	cg06636001	chr8:8085503	FLJ10661	0.54	6.99	0.42	2.84e-11	Myopia (pathological);
SARC	cis	rs6121246	0.529	rs6060296	chr20:30198480	T/C	cg13852791	chr20:30311386	BCL2L1	0.66	5.92	0.36	1.15e-8	Mean corpuscular hemoglobin;
SARC	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg22920501	chr2:26401640	FAM59B	-0.55	-7.14	-0.42	1.18e-11	Gut microbiome composition (summer);
SARC	cis	rs7779181	0.556	rs35173564	chr7:32343754	C/T	cg16719466	chr7:32338569	NA	-0.68	-5.65	-0.35	4.7e-8	Body mass index;
SARC	cis	rs4427176	0.605	rs62489424	chr8:9666582	T/G	cg21625330	chr8:9911636	MSRA	-0.59	-5.08	-0.32	7.58e-7	Mosquito bite size;
SARC	cis	rs9790314	0.502	rs7647118	chr3:161016165	T/C	cg04691961	chr3:161091175	C3orf57	-0.49	-6.15	-0.37	3.29e-9	Morning vs. evening chronotype;
SARC	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg18404041	chr3:52824283	ITIH1	-0.38	-5.68	-0.35	4.08e-8	Bipolar disorder;
SARC	cis	rs2282526	0.615	rs463738	chr21:44921166	G/A	cg17809849	chr21:44073912	PDE9A	-0.41	-5.14	-0.32	5.91e-7	Mean corpuscular hemoglobin;
SARC	cis	rs9549260	0.755	rs2755214	chr13:41149345	T/G	cg21288729	chr13:41239152	FOXO1	0.64	8.3	0.48	8.42e-15	Red blood cell count;
SARC	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg11843238	chr5:131593191	PDLIM4	-0.41	-5.07	-0.32	8.08e-7	Blood metabolite levels;
SARC	cis	rs9303280	0.806	rs35569035	chr17:38035624	C/T	cg20243544	chr17:37824526	PNMT	0.42	5.52	0.34	9.01e-8	Self-reported allergy;
SARC	cis	rs2721811	0.570	rs2721803	chr7:24781532	C/T	cg17569154	chr7:24781545	DFNA5	0.43	5.92	0.36	1.16e-8	Depressive symptoms (multi-trait analysis);
SARC	cis	rs8044995	0.563	rs3743743	chr16:68397775	C/T	cg09835421	chr16:68378352	PRMT7	-0.69	-6.47	-0.39	5.56e-10	Schizophrenia;
SARC	cis	rs739401	0.611	rs7109088	chr11:3027485	G/T	cg08508325	chr11:3079039	CARS	-0.33	-8.32	-0.48	7.52e-15	Longevity;
SARC	cis	rs2997447	0.846	rs3008234	chr1:26405458	A/G	cg19633962	chr1:26362018	EXTL1	-0.61	-5.59	-0.34	6.3e-8	QRS complex (12-leadsum);
SARC	cis	rs1062177	1.000	rs2964584	chr5:151142878	T/C	cg00977110	chr5:151150581	G3BP1	0.63	6.3	0.38	1.44e-9	Preschool internalizing problems;
SARC	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg19748678	chr4:122722346	EXOSC9	0.76	10.11	0.55	3.6e-20	Type 2 diabetes;
SARC	trans	rs7937682	0.921	rs688354	chr11:111438762	A/G	cg18187862	chr3:45730750	SACM1L	0.54	6.7	0.4	1.51e-10	Primary sclerosing cholangitis;
SARC	cis	rs12594515	1.000	rs35182335	chr15:45995184	C/G	cg14863074	chr15:45997064	NA	0.34	5.18	0.32	4.84e-7	Waist circumference;Weight;
SARC	cis	rs7647973	0.710	rs6797299	chr3:49609794	G/T	cg13072238	chr3:49761600	GMPPB	-0.61	-5.33	-0.33	2.34e-7	Menarche (age at onset);
SARC	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.49	6.23	0.38	2.15e-9	Lymphocyte counts;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg24441121	chr2:98262430	COX5B	-0.49	-6.58	-0.4	3.08e-10	Schizophrenia;
SARC	cis	rs739401	0.572	rs410820	chr11:3080102	G/A	cg20651018	chr11:3035856	CARS	-0.45	-7.02	-0.42	2.44e-11	Longevity;
SARC	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.46	-5.77	-0.35	2.54e-8	Gut microbiome composition (summer);
SARC	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2153535	0.601	rs9505474	chr6:8539794	C/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.2	0.47	1.61e-14	Motion sickness;
SARC	cis	rs453301	0.653	rs7853	chr8:8890814	A/G	cg15556689	chr8:8085844	FLJ10661	0.44	5.7	0.35	3.53e-8	Joint mobility (Beighton score);
SARC	cis	rs9660992	0.674	rs17345816	chr1:205262868	A/T	cg00857998	chr1:205179979	DSTYK	-0.43	-4.98	-0.31	1.25e-6	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs765787	0.505	rs4439707	chr15:45524216	G/A	cg26924012	chr15:45694286	SPATA5L1	0.42	4.96	0.31	1.33e-6	Uric acid levels;
SARC	cis	rs11809207	0.574	rs2783631	chr1:26504756	C/T	cg23602478	chr1:26503979	CNKSR1	0.28	5.12	0.32	6.44e-7	Height;
SARC	cis	rs6500395	0.962	rs17826468	chr16:48568271	A/G	cg04672837	chr16:48644449	N4BP1	0.42	5.52	0.34	9.11e-8	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs9513627	0.831	rs7319727	chr13:100125541	A/T	cg25919922	chr13:100150906	NA	-0.71	-5.29	-0.33	2.78e-7	Obesity-related traits;
SARC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.77	-9.94	-0.55	1.27e-19	Prudent dietary pattern;
SARC	cis	rs6772849	0.930	rs12630379	chr3:128370204	G/C	cg08795948	chr3:128337044	NA	0.54	7.68	0.45	4.41e-13	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs910316	1.000	rs4903279	chr14:75546583	C/T	cg08847533	chr14:75593920	NEK9	0.93	15.86	0.72	6.47e-39	Height;
SARC	cis	rs637571	0.522	rs542332	chr11:65744421	C/T	cg26695010	chr11:65641043	EFEMP2	-0.55	-7.23	-0.43	6.78e-12	Eosinophil percentage of white cells;
SARC	cis	rs5758511	0.680	rs5758699	chr22:42688034	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.46	6.84	0.41	6.86e-11	Birth weight;
SARC	cis	rs950776	0.518	rs1504545	chr15:78818471	C/G	cg06917634	chr15:78832804	PSMA4	-0.89	-13.58	-0.66	2.39e-31	Sudden cardiac arrest;
SARC	cis	rs62064224	0.702	rs2302277	chr17:30791509	C/G	cg25809561	chr17:30822961	MYO1D	0.41	5.97	0.36	8.97e-9	Schizophrenia;
SARC	cis	rs7246657	0.943	rs4803229	chr19:37864682	T/G	cg14683738	chr19:37701593	ZNF585B	0.5	4.88	0.3	1.99e-6	Coronary artery calcification;
SARC	cis	rs8023845	0.954	rs1680156	chr15:40447265	T/C	cg20259534	chr15:40453036	BUB1B	0.75	8.07	0.47	3.7e-14	Chronic lymphocytic leukemia;
SARC	cis	rs3749237	0.555	rs2117939	chr3:49415179	C/A	cg06212747	chr3:49208901	KLHDC8B	0.51	6.38	0.39	9.49e-10	Resting heart rate;
SARC	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg09455208	chr3:40491958	NA	0.39	5.68	0.35	4.01e-8	Renal cell carcinoma;
SARC	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg05793240	chr7:2802953	GNA12	-0.35	-5.19	-0.32	4.58e-7	Height;
SARC	cis	rs709400	0.628	rs7146506	chr14:103924477	A/G	cg26031613	chr14:104095156	KLC1	0.82	11.89	0.61	8.46e-26	Body mass index;
SARC	cis	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg13072238	chr3:49761600	GMPPB	-0.61	-6.2	-0.38	2.5e-9	Menarche (age at onset);
SARC	cis	rs1046896	0.553	rs2292965	chr17:80900645	G/A	cg05255149	chr17:80675120	FN3KRP	0.44	4.9	0.31	1.82e-6	Glycated hemoglobin levels;
SARC	cis	rs13095912	0.962	rs12374077	chr3:185317674	G/C	cg11274856	chr3:185301563	NA	0.35	4.93	0.31	1.58e-6	Systolic blood pressure;
SARC	cis	rs3820928	0.874	rs10166456	chr2:227900113	G/A	cg05526886	chr2:227700861	RHBDD1	-0.5	-5.99	-0.37	8e-9	Pulmonary function;
SARC	cis	rs17292804	0.527	rs12887734	chr14:104046834	G/T	cg26031613	chr14:104095156	KLC1	-0.58	-6.39	-0.39	8.93e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7624766	0.555	rs4525912	chr3:160527149	C/T	cg22637730	chr3:160473554	PPM1L	0.37	4.79	0.3	2.92e-6	Response to methotrexate in rheumatoid arthritis;
SARC	cis	rs2228479	0.850	rs62056102	chr16:89941438	T/C	cg12064134	chr16:90016061	DEF8	-0.56	-4.79	-0.3	3.02e-6	Skin colour saturation;
SARC	cis	rs9549260	0.755	rs2701869	chr13:41157372	G/A	cg21288729	chr13:41239152	FOXO1	0.65	8.49	0.49	2.49e-15	Red blood cell count;
SARC	cis	rs60871478	1.000	rs60871478	chr7:827325	A/G	cg05535760	chr7:792225	HEATR2	0.75	7.83	0.46	1.71e-13	Cerebrospinal P-tau181p levels;
SARC	cis	rs4974559	0.594	rs59544360	chr4:1313575	G/T	cg02980000	chr4:1222292	CTBP1	0.61	5.58	0.34	6.6e-8	Systolic blood pressure;
SARC	cis	rs35362007	0.530	rs17835086	chr14:96012465	A/G	cg13511115	chr14:96000878	GLRX5;SNHG10;SCARNA13	0.66	5.77	0.35	2.53e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs957448	1.000	rs2381885	chr8:95512202	G/A	cg26464482	chr8:95565502	KIAA1429	0.43	4.78	0.3	3.08e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs6430585	0.528	rs78274583	chr2:136734569	C/T	cg07169764	chr2:136633963	MCM6	1.02	13.33	0.66	1.72e-30	Corneal structure;
SARC	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg24250549	chr1:154909240	PMVK	0.83	12.12	0.62	1.5e-26	Prostate cancer;
SARC	cis	rs9660992	0.710	rs55671824	chr1:205249814	G/A	cg00857998	chr1:205179979	DSTYK	0.5	5.98	0.36	8.28e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs4319547	0.656	rs3817011	chr12:122819566	C/T	cg23029597	chr12:123009494	RSRC2	-0.43	-5.46	-0.34	1.19e-7	Body mass index;
SARC	cis	rs2250402	0.510	rs2291619	chr15:40329033	C/T	cg20255370	chr15:40268687	EIF2AK4	0.64	5.3	0.33	2.63e-7	Corneal curvature;
SARC	cis	rs16854884	0.632	rs10513234	chr3:143670957	A/G	cg06585982	chr3:143692056	C3orf58	-0.64	-8.46	-0.48	3.01e-15	Economic and political preferences (feminism/equality);
SARC	cis	rs17376456	0.542	rs1453003	chr5:93151611	T/C	cg25358565	chr5:93447407	FAM172A	-0.94	-10.5	-0.57	2.23e-21	Diabetic retinopathy;
SARC	cis	rs637571	0.522	rs493899	chr11:65747952	A/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.83	12.37	0.63	2.36e-27	Eosinophil percentage of white cells;
SARC	cis	rs6088580	0.634	rs6088502	chr20:33037644	A/T	cg24642439	chr20:33292090	TP53INP2	0.66	8.63	0.49	9.49e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg11494091	chr17:61959527	GH2	0.53	7.94	0.46	8.67e-14	Prudent dietary pattern;
SARC	trans	rs11098499	0.908	rs28559989	chr4:120386627	C/T	cg25214090	chr10:38739885	LOC399744	0.57	7.4	0.44	2.42e-12	Corneal astigmatism;
SARC	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg17376030	chr22:41985996	PMM1	0.74	9.39	0.52	5.58e-18	Vitiligo;
SARC	cis	rs1971762	0.527	rs2365343	chr12:54038149	C/T	cg06632207	chr12:54070931	ATP5G2	-0.61	-7.75	-0.45	2.9e-13	Height;
SARC	cis	rs11155671	0.530	rs7742993	chr6:150205095	G/A	cg00933542	chr6:150070202	PCMT1	0.29	4.77	0.3	3.18e-6	Testicular germ cell tumor;
SARC	cis	rs7647973	0.626	rs1352889	chr3:49652148	T/C	cg03060546	chr3:49711283	APEH	0.67	7.1	0.42	1.48e-11	Menarche (age at onset);
SARC	cis	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg11764359	chr7:65958608	NA	0.63	6.17	0.37	2.94e-9	Aortic root size;
SARC	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg04772025	chr11:68637568	NA	0.5	6.11	0.37	4.21e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs240764	0.817	rs12193960	chr6:101150326	C/T	cg09795085	chr6:101329169	ASCC3	-0.45	-5.91	-0.36	1.21e-8	Neuroticism;
SARC	cis	rs7247513	0.701	rs8107642	chr19:12766370	C/T	cg11738485	chr19:12877000	HOOK2	0.44	5.32	0.33	2.43e-7	Bipolar disorder;
SARC	trans	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg00938859	chr5:1591904	SDHAP3	0.79	7.66	0.45	5.1e-13	Breast cancer;
SARC	cis	rs668210	0.793	rs1786172	chr11:65770658	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	5.36	0.33	1.97e-7	Cerebrospinal fluid biomarker levels;
SARC	trans	rs11119805	0.649	rs11119816	chr1:211999488	A/G	cg24703804	chr12:69202651	MDM2	-0.58	-6.27	-0.38	1.74e-9	Stearic acid (18:0) levels;
SARC	cis	rs2120243	0.539	rs4680358	chr3:157069275	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.39	4.94	0.31	1.49e-6	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs3820928	0.874	rs10207404	chr2:227794420	T/C	cg05526886	chr2:227700861	RHBDD1	-0.54	-6.65	-0.4	2.04e-10	Pulmonary function;
SARC	cis	rs9916302	0.861	rs752314	chr17:37410700	C/T	cg07936489	chr17:37558343	FBXL20	-0.68	-9.2	-0.52	2.04e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs2652834	1.000	rs2729783	chr15:63403316	C/T	cg05507819	chr15:63340323	TPM1	0.51	4.97	0.31	1.32e-6	HDL cholesterol;
SARC	cis	rs7223966	0.921	rs7225092	chr17:61864005	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.52	-5.37	-0.33	1.91e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs911263	0.561	rs7160221	chr14:68798110	T/C	cg18825221	chr14:68749962	RAD51L1	0.42	5.81	0.36	2.01e-8	Primary biliary cholangitis;
SARC	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg11952622	chr19:58962976	ZNF324B	0.53	6.99	0.42	2.82e-11	Uric acid clearance;
SARC	cis	rs6087990	0.806	rs4911108	chr20:31375311	A/G	cg13636640	chr20:31349939	DNMT3B	0.78	12.1	0.62	1.76e-26	Ulcerative colitis;
SARC	cis	rs11098499	0.955	rs11944880	chr4:120159334	A/G	cg09307838	chr4:120376055	NA	-0.84	-11.65	-0.61	5.16e-25	Corneal astigmatism;
SARC	cis	rs3820928	0.874	rs55748731	chr2:227818629	C/A	cg05526886	chr2:227700861	RHBDD1	-0.55	-6.63	-0.4	2.26e-10	Pulmonary function;
SARC	cis	rs9916302	0.904	rs9892055	chr17:37510402	C/T	cg00129232	chr17:37814104	STARD3	0.6	7.36	0.43	3.15e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs2084898	1.000	rs569044	chr11:119999191	A/G	cg24593464	chr11:120008998	TRIM29	0.45	4.82	0.3	2.57e-6	Stroke (pediatric);
SARC	cis	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg05084668	chr3:125655381	ALG1L	-0.49	-5.49	-0.34	1.03e-7	Blood pressure (smoking interaction);
SARC	cis	rs6674176	0.660	rs11210936	chr1:44391438	A/T	cg12908607	chr1:44402522	ARTN	-0.41	-7.12	-0.42	1.34e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs7223966	0.655	rs6504165	chr17:61630076	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.47	5.21	0.32	4.09e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs965469	1.000	rs6051672	chr20:3224819	C/T	cg25506879	chr20:3388711	C20orf194	-0.53	-5.23	-0.32	3.7e-7	IFN-related cytopenia;
SARC	cis	rs748404	0.660	rs2467738	chr15:43739936	T/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.41	4.82	0.3	2.6e-6	Lung cancer;
SARC	cis	rs2777491	1.000	rs1757455	chr15:41761332	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.82	-12.15	-0.62	1.24e-26	Ulcerative colitis;
SARC	cis	rs7644634	0.649	rs2120585	chr3:105402744	A/G	cg23051926	chr3:105466016	CBLB	0.48	5.92	0.36	1.17e-8	Itch intensity from mosquito bite;
SARC	cis	rs9300255	0.739	rs4759415	chr12:123743674	C/T	cg00376283	chr12:123451042	ABCB9	-0.49	-5.55	-0.34	7.72e-8	Neutrophil percentage of white cells;
SARC	trans	rs11098499	0.865	rs4507344	chr4:120307485	C/A	cg25214090	chr10:38739885	LOC399744	0.55	7.14	0.42	1.15e-11	Corneal astigmatism;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg22960125	chr2:161194928	RBMS1	0.54	7.81	0.46	1.92e-13	Thyroid stimulating hormone;
SARC	trans	rs61931739	0.534	rs6488189	chr12:33995865	C/T	cg13010199	chr12:38710504	ALG10B	0.76	10.34	0.56	7.21e-21	Morning vs. evening chronotype;
SARC	cis	rs9916302	0.904	rs3964723	chr17:37403979	C/T	cg20243544	chr17:37824526	PNMT	0.58	7.05	0.42	2.04e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg26335602	chr6:28129616	ZNF389	0.51	5.62	0.35	5.41e-8	Parkinson's disease;
SARC	cis	rs651907	0.535	rs12633089	chr3:101528763	C/T	cg12386194	chr3:101231763	SENP7	0.48	5.44	0.34	1.34e-7	Colorectal cancer;
SARC	cis	rs1971762	0.527	rs6580952	chr12:53937452	C/T	cg06632207	chr12:54070931	ATP5G2	0.6	8.31	0.48	7.97e-15	Height;
SARC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg18404041	chr3:52824283	ITIH1	-0.41	-6.3	-0.38	1.47e-9	Bipolar disorder;
SARC	cis	rs6546324	0.625	rs1023691	chr2:67868794	G/A	cg18237512	chr2:67827392	NA	-0.57	-6.86	-0.41	6.02e-11	Endometriosis;
SARC	cis	rs16854884	0.657	rs35959290	chr3:143725566	T/A	cg06585982	chr3:143692056	C3orf58	0.64	8.44	0.48	3.36e-15	Economic and political preferences (feminism/equality);
SARC	cis	rs7119	0.717	rs11629835	chr15:77787469	G/T	cg17802220	chr15:77601643	NA	-0.43	-5.6	-0.34	5.92e-8	Type 2 diabetes;
SARC	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg00684032	chr4:1343700	KIAA1530	0.32	4.74	0.3	3.75e-6	Longevity;
SARC	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7084402	0.967	rs7087998	chr10:60271531	A/G	cg07615347	chr10:60278583	BICC1	-0.58	-8.47	-0.49	2.85e-15	Refractive error;
SARC	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	9.01	0.51	7.42e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs11168187	0.843	rs6580635	chr12:48116573	G/A	cg12761788	chr12:48120090	P11	0.36	4.76	0.3	3.43e-6	Vertical cup-disc ratio;
SARC	cis	rs10781543	0.839	rs6560632	chr9:139371786	A/C	cg14169450	chr9:139327907	INPP5E	0.44	6.42	0.39	7.71e-10	Monocyte percentage of white cells;
SARC	cis	rs3796352	1.000	rs71301808	chr3:53085577	C/G	cg27565382	chr3:53032988	SFMBT1	0.97	6.92	0.41	4.42e-11	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs11097912	0.632	rs7688411	chr4:107189665	C/T	cg09646026	chr4:107269030	AIMP1	-0.44	-4.83	-0.3	2.49e-6	Airflow obstruction;
SARC	cis	rs9902453	0.689	rs7216948	chr17:28203173	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	7.45	0.44	1.8e-12	Coffee consumption (cups per day);
SARC	cis	rs8031584	0.958	rs35256769	chr15:31237776	G/A	cg14829155	chr15:31115871	NA	-0.42	-5.28	-0.33	2.99e-7	Huntington's disease progression;
SARC	cis	rs6912958	0.712	rs2754262	chr6:88405585	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-5.32	-0.33	2.4e-7	Monocyte percentage of white cells;
SARC	cis	rs897080	0.515	rs1067351	chr2:44669907	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	5.84	0.36	1.71e-8	Height;
SARC	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg11764359	chr7:65958608	NA	-0.69	-7.88	-0.46	1.25e-13	Aortic root size;
SARC	cis	rs1008375	1.000	rs11727312	chr4:17669185	C/T	cg27347728	chr4:17578864	LAP3	0.43	5.26	0.33	3.19e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg26335602	chr6:28129616	ZNF389	0.52	5.88	0.36	1.44e-8	Depression;
SARC	cis	rs61935443	0.778	rs78522691	chr12:95267340	G/T	cg21533806	chr12:95267307	NA	0.73	8.58	0.49	1.36e-15	Schizophrenia;
SARC	cis	rs4664308	0.935	rs4292050	chr2:160940899	G/T	cg03641300	chr2:160917029	PLA2R1	-0.71	-9.8	-0.54	3.36e-19	Idiopathic membranous nephropathy;
SARC	cis	rs6708331	0.540	rs11890701	chr2:70360457	T/A	cg01613454	chr2:70366299	NA	0.46	6.47	0.39	5.78e-10	Obesity-related traits;
SARC	cis	rs9393777	0.582	rs6936561	chr6:26640895	C/T	cg12826209	chr6:26865740	GUSBL1	0.69	6.13	0.37	3.64e-9	Intelligence (multi-trait analysis);
SARC	cis	rs6598955	0.640	rs4233460	chr1:26633387	A/G	cg04990556	chr1:26633338	UBXN11	-0.61	-8.35	-0.48	6.02e-15	Obesity-related traits;
SARC	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg09467607	chr2:36825704	FEZ2	0.67	9.34	0.52	8.14e-18	Height;
SARC	cis	rs7084402	1.000	rs7073504	chr10:60271987	C/T	cg07615347	chr10:60278583	BICC1	-0.57	-8.47	-0.49	2.76e-15	Refractive error;
SARC	cis	rs739401	0.611	rs572373	chr11:3055361	T/C	cg25174290	chr11:3078921	CARS	0.58	8.38	0.48	5.02e-15	Longevity;
SARC	cis	rs9457247	0.544	rs6920858	chr6:167464630	G/A	cg23791538	chr6:167370224	RNASET2	-0.53	-6.99	-0.42	2.88e-11	Crohn's disease;
SARC	cis	rs2028299	0.879	rs986505	chr15:90418413	T/A	cg19708238	chr15:90437601	AP3S2	0.44	4.96	0.31	1.35e-6	Type 2 diabetes;
SARC	cis	rs6696846	0.630	rs6692706	chr1:205158561	G/T	cg07972983	chr1:205091412	RBBP5	0.54	6.68	0.4	1.75e-10	Red blood cell count;
SARC	cis	rs2933343	0.621	rs4927921	chr3:128568868	A/G	cg25356066	chr3:128598488	ACAD9	-0.66	-8.43	-0.48	3.65e-15	IgG glycosylation;
SARC	cis	rs7666738	0.830	rs28687737	chr4:99009226	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4481887	0.741	rs6587458	chr1:248532290	T/A	cg00666640	chr1:248458726	OR2T12	0.36	6.2	0.38	2.58e-9	Common traits (Other);
SARC	cis	rs2742234	0.541	rs1254958	chr10:43702143	C/T	cg15436174	chr10:43711423	RASGEF1A	0.41	4.81	0.3	2.7e-6	Hirschsprung disease;
SARC	cis	rs57994353	0.865	rs35857370	chr9:139354097	G/A	cg14169450	chr9:139327907	INPP5E	0.43	5.57	0.34	7.16e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs2834188	1.000	rs2834188	chr21:34689253	A/G	cg04842828	chr21:34696676	IFNAR1	0.4	4.74	0.3	3.78e-6	Narcolepsy;
SARC	cis	rs11098499	0.865	rs2389809	chr4:120377399	T/C	cg09160332	chr4:120329925	NA	-0.33	-4.74	-0.3	3.75e-6	Corneal astigmatism;
SARC	cis	rs7216064	1.000	rs4569324	chr17:65872750	C/T	cg12091567	chr17:66097778	LOC651250	-0.64	-6.45	-0.39	6.56e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs17376456	1.000	rs59472588	chr5:93511981	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	5.71	0.35	3.43e-8	Diabetic retinopathy;
SARC	cis	rs9816226	0.618	rs1516728	chr3:185829891	A/T	cg00760338	chr3:185826511	ETV5	0.92	13.15	0.65	6.7e-30	Obesity;Body mass index;
SARC	cis	rs2180341	0.960	rs7766942	chr6:127691323	G/T	cg17762328	chr6:126965162	NA	-0.45	-4.98	-0.31	1.21e-6	Breast cancer;
SARC	cis	rs9660992	0.762	rs1668871	chr1:205237137	T/C	cg00857998	chr1:205179979	DSTYK	0.47	5.89	0.36	1.37e-8	Mean corpuscular volume;Mean platelet volume;
SARC	trans	rs656319	0.605	rs17747335	chr8:10003186	A/T	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.54	-0.44	1.05e-12	Myopia (pathological);
SARC	cis	rs796364	1.000	rs281783	chr2:200751582	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.8	7.14	0.42	1.17e-11	Schizophrenia;
SARC	cis	rs838147	0.873	rs11667321	chr19:49250538	A/G	cg13540341	chr19:49222985	MAMSTR	0.29	4.87	0.3	2.06e-6	Dietary macronutrient intake;
SARC	cis	rs3771570	0.901	rs55764424	chr2:242407467	C/T	cg21155796	chr2:242212141	HDLBP	0.62	6.03	0.37	6.49e-9	Prostate cancer;
SARC	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg11843238	chr5:131593191	PDLIM4	0.43	5.82	0.36	1.93e-8	Acylcarnitine levels;
SARC	cis	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg00409905	chr10:38381863	ZNF37A	0.52	7.26	0.43	5.83e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs9487051	0.752	rs9372209	chr6:109601684	T/C	cg01475377	chr6:109611718	NA	-0.35	-5.17	-0.32	4.92e-7	Reticulocyte fraction of red cells;
SARC	cis	rs920590	0.704	rs6586867	chr8:19653050	A/G	cg17834443	chr8:19674713	INTS10	0.4	5.1	0.32	6.91e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs6502050	0.787	rs8080682	chr17:80058901	G/A	cg19223190	chr17:80058835	NA	-0.46	-6.69	-0.4	1.68e-10	Life satisfaction;
SARC	cis	rs9457247	0.765	rs9459849	chr6:167444160	G/T	cg23791538	chr6:167370224	RNASET2	-0.55	-7.31	-0.43	4.24e-12	Crohn's disease;
SARC	cis	rs16921914	0.559	rs2985140	chr11:31315886	C/T	cg26647111	chr11:31128758	NA	0.39	4.96	0.31	1.37e-6	Bone mineral density (spine);
SARC	cis	rs12682352	0.715	rs332039	chr8:8723651	C/G	cg15556689	chr8:8085844	FLJ10661	0.41	5.17	0.32	5.02e-7	Neuroticism;
SARC	cis	rs1008375	0.932	rs12500912	chr4:17603318	C/T	cg02297831	chr4:17616191	MED28	0.51	6.48	0.39	5.36e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg00990874	chr7:1149470	C7orf50	-0.54	-5.88	-0.36	1.43e-8	Bronchopulmonary dysplasia;
SARC	cis	rs2425143	0.558	rs41293082	chr20:34190970	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-4.9	-0.31	1.79e-6	Blood protein levels;
SARC	cis	rs4974559	0.739	rs28429103	chr4:1320023	G/A	cg02980000	chr4:1222292	CTBP1	0.74	5.48	0.34	1.12e-7	Systolic blood pressure;
SARC	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg03060546	chr3:49711283	APEH	0.42	5.23	0.32	3.86e-7	Parkinson's disease;
SARC	cis	rs60752752	0.852	rs12035710	chr1:153354406	T/C	cg26882115	chr1:153603048	S100A1;S100A13	-0.66	-4.94	-0.31	1.46e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs708547	0.723	rs35982175	chr4:57841365	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.43	-5.27	-0.33	3.16e-7	Response to bleomycin (chromatid breaks);
SARC	cis	rs11098499	0.874	rs10022508	chr4:120115228	A/G	cg09307838	chr4:120376055	NA	0.82	11.11	0.59	2.65e-23	Corneal astigmatism;
SARC	cis	rs2228479	0.850	rs62054610	chr16:89816920	G/A	cg26513180	chr16:89883248	FANCA	0.72	4.79	0.3	2.99e-6	Skin colour saturation;
SARC	cis	rs6570726	0.935	rs366308	chr6:145814532	T/A	cg23711669	chr6:146136114	FBXO30	0.78	11.91	0.62	7.29e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg21724239	chr8:58056113	NA	0.57	5.96	0.36	9.42e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4727027	0.933	rs917122	chr7:148848257	T/C	cg23583168	chr7:148888333	NA	-0.73	-11.15	-0.59	2.01e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs10463554	0.927	rs34810	chr5:102430749	A/T	cg23492399	chr5:102201601	PAM	-0.54	-5.91	-0.36	1.23e-8	Parkinson's disease;
SARC	trans	rs12660691	0.786	rs10872346	chr6:130012053	C/T	cg19261306	chr1:59234911	NA	-0.66	-6.36	-0.38	1.06e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
SARC	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg04317338	chr11:64019027	PLCB3	0.76	8.17	0.47	1.99e-14	Mean platelet volume;
SARC	cis	rs1865760	0.686	rs12210098	chr6:25963966	C/T	cg17691542	chr6:26056736	HIST1H1C	0.58	6.94	0.41	3.94e-11	Height;
SARC	cis	rs11235843	0.929	rs67488767	chr11:73432689	A/C	cg18195628	chr11:73498948	MRPL48	0.66	5.05	0.31	9.02e-7	Hand grip strength;
SARC	cis	rs9914544	0.545	rs7222748	chr17:18787976	T/C	cg25390199	chr17:18761479	PRPSAP2	0.46	6.05	0.37	5.66e-9	Educational attainment (years of education);
SARC	cis	rs1008375	1.000	rs10939748	chr4:17691230	T/C	cg02297831	chr4:17616191	MED28	0.41	5.09	0.32	7.32e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1030877	0.515	rs2679895	chr2:105906480	C/G	cg02079111	chr2:105885981	TGFBRAP1	0.53	6.13	0.37	3.68e-9	Obesity-related traits;
SARC	cis	rs2153535	0.601	rs2327059	chr6:8447071	A/G	cg07606381	chr6:8435919	SLC35B3	0.77	11.03	0.59	5.01e-23	Motion sickness;
SARC	cis	rs921968	0.643	rs2556384	chr2:219532903	C/T	cg02176678	chr2:219576539	TTLL4	-0.36	-5.48	-0.34	1.11e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs2239547	0.522	rs6768844	chr3:53004620	A/G	cg11645453	chr3:52864694	ITIH4	-0.33	-5.12	-0.32	6.36e-7	Schizophrenia;
SARC	cis	rs36051895	0.659	rs59225790	chr9:5042757	G/A	cg02405213	chr9:5042618	JAK2	-0.52	-5.79	-0.35	2.21e-8	Pediatric autoimmune diseases;
SARC	cis	rs10465746	0.780	rs10874423	chr1:84374071	C/T	cg10977910	chr1:84465055	TTLL7	0.39	4.79	0.3	2.91e-6	Obesity-related traits;
SARC	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg20102877	chr2:27665638	KRTCAP3	-0.37	-5.06	-0.31	8.56e-7	Total body bone mineral density;
SARC	cis	rs501120	0.866	rs607609	chr10:44750209	T/C	cg09554077	chr10:44749378	NA	0.46	6.42	0.39	7.38e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs1707322	0.686	rs2275085	chr1:46085852	C/T	cg06784218	chr1:46089804	CCDC17	-0.4	-7.1	-0.42	1.47e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6912958	0.559	rs242279	chr6:88048191	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	10.92	0.58	1.11e-22	Monocyte percentage of white cells;
SARC	trans	rs8020941	0.585	rs56871417	chr14:97520637	C/T	cg05136476	chr3:53190709	NA	-0.74	-7.44	-0.44	1.97e-12	Diabetic kidney disease;
SARC	cis	rs2425143	1.000	rs2425078	chr20:34298163	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-6.88	-0.41	5.53e-11	Blood protein levels;
SARC	trans	rs7395662	0.591	rs4882110	chr11:48558249	G/T	cg15704280	chr7:45808275	SEPT13	-0.49	-6.69	-0.4	1.6e-10	HDL cholesterol;
SARC	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg24829409	chr8:58192753	C8orf71	0.62	6.19	0.38	2.7e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2505675	0.631	rs234913	chr6:2210010	C/G	cg16550324	chr6:2245327	GMDS	0.49	5.89	0.36	1.35e-8	Tuberculosis;
SARC	cis	rs763121	0.853	rs5750664	chr22:39072769	C/T	cg21395723	chr22:39101663	GTPBP1	0.52	5.8	0.36	2.17e-8	Menopause (age at onset);
SARC	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg02018176	chr4:1364513	KIAA1530	0.61	9.13	0.51	3.31e-17	Longevity;
SARC	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg22968622	chr17:43663579	NA	1.21	16.57	0.74	2.96e-41	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	trans	rs1814175	0.645	rs28447324	chr11:50046629	C/A	cg15704280	chr7:45808275	SEPT13	-0.89	-14.15	-0.68	3.23e-33	Height;
SARC	cis	rs13144136	0.775	rs13136927	chr4:10669522	A/C	cg10242279	chr4:10666415	CLNK	-0.35	-5.4	-0.33	1.65e-7	Resistance to antihypertensive treatment in hypertension;
SARC	cis	rs739401	0.611	rs7394974	chr11:3038868	C/T	cg25174290	chr11:3078921	CARS	0.57	8.0	0.46	5.72e-14	Longevity;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg11937346	chr2:201936362	NDUFB3;FAM126B	-0.46	-6.36	-0.38	1.06e-9	Thyroid stimulating hormone;
SARC	cis	rs748404	0.660	rs542898	chr15:43719392	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	5.75	0.35	2.76e-8	Lung cancer;
SARC	cis	rs35110281	0.667	rs2070533	chr21:45122753	G/A	cg01579765	chr21:45077557	HSF2BP	-0.37	-5.91	-0.36	1.22e-8	Mean corpuscular volume;
SARC	cis	rs7647973	1.000	rs3866330	chr3:49582994	T/C	cg07636037	chr3:49044803	WDR6	0.78	8.9	0.5	1.65e-16	Menarche (age at onset);
SARC	cis	rs9303401	0.573	rs34717648	chr17:56886624	T/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	11.57	0.6	9.38e-25	Cognitive test performance;
SARC	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg27170947	chr2:26402098	FAM59B	0.37	4.8	0.3	2.79e-6	Gut microbiome composition (summer);
SARC	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg22903657	chr4:1355424	KIAA1530	-0.34	-4.77	-0.3	3.19e-6	Obesity-related traits;
SARC	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg27266027	chr21:40555129	PSMG1	-0.53	-5.93	-0.36	1.09e-8	Cognitive function;
SARC	cis	rs12142240	0.698	rs12385697	chr1:46818898	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-5.46	-0.34	1.22e-7	Menopause (age at onset);
SARC	cis	rs13314892	0.764	rs60438183	chr3:69880729	C/T	cg17445875	chr3:69859618	MITF	-0.49	-5.19	-0.32	4.51e-7	QRS complex (12-leadsum);
SARC	cis	rs2228479	0.850	rs117880578	chr16:89910230	C/G	cg00800038	chr16:89945340	TCF25	-0.82	-5.8	-0.35	2.19e-8	Skin colour saturation;
SARC	cis	rs854765	0.583	rs8070722	chr17:17813562	C/T	cg04398451	chr17:18023971	MYO15A	-0.39	-5.5	-0.34	9.94e-8	Total body bone mineral density;
SARC	cis	rs6963495	0.818	rs73192145	chr7:105203628	A/C	cg13798780	chr7:105162888	PUS7	0.57	5.23	0.32	3.86e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs6446731	0.593	rs2858084	chr4:3272118	A/C	cg06533319	chr4:3265114	C4orf44	-0.33	-5.3	-0.33	2.69e-7	Mean platelet volume;
SARC	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	10.48	0.57	2.62e-21	Alzheimer's disease;
SARC	cis	rs4566357	0.595	rs2272203	chr2:227914655	C/G	cg11843606	chr2:227700838	RHBDD1	-0.46	-6.11	-0.37	4.09e-9	Coronary artery disease;
SARC	cis	rs9549367	0.662	rs3818334	chr13:113825174	C/G	cg18105134	chr13:113819100	PROZ	-0.48	-6.86	-0.41	6.04e-11	Platelet distribution width;
SARC	cis	rs7092929	0.941	rs668923	chr10:3575664	G/T	cg14308648	chr10:3568949	NA	0.54	5.62	0.35	5.37e-8	Coronary artery calcification;
SARC	cis	rs7772486	0.654	rs6928007	chr6:146074941	G/A	cg05347473	chr6:146136440	FBXO30	-0.52	-7.26	-0.43	5.64e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg20607798	chr8:58055168	NA	0.57	5.53	0.34	8.58e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs12586317	0.576	rs10146115	chr14:35631184	C/G	cg16230307	chr14:35515116	FAM177A1	0.46	5.83	0.36	1.81e-8	Psoriasis;
SARC	cis	rs72627509	0.638	rs7658601	chr4:57781347	C/T	cg26694713	chr4:57773883	REST	0.65	6.56	0.39	3.42e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs2153535	0.580	rs7450817	chr6:8481421	G/A	cg07606381	chr6:8435919	SLC35B3	0.78	11.13	0.59	2.44e-23	Motion sickness;
SARC	cis	rs7208859	0.573	rs8078182	chr17:29149664	C/T	cg13385521	chr17:29058706	SUZ12P	0.84	7.31	0.43	4.13e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs72781680	0.898	rs72780118	chr2:23994431	G/A	cg06627628	chr2:24431161	ITSN2	-0.67	-6.35	-0.38	1.14e-9	Lymphocyte counts;
SARC	cis	rs9486715	0.867	rs9386500	chr6:96889845	A/C	cg06623918	chr6:96969491	KIAA0776	0.84	11.84	0.61	1.24e-25	Headache;
SARC	cis	rs7044106	0.762	rs1411158	chr9:123464804	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	8.88	0.5	1.78e-16	Hip circumference adjusted for BMI;
SARC	cis	rs2732480	0.577	rs1489109	chr12:48738780	C/A	cg21466736	chr12:48725269	NA	-0.34	-5.31	-0.33	2.54e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs240764	0.658	rs6925823	chr6:101179273	C/A	cg09795085	chr6:101329169	ASCC3	-0.51	-6.69	-0.4	1.68e-10	Neuroticism;
SARC	cis	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg12193833	chr17:30244370	NA	-0.44	-4.73	-0.3	3.92e-6	Hip circumference adjusted for BMI;
SARC	cis	rs9325144	0.560	rs11183189	chr12:38683770	T/A	cg26384229	chr12:38710491	ALG10B	0.57	7.3	0.43	4.61e-12	Morning vs. evening chronotype;
SARC	cis	rs787274	0.619	rs1475293	chr9:115619587	C/T	cg13803584	chr9:115635662	SNX30	0.65	5.01	0.31	1.08e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg05064044	chr6:292385	DUSP22	-0.54	-6.98	-0.42	3.1e-11	Menopause (age at onset);
SARC	cis	rs9381040	0.610	rs6940462	chr6:41020223	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.41	-4.88	-0.3	1.95e-6	Alzheimer's disease (late onset);
SARC	cis	rs7264396	0.563	rs6060580	chr20:34310512	T/C	cg01084648	chr20:34329383	RBM39	0.56	4.93	0.31	1.57e-6	Total cholesterol levels;
SARC	cis	rs6690583	0.573	rs61768854	chr1:85460021	T/C	cg22153463	chr1:85462885	MCOLN2	0.75	6.45	0.39	6.42e-10	Serum sulfate level;
SARC	cis	rs10875746	0.859	rs11558768	chr12:48577789	C/T	cg26205652	chr12:48591994	NA	0.48	5.47	0.34	1.14e-7	Longevity (90 years and older);
SARC	cis	rs7208859	0.673	rs11650305	chr17:29229361	A/C	cg13385521	chr17:29058706	SUZ12P	0.85	7.23	0.43	7.08e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg00409905	chr10:38381863	ZNF37A	-0.49	-6.74	-0.4	1.22e-10	Extrinsic epigenetic age acceleration;
SARC	cis	rs2247341	1.000	rs8051	chr4:1694809	C/T	cg07465881	chr4:1713556	SLBP	0.46	5.35	0.33	2.07e-7	Hip circumference adjusted for BMI;Height;
SARC	cis	rs2839186	0.656	rs8128380	chr21:47665693	C/T	cg03841560	chr21:47649172	MCM3APAS;LSS	0.38	5.11	0.32	6.75e-7	Testicular germ cell tumor;
SARC	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	cis	rs1348850	0.574	rs13431105	chr2:178434674	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.66	6.1	0.37	4.36e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg07308232	chr7:1071921	C7orf50	-0.53	-6.67	-0.4	1.83e-10	Longevity;Endometriosis;
SARC	cis	rs7717697	0.797	rs10064429	chr5:82744561	G/A	cg19814134	chr5:82768288	VCAN	0.42	5.01	0.31	1.08e-6	Vertical cup-disc ratio;
SARC	trans	rs1814175	0.817	rs10769641	chr11:49960141	A/G	cg03929089	chr4:120376271	NA	-0.89	-14.59	-0.69	1.1e-34	Height;
SARC	cis	rs2213920	0.619	rs7042718	chr9:118202187	C/T	cg13918206	chr9:118159781	DEC1	0.83	6.63	0.4	2.38e-10	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs36051895	0.632	rs7040806	chr9:5174782	C/T	cg02405213	chr9:5042618	JAK2	-0.48	-5.84	-0.36	1.74e-8	Pediatric autoimmune diseases;
SARC	cis	rs7617773	0.817	rs6796490	chr3:48237104	A/C	cg11946769	chr3:48343235	NME6	0.64	8.44	0.48	3.29e-15	Coronary artery disease;
SARC	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.58	7.16	0.42	1.04e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7223966	1.000	rs8076717	chr17:61850301	C/T	cg00588841	chr17:61851480	DDX42;CCDC47	0.65	6.97	0.42	3.14e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2652822	0.525	rs2053633	chr15:63505649	G/A	cg02713581	chr15:63449717	RPS27L	0.53	6.4	0.39	8.36e-10	Metabolic traits;
SARC	cis	rs2729354	1.000	rs2729354	chr11:57355970	A/G	cg17237962	chr11:57479805	MED19;TMX2	0.47	4.74	0.3	3.71e-6	Blood protein levels;
SARC	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg05313129	chr8:58192883	C8orf71	-0.6	-6.65	-0.4	2.1e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9325144	0.624	rs10783333	chr12:39118931	A/T	cg13010199	chr12:38710504	ALG10B	0.49	5.99	0.37	8.09e-9	Morning vs. evening chronotype;
SARC	cis	rs10779751	1.000	rs10779751	chr1:11284336	A/G	cg08854313	chr1:11322531	MTOR	0.8	11.47	0.6	2e-24	Body mass index;
SARC	cis	rs9894429	0.624	rs9910935	chr17:79613949	T/C	cg18240062	chr17:79603768	NPLOC4	0.81	11.32	0.6	5.99e-24	Eye color traits;
SARC	cis	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg24110177	chr3:50126178	RBM5	0.62	8.0	0.46	5.95e-14	Intelligence (multi-trait analysis);
SARC	cis	rs11583043	0.874	rs72734253	chr1:101380718	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.51	6.02	0.37	6.58e-9	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs1322639	1.000	rs9689079	chr6:169587148	A/G	cg04662567	chr6:169592167	NA	0.5	6.47	0.39	5.63e-10	Pulse pressure;
SARC	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg24642844	chr7:1081250	C7orf50	-0.57	-6.05	-0.37	5.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs918629	0.567	rs6877329	chr5:95261538	C/G	cg16656078	chr5:95278638	ELL2	-0.53	-6.65	-0.4	2.05e-10	IgG glycosylation;
SARC	cis	rs477692	0.905	rs4751106	chr10:131424653	G/T	cg05714579	chr10:131428358	MGMT	-0.57	-7.56	-0.44	8.93e-13	Response to temozolomide;
SARC	cis	rs6665290	0.835	rs11578479	chr1:227210888	A/T	cg14016676	chr1:227182615	CDC42BPA	0.38	5.47	0.34	1.15e-7	Myeloid white cell count;
SARC	trans	rs9325144	0.555	rs4882359	chr12:38726679	T/C	cg23762105	chr12:34175262	ALG10	-0.55	-7.18	-0.43	9.03e-12	Morning vs. evening chronotype;
SARC	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg11644478	chr21:40555479	PSMG1	1.06	15.22	0.71	8.95e-37	Cognitive function;
SARC	cis	rs155076	1.000	rs2478824	chr13:21844144	G/C	cg14456004	chr13:21872349	NA	-1.0	-12.77	-0.64	1.13e-28	White matter hyperintensity burden;
SARC	trans	rs7824557	0.564	rs13274106	chr8:11233958	A/G	cg06636001	chr8:8085503	FLJ10661	-0.64	-8.57	-0.49	1.42e-15	Retinal vascular caliber;
SARC	cis	rs3796352	1.000	rs34979715	chr3:53048960	G/A	cg27565382	chr3:53032988	SFMBT1	1.04	7.28	0.43	4.95e-12	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs3091242	0.967	rs3091240	chr1:25676935	G/T	cg03650068	chr1:25596491	NA	0.34	5.28	0.33	3.01e-7	Erythrocyte sedimentation rate;
SARC	cis	rs7681440	0.869	rs7680557	chr4:90763360	C/A	cg06632027	chr4:90757378	SNCA	0.41	5.88	0.36	1.38e-8	Dementia with Lewy bodies;
SARC	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg11764359	chr7:65958608	NA	-0.72	-8.45	-0.48	3.08e-15	Aortic root size;
SARC	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg23758822	chr17:41437982	NA	0.88	11.19	0.59	1.55e-23	Menopause (age at onset);
SARC	cis	rs6841333	0.628	rs4859569	chr4:76853819	A/T	cg19999035	chr4:77355817	SHROOM3	0.35	4.78	0.3	3.15e-6	Monokine induced by gamma interferon levels;
SARC	cis	rs10463316	0.862	rs7700650	chr5:150776473	C/T	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.37	-0.33	1.86e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs9790314	0.747	rs1599378	chr3:160874511	A/C	cg03342759	chr3:160939853	NMD3	-0.52	-6.29	-0.38	1.59e-9	Morning vs. evening chronotype;
SARC	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg07701084	chr6:150067640	NUP43	0.42	5.49	0.34	1.03e-7	Lung cancer;
SARC	cis	rs78456975	1.000	rs6730391	chr2:1566838	A/C	cg26248373	chr2:1572462	NA	-0.64	-6.64	-0.4	2.15e-10	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs9303401	0.614	rs66480139	chr17:57101538	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.99	10.11	0.55	3.83e-20	Cognitive test performance;
SARC	trans	rs1945213	0.694	rs10895985	chr11:55831595	T/C	cg15704280	chr7:45808275	SEPT13	0.68	7.01	0.42	2.55e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs8180040	0.966	rs4858868	chr3:47455086	G/A	cg27129171	chr3:47204927	SETD2	0.65	8.94	0.51	1.2e-16	Colorectal cancer;
SARC	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg22590775	chr19:49891494	CCDC155	0.54	6.3	0.38	1.49e-9	Multiple sclerosis;
SARC	cis	rs7614311	0.681	rs6796317	chr3:63927739	A/G	cg22134162	chr3:63841271	THOC7	-0.43	-4.75	-0.3	3.55e-6	Lung function (FVC);Lung function (FEV1);
SARC	cis	rs875971	0.545	rs75577046	chr7:65958716	A/G	cg11764359	chr7:65958608	NA	0.63	6.24	0.38	2e-9	Aortic root size;
SARC	cis	rs8028182	0.636	rs7175852	chr15:75694535	C/T	cg20655648	chr15:75932815	IMP3	0.65	7.69	0.45	4.08e-13	Sudden cardiac arrest;
SARC	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg05872129	chr22:39784769	NA	-0.4	-5.64	-0.35	4.85e-8	Intelligence (multi-trait analysis);
SARC	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg03934478	chr11:495069	RNH1	0.57	5.22	0.32	3.91e-7	Body mass index;
SARC	cis	rs10979	0.597	rs9403514	chr6:143907790	T/C	cg25407410	chr6:143891975	LOC285740	-0.51	-5.82	-0.36	1.91e-8	Hypospadias;
SARC	cis	rs12479064	0.724	rs4851203	chr2:99986932	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.46	-5.34	-0.33	2.19e-7	Chronic sinus infection;
SARC	cis	rs1878931	0.580	rs7194596	chr16:3404408	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.86	12.79	0.64	9.65e-29	Body mass index (adult);
SARC	cis	rs9457247	0.508	rs9459874	chr6:167504127	A/G	cg23791538	chr6:167370224	RNASET2	0.39	4.9	0.31	1.82e-6	Crohn's disease;
SARC	cis	rs2070488	0.965	rs6796845	chr3:38567771	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.81	-12.96	-0.65	2.79e-29	Electrocardiographic conduction measures;
SARC	cis	rs2721195	0.549	rs2958492	chr8:145919126	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.53	6.3	0.38	1.46e-9	Age at first birth;
SARC	trans	rs66573146	0.634	rs56097119	chr4:7018692	C/G	cg07817883	chr1:32538562	TMEM39B	1.25	8.14	0.47	2.33e-14	Granulocyte percentage of myeloid white cells;
SARC	cis	rs7772486	0.641	rs9390374	chr6:146368175	A/T	cg05347473	chr6:146136440	FBXO30	0.61	8.14	0.47	2.42e-14	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg10434075	chr17:55038112	COIL	0.64	6.66	0.4	1.91e-10	Lung cancer in ever smokers;
SARC	cis	rs7760949	0.889	rs9475807	chr6:13934597	T/C	cg27413430	chr6:13925136	RNF182	0.43	5.19	0.32	4.59e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs918629	0.716	rs7700895	chr5:95273410	T/A	cg16656078	chr5:95278638	ELL2	-0.62	-7.48	-0.44	1.52e-12	IgG glycosylation;
SARC	cis	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg11995313	chr8:8860691	ERI1	0.42	5.35	0.33	2.12e-7	Joint mobility (Beighton score);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg03819338	chr20:39942766	NA	0.46	6.72	0.4	1.41e-10	Thyroid stimulating hormone;
SARC	cis	rs7312774	0.618	rs4964501	chr12:107330079	C/T	cg16260113	chr12:107380972	MTERFD3	-0.86	-7.21	-0.43	7.91e-12	Severe influenza A (H1N1) infection;
SARC	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg25405998	chr7:65216604	CCT6P1	0.51	5.99	0.37	7.92e-9	Calcium levels;
SARC	cis	rs6964587	0.967	rs28594877	chr7:91644070	C/T	cg17063962	chr7:91808500	NA	0.96	16.55	0.74	3.4e-41	Breast cancer;
SARC	cis	rs10492096	0.947	rs10849482	chr12:6635274	G/A	cg13857086	chr12:6580257	VAMP1	0.66	6.66	0.4	1.99e-10	Hip geometry;
SARC	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg19671926	chr4:122722719	EXOSC9	-0.6	-6.7	-0.4	1.51e-10	Type 2 diabetes;
SARC	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg21724239	chr8:58056113	NA	0.6	5.85	0.36	1.64e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2273669	0.667	rs12197912	chr6:109338147	C/T	cg05315195	chr6:109294784	ARMC2	-0.63	-5.7	-0.35	3.6e-8	Prostate cancer;
SARC	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.73	5.57	0.34	6.83e-8	Initial pursuit acceleration;
SARC	cis	rs7633857	0.512	rs7611005	chr3:160698549	A/T	cg17135325	chr3:160939158	NMD3	0.4	4.82	0.3	2.54e-6	Educational attainment (years of education);
SARC	cis	rs11097912	0.632	rs12506658	chr4:107003908	T/C	cg09646026	chr4:107269030	AIMP1	-0.45	-4.74	-0.3	3.74e-6	Airflow obstruction;
SARC	cis	rs7647973	0.626	rs9829155	chr3:49817450	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.58	-5.81	-0.36	2e-8	Menarche (age at onset);
SARC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg23034840	chr1:205782522	SLC41A1	0.61	7.86	0.46	1.43e-13	Menarche (age at onset);
SARC	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg12564285	chr5:131593104	PDLIM4	0.42	6.16	0.37	3.24e-9	Acylcarnitine levels;
SARC	cis	rs72634258	0.520	rs12078018	chr1:7857309	G/A	cg05338066	chr1:7812865	CAMTA1	0.62	5.33	0.33	2.31e-7	Inflammatory bowel disease;
SARC	cis	rs2153535	0.580	rs986060	chr6:8465428	T/C	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs6815814	0.950	rs11722813	chr4:38810769	C/T	cg02016764	chr4:38805732	TLR1	-0.43	-5.12	-0.32	6.51e-7	Breast cancer;
SARC	cis	rs4819052	0.655	rs2330102	chr21:46690968	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.6	7.58	0.44	8.15e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs240764	0.697	rs370757	chr6:101134156	T/C	cg09795085	chr6:101329169	ASCC3	0.38	4.83	0.3	2.47e-6	Neuroticism;
SARC	cis	rs4481887	1.000	rs4430369	chr1:248464330	A/G	cg00666640	chr1:248458726	OR2T12	0.35	5.91	0.36	1.21e-8	Common traits (Other);
SARC	cis	rs7828089	1.000	rs7837521	chr8:22264151	G/T	cg12081754	chr8:22256438	SLC39A14	0.44	5.78	0.35	2.43e-8	Verbal declarative memory;
SARC	trans	rs1814175	0.817	rs1851858	chr11:49855638	G/A	cg03929089	chr4:120376271	NA	-0.89	-14.47	-0.69	2.79e-34	Height;
SARC	cis	rs7216064	1.000	rs73352808	chr17:65875157	G/A	cg12091567	chr17:66097778	LOC651250	-0.72	-7.64	-0.45	5.56e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	trans	rs208520	0.690	rs207740	chr6:66764132	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.07	14.08	0.68	5.37e-33	Exhaled nitric oxide output;
SARC	cis	rs2273669	0.667	rs2145763	chr6:109306963	C/A	cg05315195	chr6:109294784	ARMC2	-0.58	-5.14	-0.32	5.87e-7	Prostate cancer;
SARC	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg09417038	chr21:47716443	C21orf57	-0.35	-5.04	-0.31	9.52e-7	Testicular germ cell tumor;
SARC	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg00149659	chr3:10157352	C3orf10	0.69	6.9	0.41	4.76e-11	Alzheimer's disease;
SARC	cis	rs7811142	1.000	rs6972167	chr7:100080013	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	10.49	0.57	2.54e-21	Platelet count;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg04677295	chr13:100153866	TM9SF2	0.51	6.57	0.4	3.34e-10	Breast cancer;
SARC	cis	rs67079557	1	rs67079557	chr15:75930300	ATAATAAG/A	cg20655648	chr15:75932815	IMP3	0.67	8.02	0.47	5.11e-14	Breast cancer;
SARC	cis	rs950776	0.695	rs1878399	chr15:78912003	G/C	cg24631222	chr15:78858424	CHRNA5	0.38	5.03	0.31	1e-6	Sudden cardiac arrest;
SARC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg14893161	chr1:205819251	PM20D1	1.04	20.55	0.8	3.07e-54	Menarche (age at onset);
SARC	cis	rs9420	0.961	rs2847308	chr11:57498232	C/T	cg19752551	chr11:57585705	CTNND1	0.4	5.43	0.34	1.42e-7	Schizophrenia;
SARC	cis	rs853679	0.760	rs9368563	chr6:28208558	A/G	cg26450541	chr6:28235208	ZNF187	0.58	5.17	0.32	5.05e-7	Depression;
SARC	cis	rs748404	0.697	rs546722	chr15:43580819	A/G	cg12308275	chr15:43558855	TGM5	-0.4	-4.84	-0.3	2.34e-6	Lung cancer;
SARC	cis	rs11098499	0.863	rs2291185	chr4:120434833	C/A	cg24375607	chr4:120327624	NA	0.42	4.9	0.31	1.76e-6	Corneal astigmatism;
SARC	cis	rs763121	0.853	rs1569716	chr22:38998519	C/A	cg21395723	chr22:39101663	GTPBP1	0.58	6.71	0.4	1.48e-10	Menopause (age at onset);
SARC	cis	rs7084402	1.000	rs7084402	chr10:60265404	C/T	cg07615347	chr10:60278583	BICC1	0.59	8.24	0.47	1.26e-14	Refractive error;
SARC	cis	rs12478296	1.000	rs4973685	chr2:243019089	A/C	cg06360820	chr2:242988706	NA	-0.62	-4.94	-0.31	1.5e-6	Obesity-related traits;
SARC	cis	rs113835537	0.529	rs116867234	chr11:66209024	C/T	cg24851651	chr11:66362959	CCS	0.39	4.74	0.3	3.72e-6	Airway imaging phenotypes;
SARC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.79	8.2	0.47	1.63e-14	Platelet count;
SARC	cis	rs4478037	0.749	rs9681623	chr3:33131375	G/T	cg19404215	chr3:33155277	CRTAP	0.53	4.82	0.3	2.56e-6	Major depressive disorder;
SARC	cis	rs593982	0.719	rs11606668	chr11:65472758	A/G	cg08755490	chr11:65554678	OVOL1	-0.69	-7.19	-0.43	8.52e-12	Atopic dermatitis;
SARC	cis	rs7481584	0.624	rs1077335	chr11:3030524	A/G	cg05729581	chr11:3078854	CARS	0.55	7.08	0.42	1.66e-11	Calcium levels;
SARC	cis	rs6912958	0.712	rs9444525	chr6:88324142	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.47	-0.39	5.74e-10	Monocyte percentage of white cells;
SARC	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg13206674	chr6:150067644	NUP43	0.41	5.37	0.33	1.95e-7	Lung cancer;
SARC	cis	rs12479064	0.671	rs4851207	chr2:100105775	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.54	-6.11	-0.37	4.21e-9	Chronic sinus infection;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg13184539	chr1:241683111	FH	-0.52	-6.93	-0.41	4e-11	Electrocardiographic conduction measures;
SARC	cis	rs10513788	0.906	rs6774209	chr3:182059448	A/G	cg05977900	chr3:182512126	ATP11B	-0.48	-5.05	-0.31	8.71e-7	Cognitive function;
SARC	cis	rs936229	0.813	rs7085	chr15:75095483	T/C	cg14664628	chr15:75095509	CSK	-1.04	-14.6	-0.69	9.93e-35	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs4938330	0.608	rs3830008	chr11:117093764	A/C	cg01368799	chr11:117014884	PAFAH1B2	-0.52	-5.51	-0.34	9.48e-8	Blood protein levels;
SARC	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg03264133	chr6:25882463	NA	-0.56	-7.46	-0.44	1.74e-12	Blood metabolite levels;
SARC	cis	rs9341808	0.754	rs3793000	chr6:80995137	G/A	cg08355045	chr6:80787529	NA	0.36	5.74	0.35	2.98e-8	Sitting height ratio;
SARC	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.62	7.52	0.44	1.14e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4737010	0.501	rs10099197	chr8:41654458	C/T	cg08923054	chr8:41654455	ANK1	0.72	8.45	0.48	3.24e-15	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
SARC	cis	rs7223966	1.000	rs61360320	chr17:61800392	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.53	-5.55	-0.34	7.66e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7412746	0.611	rs10788794	chr1:150728676	T/C	cg15448220	chr1:150897856	SETDB1	0.48	6.23	0.38	2.15e-9	Melanoma;
SARC	cis	rs16854884	0.770	rs6784938	chr3:143817528	C/T	cg06585982	chr3:143692056	C3orf58	0.62	8.01	0.46	5.63e-14	Economic and political preferences (feminism/equality);
SARC	cis	rs3011225	0.710	rs3011224	chr1:44318483	C/T	cg12908607	chr1:44402522	ARTN	-0.33	-5.83	-0.36	1.88e-8	Amyotrophic lateral sclerosis (age of onset);
SARC	cis	rs240764	0.578	rs723743	chr6:101237504	T/C	cg09795085	chr6:101329169	ASCC3	0.45	5.66	0.35	4.42e-8	Neuroticism;
SARC	cis	rs7566780	0.596	rs7558680	chr2:16645706	T/G	cg09580478	chr2:16689509	NA	0.47	5.61	0.34	5.74e-8	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs826838	1.000	rs6582619	chr12:38729904	A/G	cg13010199	chr12:38710504	ALG10B	0.82	11.8	0.61	1.68e-25	Heart rate;
SARC	cis	rs1832871	0.655	rs6920121	chr6:158678504	C/T	cg07165851	chr6:158734300	TULP4	-0.54	-6.48	-0.39	5.5e-10	Height;
SARC	cis	rs11190604	1.000	rs2295772	chr10:102265183	G/A	cg07080220	chr10:102295463	HIF1AN	0.78	9.5	0.53	2.76e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs2985684	1.000	rs7142457	chr14:50097862	C/T	cg04989706	chr14:50066350	PPIL5	-0.53	-5.58	-0.34	6.5e-8	Carotid intima media thickness;
SARC	cis	rs7769051	0.711	rs7738071	chr6:133085116	G/A	cg07930552	chr6:133119739	C6orf192	0.79	6.28	0.38	1.65e-9	Type 2 diabetes nephropathy;
SARC	cis	rs11997175	0.574	rs7001404	chr8:33645219	G/A	ch.8.33884649F	chr8:33765107	NA	0.5	6.62	0.4	2.44e-10	Body mass index;
SARC	cis	rs611744	0.608	rs667742	chr8:109254003	T/C	cg21045802	chr8:109455806	TTC35	0.6	7.65	0.45	5.26e-13	Dupuytren's disease;
SARC	cis	rs2236918	0.687	rs1776176	chr1:242012554	C/T	cg17736920	chr1:242011382	EXO1	0.66	8.99	0.51	8.89e-17	Menopause (age at onset);
SARC	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg06634786	chr22:41940651	POLR3H	-0.51	-5.91	-0.36	1.21e-8	Vitiligo;
SARC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg06873352	chr17:61820015	STRADA	0.53	6.92	0.41	4.3e-11	Prudent dietary pattern;
SARC	cis	rs617791	0.569	rs11227370	chr11:65747693	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.57	6.97	0.42	3.24e-11	Breast cancer;
SARC	cis	rs796364	0.806	rs6435040	chr2:200861161	T/G	cg23649088	chr2:200775458	C2orf69	0.6	5.35	0.33	2.08e-7	Schizophrenia;
SARC	cis	rs7000551	0.680	rs28546543	chr8:22314872	A/C	cg12081754	chr8:22256438	SLC39A14	0.58	8.17	0.47	2.01e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg13939156	chr17:80058883	NA	-0.42	-6.48	-0.39	5.41e-10	Life satisfaction;
SARC	cis	rs228437	1.000	rs6928242	chr6:134936389	T/G	cg24504307	chr6:134963096	NA	0.53	6.12	0.37	3.96e-9	Melanoma;
SARC	cis	rs2180341	0.960	rs9375503	chr6:127677071	T/C	cg24812749	chr6:127587940	RNF146	1.02	13.42	0.66	8.61e-31	Breast cancer;
SARC	cis	rs2120243	0.539	rs35218020	chr3:157115416	G/A	cg24825693	chr3:157122686	VEPH1	-0.46	-6.43	-0.39	7.02e-10	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs9486719	0.948	rs11152953	chr6:96894305	C/T	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.01	-0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs10870270	1.000	rs10781564	chr10:133757922	A/G	cg26149184	chr10:133730230	NA	0.45	5.09	0.32	7.4e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg07701084	chr6:150067640	NUP43	0.38	5.13	0.32	6.14e-7	Lung cancer;
SARC	cis	rs734999	0.505	rs4445406	chr1:2539400	T/C	cg18854424	chr1:2615690	NA	0.31	4.81	0.3	2.77e-6	Ulcerative colitis;
SARC	cis	rs13095912	0.889	rs6778977	chr3:185302532	T/G	cg11274856	chr3:185301563	NA	0.35	4.83	0.3	2.51e-6	Systolic blood pressure;
SARC	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg12463550	chr7:65579703	CRCP	-0.5	-5.48	-0.34	1.09e-7	Aortic root size;
SARC	cis	rs3540	0.512	rs3862433	chr15:91076028	G/A	cg22089800	chr15:90895588	ZNF774	-0.59	-7.39	-0.44	2.57e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs2120019	0.938	rs2289582	chr15:75310394	T/C	cg12414181	chr15:75287860	SCAMP5	-0.52	-5.78	-0.35	2.44e-8	Blood trace element (Zn levels);
SARC	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	5.78	0.35	2.36e-8	Bipolar disorder;
SARC	cis	rs4589502	0.925	rs4259997	chr15:67153310	A/G	cg12317470	chr15:67143691	NA	-0.74	-7.14	-0.42	1.19e-11	Lung cancer (smoking interaction);
SARC	cis	rs79149102	0.579	rs6495142	chr15:75320166	C/T	cg00629941	chr15:75287862	SCAMP5	-0.7	-5.42	-0.33	1.47e-7	Lung cancer;
SARC	cis	rs818427	0.964	rs351769	chr5:112199974	C/T	cg07820702	chr5:112228657	REEP5	0.47	5.28	0.33	2.97e-7	Total body bone mineral density;
SARC	cis	rs1152591	0.524	rs1255991	chr14:64661642	G/A	cg23250157	chr14:64679961	SYNE2	0.42	5.92	0.36	1.17e-8	Atrial fibrillation;
SARC	cis	rs12681288	0.676	rs34435811	chr8:990630	T/A	cg04851639	chr8:1020857	NA	-0.29	-4.83	-0.3	2.5e-6	Schizophrenia;
SARC	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	11.41	0.6	2.96e-24	Alzheimer's disease;
SARC	cis	rs72781680	0.848	rs56371415	chr2:23932603	C/G	cg06627628	chr2:24431161	ITSN2	-0.63	-5.59	-0.34	6.42e-8	Lymphocyte counts;
SARC	cis	rs7216064	1.000	rs62084213	chr17:65842016	A/G	cg12091567	chr17:66097778	LOC651250	-0.69	-6.99	-0.42	2.89e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs3733585	0.725	rs6449201	chr4:9973894	C/T	cg11266682	chr4:10021025	SLC2A9	-0.39	-6.56	-0.39	3.49e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs17250963	0.898	rs697565	chr5:14743455	G/T	cg12465520	chr5:14733886	ANKH	0.52	4.92	0.31	1.61e-6	Homeostasis model assessment of insulin resistance (dietary factor interaction);
SARC	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg06221963	chr1:154839813	KCNN3	-0.45	-6.92	-0.41	4.42e-11	Prostate cancer;
SARC	cis	rs6831352	0.760	rs2602859	chr4:100030583	G/A	cg12011299	chr4:100065546	ADH4	0.33	5.57	0.34	6.86e-8	Alcohol dependence;
SARC	cis	rs4481887	0.800	rs4278391	chr1:248450495	C/T	cg01631408	chr1:248437212	OR2T33	-0.42	-5.35	-0.33	2.1e-7	Common traits (Other);
SARC	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg04944784	chr2:26401820	FAM59B	0.6	7.95	0.46	8.14e-14	Gut microbiome composition (summer);
SARC	cis	rs4808199	0.739	rs2240117	chr19:19418916	C/T	cg03709012	chr19:19516395	GATAD2A	1.03	8.21	0.47	1.5e-14	Nonalcoholic fatty liver disease;
SARC	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg18876405	chr7:65276391	NA	-0.72	-9.39	-0.52	5.65e-18	Aortic root size;
SARC	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg25894440	chr7:65020034	NA	-0.72	-5.46	-0.34	1.2e-7	Diabetic kidney disease;
SARC	trans	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg21659725	chr3:3221576	CRBN	-0.8	-12.22	-0.62	7.09e-27	Intelligence (multi-trait analysis);
SARC	cis	rs7589342	0.501	rs12995849	chr2:106443111	C/T	cg16077055	chr2:106428750	NCK2	0.26	4.82	0.3	2.63e-6	Addiction;
SARC	cis	rs7927771	0.929	rs66749409	chr11:47568074	C/T	cg20307385	chr11:47447363	PSMC3	-0.51	-6.31	-0.38	1.37e-9	Subjective well-being;
SARC	cis	rs4481887	0.927	rs4244184	chr1:248486895	G/T	cg13385794	chr1:248469461	NA	0.33	4.96	0.31	1.35e-6	Common traits (Other);
SARC	cis	rs7224737	0.956	rs7208907	chr17:40284783	C/T	cg20291162	chr17:40259547	DHX58	-0.33	-4.87	-0.3	2.08e-6	Fibrinogen levels;
SARC	cis	rs7208859	0.673	rs4131618	chr17:29204801	C/T	cg13385521	chr17:29058706	SUZ12P	0.86	7.34	0.43	3.54e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs6061231	0.505	rs62199217	chr20:60929539	G/A	cg24112000	chr20:60950667	NA	-0.34	-5.02	-0.31	1.04e-6	Colorectal cancer;
SARC	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg18225595	chr11:63971243	STIP1	0.42	4.94	0.31	1.5e-6	Mean platelet volume;
SARC	cis	rs910316	0.763	rs2080201	chr14:75629972	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.48	-6.23	-0.38	2.21e-9	Height;
SARC	cis	rs916888	0.821	rs199504	chr17:44861003	C/T	cg03575189	chr17:44344142	NA	-0.54	-5.31	-0.33	2.6e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs11098499	0.739	rs9996382	chr4:120151012	C/T	cg09307838	chr4:120376055	NA	0.75	10.03	0.55	6.31e-20	Corneal astigmatism;
SARC	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg12373951	chr3:133503437	NA	-0.39	-5.68	-0.35	3.99e-8	Iron status biomarkers;
SARC	cis	rs240764	0.578	rs6925065	chr6:101178856	C/T	cg09795085	chr6:101329169	ASCC3	0.52	6.77	0.41	1.04e-10	Neuroticism;
SARC	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg27572855	chr1:25598939	RHD	0.56	9.83	0.54	2.72e-19	Erythrocyte sedimentation rate;
SARC	cis	rs2898681	0.561	rs7699960	chr4:53735661	C/A	cg00338735	chr4:53728038	RASL11B	0.49	5.46	0.34	1.24e-7	Optic nerve measurement (cup area);
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg01862523	chr6:71123290	FAM135A	-0.49	-6.28	-0.38	1.63e-9	Schizophrenia;
SARC	cis	rs2115630	0.967	rs11073731	chr15:85355113	C/A	cg12501888	chr15:85177176	SCAND2	-0.46	-5.65	-0.35	4.6e-8	P wave terminal force;
SARC	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg04277193	chr17:41438351	NA	0.45	4.84	0.3	2.37e-6	Menopause (age at onset);
SARC	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg22968622	chr17:43663579	NA	-1.12	-14.6	-0.69	9.81e-35	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9303401	0.659	rs12946852	chr17:57013337	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	11.27	0.59	8.61e-24	Cognitive test performance;
SARC	cis	rs11644362	0.966	rs976011	chr16:12992910	C/T	cg06890432	chr16:12997467	SHISA9	-0.54	-7.16	-0.42	1.04e-11	Positive affect;Subjective well-being;
SARC	cis	rs9398803	0.830	rs1159619	chr6:126801144	C/A	cg19875578	chr6:126661172	C6orf173	0.63	8.55	0.49	1.64e-15	Male-pattern baldness;
SARC	cis	rs8028182	0.636	rs11636031	chr15:75815758	T/C	cg20655648	chr15:75932815	IMP3	0.64	7.41	0.44	2.38e-12	Sudden cardiac arrest;
SARC	cis	rs907683	0.545	rs3755054	chr2:220280974	C/T	cg15015639	chr2:220282977	DES	0.37	5.71	0.35	3.38e-8	Resting heart rate;
SARC	cis	rs4423214	1.000	rs12806844	chr11:71170770	G/A	cg24826892	chr11:71159390	DHCR7	0.44	5.61	0.35	5.6e-8	Vitamin D levels;
SARC	cis	rs9814567	0.762	rs13079012	chr3:134247706	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.52	5.51	0.34	9.68e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs3764563	1.000	rs8107240	chr19:15737392	A/G	cg20725493	chr19:15740067	CYP4F8	-0.76	-5.92	-0.36	1.12e-8	Inflammatory biomarkers;
SARC	cis	rs9888615	0.651	rs8008270	chr14:53372330	C/T	cg01268763	chr14:53618419	DDHD1	0.4	4.75	0.3	3.52e-6	Systolic blood pressure;
SARC	cis	rs6582630	0.539	rs4882324	chr12:38499180	T/C	cg14851346	chr12:38532713	NA	-0.44	-5.26	-0.33	3.22e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7408868	1.000	rs4809030	chr19:15273381	A/G	cg14696996	chr19:15285081	NOTCH3	1.06	8.68	0.49	6.85e-16	Pulse pressure;
SARC	cis	rs6594499	0.872	rs10050834	chr5:110427328	C/T	cg04022379	chr5:110408740	TSLP	0.49	6.01	0.37	7.02e-9	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs1448094	0.556	rs61930632	chr12:86168937	A/C	cg02569458	chr12:86230093	RASSF9	0.37	5.04	0.31	9.25e-7	Major depressive disorder;
SARC	cis	rs1322639	0.574	rs9364360	chr6:169580174	G/A	cg04662567	chr6:169592167	NA	-0.52	-5.22	-0.32	3.9e-7	Pulse pressure;
SARC	cis	rs3936840	0.686	rs2896439	chr14:102806291	A/G	cg18135206	chr14:102964638	TECPR2	0.38	4.9	0.31	1.79e-6	Plateletcrit;
SARC	cis	rs1215050	0.740	rs2555390	chr4:98999112	A/G	cg05340658	chr4:99064831	C4orf37	-0.47	-6.43	-0.39	7.03e-10	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs9914544	0.564	rs8072860	chr17:18807884	T/C	cg25390199	chr17:18761479	PRPSAP2	0.45	5.86	0.36	1.53e-8	Educational attainment (years of education);
SARC	cis	rs1050631	0.564	rs1785931	chr18:33722107	T/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.59	7.17	0.43	9.66e-12	Esophageal squamous cell cancer (length of survival);
SARC	trans	rs61931739	0.500	rs9669027	chr12:34583528	C/T	cg13010199	chr12:38710504	ALG10B	-0.78	-11.12	-0.59	2.47e-23	Morning vs. evening chronotype;
SARC	cis	rs7178572	0.743	rs62009090	chr15:77837055	T/G	cg22256960	chr15:77711686	NA	-0.51	-6.2	-0.38	2.58e-9	Type 2 diabetes;
SARC	cis	rs826838	0.967	rs826856	chr12:39115434	G/A	cg26384229	chr12:38710491	ALG10B	-0.82	-12.37	-0.63	2.35e-27	Heart rate;
SARC	cis	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg03060546	chr3:49711283	APEH	-0.67	-8.3	-0.48	8.2e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs875971	0.545	rs11766183	chr7:65839160	G/C	cg11764359	chr7:65958608	NA	0.67	6.66	0.4	1.97e-10	Aortic root size;
SARC	cis	rs10046574	0.731	rs10267977	chr7:135159392	G/A	cg27474649	chr7:135195673	CNOT4	0.87	7.13	0.42	1.27e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs1256061	0.654	rs1256031	chr14:64746179	C/T	cg23250157	chr14:64679961	SYNE2	0.42	5.91	0.36	1.18e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs9400467	0.537	rs1150081	chr6:111479016	A/G	cg15721981	chr6:111408429	SLC16A10	0.66	5.83	0.36	1.85e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-9.18	-0.52	2.35e-17	Alzheimer's disease;
SARC	cis	rs72945132	0.882	rs58039907	chr11:70183336	C/T	cg00319359	chr11:70116639	PPFIA1	0.7	6.64	0.4	2.23e-10	Coronary artery disease;
SARC	cis	rs8014204	0.836	rs7154256	chr14:75252587	A/G	cg17347104	chr14:75034677	LTBP2	-0.44	-5.42	-0.33	1.49e-7	Caffeine consumption;
SARC	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg08219700	chr8:58056026	NA	0.51	5.25	0.33	3.4e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2153535	0.541	rs9505456	chr6:8479001	T/C	cg07606381	chr6:8435919	SLC35B3	0.79	11.49	0.6	1.71e-24	Motion sickness;
SARC	cis	rs12142240	0.698	rs56344958	chr1:46814518	G/A	cg14993813	chr1:46806288	NSUN4	-0.52	-5.46	-0.34	1.22e-7	Menopause (age at onset);
SARC	cis	rs1348850	0.958	rs11684320	chr2:178456346	T/C	cg23306229	chr2:178417860	TTC30B	0.6	6.95	0.41	3.54e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1552244	0.882	rs9812006	chr3:10022658	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	9.45	0.53	3.8e-18	Alzheimer's disease;
SARC	cis	rs1865760	0.551	rs9461230	chr6:26019240	G/C	cg16482183	chr6:26056742	HIST1H1C	0.5	6.39	0.39	9.17e-10	Height;
SARC	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg04944784	chr2:26401820	FAM59B	0.6	7.96	0.46	7.46e-14	Gut microbiome composition (summer);
SARC	cis	rs995000	0.931	rs637723	chr1:62906728	C/T	cg06896770	chr1:63153194	DOCK7	0.89	13.53	0.66	3.53e-31	Triglyceride levels;
SARC	cis	rs116095464	0.558	rs28636067	chr5:199415	G/A	cg22857025	chr5:266934	NA	-1.11	-9.93	-0.55	1.37e-19	Breast cancer;
SARC	cis	rs7829975	0.617	rs4841072	chr8:8791253	C/A	cg08975724	chr8:8085496	FLJ10661	-0.41	-5.02	-0.31	1e-6	Mood instability;
SARC	cis	rs672059	0.967	rs657901	chr1:183163411	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.5	6.82	0.41	7.95e-11	Hypertriglyceridemia;
SARC	cis	rs72781680	1.000	rs72798418	chr2:24188922	A/G	cg06627628	chr2:24431161	ITSN2	-0.7	-6.71	-0.4	1.49e-10	Lymphocyte counts;
SARC	cis	rs9420	0.784	rs10896656	chr11:57668941	C/G	cg19752551	chr11:57585705	CTNND1	-0.47	-5.47	-0.34	1.16e-7	Schizophrenia;
SARC	cis	rs9303401	0.659	rs62083362	chr17:56846464	A/G	cg25039879	chr17:56429692	SUPT4H1	0.65	6.12	0.37	3.88e-9	Cognitive test performance;
SARC	trans	rs79976124	0.842	rs74881738	chr6:66621825	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.68	7.63	0.45	6.11e-13	Type 2 diabetes;
SARC	cis	rs986417	0.818	rs7144656	chr14:61032909	A/G	cg27398547	chr14:60952738	C14orf39	0.9	8.3	0.48	8.2e-15	Gut microbiota (bacterial taxa);
SARC	cis	rs6831352	0.765	rs35361391	chr4:100069281	A/T	cg13256891	chr4:100009986	ADH5	-0.65	-7.8	-0.45	2.07e-13	Alcohol dependence;
SARC	cis	rs920590	0.758	rs62496731	chr8:19659543	C/G	cg03894339	chr8:19674705	INTS10	0.58	6.89	0.41	5.06e-11	Acute lymphoblastic leukemia (childhood);
SARC	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg22968622	chr17:43663579	NA	1.17	15.55	0.71	7.14e-38	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	trans	rs11098499	0.954	rs10008392	chr4:120318839	G/A	cg25214090	chr10:38739885	LOC399744	0.59	7.69	0.45	4.1e-13	Corneal astigmatism;
SARC	cis	rs8180040	0.620	rs11707736	chr3:47069504	G/T	cg27129171	chr3:47204927	SETD2	-0.68	-9.21	-0.52	1.91e-17	Colorectal cancer;
SARC	cis	rs7617773	0.743	rs6804986	chr3:48363595	A/G	cg11946769	chr3:48343235	NME6	0.75	9.89	0.54	1.78e-19	Coronary artery disease;
SARC	cis	rs1046896	1.000	rs9909940	chr17:80689036	C/T	cg02711726	chr17:80685570	FN3KRP	-0.67	-8.45	-0.48	3.14e-15	Glycated hemoglobin levels;
SARC	cis	rs9457247	1.000	rs422094	chr6:167397033	C/G	cg07741184	chr6:167504864	NA	0.29	5.55	0.34	7.66e-8	Crohn's disease;
SARC	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg24531977	chr5:56204891	C5orf35	-0.52	-5.3	-0.33	2.73e-7	Initial pursuit acceleration;
SARC	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg12311346	chr5:56204834	C5orf35	0.39	4.83	0.3	2.5e-6	Coronary artery disease;
SARC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	11.44	0.6	2.42e-24	Platelet count;
SARC	cis	rs73206853	0.841	rs56209636	chr12:110841998	T/C	cg10860002	chr12:110842031	ANAPC7	0.63	5.04	0.31	9.52e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg08859206	chr1:53392774	SCP2	0.43	6.13	0.37	3.75e-9	Monocyte count;
SARC	trans	rs62103177	0.564	rs2115996	chr18:77701007	C/G	cg05926928	chr17:57297772	GDPD1	0.83	7.54	0.44	1.01e-12	Opioid sensitivity;
SARC	cis	rs4642101	0.765	rs9870269	chr3:12853450	T/G	cg12400702	chr3:12838781	CAND2	-0.25	-4.89	-0.31	1.88e-6	QRS complex (12-leadsum);
SARC	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.33	-0.43	3.74e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg11843238	chr5:131593191	PDLIM4	0.38	5.38	0.33	1.85e-7	Breast cancer;
SARC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.42	-6.42	-0.39	7.6e-10	Total body bone mineral density;
SARC	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg03452623	chr4:187889614	NA	-0.76	-12.32	-0.63	3.34e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs981844	0.712	rs1037652	chr4:154746565	C/T	cg14289246	chr4:154710475	SFRP2	0.45	5.24	0.32	3.58e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.01	11.4	0.6	3.36e-24	Platelet count;
SARC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg15242686	chr22:24348715	GSTTP1	0.4	5.18	0.32	4.84e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9290065	0.519	rs6770180	chr3:160703786	C/T	cg04691961	chr3:161091175	C3orf57	-0.49	-6.23	-0.38	2.12e-9	Kawasaki disease;
SARC	cis	rs6459788	0.692	rs10807645	chr7:157258979	T/C	cg03453431	chr7:157225567	NA	0.44	5.65	0.35	4.59e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs2832077	0.883	rs35672956	chr21:30189042	T/C	cg24692254	chr21:30365293	RNF160	-0.52	-4.78	-0.3	3.09e-6	Cognitive test performance;
SARC	trans	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg00938859	chr5:1591904	SDHAP3	0.79	7.66	0.45	5.1e-13	Breast cancer;
SARC	cis	rs12912251	0.689	rs7174485	chr15:38977710	A/C	cg01338139	chr15:38987640	C15orf53	0.5	5.09	0.32	7.51e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
SARC	cis	rs897080	0.552	rs1068714	chr2:44634063	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.7	0.4	1.59e-10	Height;
SARC	cis	rs9916302	0.861	rs12150493	chr17:37586154	T/C	cg20243544	chr17:37824526	PNMT	0.56	6.64	0.4	2.19e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs76419734	0.558	rs17035915	chr4:106520435	T/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.66	5.72	0.35	3.18e-8	Post bronchodilator FEV1;
SARC	cis	rs155076	0.938	rs536209	chr13:21847714	C/T	cg25811766	chr13:21894605	NA	-0.51	-5.5	-0.34	9.92e-8	White matter hyperintensity burden;
SARC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.6	0.53	1.32e-18	Prudent dietary pattern;
SARC	trans	rs3857536	0.706	rs7749120	chr6:66889832	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.6	-7.14	-0.42	1.16e-11	Blood trace element (Cu levels);
SARC	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg11494091	chr17:61959527	GH2	-0.63	-10.16	-0.55	2.66e-20	Prudent dietary pattern;
SARC	cis	rs9341808	0.727	rs4706834	chr6:81012605	G/T	cg08355045	chr6:80787529	NA	0.37	5.78	0.35	2.33e-8	Sitting height ratio;
SARC	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg08677398	chr8:58056175	NA	0.42	5.09	0.32	7.34e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs11574514	1.000	rs1133090	chr16:68021468	G/C	cg01866162	chr16:67596514	CTCF	0.97	6.25	0.38	1.9e-9	Crohn's disease;
SARC	trans	rs9929218	1.000	rs7200690	chr16:68778457	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.62	-8.05	-0.47	4.3e-14	Colorectal cancer;
SARC	cis	rs2075371	0.933	rs1833475	chr7:133958263	C/T	cg20476274	chr7:133979776	SLC35B4	0.61	8.32	0.48	7.38e-15	Mean platelet volume;
SARC	cis	rs6840360	1.000	rs10023298	chr4:152666768	A/C	cg22705602	chr4:152727874	NA	-0.36	-6.26	-0.38	1.88e-9	Intelligence (multi-trait analysis);
SARC	cis	rs6121246	0.909	rs6089071	chr20:30378384	C/G	cg13852791	chr20:30311386	BCL2L1	0.85	8.9	0.5	1.58e-16	Mean corpuscular hemoglobin;
SARC	cis	rs1043515	0.748	rs11653487	chr17:36942631	A/G	cg20826740	chr17:37024042	NA	-0.36	-4.73	-0.3	3.88e-6	Height;
SARC	cis	rs10421328	0.784	rs28635562	chr19:19769690	C/T	cg03709012	chr19:19516395	GATAD2A	0.55	6.12	0.37	3.98e-9	Parental longevity (combined parental age at death);
SARC	cis	rs1448094	0.511	rs17345975	chr12:86202318	T/A	cg00310523	chr12:86230176	RASSF9	0.32	5.13	0.32	6.09e-7	Major depressive disorder;
SARC	cis	rs6582630	0.537	rs3942440	chr12:38459672	A/G	cg26384229	chr12:38710491	ALG10B	0.84	12.0	0.62	3.64e-26	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs4699052	0.963	rs56144793	chr4:104150653	A/G	cg16532752	chr4:104119610	CENPE	-0.42	-5.0	-0.31	1.15e-6	Testicular germ cell tumor;
SARC	cis	rs752010	0.714	rs6664708	chr1:42083070	G/A	cg06885757	chr1:42089581	HIVEP3	0.41	6.32	0.38	1.33e-9	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs9381107	0.932	rs9349224	chr6:9471146	G/T	cg14735645	chr6:9486422	NA	-0.45	-5.15	-0.32	5.48e-7	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs4319547	0.586	rs7956480	chr12:122817507	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.58	-6.75	-0.4	1.15e-10	Body mass index;
SARC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg07308232	chr7:1071921	C7orf50	-0.48	-5.76	-0.35	2.71e-8	Longevity;Endometriosis;
SARC	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.91	9.32	0.52	9.06e-18	Platelet count;
SARC	cis	rs7872515	0.887	rs28727560	chr9:94864754	A/C	cg01248375	chr9:94877805	SPTLC1	0.67	5.95	0.36	9.73e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs910316	0.737	rs175499	chr14:75535927	G/A	cg11812906	chr14:75593930	NEK9	-0.77	-10.58	-0.57	1.29e-21	Height;
SARC	cis	rs11098499	0.754	rs7672778	chr4:120248585	A/G	cg09307838	chr4:120376055	NA	0.81	11.03	0.59	4.84e-23	Corneal astigmatism;
SARC	cis	rs6484504	0.576	rs208090	chr11:31190992	T/C	cg02090638	chr11:31391270	DNAJC24;DCDC1	-0.38	-4.85	-0.3	2.21e-6	Red blood cell count;
SARC	cis	rs9814567	0.806	rs4074523	chr3:134325657	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.53	-6.89	-0.41	5.13e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs2594989	0.943	rs2244617	chr3:11503097	T/C	cg00170343	chr3:11313890	ATG7	0.55	5.35	0.33	2.11e-7	Circulating chemerin levels;
SARC	cis	rs2011503	0.941	rs113145184	chr19:19419984	T/C	cg03709012	chr19:19516395	GATAD2A	0.65	5.81	0.36	2.01e-8	Bipolar disorder;
SARC	cis	rs2834188	1.000	rs2843994	chr21:34706870	G/A	cg14352951	chr21:34696688	IFNAR1	0.46	5.44	0.34	1.35e-7	Narcolepsy;
SARC	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg05896524	chr21:47604654	C21orf56	0.41	4.95	0.31	1.41e-6	Testicular germ cell tumor;
SARC	cis	rs3784262	0.631	rs4646560	chr15:58353546	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.34	-5.04	-0.31	9.45e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.35	0.38	1.12e-9	Bipolar disorder;
SARC	cis	rs7223966	1.000	rs7214312	chr17:61870863	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.52	-5.5	-0.34	1.02e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg04347867	chr16:56965804	HERPUD1	-0.51	-6.42	-0.39	7.39e-10	Breast cancer;
SARC	cis	rs9818758	0.607	rs35673421	chr3:49139406	G/A	cg07636037	chr3:49044803	WDR6	-0.79	-6.87	-0.41	5.77e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg21747090	chr2:27597821	SNX17	-0.5	-6.93	-0.41	4.01e-11	Total body bone mineral density;
SARC	trans	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg00938859	chr5:1591904	SDHAP3	0.74	6.91	0.41	4.61e-11	Breast cancer;
SARC	cis	rs12824058	0.831	rs11608407	chr12:130805869	G/A	cg23887609	chr12:130822674	PIWIL1	0.4	5.55	0.34	7.58e-8	Menopause (age at onset);
SARC	cis	rs908922	0.676	rs478926	chr1:152511533	G/T	cg09873164	chr1:152488093	CRCT1	0.65	8.72	0.5	5.41e-16	Hair morphology;
SARC	cis	rs2721195	0.845	rs3757966	chr8:145744618	G/A	cg11211951	chr8:145729740	GPT	0.63	10.07	0.55	5.08e-20	Age at first birth;
SARC	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	9.84	0.54	2.5e-19	Platelet count;
SARC	cis	rs6540556	0.608	rs4844891	chr1:209914409	A/C	cg05527609	chr1:210001259	C1orf107	-0.57	-5.86	-0.36	1.6e-8	Red blood cell count;
SARC	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg22857025	chr5:266934	NA	-1.08	-11.86	-0.61	1.06e-25	Breast cancer;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg26081062	chr2:224840482	SERPINE2	0.44	6.27	0.38	1.77e-9	Thyroid stimulating hormone;
SARC	cis	rs17023223	0.537	rs12083510	chr1:119746620	T/G	cg05756136	chr1:119680316	WARS2	-0.48	-5.4	-0.33	1.62e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs67311347	0.544	rs35112505	chr3:40337075	A/G	cg09455208	chr3:40491958	NA	0.3	4.92	0.31	1.66e-6	Renal cell carcinoma;
SARC	cis	rs3617	0.559	rs11915546	chr3:52866845	A/C	cg18404041	chr3:52824283	ITIH1	0.37	5.42	0.33	1.5e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs11098499	0.644	rs6855918	chr4:120546299	C/T	cg09307838	chr4:120376055	NA	0.77	10.48	0.57	2.73e-21	Corneal astigmatism;
SARC	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg24829409	chr8:58192753	C8orf71	-0.55	-5.99	-0.37	7.82e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs3784262	0.512	rs4646572	chr15:58343021	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.33	-4.99	-0.31	1.18e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs1949733	0.523	rs16842557	chr4:8543985	C/T	cg13073564	chr4:8508604	NA	0.5	7.44	0.44	1.88e-12	Response to antineoplastic agents;
SARC	cis	rs34779708	0.931	rs2244100	chr10:35323636	G/A	cg03585969	chr10:35415529	CREM	-0.38	-4.87	-0.3	2.04e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs11997175	0.545	rs59563980	chr8:33665377	C/T	ch.8.33884649F	chr8:33765107	NA	0.49	6.25	0.38	1.93e-9	Body mass index;
SARC	trans	rs61931739	0.513	rs1486889	chr12:33901229	A/G	cg13010199	chr12:38710504	ALG10B	0.63	8.56	0.49	1.57e-15	Morning vs. evening chronotype;
SARC	cis	rs17376456	0.877	rs13185660	chr5:93336500	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.74	0.35	2.96e-8	Diabetic retinopathy;
SARC	cis	rs9398803	0.865	rs1578060	chr6:126712247	G/C	cg20229609	chr6:126660872	C6orf173	0.39	5.64	0.35	5e-8	Male-pattern baldness;
SARC	cis	rs2479724	0.818	rs9357369	chr6:41818202	A/C	cg17623882	chr6:41773611	USP49	-0.47	-5.89	-0.36	1.37e-8	Menarche (age at onset);
SARC	cis	rs7239679	0.517	rs2847351	chr18:10447041	A/G	cg26328002	chr18:10455463	APCDD1	-0.41	-5.03	-0.31	9.62e-7	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	trans	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg21659725	chr3:3221576	CRBN	-0.79	-11.96	-0.62	5.19e-26	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg18876405	chr7:65276391	NA	-0.67	-8.16	-0.47	2.09e-14	Aortic root size;
SARC	cis	rs1799949	0.587	rs1824890	chr17:41421904	T/C	cg05368731	chr17:41323189	NBR1	0.63	6.17	0.37	2.95e-9	Menopause (age at onset);
SARC	cis	rs739401	0.611	rs572373	chr11:3055361	T/C	cg20651018	chr11:3035856	CARS	-0.48	-7.67	-0.45	4.74e-13	Longevity;
SARC	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg10207240	chr12:122356781	WDR66	0.3	5.15	0.32	5.47e-7	Mean corpuscular volume;
SARC	cis	rs524281	1.000	rs489337	chr11:65854561	A/G	cg14036092	chr11:66035641	RAB1B	0.53	5.91	0.36	1.21e-8	Electroencephalogram traits;
SARC	cis	rs1707322	1.000	rs1768807	chr1:46510570	A/G	cg03146154	chr1:46216737	IPP	-0.47	-5.67	-0.35	4.22e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2594989	0.887	rs2454498	chr3:11500953	A/G	cg00170343	chr3:11313890	ATG7	0.55	5.35	0.33	2.11e-7	Circulating chemerin levels;
SARC	cis	rs2273669	0.748	rs11759732	chr6:109370006	A/G	cg01304950	chr6:109416612	SESN1;C6orf182	0.6	5.14	0.32	5.9e-7	Prostate cancer;
SARC	cis	rs73206853	0.764	rs58535454	chr12:111003457	C/T	cg10860002	chr12:110842031	ANAPC7	0.6	5.11	0.32	6.71e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg09373136	chr17:61933544	TCAM1	-0.45	-6.12	-0.37	3.83e-9	Prudent dietary pattern;
SARC	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg23758822	chr17:41437982	NA	0.91	11.43	0.6	2.63e-24	Menopause (age at onset);
SARC	cis	rs910316	0.967	rs8013444	chr14:75661981	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.47	-6.39	-0.39	9.12e-10	Height;
SARC	cis	rs453301	0.631	rs7843369	chr8:8797786	T/G	cg11608241	chr8:8085544	FLJ10661	-0.4	-4.71	-0.3	4.17e-6	Joint mobility (Beighton score);
SARC	cis	rs9303401	0.659	rs7210700	chr17:56668186	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	11.65	0.61	5.15e-25	Cognitive test performance;
SARC	cis	rs2180341	1.000	rs9398837	chr6:127635217	G/A	cg24812749	chr6:127587940	RNF146	0.97	12.95	0.65	2.97e-29	Breast cancer;
SARC	cis	rs8114671	0.836	rs6142294	chr20:33671497	A/G	cg08999081	chr20:33150536	PIGU	-0.35	-4.92	-0.31	1.64e-6	Height;
SARC	cis	rs6831352	0.819	rs1230158	chr4:99990186	T/C	cg13256891	chr4:100009986	ADH5	0.62	8.47	0.49	2.82e-15	Alcohol dependence;
SARC	cis	rs7819412	0.765	rs17783634	chr8:11054097	C/A	cg12395012	chr8:11607386	GATA4	0.3	5.08	0.32	7.91e-7	Triglycerides;
SARC	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg20607798	chr8:58055168	NA	0.6	5.39	0.33	1.74e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9810089	0.900	rs11915629	chr3:136139730	C/G	cg15507776	chr3:136538369	TMEM22	0.44	4.94	0.31	1.47e-6	Gestational age at birth (child effect);
SARC	cis	rs6690583	0.623	rs1371143	chr1:85455532	C/T	cg22153463	chr1:85462885	MCOLN2	0.73	7.08	0.42	1.66e-11	Serum sulfate level;
SARC	cis	rs6570726	0.577	rs867056	chr6:145784805	A/C	cg05347473	chr6:146136440	FBXO30	-0.69	-9.37	-0.52	6.67e-18	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2933343	0.700	rs1683777	chr3:128624880	T/G	cg25356066	chr3:128598488	ACAD9	0.69	9.2	0.52	2.15e-17	IgG glycosylation;
SARC	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.03	12.36	0.63	2.47e-27	Platelet count;
SARC	cis	rs7614311	0.636	rs73117059	chr3:63916028	A/G	cg22134162	chr3:63841271	THOC7	-0.46	-4.91	-0.31	1.69e-6	Lung function (FVC);Lung function (FEV1);
SARC	cis	rs34779708	0.966	rs998658	chr10:35408654	A/G	cg03585969	chr10:35415529	CREM	0.4	5.08	0.32	7.56e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs4243830	0.850	rs10864612	chr1:6593830	C/G	cg04093404	chr1:6614507	TAS1R1;NOL9	0.56	4.91	0.31	1.75e-6	Body mass index;
SARC	cis	rs796364	0.616	rs6710393	chr2:200697246	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.58	4.83	0.3	2.45e-6	Schizophrenia;
SARC	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg25072359	chr17:41440525	NA	0.5	5.94	0.36	1.04e-8	Menopause (age at onset);
SARC	trans	rs7826238	0.594	rs2948285	chr8:8130538	A/T	cg16141378	chr3:129829833	LOC729375	-0.61	-7.61	-0.45	6.88e-13	Systolic blood pressure;
SARC	cis	rs7481584	0.886	rs4758621	chr11:3009640	C/T	cg05729581	chr11:3078854	CARS	-0.47	-5.87	-0.36	1.45e-8	Calcium levels;
SARC	cis	rs4901847	1.000	rs4901847	chr14:58559241	C/T	cg15908186	chr14:58618357	C14orf37	0.42	4.88	0.3	1.98e-6	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs5753618	0.509	rs4820951	chr22:31586248	G/A	cg07713946	chr22:31675144	LIMK2	-0.38	-5.29	-0.33	2.76e-7	Colorectal cancer;
SARC	cis	rs1707322	0.963	rs4508055	chr1:46257731	A/T	cg06784218	chr1:46089804	CCDC17	0.37	6.45	0.39	6.38e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1348850	0.632	rs1358328	chr2:178517532	G/A	cg23306229	chr2:178417860	TTC30B	0.47	5.26	0.33	3.27e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1008375	0.966	rs3775923	chr4:17585625	T/C	cg27347728	chr4:17578864	LAP3	0.53	6.47	0.39	5.62e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs35110281	0.805	rs2838319	chr21:44991901	A/G	cg21573476	chr21:45109991	RRP1B	-0.47	-6.85	-0.41	6.49e-11	Mean corpuscular volume;
SARC	cis	rs7595412	1.000	rs1456566	chr2:199085020	C/T	cg00208931	chr2:198669586	PLCL1	-0.66	-5.84	-0.36	1.75e-8	Hip bone size;
SARC	cis	rs8044995	0.501	rs73613999	chr16:68390099	C/A	cg05110241	chr16:68378359	PRMT7	-0.65	-6.31	-0.38	1.42e-9	Schizophrenia;
SARC	cis	rs208520	0.661	rs704519	chr6:66801136	T/C	cg07460842	chr6:66804631	NA	-1.08	-14.91	-0.7	9.19e-36	Exhaled nitric oxide output;
SARC	cis	rs6060987	1	rs6060987	chr20:30427077	T/A	cg13852791	chr20:30311386	BCL2L1	0.85	9.16	0.51	2.77e-17	Mean corpuscular volume;
SARC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg03647317	chr4:187891568	NA	-0.35	-5.03	-0.31	1e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9650657	0.585	rs4841401	chr8:10489592	C/G	cg27411982	chr8:10470053	RP1L1	-0.31	-4.96	-0.31	1.36e-6	Neuroticism;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg10938836	chr2:166810420	TTC21B	0.55	6.51	0.39	4.66e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs1153858	1.000	rs7494956	chr15:45668565	T/C	cg21132104	chr15:45694354	SPATA5L1	0.78	11.01	0.59	5.55e-23	Homoarginine levels;
SARC	cis	rs908922	0.676	rs945788	chr1:152512762	A/G	cg09873164	chr1:152488093	CRCT1	0.61	7.89	0.46	1.14e-13	Hair morphology;
SARC	cis	rs4727027	0.899	rs4727025	chr7:148862863	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	5.63	0.35	5.08e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs7412746	0.611	rs10888398	chr1:150886782	A/G	cg15448220	chr1:150897856	SETDB1	-0.52	-6.91	-0.41	4.46e-11	Melanoma;
SARC	cis	rs7635838	0.596	rs4684765	chr3:11261085	G/C	cg00170343	chr3:11313890	ATG7	0.66	8.68	0.49	6.94e-16	HDL cholesterol;
SARC	cis	rs7250872	0.606	rs12985022	chr19:1825401	A/G	cg05970437	chr19:1864622	KLF16	0.52	5.5	0.34	1e-7	Bipolar disorder;
SARC	cis	rs9807989	0.507	rs1833174	chr2:103034843	T/A	cg03938978	chr2:103052716	IL18RAP	0.32	5.12	0.32	6.49e-7	Asthma;
SARC	cis	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg24110177	chr3:50126178	RBM5	-0.39	-5.04	-0.31	9.46e-7	Intelligence (multi-trait analysis);
SARC	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg15921436	chr17:44337874	NA	0.48	4.9	0.31	1.82e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs2479724	1.000	rs2254479	chr6:41831143	G/A	cg17623882	chr6:41773611	USP49	-0.48	-6.3	-0.38	1.45e-9	Menarche (age at onset);
SARC	cis	rs9290065	0.519	rs7635796	chr3:160674689	G/C	cg17135325	chr3:160939158	NMD3	0.41	4.97	0.31	1.28e-6	Kawasaki disease;
SARC	cis	rs6570726	0.791	rs621382	chr6:145799144	T/C	cg23711669	chr6:146136114	FBXO30	0.86	14.23	0.68	1.69e-33	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs35306767	0.903	rs11253492	chr10:936873	T/C	cg26597838	chr10:835615	NA	0.77	7.87	0.46	1.37e-13	Eosinophil percentage of granulocytes;
SARC	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg14298792	chr15:30685198	CHRFAM7A	0.45	4.85	0.3	2.3e-6	Huntington's disease progression;
SARC	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	12.51	0.63	8.48e-28	Chronic sinus infection;
SARC	cis	rs9858542	1.000	rs9836291	chr3:49697459	G/A	cg07274523	chr3:49395745	GPX1	0.49	5.5	0.34	9.9e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs12594515	1.000	rs8038058	chr15:45990272	C/T	cg14863074	chr15:45997064	NA	0.34	5.24	0.32	3.57e-7	Waist circumference;Weight;
SARC	cis	rs11792861	0.591	rs2275641	chr9:111696389	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.8	10.36	0.56	6.25e-21	Menarche (age at onset);
SARC	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg11062466	chr8:58055876	NA	0.52	5.32	0.33	2.43e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs4619890	0.528	rs62289336	chr4:7877661	T/C	cg18538662	chr4:7941764	AFAP1	-0.42	-5.42	-0.33	1.47e-7	Glaucoma (primary open-angle);
SARC	cis	rs6539267	0.923	rs4964175	chr12:106753984	A/G	cg00173435	chr12:106696525	TCP11L2	-0.52	-5.07	-0.32	8.05e-7	Tourette syndrome;
SARC	cis	rs854765	0.583	rs9904163	chr17:17830553	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	9.75	0.54	4.62e-19	Total body bone mineral density;
SARC	trans	rs12310956	0.532	rs11052935	chr12:33970946	C/T	cg26384229	chr12:38710491	ALG10B	0.75	10.53	0.57	1.89e-21	Morning vs. evening chronotype;
SARC	trans	rs7815944	1.000	rs75689778	chr8:129431182	T/A	cg17342469	chr22:46473074	NA	0.71	6.72	0.4	1.36e-10	Atopic dermatitis;
SARC	cis	rs2652822	0.555	rs77171305	chr15:63536230	C/A	cg02713581	chr15:63449717	RPS27L	0.54	6.59	0.4	2.92e-10	Metabolic traits;
SARC	cis	rs8180040	0.966	rs11130128	chr3:47486632	T/C	cg27129171	chr3:47204927	SETD2	-0.68	-9.57	-0.53	1.62e-18	Colorectal cancer;
SARC	cis	rs11583043	0.918	rs11581062	chr1:101407519	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.49	-5.87	-0.36	1.49e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg08677398	chr8:58056175	NA	0.48	4.78	0.3	3.07e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg19729930	chr2:74357872	NA	0.73	10.68	0.57	6.03e-22	Gestational age at birth (maternal effect);
SARC	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	9.89	0.54	1.77e-19	Alzheimer's disease;
SARC	cis	rs2282802	0.685	rs6893253	chr5:139661279	T/C	cg26211634	chr5:139558579	C5orf32	0.37	4.81	0.3	2.75e-6	Intelligence (multi-trait analysis);
SARC	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.6	-6.31	-0.38	1.42e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs2836974	0.897	rs2776308	chr21:40715175	A/G	cg27266027	chr21:40555129	PSMG1	0.45	4.87	0.3	2.06e-6	Cognitive function;
SARC	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg00933542	chr6:150070202	PCMT1	0.33	5.63	0.35	5.13e-8	Lung cancer;
SARC	cis	rs17376456	0.825	rs13161885	chr5:93071242	A/C	cg25358565	chr5:93447407	FAM172A	1.18	12.07	0.62	2.21e-26	Diabetic retinopathy;
SARC	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg11062466	chr8:58055876	NA	0.61	5.64	0.35	5.01e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs57561814	1.000	rs57561814	chr7:22753675	G/C	cg26061582	chr7:22766209	IL6	1.07	8.12	0.47	2.69e-14	Tonsillectomy;
SARC	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg20891558	chr2:74357851	NA	0.71	9.66	0.53	8.55e-19	Gestational age at birth (maternal effect);
SARC	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg05025164	chr4:1340916	KIAA1530	0.84	11.13	0.59	2.44e-23	Longevity;
SARC	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg06636001	chr8:8085503	FLJ10661	0.76	11.08	0.59	3.29e-23	Systolic blood pressure;
SARC	cis	rs763121	0.853	rs5757208	chr22:39049230	A/C	cg06022373	chr22:39101656	GTPBP1	0.9	11.56	0.6	9.96e-25	Menopause (age at onset);
SARC	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg23262073	chr20:60523788	NA	-0.48	-7.01	-0.42	2.5e-11	Body mass index;
SARC	cis	rs35110281	0.776	rs229357	chr21:44982717	T/C	cg01579765	chr21:45077557	HSF2BP	-0.35	-5.88	-0.36	1.42e-8	Mean corpuscular volume;
SARC	cis	rs1030877	0.515	rs1020064	chr2:105897740	T/G	cg02079111	chr2:105885981	TGFBRAP1	0.55	6.38	0.39	9.7e-10	Obesity-related traits;
SARC	cis	rs7020830	0.830	rs308499	chr9:37348059	C/G	cg14294708	chr9:37120828	ZCCHC7	1.09	19.13	0.78	1.15e-49	Schizophrenia;
SARC	cis	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg08975724	chr8:8085496	FLJ10661	0.45	5.5	0.34	1.02e-7	Mood instability;
SARC	cis	rs861020	0.771	rs654470	chr1:210014093	A/T	cg23166289	chr1:210001082	C1orf107	0.54	5.71	0.35	3.38e-8	Orofacial clefts;
SARC	cis	rs2014572	0.870	rs10426580	chr19:57756221	G/A	cg24459738	chr19:57751996	ZNF805	-0.47	-5.58	-0.34	6.62e-8	Hyperactive-impulsive symptoms;
SARC	cis	rs9815354	1.000	rs9828398	chr3:41895893	C/T	cg03022575	chr3:42003672	ULK4	0.56	5.29	0.33	2.81e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9916302	0.861	rs4795376	chr17:37669043	T/C	cg07936489	chr17:37558343	FBXL20	-0.65	-8.39	-0.48	4.58e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg23758822	chr17:41437982	NA	-0.85	-10.88	-0.58	1.49e-22	Menopause (age at onset);
SARC	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg02524346	chr8:600233	NA	0.91	7.09	0.42	1.61e-11	IgG glycosylation;
SARC	cis	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg18252515	chr7:66147081	NA	-1.3	-11.63	-0.61	5.98e-25	Diabetic kidney disease;
SARC	cis	rs9457247	0.765	rs6900701	chr6:167434112	A/G	cg23791538	chr6:167370224	RNASET2	-0.51	-6.81	-0.41	8.44e-11	Crohn's disease;
SARC	cis	rs6963495	0.818	rs73190161	chr7:105156871	C/T	cg19920283	chr7:105172520	RINT1	0.65	5.48	0.34	1.09e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs1008375	0.966	rs6449330	chr4:17703949	C/T	cg16339924	chr4:17578868	LAP3	-0.54	-7.0	-0.42	2.73e-11	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs929354	0.742	rs2006844	chr7:157002851	G/A	cg05182265	chr7:156933206	UBE3C	-0.31	-4.84	-0.3	2.41e-6	Body mass index;
SARC	cis	rs2204008	0.543	rs2387018	chr12:38065638	C/T	cg13010199	chr12:38710504	ALG10B	0.77	10.72	0.57	4.51e-22	Bladder cancer;
SARC	cis	rs12950390	0.853	rs17700008	chr17:45863591	A/C	cg03474202	chr17:45855739	NA	0.41	6.31	0.38	1.37e-9	IgG glycosylation;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08602515	chr10:105727423	SLK	-0.51	-6.56	-0.39	3.54e-10	Smoking initiation;
SARC	cis	rs7592578	0.766	rs62182865	chr2:191434180	T/C	cg10560079	chr2:191398806	TMEM194B	-0.83	-9.25	-0.52	1.51e-17	Diastolic blood pressure;
SARC	cis	rs6991838	0.584	rs1053087	chr8:66515865	A/G	cg13398993	chr8:66546079	ARMC1	-0.62	-8.31	-0.48	7.95e-15	Intelligence (multi-trait analysis);
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg07496861	chr2:208489667	FAM119A	0.51	6.52	0.39	4.3e-10	Lung adenocarcinoma;
SARC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg15242686	chr22:24348715	GSTTP1	0.45	5.44	0.34	1.34e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	trans	rs9388451	0.626	rs1268074	chr6:126107791	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.57	-7.4	-0.44	2.45e-12	Brugada syndrome;
SARC	cis	rs12922317	0.538	rs446289	chr16:12070486	T/G	cg09319797	chr16:12061715	TNFRSF17	-0.37	-6.04	-0.37	5.99e-9	Schizophrenia;
SARC	cis	rs9911578	0.900	rs4793593	chr17:56892699	C/G	cg12560992	chr17:57184187	TRIM37	-0.86	-11.96	-0.62	4.97e-26	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg11062466	chr8:58055876	NA	0.54	5.56	0.34	7.55e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg24675658	chr1:53192096	ZYG11B	0.57	7.9	0.46	1.09e-13	Monocyte count;
SARC	cis	rs3733589	1.000	rs34644460	chr4:10017639	G/A	cg16430538	chr4:10459836	ZNF518B	0.64	4.89	0.3	1.92e-6	Renal overload gout;
SARC	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	9.56	0.53	1.74e-18	Platelet count;
SARC	cis	rs7296418	0.518	rs28825193	chr12:123878262	T/C	cg00376283	chr12:123451042	ABCB9	0.57	6.9	0.41	4.75e-11	Platelet count;
SARC	cis	rs7552404	0.727	rs6683437	chr1:76316619	G/A	cg03433033	chr1:76189801	ACADM	0.49	6.09	0.37	4.69e-9	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs11155671	0.530	rs6933882	chr6:150210802	A/G	cg00933542	chr6:150070202	PCMT1	0.29	4.81	0.3	2.77e-6	Testicular germ cell tumor;
SARC	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	5.45	0.34	1.3e-7	Bipolar disorder;
SARC	trans	rs1994135	0.669	rs11052747	chr12:33697913	C/G	cg26384229	chr12:38710491	ALG10B	0.7	8.51	0.49	2.2e-15	Resting heart rate;
SARC	cis	rs7223966	0.921	rs67018565	chr17:61928055	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.49	-5.0	-0.31	1.14e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg17294928	chr15:75287854	SCAMP5	0.49	6.23	0.38	2.15e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	trans	rs9354308	0.933	rs10455586	chr6:66571498	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.58	6.82	0.41	7.77e-11	Metabolite levels;
SARC	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg16325326	chr1:53192061	ZYG11B	0.71	10.34	0.56	6.95e-21	Monocyte count;
SARC	cis	rs7246657	0.943	rs1373991	chr19:37838911	T/C	cg14683738	chr19:37701593	ZNF585B	0.51	4.99	0.31	1.16e-6	Coronary artery calcification;
SARC	cis	rs9911578	0.757	rs4793954	chr17:56629527	G/T	cg12560992	chr17:57184187	TRIM37	-0.68	-7.73	-0.45	3.12e-13	Intelligence (multi-trait analysis);
SARC	cis	rs28374715	0.733	rs9568	chr15:41573612	G/T	cg18705301	chr15:41695430	NDUFAF1	-1.09	-17.13	-0.75	3.93e-43	Ulcerative colitis;
SARC	cis	rs112591243	0.685	rs117450955	chr21:47990916	T/A	cg26904215	chr21:47823096	PCNT	-0.75	-4.78	-0.3	3.05e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs9796	0.866	rs66818965	chr15:41402279	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.43	-5.88	-0.36	1.4e-8	Menopause (age at onset);
SARC	cis	rs6570726	0.967	rs9403707	chr6:145800010	A/G	cg23711669	chr6:146136114	FBXO30	0.74	11.13	0.59	2.3e-23	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg23758822	chr17:41437982	NA	-0.86	-11.59	-0.6	8.01e-25	Menopause (age at onset);
SARC	cis	rs9912789	0.744	rs9893755	chr17:79187432	C/T	cg25342872	chr17:79175132	AZI1	0.45	6.35	0.38	1.13e-9	Frontotemporal dementia;
SARC	cis	rs208520	0.545	rs6899712	chr6:66749670	T/C	cg07460842	chr6:66804631	NA	1.05	18.53	0.77	9.94e-48	Exhaled nitric oxide output;
SARC	cis	rs2204008	0.811	rs4882300	chr12:38415224	A/T	cg26384229	chr12:38710491	ALG10B	-0.81	-11.71	-0.61	3.17e-25	Bladder cancer;
SARC	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg24829409	chr8:58192753	C8orf71	-0.59	-5.1	-0.32	7.19e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6120849	0.901	rs6060273	chr20:33744323	G/C	cg24642439	chr20:33292090	TP53INP2	0.5	4.97	0.31	1.32e-6	Protein C levels;
SARC	cis	rs2952156	0.834	rs903503	chr17:37829571	C/A	cg20243544	chr17:37824526	PNMT	0.55	7.17	0.43	1e-11	Asthma;
SARC	cis	rs763121	0.853	rs3747172	chr22:39067524	A/G	cg21395723	chr22:39101663	GTPBP1	0.54	6.14	0.37	3.53e-9	Menopause (age at onset);
SARC	cis	rs10493773	0.609	rs11161660	chr1:86184066	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.6	-9.73	-0.54	5.42e-19	Urate levels in overweight individuals;
SARC	cis	rs920590	0.796	rs10788700	chr8:19635098	T/C	cg01411142	chr8:19674711	INTS10	0.41	4.75	0.3	3.61e-6	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs6500395	1.000	rs7197732	chr16:48575878	G/A	cg04672837	chr16:48644449	N4BP1	0.42	5.47	0.34	1.13e-7	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs12545109	0.917	rs10098993	chr8:57323116	T/C	cg19413350	chr8:57351067	NA	-0.43	-4.96	-0.31	1.36e-6	Obesity-related traits;
SARC	cis	rs6088580	0.634	rs11700221	chr20:32940320	T/C	cg24642439	chr20:33292090	TP53INP2	-0.65	-8.43	-0.48	3.52e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs7726839	0.561	rs72703046	chr5:580129	T/C	cg09021430	chr5:549028	NA	-0.48	-6.35	-0.38	1.12e-9	Obesity-related traits;
SARC	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg17376030	chr22:41985996	PMM1	-0.73	-9.24	-0.52	1.56e-17	Vitiligo;
SARC	cis	rs9814567	1.000	rs7426847	chr3:134267519	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	7.08	0.42	1.73e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs3008870	1.000	rs2815348	chr1:67472165	G/C	cg08660285	chr1:67390436	MIER1;WDR78	0.91	11.08	0.59	3.49e-23	Lymphocyte percentage of white cells;
SARC	cis	rs9818758	0.607	rs55873331	chr3:49597055	C/T	cg07636037	chr3:49044803	WDR6	-0.8	-6.62	-0.4	2.41e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs9398803	0.713	rs1387916	chr6:126886731	G/C	cg19875578	chr6:126661172	C6orf173	0.63	8.71	0.5	5.59e-16	Male-pattern baldness;
SARC	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg06618935	chr21:46677482	NA	-0.41	-5.39	-0.33	1.75e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs11711311	1.000	rs2305546	chr3:113503354	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	8.41	0.48	4.12e-15	IgG glycosylation;
SARC	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg18965377	chr6:91006634	BACH2	-0.48	-6.28	-0.38	1.65e-9	Parental extreme longevity (95 years and older);
SARC	cis	rs9916302	0.706	rs9906612	chr17:37547631	A/C	cg00129232	chr17:37814104	STARD3	0.54	5.71	0.35	3.45e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs13418410	0.539	rs11695597	chr2:33840024	A/G	cg04131969	chr2:33951647	MYADML	0.6	8.59	0.49	1.3e-15	Non-response to antidepressants and depression;
SARC	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg12288994	chr5:1860383	NA	0.38	6.22	0.38	2.31e-9	Cardiovascular disease risk factors;
SARC	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.63	-7.53	-0.44	1.1e-12	Gut microbiome composition (summer);
SARC	cis	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg21775007	chr8:11205619	TDH	0.47	5.85	0.36	1.66e-8	Triglycerides;
SARC	cis	rs12579753	0.917	rs10862375	chr12:82254809	C/G	cg07988820	chr12:82153109	PPFIA2	0.54	6.35	0.38	1.1e-9	Resting heart rate;
SARC	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-5.45	-0.34	1.28e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs1801251	1.000	rs71421663	chr2:233619131	A/G	cg25237894	chr2:233734115	C2orf82	0.38	4.96	0.31	1.39e-6	Coronary artery disease;
SARC	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg22968622	chr17:43663579	NA	1.15	15.12	0.7	1.91e-36	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs6700896	0.931	rs2154382	chr1:66131681	C/T	cg04111102	chr1:66153794	NA	0.36	5.66	0.35	4.49e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs2251381	0.520	rs873651	chr21:30781848	G/A	cg24692254	chr21:30365293	RNF160	0.53	7.05	0.42	2.06e-11	Selective IgA deficiency;
SARC	cis	rs2228479	0.850	rs11641147	chr16:89813589	C/T	cg26513180	chr16:89883248	FANCA	0.72	4.75	0.3	3.53e-6	Skin colour saturation;
SARC	cis	rs9462027	0.628	rs9462026	chr6:34797033	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-6.1	-0.37	4.32e-9	Systemic lupus erythematosus;
SARC	cis	rs1044826	1.000	rs9812192	chr3:139177597	C/T	cg15131784	chr3:139108705	COPB2	0.45	5.2	0.32	4.36e-7	Obesity-related traits;
SARC	cis	rs79839061	0.610	rs2279182	chr4:882625	T/G	cg07828340	chr4:882639	GAK	0.78	6.45	0.39	6.41e-10	Intelligence (multi-trait analysis);
SARC	cis	rs67460515	0.892	rs4856757	chr3:160999418	A/T	cg04691961	chr3:161091175	C3orf57	-0.47	-5.79	-0.35	2.29e-8	Parkinson's disease;
SARC	cis	rs8067354	0.830	rs57510610	chr17:57889406	T/A	cg13753209	chr17:57696993	CLTC	0.53	6.63	0.4	2.3e-10	Hemoglobin concentration;
SARC	cis	rs72627509	0.904	rs56281640	chr4:57765816	G/A	cg26694713	chr4:57773883	REST	0.64	6.54	0.39	3.8e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg05623727	chr3:50126028	RBM5	0.33	4.89	0.31	1.89e-6	Body mass index;
SARC	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg11764359	chr7:65958608	NA	0.69	8.18	0.47	1.88e-14	Aortic root size;
SARC	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs13065560	0.659	rs6599266	chr3:38926912	C/G	cg26331595	chr3:39149181	GORASP1;TTC21A	0.41	4.91	0.31	1.71e-6	Interleukin-18 levels;
SARC	cis	rs7726839	0.555	rs4541696	chr5:581053	A/G	cg23206463	chr5:561769	NA	-0.44	-6.54	-0.39	3.79e-10	Obesity-related traits;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg07533159	chr6:126307930	TRMT11	-0.59	-6.81	-0.41	7.99e-11	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs2635047	0.904	rs2635046	chr18:44728429	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.51	6.85	0.41	6.42e-11	Educational attainment;
SARC	cis	rs1580019	0.844	rs4723159	chr7:32512804	T/C	cg07520158	chr7:32535189	LSM5;AVL9	0.44	5.14	0.32	5.75e-7	Cognitive ability;
SARC	cis	rs4443100	0.916	rs875602	chr22:23395684	C/T	cg14186256	chr22:23484241	RTDR1	0.44	4.72	0.3	4.15e-6	Serum parathyroid hormone levels;
SARC	cis	rs2295359	0.892	rs72676069	chr1:67658954	T/C	cg12940439	chr1:67600707	NA	0.45	6.43	0.39	6.96e-10	Psoriasis;
SARC	cis	rs4713118	0.824	rs9468225	chr6:27745719	T/G	cg17221315	chr6:27791827	HIST1H4J	0.49	5.37	0.33	1.94e-7	Parkinson's disease;
SARC	cis	rs7918232	0.941	rs7907988	chr10:27444344	T/G	cg14240646	chr10:27532245	ACBD5	-0.54	-4.92	-0.31	1.65e-6	Breast cancer;
SARC	cis	rs4273100	0.688	rs1467028	chr17:19174874	T/C	cg18906043	chr17:18967111	NA	0.45	4.86	0.3	2.17e-6	Schizophrenia;
SARC	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg27398817	chr8:82754497	SNX16	-0.44	-5.59	-0.34	6.25e-8	Diastolic blood pressure;
SARC	cis	rs12579753	1.000	rs12579753	chr12:82219376	C/T	cg07988820	chr12:82153109	PPFIA2	-0.56	-6.43	-0.39	7.13e-10	Resting heart rate;
SARC	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg04267008	chr7:1944627	MAD1L1	-0.64	-7.23	-0.43	6.92e-12	Bipolar disorder and schizophrenia;
SARC	cis	rs8141529	0.600	rs16986825	chr22:29300306	C/T	cg02153584	chr22:29168773	CCDC117	0.67	7.3	0.43	4.47e-12	Lymphocyte counts;
SARC	cis	rs7412746	0.634	rs3754212	chr1:150738200	A/G	cg15448220	chr1:150897856	SETDB1	0.47	6.04	0.37	5.89e-9	Melanoma;
SARC	cis	rs11792861	0.591	rs7027874	chr9:111717112	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.78	9.98	0.55	9.48e-20	Menarche (age at onset);
SARC	cis	rs7560272	0.501	rs12615807	chr2:73947583	T/C	cg20560298	chr2:73613845	ALMS1	0.44	5.83	0.36	1.82e-8	Schizophrenia;
SARC	cis	rs35306767	0.903	rs11253460	chr10:887382	C/G	cg26597838	chr10:835615	NA	0.81	8.34	0.48	6.54e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs7617773	0.817	rs936426	chr3:48215253	C/T	cg11946769	chr3:48343235	NME6	0.68	8.93	0.5	1.34e-16	Coronary artery disease;
SARC	cis	rs7178909	0.872	rs10852124	chr15:90430464	C/T	cg19708238	chr15:90437601	AP3S2	0.59	7.85	0.46	1.55e-13	Common traits (Other);
SARC	cis	rs3762637	1.000	rs10049131	chr3:122202102	A/T	cg24169773	chr3:122142474	KPNA1	-0.57	-5.85	-0.36	1.67e-8	LDL cholesterol levels;
SARC	cis	rs735539	0.521	rs2762996	chr13:21373908	A/C	cg16922012	chr13:21400325	XPO4	-0.45	-6.35	-0.38	1.1e-9	Dental caries;
SARC	cis	rs1348850	0.632	rs11682717	chr2:178499240	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.5	5.73	0.35	3.08e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2795502	1.000	rs2142991	chr10:43341105	C/T	cg20628663	chr10:43360327	NA	-0.47	-6.44	-0.39	6.64e-10	Blood protein levels;
SARC	cis	rs8028182	0.636	rs28737338	chr15:75768679	C/T	cg20655648	chr15:75932815	IMP3	0.63	7.6	0.45	7.38e-13	Sudden cardiac arrest;
SARC	cis	rs921968	0.613	rs1427445	chr2:219555573	C/A	cg02176678	chr2:219576539	TTLL4	-0.33	-4.81	-0.3	2.77e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs2197308	0.765	rs10880643	chr12:37926452	C/T	cg13010199	chr12:38710504	ALG10B	-0.68	-9.06	-0.51	5.6e-17	Morning vs. evening chronotype;
SARC	trans	rs61931739	0.500	rs7488438	chr12:34531359	G/T	cg26384229	chr12:38710491	ALG10B	0.91	13.54	0.66	3.41e-31	Morning vs. evening chronotype;
SARC	cis	rs17384381	1.000	rs17388521	chr1:85897904	A/G	cg16011679	chr1:85725395	C1orf52	-0.61	-5.73	-0.35	3.09e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1580019	0.885	rs3801331	chr7:32497039	A/G	cg14728415	chr7:32535168	LSM5;AVL9	-0.43	-5.13	-0.32	6.2e-7	Cognitive ability;
SARC	cis	rs2594989	0.837	rs7642031	chr3:11453754	G/A	cg00170343	chr3:11313890	ATG7	0.62	5.78	0.35	2.36e-8	Circulating chemerin levels;
SARC	cis	rs6502050	0.761	rs11653003	chr17:80058795	G/T	cg13939156	chr17:80058883	NA	0.42	6.69	0.4	1.61e-10	Life satisfaction;
SARC	cis	rs4742903	0.967	rs10991120	chr9:106909051	C/T	cg14250997	chr9:106856677	SMC2	0.47	6.1	0.37	4.35e-9	High-grade serous ovarian cancer;Breast cancer;
SARC	trans	rs6710503	0.574	rs17791703	chr2:24881271	A/G	cg15455721	chr1:42506607	NA	0.51	6.26	0.38	1.86e-9	Lung cancer in ever smokers;Breast cancer;
SARC	cis	rs7666738	0.515	rs11733968	chr4:98906448	A/C	cg05340658	chr4:99064831	C4orf37	-0.58	-7.22	-0.43	7.19e-12	Colonoscopy-negative controls vs population controls;
SARC	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg22903657	chr4:1355424	KIAA1530	-0.42	-5.65	-0.35	4.64e-8	Obesity-related traits;
SARC	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg11987759	chr7:65425863	GUSB	-0.48	-6.04	-0.37	5.99e-9	Aortic root size;
SARC	cis	rs778371	0.723	rs6704763	chr2:233592487	C/T	cg20388707	chr2:233749442	NGEF	-0.35	-5.24	-0.32	3.64e-7	Schizophrenia;
SARC	cis	rs796364	0.951	rs10931888	chr2:201022952	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.6	-5.56	-0.34	7.2e-8	Schizophrenia;
SARC	trans	rs7927370	1.000	rs35195107	chr11:55046715	T/A	cg07162727	chr16:4848039	ROGDI	0.8	6.25	0.38	1.98e-9	Systemic lupus erythematosus;
SARC	cis	rs6580649	0.882	rs59766465	chr12:48470169	G/A	cg24011408	chr12:48396354	COL2A1	-0.48	-5.36	-0.33	2.04e-7	Lung cancer;
SARC	cis	rs3771570	1.000	rs3771570	chr2:242382864	C/T	cg21155796	chr2:242212141	HDLBP	0.7	6.35	0.38	1.09e-9	Prostate cancer;
SARC	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg08219700	chr8:58056026	NA	0.58	5.65	0.35	4.7e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs35110281	0.807	rs6518301	chr21:45016818	T/C	cg21573476	chr21:45109991	RRP1B	-0.49	-7.35	-0.43	3.33e-12	Mean corpuscular volume;
SARC	cis	rs743757	1.000	rs2236957	chr3:50440426	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.55	5.12	0.32	6.26e-7	Diastolic blood pressure;
SARC	cis	rs1728785	0.748	rs889560	chr16:68605784	A/G	cg02972257	chr16:68554789	NA	-0.47	-5.56	-0.34	7.2e-8	Ulcerative colitis;
SARC	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg13395646	chr4:1353034	KIAA1530	-0.45	-5.33	-0.33	2.29e-7	Obesity-related traits;
SARC	cis	rs67460515	0.892	rs7610985	chr3:161062848	G/A	cg17135325	chr3:160939158	NMD3	0.62	7.87	0.46	1.34e-13	Parkinson's disease;
SARC	cis	rs637571	0.528	rs11602769	chr11:65594139	T/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.48	-6.26	-0.38	1.84e-9	Eosinophil percentage of white cells;
SARC	cis	rs9398803	0.865	rs9388495	chr6:126782457	G/A	cg20229609	chr6:126660872	C6orf173	0.38	5.48	0.34	1.11e-7	Male-pattern baldness;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg23766305	chr17:27507501	MYO18A	0.49	6.35	0.38	1.13e-9	Tetralogy of Fallot;
SARC	cis	rs2204008	0.775	rs11182513	chr12:38560252	G/C	cg13010199	chr12:38710504	ALG10B	0.78	10.8	0.58	2.71e-22	Bladder cancer;
SARC	cis	rs365132	0.875	rs187114	chr5:176364039	A/G	cg16309518	chr5:176445507	NA	-0.49	-6.25	-0.38	1.97e-9	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs9916302	0.610	rs11078902	chr17:37631883	C/G	cg07936489	chr17:37558343	FBXL20	-0.7	-8.99	-0.51	8.51e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs7932354	0.528	rs7108902	chr11:47091571	C/T	cg03339077	chr11:47165057	C11orf49	-0.39	-5.23	-0.32	3.76e-7	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg08067268	chr2:26466485	HADHB;HADHA	0.46	5.77	0.35	2.54e-8	Gut microbiome composition (summer);
SARC	cis	rs11711311	0.712	rs11718013	chr3:113341661	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	7.29	0.43	4.74e-12	IgG glycosylation;
SARC	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	5.93	0.36	1.07e-8	Bipolar disorder;
SARC	cis	rs16854884	0.657	rs1025984	chr3:143756187	C/G	cg06585982	chr3:143692056	C3orf58	-0.67	-9.08	-0.51	4.64e-17	Economic and political preferences (feminism/equality);
SARC	cis	rs9325144	0.647	rs7980932	chr12:38921583	G/T	cg26384229	chr12:38710491	ALG10B	-0.57	-7.32	-0.43	3.89e-12	Morning vs. evening chronotype;
SARC	cis	rs6582630	0.615	rs3914894	chr12:38480280	C/T	cg14851346	chr12:38532713	NA	-0.48	-5.94	-0.36	1.04e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs3820928	1.000	rs7561378	chr2:227772248	T/C	cg05526886	chr2:227700861	RHBDD1	-0.5	-6.11	-0.37	4.08e-9	Pulmonary function;
SARC	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg09323728	chr8:95962352	TP53INP1	-0.31	-5.15	-0.32	5.42e-7	Type 2 diabetes;
SARC	cis	rs11625487	0.505	rs12887556	chr14:77966473	C/G	cg16049707	chr14:77965284	ISM2	0.43	5.87	0.36	1.52e-8	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
SARC	cis	rs79349575	0.749	rs12601672	chr17:47006493	T/C	cg16584676	chr17:46985605	UBE2Z	0.54	6.46	0.39	6.2e-10	Type 2 diabetes;
SARC	cis	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg18252515	chr7:66147081	NA	-1.43	-12.98	-0.65	2.35e-29	Gout;
SARC	cis	rs7089973	0.604	rs7897937	chr10:116591318	A/G	cg08188268	chr10:116634841	FAM160B1	0.28	4.77	0.3	3.18e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs870825	0.616	rs28490461	chr4:185651638	C/T	cg04058563	chr4:185651563	MLF1IP	0.8	11.37	0.6	3.9e-24	Blood protein levels;
SARC	cis	rs17209837	1.000	rs60123540	chr7:87085182	T/C	cg00919237	chr7:87102261	ABCB4	-0.5	-5.47	-0.34	1.14e-7	Gallbladder cancer;
SARC	cis	rs509477	0.718	rs273344	chr18:32603927	C/T	cg23791764	chr18:32556832	MAPRE2	0.42	5.15	0.32	5.43e-7	Cerebrospinal fluid AB1-42 levels;
SARC	cis	rs6121246	0.909	rs1994250	chr20:30287494	A/G	cg13852791	chr20:30311386	BCL2L1	0.86	9.16	0.51	2.76e-17	Mean corpuscular hemoglobin;
SARC	cis	rs3922844	1.000	rs3922844	chr3:38624253	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.42	4.9	0.31	1.76e-6	P wave duration;PR interval;QT interval;QRS duration;
SARC	cis	rs7953249	0.656	rs2178463	chr12:121389721	A/G	cg15155738	chr12:121454335	C12orf43	-0.44	-5.41	-0.33	1.57e-7	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs617791	0.508	rs10896074	chr11:65776304	C/T	cg26695010	chr11:65641043	EFEMP2	0.57	6.97	0.42	3.19e-11	Breast cancer;
SARC	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.63e-10	Life satisfaction;
SARC	cis	rs644799	0.648	rs1016031	chr11:95473365	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	-0.47	-5.64	-0.35	4.88e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs981844	0.816	rs62325148	chr4:154727993	A/G	cg14289246	chr4:154710475	SFRP2	0.58	6.37	0.39	9.77e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs2921073	0.605	rs2976933	chr8:8254875	A/G	cg08975724	chr8:8085496	FLJ10661	0.51	5.72	0.35	3.18e-8	Parkinson's disease;
SARC	trans	rs9329221	0.621	rs522483	chr8:9812969	C/G	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.64	-0.4	2.15e-10	Neuroticism;
SARC	cis	rs2916247	0.908	rs2958718	chr8:93180160	C/T	cg10183463	chr8:93005414	RUNX1T1	0.49	5.11	0.32	6.82e-7	Intelligence (multi-trait analysis);
SARC	cis	rs12464559	0.522	rs4316939	chr2:152525120	C/T	cg01189475	chr2:152685088	ARL5A	-0.61	-5.0	-0.31	1.13e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg19223190	chr17:80058835	NA	-0.42	-5.73	-0.35	3.09e-8	Life satisfaction;
SARC	cis	rs4481887	0.927	rs6671702	chr1:248482851	G/A	cg00666640	chr1:248458726	OR2T12	0.35	5.73	0.35	3.07e-8	Common traits (Other);
SARC	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg11890956	chr21:40555474	PSMG1	-0.71	-9.47	-0.53	3.27e-18	Menarche (age at onset);
SARC	trans	rs66573146	0.572	rs73199995	chr4:6955801	G/C	cg07817883	chr1:32538562	TMEM39B	1.06	8.24	0.48	1.27e-14	Granulocyte percentage of myeloid white cells;
SARC	trans	rs8073060	0.586	rs9303690	chr17:34005513	C/T	cg19694781	chr19:47549865	TMEM160	-0.71	-7.22	-0.43	7.3e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs1008375	1.000	rs55939327	chr4:17642937	T/A	cg27347728	chr4:17578864	LAP3	0.47	5.91	0.36	1.22e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs888194	0.966	rs6606725	chr12:109905368	C/A	cg08884029	chr12:110012500	MVK;MMAB	-0.33	-5.03	-0.31	9.99e-7	Neuroticism;
SARC	cis	rs6570726	0.755	rs2092296	chr6:145893684	A/C	cg23711669	chr6:146136114	FBXO30	0.84	13.98	0.68	1.14e-32	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1468333	0.667	rs35635987	chr5:137690876	A/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.72	8.23	0.47	1.29e-14	Resting heart rate;
SARC	cis	rs7607369	0.680	rs533760	chr2:219381405	T/C	cg02176678	chr2:219576539	TTLL4	0.47	7.26	0.43	5.63e-12	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg06873352	chr17:61820015	STRADA	0.53	6.91	0.41	4.63e-11	Prudent dietary pattern;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg12307764	chr15:40861449	RPUSD2	0.5	6.38	0.39	9.3e-10	Electrocardiographic conduction measures;
SARC	cis	rs7584330	0.868	rs13386290	chr2:238393136	G/C	cg11271282	chr2:238384023	NA	0.46	5.26	0.33	3.31e-7	Prostate cancer;
SARC	trans	rs6894249	1.000	rs6894249	chr5:131797547	A/G	cg12891178	chr10:135085127	ADAM8	-0.36	-6.23	-0.38	2.15e-9	Asthma;
SARC	cis	rs11648796	0.757	rs66649828	chr16:766078	A/G	cg27144592	chr16:783916	NARFL	0.46	6.81	0.41	8.01e-11	Height;
SARC	cis	rs1318878	0.915	rs11056455	chr12:15543744	T/C	cg08258403	chr12:15378311	NA	0.46	6.18	0.38	2.86e-9	Intelligence (multi-trait analysis);
SARC	trans	rs2243123	0.602	rs2133310	chr3:159716352	A/G	cg08246527	chr1:150336743	RPRD2	0.51	6.37	0.39	9.98e-10	Multiple sclerosis;
SARC	cis	rs7712401	0.562	rs30073	chr5:122290509	A/T	cg19412675	chr5:122181750	SNX24	0.4	5.13	0.32	5.98e-7	Mean platelet volume;
SARC	trans	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg21659725	chr3:3221576	CRBN	-0.78	-11.73	-0.61	2.87e-25	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg20607798	chr8:58055168	NA	0.71	5.79	0.35	2.29e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg24642844	chr7:1081250	C7orf50	-0.58	-6.03	-0.37	6.26e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs8072100	0.840	rs12453233	chr17:45454570	C/T	cg08085267	chr17:45401833	C17orf57	-0.41	-4.86	-0.3	2.17e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs1113500	0.702	rs11185262	chr1:108639742	C/T	cg06207961	chr1:108661230	NA	0.44	5.92	0.36	1.13e-8	Growth-regulated protein alpha levels;
SARC	cis	rs7216064	1.000	rs2365764	chr17:65857714	G/A	cg12091567	chr17:66097778	LOC651250	-0.64	-6.45	-0.39	6.56e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs1008375	0.898	rs4698620	chr4:17587361	C/T	cg16339924	chr4:17578868	LAP3	0.69	9.17	0.51	2.59e-17	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7918232	0.825	rs4749233	chr10:27467967	G/A	cg14240646	chr10:27532245	ACBD5	-0.56	-5.25	-0.33	3.48e-7	Breast cancer;
SARC	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg09165964	chr15:75287851	SCAMP5	0.5	6.62	0.4	2.4e-10	Breast cancer;
SARC	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg11644478	chr21:40555479	PSMG1	1.05	15.2	0.71	1e-36	Cognitive function;
SARC	cis	rs2921036	0.503	rs7817832	chr8:8380821	T/C	cg06636001	chr8:8085503	FLJ10661	0.53	5.91	0.36	1.21e-8	Neuroticism;
SARC	cis	rs35213789	0.708	rs7793984	chr7:69210523	C/T	cg10619644	chr7:69149951	AUTS2	-0.4	-5.54	-0.34	8.09e-8	Childhood ear infection;
SARC	cis	rs7659604	0.689	rs4283687	chr4:122663460	A/G	cg20573242	chr4:122745356	CCNA2	0.4	4.97	0.31	1.27e-6	Type 2 diabetes;
SARC	cis	rs3768617	0.510	rs3768621	chr1:183090057	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.1	0.55	4.11e-20	Fuchs's corneal dystrophy;
SARC	cis	rs9911578	0.933	rs74370218	chr17:57095212	C/T	cg05425664	chr17:57184151	TRIM37	0.64	8.01	0.46	5.41e-14	Intelligence (multi-trait analysis);
SARC	cis	rs7520050	0.966	rs785488	chr1:46576095	G/A	cg06784218	chr1:46089804	CCDC17	-0.26	-4.82	-0.3	2.56e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs2952156	0.684	rs931992	chr17:37821435	G/T	cg07936489	chr17:37558343	FBXL20	-0.42	-5.36	-0.33	2.03e-7	Asthma;
SARC	cis	rs9309473	0.607	rs7567343	chr2:73596605	C/A	cg20560298	chr2:73613845	ALMS1	-0.57	-7.22	-0.43	7.38e-12	Metabolite levels;
SARC	cis	rs7666738	0.830	rs4492007	chr4:98959848	A/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.42	-5.13	-0.32	6e-7	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs1865760	0.566	rs9366634	chr6:26072396	C/G	cg17691542	chr6:26056736	HIST1H1C	0.52	6.48	0.39	5.29e-10	Height;
SARC	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg26116260	chr4:7069785	GRPEL1	0.93	11.58	0.6	8.69e-25	Monocyte percentage of white cells;
SARC	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg18252515	chr7:66147081	NA	-1.3	-11.5	-0.6	1.59e-24	Diabetic kidney disease;
SARC	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg18305652	chr10:134549665	INPP5A	0.36	5.2	0.32	4.38e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs995000	0.931	rs11207990	chr1:63041086	T/C	cg06896770	chr1:63153194	DOCK7	-0.9	-13.26	-0.66	2.87e-30	Triglyceride levels;
SARC	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg07636037	chr3:49044803	WDR6	-0.88	-14.04	-0.68	7.62e-33	Menarche (age at onset);
SARC	cis	rs12995491	1.000	rs12995491	chr2:88527414	C/T	cg04511125	chr2:88470314	THNSL2	0.37	5.54	0.34	8.28e-8	Response to metformin (IC50);
SARC	cis	rs11155671	0.530	rs9397398	chr6:150193603	G/A	cg09699651	chr6:150184138	LRP11	0.54	6.59	0.4	2.88e-10	Testicular germ cell tumor;
SARC	cis	rs17376456	0.825	rs13171131	chr5:93223028	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.42	0.33	1.49e-7	Diabetic retinopathy;
SARC	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg24060327	chr5:131705240	SLC22A5	0.74	8.74	0.5	4.83e-16	Blood metabolite levels;
SARC	cis	rs35110281	0.693	rs2251253	chr21:45092257	T/A	cg01579765	chr21:45077557	HSF2BP	-0.33	-5.31	-0.33	2.5e-7	Mean corpuscular volume;
SARC	cis	rs67460515	0.892	rs11718905	chr3:161051793	G/A	cg17135325	chr3:160939158	NMD3	0.61	7.71	0.45	3.72e-13	Parkinson's disease;
SARC	cis	rs1550582	1.000	rs7822348	chr8:135542483	C/G	cg17885191	chr8:135476712	NA	0.49	5.26	0.33	3.29e-7	Educational attainment;
SARC	cis	rs13191362	0.935	rs13219926	chr6:163004213	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.57	5.38	0.33	1.85e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs13144136	0.748	rs11933682	chr4:10670911	C/G	cg10242279	chr4:10666415	CLNK	0.33	5.27	0.33	3.14e-7	Resistance to antihypertensive treatment in hypertension;
SARC	cis	rs3106136	0.967	rs17310266	chr4:95177051	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.4	-6.15	-0.37	3.41e-9	Capecitabine sensitivity;
SARC	trans	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg05660315	chr16:30543920	ZNF747	-0.47	-6.6	-0.4	2.75e-10	Immature fraction of reticulocytes;
SARC	cis	rs1023500	0.573	rs133380	chr22:42468910	C/T	cg04733989	chr22:42467013	NAGA	0.62	8.11	0.47	2.81e-14	Schizophrenia;
SARC	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.4	-5.01	-0.31	1.1e-6	Lymphocyte counts;
SARC	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg15448220	chr1:150897856	SETDB1	0.47	6.25	0.38	1.94e-9	Tonsillectomy;
SARC	cis	rs501120	0.929	rs528668	chr10:44762584	G/A	cg09554077	chr10:44749378	NA	0.48	6.45	0.39	6.48e-10	Coronary artery disease;Coronary heart disease;
SARC	trans	rs208520	0.909	rs58958359	chr6:67021381	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.82	8.32	0.48	7.56e-15	Exhaled nitric oxide output;
SARC	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg18404041	chr3:52824283	ITIH1	-0.39	-5.27	-0.33	3.18e-7	Bipolar disorder;
SARC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.42	-6.42	-0.39	7.6e-10	Total body bone mineral density;
SARC	cis	rs2228479	0.850	rs117285117	chr16:89910250	T/G	cg12064134	chr16:90016061	DEF8	-0.56	-4.81	-0.3	2.77e-6	Skin colour saturation;
SARC	cis	rs7949030	1.000	rs7949030	chr11:62394881	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.42	6.21	0.38	2.47e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs524281	0.684	rs7946447	chr11:65864338	T/C	cg14036092	chr11:66035641	RAB1B	-0.52	-5.46	-0.34	1.2e-7	Electroencephalogram traits;
SARC	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-5.63	-0.35	5.04e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs7777484	0.517	rs2644306	chr7:2831602	A/G	cg19717773	chr7:2847554	GNA12	-0.36	-4.73	-0.3	3.82e-6	Height;
SARC	cis	rs9325144	0.600	rs1817648	chr12:38733424	C/T	cg13010199	chr12:38710504	ALG10B	-0.52	-6.7	-0.4	1.57e-10	Morning vs. evening chronotype;
SARC	cis	rs2997447	0.761	rs61776585	chr1:26438498	G/C	cg19633962	chr1:26362018	EXTL1	-0.57	-5.02	-0.31	1.01e-6	QRS complex (12-leadsum);
SARC	cis	rs4780401	0.678	rs7189287	chr16:11764608	A/G	cg01061890	chr16:11836724	TXNDC11	-0.47	-5.97	-0.36	8.62e-9	Rheumatoid arthritis;
SARC	cis	rs921968	0.613	rs1344642	chr2:219555262	G/A	cg02176678	chr2:219576539	TTLL4	-0.33	-4.97	-0.31	1.31e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs881375	0.967	rs2270231	chr9:123650982	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.43	5.22	0.32	4.01e-7	Rheumatoid arthritis;
SARC	cis	rs9660992	0.573	rs1318187	chr1:205206172	T/A	cg21545522	chr1:205238299	TMCC2	0.39	5.34	0.33	2.25e-7	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs1707322	0.655	rs3014240	chr1:46089225	C/G	cg06784218	chr1:46089804	CCDC17	-0.37	-6.56	-0.4	3.37e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg24675658	chr1:53192096	ZYG11B	0.73	11.16	0.59	1.89e-23	Monocyte count;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg26381918	chr2:99225517	C2orf64;UNC50	-0.49	-6.25	-0.38	1.93e-9	Schizophrenia;
SARC	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg14829360	chr17:73884958	NA	-0.6	-7.46	-0.44	1.67e-12	Psoriasis;
SARC	cis	rs6674970	0.627	rs2864700	chr1:151028929	C/T	cg11822372	chr1:151115635	SEMA6C	0.36	4.86	0.3	2.11e-6	Childhood ear infection;
SARC	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg16606324	chr3:10149918	C3orf24	0.48	5.04	0.31	9.53e-7	Alzheimer's disease;
SARC	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg18876405	chr7:65276391	NA	0.7	8.68	0.49	6.76e-16	Aortic root size;
SARC	cis	rs137699	1.000	rs137699	chr22:39748854	A/G	cg24399712	chr22:39784796	NA	-0.33	-4.75	-0.3	3.52e-6	IgG glycosylation;
SARC	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	5.96	0.36	9.28e-9	Tonsillectomy;
SARC	cis	rs113835537	0.597	rs2075792	chr11:66334556	G/A	cg24851651	chr11:66362959	CCS	0.41	5.28	0.33	2.93e-7	Airway imaging phenotypes;
SARC	cis	rs6484504	0.576	rs2150213	chr11:31244634	A/G	cg02090638	chr11:31391270	DNAJC24;DCDC1	-0.4	-5.01	-0.31	1.1e-6	Red blood cell count;
SARC	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.41	-6.88	-0.41	5.52e-11	Total body bone mineral density;
SARC	cis	rs372883	0.648	rs2832296	chr21:30741454	C/T	cg08807101	chr21:30365312	RNF160	-0.53	-6.69	-0.4	1.65e-10	Pancreatic cancer;
SARC	cis	rs9943753	0.508	rs7138357	chr12:109832303	A/G	cg19025524	chr12:109796872	NA	-0.39	-5.78	-0.35	2.39e-8	HDL cholesterol;
SARC	cis	rs17376456	1.000	rs12188453	chr5:93560807	G/T	cg25358565	chr5:93447407	FAM172A	-1.3	-14.37	-0.69	5.97e-34	Diabetic retinopathy;
SARC	cis	rs15676	0.783	rs2997917	chr9:131586918	G/A	cg00228799	chr9:131580591	ENDOG	0.62	7.78	0.45	2.39e-13	Blood metabolite levels;
SARC	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.95	-10.36	-0.56	6.3e-21	Alzheimer's disease;
SARC	cis	rs9790314	0.502	rs34972965	chr3:160984296	G/A	cg17135325	chr3:160939158	NMD3	0.63	7.94	0.46	8.51e-14	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg11062466	chr8:58055876	NA	0.55	5.4	0.33	1.65e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7914558	0.966	rs3758543	chr10:104944744	C/G	cg04362960	chr10:104952993	NT5C2	0.4	4.72	0.3	3.99e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.82	12.64	0.64	3.01e-28	Personality dimensions;
SARC	cis	rs10911251	0.527	rs1537520	chr1:183084229	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	9.74	0.54	4.92e-19	Colorectal cancer;
SARC	cis	rs6693567	0.545	rs2012751	chr1:150438266	T/C	cg09579323	chr1:150459698	TARS2	0.44	5.58	0.34	6.5e-8	Migraine;
SARC	cis	rs11190604	1.000	rs10883492	chr10:102206089	G/A	cg07080220	chr10:102295463	HIF1AN	0.78	9.58	0.53	1.56e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs12540874	0.663	rs1451371	chr7:50553051	T/C	cg18232548	chr7:50535776	DDC	-0.45	-5.33	-0.33	2.37e-7	Systemic sclerosis;
SARC	trans	rs4332037	1.000	rs6947019	chr7:1950337	G/A	cg11693508	chr17:37793320	STARD3	0.72	6.46	0.39	5.88e-10	Bipolar disorder;
SARC	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg03060546	chr3:49711283	APEH	0.43	5.33	0.33	2.31e-7	Parkinson's disease;
SARC	cis	rs7044106	0.708	rs1324472	chr9:123375110	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.71	8.61	0.49	1.14e-15	Hip circumference adjusted for BMI;
SARC	cis	rs900145	0.817	rs11022738	chr11:13293182	A/G	cg10435282	chr11:13303971	ARNTL	0.37	4.92	0.31	1.67e-6	Menarche (age at onset);
SARC	cis	rs4664308	0.618	rs6722275	chr2:160893260	C/T	cg03641300	chr2:160917029	PLA2R1	-0.4	-5.18	-0.32	4.83e-7	Idiopathic membranous nephropathy;
SARC	cis	rs7666738	0.791	rs1593571	chr4:98963763	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7201929	1.000	rs8061877	chr16:28856819	C/T	cg01378222	chr16:28622494	SULT1A1	-0.3	-4.8	-0.3	2.79e-6	QT interval;
SARC	cis	rs644799	0.710	rs1852535	chr11:95501241	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.87	14.28	0.68	1.16e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs35306767	0.903	rs11253458	chr10:882843	T/C	cg20503657	chr10:835505	NA	0.86	8.12	0.47	2.66e-14	Eosinophil percentage of granulocytes;
SARC	cis	rs12044355	0.929	rs12045248	chr1:231850748	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.52	7.04	0.42	2.1e-11	Alzheimer's disease;
SARC	cis	rs67311347	0.549	rs60249586	chr3:40246659	G/A	cg24209194	chr3:40518798	ZNF619	0.47	5.76	0.35	2.62e-8	Renal cell carcinoma;
SARC	cis	rs62244186	0.516	rs11922470	chr3:44777795	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.77	10.7	0.57	5.21e-22	Depressive symptoms;
SARC	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg22920501	chr2:26401640	FAM59B	0.5	6.6	0.4	2.73e-10	Gut microbiome composition (summer);
SARC	cis	rs2635047	0.542	rs2668764	chr18:44790218	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.39	-4.71	-0.3	4.2e-6	Educational attainment;
SARC	cis	rs2933343	1.000	rs789213	chr3:128616359	C/G	cg25356066	chr3:128598488	ACAD9	-0.61	-6.94	-0.41	3.81e-11	IgG glycosylation;
SARC	cis	rs9911578	1.000	rs9898626	chr17:56698219	C/G	cg12560992	chr17:57184187	TRIM37	0.83	11.32	0.6	5.91e-24	Intelligence (multi-trait analysis);
SARC	cis	rs933688	1.000	rs1964292	chr5:90743608	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	12.57	0.64	5.35e-28	Smoking behavior;
SARC	trans	rs1973993	0.507	rs2759670	chr1:97002864	A/G	cg10631902	chr5:14652156	NA	0.44	7.16	0.42	1.03e-11	Weight;
SARC	cis	rs2735413	0.752	rs11642442	chr16:78080800	A/C	cg04733911	chr16:78082701	NA	-0.3	-5.47	-0.34	1.14e-7	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs2486288	0.656	rs6493144	chr15:45573489	C/G	cg26924012	chr15:45694286	SPATA5L1	0.52	6.6	0.4	2.77e-10	Glomerular filtration rate;
SARC	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg15966229	chr18:44337664	ST8SIA5	-0.36	-4.73	-0.3	3.83e-6	Personality dimensions;
SARC	cis	rs6504663	1.000	rs6504661	chr17:48580126	A/T	cg22571038	chr17:48585470	MYCBPAP	-0.43	-5.54	-0.34	8.32e-8	Visceral fat;
SARC	cis	rs2204008	0.594	rs11531211	chr12:37998007	T/G	cg26384229	chr12:38710491	ALG10B	-0.78	-11.14	-0.59	2.17e-23	Bladder cancer;
SARC	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg13877915	chr19:58951672	ZNF132	0.69	10.03	0.55	6.58e-20	Uric acid clearance;
SARC	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.95	-14.77	-0.7	2.87e-35	Chronic sinus infection;
SARC	cis	rs6141769	0.518	rs6058834	chr20:31316862	C/T	cg13636640	chr20:31349939	DNMT3B	-0.45	-4.78	-0.3	3.08e-6	Subjective well-being;
SARC	cis	rs761746	0.960	rs5753667	chr22:31905703	G/A	cg15162869	chr22:32027605	PISD	0.39	5.29	0.33	2.81e-7	Intelligence;
SARC	cis	rs7872515	0.887	rs7856177	chr9:94839342	A/G	cg01248375	chr9:94877805	SPTLC1	0.66	5.96	0.36	9.26e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs4919087	0.748	rs793517	chr10:98987522	A/G	cg25902810	chr10:99078978	FRAT1	-0.52	-5.98	-0.36	8.53e-9	Monocyte count;
SARC	trans	rs61931739	0.500	rs34107854	chr12:34482333	C/A	cg26384229	chr12:38710491	ALG10B	0.91	13.63	0.67	1.63e-31	Morning vs. evening chronotype;
SARC	cis	rs2531992	0.686	rs2531989	chr16:4028145	G/A	cg05927578	chr16:4029543	ADCY9	0.47	5.79	0.35	2.22e-8	Waist circumference;
SARC	cis	rs698833	0.926	rs786622	chr2:44606598	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.72	9.34	0.52	8e-18	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs55823223	0.702	rs3785437	chr17:73906222	G/T	cg08125733	chr17:73851984	WBP2	0.63	5.14	0.32	5.77e-7	Psoriasis;
SARC	cis	rs1843834	0.505	rs940317	chr2:225358118	C/T	cg12698349	chr2:225449008	CUL3	0.6	7.72	0.45	3.34e-13	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs240764	0.658	rs9377214	chr6:101212146	G/A	cg09795085	chr6:101329169	ASCC3	-0.44	-5.7	-0.35	3.61e-8	Neuroticism;
SARC	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg10374962	chr7:1011985	COX19	-0.43	-4.75	-0.3	3.62e-6	Bronchopulmonary dysplasia;
SARC	cis	rs2760061	0.598	rs849904	chr1:228137145	G/C	cg02753203	chr1:228287806	NA	-0.54	-7.49	-0.44	1.45e-12	Diastolic blood pressure;
SARC	cis	rs28386778	0.700	rs12452767	chr17:62010503	G/A	cg06873352	chr17:61820015	STRADA	-0.44	-5.45	-0.34	1.26e-7	Prudent dietary pattern;
SARC	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg05313129	chr8:58192883	C8orf71	-0.57	-6.43	-0.39	7.31e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs10870270	1.000	rs72636963	chr10:133771271	C/T	cg26149184	chr10:133730230	NA	0.47	5.07	0.32	8.13e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs6840360	1.000	rs2840130	chr4:152600699	T/C	cg22705602	chr4:152727874	NA	-0.38	-6.55	-0.39	3.72e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg15556689	chr8:8085844	FLJ10661	0.44	5.51	0.34	9.27e-8	Mood instability;
SARC	cis	rs344364	0.511	rs2917519	chr16:1950479	C/A	cg26617929	chr16:1858877	NA	-0.71	-5.85	-0.36	1.62e-8	Glomerular filtration rate in chronic kidney disease;
SARC	cis	rs11785693	0.862	rs62491202	chr8:5001470	C/A	cg26367366	chr8:4980734	NA	0.74	6.18	0.38	2.84e-9	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs6831352	0.918	rs29001209	chr4:100052340	C/A	cg13256891	chr4:100009986	ADH5	-0.64	-8.0	-0.46	5.7e-14	Alcohol dependence;
SARC	cis	rs7666738	0.716	rs35195511	chr4:98859660	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.6	0.49	1.22e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1635	0.655	rs73742541	chr6:28310615	T/C	cg15743358	chr6:28303923	ZNF323	-0.71	-4.83	-0.3	2.48e-6	Schizophrenia;
SARC	cis	rs7100689	0.646	rs10749581	chr10:82141651	A/G	cg01528321	chr10:82214614	TSPAN14	-0.79	-10.79	-0.58	2.89e-22	Post bronchodilator FEV1;
SARC	cis	rs7223966	1.000	rs9909992	chr17:61731931	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.49	-5.12	-0.32	6.33e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs911263	0.603	rs2145422	chr14:68797169	G/C	cg18825221	chr14:68749962	RAD51L1	0.4	6.99	0.42	2.95e-11	Primary biliary cholangitis;
SARC	cis	rs832540	0.629	rs10461616	chr5:56080347	T/C	cg12311346	chr5:56204834	C5orf35	-0.39	-4.83	-0.3	2.45e-6	Coronary artery disease;
SARC	cis	rs13256369	0.802	rs34762800	chr8:8559294	G/A	cg18904891	chr8:8559673	CLDN23	0.48	5.38	0.33	1.79e-7	Obesity-related traits;
SARC	cis	rs12586317	0.620	rs58320987	chr14:35587726	T/C	cg16230307	chr14:35515116	FAM177A1	0.92	10.56	0.57	1.49e-21	Psoriasis;
SARC	cis	rs12200560	0.505	rs4240555	chr6:97076274	T/C	cg06623918	chr6:96969491	KIAA0776	0.46	5.29	0.33	2.82e-7	Coronary heart disease;
SARC	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	15.58	0.71	5.4e-38	Chronic sinus infection;
SARC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg10862848	chr6:42927986	GNMT	-0.41	-6.51	-0.39	4.54e-10	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs72945132	0.882	rs59398290	chr11:70134819	G/A	cg00319359	chr11:70116639	PPFIA1	0.68	6.37	0.39	1.01e-9	Coronary artery disease;
SARC	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg22875332	chr1:76189707	ACADM	0.44	5.83	0.36	1.82e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs3812831	0.654	rs367312	chr13:114930195	G/A	cg08824895	chr13:115047677	UPF3A	0.44	5.57	0.34	7.16e-8	Schizophrenia;
SARC	cis	rs12681366	0.708	rs1813167	chr8:95348753	C/T	cg26464482	chr8:95565502	KIAA1429	-0.46	-5.78	-0.35	2.37e-8	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg11861562	chr11:117069780	TAGLN	-0.21	-4.74	-0.3	3.65e-6	Blood protein levels;
SARC	cis	rs11098699	0.784	rs2291933	chr4:124247183	A/G	cg09941581	chr4:124220074	SPATA5	0.37	4.82	0.3	2.61e-6	Mosquito bite size;
SARC	cis	rs1395	0.778	rs72810794	chr2:27401260	C/T	cg21747090	chr2:27597821	SNX17	-0.49	-5.74	-0.35	2.91e-8	Blood metabolite levels;
SARC	cis	rs2486288	0.656	rs62026703	chr15:45569929	G/T	cg15395560	chr15:45543142	SLC28A2	0.32	6.17	0.37	2.98e-9	Glomerular filtration rate;
SARC	cis	rs7223966	1.000	rs7214312	chr17:61870863	A/G	cg26338869	chr17:61819248	STRADA	0.47	5.08	0.32	7.71e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs981844	0.714	rs2405202	chr4:154705132	A/G	cg14289246	chr4:154710475	SFRP2	-0.58	-6.83	-0.41	7.45e-11	Response to statins (LDL cholesterol change);
SARC	cis	rs796364	0.901	rs4673762	chr2:201065171	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.53	5.28	0.33	2.99e-7	Schizophrenia;
SARC	cis	rs1420338	0.933	rs12540602	chr7:34174056	G/A	cg01275685	chr7:34179230	BMPER	-0.44	-5.55	-0.34	7.63e-8	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
SARC	cis	rs7770848	1	rs7770848	chr6:44769237	A/C	cg13991849	chr6:45390099	RUNX2	0.64	5.39	0.33	1.73e-7	Asthma (childhood onset);
SARC	cis	rs80282103	0.618	rs74120451	chr10:1126866	T/C	cg08668510	chr10:1095578	IDI1	0.74	5.01	0.31	1.09e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs1865760	0.892	rs6456705	chr6:25936056	G/A	cg17691542	chr6:26056736	HIST1H1C	0.61	7.58	0.44	7.96e-13	Height;
SARC	cis	rs2635047	0.615	rs2684819	chr18:44710691	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	5.94	0.36	1.05e-8	Educational attainment;
SARC	trans	rs9354308	0.899	rs2802056	chr6:66546219	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.57	6.66	0.4	1.92e-10	Metabolite levels;
SARC	cis	rs778371	0.723	rs1973675	chr2:233636450	C/T	cg20388707	chr2:233749442	NGEF	0.34	5.19	0.32	4.5e-7	Schizophrenia;
SARC	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg23172400	chr8:95962367	TP53INP1	0.3	5.07	0.32	8.13e-7	Type 2 diabetes;
SARC	cis	rs6430585	0.528	rs309166	chr2:136667487	C/T	cg07169764	chr2:136633963	MCM6	0.99	13.0	0.65	2.07e-29	Corneal structure;
SARC	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg11987759	chr7:65425863	GUSB	-0.47	-6.28	-0.38	1.63e-9	Aortic root size;
SARC	cis	rs10088262	0.629	rs9918907	chr8:124816862	A/G	cg20713898	chr8:124780851	FAM91A1	-0.64	-7.11	-0.42	1.42e-11	Pancreatic cancer;
SARC	cis	rs6831352	0.918	rs13112733	chr4:100050319	A/T	cg13256891	chr4:100009986	ADH5	-0.65	-8.11	-0.47	2.83e-14	Alcohol dependence;
SARC	cis	rs2635047	0.811	rs28471970	chr18:44788439	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.51	6.55	0.39	3.58e-10	Educational attainment;
SARC	cis	rs2652822	0.554	rs11635698	chr15:63478573	G/A	cg02713581	chr15:63449717	RPS27L	0.54	6.43	0.39	7.32e-10	Metabolic traits;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg02132379	chr7:30031080	SCRN1	0.48	6.78	0.41	1e-10	Thyroid stimulating hormone;
SARC	cis	rs240764	0.578	rs9399688	chr6:101215786	C/T	cg09795085	chr6:101329169	ASCC3	0.44	5.55	0.34	7.65e-8	Neuroticism;
SARC	cis	rs950173	1.000	rs13000153	chr2:172586067	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.77	-5.43	-0.34	1.4e-7	Hippocampal volume;
SARC	cis	rs7659604	0.702	rs58649165	chr4:122693752	C/A	cg19748678	chr4:122722346	EXOSC9	0.73	9.75	0.54	4.66e-19	Type 2 diabetes;
SARC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg11905131	chr22:24372483	LOC391322	-0.52	-5.68	-0.35	4.07e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2200578	1.000	rs12053519	chr2:99875018	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.55	5.17	0.32	5.07e-7	IgG glycosylation;
SARC	cis	rs240764	0.658	rs9322213	chr6:101248480	T/C	cg09795085	chr6:101329169	ASCC3	-0.45	-5.85	-0.36	1.64e-8	Neuroticism;
SARC	cis	rs2933343	0.729	rs813945	chr3:128660937	A/G	cg25356066	chr3:128598488	ACAD9	0.71	9.29	0.52	1.13e-17	IgG glycosylation;
SARC	cis	rs1318878	0.565	rs1304739	chr12:15506906	C/T	cg08258403	chr12:15378311	NA	0.47	6.65	0.4	2.03e-10	Intelligence (multi-trait analysis);
SARC	cis	rs6693567	0.565	rs497128	chr1:150269952	A/G	cg09579323	chr1:150459698	TARS2	-0.41	-5.35	-0.33	2.13e-7	Migraine;
SARC	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg11366901	chr6:160182831	ACAT2	1.03	10.98	0.58	7.22e-23	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs734999	0.545	rs12730932	chr1:2559589	T/G	cg00980319	chr1:2560884	MMEL1	0.34	4.9	0.31	1.83e-6	Ulcerative colitis;
SARC	cis	rs7223966	1.000	rs78172786	chr17:61847114	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.49	-4.91	-0.31	1.73e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1983891	1.000	rs4714485	chr6:41536587	T/G	cg15051332	chr6:41514432	FOXP4	0.54	5.96	0.36	9.49e-9	Prostate cancer;
SARC	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg05861140	chr6:150128134	PCMT1	-0.4	-4.91	-0.31	1.72e-6	Lung cancer;
SARC	cis	rs8102137	1.000	rs57894940	chr19:30293462	G/A	cg27475126	chr19:30303651	CCNE1	-0.38	-5.29	-0.33	2.8e-7	Bladder cancer;
SARC	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg12463550	chr7:65579703	CRCP	0.5	5.9	0.36	1.27e-8	Aortic root size;
SARC	cis	rs8067545	0.611	rs9907516	chr17:20070490	G/A	cg13482628	chr17:19912719	NA	0.55	7.18	0.43	9.03e-12	Schizophrenia;
SARC	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.4	-4.84	-0.3	2.31e-6	Lymphocyte counts;
SARC	cis	rs2153535	0.562	rs9379211	chr6:8463927	C/T	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg25952890	chr19:58913133	NA	0.38	5.43	0.33	1.45e-7	Uric acid clearance;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg23319546	chr10:75173760	ANXA7	0.5	6.36	0.38	1.05e-9	Breast cancer;
SARC	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg21724239	chr8:58056113	NA	0.58	5.75	0.35	2.75e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7264396	0.635	rs6058366	chr20:34512172	A/G	cg12579300	chr20:34535607	PHF20	-0.43	-4.98	-0.31	1.26e-6	Total cholesterol levels;
SARC	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg13628971	chr7:2884303	GNA12	0.64	7.56	0.44	9.4e-13	Height;
SARC	cis	rs17376456	0.877	rs10035340	chr5:93490465	C/T	cg25358565	chr5:93447407	FAM172A	1.36	14.0	0.68	1.04e-32	Diabetic retinopathy;
SARC	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg22168489	chr12:122356033	WDR66	0.66	10.14	0.55	2.9e-20	Mean corpuscular volume;
SARC	cis	rs8114671	0.562	rs725521	chr20:33516071	T/C	cg07148914	chr20:33460835	GGT7	0.42	5.07	0.32	8.08e-7	Height;
SARC	cis	rs9640161	0.789	rs4554381	chr7:150025567	G/A	cg10018233	chr7:150070692	REPIN1	0.71	9.72	0.54	5.72e-19	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs3820928	1.000	rs1835158	chr2:227763993	C/A	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.83	-0.36	1.82e-8	Pulmonary function;
SARC	cis	rs853679	0.760	rs11967137	chr6:28199764	A/G	cg26450541	chr6:28235208	ZNF187	0.56	4.98	0.31	1.26e-6	Depression;
SARC	cis	rs3981351	0.797	rs61866462	chr10:115464690	C/T	cg24846397	chr10:115438155	CASP7	-0.37	-4.78	-0.3	3.13e-6	Obesity-related traits;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg26841017	chr5:34929960	DNAJC21	0.51	6.36	0.38	1.08e-9	Breast cancer;
SARC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg25703541	chr22:24373054	LOC391322	-0.73	-9.3	-0.52	1.06e-17	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs36051895	0.664	rs7857081	chr9:5096728	G/A	cg02405213	chr9:5042618	JAK2	-0.48	-5.9	-0.36	1.28e-8	Pediatric autoimmune diseases;
SARC	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg18252515	chr7:66147081	NA	0.53	5.69	0.35	3.71e-8	Aortic root size;
SARC	cis	rs9911578	1.000	rs999431	chr17:56854441	A/G	cg12560992	chr17:57184187	TRIM37	0.88	12.08	0.62	2.02e-26	Intelligence (multi-trait analysis);
SARC	cis	rs3087591	1.000	rs2952989	chr17:29516113	G/A	cg24425628	chr17:29625626	OMG;NF1	0.5	6.19	0.38	2.68e-9	Hip circumference;
SARC	cis	rs9911578	0.967	rs2611781	chr17:56703124	C/G	cg05425664	chr17:57184151	TRIM37	-0.69	-8.62	-0.49	1.05e-15	Intelligence (multi-trait analysis);
SARC	cis	rs1670533	0.697	rs658846	chr4:1084723	G/C	cg20887711	chr4:1340912	KIAA1530	0.52	4.81	0.3	2.71e-6	Recombination rate (females);
SARC	cis	rs9399135	0.838	rs4896126	chr6:135342786	C/A	cg24558204	chr6:135376177	HBS1L	0.45	6.07	0.37	5.25e-9	Red blood cell count;
SARC	cis	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg03060546	chr3:49711283	APEH	-0.65	-8.24	-0.48	1.24e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs3762637	0.943	rs10222564	chr3:122266336	T/C	cg24169773	chr3:122142474	KPNA1	-0.55	-5.59	-0.34	6.45e-8	LDL cholesterol levels;
SARC	cis	rs2228479	0.718	rs11645376	chr16:89912281	G/C	cg00800038	chr16:89945340	TCF25	-0.82	-5.8	-0.35	2.19e-8	Skin colour saturation;
SARC	cis	rs910316	1.000	rs3742778	chr14:75538217	A/C	cg08847533	chr14:75593920	NEK9	-0.93	-16.34	-0.73	1.61e-40	Height;
SARC	cis	rs362272	0.545	rs2749783	chr4:3326098	A/C	cg08741688	chr4:3415352	RGS12	-0.49	-6.21	-0.38	2.36e-9	Serum sulfate level;
SARC	cis	rs3820928	1.000	rs6752707	chr2:227766822	C/G	cg05526886	chr2:227700861	RHBDD1	-0.49	-5.87	-0.36	1.49e-8	Pulmonary function;
SARC	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg08219700	chr8:58056026	NA	0.48	5.05	0.31	9.05e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg15837838	chr17:20280166	CCDC144C	-0.48	-6.45	-0.39	6.29e-10	Breast cancer;
SARC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg09373136	chr17:61933544	TCAM1	-0.45	-6.12	-0.37	3.97e-9	Prudent dietary pattern;
SARC	cis	rs2834188	0.924	rs2007849	chr21:34681116	G/A	cg04842828	chr21:34696676	IFNAR1	0.42	5.04	0.31	9.38e-7	Narcolepsy;
SARC	cis	rs10781543	0.839	rs7863766	chr9:139381314	T/G	cg14169450	chr9:139327907	INPP5E	0.44	6.34	0.38	1.18e-9	Monocyte percentage of white cells;
SARC	cis	rs17539620	0.628	rs62432728	chr6:154829511	G/C	cg17771515	chr6:154831774	CNKSR3	0.51	4.96	0.31	1.35e-6	Lipoprotein (a) levels;
SARC	cis	rs883565	0.528	rs4676584	chr3:38965907	C/A	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.43	-5.0	-0.31	1.13e-6	Handedness;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg06475972	chr17:34842357	ZNHIT3	-0.54	-6.86	-0.41	6.02e-11	Gallstone disease;
SARC	cis	rs9640161	0.711	rs3800781	chr7:150027324	T/A	cg10018233	chr7:150070692	REPIN1	0.69	8.7	0.5	6.19e-16	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs16976116	0.901	rs28591259	chr15:55498940	T/A	cg11288833	chr15:55489084	RSL24D1	0.63	6.13	0.37	3.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg12292205	chr6:26970375	C6orf41	0.41	5.01	0.31	1.07e-6	Intelligence (multi-trait analysis);
SARC	cis	rs72627123	0.656	rs76479281	chr14:74564609	C/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.74	5.87	0.36	1.48e-8	Morning vs. evening chronotype;
SARC	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-8.27	-0.48	1.05e-14	Chronic sinus infection;
SARC	cis	rs6142102	0.778	rs4911374	chr20:32516001	T/C	cg24642439	chr20:33292090	TP53INP2	0.45	4.78	0.3	3.15e-6	Skin pigmentation;
SARC	cis	rs694739	0.536	rs671976	chr11:64046029	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.55	7.36	0.43	3.2e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs7044106	0.791	rs735109	chr9:123488879	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.72	9.42	0.53	4.56e-18	Hip circumference adjusted for BMI;
SARC	cis	rs2073300	0.609	rs6137914	chr20:23358364	C/T	cg12062639	chr20:23401060	NAPB	0.96	6.45	0.39	6.36e-10	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs6714710	0.580	rs55886305	chr2:98495661	T/G	cg26665480	chr2:98280029	ACTR1B	0.51	6.91	0.41	4.71e-11	Posterior cortical atrophy and Alzheimer's disease;
SARC	trans	rs7937682	0.710	rs674230	chr11:111437887	A/G	cg18187862	chr3:45730750	SACM1L	0.57	7.1	0.42	1.54e-11	Primary sclerosing cholangitis;
SARC	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg18876405	chr7:65276391	NA	-0.47	-5.29	-0.33	2.84e-7	Aortic root size;
SARC	cis	rs16854884	0.586	rs2011080	chr3:143756149	T/G	cg06585982	chr3:143692056	C3orf58	0.69	9.71	0.54	6.25e-19	Economic and political preferences (feminism/equality);
SARC	cis	rs1348850	0.958	rs1405713	chr2:178461560	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.63	7.75	0.45	2.91e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs13191362	0.935	rs67368176	chr6:162968436	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.53	4.81	0.3	2.74e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2387326	0.717	rs12261194	chr10:129944464	T/C	cg16087940	chr10:129947807	NA	-0.45	-5.74	-0.35	2.98e-8	Select biomarker traits;
SARC	cis	rs2070488	0.965	rs13097628	chr3:38521156	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.83	13.37	0.66	1.23e-30	Electrocardiographic conduction measures;
SARC	cis	rs760805	0.965	rs4648883	chr1:25261203	T/C	cg22509179	chr1:25234806	RUNX3	-0.48	-6.74	-0.4	1.26e-10	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs13082711	0.911	rs17019721	chr3:27424799	A/G	cg02860705	chr3:27208620	NA	0.47	6.24	0.38	2.05e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs9316337	0.520	rs8001135	chr13:22015251	C/A	cg21080246	chr13:22033151	ZDHHC20	0.42	4.89	0.31	1.88e-6	Schizophrenia;
SARC	cis	rs554111	0.634	rs12026318	chr1:21316623	T/C	cg04902671	chr1:21058625	SH2D5	0.42	5.17	0.32	5.01e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs3815700	1.000	rs8109768	chr19:33095463	A/G	cg24916020	chr19:33096688	ANKRD27	0.57	5.47	0.34	1.15e-7	Eosinophilic esophagitis;
SARC	cis	rs7520050	0.966	rs12410071	chr1:46358886	T/C	cg06784218	chr1:46089804	CCDC17	-0.26	-4.89	-0.31	1.85e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs1050631	1.000	rs1789514	chr18:33692654	T/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.45	5.62	0.35	5.3e-8	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs12311304	1.000	rs12580862	chr12:15395548	C/T	cg08258403	chr12:15378311	NA	-0.49	-7.36	-0.43	3.14e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg02725872	chr8:58115012	NA	-0.34	-5.37	-0.33	1.91e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg21132104	chr15:45694354	SPATA5L1	0.77	10.98	0.58	6.87e-23	Homoarginine levels;
SARC	cis	rs926392	0.640	rs4616534	chr20:37693564	G/A	cg16355469	chr20:37678765	NA	0.76	9.87	0.54	1.96e-19	Dialysis-related mortality;
SARC	cis	rs35110281	0.626	rs162388	chr21:44936032	G/A	cg01579765	chr21:45077557	HSF2BP	-0.29	-5.02	-0.31	1.01e-6	Mean corpuscular volume;
SARC	cis	rs9359856	0.623	rs1179906	chr6:90323624	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.52	-4.99	-0.31	1.18e-6	Bipolar disorder;
SARC	cis	rs3825932	0.659	rs4778724	chr15:79238406	C/T	cg25744700	chr15:79237217	CTSH	0.36	4.82	0.3	2.61e-6	Type 1 diabetes;
SARC	cis	rs959260	0.588	rs7219	chr17:73315368	A/G	cg14668889	chr17:73230827	NUP85	0.55	7.09	0.42	1.58e-11	Systemic lupus erythematosus;
SARC	cis	rs7959452	0.605	rs12819406	chr12:69696400	G/T	cg14784868	chr12:69753453	YEATS4	0.39	5.15	0.32	5.47e-7	Blood protein levels;
SARC	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg01570182	chr17:44337453	NA	-0.82	-9.75	-0.54	4.71e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg00149659	chr3:10157352	C3orf10	0.61	5.29	0.33	2.77e-7	Alzheimer's disease;
SARC	cis	rs2439831	1.000	rs471229	chr15:43733994	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.77	7.67	0.45	4.62e-13	Lung cancer in ever smokers;
SARC	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg17971929	chr21:40555470	PSMG1	0.95	11.72	0.61	3.06e-25	Cognitive function;
SARC	cis	rs7826238	0.623	rs2976893	chr8:8338219	G/T	cg15556689	chr8:8085844	FLJ10661	-0.41	-5.26	-0.33	3.22e-7	Systolic blood pressure;
SARC	cis	rs12579753	0.879	rs35087297	chr12:82133398	C/T	cg07988820	chr12:82153109	PPFIA2	-0.6	-7.03	-0.42	2.3e-11	Resting heart rate;
SARC	cis	rs986417	0.748	rs10147346	chr14:61083334	G/C	cg27398547	chr14:60952738	C14orf39	0.76	7.06	0.42	1.88e-11	Gut microbiota (bacterial taxa);
SARC	cis	rs72781680	0.716	rs7564732	chr2:24034178	C/T	cg06627628	chr2:24431161	ITSN2	-0.53	-5.75	-0.35	2.72e-8	Lymphocyte counts;
SARC	cis	rs9894429	0.546	rs9906979	chr17:79608765	A/G	cg18240062	chr17:79603768	NPLOC4	0.74	9.86	0.54	2.21e-19	Eye color traits;
SARC	cis	rs3820928	0.874	rs10439363	chr2:227815065	C/T	cg05526886	chr2:227700861	RHBDD1	-0.54	-6.59	-0.4	2.88e-10	Pulmonary function;
SARC	cis	rs861020	0.630	rs585627	chr1:210004199	C/G	cg23166289	chr1:210001082	C1orf107	0.4	4.78	0.3	3.14e-6	Orofacial clefts;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg17197538	chr12:25404353	KRAS	-0.53	-6.42	-0.39	7.48e-10	Height;
SARC	cis	rs7927771	0.965	rs17788930	chr11:47752775	A/G	cg20307385	chr11:47447363	PSMC3	-0.47	-5.58	-0.34	6.63e-8	Subjective well-being;
SARC	cis	rs6456156	0.774	rs6931530	chr6:167527200	A/C	cg07741184	chr6:167504864	NA	-0.28	-5.45	-0.34	1.25e-7	Primary biliary cholangitis;
SARC	cis	rs9581857	0.556	rs9581864	chr13:28041567	T/C	cg01674679	chr13:27998804	GTF3A	-0.59	-5.87	-0.36	1.5e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	cis	rs561341	0.663	rs72821936	chr17:30224068	C/G	cg18200150	chr17:30822561	MYO1D	-0.36	-4.72	-0.3	4.01e-6	Hip circumference adjusted for BMI;
SARC	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg12564285	chr5:131593104	PDLIM4	0.36	5.37	0.33	1.9e-7	Breast cancer;
SARC	cis	rs2645694	0.626	rs2703129	chr4:77818548	T/C	cg10057126	chr4:77819792	ANKRD56	0.45	6.64	0.4	2.25e-10	Emphysema distribution in smoking;
SARC	cis	rs9790314	0.687	rs1037888	chr3:160775251	A/T	cg03342759	chr3:160939853	NMD3	-0.42	-5.03	-0.31	9.92e-7	Morning vs. evening chronotype;
SARC	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs765787	0.530	rs28815867	chr15:45526805	G/C	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.67e-7	Uric acid levels;
SARC	cis	rs13191362	1.000	rs13199223	chr6:163001083	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.49	0.34	1.04e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.98	11.82	0.61	1.49e-25	Platelet count;
SARC	cis	rs1784581	0.894	rs1790001	chr6:162387504	G/T	cg17173639	chr6:162384350	PARK2	-0.76	-10.56	-0.57	1.51e-21	Itch intensity from mosquito bite;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg26416905	chr5:122454093	PRDM6	0.44	6.43	0.39	7.06e-10	Thyroid stimulating hormone;
SARC	cis	rs7949030	0.626	rs61296092	chr11:62320838	T/C	cg22862634	chr11:62369728	EML3;MTA2	0.54	8.09	0.47	3.26e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg20607798	chr8:58055168	NA	0.58	5.55	0.34	7.69e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7172677	1.000	rs4886422	chr15:75426723	C/T	cg14664628	chr15:75095509	CSK	-0.45	-4.73	-0.3	3.85e-6	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg05623727	chr3:50126028	RBM5	0.35	5.4	0.33	1.65e-7	Intelligence (multi-trait analysis);
SARC	cis	rs11190604	0.943	rs11190574	chr10:102234331	T/C	cg07080220	chr10:102295463	HIF1AN	0.77	9.26	0.52	1.39e-17	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs1355223	0.506	rs1509660	chr11:34865017	A/G	cg11622362	chr11:34938112	PDHX;APIP	0.46	6.04	0.37	5.98e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02585790	chr2:232329254	NCL	0.63	8.25	0.48	1.16e-14	Smoking initiation;
SARC	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg18876405	chr7:65276391	NA	-0.71	-9.04	-0.51	6.43e-17	Aortic root size;
SARC	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg13298116	chr11:62369859	EML3;MTA2	0.48	7.4	0.44	2.5e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs11792861	0.888	rs72607168	chr9:111832192	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.67	7.62	0.45	6.3e-13	Menarche (age at onset);
SARC	cis	rs9457247	0.765	rs6904946	chr6:167433948	C/T	cg23791538	chr6:167370224	RNASET2	0.51	6.9	0.41	4.85e-11	Crohn's disease;
SARC	cis	rs8102137	1.000	rs17513613	chr19:30286822	T/C	cg27475126	chr19:30303651	CCNE1	-0.36	-4.85	-0.3	2.22e-6	Bladder cancer;
SARC	cis	rs4689388	0.890	rs4689397	chr4:6299387	G/A	cg25554036	chr4:6271136	WFS1	0.39	6.38	0.39	9.51e-10	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs910316	0.934	rs8006587	chr14:75664939	A/G	cg11812906	chr14:75593930	NEK9	0.82	12.38	0.63	2.27e-27	Height;
SARC	cis	rs7589728	0.516	rs79815126	chr2:88488270	G/A	cg04511125	chr2:88470314	THNSL2	0.74	5.68	0.35	4.08e-8	Plasma clusterin levels;
SARC	cis	rs2228479	1.000	rs12596492	chr16:89957169	T/G	cg12064134	chr16:90016061	DEF8	-0.55	-4.75	-0.3	3.59e-6	Skin colour saturation;
SARC	cis	rs7904368	0.568	rs10752061	chr10:16853900	A/G	cg14835575	chr10:16859367	RSU1	0.42	4.8	0.3	2.84e-6	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs6912958	0.712	rs6454638	chr6:88329427	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.51	6.84	0.41	6.78e-11	Monocyte percentage of white cells;
SARC	cis	rs35306767	0.903	rs12249828	chr10:894838	C/T	cg26597838	chr10:835615	NA	0.78	8.26	0.48	1.07e-14	Eosinophil percentage of granulocytes;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg24169248	chr11:66247869	DPP3	0.5	6.84	0.41	6.77e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs7666738	0.830	rs7678250	chr4:98922109	G/A	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs76917914	0.821	rs112500293	chr9:100763455	C/T	cg03040243	chr9:100819229	NANS	0.56	5.86	0.36	1.59e-8	Immature fraction of reticulocytes;
SARC	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-10.15	-0.55	2.85e-20	Chronic sinus infection;
SARC	cis	rs6582630	0.593	rs12816835	chr12:38533304	C/T	cg14851346	chr12:38532713	NA	-0.43	-5.18	-0.32	4.74e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1059312	0.966	rs2291349	chr12:129284248	T/C	cg09035930	chr12:129282057	SLC15A4	0.62	8.93	0.5	1.32e-16	Systemic lupus erythematosus;
SARC	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg18252515	chr7:66147081	NA	0.52	5.59	0.34	6.44e-8	Aortic root size;
SARC	cis	rs9398803	0.897	rs9398804	chr6:126703390	T/A	cg20229609	chr6:126660872	C6orf173	0.4	5.74	0.35	2.88e-8	Male-pattern baldness;
SARC	cis	rs2273669	0.667	rs12196143	chr6:109302372	C/T	cg05315195	chr6:109294784	ARMC2	-0.56	-5.14	-0.32	5.92e-7	Prostate cancer;
SARC	cis	rs6540556	0.769	rs12030655	chr1:209922123	G/T	cg05527609	chr1:210001259	C1orf107	-0.57	-5.83	-0.36	1.85e-8	Red blood cell count;
SARC	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg13628971	chr7:2884303	GNA12	0.51	5.86	0.36	1.54e-8	Height;
SARC	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.62	7.54	0.44	1.04e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6690583	0.623	rs6700723	chr1:85514234	C/T	cg22153463	chr1:85462885	MCOLN2	0.67	5.2	0.32	4.27e-7	Serum sulfate level;
SARC	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.41	0.44	2.36e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6840360	1.000	rs1877187	chr4:152605621	C/T	cg22705602	chr4:152727874	NA	-0.37	-6.25	-0.38	1.89e-9	Intelligence (multi-trait analysis);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg02750587	chr1:85156370	SSX2IP	-0.56	-6.32	-0.38	1.34e-9	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs240764	0.681	rs12209887	chr6:101156806	G/A	cg09795085	chr6:101329169	ASCC3	-0.46	-5.89	-0.36	1.36e-8	Neuroticism;
SARC	cis	rs6500395	0.584	rs1345433	chr16:48738222	A/G	cg04672837	chr16:48644449	N4BP1	0.42	4.83	0.3	2.46e-6	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs9916302	0.861	rs632202	chr17:37453294	C/A	cg00129232	chr17:37814104	STARD3	0.6	7.33	0.43	3.76e-12	Glomerular filtration rate (creatinine);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg02452627	chr10:31321325	ZNF438	-0.48	-6.52	-0.39	4.23e-10	Thyroid stimulating hormone;
SARC	cis	rs74181299	0.684	rs6736728	chr2:65305499	A/G	cg20592124	chr2:65290738	CEP68	0.34	4.74	0.3	3.8e-6	Pulse pressure;
SARC	cis	rs10504073	0.584	rs72641612	chr8:49947986	C/T	cg00325661	chr8:49890786	NA	0.53	7.02	0.42	2.36e-11	Blood metabolite ratios;
SARC	cis	rs7772486	0.742	rs4896851	chr6:146278959	T/C	cg05347473	chr6:146136440	FBXO30	-0.42	-5.59	-0.34	6.43e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs66573146	0.572	rs73199995	chr4:6955801	G/C	cg26116260	chr4:7069785	GRPEL1	-0.68	-4.98	-0.31	1.25e-6	Granulocyte percentage of myeloid white cells;
SARC	cis	rs6570726	0.935	rs12663204	chr6:145818373	G/A	cg05220968	chr6:146057943	EPM2A	-0.29	-4.83	-0.3	2.44e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6088580	0.634	rs6059867	chr20:33078103	C/T	cg08999081	chr20:33150536	PIGU	0.42	6.53	0.39	4.19e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs6060717	0.536	rs11167279	chr20:34509107	T/C	cg01084648	chr20:34329383	RBM39	0.62	4.73	0.3	3.89e-6	Hip circumference adjusted for BMI;
SARC	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg16606324	chr3:10149918	C3orf24	0.48	4.75	0.3	3.56e-6	Alzheimer's disease;
SARC	cis	rs7264396	0.563	rs2425111	chr20:34319765	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	5.68	0.35	4.03e-8	Total cholesterol levels;
SARC	cis	rs7084402	0.967	rs1649019	chr10:60288111	T/C	cg07615347	chr10:60278583	BICC1	0.61	8.99	0.51	8.84e-17	Refractive error;
SARC	cis	rs74417235	0.684	rs71590150	chr5:154060512	A/T	cg08754654	chr5:154026448	NA	0.47	4.72	0.3	3.99e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
SARC	cis	rs72945132	0.882	rs11235967	chr11:70191691	T/C	cg00319359	chr11:70116639	PPFIA1	0.7	6.58	0.4	3.12e-10	Coronary artery disease;
SARC	cis	rs1882538	0.564	rs12707090	chr7:133115163	G/A	cg10665199	chr7:133106180	EXOC4	0.43	5.43	0.33	1.45e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7027203	0.828	rs7037960	chr9:96584028	G/A	cg13679303	chr9:96623674	NA	-0.35	-5.06	-0.31	8.32e-7	DNA methylation (variation);
SARC	cis	rs9457247	1.000	rs2757047	chr6:167374489	C/T	cg23791538	chr6:167370224	RNASET2	0.63	8.74	0.5	4.81e-16	Crohn's disease;
SARC	cis	rs2404602	0.536	rs17364330	chr15:76765385	A/T	cg22467129	chr15:76604101	ETFA	-0.38	-5.0	-0.31	1.11e-6	Blood metabolite levels;
SARC	cis	rs8005677	1.000	rs1956880	chr14:23394007	A/G	cg01529538	chr14:23388837	RBM23	0.41	4.97	0.31	1.32e-6	Cognitive ability (multi-trait analysis);
SARC	cis	rs986417	0.901	rs713449	chr14:61029084	C/G	cg27398547	chr14:60952738	C14orf39	0.97	8.85	0.5	2.29e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs3087591	0.821	rs12949024	chr17:29445086	A/T	cg24425628	chr17:29625626	OMG;NF1	0.6	7.55	0.44	9.87e-13	Hip circumference;
SARC	cis	rs11098499	0.739	rs951570	chr4:120150467	T/C	cg09307838	chr4:120376055	NA	-0.79	-10.69	-0.57	6e-22	Corneal astigmatism;
SARC	cis	rs1355223	0.583	rs2941043	chr11:34870994	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.74	-10.72	-0.57	4.75e-22	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs2073300	0.609	rs17757442	chr20:23421101	A/G	cg12062639	chr20:23401060	NAPB	-0.98	-6.65	-0.4	2.03e-10	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs7223966	1.000	rs11657306	chr17:61704822	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.5	-5.56	-0.34	7.28e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg20618750	chr5:149380010	HMGXB3;TIGD6	-0.82	-6.97	-0.42	3.31e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs11770686	0.967	rs2107316	chr7:75344529	G/A	cg17787366	chr7:75369077	HIP1	0.43	5.34	0.33	2.17e-7	Essential tremor;
SARC	cis	rs7760949	0.963	rs1571565	chr6:13907185	A/G	cg27413430	chr6:13925136	RNF182	0.4	4.98	0.31	1.23e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs6977660	0.507	rs72591450	chr7:19775480	A/G	cg07541023	chr7:19748670	TWISTNB	0.93	8.12	0.47	2.77e-14	Thyroid stimulating hormone;
SARC	cis	rs889312	0.500	rs702691	chr5:56114526	T/G	cg14703610	chr5:56206110	C5orf35	0.52	6.51	0.39	4.48e-10	Breast cancer;Breast cancer (early onset);
SARC	cis	rs6449957	0.832	rs7715780	chr5:67453288	A/G	cg23036683	chr5:67512108	NA	0.53	6.27	0.38	1.74e-9	Cleft lip with or without cleft palate;
SARC	cis	rs1152591	0.792	rs1152595	chr14:64674981	T/C	cg23250157	chr14:64679961	SYNE2	0.47	6.61	0.4	2.52e-10	Atrial fibrillation;
SARC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg22791324	chr7:157949174	PTPRN2	0.3	4.8	0.3	2.84e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
SARC	cis	rs7624766	0.555	rs1829716	chr3:160477861	T/C	cg22637730	chr3:160473554	PPM1L	0.39	4.99	0.31	1.18e-6	Response to methotrexate in rheumatoid arthritis;
SARC	cis	rs11574514	1.000	rs117546864	chr16:67820252	A/T	cg01866162	chr16:67596514	CTCF	1.12	6.6	0.4	2.74e-10	Crohn's disease;
SARC	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg05036130	chr6:150231994	NA	0.3	5.14	0.32	5.73e-7	Lung cancer;
SARC	cis	rs6807306	1.000	rs9866161	chr3:167356925	A/G	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.5	5.05	0.31	8.99e-7	Mean platelet volume;
SARC	cis	rs875971	0.660	rs10229345	chr7:65982168	G/C	cg11987759	chr7:65425863	GUSB	-0.58	-7.41	-0.44	2.34e-12	Aortic root size;
SARC	cis	rs4843747	0.671	rs72818577	chr16:88111181	G/A	cg01573921	chr16:88061006	BANP	-0.48	-5.15	-0.32	5.57e-7	Menopause (age at onset);
SARC	cis	rs13191362	1.000	rs34228197	chr6:163008232	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.56	5.39	0.33	1.71e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.59	5.58	0.34	6.77e-8	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs7481584	0.669	rs12793371	chr11:3034709	A/G	cg05729581	chr11:3078854	CARS	0.53	6.69	0.4	1.66e-10	Calcium levels;
SARC	cis	rs17376456	0.825	rs66564678	chr5:93165894	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.73	6.55	0.39	3.74e-10	Diabetic retinopathy;
SARC	cis	rs9399137	0.507	rs13197750	chr6:135312380	G/A	cg24558204	chr6:135376177	HBS1L	0.61	7.94	0.46	8.39e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs17376456	0.877	rs10066791	chr5:93350255	G/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.68	0.35	3.93e-8	Diabetic retinopathy;
SARC	trans	rs10109025	0.670	rs7825690	chr8:10858257	G/T	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.76	-0.4	1.11e-10	Joint mobility (Beighton score);
SARC	cis	rs920590	0.921	rs4922099	chr8:19648486	T/C	cg03894339	chr8:19674705	INTS10	0.46	5.61	0.35	5.58e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs2153535	0.580	rs9393025	chr6:8490618	G/A	cg21535247	chr6:8435926	SLC35B3	0.57	7.26	0.43	5.7e-12	Motion sickness;
SARC	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg08859206	chr1:53392774	SCP2	0.39	5.57	0.34	7.17e-8	Monocyte count;
SARC	trans	rs3780486	0.846	rs3824458	chr9:33144809	C/T	cg20290983	chr6:43655470	MRPS18A	1.11	20.99	0.81	1.29e-55	IgG glycosylation;
SARC	trans	rs7432328	0.500	rs10513584	chr3:162240663	A/C	cg20246907	chr13:99316927	NA	0.53	6.3	0.38	1.48e-9	Response to radiotherapy in prostate cancer (toxicity, rectal bleeding);
SARC	cis	rs10795130	1.000	rs10795127	chr10:4149673	T/C	cg24830971	chr10:3180960	PITRM1	-0.46	-4.78	-0.3	3.14e-6	Sex hormone-binding globulin levels;
SARC	cis	rs10876993	0.890	rs1082502	chr12:58035706	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.44	-5.65	-0.35	4.66e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs35306767	0.903	rs12769431	chr10:922633	T/C	cg20503657	chr10:835505	NA	0.88	8.25	0.48	1.18e-14	Eosinophil percentage of granulocytes;
SARC	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg21171335	chr12:122356390	WDR66	0.39	6.39	0.39	8.83e-10	Mean corpuscular volume;
SARC	cis	rs9300255	0.568	rs1621194	chr12:123651018	T/C	cg00376283	chr12:123451042	ABCB9	0.58	6.95	0.41	3.55e-11	Neutrophil percentage of white cells;
SARC	cis	rs10463316	0.817	rs7708940	chr5:150789051	A/G	cg03212797	chr5:150827313	SLC36A1	-0.4	-4.83	-0.3	2.45e-6	Metabolite levels (Pyroglutamine);
SARC	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg11987759	chr7:65425863	GUSB	0.57	7.53	0.44	1.14e-12	Aortic root size;
SARC	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg12463550	chr7:65579703	CRCP	-0.48	-5.55	-0.34	7.9e-8	Aortic root size;
SARC	cis	rs2832191	0.967	rs2832216	chr21:30521921	C/T	cg24692254	chr21:30365293	RNF160	0.8	11.25	0.59	9.91e-24	Dental caries;
SARC	cis	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg11995313	chr8:8860691	ERI1	0.39	4.74	0.3	3.8e-6	Joint mobility (Beighton score);
SARC	cis	rs397969	0.570	rs62066349	chr17:19899940	C/G	cg13482628	chr17:19912719	NA	0.43	4.73	0.3	3.97e-6	Platelet count;
SARC	cis	rs79149102	0.579	rs6495142	chr15:75320166	C/T	cg17294928	chr15:75287854	SCAMP5	-1.08	-9.43	-0.53	4.22e-18	Lung cancer;
SARC	cis	rs3796352	1.000	rs71617204	chr3:53042951	G/A	cg27565382	chr3:53032988	SFMBT1	1.04	7.27	0.43	5.28e-12	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs56036086	1.000	rs73187250	chr22:50634552	G/A	cg16473166	chr22:50639996	SELO	0.57	4.99	0.31	1.19e-6	Platelet count;Plateletcrit;
SARC	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-8.0	-0.46	5.78e-14	Alzheimer's disease;
SARC	cis	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg18252515	chr7:66147081	NA	-1.42	-12.98	-0.65	2.41e-29	Gout;
SARC	cis	rs1348850	0.914	rs6761593	chr2:178451600	A/G	cg23306229	chr2:178417860	TTC30B	-0.61	-7.06	-0.42	1.9e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs80282103	0.867	rs12241632	chr10:1069070	A/T	cg18964960	chr10:1102726	WDR37	0.64	4.91	0.31	1.72e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs9303280	0.934	rs56380902	chr17:38066372	T/C	cg19468946	chr17:37922297	IKZF3	-0.29	-4.8	-0.3	2.79e-6	Self-reported allergy;
SARC	cis	rs34684276	1	rs34684276	chr15:78813155	G/A	cg06917634	chr15:78832804	PSMA4	-0.51	-5.28	-0.33	2.89e-7	Nicotine dependence;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg13939156	chr17:80058883	NA	-0.42	-6.48	-0.39	5.51e-10	Life satisfaction;
SARC	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg04944784	chr2:26401820	FAM59B	0.48	5.64	0.35	4.8e-8	Gut microbiome composition (summer);
SARC	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg08219700	chr8:58056026	NA	0.62	6.52	0.39	4.28e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs796364	0.806	rs203765	chr2:200903020	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.74	-6.22	-0.38	2.24e-9	Schizophrenia;
SARC	cis	rs72945132	0.882	rs56368190	chr11:70204328	T/G	cg00319359	chr11:70116639	PPFIA1	0.67	6.19	0.38	2.66e-9	Coronary artery disease;
SARC	cis	rs13191362	1.000	rs66534429	chr6:163003322	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.56	5.41	0.33	1.53e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs4803468	0.967	rs7259900	chr19:41889429	A/T	cg08477640	chr19:41863820	B9D2	0.45	5.83	0.36	1.85e-8	Height;
SARC	cis	rs9393692	1.000	rs9393692	chr6:26276650	A/G	cg00631329	chr6:26305371	NA	-0.65	-8.99	-0.51	8.64e-17	Educational attainment;
SARC	cis	rs1023500	0.551	rs2859438	chr22:42466980	A/T	cg15557168	chr22:42548783	NA	-0.35	-4.81	-0.3	2.67e-6	Schizophrenia;
SARC	cis	rs4742903	0.933	rs10820608	chr9:106890840	A/G	cg14250997	chr9:106856677	SMC2	0.54	7.31	0.43	4.34e-12	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs795484	0.633	rs904662	chr12:118581833	C/T	cg16572268	chr12:118583242	PEBP1	0.44	5.58	0.34	6.5e-8	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
SARC	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg04287289	chr16:89883240	FANCA	-0.54	-7.32	-0.43	3.88e-12	Vitiligo;
SARC	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg04277193	chr17:41438351	NA	0.44	4.73	0.3	3.83e-6	Menopause (age at onset);
SARC	cis	rs9790314	0.690	rs7614375	chr3:160851331	A/T	cg04691961	chr3:161091175	C3orf57	-0.56	-7.48	-0.44	1.52e-12	Morning vs. evening chronotype;
SARC	cis	rs748404	0.690	rs2467737	chr15:43737188	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.4	4.77	0.3	3.22e-6	Lung cancer;
SARC	cis	rs911555	0.755	rs1138400	chr14:103956833	A/G	cg12935359	chr14:103987150	CKB	-0.37	-5.18	-0.32	4.91e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.36	-5.04	-0.31	9.38e-7	Total body bone mineral density;
SARC	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg19077165	chr18:44547161	KATNAL2	-0.53	-7.29	-0.43	4.74e-12	Personality dimensions;
SARC	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg13206674	chr6:150067644	NUP43	0.41	5.36	0.33	1.98e-7	Lung cancer;
SARC	cis	rs11638352	0.661	rs11857696	chr15:44366258	T/A	cg27015174	chr15:43622946	ADAL;LCMT2	-0.76	-5.73	-0.35	3.06e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	cis	rs62158211	1.000	rs1807282	chr2:114110036	A/T	cg17784749	chr2:114082611	LOC440839	0.61	6.61	0.4	2.54e-10	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
SARC	cis	rs9479482	1.000	rs9479481	chr6:150357944	A/G	cg03788504	chr6:150331562	NA	-0.33	-5.38	-0.33	1.85e-7	Alopecia areata;
SARC	cis	rs918629	0.530	rs3777190	chr5:95247972	A/G	cg16656078	chr5:95278638	ELL2	0.59	7.05	0.42	1.96e-11	IgG glycosylation;
SARC	cis	rs2204008	0.777	rs8189597	chr12:38307739	G/C	cg13010199	chr12:38710504	ALG10B	-0.78	-11.01	-0.59	5.57e-23	Bladder cancer;
SARC	cis	rs1580019	0.563	rs13244332	chr7:32537679	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.53	6.74	0.4	1.21e-10	Cognitive ability;
SARC	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	11.03	0.59	4.93e-23	Alzheimer's disease;
SARC	cis	rs763014	0.898	rs2017567	chr16:637212	T/C	cg07343612	chr16:622815	PIGQ	-0.53	-7.16	-0.42	1.02e-11	Height;
SARC	cis	rs6570726	0.818	rs9390338	chr6:145908265	A/G	cg23711669	chr6:146136114	FBXO30	0.84	14.12	0.68	3.87e-33	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg22496380	chr5:211416	CCDC127	-0.88	-9.59	-0.53	1.47e-18	Breast cancer;
SARC	cis	rs9768139	0.733	rs71545585	chr7:158118672	G/A	cg25566285	chr7:158114605	PTPRN2	0.3	4.9	0.31	1.82e-6	Calcium levels;
SARC	cis	rs10078	0.571	rs890973	chr5:471494	T/C	cg08916839	chr5:415575	AHRR	0.84	8.0	0.46	5.66e-14	Fat distribution (HIV);
SARC	cis	rs6964587	1.000	rs6960867	chr7:91712698	A/G	cg17063962	chr7:91808500	NA	0.95	15.32	0.71	4.1e-37	Breast cancer;
SARC	cis	rs7647973	0.626	rs1996663	chr3:49878264	C/G	cg03060546	chr3:49711283	APEH	-0.64	-6.72	-0.4	1.35e-10	Menarche (age at onset);
SARC	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.74	8.74	0.5	4.81e-16	Height;
SARC	cis	rs761746	0.921	rs12171042	chr22:32011225	T/C	cg15823100	chr22:32027580	PISD	-0.35	-5.12	-0.32	6.34e-7	Intelligence;
SARC	cis	rs9951602	0.920	rs3859334	chr18:76684193	G/A	cg00806245	chr18:76673096	NA	-0.4	-5.01	-0.31	1.06e-6	Obesity-related traits;
SARC	cis	rs9916302	0.904	rs4795357	chr17:37569551	T/C	cg15445000	chr17:37608096	MED1	0.44	5.34	0.33	2.23e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs17345786	0.906	rs56171035	chr3:101111108	G/C	cg12386194	chr3:101231763	SENP7	0.81	9.48	0.53	3.14e-18	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg17376030	chr22:41985996	PMM1	0.62	7.4	0.44	2.5e-12	Vitiligo;
SARC	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg15595755	chr5:1867978	NA	0.43	5.97	0.36	8.81e-9	Cardiovascular disease risk factors;
SARC	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg18404041	chr3:52824283	ITIH1	-0.44	-6.57	-0.4	3.31e-10	Bipolar disorder;
SARC	cis	rs2594989	0.943	rs9822446	chr3:11420780	C/G	cg00170343	chr3:11313890	ATG7	0.62	5.99	0.37	7.91e-9	Circulating chemerin levels;
SARC	cis	rs8060686	0.516	rs12599238	chr16:68276235	G/A	cg27539214	chr16:67997921	SLC12A4	-0.57	-5.28	-0.33	2.92e-7	HDL cholesterol;Metabolic syndrome;
SARC	cis	rs9916302	0.706	rs7212621	chr17:37527911	T/G	cg15445000	chr17:37608096	MED1	-0.45	-4.88	-0.3	1.97e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs7635838	0.819	rs2454482	chr3:11534031	C/T	cg00170343	chr3:11313890	ATG7	0.61	8.43	0.48	3.53e-15	HDL cholesterol;
SARC	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg18357526	chr6:26021779	HIST1H4A	0.45	5.64	0.35	5.01e-8	Blood metabolite levels;
SARC	cis	rs807669	0.903	rs1780640	chr22:19174597	C/T	cg02655711	chr22:19163373	SLC25A1	0.55	7.51	0.44	1.27e-12	Metabolite levels;
SARC	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg24675658	chr1:53192096	ZYG11B	-0.59	-8.28	-0.48	9.38e-15	Monocyte count;
SARC	cis	rs3733585	0.673	rs6814664	chr4:9956228	C/T	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.95	-0.36	9.9e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs36715	0.953	rs36706	chr5:127556698	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.61	6.58	0.4	3.14e-10	Breast cancer;
SARC	cis	rs10979	1.000	rs13211390	chr6:143888010	A/T	cg25407410	chr6:143891975	LOC285740	-0.64	-8.74	-0.5	4.55e-16	Hypospadias;
SARC	trans	rs7824557	0.767	rs2060463	chr8:11161610	T/G	cg06636001	chr8:8085503	FLJ10661	0.58	7.16	0.42	1.04e-11	Retinal vascular caliber;
SARC	cis	rs8141529	0.748	rs132531	chr22:29297365	C/T	cg15103426	chr22:29168792	CCDC117	-0.67	-8.68	-0.49	6.98e-16	Lymphocyte counts;
SARC	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.74	8.47	0.49	2.79e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs79149102	0.579	rs79916508	chr15:75373721	A/C	cg17294928	chr15:75287854	SCAMP5	-0.91	-8.33	-0.48	6.76e-15	Lung cancer;
SARC	cis	rs9818758	0.607	rs35108630	chr3:49088356	T/A	cg01304814	chr3:48885189	PRKAR2A	0.65	5.25	0.33	3.46e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs3733585	0.775	rs13124007	chr4:10043931	G/C	cg11266682	chr4:10021025	SLC2A9	0.4	6.91	0.41	4.53e-11	Cleft plate (environmental tobacco smoke interaction);
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg11098622	chr5:102205822	PAM	-0.52	-6.37	-0.39	9.75e-10	Alcohol dependence;
SARC	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg11764359	chr7:65958608	NA	-0.87	-12.25	-0.63	5.81e-27	Aortic root size;
SARC	cis	rs5167	0.781	rs2075619	chr19:45495682	A/G	cg10169327	chr19:45448959	APOC2	0.31	4.98	0.31	1.27e-6	Blood protein levels;
SARC	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.7	6.74	0.4	1.21e-10	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg09021430	chr5:549028	NA	-0.42	-5.46	-0.34	1.19e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg08219700	chr8:58056026	NA	0.68	6.44	0.39	6.92e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs4803468	1.000	rs10853751	chr19:41903220	G/A	cg14132834	chr19:41945861	ATP5SL	-0.55	-7.37	-0.43	2.88e-12	Height;
SARC	cis	rs2153535	0.601	rs1855765	chr6:8444325	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs34172651	0.571	rs9922156	chr16:24704329	C/A	cg00152838	chr16:24741724	TNRC6A	0.5	5.23	0.32	3.77e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7617773	0.779	rs9833309	chr3:48327450	C/T	cg11946769	chr3:48343235	NME6	0.73	9.65	0.53	9.55e-19	Coronary artery disease;
SARC	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg25952890	chr19:58913133	NA	0.35	4.95	0.31	1.44e-6	Uric acid clearance;
SARC	cis	rs1568889	0.592	rs17652117	chr11:28483645	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.7	-8.36	-0.48	5.7e-15	Bipolar disorder;
SARC	cis	rs1949733	1.000	rs6447875	chr4:8503206	T/C	cg13073564	chr4:8508604	NA	-0.48	-7.9	-0.46	1.1e-13	Response to antineoplastic agents;
SARC	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg00933542	chr6:150070202	PCMT1	0.32	5.48	0.34	1.12e-7	Lung cancer;
SARC	cis	rs7084402	0.967	rs1621811	chr10:60320664	T/C	cg07615347	chr10:60278583	BICC1	0.59	8.39	0.48	4.59e-15	Refractive error;
SARC	trans	rs2727020	0.786	rs10839263	chr11:49354462	A/G	cg15704280	chr7:45808275	SEPT13	-0.73	-9.58	-0.53	1.52e-18	Coronary artery disease;
SARC	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.39	-5.56	-0.34	7.3900000000000007e-08	Total body bone mineral density;
SARC	cis	rs798554	1.000	rs798562	chr7:2757938	C/T	cg15847926	chr7:2749597	AMZ1	-0.3	-4.92	-0.31	1.65e-6	Height;
SARC	cis	rs73195822	0.667	rs7967386	chr12:111239162	G/A	cg10860002	chr12:110842031	ANAPC7	0.6	4.77	0.3	3.22e-6	Itch intensity from mosquito bite;
SARC	trans	rs12270115	0.656	rs11237998	chr11:79506216	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.69	-6.47	-0.39	5.76e-10	Preschool internalizing problems;
SARC	cis	rs992157	0.835	rs2271543	chr2:219142491	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.7	-10.23	-0.56	1.58e-20	Colorectal cancer;
SARC	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.54	0.44	1.06e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs593982	1.000	rs72922786	chr11:65562852	G/C	cg08755490	chr11:65554678	OVOL1	-0.88	-9.22	-0.52	1.86e-17	Atopic dermatitis;
SARC	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg21724239	chr8:58056113	NA	0.61	5.93	0.36	1.1e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs3204955	0.802	rs80057683	chr1:116244166	C/T	cg20810993	chr1:116250018	CASQ2	-0.49	-4.73	-0.3	3.87e-6	Itch intensity from mosquito bite adjusted by bite size;
SARC	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg16479474	chr6:28041457	NA	0.37	5.25	0.33	3.45e-7	Parkinson's disease;
SARC	cis	rs11997175	0.546	rs4545051	chr8:33608863	T/C	ch.8.33884649F	chr8:33765107	NA	0.48	6.01	0.37	7.26e-9	Body mass index;
SARC	cis	rs12291225	0.679	rs7934671	chr11:14305101	C/T	cg19336497	chr11:14380999	RRAS2	-0.41	-6.87	-0.41	5.8e-11	Sense of smell;
SARC	cis	rs2486288	0.586	rs12909883	chr15:45572054	G/C	cg19305227	chr15:45544335	SLC28A2	0.3	5.63	0.35	5.06e-8	Glomerular filtration rate;
SARC	cis	rs7592578	0.766	rs62181052	chr2:191387858	A/G	cg25963032	chr2:191064776	C2orf88	-0.48	-5.08	-0.32	7.86e-7	Diastolic blood pressure;
SARC	trans	rs9329221	0.683	rs3105738	chr8:9889914	A/T	cg21775007	chr8:11205619	TDH	-0.5	-6.5	-0.39	4.74e-10	Neuroticism;
SARC	cis	rs9911578	0.967	rs8082544	chr17:57185807	C/T	cg12560992	chr17:57184187	TRIM37	-0.88	-12.64	-0.64	3.03e-28	Intelligence (multi-trait analysis);
SARC	cis	rs992157	0.735	rs10932765	chr2:219099484	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.67	9.37	0.52	6.32e-18	Colorectal cancer;
SARC	trans	rs7615952	0.866	rs1976459	chr3:125647486	A/T	cg07211511	chr3:129823064	LOC729375	-0.96	-10.77	-0.58	3.15e-22	Blood pressure (smoking interaction);
SARC	cis	rs735539	0.521	rs7336905	chr13:21447278	T/C	cg16922012	chr13:21400325	XPO4	-0.42	-5.63	-0.35	5.11e-8	Dental caries;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg06178492	chr13:110835673	COL4A1	0.62	4.77	0.3	3.27e-6	Obesity-related traits;
SARC	cis	rs9814567	0.806	rs1880374	chr3:134322113	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.51	-6.63	-0.4	2.36e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs7618915	1.000	rs3852064	chr3:52349412	G/T	cg18404041	chr3:52824283	ITIH1	-0.34	-4.79	-0.3	2.96e-6	Bipolar disorder;
SARC	cis	rs1707322	1.000	rs785484	chr1:46574015	T/C	cg03146154	chr1:46216737	IPP	-0.48	-5.73	-0.35	3.11e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7772486	0.686	rs702305	chr6:145973840	A/G	cg23711669	chr6:146136114	FBXO30	-0.78	-12.61	-0.64	3.75e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7927771	0.832	rs10769258	chr11:47391039	C/T	cg20307385	chr11:47447363	PSMC3	0.55	6.94	0.41	3.87e-11	Subjective well-being;
SARC	cis	rs2479724	0.901	rs10947987	chr6:41754370	C/T	cg17623882	chr6:41773611	USP49	0.46	6.1	0.37	4.47e-9	Menarche (age at onset);
SARC	cis	rs140330585	1	rs140330585	chr15:78866445	G/A	cg18825076	chr15:78729989	IREB2	-0.42	-5.05	-0.31	8.82e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs6912958	0.712	rs7755167	chr6:88338752	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.54	-0.34	8.34e-8	Monocyte percentage of white cells;
SARC	cis	rs9733	0.650	rs61820165	chr1:150555987	C/T	cg17724175	chr1:150552817	MCL1	-0.39	-5.01	-0.31	1.09e-6	Tonsillectomy;
SARC	cis	rs11105298	0.891	rs10858898	chr12:89922111	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-5.43	-0.34	1.39e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs11122272	0.735	rs2491410	chr1:231532287	C/T	cg06096015	chr1:231504339	EGLN1	0.37	5.59	0.34	6.35e-8	Hemoglobin concentration;
SARC	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg23958373	chr8:599963	NA	0.96	7.49	0.44	1.4e-12	IgG glycosylation;
SARC	cis	rs617791	0.530	rs7952056	chr11:65744597	C/T	cg26695010	chr11:65641043	EFEMP2	0.58	7.08	0.42	1.64e-11	Breast cancer;
SARC	cis	rs9660992	0.573	rs12144980	chr1:205185104	C/T	cg21643547	chr1:205240462	TMCC2	-0.61	-8.1	-0.47	2.99e-14	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg26769984	chr7:1090371	C7orf50	0.48	5.07	0.32	8.22e-7	Bronchopulmonary dysplasia;
SARC	cis	rs1008375	0.843	rs59112113	chr4:17685336	A/T	cg16339924	chr4:17578868	LAP3	0.6	7.69	0.45	4.21e-13	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2153535	0.580	rs9328484	chr6:8524843	A/T	cg07606381	chr6:8435919	SLC35B3	0.76	10.94	0.58	9.14e-23	Motion sickness;
SARC	cis	rs79149102	0.579	rs79916508	chr15:75373721	A/C	cg09165964	chr15:75287851	SCAMP5	-0.9	-8.5	-0.49	2.23e-15	Lung cancer;
SARC	cis	rs34172651	0.917	rs17771137	chr16:24792242	G/A	cg04756594	chr16:24857601	SLC5A11	0.37	5.86	0.36	1.53e-8	Intelligence (multi-trait analysis);
SARC	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg16606324	chr3:10149918	C3orf24	0.48	5.04	0.31	9.53e-7	Alzheimer's disease;
SARC	cis	rs6665290	0.904	rs11587443	chr1:227187896	T/C	cg14016676	chr1:227182615	CDC42BPA	0.36	5.17	0.32	5.01e-7	Myeloid white cell count;
SARC	cis	rs1545257	0.537	rs2339948	chr2:24641012	A/T	cg06627628	chr2:24431161	ITSN2	-0.54	-6.98	-0.42	3.07e-11	Sjögren's syndrome;
SARC	cis	rs13392177	0.637	rs61041183	chr2:219056380	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.58	7.62	0.45	6.24e-13	Pyoderma gangrenosum in inflammatory bowel disease;
SARC	cis	rs11098499	0.908	rs28559989	chr4:120386627	C/T	cg24375607	chr4:120327624	NA	0.39	4.72	0.3	4.14e-6	Corneal astigmatism;
SARC	cis	rs2467099	0.504	rs2666005	chr17:73944596	T/G	cg06969265	chr17:73775802	H3F3B	0.57	6.85	0.41	6.43e-11	Systolic blood pressure;
SARC	cis	rs1707322	0.686	rs2991979	chr1:46055858	A/G	cg03146154	chr1:46216737	IPP	-0.51	-6.07	-0.37	5.12e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs208520	1.000	rs208536	chr6:66963440	T/C	cg07460842	chr6:66804631	NA	-0.86	-9.48	-0.53	3.09e-18	Exhaled nitric oxide output;
SARC	cis	rs617791	0.530	rs10896073	chr11:65762814	T/C	cg09462587	chr11:65769444	EIF1AD;BANF1	0.41	4.82	0.3	2.64e-6	Breast cancer;
SARC	cis	rs7568458	0.905	rs6547620	chr2:85755928	C/T	cg17127132	chr2:85788382	GGCX	0.44	5.74	0.35	2.92e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs2242116	1.000	rs2242116	chr3:46941116	A/G	cg27129171	chr3:47204927	SETD2	0.48	6.24	0.38	2.04e-9	Birth weight;
SARC	cis	rs834603	1.000	rs834603	chr7:47447921	A/G	cg23694490	chr7:47445681	TNS3	-0.4	-7.47	-0.44	1.59e-12	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs526231	0.578	rs17154821	chr5:102241341	A/T	cg23492399	chr5:102201601	PAM	-0.45	-5.35	-0.33	2.14e-7	Primary biliary cholangitis;
SARC	cis	rs6933660	0.536	rs3800274	chr6:151759192	T/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.49	5.26	0.33	3.23e-7	Menarche (age at onset);
SARC	cis	rs11122272	0.735	rs2808597	chr1:231532351	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.08	-0.55	4.68e-20	Hemoglobin concentration;
SARC	cis	rs8028182	0.636	rs7163907	chr15:75845097	T/C	cg20655648	chr15:75932815	IMP3	0.63	7.32	0.43	3.93e-12	Sudden cardiac arrest;
SARC	cis	rs1395	0.778	rs1978881	chr2:27400850	C/A	cg21747090	chr2:27597821	SNX17	-0.49	-5.78	-0.35	2.38e-8	Blood metabolite levels;
SARC	cis	rs7937682	0.663	rs35581942	chr11:111756286	C/T	cg22437258	chr11:111473054	SIK2	-0.47	-5.4	-0.33	1.61e-7	Primary sclerosing cholangitis;
SARC	cis	rs274567	0.602	rs272853	chr5:131688561	A/G	cg12564285	chr5:131593104	PDLIM4	0.41	5.84	0.36	1.7e-8	Blood metabolite levels;
SARC	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.43	-6.4	-0.39	8.26e-10	Total body bone mineral density;
SARC	cis	rs7769051	0.522	rs6927991	chr6:133113888	T/G	cg22852734	chr6:133119734	C6orf192	1.25	7.92	0.46	9.87e-14	Type 2 diabetes nephropathy;
SARC	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg10435706	chr6:150039699	LATS1	0.36	4.77	0.3	3.25e-6	Lung cancer;
SARC	cis	rs67133203	0.607	rs706801	chr12:51366092	A/G	cg13576200	chr12:52111417	SCN8A	-0.32	-4.75	-0.3	3.5e-6	Urinary tract infection frequency;
SARC	cis	rs55823223	0.648	rs11869977	chr17:73857382	C/G	cg14829360	chr17:73884958	NA	-0.62	-7.94	-0.46	8.27e-14	Psoriasis;
SARC	cis	rs2273669	0.667	rs12212402	chr6:109306681	T/C	cg05315195	chr6:109294784	ARMC2	-0.58	-5.22	-0.32	3.94e-7	Prostate cancer;
SARC	cis	rs11608355	0.545	rs35018715	chr12:109893134	T/C	cg05360138	chr12:110035743	NA	0.92	9.61	0.53	1.27e-18	Neuroticism;
SARC	cis	rs1153858	0.621	rs1706824	chr15:45579948	C/T	cg15395560	chr15:45543142	SLC28A2	-0.27	-4.85	-0.3	2.23e-6	Homoarginine levels;
SARC	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg21724239	chr8:58056113	NA	0.64	8.24	0.48	1.24e-14	Developmental language disorder (linguistic errors);
SARC	cis	rs1023500	0.505	rs2143139	chr22:42614401	G/C	cg04733989	chr22:42467013	NAGA	0.55	6.95	0.41	3.73e-11	Schizophrenia;
SARC	cis	rs3820928	0.874	rs10188770	chr2:227877037	G/A	cg11843606	chr2:227700838	RHBDD1	-0.55	-6.88	-0.41	5.45e-11	Pulmonary function;
SARC	cis	rs11585357	0.895	rs877552	chr1:17631236	C/T	cg08277548	chr1:17600880	PADI3	-0.43	-5.12	-0.32	6.47e-7	Hair shape;
SARC	cis	rs7666738	0.830	rs10440379	chr4:98902822	G/T	cg05340658	chr4:99064831	C4orf37	0.64	8.46	0.48	3.06e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs651907	0.557	rs3094297	chr3:101399260	A/G	cg12386194	chr3:101231763	SENP7	0.5	6.05	0.37	5.73e-9	Colorectal cancer;
SARC	cis	rs7223966	0.921	rs3020612	chr17:61960878	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.46	5.12	0.32	6.53e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs798554	0.610	rs2644304	chr7:2878779	T/C	cg13628971	chr7:2884303	GNA12	0.44	5.53	0.34	8.5e-8	Height;
SARC	cis	rs9309711	0.922	rs11679058	chr2:3483813	C/G	cg10845886	chr2:3471009	TTC15	-0.6	-7.53	-0.44	1.07e-12	Neurofibrillary tangles;
SARC	cis	rs2153535	0.580	rs9406158	chr6:8464152	C/T	cg21535247	chr6:8435926	SLC35B3	0.54	6.79	0.41	9.19e-11	Motion sickness;
SARC	cis	rs765787	0.530	rs2554455	chr15:45521304	T/C	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.55e-10	Uric acid levels;
SARC	cis	rs10795130	1.000	rs10795130	chr10:4151121	T/G	cg24830971	chr10:3180960	PITRM1	-0.5	-4.95	-0.31	1.43e-6	Sex hormone-binding globulin levels;
SARC	cis	rs9843304	0.529	rs72996050	chr3:149202633	T/C	cg08667024	chr3:149219783	TM4SF4	-0.4	-5.99	-0.37	7.98e-9	Gallstone disease;
SARC	cis	rs832540	0.966	rs252923	chr5:56205662	T/G	cg14703610	chr5:56206110	C5orf35	0.52	6.55	0.39	3.58e-10	Coronary artery disease;
SARC	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg11247378	chr22:39784982	NA	-0.31	-4.78	-0.3	3.07e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs4727027	0.899	rs11771339	chr7:148854132	A/T	cg23583168	chr7:148888333	NA	-0.74	-11.11	-0.59	2.72e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	11.31	0.6	6.28e-24	Alzheimer's disease;
SARC	cis	rs13256369	0.802	rs12541520	chr8:8564146	G/T	cg17143192	chr8:8559678	CLDN23	0.53	6.14	0.37	3.43e-9	Obesity-related traits;
SARC	cis	rs1008375	1.000	rs4698651	chr4:17694223	A/G	cg27347728	chr4:17578864	LAP3	0.46	5.73	0.35	3.07e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6730558	0.966	rs12993630	chr2:8753269	C/T	cg03429644	chr2:9252446	NA	0.26	5.13	0.32	6.18e-7	Mean corpuscular volume;Red cell distribution width;PR interval;
SARC	cis	rs2013441	1.000	rs2189710	chr17:20078964	C/A	cg13482628	chr17:19912719	NA	-0.48	-6.15	-0.37	3.36e-9	Obesity-related traits;
SARC	cis	rs6991838	0.778	rs11782837	chr8:66462563	A/G	cg13398993	chr8:66546079	ARMC1	0.38	4.73	0.3	3.92e-6	Intelligence (multi-trait analysis);
SARC	trans	rs61931739	0.817	rs2636084	chr12:34130210	G/A	cg13010199	chr12:38710504	ALG10B	0.56	7.62	0.45	6.2800000000000005e-13	Morning vs. evening chronotype;
SARC	cis	rs4481887	0.927	rs6678798	chr1:248476617	C/T	cg01631408	chr1:248437212	OR2T33	-0.39	-5.06	-0.31	8.56e-7	Common traits (Other);
SARC	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg05863683	chr7:1912471	MAD1L1	0.34	5.12	0.32	6.38e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs6840360	1.000	rs2007445	chr4:152600370	C/T	cg22705602	chr4:152727874	NA	-0.38	-6.54	-0.39	3.91e-10	Intelligence (multi-trait analysis);
SARC	cis	rs2952156	0.876	rs2313171	chr17:37833842	T/C	cg07936489	chr17:37558343	FBXL20	-0.4	-5.28	-0.33	2.89e-7	Asthma;
SARC	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg08219700	chr8:58056026	NA	0.66	6.64	0.4	2.23e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7178572	0.539	rs16968809	chr15:77672118	C/T	cg22256960	chr15:77711686	NA	0.47	4.73	0.3	3.85e-6	Type 2 diabetes;
SARC	cis	rs10992471	0.630	rs10992322	chr9:95159196	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.81	-0.36	2.02e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs7772486	0.641	rs960385	chr6:146371074	G/A	cg05347473	chr6:146136440	FBXO30	0.67	9.22	0.52	1.88e-17	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs427394	0.659	rs419128	chr5:6739791	G/A	cg10857441	chr5:6722123	POLS	-0.33	-4.9	-0.31	1.78e-6	Menopause (age at onset);
SARC	cis	rs2204008	0.685	rs4556621	chr12:38187236	C/A	cg13010199	chr12:38710504	ALG10B	0.78	10.64	0.57	8.61e-22	Bladder cancer;
SARC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg04013093	chr6:42928303	GNMT	-0.33	-4.95	-0.31	1.4e-6	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg16479474	chr6:28041457	NA	0.34	5.1	0.32	7.1e-7	Parkinson's disease;
SARC	cis	rs6570726	0.764	rs376257	chr6:145862949	G/A	cg23711669	chr6:146136114	FBXO30	0.87	14.71	0.69	4.26e-35	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs2727020	0.637	rs1164673	chr11:49328356	C/G	cg03929089	chr4:120376271	NA	0.52	6.7	0.4	1.51e-10	Coronary artery disease;
SARC	cis	rs17125944	0.505	rs10483617	chr14:53202605	A/G	cg00686598	chr14:53173677	PSMC6	-1.21	-8.73	-0.5	5.14e-16	Alzheimer's disease (late onset);
SARC	cis	rs3892630	0.878	rs1061686	chr19:33204544	C/T	cg22980127	chr19:33182716	NUDT19	-0.96	-8.27	-0.48	1e-14	Red blood cell traits;
SARC	cis	rs7520050	0.966	rs4660898	chr1:46402171	A/G	cg24296786	chr1:45957014	TESK2	0.38	4.8	0.3	2.82e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs7772486	0.806	rs2265477	chr6:146212338	T/C	cg05347473	chr6:146136440	FBXO30	0.46	6.26	0.38	1.87e-9	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg25972360	chr3:186288390	TBCCD1;DNAJB11	0.54	7.03	0.42	2.21e-11	Gallstone disease;
SARC	cis	rs17209837	1.000	rs2302387	chr7:87092185	G/A	cg00919237	chr7:87102261	ABCB4	-0.5	-5.47	-0.34	1.14e-7	Gallbladder cancer;
SARC	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg18876405	chr7:65276391	NA	-0.69	-8.59	-0.49	1.26e-15	Aortic root size;
SARC	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg24829409	chr8:58192753	C8orf71	-0.58	-5.24	-0.32	3.55e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7666738	0.830	rs13113899	chr4:99050422	T/C	cg05340658	chr4:99064831	C4orf37	0.64	8.6	0.49	1.18e-15	Colonoscopy-negative controls vs population controls;
SARC	trans	rs61931739	0.513	rs1463634	chr12:33899621	A/G	cg13010199	chr12:38710504	ALG10B	0.63	8.56	0.49	1.57e-15	Morning vs. evening chronotype;
SARC	cis	rs6942407	0.546	rs10257953	chr7:86799726	C/T	cg02420886	chr7:86849541	C7orf23	0.72	6.32	0.38	1.3e-9	Food allergy;
SARC	cis	rs240764	0.817	rs12201852	chr6:101149576	T/C	cg09795085	chr6:101329169	ASCC3	-0.46	-5.94	-0.36	1.01e-8	Neuroticism;
SARC	cis	rs981844	1.000	rs72731672	chr4:154664925	G/T	cg14289246	chr4:154710475	SFRP2	0.58	6.68	0.4	1.71e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs1865760	1.000	rs6905887	chr6:25912103	T/C	cg10373733	chr6:25993375	NA	0.43	5.14	0.32	5.79e-7	Height;
SARC	cis	rs2204008	0.683	rs11519834	chr12:38053575	T/A	cg13010199	chr12:38710504	ALG10B	0.78	10.73	0.57	4.45e-22	Bladder cancer;
SARC	cis	rs7264396	0.563	rs2425088	chr20:34303902	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-7.21	-0.43	7.81e-12	Total cholesterol levels;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg15249164	chr21:35288186	ATP5O	0.75	6.39	0.39	8.8e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1055129	0.537	rs1135640	chr17:73949540	C/G	cg06969265	chr17:73775802	H3F3B	-0.44	-5.34	-0.33	2.23e-7	White matter hyperintensity burden;
SARC	trans	rs9354308	0.809	rs9345693	chr6:66550984	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.53	-6.31	-0.38	1.42e-9	Metabolite levels;
SARC	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg11644478	chr21:40555479	PSMG1	-0.55	-6.75	-0.4	1.17e-10	Menarche (age at onset);
SARC	cis	rs2242194	0.816	rs6671688	chr1:154994265	T/C	cg03351412	chr1:154909251	PMVK	0.45	5.49	0.34	1.03e-7	Schizophrenia;
SARC	cis	rs2859741	1.000	rs2795009	chr1:37509494	C/T	cg09363841	chr1:37513479	NA	-0.27	-4.83	-0.3	2.46e-6	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
SARC	cis	rs3741404	0.584	rs645461	chr11:63893694	C/T	cg18225595	chr11:63971243	STIP1	-0.49	-7.55	-0.44	9.59e-13	Platelet count;
SARC	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg01316550	chr5:56110833	MAP3K1	0.54	4.92	0.31	1.62e-6	Initial pursuit acceleration;
SARC	cis	rs6688613	0.685	rs61815130	chr1:166910465	T/C	cg07049167	chr1:166818506	POGK	0.47	4.98	0.31	1.24e-6	Refractive astigmatism;
SARC	cis	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg19500275	chr17:80737654	TBCD	0.43	5.15	0.32	5.66e-7	Glycated hemoglobin levels;
SARC	cis	rs4974559	0.790	rs28712208	chr4:1316695	A/T	cg02980000	chr4:1222292	CTBP1	0.59	5.44	0.34	1.32e-7	Systolic blood pressure;
SARC	cis	rs3008870	1.000	rs35365746	chr1:67438900	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.89	-10.74	-0.58	3.95e-22	Lymphocyte percentage of white cells;
SARC	cis	rs1832871	0.672	rs11751081	chr6:158761505	G/A	cg07165851	chr6:158734300	TULP4	0.57	6.64	0.4	2.22e-10	Height;
SARC	cis	rs16866061	0.515	rs114968850	chr2:225352461	C/G	cg22509189	chr2:225307070	NA	-0.41	-5.26	-0.33	3.21e-7	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	trans	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.7	-0.4	1.58e-10	Systolic blood pressure;
SARC	cis	rs9948	0.655	rs75763821	chr2:97392694	G/A	cg01990225	chr2:97406019	LMAN2L	-0.95	-6.43	-0.39	7.25e-10	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs2718058	0.606	rs1349393	chr7:37869525	C/T	cg15028436	chr7:37888078	TXNDC3	0.4	5.14	0.32	5.72e-7	Alzheimer's disease (late onset);
SARC	cis	rs10744422	0.702	rs897392	chr12:123326326	G/A	cg25930673	chr12:123319894	HIP1R	-0.64	-4.97	-0.31	1.31e-6	Schizophrenia;
SARC	cis	rs11249608	0.548	rs7732719	chr5:178463054	A/G	cg21905437	chr5:178450457	ZNF879	0.57	7.47	0.44	1.63e-12	Pubertal anthropometrics;
SARC	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg18252515	chr7:66147081	NA	-0.47	-5.09	-0.32	7.32e-7	Aortic root size;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg02140097	chr12:110719074	ATP2A2	-0.5	-6.41	-0.39	8.15e-10	Schizophrenia;
SARC	cis	rs6700896	0.931	rs2889195	chr1:66156730	C/T	cg04111102	chr1:66153794	NA	0.35	5.37	0.33	1.88e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	trans	rs11098499	0.604	rs2389886	chr4:120570422	C/T	cg25214090	chr10:38739885	LOC399744	0.51	6.6	0.4	2.81e-10	Corneal astigmatism;
SARC	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.6	-6.31	-0.38	1.42e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg08564027	chr20:61660810	NA	0.76	11.8	0.61	1.69e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs7666738	0.830	rs13134819	chr4:98919885	G/C	cg05340658	chr4:99064831	C4orf37	0.68	9.2	0.52	2.08e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.23e-9	Life satisfaction;
SARC	cis	rs7511006	1.000	rs5771109	chr22:50678571	T/C	cg08875078	chr22:50639485	SELO	0.44	4.97	0.31	1.27e-6	Obesity-related traits;
SARC	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg22535103	chr8:58192502	C8orf71	-0.6	-6.34	-0.38	1.19e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7772486	0.754	rs9399567	chr6:146147295	C/T	cg05347473	chr6:146136440	FBXO30	0.51	7.07	0.42	1.82e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs921968	0.509	rs655441	chr2:219357545	C/T	cg02176678	chr2:219576539	TTLL4	0.46	7.12	0.42	1.33e-11	Mean corpuscular hemoglobin concentration;
SARC	cis	rs1505368	0.532	rs2888093	chr2:213328348	G/A	cg16329650	chr2:213403929	ERBB4	0.45	6.05	0.37	5.77e-9	Symmetrical dimethylarginine levels;
SARC	cis	rs7197653	0.667	rs7190070	chr16:68353983	C/T	cg05110241	chr16:68378359	PRMT7	-0.66	-5.97	-0.36	8.59e-9	Magnesium levels;
SARC	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg11764359	chr7:65958608	NA	0.69	8.18	0.47	1.88e-14	Aortic root size;
SARC	cis	rs3020736	0.500	rs6519306	chr22:42501217	T/C	cg04733989	chr22:42467013	NAGA	-0.76	-10.7	-0.57	5.23e-22	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6088580	0.505	rs6142219	chr20:33256345	G/A	cg08999081	chr20:33150536	PIGU	-0.34	-4.99	-0.31	1.17e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg24531977	chr5:56204891	C5orf35	-0.55	-5.81	-0.36	2.08e-8	Initial pursuit acceleration;
SARC	cis	rs950169	0.919	rs17300292	chr15:84762568	G/C	cg24253500	chr15:84953950	NA	0.36	5.24	0.32	3.66e-7	Schizophrenia;
SARC	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg03517284	chr6:25882590	NA	0.4	5.24	0.32	3.57e-7	Intelligence (multi-trait analysis);
SARC	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg11494091	chr17:61959527	GH2	-0.63	-10.17	-0.55	2.49e-20	Prudent dietary pattern;
SARC	cis	rs72781680	1.000	rs74704838	chr2:24158270	C/A	cg06627628	chr2:24431161	ITSN2	-0.69	-6.48	-0.39	5.36e-10	Lymphocyte counts;
SARC	cis	rs523522	0.962	rs3742052	chr12:120966921	A/G	cg12219531	chr12:120966889	COQ5	0.84	11.36	0.6	4.3e-24	High light scatter reticulocyte count;
SARC	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg05279229	chr7:1896384	MAD1L1	-0.38	-5.11	-0.32	6.76e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs2836974	0.604	rs2854727	chr21:40713787	A/G	cg17971929	chr21:40555470	PSMG1	0.62	8.11	0.47	2.95e-14	Cognitive function;
SARC	cis	rs113835537	0.529	rs11227511	chr11:66281244	A/C	cg24851651	chr11:66362959	CCS	0.37	4.74	0.3	3.73e-6	Airway imaging phenotypes;
SARC	cis	rs7927592	0.830	rs10896339	chr11:68302846	G/C	cg01657329	chr11:68192670	LRP5	-0.38	-4.91	-0.31	1.7e-6	Total body bone mineral density;
SARC	cis	rs2795502	1.000	rs2795508	chr10:43353555	G/T	cg20628663	chr10:43360327	NA	0.44	5.76	0.35	2.63e-8	Blood protein levels;
SARC	cis	rs3857536	0.904	rs979696	chr6:66896658	T/G	cg07460842	chr6:66804631	NA	-0.44	-5.27	-0.33	3.08e-7	Blood trace element (Cu levels);
SARC	cis	rs9916302	0.861	rs11078912	chr17:37671490	A/G	cg07936489	chr17:37558343	FBXL20	-0.67	-8.25	-0.48	1.2e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs918629	0.530	rs11741563	chr5:95240996	C/T	cg16656078	chr5:95278638	ELL2	-0.59	-7.19	-0.43	8.95e-12	IgG glycosylation;
SARC	cis	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg05623727	chr3:50126028	RBM5	-0.34	-5.17	-0.32	4.96e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6728642	0.572	rs2872686	chr2:97601024	A/G	cg26665480	chr2:98280029	ACTR1B	-0.69	-7.4	-0.44	2.51e-12	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs7552404	0.883	rs2185436	chr1:76203783	A/G	cg03433033	chr1:76189801	ACADM	0.52	7.51	0.44	1.28e-12	Blood metabolite levels;Acylcarnitine levels;
SARC	trans	rs11634851	0.933	rs923000	chr15:81000001	A/C	cg04669574	chr12:50297945	FAIM2	0.47	6.26	0.38	1.88e-9	Systolic blood pressure;
SARC	cis	rs910316	0.737	rs175499	chr14:75535927	G/A	cg08847533	chr14:75593920	NEK9	-0.81	-11.78	-0.61	1.88e-25	Height;
SARC	cis	rs7264396	0.561	rs6142474	chr20:34574914	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.6	5.54	0.34	8.32e-8	Total cholesterol levels;
SARC	cis	rs2522056	1.000	rs6874639	chr5:131778716	C/T	cg24060327	chr5:131705240	SLC22A5	-0.53	-5.45	-0.34	1.28e-7	Lymphocyte counts;Fibrinogen;
SARC	cis	rs6866344	0.570	rs1071881	chr5:178135917	C/T	cg03877680	chr5:178157825	ZNF354A	1.04	14.68	0.69	5.67e-35	Neutrophil percentage of white cells;
SARC	cis	rs9303401	0.555	rs8071831	chr17:57292950	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.64	7.94	0.46	8.44e-14	Cognitive test performance;
SARC	cis	rs9291683	0.588	rs35099040	chr4:10018839	T/C	cg00071950	chr4:10020882	SLC2A9	0.39	6.26	0.38	1.82e-9	Bone mineral density;
SARC	cis	rs200986	1	rs200986	chr6:27824766	G/C	cg17221315	chr6:27791827	HIST1H4J	0.48	5.55	0.34	7.87e-8	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9948	0.786	rs62156230	chr2:97424915	A/G	cg01990225	chr2:97406019	LMAN2L	-0.81	-6.31	-0.38	1.41e-9	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs6807306	0.956	rs2901037	chr3:167348070	A/G	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.52	5.02	0.31	1.02e-6	Mean platelet volume;
SARC	cis	rs1550582	0.662	rs7812708	chr8:135500832	C/T	cg17885191	chr8:135476712	NA	0.77	7.78	0.45	2.34e-13	Educational attainment;
SARC	cis	rs11785693	0.862	rs73183633	chr8:4994543	G/A	cg26367366	chr8:4980734	NA	0.75	6.62	0.4	2.46e-10	Neuroticism (multi-trait analysis);Neuroticism;
SARC	trans	rs2727020	0.521	rs7107178	chr11:49526668	G/A	cg03929089	chr4:120376271	NA	0.7	7.9	0.46	1.13e-13	Coronary artery disease;
SARC	cis	rs7828089	0.582	rs7825938	chr8:22266866	G/A	cg12081754	chr8:22256438	SLC39A14	0.64	8.73	0.5	5.06e-16	Verbal declarative memory;
SARC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg04267008	chr7:1944627	MAD1L1	-0.61	-7.13	-0.42	1.28e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs10512697	0.803	rs13190123	chr5:3578348	G/A	cg19473799	chr5:3511975	NA	-0.68	-4.86	-0.3	2.11e-6	Immune response to smallpox vaccine (IL-6);
SARC	trans	rs804280	0.509	rs12719915	chr8:11786255	A/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.32	-0.38	1.34e-9	Myopia (pathological);
SARC	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg21724239	chr8:58056113	NA	0.69	6.02	0.37	6.89e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2933343	0.953	rs2933344	chr3:128658715	A/G	cg25356066	chr3:128598488	ACAD9	0.57	6.61	0.4	2.64e-10	IgG glycosylation;
SARC	cis	rs533581	0.873	rs555191	chr16:88978850	C/T	cg05579598	chr16:88989069	CBFA2T3	0.33	4.9	0.31	1.84e-6	Social autistic-like traits;
SARC	cis	rs79149102	0.579	rs12591994	chr15:75320306	A/G	cg09165964	chr15:75287851	SCAMP5	-1.04	-8.77	-0.5	3.71e-16	Lung cancer;
SARC	cis	rs10078	0.571	rs2241597	chr5:480509	A/G	cg08916839	chr5:415575	AHRR	0.82	7.92	0.46	9.93e-14	Fat distribution (HIV);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg08208899	chr2:181931215	NA	0.56	8.14	0.47	2.34e-14	Thyroid stimulating hormone;
SARC	cis	rs1008375	1.000	rs12648232	chr4:17612537	C/T	cg02297831	chr4:17616191	MED28	-0.49	-6.11	-0.37	4.11e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7818345	0.967	rs4617172	chr8:19273362	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.43	5.78	0.35	2.38e-8	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs10911251	0.528	rs2093982	chr1:183094191	T/C	cg13390022	chr1:182993471	LAMC1	0.31	4.79	0.3	3.01e-6	Colorectal cancer;
SARC	cis	rs77972916	0.536	rs7589361	chr2:43589328	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.47	-5.22	-0.32	3.99e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs9372253	0.678	rs9372251	chr6:110700656	A/G	cg01119278	chr6:110721349	DDO	-0.39	-5.07	-0.32	7.95e-7	Platelet distribution width;
SARC	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg13902645	chr11:5959945	NA	-0.42	-5.42	-0.33	1.52e-7	DNA methylation (variation);
SARC	cis	rs6088813	0.857	rs1886692	chr20:33986549	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	-0.46	-5.47	-0.34	1.16e-7	Height;
SARC	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg00149659	chr3:10157352	C3orf10	0.73	7.0	0.42	2.64e-11	Alzheimer's disease;
SARC	cis	rs9381040	0.655	rs9394756	chr6:41016183	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.45	-5.33	-0.33	2.27e-7	Alzheimer's disease (late onset);
SARC	cis	rs738322	1.000	rs133012	chr22:38570721	G/A	cg25457927	chr22:38595422	NA	-0.29	-5.98	-0.36	8.38e-9	Cutaneous nevi;
SARC	cis	rs7043114	0.525	rs2274966	chr9:95155563	C/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.71	-0.35	3.48e-8	Height;
SARC	cis	rs10088262	0.629	rs7015861	chr8:124795613	C/T	cg15047889	chr8:124780837	FAM91A1	-0.64	-7.21	-0.43	7.87e-12	Pancreatic cancer;
SARC	cis	rs7914558	1.000	rs7896547	chr10:104866958	A/G	cg04362960	chr10:104952993	NT5C2	0.4	4.79	0.3	3.01e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs7681440	0.606	rs2737004	chr4:90750722	A/G	cg06632027	chr4:90757378	SNCA	-0.42	-5.25	-0.33	3.35e-7	Dementia with Lewy bodies;
SARC	cis	rs17030434	1.000	rs1456391	chr4:154720485	A/G	cg14289246	chr4:154710475	SFRP2	-0.76	-7.12	-0.42	1.31e-11	Electrocardiographic conduction measures;
SARC	cis	rs7626444	0.584	rs844542	chr3:196479303	C/T	cg12930392	chr3:196481615	PAK2	0.25	4.98	0.31	1.25e-6	Monocyte count;
SARC	trans	rs11250098	0.510	rs4840525	chr8:10765635	C/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.95	-0.41	3.58e-11	Morning vs. evening chronotype;
SARC	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg16405210	chr4:1374714	KIAA1530	-0.49	-6.05	-0.37	5.75e-9	Longevity;
SARC	cis	rs13082711	0.911	rs3755652	chr3:27472936	A/G	cg02860705	chr3:27208620	NA	-0.44	-5.62	-0.35	5.46e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs910316	0.967	rs11159121	chr14:75666029	A/T	cg06637938	chr14:75390232	RPS6KL1	-0.47	-6.84	-0.41	6.85e-11	Height;
SARC	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg00629941	chr15:75287862	SCAMP5	0.4	4.78	0.3	3.05e-6	Breast cancer;
SARC	cis	rs9467773	0.967	rs6456732	chr6:26514445	T/C	cg12292205	chr6:26970375	C6orf41	0.44	5.46	0.34	1.23e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2180341	1.000	rs9285460	chr6:127640190	A/G	cg24812749	chr6:127587940	RNF146	0.98	12.95	0.65	2.92e-29	Breast cancer;
SARC	cis	rs698833	0.624	rs7564087	chr2:44693647	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	7.27	0.43	5.34e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs4481887	0.927	rs12731721	chr1:248474210	G/A	cg01631408	chr1:248437212	OR2T33	-0.39	-5.06	-0.31	8.56e-7	Common traits (Other);
SARC	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg19077165	chr18:44547161	KATNAL2	0.53	7.26	0.43	5.89e-12	Personality dimensions;
SARC	cis	rs7772486	0.790	rs2254288	chr6:146204470	G/A	cg23711669	chr6:146136114	FBXO30	0.75	11.9	0.61	7.88e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3808502	0.585	rs4549730	chr8:11239078	T/G	cg21775007	chr8:11205619	TDH	-0.58	-7.71	-0.45	3.68e-13	Neuroticism;
SARC	cis	rs708547	0.671	rs1718863	chr4:57887586	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.56	6.81	0.41	8.03e-11	Response to bleomycin (chromatid breaks);
SARC	cis	rs6570726	0.526	rs9376928	chr6:145724403	T/G	cg23711669	chr6:146136114	FBXO30	-0.63	-8.17	-0.47	1.96e-14	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg00933542	chr6:150070202	PCMT1	0.31	4.81	0.3	2.73e-6	Lung cancer;
SARC	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.59	7.92	0.46	9.49e-14	Menarche (age at onset);
SARC	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg09467607	chr2:36825704	FEZ2	-0.6	-8.45	-0.48	3.09e-15	Height;
SARC	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4308124	0.708	rs6727313	chr2:111971540	G/A	cg04571233	chr2:111982156	NA	-0.51	-5.96	-0.36	9.39e-9	Vitiligo;
SARC	cis	rs7267979	0.866	rs2424698	chr20:25256106	C/T	cg03522245	chr20:25566470	NINL	0.34	4.78	0.3	3.04e-6	Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs9858542	1.000	rs1131095	chr3:49714225	T/C	cg07274523	chr3:49395745	GPX1	0.48	5.49	0.34	1.06e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg22535103	chr8:58192502	C8orf71	-0.58	-6.18	-0.38	2.8e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg27266027	chr21:40555129	PSMG1	-0.47	-5.21	-0.32	4.2e-7	Cognitive function;
SARC	cis	rs1570884	0.516	rs9535268	chr13:50175478	C/A	cg08779649	chr13:50194554	NA	0.36	6.27	0.38	1.76e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs3008870	0.755	rs2755243	chr1:67482783	T/C	cg02640540	chr1:67518911	SLC35D1	0.46	5.26	0.33	3.34e-7	Lymphocyte percentage of white cells;
SARC	cis	rs3126085	0.935	rs34188926	chr1:152293481	A/C	cg03465714	chr1:152285911	FLG	0.48	5.62	0.35	5.42e-8	Atopic dermatitis;
SARC	cis	rs7666738	0.830	rs13129479	chr4:98987860	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9581943	0.901	rs9551414	chr13:28474237	C/T	cg16302790	chr13:28498334	PDX1	0.55	8.29	0.48	8.79e-15	Pancreatic cancer;
SARC	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg11644478	chr21:40555479	PSMG1	-0.55	-6.83	-0.41	7.11e-11	Menarche (age at onset);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg05851148	chr5:179225977	MGAT4B;MIR1229	-0.41	-6.41	-0.39	8.02e-10	Chemerin levels;
SARC	cis	rs8045833	0.714	rs749681	chr16:88570675	A/G	cg05152867	chr16:88568237	ZFPM1	0.33	4.86	0.3	2.12e-6	Vascular endothelial growth factor levels;
SARC	cis	rs35213789	0.762	rs2533435	chr7:69126626	T/C	cg10619644	chr7:69149951	AUTS2	-0.35	-4.78	-0.3	3.13e-6	Childhood ear infection;
SARC	cis	rs7666738	0.546	rs10440329	chr4:98903735	C/T	cg05340658	chr4:99064831	C4orf37	0.57	7.07	0.42	1.79e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs72945132	0.882	rs7928686	chr11:70134528	T/C	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.78	-0.35	2.39e-8	Coronary artery disease;
SARC	cis	rs3126085	0.935	rs6670717	chr1:152249956	T/C	cg09127314	chr1:152161683	NA	-0.45	-4.94	-0.31	1.51e-6	Atopic dermatitis;
SARC	cis	rs910316	0.763	rs175042	chr14:75470833	A/T	cg11812906	chr14:75593930	NEK9	-0.76	-10.05	-0.55	5.64e-20	Height;
SARC	cis	rs10876993	0.826	rs1678534	chr12:58057435	A/C	cg18357645	chr12:58087776	OS9	0.44	5.7	0.35	3.54e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	5.62	0.35	5.51e-8	Bipolar disorder;
SARC	cis	rs3020736	0.500	rs11090076	chr22:42514190	T/C	cg15557168	chr22:42548783	NA	0.36	4.92	0.31	1.67e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs460214	0.576	rs2836604	chr21:40041295	A/C	cg12884169	chr21:40033163	ERG	-0.32	-4.72	-0.3	4.08e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs1215050	0.791	rs165252	chr4:98758728	A/C	cg05340658	chr4:99064831	C4orf37	0.42	5.63	0.35	5.17e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs7208859	0.623	rs58089675	chr17:29196764	C/G	cg13385521	chr17:29058706	SUZ12P	0.86	7.34	0.43	3.54e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs644799	0.648	rs1016031	chr11:95473365	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.72	-9.65	-0.53	9.41e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs10782582	0.593	rs11576534	chr1:76112751	C/T	cg03433033	chr1:76189801	ACADM	-0.4	-5.2	-0.32	4.3e-7	Daytime sleep phenotypes;
SARC	cis	rs12579753	0.869	rs12366921	chr12:82223024	G/A	cg07988820	chr12:82153109	PPFIA2	-0.55	-6.26	-0.38	1.79e-9	Resting heart rate;
SARC	cis	rs6088580	0.524	rs1853056	chr20:33262058	C/T	cg24642439	chr20:33292090	TP53INP2	-0.55	-6.74	-0.4	1.22e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg21775007	chr8:11205619	TDH	-0.5	-6.23	-0.38	2.15e-9	Neuroticism;
SARC	cis	rs6120849	0.901	rs6060278	chr20:33753262	T/C	cg24642439	chr20:33292090	TP53INP2	0.49	4.82	0.3	2.57e-6	Protein C levels;
SARC	cis	rs7633770	0.749	rs6442011	chr3:46685722	C/T	cg11219411	chr3:46661640	NA	0.43	7.06	0.42	1.85e-11	Coronary artery disease;
SARC	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1018836	0.923	rs12545279	chr8:91636373	C/G	cg16814680	chr8:91681699	NA	-0.82	-13.46	-0.66	6.17e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs453301	0.686	rs7814328	chr8:8876229	T/C	cg11995313	chr8:8860691	ERI1	0.47	6.05	0.37	5.8e-9	Joint mobility (Beighton score);
SARC	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg11890956	chr21:40555474	PSMG1	1.06	15.99	0.72	2.44e-39	Cognitive function;
SARC	cis	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg24110177	chr3:50126178	RBM5	-0.52	-6.93	-0.41	4.09e-11	Intelligence (multi-trait analysis);
SARC	cis	rs35306767	0.903	rs11253485	chr10:919362	C/T	cg26597838	chr10:835615	NA	0.84	8.41	0.48	4.07e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs9513627	1.000	rs7338537	chr13:100119581	C/A	cg25919922	chr13:100150906	NA	-0.74	-5.45	-0.34	1.26e-7	Obesity-related traits;
SARC	cis	rs7829975	0.744	rs2409092	chr8:8682192	A/T	cg14343924	chr8:8086146	FLJ10661	0.43	5.33	0.33	2.31e-7	Mood instability;
SARC	cis	rs526231	0.543	rs34791	chr5:102462104	C/A	cg23492399	chr5:102201601	PAM	-0.51	-5.55	-0.34	7.77e-8	Primary biliary cholangitis;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg12607967	chr1:70385145	LRRC7;PIN1L	-0.5	-6.67	-0.4	1.86e-10	Height;
SARC	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg02733842	chr7:1102375	C7orf50	-0.53	-6.65	-0.4	2.05e-10	Bronchopulmonary dysplasia;
SARC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.45	0.53	3.64e-18	Prudent dietary pattern;
SARC	cis	rs1030877	0.515	rs2576742	chr2:105898822	A/T	cg02079111	chr2:105885981	TGFBRAP1	0.56	6.47	0.39	5.71e-10	Obesity-related traits;
SARC	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg20887711	chr4:1340912	KIAA1530	-0.62	-7.31	-0.43	4.12e-12	Obesity-related traits;
SARC	cis	rs826838	0.935	rs1601579	chr12:39178606	G/C	cg13010199	chr12:38710504	ALG10B	0.75	9.97	0.55	9.86e-20	Heart rate;
SARC	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg11644478	chr21:40555479	PSMG1	1.03	14.29	0.68	1.1e-33	Cognitive function;
SARC	cis	rs8077889	0.956	rs4793025	chr17:41841621	T/C	cg26893861	chr17:41843967	DUSP3	0.9	10.51	0.57	2.2e-21	Triglycerides;
SARC	cis	rs11098499	0.954	rs17046116	chr4:120387259	G/A	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs73206853	0.764	rs16940881	chr12:110937818	G/C	cg10860002	chr12:110842031	ANAPC7	0.59	4.76	0.3	3.44e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs734999	0.549	rs2764845	chr1:2528999	G/T	cg18854424	chr1:2615690	NA	-0.32	-5.11	-0.32	6.76e-7	Ulcerative colitis;
SARC	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg06618935	chr21:46677482	NA	-0.41	-5.37	-0.33	1.92e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg11764359	chr7:65958608	NA	0.8	10.22	0.56	1.69e-20	Aortic root size;
SARC	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg01765077	chr12:122356316	WDR66	0.31	4.91	0.31	1.75e-6	Mean corpuscular volume;
SARC	cis	rs9393777	0.623	rs9358946	chr6:26478927	G/A	cg12826209	chr6:26865740	GUSBL1	0.81	7.39	0.44	2.59e-12	Intelligence (multi-trait analysis);
SARC	trans	rs9354352	0.935	rs7766730	chr6:66697003	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.59	7.7	0.45	3.76e-13	Initial pursuit acceleration in psychotic disorders;
SARC	cis	rs10870270	0.957	rs7074604	chr10:133740373	G/C	cg26149184	chr10:133730230	NA	0.47	5.39	0.33	1.68e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs10791097	0.568	rs4411284	chr11:130738568	A/C	cg12179176	chr11:130786555	SNX19	0.73	10.93	0.58	9.9e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs7666738	0.791	rs28579101	chr4:98843203	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.76	0.5	4.2e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9815354	0.812	rs17283243	chr3:41914792	C/T	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg21724239	chr8:58056113	NA	0.66	6.25	0.38	1.97e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7560272	0.501	rs11894953	chr2:73964631	A/G	cg20560298	chr2:73613845	ALMS1	-0.43	-5.75	-0.35	2.76e-8	Schizophrenia;
SARC	cis	rs6502050	0.761	rs7225637	chr17:80059758	A/G	cg19223190	chr17:80058835	NA	0.5	7.3	0.43	4.64e-12	Life satisfaction;
SARC	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg00031303	chr3:195681400	NA	0.49	5.54	0.34	8.35e-8	Pancreatic cancer;
SARC	cis	rs9341808	0.519	rs676311	chr6:80989750	T/G	cg08355045	chr6:80787529	NA	-0.36	-5.49	-0.34	1.02e-7	Sitting height ratio;
SARC	cis	rs477692	0.544	rs12251589	chr10:131417354	C/A	cg05714579	chr10:131428358	MGMT	-0.74	-10.46	-0.57	3.14e-21	Response to temozolomide;
SARC	trans	rs11165623	0.740	rs12126692	chr1:96889258	C/G	cg10631902	chr5:14652156	NA	0.45	7.38	0.44	2.74e-12	Hip circumference;Waist circumference;
SARC	cis	rs67460515	0.529	rs6795586	chr3:160897701	A/C	cg17135325	chr3:160939158	NMD3	0.54	6.56	0.39	3.39e-10	Parkinson's disease;
SARC	cis	rs35213789	0.853	rs7809145	chr7:69271250	G/A	cg10619644	chr7:69149951	AUTS2	0.36	4.73	0.3	3.83e-6	Childhood ear infection;
SARC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg03647317	chr4:187891568	NA	-0.35	-4.94	-0.31	1.46e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs554111	0.637	rs604659	chr1:21043913	T/C	cg08890418	chr1:21044141	KIF17	0.42	5.87	0.36	1.49e-8	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg14664628	chr15:75095509	CSK	-0.43	-5.1	-0.32	7.14e-7	Breast cancer;
SARC	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg03433033	chr1:76189801	ACADM	-0.51	-6.34	-0.38	1.19e-9	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7666738	0.753	rs7698541	chr4:98986351	T/A	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg03806693	chr22:41940476	POLR3H	0.93	13.21	0.65	4e-30	Vitiligo;
SARC	cis	rs11098499	0.954	rs1480931	chr4:120395809	G/T	cg09307838	chr4:120376055	NA	0.92	12.81	0.64	8.87e-29	Corneal astigmatism;
SARC	cis	rs9303401	0.614	rs2240719	chr17:56582477	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.05	11.45	0.6	2.24e-24	Cognitive test performance;
SARC	trans	rs7819412	1.000	rs2409722	chr8:11039816	T/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.57	-0.44	8.6e-13	Triglycerides;
SARC	cis	rs62244186	0.541	rs9859879	chr3:44840166	G/A	cg15687855	chr3:44754131	ZNF502	-0.33	-4.95	-0.31	1.44e-6	Depressive symptoms;
SARC	cis	rs7481584	0.624	rs516443	chr11:3047294	A/G	cg25174290	chr11:3078921	CARS	-0.59	-8.27	-0.48	1.02e-14	Calcium levels;
SARC	cis	rs2290416	0.892	rs3829012	chr8:144664656	C/T	cg10810860	chr8:144639591	GSDMD	-0.7	-4.91	-0.31	1.72e-6	Attention deficit hyperactivity disorder;
SARC	trans	rs641862	1	rs641862	chr13:110790232	C/T	cg16628188	chr13:113405067	ATP11A	0.77	6.23	0.38	2.13e-9	Obesity-related traits;
SARC	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg11890956	chr21:40555474	PSMG1	-1.04	-15.79	-0.72	1.12e-38	Cognitive function;
SARC	cis	rs240764	0.717	rs6907444	chr6:101163606	G/T	cg09795085	chr6:101329169	ASCC3	-0.47	-5.92	-0.36	1.15e-8	Neuroticism;
SARC	cis	rs2439831	0.867	rs2920781	chr15:43924682	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	8.21	0.47	1.53e-14	Lung cancer in ever smokers;
SARC	cis	rs2120243	0.625	rs4482625	chr3:157096009	G/A	cg01018701	chr3:157155998	VEPH1;PTX3	0.45	5.82	0.36	1.98e-8	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs611744	0.870	rs685358	chr8:109161413	T/C	cg21045802	chr8:109455806	TTC35	0.48	6.1	0.37	4.32e-9	Dupuytren's disease;
SARC	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg05896524	chr21:47604654	C21orf56	0.44	5.27	0.33	3.13e-7	Testicular germ cell tumor;
SARC	cis	rs300703	0.935	rs300755	chr2:228505	C/T	cg21211680	chr2:198530	NA	0.52	5.21	0.32	4.11e-7	Blood protein levels;
SARC	cis	rs367615	0.506	rs2963021	chr5:108800365	C/T	cg17395555	chr5:108820864	NA	0.44	6.47	0.39	5.7e-10	Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs4481887	0.741	rs6674078	chr1:248543026	G/A	cg00666640	chr1:248458726	OR2T12	0.34	5.96	0.36	9.33e-9	Common traits (Other);
SARC	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg06618935	chr21:46677482	NA	-0.4	-5.31	-0.33	2.57e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.63	-7.57	-0.44	8.86e-13	Gut microbiome composition (summer);
SARC	cis	rs8031584	0.541	rs1983459	chr15:31208749	C/T	cg08109568	chr15:31115862	NA	-0.43	-5.66	-0.35	4.33e-8	Huntington's disease progression;
SARC	cis	rs950169	1.000	rs950169	chr15:84706461	C/T	cg24253500	chr15:84953950	NA	0.35	5.01	0.31	1.07e-6	Schizophrenia;
SARC	cis	rs7647973	0.626	rs9830730	chr3:49675875	G/C	cg06212747	chr3:49208901	KLHDC8B	0.59	5.94	0.36	1.02e-8	Menarche (age at onset);
SARC	cis	rs6540556	0.643	rs2236903	chr1:209883480	A/T	cg05527609	chr1:210001259	C1orf107	-0.47	-4.75	-0.3	3.5e-6	Red blood cell count;
SARC	cis	rs9291683	0.538	rs11727199	chr4:10036190	C/T	cg00071950	chr4:10020882	SLC2A9	0.41	6.52	0.39	4.34e-10	Bone mineral density;
SARC	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg03806693	chr22:41940476	POLR3H	-0.9	-12.12	-0.62	1.57e-26	Vitiligo;
SARC	cis	rs9868809	0.772	rs2302295	chr3:48690110	T/C	cg07636037	chr3:49044803	WDR6	-0.77	-6.83	-0.41	7.39e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs1348850	0.526	rs2141157	chr2:178374112	C/T	cg23306229	chr2:178417860	TTC30B	0.79	7.68	0.45	4.31e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7700895	0.737	rs1043381	chr5:95221337	C/T	cg16656078	chr5:95278638	ELL2	-0.52	-6.37	-0.39	1e-9	IgG glycosylation;
SARC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.63	-0.4	2.28e-10	Total body bone mineral density;
SARC	cis	rs6545883	0.801	rs778142	chr2:61681428	G/T	cg15711740	chr2:61764176	XPO1	-0.43	-5.13	-0.32	6.01e-7	Tuberculosis;
SARC	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg16132339	chr22:24313637	DDTL;DDT	-0.4	-4.79	-0.3	2.97e-6	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs9300255	0.602	rs1716167	chr12:123651162	C/T	cg05973401	chr12:123451056	ABCB9	-0.48	-5.39	-0.33	1.69e-7	Neutrophil percentage of white cells;
SARC	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-15.51	-0.71	9.76e-38	Chronic sinus infection;
SARC	cis	rs6546324	0.921	rs4619594	chr2:67868480	A/C	cg18237512	chr2:67827392	NA	-0.41	-5.27	-0.33	3.1e-7	Endometriosis;
SARC	cis	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg14343924	chr8:8086146	FLJ10661	0.4	4.93	0.31	1.58e-6	Mood instability;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg17755581	chr20:56964015	VAPB	0.49	6.38	0.39	9.35e-10	Lung adenocarcinoma;
SARC	cis	rs11711311	1.000	rs12637067	chr3:113527606	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	8.72	0.5	5.29e-16	IgG glycosylation;
SARC	cis	rs483180	0.512	rs597308	chr1:120214953	G/A	cg19096424	chr1:120255104	PHGDH	0.51	5.99	0.37	7.84e-9	Macular telangiectasia type 2;
SARC	cis	rs2180341	1.000	rs7453272	chr6:127633959	C/T	cg27446573	chr6:127587934	RNF146	-1.0	-12.58	-0.64	4.88e-28	Breast cancer;
SARC	cis	rs7932354	0.528	rs1060573	chr11:47179829	A/G	cg03339077	chr11:47165057	C11orf49	-0.41	-5.64	-0.35	5.02e-8	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs7264396	0.563	rs6060560	chr20:34278890	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	5.63	0.35	5.19e-8	Total cholesterol levels;
SARC	cis	rs6582630	0.585	rs12422588	chr12:38478675	C/T	cg14851346	chr12:38532713	NA	-0.46	-5.58	-0.34	6.64e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg07701084	chr6:150067640	NUP43	0.41	5.42	0.33	1.5e-7	Lung cancer;
SARC	cis	rs9916302	0.904	rs587343	chr17:37440603	C/T	cg07936489	chr17:37558343	FBXL20	0.69	9.35	0.52	7.69e-18	Glomerular filtration rate (creatinine);
SARC	cis	rs9394841	0.692	rs56215622	chr6:41892457	G/A	cg08135965	chr6:41755394	TOMM6	0.69	7.29	0.43	4.77e-12	Mean corpuscular hemoglobin;Red cell distribution width;
SARC	cis	rs4566357	0.615	rs12328878	chr2:227918962	G/A	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.63	-0.35	5.2100000000000003e-08	Coronary artery disease;
SARC	cis	rs2304069	0.659	rs216141	chr5:149443994	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.48	-5.13	-0.32	6.19e-7	HIV-1 control;
SARC	cis	rs2273669	0.667	rs12216104	chr6:109317635	C/T	cg05315195	chr6:109294784	ARMC2	-0.59	-5.45	-0.34	1.28e-7	Prostate cancer;
SARC	cis	rs2408955	0.522	rs6580650	chr12:48418556	G/T	cg24011408	chr12:48396354	COL2A1	-0.43	-4.86	-0.3	2.2e-6	Glycated hemoglobin levels;
SARC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.35	0.52	7.64e-18	Prudent dietary pattern;
SARC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg11494091	chr17:61959527	GH2	0.48	7.46	0.44	1.72e-12	Prudent dietary pattern;
SARC	cis	rs3820928	0.874	rs4144328	chr2:227790187	A/C	cg05526886	chr2:227700861	RHBDD1	-0.54	-6.53	-0.39	4.02e-10	Pulmonary function;
SARC	cis	rs3126085	0.877	rs3120672	chr1:152255575	A/G	cg03465714	chr1:152285911	FLG	-0.45	-5.45	-0.34	1.25e-7	Atopic dermatitis;
SARC	cis	rs4588572	0.643	rs10068686	chr5:77795220	C/T	cg11547950	chr5:77652471	NA	-0.41	-5.11	-0.32	6.67e-7	Triglycerides;
SARC	trans	rs2018683	0.649	rs221193	chr7:29015784	G/T	cg19402173	chr7:128379420	CALU	-0.54	-6.85	-0.41	6.51e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs6840360	0.967	rs10028961	chr4:152668224	A/G	cg22705602	chr4:152727874	NA	-0.36	-6.34	-0.38	1.16e-9	Intelligence (multi-trait analysis);
SARC	cis	rs10484885	0.824	rs72919954	chr6:90515665	T/A	cg13799429	chr6:90582589	CASP8AP2	-0.59	-4.91	-0.31	1.73e-6	QRS interval (sulfonylurea treatment interaction);
SARC	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs992157	0.710	rs12612347	chr2:219057338	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.65	-8.7	-0.5	6.2e-16	Colorectal cancer;
SARC	trans	rs61931739	0.500	rs7306334	chr12:34482900	A/G	cg26384229	chr12:38710491	ALG10B	-0.89	-13.37	-0.66	1.25e-30	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg22535103	chr8:58192502	C8orf71	-0.66	-5.66	-0.35	4.4e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4975616	0.869	rs455433	chr5:1336243	A/G	cg26373071	chr5:1325741	CLPTM1L	0.3	4.81	0.3	2.71e-6	Lung cancer;
SARC	trans	rs9302817	0.891	rs10163244	chr16:6164252	C/A	cg20068074	chr3:48672407	SLC26A6	-0.72	-6.67	-0.4	1.85e-10	Body mass index;
SARC	cis	rs875971	0.545	rs6460298	chr7:65907770	T/C	cg11764359	chr7:65958608	NA	0.63	6.17	0.37	3.05e-9	Aortic root size;
SARC	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg00933542	chr6:150070202	PCMT1	0.3	5.15	0.32	5.66e-7	Lung cancer;
SARC	cis	rs4808199	0.895	rs2285628	chr19:19467996	T/A	cg03709012	chr19:19516395	GATAD2A	1.08	10.47	0.57	2.8e-21	Nonalcoholic fatty liver disease;
SARC	cis	rs17376456	1.000	rs9968749	chr5:93509559	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.26	0.33	3.27e-7	Diabetic retinopathy;
SARC	cis	rs644799	0.511	rs1016030	chr11:95472693	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	9.02	0.51	7.06e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs6988636	0.901	rs2602001	chr8:124195974	T/C	cg23067535	chr8:124195133	FAM83A	0.71	5.72	0.35	3.25e-8	Urinary uromodulin levels;
SARC	cis	rs765787	0.530	rs4331289	chr15:45515338	C/T	cg24006582	chr15:45444508	DUOX1	-0.49	-6.47	-0.39	5.7e-10	Uric acid levels;
SARC	cis	rs7246657	0.941	rs10418729	chr19:37737065	A/C	cg23950597	chr19:37808831	NA	-0.57	-5.32	-0.33	2.48e-7	Coronary artery calcification;
SARC	cis	rs7552404	0.731	rs7523573	chr1:76372020	G/T	cg10523679	chr1:76189770	ACADM	0.47	5.31	0.33	2.55e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7927771	0.542	rs6485775	chr11:47773518	A/G	cg20307385	chr11:47447363	PSMC3	-0.49	-6.63	-0.4	2.37e-10	Subjective well-being;
SARC	cis	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg03060546	chr3:49711283	APEH	0.75	11.19	0.59	1.56e-23	Resting heart rate;
SARC	cis	rs2011503	1.000	rs4808962	chr19:19579557	A/G	cg03709012	chr19:19516395	GATAD2A	0.63	5.56	0.34	7.3e-8	Bipolar disorder;
SARC	cis	rs7029536	0.551	rs11790967	chr9:130170561	G/A	cg09445097	chr9:130186736	ZNF79	0.53	4.92	0.31	1.67e-6	Metabolite levels (HVA);
SARC	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg13770153	chr20:60521292	NA	0.54	7.23	0.43	6.84e-12	Body mass index;
SARC	cis	rs7246657	0.943	rs10420430	chr19:37894194	C/G	cg23950597	chr19:37808831	NA	-0.63	-6.12	-0.37	3.98e-9	Coronary artery calcification;
SARC	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg23982607	chr1:1823379	GNB1	-0.64	-10.77	-0.58	3.17e-22	Body mass index;
SARC	cis	rs7089973	0.872	rs11818114	chr10:116634878	G/C	cg08188268	chr10:116634841	FAM160B1	0.36	5.74	0.35	2.86e-8	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.46	-5.76	-0.35	2.65e-8	Personality dimensions;
SARC	cis	rs11155671	0.530	rs1334510	chr6:150201179	A/G	cg09217309	chr6:150244204	RAET1G	0.39	4.95	0.31	1.44e-6	Testicular germ cell tumor;
SARC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.68	9.05	0.51	5.86e-17	Lymphocyte counts;
SARC	cis	rs7937682	0.575	rs7124696	chr11:111747297	A/G	cg22437258	chr11:111473054	SIK2	-0.46	-5.29	-0.33	2.81e-7	Primary sclerosing cholangitis;
SARC	cis	rs1949733	0.523	rs62287455	chr4:8544994	A/T	cg13073564	chr4:8508604	NA	0.48	7.21	0.43	7.88e-12	Response to antineoplastic agents;
SARC	cis	rs17209837	1.000	rs66510518	chr7:87111875	C/G	cg00919237	chr7:87102261	ABCB4	-0.47	-4.88	-0.3	1.94e-6	Gallbladder cancer;
SARC	cis	rs1008375	0.966	rs12503540	chr4:17698781	C/G	cg27347728	chr4:17578864	LAP3	-0.43	-5.38	-0.33	1.79e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg07701084	chr6:150067640	NUP43	0.41	5.42	0.33	1.5e-7	Lung cancer;
SARC	cis	rs1594829	0.553	rs2046226	chr8:26152050	G/A	cg11498726	chr8:26250323	BNIP3L	-0.4	-5.27	-0.33	3.09e-7	Height;
SARC	cis	rs3087591	0.960	rs4795575	chr17:29452625	A/G	cg24425628	chr17:29625626	OMG;NF1	0.56	7.11	0.42	1.42e-11	Hip circumference;
SARC	cis	rs1707322	0.656	rs3014210	chr1:46066608	A/G	cg06784218	chr1:46089804	CCDC17	-0.4	-6.77	-0.41	1.01e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2204008	0.744	rs12099650	chr12:38317140	C/G	cg26384229	chr12:38710491	ALG10B	0.87	12.52	0.63	7.66e-28	Bladder cancer;
SARC	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg03806693	chr22:41940476	POLR3H	0.86	12.06	0.62	2.35e-26	Cannabis dependence symptom count;
SARC	cis	rs925228	0.504	rs7568176	chr2:24313758	T/A	cg01493198	chr2:24299560	SF3B14	0.82	4.87	0.3	2.08e-6	Reticulocyte fraction of red cells;Reticulocyte count;
SARC	cis	rs2594989	1.000	rs2606756	chr3:11358181	G/A	cg00170343	chr3:11313890	ATG7	0.54	5.22	0.32	4.05e-7	Circulating chemerin levels;
SARC	cis	rs11645898	0.748	rs72791112	chr16:72204069	T/A	cg14768367	chr16:72042858	DHODH	-0.58	-5.25	-0.33	3.35e-7	Blood protein levels;
SARC	cis	rs427394	0.664	rs274696	chr5:6732213	A/C	cg10857441	chr5:6722123	POLS	-0.31	-4.75	-0.3	3.52e-6	Menopause (age at onset);
SARC	cis	rs7818345	0.935	rs7016259	chr8:19277530	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.43	5.92	0.36	1.12e-8	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg17376030	chr22:41985996	PMM1	0.64	7.52	0.44	1.15e-12	Vitiligo;
SARC	cis	rs8067545	0.611	rs2042046	chr17:20018841	A/G	cg13482628	chr17:19912719	NA	0.53	7.23	0.43	7.05e-12	Schizophrenia;
SARC	cis	rs2290402	0.536	rs58429160	chr4:875266	G/A	cg00846425	chr4:957561	DGKQ	-0.43	-5.01	-0.31	1.08e-6	Type 2 diabetes;
SARC	cis	rs2952156	1.000	rs2934967	chr17:37870378	G/A	cg20243544	chr17:37824526	PNMT	0.44	5.13	0.32	6.15e-7	Asthma;
SARC	cis	rs7659604	0.967	rs10008348	chr4:122666987	A/C	cg19671926	chr4:122722719	EXOSC9	-0.51	-6.19	-0.38	2.63e-9	Type 2 diabetes;
SARC	cis	rs778371	0.723	rs12993791	chr2:233690082	C/T	cg16596103	chr2:233749413	NGEF	0.33	4.97	0.31	1.31e-6	Schizophrenia;
SARC	cis	rs17376456	0.825	rs10038828	chr5:93124056	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.7	6.35	0.38	1.1e-9	Diabetic retinopathy;
SARC	trans	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg01514436	chr17:73127871	NT5C	0.46	6.71	0.4	1.47e-10	Immature fraction of reticulocytes;
SARC	cis	rs1729951	0.575	rs361239	chr3:136701295	G/T	cg15507776	chr3:136538369	TMEM22	0.47	5.13	0.32	6.16e-7	Neuroticism;
SARC	cis	rs826838	0.967	rs11168985	chr12:39045983	A/C	cg26384229	chr12:38710491	ALG10B	-0.92	-13.93	-0.67	1.69e-32	Heart rate;
SARC	cis	rs7937682	0.921	rs4616071	chr11:111440865	C/G	cg09085632	chr11:111637200	PPP2R1B	0.87	12.72	0.64	1.72e-28	Primary sclerosing cholangitis;
SARC	cis	rs7264396	0.790	rs6060516	chr20:34214368	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.56	5.58	0.34	6.67e-8	Total cholesterol levels;
SARC	cis	rs79839061	0.562	rs10516158	chr4:942439	A/G	cg07828340	chr4:882639	GAK	-0.83	-6.39	-0.39	8.85e-10	Intelligence (multi-trait analysis);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg22302111	chr7:33756849	NA	0.44	6.26	0.38	1.84e-9	Thyroid stimulating hormone;
SARC	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg18876405	chr7:65276391	NA	-0.71	-9.03	-0.51	6.53e-17	Aortic root size;
SARC	cis	rs2073300	0.609	rs1076776	chr20:23427399	C/T	cg12062639	chr20:23401060	NAPB	-0.88	-5.97	-0.36	8.96e-9	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg25894440	chr7:65020034	NA	-0.73	-5.48	-0.34	1.09e-7	Diabetic kidney disease;
SARC	cis	rs3936840	0.514	rs8007356	chr14:102975266	G/A	cg18135206	chr14:102964638	TECPR2	0.4	4.73	0.3	3.83e-6	Plateletcrit;
SARC	cis	rs2354432	0.607	rs11587707	chr1:146707186	T/C	cg25205988	chr1:146714368	CHD1L	-1.03	-7.52	-0.44	1.21e-12	Mitochondrial DNA levels;
SARC	cis	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg05623727	chr3:50126028	RBM5	0.36	5.23	0.32	3.83e-7	Body mass index;
SARC	cis	rs1865760	0.602	rs9467662	chr6:26021327	G/A	cg17691542	chr6:26056736	HIST1H1C	0.52	6.44	0.39	6.62e-10	Height;
SARC	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg26335602	chr6:28129616	ZNF389	0.51	5.66	0.35	4.37e-8	Depression;
SARC	cis	rs9462027	0.628	rs6937314	chr6:34799308	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-6.14	-0.37	3.58e-9	Systemic lupus erythematosus;
SARC	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg06221963	chr1:154839813	KCNN3	-0.54	-8.89	-0.5	1.76e-16	Prostate cancer;
SARC	cis	rs7553864	0.966	rs11161935	chr1:87614191	G/A	cg18153957	chr1:87613403	LOC339524	-0.46	-5.45	-0.34	1.28e-7	Smoking behavior;
SARC	cis	rs6061231	1.000	rs6061231	chr20:60956917	C/A	cg22601191	chr20:60968625	CABLES2	0.37	4.9	0.31	1.8e-6	Colorectal cancer;
SARC	cis	rs6732160	0.588	rs13390460	chr2:73371476	G/A	cg01422370	chr2:73384389	NA	0.37	5.79	0.35	2.25e-8	Intelligence (multi-trait analysis);
SARC	cis	rs6723226	0.881	rs10181198	chr2:32686582	A/G	cg02381751	chr2:32503542	YIPF4	0.77	10.16	0.55	2.58e-20	Intelligence (multi-trait analysis);
SARC	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg27347728	chr4:17578864	LAP3	0.46	5.84	0.36	1.73e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs67311347	0.544	rs9877105	chr3:40333366	T/C	cg09455208	chr3:40491958	NA	0.3	5.01	0.31	1.08e-6	Renal cell carcinoma;
SARC	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg04944784	chr2:26401820	FAM59B	0.6	7.95	0.46	8.14e-14	Gut microbiome composition (summer);
SARC	cis	rs7296418	0.699	rs11057254	chr12:123794581	A/C	cg00376283	chr12:123451042	ABCB9	0.53	6.47	0.39	5.86e-10	Platelet count;
SARC	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg05861140	chr6:150128134	PCMT1	-0.4	-5.23	-0.32	3.79e-7	Lung cancer;
SARC	cis	rs8051517	0.744	rs79517384	chr16:68328158	G/T	cg01866162	chr16:67596514	CTCF	1.11	6.41	0.39	7.98e-10	Blood protein levels;
SARC	cis	rs2645694	0.626	rs2703120	chr4:77822470	G/A	cg06046430	chr4:77819534	ANKRD56	0.54	7.75	0.45	2.87e-13	Emphysema distribution in smoking;
SARC	cis	rs12497850	1.000	rs10865952	chr3:48744484	A/G	cg07636037	chr3:49044803	WDR6	0.91	14.8	0.7	2.25e-35	Parkinson's disease;
SARC	cis	rs10870270	0.956	rs10781555	chr10:133745720	G/A	cg26149184	chr10:133730230	NA	0.46	5.27	0.33	3.11e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs1712517	0.771	rs11191645	chr10:105059308	G/T	cg05636881	chr10:105038444	INA	0.32	4.75	0.3	3.57e-6	Migraine;
SARC	cis	rs113835537	0.529	rs11227514	chr11:66286627	G/A	cg24851651	chr11:66362959	CCS	0.37	4.81	0.3	2.72e-6	Airway imaging phenotypes;
SARC	cis	rs7937682	0.663	rs35581942	chr11:111756286	C/T	cg09085632	chr11:111637200	PPP2R1B	0.77	9.97	0.55	1e-19	Primary sclerosing cholangitis;
SARC	cis	rs1707322	0.721	rs10890344	chr1:46166090	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.17	0.37	2.95e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6782228	0.606	rs58977394	chr3:128337917	C/T	cg08795948	chr3:128337044	NA	0.36	4.83	0.3	2.44e-6	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
SARC	cis	rs796364	1.000	rs796364	chr2:200716119	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.82	7.09	0.42	1.6e-11	Schizophrenia;
SARC	cis	rs11191193	0.662	rs7350429	chr10:103765790	A/G	cg15320455	chr10:103880129	LDB1	0.55	5.22	0.32	3.89e-7	Educational attainment;
SARC	cis	rs3126085	0.935	rs4845741	chr1:152183474	A/G	cg09127314	chr1:152161683	NA	0.41	4.76	0.3	3.36e-6	Atopic dermatitis;
SARC	cis	rs12142240	0.698	rs72677596	chr1:46833930	C/T	cg10495392	chr1:46806563	NSUN4	0.66	6.91	0.41	4.69e-11	Menopause (age at onset);
SARC	cis	rs10927875	0.526	rs2179615	chr1:16282426	G/A	cg21385522	chr1:16154831	NA	-0.83	-9.34	-0.52	8.07e-18	Dilated cardiomyopathy;
SARC	cis	rs9814567	0.964	rs9841180	chr3:134191880	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-6.74	-0.4	1.26e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs7551222	0.716	rs11240751	chr1:204462050	A/G	cg07972458	chr1:204535000	NA	0.37	4.78	0.3	3.13e-6	Schizophrenia;
SARC	cis	rs473651	0.837	rs563458	chr2:239345613	T/A	cg18131467	chr2:239335373	ASB1	0.94	15.75	0.72	1.51e-38	Multiple system atrophy;
SARC	cis	rs9388451	0.807	rs1269175	chr6:126040435	A/G	cg05901451	chr6:126070800	HEY2	0.56	7.41	0.44	2.27e-12	Brugada syndrome;
SARC	cis	rs10754283	0.934	rs6684676	chr1:90102173	C/T	cg21401794	chr1:90099060	LRRC8C	0.61	8.46	0.48	3.02e-15	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs2153535	0.580	rs2143357	chr6:8497196	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.04	0.59	4.63e-23	Motion sickness;
SARC	cis	rs73206853	0.620	rs17682644	chr12:111156008	C/T	cg10860002	chr12:110842031	ANAPC7	0.58	4.85	0.3	2.25e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.6	7.19	0.43	8.74e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg08219700	chr8:58056026	NA	0.57	5.23	0.32	3.82e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs722599	0.683	rs8011071	chr14:75286705	T/C	cg06637938	chr14:75390232	RPS6KL1	0.4	4.99	0.31	1.2e-6	IgG glycosylation;
SARC	trans	rs7465272	1.000	rs36050651	chr8:143681796	A/G	cg16922340	chr20:33873526	FAM83C;EIF6	0.45	6.34	0.38	1.21e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg17971929	chr21:40555470	PSMG1	-0.84	-11.06	-0.59	3.94e-23	Cognitive function;
SARC	cis	rs9467160	0.520	rs2753910	chr6:24442473	C/T	cg20631270	chr6:24437470	GPLD1	-0.41	-5.34	-0.33	2.23e-7	Liver enzyme levels;
SARC	cis	rs6088580	0.634	rs4911422	chr20:32999345	T/C	cg08999081	chr20:33150536	PIGU	-0.44	-6.65	-0.4	2.07e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs4713675	0.584	rs4713661	chr6:33674174	C/A	cg15676125	chr6:33679581	C6orf125	0.52	6.23	0.38	2.16e-9	Plateletcrit;
SARC	cis	rs7223966	0.921	rs34699959	chr17:61960720	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.45	-4.74	-0.3	3.69e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs61931739	0.500	rs7137392	chr12:34447074	T/C	cg26384229	chr12:38710491	ALG10B	0.84	12.56	0.64	5.71e-28	Morning vs. evening chronotype;
SARC	cis	rs9388451	0.559	rs1777210	chr6:126098916	T/G	cg06289844	chr6:126071538	HEY2	0.32	5.14	0.32	5.73e-7	Brugada syndrome;
SARC	cis	rs17376456	1.000	rs13174700	chr5:93554644	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.17	0.32	5e-7	Diabetic retinopathy;
SARC	cis	rs6701037	0.566	rs10753091	chr1:175134571	T/C	cg08873628	chr1:175162347	KIAA0040	0.34	4.82	0.3	2.64e-6	Alcohol dependence;
SARC	cis	rs2153535	0.580	rs2327067	chr6:8518482	C/G	cg07606381	chr6:8435919	SLC35B3	0.77	10.87	0.58	1.55e-22	Motion sickness;
SARC	cis	rs10189230	0.967	rs12990760	chr2:222354725	G/T	cg14652038	chr2:222343519	EPHA4	0.45	6.0	0.37	7.49e-9	Urate levels in lean individuals;
SARC	cis	rs1059312	0.808	rs4482069	chr12:129294252	G/C	cg09035930	chr12:129282057	SLC15A4	0.56	8.07	0.47	3.67e-14	Systemic lupus erythematosus;
SARC	cis	rs870825	0.616	rs6552810	chr4:185644143	G/A	cg04058563	chr4:185651563	MLF1IP	0.81	11.52	0.6	1.31e-24	Blood protein levels;
SARC	cis	rs273218	0.573	rs16882051	chr5:53342979	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.89	-9.8	-0.54	3.25e-19	Migraine;
SARC	cis	rs17270561	0.609	rs12203927	chr6:25732690	A/G	cg16482183	chr6:26056742	HIST1H1C	0.43	5.25	0.33	3.49e-7	Iron status biomarkers;
SARC	cis	rs9911578	1.000	rs3744109	chr17:56594197	C/T	cg12560992	chr17:57184187	TRIM37	-0.79	-10.6	-0.57	1.13e-21	Intelligence (multi-trait analysis);
SARC	cis	rs3768617	0.811	rs11590958	chr1:183023636	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.59	8.02	0.46	5.24e-14	Fuchs's corneal dystrophy;
SARC	cis	rs4727027	0.704	rs12537763	chr7:148903984	G/A	cg23583168	chr7:148888333	NA	-0.82	-13.63	-0.67	1.74e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs7208859	0.623	rs9890558	chr17:29110355	T/C	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs213599	0.579	rs9593212	chr13:31471824	A/T	cg00367615	chr13:31480979	C13orf33	-0.32	-5.24	-0.32	3.56e-7	Cognitive function;
SARC	cis	rs13314892	0.764	rs59846970	chr3:69861053	C/G	cg17445875	chr3:69859618	MITF	-0.49	-5.1	-0.32	6.98e-7	QRS complex (12-leadsum);
SARC	cis	rs995000	0.931	rs634341	chr1:62921422	T/C	cg06896770	chr1:63153194	DOCK7	0.9	13.85	0.67	3.23e-32	Triglyceride levels;
SARC	cis	rs6912958	0.712	rs7755167	chr6:88338752	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-6.46	-0.39	6.16e-10	Monocyte percentage of white cells;
SARC	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg26335602	chr6:28129616	ZNF389	0.47	5.68	0.35	4.09e-8	Depression;
SARC	cis	rs2635047	0.512	rs9962436	chr18:44599109	A/G	cg19077165	chr18:44547161	KATNAL2	-0.4	-5.3	-0.33	2.69e-7	Educational attainment;
SARC	cis	rs9768139	0.708	rs896780	chr7:158113972	C/T	cg06219351	chr7:158114137	PTPRN2	-0.29	-4.86	-0.3	2.2e-6	Calcium levels;
SARC	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg18876405	chr7:65276391	NA	-0.45	-4.94	-0.31	1.46e-6	Aortic root size;
SARC	cis	rs12681288	0.523	rs6983944	chr8:955147	A/G	cg15309053	chr8:964076	NA	0.44	7.63	0.45	6.03e-13	Schizophrenia;
SARC	cis	rs17376456	0.825	rs17314797	chr5:93234845	T/A	cg25358565	chr5:93447407	FAM172A	1.29	14.31	0.68	9.44e-34	Diabetic retinopathy;
SARC	cis	rs116095464	0.558	rs55833259	chr5:286728	G/A	cg22496380	chr5:211416	CCDC127	-0.96	-8.83	-0.5	2.59e-16	Breast cancer;
SARC	cis	rs713477	1.000	rs10134905	chr14:55911792	G/A	cg13175173	chr14:55914753	NA	-0.31	-4.84	-0.3	2.41e-6	Pediatric bone mineral content (femoral neck);
SARC	cis	rs7607369	0.536	rs6436091	chr2:219669141	T/C	cg02176678	chr2:219576539	TTLL4	-0.38	-5.67	-0.35	4.2e-8	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs651907	0.557	rs7645391	chr3:101361506	C/G	cg12386194	chr3:101231763	SENP7	0.5	5.98	0.36	8.33e-9	Colorectal cancer;
SARC	cis	rs9398803	0.723	rs853971	chr6:127066190	T/C	cg19875578	chr6:126661172	C6orf173	-0.62	-8.62	-0.49	1.06e-15	Male-pattern baldness;
SARC	cis	rs2952156	0.876	rs2313171	chr17:37833842	T/C	cg00129232	chr17:37814104	STARD3	-0.7	-10.11	-0.55	3.81e-20	Asthma;
SARC	cis	rs4642101	0.765	rs3901665	chr3:12824610	C/A	cg05775895	chr3:12838266	CAND2	0.75	12.09	0.62	1.9e-26	QRS complex (12-leadsum);
SARC	cis	rs12142240	0.667	rs66990604	chr1:46822073	G/A	cg14993813	chr1:46806288	NSUN4	-0.51	-5.34	-0.33	2.19e-7	Menopause (age at onset);
SARC	cis	rs722599	0.748	rs2300599	chr14:75359441	A/G	cg08847533	chr14:75593920	NEK9	-0.44	-5.11	-0.32	6.81e-7	IgG glycosylation;
SARC	cis	rs7824557	0.778	rs6601572	chr8:11093337	C/G	cg21775007	chr8:11205619	TDH	-0.43	-5.08	-0.32	7.85e-7	Retinal vascular caliber;
SARC	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg11494091	chr17:61959527	GH2	-0.6	-9.13	-0.51	3.43e-17	Prudent dietary pattern;
SARC	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg05025164	chr4:1340916	KIAA1530	0.44	5.01	0.31	1.07e-6	Obesity-related traits;
SARC	cis	rs9400467	0.506	rs3204953	chr6:111628626	C/T	cg15721981	chr6:111408429	SLC16A10	0.69	5.85	0.36	1.67e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs6089584	0.528	rs881994	chr20:60623931	G/A	cg13770153	chr20:60521292	NA	-0.38	-5.41	-0.33	1.53e-7	Body mass index;
SARC	cis	rs1045902	0.532	rs2288631	chr2:73455747	C/T	cg06642617	chr2:73461528	CCT7;C2orf7	0.4	4.76	0.3	3.4e-6	Intelligence (multi-trait analysis);
SARC	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.31	5.04	0.31	9.23e-7	Schizophrenia;
SARC	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg12463550	chr7:65579703	CRCP	-0.71	-5.42	-0.33	1.47e-7	Diabetic kidney disease;
SARC	cis	rs2387326	0.717	rs10829338	chr10:129943625	C/T	cg16087940	chr10:129947807	NA	-0.44	-5.48	-0.34	1.08e-7	Select biomarker traits;
SARC	cis	rs950776	0.714	rs615470	chr15:78885988	T/C	cg06917634	chr15:78832804	PSMA4	-0.71	-9.66	-0.53	8.51e-19	Sudden cardiac arrest;
SARC	cis	rs6439153	0.933	rs9822511	chr3:128705567	G/A	cg25356066	chr3:128598488	ACAD9	0.46	5.41	0.33	1.58e-7	Pneumococcal bacteremia;
SARC	cis	rs2153535	0.601	rs9505473	chr6:8538777	T/C	cg23788917	chr6:8435910	SLC35B3	0.64	8.4	0.48	4.5e-15	Motion sickness;
SARC	cis	rs7551222	0.646	rs6594015	chr1:204461622	C/T	cg20240347	chr1:204465584	NA	-0.29	-4.97	-0.31	1.27e-6	Schizophrenia;
SARC	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg05025164	chr4:1340916	KIAA1530	-0.45	-5.23	-0.32	3.86e-7	Obesity-related traits;
SARC	cis	rs79349575	0.681	rs56080003	chr17:47019049	A/T	cg16584676	chr17:46985605	UBE2Z	0.55	6.66	0.4	1.91e-10	Type 2 diabetes;
SARC	cis	rs7712401	0.715	rs13163098	chr5:122346536	A/G	cg19412675	chr5:122181750	SNX24	-0.41	-5.26	-0.33	3.18e-7	Mean platelet volume;
SARC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg23224405	chr12:12715060	DUSP16	0.54	6.9	0.41	4.91e-11	Myopia (pathological);
SARC	trans	rs7824557	0.628	rs7820301	chr8:11228672	G/A	cg06636001	chr8:8085503	FLJ10661	0.56	7.41	0.44	2.36e-12	Retinal vascular caliber;
SARC	cis	rs72945132	0.882	rs60780459	chr11:70162468	A/G	cg00319359	chr11:70116639	PPFIA1	0.67	6.08	0.37	4.85e-9	Coronary artery disease;
SARC	cis	rs826838	0.967	rs10875979	chr12:39095149	G/A	cg13010199	chr12:38710504	ALG10B	0.7	10.09	0.55	4.18e-20	Heart rate;
SARC	cis	rs11098499	0.575	rs907204	chr4:120238654	G/A	cg09307838	chr4:120376055	NA	0.81	11.01	0.58	5.67e-23	Corneal astigmatism;
SARC	trans	rs9329221	0.710	rs11249995	chr8:10238922	T/C	cg06636001	chr8:8085503	FLJ10661	0.61	7.27	0.43	5.36e-12	Neuroticism;
SARC	cis	rs6582630	0.502	rs11522899	chr12:38270637	T/C	cg26384229	chr12:38710491	ALG10B	0.91	13.64	0.67	1.61e-31	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs874628	0.851	rs28666607	chr19:18333805	C/T	cg13670957	chr19:18329801	PDE4C	0.5	5.78	0.35	2.37e-8	Multiple sclerosis;
SARC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg02475777	chr4:1388615	CRIPAK	0.66	7.69	0.45	4.2e-13	Longevity;
SARC	cis	rs668210	0.793	rs586921	chr11:65747701	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.51	-4.85	-0.3	2.25e-6	Cerebrospinal fluid biomarker levels;
SARC	cis	rs67460515	0.892	rs4856756	chr3:160999414	G/A	cg03342759	chr3:160939853	NMD3	-0.71	-9.08	-0.51	4.82e-17	Parkinson's disease;
SARC	trans	rs11098499	0.954	rs10034623	chr4:120397829	G/A	cg25214090	chr10:38739885	LOC399744	0.53	6.95	0.41	3.7e-11	Corneal astigmatism;
SARC	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.35	-0.43	3.34e-12	Gut microbiome composition (summer);
SARC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg07308232	chr7:1071921	C7orf50	-0.49	-5.8	-0.36	2.17e-8	Longevity;Endometriosis;
SARC	cis	rs11874712	0.932	rs8092674	chr18:43665982	C/T	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.46	5.5	0.34	1.02e-7	Migraine - clinic-based;
SARC	cis	rs16976116	0.619	rs10518801	chr15:55468617	G/A	cg11288833	chr15:55489084	RSL24D1	0.62	5.28	0.33	3.02e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg12310025	chr6:25882481	NA	0.54	6.97	0.42	3.18e-11	Blood metabolite levels;
SARC	cis	rs7662987	0.517	rs2924580	chr4:100032168	C/G	cg13256891	chr4:100009986	ADH5	0.68	8.58	0.49	1.31e-15	Smoking initiation;
SARC	cis	rs2997447	0.761	rs112552200	chr1:26456947	G/A	cg19633962	chr1:26362018	EXTL1	-0.57	-4.93	-0.31	1.54e-6	QRS complex (12-leadsum);
SARC	cis	rs4268898	0.722	rs11691212	chr2:24404733	A/G	cg06627628	chr2:24431161	ITSN2	0.52	7.03	0.42	2.24e-11	Asthma;
SARC	cis	rs7582720	1.000	rs77931721	chr2:203763076	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.31	0.43	4.24e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs981844	0.712	rs6855093	chr4:154754050	A/G	cg14289246	chr4:154710475	SFRP2	-0.45	-5.36	-0.33	1.96e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg11494091	chr17:61959527	GH2	0.53	8.03	0.47	4.84e-14	Prudent dietary pattern;
SARC	cis	rs12142240	0.698	rs67200518	chr1:46835777	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-5.56	-0.34	7.46e-8	Menopause (age at onset);
SARC	cis	rs4481887	1.000	rs11204636	chr1:248492409	A/C	cg01631408	chr1:248437212	OR2T33	0.45	5.41	0.33	1.6e-7	Common traits (Other);
SARC	cis	rs3768617	0.510	rs12095664	chr1:183101686	G/A	cg13390022	chr1:182993471	LAMC1	0.31	4.79	0.3	3.01e-6	Fuchs's corneal dystrophy;
SARC	cis	rs9398803	0.865	rs9385399	chr6:126759033	A/C	cg19875578	chr6:126661172	C6orf173	-0.57	-8.06	-0.47	3.88e-14	Male-pattern baldness;
SARC	cis	rs7043114	0.507	rs10761154	chr9:95144086	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.81	-0.36	2.02e-8	Height;
SARC	cis	rs57920188	0.584	rs12068729	chr1:4091650	A/G	cg20703997	chr1:4087676	NA	0.51	5.42	0.33	1.52e-7	Interleukin-17 levels;
SARC	cis	rs1878931	0.501	rs9921169	chr16:3421261	A/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.73	9.36	0.52	6.95e-18	Body mass index (adult);
SARC	cis	rs72781680	0.898	rs17509001	chr2:24021231	T/C	cg08917208	chr2:24149416	ATAD2B	0.76	7.11	0.42	1.4e-11	Lymphocyte counts;
SARC	cis	rs77372450	0.551	rs3749797	chr5:157078475	C/G	cg05585991	chr5:157099197	C5orf52	0.51	5.16	0.32	5.4e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs7264396	0.790	rs6060542	chr20:34249061	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	5.9	0.36	1.24e-8	Total cholesterol levels;
SARC	cis	rs9790314	0.967	rs10804790	chr3:161039300	T/A	cg03342759	chr3:160939853	NMD3	-0.59	-7.33	-0.43	3.82e-12	Morning vs. evening chronotype;
SARC	cis	rs4792901	0.802	rs9901586	chr17:41580891	T/G	cg22562494	chr17:41607896	ETV4	-0.32	-4.84	-0.3	2.37e-6	Dupuytren's disease;
SARC	cis	rs4820539	0.966	rs5759600	chr22:23483769	C/A	cg14186256	chr22:23484241	RTDR1	0.83	13.38	0.66	1.11e-30	Bone mineral density;
SARC	cis	rs73198271	0.740	rs67766414	chr8:8649533	C/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-5.28	-0.33	2.91e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs2997447	0.723	rs868551	chr1:26475521	C/T	cg19633962	chr1:26362018	EXTL1	0.58	5.26	0.33	3.2e-7	QRS complex (12-leadsum);
SARC	cis	rs4689388	0.853	rs13103357	chr4:6294544	A/G	cg14416269	chr4:6271139	WFS1	0.32	4.92	0.31	1.61e-6	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs798554	0.644	rs7783400	chr7:2894434	A/C	cg03185022	chr7:2884158	GNA12	-0.44	-4.86	-0.3	2.17e-6	Height;
SARC	cis	rs2439831	0.681	rs484029	chr15:43619560	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.04	11.52	0.6	1.35e-24	Lung cancer in ever smokers;
SARC	cis	rs1801251	1.000	rs6761324	chr2:233582793	T/G	cg25237894	chr2:233734115	C2orf82	0.37	4.81	0.3	2.76e-6	Coronary artery disease;
SARC	cis	rs910316	1.000	rs3742773	chr14:75579643	A/G	cg08847533	chr14:75593920	NEK9	0.93	15.6	0.71	4.93e-38	Height;
SARC	cis	rs926392	0.932	rs4812360	chr20:37689259	A/G	cg16355469	chr20:37678765	NA	0.55	7.13	0.42	1.26e-11	Dialysis-related mortality;
SARC	cis	rs4891159	0.548	rs654754	chr18:74143695	T/C	cg24786174	chr18:74118243	ZNF516	0.72	11.78	0.61	1.97e-25	Longevity;
SARC	cis	rs3091242	1.000	rs3091242	chr1:25674785	C/T	cg27572855	chr1:25598939	RHD	0.58	9.89	0.54	1.69e-19	Erythrocyte sedimentation rate;
SARC	cis	rs9898641	1	rs9898641	chr17:57571033	T/C	cg17882278	chr17:57642873	DHX40	0.4	4.74	0.3	3.68e-6	Interleukin-1-beta levels;
SARC	cis	rs3087591	0.708	rs7406783	chr17:29689980	A/G	cg24425628	chr17:29625626	OMG;NF1	0.41	5.23	0.32	3.74e-7	Hip circumference;
SARC	cis	rs7465272	1.000	rs35868630	chr8:143685933	G/A	cg10596483	chr8:143751796	JRK	0.57	6.22	0.38	2.29e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs7552404	0.656	rs11161792	chr1:76336746	C/T	cg10523679	chr1:76189770	ACADM	0.47	5.47	0.34	1.15e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7264396	0.563	rs59064961	chr20:34307950	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-7.17	-0.43	9.99e-12	Total cholesterol levels;
SARC	cis	rs599083	0.744	rs603129	chr11:68186669	A/T	cg01657329	chr11:68192670	LRP5	0.42	5.86	0.36	1.53e-8	Bone mineral density (spine);
SARC	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.97	10.3	0.56	9.25e-21	Platelet count;
SARC	cis	rs453301	0.522	rs2929455	chr8:9083433	A/T	cg15556689	chr8:8085844	FLJ10661	-0.46	-5.68	-0.35	3.92e-8	Joint mobility (Beighton score);
SARC	cis	rs35306767	0.671	rs11253473	chr10:906826	A/G	cg20503657	chr10:835505	NA	0.88	8.27	0.48	1.05e-14	Eosinophil percentage of granulocytes;
SARC	cis	rs7615952	0.546	rs11711150	chr3:125315663	C/T	cg05084668	chr3:125655381	ALG1L	-0.54	-4.83	-0.3	2.43e-6	Blood pressure (smoking interaction);
SARC	cis	rs3796352	0.881	rs34238610	chr3:53026480	A/T	cg27565382	chr3:53032988	SFMBT1	1.04	7.27	0.43	5.28e-12	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs9381040	1.000	rs9381040	chr6:41154650	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.47	-5.45	-0.34	1.29e-7	Alzheimer's disease (late onset);
SARC	cis	rs9916302	0.660	rs4795367	chr17:37608843	G/C	cg07936489	chr17:37558343	FBXL20	-0.74	-8.71	-0.5	5.81e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs7592578	0.882	rs16832765	chr2:191468762	T/C	cg10560079	chr2:191398806	TMEM194B	-0.8	-8.92	-0.5	1.4e-16	Diastolic blood pressure;
SARC	cis	rs2370759	1.000	rs79487858	chr10:32616405	T/C	cg05361325	chr10:32636312	EPC1	-0.77	-6.85	-0.41	6.33e-11	Sexual dysfunction (female);
SARC	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg23887609	chr12:130822674	PIWIL1	0.37	5.14	0.32	5.92e-7	Menopause (age at onset);
SARC	cis	rs2933343	0.729	rs1680781	chr3:128612830	C/A	cg24203234	chr3:128598194	ACAD9	0.63	7.69	0.45	4.17e-13	IgG glycosylation;
SARC	cis	rs1055129	0.516	rs7218498	chr17:73931847	C/G	cg14829360	chr17:73884958	NA	-0.57	-8.59	-0.49	1.24e-15	White matter hyperintensity burden;
SARC	cis	rs796364	0.951	rs281776	chr2:200834282	T/G	cg23649088	chr2:200775458	C2orf69	0.6	5.71	0.35	3.5e-8	Schizophrenia;
SARC	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg06074448	chr4:187884817	NA	-0.38	-5.19	-0.32	4.58e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3733585	0.699	rs7663097	chr4:9966791	T/C	cg11266682	chr4:10021025	SLC2A9	-0.37	-6.48	-0.39	5.28e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg17376030	chr22:41985996	PMM1	-0.8	-10.12	-0.55	3.37e-20	Vitiligo;
SARC	cis	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg09021430	chr5:549028	NA	-0.44	-5.67	-0.35	4.27e-8	Obesity-related traits;
SARC	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg03806693	chr22:41940476	POLR3H	-0.96	-13.3	-0.66	2.06e-30	Vitiligo;
SARC	cis	rs765787	0.556	rs10851422	chr15:45513738	T/C	cg26924012	chr15:45694286	SPATA5L1	0.44	5.55	0.34	7.83e-8	Uric acid levels;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg07945002	chr1:155165037	MIR92B	-0.47	-6.27	-0.38	1.71e-9	Schizophrenia;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg24485466	chr1:200589999	KIF14	-0.5	-6.6	-0.4	2.82e-10	Electrocardiographic conduction measures;
SARC	cis	rs9309473	1.000	rs2901438	chr2:73665656	G/A	cg20560298	chr2:73613845	ALMS1	-0.49	-5.89	-0.36	1.37e-8	Metabolite levels;
SARC	cis	rs9400467	0.500	rs1361425	chr6:111472243	A/T	cg15721981	chr6:111408429	SLC16A10	-0.44	-5.35	-0.33	2.09e-7	Blood metabolite levels;Amino acid levels;
SARC	cis	rs765787	0.530	rs11636440	chr15:45535982	C/T	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.51e-10	Uric acid levels;
SARC	cis	rs3923518	0.956	rs13088577	chr3:38929631	C/G	cg26331595	chr3:39149181	GORASP1;TTC21A	0.45	4.77	0.3	3.27e-6	Migraine;
SARC	cis	rs11098499	0.863	rs6534141	chr4:120485223	A/T	cg24375607	chr4:120327624	NA	0.4	4.82	0.3	2.64e-6	Corneal astigmatism;
SARC	cis	rs611744	0.967	rs671139	chr8:109191260	C/T	cg21045802	chr8:109455806	TTC35	0.44	5.3	0.33	2.64e-7	Dupuytren's disease;
SARC	cis	rs113835537	0.529	rs3179961	chr11:66244454	A/G	cg24851651	chr11:66362959	CCS	0.4	5.02	0.31	1.05e-6	Airway imaging phenotypes;
SARC	cis	rs812925	0.515	rs1177308	chr2:61387254	C/G	cg10580144	chr2:61372316	C2orf74	0.39	5.3	0.33	2.7e-7	Immature fraction of reticulocytes;
SARC	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg06028605	chr16:24865363	SLC5A11	-0.36	-5.6	-0.34	5.87e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg18876405	chr7:65276391	NA	-0.71	-9.03	-0.51	6.53e-17	Aortic root size;
SARC	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg11764359	chr7:65958608	NA	0.78	10.75	0.58	3.63e-22	Aortic root size;
SARC	cis	rs10089	0.953	rs1432614	chr5:127416919	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	10.3	0.56	9.83e-21	Ileal carcinoids;
SARC	cis	rs2120019	1.000	rs12898259	chr15:75369780	G/A	cg17294928	chr15:75287854	SCAMP5	-0.9	-13.28	-0.66	2.39e-30	Blood trace element (Zn levels);
SARC	cis	rs2985684	1.000	rs2985684	chr14:50101682	C/G	cg04989706	chr14:50066350	PPIL5	-0.53	-5.57	-0.34	6.93e-8	Carotid intima media thickness;
SARC	cis	rs2268241	0.938	rs9808753	chr21:34787312	A/G	cg14850771	chr21:34775459	IFNGR2	0.97	8.83	0.5	2.61e-16	Obesity-related traits;
SARC	cis	rs17376456	0.877	rs12716457	chr5:93397627	T/C	cg25358565	chr5:93447407	FAM172A	1.3	14.56	0.69	1.43e-34	Diabetic retinopathy;
SARC	cis	rs7666738	0.830	rs11097582	chr4:98772201	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.54	0.49	1.74e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2120019	1.000	rs8033837	chr15:75353975	A/C	cg12414181	chr15:75287860	SCAMP5	-0.47	-5.4	-0.33	1.67e-7	Blood trace element (Zn levels);
SARC	cis	rs2153535	0.542	rs915353	chr6:8440370	A/G	cg23788917	chr6:8435910	SLC35B3	0.64	8.13	0.47	2.47e-14	Motion sickness;
SARC	cis	rs10489202	1.000	rs2420	chr1:167886502	A/T	cg24449463	chr1:168025552	DCAF6	-0.65	-7.18	-0.43	9.13e-12	Schizophrenia;
SARC	cis	rs7246657	0.943	rs4969487	chr19:37831039	C/T	cg23950597	chr19:37808831	NA	-0.6	-5.85	-0.36	1.67e-8	Coronary artery calcification;
SARC	cis	rs1355223	0.525	rs7129533	chr11:34872292	T/C	cg11622362	chr11:34938112	PDHX;APIP	0.45	5.88	0.36	1.42e-8	Systemic lupus erythematosus and Systemic sclerosis;
SARC	trans	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg21659725	chr3:3221576	CRBN	0.81	12.46	0.63	1.2e-27	Intelligence (multi-trait analysis);
SARC	cis	rs6991838	0.551	rs7007505	chr8:66533954	C/G	cg13398993	chr8:66546079	ARMC1	0.62	8.19	0.47	1.72e-14	Intelligence (multi-trait analysis);
SARC	cis	rs722599	0.683	rs7160852	chr14:75239424	T/C	cg08847533	chr14:75593920	NEK9	0.42	4.8	0.3	2.78e-6	IgG glycosylation;
SARC	cis	rs7617773	0.780	rs6782166	chr3:48351683	A/G	cg11946769	chr3:48343235	NME6	0.76	9.7	0.54	6.55e-19	Coronary artery disease;
SARC	cis	rs826838	1.000	rs2129627	chr12:38653036	C/T	cg13010199	chr12:38710504	ALG10B	0.82	11.85	0.61	1.17e-25	Heart rate;
SARC	cis	rs477692	0.905	rs544217	chr10:131420584	A/G	cg05714579	chr10:131428358	MGMT	0.58	7.77	0.45	2.46e-13	Response to temozolomide;
SARC	cis	rs11718455	0.960	rs13083325	chr3:44005333	T/C	cg08738300	chr3:44038990	NA	0.53	5.89	0.36	1.35e-8	Coronary artery disease;
SARC	cis	rs7113874	0.613	rs4326784	chr11:8533149	G/T	cg09828998	chr11:8703972	RPL27A	0.51	5.44	0.34	1.32e-7	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg01181863	chr3:195395398	SDHAP2	-0.57	-6.51	-0.39	4.68e-10	Pancreatic cancer;
SARC	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg02018176	chr4:1364513	KIAA1530	-0.45	-6.45	-0.39	6.22e-10	Obesity-related traits;
SARC	cis	rs3126085	0.935	rs6675889	chr1:152213066	G/A	cg26876637	chr1:152193138	HRNR	0.46	5.37	0.33	1.88e-7	Atopic dermatitis;
SARC	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.39	4.73	0.3	3.89e-6	Tonsillectomy;
SARC	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg12463550	chr7:65579703	CRCP	0.51	5.74	0.35	2.94e-8	Aortic root size;
SARC	cis	rs7644634	0.661	rs3772531	chr3:105437781	T/C	cg23051926	chr3:105466016	CBLB	0.44	5.53	0.34	8.7e-8	Itch intensity from mosquito bite;
SARC	cis	rs12824058	0.831	rs11609362	chr12:130810526	T/C	cg23887609	chr12:130822674	PIWIL1	0.37	5.15	0.32	5.48e-7	Menopause (age at onset);
SARC	cis	rs910316	0.875	rs12588099	chr14:75594462	A/T	cg11812906	chr14:75593930	NEK9	0.87	13.53	0.66	3.69e-31	Height;
SARC	cis	rs7626444	0.625	rs2686595	chr3:196475142	G/C	cg12930392	chr3:196481615	PAK2	0.25	5.02	0.31	1.04e-6	Monocyte count;
SARC	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg02018176	chr4:1364513	KIAA1530	0.61	9.12	0.51	3.67e-17	Longevity;
SARC	cis	rs41271473	1.000	rs41271473	chr1:228880296	G/A	cg16512390	chr1:228756714	NA	0.49	5.09	0.32	7.25e-7	Chronic lymphocytic leukemia;
SARC	cis	rs208520	0.955	rs208538	chr6:66964492	C/G	cg07460842	chr6:66804631	NA	-0.79	-8.8	-0.5	3.1e-16	Exhaled nitric oxide output;
SARC	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg11965913	chr1:205819406	PM20D1	0.48	5.48	0.34	1.12e-7	Parkinson's disease;
SARC	cis	rs453301	0.658	rs13271797	chr8:8885954	G/A	cg11608241	chr8:8085544	FLJ10661	-0.44	-5.65	-0.35	4.74e-8	Joint mobility (Beighton score);
SARC	cis	rs2227631	0.505	rs12530730	chr7:100758591	T/A	cg18465962	chr7:100767262	NA	0.58	7.8	0.45	2.09e-13	Plasminogen activator inhibitor type 1 levels (PAI-1);
SARC	cis	rs78545713	0.649	rs11754368	chr6:26221173	G/A	cg00631329	chr6:26305371	NA	-0.71	-5.14	-0.32	5.85e-7	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg11494091	chr17:61959527	GH2	0.54	8.06	0.47	4.05e-14	Prudent dietary pattern;
SARC	cis	rs734999	0.566	rs12748729	chr1:2558740	C/T	cg00980319	chr1:2560884	MMEL1	0.34	4.9	0.31	1.83e-6	Ulcerative colitis;
SARC	cis	rs2153535	0.601	rs1855768	chr6:8472969	T/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg18305652	chr10:134549665	INPP5A	0.33	4.74	0.3	3.72e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs1865760	0.865	rs1115920	chr6:25954027	A/G	cg16482183	chr6:26056742	HIST1H1C	0.51	6.54	0.39	3.79e-10	Height;
SARC	cis	rs2153535	0.580	rs6597322	chr6:8449952	T/G	cg23788917	chr6:8435910	SLC35B3	0.63	8.38	0.48	5.16e-15	Motion sickness;
SARC	cis	rs9325144	0.560	rs10785562	chr12:38637419	A/C	cg13010199	chr12:38710504	ALG10B	-0.57	-7.07	-0.42	1.79e-11	Morning vs. evening chronotype;
SARC	cis	rs4481887	0.893	rs4423045	chr1:248479495	T/C	cg00666640	chr1:248458726	OR2T12	0.35	5.81	0.36	2.04e-8	Common traits (Other);
SARC	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg27286337	chr10:134555280	INPP5A	0.69	8.55	0.49	1.6e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs501120	1.000	rs620828	chr10:44760958	A/G	cg09554077	chr10:44749378	NA	0.48	6.45	0.39	6.48e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs7586879	0.639	rs6749170	chr2:25110962	A/G	cg04586622	chr2:25135609	ADCY3	0.34	5.67	0.35	4.13e-8	Body mass index;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg09559352	chr16:15978691	C16orf63	0.49	6.67	0.4	1.81e-10	Thyroid stimulating hormone;
SARC	cis	rs6088590	1.000	rs6120705	chr20:33313740	T/C	cg08999081	chr20:33150536	PIGU	0.34	4.92	0.31	1.63e-6	Coronary artery disease;
SARC	cis	rs2120019	1.000	rs8033837	chr15:75353975	A/C	cg09165964	chr15:75287851	SCAMP5	-0.92	-13.88	-0.67	2.59e-32	Blood trace element (Zn levels);
SARC	cis	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg02487422	chr3:49467188	NICN1	0.5	6.83	0.41	7.5e-11	Resting heart rate;
SARC	cis	rs7474896	0.537	rs2749588	chr10:38269457	C/G	cg25427524	chr10:38739819	LOC399744	-0.46	-5.71	-0.35	3.4e-8	Obesity (extreme);
SARC	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg09165964	chr15:75287851	SCAMP5	0.51	6.68	0.4	1.75e-10	Breast cancer;
SARC	cis	rs509477	1.000	rs7245165	chr18:32567007	C/A	cg23791764	chr18:32556832	MAPRE2	0.56	6.92	0.41	4.21e-11	Cerebrospinal fluid AB1-42 levels;
SARC	cis	rs2120019	0.517	rs872263	chr15:75136444	C/T	cg17294928	chr15:75287854	SCAMP5	-0.88	-8.38	-0.48	5.14e-15	Blood trace element (Zn levels);
SARC	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg15212455	chr7:39170539	POU6F2	0.4	5.03	0.31	9.64e-7	IgG glycosylation;
SARC	cis	rs9815354	0.767	rs73087378	chr3:41936827	G/A	cg03022575	chr3:42003672	ULK4	0.7	5.7	0.35	3.66e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2425143	1.000	rs73905926	chr20:34251982	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.13	0.32	6.04e-7	Blood protein levels;
SARC	cis	rs9325144	0.768	rs11168750	chr12:38992710	C/A	cg13010199	chr12:38710504	ALG10B	-0.51	-6.04	-0.37	5.93e-9	Morning vs. evening chronotype;
SARC	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg10523679	chr1:76189770	ACADM	0.49	6.09	0.37	4.65e-9	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9818758	0.556	rs11716614	chr3:49017208	C/G	cg06212747	chr3:49208901	KLHDC8B	-0.64	-4.98	-0.31	1.22e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs17376456	0.809	rs13177800	chr5:93307350	T/C	cg21475434	chr5:93447410	FAM172A	0.84	7.49	0.44	1.42e-12	Diabetic retinopathy;
SARC	cis	rs8180040	0.726	rs13094672	chr3:47149439	C/T	cg02527881	chr3:46936655	PTH1R	-0.31	-4.89	-0.3	1.92e-6	Colorectal cancer;
SARC	cis	rs62064224	0.546	rs1018866	chr17:30829664	A/C	cg18200150	chr17:30822561	MYO1D	0.36	5.59	0.34	6.36e-8	Schizophrenia;
SARC	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	14.03	0.68	8.15e-33	Chronic sinus infection;
SARC	cis	rs1355223	0.816	rs2136506	chr11:34748260	T/C	cg18508148	chr11:34937573	PDHX;APIP	-0.4	-5.07	-0.32	8.17e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs10870270	0.956	rs10870281	chr10:133762642	G/A	cg26149184	chr10:133730230	NA	0.45	4.99	0.31	1.16e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs1348850	0.526	rs6723014	chr2:178410586	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.69	6.7	0.4	1.53e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs12142240	0.738	rs41293277	chr1:46806550	C/T	cg00530320	chr1:46809349	NSUN4	0.55	6.69	0.4	1.61e-10	Menopause (age at onset);
SARC	cis	rs41271473	1.000	rs6665334	chr1:228868574	A/C	cg16512390	chr1:228756714	NA	0.5	4.95	0.31	1.43e-6	Chronic lymphocytic leukemia;
SARC	cis	rs12134245	0.755	rs11164928	chr1:92012678	G/A	cg25838465	chr1:92012736	NA	-0.76	-11.06	-0.59	3.91e-23	Breast cancer;
SARC	cis	rs1355223	0.583	rs2941060	chr11:34879154	G/A	cg18508148	chr11:34937573	PDHX;APIP	0.49	6.3	0.38	1.48e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg22800045	chr5:56110881	MAP3K1	-0.42	-5.1	-0.32	7.03e-7	Coronary artery disease;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg23521253	chr10:126653589	ZRANB1	0.53	7.21	0.43	7.71e-12	Thyroid stimulating hormone;
SARC	cis	rs3733585	0.648	rs7378305	chr4:9954893	C/T	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.94	-0.36	1.06e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7833790	1.000	rs7834808	chr8:82704996	A/G	cg17211192	chr8:82754475	SNX16	-0.59	-6.4	-0.39	8.23e-10	Diastolic blood pressure;
SARC	cis	rs2043112	1.000	rs13171123	chr5:39060643	C/T	cg04869206	chr5:39074266	RICTOR	0.53	6.32	0.38	1.35e-9	Obesity-related traits;
SARC	cis	rs7681440	0.804	rs763443	chr4:90819961	T/C	cg06632027	chr4:90757378	SNCA	0.42	5.83	0.36	1.82e-8	Dementia with Lewy bodies;
SARC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.53	-6.15	-0.37	3.4e-9	Prudent dietary pattern;
SARC	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg27286337	chr10:134555280	INPP5A	0.66	8.3	0.48	8.27e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs7385804	0.633	rs221795	chr7:100283261	C/T	cg20848291	chr7:100343083	ZAN	0.45	5.3	0.33	2.7e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
SARC	cis	rs7617773	0.778	rs11715776	chr3:48377611	G/C	cg11946769	chr3:48343235	NME6	0.77	9.63	0.53	1.05e-18	Coronary artery disease;
SARC	cis	rs958025	1	rs958025	chr15:78759348	C/T	cg24631222	chr15:78858424	CHRNA5	0.76	9.28	0.52	1.24e-17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
SARC	cis	rs4820539	1.000	rs3788347	chr22:23467804	G/A	cg14186256	chr22:23484241	RTDR1	0.91	14.73	0.69	3.74e-35	Bone mineral density;
SARC	cis	rs6815814	0.898	rs17582830	chr4:38867427	A/G	cg06935464	chr4:38784597	TLR10	0.51	4.83	0.3	2.42e-6	Breast cancer;
SARC	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg13607699	chr17:42295918	UBTF	0.43	4.84	0.3	2.35e-6	Total body bone mineral density;
SARC	cis	rs6121246	0.529	rs6058152	chr20:30178107	G/A	cg21427119	chr20:30132790	HM13	-0.48	-5.27	-0.33	3.16e-7	Mean corpuscular hemoglobin;
SARC	cis	rs1468333	0.724	rs10054835	chr5:137618772	A/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.74	9.57	0.53	1.65e-18	Resting heart rate;
SARC	cis	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg07636037	chr3:49044803	WDR6	0.63	8.37	0.48	5.44e-15	Resting heart rate;
SARC	cis	rs1538970	0.961	rs884962	chr1:45847981	G/A	cg05343316	chr1:45956843	TESK2	0.67	7.88	0.46	1.22e-13	Platelet count;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg14047339	chr6:45345544	RUNX2;SUPT3H	-0.47	-6.34	-0.38	1.19e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs826838	0.967	rs11169169	chr12:39093153	A/C	cg13010199	chr12:38710504	ALG10B	0.75	10.31	0.56	8.95e-21	Heart rate;
SARC	cis	rs7223966	1.000	rs7223412	chr17:61808172	T/C	cg00588841	chr17:61851480	DDX42;CCDC47	-0.68	-7.6	-0.45	7.42e-13	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg22834771	chr12:69754056	YEATS4	-0.44	-5.73	-0.35	3.1e-8	Blood protein levels;
SARC	trans	rs7824557	0.767	rs6991606	chr8:11176159	G/A	cg06636001	chr8:8085503	FLJ10661	0.6	7.37	0.43	2.96e-12	Retinal vascular caliber;
SARC	cis	rs13191362	0.808	rs13217502	chr6:163231414	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.61	5.85	0.36	1.65e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs6582630	0.576	rs4882258	chr12:38453686	C/T	cg13010199	chr12:38710504	ALG10B	-0.46	-5.66	-0.35	4.48e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6120849	0.663	rs6119548	chr20:33552612	A/G	cg24642439	chr20:33292090	TP53INP2	0.59	5.85	0.36	1.64e-8	Protein C levels;
SARC	cis	rs6088590	0.502	rs6059861	chr20:33068563	A/T	cg24642439	chr20:33292090	TP53INP2	0.66	8.55	0.49	1.6e-15	Coronary artery disease;
SARC	cis	rs12594515	0.967	rs11070466	chr15:45984955	C/T	cg14863074	chr15:45997064	NA	0.34	5.18	0.32	4.74e-7	Waist circumference;Weight;
SARC	cis	rs17253792	0.822	rs12323476	chr14:56172722	C/T	cg01858014	chr14:56050164	KTN1	0.67	5.61	0.35	5.59e-8	Putamen volume;
SARC	cis	rs10463316	0.747	rs10077700	chr5:150768324	A/T	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.23	-0.32	3.86e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs8114671	0.935	rs6142313	chr20:33780427	A/G	cg24642439	chr20:33292090	TP53INP2	-0.49	-5.55	-0.34	7.62e-8	Height;
SARC	cis	rs8070624	0.543	rs11078409	chr17:17876296	C/G	cg05444541	chr17:17804740	TOM1L2	-0.32	-5.22	-0.32	3.88e-7	Total body bone mineral density;
SARC	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg25072359	chr17:41440525	NA	0.49	5.69	0.35	3.71e-8	Menopause (age at onset);
SARC	cis	rs7777754	0.512	rs4470989	chr7:50562698	T/A	cg18232548	chr7:50535776	DDC	-0.46	-5.31	-0.33	2.5e-7	Response to zileuton treatment in asthma (FEV1 change interaction);
SARC	cis	rs9398803	0.865	rs9398809	chr6:126789144	C/T	cg19875578	chr6:126661172	C6orf173	0.63	8.55	0.49	1.64e-15	Male-pattern baldness;
SARC	cis	rs4619890	0.510	rs7663026	chr4:7889068	C/T	cg18538662	chr4:7941764	AFAP1	-0.39	-5.07	-0.32	8.21e-7	Glaucoma (primary open-angle);
SARC	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg08067268	chr2:26466485	HADHB;HADHA	0.51	6.23	0.38	2.14e-9	Gut microbiome composition (summer);
SARC	cis	rs6087990	0.735	rs2889703	chr20:31379184	C/A	cg13636640	chr20:31349939	DNMT3B	0.78	12.25	0.63	5.65e-27	Ulcerative colitis;
SARC	cis	rs9715521	0.935	rs56025348	chr4:59836741	T/G	cg11281224	chr4:60001000	NA	-0.39	-4.97	-0.31	1.31e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs2732480	0.557	rs2732441	chr12:48723324	C/G	cg21466736	chr12:48725269	NA	-0.32	-4.95	-0.31	1.45e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs7249142	0.549	rs72997174	chr19:19294389	T/C	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.23	4.8	0.3	2.78e-6	IgG glycosylation;
SARC	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.95	9.52	0.53	2.29e-18	Alzheimer's disease;
SARC	cis	rs829883	1.000	rs249839	chr12:98872364	T/C	cg25150519	chr12:98850993	NA	0.69	9.36	0.52	6.96e-18	Colorectal adenoma (advanced);
SARC	trans	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg08975724	chr8:8085496	FLJ10661	-0.6	-7.81	-0.46	1.98e-13	Retinal vascular caliber;
SARC	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.35	-4.87	-0.3	2.05e-6	Homoarginine levels;
SARC	cis	rs3892630	0.529	rs35300319	chr19:33409948	G/A	cg00891608	chr19:33463040	C19orf40;CCDC123	-0.5	-4.94	-0.31	1.51e-6	Red blood cell traits;
SARC	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg19077165	chr18:44547161	KATNAL2	0.57	8.03	0.47	4.69e-14	Personality dimensions;
SARC	cis	rs1971762	0.527	rs4759211	chr12:53930945	T/C	cg06632207	chr12:54070931	ATP5G2	0.57	7.84	0.46	1.65e-13	Height;
SARC	trans	rs208520	0.690	rs1738970	chr6:66809491	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.03	-14.08	-0.68	5.24e-33	Exhaled nitric oxide output;
SARC	cis	rs35306767	0.953	rs11253520	chr10:975961	C/G	cg18964960	chr10:1102726	WDR37	-0.44	-5.49	-0.34	1.05e-7	Eosinophil percentage of granulocytes;
SARC	cis	rs7412746	0.658	rs6656535	chr1:150940357	G/T	cg13175981	chr1:150552382	MCL1	-0.49	-5.84	-0.36	1.76e-8	Melanoma;
SARC	cis	rs7582720	1.000	rs72934545	chr2:203975958	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	7.8	0.45	2.11e-13	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg11987759	chr7:65425863	GUSB	-0.42	-5.63	-0.35	5.2e-8	Aortic root size;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg23092047	chr17:43238126	HEXIM2	0.52	6.86	0.41	5.98e-11	Tetralogy of Fallot;
SARC	cis	rs4969178	0.896	rs12602206	chr17:76397133	A/G	cg02836325	chr17:76403955	PGS1	0.33	5.01	0.31	1.07e-6	HDL cholesterol levels;
SARC	cis	rs12311304	0.965	rs73065457	chr12:15366321	C/T	cg08258403	chr12:15378311	NA	0.49	7.54	0.44	1.01e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs77106637	0.530	rs7122044	chr11:72462634	A/G	cg03713592	chr11:72463424	ARAP1	0.84	9.31	0.52	9.66e-18	Type 2 diabetes;
SARC	cis	rs760805	1.000	rs4648884	chr1:25261386	C/T	cg22509179	chr1:25234806	RUNX3	0.48	6.69	0.4	1.66e-10	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg11987759	chr7:65425863	GUSB	-0.47	-6.27	-0.38	1.7e-9	Aortic root size;
SARC	cis	rs11105298	0.891	rs6538189	chr12:89885923	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-5.42	-0.33	1.49e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg00745463	chr17:30367425	LRRC37B	-0.62	-5.04	-0.31	9.23e-7	Hip circumference adjusted for BMI;
SARC	cis	rs651907	0.535	rs1460097	chr3:101497569	C/T	cg12386194	chr3:101231763	SENP7	0.49	5.77	0.35	2.56e-8	Colorectal cancer;
SARC	cis	rs11758351	0.866	rs77205516	chr6:26205356	T/A	cg01420254	chr6:26195488	NA	0.56	5.01	0.31	1.05e-6	Gout;Renal underexcretion gout;
SARC	cis	rs10056811	0.510	rs10058171	chr5:74407991	C/T	cg06933384	chr5:74808293	COL4A3BP;POLK	0.51	4.93	0.31	1.55e-6	Coronary artery disease;
SARC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.45	-7.2	-0.43	8.09e-12	Longevity;Endometriosis;
SARC	cis	rs6450176	0.909	rs12659966	chr5:53292892	C/G	ch.5.1024479R	chr5:53302184	ARL15	0.67	7.66	0.45	5.09e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs4642101	0.765	rs9870269	chr3:12853450	T/G	cg05775895	chr3:12838266	CAND2	0.68	9.78	0.54	3.7e-19	QRS complex (12-leadsum);
SARC	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg03709012	chr19:19516395	GATAD2A	-0.95	-15.25	-0.71	7.23e-37	Tonsillectomy;
SARC	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg18876405	chr7:65276391	NA	0.7	8.7	0.5	6.12e-16	Aortic root size;
SARC	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg22535103	chr8:58192502	C8orf71	-0.7	-7.12	-0.42	1.31e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg04277193	chr17:41438351	NA	0.44	4.82	0.3	2.59e-6	Menopause (age at onset);
SARC	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg17294928	chr15:75287854	SCAMP5	0.49	6.14	0.37	3.48e-9	Breast cancer;
SARC	cis	rs41271473	0.526	rs12094319	chr1:228717836	G/C	cg10167378	chr1:228756711	NA	0.61	5.42	0.33	1.45e-7	Chronic lymphocytic leukemia;
SARC	cis	rs17376456	0.825	rs17372615	chr5:93124768	C/T	cg25358565	chr5:93447407	FAM172A	1.17	12.03	0.62	3.11e-26	Diabetic retinopathy;
SARC	cis	rs9733	0.519	rs11204717	chr1:150709129	T/A	cg15448220	chr1:150897856	SETDB1	0.47	6.17	0.37	3.05e-9	Tonsillectomy;
SARC	cis	rs1153858	1.000	rs12594857	chr15:45667178	A/G	cg21132104	chr15:45694354	SPATA5L1	0.78	11.01	0.59	5.55e-23	Homoarginine levels;
SARC	cis	rs9902453	0.868	rs9896012	chr17:28470091	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	6.88	0.41	5.46e-11	Coffee consumption (cups per day);
SARC	cis	rs523522	0.962	rs603574	chr12:120998443	A/G	cg27279351	chr12:120934652	DYNLL1	0.71	8.82	0.5	2.71e-16	High light scatter reticulocyte count;
SARC	cis	rs7666738	0.830	rs35822567	chr4:98654138	G/A	cg05340658	chr4:99064831	C4orf37	0.64	8.27	0.48	1.04e-14	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.45	-5.83	-0.36	1.87e-8	Longevity;Endometriosis;
SARC	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.5	-6.22	-0.38	2.27e-9	Lymphocyte counts;
SARC	cis	rs9788682	0.747	rs2656071	chr15:78745343	A/T	cg24631222	chr15:78858424	CHRNA5	-0.76	-9.53	-0.53	2.11e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs9325144	0.554	rs7960616	chr12:39096664	T/A	cg13010199	chr12:38710504	ALG10B	-0.5	-6.3	-0.38	1.49e-9	Morning vs. evening chronotype;
SARC	cis	rs6570726	0.791	rs401331	chr6:145831408	A/G	cg23711669	chr6:146136114	FBXO30	0.89	14.96	0.7	6.38e-36	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6088813	0.961	rs6088791	chr20:33907909	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.44	5.35	0.33	2.07e-7	Height;
SARC	cis	rs2120019	0.567	rs28844983	chr15:75178088	T/A	cg09165964	chr15:75287851	SCAMP5	-0.96	-10.86	-0.58	1.69e-22	Blood trace element (Zn levels);
SARC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.33	5.11	0.32	6.72e-7	Bipolar disorder;
SARC	cis	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg08045932	chr20:61659980	NA	0.52	7.12	0.42	1.33e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs7255045	0.788	rs6511843	chr19:12955544	A/C	cg21491176	chr19:12958399	MAST1	-0.36	-5.15	-0.32	5.57e-7	Mean corpuscular volume;
SARC	cis	rs8077889	0.672	rs2074143	chr17:41856622	A/G	cg26893861	chr17:41843967	DUSP3	0.98	15.6	0.71	4.78e-38	Triglycerides;
SARC	cis	rs10735851	1	rs10735851	chr12:53743064	G/A	cg26875137	chr12:53738046	NA	0.43	5.3	0.33	2.72e-7	Total body bone mineral density;
SARC	cis	rs854765	0.583	rs4925126	chr17:17798633	C/T	cg05444541	chr17:17804740	TOM1L2	-0.31	-5.19	-0.32	4.61e-7	Total body bone mineral density;
SARC	cis	rs11098499	0.954	rs28429722	chr4:120300093	G/A	cg09160332	chr4:120329925	NA	-0.33	-4.77	-0.3	3.27e-6	Corneal astigmatism;
SARC	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg11764359	chr7:65958608	NA	-0.77	-9.36	-0.52	6.84e-18	Aortic root size;
SARC	cis	rs9815354	0.812	rs73071315	chr3:41805887	T/C	cg03022575	chr3:42003672	ULK4	0.72	5.99	0.37	7.83e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs1008375	1.000	rs1860596	chr4:17660082	C/T	cg16339924	chr4:17578868	LAP3	0.66	8.72	0.5	5.44e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs8031584	0.958	rs7168641	chr15:31235452	G/A	cg08109568	chr15:31115862	NA	-0.47	-5.8	-0.35	2.2e-8	Huntington's disease progression;
SARC	cis	rs7599312	0.534	rs7355673	chr2:213404389	T/C	cg20637307	chr2:213403960	ERBB4	0.8	12.5	0.63	8.9e-28	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs9486715	0.838	rs4839840	chr6:96941149	T/C	cg06623918	chr6:96969491	KIAA0776	0.89	12.91	0.65	3.96e-29	Headache;
SARC	cis	rs7216064	0.953	rs12601759	chr17:65955284	A/G	cg12091567	chr17:66097778	LOC651250	-0.72	-7.46	-0.44	1.65e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs1209950	0.966	rs1209948	chr21:40170078	C/T	cg01359822	chr21:40176597	ETS2	0.33	4.97	0.31	1.31e-6	Non-small cell lung cancer (survival);
SARC	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg12463550	chr7:65579703	CRCP	0.49	5.82	0.36	1.91e-8	Aortic root size;
SARC	cis	rs6991838	0.733	rs10111844	chr8:66602609	C/T	cg13398993	chr8:66546079	ARMC1	0.44	5.59	0.34	6.19e-8	Intelligence (multi-trait analysis);
SARC	trans	rs7824557	0.767	rs6985146	chr8:11170721	A/C	cg06636001	chr8:8085503	FLJ10661	0.57	7.2	0.43	8.25e-12	Retinal vascular caliber;
SARC	cis	rs7220711	1.000	rs59303349	chr17:41793668	A/G	cg26893861	chr17:41843967	DUSP3	0.42	5.3	0.33	2.67e-7	Bone mineral density (spine);Bone mineral density (hip);
SARC	cis	rs7481584	0.624	rs377765	chr11:3046298	C/T	cg20651018	chr11:3035856	CARS	0.41	6.01	0.37	7.01e-9	Calcium levels;
SARC	cis	rs7552404	0.696	rs12140121	chr1:76455001	A/G	cg10523679	chr1:76189770	ACADM	0.49	5.55	0.34	7.68e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg22535103	chr8:58192502	C8orf71	-0.73	-7.24	-0.43	6.52e-12	Developmental language disorder (linguistic errors);
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg11771402	chr17:27621314	NUFIP2	-0.48	-6.69	-0.4	1.65e-10	Neuroticism;
SARC	cis	rs1949733	0.636	rs16842498	chr4:8539529	C/T	cg13073564	chr4:8508604	NA	0.51	7.85	0.46	1.52e-13	Response to antineoplastic agents;
SARC	cis	rs9341808	0.935	rs2298307	chr6:80816296	A/G	cg08355045	chr6:80787529	NA	0.32	5.29	0.33	2.84e-7	Sitting height ratio;
SARC	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.48	6.01	0.37	7.06e-9	Gut microbiome composition (summer);
SARC	cis	rs11997175	0.598	rs4599769	chr8:33601425	T/C	ch.8.33884649F	chr8:33765107	NA	0.48	6.05	0.37	5.62e-9	Body mass index;
SARC	cis	rs7264396	0.747	rs2425158	chr20:34419664	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-7.15	-0.42	1.1e-11	Total cholesterol levels;
SARC	cis	rs9486719	0.895	rs3734239	chr6:96996244	A/G	cg06623918	chr6:96969491	KIAA0776	-0.79	-8.63	-0.49	9.42e-16	Migraine;Coronary artery disease;
SARC	trans	rs61931739	0.500	rs7309421	chr12:34553795	C/T	cg26384229	chr12:38710491	ALG10B	0.92	13.82	0.67	4.07e-32	Morning vs. evening chronotype;
SARC	cis	rs2377585	0.653	rs10505735	chr12:8841741	A/G	cg03761649	chr12:8850719	RIMKLB	0.47	4.91	0.31	1.69e-6	Reticulocyte fraction of red cells;
SARC	cis	rs72945132	0.882	rs7940090	chr11:70227824	C/G	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.84	-0.36	1.71e-8	Coronary artery disease;
SARC	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg00152838	chr16:24741724	TNRC6A	0.58	5.98	0.36	8.38e-9	Intelligence (multi-trait analysis);
SARC	cis	rs12200560	0.505	rs172425	chr6:97075299	A/T	cg06623918	chr6:96969491	KIAA0776	0.45	5.12	0.32	6.36e-7	Coronary heart disease;
SARC	cis	rs7560272	0.538	rs12233112	chr2:73931764	G/A	cg20560298	chr2:73613845	ALMS1	0.49	6.55	0.39	3.75e-10	Schizophrenia;
SARC	cis	rs2760061	0.545	rs1636196	chr1:228204030	A/G	cg01200585	chr1:228362443	C1orf69	0.45	5.67	0.35	4.11e-8	Diastolic blood pressure;
SARC	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.65	6.26	0.38	1.86e-9	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs933688	0.526	rs9293565	chr5:90609736	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.61	5.49	0.34	1.07e-7	Smoking behavior;
SARC	cis	rs2486288	0.656	rs11629858	chr15:45547114	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.44	-5.45	-0.34	1.26e-7	Glomerular filtration rate;
SARC	cis	rs9325144	0.650	rs6582624	chr12:38733475	A/T	cg26384229	chr12:38710491	ALG10B	-0.63	-8.16	-0.47	2.03e-14	Morning vs. evening chronotype;
SARC	cis	rs910316	0.967	rs2268619	chr14:75640354	C/G	cg11812906	chr14:75593930	NEK9	-0.8	-10.48	-0.57	2.59e-21	Height;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg07276083	chr5:54848335	NA	0.54	6.36	0.38	1.06e-9	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs6733011	0.508	rs13004700	chr2:99527568	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-6.11	-0.37	4.2e-9	Bipolar disorder;
SARC	cis	rs854765	0.583	rs4077198	chr17:17834563	T/C	cg05444541	chr17:17804740	TOM1L2	-0.3	-5.06	-0.31	8.38e-7	Total body bone mineral density;
SARC	cis	rs4819052	0.565	rs35776291	chr21:46706142	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	6.38	0.39	9.65e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9868809	0.505	rs73080312	chr3:48737847	C/T	cg01304814	chr3:48885189	PRKAR2A	0.84	6.18	0.38	2.88e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs2832191	0.791	rs2832196	chr21:30497412	G/A	cg08807101	chr21:30365312	RNF160	-0.79	-10.93	-0.58	1.02e-22	Dental caries;
SARC	cis	rs10782582	0.632	rs11810154	chr1:76239973	C/G	cg03433033	chr1:76189801	ACADM	-0.4	-5.11	-0.32	6.57e-7	Daytime sleep phenotypes;
SARC	cis	rs3749237	0.595	rs6797765	chr3:49423976	A/G	cg06212747	chr3:49208901	KLHDC8B	0.51	6.38	0.39	9.49e-10	Resting heart rate;
SARC	cis	rs8114671	0.562	rs2378292	chr20:33485178	T/C	cg07148914	chr20:33460835	GGT7	0.44	5.41	0.33	1.6e-7	Height;
SARC	cis	rs4481887	1.000	rs6671789	chr1:248482931	G/A	cg01631408	chr1:248437212	OR2T33	-0.43	-5.32	-0.33	2.38e-7	Common traits (Other);
SARC	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.79	10.96	0.58	8.35e-23	Total body bone mineral density;
SARC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg08677398	chr8:58056175	NA	0.44	5.27	0.33	3.14e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs4253772	0.515	rs6008591	chr22:46703664	T/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.63	5.24	0.32	3.56e-7	LDL cholesterol;Cholesterol, total;
SARC	cis	rs757978	0.777	rs11693232	chr2:242362240	A/G	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.8	-6.82	-0.41	7.7e-11	Chronic lymphocytic leukemia;
SARC	cis	rs2832077	0.527	rs9981922	chr21:30212718	A/G	cg24692254	chr21:30365293	RNF160	-0.65	-7.78	-0.45	2.27e-13	Cognitive test performance;
SARC	cis	rs9911578	0.967	rs2333410	chr17:57137129	G/A	cg20303301	chr17:57937339	TUBD1	0.34	5.03	0.31	9.58e-7	Intelligence (multi-trait analysis);
SARC	cis	rs453301	0.658	rs6983877	chr8:8904639	T/C	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.49	-0.49	2.44e-15	Joint mobility (Beighton score);
SARC	cis	rs10992471	0.598	rs2398751	chr9:95206240	C/T	cg13798575	chr9:95087839	CENPP;NOL8	0.41	4.98	0.31	1.25e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs6963495	0.818	rs6944787	chr7:105147309	C/T	cg19920283	chr7:105172520	RINT1	0.67	5.8	0.36	2.14e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs7412746	0.658	rs6656535	chr1:150940357	G/T	cg15448220	chr1:150897856	SETDB1	0.52	6.67	0.4	1.85e-10	Melanoma;
SARC	cis	rs10463316	0.817	rs730526	chr5:150789232	A/G	cg03212797	chr5:150827313	SLC36A1	-0.46	-5.55	-0.34	7.57e-8	Metabolite levels (Pyroglutamine);
SARC	cis	rs11697848	1.000	rs75406401	chr20:48528509	T/G	cg17849948	chr20:48532315	SPATA2	0.87	5.2	0.32	4.3e-7	Systemic lupus erythematosus;
SARC	cis	rs9354308	0.802	rs2814102	chr6:66523230	A/G	cg07460842	chr6:66804631	NA	0.5	5.59	0.34	6.21e-8	Metabolite levels;
SARC	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg11987759	chr7:65425863	GUSB	-0.57	-7.34	-0.43	3.51e-12	Aortic root size;
SARC	trans	rs9650657	0.538	rs6984496	chr8:10796093	G/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.56	-0.44	9.44e-13	Neuroticism;
SARC	cis	rs4481887	0.893	rs10788763	chr1:248429070	A/T	cg00666640	chr1:248458726	OR2T12	-0.29	-4.83	-0.3	2.48e-6	Common traits (Other);
SARC	cis	rs7726839	0.561	rs6555357	chr5:560923	A/G	cg09021430	chr5:549028	NA	-0.45	-6.11	-0.37	4.19e-9	Obesity-related traits;
SARC	cis	rs11098499	0.955	rs7685268	chr4:120162188	G/A	cg24375607	chr4:120327624	NA	0.39	4.72	0.3	4.14e-6	Corneal astigmatism;
SARC	cis	rs2228479	0.702	rs11649501	chr16:89850957	A/T	cg06558623	chr16:89946397	TCF25	0.93	6.44	0.39	6.63e-10	Skin colour saturation;
SARC	cis	rs1451375	0.617	rs10271341	chr7:50591583	A/C	cg18232548	chr7:50535776	DDC	0.48	4.85	0.3	2.24e-6	Malaria;
SARC	trans	rs9650657	0.601	rs10903330	chr8:10673104	C/T	cg06636001	chr8:8085503	FLJ10661	0.5	6.27	0.38	1.78e-9	Neuroticism;
SARC	cis	rs17854409	0.803	rs1048100	chr20:61472073	C/A	cg05147244	chr20:61493195	TCFL5	0.97	6.49	0.39	5.13e-10	Obesity-related traits;
SARC	cis	rs911555	0.755	rs55742283	chr14:103942965	A/G	cg24130564	chr14:104152367	KLC1	0.49	5.77	0.35	2.48e-8	Intelligence (multi-trait analysis);
SARC	trans	rs561341	1.000	rs483301	chr17:30293398	G/T	cg20587970	chr11:113659929	NA	-1.38	-13.71	-0.67	8.88e-32	Hip circumference adjusted for BMI;
SARC	cis	rs668210	0.894	rs1786171	chr11:65769809	G/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.55	5.99	0.37	7.91e-9	Cerebrospinal fluid biomarker levels;
SARC	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg18252515	chr7:66147081	NA	1.29	11.21	0.59	1.32e-23	Diabetic kidney disease;
SARC	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg22535103	chr8:58192502	C8orf71	-0.73	-6.78	-0.41	9.94e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs9341808	0.935	rs2322633	chr6:80845989	C/T	cg08355045	chr6:80787529	NA	-0.33	-5.32	-0.33	2.49e-7	Sitting height ratio;
SARC	cis	rs13077101	0.962	rs447978	chr3:120491086	C/T	cg24332942	chr3:120408071	RABL3	-0.44	-5.48	-0.34	1.11e-7	Obesity-related traits;
SARC	cis	rs7659604	0.540	rs4361412	chr4:122669403	C/T	cg19671926	chr4:122722719	EXOSC9	0.54	6.81	0.41	8.14e-11	Type 2 diabetes;
SARC	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg26335602	chr6:28129616	ZNF389	0.51	5.56	0.34	7.41e-8	Parkinson's disease;
SARC	cis	rs2730245	1.000	rs6965685	chr7:158726462	C/T	cg24397884	chr7:158709396	WDR60	1.02	16.33	0.73	1.73e-40	Height;
SARC	cis	rs2425143	1.000	rs56116518	chr20:34286251	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-5.84	-0.36	1.77e-8	Blood protein levels;
SARC	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg07636037	chr3:49044803	WDR6	1.01	17.84	0.76	1.85e-45	Parkinson's disease;
SARC	cis	rs1448094	0.512	rs7134732	chr12:86241908	T/C	cg02569458	chr12:86230093	RASSF9	0.39	5.44	0.34	1.34e-7	Major depressive disorder;
SARC	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg04277193	chr17:41438351	NA	0.47	5.04	0.31	9.3e-7	Menopause (age at onset);
SARC	cis	rs9788682	0.747	rs2656069	chr15:78745707	C/T	cg24631222	chr15:78858424	CHRNA5	-0.75	-9.33	-0.52	8.73e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg04772025	chr11:68637568	NA	0.53	6.91	0.41	4.55e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg18252515	chr7:66147081	NA	0.51	5.5	0.34	1.01e-7	Aortic root size;
SARC	cis	rs2832191	1.000	rs2832183	chr21:30482150	G/A	cg24692254	chr21:30365293	RNF160	-0.77	-10.73	-0.58	4.22e-22	Dental caries;
SARC	cis	rs2073499	1.000	rs57319506	chr3:50285677	T/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.62	5.81	0.36	2.06e-8	Schizophrenia;
SARC	cis	rs11758351	1.000	rs16891405	chr6:26204506	A/G	cg01420254	chr6:26195488	NA	0.55	4.83	0.3	2.51e-6	Gout;Renal underexcretion gout;
SARC	cis	rs7766436	0.583	rs988972	chr6:22558502	A/C	cg13666174	chr6:22585274	NA	-0.58	-6.02	-0.37	6.56e-9	Coronary artery disease;
SARC	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.95	-13.96	-0.67	1.32e-32	Gut microbiome composition (summer);
SARC	cis	rs56104184	0.779	rs17206686	chr19:49356317	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.86	-8.85	-0.5	2.22e-16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs35110281	0.720	rs162376	chr21:44926759	G/T	cg21573476	chr21:45109991	RRP1B	0.54	7.88	0.46	1.21e-13	Mean corpuscular volume;
SARC	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg22974920	chr21:40686053	BRWD1	-0.44	-4.82	-0.3	2.54e-6	Cognitive function;
SARC	cis	rs8005677	1.000	rs4982710	chr14:23398902	C/T	cg01529538	chr14:23388837	RBM23	0.44	5.32	0.33	2.46e-7	Cognitive ability (multi-trait analysis);
SARC	cis	rs28374715	0.578	rs13313520	chr15:41629127	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.17	-19.36	-0.79	2.1e-50	Ulcerative colitis;
SARC	trans	rs12310956	0.510	rs7301767	chr12:33886529	A/T	cg13010199	chr12:38710504	ALG10B	0.57	7.38	0.44	2.7e-12	Morning vs. evening chronotype;
SARC	cis	rs6570726	0.967	rs441364	chr6:145853662	G/C	cg23711669	chr6:146136114	FBXO30	0.73	10.59	0.57	1.22e-21	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs9650657	0.805	rs6982210	chr8:10599994	G/A	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.79	-0.41	9.25e-11	Neuroticism;
SARC	cis	rs870825	0.655	rs2017101	chr4:185637381	G/A	cg04058563	chr4:185651563	MLF1IP	0.84	11.36	0.6	4.49e-24	Blood protein levels;
SARC	cis	rs7084402	0.967	rs1658418	chr10:60333003	G/A	cg07615347	chr10:60278583	BICC1	0.58	8.47	0.49	2.76e-15	Refractive error;
SARC	trans	rs11165623	0.543	rs60982887	chr1:96989155	T/G	cg10631902	chr5:14652156	NA	-0.42	-6.29	-0.38	1.57e-9	Hip circumference;Waist circumference;
SARC	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg04104256	chr11:46868062	CKAP5	-0.51	-6.43	-0.39	7.04e-10	Thyroid cancer;
SARC	cis	rs10078	0.571	rs2721014	chr5:463539	G/A	cg26072250	chr5:443457	EXOC3;C5orf55	0.67	5.56	0.34	7.48e-8	Fat distribution (HIV);
SARC	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg11366901	chr6:160182831	ACAT2	0.61	6.43	0.39	7.17e-10	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs1865760	0.566	rs9379825	chr6:26083871	C/A	cg16482183	chr6:26056742	HIST1H1C	0.47	5.91	0.36	1.22e-8	Height;
SARC	cis	rs2952156	1.000	rs2643194	chr17:37853048	C/T	cg20243544	chr17:37824526	PNMT	0.46	5.45	0.34	1.31e-7	Asthma;
SARC	cis	rs4423214	0.840	rs1790344	chr11:71176897	A/G	cg05163923	chr11:71159392	DHCR7	-0.61	-7.39	-0.44	2.64e-12	Vitamin D levels;
SARC	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg16606324	chr3:10149918	C3orf24	0.49	4.82	0.3	2.56e-6	Alzheimer's disease;
SARC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg06873352	chr17:61820015	STRADA	0.51	6.58	0.4	3.04e-10	Prudent dietary pattern;
SARC	cis	rs3087591	0.708	rs7350943	chr17:29684553	C/T	cg24425628	chr17:29625626	OMG;NF1	0.42	5.32	0.33	2.39e-7	Hip circumference;
SARC	cis	rs9393692	0.967	rs6456712	chr6:26302573	A/C	cg00631329	chr6:26305371	NA	-0.67	-9.55	-0.53	1.93e-18	Educational attainment;
SARC	cis	rs7635838	0.963	rs7627171	chr3:11413429	G/C	cg00170343	chr3:11313890	ATG7	0.54	6.95	0.41	3.57e-11	HDL cholesterol;
SARC	cis	rs16854884	0.657	rs13086088	chr3:143723942	G/A	cg06585982	chr3:143692056	C3orf58	0.67	9.14	0.51	3.13e-17	Economic and political preferences (feminism/equality);
SARC	cis	rs9467773	1.000	rs6456733	chr6:26566804	C/T	cg11502198	chr6:26597334	ABT1	0.53	6.46	0.39	6.13e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7044106	1.000	rs7044106	chr9:123494062	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	5.39	0.33	1.72e-7	Hip circumference adjusted for BMI;
SARC	cis	rs9902453	1.000	rs4575590	chr17:28361969	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.53	-6.96	-0.41	3.52e-11	Coffee consumption (cups per day);
SARC	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg11764359	chr7:65958608	NA	-0.75	-9.13	-0.51	3.43e-17	Aortic root size;
SARC	cis	rs853679	1.000	rs853679	chr6:28296863	C/A	cg26450541	chr6:28235208	ZNF187	0.62	5.19	0.32	4.64e-7	Depression;
SARC	cis	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg24110177	chr3:50126178	RBM5	0.53	7.03	0.42	2.26e-11	Intelligence (multi-trait analysis);
SARC	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg09699651	chr6:150184138	LRP11	0.49	5.88	0.36	1.39e-8	Lung cancer;
SARC	cis	rs8141529	0.764	rs5762854	chr22:29246278	T/C	cg15103426	chr22:29168792	CCDC117	0.68	8.95	0.51	1.17e-16	Lymphocyte counts;
SARC	cis	rs17539620	0.624	rs62432737	chr6:154834772	G/A	cg17771515	chr6:154831774	CNKSR3	0.53	5.08	0.32	7.61e-7	Lipoprotein (a) levels;
SARC	cis	rs3796352	1.000	rs13072818	chr3:53074263	C/T	cg15956490	chr3:53032818	SFMBT1	0.76	5.35	0.33	2.05e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs710216	0.917	rs900834	chr1:43412343	A/G	cg22176566	chr1:43424700	SLC2A1	-0.52	-5.18	-0.32	4.7e-7	Red cell distribution width;
SARC	cis	rs35110281	0.600	rs914198	chr21:45117456	A/C	cg01579765	chr21:45077557	HSF2BP	-0.35	-5.62	-0.35	5.35e-8	Mean corpuscular volume;
SARC	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg14829155	chr15:31115871	NA	-0.49	-6.29	-0.38	1.59e-9	Huntington's disease progression;
SARC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg07167872	chr1:205819463	PM20D1	0.49	6.49	0.39	5.11e-10	Menarche (age at onset);
SARC	cis	rs7595412	0.735	rs12468642	chr2:199077727	G/T	cg00208931	chr2:198669586	PLCL1	-0.61	-5.03	-0.31	9.8e-7	Hip bone size;
SARC	cis	rs77633900	0.614	rs2439984	chr15:76923917	T/C	cg21673338	chr15:77095150	SCAPER	-0.62	-5.15	-0.32	5.56e-7	Non-glioblastoma glioma;Glioma;
SARC	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg16606324	chr3:10149918	C3orf24	0.48	5.04	0.31	9.53e-7	Alzheimer's disease;
SARC	cis	rs36051895	0.664	rs10117501	chr9:5094246	G/A	cg02405213	chr9:5042618	JAK2	-0.47	-5.86	-0.36	1.55e-8	Pediatric autoimmune diseases;
SARC	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg08677398	chr8:58056175	NA	0.42	4.87	0.3	2.1e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs12042938	0.935	rs1417585	chr1:231803604	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.58	8.12	0.47	2.77e-14	Neuranatomic and neurocognitive phenotypes;
SARC	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg24675658	chr1:53192096	ZYG11B	0.59	8.28	0.48	9.42e-15	Monocyte count;
SARC	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg22535103	chr8:58192502	C8orf71	-0.57	-5.5	-0.34	9.76e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg06873352	chr17:61820015	STRADA	-0.42	-5.57	-0.34	6.96e-8	Prudent dietary pattern;
SARC	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg27266027	chr21:40555129	PSMG1	0.52	5.67	0.35	4.2e-8	Cognitive function;
SARC	cis	rs10911232	0.507	rs5022057	chr1:182997761	T/C	cg13390022	chr1:182993471	LAMC1	0.33	4.97	0.31	1.31e-6	Hypertriglyceridemia;
SARC	cis	rs6545883	0.965	rs7421663	chr2:61753786	C/T	cg15711740	chr2:61764176	XPO1	-0.45	-5.48	-0.34	1.09e-7	Tuberculosis;
SARC	cis	rs4737010	0.501	rs2111805	chr8:41643457	G/C	cg08923054	chr8:41654455	ANK1	0.66	7.89	0.46	1.16e-13	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
SARC	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg18357526	chr6:26021779	HIST1H4A	0.81	10.38	0.56	5.36e-21	Intelligence (multi-trait analysis);
SARC	cis	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg24110177	chr3:50126178	RBM5	-0.54	-7.17	-0.43	1e-11	Intelligence (multi-trait analysis);
SARC	cis	rs60871478	0.947	rs7790823	chr7:788923	T/G	cg05535760	chr7:792225	HEATR2	0.8	8.1	0.47	3.07e-14	Cerebrospinal P-tau181p levels;
SARC	cis	rs79149102	0.522	rs28854237	chr15:74803620	T/A	cg09165964	chr15:75287851	SCAMP5	-0.63	-4.98	-0.31	1.25e-6	Lung cancer;
SARC	cis	rs11209002	0.567	rs2755269	chr1:67541065	T/C	cg02640540	chr1:67518911	SLC35D1	0.59	6.66	0.4	1.99e-10	Crohn's disease;
SARC	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg08975724	chr8:8085496	FLJ10661	0.61	8.14	0.47	2.35e-14	Mood instability;
SARC	cis	rs2180341	0.960	rs7766802	chr6:127709871	T/G	cg27446573	chr6:127587934	RNF146	1.05	14.0	0.68	1.04e-32	Breast cancer;
SARC	cis	rs3018712	0.508	rs4930581	chr11:68411093	A/G	cg01657329	chr11:68192670	LRP5	0.57	5.25	0.33	3.35e-7	Total body bone mineral density;
SARC	cis	rs9467773	1.000	rs9393729	chr6:26514166	C/T	cg11502198	chr6:26597334	ABT1	0.47	5.93	0.36	1.1e-8	Intelligence (multi-trait analysis);
SARC	cis	rs4555082	0.957	rs2816622	chr14:105733114	T/C	cg10792982	chr14:105748885	BRF1	0.53	7.9	0.46	1.1e-13	Mean platelet volume;Platelet distribution width;
SARC	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg04277193	chr17:41438351	NA	0.44	4.73	0.3	3.83e-6	Menopause (age at onset);
SARC	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg04277193	chr17:41438351	NA	0.44	4.86	0.3	2.18e-6	Menopause (age at onset);
SARC	cis	rs67311347	1.000	rs9841335	chr3:40475858	G/A	cg24209194	chr3:40518798	ZNF619	0.61	7.88	0.46	1.24e-13	Renal cell carcinoma;
SARC	trans	rs61931739	0.500	rs7489130	chr12:34539674	C/A	cg13010199	chr12:38710504	ALG10B	0.83	11.73	0.61	2.89e-25	Morning vs. evening chronotype;
SARC	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg12564285	chr5:131593104	PDLIM4	0.45	6.29	0.38	1.57e-9	Breast cancer;
SARC	cis	rs17270561	0.583	rs12662869	chr6:25784481	A/C	cg17691542	chr6:26056736	HIST1H1C	-0.51	-6.43	-0.39	7.31e-10	Iron status biomarkers;
SARC	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg07636037	chr3:49044803	WDR6	-0.93	-16.17	-0.73	6.14e-40	Menarche (age at onset);
SARC	cis	rs644799	1.000	rs534497	chr11:95562868	C/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.68	9.17	0.51	2.6e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg16405210	chr4:1374714	KIAA1530	-0.96	-13.5	-0.66	4.67e-31	Longevity;
SARC	cis	rs7959452	0.901	rs1384	chr12:69747834	C/T	cg20891283	chr12:69753455	YEATS4	0.44	5.92	0.36	1.15e-8	Blood protein levels;
SARC	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg25952890	chr19:58913133	NA	0.36	5.11	0.32	6.83e-7	Uric acid clearance;
SARC	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg19223190	chr17:80058835	NA	0.43	5.96	0.36	9.3e-9	Life satisfaction;
SARC	cis	rs477692	0.789	rs568166	chr10:131400088	G/A	cg05714579	chr10:131428358	MGMT	0.56	7.14	0.42	1.21e-11	Response to temozolomide;
SARC	cis	rs7264396	0.635	rs6060656	chr20:34466382	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.4	-0.44	2.51e-12	Total cholesterol levels;
SARC	cis	rs2180341	0.751	rs9388553	chr6:127574044	A/G	cg24812749	chr6:127587940	RNF146	0.89	11.92	0.62	6.82e-26	Breast cancer;
SARC	cis	rs2304069	0.507	rs7728264	chr5:149394954	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.6	7.02	0.42	2.37e-11	HIV-1 control;
SARC	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg13175981	chr1:150552382	MCL1	-0.48	-5.98	-0.36	8.36e-9	Melanoma;
SARC	cis	rs5758659	0.967	rs5758670	chr22:42636687	T/C	cg15128208	chr22:42549153	NA	-0.37	-5.41	-0.33	1.53e-7	Cognitive function;
SARC	cis	rs11608355	0.545	rs11612500	chr12:109897136	T/C	cg05360138	chr12:110035743	NA	0.92	9.65	0.53	9.69e-19	Neuroticism;
SARC	cis	rs9325144	0.560	rs7304568	chr12:38632408	G/A	cg13010199	chr12:38710504	ALG10B	-0.55	-7.13	-0.42	1.26e-11	Morning vs. evening chronotype;
SARC	cis	rs17021463	0.902	rs10516950	chr4:95254730	C/T	cg11021082	chr4:95130006	SMARCAD1	0.41	6.36	0.38	1.06e-9	Testicular germ cell tumor;
SARC	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.45	5.58	0.34	6.78e-8	Tonsillectomy;
SARC	cis	rs453301	0.686	rs3989373	chr8:8911308	G/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.15	-0.42	1.14e-11	Joint mobility (Beighton score);
SARC	cis	rs7520050	0.902	rs9429088	chr1:46497500	T/A	cg06784218	chr1:46089804	CCDC17	-0.26	-4.86	-0.3	2.17e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs2204008	0.539	rs1283295	chr12:38146014	A/C	cg13010199	chr12:38710504	ALG10B	-0.61	-7.72	-0.45	3.36e-13	Bladder cancer;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg13566674	chr9:77562480	C9orf40	0.54	7.31	0.43	4.33e-12	Thyroid stimulating hormone;
SARC	cis	rs1865760	0.663	rs9348704	chr6:26000393	A/C	cg16482183	chr6:26056742	HIST1H1C	0.5	6.69	0.4	1.6e-10	Height;
SARC	cis	rs9513627	0.522	rs9557241	chr13:100116404	T/C	cg25919922	chr13:100150906	NA	-0.68	-6.74	-0.4	1.21e-10	Obesity-related traits;
SARC	cis	rs3733585	0.699	rs57574512	chr4:9960182	T/C	cg11266682	chr4:10021025	SLC2A9	-0.35	-6.03	-0.37	6.35e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs35164067	1.000	rs11879191	chr19:10512911	G/A	cg21868191	chr19:10515988	NA	-0.42	-5.26	-0.33	3.19e-7	Inflammatory bowel disease;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg10494282	chr1:44440945	ATP6V0B	0.51	6.82	0.41	7.98e-11	Chemerin levels;
SARC	cis	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg08564027	chr20:61660810	NA	0.77	11.69	0.61	3.87e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs17001868	0.568	rs12484697	chr22:40736472	A/G	cg07138101	chr22:40742427	ADSL	-0.56	-6.13	-0.37	3.79e-9	Mammographic density (dense area);
SARC	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.39	-6.24	-0.38	2.1e-9	Menopause (age at onset);
SARC	cis	rs10504073	0.584	rs55908480	chr8:49923431	G/A	cg00325661	chr8:49890786	NA	0.51	6.82	0.41	7.54e-11	Blood metabolite ratios;
SARC	cis	rs58904263	1	rs58904263	chr20:30401406	A/AG	cg13852791	chr20:30311386	BCL2L1	0.8	8.54	0.49	1.78e-15	Monocyte count;
SARC	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg09165964	chr15:75287851	SCAMP5	0.58	8.13	0.47	2.47e-14	Breast cancer;
SARC	cis	rs9291683	0.632	rs11734375	chr4:10046298	A/G	cg00071950	chr4:10020882	SLC2A9	0.39	6.29	0.38	1.52e-9	Bone mineral density;
SARC	cis	rs5821446	1	rs5821446	chr17:65962538	A/AT	cg12091567	chr17:66097778	LOC651250	0.69	7.68	0.45	4.33e-13	Eosinophil percentage of granulocytes;
SARC	cis	rs3762637	0.941	rs9289192	chr3:122076115	C/G	cg24169773	chr3:122142474	KPNA1	-0.55	-5.19	-0.32	4.6e-7	LDL cholesterol levels;
SARC	cis	rs3815700	1.000	rs10407204	chr19:33097353	C/T	cg02997394	chr19:33096574	ANKRD27	0.77	8.29	0.48	9.02e-15	Eosinophilic esophagitis;
SARC	cis	rs4595586	0.545	rs7486598	chr12:39371159	C/T	cg26384229	chr12:38710491	ALG10B	0.51	6.25	0.38	1.9e-9	Morning vs. evening chronotype;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg02065717	chr1:101437439	SLC30A7	0.44	6.33	0.38	1.28e-9	Thyroid stimulating hormone;
SARC	cis	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg09021430	chr5:549028	NA	-0.44	-5.73	-0.35	3.02e-8	Obesity-related traits;
SARC	cis	rs9462027	0.628	rs2477508	chr6:34703695	A/G	cg07306190	chr6:34760872	UHRF1BP1	0.41	5.68	0.35	4.05e-8	Systemic lupus erythematosus;
SARC	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg08219700	chr8:58056026	NA	0.51	5.18	0.32	4.74e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs7395662	0.504	rs11039701	chr11:48389838	A/G	cg15704280	chr7:45808275	SEPT13	-0.49	-6.64	-0.4	2.16e-10	HDL cholesterol;
SARC	cis	rs3091242	0.933	rs35530120	chr1:25785451	A/G	cg27572855	chr1:25598939	RHD	-0.54	-9.26	-0.52	1.44e-17	Erythrocyte sedimentation rate;
SARC	cis	rs7508	0.574	rs4288422	chr8:17922885	G/T	cg18067069	chr8:17937731	ASAH1	-0.4	-4.95	-0.31	1.44e-6	Atrial fibrillation;
SARC	cis	rs79349575	0.783	rs62075852	chr17:47017176	T/C	cg16584676	chr17:46985605	UBE2Z	0.55	6.66	0.4	1.91e-10	Type 2 diabetes;
SARC	cis	rs6546324	0.625	rs4260227	chr2:67843537	G/A	cg18237512	chr2:67827392	NA	-0.54	-6.46	-0.39	6.15e-10	Endometriosis;
SARC	cis	rs2952156	0.920	rs8078228	chr17:37834998	C/T	cg20243544	chr17:37824526	PNMT	0.56	7.44	0.44	1.94e-12	Asthma;
SARC	cis	rs875971	0.660	rs10229345	chr7:65982168	G/C	cg18876405	chr7:65276391	NA	0.75	9.29	0.52	1.14e-17	Aortic root size;
SARC	cis	rs9300255	0.739	rs11057210	chr12:123733799	A/G	cg00376283	chr12:123451042	ABCB9	0.52	5.98	0.36	8.35e-9	Neutrophil percentage of white cells;
SARC	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg25894440	chr7:65020034	NA	-0.73	-5.54	-0.34	8.11e-8	Diabetic kidney disease;
SARC	cis	rs35398779	1	rs35398779	chr17:19853094	GA/G	cg04132472	chr17:19861366	AKAP10	0.41	5.33	0.33	2.32e-7	Platelet count;
SARC	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg18876405	chr7:65276391	NA	-0.69	-8.47	-0.49	2.72e-15	Aortic root size;
SARC	cis	rs738321	0.701	rs2413506	chr22:38593128	T/C	cg25457927	chr22:38595422	NA	-0.31	-5.48	-0.34	1.12e-7	Breast cancer;
SARC	cis	rs473651	0.904	rs10929275	chr2:239323169	A/G	cg21699342	chr2:239360505	ASB1	0.42	6.03	0.37	6.52e-9	Multiple system atrophy;
SARC	cis	rs7084402	0.935	rs10763564	chr10:60360423	C/A	cg07615347	chr10:60278583	BICC1	0.6	8.68	0.49	7.06e-16	Refractive error;
SARC	cis	rs3749237	0.595	rs1464567	chr3:49459252	C/G	cg06212747	chr3:49208901	KLHDC8B	-0.57	-6.82	-0.41	7.55e-11	Resting heart rate;
SARC	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg22535103	chr8:58192502	C8orf71	-0.74	-7.22	-0.43	7.47e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs17826219	0.568	rs11658027	chr17:29094882	A/G	cg13385521	chr17:29058706	SUZ12P	-0.86	-7.78	-0.45	2.42e-13	Body mass index;
SARC	cis	rs2276314	0.793	rs77590522	chr18:33629410	C/G	cg19628046	chr18:33552617	C18orf21	0.62	6.09	0.37	4.52e-9	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs2013441	1.000	rs2703806	chr17:20108239	A/T	cg13482628	chr17:19912719	NA	-0.45	-5.89	-0.36	1.35e-8	Obesity-related traits;
SARC	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg18135555	chr8:22132992	PIWIL2	0.41	6.13	0.37	3.71e-9	Hypertriglyceridemia;
SARC	cis	rs2235642	0.717	rs2236269	chr16:1652614	T/A	cg03715980	chr16:1756201	MAPK8IP3	0.41	4.97	0.31	1.29e-6	Coronary artery disease;
SARC	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2439831	0.681	rs528517	chr15:43612925	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.05	11.87	0.61	9.91e-26	Lung cancer in ever smokers;
SARC	cis	rs7681440	0.874	rs1372524	chr4:90776045	A/G	cg02192967	chr4:90758406	SNCA	0.37	5.26	0.33	3.25e-7	Dementia with Lewy bodies;
SARC	cis	rs7208859	0.673	rs73277986	chr17:29196197	C/T	cg13385521	chr17:29058706	SUZ12P	0.86	7.34	0.43	3.54e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg06873352	chr17:61820015	STRADA	0.53	6.91	0.41	4.63e-11	Prudent dietary pattern;
SARC	cis	rs2153904	0.793	rs12118655	chr1:205663478	A/G	cg14893161	chr1:205819251	PM20D1	-0.62	-5.2	-0.32	4.4e-7	Prostate-specific antigen levels;
SARC	cis	rs13191362	0.935	rs34035978	chr6:163165336	G/C	cg06582575	chr6:163149167	PACRG;PARK2	0.59	5.39	0.33	1.7e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs6545883	0.931	rs778765	chr2:61786385	A/T	cg15711740	chr2:61764176	XPO1	-0.45	-5.52	-0.34	9.03e-8	Tuberculosis;
SARC	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg20607798	chr8:58055168	NA	0.57	5.33	0.33	2.27e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs9818941	0.744	rs13098886	chr3:157613783	C/T	cg04887335	chr3:196044632	TCTEX1D2	0.56	6.61	0.4	2.61e-10	Height;
SARC	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.4	-5.01	-0.31	1.06e-6	Menarche (age at onset);
SARC	cis	rs1023500	0.551	rs2301521	chr22:42423110	G/C	cg04733989	chr22:42467013	NAGA	0.73	9.67	0.54	8.12e-19	Schizophrenia;
SARC	cis	rs9916302	0.706	rs903507	chr17:37726423	A/G	cg07936489	chr17:37558343	FBXL20	-0.74	-8.4	-0.48	4.37e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg23758822	chr17:41437982	NA	0.87	10.66	0.57	7.3e-22	Menopause (age at onset);
SARC	cis	rs8060686	0.668	rs255056	chr16:68016185	G/C	cg04539111	chr16:67997858	SLC12A4	-0.48	-4.72	-0.3	4.11e-6	HDL cholesterol;Metabolic syndrome;
SARC	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg02733842	chr7:1102375	C7orf50	-0.59	-7.42	-0.44	2.17e-12	Bronchopulmonary dysplasia;
SARC	cis	rs2439831	0.681	rs28578454	chr15:43603032	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	6.75	0.4	1.18e-10	Lung cancer in ever smokers;
SARC	cis	rs8014204	0.935	rs8010840	chr14:75355203	T/C	cg17347104	chr14:75034677	LTBP2	0.4	4.93	0.31	1.55e-6	Caffeine consumption;
SARC	cis	rs9921222	0.521	rs62032884	chr16:363415	C/T	cg00101154	chr16:420108	MRPL28	-0.48	-6.55	-0.39	3.65e-10	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs896854	0.738	rs1713669	chr8:95958637	C/G	cg16049864	chr8:95962084	TP53INP1	-0.42	-6.42	-0.39	7.55e-10	Type 2 diabetes;
SARC	cis	rs17023223	0.537	rs12092807	chr1:119750644	A/G	cg05756136	chr1:119680316	WARS2	0.49	4.78	0.3	3.05e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs12579753	1.000	rs11613196	chr12:82173251	A/T	cg07988820	chr12:82153109	PPFIA2	0.58	6.87	0.41	5.88e-11	Resting heart rate;
SARC	cis	rs13161115	0.919	rs36044695	chr5:107054550	G/A	cg15160843	chr5:107008084	EFNA5	0.5	4.72	0.3	4.07e-6	Number of children ever born;
SARC	cis	rs9916302	0.904	rs35285898	chr17:37555872	A/C	cg07936489	chr17:37558343	FBXL20	0.69	9.17	0.52	2.52e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs9399135	1.000	rs4896130	chr6:135355118	C/T	cg24558204	chr6:135376177	HBS1L	0.45	6.04	0.37	5.99e-9	Red blood cell count;
SARC	cis	rs9325144	0.555	rs61929925	chr12:38698828	C/A	cg26384229	chr12:38710491	ALG10B	-0.62	-8.24	-0.48	1.23e-14	Morning vs. evening chronotype;
SARC	cis	rs6545883	0.794	rs778152	chr2:61608540	C/A	cg15711740	chr2:61764176	XPO1	0.39	4.77	0.3	3.2e-6	Tuberculosis;
SARC	cis	rs2425143	1.000	rs6060643	chr20:34449851	C/T	cg01084648	chr20:34329383	RBM39	0.64	4.95	0.31	1.44e-6	Blood protein levels;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg03158666	chr17:7199744	NA	0.57	7.15	0.42	1.09e-11	Breast cancer;
SARC	cis	rs644799	0.511	rs10831420	chr11:95478209	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.72	9.34	0.52	8.18e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs240764	0.658	rs2132168	chr6:101178491	G/A	cg09795085	chr6:101329169	ASCC3	-0.51	-6.69	-0.4	1.61e-10	Neuroticism;
SARC	cis	rs6704644	0.722	rs72980338	chr2:234325023	C/T	cg27060346	chr2:234359958	DGKD	-0.78	-5.7	-0.35	3.69e-8	Bilirubin levels;
SARC	cis	rs1050631	0.657	rs1789551	chr18:33716092	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.59	7.17	0.43	9.66e-12	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs9611519	1.000	rs9611505	chr22:41540279	T/C	cg17376030	chr22:41985996	PMM1	0.47	5.24	0.32	3.56e-7	Neuroticism;
SARC	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg21226059	chr5:178986404	RUFY1	0.35	4.91	0.31	1.72e-6	Lung cancer;
SARC	cis	rs6700896	0.897	rs28480230	chr1:66124075	C/T	cg04111102	chr1:66153794	NA	0.36	5.66	0.35	4.49e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg13770153	chr20:60521292	NA	-0.75	-11.0	-0.58	5.99e-23	Obesity-related traits;
SARC	cis	rs6908034	0.546	rs74514942	chr6:19810520	G/A	cg02682789	chr6:19804855	NA	0.69	5.6	0.34	6.02e-8	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg16049864	chr8:95962084	TP53INP1	-0.52	-8.51	-0.49	2.12e-15	Type 2 diabetes;
SARC	cis	rs1008375	0.966	rs10939736	chr4:17581617	T/A	cg16339924	chr4:17578868	LAP3	0.69	9.17	0.51	2.59e-17	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2180341	0.538	rs11154402	chr6:127711932	C/A	cg24812749	chr6:127587940	RNF146	0.46	5.58	0.34	6.82e-8	Breast cancer;
SARC	cis	rs4919694	1.000	rs4917382	chr10:104838510	G/A	cg04362960	chr10:104952993	NT5C2	0.66	5.4	0.33	1.66e-7	Arsenic metabolism;
SARC	cis	rs12682352	0.602	rs6988939	chr8:8666916	C/T	cg06636001	chr8:8085503	FLJ10661	0.54	6.81	0.41	8.06e-11	Neuroticism;
SARC	cis	rs6570726	0.967	rs9403706	chr6:145795187	C/T	cg23711669	chr6:146136114	FBXO30	-0.71	-10.61	-0.57	1.07e-21	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg09373136	chr17:61933544	TCAM1	-0.45	-6.2	-0.38	2.48e-9	Prudent dietary pattern;
SARC	cis	rs35084382	1.000	rs2431663	chr5:172196711	A/C	cg19801141	chr5:172198162	DUSP1	0.87	4.77	0.3	3.25e-6	Optic cup area;
SARC	cis	rs11098499	0.820	rs28394116	chr4:120524283	T/G	cg09307838	chr4:120376055	NA	0.83	11.31	0.6	6.28e-24	Corneal astigmatism;
SARC	cis	rs11209002	0.567	rs983111	chr1:67539356	T/C	cg02640540	chr1:67518911	SLC35D1	0.59	6.66	0.4	1.99e-10	Crohn's disease;
SARC	cis	rs4595586	0.563	rs2388178	chr12:39364366	T/G	cg13010199	chr12:38710504	ALG10B	0.4	4.75	0.3	3.57e-6	Morning vs. evening chronotype;
SARC	cis	rs11249608	0.789	rs7704963	chr5:178436854	A/G	cg21905437	chr5:178450457	ZNF879	0.51	7.0	0.42	2.69e-11	Pubertal anthropometrics;
SARC	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg18876405	chr7:65276391	NA	0.7	8.7	0.5	6.12e-16	Aortic root size;
SARC	cis	rs41271473	1.000	rs55956922	chr1:228872549	T/A	cg10167378	chr1:228756711	NA	0.48	4.72	0.3	4.04e-6	Chronic lymphocytic leukemia;
SARC	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	13.86	0.67	2.88e-32	Chronic sinus infection;
SARC	cis	rs2733201	1.000	rs2615285	chr15:44417376	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	-0.77	-5.84	-0.36	1.78e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	cis	rs9443189	0.615	rs618239	chr6:76350038	A/G	cg01950844	chr6:76311363	SENP6	0.84	7.98	0.46	6.61e-14	Prostate cancer;
SARC	cis	rs875971	0.545	rs10950027	chr7:65634151	C/T	cg25894440	chr7:65020034	NA	0.51	4.76	0.3	3.33e-6	Aortic root size;
SARC	cis	rs6546550	0.694	rs12467361	chr2:70019127	G/A	cg02498382	chr2:70120550	SNRNP27	-0.32	-5.11	-0.32	6.65e-7	Prevalent atrial fibrillation;
SARC	cis	rs6580649	1.000	rs6580647	chr12:48403229	G/T	cg05342945	chr12:48394962	COL2A1	0.54	6.02	0.37	6.75e-9	Lung cancer;
SARC	cis	rs1448094	0.511	rs10863083	chr12:86226739	C/A	cg02569458	chr12:86230093	RASSF9	0.41	5.75	0.35	2.79e-8	Major depressive disorder;
SARC	cis	rs765787	0.530	rs11636018	chr15:45539137	T/C	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.51e-10	Uric acid levels;
SARC	cis	rs11625487	0.515	rs12434419	chr14:77855617	G/A	cg20045696	chr14:77926864	AHSA1	-0.48	-6.27	-0.38	1.69e-9	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
SARC	cis	rs28374715	0.528	rs7178360	chr15:41631175	T/A	cg18705301	chr15:41695430	NDUFAF1	-1.17	-19.16	-0.78	8.85e-50	Ulcerative colitis;
SARC	cis	rs55823223	0.618	rs11867339	chr17:73862093	A/G	cg14829360	chr17:73884958	NA	-0.62	-7.67	-0.45	4.67e-13	Psoriasis;
SARC	cis	rs796364	0.951	rs11897245	chr2:201063644	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.54	5.56	0.34	7.28e-8	Schizophrenia;
SARC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.42	0.53	4.71e-18	Prudent dietary pattern;
SARC	cis	rs6993270	1.000	rs6469877	chr8:120936521	T/C	cg21659575	chr8:120844832	TAF2	0.49	4.72	0.3	4.14e-6	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg24642844	chr7:1081250	C7orf50	-0.38	-5.23	-0.32	3.7e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg06873352	chr17:61820015	STRADA	0.52	6.8	0.41	8.81e-11	Prudent dietary pattern;
SARC	cis	rs611744	0.647	rs647907	chr8:109251374	T/C	cg21045802	chr8:109455806	TTC35	0.6	7.54	0.44	1.02e-12	Dupuytren's disease;
SARC	cis	rs8067354	0.645	rs2645489	chr17:57883371	T/G	cg02344993	chr17:57696989	CLTC	0.66	6.86	0.41	6.07e-11	Hemoglobin concentration;
SARC	cis	rs6545883	0.859	rs35760550	chr2:61603865	T/A	cg15711740	chr2:61764176	XPO1	0.4	4.73	0.3	3.92e-6	Tuberculosis;
SARC	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg12463550	chr7:65579703	CRCP	-0.49	-5.88	-0.36	1.4e-8	Aortic root size;
SARC	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.62	7.45	0.44	1.8e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2075371	0.829	rs11770764	chr7:134003308	T/C	cg20476274	chr7:133979776	SLC35B4	0.56	7.12	0.42	1.3e-11	Mean platelet volume;
SARC	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg18252515	chr7:66147081	NA	0.58	6.26	0.38	1.79e-9	Aortic root size;
SARC	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg25894440	chr7:65020034	NA	-0.71	-5.4	-0.33	1.62e-7	Diabetic kidney disease;
SARC	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-9.58	-0.53	1.53e-18	Chronic sinus infection;
SARC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg10150615	chr22:24372951	LOC391322	-0.48	-5.38	-0.33	1.81e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6570726	0.935	rs382910	chr6:145865941	G/A	cg23711669	chr6:146136114	FBXO30	0.75	11.29	0.59	7.15e-24	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg13206674	chr6:150067644	NUP43	0.51	6.47	0.39	5.81e-10	Lung cancer;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg05152629	chr11:207881	BET1L;RIC8A	-0.47	-6.27	-0.38	1.73e-9	Chemerin levels;
SARC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.34	5.06	0.31	8.43e-7	Bipolar disorder;
SARC	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg27170947	chr2:26402098	FAM59B	0.39	4.92	0.31	1.63e-6	Gut microbiome composition (summer);
SARC	cis	rs1448094	0.773	rs11117100	chr12:86310392	A/G	cg02569458	chr12:86230093	RASSF9	0.38	4.96	0.31	1.34e-6	Major depressive disorder;
SARC	cis	rs9325144	0.723	rs10161183	chr12:39182087	T/C	cg13010199	chr12:38710504	ALG10B	-0.5	-6.0	-0.37	7.46e-9	Morning vs. evening chronotype;
SARC	cis	rs763121	0.853	rs35522482	chr22:39063015	C/A	cg14440974	chr22:39074834	NA	-0.35	-5.11	-0.32	6.58e-7	Menopause (age at onset);
SARC	cis	rs12142240	0.698	rs1135459	chr1:46815930	C/T	cg00530320	chr1:46809349	NSUN4	0.57	6.92	0.41	4.4e-11	Menopause (age at onset);
SARC	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	11.84	0.61	1.28e-25	Alzheimer's disease;
SARC	trans	rs9427116	0.502	rs12125166	chr1:154582129	A/G	cg07719737	chr20:35917850	MANBAL	-0.55	-7.09	-0.42	1.54e-11	Blood protein levels;
SARC	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg25072359	chr17:41440525	NA	0.51	6.02	0.37	6.83e-9	Menopause (age at onset);
SARC	cis	rs694739	1.000	rs11231757	chr11:64106317	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.75	10.29	0.56	9.95e-21	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg19723775	chr5:179050963	HNRNPH1	0.41	5.27	0.33	3.13e-7	Lung cancer;
SARC	trans	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.58	-7.25	-0.43	6.15e-12	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9640161	0.789	rs11767409	chr7:150058043	C/T	cg10018233	chr7:150070692	REPIN1	0.66	8.4	0.48	4.31e-15	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs8141529	0.644	rs5752795	chr22:29178820	T/C	cg15103426	chr22:29168792	CCDC117	0.69	9.21	0.52	1.94e-17	Lymphocyte counts;
SARC	cis	rs10988449	0.891	rs13440406	chr9:132394199	G/T	cg18327994	chr9:132372705	NA	-0.48	-4.91	-0.31	1.74e-6	Response to anti-depressant treatment in major depressive disorder;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg01082422	chr5:179224751	MGAT4B	-0.81	-6.67	-0.4	1.82e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs12802200	0.561	rs746707	chr11:571984	C/T	cg16486109	chr11:613632	IRF7	0.35	4.94	0.31	1.52e-6	Systemic lupus erythematosus;
SARC	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg11766577	chr21:47581405	C21orf56	-0.41	-5.04	-0.31	9.15e-7	Testicular germ cell tumor;
SARC	cis	rs12291225	0.585	rs4757250	chr11:14375683	C/A	cg19336497	chr11:14380999	RRAS2	-0.44	-7.83	-0.46	1.75e-13	Sense of smell;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg20746762	chr13:53191547	HNRNPA1L2	-0.49	-6.66	-0.4	1.96e-10	Neuroticism;
SARC	cis	rs239198	0.602	rs9377240	chr6:101323752	C/T	cg09795085	chr6:101329169	ASCC3	0.46	5.86	0.36	1.56e-8	Menarche (age at onset);
SARC	cis	rs7481584	0.624	rs80871	chr11:3049843	A/C	cg08508325	chr11:3079039	CARS	0.23	5.15	0.32	5.5e-7	Calcium levels;
SARC	cis	rs1035144	0.505	rs11159479	chr14:81460651	C/T	cg06600135	chr14:81408086	NA	-0.46	-5.93	-0.36	1.06e-8	Male sexual orientation;
SARC	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg08859206	chr1:53392774	SCP2	0.43	6.22	0.38	2.31e-9	Monocyte count;
SARC	cis	rs72781680	1.000	rs72788286	chr2:24098321	A/C	cg08917208	chr2:24149416	ATAD2B	0.76	7.49	0.44	1.42e-12	Lymphocyte counts;
SARC	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg24633833	chr3:10029261	TMEM111	0.52	5.25	0.33	3.43e-7	Alzheimer's disease;
SARC	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg13770153	chr20:60521292	NA	-0.49	-6.53	-0.39	4.08e-10	Body mass index;
SARC	trans	rs2727020	0.681	rs1976901	chr11:49378697	T/C	cg03929089	chr4:120376271	NA	-0.76	-11.22	-0.59	1.21e-23	Coronary artery disease;
SARC	cis	rs9715521	0.775	rs62301191	chr4:59842587	T/G	cg11281224	chr4:60001000	NA	-0.42	-5.25	-0.33	3.48e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs2933343	0.601	rs1680759	chr3:128594896	C/G	cg24203234	chr3:128598194	ACAD9	0.63	8.11	0.47	2.89e-14	IgG glycosylation;
SARC	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg17376030	chr22:41985996	PMM1	-0.65	-7.99	-0.46	6.38e-14	Vitiligo;
SARC	cis	rs11578119	0.836	rs12130520	chr1:170539500	G/A	cg09767346	chr1:170501363	GORAB	0.44	5.19	0.32	4.61e-7	Male-pattern baldness;
SARC	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.5e-10	Life satisfaction;
SARC	cis	rs876084	0.510	rs10096137	chr8:121101910	A/G	cg06265175	chr8:121136014	COL14A1	0.58	7.68	0.45	4.35e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs920590	0.510	rs4922101	chr8:19648895	A/G	cg01411142	chr8:19674711	INTS10	0.58	6.0	0.37	7.66e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg12923728	chr3:195709715	SDHAP1	-0.69	-8.53	-0.49	1.91e-15	Pancreatic cancer;
SARC	cis	rs6568686	0.627	rs4245546	chr6:111903950	C/A	cg15721981	chr6:111408429	SLC16A10	-0.56	-4.8	-0.3	2.82e-6	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg13628971	chr7:2884303	GNA12	0.56	6.48	0.39	5.53e-10	Height;
SARC	cis	rs4728302	0.559	rs12707093	chr7:133200817	C/T	cg10665199	chr7:133106180	EXOC4	0.41	5.09	0.32	7.42e-7	Intelligence;Intelligence (multi-trait analysis);
SARC	cis	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg22857025	chr5:266934	NA	0.98	10.82	0.58	2.21e-22	Breast cancer;
SARC	cis	rs963731	0.649	rs10172714	chr2:39197543	C/G	cg04010122	chr2:39346883	SOS1	-0.81	-4.86	-0.3	2.16e-6	Corticobasal degeneration;
SARC	cis	rs10085978	0.604	rs10104197	chr8:143235315	C/G	cg24634471	chr8:143751801	JRK	0.41	4.75	0.3	3.53e-6	Mosquito bite size;
SARC	cis	rs2276314	0.857	rs4799408	chr18:33588982	C/T	cg19628046	chr18:33552617	C18orf21	-0.56	-5.76	-0.35	2.66e-8	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs9910055	0.530	rs11652651	chr17:42302907	A/G	cg19774624	chr17:42201019	HDAC5	0.49	6.69	0.4	1.64e-10	Total body bone mineral density;
SARC	cis	rs2242194	0.844	rs11264295	chr1:154987526	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.35	6.03	0.37	6.53e-9	Schizophrenia;
SARC	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg11987759	chr7:65425863	GUSB	0.45	5.68	0.35	3.98e-8	Aortic root size;
SARC	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg05368731	chr17:41323189	NBR1	0.78	9.29	0.52	1.13e-17	Menopause (age at onset);
SARC	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg04756594	chr16:24857601	SLC5A11	0.46	6.02	0.37	6.57e-9	Intelligence (multi-trait analysis);
SARC	cis	rs9381040	0.610	rs2294694	chr6:41046177	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.43	-4.94	-0.31	1.5e-6	Alzheimer's disease (late onset);
SARC	cis	rs76419734	1.000	rs11726124	chr4:106766496	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	-0.78	-5.5	-0.34	9.92e-8	Post bronchodilator FEV1;
SARC	cis	rs7937682	0.562	rs527847	chr11:111369132	A/C	cg09085632	chr11:111637200	PPP2R1B	0.52	6.58	0.4	3.1e-10	Primary sclerosing cholangitis;
SARC	cis	rs2976388	0.609	rs2585150	chr8:143792669	C/T	cg06565975	chr8:143823917	SLURP1	0.3	5.24	0.32	3.65e-7	Urinary tract infection frequency;
SARC	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg26913058	chr16:419975	MRPL28	0.36	6.43	0.39	7.35e-10	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs67311347	0.955	rs60554147	chr3:40472503	T/C	cg09455208	chr3:40491958	NA	0.42	6.69	0.4	1.62e-10	Renal cell carcinoma;
SARC	cis	rs11874712	0.527	rs9807399	chr18:43640714	A/C	cg26436583	chr18:43649176	PSTPIP2	-0.44	-5.66	-0.35	4.5e-8	Migraine - clinic-based;
SARC	trans	rs6716963	0.585	rs11687224	chr2:194568323	A/G	cg17499041	chr6:35310257	PPARD	0.53	6.48	0.39	5.44e-10	Schizophrenia;
SARC	cis	rs1707322	0.686	rs2230658	chr1:46078854	A/G	cg06784218	chr1:46089804	CCDC17	-0.38	-6.66	-0.4	1.92e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs78456975	0.943	rs10470006	chr2:1580971	A/C	cg12573674	chr2:1569213	NA	-0.53	-4.83	-0.3	2.48e-6	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs11122272	0.735	rs2437150	chr1:231488524	A/G	cg06096015	chr1:231504339	EGLN1	-0.37	-5.53	-0.34	8.47e-8	Hemoglobin concentration;
SARC	cis	rs614226	0.938	rs7963543	chr12:120923948	C/A	cg01236616	chr12:121019343	POP5	1.24	17.92	0.76	1.03e-45	Type 1 diabetes nephropathy;
SARC	cis	rs748404	0.578	rs510108	chr15:43605439	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.44	5.46	0.34	1.19e-7	Lung cancer;
SARC	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg15556689	chr8:8085844	FLJ10661	0.49	6.34	0.38	1.16e-9	Mood instability;
SARC	cis	rs10504229	0.679	rs7840100	chr8:58036662	T/G	cg22535103	chr8:58192502	C8orf71	-0.53	-5.46	-0.34	1.21e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2120243	0.510	rs7623173	chr3:157119949	A/G	cg24825693	chr3:157122686	VEPH1	-0.46	-6.42	-0.39	7.36e-10	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs3768617	0.782	rs10752893	chr1:183046261	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.6	8.0	0.46	5.99e-14	Fuchs's corneal dystrophy;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg00101436	chr7:90755643	CDK14	0.52	7.05	0.42	2.07e-11	Thyroid stimulating hormone;
SARC	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg22535103	chr8:58192502	C8orf71	-0.81	-9.35	-0.52	7.66e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs7264396	0.836	rs2010565	chr20:34182517	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.54	-5.82	-0.36	1.89e-8	Total cholesterol levels;
SARC	cis	rs1008375	0.966	rs4235391	chr4:17696409	A/G	cg27347728	chr4:17578864	LAP3	0.44	5.67	0.35	4.14e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.49	-6.1	-0.37	4.49e-9	Personality dimensions;
SARC	cis	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg06636001	chr8:8085503	FLJ10661	0.69	9.2	0.52	2.15e-17	Mood instability;
SARC	cis	rs2050392	0.517	rs602966	chr10:30755853	C/T	cg25182066	chr10:30743637	MAP3K8	0.46	6.32	0.38	1.35e-9	Inflammatory bowel disease;
SARC	cis	rs3820928	0.874	rs4675137	chr2:227883910	G/C	cg11843606	chr2:227700838	RHBDD1	-0.57	-7.32	-0.43	3.95e-12	Pulmonary function;
SARC	cis	rs7589342	0.929	rs7590652	chr2:106440306	A/G	cg14210321	chr2:106509881	NCK2	-0.45	-5.27	-0.33	3.11e-7	Addiction;
SARC	cis	rs9840812	0.683	rs8045	chr3:136055459	T/C	cg15507776	chr3:136538369	TMEM22	-0.52	-5.28	-0.33	3.01e-7	Fibrinogen levels;
SARC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg11494091	chr17:61959527	GH2	0.53	8.04	0.47	4.44e-14	Prudent dietary pattern;
SARC	cis	rs4234284	0.501	rs2358559	chr3:127046788	A/G	cg27326032	chr3:127006922	NA	0.36	4.74	0.3	3.64e-6	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
SARC	cis	rs13256369	0.802	rs35382339	chr8:8559255	G/A	cg18904891	chr8:8559673	CLDN23	0.48	5.38	0.33	1.79e-7	Obesity-related traits;
SARC	cis	rs2180341	0.640	rs11154395	chr6:127629138	T/C	cg24812749	chr6:127587940	RNF146	0.6	7.48	0.44	1.54e-12	Breast cancer;
SARC	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg22683308	chr4:1340831	KIAA1530	0.44	5.23	0.32	3.85e-7	Longevity;
SARC	cis	rs72945132	0.882	rs55758686	chr11:70172204	C/T	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.68	-0.35	4e-8	Coronary artery disease;
SARC	cis	rs4566357	0.615	rs10174591	chr2:227913140	G/A	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.86	-0.36	1.61e-8	Coronary artery disease;
SARC	cis	rs17539620	0.624	rs117591255	chr6:154839118	G/A	cg17771515	chr6:154831774	CNKSR3	0.53	4.99	0.31	1.21e-6	Lipoprotein (a) levels;
SARC	cis	rs2731664	0.792	rs465670	chr5:176877624	C/T	cg23176889	chr5:176863531	GRK6	-0.56	-8.4	-0.48	4.42e-15	Intelligence (multi-trait analysis);
SARC	cis	rs897984	0.683	rs13337900	chr16:30822409	G/A	cg02466173	chr16:30829666	NA	-0.5	-7.16	-0.42	1.06e-11	Dementia with Lewy bodies;
SARC	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg19680485	chr15:31195859	MTMR15	-0.53	-6.18	-0.38	2.86e-9	Huntington's disease progression;
SARC	cis	rs9549260	0.753	rs61963266	chr13:41171036	G/A	cg21288729	chr13:41239152	FOXO1	0.56	5.38	0.33	1.85e-7	Red blood cell count;
SARC	cis	rs425277	1.000	rs74877653	chr1:2065949	C/T	cg24578937	chr1:2090814	PRKCZ	0.32	5.97	0.36	8.96e-9	Height;
SARC	cis	rs25645	0.771	rs10445310	chr17:38205396	C/A	cg17467752	chr17:38218738	THRA	-0.44	-5.62	-0.35	5.39e-8	Myeloid white cell count;
SARC	cis	rs7223966	1.000	rs2665826	chr17:61944924	A/G	cg00588841	chr17:61851480	DDX42;CCDC47	-0.57	-6.03	-0.37	6.35e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg13939156	chr17:80058883	NA	-0.42	-6.46	-0.39	6.11e-10	Life satisfaction;
SARC	trans	rs11722228	0.522	rs62286604	chr4:10131161	A/G	cg26043149	chr18:55253948	FECH	0.74	8.83	0.5	2.48e-16	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg11203670	chr7:100026453	MEPCE;ZCWPW1	0.49	4.84	0.3	2.33e-6	Platelet count;
SARC	cis	rs2153535	0.562	rs6901765	chr6:8455436	A/T	cg21535247	chr6:8435926	SLC35B3	0.52	6.54	0.39	3.96e-10	Motion sickness;
SARC	cis	rs9790314	0.521	rs1376122	chr3:161087857	A/G	cg04691961	chr3:161091175	C3orf57	-0.58	-7.67	-0.45	4.63e-13	Morning vs. evening chronotype;
SARC	cis	rs7666738	0.830	rs28802909	chr4:99039410	G/A	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs16944613	0.541	rs4288973	chr15:91093676	G/A	cg26821196	chr15:91095069	CRTC3	0.53	5.46	0.34	1.23e-7	Colorectal cancer;
SARC	cis	rs6665290	0.566	rs1513617	chr1:227447213	C/T	cg14016676	chr1:227182615	CDC42BPA	-0.35	-4.74	-0.3	3.71e-6	Myeloid white cell count;
SARC	cis	rs10089	1.000	rs3816006	chr5:127450581	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	10.32	0.56	8.06e-21	Ileal carcinoids;
SARC	trans	rs1493916	0.905	rs1586988	chr18:31396001	G/C	cg27147174	chr7:100797783	AP1S1	-0.58	-7.27	-0.43	5.3e-12	Life satisfaction;
SARC	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg24642844	chr7:1081250	C7orf50	-0.59	-6.29	-0.38	1.54e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs875971	0.964	rs160635	chr7:65528918	T/C	cg11764359	chr7:65958608	NA	0.78	10.72	0.57	4.76e-22	Aortic root size;
SARC	cis	rs13191362	0.935	rs35942036	chr6:163163297	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.75	6.38	0.39	9.54e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	trans	rs11098499	0.820	rs6829903	chr4:120506884	C/T	cg25214090	chr10:38739885	LOC399744	0.57	7.25	0.43	6.27e-12	Corneal astigmatism;
SARC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg11965913	chr1:205819406	PM20D1	0.59	7.83	0.46	1.68e-13	Menarche (age at onset);
SARC	cis	rs11098499	0.866	rs72676074	chr4:120359841	A/C	cg09160332	chr4:120329925	NA	-0.34	-4.86	-0.3	2.2e-6	Corneal astigmatism;
SARC	cis	rs11190604	0.697	rs12355942	chr10:102201320	T/C	cg14256752	chr10:102295592	HIF1AN	-0.41	-4.71	-0.3	4.18e-6	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs921968	0.541	rs7604319	chr2:219538799	A/C	cg02176678	chr2:219576539	TTLL4	-0.53	-7.94	-0.46	8.6e-14	Mean corpuscular hemoglobin concentration;
SARC	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg22903471	chr2:27725779	GCKR	-0.47	-7.12	-0.42	1.34e-11	Total body bone mineral density;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg20319308	chr1:224518106	NVL	-0.52	-6.97	-0.42	3.26e-11	Neuroticism;
SARC	trans	rs453301	0.571	rs330054	chr8:9088291	G/A	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.46	-0.39	6.03e-10	Joint mobility (Beighton score);
SARC	trans	rs6445754	0.600	rs4955877	chr3:55805322	G/C	cg26065841	chr15:41244853	CHAC1	-0.57	-6.35	-0.38	1.1e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs5997397	0.967	rs5762777	chr22:29150044	T/C	cg15103426	chr22:29168792	CCDC117	0.51	6.56	0.4	3.35e-10	Red cell distribution width;
SARC	cis	rs1568889	1.000	rs12797155	chr11:28290866	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	10.27	0.56	1.19e-20	Bipolar disorder;
SARC	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg05025164	chr4:1340916	KIAA1530	0.56	6.88	0.41	5.47e-11	Longevity;
SARC	cis	rs11098499	0.604	rs10022185	chr4:120571765	C/G	cg09307838	chr4:120376055	NA	0.81	10.7	0.57	5.29e-22	Corneal astigmatism;
SARC	cis	rs4148883	0.689	rs2851275	chr4:100024883	A/G	cg12011299	chr4:100065546	ADH4	0.37	6.86	0.41	6.33e-11	Alcohol dependence;
SARC	cis	rs2806561	0.734	rs667211	chr1:23516142	T/C	cg12483005	chr1:23474871	LUZP1	0.45	5.9	0.36	1.3e-8	Height;
SARC	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg06636001	chr8:8085503	FLJ10661	0.65	8.67	0.49	7.69e-16	Mood instability;
SARC	cis	rs6568686	0.786	rs2181356	chr6:111815604	A/G	cg15721981	chr6:111408429	SLC16A10	-0.6	-4.89	-0.31	1.89e-6	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg24829409	chr8:58192753	C8orf71	-0.62	-6.36	-0.38	1.03e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs432925	0.625	rs2685119	chr16:341476	T/C	cg06233593	chr16:337645	AXIN1	0.36	4.91	0.31	1.73e-6	Morning vs. evening chronotype;
SARC	trans	rs747334	0.846	rs7897603	chr10:92708759	C/G	cg04413180	chr2:236847057	AGAP1	-0.5	-6.82	-0.41	7.9e-11	Fibroblast growth factor basic levels;
SARC	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg04234412	chr22:24373322	LOC391322	0.52	6.24	0.38	2.02e-9	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs4819052	0.679	rs2255761	chr21:46683622	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.53	6.42	0.39	7.42e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9549367	0.713	rs9549682	chr13:113830181	C/T	cg18105134	chr13:113819100	PROZ	-0.49	-7.01	-0.42	2.49e-11	Platelet distribution width;
SARC	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	11.03	0.59	4.93e-23	Alzheimer's disease;
SARC	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg03735888	chr19:58951602	ZNF132	0.39	5.08	0.32	7.64e-7	Uric acid clearance;
SARC	cis	rs17376456	0.569	rs7729807	chr5:93104089	C/T	cg25358565	chr5:93447407	FAM172A	0.93	10.37	0.56	5.99e-21	Diabetic retinopathy;
SARC	cis	rs2732480	0.517	rs2634676	chr12:48738236	A/G	cg24011408	chr12:48396354	COL2A1	0.43	5.11	0.32	6.81e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs6912958	0.781	rs4707376	chr6:88270947	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.44	-0.34	1.35e-7	Monocyte percentage of white cells;
SARC	cis	rs1865760	0.602	rs2157050	chr6:26020431	C/T	cg10373733	chr6:25993375	NA	0.41	4.99	0.31	1.2e-6	Height;
SARC	cis	rs7666738	0.830	rs28451101	chr4:99001190	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9677476	0.731	rs1477470	chr2:232076724	A/C	cg23338755	chr2:231921595	PSMD1	0.46	5.5	0.34	9.82e-8	Food antigen IgG levels;
SARC	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg01570182	chr17:44337453	NA	-0.82	-9.63	-0.53	1.06e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs10752881	0.935	rs10911235	chr1:183053746	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.35	0.56	6.8e-21	Colorectal cancer;
SARC	cis	rs10489202	0.632	rs203779	chr1:167877647	T/G	cg24449463	chr1:168025552	DCAF6	-0.65	-9.0	-0.51	8.28e-17	Schizophrenia;
SARC	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg05025164	chr4:1340916	KIAA1530	0.53	6.28	0.38	1.67e-9	Obesity-related traits;
SARC	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg21782813	chr7:2030301	MAD1L1	0.37	5.71	0.35	3.44e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg23221052	chr5:179740743	GFPT2	-0.55	-6.76	-0.41	1.07e-10	Height;
SARC	cis	rs7223966	1.000	rs56383601	chr17:61929968	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.71	7.68	0.45	4.45e-13	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1580019	0.534	rs13237495	chr7:32560687	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.6	7.89	0.46	1.17e-13	Cognitive ability;
SARC	cis	rs8114671	0.539	rs2064453	chr20:33460810	T/C	cg24642439	chr20:33292090	TP53INP2	0.53	6.31	0.38	1.37e-9	Height;
SARC	cis	rs8077889	0.956	rs17742347	chr17:41846468	A/G	cg26893861	chr17:41843967	DUSP3	-0.9	-10.4	-0.56	4.78e-21	Triglycerides;
SARC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg03395511	chr6:291903	DUSP22	-0.54	-6.93	-0.41	4.17e-11	Menopause (age at onset);
SARC	cis	rs4253772	0.591	rs6008362	chr22:46652737	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.64	7.09	0.42	1.61e-11	LDL cholesterol;Cholesterol, total;
SARC	cis	rs9875589	0.509	rs7653289	chr3:13986333	C/T	cg19554555	chr3:13937349	NA	-0.41	-5.25	-0.33	3.39e-7	Ovarian reserve;
SARC	cis	rs7772486	0.743	rs111332144	chr6:146056681	C/T	cg23711669	chr6:146136114	FBXO30	-0.78	-11.75	-0.61	2.39e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs13161895	1.000	rs864482	chr5:179427873	A/G	cg06664874	chr5:179499304	RNF130	0.49	4.78	0.3	3.14e-6	LDL cholesterol;
SARC	cis	rs4481887	0.741	rs6421453	chr1:248533285	A/G	cg00666640	chr1:248458726	OR2T12	0.36	6.2	0.38	2.58e-9	Common traits (Other);
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg24713789	chr21:45285448	AGPAT3	0.52	6.99	0.42	2.85e-11	Tetralogy of Fallot;
SARC	cis	rs6750795	0.502	rs11685196	chr2:232381298	A/G	cg07301105	chr2:232379665	C2orf52	0.32	5.15	0.32	5.6e-7	Height;
SARC	cis	rs10911232	0.560	rs10911221	chr1:183046737	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.64	8.93	0.51	1.29e-16	Hypertriglyceridemia;
SARC	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg25894440	chr7:65020034	NA	-0.75	-5.77	-0.35	2.56e-8	Diabetic kidney disease;
SARC	cis	rs9790314	0.586	rs34727114	chr3:161138929	A/C	cg17135325	chr3:160939158	NMD3	0.53	6.53	0.39	4.04e-10	Morning vs. evening chronotype;
SARC	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg03433033	chr1:76189801	ACADM	0.55	7.74	0.45	2.97e-13	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg18252515	chr7:66147081	NA	0.48	5.14	0.32	5.88e-7	Aortic root size;
SARC	cis	rs1707322	0.752	rs28550303	chr1:46188914	G/T	cg06784218	chr1:46089804	CCDC17	0.36	6.29	0.38	1.55e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.42	-5.17	-0.32	4.93e-7	Eosinophil percentage of white cells;
SARC	trans	rs11098499	0.954	rs2389803	chr4:120393511	A/G	cg25214090	chr10:38739885	LOC399744	-0.53	-6.92	-0.41	4.23e-11	Corneal astigmatism;
SARC	cis	rs3540	0.960	rs7167704	chr15:90956801	G/T	cg22089800	chr15:90895588	ZNF774	0.48	5.14	0.32	5.78e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs2425143	1.000	rs6060557	chr20:34270266	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.13	0.32	6.04e-7	Blood protein levels;
SARC	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	14.03	0.68	8.15e-33	Chronic sinus infection;
SARC	cis	rs7474896	0.526	rs1208633	chr10:38156873	A/C	cg00409905	chr10:38381863	ZNF37A	0.46	5.06	0.31	8.54e-7	Obesity (extreme);
SARC	cis	rs2933343	0.621	rs789249	chr3:128578453	T/C	cg25356066	chr3:128598488	ACAD9	0.71	9.46	0.53	3.63e-18	IgG glycosylation;
SARC	cis	rs910316	0.967	rs10246	chr14:75544470	T/A	cg11812906	chr14:75593930	NEK9	0.89	13.48	0.66	5.48e-31	Height;
SARC	cis	rs2228479	0.541	rs9922515	chr16:89954138	G/C	cg00800038	chr16:89945340	TCF25	-0.57	-4.92	-0.31	1.62e-6	Skin colour saturation;
SARC	cis	rs2486288	0.656	rs1060896	chr15:45554267	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.45	-5.6	-0.34	6.16e-8	Glomerular filtration rate;
SARC	cis	rs33912345	0.695	rs1314387	chr14:60877399	T/C	cg27398547	chr14:60952738	C14orf39	-0.39	-4.73	-0.3	3.85e-6	Glaucoma (high intraocular pressure);
SARC	cis	rs9790314	1.000	rs6441373	chr3:161026717	T/G	cg04691961	chr3:161091175	C3orf57	-0.79	-11.53	-0.6	1.27e-24	Morning vs. evening chronotype;
SARC	cis	rs5753618	0.561	rs5753521	chr22:31638027	T/C	cg13145458	chr22:31556086	RNF185	0.47	5.05	0.31	8.93e-7	Colorectal cancer;
SARC	cis	rs818427	0.896	rs455412	chr5:112224389	G/T	cg07820702	chr5:112228657	REEP5	-0.46	-5.21	-0.32	4.2e-7	Total body bone mineral density;
SARC	cis	rs3768617	0.510	rs1413388	chr1:183096694	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.82e-21	Fuchs's corneal dystrophy;
SARC	cis	rs9818758	0.607	rs35283189	chr3:49113668	T/C	cg01304814	chr3:48885189	PRKAR2A	0.65	5.25	0.33	3.43e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs2933343	0.700	rs1683787	chr3:128627021	C/T	cg24203234	chr3:128598194	ACAD9	-0.63	-7.93	-0.46	9.07e-14	IgG glycosylation;
SARC	cis	rs4319547	0.956	rs10744275	chr12:123048618	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.66	-7.98	-0.46	6.6e-14	Body mass index;
SARC	cis	rs4711350	0.765	rs2395446	chr6:33743264	C/T	cg18005901	chr6:33739558	LEMD2	-0.42	-4.95	-0.31	1.43e-6	Schizophrenia;
SARC	cis	rs17209837	1.000	rs4148807	chr7:87105812	G/A	cg00919237	chr7:87102261	ABCB4	-0.47	-4.87	-0.3	2.07e-6	Gallbladder cancer;
SARC	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg18252515	chr7:66147081	NA	-0.52	-5.81	-0.36	2.09e-8	Aortic root size;
SARC	cis	rs16866061	1.000	rs72974269	chr2:225454907	C/T	cg12698349	chr2:225449008	CUL3	0.73	10.59	0.57	1.23e-21	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	cis	rs7635838	0.684	rs2594965	chr3:11323799	G/C	cg00170343	chr3:11313890	ATG7	0.64	8.9	0.5	1.6e-16	HDL cholesterol;
SARC	trans	rs9929218	0.551	rs2296409	chr16:68713730	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.85	14.23	0.68	1.79e-33	Colorectal cancer;
SARC	cis	rs1865760	0.516	rs9295684	chr6:26069669	T/C	cg18357526	chr6:26021779	HIST1H4A	0.45	5.72	0.35	3.23e-8	Height;
SARC	cis	rs2204008	0.624	rs2320449	chr12:38224190	T/C	cg26384229	chr12:38710491	ALG10B	0.88	12.85	0.64	6.54e-29	Bladder cancer;
SARC	cis	rs3733585	0.699	rs6823361	chr4:9963127	A/G	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.35	-0.33	2.06e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs9389248	0.690	rs2294321	chr6:135253048	T/G	cg24558204	chr6:135376177	HBS1L	-0.53	-6.57	-0.4	3.2e-10	High light scatter reticulocyte percentage of red cells;
SARC	cis	rs7312774	1.000	rs7312774	chr12:107305728	G/A	cg16260113	chr12:107380972	MTERFD3	0.71	6.16	0.37	3.2e-9	Severe influenza A (H1N1) infection;
SARC	cis	rs12478296	1.000	rs60533128	chr2:243028088	A/G	cg06360820	chr2:242988706	NA	-0.8	-6.0	-0.37	7.54e-9	Obesity-related traits;
SARC	cis	rs11203032	0.908	rs11812888	chr10:90957546	G/T	cg16672925	chr10:90967113	CH25H	0.54	6.03	0.37	6.38e-9	Heart failure;
SARC	cis	rs8031584	1.000	rs35607976	chr15:31277788	T/C	cg19680485	chr15:31195859	MTMR15	-0.55	-5.94	-0.36	1.04e-8	Huntington's disease progression;
SARC	cis	rs1008375	0.966	rs2098152	chr4:17684392	G/T	cg27347728	chr4:17578864	LAP3	0.45	5.52	0.34	8.87e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1348850	0.914	rs6761593	chr2:178451600	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.68	-8.23	-0.47	1.36e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg00149659	chr3:10157352	C3orf10	0.65	6.24	0.38	2.07e-9	Alzheimer's disease;
SARC	cis	rs8114671	0.836	rs3746432	chr20:33592763	C/T	cg08999081	chr20:33150536	PIGU	-0.33	-4.76	-0.3	3.38e-6	Height;
SARC	cis	rs6088580	0.524	rs1321306	chr20:33266379	T/A	cg07148914	chr20:33460835	GGT7	-0.42	-5.16	-0.32	5.4e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs651907	0.535	rs11707250	chr3:101509371	A/T	cg12386194	chr3:101231763	SENP7	-0.47	-5.27	-0.33	3.15e-7	Colorectal cancer;
SARC	cis	rs9325144	0.555	rs2387847	chr12:38687434	C/T	cg10518543	chr12:38710700	ALG10B	0.38	4.88	0.3	2.01e-6	Morning vs. evening chronotype;
SARC	cis	rs7264396	0.563	rs2425109	chr20:34316218	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-7.19	-0.43	8.93e-12	Total cholesterol levels;
SARC	cis	rs7089973	0.872	rs36036948	chr10:116631649	A/G	cg08188268	chr10:116634841	FAM160B1	0.36	5.82	0.36	1.96e-8	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	trans	rs208520	0.874	rs208518	chr6:66948501	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.9	10.47	0.57	2.85e-21	Exhaled nitric oxide output;
SARC	trans	rs72809865	0.530	rs1040660	chr10:83254437	G/T	cg01169021	chr5:140792918	PCDHGA4;PCDHGA6;PCDHGA9;PCDHGA1;PCDHGA8;PCDHGA5;PCDHGB1;PCDHGA10;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGB6;PCDHGA7;PCDHGB2;PCDHGB5;PCDHGB3	-0.86	-6.32	-0.38	1.29e-9	Kidney disease (early and late stages) in type 1 diabetes;
SARC	cis	rs9398803	0.830	rs4053271	chr6:126830512	T/C	cg19875578	chr6:126661172	C6orf173	0.63	8.53	0.49	1.82e-15	Male-pattern baldness;
SARC	cis	rs4589502	1.000	rs80263963	chr15:67127228	C/T	cg12317470	chr15:67143691	NA	0.74	5.15	0.32	5.52e-7	Lung cancer (smoking interaction);
SARC	cis	rs9436747	0.626	rs17412682	chr1:65952293	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	-0.38	-4.86	-0.3	2.19e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs80130819	0.748	rs2732446	chr12:48690177	T/C	cg24011408	chr12:48396354	COL2A1	0.54	6.02	0.37	6.86e-9	Prostate cancer;
SARC	cis	rs2769264	0.546	rs12071705	chr1:151430504	G/C	cg18801370	chr1:151430492	POGZ	1.0	11.27	0.59	8.61e-24	Blood trace element (Cu levels);
SARC	cis	rs7568458	0.870	rs1010	chr2:85808982	C/T	cg17127132	chr2:85788382	GGCX	-0.44	-5.91	-0.36	1.22e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs6120849	0.663	rs6119548	chr20:33552612	A/G	cg06115741	chr20:33292138	TP53INP2	0.55	5.42	0.33	1.49e-7	Protein C levels;
SARC	cis	rs7568458	0.870	rs1972297	chr2:85808573	T/C	cg23752985	chr2:85803571	VAMP8	0.34	5.0	0.31	1.14e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs9902453	1.000	rs4328498	chr17:28344276	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.52	-6.74	-0.4	1.23e-10	Coffee consumption (cups per day);
SARC	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg13206674	chr6:150067644	NUP43	0.46	6.1	0.37	4.29e-9	Lung cancer;
SARC	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg11062466	chr8:58055876	NA	0.6	5.71	0.35	3.44e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs713477	0.935	rs12888181	chr14:55906082	A/C	cg13175173	chr14:55914753	NA	-0.31	-4.8	-0.3	2.85e-6	Pediatric bone mineral content (femoral neck);
SARC	cis	rs4727027	0.866	rs1405124	chr7:148779618	C/T	cg23583168	chr7:148888333	NA	-0.73	-10.89	-0.58	1.32e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs2531992	1.000	rs2531992	chr16:4021734	A/G	cg02839220	chr16:4400790	Magmas	0.49	4.76	0.3	3.4e-6	Waist circumference;
SARC	cis	rs2952156	0.959	rs907087	chr17:37828787	G/A	cg20243544	chr17:37824526	PNMT	0.49	5.92	0.36	1.15e-8	Asthma;
SARC	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg05861140	chr6:150128134	PCMT1	-0.37	-4.77	-0.3	3.24e-6	Lung cancer;
SARC	cis	rs8102137	1.000	rs59592823	chr19:30297516	A/G	cg27475126	chr19:30303651	CCNE1	-0.42	-5.87	-0.36	1.51e-8	Bladder cancer;
SARC	cis	rs62244186	0.566	rs55901755	chr3:44834707	C/T	cg15687855	chr3:44754131	ZNF502	-0.34	-5.12	-0.32	6.44e-7	Depressive symptoms;
SARC	cis	rs1468333	0.824	rs28704868	chr5:137590786	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.79	10.32	0.56	8.29e-21	Resting heart rate;
SARC	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg16606324	chr3:10149918	C3orf24	0.51	4.95	0.31	1.39e-6	Alzheimer's disease;
SARC	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg18225595	chr11:63971243	STIP1	0.43	5.15	0.32	5.43e-7	Mean platelet volume;
SARC	cis	rs10791323	0.572	rs10750551	chr11:133737462	G/A	cg13461336	chr11:133711254	SPATA19	-0.29	-5.24	-0.32	3.55e-7	Childhood ear infection;
SARC	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg11494091	chr17:61959527	GH2	-0.48	-7.38	-0.44	2.84e-12	Prudent dietary pattern;
SARC	cis	rs926938	0.584	rs6689326	chr1:115369112	T/A	cg12756093	chr1:115239321	AMPD1	-0.37	-4.86	-0.3	2.12e-6	Autism;
SARC	cis	rs3796352	1.000	rs17052727	chr3:53070914	T/C	cg15956490	chr3:53032818	SFMBT1	0.71	5.3	0.33	2.72e-7	Immune reponse to smallpox (secreted IL-2);
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg20918903	chr2:86668501	KDM3A	-0.51	-6.46	-0.39	6.1e-10	Schizophrenia;
SARC	cis	rs7000551	0.700	rs2461480	chr8:22381839	C/T	cg12081754	chr8:22256438	SLC39A14	0.57	7.88	0.46	1.22e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs7617773	0.780	rs2541	chr3:48339618	A/G	cg11946769	chr3:48343235	NME6	0.76	9.72	0.54	5.94e-19	Coronary artery disease;
SARC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg19678392	chr7:94953810	PON1	-0.42	-6.2	-0.38	2.54e-9	Paraoxonase activity;
SARC	cis	rs6456156	1.000	rs7761159	chr6:167519907	T/A	cg07741184	chr6:167504864	NA	0.31	5.63	0.35	5.26e-8	Primary biliary cholangitis;
SARC	cis	rs2153535	0.601	rs2327091	chr6:8540369	G/A	cg07606381	chr6:8435919	SLC35B3	0.76	10.75	0.58	3.89e-22	Motion sickness;
SARC	cis	rs36051895	0.589	rs17492549	chr9:5202830	A/C	cg02405213	chr9:5042618	JAK2	-0.5	-5.62	-0.35	5.5e-8	Pediatric autoimmune diseases;
SARC	cis	rs6733011	0.542	rs6542860	chr2:99679376	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.56	-7.27	-0.43	5.41e-12	Bipolar disorder;
SARC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.19	0.8	4.45e-53	Prudent dietary pattern;
SARC	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.74	10.08	0.55	4.46e-20	Menarche (age at onset);
SARC	cis	rs7084402	0.935	rs4948523	chr10:60339098	A/C	cg07615347	chr10:60278583	BICC1	0.51	7.14	0.42	1.16e-11	Refractive error;
SARC	cis	rs854765	0.547	rs4643387	chr17:17972973	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	9.45	0.53	3.72e-18	Total body bone mineral density;
SARC	cis	rs9790314	0.934	rs462413	chr3:161101587	T/C	cg04691961	chr3:161091175	C3orf57	-0.78	-11.58	-0.6	8.8e-25	Morning vs. evening chronotype;
SARC	cis	rs1707322	1.000	rs6429580	chr1:46275648	A/G	cg03146154	chr1:46216737	IPP	0.47	5.62	0.35	5.38e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6088580	0.524	rs6088569	chr20:33268199	G/A	cg07148914	chr20:33460835	GGT7	-0.42	-5.1	-0.32	7.15e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs12142240	0.583	rs5013330	chr1:46815154	G/A	cg14993813	chr1:46806288	NSUN4	-0.52	-5.46	-0.34	1.22e-7	Menopause (age at onset);
SARC	cis	rs1580019	0.844	rs1037322	chr7:32501857	C/T	cg14728415	chr7:32535168	LSM5;AVL9	0.47	5.63	0.35	5.11e-8	Cognitive ability;
SARC	cis	rs8038465	0.592	rs1542580	chr15:73935834	C/G	cg15420318	chr15:73925796	NPTN	0.67	7.66	0.45	5.08e-13	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9486715	0.838	rs9486275	chr6:96901187	C/T	cg06623918	chr6:96969491	KIAA0776	0.88	12.7	0.64	1.95e-28	Headache;
SARC	cis	rs2204008	0.538	rs61931093	chr12:38242911	C/T	cg26384229	chr12:38710491	ALG10B	-0.6	-7.63	-0.45	5.8e-13	Bladder cancer;
SARC	cis	rs1401999	0.690	rs1402001	chr3:183642751	A/G	cg01324343	chr3:183735012	ABCC5	0.59	10.55	0.57	1.64e-21	Anterior chamber depth;
SARC	cis	rs6964587	0.626	rs68009402	chr7:91516226	G/A	cg17063962	chr7:91808500	NA	-0.78	-11.48	-0.6	1.78e-24	Breast cancer;
SARC	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg11987759	chr7:65425863	GUSB	0.44	5.91	0.36	1.22e-8	Aortic root size;
SARC	cis	rs734999	0.588	rs2843402	chr1:2528682	T/C	cg00980319	chr1:2560884	MMEL1	0.35	4.95	0.31	1.42e-6	Ulcerative colitis;
SARC	cis	rs453301	0.686	rs11785819	chr8:8870378	T/G	cg11995313	chr8:8860691	ERI1	0.48	6.08	0.37	4.77e-9	Joint mobility (Beighton score);
SARC	cis	rs7264396	0.563	rs2425094	chr20:34306974	G/A	cg01084648	chr20:34329383	RBM39	0.56	4.93	0.31	1.57e-6	Total cholesterol levels;
SARC	cis	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg07777115	chr5:623756	CEP72	-0.56	-5.03	-0.31	9.96e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs6988636	1.000	rs6983795	chr8:124185296	T/C	cg23067535	chr8:124195133	FAM83A	-0.64	-5.3	-0.33	2.72e-7	Urinary uromodulin levels;
SARC	cis	rs3762637	0.943	rs9289196	chr3:122268506	T/C	cg24169773	chr3:122142474	KPNA1	-0.54	-5.65	-0.35	4.59e-8	LDL cholesterol levels;
SARC	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg17294928	chr15:75287854	SCAMP5	0.54	6.89	0.41	5.06e-11	Breast cancer;
SARC	cis	rs6456156	0.792	rs4710179	chr6:167513692	G/T	cg23791538	chr6:167370224	RNASET2	-0.41	-5.24	-0.32	3.66e-7	Primary biliary cholangitis;
SARC	cis	rs6831352	0.918	rs29001209	chr4:100052340	C/A	cg12011299	chr4:100065546	ADH4	-0.34	-5.74	-0.35	2.95e-8	Alcohol dependence;
SARC	cis	rs76917914	0.589	rs12552242	chr9:100866201	A/C	cg03040243	chr9:100819229	NANS	0.54	5.82	0.36	1.95e-8	Immature fraction of reticulocytes;
SARC	cis	rs818427	0.727	rs460301	chr5:112206816	G/A	cg07820702	chr5:112228657	REEP5	0.47	5.28	0.33	2.97e-7	Total body bone mineral density;
SARC	cis	rs2549003	0.966	rs10065633	chr5:131816716	T/C	cg21138405	chr5:131827807	IRF1	0.27	5.44	0.34	1.32e-7	Asthma (sex interaction);
SARC	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg12463550	chr7:65579703	CRCP	-0.49	-5.31	-0.33	2.6e-7	Aortic root size;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg02364793	chr5:175964512	RNF44	-0.48	-6.32	-0.38	1.33e-9	Height;
SARC	cis	rs2112347	0.502	rs34339	chr5:74931333	G/T	cg19683494	chr5:74908142	NA	-0.55	-4.97	-0.31	1.28e-6	Body mass index (joint analysis main effects and smoking interaction);Waist circumference;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Hip circumference;Body mass index;Body mass index in physically active individuals;Obesity;
SARC	cis	rs7552404	0.727	rs5745390	chr1:76306591	A/C	cg10523679	chr1:76189770	ACADM	0.46	5.37	0.33	1.89e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.69	8.88	0.5	1.86e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs12497850	0.931	rs3774628	chr3:48801840	C/T	cg03060546	chr3:49711283	APEH	0.42	5.28	0.33	3e-7	Parkinson's disease;
SARC	cis	rs899997	0.862	rs11072787	chr15:78972977	T/C	cg04896959	chr15:78267971	NA	-0.45	-5.72	-0.35	3.21e-8	Coronary artery disease or large artery stroke;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg26246411	chr19:1753483	ONECUT3	-0.52	-6.57	-0.4	3.22e-10	Schizophrenia;
SARC	cis	rs9303401	0.538	rs8078280	chr17:56473132	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	10.49	0.57	2.5e-21	Cognitive test performance;
SARC	cis	rs9467711	0.591	rs116201501	chr6:25999149	C/T	cg21479132	chr6:26055353	NA	0.94	6.28	0.38	1.62e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs763121	0.853	rs138712	chr22:39141600	C/T	cg21395723	chr22:39101663	GTPBP1	0.49	5.71	0.35	3.36e-8	Menopause (age at onset);
SARC	cis	rs12348691	0.503	rs10739513	chr9:100592705	C/T	cg13688889	chr9:100608707	NA	-0.46	-4.85	-0.3	2.25e-6	Alopecia areata;
SARC	cis	rs8067545	0.641	rs203479	chr17:19829311	T/C	cg04132472	chr17:19861366	AKAP10	0.38	5.08	0.32	7.88e-7	Schizophrenia;
SARC	cis	rs13226913	0.967	rs4318980	chr7:7256490	G/A	cg19603390	chr7:7222222	C1GALT1	0.4	5.02	0.31	1.02e-6	Serum galactose-deficient IgA1 levels;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg21679674	chr2:128283815	IWS1	0.5	6.53	0.39	4.07e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs6912958	0.559	rs451829	chr6:88041919	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	11.04	0.59	4.52e-23	Monocyte percentage of white cells;
SARC	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg05368731	chr17:41323189	NBR1	0.81	9.93	0.55	1.35e-19	Menopause (age at onset);
SARC	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.41	-6.76	-0.4	1.1e-10	Total body bone mineral density;
SARC	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-9.2	-0.52	2.1e-17	Alzheimer's disease;
SARC	cis	rs734999	0.545	rs3890745	chr1:2553624	C/T	cg18854424	chr1:2615690	NA	-0.3	-4.73	-0.3	3.91e-6	Ulcerative colitis;
SARC	cis	rs73206853	0.697	rs16934006	chr12:110527907	T/A	cg10860002	chr12:110842031	ANAPC7	0.64	5.1	0.32	6.95e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	trans	rs9329221	0.710	rs11779205	chr8:10260100	C/T	cg06636001	chr8:8085503	FLJ10661	0.59	7.27	0.43	5.32e-12	Neuroticism;
SARC	cis	rs6570726	0.967	rs403584	chr6:145807010	G/A	cg23711669	chr6:146136114	FBXO30	0.73	11.24	0.59	1.04e-23	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs10782582	0.758	rs6687882	chr1:76364825	C/A	cg22767735	chr17:19551663	ALDH3A2	-0.48	-6.29	-0.38	1.54e-9	Daytime sleep phenotypes;
SARC	cis	rs7568458	0.837	rs3731827	chr2:85806068	T/C	cg02493740	chr2:85810744	VAMP5	-0.34	-4.97	-0.31	1.32e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg09455208	chr3:40491958	NA	0.43	6.61	0.4	2.66e-10	Renal cell carcinoma;
SARC	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg13628971	chr7:2884303	GNA12	0.56	6.66	0.4	1.94e-10	Height;
SARC	cis	rs7666738	0.830	rs13124127	chr4:98990729	G/A	cg05340658	chr4:99064831	C4orf37	0.64	8.6	0.49	1.18e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6570726	0.935	rs372378	chr6:145816227	A/G	cg23711669	chr6:146136114	FBXO30	0.78	11.91	0.62	7.29e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6540556	0.954	rs643118	chr1:209934841	C/T	cg23920097	chr1:209922102	NA	-0.62	-7.5	-0.44	1.35e-12	Red blood cell count;
SARC	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg01341218	chr17:43662625	NA	-0.72	-8.55	-0.49	1.69e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs3617	0.625	rs2239548	chr3:52854186	A/C	cg18404041	chr3:52824283	ITIH1	-0.36	-5.27	-0.33	3.06e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs67311347	1.000	rs66841330	chr3:40531123	G/A	cg24209194	chr3:40518798	ZNF619	0.63	7.93	0.46	9.03e-14	Renal cell carcinoma;
SARC	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg03999130	chr15:45571217	NA	0.39	5.09	0.32	7.55e-7	Homoarginine levels;
SARC	cis	rs7772486	0.790	rs9403750	chr6:146167762	G/A	cg05347473	chr6:146136440	FBXO30	0.51	7.3	0.43	4.62e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2295359	0.892	rs10789224	chr1:67605134	C/T	cg08029281	chr1:67600428	NA	-0.42	-5.56	-0.34	7.25e-8	Psoriasis;
SARC	cis	rs3106136	0.534	rs13109764	chr4:95304506	T/C	cg11021082	chr4:95130006	SMARCAD1	0.33	4.98	0.31	1.24e-6	Capecitabine sensitivity;
SARC	trans	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg23901063	chr10:62704070	RHOBTB1	-0.73	-6.83	-0.41	7.3e-11	Cutaneous psoriasis;
SARC	cis	rs9581943	0.901	rs9551414	chr13:28474237	C/T	cg25299895	chr13:28498091	PDX1	0.37	4.98	0.31	1.24e-6	Pancreatic cancer;
SARC	cis	rs708547	0.647	rs6843644	chr4:57891239	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.58	7.16	0.42	1.02e-11	Response to bleomycin (chromatid breaks);
SARC	cis	rs6088813	0.857	rs6142378	chr20:33997291	T/A	cg23207816	chr20:34252616	CPNE1;RBM12	-0.45	-5.39	-0.33	1.75e-7	Height;
SARC	trans	rs2727020	0.576	rs11040223	chr11:49034633	G/T	cg03929089	chr4:120376271	NA	-0.51	-6.77	-0.41	1.02e-10	Coronary artery disease;
SARC	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.75	7.21	0.43	7.87e-12	Platelet count;
SARC	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg27121462	chr16:89883253	FANCA	0.64	10.02	0.55	7.16e-20	Vitiligo;
SARC	cis	rs7833986	0.501	rs9650314	chr8:56903610	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.67	6.53	0.39	4.13e-10	Height;
SARC	cis	rs2236918	0.710	rs2526698	chr1:242029101	T/C	cg17736920	chr1:242011382	EXO1	0.64	8.55	0.49	1.63e-15	Menopause (age at onset);
SARC	cis	rs55823223	0.648	rs11867560	chr17:73857206	A/G	cg08125733	chr17:73851984	WBP2	0.63	6.94	0.41	3.89e-11	Psoriasis;
SARC	cis	rs11722228	1.000	rs4697695	chr4:9915850	C/T	cg00071950	chr4:10020882	SLC2A9	0.35	5.39	0.33	1.71e-7	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs11098499	0.874	rs28452522	chr4:120110784	A/G	cg09307838	chr4:120376055	NA	0.83	11.07	0.59	3.6e-23	Corneal astigmatism;
SARC	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg12564285	chr5:131593104	PDLIM4	0.35	5.24	0.32	3.53e-7	Breast cancer;
SARC	cis	rs1920116	0.661	rs13062210	chr3:169549773	A/T	cg08193579	chr3:169529701	LRRC34	0.42	4.91	0.31	1.68e-6	Glioma (high-grade);
SARC	cis	rs7647973	1.000	rs2140270	chr3:49439440	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.56	-5.75	-0.35	2.8e-8	Menarche (age at onset);
SARC	cis	rs6448317	0.556	rs73250624	chr4:24910737	C/T	cg21108841	chr4:24914750	CCDC149	-0.55	-4.74	-0.3	3.75e-6	Heschl's gyrus morphology;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg16758764	chr3:113529180	ATP6V1A	0.49	6.95	0.41	3.68e-11	Thyroid stimulating hormone;
SARC	cis	rs7412746	0.611	rs1889740	chr1:150799755	C/T	cg13175981	chr1:150552382	MCL1	-0.55	-6.85	-0.41	6.4e-11	Melanoma;
SARC	cis	rs17079247	1.000	rs9575815	chr13:85761183	C/T	ch.13.84760847R	chr13:85862846	NA	-0.57	-5.02	-0.31	1.05e-6	Bipolar disorder (mania);
SARC	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg12648201	chr2:27665141	KRTCAP3	-0.33	-4.93	-0.31	1.54e-6	Menopause (age at onset);
SARC	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg11764359	chr7:65958608	NA	-0.65	-7.61	-0.45	6.85e-13	Aortic root size;
SARC	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg24633833	chr3:10029261	TMEM111	0.53	5.26	0.33	3.23e-7	Alzheimer's disease;
SARC	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg24549020	chr5:56110836	MAP3K1	0.7	7.17	0.42	1.01e-11	Initial pursuit acceleration;
SARC	cis	rs634534	0.561	rs613924	chr11:65769295	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.43	-5.39	-0.33	1.75e-7	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs6088580	0.634	rs6058070	chr20:33103521	G/C	cg08999081	chr20:33150536	PIGU	0.43	6.75	0.4	1.14e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs6582630	0.593	rs11182590	chr12:38574274	A/T	cg13010199	chr12:38710504	ALG10B	0.63	8.05	0.47	4.3e-14	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg03806693	chr22:41940476	POLR3H	0.82	10.64	0.57	8.57e-22	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs7937682	0.575	rs34695265	chr11:111719128	T/C	cg22437258	chr11:111473054	SIK2	-0.47	-5.51	-0.34	9.63e-8	Primary sclerosing cholangitis;
SARC	cis	rs8067545	0.611	rs2158472	chr17:20171524	C/T	cg13482628	chr17:19912719	NA	-0.56	-7.43	-0.44	1.99e-12	Schizophrenia;
SARC	cis	rs79149102	0.579	rs7172715	chr15:75287375	C/G	cg09165964	chr15:75287851	SCAMP5	-1.08	-9.26	-0.52	1.42e-17	Lung cancer;
SARC	cis	rs17666538	1.000	rs61122136	chr8:585027	G/C	cg13264159	chr8:625131	ERICH1	0.7	4.72	0.3	4.13e-6	IgG glycosylation;
SARC	trans	rs8073060	0.544	rs225252	chr17:33952401	G/A	cg19694781	chr19:47549865	TMEM160	-0.68	-6.84	-0.41	7.09e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs2777491	0.872	rs61037359	chr15:41585926	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.73	-10.96	-0.58	8.44e-23	Ulcerative colitis;
SARC	cis	rs5753618	0.539	rs737888	chr22:31611549	A/G	cg02404636	chr22:31891804	SFI1	-0.47	-4.93	-0.31	1.54e-6	Colorectal cancer;
SARC	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg00149659	chr3:10157352	C3orf10	0.69	6.9	0.41	4.76e-11	Alzheimer's disease;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg25877054	chr1:95700082	RWDD3	0.48	6.4	0.39	8.38e-10	Thyroid stimulating hormone;
SARC	cis	rs734999	0.545	rs4648356	chr1:2709164	C/A	cg18854424	chr1:2615690	NA	0.33	5.27	0.33	3.15e-7	Ulcerative colitis;
SARC	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.38	-4.91	-0.31	1.69e-6	Gut microbiome composition (summer);
SARC	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg11987759	chr7:65425863	GUSB	-0.48	-6.54	-0.39	3.9e-10	Aortic root size;
SARC	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg05872129	chr22:39784769	NA	-0.42	-5.88	-0.36	1.42e-8	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.520	rs55967509	chr8:57992448	A/G	cg08219700	chr8:58056026	NA	0.63	5.99	0.37	7.78e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1008375	0.932	rs6449315	chr4:17590219	A/G	cg16339924	chr4:17578868	LAP3	0.72	9.39	0.52	5.75e-18	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg04518342	chr5:131593106	PDLIM4	-0.45	-5.61	-0.34	5.86e-8	Breast cancer;
SARC	cis	rs10791323	0.569	rs10750553	chr11:133740251	T/C	cg15485101	chr11:133734466	NA	0.32	5.26	0.33	3.21e-7	Childhood ear infection;
SARC	cis	rs10979	0.782	rs9390108	chr6:143892722	A/T	cg25407410	chr6:143891975	LOC285740	-0.65	-8.85	-0.5	2.24e-16	Hypospadias;
SARC	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg02725872	chr8:58115012	NA	-0.34	-5.38	-0.33	1.78e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg25894440	chr7:65020034	NA	0.73	5.51	0.34	9.25e-8	Diabetic kidney disease;
SARC	cis	rs3204270	0.684	rs62080212	chr17:79642500	G/A	cg26965718	chr17:79658957	HGS	-0.63	-5.31	-0.33	2.56e-7	Dental caries;
SARC	cis	rs7959452	0.535	rs4761228	chr12:69682327	G/A	cg14784868	chr12:69753453	YEATS4	0.39	5.17	0.32	5e-7	Blood protein levels;
SARC	cis	rs11166927	0.901	rs7014257	chr8:140802694	G/T	cg16909799	chr8:140841666	TRAPPC9	0.35	4.81	0.3	2.68e-6	Pediatric non-alcoholic fatty liver disease activity score;
SARC	cis	rs8070128	0.601	rs8080602	chr17:17954728	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-9.75	-0.54	4.63e-19	Total body bone mineral density;
SARC	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg09359103	chr1:154839909	KCNN3	-0.46	-7.68	-0.45	4.46e-13	Prostate cancer;
SARC	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	5.8	0.36	2.17e-8	Personality dimensions;
SARC	cis	rs208520	0.560	rs2351880	chr6:66863707	G/A	cg07460842	chr6:66804631	NA	-1.06	-14.96	-0.7	6.65e-36	Exhaled nitric oxide output;
SARC	cis	rs6429082	0.818	rs291340	chr1:235674379	C/T	cg26050004	chr1:235667680	B3GALNT2	0.65	7.58	0.44	7.96e-13	Adiposity;
SARC	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg03351412	chr1:154909251	PMVK	0.65	8.4	0.48	4.47e-15	Prostate cancer;
SARC	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg04772025	chr11:68637568	NA	0.48	6.0	0.37	7.65e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs72945132	0.825	rs58532402	chr11:70189491	C/T	cg05964544	chr11:70165517	PPFIA1	-0.58	-5.6	-0.34	5.95e-8	Coronary artery disease;
SARC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9660992	0.573	rs7531256	chr1:205191202	T/G	cg21545522	chr1:205238299	TMCC2	0.4	5.39	0.33	1.73e-7	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs9300255	0.739	rs4759417	chr12:123746510	C/T	cg05973401	chr12:123451056	ABCB9	0.45	4.91	0.31	1.75e-6	Neutrophil percentage of white cells;
SARC	cis	rs838147	0.844	rs8104897	chr19:49249814	C/A	cg13540341	chr19:49222985	MAMSTR	0.28	4.84	0.3	2.32e-6	Dietary macronutrient intake;
SARC	cis	rs950776	0.518	rs8025429	chr15:78836362	G/A	cg17108064	chr15:78857060	CHRNA5	-0.28	-4.72	-0.3	3.98e-6	Sudden cardiac arrest;
SARC	cis	rs2952156	0.684	rs1877031	chr17:37814080	G/A	cg00129232	chr17:37814104	STARD3	-0.8	-11.7	-0.61	3.63e-25	Asthma;
SARC	cis	rs7178909	0.902	rs3784386	chr15:90437426	A/G	cg19708238	chr15:90437601	AP3S2	0.59	7.94	0.46	8.28e-14	Common traits (Other);
SARC	cis	rs17376456	0.825	rs12716454	chr5:93272279	A/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.59	0.34	6.3e-8	Diabetic retinopathy;
SARC	cis	rs12188164	0.965	rs11739543	chr5:443676	G/A	cg26850624	chr5:429559	AHRR	-0.31	-4.77	-0.3	3.21e-6	Cystic fibrosis severity;
SARC	cis	rs4648739	0.613	rs13303201	chr1:1903712	G/T	cg03688085	chr1:1910585	KIAA1751	-0.46	-6.34	-0.38	1.19e-9	Severe influenza A (H1N1) infection;
SARC	cis	rs72781680	1.000	rs72796316	chr2:24132272	T/C	cg08917208	chr2:24149416	ATAD2B	0.79	7.4	0.44	2.5e-12	Lymphocyte counts;
SARC	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-8.45	-0.48	3.14e-15	Alzheimer's disease;
SARC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.42	-6.42	-0.39	7.6e-10	Total body bone mineral density;
SARC	cis	rs6732160	0.588	rs11126392	chr2:73374454	A/G	cg01422370	chr2:73384389	NA	0.37	5.72	0.35	3.22e-8	Intelligence (multi-trait analysis);
SARC	cis	rs12142240	0.659	rs72677591	chr1:46818219	T/G	cg10495392	chr1:46806563	NSUN4	0.65	6.83	0.41	7.25e-11	Menopause (age at onset);
SARC	cis	rs3858526	0.916	rs11039551	chr11:5930773	C/T	cg02574844	chr11:5959923	NA	-0.42	-5.24	-0.32	3.58e-7	DNA methylation (variation);
SARC	cis	rs7566780	0.596	rs1465614	chr2:16653293	C/T	cg09580478	chr2:16689509	NA	0.52	6.26	0.38	1.85e-9	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs796364	0.760	rs56285751	chr2:200919836	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-6.61	-0.4	2.63e-10	Schizophrenia;
SARC	cis	rs34172651	0.917	rs7204281	chr16:24784475	C/T	cg04756594	chr16:24857601	SLC5A11	0.38	6.02	0.37	6.65e-9	Intelligence (multi-trait analysis);
SARC	cis	rs11098499	0.542	rs10440343	chr4:120309787	G/C	cg09307838	chr4:120376055	NA	0.91	12.88	0.65	4.9e-29	Corneal astigmatism;
SARC	trans	rs1814175	0.765	rs11493326	chr11:50018063	T/C	cg03929089	chr4:120376271	NA	-0.87	-13.97	-0.68	1.25e-32	Height;
SARC	cis	rs7223966	1.000	rs8070650	chr17:61744040	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	6.35	0.38	1.1e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-10.5	-0.57	2.35e-21	Chronic sinus infection;
SARC	cis	rs10513788	0.665	rs1488134	chr3:181983547	G/C	cg05977900	chr3:182512126	ATP11B	0.5	5.16	0.32	5.36e-7	Cognitive function;
SARC	cis	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg11608241	chr8:8085544	FLJ10661	0.4	4.91	0.31	1.68e-6	Mood instability;
SARC	cis	rs2070677	0.935	rs7907312	chr10:135417364	A/G	cg20169779	chr10:135381914	SYCE1	-0.51	-6.05	-0.37	5.79e-9	Gout;
SARC	cis	rs2066819	0.818	rs703830	chr12:56701872	T/C	cg26734620	chr12:56694298	CS	-0.86	-6.37	-0.39	1.01e-9	Psoriasis vulgaris;
SARC	trans	rs804280	0.509	rs35626932	chr8:11786932	C/A	cg06636001	chr8:8085503	FLJ10661	0.52	6.61	0.4	2.59e-10	Myopia (pathological);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg16573901	chr1:38061607	GNL2	0.8	6.72	0.4	1.38e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs870825	0.616	rs2130393	chr4:185642335	T/C	cg04058563	chr4:185651563	MLF1IP	0.83	11.73	0.61	2.78e-25	Blood protein levels;
SARC	cis	rs950027	0.620	rs2453533	chr15:45641225	C/A	cg21132104	chr15:45694354	SPATA5L1	0.55	7.1	0.42	1.49e-11	Response to fenofibrate (adiponectin levels);
SARC	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg00933542	chr6:150070202	PCMT1	0.3	5.14	0.32	5.77e-7	Lung cancer;
SARC	cis	rs35110281	0.713	rs1378079	chr21:45011187	A/G	cg01579765	chr21:45077557	HSF2BP	-0.34	-5.8	-0.36	2.16e-8	Mean corpuscular volume;
SARC	trans	rs9325144	0.647	rs1386018	chr12:39104360	C/T	cg23762105	chr12:34175262	ALG10	0.49	6.25	0.38	1.96e-9	Morning vs. evening chronotype;
SARC	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg26681399	chr22:41777847	TEF	0.43	4.85	0.3	2.24e-6	Vitiligo;
SARC	cis	rs9368481	0.761	rs4713062	chr6:26948195	A/G	cg12292205	chr6:26970375	C6orf41	-0.43	-4.84	-0.3	2.37e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs3762637	1.000	rs7617042	chr3:122190985	C/T	cg24169773	chr3:122142474	KPNA1	-0.57	-5.85	-0.36	1.67e-8	LDL cholesterol levels;
SARC	cis	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg05623727	chr3:50126028	RBM5	-0.34	-5.19	-0.32	4.52e-7	Intelligence (multi-trait analysis);
SARC	cis	rs10791097	0.694	rs11222370	chr11:130744767	T/G	cg12179176	chr11:130786555	SNX19	0.74	11.09	0.59	3.11e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs6088580	0.634	rs1890002	chr20:32919219	A/G	cg24642439	chr20:33292090	TP53INP2	-0.68	-8.76	-0.5	4.11e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs672059	1.000	rs559476	chr1:183160704	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.51	6.97	0.42	3.21e-11	Hypertriglyceridemia;
SARC	cis	rs36051895	0.632	rs7469563	chr9:5139489	C/T	cg02405213	chr9:5042618	JAK2	-0.46	-5.64	-0.35	4.81e-8	Pediatric autoimmune diseases;
SARC	cis	rs1580019	0.587	rs6972365	chr7:32548931	T/A	cg14728415	chr7:32535168	LSM5;AVL9	0.54	6.95	0.41	3.56e-11	Cognitive ability;
SARC	cis	rs62244186	0.566	rs6766221	chr3:44882784	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.57	7.55	0.44	9.52e-13	Depressive symptoms;
SARC	cis	rs2718058	0.630	rs2718045	chr7:37795438	C/G	cg24998770	chr7:37888106	TXNDC3	-0.32	-4.85	-0.3	2.23e-6	Alzheimer's disease (late onset);
SARC	trans	rs17066873	0.826	rs1323037	chr13:77475402	G/A	cg21804574	chr18:76126700	NA	0.9	6.78	0.41	9.98e-11	Pharmacokinetics of antiepileptic drugs in severe mental disorder (concentration drug ratio);
SARC	cis	rs826838	1.000	rs826888	chr12:39104719	C/G	cg26384229	chr12:38710491	ALG10B	-0.77	-12.03	-0.62	2.95e-26	Heart rate;
SARC	cis	rs2228479	0.850	rs62056069	chr16:89912000	C/T	cg06558623	chr16:89946397	TCF25	0.93	6.61	0.4	2.59e-10	Skin colour saturation;
SARC	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg11952622	chr19:58962976	ZNF324B	0.58	7.63	0.45	5.84e-13	Uric acid clearance;
SARC	cis	rs4974559	0.895	rs10004411	chr4:1354306	T/G	cg02980000	chr4:1222292	CTBP1	0.56	4.76	0.3	3.45e-6	Systolic blood pressure;
SARC	cis	rs1534166	0.647	rs7355929	chr3:133514190	C/T	cg01448562	chr3:133502909	NA	0.33	4.78	0.3	3.17e-6	Alcohol consumption (transferrin glycosylation);
SARC	cis	rs6963495	0.818	rs116845562	chr7:105217038	T/C	cg13798780	chr7:105162888	PUS7	0.57	5.23	0.32	3.86e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.77	11.49	0.6	1.7e-24	Menarche (age at onset);
SARC	cis	rs7224737	1.000	rs11869069	chr17:40287101	C/G	cg20291162	chr17:40259547	DHX58	-0.33	-4.87	-0.3	2.08e-6	Fibrinogen levels;
SARC	cis	rs67311347	0.956	rs4974029	chr3:40521318	C/G	cg09455208	chr3:40491958	NA	0.35	5.35	0.33	2.1e-7	Renal cell carcinoma;
SARC	trans	rs12310956	0.510	rs11052882	chr12:33890017	T/C	cg13010199	chr12:38710504	ALG10B	0.56	7.31	0.43	4.33e-12	Morning vs. evening chronotype;
SARC	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.42	5.2	0.32	4.37e-7	Tonsillectomy;
SARC	trans	rs17685	0.753	rs4398845	chr7:75716781	G/A	cg19862616	chr7:65841803	NCRNA00174	0.64	7.88	0.46	1.25e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs2011503	0.882	rs113841472	chr19:19565482	T/G	cg03709012	chr19:19516395	GATAD2A	0.64	5.69	0.35	3.77e-8	Bipolar disorder;
SARC	cis	rs4919694	0.901	rs12264456	chr10:104830634	C/T	cg04362960	chr10:104952993	NT5C2	0.65	5.49	0.34	1.03e-7	Arsenic metabolism;
SARC	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg10295955	chr4:187884368	NA	-1.07	-20.91	-0.81	2.19e-55	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs35110281	0.805	rs4818843	chr21:45006607	C/T	cg21573476	chr21:45109991	RRP1B	-0.48	-7.02	-0.42	2.34e-11	Mean corpuscular volume;
SARC	cis	rs7520050	0.801	rs6703960	chr1:46232723	C/T	cg06784218	chr1:46089804	CCDC17	-0.27	-4.83	-0.3	2.49e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs17345786	0.520	rs1476123	chr3:101313413	C/G	cg12386194	chr3:101231763	SENP7	0.59	7.07	0.42	1.8e-11	Colonoscopy-negative controls vs population controls;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg14520079	chr3:106825871	NA	-0.57	-7.25	-0.43	6.08e-12	Height;
SARC	cis	rs4642101	0.561	rs9831765	chr3:12805934	A/T	cg24848339	chr3:12840334	CAND2	0.35	5.32	0.33	2.43e-7	QRS complex (12-leadsum);
SARC	cis	rs7944584	0.552	rs12361415	chr11:47474146	T/G	cg20307385	chr11:47447363	PSMC3	0.74	9.52	0.53	2.32e-18	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs60871478	1.000	rs4374882	chr7:821798	C/T	cg05535760	chr7:792225	HEATR2	0.77	7.97	0.46	7.2e-14	Cerebrospinal P-tau181p levels;
SARC	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg13393036	chr8:95962371	TP53INP1	-0.31	-5.25	-0.33	3.45e-7	Type 2 diabetes;
SARC	cis	rs9325144	0.510	rs7952795	chr12:38720686	C/T	cg10518543	chr12:38710700	ALG10B	0.38	4.79	0.3	2.99e-6	Morning vs. evening chronotype;
SARC	trans	rs629535	0.814	rs604254	chr8:70059164	A/G	cg21567404	chr3:27674614	NA	1.06	13.55	0.66	3.23e-31	Dupuytren's disease;
SARC	cis	rs7617773	0.817	rs9853804	chr3:48327729	T/C	cg11946769	chr3:48343235	NME6	0.73	9.65	0.53	9.55e-19	Coronary artery disease;
SARC	cis	rs7223966	1.000	rs8074771	chr17:61735865	C/T	cg00588841	chr17:61851480	DDX42;CCDC47	-0.61	-6.61	-0.4	2.61e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg01276201	chr10:134613136	NA	0.32	5.49	0.34	1.06e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	16.84	0.74	3.62e-42	Height;
SARC	cis	rs6942407	0.546	rs3789251	chr7:86793303	A/G	cg02420886	chr7:86849541	C7orf23	0.72	6.32	0.38	1.3e-9	Food allergy;
SARC	cis	rs36051895	0.530	rs2093447	chr9:5230374	G/T	cg02405213	chr9:5042618	JAK2	-0.42	-4.92	-0.31	1.67e-6	Pediatric autoimmune diseases;
SARC	cis	rs2952156	0.920	rs2517959	chr17:37846512	A/T	cg20243544	chr17:37824526	PNMT	0.5	6.01	0.37	6.93e-9	Asthma;
SARC	cis	rs858239	0.712	rs200717	chr7:23392271	A/G	cg23682824	chr7:23144976	KLHL7	0.53	6.61	0.4	2.57e-10	Cerebrospinal fluid biomarker levels;
SARC	cis	rs6062302	0.522	rs3810492	chr20:62219740	G/A	cg09650180	chr20:62225654	GMEB2	-0.48	-5.86	-0.36	1.56e-8	Glioblastoma;
SARC	cis	rs6429082	0.791	rs61836205	chr1:235638753	C/G	cg26050004	chr1:235667680	B3GALNT2	0.66	7.87	0.46	1.33e-13	Adiposity;
SARC	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg26335602	chr6:28129616	ZNF389	0.51	5.62	0.35	5.41e-8	Depression;
SARC	cis	rs9303401	0.614	rs7215900	chr17:56654850	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.06	11.08	0.59	3.34e-23	Cognitive test performance;
SARC	cis	rs965469	0.895	rs6051844	chr20:3402674	G/T	cg25506879	chr20:3388711	C20orf194	0.54	5.73	0.35	3.03e-8	IFN-related cytopenia;
SARC	cis	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg06115741	chr20:33292138	TP53INP2	-0.58	-7.47	-0.44	1.6e-12	Coronary artery disease;
SARC	cis	rs3739821	0.841	rs943392	chr9:130725441	A/G	cg13668314	chr9:130692638	PIP5KL1	0.36	4.73	0.3	3.96e-6	Glaucoma (primary angle closure);
SARC	cis	rs6484504	0.576	rs441975	chr11:31233351	C/T	cg02090638	chr11:31391270	DNAJC24;DCDC1	-0.4	-5.01	-0.31	1.06e-6	Red blood cell count;
SARC	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg24250549	chr1:154909240	PMVK	0.84	12.48	0.63	1.07e-27	Prostate cancer;
SARC	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg23172400	chr8:95962367	TP53INP1	-0.31	-5.3	-0.33	2.64e-7	Type 2 diabetes;
SARC	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7264396	0.676	rs6058380	chr20:34552900	T/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	5.3	0.33	2.71e-7	Total cholesterol levels;
SARC	cis	rs10782582	0.609	rs5745347	chr1:76274520	C/T	cg03433033	chr1:76189801	ACADM	0.39	5.04	0.31	9.29e-7	Daytime sleep phenotypes;
SARC	cis	rs116095464	1.000	rs7723693	chr5:306032	G/A	cg22857025	chr5:266934	NA	-1.02	-8.18	-0.47	1.86e-14	Breast cancer;
SARC	cis	rs71636778	0.631	rs77402838	chr1:27197733	T/A	cg04852280	chr1:26496234	ZNF593	0.58	5.12	0.32	6.47e-7	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs6570726	0.935	rs401888	chr6:145831535	A/G	cg23711669	chr6:146136114	FBXO30	0.78	11.86	0.61	1.04e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg05861140	chr6:150128134	PCMT1	-0.41	-5.36	-0.33	1.95e-7	Lung cancer;
SARC	cis	rs10892173	0.904	rs10892172	chr11:117672474	C/A	cg07621104	chr11:117668040	DSCAML1	0.45	5.84	0.36	1.74e-8	Myopia;
SARC	cis	rs12681288	0.578	rs10503154	chr8:969343	C/G	cg15309053	chr8:964076	NA	0.49	7.96	0.46	7.57e-14	Schizophrenia;
SARC	cis	rs34330	0.562	rs17212236	chr12:12855483	G/C	cg04607235	chr12:12878440	APOLD1	-0.57	-5.54	-0.34	8.19e-8	Systemic lupus erythematosus;
SARC	cis	rs2425143	0.598	rs2425118	chr20:34324098	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	5.68	0.35	4.03e-8	Blood protein levels;
SARC	cis	rs1044826	1.000	rs9834607	chr3:139234184	A/G	cg15131784	chr3:139108705	COPB2	0.45	5.2	0.32	4.3e-7	Obesity-related traits;
SARC	cis	rs7772486	0.686	rs6570701	chr6:145954090	A/G	cg05220968	chr6:146057943	EPM2A	-0.28	-4.88	-0.3	1.93e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9814567	0.712	rs4955545	chr3:134332926	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.52	-6.69	-0.4	1.68e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs6120849	0.851	rs13040631	chr20:33747714	T/C	cg24642439	chr20:33292090	TP53INP2	0.49	4.81	0.3	2.66e-6	Protein C levels;
SARC	cis	rs2479724	0.613	rs9367113	chr6:41809801	T/G	cg17623882	chr6:41773611	USP49	-0.43	-4.99	-0.31	1.16e-6	Menarche (age at onset);
SARC	cis	rs3768617	0.510	rs2027083	chr1:183088330	T/C	cg13390022	chr1:182993471	LAMC1	0.32	4.83	0.3	2.44e-6	Fuchs's corneal dystrophy;
SARC	cis	rs7786877	0.761	rs11772705	chr7:100298904	T/C	cg20848291	chr7:100343083	ZAN	-0.54	-6.2	-0.38	2.49e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg16405210	chr4:1374714	KIAA1530	-0.45	-5.2	-0.32	4.42e-7	Obesity-related traits;
SARC	cis	rs883565	0.569	rs784513	chr3:39164915	G/A	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.44	-5.12	-0.32	6.37e-7	Handedness;
SARC	cis	rs9303401	0.538	rs2240258	chr17:56458183	C/A	cg25039879	chr17:56429692	SUPT4H1	0.68	5.87	0.36	1.51e-8	Cognitive test performance;
SARC	cis	rs7512552	0.839	rs6703652	chr1:150465953	T/G	cg15654264	chr1:150340011	RPRD2	0.37	4.73	0.3	3.98e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs2011503	1.000	rs2916070	chr19:19524105	C/T	cg03709012	chr19:19516395	GATAD2A	0.67	5.8	0.36	2.15e-8	Bipolar disorder;
SARC	trans	rs1814175	0.869	rs10769600	chr11:49681832	C/T	cg03929089	chr4:120376271	NA	-0.85	-13.46	-0.66	6.34e-31	Height;
SARC	cis	rs875971	0.522	rs9530	chr7:65425894	A/G	cg11987759	chr7:65425863	GUSB	-0.62	-8.51	-0.49	2.18e-15	Aortic root size;
SARC	cis	rs2043112	0.691	rs10941417	chr5:39080660	G/C	cg04869206	chr5:39074266	RICTOR	0.51	6.43	0.39	7.22e-10	Obesity-related traits;
SARC	cis	rs611744	0.967	rs2597654	chr8:109221090	A/G	cg21045802	chr8:109455806	TTC35	0.46	5.43	0.34	1.38e-7	Dupuytren's disease;
SARC	cis	rs9914988	0.943	rs4795459	chr17:27113726	G/C	cg20469991	chr17:27169893	C17orf63	-0.5	-5.21	-0.32	4.1e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs35306767	0.623	rs34034003	chr10:1143435	G/A	cg18964960	chr10:1102726	WDR37	0.7	6.81	0.41	8.36e-11	Eosinophil percentage of granulocytes;
SARC	cis	rs2153535	0.580	rs7743686	chr6:8526111	A/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.19	0.47	1.75e-14	Motion sickness;
SARC	cis	rs698833	0.859	rs1067360	chr2:44661817	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.64	8.03	0.47	4.68e-14	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg16479474	chr6:28041457	NA	0.37	5.35	0.33	2.08e-7	Parkinson's disease;
SARC	cis	rs3820928	0.839	rs4675123	chr2:227800205	T/C	cg05526886	chr2:227700861	RHBDD1	-0.54	-6.54	-0.39	3.76e-10	Pulmonary function;
SARC	cis	rs7843479	0.870	rs1809498	chr8:21836384	C/G	cg17168535	chr8:21777572	XPO7	-0.64	-8.18	-0.47	1.79e-14	Mean corpuscular volume;
SARC	cis	rs9868809	0.772	rs9877794	chr3:48718388	G/C	cg12468774	chr3:49236860	CCDC36	0.45	4.83	0.3	2.45e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs12545109	0.800	rs2670055	chr8:57421575	T/C	cg09654669	chr8:57350985	NA	-0.38	-4.93	-0.31	1.56e-6	Obesity-related traits;
SARC	cis	rs9733	0.744	rs12126004	chr1:150889877	T/C	cg13175981	chr1:150552382	MCL1	0.6	8.07	0.47	3.76e-14	Tonsillectomy;
SARC	cis	rs9467711	0.591	rs34351439	chr6:25833010	T/C	cg21479132	chr6:26055353	NA	0.78	5.0	0.31	1.1e-6	Autism spectrum disorder or schizophrenia;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg25601661	chr11:72525334	ATG16L2	-0.5	-6.27	-0.38	1.71e-9	Breast cancer;
SARC	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg13939156	chr17:80058883	NA	-0.44	-6.79	-0.41	9.27e-11	Life satisfaction;
SARC	cis	rs9467711	0.591	rs13214280	chr6:26008620	C/T	cg21479132	chr6:26055353	NA	0.94	6.28	0.38	1.62e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg08219700	chr8:58056026	NA	0.49	5.08	0.32	7.7300000000000005e-07	Developmental language disorder (linguistic errors);
SARC	cis	rs7589342	0.831	rs11124062	chr2:106455967	G/A	cg16077055	chr2:106428750	NCK2	0.4	7.5	0.44	1.31e-12	Addiction;
SARC	cis	rs7927592	0.956	rs7126340	chr11:68257293	C/T	cg01657329	chr11:68192670	LRP5	-0.39	-4.94	-0.31	1.49e-6	Total body bone mineral density;
SARC	cis	rs4130590	0.966	rs6478770	chr9:130112231	T/C	cg13736810	chr9:130213283	LRSAM1;RPL12	0.48	5.93	0.36	1.08e-8	Bipolar disorder;
SARC	cis	rs11785400	0.762	rs4401833	chr8:143739731	A/T	cg24634471	chr8:143751801	JRK	0.59	7.45	0.44	1.83e-12	Schizophrenia;
SARC	cis	rs1707322	0.964	rs6675259	chr1:46502295	G/A	cg03146154	chr1:46216737	IPP	-0.47	-5.61	-0.35	5.58e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs763121	0.819	rs6001205	chr22:39100264	T/A	cg06022373	chr22:39101656	GTPBP1	0.84	10.34	0.56	7.41e-21	Menopause (age at onset);
SARC	cis	rs6121246	0.529	rs56153385	chr20:30187609	C/T	cg21427119	chr20:30132790	HM13	-0.45	-4.98	-0.31	1.23e-6	Mean corpuscular hemoglobin;
SARC	cis	rs8067545	0.641	rs119672	chr17:19818601	A/G	cg13482628	chr17:19912719	NA	0.48	6.02	0.37	6.77e-9	Schizophrenia;
SARC	cis	rs2180341	0.618	rs11154396	chr6:127638911	C/T	cg24812749	chr6:127587940	RNF146	0.59	7.23	0.43	6.71e-12	Breast cancer;
SARC	cis	rs8180040	0.726	rs6774733	chr3:46991241	G/A	cg27129171	chr3:47204927	SETD2	0.65	9.04	0.51	6.39e-17	Colorectal cancer;
SARC	cis	rs2013441	1.000	rs9896709	chr17:20180550	G/A	cg13482628	chr17:19912719	NA	-0.47	-6.17	-0.37	2.92e-9	Obesity-related traits;
SARC	cis	rs9894429	0.934	rs35868252	chr17:79575472	C/G	cg18240062	chr17:79603768	NPLOC4	-0.71	-9.81	-0.54	3.03e-19	Eye color traits;
SARC	cis	rs7927592	0.717	rs7126451	chr11:68257386	A/G	cg01657329	chr11:68192670	LRP5	0.34	4.74	0.3	3.76e-6	Total body bone mineral density;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg16511841	chr6:97730490	C6orf167;MIR548H3	-0.54	-7.47	-0.44	1.58e-12	Thyroid stimulating hormone;
SARC	cis	rs11731606	0.508	rs9993839	chr4:95307863	T/C	cg20625393	chr4:95128694	SMARCAD1	0.48	4.83	0.3	2.51e-6	Mean platelet volume;
SARC	cis	rs2153535	0.580	rs2225765	chr6:8481785	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.16	0.59	1.88e-23	Motion sickness;
SARC	cis	rs9790314	0.586	rs1811483	chr3:161130900	A/G	cg03342759	chr3:160939853	NMD3	-0.59	-7.39	-0.44	2.66e-12	Morning vs. evening chronotype;
SARC	cis	rs9323205	0.765	rs2999389	chr14:51654510	G/A	cg23942311	chr14:51606299	NA	0.3	5.02	0.31	1.02e-6	Cancer;
SARC	cis	rs9487051	0.872	rs4601178	chr6:109611246	C/T	cg01475377	chr6:109611718	NA	-0.41	-5.83	-0.36	1.87e-8	Reticulocyte fraction of red cells;
SARC	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg20102877	chr2:27665638	KRTCAP3	-0.37	-5.05	-0.31	8.87e-7	Total body bone mineral density;
SARC	cis	rs7296418	0.630	rs7974099	chr12:123771475	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.39	-5.15	-0.32	5.51e-7	Platelet count;
SARC	cis	rs11054731	0.748	rs7975772	chr12:12436199	A/G	cg08064997	chr12:11905431	ETV6	0.36	4.8	0.3	2.77e-6	Coronary artery calcification;
SARC	cis	rs9796	0.624	rs9920619	chr15:41318845	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.51	-7.03	-0.42	2.25e-11	Menopause (age at onset);
SARC	cis	rs6582630	0.621	rs10880656	chr12:38571220	A/C	cg13010199	chr12:38710504	ALG10B	-0.53	-6.63	-0.4	2.32e-10	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg03435698	chr2:144827306	GTDC1	-0.47	-6.54	-0.39	3.75e-10	Alcohol dependence;
SARC	cis	rs950169	0.960	rs35159785	chr15:84804014	G/A	cg24253500	chr15:84953950	NA	0.37	5.25	0.33	3.38e-7	Schizophrenia;
SARC	cis	rs798554	0.548	rs1639064	chr7:2896544	G/A	cg04166393	chr7:2884313	GNA12	0.48	5.73	0.35	3.16e-8	Height;
SARC	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg04166393	chr7:2884313	GNA12	0.48	5.63	0.35	5.08e-8	Height;
SARC	cis	rs17253792	0.749	rs17747301	chr14:56125030	C/G	cg01858014	chr14:56050164	KTN1	-0.67	-5.19	-0.32	4.67e-7	Putamen volume;
SARC	cis	rs7766436	1.000	rs13217022	chr6:22612757	T/C	cg13666174	chr6:22585274	NA	-0.57	-7.4	-0.44	2.42e-12	Coronary artery disease;
SARC	cis	rs5753618	0.529	rs5749298	chr22:31941032	C/T	cg07713946	chr22:31675144	LIMK2	0.36	5.13	0.32	6.01e-7	Colorectal cancer;
SARC	cis	rs739401	0.611	rs10833048	chr11:3020040	A/G	cg08508325	chr11:3079039	CARS	-0.33	-8.19	-0.47	1.74e-14	Longevity;
SARC	cis	rs17376456	0.569	rs7701114	chr5:93096028	T/C	cg21475434	chr5:93447410	FAM172A	0.59	5.78	0.35	2.33e-8	Diabetic retinopathy;
SARC	cis	rs7666738	0.830	rs11725652	chr4:98878362	G/A	cg05340658	chr4:99064831	C4orf37	0.64	8.53	0.49	1.83e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg13012494	chr21:47604986	C21orf56	-0.45	-5.17	-0.32	5.07e-7	Testicular germ cell tumor;
SARC	cis	rs9430161	0.564	rs12081176	chr1:11034145	T/C	cg02454025	chr1:11042201	C1orf127	0.87	12.08	0.62	2.04e-26	Ewing sarcoma;
SARC	cis	rs2985684	1.000	rs2224949	chr14:50096560	A/G	cg15316458	chr14:50087796	RPL36AL;MGAT2	-0.46	-4.82	-0.3	2.6e-6	Carotid intima media thickness;
SARC	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg02733842	chr7:1102375	C7orf50	-0.43	-5.31	-0.33	2.54e-7	Bronchopulmonary dysplasia;
SARC	cis	rs9916302	0.861	rs7503514	chr17:37669884	G/C	cg20243544	chr17:37824526	PNMT	0.56	6.72	0.4	1.37e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg00684032	chr4:1343700	KIAA1530	0.38	5.55	0.34	7.9e-8	Obesity-related traits;
SARC	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg22968622	chr17:43663579	NA	-1.12	-15.05	-0.7	3.24e-36	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs2562456	0.876	rs11085467	chr19:21751843	A/G	cg00806126	chr19:22604979	ZNF98	-0.48	-4.96	-0.31	1.38e-6	Pain;
SARC	cis	rs9443189	1.000	rs6920348	chr6:76502328	T/G	cg01950844	chr6:76311363	SENP6	0.65	5.7	0.35	3.65e-8	Prostate cancer;
SARC	cis	rs11971779	0.680	rs3924296	chr7:139041927	T/C	cg23387468	chr7:139079360	LUC7L2	0.33	4.71	0.3	4.2e-6	Diisocyanate-induced asthma;
SARC	cis	rs9921222	0.656	rs12719801	chr16:381141	C/T	cg00101154	chr16:420108	MRPL28	-0.62	-10.45	-0.56	3.26e-21	Bone mineral density (spine);Bone mineral density;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg26297866	chr1:156052538	MEX3A	-0.66	-6.95	-0.41	3.74e-11	Lung cancer in ever smokers;
SARC	cis	rs918629	0.567	rs2348984	chr5:95236010	A/C	cg16656078	chr5:95278638	ELL2	-0.52	-6.64	-0.4	2.21e-10	IgG glycosylation;
SARC	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg03161606	chr19:29218774	NA	0.47	6.76	0.4	1.09e-10	Methadone dose in opioid dependence;
SARC	cis	rs1983891	0.955	rs6917029	chr6:41548540	C/G	cg15051332	chr6:41514432	FOXP4	0.51	5.71	0.35	3.35e-8	Prostate cancer;
SARC	cis	rs9916302	0.904	rs801426	chr17:37441109	C/T	cg15445000	chr17:37608096	MED1	-0.42	-5.06	-0.31	8.56e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs12142240	0.698	rs17357628	chr1:46808462	A/G	cg00530320	chr1:46809349	NSUN4	0.58	7.07	0.42	1.74e-11	Menopause (age at onset);
SARC	cis	rs1008375	1.000	rs7673500	chr4:17621383	C/T	cg02297831	chr4:17616191	MED28	0.53	6.78	0.41	9.89e-11	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.6	-6.31	-0.38	1.42e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs2120019	0.938	rs5020842	chr15:75322310	T/C	cg12414181	chr15:75287860	SCAMP5	-0.47	-5.34	-0.33	2.21e-7	Blood trace element (Zn levels);
SARC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg09373136	chr17:61933544	TCAM1	-0.45	-6.23	-0.38	2.18e-9	Prudent dietary pattern;
SARC	cis	rs2933343	0.700	rs2249514	chr3:128643812	C/T	cg25356066	chr3:128598488	ACAD9	0.71	9.47	0.53	3.18e-18	IgG glycosylation;
SARC	cis	rs2933343	0.672	rs1872545	chr3:128645039	G/C	cg25356066	chr3:128598488	ACAD9	0.7	9.29	0.52	1.17e-17	IgG glycosylation;
SARC	cis	rs7552404	0.924	rs1146581	chr1:76213024	T/G	cg22875332	chr1:76189707	ACADM	0.41	5.88	0.36	1.38e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7246657	0.823	rs4802236	chr19:37919246	A/G	cg23950597	chr19:37808831	NA	-0.63	-6.03	-0.37	6.33e-9	Coronary artery calcification;
SARC	cis	rs8060686	0.591	rs255054	chr16:68017356	A/G	cg09117114	chr16:67998030	SLC12A4	-0.48	-4.99	-0.31	1.16e-6	HDL cholesterol;Metabolic syndrome;
SARC	cis	rs34366173	1	rs34366173	chr15:63998914	CTT/C	cg12036633	chr15:63758958	NA	-0.45	-5.42	-0.33	1.47e-7	Reticulocyte fraction of red cells;
SARC	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg18876405	chr7:65276391	NA	0.7	8.91	0.5	1.52e-16	Aortic root size;
SARC	cis	rs12421382	0.576	rs116158609	chr11:109389358	T/A	cg16359550	chr11:109292809	C11orf87	0.34	5.14	0.32	5.73e-7	Schizophrenia;
SARC	cis	rs9420	0.961	rs71484468	chr11:57632799	G/C	cg19752551	chr11:57585705	CTNND1	-0.5	-6.71	-0.4	1.48e-10	Schizophrenia;
SARC	cis	rs6912958	0.684	rs6931069	chr6:88367082	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.3	-5.13	-0.32	6.24e-7	Monocyte percentage of white cells;
SARC	cis	rs12479064	0.724	rs3087403	chr2:100058870	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.66	-7.63	-0.45	5.99e-13	Chronic sinus infection;
SARC	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg03060546	chr3:49711283	APEH	0.45	5.66	0.35	4.44e-8	Parkinson's disease;
SARC	cis	rs12709013	0.671	rs1369933	chr16:58787831	T/C	cg04273148	chr16:57808038	KIFC3	0.32	4.72	0.3	4.08e-6	Blood metabolite ratios;
SARC	cis	rs9911578	1.000	rs4372750	chr17:57013803	A/C	cg12560992	chr17:57184187	TRIM37	-0.84	-11.36	-0.6	4.29e-24	Intelligence (multi-trait analysis);
SARC	cis	rs9436747	0.626	rs17412403	chr1:65942266	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	-0.41	-5.09	-0.32	7.23e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs644799	0.965	rs3789960	chr11:95509037	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	15.47	0.71	1.31e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs72781680	0.716	rs2551325	chr2:23979729	C/T	cg06627628	chr2:24431161	ITSN2	-0.52	-5.52	-0.34	9.05e-8	Lymphocyte counts;
SARC	cis	rs6558174	0.863	rs17746902	chr8:22491980	A/C	cg03733263	chr8:22462867	KIAA1967	-0.51	-6.08	-0.37	4.8e-9	Breast cancer;
SARC	cis	rs6542838	0.588	rs4851175	chr2:99530118	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.53	-6.92	-0.41	4.31e-11	Fear of minor pain;
SARC	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg05793240	chr7:2802953	GNA12	-0.38	-5.3	-0.33	2.65e-7	Height;
SARC	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg27541892	chr1:1571801	CDK11B	0.4	5.51	0.34	9.66e-8	Body mass index;
SARC	cis	rs798554	0.610	rs2251491	chr7:2852835	T/C	cg13628971	chr7:2884303	GNA12	0.48	5.97	0.36	8.6e-9	Height;
SARC	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg22974920	chr21:40686053	BRWD1	0.46	5.04	0.31	9.54e-7	Cognitive function;
SARC	trans	rs459571	0.792	rs55923934	chr9:136888233	C/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.58	-6.64	-0.4	2.13e-10	Platelet distribution width;
SARC	cis	rs9297145	0.565	rs7794690	chr7:98764768	G/A	cg05967295	chr7:98741636	SMURF1	-0.52	-5.78	-0.35	2.4e-8	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
SARC	cis	rs7647973	0.588	rs4855848	chr3:49653457	C/T	cg13072238	chr3:49761600	GMPPB	-0.61	-6.14	-0.37	3.48e-9	Menarche (age at onset);
SARC	cis	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg07777115	chr5:623756	CEP72	-0.56	-5.03	-0.31	9.96e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs425277	1.000	rs262641	chr1:2104981	C/T	cg21442419	chr1:2182373	SKI	0.5	6.3	0.38	1.47e-9	Height;
SARC	cis	rs2304069	0.954	rs10045945	chr5:149419297	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.9	9.6	0.53	1.38e-18	HIV-1 control;
SARC	cis	rs7412746	0.658	rs11204750	chr1:150939744	C/A	cg13175981	chr1:150552382	MCL1	-0.49	-5.84	-0.36	1.76e-8	Melanoma;
SARC	cis	rs4589502	1.000	rs12440279	chr15:67133339	G/A	cg12317470	chr15:67143691	NA	0.7	5.21	0.32	4.1e-7	Lung cancer (smoking interaction);
SARC	cis	rs459571	0.916	rs467303	chr9:136904835	C/T	cg01294253	chr9:136912663	BRD3	0.42	5.49	0.34	1.05e-7	Platelet distribution width;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg06742800	chr2:27255708	TMEM214	0.48	6.32	0.38	1.31e-9	Chemerin levels;
SARC	cis	rs17401966	0.931	rs11585794	chr1:10443867	G/A	cg15208524	chr1:10270712	KIF1B	0.5	6.0	0.37	7.68e-9	Hepatocellular carcinoma;
SARC	cis	rs3809566	0.963	rs4775608	chr15:63331940	A/G	cg05507819	chr15:63340323	TPM1	0.53	5.96	0.36	9.21e-9	Platelet count;
SARC	cis	rs8078723	1.000	rs709592	chr17:38175553	C/T	cg17467752	chr17:38218738	THRA	0.47	5.96	0.36	9.44e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs10435719	0.638	rs67146188	chr8:11782433	A/G	cg02127589	chr8:12458309	NA	-0.32	-4.78	-0.3	3.13e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
SARC	trans	rs11767400	0.745	rs13222290	chr7:122220894	A/G	cg04856042	chr3:115752704	LSAMP	0.44	6.23	0.38	2.13e-9	Menarche (age at onset);
SARC	cis	rs3087591	1.000	rs7214792	chr17:29460673	G/A	cg24425628	chr17:29625626	OMG;NF1	0.55	6.95	0.41	3.66e-11	Hip circumference;
SARC	cis	rs13191362	0.507	rs1954806	chr6:163051858	G/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.46	-4.94	-0.31	1.49e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs8077889	0.917	rs72836559	chr17:41913529	C/T	cg26893861	chr17:41843967	DUSP3	0.92	11.34	0.6	4.92e-24	Triglycerides;
SARC	cis	rs9467711	0.559	rs13208916	chr6:26601940	G/A	cg12826209	chr6:26865740	GUSBL1	0.74	4.91	0.31	1.73e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1448094	0.549	rs4919770	chr12:86238050	G/T	cg00310523	chr12:86230176	RASSF9	0.31	5.08	0.32	7.57e-7	Major depressive disorder;
SARC	cis	rs10782582	0.593	rs17848068	chr1:76190216	G/A	cg03433033	chr1:76189801	ACADM	-0.42	-5.52	-0.34	9.19e-8	Daytime sleep phenotypes;
SARC	cis	rs7766436	0.648	rs7757111	chr6:22591154	C/A	cg13666174	chr6:22585274	NA	-0.55	-7.28	-0.43	5e-12	Coronary artery disease;
SARC	cis	rs526231	0.508	rs34805	chr5:102428312	A/G	cg23492399	chr5:102201601	PAM	-0.54	-5.91	-0.36	1.23e-8	Primary biliary cholangitis;
SARC	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg24690094	chr11:67383802	NA	0.5	7.57	0.44	8.49e-13	Mean corpuscular volume;
SARC	cis	rs6545883	0.507	rs10169662	chr2:61507936	T/C	cg10580144	chr2:61372316	C2orf74	-0.4	-5.36	-0.33	2.03e-7	Tuberculosis;
SARC	cis	rs61823972	0.510	rs11240351	chr1:205044339	C/T	cg07972983	chr1:205091412	RBBP5	0.49	6.28	0.38	1.62e-9	Immature fraction of reticulocytes;Mean corpuscular volume;Mean corpuscular hemoglobin;Mean corpuscular hemoglobin concentration;High light scatter reticulocyte count;
SARC	cis	rs72781680	1.000	rs75046532	chr2:24167267	A/G	cg06627628	chr2:24431161	ITSN2	-0.7	-6.65	-0.4	2.1e-10	Lymphocyte counts;
SARC	cis	rs9341808	0.718	rs9361584	chr6:80819946	G/C	cg08355045	chr6:80787529	NA	0.34	5.48	0.34	1.09e-7	Sitting height ratio;
SARC	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg11952622	chr19:58962976	ZNF324B	0.56	7.42	0.44	2.23e-12	Uric acid clearance;
SARC	cis	rs4820539	1.000	rs4822362	chr22:23482744	C/A	cg14186256	chr22:23484241	RTDR1	0.89	14.59	0.69	1.08e-34	Bone mineral density;
SARC	cis	rs1580019	0.844	rs1901202	chr7:32503724	A/T	cg07520158	chr7:32535189	LSM5;AVL9	0.42	4.94	0.31	1.53e-6	Cognitive ability;
SARC	cis	rs9660992	0.674	rs72745221	chr1:205262337	G/A	cg19090574	chr1:205240910	TMCC2	-0.4	-4.75	-0.3	3.49e-6	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs9916302	0.904	rs68178216	chr17:37526241	A/C	cg07936489	chr17:37558343	FBXL20	0.7	9.39	0.52	5.65e-18	Glomerular filtration rate (creatinine);
SARC	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.69	9.2	0.52	2.07e-17	Menarche (age at onset);
SARC	cis	rs4481887	0.927	rs4586010	chr1:248437568	G/A	cg00666640	chr1:248458726	OR2T12	0.36	5.78	0.35	2.45e-8	Common traits (Other);
SARC	cis	rs2486288	0.656	rs11854325	chr15:45548959	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.5	-6.29	-0.38	1.57e-9	Glomerular filtration rate;
SARC	cis	rs11711311	1.000	rs2603789	chr3:113470479	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	7.92	0.46	9.39e-14	IgG glycosylation;
SARC	cis	rs1044826	0.642	rs1080371	chr3:139210894	C/T	cg15131784	chr3:139108705	COPB2	0.4	5.01	0.31	1.09e-6	Obesity-related traits;
SARC	cis	rs6500395	0.926	rs9929569	chr16:48677584	C/T	cg04672837	chr16:48644449	N4BP1	0.43	5.73	0.35	3.16e-8	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs11122272	0.735	rs2790890	chr1:231514567	C/T	cg06096015	chr1:231504339	EGLN1	0.38	5.72	0.35	3.28e-8	Hemoglobin concentration;
SARC	trans	rs208520	0.690	rs4710311	chr6:66823223	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-13.59	-0.66	2.29e-31	Exhaled nitric oxide output;
SARC	cis	rs72945132	0.769	rs11235754	chr11:70136092	C/T	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.78	-0.35	2.39e-8	Coronary artery disease;
SARC	trans	rs4295623	0.553	rs34962960	chr8:11594597	G/A	cg08975724	chr8:8085496	FLJ10661	-0.55	-6.84	-0.41	6.74e-11	Morning vs. evening chronotype;
SARC	cis	rs710216	1.000	rs710216	chr1:43428757	A/G	cg07803811	chr1:43423981	SLC2A1	0.53	5.18	0.32	4.83e-7	Red cell distribution width;
SARC	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg22535103	chr8:58192502	C8orf71	-0.7	-8.42	-0.48	3.82e-15	Developmental language disorder (linguistic errors);
SARC	cis	rs76419734	0.510	rs28391170	chr4:106629246	A/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.79	9.52	0.53	2.25e-18	Post bronchodilator FEV1;
SARC	cis	rs9329221	0.506	rs6993610	chr8:10330994	C/G	cg21775007	chr8:11205619	TDH	-0.38	-5.03	-0.31	9.65e-7	Neuroticism;
SARC	cis	rs826838	0.935	rs1684406	chr12:39127265	A/G	cg13010199	chr12:38710504	ALG10B	-0.63	-8.88	-0.5	1.87e-16	Heart rate;
SARC	cis	rs3106136	0.900	rs13142645	chr4:95208714	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.4	-6.15	-0.37	3.43e-9	Capecitabine sensitivity;
SARC	cis	rs8028182	0.636	rs7171507	chr15:75737287	T/C	cg20655648	chr15:75932815	IMP3	0.65	7.73	0.45	3.21e-13	Sudden cardiac arrest;
SARC	cis	rs11676348	0.818	rs7425447	chr2:218980183	T/C	cg00012203	chr2:219082015	ARPC2	-0.54	-7.33	-0.43	3.7e-12	Ulcerative colitis;
SARC	cis	rs7552404	0.924	rs1611823	chr1:76221706	T/G	cg22875332	chr1:76189707	ACADM	0.39	5.43	0.34	1.41e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs1451375	0.572	rs3807558	chr7:50571022	A/G	cg18232548	chr7:50535776	DDC	-0.49	-5.05	-0.31	8.79e-7	Malaria;
SARC	cis	rs7512552	0.839	rs2873669	chr1:150426224	C/T	cg15654264	chr1:150340011	RPRD2	-0.37	-4.72	-0.3	4.13e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg17294928	chr15:75287854	SCAMP5	0.49	6.26	0.38	1.84e-9	Breast cancer;
SARC	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.11	20.31	0.8	1.81e-53	Chronic sinus infection;
SARC	cis	rs16976116	0.704	rs7183603	chr15:55513718	C/A	cg11288833	chr15:55489084	RSL24D1	0.52	5.22	0.32	4.03e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs9388451	0.626	rs7748729	chr6:126077381	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.62	-8.11	-0.47	2.98e-14	Brugada syndrome;
SARC	cis	rs12477438	0.539	rs720228	chr2:99704547	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	26.17	0.86	2.52e-71	Chronic sinus infection;
SARC	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg24399712	chr22:39784796	NA	-0.39	-5.0	-0.31	1.12e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg25894440	chr7:65020034	NA	-0.71	-5.4	-0.33	1.62e-7	Diabetic kidney disease;
SARC	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-1.06	-16.02	-0.72	1.98e-39	Height;
SARC	cis	rs2075371	1.000	rs2504	chr7:133979545	A/T	cg00033643	chr7:134001901	SLC35B4	0.4	4.91	0.31	1.68e-6	Mean platelet volume;
SARC	cis	rs4148883	0.615	rs2187483	chr4:100134103	G/T	cg13256891	chr4:100009986	ADH5	-0.5	-6.4	-0.39	8.63e-10	Alcohol dependence;
SARC	cis	rs4660306	0.961	rs937290	chr1:45961955	A/G	cg24296786	chr1:45957014	TESK2	0.57	6.68	0.4	1.76e-10	Homocysteine levels;
SARC	cis	rs4742903	0.935	rs10122352	chr9:106993511	T/C	cg14250997	chr9:106856677	SMC2	0.39	4.95	0.31	1.41e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs870825	0.929	rs72689256	chr4:185590174	C/T	cg04058563	chr4:185651563	MLF1IP	0.79	8.79	0.5	3.26e-16	Blood protein levels;
SARC	trans	rs2727020	0.681	rs2866362	chr11:49379316	A/G	cg15704280	chr7:45808275	SEPT13	-0.82	-13.3	-0.66	2.06e-30	Coronary artery disease;
SARC	cis	rs4808199	1.000	rs12972397	chr19:19562349	G/A	cg03709012	chr19:19516395	GATAD2A	1.18	13.34	0.66	1.52e-30	Nonalcoholic fatty liver disease;
SARC	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg19680485	chr15:31195859	MTMR15	-0.58	-6.88	-0.41	5.42e-11	Huntington's disease progression;
SARC	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg14893161	chr1:205819251	PM20D1	0.6	6.9	0.41	4.76e-11	Prostate-specific antigen levels;
SARC	cis	rs17376456	1.000	rs13181660	chr5:93533658	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.44	0.34	1.37e-7	Diabetic retinopathy;
SARC	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.79	12.02	0.62	3.22e-26	Personality dimensions;
SARC	cis	rs10883723	0.810	rs7079810	chr10:104243883	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.63	8.08	0.47	3.57e-14	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs2073499	0.872	rs2282751	chr3:50291785	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.64	-6.85	-0.41	6.39e-11	Schizophrenia;
SARC	cis	rs995000	0.899	rs11207974	chr1:62949960	T/C	cg06896770	chr1:63153194	DOCK7	0.95	14.44	0.69	3.41e-34	Triglyceride levels;
SARC	cis	rs910316	0.737	rs175072	chr14:75502827	T/C	cg11812906	chr14:75593930	NEK9	-0.78	-10.8	-0.58	2.58e-22	Height;
SARC	cis	rs6089584	0.606	rs2273989	chr20:60579138	G/A	cg06108461	chr20:60628389	TAF4	-0.64	-8.02	-0.47	5e-14	Body mass index;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg10246038	chr2:38244725	FAM82A1	0.54	7.6	0.45	7e-13	Thyroid stimulating hormone;
SARC	cis	rs6546324	0.625	rs2902024	chr2:67836718	T/C	cg18237512	chr2:67827392	NA	-0.46	-5.6	-0.34	5.95e-8	Endometriosis;
SARC	cis	rs4803468	1.000	rs284650	chr19:41927129	A/G	cg08477640	chr19:41863820	B9D2	0.44	5.53	0.34	8.62e-8	Height;
SARC	cis	rs7011049	1.000	rs72643577	chr8:53846358	A/T	cg26025543	chr8:53854495	NA	0.6	5.43	0.34	1.42e-7	Systolic blood pressure;
SARC	cis	rs897984	0.568	rs67456613	chr16:30888295	G/A	cg02466173	chr16:30829666	NA	-0.4	-4.74	-0.3	3.65e-6	Dementia with Lewy bodies;
SARC	cis	rs921968	0.678	rs660432	chr2:219432127	C/T	cg02176678	chr2:219576539	TTLL4	0.37	5.49	0.34	1.02e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs7520050	0.966	rs785492	chr1:46583607	G/A	cg24296786	chr1:45957014	TESK2	0.38	4.83	0.3	2.44e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs1707322	0.752	rs11211145	chr1:46108491	A/C	cg06784218	chr1:46089804	CCDC17	0.4	6.69	0.4	1.69e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1865760	1.000	rs9358893	chr6:25921761	A/G	cg10373733	chr6:25993375	NA	0.46	5.51	0.34	9.61e-8	Height;
SARC	cis	rs7769051	0.614	rs17061930	chr6:133223799	T/C	cg22852734	chr6:133119734	C6orf192	0.89	5.61	0.35	5.68e-8	Type 2 diabetes nephropathy;
SARC	cis	rs7555523	0.887	rs4657476	chr1:165732661	A/G	cg19769164	chr1:165738335	TMCO1	-0.59	-4.83	-0.3	2.46e-6	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg20891283	chr12:69753455	YEATS4	0.55	7.56	0.44	9.09e-13	Blood protein levels;
SARC	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg03709012	chr19:19516395	GATAD2A	0.93	14.67	0.69	5.94e-35	Tonsillectomy;
SARC	cis	rs9326248	0.813	rs588534	chr11:117068504	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.48	4.91	0.31	1.74e-6	Blood protein levels;
SARC	cis	rs7727544	0.684	rs2516788	chr5:131715565	G/C	cg24060327	chr5:131705240	SLC22A5	0.72	9.2	0.52	2.09e-17	Blood metabolite levels;
SARC	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg22903657	chr4:1355424	KIAA1530	-0.36	-4.83	-0.3	2.44e-6	Obesity-related traits;
SARC	cis	rs7927592	0.956	rs7106259	chr11:68298512	T/G	cg01657329	chr11:68192670	LRP5	-0.41	-5.09	-0.32	7.34e-7	Total body bone mineral density;
SARC	cis	rs9911578	0.935	rs12948039	chr17:57045184	C/T	cg12560992	chr17:57184187	TRIM37	0.68	8.68	0.49	6.81e-16	Intelligence (multi-trait analysis);
SARC	trans	rs9650657	0.515	rs7820860	chr8:10950396	C/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.04	-0.42	2.18e-11	Neuroticism;
SARC	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg15448220	chr1:150897856	SETDB1	0.45	6.01	0.37	7.09e-9	Tonsillectomy;
SARC	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg24675658	chr1:53192096	ZYG11B	-0.62	-9.31	-0.52	9.75e-18	Monocyte count;
SARC	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.95	-13.96	-0.67	1.32e-32	Gut microbiome composition (summer);
SARC	cis	rs2777491	1.000	rs316610	chr15:41752852	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.82	-12.15	-0.62	1.24e-26	Ulcerative colitis;
SARC	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg20887711	chr4:1340912	KIAA1530	0.45	5.44	0.34	1.34e-7	Longevity;
SARC	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.88	-11.9	-0.61	7.9e-26	Intelligence (multi-trait analysis);
SARC	cis	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg06636001	chr8:8085503	FLJ10661	-0.69	-9.31	-0.52	9.56e-18	Joint mobility (Beighton score);
SARC	cis	rs4268898	0.636	rs72787385	chr2:24585820	G/A	cg06627628	chr2:24431161	ITSN2	-0.78	-9.34	-0.52	8.29e-18	Asthma;
SARC	cis	rs6772849	1.000	rs9836257	chr3:128303483	C/T	cg08795948	chr3:128337044	NA	0.38	4.98	0.31	1.27e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs76917914	1.000	rs76917914	chr9:100771440	A/G	cg03040243	chr9:100819229	NANS	0.59	6.13	0.37	3.8e-9	Immature fraction of reticulocytes;
SARC	cis	rs7644634	0.531	rs13315174	chr3:105406468	G/A	cg23051926	chr3:105466016	CBLB	0.47	5.38	0.33	1.84e-7	Itch intensity from mosquito bite;
SARC	cis	rs708547	0.624	rs1277284	chr4:57855361	T/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.44	-5.47	-0.34	1.16e-7	Response to bleomycin (chromatid breaks);
SARC	cis	rs743757	1.000	rs2236965	chr3:50453456	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.55	5.11	0.32	6.87e-7	Diastolic blood pressure;
SARC	cis	rs4888262	0.526	rs7205258	chr16:74642539	C/T	ch.16.1684049R	chr16:74565916	GLG1	0.35	4.72	0.3	4.1e-6	Testicular germ cell tumor;
SARC	cis	rs5760092	0.755	rs11090298	chr22:24262061	G/A	cg12419862	chr22:24373484	LOC391322	0.76	8.66	0.49	8.14e-16	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs9393692	0.557	rs2893842	chr6:26338434	T/G	cg13736514	chr6:26305472	NA	-0.44	-5.11	-0.32	6.57e-7	Educational attainment;
SARC	trans	rs7824557	0.527	rs2736305	chr8:11237773	T/C	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.77	-0.45	2.53e-13	Retinal vascular caliber;
SARC	cis	rs9902453	0.753	rs3097118	chr17:27978466	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	7.03	0.42	2.28e-11	Coffee consumption (cups per day);
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg20553577	chr13:111128071	COL4A2	0.63	4.82	0.3	2.56e-6	Obesity-related traits;
SARC	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg17221315	chr6:27791827	HIST1H4J	0.51	5.28	0.33	2.97e-7	Parkinson's disease;
SARC	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg12463550	chr7:65579703	CRCP	0.49	5.5	0.34	1.02e-7	Aortic root size;
SARC	cis	rs10448080	0.879	rs240946	chr8:28568905	A/G	cg19781013	chr8:27950282	ELP3	0.39	5.11	0.32	6.83e-7	Height;
SARC	cis	rs4509693	1.000	rs4509693	chr10:102501571	C/T	cg15234845	chr10:102496500	NA	0.32	4.86	0.3	2.13e-6	Alzheimer's disease;
SARC	cis	rs6088590	0.687	rs73106933	chr20:33287425	T/C	cg08999081	chr20:33150536	PIGU	0.43	6.43	0.39	7.11e-10	Coronary artery disease;
SARC	cis	rs7223966	1.000	rs8069687	chr17:61883023	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	5.16	0.32	5.26e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg02841227	chr6:26021843	HIST1H4A	-0.66	-7.96	-0.46	7.3e-14	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg05313129	chr8:58192883	C8orf71	0.51	4.87	0.3	2.06e-6	Developmental language disorder (linguistic errors);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg16975985	chr12:49524048	TUBA1B	0.49	6.43	0.39	7.3e-10	Chemerin levels;
SARC	cis	rs763121	0.853	rs5750649	chr22:39036769	T/C	cg21395723	chr22:39101663	GTPBP1	0.58	6.91	0.41	4.55e-11	Menopause (age at onset);
SARC	cis	rs858239	0.601	rs10224327	chr7:23161820	T/C	cg23682824	chr7:23144976	KLHL7	0.71	8.95	0.51	1.14e-16	Cerebrospinal fluid biomarker levels;
SARC	cis	rs10791097	0.967	rs1944142	chr11:130717440	C/T	cg12179176	chr11:130786555	SNX19	0.58	8.1	0.47	3.1e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs2075371	0.965	rs2544216	chr7:133987902	G/A	cg00033643	chr7:134001901	SLC35B4	0.4	4.85	0.3	2.25e-6	Mean platelet volume;
SARC	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg13395646	chr4:1353034	KIAA1530	-0.48	-5.66	-0.35	4.43e-8	Obesity-related traits;
SARC	cis	rs453301	0.686	rs7814328	chr8:8876229	T/C	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.64	-0.45	5.7e-13	Joint mobility (Beighton score);
SARC	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg19671926	chr4:122722719	EXOSC9	-0.62	-7.18	-0.43	9.18e-12	Type 2 diabetes;
SARC	trans	rs9929218	1.000	rs12596061	chr16:68807828	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.54	-6.77	-0.41	1.05e-10	Colorectal cancer;
SARC	cis	rs3733585	0.699	rs6844787	chr4:9959233	A/G	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.55	-0.34	7.65e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs8114671	0.562	rs6120746	chr20:33448496	A/G	cg24642439	chr20:33292090	TP53INP2	0.52	6.32	0.38	1.31e-9	Height;
SARC	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg07701084	chr6:150067640	NUP43	0.4	5.27	0.33	3.09e-7	Lung cancer;
SARC	cis	rs910316	0.737	rs175045	chr14:75475275	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.45	-5.6	-0.34	6.14e-8	Height;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg02629227	chr12:105501526	KIAA1033	0.53	6.59	0.4	2.93e-10	Breast cancer;
SARC	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg09263875	chr16:632152	PIGQ	0.55	8.54	0.49	1.8e-15	Height;
SARC	cis	rs6714710	0.603	rs2044458	chr2:98377512	A/T	cg26665480	chr2:98280029	ACTR1B	0.48	6.36	0.38	1.07e-9	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs453301	0.598	rs10104303	chr8:8834528	A/T	cg08975724	chr8:8085496	FLJ10661	0.37	4.86	0.3	2.13e-6	Joint mobility (Beighton score);
SARC	cis	rs1348850	0.567	rs1405714	chr2:178538584	A/G	cg23306229	chr2:178417860	TTC30B	-0.46	-5.29	-0.33	2.77e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs3733585	0.699	rs6856127	chr4:9965443	T/C	cg11266682	chr4:10021025	SLC2A9	-0.35	-6.05	-0.37	5.58e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7647973	0.961	rs4955430	chr3:49378088	G/A	cg07636037	chr3:49044803	WDR6	0.74	8.17	0.47	1.97e-14	Menarche (age at onset);
SARC	cis	rs34172651	0.502	rs12930727	chr16:24838497	G/T	cg06028605	chr16:24865363	SLC5A11	-0.34	-5.84	-0.36	1.76e-8	Intelligence (multi-trait analysis);
SARC	cis	rs73001065	0.551	rs10424702	chr19:19508013	A/G	cg03709012	chr19:19516395	GATAD2A	1.09	8.19	0.47	1.76e-14	LDL cholesterol;
SARC	cis	rs7552404	0.731	rs5745445	chr1:76344332	G/A	cg10523679	chr1:76189770	ACADM	0.45	5.3	0.33	2.7e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9513627	0.915	rs80270035	chr13:100121784	C/T	cg25919922	chr13:100150906	NA	-0.7	-5.26	-0.33	3.26e-7	Obesity-related traits;
SARC	trans	rs10506458	0.834	rs73125186	chr12:63373400	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.76	-6.77	-0.41	1.04e-10	Hemostatic factors and hematological phenotypes;
SARC	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs12142240	0.698	rs67941619	chr1:46838219	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-5.56	-0.34	7.46e-8	Menopause (age at onset);
SARC	cis	rs497273	0.534	rs608394	chr12:121194053	C/T	cg02403541	chr12:121454288	C12orf43	0.47	5.66	0.35	4.47e-8	Systemic lupus erythematosus;
SARC	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg05861140	chr6:150128134	PCMT1	0.37	4.79	0.3	3.02e-6	Lung cancer;
SARC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg11494091	chr17:61959527	GH2	0.53	7.86	0.46	1.4e-13	Prudent dietary pattern;
SARC	cis	rs13191362	1.000	rs34052221	chr6:163160803	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.75	6.38	0.39	9.54e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs4969178	0.965	rs8071889	chr17:76398101	A/G	cg02836325	chr17:76403955	PGS1	0.33	5.12	0.32	6.34e-7	HDL cholesterol levels;
SARC	cis	rs7666738	0.830	rs2114426	chr4:98933130	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9611565	0.506	rs4822020	chr22:41700203	C/T	cg03806693	chr22:41940476	POLR3H	-0.72	-9.45	-0.53	3.76e-18	Vitiligo;
SARC	cis	rs113835537	1.000	rs113835537	chr11:66339639	A/G	cg24851651	chr11:66362959	CCS	0.47	4.94	0.31	1.51e-6	Airway imaging phenotypes;
SARC	cis	rs4588572	0.606	rs2362828	chr5:77718835	C/T	cg18281939	chr5:77783895	LHFPL2	0.34	4.75	0.3	3.57e-6	Triglycerides;
SARC	cis	rs12142240	0.698	rs10158572	chr1:46822440	G/T	cg10495392	chr1:46806563	NSUN4	0.65	6.8	0.41	8.89e-11	Menopause (age at onset);
SARC	cis	rs16976116	0.643	rs7181237	chr15:55517231	C/G	cg11288833	chr15:55489084	RSL24D1	0.51	5.1	0.32	7.09e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7932354	0.528	rs7946709	chr11:47100796	G/T	cg03339077	chr11:47165057	C11orf49	-0.45	-6.16	-0.37	3.08e-9	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs7223966	1.000	rs7223672	chr17:61720565	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.56	-6.11	-0.37	4.05e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs8177876	0.731	rs4889227	chr16:81109181	T/C	cg14909325	chr11:1674770	HCCA2	-0.65	-6.42	-0.39	7.51e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
SARC	cis	rs2370759	1.000	rs77165999	chr10:32577131	T/C	cg18270830	chr10:32634957	EPC1	0.65	5.77	0.35	2.46e-8	Sexual dysfunction (female);
SARC	cis	rs7626444	0.628	rs1684464	chr3:196485514	A/C	cg12930392	chr3:196481615	PAK2	0.25	4.9	0.31	1.79e-6	Monocyte count;
SARC	cis	rs4595586	0.546	rs11169801	chr12:39241429	G/A	cg26384229	chr12:38710491	ALG10B	0.68	8.44	0.48	3.29e-15	Morning vs. evening chronotype;
SARC	cis	rs476633	0.691	rs2164996	chr15:41536624	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.56	-7.95	-0.46	7.8500000000000006e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs6121246	0.954	rs6060978	chr20:30416893	G/A	cg13852791	chr20:30311386	BCL2L1	0.78	8.5	0.49	2.27e-15	Mean corpuscular hemoglobin;
SARC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg11494091	chr17:61959527	GH2	0.5	7.48	0.44	1.51e-12	Prudent dietary pattern;
SARC	cis	rs7582180	0.607	rs6725052	chr2:100935817	G/A	cg14675211	chr2:100938903	LONRF2	0.5	7.41	0.44	2.27e-12	Intelligence (multi-trait analysis);
SARC	cis	rs7044106	0.791	rs747819	chr9:123488441	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	6.36	0.38	1.05e-9	Hip circumference adjusted for BMI;
SARC	cis	rs9612	0.948	rs12609587	chr19:44268654	T/C	cg07522664	chr19:44259120	C19orf61	0.5	5.61	0.34	5.83e-8	Exhaled nitric oxide output;
SARC	cis	rs17376456	1.000	rs9968691	chr5:93509756	C/G	cg21475434	chr5:93447410	FAM172A	0.92	7.93	0.46	9.34e-14	Diabetic retinopathy;
SARC	cis	rs965604	1.000	rs12593229	chr15:78765290	T/G	cg24631222	chr15:78858424	CHRNA5	-0.46	-5.97	-0.36	8.56e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs11690462	0.528	rs11691698	chr2:26642190	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.42	5.0	0.31	1.13e-6	Coronary artery disease;
SARC	cis	rs2013441	1.000	rs9915059	chr17:20177104	G/T	cg13482628	chr17:19912719	NA	-0.46	-5.63	-0.35	5.18e-8	Obesity-related traits;
SARC	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.62	5.0	0.31	1.11e-6	Initial pursuit acceleration;
SARC	cis	rs3741151	1.000	rs75007932	chr11:73080336	G/A	cg17517138	chr11:73019481	ARHGEF17	0.99	6.97	0.42	3.2e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg07701084	chr6:150067640	NUP43	0.4	5.24	0.32	3.64e-7	Lung cancer;
SARC	cis	rs1008375	0.931	rs2098151	chr4:17577490	T/C	cg27347728	chr4:17578864	LAP3	0.48	5.86	0.36	1.61e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs910316	0.967	rs119076	chr14:75572419	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.51	-7.25	-0.43	6.11e-12	Height;
SARC	cis	rs4601821	0.858	rs4938012	chr11:113259654	A/G	cg14159747	chr11:113255604	NA	0.41	5.21	0.32	4.23e-7	Alcoholic chronic pancreatitis;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg24409649	chr12:31479318	FAM60A	0.57	7.13	0.42	1.27e-11	Breast cancer;
SARC	cis	rs9790314	0.521	rs13084746	chr3:161086038	G/A	cg04691961	chr3:161091175	C3orf57	-0.58	-7.67	-0.45	4.63e-13	Morning vs. evening chronotype;
SARC	cis	rs1348850	0.874	rs2166558	chr2:178373652	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.71	8.82	0.5	2.78e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7666738	0.515	rs13118898	chr4:98792893	T/A	cg05340658	chr4:99064831	C4orf37	0.59	7.17	0.43	9.77e-12	Colonoscopy-negative controls vs population controls;
SARC	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg16325326	chr1:53192061	ZYG11B	-0.81	-12.64	-0.64	3.17e-28	Monocyte count;
SARC	cis	rs4727027	0.933	rs12704062	chr7:148827865	G/A	cg23583168	chr7:148888333	NA	-0.73	-10.97	-0.58	7.57e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs2777491	0.957	rs7181911	chr15:41674060	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.75	-11.26	-0.59	9.09e-24	Ulcerative colitis;
SARC	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg06634786	chr22:41940651	POLR3H	-0.52	-6.32	-0.38	1.35e-9	Vitiligo;
SARC	cis	rs13256369	1.000	rs4840352	chr8:8573508	A/G	cg18904891	chr8:8559673	CLDN23	0.5	5.77	0.35	2.49e-8	Obesity-related traits;
SARC	cis	rs7712401	0.601	rs13185741	chr5:122338010	A/G	cg19412675	chr5:122181750	SNX24	-0.43	-5.43	-0.34	1.41e-7	Mean platelet volume;
SARC	cis	rs72781680	0.848	rs715646	chr2:24010566	G/A	cg06627628	chr2:24431161	ITSN2	-0.66	-6.26	-0.38	1.83e-9	Lymphocyte counts;
SARC	cis	rs933688	1.000	rs35712350	chr5:90679519	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.02	13.11	0.65	8.53e-30	Smoking behavior;
SARC	cis	rs7662987	0.517	rs1453873	chr4:100022571	T/C	cg13256891	chr4:100009986	ADH5	0.66	8.13	0.47	2.55e-14	Smoking initiation;
SARC	cis	rs921968	0.541	rs532425	chr2:219434194	A/G	cg02176678	chr2:219576539	TTLL4	0.47	7.13	0.42	1.28e-11	Mean corpuscular hemoglobin concentration;
SARC	cis	rs6495122	0.532	rs2470890	chr15:75047426	C/T	cg09165964	chr15:75287851	SCAMP5	0.46	5.27	0.33	3.16e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	cis	rs6772849	0.830	rs4857917	chr3:128376178	C/T	cg01163369	chr3:128370232	RPN1	-0.33	-4.76	-0.3	3.46e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.42	0.53	4.71e-18	Prudent dietary pattern;
SARC	cis	rs4664308	0.870	rs2305818	chr2:161029218	G/A	cg03641300	chr2:160917029	PLA2R1	-0.63	-8.35	-0.48	6.18e-15	Idiopathic membranous nephropathy;
SARC	cis	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg20965017	chr5:231967	SDHA	-0.56	-5.36	-0.33	2e-7	Breast cancer;
SARC	cis	rs73206853	0.614	rs12322130	chr12:110512408	C/T	cg08946844	chr12:110511112	NA	0.63	5.01	0.31	1.07e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	trans	rs12310956	0.532	rs1589903	chr12:33943019	C/T	cg13010199	chr12:38710504	ALG10B	0.74	9.94	0.55	1.26e-19	Morning vs. evening chronotype;
SARC	cis	rs10493773	0.609	rs11161651	chr1:86177816	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.6	-9.73	-0.54	5.42e-19	Urate levels in overweight individuals;
SARC	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg19318889	chr4:1322082	MAEA	0.4	4.86	0.3	2.17e-6	Longevity;
SARC	cis	rs2295359	1.000	rs4655683	chr1:67611613	C/T	cg11235152	chr1:67600687	NA	0.46	7.02	0.42	2.42e-11	Psoriasis;
SARC	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg11062466	chr8:58055876	NA	0.56	5.67	0.35	4.19e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg22857025	chr5:266934	NA	-0.99	-11.54	-0.6	1.14e-24	Breast cancer;
SARC	cis	rs13392177	0.660	rs10932762	chr2:219076213	G/C	cg00012203	chr2:219082015	ARPC2	-0.69	-9.62	-0.53	1.18e-18	Pyoderma gangrenosum in inflammatory bowel disease;
SARC	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.47	5.69	0.35	3.8e-8	Gut microbiome composition (summer);
SARC	cis	rs72781680	0.665	rs2953028	chr2:24068126	T/C	cg08917208	chr2:24149416	ATAD2B	0.59	5.97	0.36	8.61e-9	Lymphocyte counts;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg23939166	chr14:55032812	NA	-0.54	-6.72	-0.4	1.4e-10	Height;
SARC	cis	rs7582180	0.652	rs11123830	chr2:100974747	A/G	cg14675211	chr2:100938903	LONRF2	0.55	8.25	0.48	1.18e-14	Intelligence (multi-trait analysis);
SARC	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg13126279	chr21:47581558	C21orf56	-0.52	-6.38	-0.39	9.25e-10	Testicular germ cell tumor;
SARC	cis	rs17095355	1.000	rs12263484	chr10:111697255	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.47	-5.65	-0.35	4.73e-8	Biliary atresia;
SARC	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg15921436	chr17:44337874	NA	0.51	5.13	0.32	6.18e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs10958369	0.613	rs1477957	chr8:54435433	T/C	cg12485204	chr8:54507357	NA	0.46	6.53	0.39	3.97e-10	Response to antineoplastic agents;
SARC	cis	rs77372450	0.551	rs57823519	chr5:157101500	G/A	cg05585991	chr5:157099197	C5orf52	0.54	5.34	0.33	2.17e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs1034435	0.755	rs6007871	chr22:48894392	C/G	cg05992904	chr22:48892994	FAM19A5	-0.48	-6.91	-0.41	4.68e-11	Late-onset Alzheimer's disease;
SARC	cis	rs13191362	0.935	rs67673890	chr6:163107647	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.73	6.39	0.39	9.18e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2075371	0.637	rs2544165	chr7:133920443	A/G	cg11752832	chr7:134001865	SLC35B4	-0.48	-6.12	-0.37	3.83e-9	Mean platelet volume;
SARC	cis	rs6688613	0.649	rs2280995	chr1:166846069	A/G	cg07049167	chr1:166818506	POGK	0.47	4.77	0.3	3.19e-6	Refractive astigmatism;
SARC	cis	rs1153858	1.000	rs7163720	chr15:45639374	G/A	cg26924012	chr15:45694286	SPATA5L1	0.75	10.34	0.56	7.46e-21	Homoarginine levels;
SARC	cis	rs713477	0.967	rs4898865	chr14:55910998	G/A	cg13175173	chr14:55914753	NA	-0.3	-4.75	-0.3	3.63e-6	Pediatric bone mineral content (femoral neck);
SARC	cis	rs12497850	1.000	rs12497850	chr3:48748989	G/T	cg06212747	chr3:49208901	KLHDC8B	0.65	8.83	0.5	2.6e-16	Parkinson's disease;
SARC	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg25894440	chr7:65020034	NA	-0.77	-5.85	-0.36	1.67e-8	Diabetic kidney disease;
SARC	cis	rs7927592	0.513	rs901823	chr11:68205578	T/C	cg01657329	chr11:68192670	LRP5	-0.37	-4.82	-0.3	2.63e-6	Total body bone mineral density;
SARC	cis	rs875971	1.000	rs1167411	chr7:65539264	C/G	cg11987759	chr7:65425863	GUSB	0.43	5.66	0.35	4.32e-8	Aortic root size;
SARC	cis	rs910316	0.967	rs4903293	chr14:75656568	A/G	cg08847533	chr14:75593920	NEK9	-0.85	-12.97	-0.65	2.49e-29	Height;
SARC	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg04267008	chr7:1944627	MAD1L1	-0.46	-5.58	-0.34	6.58e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg04166393	chr7:2884313	GNA12	0.67	8.13	0.47	2.58e-14	Height;
SARC	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg12463550	chr7:65579703	CRCP	0.51	5.71	0.35	3.42e-8	Aortic root size;
SARC	cis	rs3617	0.572	rs2256332	chr3:52855865	A/G	cg18404041	chr3:52824283	ITIH1	0.36	5.42	0.33	1.48e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs7786877	0.521	rs2293767	chr7:100361675	A/G	cg16850897	chr7:100343110	ZAN	0.43	5.24	0.32	3.6e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs735396	0.770	rs2259820	chr12:121435342	C/T	cg15155738	chr12:121454335	C12orf43	0.52	6.47	0.39	5.58e-10	N-glycan levels;
SARC	trans	rs61931739	0.500	rs9705909	chr12:34576419	G/C	cg13010199	chr12:38710504	ALG10B	0.83	11.69	0.61	3.9e-25	Morning vs. evening chronotype;
SARC	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg06028808	chr11:68637592	NA	0.48	6.23	0.38	2.15e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs12311304	1.000	rs56090796	chr12:15406228	T/A	cg08258403	chr12:15378311	NA	0.49	7.29	0.43	4.84e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs9916302	0.904	rs8070695	chr17:37478062	C/T	cg15445000	chr17:37608096	MED1	-0.43	-4.97	-0.31	1.33e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs2997447	0.655	rs1317709	chr1:26384690	A/C	cg19633962	chr1:26362018	EXTL1	-0.8	-8.59	-0.49	1.3e-15	QRS complex (12-leadsum);
SARC	cis	rs910316	0.967	rs175505	chr14:75529619	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.58	-8.28	-0.48	9.34e-15	Height;
SARC	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg17971929	chr21:40555470	PSMG1	0.95	11.6	0.61	7.39e-25	Cognitive function;
SARC	cis	rs6912958	0.703	rs9359748	chr6:88095500	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.36	6.28	0.38	1.65e-9	Monocyte percentage of white cells;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg22571926	chr5:56112222	MAP3K1	0.51	6.74	0.4	1.24e-10	Chemerin levels;
SARC	cis	rs453301	0.522	rs2929455	chr8:9083433	A/T	cg11995313	chr8:8860691	ERI1	0.4	4.88	0.3	2e-6	Joint mobility (Beighton score);
SARC	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg02951883	chr7:2050386	MAD1L1	-0.4	-5.06	-0.31	8.47e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs6087990	0.965	rs742630	chr20:31350664	C/G	cg13636640	chr20:31349939	DNMT3B	0.81	12.89	0.65	4.57e-29	Ulcerative colitis;
SARC	cis	rs7560272	0.512	rs2421677	chr2:73965917	G/T	cg20560298	chr2:73613845	ALMS1	0.44	5.84	0.36	1.7e-8	Schizophrenia;
SARC	cis	rs2712184	0.756	rs2541395	chr2:217647675	C/T	cg05032264	chr2:217675019	NA	-0.52	-6.89	-0.41	5.02e-11	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
SARC	trans	rs3942852	0.806	rs10734562	chr11:48128189	A/T	cg03929089	chr4:120376271	NA	0.56	6.27	0.38	1.77e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs6977660	0.507	rs28402966	chr7:19774469	A/C	cg05791153	chr7:19748676	TWISTNB	0.9	7.53	0.44	1.1e-12	Thyroid stimulating hormone;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg16516888	chr11:77532772	C11orf67;RSF1	-0.72	-6.3	-0.38	1.48e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs4481887	0.927	rs4376768	chr1:248476088	A/G	cg01631408	chr1:248437212	OR2T33	0.38	4.87	0.3	2.04e-6	Common traits (Other);
SARC	cis	rs9325144	0.556	rs34565156	chr12:39028239	G/A	cg26384229	chr12:38710491	ALG10B	-0.6	-7.83	-0.46	1.69e-13	Morning vs. evening chronotype;
SARC	cis	rs4481887	0.927	rs4537599	chr1:248508741	G/A	cg01631408	chr1:248437212	OR2T33	-0.46	-5.78	-0.35	2.42e-8	Common traits (Other);
SARC	trans	rs208520	1.000	rs72884017	chr6:66992513	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	9.32	0.52	9.16e-18	Exhaled nitric oxide output;
SARC	cis	rs73635312	0.850	rs79134926	chr10:8964984	G/T	cg24467326	chr10:9646929	NA	0.61	5.08	0.32	7.78e-7	Basal cell carcinoma;
SARC	cis	rs4423214	0.921	rs11603330	chr11:71153459	C/A	cg24826892	chr11:71159390	DHCR7	0.45	5.55	0.34	7.88e-8	Vitamin D levels;
SARC	cis	rs72781680	0.898	rs72780111	chr2:23991146	G/A	cg06627628	chr2:24431161	ITSN2	-0.67	-6.35	-0.38	1.14e-9	Lymphocyte counts;
SARC	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg03354898	chr7:1950403	MAD1L1	0.37	4.96	0.31	1.37e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs561341	0.769	rs8074383	chr17:30178793	C/T	cg13647721	chr17:30228624	UTP6	-0.7	-5.3	-0.33	2.66e-7	Hip circumference adjusted for BMI;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg22519947	chr1:2271419	MORN1	0.46	6.32	0.38	1.3e-9	Schizophrenia;
SARC	cis	rs17376456	0.877	rs9314101	chr5:93461593	A/T	cg25358565	chr5:93447407	FAM172A	1.31	15.17	0.7	1.33e-36	Diabetic retinopathy;
SARC	cis	rs9309473	0.950	rs7596773	chr2:73846000	C/T	cg20560298	chr2:73613845	ALMS1	-0.45	-5.59	-0.34	6.2e-8	Metabolite levels;
SARC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg11494091	chr17:61959527	GH2	0.54	8.15	0.47	2.18e-14	Prudent dietary pattern;
SARC	cis	rs11112613	0.713	rs4015312	chr12:105948757	A/G	cg03607813	chr12:105948248	NA	0.54	6.94	0.41	3.88e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs11583043	1.000	rs11583043	chr1:101466054	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.49	5.96	0.36	9.07e-9	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs3820928	0.874	rs13393902	chr2:227880554	A/G	cg11843606	chr2:227700838	RHBDD1	-0.57	-7.32	-0.43	3.95e-12	Pulmonary function;
SARC	cis	rs9303401	0.661	rs9902820	chr17:56637545	A/C	cg05425664	chr17:57184151	TRIM37	-0.42	-5.07	-0.32	7.94e-7	Cognitive test performance;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg08290995	chr4:159593107	C4orf46;ETFDH	0.51	6.42	0.39	7.58e-10	Blood pressure;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg00964355	chr1:228465440	OBSCN	0.46	6.6	0.4	2.74e-10	Schizophrenia;
SARC	cis	rs7223966	1.000	rs8077265	chr17:61732727	A/G	cg26338869	chr17:61819248	STRADA	0.43	4.86	0.3	2.11e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg11764359	chr7:65958608	NA	-0.67	-7.97	-0.46	7.26e-14	Aortic root size;
SARC	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg05279229	chr7:1896384	MAD1L1	-0.35	-4.93	-0.31	1.54e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs9843304	0.529	rs4681510	chr3:149201573	A/T	cg08667024	chr3:149219783	TM4SF4	-0.4	-5.91	-0.36	1.21e-8	Gallstone disease;
SARC	cis	rs847851	0.617	rs9394267	chr6:34960760	C/T	cg13137465	chr6:34857473	ANKS1A	-0.59	-4.89	-0.31	1.88e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs17376456	0.825	rs17314074	chr5:93161467	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.67	5.44	0.34	1.32e-7	Diabetic retinopathy;
SARC	cis	rs67311347	0.956	rs13066971	chr3:40462510	A/T	cg24209194	chr3:40518798	ZNF619	-0.64	-8.42	-0.48	3.77e-15	Renal cell carcinoma;
SARC	cis	rs9325144	0.555	rs4550281	chr12:38689937	A/G	cg04568710	chr12:38710424	ALG10B	0.38	4.74	0.3	3.69e-6	Morning vs. evening chronotype;
SARC	cis	rs76419734	0.850	rs11725523	chr4:106517866	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.75	4.74	0.3	3.66e-6	Post bronchodilator FEV1;
SARC	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg12463550	chr7:65579703	CRCP	-0.7	-5.31	-0.33	2.51e-7	Diabetic kidney disease;
SARC	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.75	10.81	0.58	2.42e-22	Personality dimensions;
SARC	cis	rs4242434	0.819	rs2291230	chr8:22463697	C/G	cg03733263	chr8:22462867	KIAA1967	0.93	15.19	0.71	1.13e-36	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg19223190	chr17:80058835	NA	0.43	6.07	0.37	5.09e-9	Life satisfaction;
SARC	cis	rs7937682	0.632	rs4935811	chr11:111679262	C/T	cg09085632	chr11:111637200	PPP2R1B	0.79	10.64	0.57	8.23e-22	Primary sclerosing cholangitis;
SARC	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs35110281	0.776	rs2838338	chr21:45075582	T/C	cg21573476	chr21:45109991	RRP1B	-0.57	-8.53	-0.49	1.94e-15	Mean corpuscular volume;
SARC	cis	rs3087591	0.922	rs2905806	chr17:29502507	A/G	cg24425628	chr17:29625626	OMG;NF1	0.5	6.23	0.38	2.22e-9	Hip circumference;
SARC	trans	rs61931739	0.500	rs7310237	chr12:34483435	G/A	cg26384229	chr12:38710491	ALG10B	0.83	12.44	0.63	1.43e-27	Morning vs. evening chronotype;
SARC	cis	rs4763879	0.778	rs2895989	chr12:9841331	A/G	cg27502298	chr12:9555721	NA	0.47	5.25	0.33	3.38e-7	Type 1 diabetes;
SARC	cis	rs17666538	1.000	rs57896286	chr8:571479	T/C	cg23958373	chr8:599963	NA	-0.92	-6.59	-0.4	2.92e-10	IgG glycosylation;
SARC	cis	rs835154	1.000	rs2934814	chr5:14872689	C/T	cg18064842	chr5:14874549	NA	-0.48	-6.46	-0.39	6.2e-10	Blood metabolite levels;
SARC	cis	rs4595586	0.505	rs11613808	chr12:39390823	T/A	cg26384229	chr12:38710491	ALG10B	0.53	6.18	0.38	2.8e-9	Morning vs. evening chronotype;
SARC	cis	rs10870270	1.000	rs9971066	chr10:133788233	G/A	cg26149184	chr10:133730230	NA	0.45	4.75	0.3	3.61e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs3741151	0.892	rs60078907	chr11:73085834	T/C	cg17517138	chr11:73019481	ARHGEF17	0.63	5.29	0.33	2.88e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs9906944	0.713	rs9899580	chr17:47106878	T/G	cg16584676	chr17:46985605	UBE2Z	-0.43	-5.26	-0.33	3.33e-7	Intelligence (multi-trait analysis);Body fat percentage;
SARC	cis	rs9902453	0.740	rs2729446	chr17:28102499	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.19	-0.43	8.82e-12	Coffee consumption (cups per day);
SARC	cis	rs79149102	0.579	rs6495138	chr15:75304692	A/G	cg00629941	chr15:75287862	SCAMP5	-0.66	-5.39	-0.33	1.7e-7	Lung cancer;
SARC	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg07343612	chr16:622815	PIGQ	-0.58	-8.17	-0.47	1.98e-14	Height;
SARC	cis	rs7681440	0.606	rs2737033	chr4:90707947	T/C	cg06632027	chr4:90757378	SNCA	-0.42	-5.12	-0.32	6.37e-7	Dementia with Lewy bodies;
SARC	trans	rs61931739	0.500	rs10844844	chr12:34380350	G/T	cg13010199	chr12:38710504	ALG10B	0.81	11.5	0.6	1.58e-24	Morning vs. evening chronotype;
SARC	cis	rs10421328	0.784	rs12983292	chr19:19787767	G/A	cg03709012	chr19:19516395	GATAD2A	0.56	6.04	0.37	6.21e-9	Parental longevity (combined parental age at death);
SARC	cis	rs13161895	0.818	rs116463976	chr5:179484519	G/C	cg06664874	chr5:179499304	RNF130	0.62	5.65	0.35	4.6e-8	LDL cholesterol;
SARC	cis	rs7937682	0.921	rs4534611	chr11:111440425	C/G	cg22437258	chr11:111473054	SIK2	0.67	8.96	0.51	1.08e-16	Primary sclerosing cholangitis;
SARC	cis	rs6693567	0.545	rs1260403	chr1:150303666	A/G	cg09579323	chr1:150459698	TARS2	0.41	5.11	0.32	6.8e-7	Migraine;
SARC	cis	rs9486715	0.867	rs3849199	chr6:97049191	T/C	cg06623918	chr6:96969491	KIAA0776	-0.94	-14.57	-0.69	1.25e-34	Headache;
SARC	trans	rs36093844	0.706	rs79814326	chr11:85585573	A/G	cg15359163	chr5:122429178	PRDM6	-0.54	-6.44	-0.39	6.72e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs7607369	0.572	rs629177	chr2:219454801	T/G	cg02176678	chr2:219576539	TTLL4	0.46	6.89	0.41	5.03e-11	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs7551222	0.752	rs11240758	chr1:204528651	C/T	cg20240347	chr1:204465584	NA	-0.32	-5.52	-0.34	9.09e-8	Schizophrenia;
SARC	cis	rs8017423	0.967	rs8021881	chr14:90722276	T/C	cg20276874	chr14:90721474	PSMC1	-0.39	-5.49	-0.34	1.06e-7	Mortality in heart failure;
SARC	cis	rs2120019	0.938	rs13056	chr15:75312187	A/G	cg00629941	chr15:75287862	SCAMP5	-0.7	-8.35	-0.48	6.18e-15	Blood trace element (Zn levels);
SARC	trans	rs1814175	0.645	rs28441045	chr11:50048971	C/T	cg15704280	chr7:45808275	SEPT13	-0.91	-14.49	-0.69	2.43e-34	Height;
SARC	cis	rs7084402	1.000	rs4113952	chr10:60268599	A/G	cg07615347	chr10:60278583	BICC1	0.6	8.43	0.48	3.63e-15	Refractive error;
SARC	trans	rs34421088	0.560	rs2248315	chr8:11397086	T/A	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.35	-0.38	1.09e-9	Neuroticism;
SARC	cis	rs10779751	0.734	rs2791650	chr1:11132541	G/C	cg08854313	chr1:11322531	MTOR	0.82	11.29	0.59	7.2e-24	Body mass index;
SARC	cis	rs9354308	0.840	rs1827157	chr6:66615761	A/G	cg07460842	chr6:66804631	NA	0.49	5.5	0.34	9.96e-8	Metabolite levels;
SARC	cis	rs9381040	0.655	rs2268190	chr6:41030226	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.44	-5.04	-0.31	9.2e-7	Alzheimer's disease (late onset);
SARC	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7555523	0.779	rs6662839	chr1:165722646	T/G	cg19769164	chr1:165738335	TMCO1	0.59	4.91	0.31	1.7e-6	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	cis	rs986417	1.000	rs1950904	chr14:60964954	G/C	cg27398547	chr14:60952738	C14orf39	0.97	9.02	0.51	7.2e-17	Gut microbiota (bacterial taxa);
SARC	cis	rs11785400	0.793	rs11543967	chr8:143739435	A/G	cg10596483	chr8:143751796	JRK	-0.55	-6.82	-0.41	7.63e-11	Schizophrenia;
SARC	cis	rs1008375	1.000	rs4642241	chr4:17617111	T/C	cg27347728	chr4:17578864	LAP3	0.46	5.68	0.35	3.95e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg06873352	chr17:61820015	STRADA	0.48	6.29	0.38	1.55e-9	Prudent dietary pattern;
SARC	cis	rs78132593	0.759	rs17599629	chr1:150658287	A/G	cg13175981	chr1:150552382	MCL1	0.47	5.03	0.31	9.88e-7	High light scatter reticulocyte count;
SARC	cis	rs826838	0.967	rs11169142	chr12:39085773	A/T	cg26384229	chr12:38710491	ALG10B	-0.8	-12.53	-0.63	6.89e-28	Heart rate;
SARC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg09373136	chr17:61933544	TCAM1	-0.44	-6.09	-0.37	4.59e-9	Prudent dietary pattern;
SARC	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg21724239	chr8:58056113	NA	0.58	6.06	0.37	5.42e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg14664628	chr15:75095509	CSK	-0.47	-5.65	-0.35	4.77e-8	Breast cancer;
SARC	cis	rs7223966	1.000	rs9912904	chr17:61763534	A/C	cg26338869	chr17:61819248	STRADA	0.44	4.82	0.3	2.56e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7208859	0.673	rs2433	chr17:29226228	T/C	cg13385521	chr17:29058706	SUZ12P	0.85	7.23	0.43	7.08e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs6540556	0.723	rs11119327	chr1:209883804	T/C	cg05527609	chr1:210001259	C1orf107	-0.57	-5.31	-0.33	2.58e-7	Red blood cell count;
SARC	cis	rs11644362	1.000	rs72782620	chr16:12987416	T/A	cg06890432	chr16:12997467	SHISA9	-0.54	-7.19	-0.43	8.99e-12	Positive affect;Subjective well-being;
SARC	cis	rs114858855	1.000	rs6917383	chr6:110007240	C/T	cg26835506	chr6:109038353	NA	-0.61	-5.04	-0.31	9.22e-7	Plasma trimethylamine N-oxide levels;
SARC	cis	rs12824058	0.831	rs11060826	chr12:130809931	G/C	cg23887609	chr12:130822674	PIWIL1	0.37	5.15	0.32	5.48e-7	Menopause (age at onset);
SARC	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.33	-4.94	-0.31	1.5e-6	Total body bone mineral density;
SARC	cis	rs56176327	0.583	rs7613603	chr3:49812866	C/T	cg07636037	chr3:49044803	WDR6	-0.62	-6.31	-0.38	1.41e-9	Intelligence (multi-trait analysis);
SARC	cis	rs2204008	0.837	rs11168341	chr12:37961951	C/T	cg13010199	chr12:38710504	ALG10B	0.79	11.02	0.59	5.42e-23	Bladder cancer;
SARC	cis	rs950776	0.752	rs2869546	chr15:78907345	C/T	cg06917634	chr15:78832804	PSMA4	-0.76	-10.48	-0.57	2.62e-21	Sudden cardiac arrest;
SARC	cis	rs7666738	0.830	rs62318504	chr4:98935558	T/G	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2075371	0.897	rs1646743	chr7:134003451	C/A	cg11752832	chr7:134001865	SLC35B4	0.64	8.4	0.48	4.33e-15	Mean platelet volume;
SARC	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg17971929	chr21:40555470	PSMG1	0.98	13.83	0.67	3.76e-32	Cognitive function;
SARC	cis	rs7937682	0.564	rs11600652	chr11:111754368	A/T	cg22437258	chr11:111473054	SIK2	-0.47	-5.45	-0.34	1.28e-7	Primary sclerosing cholangitis;
SARC	trans	rs116095464	0.558	rs56298907	chr5:283280	C/A	cg00938859	chr5:1591904	SDHAP3	0.77	6.36	0.38	1.08e-9	Breast cancer;
SARC	cis	rs79149102	0.579	rs58294763	chr15:75299768	G/A	cg17294928	chr15:75287854	SCAMP5	-1.02	-8.87	-0.5	2e-16	Lung cancer;
SARC	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg04267008	chr7:1944627	MAD1L1	-0.54	-6.24	-0.38	2.1e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs7561149	0.768	rs6709734	chr2:179729141	C/T	cg17765952	chr2:179737173	CCDC141	-0.48	-6.59	-0.4	2.94e-10	QT interval;
SARC	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg11764359	chr7:65958608	NA	0.78	9.93	0.55	1.37e-19	Aortic root size;
SARC	cis	rs6912958	0.728	rs7773906	chr6:88251869	T/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.52	-7.08	-0.42	1.66e-11	Monocyte percentage of white cells;
SARC	cis	rs10752881	1.000	rs6673559	chr1:182983197	G/C	cg13390022	chr1:182993471	LAMC1	0.34	5.17	0.32	5.11e-7	Colorectal cancer;
SARC	cis	rs7223966	1.000	rs752621	chr17:61901880	G/C	cg26338869	chr17:61819248	STRADA	0.52	5.44	0.34	1.37e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9354308	0.933	rs2802064	chr6:66564352	C/T	cg07460842	chr6:66804631	NA	0.48	5.45	0.34	1.3e-7	Metabolite levels;
SARC	cis	rs9527	0.590	rs7897663	chr10:104905604	T/C	cg04362960	chr10:104952993	NT5C2	0.44	5.18	0.32	4.78e-7	Arsenic metabolism;
SARC	cis	rs2845885	0.793	rs56241103	chr11:63882364	C/T	cg24431193	chr11:63883947	FLRT1;MACROD1	0.75	6.95	0.41	3.73e-11	Body mass index;
SARC	cis	rs6570726	0.791	rs385729	chr6:145855465	T/C	cg05347473	chr6:146136440	FBXO30	0.54	7.45	0.44	1.82e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg11062466	chr8:58055876	NA	0.64	8.16	0.47	2.14e-14	Developmental language disorder (linguistic errors);
SARC	cis	rs7264396	0.580	rs2064511	chr20:34448810	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.66	6.83	0.41	7.33e-11	Total cholesterol levels;
SARC	trans	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.72	10.44	0.56	3.49e-21	Intelligence (multi-trait analysis);
SARC	cis	rs796364	1.000	rs11895190	chr2:200838613	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.75	-6.86	-0.41	6.28e-11	Schizophrenia;
SARC	cis	rs193541	0.530	rs9327272	chr5:122073548	T/C	cg19412675	chr5:122181750	SNX24	0.45	6.02	0.37	6.81e-9	Glucose homeostasis traits;
SARC	cis	rs35213789	0.734	rs2533427	chr7:69142958	G/A	cg10619644	chr7:69149951	AUTS2	-0.35	-4.82	-0.3	2.57e-6	Childhood ear infection;
SARC	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg06634786	chr22:41940651	POLR3H	-0.55	-6.49	-0.39	5.22e-10	Vitiligo;
SARC	cis	rs9815354	0.812	rs4434125	chr3:42004681	A/G	cg03022575	chr3:42003672	ULK4	0.68	5.89	0.36	1.34e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs16854884	1.000	rs7649614	chr3:143789028	G/A	cg06585982	chr3:143692056	C3orf58	0.58	7.0	0.42	2.74e-11	Economic and political preferences (feminism/equality);
SARC	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.06	0.37	5.52e-9	Height;
SARC	cis	rs3733585	0.699	rs6844316	chr4:9958977	A/G	cg11266682	chr4:10021025	SLC2A9	-0.35	-6.03	-0.37	6.35e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs644799	1.000	rs472231	chr11:95532166	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	15.35	0.71	3.21e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.22	0.38	2.3e-9	Electroencephalogram traits;
SARC	cis	rs1552244	0.706	rs279545	chr3:9972493	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.73	8.62	0.49	1.05e-15	Alzheimer's disease;
SARC	cis	rs12421382	0.659	rs11213103	chr11:109385935	A/G	cg27471124	chr11:109292789	C11orf87	0.35	4.8	0.3	2.87e-6	Schizophrenia;
SARC	cis	rs1355223	1.000	rs1396879	chr11:34766653	A/C	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.43	-0.39	7.3e-10	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs526231	0.511	rs4421079	chr5:102369076	C/T	cg23492399	chr5:102201601	PAM	-0.51	-5.58	-0.34	6.63e-8	Primary biliary cholangitis;
SARC	cis	rs7769051	1.000	rs6910639	chr6:133120553	A/G	cg07930552	chr6:133119739	C6orf192	0.89	8.0	0.46	5.83e-14	Type 2 diabetes nephropathy;
SARC	cis	rs4689388	0.889	rs13128674	chr4:6294517	C/T	cg14416269	chr4:6271139	WFS1	0.32	4.92	0.31	1.61e-6	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg11987759	chr7:65425863	GUSB	-0.49	-6.21	-0.38	2.46e-9	Aortic root size;
SARC	cis	rs1371867	0.846	rs1660332	chr8:101309490	A/G	cg11906718	chr8:101322791	RNF19A	-0.64	-8.33	-0.48	6.8e-15	Atrioventricular conduction;
SARC	cis	rs72945132	0.882	rs4261311	chr11:70132902	C/T	cg00319359	chr11:70116639	PPFIA1	0.68	6.37	0.39	1.01e-9	Coronary artery disease;
SARC	cis	rs9457247	1.000	rs409356	chr6:167405226	T/A	cg07741184	chr6:167504864	NA	0.29	5.55	0.34	7.72e-8	Crohn's disease;
SARC	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg06558623	chr16:89946397	TCF25	0.98	8.13	0.47	2.6e-14	Skin colour saturation;
SARC	cis	rs12142240	0.667	rs12062	chr1:46830447	G/T	cg14993813	chr1:46806288	NSUN4	0.53	5.7	0.35	3.67e-8	Menopause (age at onset);
SARC	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg08219700	chr8:58056026	NA	0.58	6.19	0.38	2.71e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.593	rs58647001	chr8:58025132	G/A	cg08677398	chr8:58056175	NA	0.41	4.79	0.3	2.93e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs9660992	0.710	rs1151787	chr1:205254238	G/A	cg07972983	chr1:205091412	RBBP5	0.53	6.41	0.39	8.08e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs9326248	0.520	rs1446105	chr11:116798544	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.61	7.69	0.45	4.1e-13	Blood protein levels;
SARC	cis	rs6964587	1.000	rs417	chr7:91581121	C/A	cg17063962	chr7:91808500	NA	-0.93	-14.92	-0.7	8.86e-36	Breast cancer;
SARC	cis	rs12912251	0.591	rs2624272	chr15:39003409	A/G	cg10631289	chr15:39006617	NA	-0.4	-4.91	-0.31	1.72e-6	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
SARC	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg17221315	chr6:27791827	HIST1H4J	0.45	4.75	0.3	3.57e-6	Depression;
SARC	cis	rs796364	0.906	rs281784	chr2:200749749	T/A	cg23649088	chr2:200775458	C2orf69	0.59	5.37	0.33	1.87e-7	Schizophrenia;
SARC	cis	rs2777491	0.574	rs2730056	chr15:41735785	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.16	-17.92	-0.76	1.03e-45	Ulcerative colitis;
SARC	cis	rs76419734	1.000	rs11730354	chr4:106773435	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	5.26	0.33	3.24e-7	Post bronchodilator FEV1;
SARC	cis	rs6087990	0.735	rs2424922	chr20:31386449	T/C	cg13636640	chr20:31349939	DNMT3B	0.78	12.0	0.62	3.77e-26	Ulcerative colitis;
SARC	cis	rs11122272	0.668	rs1538664	chr1:231555295	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-9.21	-0.52	1.9e-17	Hemoglobin concentration;
SARC	cis	rs240764	0.559	rs9404049	chr6:101237129	C/A	cg09795085	chr6:101329169	ASCC3	-0.44	-5.7	-0.35	3.54e-8	Neuroticism;
SARC	cis	rs2204008	0.837	rs11181857	chr12:38413255	C/G	cg26384229	chr12:38710491	ALG10B	0.83	11.99	0.62	4.04e-26	Bladder cancer;
SARC	cis	rs1865721	0.804	rs3826652	chr18:73142153	C/T	cg26385618	chr18:73139727	C18orf62	0.35	4.94	0.31	1.47e-6	Intelligence;
SARC	cis	rs6484504	0.576	rs286653	chr11:31227824	C/T	cg02090638	chr11:31391270	DNAJC24;DCDC1	-0.39	-4.88	-0.3	2e-6	Red blood cell count;
SARC	cis	rs6456156	0.792	rs4710181	chr6:167513998	T/C	cg23791538	chr6:167370224	RNASET2	-0.41	-5.26	-0.33	3.19e-7	Primary biliary cholangitis;
SARC	cis	rs12979813	1.000	rs3810307	chr19:11332570	T/A	cg00586551	chr19:11347513	LOC55908;DOCK6	0.43	5.3	0.33	2.69e-7	HDL cholesterol;
SARC	cis	rs9303401	0.659	rs7225896	chr17:56637337	T/C	cg25039879	chr17:56429692	SUPT4H1	0.69	6.29	0.38	1.56e-9	Cognitive test performance;
SARC	cis	rs9682041	0.877	rs10755126	chr3:170071694	C/G	cg11886554	chr3:170076028	SKIL	-0.63	-6.3	-0.38	1.47e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	trans	rs1853207	1.000	rs113348400	chr10:96704918	A/G	cg02737782	chr1:8014393	NA	-0.99	-6.74	-0.4	1.21e-10	Blood metabolite levels;
SARC	cis	rs933688	1.000	rs12654787	chr5:90713259	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.08	13.76	0.67	6.36e-32	Smoking behavior;
SARC	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg11987759	chr7:65425863	GUSB	0.47	5.73	0.35	3.15e-8	Aortic root size;
SARC	cis	rs9660992	0.736	rs1180734	chr1:205255438	A/G	cg19090574	chr1:205240910	TMCC2	-0.37	-4.78	-0.3	3.04e-6	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs3020736	0.500	rs5996111	chr22:42493902	C/T	cg04733989	chr22:42467013	NAGA	-0.77	-10.67	-0.57	6.65e-22	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2834188	0.924	rs6517160	chr21:34683512	A/G	cg15382669	chr21:34697036	IFNAR1	0.42	4.81	0.3	2.77e-6	Narcolepsy;
SARC	cis	rs5753618	0.561	rs2283879	chr22:31638448	G/A	cg13145458	chr22:31556086	RNF185	0.5	5.34	0.33	2.19e-7	Colorectal cancer;
SARC	trans	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg06437703	chr8:37914619	EIF4EBP1	-0.68	-9.0	-0.51	8.26e-17	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9611565	0.921	rs2143695	chr22:41728620	A/G	cg06634786	chr22:41940651	POLR3H	-0.39	-4.77	-0.3	3.2e-6	Vitiligo;
SARC	cis	rs1355223	0.583	rs2956076	chr11:34874124	T/C	cg11058730	chr11:34937778	PDHX;APIP	0.75	10.59	0.57	1.16e-21	Systemic lupus erythematosus and Systemic sclerosis;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg12842219	chr17:41476263	ARL4D	0.55	7.32	0.43	4.11e-12	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs8180040	0.676	rs13098228	chr3:47138253	A/G	cg27129171	chr3:47204927	SETD2	0.68	9.59	0.53	1.4e-18	Colorectal cancer;
SARC	trans	rs7824557	0.564	rs13260727	chr8:11232860	A/G	cg15556689	chr8:8085844	FLJ10661	0.5	6.34	0.38	1.21e-9	Retinal vascular caliber;
SARC	trans	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg23738833	chr1:28832381	SNHG3-RCC1;SNHG3	-0.52	-6.43	-0.39	7.02e-10	Colonoscopy-negative controls vs population controls;
SARC	cis	rs11739663	0.574	rs67276442	chr5:583918	T/C	cg16447950	chr5:562315	NA	-0.5	-7.13	-0.42	1.27e-11	Ulcerative colitis;
SARC	cis	rs3764563	1.000	rs3764563	chr19:15724203	A/G	cg20725493	chr19:15740067	CYP4F8	-0.64	-4.79	-0.3	3.02e-6	Inflammatory biomarkers;
SARC	cis	rs2421770	0.530	rs11033084	chr11:35367408	T/G	cg13971030	chr11:35366721	SLC1A2	-0.35	-5.34	-0.33	2.21e-7	Staphylococcus aureus nasal carriage (persistent);
SARC	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg02018176	chr4:1364513	KIAA1530	0.45	6.67	0.4	1.83e-10	Longevity;
SARC	cis	rs12586317	0.547	rs2273154	chr14:35433187	C/T	cg26967526	chr14:35346199	BAZ1A	-0.68	-6.6	-0.4	2.73e-10	Psoriasis;
SARC	cis	rs9787249	0.957	rs10888958	chr1:40211737	T/C	cg02773041	chr1:40204384	PPIE	0.53	6.43	0.39	7.05e-10	Blood protein levels;
SARC	cis	rs4727027	0.866	rs2373438	chr7:148780287	C/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.48	5.76	0.35	2.62e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.9	-0.5	1.61e-16	Alzheimer's disease;
SARC	cis	rs9843304	0.721	rs4681175	chr3:149201863	G/A	cg08667024	chr3:149219783	TM4SF4	-0.37	-5.4	-0.33	1.66e-7	Gallstone disease;
SARC	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg03060546	chr3:49711283	APEH	0.41	5.15	0.32	5.63e-7	Parkinson's disease;
SARC	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.64	-7.41	-0.44	2.37e-12	Gut microbiome composition (summer);
SARC	cis	rs8072100	0.967	rs2317826	chr17:45730899	C/T	cg08085267	chr17:45401833	C17orf57	-0.42	-4.79	-0.3	2.98e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs9486719	1.000	rs11152968	chr6:96908653	A/G	cg06623918	chr6:96969491	KIAA0776	0.72	7.76	0.45	2.73e-13	Migraine;Coronary artery disease;
SARC	cis	rs7666738	0.830	rs28615340	chr4:98896922	T/C	cg05340658	chr4:99064831	C4orf37	0.64	8.46	0.48	3.06e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg00684032	chr4:1343700	KIAA1530	0.34	4.85	0.3	2.3e-6	Obesity-related traits;
SARC	cis	rs73198271	0.740	rs10098636	chr8:8647324	C/T	cg06636001	chr8:8085503	FLJ10661	-0.47	-5.0	-0.31	1.15e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs735539	0.556	rs9552277	chr13:21352287	T/A	cg16922012	chr13:21400325	XPO4	-0.38	-5.3	-0.33	2.65e-7	Dental caries;
SARC	cis	rs4563143	0.514	rs73029076	chr19:29292032	G/T	cg14983838	chr19:29218262	NA	0.68	7.95	0.46	8.03e-14	Methadone dose in opioid dependence;
SARC	cis	rs748404	0.697	rs473554	chr15:43568207	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.41	5.13	0.32	6.09e-7	Lung cancer;
SARC	cis	rs4481887	0.790	rs10888364	chr1:248488387	T/G	cg00666640	chr1:248458726	OR2T12	0.37	6.02	0.37	6.83e-9	Common traits (Other);
SARC	cis	rs1215050	0.755	rs7696354	chr4:98820330	T/C	cg05340658	chr4:99064831	C4orf37	0.43	5.72	0.35	3.31e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs12142240	0.698	rs6667861	chr1:46815749	T/C	cg10495392	chr1:46806563	NSUN4	0.65	6.83	0.41	7.25e-11	Menopause (age at onset);
SARC	cis	rs2153535	0.580	rs7745043	chr6:8513507	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	7.33	0.43	3.86e-12	Motion sickness;
SARC	cis	rs9400467	0.506	rs79720667	chr6:111779833	G/T	cg15721981	chr6:111408429	SLC16A10	0.65	5.67	0.35	4.31e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs9457247	1.000	rs2757042	chr6:167371234	A/T	cg23791538	chr6:167370224	RNASET2	0.62	8.56	0.49	1.51e-15	Crohn's disease;
SARC	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg06634786	chr22:41940651	POLR3H	0.51	5.94	0.36	1.04e-8	Vitiligo;
SARC	cis	rs8180040	0.627	rs58956475	chr3:47224615	G/C	cg27129171	chr3:47204927	SETD2	-0.69	-9.4	-0.52	5.33e-18	Colorectal cancer;
SARC	cis	rs9457247	1.000	rs422694	chr6:167406074	G/T	cg23791538	chr6:167370224	RNASET2	-0.63	-8.74	-0.5	4.69e-16	Crohn's disease;
SARC	cis	rs6121246	0.609	rs1009453	chr20:30404840	C/G	cg13852791	chr20:30311386	BCL2L1	0.81	10.14	0.55	3.06e-20	Mean corpuscular hemoglobin;
SARC	cis	rs4805272	0.512	rs7260055	chr19:29341599	G/A	cg04546413	chr19:29218101	NA	0.46	5.17	0.32	5.12e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs7589728	1.000	rs7589728	chr2:88518440	G/A	cg04511125	chr2:88470314	THNSL2	0.66	5.81	0.36	2.08e-8	Plasma clusterin levels;
SARC	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg11644478	chr21:40555479	PSMG1	1.0	12.63	0.64	3.41e-28	Cognitive function;
SARC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.54	6.14	0.37	3.48e-9	Prudent dietary pattern;
SARC	cis	rs644799	0.710	rs11021309	chr11:95501898	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.61	8.27	0.48	1.05e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7666738	0.546	rs9993299	chr4:98815976	G/A	cg05340658	chr4:99064831	C4orf37	0.59	7.17	0.43	9.71e-12	Colonoscopy-negative controls vs population controls;
SARC	cis	rs11249608	0.510	rs6861539	chr5:178452307	A/G	cg21905437	chr5:178450457	ZNF879	0.58	8.04	0.47	4.6e-14	Pubertal anthropometrics;
SARC	cis	rs5167	0.566	rs35080293	chr19:45496624	T/G	cg13119609	chr19:45449297	APOC2	0.38	5.42	0.33	1.51e-7	Blood protein levels;
SARC	cis	rs35110281	0.713	rs6518310	chr21:45098670	T/A	cg01579765	chr21:45077557	HSF2BP	-0.32	-5.0	-0.31	1.12e-6	Mean corpuscular volume;
SARC	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg24549020	chr5:56110836	MAP3K1	0.81	8.4	0.48	4.37e-15	Initial pursuit acceleration;
SARC	trans	rs61931739	0.500	rs10844789	chr12:34202279	C/G	cg26384229	chr12:38710491	ALG10B	0.84	12.1	0.62	1.76e-26	Morning vs. evening chronotype;
SARC	cis	rs9811216	0.916	rs12638862	chr3:169477506	C/T	cg14222479	chr3:169487675	ARPM1	-0.45	-5.12	-0.32	6.49e-7	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs1256061	0.603	rs1256038	chr14:64740739	T/C	cg23250157	chr14:64679961	SYNE2	0.48	6.62	0.4	2.49e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs7264396	0.622	rs3787165	chr20:34228946	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-8.03	-0.47	4.85e-14	Total cholesterol levels;
SARC	cis	rs9790314	0.967	rs460165	chr3:161087710	G/A	cg04691961	chr3:161091175	C3orf57	-0.83	-13.29	-0.66	2.28e-30	Morning vs. evening chronotype;
SARC	cis	rs28829049	0.597	rs12745238	chr1:19393710	C/T	cg13387374	chr1:19411106	UBR4	0.46	5.59	0.34	6.17e-8	QRS duration in Tripanosoma cruzi seropositivity;
SARC	cis	rs9611519	0.639	rs7289989	chr22:41476799	A/C	cg17376030	chr22:41985996	PMM1	0.39	4.94	0.31	1.51e-6	Neuroticism;
SARC	cis	rs10791323	0.559	rs10750549	chr11:133730820	A/G	cg15485101	chr11:133734466	NA	0.3	4.74	0.3	3.72e-6	Childhood ear infection;
SARC	cis	rs12971120	0.891	rs2278159	chr18:72178161	T/C	cg26446133	chr18:72167187	CNDP2	-0.47	-6.32	-0.38	1.32e-9	Refractive error;
SARC	cis	rs854765	0.619	rs1101727	chr17:18016148	T/C	cg05444541	chr17:17804740	TOM1L2	-0.31	-5.02	-0.31	1.05e-6	Total body bone mineral density;
SARC	cis	rs721399	0.614	rs4646246	chr8:18248661	A/G	cg18736775	chr8:18248649	NAT2	-0.65	-7.38	-0.44	2.74e-12	Blood metabolite levels;
SARC	cis	rs7639513	0.520	rs4684111	chr3:12729485	T/G	cg23032965	chr3:12705835	RAF1	0.72	8.24	0.48	1.25e-14	Itch intensity from mosquito bite;
SARC	cis	rs78132593	0.718	rs72702521	chr1:150650194	C/T	cg13175981	chr1:150552382	MCL1	0.48	4.79	0.3	2.98e-6	High light scatter reticulocyte count;
SARC	cis	rs61935443	0.501	rs10859754	chr12:95192729	C/T	cg21533806	chr12:95267307	NA	0.38	4.8	0.3	2.82e-6	Schizophrenia;
SARC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg12648201	chr2:27665141	KRTCAP3	-0.33	-5.0	-0.31	1.11e-6	Total body bone mineral density;
SARC	cis	rs7666738	0.791	rs2903142	chr4:99040071	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs5167	0.566	rs7253458	chr19:45482570	C/T	cg13119609	chr19:45449297	APOC2	0.39	5.53	0.34	8.77e-8	Blood protein levels;
SARC	cis	rs787274	1.000	rs72768411	chr9:115502670	C/A	cg13803584	chr9:115635662	SNX30	0.79	5.41	0.33	1.56e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs6693567	0.565	rs1260404	chr1:150304150	T/A	cg09579323	chr1:150459698	TARS2	0.42	5.31	0.33	2.56e-7	Migraine;
SARC	cis	rs936229	0.690	rs2445618	chr15:75035256	T/C	cg14664628	chr15:75095509	CSK	-0.98	-12.3	-0.63	4.08e-27	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs6740322	1.000	rs4128209	chr2:43554729	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.51	-6.38	-0.39	9.32e-10	Coronary artery disease;
SARC	cis	rs950027	0.549	rs11070452	chr15:45594836	C/A	cg15395560	chr15:45543142	SLC28A2	0.29	5.48	0.34	1.08e-7	Response to fenofibrate (adiponectin levels);
SARC	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	10.84	0.58	2.01e-22	Alzheimer's disease;
SARC	cis	rs763121	0.853	rs3761454	chr22:39066820	C/T	cg21395723	chr22:39101663	GTPBP1	0.53	5.94	0.36	1.03e-8	Menopause (age at onset);
SARC	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	9.87	0.54	2.04e-19	Platelet count;
SARC	cis	rs2180341	0.781	rs7742161	chr6:127571676	T/C	cg27446573	chr6:127587934	RNF146	0.89	12.65	0.64	2.96e-28	Breast cancer;
SARC	cis	rs4919087	1.000	rs11189132	chr10:99086195	G/C	cg25902810	chr10:99078978	FRAT1	-0.47	-5.79	-0.35	2.31e-8	Monocyte count;
SARC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg09373136	chr17:61933544	TCAM1	-0.45	-6.09	-0.37	4.56e-9	Prudent dietary pattern;
SARC	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.53	-5.77	-0.35	2.49e-8	Huntington's disease progression;
SARC	cis	rs7589342	0.831	rs6714861	chr2:106518893	C/T	cg16077055	chr2:106428750	NCK2	-0.37	-6.69	-0.4	1.64e-10	Addiction;
SARC	cis	rs13034020	0.594	rs10496090	chr2:61254033	T/C	cg18625361	chr2:61244694	PEX13;PUS10	0.65	5.24	0.32	3.51e-7	Hodgkin's lymphoma;
SARC	cis	rs2997447	0.706	rs17184898	chr1:26447870	A/T	cg19633962	chr1:26362018	EXTL1	-0.56	-5.06	-0.31	8.55e-7	QRS complex (12-leadsum);
SARC	cis	rs9916302	0.904	rs8066704	chr17:37477218	C/T	cg00129232	chr17:37814104	STARD3	0.6	7.34	0.43	3.5e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg27266027	chr21:40555129	PSMG1	0.51	5.57	0.34	6.84e-8	Cognitive function;
SARC	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg15448220	chr1:150897856	SETDB1	0.47	6.24	0.38	2.06e-9	Tonsillectomy;
SARC	cis	rs9786986	0.665	rs12401438	chr1:235701732	C/T	cg08848088	chr1:235714526	GNG4	0.53	5.3	0.33	2.66e-7	Body mass index;
SARC	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg11890956	chr21:40555474	PSMG1	1.13	15.78	0.72	1.2e-38	Cognitive function;
SARC	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg22903471	chr2:27725779	GCKR	-0.44	-6.61	-0.4	2.52e-10	Total body bone mineral density;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg22514863	chr19:42806860	PAFAH1B3;PRR19	-0.48	-6.36	-0.38	1.07e-9	Neuroticism;
SARC	cis	rs9443189	0.570	rs9343316	chr6:76411800	G/A	cg01950844	chr6:76311363	SENP6	0.86	8.18	0.47	1.82e-14	Prostate cancer;
SARC	cis	rs9296092	0.560	rs3846854	chr6:33528466	T/C	cg13560919	chr6:33536144	NA	-0.52	-6.38	-0.39	9.28e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs3087591	0.708	rs12940802	chr17:29643564	C/A	cg24425628	chr17:29625626	OMG;NF1	0.43	5.49	0.34	1.03e-7	Hip circumference;
SARC	trans	rs61931739	0.534	rs4086956	chr12:34105047	A/T	cg26384229	chr12:38710491	ALG10B	0.74	10.17	0.55	2.5e-20	Morning vs. evening chronotype;
SARC	cis	rs7296418	0.663	rs11057276	chr12:123820397	C/T	cg00376283	chr12:123451042	ABCB9	-0.54	-6.61	-0.4	2.6200000000000003e-10	Platelet count;
SARC	cis	rs7824557	0.602	rs11781375	chr8:11204532	A/G	cg21775007	chr8:11205619	TDH	0.67	8.63	0.49	9.62e-16	Retinal vascular caliber;
SARC	cis	rs546131	0.600	rs502857	chr11:34854662	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.44	4.84	0.3	2.42e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs13191362	0.872	rs35672319	chr6:163245464	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.63	6.01	0.37	7.15e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs8067545	0.611	rs757494	chr17:20150340	C/T	cg13482628	chr17:19912719	NA	-0.54	-6.97	-0.42	3.23e-11	Schizophrenia;
SARC	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg26116260	chr4:7069785	GRPEL1	0.89	11.17	0.59	1.8e-23	Monocyte percentage of white cells;
SARC	cis	rs9457247	1.000	rs2149091	chr6:167372786	C/T	cg07741184	chr6:167504864	NA	-0.3	-5.61	-0.34	5.78e-8	Crohn's disease;
SARC	cis	rs9467711	0.591	rs3734523	chr6:25925987	G/A	cg21479132	chr6:26055353	NA	0.75	4.84	0.3	2.41e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs763121	0.853	rs1056610	chr22:39080078	C/T	cg21395723	chr22:39101663	GTPBP1	-0.56	-6.74	-0.4	1.25e-10	Menopause (age at onset);
SARC	trans	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg00938859	chr5:1591904	SDHAP3	0.79	7.61	0.45	6.69e-13	Breast cancer;
SARC	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg26039829	chr8:22132926	PIWIL2	0.46	6.63	0.4	2.25e-10	Hypertriglyceridemia;
SARC	cis	rs7481584	0.581	rs399565	chr11:3061780	C/T	cg05729581	chr11:3078854	CARS	0.53	6.91	0.41	4.49e-11	Calcium levels;
SARC	cis	rs4948523	0.530	rs11006182	chr10:60309128	G/A	cg07615347	chr10:60278583	BICC1	-0.38	-5.08	-0.32	7.9e-7	Myopia;
SARC	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg02725872	chr8:58115012	NA	-0.27	-4.87	-0.3	2.05e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs7772486	0.875	rs1331639	chr6:146431869	A/G	cg23711669	chr6:146136114	FBXO30	-0.68	-10.16	-0.55	2.56e-20	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg17971929	chr21:40555470	PSMG1	0.58	7.26	0.43	5.74e-12	Menarche (age at onset);
SARC	cis	rs2576037	0.899	rs12955429	chr18:44585484	C/T	cg19077165	chr18:44547161	KATNAL2	0.48	6.59	0.4	2.93e-10	Personality dimensions;
SARC	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg15049968	chr18:44337910	ST8SIA5	0.37	5.89	0.36	1.37e-8	Personality dimensions;
SARC	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg22496380	chr5:211416	CCDC127	-0.88	-9.35	-0.52	7.72e-18	Breast cancer;
SARC	cis	rs2204008	0.682	rs2320517	chr12:38259239	A/T	cg13010199	chr12:38710504	ALG10B	0.81	11.31	0.6	6.33e-24	Bladder cancer;
SARC	cis	rs35213789	0.853	rs2533432	chr7:69132631	T/C	cg10619644	chr7:69149951	AUTS2	-0.44	-5.89	-0.36	1.35e-8	Childhood ear infection;
SARC	cis	rs4423214	1.000	rs2002063	chr11:71163476	T/C	cg05163923	chr11:71159392	DHCR7	0.65	8.57	0.49	1.4e-15	Vitamin D levels;
SARC	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg16405210	chr4:1374714	KIAA1530	-0.43	-5.12	-0.32	6.26e-7	Obesity-related traits;
SARC	cis	rs10463316	0.928	rs4958267	chr5:150752643	A/T	cg03212797	chr5:150827313	SLC36A1	-0.52	-6.32	-0.38	1.29e-9	Metabolite levels (Pyroglutamine);
SARC	cis	rs7953249	0.594	rs11065384	chr12:121423285	T/C	cg02403541	chr12:121454288	C12orf43	-0.78	-10.71	-0.57	5.04e-22	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg25427524	chr10:38739819	LOC399744	-0.6	-9.59	-0.53	1.38e-18	Extrinsic epigenetic age acceleration;
SARC	cis	rs6120849	0.754	rs3746436	chr20:33586193	C/T	cg06115741	chr20:33292138	TP53INP2	0.56	5.36	0.33	1.95e-7	Protein C levels;
SARC	cis	rs1153858	1.000	rs4534782	chr15:45652933	G/A	cg21132104	chr15:45694354	SPATA5L1	0.77	10.99	0.58	6.68e-23	Homoarginine levels;
SARC	cis	rs6977660	0.714	rs12700077	chr7:19791607	A/G	cg07541023	chr7:19748670	TWISTNB	-0.75	-7.06	-0.42	1.92e-11	Thyroid stimulating hormone;
SARC	cis	rs2758596	1.000	rs2758617	chr1:156160693	A/G	cg24450063	chr1:156163899	SLC25A44	0.86	5.6	0.34	5.91e-8	Paclitaxel disposition in epithelial ovarian cancer;
SARC	trans	rs2727020	0.638	rs1164668	chr11:49330627	A/C	cg03929089	chr4:120376271	NA	0.76	11.24	0.59	1.06e-23	Coronary artery disease;
SARC	cis	rs74781061	0.790	rs74788606	chr15:74824990	C/T	cg09165964	chr15:75287851	SCAMP5	-0.65	-5.04	-0.31	9.56e-7	Endometriosis;
SARC	cis	rs6088590	0.561	rs6087600	chr20:33157217	T/C	cg24642439	chr20:33292090	TP53INP2	0.66	8.51	0.49	2.12e-15	Coronary artery disease;
SARC	cis	rs12579753	0.956	rs11115039	chr12:82217338	A/C	cg07988820	chr12:82153109	PPFIA2	-0.54	-6.04	-0.37	6.17e-9	Resting heart rate;
SARC	trans	rs9388451	0.559	rs1777210	chr6:126098916	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.58	-7.43	-0.44	1.99e-12	Brugada syndrome;
SARC	cis	rs2180341	0.924	rs6930849	chr6:127630963	A/T	cg17762328	chr6:126965162	NA	-0.46	-5.24	-0.32	3.55e-7	Breast cancer;
SARC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-4.93	-0.31	1.59e-6	Total body bone mineral density;
SARC	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg11987759	chr7:65425863	GUSB	-0.58	-7.64	-0.45	5.63e-13	Aortic root size;
SARC	cis	rs11874712	1.000	rs9962458	chr18:43678625	G/C	cg25174615	chr18:43684699	ATP5A1;HAUS1	0.41	4.84	0.3	2.37e-6	Migraine - clinic-based;
SARC	cis	rs4889855	0.530	rs12946972	chr17:78618922	A/G	cg17956530	chr17:78667699	RPTOR	-0.46	-5.28	-0.33	2.97e-7	Fractional excretion of uric acid;
SARC	cis	rs13082711	0.911	rs3816881	chr3:27432888	T/C	cg02860705	chr3:27208620	NA	0.46	6.14	0.37	3.59e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs1298908	0.639	rs2993763	chr10:82033594	G/A	cg01528321	chr10:82214614	TSPAN14	0.35	4.74	0.3	3.76e-6	Diabetic kidney disease;
SARC	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg11062466	chr8:58055876	NA	0.48	4.88	0.3	1.93e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs2278426	1.000	rs17699030	chr19:11330942	C/T	cg00586551	chr19:11347513	LOC55908;DOCK6	-0.59	-4.88	-0.3	1.97e-6	HDL cholesterol;
SARC	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg13175981	chr1:150552382	MCL1	-0.48	-5.69	-0.35	3.78e-8	Melanoma;
SARC	cis	rs1153858	1.000	rs7164602	chr15:45671325	A/G	cg26924012	chr15:45694286	SPATA5L1	0.79	11.28	0.59	7.91e-24	Homoarginine levels;
SARC	cis	rs473651	0.837	rs563458	chr2:239345613	T/A	cg21699342	chr2:239360505	ASB1	0.47	6.92	0.41	4.44e-11	Multiple system atrophy;
SARC	cis	rs6988636	1.000	rs59601467	chr8:124193488	C/T	cg23067535	chr8:124195133	FAM83A	-0.71	-5.68	-0.35	3.96e-8	Urinary uromodulin levels;
SARC	cis	rs35213789	0.887	rs6957302	chr7:69227373	G/A	cg10619644	chr7:69149951	AUTS2	-0.42	-5.66	-0.35	4.45e-8	Childhood ear infection;
SARC	cis	rs2153535	0.580	rs1034273	chr6:8468145	A/G	cg23788917	chr6:8435910	SLC35B3	0.64	8.39	0.48	4.57e-15	Motion sickness;
SARC	cis	rs892961	0.932	rs7223768	chr17:75410521	G/A	cg05865280	chr17:75406074	SEPT9	0.56	8.36	0.48	5.64e-15	Airflow obstruction;
SARC	cis	rs1153858	0.943	rs8038342	chr15:45651537	T/C	cg03999130	chr15:45571217	NA	0.39	4.97	0.31	1.27e-6	Homoarginine levels;
SARC	cis	rs11971779	0.616	rs6944244	chr7:139051186	T/C	cg23387468	chr7:139079360	LUC7L2	0.33	4.71	0.3	4.2e-6	Diisocyanate-induced asthma;
SARC	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg22857025	chr5:266934	NA	-1.04	-11.74	-0.61	2.61e-25	Breast cancer;
SARC	cis	rs13144136	0.687	rs11726388	chr4:10660245	G/A	cg10242279	chr4:10666415	CLNK	-0.42	-6.89	-0.41	5.04e-11	Resistance to antihypertensive treatment in hypertension;
SARC	cis	rs7927771	0.864	rs55927797	chr11:47446292	A/T	cg05585544	chr11:47624801	NA	-0.37	-4.92	-0.31	1.63e-6	Subjective well-being;
SARC	cis	rs6570726	0.935	rs395948	chr6:145820185	G/A	cg05347473	chr6:146136440	FBXO30	0.49	6.48	0.39	5.27e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1345301	0.609	rs56389410	chr2:102867663	C/T	cg12451869	chr2:102867685	NA	0.42	5.82	0.36	1.96e-8	Waist circumference;
SARC	cis	rs11025523	0.848	rs10833309	chr11:20378045	A/G	cg19653624	chr11:20408972	PRMT3	0.54	5.08	0.32	7.6e-7	Obesity-related traits;
SARC	cis	rs12291225	0.679	rs4756786	chr11:14285900	C/A	cg19336497	chr11:14380999	RRAS2	-0.4	-6.65	-0.4	2.07e-10	Sense of smell;
SARC	cis	rs3820928	0.874	rs1949807	chr2:227891861	A/G	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.22	-0.32	3.94e-7	Pulmonary function;
SARC	cis	rs748404	0.660	rs2467741	chr15:43742626	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.4	4.8	0.3	2.84e-6	Lung cancer;
SARC	cis	rs80130819	0.688	rs10783232	chr12:48583491	A/G	cg05342945	chr12:48394962	COL2A1	-0.52	-5.45	-0.34	1.29e-7	Prostate cancer;
SARC	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg12696929	chr3:195401817	SDHAP2	0.39	5.26	0.33	3.33e-7	Pancreatic cancer;
SARC	cis	rs9814567	1.000	rs6439484	chr3:134249899	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.1	-0.42	1.49e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs11997175	0.716	rs7460818	chr8:33816362	A/G	ch.8.33884649F	chr8:33765107	NA	0.48	6.28	0.38	1.68e-9	Body mass index;
SARC	cis	rs1707322	1.000	rs785507	chr1:46541558	C/T	cg06784218	chr1:46089804	CCDC17	-0.37	-6.41	-0.39	7.88e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs72781680	1.000	rs12616985	chr2:24165511	A/C	cg08917208	chr2:24149416	ATAD2B	0.77	7.19	0.43	8.94e-12	Lymphocyte counts;
SARC	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg11764359	chr7:65958608	NA	-0.63	-7.67	-0.45	4.55e-13	Aortic root size;
SARC	cis	rs34172651	0.917	rs12599173	chr16:24823619	T/C	cg00152838	chr16:24741724	TNRC6A	-0.4	-4.91	-0.31	1.74e-6	Intelligence (multi-trait analysis);
SARC	cis	rs11677370	0.533	rs12711971	chr2:3820821	G/C	cg17052675	chr2:3827356	NA	-0.5	-5.77	-0.35	2.57e-8	Type 2 diabetes;
SARC	cis	rs849898	1	rs849898	chr1:228153917	A/G	cg02753203	chr1:228287806	NA	-0.69	-9.91	-0.54	1.49e-19	Parkinson's disease;
SARC	cis	rs6466055	0.645	rs4730073	chr7:104855871	A/C	cg04380332	chr7:105027541	SRPK2	-0.42	-5.14	-0.32	5.82e-7	Schizophrenia;
SARC	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg06212747	chr3:49208901	KLHDC8B	0.68	9.04	0.51	6.29e-17	Parkinson's disease;
SARC	cis	rs6121246	0.633	rs6060986	chr20:30426297	G/A	cg13852791	chr20:30311386	BCL2L1	0.85	10.66	0.57	7.36e-22	Mean corpuscular hemoglobin;
SARC	cis	rs4555082	1.000	rs4555082	chr14:105758964	C/T	cg13114125	chr14:105738426	BRF1	-0.8	-11.76	-0.61	2.32e-25	Mean platelet volume;Platelet distribution width;
SARC	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg21747090	chr2:27597821	SNX17	-0.54	-7.52	-0.44	1.16e-12	Total body bone mineral density;
SARC	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg18876405	chr7:65276391	NA	-0.46	-5.15	-0.32	5.63e-7	Aortic root size;
SARC	cis	rs2645694	0.626	rs2703118	chr4:77823672	A/G	cg06046430	chr4:77819534	ANKRD56	0.54	7.98	0.46	6.82e-14	Emphysema distribution in smoking;
SARC	cis	rs1008375	0.932	rs2302394	chr4:17641188	A/G	cg02297831	chr4:17616191	MED28	0.48	6.09	0.37	4.55e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs3733585	0.746	rs4318650	chr4:10016868	T/C	cg11266682	chr4:10021025	SLC2A9	0.39	6.79	0.41	9.41e-11	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs6988636	0.579	rs28528232	chr8:124189308	G/A	cg23067535	chr8:124195133	FAM83A	-0.69	-5.46	-0.34	1.24e-7	Urinary uromodulin levels;
SARC	cis	rs17030434	0.813	rs11732480	chr4:154665733	C/A	cg14289246	chr4:154710475	SFRP2	-0.63	-6.37	-0.39	9.91e-10	Electrocardiographic conduction measures;
SARC	cis	rs9840812	0.655	rs4452981	chr3:136307767	A/G	cg15507776	chr3:136538369	TMEM22	0.49	5.46	0.34	1.21e-7	Fibrinogen levels;
SARC	cis	rs3126085	0.877	rs4845742	chr1:152183949	G/A	cg26876637	chr1:152193138	HRNR	0.47	5.39	0.33	1.7e-7	Atopic dermatitis;
SARC	trans	rs61931739	0.517	rs1586409	chr12:34046614	C/A	cg26384229	chr12:38710491	ALG10B	0.75	10.56	0.57	1.44e-21	Morning vs. evening chronotype;
SARC	cis	rs3820928	0.967	rs12622456	chr2:227768868	G/A	cg11843606	chr2:227700838	RHBDD1	-0.55	-7.04	-0.42	2.11e-11	Pulmonary function;
SARC	cis	rs7681440	0.801	rs1372513	chr4:90790237	G/A	cg06632027	chr4:90757378	SNCA	0.39	5.4	0.33	1.68e-7	Dementia with Lewy bodies;
SARC	cis	rs2832191	0.550	rs66484040	chr21:30511691	G/A	cg24692254	chr21:30365293	RNF160	-0.68	-8.19	-0.47	1.73e-14	Dental caries;
SARC	cis	rs2290159	0.800	rs9849807	chr3:12675026	A/G	cg23032965	chr3:12705835	RAF1	0.78	8.68	0.49	6.81e-16	Cholesterol, total;
SARC	cis	rs2832191	0.791	rs2251517	chr21:30531951	T/G	cg08807101	chr21:30365312	RNF160	0.89	13.31	0.66	1.86e-30	Dental caries;
SARC	cis	rs2658782	0.789	rs2658776	chr11:93147927	A/G	cg15737290	chr11:93063684	CCDC67	0.69	7.58	0.44	8.39e-13	Pulmonary function decline;
SARC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg01238044	chr22:24384105	GSTT1	-0.73	-9.38	-0.52	5.9e-18	Liver enzyme levels (gamma-glutamyl transferase);
SARC	trans	rs7824557	0.603	rs2736278	chr8:11219781	C/T	cg15556689	chr8:8085844	FLJ10661	0.51	6.34	0.38	1.2e-9	Retinal vascular caliber;
SARC	cis	rs4689388	0.890	rs4481292	chr4:6298375	C/T	cg25554036	chr4:6271136	WFS1	0.39	6.39	0.39	8.85e-10	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs9911578	0.935	rs12948039	chr17:57045184	C/T	cg05425664	chr17:57184151	TRIM37	-0.55	-6.73	-0.4	1.34e-10	Intelligence (multi-trait analysis);
SARC	trans	rs61931739	0.513	rs1608908	chr12:33895389	C/A	cg26384229	chr12:38710491	ALG10B	0.69	9.44	0.53	4.15e-18	Morning vs. evening chronotype;
SARC	cis	rs10782582	0.593	rs1412717	chr1:76125471	C/T	cg03433033	chr1:76189801	ACADM	-0.4	-5.23	-0.32	3.85e-7	Daytime sleep phenotypes;
SARC	cis	rs7625806	0.864	rs6762863	chr3:38100293	T/G	cg15121877	chr3:38081287	DLEC1	0.35	4.84	0.3	2.4e-6	Carotid intima media thickness;
SARC	cis	rs6060717	0.536	rs6060676	chr20:34498551	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-5.56	-0.34	7.49e-8	Hip circumference adjusted for BMI;
SARC	cis	rs1448094	0.511	rs7967183	chr12:86216845	T/G	cg00310523	chr12:86230176	RASSF9	0.32	5.11	0.32	6.65e-7	Major depressive disorder;
SARC	cis	rs11249608	0.548	rs34881171	chr5:178451932	C/T	cg21905437	chr5:178450457	ZNF879	0.58	7.88	0.46	1.27e-13	Pubertal anthropometrics;
SARC	cis	rs8067545	0.750	rs7208025	chr17:19997870	T/C	cg13482628	chr17:19912719	NA	0.52	7.09	0.42	1.6e-11	Schizophrenia;
SARC	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg14773178	chr5:1868261	NA	0.36	5.53	0.34	8.61e-8	Cardiovascular disease risk factors;
SARC	cis	rs921968	0.643	rs585859	chr2:219383121	C/T	cg02176678	chr2:219576539	TTLL4	0.38	5.72	0.35	3.21e-8	Mean corpuscular hemoglobin concentration;
SARC	cis	rs981844	0.767	rs6857738	chr4:154689140	A/C	cg14289246	chr4:154710475	SFRP2	-0.61	-7.22	-0.43	7.2e-12	Response to statins (LDL cholesterol change);
SARC	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg08662619	chr6:150070041	PCMT1	0.34	4.77	0.3	3.28e-6	Lung cancer;
SARC	cis	rs911555	0.713	rs1107070	chr14:103970508	G/T	cg24130564	chr14:104152367	KLC1	0.49	5.64	0.35	4.92e-8	Intelligence (multi-trait analysis);
SARC	cis	rs3771570	1.000	rs56052835	chr2:242243251	T/G	cg21155796	chr2:242212141	HDLBP	0.63	5.48	0.34	1.09e-7	Prostate cancer;
SARC	cis	rs7945705	0.747	rs2653605	chr11:8993309	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.5	-6.99	-0.42	2.82e-11	Hemoglobin concentration;
SARC	cis	rs10463316	0.832	rs1019467	chr5:150734323	A/G	cg03212797	chr5:150827313	SLC36A1	-0.5	-6.26	-0.38	1.79e-9	Metabolite levels (Pyroglutamine);
SARC	trans	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg11693508	chr17:37793320	STARD3	0.66	6.61	0.4	2.58e-10	Bipolar disorder;
SARC	cis	rs9457247	1.000	rs4710147	chr6:167374239	G/A	cg23791538	chr6:167370224	RNASET2	0.63	8.74	0.5	4.81e-16	Crohn's disease;
SARC	cis	rs11719291	0.584	rs13080725	chr3:49076092	G/A	cg00383909	chr3:49044727	WDR6	0.78	6.77	0.41	1.04e-10	Cognitive function;
SARC	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg17279839	chr7:150038598	RARRES2	0.48	6.75	0.4	1.14e-10	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs3733585	0.699	rs4339211	chr4:9947658	C/T	cg11266682	chr4:10021025	SLC2A9	-0.38	-6.48	-0.39	5.28e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs244293	0.701	rs4793783	chr17:53025480	T/C	cg19360675	chr17:53046073	COX11;STXBP4	-0.41	-4.99	-0.31	1.2e-6	Menarche (age at onset);
SARC	trans	rs12310956	0.532	rs7979535	chr12:33947450	A/C	cg26384229	chr12:38710491	ALG10B	-0.87	-12.56	-0.64	5.5e-28	Morning vs. evening chronotype;
SARC	cis	rs9397240	0.789	rs3734320	chr6:155606460	T/A	cg07943832	chr6:155568918	TIAM2	-0.6	-5.77	-0.35	2.54e-8	Life satisfaction;
SARC	cis	rs672059	1.000	rs479994	chr1:183161729	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.51	6.95	0.41	3.54e-11	Hypertriglyceridemia;
SARC	cis	rs4423214	0.918	rs11233789	chr11:71181085	A/G	cg24826892	chr11:71159390	DHCR7	0.49	6.28	0.38	1.61e-9	Vitamin D levels;
SARC	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs734999	0.588	rs2764848	chr1:2530694	G/A	cg20673091	chr1:2541236	MMEL1	-0.33	-5.13	-0.32	5.98e-7	Ulcerative colitis;
SARC	cis	rs9368481	0.761	rs7775041	chr6:27009512	T/A	cg12292205	chr6:26970375	C6orf41	-0.44	-4.84	-0.3	2.32e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1008375	1.000	rs2315560	chr4:17677305	C/G	cg02297831	chr4:17616191	MED28	0.43	5.47	0.34	1.16e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4720575	1.000	rs4507670	chr7:47097526	C/T	cg00036614	chr7:47093842	NA	-0.46	-6.53	-0.39	4.19e-10	Angiotensin-converting enzyme inhibitor intolerance;
SARC	cis	rs778371	0.723	rs35491427	chr2:233688542	C/T	cg16596103	chr2:233749413	NGEF	0.34	5.09	0.32	7.28e-7	Schizophrenia;
SARC	cis	rs12478296	1.000	rs73007138	chr2:243007041	C/T	cg06360820	chr2:242988706	NA	-0.8	-6.08	-0.37	4.82e-9	Obesity-related traits;
SARC	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg27347728	chr4:17578864	LAP3	0.48	6.1	0.37	4.5e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg12756686	chr19:29218302	NA	0.69	9.02	0.51	7.08e-17	Methadone dose in opioid dependence;
SARC	cis	rs13314892	0.764	rs62251030	chr3:69864948	G/A	cg17445875	chr3:69859618	MITF	-0.48	-5.08	-0.32	7.89e-7	QRS complex (12-leadsum);
SARC	cis	rs1371867	0.839	rs1788186	chr8:101335686	T/C	cg11906718	chr8:101322791	RNF19A	0.66	8.65	0.49	8.33e-16	Atrioventricular conduction;
SARC	cis	rs2658782	0.789	rs2259633	chr11:93141580	C/A	cg15737290	chr11:93063684	CCDC67	0.7	7.37	0.43	2.9e-12	Pulmonary function decline;
SARC	cis	rs80130819	0.515	rs1476608	chr12:48493731	C/T	cg05342945	chr12:48394962	COL2A1	-0.58	-6.24	-0.38	2.05e-9	Prostate cancer;
SARC	cis	rs10504229	0.679	rs12375445	chr8:58040082	A/G	cg08219700	chr8:58056026	NA	0.62	6.3	0.38	1.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1707322	1.000	rs785467	chr1:46521559	A/T	cg06784218	chr1:46089804	CCDC17	-0.38	-6.77	-0.41	1.06e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	6.1	0.37	4.5e-9	Prudent dietary pattern;
SARC	cis	rs6570726	0.967	rs365515	chr6:145802833	C/T	cg05347473	chr6:146136440	FBXO30	-0.46	-6.15	-0.37	3.33e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7481584	0.924	rs12805661	chr11:3020740	C/T	cg08508325	chr11:3079039	CARS	0.23	4.87	0.3	2.09e-6	Calcium levels;
SARC	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg16606324	chr3:10149918	C3orf24	0.48	5.04	0.31	9.53e-7	Alzheimer's disease;
SARC	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg11366901	chr6:160182831	ACAT2	0.94	9.52	0.53	2.29e-18	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg05623727	chr3:50126028	RBM5	-0.33	-5.0	-0.31	1.14e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7953249	0.722	rs2255531	chr12:121414915	G/A	cg25281562	chr12:121454272	C12orf43	0.48	6.06	0.37	5.48e-9	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs2985684	0.894	rs2281837	chr14:50065359	C/G	cg04989706	chr14:50066350	PPIL5	-0.53	-5.86	-0.36	1.58e-8	Carotid intima media thickness;
SARC	cis	rs1008375	1.000	rs2315556	chr4:17670861	T/C	cg16339924	chr4:17578868	LAP3	0.64	8.48	0.49	2.6e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1865760	0.515	rs2003208	chr6:25940719	G/C	cg16482183	chr6:26056742	HIST1H1C	0.44	5.6	0.34	6.08e-8	Height;
SARC	trans	rs8073060	0.586	rs72829922	chr17:34044809	G/A	cg19694781	chr19:47549865	TMEM160	0.72	6.95	0.41	3.67e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs12291225	0.546	rs12795545	chr11:14355564	G/A	cg19336497	chr11:14380999	RRAS2	-0.45	-8.13	-0.47	2.61e-14	Sense of smell;
SARC	cis	rs17270561	0.609	rs1317817	chr6:25765377	G/A	cg17691542	chr6:26056736	HIST1H1C	0.56	6.96	0.42	3.34e-11	Iron status biomarkers;
SARC	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg11987759	chr7:65425863	GUSB	-0.38	-4.87	-0.3	2.07e-6	Calcium levels;
SARC	cis	rs950169	1.000	rs1911155	chr15:84787635	A/G	cg17507749	chr15:85114479	UBE2QP1	0.76	9.19	0.52	2.21e-17	Schizophrenia;
SARC	cis	rs7589342	0.895	rs2033008	chr2:106502585	T/A	cg16077055	chr2:106428750	NCK2	0.36	6.5	0.39	4.93e-10	Addiction;
SARC	cis	rs2075371	1.000	rs378358	chr7:133970628	A/G	cg11752832	chr7:134001865	SLC35B4	0.55	7.24	0.43	6.57e-12	Mean platelet volume;
SARC	cis	rs2046867	0.644	rs56947804	chr3:72788435	T/C	cg25664220	chr3:72788482	NA	-0.29	-4.9	-0.31	1.8e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
SARC	cis	rs67311347	1.000	rs977652	chr3:40479169	A/G	cg24209194	chr3:40518798	ZNF619	0.62	8.15	0.47	2.27e-14	Renal cell carcinoma;
SARC	cis	rs4642101	0.765	rs4321514	chr3:12825901	C/T	cg24848339	chr3:12840334	CAND2	0.32	4.94	0.31	1.49e-6	QRS complex (12-leadsum);
SARC	cis	rs41271473	0.526	rs1925720	chr1:228728377	G/C	cg16512390	chr1:228756714	NA	0.61	5.45	0.34	1.26e-7	Chronic lymphocytic leukemia;
SARC	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg11987759	chr7:65425863	GUSB	0.49	5.98	0.36	8.43e-9	Aortic root size;
SARC	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg18876405	chr7:65276391	NA	-0.43	-4.88	-0.3	1.96e-6	Aortic root size;
SARC	trans	rs66573146	1.000	rs55833486	chr4:6978729	C/A	cg07817883	chr1:32538562	TMEM39B	1.32	8.67	0.49	7.41e-16	Granulocyte percentage of myeloid white cells;
SARC	cis	rs8078723	0.510	rs11655264	chr17:38138995	G/C	cg17344932	chr17:38183730	MED24;SNORD124	0.31	5.83	0.36	1.88e-8	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs6088580	0.524	rs6088567	chr20:33263872	A/T	cg24642439	chr20:33292090	TP53INP2	-0.54	-6.65	-0.4	2.07e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs9911578	1.000	rs304299	chr17:56838472	C/G	cg05425664	chr17:57184151	TRIM37	-0.66	-8.1	-0.47	3.14e-14	Intelligence (multi-trait analysis);
SARC	cis	rs11098499	0.954	rs3733520	chr4:120423480	C/G	cg24375607	chr4:120327624	NA	0.4	4.74	0.3	3.75e-6	Corneal astigmatism;
SARC	cis	rs1355223	0.545	rs7123029	chr11:34874815	G/A	cg11622362	chr11:34938112	PDHX;APIP	0.45	5.88	0.36	1.42e-8	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs11574514	1.000	rs117417273	chr16:68299697	C/T	cg01866162	chr16:67596514	CTCF	1.11	6.51	0.39	4.48e-10	Crohn's disease;
SARC	cis	rs739401	0.611	rs494427	chr11:3048140	A/G	cg08508325	chr11:3079039	CARS	-0.31	-7.59	-0.45	7.44e-13	Longevity;
SARC	cis	rs10193935	0.901	rs72800020	chr2:42655615	A/G	cg27598129	chr2:42591480	NA	-0.37	-5.09	-0.32	7.42e-7	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9462027	0.628	rs58671447	chr6:34752351	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.85	-0.36	1.69e-8	Systemic lupus erythematosus;
SARC	trans	rs9858542	0.953	rs71324979	chr3:49619651	T/C	cg21659725	chr3:3221576	CRBN	-0.55	-6.38	-0.39	9.23e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg16049864	chr8:95962084	TP53INP1	-0.47	-7.53	-0.44	1.08e-12	Type 2 diabetes;
SARC	cis	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg14541582	chr5:601475	NA	-0.4	-4.96	-0.31	1.35e-6	Obesity-related traits;
SARC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg09373136	chr17:61933544	TCAM1	0.44	5.97	0.36	8.99e-9	Prudent dietary pattern;
SARC	cis	rs950169	0.887	rs220333	chr15:85091133	C/T	cg24253500	chr15:84953950	NA	0.38	5.52	0.34	8.99e-8	Schizophrenia;
SARC	cis	rs9660992	0.674	rs17345837	chr1:205263122	C/T	cg21545522	chr1:205238299	TMCC2	0.4	5.3	0.33	2.64e-7	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs57561814	0.826	rs116542785	chr7:22747720	G/A	cg01770232	chr7:22766155	IL6	0.62	4.95	0.31	1.4e-6	Tonsillectomy;
SARC	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.12	26.16	0.86	2.82e-71	Chronic sinus infection;
SARC	cis	rs763121	0.706	rs3827356	chr22:39064806	G/T	cg14440974	chr22:39074834	NA	0.31	4.82	0.3	2.58e-6	Menopause (age at onset);
SARC	cis	rs13191362	1.000	rs73035012	chr6:162997279	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.57	5.38	0.33	1.85e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg24531977	chr5:56204891	C5orf35	-0.56	-5.67	-0.35	4.23e-8	Initial pursuit acceleration;
SARC	cis	rs4971059	0.654	rs10157801	chr1:155120012	A/G	cg22049894	chr1:155113146	DPM3	0.41	5.17	0.32	4.96e-7	Breast cancer;
SARC	cis	rs986417	0.901	rs6573314	chr14:60972045	C/T	cg27398547	chr14:60952738	C14orf39	0.99	9.02	0.51	6.89e-17	Gut microbiota (bacterial taxa);
SARC	cis	rs67311347	0.955	rs6773383	chr3:40377412	A/T	cg09455208	chr3:40491958	NA	0.39	6.12	0.37	3.94e-9	Renal cell carcinoma;
SARC	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg06618935	chr21:46677482	NA	-0.41	-5.36	-0.33	2.03e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs36093844	0.698	rs79435802	chr11:85585206	T/C	cg15359163	chr5:122429178	PRDM6	-0.53	-6.31	-0.38	1.43e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs9788682	0.747	rs2568499	chr15:78722359	T/C	cg06917634	chr15:78832804	PSMA4	0.53	5.34	0.33	2.16e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs6540556	0.954	rs10489342	chr1:209935778	A/G	cg05527609	chr1:210001259	C1orf107	-0.58	-5.95	-0.36	9.56e-9	Red blood cell count;
SARC	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.31	-0.56	9.06e-21	Chronic sinus infection;
SARC	cis	rs9911578	1.000	rs3744109	chr17:56594197	C/T	cg05425664	chr17:57184151	TRIM37	0.63	7.8	0.45	2.08e-13	Intelligence (multi-trait analysis);
SARC	cis	rs7216064	0.953	rs62086044	chr17:65970837	G/T	cg12091567	chr17:66097778	LOC651250	-0.63	-6.53	-0.39	4.12e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs35110281	0.720	rs162400	chr21:44950305	A/C	cg21573476	chr21:45109991	RRP1B	-0.52	-7.87	-0.46	1.3e-13	Mean corpuscular volume;
SARC	cis	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg22496380	chr5:211416	CCDC127	0.79	8.33	0.48	7.05e-15	Breast cancer;
SARC	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg10523679	chr1:76189770	ACADM	-0.43	-5.31	-0.33	2.61e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9868809	0.505	rs9811027	chr3:48725014	G/C	cg06212747	chr3:49208901	KLHDC8B	-0.6	-5.51	-0.34	9.39e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg04277193	chr17:41438351	NA	0.44	4.73	0.3	3.83e-6	Menopause (age at onset);
SARC	cis	rs1874564	1.000	rs2703145	chr4:77856215	G/T	cg00874691	chr4:77867684	NA	-0.37	-5.09	-0.32	7.43e-7	Papillary thyroid cancer;Differentiated thyroid cancer;
SARC	cis	rs9467773	0.935	rs11752946	chr6:26560364	C/A	cg11502198	chr6:26597334	ABT1	0.42	4.91	0.31	1.75e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7927771	0.832	rs4752994	chr11:47411065	A/T	cg20307385	chr11:47447363	PSMC3	0.58	7.37	0.43	2.98e-12	Subjective well-being;
SARC	cis	rs57994353	0.578	rs10448340	chr9:139320069	A/C	cg14169450	chr9:139327907	INPP5E	0.38	4.86	0.3	2.18e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs2120243	0.539	rs4640512	chr3:157120066	C/T	cg24825693	chr3:157122686	VEPH1	-0.46	-6.44	-0.39	6.67e-10	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs8027181	0.839	rs62017600	chr15:73072236	T/A	cg25996835	chr15:72978165	BBS4;HIGD2B	0.43	5.63	0.35	5.27e-8	Triglyceride levels;
SARC	cis	rs6088580	0.524	rs6088567	chr20:33263872	A/T	cg07148914	chr20:33460835	GGT7	-0.42	-5.16	-0.32	5.4e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs9359856	0.510	rs2768936	chr6:90441851	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.53	-4.85	-0.3	2.25e-6	Bipolar disorder;
SARC	cis	rs1865760	0.566	rs10807006	chr6:26048752	C/A	cg18357526	chr6:26021779	HIST1H4A	0.42	5.29	0.33	2.84e-7	Height;
SARC	cis	rs11997175	0.624	rs4526317	chr8:33682936	T/A	ch.8.33884649F	chr8:33765107	NA	0.62	8.36	0.48	5.9e-15	Body mass index;
SARC	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg13393036	chr8:95962371	TP53INP1	-0.39	-6.75	-0.4	1.13e-10	Type 2 diabetes;
SARC	cis	rs1267303	0.682	rs1998545	chr1:46954587	C/T	cg22795216	chr1:47078649	MOBKL2C	-0.46	-5.53	-0.34	8.37e-8	Monobrow;
SARC	cis	rs8067354	0.789	rs4622571	chr17:57884397	T/A	cg13753209	chr17:57696993	CLTC	0.52	6.52	0.39	4.36e-10	Hemoglobin concentration;
SARC	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.85	12.14	0.62	1.29e-26	Chronic sinus infection;
SARC	cis	rs10911232	0.507	rs4129857	chr1:183004547	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.32	0.56	8.28e-21	Hypertriglyceridemia;
SARC	cis	rs12824058	0.831	rs4759655	chr12:130815740	A/G	cg26677194	chr12:130822605	PIWIL1	-0.5	-6.93	-0.41	4.15e-11	Menopause (age at onset);
SARC	cis	rs523522	0.924	rs11065150	chr12:120958875	T/G	cg12219531	chr12:120966889	COQ5	0.84	11.24	0.59	1.05e-23	High light scatter reticulocyte count;
SARC	cis	rs897080	0.552	rs698793	chr2:44685685	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	5.68	0.35	3.99e-8	Height;
SARC	cis	rs870825	0.616	rs6818447	chr4:185650154	G/A	cg04058563	chr4:185651563	MLF1IP	0.8	11.37	0.6	3.9e-24	Blood protein levels;
SARC	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg05535760	chr7:792225	HEATR2	0.84	8.32	0.48	7.31e-15	Cerebrospinal P-tau181p levels;
SARC	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg22974920	chr21:40686053	BRWD1	-0.44	-4.83	-0.3	2.45e-6	Cognitive function;
SARC	cis	rs7481584	0.624	rs451060	chr11:3056389	G/A	cg08508325	chr11:3079039	CARS	0.21	4.76	0.3	3.38e-6	Calcium levels;
SARC	cis	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg03060546	chr3:49711283	APEH	0.74	10.7	0.57	5.32e-22	Resting heart rate;
SARC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg06873352	chr17:61820015	STRADA	0.53	6.89	0.41	5.29e-11	Prudent dietary pattern;
SARC	cis	rs7044106	0.791	rs10760116	chr9:123494681	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.59	0.53	1.39e-18	Hip circumference adjusted for BMI;
SARC	cis	rs7647973	0.961	rs4955430	chr3:49378088	G/A	cg06212747	chr3:49208901	KLHDC8B	0.58	6.0	0.37	7.54e-9	Menarche (age at onset);
SARC	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg18230493	chr5:56204884	C5orf35	0.5	4.98	0.31	1.24e-6	Initial pursuit acceleration;
SARC	cis	rs6542838	0.641	rs6741166	chr2:99534926	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-5.17	-0.32	5.02e-7	Fear of minor pain;
SARC	cis	rs2033711	0.654	rs734380	chr19:58898963	A/C	cg25952890	chr19:58913133	NA	0.35	4.74	0.3	3.65e-6	Uric acid clearance;
SARC	cis	rs13082711	0.911	rs7650165	chr3:27462440	C/T	cg02860705	chr3:27208620	NA	0.44	5.82	0.36	1.89e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs6912958	0.703	rs6903219	chr6:88096498	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.35	6.03	0.37	6.47e-9	Monocyte percentage of white cells;
SARC	cis	rs6674176	0.597	rs6671164	chr1:44403489	G/T	cg12908607	chr1:44402522	ARTN	-0.43	-7.4	-0.44	2.48e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg24209194	chr3:40518798	ZNF619	0.66	7.88	0.46	1.28e-13	Renal cell carcinoma;
SARC	cis	rs2425143	1.000	rs11699044	chr20:34312713	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.57	-5.07	-0.32	8.1e-7	Blood protein levels;
SARC	cis	rs1003719	0.679	rs2835638	chr21:38534533	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.48	-0.53	3.11e-18	Eye color traits;
SARC	cis	rs17401966	1.000	rs35837142	chr1:10322358	C/G	cg15208524	chr1:10270712	KIF1B	0.58	6.52	0.39	4.26e-10	Hepatocellular carcinoma;
SARC	cis	rs5762813	0.560	rs5762823	chr22:29220758	C/G	cg15103426	chr22:29168792	CCDC117	0.61	5.94	0.36	1.03e-8	Hematocrit;Hemoglobin concentration;
SARC	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg20102877	chr2:27665638	KRTCAP3	-0.36	-4.93	-0.31	1.59e-6	Total body bone mineral density;
SARC	cis	rs12950390	0.853	rs12450733	chr17:45855404	A/G	cg24803719	chr17:45855879	NA	-0.47	-7.75	-0.45	2.9e-13	IgG glycosylation;
SARC	cis	rs854765	0.583	rs6502627	chr17:17849671	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.44	5.61	0.34	5.84e-8	Total body bone mineral density;
SARC	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg07648498	chr16:89883185	FANCA	0.44	5.67	0.35	4.19e-8	Vitiligo;
SARC	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg04277193	chr17:41438351	NA	0.45	4.84	0.3	2.37e-6	Menopause (age at onset);
SARC	cis	rs4810685	0.816	rs1316709	chr20:46407509	C/T	cg08288986	chr20:46415360	SULF2	-0.44	-5.19	-0.32	4.68e-7	Attention deficit hyperactivity disorder (time to onset);
SARC	cis	rs9894429	0.716	rs7405578	chr17:79588306	C/A	cg21984481	chr17:79567631	NPLOC4	-0.35	-4.77	-0.3	3.25e-6	Eye color traits;
SARC	cis	rs7772486	0.790	rs11760	chr6:146205973	G/T	cg23711669	chr6:146136114	FBXO30	0.8	12.61	0.64	3.91e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7236492	0.532	rs8090536	chr18:77195553	C/T	cg15644404	chr18:77186268	NFATC1	-0.49	-5.57	-0.34	6.84e-8	Inflammatory bowel disease;Crohn's disease;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg16600432	chr14:64970085	ZBTB1;ZBTB25	0.49	7.02	0.42	2.43e-11	Chemerin levels;
SARC	cis	rs7666738	0.687	rs6839454	chr4:99073914	T/C	cg05340658	chr4:99064831	C4orf37	0.58	7.46	0.44	1.69e-12	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg03351412	chr1:154909251	PMVK	0.64	8.15	0.47	2.17e-14	Prostate cancer;
SARC	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.0	12.14	0.62	1.28e-26	Platelet count;
SARC	cis	rs910316	1.000	rs10143132	chr14:75525850	G/A	cg06637938	chr14:75390232	RPS6KL1	0.57	8.13	0.47	2.57e-14	Height;
SARC	cis	rs4891159	0.584	rs2848958	chr18:74157068	C/T	cg24786174	chr18:74118243	ZNF516	0.7	11.23	0.59	1.11e-23	Longevity;
SARC	cis	rs208520	0.690	rs12213561	chr6:66705646	T/C	cg07460842	chr6:66804631	NA	1.06	14.43	0.69	3.63e-34	Exhaled nitric oxide output;
SARC	cis	rs2230307	0.536	rs56215716	chr1:100447486	G/A	cg24955406	chr1:100503596	HIAT1	0.66	6.54	0.39	3.77e-10	Carotid intima media thickness;
SARC	cis	rs7312774	0.748	rs12308071	chr12:107314539	T/A	cg16260113	chr12:107380972	MTERFD3	0.68	5.8	0.35	2.2e-8	Severe influenza A (H1N1) infection;
SARC	cis	rs992157	0.731	rs1399132	chr2:219159770	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.62	8.66	0.49	8.21e-16	Colorectal cancer;
SARC	cis	rs1707322	1.000	rs1707337	chr1:46508769	A/G	cg03146154	chr1:46216737	IPP	-0.47	-5.67	-0.35	4.22e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs11098499	0.954	rs11722872	chr4:120233030	G/C	cg25214090	chr10:38739885	LOC399744	0.55	7.06	0.42	1.87e-11	Corneal astigmatism;
SARC	cis	rs2836974	0.565	rs2836939	chr21:40578546	C/T	cg17971929	chr21:40555470	PSMG1	0.68	6.0	0.37	7.45e-9	Cognitive function;
SARC	cis	rs11509153	0.565	rs6415232	chr7:12257938	A/G	cg23422036	chr7:12250390	TMEM106B	0.47	6.03	0.37	6.26e-9	Residual cognition;
SARC	cis	rs73635312	0.778	rs74814866	chr10:8942802	G/A	cg24467326	chr10:9646929	NA	0.56	4.88	0.3	1.95e-6	Basal cell carcinoma;
SARC	cis	rs2290159	0.948	rs5746255	chr3:12624321	A/G	cg23032965	chr3:12705835	RAF1	0.66	6.93	0.41	4.14e-11	Cholesterol, total;
SARC	cis	rs9616064	0.853	rs7284865	chr22:46996529	C/T	cg05621596	chr22:47072043	GRAMD4	-0.36	-4.73	-0.3	3.9e-6	Urate levels in obese individuals;
SARC	cis	rs6831352	0.918	rs34876213	chr4:100062216	G/A	cg12011299	chr4:100065546	ADH4	-0.34	-5.67	-0.35	4.2e-8	Alcohol dependence;
SARC	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg13877915	chr19:58951672	ZNF132	0.63	9.34	0.52	7.9e-18	Uric acid clearance;
SARC	cis	rs9303401	0.659	rs7216648	chr17:56790858	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	12.31	0.63	3.57e-27	Cognitive test performance;
SARC	cis	rs240764	0.621	rs6925840	chr6:101209386	C/T	cg09795085	chr6:101329169	ASCC3	-0.5	-6.74	-0.4	1.24e-10	Neuroticism;
SARC	cis	rs17376456	0.569	rs7732578	chr5:93410244	C/T	cg25358565	chr5:93447407	FAM172A	-0.85	-9.98	-0.55	9.16e-20	Diabetic retinopathy;
SARC	cis	rs1008375	0.897	rs6820164	chr4:17630115	G/A	cg02297831	chr4:17616191	MED28	0.48	6.13	0.37	3.65e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4238585	0.583	rs4238579	chr16:20212797	C/T	cg05160554	chr16:19468264	TMC5	0.28	4.76	0.3	3.38e-6	Body mass index;
SARC	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	23.01	0.83	6.44e-62	Chronic sinus infection;
SARC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.98	11.25	0.59	9.74e-24	Platelet count;
SARC	cis	rs2985684	0.948	rs2985685	chr14:50101370	G/A	cg04989706	chr14:50066350	PPIL5	-0.53	-5.57	-0.34	6.93e-8	Carotid intima media thickness;
SARC	cis	rs2933343	1.000	rs789227	chr3:128600585	C/G	cg24203234	chr3:128598194	ACAD9	0.53	5.93	0.36	1.11e-8	IgG glycosylation;
SARC	cis	rs6500602	0.647	rs1659497	chr16:4594635	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.31	-5.07	-0.32	8.01e-7	Schizophrenia;
SARC	cis	rs6834538	1.000	rs6816676	chr4:113483843	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.45	5.4	0.33	1.62e-7	Free thyroxine concentration;
SARC	cis	rs72781680	1.000	rs12617839	chr2:24166277	A/T	cg08917208	chr2:24149416	ATAD2B	0.78	7.36	0.43	3.09e-12	Lymphocyte counts;
SARC	cis	rs897080	0.515	rs1067368	chr2:44654889	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.58	0.4	3.06e-10	Height;
SARC	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg11644478	chr21:40555479	PSMG1	1.03	12.85	0.64	6.54e-29	Cognitive function;
SARC	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg03213289	chr20:61660250	NA	-0.4	-5.34	-0.33	2.21e-7	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs910316	0.737	rs175043	chr14:75471803	G/A	cg11812906	chr14:75593930	NEK9	-0.74	-9.63	-0.53	1.11e-18	Height;
SARC	cis	rs6582630	0.502	rs11181214	chr12:38298313	C/A	cg26384229	chr12:38710491	ALG10B	0.85	12.48	0.63	1.01e-27	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs17345786	1.000	rs11715368	chr3:101336380	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.49	5.41	0.33	1.54e-7	Colonoscopy-negative controls vs population controls;
SARC	cis	rs36051895	0.658	rs62541531	chr9:5011795	C/T	cg02405213	chr9:5042618	JAK2	-0.5	-5.9	-0.36	1.24e-8	Pediatric autoimmune diseases;
SARC	cis	rs6121246	0.528	rs6060252	chr20:30191084	A/G	cg21427119	chr20:30132790	HM13	-0.48	-5.29	-0.33	2.84e-7	Mean corpuscular hemoglobin;
SARC	cis	rs854765	0.583	rs7213225	chr17:17869111	T/C	cg04398451	chr17:18023971	MYO15A	-0.41	-5.72	-0.35	3.2e-8	Total body bone mineral density;
SARC	cis	rs2952156	0.883	rs2941505	chr17:37832704	A/G	cg20243544	chr17:37824526	PNMT	0.54	7.21	0.43	7.62e-12	Asthma;
SARC	cis	rs11731606	0.508	rs56943028	chr4:95285813	T/C	cg00507259	chr4:95128692	SMARCAD1	0.56	5.41	0.33	1.59e-7	Mean platelet volume;
SARC	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg08219700	chr8:58056026	NA	0.64	6.4	0.39	8.64e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9462027	0.628	rs6919654	chr6:34810739	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-6.05	-0.37	5.63e-9	Systemic lupus erythematosus;
SARC	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg11062466	chr8:58055876	NA	0.7	6.14	0.37	3.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg03161606	chr19:29218774	NA	0.47	6.76	0.4	1.09e-10	Methadone dose in opioid dependence;
SARC	cis	rs6963495	0.651	rs3892298	chr7:105152187	A/G	cg19920283	chr7:105172520	RINT1	0.62	5.15	0.32	5.67e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs6912958	0.558	rs9444530	chr6:88343318	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.46	6.12	0.37	3.89e-9	Monocyte percentage of white cells;
SARC	cis	rs4927850	0.794	rs13070153	chr3:195741185	A/T	cg18569988	chr3:195679450	NA	0.32	4.75	0.3	3.62e-6	Pancreatic cancer;
SARC	cis	rs2952156	0.883	rs12150603	chr17:37834715	G/A	cg00129232	chr17:37814104	STARD3	-0.71	-10.12	-0.55	3.4e-20	Asthma;
SARC	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg08677398	chr8:58056175	NA	0.45	5.15	0.32	5.51e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg24846343	chr22:24311635	DDTL	-0.49	-6.5	-0.39	4.71e-10	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg08280861	chr8:58055591	NA	0.61	5.96	0.36	9.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg12463550	chr7:65579703	CRCP	0.66	5.05	0.31	9.09e-7	Diabetic kidney disease;
SARC	trans	rs3808502	0.526	rs7843987	chr8:11422130	T/C	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.47	-0.39	5.73e-10	Neuroticism;
SARC	cis	rs6429082	0.871	rs9662392	chr1:235576949	G/T	cg26050004	chr1:235667680	B3GALNT2	-0.4	-5.19	-0.32	4.6e-7	Adiposity;
SARC	cis	rs1008375	0.966	rs4235391	chr4:17696409	A/G	cg16339924	chr4:17578868	LAP3	0.52	6.64	0.4	2.24e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg20965017	chr5:231967	SDHA	-0.55	-5.26	-0.33	3.23e-7	Breast cancer;
SARC	cis	rs7264396	0.635	rs6060675	chr20:34493614	C/T	cg12579300	chr20:34535607	PHF20	-0.41	-4.86	-0.3	2.18e-6	Total cholesterol levels;
SARC	cis	rs9612	0.948	rs12609587	chr19:44268654	T/C	cg08581076	chr19:44259116	C19orf61	0.69	8.35	0.48	5.98e-15	Exhaled nitric oxide output;
SARC	cis	rs2732480	0.537	rs1061986	chr12:48736439	T/C	cg21466736	chr12:48725269	NA	-0.33	-5.18	-0.32	4.83e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs734999	0.545	rs28568531	chr1:2555640	T/A	cg20673091	chr1:2541236	MMEL1	0.33	5.06	0.31	8.3e-7	Ulcerative colitis;
SARC	cis	rs523522	0.962	rs4767903	chr12:120930046	G/A	cg12219531	chr12:120966889	COQ5	0.82	11.15	0.59	1.99e-23	High light scatter reticulocyte count;
SARC	trans	rs11098499	0.738	rs72918577	chr4:120326701	G/A	cg25214090	chr10:38739885	LOC399744	0.54	7.09	0.42	1.56e-11	Corneal astigmatism;
SARC	cis	rs12134245	0.776	rs12125947	chr1:91990487	T/C	cg25838465	chr1:92012736	NA	-0.68	-9.85	-0.54	2.33e-19	Breast cancer;
SARC	cis	rs2645694	0.626	rs2703126	chr4:77819842	T/C	cg18351406	chr4:77819688	ANKRD56	0.45	6.24	0.38	2.07e-9	Emphysema distribution in smoking;
SARC	cis	rs1707322	0.721	rs12043945	chr1:46106922	T/A	cg03146154	chr1:46216737	IPP	0.52	6.18	0.38	2.82e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9810089	0.802	rs833861	chr3:136231067	T/A	cg15507776	chr3:136538369	TMEM22	0.45	5.03	0.31	9.76e-7	Gestational age at birth (child effect);
SARC	cis	rs644799	0.965	rs607039	chr11:95547086	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.7	9.55	0.53	1.87e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs763121	0.853	rs5750677	chr22:39147715	C/T	cg21395723	chr22:39101663	GTPBP1	0.55	6.23	0.38	2.13e-9	Menopause (age at onset);
SARC	cis	rs9309473	0.898	rs10170786	chr2:73812988	C/T	cg07208825	chr2:73871855	ALMS1P	0.32	4.77	0.3	3.19e-6	Metabolite levels;
SARC	cis	rs72945132	0.882	rs66989619	chr11:70202127	G/C	cg05964544	chr11:70165517	PPFIA1	-0.57	-5.46	-0.34	1.19e-7	Coronary artery disease;
SARC	cis	rs939574	1.000	rs45488900	chr2:220116509	G/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.63	5.01	0.31	1.09e-6	Platelet distribution width;
SARC	cis	rs9814567	0.752	rs6779326	chr3:134330027	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.51	-6.61	-0.4	2.53e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7819412	0.540	rs11777355	chr8:11044689	A/G	cg12395012	chr8:11607386	GATA4	0.33	5.58	0.34	6.74e-8	Triglycerides;
SARC	cis	rs7255045	0.788	rs8110185	chr19:12959827	T/A	cg21491176	chr19:12958399	MAST1	-0.34	-4.74	-0.3	3.79e-6	Mean corpuscular volume;
SARC	cis	rs7847628	0.765	rs7026635	chr9:123550027	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.53	-5.61	-0.35	5.65e-8	Birth weight;
SARC	cis	rs870825	0.929	rs72689265	chr4:185590982	A/G	cg04058563	chr4:185651563	MLF1IP	0.79	8.8	0.5	3.22e-16	Blood protein levels;
SARC	cis	rs7729447	0.776	rs58739438	chr5:32693994	G/C	cg16267343	chr5:32710456	NPR3	0.65	8.59	0.49	1.24e-15	Blood pressure;
SARC	cis	rs9905704	0.671	rs28709536	chr17:57008912	C/A	cg12560992	chr17:57184187	TRIM37	0.4	4.8	0.3	2.88e-6	Testicular germ cell tumor;
SARC	trans	rs2727020	0.554	rs2866490	chr11:49425463	A/G	cg15704280	chr7:45808275	SEPT13	-0.72	-8.22	-0.47	1.41e-14	Coronary artery disease;
SARC	cis	rs7197653	0.586	rs55856208	chr16:68324210	A/T	cg05110241	chr16:68378359	PRMT7	-0.65	-5.62	-0.35	5.33e-8	Magnesium levels;
SARC	cis	rs7959452	0.535	rs11615712	chr12:69619736	A/T	cg14784868	chr12:69753453	YEATS4	-0.36	-4.76	-0.3	3.43e-6	Blood protein levels;
SARC	cis	rs2652822	0.935	rs12148069	chr15:63443792	A/T	cg02713581	chr15:63449717	RPS27L	0.71	9.57	0.53	1.67e-18	Metabolic traits;
SARC	cis	rs7127900	0.583	rs11043147	chr11:2234169	C/G	cg25635251	chr11:2234043	NA	0.48	6.91	0.41	4.5e-11	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
SARC	cis	rs763121	0.853	rs5750662	chr22:39072472	G/A	cg06022373	chr22:39101656	GTPBP1	0.85	10.65	0.57	7.52e-22	Menopause (age at onset);
SARC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.72	7.38	0.44	2.84e-12	Platelet count;
SARC	cis	rs2120019	1.000	rs7175720	chr15:75348962	C/G	cg17294928	chr15:75287854	SCAMP5	0.93	13.15	0.65	6.5e-30	Blood trace element (Zn levels);
SARC	cis	rs11155671	0.517	rs9397058	chr6:150207249	C/T	cg05036130	chr6:150231994	NA	0.29	5.05	0.31	8.9e-7	Testicular germ cell tumor;
SARC	cis	rs3780378	0.870	rs2149556	chr9:5059440	C/T	cg02405213	chr9:5042618	JAK2	-0.4	-5.1	-0.32	7.07e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
SARC	cis	rs16976116	0.901	rs8027098	chr15:55492269	C/T	cg11288833	chr15:55489084	RSL24D1	0.63	6.07	0.37	5.17e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9818758	0.607	rs13068038	chr3:49294250	C/A	cg06212747	chr3:49208901	KLHDC8B	-0.69	-5.9	-0.36	1.29e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs2115630	0.691	rs8040066	chr15:85176465	G/C	cg12501888	chr15:85177176	SCAND2	-0.51	-6.22	-0.38	2.24e-9	P wave terminal force;
SARC	cis	rs9389248	0.690	rs2072826	chr6:135253558	G/C	cg24558204	chr6:135376177	HBS1L	-0.53	-6.59	-0.4	2.86e-10	High light scatter reticulocyte percentage of red cells;
SARC	cis	rs78487399	0.808	rs7567535	chr2:43668261	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-5.69	-0.35	3.78e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs911263	0.603	rs10483807	chr14:68808824	A/G	cg18825221	chr14:68749962	RAD51L1	0.43	7.7	0.45	3.86e-13	Primary biliary cholangitis;
SARC	cis	rs1949733	1.000	rs1357481	chr4:8496221	A/T	cg11789530	chr4:8429930	ACOX3	0.82	11.01	0.59	5.6e-23	Response to antineoplastic agents;
SARC	cis	rs7833790	0.724	rs4739627	chr8:82734657	A/G	cg27398817	chr8:82754497	SNX16	-0.43	-5.42	-0.33	1.46e-7	Diastolic blood pressure;
SARC	cis	rs2180341	1.000	rs6569480	chr6:127621748	A/G	cg27446573	chr6:127587934	RNF146	1.01	14.45	0.69	3.24e-34	Breast cancer;
SARC	cis	rs12950390	0.853	rs4793647	chr17:45854090	G/C	cg03474202	chr17:45855739	NA	-0.43	-6.72	-0.4	1.4e-10	IgG glycosylation;
SARC	cis	rs2952156	0.920	rs12150298	chr17:37834541	T/C	cg20243544	chr17:37824526	PNMT	0.56	7.44	0.44	1.94e-12	Asthma;
SARC	trans	rs79976124	0.760	rs74295030	chr6:66654441	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	7.9	0.46	1.09e-13	Type 2 diabetes;
SARC	cis	rs17125944	0.686	rs2357946	chr14:53345266	G/C	cg00686598	chr14:53173677	PSMC6	-0.66	-4.82	-0.3	2.64e-6	Alzheimer's disease (late onset);
SARC	cis	rs1044826	1.000	rs3772878	chr3:139187375	T/C	cg15131784	chr3:139108705	COPB2	0.45	5.19	0.32	4.69e-7	Obesity-related traits;
SARC	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9660992	0.710	rs1172111	chr1:205232980	C/T	cg07972983	chr1:205091412	RBBP5	0.55	6.83	0.41	7.17e-11	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs9815354	0.953	rs1629462	chr3:41927452	G/C	cg03022575	chr3:42003672	ULK4	-0.56	-5.38	-0.33	1.79e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6540556	1.000	rs6540556	chr1:209936631	G/A	cg23920097	chr1:209922102	NA	-0.63	-7.08	-0.42	1.7e-11	Red blood cell count;
SARC	trans	rs17685	0.712	rs56965035	chr7:75795670	G/A	cg19862616	chr7:65841803	NCRNA00174	0.64	8.01	0.46	5.5e-14	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs2834188	0.737	rs2834179	chr21:34679731	A/G	cg04842828	chr21:34696676	IFNAR1	0.39	4.93	0.31	1.57e-6	Narcolepsy;
SARC	cis	rs3106136	0.546	rs2632417	chr4:95137542	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.47	-7.05	-0.42	2.06e-11	Capecitabine sensitivity;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg15574972	chr11:65265134	MALAT1	-0.5	-6.28	-0.38	1.68e-9	Schizophrenia;
SARC	cis	rs736801	0.964	rs17622656	chr5:131820997	A/G	cg07395648	chr5:131743802	NA	0.49	5.54	0.34	8.34e-8	Breast cancer;Mosquito bite size;
SARC	cis	rs4780401	0.755	rs8191285	chr16:11765408	A/G	cg01061890	chr16:11836724	TXNDC11	-0.46	-5.8	-0.36	2.12e-8	Rheumatoid arthritis;
SARC	cis	rs17666538	0.710	rs1703941	chr8:658447	G/A	cg07685180	chr8:600429	NA	0.62	4.84	0.3	2.36e-6	IgG glycosylation;
SARC	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg04944784	chr2:26401820	FAM59B	-0.48	-6.0	-0.37	7.54e-9	Gut microbiome composition (summer);
SARC	cis	rs360798	0.817	rs10208675	chr2:62906722	C/T	cg16915676	chr2:62734870	TMEM17	0.43	5.35	0.33	2.1e-7	Coronary artery disease;
SARC	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg05872129	chr22:39784769	NA	-0.42	-5.93	-0.36	1.06e-8	Intelligence (multi-trait analysis);
SARC	cis	rs4642101	0.535	rs55692304	chr3:12840057	C/T	cg05775895	chr3:12838266	CAND2	0.77	12.82	0.64	8.2e-29	QRS complex (12-leadsum);
SARC	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg03161606	chr19:29218774	NA	0.51	7.27	0.43	5.52e-12	Methadone dose in opioid dependence;
SARC	cis	rs963731	0.649	rs6716101	chr2:39188510	A/G	cg04010122	chr2:39346883	SOS1	-0.86	-5.53	-0.34	8.76e-8	Corticobasal degeneration;
SARC	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg22535103	chr8:58192502	C8orf71	-0.59	-6.21	-0.38	2.35e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg13902645	chr11:5959945	NA	0.48	6.25	0.38	1.89e-9	DNA methylation (variation);
SARC	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs35110281	0.837	rs2838343	chr21:45078035	C/T	cg01579765	chr21:45077557	HSF2BP	-0.32	-5.39	-0.33	1.76e-7	Mean corpuscular volume;
SARC	cis	rs9815354	0.767	rs17281182	chr3:41817263	C/T	cg03022575	chr3:42003672	ULK4	0.71	5.89	0.36	1.34e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs78456975	1.000	rs72778004	chr2:1571892	T/A	cg26248373	chr2:1572462	NA	-0.64	-6.4	-0.39	8.53e-10	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs7666738	0.830	rs9992639	chr4:98940400	G/T	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs72781680	0.612	rs33913065	chr2:24344060	T/G	cg08917208	chr2:24149416	ATAD2B	0.59	6.2	0.38	2.54e-9	Lymphocyte counts;
SARC	cis	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg11266682	chr4:10021025	SLC2A9	0.4	7.18	0.43	9.35e-12	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs17401966	0.838	rs12738317	chr1:10419663	C/T	cg15208524	chr1:10270712	KIF1B	0.47	5.58	0.34	6.71e-8	Hepatocellular carcinoma;
SARC	cis	rs2303759	0.670	rs45549132	chr19:49794028	G/T	cg22307029	chr19:49891270	CCDC155	0.59	6.62	0.4	2.47e-10	Multiple sclerosis;
SARC	cis	rs12893668	0.703	rs4906336	chr14:104033265	C/G	cg26031613	chr14:104095156	KLC1	-0.51	-5.42	-0.33	1.48e-7	Reticulocyte count;
SARC	cis	rs5167	0.505	rs7257468	chr19:45453144	C/T	cg09555818	chr19:45449301	APOC2	0.56	8.96	0.51	1.05e-16	Blood protein levels;
SARC	cis	rs11098499	0.738	rs72918577	chr4:120326701	G/A	cg09160332	chr4:120329925	NA	-0.33	-4.72	-0.3	4.08e-6	Corneal astigmatism;
SARC	cis	rs7843479	1.000	rs727694	chr8:21849962	T/C	cg17168535	chr8:21777572	XPO7	0.65	8.4	0.48	4.48e-15	Mean corpuscular volume;
SARC	cis	rs908922	0.651	rs6671924	chr1:152485830	T/C	cg09873164	chr1:152488093	CRCT1	0.64	8.3	0.48	8.7e-15	Hair morphology;
SARC	cis	rs995000	0.931	rs11207970	chr1:62915473	C/T	cg06896770	chr1:63153194	DOCK7	0.99	15.57	0.71	5.94e-38	Triglyceride levels;
SARC	cis	rs2153535	0.580	rs6912374	chr6:8456423	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	6.55	0.39	3.66e-10	Motion sickness;
SARC	cis	rs72949976	0.646	rs1441170	chr2:214033563	A/G	cg08319019	chr2:214017104	IKZF2	-0.46	-5.78	-0.35	2.32e-8	Lung cancer;Squamous cell lung carcinoma;
SARC	cis	rs986417	0.901	rs1950316	chr14:61018305	T/C	cg27398547	chr14:60952738	C14orf39	0.98	8.89	0.5	1.66e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs736801	0.891	rs11242115	chr5:131826413	G/C	cg07395648	chr5:131743802	NA	-0.48	-5.14	-0.32	5.79e-7	Breast cancer;Mosquito bite size;
SARC	cis	rs1797081	0.840	rs10904820	chr10:16848473	A/G	cg23933602	chr10:16859644	RSU1	0.79	12.28	0.63	4.8e-27	Platelet distribution width;
SARC	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-9.15	-0.51	2.85e-17	Alzheimer's disease;
SARC	cis	rs4917300	0.650	rs10094562	chr8:143072936	C/T	cg06573787	chr8:143070187	NA	0.37	5.51	0.34	9.54e-8	Amyotrophic lateral sclerosis;
SARC	cis	rs208515	0.525	rs10944859	chr6:66665197	A/G	cg07460842	chr6:66804631	NA	0.98	11.11	0.59	2.72e-23	Exhaled nitric oxide levels;
SARC	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg25072359	chr17:41440525	NA	0.49	5.69	0.35	3.8e-8	Menopause (age at onset);
SARC	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg11608241	chr8:8085544	FLJ10661	0.44	5.4	0.33	1.61e-7	Neuroticism;
SARC	cis	rs10504229	0.679	rs6474100	chr8:58031161	G/A	cg22535103	chr8:58192502	C8orf71	-0.55	-5.6	-0.34	5.89e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6723226	0.772	rs2366894	chr2:32713706	A/T	cg02381751	chr2:32503542	YIPF4	0.73	10.36	0.56	6.43e-21	Intelligence (multi-trait analysis);
SARC	cis	rs2624839	0.639	rs2526389	chr3:50192826	C/T	cg24110177	chr3:50126178	RBM5	-0.39	-4.94	-0.31	1.51e-6	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg08677398	chr8:58056175	NA	0.43	5.05	0.31	8.92e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2228479	0.850	rs11642010	chr16:89845111	T/C	cg12064134	chr16:90016061	DEF8	-0.57	-4.76	-0.3	3.48e-6	Skin colour saturation;
SARC	trans	rs1973993	0.745	rs56119386	chr1:96962215	C/T	cg10631902	chr5:14652156	NA	-0.43	-7.01	-0.42	2.57e-11	Weight;
SARC	cis	rs2859741	0.967	rs575939	chr1:37513854	T/C	cg09363841	chr1:37513479	NA	-0.29	-5.26	-0.33	3.29e-7	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
SARC	cis	rs9400467	0.506	rs80354920	chr6:111794482	T/G	cg15721981	chr6:111408429	SLC16A10	0.65	5.71	0.35	3.5e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.76	7.34	0.43	3.51e-12	Platelet count;
SARC	cis	rs6570726	0.818	rs398812	chr6:145817271	T/C	cg05347473	chr6:146136440	FBXO30	0.49	6.48	0.39	5.27e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1050631	0.564	rs8098627	chr18:33721636	T/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.59	7.17	0.43	9.69e-12	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs2425143	1.000	rs78877130	chr20:34344947	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.67	5.22	0.32	3.99e-7	Blood protein levels;
SARC	trans	rs561341	1.000	rs542132	chr17:30307193	A/T	cg20587970	chr11:113659929	NA	-1.33	-13.84	-0.67	3.4e-32	Hip circumference adjusted for BMI;
SARC	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-9.58	-0.53	1.53e-18	Chronic sinus infection;
SARC	cis	rs854765	0.583	rs4414547	chr17:17859052	G/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.43	5.52	0.34	9.04e-8	Total body bone mineral density;
SARC	cis	rs2467099	0.504	rs2608881	chr17:73936653	C/G	cg06969265	chr17:73775802	H3F3B	0.57	6.87	0.41	5.96e-11	Systolic blood pressure;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06527865	chr1:234746497	IRF2BP2	-0.52	-6.49	-0.39	5.17e-10	Smoking initiation;
SARC	cis	rs17253792	0.915	rs28375514	chr14:56179941	G/A	cg01858014	chr14:56050164	KTN1	-0.62	-4.86	-0.3	2.19e-6	Putamen volume;
SARC	trans	rs7829975	0.511	rs2955578	chr8:8137083	T/C	cg16141378	chr3:129829833	LOC729375	-0.6	-7.45	-0.44	1.85e-12	Mood instability;
SARC	cis	rs6991838	0.584	rs13268343	chr8:66543977	C/T	cg13398993	chr8:66546079	ARMC1	0.62	8.19	0.47	1.72e-14	Intelligence (multi-trait analysis);
SARC	cis	rs4243830	0.850	rs4908904	chr1:6580250	A/G	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.56	-5.12	-0.32	6.39e-7	Body mass index;
SARC	cis	rs10463554	0.927	rs158253	chr5:102405206	G/A	cg23492399	chr5:102201601	PAM	-0.51	-5.67	-0.35	4.23e-8	Parkinson's disease;
SARC	cis	rs11112613	0.775	rs10507194	chr12:105959488	G/A	cg03607813	chr12:105948248	NA	0.55	7.42	0.44	2.18e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs7512552	0.839	rs17596326	chr1:150433819	A/G	cg15654264	chr1:150340011	RPRD2	0.39	5.13	0.32	6.09e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs995000	0.524	rs61775962	chr1:63199350	A/T	cg06896770	chr1:63153194	DOCK7	-0.52	-6.71	-0.4	1.47e-10	Triglyceride levels;
SARC	cis	rs9300255	0.602	rs1716160	chr12:123700225	C/T	cg05973401	chr12:123451056	ABCB9	0.52	5.89	0.36	1.34e-8	Neutrophil percentage of white cells;
SARC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg11965913	chr1:205819406	PM20D1	0.89	14.4	0.69	4.56e-34	Menarche (age at onset);
SARC	cis	rs853679	1.000	rs6901575	chr6:28250984	G/A	cg26450541	chr6:28235208	ZNF187	0.61	5.08	0.32	7.64e-7	Depression;
SARC	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg18404041	chr3:52824283	ITIH1	-0.39	-5.68	-0.35	3.96e-8	Bipolar disorder;
SARC	cis	rs6062509	0.965	rs6062506	chr20:62352389	T/G	cg27236539	chr20:62289627	RTEL1	0.52	5.86	0.36	1.59e-8	Prostate cancer;
SARC	cis	rs1559088	0.948	rs3760893	chr19:33597930	C/A	cg17764715	chr19:33622953	WDR88	0.49	6.72	0.4	1.4e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7481584	0.961	rs729662	chr11:3028140	G/A	cg25174290	chr11:3078921	CARS	-0.52	-6.62	-0.4	2.49e-10	Calcium levels;
SARC	cis	rs7937682	0.632	rs7112886	chr11:111743232	T/C	cg09085632	chr11:111637200	PPP2R1B	0.77	10.07	0.55	4.8e-20	Primary sclerosing cholangitis;
SARC	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg06221963	chr1:154839813	KCNN3	-0.51	-8.13	-0.47	2.53e-14	Prostate cancer;
SARC	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg01324507	chr7:1177794	C7orf50	0.48	4.72	0.3	4.14e-6	Bronchopulmonary dysplasia;
SARC	cis	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg24110177	chr3:50126178	RBM5	0.38	4.83	0.3	2.43e-6	Intelligence (multi-trait analysis);
SARC	cis	rs11098499	0.954	rs11734241	chr4:120416872	A/G	cg24375607	chr4:120327624	NA	0.41	4.86	0.3	2.12e-6	Corneal astigmatism;
SARC	trans	rs6792151	0.782	rs7638225	chr3:171501494	A/G	cg16086185	chr12:133324413	ANKLE2	-0.65	-6.26	-0.38	1.87e-9	Red cell distribution width;
SARC	cis	rs9815354	0.812	rs17284313	chr3:41986787	G/T	cg03022575	chr3:42003672	ULK4	-0.72	-6.26	-0.38	1.79e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6500395	1.000	rs2129243	chr16:48646852	A/T	cg04672837	chr16:48644449	N4BP1	0.51	6.6	0.4	2.8e-10	Response to tocilizumab in rheumatoid arthritis;
SARC	trans	rs61931739	0.534	rs7302688	chr12:34235064	A/G	cg26384229	chr12:38710491	ALG10B	0.84	12.03	0.62	3.02e-26	Morning vs. evening chronotype;
SARC	trans	rs561341	0.663	rs72821936	chr17:30224068	C/G	cg20587970	chr11:113659929	NA	-0.58	-6.72	-0.4	1.39e-10	Hip circumference adjusted for BMI;
SARC	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.86	8.86	0.5	2.13e-16	Platelet count;
SARC	cis	rs240764	0.612	rs7773661	chr6:100919209	A/G	cg09795085	chr6:101329169	ASCC3	-0.4	-4.85	-0.3	2.23e-6	Neuroticism;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg04528024	chr13:111366565	ING1	0.82	5.71	0.35	3.37e-8	Obesity-related traits;
SARC	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg26119090	chr2:26468346	HADHA;HADHB	0.69	8.04	0.47	4.66e-14	Gut microbiome composition (summer);
SARC	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg23758822	chr17:41437982	NA	0.9	11.44	0.6	2.48e-24	Menopause (age at onset);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg14690181	chr5:115387984	NA	-0.6	-7.65	-0.45	5.34e-13	Height;
SARC	cis	rs73198271	0.740	rs10100066	chr8:8650393	T/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-5.49	-0.34	1.07e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs11718455	0.960	rs13059547	chr3:44004492	G/A	cg21419209	chr3:44054225	NA	-0.41	-5.02	-0.31	1.02e-6	Coronary artery disease;
SARC	cis	rs13326165	0.543	rs1769	chr3:52290550	A/G	cg01348873	chr3:52349823	DNAH1	0.54	4.77	0.3	3.22e-6	HDL cholesterol;HDL cholesterol levels;
SARC	cis	rs35213789	0.878	rs17365375	chr7:69546249	C/G	cg10619644	chr7:69149951	AUTS2	0.41	5.07	0.32	8.06e-7	Childhood ear infection;
SARC	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg15448220	chr1:150897856	SETDB1	0.47	6.25	0.38	1.94e-9	Tonsillectomy;
SARC	cis	rs4588572	0.643	rs11744479	chr5:77729220	T/G	cg11547950	chr5:77652471	NA	-0.41	-5.02	-0.31	1.02e-6	Triglycerides;
SARC	cis	rs6690583	0.697	rs10873684	chr1:85522196	T/C	cg22153463	chr1:85462885	MCOLN2	-0.62	-6.47	-0.39	5.81e-10	Serum sulfate level;
SARC	cis	rs17401966	0.898	rs61784570	chr1:10258343	C/A	cg15208524	chr1:10270712	KIF1B	0.49	5.72	0.35	3.33e-8	Hepatocellular carcinoma;
SARC	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs78487399	0.808	rs74365854	chr2:43661482	T/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-5.69	-0.35	3.88e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs7615952	0.546	rs112919177	chr3:125346070	G/A	cg05084668	chr3:125655381	ALG1L	-0.53	-5.01	-0.31	1.1e-6	Blood pressure (smoking interaction);
SARC	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg13395646	chr4:1353034	KIAA1530	-0.44	-5.46	-0.34	1.21e-7	Longevity;
SARC	cis	rs9290065	0.519	rs2121721	chr3:160685788	A/G	cg04691961	chr3:161091175	C3orf57	-0.45	-5.49	-0.34	1.05e-7	Kawasaki disease;
SARC	cis	rs9905704	0.846	rs372648	chr17:56736785	A/C	cg12560992	chr17:57184187	TRIM37	0.42	4.87	0.3	2.03e-6	Testicular germ cell tumor;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg05633190	chr21:35986746	RCAN1	-0.51	-6.39	-0.39	9.15e-10	Gallstone disease;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg26881277	chr10:112632601	PDCD4	0.49	6.3	0.38	1.48e-9	Breast cancer;
SARC	cis	rs2239547	0.603	rs9870898	chr3:53092375	A/G	cg11645453	chr3:52864694	ITIH4	0.32	4.89	0.31	1.87e-6	Schizophrenia;
SARC	cis	rs7264396	0.790	rs4519606	chr20:34324648	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	5.51	0.34	9.42e-8	Total cholesterol levels;
SARC	cis	rs9399137	0.507	rs4895437	chr6:135317354	G/A	cg24558204	chr6:135376177	HBS1L	0.61	7.94	0.46	8.39e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs2834188	1.000	rs1018741	chr21:34686345	G/A	cg04842828	chr21:34696676	IFNAR1	0.4	4.72	0.3	4e-6	Narcolepsy;
SARC	cis	rs965469	1.000	rs6051831	chr20:3373712	G/T	cg25506879	chr20:3388711	C20orf194	0.48	5.08	0.32	7.9e-7	IFN-related cytopenia;
SARC	cis	rs6088813	1.000	rs6088825	chr20:33995972	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	-0.44	-5.29	-0.33	2.85e-7	Height;
SARC	cis	rs6991838	0.800	rs28709439	chr8:66471572	G/A	cg13398993	chr8:66546079	ARMC1	0.48	6.45	0.39	6.43e-10	Intelligence (multi-trait analysis);
SARC	cis	rs12311304	1.000	rs12300553	chr12:15381210	C/T	cg08258403	chr12:15378311	NA	0.49	7.44	0.44	1.97e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs6732160	0.613	rs6546804	chr2:73385919	G/A	cg01422370	chr2:73384389	NA	0.37	5.71	0.35	3.45e-8	Intelligence (multi-trait analysis);
SARC	cis	rs12898370	0.641	rs11632999	chr15:77436995	T/G	cg17802220	chr15:77601643	NA	-0.45	-5.03	-0.31	9.89e-7	Risky sexual behaviors (alcohol dependence interaction);
SARC	cis	rs3126085	0.877	rs3126045	chr1:152256794	A/G	cg03465714	chr1:152285911	FLG	-0.45	-5.45	-0.34	1.25e-7	Atopic dermatitis;
SARC	cis	rs2952156	1.000	rs2934971	chr17:37854507	G/T	cg20243544	chr17:37824526	PNMT	0.46	5.44	0.34	1.32e-7	Asthma;
SARC	cis	rs11098499	0.866	rs12499602	chr4:120284387	T/A	cg09307838	chr4:120376055	NA	0.83	11.82	0.61	1.46e-25	Corneal astigmatism;
SARC	cis	rs2280018	0.963	rs4985147	chr16:15168760	T/C	cg07549590	chr16:15018862	NA	-0.37	-5.38	-0.33	1.79e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs739401	0.611	rs2071104	chr11:3036933	G/T	cg08508325	chr11:3079039	CARS	-0.33	-8.21	-0.47	1.53e-14	Longevity;
SARC	cis	rs6815814	0.950	rs5743571	chr4:38805489	C/T	cg02016764	chr4:38805732	TLR1	-0.42	-4.89	-0.31	1.89e-6	Breast cancer;
SARC	cis	rs9325144	0.560	rs6582539	chr12:38630097	C/T	cg26384229	chr12:38710491	ALG10B	-0.64	-8.42	-0.48	3.96e-15	Morning vs. evening chronotype;
SARC	cis	rs9788721	0.967	rs2036527	chr15:78851615	G/A	cg06917634	chr15:78832804	PSMA4	-0.52	-5.63	-0.35	5.1e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg21747090	chr2:27597821	SNX17	-0.52	-7.3	-0.43	4.56e-12	Total body bone mineral density;
SARC	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg06618935	chr21:46677482	NA	-0.38	-5.04	-0.31	9.13e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	8.88	0.5	1.83e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs3733585	0.673	rs4447861	chr4:9953940	C/T	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.94	-0.36	1.06e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs1348850	0.914	rs10170667	chr2:178336878	A/G	cg23306229	chr2:178417860	TTC30B	0.55	6.41	0.39	7.79e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs41271473	1.000	rs6665334	chr1:228868574	A/C	cg10167378	chr1:228756711	NA	0.49	4.73	0.3	3.94e-6	Chronic lymphocytic leukemia;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.51	6.27	0.38	1.74e-9	Breast cancer;
SARC	cis	rs7582720	1.000	rs72936856	chr2:203775712	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.26	0.43	5.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs9300255	0.507	rs1615350	chr12:123650335	C/T	cg00376283	chr12:123451042	ABCB9	0.59	7.09	0.42	1.62e-11	Neutrophil percentage of white cells;
SARC	cis	rs9916302	0.904	rs9892055	chr17:37510402	C/T	cg07936489	chr17:37558343	FBXL20	0.69	9.14	0.51	3.18e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs72627123	0.867	rs74395411	chr14:74478584	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.76	5.99	0.37	7.73e-9	Morning vs. evening chronotype;
SARC	cis	rs73206853	0.698	rs73191806	chr12:110899913	A/G	cg10860002	chr12:110842031	ANAPC7	0.64	5.11	0.32	6.75e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs2562456	1.000	rs2359155	chr19:21671869	C/A	cg00806126	chr19:22604979	ZNF98	0.48	4.87	0.3	2.03e-6	Pain;
SARC	cis	rs858239	0.600	rs10256359	chr7:23123877	C/T	cg23682824	chr7:23144976	KLHL7	0.67	8.83	0.5	2.59e-16	Cerebrospinal fluid biomarker levels;
SARC	cis	rs6582630	0.555	rs11181657	chr12:38381858	T/C	cg13010199	chr12:38710504	ALG10B	-0.74	-10.54	-0.57	1.7e-21	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9486719	0.656	rs6924957	chr6:96853579	G/T	cg18709589	chr6:96969512	KIAA0776	0.43	4.83	0.3	2.5e-6	Migraine;Coronary artery disease;
SARC	cis	rs9398803	0.661	rs864937	chr6:127015083	G/A	cg20229609	chr6:126660872	C6orf173	-0.34	-4.85	-0.3	2.25e-6	Male-pattern baldness;
SARC	trans	rs7824557	0.707	rs3808518	chr8:11143272	A/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-6.87	-0.41	5.81e-11	Retinal vascular caliber;
SARC	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg26513180	chr16:89883248	FANCA	0.92	15.98	0.72	2.67e-39	Vitiligo;
SARC	cis	rs7551222	0.646	rs2926536	chr1:204456983	T/G	cg20240347	chr1:204465584	NA	0.29	4.92	0.31	1.64e-6	Schizophrenia;
SARC	trans	rs7824557	0.564	rs2572392	chr8:11235605	T/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-6.99	-0.42	2.8e-11	Retinal vascular caliber;
SARC	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg12310025	chr6:25882481	NA	-0.6	-8.07	-0.47	3.73e-14	Uric acid levels;
SARC	cis	rs1865760	0.622	rs9968910	chr6:26072095	A/C	cg17691542	chr6:26056736	HIST1H1C	0.67	8.0	0.46	5.83e-14	Height;
SARC	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg24642844	chr7:1081250	C7orf50	-0.6	-6.14	-0.37	3.53e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs7000551	0.751	rs2443505	chr8:22375341	G/A	cg12081754	chr8:22256438	SLC39A14	0.57	7.97	0.46	6.84e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs2645694	0.626	rs2703140	chr4:77830057	C/G	cg06046430	chr4:77819534	ANKRD56	0.52	7.4	0.44	2.43e-12	Emphysema distribution in smoking;
SARC	cis	rs943466	1.000	rs73412140	chr6:33757014	G/T	cg04676172	chr6:33757040	LEMD2	0.45	4.77	0.3	3.23e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
SARC	cis	rs72627123	0.656	rs117145347	chr14:74564164	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.74	5.87	0.36	1.48e-8	Morning vs. evening chronotype;
SARC	cis	rs7089973	0.604	rs7920216	chr10:116611794	G/A	cg03647239	chr10:116582469	FAM160B1	0.49	6.14	0.37	3.52e-9	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs7587476	0.601	rs17489363	chr2:215674341	A/G	cg04530015	chr2:215796436	ABCA12	0.45	7.54	0.44	1.01e-12	Neuroblastoma;
SARC	cis	rs7103648	0.864	rs12801188	chr11:47388214	G/A	cg20307385	chr11:47447363	PSMC3	0.79	11.17	0.59	1.8e-23	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs11764590	0.694	rs11773643	chr7:2104063	A/G	cg21782813	chr7:2030301	MAD1L1	-0.37	-5.37	-0.33	1.86e-7	Neuroticism;
SARC	cis	rs72945132	0.882	rs56368270	chr11:70162590	A/G	cg00319359	chr11:70116639	PPFIA1	0.68	6.19	0.38	2.66e-9	Coronary artery disease;
SARC	cis	rs72781680	0.611	rs4149373	chr2:24300023	C/T	cg08917208	chr2:24149416	ATAD2B	0.62	6.36	0.38	1.05e-9	Lymphocyte counts;
SARC	cis	rs4128725	0.925	rs4326616	chr1:159436505	G/A	cg25076881	chr1:159409836	OR10J1	0.4	4.8	0.3	2.84e-6	Select biomarker traits;
SARC	cis	rs4481887	0.927	rs4603165	chr1:248473799	T/A	cg13385794	chr1:248469461	NA	0.34	5.32	0.33	2.46e-7	Common traits (Other);
SARC	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg02733842	chr7:1102375	C7orf50	-0.57	-6.94	-0.41	3.95e-11	Bronchopulmonary dysplasia;
SARC	trans	rs9650657	0.513	rs7005884	chr8:10796472	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.03	-0.42	2.24e-11	Neuroticism;
SARC	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg11062466	chr8:58055876	NA	0.62	5.8	0.36	2.15e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs921968	0.541	rs832798	chr2:219464810	G/A	cg02176678	chr2:219576539	TTLL4	0.47	7.11	0.42	1.43e-11	Mean corpuscular hemoglobin concentration;
SARC	cis	rs6988636	0.818	rs1713733	chr8:124199458	A/G	cg23067535	chr8:124195133	FAM83A	0.62	5.28	0.33	2.9e-7	Urinary uromodulin levels;
SARC	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg20607798	chr8:58055168	NA	0.56	5.27	0.33	3.12e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6449957	0.639	rs706711	chr5:67520226	G/A	cg23036683	chr5:67512108	NA	0.41	4.82	0.3	2.56e-6	Cleft lip with or without cleft palate;
SARC	cis	rs7584330	0.666	rs72620818	chr2:238354652	G/A	cg14458575	chr2:238380390	NA	0.58	6.36	0.38	1.05e-9	Prostate cancer;
SARC	cis	rs7605378	1.000	rs769954	chr2:200692159	C/G	cg23649088	chr2:200775458	C2orf69	-0.54	-6.41	-0.39	7.9e-10	Osteoporosis;
SARC	cis	rs3126085	0.935	rs74127901	chr1:152195579	G/A	cg03465714	chr1:152285911	FLG	0.5	5.77	0.35	2.53e-8	Atopic dermatitis;
SARC	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.78	7.75	0.45	2.89e-13	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs11225247	0.649	rs11605087	chr11:102225219	C/T	cg11690896	chr11:102217788	BIRC2	0.73	5.26	0.33	3.23e-7	Vein graft stenosis in coronary artery bypass grafting;
SARC	trans	rs10435719	0.867	rs62493601	chr8:11788307	C/T	cg06636001	chr8:8085503	FLJ10661	0.5	6.34	0.38	1.17e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
SARC	cis	rs11690935	1.000	rs312925	chr2:172563922	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.99	-15.67	-0.72	2.72e-38	Schizophrenia;
SARC	cis	rs7932354	0.528	rs6485739	chr11:47145072	G/A	cg03339077	chr11:47165057	C11orf49	-0.47	-6.64	-0.4	2.16e-10	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs651907	0.557	rs1031710	chr3:101463895	C/T	cg12386194	chr3:101231763	SENP7	0.48	5.74	0.35	2.96e-8	Colorectal cancer;
SARC	cis	rs67460515	0.531	rs1585483	chr3:160843111	G/A	cg04691961	chr3:161091175	C3orf57	-0.4	-4.75	-0.3	3.51e-6	Parkinson's disease;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08139833	chr11:67798212	NDUFS8	-0.5	-6.28	-0.38	1.61e-9	Smoking initiation;
SARC	cis	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg08045932	chr20:61659980	NA	0.5	6.84	0.41	7.06e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg20607798	chr8:58055168	NA	0.58	5.57	0.34	6.9e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2228479	0.717	rs2074904	chr16:89811546	A/G	cg00800038	chr16:89945340	TCF25	-0.74	-5.1	-0.32	7.08e-7	Skin colour saturation;
SARC	trans	rs208520	1.000	rs12190773	chr6:66968194	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.82	8.98	0.51	9.32e-17	Exhaled nitric oxide output;
SARC	cis	rs829883	0.714	rs249847	chr12:98867716	C/T	cg25150519	chr12:98850993	NA	0.83	13.48	0.66	5.31e-31	Colorectal adenoma (advanced);
SARC	cis	rs6429082	0.715	rs2172718	chr1:235580727	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.58	-7.55	-0.44	9.58e-13	Adiposity;
SARC	cis	rs4718428	0.672	rs36038499	chr7:66289615	A/G	cg12165864	chr7:66369176	NA	-0.43	-4.78	-0.3	3.14e-6	Corneal structure;
SARC	cis	rs1949733	0.701	rs940134	chr4:8454870	C/T	cg11789530	chr4:8429930	ACOX3	0.83	10.77	0.58	3.24e-22	Response to antineoplastic agents;
SARC	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg23758822	chr17:41437982	NA	0.89	11.37	0.6	3.91e-24	Menopause (age at onset);
SARC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.8	10.36	0.56	6.16e-21	Prudent dietary pattern;
SARC	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg00933542	chr6:150070202	PCMT1	0.3	5.22	0.32	3.91e-7	Lung cancer;
SARC	cis	rs7017697	1.000	rs10092772	chr8:19686385	A/T	cg03894339	chr8:19674705	INTS10	-0.42	-5.09	-0.32	7.49e-7	Breast cancer;
SARC	cis	rs60871478	1.000	rs34260834	chr7:822958	A/G	cg05535760	chr7:792225	HEATR2	0.77	7.91	0.46	1.04e-13	Cerebrospinal P-tau181p levels;
SARC	cis	rs2120019	0.567	rs68036747	chr15:75203200	A/C	cg12414181	chr15:75287860	SCAMP5	-0.51	-4.84	-0.3	2.37e-6	Blood trace element (Zn levels);
SARC	cis	rs4711350	0.734	rs7739273	chr6:33758065	G/A	cg18005901	chr6:33739558	LEMD2	-0.41	-4.76	-0.3	3.35e-6	Schizophrenia;
SARC	cis	rs9296092	0.560	rs62407561	chr6:33528103	T/C	cg13560919	chr6:33536144	NA	-0.52	-6.38	-0.39	9.28e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs7762018	0.655	rs2184195	chr6:170148397	C/T	cg13891659	chr6:170190454	C6orf122;C6orf208	0.55	4.88	0.3	2e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	trans	rs1493916	0.837	rs10401087	chr18:31320716	A/G	cg27147174	chr7:100797783	AP1S1	-0.5	-6.49	-0.39	5.03e-10	Life satisfaction;
SARC	cis	rs76419734	0.510	rs2553456	chr4:106751028	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	-0.73	-7.38	-0.44	2.7e-12	Post bronchodilator FEV1;
SARC	cis	rs8180040	1.000	rs11714294	chr3:47339723	G/A	cg27129171	chr3:47204927	SETD2	-0.68	-9.5	-0.53	2.67e-18	Colorectal cancer;
SARC	cis	rs13336428	0.730	rs3946124	chr16:1525779	A/G	cg07835181	chr16:1525278	CLCN7	-0.69	-10.45	-0.56	3.24e-21	Bone mineral density;
SARC	cis	rs2153535	0.526	rs7748404	chr6:8472500	A/T	cg07606381	chr6:8435919	SLC35B3	0.76	10.8	0.58	2.71e-22	Motion sickness;
SARC	cis	rs57994353	0.759	rs35873563	chr9:139324029	C/T	cg13611204	chr9:139324423	INPP5E	-0.3	-5.15	-0.32	5.54e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.77	9.74	0.54	5.03e-19	Prudent dietary pattern;
SARC	cis	rs9611565	0.918	rs2281333	chr22:41749630	T/C	cg03806693	chr22:41940476	POLR3H	-0.78	-10.71	-0.57	5.04e-22	Vitiligo;
SARC	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg07701084	chr6:150067640	NUP43	0.41	5.39	0.33	1.75e-7	Lung cancer;
SARC	cis	rs763121	0.853	rs138709	chr22:39139216	C/G	cg21395723	chr22:39101663	GTPBP1	0.56	6.74	0.4	1.26e-10	Menopause (age at onset);
SARC	cis	rs62244186	0.535	rs59726036	chr3:44850074	G/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.55	7.1	0.42	1.51e-11	Depressive symptoms;
SARC	cis	rs72781680	1.000	rs72788286	chr2:24098321	A/C	cg06627628	chr2:24431161	ITSN2	-0.66	-6.46	-0.39	5.99e-10	Lymphocyte counts;
SARC	cis	rs10463316	0.817	rs3846713	chr5:150799739	C/T	cg03212797	chr5:150827313	SLC36A1	-0.47	-5.62	-0.35	5.4e-8	Metabolite levels (Pyroglutamine);
SARC	cis	rs155076	0.938	rs485361	chr13:21845826	G/T	cg11317459	chr13:21872234	NA	-0.98	-12.36	-0.63	2.52e-27	White matter hyperintensity burden;
SARC	cis	rs7674212	0.570	rs2251634	chr4:104082349	C/T	cg16532752	chr4:104119610	CENPE	-0.48	-6.04	-0.37	6.16e-9	Type 2 diabetes;
SARC	cis	rs9398803	0.865	rs4897181	chr6:126753564	C/T	cg19875578	chr6:126661172	C6orf173	0.59	7.98	0.46	6.8e-14	Male-pattern baldness;
SARC	cis	rs35110281	0.837	rs12627667	chr21:45071396	A/C	cg01579765	chr21:45077557	HSF2BP	-0.32	-5.45	-0.34	1.3e-7	Mean corpuscular volume;
SARC	cis	rs912057	0.609	rs1294431	chr6:6745003	G/C	cg06612196	chr6:6737390	NA	0.63	9.53	0.53	2.18e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs10463554	0.553	rs72785712	chr5:102324397	A/G	cg23492399	chr5:102201601	PAM	-0.53	-6.74	-0.4	1.2e-10	Parkinson's disease;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg23024448	chr19:51222118	NA	0.75	6.28	0.38	1.65e-9	Autism spectrum disorder or schizophrenia;
SARC	trans	rs7819412	0.875	rs6981523	chr8:11061792	C/T	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.46	-0.39	6.01e-10	Triglycerides;
SARC	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg11764359	chr7:65958608	NA	-0.78	-9.41	-0.52	4.93e-18	Aortic root size;
SARC	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg07701084	chr6:150067640	NUP43	0.43	5.63	0.35	5.26e-8	Lung cancer;
SARC	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg27266027	chr21:40555129	PSMG1	0.48	5.2	0.32	4.34e-7	Cognitive function;
SARC	cis	rs7772486	0.686	rs1045820	chr6:145947080	C/T	cg23711669	chr6:146136114	FBXO30	0.77	12.2	0.62	8.53e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6728642	0.561	rs62152901	chr2:97564898	A/G	cg26665480	chr2:98280029	ACTR1B	-0.65	-5.7	-0.35	3.56e-8	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs9818758	0.607	rs9837237	chr3:49215583	G/T	cg06212747	chr3:49208901	KLHDC8B	-0.74	-6.42	-0.39	7.64e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg20607798	chr8:58055168	NA	0.66	5.15	0.32	5.52e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7927592	0.913	rs6591346	chr11:68384618	T/A	cg20283391	chr11:68216788	NA	-0.41	-4.72	-0.3	4.07e-6	Total body bone mineral density;
SARC	cis	rs67460515	0.892	rs11711413	chr3:160998910	C/G	cg03342759	chr3:160939853	NMD3	-0.71	-9.02	-0.51	7.27e-17	Parkinson's disease;
SARC	cis	rs1707322	1.000	rs11211217	chr1:46348229	C/G	cg03146154	chr1:46216737	IPP	0.47	5.72	0.35	3.32e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1941023	0.503	rs4939349	chr11:60135880	G/A	cg08716584	chr11:60157161	MS4A7	-0.4	-6.68	-0.4	1.76e-10	Congenital heart disease (maternal effect);
SARC	cis	rs959260	0.623	rs7207618	chr17:73321687	T/C	cg07104495	chr17:73266070	MIF4GD	-0.33	-4.96	-0.31	1.34e-6	Systemic lupus erythematosus;
SARC	cis	rs4727027	0.704	rs12704073	chr7:148905067	G/A	cg23583168	chr7:148888333	NA	-0.83	-13.41	-0.66	8.89e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs6088580	0.634	rs13041646	chr20:33082881	T/A	cg24642439	chr20:33292090	TP53INP2	0.66	8.74	0.5	4.7e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs262150	0.630	rs2730274	chr7:158796062	C/A	cg19418458	chr7:158789849	NA	-0.48	-6.62	-0.4	2.45e-10	Facial morphology (factor 20);
SARC	cis	rs8114671	0.967	rs2069952	chr20:33763951	C/T	cg24642439	chr20:33292090	TP53INP2	0.51	5.88	0.36	1.44e-8	Height;
SARC	cis	rs9303401	0.614	rs2240719	chr17:56582477	G/C	cg25039879	chr17:56429692	SUPT4H1	0.63	5.81	0.36	2.03e-8	Cognitive test performance;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg08497199	chr4:57253643	AASDH	0.49	6.4	0.39	8.51e-10	Chemerin levels;
SARC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg06873352	chr17:61820015	STRADA	0.53	6.92	0.41	4.3e-11	Prudent dietary pattern;
SARC	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg20607798	chr8:58055168	NA	0.61	5.41	0.33	1.57e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs925098	0.556	rs1506613	chr4:17948939	T/C	cg08521178	chr6:170491202	NA	0.42	6.57	0.4	3.17e-10	Birth weight;Height;
SARC	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg17971929	chr21:40555470	PSMG1	0.99	14.16	0.68	2.89e-33	Cognitive function;
SARC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg04234412	chr22:24373322	LOC391322	0.55	6.47	0.39	5.83e-10	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs11112613	0.775	rs7299470	chr12:105961773	G/A	cg03607813	chr12:105948248	NA	0.53	7.35	0.43	3.33e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs13082711	0.863	rs34611823	chr3:27500344	A/G	cg02860705	chr3:27208620	NA	0.46	5.89	0.36	1.33e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs12586317	0.620	rs12437439	chr14:35585669	C/A	cg26967526	chr14:35346199	BAZ1A	-0.62	-6.29	-0.38	1.55e-9	Psoriasis;
SARC	cis	rs910316	1.000	rs7145159	chr14:75583268	A/G	cg06637938	chr14:75390232	RPS6KL1	0.52	7.35	0.43	3.35e-12	Height;
SARC	cis	rs9487051	0.872	rs9487033	chr6:109605388	C/G	cg01475377	chr6:109611718	NA	0.44	6.18	0.38	2.86e-9	Reticulocyte fraction of red cells;
SARC	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	7.73	0.45	3.1400000000000003e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg00067365	chr5:43121575	ZNF131	0.48	6.34	0.38	1.21e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs12912251	0.947	rs12898460	chr15:38986813	C/T	cg01338139	chr15:38987640	C15orf53	-0.49	-5.52	-0.34	8.83e-8	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
SARC	trans	rs656319	0.605	rs60278284	chr8:10003210	G/C	cg06636001	chr8:8085503	FLJ10661	-0.6	-7.68	-0.45	4.3e-13	Myopia (pathological);
SARC	cis	rs9677476	0.863	rs10187005	chr2:232077948	C/T	cg23338755	chr2:231921595	PSMD1	0.46	5.5	0.34	9.82e-8	Food antigen IgG levels;
SARC	cis	rs6582630	0.555	rs10880520	chr12:38464111	C/T	cg13010199	chr12:38710504	ALG10B	0.75	10.21	0.56	1.79e-20	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2235544	0.554	rs605272	chr1:54467026	T/A	cg10336722	chr1:54665764	CYB5RL;MRPL37	-0.38	-4.74	-0.3	3.66e-6	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
SARC	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg10591111	chr5:226296	SDHA	0.52	4.83	0.3	2.42e-6	Breast cancer;
SARC	cis	rs1949733	0.628	rs1543246	chr4:8504909	A/T	cg11789530	chr4:8429930	ACOX3	0.71	9.36	0.52	6.8e-18	Response to antineoplastic agents;
SARC	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg18404041	chr3:52824283	ITIH1	-0.34	-5.07	-0.32	8.17e-7	Electroencephalogram traits;
SARC	cis	rs9650315	0.530	rs7830138	chr8:57084125	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.47	4.8	0.3	2.89e-6	Height;
SARC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg09373136	chr17:61933544	TCAM1	-0.45	-6.1	-0.37	4.27e-9	Prudent dietary pattern;
SARC	cis	rs41271473	1.000	rs55956922	chr1:228872549	T/A	cg16512390	chr1:228756714	NA	0.49	4.93	0.31	1.54e-6	Chronic lymphocytic leukemia;
SARC	cis	rs1018836	0.892	rs5005585	chr8:91581975	A/G	cg16814680	chr8:91681699	NA	-0.74	-11.22	-0.59	1.21e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.97	12.03	0.62	3.02e-26	Platelet count;
SARC	cis	rs10193935	0.901	rs6733914	chr2:42674741	A/G	cg27598129	chr2:42591480	NA	0.38	5.25	0.33	3.42e-7	Colonoscopy-negative controls vs population controls;
SARC	cis	rs34172651	0.606	rs7194189	chr16:24703484	G/T	cg04756594	chr16:24857601	SLC5A11	-0.39	-5.08	-0.32	7.64e-7	Intelligence (multi-trait analysis);
SARC	cis	rs514406	0.505	rs431427	chr1:53179094	C/A	cg24675658	chr1:53192096	ZYG11B	-0.66	-9.69	-0.54	7.19e-19	Monocyte count;
SARC	cis	rs12142240	0.698	rs6679898	chr1:46820589	A/C	cg00530320	chr1:46809349	NSUN4	0.57	6.79	0.41	9.05e-11	Menopause (age at onset);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg07432643	chr22:50247581	ZBED4	0.46	6.37	0.39	9.82e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs9807989	0.801	rs6734742	chr2:102967857	C/T	cg09003973	chr2:102972529	NA	0.41	5.6	0.34	6.11e-8	Asthma;
SARC	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg07701084	chr6:150067640	NUP43	0.37	4.9	0.31	1.82e-6	Lung cancer;
SARC	cis	rs950776	0.593	rs601079	chr15:78869579	T/A	cg17108064	chr15:78857060	CHRNA5	-0.29	-4.97	-0.31	1.32e-6	Sudden cardiac arrest;
SARC	cis	rs7223966	1.000	rs752621	chr17:61901880	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.5	5.14	0.32	5.85e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9868809	0.656	rs13324119	chr3:48710606	G/C	cg07636037	chr3:49044803	WDR6	-0.69	-6.05	-0.37	5.6e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg05623727	chr3:50126028	RBM5	-0.34	-5.19	-0.32	4.53e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2075371	0.966	rs2544224	chr7:133995832	A/G	cg20476274	chr7:133979776	SLC35B4	0.63	8.51	0.49	2.17e-15	Mean platelet volume;
SARC	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg22968622	chr17:43663579	NA	1.24	16.33	0.73	1.72e-40	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs36051895	0.659	rs58345215	chr9:5043767	A/T	cg02405213	chr9:5042618	JAK2	-0.52	-5.79	-0.35	2.21e-8	Pediatric autoimmune diseases;
SARC	cis	rs7819412	0.659	rs4073948	chr8:10772644	A/T	cg00262122	chr8:11665843	FDFT1	-0.41	-4.83	-0.3	2.53e-6	Triglycerides;
SARC	cis	rs7044106	0.887	rs1359328	chr9:123370822	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.55	5.9	0.36	1.3e-8	Hip circumference adjusted for BMI;
SARC	cis	rs7726839	0.526	rs11960158	chr5:568665	C/T	cg07777115	chr5:623756	CEP72	-0.56	-5.16	-0.32	5.32e-7	Obesity-related traits;
SARC	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg24549020	chr5:56110836	MAP3K1	0.81	8.4	0.48	4.37e-15	Initial pursuit acceleration;
SARC	cis	rs7208859	0.623	rs8082537	chr17:29015932	T/C	cg13385521	chr17:29058706	SUZ12P	0.9	7.79	0.45	2.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs1008375	1.000	rs60178264	chr4:17685308	G/T	cg16339924	chr4:17578868	LAP3	0.62	8.1	0.47	3.05e-14	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1790761	0.520	rs12805884	chr11:67387977	G/A	cg00290607	chr11:67383545	NA	-0.45	-5.79	-0.35	2.3e-8	Mean corpuscular volume;
SARC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg06873352	chr17:61820015	STRADA	0.53	6.91	0.41	4.65e-11	Prudent dietary pattern;
SARC	cis	rs858239	0.600	rs7456915	chr7:23143049	T/C	cg23682824	chr7:23144976	KLHL7	0.69	9.39	0.52	5.65e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs1483890	0.642	rs9825849	chr3:69404575	C/T	cg22125112	chr3:69402811	FRMD4B	0.3	4.89	0.31	1.84e-6	Resting heart rate;
SARC	cis	rs9831754	0.756	rs9817660	chr3:78426373	T/C	cg06138941	chr3:78371609	NA	-0.57	-6.86	-0.41	6.04e-11	Calcium levels;
SARC	cis	rs6930083	0.713	rs1321309	chr6:36638636	G/A	cg08179530	chr6:36648295	CDKN1A	-0.85	-12.32	-0.63	3.32e-27	Coronary artery disease;
SARC	cis	rs17376456	0.825	rs10058331	chr5:93279115	T/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.67	0.35	4.28e-8	Diabetic retinopathy;
SARC	cis	rs2760061	0.583	rs708121	chr1:228208257	A/G	cg02753203	chr1:228287806	NA	0.79	11.09	0.59	3.23e-23	Diastolic blood pressure;
SARC	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	5.98	0.36	8.3e-9	Height;
SARC	cis	rs3087591	1.000	rs9904169	chr17:29572518	C/T	cg24425628	chr17:29625626	OMG;NF1	-0.51	-6.31	-0.38	1.4e-9	Hip circumference;
SARC	cis	rs2304069	0.954	rs1962603	chr5:149393006	G/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.88	9.28	0.52	1.2e-17	HIV-1 control;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg12114820	chr12:76953697	OSBPL8	0.51	6.25	0.38	1.95e-9	Breast cancer;
SARC	cis	rs3796352	1.000	rs34121720	chr3:53072167	C/T	cg12962167	chr3:53033115	SFMBT1	0.72	5.0	0.31	1.14e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs11122272	0.735	rs2244994	chr1:231537127	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.08	-0.55	4.68e-20	Hemoglobin concentration;
SARC	cis	rs11098499	0.738	rs34566984	chr4:120361270	G/A	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg07636037	chr3:49044803	WDR6	1.01	17.84	0.76	1.85e-45	Parkinson's disease;
SARC	cis	rs7236492	0.748	rs11664153	chr18:77195813	G/A	cg15644404	chr18:77186268	NFATC1	-0.65	-6.53	-0.39	4.08e-10	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs4865169	0.783	rs7668814	chr4:57825190	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.47	5.78	0.35	2.33e-8	Breast cancer;
SARC	cis	rs8114671	0.839	rs6142290	chr20:33654672	A/C	cg08999081	chr20:33150536	PIGU	-0.34	-4.84	-0.3	2.38e-6	Height;
SARC	cis	rs2075371	1.000	rs2544211	chr7:133973230	A/G	cg11752832	chr7:134001865	SLC35B4	0.54	6.92	0.41	4.21e-11	Mean platelet volume;
SARC	cis	rs9325144	0.560	rs10506125	chr12:39120287	C/T	cg13010199	chr12:38710504	ALG10B	0.62	7.96	0.46	7.43e-14	Morning vs. evening chronotype;
SARC	cis	rs472402	0.623	rs8192130	chr5:6636450	G/A	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.42	-5.12	-0.32	6.5e-7	Response to amphetamines;
SARC	cis	rs7250872	0.568	rs749109	chr19:1819736	G/A	cg05970437	chr19:1864622	KLF16	0.51	5.4	0.33	1.64e-7	Bipolar disorder;
SARC	cis	rs7084402	0.967	rs1365740	chr10:60277549	A/C	cg07615347	chr10:60278583	BICC1	-0.6	-8.82	-0.5	2.78e-16	Refractive error;
SARC	cis	rs10489525	0.560	rs10858062	chr1:115602563	A/G	cg01522456	chr1:115632236	TSPAN2	0.46	5.46	0.34	1.21e-7	Autism;
SARC	cis	rs9815354	0.859	rs9822288	chr3:41954588	C/T	cg03022575	chr3:42003672	ULK4	-0.55	-5.27	-0.33	3.16e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs7511006	1.000	rs17836662	chr22:50672154	A/G	cg16473166	chr22:50639996	SELO	-0.43	-4.73	-0.3	3.87e-6	Obesity-related traits;
SARC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.3	-4.74	-0.3	3.71e-6	Total body bone mineral density;
SARC	cis	rs6580649	0.941	rs4141065	chr12:48523499	G/A	cg24011408	chr12:48396354	COL2A1	-0.46	-5.18	-0.32	4.85e-7	Lung cancer;
SARC	cis	rs79976124	0.800	rs10944857	chr6:66637078	C/T	cg07460842	chr6:66804631	NA	0.63	7.01	0.42	2.5e-11	Type 2 diabetes;
SARC	cis	rs400736	0.729	rs2493216	chr1:8008366	C/A	cg25007680	chr1:8021821	PARK7	-0.44	-5.92	-0.36	1.16e-8	Response to antidepressants and depression;
SARC	cis	rs34779708	0.931	rs4934721	chr10:35377715	A/G	cg03585969	chr10:35415529	CREM	0.41	5.0	0.31	1.11e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs11874712	1.000	rs9945606	chr18:43673325	A/G	cg25174615	chr18:43684699	ATP5A1;HAUS1	0.4	4.77	0.3	3.31e-6	Migraine - clinic-based;
SARC	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	-0.99	-10.94	-0.58	9.68e-23	Platelet count;
SARC	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg00933542	chr6:150070202	PCMT1	0.33	5.63	0.35	5.13e-8	Lung cancer;
SARC	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg12463550	chr7:65579703	CRCP	-0.7	-5.31	-0.33	2.51e-7	Diabetic kidney disease;
SARC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg11062466	chr8:58055876	NA	0.54	5.53	0.34	8.37e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg09699651	chr6:150184138	LRP11	0.39	4.87	0.3	2.04e-6	Lung cancer;
SARC	cis	rs11098499	0.754	rs1511017	chr4:120250805	G/A	cg09307838	chr4:120376055	NA	0.81	11.03	0.59	4.84e-23	Corneal astigmatism;
SARC	cis	rs712039	0.652	rs853197	chr17:35848716	T/C	cg16670864	chr17:35848621	DUSP14	0.45	4.95	0.31	1.4e-6	Tuberculosis;
SARC	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg26335602	chr6:28129616	ZNF389	-0.46	-5.49	-0.34	1.03e-7	Depression;
SARC	cis	rs7084402	1.000	rs7917717	chr10:60269100	C/A	cg07615347	chr10:60278583	BICC1	-0.58	-8.47	-0.49	2.83e-15	Refractive error;
SARC	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg08109568	chr15:31115862	NA	0.53	6.44	0.39	6.87e-10	Huntington's disease progression;
SARC	cis	rs2153535	0.580	rs1832100	chr6:8446956	G/A	cg21535247	chr6:8435926	SLC35B3	0.55	6.87	0.41	5.72e-11	Motion sickness;
SARC	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg27266027	chr21:40555129	PSMG1	-0.5	-5.5	-0.34	1.01e-7	Cognitive function;
SARC	cis	rs2153535	0.967	rs10484750	chr6:8378609	A/G	cg21535247	chr6:8435926	SLC35B3	-0.4	-4.75	-0.3	3.57e-6	Motion sickness;
SARC	trans	rs4883201	0.656	rs10129061	chr12:9105835	T/C	cg24352934	chr17:1053717	ABR	0.56	6.27	0.38	1.76e-9	Cholesterol, total;Total cholesterol levels;
SARC	cis	rs7223966	0.515	rs2727315	chr17:61961458	C/T	cg00588841	chr17:61851480	DDX42;CCDC47	-0.61	-6.48	-0.39	5.43e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs13256369	0.851	rs13256611	chr8:8564341	G/A	cg18904891	chr8:8559673	CLDN23	0.49	5.49	0.34	1.04e-7	Obesity-related traits;
SARC	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg08219700	chr8:58056026	NA	0.6	5.71	0.35	3.49e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs13191362	1.000	rs1333963	chr6:163192571	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.72	6.11	0.37	4.25e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2204008	0.777	rs6582664	chr12:37947022	A/G	cg26384229	chr12:38710491	ALG10B	-0.78	-11.23	-0.59	1.14e-23	Bladder cancer;
SARC	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg05444541	chr17:17804740	TOM1L2	-0.31	-5.13	-0.32	6.03e-7	Total body bone mineral density;
SARC	cis	rs3091242	0.933	rs9438905	chr1:25764177	A/G	cg02931644	chr1:25747376	RHCE	0.45	7.48	0.44	1.51e-12	Erythrocyte sedimentation rate;
SARC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg20887711	chr4:1340912	KIAA1530	0.77	9.85	0.54	2.31e-19	Longevity;
SARC	cis	rs11252926	0.583	rs4881333	chr10:519164	G/C	cg08603382	chr10:743973	NA	0.4	5.44	0.34	1.35e-7	Psychosis in Alzheimer's disease;
SARC	cis	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg11764359	chr7:65958608	NA	0.65	6.39	0.39	9.05e-10	Aortic root size;
SARC	cis	rs7084402	0.902	rs1649017	chr10:60288531	T/C	cg07615347	chr10:60278583	BICC1	0.6	8.86	0.5	2.16e-16	Refractive error;
SARC	cis	rs7247513	0.930	rs35275129	chr19:12716493	G/A	cg01871581	chr19:12707946	ZNF490	-0.88	-13.59	-0.67	2.24e-31	Bipolar disorder;
SARC	cis	rs2415984	0.562	rs61991051	chr14:46904538	C/A	cg14871534	chr14:47121158	RPL10L	0.39	5.27	0.33	3.06e-7	Number of children ever born;
SARC	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg20891283	chr12:69753455	YEATS4	0.55	7.56	0.44	9.09e-13	Blood protein levels;
SARC	cis	rs8044995	0.563	rs7500163	chr16:68364358	C/G	cg09835421	chr16:68378352	PRMT7	-0.64	-5.83	-0.36	1.87e-8	Schizophrenia;
SARC	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg26116260	chr4:7069785	GRPEL1	0.93	11.52	0.6	1.38e-24	Monocyte percentage of white cells;
SARC	cis	rs17023223	0.537	rs1325938	chr1:119582642	C/T	cg05756136	chr1:119680316	WARS2	-0.45	-5.44	-0.34	1.35e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs7236492	0.577	rs7236190	chr18:77198217	T/C	cg15644404	chr18:77186268	NFATC1	-0.48	-5.55	-0.34	7.6e-8	Inflammatory bowel disease;Crohn's disease;
SARC	trans	rs1814175	0.817	rs4881658	chr11:49941123	G/A	cg03929089	chr4:120376271	NA	-0.88	-14.13	-0.68	3.62e-33	Height;
SARC	cis	rs79839061	0.518	rs11734537	chr4:869174	A/G	cg07828340	chr4:882639	GAK	0.77	5.84	0.36	1.75e-8	Intelligence (multi-trait analysis);
SARC	cis	rs611744	0.647	rs2298603	chr8:109271426	C/T	cg21045802	chr8:109455806	TTC35	0.51	6.15	0.37	3.39e-9	Dupuytren's disease;
SARC	cis	rs6840360	0.555	rs4554052	chr4:152726610	T/C	cg22705602	chr4:152727874	NA	0.48	8.33	0.48	7.16e-15	Intelligence (multi-trait analysis);
SARC	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg05340658	chr4:99064831	C4orf37	0.57	7.16	0.42	1.02e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7772486	0.754	rs2328709	chr6:146106819	A/G	cg05347473	chr6:146136440	FBXO30	-0.55	-7.69	-0.45	4.11e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs5769765	0.505	rs4561759	chr22:50256686	C/T	cg03033257	chr22:50311977	ALG12;CRELD2	-0.54	-4.72	-0.3	4.08e-6	Schizophrenia;
SARC	cis	rs7223966	1.000	rs752621	chr17:61901880	G/C	cg00588841	chr17:61851480	DDX42;CCDC47	-0.62	-6.4	-0.39	8.37e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs4713118	0.738	rs200465	chr6:27757654	T/A	cg17221315	chr6:27791827	HIST1H4J	0.47	5.12	0.32	6.43e-7	Parkinson's disease;
SARC	cis	rs995000	0.965	rs11207995	chr1:63049551	G/T	cg06896770	chr1:63153194	DOCK7	-0.98	-15.53	-0.71	8.36e-38	Triglyceride levels;
SARC	cis	rs7927592	0.956	rs60212556	chr11:68305494	C/T	cg01657329	chr11:68192670	LRP5	-0.38	-4.74	-0.3	3.68e-6	Total body bone mineral density;
SARC	cis	rs6598955	0.724	rs869683	chr1:26570993	T/A	cg04990556	chr1:26633338	UBXN11	-0.6	-8.3	-0.48	8.56e-15	Obesity-related traits;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg27254601	chr16:29817104	MAZ	-0.82	-6.89	-0.41	5.18e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6964587	1.000	rs6976122	chr7:91610962	T/C	cg17063962	chr7:91808500	NA	0.93	15.52	0.71	8.63e-38	Breast cancer;
SARC	cis	rs9916302	0.861	rs11658219	chr17:37709782	G/A	cg00129232	chr17:37814104	STARD3	-0.65	-7.97	-0.46	6.93e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs7552404	0.924	rs7550974	chr1:76204185	A/G	cg10523679	chr1:76189770	ACADM	0.51	6.92	0.41	4.41e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs10779751	0.734	rs12569242	chr1:11127511	A/C	cg04508216	chr1:11107452	MASP2	0.34	4.79	0.3	2.91e-6	Body mass index;
SARC	cis	rs40363	0.723	rs757269	chr16:3538003	A/G	cg22508957	chr16:3507546	NAT15	-0.49	-4.78	-0.3	3.05e-6	Tuberculosis;
SARC	trans	rs9929218	0.817	rs3118228	chr16:68710737	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.64	-7.94	-0.46	8.37e-14	Colorectal cancer;
SARC	cis	rs9788721	0.836	rs17483929	chr15:78742376	C/T	cg18825076	chr15:78729989	IREB2	-0.48	-5.83	-0.36	1.83e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs6693567	0.526	rs698918	chr1:150319762	A/G	cg09579323	chr1:150459698	TARS2	0.42	5.31	0.33	2.56e-7	Migraine;
SARC	cis	rs12681288	0.862	rs2701898	chr8:1020812	C/T	cg15309053	chr8:964076	NA	0.39	6.34	0.38	1.2e-9	Schizophrenia;
SARC	cis	rs9354352	0.935	rs7766730	chr6:66697003	C/A	cg07460842	chr6:66804631	NA	0.59	7.69	0.45	4.08e-13	Initial pursuit acceleration in psychotic disorders;
SARC	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg22535103	chr8:58192502	C8orf71	-0.83	-9.51	-0.53	2.52e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs6831352	0.879	rs56272995	chr4:100060882	A/G	cg12011299	chr4:100065546	ADH4	-0.35	-5.75	-0.35	2.8e-8	Alcohol dependence;
SARC	cis	rs17270561	0.609	rs9356984	chr6:25725481	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.54	-6.47	-0.39	5.77e-10	Iron status biomarkers;
SARC	cis	rs9503598	0.610	rs1328687	chr6:3468377	A/C	cg00476032	chr6:3446245	SLC22A23	0.38	6.01	0.37	7.15e-9	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
SARC	cis	rs6570726	0.846	rs411468	chr6:145832792	A/G	cg05347473	chr6:146136440	FBXO30	0.48	6.42	0.39	7.51e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6088590	0.735	rs2273684	chr20:33529766	G/T	cg08999081	chr20:33150536	PIGU	-0.32	-4.75	-0.3	3.51e-6	Coronary artery disease;
SARC	cis	rs11644362	1.000	rs976243	chr16:12991679	A/T	cg06890432	chr16:12997467	SHISA9	-0.56	-7.32	-0.43	4.09e-12	Positive affect;Subjective well-being;
SARC	cis	rs1008375	0.931	rs6449328	chr4:17700474	C/T	cg27347728	chr4:17578864	LAP3	0.46	5.75	0.35	2.73e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs11208691	0.513	rs72480644	chr1:66159417	C/G	cg04111102	chr1:66153794	NA	0.45	4.76	0.3	3.36e-6	Lymphocyte percentage of white cells;
SARC	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg21144161	chr5:423903	AHRR	0.31	4.84	0.3	2.39e-6	Cystic fibrosis severity;
SARC	cis	rs56104184	0.830	rs45589039	chr19:49355385	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.97	-8.86	-0.5	2.03e-16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs41271473	0.526	rs10916339	chr1:228716894	C/T	cg16512390	chr1:228756714	NA	0.58	5.5	0.34	1e-7	Chronic lymphocytic leukemia;
SARC	cis	rs1322639	0.614	rs9364361	chr6:169580499	C/T	cg04662567	chr6:169592167	NA	-0.56	-5.83	-0.36	1.86e-8	Pulse pressure;
SARC	cis	rs9787249	0.507	rs34984427	chr1:40245904	G/C	cg18217145	chr1:40254695	BMP8B	-0.61	-5.53	-0.34	8.6e-8	Blood protein levels;
SARC	cis	rs2404602	0.716	rs117129193	chr15:76656803	A/G	cg22467129	chr15:76604101	ETFA	-0.37	-4.84	-0.3	2.4e-6	Blood metabolite levels;
SARC	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg13206674	chr6:150067644	NUP43	0.46	6.1	0.37	4.29e-9	Lung cancer;
SARC	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	11.4	0.6	3.34e-24	Alzheimer's disease;
SARC	cis	rs7712401	0.601	rs454617	chr5:122321927	A/C	cg19412675	chr5:122181750	SNX24	-0.43	-5.47	-0.34	1.15e-7	Mean platelet volume;
SARC	cis	rs9858542	0.953	rs9841110	chr3:49492481	C/G	cg07274523	chr3:49395745	GPX1	0.53	6.1	0.37	4.27e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs9840812	0.728	rs6439646	chr3:136273563	T/C	cg15507776	chr3:136538369	TMEM22	0.52	5.74	0.35	2.92e-8	Fibrinogen levels;
SARC	cis	rs67311347	1.000	rs11129876	chr3:40401636	C/T	cg24209194	chr3:40518798	ZNF619	-0.63	-7.87	-0.46	1.33e-13	Renal cell carcinoma;
SARC	cis	rs6545883	0.929	rs1838978	chr2:61540923	T/C	cg15711740	chr2:61764176	XPO1	0.39	4.72	0.3	4.09e-6	Tuberculosis;
SARC	cis	rs911263	0.546	rs4902567	chr14:68800600	T/C	cg18825221	chr14:68749962	RAD51L1	0.47	6.34	0.38	1.16e-9	Primary biliary cholangitis;
SARC	cis	rs11105298	0.891	rs11105310	chr12:89918677	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-5.43	-0.34	1.39e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs17125944	0.686	rs7145440	chr14:53333717	A/G	cg00686598	chr14:53173677	PSMC6	-0.67	-5.31	-0.33	2.61e-7	Alzheimer's disease (late onset);
SARC	cis	rs2439831	0.681	rs540388	chr15:43606494	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.78	8.69	0.49	6.55e-16	Lung cancer in ever smokers;
SARC	cis	rs3126085	0.935	rs12409762	chr1:152175398	G/A	cg03465714	chr1:152285911	FLG	0.47	5.65	0.35	4.71e-8	Atopic dermatitis;
SARC	cis	rs910316	0.967	rs10246	chr14:75544470	T/A	cg23033748	chr14:75592666	NEK9	0.36	5.0	0.31	1.12e-6	Height;
SARC	cis	rs11098499	0.604	rs2389882	chr4:120566733	A/C	cg09307838	chr4:120376055	NA	0.8	10.59	0.57	1.22e-21	Corneal astigmatism;
SARC	cis	rs4308124	0.679	rs7600458	chr2:111963590	G/C	cg04571233	chr2:111982156	NA	-0.48	-5.57	-0.34	7.09e-8	Vitiligo;
SARC	cis	rs7674212	0.539	rs6815783	chr4:104122146	A/C	cg16532752	chr4:104119610	CENPE	-0.49	-6.08	-0.37	4.81e-9	Type 2 diabetes;
SARC	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg27170947	chr2:26402098	FAM59B	-0.37	-4.8	-0.3	2.79e-6	Gut microbiome composition (summer);
SARC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg15242686	chr22:24348715	GSTTP1	0.43	5.15	0.32	5.63e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs79149102	0.649	rs2229730	chr15:75093389	C/T	cg09165964	chr15:75287851	SCAMP5	-1.03	-5.46	-0.34	1.19e-7	Lung cancer;
SARC	cis	rs40363	0.723	rs8060367	chr16:3537919	C/A	cg22508957	chr16:3507546	NAT15	-0.59	-5.13	-0.32	6.01e-7	Tuberculosis;
SARC	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-9.96	-0.55	1.05e-19	Chronic sinus infection;
SARC	cis	rs2239547	0.522	rs2581805	chr3:52979050	T/C	cg07507251	chr3:52567010	NT5DC2	-0.38	-5.0	-0.31	1.13e-6	Schizophrenia;
SARC	cis	rs921968	0.565	rs12611632	chr2:219621258	C/T	cg02176678	chr2:219576539	TTLL4	-0.32	-4.88	-0.3	1.93e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs9814567	0.712	rs9838467	chr3:134332222	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.51	-6.61	-0.4	2.53e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs6964587	0.869	rs7778667	chr7:91520816	C/G	cg17063962	chr7:91808500	NA	-0.91	-13.72	-0.67	8.19e-32	Breast cancer;
SARC	cis	rs17376456	0.877	rs35747258	chr5:93310129	C/T	cg21475434	chr5:93447410	FAM172A	0.84	7.56	0.44	9.44e-13	Diabetic retinopathy;
SARC	cis	rs754466	0.651	rs11002316	chr10:79617511	C/G	cg17075019	chr10:79541650	NA	-0.8	-12.63	-0.64	3.25e-28	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2658782	1.000	rs2605583	chr11:93164957	T/A	cg15737290	chr11:93063684	CCDC67	0.72	7.74	0.45	3e-13	Pulmonary function decline;
SARC	cis	rs818427	0.964	rs434090	chr5:112229523	A/G	cg07820702	chr5:112228657	REEP5	-0.49	-5.37	-0.33	1.86e-7	Total body bone mineral density;
SARC	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg13126279	chr21:47581558	C21orf56	0.51	6.22	0.38	2.32e-9	Testicular germ cell tumor;
SARC	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg01316550	chr5:56110833	MAP3K1	0.54	4.92	0.31	1.62e-6	Initial pursuit acceleration;
SARC	cis	rs2130392	1.000	rs3796689	chr4:185649866	C/A	cg04058563	chr4:185651563	MLF1IP	0.41	5.84	0.36	1.73e-8	Kawasaki disease;
SARC	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg11890956	chr21:40555474	PSMG1	-0.71	-9.29	-0.52	1.14e-17	Menarche (age at onset);
SARC	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg02951883	chr7:2050386	MAD1L1	-0.42	-5.38	-0.33	1.84e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs854765	0.547	rs6502633	chr17:17941037	G/C	cg04398451	chr17:18023971	MYO15A	-0.47	-6.58	-0.4	2.99e-10	Total body bone mineral density;
SARC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.76	9.66	0.53	8.56e-19	Prudent dietary pattern;
SARC	cis	rs2153535	0.580	rs1328862	chr6:8526681	A/T	cg07606381	chr6:8435919	SLC35B3	0.76	10.99	0.58	6.38e-23	Motion sickness;
SARC	cis	rs7729447	0.776	rs1458053	chr5:32690413	G/A	cg16267343	chr5:32710456	NPR3	0.65	8.51	0.49	2.12e-15	Blood pressure;
SARC	trans	rs7395662	0.500	rs10838984	chr11:48640485	C/T	cg15704280	chr7:45808275	SEPT13	-0.5	-6.63	-0.4	2.34e-10	HDL cholesterol;
SARC	cis	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg25427524	chr10:38739819	LOC399744	-0.54	-8.39	-0.48	4.58e-15	Extrinsic epigenetic age acceleration;
SARC	cis	rs7584330	0.868	rs2325839	chr2:238386286	T/C	cg14458575	chr2:238380390	NA	0.43	5.29	0.33	2.75e-7	Prostate cancer;
SARC	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-7.66	-0.45	5.08e-13	Alzheimer's disease;
SARC	cis	rs67478160	0.583	rs12879612	chr14:104233618	T/A	cg08213375	chr14:104286397	PPP1R13B	0.27	4.9	0.31	1.77e-6	Schizophrenia;
SARC	cis	rs2228479	0.850	rs62056066	chr16:89906563	G/A	cg00800038	chr16:89945340	TCF25	-0.82	-5.8	-0.35	2.19e-8	Skin colour saturation;
SARC	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg19223190	chr17:80058835	NA	0.45	6.22	0.38	2.3e-9	Life satisfaction;
SARC	cis	rs4780401	0.933	rs7203803	chr16:11812291	A/G	cg01061890	chr16:11836724	TXNDC11	0.48	6.18	0.38	2.87e-9	Rheumatoid arthritis;
SARC	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg13395646	chr4:1353034	KIAA1530	-0.47	-5.64	-0.35	5.01e-8	Obesity-related traits;
SARC	cis	rs7626444	0.625	rs7638090	chr3:196476836	A/G	cg12930392	chr3:196481615	PAK2	0.25	5.0	0.31	1.13e-6	Monocyte count;
SARC	trans	rs9650657	0.740	rs10481451	chr8:10649328	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.44	-0.39	6.84e-10	Neuroticism;
SARC	cis	rs9436747	0.803	rs1751490	chr1:66007430	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.42	4.81	0.3	2.67e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs6912958	0.535	rs1753154	chr6:88032843	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.75	11.15	0.59	1.97e-23	Monocyte percentage of white cells;
SARC	cis	rs8070128	0.583	rs7406982	chr17:17942613	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.42	5.24	0.32	3.6e-7	Total body bone mineral density;
SARC	cis	rs1035144	0.785	rs4903962	chr14:81464486	A/G	cg06600135	chr14:81408086	NA	0.42	5.24	0.32	3.61e-7	Male sexual orientation;
SARC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	11.32	0.6	5.71e-24	Platelet count;
SARC	cis	rs826838	0.510	rs10876149	chr12:39228083	C/G	cg13010199	chr12:38710504	ALG10B	-0.58	-7.06	-0.42	1.9e-11	Heart rate;
SARC	cis	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg03213289	chr20:61660250	NA	0.46	6.43	0.39	7.22e-10	Prostate cancer (SNP x SNP interaction);
SARC	trans	rs61931739	0.556	rs7954221	chr12:33825077	C/T	cg26384229	chr12:38710491	ALG10B	0.58	7.77	0.45	2.56e-13	Morning vs. evening chronotype;
SARC	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg11878867	chr6:150167359	LRP11	-0.34	-4.72	-0.3	4.01e-6	Lung cancer;
SARC	cis	rs3796352	1.000	rs34313969	chr3:52995166	A/G	cg27565382	chr3:53032988	SFMBT1	0.83	5.57	0.34	7.16e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2242194	0.844	rs11264295	chr1:154987526	C/T	cg06221963	chr1:154839813	KCNN3	-0.41	-6.19	-0.38	2.65e-9	Schizophrenia;
SARC	cis	rs10128251	0.625	rs9424204	chr10:5726376	C/G	cg09234995	chr10:5726438	C10orf18	0.4	5.18	0.32	4.81e-7	Childhood ear infection;
SARC	cis	rs13082711	0.911	rs36101969	chr3:27438181	G/A	cg02860705	chr3:27208620	NA	0.47	6.19	0.38	2.7e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs1044826	0.642	rs1580642	chr3:139132203	A/C	cg15131784	chr3:139108705	COPB2	-0.45	-5.6	-0.34	6.06e-8	Obesity-related traits;
SARC	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg18305652	chr10:134549665	INPP5A	0.36	5.1	0.32	7.09e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs2304069	0.954	rs2276983	chr5:149424966	C/T	cg12661370	chr5:149340060	SLC26A2	0.55	5.42	0.33	1.51e-7	HIV-1 control;
SARC	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg18357526	chr6:26021779	HIST1H4A	0.44	5.62	0.35	5.39e-8	Blood metabolite levels;
SARC	cis	rs79349575	0.778	rs12950328	chr17:46967061	C/T	cg07967210	chr17:47022446	SNF8	0.38	4.86	0.3	2.19e-6	Type 2 diabetes;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg13841734	chr4:129209112	PGRMC2	0.53	6.67	0.4	1.8e-10	Breast cancer;
SARC	cis	rs6815814	0.851	rs9715769	chr4:38774489	A/C	cg06935464	chr4:38784597	TLR10	0.63	5.97	0.36	8.89e-9	Breast cancer;
SARC	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg22800045	chr5:56110881	MAP3K1	0.74	7.83	0.46	1.74e-13	Initial pursuit acceleration;
SARC	cis	rs478304	0.654	rs12289836	chr11:65436888	C/T	cg27068330	chr11:65405492	SIPA1	0.43	4.92	0.31	1.66e-6	Acne (severe);
SARC	cis	rs6582630	0.584	rs12832156	chr12:38419435	C/T	cg26384229	chr12:38710491	ALG10B	-0.57	-7.05	-0.42	2.02e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4417855	0.762	rs1056932	chr3:187447032	C/T	cg08969912	chr3:187456781	BCL6	-0.46	-5.2	-0.32	4.32e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs17253792	0.731	rs28587929	chr14:56097492	C/T	cg01858014	chr14:56050164	KTN1	-0.68	-5.37	-0.33	1.86e-7	Putamen volume;
SARC	cis	rs1801251	1.000	rs7578299	chr2:233573469	G/T	cg25237894	chr2:233734115	C2orf82	0.37	4.89	0.31	1.85e-6	Coronary artery disease;
SARC	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	10.47	0.57	2.77e-21	Platelet count;
SARC	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg16325326	chr1:53192061	ZYG11B	-0.82	-13.16	-0.65	6.1e-30	Monocyte count;
SARC	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg11644478	chr21:40555479	PSMG1	-0.86	-10.81	-0.58	2.38e-22	Cognitive function;
SARC	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg22875332	chr1:76189707	ACADM	0.46	6.62	0.4	2.43e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs8067545	0.611	rs2703805	chr17:20107773	T/C	cg13482628	chr17:19912719	NA	-0.52	-6.65	-0.4	2.08e-10	Schizophrenia;
SARC	cis	rs2204008	0.754	rs11181643	chr12:38380553	G/A	cg26384229	chr12:38710491	ALG10B	0.87	12.69	0.64	2.17e-28	Bladder cancer;
SARC	trans	rs208520	1.000	rs9453671	chr6:66991208	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	8.75	0.5	4.41e-16	Exhaled nitric oxide output;
SARC	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg13628971	chr7:2884303	GNA12	0.56	6.56	0.39	3.39e-10	Height;
SARC	trans	rs1814175	0.817	rs3974439	chr11:50022607	G/A	cg03929089	chr4:120376271	NA	-0.87	-13.86	-0.67	2.91e-32	Height;
SARC	cis	rs9486719	1.000	rs6921291	chr6:97066242	C/T	cg06623918	chr6:96969491	KIAA0776	-0.7	-7.35	-0.43	3.34e-12	Migraine;Coronary artery disease;
SARC	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	5.4	0.33	1.67e-7	Bipolar disorder;
SARC	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg11987759	chr7:65425863	GUSB	0.62	8.24	0.48	1.25e-14	Aortic root size;
SARC	cis	rs2074585	0.806	rs8033813	chr15:90999715	A/T	cg22089800	chr15:90895588	ZNF774	0.68	8.75	0.5	4.49e-16	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg02725872	chr8:58115012	NA	-0.36	-5.52	-0.34	9.23e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4972806	0.849	rs1542180	chr2:177028767	C/T	cg13092806	chr2:177043255	NA	0.39	4.93	0.31	1.53e-6	IgG glycosylation;
SARC	trans	rs3780486	0.846	rs7849148	chr9:33138352	A/T	cg20290983	chr6:43655470	MRPS18A	1.15	22.01	0.82	8.17e-59	IgG glycosylation;
SARC	cis	rs3126085	0.935	rs6681433	chr1:152277396	T/C	cg26876637	chr1:152193138	HRNR	-0.5	-5.58	-0.34	6.59e-8	Atopic dermatitis;
SARC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg18402987	chr7:1209562	NA	0.43	5.7	0.35	3.6e-8	Longevity;Endometriosis;
SARC	trans	rs61931739	0.534	rs10506120	chr12:34235603	G/A	cg13010199	chr12:38710504	ALG10B	0.74	10.03	0.55	6.5e-20	Morning vs. evening chronotype;
SARC	cis	rs6762477	0.505	rs17304079	chr3:50085153	A/G	cg14019146	chr3:50243930	SLC38A3	-0.35	-4.95	-0.31	1.44e-6	Menarche (age at onset);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg20012172	chr22:38902550	DDX17	0.51	6.69	0.4	1.63e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs11105298	0.891	rs11105314	chr12:89924559	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.53	-5.34	-0.33	2.2e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg14343924	chr8:8086146	FLJ10661	0.41	4.92	0.31	1.6e-6	Mood instability;
SARC	cis	rs10927875	0.541	rs1739841	chr1:16342727	A/G	cg21385522	chr1:16154831	NA	0.55	6.58	0.4	3.05e-10	Dilated cardiomyopathy;
SARC	cis	rs6540556	0.954	rs654984	chr1:209937382	C/T	cg05527609	chr1:210001259	C1orf107	0.57	6.18	0.38	2.86e-9	Red blood cell count;
SARC	cis	rs763121	0.719	rs138699	chr22:39129708	G/A	cg21395723	chr22:39101663	GTPBP1	0.59	6.74	0.4	1.23e-10	Menopause (age at onset);
SARC	cis	rs4713118	0.597	rs172166	chr6:28020820	C/G	cg16479474	chr6:28041457	NA	0.36	5.07	0.31	8.29e-7	Parkinson's disease;
SARC	cis	rs6963495	0.592	rs114793754	chr7:105152162	G/C	cg13798780	chr7:105162888	PUS7	0.58	5.2	0.32	4.42e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs10876993	0.890	rs774891	chr12:58068571	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.47	-5.91	-0.36	1.21e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs2354432	0.505	rs72691009	chr1:146708397	C/T	cg25205988	chr1:146714368	CHD1L	-1.03	-7.52	-0.44	1.21e-12	Mitochondrial DNA levels;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08417804	chr9:133588801	ABL1	0.51	6.31	0.38	1.35e-9	Fibrinogen levels;
SARC	cis	rs11697848	1.000	rs2235621	chr20:48473731	G/A	cg17849948	chr20:48532315	SPATA2	0.81	4.87	0.3	2.09e-6	Systemic lupus erythematosus;
SARC	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg25894440	chr7:65020034	NA	-0.73	-5.54	-0.34	8.32e-8	Diabetic kidney disease;
SARC	cis	rs7224737	1.000	rs2014521	chr17:40283413	C/G	cg20291162	chr17:40259547	DHX58	-0.33	-4.87	-0.3	2.08e-6	Fibrinogen levels;
SARC	cis	rs6087990	0.765	rs6058900	chr20:31400673	T/C	cg13636640	chr20:31349939	DNMT3B	0.73	10.89	0.58	1.36e-22	Ulcerative colitis;
SARC	cis	rs9325144	0.600	rs10748442	chr12:38732939	A/T	cg26384229	chr12:38710491	ALG10B	0.6	7.88	0.46	1.25e-13	Morning vs. evening chronotype;
SARC	cis	rs1728785	0.901	rs1728787	chr16:68593042	G/C	cg02972257	chr16:68554789	NA	-0.45	-5.32	-0.33	2.48e-7	Ulcerative colitis;
SARC	cis	rs2985684	0.895	rs3007033	chr14:50103816	T/C	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.46	4.8	0.3	2.88e-6	Carotid intima media thickness;
SARC	cis	rs7000551	0.725	rs1075534	chr8:22374074	A/G	cg12081754	chr8:22256438	SLC39A14	0.53	7.36	0.43	3.13e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs12432203	1.000	rs4566067	chr14:51729487	A/G	cg14098780	chr14:51061306	ATL1	-0.58	-4.77	-0.3	3.18e-6	Cancer;
SARC	cis	rs12142240	0.698	rs72886911	chr1:46814352	G/A	cg14993813	chr1:46806288	NSUN4	-0.52	-5.46	-0.34	1.22e-7	Menopause (age at onset);
SARC	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg17971929	chr21:40555470	PSMG1	0.99	13.88	0.67	2.43e-32	Cognitive function;
SARC	cis	rs9916302	0.904	rs57399933	chr17:37551189	A/G	cg00129232	chr17:37814104	STARD3	0.62	7.56	0.44	8.95e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs6582630	0.519	rs11495373	chr12:38275470	T/C	cg13010199	chr12:38710504	ALG10B	0.8	11.14	0.59	2.21e-23	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg16479474	chr6:28041457	NA	0.37	5.37	0.33	1.94e-7	Depression;
SARC	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg00933542	chr6:150070202	PCMT1	0.3	5.16	0.32	5.22e-7	Lung cancer;
SARC	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.61	7.4	0.44	2.43e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg26338869	chr17:61819248	STRADA	0.81	10.68	0.57	6.45e-22	Prudent dietary pattern;
SARC	cis	rs35110281	0.720	rs162374	chr21:44927089	T/C	cg21573476	chr21:45109991	RRP1B	0.49	7.22	0.43	7.21e-12	Mean corpuscular volume;
SARC	cis	rs2153535	0.623	rs6597338	chr6:8533508	A/C	cg23788917	chr6:8435910	SLC35B3	0.61	8.19	0.47	1.75e-14	Motion sickness;
SARC	cis	rs11711311	0.869	rs12493635	chr3:113373019	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	7.26	0.43	5.87e-12	IgG glycosylation;
SARC	cis	rs2439831	0.867	rs2614811	chr15:43913487	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	8.26	0.48	1.06e-14	Lung cancer in ever smokers;
SARC	cis	rs865483	0.929	rs853194	chr17:35848045	A/C	cg06561646	chr17:35873369	DUSP14	-0.49	-6.49	-0.39	4.99e-10	Monocyte count;
SARC	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg18876405	chr7:65276391	NA	0.49	6.04	0.37	6e-9	Aortic root size;
SARC	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs9362426	1.000	rs414013	chr6:88085866	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.41	4.97	0.31	1.3e-6	Depressive episodes in bipolar disorder;
SARC	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg11987759	chr7:65425863	GUSB	-0.5	-6.19	-0.38	2.62e-9	Aortic root size;
SARC	cis	rs6815814	0.861	rs28690449	chr4:38789132	C/T	cg06935464	chr4:38784597	TLR10	0.51	5.73	0.35	3.02e-8	Breast cancer;
SARC	cis	rs9420	0.961	rs12805841	chr11:57443842	G/A	cg19752551	chr11:57585705	CTNND1	-0.5	-6.82	-0.41	7.93e-11	Schizophrenia;
SARC	cis	rs6570726	0.935	rs368848	chr6:145855281	A/T	cg05220968	chr6:146057943	EPM2A	-0.3	-5.17	-0.32	5.07e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs898097	0.691	rs7222773	chr17:80907283	A/G	cg10494973	chr17:80897199	TBCD	-0.43	-5.56	-0.34	7.44e-8	Breast cancer;
SARC	cis	rs835154	0.845	rs835156	chr5:14875813	C/A	cg18064842	chr5:14874549	NA	-0.66	-10.48	-0.57	2.65e-21	Blood metabolite levels;
SARC	cis	rs72634258	0.945	rs161802	chr1:8042826	G/T	cg00042356	chr1:8021962	PARK7	0.53	5.21	0.32	4.12e-7	Inflammatory bowel disease;
SARC	cis	rs11690935	0.959	rs6722757	chr2:172591963	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.99	-15.89	-0.72	5.28e-39	Schizophrenia;
SARC	cis	rs1008375	1.000	rs1121091	chr4:17676386	A/C	cg02297831	chr4:17616191	MED28	0.43	5.47	0.34	1.16e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	5.67	0.35	4.18e-8	Personality dimensions;
SARC	cis	rs7551222	0.752	rs4252677	chr1:204495253	G/A	cg20240347	chr1:204465584	NA	-0.34	-5.92	-0.36	1.14e-8	Schizophrenia;
SARC	cis	rs56011263	0.687	rs4690292	chr4:703712	A/G	cg17689763	chr4:710664	PCGF3	-0.67	-9.36	-0.52	6.99e-18	White blood cell count;
SARC	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.61	7.4	0.44	2.43e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs992157	0.735	rs13393821	chr2:219076742	C/G	cg00012203	chr2:219082015	ARPC2	0.85	13.88	0.67	2.6e-32	Colorectal cancer;
SARC	cis	rs1497406	0.744	rs7538216	chr1:16509671	T/C	cg20430773	chr1:16534157	ARHGEF19	0.46	7.09	0.42	1.6e-11	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2153535	0.541	rs6923558	chr6:8461467	T/G	cg23788917	chr6:8435910	SLC35B3	0.63	8.3	0.48	8.25e-15	Motion sickness;
SARC	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg16405210	chr4:1374714	KIAA1530	-0.49	-5.65	-0.35	4.67e-8	Obesity-related traits;
SARC	cis	rs9527	0.545	rs10883847	chr10:104958284	C/T	cg04362960	chr10:104952993	NT5C2	0.43	5.06	0.31	8.57e-7	Arsenic metabolism;
SARC	cis	rs9443189	0.901	rs2038625	chr6:76560968	G/A	cg01950844	chr6:76311363	SENP6	-0.76	-6.4	-0.39	8.38e-10	Prostate cancer;
SARC	cis	rs4924935	0.798	rs1737940	chr17:18845320	T/G	cg26378065	chr17:18585709	ZNF286B	0.4	4.77	0.3	3.21e-6	Pancreatic cancer;
SARC	cis	rs7681440	0.874	rs1372524	chr4:90776045	A/G	cg06632027	chr4:90757378	SNCA	0.4	5.68	0.35	3.91e-8	Dementia with Lewy bodies;
SARC	cis	rs10779751	0.734	rs1148485	chr1:11148759	G/A	cg08854313	chr1:11322531	MTOR	0.83	10.22	0.56	1.7e-20	Body mass index;
SARC	cis	rs5167	0.566	rs2075620	chr19:45480037	C/T	cg13119609	chr19:45449297	APOC2	-0.39	-5.55	-0.34	7.71e-8	Blood protein levels;
SARC	trans	rs7824557	0.591	rs2043510	chr8:11225168	G/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.1	-0.42	1.54e-11	Retinal vascular caliber;
SARC	cis	rs1003719	0.715	rs2835639	chr21:38537016	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.36	-0.52	6.96e-18	Eye color traits;
SARC	cis	rs1008375	1.000	rs2286771	chr4:17643848	G/A	cg27347728	chr4:17578864	LAP3	0.47	5.91	0.36	1.22e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1949733	1.000	rs3103067	chr4:8511223	A/G	cg11789530	chr4:8429930	ACOX3	0.8	10.66	0.57	7.23e-22	Response to antineoplastic agents;
SARC	cis	rs5997397	0.934	rs6005864	chr22:29157487	A/G	cg02153584	chr22:29168773	CCDC117	-0.58	-7.9	-0.46	1.07e-13	Red cell distribution width;
SARC	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.76	9.64	0.53	9.91e-19	Height;
SARC	cis	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg07636037	chr3:49044803	WDR6	0.64	6.48	0.39	5.4e-10	Menarche (age at onset);
SARC	cis	rs1865760	1.000	rs9348698	chr6:25929689	T/A	cg17691542	chr6:26056736	HIST1H1C	0.58	7.04	0.42	2.08e-11	Height;
SARC	cis	rs1395	1.000	rs1275537	chr2:27441302	C/G	cg21747090	chr2:27597821	SNX17	-0.41	-5.22	-0.32	3.89e-7	Blood metabolite levels;
SARC	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg13206674	chr6:150067644	NUP43	0.46	6.01	0.37	6.92e-9	Lung cancer;
SARC	cis	rs7219021	0.739	rs1800632	chr17:46970509	G/A	cg16584676	chr17:46985605	UBE2Z	-0.48	-5.31	-0.33	2.58e-7	Schizophrenia or bipolar disorder;
SARC	cis	rs6429082	0.818	rs704714	chr1:235632094	T/C	cg26050004	chr1:235667680	B3GALNT2	0.66	8.05	0.47	4.15e-14	Adiposity;
SARC	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg05313129	chr8:58192883	C8orf71	-0.62	-6.34	-0.38	1.18e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs17030434	1.000	rs12645134	chr4:154713430	T/C	cg14289246	chr4:154710475	SFRP2	-0.76	-7.47	-0.44	1.64e-12	Electrocardiographic conduction measures;
SARC	cis	rs10791097	0.690	rs12286234	chr11:130730528	T/C	cg09137382	chr11:130731461	NA	0.33	5.15	0.32	5.48e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg15448220	chr1:150897856	SETDB1	0.47	6.22	0.38	2.28e-9	Tonsillectomy;
SARC	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg12463550	chr7:65579703	CRCP	-0.51	-5.76	-0.35	2.61e-8	Aortic root size;
SARC	cis	rs1865760	0.593	rs2097273	chr6:25941310	A/C	cg16482183	chr6:26056742	HIST1H1C	0.43	5.49	0.34	1.04e-7	Height;
SARC	cis	rs67311347	0.955	rs4973999	chr3:40460383	G/A	cg09455208	chr3:40491958	NA	0.43	6.89	0.41	5.06e-11	Renal cell carcinoma;
SARC	cis	rs2070433	0.800	rs2073380	chr21:47863757	A/C	cg12379764	chr21:47803548	PCNT	0.58	5.21	0.32	4.08e-7	Lymphocyte counts;
SARC	cis	rs7000551	0.751	rs2449340	chr8:22389900	T/G	cg12081754	chr8:22256438	SLC39A14	0.56	7.91	0.46	1.05e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg14664628	chr15:75095509	CSK	-0.42	-5.07	-0.32	7.94e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	cis	rs17401966	1.000	rs58053556	chr1:10442903	A/G	cg15208524	chr1:10270712	KIF1B	0.57	6.19	0.38	2.71e-9	Hepatocellular carcinoma;
SARC	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg03264133	chr6:25882463	NA	-0.41	-5.29	-0.33	2.84e-7	Intelligence (multi-trait analysis);
SARC	cis	rs76419734	0.558	rs7696836	chr4:106583826	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.7	8.06	0.47	4.05e-14	Post bronchodilator FEV1;
SARC	cis	rs12477438	0.822	rs6727170	chr2:99588042	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-6.67	-0.4	1.88e-10	Chronic sinus infection;
SARC	cis	rs1185460	1.000	rs7127212	chr11:118953202	A/G	cg23280166	chr11:118938394	VPS11	-0.69	-8.79	-0.5	3.37e-16	Coronary artery disease;
SARC	cis	rs2733201	1.000	rs1426658	chr15:44338919	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.7	-5.3	-0.33	2.66e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg13939156	chr17:80058883	NA	-0.42	-6.48	-0.39	5.51e-10	Life satisfaction;
SARC	cis	rs9527	0.615	rs3897401	chr10:104696379	T/C	cg04362960	chr10:104952993	NT5C2	0.41	4.77	0.3	3.32e-6	Arsenic metabolism;
SARC	cis	rs17376456	0.877	rs2085960	chr5:93399934	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.68	0.35	3.93e-8	Diabetic retinopathy;
SARC	cis	rs28386778	0.703	rs2286565	chr17:62010232	G/T	cg11494091	chr17:61959527	GH2	-0.45	-6.46	-0.39	5.93e-10	Prudent dietary pattern;
SARC	cis	rs6840360	0.967	rs4383600	chr4:152694383	T/C	cg22705602	chr4:152727874	NA	-0.4	-7.07	-0.42	1.78e-11	Intelligence (multi-trait analysis);
SARC	cis	rs9660992	0.573	rs12126439	chr1:205200720	C/T	cg07972983	chr1:205091412	RBBP5	0.57	7.02	0.42	2.35e-11	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	11.69	0.61	3.76e-25	Alzheimer's disease;
SARC	cis	rs7666738	0.546	rs10026181	chr4:98814118	C/T	cg05340658	chr4:99064831	C4orf37	-0.58	-7.35	-0.43	3.34e-12	Colonoscopy-negative controls vs population controls;
SARC	cis	rs35110281	0.666	rs2236665	chr21:45108987	C/A	cg21573476	chr21:45109991	RRP1B	-0.6	-8.47	-0.49	2.78e-15	Mean corpuscular volume;
SARC	cis	rs854765	0.552	rs6502624	chr17:17847936	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.45	5.71	0.35	3.47e-8	Total body bone mineral density;
SARC	cis	rs17253792	0.822	rs10129890	chr14:56040413	A/T	cg01858014	chr14:56050164	KTN1	-0.64	-4.78	-0.3	3.14e-6	Putamen volume;
SARC	cis	rs7927771	1.000	rs7120333	chr11:47817441	C/T	cg20307385	chr11:47447363	PSMC3	-0.47	-5.59	-0.34	6.3e-8	Subjective well-being;
SARC	cis	rs116095464	0.558	rs28636067	chr5:199415	G/A	cg22496380	chr5:211416	CCDC127	-0.89	-7.7	-0.45	3.77e-13	Breast cancer;
SARC	cis	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg14019146	chr3:50243930	SLC38A3	-0.3	-4.76	-0.3	3.33e-6	Body mass index;
SARC	cis	rs9467773	1.000	rs6903973	chr6:26499942	C/A	cg12292205	chr6:26970375	C6orf41	0.43	5.25	0.33	3.5e-7	Intelligence (multi-trait analysis);
SARC	cis	rs35110281	0.811	rs9980185	chr21:45057905	A/G	cg21573476	chr21:45109991	RRP1B	-0.52	-7.74	-0.45	3.02e-13	Mean corpuscular volume;
SARC	cis	rs2153535	0.580	rs9406162	chr6:8466196	C/T	cg23788917	chr6:8435910	SLC35B3	0.64	8.39	0.48	4.57e-15	Motion sickness;
SARC	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg22903471	chr2:27725779	GCKR	-0.51	-7.68	-0.45	4.26e-13	Total body bone mineral density;
SARC	cis	rs10463316	0.604	rs28744577	chr5:150768983	A/T	cg03212797	chr5:150827313	SLC36A1	-0.46	-5.4	-0.33	1.66e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs11509153	0.634	rs1548882	chr7:12286225	A/G	cg23422036	chr7:12250390	TMEM106B	-0.44	-5.93	-0.36	1.11e-8	Residual cognition;
SARC	cis	rs3091242	0.900	rs1811832	chr1:25753565	G/A	cg27572855	chr1:25598939	RHD	0.54	9.09	0.51	4.34e-17	Erythrocyte sedimentation rate;
SARC	cis	rs76533333	0.564	rs9604433	chr13:113420658	G/C	cg17831440	chr13:113699526	MCF2L	-0.59	-4.86	-0.3	2.13e-6	Red cell distribution width;
SARC	cis	rs3750965	0.734	rs11604251	chr11:68820429	A/G	cg06818126	chr11:68850279	TPCN2	0.44	4.82	0.3	2.6e-6	Hair color;
SARC	cis	rs2976388	0.609	rs2585140	chr8:143806896	A/G	cg06565975	chr8:143823917	SLURP1	0.28	4.73	0.3	3.92e-6	Urinary tract infection frequency;
SARC	cis	rs861020	1.000	rs12134698	chr1:209987801	C/A	cg05527609	chr1:210001259	C1orf107	-0.96	-11.13	-0.59	2.38e-23	Orofacial clefts;
SARC	cis	rs6580649	0.941	rs72644845	chr12:48503881	G/A	cg24011408	chr12:48396354	COL2A1	-0.47	-5.28	-0.33	2.92e-7	Lung cancer;
SARC	cis	rs2180341	0.960	rs7773484	chr6:127670779	T/C	cg17762328	chr6:126965162	NA	-0.44	-4.85	-0.3	2.22e-6	Breast cancer;
SARC	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg12064134	chr16:90016061	DEF8	-0.59	-5.05	-0.31	8.75e-7	Skin colour saturation;
SARC	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.96	15.3	0.71	4.75e-37	Chronic sinus infection;
SARC	cis	rs2953174	0.507	rs2953172	chr2:241525316	C/T	cg07929629	chr2:241523174	NA	0.39	4.74	0.3	3.78e-6	Bipolar disorder;
SARC	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg11987759	chr7:65425863	GUSB	0.58	7.6	0.45	7.01e-13	Aortic root size;
SARC	cis	rs2976388	0.609	rs1469811	chr8:143787999	C/T	cg06565975	chr8:143823917	SLURP1	0.3	5.25	0.33	3.42e-7	Urinary tract infection frequency;
SARC	cis	rs9527	0.590	rs10883843	chr10:104947493	C/G	cg04362960	chr10:104952993	NT5C2	0.43	5.02	0.31	1.02e-6	Arsenic metabolism;
SARC	trans	rs7824557	0.778	rs3808502	chr8:11179458	G/T	cg08975724	chr8:8085496	FLJ10661	0.51	6.55	0.39	3.74e-10	Retinal vascular caliber;
SARC	cis	rs7762018	1.000	rs11961560	chr6:170130121	T/C	cg15038512	chr6:170123185	PHF10	0.5	4.77	0.3	3.23e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs933688	0.941	rs6452954	chr5:90735692	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.93	11.94	0.62	6.02e-26	Smoking behavior;
SARC	cis	rs9467773	1.000	rs28558133	chr6:26531433	G/C	cg11502198	chr6:26597334	ABT1	0.46	5.53	0.34	8.38e-8	Intelligence (multi-trait analysis);
SARC	cis	rs17401966	0.931	rs2185252	chr1:10415912	T/C	cg15208524	chr1:10270712	KIF1B	0.51	6.09	0.37	4.56e-9	Hepatocellular carcinoma;
SARC	cis	rs9611565	0.525	rs1883827	chr22:41703579	A/G	cg03806693	chr22:41940476	POLR3H	-0.71	-9.38	-0.52	6.19e-18	Vitiligo;
SARC	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7937682	0.924	rs489783	chr11:111520522	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.93	-15.22	-0.71	8.48e-37	Primary sclerosing cholangitis;
SARC	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.32	-4.88	-0.3	1.98e-6	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg03060546	chr3:49711283	APEH	0.42	5.26	0.33	3.27e-7	Parkinson's disease;
SARC	cis	rs1355223	0.525	rs7129533	chr11:34872292	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.5	-6.36	-0.38	1.06e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs72634258	0.519	rs36040967	chr1:7931804	A/G	cg00042356	chr1:8021962	PARK7	0.64	5.5	0.34	1.02e-7	Inflammatory bowel disease;
SARC	cis	rs78487399	0.808	rs17030890	chr2:43704092	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-5.04	-0.31	9.18e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs9532669	0.963	rs9532662	chr13:41500351	A/C	cg24676409	chr13:41635512	WBP4	0.43	5.5	0.34	9.73e-8	Cervical cancer;
SARC	cis	rs2635047	0.593	rs7239323	chr18:44636506	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	5.84	0.36	1.74e-8	Educational attainment;
SARC	cis	rs6582630	0.554	rs8189625	chr12:38401177	C/T	cg14851346	chr12:38532713	NA	-0.48	-5.83	-0.36	1.82e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg16606324	chr3:10149918	C3orf24	0.49	4.82	0.3	2.56e-6	Alzheimer's disease;
SARC	cis	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg15556689	chr8:8085844	FLJ10661	0.44	5.5	0.34	9.72e-8	Mood instability;
SARC	cis	rs3820928	0.839	rs4673174	chr2:227801316	A/T	cg11843606	chr2:227700838	RHBDD1	-0.56	-7.12	-0.42	1.33e-11	Pulmonary function;
SARC	cis	rs4689388	0.926	rs28420833	chr4:6279504	G/A	cg00701064	chr4:6280414	WFS1	0.57	9.35	0.52	7.67e-18	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg07636037	chr3:49044803	WDR6	0.91	15.5	0.71	1.03e-37	Menarche (age at onset);
SARC	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg12310025	chr6:25882481	NA	-0.47	-6.1	-0.37	4.41e-9	Blood metabolite levels;
SARC	cis	rs637571	0.512	rs660118	chr11:65735174	G/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.84	12.43	0.63	1.51e-27	Eosinophil percentage of white cells;
SARC	cis	rs6424115	0.830	rs2502999	chr1:24198321	A/G	cg09473613	chr1:24152604	HMGCL	0.33	4.75	0.3	3.49e-6	Immature fraction of reticulocytes;
SARC	cis	rs2011503	0.882	rs113841472	chr19:19565482	T/G	cg15839431	chr19:19639596	YJEFN3	-0.47	-4.74	-0.3	3.78e-6	Bipolar disorder;
SARC	cis	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg02788597	chr15:44828908	EIF3J	0.52	5.03	0.31	9.7e-7	Lung cancer in ever smokers;
SARC	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg24642844	chr7:1081250	C7orf50	-0.59	-6.11	-0.37	4.26e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg05313129	chr8:58192883	C8orf71	-0.57	-6.29	-0.38	1.54e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6901004	0.709	rs354534	chr6:111521030	T/A	cg15721981	chr6:111408429	SLC16A10	-0.46	-5.61	-0.35	5.68e-8	Blood metabolite levels;
SARC	cis	rs7819412	0.875	rs6981523	chr8:11061792	C/T	cg03403963	chr8:11986501	LOC392196;FAM66D	-0.33	-4.8	-0.3	2.87e-6	Triglycerides;
SARC	cis	rs4481887	1.000	rs7553333	chr1:248493956	C/G	cg01631408	chr1:248437212	OR2T33	-0.44	-5.43	-0.34	1.41e-7	Common traits (Other);
SARC	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg04166393	chr7:2884313	GNA12	0.55	6.07	0.37	5.02e-9	Height;
SARC	cis	rs2013441	1.000	rs2526467	chr17:20165054	T/A	cg13482628	chr17:19912719	NA	-0.47	-6.18	-0.38	2.87e-9	Obesity-related traits;
SARC	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg17971929	chr21:40555470	PSMG1	-0.86	-11.41	-0.6	2.97e-24	Cognitive function;
SARC	cis	rs941873	0.805	rs876678	chr10:81111036	G/T	cg09469691	chr10:81107165	PPIF	0.59	8.48	0.49	2.61e-15	Height;
SARC	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.61	8.15	0.47	2.2e-14	Menarche (age at onset);
SARC	cis	rs72781680	0.898	rs72796158	chr2:23935727	T/C	cg06627628	chr2:24431161	ITSN2	-0.63	-5.59	-0.34	6.42e-8	Lymphocyte counts;
SARC	cis	rs9911578	0.967	rs7503190	chr17:57184162	A/C	cg20303301	chr17:57937339	TUBD1	-0.34	-4.87	-0.3	2.04e-6	Intelligence (multi-trait analysis);
SARC	cis	rs6604026	0.630	rs2391177	chr1:93353943	G/A	cg17283838	chr1:93427260	FAM69A	-0.42	-4.77	-0.3	3.24e-6	Multiple sclerosis;
SARC	cis	rs9807989	0.507	rs1420105	chr2:103035119	A/G	cg03938978	chr2:103052716	IL18RAP	0.31	5.08	0.32	7.68e-7	Asthma;
SARC	cis	rs7020830	0.931	rs13293916	chr9:37136359	C/G	cg14294708	chr9:37120828	ZCCHC7	1.12	19.26	0.78	4.17e-50	Schizophrenia;
SARC	cis	rs898097	0.841	rs12453162	chr17:80859971	C/T	cg20578329	chr17:80767326	TBCD	-0.53	-7.17	-0.42	1.01e-11	Breast cancer;
SARC	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg05025164	chr4:1340916	KIAA1530	-0.45	-5.15	-0.32	5.63e-7	Obesity-related traits;
SARC	cis	rs858239	0.699	rs1881200	chr7:23201637	T/C	cg23682824	chr7:23144976	KLHL7	-0.6	-7.39	-0.44	2.66e-12	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg15448220	chr1:150897856	SETDB1	0.47	6.25	0.38	1.94e-9	Tonsillectomy;
SARC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg26338869	chr17:61819248	STRADA	0.79	10.63	0.57	8.77e-22	Prudent dietary pattern;
SARC	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg22857025	chr5:266934	NA	-1.04	-11.74	-0.61	2.61e-25	Breast cancer;
SARC	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg05025164	chr4:1340916	KIAA1530	-0.48	-5.63	-0.35	5.06e-8	Obesity-related traits;
SARC	trans	rs7615952	0.611	rs78137633	chr3:125775061	C/T	cg07211511	chr3:129823064	LOC729375	-0.81	-6.47	-0.39	5.73e-10	Blood pressure (smoking interaction);
SARC	cis	rs9715521	1.000	rs9715521	chr4:59824487	G/A	cg11281224	chr4:60001000	NA	-0.37	-4.74	-0.3	3.74e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-8.29	-0.48	9.21e-15	Chronic sinus infection;
SARC	cis	rs28795989	0.795	rs7694650	chr4:7903416	A/G	cg18538662	chr4:7941764	AFAP1	-0.42	-5.38	-0.33	1.79e-7	Intraocular pressure;
SARC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.53	-6.04	-0.37	5.97e-9	Prudent dietary pattern;
SARC	cis	rs2075371	0.932	rs2598290	chr7:133987736	C/G	cg00033643	chr7:134001901	SLC35B4	0.4	4.85	0.3	2.25e-6	Mean platelet volume;
SARC	cis	rs2120019	0.938	rs8040169	chr15:75370958	C/A	cg17294928	chr15:75287854	SCAMP5	-0.9	-13.28	-0.66	2.39e-30	Blood trace element (Zn levels);
SARC	cis	rs2370759	1.000	rs11594963	chr10:32625736	G/A	cg05361325	chr10:32636312	EPC1	-0.76	-6.79	-0.41	9.44e-11	Sexual dysfunction (female);
SARC	cis	rs7592578	0.508	rs62180987	chr2:191267173	A/G	cg10560079	chr2:191398806	TMEM194B	-0.62	-6.87	-0.41	5.71e-11	Diastolic blood pressure;
SARC	cis	rs796364	0.806	rs79053279	chr2:201057443	C/T	cg23649088	chr2:200775458	C2orf69	-0.63	-5.46	-0.34	1.23e-7	Schizophrenia;
SARC	cis	rs11098499	0.955	rs35197422	chr4:120169314	T/G	cg09307838	chr4:120376055	NA	0.85	11.65	0.61	4.92e-25	Corneal astigmatism;
SARC	cis	rs16976116	0.803	rs9920136	chr15:55504102	A/G	cg17854078	chr15:55489399	RSL24D1	0.65	6.33	0.38	1.23e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg00938859	chr5:1591904	SDHAP3	-0.84	-8.12	-0.47	2.73e-14	Breast cancer;
SARC	cis	rs6570726	0.935	rs385134	chr6:145851005	C/T	cg23711669	chr6:146136114	FBXO30	0.78	12.08	0.62	2.13e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs708547	0.874	rs1718869	chr4:57880232	A/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.68	7.99	0.46	6.22e-14	Response to bleomycin (chromatid breaks);
SARC	cis	rs7011049	1.000	rs113124539	chr8:53854321	G/A	cg26025543	chr8:53854495	NA	0.6	5.46	0.34	1.24e-7	Systolic blood pressure;
SARC	cis	rs7829975	0.682	rs7013471	chr8:8687325	A/G	cg15556689	chr8:8085844	FLJ10661	-0.43	-5.28	-0.33	2.89e-7	Mood instability;
SARC	cis	rs559928	0.606	rs78038516	chr11:63978067	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	5.09	0.32	7.3e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs4268898	0.722	rs6723257	chr2:24391129	A/G	cg06627628	chr2:24431161	ITSN2	0.55	7.18	0.43	9.12e-12	Asthma;
SARC	cis	rs7959452	0.535	rs10878953	chr12:69674187	A/G	cg22834771	chr12:69754056	YEATS4	-0.4	-5.31	-0.33	2.6e-7	Blood protein levels;
SARC	cis	rs3737883	1.000	rs4950913	chr1:203032153	A/G	cg03900565	chr1:203031815	PPFIA4	0.34	5.39	0.33	1.74e-7	Early onset atrial fibrillation;
SARC	trans	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg21659725	chr3:3221576	CRBN	0.8	12.22	0.62	7.09e-27	Intelligence (multi-trait analysis);
SARC	cis	rs9341808	0.667	rs7745301	chr6:80922561	G/T	cg08355045	chr6:80787529	NA	0.37	5.79	0.35	2.23e-8	Sitting height ratio;
SARC	cis	rs1483890	0.662	rs6780513	chr3:69405494	G/A	cg22125112	chr3:69402811	FRMD4B	0.3	4.84	0.3	2.32e-6	Resting heart rate;
SARC	cis	rs7592578	0.882	rs16832765	chr2:191468762	T/C	cg25963032	chr2:191064776	C2orf88	-0.48	-5.35	-0.33	2.13e-7	Diastolic blood pressure;
SARC	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg17971929	chr21:40555470	PSMG1	0.99	13.54	0.66	3.33e-31	Cognitive function;
SARC	cis	rs7937682	0.855	rs539693	chr11:111477387	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.88	-13.98	-0.68	1.14e-32	Primary sclerosing cholangitis;
SARC	cis	rs947211	0.898	rs1772153	chr1:205745782	C/T	cg24503407	chr1:205819492	PM20D1	-0.43	-4.93	-0.31	1.57e-6	Parkinson's disease;
SARC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.35	0.52	7.64e-18	Prudent dietary pattern;
SARC	cis	rs7246657	0.943	rs7259968	chr19:37811854	T/C	cg23950597	chr19:37808831	NA	-0.53	-5.34	-0.33	2.21e-7	Coronary artery calcification;
SARC	cis	rs710216	0.917	rs3754223	chr1:43419091	A/T	cg22176566	chr1:43424700	SLC2A1	0.53	5.48	0.34	1.09e-7	Red cell distribution width;
SARC	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.7	6.55	0.39	3.61e-10	Platelet count;
SARC	cis	rs763121	0.962	rs5757130	chr22:38937794	G/A	cg06022373	chr22:39101656	GTPBP1	0.75	9.62	0.53	1.17e-18	Menopause (age at onset);
SARC	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg02931644	chr1:25747376	RHCE	0.45	7.63	0.45	6.12e-13	Erythrocyte sedimentation rate;
SARC	cis	rs67460515	0.892	rs1382429	chr3:161015153	T/C	cg03342759	chr3:160939853	NMD3	-0.7	-8.9	-0.5	1.6e-16	Parkinson's disease;
SARC	cis	rs10128251	0.847	rs12777965	chr10:5724297	T/C	cg09234995	chr10:5726438	C10orf18	-0.44	-5.12	-0.32	6.5e-7	Childhood ear infection;
SARC	trans	rs8073060	0.586	rs72829933	chr17:34056406	C/T	cg19694781	chr19:47549865	TMEM160	0.7	6.72	0.4	1.35e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs9436747	0.641	rs11208675	chr1:66045424	T/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.47	4.88	0.3	1.92e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	trans	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg21659725	chr3:3221576	CRBN	0.79	11.85	0.61	1.17e-25	Intelligence (multi-trait analysis);
SARC	trans	rs61931739	0.500	rs11053207	chr12:34459827	A/G	cg26384229	chr12:38710491	ALG10B	0.84	12.49	0.63	9.25e-28	Morning vs. evening chronotype;
SARC	cis	rs7647973	0.710	rs34890793	chr3:49619493	C/T	cg03060546	chr3:49711283	APEH	0.73	6.76	0.4	1.12e-10	Menarche (age at onset);
SARC	cis	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg25894440	chr7:65020034	NA	0.73	5.58	0.34	6.57e-8	Diabetic kidney disease;
SARC	cis	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg24110177	chr3:50126178	RBM5	0.63	8.44	0.48	3.41e-15	Body mass index;
SARC	cis	rs7520050	0.751	rs2230657	chr1:46073489	G/A	cg06784218	chr1:46089804	CCDC17	-0.27	-4.97	-0.31	1.32e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs9393692	0.645	rs11756673	chr6:26323505	A/G	cg13736514	chr6:26305472	NA	-0.7	-9.04	-0.51	6.22e-17	Educational attainment;
SARC	trans	rs12310956	0.532	rs1525903	chr12:33964163	T/C	cg26384229	chr12:38710491	ALG10B	0.74	10.25	0.56	1.39e-20	Morning vs. evening chronotype;
SARC	trans	rs61931739	0.500	rs11053243	chr12:34514155	T/C	cg26384229	chr12:38710491	ALG10B	0.83	12.41	0.63	1.78e-27	Morning vs. evening chronotype;
SARC	cis	rs3106136	0.934	rs35995707	chr4:95167150	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.39	-6.03	-0.37	6.38e-9	Capecitabine sensitivity;
SARC	cis	rs4481887	1.000	rs4489592	chr1:248470697	A/T	cg01631408	chr1:248437212	OR2T33	-0.41	-5.16	-0.32	5.18e-7	Common traits (Other);
SARC	cis	rs9457247	0.663	rs7749278	chr6:167435325	C/T	cg07741184	chr6:167504864	NA	-0.3	-5.72	-0.35	3.27e-8	Crohn's disease;
SARC	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6540556	0.736	rs2076152	chr1:209936060	A/G	cg05527609	chr1:210001259	C1orf107	-0.47	-4.97	-0.31	1.27e-6	Red blood cell count;
SARC	cis	rs986417	1.000	rs10136642	chr14:60946098	G/C	cg27398547	chr14:60952738	C14orf39	1.03	9.89	0.54	1.74e-19	Gut microbiota (bacterial taxa);
SARC	cis	rs9393692	0.905	rs6931391	chr6:26279235	G/C	cg05868516	chr6:26286170	HIST1H4H	0.57	7.66	0.45	5.08e-13	Educational attainment;
SARC	cis	rs9325144	0.600	rs11183505	chr12:38759110	G/T	cg26384229	chr12:38710491	ALG10B	-0.6	-7.9	-0.46	1.08e-13	Morning vs. evening chronotype;
SARC	cis	rs74417235	0.684	rs13179358	chr5:154059746	C/A	cg17344516	chr5:154026930	NA	0.52	5.25	0.33	3.39e-7	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
SARC	cis	rs6772849	0.931	rs60825080	chr3:128384834	G/T	cg01163369	chr3:128370232	RPN1	-0.33	-4.78	-0.3	3.17e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs2228479	0.850	rs117285117	chr16:89910250	T/G	cg06558623	chr16:89946397	TCF25	0.92	6.43	0.39	7.29e-10	Skin colour saturation;
SARC	cis	rs7071206	1.000	rs7071206	chr10:79401316	C/T	cg07817648	chr10:79422355	NA	0.4	5.06	0.31	8.4e-7	Bone mineral density;
SARC	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg03999130	chr15:45571217	NA	0.39	5.09	0.32	7.55e-7	Homoarginine levels;
SARC	cis	rs6912958	0.781	rs9450755	chr6:88303702	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.54	-0.34	8.32e-8	Monocyte percentage of white cells;
SARC	cis	rs5750830	0.594	rs5757648	chr22:39775156	G/A	cg24399712	chr22:39784796	NA	-0.44	-6.11	-0.37	4.14e-9	Intelligence (multi-trait analysis);
SARC	cis	rs4268898	1.000	rs1203	chr2:24443330	A/G	cg26838691	chr2:24397539	C2orf84	0.37	5.09	0.32	7.5e-7	Asthma;
SARC	cis	rs17270561	0.636	rs7775354	chr6:25745266	T/A	cg16482183	chr6:26056742	HIST1H1C	0.43	5.08	0.32	7.76e-7	Iron status biomarkers;
SARC	cis	rs2486288	0.656	rs8039352	chr15:45551790	A/G	cg19305227	chr15:45544335	SLC28A2	0.28	5.32	0.33	2.41e-7	Glomerular filtration rate;
SARC	cis	rs7438	0.506	rs12647126	chr4:170376705	A/G	cg07701716	chr4:170533879	NEK1	0.4	4.76	0.3	3.46e-6	Schizophrenia;
SARC	cis	rs898097	0.812	rs55794221	chr17:80849003	G/A	cg15369054	chr17:80825471	TBCD	0.55	7.65	0.45	5.13e-13	Breast cancer;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg19140410	chr17:78518857	RPTOR	0.66	6.74	0.4	1.24e-10	Lung cancer in ever smokers;
SARC	cis	rs4605213	0.605	rs41524846	chr17:49252238	A/G	cg00965052	chr17:49230932	NME1;NME1-NME2	0.48	4.98	0.31	1.25e-6	Height;
SARC	trans	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.07	-0.42	1.84e-11	Extrinsic epigenetic age acceleration;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg04044021	chr22:38577768	PLA2G6	-0.49	-6.32	-0.38	1.33e-9	Gallstone disease;
SARC	cis	rs34172651	0.606	rs7194189	chr16:24703484	G/T	cg00339695	chr16:24857497	SLC5A11	-0.44	-6.18	-0.38	2.87e-9	Intelligence (multi-trait analysis);
SARC	cis	rs12579753	0.827	rs7311917	chr12:82187551	G/T	cg07988820	chr12:82153109	PPFIA2	-0.52	-6.15	-0.37	3.3e-9	Resting heart rate;
SARC	cis	rs7395581	0.877	rs7127907	chr11:47324472	A/C	cg25783544	chr11:47291846	MADD	0.51	5.77	0.35	2.48e-8	HDL cholesterol;
SARC	trans	rs629535	0.767	rs62513418	chr8:70114376	G/T	cg21567404	chr3:27674614	NA	-1.07	-13.83	-0.67	3.58e-32	Dupuytren's disease;
SARC	cis	rs950169	0.881	rs4081123	chr15:84956235	A/G	cg17507749	chr15:85114479	UBE2QP1	0.77	9.42	0.53	4.67e-18	Schizophrenia;
SARC	cis	rs8014204	0.743	rs35809608	chr14:75254762	A/G	cg06637938	chr14:75390232	RPS6KL1	0.7	10.09	0.55	4.32e-20	Caffeine consumption;
SARC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.64	0.57	8.23e-22	Prudent dietary pattern;
SARC	cis	rs9814567	0.537	rs9879993	chr3:134162559	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.44	5.6	0.34	6.02e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg00684032	chr4:1343700	KIAA1530	0.37	5.27	0.33	3.05e-7	Obesity-related traits;
SARC	cis	rs11097912	0.603	rs3805407	chr4:107240689	T/A	cg09646026	chr4:107269030	AIMP1	-0.45	-4.87	-0.3	2.08e-6	Airflow obstruction;
SARC	cis	rs10791097	0.720	rs6590518	chr11:130733530	C/T	cg12179176	chr11:130786555	SNX19	0.7	10.38	0.56	5.31e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg22834771	chr12:69754056	YEATS4	-0.48	-6.29	-0.38	1.55e-9	Cerebrospinal fluid biomarker levels;
SARC	cis	rs282587	0.502	rs382758	chr13:113400169	C/T	cg02820901	chr13:113351484	ATP11A	-0.49	-4.98	-0.31	1.24e-6	Glycated hemoglobin levels;
SARC	cis	rs449789	0.857	rs625284	chr6:159703373	G/T	cg14500486	chr6:159655392	FNDC1	-0.44	-5.02	-0.31	1.01e-6	Pulse pressure;
SARC	trans	rs9329221	0.686	rs35406700	chr8:10244593	A/G	cg06636001	chr8:8085503	FLJ10661	0.62	7.8	0.46	2.08e-13	Neuroticism;
SARC	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg02462569	chr6:150064036	NUP43	-0.37	-4.82	-0.3	2.59e-6	Lung cancer;
SARC	cis	rs6141769	0.518	rs6057631	chr20:31319149	A/G	cg13636640	chr20:31349939	DNMT3B	-0.44	-4.74	-0.3	3.69e-6	Subjective well-being;
SARC	cis	rs4900538	0.855	rs9788420	chr14:102839338	A/G	cg18135206	chr14:102964638	TECPR2	-0.59	-7.54	-0.44	1.02e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs72634258	0.945	rs67717282	chr1:8041290	C/T	cg00042356	chr1:8021962	PARK7	0.79	7.33	0.43	3.86e-12	Inflammatory bowel disease;
SARC	cis	rs10791097	0.608	rs12363140	chr11:130744268	A/C	cg12179176	chr11:130786555	SNX19	0.73	10.9	0.58	1.26e-22	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs10791323	0.536	rs4937842	chr11:133734542	C/G	cg03690763	chr11:133734501	NA	0.34	5.78	0.35	2.37e-8	Childhood ear infection;
SARC	cis	rs6459804	0.787	rs78566714	chr7:157508951	G/A	cg05731713	chr7:157510257	PTPRN2	0.29	5.53	0.34	8.48e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs9296095	1.000	rs5745568	chr6:33548394	G/T	cg14003231	chr6:33640908	ITPR3	0.4	6.01	0.37	7.23e-9	Platelet count;
SARC	cis	rs7666738	0.830	rs7664169	chr4:99037859	C/T	cg05340658	chr4:99064831	C4orf37	-0.67	-9.05	-0.51	6.01e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs17270561	0.609	rs9358883	chr6:25755515	A/G	cg16482183	chr6:26056742	HIST1H1C	0.42	5.03	0.31	9.6e-7	Iron status biomarkers;
SARC	cis	rs1419980	0.722	rs752452	chr12:7781021	G/A	cg10578777	chr12:7781093	NA	0.56	6.01	0.37	6.92e-9	HDL cholesterol levels;
SARC	cis	rs8114671	0.562	rs6120757	chr20:33488771	C/T	cg24642439	chr20:33292090	TP53INP2	0.5	6.13	0.37	3.65e-9	Height;
SARC	cis	rs7095944	0.584	rs11245347	chr10:126427037	G/T	cg08799069	chr10:126477246	METTL10	-0.4	-4.94	-0.31	1.49e-6	Asthma;
SARC	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs12967884	0.892	rs9965796	chr18:76557002	G/A	cg10946435	chr1:154843044	KCNN3	0.57	6.27	0.38	1.76e-9	Subcutaneous adipose tissue;
SARC	trans	rs9650657	0.655	rs1991651	chr8:10706411	C/G	cg06636001	chr8:8085503	FLJ10661	0.56	7.14	0.42	1.17e-11	Neuroticism;
SARC	cis	rs7659604	0.521	rs6822155	chr4:122673274	C/A	cg19671926	chr4:122722719	EXOSC9	0.56	6.98	0.42	3.02e-11	Type 2 diabetes;
SARC	cis	rs2153535	0.541	rs1414353	chr6:8485642	C/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.43	0.6	2.65e-24	Motion sickness;
SARC	cis	rs4308124	0.708	rs61358692	chr2:111965159	T/C	cg04571233	chr2:111982156	NA	-0.49	-5.7	-0.35	3.63e-8	Vitiligo;
SARC	cis	rs4888262	0.526	rs7193423	chr16:74626340	A/C	ch.16.1684049R	chr16:74565916	GLG1	0.38	4.9	0.31	1.77e-6	Testicular germ cell tumor;
SARC	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg16479474	chr6:28041457	NA	0.37	5.44	0.34	1.37e-7	Depression;
SARC	cis	rs9341808	0.527	rs2505946	chr6:80810683	A/G	cg08355045	chr6:80787529	NA	0.39	6.25	0.38	1.95e-9	Sitting height ratio;
SARC	cis	rs10779751	0.726	rs1205593	chr1:11252716	T/C	cg08854313	chr1:11322531	MTOR	0.79	10.04	0.55	6.21e-20	Body mass index;
SARC	cis	rs7843479	0.562	rs4872191	chr8:21824547	A/G	cg17168535	chr8:21777572	XPO7	0.86	13.42	0.66	8.64e-31	Mean corpuscular volume;
SARC	cis	rs72627123	0.867	rs80083802	chr14:74456996	C/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	5.52	0.34	8.92e-8	Morning vs. evening chronotype;
SARC	cis	rs3784262	1.000	rs4646622	chr15:58257199	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.4	-5.92	-0.36	1.13e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs10420951	0.535	rs79557920	chr19:18528362	G/A	cg17952467	chr19:17758336	UNC13A	0.6	4.81	0.3	2.66e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg15052019	chr19:19431593	KIAA0892;SF4	-0.39	-4.75	-0.3	3.58e-6	Tonsillectomy;
SARC	cis	rs7769051	0.522	rs6928933	chr6:133116073	G/A	cg22852734	chr6:133119734	C6orf192	1.25	7.92	0.46	9.87e-14	Type 2 diabetes nephropathy;
SARC	cis	rs9291683	0.530	rs35908990	chr4:9976105	G/A	cg11266682	chr4:10021025	SLC2A9	0.39	6.99	0.42	2.85e-11	Bone mineral density;
SARC	cis	rs6570726	0.791	rs9497357	chr6:145912888	G/A	cg23711669	chr6:146136114	FBXO30	0.83	13.24	0.66	3.17e-30	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg08280861	chr8:58055591	NA	0.6	5.84	0.36	1.75e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7264396	0.635	rs2024854	chr20:34511189	T/C	cg12579300	chr20:34535607	PHF20	-0.43	-4.98	-0.31	1.26e-6	Total cholesterol levels;
SARC	cis	rs4563143	0.514	rs55727361	chr19:29300415	A/T	cg04546413	chr19:29218101	NA	0.58	6.95	0.41	3.56e-11	Methadone dose in opioid dependence;
SARC	cis	rs1797081	0.561	rs2603795	chr10:16860256	A/G	cg23933602	chr10:16859644	RSU1	0.78	11.25	0.59	9.58e-24	Platelet distribution width;
SARC	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg06558623	chr16:89946397	TCF25	0.9	6.1	0.37	4.45e-9	Skin colour saturation;
SARC	cis	rs35110281	0.774	rs1003280	chr21:44997322	A/G	cg21573476	chr21:45109991	RRP1B	-0.47	-6.89	-0.41	5.29e-11	Mean corpuscular volume;
SARC	cis	rs9814567	0.929	rs2241556	chr3:134183312	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.5	6.21	0.38	2.45e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs11077998	0.903	rs8064554	chr17:80501093	A/G	cg10255544	chr17:80519551	FOXK2	0.43	6.32	0.38	1.32e-9	Reticulocyte fraction of red cells;
SARC	cis	rs2718058	0.630	rs2722228	chr7:37859818	G/A	cg15028436	chr7:37888078	TXNDC3	0.39	4.93	0.31	1.54e-6	Alzheimer's disease (late onset);
SARC	cis	rs12142240	0.698	rs932816	chr1:46859749	G/A	cg10495392	chr1:46806563	NSUN4	0.65	6.88	0.41	5.6e-11	Menopause (age at onset);
SARC	cis	rs17854409	1.000	rs66956644	chr20:61484499	T/C	cg05147244	chr20:61493195	TCFL5	0.94	5.81	0.36	2.09e-8	Obesity-related traits;
SARC	cis	rs918629	0.716	rs6861531	chr5:95274702	A/G	cg16656078	chr5:95278638	ELL2	-0.62	-7.54	-0.44	1.03e-12	IgG glycosylation;
SARC	cis	rs12079745	0.793	rs10800443	chr1:169355529	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.81	-5.31	-0.33	2.62e-7	QT interval;
SARC	cis	rs12545109	0.800	rs2610058	chr8:57409120	G/A	cg19413350	chr8:57351067	NA	-0.43	-4.77	-0.3	3.18e-6	Obesity-related traits;
SARC	cis	rs11155671	0.530	rs6557133	chr6:150195384	G/T	cg09699651	chr6:150184138	LRP11	0.49	6.01	0.37	7.19e-9	Testicular germ cell tumor;
SARC	cis	rs6831352	0.918	rs2602894	chr4:100045647	A/G	cg12011299	chr4:100065546	ADH4	0.34	5.64	0.35	4.82e-8	Alcohol dependence;
SARC	cis	rs9814567	0.752	rs13075117	chr3:134329535	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.5	6.5	0.39	4.83e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg25952890	chr19:58913133	NA	0.39	5.54	0.34	8.18e-8	Uric acid clearance;
SARC	cis	rs13191362	1.000	rs28360546	chr6:163210973	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.65	5.72	0.35	3.18e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs72781680	0.950	rs72798404	chr2:24180125	C/T	cg08917208	chr2:24149416	ATAD2B	0.94	9.09	0.51	4.53e-17	Lymphocyte counts;
SARC	cis	rs7524258	0.868	rs11120885	chr1:7306755	C/G	cg07173049	chr1:7289937	CAMTA1	0.34	6.41	0.39	7.81e-10	Tourette's syndrome or obsessive-compulsive disorder;
SARC	cis	rs7551222	0.752	rs4328119	chr1:204564986	C/T	cg20240347	chr1:204465584	NA	-0.27	-4.93	-0.31	1.58e-6	Schizophrenia;
SARC	cis	rs748404	0.660	rs693510	chr15:43714625	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	5.75	0.35	2.76e-8	Lung cancer;
SARC	cis	rs9325144	0.555	rs7960411	chr12:38703019	A/G	cg13010199	chr12:38710504	ALG10B	-0.54	-6.89	-0.41	5.11e-11	Morning vs. evening chronotype;
SARC	cis	rs7551222	0.716	rs4951083	chr1:204582730	A/G	cg07972458	chr1:204535000	NA	0.36	4.76	0.3	3.46e-6	Schizophrenia;
SARC	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg22535103	chr8:58192502	C8orf71	-0.73	-7.31	-0.43	4.37e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs735539	0.521	rs2762989	chr13:21392521	C/G	cg16922012	chr13:21400325	XPO4	-0.39	-5.08	-0.32	7.92e-7	Dental caries;
SARC	cis	rs3796352	1.000	rs58660500	chr3:53086573	C/T	cg07884673	chr3:53033167	SFMBT1	0.86	5.68	0.35	3.95e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg04772025	chr11:68637568	NA	-0.5	-6.24	-0.38	2.02e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs4423214	0.959	rs11606611	chr11:71164046	C/G	cg05163923	chr11:71159392	DHCR7	0.65	8.66	0.49	8.18e-16	Vitamin D levels;
SARC	trans	rs61931739	0.500	rs7309421	chr12:34553795	C/T	cg13010199	chr12:38710504	ALG10B	0.83	11.77	0.61	2.09e-25	Morning vs. evening chronotype;
SARC	cis	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg03060546	chr3:49711283	APEH	0.59	7.42	0.44	2.22e-12	Resting heart rate;
SARC	cis	rs9911578	1.000	rs11869828	chr17:56609525	G/A	cg05425664	chr17:57184151	TRIM37	0.65	7.98	0.46	6.49e-14	Intelligence (multi-trait analysis);
SARC	cis	rs72945132	0.882	rs17160753	chr11:70131462	A/G	cg05964544	chr11:70165517	PPFIA1	-0.6	-5.85	-0.36	1.66e-8	Coronary artery disease;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg06160221	chr16:89734445	C16orf55	-0.77	-6.58	-0.4	3.03e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg22857025	chr5:266934	NA	-1.06	-11.63	-0.61	5.91e-25	Breast cancer;
SARC	cis	rs1580019	0.510	rs4723162	chr7:32543804	C/A	cg06627557	chr7:32535165	LSM5;AVL9	0.98	17.52	0.75	2.08e-44	Cognitive ability;
SARC	cis	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg18252515	chr7:66147081	NA	-1.41	-12.63	-0.64	3.24e-28	Gout;
SARC	cis	rs7412746	0.658	rs72704682	chr1:150897677	A/T	cg15448220	chr1:150897856	SETDB1	0.51	6.65	0.4	2.02e-10	Melanoma;
SARC	cis	rs7681440	0.560	rs1442147	chr4:90748738	C/T	cg06632027	chr4:90757378	SNCA	-0.42	-5.25	-0.33	3.41e-7	Dementia with Lewy bodies;
SARC	cis	rs7552404	0.696	rs67487205	chr1:76373756	T/C	cg10523679	chr1:76189770	ACADM	0.45	5.13	0.32	6.08e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs10861342	1.000	rs115224406	chr12:105578060	C/T	cg23923672	chr12:105501055	KIAA1033	0.7	5.25	0.33	3.49e-7	IgG glycosylation;
SARC	cis	rs7474896	0.559	rs1208779	chr10:38077729	A/C	cg00409905	chr10:38381863	ZNF37A	-0.44	-4.93	-0.31	1.54e-6	Obesity (extreme);
SARC	cis	rs7666738	0.753	rs28390295	chr4:99028497	C/A	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg09699651	chr6:150184138	LRP11	0.39	4.87	0.3	2.04e-6	Lung cancer;
SARC	cis	rs57506017	0.585	rs10950391	chr7:12261829	A/G	cg23422036	chr7:12250390	TMEM106B	0.49	6.41	0.39	8.02e-10	Neuroticism;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg00619915	chr2:44497795	NA	0.54	6.41	0.39	7.87e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs1215050	0.755	rs9991112	chr4:98651479	A/C	cg05340658	chr4:99064831	C4orf37	-0.46	-6.0	-0.37	7.57e-9	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg11644478	chr21:40555479	PSMG1	1.04	14.62	0.69	8.99e-35	Cognitive function;
SARC	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg05896524	chr21:47604654	C21orf56	0.51	6.4	0.39	8.57e-10	Testicular germ cell tumor;
SARC	cis	rs8023845	1.000	rs3759843	chr15:40453075	A/G	cg20259534	chr15:40453036	BUB1B	-0.78	-8.91	-0.5	1.52e-16	Chronic lymphocytic leukemia;
SARC	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg22903471	chr2:27725779	GCKR	-0.43	-6.4	-0.39	8.46e-10	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs116095464	0.558	rs10056628	chr5:279512	G/A	cg22857025	chr5:266934	NA	-1.11	-10.4	-0.56	4.75e-21	Breast cancer;
SARC	trans	rs9329221	0.521	rs4841294	chr8:10105068	G/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.59	-0.45	7.67e-13	Neuroticism;
SARC	cis	rs2180341	1.000	rs13218061	chr6:127653758	G/A	cg27446573	chr6:127587934	RNF146	1.04	14.77	0.7	2.87e-35	Breast cancer;
SARC	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg04944784	chr2:26401820	FAM59B	0.6	7.81	0.46	1.93e-13	Gut microbiome composition (summer);
SARC	cis	rs2766692	0.843	rs10873515	chr14:100766664	C/T	cg14866419	chr14:100704911	YY1	-0.47	-5.43	-0.34	1.4e-7	Electroencephalographic traits in alcoholism;
SARC	cis	rs1348850	0.651	rs4893936	chr2:178240676	C/G	cg23306229	chr2:178417860	TTC30B	0.41	4.81	0.3	2.68e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9875589	0.957	rs62234598	chr3:13964610	G/A	cg19554555	chr3:13937349	NA	0.53	6.73	0.4	1.3e-10	Ovarian reserve;
SARC	trans	rs9929218	0.551	rs9888942	chr16:68727572	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.86	15.01	0.7	4.54e-36	Colorectal cancer;
SARC	cis	rs1448094	0.556	rs61930626	chr12:86167445	A/G	cg02569458	chr12:86230093	RASSF9	0.37	5.03	0.31	9.77e-7	Major depressive disorder;
SARC	trans	rs2898290	0.506	rs2736311	chr8:11252170	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.63	-0.4	2.31e-10	Systolic blood pressure;
SARC	cis	rs7412746	0.611	rs66847267	chr1:150875173	C/A	cg15448220	chr1:150897856	SETDB1	0.52	6.87	0.41	5.67e-11	Melanoma;
SARC	cis	rs11250098	0.547	rs2409764	chr8:11281273	C/T	cg00262122	chr8:11665843	FDFT1	0.4	4.96	0.31	1.34e-6	Morning vs. evening chronotype;
SARC	cis	rs3126085	0.935	rs11584427	chr1:152299788	A/G	cg26876637	chr1:152193138	HRNR	-0.52	-5.42	-0.33	1.45e-7	Atopic dermatitis;
SARC	cis	rs9291683	0.588	rs3796842	chr4:9995851	A/T	cg11266682	chr4:10021025	SLC2A9	0.44	7.84	0.46	1.6e-13	Bone mineral density;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg05839201	chr16:30194815	CORO1A	-0.62	-6.35	-0.38	1.13e-9	Lung cancer in ever smokers;
SARC	cis	rs2952156	0.920	rs903502	chr17:37829604	C/T	cg00129232	chr17:37814104	STARD3	-0.7	-9.9	-0.54	1.66e-19	Asthma;
SARC	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg24675658	chr1:53192096	ZYG11B	0.66	9.49	0.53	2.85e-18	Monocyte count;
SARC	cis	rs854765	0.647	rs741782	chr17:18019712	T/C	cg04398451	chr17:18023971	MYO15A	-0.58	-8.9	-0.5	1.55e-16	Total body bone mineral density;
SARC	cis	rs11630290	0.592	rs4777332	chr15:64158112	A/G	cg12036633	chr15:63758958	NA	0.49	5.27	0.33	3.16e-7	Iris characteristics;
SARC	cis	rs262150	0.522	rs2527182	chr7:158813812	A/G	cg19418458	chr7:158789849	NA	-0.42	-6.01	-0.37	6.98e-9	Facial morphology (factor 20);
SARC	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.47	5.91	0.36	1.21e-8	Tonsillectomy;
SARC	cis	rs698813	0.763	rs786614	chr2:44590567	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.65	7.73	0.45	3.3e-13	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs7481584	0.581	rs515481	chr11:3047184	A/G	cg25174290	chr11:3078921	CARS	-0.59	-8.27	-0.48	1.02e-14	Calcium levels;
SARC	cis	rs1008375	1.000	rs2315560	chr4:17677305	C/G	cg27347728	chr4:17578864	LAP3	0.45	5.54	0.34	8.23e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs921968	0.643	rs483172	chr2:219428299	A/G	cg02176678	chr2:219576539	TTLL4	0.35	5.16	0.32	5.3e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg27266027	chr21:40555129	PSMG1	-0.45	-5.05	-0.31	9.11e-7	Cognitive function;
SARC	cis	rs1144333	0.655	rs1938323	chr1:76464492	G/A	cg03433033	chr1:76189801	ACADM	0.63	5.15	0.32	5.47e-7	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs7572733	0.555	rs11903129	chr2:198918591	A/T	cg00792783	chr2:198669748	PLCL1	0.43	4.75	0.3	3.62e-6	Dermatomyositis;
SARC	cis	rs2594989	0.943	rs2594995	chr3:11369117	A/G	cg00170343	chr3:11313890	ATG7	-0.52	-4.94	-0.31	1.47e-6	Circulating chemerin levels;
SARC	cis	rs6866344	0.697	rs58549512	chr5:178133204	C/T	cg10224037	chr5:178157518	ZNF354A	1.01	12.62	0.64	3.65e-28	Neutrophil percentage of white cells;
SARC	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.82	12.45	0.63	1.27e-27	Personality dimensions;
SARC	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg13385521	chr17:29058706	SUZ12P	0.57	5.13	0.32	5.99e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg13206674	chr6:150067644	NUP43	0.41	5.36	0.33	2.01e-7	Lung cancer;
SARC	cis	rs9948	0.786	rs56797569	chr2:97413555	G/T	cg01990225	chr2:97406019	LMAN2L	-0.95	-6.57	-0.4	3.25e-10	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.34	-5.13	-0.32	6.06e-7	Longevity;Endometriosis;
SARC	cis	rs6570726	0.935	rs369214	chr6:145856709	G/A	cg23711669	chr6:146136114	FBXO30	0.78	12.0	0.62	3.86e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4689388	0.791	rs1046317	chr4:6304242	T/C	cg00701064	chr4:6280414	WFS1	0.53	7.53	0.44	1.11e-12	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs3087591	1.000	rs9902893	chr17:29625638	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.53	-6.53	-0.39	4.04e-10	Hip circumference;
SARC	cis	rs35164067	1.000	rs35164067	chr19:10525181	G/A	cg21868191	chr19:10515988	NA	-0.42	-5.31	-0.33	2.54e-7	Inflammatory bowel disease;
SARC	cis	rs9398803	0.796	rs1361107	chr6:126767511	A/C	cg20229609	chr6:126660872	C6orf173	0.4	5.73	0.35	3.09e-8	Male-pattern baldness;
SARC	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg13628971	chr7:2884303	GNA12	0.59	6.72	0.4	1.38e-10	Height;
SARC	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	8.54	0.49	1.71e-15	Alzheimer's disease;
SARC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg08677398	chr8:58056175	NA	0.44	5.27	0.33	3.14e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs1853207	0.867	rs78431362	chr10:96603091	T/A	cg02737782	chr1:8014393	NA	-0.95	-6.37	-0.39	1.01e-9	Blood metabolite levels;
SARC	cis	rs6952808	0.707	rs13244345	chr7:1973004	A/G	cg21782813	chr7:2030301	MAD1L1	0.35	5.34	0.33	2.2e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg16325326	chr1:53192061	ZYG11B	0.68	9.32	0.52	9.11e-18	Monocyte count;
SARC	cis	rs7523050	0.643	rs35520362	chr1:109419841	C/T	cg08274380	chr1:109419600	GPSM2	1.07	8.41	0.48	4.12e-15	Fat distribution (HIV);
SARC	cis	rs735396	1.000	rs735396	chr12:121438844	T/C	cg02403541	chr12:121454288	C12orf43	0.72	9.48	0.53	2.97e-18	N-glycan levels;
SARC	cis	rs13191362	0.935	rs35049401	chr6:162968464	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.53	4.76	0.3	3.4e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs752010	0.668	rs10890147	chr1:42089725	A/T	cg06885757	chr1:42089581	HIVEP3	0.57	8.46	0.48	3.04e-15	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs1018836	0.884	rs13279263	chr8:91648780	T/C	cg16814680	chr8:91681699	NA	-0.81	-12.99	-0.65	2.14e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs6088813	0.883	rs2425061	chr20:33915571	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.43	5.2	0.32	4.39e-7	Height;
SARC	cis	rs473651	0.716	rs548179	chr2:239320505	G/A	cg21699342	chr2:239360505	ASB1	0.38	5.47	0.34	1.19e-7	Multiple system atrophy;
SARC	cis	rs9399135	0.933	rs28384512	chr6:135376232	C/T	cg24558204	chr6:135376177	HBS1L	0.46	6.18	0.38	2.88e-9	Red blood cell count;
SARC	cis	rs34172651	0.917	rs6497756	chr16:24798291	G/T	cg04756594	chr16:24857601	SLC5A11	0.35	5.61	0.35	5.65e-8	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg18876405	chr7:65276391	NA	-0.44	-4.91	-0.31	1.75e-6	Aortic root size;
SARC	cis	rs7772486	0.754	rs6922507	chr6:146250155	A/T	cg23711669	chr6:146136114	FBXO30	-0.81	-12.93	-0.65	3.43e-29	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.63	-0.4	2.28e-10	Total body bone mineral density;
SARC	cis	rs950169	0.922	rs2033284	chr15:84946273	C/T	cg24253500	chr15:84953950	NA	0.36	5.18	0.32	4.78e-7	Schizophrenia;
SARC	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg03433033	chr1:76189801	ACADM	-0.42	-5.4	-0.33	1.66e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs72945132	0.882	rs7943840	chr11:70228615	C/A	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.88	-0.36	1.41e-8	Coronary artery disease;
SARC	cis	rs965469	0.895	rs6139123	chr20:3396634	C/T	cg25506879	chr20:3388711	C20orf194	-0.57	-5.92	-0.36	1.16e-8	IFN-related cytopenia;
SARC	cis	rs11190604	1.000	rs2495745	chr10:102329075	A/G	cg07080220	chr10:102295463	HIF1AN	0.77	8.98	0.51	9.28e-17	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs10892173	0.846	rs2298647	chr11:117671641	A/T	cg21640587	chr11:117668038	DSCAML1	0.48	6.73	0.4	1.29e-10	Myopia;
SARC	cis	rs3857536	0.842	rs2188591	chr6:66939511	A/T	cg07460842	chr6:66804631	NA	-0.51	-5.83	-0.36	1.86e-8	Blood trace element (Cu levels);
SARC	cis	rs55692411	0.537	rs62262118	chr3:50003586	G/A	cg14019146	chr3:50243930	SLC38A3	-0.37	-5.29	-0.33	2.78e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.51	-6.47	-0.39	5.68e-10	Lymphocyte counts;
SARC	cis	rs35995292	0.534	rs917322	chr7:38943165	A/T	cg19327137	chr7:38886074	VPS41	-0.53	-7.86	-0.46	1.41e-13	Subjective well-being (multi-trait analysis);
SARC	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg22496380	chr5:211416	CCDC127	-0.88	-9.51	-0.53	2.5e-18	Breast cancer;
SARC	cis	rs9381040	1.000	rs2093396	chr6:41155000	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.48	-5.45	-0.34	1.29e-7	Alzheimer's disease (late onset);
SARC	cis	rs7949030	0.653	rs2849030	chr11:62366986	G/A	cg13298116	chr11:62369859	EML3;MTA2	-0.45	-7.13	-0.42	1.26e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs17376456	0.825	rs10036024	chr5:93074804	C/A	cg21475434	chr5:93447410	FAM172A	0.65	5.09	0.32	7.24e-7	Diabetic retinopathy;
SARC	cis	rs9392653	1.000	rs9392650	chr6:5070660	A/C	cg00563771	chr6:5110810	LYRM4	-0.45	-5.24	-0.32	3.6e-7	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs6598955	0.543	rs17163720	chr1:26549399	A/G	cg04990556	chr1:26633338	UBXN11	-0.72	-7.67	-0.45	4.58e-13	Obesity-related traits;
SARC	cis	rs637571	0.522	rs679581	chr11:65746653	A/G	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.42	-5.1	-0.32	6.99e-7	Eosinophil percentage of white cells;
SARC	cis	rs2370759	1.000	rs11008865	chr10:32574842	C/T	cg05361325	chr10:32636312	EPC1	-0.74	-6.51	-0.39	4.62e-10	Sexual dysfunction (female);
SARC	cis	rs748404	0.660	rs2444251	chr15:43788595	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	5.58	0.34	6.68e-8	Lung cancer;
SARC	cis	rs11583043	0.918	rs11581062	chr1:101407519	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.48	-5.89	-0.36	1.33e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs6448317	0.556	rs4697076	chr4:24908601	G/A	cg21108841	chr4:24914750	CCDC149	0.49	4.79	0.3	3.04e-6	Heschl's gyrus morphology;
SARC	cis	rs763121	0.853	rs2267393	chr22:39101619	G/C	cg21395723	chr22:39101663	GTPBP1	0.55	6.56	0.39	3.46e-10	Menopause (age at onset);
SARC	cis	rs7178909	0.872	rs2165070	chr15:90408976	C/A	cg19708238	chr15:90437601	AP3S2	0.6	7.51	0.44	1.26e-12	Common traits (Other);
SARC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.05	0.8	1.19e-52	Prudent dietary pattern;
SARC	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg19223190	chr17:80058835	NA	0.45	6.35	0.38	1.13e-9	Life satisfaction;
SARC	trans	rs11098499	0.909	rs28714195	chr4:120316950	A/T	cg25214090	chr10:38739885	LOC399744	0.55	7.14	0.42	1.15e-11	Corneal astigmatism;
SARC	cis	rs9858542	0.953	rs7623659	chr3:49414791	C/T	cg03060546	chr3:49711283	APEH	-0.57	-7.14	-0.42	1.19e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs3008870	0.755	rs3736905	chr1:67392614	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.62	7.88	0.46	1.23e-13	Lymphocyte percentage of white cells;
SARC	cis	rs6807915	0.504	rs167467	chr3:12281183	A/G	cg04748988	chr3:12329223	PPARG	0.44	6.0	0.37	7.3e-9	Leprosy;
SARC	cis	rs16976116	0.619	rs7172575	chr15:55462544	T/C	cg11288833	chr15:55489084	RSL24D1	-0.62	-5.4	-0.33	1.65e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs17270561	0.636	rs1165216	chr6:25797971	G/A	cg16482183	chr6:26056742	HIST1H1C	0.48	6.15	0.37	3.3e-9	Iron status biomarkers;
SARC	cis	rs1881797	1.000	rs12061460	chr1:247686787	G/A	cg18198730	chr1:247681584	NA	0.48	5.29	0.33	2.85e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs7011049	1.000	rs72643585	chr8:53847651	A/G	cg26025543	chr8:53854495	NA	0.6	5.43	0.34	1.42e-7	Systolic blood pressure;
SARC	cis	rs7208859	0.573	rs7222803	chr17:29119897	A/G	cg13385521	chr17:29058706	SUZ12P	0.89	7.74	0.45	2.96e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg17971929	chr21:40555470	PSMG1	-0.59	-7.51	-0.44	1.27e-12	Menarche (age at onset);
SARC	trans	rs459571	0.839	rs10993895	chr9:136887726	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	0.58	6.84	0.41	7.03e-11	Platelet distribution width;
SARC	cis	rs2153535	0.580	rs2327056	chr6:8443305	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg24110177	chr3:50126178	RBM5	-0.62	-8.02	-0.47	5.18e-14	Intelligence (multi-trait analysis);
SARC	cis	rs7647973	0.593	rs7620848	chr3:49828021	G/C	cg03060546	chr3:49711283	APEH	-0.63	-6.63	-0.4	2.28e-10	Menarche (age at onset);
SARC	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg07701084	chr6:150067640	NUP43	0.41	5.42	0.33	1.5e-7	Lung cancer;
SARC	cis	rs11168351	1.000	rs11168351	chr12:48403765	C/T	cg24011408	chr12:48396354	COL2A1	0.49	6.04	0.37	6.05e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs559928	0.606	rs12419038	chr11:63912736	A/G	cg05555928	chr11:63887634	MACROD1	-0.51	-5.11	-0.32	6.63e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs7772486	0.790	rs3923579	chr6:146230232	C/G	cg05347473	chr6:146136440	FBXO30	-0.49	-6.63	-0.4	2.33e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs79149102	0.579	rs73436579	chr15:75294514	C/T	cg09165964	chr15:75287851	SCAMP5	-0.95	-8.78	-0.5	3.63e-16	Lung cancer;
SARC	cis	rs6952809	0.532	rs6956223	chr7:2431331	T/C	cg05083358	chr7:2394359	EIF3B	-0.6	-5.6	-0.34	6.08e-8	Multiple sclerosis;
SARC	cis	rs6732160	0.845	rs10203125	chr2:73361151	C/G	cg01422370	chr2:73384389	NA	0.33	5.44	0.34	1.36e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.44	-5.6	-0.34	5.98e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7615952	1.000	rs7616044	chr3:125649354	G/C	cg05084668	chr3:125655381	ALG1L	-0.68	-6.94	-0.41	3.95e-11	Blood pressure (smoking interaction);
SARC	cis	rs74181299	0.890	rs2723062	chr2:65280220	G/A	cg20592124	chr2:65290738	CEP68	0.45	6.51	0.39	4.49e-10	Pulse pressure;
SARC	cis	rs995000	0.931	rs2366636	chr1:63056670	G/A	cg06896770	chr1:63153194	DOCK7	0.9	13.28	0.66	2.36e-30	Triglyceride levels;
SARC	cis	rs12908161	1.000	rs62019464	chr15:85294469	T/A	cg17507749	chr15:85114479	UBE2QP1	0.55	6.22	0.38	2.33e-9	Schizophrenia;
SARC	cis	rs7312933	0.558	rs11181501	chr12:42822671	G/A	cg19980929	chr12:42632907	YAF2	0.46	6.58	0.4	3e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs765787	0.530	rs1648285	chr15:45517505	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.18	-0.32	4.82e-7	Uric acid levels;
SARC	cis	rs7680126	0.644	rs4697703	chr4:10107431	A/G	cg11266682	chr4:10021025	SLC2A9	-0.36	-4.97	-0.31	1.27e-6	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
SARC	cis	rs9916302	0.706	rs667193	chr17:37448835	T/C	cg15445000	chr17:37608096	MED1	-0.45	-4.92	-0.31	1.62e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs644799	0.965	rs2508713	chr11:95547927	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	15.09	0.7	2.3e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg05872129	chr22:39784769	NA	-0.44	-6.18	-0.38	2.8e-9	Intelligence (multi-trait analysis);
SARC	cis	rs6582630	0.502	rs11504451	chr12:38425294	G/A	cg26384229	chr12:38710491	ALG10B	0.81	10.79	0.58	2.8e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9807989	0.507	rs3755266	chr2:103042712	G/A	cg03938978	chr2:103052716	IL18RAP	0.32	5.18	0.32	4.72e-7	Asthma;
SARC	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg11764359	chr7:65958608	NA	-0.66	-7.91	-0.46	1.04e-13	Aortic root size;
SARC	cis	rs4891159	0.790	rs56077581	chr18:74116865	T/G	cg24786174	chr18:74118243	ZNF516	-0.68	-9.82	-0.54	2.85e-19	Longevity;
SARC	cis	rs7552404	0.731	rs10873788	chr1:76367857	A/C	cg03433033	chr1:76189801	ACADM	0.43	4.9	0.31	1.76e-6	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs11122272	0.735	rs2474630	chr1:231535335	G/A	cg06096015	chr1:231504339	EGLN1	0.38	5.66	0.35	4.48e-8	Hemoglobin concentration;
SARC	cis	rs35213789	0.562	rs12671695	chr7:69033614	G/A	cg10619644	chr7:69149951	AUTS2	-0.36	-5.07	-0.32	8.07e-7	Childhood ear infection;
SARC	cis	rs7635838	0.859	rs34621655	chr3:11530121	T/C	cg00170343	chr3:11313890	ATG7	0.6	8.21	0.47	1.51e-14	HDL cholesterol;
SARC	cis	rs2439831	0.702	rs28699233	chr15:44122866	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.93	7.72	0.45	3.41e-13	Lung cancer in ever smokers;
SARC	cis	rs9640161	0.871	rs56156367	chr7:150047201	A/T	cg21361702	chr7:150065534	REPIN1	0.51	5.45	0.34	1.26e-7	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs76419734	1.000	rs11723240	chr4:106736936	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	5.33	0.33	2.37e-7	Post bronchodilator FEV1;
SARC	trans	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg04751069	chr16:89787483	ZNF276;C16orf7	-0.69	-6.3	-0.38	1.47e-9	Cutaneous psoriasis;
SARC	cis	rs16973500	0.808	rs57807129	chr16:71948043	T/C	cg09427745	chr16:71932006	KIAA0174	-0.56	-5.3	-0.33	2.71e-7	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
SARC	trans	rs61931739	1.000	rs61931739	chr12:34089973	C/T	cg26384229	chr12:38710491	ALG10B	-0.57	-6.86	-0.41	6.13e-11	Morning vs. evening chronotype;
SARC	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.67	5.42	0.33	1.47e-7	Initial pursuit acceleration;
SARC	cis	rs4423214	1.000	rs12789751	chr11:71164471	G/A	cg05163923	chr11:71159392	DHCR7	0.65	8.57	0.49	1.4e-15	Vitamin D levels;
SARC	cis	rs10754283	0.967	rs10801759	chr1:90113745	A/G	cg21401794	chr1:90099060	LRRC8C	0.59	8.09	0.47	3.24e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs2180341	1.000	rs9321073	chr6:127609691	C/T	cg27446573	chr6:127587934	RNF146	1.01	14.2	0.68	2.18e-33	Breast cancer;
SARC	cis	rs7216064	0.954	rs4790974	chr17:65951107	A/T	cg12091567	chr17:66097778	LOC651250	0.77	8.57	0.49	1.42e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg06873352	chr17:61820015	STRADA	0.53	6.82	0.41	7.72e-11	Prudent dietary pattern;
SARC	cis	rs17376456	0.825	rs17372649	chr5:93126096	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.71	6.57	0.4	3.3e-10	Diabetic retinopathy;
SARC	trans	rs36093844	0.605	rs79719453	chr11:85582217	C/A	cg27065003	chr5:122429449	PRDM6	-0.55	-6.46	-0.39	5.9e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs12048904	0.505	rs10493936	chr1:101213335	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.64	-7.32	-0.43	4.09e-12	Multiple sclerosis;
SARC	trans	rs10746997	0.617	rs1353343	chr9:78851588	C/T	cg22374213	chr18:67136976	DOK6	0.39	6.52	0.39	4.31e-10	Response to fenofibrate (adiponectin levels);
SARC	cis	rs6121246	0.909	rs3203770	chr20:30382315	A/G	cg13852791	chr20:30311386	BCL2L1	0.84	9.07	0.51	5.06e-17	Mean corpuscular hemoglobin;
SARC	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg07343612	chr16:622815	PIGQ	-0.62	-8.74	-0.5	4.55e-16	Height;
SARC	cis	rs72781680	0.582	rs72783611	chr2:24291445	C/T	cg06627628	chr2:24431161	ITSN2	-0.57	-6.02	-0.37	6.7e-9	Lymphocyte counts;
SARC	cis	rs1568889	0.667	rs7123947	chr11:28399908	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.66	7.99	0.46	6.09e-14	Bipolar disorder;
SARC	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg13393036	chr8:95962371	TP53INP1	-0.39	-6.55	-0.39	3.61e-10	Type 2 diabetes;
SARC	cis	rs11098499	0.865	rs28753180	chr4:120405367	A/T	cg24375607	chr4:120327624	NA	0.42	4.99	0.31	1.17e-6	Corneal astigmatism;
SARC	cis	rs9788682	0.747	rs2958719	chr15:78743029	G/A	cg06917634	chr15:78832804	PSMA4	0.51	5.35	0.33	2.09e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs9814567	1.000	rs6763088	chr3:134254989	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	7.08	0.42	1.73e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.42	-6.45	-0.39	6.22e-10	Total body bone mineral density;
SARC	cis	rs7084402	0.967	rs1626532	chr10:60294685	A/T	cg07615347	chr10:60278583	BICC1	0.6	8.91	0.5	1.45e-16	Refractive error;
SARC	cis	rs4481887	0.927	rs6666903	chr1:248465582	T/A	cg00666640	chr1:248458726	OR2T12	0.32	5.5	0.34	9.86e-8	Common traits (Other);
SARC	cis	rs11098499	0.818	rs12498599	chr4:120468503	C/T	cg09307838	chr4:120376055	NA	0.91	12.25	0.63	5.66e-27	Corneal astigmatism;
SARC	cis	rs1468333	0.567	rs6889491	chr5:137672151	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.62	7.31	0.43	4.32e-12	Resting heart rate;
SARC	cis	rs950169	0.580	rs17532346	chr15:85171495	A/C	cg17507749	chr15:85114479	UBE2QP1	0.58	6.91	0.41	4.72e-11	Schizophrenia;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg22553461	chr17:26989142	SUPT6H;SDF2	-0.5	-6.29	-0.38	1.54e-9	Schizophrenia;
SARC	cis	rs595982	0.527	rs73061658	chr19:49372376	G/C	cg15549821	chr19:49342101	PLEKHA4	-0.64	-7.15	-0.42	1.09e-11	Red cell distribution width;
SARC	cis	rs8114671	0.562	rs6119545	chr20:33522869	T/C	cg08999081	chr20:33150536	PIGU	0.33	4.89	0.3	1.89e-6	Height;
SARC	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-5.62	-0.35	5.49e-8	Bipolar disorder;
SARC	cis	rs9640161	0.830	rs17173681	chr7:150059414	A/G	cg17279839	chr7:150038598	RARRES2	-0.35	-5.25	-0.33	3.43e-7	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs9910055	0.529	rs400460	chr17:42182770	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.46	-5.5	-0.34	1.01e-7	Total body bone mineral density;
SARC	cis	rs643506	0.967	rs2850248	chr11:111644824	C/A	cg09085632	chr11:111637200	PPP2R1B	0.51	5.77	0.35	2.53e-8	Breast cancer;
SARC	cis	rs2836950	1.000	rs2836950	chr21:40604429	C/G	cg11890956	chr21:40555474	PSMG1	-0.58	-6.8	-0.41	8.61e-11	Menarche (age at onset);
SARC	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	5.42	0.33	1.47e-7	Bipolar disorder;
SARC	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg17971929	chr21:40555470	PSMG1	-0.86	-11.54	-0.6	1.12e-24	Cognitive function;
SARC	cis	rs2777491	0.574	rs1757468	chr15:41743574	T/A	cg18705301	chr15:41695430	NDUFAF1	-1.16	-19.02	-0.78	2.61e-49	Ulcerative colitis;
SARC	cis	rs5769765	0.817	rs8142561	chr22:50291750	T/C	cg03033257	chr22:50311977	ALG12;CRELD2	0.52	5.33	0.33	2.28e-7	Schizophrenia;
SARC	cis	rs12912251	1.000	rs2172835	chr15:38990171	C/T	cg01338139	chr15:38987640	C15orf53	-0.5	-5.6	-0.34	6.12e-8	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
SARC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg11965913	chr1:205819406	PM20D1	1.01	18.65	0.77	4.26e-48	Menarche (age at onset);
SARC	cis	rs7123876	0.587	rs72962169	chr11:72365669	C/T	cg03713592	chr11:72463424	ARAP1	0.54	4.89	0.3	1.91e-6	Body mass index;
SARC	cis	rs7246657	0.525	rs997516	chr19:37474264	T/C	cg23950597	chr19:37808831	NA	-0.56	-5.11	-0.32	6.68e-7	Coronary artery calcification;
SARC	cis	rs754466	0.580	rs11002293	chr10:79537965	C/T	cg17075019	chr10:79541650	NA	-0.84	-13.17	-0.65	5.7e-30	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs526231	0.543	rs34379	chr5:102398698	C/T	cg23492399	chr5:102201601	PAM	0.49	5.3	0.33	2.74e-7	Primary biliary cholangitis;
SARC	cis	rs9788682	0.747	rs8042059	chr15:78907859	A/C	cg06917634	chr15:78832804	PSMA4	-0.44	-4.99	-0.31	1.19e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs6696846	0.905	rs12117194	chr1:205040943	C/G	cg21545522	chr1:205238299	TMCC2	-0.34	-4.83	-0.3	2.53e-6	Red blood cell count;
SARC	cis	rs17253792	0.822	rs28481586	chr14:56053863	C/G	cg01858014	chr14:56050164	KTN1	-0.68	-4.94	-0.31	1.52e-6	Putamen volume;
SARC	cis	rs709400	1.000	rs55885592	chr14:104126024	C/T	cg26031613	chr14:104095156	KLC1	0.99	18.61	0.77	5.65e-48	Body mass index;
SARC	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg12463550	chr7:65579703	CRCP	-0.46	-5.5	-0.34	1e-7	Aortic root size;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg06299186	chr18:20513667	RBBP8	0.48	6.35	0.38	1.11e-9	Lung adenocarcinoma;
SARC	cis	rs9818758	0.607	rs34784192	chr3:49274823	G/T	cg00383909	chr3:49044727	WDR6	0.67	5.88	0.36	1.39e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs4423214	0.592	rs7120029	chr11:71198957	G/A	cg05163923	chr11:71159392	DHCR7	-0.52	-5.24	-0.32	3.56e-7	Vitamin D levels;
SARC	cis	rs1475911	0.708	rs56109792	chr21:43520060	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	0.59	6.94	0.41	3.76e-11	IgG glycosylation;
SARC	cis	rs9354308	0.840	rs17508021	chr6:66569748	G/A	cg07460842	chr6:66804631	NA	0.49	5.59	0.34	6.34e-8	Metabolite levels;
SARC	cis	rs6840360	0.593	rs10013612	chr4:152693622	A/G	cg22705602	chr4:152727874	NA	-0.5	-8.81	-0.5	2.85e-16	Intelligence (multi-trait analysis);
SARC	cis	rs4660306	0.677	rs1006215	chr1:45909945	T/A	cg24296786	chr1:45957014	TESK2	-0.53	-5.15	-0.32	5.63e-7	Homocysteine levels;
SARC	cis	rs7937682	0.883	rs11213941	chr11:111434094	T/C	cg22437258	chr11:111473054	SIK2	-0.76	-9.94	-0.55	1.24e-19	Primary sclerosing cholangitis;
SARC	cis	rs7432375	0.610	rs7633629	chr3:136517028	T/A	cg15507776	chr3:136538369	TMEM22	0.61	7.58	0.44	8.18e-13	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg14094449	chr14:60558589	C14orf135	-0.76	-6.26	-0.38	1.81e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs28655083	0.956	rs7184167	chr16:77069451	T/A	cg01504555	chr16:77246968	SYCE1L	-0.39	-5.08	-0.32	7.59e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg03709012	chr19:19516395	GATAD2A	1.01	17.45	0.75	3.42e-44	Tonsillectomy;
SARC	cis	rs2731664	0.792	rs335432	chr5:176866258	G/A	cg23176889	chr5:176863531	GRK6	-0.58	-8.45	-0.48	3.14e-15	Intelligence (multi-trait analysis);
SARC	cis	rs4595586	0.525	rs73096109	chr12:39355720	C/A	cg26384229	chr12:38710491	ALG10B	0.52	6.08	0.37	4.97e-9	Morning vs. evening chronotype;
SARC	trans	rs1814175	0.791	rs1722023	chr11:49908136	G/C	cg03929089	chr4:120376271	NA	-0.88	-13.97	-0.68	1.25e-32	Height;
SARC	trans	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg18944383	chr4:111397179	ENPEP	0.4	6.58	0.4	3.09e-10	Height;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg18348936	chr3:15642978	HACL1;BTD	-0.46	-6.31	-0.38	1.42e-9	Thyroid stimulating hormone;
SARC	cis	rs7587476	0.643	rs6714373	chr2:215719014	A/G	cg04530015	chr2:215796436	ABCA12	-0.42	-6.66	-0.4	1.95e-10	Neuroblastoma;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg12043722	chr15:68870836	CORO2B	0.48	6.36	0.38	1.03e-9	Chemerin levels;
SARC	cis	rs9879311	0.966	rs28113	chr3:10400643	G/A	cg11030744	chr3:10328490	GHRL;GHRLOS	0.46	5.66	0.35	4.37e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	cis	rs453301	0.686	rs13252797	chr8:8861430	A/G	cg06636001	chr8:8085503	FLJ10661	0.51	6.6	0.4	2.73e-10	Joint mobility (Beighton score);
SARC	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	7.88	0.46	1.28e-13	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs17021463	0.902	rs11097413	chr4:95249286	C/T	cg11021082	chr4:95130006	SMARCAD1	0.45	6.9	0.41	4.92e-11	Testicular germ cell tumor;
SARC	cis	rs7712401	0.623	rs30044	chr5:122272080	T/C	cg19412675	chr5:122181750	SNX24	0.4	5.17	0.32	4.98e-7	Mean platelet volume;
SARC	cis	rs367943	1.000	rs460079	chr5:112800525	G/A	cg12552261	chr5:112820674	MCC	-0.46	-5.3	-0.33	2.72e-7	Type 2 diabetes;
SARC	cis	rs2033711	0.870	rs4801583	chr19:58918405	A/G	cg26874164	chr19:58962979	ZNF324B	0.48	6.19	0.38	2.73e-9	Uric acid clearance;
SARC	cis	rs9457247	0.508	rs7760495	chr6:167506795	C/T	cg07741184	chr6:167504864	NA	0.33	6.2	0.38	2.53e-9	Crohn's disease;
SARC	cis	rs1707322	1.000	rs785497	chr1:46591903	G/C	cg03146154	chr1:46216737	IPP	-0.48	-5.6	-0.34	6.03e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs739401	0.611	rs391188	chr11:3047634	G/A	cg08508325	chr11:3079039	CARS	-0.31	-7.58	-0.44	8.16e-13	Longevity;
SARC	cis	rs3741404	0.609	rs641378	chr11:63869493	T/C	cg18225595	chr11:63971243	STIP1	0.4	5.67	0.35	4.24e-8	Platelet count;
SARC	cis	rs9916302	0.904	rs2338755	chr17:37419317	C/T	cg20243544	chr17:37824526	PNMT	-0.54	-6.55	-0.39	3.71e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg10435706	chr6:150039699	LATS1	0.36	4.76	0.3	3.45e-6	Lung cancer;
SARC	cis	rs1881797	1.000	rs12063141	chr1:247688343	G/A	cg11166453	chr1:247681781	NA	0.46	5.05	0.31	8.96e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs920590	0.573	rs4392917	chr8:19680635	G/C	cg01411142	chr8:19674711	INTS10	-0.47	-5.58	-0.34	6.63e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs288326	0.561	rs17265859	chr2:183724612	A/T	cg09997497	chr2:183902928	NCKAP1	0.72	4.98	0.31	1.22e-6	Blood protein levels;
SARC	cis	rs854765	0.575	rs7207821	chr17:17891781	A/G	cg05444541	chr17:17804740	TOM1L2	-0.3	-4.81	-0.3	2.65e-6	Total body bone mineral density;
SARC	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg19077165	chr18:44547161	KATNAL2	-0.49	-6.73	-0.4	1.33e-10	Personality dimensions;
SARC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg09033563	chr22:24373618	LOC391322	0.49	5.5	0.34	1e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9814567	1.000	rs3932818	chr3:134206069	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-7.09	-0.42	1.57e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs1215050	0.791	rs1605259	chr4:98799732	T/C	cg05340658	chr4:99064831	C4orf37	0.44	5.85	0.36	1.62e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs5167	0.743	rs8111069	chr19:45483438	A/C	cg10169327	chr19:45448959	APOC2	0.31	4.92	0.31	1.61e-6	Blood protein levels;
SARC	cis	rs13401104	0.796	rs10929171	chr2:237115622	G/A	cg19324714	chr2:237145437	ASB18	0.56	5.44	0.34	1.36e-7	Educational attainment;
SARC	cis	rs12950390	0.893	rs72831644	chr17:45824391	T/C	cg24803719	chr17:45855879	NA	-0.5	-8.04	-0.47	4.45e-14	IgG glycosylation;
SARC	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg02187348	chr16:89574699	SPG7	0.52	7.14	0.42	1.18e-11	Multiple myeloma (IgH translocation);
SARC	trans	rs7824557	0.603	rs11250130	chr8:11214455	C/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.44	-0.39	6.81e-10	Retinal vascular caliber;
SARC	cis	rs17376456	1.000	rs61132622	chr5:93539684	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.19	0.32	4.5e-7	Diabetic retinopathy;
SARC	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg10523679	chr1:76189770	ACADM	0.69	10.64	0.57	8.05e-22	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg25703541	chr22:24373054	LOC391322	0.77	10.63	0.57	8.93e-22	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs861020	0.606	rs689210	chr1:210013723	A/C	cg23166289	chr1:210001082	C1orf107	0.39	4.74	0.3	3.73e-6	Orofacial clefts;
SARC	cis	rs11581859	0.613	rs28435978	chr1:99191063	C/T	cg20286094	chr1:99190917	SNX7	-0.42	-4.93	-0.31	1.55e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg14829360	chr17:73884958	NA	-0.57	-7.22	-0.43	7.17e-12	Psoriasis;
SARC	trans	rs56279505	0.629	rs2866153	chr4:100263695	A/T	cg21156590	chr1:3420848	MEGF6	-0.83	-6.41	-0.39	8.04e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6430585	0.528	rs614193	chr2:136653925	A/T	cg07169764	chr2:136633963	MCM6	1.02	13.0	0.65	2.09e-29	Corneal structure;
SARC	cis	rs6570726	0.935	rs386344	chr6:145855622	A/G	cg05347473	chr6:146136440	FBXO30	0.47	6.22	0.38	2.24e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg10591111	chr5:226296	SDHA	-0.55	-4.97	-0.31	1.31e-6	Breast cancer;
SARC	trans	rs4834272	0.662	rs6851489	chr4:113305433	G/A	cg04861380	chr7:150497663	TMEM176B;TMEM176A	-0.45	-6.24	-0.38	2.1e-9	Body mass index;
SARC	cis	rs3858526	0.874	rs10838879	chr11:5950169	C/T	cg02574844	chr11:5959923	NA	-0.43	-5.32	-0.33	2.47e-7	DNA methylation (variation);
SARC	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg12463550	chr7:65579703	CRCP	-0.48	-5.25	-0.33	3.44e-7	Aortic root size;
SARC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg24101359	chr6:42928495	GNMT	0.41	5.67	0.35	4.19e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	trans	rs877282	0.533	rs10904565	chr10:819991	G/T	cg22713356	chr15:30763199	NA	0.93	8.8	0.5	3.09e-16	Uric acid levels;
SARC	cis	rs6088813	1.000	rs6142369	chr20:33973315	T/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.45	-5.39	-0.33	1.71e-7	Height;
SARC	cis	rs11122272	0.735	rs2247124	chr1:231493687	A/G	cg06096015	chr1:231504339	EGLN1	0.36	5.28	0.33	2.9e-7	Hemoglobin concentration;
SARC	cis	rs8031584	0.560	rs7171208	chr15:31198929	A/G	cg08109568	chr15:31115862	NA	0.43	5.7	0.35	3.6e-8	Huntington's disease progression;
SARC	trans	rs11039798	0.512	rs11040205	chr11:49007360	G/C	cg15704280	chr7:45808275	SEPT13	0.7	7.01	0.42	2.57e-11	Axial length;
SARC	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg19077165	chr18:44547161	KATNAL2	0.55	7.73	0.45	3.26e-13	Personality dimensions;
SARC	cis	rs2120243	0.539	rs1456108	chr3:157119054	A/G	cg24825693	chr3:157122686	VEPH1	-0.46	-6.42	-0.39	7.36e-10	Hepatocellular carcinoma in hepatitis B infection;
SARC	trans	rs61931739	0.500	rs7133447	chr12:34041901	A/G	cg26384229	chr12:38710491	ALG10B	0.75	10.82	0.58	2.31e-22	Morning vs. evening chronotype;
SARC	cis	rs4820294	1.000	rs713835	chr22:38064650	C/T	cg21798802	chr22:38057573	PDXP	0.37	5.65	0.35	4.69e-8	Fat distribution (HIV);
SARC	cis	rs9549260	0.620	rs9532580	chr13:41244260	T/C	cg21288729	chr13:41239152	FOXO1	0.52	5.67	0.35	4.17e-8	Red blood cell count;
SARC	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg00933542	chr6:150070202	PCMT1	0.3	5.14	0.32	5.89e-7	Lung cancer;
SARC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.44	5.57	0.34	7.11e-8	Lymphocyte counts;
SARC	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg02524346	chr8:600233	NA	0.69	5.69	0.35	3.77e-8	IgG glycosylation;
SARC	cis	rs9818758	0.607	rs73084135	chr3:49272218	A/G	cg07636037	chr3:49044803	WDR6	-0.8	-6.99	-0.42	2.85e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	trans	rs629535	0.773	rs568159	chr8:70032908	C/G	cg21567404	chr3:27674614	NA	1.05	14.23	0.68	1.78e-33	Dupuytren's disease;
SARC	cis	rs9807989	0.507	rs6734762	chr2:103062926	C/T	cg03938978	chr2:103052716	IL18RAP	0.31	5.01	0.31	1.07e-6	Asthma;
SARC	cis	rs7568458	0.783	rs2166529	chr2:85742175	A/C	cg02493740	chr2:85810744	VAMP5	0.34	5.21	0.32	4.21e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg01316550	chr5:56110833	MAP3K1	0.53	4.85	0.3	2.29e-6	Initial pursuit acceleration;
SARC	cis	rs8070128	0.583	rs7406982	chr17:17942613	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	9.76	0.54	4.36e-19	Total body bone mineral density;
SARC	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg16606324	chr3:10149918	C3orf24	0.52	5.14	0.32	5.69e-7	Alzheimer's disease;
SARC	cis	rs7937890	0.904	rs67623158	chr11:14295196	T/C	cg02886208	chr11:14281011	SPON1	0.42	6.01	0.37	7e-9	Mitochondrial DNA levels;
SARC	cis	rs17376456	0.877	rs9314100	chr5:93447394	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.73	0.35	3.03e-8	Diabetic retinopathy;
SARC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.68	9.32	0.52	9.26e-18	Lymphocyte counts;
SARC	cis	rs8044995	0.517	rs2863973	chr16:68409435	A/C	cg05110241	chr16:68378359	PRMT7	-0.45	-5.21	-0.32	4.12e-7	Schizophrenia;
SARC	cis	rs11719291	0.833	rs34037363	chr3:48821036	C/T	cg07636037	chr3:49044803	WDR6	-0.73	-6.4	-0.39	8.56e-10	Cognitive function;
SARC	cis	rs9640161	0.783	rs35435439	chr7:150063534	C/T	cg17279839	chr7:150038598	RARRES2	0.34	4.78	0.3	3.04e-6	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs2842992	0.747	rs4709378	chr6:160227435	G/C	cg26839252	chr6:160211577	TCP1;MRPL18	0.58	5.1	0.32	7.1e-7	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs2742234	0.541	rs1059484	chr10:43679800	T/G	cg15436174	chr10:43711423	RASGEF1A	-0.4	-4.74	-0.3	3.67e-6	Hirschsprung disease;
SARC	cis	rs4805272	0.539	rs1075733	chr19:29324460	C/T	cg04546413	chr19:29218101	NA	0.54	6.38	0.39	9.2e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	trans	rs9650657	0.504	rs7813802	chr8:11033976	C/T	cg08975724	chr8:8085496	FLJ10661	0.52	6.58	0.4	3.02e-10	Neuroticism;
SARC	cis	rs13082711	0.911	rs17019809	chr3:27509080	A/G	cg02860705	chr3:27208620	NA	0.4	5.26	0.33	3.22e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs2439831	0.850	rs12442129	chr15:44055856	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	8.57	0.49	1.44e-15	Lung cancer in ever smokers;
SARC	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg19748678	chr4:122722346	EXOSC9	0.76	9.43	0.53	4.18e-18	Type 2 diabetes;
SARC	cis	rs734999	0.545	rs6666788	chr1:2567500	A/G	cg00980319	chr1:2560884	MMEL1	0.35	4.94	0.31	1.5e-6	Ulcerative colitis;
SARC	cis	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg03060546	chr3:49711283	APEH	0.73	6.76	0.4	1.11e-10	Menarche (age at onset);
SARC	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg08219700	chr8:58056026	NA	0.61	6.36	0.38	1.05e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs12432203	1.000	rs4566067	chr14:51729487	A/G	cg16237204	chr14:52000941	FRMD6	-0.55	-5.1	-0.32	7.13e-7	Cancer;
SARC	cis	rs9948	0.655	rs17119591	chr2:97435557	G/A	cg01990225	chr2:97406019	LMAN2L	-0.96	-6.78	-0.41	9.82e-11	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs9815354	1.000	rs11928580	chr3:41885722	C/T	cg03022575	chr3:42003672	ULK4	0.57	5.4	0.33	1.61e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2439831	0.850	rs2439832	chr15:43779686	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.06	10.29	0.56	1.02e-20	Lung cancer in ever smokers;
SARC	cis	rs7296418	0.961	rs7957096	chr12:123544878	A/G	cg16085171	chr12:123569118	PITPNM2	-0.4	-5.06	-0.31	8.63e-7	Platelet count;
SARC	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg02297831	chr4:17616191	MED28	0.52	6.79	0.41	9.4e-11	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs7824557	0.713	rs6601575	chr8:11097804	A/C	cg08975724	chr8:8085496	FLJ10661	0.51	6.42	0.39	7.55e-10	Retinal vascular caliber;
SARC	cis	rs597539	0.521	rs7943745	chr11:68605828	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.44	-5.39	-0.33	1.73e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs1476029	0.561	rs132648	chr22:36552402	A/G	cg23889684	chr22:36556813	APOL3	0.48	5.03	0.31	9.98e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
SARC	trans	rs8073060	0.586	rs225291	chr17:33927126	A/G	cg19694781	chr19:47549865	TMEM160	-0.59	-6.3	-0.38	1.5e-9	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs600231	0.708	rs2957268	chr11:65245816	A/G	cg17120908	chr11:65337727	SSSCA1	-0.43	-5.51	-0.34	9.24e-8	Bone mineral density;
SARC	trans	rs9929218	0.953	rs3118235	chr16:68732977	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.57	6.91	0.41	4.7e-11	Colorectal cancer;
SARC	cis	rs6429082	0.597	rs6683978	chr1:235541425	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.61	-7.07	-0.42	1.83e-11	Adiposity;
SARC	cis	rs3768617	0.510	rs3768616	chr1:183103551	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.67	9.69	0.54	7.1e-19	Fuchs's corneal dystrophy;
SARC	cis	rs1371867	0.875	rs1788176	chr8:101332112	A/G	cg11906718	chr8:101322791	RNF19A	0.71	9.13	0.51	3.37e-17	Atrioventricular conduction;
SARC	cis	rs1322639	0.614	rs6900200	chr6:169566173	T/C	cg03254818	chr6:169586852	NA	0.73	7.63	0.45	6.07e-13	Pulse pressure;
SARC	cis	rs7666738	0.830	rs991169	chr4:98928567	C/A	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg08280861	chr8:58055591	NA	0.6	5.28	0.33	2.92e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1865760	0.593	rs9393676	chr6:25936944	G/A	cg16482183	chr6:26056742	HIST1H1C	0.46	5.74	0.35	2.96e-8	Height;
SARC	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg25072359	chr17:41440525	NA	0.49	5.81	0.36	2.05e-8	Menopause (age at onset);
SARC	trans	rs9463078	0.547	rs764396	chr6:44710691	C/G	cg03948781	chr1:205179583	DSTYK	0.39	6.26	0.38	1.83e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
SARC	cis	rs9811216	0.958	rs9827710	chr3:169522387	G/C	cg14222479	chr3:169487675	ARPM1	0.43	5.27	0.33	3.04e-7	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs11785400	0.793	rs1137521	chr8:143739162	C/T	cg24634471	chr8:143751801	JRK	0.59	7.56	0.44	9.12e-13	Schizophrenia;
SARC	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg09699651	chr6:150184138	LRP11	0.4	5.02	0.31	1.05e-6	Lung cancer;
SARC	cis	rs4803468	1.000	rs10413735	chr19:41921071	C/T	cg08477640	chr19:41863820	B9D2	0.46	5.88	0.36	1.43e-8	Height;
SARC	cis	rs9467773	0.620	rs2494700	chr6:26631306	C/T	cg11502198	chr6:26597334	ABT1	0.63	8.63	0.49	9.91e-16	Intelligence (multi-trait analysis);
SARC	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg19723775	chr5:179050963	HNRNPH1	0.41	5.22	0.32	4e-7	Lung cancer;
SARC	cis	rs2644899	0.750	rs2604869	chr19:41283693	G/A	cg24958765	chr19:41283667	RAB4B	0.59	6.41	0.39	8.21e-10	Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs1044826	0.619	rs7375091	chr3:139090389	T/A	cg15131784	chr3:139108705	COPB2	-0.39	-4.97	-0.31	1.33e-6	Obesity-related traits;
SARC	cis	rs17095355	1.000	rs11194924	chr10:111695773	G/C	cg00817464	chr10:111662876	XPNPEP1	-0.41	-4.72	-0.3	3.98e-6	Biliary atresia;
SARC	cis	rs2061333	0.500	rs8113750	chr19:44608789	C/T	cg18700516	chr19:44507157	ZNF230	-0.55	-5.21	-0.32	4.15e-7	Alzheimer's disease;
SARC	cis	rs9341808	0.935	rs9343974	chr6:80924645	A/G	cg08355045	chr6:80787529	NA	0.35	5.82	0.36	1.95e-8	Sitting height ratio;
SARC	cis	rs11155671	0.530	rs7774787	chr6:150209432	G/A	cg00933542	chr6:150070202	PCMT1	0.29	4.81	0.3	2.77e-6	Testicular germ cell tumor;
SARC	cis	rs4808199	0.895	rs10403731	chr19:19469296	G/A	cg03709012	chr19:19516395	GATAD2A	1.07	11.09	0.59	3.12e-23	Nonalcoholic fatty liver disease;
SARC	cis	rs71277158	0.688	rs888507	chr3:169811039	G/C	cg04067573	chr3:169899625	PHC3	0.57	5.06	0.31	8.67e-7	Prostate cancer;
SARC	cis	rs7659604	0.517	rs6856996	chr4:122671271	C/T	cg20573242	chr4:122745356	CCNA2	0.44	4.99	0.31	1.19e-6	Type 2 diabetes;
SARC	cis	rs16976116	0.901	rs9920737	chr15:55505761	C/G	cg17854078	chr15:55489399	RSL24D1	0.61	5.71	0.35	3.35e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg21017887	chr14:105400489	NA	0.49	6.95	0.41	3.65e-11	Rheumatoid arthritis;
SARC	cis	rs735539	0.521	rs9550675	chr13:21466641	C/A	cg16922012	chr13:21400325	XPO4	-0.44	-5.74	-0.35	2.91e-8	Dental caries;
SARC	cis	rs1707322	0.682	rs10890334	chr1:46100378	A/T	cg06784218	chr1:46089804	CCDC17	0.36	6.19	0.38	2.64e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4141404	0.851	rs5749248	chr22:31683711	C/A	cg00478049	chr22:31556069	RNF185	0.52	5.19	0.32	4.62e-7	Paclitaxel-induced neuropathy;
SARC	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg00450029	chr8:599525	NA	0.6	5.04	0.31	9.14e-7	IgG glycosylation;
SARC	cis	rs6594499	1.000	rs1438673	chr5:110467499	C/T	cg04022379	chr5:110408740	TSLP	0.44	5.06	0.31	8.6e-7	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs1983170	0.741	rs6685054	chr1:92018238	T/G	cg25838465	chr1:92012736	NA	0.45	5.47	0.34	1.17e-7	Eosinophil percentage of white cells;
SARC	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	8.82	0.5	2.77e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7246657	1.000	rs12709812	chr19:37794850	A/G	cg23950597	chr19:37808831	NA	0.53	5.06	0.31	8.56e-7	Coronary artery calcification;
SARC	cis	rs17270561	0.666	rs1937129	chr6:25789132	A/G	cg16482183	chr6:26056742	HIST1H1C	0.46	5.71	0.35	3.36e-8	Iron status biomarkers;
SARC	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg03060546	chr3:49711283	APEH	0.42	5.3	0.33	2.71e-7	Parkinson's disease;
SARC	cis	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg14541582	chr5:601475	NA	-0.41	-5.02	-0.31	1.03e-6	Obesity-related traits;
SARC	cis	rs2073300	0.609	rs17757228	chr20:23351288	A/T	cg12062639	chr20:23401060	NAPB	1.04	6.97	0.42	3.14e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs78545713	0.502	rs57145038	chr6:26311510	A/C	cg13736514	chr6:26305472	NA	-0.53	-4.9	-0.31	1.8e-6	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs2153535	0.606	rs11243253	chr6:8380193	T/C	cg07606381	chr6:8435919	SLC35B3	-0.78	-10.81	-0.58	2.46e-22	Motion sickness;
SARC	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg06212747	chr3:49208901	KLHDC8B	0.66	8.79	0.5	3.35e-16	Parkinson's disease;
SARC	cis	rs933688	0.509	rs2973472	chr5:90519496	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.43	-4.74	-0.3	3.76e-6	Smoking behavior;
SARC	cis	rs883565	0.569	rs784508	chr3:39166484	C/T	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.44	-5.12	-0.32	6.37e-7	Handedness;
SARC	cis	rs6840360	0.571	rs4696272	chr4:152528229	A/G	cg22705602	chr4:152727874	NA	-0.41	-6.45	-0.39	6.45e-10	Intelligence (multi-trait analysis);
SARC	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg09359103	chr1:154839909	KCNN3	-0.39	-6.07	-0.37	5.14e-9	Prostate cancer;
SARC	cis	rs6088813	1.000	rs224329	chr20:34019579	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.43	5.19	0.32	4.5e-7	Height;
SARC	cis	rs2303759	0.709	rs10414921	chr19:49823047	C/T	cg22590775	chr19:49891494	CCDC155	0.48	5.32	0.33	2.41e-7	Multiple sclerosis;
SARC	cis	rs9399137	0.507	rs4896129	chr6:135349845	C/T	cg24558204	chr6:135376177	HBS1L	0.62	8.02	0.47	5.03e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg18876405	chr7:65276391	NA	-0.46	-5.18	-0.32	4.8e-7	Aortic root size;
SARC	cis	rs9828933	0.577	rs704374	chr3:63865947	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.86	8.16	0.47	2.05e-14	Type 2 diabetes;
SARC	cis	rs9916302	0.706	rs8182252	chr17:37727950	T/C	cg07936489	chr17:37558343	FBXL20	0.77	9.55	0.53	1.94e-18	Glomerular filtration rate (creatinine);
SARC	cis	rs12808519	0.688	rs3740640	chr11:69587583	C/T	cg19831575	chr11:69590090	FGF4	-0.53	-4.82	-0.3	2.56e-6	Urate levels in overweight individuals;
SARC	cis	rs870825	0.616	rs56844261	chr4:185632478	T/C	cg04058563	chr4:185651563	MLF1IP	0.83	11.16	0.59	1.91e-23	Blood protein levels;
SARC	cis	rs17030434	0.784	rs11099900	chr4:154669471	C/T	cg14289246	chr4:154710475	SFRP2	-0.53	-5.95	-0.36	9.86e-9	Electrocardiographic conduction measures;
SARC	cis	rs9309711	0.666	rs6723126	chr2:3484500	T/C	cg15541040	chr2:3486749	NA	-0.43	-5.76	-0.35	2.6e-8	Neurofibrillary tangles;
SARC	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg00149659	chr3:10157352	C3orf10	0.66	6.6	0.4	2.82e-10	Alzheimer's disease;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg10769393	chr19:2819754	ZNF554	0.49	6.39	0.39	8.85e-10	Tetralogy of Fallot;
SARC	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg08742575	chr21:47604166	C21orf56	0.46	5.92	0.36	1.15e-8	Testicular germ cell tumor;
SARC	cis	rs875971	0.545	rs1638724	chr7:66040481	A/G	cg11764359	chr7:65958608	NA	-0.61	-5.95	-0.36	1e-8	Aortic root size;
SARC	cis	rs3784262	0.669	rs12914455	chr15:58312096	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.33	-4.86	-0.3	2.21e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs79149102	0.850	rs78646589	chr15:75170580	C/T	cg17294928	chr15:75287854	SCAMP5	-0.89	-5.41	-0.33	1.54e-7	Lung cancer;
SARC	cis	rs2239547	0.563	rs4687699	chr3:53101224	C/T	cg11645453	chr3:52864694	ITIH4	0.32	5.19	0.32	4.59e-7	Schizophrenia;
SARC	cis	rs35110281	0.565	rs7278003	chr21:44966069	T/C	cg01579765	chr21:45077557	HSF2BP	-0.29	-4.92	-0.31	1.67e-6	Mean corpuscular volume;
SARC	cis	rs9875589	0.509	rs2607761	chr3:14091428	A/G	cg19554555	chr3:13937349	NA	-0.41	-5.28	-0.33	3.03e-7	Ovarian reserve;
SARC	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg04772025	chr11:68637568	NA	0.49	6.02	0.37	6.69e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs514406	0.505	rs436363	chr1:53172163	T/C	cg16325326	chr1:53192061	ZYG11B	0.93	17.12	0.75	4.38e-43	Monocyte count;
SARC	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg26924012	chr15:45694286	SPATA5L1	0.77	10.99	0.58	6.8e-23	Homoarginine levels;
SARC	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg04267008	chr7:1944627	MAD1L1	-0.46	-5.11	-0.32	6.77e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs60012524	1	rs60012524	chr2:99559117	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-6.17	-0.37	3.06e-9	Chronic sinus infection;
SARC	cis	rs16912285	0.748	rs7104694	chr11:24280281	A/C	ch.11.24196551F	chr11:24239977	NA	0.49	4.73	0.3	3.81e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs12478296	0.901	rs7603560	chr2:243043256	C/T	cg06360820	chr2:242988706	NA	-0.6	-4.75	-0.3	3.61e-6	Obesity-related traits;
SARC	cis	rs8031584	0.958	rs8034856	chr15:31240957	T/C	cg14298792	chr15:30685198	CHRFAM7A	-0.45	-4.99	-0.31	1.17e-6	Huntington's disease progression;
SARC	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg12564285	chr5:131593104	PDLIM4	0.44	6.13	0.37	3.65e-9	Breast cancer;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg24376286	chr2:198245629	NA	-0.47	-6.38	-0.39	9.33e-10	Electrocardiographic conduction measures;
SARC	cis	rs7843479	0.601	rs6557712	chr8:21826421	C/T	cg17168535	chr8:21777572	XPO7	0.86	13.38	0.66	1.11e-30	Mean corpuscular volume;
SARC	cis	rs712039	0.652	rs712038	chr17:35762557	G/A	cg16670864	chr17:35848621	DUSP14	0.49	5.43	0.33	1.45e-7	Tuberculosis;
SARC	cis	rs9843304	0.529	rs61382471	chr3:149202160	G/A	cg08667024	chr3:149219783	TM4SF4	-0.4	-5.91	-0.36	1.21e-8	Gallstone disease;
SARC	cis	rs1062177	0.950	rs892005	chr5:151180621	A/G	cg00977110	chr5:151150581	G3BP1	0.56	5.66	0.35	4.49e-8	Preschool internalizing problems;
SARC	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.5e-10	Life satisfaction;
SARC	cis	rs17428041	0.521	rs13255951	chr8:21722998	T/C	cg17168535	chr8:21777572	XPO7	-0.44	-5.0	-0.31	1.1e-6	Neuropathic pain in type 2 diabetes;
SARC	cis	rs7568458	0.840	rs2886722	chr2:85742297	C/T	cg23752985	chr2:85803571	VAMP8	-0.37	-5.24	-0.32	3.63e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs11785400	1.000	rs4266629	chr8:143736635	A/G	cg10596483	chr8:143751796	JRK	0.65	8.72	0.5	5.36e-16	Schizophrenia;
SARC	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg18876405	chr7:65276391	NA	0.47	5.72	0.35	3.21e-8	Aortic root size;
SARC	cis	rs950169	0.763	rs35372971	chr15:84941795	G/A	cg17507749	chr15:85114479	UBE2QP1	0.79	9.6	0.53	1.32e-18	Schizophrenia;
SARC	cis	rs17376456	0.877	rs10059630	chr5:93459807	C/A	cg25358565	chr5:93447407	FAM172A	1.31	15.17	0.7	1.33e-36	Diabetic retinopathy;
SARC	cis	rs9807989	0.507	rs1035129	chr2:103019785	T/C	cg03938978	chr2:103052716	IL18RAP	0.31	4.91	0.31	1.72e-6	Asthma;
SARC	cis	rs6912958	0.781	rs4707376	chr6:88270947	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-6.74	-0.4	1.23e-10	Monocyte percentage of white cells;
SARC	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg17990871	chr1:1677678	SLC35E2	-0.44	-5.17	-0.32	5.03e-7	Body mass index;
SARC	cis	rs425277	1.000	rs262672	chr1:2080813	G/T	cg24578937	chr1:2090814	PRKCZ	0.31	5.85	0.36	1.63e-8	Height;
SARC	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg03806693	chr22:41940476	POLR3H	0.93	13.04	0.65	1.54e-29	Vitiligo;
SARC	cis	rs4660306	0.961	rs7539253	chr1:45947420	C/T	cg24296786	chr1:45957014	TESK2	0.58	6.72	0.4	1.35e-10	Homocysteine levels;
SARC	cis	rs17401966	0.867	rs7546364	chr1:10418815	G/A	cg15208524	chr1:10270712	KIF1B	0.48	5.67	0.35	4.12e-8	Hepatocellular carcinoma;
SARC	cis	rs2439831	0.702	rs8033995	chr15:44013509	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.99	8.57	0.49	1.43e-15	Lung cancer in ever smokers;
SARC	trans	rs61931739	0.500	rs11053222	chr12:34481100	C/A	cg13010199	chr12:38710504	ALG10B	0.82	11.46	0.6	2.04e-24	Morning vs. evening chronotype;
SARC	cis	rs6831352	0.918	rs3919370	chr4:100064326	A/T	cg12011299	chr4:100065546	ADH4	-0.31	-4.98	-0.31	1.25e-6	Alcohol dependence;
SARC	cis	rs926938	0.618	rs1286555	chr1:115361896	C/T	cg12756093	chr1:115239321	AMPD1	-0.39	-5.1	-0.32	7.16e-7	Autism;
SARC	cis	rs7617773	0.780	rs11718350	chr3:48360992	T/G	cg11946769	chr3:48343235	NME6	0.76	9.67	0.54	8.16e-19	Coronary artery disease;
SARC	cis	rs7980687	0.628	rs2102949	chr12:123676763	G/A	cg05973401	chr12:123451056	ABCB9	0.55	6.38	0.39	9.28e-10	Height;Educational attainment;Head circumference (infant);
SARC	cis	rs6963495	0.745	rs73190179	chr7:105162812	C/A	cg13798780	chr7:105162888	PUS7	0.6	5.45	0.34	1.31e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs505401	0.554	rs8108378	chr19:6095210	A/G	cg18109231	chr19:6110877	RFX2	0.68	4.77	0.3	3.18e-6	Mean platelet volume;
SARC	cis	rs5753618	0.561	rs5753543	chr22:31685458	G/A	cg00478049	chr22:31556069	RNF185	0.44	4.78	0.3	3.07e-6	Colorectal cancer;
SARC	cis	rs11168187	0.783	rs3764018	chr12:48120835	G/T	cg12761788	chr12:48120090	P11	0.39	5.06	0.31	8.51e-7	Vertical cup-disc ratio;
SARC	cis	rs12545109	0.837	rs1437277	chr8:57356734	T/C	cg19413350	chr8:57351067	NA	-0.45	-4.92	-0.31	1.61e-6	Obesity-related traits;
SARC	trans	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.53	6.73	0.4	1.34e-10	Intelligence (multi-trait analysis);
SARC	cis	rs17376456	0.877	rs10476597	chr5:93367172	C/T	cg25358565	chr5:93447407	FAM172A	-1.29	-14.11	-0.68	4.36e-33	Diabetic retinopathy;
SARC	cis	rs3820928	0.874	rs116652884	chr2:227902285	C/T	cg11843606	chr2:227700838	RHBDD1	-0.55	-6.78	-0.41	9.94e-11	Pulmonary function;
SARC	cis	rs9443189	0.762	rs2647417	chr6:76435943	A/G	cg01950844	chr6:76311363	SENP6	-0.88	-8.24	-0.47	1.28e-14	Prostate cancer;
SARC	cis	rs2645694	0.532	rs2645706	chr4:77829606	A/C	cg18351406	chr4:77819688	ANKRD56	0.41	5.68	0.35	4.08e-8	Emphysema distribution in smoking;
SARC	cis	rs7103648	0.897	rs11606287	chr11:47407439	C/A	cg10504702	chr11:47789108	FNBP4	0.54	6.49	0.39	5.21e-10	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg17376030	chr22:41985996	PMM1	0.75	9.44	0.53	4.14e-18	Vitiligo;
SARC	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg24642844	chr7:1081250	C7orf50	-0.56	-5.92	-0.36	1.12e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.72	-7.24	-0.43	6.52e-12	Platelet count;
SARC	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg16414030	chr3:133502952	NA	-0.46	-6.12	-0.37	4.02e-9	Iron status biomarkers;
SARC	cis	rs2836633	0.929	rs4514962	chr21:40041753	C/T	cg12884169	chr21:40033163	ERG	0.49	8.97	0.51	1.02e-16	Coronary artery disease;
SARC	trans	rs11098499	0.505	rs75122014	chr4:120362426	G/C	cg25214090	chr10:38739885	LOC399744	0.58	7.62	0.45	6.35e-13	Corneal astigmatism;
SARC	trans	rs2727020	0.521	rs937430	chr11:49542457	A/G	cg15704280	chr7:45808275	SEPT13	0.7	8.17	0.47	1.99e-14	Coronary artery disease;
SARC	cis	rs6456156	0.774	rs9347175	chr6:167527644	A/T	cg07741184	chr6:167504864	NA	-0.28	-5.43	-0.34	1.38e-7	Primary biliary cholangitis;
SARC	cis	rs911263	0.603	rs12890109	chr14:68781593	C/A	cg18825221	chr14:68749962	RAD51L1	0.42	7.54	0.44	1.07e-12	Primary biliary cholangitis;
SARC	cis	rs9814567	1.000	rs7432268	chr3:134242051	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-7.11	-0.42	1.39e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs3218477	1.000	rs3218467	chr7:152359552	C/G	cg06618968	chr7:152373420	XRCC2	-0.71	-4.72	-0.3	4.13e-6	Mean platelet volume;
SARC	cis	rs3741151	0.764	rs73548680	chr11:73271335	T/C	cg17517138	chr11:73019481	ARHGEF17	0.92	6.85	0.41	6.54e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs1568889	0.838	rs716366	chr11:28121536	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.87	14.92	0.7	9.1e-36	Bipolar disorder;
SARC	cis	rs17401966	0.931	rs12753426	chr1:10372110	T/C	cg15208524	chr1:10270712	KIF1B	0.51	5.99	0.37	8.04e-9	Hepatocellular carcinoma;
SARC	cis	rs7589342	0.536	rs7563690	chr2:106396935	C/T	cg16077055	chr2:106428750	NCK2	0.31	6.1	0.37	4.38e-9	Addiction;
SARC	cis	rs11155671	0.530	rs2342767	chr6:150209717	C/G	cg05036130	chr6:150231994	NA	0.28	4.87	0.3	2.04e-6	Testicular germ cell tumor;
SARC	cis	rs2153535	0.541	rs9392222	chr6:8467649	G/A	cg23788917	chr6:8435910	SLC35B3	0.64	8.39	0.48	4.57e-15	Motion sickness;
SARC	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg20120463	chr17:44301886	NA	-0.33	-5.17	-0.32	4.96e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9467711	0.591	rs16891235	chr6:26017542	T/C	cg21479132	chr6:26055353	NA	0.98	7.08	0.42	1.68e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg13607699	chr17:42295918	UBTF	0.51	6.3	0.38	1.47e-9	Total body bone mineral density;
SARC	cis	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg00071950	chr4:10020882	SLC2A9	0.39	6.31	0.38	1.41e-9	Bone mineral density;
SARC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg16081228	chr2:148602278	ACVR2A	-0.55	-6.24	-0.38	2.05e-9	Hepatitis;
SARC	cis	rs6570726	0.935	rs425717	chr6:145838620	A/T	cg23711669	chr6:146136114	FBXO30	0.78	11.86	0.61	1.04e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7264396	1.000	rs7264396	chr20:34154741	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.46	5.27	0.33	3.08e-7	Total cholesterol levels;
SARC	cis	rs1322639	0.618	rs9505942	chr6:169591793	T/C	cg03254818	chr6:169586852	NA	0.67	6.71	0.4	1.43e-10	Pulse pressure;
SARC	cis	rs1707322	0.682	rs3014241	chr1:46087879	A/G	cg03146154	chr1:46216737	IPP	-0.51	-6.06	-0.37	5.52e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7239679	0.517	rs2847350	chr18:10448334	A/G	cg26328002	chr18:10455463	APCDD1	-0.41	-5.09	-0.32	7.44e-7	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs7084402	0.967	rs11817440	chr10:60272369	T/C	cg07615347	chr10:60278583	BICC1	-0.58	-8.43	-0.48	3.67e-15	Refractive error;
SARC	cis	rs4144743	0.877	rs7223766	chr17:45326734	T/G	cg18085866	chr17:45331354	ITGB3	-0.73	-7.41	-0.44	2.29e-12	Body mass index;
SARC	cis	rs1062177	1.000	rs12515762	chr5:151209922	G/T	cg00977110	chr5:151150581	G3BP1	0.57	5.58	0.34	6.71e-8	Preschool internalizing problems;
SARC	cis	rs950776	0.506	rs12915366	chr15:78831753	G/A	cg06917634	chr15:78832804	PSMA4	0.91	14.24	0.68	1.63e-33	Sudden cardiac arrest;
SARC	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg03735888	chr19:58951602	ZNF132	0.39	5.21	0.32	4.17e-7	Uric acid clearance;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg10231862	chr6:20641512	CDKAL1	0.5	6.79	0.41	9.24e-11	Thyroid stimulating hormone;
SARC	cis	rs7246760	0.867	rs56307296	chr19:9744099	G/T	cg16876255	chr19:9731953	ZNF561	0.83	5.06	0.31	8.55e-7	Pursuit maintenance gain;
SARC	cis	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg09021430	chr5:549028	NA	-0.43	-5.54	-0.34	8.24e-8	Obesity-related traits;
SARC	cis	rs9916302	0.904	rs4794813	chr17:37670994	A/T	cg20243544	chr17:37824526	PNMT	0.58	6.91	0.41	4.65e-11	Glomerular filtration rate (creatinine);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg27454894	chr16:88878596	APRT	0.48	6.23	0.38	2.11e-9	Chemerin levels;
SARC	trans	rs1814175	0.740	rs10839439	chr11:49918240	C/T	cg15704280	chr7:45808275	SEPT13	-0.96	-18.03	-0.76	4.27e-46	Height;
SARC	cis	rs11583043	0.708	rs12754497	chr1:101571888	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.45	-4.98	-0.31	1.27e-6	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs5762813	0.566	rs4055	chr22:29352495	A/C	cg02153584	chr22:29168773	CCDC117	0.67	7.06	0.42	1.95e-11	Hematocrit;Hemoglobin concentration;
SARC	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg16479474	chr6:28041457	NA	0.37	5.44	0.34	1.37e-7	Depression;
SARC	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg16325326	chr1:53192061	ZYG11B	-0.76	-11.83	-0.61	1.32e-25	Monocyte count;
SARC	cis	rs7223966	1.000	rs6504169	chr17:61709145	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-5.88	-0.36	1.43e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs861020	0.563	rs35898529	chr1:210053096	G/A	cg05527609	chr1:210001259	C1orf107	-0.79	-7.91	-0.46	1.04e-13	Orofacial clefts;
SARC	trans	rs35833281	1.000	rs35833281	chr6:55021561	G/C	cg19977494	chr7:128431264	CCDC136	-0.73	-6.53	-0.39	4.13e-10	Morning vs. evening chronotype;
SARC	trans	rs61931739	0.613	rs1525898	chr12:33904445	G/T	cg26384229	chr12:38710491	ALG10B	0.57	7.39	0.44	2.67e-12	Morning vs. evening chronotype;
SARC	cis	rs1707322	0.721	rs10430124	chr1:46221617	C/T	cg03146154	chr1:46216737	IPP	0.51	6.11	0.37	4.06e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs11809207	0.574	rs2783630	chr1:26504741	G/A	cg00300879	chr1:26503847	CNKSR1	0.31	4.91	0.31	1.68e-6	Height;
SARC	cis	rs2718058	0.519	rs2722233	chr7:37875982	A/T	cg15028436	chr7:37888078	TXNDC3	0.39	5.21	0.32	4.14e-7	Alzheimer's disease (late onset);
SARC	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	8.55	0.49	1.62e-15	Age-related macular degeneration (geographic atrophy);
SARC	trans	rs61931739	0.746	rs1687003	chr12:34170099	T/A	cg13010199	chr12:38710504	ALG10B	0.59	7.75	0.45	2.86e-13	Morning vs. evening chronotype;
SARC	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg15352829	chr14:105391018	PLD4	-0.33	-6.34	-0.38	1.19e-9	Rheumatoid arthritis;
SARC	cis	rs1355223	0.902	rs1453380	chr11:34703682	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-5.25	-0.33	3.48e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-7.06	-0.42	1.87e-11	Gut microbiome composition (summer);
SARC	cis	rs644799	1.000	rs525404	chr11:95566520	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.9	14.01	0.68	9.11e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg07701084	chr6:150067640	NUP43	0.44	5.66	0.35	4.53e-8	Lung cancer;
SARC	cis	rs6582630	0.537	rs1949610	chr12:38387838	C/T	cg26384229	chr12:38710491	ALG10B	0.87	12.69	0.64	2.17e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs4688759	0.719	rs73079018	chr3:49875327	T/C	cg00383909	chr3:49044727	WDR6	0.75	6.36	0.38	1.05e-9	Blood protein levels;
SARC	cis	rs9611519	0.780	rs2235852	chr22:41661154	G/T	cg17376030	chr22:41985996	PMM1	0.46	5.7	0.35	3.69e-8	Neuroticism;
SARC	cis	rs6866344	0.697	rs17184344	chr5:178129281	A/G	cg10224037	chr5:178157518	ZNF354A	0.99	12.11	0.62	1.7e-26	Neutrophil percentage of white cells;
SARC	cis	rs995000	0.931	rs1748199	chr1:63057136	T/C	cg06896770	chr1:63153194	DOCK7	0.9	13.28	0.66	2.36e-30	Triglyceride levels;
SARC	cis	rs11758351	1.000	rs16891378	chr6:26188864	A/G	cg23601095	chr6:26197514	HIST1H3D	0.63	5.59	0.34	6.41e-8	Gout;Renal underexcretion gout;
SARC	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg21644426	chr2:191273491	MFSD6	-0.5	-6.57	-0.4	3.23e-10	Pulse pressure;
SARC	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg04518342	chr5:131593106	PDLIM4	0.43	5.55	0.34	7.73e-8	Breast cancer;
SARC	cis	rs2180341	0.920	rs4472373	chr6:127705983	G/A	cg24812749	chr6:127587940	RNF146	1.03	13.28	0.66	2.34e-30	Breast cancer;
SARC	cis	rs739401	0.611	rs12284275	chr11:3024384	T/C	cg20651018	chr11:3035856	CARS	-0.44	-6.7	-0.4	1.57e-10	Longevity;
SARC	trans	rs208520	0.526	rs7776413	chr6:66783241	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.11	-22.06	-0.82	5.65e-59	Exhaled nitric oxide output;
SARC	cis	rs12142240	0.698	rs966907	chr1:46817125	C/G	cg14993813	chr1:46806288	NSUN4	-0.52	-5.46	-0.34	1.22e-7	Menopause (age at onset);
SARC	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.42	-6.22	-0.38	2.32e-9	Total body bone mineral density;
SARC	cis	rs55871839	0.533	rs7813733	chr8:59852429	C/T	cg07426533	chr8:59803705	TOX	0.49	5.84	0.36	1.7e-8	Pneumonia;
SARC	cis	rs7937682	1.000	rs2186839	chr11:111534442	T/G	cg22437258	chr11:111473054	SIK2	0.74	9.82	0.54	2.87e-19	Primary sclerosing cholangitis;
SARC	cis	rs360798	0.512	rs2710642	chr2:63149557	G/A	cg17519650	chr2:63277830	OTX1	0.4	4.97	0.31	1.28e-6	Coronary artery disease;
SARC	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg22496380	chr5:211416	CCDC127	-0.88	-9.35	-0.52	7.72e-18	Breast cancer;
SARC	cis	rs796364	0.806	rs10931889	chr2:201101900	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.66	-5.41	-0.33	1.58e-7	Schizophrenia;
SARC	cis	rs9486715	0.867	rs211159	chr6:97023026	G/A	cg06623918	chr6:96969491	KIAA0776	-0.9	-13.55	-0.66	3.22e-31	Headache;
SARC	cis	rs7566780	0.602	rs10198308	chr2:16683402	C/T	cg09580478	chr2:16689509	NA	0.57	7.0	0.42	2.78e-11	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg13395646	chr4:1353034	KIAA1530	-0.52	-6.18	-0.38	2.78e-9	Obesity-related traits;
SARC	cis	rs34245846	0.769	rs12729486	chr1:154827366	T/C	cg24250549	chr1:154909240	PMVK	-0.44	-4.8	-0.3	2.86e-6	Atrial fibrillation;
SARC	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg08219700	chr8:58056026	NA	0.6	6.39	0.39	8.96e-10	Developmental language disorder (linguistic errors);
SARC	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg18555811	chr3:193852889	HES1	0.45	6.25	0.38	1.96e-9	Cancer;
SARC	cis	rs6582630	0.638	rs12424222	chr12:38548273	C/T	cg14851346	chr12:38532713	NA	-0.48	-5.85	-0.36	1.63e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7044106	0.791	rs10985000	chr9:123484115	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.58	0.53	1.57e-18	Hip circumference adjusted for BMI;
SARC	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg06420487	chr17:61919686	SMARCD2	-0.48	-5.77	-0.35	2.55e-8	Height;
SARC	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg16479474	chr6:28041457	NA	0.36	5.67	0.35	4.22e-8	Depression;
SARC	cis	rs9611565	0.879	rs2235845	chr22:41729294	T/G	cg17376030	chr22:41985996	PMM1	0.5	6.49	0.39	5.25e-10	Vitiligo;
SARC	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg25072359	chr17:41440525	NA	0.55	6.75	0.4	1.16e-10	Menopause (age at onset);
SARC	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg19223190	chr17:80058835	NA	-0.4	-5.56	-0.34	7.43e-8	Life satisfaction;
SARC	cis	rs344364	0.602	rs12325217	chr16:1887108	A/T	cg01637482	chr16:1880436	FAHD1	-0.37	-5.41	-0.33	1.54e-7	Glomerular filtration rate in chronic kidney disease;
SARC	cis	rs3741151	0.764	rs79892955	chr11:73096280	G/T	cg17517138	chr11:73019481	ARHGEF17	0.79	5.99	0.37	7.87e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs1691799	0.899	rs1168329	chr12:66731864	C/A	cg16791601	chr12:66731901	HELB	-0.72	-10.61	-0.57	1e-21	White blood cell count (basophil);
SARC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg07308232	chr7:1071921	C7orf50	0.46	5.63	0.35	5.05e-8	Longevity;Endometriosis;
SARC	trans	rs2410182	0.615	rs458297	chr21:41183190	A/G	cg10216615	chr20:37353158	SLC32A1	0.38	6.26	0.38	1.79e-9	Systolic blood pressure (alcohol consumption interaction);
SARC	trans	rs3780486	0.505	rs7868663	chr9:33141229	A/G	cg04842962	chr6:43655489	MRPS18A	0.89	12.78	0.64	1.08e-28	IgG glycosylation;
SARC	cis	rs7666738	0.830	rs7661264	chr4:98961574	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs763121	0.853	rs1065201	chr22:39069510	T/C	cg14440974	chr22:39074834	NA	-0.33	-4.8	-0.3	2.84e-6	Menopause (age at onset);
SARC	cis	rs698833	0.892	rs698796	chr2:44689669	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.7	9.33	0.52	8.69e-18	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs10489202	0.632	rs6659713	chr1:168072249	G/T	cg24449463	chr1:168025552	DCAF6	0.6	8.16	0.47	2.15e-14	Schizophrenia;
SARC	cis	rs6991838	0.584	rs73236948	chr8:66521411	T/G	cg13398993	chr8:66546079	ARMC1	-0.62	-8.39	-0.48	4.67e-15	Intelligence (multi-trait analysis);
SARC	cis	rs7312933	0.618	rs6582390	chr12:42634586	C/T	cg19980929	chr12:42632907	YAF2	0.49	7.03	0.42	2.32e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg11062466	chr8:58055876	NA	0.52	5.38	0.33	1.85e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg02725872	chr8:58115012	NA	-0.37	-6.52	-0.39	4.27e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs72781680	0.898	rs72786288	chr2:24075416	G/T	cg08917208	chr2:24149416	ATAD2B	0.78	7.43	0.44	2.09e-12	Lymphocyte counts;
SARC	cis	rs10463554	0.927	rs56361326	chr5:102389888	T/C	cg23492399	chr5:102201601	PAM	-0.44	-4.83	-0.3	2.45e-6	Parkinson's disease;
SARC	cis	rs4953404	0.613	rs2346877	chr2:46892958	C/G	cg09399716	chr2:46890238	NA	-0.24	-5.0	-0.31	1.11e-6	Pulse pressure (alcohol consumption interaction);
SARC	cis	rs6570726	0.935	rs454614	chr6:145832633	C/T	cg23711669	chr6:146136114	FBXO30	0.78	11.86	0.61	1.04e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs155076	1.000	rs261407	chr13:21855213	C/A	cg11317459	chr13:21872234	NA	-0.96	-11.94	-0.62	6.08e-26	White matter hyperintensity burden;
SARC	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg22683308	chr4:1340831	KIAA1530	0.4	4.88	0.3	1.99e-6	Longevity;
SARC	cis	rs7592578	0.882	rs7569128	chr2:191446691	C/A	cg27211696	chr2:191398769	TMEM194B	0.57	6.04	0.37	6.07e-9	Diastolic blood pressure;
SARC	cis	rs2439831	0.867	rs3101443	chr15:43912372	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	7.74	0.45	2.93e-13	Lung cancer in ever smokers;
SARC	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg11644478	chr21:40555479	PSMG1	-0.86	-11.03	-0.59	5.02e-23	Cognitive function;
SARC	cis	rs11997175	0.546	rs1561913	chr8:33587002	A/T	ch.8.33884649F	chr8:33765107	NA	0.48	6.15	0.37	3.38e-9	Body mass index;
SARC	cis	rs11583043	0.708	rs1335745	chr1:101546439	T/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.45	4.82	0.3	2.62e-6	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs2239547	0.657	rs6445539	chr3:52874296	G/A	cg18404041	chr3:52824283	ITIH1	-0.42	-5.26	-0.33	3.31e-7	Schizophrenia;
SARC	cis	rs12142240	0.698	rs66483119	chr1:46838389	T/C	cg10495392	chr1:46806563	NSUN4	0.65	6.88	0.41	5.6e-11	Menopause (age at onset);
SARC	cis	rs6963495	0.818	rs73190186	chr7:105164368	G/C	cg13798780	chr7:105162888	PUS7	0.6	5.45	0.34	1.31e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs6495122	0.699	rs12905199	chr15:75070196	A/G	cg09165964	chr15:75287851	SCAMP5	0.4	4.75	0.3	3.51e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	cis	rs6426558	0.524	rs2813948	chr1:227459621	A/T	cg10327440	chr1:227177885	CDC42BPA	0.43	5.04	0.31	9.53e-7	Neutrophil percentage of white cells;
SARC	cis	rs11122272	0.735	rs722302	chr1:231480152	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-10.4	-0.56	4.78e-21	Hemoglobin concentration;
SARC	cis	rs11122272	0.705	rs2486731	chr1:231532511	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.64	9.32	0.52	9.12e-18	Hemoglobin concentration;
SARC	cis	rs3813567	0.759	rs7163204	chr15:78953740	G/A	cg24631222	chr15:78858424	CHRNA5	0.49	4.72	0.3	4.03e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
SARC	cis	rs2354432	0.607	rs6685775	chr1:146744294	A/G	cg25205988	chr1:146714368	CHD1L	-1.0	-7.56	-0.44	9.4e-13	Mitochondrial DNA levels;
SARC	cis	rs2070488	0.775	rs9838614	chr3:38537671	A/C	cg27533700	chr3:38537683	EXOG	0.37	4.82	0.3	2.61e-6	Electrocardiographic conduction measures;
SARC	cis	rs7586879	0.681	rs6545790	chr2:25109302	A/G	cg04586622	chr2:25135609	ADCY3	0.33	5.57	0.34	6.88e-8	Body mass index;
SARC	cis	rs2115630	1.000	rs1030863	chr15:85282635	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.46	-5.46	-0.34	1.24e-7	P wave terminal force;
SARC	cis	rs356220	0.617	rs356169	chr4:90632768	G/T	cg06632027	chr4:90757378	SNCA	0.41	5.4	0.33	1.63e-7	Parkinson's disease;
SARC	trans	rs36093844	0.706	rs1445503	chr11:85585011	G/A	cg27065003	chr5:122429449	PRDM6	-0.55	-6.46	-0.39	5.9e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs6545883	0.859	rs2694644	chr2:61604856	A/T	cg15711740	chr2:61764176	XPO1	0.41	4.91	0.31	1.73e-6	Tuberculosis;
SARC	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg09359103	chr1:154839909	KCNN3	-0.48	-8.12	-0.47	2.73e-14	Prostate cancer;
SARC	cis	rs4642101	0.793	rs13086170	chr3:12832604	G/C	cg24848339	chr3:12840334	CAND2	0.32	4.81	0.3	2.75e-6	QRS complex (12-leadsum);
SARC	cis	rs11997175	0.609	rs4733459	chr8:33663793	T/C	ch.8.33884649F	chr8:33765107	NA	0.46	6.04	0.37	6e-9	Body mass index;
SARC	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg06420487	chr17:61919686	SMARCD2	0.49	5.71	0.35	3.46e-8	Height;
SARC	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg24642844	chr7:1081250	C7orf50	-0.39	-5.39	-0.33	1.69e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs17264034	0.500	rs10475468	chr5:9538757	C/T	cg18616062	chr5:9546347	SEMA5A	0.44	5.14	0.32	5.68e-7	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;
SARC	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg22535103	chr8:58192502	C8orf71	-0.71	-6.82	-0.41	7.73e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs17376456	0.877	rs12153788	chr5:93405437	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.86	0.36	1.59e-8	Diabetic retinopathy;
SARC	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg18876405	chr7:65276391	NA	0.71	9.04	0.51	6.42e-17	Calcium levels;
SARC	cis	rs8072100	0.713	rs11079776	chr17:45546893	C/T	cg08085267	chr17:45401833	C17orf57	-0.43	-5.13	-0.32	6.24e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs3859192	0.539	rs2305481	chr17:38138624	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.41	7.53	0.44	1.1e-12	White blood cell count;
SARC	cis	rs10992471	0.603	rs12336415	chr9:95195458	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.26	-0.33	3.34e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg05332525	chr7:65337924	VKORC1L1	0.43	4.83	0.3	2.44e-6	Calcium levels;
SARC	cis	rs7772486	0.720	rs6931553	chr6:146112348	T/C	cg23711669	chr6:146136114	FBXO30	-0.91	-16.06	-0.72	1.46e-39	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg18252515	chr7:66147081	NA	-1.34	-12.05	-0.62	2.51e-26	Diabetic kidney disease;
SARC	cis	rs2153535	0.580	rs7742689	chr6:8452433	C/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.49	1.52e-15	Motion sickness;
SARC	cis	rs1059312	0.772	rs11609637	chr12:129300202	T/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.46	-5.65	-0.35	4.67e-8	Systemic lupus erythematosus;
SARC	cis	rs28374715	0.662	rs513280	chr15:41482800	T/C	cg18705301	chr15:41695430	NDUFAF1	0.94	13.5	0.66	4.6e-31	Ulcerative colitis;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg27622405	chr5:54830971	PPAP2A;RNF138P1	0.48	6.23	0.38	2.14e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs2235642	0.928	rs9932984	chr16:1605051	A/G	cg09065629	chr16:1709722	CRAMP1L	0.38	5.23	0.32	3.73e-7	Coronary artery disease;
SARC	cis	rs2153535	0.580	rs2184582	chr6:8447793	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	8.38	0.48	5.16e-15	Motion sickness;
SARC	cis	rs6570726	0.791	rs7765687	chr6:145915100	A/C	cg05347473	chr6:146136440	FBXO30	0.51	7.14	0.42	1.17e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs13088645	0.683	rs9790169	chr3:134151959	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.37	-4.71	-0.3	4.19e-6	Coronary artery disease;
SARC	cis	rs2016266	0.964	rs2272313	chr12:53671549	A/G	cg26875137	chr12:53738046	NA	0.35	4.83	0.3	2.44e-6	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	15.18	0.71	1.22e-36	Chronic sinus infection;
SARC	cis	rs9290065	0.519	rs7644586	chr3:160674133	T/C	cg04691961	chr3:161091175	C3orf57	-0.51	-6.38	-0.39	9.5e-10	Kawasaki disease;
SARC	cis	rs7223966	1.000	rs6504171	chr17:61710010	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.47	-5.12	-0.32	6.5e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs3824867	0.770	rs11820680	chr11:47452744	C/T	cg20307385	chr11:47447363	PSMC3	-0.47	-5.2	-0.32	4.35e-7	Mean corpuscular hemoglobin;
SARC	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg16680214	chr1:154839983	KCNN3	0.35	5.53	0.34	8.79e-8	Prostate cancer;
SARC	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg11941060	chr3:133502564	NA	-0.34	-4.85	-0.3	2.28e-6	Iron status biomarkers;
SARC	cis	rs1322639	0.531	rs11751421	chr6:169574993	T/C	cg03254818	chr6:169586852	NA	-0.4	-5.23	-0.32	3.8e-7	Pulse pressure;
SARC	cis	rs9948	1.000	rs58147284	chr2:97508082	G/C	cg01990225	chr2:97406019	LMAN2L	-0.65	-5.08	-0.32	7.6e-7	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs8114671	0.967	rs6088747	chr20:33754604	G/T	cg24642439	chr20:33292090	TP53INP2	0.53	6.08	0.37	4.98e-9	Height;
SARC	trans	rs79976124	0.837	rs12201218	chr6:66653619	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.72	-8.35	-0.48	6.27e-15	Type 2 diabetes;
SARC	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg13126279	chr21:47581558	C21orf56	0.42	4.91	0.31	1.71e-6	Testicular germ cell tumor;
SARC	cis	rs2276314	1.000	rs4799835	chr18:33571268	G/A	cg05985134	chr18:33552581	C18orf21	0.73	7.64	0.45	5.61e-13	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs2235642	0.893	rs2076445	chr16:1592266	A/T	cg09065629	chr16:1709722	CRAMP1L	0.35	4.86	0.3	2.18e-6	Coronary artery disease;
SARC	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg18876405	chr7:65276391	NA	0.71	9.2	0.52	2.13e-17	Aortic root size;
SARC	cis	rs11098499	0.754	rs10212775	chr4:120239244	G/C	cg09307838	chr4:120376055	NA	0.81	11.15	0.59	2.11e-23	Corneal astigmatism;
SARC	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg25072359	chr17:41440525	NA	-0.52	-6.39	-0.39	8.89e-10	Menopause (age at onset);
SARC	trans	rs1814175	0.646	rs61904497	chr11:49883449	A/T	cg15704280	chr7:45808275	SEPT13	-0.87	-13.81	-0.67	4.37e-32	Height;
SARC	cis	rs3741404	0.620	rs2236648	chr11:63964657	C/T	cg04317338	chr11:64019027	PLCB3	0.41	4.89	0.31	1.87e-6	Platelet count;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg03366574	chr7:2764599	NA	0.49	6.52	0.39	4.39e-10	Schizophrenia;
SARC	cis	rs734999	0.505	rs4073285	chr1:2539796	C/T	cg18854424	chr1:2615690	NA	0.32	5.12	0.32	6.55e-7	Ulcerative colitis;
SARC	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.46	5.52	0.34	8.94e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7927771	0.524	rs4752796	chr11:47841862	A/G	cg20307385	chr11:47447363	PSMC3	-0.49	-6.63	-0.4	2.36e-10	Subjective well-being;
SARC	trans	rs7937682	1.000	rs7121011	chr11:111568681	C/T	cg18187862	chr3:45730750	SACM1L	-0.55	-6.9	-0.41	4.84e-11	Primary sclerosing cholangitis;
SARC	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg02018176	chr4:1364513	KIAA1530	-0.44	-6.31	-0.38	1.36e-9	Obesity-related traits;
SARC	cis	rs1046896	0.520	rs9895409	chr17:80902719	C/T	cg02711726	chr17:80685570	FN3KRP	-0.56	-6.81	-0.41	8.41e-11	Glycated hemoglobin levels;
SARC	cis	rs933688	0.532	rs28693622	chr5:90538722	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.47	-5.47	-0.34	1.15e-7	Smoking behavior;
SARC	cis	rs1348850	0.914	rs4893957	chr2:178380409	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.71	8.83	0.5	2.53e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg21280719	chr6:42927975	GNMT	-0.46	-8.29	-0.48	9.3e-15	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg11644478	chr21:40555479	PSMG1	-0.86	-11.28	-0.59	7.99e-24	Cognitive function;
SARC	cis	rs9457247	0.561	rs916331	chr6:167470559	T/G	cg23791538	chr6:167370224	RNASET2	-0.53	-7.01	-0.42	2.51e-11	Crohn's disease;
SARC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg24101359	chr6:42928495	GNMT	0.47	6.27	0.38	1.75e-9	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs9399135	1.000	rs6569988	chr6:135352303	C/A	cg24558204	chr6:135376177	HBS1L	0.45	6.15	0.37	3.41e-9	Red blood cell count;
SARC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.63	0.57	8.91e-22	Prudent dietary pattern;
SARC	cis	rs4891159	0.790	rs8087557	chr18:74116848	G/C	cg24786174	chr18:74118243	ZNF516	-0.68	-10.36	-0.56	6.24e-21	Longevity;
SARC	cis	rs2629540	0.889	rs4962699	chr10:126477209	A/G	cg08799069	chr10:126477246	METTL10	-0.67	-7.48	-0.44	1.5e-12	Cocaine dependence;
SARC	cis	rs9300255	0.543	rs655293	chr12:123528405	G/A	cg05973401	chr12:123451056	ABCB9	0.53	5.69	0.35	3.83e-8	Neutrophil percentage of white cells;
SARC	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg23758822	chr17:41437982	NA	0.86	10.63	0.57	9.17e-22	Menopause (age at onset);
SARC	cis	rs7617773	0.817	rs3731497	chr3:48226553	T/G	cg11946769	chr3:48343235	NME6	0.72	9.33	0.52	8.8e-18	Coronary artery disease;
SARC	cis	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg21573476	chr21:45109991	RRP1B	-0.56	-8.23	-0.47	1.32e-14	Mean corpuscular volume;
SARC	cis	rs6815814	0.950	rs3924112	chr4:38795810	C/T	cg02016764	chr4:38805732	TLR1	-0.41	-4.72	-0.3	4.06e-6	Breast cancer;
SARC	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg01516881	chr6:292596	DUSP22	-0.53	-6.53	-0.39	4.03e-10	Menopause (age at onset);
SARC	cis	rs739401	0.611	rs2239899	chr11:3024624	A/G	cg25174290	chr11:3078921	CARS	-0.59	-8.16	-0.47	2.08e-14	Longevity;
SARC	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.33	-0.43	3.74e-12	Extrinsic epigenetic age acceleration;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg20557037	chr2:165698099	COBLL1	-0.56	-7.89	-0.46	1.17e-13	Thyroid stimulating hormone;
SARC	cis	rs12421382	0.659	rs11600110	chr11:109392438	A/G	cg16359550	chr11:109292809	C11orf87	0.37	5.45	0.34	1.31e-7	Schizophrenia;
SARC	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg11987759	chr7:65425863	GUSB	-0.6	-7.96	-0.46	7.38e-14	Aortic root size;
SARC	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.49	5.79	0.35	2.28e-8	Gut microbiome composition (summer);
SARC	cis	rs17253792	0.822	rs77544029	chr14:56087917	T/C	cg01858014	chr14:56050164	KTN1	-0.67	-5.11	-0.32	6.86e-7	Putamen volume;
SARC	cis	rs3091242	0.933	rs28633797	chr1:25741629	C/A	cg27572855	chr1:25598939	RHD	0.56	9.61	0.53	1.21e-18	Erythrocyte sedimentation rate;
SARC	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg08492202	chr8:42911315	FNTA	-0.51	-6.28	-0.38	1.66e-9	Migraine with aura;
SARC	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg09417038	chr21:47716443	C21orf57	0.35	5.23	0.32	3.73e-7	Testicular germ cell tumor;
SARC	cis	rs2834188	1.000	rs2834187	chr21:34687410	A/G	cg04842828	chr21:34696676	IFNAR1	0.41	4.74	0.3	3.65e-6	Narcolepsy;
SARC	cis	rs1035144	0.505	rs10145099	chr14:81456694	C/T	cg06600135	chr14:81408086	NA	-0.46	-5.93	-0.36	1.08e-8	Male sexual orientation;
SARC	cis	rs1707322	1.000	rs4489497	chr1:46438698	C/T	cg06784218	chr1:46089804	CCDC17	0.34	5.95	0.36	9.76e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	10.66	0.57	7.14e-22	Platelet count;
SARC	cis	rs3126085	0.736	rs11581433	chr1:152283236	T/C	cg03465714	chr1:152285911	FLG	0.48	5.59	0.34	6.32e-8	Atopic dermatitis;
SARC	cis	rs757110	0.866	rs5215	chr11:17408630	C/T	cg15432903	chr11:17409602	KCNJ11	0.56	9.1	0.51	4.01e-17	Type 2 diabetes;
SARC	cis	rs7000551	0.675	rs2469758	chr8:22363032	C/T	cg12081754	chr8:22256438	SLC39A14	0.57	8.14	0.47	2.36e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg22535103	chr8:58192502	C8orf71	-0.73	-7.24	-0.43	6.52e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17135325	chr3:160939158	NMD3	0.59	7.51	0.44	1.25e-12	Parkinson's disease;
SARC	cis	rs4780401	0.655	rs11648550	chr16:11787714	C/G	cg01061890	chr16:11836724	TXNDC11	0.44	5.89	0.36	1.33e-8	Rheumatoid arthritis;
SARC	cis	rs3820928	1.000	rs4675116	chr2:227769607	A/C	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.86	-0.36	1.56e-8	Pulmonary function;
SARC	cis	rs7582720	1.000	rs72926786	chr2:203816494	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs17401966	0.838	rs1556917	chr1:10400990	G/T	cg15208524	chr1:10270712	KIF1B	0.44	5.11	0.32	6.74e-7	Hepatocellular carcinoma;
SARC	cis	rs933688	0.527	rs10038090	chr5:90582456	C/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.54	-4.86	-0.3	2.2e-6	Smoking behavior;
SARC	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg23758822	chr17:41437982	NA	0.85	11.18	0.59	1.67e-23	Menopause (age at onset);
SARC	cis	rs10870270	0.956	rs67378218	chr10:133752420	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.85	-10.91	-0.58	1.16e-22	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg23262073	chr20:60523788	NA	-0.38	-5.26	-0.33	3.27e-7	Body mass index;
SARC	cis	rs796364	0.951	rs7586284	chr2:201068002	G/A	cg05691004	chr2:201170426	SPATS2L	-0.46	-5.06	-0.31	8.58e-7	Schizophrenia;
SARC	cis	rs2645424	0.550	rs28577034	chr8:11708715	A/T	cg21281001	chr8:11725306	CTSB	0.49	6.08	0.37	4.99e-9	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
SARC	cis	rs4737010	0.501	rs12548116	chr8:41645074	A/G	cg17182837	chr8:41585554	ANK1	-0.47	-5.23	-0.32	3.76e-7	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
SARC	cis	rs10489202	0.632	rs202259	chr1:167962072	G/A	cg17859187	chr1:168147929	TIPRL	0.4	4.89	0.31	1.88e-6	Schizophrenia;
SARC	cis	rs2295359	1.000	rs4655683	chr1:67611613	C/T	cg08029281	chr1:67600428	NA	0.37	5.28	0.33	3.02e-7	Psoriasis;
SARC	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg13880726	chr7:1868755	MAD1L1	0.49	5.77	0.35	2.53e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs7089973	0.872	rs7923295	chr10:116625159	C/G	cg08188268	chr10:116634841	FAM160B1	-0.36	-5.86	-0.36	1.58e-8	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	trans	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg02871028	chr19:32896878	DPY19L3	0.45	6.32	0.38	1.29e-9	Immature fraction of reticulocytes;
SARC	cis	rs5758511	0.514	rs5751211	chr22:42486056	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.42	6.04	0.37	6.11e-9	Birth weight;
SARC	cis	rs17381785	0.835	rs11725063	chr4:14913852	G/A	cg18497811	chr4:14860861	NA	0.5	5.27	0.33	3.11e-7	Urate levels in overweight individuals;
SARC	cis	rs7089973	0.604	rs7914792	chr10:116591391	T/C	cg08188268	chr10:116634841	FAM160B1	0.28	4.77	0.3	3.18e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg06636001	chr8:8085503	FLJ10661	0.67	9.22	0.52	1.81e-17	Mood instability;
SARC	cis	rs950169	0.544	rs62021193	chr15:85170583	C/G	cg17507749	chr15:85114479	UBE2QP1	0.58	6.77	0.41	1.03e-10	Schizophrenia;
SARC	cis	rs10791097	0.765	rs4622274	chr11:130729486	C/T	cg12179176	chr11:130786555	SNX19	0.63	8.6	0.49	1.2e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs7659604	0.540	rs28615388	chr4:122678418	C/T	cg19671926	chr4:122722719	EXOSC9	0.55	6.98	0.42	3.02e-11	Type 2 diabetes;
SARC	trans	rs208520	0.754	rs851592	chr6:66875175	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.09	-14.37	-0.69	5.71e-34	Exhaled nitric oxide output;
SARC	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	16.56	0.74	3.2e-41	Height;
SARC	cis	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.39	-0.39	9.05e-10	Joint mobility (Beighton score);
SARC	cis	rs3812049	0.784	rs2617617	chr5:127455008	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.88	9.61	0.53	1.21e-18	Lymphocyte counts;Red cell distribution width;
SARC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg03647317	chr4:187891568	NA	-0.37	-5.1	-0.32	7.18e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2011503	1.000	rs4808205	chr19:19645493	T/G	cg15839431	chr19:19639596	YJEFN3	-0.48	-4.77	-0.3	3.32e-6	Bipolar disorder;
SARC	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg15966229	chr18:44337664	ST8SIA5	-0.38	-4.91	-0.31	1.68e-6	Personality dimensions;
SARC	cis	rs2153535	0.562	rs10458225	chr6:8386004	G/A	cg21535247	chr6:8435926	SLC35B3	-0.58	-7.09	-0.42	1.56e-11	Motion sickness;
SARC	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg03352830	chr11:487213	PTDSS2	0.54	5.51	0.34	9.42e-8	Body mass index;
SARC	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.38	-4.82	-0.3	2.54e-6	Lymphocyte counts;
SARC	cis	rs113835537	0.559	rs11227497	chr11:66269464	T/C	cg24851651	chr11:66362959	CCS	0.37	4.79	0.3	3.01e-6	Airway imaging phenotypes;
SARC	cis	rs7599312	0.534	rs6735626	chr2:213403972	G/A	cg20637307	chr2:213403960	ERBB4	0.8	12.5	0.63	8.9e-28	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs11098499	1.000	rs13435802	chr4:120177960	A/T	cg24375607	chr4:120327624	NA	-0.39	-4.9	-0.31	1.82e-6	Corneal astigmatism;
SARC	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	6.03	0.37	6.25e-9	Height;
SARC	cis	rs6831352	0.879	rs7672728	chr4:100055173	A/G	cg13256891	chr4:100009986	ADH5	-0.64	-8.0	-0.46	5.7e-14	Alcohol dependence;
SARC	cis	rs7932354	0.528	rs4752957	chr11:47125632	T/G	cg03339077	chr11:47165057	C11orf49	-0.41	-5.62	-0.35	5.55e-8	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg02951883	chr7:2050386	MAD1L1	-0.41	-5.06	-0.31	8.53e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs1348850	0.872	rs12991272	chr2:178457339	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.63	7.41	0.44	2.26e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs11605924	1.000	rs12794698	chr11:45871861	G/A	ch.11.939596F	chr11:45881766	CRY2	-0.46	-5.57	-0.34	6.97e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs7621025	0.691	rs9845762	chr3:136356464	C/T	cg15507776	chr3:136538369	TMEM22	0.44	4.99	0.31	1.21e-6	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
SARC	cis	rs72945132	0.882	rs72949078	chr11:70217708	T/C	cg00319359	chr11:70116639	PPFIA1	0.69	6.39	0.39	9.15e-10	Coronary artery disease;
SARC	cis	rs6540556	0.517	rs1474655	chr1:209884730	G/C	cg05527609	chr1:210001259	C1orf107	-0.54	-4.75	-0.3	3.61e-6	Red blood cell count;
SARC	cis	rs3126085	0.877	rs4845742	chr1:152183949	G/A	cg03465714	chr1:152285911	FLG	-0.46	-5.5	-0.34	1e-7	Atopic dermatitis;
SARC	trans	rs9325144	0.555	rs1843867	chr12:38703855	A/G	cg23762105	chr12:34175262	ALG10	0.56	7.39	0.44	2.65e-12	Morning vs. evening chronotype;
SARC	cis	rs1448094	0.512	rs1584368	chr12:86245117	A/C	cg02569458	chr12:86230093	RASSF9	0.38	5.22	0.32	3.92e-7	Major depressive disorder;
SARC	cis	rs7872515	0.793	rs10820936	chr9:94830974	C/T	cg01248375	chr9:94877805	SPTLC1	-0.54	-5.19	-0.32	4.6e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs526231	0.511	rs55810112	chr5:102362349	C/T	cg23492399	chr5:102201601	PAM	-0.5	-5.51	-0.34	9.29e-8	Primary biliary cholangitis;
SARC	cis	rs1953600	1.000	rs2573346	chr10:81918041	G/A	cg00277334	chr10:82204260	NA	-0.35	-5.02	-0.31	1.01e-6	Sarcoidosis;
SARC	cis	rs1348850	0.918	rs12622298	chr2:178450651	C/T	cg23306229	chr2:178417860	TTC30B	0.6	7.35	0.43	3.29e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9916302	0.904	rs68178216	chr17:37526241	A/C	cg20243544	chr17:37824526	PNMT	-0.57	-7.0	-0.42	2.73e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs911555	0.617	rs7156036	chr14:103908142	A/G	cg12935359	chr14:103987150	CKB	0.4	5.45	0.34	1.26e-7	Intelligence (multi-trait analysis);
SARC	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg22618164	chr12:122356400	WDR66	0.47	7.47	0.44	1.59e-12	Mean platelet volume;
SARC	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg09699651	chr6:150184138	LRP11	-0.39	-4.85	-0.3	2.22e-6	Lung cancer;
SARC	cis	rs9398803	0.687	rs4629707	chr6:126937890	T/C	cg20229609	chr6:126660872	C6orf173	0.35	5.07	0.31	8.26e-7	Male-pattern baldness;
SARC	cis	rs17376456	0.569	rs12653528	chr5:93212833	T/C	cg25358565	chr5:93447407	FAM172A	-0.96	-10.77	-0.58	3.35e-22	Diabetic retinopathy;
SARC	cis	rs4233949	1.000	rs4233949	chr2:54659707	C/G	cg24760922	chr2:54683707	SPTBN1	-0.4	-5.16	-0.32	5.16e-7	Bone mineral density;
SARC	cis	rs79349575	0.783	rs4794000	chr17:47022755	C/G	cg07967210	chr17:47022446	SNF8	0.38	4.77	0.3	3.2e-6	Type 2 diabetes;
SARC	cis	rs2908197	0.699	rs2860469	chr7:75960506	A/C	cg22830091	chr7:75961684	YWHAG	-0.35	-5.23	-0.32	3.79e-7	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg11062466	chr8:58055876	NA	0.64	5.42	0.33	1.51e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2916247	1.000	rs10089969	chr8:93060896	G/T	cg10183463	chr8:93005414	RUNX1T1	-0.58	-5.95	-0.36	1e-8	Intelligence (multi-trait analysis);
SARC	cis	rs17539620	0.624	rs4566892	chr6:154837346	C/T	cg20019720	chr6:154832845	CNKSR3	0.41	4.84	0.3	2.39e-6	Lipoprotein (a) levels;
SARC	cis	rs9611519	0.754	rs4820435	chr22:41652846	G/T	cg03806693	chr22:41940476	POLR3H	-0.74	-9.49	-0.53	2.77e-18	Neuroticism;
SARC	cis	rs6834538	0.597	rs1486865	chr4:113465651	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.54	7.33	0.43	3.86e-12	Free thyroxine concentration;
SARC	cis	rs10256972	0.647	rs10233430	chr7:1051664	T/C	cg00431813	chr7:1051703	C7orf50	-0.34	-5.15	-0.32	5.48e-7	Longevity;Endometriosis;
SARC	cis	rs554111	0.685	rs113664832	chr1:21058655	G/A	cg04902671	chr1:21058625	SH2D5	0.48	5.66	0.35	4.5e-8	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs1468333	0.567	rs6861656	chr5:137667512	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.63	7.46	0.44	1.72e-12	Resting heart rate;
SARC	cis	rs1941023	0.503	rs12798266	chr11:60118851	G/A	cg08716584	chr11:60157161	MS4A7	-0.38	-6.34	-0.38	1.15e-9	Congenital heart disease (maternal effect);
SARC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg16405210	chr4:1374714	KIAA1530	-0.86	-11.25	-0.59	9.48e-24	Longevity;
SARC	cis	rs2463822	0.925	rs17157227	chr11:62169772	A/G	cg06239285	chr11:62104954	ASRGL1	0.82	7.57	0.44	8.52e-13	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs6866344	0.697	rs62392831	chr5:178134365	A/G	cg03877680	chr5:178157825	ZNF354A	1.02	12.68	0.64	2.26e-28	Neutrophil percentage of white cells;
SARC	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg22903657	chr4:1355424	KIAA1530	-0.35	-4.82	-0.3	2.55e-6	Obesity-related traits;
SARC	cis	rs7772486	0.597	rs7746618	chr6:146281367	T/C	cg05347473	chr6:146136440	FBXO30	-0.73	-9.84	-0.54	2.57e-19	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs35995292	1.000	rs3779119	chr7:38942248	C/G	cg19327137	chr7:38886074	VPS41	0.36	5.12	0.32	6.52e-7	Subjective well-being (multi-trait analysis);
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg14313443	chr15:66995985	SMAD6	0.5	6.38	0.39	9.39e-10	Blood pressure;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg04820411	chr13:111525614	NA	0.81	6.14	0.37	3.49e-9	Obesity-related traits;
SARC	cis	rs854765	0.534	rs7207461	chr17:17949789	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-9.75	-0.54	4.63e-19	Total body bone mineral density;
SARC	cis	rs763121	0.813	rs4821807	chr22:39065582	A/G	cg21395723	chr22:39101663	GTPBP1	0.54	6.05	0.37	5.82e-9	Menopause (age at onset);
SARC	cis	rs9790314	0.747	rs1610158	chr3:160815050	A/G	cg04691961	chr3:161091175	C3orf57	0.63	8.62	0.49	1.01e-15	Morning vs. evening chronotype;
SARC	cis	rs6714710	0.535	rs13006932	chr2:98370698	T/A	cg26665480	chr2:98280029	ACTR1B	0.55	7.33	0.43	3.85e-12	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg19346786	chr7:2764209	NA	-0.41	-6.06	-0.37	5.52e-9	Height;
SARC	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg20607798	chr8:58055168	NA	0.61	5.41	0.33	1.57e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg18404041	chr3:52824283	ITIH1	-0.39	-5.98	-0.36	8.45e-9	Electroencephalogram traits;
SARC	cis	rs12200560	0.505	rs211163	chr6:97067654	A/G	cg06623918	chr6:96969491	KIAA0776	0.44	4.9	0.31	1.8e-6	Coronary heart disease;
SARC	cis	rs7666738	0.791	rs1426674	chr4:98924247	C/A	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7914558	1.000	rs10748838	chr10:104943986	T/A	cg04362960	chr10:104952993	NT5C2	0.4	4.72	0.3	3.99e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs2354432	0.556	rs2353984	chr1:146813358	C/T	cg25205988	chr1:146714368	CHD1L	0.93	7.01	0.42	2.61e-11	Mitochondrial DNA levels;
SARC	cis	rs2594989	0.779	rs2443702	chr3:11586435	C/T	cg00170343	chr3:11313890	ATG7	-0.55	-5.88	-0.36	1.4e-8	Circulating chemerin levels;
SARC	trans	rs9329221	0.597	rs17751178	chr8:10116730	A/G	cg06636001	chr8:8085503	FLJ10661	0.54	7.2	0.43	8.23e-12	Neuroticism;
SARC	cis	rs9436747	0.714	rs1751492	chr1:65992625	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.5	-5.47	-0.34	1.18e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs10483282	1.000	rs1958311	chr14:24255003	C/T	cg02879798	chr14:24800305	ADCY4	-0.33	-5.07	-0.32	7.96e-7	Alcohol dependence;
SARC	cis	rs2075371	0.764	rs1643034	chr7:134006176	A/G	cg00033643	chr7:134001901	SLC35B4	0.5	6.29	0.38	1.52e-9	Mean platelet volume;
SARC	cis	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg00409905	chr10:38381863	ZNF37A	0.56	8.12	0.47	2.74e-14	Extrinsic epigenetic age acceleration;
SARC	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.54	8.13	0.47	2.5e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs9290065	0.558	rs9846254	chr3:160770370	C/T	cg03342759	chr3:160939853	NMD3	-0.55	-6.64	-0.4	2.18e-10	Kawasaki disease;
SARC	cis	rs3733585	0.605	rs4697710	chr4:10122649	T/C	cg00071950	chr4:10020882	SLC2A9	-0.38	-5.57	-0.34	7.05e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs4803468	1.000	rs11670757	chr19:41913431	G/T	cg14132834	chr19:41945861	ATP5SL	-0.55	-7.31	-0.43	4.37e-12	Height;
SARC	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg06028808	chr11:68637592	NA	-0.48	-6.26	-0.38	1.84e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7412746	0.658	rs10888397	chr1:150886752	A/G	cg15448220	chr1:150897856	SETDB1	-0.51	-6.88	-0.41	5.6e-11	Melanoma;
SARC	cis	rs870825	0.655	rs10013685	chr4:185617785	C/T	cg04058563	chr4:185651563	MLF1IP	0.84	11.62	0.61	6.27e-25	Blood protein levels;
SARC	cis	rs4128725	0.925	rs10908724	chr1:159450168	G/T	cg25076881	chr1:159409836	OR10J1	0.43	5.11	0.32	6.56e-7	Select biomarker traits;
SARC	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg22535103	chr8:58192502	C8orf71	-0.59	-5.7	-0.35	3.57e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1008375	0.931	rs10939734	chr4:17570709	C/T	cg16339924	chr4:17578868	LAP3	0.68	8.81	0.5	2.95e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs290268	1.000	rs188313	chr9:93548302	C/T	cg02608019	chr9:93564028	SYK	0.34	4.84	0.3	2.34e-6	Platelet count;
SARC	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg03433033	chr1:76189801	ACADM	-0.42	-5.4	-0.33	1.66e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9398803	0.865	rs1907067	chr6:126837663	A/C	cg19875578	chr6:126661172	C6orf173	0.63	8.62	0.49	1e-15	Male-pattern baldness;
SARC	cis	rs10493773	0.928	rs12751296	chr1:86176968	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.5	-7.09	-0.42	1.56e-11	Urate levels in overweight individuals;
SARC	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg11890956	chr21:40555474	PSMG1	-0.71	-9.52	-0.53	2.29e-18	Menarche (age at onset);
SARC	cis	rs743757	0.878	rs1467914	chr3:50523668	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.54	4.9	0.31	1.82e-6	Diastolic blood pressure;
SARC	cis	rs4689388	0.890	rs4689398	chr4:6302199	C/T	cg14416269	chr4:6271139	WFS1	0.31	4.75	0.3	3.59e-6	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs460214	0.576	rs28446127	chr21:40029568	C/A	cg12884169	chr21:40033163	ERG	-0.34	-4.9	-0.31	1.8e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg16486109	chr11:613632	IRF7	0.46	6.09	0.37	4.68e-9	Systemic lupus erythematosus;
SARC	cis	rs933688	0.532	rs997737	chr5:90567031	C/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.49	-5.5	-0.34	9.77e-8	Smoking behavior;
SARC	cis	rs698833	0.886	rs2304770	chr2:44569328	T/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.72	9.59	0.53	1.39e-18	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	trans	rs9329221	0.905	rs6601451	chr8:10243681	C/G	cg08975724	chr8:8085496	FLJ10661	-0.57	-7.28	-0.43	4.94e-12	Neuroticism;
SARC	cis	rs9814567	0.806	rs4074522	chr3:134325626	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.54	6.96	0.41	3.5e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg25072359	chr17:41440525	NA	0.52	6.11	0.37	4.12e-9	Menopause (age at onset);
SARC	cis	rs9815354	0.812	rs114034165	chr3:41823297	G/A	cg03022575	chr3:42003672	ULK4	0.71	5.89	0.36	1.34e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6582630	0.555	rs2004152	chr12:38478951	C/T	cg26384229	chr12:38710491	ALG10B	0.87	12.52	0.63	7.68e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg11987759	chr7:65425863	GUSB	-0.47	-6.27	-0.38	1.7e-9	Aortic root size;
SARC	cis	rs72945132	0.882	rs57810426	chr11:70230030	G/A	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.88	-0.36	1.41e-8	Coronary artery disease;
SARC	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.41	0.44	2.36e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2153535	0.580	rs6918391	chr6:8461178	A/C	cg07606381	chr6:8435919	SLC35B3	0.75	10.69	0.57	5.96e-22	Motion sickness;
SARC	cis	rs9341808	0.527	rs7453746	chr6:80810013	T/G	cg08355045	chr6:80787529	NA	0.35	5.56	0.34	7.43e-8	Sitting height ratio;
SARC	cis	rs11785693	0.862	rs7007542	chr8:4996718	G/A	cg26367366	chr8:4980734	NA	0.75	6.64	0.4	2.24e-10	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs80130819	0.748	rs2258342	chr12:48690363	T/C	cg05342945	chr12:48394962	COL2A1	-0.54	-5.66	-0.35	4.34e-8	Prostate cancer;
SARC	cis	rs11608355	0.515	rs7955932	chr12:109941303	G/A	cg05360138	chr12:110035743	NA	0.92	9.39	0.52	5.78e-18	Neuroticism;
SARC	cis	rs7103648	0.966	rs1377416	chr11:47416746	C/T	cg10504702	chr11:47789108	FNBP4	0.6	7.87	0.46	1.32e-13	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs41271473	0.519	rs9660783	chr1:228886880	C/T	cg00850481	chr1:228891306	NA	-0.32	-5.08	-0.32	7.7300000000000005e-07	Chronic lymphocytic leukemia;
SARC	cis	rs10754283	0.935	rs1934046	chr1:90119290	A/T	cg21401794	chr1:90099060	LRRC8C	-0.56	-7.76	-0.45	2.69e-13	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs2963155	0.518	rs1438732	chr5:142756266	G/C	cg17617527	chr5:142782415	NR3C1	0.86	6.32	0.38	1.35e-9	Breast cancer;
SARC	trans	rs61931739	0.635	rs10772123	chr12:33975557	C/T	cg13010199	chr12:38710504	ALG10B	0.56	7.14	0.42	1.2e-11	Morning vs. evening chronotype;
SARC	cis	rs7474896	0.515	rs624359	chr10:38299132	T/C	cg00409905	chr10:38381863	ZNF37A	0.44	4.93	0.31	1.57e-6	Obesity (extreme);
SARC	cis	rs16854884	0.632	rs34038325	chr3:143685097	G/A	cg06585982	chr3:143692056	C3orf58	0.65	8.46	0.48	2.99e-15	Economic and political preferences (feminism/equality);
SARC	cis	rs8031584	0.958	rs7168641	chr15:31235452	G/A	cg14829155	chr15:31115871	NA	-0.42	-5.28	-0.33	2.99e-7	Huntington's disease progression;
SARC	cis	rs10782582	0.593	rs12129523	chr1:76129223	C/A	cg10523679	chr1:76189770	ACADM	-0.43	-5.28	-0.33	2.91e-7	Daytime sleep phenotypes;
SARC	cis	rs67257959	0.586	rs111818766	chr19:17158092	G/A	cg16202187	chr19:17186497	HAUS8;MYO9B	0.41	4.83	0.3	2.43e-6	Selective IgA deficiency;
SARC	cis	rs3768617	1.000	rs12026314	chr1:183104527	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	8.52	0.49	2.01e-15	Fuchs's corneal dystrophy;
SARC	cis	rs2749592	0.550	rs7917262	chr10:37874602	A/C	cg25427524	chr10:38739819	LOC399744	0.45	6.52	0.39	4.24e-10	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg08045932	chr20:61659980	NA	0.5	6.84	0.41	7.06e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg04277193	chr17:41438351	NA	0.46	5.0	0.31	1.13e-6	Menopause (age at onset);
SARC	trans	rs61931739	0.534	rs28548399	chr12:34188151	G/A	cg26384229	chr12:38710491	ALG10B	0.85	12.17	0.62	1.07e-26	Morning vs. evening chronotype;
SARC	cis	rs17270561	0.636	rs12194699	chr6:25729229	G/C	cg17691542	chr6:26056736	HIST1H1C	0.58	7.09	0.42	1.59e-11	Iron status biomarkers;
SARC	cis	rs57506017	0.585	rs1990620	chr7:12284008	A/G	cg23422036	chr7:12250390	TMEM106B	0.48	6.37	0.38	1.02e-9	Neuroticism;
SARC	cis	rs9818758	0.505	rs11716159	chr3:49631585	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.66	-5.3	-0.33	2.64e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs6669919	0.967	rs6678844	chr1:211674774	G/T	cg10512769	chr1:211675356	NA	-0.28	-4.73	-0.3	3.96e-6	Intelligence (multi-trait analysis);
SARC	cis	rs11719291	0.504	rs71324924	chr3:48865444	G/A	cg00383909	chr3:49044727	WDR6	0.76	6.79	0.41	9.41e-11	Cognitive function;
SARC	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg05368731	chr17:41323189	NBR1	0.8	9.59	0.53	1.43e-18	Menopause (age at onset);
SARC	cis	rs58235267	0.553	rs11890276	chr2:63366191	C/T	cg17519650	chr2:63277830	OTX1	0.41	4.82	0.3	2.6e-6	Prostate-specific antigen levels (conditioned on lead SNPs);
SARC	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg18252515	chr7:66147081	NA	-1.33	-11.84	-0.61	1.22e-25	Diabetic kidney disease;
SARC	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg10523679	chr1:76189770	ACADM	0.51	6.71	0.4	1.47e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9788682	0.747	rs8042374	chr15:78908032	A/G	cg06917634	chr15:78832804	PSMA4	-0.47	-5.37	-0.33	1.89e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs1784581	0.851	rs1784591	chr6:162388893	C/G	cg17173639	chr6:162384350	PARK2	-0.78	-11.1	-0.59	2.94e-23	Itch intensity from mosquito bite;
SARC	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg01017244	chr2:74357527	NA	0.54	6.54	0.39	3.84e-10	Gestational age at birth (maternal effect);
SARC	cis	rs1865760	0.663	rs9467656	chr6:25993559	G/A	cg17691542	chr6:26056736	HIST1H1C	0.5	6.42	0.39	7.71e-10	Height;
SARC	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg24209194	chr3:40518798	ZNF619	0.59	7.21	0.43	7.84e-12	Renal cell carcinoma;
SARC	cis	rs5995756	0.834	rs132575	chr22:39982721	A/G	cg10455938	chr22:40058150	CACNA1I	-0.37	-4.79	-0.3	2.95e-6	Autism spectrum disorder or schizophrenia;
SARC	trans	rs7815944	0.744	rs16902889	chr8:129424715	G/C	cg25487405	chr22:46473039	NA	0.64	6.35	0.38	1.09e-9	Atopic dermatitis;
SARC	cis	rs13191362	0.507	rs13211655	chr6:163177542	C/G	cg21926612	chr6:163149169	PACRG;PARK2	0.49	5.31	0.33	2.57e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs73086581	0.592	rs2300217	chr20:3938575	A/G	cg02187196	chr20:3869020	PANK2	0.43	5.04	0.31	9.28e-7	Response to antidepressants in depression;
SARC	cis	rs4780401	0.728	rs7188511	chr16:11773743	G/T	cg01061890	chr16:11836724	TXNDC11	-0.5	-6.62	-0.4	2.38e-10	Rheumatoid arthritis;
SARC	cis	rs9916302	0.904	rs650106	chr17:37451559	A/G	cg20243544	chr17:37824526	PNMT	-0.55	-6.64	-0.4	2.19e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs4481887	0.893	rs28451623	chr1:248509783	G/A	cg00666640	chr1:248458726	OR2T12	0.32	5.56	0.34	7.31e-8	Common traits (Other);
SARC	cis	rs17376456	0.877	rs17315943	chr5:93442830	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.89	0.36	1.36e-8	Diabetic retinopathy;
SARC	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg22535103	chr8:58192502	C8orf71	-0.7	-8.45	-0.48	3.22e-15	Developmental language disorder (linguistic errors);
SARC	cis	rs3784262	0.527	rs4646557	chr15:58354697	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.33	-4.87	-0.3	2.07e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs17023223	0.509	rs56195272	chr1:119713997	A/T	cg05756136	chr1:119680316	WARS2	-0.49	-5.62	-0.35	5.47e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs17401966	1.000	rs12734551	chr1:10391536	A/C	cg15208524	chr1:10270712	KIF1B	0.59	6.58	0.4	2.99e-10	Hepatocellular carcinoma;
SARC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.41	-6.87	-0.41	5.7e-11	Total body bone mineral density;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg10982500	chr5:107252830	FBXL17	0.51	7.43	0.44	2.06e-12	Thyroid stimulating hormone;
SARC	cis	rs7223966	1.000	rs1877316	chr17:61766880	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	6.67	0.4	1.86e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2486288	0.656	rs2461705	chr15:45570241	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.54	-6.72	-0.4	1.42e-10	Glomerular filtration rate;
SARC	cis	rs10779751	0.734	rs2259886	chr1:11137778	C/T	cg08854313	chr1:11322531	MTOR	0.85	11.94	0.62	6.12e-26	Body mass index;
SARC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg26354017	chr1:205819088	PM20D1	0.56	7.25	0.43	6.18e-12	Menarche (age at onset);
SARC	cis	rs6831352	0.589	rs2602836	chr4:100014805	C/T	cg12011299	chr4:100065546	ADH4	-0.3	-5.87	-0.36	1.48e-8	Alcohol dependence;
SARC	cis	rs56330463	0.967	rs1432623	chr5:148204008	C/T	cg21580376	chr5:148206412	ADRB2	0.4	5.46	0.34	1.21e-7	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Monocyte percentage of white cells;Eosinophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;
SARC	cis	rs7819412	0.595	rs10106914	chr8:10987651	T/G	cg21775007	chr8:11205619	TDH	-0.42	-5.16	-0.32	5.32e-7	Triglycerides;
SARC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg23131131	chr22:24373011	LOC391322	-0.5	-5.45	-0.34	1.25e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2011503	1.000	rs77616520	chr19:19652776	G/A	cg03709012	chr19:19516395	GATAD2A	0.6	5.29	0.33	2.8e-7	Bipolar disorder;
SARC	cis	rs7103648	0.695	rs10838726	chr11:47568344	C/G	cg10504702	chr11:47789108	FNBP4	0.7	9.16	0.51	2.79e-17	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs55871839	0.708	rs13268621	chr8:59811724	T/G	cg07426533	chr8:59803705	TOX	-0.43	-5.77	-0.35	2.51e-8	Pneumonia;
SARC	cis	rs13427251	0.903	rs6746402	chr2:100150443	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.48	-5.96	-0.36	9.51e-9	Chronic sinus infection;
SARC	cis	rs7216064	0.953	rs58141639	chr17:65864902	C/T	cg12091567	chr17:66097778	LOC651250	-0.64	-6.45	-0.39	6.56e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs9325144	0.581	rs2653758	chr12:38946233	G/T	cg26384229	chr12:38710491	ALG10B	-0.69	-9.18	-0.52	2.4e-17	Morning vs. evening chronotype;
SARC	cis	rs5760092	0.755	rs6003959	chr22:24264395	C/T	cg15242686	chr22:24348715	GSTTP1	-0.48	-5.44	-0.34	1.36e-7	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs2370759	1.000	rs11599044	chr10:32615445	A/G	cg05361325	chr10:32636312	EPC1	-0.74	-6.6	-0.4	2.8e-10	Sexual dysfunction (female);
SARC	cis	rs7582720	0.945	rs72936860	chr2:203783484	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs12586317	0.620	rs8021414	chr14:35581480	T/A	cg26967526	chr14:35346199	BAZ1A	-0.64	-6.96	-0.41	3.45e-11	Psoriasis;
SARC	cis	rs6733011	0.578	rs6714243	chr2:99510039	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-5.41	-0.33	1.57e-7	Bipolar disorder;
SARC	cis	rs9314323	0.737	rs7818293	chr8:26264116	C/A	cg11498726	chr8:26250323	BNIP3L	0.61	6.68	0.4	1.7e-10	Red cell distribution width;
SARC	cis	rs829883	0.624	rs829881	chr12:98881228	T/G	cg25150519	chr12:98850993	NA	0.42	5.39	0.33	1.7e-7	Colorectal adenoma (advanced);
SARC	cis	rs7927771	0.864	rs3781627	chr11:47441472	T/A	cg20307385	chr11:47447363	PSMC3	0.62	7.71	0.45	3.64e-13	Subjective well-being;
SARC	cis	rs4713118	0.824	rs9468223	chr6:27740666	C/T	cg17221315	chr6:27791827	HIST1H4J	0.49	5.39	0.33	1.74e-7	Parkinson's disease;
SARC	cis	rs748404	0.578	rs510108	chr15:43605439	T/G	cg08831455	chr15:43942014	CATSPER2	-0.41	-4.84	-0.3	2.36e-6	Lung cancer;
SARC	cis	rs7520050	0.778	rs3013597	chr1:46128356	C/A	cg24296786	chr1:45957014	TESK2	-0.44	-5.7	-0.35	3.63e-8	Red blood cell count;Reticulocyte count;
SARC	cis	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg25427524	chr10:38739819	LOC399744	-0.53	-8.46	-0.48	2.95e-15	Extrinsic epigenetic age acceleration;
SARC	cis	rs2070677	0.935	rs12245634	chr10:135420002	A/G	cg20169779	chr10:135381914	SYCE1	-0.52	-6.46	-0.39	6e-10	Gout;
SARC	cis	rs4555082	0.957	rs10140586	chr14:105749582	A/G	cg13114125	chr14:105738426	BRF1	-0.73	-11.13	-0.59	2.29e-23	Mean platelet volume;Platelet distribution width;
SARC	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg17524265	chr8:144659883	NAPRT1	-0.57	-5.13	-0.32	6.16e-7	Attention deficit hyperactivity disorder;
SARC	cis	rs8114671	0.562	rs6058120	chr20:33402829	A/G	cg07148914	chr20:33460835	GGT7	0.41	5.19	0.32	4.5e-7	Height;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg01863319	chr19:1429261	DAZAP1	0.44	6.34	0.38	1.21e-9	Schizophrenia;
SARC	cis	rs9814567	0.752	rs13075253	chr3:134329600	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.5	6.5	0.39	4.83e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs6840360	0.653	rs13136369	chr4:152731283	T/G	cg22705602	chr4:152727874	NA	0.32	5.3	0.33	2.74e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7647973	0.667	rs4241405	chr3:49642027	C/T	cg03060546	chr3:49711283	APEH	0.72	6.73	0.4	1.34e-10	Menarche (age at onset);
SARC	cis	rs7560272	0.513	rs7558546	chr2:73937732	A/T	cg20560298	chr2:73613845	ALMS1	0.42	5.54	0.34	8.23e-8	Schizophrenia;
SARC	cis	rs7397814	0.558	rs4764447	chr12:9579109	C/T	cg27502298	chr12:9555721	NA	0.71	8.48	0.49	2.65e-15	IgG glycosylation;
SARC	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg19223190	chr17:80058835	NA	0.46	6.43	0.39	7.11e-10	Life satisfaction;
SARC	cis	rs6088580	0.542	rs6059882	chr20:33090167	T/C	cg24642439	chr20:33292090	TP53INP2	0.66	8.69	0.49	6.61e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs1568889	0.730	rs6484350	chr11:28113658	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.87	-14.88	-0.7	1.16e-35	Bipolar disorder;
SARC	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg13939156	chr17:80058883	NA	-0.41	-6.35	-0.38	1.11e-9	Life satisfaction;
SARC	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg05861140	chr6:150128134	PCMT1	-0.42	-5.36	-0.33	2.01e-7	Lung cancer;
SARC	cis	rs9467160	0.644	rs3846833	chr6:24462367	C/T	cg16211469	chr6:24423932	MRS2	0.39	4.82	0.3	2.6e-6	Liver enzyme levels;
SARC	cis	rs6424115	0.830	rs2503002	chr1:24196957	C/G	cg15997130	chr1:24165203	NA	0.39	5.34	0.33	2.22e-7	Immature fraction of reticulocytes;
SARC	cis	rs1707322	0.627	rs3014213	chr1:46045522	T/C	cg06784218	chr1:46089804	CCDC17	-0.38	-6.63	-0.4	2.32e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs875971	0.545	rs12673308	chr7:65631361	C/A	cg25894440	chr7:65020034	NA	0.51	4.74	0.3	3.69e-6	Aortic root size;
SARC	cis	rs6831352	0.704	rs1800759	chr4:100065509	T/G	cg13256891	chr4:100009986	ADH5	0.73	10.48	0.57	2.57e-21	Alcohol dependence;
SARC	cis	rs11719291	0.915	rs1048940	chr3:48725707	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.65	-4.74	-0.3	3.8e-6	Cognitive function;
SARC	cis	rs2011503	1.000	rs6511029	chr19:19471419	G/T	cg03709012	chr19:19516395	GATAD2A	-0.68	-5.91	-0.36	1.2e-8	Bipolar disorder;
SARC	cis	rs2645694	0.533	rs2645674	chr4:77818202	T/C	cg10057126	chr4:77819792	ANKRD56	0.44	6.57	0.4	3.3e-10	Emphysema distribution in smoking;
SARC	cis	rs10927875	0.619	rs12121764	chr1:16138059	A/T	cg22431228	chr1:16359049	CLCNKA	0.3	4.91	0.31	1.69e-6	Dilated cardiomyopathy;
SARC	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg15105969	chr2:36825350	FEZ2	-0.41	-4.72	-0.3	4.06e-6	Height;
SARC	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-4.81	-0.3	2.77e-6	Total body bone mineral density;
SARC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg06873352	chr17:61820015	STRADA	0.52	6.8	0.41	8.81e-11	Prudent dietary pattern;
SARC	cis	rs11235843	0.759	rs3741147	chr11:73366751	T/G	cg18195628	chr11:73498948	MRPL48	0.66	5.38	0.33	1.8e-7	Hand grip strength;
SARC	cis	rs7429990	0.965	rs11707679	chr3:47956506	T/C	cg11946769	chr3:48343235	NME6	0.47	5.08	0.32	7.76e-7	Educational attainment (years of education);
SARC	trans	rs3808502	0.549	rs11991139	chr8:11428395	C/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.81	-0.41	8.08e-11	Neuroticism;
SARC	cis	rs986417	0.901	rs1955692	chr14:61008408	C/A	cg27398547	chr14:60952738	C14orf39	0.96	8.75	0.5	4.38e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs16976116	0.951	rs11857087	chr15:55487181	T/A	cg11288833	chr15:55489084	RSL24D1	0.59	5.63	0.35	5.17e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2732480	0.577	rs2732457	chr12:48758379	A/G	cg21466736	chr12:48725269	NA	0.31	4.82	0.3	2.59e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs9303401	0.659	rs62083436	chr17:57031742	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	11.27	0.59	8.61e-24	Cognitive test performance;
SARC	cis	rs6840360	0.571	rs2406976	chr4:152541056	G/C	cg22705602	chr4:152727874	NA	-0.41	-6.43	-0.39	7.24e-10	Intelligence (multi-trait analysis);
SARC	cis	rs4481887	1.000	rs4360553	chr1:248467092	A/G	cg13385794	chr1:248469461	NA	0.36	5.5	0.34	9.8e-8	Common traits (Other);
SARC	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg18357526	chr6:26021779	HIST1H4A	0.41	5.15	0.32	5.44e-7	Blood metabolite levels;
SARC	cis	rs6991838	0.584	rs2175810	chr8:66555818	A/C	cg13398993	chr8:66546079	ARMC1	-0.56	-7.18	-0.43	9.05e-12	Intelligence (multi-trait analysis);
SARC	cis	rs3733585	0.637	rs6850684	chr4:9964380	G/T	cg00071950	chr4:10020882	SLC2A9	-0.38	-5.91	-0.36	1.2e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg22974920	chr21:40686053	BRWD1	-0.42	-4.74	-0.3	3.75e-6	Cognitive function;
SARC	cis	rs7568458	0.870	rs6733913	chr2:85757379	T/C	cg17127132	chr2:85788382	GGCX	0.41	5.35	0.33	2.09e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs644799	0.544	rs687559	chr11:95598629	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.75	-9.74	-0.54	4.94e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9814567	0.806	rs4955525	chr3:134317008	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.5	-6.49	-0.39	4.99e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs7666738	0.830	rs2865951	chr4:99040191	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.88	0.5	1.78e-16	Colonoscopy-negative controls vs population controls;
SARC	trans	rs1814175	0.588	rs10839463	chr11:49971643	A/G	cg15704280	chr7:45808275	SEPT13	-0.89	-14.17	-0.68	2.8e-33	Height;
SARC	cis	rs936229	0.861	rs7176022	chr15:75107880	G/T	cg14664628	chr15:75095509	CSK	1.07	15.79	0.72	1.09e-38	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs10623258	1	rs10623258	chr14:105212261	C/CTT	cg07523784	chr14:105186699	NA	-0.35	-5.05	-0.31	8.88e-7	Breast cancer;
SARC	cis	rs7762018	0.556	rs78864023	chr6:170059755	T/A	cg13015042	chr6:170102002	WDR27;C6orf120	0.7	5.06	0.31	8.62e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs546131	0.642	rs523246	chr11:34845011	C/G	cg11058730	chr11:34937778	PDHX;APIP	0.45	5.14	0.32	5.79e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs9911578	0.967	rs8072712	chr17:57162464	A/T	cg12560992	chr17:57184187	TRIM37	0.86	12.17	0.62	1.09e-26	Intelligence (multi-trait analysis);
SARC	cis	rs6860806	0.507	rs273901	chr5:131694360	G/T	cg24060327	chr5:131705240	SLC22A5	-0.71	-8.46	-0.48	2.92e-15	Breast cancer;
SARC	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg22535103	chr8:58192502	C8orf71	0.68	6.36	0.38	1.04e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg16680214	chr1:154839983	KCNN3	-0.35	-5.4	-0.33	1.62e-7	Prostate cancer;
SARC	cis	rs1949733	0.523	rs16842557	chr4:8543985	C/T	cg05004818	chr4:8539015	NA	0.38	4.83	0.3	2.45e-6	Response to antineoplastic agents;
SARC	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg18252515	chr7:66147081	NA	-1.3	-11.62	-0.61	6.33e-25	Diabetic kidney disease;
SARC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg05165339	chr4:1420672	NA	0.23	4.98	0.31	1.26e-6	Longevity;
SARC	cis	rs1467026	0.584	rs11712581	chr3:12807781	T/C	cg05775895	chr3:12838266	CAND2	0.61	8.92	0.5	1.37e-16	P wave duration;
SARC	cis	rs8064299	0.565	rs12453550	chr17:72786086	G/T	cg25054828	chr17:72772726	NAT9;TMEM104	0.75	9.73	0.54	5.23e-19	Monocyte count;
SARC	cis	rs6693567	0.565	rs698914	chr1:150298750	A/G	cg09579323	chr1:150459698	TARS2	0.41	5.11	0.32	6.8e-7	Migraine;
SARC	trans	rs61931739	0.534	rs11052959	chr12:33997095	T/C	cg13010199	chr12:38710504	ALG10B	0.76	10.28	0.56	1.07e-20	Morning vs. evening chronotype;
SARC	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg05368731	chr17:41323189	NBR1	0.79	9.57	0.53	1.59e-18	Menopause (age at onset);
SARC	cis	rs7103648	1.000	rs7947450	chr11:47429904	G/A	cg20307385	chr11:47447363	PSMC3	0.87	14.51	0.69	2.03e-34	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs9682041	0.696	rs13067560	chr3:170094190	G/A	cg11886554	chr3:170076028	SKIL	0.83	7.75	0.45	2.91e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs1865760	0.566	rs1539183	chr6:26075051	G/C	cg16482183	chr6:26056742	HIST1H1C	0.47	5.9	0.36	1.3e-8	Height;
SARC	cis	rs9818758	0.556	rs116432667	chr3:48947589	C/T	cg00383909	chr3:49044727	WDR6	0.75	6.7	0.4	1.54e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs7633857	0.532	rs9839984	chr3:160768912	C/T	cg04691961	chr3:161091175	C3orf57	-0.48	-5.99	-0.37	7.8e-9	Educational attainment (years of education);
SARC	cis	rs7766436	0.885	rs6908600	chr6:22582002	C/T	cg13666174	chr6:22585274	NA	-0.6	-7.74	-0.45	3.04e-13	Coronary artery disease;
SARC	cis	rs4713675	0.565	rs4713671	chr6:33699899	A/G	cg15676125	chr6:33679581	C6orf125	0.52	6.61	0.4	2.66e-10	Plateletcrit;
SARC	cis	rs1475911	0.708	rs56185023	chr21:43521538	T/C	cg19766460	chr21:43528205	UMODL1;C21orf128	0.57	6.79	0.41	9.2e-11	IgG glycosylation;
SARC	cis	rs7568458	0.846	rs1078004	chr2:85769711	C/G	cg17127132	chr2:85788382	GGCX	0.48	6.53	0.39	3.98e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs7681440	0.804	rs763443	chr4:90819961	T/C	cg02192967	chr4:90758406	SNCA	0.35	4.82	0.3	2.59e-6	Dementia with Lewy bodies;
SARC	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg05368731	chr17:41323189	NBR1	0.81	9.96	0.55	1.06e-19	Menopause (age at onset);
SARC	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg11742103	chr11:62369870	EML3;MTA2	0.43	6.4	0.39	8.27e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs2594989	1.000	rs2594990	chr3:11317897	G/T	cg00170343	chr3:11313890	ATG7	0.56	5.41	0.33	1.59e-7	Circulating chemerin levels;
SARC	cis	rs6456042	1.000	rs3099355	chr6:166534826	T/C	cg11088901	chr6:166572345	T	-0.33	-4.84	-0.3	2.32e-6	Asthma;
SARC	cis	rs3845702	0.736	rs72960664	chr2:180832672	C/T	cg01881094	chr2:180872142	CWC22	1.14	9.42	0.53	4.69e-18	Schizophrenia;
SARC	cis	rs752010	0.619	rs4393146	chr1:42118766	A/G	cg06885757	chr1:42089581	HIVEP3	0.48	6.67	0.4	1.82e-10	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs738322	0.868	rs8139952	chr22:38606989	C/A	cg25457927	chr22:38595422	NA	0.34	7.03	0.42	2.31e-11	Cutaneous nevi;
SARC	cis	rs2070997	0.816	rs1800609	chr9:133731184	A/G	cg03924115	chr9:133768966	QRFP	0.49	5.39	0.33	1.73e-7	Response to amphetamines;
SARC	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg04287289	chr16:89883240	FANCA	-0.55	-7.54	-0.44	1.05e-12	Vitiligo;
SARC	cis	rs7011049	1.000	rs72648413	chr8:53860576	C/T	cg26025543	chr8:53854495	NA	0.56	5.09	0.32	7.25e-7	Systolic blood pressure;
SARC	cis	rs2370759	1.000	rs11594459	chr10:32561858	A/C	cg18270830	chr10:32634957	EPC1	0.63	5.57	0.34	7.02e-8	Sexual dysfunction (female);
SARC	cis	rs2916247	0.773	rs1471763	chr8:93100864	A/T	cg10183463	chr8:93005414	RUNX1T1	0.66	6.71	0.4	1.47e-10	Intelligence (multi-trait analysis);
SARC	cis	rs3741404	0.537	rs1123251	chr11:63917601	G/T	cg05555928	chr11:63887634	MACROD1	0.46	8.2	0.47	1.6e-14	Platelet count;
SARC	cis	rs6963495	0.818	rs56251768	chr7:105165591	A/G	cg19920283	chr7:105172520	RINT1	0.66	5.62	0.35	5.45e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs6831352	0.840	rs34634551	chr4:100067362	C/A	cg12011299	chr4:100065546	ADH4	-0.32	-5.09	-0.32	7.33e-7	Alcohol dependence;
SARC	cis	rs698833	0.638	rs698786	chr2:44744897	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	6.27	0.38	1.78e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs11112613	0.713	rs11112591	chr12:105951620	C/T	cg03607813	chr12:105948248	NA	0.54	7.54	0.44	1.04e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg21171335	chr12:122356390	WDR66	-0.35	-5.57	-0.34	6.9e-8	Mean corpuscular volume;
SARC	cis	rs11097912	0.632	rs34899289	chr4:107194390	A/G	cg09646026	chr4:107269030	AIMP1	-0.45	-4.86	-0.3	2.13e-6	Airflow obstruction;
SARC	cis	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg06558623	chr16:89946397	TCF25	0.89	6.23	0.38	2.14e-9	Skin colour saturation;
SARC	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg13395646	chr4:1353034	KIAA1530	-0.56	-6.69	-0.4	1.66e-10	Obesity-related traits;
SARC	cis	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg13072238	chr3:49761600	GMPPB	-0.44	-5.64	-0.35	4.82e-8	Intelligence (multi-trait analysis);
SARC	cis	rs6058796	1.000	rs6057614	chr20:31255800	C/T	cg13636640	chr20:31349939	DNMT3B	0.56	5.05	0.31	9.02e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg25894440	chr7:65020034	NA	-0.74	-5.57	-0.34	6.83e-8	Diabetic kidney disease;
SARC	cis	rs858239	0.539	rs4559148	chr7:23185967	G/A	cg23682824	chr7:23144976	KLHL7	0.66	8.16	0.47	2.05e-14	Cerebrospinal fluid biomarker levels;
SARC	cis	rs6912958	0.535	rs242283	chr6:88030931	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.37	6.35	0.38	1.09e-9	Monocyte percentage of white cells;
SARC	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg09359103	chr1:154839909	KCNN3	-0.46	-7.7	-0.45	3.87e-13	Prostate cancer;
SARC	cis	rs3008870	0.701	rs2815358	chr1:67493778	T/C	cg02640540	chr1:67518911	SLC35D1	0.46	5.25	0.33	3.48e-7	Lymphocyte percentage of white cells;
SARC	cis	rs733592	0.524	rs10875727	chr12:48426143	T/C	cg24011408	chr12:48396354	COL2A1	-0.51	-7.08	-0.42	1.73e-11	Plateletcrit;
SARC	cis	rs3857067	0.773	rs2865344	chr4:95103040	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.03	-0.31	9.73e-7	QT interval;
SARC	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.49	-6.15	-0.37	3.41e-9	Electroencephalogram traits;
SARC	cis	rs1355223	0.902	rs1597962	chr11:34727172	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-5.27	-0.33	3.13e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg12463550	chr7:65579703	CRCP	0.44	5.06	0.31	8.54e-7	Aortic root size;
SARC	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg18876405	chr7:65276391	NA	0.44	5.54	0.34	8.34e-8	Aortic root size;
SARC	cis	rs9291683	0.597	rs11723016	chr4:10126189	A/G	cg11266682	chr4:10021025	SLC2A9	-0.37	-6.59	-0.4	2.99e-10	Bone mineral density;
SARC	cis	rs11252926	0.537	rs4554800	chr10:458477	G/T	cg08603382	chr10:743973	NA	-0.41	-5.6	-0.34	5.97e-8	Psychosis in Alzheimer's disease;
SARC	cis	rs7000551	0.778	rs2469760	chr8:22365945	A/G	cg12081754	chr8:22256438	SLC39A14	0.51	7.26	0.43	5.63e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs2688419	0.509	rs115374	chr3:23048377	A/G	cg00327796	chr3:23032191	NA	-0.41	-5.77	-0.35	2.57e-8	Type 2 diabetes;
SARC	cis	rs1059312	1.000	rs7970815	chr12:129288366	G/A	cg09035930	chr12:129282057	SLC15A4	0.61	8.57	0.49	1.41e-15	Systemic lupus erythematosus;
SARC	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg10381488	chr15:45694016	SPATA5L1	-0.39	-4.74	-0.3	3.68e-6	Homoarginine levels;
SARC	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg25894440	chr7:65020034	NA	-0.75	-5.77	-0.35	2.56e-8	Diabetic kidney disease;
SARC	cis	rs8014204	0.901	rs6574200	chr14:75364451	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.76	-11.28	-0.59	7.77e-24	Caffeine consumption;
SARC	cis	rs801193	0.613	rs2016325	chr7:66323500	T/C	cg11987759	chr7:65425863	GUSB	0.45	5.9	0.36	1.27e-8	Aortic root size;
SARC	cis	rs7254192	0.625	rs736625	chr19:41265201	C/T	cg24958765	chr19:41283667	RAB4B	-0.45	-5.44	-0.34	1.32e-7	Post bronchodilator FEV1;
SARC	cis	rs12190007	0.508	rs7452203	chr6:169741858	C/T	cg16388071	chr6:169726476	NA	-0.51	-6.93	-0.41	3.97e-11	Obesity-related traits;
SARC	cis	rs4975616	0.714	rs27069	chr5:1347128	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.44	-6.17	-0.37	3.03e-9	Lung cancer;
SARC	cis	rs9291683	0.632	rs13101785	chr4:10042915	T/A	cg11266682	chr4:10021025	SLC2A9	0.4	7.27	0.43	5.35e-12	Bone mineral density;
SARC	cis	rs10870270	1.000	rs6560694	chr10:133773448	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.83	-10.33	-0.56	7.55e-21	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs6570726	0.791	rs6570693	chr6:145910841	C/T	cg23711669	chr6:146136114	FBXO30	0.84	14.12	0.68	3.87e-33	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg26681399	chr22:41777847	TEF	0.44	4.81	0.3	2.7e-6	Vitiligo;
SARC	cis	rs10883723	0.810	rs10883728	chr10:104269301	A/G	cg22532475	chr10:104410764	TRIM8	0.24	4.76	0.3	3.47e-6	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs9300255	0.722	rs10773008	chr12:123800820	A/G	cg00376283	chr12:123451042	ABCB9	0.47	4.84	0.3	2.41e-6	Neutrophil percentage of white cells;
SARC	cis	rs10492096	1.000	rs12422771	chr12:6580273	G/T	cg13857086	chr12:6580257	VAMP1	0.76	7.57	0.44	8.56e-13	Hip geometry;
SARC	cis	rs10911232	0.507	rs10797820	chr1:183011366	G/A	cg13390022	chr1:182993471	LAMC1	0.36	5.42	0.33	1.48e-7	Hypertriglyceridemia;
SARC	cis	rs10876993	0.784	rs7314152	chr12:58017701	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.46	5.7	0.35	3.55e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs5995756	0.697	rs713865	chr22:39997630	C/T	cg10455938	chr22:40058150	CACNA1I	-0.49	-6.35	-0.38	1.09e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6540556	0.723	rs1999826	chr1:209919275	C/T	cg05527609	chr1:210001259	C1orf107	-0.6	-6.02	-0.37	6.87e-9	Red blood cell count;
SARC	trans	rs1814175	0.935	rs11040465	chr11:49689323	C/T	cg15704280	chr7:45808275	SEPT13	-0.93	-16.52	-0.73	4.14e-41	Height;
SARC	cis	rs370915	0.890	rs28610515	chr4:187835260	A/T	cg19519643	chr4:187840862	NA	-0.41	-5.01	-0.31	1.06e-6	Gout;
SARC	cis	rs644799	1.000	rs632388	chr11:95563775	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.68	9.17	0.51	2.6e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs11098499	0.954	rs71629403	chr4:120372567	C/T	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg07061783	chr6:25882402	NA	-0.44	-5.34	-0.33	2.21e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2273669	0.667	rs75675305	chr6:109324353	T/C	cg05315195	chr6:109294784	ARMC2	-0.59	-5.45	-0.34	1.28e-7	Prostate cancer;
SARC	cis	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg05084668	chr3:125655381	ALG1L	-0.5	-5.61	-0.35	5.57e-8	Blood pressure (smoking interaction);
SARC	cis	rs11583043	1.000	rs11583043	chr1:101466054	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	5.76	0.35	2.67e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs7551222	0.714	rs2926534	chr1:204464181	C/T	cg20240347	chr1:204465584	NA	0.31	5.14	0.32	5.87e-7	Schizophrenia;
SARC	cis	rs5753618	0.539	rs5997933	chr22:31672752	A/C	cg07713946	chr22:31675144	LIMK2	-0.37	-5.24	-0.32	3.63e-7	Colorectal cancer;
SARC	cis	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg18252515	chr7:66147081	NA	-1.42	-13.18	-0.65	5.36e-30	Gout;
SARC	cis	rs6693567	0.565	rs698921	chr1:150379517	G/A	cg09579323	chr1:150459698	TARS2	0.44	5.66	0.35	4.4e-8	Migraine;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg04009254	chr15:59280078	RNF111	0.84	6.77	0.41	1.02e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs67981189	0.593	rs221906	chr14:71597393	C/G	cg15332261	chr14:71375349	PCNX	-0.39	-4.79	-0.3	2.93e-6	Schizophrenia;
SARC	cis	rs7659604	1.000	rs28532673	chr4:122664323	A/G	cg19671926	chr4:122722719	EXOSC9	0.49	5.99	0.37	7.87e-9	Type 2 diabetes;
SARC	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg16325326	chr1:53192061	ZYG11B	-0.81	-12.49	-0.63	9.6e-28	Monocyte count;
SARC	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs116095464	0.558	rs6866632	chr5:264429	C/G	cg22857025	chr5:266934	NA	-1.09	-11.37	-0.6	3.9e-24	Breast cancer;
SARC	cis	rs644799	0.965	rs534488	chr11:95562327	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	14.89	0.7	1.07e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs6809651	0.524	rs56940353	chr3:185798296	T/C	cg00760338	chr3:185826511	ETV5	-0.83	-10.66	-0.57	6.97e-22	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
SARC	cis	rs13256369	0.950	rs13270006	chr8:8574197	C/A	cg17143192	chr8:8559678	CLDN23	0.51	5.77	0.35	2.5e-8	Obesity-related traits;
SARC	cis	rs950776	0.518	rs11632604	chr15:78821914	T/C	cg22563815	chr15:78856949	CHRNA5	0.41	6.82	0.41	7.56e-11	Sudden cardiac arrest;
SARC	cis	rs6871536	1.000	rs6871536	chr5:131969874	T/C	cg11797159	chr5:131991491	NA	0.37	4.89	0.31	1.86e-6	Asthma (childhood onset);
SARC	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-6.82	-0.41	7.95e-11	Personality dimensions;
SARC	cis	rs16976116	0.619	rs7169407	chr15:55465652	T/C	cg11288833	chr15:55489084	RSL24D1	0.61	5.24	0.32	3.62e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs950776	0.518	rs3813571	chr15:78832792	G/T	cg06917634	chr15:78832804	PSMA4	0.9	14.44	0.69	3.5e-34	Sudden cardiac arrest;
SARC	cis	rs2730245	0.563	rs2709857	chr7:158685257	T/C	cg24397884	chr7:158709396	WDR60	0.71	8.93	0.5	1.33e-16	Height;
SARC	cis	rs9486715	0.929	rs7775721	chr6:97056979	C/T	cg06623918	chr6:96969491	KIAA0776	-0.87	-12.1	-0.62	1.78e-26	Headache;
SARC	cis	rs36051895	0.626	rs9695934	chr9:5153108	C/G	cg02405213	chr9:5042618	JAK2	-0.45	-5.39	-0.33	1.72e-7	Pediatric autoimmune diseases;
SARC	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg24675658	chr1:53192096	ZYG11B	-0.72	-10.22	-0.56	1.73e-20	Monocyte count;
SARC	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg23172400	chr8:95962367	TP53INP1	-0.33	-5.75	-0.35	2.73e-8	Type 2 diabetes;
SARC	cis	rs16976116	0.806	rs28466870	chr15:55495113	C/T	cg11288833	chr15:55489084	RSL24D1	0.63	6.13	0.37	3.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26141063	chr18:32870200	ZNF271;ZNF397OS	0.59	7.56	0.44	8.95e-13	Smoking initiation;
SARC	cis	rs208520	1.000	rs72884017	chr6:66992513	T/G	cg07460842	chr6:66804631	NA	0.9	10.25	0.56	1.39e-20	Exhaled nitric oxide output;
SARC	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg21724239	chr8:58056113	NA	0.57	6.07	0.37	5.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs910316	1.000	rs10142865	chr14:75555624	G/A	cg06637938	chr14:75390232	RPS6KL1	0.54	7.72	0.45	3.41e-13	Height;
SARC	cis	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg24110177	chr3:50126178	RBM5	-0.55	-7.26	-0.43	5.58e-12	Intelligence (multi-trait analysis);
SARC	cis	rs12681366	0.659	rs2046666	chr8:95388148	G/A	cg26464482	chr8:95565502	KIAA1429	-0.43	-5.27	-0.33	3.12e-7	Nonsyndromic cleft lip with cleft palate;
SARC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg01171360	chr6:293285	DUSP22	-0.56	-7.1	-0.42	1.51e-11	Menopause (age at onset);
SARC	cis	rs7772486	0.754	rs4566902	chr6:146244128	A/G	cg23711669	chr6:146136114	FBXO30	-0.8	-12.46	-0.63	1.2100000000000001e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2153535	0.563	rs1737584	chr6:8536742	C/T	cg21535247	chr6:8435926	SLC35B3	0.54	6.77	0.41	1.03e-10	Motion sickness;
SARC	cis	rs17666538	1.000	rs57896286	chr8:571479	T/C	cg02524346	chr8:600233	NA	-0.86	-6.09	-0.37	4.67e-9	IgG glycosylation;
SARC	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg09359103	chr1:154839909	KCNN3	-0.46	-7.8	-0.46	2e-13	Prostate cancer;
SARC	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg00908189	chr16:619842	PIGQ	0.85	12.4	0.63	1.95e-27	Height;
SARC	cis	rs72781680	0.611	rs55868657	chr2:24295385	G/A	cg08917208	chr2:24149416	ATAD2B	0.62	6.36	0.38	1.05e-9	Lymphocyte counts;
SARC	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg22920501	chr2:26401640	FAM59B	-0.51	-6.64	-0.4	2.16e-10	Gut microbiome composition (summer);
SARC	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg19223190	chr17:80058835	NA	0.45	6.16	0.37	3.2e-9	Life satisfaction;
SARC	cis	rs950880	0.710	rs3821203	chr2:102996872	C/T	cg03938978	chr2:103052716	IL18RAP	-0.34	-4.86	-0.3	2.12e-6	Serum protein levels (sST2);
SARC	cis	rs6545883	0.524	rs7561697	chr2:61519165	G/C	cg10580144	chr2:61372316	C2orf74	-0.38	-5.12	-0.32	6.26e-7	Tuberculosis;
SARC	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg18357526	chr6:26021779	HIST1H4A	-0.53	-6.06	-0.37	5.52e-9	Blood metabolite levels;
SARC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg14159672	chr1:205819179	PM20D1	0.86	13.91	0.67	2.06e-32	Menarche (age at onset);
SARC	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg11764359	chr7:65958608	NA	0.55	6.52	0.39	4.22e-10	Aortic root size;
SARC	cis	rs7829975	0.606	rs6422352	chr8:8794193	A/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.35	-0.43	3.26e-12	Mood instability;
SARC	cis	rs7223966	1.000	rs6504168	chr17:61697469	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.45	4.72	0.3	4.03e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs911263	0.581	rs61985135	chr14:68769195	C/T	cg18825221	chr14:68749962	RAD51L1	0.45	8.05	0.47	4.17e-14	Primary biliary cholangitis;
SARC	cis	rs911555	0.755	rs8014800	chr14:103946302	T/C	cg12935359	chr14:103987150	CKB	0.38	5.28	0.33	2.99e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9660992	0.590	rs1779411	chr1:205238530	C/T	cg00857998	chr1:205179979	DSTYK	0.52	6.33	0.38	1.28e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs796364	1.000	rs769950	chr2:200730028	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.58	0.4	3.11e-10	Schizophrenia;
SARC	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg11890956	chr21:40555474	PSMG1	1.18	16.97	0.74	1.32e-42	Cognitive function;
SARC	cis	rs6120849	0.617	rs12480442	chr20:33648388	C/G	cg24642439	chr20:33292090	TP53INP2	0.56	5.31	0.33	2.53e-7	Protein C levels;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg09321747	chr14:23821445	SLC22A17	0.6	6.45	0.39	6.34e-10	Lung cancer in ever smokers;
SARC	cis	rs12579753	0.917	rs11115058	chr12:82263427	T/C	cg07988820	chr12:82153109	PPFIA2	-0.5	-5.94	-0.36	1.03e-8	Resting heart rate;
SARC	cis	rs7264396	0.563	rs6060592	chr20:34352414	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-6.56	-0.39	3.47e-10	Total cholesterol levels;
SARC	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg13175981	chr1:150552382	MCL1	-0.48	-5.97	-0.36	8.78e-9	Tonsillectomy;
SARC	cis	rs7819412	0.540	rs2409725	chr8:11041661	T/C	cg21775007	chr8:11205619	TDH	-0.47	-5.88	-0.36	1.39e-8	Triglycerides;
SARC	cis	rs9807989	0.507	rs11465721	chr2:103063240	T/G	cg03938978	chr2:103052716	IL18RAP	0.31	5.01	0.31	1.08e-6	Asthma;
SARC	cis	rs9426691	1	rs9426691	chr1:23484904	A/G	cg12483005	chr1:23474871	LUZP1	0.47	5.91	0.36	1.22e-8	Coenzyme Q10 levels;
SARC	cis	rs9486719	1.000	rs2472880	chr6:96860130	G/A	cg06623918	chr6:96969491	KIAA0776	0.72	7.67	0.45	4.53e-13	Migraine;Coronary artery disease;
SARC	cis	rs2239547	0.657	rs2072391	chr3:52862200	C/T	cg18404041	chr3:52824283	ITIH1	-0.42	-5.01	-0.31	1.05e-6	Schizophrenia;
SARC	cis	rs7568458	0.846	rs2028900	chr2:85767735	A/G	cg02493740	chr2:85810744	VAMP5	0.34	4.94	0.31	1.47e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	12.23	0.63	6.54e-27	Chronic sinus infection;
SARC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg01027498	chr5:76788287	WDR41	-0.56	-6.24	-0.38	2e-9	Hepatitis;
SARC	cis	rs7100689	0.516	rs10788546	chr10:82034854	T/C	cg01528321	chr10:82214614	TSPAN14	0.57	7.44	0.44	1.93e-12	Post bronchodilator FEV1;
SARC	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg04772025	chr11:68637568	NA	0.5	6.15	0.37	3.25e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs8141529	0.748	rs5752826	chr22:29269808	A/G	cg15103426	chr22:29168792	CCDC117	0.65	8.59	0.49	1.3e-15	Lymphocyte counts;
SARC	cis	rs709400	0.628	rs7154246	chr14:103876794	G/A	cg26031613	chr14:104095156	KLC1	-0.76	-10.54	-0.57	1.67e-21	Body mass index;
SARC	cis	rs12586317	0.547	rs78609489	chr14:35497285	T/C	cg26967526	chr14:35346199	BAZ1A	-0.57	-5.87	-0.36	1.49e-8	Psoriasis;
SARC	cis	rs1538970	0.962	rs9429160	chr1:45827968	G/T	cg05343316	chr1:45956843	TESK2	0.68	7.98	0.46	6.78e-14	Platelet count;
SARC	cis	rs501120	0.810	rs473501	chr10:44749171	G/A	cg09554077	chr10:44749378	NA	0.47	6.48	0.39	5.32e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs4803468	1.000	rs10422783	chr19:41906436	T/C	cg09537434	chr19:41945824	ATP5SL	-0.94	-16.3	-0.73	2.27e-40	Height;
SARC	cis	rs1983170	1.000	rs597288	chr1:91999296	C/T	cg25838465	chr1:92012736	NA	0.53	5.93	0.36	1.1e-8	Eosinophil percentage of white cells;
SARC	cis	rs6582630	0.638	rs12231073	chr12:38526901	T/G	cg13010199	chr12:38710504	ALG10B	-0.56	-6.97	-0.42	3.28e-11	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs11165623	0.792	rs6671371	chr1:96977039	A/G	cg10631902	chr5:14652156	NA	-0.46	-7.53	-0.44	1.14e-12	Hip circumference;Waist circumference;
SARC	cis	rs7264396	0.790	rs6060562	chr20:34282053	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-7.41	-0.44	2.38e-12	Total cholesterol levels;
SARC	cis	rs35110281	0.782	rs1454650	chr21:45012353	C/T	cg01579765	chr21:45077557	HSF2BP	-0.37	-6.26	-0.38	1.81e-9	Mean corpuscular volume;
SARC	trans	rs61931739	0.534	rs1490113	chr12:34132394	A/G	cg13010199	chr12:38710504	ALG10B	0.77	10.39	0.56	4.92e-21	Morning vs. evening chronotype;
SARC	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg15049968	chr18:44337910	ST8SIA5	-0.34	-5.45	-0.34	1.27e-7	Personality dimensions;
SARC	cis	rs11025559	0.812	rs10833338	chr11:20514709	A/G	cg19653624	chr11:20408972	PRMT3	-0.54	-6.03	-0.37	6.47e-9	Pursuit maintenance gain;
SARC	cis	rs13202913	0.837	rs3734800	chr6:151766552	G/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.62	5.24	0.32	3.55e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-8.03	-0.47	4.67e-14	Chronic sinus infection;
SARC	trans	rs877282	0.797	rs11253329	chr10:753200	A/T	cg22713356	chr15:30763199	NA	0.99	9.88	0.54	1.92e-19	Uric acid levels;
SARC	cis	rs9611519	0.929	rs11090039	chr22:41496800	G/A	cg03806693	chr22:41940476	POLR3H	-0.55	-6.21	-0.38	2.38e-9	Neuroticism;
SARC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	9.8	0.54	3.29e-19	Platelet count;
SARC	cis	rs6484504	0.576	rs11031324	chr11:31250299	T/C	cg02090638	chr11:31391270	DNAJC24;DCDC1	-0.4	-5.1	-0.32	7.16e-7	Red blood cell count;
SARC	cis	rs995000	0.931	rs1168098	chr1:63121294	G/A	cg06896770	chr1:63153194	DOCK7	-0.89	-13.52	-0.66	4.03e-31	Triglyceride levels;
SARC	cis	rs1034435	0.575	rs6007865	chr22:48883476	C/T	cg05992904	chr22:48892994	FAM19A5	-0.41	-5.15	-0.32	5.45e-7	Late-onset Alzheimer's disease;
SARC	cis	rs6060717	0.536	rs2425104	chr20:34312346	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.11	-0.37	4.17e-9	Hip circumference adjusted for BMI;
SARC	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg26335602	chr6:28129616	ZNF389	-0.53	-5.7	-0.35	3.56e-8	Depression;
SARC	cis	rs1215050	0.791	rs7681599	chr4:98664109	C/T	cg05340658	chr4:99064831	C4orf37	-0.43	-5.78	-0.35	2.42e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.35	-5.34	-0.33	2.21e-7	Longevity;Endometriosis;
SARC	cis	rs1003719	0.788	rs9974286	chr21:38456832	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-9.52	-0.53	2.34e-18	Eye color traits;
SARC	cis	rs4148883	0.675	rs11724783	chr4:100099688	C/A	cg12011299	chr4:100065546	ADH4	0.36	6.77	0.41	1.03e-10	Alcohol dependence;
SARC	cis	rs3845702	0.736	rs56401468	chr2:180857757	C/T	cg01881094	chr2:180872142	CWC22	1.14	8.85	0.5	2.2e-16	Schizophrenia;
SARC	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg03806693	chr22:41940476	POLR3H	0.83	11.73	0.61	2.8e-25	Vitiligo;
SARC	cis	rs9733	0.566	rs11204675	chr1:150570985	A/C	cg18016565	chr1:150552671	MCL1	-0.4	-5.39	-0.33	1.75e-7	Tonsillectomy;
SARC	cis	rs35213789	0.878	rs13242485	chr7:69530888	G/A	cg10619644	chr7:69149951	AUTS2	0.41	5.09	0.32	7.28e-7	Childhood ear infection;
SARC	trans	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg00938859	chr5:1591904	SDHAP3	0.79	7.66	0.45	5.1e-13	Breast cancer;
SARC	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg11987759	chr7:65425863	GUSB	-0.5	-6.56	-0.39	3.41e-10	Aortic root size;
SARC	cis	rs3858526	0.883	rs7481882	chr11:5944221	A/G	cg02574844	chr11:5959923	NA	-0.43	-5.16	-0.32	5.22e-7	DNA methylation (variation);
SARC	cis	rs76917914	0.820	rs12554583	chr9:100812569	A/G	cg03040243	chr9:100819229	NANS	0.72	7.91	0.46	1.06e-13	Immature fraction of reticulocytes;
SARC	cis	rs155076	0.938	rs9509633	chr13:21844482	G/C	cg11317459	chr13:21872234	NA	-0.98	-12.36	-0.63	2.52e-27	White matter hyperintensity burden;
SARC	cis	rs1153858	1.000	rs8032904	chr15:45651309	C/T	cg26924012	chr15:45694286	SPATA5L1	0.77	11.06	0.59	3.9e-23	Homoarginine levels;
SARC	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg22433210	chr17:43662623	NA	1.06	12.55	0.64	5.97e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs739401	0.869	rs395188	chr11:3072631	A/G	cg05729581	chr11:3078854	CARS	0.48	6.38	0.39	9.45e-10	Longevity;
SARC	cis	rs2204008	0.575	rs10444564	chr12:38043782	T/C	cg26384229	chr12:38710491	ALG10B	0.89	13.1	0.65	9.74e-30	Bladder cancer;
SARC	trans	rs9395865	0.501	rs2067833	chr6:53330356	A/G	cg17260383	chr8:22298246	PPP3CC	-0.52	-6.36	-0.38	1.03e-9	Electroencephalographic traits in alcoholism;
SARC	cis	rs2180341	0.782	rs4897214	chr6:127723625	G/T	cg24812749	chr6:127587940	RNF146	0.76	10.11	0.55	3.65e-20	Breast cancer;
SARC	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	8.8	0.5	3.1e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7412746	0.553	rs59337856	chr1:150746406	G/T	cg13175981	chr1:150552382	MCL1	-0.54	-6.57	-0.4	3.32e-10	Melanoma;
SARC	trans	rs7980799	0.649	rs1601003	chr12:33689436	A/T	cg26384229	chr12:38710491	ALG10B	0.66	7.85	0.46	1.47e-13	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs2153535	0.580	rs7767780	chr6:8453462	A/G	cg07606381	chr6:8435919	SLC35B3	0.8	11.52	0.6	1.3e-24	Motion sickness;
SARC	trans	rs2727020	0.688	rs2734002	chr11:49234162	A/G	cg03929089	chr4:120376271	NA	0.73	10.25	0.56	1.38e-20	Coronary artery disease;
SARC	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg05313129	chr8:58192883	C8orf71	-0.57	-6.31	-0.38	1.41e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10911232	0.507	rs4072709	chr1:183028855	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.13	0.55	3.15e-20	Hypertriglyceridemia;
SARC	cis	rs950776	0.518	rs28438420	chr15:78836288	A/T	cg06917634	chr15:78832804	PSMA4	-0.85	-12.89	-0.65	4.61e-29	Sudden cardiac arrest;
SARC	cis	rs11718455	0.960	rs1852036	chr3:44003862	C/T	cg08738300	chr3:44038990	NA	0.53	5.9	0.36	1.3e-8	Coronary artery disease;
SARC	cis	rs7084402	0.967	rs7078900	chr10:60273430	G/A	cg07615347	chr10:60278583	BICC1	-0.59	-8.56	-0.49	1.58e-15	Refractive error;
SARC	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg18876405	chr7:65276391	NA	-0.72	-9.18	-0.52	2.4e-17	Aortic root size;
SARC	cis	rs9911578	1.000	rs6503870	chr17:56659018	C/T	cg05425664	chr17:57184151	TRIM37	-0.66	-8.29	-0.48	8.87e-15	Intelligence (multi-trait analysis);
SARC	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg01475735	chr3:40494733	NA	-0.5	-5.47	-0.34	1.16e-7	Renal cell carcinoma;
SARC	cis	rs9902453	0.817	rs17226179	chr17:28168573	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	7.21	0.43	7.57e-12	Coffee consumption (cups per day);
SARC	cis	rs6088580	0.524	rs6088560	chr20:33228549	T/C	cg24642439	chr20:33292090	TP53INP2	-0.54	-6.73	-0.4	1.3e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs4595586	0.545	rs67985200	chr12:39386891	C/T	cg26384229	chr12:38710491	ALG10B	0.52	6.21	0.38	2.4e-9	Morning vs. evening chronotype;
SARC	cis	rs3020736	0.500	rs28791586	chr22:42500483	A/G	cg04733989	chr22:42467013	NAGA	-0.76	-10.7	-0.57	5.23e-22	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2370759	1.000	rs78959390	chr10:32616346	C/T	cg05361325	chr10:32636312	EPC1	-0.77	-6.85	-0.41	6.33e-11	Sexual dysfunction (female);
SARC	cis	rs6570726	0.791	rs441290	chr6:145883183	A/G	cg05347473	chr6:146136440	FBXO30	0.51	7.25	0.43	5.99e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	9.15	0.51	3.02e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs72781680	0.800	rs72780112	chr2:23991182	C/T	cg06627628	chr2:24431161	ITSN2	-0.67	-6.35	-0.38	1.14e-9	Lymphocyte counts;
SARC	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg07701084	chr6:150067640	NUP43	0.41	5.37	0.33	1.87e-7	Lung cancer;
SARC	cis	rs611744	0.846	rs405534	chr8:109154408	T/A	cg21045802	chr8:109455806	TTC35	0.43	5.1	0.32	6.98e-7	Dupuytren's disease;
SARC	cis	rs870825	0.616	rs6834156	chr4:185639903	G/C	cg04058563	chr4:185651563	MLF1IP	0.79	11.24	0.59	1.03e-23	Blood protein levels;
SARC	cis	rs7666738	0.800	rs13107147	chr4:99028753	C/T	cg05340658	chr4:99064831	C4orf37	0.64	8.6	0.49	1.18e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10789491	1.000	rs1371834	chr1:47176894	G/A	cg15501359	chr1:47185051	KIAA0494	0.78	8.26	0.48	1.1e-14	Response to hepatitis C treatment;
SARC	cis	rs854765	0.583	rs8070128	chr17:17804725	C/T	cg04398451	chr17:18023971	MYO15A	0.35	5.1	0.32	6.98e-7	Total body bone mineral density;
SARC	trans	rs7937682	0.889	rs1784785	chr11:111483306	A/G	cg18187862	chr3:45730750	SACM1L	0.55	6.97	0.42	3.29e-11	Primary sclerosing cholangitis;
SARC	cis	rs941408	0.515	rs2110118	chr19:2775144	T/C	cg00079169	chr19:2811669	THOP1	0.46	5.06	0.31	8.48e-7	Total cholesterol levels;
SARC	cis	rs9303401	0.614	rs62084387	chr17:57148027	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.03	10.0	0.55	8.05e-20	Cognitive test performance;
SARC	cis	rs66887589	0.837	rs7661498	chr4:120408108	T/C	cg09307838	chr4:120376055	NA	0.55	7.46	0.44	1.65e-12	Diastolic blood pressure;
SARC	cis	rs11122272	0.701	rs11582413	chr1:231530098	C/G	cg06096015	chr1:231504339	EGLN1	0.39	5.81	0.36	1.99e-8	Hemoglobin concentration;
SARC	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.8	-11.78	-0.61	1.99e-25	Chronic sinus infection;
SARC	cis	rs9296092	0.560	rs7765393	chr6:33525598	A/T	cg13560919	chr6:33536144	NA	-0.53	-6.45	-0.39	6.31e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs4144743	0.938	rs35439279	chr17:45321694	C/T	cg18085866	chr17:45331354	ITGB3	-0.73	-7.4	-0.44	2.42e-12	Body mass index;
SARC	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg13206674	chr6:150067644	NUP43	0.45	5.86	0.36	1.57e-8	Lung cancer;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg13964393	chr15:45003702	B2M	-0.49	-6.32	-0.38	1.31e-9	Electrocardiographic conduction measures;
SARC	cis	rs780096	0.526	rs11682621	chr2:27749669	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.35	-5.28	-0.33	3.02e-7	Total body bone mineral density;
SARC	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg02297831	chr4:17616191	MED28	0.49	6.39	0.39	8.72e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs11581859	0.613	rs56242843	chr1:99188599	C/T	cg20286094	chr1:99190917	SNX7	-0.41	-4.88	-0.3	1.97e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg24074884	chr19:17356310	NR2F6	0.78	6.77	0.41	1.04e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1707322	0.686	rs3014239	chr1:46089801	G/A	cg06784218	chr1:46089804	CCDC17	-0.38	-6.55	-0.39	3.61e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7772486	0.686	rs9390357	chr6:146129347	A/G	cg05347473	chr6:146136440	FBXO30	0.51	7.17	0.43	9.99e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs899997	1.000	rs7182567	chr15:79045054	A/G	cg04896959	chr15:78267971	NA	0.5	6.0	0.37	7.39e-9	Coronary artery disease or large artery stroke;
SARC	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg22105103	chr4:187893119	NA	0.51	6.85	0.41	6.35e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs288326	0.561	rs7595898	chr2:183819892	C/A	cg09997497	chr2:183902928	NCKAP1	0.74	5.12	0.32	6.43e-7	Blood protein levels;
SARC	cis	rs73206853	0.686	rs60439011	chr12:110909179	T/C	cg10860002	chr12:110842031	ANAPC7	0.63	5.03	0.31	9.77e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	trans	rs11098499	0.863	rs11098531	chr4:120465001	G/A	cg25214090	chr10:38739885	LOC399744	0.57	7.25	0.43	6.27e-12	Corneal astigmatism;
SARC	cis	rs7772486	0.805	rs4896831	chr6:145959481	T/C	cg05347473	chr6:146136440	FBXO30	0.5	6.82	0.41	7.69e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.6	-6.31	-0.38	1.42e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg01341218	chr17:43662625	NA	0.69	8.24	0.48	1.22e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg19223190	chr17:80058835	NA	0.45	6.26	0.38	1.84e-9	Life satisfaction;
SARC	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	7.28	0.43	5.23e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.03	12.03	0.62	3.06e-26	Alzheimer's disease;
SARC	cis	rs6674176	0.660	rs2108202	chr1:44395786	A/G	cg12908607	chr1:44402522	ARTN	0.39	6.83	0.41	7.52e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	trans	rs12310956	0.532	rs1525903	chr12:33964163	T/C	cg13010199	chr12:38710504	ALG10B	0.64	8.44	0.48	3.43e-15	Morning vs. evening chronotype;
SARC	cis	rs11122272	0.735	rs10489611	chr1:231517854	A/T	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs6121246	0.559	rs6058352	chr20:30269179	T/C	cg13852791	chr20:30311386	BCL2L1	0.88	10.96	0.58	8.1e-23	Mean corpuscular hemoglobin;
SARC	cis	rs3087591	1.000	rs2057769	chr17:29691368	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.49	-5.94	-0.36	1.03e-8	Hip circumference;
SARC	cis	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg22857025	chr5:266934	NA	-1.06	-11.8	-0.61	1.74e-25	Breast cancer;
SARC	cis	rs6942407	0.592	rs6959152	chr7:86751607	G/T	cg02420886	chr7:86849541	C7orf23	0.6	5.44	0.34	1.32e-7	Food allergy;
SARC	cis	rs7729447	0.813	rs10941022	chr5:32691416	C/T	cg16267343	chr5:32710456	NPR3	0.62	8.29	0.48	8.79e-15	Blood pressure;
SARC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg15242686	chr22:24348715	GSTTP1	0.4	5.06	0.31	8.4e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	trans	rs2727020	0.576	rs10839305	chr11:49598733	T/C	cg03929089	chr4:120376271	NA	-0.82	-12.66	-0.64	2.58e-28	Coronary artery disease;
SARC	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg10295955	chr4:187884368	NA	-1.02	-17.67	-0.76	6.42e-45	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg05234568	chr11:5960015	NA	0.43	5.7	0.35	3.54e-8	DNA methylation (variation);
SARC	cis	rs7011049	1.000	rs72648409	chr8:53857307	T/C	cg26025543	chr8:53854495	NA	0.6	5.37	0.33	1.91e-7	Systolic blood pressure;
SARC	cis	rs7647973	0.731	rs7617480	chr3:49210732	G/T	cg07636037	chr3:49044803	WDR6	-0.84	-9.31	-0.52	1e-17	Menarche (age at onset);
SARC	cis	rs1008375	0.797	rs6843530	chr4:17593605	G/T	cg16339924	chr4:17578868	LAP3	0.68	8.85	0.5	2.27e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg08564027	chr20:61660810	NA	0.76	11.8	0.61	1.69e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs7681440	0.874	rs1372525	chr4:90776165	G/A	cg02192967	chr4:90758406	SNCA	0.37	5.26	0.33	3.25e-7	Dementia with Lewy bodies;
SARC	cis	rs6867032	1.000	rs16902321	chr5:2015148	A/G	cg26168224	chr5:2018326	NA	0.9	15.29	0.71	5.2e-37	Gut microbiome composition (winter);
SARC	cis	rs7927592	0.763	rs1193699	chr11:68249480	C/G	cg01657329	chr11:68192670	LRP5	-0.35	-4.89	-0.31	1.89e-6	Total body bone mineral density;
SARC	cis	rs9399135	0.622	rs3817776	chr6:135256756	C/T	cg22676075	chr6:135203613	NA	-0.37	-5.1	-0.32	6.98e-7	Red blood cell count;
SARC	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs4930561	0.765	rs34493482	chr11:67969508	T/C	cg16338278	chr11:67432957	ALDH3B2	0.35	5.75	0.35	2.77e-8	Breast cancer in childhood cancer survivors;IgG glycosylation;
SARC	cis	rs2806561	0.765	rs1612905	chr1:23510023	G/T	cg12483005	chr1:23474871	LUZP1	0.44	5.73	0.35	3.04e-8	Height;
SARC	cis	rs2011503	0.943	rs8100927	chr19:19643636	C/G	cg15839431	chr19:19639596	YJEFN3	-0.48	-4.77	-0.3	3.32e-6	Bipolar disorder;
SARC	cis	rs752010	0.619	rs6703992	chr1:42115888	G/A	cg06885757	chr1:42089581	HIVEP3	0.45	6.24	0.38	2.09e-9	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs6570726	0.905	rs375692	chr6:145840368	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.47	0.39	5.7e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg05185784	chr16:90016020	DEF8	-0.45	-4.76	-0.3	3.32e-6	Skin colour saturation;
SARC	cis	rs2153535	0.580	rs4587214	chr6:8454119	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	6.5	0.39	4.87e-10	Motion sickness;
SARC	cis	rs16986825	0.664	rs5997409	chr22:29222096	T/C	cg15103426	chr22:29168792	CCDC117	0.61	6.38	0.39	9.69e-10	Pancreatic cancer;
SARC	cis	rs1371867	0.775	rs6511	chr8:101252680	T/C	cg11906718	chr8:101322791	RNF19A	-0.67	-8.48	-0.49	2.56e-15	Atrioventricular conduction;
SARC	cis	rs12142240	0.698	rs1057534	chr1:46815880	A/C	cg10495392	chr1:46806563	NSUN4	0.65	6.83	0.41	7.25e-11	Menopause (age at onset);
SARC	cis	rs7937682	0.924	rs4630327	chr11:111539327	C/T	cg09085632	chr11:111637200	PPP2R1B	0.94	16.24	0.73	3.53e-40	Primary sclerosing cholangitis;
SARC	cis	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg09021430	chr5:549028	NA	-0.45	-5.7	-0.35	3.69e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg04277193	chr17:41438351	NA	0.45	4.88	0.3	1.95e-6	Menopause (age at onset);
SARC	cis	rs2599510	0.744	rs4952212	chr2:32618493	G/C	cg02381751	chr2:32503542	YIPF4	-0.46	-5.6	-0.34	5.87e-8	Interleukin-18 levels;
SARC	cis	rs9392653	1.000	rs441144	chr6:5073292	C/G	cg00563771	chr6:5110810	LYRM4	0.44	4.96	0.31	1.34e-6	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs6542838	0.583	rs7565819	chr2:99519265	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-5.76	-0.35	2.66e-8	Fear of minor pain;
SARC	trans	rs11098499	0.909	rs79026312	chr4:120440677	C/A	cg25214090	chr10:38739885	LOC399744	0.55	6.79	0.41	9.25e-11	Corneal astigmatism;
SARC	cis	rs2153535	0.580	rs1414342	chr6:8462552	A/G	cg21535247	chr6:8435926	SLC35B3	0.55	6.83	0.41	7.45e-11	Motion sickness;
SARC	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg06212747	chr3:49208901	KLHDC8B	0.66	8.8	0.5	3.19e-16	Parkinson's disease;
SARC	cis	rs9916302	0.861	rs3889368	chr17:37683231	C/T	cg20243544	chr17:37824526	PNMT	0.56	6.7	0.4	1.58e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg12591125	chr7:1885375	MAD1L1	0.5	5.26	0.33	3.25e-7	Bipolar disorder;
SARC	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	11.07	0.59	3.59e-23	Alzheimer's disease;
SARC	cis	rs9325144	0.560	rs7304568	chr12:38632408	G/A	cg26384229	chr12:38710491	ALG10B	-0.64	-8.64	-0.49	9.27e-16	Morning vs. evening chronotype;
SARC	cis	rs7638909	0.512	rs6793245	chr3:38599037	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.4	4.82	0.3	2.61e-6	Electrocardiographic conduction measures;
SARC	cis	rs13256369	0.951	rs13259955	chr8:8565885	C/G	cg17143192	chr8:8559678	CLDN23	0.52	5.81	0.36	2.04e-8	Obesity-related traits;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg03783058	chr20:3451627	ATRN	0.66	6.96	0.41	3.44e-11	Lung cancer in ever smokers;
SARC	cis	rs2354432	0.556	rs2353977	chr1:146839637	G/T	cg25205988	chr1:146714368	CHD1L	0.96	7.07	0.42	1.84e-11	Mitochondrial DNA levels;
SARC	cis	rs76419734	1.000	rs75817507	chr4:106767623	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	5.31	0.33	2.52e-7	Post bronchodilator FEV1;
SARC	cis	rs9303401	0.659	rs62083368	chr17:56878062	G/A	cg25039879	chr17:56429692	SUPT4H1	0.65	6.12	0.37	3.88e-9	Cognitive test performance;
SARC	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg09359103	chr1:154839909	KCNN3	-0.46	-7.71	-0.45	3.72e-13	Prostate cancer;
SARC	cis	rs9325144	0.602	rs10785590	chr12:38694145	C/T	cg26384229	chr12:38710491	ALG10B	0.6	8.03	0.47	4.66e-14	Morning vs. evening chronotype;
SARC	cis	rs6502050	0.736	rs11658040	chr17:80059891	C/T	cg19223190	chr17:80058835	NA	-0.46	-6.59	-0.4	2.93e-10	Life satisfaction;
SARC	cis	rs35110281	0.744	rs162395	chr21:44945759	T/C	cg21573476	chr21:45109991	RRP1B	-0.43	-6.21	-0.38	2.41e-9	Mean corpuscular volume;
SARC	cis	rs77633900	0.614	rs2459363	chr15:76874952	T/C	cg21673338	chr15:77095150	SCAPER	-0.76	-6.34	-0.38	1.16e-9	Non-glioblastoma glioma;Glioma;
SARC	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg11247378	chr22:39784982	NA	0.31	5.01	0.31	1.08e-6	Intelligence (multi-trait analysis);
SARC	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.48	5.5	0.34	9.88e-8	Renal function-related traits (BUN);
SARC	cis	rs9325144	0.625	rs12227353	chr12:38734542	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-8.07	-0.47	3.63e-14	Morning vs. evening chronotype;
SARC	cis	rs7092929	0.883	rs588410	chr10:3618792	T/C	cg14308648	chr10:3568949	NA	0.51	5.16	0.32	5.38e-7	Coronary artery calcification;
SARC	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg03452623	chr4:187889614	NA	-0.75	-11.74	-0.61	2.7e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.78	7.8	0.45	2.1e-13	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs6426558	0.502	rs6697665	chr1:227474665	T/C	cg10327440	chr1:227177885	CDC42BPA	0.45	5.22	0.32	3.86e-7	Neutrophil percentage of white cells;
SARC	cis	rs1707322	0.721	rs6697821	chr1:46216722	A/G	cg06784218	chr1:46089804	CCDC17	0.36	6.22	0.38	2.26e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg17376030	chr22:41985996	PMM1	0.75	9.44	0.53	4.14e-18	Vitiligo;
SARC	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg26818010	chr10:134567672	INPP5A	-0.61	-6.77	-0.41	1.06e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg10464529	chr16:58030730	ZNF319	-0.68	-7.12	-0.42	1.37e-11	Lung cancer in ever smokers;
SARC	cis	rs7666738	0.830	rs880470	chr4:98922522	A/T	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9303401	0.614	rs3803752	chr17:56540267	C/T	cg25039879	chr17:56429692	SUPT4H1	0.67	6.04	0.37	5.9e-9	Cognitive test performance;
SARC	cis	rs9388451	0.903	rs7758115	chr6:126061502	C/T	cg06289844	chr6:126071538	HEY2	0.38	6.25	0.38	1.97e-9	Brugada syndrome;
SARC	cis	rs3857536	0.813	rs9453639	chr6:66933538	C/T	cg07460842	chr6:66804631	NA	-0.51	-5.8	-0.36	2.14e-8	Blood trace element (Cu levels);
SARC	cis	rs4555082	0.834	rs2816652	chr14:105712493	C/T	cg13114125	chr14:105738426	BRF1	-0.8	-11.97	-0.62	4.76e-26	Mean platelet volume;Platelet distribution width;
SARC	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2075371	0.611	rs1862045	chr7:134023412	A/G	cg00033643	chr7:134001901	SLC35B4	0.46	5.54	0.34	8.15e-8	Mean platelet volume;
SARC	cis	rs79149102	0.579	rs7163390	chr15:75280426	T/C	cg00629941	chr15:75287862	SCAMP5	-0.64	-5.21	-0.32	4.16e-7	Lung cancer;
SARC	cis	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg08045932	chr20:61659980	NA	0.5	6.84	0.41	7.06e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs16976116	0.901	rs9920219	chr15:55503964	T/C	cg11288833	chr15:55489084	RSL24D1	0.6	5.76	0.35	2.62e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs10791323	0.559	rs10750548	chr11:133729469	A/G	cg03690763	chr11:133734501	NA	-0.31	-4.97	-0.31	1.27e-6	Childhood ear infection;
SARC	cis	rs73206853	0.764	rs73206868	chr12:110816835	G/T	cg10860002	chr12:110842031	ANAPC7	0.64	5.15	0.32	5.49e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg03188948	chr7:1209495	NA	0.42	5.51	0.34	9.61e-8	Longevity;Endometriosis;
SARC	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.95	-15.47	-0.71	1.34e-37	Chronic sinus infection;
SARC	cis	rs7633857	0.532	rs1580254	chr3:160767278	C/T	cg04691961	chr3:161091175	C3orf57	-0.48	-5.97	-0.36	8.59e-9	Educational attainment (years of education);
SARC	cis	rs739401	0.527	rs418832	chr11:3072236	C/T	cg05729581	chr11:3078854	CARS	-0.48	-6.19	-0.38	2.69e-9	Longevity;
SARC	cis	rs11809207	0.523	rs2802343	chr1:26498570	T/C	cg23602478	chr1:26503979	CNKSR1	0.28	5.04	0.31	9.15e-7	Height;
SARC	cis	rs9291683	0.655	rs35750364	chr4:10049049	T/C	cg00071950	chr4:10020882	SLC2A9	0.39	6.29	0.38	1.52e-9	Bone mineral density;
SARC	cis	rs4851254	0.660	rs77023845	chr2:100712346	G/A	cg17356467	chr2:100759845	AFF3	0.33	4.73	0.3	3.82e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9395865	0.520	rs6903708	chr6:53332940	A/G	cg23554129	chr6:53413076	NA	-0.41	-4.87	-0.3	2.08e-6	Electroencephalographic traits in alcoholism;
SARC	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg24531977	chr5:56204891	C5orf35	0.55	5.75	0.35	2.85e-8	Initial pursuit acceleration;
SARC	cis	rs2302729	0.789	rs876503	chr12:2797179	A/G	cg19945202	chr12:2788847	CACNA1C	-0.57	-5.13	-0.32	6.13e-7	Sleep quality;
SARC	cis	rs753778	0.667	rs10103731	chr8:142206068	C/T	cg18755752	chr8:142205143	DENND3	-0.52	-7.53	-0.44	1.09e-12	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg25010444	chr12:123717480	C12orf65	0.5	6.37	0.39	9.97e-10	Lung adenocarcinoma;
SARC	cis	rs3136441	1.000	rs2290883	chr11:46890197	A/G	cg25783544	chr11:47291846	MADD	-0.65	-5.1	-0.32	7.11e-7	HDL cholesterol;
SARC	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg12648201	chr2:27665141	KRTCAP3	-0.33	-4.97	-0.31	1.32e-6	Total body bone mineral density;
SARC	cis	rs6495122	0.699	rs3784789	chr15:75082552	C/G	cg14664628	chr15:75095509	CSK	-0.8	-10.52	-0.57	1.99e-21	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg19403339	chr2:183580841	DNAJC10	0.62	6.35	0.38	1.1e-9	Lung cancer in ever smokers;
SARC	cis	rs1707322	0.964	rs10437063	chr1:46273666	G/A	cg03146154	chr1:46216737	IPP	0.47	5.62	0.35	5.38e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1580019	0.537	rs7804609	chr7:32558094	A/C	cg14728415	chr7:32535168	LSM5;AVL9	0.54	6.99	0.42	2.9e-11	Cognitive ability;
SARC	cis	rs8141529	0.529	rs35017742	chr22:29216585	C/T	cg15103426	chr22:29168792	CCDC117	0.59	5.64	0.35	4.82e-8	Lymphocyte counts;
SARC	cis	rs735539	0.521	rs2818996	chr13:21428271	A/T	cg16922012	chr13:21400325	XPO4	-0.43	-5.82	-0.36	1.95e-8	Dental caries;
SARC	cis	rs9300255	0.602	rs1716177	chr12:123655457	C/T	cg00376283	chr12:123451042	ABCB9	0.6	6.79	0.41	9.43e-11	Neutrophil percentage of white cells;
SARC	cis	rs2486288	0.656	rs62026703	chr15:45569929	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.54	-6.88	-0.41	5.51e-11	Glomerular filtration rate;
SARC	cis	rs7592578	0.771	rs10432434	chr2:191387079	T/G	cg25963032	chr2:191064776	C2orf88	-0.48	-5.29	-0.33	2.78e-7	Diastolic blood pressure;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg10384784	chr10:25012964	ARHGAP21	0.49	6.26	0.38	1.86e-9	Breast cancer;
SARC	cis	rs7264396	0.563	rs61191623	chr20:34219987	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-5.98	-0.36	8.32e-9	Total cholesterol levels;
SARC	trans	rs9987289	0.614	rs6984305	chr8:9178268	A/T	cg01143607	chr1:40026447	LOC728448	-0.63	-6.44	-0.39	6.85e-10	HDL Cholesterol - Triglycerides (HDLC-TG);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);C-reactive protein levels or triglyceride levels (pleiotropy);LDL cholesterol;HDL cholesterol;Cholesterol, total;C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Metabolic syndrome (bivariate traits);Total cholesterol levels;Plasma lactate levels;C-reactive protein levels;LDL cholesterol levels;
SARC	cis	rs2153535	0.601	rs2015281	chr6:8539673	G/A	cg23788917	chr6:8435910	SLC35B3	0.62	8.2	0.47	1.61e-14	Motion sickness;
SARC	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg22027946	chr17:80790580	TBCD;ZNF750	0.39	4.94	0.31	1.46e-6	Glycated hemoglobin levels;
SARC	cis	rs13082711	0.911	rs7625337	chr3:27516853	G/T	cg02860705	chr3:27208620	NA	0.44	5.61	0.35	5.63e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs4819052	0.788	rs2236449	chr21:46702506	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	6.93	0.41	4.11e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs637571	0.584	rs659824	chr11:65636509	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.38	-4.75	-0.3	3.56e-6	Eosinophil percentage of white cells;
SARC	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg13770153	chr20:60521292	NA	-0.45	-6.31	-0.38	1.39e-9	Body mass index;
SARC	cis	rs11025559	0.812	rs11025583	chr11:20513260	C/T	cg04101203	chr11:20408940	PRMT3	0.47	5.17	0.32	5e-7	Pursuit maintenance gain;
SARC	cis	rs6062509	0.839	rs6062298	chr20:62301970	G/A	cg27236539	chr20:62289627	RTEL1	0.53	5.85	0.36	1.69e-8	Prostate cancer;
SARC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	9.3	0.52	1.04e-17	Prudent dietary pattern;
SARC	cis	rs2239547	0.603	rs6805298	chr3:53096552	A/G	cg11645453	chr3:52864694	ITIH4	-0.3	-4.94	-0.31	1.47e-6	Schizophrenia;
SARC	cis	rs2486288	0.656	rs10519018	chr15:45549265	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.54	-6.92	-0.41	4.35e-11	Glomerular filtration rate;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg00609296	chr2:3461755	TTC15	0.43	6.37	0.39	1.02e-9	Schizophrenia;
SARC	cis	rs9359856	0.529	rs72915915	chr6:90430593	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.58	-4.73	-0.3	3.81e-6	Bipolar disorder;
SARC	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg04087434	chr1:1669123	SLC35E2	-0.36	-4.75	-0.3	3.62e-6	Body mass index;
SARC	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.46	-5.87	-0.36	1.53e-8	Gut microbiome composition (summer);
SARC	cis	rs9815354	0.951	rs6793520	chr3:41865289	C/G	cg03022575	chr3:42003672	ULK4	0.57	5.32	0.33	2.38e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9916302	0.851	rs4794810	chr17:37603774	T/C	cg00129232	chr17:37814104	STARD3	-0.63	-7.88	-0.46	1.23e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg12463550	chr7:65579703	CRCP	-0.5	-5.55	-0.34	7.9e-8	Aortic root size;
SARC	cis	rs3741151	0.686	rs60860405	chr11:73248673	A/C	cg17517138	chr11:73019481	ARHGEF17	0.69	5.92	0.36	1.14e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg22535103	chr8:58192502	C8orf71	-0.73	-7.31	-0.43	4.37e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-9.14	-0.51	3.2e-17	Alzheimer's disease;
SARC	cis	rs36051895	0.623	rs1120679	chr9:5248073	C/G	cg02405213	chr9:5042618	JAK2	-0.43	-5.04	-0.31	9.25e-7	Pediatric autoimmune diseases;
SARC	cis	rs17213078	0.510	rs17032713	chr2:106886839	T/C	cg23109721	chr2:106886537	NA	-0.39	-4.76	-0.3	3.37e-6	Facial morphology (factor 23);
SARC	trans	rs3780486	0.629	rs10971439	chr9:33180813	C/T	cg20290983	chr6:43655470	MRPS18A	-0.87	-9.6	-0.53	1.33e-18	IgG glycosylation;
SARC	trans	rs1814175	0.646	rs1722010	chr11:49897958	A/G	cg03929089	chr4:120376271	NA	-0.82	-11.77	-0.61	2.09e-25	Height;
SARC	cis	rs9790314	0.540	rs35462273	chr3:160991877	C/T	cg17135325	chr3:160939158	NMD3	0.63	7.87	0.46	1.32e-13	Morning vs. evening chronotype;
SARC	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg25072359	chr17:41440525	NA	0.54	6.74	0.4	1.26e-10	Menopause (age at onset);
SARC	cis	rs2694528	0.844	rs9291696	chr5:60064385	C/T	cg11474532	chr5:59995715	DEPDC1B	0.68	5.0	0.31	1.1e-6	Parkinson's disease;
SARC	cis	rs7937682	0.883	rs486038	chr11:111465963	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.93	-14.06	-0.68	6.32e-33	Primary sclerosing cholangitis;
SARC	cis	rs7116495	1.000	rs6592455	chr11:71689541	C/T	cg26138937	chr11:71823887	C11orf51	0.72	4.72	0.3	4.07e-6	Severe influenza A (H1N1) infection;
SARC	cis	rs10463554	0.963	rs34381	chr5:102396556	C/T	cg23492399	chr5:102201601	PAM	-0.52	-5.73	-0.35	3.13e-8	Parkinson's disease;
SARC	cis	rs2952156	0.920	rs2934956	chr17:37830447	T/A	cg00129232	chr17:37814104	STARD3	-0.7	-9.88	-0.54	1.83e-19	Asthma;
SARC	cis	rs796364	0.616	rs2103094	chr2:200687954	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.55	4.74	0.3	3.76e-6	Schizophrenia;
SARC	cis	rs5995756	0.543	rs136811	chr22:40021256	T/A	cg10455938	chr22:40058150	CACNA1I	0.55	7.13	0.42	1.26e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg09021430	chr5:549028	NA	-0.43	-5.68	-0.35	3.92e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs11225247	0.881	rs12271457	chr11:102247928	C/T	cg11690896	chr11:102217788	BIRC2	0.79	5.34	0.33	2.16e-7	Vein graft stenosis in coronary artery bypass grafting;
SARC	cis	rs739401	0.611	rs402276	chr11:3051404	C/G	cg25174290	chr11:3078921	CARS	0.59	8.31	0.48	7.72e-15	Longevity;
SARC	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg11764359	chr7:65958608	NA	0.6	7.19	0.43	8.82e-12	Calcium levels;
SARC	cis	rs611744	0.868	rs612722	chr8:109194850	C/T	cg21045802	chr8:109455806	TTC35	0.44	5.3	0.33	2.63e-7	Dupuytren's disease;
SARC	trans	rs1853207	1.000	rs2093433	chr10:96638896	G/A	cg02737782	chr1:8014393	NA	-0.97	-6.42	-0.39	7.44e-10	Blood metabolite levels;
SARC	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg12463550	chr7:65579703	CRCP	0.66	5.06	0.31	8.64e-7	Diabetic kidney disease;
SARC	cis	rs12497850	0.966	rs6792510	chr3:48723302	G/C	cg06212747	chr3:49208901	KLHDC8B	0.67	8.68	0.49	6.84e-16	Parkinson's disease;
SARC	cis	rs1468333	0.704	rs4835675	chr5:137623683	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.73	8.64	0.49	9.02e-16	Resting heart rate;
SARC	cis	rs7223966	1.000	rs15637	chr17:61772050	C/G	cg00588841	chr17:61851480	DDX42;CCDC47	-0.59	-6.86	-0.41	6.03e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6964587	1.000	rs7789492	chr7:91668854	C/T	cg17063962	chr7:91808500	NA	0.96	16.6	0.74	2.21e-41	Breast cancer;
SARC	cis	rs2645694	0.626	rs2645708	chr4:77822682	G/A	cg10057126	chr4:77819792	ANKRD56	0.43	6.49	0.39	5.11e-10	Emphysema distribution in smoking;
SARC	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg22433210	chr17:43662623	NA	-0.98	-11.44	-0.6	2.34e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9815354	1.000	rs9826058	chr3:41762062	A/G	cg03022575	chr3:42003672	ULK4	0.53	5.01	0.31	1.07e-6	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg08048268	chr3:133502702	NA	-0.43	-5.79	-0.35	2.24e-8	Iron status biomarkers;
SARC	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg20965017	chr5:231967	SDHA	-0.54	-5.18	-0.32	4.84e-7	Breast cancer;
SARC	cis	rs4481887	0.927	rs4307598	chr1:248474544	T/C	cg01631408	chr1:248437212	OR2T33	-0.38	-4.92	-0.31	1.67e-6	Common traits (Other);
SARC	cis	rs1057510	0.790	rs11064281	chr12:6721425	A/C	cg25017194	chr12:6566966	TAPBPL	-0.49	-4.75	-0.3	3.57e-6	Myopia (pathological);
SARC	cis	rs7647973	0.961	rs7619016	chr3:49272589	C/T	cg06212747	chr3:49208901	KLHDC8B	0.58	5.97	0.36	8.99e-9	Menarche (age at onset);
SARC	cis	rs34172651	0.876	rs11074653	chr16:24795959	C/T	cg00152838	chr16:24741724	TNRC6A	-0.5	-6.12	-0.37	3.88e-9	Intelligence (multi-trait analysis);
SARC	trans	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg17830980	chr10:43048298	ZNF37B	-0.51	-7.02	-0.42	2.42e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs1865760	0.892	rs9379806	chr6:25940958	G/A	cg17691542	chr6:26056736	HIST1H1C	0.61	7.7	0.45	3.92e-13	Height;
SARC	cis	rs7959452	0.640	rs4761233	chr12:69722880	T/C	cg20891283	chr12:69753455	YEATS4	0.43	5.65	0.35	4.69e-8	Blood protein levels;
SARC	cis	rs8067354	0.872	rs7224006	chr17:57896338	C/T	cg02344993	chr17:57696989	CLTC	-0.44	-5.13	-0.32	5.97e-7	Hemoglobin concentration;
SARC	cis	rs1008375	0.966	rs6832962	chr4:17652133	T/C	cg27347728	chr4:17578864	LAP3	0.5	6.27	0.38	1.72e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs7762018	0.607	rs79897010	chr6:170042874	C/G	cg19338460	chr6:170058176	WDR27	-0.78	-5.16	-0.32	5.37e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs12472274	0.646	rs11677736	chr2:239087198	A/T	cg17459225	chr2:239074497	NA	0.62	6.58	0.4	3.04e-10	Phospholipid levels (plasma);
SARC	cis	rs9788682	0.747	rs2656074	chr15:78741384	T/C	cg06917634	chr15:78832804	PSMA4	0.52	5.42	0.33	1.48e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs78545713	0.536	rs116337444	chr6:26208269	G/A	cg00631329	chr6:26305371	NA	-0.73	-4.73	-0.3	3.93e-6	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs11718455	1.000	rs28731098	chr3:44019816	A/C	cg08738300	chr3:44038990	NA	0.51	5.7	0.35	3.56e-8	Coronary artery disease;
SARC	cis	rs9790314	0.747	rs1599386	chr3:160856314	C/T	cg03342759	chr3:160939853	NMD3	0.47	5.73	0.35	3.1e-8	Morning vs. evening chronotype;
SARC	cis	rs7027203	0.797	rs57882762	chr9:96580825	T/G	cg14598338	chr9:96623480	NA	-0.55	-7.73	-0.45	3.12e-13	DNA methylation (variation);
SARC	cis	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg21573476	chr21:45109991	RRP1B	-0.54	-7.89	-0.46	1.15e-13	Mean corpuscular volume;
SARC	cis	rs4851254	0.920	rs11123808	chr2:100750750	A/C	cg04109781	chr2:100722022	AFF3	0.33	4.81	0.3	2.68e-6	Intelligence (multi-trait analysis);
SARC	cis	rs3733585	0.673	rs6840802	chr4:9965633	C/G	cg00071950	chr4:10020882	SLC2A9	0.33	4.79	0.3	3.01e-6	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs6570726	0.935	rs399169	chr6:145836353	C/A	cg05347473	chr6:146136440	FBXO30	0.48	6.42	0.39	7.51e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6450176	1.000	rs6450176	chr5:53298025	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.66	-7.64	-0.45	5.69e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs832540	0.552	rs702681	chr5:56218029	C/T	cg12311346	chr5:56204834	C5orf35	-0.4	-4.81	-0.3	2.66e-6	Coronary artery disease;
SARC	cis	rs4800452	0.826	rs8094261	chr18:20746728	C/G	cg13313047	chr18:20735648	CABLES1	-0.47	-5.52	-0.34	8.89e-8	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
SARC	cis	rs3126085	0.877	rs4456097	chr1:152229741	G/A	cg03465714	chr1:152285911	FLG	-0.45	-5.38	-0.33	1.85e-7	Atopic dermatitis;
SARC	cis	rs672059	1.000	rs674343	chr1:183162052	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.51	6.96	0.41	3.47e-11	Hypertriglyceridemia;
SARC	cis	rs8180040	0.966	rs13072802	chr3:47346415	G/C	cg27129171	chr3:47204927	SETD2	0.67	9.36	0.52	7.09e-18	Colorectal cancer;
SARC	cis	rs73198271	0.531	rs17630714	chr8:8657681	C/T	cg01851573	chr8:8652454	MFHAS1	0.4	4.72	0.3	4.04e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.99	10.59	0.57	1.17e-21	Platelet count;
SARC	cis	rs6493487	0.512	rs11070825	chr15:51249529	C/A	cg02338191	chr15:51200825	AP4E1	0.53	4.91	0.31	1.73e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs921968	0.643	rs678218	chr2:219379709	C/A	cg02176678	chr2:219576539	TTLL4	0.38	5.64	0.35	4.8e-8	Mean corpuscular hemoglobin concentration;
SARC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg11494091	chr17:61959527	GH2	0.53	8.0	0.46	5.72e-14	Prudent dietary pattern;
SARC	cis	rs3768617	0.510	rs10911239	chr1:183062450	T/C	cg13390022	chr1:182993471	LAMC1	0.33	4.94	0.31	1.5e-6	Fuchs's corneal dystrophy;
SARC	cis	rs13082711	0.516	rs1388786	chr3:27372222	G/A	cg02860705	chr3:27208620	NA	-0.49	-6.66	-0.4	1.97e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs5753618	0.561	rs4820043	chr22:31647094	A/G	cg13145458	chr22:31556086	RNF185	0.52	5.52	0.34	9.17e-8	Colorectal cancer;
SARC	cis	rs2130392	0.892	rs11728389	chr4:185622046	C/T	cg04058563	chr4:185651563	MLF1IP	-0.34	-4.94	-0.31	1.49e-6	Kawasaki disease;
SARC	cis	rs314370	0.951	rs3757868	chr7:100482720	G/A	cg10426581	chr7:100472382	SRRT	0.62	6.5	0.39	4.7e-10	Resting heart rate;
SARC	cis	rs1707322	1.000	rs6695421	chr1:46380207	T/C	cg06784218	chr1:46089804	CCDC17	0.34	5.94	0.36	1.03e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2075671	0.810	rs12531792	chr7:100280624	G/A	cg20848291	chr7:100343083	ZAN	-0.69	-7.64	-0.45	5.51e-13	Other erythrocyte phenotypes;
SARC	cis	rs7512552	0.839	rs834236	chr1:150362968	C/T	cg15654264	chr1:150340011	RPRD2	0.38	4.81	0.3	2.7e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	-0.39	-4.73	-0.3	3.94e-6	Tonsillectomy;
SARC	cis	rs838147	0.537	rs632111	chr19:49208978	A/G	cg21064579	chr19:49206444	FUT2	0.34	4.9	0.31	1.76e-6	Dietary macronutrient intake;
SARC	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg13770153	chr20:60521292	NA	-0.46	-6.44	-0.39	6.66e-10	Body mass index;
SARC	cis	rs16976116	0.619	rs11071173	chr15:55467558	C/G	cg11288833	chr15:55489084	RSL24D1	-0.62	-5.28	-0.33	3.02e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9660992	0.674	rs1151784	chr1:205232447	C/T	cg21643547	chr1:205240462	TMCC2	-0.64	-8.25	-0.48	1.2e-14	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg13206674	chr6:150067644	NUP43	0.43	5.6	0.34	6.04e-8	Lung cancer;
SARC	cis	rs7084402	0.935	rs1658456	chr10:60304326	C/T	cg07615347	chr10:60278583	BICC1	0.57	8.35	0.48	6.07e-15	Refractive error;
SARC	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg13393036	chr8:95962371	TP53INP1	-0.36	-6.12	-0.37	3.92e-9	Type 2 diabetes;
SARC	cis	rs11225247	0.772	rs12275349	chr11:102237720	C/T	cg11690896	chr11:102217788	BIRC2	0.74	5.3	0.33	2.63e-7	Vein graft stenosis in coronary artery bypass grafting;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg09549848	chr9:113800279	LPAR1	-0.52	-6.47	-0.39	5.87e-10	Height;
SARC	cis	rs9341808	1.000	rs1359239	chr6:80956146	G/A	cg08355045	chr6:80787529	NA	0.37	6.24	0.38	2.09e-9	Sitting height ratio;
SARC	cis	rs3008870	0.755	rs2755242	chr1:67479598	T/C	cg02640540	chr1:67518911	SLC35D1	0.46	5.26	0.33	3.34e-7	Lymphocyte percentage of white cells;
SARC	cis	rs748404	0.631	rs6493084	chr15:43647627	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	5.83	0.36	1.79e-8	Lung cancer;
SARC	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg22169418	chr11:62359237	TUT1	-0.5	-6.29	-0.38	1.56e-9	Thyroid cancer;
SARC	cis	rs4820539	1.000	rs2157710	chr22:23457486	C/T	cg14186256	chr22:23484241	RTDR1	0.88	13.4	0.66	9.67e-31	Bone mineral density;
SARC	cis	rs2439831	1.000	rs1814538	chr15:43759774	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-1.01	-10.96	-0.58	8.41e-23	Lung cancer in ever smokers;
SARC	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg06221963	chr1:154839813	KCNN3	-0.53	-8.66	-0.49	8.2e-16	Prostate cancer;
SARC	cis	rs9807989	0.839	rs10192157	chr2:102968356	C/T	cg09003973	chr2:102972529	NA	0.41	5.6	0.34	6.11e-8	Asthma;
SARC	cis	rs9513593	1.000	rs4772181	chr13:99860966	C/G	cg21788972	chr13:99853209	UBAC2	0.5	4.79	0.3	2.92e-6	Psoriasis;
SARC	cis	rs631288	0.557	rs7546434	chr1:146676339	A/G	cg25205988	chr1:146714368	CHD1L	1.08	6.4	0.39	8.34e-10	PR interval in Tripanosoma cruzi seropositivity;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg23542426	chr17:78789620	RPTOR	0.57	7.15	0.42	1.11e-11	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs12824058	0.831	rs4759653	chr12:130812604	T/C	cg24838063	chr12:130822603	PIWIL1	0.63	8.93	0.5	1.34e-16	Menopause (age at onset);
SARC	cis	rs6083	0.549	rs11858020	chr15:58852422	A/T	cg05156742	chr15:59063176	FAM63B	0.63	8.28	0.48	9.77e-15	Schizophrenia;
SARC	cis	rs11651000	0.857	rs11658383	chr17:45842354	A/C	cg24803719	chr17:45855879	NA	-0.5	-7.42	-0.44	2.22e-12	IgG glycosylation;
SARC	cis	rs11122272	0.735	rs2572252	chr1:231513653	T/C	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs870825	0.616	rs28582728	chr4:185646920	C/T	cg04058563	chr4:185651563	MLF1IP	0.8	11.35	0.6	4.56e-24	Blood protein levels;
SARC	cis	rs6582630	0.519	rs1851121	chr12:38389467	T/C	cg13010199	chr12:38710504	ALG10B	0.78	10.86	0.58	1.6400000000000001e-22	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg25019564	chr18:9475492	RALBP1	0.48	6.47	0.39	5.58e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg24642844	chr7:1081250	C7orf50	-0.6	-6.15	-0.37	3.26e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg20965017	chr5:231967	SDHA	-0.54	-5.12	-0.32	6.3e-7	Breast cancer;
SARC	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs13161895	1.000	rs35592104	chr5:179447661	A/T	cg02702477	chr5:179499311	RNF130	0.68	6.77	0.41	1.04e-10	LDL cholesterol;
SARC	cis	rs6594499	0.872	rs6880351	chr5:110451664	C/G	cg04022379	chr5:110408740	TSLP	0.48	6.02	0.37	6.9e-9	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs735396	0.770	rs2257764	chr12:121446446	T/A	cg25281562	chr12:121454272	C12orf43	-0.57	-7.15	-0.42	1.1e-11	N-glycan levels;
SARC	cis	rs13277976	0.509	rs4738816	chr8:61613025	C/T	cg03275056	chr8:61591461	CHD7	-0.4	-4.84	-0.3	2.41e-6	Eosinophil counts;
SARC	cis	rs17345786	0.628	rs11718446	chr3:101552553	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	5.85	0.36	1.66e-8	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10992471	0.565	rs12552866	chr9:95110549	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.4	-4.94	-0.31	1.48e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs2730245	1.000	rs2730241	chr7:158723014	T/C	cg14689365	chr7:158441557	NCAPG2	-0.42	-4.74	-0.3	3.68e-6	Height;
SARC	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg03806693	chr22:41940476	POLR3H	0.9	12.82	0.64	8.04e-29	Vitiligo;
SARC	cis	rs2658782	0.526	rs3020062	chr11:93061159	T/C	cg15737290	chr11:93063684	CCDC67	0.97	13.67	0.67	1.23e-31	Pulmonary function decline;
SARC	trans	rs61931739	0.500	rs7307583	chr12:34521711	T/C	cg26384229	chr12:38710491	ALG10B	0.85	12.66	0.64	2.57e-28	Morning vs. evening chronotype;
SARC	cis	rs79149102	0.579	rs9673012	chr15:75293737	C/T	cg09165964	chr15:75287851	SCAMP5	-0.95	-8.78	-0.5	3.63e-16	Lung cancer;
SARC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg17178900	chr1:205818956	PM20D1	-0.64	-9.41	-0.52	4.92e-18	Menarche (age at onset);
SARC	cis	rs6493487	0.512	rs35496548	chr15:51139135	T/C	cg02338191	chr15:51200825	AP4E1	0.54	5.08	0.32	7.9e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs4835937	0.681	rs10068883	chr5:127331614	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.52	4.81	0.3	2.72e-6	Cancer;
SARC	cis	rs763121	0.962	rs5757135	chr22:38952573	C/T	cg21395723	chr22:39101663	GTPBP1	0.51	6.13	0.37	3.79e-9	Menopause (age at onset);
SARC	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg04277193	chr17:41438351	NA	0.45	4.89	0.31	1.89e-6	Menopause (age at onset);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg24503272	chr6:160210831	MRPL18;TCP1	-0.58	-6.49	-0.39	5e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg22535103	chr8:58192502	C8orf71	-0.78	-9.33	-0.52	8.42e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs72615157	0.539	rs4729575	chr7:99686873	G/T	cg22004693	chr7:99632812	ZKSCAN1	0.74	9.1	0.51	4.14e-17	Lung function (FEV1/FVC);
SARC	cis	rs4319547	0.956	rs10847179	chr12:123040985	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.65	-7.86	-0.46	1.45e-13	Body mass index;
SARC	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg20607798	chr8:58055168	NA	0.49	5.03	0.31	9.89e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	11.07	0.59	3.6e-23	Alzheimer's disease;
SARC	cis	rs7555523	0.830	rs6660601	chr1:165695855	C/T	cg24409356	chr1:165738333	TMCO1	0.8	6.67	0.4	1.88e-10	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	trans	rs2018683	0.768	rs10282015	chr7:29022138	G/A	cg19402173	chr7:128379420	CALU	-0.56	-6.79	-0.41	9.36e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg08309023	chr2:148839265	NA	-0.5	-6.39	-0.39	8.87e-10	Alcohol dependence;
SARC	cis	rs4268898	0.931	rs55642516	chr2:24502305	A/G	cg06627628	chr2:24431161	ITSN2	-0.67	-9.53	-0.53	2.09e-18	Asthma;
SARC	cis	rs6807306	1.000	rs4642126	chr3:167387528	A/G	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.49	4.91	0.31	1.74e-6	Mean platelet volume;
SARC	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.38	4.71	0.3	4.2e-6	Tonsillectomy;
SARC	cis	rs9457247	0.663	rs9459839	chr6:167431829	T/C	cg23791538	chr6:167370224	RNASET2	-0.51	-6.84	-0.41	6.89e-11	Crohn's disease;
SARC	cis	rs73001065	0.901	rs73004962	chr19:19713069	A/T	cg03709012	chr19:19516395	GATAD2A	0.86	5.98	0.36	8.37e-9	LDL cholesterol;
SARC	cis	rs3768617	0.510	rs3768619	chr1:183092404	C/G	cg13390022	chr1:182993471	LAMC1	0.31	4.73	0.3	3.89e-6	Fuchs's corneal dystrophy;
SARC	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg07701084	chr6:150067640	NUP43	0.39	5.14	0.32	5.83e-7	Lung cancer;
SARC	trans	rs2727020	0.595	rs7924311	chr11:49507573	G/A	cg03929089	chr4:120376271	NA	-0.81	-11.97	-0.62	4.59e-26	Coronary artery disease;
SARC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg06873352	chr17:61820015	STRADA	0.53	6.83	0.41	7.25e-11	Prudent dietary pattern;
SARC	trans	rs35847492	1.000	rs35847492	chr8:9276025	G/C	cg06636001	chr8:8085503	FLJ10661	0.6	6.75	0.4	1.17e-10	Neuroticism;
SARC	cis	rs10779751	0.734	rs2791653	chr1:11129848	A/G	cg08854313	chr1:11322531	MTOR	0.79	10.23	0.56	1.55e-20	Body mass index;
SARC	cis	rs10752881	1.000	rs6424879	chr1:182986592	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.7	0.57	5.56e-22	Colorectal cancer;
SARC	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg27266027	chr21:40555129	PSMG1	-0.51	-5.48	-0.34	1.12e-7	Cognitive function;
SARC	cis	rs7818688	0.697	rs76631135	chr8:95980988	G/T	cg13393036	chr8:95962371	TP53INP1	0.42	5.1	0.32	7.06e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs3741151	0.764	rs7101561	chr11:73264219	G/C	cg17517138	chr11:73019481	ARHGEF17	0.93	6.88	0.41	5.4e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs11098499	0.863	rs3822195	chr4:120471660	C/T	cg09307838	chr4:120376055	NA	0.91	12.25	0.63	5.66e-27	Corneal astigmatism;
SARC	cis	rs17270561	0.636	rs6456698	chr6:25741664	A/C	cg17691542	chr6:26056736	HIST1H1C	0.61	7.36	0.43	3.06e-12	Iron status biomarkers;
SARC	cis	rs25645	0.792	rs8077456	chr17:38128765	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.39	6.85	0.41	6.42e-11	Myeloid white cell count;
SARC	cis	rs1008375	0.898	rs2079892	chr4:17577163	G/A	cg27347728	chr4:17578864	LAP3	0.49	6.06	0.37	5.46e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7084402	0.967	rs1658436	chr10:60326910	G/A	cg07615347	chr10:60278583	BICC1	0.53	7.77	0.45	2.46e-13	Refractive error;
SARC	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg04267008	chr7:1944627	MAD1L1	-0.51	-6.1	-0.37	4.44e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs11098499	0.739	rs9996382	chr4:120151012	C/T	cg24375607	chr4:120327624	NA	0.38	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs35213789	0.878	rs7800317	chr7:69469874	G/A	cg10619644	chr7:69149951	AUTS2	0.44	5.35	0.33	2.13e-7	Childhood ear infection;
SARC	cis	rs7712401	0.601	rs442911	chr5:122325551	T/C	cg19412675	chr5:122181750	SNX24	-0.43	-5.43	-0.34	1.41e-7	Mean platelet volume;
SARC	cis	rs7776701	1.000	rs7776701	chr7:47442633	T/C	cg23694490	chr7:47445681	TNS3	0.33	5.88	0.36	1.44e-8	Basal cell carcinoma;
SARC	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg11301795	chr4:187892539	NA	0.71	10.67	0.57	6.53e-22	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.62	0.45	6.48e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2070488	0.745	rs7649153	chr3:38467753	T/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.63	8.11	0.47	2.8e-14	Electrocardiographic conduction measures;
SARC	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.71	-9.73	-0.54	5.23e-19	Homoarginine levels;
SARC	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg11644478	chr21:40555479	PSMG1	1.02	14.06	0.68	6.55e-33	Cognitive function;
SARC	cis	rs7552404	0.727	rs2172508	chr1:76320215	A/G	cg22875332	chr1:76189707	ACADM	0.44	5.4	0.33	1.61e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7592578	1.000	rs7592578	chr2:191439591	T/G	cg27211696	chr2:191398769	TMEM194B	0.57	6.01	0.37	7.15e-9	Diastolic blood pressure;
SARC	cis	rs763121	0.962	rs1980455	chr22:38925719	A/C	cg06022373	chr22:39101656	GTPBP1	0.74	9.65	0.53	9.5e-19	Menopause (age at onset);
SARC	cis	rs2276314	0.857	rs28379448	chr18:33604364	C/A	cg05985134	chr18:33552581	C18orf21	0.65	6.51	0.39	4.63e-10	Endometriosis;Drug-induced torsades de pointes;
SARC	trans	rs7215990	0.906	rs12603854	chr17:6035179	C/T	cg22735324	chr8:48691148	PRKDC	0.62	6.23	0.38	2.11e-9	Menarche (age at onset);
SARC	cis	rs9807989	0.507	rs2160201	chr2:103033961	T/C	cg03938978	chr2:103052716	IL18RAP	0.31	4.96	0.31	1.34e-6	Asthma;
SARC	cis	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg18252515	chr7:66147081	NA	-1.43	-12.98	-0.65	2.35e-29	Gout;
SARC	cis	rs637571	0.522	rs538954	chr11:65756808	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.84	12.95	0.65	3.02e-29	Eosinophil percentage of white cells;
SARC	trans	rs7647973	0.593	rs4855885	chr3:49690199	G/A	cg21659725	chr3:3221576	CRBN	-0.7	-6.63	-0.4	2.29e-10	Menarche (age at onset);
SARC	cis	rs2303759	0.709	rs10414921	chr19:49823047	C/T	cg24324837	chr19:49891574	CCDC155	0.4	4.78	0.3	3.09e-6	Multiple sclerosis;
SARC	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-4.88	-0.3	2e-6	Total body bone mineral density;
SARC	cis	rs12479064	0.724	rs6748200	chr2:100080895	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.54	-6.32	-0.38	1.33e-9	Chronic sinus infection;
SARC	cis	rs6500602	0.702	rs2304634	chr16:4500544	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.36	6.05	0.37	5.82e-9	Schizophrenia;
SARC	trans	rs2420915	0.630	rs2243609	chr10:122874348	A/C	cg19434433	chr17:44849214	WNT3	-0.53	-6.31	-0.38	1.36e-9	Fibrinogen levels;
SARC	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg05861140	chr6:150128134	PCMT1	-0.38	-4.91	-0.31	1.7e-6	Lung cancer;
SARC	cis	rs3824867	0.920	rs7126210	chr11:47460306	A/G	cg20307385	chr11:47447363	PSMC3	0.47	5.03	0.31	9.58e-7	Mean corpuscular hemoglobin;
SARC	cis	rs3018712	0.532	rs4930588	chr11:68415235	A/C	cg01657329	chr11:68192670	LRP5	-0.56	-5.19	-0.32	4.62e-7	Total body bone mineral density;
SARC	trans	rs61931739	0.500	rs11053242	chr12:34511625	A/G	cg26384229	chr12:38710491	ALG10B	0.83	12.41	0.63	1.78e-27	Morning vs. evening chronotype;
SARC	cis	rs1153858	1.000	rs66939267	chr15:45676902	T/A	cg21132104	chr15:45694354	SPATA5L1	0.78	11.01	0.59	5.55e-23	Homoarginine levels;
SARC	cis	rs10046574	0.519	rs11505985	chr7:135210197	G/T	cg27474649	chr7:135195673	CNOT4	0.81	7.74	0.45	3e-13	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs6088590	1.000	rs28542147	chr20:33376323	G/A	cg06115741	chr20:33292138	TP53INP2	0.57	6.83	0.41	7.46e-11	Coronary artery disease;
SARC	trans	rs804280	0.542	rs35647515	chr8:11791629	C/T	cg06636001	chr8:8085503	FLJ10661	0.5	6.28	0.38	1.64e-9	Myopia (pathological);
SARC	cis	rs72781680	0.848	rs72780199	chr2:24016269	A/C	cg06627628	chr2:24431161	ITSN2	-0.66	-6.26	-0.38	1.83e-9	Lymphocyte counts;
SARC	cis	rs1348850	0.801	rs11890163	chr2:178327134	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.7	6.52	0.39	4.35e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg07588614	chr3:113604183	GRAMD1C	-0.5	-6.41	-0.39	7.85e-10	Height;
SARC	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg07701084	chr6:150067640	NUP43	0.4	5.23	0.32	3.74e-7	Lung cancer;
SARC	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg19748678	chr4:122722346	EXOSC9	0.77	9.53	0.53	2.23e-18	Type 2 diabetes;
SARC	cis	rs2832191	0.703	rs2853827	chr21:30443596	T/C	cg24692254	chr21:30365293	RNF160	1.03	18.19	0.77	1.28e-46	Dental caries;
SARC	cis	rs9868809	0.772	rs9841602	chr3:48713570	A/G	cg03060546	chr3:49711283	APEH	-0.54	-5.08	-0.32	7.83e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs7216064	0.953	rs4791048	chr17:65848994	G/A	cg12091567	chr17:66097778	LOC651250	-0.72	-7.92	-0.46	9.5e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg08564027	chr20:61660810	NA	0.76	11.8	0.61	1.69e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs6088590	0.561	rs2295444	chr20:33173883	C/T	cg24642439	chr20:33292090	TP53INP2	0.66	8.51	0.49	2.18e-15	Coronary artery disease;
SARC	trans	rs61931739	0.513	rs1486889	chr12:33901229	A/G	cg26384229	chr12:38710491	ALG10B	0.69	9.57	0.53	1.64e-18	Morning vs. evening chronotype;
SARC	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg00339695	chr16:24857497	SLC5A11	0.41	5.78	0.35	2.37e-8	Intelligence (multi-trait analysis);
SARC	cis	rs12681288	0.862	rs935821	chr8:1022455	G/A	cg15309053	chr8:964076	NA	0.42	6.9	0.41	4.94e-11	Schizophrenia;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg01804627	chr6:49431037	CENPQ;MUT	0.51	6.6	0.4	2.72e-10	Breast cancer;
SARC	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg12751644	chr20:60527061	NA	0.38	4.8	0.3	2.88e-6	Obesity-related traits;
SARC	cis	rs2177596	0.617	rs13411764	chr2:227935910	A/G	cg11843606	chr2:227700838	RHBDD1	-0.45	-4.91	-0.31	1.69e-6	Body mass index;
SARC	trans	rs11250098	0.583	rs66724331	chr8:10789345	C/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.58	-0.4	3.03e-10	Morning vs. evening chronotype;
SARC	cis	rs763121	0.889	rs4820335	chr22:38935927	C/G	cg06022373	chr22:39101656	GTPBP1	-0.74	-9.31	-0.52	1.01e-17	Menopause (age at onset);
SARC	cis	rs9291683	0.546	rs13129453	chr4:10044784	T/C	cg11266682	chr4:10021025	SLC2A9	0.4	6.91	0.41	4.53e-11	Bone mineral density;
SARC	cis	rs17023223	0.537	rs2794313	chr1:119587440	T/C	cg05756136	chr1:119680316	WARS2	-0.45	-5.44	-0.34	1.35e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs11264799	0.520	rs861998	chr1:157543878	G/A	cg18268488	chr1:157545234	FCRL4	0.31	5.51	0.34	9.48e-8	IgA nephropathy;
SARC	cis	rs4718428	0.672	rs4718412	chr7:66286867	C/T	cg18252515	chr7:66147081	NA	0.53	5.72	0.35	3.25e-8	Corneal structure;
SARC	cis	rs4481887	1.000	rs4474293	chr1:248470438	T/C	cg01631408	chr1:248437212	OR2T33	-0.42	-5.3	-0.33	2.68e-7	Common traits (Other);
SARC	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.81	-11.89	-0.61	8.87e-26	Chronic sinus infection;
SARC	cis	rs965469	0.947	rs6051773	chr20:3330382	C/G	cg25506879	chr20:3388711	C20orf194	-0.51	-5.21	-0.32	4.1e-7	IFN-related cytopenia;
SARC	cis	rs7113850	0.541	rs74702708	chr11:24226866	T/C	ch.11.24196551F	chr11:24239977	NA	0.74	5.6	0.34	5.87e-8	Bone fracture in osteoporosis;
SARC	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg27266027	chr21:40555129	PSMG1	-0.49	-5.47	-0.34	1.15e-7	Cognitive function;
SARC	cis	rs826838	0.586	rs10785554	chr12:38628749	T/A	cg13010199	chr12:38710504	ALG10B	0.51	6.5	0.39	4.9e-10	Heart rate;
SARC	trans	rs656319	0.559	rs17689007	chr8:9974824	G/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.31	-0.43	4.25e-12	Myopia (pathological);
SARC	cis	rs11711311	0.955	rs9881563	chr3:113414031	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.68	-8.43	-0.48	3.6e-15	IgG glycosylation;
SARC	cis	rs1124376	1.000	rs11712709	chr3:20139777	G/C	cg05072819	chr3:20081367	KAT2B	0.5	4.72	0.3	4.16e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs6901004	0.570	rs783084	chr6:111477887	T/C	cg15721981	chr6:111408429	SLC16A10	0.6	7.02	0.42	2.4e-11	Blood metabolite levels;
SARC	cis	rs10078	0.571	rs2721014	chr5:463539	G/A	cg08916839	chr5:415575	AHRR	0.84	8.0	0.46	5.66e-14	Fat distribution (HIV);
SARC	cis	rs698833	0.509	rs1372080	chr2:44540241	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.6	6.83	0.41	7.53e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs7246657	0.508	rs1644702	chr19:37491907	C/T	cg14683738	chr19:37701593	ZNF585B	0.56	4.9	0.31	1.79e-6	Coronary artery calcification;
SARC	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg24531977	chr5:56204891	C5orf35	-0.54	-5.45	-0.34	1.26e-7	Initial pursuit acceleration;
SARC	cis	rs8114671	0.562	rs2378294	chr20:33500378	G/A	cg08999081	chr20:33150536	PIGU	0.33	4.91	0.31	1.72e-6	Height;
SARC	cis	rs7647973	1.000	rs62261249	chr3:49594060	T/C	cg07636037	chr3:49044803	WDR6	-0.74	-7.75	-0.45	2.89e-13	Menarche (age at onset);
SARC	cis	rs2153535	0.601	rs4140585	chr6:8503298	T/A	cg21535247	chr6:8435926	SLC35B3	0.58	7.28	0.43	4.95e-12	Motion sickness;
SARC	cis	rs6831352	0.918	rs29001224	chr4:100047373	G/A	cg12011299	chr4:100065546	ADH4	-0.34	-5.66	-0.35	4.44e-8	Alcohol dependence;
SARC	cis	rs959260	1.000	rs2891713	chr17:73386622	G/C	cg14668889	chr17:73230827	NUP85	-0.43	-4.74	-0.3	3.7e-6	Systemic lupus erythematosus;
SARC	cis	rs13034020	0.641	rs34230978	chr2:61221523	A/T	cg18625361	chr2:61244694	PEX13;PUS10	0.7	5.61	0.35	5.68e-8	Hodgkin's lymphoma;
SARC	trans	rs6695352	0.802	rs12026786	chr1:214969949	C/T	cg20253302	chr4:186288186	LRP2BP	0.46	6.45	0.39	6.32e-10	Migraine without aura;
SARC	cis	rs6910061	1.000	rs34846077	chr6:11096561	G/A	cg27233058	chr6:11094804	LOC221710	0.58	5.56	0.34	7.5e-8	Diabetic kidney disease;
SARC	cis	rs892961	0.932	rs3987887	chr17:75414862	T/C	cg05865280	chr17:75406074	SEPT9	0.55	8.02	0.46	5.22e-14	Airflow obstruction;
SARC	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.57	5.34	0.33	2.24e-7	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs1552244	0.554	rs3846169	chr3:9997054	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.47	-5.81	-0.36	2.04e-8	Alzheimer's disease;
SARC	cis	rs8072100	0.905	rs8077106	chr17:45653291	T/G	cg08085267	chr17:45401833	C17orf57	0.41	4.79	0.3	3e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg24829409	chr8:58192753	C8orf71	-0.62	-6.42	-0.39	7.57e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs12477438	1.000	rs6542873	chr2:99824965	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-8.42	-0.48	3.91e-15	Chronic sinus infection;
SARC	cis	rs4481887	0.962	rs12037921	chr1:248454167	T/G	cg00666640	chr1:248458726	OR2T12	0.35	5.72	0.35	3.2e-8	Common traits (Other);
SARC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg11062466	chr8:58055876	NA	0.54	5.53	0.34	8.37e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2760061	0.505	rs708109	chr1:228190657	C/T	cg01200585	chr1:228362443	C1orf69	0.46	5.69	0.35	3.75e-8	Diastolic blood pressure;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg20865740	chr3:119063744	CDGAP	0.42	6.32	0.38	1.3e-9	Thyroid stimulating hormone;
SARC	cis	rs7647973	1.000	rs73088137	chr3:49448423	G/A	cg07636037	chr3:49044803	WDR6	-0.74	-7.54	-0.44	1.06e-12	Menarche (age at onset);
SARC	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg19077165	chr18:44547161	KATNAL2	-0.56	-7.75	-0.45	2.75e-13	Personality dimensions;
SARC	cis	rs9527	0.615	rs7089065	chr10:104723022	C/T	cg04362960	chr10:104952993	NT5C2	0.4	4.73	0.3	3.95e-6	Arsenic metabolism;
SARC	cis	rs7945705	0.712	rs61876274	chr11:9019190	A/T	cg21881798	chr11:8931708	C11orf17;ST5	0.41	5.73	0.35	3.15e-8	Hemoglobin concentration;
SARC	cis	rs116095464	1.000	rs6555159	chr5:311562	G/A	cg22857025	chr5:266934	NA	-1.12	-8.86	-0.5	2.04e-16	Breast cancer;
SARC	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	10.68	0.57	6.06e-22	Platelet count;
SARC	trans	rs1865760	0.929	rs9461224	chr6:25936402	G/T	cg21893314	chr15:40453133	BUB1B	-0.56	-6.85	-0.41	6.39e-11	Height;
SARC	cis	rs12142240	0.698	rs72679807	chr1:46846490	G/A	cg14993813	chr1:46806288	NSUN4	-0.52	-5.56	-0.34	7.46e-8	Menopause (age at onset);
SARC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg10295955	chr4:187884368	NA	-1.07	-20.16	-0.8	5.35e-53	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6456156	0.586	rs10946208	chr6:167459596	C/T	cg07741184	chr6:167504864	NA	0.36	6.83	0.41	7.23e-11	Primary biliary cholangitis;
SARC	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg12463550	chr7:65579703	CRCP	0.64	4.92	0.31	1.65e-6	Diabetic kidney disease;
SARC	cis	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg22496380	chr5:211416	CCDC127	-0.88	-9.19	-0.52	2.18e-17	Breast cancer;
SARC	cis	rs561341	0.602	rs114562703	chr17:30233899	G/T	cg13647721	chr17:30228624	UTP6	0.67	6.4	0.39	8.36e-10	Hip circumference adjusted for BMI;
SARC	cis	rs9457247	1.000	rs1794693	chr6:167405670	T/C	cg07741184	chr6:167504864	NA	0.29	5.55	0.34	7.72e-8	Crohn's disease;
SARC	cis	rs1570884	0.516	rs7330830	chr13:50167929	T/A	cg08779649	chr13:50194554	NA	0.38	6.69	0.4	1.67e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs554111	0.593	rs9426660	chr1:21520449	A/G	cg08890418	chr1:21044141	KIF17	0.37	5.03	0.31	9.75e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs7714584	1.000	rs4958424	chr5:150225036	C/T	cg22134413	chr5:150180641	NA	0.78	6.56	0.39	3.42e-10	Crohn's disease;
SARC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg26338869	chr17:61819248	STRADA	0.78	10.45	0.57	3.21e-21	Prudent dietary pattern;
SARC	cis	rs4509693	1.000	rs4277047	chr10:102499416	T/A	cg15234845	chr10:102496500	NA	0.32	4.86	0.3	2.13e-6	Alzheimer's disease;
SARC	cis	rs61823972	0.547	rs12048743	chr1:205114873	C/G	cg00857998	chr1:205179979	DSTYK	0.43	5.48	0.34	1.11e-7	Immature fraction of reticulocytes;Mean corpuscular volume;Mean corpuscular hemoglobin;Mean corpuscular hemoglobin concentration;High light scatter reticulocyte count;
SARC	cis	rs2075371	1.000	rs1421486	chr7:133985196	T/C	cg00033643	chr7:134001901	SLC35B4	0.4	4.85	0.3	2.25e-6	Mean platelet volume;
SARC	cis	rs6570726	1.000	rs405622	chr6:145871897	G/T	cg05220968	chr6:146057943	EPM2A	-0.29	-4.91	-0.31	1.72e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg21724239	chr8:58056113	NA	0.63	6.38	0.39	9.53e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs10876993	0.784	rs7314152	chr12:58017701	T/G	cg18357645	chr12:58087776	OS9	-0.42	-5.36	-0.33	2.01e-7	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs7246657	1.000	rs6508710	chr19:37749886	A/G	cg14683738	chr19:37701593	ZNF585B	0.59	5.55	0.34	7.69e-8	Coronary artery calcification;
SARC	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg17971929	chr21:40555470	PSMG1	0.99	13.94	0.67	1.56e-32	Cognitive function;
SARC	cis	rs1042058	0.565	rs2480297	chr10:30754512	A/G	cg25182066	chr10:30743637	MAP3K8	0.44	6.35	0.38	1.11e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs3820928	0.874	rs7582251	chr2:227791703	G/T	cg05526886	chr2:227700861	RHBDD1	-0.54	-6.65	-0.4	2.04e-10	Pulmonary function;
SARC	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg16414030	chr3:133502952	NA	0.4	5.5	0.34	9.85e-8	Iron status biomarkers;
SARC	cis	rs1707322	1.000	rs11211237	chr1:46447329	G/C	cg03146154	chr1:46216737	IPP	0.45	5.41	0.33	1.57e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6058796	1.000	rs6141781	chr20:31263342	C/T	cg13636640	chr20:31349939	DNMT3B	0.58	5.18	0.32	4.89e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg06636001	chr8:8085503	FLJ10661	0.91	13.62	0.67	1.81e-31	Systolic blood pressure;
SARC	cis	rs526231	0.511	rs158402	chr5:102415525	G/A	cg23492399	chr5:102201601	PAM	-0.5	-5.42	-0.33	1.49e-7	Primary biliary cholangitis;
SARC	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg21724239	chr8:58056113	NA	0.75	6.81	0.41	7.99e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs9868809	0.772	rs9809222	chr3:48714411	C/T	cg12468774	chr3:49236860	CCDC36	0.45	4.77	0.3	3.18e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg11764359	chr7:65958608	NA	0.81	11.08	0.59	3.31e-23	Aortic root size;
SARC	cis	rs7223966	0.921	rs67018565	chr17:61928055	C/A	cg00588841	chr17:61851480	DDX42;CCDC47	-0.62	-6.67	-0.4	1.87e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg20102877	chr2:27665638	KRTCAP3	-0.37	-5.25	-0.33	3.44e-7	Total body bone mineral density;
SARC	cis	rs57920188	0.703	rs10915642	chr1:4089244	T/C	cg20703997	chr1:4087676	NA	0.44	4.77	0.3	3.29e-6	Interleukin-17 levels;
SARC	cis	rs870825	0.616	rs10006828	chr4:185651416	C/T	cg04058563	chr4:185651563	MLF1IP	0.8	11.37	0.6	3.9e-24	Blood protein levels;
SARC	cis	rs7726839	0.794	rs6883536	chr5:599274	G/A	cg09021430	chr5:549028	NA	-0.47	-7.06	-0.42	1.88e-11	Obesity-related traits;
SARC	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-7.01	-0.42	2.61e-11	Gut microbiome composition (summer);
SARC	cis	rs11997175	0.646	rs2006792	chr8:33694423	G/A	ch.8.33884649F	chr8:33765107	NA	0.63	8.6	0.49	1.21e-15	Body mass index;
SARC	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg18252515	chr7:66147081	NA	0.44	4.82	0.3	2.56e-6	Aortic root size;
SARC	cis	rs17376456	0.877	rs10064520	chr5:93427358	T/C	cg21475434	chr5:93447410	FAM172A	0.86	7.71	0.45	3.65e-13	Diabetic retinopathy;
SARC	cis	rs13191362	1.000	rs67747005	chr6:163150845	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.59	5.4	0.33	1.65e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg06420487	chr17:61919686	SMARCD2	0.49	5.71	0.35	3.46e-8	Height;
SARC	cis	rs7552404	0.731	rs12078299	chr1:76365764	T/A	cg10523679	chr1:76189770	ACADM	0.47	5.4	0.33	1.66e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg18418962	chr18:2571633	METTL4;NDC80	-0.44	-4.9	-0.31	1.84e-6	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs4853036	0.951	rs13011127	chr2:70040147	T/C	cg02498382	chr2:70120550	SNRNP27	-0.37	-4.96	-0.31	1.36e-6	Colorectal or endometrial cancer;
SARC	cis	rs7512552	0.839	rs12045304	chr1:150399818	G/A	cg15654264	chr1:150340011	RPRD2	0.4	5.14	0.32	5.86e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs6088813	1.000	rs6088813	chr20:33975181	C/A	cg23207816	chr20:34252616	CPNE1;RBM12	-0.43	-5.24	-0.32	3.67e-7	Height;
SARC	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg12463550	chr7:65579703	CRCP	0.67	5.06	0.31	8.43e-7	Diabetic kidney disease;
SARC	cis	rs2153535	0.580	rs1414349	chr6:8472290	A/G	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	cis	rs677665	0.537	rs12121476	chr1:9335327	C/G	cg25755851	chr1:9335794	NA	0.61	8.54	0.49	1.77e-15	Eosinophil percentage of white cells;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg15727308	chr3:123752836	NA	-0.72	-6.33	-0.38	1.23e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs12908161	0.960	rs11633450	chr15:85307287	C/T	cg17507749	chr15:85114479	UBE2QP1	0.52	5.59	0.34	6.46e-8	Schizophrenia;
SARC	cis	rs611744	0.647	rs1448151	chr8:109276283	C/A	cg21045802	chr8:109455806	TTC35	0.61	7.54	0.44	1.06e-12	Dupuytren's disease;
SARC	cis	rs7568458	0.783	rs1561198	chr2:85809989	C/T	cg17127132	chr2:85788382	GGCX	0.48	6.76	0.41	1.08e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs2239547	0.657	rs2276817	chr3:52860936	C/T	cg18404041	chr3:52824283	ITIH1	-0.42	-5.01	-0.31	1.05e-6	Schizophrenia;
SARC	trans	rs877282	1.000	rs11253369	chr10:773610	C/G	cg22713356	chr15:30763199	NA	0.72	7.21	0.43	7.99e-12	Uric acid levels;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg11081941	chr7:30518533	NOD1	0.65	6.74	0.4	1.22e-10	Lung cancer in ever smokers;
SARC	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg09699651	chr6:150184138	LRP11	0.39	4.86	0.3	2.19e-6	Lung cancer;
SARC	cis	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg06558623	chr16:89946397	TCF25	0.92	6.39	0.39	8.93e-10	Skin colour saturation;
SARC	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg21724239	chr8:58056113	NA	0.57	6.08	0.37	4.82e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7662987	0.517	rs4235436	chr4:100039620	G/A	cg13256891	chr4:100009986	ADH5	0.68	8.61	0.49	1.13e-15	Smoking initiation;
SARC	cis	rs7927592	0.956	rs12277225	chr11:68340967	T/C	cg01657329	chr11:68192670	LRP5	-0.4	-4.86	-0.3	2.12e-6	Total body bone mineral density;
SARC	cis	rs7826238	0.653	rs2979202	chr8:8344127	T/C	cg08975724	chr8:8085496	FLJ10661	0.52	6.92	0.41	4.23e-11	Systolic blood pressure;
SARC	cis	rs9291683	0.530	rs4697698	chr4:9942577	C/T	cg00071950	chr4:10020882	SLC2A9	0.42	6.72	0.4	1.37e-10	Bone mineral density;
SARC	cis	rs6933660	0.646	rs6911456	chr6:151778934	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.66	8.86	0.5	2.06e-16	Menarche (age at onset);
SARC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg20119798	chr7:94954144	PON1	-0.35	-4.81	-0.3	2.66e-6	Paraoxonase activity;
SARC	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs8114671	0.562	rs959829	chr20:33346047	T/C	cg08999081	chr20:33150536	PIGU	-0.32	-4.77	-0.3	3.27e-6	Height;
SARC	cis	rs16854884	0.657	rs35796781	chr3:143731662	T/C	cg06585982	chr3:143692056	C3orf58	0.63	8.44	0.48	3.36e-15	Economic and political preferences (feminism/equality);
SARC	cis	rs739401	0.572	rs389285	chr11:3062673	G/A	cg25174290	chr11:3078921	CARS	0.59	8.33	0.48	7.07e-15	Longevity;
SARC	cis	rs2304069	0.545	rs7728248	chr5:149394965	A/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.44	4.94	0.31	1.46e-6	HIV-1 control;
SARC	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg16606324	chr3:10149918	C3orf24	0.48	5.2	0.32	4.43e-7	Alzheimer's disease;
SARC	cis	rs854765	0.647	rs854790	chr17:18028318	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.56	7.54	0.44	1.06e-12	Total body bone mineral density;
SARC	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg12064134	chr16:90016061	DEF8	-0.57	-4.76	-0.3	3.38e-6	Skin colour saturation;
SARC	cis	rs2120019	0.567	rs28844983	chr15:75178088	T/A	cg12414181	chr15:75287860	SCAMP5	-0.52	-4.93	-0.31	1.57e-6	Blood trace element (Zn levels);
SARC	cis	rs9638182	1.000	rs34594435	chr7:72977249	C/T	cg07467649	chr7:72856462	BAZ1B	0.46	4.82	0.3	2.53e-6	Triglycerides;
SARC	cis	rs10779751	0.770	rs1057079	chr1:11205058	A/G	cg04508216	chr1:11107452	MASP2	-0.33	-4.78	-0.3	3.04e-6	Body mass index;
SARC	cis	rs1865721	0.804	rs59187673	chr18:73143964	A/G	cg26385618	chr18:73139727	C18orf62	-0.38	-5.24	-0.32	3.6e-7	Intelligence;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg04707863	chr7:1706305	NA	-0.5	-6.53	-0.39	4.19e-10	Schizophrenia;
SARC	cis	rs10782582	0.609	rs5745430	chr1:76332994	C/T	cg03433033	chr1:76189801	ACADM	-0.37	-4.78	-0.3	3.13e-6	Daytime sleep phenotypes;
SARC	cis	rs6732160	0.613	rs59979991	chr2:73384422	G/A	cg01422370	chr2:73384389	NA	0.37	5.76	0.35	2.71e-8	Intelligence (multi-trait analysis);
SARC	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg16325326	chr1:53192061	ZYG11B	-0.81	-12.97	-0.65	2.49e-29	Monocyte count;
SARC	cis	rs10463316	0.894	rs13361298	chr5:150765549	T/C	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.28	-0.33	2.89e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg14784868	chr12:69753453	YEATS4	0.51	6.77	0.41	1.05e-10	Blood protein levels;
SARC	cis	rs2439831	0.850	rs16965120	chr15:44100342	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.76	7.41	0.44	2.29e-12	Lung cancer in ever smokers;
SARC	cis	rs2522056	1.000	rs2706339	chr5:131800105	G/T	cg24060327	chr5:131705240	SLC22A5	0.49	4.91	0.31	1.75e-6	Lymphocyte counts;Fibrinogen;
SARC	cis	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.42	-5.19	-0.32	4.61e-7	Eosinophil percentage of white cells;
SARC	cis	rs9815354	0.812	rs55916855	chr3:42002761	A/G	cg03022575	chr3:42003672	ULK4	0.71	6.03	0.37	6.5e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg05861140	chr6:150128134	PCMT1	-0.39	-5.03	-0.31	9.91e-7	Lung cancer;
SARC	trans	rs7742915	0.962	rs9462404	chr6:38156552	A/G	cg08826839	chr2:163100125	FAP	0.27	6.25	0.38	1.98e-9	Colorectal cancer;
SARC	cis	rs1957429	0.614	rs78603758	chr14:65396648	C/G	cg23373153	chr14:65346875	NA	-1.03	-6.42	-0.39	7.58e-10	Pediatric areal bone mineral density (radius);
SARC	cis	rs2729354	1.000	rs2848630	chr11:57356907	T/C	cg17237962	chr11:57479805	MED19;TMX2	0.47	4.74	0.3	3.71e-6	Blood protein levels;
SARC	cis	rs881375	0.933	rs7859805	chr9:123664123	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	4.87	0.3	2.03e-6	Rheumatoid arthritis;
SARC	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.49	5.59	0.34	6.49e-8	Renal function-related traits (BUN);
SARC	cis	rs2213920	0.619	rs7857548	chr9:118199365	C/T	cg13918206	chr9:118159781	DEC1	0.82	6.54	0.39	3.77e-10	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.43	5.26	0.33	3.23e-7	Bipolar disorder;
SARC	cis	rs2072499	0.966	rs6427304	chr1:156156789	A/G	cg25208724	chr1:156163844	SLC25A44	0.88	11.65	0.61	4.97e-25	Testicular germ cell tumor;
SARC	cis	rs3733589	0.590	rs35201034	chr4:10007451	C/G	cg16430538	chr4:10459836	ZNF518B	0.56	5.2	0.32	4.26e-7	Renal overload gout;
SARC	cis	rs2180341	0.814	rs9401958	chr6:127736357	T/G	cg27446573	chr6:127587934	RNF146	0.8	10.39	0.56	4.87e-21	Breast cancer;
SARC	cis	rs2075371	0.830	rs12669960	chr7:133931782	A/G	cg20476274	chr7:133979776	SLC35B4	0.51	6.39	0.39	8.79e-10	Mean platelet volume;
SARC	cis	rs7917772	0.636	rs2250580	chr10:104505687	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.57	6.42	0.39	7.57e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs9486719	0.948	rs2499813	chr6:96875338	T/C	cg06623918	chr6:96969491	KIAA0776	0.71	7.63	0.45	6.03e-13	Migraine;Coronary artery disease;
SARC	cis	rs11724804	0.532	rs62295557	chr4:855708	G/A	cg08222618	chr4:941054	TMEM175	0.38	4.92	0.31	1.64e-6	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
SARC	cis	rs11190604	1.000	rs11190589	chr10:102275471	A/G	cg07080220	chr10:102295463	HIF1AN	0.76	9.0	0.51	8.3e-17	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs2180341	1.000	rs6903878	chr6:127638600	C/G	cg17762328	chr6:126965162	NA	-0.45	-5.06	-0.31	8.34e-7	Breast cancer;
SARC	cis	rs67311347	0.544	rs13062243	chr3:40336789	G/A	cg24209194	chr3:40518798	ZNF619	0.48	6.42	0.39	7.46e-10	Renal cell carcinoma;
SARC	cis	rs11716531	0.573	rs642570	chr3:27342595	C/G	cg02860705	chr3:27208620	NA	0.45	6.02	0.37	6.73e-9	Diastolic blood pressure;
SARC	cis	rs9815354	1.000	rs6763829	chr3:41897046	A/G	cg03022575	chr3:42003672	ULK4	0.56	5.29	0.33	2.86e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9916302	0.904	rs12452880	chr17:37591149	G/C	cg15445000	chr17:37608096	MED1	0.43	5.1	0.32	6.92e-7	Glomerular filtration rate (creatinine);
SARC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg03395511	chr6:291903	DUSP22	-0.53	-6.8	-0.41	8.94e-11	Menopause (age at onset);
SARC	cis	rs9303401	0.538	rs3785493	chr17:56472119	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	-1.02	-10.06	-0.55	5.38e-20	Cognitive test performance;
SARC	cis	rs10465746	0.752	rs10874426	chr1:84451820	A/G	cg10977910	chr1:84465055	TTLL7	0.46	5.74	0.35	2.89e-8	Obesity-related traits;
SARC	cis	rs698833	0.509	rs4953096	chr2:44767402	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.4	5.14	0.32	5.69e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs8180040	0.967	rs17411375	chr3:47395135	C/T	cg27129171	chr3:47204927	SETD2	-0.7	-9.89	-0.54	1.77e-19	Colorectal cancer;
SARC	cis	rs854765	0.583	rs9912895	chr17:17826020	C/T	cg04398451	chr17:18023971	MYO15A	0.38	5.26	0.33	3.26e-7	Total body bone mineral density;
SARC	cis	rs17376456	0.877	rs12374463	chr5:93483569	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.62	5.28	0.33	3.02e-7	Diabetic retinopathy;
SARC	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg03709012	chr19:19516395	GATAD2A	1.0	17.43	0.75	3.97e-44	Tonsillectomy;
SARC	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg18876405	chr7:65276391	NA	0.68	8.54	0.49	1.77e-15	Aortic root size;
SARC	cis	rs1476670	0.710	rs2477616	chr1:44504809	G/A	cg09470012	chr1:44509516	NA	0.42	5.42	0.33	1.47e-7	Eotaxin levels;
SARC	cis	rs2963155	0.518	rs10515522	chr5:142758394	A/G	cg17617527	chr5:142782415	NR3C1	0.64	5.06	0.31	8.31e-7	Breast cancer;
SARC	trans	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg16531660	chr3:141457093	RNF7	0.47	6.29	0.38	1.58e-9	Immature fraction of reticulocytes;
SARC	cis	rs651907	0.514	rs55654108	chr3:101425703	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	6.42	0.39	7.64e-10	Colorectal cancer;
SARC	cis	rs875971	1.000	rs1144894	chr7:65542894	A/G	cg11764359	chr7:65958608	NA	-0.85	-11.95	-0.62	5.53e-26	Aortic root size;
SARC	cis	rs11651000	0.817	rs11657479	chr17:45822901	T/C	cg24803719	chr17:45855879	NA	-0.45	-6.6	-0.4	2.74e-10	IgG glycosylation;
SARC	cis	rs950776	0.518	rs2869544	chr15:78839400	G/A	cg06917634	chr15:78832804	PSMA4	-0.9	-13.92	-0.67	1.81e-32	Sudden cardiac arrest;
SARC	cis	rs9302635	0.816	rs7202323	chr16:72217113	T/G	cg01557791	chr16:72042693	DHODH	-0.49	-5.06	-0.31	8.43e-7	Blood protein levels;
SARC	cis	rs1348850	0.632	rs11678875	chr2:178509068	A/G	cg23306229	chr2:178417860	TTC30B	0.46	5.17	0.32	4.92e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs738322	0.839	rs9607517	chr22:38596100	G/A	cg25457927	chr22:38595422	NA	0.35	7.36	0.43	3.04e-12	Cutaneous nevi;
SARC	trans	rs61931739	0.890	rs1687020	chr12:34137924	G/C	cg26384229	chr12:38710491	ALG10B	0.6	7.93	0.46	9.2e-14	Morning vs. evening chronotype;
SARC	cis	rs9914544	0.524	rs8071147	chr17:18790678	A/G	cg25390199	chr17:18761479	PRPSAP2	0.46	6.05	0.37	5.66e-9	Educational attainment (years of education);
SARC	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg20607798	chr8:58055168	NA	0.73	6.15	0.37	3.38e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4243830	0.850	rs4908911	chr1:6599523	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.01	-9.9	-0.54	1.61e-19	Body mass index;
SARC	cis	rs1153858	0.943	rs7402632	chr15:45701913	A/T	cg15395560	chr15:45543142	SLC28A2	-0.26	-4.73	-0.3	3.9e-6	Homoarginine levels;
SARC	cis	rs4243830	0.737	rs56036909	chr1:6608503	C/T	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.61	-5.09	-0.32	7.38e-7	Body mass index;
SARC	cis	rs79149102	0.579	rs6495135	chr15:75295030	T/C	cg00629941	chr15:75287862	SCAMP5	-0.64	-5.11	-0.32	6.76e-7	Lung cancer;
SARC	cis	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg25427524	chr10:38739819	LOC399744	-0.61	-9.94	-0.55	1.26e-19	Extrinsic epigenetic age acceleration;
SARC	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg22535103	chr8:58192502	C8orf71	-0.6	-6.38	-0.39	9.22e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg11890956	chr21:40555474	PSMG1	1.18	19.61	0.79	3.1e-51	Cognitive function;
SARC	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg24531977	chr5:56204891	C5orf35	-0.52	-5.22	-0.32	4.03e-7	Initial pursuit acceleration;
SARC	cis	rs1707322	1.000	rs1768818	chr1:46514286	G/C	cg03146154	chr1:46216737	IPP	-0.47	-5.65	-0.35	4.59e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg00891125	chr16:53738439	FTO;RPGRIP1L	-0.56	-6.35	-0.38	1.11e-9	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs3213545	0.676	rs1179998	chr12:121483653	G/A	cg25281562	chr12:121454272	C12orf43	0.43	5.01	0.31	1.07e-6	Subjective well-being;Cardiovascular disease risk factors;
SARC	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg06074448	chr4:187884817	NA	-0.37	-5.09	-0.32	7.52e-7	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg06636001	chr8:8085503	FLJ10661	0.71	10.02	0.55	6.9e-20	Triglycerides;
SARC	cis	rs262150	0.503	rs11769917	chr7:158817498	C/T	cg19418458	chr7:158789849	NA	-0.41	-5.8	-0.36	2.15e-8	Facial morphology (factor 20);
SARC	cis	rs9894429	0.789	rs7219915	chr17:79591813	C/T	cg18240062	chr17:79603768	NPLOC4	0.88	13.71	0.67	9.24e-32	Eye color traits;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg26382848	chr14:23451889	JUB	0.54	7.33	0.43	3.75e-12	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs453301	0.686	rs1045527	chr8:8890041	A/G	cg11608241	chr8:8085544	FLJ10661	-0.43	-5.54	-0.34	8.09e-8	Joint mobility (Beighton score);
SARC	cis	rs600231	0.665	rs2846861	chr11:65222305	A/G	cg17120908	chr11:65337727	SSSCA1	-0.42	-5.35	-0.33	2.12e-7	Bone mineral density;
SARC	cis	rs2075671	0.903	rs62483570	chr7:100300649	C/T	cg16850897	chr7:100343110	ZAN	-0.64	-6.86	-0.41	6.32e-11	Other erythrocyte phenotypes;
SARC	cis	rs875971	0.520	rs12666485	chr7:65625122	T/C	cg25894440	chr7:65020034	NA	0.51	4.74	0.3	3.69e-6	Aortic root size;
SARC	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg18876405	chr7:65276391	NA	-0.47	-5.37	-0.33	1.9e-7	Aortic root size;
SARC	cis	rs9457247	0.967	rs402191	chr6:167405553	T/C	cg23791538	chr6:167370224	RNASET2	-0.63	-8.74	-0.5	4.69e-16	Crohn's disease;
SARC	cis	rs7044106	0.791	rs4836829	chr9:123482747	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	6.22	0.38	2.31e-9	Hip circumference adjusted for BMI;
SARC	cis	rs644799	0.540	rs10831422	chr11:95478968	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.57	6.91	0.41	4.7e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs1348850	0.567	rs3770011	chr2:178537890	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.43	5.06	0.31	8.56e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	9.08	0.51	4.64e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9303401	0.659	rs8074016	chr17:56840587	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.06	11.75	0.61	2.49e-25	Cognitive test performance;
SARC	cis	rs651907	0.535	rs11919389	chr3:101424458	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	6.42	0.39	7.64e-10	Colorectal cancer;
SARC	cis	rs2404602	0.716	rs17460201	chr15:76673627	C/T	cg22467129	chr15:76604101	ETFA	0.4	5.27	0.33	3.11e-7	Blood metabolite levels;
SARC	cis	rs7223966	1.000	rs8067064	chr17:61825984	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	7.12	0.42	1.33e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2204008	0.837	rs11168341	chr12:37961951	C/T	cg26384229	chr12:38710491	ALG10B	0.9	13.32	0.66	1.82e-30	Bladder cancer;
SARC	cis	rs3796352	1.000	rs2336541	chr3:52974630	G/C	cg12962167	chr3:53033115	SFMBT1	0.75	4.9	0.31	1.8e-6	Immune reponse to smallpox (secreted IL-2);
SARC	trans	rs61931739	0.620	rs708143	chr12:33719962	A/C	cg26384229	chr12:38710491	ALG10B	0.62	8.11	0.47	2.82e-14	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg22535103	chr8:58192502	C8orf71	-0.7	-8.43	-0.48	3.66e-15	Developmental language disorder (linguistic errors);
SARC	cis	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg12623918	chr2:306882	NA	0.3	5.08	0.32	7.76e-7	Spherical equivalent (joint analysis main effects and education interaction);
SARC	cis	rs7819412	0.521	rs10110684	chr8:11039159	G/C	cg12395012	chr8:11607386	GATA4	0.32	5.59	0.34	6.47e-8	Triglycerides;
SARC	cis	rs505401	0.554	rs28479876	chr19:6087009	T/C	cg18109231	chr19:6110877	RFX2	0.8	5.36	0.33	1.97e-7	Mean platelet volume;
SARC	cis	rs4568518	0.869	rs12699944	chr7:18037784	A/T	cg00911873	chr7:18067463	PRPS1L1	-0.33	-4.72	-0.3	4.15e-6	Measles;
SARC	cis	rs34779708	0.966	rs878264	chr10:35440581	T/C	cg03585969	chr10:35415529	CREM	0.38	4.92	0.31	1.62e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	14.0	0.68	9.94e-33	Chronic sinus infection;
SARC	cis	rs3784262	1.000	rs4646593	chr15:58302467	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.39	-5.88	-0.36	1.44e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs1008375	1.000	rs4698648	chr4:17692715	C/G	cg27347728	chr4:17578864	LAP3	0.46	5.74	0.35	2.94e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9393777	0.513	rs13190754	chr6:26587406	G/A	cg12292205	chr6:26970375	C6orf41	-0.52	-4.79	-0.3	3.01e-6	Intelligence (multi-trait analysis);
SARC	cis	rs6815814	0.851	rs11736207	chr4:38766285	G/A	cg02016764	chr4:38805732	TLR1	-0.44	-4.79	-0.3	2.93e-6	Breast cancer;
SARC	cis	rs7044106	0.664	rs7861679	chr9:123375589	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.62	-7.7	-0.45	3.84e-13	Hip circumference adjusted for BMI;
SARC	cis	rs8180040	1.000	rs807936	chr3:47322496	C/T	cg27129171	chr3:47204927	SETD2	0.67	9.24	0.52	1.54e-17	Colorectal cancer;
SARC	cis	rs1691799	0.899	rs1168318	chr12:66745269	A/G	cg16791601	chr12:66731901	HELB	0.77	11.86	0.61	1.04e-25	White blood cell count (basophil);
SARC	cis	rs6834538	0.597	rs9991830	chr4:113485372	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.53	7.15	0.42	1.1e-11	Free thyroxine concentration;
SARC	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg07343612	chr16:622815	PIGQ	-0.59	-8.38	-0.48	4.98e-15	Height;
SARC	cis	rs36051895	0.632	rs9657576	chr9:5183028	T/G	cg02405213	chr9:5042618	JAK2	-0.45	-5.24	-0.32	3.53e-7	Pediatric autoimmune diseases;
SARC	cis	rs7762018	0.505	rs79843499	chr6:170068420	A/G	cg19338460	chr6:170058176	WDR27	-0.81	-5.74	-0.35	2.88e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs7615952	0.688	rs4422259	chr3:125545831	C/T	cg05084668	chr3:125655381	ALG1L	-0.48	-5.16	-0.32	5.25e-7	Blood pressure (smoking interaction);
SARC	cis	rs2635047	0.967	rs2576056	chr18:44675462	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.54	7.24	0.43	6.57e-12	Educational attainment;
SARC	cis	rs3741404	0.609	rs592271	chr11:63872029	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	9.05	0.51	5.95e-17	Platelet count;
SARC	cis	rs3858526	0.883	rs11039686	chr11:5948725	T/C	cg13902645	chr11:5959945	NA	-0.44	-5.21	-0.32	4.25e-7	DNA methylation (variation);
SARC	cis	rs2273669	0.915	rs4992383	chr6:109292816	C/A	cg05315195	chr6:109294784	ARMC2	-0.49	-4.88	-0.3	1.94e-6	Prostate cancer;
SARC	trans	rs2495478	1.000	rs2495479	chr1:55511068	T/C	cg03587650	chr8:58057665	NA	0.86	6.47	0.39	5.56e-10	Wilms tumor;
SARC	cis	rs2916247	0.865	rs7834277	chr8:93110255	A/G	cg10183463	chr8:93005414	RUNX1T1	0.48	5.19	0.32	4.5e-7	Intelligence (multi-trait analysis);
SARC	cis	rs59918340	0.764	rs4961258	chr8:142232878	A/G	cg18755752	chr8:142205143	DENND3	0.33	4.72	0.3	4.11e-6	Immature fraction of reticulocytes;
SARC	cis	rs7937682	0.824	rs510866	chr11:111484113	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.89	-14.14	-0.68	3.36e-33	Primary sclerosing cholangitis;
SARC	cis	rs818427	0.737	rs448162	chr5:112182691	A/G	cg07820702	chr5:112228657	REEP5	0.44	4.92	0.31	1.61e-6	Total body bone mineral density;
SARC	cis	rs6137287	0.924	rs6047273	chr20:21134799	A/G	cg22058250	chr20:21685842	PAX1	-0.4	-4.81	-0.3	2.67e-6	Height;
SARC	cis	rs10791097	0.694	rs4264159	chr11:130755784	G/T	cg12179176	chr11:130786555	SNX19	0.76	11.24	0.59	1.03e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs2832191	0.967	rs2898160	chr21:30487496	A/G	cg24692254	chr21:30365293	RNF160	-0.78	-10.9	-0.58	1.28e-22	Dental caries;
SARC	cis	rs1712517	0.873	rs1712510	chr10:105009086	A/G	cg05636881	chr10:105038444	INA	-0.32	-4.74	-0.3	3.67e-6	Migraine;
SARC	cis	rs2814982	0.605	rs114032116	chr6:34468333	C/T	cg17674042	chr6:34482479	PACSIN1	-0.57	-4.9	-0.31	1.81e-6	Cholesterol, total;Total cholesterol levels;
SARC	cis	rs9467711	0.584	rs34391493	chr6:26022648	A/C	cg21479132	chr6:26055353	NA	0.96	7.01	0.42	2.61e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs735396	0.770	rs2259820	chr12:121435342	C/T	cg02403541	chr12:121454288	C12orf43	0.85	12.54	0.63	6.59e-28	N-glycan levels;
SARC	cis	rs9341808	0.556	rs2223875	chr6:81045452	C/T	cg08355045	chr6:80787529	NA	0.33	5.18	0.32	4.81e-7	Sitting height ratio;
SARC	cis	rs2952156	0.920	rs2941506	chr17:37833035	A/G	cg20243544	chr17:37824526	PNMT	0.54	7.21	0.43	7.62e-12	Asthma;
SARC	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg20887711	chr4:1340912	KIAA1530	0.52	6.32	0.38	1.32e-9	Longevity;
SARC	cis	rs7681440	0.583	rs2619362	chr4:90757845	C/T	cg06632027	chr4:90757378	SNCA	-0.43	-5.34	-0.33	2.16e-7	Dementia with Lewy bodies;
SARC	cis	rs10504229	0.679	rs12679920	chr8:58051710	G/T	cg08280861	chr8:58055591	NA	0.54	4.98	0.31	1.26e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg16325326	chr1:53192061	ZYG11B	0.8	12.86	0.64	6.05e-29	Monocyte count;
SARC	cis	rs9715521	0.867	rs7437815	chr4:59826005	T/C	cg11281224	chr4:60001000	NA	-0.38	-4.85	-0.3	2.23e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg08219700	chr8:58056026	NA	0.52	5.66	0.35	4.52e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9911578	1.000	rs12952832	chr17:56906254	T/C	cg05425664	chr17:57184151	TRIM37	-0.63	-7.79	-0.45	2.23e-13	Intelligence (multi-trait analysis);
SARC	cis	rs35955747	0.902	rs131202	chr22:31709309	A/C	cg13145458	chr22:31556086	RNF185	-0.39	-4.92	-0.31	1.65e-6	Neutrophil count;Sum basophil neutrophil counts;
SARC	cis	rs9788682	0.694	rs3825845	chr15:78910258	C/T	cg24631222	chr15:78858424	CHRNA5	0.67	8.53	0.49	1.92e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs67460515	0.892	rs11710489	chr3:161093332	G/A	cg04691961	chr3:161091175	C3orf57	-0.53	-6.6	-0.4	2.72e-10	Parkinson's disease;
SARC	cis	rs7551222	0.749	rs7532236	chr1:204561617	A/G	cg20240347	chr1:204465584	NA	0.29	5.24	0.32	3.62e-7	Schizophrenia;
SARC	cis	rs7582180	0.629	rs13031906	chr2:100939524	T/C	cg14675211	chr2:100938903	LONRF2	0.52	7.71	0.45	3.58e-13	Intelligence (multi-trait analysis);
SARC	cis	rs4132509	1.000	rs3766673	chr1:243720473	T/C	cg21452805	chr1:244014465	NA	0.52	5.85	0.36	1.69e-8	RR interval (heart rate);
SARC	cis	rs57506017	0.585	rs12699332	chr7:12269762	G/T	cg23422036	chr7:12250390	TMEM106B	0.45	5.87	0.36	1.49e-8	Neuroticism;
SARC	cis	rs9653442	0.835	rs1561230	chr2:100746642	C/T	cg22139774	chr2:100720529	AFF3	0.27	4.71	0.3	4.19e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
SARC	cis	rs2147959	0.700	rs12725863	chr1:228630986	C/T	cg16894439	chr1:228634806	NA	-0.44	-4.74	-0.3	3.74e-6	Adult asthma;
SARC	cis	rs9457247	0.602	rs13204839	chr6:167471119	G/A	cg23791538	chr6:167370224	RNASET2	-0.53	-7.01	-0.42	2.51e-11	Crohn's disease;
SARC	cis	rs910316	0.935	rs2268620	chr14:75640403	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.5	-6.83	-0.41	7.28e-11	Height;
SARC	cis	rs2766692	1.000	rs4905941	chr14:100725438	A/G	cg14866419	chr14:100704911	YY1	0.6	7.23	0.43	6.83e-12	Electroencephalographic traits in alcoholism;
SARC	cis	rs12477438	0.765	rs28648058	chr2:99696417	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.92	-14.56	-0.69	1.35e-34	Chronic sinus infection;
SARC	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg11890956	chr21:40555474	PSMG1	-1.04	-15.37	-0.71	2.75e-37	Cognitive function;
SARC	cis	rs1215050	0.791	rs165254	chr4:98763564	C/T	cg05340658	chr4:99064831	C4orf37	0.44	5.85	0.36	1.62e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg22496380	chr5:211416	CCDC127	-0.84	-8.6	-0.49	1.19e-15	Breast cancer;
SARC	cis	rs6484504	0.532	rs7116443	chr11:31283170	T/C	cg26647111	chr11:31128758	NA	-0.39	-5.09	-0.32	7.22e-7	Red blood cell count;
SARC	cis	rs6788895	1.000	rs6769917	chr3:150509604	A/T	cg09723797	chr3:150481914	SIAH2	-0.86	-5.51	-0.34	9.54e-8	Breast cancer;
SARC	cis	rs11792861	0.541	rs838824	chr9:111670707	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.65	-8.27	-0.48	1.04e-14	Menarche (age at onset);
SARC	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg08219700	chr8:58056026	NA	0.7	6.57	0.4	3.22e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs12681288	0.550	rs4272405	chr8:959014	C/G	cg15309053	chr8:964076	NA	0.47	7.81	0.46	1.91e-13	Schizophrenia;
SARC	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg27588902	chr6:42928151	GNMT	-0.36	-5.36	-0.33	2.01e-7	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.35	-5.23	-0.32	3.72e-7	Longevity;Endometriosis;
SARC	cis	rs12893668	0.703	rs35026580	chr14:104042753	A/G	cg26031613	chr14:104095156	KLC1	-0.57	-6.31	-0.38	1.38e-9	Reticulocyte count;
SARC	cis	rs7819412	0.502	rs4841499	chr8:10988138	A/C	cg12395012	chr8:11607386	GATA4	0.3	4.75	0.3	3.59e-6	Triglycerides;
SARC	trans	rs1853207	1.000	rs76063586	chr10:96642431	C/G	cg02737782	chr1:8014393	NA	-0.97	-6.42	-0.39	7.44e-10	Blood metabolite levels;
SARC	cis	rs7568458	0.837	rs3770098	chr2:85805367	C/A	cg17127132	chr2:85788382	GGCX	0.44	5.8	0.36	2.17e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs6570726	0.934	rs430003	chr6:145819506	C/T	cg05347473	chr6:146136440	FBXO30	0.49	6.48	0.39	5.27e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4841097	0.806	rs6992247	chr8:8948469	G/T	cg08975724	chr8:8085496	FLJ10661	0.41	5.13	0.32	6.22e-7	Platelet distribution width;
SARC	cis	rs503734	0.502	rs348861	chr3:100955259	G/A	cg27318481	chr3:100970896	IMPG2	-0.47	-5.53	-0.34	8.67e-8	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs11785400	0.793	rs6996760	chr8:143722386	G/A	cg10596483	chr8:143751796	JRK	0.58	7.53	0.44	1.08e-12	Schizophrenia;
SARC	cis	rs12142240	0.698	rs57267378	chr1:46816644	A/G	cg00530320	chr1:46809349	NSUN4	0.57	6.92	0.41	4.4e-11	Menopause (age at onset);
SARC	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg05861140	chr6:150128134	PCMT1	-0.42	-5.44	-0.34	1.32e-7	Lung cancer;
SARC	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg09455208	chr3:40491958	NA	0.38	5.61	0.34	5.73e-8	Renal cell carcinoma;
SARC	cis	rs9325144	0.555	rs7301258	chr12:38706942	C/T	cg10518543	chr12:38710700	ALG10B	0.42	5.28	0.33	3.01e-7	Morning vs. evening chronotype;
SARC	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg24549020	chr5:56110836	MAP3K1	0.72	7.41	0.44	2.3e-12	Initial pursuit acceleration;
SARC	cis	rs6120849	0.586	rs2025096	chr20:33540000	G/A	cg06115741	chr20:33292138	TP53INP2	0.54	5.34	0.33	2.26e-7	Protein C levels;
SARC	cis	rs1003719	0.715	rs13046581	chr21:38551985	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.21	-0.52	1.95e-17	Eye color traits;
SARC	cis	rs3857067	0.806	rs6532471	chr4:95108584	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.07	-0.32	8.15e-7	QT interval;
SARC	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.44	-5.57	-0.34	6.95e-8	Personality dimensions;
SARC	cis	rs3771570	0.901	rs10190033	chr2:242412358	A/C	cg21155796	chr2:242212141	HDLBP	0.52	5.34	0.33	2.21e-7	Prostate cancer;
SARC	cis	rs2072499	0.931	rs1052053	chr1:156202173	A/G	cg24450063	chr1:156163899	SLC25A44	1.05	16.05	0.72	1.53e-39	Testicular germ cell tumor;
SARC	cis	rs909674	0.734	rs5757675	chr22:39838892	G/T	cg05872129	chr22:39784769	NA	-0.42	-5.8	-0.35	2.2e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs6087990	0.966	rs1883730	chr20:31337487	T/A	cg13636640	chr20:31349939	DNMT3B	0.8	13.03	0.65	1.64e-29	Ulcerative colitis;
SARC	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg11644478	chr21:40555479	PSMG1	1.02	14.38	0.69	5.5e-34	Cognitive function;
SARC	cis	rs7084402	0.967	rs1620404	chr10:60327830	G/A	cg07615347	chr10:60278583	BICC1	0.58	8.58	0.49	1.36e-15	Refractive error;
SARC	cis	rs2652834	1.000	rs34575783	chr15:63397686	G/C	cg05507819	chr15:63340323	TPM1	0.54	5.36	0.33	2e-7	HDL cholesterol;
SARC	cis	rs1355223	0.902	rs34610590	chr11:34725440	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-5.31	-0.33	2.6e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs4238585	0.583	rs4238580	chr16:20212838	T/C	cg05160554	chr16:19468264	TMC5	0.28	4.76	0.3	3.38e-6	Body mass index;
SARC	trans	rs6815916	0.619	rs62339499	chr4:182553953	C/G	cg13864546	chr1:2310327	MORN1	0.68	6.41	0.39	7.98e-10	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg11644478	chr21:40555479	PSMG1	-0.88	-11.39	-0.6	3.49e-24	Cognitive function;
SARC	cis	rs240764	0.711	rs240112	chr6:101059253	C/A	cg09795085	chr6:101329169	ASCC3	0.46	5.72	0.35	3.2e-8	Neuroticism;
SARC	cis	rs35955747	0.902	rs4820961	chr22:31679449	C/T	cg13145458	chr22:31556086	RNF185	0.42	5.29	0.33	2.84e-7	Neutrophil count;Sum basophil neutrophil counts;
SARC	cis	rs6570726	0.935	rs365658	chr6:145844588	C/T	cg05220968	chr6:146057943	EPM2A	-0.31	-5.34	-0.33	2.23e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11122272	0.705	rs2790879	chr1:231534389	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-9.38	-0.52	6.26e-18	Hemoglobin concentration;
SARC	cis	rs763121	0.853	rs5750668	chr22:39079964	T/C	cg21395723	chr22:39101663	GTPBP1	0.52	5.79	0.35	2.3e-8	Menopause (age at onset);
SARC	cis	rs2228479	0.764	rs11641201	chr16:89983276	T/C	cg00800038	chr16:89945340	TCF25	-0.59	-5.03	-0.31	1e-6	Skin colour saturation;
SARC	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg23958373	chr8:599963	NA	0.83	6.8	0.41	8.63e-11	IgG glycosylation;
SARC	cis	rs1003719	0.667	rs28666643	chr21:38455999	T/G	cg10648535	chr21:38446584	PIGP;TTC3	0.55	7.64	0.45	5.73e-13	Eye color traits;
SARC	cis	rs950776	0.714	rs3743073	chr15:78909539	G/T	cg22563815	chr15:78856949	CHRNA5	-0.31	-4.95	-0.31	1.41e-6	Sudden cardiac arrest;
SARC	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.9	-0.5	1.61e-16	Alzheimer's disease;
SARC	cis	rs67460515	0.892	rs4856769	chr3:161004549	C/A	cg04691961	chr3:161091175	C3orf57	-0.5	-6.18	-0.38	2.85e-9	Parkinson's disease;
SARC	cis	rs2688419	0.545	rs6550719	chr3:23072185	C/G	cg00327796	chr3:23032191	NA	-0.42	-5.89	-0.36	1.37e-8	Type 2 diabetes;
SARC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg10150615	chr22:24372951	LOC391322	-0.45	-5.08	-0.32	7.78e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs4927850	1.000	rs4927704	chr3:195738228	C/T	cg12696929	chr3:195401817	SDHAP2	0.39	5.09	0.32	7.38e-7	Pancreatic cancer;
SARC	cis	rs295140	0.803	rs4516415	chr2:201129608	C/G	cg05691004	chr2:201170426	SPATS2L	0.35	4.98	0.31	1.24e-6	QT interval;
SARC	cis	rs13040088	1.000	rs12480870	chr20:61543606	A/C	cg23096297	chr20:61557774	DIDO1	0.95	10.39	0.56	5.21e-21	Menopause (age at onset);
SARC	cis	rs2439831	1.000	rs2601014	chr15:43756013	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.08	9.49	0.53	2.86e-18	Lung cancer in ever smokers;
SARC	cis	rs12887734	0.524	rs4906363	chr14:104210239	G/A	cg26031613	chr14:104095156	KLC1	-0.47	-5.37	-0.33	1.95e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	cis	rs11997175	0.646	rs6468195	chr8:33724817	A/G	ch.8.33884649F	chr8:33765107	NA	0.64	8.74	0.5	4.68e-16	Body mass index;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg11225435	chr1:211849015	NEK2	-0.49	-6.48	-0.39	5.36e-10	Chemerin levels;
SARC	cis	rs2732480	0.577	rs2732481	chr12:48736985	T/G	cg21466736	chr12:48725269	NA	-0.34	-5.31	-0.33	2.54e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs6060717	0.654	rs6060686	chr20:34512606	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	4.99	0.31	1.18e-6	Hip circumference adjusted for BMI;
SARC	cis	rs4280164	0.945	rs11158635	chr14:24776769	G/T	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.59	-5.56	-0.34	7.38e-8	Parent of origin effect on language impairment (paternal);
SARC	cis	rs7560272	0.723	rs7566315	chr2:73791808	C/T	cg20560298	chr2:73613845	ALMS1	-0.51	-7.11	-0.42	1.38e-11	Schizophrenia;
SARC	cis	rs9733	0.503	rs7556451	chr1:150913142	A/G	cg15448220	chr1:150897856	SETDB1	0.52	6.89	0.41	5.25e-11	Tonsillectomy;
SARC	cis	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg09324608	chr17:30823087	MYO1D	-0.33	-4.84	-0.3	2.37e-6	Schizophrenia;
SARC	cis	rs3820928	0.874	rs56324594	chr2:227868854	C/T	cg11843606	chr2:227700838	RHBDD1	-0.49	-6.01	-0.37	7.25e-9	Pulmonary function;
SARC	cis	rs10242455	0.571	rs11734	chr7:99229768	C/G	cg25640893	chr7:99214727	ZNF498	-0.96	-5.08	-0.32	7.63e-7	Blood metabolite levels;
SARC	cis	rs477692	0.583	rs2008387	chr10:131448764	C/T	cg05714579	chr10:131428358	MGMT	-0.71	-9.83	-0.54	2.69e-19	Response to temozolomide;
SARC	cis	rs6912958	0.781	rs4707379	chr6:88310623	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.54	-0.34	8.32e-8	Monocyte percentage of white cells;
SARC	cis	rs11203032	0.831	rs10788638	chr10:90950683	A/G	cg16672925	chr10:90967113	CH25H	0.53	5.92	0.36	1.13e-8	Heart failure;
SARC	cis	rs644799	1.000	rs566204	chr11:95580926	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	14.69	0.69	5.22e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs709400	0.663	rs72710714	chr14:103981849	T/G	cg12935359	chr14:103987150	CKB	-0.4	-5.87	-0.36	1.48e-8	Body mass index;
SARC	cis	rs1982963	0.901	rs1566131	chr14:52514684	G/A	cg10843707	chr14:52510701	NID2	-0.41	-4.82	-0.3	2.59e-6	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs10128251	0.847	rs12777965	chr10:5724297	T/C	cg09072322	chr10:5726702	C10orf18	-0.47	-4.85	-0.3	2.31e-6	Childhood ear infection;
SARC	cis	rs2486288	0.587	rs12899942	chr15:45547280	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.45	-5.55	-0.34	7.66e-8	Glomerular filtration rate;
SARC	cis	rs7043114	0.544	rs4302908	chr9:95321641	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.5	-6.2	-0.38	2.54e-9	Height;
SARC	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg22535103	chr8:58192502	C8orf71	-0.6	-6.15	-0.37	3.42e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.35	0.52	7.64e-18	Prudent dietary pattern;
SARC	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg19223190	chr17:80058835	NA	-0.4	-5.56	-0.34	7.43e-8	Life satisfaction;
SARC	cis	rs78456975	1.000	rs7584264	chr2:1565555	A/G	cg01028140	chr2:1542097	TPO	-0.45	-5.14	-0.32	5.82e-7	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs6952808	0.931	rs12537430	chr7:1868761	A/G	cg21782813	chr7:2030301	MAD1L1	-0.34	-5.2	-0.32	4.41e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg25838465	chr1:92012736	NA	-0.67	-9.87	-0.54	2.04e-19	Breast cancer;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg18126840	chr2:44689831	C2orf34	0.5	7.3	0.43	4.4e-12	Thyroid stimulating hormone;
SARC	cis	rs73198271	0.700	rs10103282	chr8:8650757	T/G	cg06636001	chr8:8085503	FLJ10661	-0.48	-5.4	-0.33	1.65e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs1580019	0.922	rs766658	chr7:32499391	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.74	9.9	0.54	1.68e-19	Cognitive ability;
SARC	cis	rs911263	0.581	rs3825730	chr14:68790579	G/A	cg18825221	chr14:68749962	RAD51L1	0.41	7.35	0.43	3.4e-12	Primary biliary cholangitis;
SARC	cis	rs1448094	0.512	rs1900701	chr12:86236231	T/C	cg02569458	chr12:86230093	RASSF9	0.4	5.63	0.35	5.08e-8	Major depressive disorder;
SARC	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg22433210	chr17:43662623	NA	-0.68	-7.95	-0.46	7.92e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs1048238	0.506	rs6668183	chr1:16173814	G/C	cg21385522	chr1:16154831	NA	0.48	6.08	0.37	4.8e-9	Systolic blood pressure;
SARC	cis	rs2594989	0.943	rs2454504	chr3:11498423	G/A	cg00170343	chr3:11313890	ATG7	0.55	5.4	0.33	1.62e-7	Circulating chemerin levels;
SARC	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2404602	0.647	rs2404604	chr15:76991105	A/G	cg15268244	chr15:77196840	NA	0.45	5.18	0.32	4.83e-7	Blood metabolite levels;
SARC	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg26119090	chr2:26468346	HADHA;HADHB	0.94	13.16	0.65	5.86e-30	Gut microbiome composition (summer);
SARC	cis	rs4466137	1.000	rs1154888	chr5:82977410	C/A	cg16102102	chr5:83017553	HAPLN1	-0.75	-9.5	-0.53	2.59e-18	Prostate cancer;
SARC	cis	rs6752107	1.000	rs6752107	chr2:234161448	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.47	6.11	0.37	4.12e-9	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs453301	0.606	rs7462373	chr8:8899318	G/C	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.7	-0.4	1.56e-10	Joint mobility (Beighton score);
SARC	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.06	14.95	0.7	6.91e-36	Height;
SARC	cis	rs6674176	0.628	rs12145999	chr1:44428632	C/T	cg12908607	chr1:44402522	ARTN	-0.4	-6.83	-0.41	7.43e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs12950390	0.853	rs67441169	chr17:45854462	T/G	cg24803719	chr17:45855879	NA	-0.46	-7.55	-0.44	9.68e-13	IgG glycosylation;
SARC	cis	rs3820928	1.000	rs10210763	chr2:227776029	G/T	cg05526886	chr2:227700861	RHBDD1	-0.5	-6.11	-0.37	4.08e-9	Pulmonary function;
SARC	cis	rs9916302	0.706	rs7208487	chr17:37543449	T/G	cg07936489	chr17:37558343	FBXL20	0.78	9.36	0.52	6.81e-18	Glomerular filtration rate (creatinine);
SARC	cis	rs2652834	1.000	rs68088462	chr15:63397617	T/C	cg05507819	chr15:63340323	TPM1	0.54	5.36	0.33	2e-7	HDL cholesterol;
SARC	cis	rs4919087	0.590	rs1253400	chr10:99049566	G/A	cg25902810	chr10:99078978	FRAT1	-0.56	-6.14	-0.37	3.43e-9	Monocyte count;
SARC	cis	rs2180341	0.618	rs6683	chr6:127610021	G/A	cg27446573	chr6:127587934	RNF146	0.66	8.71	0.5	5.84e-16	Breast cancer;
SARC	cis	rs2075371	1.000	rs2598294	chr7:133991690	C/T	cg00033643	chr7:134001901	SLC35B4	0.4	4.85	0.3	2.25e-6	Mean platelet volume;
SARC	cis	rs3820928	0.904	rs1835159	chr2:227764057	A/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-6.69	-0.4	1.61e-10	Pulmonary function;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg17167924	chr1:8938131	ENO1	0.48	6.26	0.38	1.83e-9	Chemerin levels;
SARC	cis	rs1538970	0.924	rs4660858	chr1:45936351	G/A	cg05343316	chr1:45956843	TESK2	0.77	8.82	0.5	2.77e-16	Platelet count;
SARC	cis	rs10189230	0.904	rs13029372	chr2:222348434	A/G	cg14652038	chr2:222343519	EPHA4	0.44	5.82	0.36	1.98e-8	Urate levels in lean individuals;
SARC	cis	rs7927771	0.965	rs12787112	chr11:47687147	A/G	cg05585544	chr11:47624801	NA	-0.38	-5.01	-0.31	1.06e-6	Subjective well-being;
SARC	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg20607798	chr8:58055168	NA	0.58	5.57	0.34	6.9e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7408868	0.908	rs1044006	chr19:15285052	T/C	cg14696996	chr19:15285081	NOTCH3	0.99	9.09	0.51	4.38e-17	Pulse pressure;
SARC	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg18225595	chr11:63971243	STIP1	0.45	5.43	0.34	1.4e-7	Mean platelet volume;
SARC	cis	rs7647973	0.961	rs11130187	chr3:49307872	T/C	cg07636037	chr3:49044803	WDR6	0.78	9.15	0.51	2.9e-17	Menarche (age at onset);
SARC	cis	rs7208859	0.623	rs3794796	chr17:29130880	G/C	cg13385521	chr17:29058706	SUZ12P	0.83	6.93	0.41	4e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs3749237	0.595	rs6797765	chr3:49423976	A/G	cg07636037	chr3:49044803	WDR6	0.62	8.07	0.47	3.76e-14	Resting heart rate;
SARC	cis	rs8114671	0.562	rs6088635	chr20:33466501	A/G	cg24642439	chr20:33292090	TP53INP2	0.47	5.66	0.35	4.34e-8	Height;
SARC	trans	rs1865760	0.929	rs9461224	chr6:25936402	G/T	cg11673391	chr1:10459052	PGD	-0.54	-6.48	-0.39	5.33e-10	Height;
SARC	cis	rs7584330	0.868	rs67071074	chr2:238395429	T/C	cg14458575	chr2:238380390	NA	0.42	5.07	0.32	8.15e-7	Prostate cancer;
SARC	cis	rs35110281	0.563	rs162371	chr21:44931489	G/T	cg01579765	chr21:45077557	HSF2BP	-0.33	-5.57	-0.34	7.05e-8	Mean corpuscular volume;
SARC	cis	rs709400	0.597	rs1013650	chr14:103909203	G/A	cg26031613	chr14:104095156	KLC1	0.8	11.45	0.6	2.26e-24	Body mass index;
SARC	cis	rs4595586	0.545	rs969468	chr12:39367278	A/C	cg13010199	chr12:38710504	ALG10B	0.4	4.75	0.3	3.57e-6	Morning vs. evening chronotype;
SARC	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg06221963	chr1:154839813	KCNN3	0.52	8.22	0.47	1.41e-14	Prostate cancer;
SARC	cis	rs10911251	0.528	rs2333622	chr1:183075456	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.68	10.06	0.55	5.36e-20	Colorectal cancer;
SARC	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg03161606	chr19:29218774	NA	0.47	6.93	0.41	4.07e-11	Methadone dose in opioid dependence;
SARC	cis	rs9790314	1.000	rs9850455	chr3:161017192	G/A	cg04691961	chr3:161091175	C3orf57	-0.75	-10.78	-0.58	2.93e-22	Morning vs. evening chronotype;
SARC	cis	rs262150	1.000	rs262150	chr7:158777934	G/A	cg19418458	chr7:158789849	NA	-0.44	-5.74	-0.35	2.86e-8	Facial morphology (factor 20);
SARC	cis	rs2120243	0.592	rs7618502	chr3:157095544	C/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.45	5.69	0.35	3.87e-8	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs2228479	0.850	rs117675822	chr16:89919081	C/A	cg00800038	chr16:89945340	TCF25	-0.82	-5.8	-0.35	2.19e-8	Skin colour saturation;
SARC	cis	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg22496380	chr5:211416	CCDC127	-0.86	-9.02	-0.51	6.97e-17	Breast cancer;
SARC	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg11062466	chr8:58055876	NA	0.61	5.75	0.35	2.77e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7264396	0.836	rs4911183	chr20:34181553	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.57	6.22	0.38	2.25e-9	Total cholesterol levels;
SARC	cis	rs17270561	0.608	rs4711102	chr6:25742075	T/C	cg17691542	chr6:26056736	HIST1H1C	0.61	7.36	0.43	3.06e-12	Iron status biomarkers;
SARC	trans	rs1961637	0.603	rs1550423	chr2:223885812	C/T	cg03665832	chr7:98923565	ARPC1A	-0.46	-6.26	-0.38	1.88e-9	Oropharynx cancer;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg06540715	chr13:111568383	ANKRD10	-0.67	-5.04	-0.31	9.39e-7	Obesity-related traits;
SARC	cis	rs2594989	0.943	rs2454492	chr3:11507793	G/A	cg00170343	chr3:11313890	ATG7	0.53	5.24	0.32	3.64e-7	Circulating chemerin levels;
SARC	cis	rs9816226	0.591	rs57912727	chr3:185804583	A/C	cg00760338	chr3:185826511	ETV5	-0.8	-7.92	-0.46	9.63e-14	Obesity;Body mass index;
SARC	cis	rs72781680	0.611	rs72781692	chr2:24263319	T/G	cg06627628	chr2:24431161	ITSN2	-0.61	-6.04	-0.37	6.18e-9	Lymphocyte counts;
SARC	cis	rs6991838	0.800	rs28547533	chr8:66471553	T/C	cg13398993	chr8:66546079	ARMC1	0.48	6.45	0.39	6.43e-10	Intelligence (multi-trait analysis);
SARC	cis	rs9325144	0.555	rs1825806	chr12:38692547	G/A	cg04568710	chr12:38710424	ALG10B	0.38	4.74	0.3	3.69e-6	Morning vs. evening chronotype;
SARC	cis	rs1348850	0.757	rs4893969	chr2:178478476	T/A	cg22681709	chr2:178499509	PDE11A	-0.4	-5.21	-0.32	4.08e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs4727027	0.933	rs1044358	chr7:148879951	C/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.48	5.84	0.36	1.75e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs17826219	0.636	rs8080829	chr17:29058730	C/T	cg13385521	chr17:29058706	SUZ12P	0.89	8.0	0.46	5.9e-14	Body mass index;
SARC	cis	rs881375	0.967	rs2239658	chr9:123671837	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.42	5.05	0.31	8.78e-7	Rheumatoid arthritis;
SARC	cis	rs2228479	0.702	rs62056092	chr16:89930426	A/G	cg04013166	chr16:89971882	TCF25	0.55	4.86	0.3	2.16e-6	Skin colour saturation;
SARC	cis	rs4481887	0.927	rs12744455	chr1:248479960	A/G	cg13385794	chr1:248469461	NA	0.34	5.22	0.32	4e-7	Common traits (Other);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg05699592	chr3:48885332	PRKAR2A	0.5	6.54	0.39	3.86e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs8141529	0.732	rs5762788	chr22:29174770	G/T	cg02153584	chr22:29168773	CCDC117	0.83	13.03	0.65	1.56e-29	Lymphocyte counts;
SARC	cis	rs3126085	1.000	rs72696952	chr1:152172694	A/T	cg03465714	chr1:152285911	FLG	0.46	4.86	0.3	2.15e-6	Atopic dermatitis;
SARC	cis	rs7712401	0.601	rs154501	chr5:122211594	T/C	cg19412675	chr5:122181750	SNX24	0.41	5.24	0.32	3.51e-7	Mean platelet volume;
SARC	cis	rs12477438	0.765	rs2309521	chr2:99592069	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.95	-15.6	-0.71	4.87e-38	Chronic sinus infection;
SARC	cis	rs1153858	0.725	rs74572151	chr15:45647526	T/G	cg21132104	chr15:45694354	SPATA5L1	0.77	10.98	0.58	6.87e-23	Homoarginine levels;
SARC	cis	rs3126085	0.735	rs35061954	chr1:152240583	G/T	cg03465714	chr1:152285911	FLG	-0.42	-4.82	-0.3	2.64e-6	Atopic dermatitis;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg24963443	chr5:180673122	NA	0.48	6.3	0.38	1.44e-9	Chemerin levels;
SARC	cis	rs9486719	1.000	rs2064947	chr6:97052754	C/T	cg06623918	chr6:96969491	KIAA0776	-0.76	-8.45	-0.48	3.13e-15	Migraine;Coronary artery disease;
SARC	cis	rs5753037	0.653	rs131277	chr22:30154101	C/A	cg01021169	chr22:30184971	ASCC2	-0.45	-6.31	-0.38	1.39e-9	Type 1 diabetes;
SARC	cis	rs74417235	0.684	rs13179754	chr5:154059845	C/T	cg08754654	chr5:154026448	NA	0.46	4.75	0.3	3.5e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
SARC	cis	rs6693567	0.565	rs11205370	chr1:150397567	A/G	cg09579323	chr1:150459698	TARS2	0.44	5.66	0.35	4.4e-8	Migraine;
SARC	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg08564027	chr20:61660810	NA	0.76	11.8	0.61	1.69e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs950169	0.580	rs4603535	chr15:85173872	C/T	cg17507749	chr15:85114479	UBE2QP1	0.58	6.77	0.41	1.03e-10	Schizophrenia;
SARC	cis	rs9604529	0.532	rs41291213	chr13:114774991	C/T	cg04826882	chr13:114838756	RASA3	-0.46	-5.08	-0.32	7.62e-7	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs28374715	0.662	rs13329579	chr15:41467435	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.0	-13.86	-0.67	2.89e-32	Ulcerative colitis;
SARC	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg16479474	chr6:28041457	NA	0.33	5.26	0.33	3.22e-7	Cardiac Troponin-T levels;
SARC	cis	rs9479482	1.000	rs11754987	chr6:150351204	G/A	cg03788504	chr6:150331562	NA	-0.33	-5.49	-0.34	1.06e-7	Alopecia areata;
SARC	cis	rs3126085	0.935	rs72696975	chr1:152206090	A/G	cg03465714	chr1:152285911	FLG	0.46	5.0	0.31	1.13e-6	Atopic dermatitis;
SARC	trans	rs11039798	0.588	rs666165	chr11:48457439	C/T	cg15704280	chr7:45808275	SEPT13	-0.64	-6.76	-0.4	1.09e-10	Axial length;
SARC	cis	rs2735413	0.918	rs2344494	chr16:78078111	C/T	cg04733911	chr16:78082701	NA	-0.31	-5.61	-0.34	5.78e-8	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs9457247	0.765	rs2237276	chr6:167442115	C/T	cg07741184	chr6:167504864	NA	0.38	7.49	0.44	1.46e-12	Crohn's disease;
SARC	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg04267008	chr7:1944627	MAD1L1	-0.68	-8.04	-0.47	4.41e-14	Bipolar disorder and schizophrenia;
SARC	cis	rs1568889	0.592	rs7110074	chr11:28469325	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.7	8.12	0.47	2.79e-14	Bipolar disorder;
SARC	cis	rs9913156	0.793	rs55682338	chr17:4582183	G/A	cg19197139	chr17:4613644	ARRB2	0.86	9.46	0.53	3.49e-18	Lymphocyte counts;
SARC	cis	rs2230307	0.536	rs581097	chr1:100515920	C/T	cg24955406	chr1:100503596	HIAT1	0.7	6.84	0.41	7e-11	Carotid intima media thickness;
SARC	cis	rs2933343	0.729	rs1680780	chr3:128612659	G/C	cg24203234	chr3:128598194	ACAD9	0.63	7.68	0.45	4.46e-13	IgG glycosylation;
SARC	cis	rs67460515	0.563	rs6794882	chr3:160851849	G/A	cg03342759	chr3:160939853	NMD3	-0.63	-7.65	-0.45	5.2e-13	Parkinson's disease;
SARC	cis	rs3771395	1.000	rs3771395	chr2:71133014	A/G	cg21294935	chr2:71128538	VAX2	-0.62	-5.46	-0.34	1.25e-7	Corneal astigmatism;
SARC	cis	rs2153535	0.580	rs1335636	chr6:8465047	T/C	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	cis	rs748404	0.587	rs9920879	chr15:43639770	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	5.83	0.36	1.87e-8	Lung cancer;
SARC	cis	rs2712381	0.797	rs62270806	chr3:128376269	C/T	cg08795948	chr3:128337044	NA	0.36	4.86	0.3	2.12e-6	Monocyte count;
SARC	cis	rs2834188	0.924	rs2040107	chr21:34675962	C/G	cg14352951	chr21:34696688	IFNAR1	-0.44	-5.38	-0.33	1.8e-7	Narcolepsy;
SARC	cis	rs7666738	0.579	rs7672718	chr4:98645122	A/G	cg05340658	chr4:99064831	C4orf37	0.59	7.11	0.42	1.41e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs78456975	1.000	rs10205916	chr2:1558451	A/T	cg01028140	chr2:1542097	TPO	0.51	5.25	0.33	3.39e-7	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs8114671	0.967	rs6088747	chr20:33754604	G/T	cg07148914	chr20:33460835	GGT7	0.43	4.82	0.3	2.6e-6	Height;
SARC	cis	rs2455601	0.507	rs7948452	chr11:8877704	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.39	-4.94	-0.31	1.47e-6	Schizophrenia;
SARC	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg22875332	chr1:76189707	ACADM	0.44	5.85	0.36	1.63e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7772486	0.686	rs9497396	chr6:146014963	C/A	cg23711669	chr6:146136114	FBXO30	-0.8	-12.87	-0.64	5.56e-29	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12971120	1.000	rs12971120	chr18:72174023	A/G	cg25817165	chr18:72167213	CNDP2	-0.5	-7.53	-0.44	1.12e-12	Refractive error;
SARC	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg05234568	chr11:5960015	NA	-0.42	-5.49	-0.34	1.04e-7	DNA methylation (variation);
SARC	cis	rs16866061	1.000	rs10933068	chr2:225418360	G/A	cg12698349	chr2:225449008	CUL3	0.73	10.9	0.58	1.27e-22	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	trans	rs3780486	0.522	rs10217770	chr9:33146393	C/A	cg20290983	chr6:43655470	MRPS18A	0.91	12.93	0.65	3.34e-29	IgG glycosylation;
SARC	cis	rs7819412	0.645	rs4841508	chr8:11065003	C/A	cg12395012	chr8:11607386	GATA4	0.32	5.23	0.32	3.73e-7	Triglycerides;
SARC	cis	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg12489773	chr10:65390263	NA	-0.56	-5.3	-0.33	2.72e-7	Cutaneous psoriasis;
SARC	cis	rs6840360	0.935	rs3919716	chr4:152456387	A/G	cg22705602	chr4:152727874	NA	-0.37	-6.09	-0.37	4.71e-9	Intelligence (multi-trait analysis);
SARC	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg22496380	chr5:211416	CCDC127	-0.86	-8.85	-0.5	2.23e-16	Breast cancer;
SARC	cis	rs6840360	0.598	rs11944921	chr4:152731109	A/G	cg22705602	chr4:152727874	NA	0.31	5.25	0.33	3.4e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9581857	0.685	rs9319368	chr13:28042275	T/G	cg01674679	chr13:27998804	GTF3A	-0.64	-4.86	-0.3	2.19e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg11764359	chr7:65958608	NA	-0.6	-6.88	-0.41	5.49e-11	Aortic root size;
SARC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg26338869	chr17:61819248	STRADA	0.81	10.9	0.58	1.23e-22	Prudent dietary pattern;
SARC	cis	rs9815354	0.903	rs9822598	chr3:41954587	G/A	cg03022575	chr3:42003672	ULK4	-0.55	-5.27	-0.33	3.16e-7	Pulse pressure;Diastolic blood pressure;
SARC	trans	rs61931739	0.534	rs1705757	chr12:34091637	A/G	cg13010199	chr12:38710504	ALG10B	0.67	8.9	0.5	1.56e-16	Morning vs. evening chronotype;
SARC	cis	rs9399135	0.967	rs4896123	chr6:135295410	T/G	cg24558204	chr6:135376177	HBS1L	0.44	5.79	0.35	2.21e-8	Red blood cell count;
SARC	cis	rs2180341	0.814	rs6919277	chr6:127738050	T/C	cg24812749	chr6:127587940	RNF146	0.8	9.99	0.55	8.67e-20	Breast cancer;
SARC	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg27347728	chr4:17578864	LAP3	0.46	5.74	0.35	2.86e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs8070463	0.520	rs11652969	chr17:45817367	G/A	cg03474202	chr17:45855739	NA	-0.33	-5.22	-0.32	3.93e-7	Multiple sclerosis;Ankylosing spondylitis;
SARC	cis	rs9660992	0.710	rs55671824	chr1:205249814	G/A	cg07972983	chr1:205091412	RBBP5	0.55	6.57	0.4	3.2e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs11098499	0.909	rs7659501	chr4:120371552	G/T	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs9790314	1.000	rs336577	chr3:161066294	C/T	cg03342759	chr3:160939853	NMD3	-0.6	-7.48	-0.44	1.46e-12	Morning vs. evening chronotype;
SARC	cis	rs3741798	1.000	rs61922052	chr12:12497620	A/G	cg08615371	chr12:12503544	MANSC1	0.68	5.43	0.34	1.43e-7	Cerebrospinal fluid biomarker levels;
SARC	cis	rs561341	0.941	rs4795664	chr17:30233467	C/T	cg25833597	chr17:30823145	MYO1D	-0.55	-5.06	-0.31	8.48e-7	Hip circumference adjusted for BMI;
SARC	cis	rs13144136	0.786	rs10938921	chr4:10666960	C/T	cg10242279	chr4:10666415	CLNK	-0.36	-5.67	-0.35	4.12e-8	Resistance to antihypertensive treatment in hypertension;
SARC	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg24549020	chr5:56110836	MAP3K1	0.81	8.46	0.48	2.97e-15	Initial pursuit acceleration;
SARC	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg03806693	chr22:41940476	POLR3H	0.93	12.74	0.64	1.45e-28	Vitiligo;
SARC	trans	rs7937682	0.847	rs583032	chr11:111432757	C/T	cg18187862	chr3:45730750	SACM1L	0.54	6.44	0.39	6.88e-10	Primary sclerosing cholangitis;
SARC	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg22834771	chr12:69754056	YEATS4	-0.48	-6.29	-0.38	1.59e-9	Cerebrospinal fluid biomarker levels;
SARC	cis	rs7659604	1.000	rs6823488	chr4:122664819	A/G	cg19671926	chr4:122722719	EXOSC9	-0.48	-5.77	-0.35	2.54e-8	Type 2 diabetes;
SARC	cis	rs1843834	0.624	rs2396110	chr2:225560219	A/G	cg22509189	chr2:225307070	NA	-0.54	-6.54	-0.39	3.76e-10	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs7819412	0.502	rs11777918	chr8:11036919	A/G	cg12395012	chr8:11607386	GATA4	-0.28	-4.83	-0.3	2.52e-6	Triglycerides;
SARC	cis	rs672059	0.812	rs61418038	chr1:183155717	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.53	7.25	0.43	5.92e-12	Hypertriglyceridemia;
SARC	cis	rs13202913	0.518	rs13205543	chr6:151813779	C/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.62	5.27	0.33	3.09e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs7666738	0.830	rs7680909	chr4:98934604	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg14870128	chr10:70931312	VPS26A	0.46	6.24	0.38	2.01e-9	Tetralogy of Fallot;
SARC	cis	rs10870270	1.000	rs7077744	chr10:133770201	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.84	-10.43	-0.56	3.71e-21	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs2180341	1.000	rs6569483	chr6:127658855	G/A	cg27446573	chr6:127587934	RNF146	1.04	14.77	0.7	2.87e-35	Breast cancer;
SARC	trans	rs1814175	0.616	rs10769644	chr11:49987676	C/A	cg15704280	chr7:45808275	SEPT13	-0.89	-14.17	-0.68	2.8e-33	Height;
SARC	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg03433033	chr1:76189801	ACADM	-0.73	-12.35	-0.63	2.75e-27	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2760061	0.626	rs592736	chr1:228116831	A/G	cg02753203	chr1:228287806	NA	-0.5	-6.89	-0.41	5.29e-11	Diastolic blood pressure;
SARC	cis	rs36051895	0.593	rs2094619	chr9:5167712	G/C	cg02405213	chr9:5042618	JAK2	-0.55	-6.4	-0.39	8.41e-10	Pediatric autoimmune diseases;
SARC	cis	rs4481887	0.927	rs9651177	chr1:248445702	A/G	cg00666640	chr1:248458726	OR2T12	0.31	5.36	0.33	1.99e-7	Common traits (Other);
SARC	trans	rs73036520	0.958	rs11670562	chr19:45743640	T/C	cg23345151	chr18:77292947	NA	0.43	6.35	0.38	1.11e-9	Monocyte percentage of white cells;
SARC	cis	rs6815814	0.851	rs11736207	chr4:38766285	G/A	cg06935464	chr4:38784597	TLR10	0.58	5.26	0.33	3.29e-7	Breast cancer;
SARC	cis	rs7824557	0.544	rs1865521	chr8:11231249	T/C	cg12395012	chr8:11607386	GATA4	-0.29	-4.78	-0.3	3.14e-6	Retinal vascular caliber;
SARC	cis	rs17270561	0.583	rs6926425	chr6:25785304	T/C	cg17691542	chr6:26056736	HIST1H1C	0.52	6.54	0.39	3.85e-10	Iron status biomarkers;
SARC	cis	rs11098499	0.779	rs7356491	chr4:120381974	C/T	cg09160332	chr4:120329925	NA	-0.33	-4.74	-0.3	3.75e-6	Corneal astigmatism;
SARC	cis	rs16976116	0.901	rs28630909	chr15:55500102	G/A	cg17854078	chr15:55489399	RSL24D1	0.66	6.53	0.39	4.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs3106136	0.967	rs13132963	chr4:95219780	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.39	-6.05	-0.37	5.71e-9	Capecitabine sensitivity;
SARC	cis	rs4555082	0.874	rs78923231	chr14:105754033	C/T	cg13114125	chr14:105738426	BRF1	-0.79	-11.34	-0.6	5.05e-24	Mean platelet volume;Platelet distribution width;
SARC	cis	rs7208859	0.673	rs79541516	chr17:29240583	C/T	cg13385521	chr17:29058706	SUZ12P	0.83	6.32	0.38	1.29e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	trans	rs2018683	0.600	rs717891	chr7:29000374	C/T	cg19402173	chr7:128379420	CALU	-0.69	-8.22	-0.47	1.43e-14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg17376030	chr22:41985996	PMM1	-0.65	-8.15	-0.47	2.27e-14	Cannabis dependence symptom count;
SARC	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg02487422	chr3:49467188	NICN1	0.49	6.56	0.39	3.53e-10	Resting heart rate;
SARC	cis	rs3820928	0.934	rs16822890	chr2:227761477	G/A	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.83	-0.36	1.82e-8	Pulmonary function;
SARC	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg06634786	chr22:41940651	POLR3H	0.53	6.41	0.39	7.81e-10	Vitiligo;
SARC	cis	rs748404	0.631	rs3809482	chr15:43661802	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	5.74	0.35	2.87e-8	Lung cancer;
SARC	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.45	5.14	0.32	5.82e-7	Renal function-related traits (BUN);
SARC	cis	rs4689388	0.926	rs3889821	chr4:6282596	C/T	cg25554036	chr4:6271136	WFS1	0.42	6.86	0.41	6.32e-11	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg24531977	chr5:56204891	C5orf35	-0.54	-5.45	-0.34	1.26e-7	Initial pursuit acceleration;
SARC	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg00825309	chr19:58991885	ZNF446	-0.58	-8.03	-0.47	4.67e-14	Uric acid clearance;
SARC	cis	rs912057	0.965	rs1294415	chr6:6740633	G/A	cg06612196	chr6:6737390	NA	0.66	9.34	0.52	8.07e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs7766436	0.648	rs6908475	chr6:22572798	A/G	cg13666174	chr6:22585274	NA	-0.46	-6.01	-0.37	7.24e-9	Coronary artery disease;
SARC	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg27266027	chr21:40555129	PSMG1	0.5	5.43	0.34	1.41e-7	Cognitive function;
SARC	cis	rs1050631	0.564	rs1789549	chr18:33722425	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.59	7.17	0.43	9.66e-12	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg25427524	chr10:38739819	LOC399744	-0.53	-8.32	-0.48	7.33e-15	Extrinsic epigenetic age acceleration;
SARC	cis	rs796364	0.789	rs176008	chr2:200814720	A/T	cg23649088	chr2:200775458	C2orf69	0.63	5.92	0.36	1.13e-8	Schizophrenia;
SARC	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.1	21.48	0.82	3.55e-57	Chronic sinus infection;
SARC	cis	rs7762018	1.000	rs73242910	chr6:170114670	A/G	cg13891659	chr6:170190454	C6orf122;C6orf208	0.56	4.83	0.3	2.42e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	trans	rs9870680	0.677	rs1119406	chr3:7547142	C/G	cg14106308	chr3:157217286	VEPH1	-0.4	-6.23	-0.38	2.12e-9	Major depressive disorder (broad);
SARC	cis	rs1348850	0.914	rs7604673	chr2:178392346	A/G	cg23306229	chr2:178417860	TTC30B	0.55	6.32	0.38	1.35e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs523522	0.962	rs10744752	chr12:120900554	T/G	cg27279351	chr12:120934652	DYNLL1	0.71	8.63	0.49	9.89e-16	High light scatter reticulocyte count;
SARC	cis	rs854765	0.533	rs2955354	chr17:17948716	G/C	cg05444541	chr17:17804740	TOM1L2	0.3	4.89	0.31	1.85e-6	Total body bone mineral density;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg01159004	chr20:48330681	B4GALT5	-0.46	-6.62	-0.4	2.48e-10	Neuroticism;
SARC	cis	rs55823223	0.564	rs4572466	chr17:73846314	A/C	cg08125733	chr17:73851984	WBP2	0.56	6.53	0.39	4.17e-10	Psoriasis;
SARC	cis	rs9875589	0.509	rs2731336	chr3:14091908	G/A	cg19554555	chr3:13937349	NA	-0.39	-4.91	-0.31	1.73e-6	Ovarian reserve;
SARC	cis	rs72949976	1.000	rs6747328	chr2:214032156	C/G	cg08319019	chr2:214017104	IKZF2	-0.52	-7.14	-0.42	1.2e-11	Lung cancer;Squamous cell lung carcinoma;
SARC	cis	rs4423214	1.000	rs11600569	chr11:71173747	C/G	cg24826892	chr11:71159390	DHCR7	0.44	5.62	0.35	5.31e-8	Vitamin D levels;
SARC	cis	rs35213789	0.887	rs2851512	chr7:69077247	A/G	cg10619644	chr7:69149951	AUTS2	-0.44	-5.73	-0.35	3.08e-8	Childhood ear infection;
SARC	cis	rs7566780	0.743	rs12997119	chr2:16734284	C/T	cg09580478	chr2:16689509	NA	0.46	5.09	0.32	7.32e-7	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg18404041	chr3:52824283	ITIH1	-0.38	-5.68	-0.35	3.93e-8	Bipolar disorder;
SARC	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg11987759	chr7:65425863	GUSB	-0.6	-7.96	-0.46	7.64e-14	Aortic root size;
SARC	cis	rs11098499	0.954	rs10017371	chr4:120293776	A/G	cg09160332	chr4:120329925	NA	-0.34	-4.76	-0.3	3.36e-6	Corneal astigmatism;
SARC	cis	rs765787	0.530	rs1706830	chr15:45516229	G/A	cg25801113	chr15:45476975	SHF	0.28	4.72	0.3	4.06e-6	Uric acid levels;
SARC	cis	rs16866061	0.962	rs16866045	chr2:225413020	G/A	cg12698349	chr2:225449008	CUL3	0.72	10.55	0.57	1.6e-21	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	trans	rs3780486	0.757	rs10813949	chr9:33123464	G/A	cg20290983	chr6:43655470	MRPS18A	1.14	23.61	0.84	9.56e-64	IgG glycosylation;
SARC	cis	rs7568458	0.704	rs10176176	chr2:85762048	A/T	cg02493740	chr2:85810744	VAMP5	-0.36	-5.24	-0.32	3.6e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.6	0.53	1.32e-18	Prudent dietary pattern;
SARC	cis	rs80282103	0.618	rs7100114	chr10:1110231	A/G	cg08668510	chr10:1095578	IDI1	0.78	5.27	0.33	3.04e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs1707322	1.000	rs12060274	chr1:46291062	G/T	cg03146154	chr1:46216737	IPP	0.47	5.62	0.35	5.38e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2486288	0.656	rs1706770	chr15:45575062	T/C	cg15395560	chr15:45543142	SLC28A2	0.32	6.03	0.37	6.25e-9	Glomerular filtration rate;
SARC	cis	rs2882877	0.648	rs35078179	chr2:190391921	A/C	cg21926118	chr2:190387206	NA	-0.41	-5.13	-0.32	6.24e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg16606324	chr3:10149918	C3orf24	0.48	4.75	0.3	3.56e-6	Alzheimer's disease;
SARC	cis	rs2658782	0.654	rs2248531	chr11:93255363	G/T	cg15737290	chr11:93063684	CCDC67	0.71	8.47	0.49	2.85e-15	Pulmonary function decline;
SARC	cis	rs10504073	0.584	rs10504070	chr8:49978554	A/G	cg00325661	chr8:49890786	NA	-0.51	-6.75	-0.4	1.13e-10	Blood metabolite ratios;
SARC	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg10591111	chr5:226296	SDHA	-0.55	-4.97	-0.31	1.31e-6	Breast cancer;
SARC	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg13206674	chr6:150067644	NUP43	0.46	6.06	0.37	5.4e-9	Lung cancer;
SARC	cis	rs2075371	1.000	rs2544210	chr7:133971535	C/T	cg20476274	chr7:133979776	SLC35B4	0.61	8.52	0.49	1.94e-15	Mean platelet volume;
SARC	cis	rs826838	1.000	rs11168505	chr12:38939057	A/T	cg26384229	chr12:38710491	ALG10B	-0.91	-13.95	-0.67	1.5e-32	Heart rate;
SARC	cis	rs7089973	0.610	rs61869271	chr10:116731329	T/C	cg08188268	chr10:116634841	FAM160B1	0.42	5.67	0.35	4.29e-8	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs2486288	0.656	rs8041702	chr15:45547093	C/T	cg19305227	chr15:45544335	SLC28A2	0.28	5.25	0.33	3.42e-7	Glomerular filtration rate;
SARC	cis	rs911555	0.713	rs1107070	chr14:103970508	G/T	cg12935359	chr14:103987150	CKB	0.42	5.6	0.34	5.9e-8	Intelligence (multi-trait analysis);
SARC	cis	rs6815814	0.950	rs73236615	chr4:38786869	G/T	cg02016764	chr4:38805732	TLR1	-0.42	-4.98	-0.31	1.23e-6	Breast cancer;
SARC	cis	rs13343954	0.518	rs7252086	chr19:33534929	T/C	cg17764715	chr19:33622953	WDR88	0.52	6.99	0.42	2.95e-11	Colorectal cancer;
SARC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg14159672	chr1:205819179	PM20D1	0.86	14.17	0.68	2.76e-33	Menarche (age at onset);
SARC	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg00149659	chr3:10157352	C3orf10	0.65	6.18	0.38	2.9e-9	Alzheimer's disease;
SARC	cis	rs599083	0.530	rs640569	chr11:68184820	A/G	cg01657329	chr11:68192670	LRP5	0.47	6.36	0.38	1.07e-9	Bone mineral density (spine);
SARC	cis	rs7336332	0.598	rs1885989	chr13:28010117	G/A	cg01674679	chr13:27998804	GTF3A	-0.56	-5.2	-0.32	4.26e-7	Weight;
SARC	cis	rs2204008	0.774	rs7305085	chr12:38263511	C/T	cg13010199	chr12:38710504	ALG10B	0.81	11.31	0.6	6.33e-24	Bladder cancer;
SARC	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg00684032	chr4:1343700	KIAA1530	0.37	5.32	0.33	2.49e-7	Obesity-related traits;
SARC	cis	rs6582630	0.502	rs11520234	chr12:38255005	G/A	cg26384229	chr12:38710491	ALG10B	0.91	13.64	0.67	1.61e-31	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs3762637	0.943	rs9841897	chr3:122282569	T/C	cg24169773	chr3:122142474	KPNA1	-0.55	-5.58	-0.34	6.82e-8	LDL cholesterol levels;
SARC	cis	rs921968	0.510	rs2577761	chr2:219462500	G/A	cg02176678	chr2:219576539	TTLL4	0.46	6.89	0.41	5.03e-11	Mean corpuscular hemoglobin concentration;
SARC	cis	rs7043114	0.525	rs7020874	chr9:95112560	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.81	-0.36	2.02e-8	Height;
SARC	trans	rs8081395	0.775	rs2526355	chr17:57953233	G/C	cg15604357	chr1:160386408	VANGL2	0.38	6.55	0.39	3.72e-10	White blood cell count;
SARC	cis	rs11122272	0.705	rs1416914	chr1:231533196	C/T	cg06096015	chr1:231504339	EGLN1	0.38	5.66	0.35	4.45e-8	Hemoglobin concentration;
SARC	cis	rs11098499	0.863	rs1383532	chr4:120434404	A/T	cg09307838	chr4:120376055	NA	-0.91	-12.25	-0.63	5.8e-27	Corneal astigmatism;
SARC	cis	rs734999	0.545	rs28568531	chr1:2555640	T/A	cg00980319	chr1:2560884	MMEL1	-0.34	-4.83	-0.3	2.42e-6	Ulcerative colitis;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg08662619	chr6:150070041	PCMT1	0.42	6.28	0.38	1.67e-9	Neuroticism;
SARC	cis	rs9790314	0.502	rs34972965	chr3:160984296	G/A	cg03342759	chr3:160939853	NMD3	-0.71	-9.12	-0.51	3.55e-17	Morning vs. evening chronotype;
SARC	cis	rs7582720	1.000	rs114123510	chr2:203831212	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs9302635	0.513	rs12444701	chr16:72155240	C/T	cg01557791	chr16:72042693	DHODH	-0.58	-6.44	-0.39	6.63e-10	Blood protein levels;
SARC	cis	rs17376456	0.877	rs66696214	chr5:93424533	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.73	0.35	3.03e-8	Diabetic retinopathy;
SARC	cis	rs11785400	1.000	rs3824208	chr8:143743653	C/G	cg24634471	chr8:143751801	JRK	0.68	9.17	0.52	2.5e-17	Schizophrenia;
SARC	cis	rs1728785	1.000	rs7118	chr16:68600855	G/T	cg02972257	chr16:68554789	NA	-0.46	-5.52	-0.34	9.09e-8	Ulcerative colitis;
SARC	cis	rs7044106	0.718	rs1960421	chr9:123394894	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	8.56	0.49	1.55e-15	Hip circumference adjusted for BMI;
SARC	cis	rs11785400	0.762	rs2280880	chr8:143721929	C/A	cg10596483	chr8:143751796	JRK	0.58	7.53	0.44	1.08e-12	Schizophrenia;
SARC	cis	rs9325144	0.647	rs3759139	chr12:39087609	G/A	cg13010199	chr12:38710504	ALG10B	-0.55	-6.89	-0.41	5.16e-11	Morning vs. evening chronotype;
SARC	cis	rs11098499	0.954	rs7436506	chr4:120393769	T/C	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	cis	rs7659604	0.502	rs13108419	chr4:122687238	A/G	cg19748678	chr4:122722346	EXOSC9	-0.42	-5.1	-0.32	7.08e-7	Type 2 diabetes;
SARC	cis	rs11997175	0.568	rs4733169	chr8:33581855	T/C	ch.8.33884649F	chr8:33765107	NA	0.46	5.85	0.36	1.67e-8	Body mass index;
SARC	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-9.7	-0.54	6.63e-19	Chronic sinus infection;
SARC	cis	rs7666738	0.830	rs13106434	chr4:98991651	T/A	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg11941060	chr3:133502564	NA	-0.41	-5.77	-0.35	2.54e-8	Iron status biomarkers;
SARC	cis	rs10463554	0.892	rs17154860	chr5:102291145	C/T	cg23492399	chr5:102201601	PAM	-0.47	-5.63	-0.35	5.05e-8	Parkinson's disease;
SARC	cis	rs9457247	0.588	rs35171809	chr6:167432766	A/G	cg23791538	chr6:167370224	RNASET2	-0.5	-6.69	-0.4	1.64e-10	Crohn's disease;
SARC	cis	rs11608355	0.506	rs11066471	chr12:109828039	T/C	cg05360138	chr12:110035743	NA	0.54	6.2	0.38	2.54e-9	Neuroticism;
SARC	cis	rs853679	0.713	rs200991	chr6:27815494	A/C	cg17221315	chr6:27791827	HIST1H4J	-0.65	-5.42	-0.33	1.47e-7	Depression;
SARC	cis	rs1707322	0.686	rs2050376	chr1:46078630	C/T	cg03146154	chr1:46216737	IPP	0.51	6.03	0.37	6.41e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7824557	0.670	rs2736381	chr8:11132766	A/T	cg21775007	chr8:11205619	TDH	-0.47	-5.73	-0.35	3.13e-8	Retinal vascular caliber;
SARC	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg22535103	chr8:58192502	C8orf71	-0.58	-6.17	-0.37	3.04e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg05313129	chr8:58192883	C8orf71	-0.51	-5.92	-0.36	1.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2228479	0.557	rs62056097	chr16:89933420	A/G	cg00800038	chr16:89945340	TCF25	-0.72	-5.22	-0.32	3.97e-7	Skin colour saturation;
SARC	cis	rs2016266	0.855	rs930900	chr12:53727545	T/C	cg26875137	chr12:53738046	NA	0.48	6.29	0.38	1.52e-9	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs1483890	0.962	rs1483891	chr3:69410416	G/C	cg22125112	chr3:69402811	FRMD4B	0.31	5.27	0.33	3.04e-7	Resting heart rate;
SARC	cis	rs10411936	0.626	rs8109817	chr19:16587889	T/C	cg10248733	chr19:16607483	C19orf44;CALR3	0.62	7.54	0.44	1.03e-12	White blood cell count;Multiple sclerosis;
SARC	cis	rs4924935	0.770	rs4924946	chr17:18846525	A/T	cg26306683	chr17:18585705	ZNF286B	-0.46	-5.52	-0.34	8.89e-8	Pancreatic cancer;
SARC	trans	rs1973993	0.745	rs986427	chr1:96932736	A/G	cg10631902	chr5:14652156	NA	-0.42	-6.8	-0.41	8.88e-11	Weight;
SARC	cis	rs4563143	0.514	rs73029081	chr19:29295583	C/G	cg12756686	chr19:29218302	NA	0.59	6.75	0.4	1.16e-10	Methadone dose in opioid dependence;
SARC	cis	rs10916814	0.632	rs10799645	chr1:20903784	T/C	cg24502330	chr1:20914028	CDA	-0.29	-4.99	-0.31	1.17e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg12923728	chr3:195709715	SDHAP1	-0.69	-8.45	-0.48	3.11e-15	Pancreatic cancer;
SARC	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg22683308	chr4:1340831	KIAA1530	0.44	5.23	0.32	3.8e-7	Longevity;
SARC	cis	rs9296092	0.538	rs7761464	chr6:33519417	C/A	cg13560919	chr6:33536144	NA	-0.51	-6.24	-0.38	2.08e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	trans	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-6.8	-0.41	8.51e-11	Intelligence (multi-trait analysis);
SARC	cis	rs698833	0.798	rs1067391	chr2:44639434	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.68	8.81	0.5	2.93e-16	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs5753618	0.504	rs5749295	chr22:31932895	A/T	cg02404636	chr22:31891804	SFI1	0.55	6.71	0.4	1.5e-10	Colorectal cancer;
SARC	cis	rs6570726	0.902	rs373321	chr6:145854150	T/A	cg05347473	chr6:146136440	FBXO30	0.49	6.58	0.4	3.04e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg27266027	chr21:40555129	PSMG1	0.47	5.08	0.32	7.79e-7	Cognitive function;
SARC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg10295955	chr4:187884368	NA	1.1	19.88	0.79	4.21e-52	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg11764359	chr7:65958608	NA	-0.67	-7.95	-0.46	7.86e-14	Aortic root size;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg01010781	chr7:44622047	TMED4	-0.59	-6.74	-0.4	1.22e-10	Brain volume in infants (cerebrospinal fluid);
SARC	trans	rs1994135	0.669	rs11052746	chr12:33697473	A/C	cg26384229	chr12:38710491	ALG10B	-0.66	-8.13	-0.47	2.54e-14	Resting heart rate;
SARC	cis	rs7326068	0.610	rs2818985	chr13:21314209	G/T	cg16922012	chr13:21400325	XPO4	-0.42	-5.72	-0.35	3.21e-8	Schizophrenia, bipolar disorder and depression (combined);
SARC	cis	rs7592578	0.679	rs4287794	chr2:191327147	T/C	cg10560079	chr2:191398806	TMEM194B	-0.76	-8.41	-0.48	4.07e-15	Diastolic blood pressure;
SARC	cis	rs3796352	0.571	rs11713926	chr3:53155072	C/T	cg27565382	chr3:53032988	SFMBT1	0.9	6.04	0.37	6.16e-9	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs4901847	0.643	rs36051876	chr14:58596241	C/T	cg15908186	chr14:58618357	C14orf37	0.59	7.72	0.45	3.49e-13	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs7735319	0.727	rs34095090	chr5:33105969	C/T	cg21580394	chr5:33502217	NA	-0.35	-4.72	-0.3	4.08e-6	Systolic blood pressure;
SARC	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg23262073	chr20:60523788	NA	-0.39	-5.63	-0.35	5.17e-8	Body mass index;
SARC	cis	rs735539	0.521	rs1966190	chr13:21409137	A/C	cg16922012	chr13:21400325	XPO4	-0.43	-5.91	-0.36	1.22e-8	Dental caries;
SARC	cis	rs9400467	0.537	rs12111379	chr6:111434809	T/C	cg15721981	chr6:111408429	SLC16A10	0.65	5.76	0.35	2.59e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs9325144	0.534	rs1843887	chr12:38692380	T/C	cg13010199	chr12:38710504	ALG10B	0.55	7.22	0.43	7.12e-12	Morning vs. evening chronotype;
SARC	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.95	14.01	0.68	9.46e-33	Chronic sinus infection;
SARC	cis	rs7587476	0.906	rs62201985	chr2:215658638	A/G	cg04530015	chr2:215796436	ABCA12	-0.43	-6.4	-0.39	8.46e-10	Neuroblastoma;
SARC	cis	rs7208859	0.623	rs8080882	chr17:29081146	G/A	cg13385521	chr17:29058706	SUZ12P	0.88	7.75	0.45	2.9e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs3762637	0.943	rs28403550	chr3:122251838	C/A	cg24169773	chr3:122142474	KPNA1	-0.57	-5.77	-0.35	2.55e-8	LDL cholesterol levels;
SARC	cis	rs7005380	0.581	rs2017310	chr8:120933341	A/G	cg21744203	chr8:120868354	DSCC1	0.44	5.13	0.32	6.1e-7	Interstitial lung disease;
SARC	cis	rs7617773	0.710	rs36064160	chr3:48243101	C/G	cg11946769	chr3:48343235	NME6	0.72	9.31	0.52	9.87e-18	Coronary artery disease;
SARC	cis	rs10484885	0.878	rs17763820	chr6:90569634	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.59	-5.22	-0.32	4e-7	QRS interval (sulfonylurea treatment interaction);
SARC	cis	rs6429082	0.518	rs1812350	chr1:235659920	C/A	cg26050004	chr1:235667680	B3GALNT2	0.8	13.18	0.65	5.17e-30	Adiposity;
SARC	cis	rs6840360	0.571	rs28608620	chr4:152504791	C/T	cg22705602	chr4:152727874	NA	-0.41	-6.47	-0.39	5.71e-10	Intelligence (multi-trait analysis);
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg13800586	chr2:242626324	DTYMK	0.65	6.57	0.4	3.17e-10	Lung cancer in ever smokers;
SARC	cis	rs4268898	0.722	rs35520052	chr2:24415277	C/T	cg26838691	chr2:24397539	C2orf84	0.4	5.39	0.33	1.77e-7	Asthma;
SARC	cis	rs6910061	0.830	rs13190922	chr6:11125002	T/C	cg27233058	chr6:11094804	LOC221710	0.59	5.46	0.34	1.23e-7	Diabetic kidney disease;
SARC	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg22920501	chr2:26401640	FAM59B	0.54	6.92	0.41	4.44e-11	Gut microbiome composition (summer);
SARC	cis	rs55986470	0.703	rs11887099	chr2:239447550	T/C	cg18131467	chr2:239335373	ASB1	-0.57	-5.22	-0.32	4.04e-7	Chronotype;
SARC	cis	rs3126085	0.935	rs11204939	chr1:152200942	G/C	cg03465714	chr1:152285911	FLG	-0.47	-5.71	-0.35	3.45e-8	Atopic dermatitis;
SARC	cis	rs6674176	0.628	rs4660758	chr1:44424879	A/C	cg13606994	chr1:44402422	ARTN	-0.32	-5.26	-0.33	3.34e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg02725872	chr8:58115012	NA	-0.34	-5.37	-0.33	1.91e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2952156	0.920	rs2517957	chr17:37838716	G/A	cg07936489	chr17:37558343	FBXL20	-0.45	-5.75	-0.35	2.76e-8	Asthma;
SARC	cis	rs7833986	1.000	rs35883156	chr8:57078933	G/T	cg26371346	chr8:56986568	SNORD54;RPS20	0.59	5.0	0.31	1.15e-6	Height;
SARC	trans	rs61931739	0.517	rs1843735	chr12:34047389	C/G	cg26384229	chr12:38710491	ALG10B	0.76	10.91	0.58	1.14e-22	Morning vs. evening chronotype;
SARC	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg25072359	chr17:41440525	NA	0.52	6.19	0.38	2.69e-9	Menopause (age at onset);
SARC	cis	rs12824058	0.831	rs12322456	chr12:130813594	A/G	cg26677194	chr12:130822605	PIWIL1	0.55	7.55	0.44	9.94e-13	Menopause (age at onset);
SARC	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg18876405	chr7:65276391	NA	0.71	9.1	0.51	4.1e-17	Aortic root size;
SARC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	17.75	0.76	3.54e-45	Prudent dietary pattern;
SARC	cis	rs2153535	0.580	rs7341206	chr6:8470489	T/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	trans	rs17685	0.753	rs11982200	chr7:75714883	T/C	cg19862616	chr7:65841803	NCRNA00174	0.63	7.83	0.46	1.68e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs57561814	0.655	rs8180726	chr7:22749306	A/C	cg01770232	chr7:22766155	IL6	0.63	4.99	0.31	1.18e-6	Tonsillectomy;
SARC	cis	rs8067354	0.872	rs1292060	chr17:57913849	A/G	cg02344993	chr17:57696989	CLTC	0.42	4.83	0.3	2.49e-6	Hemoglobin concentration;
SARC	cis	rs2204008	0.527	rs1315367	chr12:38177487	G/T	cg13010199	chr12:38710504	ALG10B	-0.61	-7.72	-0.45	3.36e-13	Bladder cancer;
SARC	cis	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg15145296	chr3:125709740	NA	-0.48	-4.86	-0.3	2.19e-6	Blood pressure (smoking interaction);
SARC	cis	rs36051895	0.623	rs10118434	chr9:5238460	A/G	cg02405213	chr9:5042618	JAK2	-0.46	-5.41	-0.33	1.54e-7	Pediatric autoimmune diseases;
SARC	cis	rs9815354	0.812	rs73071338	chr3:41824328	G/A	cg03022575	chr3:42003672	ULK4	0.71	5.89	0.36	1.34e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs459571	0.959	rs456205	chr9:136911146	G/A	cg13789015	chr9:136890014	NCRNA00094	0.63	8.64	0.49	9.18e-16	Platelet distribution width;
SARC	cis	rs11112613	0.762	rs66754070	chr12:105949779	G/A	cg03607813	chr12:105948248	NA	0.56	7.48	0.44	1.5e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs12478296	0.901	rs6731775	chr2:242999443	T/C	cg06360820	chr2:242988706	NA	-0.68	-6.75	-0.4	1.19e-10	Obesity-related traits;
SARC	cis	rs7005380	0.581	rs13265734	chr8:120919948	C/A	cg21744203	chr8:120868354	DSCC1	-0.47	-5.46	-0.34	1.23e-7	Interstitial lung disease;
SARC	cis	rs8014204	0.566	rs752857	chr14:75130944	C/T	cg06637938	chr14:75390232	RPS6KL1	0.58	8.35	0.48	6.31e-15	Caffeine consumption;
SARC	cis	rs722599	0.715	rs2300598	chr14:75359229	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.43	-5.4	-0.33	1.63e-7	IgG glycosylation;
SARC	cis	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg05623727	chr3:50126028	RBM5	0.34	5.04	0.31	9.37e-7	Intelligence (multi-trait analysis);
SARC	cis	rs10845606	1.000	rs10845610	chr12:12839107	G/A	cg09462578	chr12:12878428	APOLD1	-0.52	-5.08	-0.32	7.75e-7	Systemic lupus erythematosus;
SARC	cis	rs7772486	0.686	rs9497380	chr6:145955305	T/C	cg05347473	chr6:146136440	FBXO30	0.5	6.99	0.42	2.84e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3126085	0.935	rs12063165	chr1:152176357	C/T	cg26876637	chr1:152193138	HRNR	0.48	5.43	0.34	1.38e-7	Atopic dermatitis;
SARC	cis	rs9473924	0.542	rs4294001	chr6:50850065	G/A	cg14470998	chr6:50812995	TFAP2B	0.71	6.79	0.41	9.42e-11	Body mass index;
SARC	cis	rs6933660	0.646	rs6915598	chr6:151778664	T/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.51	5.91	0.36	1.18e-8	Menarche (age at onset);
SARC	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg00149659	chr3:10157352	C3orf10	0.69	6.44	0.39	6.6e-10	Alzheimer's disease;
SARC	cis	rs2153535	0.541	rs9405386	chr6:8458067	C/G	cg21535247	chr6:8435926	SLC35B3	0.52	6.55	0.39	3.66e-10	Motion sickness;
SARC	cis	rs1559088	0.576	rs10407255	chr19:33581150	A/G	cg27124370	chr19:33622961	WDR88	-0.5	-6.74	-0.4	1.25e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs7103648	0.669	rs11039332	chr11:47695840	G/A	cg20307385	chr11:47447363	PSMC3	0.76	10.51	0.57	2.16e-21	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs1008375	0.932	rs13127157	chr4:17618049	A/G	cg16339924	chr4:17578868	LAP3	-0.62	-7.99	-0.46	6.13e-14	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg05861140	chr6:150128134	PCMT1	0.4	4.75	0.3	3.57e-6	Lung cancer;
SARC	cis	rs12142240	0.660	rs72886903	chr1:46813860	C/T	cg10495392	chr1:46806563	NSUN4	0.65	6.83	0.41	7.25e-11	Menopause (age at onset);
SARC	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg04166393	chr7:2884313	GNA12	0.65	7.63	0.45	5.92e-13	Height;
SARC	cis	rs72480748	0.509	rs3865457	chr19:41398969	C/T	cg17435250	chr19:41386441	CYP2A7	-0.41	-5.59	-0.34	6.32e-8	Post bronchodilator FEV1;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
SARC	cis	rs2228479	0.850	rs12598316	chr16:89916600	C/A	cg12064134	chr16:90016061	DEF8	-0.56	-4.83	-0.3	2.47e-6	Skin colour saturation;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg03574289	chr7:149571017	LOC401431;ATP6V0E2	0.5	6.38	0.39	9.59e-10	Tetralogy of Fallot;
SARC	cis	rs9815354	1.000	rs56158380	chr3:41885588	G/A	cg03022575	chr3:42003672	ULK4	0.62	5.43	0.34	1.39e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs1920116	0.778	rs6807681	chr3:169562443	C/T	cg08193579	chr3:169529701	LRRC34	0.39	4.72	0.3	3.98e-6	Glioma (high-grade);
SARC	cis	rs7524258	0.835	rs7521425	chr1:7306543	C/T	cg07173049	chr1:7289937	CAMTA1	0.34	6.59	0.4	2.91e-10	Tourette's syndrome or obsessive-compulsive disorder;
SARC	cis	rs3008870	0.755	rs2815355	chr1:67485034	A/G	cg02640540	chr1:67518911	SLC35D1	0.46	5.26	0.33	3.34e-7	Lymphocyte percentage of white cells;
SARC	cis	rs8038465	0.622	rs710086	chr15:73877001	C/T	cg15420318	chr15:73925796	NPTN	0.6	6.74	0.4	1.26e-10	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1497406	0.744	rs924203	chr1:16511539	G/T	cg20430773	chr1:16534157	ARHGEF19	0.47	7.25	0.43	6.25e-12	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6860806	0.507	rs270608	chr5:131648406	C/T	cg24060327	chr5:131705240	SLC22A5	-0.72	-8.46	-0.48	3e-15	Breast cancer;
SARC	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg02297831	chr4:17616191	MED28	0.51	6.63	0.4	2.36e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9486719	1.000	rs4839837	chr6:96908706	G/A	cg18709589	chr6:96969512	KIAA0776	0.51	5.29	0.33	2.78e-7	Migraine;Coronary artery disease;
SARC	cis	rs5758659	0.652	rs133340	chr22:42417687	A/T	cg04692870	chr22:42525206	CYP2D6	-0.34	-4.88	-0.3	1.93e-6	Cognitive function;
SARC	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg24675658	chr1:53192096	ZYG11B	0.68	10.32	0.56	8.38e-21	Monocyte count;
SARC	cis	rs7561149	0.902	rs6733291	chr2:179649871	G/A	cg17765952	chr2:179737173	CCDC141	-0.36	-4.73	-0.3	3.82e-6	QT interval;
SARC	trans	rs9951602	0.512	rs4798995	chr18:76654344	T/G	cg02800362	chr5:177631904	HNRNPAB	0.7	8.92	0.5	1.4e-16	Obesity-related traits;
SARC	cis	rs7726839	0.794	rs10474792	chr5:600058	G/A	cg09021430	chr5:549028	NA	-0.47	-6.92	-0.41	4.3e-11	Obesity-related traits;
SARC	cis	rs7520050	0.902	rs4638056	chr1:46458153	T/G	cg24296786	chr1:45957014	TESK2	0.38	4.87	0.3	2.03e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs6089584	0.528	rs4925334	chr20:60626769	C/T	cg13770153	chr20:60521292	NA	-0.38	-5.41	-0.33	1.53e-7	Body mass index;
SARC	cis	rs9868809	0.505	rs11719291	chr3:48735706	A/G	cg00383909	chr3:49044727	WDR6	0.62	5.76	0.35	2.68e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	8.86	0.5	2.11e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6911965	0.641	rs7766290	chr6:24485429	G/A	cg20631270	chr6:24437470	GPLD1	0.51	4.82	0.3	2.59e-6	Hematological and biochemical traits;
SARC	cis	rs6693567	0.507	rs828784	chr1:150335240	T/A	cg09579323	chr1:150459698	TARS2	0.46	5.85	0.36	1.63e-8	Migraine;
SARC	cis	rs5753618	0.561	rs2413047	chr22:31666026	A/G	cg02404636	chr22:31891804	SFI1	-0.49	-5.24	-0.32	3.53e-7	Colorectal cancer;
SARC	cis	rs9733	0.650	rs6698495	chr1:150564476	T/C	cg17724175	chr1:150552817	MCL1	-0.4	-5.23	-0.32	3.78e-7	Tonsillectomy;
SARC	cis	rs11697848	0.737	rs79102316	chr20:48453876	C/T	cg17849948	chr20:48532315	SPATA2	0.8	4.84	0.3	2.32e-6	Systemic lupus erythematosus;
SARC	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg05861140	chr6:150128134	PCMT1	-0.42	-5.44	-0.34	1.32e-7	Lung cancer;
SARC	cis	rs4243830	0.850	rs11122043	chr1:6580429	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.77	-7.52	-0.44	1.17e-12	Body mass index;
SARC	cis	rs6459804	1.000	rs6459805	chr7:157510294	T/C	cg05731713	chr7:157510257	PTPRN2	0.31	5.99	0.37	8.01e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs2273669	0.667	rs12206834	chr6:109303967	T/G	cg05315195	chr6:109294784	ARMC2	-0.57	-5.24	-0.32	3.62e-7	Prostate cancer;
SARC	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg16680214	chr1:154839983	KCNN3	-0.34	-5.44	-0.34	1.37e-7	Prostate cancer;
SARC	cis	rs6582630	0.533	rs2120464	chr12:38280289	A/C	cg13010199	chr12:38710504	ALG10B	0.48	5.93	0.36	1.09e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7833790	0.700	rs7834483	chr8:82704828	A/G	cg06027949	chr8:82754900	SNX16	-0.48	-5.75	-0.35	2.85e-8	Diastolic blood pressure;
SARC	cis	rs6450176	0.625	rs67656636	chr5:53288455	C/A	ch.5.1024479R	chr5:53302184	ARL15	-0.86	-10.05	-0.55	5.8e-20	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs6570726	0.935	rs415590	chr6:145851244	T/C	cg05347473	chr6:146136440	FBXO30	0.49	6.55	0.39	3.56e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs739401	0.611	rs7394974	chr11:3038868	C/T	cg20651018	chr11:3035856	CARS	-0.44	-6.77	-0.41	1.05e-10	Longevity;
SARC	cis	rs920590	0.758	rs1826420	chr8:19664878	G/T	cg01411142	chr8:19674711	INTS10	0.5	5.92	0.36	1.17e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs3796352	1.000	rs750474	chr3:53085280	A/C	cg15956490	chr3:53032818	SFMBT1	0.57	4.78	0.3	3.07e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg01475735	chr3:40494733	NA	-0.49	-5.37	-0.33	1.95e-7	Renal cell carcinoma;
SARC	cis	rs35213789	0.522	rs7800272	chr7:69028691	C/T	cg10619644	chr7:69149951	AUTS2	0.36	5.08	0.32	7.72e-7	Childhood ear infection;
SARC	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg08280861	chr8:58055591	NA	0.6	5.87	0.36	1.45e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1153858	1.000	rs1049503	chr15:45653707	T/C	cg03999130	chr15:45571217	NA	0.39	4.97	0.31	1.27e-6	Homoarginine levels;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg23911396	chr17:36831425	C17orf96	0.53	7.09	0.42	1.57e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs113835537	0.529	rs2276406	chr11:66283257	C/T	cg24851651	chr11:66362959	CCS	0.37	4.76	0.3	3.36e-6	Airway imaging phenotypes;
SARC	cis	rs796364	0.951	rs12996313	chr2:200997916	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.62	-5.83	-0.36	1.8e-8	Schizophrenia;
SARC	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.76	11.33	0.6	5.6e-24	Menarche (age at onset);
SARC	cis	rs7772486	0.754	rs6921073	chr6:146144377	G/A	cg23711669	chr6:146136114	FBXO30	0.82	13.68	0.67	1.19e-31	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9462027	0.630	rs7341267	chr6:34727031	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.84	-0.36	1.71e-8	Systemic lupus erythematosus;
SARC	cis	rs72781680	0.611	rs78861366	chr2:24354428	A/G	cg06627628	chr2:24431161	ITSN2	-0.5	-4.99	-0.31	1.17e-6	Lymphocyte counts;
SARC	cis	rs73206853	0.764	rs28840785	chr12:110844920	C/G	cg10860002	chr12:110842031	ANAPC7	0.63	5.04	0.31	9.52e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs4921915	0.598	rs55686478	chr8:18250375	G/A	cg18736775	chr8:18248649	NAT2	-0.61	-6.1	-0.37	4.34e-9	Iron status biomarkers (transferrin levels);
SARC	cis	rs9896052	0.608	rs9797247	chr17:73445814	C/T	cg04121983	chr17:73511085	CASKIN2	0.42	5.02	0.31	1.04e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg12013930	chr2:219264803	CTDSP1	0.5	6.39	0.39	9.17e-10	Lung adenocarcinoma;
SARC	cis	rs644799	0.965	rs11021317	chr11:95517576	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	9.57	0.53	1.6e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9309473	0.607	rs1403412	chr2:73598092	T/C	cg20560298	chr2:73613845	ALMS1	-0.54	-6.85	-0.41	6.37e-11	Metabolite levels;
SARC	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	5.37	0.33	1.9e-7	Tonsillectomy;
SARC	cis	rs6582630	0.638	rs12231073	chr12:38526901	T/G	cg14851346	chr12:38532713	NA	-0.42	-4.96	-0.31	1.34e-6	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7312933	1.000	rs10880230	chr12:42450253	G/A	cg19980929	chr12:42632907	YAF2	0.33	4.75	0.3	3.52e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	trans	rs208515	0.556	rs12214562	chr6:66681011	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.99	11.54	0.6	1.13e-24	Exhaled nitric oxide levels;
SARC	cis	rs9911578	1.000	rs9901114	chr17:56575208	G/A	cg12560992	chr17:57184187	TRIM37	-0.77	-10.08	-0.55	4.64e-20	Intelligence (multi-trait analysis);
SARC	cis	rs72781680	0.898	rs2339851	chr2:23938883	G/A	cg08917208	chr2:24149416	ATAD2B	0.92	8.77	0.5	3.93e-16	Lymphocyte counts;
SARC	cis	rs2235544	0.565	rs605182	chr1:54466956	A/G	cg10336722	chr1:54665764	CYB5RL;MRPL37	-0.38	-4.74	-0.3	3.66e-6	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
SARC	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg04944784	chr2:26401820	FAM59B	-0.53	-6.63	-0.4	2.34e-10	Gut microbiome composition (summer);
SARC	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg00908189	chr16:619842	PIGQ	0.85	12.24	0.63	6.5e-27	Height;
SARC	cis	rs9611565	1.000	rs5751086	chr22:41768862	C/T	cg17376030	chr22:41985996	PMM1	0.46	5.88	0.36	1.39e-8	Vitiligo;
SARC	cis	rs365132	0.875	rs353496	chr5:176429898	T/C	cg16309518	chr5:176445507	NA	-0.48	-6.29	-0.38	1.53e-9	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs7223966	1.000	rs7220892	chr17:61908316	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.52	-5.44	-0.34	1.37e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg13395646	chr4:1353034	KIAA1530	-0.6	-7.09	-0.42	1.59e-11	Obesity-related traits;
SARC	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg19500275	chr17:80737654	TBCD	0.43	5.1	0.32	7.12e-7	Glycated hemoglobin levels;
SARC	cis	rs568617	0.768	rs12225345	chr11:65647105	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.61	6.64	0.4	2.18e-10	Crohn's disease;
SARC	cis	rs909674	0.818	rs8136980	chr22:39844574	G/A	cg05872129	chr22:39784769	NA	-0.43	-5.86	-0.36	1.59e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs1707322	1.000	rs785517	chr1:46567535	A/T	cg06784218	chr1:46089804	CCDC17	-0.36	-6.28	-0.38	1.61e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7364180	0.515	rs6002503	chr22:42208672	A/G	cg17376030	chr22:41985996	PMM1	0.39	4.95	0.31	1.41e-6	Alzheimer's disease biomarkers;
SARC	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg12463550	chr7:65579703	CRCP	-0.47	-5.03	-0.31	9.64e-7	Aortic root size;
SARC	cis	rs17079247	1.000	rs9575820	chr13:85764196	G/T	ch.13.84760847R	chr13:85862846	NA	0.56	4.95	0.31	1.42e-6	Bipolar disorder (mania);
SARC	cis	rs2288912	0.807	rs10423208	chr19:45453656	G/A	cg09555818	chr19:45449301	APOC2	0.56	8.96	0.51	1.1e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs2304069	0.954	rs9324638	chr5:149400718	A/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	-0.7	-7.01	-0.42	2.63e-11	HIV-1 control;
SARC	cis	rs1707322	1.000	rs1707322	chr1:46505147	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.48	0.39	5.48e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6540556	0.723	rs3766619	chr1:209895298	C/G	cg05527609	chr1:210001259	C1orf107	-0.61	-5.69	-0.35	3.75e-8	Red blood cell count;
SARC	cis	rs1345301	1.000	rs13405355	chr2:102878206	C/T	cg12451869	chr2:102867685	NA	0.38	5.39	0.33	1.71e-7	Waist circumference;
SARC	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	11.31	0.6	6.28e-24	Alzheimer's disease;
SARC	cis	rs7568458	0.811	rs3755014	chr2:85764006	C/T	cg17127132	chr2:85788382	GGCX	0.46	6.21	0.38	2.36e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg11764359	chr7:65958608	NA	0.57	6.55	0.39	3.71e-10	Aortic root size;
SARC	cis	rs9393692	0.645	rs9467703	chr6:26318903	A/G	cg00631329	chr6:26305371	NA	-0.58	-7.36	-0.43	3.21e-12	Educational attainment;
SARC	cis	rs72827839	0.516	rs111630961	chr17:45938097	T/G	cg23391107	chr17:45924227	SP6	0.42	4.79	0.3	2.96e-6	Ease of getting up in the morning;
SARC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg11301795	chr4:187892539	NA	-0.71	-10.14	-0.55	3.07e-20	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs16976116	0.901	rs1061870	chr15:55496769	G/T	cg17854078	chr15:55489399	RSL24D1	0.66	6.53	0.39	4.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs698833	0.926	rs1067339	chr2:44624448	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.71	9.37	0.52	6.6e-18	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs112591243	0.685	rs2839338	chr21:47987984	C/T	cg26904215	chr21:47823096	PCNT	-0.72	-5.41	-0.33	1.53e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs734999	0.572	rs2985857	chr1:2532624	C/T	cg20673091	chr1:2541236	MMEL1	-0.34	-5.2	-0.32	4.37e-7	Ulcerative colitis;
SARC	cis	rs9300255	0.602	rs1716172	chr12:123712712	G/T	cg05973401	chr12:123451056	ABCB9	0.48	5.43	0.34	1.41e-7	Neutrophil percentage of white cells;
SARC	cis	rs752010	1.000	rs6664724	chr1:42093821	G/A	cg06885757	chr1:42089581	HIVEP3	0.34	5.47	0.34	1.13e-7	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs10870270	1.000	rs3935905	chr10:133758262	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.84	-11.02	-0.59	5.29e-23	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs1059312	0.808	rs10847694	chr12:129292457	C/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.49	7.17	0.43	9.93e-12	Systemic lupus erythematosus;
SARC	cis	rs28830936	0.510	rs2412640	chr15:42124082	C/T	cg17847044	chr15:42102381	MAPKBP1	0.45	7.06	0.42	1.89e-11	Diastolic blood pressure;
SARC	cis	rs6062302	0.522	rs6090475	chr20:62245397	C/A	cg16989086	chr20:62203971	PRIC285	0.47	4.73	0.3	3.92e-6	Glioblastoma;
SARC	cis	rs986417	0.892	rs2273624	chr14:60790430	C/A	cg27398547	chr14:60952738	C14orf39	-1.06	-8.79	-0.5	3.34e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs908922	0.584	rs71626721	chr1:152532745	A/G	cg09873164	chr1:152488093	CRCT1	0.58	7.47	0.44	1.64e-12	Hair morphology;
SARC	cis	rs1832871	0.643	rs112195967	chr6:158775695	C/T	cg07165851	chr6:158734300	TULP4	0.55	6.56	0.39	3.53e-10	Height;
SARC	cis	rs1594829	0.535	rs17055121	chr8:26170975	C/T	cg11498726	chr8:26250323	BNIP3L	-0.41	-5.29	-0.33	2.77e-7	Height;
SARC	cis	rs11608355	0.545	rs11615949	chr12:109894347	G/A	cg05360138	chr12:110035743	NA	0.92	9.61	0.53	1.27e-18	Neuroticism;
SARC	cis	rs4742903	0.935	rs17236663	chr9:106928402	G/A	cg14250997	chr9:106856677	SMC2	0.44	5.5	0.34	1.01e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs7103648	0.966	rs1534576	chr11:47419663	A/C	cg20307385	chr11:47447363	PSMC3	-0.89	-15.13	-0.7	1.73e-36	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs4969178	0.965	rs938351	chr17:76399404	C/T	cg02836325	chr17:76403955	PGS1	0.33	5.12	0.32	6.36e-7	HDL cholesterol levels;
SARC	cis	rs11608355	0.508	rs12822899	chr12:109800978	A/G	cg19025524	chr12:109796872	NA	-0.42	-5.23	-0.32	3.77e-7	Neuroticism;
SARC	cis	rs16976116	0.901	rs28708989	chr15:55498934	C/T	cg17854078	chr15:55489399	RSL24D1	0.66	6.53	0.39	4.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4356932	1.000	rs10000130	chr4:76939335	T/C	cg24176760	chr4:76958061	ART3;CXCL11	-0.28	-4.72	-0.3	4.03e-6	Blood protein levels;
SARC	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg24633833	chr3:10029261	TMEM111	0.51	5.09	0.32	7.27e-7	Alzheimer's disease;
SARC	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg06618935	chr21:46677482	NA	-0.39	-5.14	-0.32	5.72e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2006771	0.810	rs2006648	chr22:32081929	T/C	cg02404636	chr22:31891804	SFI1	-0.37	-4.89	-0.3	1.91e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs933688	0.938	rs7705465	chr5:90680949	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.06	13.47	0.66	5.91e-31	Smoking behavior;
SARC	trans	rs61931739	0.500	rs7295779	chr12:34460652	T/C	cg26384229	chr12:38710491	ALG10B	0.83	12.43	0.63	1.54e-27	Morning vs. evening chronotype;
SARC	cis	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg24110177	chr3:50126178	RBM5	-0.38	-4.87	-0.3	2.11e-6	Intelligence (multi-trait analysis);
SARC	cis	rs4481887	0.893	rs7515080	chr1:248494073	A/G	cg01631408	chr1:248437212	OR2T33	-0.43	-5.4	-0.33	1.68e-7	Common traits (Other);
SARC	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg26513180	chr16:89883248	FANCA	0.75	4.84	0.3	2.35e-6	Skin colour saturation;
SARC	cis	rs1949733	0.635	rs4358384	chr4:8536913	C/T	cg13073564	chr4:8508604	NA	0.48	7.49	0.44	1.42e-12	Response to antineoplastic agents;
SARC	cis	rs7481584	0.517	rs80872	chr11:3049984	G/T	cg20651018	chr11:3035856	CARS	0.41	6.12	0.37	4.01e-9	Calcium levels;
SARC	cis	rs2282300	0.739	rs1222211	chr11:30362239	A/C	cg25418670	chr11:30344373	C11orf46	-0.41	-5.3	-0.33	2.68e-7	Morning vs. evening chronotype;
SARC	cis	rs61935443	0.501	rs9668170	chr12:95175812	G/A	cg21533806	chr12:95267307	NA	0.39	4.84	0.3	2.39e-6	Schizophrenia;
SARC	cis	rs35213789	0.762	rs1860488	chr7:69150131	C/G	cg10619644	chr7:69149951	AUTS2	-0.36	-4.95	-0.31	1.44e-6	Childhood ear infection;
SARC	cis	rs3733585	0.699	rs6449171	chr4:9965998	C/T	cg00071950	chr4:10020882	SLC2A9	0.37	5.7	0.35	3.6e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs1355223	0.506	rs7947848	chr11:34866220	T/C	cg11622362	chr11:34938112	PDHX;APIP	0.46	6.04	0.37	5.98e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs6456156	0.792	rs4710183	chr6:167514083	A/G	cg07741184	chr6:167504864	NA	-0.36	-7.15	-0.42	1.12e-11	Primary biliary cholangitis;
SARC	cis	rs4423214	1.000	rs11606631	chr11:71164121	C/A	cg24826892	chr11:71159390	DHCR7	0.44	5.3	0.33	2.74e-7	Vitamin D levels;
SARC	cis	rs793571	0.544	rs11638244	chr15:58907151	A/T	cg05156742	chr15:59063176	FAM63B	0.77	10.81	0.58	2.44e-22	Schizophrenia;
SARC	cis	rs6701037	1.000	rs7512413	chr1:175124789	C/T	cg00321850	chr1:175162397	KIAA0040	-0.34	-5.02	-0.31	1.03e-6	Alcohol dependence;
SARC	cis	rs5753037	0.653	rs131270	chr22:30149896	C/T	cg01021169	chr22:30184971	ASCC2	-0.46	-6.33	-0.38	1.27e-9	Type 1 diabetes;
SARC	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.75	7.21	0.43	7.87e-12	Platelet count;
SARC	cis	rs7959452	0.640	rs11177599	chr12:69721970	G/A	cg20891283	chr12:69753455	YEATS4	0.43	5.74	0.35	2.87e-8	Blood protein levels;
SARC	cis	rs13191362	1.000	rs1333963	chr6:163192571	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.75	6.38	0.39	9.54e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs5167	0.566	rs204905	chr19:45460764	G/A	cg13119609	chr19:45449297	APOC2	0.51	8.68	0.49	7.16e-16	Blood protein levels;
SARC	cis	rs7178572	0.524	rs11853287	chr15:77399371	A/G	cg22256960	chr15:77711686	NA	-0.53	-5.58	-0.34	6.71e-8	Type 2 diabetes;
SARC	cis	rs7843479	0.965	rs9314269	chr8:21804989	A/G	cg17168535	chr8:21777572	XPO7	0.62	7.95	0.46	7.8e-14	Mean corpuscular volume;
SARC	cis	rs73036520	0.958	rs11670562	chr19:45743640	T/C	cg01416317	chr19:45737208	EXOC3L2	0.35	4.78	0.3	3.09e-6	Monocyte percentage of white cells;
SARC	cis	rs765787	0.530	rs11854294	chr15:45527996	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.67e-7	Uric acid levels;
SARC	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg11644478	chr21:40555479	PSMG1	1.03	14.14	0.68	3.47e-33	Cognitive function;
SARC	cis	rs826838	1.000	rs2129627	chr12:38653036	C/T	cg26384229	chr12:38710491	ALG10B	0.93	14.73	0.69	3.88e-35	Heart rate;
SARC	cis	rs6693567	0.565	rs1776275	chr1:150269437	G/T	cg09579323	chr1:150459698	TARS2	-0.43	-5.46	-0.34	1.24e-7	Migraine;
SARC	cis	rs2075671	0.810	rs12531792	chr7:100280624	G/A	cg03098644	chr7:100410630	EPHB4	0.46	5.02	0.31	1.04e-6	Other erythrocyte phenotypes;
SARC	cis	rs736408	0.648	rs2268023	chr3:52819327	T/A	cg18404041	chr3:52824283	ITIH1	-0.43	-6.2	-0.38	2.48e-9	Bipolar disorder;
SARC	cis	rs370915	0.890	rs1425952	chr4:187833545	A/G	cg19519643	chr4:187840862	NA	-0.4	-4.96	-0.31	1.36e-6	Gout;
SARC	cis	rs17376456	0.825	rs10052662	chr5:93271385	A/G	cg21475434	chr5:93447410	FAM172A	0.85	7.57	0.44	8.53e-13	Diabetic retinopathy;
SARC	cis	rs6732160	1.000	rs6732160	chr2:73387228	A/G	cg01422370	chr2:73384389	NA	0.31	5.1	0.32	6.94e-7	Intelligence (multi-trait analysis);
SARC	cis	rs8078723	0.866	rs3935280	chr17:38189055	A/G	cg17467752	chr17:38218738	THRA	-0.55	-7.25	-0.43	5.97e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs6087771	0.682	rs2038397	chr20:30217759	A/G	cg13852791	chr20:30311386	BCL2L1	0.66	6.62	0.4	2.45e-10	Subcortical brain region volumes;Putamen volume;
SARC	cis	rs9473924	0.505	rs7738924	chr6:50850600	C/T	cg14470998	chr6:50812995	TFAP2B	0.77	7.24	0.43	6.59e-12	Body mass index;
SARC	cis	rs911555	0.504	rs61995761	chr14:104075712	T/C	cg17925084	chr14:104152323	KLC1	0.39	5.5	0.34	9.94e-8	Intelligence (multi-trait analysis);
SARC	cis	rs3008870	0.755	rs2815365	chr1:67499628	C/T	cg02640540	chr1:67518911	SLC35D1	0.46	5.22	0.32	4.03e-7	Lymphocyte percentage of white cells;
SARC	cis	rs4481887	0.790	rs4453078	chr1:248411889	A/G	cg00666640	chr1:248458726	OR2T12	-0.29	-4.76	-0.3	3.38e-6	Common traits (Other);
SARC	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.75	10.75	0.58	3.75e-22	Personality dimensions;
SARC	cis	rs9398803	0.671	rs1155939	chr6:126866133	C/A	cg20229609	chr6:126660872	C6orf173	0.4	5.79	0.35	2.26e-8	Male-pattern baldness;
SARC	cis	rs7223966	1.000	rs9893348	chr17:61676534	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.53	-5.01	-0.31	1.09e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7914558	1.000	rs10509757	chr10:104752960	C/T	cg04362960	chr10:104952993	NT5C2	0.41	4.95	0.31	1.41e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs4073582	0.595	rs1151540	chr11:66041807	A/C	cg14036092	chr11:66035641	RAB1B	0.62	8.84	0.5	2.39e-16	Gout;
SARC	cis	rs55823223	0.646	rs55868394	chr17:73851113	C/A	cg02397686	chr17:73851076	WBP2	0.59	5.17	0.32	5.12e-7	Psoriasis;
SARC	cis	rs4891159	0.757	rs11665018	chr18:74123589	C/T	cg24786174	chr18:74118243	ZNF516	-0.67	-9.83	-0.54	2.59e-19	Longevity;
SARC	cis	rs7179456	0.545	rs507801	chr15:59053345	T/G	cg05156742	chr15:59063176	FAM63B	0.65	8.27	0.48	1.01e-14	Asperger disorder;
SARC	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	8.88	0.5	1.89e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg16049864	chr8:95962084	TP53INP1	-0.55	-8.88	-0.5	1.89e-16	Type 2 diabetes;
SARC	cis	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg24110177	chr3:50126178	RBM5	-0.55	-7.3	-0.43	4.64e-12	Intelligence (multi-trait analysis);
SARC	cis	rs6459788	0.693	rs11981578	chr7:157250133	C/T	cg03453431	chr7:157225567	NA	-0.42	-6.41	-0.39	8.01e-10	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs1468333	1.000	rs2967781	chr5:137557609	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.8	10.96	0.58	8.15e-23	Resting heart rate;
SARC	cis	rs1609391	0.543	rs6800690	chr3:136623026	G/A	cg15507776	chr3:136538369	TMEM22	0.83	11.54	0.6	1.17e-24	Neuroticism;
SARC	cis	rs4423214	1.000	rs909217	chr11:71146577	G/A	cg05163923	chr11:71159392	DHCR7	0.66	8.77	0.5	3.9e-16	Vitamin D levels;
SARC	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg16479474	chr6:28041457	NA	0.38	5.58	0.34	6.78e-8	Depression;
SARC	cis	rs72827839	0.516	rs72833458	chr17:45938051	A/G	cg23391107	chr17:45924227	SP6	0.41	4.72	0.3	4.01e-6	Ease of getting up in the morning;
SARC	cis	rs9326248	0.911	rs11216284	chr11:117003060	C/T	cg10130564	chr11:117069849	TAGLN	0.23	4.91	0.31	1.71e-6	Blood protein levels;
SARC	cis	rs7312933	0.567	rs11181399	chr12:42666412	G/A	cg17420585	chr12:42539391	GXYLT1	-0.34	-4.85	-0.3	2.28e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs6088813	1.000	rs6141546	chr20:33949282	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	-0.44	-5.35	-0.33	2.07e-7	Height;
SARC	cis	rs362272	0.505	rs3129310	chr4:3301388	T/G	cg06533319	chr4:3265114	C4orf44	-0.34	-5.36	-0.33	2.04e-7	Serum sulfate level;
SARC	cis	rs448720	0.811	rs694267	chr15:68183377	C/T	cg05925327	chr15:68127851	NA	-0.36	-5.3	-0.33	2.7e-7	Cognitive performance;
SARC	cis	rs1953600	0.837	rs2819946	chr10:81951635	G/A	cg00277334	chr10:82204260	NA	0.36	5.29	0.33	2.78e-7	Sarcoidosis;
SARC	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg20503657	chr10:835505	NA	-1.11	-10.51	-0.57	2.11e-21	Eosinophil percentage of granulocytes;
SARC	cis	rs4792901	0.722	rs7220615	chr17:41540644	G/A	cg22562494	chr17:41607896	ETV4	-0.3	-4.86	-0.3	2.16e-6	Dupuytren's disease;
SARC	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg20607798	chr8:58055168	NA	0.53	5.13	0.32	6.12e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs3126085	0.935	rs12027807	chr1:152253726	C/G	cg26876637	chr1:152193138	HRNR	0.46	5.29	0.33	2.86e-7	Atopic dermatitis;
SARC	cis	rs7223966	1.000	rs56383601	chr17:61929968	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	5.3	0.33	2.73e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs3768617	0.510	rs3768615	chr1:183103604	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.68	9.89	0.54	1.7e-19	Fuchs's corneal dystrophy;
SARC	cis	rs17376456	0.825	rs56108532	chr5:93276342	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.67	6.14	0.37	3.48e-9	Diabetic retinopathy;
SARC	cis	rs9640161	0.789	rs4554381	chr7:150025567	G/A	cg17279839	chr7:150038598	RARRES2	0.49	7.13	0.42	1.23e-11	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg19077165	chr18:44547161	KATNAL2	-0.51	-7.09	-0.42	1.63e-11	Personality dimensions;
SARC	cis	rs7772486	0.790	rs2265472	chr6:146220758	G/C	cg23711669	chr6:146136114	FBXO30	0.8	12.59	0.64	4.55e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11630290	0.592	rs11071769	chr15:64156842	G/C	cg12036633	chr15:63758958	NA	0.48	4.96	0.31	1.34e-6	Iris characteristics;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg11231018	chr10:90423408	LIPF	0.47	6.69	0.4	1.66e-10	Thyroid stimulating hormone;
SARC	cis	rs9840812	0.769	rs489398	chr3:135995498	T/C	cg15507776	chr3:136538369	TMEM22	0.5	4.91	0.31	1.68e-6	Fibrinogen levels;
SARC	cis	rs2865116	0.851	rs1984505	chr7:68948356	C/T	cg10619644	chr7:69149951	AUTS2	0.34	4.76	0.3	3.33e-6	Positive affect;
SARC	cis	rs9486719	0.802	rs2983896	chr6:97029871	G/A	cg06623918	chr6:96969491	KIAA0776	-0.78	-9.4	-0.52	5.32e-18	Migraine;Coronary artery disease;
SARC	cis	rs503734	0.502	rs1994201	chr3:100970062	C/T	cg27318481	chr3:100970896	IMPG2	0.46	5.51	0.34	9.64e-8	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg05313129	chr8:58192883	C8orf71	-0.49	-5.78	-0.35	2.44e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7474896	0.561	rs2474603	chr10:38445682	C/T	cg00409905	chr10:38381863	ZNF37A	-0.54	-5.25	-0.33	3.46e-7	Obesity (extreme);
SARC	cis	rs9527	0.640	rs6584541	chr10:104929124	A/G	cg04362960	chr10:104952993	NT5C2	0.42	5.03	0.31	1e-6	Arsenic metabolism;
SARC	cis	rs950776	0.714	rs514743	chr15:78884227	A/T	cg22563815	chr15:78856949	CHRNA5	-0.32	-5.03	-0.31	9.62e-7	Sudden cardiac arrest;
SARC	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg00933542	chr6:150070202	PCMT1	0.33	5.44	0.34	1.35e-7	Lung cancer;
SARC	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	9.91	0.54	1.53e-19	Platelet count;
SARC	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg24642844	chr7:1081250	C7orf50	-0.57	-6.05	-0.37	5.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg03433033	chr1:76189801	ACADM	-0.43	-5.64	-0.35	4.81e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2814982	0.605	rs35429796	chr6:34474639	G/T	cg14254433	chr6:34482411	PACSIN1	-0.5	-4.77	-0.3	3.2e-6	Cholesterol, total;Total cholesterol levels;
SARC	cis	rs8177253	0.514	rs6790668	chr3:133442481	T/A	cg01448562	chr3:133502909	NA	-0.32	-4.76	-0.3	3.42e-6	Iron status biomarkers;
SARC	cis	rs11055034	0.560	rs2024385	chr12:12888438	A/T	cg09462578	chr12:12878428	APOLD1	0.49	6.37	0.39	1e-9	Birth weight;
SARC	cis	rs11583043	0.918	rs17525451	chr1:101422409	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.48	5.88	0.36	1.38e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg11494091	chr17:61959527	GH2	0.54	8.07	0.47	3.81e-14	Prudent dietary pattern;
SARC	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg16405210	chr4:1374714	KIAA1530	-0.48	-5.97	-0.36	8.72e-9	Longevity;
SARC	cis	rs34172651	0.917	rs8049667	chr16:24773524	G/A	cg00339695	chr16:24857497	SLC5A11	0.3	4.9	0.31	1.8e-6	Intelligence (multi-trait analysis);
SARC	cis	rs11098499	0.863	rs10004484	chr4:120442428	C/T	cg09307838	chr4:120376055	NA	0.94	12.99	0.65	2.15e-29	Corneal astigmatism;
SARC	cis	rs3764563	0.877	rs4019751	chr19:15740716	T/G	cg20725493	chr19:15740067	CYP4F8	-0.77	-5.96	-0.36	9.12e-9	Inflammatory biomarkers;
SARC	cis	rs472402	0.870	rs187470	chr5:6643491	T/C	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.39	-4.98	-0.31	1.25e-6	Response to amphetamines;
SARC	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg27266027	chr21:40555129	PSMG1	-0.45	-5.05	-0.31	9.11e-7	Cognitive function;
SARC	cis	rs72781680	0.898	rs12623316	chr2:24087857	A/G	cg08917208	chr2:24149416	ATAD2B	0.75	7.33	0.43	3.77e-12	Lymphocyte counts;
SARC	cis	rs7246657	0.943	rs7408563	chr19:37808585	G/C	cg14683738	chr19:37701593	ZNF585B	0.52	4.87	0.3	2.04e-6	Coronary artery calcification;
SARC	cis	rs911555	0.755	rs11627446	chr14:103946450	G/C	cg24130564	chr14:104152367	KLC1	-0.5	-5.94	-0.36	1.01e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2239547	0.563	rs6445547	chr3:52908577	T/C	cg11645453	chr3:52864694	ITIH4	0.32	4.77	0.3	3.32e-6	Schizophrenia;
SARC	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg18252515	chr7:66147081	NA	-0.62	-6.59	-0.4	2.98e-10	Aortic root size;
SARC	cis	rs12545912	0.821	rs4841183	chr8:9470862	T/A	cg21625330	chr8:9911636	MSRA	-0.51	-4.89	-0.31	1.84e-6	Multiple myeloma (hyperdiploidy);
SARC	cis	rs1153858	0.945	rs1974981	chr15:45729123	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.71	-9.16	-0.51	2.77e-17	Homoarginine levels;
SARC	cis	rs12190007	0.547	rs1018559	chr6:169854176	A/G	cg15038512	chr6:170123185	PHF10	-0.49	-6.52	-0.39	4.26e-10	Obesity-related traits;
SARC	trans	rs9951602	0.512	rs8089108	chr18:76651361	C/T	cg02800362	chr5:177631904	HNRNPAB	0.71	9.0	0.51	8.26e-17	Obesity-related traits;
SARC	cis	rs2439831	0.557	rs13329084	chr15:44151063	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.87	-7.44	-0.44	1.89e-12	Lung cancer in ever smokers;
SARC	cis	rs7552404	0.924	rs2173378	chr1:76201992	G/T	cg10523679	chr1:76189770	ACADM	0.45	6.2	0.38	2.53e-9	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	5.29	0.33	2.79e-7	Bipolar disorder;
SARC	trans	rs6894249	1.000	rs6894249	chr5:131797547	A/G	cg03037622	chr3:51430415	RBM15B	-0.47	-6.53	-0.39	4.15e-10	Asthma;
SARC	cis	rs7246657	1.000	rs35398388	chr19:37740358	A/G	cg23950597	chr19:37808831	NA	-0.58	-5.34	-0.33	2.18e-7	Coronary artery calcification;
SARC	cis	rs2370759	0.945	rs74625866	chr10:32597618	A/T	cg18270830	chr10:32634957	EPC1	0.63	5.57	0.34	7.04e-8	Sexual dysfunction (female);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg07352234	chr8:121457652	MTBP;MRPL13	0.84	6.94	0.41	3.91e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg25427524	chr10:38739819	LOC399744	0.58	9.22	0.52	1.87e-17	Extrinsic epigenetic age acceleration;
SARC	cis	rs208520	1.000	rs208537	chr6:66963544	A/G	cg07460842	chr6:66804631	NA	-0.86	-9.48	-0.53	3.09e-18	Exhaled nitric oxide output;
SARC	cis	rs7647973	0.961	rs7619016	chr3:49272589	C/T	cg07636037	chr3:49044803	WDR6	0.73	7.84	0.46	1.62e-13	Menarche (age at onset);
SARC	cis	rs644799	1.000	rs651445	chr11:95539122	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	15.35	0.71	3.21e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs909674	0.775	rs8138462	chr22:39839670	G/C	cg05872129	chr22:39784769	NA	-0.42	-5.8	-0.35	2.2e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs1348850	0.958	rs10497501	chr2:178462299	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	7.64	0.45	5.64e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs57506017	0.585	rs6460906	chr7:12283276	T/C	cg23422036	chr7:12250390	TMEM106B	0.48	6.35	0.38	1.12e-9	Neuroticism;
SARC	cis	rs2204008	0.805	rs4589389	chr12:37946120	C/A	cg26384229	chr12:38710491	ALG10B	-0.78	-11.28	-0.59	8.07e-24	Bladder cancer;
SARC	cis	rs9457247	0.967	rs382009	chr6:167403121	G/C	cg23791538	chr6:167370224	RNASET2	-0.63	-8.73	-0.5	4.84e-16	Crohn's disease;
SARC	cis	rs911555	0.755	rs975892	chr14:103883349	A/T	cg24130564	chr14:104152367	KLC1	-0.5	-6.01	-0.37	7.05e-9	Intelligence (multi-trait analysis);
SARC	cis	rs453301	0.606	rs7462373	chr8:8899318	G/C	cg11608241	chr8:8085544	FLJ10661	-0.42	-5.37	-0.33	1.93e-7	Joint mobility (Beighton score);
SARC	cis	rs7617480	0.648	rs6796790	chr3:48780317	G/A	cg07636037	chr3:49044803	WDR6	0.88	10.29	0.56	1.02e-20	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs6991838	0.584	rs2048650	chr8:66537899	A/G	cg13398993	chr8:66546079	ARMC1	0.62	8.19	0.47	1.72e-14	Intelligence (multi-trait analysis);
SARC	cis	rs2425143	1.000	rs6060588	chr20:34337480	G/A	cg01084648	chr20:34329383	RBM39	0.62	4.92	0.31	1.63e-6	Blood protein levels;
SARC	cis	rs4588572	0.644	rs11742212	chr5:77779033	G/A	cg18281939	chr5:77783895	LHFPL2	0.34	4.75	0.3	3.56e-6	Triglycerides;
SARC	trans	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg21659725	chr3:3221576	CRBN	0.5	6.26	0.38	1.88e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7223966	1.000	rs7211213	chr17:61769456	A/G	cg26338869	chr17:61819248	STRADA	0.45	5.27	0.33	3.04e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1881797	1.000	rs10925069	chr1:247681313	C/T	cg18198730	chr1:247681584	NA	-0.53	-5.87	-0.36	1.45e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs10799445	0.531	rs6697867	chr1:227745674	G/C	cg26340147	chr1:227730820	NA	0.33	4.82	0.3	2.56e-6	Height;
SARC	cis	rs17270561	0.609	rs1165181	chr6:25825390	T/A	cg16482183	chr6:26056742	HIST1H1C	0.52	6.96	0.41	3.5e-11	Iron status biomarkers;
SARC	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg25894440	chr7:65020034	NA	-0.73	-5.48	-0.34	1.09e-7	Diabetic kidney disease;
SARC	cis	rs9916302	0.904	rs1966916	chr17:37425238	T/G	cg00129232	chr17:37814104	STARD3	-0.59	-7.39	-0.44	2.69e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs2834188	0.557	rs2834186	chr21:34686753	C/T	cg14352951	chr21:34696688	IFNAR1	0.42	5.28	0.33	2.99e-7	Narcolepsy;
SARC	cis	rs4774830	0.744	rs62045236	chr15:56291171	A/G	cg24530489	chr15:56299380	NA	-0.85	-4.79	-0.3	2.96e-6	Delta-5 desaturase activity;
SARC	cis	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.57	8.77	0.5	3.8e-16	Eosinophil percentage of white cells;
SARC	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg13395646	chr4:1353034	KIAA1530	-0.56	-6.74	-0.4	1.23e-10	Obesity-related traits;
SARC	cis	rs35110281	0.659	rs73367822	chr21:45024252	C/T	cg21573476	chr21:45109991	RRP1B	-0.49	-7.25	-0.43	5.96e-12	Mean corpuscular volume;
SARC	cis	rs1451375	0.572	rs4948205	chr7:50557774	G/A	cg18232548	chr7:50535776	DDC	-0.46	-4.78	-0.3	3.14e-6	Malaria;
SARC	cis	rs911555	0.706	rs10129426	chr14:104018455	C/T	cg24130564	chr14:104152367	KLC1	-0.49	-6.54	-0.39	3.85e-10	Intelligence (multi-trait analysis);
SARC	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg09699651	chr6:150184138	LRP11	0.39	4.84	0.3	2.39e-6	Lung cancer;
SARC	cis	rs2795502	1.000	rs2744092	chr10:43339343	T/C	cg20628663	chr10:43360327	NA	-0.47	-6.32	-0.38	1.33e-9	Blood protein levels;
SARC	cis	rs35110281	0.774	rs162344	chr21:44954522	G/A	cg01579765	chr21:45077557	HSF2BP	-0.3	-4.97	-0.31	1.29e-6	Mean corpuscular volume;
SARC	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg11062466	chr8:58055876	NA	0.51	5.26	0.33	3.22e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	cis	rs13256369	0.802	rs11781257	chr8:8559663	A/T	cg17143192	chr8:8559678	CLDN23	0.52	5.81	0.36	2.07e-8	Obesity-related traits;
SARC	cis	rs7465272	0.515	rs34087536	chr8:143720876	G/A	cg24634471	chr8:143751801	JRK	0.61	7.93	0.46	9.33e-14	Bipolar disorder and schizophrenia;
SARC	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg00933542	chr6:150070202	PCMT1	0.33	5.69	0.35	3.81e-8	Lung cancer;
SARC	cis	rs9527	0.622	rs12779263	chr10:104886533	G/T	cg04362960	chr10:104952993	NT5C2	0.42	4.8	0.3	2.79e-6	Arsenic metabolism;
SARC	cis	rs7089973	0.872	rs60820172	chr10:116625891	C/T	cg08188268	chr10:116634841	FAM160B1	0.37	5.89	0.36	1.33e-8	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs1707322	0.752	rs12047629	chr1:46162802	G/A	cg03146154	chr1:46216737	IPP	0.52	6.28	0.38	1.6e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7666738	0.716	rs6817529	chr4:99023213	T/C	cg05340658	chr4:99064831	C4orf37	0.66	9.04	0.51	6.35e-17	Colonoscopy-negative controls vs population controls;
SARC	trans	rs208520	0.909	rs9453672	chr6:66991431	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	8.69	0.49	6.7e-16	Exhaled nitric oxide output;
SARC	cis	rs9815354	0.812	rs73081392	chr3:41923009	G/A	cg03022575	chr3:42003672	ULK4	0.69	5.65	0.35	4.69e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9303280	0.901	rs7359623	chr17:38049589	C/T	cg20243544	chr17:37824526	PNMT	0.43	5.69	0.35	3.81e-8	Self-reported allergy;
SARC	cis	rs9486719	0.656	rs6924957	chr6:96853579	G/T	cg06623918	chr6:96969491	KIAA0776	0.63	7.53	0.44	1.11e-12	Migraine;Coronary artery disease;
SARC	cis	rs4295623	0.531	rs2898295	chr8:11595969	C/T	cg02569740	chr8:10878898	XKR6	-0.35	-4.76	-0.3	3.41e-6	Morning vs. evening chronotype;
SARC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg10942707	chr12:75905227	KRR1	-0.56	-6.33	-0.38	1.25e-9	Hepatitis;
SARC	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg03709012	chr19:19516395	GATAD2A	1.01	17.65	0.76	7.75e-45	Tonsillectomy;
SARC	cis	rs6570726	0.791	rs11155435	chr6:145938545	T/C	cg23711669	chr6:146136114	FBXO30	0.89	15.28	0.71	5.63e-37	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg25072359	chr17:41440525	NA	0.5	5.94	0.36	1.04e-8	Menopause (age at onset);
SARC	cis	rs2204008	0.623	rs4882302	chr12:38415608	T/A	cg26384229	chr12:38710491	ALG10B	-0.56	-6.98	-0.42	3.13e-11	Bladder cancer;
SARC	cis	rs380904	0.926	rs7842979	chr8:144601896	T/G	cg20583945	chr8:144636462	GSDMD	0.36	5.07	0.32	8.09e-7	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg24675658	chr1:53192096	ZYG11B	-0.69	-10.29	-0.56	1.04e-20	Monocyte count;
SARC	cis	rs4268898	0.662	rs58971404	chr2:24403753	G/A	cg26838691	chr2:24397539	C2orf84	-0.55	-6.33	-0.38	1.24e-9	Asthma;
SARC	cis	rs4742903	0.935	rs7024069	chr9:107008176	A/G	cg14250997	chr9:106856677	SMC2	0.4	4.86	0.3	2.16e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg06060754	chr5:176797920	RGS14	-0.61	-8.27	-0.48	1.06e-14	Urinary electrolytes (magnesium/calcium ratio);
SARC	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	23.11	0.83	3.31e-62	Chronic sinus infection;
SARC	cis	rs6545883	0.899	rs12473030	chr2:61720497	T/A	cg15711740	chr2:61764176	XPO1	-0.44	-5.37	-0.33	1.94e-7	Tuberculosis;
SARC	cis	rs9875589	0.509	rs7636901	chr3:14030958	G/A	cg19554555	chr3:13937349	NA	-0.4	-5.22	-0.32	4.03e-7	Ovarian reserve;
SARC	cis	rs2354432	0.556	rs1932979	chr1:146708912	A/G	cg25205988	chr1:146714368	CHD1L	-1.03	-7.37	-0.43	2.92e-12	Mitochondrial DNA levels;
SARC	cis	rs4765905	0.610	rs2239024	chr12:2311313	C/T	cg10668781	chr12:2307325	CACNA1C	-0.3	-4.74	-0.3	3.69e-6	Schizophrenia;
SARC	cis	rs2043112	0.800	rs6895953	chr5:39084471	G/A	cg04869206	chr5:39074266	RICTOR	0.5	6.21	0.38	2.37e-9	Obesity-related traits;
SARC	cis	rs9916302	0.706	rs6503500	chr17:37485925	C/T	cg00129232	chr17:37814104	STARD3	-0.53	-5.62	-0.35	5.43e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs862034	0.509	rs12586772	chr14:74932641	A/T	cg16374328	chr14:74960395	NPC2;ISCA2	0.45	5.65	0.35	4.56e-8	Height;
SARC	cis	rs10911251	0.528	rs2182020	chr1:183074964	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.17	0.55	2.42e-20	Colorectal cancer;
SARC	cis	rs1865760	0.963	rs3846838	chr6:25911775	T/C	cg10373733	chr6:25993375	NA	0.46	5.54	0.34	8.23e-8	Height;
SARC	cis	rs60752752	0.852	rs3006483	chr1:153356513	T/G	cg26882115	chr1:153603048	S100A1;S100A13	-0.66	-5.07	-0.32	8.15e-7	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs12681288	0.550	rs12549204	chr8:959085	G/T	cg15309053	chr8:964076	NA	0.47	7.8	0.46	2.04e-13	Schizophrenia;
SARC	cis	rs2204008	0.744	rs11181635	chr12:38378420	C/T	cg26384229	chr12:38710491	ALG10B	0.91	13.46	0.66	6.11e-31	Bladder cancer;
SARC	cis	rs2075371	0.966	rs2544214	chr7:133985736	G/A	cg20476274	chr7:133979776	SLC35B4	0.62	8.41	0.48	4.18e-15	Mean platelet volume;
SARC	cis	rs6723226	0.732	rs390480	chr2:32510072	A/C	cg02381751	chr2:32503542	YIPF4	-0.84	-12.46	-0.63	1.22e-27	Intelligence (multi-trait analysis);
SARC	cis	rs7084402	0.967	rs1303968	chr10:60298941	G/A	cg07615347	chr10:60278583	BICC1	0.59	8.77	0.5	3.93e-16	Refractive error;
SARC	trans	rs9650657	0.707	rs4841452	chr8:10687121	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.21	-0.43	7.79e-12	Neuroticism;
SARC	cis	rs2865126	0.523	rs2865119	chr18:10759935	A/G	cg21165219	chr18:10698044	FAM38B	-0.48	-4.79	-0.3	2.9e-6	Metabolite levels (5-HIAA/ MHPG Ratio);
SARC	cis	rs826838	0.935	rs11183940	chr12:38851642	A/G	cg13010199	chr12:38710504	ALG10B	0.78	11.08	0.59	3.29e-23	Heart rate;
SARC	cis	rs9329221	0.905	rs4433149	chr8:10249268	A/T	cg21775007	chr8:11205619	TDH	-0.4	-4.93	-0.31	1.55e-6	Neuroticism;
SARC	cis	rs7792596	0.565	rs58784836	chr7:93985600	G/C	cg20814616	chr7:94014465	NA	-0.49	-5.32	-0.33	2.47e-7	Intelligence;
SARC	cis	rs9303280	0.806	rs4795399	chr17:38061439	T/C	cg20243544	chr17:37824526	PNMT	0.43	5.75	0.35	2.71e-8	Self-reported allergy;
SARC	cis	rs7937890	0.904	rs7484197	chr11:14283654	C/T	cg02886208	chr11:14281011	SPON1	-0.38	-5.34	-0.33	2.16e-7	Mitochondrial DNA levels;
SARC	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg08859206	chr1:53392774	SCP2	0.43	6.12	0.37	4.03e-9	Monocyte count;
SARC	cis	rs2730245	0.527	rs1188974	chr7:158665748	C/T	cg24397884	chr7:158709396	WDR60	1.1	9.82	0.54	2.85e-19	Height;
SARC	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg19077165	chr18:44547161	KATNAL2	-0.47	-6.4	-0.39	8.34e-10	Personality dimensions;
SARC	cis	rs703842	0.616	rs4760332	chr12:58222672	A/C	cg00677455	chr12:58241039	CTDSP2	-0.57	-7.52	-0.44	1.15e-12	Multiple sclerosis;
SARC	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg24642844	chr7:1081250	C7orf50	-0.59	-6.04	-0.37	6.07e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg01798391	chr3:16306595	OXNAD1;DPH3	0.53	6.4	0.39	8.58e-10	Breast cancer;
SARC	cis	rs1691799	0.899	rs1168315	chr12:66746694	A/G	cg16791601	chr12:66731901	HELB	-0.71	-10.85	-0.58	1.89e-22	White blood cell count (basophil);
SARC	cis	rs5753618	0.583	rs5753639	chr22:31870400	A/G	cg02404636	chr22:31891804	SFI1	-0.64	-8.19	-0.47	1.77e-14	Colorectal cancer;
SARC	cis	rs11105298	0.891	rs4842653	chr12:89834113	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.5	-5.01	-0.31	1.1e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg02725872	chr8:58115012	NA	-0.34	-5.46	-0.34	1.19e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs644799	0.965	rs565771	chr11:95644179	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	14.54	0.69	1.59e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2718058	0.606	rs2722247	chr7:37869308	C/T	cg15028436	chr7:37888078	TXNDC3	-0.38	-4.97	-0.31	1.29e-6	Alzheimer's disease (late onset);
SARC	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg18252515	chr7:66147081	NA	-0.51	-5.77	-0.35	2.45e-8	Aortic root size;
SARC	cis	rs8180040	0.726	rs9843075	chr3:47195630	A/G	cg27129171	chr3:47204927	SETD2	0.65	8.59	0.49	1.28e-15	Colorectal cancer;
SARC	cis	rs9303401	0.625	rs34963822	chr17:56988424	C/A	cg25039879	chr17:56429692	SUPT4H1	0.65	6.13	0.37	3.77e-9	Cognitive test performance;
SARC	cis	rs1538970	1.000	rs2492840	chr1:45849792	C/A	cg05343316	chr1:45956843	TESK2	0.65	7.93	0.46	8.82e-14	Platelet count;
SARC	cis	rs11098499	0.644	rs17517414	chr4:120262101	G/C	cg09307838	chr4:120376055	NA	0.75	10.4	0.56	4.7e-21	Corneal astigmatism;
SARC	cis	rs35110281	0.667	rs4819288	chr21:45120173	C/G	cg21573476	chr21:45109991	RRP1B	-0.6	-8.58	-0.49	1.33e-15	Mean corpuscular volume;
SARC	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg05368731	chr17:41323189	NBR1	0.73	8.81	0.5	2.98e-16	Menopause (age at onset);
SARC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg03647317	chr4:187891568	NA	-0.35	-5.11	-0.32	6.7e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2439831	0.681	rs524527	chr15:43599116	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.73	-7.92	-0.46	9.75e-14	Lung cancer in ever smokers;
SARC	cis	rs7829975	0.511	rs2921028	chr8:8340477	T/C	cg06636001	chr8:8085503	FLJ10661	0.6	8.4	0.48	4.4e-15	Mood instability;
SARC	cis	rs8180040	0.966	rs12636851	chr3:47463567	C/T	cg27129171	chr3:47204927	SETD2	0.66	9.36	0.52	7.14e-18	Colorectal cancer;
SARC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.34	5.09	0.32	7.49e-7	Electroencephalogram traits;
SARC	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg20607798	chr8:58055168	NA	0.58	5.57	0.34	6.9e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg20607798	chr8:58055168	NA	0.61	5.41	0.33	1.57e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.44	-5.34	-0.33	2.19e-7	Calcium levels;
SARC	cis	rs3106136	0.843	rs4282187	chr4:95273145	T/C	cg11021082	chr4:95130006	SMARCAD1	0.37	5.67	0.35	4.13e-8	Capecitabine sensitivity;
SARC	cis	rs208520	1.000	rs208521	chr6:66953625	C/T	cg07460842	chr6:66804631	NA	-0.86	-9.56	-0.53	1.79e-18	Exhaled nitric oxide output;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg00547444	chr16:2587590	PDPK1	0.57	7.22	0.43	7.2e-12	Breast cancer;
SARC	cis	rs6991838	0.800	rs28626262	chr8:66471570	C/A	cg13398993	chr8:66546079	ARMC1	0.48	6.45	0.39	6.43e-10	Intelligence (multi-trait analysis);
SARC	cis	rs881375	0.933	rs7028641	chr9:123691141	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	5.37	0.33	1.94e-7	Rheumatoid arthritis;
SARC	cis	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg13072238	chr3:49761600	GMPPB	0.44	5.64	0.35	4.82e-8	Intelligence (multi-trait analysis);
SARC	trans	rs9329221	0.657	rs17694485	chr8:10114458	A/T	cg05308639	chr19:1525316	PLK5P	0.4	6.33	0.38	1.24e-9	Neuroticism;
SARC	cis	rs7762018	0.607	rs77004024	chr6:170063437	G/A	cg19338460	chr6:170058176	WDR27	-0.78	-5.24	-0.32	3.6e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs12421382	0.543	rs10890996	chr11:109328421	A/G	cg06719900	chr11:109292894	C11orf87	-0.36	-4.98	-0.31	1.25e-6	Schizophrenia;
SARC	cis	rs1008375	1.000	rs7673500	chr4:17621383	C/T	cg27347728	chr4:17578864	LAP3	0.47	5.78	0.35	2.32e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.94	9.94	0.55	1.25e-19	Platelet count;
SARC	cis	rs3126085	1.000	rs6661167	chr1:152312870	A/G	cg26876637	chr1:152193138	HRNR	-0.48	-4.89	-0.31	1.84e-6	Atopic dermatitis;
SARC	cis	rs7247513	0.897	rs12972944	chr19:12713808	G/A	cg01871581	chr19:12707946	ZNF490	-0.9	-13.17	-0.65	5.8e-30	Bipolar disorder;
SARC	cis	rs1008375	1.000	rs10939742	chr4:17659936	G/T	cg02297831	chr4:17616191	MED28	0.49	6.32	0.38	1.34e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs546131	1.000	rs546131	chr11:34851760	G/C	cg11058730	chr11:34937778	PDHX;APIP	0.43	5.35	0.33	2.1e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs2832191	0.791	rs2832181	chr21:30481371	G/T	cg08807101	chr21:30365312	RNF160	-0.84	-11.81	-0.61	1.6e-25	Dental caries;
SARC	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg27170947	chr2:26402098	FAM59B	-0.36	-4.75	-0.3	3.56e-6	Gut microbiome composition (summer);
SARC	cis	rs57994353	0.667	rs34985258	chr9:139327154	C/T	cg13611204	chr9:139324423	INPP5E	-0.3	-5.21	-0.32	4.06e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs2732480	0.577	rs2732448	chr12:48730600	T/C	cg21466736	chr12:48725269	NA	-0.34	-5.25	-0.33	3.49e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg11987759	chr7:65425863	GUSB	0.47	5.77	0.35	2.51e-8	Aortic root size;
SARC	cis	rs7086627	0.515	rs4933390	chr10:82213081	A/C	cg01528321	chr10:82214614	TSPAN14	0.56	8.13	0.47	2.53e-14	Post bronchodilator FEV1;
SARC	cis	rs1008375	0.932	rs4698626	chr4:17605821	G/C	cg16339924	chr4:17578868	LAP3	0.67	8.83	0.5	2.6e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1059312	0.808	rs10847693	chr12:129292006	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.45	-5.57	-0.34	7.15e-8	Systemic lupus erythematosus;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg05670459	chr19:6531335	TNFSF9	0.47	6.51	0.39	4.67e-10	Chemerin levels;
SARC	cis	rs3818285	0.515	rs4918471	chr10:111660500	C/A	cg00817464	chr10:111662876	XPNPEP1	-0.54	-7.3	-0.43	4.57e-12	Superior crus of antihelix expression;
SARC	trans	rs12310956	0.532	rs1352211	chr12:33983132	G/A	cg26384229	chr12:38710491	ALG10B	0.75	10.56	0.57	1.45e-21	Morning vs. evening chronotype;
SARC	cis	rs9291683	0.620	rs717615	chr4:10104670	C/T	cg00071950	chr4:10020882	SLC2A9	0.34	5.24	0.32	3.6e-7	Bone mineral density;
SARC	trans	rs17685	0.672	rs55807301	chr7:75807401	C/A	cg19862616	chr7:65841803	NCRNA00174	0.63	7.71	0.45	3.66e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	trans	rs61931739	0.500	rs11053274	chr12:34547605	G/A	cg13010199	chr12:38710504	ALG10B	0.82	11.46	0.6	2.07e-24	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg08219700	chr8:58056026	NA	0.59	6.35	0.38	1.11e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg27497049	chr8:94712646	FAM92A1	0.65	6.64	0.4	2.15e-10	Lung cancer in ever smokers;
SARC	cis	rs1983891	0.909	rs4714482	chr6:41528199	G/A	cg15051332	chr6:41514432	FOXP4	0.54	6.0	0.37	7.67e-9	Prostate cancer;
SARC	cis	rs300703	0.719	rs437853	chr2:196973	C/T	cg21211680	chr2:198530	NA	-0.47	-5.21	-0.32	4.14e-7	Blood protein levels;
SARC	cis	rs9911578	0.935	rs304261	chr17:56813782	A/G	cg05425664	chr17:57184151	TRIM37	-0.67	-8.29	-0.48	8.94e-15	Intelligence (multi-trait analysis);
SARC	cis	rs16976116	0.851	rs28889339	chr15:55503205	T/G	cg11288833	chr15:55489084	RSL24D1	0.63	6.08	0.37	4.81e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6759839	0.761	rs7563815	chr2:16624337	C/T	cg09580478	chr2:16689509	NA	0.44	5.62	0.35	5.31e-8	Mean platelet volume;
SARC	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg11764359	chr7:65958608	NA	-0.75	-8.85	-0.5	2.22e-16	Aortic root size;
SARC	cis	rs11168187	0.843	rs2239188	chr12:48117535	A/C	cg12761788	chr12:48120090	P11	-0.36	-4.77	-0.3	3.23e-6	Vertical cup-disc ratio;
SARC	cis	rs4713118	0.513	rs149944	chr6:28002818	C/T	cg26335602	chr6:28129616	ZNF389	0.45	5.29	0.33	2.85e-7	Parkinson's disease;
SARC	cis	rs6570726	0.526	rs7755237	chr6:145731852	T/C	cg23711669	chr6:146136114	FBXO30	-0.66	-9.0	-0.51	8.06e-17	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg22875332	chr1:76189707	ACADM	0.46	6.25	0.38	1.9e-9	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6912958	0.781	rs7761814	chr6:88188309	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.29	-5.0	-0.31	1.14e-6	Monocyte percentage of white cells;
SARC	cis	rs920590	0.758	rs35896770	chr8:19665616	G/C	cg03894339	chr8:19674705	INTS10	0.58	6.9	0.41	4.92e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs10504229	0.679	rs60869047	chr8:58053221	G/A	cg08219700	chr8:58056026	NA	0.59	6.0	0.37	7.67e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2204008	0.580	rs1315373	chr12:38179114	T/G	cg26384229	chr12:38710491	ALG10B	-0.68	-8.82	-0.5	2.75e-16	Bladder cancer;
SARC	cis	rs17376456	0.690	rs6892055	chr5:93113023	A/T	cg25358565	chr5:93447407	FAM172A	1.13	11.29	0.59	7.12e-24	Diabetic retinopathy;
SARC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.43	-4.99	-0.31	1.18e-6	Longevity;Endometriosis;
SARC	cis	rs7412746	0.611	rs6660084	chr1:150748803	T/C	cg15448220	chr1:150897856	SETDB1	0.48	6.25	0.38	1.99e-9	Melanoma;
SARC	cis	rs10932679	0.901	rs12465693	chr2:217653567	A/G	cg05032264	chr2:217675019	NA	0.56	5.4	0.33	1.67e-7	Pulse pressure;
SARC	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg22484793	chr3:52261325	TLR9	0.29	4.73	0.3	3.85e-6	Bipolar disorder;
SARC	cis	rs7666738	0.830	rs28622458	chr4:98916651	A/G	cg05340658	chr4:99064831	C4orf37	0.65	8.64	0.49	9.2e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg25072359	chr17:41440525	NA	0.51	6.03	0.37	6.45e-9	Menopause (age at onset);
SARC	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6696846	0.715	rs61822659	chr1:205142847	G/A	cg07972983	chr1:205091412	RBBP5	0.55	6.72	0.4	1.42e-10	Red blood cell count;
SARC	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg05896524	chr21:47604654	C21orf56	0.42	5.04	0.31	9.35e-7	Testicular germ cell tumor;
SARC	cis	rs941408	1.000	rs1640271	chr19:2799979	C/T	cg06609049	chr19:2785107	THOP1	0.77	10.07	0.55	4.95e-20	Total cholesterol levels;
SARC	cis	rs2273669	0.504	rs77373614	chr6:109418075	T/C	cg05315195	chr6:109294784	ARMC2	-0.6	-5.05	-0.31	8.79e-7	Prostate cancer;
SARC	cis	rs2295359	1.000	rs2295359	chr1:67635950	G/A	cg11235152	chr1:67600687	NA	0.49	7.26	0.43	5.73e-12	Psoriasis;
SARC	cis	rs6540556	0.608	rs7532324	chr1:209918090	C/T	cg23920097	chr1:209922102	NA	-0.53	-5.79	-0.35	2.28e-8	Red blood cell count;
SARC	cis	rs709400	0.627	rs62007686	chr14:103899344	A/G	cg12935359	chr14:103987150	CKB	-0.4	-5.83	-0.36	1.85e-8	Body mass index;
SARC	cis	rs72634258	0.519	rs35267144	chr1:7934258	G/A	cg00042356	chr1:8021962	PARK7	0.59	5.3	0.33	2.65e-7	Inflammatory bowel disease;
SARC	cis	rs1451375	0.617	rs10277662	chr7:50594836	C/T	cg18232548	chr7:50535776	DDC	0.5	5.03	0.31	9.71e-7	Malaria;
SARC	cis	rs12681366	0.564	rs10808669	chr8:95481061	A/C	cg13257157	chr8:95487014	RAD54B	0.4	4.82	0.3	2.64e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs4819052	0.679	rs2236450	chr21:46702553	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.61	7.61	0.45	6.93e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg11211951	chr8:145729740	GPT	0.45	6.63	0.4	2.32e-10	Age at first birth;
SARC	trans	rs1814175	0.645	rs11040535	chr11:49808669	C/T	cg15704280	chr7:45808275	SEPT13	-0.88	-13.86	-0.67	2.93e-32	Height;
SARC	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg08677398	chr8:58056175	NA	0.43	4.98	0.31	1.24e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs2354432	0.607	rs59606861	chr1:146761478	G/A	cg25205988	chr1:146714368	CHD1L	-1.02	-7.73	-0.45	3.15e-13	Mitochondrial DNA levels;
SARC	cis	rs3768617	0.727	rs12066735	chr1:183101451	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.57	7.65	0.45	5.4e-13	Fuchs's corneal dystrophy;
SARC	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg18876405	chr7:65276391	NA	0.7	9.26	0.52	1.36e-17	Calcium levels;
SARC	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg13206674	chr6:150067644	NUP43	0.45	5.88	0.36	1.38e-8	Lung cancer;
SARC	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg22920501	chr2:26401640	FAM59B	-0.55	-7.14	-0.42	1.18e-11	Gut microbiome composition (summer);
SARC	cis	rs11997175	0.583	rs4386938	chr8:33673156	A/G	ch.8.33884649F	chr8:33765107	NA	0.52	6.74	0.4	1.26e-10	Body mass index;
SARC	cis	rs1348850	0.914	rs4893944	chr2:178289357	G/T	cg23306229	chr2:178417860	TTC30B	0.49	5.7	0.35	3.65e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7772486	0.686	rs6933161	chr6:146081369	G/A	cg23711669	chr6:146136114	FBXO30	-0.79	-12.66	-0.64	2.72e-28	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs61931739	0.513	rs1608906	chr12:33894986	T/C	cg13010199	chr12:38710504	ALG10B	0.58	7.5	0.44	1.32e-12	Morning vs. evening chronotype;
SARC	cis	rs1008375	0.932	rs3846356	chr4:17614176	C/T	cg27347728	chr4:17578864	LAP3	0.45	5.55	0.34	7.89e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9788682	1.000	rs2036534	chr15:78826948	T/C	cg24631222	chr15:78858424	CHRNA5	0.76	10.22	0.56	1.7e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs4711336	1.000	rs3818523	chr6:33660371	G/A	cg15676125	chr6:33679581	C6orf125	0.57	6.98	0.42	3.07e-11	Height;
SARC	cis	rs7092929	0.883	rs705459	chr10:3615477	T/C	cg14308648	chr10:3568949	NA	0.52	5.19	0.32	4.6e-7	Coronary artery calcification;
SARC	cis	rs7084402	0.967	rs1649065	chr10:60306386	T/G	cg07615347	chr10:60278583	BICC1	0.59	8.61	0.49	1.12e-15	Refractive error;
SARC	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg18252515	chr7:66147081	NA	0.42	4.77	0.3	3.21e-6	Aortic root size;
SARC	cis	rs5750830	0.594	rs9611165	chr22:39775250	A/G	cg05872129	chr22:39784769	NA	-0.46	-6.67	-0.4	1.81e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7264396	0.709	rs2425073	chr20:34293699	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-8.61	-0.49	1.14e-15	Total cholesterol levels;
SARC	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg04166393	chr7:2884313	GNA12	0.42	5.16	0.32	5.32e-7	Height;
SARC	cis	rs2115630	0.755	rs7169629	chr15:85191274	C/G	cg17507749	chr15:85114479	UBE2QP1	0.42	4.97	0.31	1.31e-6	P wave terminal force;
SARC	cis	rs17376456	0.778	rs72786662	chr5:93137630	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.7	6.56	0.39	3.42e-10	Diabetic retinopathy;
SARC	cis	rs2288073	0.965	rs10192600	chr2:24396680	A/G	cg06627628	chr2:24431161	ITSN2	-0.62	-7.39	-0.44	2.6e-12	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs1355223	0.623	rs286878	chr11:34694856	G/C	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.05	-0.31	8.78e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs6570726	0.791	rs6923074	chr6:145893332	T/C	cg05347473	chr6:146136440	FBXO30	0.51	7.17	0.43	9.59e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9788682	1.000	rs34138960	chr15:78831668	A/G	cg06917634	chr15:78832804	PSMA4	-0.58	-6.52	-0.39	4.36e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs7772486	0.686	rs1415744	chr6:146022531	C/T	cg05347473	chr6:146136440	FBXO30	0.51	7.16	0.42	1.07e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7772486	0.764	rs9399569	chr6:146242942	C/T	cg23711669	chr6:146136114	FBXO30	-0.75	-11.76	-0.61	2.19e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs282587	0.502	rs375741	chr13:113397794	G/C	cg02820901	chr13:113351484	ATP11A	-0.5	-4.92	-0.31	1.65e-6	Glycated hemoglobin levels;
SARC	cis	rs11098499	0.604	rs2389887	chr4:120570644	T/C	cg09307838	chr4:120376055	NA	0.81	10.65	0.57	7.74e-22	Corneal astigmatism;
SARC	cis	rs2832191	0.636	rs8131295	chr21:30516819	A/T	cg08807101	chr21:30365312	RNF160	-0.71	-8.59	-0.49	1.28e-15	Dental caries;
SARC	cis	rs7666738	0.830	rs17027102	chr4:98919221	A/G	cg05340658	chr4:99064831	C4orf37	-0.7	-9.67	-0.53	8.43e-19	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg12064134	chr16:90016061	DEF8	-0.59	-5.05	-0.31	8.75e-7	Skin colour saturation;
SARC	cis	rs56235845	0.694	rs36102285	chr5:176774018	C/T	cg17509989	chr5:176798049	RGS14	0.59	7.91	0.46	1.03e-13	Hemoglobin concentration;Hematocrit;
SARC	cis	rs748404	0.518	rs480108	chr15:43817406	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.46	5.0	0.31	1.13e-6	Lung cancer;
SARC	cis	rs6991838	0.612	rs12335276	chr8:66531903	A/G	cg13398993	chr8:66546079	ARMC1	0.62	8.19	0.47	1.72e-14	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg18252515	chr7:66147081	NA	0.58	6.23	0.38	2.16e-9	Aortic root size;
SARC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.03	0.37	6.27e-9	Prudent dietary pattern;
SARC	cis	rs10927875	0.688	rs2009371	chr1:16348083	A/T	cg21385522	chr1:16154831	NA	0.71	9.1	0.51	4.19e-17	Dilated cardiomyopathy;
SARC	cis	rs7615952	0.611	rs79405914	chr3:125723623	C/T	cg05084668	chr3:125655381	ALG1L	-0.94	-7.57	-0.44	8.76e-13	Blood pressure (smoking interaction);
SARC	cis	rs708547	0.874	rs1718837	chr4:57871203	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.71	8.94	0.51	1.26e-16	Response to bleomycin (chromatid breaks);
SARC	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.52	-6.37	-0.39	9.78e-10	Height;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg07985359	chr19:7894666	EVI5L	-0.49	-6.3	-0.38	1.46e-9	Thyroid stimulating hormone;
SARC	cis	rs10046574	0.831	rs28399231	chr7:135093154	G/A	cg27474649	chr7:135195673	CNOT4	0.88	7.16	0.42	1.02e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.09	0.37	4.51e-9	Height;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg04809093	chr3:114862175	ZBTB20	0.46	6.59	0.4	2.94e-10	Thyroid stimulating hormone;
SARC	cis	rs17270561	0.609	rs9358884	chr6:25756592	A/G	cg17691542	chr6:26056736	HIST1H1C	0.6	7.28	0.43	5.11e-12	Iron status biomarkers;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg23127434	chr2:183880090	NCKAP1	-0.51	-6.36	-0.38	1.03e-9	Alcohol dependence;
SARC	cis	rs9486719	0.843	rs3860229	chr6:97036559	T/C	cg18709589	chr6:96969512	KIAA0776	-0.51	-5.64	-0.35	4.81e-8	Migraine;Coronary artery disease;
SARC	cis	rs1448094	0.845	rs10863123	chr12:86346254	G/A	cg02569458	chr12:86230093	RASSF9	0.42	6.07	0.37	5.16e-9	Major depressive disorder;
SARC	cis	rs9436747	0.748	rs1171270	chr1:65997841	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	-0.5	-4.85	-0.3	2.25e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs7223966	1.000	rs11657081	chr17:61792339	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	6.74	0.4	1.24e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs709400	0.663	rs3742458	chr14:103950368	A/G	cg12935359	chr14:103987150	CKB	-0.39	-5.79	-0.35	2.22e-8	Body mass index;
SARC	cis	rs6598955	0.694	rs4659416	chr1:26580937	T/G	cg04990556	chr1:26633338	UBXN11	-0.6	-8.33	-0.48	6.91e-15	Obesity-related traits;
SARC	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg20607798	chr8:58055168	NA	0.61	5.41	0.33	1.57e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg20887711	chr4:1340912	KIAA1530	0.78	9.78	0.54	3.73e-19	Longevity;
SARC	cis	rs9840812	0.953	rs61791721	chr3:135804550	T/A	cg15507776	chr3:136538369	TMEM22	-0.47	-4.91	-0.31	1.72e-6	Fibrinogen levels;
SARC	cis	rs921968	0.643	rs2243911	chr2:219529348	C/T	cg02176678	chr2:219576539	TTLL4	-0.36	-5.48	-0.34	1.11e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg26335602	chr6:28129616	ZNF389	0.53	5.88	0.36	1.43e-8	Depression;
SARC	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg10876282	chr6:28092338	ZSCAN16	0.47	4.8	0.3	2.85e-6	Parkinson's disease;
SARC	cis	rs4906332	0.901	rs4900575	chr14:103899169	G/C	cg26031613	chr14:104095156	KLC1	-0.49	-5.74	-0.35	2.89e-8	Coronary artery disease;
SARC	trans	rs17685	0.743	rs10277259	chr7:75802674	A/C	cg19862616	chr7:65841803	NCRNA00174	0.64	8.02	0.47	5e-14	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs6665290	0.868	rs2183836	chr1:227199404	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.04	-22.84	-0.83	2.21e-61	Myeloid white cell count;
SARC	cis	rs2228479	0.867	rs12930056	chr16:89946649	C/A	cg00800038	chr16:89945340	TCF25	-0.72	-5.75	-0.35	2.8e-8	Skin colour saturation;
SARC	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.41	5.14	0.32	5.87e-7	Lymphocyte counts;
SARC	cis	rs6964587	0.732	rs12539523	chr7:91710836	G/A	cg17063962	chr7:91808500	NA	0.97	15.63	0.72	3.75e-38	Breast cancer;
SARC	cis	rs9916302	0.904	rs2168785	chr17:37407135	C/T	cg00129232	chr17:37814104	STARD3	-0.59	-7.21	-0.43	7.54e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg00149659	chr3:10157352	C3orf10	1.09	10.0	0.55	7.87e-20	Alzheimer's disease;
SARC	cis	rs3820928	0.845	rs13384342	chr2:227805010	G/A	cg05526886	chr2:227700861	RHBDD1	-0.53	-6.52	-0.39	4.25e-10	Pulmonary function;
SARC	trans	rs7824557	0.564	rs2437152	chr8:11235497	G/A	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.71	-0.5	5.7e-16	Retinal vascular caliber;
SARC	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg06713675	chr4:122721982	EXOSC9	-0.5	-6.6	-0.4	2.74e-10	Type 2 diabetes;
SARC	cis	rs1348850	0.526	rs9288003	chr2:178446572	T/G	cg23306229	chr2:178417860	TTC30B	0.75	7.94	0.46	8.27e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg02167678	chr16:88815867	FAM38A	-0.47	-6.45	-0.39	6.41e-10	Gallstone disease;
SARC	cis	rs9400467	0.506	rs73530915	chr6:111457448	A/G	cg15721981	chr6:111408429	SLC16A10	0.64	5.67	0.35	4.19e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs7264396	0.570	rs1970576	chr20:34336720	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-8.26	-0.48	1.12e-14	Total cholesterol levels;
SARC	cis	rs7264396	0.790	rs10211771	chr20:34219994	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-7.76	-0.45	2.66e-13	Total cholesterol levels;
SARC	cis	rs7647973	0.626	rs35129566	chr3:49866584	T/G	cg03060546	chr3:49711283	APEH	-0.66	-6.95	-0.41	3.73e-11	Menarche (age at onset);
SARC	trans	rs208520	0.909	rs9354410	chr6:67018584	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.82	8.41	0.48	4.2e-15	Exhaled nitric oxide output;
SARC	cis	rs11711311	1.000	rs9848993	chr3:113497914	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	8.69	0.49	6.43e-16	IgG glycosylation;
SARC	cis	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg15145296	chr3:125709740	NA	-0.49	-4.74	-0.3	3.67e-6	Blood pressure (smoking interaction);
SARC	cis	rs66887589	0.592	rs62320740	chr4:120279486	C/A	cg09307838	chr4:120376055	NA	0.61	8.44	0.48	3.49e-15	Diastolic blood pressure;
SARC	cis	rs965469	1.000	rs6037538	chr20:3282978	T/C	cg25506879	chr20:3388711	C20orf194	-0.48	-4.87	-0.3	2.04e-6	IFN-related cytopenia;
SARC	cis	rs9443189	0.703	rs2748950	chr6:76442985	A/G	cg01950844	chr6:76311363	SENP6	-0.72	-6.75	-0.4	1.17e-10	Prostate cancer;
SARC	cis	rs9807841	0.670	rs8102380	chr19:10801185	G/A	cg17710535	chr19:10819994	QTRT1	0.43	4.79	0.3	2.92e-6	Inflammatory skin disease;
SARC	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg16680214	chr1:154839983	KCNN3	-0.33	-5.22	-0.32	3.96e-7	Prostate cancer;
SARC	cis	rs2439831	0.850	rs8042868	chr15:43939642	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	7.23	0.43	6.89e-12	Lung cancer in ever smokers;
SARC	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	8.71	0.5	5.56e-16	Alzheimer's disease;
SARC	cis	rs9388451	0.626	rs1935983	chr6:126068914	C/T	cg06289844	chr6:126071538	HEY2	0.36	5.53	0.34	8.59e-8	Brugada syndrome;
SARC	cis	rs13401104	0.796	rs10929166	chr2:237111201	C/T	cg19324714	chr2:237145437	ASB18	0.58	6.02	0.37	6.73e-9	Educational attainment;
SARC	cis	rs2153535	0.601	rs9502715	chr6:8455709	C/T	cg07606381	chr6:8435919	SLC35B3	0.75	10.66	0.57	7.43e-22	Motion sickness;
SARC	cis	rs7264396	0.563	rs2425086	chr20:34302873	G/A	cg01084648	chr20:34329383	RBM39	0.57	4.95	0.31	1.45e-6	Total cholesterol levels;
SARC	cis	rs9296092	0.560	rs17627049	chr6:33537802	G/T	cg13560919	chr6:33536144	NA	-0.56	-6.65	-0.4	2.08e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs6866344	0.570	rs1132336	chr5:178140090	C/T	cg03877680	chr5:178157825	ZNF354A	1.02	14.39	0.69	5.19e-34	Neutrophil percentage of white cells;
SARC	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg00684032	chr4:1343700	KIAA1530	0.42	6.18	0.38	2.79e-9	Obesity-related traits;
SARC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg17178900	chr1:205818956	PM20D1	0.65	9.26	0.52	1.35e-17	Menarche (age at onset);
SARC	cis	rs7223966	1.000	rs6504173	chr17:61735056	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.46	-5.02	-0.31	1.01e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs72945132	0.882	rs67093918	chr11:70198999	C/A	cg05964544	chr11:70165517	PPFIA1	-0.56	-5.37	-0.33	1.93e-7	Coronary artery disease;
SARC	cis	rs7424096	0.582	rs7600245	chr2:37220614	A/C	cg14987922	chr2:37194071	STRN	0.58	6.69	0.4	1.6e-10	High light scatter reticulocyte percentage of red cells;
SARC	cis	rs763121	0.925	rs4821797	chr22:39016182	T/C	cg06022373	chr22:39101656	GTPBP1	0.84	10.96	0.58	8.04e-23	Menopause (age at onset);
SARC	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg25072359	chr17:41440525	NA	0.51	6.0	0.37	7.33e-9	Menopause (age at onset);
SARC	cis	rs5417	0.689	rs55868524	chr17:7170665	G/A	cg25750800	chr17:7185070	SLC2A4	-0.4	-5.17	-0.32	5.16e-7	Diastolic blood pressure;
SARC	cis	rs7772486	0.790	rs9399571	chr6:146282061	A/G	cg05347473	chr6:146136440	FBXO30	-0.48	-6.43	-0.39	7.2e-10	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg08483723	chr3:45267960	TMEM158	0.5	6.57	0.4	3.19e-10	Migraine with aura;
SARC	cis	rs9549260	0.755	rs2701863	chr13:41170140	C/T	cg21288729	chr13:41239152	FOXO1	0.61	7.94	0.46	8.37e-14	Red blood cell count;
SARC	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg20120463	chr17:44301886	NA	-0.39	-5.96	-0.36	9.48e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg22903657	chr4:1355424	KIAA1530	-0.35	-5.1	-0.32	7.17e-7	Longevity;
SARC	cis	rs4690686	0.500	rs7667671	chr4:177275599	T/C	cg17059388	chr4:177262070	NA	0.38	4.99	0.31	1.19e-6	Essential tremor;
SARC	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg03264133	chr6:25882463	NA	0.37	4.96	0.31	1.33e-6	Intelligence (multi-trait analysis);
SARC	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-8.65	-0.49	8.29e-16	Chronic sinus infection;
SARC	cis	rs11574514	1.000	rs13333317	chr16:67872251	A/C	cg01866162	chr16:67596514	CTCF	0.99	5.95	0.36	9.66e-9	Crohn's disease;
SARC	trans	rs8073060	0.586	rs6505484	chr17:33993152	G/A	cg19694781	chr19:47549865	TMEM160	-0.7	-7.01	-0.42	2.53e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs4711336	1.000	rs2296742	chr6:33659793	G/A	cg15676125	chr6:33679581	C6orf125	0.57	7.01	0.42	2.49e-11	Height;
SARC	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg27347728	chr4:17578864	LAP3	0.49	6.08	0.37	4.76e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs17666538	0.585	rs4333567	chr8:636611	C/T	cg23958373	chr8:599963	NA	0.68	4.82	0.3	2.54e-6	IgG glycosylation;
SARC	cis	rs6138458	0.743	rs3746330	chr20:24999795	A/G	cg26195577	chr20:24973756	C20orf3	0.75	8.69	0.49	6.6e-16	Blood protein levels;
SARC	cis	rs2288073	0.965	rs72789923	chr2:24394504	A/C	cg26838691	chr2:24397539	C2orf84	-0.56	-6.86	-0.41	6.17e-11	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg06873352	chr17:61820015	STRADA	0.52	6.85	0.41	6.33e-11	Prudent dietary pattern;
SARC	cis	rs2370759	1.000	rs16933225	chr10:32599464	C/T	cg18270830	chr10:32634957	EPC1	0.72	7.08	0.42	1.64e-11	Sexual dysfunction (female);
SARC	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg18252515	chr7:66147081	NA	-0.57	-6.2	-0.38	2.51e-9	Aortic root size;
SARC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg07167872	chr1:205819463	PM20D1	0.86	15.0	0.7	4.66e-36	Menarche (age at onset);
SARC	cis	rs12311304	1.000	rs34562067	chr12:15375929	A/G	cg08258403	chr12:15378311	NA	0.5	7.37	0.43	2.94e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs6546324	1.000	rs6710685	chr2:67858666	T/C	cg18237512	chr2:67827392	NA	-0.45	-5.69	-0.35	3.82e-8	Endometriosis;
SARC	cis	rs2228479	0.702	rs12599561	chr16:89894358	C/G	cg06558623	chr16:89946397	TCF25	0.93	6.62	0.4	2.48e-10	Skin colour saturation;
SARC	cis	rs7395581	0.918	rs4752824	chr11:47324666	A/T	cg25783544	chr11:47291846	MADD	0.49	5.61	0.35	5.69e-8	HDL cholesterol;
SARC	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg03647317	chr4:187891568	NA	-0.35	-4.95	-0.31	1.39e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.5	5.71	0.35	3.39e-8	Prudent dietary pattern;
SARC	cis	rs2380220	0.678	rs4308568	chr6:96009525	A/C	cg04719120	chr6:96025338	MANEA	-0.68	-7.93	-0.46	9.19e-14	Behavioural disinhibition (generation interaction);
SARC	cis	rs7772486	0.727	rs12190966	chr6:146146820	T/G	cg05347473	chr6:146136440	FBXO30	0.5	7.08	0.42	1.69e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs8053891	0.507	rs66553600	chr16:72028198	G/C	cg01557791	chr16:72042693	DHODH	-0.42	-5.0	-0.31	1.14e-6	Coronary artery disease;
SARC	cis	rs2749592	0.550	rs12255038	chr10:37869332	T/C	cg00409905	chr10:38381863	ZNF37A	0.54	7.21	0.43	7.55e-12	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs2651899	0.867	rs2742675	chr1:3079905	A/G	cg22674798	chr1:3096360	PRDM16	0.25	5.23	0.32	3.75e-7	Migraine;
SARC	cis	rs56011263	0.687	rs4690292	chr4:703712	A/G	cg05835009	chr4:710272	PCGF3	0.57	6.67	0.4	1.89e-10	White blood cell count;
SARC	cis	rs6918586	0.658	rs198822	chr6:26123539	G/C	cg18357526	chr6:26021779	HIST1H4A	-0.45	-5.74	-0.35	2.9e-8	Schizophrenia;
SARC	cis	rs7617480	0.544	rs6442129	chr3:48735256	T/C	cg06212747	chr3:49208901	KLHDC8B	0.49	4.79	0.3	2.93e-6	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs950776	0.518	rs11636131	chr15:78821606	C/T	cg22563815	chr15:78856949	CHRNA5	0.41	6.82	0.41	7.56e-11	Sudden cardiac arrest;
SARC	cis	rs9916302	0.904	rs7223438	chr17:37521355	T/C	cg20243544	chr17:37824526	PNMT	-0.58	-7.11	-0.42	1.38e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs6733011	0.581	rs4851162	chr2:99466659	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.4	-4.95	-0.31	1.44e-6	Bipolar disorder;
SARC	cis	rs2153535	0.580	rs1414340	chr6:8491139	G/A	cg21535247	chr6:8435926	SLC35B3	0.57	7.26	0.43	5.7e-12	Motion sickness;
SARC	cis	rs3768617	0.510	rs12078729	chr1:183060072	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.65	0.57	7.74e-22	Fuchs's corneal dystrophy;
SARC	cis	rs12239736	0.527	rs12133507	chr1:63215918	T/G	cg06896770	chr1:63153194	DOCK7	0.61	5.59	0.34	6.32e-8	Cholesterol, total;
SARC	cis	rs2153535	0.580	rs9505467	chr6:8520219	G/A	cg23788917	chr6:8435910	SLC35B3	0.64	8.66	0.49	7.75e-16	Motion sickness;
SARC	cis	rs4417855	0.794	rs3868898	chr3:187425632	A/T	cg08969912	chr3:187456781	BCL6	0.41	4.91	0.31	1.75e-6	Granulocyte percentage of myeloid white cells;
SARC	cis	rs918629	0.716	rs3756703	chr5:95276063	G/A	cg16656078	chr5:95278638	ELL2	-0.58	-6.57	-0.4	3.3e-10	IgG glycosylation;
SARC	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg18404041	chr3:52824283	ITIH1	-0.44	-6.59	-0.4	2.89e-10	Bipolar disorder;
SARC	cis	rs6912958	0.967	rs9450688	chr6:88159276	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.46	-0.34	1.2e-7	Monocyte percentage of white cells;
SARC	cis	rs7223966	0.960	rs2854222	chr17:61939015	C/T	cg26338869	chr17:61819248	STRADA	0.46	5.16	0.32	5.27e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg00825309	chr19:58991885	ZNF446	-0.55	-7.71	-0.45	3.74e-13	Uric acid clearance;
SARC	cis	rs79839061	0.656	rs3775126	chr4:886345	C/T	cg07828340	chr4:882639	GAK	0.78	6.45	0.39	6.41e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7659604	0.605	rs67772833	chr4:122723106	G/A	cg19671926	chr4:122722719	EXOSC9	-0.68	-8.18	-0.47	1.87e-14	Type 2 diabetes;
SARC	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg12564285	chr5:131593104	PDLIM4	-0.48	-6.37	-0.39	1e-9	Breast cancer;
SARC	cis	rs7149337	1.000	rs7149337	chr14:51709017	G/T	cg23942311	chr14:51606299	NA	0.33	5.83	0.36	1.85e-8	Cancer;
SARC	cis	rs2652834	0.808	rs4775614	chr15:63351687	A/G	cg05507819	chr15:63340323	TPM1	0.64	6.52	0.39	4.42e-10	HDL cholesterol;
SARC	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg11764359	chr7:65958608	NA	0.67	7.73	0.45	3.24e-13	Aortic root size;
SARC	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg02841227	chr6:26021843	HIST1H4A	0.64	7.47	0.44	1.64e-12	Intelligence (multi-trait analysis);
SARC	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg08048268	chr3:133502702	NA	-0.43	-5.83	-0.36	1.86e-8	Iron status biomarkers;
SARC	cis	rs9392918	0.622	rs4960344	chr6:7705559	G/A	cg23089261	chr6:7723385	NA	0.5	6.47	0.39	5.86e-10	Height;
SARC	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg10295955	chr4:187884368	NA	-1.05	-17.53	-0.75	1.93e-44	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11098499	0.780	rs7680914	chr4:120563053	A/G	cg24375607	chr4:120327624	NA	0.39	4.75	0.3	3.56e-6	Corneal astigmatism;
SARC	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg22484793	chr3:52261325	TLR9	0.3	4.83	0.3	2.51e-6	Bipolar disorder;
SARC	cis	rs858239	0.601	rs6969733	chr7:23168377	T/C	cg23682824	chr7:23144976	KLHL7	0.72	9.45	0.53	3.86e-18	Cerebrospinal fluid biomarker levels;
SARC	trans	rs61931739	0.517	rs4931771	chr12:34044557	G/A	cg13010199	chr12:38710504	ALG10B	0.76	10.32	0.56	8.23e-21	Morning vs. evening chronotype;
SARC	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	10.15	0.55	2.86e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs6120849	0.754	rs3746435	chr20:33587198	G/C	cg24642439	chr20:33292090	TP53INP2	0.59	5.67	0.35	4.13e-8	Protein C levels;
SARC	cis	rs6089584	0.526	rs6061965	chr20:60607858	A/C	cg23262073	chr20:60523788	NA	-0.35	-5.37	-0.33	1.94e-7	Body mass index;
SARC	cis	rs9462027	0.628	rs10738078	chr6:34693917	G/A	cg07306190	chr6:34760872	UHRF1BP1	0.42	5.91	0.36	1.19e-8	Systemic lupus erythematosus;
SARC	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg11764359	chr7:65958608	NA	-0.85	-12.11	-0.62	1.72e-26	Aortic root size;
SARC	cis	rs2777491	0.915	rs8036498	chr15:41603276	A/G	cg01768344	chr15:41576519	LOC729082	0.44	4.84	0.3	2.33e-6	Ulcerative colitis;
SARC	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg03351412	chr1:154909251	PMVK	0.65	8.47	0.48	2.88e-15	Prostate cancer;
SARC	trans	rs4332037	0.950	rs11767515	chr7:1941051	C/T	cg11693508	chr17:37793320	STARD3	0.72	6.54	0.39	3.95e-10	Bipolar disorder;
SARC	cis	rs12956009	0.583	rs9653018	chr18:44895853	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	7.64	0.45	5.68e-13	Educational attainment (years of education);
SARC	cis	rs2916247	0.954	rs7007307	chr8:93063802	A/C	cg10183463	chr8:93005414	RUNX1T1	-0.58	-5.95	-0.36	1e-8	Intelligence (multi-trait analysis);
SARC	cis	rs12369635	1.000	rs9645723	chr12:129554501	C/T	cg01909103	chr12:129572610	TMEM132D	-0.67	-6.13	-0.37	3.69e-9	Schizophrenia (inflammation and infection response interaction);
SARC	cis	rs7552404	0.656	rs11161792	chr1:76336746	C/T	cg22875332	chr1:76189707	ACADM	0.44	5.35	0.33	2.14e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7786877	0.680	rs28584500	chr7:100216341	G/A	cg16850897	chr7:100343110	ZAN	-0.59	-5.35	-0.33	2.06e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs918629	0.798	rs3777168	chr5:95285771	G/A	cg16656078	chr5:95278638	ELL2	-0.7	-8.29	-0.48	8.84e-15	IgG glycosylation;
SARC	trans	rs3780486	0.846	rs10813948	chr9:33121570	G/A	cg04842962	chr6:43655489	MRPS18A	1.09	20.71	0.8	9.95e-55	IgG glycosylation;
SARC	cis	rs2013441	0.965	rs2703820	chr17:20121479	G/A	cg13482628	chr17:19912719	NA	-0.46	-5.97	-0.36	8.87e-9	Obesity-related traits;
SARC	cis	rs7769051	1.000	rs9493444	chr6:133125320	C/G	cg07930552	chr6:133119739	C6orf192	0.87	7.85	0.46	1.47e-13	Type 2 diabetes nephropathy;
SARC	cis	rs9818758	0.607	rs34566463	chr3:49245077	T/C	cg07636037	chr3:49044803	WDR6	-0.77	-6.94	-0.41	3.77e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs11770686	0.632	rs2285874	chr7:75311214	C/T	cg17787366	chr7:75369077	HIP1	0.39	4.85	0.3	2.28e-6	Essential tremor;
SARC	cis	rs7666738	0.830	rs10470951	chr4:99037051	G/A	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg11941060	chr3:133502564	NA	-0.33	-4.84	-0.3	2.34e-6	Iron status biomarkers;
SARC	cis	rs11583043	0.874	rs41312668	chr1:101443582	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	6.01	0.37	7.19e-9	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs554111	0.656	rs10799680	chr1:21361181	C/T	cg08890418	chr1:21044141	KIF17	-0.37	-5.16	-0.32	5.38e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs898097	0.845	rs7213006	chr17:80899928	T/C	cg05255149	chr17:80675120	FN3KRP	0.43	5.47	0.34	1.19e-7	Breast cancer;
SARC	trans	rs561341	0.739	rs6505267	chr17:30225950	A/C	cg20587970	chr11:113659929	NA	-0.75	-7.6	-0.45	6.99e-13	Hip circumference adjusted for BMI;
SARC	cis	rs921968	0.565	rs6436083	chr2:219639719	C/T	cg02176678	chr2:219576539	TTLL4	-0.33	-5.03	-0.31	9.92e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs924043	0.636	rs75738781	chr6:170376849	A/G	cg17770813	chr6:170484120	NA	0.51	5.26	0.33	3.31e-7	Type 1 diabetes;
SARC	trans	rs10085978	0.604	rs11167128	chr8:143225883	A/G	cg11942548	chr13:22248814	FGF9	0.48	6.6	0.4	2.81e-10	Mosquito bite size;
SARC	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg08859206	chr1:53392774	SCP2	-0.39	-5.55	-0.34	7.87e-8	Monocyte count;
SARC	cis	rs3126085	1.000	rs72696969	chr1:152196339	G/A	cg03465714	chr1:152285911	FLG	0.46	4.88	0.3	1.95e-6	Atopic dermatitis;
SARC	cis	rs1865721	0.804	rs719179	chr18:73146396	A/G	cg26385618	chr18:73139727	C18orf62	-0.37	-5.1	-0.32	6.93e-7	Intelligence;
SARC	cis	rs9309473	0.519	rs1083922	chr2:73704003	A/G	cg20560298	chr2:73613845	ALMS1	0.52	6.83	0.41	7.46e-11	Metabolite levels;
SARC	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	5.96	0.36	9.28e-9	Tonsillectomy;
SARC	trans	rs10767455	1.000	rs16914608	chr11:25794091	C/T	cg01353486	chr6:88117432	C6orf165	-0.47	-6.25	-0.38	1.93e-9	QRS interval (sulfonylurea treatment interaction);
SARC	cis	rs453301	0.653	rs7853	chr8:8890814	A/G	cg08975724	chr8:8085496	FLJ10661	0.4	5.14	0.32	5.95e-7	Joint mobility (Beighton score);
SARC	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg01324507	chr7:1177794	C7orf50	0.48	4.72	0.3	4.14e-6	Bronchopulmonary dysplasia;
SARC	cis	rs2758596	0.850	rs2241110	chr1:156172487	A/G	cg24450063	chr1:156163899	SLC25A44	0.82	5.29	0.33	2.8e-7	Paclitaxel disposition in epithelial ovarian cancer;
SARC	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg06221963	chr1:154839813	KCNN3	-0.51	-8.24	-0.47	1.27e-14	Prostate cancer;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg04274916	chr22:41252959	ST13;XPNPEP3	0.53	6.38	0.39	9.22e-10	Breast cancer;
SARC	cis	rs7927771	1.000	rs1317149	chr11:47486885	C/T	cg20307385	chr11:47447363	PSMC3	-0.52	-6.31	-0.38	1.36e-9	Subjective well-being;
SARC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg26338869	chr17:61819248	STRADA	0.8	10.67	0.57	6.8e-22	Prudent dietary pattern;
SARC	cis	rs826838	1.000	rs9795768	chr12:39012479	T/C	cg13010199	chr12:38710504	ALG10B	0.77	10.76	0.58	3.47e-22	Heart rate;
SARC	cis	rs72945132	0.882	rs7928686	chr11:70134528	T/C	cg00319359	chr11:70116639	PPFIA1	0.68	6.37	0.39	1.01e-9	Coronary artery disease;
SARC	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg07701084	chr6:150067640	NUP43	0.41	5.39	0.33	1.68e-7	Lung cancer;
SARC	cis	rs7587476	0.906	rs17487827	chr2:215644335	C/G	cg04004882	chr2:215674386	BARD1	0.58	6.11	0.37	4.08e-9	Neuroblastoma;
SARC	cis	rs2153535	0.580	rs763376	chr6:8492776	G/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.11	0.59	2.71e-23	Motion sickness;
SARC	cis	rs12142240	0.667	rs45524035	chr1:46862780	C/T	cg00530320	chr1:46809349	NSUN4	0.57	6.97	0.42	3.29e-11	Menopause (age at onset);
SARC	cis	rs11638352	0.661	rs2114422	chr15:44420244	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	-0.76	-5.91	-0.36	1.23e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg21280719	chr6:42927975	GNMT	-0.41	-7.15	-0.42	1.09e-11	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs2120019	1.000	rs7167285	chr15:75368769	A/G	cg09165964	chr15:75287851	SCAMP5	-0.87	-13.08	-0.65	1.1e-29	Blood trace element (Zn levels);
SARC	cis	rs7412746	0.622	rs72704654	chr1:150826410	G/A	cg13175981	chr1:150552382	MCL1	-0.5	-6.06	-0.37	5.3e-9	Melanoma;
SARC	cis	rs910316	0.935	rs175422	chr14:75627319	T/A	cg06637938	chr14:75390232	RPS6KL1	-0.53	-7.28	-0.43	5.2e-12	Height;
SARC	cis	rs12579753	0.917	rs7972839	chr12:82178920	C/T	cg07988820	chr12:82153109	PPFIA2	-0.53	-6.32	-0.38	1.29e-9	Resting heart rate;
SARC	cis	rs710216	0.752	rs841849	chr1:43402205	G/A	cg03128534	chr1:43423976	SLC2A1	0.62	5.79	0.35	2.21e-8	Red cell distribution width;
SARC	cis	rs11098499	0.562	rs2389879	chr4:120557684	G/A	cg09307838	chr4:120376055	NA	-0.7	-9.69	-0.54	7.36e-19	Corneal astigmatism;
SARC	cis	rs6546550	0.743	rs6731941	chr2:70018496	A/G	cg02498382	chr2:70120550	SNRNP27	-0.35	-5.52	-0.34	9.18e-8	Prevalent atrial fibrillation;
SARC	cis	rs28374715	0.532	rs28703570	chr15:41679492	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.18	-20.12	-0.8	7.35e-53	Ulcerative colitis;
SARC	cis	rs9815354	1.000	rs73069396	chr3:41787236	A/T	cg03022575	chr3:42003672	ULK4	0.58	5.6	0.34	5.92e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs10979	0.964	rs12526234	chr6:143898680	A/T	cg25407410	chr6:143891975	LOC285740	-0.64	-8.55	-0.49	1.65e-15	Hypospadias;
SARC	cis	rs1707322	1.000	rs34694458	chr1:46332696	G/A	cg06784218	chr1:46089804	CCDC17	0.33	5.75	0.35	2.84e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs9354308	0.903	rs1938064	chr6:66559172	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.55	-6.61	-0.4	2.63e-10	Metabolite levels;
SARC	cis	rs9902453	0.691	rs140701	chr17:28538532	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.48	5.95	0.36	9.78e-9	Coffee consumption (cups per day);
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg19081759	chr2:9771089	YWHAQ	0.6	6.3	0.38	1.46e-9	Lung cancer in ever smokers;
SARC	cis	rs9399137	0.507	rs13196486	chr6:135283874	C/G	cg22676075	chr6:135203613	NA	0.39	4.97	0.31	1.32e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs6918586	0.658	rs198837	chr6:26113398	A/T	cg21479132	chr6:26055353	NA	0.4	4.81	0.3	2.67e-6	Schizophrenia;
SARC	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg14893161	chr1:205819251	PM20D1	0.47	5.23	0.32	3.72e-7	Parkinson's disease;
SARC	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.7	-7.23	-0.43	6.97e-12	Platelet count;
SARC	cis	rs796364	1.000	rs11694369	chr2:200741720	G/A	cg23649088	chr2:200775458	C2orf69	-0.58	-5.0	-0.31	1.1e-6	Schizophrenia;
SARC	cis	rs734999	0.549	rs6670198	chr1:2520527	T/C	cg00980319	chr1:2560884	MMEL1	-0.34	-4.81	-0.3	2.71e-6	Ulcerative colitis;
SARC	cis	rs12950390	0.853	rs59513807	chr17:45867925	G/A	cg24803719	chr17:45855879	NA	-0.46	-7.49	-0.44	1.4e-12	IgG glycosylation;
SARC	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.47	5.74	0.35	2.93e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7847628	0.587	rs10760117	chr9:123586737	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.93	14.81	0.7	1.99e-35	Birth weight;
SARC	cis	rs1707322	1.000	rs11211236	chr1:46443767	C/A	cg06784218	chr1:46089804	CCDC17	0.34	5.95	0.36	9.76e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2075371	0.829	rs10954442	chr7:134007587	A/G	cg00033643	chr7:134001901	SLC35B4	-0.45	-5.48	-0.34	1.09e-7	Mean platelet volume;
SARC	cis	rs12950390	1.000	rs8068453	chr17:45852354	A/G	cg24803719	chr17:45855879	NA	0.39	5.67	0.35	4.27e-8	IgG glycosylation;
SARC	cis	rs3087591	1.000	rs8068801	chr17:29570587	G/T	cg24425628	chr17:29625626	OMG;NF1	-0.5	-6.12	-0.37	3.93e-9	Hip circumference;
SARC	cis	rs1559088	0.600	rs7255229	chr19:33562807	A/G	cg27124370	chr19:33622961	WDR88	0.47	6.04	0.37	5.98e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs858239	0.600	rs13438179	chr7:23143851	T/C	cg23682824	chr7:23144976	KLHL7	0.69	9.51	0.53	2.47e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs2832077	0.527	rs2738953	chr21:30238363	G/C	cg24692254	chr21:30365293	RNF160	0.57	6.25	0.38	1.9e-9	Cognitive test performance;
SARC	cis	rs6952808	0.964	rs10950407	chr7:1895666	T/G	cg04267008	chr7:1944627	MAD1L1	-0.52	-5.88	-0.36	1.39e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs2387326	0.717	rs10829336	chr10:129943532	T/C	cg16087940	chr10:129947807	NA	-0.44	-5.48	-0.34	1.08e-7	Select biomarker traits;
SARC	cis	rs2486288	0.656	rs11629858	chr15:45547114	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.5	-6.22	-0.38	2.34e-9	Glomerular filtration rate;
SARC	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg22535103	chr8:58192502	C8orf71	-0.7	-6.55	-0.39	3.61e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9462027	0.628	rs9469889	chr6:34763900	G/C	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.85	-0.36	1.63e-8	Systemic lupus erythematosus;
SARC	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg21724239	chr8:58056113	NA	0.61	6.14	0.37	3.5e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2011503	0.941	rs2074302	chr19:19381728	G/C	cg03709012	chr19:19516395	GATAD2A	0.59	5.33	0.33	2.27e-7	Bipolar disorder;
SARC	cis	rs2645694	0.626	rs2703126	chr4:77819842	T/C	cg10057126	chr4:77819792	ANKRD56	0.43	6.38	0.39	9.46e-10	Emphysema distribution in smoking;
SARC	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg03033257	chr22:50311977	ALG12;CRELD2	0.56	5.41	0.33	1.54e-7	Schizophrenia;
SARC	cis	rs7589342	0.929	rs7562054	chr2:106433513	G/C	cg14210321	chr2:106509881	NCK2	-0.46	-5.36	-0.33	2e-7	Addiction;
SARC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg20887711	chr4:1340912	KIAA1530	0.82	10.36	0.56	6.31e-21	Longevity;
SARC	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg12463550	chr7:65579703	CRCP	-0.46	-5.28	-0.33	2.96e-7	Aortic root size;
SARC	cis	rs477692	0.624	rs880300	chr10:131329486	G/A	cg14263093	chr10:131365266	MGMT	0.41	5.8	0.36	2.14e-8	Response to temozolomide;
SARC	cis	rs8180040	0.593	rs12715421	chr3:47084859	A/G	cg27129171	chr3:47204927	SETD2	0.7	9.55	0.53	1.95e-18	Colorectal cancer;
SARC	trans	rs3010562	0.668	rs9457306	chr6:167764791	C/G	cg13679164	chr6:161258479	NA	-0.53	-7.63	-0.45	6.12e-13	Gut microbiome composition (summer and winter);
SARC	trans	rs7937682	0.924	rs495460	chr11:111504777	G/A	cg18187862	chr3:45730750	SACM1L	0.55	6.96	0.41	3.46e-11	Primary sclerosing cholangitis;
SARC	cis	rs3796352	1.000	rs116616340	chr3:53132371	C/G	cg27565382	chr3:53032988	SFMBT1	0.79	5.56	0.34	7.32e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	5.01	0.31	1.08e-6	Personality dimensions;
SARC	cis	rs11690935	0.959	rs76324055	chr2:172620150	T/A	cg13550731	chr2:172543902	DYNC1I2	-0.99	-14.79	-0.7	2.39e-35	Schizophrenia;
SARC	cis	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg14541582	chr5:601475	NA	-0.41	-5.04	-0.31	9.52e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs6582630	0.500	rs35251810	chr12:38577666	T/C	cg14851346	chr12:38532713	NA	-0.43	-5.22	-0.32	3.96e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg22535103	chr8:58192502	C8orf71	-0.73	-7.24	-0.43	6.52e-12	Developmental language disorder (linguistic errors);
SARC	trans	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg21659725	chr3:3221576	CRBN	0.53	6.88	0.41	5.37e-11	Intelligence (multi-trait analysis);
SARC	cis	rs9392918	0.967	rs11964049	chr6:7709052	G/T	cg23089261	chr6:7723385	NA	0.38	5.11	0.32	6.7e-7	Height;
SARC	cis	rs12048904	0.533	rs1590580	chr1:101292668	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.86	10.51	0.57	2.09e-21	Multiple sclerosis;
SARC	cis	rs370915	0.542	rs1895844	chr4:187833759	C/T	cg19519643	chr4:187840862	NA	-0.55	-7.69	-0.45	4.21e-13	Gout;
SARC	cis	rs2425143	1.000	rs8124505	chr20:34307247	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.09	-0.37	4.6e-9	Blood protein levels;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg16232504	chr1:99127707	SNX7	-0.6	-6.78	-0.41	9.72e-11	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs9815354	1.000	rs2625668	chr3:41905930	T/C	cg03022575	chr3:42003672	ULK4	0.56	5.29	0.33	2.81e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs4423214	1.000	rs4944958	chr11:71168073	A/G	cg24826892	chr11:71159390	DHCR7	0.45	5.7	0.35	3.67e-8	Vitamin D levels;
SARC	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg11764359	chr7:65958608	NA	0.78	9.86	0.54	2.14e-19	Aortic root size;
SARC	cis	rs11785400	0.793	rs4736362	chr8:143741381	G/A	cg24634471	chr8:143751801	JRK	0.59	7.45	0.44	1.83e-12	Schizophrenia;
SARC	cis	rs9916302	0.706	rs11078894	chr17:37396805	C/G	cg20243544	chr17:37824526	PNMT	0.54	5.69	0.35	3.87e-8	Glomerular filtration rate (creatinine);
SARC	trans	rs3808502	0.526	rs36048422	chr8:11417144	T/C	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.59	-0.4	2.95e-10	Neuroticism;
SARC	cis	rs4423214	1.000	rs2276360	chr11:71169547	C/G	cg05163923	chr11:71159392	DHCR7	0.67	9.14	0.51	3.06e-17	Vitamin D levels;
SARC	cis	rs898097	0.607	rs2199111	chr17:80823203	A/G	cg15664640	chr17:80829946	TBCD	-0.35	-5.48	-0.34	1.08e-7	Breast cancer;
SARC	cis	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg22857025	chr5:266934	NA	-1.1	-11.6	-0.61	7.15e-25	Breast cancer;
SARC	cis	rs3733589	0.744	rs13114106	chr4:10022125	T/C	cg16430538	chr4:10459836	ZNF518B	0.61	4.92	0.31	1.62e-6	Renal overload gout;
SARC	trans	rs1814175	0.617	rs6486020	chr11:49769149	T/G	cg03929089	chr4:120376271	NA	-0.84	-12.3	-0.63	4.13e-27	Height;
SARC	cis	rs561341	1.000	rs508192	chr17:30315147	C/T	cg00745463	chr17:30367425	LRRC37B	0.62	4.91	0.31	1.74e-6	Hip circumference adjusted for BMI;
SARC	cis	rs72945132	0.882	rs4567496	chr11:70193208	A/T	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.58	-0.34	6.81e-8	Coronary artery disease;
SARC	cis	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg06636001	chr8:8085503	FLJ10661	0.56	7.47	0.44	1.6e-12	Joint mobility (Beighton score);
SARC	cis	rs9388451	0.839	rs3799709	chr6:126078361	A/G	cg05901451	chr6:126070800	HEY2	-0.66	-9.21	-0.52	2.01e-17	Brugada syndrome;
SARC	cis	rs981844	0.775	rs17299561	chr4:154765480	C/T	cg14289246	chr4:154710475	SFRP2	0.59	6.7	0.4	1.58e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs921968	0.643	rs864990	chr2:219494037	G/A	cg02176678	chr2:219576539	TTLL4	0.35	5.05	0.31	8.84e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs9436747	0.605	rs2025803	chr1:65946506	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	-0.41	-5.12	-0.32	6.32e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs4660306	0.961	rs12082256	chr1:45951380	A/G	cg24296786	chr1:45957014	TESK2	0.58	6.72	0.4	1.35e-10	Homocysteine levels;
SARC	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg20120463	chr17:44301886	NA	-0.38	-5.94	-0.36	1.06e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs2594989	0.778	rs6801721	chr3:11470267	T/C	cg00170343	chr3:11313890	ATG7	0.6	5.39	0.33	1.74e-7	Circulating chemerin levels;
SARC	cis	rs16866061	1.000	rs11686590	chr2:225334070	A/G	cg12698349	chr2:225449008	CUL3	0.71	10.59	0.57	1.16e-21	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg19077165	chr18:44547161	KATNAL2	-0.53	-7.42	-0.44	2.13e-12	Personality dimensions;
SARC	cis	rs897984	0.568	rs67264578	chr16:30879395	G/A	cg00531865	chr16:30841666	NA	-0.51	-5.28	-0.33	2.96e-7	Dementia with Lewy bodies;
SARC	cis	rs9916302	0.904	rs10491128	chr17:37551988	G/A	cg15445000	chr17:37608096	MED1	-0.44	-5.33	-0.33	2.31e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs2200578	1.000	rs62153845	chr2:99887162	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.66	6.48	0.39	5.4e-10	IgG glycosylation;
SARC	cis	rs910316	0.967	rs175451	chr14:75589729	C/T	cg11812906	chr14:75593930	NEK9	-0.82	-12.24	-0.63	6.3100000000000004e-27	Height;
SARC	cis	rs4721295	0.546	rs1637766	chr7:2204400	G/A	cg04267008	chr7:1944627	MAD1L1	0.47	5.12	0.32	6.34e-7	Schizophrenia, schizoaffective disorder or bipolar disorder;
SARC	cis	rs2658782	0.593	rs2243410	chr11:93255519	T/G	cg15737290	chr11:93063684	CCDC67	0.72	8.13	0.47	2.61e-14	Pulmonary function decline;
SARC	cis	rs7589342	0.831	rs34554853	chr2:106448931	G/A	cg14210321	chr2:106509881	NCK2	-0.44	-5.07	-0.32	8.08e-7	Addiction;
SARC	cis	rs73206853	0.764	rs73206878	chr12:110835015	A/C	cg10860002	chr12:110842031	ANAPC7	0.66	5.05	0.31	8.98e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg16479474	chr6:28041457	NA	0.37	5.49	0.34	1.04e-7	Depression;
SARC	cis	rs17376456	0.877	rs10060462	chr5:93455073	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.54	0.34	8.18e-8	Diabetic retinopathy;
SARC	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg16405210	chr4:1374714	KIAA1530	0.69	8.49	0.49	2.41e-15	Obesity-related traits;
SARC	cis	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg05623727	chr3:50126028	RBM5	0.33	4.95	0.31	1.4e-6	Intelligence (multi-trait analysis);
SARC	cis	rs6908034	0.607	rs73378506	chr6:19819987	T/C	cg02682789	chr6:19804855	NA	0.7	6.64	0.4	2.2e-10	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs1669338	0.588	rs3931974	chr3:3186894	A/G	cg16797762	chr3:3221439	CRBN	0.84	8.26	0.48	1.08e-14	White matter integrity;
SARC	cis	rs787274	1.000	rs4246892	chr9:115588649	G/A	cg13803584	chr9:115635662	SNX30	-0.83	-5.03	-0.31	9.96e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs3126085	0.877	rs12133847	chr1:152170101	T/G	cg26876637	chr1:152193138	HRNR	0.48	5.5	0.34	9.84e-8	Atopic dermatitis;
SARC	trans	rs7824557	0.545	rs34482136	chr8:11227885	C/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.38	-0.39	9.54e-10	Retinal vascular caliber;
SARC	trans	rs8073060	0.586	rs7217533	chr17:34015876	A/G	cg19694781	chr19:47549865	TMEM160	-0.71	-6.94	-0.41	3.88e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	trans	rs2727020	0.894	rs11040333	chr11:49346332	G/A	cg03929089	chr4:120376271	NA	-0.7	-8.69	-0.49	6.46e-16	Coronary artery disease;
SARC	cis	rs56775891	1.000	rs56775891	chr18:77575613	C/T	cg24058013	chr18:77568902	NA	-0.36	-4.72	-0.3	4.15e-6	Schizophrenia;
SARC	cis	rs751728	1.000	rs1359781	chr6:33762104	T/C	cg25922239	chr6:33757077	LEMD2	0.77	10.26	0.56	1.25e-20	Crohn's disease;
SARC	cis	rs546131	0.642	rs11603751	chr11:34820809	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-4.92	-0.31	1.67e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs10484885	0.793	rs9359862	chr6:90474508	A/G	cg13799429	chr6:90582589	CASP8AP2	0.58	5.14	0.32	5.7e-7	QRS interval (sulfonylurea treatment interaction);
SARC	cis	rs7223966	1.000	rs11542436	chr17:61778689	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	6.5	0.39	4.86e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs3087591	0.960	rs4559963	chr17:29438558	G/A	cg24425628	chr17:29625626	OMG;NF1	0.55	6.92	0.41	4.27e-11	Hip circumference;
SARC	cis	rs4588572	0.643	rs1019739	chr5:77770241	G/C	cg11547950	chr5:77652471	NA	-0.42	-5.17	-0.32	5.14e-7	Triglycerides;
SARC	cis	rs4713118	0.824	rs742046	chr6:27739254	A/G	cg17221315	chr6:27791827	HIST1H4J	0.44	4.76	0.3	3.47e-6	Parkinson's disease;
SARC	cis	rs2197308	0.606	rs12314897	chr12:38392293	C/T	cg13010199	chr12:38710504	ALG10B	-0.48	-5.83	-0.36	1.81e-8	Morning vs. evening chronotype;
SARC	cis	rs6088580	0.634	rs4142007	chr20:32990050	G/T	cg08999081	chr20:33150536	PIGU	-0.42	-6.49	-0.39	4.98e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs6901004	0.803	rs354544	chr6:111531159	T/C	cg15721981	chr6:111408429	SLC16A10	-0.45	-5.46	-0.34	1.24e-7	Blood metabolite levels;
SARC	cis	rs870825	0.616	rs4437295	chr4:185643336	C/T	cg04058563	chr4:185651563	MLF1IP	0.81	11.52	0.6	1.31e-24	Blood protein levels;
SARC	cis	rs7561528	0.501	rs59176034	chr2:127891623	C/T	cg12632573	chr2:127783243	NA	0.64	5.8	0.36	2.11e-8	Alzheimer's disease;Alzheimer's disease (late onset);
SARC	cis	rs838147	0.537	rs503279	chr19:49209010	C/T	cg21064579	chr19:49206444	FUT2	-0.34	-4.83	-0.3	2.45e-6	Dietary macronutrient intake;
SARC	cis	rs950776	0.518	rs8053	chr15:78841220	T/C	cg06917634	chr15:78832804	PSMA4	-0.9	-13.91	-0.67	2.04e-32	Sudden cardiac arrest;
SARC	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg01448562	chr3:133502909	NA	-0.58	-8.99	-0.51	8.65e-17	Iron status biomarkers;
SARC	cis	rs9303401	0.659	rs34382037	chr17:56643550	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.09	12.25	0.63	5.64e-27	Cognitive test performance;
SARC	cis	rs12950390	0.814	rs4794099	chr17:45838358	T/C	cg24803719	chr17:45855879	NA	-0.49	-7.98	-0.46	6.41e-14	IgG glycosylation;
SARC	cis	rs1345301	0.518	rs17689452	chr2:102864681	A/G	cg12451869	chr2:102867685	NA	0.42	5.76	0.35	2.65e-8	Waist circumference;
SARC	cis	rs6582630	0.555	rs10785454	chr12:38476260	C/T	cg13010199	chr12:38710504	ALG10B	0.75	10.21	0.56	1.79e-20	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg04267008	chr7:1944627	MAD1L1	-0.53	-6.18	-0.38	2.83e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg11987759	chr7:65425863	GUSB	0.5	6.21	0.38	2.36e-9	Aortic root size;
SARC	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg05313129	chr8:58192883	C8orf71	-0.49	-4.74	-0.3	3.69e-6	Developmental language disorder (linguistic errors);
SARC	trans	rs981844	0.712	rs1037650	chr4:154737657	G/A	cg25721732	chr2:74602550	DCTN1	-0.5	-6.23	-0.38	2.1e-9	Response to statins (LDL cholesterol change);
SARC	cis	rs5758659	1.000	rs134900	chr22:42683343	C/G	cg15128208	chr22:42549153	NA	-0.34	-4.84	-0.3	2.37e-6	Cognitive function;
SARC	cis	rs12973672	1.000	rs1051995	chr19:35770292	C/T	cg12095397	chr19:35769544	USF2	0.38	4.79	0.3	2.9e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs8044995	0.563	rs56331745	chr16:68368770	G/T	cg09835421	chr16:68378352	PRMT7	-0.64	-5.82	-0.36	1.92e-8	Schizophrenia;
SARC	cis	rs7931462	0.655	rs6483208	chr11:92705844	A/C	cg16394304	chr11:93468442	SNORA40	-0.62	-5.26	-0.33	3.23e-7	DNA methylation (parent-of-origin);
SARC	cis	rs1008375	0.866	rs2109518	chr4:17572162	G/A	cg16339924	chr4:17578868	LAP3	0.68	8.81	0.5	2.95e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg11877270	chr2:65658583	SPRED2	-0.68	-7.9	-0.46	1.12e-13	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs644799	1.000	rs488246	chr11:95560473	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.9	14.03	0.68	7.82e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg10435706	chr6:150039699	LATS1	0.35	4.74	0.3	3.64e-6	Lung cancer;
SARC	cis	rs7666738	0.830	rs1534319	chr4:98964804	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4595586	0.563	rs11169769	chr12:39233134	C/G	cg26384229	chr12:38710491	ALG10B	0.69	8.52	0.49	1.94e-15	Morning vs. evening chronotype;
SARC	cis	rs240764	0.658	rs9399685	chr6:101204318	C/G	cg09795085	chr6:101329169	ASCC3	-0.44	-5.64	-0.35	4.99e-8	Neuroticism;
SARC	cis	rs10875746	0.669	rs10875767	chr12:48599257	A/C	cg26205652	chr12:48591994	NA	0.46	5.09	0.32	7.41e-7	Longevity (90 years and older);
SARC	cis	rs3120667	0.790	rs12049036	chr1:152389840	G/A	cg26876637	chr1:152193138	HRNR	-0.48	-4.84	-0.3	2.34e-6	Eating disorders;
SARC	cis	rs17376456	0.825	rs10061377	chr5:93174513	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.69	5.99	0.37	8.06e-9	Diabetic retinopathy;
SARC	cis	rs854765	0.547	rs2955355	chr17:17948475	G/A	cg04398451	chr17:18023971	MYO15A	0.45	6.42	0.39	7.45e-10	Total body bone mineral density;
SARC	cis	rs6866344	0.570	rs6896799	chr5:178147014	G/C	cg10224037	chr5:178157518	ZNF354A	0.98	12.77	0.64	1.17e-28	Neutrophil percentage of white cells;
SARC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg11062466	chr8:58055876	NA	0.54	5.53	0.34	8.37e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs11605924	0.901	rs6485644	chr11:45855998	C/T	ch.11.939596F	chr11:45881766	CRY2	-0.47	-5.62	-0.35	5.45e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs7766436	0.621	rs9348527	chr6:22604319	C/T	cg13666174	chr6:22585274	NA	-0.49	-6.7	-0.4	1.59e-10	Coronary artery disease;
SARC	cis	rs4481887	0.962	rs10788770	chr1:248457474	T/G	cg13385794	chr1:248469461	NA	0.33	5.04	0.31	9.35e-7	Common traits (Other);
SARC	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg21782813	chr7:2030301	MAD1L1	0.41	6.47	0.39	5.73e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs61989804	0.826	rs61987797	chr14:65704002	C/G	cg15999311	chr14:65749247	NA	0.54	5.17	0.32	5.07e-7	Midgestational circulating levels of PCBs (fetal genetic effect);
SARC	cis	rs7786877	0.723	rs62482239	chr7:100217810	C/T	cg20848291	chr7:100343083	ZAN	-0.64	-5.97	-0.36	8.71e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs61935443	0.832	rs11107773	chr12:95282000	C/T	cg21533806	chr12:95267307	NA	0.7	8.5	0.49	2.33e-15	Schizophrenia;
SARC	cis	rs8014204	0.935	rs2300596	chr14:75353855	C/T	cg06637938	chr14:75390232	RPS6KL1	0.77	11.85	0.61	1.18e-25	Caffeine consumption;
SARC	cis	rs1371867	0.846	rs1660345	chr8:101322762	C/A	cg11906718	chr8:101322791	RNF19A	0.71	9.12	0.51	3.68e-17	Atrioventricular conduction;
SARC	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg13298116	chr11:62369859	EML3;MTA2	0.47	7.27	0.43	5.37e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs67460515	0.563	rs16831981	chr3:160897780	T/C	cg17135325	chr3:160939158	NMD3	0.66	8.61	0.49	1.14e-15	Parkinson's disease;
SARC	cis	rs4268898	0.662	rs2288074	chr2:24413595	C/T	cg26838691	chr2:24397539	C2orf84	-0.57	-6.43	-0.39	7.04e-10	Asthma;
SARC	cis	rs12950390	0.853	rs66471233	chr17:45867086	C/T	cg03474202	chr17:45855739	NA	-0.43	-6.71	-0.4	1.48e-10	IgG glycosylation;
SARC	cis	rs2290159	0.800	rs3730269	chr3:12653233	G/T	cg23032965	chr3:12705835	RAF1	0.74	8.0	0.46	5.66e-14	Cholesterol, total;
SARC	cis	rs2559856	1.000	rs2695292	chr12:102087290	G/A	cg12924262	chr12:102091054	CHPT1	0.56	7.74	0.45	3.01e-13	Blood protein levels;
SARC	trans	rs9650657	0.504	rs2409724	chr8:11041642	A/T	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.75	-0.45	2.86e-13	Neuroticism;
SARC	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg03452623	chr4:187889614	NA	-0.76	-11.77	-0.61	2.03e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.56	7.14	0.42	1.15e-11	Lymphocyte counts;
SARC	cis	rs116095464	0.558	rs62346508	chr5:203668	T/C	cg22857025	chr5:266934	NA	-1.15	-10.84	-0.58	1.95e-22	Breast cancer;
SARC	cis	rs3741404	0.560	rs2875748	chr11:63915537	G/A	cg18225595	chr11:63971243	STIP1	-0.42	-6.53	-0.39	4.03e-10	Platelet count;
SARC	cis	rs734999	0.588	rs60520190	chr1:2533706	G/A	cg18854424	chr1:2615690	NA	0.3	4.79	0.3	2.96e-6	Ulcerative colitis;
SARC	cis	rs7712401	0.562	rs30053	chr5:122303643	C/G	cg19412675	chr5:122181750	SNX24	0.4	5.13	0.32	5.98e-7	Mean platelet volume;
SARC	cis	rs56235845	0.694	rs9313758	chr5:176773091	T/G	cg17509989	chr5:176798049	RGS14	0.61	8.28	0.48	9.33e-15	Hemoglobin concentration;Hematocrit;
SARC	cis	rs9920	0.585	rs35867035	chr7:116162619	C/G	cg24770985	chr7:116166421	CAV1	0.87	5.69	0.35	3.81e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Immature fraction of reticulocytes;QT interval;
SARC	cis	rs5769765	0.778	rs4574208	chr22:50256738	C/T	cg03033257	chr22:50311977	ALG12;CRELD2	-0.55	-5.72	-0.35	3.26e-8	Schizophrenia;
SARC	cis	rs921968	0.541	rs2556391	chr2:219556346	T/C	cg02176678	chr2:219576539	TTLL4	-0.5	-7.68	-0.45	4.29e-13	Mean corpuscular hemoglobin concentration;
SARC	cis	rs1144333	0.655	rs7521538	chr1:76420440	A/G	cg03433033	chr1:76189801	ACADM	0.62	5.08	0.32	7.87e-7	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs2425143	0.915	rs2378408	chr20:34367732	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	-0.64	-5.23	-0.32	3.83e-7	Blood protein levels;
SARC	trans	rs6981523	0.553	rs11783890	chr8:11056388	T/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.79	-0.41	9.12e-11	Neuroticism;
SARC	cis	rs9902453	0.765	rs2259857	chr17:28097780	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.17	-0.43	9.6e-12	Coffee consumption (cups per day);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg21153342	chr3:186144610	NA	0.46	7.5	0.44	1.31e-12	Thyroid stimulating hormone;
SARC	cis	rs9911578	0.835	rs723991	chr17:56482039	G/A	cg12560992	chr17:57184187	TRIM37	-0.75	-9.62	-0.53	1.15e-18	Intelligence (multi-trait analysis);
SARC	cis	rs1215050	0.791	rs1669745	chr4:98842047	G/A	cg05340658	chr4:99064831	C4orf37	-0.43	-5.85	-0.36	1.66e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg22800045	chr5:56110881	MAP3K1	0.74	7.8	0.46	2.06e-13	Initial pursuit acceleration;
SARC	cis	rs35362007	0.530	rs11621250	chr14:96011442	C/T	cg13511115	chr14:96000878	GLRX5;SNHG10;SCARNA13	0.66	5.79	0.35	2.3e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs6977660	0.714	rs10228783	chr7:19789290	C/T	cg07541023	chr7:19748670	TWISTNB	0.75	6.86	0.41	6.1e-11	Thyroid stimulating hormone;
SARC	cis	rs7106204	0.764	rs7933686	chr11:24246790	G/C	ch.11.24196551F	chr11:24239977	NA	0.81	5.61	0.34	5.84e-8	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs3540	0.921	rs8034050	chr15:91000206	C/T	cg22089800	chr15:90895588	ZNF774	0.51	5.8	0.35	2.19e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs7106204	0.534	rs77470639	chr11:24250082	C/T	ch.11.24196551F	chr11:24239977	NA	0.64	4.78	0.3	3.11e-6	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs72781680	0.898	rs12612492	chr2:24093756	C/T	cg08917208	chr2:24149416	ATAD2B	0.91	9.19	0.52	2.27e-17	Lymphocyte counts;
SARC	cis	rs3768617	0.510	rs2027078	chr1:183073478	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.67	9.71	0.54	6.11e-19	Fuchs's corneal dystrophy;
SARC	cis	rs4319547	0.774	rs7307233	chr12:123124301	C/G	cg23029597	chr12:123009494	RSRC2	-0.45	-5.86	-0.36	1.53e-8	Body mass index;
SARC	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg15448220	chr1:150897856	SETDB1	0.47	6.22	0.38	2.24e-9	Tonsillectomy;
SARC	cis	rs4727443	0.653	rs6465759	chr7:99587980	T/C	cg22004693	chr7:99632812	ZKSCAN1	-0.59	-7.39	-0.44	2.62e-12	Interstitial lung disease;
SARC	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg13866156	chr1:1669148	SLC35E2	-0.64	-9.66	-0.53	8.65e-19	Body mass index;
SARC	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg13395646	chr4:1353034	KIAA1530	-0.55	-6.58	-0.4	3.03e-10	Obesity-related traits;
SARC	cis	rs10489202	1.000	rs12408205	chr1:167982332	A/G	cg24449463	chr1:168025552	DCAF6	-0.64	-7.01	-0.42	2.5e-11	Schizophrenia;
SARC	cis	rs1707322	0.691	rs11211174	chr1:46220816	C/G	cg03146154	chr1:46216737	IPP	0.53	6.31	0.38	1.38e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg24549020	chr5:56110836	MAP3K1	0.81	8.46	0.48	3.01e-15	Initial pursuit acceleration;
SARC	trans	rs629535	0.862	rs654604	chr8:70048939	C/A	cg21567404	chr3:27674614	NA	1.04	13.82	0.67	3.98e-32	Dupuytren's disease;
SARC	cis	rs6121246	0.909	rs2376992	chr20:30263418	T/C	cg13852791	chr20:30311386	BCL2L1	0.85	8.94	0.51	1.25e-16	Mean corpuscular hemoglobin;
SARC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg09373136	chr17:61933544	TCAM1	-0.45	-6.17	-0.37	2.94e-9	Prudent dietary pattern;
SARC	cis	rs10911232	0.507	rs10732271	chr1:183025898	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.11	0.55	3.63e-20	Hypertriglyceridemia;
SARC	cis	rs9393692	0.905	rs2393592	chr6:26285560	A/G	cg13736514	chr6:26305472	NA	-0.62	-8.63	-0.49	9.5e-16	Educational attainment;
SARC	trans	rs61931739	0.500	rs11053066	chr12:34185318	G/A	cg26384229	chr12:38710491	ALG10B	0.85	12.17	0.62	1.07e-26	Morning vs. evening chronotype;
SARC	cis	rs7223966	1.000	rs8075422	chr17:61804686	G/A	cg00588841	chr17:61851480	DDX42;CCDC47	-0.63	-7.21	-0.43	7.62e-12	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs7824557	0.843	rs2736375	chr8:11115749	C/T	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.2	-0.43	8.31e-12	Retinal vascular caliber;
SARC	cis	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg22857025	chr5:266934	NA	-1.04	-11.62	-0.61	6.46e-25	Breast cancer;
SARC	cis	rs740474	0.652	rs251022	chr5:140892643	T/C	cg00076195	chr5:140892677	NA	0.35	5.08	0.32	7.58e-7	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs7615952	0.546	rs2922194	chr3:125332263	G/A	cg05084668	chr3:125655381	ALG1L	-0.56	-4.97	-0.31	1.29e-6	Blood pressure (smoking interaction);
SARC	cis	rs3018712	0.532	rs11228312	chr11:68415517	G/T	cg01657329	chr11:68192670	LRP5	0.59	5.38	0.33	1.81e-7	Total body bone mineral density;
SARC	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg14784868	chr12:69753453	YEATS4	0.51	6.77	0.41	1.01e-10	Blood protein levels;
SARC	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.76	9.04	0.51	6.17e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg07701084	chr6:150067640	NUP43	0.41	5.39	0.33	1.75e-7	Lung cancer;
SARC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg09436375	chr6:42928200	GNMT	-0.38	-6.26	-0.38	1.81e-9	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs1008375	0.835	rs9760627	chr4:17651508	C/T	cg02297831	chr4:17616191	MED28	0.49	6.31	0.38	1.42e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs2018683	0.707	rs2391718	chr7:28974988	T/C	cg19402173	chr7:128379420	CALU	-0.5	-6.48	-0.39	5.38e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs11098499	0.954	rs28685688	chr4:120420334	T/C	cg09307838	chr4:120376055	NA	0.93	12.73	0.64	1.6e-28	Corneal astigmatism;
SARC	cis	rs2354432	0.556	rs4295925	chr1:146857335	T/C	cg25205988	chr1:146714368	CHD1L	0.96	7.11	0.42	1.44e-11	Mitochondrial DNA levels;
SARC	cis	rs1801251	0.893	rs6733151	chr2:233592341	A/C	cg25237894	chr2:233734115	C2orf82	0.38	5.04	0.31	9.14e-7	Coronary artery disease;
SARC	cis	rs75884327	0.584	rs2836901	chr21:40499194	A/G	cg11890956	chr21:40555474	PSMG1	0.65	5.04	0.31	9.24e-7	Daytime sleep phenotypes;
SARC	cis	rs7223966	1.000	rs8068603	chr17:61755211	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.57	-6.67	-0.4	1.87e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7626444	0.625	rs2686599	chr3:196483794	G/A	cg12930392	chr3:196481615	PAK2	0.25	4.9	0.31	1.79e-6	Monocyte count;
SARC	cis	rs4689388	0.926	rs4416547	chr4:6293967	G/A	cg00701064	chr4:6280414	WFS1	0.54	8.58	0.49	1.38e-15	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs6831352	0.760	rs1311616	chr4:100012303	T/G	cg13256891	chr4:100009986	ADH5	0.66	8.33	0.48	7.17e-15	Alcohol dependence;
SARC	cis	rs9300255	0.544	rs1716174	chr12:123660717	T/C	cg00376283	chr12:123451042	ABCB9	0.58	5.65	0.35	4.71e-8	Neutrophil percentage of white cells;
SARC	cis	rs4900538	0.819	rs72698595	chr14:102863099	G/A	cg18135206	chr14:102964638	TECPR2	-0.61	-7.87	-0.46	1.3e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs7937682	0.924	rs7938360	chr11:111539875	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.94	-16.05	-0.72	1.54e-39	Primary sclerosing cholangitis;
SARC	cis	rs1355223	0.902	rs2226113	chr11:34746289	C/T	cg18508148	chr11:34937573	PDHX;APIP	-0.39	-4.9	-0.31	1.79e-6	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs12367572	0.930	rs10880695	chr12:45233261	T/C	cg04608330	chr12:45269318	NELL2	-0.46	-5.72	-0.35	3.24e-8	Gut microbiome composition (summer);
SARC	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg12564285	chr5:131593104	PDLIM4	-0.48	-6.32	-0.38	1.31e-9	Breast cancer;
SARC	cis	rs1580019	0.961	rs11768506	chr7:32494788	A/C	cg06627557	chr7:32535165	LSM5;AVL9	0.73	9.78	0.54	3.93e-19	Cognitive ability;
SARC	cis	rs7264396	0.635	rs3827030	chr20:34474947	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.63	6.71	0.4	1.45e-10	Total cholesterol levels;
SARC	cis	rs4642101	0.640	rs9877049	chr3:12821231	A/G	cg05775895	chr3:12838266	CAND2	0.83	15.28	0.71	5.56e-37	QRS complex (12-leadsum);
SARC	trans	rs61931739	0.500	rs34080094	chr12:34547952	G/A	cg26384229	chr12:38710491	ALG10B	0.91	13.78	0.67	5.4e-32	Morning vs. evening chronotype;
SARC	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg27170947	chr2:26402098	FAM59B	-0.37	-4.73	-0.3	3.88e-6	Gut microbiome composition (summer);
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg21907156	chr5:79703652	ZFYVE16	-0.49	-6.42	-0.39	7.45e-10	Electrocardiographic conduction measures;
SARC	cis	rs9285223	0.891	rs9317086	chr13:23135024	A/G	cg08083251	chr13:23309930	NA	0.44	4.73	0.3	3.98e-6	Idiopathic osteonecrosis of the femoral head;
SARC	cis	rs9894429	1.000	rs35435780	chr17:79579602	G/T	cg18240062	chr17:79603768	NPLOC4	0.71	9.81	0.54	3.03e-19	Eye color traits;
SARC	cis	rs739401	0.566	rs7931504	chr11:3026712	C/T	cg08508325	chr11:3079039	CARS	-0.31	-7.49	-0.44	1.4e-12	Longevity;
SARC	cis	rs6912958	0.525	rs242262	chr6:88018057	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.76	11.14	0.59	2.25e-23	Monocyte percentage of white cells;
SARC	cis	rs3780378	0.870	rs7034878	chr9:5058991	G/T	cg02405213	chr9:5042618	JAK2	0.37	4.86	0.3	2.21e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
SARC	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg20607798	chr8:58055168	NA	0.61	5.41	0.33	1.57e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg14558471	chr13:111365058	ING1	-0.71	-4.96	-0.31	1.38e-6	Obesity-related traits;
SARC	cis	rs11599315	0.507	rs12218307	chr10:1341914	G/A	cg09624528	chr10:1369823	ADARB2	0.43	6.79	0.41	9.47e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	trans	rs2727020	0.554	rs2866490	chr11:49425463	A/G	cg03929089	chr4:120376271	NA	-0.73	-8.03	-0.47	4.78e-14	Coronary artery disease;
SARC	cis	rs2645424	0.639	rs35581201	chr8:11706834	T/C	cg21281001	chr8:11725306	CTSB	0.41	4.95	0.31	1.42e-6	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
SARC	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg21171335	chr12:122356390	WDR66	0.41	6.51	0.39	4.57e-10	Mean corpuscular volume;
SARC	cis	rs644799	0.582	rs473157	chr11:95596874	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	10.12	0.55	3.53e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs6693567	0.565	rs7544900	chr1:150262333	A/C	cg09579323	chr1:150459698	TARS2	-0.4	-4.96	-0.31	1.34e-6	Migraine;
SARC	cis	rs7833790	0.700	rs7834483	chr8:82704828	A/G	cg27398817	chr8:82754497	SNX16	-0.43	-5.19	-0.32	4.53e-7	Diastolic blood pressure;
SARC	trans	rs9650657	0.746	rs4841441	chr8:10630898	C/A	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.25	-0.38	1.96e-9	Neuroticism;
SARC	trans	rs12310956	0.515	rs1852221	chr12:33945489	G/T	cg13010199	chr12:38710504	ALG10B	0.64	8.45	0.48	3.11e-15	Morning vs. evening chronotype;
SARC	cis	rs2594989	0.708	rs2594997	chr3:11365739	A/T	cg00170343	chr3:11313890	ATG7	0.54	5.28	0.33	3e-7	Circulating chemerin levels;
SARC	cis	rs3820928	0.874	rs55743026	chr2:227802813	G/A	cg05526886	chr2:227700861	RHBDD1	-0.54	-6.65	-0.4	2.04e-10	Pulmonary function;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08935243	chr5:89705635	CETN3	-0.48	-6.26	-0.38	1.79e-9	Smoking initiation;
SARC	cis	rs244731	0.959	rs11740250	chr5:176721272	G/C	cg17509989	chr5:176798049	RGS14	0.67	8.32	0.48	7.41e-15	Urate levels in lean individuals;
SARC	cis	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg12257692	chr3:49977190	RBM6	-0.29	-5.05	-0.31	9.1e-7	Body mass index;
SARC	cis	rs4718428	0.672	rs36038499	chr7:66289615	A/G	cg18252515	chr7:66147081	NA	-0.58	-6.4	-0.39	8.42e-10	Corneal structure;
SARC	cis	rs4969178	0.930	rs7208596	chr17:76396528	C/G	cg20026190	chr17:76395443	PGS1	0.4	5.37	0.33	1.94e-7	HDL cholesterol levels;
SARC	cis	rs950776	0.593	rs555018	chr15:78879242	G/A	cg22563815	chr15:78856949	CHRNA5	-0.4	-6.7	-0.4	1.59e-10	Sudden cardiac arrest;
SARC	cis	rs6952809	0.590	rs1468337	chr7:2432211	C/T	cg23289794	chr7:2394357	EIF3B	-0.62	-5.9	-0.36	1.26e-8	Multiple sclerosis;
SARC	cis	rs7084402	0.967	rs1658493	chr10:60281090	C/T	cg07615347	chr10:60278583	BICC1	-0.6	-8.79	-0.5	3.33e-16	Refractive error;
SARC	trans	rs61931739	1.000	rs12298806	chr12:34036528	C/G	cg26384229	chr12:38710491	ALG10B	-0.58	-7.27	-0.43	5.33e-12	Morning vs. evening chronotype;
SARC	cis	rs6594499	0.872	rs13178997	chr5:110444249	G/T	cg04022379	chr5:110408740	TSLP	0.46	5.89	0.36	1.37e-8	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg26116260	chr4:7069785	GRPEL1	-0.83	-9.78	-0.54	3.81e-19	Monocyte percentage of white cells;
SARC	cis	rs7617773	0.784	rs11715799	chr3:48255220	A/G	cg11946769	chr3:48343235	NME6	0.72	9.36	0.52	7.22e-18	Coronary artery disease;
SARC	cis	rs6500395	1.000	rs3826174	chr16:48591012	T/C	cg04672837	chr16:48644449	N4BP1	0.46	6.13	0.37	3.71e-9	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs459571	0.959	rs408307	chr9:136892523	A/G	cg13789015	chr9:136890014	NCRNA00094	-0.56	-7.58	-0.44	7.9e-13	Platelet distribution width;
SARC	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg25072359	chr17:41440525	NA	-0.49	-5.83	-0.36	1.87e-8	Menopause (age at onset);
SARC	cis	rs2073300	0.609	rs74273791	chr20:23418067	A/T	cg12062639	chr20:23401060	NAPB	0.98	6.65	0.4	2.03e-10	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs736801	0.740	rs12515180	chr5:131785684	C/T	cg07395648	chr5:131743802	NA	-0.42	-4.74	-0.3	3.64e-6	Breast cancer;Mosquito bite size;
SARC	cis	rs3857536	0.813	rs9354403	chr6:66943426	A/G	cg07460842	chr6:66804631	NA	-0.51	-5.83	-0.36	1.86e-8	Blood trace element (Cu levels);
SARC	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.58	-7.07	-0.42	1.82e-11	Prudent dietary pattern;
SARC	cis	rs11168187	0.891	rs10875683	chr12:48128283	C/G	cg12761788	chr12:48120090	P11	0.39	5.04	0.31	9.16e-7	Vertical cup-disc ratio;
SARC	cis	rs2075371	1.000	rs432487	chr7:133990114	T/G	cg11752832	chr7:134001865	SLC35B4	0.56	7.26	0.43	5.74e-12	Mean platelet volume;
SARC	cis	rs911555	0.723	rs56227024	chr14:103861706	A/G	cg12935359	chr14:103987150	CKB	0.4	5.45	0.34	1.31e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7208859	0.623	rs3752021	chr17:29111043	G/C	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs6882046	0.513	rs254780	chr5:88019747	G/C	cg22951263	chr5:87985283	NA	-0.36	-4.78	-0.3	3.16e-6	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
SARC	cis	rs477692	0.637	rs10829598	chr10:131319774	C/G	cg14263093	chr10:131365266	MGMT	0.4	5.68	0.35	3.99e-8	Response to temozolomide;
SARC	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.86	10.22	0.56	1.74e-20	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs7937682	1.000	rs12363179	chr11:111568091	G/A	cg22437258	chr11:111473054	SIK2	-0.67	-8.71	-0.5	5.73e-16	Primary sclerosing cholangitis;
SARC	cis	rs9457247	1.000	rs408080	chr6:167392522	T/C	cg23791538	chr6:167370224	RNASET2	-0.61	-8.47	-0.49	2.72e-15	Crohn's disease;
SARC	cis	rs9399135	0.507	rs2072825	chr6:135253451	A/G	cg22676075	chr6:135203613	NA	-0.43	-5.58	-0.34	6.52e-8	Red blood cell count;
SARC	cis	rs1865721	0.804	rs72977818	chr18:73146852	T/C	cg26385618	chr18:73139727	C18orf62	-0.37	-5.14	-0.32	5.79e-7	Intelligence;
SARC	cis	rs1008375	1.000	rs7654345	chr4:17691796	A/G	cg27347728	chr4:17578864	LAP3	0.46	5.74	0.35	2.94e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6831352	0.734	rs3100630	chr4:100031715	T/A	cg12011299	chr4:100065546	ADH4	0.28	4.8	0.3	2.86e-6	Alcohol dependence;
SARC	trans	rs11098499	0.731	rs9995026	chr4:120490499	T/A	cg25214090	chr10:38739885	LOC399744	0.57	7.25	0.43	6.27e-12	Corneal astigmatism;
SARC	cis	rs17270561	0.609	rs9356986	chr6:25739119	T/C	cg16482183	chr6:26056742	HIST1H1C	0.43	5.22	0.32	3.92e-7	Iron status biomarkers;
SARC	cis	rs10791097	0.720	rs6590515	chr11:130733365	A/G	cg12179176	chr11:130786555	SNX19	-0.71	-10.58	-0.57	1.28e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs12451471	0.637	rs12950757	chr17:78096800	T/G	cg06718696	chr17:78121285	EIF4A3	0.93	10.6	0.57	1.09e-21	Plateletcrit;Mean corpuscular hemoglobin concentration;
SARC	cis	rs881375	0.967	rs1860823	chr9:123659304	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.42	4.99	0.31	1.16e-6	Rheumatoid arthritis;
SARC	cis	rs780094	0.606	rs6729709	chr2:27583156	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.41	-6.15	-0.37	3.31e-9	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs8114671	0.836	rs2038504	chr20:33648187	T/C	cg24642439	chr20:33292090	TP53INP2	-0.51	-5.96	-0.36	9.41e-9	Height;
SARC	cis	rs7412746	0.658	rs2864869	chr1:150734655	G/A	cg15448220	chr1:150897856	SETDB1	0.47	6.07	0.37	5.12e-9	Melanoma;
SARC	cis	rs240764	0.604	rs1336242	chr6:101199634	C/T	cg09795085	chr6:101329169	ASCC3	0.47	5.98	0.36	8.3e-9	Neuroticism;
SARC	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg15595755	chr5:1867978	NA	0.51	7.08	0.42	1.7e-11	Cardiovascular disease risk factors;
SARC	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg25072359	chr17:41440525	NA	0.49	5.8	0.36	2.15e-8	Menopause (age at onset);
SARC	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg09263875	chr16:632152	PIGQ	0.53	8.14	0.47	2.44e-14	Height;
SARC	cis	rs2235642	0.750	rs763152	chr16:1658056	T/C	cg03715980	chr16:1756201	MAPK8IP3	0.41	5.04	0.31	9.43e-7	Coronary artery disease;
SARC	cis	rs7551222	0.752	rs885012	chr1:204544001	C/A	cg20240347	chr1:204465584	NA	-0.32	-5.68	-0.35	3.95e-8	Schizophrenia;
SARC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg06873352	chr17:61820015	STRADA	0.53	6.9	0.41	4.75e-11	Prudent dietary pattern;
SARC	cis	rs4073582	0.595	rs2508657	chr11:66043898	G/A	cg14036092	chr11:66035641	RAB1B	0.62	8.92	0.5	1.41e-16	Gout;
SARC	cis	rs3857067	0.806	rs4560373	chr4:95113229	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.05	-0.31	8.98e-7	QT interval;
SARC	cis	rs12348691	0.503	rs7848950	chr9:100612774	T/C	cg13688889	chr9:100608707	NA	-0.47	-5.0	-0.31	1.15e-6	Alopecia areata;
SARC	cis	rs34779708	0.931	rs66887762	chr10:35330577	C/T	cg03585969	chr10:35415529	CREM	0.41	5.11	0.32	6.57e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs7760949	0.963	rs7761500	chr6:13917140	G/A	cg27413430	chr6:13925136	RNF182	0.42	5.11	0.32	6.75e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs986417	1.000	rs4901995	chr14:61090629	C/G	cg27398547	chr14:60952738	C14orf39	0.85	7.52	0.44	1.16e-12	Gut microbiota (bacterial taxa);
SARC	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg01017244	chr2:74357527	NA	0.54	6.7	0.4	1.55e-10	Gestational age at birth (maternal effect);
SARC	cis	rs9322193	0.607	rs12204653	chr6:150213021	C/G	cg11878867	chr6:150167359	LRP11	-0.4	-4.78	-0.3	3.1e-6	Lung cancer;
SARC	cis	rs11097912	0.632	rs75055072	chr4:107201362	T/A	cg09646026	chr4:107269030	AIMP1	-0.45	-4.86	-0.3	2.13e-6	Airflow obstruction;
SARC	cis	rs10256972	0.630	rs10282584	chr7:1081442	C/T	cg07308232	chr7:1071921	C7orf50	-0.45	-5.65	-0.35	4.75e-8	Longevity;Endometriosis;
SARC	cis	rs763121	0.853	rs2413545	chr22:39092524	C/T	cg21395723	chr22:39101663	GTPBP1	0.52	5.69	0.35	3.74e-8	Menopause (age at onset);
SARC	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.75	-7.92	-0.46	9.77e-14	Platelet count;
SARC	cis	rs929354	0.772	rs4716460	chr7:156970054	T/C	cg05182265	chr7:156933206	UBE3C	-0.33	-5.08	-0.32	7.67e-7	Body mass index;
SARC	cis	rs288326	0.561	rs41270217	chr2:183850877	C/T	cg09997497	chr2:183902928	NCKAP1	0.74	5.1	0.32	6.97e-7	Blood protein levels;
SARC	cis	rs10489202	0.608	rs10918826	chr1:168075316	C/T	cg24449463	chr1:168025552	DCAF6	-0.6	-7.82	-0.46	1.81e-13	Schizophrenia;
SARC	cis	rs7552404	0.924	rs12136754	chr1:76230232	C/A	cg10523679	chr1:76189770	ACADM	0.5	6.72	0.4	1.38e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs8031584	0.958	rs61997076	chr15:31216225	C/T	cg19680485	chr15:31195859	MTMR15	-0.53	-5.54	-0.34	8.02e-8	Huntington's disease progression;
SARC	trans	rs1973993	0.708	rs6593605	chr1:96956775	A/G	cg10631902	chr5:14652156	NA	-0.42	-6.88	-0.41	5.33e-11	Weight;
SARC	cis	rs1355223	0.506	rs11032899	chr11:34870234	G/A	cg11622362	chr11:34938112	PDHX;APIP	0.46	6.03	0.37	6.55e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg05313129	chr8:58192883	C8orf71	0.63	6.27	0.38	1.74e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg23429981	chr6:97345948	NDUFAF4	0.48	6.34	0.38	1.16e-9	Chemerin levels;
SARC	cis	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg14541582	chr5:601475	NA	-0.41	-5.15	-0.32	5.43e-7	Obesity-related traits;
SARC	cis	rs7247513	1.000	rs7247513	chr19:12691185	C/T	cg01871581	chr19:12707946	ZNF490	-0.78	-11.03	-0.59	4.8e-23	Bipolar disorder;
SARC	cis	rs950776	0.518	rs3813572	chr15:78832588	T/C	cg06917634	chr15:78832804	PSMA4	0.91	14.24	0.68	1.6e-33	Sudden cardiac arrest;
SARC	cis	rs921968	0.612	rs4674323	chr2:219517088	T/C	cg02176678	chr2:219576539	TTLL4	0.36	5.39	0.33	1.76e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs453301	0.605	rs7843024	chr8:8799976	G/A	cg08975724	chr8:8085496	FLJ10661	-0.42	-5.08	-0.32	7.85e-7	Joint mobility (Beighton score);
SARC	cis	rs9470366	0.883	rs7756236	chr6:36627053	A/G	cg08179530	chr6:36648295	CDKN1A	0.56	5.91	0.36	1.18e-8	QRS duration;
SARC	cis	rs2011503	1.000	rs45556231	chr19:19654189	G/A	cg15839431	chr19:19639596	YJEFN3	-0.48	-4.77	-0.3	3.32e-6	Bipolar disorder;
SARC	cis	rs6582630	0.598	rs10880614	chr12:38509766	G/A	cg13010199	chr12:38710504	ALG10B	-0.51	-6.34	-0.38	1.18e-9	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg24642844	chr7:1081250	C7orf50	-0.6	-6.11	-0.37	4.06e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs34779708	0.931	rs10437420	chr10:35335044	A/C	cg03585969	chr10:35415529	CREM	-0.4	-5.09	-0.32	7.25e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs10911232	0.507	rs4442336	chr1:182982538	T/G	cg13390022	chr1:182993471	LAMC1	0.34	5.17	0.32	5.11e-7	Hypertriglyceridemia;
SARC	cis	rs1348850	0.914	rs2060929	chr2:178280031	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.7	8.97	0.51	9.91e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs11249608	0.548	rs11958355	chr5:178451640	T/C	cg21905437	chr5:178450457	ZNF879	0.58	7.92	0.46	9.53e-14	Pubertal anthropometrics;
SARC	cis	rs933688	1.000	rs6867091	chr5:90734333	C/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	13.46	0.66	6.09e-31	Smoking behavior;
SARC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg07157834	chr1:205819609	PM20D1	0.84	15.39	0.71	2.33e-37	Menarche (age at onset);
SARC	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg01448562	chr3:133502909	NA	-0.45	-6.65	-0.4	2.08e-10	Iron status biomarkers;
SARC	cis	rs2213920	1.000	rs9409169	chr9:118273407	A/G	cg13918206	chr9:118159781	DEC1	-0.62	-5.08	-0.32	7.66e-7	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs2279817	0.954	rs12143113	chr1:18018857	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.47	4.9	0.31	1.77e-6	Neuroticism;
SARC	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg11843238	chr5:131593191	PDLIM4	0.39	5.48	0.34	1.11e-7	Breast cancer;
SARC	cis	rs2180341	1.000	rs6569478	chr6:127598619	G/A	cg17762328	chr6:126965162	NA	-0.46	-5.22	-0.32	3.95e-7	Breast cancer;
SARC	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg19077165	chr18:44547161	KATNAL2	-0.53	-7.06	-0.42	1.89e-11	Personality dimensions;
SARC	cis	rs6772849	0.796	rs9841521	chr3:128392274	A/G	cg01163369	chr3:128370232	RPN1	-0.34	-4.82	-0.3	2.62e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs4900538	0.928	rs1190551	chr14:102911508	A/G	cg18135206	chr14:102964638	TECPR2	-0.69	-9.36	-0.52	6.87e-18	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs3091242	0.900	rs35345536	chr1:25766488	A/G	cg27572855	chr1:25598939	RHD	0.53	8.87	0.5	1.98e-16	Erythrocyte sedimentation rate;
SARC	cis	rs10927875	1.000	rs12138117	chr1:16305279	T/C	cg07117364	chr1:16154769	NA	-0.41	-4.82	-0.3	2.63e-6	Dilated cardiomyopathy;
SARC	trans	rs1814175	0.616	rs10839388	chr11:49842603	C/T	cg03929089	chr4:120376271	NA	-0.83	-12.17	-0.62	1.09e-26	Height;
SARC	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg00149659	chr3:10157352	C3orf10	0.69	6.9	0.41	4.76e-11	Alzheimer's disease;
SARC	cis	rs7710178	0.816	rs32086	chr5:156126969	G/C	cg26439139	chr5:155924786	SGCD	-0.45	-4.77	-0.3	3.2e-6	Airway responsiveness in chronic obstructive pulmonary disease;
SARC	cis	rs79149102	0.579	rs76518150	chr15:75292721	C/G	cg09165964	chr15:75287851	SCAMP5	-1.03	-9.15	-0.51	2.86e-17	Lung cancer;
SARC	cis	rs10046574	0.519	rs7781819	chr7:135205700	A/T	cg27474649	chr7:135195673	CNOT4	0.81	7.79	0.45	2.25e-13	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs12142240	0.698	rs41294476	chr1:46818374	C/A	cg00530320	chr1:46809349	NSUN4	0.57	6.92	0.41	4.4e-11	Menopause (age at onset);
SARC	cis	rs4319547	0.737	rs10773176	chr12:122944713	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.52	-6.11	-0.37	4.14e-9	Body mass index;
SARC	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg13880726	chr7:1868755	MAD1L1	0.52	6.19	0.38	2.76e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs2718058	0.565	rs2598078	chr7:37864078	G/C	cg15028436	chr7:37888078	TXNDC3	0.39	4.93	0.31	1.54e-6	Alzheimer's disease (late onset);
SARC	cis	rs7000551	0.751	rs1116085	chr8:22394920	A/G	cg12081754	chr8:22256438	SLC39A14	0.56	7.69	0.45	4.12e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs75804782	0.641	rs57080728	chr2:239350487	T/C	cg21699342	chr2:239360505	ASB1	-0.58	-4.81	-0.3	2.68e-6	Morning vs. evening chronotype;Chronotype;
SARC	cis	rs7412746	0.611	rs2280627	chr1:150935872	A/G	cg10589385	chr1:150898437	SETDB1	0.38	5.02	0.31	1.03e-6	Melanoma;
SARC	cis	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg06636001	chr8:8085503	FLJ10661	0.66	8.86	0.5	2.08e-16	Mood instability;
SARC	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg11764359	chr7:65958608	NA	0.73	8.72	0.5	5.25e-16	Aortic root size;
SARC	cis	rs11098499	0.820	rs28578366	chr4:120536905	A/G	cg09307838	chr4:120376055	NA	-0.81	-11.1	-0.59	2.87e-23	Corneal astigmatism;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg22902478	chr11:67085251	LOC100130987	0.78	6.41	0.39	8.16e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9381040	0.655	rs2294696	chr6:41036988	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	0.43	4.86	0.3	2.14e-6	Alzheimer's disease (late onset);
SARC	trans	rs3808502	0.647	rs7821302	chr8:11236572	T/A	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.0	-0.42	2.66e-11	Neuroticism;
SARC	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg07636037	chr3:49044803	WDR6	0.99	17.31	0.75	1.02e-43	Parkinson's disease;
SARC	cis	rs13202913	0.652	rs9383578	chr6:151838192	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.56	5.4	0.33	1.63e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg22903657	chr4:1355424	KIAA1530	-0.35	-4.73	-0.3	3.96e-6	Obesity-related traits;
SARC	cis	rs9300255	0.602	rs1051431	chr12:123645803	G/A	cg00376283	chr12:123451042	ABCB9	0.58	6.9	0.41	4.89e-11	Neutrophil percentage of white cells;
SARC	trans	rs3804024	1.000	rs13046040	chr21:41989863	C/G	cg03228353	chr1:161520094	FCGR3A	0.56	6.92	0.41	4.38e-11	Obesity-related traits;
SARC	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.43	-5.31	-0.33	2.6e-7	Lymphocyte counts;
SARC	cis	rs7712401	0.601	rs436546	chr5:122322790	G/A	cg19412675	chr5:122181750	SNX24	-0.43	-5.43	-0.34	1.41e-7	Mean platelet volume;
SARC	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg16325326	chr1:53192061	ZYG11B	-0.79	-12.63	-0.64	3.38e-28	Monocyte count;
SARC	trans	rs7815944	1.000	rs6651251	chr8:129422806	T/C	cg25487405	chr22:46473039	NA	0.64	6.35	0.38	1.09e-9	Atopic dermatitis;
SARC	cis	rs7312774	0.748	rs1861745	chr12:107301642	C/T	cg16260113	chr12:107380972	MTERFD3	0.85	7.02	0.42	2.35e-11	Severe influenza A (H1N1) infection;
SARC	cis	rs644799	0.965	rs11021313	chr11:95506907	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.88	13.76	0.67	6.16e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs6831352	0.918	rs17218073	chr4:100055739	G/A	cg12011299	chr4:100065546	ADH4	-0.34	-5.74	-0.35	2.95e-8	Alcohol dependence;
SARC	cis	rs1728785	0.818	rs1728772	chr16:68584526	C/T	cg02972257	chr16:68554789	NA	-0.43	-5.01	-0.31	1.08e-6	Ulcerative colitis;
SARC	cis	rs9818758	0.607	rs9855123	chr3:49229457	C/T	cg00383909	chr3:49044727	WDR6	0.7	6.03	0.37	6.31e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs899997	1.000	rs9888691	chr15:79010046	T/C	cg04896959	chr15:78267971	NA	0.52	6.38	0.39	9.42e-10	Coronary artery disease or large artery stroke;
SARC	cis	rs123509	0.687	rs6865	chr3:42826041	A/C	cg12982090	chr3:42733453	KBTBD5	-0.53	-6.14	-0.37	3.49e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2180341	0.960	rs7756884	chr6:127684018	A/G	cg27446573	chr6:127587934	RNF146	1.06	14.76	0.7	2.94e-35	Breast cancer;
SARC	cis	rs921968	0.541	rs41461846	chr2:219313354	A/G	cg02176678	chr2:219576539	TTLL4	-0.53	-8.11	-0.47	2.87e-14	Mean corpuscular hemoglobin concentration;
SARC	cis	rs412050	1.000	rs56138298	chr22:22316540	G/A	cg17089214	chr22:22089827	YPEL1	0.63	5.98	0.36	8.18e-9	Attention deficit hyperactivity disorder;
SARC	cis	rs765787	0.530	rs11639403	chr15:45538350	A/G	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.81e-6	Uric acid levels;
SARC	cis	rs735539	0.521	rs2818991	chr13:21397196	A/G	cg16922012	chr13:21400325	XPO4	-0.4	-5.46	-0.34	1.2e-7	Dental caries;
SARC	cis	rs12188164	0.525	rs2561665	chr5:460135	A/G	cg16584290	chr5:462447	EXOC3	0.44	6.71	0.4	1.47e-10	Cystic fibrosis severity;
SARC	trans	rs2243123	0.602	rs2133310	chr3:159716352	A/G	cg04342538	chr1:43232911	LEPRE1;C1orf50	0.51	6.4	0.39	8.26e-10	Multiple sclerosis;
SARC	cis	rs7043114	0.525	rs9299404	chr9:95170338	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.46	5.66	0.35	4.46e-8	Height;
SARC	cis	rs7647973	0.560	rs62262671	chr3:49649873	A/G	cg13072238	chr3:49761600	GMPPB	0.72	5.81	0.36	2.02e-8	Menarche (age at onset);
SARC	cis	rs35110281	0.748	rs162403	chr21:44963365	C/G	cg21573476	chr21:45109991	RRP1B	-0.51	-7.51	-0.44	1.29e-12	Mean corpuscular volume;
SARC	cis	rs17376456	0.809	rs12152763	chr5:93405509	T/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.7	0.35	3.55e-8	Diabetic retinopathy;
SARC	trans	rs1814175	0.527	rs10769595	chr11:49638212	A/G	cg15704280	chr7:45808275	SEPT13	-0.7	-8.22	-0.47	1.4e-14	Height;
SARC	trans	rs208520	0.690	rs207102	chr6:66795671	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.06	-14.41	-0.69	4.36e-34	Exhaled nitric oxide output;
SARC	cis	rs12709013	0.636	rs1626006	chr16:58787595	C/G	cg04273148	chr16:57808038	KIFC3	0.32	4.72	0.3	4.08e-6	Blood metabolite ratios;
SARC	cis	rs7762018	1.000	rs6923339	chr6:170128033	T/A	cg17545662	chr6:170176663	C6orf70	0.42	4.81	0.3	2.74e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs12681288	0.676	rs35389636	chr8:1010613	G/T	cg15309053	chr8:964076	NA	0.43	6.74	0.4	1.21e-10	Schizophrenia;
SARC	cis	rs7044106	0.762	rs10984972	chr9:123409864	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	5.46	0.34	1.2e-7	Hip circumference adjusted for BMI;
SARC	cis	rs17376456	0.877	rs12153501	chr5:93360866	T/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.76	0.35	2.64e-8	Diabetic retinopathy;
SARC	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg21248554	chr2:27665150	KRTCAP3	-0.32	-4.78	-0.3	3.05e-6	Total body bone mineral density;
SARC	cis	rs6456156	0.586	rs6909180	chr6:167460537	A/G	cg07741184	chr6:167504864	NA	0.35	6.83	0.41	7.46e-11	Primary biliary cholangitis;
SARC	cis	rs926392	0.932	rs6124105	chr20:37686081	G/A	cg16355469	chr20:37678765	NA	0.59	7.54	0.44	1.06e-12	Dialysis-related mortality;
SARC	cis	rs7582180	0.764	rs4635546	chr2:100921125	G/A	cg14675211	chr2:100938903	LONRF2	0.51	7.53	0.44	1.1e-12	Intelligence (multi-trait analysis);
SARC	cis	rs9309473	1.000	rs6736866	chr2:73661986	C/G	cg20560298	chr2:73613845	ALMS1	-0.5	-5.8	-0.36	2.1e-8	Metabolite levels;
SARC	cis	rs9513627	0.833	rs112671387	chr13:100123073	A/G	cg25919922	chr13:100150906	NA	-0.69	-5.22	-0.32	3.95e-7	Obesity-related traits;
SARC	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg25036284	chr2:26402008	FAM59B	0.49	5.91	0.36	1.18e-8	Gut microbiome composition (summer);
SARC	cis	rs796364	0.901	rs4673762	chr2:201065171	C/G	cg23649088	chr2:200775458	C2orf69	0.65	7.02	0.42	2.46e-11	Schizophrenia;
SARC	trans	rs208520	0.690	rs12209753	chr6:66703951	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	14.02	0.68	8.85e-33	Exhaled nitric oxide output;
SARC	cis	rs4332037	0.624	rs11766944	chr7:1888051	G/A	cg12591125	chr7:1885375	MAD1L1	0.5	5.26	0.33	3.25e-7	Bipolar disorder;
SARC	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg13866156	chr1:1669148	SLC35E2	-0.63	-9.61	-0.53	1.21e-18	Body mass index;
SARC	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.01	11.2	0.59	1.42e-23	Platelet count;
SARC	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg06221963	chr1:154839813	KCNN3	-0.48	-7.44	-0.44	1.96e-12	Prostate cancer;
SARC	cis	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg12257692	chr3:49977190	RBM6	-0.28	-4.91	-0.31	1.7e-6	Body mass index;
SARC	cis	rs9650657	0.504	rs10109167	chr8:11033525	C/T	cg12395012	chr8:11607386	GATA4	0.3	5.01	0.31	1.09e-6	Neuroticism;
SARC	cis	rs611744	0.967	rs631031	chr8:109190032	G/A	cg21045802	chr8:109455806	TTC35	0.44	5.3	0.33	2.64e-7	Dupuytren's disease;
SARC	cis	rs10078	0.515	rs890984	chr5:479540	A/G	cg26072250	chr5:443457	EXOC3;C5orf55	0.67	5.62	0.35	5.51e-8	Fat distribution (HIV);
SARC	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg04277193	chr17:41438351	NA	0.44	4.86	0.3	2.18e-6	Menopause (age at onset);
SARC	cis	rs295140	0.546	rs295134	chr2:201110223	A/G	cg23649088	chr2:200775458	C2orf69	-0.51	-7.15	-0.42	1.13e-11	QT interval;
SARC	cis	rs34172651	0.571	rs9922156	chr16:24704329	C/A	cg04756594	chr16:24857601	SLC5A11	-0.37	-5.0	-0.31	1.14e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7223966	1.000	rs8070650	chr17:61744040	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.51	-5.36	-0.33	2e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg19671926	chr4:122722719	EXOSC9	-0.6	-6.83	-0.41	7.49e-11	Type 2 diabetes;
SARC	cis	rs950776	0.518	rs12900783	chr15:78815523	G/A	cg17108064	chr15:78857060	CHRNA5	0.29	4.88	0.3	1.95e-6	Sudden cardiac arrest;
SARC	cis	rs13314892	0.764	rs62251031	chr3:69865083	T/C	cg17445875	chr3:69859618	MITF	-0.49	-5.12	-0.32	6.44e-7	QRS complex (12-leadsum);
SARC	cis	rs2130392	0.926	rs4610379	chr4:185624388	A/G	cg04058563	chr4:185651563	MLF1IP	0.34	4.87	0.3	2.1e-6	Kawasaki disease;
SARC	trans	rs1814175	0.645	rs1851849	chr11:50012164	G/A	cg15704280	chr7:45808275	SEPT13	-0.91	-14.63	-0.69	8.38e-35	Height;
SARC	cis	rs9389248	0.708	rs7750574	chr6:135350932	G/C	cg24558204	chr6:135376177	HBS1L	0.62	8.02	0.47	5.03e-14	High light scatter reticulocyte percentage of red cells;
SARC	cis	rs1957429	0.634	rs59000318	chr14:65419473	C/A	cg23373153	chr14:65346875	NA	-0.82	-7.9	-0.46	1.12e-13	Pediatric areal bone mineral density (radius);
SARC	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg03575189	chr17:44344142	NA	-0.53	-5.2	-0.32	4.37e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7587476	0.784	rs62202001	chr2:215690359	C/G	cg04004882	chr2:215674386	BARD1	0.56	6.4	0.39	8.5e-10	Neuroblastoma;
SARC	cis	rs79146658	0.688	rs12693171	chr2:179748447	A/G	cg17765952	chr2:179737173	CCDC141	-0.55	-4.95	-0.31	1.46e-6	Diastolic blood pressure;
SARC	trans	rs61931739	0.929	rs1844524	chr12:34094709	A/T	cg13010199	chr12:38710504	ALG10B	-0.51	-6.89	-0.41	5.28e-11	Morning vs. evening chronotype;
SARC	cis	rs6908034	0.607	rs62404179	chr6:19806272	T/C	cg02682789	chr6:19804855	NA	0.72	5.45	0.34	1.31e-7	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs2043112	0.867	rs1239274	chr5:39010209	C/G	cg04869206	chr5:39074266	RICTOR	0.46	5.6	0.34	6.01e-8	Obesity-related traits;
SARC	cis	rs644799	0.965	rs687529	chr11:95545587	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	14.15	0.68	3.08e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2735413	0.874	rs12917942	chr16:78064220	T/G	cg04733911	chr16:78082701	NA	-0.28	-4.98	-0.31	1.23e-6	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs7818345	0.874	rs56298301	chr8:19305937	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.37	4.79	0.3	2.97e-6	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.56	5.23	0.32	3.8e-7	Lung function (FEV1/FVC);
SARC	cis	rs13314892	0.728	rs74956589	chr3:69886006	A/G	cg17445875	chr3:69859618	MITF	-0.5	-5.24	-0.32	3.6e-7	QRS complex (12-leadsum);
SARC	cis	rs28374715	0.662	rs72737793	chr15:41516823	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.99	-14.16	-0.68	3.03e-33	Ulcerative colitis;
SARC	cis	rs7216064	1.000	rs12451721	chr17:65939075	G/A	cg12091567	chr17:66097778	LOC651250	-0.71	-7.25	-0.43	6.16e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg06221963	chr1:154839813	KCNN3	-0.45	-6.66	-0.4	2e-10	Prostate cancer;
SARC	cis	rs9916302	0.904	rs3964723	chr17:37403979	C/T	cg15445000	chr17:37608096	MED1	0.4	4.87	0.3	2.08e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs2070488	0.745	rs9838792	chr3:38546726	G/A	cg27533700	chr3:38537683	EXOG	0.37	4.79	0.3	2.9e-6	Electrocardiographic conduction measures;
SARC	cis	rs2288073	0.965	rs6545335	chr2:24422011	G/A	cg26838691	chr2:24397539	C2orf84	-0.54	-6.68	-0.4	1.72e-10	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg04944784	chr2:26401820	FAM59B	-0.47	-5.76	-0.35	2.66e-8	Gut microbiome composition (summer);
SARC	cis	rs7647973	1.000	rs3905330	chr3:49550774	A/G	cg07636037	chr3:49044803	WDR6	0.79	8.96	0.51	1.08e-16	Menarche (age at onset);
SARC	cis	rs6840360	0.571	rs1822346	chr4:152525303	G/C	cg22705602	chr4:152727874	NA	-0.41	-6.45	-0.39	6.45e-10	Intelligence (multi-trait analysis);
SARC	cis	rs6831352	0.918	rs2213035	chr4:100064233	G/A	cg12011299	chr4:100065546	ADH4	-0.31	-4.98	-0.31	1.25e-6	Alcohol dependence;
SARC	cis	rs472402	0.623	rs8192131	chr5:6636465	C/T	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.4	-4.9	-0.31	1.78e-6	Response to amphetamines;
SARC	cis	rs4253772	0.530	rs9627387	chr22:46684678	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.71	7.3	0.43	4.6e-12	LDL cholesterol;Cholesterol, total;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg15641998	chr4:88312323	HSD17B11	-0.46	-6.28	-0.38	1.64e-9	Thyroid stimulating hormone;
SARC	cis	rs67478160	0.634	rs941475	chr14:104240618	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.34	-4.73	-0.3	3.86e-6	Schizophrenia;
SARC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	19.04	0.78	2.21e-49	Prudent dietary pattern;
SARC	cis	rs611744	0.967	rs536860	chr8:109230722	A/C	cg21045802	chr8:109455806	TTC35	0.46	5.43	0.34	1.38e-7	Dupuytren's disease;
SARC	cis	rs2370759	1.000	rs76467481	chr10:32610740	T/G	cg05361325	chr10:32636312	EPC1	-0.76	-6.81	-0.41	8.25e-11	Sexual dysfunction (female);
SARC	cis	rs17253792	0.822	rs77676035	chr14:56096229	G/A	cg01858014	chr14:56050164	KTN1	-0.68	-5.37	-0.33	1.86e-7	Putamen volume;
SARC	cis	rs7927592	0.913	rs4084149	chr11:68288567	A/G	cg01657329	chr11:68192670	LRP5	-0.4	-4.94	-0.31	1.48e-6	Total body bone mineral density;
SARC	cis	rs981844	0.775	rs17299246	chr4:154743504	C/T	cg14289246	chr4:154710475	SFRP2	0.54	5.99	0.37	8.1e-9	Response to statins (LDL cholesterol change);
SARC	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg19223190	chr17:80058835	NA	0.44	6.04	0.37	6.02e-9	Life satisfaction;
SARC	cis	rs3812831	0.661	rs2987458	chr13:114919835	A/G	cg06611532	chr13:114900021	NA	0.35	5.8	0.36	2.14e-8	Schizophrenia;
SARC	trans	rs61931739	0.500	rs2389269	chr12:34034179	C/T	cg13010199	chr12:38710504	ALG10B	0.76	10.41	0.56	4.45e-21	Morning vs. evening chronotype;
SARC	cis	rs838147	0.508	rs507766	chr19:49208543	T/C	cg07051648	chr19:49177693	NTN5;SEC1	-0.41	-5.17	-0.32	4.93e-7	Dietary macronutrient intake;
SARC	cis	rs11098499	0.955	rs11931312	chr4:120159023	T/C	cg09307838	chr4:120376055	NA	0.84	11.55	0.6	1.04e-24	Corneal astigmatism;
SARC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg16405210	chr4:1374714	KIAA1530	-0.88	-11.63	-0.61	6.08e-25	Longevity;
SARC	cis	rs787274	1.000	rs7038684	chr9:115601431	A/G	cg13803584	chr9:115635662	SNX30	-0.83	-5.06	-0.31	8.34e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs923375	0.533	rs923376	chr17:3393086	A/G	cg02458198	chr17:3375211	SPATA22	0.42	5.72	0.35	3.23e-8	Myopia (pathological);
SARC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg26338869	chr17:61819248	STRADA	0.78	10.45	0.57	3.21e-21	Prudent dietary pattern;
SARC	cis	rs4727027	0.625	rs75129390	chr7:148846775	T/A	cg23583168	chr7:148888333	NA	-0.73	-10.76	-0.58	3.57e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs6964587	1.000	rs10270598	chr7:91700827	T/C	cg17063962	chr7:91808500	NA	0.96	16.21	0.73	4.33e-40	Breast cancer;
SARC	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg26769984	chr7:1090371	C7orf50	0.5	5.09	0.32	7.25e-7	Bronchopulmonary dysplasia;
SARC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg22720560	chr5:65222058	ERBB2IP	-0.59	-6.6	-0.4	2.79e-10	Hepatitis;
SARC	cis	rs7511006	1.000	rs7364173	chr22:50681029	C/T	cg08875078	chr22:50639485	SELO	-0.42	-4.81	-0.3	2.68e-6	Obesity-related traits;
SARC	cis	rs17125944	0.686	rs73304351	chr14:53375140	G/A	cg00686598	chr14:53173677	PSMC6	0.85	5.88	0.36	1.4e-8	Alzheimer's disease (late onset);
SARC	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg11987759	chr7:65425863	GUSB	0.58	7.93	0.46	9.38e-14	Calcium levels;
SARC	trans	rs62103177	0.810	rs62103189	chr18:77627815	G/A	cg05926928	chr17:57297772	GDPD1	1.09	9.19	0.52	2.24e-17	Opioid sensitivity;
SARC	cis	rs8014204	0.967	rs4903266	chr14:75344941	C/G	cg17347104	chr14:75034677	LTBP2	0.41	4.99	0.31	1.19e-6	Caffeine consumption;
SARC	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg01341218	chr17:43662625	NA	0.99	11.46	0.6	2.01e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.63	0.53	1.05e-18	Prudent dietary pattern;
SARC	cis	rs4242434	0.672	rs10113779	chr8:22485934	G/C	cg03733263	chr8:22462867	KIAA1967	0.87	13.6	0.67	2.08e-31	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs6665290	0.669	rs12406714	chr1:227177061	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.02	-20.72	-0.81	8.85e-55	Myeloid white cell count;
SARC	cis	rs4481887	0.962	rs10788768	chr1:248456027	G/A	cg13385794	chr1:248469461	NA	0.34	5.15	0.32	5.62e-7	Common traits (Other);
SARC	cis	rs7945705	0.935	rs2653567	chr11:8889630	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.46	-6.63	-0.4	2.29e-10	Hemoglobin concentration;
SARC	cis	rs9341808	0.600	rs668329	chr6:80968578	G/A	cg08355045	chr6:80787529	NA	-0.35	-5.69	-0.35	3.79e-8	Sitting height ratio;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg02898122	chr1:95699846	RWDD3	0.49	6.47	0.39	5.7e-10	Chemerin levels;
SARC	cis	rs2153535	0.541	rs6923558	chr6:8461467	T/G	cg21535247	chr6:8435926	SLC35B3	0.54	6.75	0.4	1.14e-10	Motion sickness;
SARC	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg11366901	chr6:160182831	ACAT2	1.05	10.89	0.58	1.33e-22	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs2197308	0.667	rs61920838	chr12:37856814	T/C	cg13010199	chr12:38710504	ALG10B	-0.73	-10.15	-0.55	2.78e-20	Morning vs. evening chronotype;
SARC	cis	rs12478296	0.591	rs12719765	chr2:242997202	C/G	cg06360820	chr2:242988706	NA	-0.48	-4.96	-0.31	1.39e-6	Obesity-related traits;
SARC	cis	rs1949733	1.000	rs6447875	chr4:8503206	T/C	cg11789530	chr4:8429930	ACOX3	0.83	11.23	0.59	1.15e-23	Response to antineoplastic agents;
SARC	cis	rs1580019	0.587	rs7806941	chr7:32553319	G/T	cg06627557	chr7:32535165	LSM5;AVL9	0.98	17.81	0.76	2.27e-45	Cognitive ability;
SARC	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg08280861	chr8:58055591	NA	0.7	5.74	0.35	2.91e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs78545713	1.000	rs78545713	chr6:26248840	A/G	cg00631329	chr6:26305371	NA	-0.74	-6.42	-0.39	7.7e-10	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs921968	0.565	rs6745700	chr2:219639862	T/C	cg02176678	chr2:219576539	TTLL4	-0.33	-5.03	-0.31	9.92e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs7264396	0.563	rs2425084	chr20:34301871	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-7.37	-0.43	2.88e-12	Total cholesterol levels;
SARC	cis	rs2327429	0.858	rs10457618	chr6:134188626	C/T	cg25632230	chr6:134101081	NA	-0.47	-5.7	-0.35	3.59e-8	Coronary artery disease;
SARC	cis	rs1008375	0.646	rs4235387	chr4:17569327	T/G	cg27347728	chr4:17578864	LAP3	0.48	5.67	0.35	4.26e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs66573146	0.572	rs66819208	chr4:6946128	A/G	cg07817883	chr1:32538562	TMEM39B	1.08	8.42	0.48	3.91e-15	Granulocyte percentage of myeloid white cells;
SARC	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg24250549	chr1:154909240	PMVK	0.78	11.24	0.59	1.07e-23	Prostate cancer;
SARC	cis	rs3617	0.573	rs62253583	chr3:52928334	G/A	cg18404041	chr3:52824283	ITIH1	0.33	4.75	0.3	3.52e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg00933542	chr6:150070202	PCMT1	0.3	4.91	0.31	1.73e-6	Testicular germ cell tumor;
SARC	cis	rs9300255	0.568	rs1727300	chr12:123664205	C/T	cg00376283	chr12:123451042	ABCB9	0.55	6.53	0.39	4.09e-10	Neutrophil percentage of white cells;
SARC	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg18876405	chr7:65276391	NA	-0.45	-5.15	-0.32	5.56e-7	Aortic root size;
SARC	cis	rs7927592	0.913	rs6591340	chr11:68297636	A/G	cg01657329	chr11:68192670	LRP5	-0.4	-4.91	-0.31	1.7e-6	Total body bone mineral density;
SARC	cis	rs9394841	0.667	rs9394831	chr6:41753084	C/T	cg08135965	chr6:41755394	TOMM6	0.62	6.55	0.39	3.7e-10	Mean corpuscular hemoglobin;Red cell distribution width;
SARC	cis	rs4319547	0.656	rs28730465	chr12:122863864	A/C	cg23029597	chr12:123009494	RSRC2	0.43	5.29	0.33	2.85e-7	Body mass index;
SARC	cis	rs6570726	0.935	rs447818	chr6:145868996	C/T	cg05220968	chr6:146057943	EPM2A	-0.29	-4.9	-0.31	1.82e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7681440	0.583	rs2737019	chr4:90744903	G/T	cg06632027	chr4:90757378	SNCA	-0.43	-5.31	-0.33	2.5e-7	Dementia with Lewy bodies;
SARC	cis	rs2732480	0.577	rs2732479	chr12:48736260	A/C	cg21466736	chr12:48725269	NA	-0.33	-5.18	-0.32	4.83e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs5753037	0.585	rs36572	chr22:30200936	T/C	cg01021169	chr22:30184971	ASCC2	-0.53	-7.43	-0.44	2.09e-12	Type 1 diabetes;
SARC	cis	rs568617	1.000	rs687672	chr11:65649984	T/C	cg26695010	chr11:65641043	EFEMP2	0.49	5.74	0.35	3e-8	Crohn's disease;
SARC	cis	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg14541582	chr5:601475	NA	-0.41	-5.12	-0.32	6.26e-7	Obesity-related traits;
SARC	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg11644478	chr21:40555479	PSMG1	-0.55	-6.79	-0.41	8.97e-11	Menarche (age at onset);
SARC	cis	rs7772486	0.754	rs6910790	chr6:146255330	G/A	cg05347473	chr6:146136440	FBXO30	-0.48	-6.52	-0.39	4.23e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2624839	0.629	rs2526397	chr3:50187790	A/C	cg24110177	chr3:50126178	RBM5	0.45	5.56	0.34	7.32e-8	Intelligence (multi-trait analysis);
SARC	cis	rs3741151	0.892	rs7105681	chr11:73059341	G/A	cg17517138	chr11:73019481	ARHGEF17	0.8	6.69	0.4	1.63e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs1707322	0.686	rs61784833	chr1:46233772	T/C	cg03146154	chr1:46216737	IPP	0.51	6.13	0.37	3.77e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9611519	0.761	rs35445172	chr22:41660301	G/A	cg03806693	chr22:41940476	POLR3H	-0.67	-8.87	-0.5	1.97e-16	Neuroticism;
SARC	cis	rs9457247	0.967	rs377753	chr6:167389496	A/T	cg23791538	chr6:167370224	RNASET2	-0.62	-8.66	-0.49	8.17e-16	Crohn's disease;
SARC	cis	rs763121	0.853	rs1062687	chr22:39134715	T/C	cg06022373	chr22:39101656	GTPBP1	0.89	12.73	0.64	1.6e-28	Menopause (age at onset);
SARC	cis	rs6456156	0.586	rs2001114	chr6:167486578	A/G	cg07741184	chr6:167504864	NA	0.37	6.98	0.42	2.99e-11	Primary biliary cholangitis;
SARC	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg16479474	chr6:28041457	NA	0.37	5.44	0.34	1.37e-7	Depression;
SARC	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg12373951	chr3:133503437	NA	0.39	5.72	0.35	3.21e-8	Iron status biomarkers;
SARC	cis	rs6496667	0.683	rs2589973	chr15:90892293	C/T	cg22089800	chr15:90895588	ZNF774	0.62	7.13	0.42	1.23e-11	Rheumatoid arthritis;
SARC	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg27541892	chr1:1571801	CDK11B	-0.64	-8.36	-0.48	5.73e-15	Body mass index;
SARC	cis	rs7589342	0.929	rs2060036	chr2:106436101	G/A	cg16077055	chr2:106428750	NCK2	0.4	7.49	0.44	1.44e-12	Addiction;
SARC	cis	rs854765	0.583	rs4413022	chr17:17858280	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	9.85	0.54	2.34e-19	Total body bone mineral density;
SARC	cis	rs2204008	0.774	rs11495520	chr12:38060605	T/G	cg26384229	chr12:38710491	ALG10B	0.89	13.14	0.65	6.99e-30	Bladder cancer;
SARC	cis	rs13256369	0.851	rs13249700	chr8:8563637	C/T	cg18904891	chr8:8559673	CLDN23	0.49	5.49	0.34	1.02e-7	Obesity-related traits;
SARC	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg17221315	chr6:27791827	HIST1H4J	0.45	4.89	0.31	1.89e-6	Cardiac Troponin-T levels;
SARC	cis	rs735396	0.595	rs1169279	chr12:121455873	C/T	cg25281562	chr12:121454272	C12orf43	0.57	7.47	0.44	1.61e-12	N-glycan levels;
SARC	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6815814	0.950	rs5743566	chr4:38805942	G/C	cg06935464	chr4:38784597	TLR10	0.63	6.31	0.38	1.41e-9	Breast cancer;
SARC	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.35	-0.43	3.34e-12	Gut microbiome composition (summer);
SARC	cis	rs3741798	0.908	rs61922046	chr12:12495675	A/T	cg08615371	chr12:12503544	MANSC1	0.69	5.45	0.34	1.25e-7	Cerebrospinal fluid biomarker levels;
SARC	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.48	5.98	0.36	8.29e-9	Tonsillectomy;
SARC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.99	12.16	0.62	1.18e-26	Platelet count;
SARC	cis	rs7647973	1.000	rs6783003	chr3:49524778	G/C	cg07636037	chr3:49044803	WDR6	-0.75	-7.99	-0.46	6.22e-14	Menarche (age at onset);
SARC	cis	rs1008375	0.966	rs2315645	chr4:17579678	G/C	cg16339924	chr4:17578868	LAP3	0.69	9.17	0.51	2.59e-17	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs1814175	0.647	rs10839394	chr11:49844747	T/C	cg03929089	chr4:120376271	NA	-0.87	-13.51	-0.66	4.18e-31	Height;
SARC	cis	rs796364	0.951	rs7586320	chr2:201068209	C/G	cg05691004	chr2:201170426	SPATS2L	-0.46	-5.06	-0.31	8.58e-7	Schizophrenia;
SARC	cis	rs4427176	0.714	rs7827278	chr8:9471302	G/T	cg21625330	chr8:9911636	MSRA	-0.62	-4.78	-0.3	3.09e-6	Mosquito bite size;
SARC	cis	rs4563143	0.514	rs73029076	chr19:29292032	G/T	cg12756686	chr19:29218302	NA	0.6	6.8	0.41	8.53e-11	Methadone dose in opioid dependence;
SARC	cis	rs6570726	0.791	rs435671	chr6:145881215	A/G	cg05347473	chr6:146136440	FBXO30	0.54	7.54	0.44	1.05e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1348850	0.831	rs7606235	chr2:178401288	T/C	cg23306229	chr2:178417860	TTC30B	0.54	6.15	0.37	3.41e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs796364	0.951	rs6722092	chr2:201059371	G/T	cg05691004	chr2:201170426	SPATS2L	-0.47	-5.33	-0.33	2.32e-7	Schizophrenia;
SARC	cis	rs617791	0.508	rs747526	chr11:65776071	C/A	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.42	-4.73	-0.3	3.84e-6	Breast cancer;
SARC	cis	rs2370759	1.000	rs7910776	chr10:32639093	C/T	cg18270830	chr10:32634957	EPC1	0.53	4.79	0.3	3.03e-6	Sexual dysfunction (female);
SARC	cis	rs6840360	0.550	rs7675818	chr4:152690777	C/G	cg22705602	chr4:152727874	NA	-0.5	-8.95	-0.51	1.15e-16	Intelligence (multi-trait analysis);
SARC	cis	rs11764590	0.694	rs3996323	chr7:2079428	G/T	cg21782813	chr7:2030301	MAD1L1	-0.32	-4.91	-0.31	1.74e-6	Neuroticism;
SARC	trans	rs7819412	0.775	rs4545055	chr8:10935366	T/C	cg06636001	chr8:8085503	FLJ10661	-0.7	-9.87	-0.54	2.04e-19	Triglycerides;
SARC	cis	rs16976116	0.901	rs28499113	chr15:55503621	T/C	cg11288833	chr15:55489084	RSL24D1	0.61	5.91	0.36	1.19e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs67311347	0.866	rs9826419	chr3:40352051	G/A	cg09455208	chr3:40491958	NA	0.39	6.1	0.37	4.32e-9	Renal cell carcinoma;
SARC	cis	rs593982	0.843	rs680948	chr11:65472394	C/G	cg08755490	chr11:65554678	OVOL1	0.82	7.99	0.46	6.35e-14	Atopic dermatitis;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13428921	chr9:138837056	UBAC1	0.4	6.56	0.39	3.37e-10	Smoking initiation;
SARC	cis	rs9818758	0.607	rs34784192	chr3:49274823	G/T	cg01304814	chr3:48885189	PRKAR2A	0.61	5.07	0.32	8.11e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg20102877	chr2:27665638	KRTCAP3	-0.37	-5.25	-0.33	3.44e-7	Total body bone mineral density;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg10046127	chr14:57735694	MUDENG;EXOC5	0.7	7.19	0.43	8.95e-12	Lung cancer in ever smokers;
SARC	trans	rs7824557	0.591	rs2293859	chr8:11216761	T/G	cg06636001	chr8:8085503	FLJ10661	0.53	6.39	0.39	8.99e-10	Retinal vascular caliber;
SARC	trans	rs208520	0.837	rs208488	chr6:66926902	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-11.06	-0.59	3.85e-23	Exhaled nitric oxide output;
SARC	cis	rs79149102	0.579	rs12592477	chr15:75292699	C/T	cg17294928	chr15:75287854	SCAMP5	-1.05	-9.01	-0.51	7.57e-17	Lung cancer;
SARC	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg01570182	chr17:44337453	NA	0.83	9.6	0.53	1.33e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs3540	0.960	rs2238327	chr15:91012949	G/A	cg22089800	chr15:90895588	ZNF774	0.51	5.78	0.35	2.33e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	5.42	0.33	1.47e-7	Bipolar disorder;
SARC	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg20887711	chr4:1340912	KIAA1530	0.45	5.48	0.34	1.12e-7	Longevity;
SARC	cis	rs1728785	1.000	rs1728792	chr16:68596534	G/C	cg02972257	chr16:68554789	NA	-0.45	-5.29	-0.33	2.82e-7	Ulcerative colitis;
SARC	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg08219700	chr8:58056026	NA	0.49	5.01	0.31	1.07e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs2730245	0.563	rs2709857	chr7:158685257	T/C	cg17136484	chr7:158649327	WDR60	0.47	5.59	0.34	6.48e-8	Height;
SARC	cis	rs637571	0.584	rs594689	chr11:65635559	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.4	-4.92	-0.31	1.64e-6	Eosinophil percentage of white cells;
SARC	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.75	8.87	0.5	1.91e-16	Height;
SARC	cis	rs2050392	0.590	rs17547917	chr10:30718303	G/A	cg25182066	chr10:30743637	MAP3K8	0.41	5.59	0.34	6.27e-8	Inflammatory bowel disease;
SARC	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg22433210	chr17:43662623	NA	0.69	8.25	0.48	1.16e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs6540556	0.608	rs2884090	chr1:209884059	C/T	cg05527609	chr1:210001259	C1orf107	-0.47	-4.75	-0.3	3.5e-6	Red blood cell count;
SARC	cis	rs2204008	0.837	rs11495548	chr12:38076756	C/T	cg13010199	chr12:38710504	ALG10B	0.78	10.63	0.57	8.91e-22	Bladder cancer;
SARC	cis	rs72781680	0.898	rs17509001	chr2:24021231	T/C	cg06627628	chr2:24431161	ITSN2	-0.66	-6.27	-0.38	1.69e-9	Lymphocyte counts;
SARC	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg12667521	chr19:29218732	NA	0.39	5.31	0.33	2.56e-7	Methadone dose in opioid dependence;
SARC	cis	rs4555082	0.834	rs2816631	chr14:105739477	G/A	cg13114125	chr14:105738426	BRF1	-0.8	-11.65	-0.61	5.26e-25	Mean platelet volume;Platelet distribution width;
SARC	cis	rs921968	0.643	rs586374	chr2:219383003	A/C	cg02176678	chr2:219576539	TTLL4	0.37	5.65	0.35	4.64e-8	Mean corpuscular hemoglobin concentration;
SARC	cis	rs2836974	0.653	rs8130556	chr21:40516872	C/T	cg27266027	chr21:40555129	PSMG1	0.53	5.68	0.35	4.04e-8	Cognitive function;
SARC	cis	rs9815354	0.812	rs73073358	chr3:41842527	G/A	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs12140703	0.510	rs1572993	chr1:205045087	G/A	cg07972983	chr1:205091412	RBBP5	-0.45	-5.85	-0.36	1.65e-8	Reticulocyte count;
SARC	cis	rs2180341	0.960	rs6913424	chr6:127707010	A/C	cg17762328	chr6:126965162	NA	-0.45	-4.95	-0.31	1.4e-6	Breast cancer;
SARC	cis	rs7208859	0.623	rs11652533	chr17:29060601	A/C	cg13385521	chr17:29058706	SUZ12P	0.84	7.31	0.43	4.29e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9322817	0.691	rs17680345	chr6:105337409	A/T	cg02098413	chr6:105308735	HACE1	0.39	6.06	0.37	5.5e-9	Thyroid stimulating hormone;
SARC	cis	rs6456156	0.586	rs12203510	chr6:167473006	C/T	cg07741184	chr6:167504864	NA	0.35	6.8	0.41	8.55e-11	Primary biliary cholangitis;
SARC	cis	rs7666738	0.830	rs13116691	chr4:98929771	A/C	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs950027	0.620	rs1153857	chr15:45659095	G/T	cg26924012	chr15:45694286	SPATA5L1	0.53	6.79	0.41	9.19e-11	Response to fenofibrate (adiponectin levels);
SARC	cis	rs748404	0.660	rs2467741	chr15:43742626	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	5.59	0.34	6.25e-8	Lung cancer;
SARC	cis	rs10463316	0.709	rs3857426	chr5:150789831	C/A	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.35	-0.33	2.06e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs2072499	0.750	rs72708291	chr1:156177285	A/T	cg24450063	chr1:156163899	SLC25A44	1.03	13.02	0.65	1.7e-29	Testicular germ cell tumor;
SARC	cis	rs2952156	0.920	rs2517957	chr17:37838716	G/A	cg00129232	chr17:37814104	STARD3	-0.71	-10.04	-0.55	6.16e-20	Asthma;
SARC	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.91	11.07	0.59	3.6e-23	Age-related macular degeneration (geographic atrophy);
SARC	trans	rs7819412	0.811	rs2409691	chr8:10943276	C/T	cg06636001	chr8:8085503	FLJ10661	-0.64	-9.12	-0.51	3.59e-17	Triglycerides;
SARC	cis	rs5758511	0.679	rs55867855	chr22:42623258	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.46	6.9	0.41	4.87e-11	Birth weight;
SARC	cis	rs6582630	0.519	rs11182021	chr12:38443709	A/T	cg26384229	chr12:38710491	ALG10B	-0.8	-11.57	-0.6	9.48e-25	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs57506017	0.585	rs1060700	chr7:12275818	A/G	cg23422036	chr7:12250390	TMEM106B	0.47	6.07	0.37	5.1e-9	Neuroticism;
SARC	cis	rs6570726	0.935	rs409121	chr6:145839793	G/A	cg23711669	chr6:146136114	FBXO30	0.78	11.86	0.61	1.04e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg05036130	chr6:150231994	NA	0.31	5.32	0.33	2.43e-7	Testicular germ cell tumor;
SARC	cis	rs9814567	1.000	rs11927068	chr3:134266321	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	7.08	0.42	1.73e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs9916302	0.861	rs12150493	chr17:37586154	T/C	cg07936489	chr17:37558343	FBXL20	-0.69	-9.17	-0.52	2.52e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs7845219	0.597	rs7002058	chr8:95873993	G/C	cg16049864	chr8:95962084	TP53INP1	-0.38	-6.28	-0.38	1.65e-9	Type 2 diabetes;
SARC	cis	rs7614311	0.681	rs6809100	chr3:63901180	A/G	cg22134162	chr3:63841271	THOC7	-0.45	-4.86	-0.3	2.15e-6	Lung function (FVC);Lung function (FEV1);
SARC	cis	rs4642101	0.537	rs4997708	chr3:12839603	G/A	cg05775895	chr3:12838266	CAND2	0.69	10.08	0.55	4.65e-20	QRS complex (12-leadsum);
SARC	cis	rs79149102	0.579	rs74025863	chr15:75284161	T/C	cg00629941	chr15:75287862	SCAMP5	-0.65	-5.22	-0.32	3.93e-7	Lung cancer;
SARC	cis	rs2865126	0.644	rs5024299	chr18:10741011	C/T	cg21165219	chr18:10698044	FAM38B	-0.46	-4.75	-0.3	3.53e-6	Metabolite levels (5-HIAA/ MHPG Ratio);
SARC	cis	rs754466	0.580	rs11002294	chr10:79540588	T/C	cg17075019	chr10:79541650	NA	-0.84	-13.29	-0.66	2.2e-30	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs644799	1.000	rs494829	chr11:95571750	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	14.8	0.7	2.24e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs11153147	0.730	rs2798646	chr6:109310596	C/A	cg05315195	chr6:109294784	ARMC2	0.62	5.54	0.34	8.19e-8	Mean corpuscular volume;
SARC	cis	rs2425143	1.000	rs6058311	chr20:34321895	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-5.62	-0.35	5.31e-8	Blood protein levels;
SARC	cis	rs7249142	0.549	rs3787040	chr19:19297292	A/G	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.24	5.18	0.32	4.84e-7	IgG glycosylation;
SARC	cis	rs6540556	0.769	rs17389198	chr1:209922058	G/A	cg23920097	chr1:209922102	NA	-0.59	-6.08	-0.37	4.8e-9	Red blood cell count;
SARC	cis	rs2559856	0.935	rs2695287	chr12:102088361	T/C	cg12924262	chr12:102091054	CHPT1	0.57	7.85	0.46	1.54e-13	Blood protein levels;
SARC	cis	rs9902453	0.791	rs6505141	chr17:27998187	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	7.27	0.43	5.49e-12	Coffee consumption (cups per day);
SARC	cis	rs9303401	0.580	rs12603808	chr17:56578508	T/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.03	10.73	0.57	4.48e-22	Cognitive test performance;
SARC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg26338869	chr17:61819248	STRADA	0.81	10.89	0.58	1.38e-22	Prudent dietary pattern;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg26607991	chr16:669235	RAB40C	0.49	6.32	0.38	1.34e-9	Height;
SARC	cis	rs7662987	0.517	rs2851277	chr4:100022910	G/T	cg12011299	chr4:100065546	ADH4	0.32	5.25	0.33	3.44e-7	Smoking initiation;
SARC	trans	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg20587970	chr11:113659929	NA	-1.38	-13.71	-0.67	8.88e-32	Hip circumference adjusted for BMI;
SARC	cis	rs34330	0.562	rs11055023	chr12:12853197	A/G	cg09462578	chr12:12878428	APOLD1	-0.6	-5.78	-0.35	2.43e-8	Systemic lupus erythematosus;
SARC	cis	rs7824557	0.527	rs2409756	chr8:11242025	A/C	cg21775007	chr8:11205619	TDH	-0.55	-6.85	-0.41	6.36e-11	Retinal vascular caliber;
SARC	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.87	12.15	0.62	1.28e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg13770153	chr20:60521292	NA	-0.52	-7.35	-0.43	3.42e-12	Body mass index;
SARC	cis	rs7712401	0.562	rs2407403	chr5:122174031	C/T	cg19412675	chr5:122181750	SNX24	0.44	5.6	0.34	6.11e-8	Mean platelet volume;
SARC	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg15448220	chr1:150897856	SETDB1	0.48	6.38	0.39	9.29e-10	Tonsillectomy;
SARC	trans	rs4481887	0.927	rs4292985	chr1:248473692	T/A	cg12668902	chr6:7261808	NA	-0.5	-6.27	-0.38	1.78e-9	Common traits (Other);
SARC	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.71	-8.04	-0.47	4.65e-14	Multiple sclerosis;
SARC	cis	rs60752752	0.852	rs2916201	chr1:153354450	G/T	cg26882115	chr1:153603048	S100A1;S100A13	-0.66	-5.0	-0.31	1.13e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs1003719	0.715	rs762139	chr21:38568475	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.53	7.31	0.43	4.16e-12	Eye color traits;
SARC	cis	rs2120019	1.000	rs12185102	chr15:75352201	G/A	cg17294928	chr15:75287854	SCAMP5	-0.96	-14.22	-0.68	1.85e-33	Blood trace element (Zn levels);
SARC	cis	rs11997175	0.902	rs7462140	chr8:33717880	A/G	ch.8.33884649F	chr8:33765107	NA	0.61	8.27	0.48	1.04e-14	Body mass index;
SARC	cis	rs10789491	1.000	rs10789491	chr1:47179310	A/G	cg15501359	chr1:47185051	KIAA0494	0.78	8.26	0.48	1.1e-14	Response to hepatitis C treatment;
SARC	cis	rs921968	0.643	rs711191	chr2:219386084	T/A	cg02176678	chr2:219576539	TTLL4	0.36	5.61	0.34	5.83e-8	Mean corpuscular hemoglobin concentration;
SARC	cis	rs7666738	0.830	rs7678567	chr4:99057346	A/G	cg05340658	chr4:99064831	C4orf37	0.64	8.6	0.49	1.22e-15	Colonoscopy-negative controls vs population controls;
SARC	trans	rs61931739	0.534	rs12372721	chr12:34175301	C/T	cg26384229	chr12:38710491	ALG10B	0.85	12.24	0.63	6.32e-27	Morning vs. evening chronotype;
SARC	cis	rs854765	0.565	rs4072738	chr17:17884547	A/C	cg04398451	chr17:18023971	MYO15A	-0.45	-6.22	-0.38	2.33e-9	Total body bone mineral density;
SARC	cis	rs1707322	0.963	rs9787412	chr1:46371596	C/T	cg06784218	chr1:46089804	CCDC17	0.34	5.94	0.36	1.03e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2885056	0.783	rs12459941	chr19:10666112	A/G	cg06529468	chr19:10676722	KRI1	0.47	5.15	0.32	5.5e-7	Red cell distribution width;
SARC	cis	rs9790314	0.747	rs9820825	chr3:160848155	A/G	cg03342759	chr3:160939853	NMD3	-0.49	-6.02	-0.37	6.64e-9	Morning vs. evening chronotype;
SARC	cis	rs1865760	0.516	rs9393683	chr6:26066198	A/G	cg17691542	chr6:26056736	HIST1H1C	0.49	6.18	0.38	2.84e-9	Height;
SARC	cis	rs2180341	0.532	rs6933893	chr6:127707250	A/G	cg27446573	chr6:127587934	RNF146	0.64	8.05	0.47	4.29e-14	Breast cancer;
SARC	cis	rs7208859	0.623	rs7219712	chr17:29080570	G/T	cg13385521	chr17:29058706	SUZ12P	0.88	7.75	0.45	2.9e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs7250872	0.619	rs2396359	chr19:1819125	T/C	cg18850929	chr19:1828978	REXO1	0.43	5.43	0.34	1.42e-7	Bipolar disorder;
SARC	cis	rs2070488	0.965	rs2154778	chr3:38553639	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.8	-12.66	-0.64	2.73e-28	Electrocardiographic conduction measures;
SARC	cis	rs7149337	0.780	rs4369569	chr14:51689181	C/G	cg23942311	chr14:51606299	NA	-0.29	-5.02	-0.31	1.03e-6	Cancer;
SARC	cis	rs11122272	0.735	rs2790881	chr1:231534181	A/G	cg06096015	chr1:231504339	EGLN1	0.38	5.64	0.35	4.92e-8	Hemoglobin concentration;
SARC	trans	rs7395662	0.591	rs7483212	chr11:48607182	T/A	cg15704280	chr7:45808275	SEPT13	-0.49	-6.49	-0.39	5.1e-10	HDL cholesterol;
SARC	trans	rs56279505	0.629	rs17586163	chr4:100274571	T/C	cg18024358	chr1:3420815	MEGF6	-0.84	-6.43	-0.39	7.27e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2228479	0.850	rs45567439	chr16:89814604	G/A	cg26513180	chr16:89883248	FANCA	0.71	4.75	0.3	3.56e-6	Skin colour saturation;
SARC	cis	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg09021430	chr5:549028	NA	-0.48	-6.35	-0.38	1.12e-9	Obesity-related traits;
SARC	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg05234568	chr11:5960015	NA	-0.41	-5.46	-0.34	1.21e-7	DNA methylation (variation);
SARC	cis	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg12064134	chr16:90016061	DEF8	-0.58	-5.01	-0.31	1.08e-6	Skin colour saturation;
SARC	cis	rs607987	0.841	rs4923632	chr11:30302023	C/A	cg06241208	chr11:30344200	C11orf46	0.41	4.97	0.31	1.31e-6	Body mass index;
SARC	cis	rs6456156	0.586	rs2001115	chr6:167486218	A/C	cg07741184	chr6:167504864	NA	0.36	6.99	0.42	2.83e-11	Primary biliary cholangitis;
SARC	cis	rs62380364	0.507	rs34321	chr5:88020319	C/G	cg22951263	chr5:87985283	NA	-0.36	-4.78	-0.3	3.16e-6	Intelligence (multi-trait analysis);
SARC	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg10546459	chr2:36825355	FEZ2	0.49	5.6	0.34	5.98e-8	Height;
SARC	cis	rs9399135	0.967	rs13191501	chr6:135366880	T/C	cg24558204	chr6:135376177	HBS1L	0.46	6.18	0.38	2.88e-9	Red blood cell count;
SARC	cis	rs4951011	0.938	rs12048085	chr1:203761807	C/G	cg05526099	chr1:203152295	CHI3L1	0.35	4.82	0.3	2.55e-6	Breast cancer;
SARC	cis	rs6910061	0.830	rs6906360	chr6:11118427	C/T	cg27233058	chr6:11094804	LOC221710	0.63	6.01	0.37	6.95e-9	Diabetic kidney disease;
SARC	cis	rs7589342	0.598	rs7602442	chr2:106402795	C/T	cg16077055	chr2:106428750	NCK2	-0.28	-5.14	-0.32	5.74e-7	Addiction;
SARC	cis	rs668210	0.739	rs543952	chr11:65744275	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.55	5.51	0.34	9.31e-8	Cerebrospinal fluid biomarker levels;
SARC	cis	rs11969893	0.850	rs9485417	chr6:101300038	C/T	cg12253828	chr6:101329408	ASCC3	-1.24	-7.82	-0.46	1.85e-13	Economic and political preferences (immigration/crime);
SARC	cis	rs7756236	0.521	rs9394368	chr6:36630525	C/G	cg08179530	chr6:36648295	CDKN1A	-0.66	-8.88	-0.5	1.88e-16	QRS duration;
SARC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg05025164	chr4:1340916	KIAA1530	0.87	11.31	0.6	6.2e-24	Longevity;
SARC	cis	rs703842	0.616	rs4760171	chr12:58225904	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.62	8.39	0.48	4.61e-15	Multiple sclerosis;
SARC	cis	rs1215050	0.535	rs6822100	chr4:98435890	A/G	cg05340658	chr4:99064831	C4orf37	-0.45	-5.3	-0.33	2.66e-7	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs3768617	0.510	rs1413390	chr1:183096634	G/A	cg13390022	chr1:182993471	LAMC1	0.31	4.79	0.3	3.01e-6	Fuchs's corneal dystrophy;
SARC	cis	rs6582630	0.555	rs10880612	chr12:38509427	A/G	cg13010199	chr12:38710504	ALG10B	0.76	10.49	0.57	2.39e-21	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7223966	0.881	rs3020608	chr17:61979993	C/A	cg26338869	chr17:61819248	STRADA	0.5	5.1	0.32	6.96e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.8	10.32	0.56	8.57e-21	Prudent dietary pattern;
SARC	cis	rs2050392	0.737	rs7898978	chr10:30699800	T/C	cg25182066	chr10:30743637	MAP3K8	-0.44	-5.84	-0.36	1.73e-8	Inflammatory bowel disease;
SARC	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg23758822	chr17:41437982	NA	0.9	11.39	0.6	3.52e-24	Menopause (age at onset);
SARC	cis	rs1976403	0.510	rs1697421	chr1:21823292	C/T	cg21906605	chr1:21766650	NBPF3	0.37	4.88	0.3	2.01e-6	Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg22974920	chr21:40686053	BRWD1	0.48	5.32	0.33	2.43e-7	Cognitive function;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg06128195	chr6:166400879	C6orf176;LOC441177	-0.55	-6.46	-0.39	5.88e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs6545883	1.000	rs778762	chr2:61782921	G/T	cg15711740	chr2:61764176	XPO1	-0.43	-5.23	-0.32	3.74e-7	Tuberculosis;
SARC	cis	rs644799	0.544	rs1727165	chr11:95521648	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.74	9.94	0.55	1.21e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9911578	0.835	rs9303398	chr17:56484257	T/C	cg12560992	chr17:57184187	TRIM37	-0.76	-9.74	-0.54	4.97e-19	Intelligence (multi-trait analysis);
SARC	cis	rs12477438	0.765	rs2278895	chr2:99613484	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.95	-15.47	-0.71	1.34e-37	Chronic sinus infection;
SARC	cis	rs76419734	0.850	rs17036076	chr4:106575269	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	-0.72	-5.01	-0.31	1.09e-6	Post bronchodilator FEV1;
SARC	cis	rs2070433	0.800	rs11700596	chr21:47874054	G/C	cg12379764	chr21:47803548	PCNT	0.55	5.0	0.31	1.15e-6	Lymphocyte counts;
SARC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg16132339	chr22:24313637	DDTL;DDT	0.44	5.83	0.36	1.88e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg16405210	chr4:1374714	KIAA1530	0.78	10.0	0.55	7.88e-20	Longevity;
SARC	cis	rs6456156	0.586	rs9457266	chr6:167482555	T/C	cg23791538	chr6:167370224	RNASET2	-0.53	-6.99	-0.42	2.86e-11	Primary biliary cholangitis;
SARC	cis	rs17376456	0.825	rs6874766	chr5:93213807	C/G	cg25358565	chr5:93447407	FAM172A	-1.25	-12.0	-0.62	3.87e-26	Diabetic retinopathy;
SARC	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg21644426	chr2:191273491	MFSD6	0.5	6.62	0.4	2.46e-10	Pulse pressure;
SARC	cis	rs6977660	0.714	rs10260866	chr7:19793151	T/C	cg05791153	chr7:19748676	TWISTNB	0.73	6.58	0.4	3.08e-10	Thyroid stimulating hormone;
SARC	cis	rs72781680	1.000	rs72798408	chr2:24181845	G/C	cg08917208	chr2:24149416	ATAD2B	0.94	9.09	0.51	4.53e-17	Lymphocyte counts;
SARC	cis	rs9486719	0.857	rs11759769	chr6:97065212	G/A	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.51	-0.34	9.35e-8	Migraine;Coronary artery disease;
SARC	cis	rs17376456	0.569	rs13186432	chr5:93336940	G/A	cg25358565	chr5:93447407	FAM172A	-0.86	-10.0	-0.55	8.15e-20	Diabetic retinopathy;
SARC	cis	rs9790314	0.663	rs778657	chr3:160719577	C/A	cg03342759	chr3:160939853	NMD3	-0.38	-4.74	-0.3	3.7e-6	Morning vs. evening chronotype;
SARC	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg11764359	chr7:65958608	NA	-0.78	-9.41	-0.52	4.86e-18	Aortic root size;
SARC	cis	rs9916302	0.861	rs593480	chr17:37453780	A/C	cg00129232	chr17:37814104	STARD3	0.6	7.33	0.43	3.76e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs6732160	0.834	rs57456443	chr2:73366441	C/A	cg01422370	chr2:73384389	NA	0.31	4.94	0.31	1.46e-6	Intelligence (multi-trait analysis);
SARC	cis	rs13006833	0.668	rs291445	chr2:191176479	G/A	cg25963032	chr2:191064776	C2orf88	0.38	5.38	0.33	1.79e-7	Urinary metabolites;
SARC	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg09699651	chr6:150184138	LRP11	0.4	4.92	0.31	1.62e-6	Lung cancer;
SARC	cis	rs11764590	0.651	rs12673687	chr7:2081873	C/T	cg21782813	chr7:2030301	MAD1L1	-0.31	-4.74	-0.3	3.65e-6	Neuroticism;
SARC	cis	rs72945132	0.882	rs58039907	chr11:70183336	C/T	cg05964544	chr11:70165517	PPFIA1	-0.57	-5.54	-0.34	8.15e-8	Coronary artery disease;
SARC	cis	rs7617480	0.648	rs9864243	chr3:48982732	G/A	cg07636037	chr3:49044803	WDR6	0.86	9.25	0.52	1.45e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs9910055	0.529	rs228748	chr17:42174390	G/A	cg13607699	chr17:42295918	UBTF	-0.45	-5.02	-0.31	1.01e-6	Total body bone mineral density;
SARC	cis	rs6088590	0.965	rs6088620	chr20:33412022	A/G	cg24642439	chr20:33292090	TP53INP2	0.85	11.82	0.61	1.48e-25	Coronary artery disease;
SARC	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg18252515	chr7:66147081	NA	-1.29	-11.31	-0.6	6.31e-24	Diabetic kidney disease;
SARC	cis	rs950776	0.642	rs922691	chr15:78963994	A/G	cg06917634	chr15:78832804	PSMA4	0.48	5.42	0.33	1.46e-7	Sudden cardiac arrest;
SARC	cis	rs4481887	0.893	rs10888349	chr1:248448625	T/C	cg00666640	chr1:248458726	OR2T12	0.34	5.6	0.34	5.91e-8	Common traits (Other);
SARC	cis	rs10411936	0.692	rs3810196	chr19:16601154	T/C	cg10248733	chr19:16607483	C19orf44;CALR3	0.58	6.94	0.41	3.9e-11	White blood cell count;Multiple sclerosis;
SARC	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9787249	0.957	rs2274949	chr1:40221067	G/A	cg02773041	chr1:40204384	PPIE	0.5	6.21	0.38	2.47e-9	Blood protein levels;
SARC	cis	rs77633900	0.614	rs280030	chr15:77026853	T/C	cg21673338	chr15:77095150	SCAPER	-0.61	-5.12	-0.32	6.48e-7	Non-glioblastoma glioma;Glioma;
SARC	cis	rs9549260	0.755	rs17061503	chr13:41246758	A/G	cg21288729	chr13:41239152	FOXO1	-0.65	-8.72	-0.5	5.18e-16	Red blood cell count;
SARC	cis	rs1055129	0.560	rs3682	chr17:73942150	A/G	cg14829360	chr17:73884958	NA	-0.55	-8.29	-0.48	9.13e-15	White matter hyperintensity burden;
SARC	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-9.68	-0.54	7.67e-19	Chronic sinus infection;
SARC	cis	rs3858526	0.959	rs4758219	chr11:5951846	G/C	cg13902645	chr11:5959945	NA	-0.46	-5.3	-0.33	2.62e-7	DNA methylation (variation);
SARC	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg01017244	chr2:74357527	NA	0.55	6.73	0.4	1.3100000000000001e-10	Gestational age at birth (maternal effect);
SARC	cis	rs9549367	0.789	rs8001506	chr13:113867153	A/C	cg18105134	chr13:113819100	PROZ	-0.39	-5.96	-0.36	9.08e-9	Platelet distribution width;
SARC	cis	rs17376456	0.932	rs3940842	chr5:93534858	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.14	0.32	5.94e-7	Diabetic retinopathy;
SARC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg04155289	chr7:94953770	PON1	-0.36	-4.88	-0.3	1.94e-6	Paraoxonase activity;
SARC	cis	rs734999	0.588	rs78506337	chr1:2537095	G/A	cg00980319	chr1:2560884	MMEL1	-0.33	-4.73	-0.3	3.9e-6	Ulcerative colitis;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg08860119	chr8:143695901	ARC	0.49	6.23	0.38	2.1e-9	Chemerin levels;
SARC	cis	rs34375054	0.738	rs10846834	chr12:125625570	A/G	cg25124228	chr12:125621409	AACS	-0.56	-7.18	-0.43	9.22e-12	Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs35851103	0.506	rs4841659	chr8:11828200	C/T	cg21775007	chr8:11205619	TDH	0.4	4.95	0.31	1.44e-6	Neuroticism;
SARC	cis	rs16854884	0.789	rs34096668	chr3:143794483	C/T	cg06585982	chr3:143692056	C3orf58	0.6	7.84	0.46	1.6e-13	Economic and political preferences (feminism/equality);
SARC	cis	rs36051895	0.623	rs62541543	chr9:5042082	G/A	cg02405213	chr9:5042618	JAK2	-0.53	-5.98	-0.36	8.31e-9	Pediatric autoimmune diseases;
SARC	cis	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg14019146	chr3:50243930	SLC38A3	0.31	4.78	0.3	3.1e-6	Body mass index;
SARC	cis	rs9303401	0.527	rs34835800	chr17:56764990	G/A	cg25039879	chr17:56429692	SUPT4H1	0.69	6.33	0.38	1.25e-9	Cognitive test performance;
SARC	cis	rs7662987	0.517	rs1154405	chr4:100008750	G/A	cg13256891	chr4:100009986	ADH5	0.66	8.33	0.48	7.17e-15	Smoking initiation;
SARC	cis	rs7100689	0.784	rs7082705	chr10:82170856	C/T	cg01528321	chr10:82214614	TSPAN14	-0.83	-12.23	-0.63	6.82e-27	Post bronchodilator FEV1;
SARC	cis	rs910316	0.763	rs2080201	chr14:75629972	C/T	cg11812906	chr14:75593930	NEK9	-0.74	-9.71	-0.54	6.21e-19	Height;
SARC	trans	rs9395865	0.501	rs2067833	chr6:53330356	A/G	cg13501085	chr19:17326416	USE1	-0.53	-6.68	-0.4	1.7e-10	Electroencephalographic traits in alcoholism;
SARC	cis	rs317689	0.513	rs529268	chr12:69687051	G/A	cg22834771	chr12:69754056	YEATS4	-0.49	-6.23	-0.38	2.12e-9	Response to diuretic therapy;
SARC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg06873352	chr17:61820015	STRADA	0.53	6.92	0.41	4.3e-11	Prudent dietary pattern;
SARC	cis	rs3859192	0.577	rs2227333	chr17:38174167	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.39	7.21	0.43	7.66e-12	White blood cell count;
SARC	cis	rs9309473	1.000	rs2140195	chr2:73702344	A/G	cg20560298	chr2:73613845	ALMS1	-0.49	-5.97	-0.36	8.77e-9	Metabolite levels;
SARC	cis	rs1801251	0.964	rs6748027	chr2:233629552	T/C	cg25237894	chr2:233734115	C2orf82	0.37	4.77	0.3	3.19e-6	Coronary artery disease;
SARC	cis	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg25427524	chr10:38739819	LOC399744	-0.53	-8.34	-0.48	6.7e-15	Extrinsic epigenetic age acceleration;
SARC	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	5.29	0.33	2.83e-7	Intelligence (multi-trait analysis);
SARC	cis	rs72781680	0.560	rs111310684	chr2:24265682	C/G	cg08917208	chr2:24149416	ATAD2B	0.66	6.39	0.39	8.72e-10	Lymphocyte counts;
SARC	cis	rs11578119	1.000	rs11578119	chr1:170501456	C/T	cg09767346	chr1:170501363	GORAB	0.4	4.73	0.3	3.83e-6	Male-pattern baldness;
SARC	cis	rs7927592	0.913	rs7106010	chr11:68365212	C/T	cg01657329	chr11:68192670	LRP5	-0.43	-5.12	-0.32	6.29e-7	Total body bone mineral density;
SARC	cis	rs7666738	0.606	rs3846446	chr4:99099768	C/A	cg05340658	chr4:99064831	C4orf37	0.48	6.08	0.37	4.78e-9	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6582630	0.622	rs11831595	chr12:38511489	C/A	cg13010199	chr12:38710504	ALG10B	-0.47	-5.86	-0.36	1.56e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	7.18	0.43	9.56e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4713675	0.584	rs7759668	chr6:33670406	C/T	cg15676125	chr6:33679581	C6orf125	-0.47	-5.57	-0.34	7.1e-8	Plateletcrit;
SARC	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg21724239	chr8:58056113	NA	0.6	6.31	0.38	1.43e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs3733585	0.699	rs7699609	chr4:9961059	A/G	cg11266682	chr4:10021025	SLC2A9	-0.35	-6.0	-0.37	7.48e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs40363	0.680	rs72778116	chr16:3530752	A/G	cg22508957	chr16:3507546	NAT15	0.59	5.16	0.32	5.39e-7	Tuberculosis;
SARC	cis	rs3771570	1.000	rs62193205	chr2:242316512	C/T	cg21155796	chr2:242212141	HDLBP	0.68	6.1	0.37	4.38e-9	Prostate cancer;
SARC	cis	rs7264396	0.635	rs6058358	chr20:34492560	A/T	cg12579300	chr20:34535607	PHF20	-0.41	-4.86	-0.3	2.18e-6	Total cholesterol levels;
SARC	cis	rs6138458	0.847	rs56312312	chr20:24959386	C/A	cg26195577	chr20:24973756	C20orf3	0.89	9.08	0.51	4.85e-17	Blood protein levels;
SARC	trans	rs6934651	0.655	rs62420061	chr6:85933296	A/G	cg04848555	chr14:53975804	NA	0.65	6.33	0.38	1.25e-9	Breast cancer;
SARC	cis	rs943466	0.614	rs4713677	chr6:33731225	C/G	cg25922239	chr6:33757077	LEMD2	-0.43	-5.15	-0.32	5.6e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
SARC	cis	rs7312774	0.748	rs7295619	chr12:107316934	T/A	cg16260113	chr12:107380972	MTERFD3	0.68	5.78	0.35	2.38e-8	Severe influenza A (H1N1) infection;
SARC	cis	rs4742903	1.000	rs3780535	chr9:106894211	A/C	cg14250997	chr9:106856677	SMC2	0.54	7.31	0.43	4.34e-12	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs7772486	0.743	rs9403742	chr6:146060193	A/C	cg23711669	chr6:146136114	FBXO30	0.82	13.33	0.66	1.67e-30	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg04944784	chr2:26401820	FAM59B	-0.6	-7.86	-0.46	1.46e-13	Gut microbiome composition (summer);
SARC	cis	rs2439831	0.850	rs11070408	chr15:44034788	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	8.57	0.49	1.44e-15	Lung cancer in ever smokers;
SARC	cis	rs910316	0.763	rs175044	chr14:75472109	G/A	cg11812906	chr14:75593930	NEK9	-0.75	-9.81	-0.54	3.13e-19	Height;
SARC	cis	rs6964587	0.839	rs6950538	chr7:91417816	T/C	cg17063962	chr7:91808500	NA	0.83	11.77	0.61	2.08e-25	Breast cancer;
SARC	cis	rs2153535	0.580	rs6597330	chr6:8492076	T/C	cg23788917	chr6:8435910	SLC35B3	0.64	8.44	0.48	3.45e-15	Motion sickness;
SARC	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg13939156	chr17:80058883	NA	0.41	6.26	0.38	1.82e-9	Life satisfaction;
SARC	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	7.39	0.44	2.59e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs514406	0.861	rs7518390	chr1:53233374	A/G	cg08859206	chr1:53392774	SCP2	0.39	5.62	0.35	5.32e-8	Monocyte count;
SARC	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg05025164	chr4:1340916	KIAA1530	0.5	6.14	0.37	3.58e-9	Longevity;
SARC	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.95	13.96	0.67	1.32e-32	Gut microbiome composition (summer);
SARC	cis	rs950027	0.549	rs11636114	chr15:45601412	C/G	cg21132104	chr15:45694354	SPATA5L1	0.49	5.83	0.36	1.85e-8	Response to fenofibrate (adiponectin levels);
SARC	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	-0.39	-4.78	-0.3	3.1e-6	Tonsillectomy;
SARC	cis	rs13082711	0.911	rs13077400	chr3:27473066	A/G	cg02860705	chr3:27208620	NA	0.44	6.0	0.37	7.56e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs7772486	0.790	rs7753833	chr6:146161432	C/A	cg23711669	chr6:146136114	FBXO30	0.79	13.02	0.65	1.76e-29	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs17376456	0.825	rs28534784	chr5:93063332	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.7	6.34	0.38	1.15e-9	Diabetic retinopathy;
SARC	cis	rs7662987	0.517	rs2851256	chr4:100039549	G/A	cg13256891	chr4:100009986	ADH5	0.68	8.61	0.49	1.13e-15	Smoking initiation;
SARC	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg00450029	chr8:599525	NA	0.59	5.03	0.31	9.88e-7	IgG glycosylation;
SARC	cis	rs244731	0.959	rs11740250	chr5:176721272	G/C	cg06060754	chr5:176797920	RGS14	0.43	5.02	0.31	1.03e-6	Urate levels in lean individuals;
SARC	cis	rs2732480	0.500	rs7297824	chr12:48598650	T/C	cg24011408	chr12:48396354	COL2A1	0.46	5.37	0.33	1.89e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg00322919	chr10:17172000	CUBN	0.47	6.39	0.39	8.89e-10	Thyroid stimulating hormone;
SARC	cis	rs2070488	0.775	rs2268762	chr3:38516075	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.81	12.3	0.63	4.01e-27	Electrocardiographic conduction measures;
SARC	cis	rs72781680	0.846	rs55707417	chr2:24029928	G/A	cg06627628	chr2:24431161	ITSN2	-0.7	-6.44	-0.39	6.77e-10	Lymphocyte counts;
SARC	cis	rs11864453	0.826	rs9941087	chr16:72118324	G/A	cg16558253	chr16:72132732	DHX38	-0.57	-9.06	-0.51	5.38e-17	Fibrinogen levels;
SARC	cis	rs472402	0.580	rs7720479	chr5:6640049	A/G	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.42	-5.09	-0.32	7.29e-7	Response to amphetamines;
SARC	cis	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg22496380	chr5:211416	CCDC127	-0.89	-9.17	-0.51	2.63e-17	Breast cancer;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01112923	chr4:170533425	NEK1	-0.49	-6.29	-0.38	1.52e-9	Smoking initiation;
SARC	cis	rs10791097	0.694	rs7125622	chr11:130743388	T/C	cg12179176	chr11:130786555	SNX19	0.73	10.95	0.58	8.7e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg07701084	chr6:150067640	NUP43	0.41	5.36	0.33	1.98e-7	Lung cancer;
SARC	cis	rs113835537	0.529	rs7950407	chr11:66258006	A/G	cg24851651	chr11:66362959	CCS	0.37	4.73	0.3	3.9e-6	Airway imaging phenotypes;
SARC	trans	rs7937682	0.855	rs7934922	chr11:111500026	T/C	cg18187862	chr3:45730750	SACM1L	0.57	7.11	0.42	1.45e-11	Primary sclerosing cholangitis;
SARC	cis	rs7584330	0.617	rs10202195	chr2:238352128	A/G	cg14458575	chr2:238380390	NA	0.52	6.12	0.37	4.01e-9	Prostate cancer;
SARC	cis	rs7044106	0.664	rs7861679	chr9:123375589	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.42	-5.01	-0.31	1.09e-6	Hip circumference adjusted for BMI;
SARC	cis	rs7818345	1.000	rs4392915	chr8:19308938	T/G	cg11303988	chr8:19266685	CSGALNACT1	0.39	5.16	0.32	5.31e-7	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs1451375	0.572	rs745042	chr7:50544138	A/G	cg14593290	chr7:50529359	DDC	-0.44	-4.84	-0.3	2.36e-6	Malaria;
SARC	cis	rs11785400	0.762	rs7460801	chr8:143730972	C/A	cg24634471	chr8:143751801	JRK	0.6	7.74	0.45	2.98e-13	Schizophrenia;
SARC	cis	rs9733	0.818	rs12403609	chr1:150676485	T/C	cg15448220	chr1:150897856	SETDB1	-0.36	-4.72	-0.3	3.98e-6	Tonsillectomy;
SARC	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.93	12.84	0.64	6.67e-29	Platelet count;
SARC	cis	rs11711311	0.911	rs13321446	chr3:113522544	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.69	8.33	0.48	6.8e-15	IgG glycosylation;
SARC	cis	rs9303401	1.000	rs9904677	chr17:56873025	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.68	7.91	0.46	1.01e-13	Cognitive test performance;
SARC	cis	rs4706831	0.663	rs1984242	chr6:81051245	A/G	cg08355045	chr6:80787529	NA	0.31	4.82	0.3	2.63e-6	Joint mobility (Beighton score);
SARC	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg05793240	chr7:2802953	GNA12	-0.35	-4.97	-0.31	1.28e-6	Height;
SARC	cis	rs763121	0.853	rs6001191	chr22:39074452	T/C	cg21395723	chr22:39101663	GTPBP1	0.52	5.8	0.36	2.17e-8	Menopause (age at onset);
SARC	cis	rs7208859	0.623	rs7503335	chr17:29073962	G/A	cg13385521	chr17:29058706	SUZ12P	0.88	7.94	0.46	8.37e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs7772486	0.686	rs4896827	chr6:145953338	T/A	cg05347473	chr6:146136440	FBXO30	0.5	7.1	0.42	1.48e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7824557	0.591	rs2043510	chr8:11225168	G/A	cg21775007	chr8:11205619	TDH	-0.66	-8.77	-0.5	3.89e-16	Retinal vascular caliber;
SARC	cis	rs12311304	0.965	rs7303854	chr12:15359241	A/T	cg08258403	chr12:15378311	NA	0.48	7.47	0.44	1.61e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs477692	0.905	rs489966	chr10:131422115	C/G	cg05714579	chr10:131428358	MGMT	-0.59	-7.76	-0.45	2.67e-13	Response to temozolomide;
SARC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg20607798	chr8:58055168	NA	0.58	5.55	0.34	7.69e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6456156	0.586	rs12527827	chr6:167469271	C/T	cg07741184	chr6:167504864	NA	0.36	7.09	0.42	1.62e-11	Primary biliary cholangitis;
SARC	cis	rs911263	0.603	rs11158729	chr14:68776060	T/C	cg18825221	chr14:68749962	RAD51L1	0.42	7.57	0.44	8.76e-13	Primary biliary cholangitis;
SARC	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	15.01	0.7	4.27e-36	Chronic sinus infection;
SARC	cis	rs10489525	0.599	rs7526323	chr1:115604241	G/A	cg01522456	chr1:115632236	TSPAN2	0.45	5.42	0.33	1.46e-7	Autism;
SARC	cis	rs9300255	0.544	rs1727310	chr12:123660510	A/G	cg00376283	chr12:123451042	ABCB9	0.57	5.54	0.34	8.32e-8	Neutrophil percentage of white cells;
SARC	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg00933542	chr6:150070202	PCMT1	0.3	5.04	0.31	9.17e-7	Lung cancer;
SARC	cis	rs7481584	0.962	rs2237905	chr11:2976584	T/C	cg05729581	chr11:3078854	CARS	0.49	6.1	0.37	4.49e-9	Calcium levels;
SARC	cis	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg18252515	chr7:66147081	NA	-1.12	-9.81	-0.54	3.17e-19	Diabetic kidney disease;
SARC	cis	rs2463822	0.920	rs11828383	chr11:62067818	C/T	cg06239285	chr11:62104954	ASRGL1	-0.8	-7.65	-0.45	5.31e-13	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	23.01	0.83	6.44e-62	Chronic sinus infection;
SARC	trans	rs3780486	0.846	rs10124479	chr9:33136233	T/G	cg04842962	chr6:43655489	MRPS18A	1.09	19.8	0.79	7.63e-52	IgG glycosylation;
SARC	cis	rs9640161	0.750	rs11769348	chr7:150026753	C/T	cg10018233	chr7:150070692	REPIN1	-0.73	-9.55	-0.53	1.94e-18	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs9291683	0.632	rs7679916	chr4:10042160	C/T	cg11266682	chr4:10021025	SLC2A9	0.4	7.27	0.43	5.35e-12	Bone mineral density;
SARC	cis	rs6088580	0.609	rs2378205	chr20:33110803	C/G	cg24642439	chr20:33292090	TP53INP2	0.68	8.84	0.5	2.39e-16	Glomerular filtration rate (creatinine);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg23886783	chr2:113403248	SLC20A1	0.48	6.25	0.38	1.97e-9	Chemerin levels;
SARC	cis	rs7659604	1.000	rs7660078	chr4:122665577	G/T	cg19671926	chr4:122722719	EXOSC9	-0.51	-6.14	-0.37	3.44e-9	Type 2 diabetes;
SARC	cis	rs861020	0.771	rs126280	chr1:210019824	A/G	cg23166289	chr1:210001082	C1orf107	0.43	4.88	0.3	1.98e-6	Orofacial clefts;
SARC	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg20102877	chr2:27665638	KRTCAP3	-0.34	-4.73	-0.3	3.85e-6	Menopause (age at onset);
SARC	cis	rs883565	0.528	rs9311200	chr3:38953896	C/T	cg26331595	chr3:39149181	GORASP1;TTC21A	0.42	5.02	0.31	1.05e-6	Handedness;
SARC	cis	rs2033732	0.706	rs1437509	chr8:85065342	G/T	cg05716166	chr8:85095498	RALYL	0.47	5.62	0.35	5.51e-8	Body mass index;
SARC	cis	rs7932354	0.710	rs6485702	chr11:46898771	T/C	cg03339077	chr11:47165057	C11orf49	-0.39	-5.33	-0.33	2.27e-7	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs4319547	0.915	rs7966094	chr12:123115771	A/G	cg23029597	chr12:123009494	RSRC2	-0.44	-5.45	-0.34	1.29e-7	Body mass index;
SARC	cis	rs916888	0.610	rs199446	chr17:44813169	G/A	cg15921436	chr17:44337874	NA	-0.5	-5.76	-0.35	2.67e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg05368731	chr17:41323189	NBR1	0.79	9.83	0.54	2.62e-19	Menopause (age at onset);
SARC	cis	rs10791097	0.694	rs4937583	chr11:130741606	A/G	cg12179176	chr11:130786555	SNX19	0.73	10.91	0.58	1.19e-22	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	trans	rs11098499	0.954	rs6846442	chr4:120326323	G/A	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	cis	rs34172651	0.874	rs200534	chr16:24752641	G/A	cg00152838	chr16:24741724	TNRC6A	0.48	5.84	0.36	1.77e-8	Intelligence (multi-trait analysis);
SARC	trans	rs7615952	0.688	rs7624806	chr3:125599074	G/A	cg07211511	chr3:129823064	LOC729375	-0.92	-10.79	-0.58	2.9e-22	Blood pressure (smoking interaction);
SARC	cis	rs36051895	0.622	rs10815143	chr9:5009541	G/A	cg02405213	chr9:5042618	JAK2	-0.56	-6.47	-0.39	5.58e-10	Pediatric autoimmune diseases;
SARC	cis	rs62064224	0.593	rs916663	chr17:30835833	A/C	cg09324608	chr17:30823087	MYO1D	-0.33	-4.85	-0.3	2.24e-6	Schizophrenia;
SARC	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg09359103	chr1:154839909	KCNN3	-0.46	-7.76	-0.45	2.7e-13	Prostate cancer;
SARC	cis	rs72781680	1.000	rs72781683	chr2:24247423	T/C	cg08917208	chr2:24149416	ATAD2B	0.89	8.7	0.5	6.13e-16	Lymphocyte counts;
SARC	cis	rs910316	0.819	rs175461	chr14:75581816	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.52	-7.08	-0.42	1.73e-11	Height;
SARC	trans	rs1973993	0.561	rs56983671	chr1:96988608	C/T	cg10631902	chr5:14652156	NA	-0.44	-6.28	-0.38	1.67e-9	Weight;
SARC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.53	6.8	0.41	8.51e-11	Lymphocyte counts;
SARC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg03188948	chr7:1209495	NA	0.48	6.38	0.39	9.49e-10	Longevity;Endometriosis;
SARC	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg25894440	chr7:65020034	NA	-0.72	-5.46	-0.34	1.2e-7	Diabetic kidney disease;
SARC	cis	rs2070488	1.000	rs6772046	chr3:38479660	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	14.25	0.68	1.44e-33	Electrocardiographic conduction measures;
SARC	cis	rs7712401	0.601	rs30055	chr5:122301079	T/G	cg19412675	chr5:122181750	SNX24	0.4	5.13	0.32	5.98e-7	Mean platelet volume;
SARC	cis	rs2180341	0.960	rs9398842	chr6:127674662	T/C	cg24812749	chr6:127587940	RNF146	0.99	12.85	0.64	6.29e-29	Breast cancer;
SARC	cis	rs17125944	0.505	rs80211268	chr14:53265483	C/G	cg00686598	chr14:53173677	PSMC6	1.3	9.09	0.51	4.32e-17	Alzheimer's disease (late onset);
SARC	cis	rs694739	0.595	rs11542299	chr11:64138805	T/C	cg23796481	chr11:64053134	BAD;GPR137	0.66	7.45	0.44	1.81e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs6582630	0.555	rs10880421	chr12:38423015	C/T	cg13010199	chr12:38710504	ALG10B	0.77	10.39	0.56	5.04e-21	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7474896	0.609	rs1830612	chr10:37999883	A/G	cg00409905	chr10:38381863	ZNF37A	-0.45	-4.85	-0.3	2.21e-6	Obesity (extreme);
SARC	cis	rs9796	0.727	rs61203391	chr15:41352912	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.5	-6.78	-0.41	9.9e-11	Menopause (age at onset);
SARC	cis	rs453301	0.686	rs1045527	chr8:8890041	A/G	cg11995313	chr8:8860691	ERI1	0.43	5.5	0.34	1e-7	Joint mobility (Beighton score);
SARC	cis	rs9948	0.867	rs62152860	chr2:97516818	C/A	cg01990225	chr2:97406019	LMAN2L	-0.87	-5.71	-0.35	3.36e-8	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs1552244	0.700	rs9833566	chr3:9981671	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.73	-7.02	-0.42	2.37e-11	Alzheimer's disease;
SARC	cis	rs9815354	0.951	rs9850310	chr3:41891098	T/C	cg03022575	chr3:42003672	ULK4	0.67	5.73	0.35	3.13e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg00990874	chr7:1149470	C7orf50	-0.58	-6.16	-0.37	3.14e-9	Bronchopulmonary dysplasia;
SARC	cis	rs40363	0.671	rs4786425	chr16:3537650	A/G	cg22508957	chr16:3507546	NAT15	-0.59	-5.02	-0.31	1.02e-6	Tuberculosis;
SARC	cis	rs897984	0.568	rs72799330	chr16:30893555	C/A	cg00531865	chr16:30841666	NA	-0.51	-5.33	-0.33	2.33e-7	Dementia with Lewy bodies;
SARC	cis	rs3020736	0.500	rs5996109	chr22:42493098	A/G	cg15557168	chr22:42548783	NA	0.35	4.8	0.3	2.85e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7550918	1	rs7550918	chr1:247675559	C/T	cg11166453	chr1:247681781	NA	-0.45	-5.15	-0.32	5.48e-7	Platelet count;
SARC	cis	rs11098499	0.863	rs2306456	chr4:120472422	C/G	cg24375607	chr4:120327624	NA	0.42	4.92	0.31	1.64e-6	Corneal astigmatism;
SARC	trans	rs561341	1.000	rs8064843	chr17:30245744	A/G	cg20587970	chr11:113659929	NA	-0.99	-9.93	-0.55	1.36e-19	Hip circumference adjusted for BMI;
SARC	cis	rs11785400	0.793	rs4301430	chr8:143737416	A/G	cg10596483	chr8:143751796	JRK	0.55	7.05	0.42	2.04e-11	Schizophrenia;
SARC	cis	rs3733589	0.744	rs2240723	chr4:10021151	G/A	cg16430538	chr4:10459836	ZNF518B	0.64	5.0	0.31	1.13e-6	Renal overload gout;
SARC	cis	rs4076764	0.958	rs11590567	chr1:163396438	A/G	cg06092702	chr1:163392909	NA	-0.29	-4.75	-0.3	3.56e-6	Motion sickness;
SARC	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg24531977	chr5:56204891	C5orf35	0.61	5.7	0.35	3.67e-8	Initial pursuit acceleration;
SARC	cis	rs7621025	0.505	rs34613715	chr3:136455007	A/T	cg15507776	chr3:136538369	TMEM22	-0.99	-8.4	-0.48	4.53e-15	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
SARC	trans	rs6894249	1.000	rs6894249	chr5:131797547	A/G	cg03366574	chr7:2764599	NA	-0.46	-6.24	-0.38	2.04e-9	Asthma;
SARC	cis	rs2531992	0.702	rs1045475	chr16:4015316	A/G	cg07628416	chr16:4033297	ADCY9	-0.32	-5.05	-0.31	8.87e-7	Waist circumference;
SARC	cis	rs3105593	0.575	rs3098174	chr15:50778853	C/T	cg05456662	chr15:50716270	USP8	0.42	5.1	0.32	7.18e-7	QT interval;
SARC	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg17221315	chr6:27791827	HIST1H4J	0.46	4.92	0.31	1.62e-6	Cardiac Troponin-T levels;
SARC	cis	rs734999	0.545	rs28690427	chr1:2571823	A/G	cg20673091	chr1:2541236	MMEL1	-0.32	-4.91	-0.31	1.74e-6	Ulcerative colitis;
SARC	cis	rs477895	0.941	rs71456309	chr11:64108262	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.67	5.27	0.33	3.15e-7	Mean platelet volume;
SARC	cis	rs796364	0.951	rs281793	chr2:200847990	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.78	7.37	0.43	2.97e-12	Schizophrenia;
SARC	cis	rs2204008	0.527	rs1315367	chr12:38177487	G/T	cg26384229	chr12:38710491	ALG10B	-0.68	-8.82	-0.5	2.75e-16	Bladder cancer;
SARC	cis	rs4423214	0.959	rs11233747	chr11:71171642	G/A	cg05163923	chr11:71159392	DHCR7	0.64	8.94	0.51	1.25e-16	Vitamin D levels;
SARC	cis	rs635808	0.520	rs656938	chr6:167172048	C/T	cg09682183	chr6:167705253	UNC93A	0.24	4.72	0.3	4.13e-6	Dental caries;
SARC	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	13.84	0.67	3.51e-32	Chronic sinus infection;
SARC	cis	rs1113500	0.933	rs745795	chr1:108629345	C/T	cg06207961	chr1:108661230	NA	0.44	5.82	0.36	1.93e-8	Growth-regulated protein alpha levels;
SARC	cis	rs883565	0.655	rs4676670	chr3:39049594	A/C	cg01426195	chr3:39028469	NA	-0.36	-5.24	-0.32	3.54e-7	Handedness;
SARC	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg23172400	chr8:95962367	TP53INP1	-0.31	-5.36	-0.33	2.02e-7	Type 2 diabetes;
SARC	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg25036284	chr2:26402008	FAM59B	-0.44	-5.38	-0.33	1.79e-7	Gut microbiome composition (summer);
SARC	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg11987759	chr7:65425863	GUSB	-0.58	-7.96	-0.46	7.3e-14	Aortic root size;
SARC	cis	rs6942407	0.592	rs1859128	chr7:86752171	G/C	cg02420886	chr7:86849541	C7orf23	0.6	5.44	0.34	1.32e-7	Food allergy;
SARC	cis	rs2075671	0.903	rs62482252	chr7:100274063	C/A	cg20848291	chr7:100343083	ZAN	-0.71	-7.63	-0.45	5.85e-13	Other erythrocyte phenotypes;
SARC	cis	rs2227564	0.729	rs2675675	chr10:75649048	G/A	cg16540259	chr10:75572220	NDST2	0.35	4.94	0.31	1.49e-6	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs751728	0.664	rs4711347	chr6:33735292	G/A	cg15252951	chr6:33757062	LEMD2	0.4	4.74	0.3	3.68e-6	Crohn's disease;
SARC	cis	rs2292864	0.764	rs1969269	chr17:45335537	C/A	cg18085866	chr17:45331354	ITGB3	-0.79	-5.76	-0.35	2.58e-8	Left atrial antero-posterior diameter;
SARC	cis	rs6733011	0.600	rs1356424	chr2:99425838	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.39	-4.77	-0.3	3.31e-6	Bipolar disorder;
SARC	cis	rs7412746	0.611	rs3768018	chr1:150723747	T/C	cg15448220	chr1:150897856	SETDB1	0.48	6.09	0.37	4.55e-9	Melanoma;
SARC	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.72	-10.16	-0.55	2.69e-20	Age at first birth;
SARC	cis	rs7586879	0.598	rs6724772	chr2:25128730	T/C	cg04586622	chr2:25135609	ADCY3	0.31	5.29	0.33	2.8e-7	Body mass index;
SARC	cis	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg24110177	chr3:50126178	RBM5	0.38	4.87	0.3	2.11e-6	Intelligence (multi-trait analysis);
SARC	trans	rs1814175	0.626	rs1722008	chr11:49897676	A/T	cg15704280	chr7:45808275	SEPT13	-0.97	-18.21	-0.77	1.1e-46	Height;
SARC	cis	rs13082711	0.911	rs11708710	chr3:27457348	A/C	cg02860705	chr3:27208620	NA	0.46	6.02	0.37	6.7e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs4481887	0.772	rs4916127	chr1:248466615	A/G	cg01631408	chr1:248437212	OR2T33	-0.44	-5.66	-0.35	4.35e-8	Common traits (Other);
SARC	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg05872129	chr22:39784769	NA	0.4	5.71	0.35	3.35e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs2180341	0.960	rs9398840	chr6:127669744	G/A	cg17762328	chr6:126965162	NA	-0.44	-4.85	-0.3	2.22e-6	Breast cancer;
SARC	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg07343612	chr16:622815	PIGQ	-0.61	-8.65	-0.49	8.73e-16	Height;
SARC	cis	rs3087591	0.708	rs2525568	chr17:29675878	T/G	cg24425628	chr17:29625626	OMG;NF1	0.43	5.45	0.34	1.3e-7	Hip circumference;
SARC	cis	rs1707322	0.721	rs9793568	chr1:46130373	G/A	cg06784218	chr1:46089804	CCDC17	0.36	6.25	0.38	1.93e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs1814175	0.817	rs1818890	chr11:49856882	T/C	cg03929089	chr4:120376271	NA	-0.9	-15.01	-0.7	4.47e-36	Height;
SARC	cis	rs282587	0.502	rs393320	chr13:113396469	C/A	cg02820901	chr13:113351484	ATP11A	-0.53	-5.08	-0.32	7.67e-7	Glycated hemoglobin levels;
SARC	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs11630290	1.000	rs72750990	chr15:64005333	C/T	cg12036633	chr15:63758958	NA	-0.58	-5.56	-0.34	7.29e-8	Iris characteristics;
SARC	cis	rs7819412	0.540	rs11777355	chr8:11044689	A/G	cg21775007	chr8:11205619	TDH	-0.47	-5.92	-0.36	1.14e-8	Triglycerides;
SARC	cis	rs17376456	0.877	rs7702521	chr5:93484579	G/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.62	5.26	0.33	3.22e-7	Diabetic retinopathy;
SARC	cis	rs9400467	0.537	rs12210707	chr6:111538387	C/T	cg15721981	chr6:111408429	SLC16A10	0.68	5.72	0.35	3.24e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs11583043	0.575	rs56403901	chr1:101586047	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.45	4.98	0.31	1.26e-6	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs2273669	0.667	rs76267985	chr6:109326183	A/T	cg05315195	chr6:109294784	ARMC2	-0.56	-5.24	-0.32	3.51e-7	Prostate cancer;
SARC	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg07167872	chr1:205819463	PM20D1	-0.38	-4.88	-0.3	1.99e-6	Menarche (age at onset);
SARC	cis	rs9430161	0.611	rs12081197	chr1:11034239	T/C	cg27631724	chr1:11040367	C1orf127	0.33	4.71	0.3	4.2e-6	Ewing sarcoma;
SARC	cis	rs9329289	0.590	rs11251295	chr10:2563183	C/T	cg18171855	chr10:2543474	NA	0.38	5.31	0.33	2.54e-7	Age-related hearing impairment;
SARC	cis	rs13191362	1.000	rs66529337	chr6:163005662	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.57	5.51	0.34	9.61e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2115630	0.936	rs6496318	chr15:85215229	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.48	-5.72	-0.35	3.32e-8	P wave terminal force;
SARC	cis	rs1050631	0.564	rs1785910	chr18:33729871	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.59	7.25	0.43	6.16e-12	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs9314323	0.698	rs1064807	chr8:26236978	C/T	cg11498726	chr8:26250323	BNIP3L	-0.64	-8.4	-0.48	4.47e-15	Red cell distribution width;
SARC	cis	rs3785574	0.705	rs2665856	chr17:61982721	T/A	cg06420487	chr17:61919686	SMARCD2	-0.46	-4.96	-0.31	1.34e-6	Height;
SARC	cis	rs17376456	0.542	rs1982439	chr5:93160560	C/G	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.51	-5.14	-0.32	5.85e-7	Diabetic retinopathy;
SARC	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg22834771	chr12:69754056	YEATS4	-0.47	-6.3	-0.38	1.51e-9	Cerebrospinal fluid biomarker levels;
SARC	cis	rs910316	0.737	rs175510	chr14:75524839	G/A	cg08847533	chr14:75593920	NEK9	-0.85	-12.61	-0.64	3.81e-28	Height;
SARC	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg11843238	chr5:131593191	PDLIM4	0.38	5.38	0.33	1.82e-7	Breast cancer;
SARC	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.65	-0.4	2.1e-10	Menopause (age at onset);
SARC	cis	rs7827545	0.644	rs3739427	chr8:135524938	T/C	cg17885191	chr8:135476712	NA	-0.46	-5.2	-0.32	4.31e-7	Hypertension (SNP x SNP interaction);
SARC	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg04277193	chr17:41438351	NA	0.44	4.73	0.3	3.83e-6	Menopause (age at onset);
SARC	cis	rs13108904	0.604	rs13103860	chr4:1320120	G/A	cg13395646	chr4:1353034	KIAA1530	-0.59	-6.96	-0.41	3.43e-11	Obesity-related traits;
SARC	cis	rs73086581	0.947	rs17287577	chr20:3966254	C/T	cg02187196	chr20:3869020	PANK2	0.67	6.4	0.39	8.3e-10	Response to antidepressants in depression;
SARC	cis	rs2276314	0.947	rs4799831	chr18:33554775	A/G	cg05985134	chr18:33552581	C18orf21	0.71	7.65	0.45	5.4e-13	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg07308232	chr7:1071921	C7orf50	-0.64	-7.88	-0.46	1.24e-13	Longevity;Endometriosis;
SARC	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg13175981	chr1:150552382	MCL1	-0.54	-6.9	-0.41	4.97e-11	Tonsillectomy;
SARC	cis	rs826838	0.900	rs11169301	chr12:39128497	C/A	cg13010199	chr12:38710504	ALG10B	0.72	9.48	0.53	3.03e-18	Heart rate;
SARC	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg11987759	chr7:65425863	GUSB	0.59	7.75	0.45	2.87e-13	Aortic root size;
SARC	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg18404041	chr3:52824283	ITIH1	-0.35	-5.22	-0.32	3.91e-7	Electroencephalogram traits;
SARC	cis	rs7918232	0.830	rs7087033	chr10:27392522	A/G	cg14442939	chr10:27389572	ANKRD26	0.69	6.01	0.37	7.05e-9	Breast cancer;
SARC	cis	rs9473924	0.542	rs55648125	chr6:50816718	A/G	cg14470998	chr6:50812995	TFAP2B	0.67	5.53	0.34	8.45e-8	Body mass index;
SARC	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg24633833	chr3:10029261	TMEM111	0.5	4.89	0.3	1.9e-6	Alzheimer's disease;
SARC	cis	rs6088590	1.000	rs6120748	chr20:33458284	T/G	cg24642439	chr20:33292090	TP53INP2	0.77	10.19	0.56	2.05e-20	Coronary artery disease;
SARC	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg13866156	chr1:1669148	SLC35E2	0.54	7.83	0.46	1.69e-13	Body mass index;
SARC	cis	rs10463316	0.817	rs6897109	chr5:150777738	T/C	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.32	-0.33	2.46e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs1915919	0.794	rs12488378	chr3:20022495	C/G	cg05072819	chr3:20081367	KAT2B	0.45	5.24	0.32	3.6e-7	Post-traumatic stress disorder;
SARC	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg23758822	chr17:41437982	NA	0.9	11.33	0.6	5.44e-24	Menopause (age at onset);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg24512134	chr21:32490996	TIAM1	0.52	6.93	0.41	4.18e-11	Thyroid stimulating hormone;
SARC	cis	rs2197308	0.765	rs11182964	chr12:37935052	C/T	cg13010199	chr12:38710504	ALG10B	0.8	11.14	0.59	2.24e-23	Morning vs. evening chronotype;
SARC	cis	rs3771395	0.925	rs78178988	chr2:71128574	G/T	cg21294935	chr2:71128538	VAX2	0.66	5.42	0.33	1.46e-7	Corneal astigmatism;
SARC	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg15448220	chr1:150897856	SETDB1	0.47	6.03	0.37	6.37e-9	Melanoma;
SARC	cis	rs9394841	0.692	rs9381095	chr6:41806708	T/A	cg08135965	chr6:41755394	TOMM6	0.6	6.42	0.39	7.49e-10	Mean corpuscular hemoglobin;Red cell distribution width;
SARC	cis	rs11676348	0.783	rs4674252	chr2:218984478	G/A	cg00012203	chr2:219082015	ARPC2	-0.55	-7.32	-0.43	3.92e-12	Ulcerative colitis;
SARC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg07695089	chr8:142221192	SLC45A4	0.42	6.34	0.38	1.21e-9	HDL cholesterol;
SARC	cis	rs7590368	0.600	rs56143168	chr2:10916233	A/G	cg25617230	chr2:10952979	PDIA6	0.65	5.38	0.33	1.83e-7	Educational attainment (years of education);
SARC	cis	rs9341808	0.718	rs12208016	chr6:80823563	G/A	cg08355045	chr6:80787529	NA	0.34	5.5	0.34	1.02e-7	Sitting height ratio;
SARC	cis	rs12142240	0.698	rs72677592	chr1:46818288	A/G	cg10495392	chr1:46806563	NSUN4	0.65	6.88	0.41	5.33e-11	Menopause (age at onset);
SARC	cis	rs73242632	0.881	rs55734441	chr4:57833717	G/A	cg20415529	chr4:57845134	POLR2B;C4orf14	1.04	6.01	0.37	7.28e-9	Congenital heart disease (maternal effect);
SARC	cis	rs6991838	0.584	rs4275254	chr8:66501364	A/G	cg13398993	chr8:66546079	ARMC1	-0.6	-8.09	-0.47	3.35e-14	Intelligence (multi-trait analysis);
SARC	cis	rs80282103	0.764	rs12247779	chr10:1107957	T/G	cg08668510	chr10:1095578	IDI1	0.7	5.06	0.31	8.61e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg03517284	chr6:25882590	NA	-0.5	-6.48	-0.39	5.36e-10	Intelligence (multi-trait analysis);
SARC	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg26818010	chr10:134567672	INPP5A	-0.64	-6.65	-0.4	2.01e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs473651	0.935	rs482775	chr2:239335403	G/C	cg00800569	chr2:239229395	TRAF3IP1	0.42	5.07	0.32	7.98e-7	Multiple system atrophy;
SARC	cis	rs6696846	0.777	rs9651228	chr1:205049383	A/G	cg21643547	chr1:205240462	TMCC2	-0.49	-6.5	-0.39	4.72e-10	Red blood cell count;
SARC	cis	rs6089584	0.927	rs6089593	chr20:60572312	G/A	cg06108461	chr20:60628389	TAF4	-0.89	-11.77	-0.61	2.06e-25	Body mass index;
SARC	cis	rs698813	0.674	rs4953080	chr2:44500849	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.38	0.39	9.35e-10	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg20120463	chr17:44301886	NA	0.31	4.95	0.31	1.41e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs2718058	0.630	rs2722290	chr7:37820403	C/G	cg15028436	chr7:37888078	TXNDC3	0.4	5.11	0.32	6.79e-7	Alzheimer's disease (late onset);
SARC	cis	rs5769765	0.955	rs6520066	chr22:50294988	C/T	cg03033257	chr22:50311977	ALG12;CRELD2	0.52	5.46	0.34	1.2e-7	Schizophrenia;
SARC	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg12564285	chr5:131593104	PDLIM4	0.4	5.72	0.35	3.22e-8	Acylcarnitine levels;
SARC	cis	rs35110281	0.748	rs2838324	chr21:44999820	T/C	cg21573476	chr21:45109991	RRP1B	-0.52	-7.68	-0.45	4.39e-13	Mean corpuscular volume;
SARC	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg17971929	chr21:40555470	PSMG1	-0.56	-6.94	-0.41	3.93e-11	Menarche (age at onset);
SARC	cis	rs3204270	0.639	rs1126818	chr17:79617830	G/A	cg26965718	chr17:79658957	HGS	-0.62	-4.95	-0.31	1.43e-6	Dental caries;
SARC	cis	rs1003719	0.667	rs2835606	chr21:38490851	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.54	7.37	0.43	2.99e-12	Eye color traits;
SARC	cis	rs9486719	1.000	rs9400016	chr6:96940883	G/T	cg06623918	chr6:96969491	KIAA0776	-0.74	-8.03	-0.47	4.93e-14	Migraine;Coronary artery disease;
SARC	cis	rs950169	0.922	rs11630760	chr15:85113337	G/T	cg24253500	chr15:84953950	NA	0.37	5.34	0.33	2.24e-7	Schizophrenia;
SARC	cis	rs1865760	1.000	rs6910138	chr6:25904352	C/G	cg10373733	chr6:25993375	NA	0.42	5.05	0.31	8.91e-7	Height;
SARC	cis	rs10089	1.000	rs6595806	chr5:127499764	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.79	9.74	0.54	5.03e-19	Ileal carcinoids;
SARC	cis	rs6495122	0.501	rs7163636	chr15:75346760	C/T	cg17294928	chr15:75287854	SCAMP5	0.5	6.56	0.39	3.4e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	cis	rs765787	0.530	rs3759893	chr15:45542950	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.67e-7	Uric acid levels;
SARC	cis	rs17376456	0.825	rs10057130	chr5:93282557	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.82	0.36	1.92e-8	Diabetic retinopathy;
SARC	cis	rs2576037	0.901	rs2576036	chr18:44587102	G/T	cg19077165	chr18:44547161	KATNAL2	-0.49	-7.04	-0.42	2.17e-11	Personality dimensions;
SARC	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg11489262	chr17:43973426	MAPT;LOC100128977;LOC100130148	0.45	4.88	0.3	1.94e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs1348850	0.915	rs10930798	chr2:178446141	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.66	8.55	0.49	1.65e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs13256369	1.000	rs13282915	chr8:8570891	T/G	cg18904891	chr8:8559673	CLDN23	0.5	5.87	0.36	1.49e-8	Obesity-related traits;
SARC	cis	rs798554	0.686	rs2527690	chr7:2854250	C/T	cg04166393	chr7:2884313	GNA12	0.42	5.19	0.32	4.53e-7	Height;
SARC	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.31	-0.38	1.36e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7659604	0.846	rs60340409	chr4:122666355	G/C	cg20573242	chr4:122745356	CCNA2	0.44	5.66	0.35	4.33e-8	Type 2 diabetes;
SARC	cis	rs9914988	0.887	rs8078402	chr17:27145124	T/A	cg20469991	chr17:27169893	C17orf63	-0.52	-5.39	-0.33	1.74e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs2916247	1.000	rs6988317	chr8:93042221	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.59	-6.03	-0.37	6.24e-9	Intelligence (multi-trait analysis);
SARC	cis	rs6807306	1.000	rs6444552	chr3:167434075	A/G	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.51	4.94	0.31	1.52e-6	Mean platelet volume;
SARC	cis	rs10736390	0.640	rs10888858	chr1:55108978	A/G	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.34	-4.83	-0.3	2.53e-6	Survival in pancreatic cancer;
SARC	cis	rs6088590	0.561	rs6059934	chr20:33178324	G/T	cg24642439	chr20:33292090	TP53INP2	0.66	8.51	0.49	2.12e-15	Coronary artery disease;
SARC	cis	rs55871839	0.708	rs10093993	chr8:59811454	T/C	cg07426533	chr8:59803705	TOX	-0.43	-5.77	-0.35	2.51e-8	Pneumonia;
SARC	cis	rs3733585	0.736	rs4543113	chr4:10008305	G/A	cg00071950	chr4:10020882	SLC2A9	0.36	5.45	0.34	1.28e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg27170947	chr2:26402098	FAM59B	0.37	4.8	0.3	2.79e-6	Gut microbiome composition (summer);
SARC	cis	rs9379945	1	rs9379945	chr6:26907831	T/C	cg12826209	chr6:26865740	GUSBL1	0.86	5.83	0.36	1.85e-8	Intelligence (multi-trait analysis);
SARC	cis	rs1707322	1.000	rs6693336	chr1:46354595	C/T	cg03146154	chr1:46216737	IPP	0.47	5.69	0.35	3.76e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs62344088	0.590	rs6889904	chr5:177264	A/C	cg20965017	chr5:231967	SDHA	-0.75	-5.87	-0.36	1.48e-8	Asthma (childhood onset);
SARC	cis	rs2204008	0.521	rs7311188	chr12:38542813	C/G	cg13010199	chr12:38710504	ALG10B	-0.48	-5.97	-0.36	8.56e-9	Bladder cancer;
SARC	cis	rs12956009	0.518	rs10163861	chr18:44820214	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.57	7.64	0.45	5.58e-13	Educational attainment (years of education);
SARC	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg22307029	chr19:49891270	CCDC155	0.63	7.57	0.44	8.54e-13	Multiple sclerosis;
SARC	cis	rs1348850	0.645	rs11889272	chr2:178432378	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.67	6.81	0.41	8.33e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs36051895	0.575	rs7035251	chr9:5133665	T/A	cg02405213	chr9:5042618	JAK2	-0.45	-5.45	-0.34	1.29e-7	Pediatric autoimmune diseases;
SARC	cis	rs11249608	0.548	rs34054398	chr5:178458371	A/G	cg21905437	chr5:178450457	ZNF879	0.56	7.45	0.44	1.82e-12	Pubertal anthropometrics;
SARC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg18404041	chr3:52824283	ITIH1	-0.33	-5.01	-0.31	1.09e-6	Electroencephalogram traits;
SARC	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg11764359	chr7:65958608	NA	-0.87	-12.67	-0.64	2.52e-28	Aortic root size;
SARC	cis	rs1153858	0.895	rs12593402	chr15:45617392	G/A	cg03999130	chr15:45571217	NA	0.4	5.07	0.32	8.23e-7	Homoarginine levels;
SARC	cis	rs4722166	0.508	rs1474348	chr7:22767908	C/G	cg26061582	chr7:22766209	IL6	0.59	6.76	0.4	1.11e-10	Lung cancer;
SARC	cis	rs5743618	0.537	rs11096957	chr4:38776491	A/C	cg06935464	chr4:38784597	TLR10	0.42	5.44	0.34	1.33e-7	Asthma;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs12579753	1.000	rs7975863	chr12:82227288	C/T	cg07988820	chr12:82153109	PPFIA2	-0.52	-6.07	-0.37	5.24e-9	Resting heart rate;
SARC	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg07701084	chr6:150067640	NUP43	0.41	5.29	0.33	2.81e-7	Lung cancer;
SARC	cis	rs7772486	0.682	rs1337840	chr6:146042558	T/C	cg05347473	chr6:146136440	FBXO30	-0.49	-6.55	-0.39	3.64e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs35079168	0.735	rs3118540	chr9:137307106	C/T	cg00753924	chr9:137298813	RXRA	-0.39	-4.82	-0.3	2.59e-6	Intelligence;
SARC	cis	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg22496380	chr5:211416	CCDC127	-0.86	-8.95	-0.51	1.15e-16	Breast cancer;
SARC	cis	rs7621025	0.554	rs1471740	chr3:136328270	T/C	cg15507776	chr3:136538369	TMEM22	0.46	4.93	0.31	1.57e-6	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
SARC	trans	rs10209086	0.736	rs1584436	chr2:138298878	A/G	cg12390588	chr17:44702619	NSF	0.45	6.35	0.38	1.1e-9	Multiple system atrophy;
SARC	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg20607798	chr8:58055168	NA	0.66	5.71	0.35	3.48e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2425143	1.000	rs1056196	chr20:34327159	T/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	5.11	0.32	6.74e-7	Blood protein levels;
SARC	cis	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg08045932	chr20:61659980	NA	0.5	6.84	0.41	7.06e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs8044868	0.530	rs2287998	chr16:72059269	C/T	cg01557791	chr16:72042693	DHODH	0.37	4.73	0.3	3.93e-6	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
SARC	cis	rs2576037	0.796	rs2571018	chr18:44585344	T/A	cg19077165	chr18:44547161	KATNAL2	0.45	6.25	0.38	1.92e-9	Personality dimensions;
SARC	cis	rs12079745	0.793	rs12071630	chr1:169421023	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.87	-5.15	-0.32	5.55e-7	QT interval;
SARC	cis	rs3772130	0.564	rs28620947	chr3:121585631	G/A	cg20356878	chr3:121714668	ILDR1	0.4	6.3	0.38	1.46e-9	Cognitive performance;
SARC	cis	rs7937682	0.921	rs1944119	chr11:111436387	A/G	cg22437258	chr11:111473054	SIK2	-0.68	-9.05	-0.51	5.92e-17	Primary sclerosing cholangitis;
SARC	cis	rs12200560	0.505	rs1988040	chr6:97076271	G/A	cg06623918	chr6:96969491	KIAA0776	0.46	5.29	0.33	2.82e-7	Coronary heart disease;
SARC	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg12463550	chr7:65579703	CRCP	0.66	5.06	0.31	8.64e-7	Diabetic kidney disease;
SARC	cis	rs6901004	0.803	rs1040903	chr6:111470153	A/C	cg15721981	chr6:111408429	SLC16A10	-0.44	-5.49	-0.34	1.05e-7	Blood metabolite levels;
SARC	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg18357526	chr6:26021779	HIST1H4A	0.45	5.65	0.35	4.58e-8	Blood metabolite levels;
SARC	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg00149659	chr3:10157352	C3orf10	0.69	6.9	0.41	4.76e-11	Alzheimer's disease;
SARC	cis	rs832540	0.519	rs10039338	chr5:56260363	C/T	cg14703610	chr5:56206110	C5orf35	-0.49	-5.94	-0.36	1.01e-8	Coronary artery disease;
SARC	cis	rs9916302	0.660	rs4795379	chr17:37674683	T/G	cg00129232	chr17:37814104	STARD3	-0.58	-6.16	-0.37	3.21e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs12348691	0.503	rs10983975	chr9:100614188	A/C	cg13688889	chr9:100608707	NA	-0.47	-5.0	-0.31	1.15e-6	Alopecia areata;
SARC	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.43	0.44	1.99e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg15993834	chr1:222791051	MIA3	-0.48	-6.61	-0.4	2.54e-10	Breast cancer;
SARC	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	11.4	0.6	3.34e-24	Alzheimer's disease;
SARC	cis	rs1957429	0.808	rs763346	chr14:65330386	A/G	cg23373153	chr14:65346875	NA	-0.88	-9.23	-0.52	1.68e-17	Pediatric areal bone mineral density (radius);
SARC	cis	rs453301	0.598	rs10104303	chr8:8834528	A/T	cg06636001	chr8:8085503	FLJ10661	0.48	6.47	0.39	5.58e-10	Joint mobility (Beighton score);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg17101553	chr19:58790125	ZNF8	-0.76	-6.28	-0.38	1.68e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7247513	0.797	rs3815914	chr19:12760664	T/C	cg01871581	chr19:12707946	ZNF490	-0.72	-9.43	-0.53	4.33e-18	Bipolar disorder;
SARC	cis	rs12908161	1.000	rs17600551	chr15:85319258	A/G	cg17507749	chr15:85114479	UBE2QP1	0.54	6.2	0.38	2.61e-9	Schizophrenia;
SARC	cis	rs34172651	0.917	rs2343606	chr16:24793741	C/T	cg00152838	chr16:24741724	TNRC6A	-0.5	-6.12	-0.37	3.88e-9	Intelligence (multi-trait analysis);
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg07157506	chr18:12883603	PTPN2	0.54	6.87	0.41	5.64e-11	Lung adenocarcinoma;
SARC	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg06212747	chr3:49208901	KLHDC8B	0.64	8.59	0.49	1.3e-15	Parkinson's disease;
SARC	cis	rs1046896	0.553	rs2292965	chr17:80900645	G/A	cg02711726	chr17:80685570	FN3KRP	-0.56	-6.88	-0.41	5.47e-11	Glycated hemoglobin levels;
SARC	cis	rs3733585	0.699	rs7677710	chr4:9969517	T/G	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.65	-0.35	4.69e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs1865760	0.713	rs7766342	chr6:25990674	C/A	cg10373733	chr6:25993375	NA	0.46	5.95	0.36	9.84e-9	Height;
SARC	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	8.89	0.5	1.76e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs644148	0.803	rs2686771	chr19:44999494	T/C	cg15540054	chr19:45004280	ZNF180	-0.45	-5.09	-0.32	7.24e-7	Personality dimensions;
SARC	cis	rs3540	0.576	rs12907587	chr15:91045851	G/C	cg22089800	chr15:90895588	ZNF774	-0.59	-7.63	-0.45	5.79e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs7635838	0.650	rs1375206	chr3:11339117	C/G	cg00170343	chr3:11313890	ATG7	0.62	8.46	0.48	3.07e-15	HDL cholesterol;
SARC	cis	rs1692580	0.870	rs263532	chr1:2164116	T/C	cg21442419	chr1:2182373	SKI	-0.7	-11.32	-0.6	5.75e-24	Coronary artery disease;
SARC	cis	rs3858526	0.920	rs10742832	chr11:5926020	C/G	cg13902645	chr11:5959945	NA	-0.44	-5.1	-0.32	7.04e-7	DNA methylation (variation);
SARC	cis	rs4319547	0.956	rs9988963	chr12:122991478	C/G	cg23029597	chr12:123009494	RSRC2	-0.43	-5.52	-0.34	8.79e-8	Body mass index;
SARC	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg16680214	chr1:154839983	KCNN3	-0.36	-5.69	-0.35	3.7e-8	Prostate cancer;
SARC	cis	rs10771431	0.817	rs17202253	chr12:9361850	A/G	cg08997352	chr12:9597637	DDX12	-0.64	-9.35	-0.52	7.44e-18	Breast size;
SARC	cis	rs3126085	0.935	rs3126046	chr1:152256925	G/A	cg26876637	chr1:152193138	HRNR	-0.46	-5.29	-0.33	2.86e-7	Atopic dermatitis;
SARC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg24829409	chr8:58192753	C8orf71	-0.6	-5.08	-0.32	7.82e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg24531977	chr5:56204891	C5orf35	-0.54	-5.51	-0.34	9.41e-8	Initial pursuit acceleration;
SARC	cis	rs911555	0.511	rs8007489	chr14:104054572	A/G	cg24130564	chr14:104152367	KLC1	0.61	8.5	0.49	2.23e-15	Intelligence (multi-trait analysis);
SARC	cis	rs6088813	0.767	rs4911179	chr20:33972899	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	-0.43	-5.24	-0.32	3.67e-7	Height;
SARC	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg05863683	chr7:1912471	MAD1L1	0.33	4.76	0.3	3.36e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.32	-4.81	-0.3	2.69e-6	Total body bone mineral density;
SARC	cis	rs8067354	0.830	rs57510610	chr17:57889406	T/A	cg02344993	chr17:57696989	CLTC	0.43	4.94	0.31	1.5e-6	Hemoglobin concentration;
SARC	cis	rs7312933	0.558	rs1669936	chr12:42813509	C/A	cg19980929	chr12:42632907	YAF2	-0.44	-6.52	-0.39	4.35e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs7714584	0.793	rs35707106	chr5:150225377	G/A	cg22134413	chr5:150180641	NA	0.78	6.56	0.39	3.42e-10	Crohn's disease;
SARC	cis	rs10875746	0.624	rs10875777	chr12:48622071	T/C	cg26205652	chr12:48591994	NA	0.46	4.97	0.31	1.3e-6	Longevity (90 years and older);
SARC	trans	rs3780486	0.801	rs10971424	chr9:33138775	T/C	cg20290983	chr6:43655470	MRPS18A	1.14	22.57	0.83	1.44e-60	IgG glycosylation;
SARC	trans	rs61931739	0.500	rs6488224	chr12:34537205	T/C	cg26384229	chr12:38710491	ALG10B	0.85	12.63	0.64	3.4e-28	Morning vs. evening chronotype;
SARC	cis	rs7412746	0.563	rs3768013	chr1:150815411	G/A	cg15448220	chr1:150897856	SETDB1	0.5	6.61	0.4	2.61e-10	Melanoma;
SARC	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg02524346	chr8:600233	NA	0.98	7.35	0.43	3.3e-12	IgG glycosylation;
SARC	cis	rs924840	0.634	rs2869030	chr15:78711803	A/C	cg24631222	chr15:78858424	CHRNA5	0.55	6.77	0.41	1.04e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
SARC	cis	rs7772486	0.790	rs9403749	chr6:146162239	A/G	cg05347473	chr6:146136440	FBXO30	0.56	7.8	0.45	2.1e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2153535	0.580	rs5001130	chr6:8442298	G/A	cg23788917	chr6:8435910	SLC35B3	0.64	8.19	0.47	1.77e-14	Motion sickness;
SARC	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg08280861	chr8:58055591	NA	0.65	5.53	0.34	8.55e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs11676348	0.751	rs6715591	chr2:219019871	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.43	-5.61	-0.34	5.85e-8	Ulcerative colitis;
SARC	cis	rs10504229	0.724	rs72649117	chr8:58037639	A/G	cg11062466	chr8:58055876	NA	0.49	4.88	0.3	1.95e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs56235845	0.694	rs6875461	chr5:176754665	C/T	cg16006841	chr5:176797999	RGS14	-0.52	-7.05	-0.42	2.03e-11	Hemoglobin concentration;Hematocrit;
SARC	cis	rs796364	0.587	rs7588746	chr2:200986345	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.48	4.76	0.3	3.48e-6	Schizophrenia;
SARC	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg20607798	chr8:58055168	NA	-0.63	-5.38	-0.33	1.83e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2974760	0.606	rs2858918	chr16:201183	T/C	cg08400316	chr16:204221	HBZ	0.86	11.32	0.6	6.04e-24	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-6.35	-0.38	1.14e-9	Personality dimensions;
SARC	cis	rs9399137	0.507	rs11753673	chr6:135316476	T/C	cg22676075	chr6:135203613	NA	0.38	4.84	0.3	2.32e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs7940866	0.774	rs7480903	chr11:130832276	A/G	cg12179176	chr11:130786555	SNX19	0.69	9.66	0.53	9.06e-19	Schizophrenia;
SARC	cis	rs1580019	0.587	rs34488151	chr7:32548146	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.98	17.41	0.75	4.7e-44	Cognitive ability;
SARC	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg12463550	chr7:65579703	CRCP	-0.49	-5.32	-0.33	2.4e-7	Aortic root size;
SARC	cis	rs7106204	0.764	rs79362440	chr11:24212972	G/A	ch.11.24196551F	chr11:24239977	NA	0.71	6.63	0.4	2.37e-10	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.98	11.32	0.6	5.83e-24	Platelet count;
SARC	trans	rs1994135	0.715	rs10506110	chr12:33708552	A/C	cg13010199	chr12:38710504	ALG10B	0.72	8.66	0.49	7.81e-16	Resting heart rate;
SARC	cis	rs12239736	0.527	rs6657622	chr1:63214530	T/A	cg06896770	chr1:63153194	DOCK7	0.5	4.88	0.3	2e-6	Cholesterol, total;
SARC	cis	rs2153535	0.580	rs7341383	chr6:8470634	A/C	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	cis	rs1448094	0.706	rs10863149	chr12:86425498	A/T	cg02569458	chr12:86230093	RASSF9	0.41	5.84	0.36	1.71e-8	Major depressive disorder;
SARC	cis	rs2760061	0.717	rs708117	chr1:228199902	G/A	cg02753203	chr1:228287806	NA	0.57	7.84	0.46	1.63e-13	Diastolic blood pressure;
SARC	cis	rs2486288	0.656	rs7162022	chr15:45565253	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.5	-6.17	-0.37	3.02e-9	Glomerular filtration rate;
SARC	cis	rs9788721	0.836	rs17484235	chr15:78761414	C/G	cg18825076	chr15:78729989	IREB2	-0.53	-6.41	-0.39	7.93e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs4711336	0.527	rs28651968	chr6:33717424	T/C	cg15676125	chr6:33679581	C6orf125	0.58	7.13	0.42	1.22e-11	Height;
SARC	cis	rs7223966	0.729	rs9902761	chr17:62010627	A/G	cg00588841	chr17:61851480	DDX42;CCDC47	-0.64	-6.52	-0.39	4.34e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs854765	0.583	rs62064158	chr17:17826935	T/C	cg05444541	chr17:17804740	TOM1L2	-0.29	-4.98	-0.31	1.22e-6	Total body bone mineral density;
SARC	cis	rs9467773	1.000	rs9467791	chr6:26562486	A/G	cg12292205	chr6:26970375	C6orf41	-0.46	-5.61	-0.34	5.83e-8	Intelligence (multi-trait analysis);
SARC	cis	rs854765	0.534	rs7207461	chr17:17949789	T/G	cg05444541	chr17:17804740	TOM1L2	0.3	4.89	0.31	1.85e-6	Total body bone mineral density;
SARC	cis	rs9818758	0.545	rs55921200	chr3:49189316	T/C	cg07636037	chr3:49044803	WDR6	-0.69	-5.4	-0.33	1.65e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs459571	0.635	rs379471	chr9:136890649	G/A	cg13789015	chr9:136890014	NCRNA00094	0.62	8.71	0.5	5.71e-16	Platelet distribution width;
SARC	cis	rs713477	0.967	rs12887653	chr14:55911030	T/A	cg13175173	chr14:55914753	NA	-0.3	-4.75	-0.3	3.63e-6	Pediatric bone mineral content (femoral neck);
SARC	cis	rs10979	0.597	rs9399449	chr6:143908376	C/T	cg25407410	chr6:143891975	LOC285740	-0.51	-5.82	-0.36	1.91e-8	Hypospadias;
SARC	cis	rs453301	0.686	rs2409120	chr8:8882571	G/C	cg06636001	chr8:8085503	FLJ10661	-0.6	-8.18	-0.47	1.88e-14	Joint mobility (Beighton score);
SARC	cis	rs796364	0.951	rs281769	chr2:200809709	T/C	cg23649088	chr2:200775458	C2orf69	0.64	6.06	0.37	5.52e-9	Schizophrenia;
SARC	cis	rs1865760	0.663	rs9467656	chr6:25993559	G/A	cg10373733	chr6:25993375	NA	0.46	5.97	0.36	8.83e-9	Height;
SARC	cis	rs72781680	0.821	rs72796369	chr2:24162663	G/T	cg06627628	chr2:24431161	ITSN2	-0.57	-5.91	-0.36	1.21e-8	Lymphocyte counts;
SARC	cis	rs2304069	0.826	rs2244195	chr5:149403528	C/A	cg12661370	chr5:149340060	SLC26A2	0.62	6.3	0.38	1.46e-9	HIV-1 control;
SARC	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg24549020	chr5:56110836	MAP3K1	0.79	8.36	0.48	5.88e-15	Initial pursuit acceleration;
SARC	cis	rs17376456	0.877	rs13185660	chr5:93336500	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.49	0.34	1.06e-7	Diabetic retinopathy;
SARC	cis	rs8014204	0.566	rs752857	chr14:75130944	C/T	cg17347104	chr14:75034677	LTBP2	-0.51	-6.79	-0.41	9.18e-11	Caffeine consumption;
SARC	cis	rs13144136	0.687	rs7677121	chr4:10654107	G/T	cg10242279	chr4:10666415	CLNK	-0.42	-6.82	-0.41	7.86e-11	Resistance to antihypertensive treatment in hypertension;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg03745386	chr12:29534188	ERGIC2	0.49	6.29	0.38	1.55e-9	Electrocardiographic conduction measures;
SARC	cis	rs9300255	0.596	rs1727331	chr12:123718879	C/G	cg05973401	chr12:123451056	ABCB9	-0.54	-6.13	-0.37	3.67e-9	Neutrophil percentage of white cells;
SARC	cis	rs752010	0.905	rs10890150	chr1:42095603	A/C	cg06885757	chr1:42089581	HIVEP3	0.46	7.26	0.43	5.9e-12	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs9393692	0.902	rs6456711	chr6:26302572	A/C	cg13736514	chr6:26305472	NA	-0.7	-9.49	-0.53	2.83e-18	Educational attainment;
SARC	cis	rs10140922	0.966	rs10083375	chr14:35823531	C/T	cg26967526	chr14:35346199	BAZ1A	-0.4	-5.01	-0.31	1.09e-6	Hip circumference adjusted for BMI;
SARC	cis	rs2070488	0.775	rs2300669	chr3:38541318	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.74	-10.66	-0.57	6.99e-22	Electrocardiographic conduction measures;
SARC	cis	rs826838	0.967	rs1719853	chr12:39128515	A/G	cg13010199	chr12:38710504	ALG10B	-0.63	-8.68	-0.49	6.88e-16	Heart rate;
SARC	cis	rs858239	0.539	rs10270695	chr7:23188988	C/T	cg23682824	chr7:23144976	KLHL7	-0.64	-7.94	-0.46	8.42e-14	Cerebrospinal fluid biomarker levels;
SARC	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg16606324	chr3:10149918	C3orf24	0.48	5.04	0.31	9.53e-7	Alzheimer's disease;
SARC	cis	rs10992471	0.756	rs10992319	chr9:95127895	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-6.69	-0.4	1.67e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg00339695	chr16:24857497	SLC5A11	0.42	5.92	0.36	1.14e-8	Intelligence (multi-trait analysis);
SARC	cis	rs6089584	1.000	rs6089584	chr20:60564086	G/C	cg06108461	chr20:60628389	TAF4	-0.9	-11.82	-0.61	1.45e-25	Body mass index;
SARC	cis	rs1062177	0.756	rs2964587	chr5:151119972	C/T	cg00977110	chr5:151150581	G3BP1	-0.55	-5.53	-0.34	8.58e-8	Preschool internalizing problems;
SARC	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg05861140	chr6:150128134	PCMT1	-0.38	-4.91	-0.31	1.7e-6	Lung cancer;
SARC	cis	rs11581859	0.613	rs66523281	chr1:99198845	C/T	cg20286094	chr1:99190917	SNX7	-0.42	-4.99	-0.31	1.2e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs943466	0.513	rs755497	chr6:33734419	C/T	cg25922239	chr6:33757077	LEMD2	-0.44	-5.24	-0.32	3.65e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
SARC	cis	rs9309473	0.687	rs6747145	chr2:73609177	C/T	cg20560298	chr2:73613845	ALMS1	-0.52	-6.89	-0.41	5.2e-11	Metabolite levels;
SARC	cis	rs523522	0.962	rs9040	chr12:120900274	C/T	cg12219531	chr12:120966889	COQ5	0.82	10.5	0.57	2.21e-21	High light scatter reticulocyte count;
SARC	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg13770153	chr20:60521292	NA	-0.47	-6.4	-0.39	8.26e-10	Body mass index;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg02602699	chr17:235235	NA	0.46	6.38	0.39	9.71e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs12960472	0.666	rs8095331	chr18:52243913	G/A	cg04730925	chr18:51795821	POLI	-0.45	-4.75	-0.3	3.48e-6	Positive affect;
SARC	cis	rs7833986	1.000	rs66553445	chr8:57096781	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.6	5.33	0.33	2.36e-7	Height;
SARC	cis	rs4148883	0.737	rs13148577	chr4:100060836	G/A	cg12011299	chr4:100065546	ADH4	0.4	7.5	0.44	1.34e-12	Alcohol dependence;
SARC	cis	rs7412746	0.634	rs4451553	chr1:150937329	C/T	cg13175981	chr1:150552382	MCL1	-0.45	-5.19	-0.32	4.47e-7	Melanoma;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg08232264	chr8:79578116	FAM164A	0.6	6.33	0.38	1.22e-9	Lung cancer in ever smokers;
SARC	cis	rs7827545	0.644	rs7386524	chr8:135534005	T/C	cg17885191	chr8:135476712	NA	-0.45	-5.05	-0.31	8.81e-7	Hypertension (SNP x SNP interaction);
SARC	cis	rs6840360	0.638	rs2406974	chr4:152601841	G/A	cg22705602	chr4:152727874	NA	-0.47	-8.02	-0.46	5.29e-14	Intelligence (multi-trait analysis);
SARC	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg06212747	chr3:49208901	KLHDC8B	0.69	9.45	0.53	3.68e-18	Parkinson's disease;
SARC	trans	rs11088226	0.681	rs2833926	chr21:33975279	A/G	cg09050820	chr6:167586206	TCP10L2	0.62	6.93	0.41	4.04e-11	Gastritis;
SARC	cis	rs765787	0.530	rs2668751	chr15:45517293	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.44	-5.43	-0.34	1.42e-7	Uric acid levels;
SARC	cis	rs6582630	0.548	rs8189608	chr12:38327775	T/G	cg26384229	chr12:38710491	ALG10B	-0.59	-7.22	-0.43	7.27e-12	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg24250549	chr1:154909240	PMVK	0.82	11.83	0.61	1.3e-25	Prostate cancer;
SARC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg24101359	chr6:42928495	GNMT	0.42	5.69	0.35	3.72e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg02725872	chr8:58115012	NA	-0.34	-5.37	-0.33	1.91e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs910316	1.000	rs175436	chr14:75608683	C/G	cg11812906	chr14:75593930	NEK9	-0.84	-12.33	-0.63	3.3e-27	Height;
SARC	cis	rs7927771	1.000	rs12363232	chr11:47623890	C/T	cg20307385	chr11:47447363	PSMC3	-0.52	-6.36	-0.38	1.03e-9	Subjective well-being;
SARC	cis	rs2153535	0.580	rs9393025	chr6:8490618	G/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.45	0.6	2.26e-24	Motion sickness;
SARC	cis	rs13256369	0.756	rs13282580	chr8:8562903	C/T	cg17143192	chr8:8559678	CLDN23	0.52	5.84	0.36	1.77e-8	Obesity-related traits;
SARC	cis	rs1904096	0.506	rs6841121	chr4:95222995	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.5	-7.45	-0.44	1.81e-12	Type 2 diabetes;
SARC	cis	rs9814567	1.000	rs1534026	chr3:134284767	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.04	-0.42	2.19e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs3820928	0.874	rs13430941	chr2:227904447	G/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-6.44	-0.39	6.84e-10	Pulmonary function;
SARC	cis	rs9341808	0.754	rs9343973	chr6:80913216	A/G	cg08355045	chr6:80787529	NA	0.33	5.32	0.33	2.45e-7	Sitting height ratio;
SARC	cis	rs17384381	1.000	rs12758768	chr1:85835206	C/T	cg16011679	chr1:85725395	C1orf52	0.65	5.93	0.36	1.1e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs950776	0.518	rs56007453	chr15:78826239	T/C	cg22563815	chr15:78856949	CHRNA5	0.41	6.82	0.41	7.56e-11	Sudden cardiac arrest;
SARC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg26338869	chr17:61819248	STRADA	0.77	10.1	0.55	3.96e-20	Prudent dietary pattern;
SARC	cis	rs992157	0.710	rs6752254	chr2:219058743	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.64	8.97	0.51	1.03e-16	Colorectal cancer;
SARC	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg18252515	chr7:66147081	NA	-1.33	-11.84	-0.61	1.22e-25	Diabetic kidney disease;
SARC	cis	rs7772486	0.790	rs2247206	chr6:146216184	C/T	cg05347473	chr6:146136440	FBXO30	0.47	6.41	0.39	7.77e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1215050	0.791	rs260893	chr4:98744785	A/C	cg05340658	chr4:99064831	C4orf37	0.44	5.85	0.36	1.62e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs883565	0.502	rs4374473	chr3:38942618	C/T	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.43	-5.13	-0.32	5.98e-7	Handedness;
SARC	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg00990874	chr7:1149470	C7orf50	-0.53	-5.71	-0.35	3.43e-8	Bronchopulmonary dysplasia;
SARC	cis	rs11599315	0.507	rs12220554	chr10:1341852	C/T	cg01270228	chr10:1369114	ADARB2	0.32	5.23	0.32	3.73e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs10492096	0.947	rs10849484	chr12:6637941	C/T	cg13857086	chr12:6580257	VAMP1	0.68	6.8	0.41	8.64e-11	Hip geometry;
SARC	cis	rs4774830	0.744	rs77377502	chr15:56307889	A/G	cg24530489	chr15:56299380	NA	-0.93	-4.87	-0.3	2.1e-6	Delta-5 desaturase activity;
SARC	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg26681399	chr22:41777847	TEF	0.48	5.24	0.32	3.63e-7	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs73206853	0.764	rs73206878	chr12:110835015	A/C	cg08946844	chr12:110511112	NA	0.61	4.73	0.3	3.82e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	trans	rs4883201	0.656	rs4883203	chr12:9111797	A/G	cg24352934	chr17:1053717	ABR	0.56	6.26	0.38	1.79e-9	Cholesterol, total;Total cholesterol levels;
SARC	cis	rs7224737	1.000	rs8074708	chr17:40286354	A/G	cg20291162	chr17:40259547	DHX58	0.32	4.78	0.3	3.06e-6	Fibrinogen levels;
SARC	cis	rs6991838	0.584	rs4637885	chr8:66497084	T/C	cg13398993	chr8:66546079	ARMC1	-0.62	-8.31	-0.48	7.89e-15	Intelligence (multi-trait analysis);
SARC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg03647317	chr4:187891568	NA	-0.35	-4.97	-0.31	1.27e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.65	-6.44	-0.39	6.6e-10	Platelet count;
SARC	cis	rs17666538	1.000	rs57255985	chr8:574131	C/T	cg07234876	chr8:600039	NA	-0.95	-6.72	-0.4	1.38e-10	IgG glycosylation;
SARC	cis	rs3733585	0.806	rs11723382	chr4:9954660	T/C	cg00071950	chr4:10020882	SLC2A9	-0.4	-6.4	-0.39	8.26e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg26874164	chr19:58962979	ZNF324B	0.46	6.01	0.37	7.04e-9	Uric acid clearance;
SARC	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg19077165	chr18:44547161	KATNAL2	-0.52	-7.29	-0.43	4.74e-12	Personality dimensions;
SARC	cis	rs995000	0.899	rs6696502	chr1:63039533	C/T	cg06896770	chr1:63153194	DOCK7	-0.9	-13.26	-0.66	2.87e-30	Triglyceride levels;
SARC	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.5	0.39	4.96e-10	Bipolar disorder;
SARC	cis	rs7000551	0.532	rs4872486	chr8:22256359	G/T	cg12081754	chr8:22256438	SLC39A14	0.8	11.61	0.61	6.83e-25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	trans	rs3779273	0.965	rs3779274	chr7:77828739	G/A	cg05596911	chr5:118502651	DMXL1	0.52	6.66	0.4	1.95e-10	Body mass index;
SARC	cis	rs10489202	0.686	rs12754453	chr1:167844896	A/T	cg24449463	chr1:168025552	DCAF6	-0.65	-5.71	-0.35	3.38e-8	Schizophrenia;
SARC	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.01	-17.36	-0.75	6.9e-44	Chronic sinus infection;
SARC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.63	-0.4	2.28e-10	Total body bone mineral density;
SARC	cis	rs8067354	0.645	rs2645486	chr17:57885901	T/A	cg13753209	chr17:57696993	CLTC	0.66	7.23	0.43	6.94e-12	Hemoglobin concentration;
SARC	cis	rs35110281	0.627	rs56369437	chr21:44970275	A/G	cg21573476	chr21:45109991	RRP1B	-0.39	-5.49	-0.34	1.07e-7	Mean corpuscular volume;
SARC	cis	rs9660992	0.736	rs72745207	chr1:205251991	C/G	cg21643547	chr1:205240462	TMCC2	-0.63	-8.04	-0.47	4.47e-14	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg11987759	chr7:65425863	GUSB	0.51	6.83	0.41	7.2e-11	Aortic root size;
SARC	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.38	-4.94	-0.31	1.52e-6	Intelligence (multi-trait analysis);
SARC	cis	rs706293	0.659	rs706292	chr5:14764442	A/G	cg03872649	chr5:14012034	NA	0.45	5.02	0.31	1e-6	Urate levels (BMI interaction);
SARC	cis	rs820218	0.787	rs1093995	chr17:73614914	T/C	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.5	6.14	0.37	3.44e-9	Rotator cuff tears;
SARC	cis	rs10465746	0.740	rs1536165	chr1:84465073	C/A	cg04407776	chr1:84465009	TTLL7	-0.4	-4.73	-0.3	3.82e-6	Obesity-related traits;
SARC	cis	rs7223966	1.000	rs7217982	chr17:61832150	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.53	-5.55	-0.34	7.64e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg05368731	chr17:41323189	NBR1	0.66	7.91	0.46	1.05e-13	Menopause (age at onset);
SARC	cis	rs1008375	0.932	rs6449321	chr4:17644472	A/G	cg02297831	chr4:17616191	MED28	0.5	6.52	0.39	4.41e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs201779	1.000	rs200221	chr13:50960177	A/G	cg02621481	chr13:50931836	NA	-0.51	-5.0	-0.31	1.12e-6	Left atrial antero-posterior diameter;
SARC	cis	rs10849893	0.595	rs10444490	chr12:121876385	G/C	cg01154721	chr12:121881891	KDM2B	-0.36	-5.07	-0.32	8.12e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs7659604	1.000	rs6814995	chr4:122664963	A/T	cg19748678	chr4:122722346	EXOSC9	-0.45	-5.62	-0.35	5.29e-8	Type 2 diabetes;
SARC	cis	rs1943345	0.556	rs665714	chr11:82911261	A/C	cg07047830	chr11:82868014	PCF11	0.47	6.0	0.37	7.43e-9	Obesity-related traits;
SARC	trans	rs916888	0.647	rs199524	chr17:44848438	G/T	cg22968622	chr17:43663579	NA	-0.9	-10.76	-0.58	3.56e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg20891283	chr12:69753455	YEATS4	0.66	9.45	0.53	3.79e-18	Cerebrospinal fluid biomarker levels;
SARC	trans	rs453301	0.624	rs330049	chr8:9087299	C/T	cg15556689	chr8:8085844	FLJ10661	0.53	6.87	0.41	5.68e-11	Joint mobility (Beighton score);
SARC	cis	rs7927771	0.965	rs3817335	chr11:47643891	T/A	cg20307385	chr11:47447363	PSMC3	-0.52	-6.45	-0.39	6.35e-10	Subjective well-being;
SARC	cis	rs155076	1.000	rs2478824	chr13:21844144	G/C	cg25811766	chr13:21894605	NA	-0.51	-5.5	-0.34	9.92e-8	White matter hyperintensity burden;
SARC	cis	rs4481887	1.000	rs4474293	chr1:248470438	T/C	cg13385794	chr1:248469461	NA	0.36	5.59	0.34	6.44e-8	Common traits (Other);
SARC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.72	7.51	0.44	1.22e-12	Platelet count;
SARC	cis	rs74781061	0.722	rs4073149	chr15:74898419	A/G	cg09165964	chr15:75287851	SCAMP5	0.6	5.2	0.32	4.27e-7	Endometriosis;
SARC	cis	rs9814567	0.727	rs7430034	chr3:134342127	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.49	-6.37	-0.39	9.92e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	trans	rs1478897	0.804	rs9329246	chr8:11392880	A/G	cg06636001	chr8:8085503	FLJ10661	0.6	8.04	0.47	4.43e-14	Systemic lupus erythematosus;
SARC	cis	rs2282300	0.739	rs10835647	chr11:30313268	A/G	cg25418670	chr11:30344373	C11orf46	-0.42	-5.57	-0.34	7e-8	Morning vs. evening chronotype;
SARC	cis	rs8013055	0.796	rs4075105	chr14:106000231	C/T	cg19700328	chr14:106028568	NA	-0.59	-8.35	-0.48	6.15e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg07912561	chr17:41322333	NBR1	-0.53	-6.64	-0.4	2.15e-10	Gallstone disease;
SARC	cis	rs6424115	0.708	rs12748109	chr1:24181177	C/T	cg15997130	chr1:24165203	NA	-0.42	-5.18	-0.32	4.74e-7	Immature fraction of reticulocytes;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg22690096	chr10:69774146	HERC4	0.49	6.88	0.41	5.6e-11	Thyroid stimulating hormone;
SARC	cis	rs2228479	0.850	rs74251570	chr16:89910068	C/A	cg00800038	chr16:89945340	TCF25	-0.82	-5.8	-0.35	2.19e-8	Skin colour saturation;
SARC	cis	rs2908197	0.843	rs1076437	chr7:75939721	A/G	cg22830091	chr7:75961684	YWHAG	-0.34	-4.93	-0.31	1.6e-6	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs6545883	0.929	rs2694625	chr2:61616055	G/A	cg15711740	chr2:61764176	XPO1	0.42	5.09	0.32	7.38e-7	Tuberculosis;
SARC	cis	rs314370	0.570	rs314313	chr7:100423365	C/T	cg10426581	chr7:100472382	SRRT	-0.41	-5.28	-0.33	2.93e-7	Resting heart rate;
SARC	cis	rs2816062	0.735	rs2816045	chr1:18892999	A/G	cg10574377	chr1:18908098	NA	0.36	5.14	0.32	5.77e-7	Urate levels in lean individuals;
SARC	cis	rs2985684	0.846	rs10150624	chr14:50051565	A/G	cg04989706	chr14:50066350	PPIL5	-0.53	-5.88	-0.36	1.44e-8	Carotid intima media thickness;
SARC	cis	rs826838	0.585	rs12296822	chr12:38625829	A/T	cg14851346	chr12:38532713	NA	-0.44	-5.32	-0.33	2.39e-7	Heart rate;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg24003273	chr1:46112691	RPS15AP10;GPBP1L1	0.49	6.85	0.41	6.48e-11	Thyroid stimulating hormone;
SARC	cis	rs644799	0.965	rs11021317	chr11:95517576	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.87	13.85	0.67	3.22e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs12541335	0.579	rs59283125	chr8:22212311	G/A	cg26039829	chr8:22132926	PIWIL2	0.45	6.2	0.38	2.5e-9	Hypertriglyceridemia;
SARC	cis	rs9815354	1.000	rs1716693	chr3:41985600	C/T	cg03022575	chr3:42003672	ULK4	-0.57	-5.61	-0.34	5.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs72945132	0.882	rs7942613	chr11:70210675	C/T	cg00319359	chr11:70116639	PPFIA1	0.69	6.43	0.39	7.13e-10	Coronary artery disease;
SARC	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7772486	0.641	rs9390374	chr6:146368175	A/T	cg23711669	chr6:146136114	FBXO30	0.67	8.94	0.51	1.25e-16	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs12310956	0.532	rs1525904	chr12:33962448	T/C	cg26384229	chr12:38710491	ALG10B	0.85	12.3	0.63	4.14e-27	Morning vs. evening chronotype;
SARC	cis	rs1580019	0.563	rs13225132	chr7:32800975	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.93	14.91	0.7	9.66e-36	Cognitive ability;
SARC	cis	rs7465272	1.000	rs35476574	chr8:143683784	C/A	cg24634471	chr8:143751801	JRK	0.59	6.37	0.39	9.75e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs7000551	0.527	rs12677619	chr8:22243326	G/A	cg12081754	chr8:22256438	SLC39A14	0.83	11.24	0.59	1.04e-23	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs17270561	0.779	rs1165200	chr6:25875212	C/T	cg16482183	chr6:26056742	HIST1H1C	-0.52	-5.97	-0.36	8.97e-9	Iron status biomarkers;
SARC	trans	rs7815944	1.000	rs75689778	chr8:129431182	T/A	cg25487405	chr22:46473039	NA	0.64	6.36	0.38	1.07e-9	Atopic dermatitis;
SARC	cis	rs6723226	0.572	rs176411	chr2:32643528	A/G	cg02381751	chr2:32503542	YIPF4	0.54	7.01	0.42	2.52e-11	Intelligence (multi-trait analysis);
SARC	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg01316550	chr5:56110833	MAP3K1	0.53	4.85	0.3	2.29e-6	Initial pursuit acceleration;
SARC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg20102877	chr2:27665638	KRTCAP3	-0.37	-5.25	-0.33	3.44e-7	Total body bone mineral density;
SARC	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	0.39	4.77	0.3	3.28e-6	Tonsillectomy;
SARC	cis	rs533581	0.866	rs475796	chr16:88970776	C/G	cg03970086	chr16:88974840	CBFA2T3	0.34	5.09	0.32	7.24e-7	Social autistic-like traits;
SARC	cis	rs7772486	0.743	rs9403742	chr6:146060193	A/C	cg05347473	chr6:146136440	FBXO30	0.49	6.77	0.41	1.03e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg15556689	chr8:8085844	FLJ10661	-0.45	-5.63	-0.35	5.29e-8	Mood instability;
SARC	cis	rs16976116	0.951	rs9300	chr15:55489065	G/A	cg17854078	chr15:55489399	RSL24D1	0.62	6.17	0.37	2.92e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7666738	0.546	rs13149516	chr4:98913030	T/A	cg05340658	chr4:99064831	C4orf37	0.59	7.24	0.43	6.6e-12	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10089	1.000	rs10064357	chr5:127417272	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.83	9.92	0.54	1.41e-19	Ileal carcinoids;
SARC	cis	rs6424115	0.830	rs2503002	chr1:24196957	C/G	cg09473613	chr1:24152604	HMGCL	0.32	4.73	0.3	3.82e-6	Immature fraction of reticulocytes;
SARC	cis	rs3126085	0.825	rs868303	chr1:152178563	C/A	cg09127314	chr1:152161683	NA	0.41	4.76	0.3	3.39e-6	Atopic dermatitis;
SARC	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg07061783	chr6:25882402	NA	-0.47	-5.62	-0.35	5.43e-8	Intelligence (multi-trait analysis);
SARC	cis	rs57502260	0.704	rs2306862	chr11:68177510	C/T	cg01657329	chr11:68192670	LRP5	-0.55	-5.82	-0.36	1.94e-8	Total body bone mineral density (age 45-60);
SARC	cis	rs889312	0.500	rs252920	chr5:56148741	C/A	cg14703610	chr5:56206110	C5orf35	0.54	6.75	0.4	1.17e-10	Breast cancer;Breast cancer (early onset);
SARC	cis	rs981844	0.885	rs62325082	chr4:154661274	A/G	cg14289246	chr4:154710475	SFRP2	0.59	6.74	0.4	1.25e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs826838	1.000	rs1684395	chr12:39083161	T/G	cg13010199	chr12:38710504	ALG10B	-0.66	-9.56	-0.53	1.79e-18	Heart rate;
SARC	cis	rs920590	0.758	rs7011322	chr8:19661937	C/T	cg01411142	chr8:19674711	INTS10	0.48	5.55	0.34	7.86e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs7680126	0.530	rs2903827	chr4:10175872	C/G	cg00071950	chr4:10020882	SLC2A9	-0.41	-4.99	-0.31	1.19e-6	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
SARC	cis	rs7644634	0.512	rs12493560	chr3:105444077	C/T	cg23051926	chr3:105466016	CBLB	0.46	5.18	0.32	4.72e-7	Itch intensity from mosquito bite;
SARC	cis	rs6142102	0.923	rs6059586	chr20:32540501	G/A	cg24642439	chr20:33292090	TP53INP2	0.43	4.72	0.3	4.11e-6	Skin pigmentation;
SARC	cis	rs1322639	1.000	rs1322639	chr6:169587103	G/A	cg03254818	chr6:169586852	NA	-0.67	-8.76	-0.5	4.22e-16	Pulse pressure;
SARC	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	11.15	0.59	2.1e-23	Alzheimer's disease;
SARC	cis	rs1957429	0.522	rs73279816	chr14:65348375	G/A	cg23373153	chr14:65346875	NA	-0.96	-7.3	-0.43	4.39e-12	Pediatric areal bone mineral density (radius);
SARC	cis	rs7412746	0.634	rs12409208	chr1:150860055	A/G	cg13175981	chr1:150552382	MCL1	-0.49	-5.9	-0.36	1.29e-8	Melanoma;
SARC	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg08677398	chr8:58056175	NA	0.44	5.24	0.32	3.59e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6963495	0.818	rs73190200	chr7:105165856	T/C	cg19920283	chr7:105172520	RINT1	0.66	5.62	0.35	5.45e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs9790314	0.902	rs9863590	chr3:161116445	T/C	cg03342759	chr3:160939853	NMD3	-0.54	-6.7	-0.4	1.55e-10	Morning vs. evening chronotype;
SARC	cis	rs910316	0.737	rs175071	chr14:75498177	A/G	cg11812906	chr14:75593930	NEK9	-0.79	-11.02	-0.59	5.19e-23	Height;
SARC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg12419862	chr22:24373484	LOC391322	0.73	8.89	0.5	1.68e-16	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7223966	1.000	rs3817181	chr17:61776538	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.5	-5.12	-0.32	6.53e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg14898116	chr10:17272764	VIM	-0.48	-6.46	-0.39	6.1e-10	Thyroid stimulating hormone;
SARC	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg00684032	chr4:1343700	KIAA1530	-0.44	-6.56	-0.39	3.42e-10	Obesity-related traits;
SARC	cis	rs9486715	0.867	rs9373887	chr6:96957004	C/T	cg18709589	chr6:96969512	KIAA0776	0.59	7.33	0.43	3.65e-12	Headache;
SARC	cis	rs684232	0.666	rs423887	chr17:593600	A/G	cg15660573	chr17:549704	VPS53	-0.6	-8.25	-0.48	1.15e-14	Prostate cancer;
SARC	cis	rs3820928	0.874	rs4234062	chr2:227819050	C/A	cg05526886	chr2:227700861	RHBDD1	-0.54	-6.65	-0.4	2.04e-10	Pulmonary function;
SARC	cis	rs11098499	0.909	rs10017335	chr4:120381523	C/G	cg09307838	chr4:120376055	NA	-0.87	-11.8	-0.61	1.67e-25	Corneal astigmatism;
SARC	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg15448220	chr1:150897856	SETDB1	-0.4	-5.27	-0.33	3.13e-7	Urate levels;
SARC	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg04277193	chr17:41438351	NA	0.44	4.82	0.3	2.59e-6	Menopause (age at onset);
SARC	cis	rs9916302	0.904	rs600010	chr17:37433517	T/C	cg20243544	chr17:37824526	PNMT	0.56	6.82	0.41	7.65e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg08280861	chr8:58055591	NA	0.7	5.85	0.36	1.64e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10892173	0.566	rs12364667	chr11:117675286	A/C	cg21640587	chr11:117668038	DSCAML1	0.72	9.96	0.55	1.08e-19	Myopia;
SARC	cis	rs9329221	0.527	rs10903328	chr8:10332167	G/C	cg21775007	chr8:11205619	TDH	0.37	4.79	0.3	2.91e-6	Neuroticism;
SARC	cis	rs883565	0.792	rs784498	chr3:39180099	A/G	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.51	-5.45	-0.34	1.25e-7	Handedness;
SARC	cis	rs9303401	0.704	rs7359501	chr17:56641200	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.18	0.32	4.76e-7	Cognitive test performance;
SARC	cis	rs7683537	0.673	rs1401363	chr4:185643862	A/G	cg04058563	chr4:185651563	MLF1IP	0.83	11.73	0.61	2.78e-25	Systemic lupus erythematosus;
SARC	cis	rs28374715	0.681	rs7163989	chr15:41614621	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.96	-15.05	-0.7	3.26e-36	Ulcerative colitis;
SARC	cis	rs9911578	0.967	rs2429369	chr17:56501420	A/G	cg05425664	chr17:57184151	TRIM37	-0.59	-7.03	-0.42	2.33e-11	Intelligence (multi-trait analysis);
SARC	cis	rs10744422	0.858	rs2292136	chr12:123339344	A/G	cg25930673	chr12:123319894	HIP1R	-0.64	-4.74	-0.3	3.68e-6	Schizophrenia;
SARC	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg04756594	chr16:24857601	SLC5A11	0.42	5.68	0.35	4e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg22168489	chr12:122356033	WDR66	0.66	10.27	0.56	1.15e-20	Mean corpuscular volume;
SARC	cis	rs208520	0.690	rs12198297	chr6:66714665	G/A	cg07460842	chr6:66804631	NA	1.06	14.4	0.69	4.75e-34	Exhaled nitric oxide output;
SARC	cis	rs778371	0.676	rs921055	chr2:233697337	A/C	cg16596103	chr2:233749413	NGEF	0.33	4.97	0.31	1.31e-6	Schizophrenia;
SARC	cis	rs240764	0.578	rs11155613	chr6:101176642	T/C	cg09795085	chr6:101329169	ASCC3	0.53	6.73	0.4	1.34e-10	Neuroticism;
SARC	cis	rs17270561	0.609	rs12663099	chr6:25739518	C/T	cg17691542	chr6:26056736	HIST1H1C	0.58	7.09	0.42	1.6e-11	Iron status biomarkers;
SARC	cis	rs1008375	1.000	rs56974987	chr4:17627856	G/A	cg16339924	chr4:17578868	LAP3	0.66	8.61	0.49	1.1e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-4.93	-0.31	1.59e-6	Total body bone mineral density;
SARC	cis	rs4443100	0.670	rs13056137	chr22:23407261	C/A	cg14186256	chr22:23484241	RTDR1	0.58	5.87	0.36	1.5e-8	Serum parathyroid hormone levels;
SARC	cis	rs9486715	0.867	rs4438964	chr6:96917563	T/G	cg06623918	chr6:96969491	KIAA0776	0.89	12.94	0.65	3.25e-29	Headache;
SARC	cis	rs6580649	0.882	rs2286022	chr12:48436647	G/A	cg05342945	chr12:48394962	COL2A1	0.55	5.71	0.35	3.43e-8	Lung cancer;
SARC	cis	rs11785400	0.963	rs6990126	chr8:143728387	T/C	cg10596483	chr8:143751796	JRK	0.64	8.45	0.48	3.13e-15	Schizophrenia;
SARC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	6.04	0.37	6.2e-9	Prudent dietary pattern;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg02028389	chr2:152955783	CACNB4	-0.75	-6.5	-0.39	4.91e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7512552	0.780	rs1260411	chr1:150382088	G/A	cg15654264	chr1:150340011	RPRD2	0.38	4.84	0.3	2.32e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs6582630	0.537	rs11611326	chr12:38547958	C/A	cg26384229	chr12:38710491	ALG10B	0.89	13.03	0.65	1.56e-29	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs2898290	0.694	rs2248909	chr8:11392093	A/C	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.68	-0.49	7.08e-16	Systolic blood pressure;
SARC	cis	rs1865760	0.516	rs9379819	chr6:26049819	A/C	cg18357526	chr6:26021779	HIST1H4A	0.44	5.63	0.35	5.27e-8	Height;
SARC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg06074448	chr4:187884817	NA	-0.37	-5.06	-0.31	8.5e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	11.14	0.59	2.19e-23	Platelet count;
SARC	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg11764359	chr7:65958608	NA	0.88	12.58	0.64	4.89e-28	Aortic root size;
SARC	cis	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg25427524	chr10:38739819	LOC399744	-0.55	-8.74	-0.5	4.54e-16	Extrinsic epigenetic age acceleration;
SARC	cis	rs763121	0.744	rs5757140	chr22:38957013	T/C	cg06022373	chr22:39101656	GTPBP1	0.88	11.45	0.6	2.17e-24	Menopause (age at onset);
SARC	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg05368731	chr17:41323189	NBR1	0.8	9.84	0.54	2.52e-19	Menopause (age at onset);
SARC	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg16680214	chr1:154839983	KCNN3	-0.38	-6.06	-0.37	5.53e-9	Prostate cancer;
SARC	trans	rs9463078	0.526	rs9472337	chr6:44711576	C/A	cg03948781	chr1:205179583	DSTYK	0.39	6.26	0.38	1.83e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
SARC	cis	rs1707322	0.721	rs4431884	chr1:46101323	C/T	cg03146154	chr1:46216737	IPP	0.49	5.82	0.36	1.9e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs965469	1.000	rs6051712	chr20:3265029	T/A	cg25506879	chr20:3388711	C20orf194	-0.47	-4.76	-0.3	3.42e-6	IFN-related cytopenia;
SARC	trans	rs1994135	0.617	rs1384590	chr12:33734271	C/T	cg13010199	chr12:38710504	ALG10B	0.59	6.94	0.41	3.84e-11	Resting heart rate;
SARC	cis	rs965469	0.947	rs4611719	chr20:3228423	G/A	cg25506879	chr20:3388711	C20orf194	-0.53	-5.23	-0.32	3.7e-7	IFN-related cytopenia;
SARC	cis	rs3087591	0.821	rs1034705	chr17:29536133	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.51	-6.48	-0.39	5.33e-10	Hip circumference;
SARC	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	5.73	0.35	3.14e-8	Bipolar disorder;
SARC	cis	rs142483589	1	rs142483589	chr9:139320323	CCG/C	cg14169450	chr9:139327907	INPP5E	0.44	5.57	0.34	7.11e-8	White blood cell count;
SARC	cis	rs10197940	0.662	rs13555	chr2:152333304	C/A	cg19508488	chr2:152266495	RIF1	0.47	5.2	0.32	4.35e-7	Lung cancer;
SARC	cis	rs1008375	0.900	rs6812675	chr4:17597549	A/G	cg16339924	chr4:17578868	LAP3	0.69	8.82	0.5	2.79e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7589342	1.000	rs7589342	chr2:106433478	C/T	cg14210321	chr2:106509881	NCK2	-0.46	-5.36	-0.33	2e-7	Addiction;
SARC	cis	rs13392177	0.684	rs62185965	chr2:219073779	T/C	cg00012203	chr2:219082015	ARPC2	-0.69	-9.61	-0.53	1.23e-18	Pyoderma gangrenosum in inflammatory bowel disease;
SARC	cis	rs26232	0.583	rs154258	chr5:102363623	G/A	cg23492399	chr5:102201601	PAM	0.49	5.45	0.34	1.28e-7	Rheumatoid arthritis;
SARC	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg09035930	chr12:129282057	SLC15A4	0.56	8.07	0.47	3.67e-14	Systemic lupus erythematosus;
SARC	cis	rs72781680	1.000	rs17711825	chr2:24124578	A/G	cg06627628	chr2:24431161	ITSN2	-0.61	-6.05	-0.37	5.67e-9	Lymphocyte counts;
SARC	cis	rs911555	0.723	rs56227024	chr14:103861706	A/G	cg24130564	chr14:104152367	KLC1	0.48	5.52	0.34	9e-8	Intelligence (multi-trait analysis);
SARC	cis	rs72781680	1.000	rs72796326	chr2:24137047	G/A	cg08917208	chr2:24149416	ATAD2B	0.77	7.18	0.43	9.09e-12	Lymphocyte counts;
SARC	trans	rs61931739	0.500	rs7955933	chr12:34473608	A/G	cg26384229	chr12:38710491	ALG10B	0.81	11.76	0.61	2.27e-25	Morning vs. evening chronotype;
SARC	cis	rs4481887	0.927	rs7534188	chr1:248434303	C/T	cg01631408	chr1:248437212	OR2T33	0.42	5.28	0.33	2.89e-7	Common traits (Other);
SARC	cis	rs11718455	0.960	rs4682712	chr3:43997971	T/C	cg08738300	chr3:44038990	NA	0.55	6.07	0.37	5.23e-9	Coronary artery disease;
SARC	cis	rs763121	0.853	rs5750664	chr22:39072769	C/T	cg06022373	chr22:39101656	GTPBP1	0.84	10.39	0.56	4.96e-21	Menopause (age at onset);
SARC	cis	rs9788721	0.934	rs1317286	chr15:78896129	A/G	cg18825076	chr15:78729989	IREB2	-0.47	-5.63	-0.35	5.04e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs9911578	0.967	rs686425	chr17:56776730	A/G	cg05425664	chr17:57184151	TRIM37	-0.65	-8.12	-0.47	2.72e-14	Intelligence (multi-trait analysis);
SARC	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg17221315	chr6:27791827	HIST1H4J	0.51	5.28	0.33	2.97e-7	Parkinson's disease;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg07715894	chr16:11439533	C16orf75	-0.52	-6.38	-0.39	9.22e-10	Height;
SARC	cis	rs7659604	0.728	rs3924987	chr4:122689784	G/T	cg19748678	chr4:122722346	EXOSC9	0.76	10.01	0.55	7.45e-20	Type 2 diabetes;
SARC	cis	rs526231	0.543	rs152123	chr5:102531919	A/G	cg23492399	chr5:102201601	PAM	0.47	5.13	0.32	6.17e-7	Primary biliary cholangitis;
SARC	cis	rs2153535	0.601	rs9505451	chr6:8469950	C/T	cg21535247	chr6:8435926	SLC35B3	0.54	6.79	0.41	9.19e-11	Motion sickness;
SARC	cis	rs72781680	1.000	rs72796388	chr2:24171509	A/C	cg06627628	chr2:24431161	ITSN2	-0.7	-6.69	-0.4	1.64e-10	Lymphocyte counts;
SARC	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg24399712	chr22:39784796	NA	-0.44	-5.89	-0.36	1.35e-8	Intelligence (multi-trait analysis);
SARC	cis	rs6674176	0.660	rs2108202	chr1:44395786	A/G	cg13606994	chr1:44402422	ARTN	0.33	5.35	0.33	2.09e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg05048917	chr6:107077187	QRSL1;RTN4IP1	-0.5	-7.63	-0.45	5.88e-13	Thyroid stimulating hormone;
SARC	cis	rs3820928	1.000	rs7579961	chr2:227776976	T/A	cg05526886	chr2:227700861	RHBDD1	-0.5	-6.14	-0.37	3.52e-9	Pulmonary function;
SARC	cis	rs61935443	0.501	rs4761668	chr12:95184376	C/T	cg21533806	chr12:95267307	NA	0.37	4.73	0.3	3.9e-6	Schizophrenia;
SARC	cis	rs9303401	0.614	rs35057477	chr17:57097064	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	10.57	0.57	1.4e-21	Cognitive test performance;
SARC	cis	rs11792861	0.926	rs56899598	chr9:111867271	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.69	7.9	0.46	1.08e-13	Menarche (age at onset);
SARC	cis	rs4642101	0.793	rs56082700	chr3:12833833	T/C	cg05775895	chr3:12838266	CAND2	0.73	11.39	0.6	3.4e-24	QRS complex (12-leadsum);
SARC	cis	rs3087591	0.960	rs2952991	chr17:29526742	T/C	cg24425628	chr17:29625626	OMG;NF1	0.49	6.03	0.37	6.26e-9	Hip circumference;
SARC	cis	rs72627123	0.867	rs73303116	chr14:74483615	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.74	5.84	0.36	1.78e-8	Morning vs. evening chronotype;
SARC	cis	rs6582630	0.502	rs11181210	chr12:38298069	G/A	cg26384229	chr12:38710491	ALG10B	0.85	12.48	0.63	1.01e-27	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg11494091	chr17:61959527	GH2	0.53	7.98	0.46	6.66e-14	Prudent dietary pattern;
SARC	cis	rs17270561	0.609	rs9358887	chr6:25759406	G/T	cg16482183	chr6:26056742	HIST1H1C	0.48	5.89	0.36	1.36e-8	Iron status biomarkers;
SARC	cis	rs6580649	0.941	rs17122611	chr12:48458149	C/T	cg05342945	chr12:48394962	COL2A1	0.57	6.15	0.37	3.42e-9	Lung cancer;
SARC	cis	rs453301	0.686	rs28665409	chr8:8869277	G/A	cg15556689	chr8:8085844	FLJ10661	-0.47	-5.79	-0.35	2.26e-8	Joint mobility (Beighton score);
SARC	cis	rs9467773	0.844	rs2393669	chr6:26503873	C/T	cg12292205	chr6:26970375	C6orf41	0.43	5.24	0.32	3.66e-7	Intelligence (multi-trait analysis);
SARC	cis	rs854765	0.619	rs1101727	chr17:18016148	T/C	cg04398451	chr17:18023971	MYO15A	-0.59	-8.78	-0.5	3.59e-16	Total body bone mineral density;
SARC	cis	rs477895	0.941	rs71456309	chr11:64108262	T/G	cg04317338	chr11:64019027	PLCB3	0.64	5.09	0.32	7.25e-7	Mean platelet volume;
SARC	cis	rs2304069	0.733	rs216138	chr5:149437190	C/G	cg12661370	chr5:149340060	SLC26A2	0.53	5.51	0.34	9.58e-8	HIV-1 control;
SARC	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg11843238	chr5:131593191	PDLIM4	0.42	5.65	0.35	4.62e-8	Acylcarnitine levels;
SARC	cis	rs7412746	0.611	rs2864873	chr1:150814174	A/G	cg15448220	chr1:150897856	SETDB1	0.48	6.32	0.38	1.29e-9	Melanoma;
SARC	cis	rs2412819	0.597	rs78282429	chr15:43922003	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.46	5.06	0.31	8.64e-7	Lung cancer;
SARC	cis	rs9916302	0.904	rs801426	chr17:37441109	C/T	cg20243544	chr17:37824526	PNMT	-0.54	-6.55	-0.39	3.63e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg26681399	chr22:41777847	TEF	0.47	5.24	0.32	3.55e-7	Vitiligo;
SARC	cis	rs7223966	0.960	rs2319990	chr17:61705397	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.53	-5.83	-0.36	1.82e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7772486	0.686	rs2072911	chr6:146056801	G/A	cg05347473	chr6:146136440	FBXO30	-0.51	-7.05	-0.42	2.03e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7833790	0.963	rs7836040	chr8:82698328	G/A	cg27398817	chr8:82754497	SNX16	-0.52	-5.63	-0.35	5.05e-8	Diastolic blood pressure;
SARC	cis	rs2070488	0.932	rs4678604	chr3:38444273	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	14.45	0.69	3.14e-34	Electrocardiographic conduction measures;
SARC	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg18404041	chr3:52824283	ITIH1	-0.39	-5.98	-0.36	8.45e-9	Electroencephalogram traits;
SARC	cis	rs11255291	1.000	rs7917456	chr10:7732323	A/G	cg00997801	chr10:7671259	ITIH5	0.35	4.82	0.3	2.56e-6	Ovarian reserve;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg24055398	chr17:73127994	NT5C	-0.52	-6.55	-0.39	3.61e-10	Gallstone disease;
SARC	cis	rs114858855	1.000	rs60640103	chr6:109828896	C/T	cg26835506	chr6:109038353	NA	-0.63	-5.17	-0.32	5.02e-7	Plasma trimethylamine N-oxide levels;
SARC	trans	rs7824557	0.564	rs2736302	chr8:11236419	T/C	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.0	-0.42	2.66e-11	Retinal vascular caliber;
SARC	cis	rs17376456	0.825	rs12153021	chr5:93073913	A/G	cg21475434	chr5:93447410	FAM172A	0.74	6.27	0.38	1.77e-9	Diabetic retinopathy;
SARC	cis	rs66573146	0.803	rs59742225	chr4:6969942	C/T	cg00086871	chr4:6988644	TBC1D14	0.91	5.1	0.32	7.2e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs11039389	1	rs11039389	chr11:47796062	T/C	cg05585544	chr11:47624801	NA	-0.36	-4.88	-0.3	1.99e-6	Neuroticism;
SARC	cis	rs7712401	0.584	rs39820	chr5:122299921	G/A	cg19412675	chr5:122181750	SNX24	0.4	5.13	0.32	5.98e-7	Mean platelet volume;
SARC	trans	rs61931739	0.534	rs4931775	chr12:34050729	G/A	cg13010199	chr12:38710504	ALG10B	0.76	10.39	0.56	4.9e-21	Morning vs. evening chronotype;
SARC	cis	rs8067545	0.640	rs17759083	chr17:19963605	T/A	cg13482628	chr17:19912719	NA	0.53	6.84	0.41	6.82e-11	Schizophrenia;
SARC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.78	-10.38	-0.56	5.32e-21	Prudent dietary pattern;
SARC	cis	rs2933343	0.729	rs1683816	chr3:128651195	G/T	cg24203234	chr3:128598194	ACAD9	-0.62	-7.74	-0.45	2.93e-13	IgG glycosylation;
SARC	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg00152838	chr16:24741724	TNRC6A	-0.59	-6.14	-0.37	3.45e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs6121246	0.559	rs10439607	chr20:30258541	G/A	cg13852791	chr20:30311386	BCL2L1	0.81	9.9	0.54	1.69e-19	Mean corpuscular hemoglobin;
SARC	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	7.77	0.45	2.56e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs5417	0.689	rs55868524	chr17:7170665	G/A	cg14660024	chr17:7154518	C17orf81;DULLARD	0.37	5.24	0.32	3.55e-7	Diastolic blood pressure;
SARC	cis	rs7124681	0.584	rs1471712	chr11:47912150	G/A	cg20307385	chr11:47447363	PSMC3	-0.49	-6.64	-0.4	2.2e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
SARC	cis	rs7659604	0.540	rs28672860	chr4:122705051	G/A	cg19671926	chr4:122722719	EXOSC9	0.68	8.88	0.5	1.86e-16	Type 2 diabetes;
SARC	cis	rs8523	0.901	rs9368513	chr6:10975796	C/T	cg13562911	chr6:11044106	ELOVL2	0.37	4.85	0.3	2.27e-6	Red blood cell fatty acid levels;
SARC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg22903471	chr2:27725779	GCKR	-0.45	-6.45	-0.39	6.36e-10	Total body bone mineral density;
SARC	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg11890956	chr21:40555474	PSMG1	1.17	18.83	0.78	1.07e-48	Cognitive function;
SARC	cis	rs870825	0.929	rs55635512	chr4:185589982	G/T	cg04058563	chr4:185651563	MLF1IP	0.8	8.88	0.5	1.81e-16	Blood protein levels;
SARC	cis	rs16976116	0.951	rs28706531	chr15:55477072	G/A	cg11288833	chr15:55489084	RSL24D1	0.63	6.3	0.38	1.49e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs11758351	1.000	rs2143347	chr6:26198494	C/T	cg01420254	chr6:26195488	NA	0.55	4.75	0.3	3.62e-6	Gout;Renal underexcretion gout;
SARC	cis	rs1707322	0.721	rs6699418	chr1:46100181	G/A	cg06784218	chr1:46089804	CCDC17	0.35	6.14	0.37	3.54e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg24829409	chr8:58192753	C8orf71	-0.62	-6.45	-0.39	6.53e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7474896	0.583	rs10827817	chr10:37997974	A/G	cg00409905	chr10:38381863	ZNF37A	-0.44	-4.94	-0.31	1.47e-6	Obesity (extreme);
SARC	cis	rs10892173	0.904	rs10892172	chr11:117672474	C/A	cg21014159	chr11:117668035	DSCAML1	0.35	4.77	0.3	3.2e-6	Myopia;
SARC	cis	rs9393692	0.902	rs6456711	chr6:26302572	A/C	cg00631329	chr6:26305371	NA	-0.67	-9.55	-0.53	1.93e-18	Educational attainment;
SARC	cis	rs9905704	0.647	rs12943705	chr17:57097047	T/C	cg12560992	chr17:57184187	TRIM37	-0.44	-5.32	-0.33	2.4e-7	Testicular germ cell tumor;
SARC	cis	rs854765	0.547	rs4459604	chr17:17888549	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.41	5.24	0.32	3.62e-7	Total body bone mineral density;
SARC	cis	rs1395	0.744	rs1975384	chr2:27542041	C/T	cg22903471	chr2:27725779	GCKR	-0.4	-4.78	-0.3	3.06e-6	Blood metabolite levels;
SARC	cis	rs1371867	0.846	rs1660316	chr8:101333049	T/C	cg11906718	chr8:101322791	RNF19A	0.71	9.13	0.51	3.37e-17	Atrioventricular conduction;
SARC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.33	-5.16	-0.32	5.17e-7	Total body bone mineral density;
SARC	cis	rs4689388	0.853	rs1079216	chr4:6282473	T/C	cg25554036	chr4:6271136	WFS1	0.42	6.61	0.4	2.65e-10	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs7607369	0.580	rs7568196	chr2:219652373	G/A	cg02176678	chr2:219576539	TTLL4	-0.48	-7.62	-0.45	6.2800000000000005e-13	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs34779708	0.931	rs35997236	chr10:35376690	C/T	cg03585969	chr10:35415529	CREM	0.39	4.86	0.3	2.17e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs2742234	0.666	rs715106	chr10:43616751	C/A	cg15436174	chr10:43711423	RASGEF1A	-0.4	-4.94	-0.31	1.49e-6	Hirschsprung disease;
SARC	cis	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg08975724	chr8:8085496	FLJ10661	0.49	6.2	0.38	2.51e-9	Mood instability;
SARC	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.54	0.44	1.06e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg10435706	chr6:150039699	LATS1	0.36	4.71	0.3	4.18e-6	Lung cancer;
SARC	cis	rs4713118	0.869	rs9348775	chr6:27695329	C/T	cg17221315	chr6:27791827	HIST1H4J	0.49	5.34	0.33	2.18e-7	Parkinson's disease;
SARC	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg07701084	chr6:150067640	NUP43	0.39	5.08	0.32	7.86e-7	Lung cancer;
SARC	cis	rs10504229	0.679	rs73681882	chr8:58030038	A/G	cg22535103	chr8:58192502	C8orf71	-0.59	-5.86	-0.36	1.53e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg00149659	chr3:10157352	C3orf10	0.64	6.04	0.37	6.05e-9	Alzheimer's disease;
SARC	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg24399712	chr22:39784796	NA	-0.41	-5.49	-0.34	1.07e-7	Intelligence (multi-trait analysis);
SARC	cis	rs35110281	0.776	rs1073522	chr21:45009219	T/A	cg01579765	chr21:45077557	HSF2BP	-0.35	-5.79	-0.35	2.24e-8	Mean corpuscular volume;
SARC	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg07636037	chr3:49044803	WDR6	0.91	15.35	0.71	3.14e-37	Menarche (age at onset);
SARC	cis	rs6570726	0.935	rs392014	chr6:145843691	A/C	cg23711669	chr6:146136114	FBXO30	0.77	11.79	0.61	1.84e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7644634	0.584	rs999046	chr3:105420265	T/C	cg23051926	chr3:105466016	CBLB	0.43	5.44	0.34	1.32e-7	Itch intensity from mosquito bite;
SARC	cis	rs1348850	0.914	rs12693120	chr2:178283288	A/G	cg23306229	chr2:178417860	TTC30B	0.54	6.4	0.39	8.62e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs5758511	0.680	rs1107554	chr22:42667594	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.43	6.49	0.39	5.2400000000000005e-10	Birth weight;
SARC	cis	rs74781061	0.722	rs12441817	chr15:75025814	T/C	cg09165964	chr15:75287851	SCAMP5	-0.66	-5.25	-0.32	3.5e-7	Endometriosis;
SARC	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg24209194	chr3:40518798	ZNF619	-0.65	-7.66	-0.45	4.95e-13	Renal cell carcinoma;
SARC	cis	rs9640161	0.830	rs17173702	chr7:150068605	G/A	cg21361702	chr7:150065534	REPIN1	0.6	6.58	0.4	2.99e-10	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg03213289	chr20:61660250	NA	0.45	6.08	0.37	4.87e-9	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs1008375	0.966	rs1860591	chr4:17577329	A/G	cg02297831	chr4:17616191	MED28	0.45	5.49	0.34	1.03e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg12310025	chr6:25882481	NA	-0.72	-9.67	-0.53	8.45e-19	Urate levels;
SARC	cis	rs2011503	1.000	rs2965184	chr19:19545428	C/T	cg03709012	chr19:19516395	GATAD2A	-0.67	-5.85	-0.36	1.66e-8	Bipolar disorder;
SARC	cis	rs1448094	0.511	rs61930074	chr12:86218759	G/C	cg02569458	chr12:86230093	RASSF9	0.42	5.83	0.36	1.88e-8	Major depressive disorder;
SARC	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg19077165	chr18:44547161	KATNAL2	0.53	7.26	0.43	5.68e-12	Personality dimensions;
SARC	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg05368731	chr17:41323189	NBR1	0.64	7.9	0.46	1.08e-13	Menopause (age at onset);
SARC	cis	rs2290402	0.536	rs56253935	chr4:853871	A/T	cg00846425	chr4:957561	DGKQ	-0.45	-5.17	-0.32	5.03e-7	Type 2 diabetes;
SARC	cis	rs7666738	0.800	rs13107586	chr4:99028788	G/C	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6665290	0.904	rs11578103	chr1:227189642	C/A	cg10327440	chr1:227177885	CDC42BPA	-1.09	-25.56	-0.86	1.54e-69	Myeloid white cell count;
SARC	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg08219700	chr8:58056026	NA	0.6	5.71	0.35	3.49e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs12142240	0.660	rs72890715	chr1:46852077	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-5.56	-0.34	7.46e-8	Menopause (age at onset);
SARC	cis	rs17030434	0.953	rs76442373	chr4:154694783	G/A	cg14289246	chr4:154710475	SFRP2	-0.8	-7.93	-0.46	9.34e-14	Electrocardiographic conduction measures;
SARC	cis	rs6912958	0.712	rs6454638	chr6:88329427	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.33	5.69	0.35	3.88e-8	Monocyte percentage of white cells;
SARC	cis	rs668210	0.793	rs677350	chr11:65761967	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	5.49	0.34	1.06e-7	Cerebrospinal fluid biomarker levels;
SARC	cis	rs425277	1.000	rs262657	chr1:2088577	G/A	cg21442419	chr1:2182373	SKI	-0.52	-6.62	-0.4	2.44e-10	Height;
SARC	cis	rs12464559	0.522	rs10200512	chr2:152626147	T/C	cg01189475	chr2:152685088	ARL5A	0.62	5.12	0.32	6.43e-7	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs2070677	0.866	rs2492664	chr10:135387240	G/T	cg20169779	chr10:135381914	SYCE1	-0.52	-6.2	-0.38	2.6e-9	Gout;
SARC	cis	rs9399135	0.935	rs6908681	chr6:135337733	A/G	cg24558204	chr6:135376177	HBS1L	0.45	6.03	0.37	6.24e-9	Red blood cell count;
SARC	cis	rs7520050	0.966	rs12564541	chr1:46380237	G/A	cg24296786	chr1:45957014	TESK2	0.38	4.82	0.3	2.55e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs7223966	1.000	rs9903903	chr17:61762044	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.57	-6.67	-0.4	1.87e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1008375	1.000	rs3846357	chr4:17635887	A/T	cg16339924	chr4:17578868	LAP3	0.66	8.83	0.5	2.57e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg21280719	chr6:42927975	GNMT	-0.46	-8.12	-0.47	2.76e-14	Alzheimer's disease in APOE e4+ carriers;
SARC	trans	rs61931739	0.517	rs56308002	chr12:34016021	C/G	cg26384229	chr12:38710491	ALG10B	0.85	12.24	0.63	6.08e-27	Morning vs. evening chronotype;
SARC	cis	rs826838	0.709	rs4882355	chr12:38721462	A/T	cg26384229	chr12:38710491	ALG10B	0.62	8.15	0.47	2.25e-14	Heart rate;
SARC	cis	rs7149337	0.836	rs34953083	chr14:51672432	A/G	cg23942311	chr14:51606299	NA	0.34	6.02	0.37	6.86e-9	Cancer;
SARC	cis	rs17001868	0.568	rs2075764	chr22:40758581	C/T	cg07138101	chr22:40742427	ADSL	0.57	6.09	0.37	4.71e-9	Mammographic density (dense area);
SARC	cis	rs1707322	1.000	rs7517560	chr1:46425943	A/G	cg03146154	chr1:46216737	IPP	0.45	5.41	0.33	1.56e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6964587	0.934	rs2961019	chr7:91572749	T/G	cg17063962	chr7:91808500	NA	-0.9	-13.36	-0.66	1.29e-30	Breast cancer;
SARC	cis	rs11997175	0.600	rs6468188	chr8:33639478	T/C	ch.8.33884649F	chr8:33765107	NA	0.51	6.69	0.4	1.64e-10	Body mass index;
SARC	cis	rs9303401	0.538	rs35454383	chr17:56475599	C/T	cg25039879	chr17:56429692	SUPT4H1	0.7	6.15	0.37	3.33e-9	Cognitive test performance;
SARC	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg17971929	chr21:40555470	PSMG1	-0.83	-10.81	-0.58	2.37e-22	Cognitive function;
SARC	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg05861140	chr6:150128134	PCMT1	-0.4	-5.23	-0.32	3.79e-7	Lung cancer;
SARC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg23411876	chr7:140396886	LOC100134713;NDUFB2	0.57	6.38	0.39	9.57e-10	Myopia (pathological);
SARC	cis	rs911263	0.961	rs2208397	chr14:68753287	T/G	cg18825221	chr14:68749962	RAD51L1	0.49	8.45	0.48	3.15e-15	Primary biliary cholangitis;
SARC	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg13206674	chr6:150067644	NUP43	0.46	6.1	0.37	4.29e-9	Lung cancer;
SARC	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg03709012	chr19:19516395	GATAD2A	-1.02	-17.9	-0.76	1.17e-45	Tonsillectomy;
SARC	cis	rs11155671	0.530	rs4458704	chr6:150232879	A/C	cg09699651	chr6:150184138	LRP11	0.49	6.0	0.37	7.46e-9	Testicular germ cell tumor;
SARC	cis	rs7681440	0.904	rs6532193	chr4:90764188	G/A	cg02192967	chr4:90758406	SNCA	0.36	5.14	0.32	5.76e-7	Dementia with Lewy bodies;
SARC	cis	rs9303401	0.659	rs11079357	chr17:56902778	A/G	cg25039879	chr17:56429692	SUPT4H1	0.65	6.13	0.37	3.77e-9	Cognitive test performance;
SARC	cis	rs2486288	0.656	rs8039352	chr15:45551790	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.5	-6.36	-0.38	1.06e-9	Glomerular filtration rate;
SARC	cis	rs6701037	0.566	rs13373754	chr1:175139275	C/A	cg00321850	chr1:175162397	KIAA0040	0.37	5.79	0.35	2.3e-8	Alcohol dependence;
SARC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg06873352	chr17:61820015	STRADA	0.53	6.92	0.41	4.3e-11	Prudent dietary pattern;
SARC	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg05368731	chr17:41323189	NBR1	0.79	9.45	0.53	3.89e-18	Menopause (age at onset);
SARC	cis	rs2228479	0.541	rs12918575	chr16:89811151	A/G	cg06558623	chr16:89946397	TCF25	0.87	6.94	0.41	3.78e-11	Skin colour saturation;
SARC	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg06027949	chr8:82754900	SNX16	-0.49	-6.2	-0.38	2.59e-9	Diastolic blood pressure;
SARC	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg13866156	chr1:1669148	SLC35E2	-0.64	-9.71	-0.54	6.4e-19	Body mass index;
SARC	cis	rs8067545	0.532	rs3862151	chr17:19957289	A/G	cg13482628	chr17:19912719	NA	0.43	4.88	0.3	1.99e-6	Schizophrenia;
SARC	trans	rs6600671	0.899	rs6674392	chr1:121260662	C/G	cg00646200	chr1:148855367	NA	0.52	7.14	0.42	1.15e-11	Hip geometry;
SARC	cis	rs7395581	1.000	rs7395581	chr11:47246397	G/A	cg25783544	chr11:47291846	MADD	-0.45	-4.85	-0.3	2.28e-6	HDL cholesterol;
SARC	cis	rs7772486	0.790	rs9390365	chr6:146235626	A/G	cg05347473	chr6:146136440	FBXO30	-0.48	-6.51	-0.39	4.47e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6977660	1.000	rs1468288	chr7:19810580	C/G	cg07541023	chr7:19748670	TWISTNB	0.52	4.89	0.31	1.89e-6	Thyroid stimulating hormone;
SARC	cis	rs7584330	0.737	rs60187585	chr2:238365159	C/T	cg14458575	chr2:238380390	NA	0.45	5.57	0.34	7.08e-8	Prostate cancer;
SARC	cis	rs2354432	0.607	rs6703847	chr1:146669444	G/A	cg25205988	chr1:146714368	CHD1L	1.05	8.93	0.51	1.29e-16	Mitochondrial DNA levels;
SARC	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg18876405	chr7:65276391	NA	-0.72	-9.19	-0.52	2.25e-17	Aortic root size;
SARC	cis	rs7659604	0.540	rs13113421	chr4:122670064	G/A	cg19671926	chr4:122722719	EXOSC9	0.56	6.91	0.41	4.71e-11	Type 2 diabetes;
SARC	cis	rs6963495	0.745	rs73192152	chr7:105212258	A/C	cg13798780	chr7:105162888	PUS7	0.57	5.19	0.32	4.5e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs11264799	0.520	rs849828	chr1:157545047	A/G	cg18268488	chr1:157545234	FCRL4	0.32	5.75	0.35	2.73e-8	IgA nephropathy;
SARC	cis	rs765787	0.530	rs7167389	chr15:45535683	A/G	cg24006582	chr15:45444508	DUOX1	-0.49	-6.4	-0.39	8.32e-10	Uric acid levels;
SARC	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg00149659	chr3:10157352	C3orf10	0.64	6.01	0.37	7.21e-9	Alzheimer's disease;
SARC	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg06634786	chr22:41940651	POLR3H	-0.63	-7.56	-0.44	9.09e-13	Vitiligo;
SARC	cis	rs15676	0.947	rs2977999	chr9:131579807	G/A	cg00228799	chr9:131580591	ENDOG	0.59	7.33	0.43	3.82e-12	Blood metabolite levels;
SARC	cis	rs9467773	0.620	rs6925087	chr6:26592853	T/A	cg12292205	chr6:26970375	C6orf41	0.43	5.36	0.33	2.03e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg12463550	chr7:65579703	CRCP	0.68	5.09	0.32	7.53e-7	Gout;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg16144447	chr1:36184773	C1orf216	0.81	6.91	0.41	4.48e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9300255	0.639	rs941306	chr12:123715113	C/T	cg05973401	chr12:123451056	ABCB9	0.47	5.29	0.33	2.84e-7	Neutrophil percentage of white cells;
SARC	cis	rs75920871	0.702	rs7946869	chr11:116963312	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.55	-4.74	-0.3	3.76e-6	Subjective well-being;
SARC	cis	rs116095464	0.558	rs10065239	chr5:275288	C/T	cg22857025	chr5:266934	NA	-1.1	-10.33	-0.56	7.8e-21	Breast cancer;
SARC	cis	rs11122272	0.735	rs2486743	chr1:231506928	C/G	cg06096015	chr1:231504339	EGLN1	0.38	5.79	0.35	2.22e-8	Hemoglobin concentration;
SARC	cis	rs17376456	0.569	rs11135394	chr5:93187135	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.52	-5.78	-0.35	2.4e-8	Diabetic retinopathy;
SARC	cis	rs2952156	1.000	rs2088126	chr17:37879030	A/G	cg00129232	chr17:37814104	STARD3	-0.66	-8.34	-0.48	6.4e-15	Asthma;
SARC	trans	rs1814175	0.647	rs10769646	chr11:49992204	C/A	cg03929089	chr4:120376271	NA	-0.82	-11.88	-0.61	9.2e-26	Height;
SARC	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg05564831	chr3:52568323	NT5DC2	0.27	4.88	0.3	1.98e-6	Hemoglobin concentration;
SARC	cis	rs7520050	0.778	rs3014218	chr1:46026328	A/C	cg24296786	chr1:45957014	TESK2	0.47	6.06	0.37	5.45e-9	Red blood cell count;Reticulocyte count;
SARC	cis	rs599083	0.590	rs661988	chr11:68189251	T/G	cg01657329	chr11:68192670	LRP5	-0.47	-5.67	-0.35	4.19e-8	Bone mineral density (spine);
SARC	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg22834771	chr12:69754056	YEATS4	-0.48	-6.32	-0.38	1.29e-9	Cerebrospinal fluid biomarker levels;
SARC	cis	rs367943	1.000	rs348963	chr5:112819027	A/G	cg12552261	chr5:112820674	MCC	-0.44	-5.15	-0.32	5.57e-7	Type 2 diabetes;
SARC	cis	rs10782582	0.609	rs80059220	chr1:76279112	G/T	cg10523679	chr1:76189770	ACADM	-0.43	-5.29	-0.33	2.78e-7	Daytime sleep phenotypes;
SARC	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg15049968	chr18:44337910	ST8SIA5	-0.34	-5.45	-0.34	1.27e-7	Personality dimensions;
SARC	cis	rs4588572	0.643	rs10075726	chr5:77669053	T/A	cg11547950	chr5:77652471	NA	0.41	4.84	0.3	2.36e-6	Triglycerides;
SARC	cis	rs12971120	0.891	rs11151961	chr18:72177340	C/T	cg25817165	chr18:72167213	CNDP2	-0.5	-6.76	-0.41	1.08e-10	Refractive error;
SARC	cis	rs2645694	0.626	rs2703116	chr4:77824289	C/T	cg18351406	chr4:77819688	ANKRD56	-0.43	-6.13	-0.37	3.7e-9	Emphysema distribution in smoking;
SARC	cis	rs11097912	0.632	rs6533246	chr4:107203084	C/T	cg09646026	chr4:107269030	AIMP1	-0.43	-4.79	-0.3	2.96e-6	Airflow obstruction;
SARC	cis	rs36051895	0.659	rs7036476	chr9:5063664	T/C	cg02405213	chr9:5042618	JAK2	-0.49	-5.87	-0.36	1.5e-8	Pediatric autoimmune diseases;
SARC	cis	rs4253772	0.720	rs4253778	chr22:46630634	C/G	cg24881330	chr22:46731750	TRMU	0.56	6.34	0.38	1.17e-9	LDL cholesterol;Cholesterol, total;
SARC	cis	rs2075371	1.000	rs432487	chr7:133990114	T/G	cg20476274	chr7:133979776	SLC35B4	0.62	8.49	0.49	2.43e-15	Mean platelet volume;
SARC	cis	rs7264396	0.623	rs2590984	chr20:34597031	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.49	4.77	0.3	3.24e-6	Total cholesterol levels;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg10957584	chr16:5148097	FAM86A	-0.54	-6.67	-0.4	1.84e-10	Height;
SARC	trans	rs61931739	0.500	rs34107854	chr12:34482333	C/A	cg13010199	chr12:38710504	ALG10B	0.82	11.58	0.6	8.37e-25	Morning vs. evening chronotype;
SARC	cis	rs1322639	0.614	rs4708414	chr6:169574144	C/G	cg03254818	chr6:169586852	NA	0.38	4.79	0.3	2.91e-6	Pulse pressure;
SARC	trans	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg06437703	chr8:37914619	EIF4EBP1	-0.61	-7.43	-0.44	2.1e-12	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.72	7.13	0.42	1.24e-11	Platelet count;
SARC	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg24675658	chr1:53192096	ZYG11B	0.59	8.28	0.48	9.42e-15	Monocyte count;
SARC	cis	rs4660306	0.961	rs4660871	chr1:45995232	C/A	cg24296786	chr1:45957014	TESK2	0.55	6.46	0.39	6.07e-10	Homocysteine levels;
SARC	cis	rs34172651	0.917	rs200536	chr16:24749203	G/A	cg00152838	chr16:24741724	TNRC6A	0.46	5.62	0.35	5.46e-8	Intelligence (multi-trait analysis);
SARC	cis	rs12458462	0.892	rs58675823	chr18:77463672	G/A	cg23301140	chr18:77439876	CTDP1	0.63	8.29	0.48	9.29e-15	Monocyte count;
SARC	cis	rs6752107	1.000	rs3828309	chr2:234180410	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	-0.37	-4.74	-0.3	3.76e-6	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg24399712	chr22:39784796	NA	-0.43	-5.8	-0.36	2.15e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg00800038	chr16:89945340	TCF25	-0.76	-5.29	-0.33	2.81e-7	Skin colour saturation;
SARC	cis	rs4742903	0.935	rs7872034	chr9:106896809	G/A	cg14250997	chr9:106856677	SMC2	0.5	6.56	0.39	3.46e-10	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs9814567	0.806	rs12637301	chr3:134317966	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.51	-6.63	-0.4	2.36e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs1113500	0.933	rs61797345	chr1:108623728	G/A	cg06207961	chr1:108661230	NA	0.45	5.93	0.36	1.1e-8	Growth-regulated protein alpha levels;
SARC	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg16479474	chr6:28041457	NA	0.36	5.45	0.34	1.25e-7	Depression;
SARC	cis	rs11997175	0.574	rs4236733	chr8:33655582	G/A	ch.8.33884649F	chr8:33765107	NA	0.48	6.45	0.39	6.25e-10	Body mass index;
SARC	cis	rs965469	0.744	rs6139093	chr20:3334838	A/G	cg25506879	chr20:3388711	C20orf194	-0.46	-4.99	-0.31	1.17e-6	IFN-related cytopenia;
SARC	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg21724239	chr8:58056113	NA	0.6	6.37	0.38	1.03e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs11098499	0.775	rs2002049	chr4:120257417	A/G	cg09307838	chr4:120376055	NA	0.81	11.03	0.59	4.84e-23	Corneal astigmatism;
SARC	cis	rs9640161	0.783	rs1132261	chr7:150059987	G/A	cg10018233	chr7:150070692	REPIN1	0.7	10.28	0.56	1.08e-20	Blood protein levels;Circulating chemerin levels;
SARC	trans	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg20587970	chr11:113659929	NA	-1.35	-13.48	-0.66	5.32e-31	Hip circumference adjusted for BMI;
SARC	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg16325326	chr1:53192061	ZYG11B	0.71	10.18	0.55	2.29e-20	Monocyte count;
SARC	cis	rs3762637	0.941	rs9863712	chr3:122099906	C/T	cg24169773	chr3:122142474	KPNA1	-0.56	-5.52	-0.34	9.04e-8	LDL cholesterol levels;
SARC	cis	rs12545109	0.800	rs2670055	chr8:57421575	T/C	cg19413350	chr8:57351067	NA	-0.44	-5.5	-0.34	1.01e-7	Obesity-related traits;
SARC	cis	rs5758659	0.657	rs5758587	chr22:42517636	C/G	cg04733989	chr22:42467013	NAGA	-0.5	-6.1	-0.37	4.31e-9	Cognitive function;
SARC	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg22920501	chr2:26401640	FAM59B	-0.54	-7.06	-0.42	1.86e-11	Gut microbiome composition (summer);
SARC	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg03575189	chr17:44344142	NA	-0.53	-5.2	-0.32	4.37e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs4242434	0.927	rs7843616	chr8:22466541	T/C	cg03733263	chr8:22462867	KIAA1967	1.04	18.18	0.77	1.36e-46	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs6570726	0.875	rs416243	chr6:145868081	A/T	cg05347473	chr6:146136440	FBXO30	0.49	6.58	0.4	3.04e-10	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg26365460	chr6:47748696	OPN5	-0.51	-6.98	-0.42	3.05e-11	Thyroid stimulating hormone;
SARC	cis	rs10791323	0.559	rs10750549	chr11:133730820	A/G	cg14349672	chr11:133703707	NA	-0.34	-5.04	-0.31	9.17e-7	Childhood ear infection;
SARC	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg22618164	chr12:122356400	WDR66	-0.42	-6.72	-0.4	1.36e-10	Mean corpuscular volume;
SARC	cis	rs6546550	0.901	rs6754896	chr2:70138170	T/C	cg02498382	chr2:70120550	SNRNP27	-0.32	-5.13	-0.32	6.02e-7	Prevalent atrial fibrillation;
SARC	cis	rs1971762	0.522	rs10747680	chr12:54077776	T/G	cg06632207	chr12:54070931	ATP5G2	0.44	5.72	0.35	3.32e-8	Height;
SARC	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg25427524	chr10:38739819	LOC399744	-0.6	-9.34	-0.52	7.96e-18	Extrinsic epigenetic age acceleration;
SARC	cis	rs7552404	0.924	rs1303169	chr1:76195041	T/C	cg10523679	chr1:76189770	ACADM	0.46	6.31	0.38	1.39e-9	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg25703541	chr22:24373054	LOC391322	-0.84	-12.4	-0.63	1.93e-27	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2120019	0.567	rs72625793	chr15:75207083	A/G	cg00629941	chr15:75287862	SCAMP5	-0.59	-5.43	-0.34	1.38e-7	Blood trace element (Zn levels);
SARC	cis	rs3540	0.533	rs12916560	chr15:91056259	A/C	cg22089800	chr15:90895588	ZNF774	-0.6	-7.47	-0.44	1.56e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs79976124	0.837	rs75346757	chr6:66648386	A/T	cg07460842	chr6:66804631	NA	0.63	6.8	0.41	8.87e-11	Type 2 diabetes;
SARC	cis	rs4792901	0.918	rs79158595	chr17:41623212	G/A	cg22562494	chr17:41607896	ETV4	-0.31	-4.86	-0.3	2.13e-6	Dupuytren's disease;
SARC	cis	rs9323205	0.834	rs12434435	chr14:51667524	G/T	cg23942311	chr14:51606299	NA	0.36	5.62	0.35	5.43e-8	Cancer;
SARC	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.43	0.39	7.27e-10	Height;
SARC	cis	rs898097	0.801	rs68141193	chr17:80878816	C/T	cg15369054	chr17:80825471	TBCD	0.53	7.59	0.45	7.68e-13	Breast cancer;
SARC	cis	rs13256369	1.000	rs873064	chr8:8572380	G/A	cg17143192	chr8:8559678	CLDN23	0.52	6.03	0.37	6.55e-9	Obesity-related traits;
SARC	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg10435706	chr6:150039699	LATS1	0.36	4.8	0.3	2.88e-6	Lung cancer;
SARC	cis	rs17376456	0.825	rs10078941	chr5:93279029	C/T	cg21475434	chr5:93447410	FAM172A	0.86	7.67	0.45	4.52e-13	Diabetic retinopathy;
SARC	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg11366901	chr6:160182831	ACAT2	1.02	10.79	0.58	2.78e-22	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs12682352	0.579	rs7006589	chr8:8668486	A/G	cg15556689	chr8:8085844	FLJ10661	0.39	4.87	0.3	2.02e-6	Neuroticism;
SARC	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg04267008	chr7:1944627	MAD1L1	-0.65	-7.78	-0.45	2.3e-13	Bipolar disorder and schizophrenia;
SARC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	20.44	0.8	7e-54	Prudent dietary pattern;
SARC	cis	rs7592578	0.639	rs13417431	chr2:191293055	A/G	cg27211696	chr2:191398769	TMEM194B	-0.45	-4.97	-0.31	1.31e-6	Diastolic blood pressure;
SARC	cis	rs933688	1.000	rs12655973	chr5:90736537	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	13.25	0.66	3.02e-30	Smoking behavior;
SARC	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg08677398	chr8:58056175	NA	0.43	5.05	0.31	8.92e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1008375	0.932	rs11935124	chr4:17668200	G/A	cg16339924	chr4:17578868	LAP3	-0.62	-7.91	-0.46	1.06e-13	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10875746	0.951	rs4760690	chr12:48563653	G/A	cg26205652	chr12:48591994	NA	0.54	6.01	0.37	6.92e-9	Longevity (90 years and older);
SARC	cis	rs1949733	0.598	rs16842480	chr4:8535621	G/T	cg13073564	chr4:8508604	NA	0.44	6.72	0.4	1.4e-10	Response to antineoplastic agents;
SARC	cis	rs12200560	0.505	rs9400166	chr6:97077101	G/A	cg06623918	chr6:96969491	KIAA0776	0.46	5.29	0.33	2.82e-7	Coronary heart disease;
SARC	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg06634786	chr22:41940651	POLR3H	0.5	6.12	0.37	3.99e-9	Vitiligo;
SARC	cis	rs7666738	0.753	rs2903143	chr4:99040480	C/T	cg05340658	chr4:99064831	C4orf37	0.64	8.6	0.49	1.18e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9462027	0.628	rs9469891	chr6:34767396	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.81	-0.36	2e-8	Systemic lupus erythematosus;
SARC	cis	rs1318878	0.876	rs10846170	chr12:15533131	G/A	cg08258403	chr12:15378311	NA	0.34	4.74	0.3	3.68e-6	Intelligence (multi-trait analysis);
SARC	cis	rs4805272	0.626	rs12608533	chr19:29331405	C/G	cg14983838	chr19:29218262	NA	0.58	6.83	0.41	7.45e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs2304069	0.545	rs7445660	chr5:149413610	A/C	cg12661370	chr5:149340060	SLC26A2	0.58	6.88	0.41	5.35e-11	HIV-1 control;
SARC	cis	rs17376456	0.569	rs10067754	chr5:93093110	T/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.5	5.05	0.31	8.86e-7	Diabetic retinopathy;
SARC	cis	rs4481887	1.000	rs4916124	chr1:248466495	T/C	cg01631408	chr1:248437212	OR2T33	-0.44	-5.66	-0.35	4.35e-8	Common traits (Other);
SARC	cis	rs3106136	0.967	rs2306802	chr4:95186055	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.35	-5.41	-0.33	1.59e-7	Capecitabine sensitivity;
SARC	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg11890956	chr21:40555474	PSMG1	1.18	20.29	0.8	2.03e-53	Cognitive function;
SARC	cis	rs3812049	0.532	rs251216	chr5:127543280	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.69	7.35	0.43	3.32e-12	Lymphocyte counts;Red cell distribution width;
SARC	cis	rs9341808	0.718	rs3812121	chr6:80968727	A/G	cg08355045	chr6:80787529	NA	0.34	5.58	0.34	6.64e-8	Sitting height ratio;
SARC	cis	rs3741404	0.620	rs11231722	chr11:63967770	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	9.99	0.55	8.75e-20	Platelet count;
SARC	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg03264133	chr6:25882463	NA	-0.41	-5.34	-0.33	2.21e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7662987	0.517	rs2851256	chr4:100039549	G/A	cg12011299	chr4:100065546	ADH4	0.33	5.47	0.34	1.13e-7	Smoking initiation;
SARC	cis	rs9300255	0.602	rs1616181	chr12:123619856	T/A	cg05973401	chr12:123451056	ABCB9	0.52	5.85	0.36	1.68e-8	Neutrophil percentage of white cells;
SARC	trans	rs61931739	0.500	rs11053166	chr12:34385898	A/C	cg26384229	chr12:38710491	ALG10B	-0.86	-12.44	-0.63	1.41e-27	Morning vs. evening chronotype;
SARC	cis	rs826838	0.834	rs2387842	chr12:38736442	T/C	cg26384229	chr12:38710491	ALG10B	0.97	15.88	0.72	5.47e-39	Heart rate;
SARC	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg04166393	chr7:2884313	GNA12	-0.5	-5.95	-0.36	9.64e-9	Height;
SARC	cis	rs2153535	0.580	rs965706	chr6:8464708	G/A	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs2273669	0.667	rs12195836	chr6:109357701	T/G	cg05315195	chr6:109294784	ARMC2	-0.62	-5.59	-0.34	6.46e-8	Prostate cancer;
SARC	cis	rs1468333	0.964	rs2967785	chr5:137543713	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.82	11.73	0.61	2.72e-25	Resting heart rate;
SARC	cis	rs2204008	0.837	rs11519926	chr12:38348992	G/A	cg13010199	chr12:38710504	ALG10B	0.8	11.05	0.59	4.21e-23	Bladder cancer;
SARC	cis	rs950169	0.580	rs11634320	chr15:85172183	A/C	cg17507749	chr15:85114479	UBE2QP1	-0.57	-6.56	-0.39	3.48e-10	Schizophrenia;
SARC	cis	rs208520	0.633	rs79679034	chr6:66701724	A/C	cg07460842	chr6:66804631	NA	1.07	13.93	0.67	1.74e-32	Exhaled nitric oxide output;
SARC	cis	rs7027203	0.828	rs4744287	chr9:96585567	A/G	cg14598338	chr9:96623480	NA	0.56	8.16	0.47	2.05e-14	DNA methylation (variation);
SARC	cis	rs9326248	1.000	rs3736120	chr11:117032125	G/T	cg01368799	chr11:117014884	PAFAH1B2	0.58	6.31	0.38	1.38e-9	Blood protein levels;
SARC	trans	rs9929218	0.679	rs9924886	chr16:68743939	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.64	-7.91	-0.46	1.04e-13	Colorectal cancer;
SARC	cis	rs6141769	0.569	rs11905501	chr20:31270962	C/A	cg17884169	chr20:31446444	EFCAB8	-0.45	-4.77	-0.3	3.27e-6	Subjective well-being;
SARC	cis	rs910316	0.763	rs175057	chr14:75489632	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.48	-6.21	-0.38	2.4e-9	Height;
SARC	cis	rs801193	0.591	rs9986881	chr7:66173040	A/G	cg18876405	chr7:65276391	NA	0.47	5.35	0.33	2.11e-7	Aortic root size;
SARC	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.41	0.44	2.36e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7432375	0.580	rs4678441	chr3:136532828	T/C	cg15507776	chr3:136538369	TMEM22	0.62	7.7	0.45	3.93e-13	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	cis	rs2153535	0.563	rs1737584	chr6:8536742	C/T	cg07606381	chr6:8435919	SLC35B3	0.76	10.83	0.58	2.16e-22	Motion sickness;
SARC	trans	rs877282	1.000	rs2004479	chr10:770854	G/A	cg22713356	chr15:30763199	NA	1.03	9.98	0.55	9.07e-20	Uric acid levels;
SARC	cis	rs2043112	0.965	rs12233987	chr5:39053547	T/C	cg04869206	chr5:39074266	RICTOR	0.51	6.16	0.37	3.21e-9	Obesity-related traits;
SARC	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.7	9.36	0.52	7e-18	Menarche (age at onset);
SARC	cis	rs77633900	0.614	rs280001	chr15:77003566	C/A	cg21673338	chr15:77095150	SCAPER	-0.76	-6.31	-0.38	1.42e-9	Non-glioblastoma glioma;Glioma;
SARC	cis	rs763121	0.815	rs9306328	chr22:39028913	C/T	cg21395723	chr22:39101663	GTPBP1	0.52	6.04	0.37	5.94e-9	Menopause (age at onset);
SARC	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg01475735	chr3:40494733	NA	0.49	5.64	0.35	4.78e-8	Renal cell carcinoma;
SARC	cis	rs9815354	0.903	rs11705749	chr3:41947294	C/T	cg03022575	chr3:42003672	ULK4	-0.55	-5.22	-0.32	4.05e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg11247378	chr22:39784982	NA	-0.3	-4.92	-0.31	1.63e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9291683	0.510	rs4318649	chr4:10016815	T/C	cg00071950	chr4:10020882	SLC2A9	0.32	4.88	0.3	1.93e-6	Bone mineral density;
SARC	cis	rs35110281	0.807	rs28840140	chr21:45039163	T/C	cg21573476	chr21:45109991	RRP1B	-0.5	-7.44	-0.44	1.94e-12	Mean corpuscular volume;
SARC	cis	rs7568458	0.870	rs1972297	chr2:85808573	T/C	cg17127132	chr2:85788382	GGCX	0.39	5.11	0.32	6.68e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg18876405	chr7:65276391	NA	-0.7	-8.81	-0.5	3e-16	Aortic root size;
SARC	cis	rs698813	0.703	rs2053457	chr2:44572164	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.66	7.64	0.45	5.67e-13	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs9916302	0.904	rs68178216	chr17:37526241	A/C	cg00129232	chr17:37814104	STARD3	0.6	7.4	0.44	2.5e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs7208859	0.623	rs1061346	chr17:29114229	G/A	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9296092	0.538	rs9296094	chr6:33520064	A/G	cg13560919	chr6:33536144	NA	-0.49	-5.95	-0.36	9.74e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.99	11.36	0.6	4.27e-24	Platelet count;
SARC	cis	rs6568686	0.627	rs12191726	chr6:111769524	T/C	cg15721981	chr6:111408429	SLC16A10	0.65	5.67	0.35	4.31e-8	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs4268898	0.760	rs4665675	chr2:24468132	C/T	cg06627628	chr2:24431161	ITSN2	-0.5	-6.8	-0.41	8.67e-11	Asthma;
SARC	cis	rs4951011	0.938	rs7414107	chr1:203756859	A/G	cg05526099	chr1:203152295	CHI3L1	-0.34	-4.75	-0.3	3.54e-6	Breast cancer;
SARC	cis	rs4713118	0.629	rs203888	chr6:28021589	C/T	cg17221315	chr6:27791827	HIST1H4J	0.53	5.31	0.33	2.56e-7	Parkinson's disease;
SARC	cis	rs6594499	0.542	rs4530809	chr5:110462230	A/G	cg04022379	chr5:110408740	TSLP	0.57	7.71	0.45	3.54e-13	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs7044106	0.718	rs10616	chr9:123363533	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	5.37	0.33	1.88e-7	Hip circumference adjusted for BMI;
SARC	cis	rs7833790	1.000	rs7460277	chr8:82709777	T/C	cg17211192	chr8:82754475	SNX16	-0.58	-6.45	-0.39	6.55e-10	Diastolic blood pressure;
SARC	cis	rs611744	0.935	rs679077	chr8:109244742	G/T	cg21045802	chr8:109455806	TTC35	0.45	5.38	0.33	1.85e-7	Dupuytren's disease;
SARC	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg22800045	chr5:56110881	MAP3K1	0.74	7.76	0.45	2.64e-13	Initial pursuit acceleration;
SARC	cis	rs11098499	0.698	rs4422403	chr4:120258194	C/T	cg09307838	chr4:120376055	NA	0.75	10.4	0.56	4.7e-21	Corneal astigmatism;
SARC	cis	rs80130819	0.748	rs2732487	chr12:48686741	T/C	cg05342945	chr12:48394962	COL2A1	-0.52	-5.45	-0.34	1.27e-7	Prostate cancer;
SARC	cis	rs9733	0.519	rs1134067	chr1:150721175	G/T	cg15448220	chr1:150897856	SETDB1	0.47	5.92	0.36	1.14e-8	Tonsillectomy;
SARC	trans	rs7613875	0.654	rs3774751	chr3:50209053	G/T	cg21659725	chr3:3221576	CRBN	-0.5	-6.34	-0.38	1.2e-9	Body mass index;
SARC	cis	rs7513165	0.867	rs4951318	chr1:204161513	G/C	cg23788856	chr1:204159729	KISS1	-0.36	-5.48	-0.34	1.12e-7	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
SARC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg07414643	chr4:187882934	NA	0.52	7.86	0.46	1.42e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg03806693	chr22:41940476	POLR3H	-0.84	-11.08	-0.59	3.42e-23	Vitiligo;
SARC	cis	rs7582720	1.000	rs72934764	chr2:203758521	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.31	0.43	4.24e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs12887734	0.546	rs66676135	chr14:104271504	G/A	cg26031613	chr14:104095156	KLC1	-0.45	-5.18	-0.32	4.83e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	cis	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg24110177	chr3:50126178	RBM5	0.56	7.56	0.44	9.38e-13	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg08677398	chr8:58056175	NA	0.42	5.07	0.32	8.07e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	9.15	0.51	3.02e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6696846	0.691	rs11240370	chr1:205118336	T/G	cg21643547	chr1:205240462	TMCC2	-0.59	-8.04	-0.47	4.56e-14	Red blood cell count;
SARC	cis	rs6570726	0.791	rs9373463	chr6:145894762	C/T	cg23711669	chr6:146136114	FBXO30	0.84	13.98	0.68	1.14e-32	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs9354308	0.933	rs1938068	chr6:66607807	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.59	6.87	0.41	5.81e-11	Metabolite levels;
SARC	cis	rs881375	1.000	rs4323544	chr9:123647377	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.43	5.22	0.32	4.01e-7	Rheumatoid arthritis;
SARC	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	11.95	0.62	5.37e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs4713118	0.955	rs9468201	chr6:27687035	C/T	cg17221315	chr6:27791827	HIST1H4J	0.49	4.92	0.31	1.67e-6	Parkinson's disease;
SARC	cis	rs950169	0.922	rs62021167	chr15:85118051	T/A	cg03959625	chr15:84868606	LOC388152	0.36	4.95	0.31	1.44e-6	Schizophrenia;
SARC	cis	rs1008375	0.866	rs12233712	chr4:17570063	T/A	cg27347728	chr4:17578864	LAP3	0.43	5.15	0.32	5.64e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2228479	0.702	rs11646374	chr16:89857935	G/A	cg06558623	chr16:89946397	TCF25	0.92	6.57	0.4	3.34e-10	Skin colour saturation;
SARC	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	16.55	0.74	3.34e-41	Height;
SARC	cis	rs10463316	0.894	rs7712569	chr5:150766089	A/C	cg03212797	chr5:150827313	SLC36A1	-0.44	-5.26	-0.33	3.34e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs4699052	1.000	rs4699052	chr4:104137790	C/T	cg16532752	chr4:104119610	CENPE	-0.41	-4.85	-0.3	2.28e-6	Testicular germ cell tumor;
SARC	cis	rs1008375	1.000	rs62295634	chr4:17685346	C/A	cg02297831	chr4:17616191	MED28	0.43	5.41	0.33	1.57e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4253772	0.832	rs6008259	chr22:46633782	G/A	cg24881330	chr22:46731750	TRMU	0.55	5.74	0.35	2.89e-8	LDL cholesterol;Cholesterol, total;
SARC	cis	rs60843830	0.964	rs17713879	chr2:254215	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.63	9.09	0.51	4.46e-17	Spherical equivalent (joint analysis main effects and education interaction);
SARC	cis	rs9916302	0.904	rs11869109	chr17:37518205	G/T	cg00129232	chr17:37814104	STARD3	0.6	7.36	0.43	3.15e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs12586317	0.547	rs28577270	chr14:35498443	G/A	cg26967526	chr14:35346199	BAZ1A	-0.57	-5.71	-0.35	3.4e-8	Psoriasis;
SARC	cis	rs7178572	0.568	rs28524916	chr15:77599002	T/A	cg22256960	chr15:77711686	NA	0.48	5.18	0.32	4.76e-7	Type 2 diabetes;
SARC	cis	rs11574514	0.661	rs77151487	chr16:68318185	G/A	cg01866162	chr16:67596514	CTCF	1.08	6.42	0.39	7.67e-10	Crohn's disease;
SARC	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg05872129	chr22:39784769	NA	-0.41	-5.4	-0.33	1.68e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg03060546	chr3:49711283	APEH	0.69	7.41	0.44	2.36e-12	Menarche (age at onset);
SARC	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.75	6.01	0.37	7.07e-9	Initial pursuit acceleration;
SARC	cis	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg01579765	chr21:45077557	HSF2BP	-0.37	-6.31	-0.38	1.39e-9	Mean corpuscular volume;
SARC	cis	rs7086627	0.515	rs7078254	chr10:82212193	C/T	cg01528321	chr10:82214614	TSPAN14	0.57	8.2	0.47	1.63e-14	Post bronchodilator FEV1;
SARC	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg21171335	chr12:122356390	WDR66	0.42	6.66	0.4	1.99e-10	Mean corpuscular volume;
SARC	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg18876405	chr7:65276391	NA	-0.54	-6.81	-0.41	8.26e-11	Calcium levels;
SARC	cis	rs1729951	0.575	rs1654923	chr3:136692620	A/T	cg15507776	chr3:136538369	TMEM22	0.5	5.6	0.34	6.04e-8	Neuroticism;
SARC	cis	rs1215050	0.740	rs1214997	chr4:99041533	A/T	cg05340658	chr4:99064831	C4orf37	0.5	6.73	0.4	1.27e-10	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs7223966	1.000	rs6504169	chr17:61709145	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.07	0.37	5.07e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs17376456	0.825	rs10053405	chr5:93275403	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.64	-5.35	-0.33	2.07e-7	Diabetic retinopathy;
SARC	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg09323728	chr8:95962352	TP53INP1	-0.29	-4.91	-0.31	1.69e-6	Type 2 diabetes;
SARC	cis	rs67460515	0.892	rs2100238	chr3:161058055	T/A	cg03342759	chr3:160939853	NMD3	-0.68	-8.79	-0.5	3.41e-16	Parkinson's disease;
SARC	cis	rs16870629	0.541	rs2334955	chr5:1062444	A/G	cg18655438	chr5:1077845	SLC12A7	-0.43	-5.9	-0.36	1.25e-8	QT interval;
SARC	cis	rs735396	0.694	rs2264750	chr12:121450165	C/T	cg02403541	chr12:121454288	C12orf43	0.85	12.56	0.64	5.51e-28	N-glycan levels;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg25509121	chr17:61851092	DDX42;CCDC47	-0.53	-6.74	-0.4	1.21e-10	Height;
SARC	cis	rs4595586	0.563	rs2388178	chr12:39364366	T/G	cg26384229	chr12:38710491	ALG10B	0.51	6.25	0.38	1.9e-9	Morning vs. evening chronotype;
SARC	cis	rs1008375	1.000	rs2159583	chr4:17658838	T/C	cg27347728	chr4:17578864	LAP3	0.47	5.89	0.36	1.36e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6912958	0.781	rs9450723	chr6:88226641	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.5	6.76	0.4	1.12e-10	Monocyte percentage of white cells;
SARC	cis	rs17270561	0.636	rs77343532	chr6:25828828	G/A	cg16482183	chr6:26056742	HIST1H1C	0.5	6.46	0.39	5.91e-10	Iron status biomarkers;
SARC	cis	rs10131894	0.611	rs175002	chr14:75436466	C/G	cg06637938	chr14:75390232	RPS6KL1	0.55	7.47	0.44	1.65e-12	Coronary artery disease;
SARC	cis	rs1707322	1.000	rs10890376	chr1:46406582	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.35	0.38	1.09e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg18252515	chr7:66147081	NA	-0.53	-5.69	-0.35	3.86e-8	Aortic root size;
SARC	cis	rs1008375	0.966	rs1860591	chr4:17577329	A/G	cg16339924	chr4:17578868	LAP3	0.67	8.67	0.49	7.21e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6456042	1.000	rs3127413	chr6:166535728	G/T	cg11088901	chr6:166572345	T	-0.33	-4.82	-0.3	2.61e-6	Asthma;
SARC	trans	rs877282	0.898	rs11253352	chr10:766598	C/A	cg22713356	chr15:30763199	NA	1.04	10.08	0.55	4.55e-20	Uric acid levels;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg25021893	chr21:47856140	PCNT	0.51	6.35	0.38	1.15e-9	Schizophrenia;
SARC	trans	rs61931739	0.500	rs3924705	chr12:34557825	A/T	cg13010199	chr12:38710504	ALG10B	0.78	11.09	0.59	3.19e-23	Morning vs. evening chronotype;
SARC	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg14829155	chr15:31115871	NA	-0.49	-6.3	-0.38	1.46e-9	Huntington's disease progression;
SARC	cis	rs2204008	0.713	rs2320522	chr12:38251438	C/T	cg26384229	chr12:38710491	ALG10B	0.91	13.64	0.67	1.61e-31	Bladder cancer;
SARC	cis	rs2832077	0.527	rs2250141	chr21:30241984	A/T	cg24692254	chr21:30365293	RNF160	0.6	6.53	0.39	4.09e-10	Cognitive test performance;
SARC	cis	rs7937682	0.883	rs1784775	chr11:111472460	T/C	cg22437258	chr11:111473054	SIK2	0.75	10.37	0.56	5.96e-21	Primary sclerosing cholangitis;
SARC	cis	rs1559088	0.847	rs10416265	chr19:33605300	A/G	cg27124370	chr19:33622961	WDR88	0.4	5.19	0.32	4.47e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs9807989	0.507	rs10204757	chr2:102998974	A/C	cg03938978	chr2:103052716	IL18RAP	0.32	5.17	0.32	5.14e-7	Asthma;
SARC	trans	rs66573146	0.572	rs55740475	chr4:6954092	C/G	cg07817883	chr1:32538562	TMEM39B	1.08	8.4	0.48	4.51e-15	Granulocyte percentage of myeloid white cells;
SARC	cis	rs10088262	0.634	rs7815695	chr8:124783978	C/G	cg20713898	chr8:124780851	FAM91A1	-0.68	-7.14	-0.42	1.2e-11	Pancreatic cancer;
SARC	cis	rs9309473	1.000	rs10187192	chr2:73713500	T/C	cg20560298	chr2:73613845	ALMS1	-0.57	-6.49	-0.39	5.22e-10	Metabolite levels;
SARC	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs854765	0.547	rs7223696	chr17:17915791	G/T	cg04398451	chr17:18023971	MYO15A	-0.44	-6.29	-0.38	1.53e-9	Total body bone mineral density;
SARC	cis	rs870825	0.616	rs7667409	chr4:185650941	C/T	cg04058563	chr4:185651563	MLF1IP	-0.78	-10.89	-0.58	1.32e-22	Blood protein levels;
SARC	cis	rs66573146	0.808	rs73202120	chr4:7005588	A/G	cg00086871	chr4:6988644	TBC1D14	0.89	5.75	0.35	2.78e-8	Granulocyte percentage of myeloid white cells;
SARC	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg13939156	chr17:80058883	NA	-0.36	-5.65	-0.35	4.64e-8	Life satisfaction;
SARC	cis	rs921968	0.565	rs62191658	chr2:219630294	A/G	cg02176678	chr2:219576539	TTLL4	-0.33	-5.03	-0.31	9.92e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg03060546	chr3:49711283	APEH	0.42	5.24	0.32	3.51e-7	Parkinson's disease;
SARC	cis	rs4843747	0.671	rs28671027	chr16:88116323	G/A	cg01573921	chr16:88061006	BANP	-0.48	-5.12	-0.32	6.44e-7	Menopause (age at onset);
SARC	cis	rs710216	0.843	rs710220	chr1:43415346	G/T	cg22176566	chr1:43424700	SLC2A1	0.52	5.55	0.34	7.77e-8	Red cell distribution width;
SARC	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg20607798	chr8:58055168	NA	0.57	5.25	0.33	3.49e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7829975	0.509	rs7838674	chr8:8797073	A/T	cg15556689	chr8:8085844	FLJ10661	-0.4	-4.82	-0.3	2.57e-6	Mood instability;
SARC	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg08048268	chr3:133502702	NA	-0.49	-6.46	-0.39	6.2e-10	Iron status biomarkers;
SARC	cis	rs1832871	0.711	rs76962726	chr6:158674041	C/T	cg07165851	chr6:158734300	TULP4	0.56	6.79	0.41	9.29e-11	Height;
SARC	cis	rs7666738	0.830	rs13122456	chr4:98936011	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs34779708	0.966	rs12775548	chr10:35479504	G/T	cg03585969	chr10:35415529	CREM	0.4	4.93	0.31	1.6e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg10876282	chr6:28092338	ZSCAN16	-0.47	-4.76	-0.3	3.35e-6	Depression;
SARC	cis	rs9902453	0.933	rs7221154	chr17:28505024	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.52	-6.69	-0.4	1.69e-10	Coffee consumption (cups per day);
SARC	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg16405210	chr4:1374714	KIAA1530	-0.47	-5.55	-0.34	7.63e-8	Obesity-related traits;
SARC	cis	rs9467773	0.967	rs7753565	chr6:26560012	A/G	cg12292205	chr6:26970375	C6orf41	0.45	5.36	0.33	2.02e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7086627	0.515	rs2125040	chr10:82208422	G/C	cg00277334	chr10:82204260	NA	-0.57	-9.46	-0.53	3.6e-18	Post bronchodilator FEV1;
SARC	cis	rs870825	0.655	rs67380800	chr4:185623788	T/C	cg04058563	chr4:185651563	MLF1IP	0.84	11.62	0.61	6.27e-25	Blood protein levels;
SARC	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg03806693	chr22:41940476	POLR3H	-0.98	-13.6	-0.67	2.18e-31	Vitiligo;
SARC	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg12463550	chr7:65579703	CRCP	-0.48	-5.26	-0.33	3.28e-7	Aortic root size;
SARC	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg18876405	chr7:65276391	NA	0.7	8.91	0.5	1.52e-16	Aortic root size;
SARC	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg12564285	chr5:131593104	PDLIM4	0.42	6.16	0.37	3.24e-9	Acylcarnitine levels;
SARC	cis	rs7005380	0.538	rs7461170	chr8:120916254	A/G	cg21744203	chr8:120868354	DSCC1	-0.48	-5.56	-0.34	7.48e-8	Interstitial lung disease;
SARC	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg00908189	chr16:619842	PIGQ	0.85	12.4	0.63	1.96e-27	Height;
SARC	trans	rs208520	0.690	rs12192851	chr6:66705862	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	14.02	0.68	8.85e-33	Exhaled nitric oxide output;
SARC	cis	rs362296	0.661	rs3095077	chr4:3265710	A/G	cg06533319	chr4:3265114	C4orf44	-0.33	-5.39	-0.33	1.7e-7	Parental longevity (mother's age at death);
SARC	cis	rs920590	0.758	rs7010174	chr8:19661930	G/C	cg03894339	chr8:19674705	INTS10	0.54	6.32	0.38	1.31e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg06925236	chr11:68039653	C11orf24	0.46	6.59	0.4	2.84e-10	Cancer;
SARC	cis	rs12594515	1.000	rs6493172	chr15:45987213	T/G	cg14863074	chr15:45997064	NA	0.35	5.28	0.33	2.94e-7	Waist circumference;Weight;
SARC	cis	rs870825	0.616	rs12502860	chr4:185636105	T/C	cg04058563	chr4:185651563	MLF1IP	0.84	11.36	0.6	4.49e-24	Blood protein levels;
SARC	cis	rs9467773	1.000	rs1078679	chr6:26568741	C/T	cg11502198	chr6:26597334	ABT1	0.53	6.46	0.39	6.05e-10	Intelligence (multi-trait analysis);
SARC	cis	rs9790314	0.521	rs2122527	chr3:161091636	G/A	cg03342759	chr3:160939853	NMD3	-0.54	-6.8	-0.41	8.61e-11	Morning vs. evening chronotype;
SARC	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg08975724	chr8:8085496	FLJ10661	0.53	6.73	0.4	1.28e-10	Mood instability;
SARC	cis	rs79149102	0.649	rs2899827	chr15:75101127	A/G	cg09165964	chr15:75287851	SCAMP5	-0.86	-4.93	-0.31	1.57e-6	Lung cancer;
SARC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg07414643	chr4:187882934	NA	0.52	7.83	0.46	1.66e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs986417	0.579	rs1254281	chr14:60854300	T/C	cg27398547	chr14:60952738	C14orf39	-1.01	-8.72	-0.5	5.17e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg17971929	chr21:40555470	PSMG1	0.99	13.64	0.67	1.61e-31	Cognitive function;
SARC	cis	rs7044106	0.791	rs10739572	chr9:123489815	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	6.23	0.38	2.17e-9	Hip circumference adjusted for BMI;
SARC	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg16486109	chr11:613632	IRF7	0.47	6.62	0.4	2.39e-10	Systemic lupus erythematosus;
SARC	cis	rs1865760	1.000	rs3830057	chr6:25918510	G/T	cg10373733	chr6:25993375	NA	0.45	5.32	0.33	2.41e-7	Height;
SARC	cis	rs2074585	0.806	rs2657949	chr15:90950790	G/A	cg22089800	chr15:90895588	ZNF774	0.64	7.93	0.46	9.3e-14	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs3733585	0.683	rs13112015	chr4:9933796	C/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.31	-0.43	4.19e-12	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.76	9.58	0.53	1.49e-18	Prudent dietary pattern;
SARC	cis	rs3772130	0.603	rs10470410	chr3:121434977	G/T	cg20356878	chr3:121714668	ILDR1	0.39	6.23	0.38	2.14e-9	Cognitive performance;
SARC	trans	rs488628	0.652	rs12233581	chr3:118177116	C/T	cg26413987	chr12:121124951	MLEC	0.73	6.43	0.39	6.98e-10	White matter integrity (bipolar disorder risk interaction);
SARC	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs6942407	0.546	rs2108272	chr7:86805399	C/T	cg02420886	chr7:86849541	C7orf23	0.7	5.99	0.37	7.92e-9	Food allergy;
SARC	cis	rs17023223	0.581	rs11811859	chr1:119707680	A/G	cg05756136	chr1:119680316	WARS2	-0.44	-5.09	-0.32	7.32e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs77633900	0.614	rs280014	chr15:76986890	A/G	cg21673338	chr15:77095150	SCAPER	-0.6	-5.05	-0.31	8.79e-7	Non-glioblastoma glioma;Glioma;
SARC	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg21724239	chr8:58056113	NA	0.61	5.91	0.36	1.19e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg11494091	chr17:61959527	GH2	0.56	8.41	0.48	4.23e-15	Prudent dietary pattern;
SARC	cis	rs12421382	0.614	rs11213104	chr11:109391297	G/T	cg27471124	chr11:109292789	C11orf87	0.36	5.18	0.32	4.83e-7	Schizophrenia;
SARC	cis	rs75920871	0.588	rs3181	chr11:116907043	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.5	-4.99	-0.31	1.17e-6	Subjective well-being;
SARC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.42	0.53	4.71e-18	Prudent dietary pattern;
SARC	cis	rs1008375	1.000	rs56974987	chr4:17627856	G/A	cg27347728	chr4:17578864	LAP3	0.48	5.91	0.36	1.2e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs796364	0.951	rs7608668	chr2:201000017	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.51	-5.14	-0.32	5.82e-7	Schizophrenia;
SARC	cis	rs60752752	0.852	rs11205281	chr1:153364662	C/T	cg26882115	chr1:153603048	S100A1;S100A13	-0.6	-4.72	-0.3	4.11e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs72627123	0.867	rs79250763	chr14:74491121	G/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	5.51	0.34	9.28e-8	Morning vs. evening chronotype;
SARC	cis	rs67478160	0.643	rs4900594	chr14:104251006	C/T	cg08213375	chr14:104286397	PPP1R13B	0.26	4.72	0.3	4.02e-6	Schizophrenia;
SARC	cis	rs9902453	0.765	rs8079209	chr17:28186773	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	7.57	0.44	8.93e-13	Coffee consumption (cups per day);
SARC	cis	rs2033732	0.706	rs1866086	chr8:85071556	G/C	cg05716166	chr8:85095498	RALYL	0.47	5.64	0.35	4.83e-8	Body mass index;
SARC	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg25894440	chr7:65020034	NA	-0.71	-5.4	-0.33	1.62e-7	Diabetic kidney disease;
SARC	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg11764359	chr7:65958608	NA	-0.77	-9.36	-0.52	6.84e-18	Aortic root size;
SARC	cis	rs7481584	0.624	rs516443	chr11:3047294	A/G	cg05729581	chr11:3078854	CARS	0.57	7.42	0.44	2.13e-12	Calcium levels;
SARC	cis	rs17030434	0.906	rs12643219	chr4:154670798	T/C	cg14289246	chr4:154710475	SFRP2	-0.71	-7.09	-0.42	1.63e-11	Electrocardiographic conduction measures;
SARC	cis	rs7937682	0.632	rs14133	chr11:111782697	C/G	cg22437258	chr11:111473054	SIK2	-0.47	-5.37	-0.33	1.92e-7	Primary sclerosing cholangitis;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg11416597	chr1:33722623	ZNF362	-0.67	-7.13	-0.42	1.28e-11	Lung cancer in ever smokers;
SARC	cis	rs6835098	0.962	rs10014010	chr4:174083230	C/T	cg08422745	chr4:174089978	GALNT7	-0.75	-10.19	-0.56	2.1e-20	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs4689388	0.853	rs13114527	chr4:6294655	T/G	cg25554036	chr4:6271136	WFS1	0.39	6.42	0.39	7.48e-10	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs11122272	0.701	rs2790887	chr1:231523724	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs5753037	0.543	rs131287	chr22:30158463	C/T	cg01021169	chr22:30184971	ASCC2	-0.49	-6.7	-0.4	1.51e-10	Type 1 diabetes;
SARC	cis	rs644799	1.000	rs693597	chr11:95589629	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	13.87	0.67	2.75e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg08376864	chr3:192958726	MGC2889;HRASLS	-0.56	-6.54	-0.39	3.95e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs4986172	0.690	rs11657325	chr17:43242694	C/T	cg27395066	chr17:43221220	ACBD4	0.39	5.02	0.31	1.01e-6	Height;
SARC	cis	rs6831352	0.918	rs13113166	chr4:100050528	A/G	cg13256891	chr4:100009986	ADH5	-0.65	-8.11	-0.47	2.83e-14	Alcohol dependence;
SARC	cis	rs13191362	1.000	rs34653853	chr6:163114362	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.76	6.64	0.4	2.14e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs10992471	0.598	rs10761156	chr9:95171852	C/T	cg13798575	chr9:95087839	CENPP;NOL8	0.41	4.95	0.31	1.42e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs10782582	0.593	rs11163967	chr1:76154185	T/C	cg03433033	chr1:76189801	ACADM	-0.42	-5.45	-0.34	1.26e-7	Daytime sleep phenotypes;
SARC	cis	rs2070488	1.000	rs2070488	chr3:38442490	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.85	-14.17	-0.68	2.72e-33	Electrocardiographic conduction measures;
SARC	cis	rs10791097	0.694	rs6590520	chr11:130747386	C/G	cg09137382	chr11:130731461	NA	0.31	4.76	0.3	3.48e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs6087990	0.814	rs2424895	chr20:31335978	C/T	cg13636640	chr20:31349939	DNMT3B	-0.77	-12.23	-0.63	6.83e-27	Ulcerative colitis;
SARC	cis	rs7638909	0.512	rs6804918	chr3:38598956	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.41	-5.0	-0.31	1.11e-6	Electrocardiographic conduction measures;
SARC	cis	rs12142240	0.698	rs56358525	chr1:46849520	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-5.49	-0.34	1.06e-7	Menopause (age at onset);
SARC	cis	rs568617	0.953	rs645900	chr11:65648135	G/A	cg00576331	chr11:65640516	EFEMP2	0.47	5.45	0.34	1.27e-7	Crohn's disease;
SARC	cis	rs9596270	0.772	rs11842790	chr13:50924448	A/G	cg05091135	chr13:51103373	NA	-0.42	-5.56	-0.34	7.31e-8	Multiple sclerosis;
SARC	cis	rs1580019	0.539	rs11769109	chr7:32571352	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.61	8.21	0.47	1.53e-14	Cognitive ability;
SARC	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-4.81	-0.3	2.77e-6	Menopause (age at onset);
SARC	cis	rs4891159	0.548	rs690423	chr18:74117984	G/A	cg24786174	chr18:74118243	ZNF516	0.76	13.04	0.65	1.46e-29	Longevity;
SARC	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg01316550	chr5:56110833	MAP3K1	-0.51	-4.73	-0.3	3.87e-6	Initial pursuit acceleration;
SARC	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg22484793	chr3:52261325	TLR9	0.29	4.77	0.3	3.31e-6	Bipolar disorder;
SARC	cis	rs2486288	0.656	rs11629807	chr15:45547037	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.45	-5.55	-0.34	7.66e-8	Glomerular filtration rate;
SARC	cis	rs12579753	0.719	rs4384447	chr12:82268069	G/C	cg07988820	chr12:82153109	PPFIA2	-0.45	-5.46	-0.34	1.21e-7	Resting heart rate;
SARC	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg15595755	chr5:1867978	NA	0.46	6.3	0.38	1.5e-9	Cardiovascular disease risk factors;
SARC	cis	rs2562456	0.917	rs6511256	chr19:21693315	G/T	cg00806126	chr19:22604979	ZNF98	0.47	4.85	0.3	2.27e-6	Pain;
SARC	trans	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg00938859	chr5:1591904	SDHAP3	0.79	7.66	0.45	5.1e-13	Breast cancer;
SARC	trans	rs11098499	0.863	rs7695620	chr4:120452776	G/A	cg25214090	chr10:38739885	LOC399744	0.57	7.35	0.43	3.31e-12	Corneal astigmatism;
SARC	cis	rs2836974	0.565	rs34304022	chr21:40579619	G/A	cg17971929	chr21:40555470	PSMG1	0.68	5.82	0.36	1.97e-8	Cognitive function;
SARC	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg13699009	chr12:122356056	WDR66	0.58	9.2	0.52	2.07e-17	Mean corpuscular volume;
SARC	cis	rs911555	0.723	rs2273701	chr14:103923225	G/T	cg24130564	chr14:104152367	KLC1	0.5	5.86	0.36	1.55e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7246657	0.943	rs28373708	chr19:37976659	C/T	cg23950597	chr19:37808831	NA	-0.57	-5.63	-0.35	5.05e-8	Coronary artery calcification;
SARC	cis	rs62244186	0.541	rs9859879	chr3:44840166	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.56	7.43	0.44	2.04e-12	Depressive symptoms;
SARC	cis	rs10463554	0.927	rs62362489	chr5:102245545	C/T	cg23492399	chr5:102201601	PAM	-0.49	-5.71	-0.35	3.37e-8	Parkinson's disease;
SARC	cis	rs11249608	0.548	rs6894076	chr5:178449813	T/C	cg01312482	chr5:178451176	ZNF879	-0.37	-4.86	-0.3	2.15e-6	Pubertal anthropometrics;
SARC	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg11766577	chr21:47581405	C21orf56	0.5	6.07	0.37	5.22e-9	Testicular germ cell tumor;
SARC	cis	rs6450176	1.000	rs3776703	chr5:53305259	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.68	-7.89	-0.46	1.17e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	trans	rs1941687	0.563	rs7232237	chr18:31324934	C/T	cg27147174	chr7:100797783	AP1S1	0.5	6.38	0.39	9.25e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
SARC	cis	rs7520050	0.751	rs2230657	chr1:46073489	G/A	cg24296786	chr1:45957014	TESK2	0.42	5.45	0.34	1.27e-7	Red blood cell count;Reticulocyte count;
SARC	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.77	11.08	0.59	3.34e-23	Total body bone mineral density;
SARC	cis	rs17376456	0.877	rs10057814	chr5:93399092	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.67	6.39	0.39	9.06e-10	Diabetic retinopathy;
SARC	cis	rs854765	0.647	rs741782	chr17:18019712	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.55	7.73	0.45	3.11e-13	Total body bone mineral density;
SARC	cis	rs10779751	0.690	rs910661	chr1:11130116	C/A	cg08854313	chr1:11322531	MTOR	0.83	11.49	0.6	1.66e-24	Body mass index;
SARC	cis	rs8017423	0.967	rs11621431	chr14:90709221	C/T	cg20276874	chr14:90721474	PSMC1	-0.36	-5.02	-0.31	1.04e-6	Mortality in heart failure;
SARC	cis	rs950169	1.000	rs12915234	chr15:84758301	G/A	cg17507749	chr15:85114479	UBE2QP1	0.75	9.14	0.51	3.12e-17	Schizophrenia;
SARC	cis	rs9303401	0.614	rs3803752	chr17:56540267	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.03	10.73	0.57	4.48e-22	Cognitive test performance;
SARC	cis	rs10752881	0.875	rs10752894	chr1:183050610	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.35	0.56	6.82e-21	Colorectal cancer;
SARC	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg26681399	chr22:41777847	TEF	-0.42	-4.84	-0.3	2.31e-6	Vitiligo;
SARC	cis	rs9905704	0.647	rs3809723	chr17:57061978	T/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.4	-4.85	-0.3	2.23e-6	Testicular germ cell tumor;
SARC	cis	rs1008375	0.898	rs2079892	chr4:17577163	G/A	cg02297831	chr4:17616191	MED28	0.49	6.22	0.38	2.31e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs3809566	0.963	rs3809565	chr15:63333619	A/G	cg05507819	chr15:63340323	TPM1	0.54	5.93	0.36	1.06e-8	Platelet count;
SARC	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg11764359	chr7:65958608	NA	0.71	8.66	0.49	8.11e-16	Aortic root size;
SARC	cis	rs3204270	0.500	rs62077175	chr17:79649568	G/T	cg26965718	chr17:79658957	HGS	-0.61	-5.02	-0.31	1.03e-6	Dental caries;
SARC	cis	rs9398803	0.865	rs9372840	chr6:126822635	A/C	cg19875578	chr6:126661172	C6orf173	0.61	8.31	0.48	7.93e-15	Male-pattern baldness;
SARC	cis	rs7250872	0.647	rs7259484	chr19:1813207	A/G	cg05970437	chr19:1864622	KLF16	0.44	4.78	0.3	3.12e-6	Bipolar disorder;
SARC	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg15049968	chr18:44337910	ST8SIA5	0.37	6.07	0.37	5.19e-9	Personality dimensions;
SARC	cis	rs6570726	0.967	rs439017	chr6:145806123	T/C	cg05347473	chr6:146136440	FBXO30	0.45	6.04	0.37	6.03e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs62432291	0.681	rs1699442	chr6:159655918	A/C	cg14500486	chr6:159655392	FNDC1	0.59	6.04	0.37	6.09e-9	Joint mobility (Beighton score);
SARC	cis	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg24110177	chr3:50126178	RBM5	-0.55	-7.3	-0.43	4.64e-12	Intelligence (multi-trait analysis);
SARC	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg23758822	chr17:41437982	NA	0.88	11.19	0.59	1.55e-23	Menopause (age at onset);
SARC	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg04944784	chr2:26401820	FAM59B	-0.6	-7.95	-0.46	8.14e-14	Gut microbiome composition (summer);
SARC	cis	rs3812049	0.667	rs6888037	chr5:127406259	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.89	9.63	0.53	1.05e-18	Lymphocyte counts;Red cell distribution width;
SARC	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg03709012	chr19:19516395	GATAD2A	1.01	17.66	0.76	7.08e-45	Tonsillectomy;
SARC	cis	rs10463316	0.894	rs6891252	chr5:150762807	G/T	cg03212797	chr5:150827313	SLC36A1	-0.52	-6.2	-0.38	2.57e-9	Metabolite levels (Pyroglutamine);
SARC	cis	rs7412746	0.658	rs2275235	chr1:150730279	A/G	cg15448220	chr1:150897856	SETDB1	0.47	6.07	0.37	5.12e-9	Melanoma;
SARC	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg08219700	chr8:58056026	NA	0.78	7.03	0.42	2.21e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs4423214	0.840	rs1790328	chr11:71148038	G/A	cg05163923	chr11:71159392	DHCR7	-0.58	-6.77	-0.41	1.03e-10	Vitamin D levels;
SARC	cis	rs9916302	0.904	rs10491128	chr17:37551988	G/A	cg00129232	chr17:37814104	STARD3	0.61	7.54	0.44	1.02e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs7560272	0.538	rs4241257	chr2:73938607	T/C	cg20560298	chr2:73613845	ALMS1	0.42	5.6	0.34	6.02e-8	Schizophrenia;
SARC	cis	rs16866061	1.000	rs4674916	chr2:225365635	C/A	cg12698349	chr2:225449008	CUL3	0.7	10.09	0.55	4.15e-20	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	cis	rs1865760	0.786	rs2164487	chr6:25950800	A/C	cg18357526	chr6:26021779	HIST1H4A	0.39	4.72	0.3	4.1e-6	Height;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg25923162	chr2:234394645	USP40	-0.49	-6.56	-0.39	3.38e-10	Breast cancer;
SARC	cis	rs9815354	0.868	rs1716653	chr3:41975598	C/A	cg03022575	chr3:42003672	ULK4	-0.61	-5.73	-0.35	3.04e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs735396	1.000	rs2464195	chr12:121435475	G/A	cg25281562	chr12:121454272	C12orf43	0.51	6.11	0.37	4.22e-9	N-glycan levels;
SARC	cis	rs55962025	0.883	rs362275	chr4:3224602	C/T	cg06533319	chr4:3265114	C4orf44	0.34	5.07	0.32	8.2e-7	Parental longevity (mother's age at death);
SARC	cis	rs9479482	1.000	rs5017316	chr6:150333489	A/T	cg03788504	chr6:150331562	NA	-0.3	-4.88	-0.3	1.98e-6	Alopecia areata;
SARC	cis	rs933688	0.532	rs13165085	chr5:90538448	G/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.48	-5.3	-0.33	2.7e-7	Smoking behavior;
SARC	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg11644478	chr21:40555479	PSMG1	0.7	9.05	0.51	5.82e-17	Cognitive function;
SARC	cis	rs7635838	0.819	rs2454481	chr3:11535178	C/T	cg00170343	chr3:11313890	ATG7	0.6	8.31	0.48	7.9e-15	HDL cholesterol;
SARC	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg13770153	chr20:60521292	NA	0.74	10.7	0.57	5.46e-22	Obesity-related traits;
SARC	cis	rs4795067	1.000	rs4795067	chr17:26106675	C/T	cg13208054	chr17:25936354	KSR1	0.37	4.75	0.3	3.53e-6	Psoriatic arthritis;Psoriasis;Cutaneous psoriasis;Inflammatory skin disease;
SARC	cis	rs10883723	0.810	rs2296581	chr10:104242886	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.63	7.99	0.46	6.12e-14	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs6918586	0.557	rs198827	chr6:26121002	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.46	-5.8	-0.36	2.17e-8	Schizophrenia;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg17330273	chr5:96107758	CAST;ERAP1	0.46	6.71	0.4	1.5e-10	Chemerin levels;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg05357137	chr10:28527770	MPP7	0.49	6.61	0.4	2.6e-10	Thyroid stimulating hormone;
SARC	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg22535103	chr8:58192502	C8orf71	-0.69	-6.24	-0.38	2.05e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4642101	0.793	rs6799179	chr3:12829095	A/C	cg05775895	chr3:12838266	CAND2	0.73	11.58	0.6	8.37e-25	QRS complex (12-leadsum);
SARC	cis	rs9790314	1.000	rs1600209	chr3:161038217	A/T	cg03342759	chr3:160939853	NMD3	-0.59	-7.44	-0.44	1.9e-12	Morning vs. evening chronotype;
SARC	cis	rs16866061	1.000	rs72974203	chr2:225408430	G/A	cg12698349	chr2:225449008	CUL3	0.72	10.53	0.57	1.84e-21	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	cis	rs523522	1.000	rs523522	chr12:121020250	A/T	cg27279351	chr12:120934652	DYNLL1	0.68	8.02	0.46	5.27e-14	High light scatter reticulocyte count;
SARC	cis	rs13082711	0.522	rs3103745	chr3:27342927	T/C	cg02860705	chr3:27208620	NA	0.45	5.93	0.36	1.09e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	trans	rs877282	0.891	rs10904557	chr10:797490	C/T	cg22713356	chr15:30763199	NA	-1.18	-11.66	-0.61	4.67e-25	Uric acid levels;
SARC	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg24399712	chr22:39784796	NA	-0.42	-5.62	-0.35	5.42e-8	Intelligence (multi-trait analysis);
SARC	cis	rs5753618	0.561	rs5753543	chr22:31685458	G/A	cg07713946	chr22:31675144	LIMK2	-0.38	-5.25	-0.33	3.39e-7	Colorectal cancer;
SARC	cis	rs2732480	0.538	rs2732462	chr12:48696384	A/G	cg24011408	chr12:48396354	COL2A1	0.48	5.68	0.35	4.01e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs1215050	0.755	rs2952911	chr4:98850666	T/C	cg05340658	chr4:99064831	C4orf37	-0.44	-5.89	-0.36	1.37e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs881375	0.967	rs7848332	chr9:123669496	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	4.87	0.3	2.03e-6	Rheumatoid arthritis;
SARC	cis	rs778371	0.723	rs12999865	chr2:233627250	T/C	cg16596103	chr2:233749413	NGEF	-0.37	-5.66	-0.35	4.35e-8	Schizophrenia;
SARC	cis	rs1045529	0.524	rs34251783	chr8:8891376	T/C	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.89	-0.41	5.18e-11	Myopia;Myopia (pathological);
SARC	cis	rs12421382	0.614	rs12418763	chr11:109390360	C/T	cg27471124	chr11:109292789	C11orf87	0.35	5.05	0.31	9.02e-7	Schizophrenia;
SARC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg26338869	chr17:61819248	STRADA	0.79	10.45	0.56	3.32e-21	Prudent dietary pattern;
SARC	cis	rs11690935	0.549	rs62183819	chr2:172904520	G/T	cg13550731	chr2:172543902	DYNC1I2	0.59	7.78	0.45	2.27e-13	Schizophrenia;
SARC	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg16325326	chr1:53192061	ZYG11B	-0.97	-18.69	-0.77	3.09e-48	Monocyte count;
SARC	trans	rs561341	0.654	rs6505265	chr17:30172580	C/T	cg20587970	chr11:113659929	NA	0.76	7.19	0.43	8.6e-12	Hip circumference adjusted for BMI;
SARC	cis	rs17376456	1.000	rs59472588	chr5:93511981	A/G	cg25358565	chr5:93447407	FAM172A	1.36	14.48	0.69	2.53e-34	Diabetic retinopathy;
SARC	cis	rs3008870	1.000	rs2815351	chr1:67477980	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.92	10.84	0.58	1.99e-22	Lymphocyte percentage of white cells;
SARC	trans	rs7980799	0.653	rs1384598	chr12:33622899	T/A	cg26384229	chr12:38710491	ALG10B	-0.63	-7.77	-0.45	2.52e-13	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs7712401	0.601	rs154506	chr5:122202781	A/G	cg19412675	chr5:122181750	SNX24	0.44	5.66	0.35	4.34e-8	Mean platelet volume;
SARC	cis	rs3733585	0.673	rs4235347	chr4:9951956	C/T	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.94	-0.36	1.06e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs1448094	0.511	rs61930587	chr12:86158793	T/C	cg02569458	chr12:86230093	RASSF9	0.36	4.73	0.3	3.86e-6	Major depressive disorder;
SARC	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg23262073	chr20:60523788	NA	-0.46	-6.78	-0.41	9.56e-11	Body mass index;
SARC	cis	rs67311347	1.000	rs9848083	chr3:40466979	A/G	cg09455208	chr3:40491958	NA	-0.42	-6.8	-0.41	8.81e-11	Renal cell carcinoma;
SARC	cis	rs78545713	0.649	rs16891464	chr6:26235300	A/G	cg00631329	chr6:26305371	NA	-0.61	-4.86	-0.3	2.16e-6	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs4771122	0.728	rs1475221	chr13:28037566	C/T	cg22138327	chr13:27999177	GTF3A	-0.45	-4.77	-0.3	3.22e-6	Body mass index;
SARC	trans	rs9463078	0.547	rs9472336	chr6:44710392	G/A	cg03948781	chr1:205179583	DSTYK	0.39	6.39	0.39	8.88e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
SARC	cis	rs7617773	0.539	rs13069884	chr3:48381148	T/A	cg11946769	chr3:48343235	NME6	0.55	6.76	0.4	1.11e-10	Coronary artery disease;
SARC	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg05793240	chr7:2802953	GNA12	-0.35	-4.98	-0.31	1.26e-6	Height;
SARC	cis	rs7666738	0.830	rs11725477	chr4:98803266	G/T	cg05340658	chr4:99064831	C4orf37	0.65	8.44	0.48	3.43e-15	Colonoscopy-negative controls vs population controls;
SARC	trans	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg06437703	chr8:37914619	EIF4EBP1	-0.7	-9.54	-0.53	2.04e-18	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg08045932	chr20:61659980	NA	0.5	6.84	0.41	7.06e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg20607798	chr8:58055168	NA	0.53	5.13	0.32	6.12e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1008375	1.000	rs4698648	chr4:17692715	C/G	cg16339924	chr4:17578868	LAP3	0.56	7.03	0.42	2.24e-11	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6580649	0.941	rs72644845	chr12:48503881	G/A	cg05342945	chr12:48394962	COL2A1	0.52	5.62	0.35	5.38e-8	Lung cancer;
SARC	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg01316550	chr5:56110833	MAP3K1	0.54	4.92	0.31	1.62e-6	Initial pursuit acceleration;
SARC	cis	rs12142240	0.698	rs1135460	chr1:46815970	T/C	cg10495392	chr1:46806563	NSUN4	0.65	6.83	0.41	7.25e-11	Menopause (age at onset);
SARC	cis	rs9420	0.961	rs71484468	chr11:57632799	G/C	cg23127183	chr11:57508653	C11orf31	-0.59	-6.75	-0.4	1.18e-10	Schizophrenia;
SARC	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg18357526	chr6:26021779	HIST1H4A	0.9	12.67	0.64	2.55e-28	Intelligence (multi-trait analysis);
SARC	cis	rs13096760	1	rs13096760	chr3:49476806	T/C	cg02487422	chr3:49467188	NICN1	0.5	6.85	0.41	6.52e-11	Intelligence (multi-trait analysis);
SARC	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.44	-5.58	-0.34	6.52e-8	Longevity;Endometriosis;
SARC	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg11764359	chr7:65958608	NA	0.88	12.58	0.64	4.89e-28	Aortic root size;
SARC	cis	rs1728785	1.000	rs1728781	chr16:68567794	A/T	cg02972257	chr16:68554789	NA	-0.44	-5.15	-0.32	5.43e-7	Ulcerative colitis;
SARC	cis	rs9902453	0.934	rs7211246	chr17:28485762	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	6.66	0.4	1.98e-10	Coffee consumption (cups per day);
SARC	cis	rs9911578	0.835	rs58647683	chr17:56483194	T/C	cg05425664	chr17:57184151	TRIM37	0.66	8.08	0.47	3.6e-14	Intelligence (multi-trait analysis);
SARC	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg25072359	chr17:41440525	NA	0.49	5.8	0.36	2.15e-8	Menopause (age at onset);
SARC	cis	rs7523050	0.730	rs77425121	chr1:109417677	C/A	cg08274380	chr1:109419600	GPSM2	1.08	8.35	0.48	6.26e-15	Fat distribution (HIV);
SARC	cis	rs523522	0.962	rs10774549	chr12:120891172	C/T	cg27279351	chr12:120934652	DYNLL1	0.71	8.41	0.48	4.25e-15	High light scatter reticulocyte count;
SARC	cis	rs9858542	0.953	rs11706370	chr3:49441091	G/A	cg03060546	chr3:49711283	APEH	-0.58	-7.24	-0.43	6.34e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs933688	1.000	rs9293568	chr5:90737845	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	13.03	0.65	1.61e-29	Smoking behavior;
SARC	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.72	-7.58	-0.44	8e-13	Platelet count;
SARC	cis	rs765787	0.530	rs12905246	chr15:45500841	C/T	cg24006582	chr15:45444508	DUOX1	0.48	6.13	0.37	3.78e-9	Uric acid levels;
SARC	trans	rs61931739	0.534	rs1586410	chr12:33999142	C/T	cg26384229	chr12:38710491	ALG10B	0.86	12.43	0.63	1.52e-27	Morning vs. evening chronotype;
SARC	cis	rs9303401	0.614	rs34678056	chr17:57177549	G/A	cg25039879	chr17:56429692	SUPT4H1	0.58	5.22	0.32	3.88e-7	Cognitive test performance;
SARC	cis	rs4805272	0.512	rs8106166	chr19:29339578	A/G	cg14983838	chr19:29218262	NA	-0.5	-5.25	-0.33	3.36e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs10875746	0.951	rs58865997	chr12:48566873	G/A	cg26205652	chr12:48591994	NA	0.53	5.88	0.36	1.38e-8	Longevity (90 years and older);
SARC	cis	rs9486715	0.867	rs4839842	chr6:96955387	A/T	cg06623918	chr6:96969491	KIAA0776	0.89	12.91	0.65	3.96e-29	Headache;
SARC	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg12463550	chr7:65579703	CRCP	0.45	5.15	0.32	5.55e-7	Aortic root size;
SARC	cis	rs9787249	0.915	rs58589165	chr1:40213670	A/T	cg24920358	chr1:40204285	PPIE	0.43	5.25	0.33	3.45e-7	Blood protein levels;
SARC	cis	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg10591111	chr5:226296	SDHA	-0.52	-4.85	-0.3	2.24e-6	Breast cancer;
SARC	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	16.23	0.73	3.75e-40	Height;
SARC	cis	rs17253792	0.915	rs28537145	chr14:56179119	G/A	cg01858014	chr14:56050164	KTN1	-0.62	-4.86	-0.3	2.19e-6	Putamen volume;
SARC	cis	rs4253772	0.591	rs8135363	chr22:46651713	T/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.64	6.81	0.41	8.27e-11	LDL cholesterol;Cholesterol, total;
SARC	cis	rs898097	0.691	rs7222773	chr17:80907283	A/G	cg20578329	chr17:80767326	TBCD	0.37	5.15	0.32	5.46e-7	Breast cancer;
SARC	cis	rs10484885	0.763	rs56401039	chr6:90522486	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.59	-4.91	-0.31	1.73e-6	QRS interval (sulfonylurea treatment interaction);
SARC	cis	rs12421382	0.659	rs1371330	chr11:109382692	G/T	cg16359550	chr11:109292809	C11orf87	0.35	5.1	0.32	7.18e-7	Schizophrenia;
SARC	cis	rs7727544	0.684	rs272893	chr5:131663062	T/C	cg07395648	chr5:131743802	NA	-0.41	-4.82	-0.3	2.64e-6	Blood metabolite levels;
SARC	cis	rs9300255	0.568	rs1790108	chr12:123636841	A/G	cg05973401	chr12:123451056	ABCB9	0.53	6.05	0.37	5.67e-9	Neutrophil percentage of white cells;
SARC	cis	rs3768617	0.528	rs10737242	chr1:183098249	A/G	cg13390022	chr1:182993471	LAMC1	0.31	4.79	0.3	3.01e-6	Fuchs's corneal dystrophy;
SARC	cis	rs1707322	1.000	rs4660331	chr1:46458783	A/C	cg03146154	chr1:46216737	IPP	0.46	5.61	0.34	5.74e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs61931739	0.817	rs10772144	chr12:34242463	A/C	cg13010199	chr12:38710504	ALG10B	0.58	7.42	0.44	2.11e-12	Morning vs. evening chronotype;
SARC	cis	rs1023500	0.505	rs134899	chr22:42683030	T/G	cg15557168	chr22:42548783	NA	-0.38	-5.48	-0.34	1.08e-7	Schizophrenia;
SARC	cis	rs9902453	0.845	rs12601963	chr17:28246358	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	6.95	0.41	3.67e-11	Coffee consumption (cups per day);
SARC	cis	rs35955747	0.902	rs5997929	chr22:31664032	C/T	cg13145458	chr22:31556086	RNF185	0.4	4.9	0.31	1.83e-6	Neutrophil count;Sum basophil neutrophil counts;
SARC	cis	rs1451375	1.000	rs921451	chr7:50623285	A/G	cg18232548	chr7:50535776	DDC	0.43	4.73	0.3	3.98e-6	Malaria;
SARC	cis	rs67460515	0.596	rs35127376	chr3:160927289	T/C	cg03342759	chr3:160939853	NMD3	-0.65	-8.08	-0.47	3.4e-14	Parkinson's disease;
SARC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-4.93	-0.31	1.59e-6	Total body bone mineral density;
SARC	cis	rs959260	0.541	rs61417295	chr17:73356848	T/C	cg14668889	chr17:73230827	NUP85	0.53	5.16	0.32	5.27e-7	Systemic lupus erythematosus;
SARC	cis	rs72781680	0.898	rs10490752	chr2:24025132	C/T	cg06627628	chr2:24431161	ITSN2	-0.66	-6.27	-0.38	1.69e-9	Lymphocyte counts;
SARC	cis	rs6690583	0.623	rs75918067	chr1:85453413	T/C	cg22153463	chr1:85462885	MCOLN2	0.72	6.96	0.42	3.33e-11	Serum sulfate level;
SARC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg23034840	chr1:205782522	SLC41A1	0.61	7.7	0.45	3.85e-13	Menarche (age at onset);
SARC	cis	rs9815354	1.000	rs1716668	chr3:41907850	T/C	cg03022575	chr3:42003672	ULK4	0.55	5.27	0.33	3.16e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg23758822	chr17:41437982	NA	0.92	12.6	0.64	4.12e-28	Menopause (age at onset);
SARC	cis	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg05623727	chr3:50126028	RBM5	0.33	4.91	0.31	1.69e-6	Intelligence (multi-trait analysis);
SARC	cis	rs644799	1.000	rs11021319	chr11:95523123	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	14.28	0.68	1.22e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg13774095	chr9:103189168	C9orf30	0.49	6.32	0.38	1.31e-9	Electrocardiographic conduction measures;
SARC	cis	rs698833	0.886	rs4953090	chr2:44565194	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.68	8.84	0.5	2.36e-16	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs483180	0.512	rs606312	chr1:120222582	G/A	cg19096424	chr1:120255104	PHGDH	0.53	6.19	0.38	2.76e-9	Macular telangiectasia type 2;
SARC	cis	rs11190604	1.000	rs10883499	chr10:102232188	T/A	cg07080220	chr10:102295463	HIF1AN	0.76	9.07	0.51	5.2e-17	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg04944784	chr2:26401820	FAM59B	0.6	7.95	0.46	8.14e-14	Gut microbiome composition (summer);
SARC	cis	rs7551222	0.752	rs4245737	chr1:204486242	A/G	cg20240347	chr1:204465584	NA	-0.33	-5.94	-0.36	1e-8	Schizophrenia;
SARC	cis	rs763121	0.853	rs138705	chr22:39133803	C/T	cg21395723	chr22:39101663	GTPBP1	0.59	6.79	0.41	9.24e-11	Menopause (age at onset);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg10571168	chr7:156583547	LMBR1	0.49	7.08	0.42	1.68e-11	Thyroid stimulating hormone;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg14448195	chr7:79086223	NA	0.46	6.68	0.4	1.73e-10	Thyroid stimulating hormone;
SARC	cis	rs112591243	0.685	rs117443865	chr21:47959731	C/G	cg26904215	chr21:47823096	PCNT	-0.74	-4.75	-0.3	3.55e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs910316	0.737	rs108621	chr14:75480637	T/C	cg08847533	chr14:75593920	NEK9	-0.82	-11.57	-0.6	9.34e-25	Height;
SARC	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg22920501	chr2:26401640	FAM59B	-0.61	-8.19	-0.47	1.71e-14	Gut microbiome composition (summer);
SARC	cis	rs703842	1.000	rs6581155	chr12:58178162	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.76	11.27	0.59	8.53e-24	Multiple sclerosis;
SARC	cis	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg24110177	chr3:50126178	RBM5	-0.62	-8.25	-0.48	1.2e-14	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg24829409	chr8:58192753	C8orf71	-0.69	-6.17	-0.37	3.03e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9902453	1.000	rs4795525	chr17:28388487	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.53	-6.96	-0.41	3.52e-11	Coffee consumption (cups per day);
SARC	cis	rs950169	0.840	rs12905223	chr15:85114268	T/C	cg17507749	chr15:85114479	UBE2QP1	0.79	9.46	0.53	3.47e-18	Schizophrenia;
SARC	cis	rs7932354	0.528	rs7931260	chr11:47088303	T/C	cg03339077	chr11:47165057	C11orf49	-0.39	-5.23	-0.32	3.76e-7	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg05861140	chr6:150128134	PCMT1	-0.37	-4.79	-0.3	2.92e-6	Lung cancer;
SARC	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg08280861	chr8:58055591	NA	0.61	5.46	0.34	1.19e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1348850	0.918	rs4893966	chr2:178470138	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.55	6.37	0.38	1.02e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs6840360	0.533	rs11099829	chr4:152727299	A/G	cg22705602	chr4:152727874	NA	0.47	8.16	0.47	2.14e-14	Intelligence (multi-trait analysis);
SARC	cis	rs1878931	0.597	rs37816	chr16:3456371	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.68	-7.66	-0.45	4.83e-13	Body mass index (adult);
SARC	cis	rs4810685	0.526	rs6018686	chr20:46410965	A/C	cg08288986	chr20:46415360	SULF2	0.52	5.87	0.36	1.49e-8	Attention deficit hyperactivity disorder (time to onset);
SARC	cis	rs1865760	0.516	rs9379818	chr6:26023206	G/T	cg10373733	chr6:25993375	NA	0.4	4.96	0.31	1.35e-6	Height;
SARC	cis	rs76917914	0.820	rs7869762	chr9:100814573	G/T	cg03040243	chr9:100819229	NANS	0.73	7.74	0.45	2.93e-13	Immature fraction of reticulocytes;
SARC	cis	rs9916302	0.706	rs57933226	chr17:37412829	C/T	cg00129232	chr17:37814104	STARD3	-0.56	-6.03	-0.37	6.36e-9	Glomerular filtration rate (creatinine);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg19001237	chr11:18548595	TSG101	-0.58	-7.4	-0.44	2.45e-12	Height;
SARC	cis	rs10979	1.000	rs9390112	chr6:143896147	G/A	cg25407410	chr6:143891975	LOC285740	-0.63	-8.6	-0.49	1.21e-15	Hypospadias;
SARC	cis	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg18252515	chr7:66147081	NA	-1.16	-10.13	-0.55	3.21e-20	Diabetic kidney disease;
SARC	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg00933542	chr6:150070202	PCMT1	0.29	5.09	0.32	7.37e-7	Lung cancer;
SARC	cis	rs7709909	0.782	rs3958547	chr5:79995570	T/G	cg04186980	chr5:79953697	MSH3	0.36	4.76	0.3	3.41e-6	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
SARC	cis	rs15676	0.947	rs2280842	chr9:131585808	C/G	cg00228799	chr9:131580591	ENDOG	0.61	7.69	0.45	4.02e-13	Blood metabolite levels;
SARC	cis	rs7625806	0.864	rs6762423	chr3:38098880	A/G	cg15121877	chr3:38081287	DLEC1	0.35	4.83	0.3	2.44e-6	Carotid intima media thickness;
SARC	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg04234412	chr22:24373322	LOC391322	0.59	6.49	0.39	5.02e-10	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs1976403	0.659	rs10799700	chr1:21820968	G/C	cg21906605	chr1:21766650	NBPF3	0.48	6.49	0.39	5.07e-10	Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs1580019	0.961	rs4255041	chr7:32496383	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.73	9.78	0.54	3.93e-19	Cognitive ability;
SARC	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg02524346	chr8:600233	NA	0.7	5.29	0.33	2.8e-7	IgG glycosylation;
SARC	cis	rs3820928	0.874	rs7423610	chr2:227836262	A/G	cg05526886	chr2:227700861	RHBDD1	-0.56	-6.78	-0.41	9.69e-11	Pulmonary function;
SARC	cis	rs748404	0.697	rs524547	chr15:43551023	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.53	6.37	0.39	9.92e-10	Lung cancer;
SARC	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg21782813	chr7:2030301	MAD1L1	0.45	7.18	0.43	9.41e-12	Bipolar disorder and schizophrenia;
SARC	cis	rs9296092	0.517	rs78978280	chr6:33520747	T/A	cg13560919	chr6:33536144	NA	-0.49	-5.95	-0.36	9.74e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs2486288	0.656	rs11637364	chr15:45579238	C/T	cg19305227	chr15:45544335	SLC28A2	0.3	5.57	0.34	7.05e-8	Glomerular filtration rate;
SARC	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg12463550	chr7:65579703	CRCP	0.5	5.9	0.36	1.27e-8	Aortic root size;
SARC	cis	rs11190604	0.767	rs10736150	chr10:102195341	G/A	cg07080220	chr10:102295463	HIF1AN	-0.69	-8.38	-0.48	4.91e-15	Palmitoleic acid (16:1n-7) levels;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg10205151	chr7:931109	C7orf20	0.53	6.96	0.41	3.49e-11	Schizophrenia;
SARC	cis	rs4901847	0.529	rs12895032	chr14:58618345	T/G	cg15908186	chr14:58618357	C14orf37	0.61	8.08	0.47	3.53e-14	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs11786130	1.000	rs10808565	chr8:129007412	C/T	cg17583432	chr8:129005567	PVT1	-0.39	-6.73	-0.4	1.32e-10	Eosinophil counts;Sum eosinophil basophil counts;
SARC	cis	rs208520	0.526	rs7776413	chr6:66783241	A/G	cg07460842	chr6:66804631	NA	-1.12	-22.64	-0.83	8.87e-61	Exhaled nitric oxide output;
SARC	cis	rs10895987	0.955	rs11227136	chr11:64931964	G/A	cg21152694	chr11:64885413	ZNHIT2	-0.44	-4.79	-0.3	2.94e-6	Blood protein levels;
SARC	cis	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg07777115	chr5:623756	CEP72	-0.6	-5.42	-0.33	1.52e-7	Obesity-related traits;
SARC	cis	rs208520	0.545	rs10944874	chr6:66752080	C/T	cg07460842	chr6:66804631	NA	-1.08	-19.25	-0.78	4.75e-50	Exhaled nitric oxide output;
SARC	cis	rs1799949	0.827	rs74252763	chr17:41402020	C/T	cg05368731	chr17:41323189	NBR1	0.78	8.97	0.51	9.93e-17	Menopause (age at onset);
SARC	cis	rs1062177	0.826	rs1549920	chr5:151140844	A/T	cg00977110	chr5:151150581	G3BP1	0.62	6.38	0.39	9.23e-10	Preschool internalizing problems;
SARC	cis	rs67311347	0.910	rs7617361	chr3:40373259	G/T	cg09455208	chr3:40491958	NA	0.37	5.86	0.36	1.56e-8	Renal cell carcinoma;
SARC	trans	rs561341	1.000	rs510264	chr17:30323414	A/G	cg20587970	chr11:113659929	NA	-1.36	-14.02	-0.68	8.31e-33	Hip circumference adjusted for BMI;
SARC	cis	rs11758351	1.000	rs11755210	chr6:26202768	C/T	cg23601095	chr6:26197514	HIST1H3D	0.6	5.26	0.33	3.27e-7	Gout;Renal underexcretion gout;
SARC	cis	rs5167	0.566	rs204905	chr19:45460764	G/A	cg10169327	chr19:45448959	APOC2	0.3	4.95	0.31	1.4e-6	Blood protein levels;
SARC	cis	rs637571	0.522	rs679581	chr11:65746653	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.42	5.25	0.33	3.42e-7	Eosinophil percentage of white cells;
SARC	cis	rs9811216	0.917	rs12637184	chr3:169487437	G/A	cg14222479	chr3:169487675	ARPM1	0.47	5.32	0.33	2.42e-7	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs9916302	0.904	rs2061338	chr17:37421767	T/C	cg00129232	chr17:37814104	STARD3	-0.59	-7.33	-0.43	3.69e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs7818688	0.697	rs11782590	chr8:95970158	G/C	cg13393036	chr8:95962371	TP53INP1	0.42	5.16	0.32	5.41e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg20965017	chr5:231967	SDHA	-0.55	-5.26	-0.33	3.23e-7	Breast cancer;
SARC	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg04277193	chr17:41438351	NA	0.46	5.0	0.31	1.1e-6	Menopause (age at onset);
SARC	cis	rs2652822	0.530	rs12595312	chr15:63494159	T/C	cg02713581	chr15:63449717	RPS27L	0.47	5.2	0.32	4.3e-7	Metabolic traits;
SARC	cis	rs847851	0.798	rs10947536	chr6:34975993	A/G	cg17149859	chr6:34856158	ANKS1A;TAF11	-0.45	-4.76	-0.3	3.39e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs858239	0.601	rs1034963	chr7:23148473	T/C	cg23682824	chr7:23144976	KLHL7	0.71	9.72	0.54	5.76e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg13175981	chr1:150552382	MCL1	-0.54	-6.84	-0.41	6.75e-11	Tonsillectomy;
SARC	cis	rs6964587	0.836	rs757040	chr7:91552016	A/G	cg17063962	chr7:91808500	NA	-0.85	-11.97	-0.62	4.85e-26	Breast cancer;
SARC	cis	rs10779751	1.000	rs2300092	chr1:11266464	T/C	cg08854313	chr1:11322531	MTOR	0.85	13.11	0.65	8.62e-30	Body mass index;
SARC	trans	rs17221829	0.733	rs11018668	chr11:89356178	C/T	cg27169873	chr19:3700615	PIP5K1C	0.44	6.28	0.38	1.6e-9	Anxiety in major depressive disorder;
SARC	cis	rs3106136	0.843	rs724260	chr4:95260685	A/G	cg11021082	chr4:95130006	SMARCAD1	0.35	5.38	0.33	1.83e-7	Capecitabine sensitivity;
SARC	cis	rs6762	0.550	rs8672	chr11:838634	C/G	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.58	-7.35	-0.43	3.33e-12	Mean platelet volume;
SARC	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg03351412	chr1:154909251	PMVK	0.59	7.65	0.45	5.32e-13	Prostate cancer;
SARC	trans	rs61931739	0.529	rs1525900	chr12:33976652	T/G	cg26384229	chr12:38710491	ALG10B	0.62	8.09	0.47	3.34e-14	Morning vs. evening chronotype;
SARC	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg18876405	chr7:65276391	NA	-0.7	-8.81	-0.5	3e-16	Aortic root size;
SARC	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg06028808	chr11:68637592	NA	0.43	5.44	0.34	1.32e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg02776933	chr6:79577177	IRAK1BP1	-0.49	-6.83	-0.41	7.22e-11	Electrocardiographic conduction measures;
SARC	cis	rs7582180	0.577	rs6542942	chr2:100985378	G/T	cg14675211	chr2:100938903	LONRF2	0.58	8.77	0.5	3.82e-16	Intelligence (multi-trait analysis);
SARC	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg09699651	chr6:150184138	LRP11	0.41	5.11	0.32	6.6e-7	Lung cancer;
SARC	cis	rs9326248	0.603	rs7396061	chr11:116750874	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.59	7.56	0.44	9.02e-13	Blood protein levels;
SARC	cis	rs12421382	0.615	rs11607972	chr11:109392155	A/G	cg27471124	chr11:109292789	C11orf87	0.39	5.36	0.33	2.04e-7	Schizophrenia;
SARC	cis	rs10752881	1.000	rs8179262	chr1:182973186	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.72	10.86	0.58	1.69e-22	Colorectal cancer;
SARC	cis	rs9788682	0.894	rs4461039	chr15:78817447	A/T	cg06917634	chr15:78832804	PSMA4	0.58	6.78	0.41	9.53e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs12142240	0.698	rs56344958	chr1:46814518	G/A	cg00530320	chr1:46809349	NSUN4	0.57	6.92	0.41	4.4e-11	Menopause (age at onset);
SARC	cis	rs7647973	0.925	rs4955423	chr3:49220448	G/A	cg07636037	chr3:49044803	WDR6	0.8	9.19	0.52	2.19e-17	Menarche (age at onset);
SARC	cis	rs9300255	0.602	rs1727313	chr12:123640853	C/G	cg05973401	chr12:123451056	ABCB9	0.55	5.17	0.32	4.94e-7	Neutrophil percentage of white cells;
SARC	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg16606324	chr3:10149918	C3orf24	0.49	4.82	0.3	2.56e-6	Alzheimer's disease;
SARC	cis	rs7412746	0.658	rs10305714	chr1:150800655	C/T	cg10589385	chr1:150898437	SETDB1	-0.39	-5.28	-0.33	2.97e-7	Melanoma;
SARC	cis	rs916888	0.779	rs199498	chr17:44865603	A/G	cg15921436	chr17:44337874	NA	0.44	4.82	0.3	2.63e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs11190604	0.943	rs11190568	chr10:102224277	C/T	cg07080220	chr10:102295463	HIF1AN	0.75	8.77	0.5	3.79e-16	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs12956009	0.518	rs4458096	chr18:44819555	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.54	-6.92	-0.41	4.31e-11	Educational attainment (years of education);
SARC	cis	rs7274811	0.681	rs291705	chr20:31969658	A/G	cg21523528	chr20:32077966	CBFA2T2	0.41	4.9	0.31	1.78e-6	Height;
SARC	cis	rs172166	0.769	rs149965	chr6:28018689	T/A	cg16479474	chr6:28041457	NA	0.32	4.72	0.3	4.13e-6	Cardiac Troponin-T levels;
SARC	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg08645402	chr16:4508243	NA	0.4	4.81	0.3	2.72e-6	Schizophrenia;
SARC	cis	rs6456156	0.716	rs6905911	chr6:167521624	C/T	cg07741184	chr6:167504864	NA	0.31	5.84	0.36	1.74e-8	Primary biliary cholangitis;
SARC	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.38	6.32	0.38	1.35e-9	Schizophrenia;
SARC	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.85	12.26	0.63	5.5e-27	Chronic sinus infection;
SARC	cis	rs6121246	0.529	rs6060134	chr20:30176794	A/G	cg13852791	chr20:30311386	BCL2L1	0.67	5.77	0.35	2.46e-8	Mean corpuscular hemoglobin;
SARC	cis	rs9467773	1.000	rs9467782	chr6:26542773	G/A	cg11502198	chr6:26597334	ABT1	0.46	5.61	0.34	5.83e-8	Intelligence (multi-trait analysis);
SARC	trans	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg21659725	chr3:3221576	CRBN	-0.53	-6.84	-0.41	6.96e-11	Intelligence (multi-trait analysis);
SARC	cis	rs15676	0.838	rs2280841	chr9:131600111	T/C	cg00228799	chr9:131580591	ENDOG	0.6	7.3	0.43	4.38e-12	Blood metabolite levels;
SARC	cis	rs12681288	0.754	rs4735975	chr8:1000470	T/C	cg15309053	chr8:964076	NA	0.42	7.06	0.42	1.92e-11	Schizophrenia;
SARC	cis	rs9467711	0.651	rs16891264	chr6:26072445	C/T	cg21479132	chr6:26055353	NA	-0.88	-5.8	-0.35	2.2e-8	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9354308	0.933	rs2802063	chr6:66564148	T/C	cg07460842	chr6:66804631	NA	0.48	5.45	0.34	1.3e-7	Metabolite levels;
SARC	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.62	-6.73	-0.4	1.29e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg03851984	chr5:146258354	PPP2R2B	0.5	6.35	0.38	1.1e-9	Breast cancer;
SARC	cis	rs2304069	0.779	rs245081	chr5:149356075	G/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.62	6.72	0.4	1.41e-10	HIV-1 control;
SARC	cis	rs7914558	0.966	rs56946876	chr10:104653545	T/C	cg04362960	chr10:104952993	NT5C2	0.41	4.95	0.31	1.42e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs72781680	1.000	rs56205282	chr2:24221317	C/T	cg08917208	chr2:24149416	ATAD2B	0.93	9.16	0.51	2.8e-17	Lymphocyte counts;
SARC	cis	rs2304069	0.779	rs245080	chr5:149354805	A/G	cg12661370	chr5:149340060	SLC26A2	-0.62	-6.7	-0.4	1.55e-10	HIV-1 control;
SARC	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg04166393	chr7:2884313	GNA12	0.68	8.37	0.48	5.33e-15	Height;
SARC	cis	rs12479064	0.724	rs4851203	chr2:99986932	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.65	-8.02	-0.46	5.23e-14	Chronic sinus infection;
SARC	cis	rs16854884	0.657	rs6769910	chr3:143737830	C/G	cg06585982	chr3:143692056	C3orf58	0.67	9.14	0.51	3.13e-17	Economic and political preferences (feminism/equality);
SARC	cis	rs6121246	0.529	rs2889528	chr20:30210021	C/T	cg21427119	chr20:30132790	HM13	-0.46	-5.05	-0.31	8.92e-7	Mean corpuscular hemoglobin;
SARC	cis	rs6570726	0.935	rs419847	chr6:145827278	A/G	cg23711669	chr6:146136114	FBXO30	0.79	12.01	0.62	3.49e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6860806	0.531	rs274556	chr5:131722075	A/G	cg04518342	chr5:131593106	PDLIM4	-0.44	-5.58	-0.34	6.81e-8	Breast cancer;
SARC	trans	rs561341	0.609	rs739800	chr17:30190083	T/A	cg20587970	chr11:113659929	NA	0.68	6.54	0.39	3.95e-10	Hip circumference adjusted for BMI;
SARC	cis	rs17125944	0.615	rs7146179	chr14:53298853	A/G	cg00686598	chr14:53173677	PSMC6	-0.75	-5.75	-0.35	2.72e-8	Alzheimer's disease (late onset);
SARC	cis	rs897080	0.552	rs1067326	chr2:44628605	T/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.7	0.4	1.59e-10	Height;
SARC	cis	rs4481887	1.000	rs10788781	chr1:248494262	C/T	cg01631408	chr1:248437212	OR2T33	-0.43	-5.4	-0.33	1.68e-7	Common traits (Other);
SARC	cis	rs9650657	0.771	rs4840516	chr8:10667335	C/G	cg21775007	chr8:11205619	TDH	0.39	4.98	0.31	1.26e-6	Neuroticism;
SARC	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg08045932	chr20:61659980	NA	0.5	6.84	0.41	7.06e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs911263	0.603	rs2877455	chr14:68760986	C/G	cg18825221	chr14:68749962	RAD51L1	0.42	7.45	0.44	1.8e-12	Primary biliary cholangitis;
SARC	cis	rs561341	1.000	rs530209	chr17:30315287	A/G	cg00745463	chr17:30367425	LRRC37B	-0.67	-5.32	-0.33	2.4e-7	Hip circumference adjusted for BMI;
SARC	cis	rs2070488	0.775	rs961179	chr3:38509618	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	12.56	0.64	5.73e-28	Electrocardiographic conduction measures;
SARC	cis	rs2952156	0.920	rs1476278	chr17:37836243	C/T	cg20243544	chr17:37824526	PNMT	0.56	7.3	0.43	4.38e-12	Asthma;
SARC	cis	rs7336332	0.598	rs77055070	chr13:28010516	C/G	cg01674679	chr13:27998804	GTF3A	-0.55	-5.13	-0.32	5.96e-7	Weight;
SARC	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg26924012	chr15:45694286	SPATA5L1	0.77	10.99	0.58	6.8e-23	Homoarginine levels;
SARC	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg23758822	chr17:41437982	NA	0.88	11.15	0.59	2.0500000000000001e-23	Menopause (age at onset);
SARC	cis	rs7615952	0.546	rs2922194	chr3:125332263	G/A	cg21696256	chr3:125484277	NA	-0.4	-4.73	-0.3	3.98e-6	Blood pressure (smoking interaction);
SARC	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg12698349	chr2:225449008	CUL3	0.61	7.98	0.46	6.75e-14	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg26335602	chr6:28129616	ZNF389	0.52	5.88	0.36	1.44e-8	Depression;
SARC	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs1348850	0.914	rs12104588	chr2:178253675	G/A	cg23306229	chr2:178417860	TTC30B	0.55	6.38	0.39	9.67e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.74	11.04	0.59	4.62e-23	Personality dimensions;
SARC	trans	rs75763843	0.941	rs12456054	chr18:42077425	A/G	cg07323648	chr17:35291127	NA	0.59	6.43	0.39	7.21e-10	Mean platelet volume;
SARC	cis	rs8180040	0.691	rs12489211	chr3:47221451	T/A	cg02527881	chr3:46936655	PTH1R	-0.31	-4.96	-0.31	1.35e-6	Colorectal cancer;
SARC	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg03806693	chr22:41940476	POLR3H	-0.96	-13.05	-0.65	1.35e-29	Vitiligo;
SARC	cis	rs14978	1.000	rs1548885	chr7:12279559	G/C	cg23422036	chr7:12250390	TMEM106B	0.44	5.28	0.33	3e-7	Response to amphetamines;
SARC	cis	rs1018836	0.884	rs7823461	chr8:91581075	T/C	cg16814680	chr8:91681699	NA	-0.8	-12.57	-0.64	5.44e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs7011049	1.000	rs72643586	chr8:53847859	A/T	cg26025543	chr8:53854495	NA	0.6	5.43	0.34	1.42e-7	Systolic blood pressure;
SARC	cis	rs11625487	0.609	rs74063385	chr14:77966859	C/T	cg16049707	chr14:77965284	ISM2	-0.63	-4.74	-0.3	3.68e-6	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
SARC	cis	rs7727544	0.735	rs2631370	chr5:131703776	T/C	cg12564285	chr5:131593104	PDLIM4	-0.34	-4.73	-0.3	3.92e-6	Blood metabolite levels;
SARC	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-6.31	-0.38	1.38e-9	Personality dimensions;
SARC	cis	rs8031584	0.918	rs35784593	chr15:31254588	G/A	cg08109568	chr15:31115862	NA	-0.47	-5.84	-0.36	1.73e-8	Huntington's disease progression;
SARC	cis	rs9814567	1.000	rs13081177	chr3:134289860	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	7.01	0.42	2.54e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	7.67	0.45	4.58e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg16325326	chr1:53192061	ZYG11B	0.78	12.14	0.62	1.29e-26	Monocyte count;
SARC	cis	rs7327064	0.960	rs7334592	chr13:36756485	A/G	cg13455704	chr13:36871754	C13orf38	-0.44	-4.86	-0.3	2.17e-6	Economic and political preferences;
SARC	trans	rs12310956	0.510	rs1565026	chr12:33887499	A/G	cg13010199	chr12:38710504	ALG10B	0.58	7.49	0.44	1.38e-12	Morning vs. evening chronotype;
SARC	cis	rs9326248	0.581	rs10502222	chr11:116833730	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.6	7.72	0.45	3.52e-13	Blood protein levels;
SARC	cis	rs17125944	0.615	rs7150808	chr14:53304871	C/T	cg00686598	chr14:53173677	PSMC6	-0.73	-5.44	-0.34	1.34e-7	Alzheimer's disease (late onset);
SARC	cis	rs738322	0.574	rs738323	chr22:38569527	C/T	cg25457927	chr22:38595422	NA	-0.25	-4.73	-0.3	3.92e-6	Cutaneous nevi;
SARC	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.83	-12.8	-0.64	9.58e-29	Personality dimensions;
SARC	cis	rs1018836	0.847	rs2285231	chr8:91545387	G/T	cg16814680	chr8:91681699	NA	-0.76	-11.93	-0.62	6.44e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs3768617	0.510	rs2224933	chr1:183095765	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.82e-21	Fuchs's corneal dystrophy;
SARC	cis	rs2204008	0.548	rs8189475	chr12:38037115	C/T	cg26384229	chr12:38710491	ALG10B	0.79	11.29	0.59	7.12e-24	Bladder cancer;
SARC	cis	rs17780086	0.529	rs7406406	chr17:30220153	T/G	cg18200150	chr17:30822561	MYO1D	-0.36	-4.73	-0.3	3.84e-6	Height;
SARC	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg21724239	chr8:58056113	NA	0.65	5.93	0.36	1.1e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs432925	0.625	rs2858003	chr16:342191	A/G	cg06233593	chr16:337645	AXIN1	0.36	4.93	0.31	1.58e-6	Morning vs. evening chronotype;
SARC	cis	rs10911232	0.507	rs9787327	chr1:182978459	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.76	0.58	3.38e-22	Hypertriglyceridemia;
SARC	cis	rs78487399	0.710	rs6731998	chr2:43677273	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-5.01	-0.31	1.08e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs2180341	0.960	rs9398842	chr6:127674662	T/C	cg27446573	chr6:127587934	RNF146	1.04	14.39	0.69	4.89e-34	Breast cancer;
SARC	cis	rs6964587	1.000	rs36120033	chr7:91679298	G/A	cg17063962	chr7:91808500	NA	0.94	15.98	0.72	2.68e-39	Breast cancer;
SARC	cis	rs981844	0.683	rs1037655	chr4:154750408	A/G	cg14289246	chr4:154710475	SFRP2	-0.45	-5.36	-0.33	1.96e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs4253772	0.720	rs4253778	chr22:46630634	C/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.47	5.21	0.32	4.13e-7	LDL cholesterol;Cholesterol, total;
SARC	cis	rs7582720	1.000	rs72936881	chr2:203794262	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs796364	0.813	rs7565417	chr2:201057491	G/A	cg05691004	chr2:201170426	SPATS2L	-0.47	-5.26	-0.33	3.31e-7	Schizophrenia;
SARC	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg04317338	chr11:64019027	PLCB3	0.61	7.07	0.42	1.84e-11	Platelet count;
SARC	cis	rs4132509	1.000	rs7514984	chr1:243965623	C/T	cg21452805	chr1:244014465	NA	0.52	5.68	0.35	4.03e-8	RR interval (heart rate);
SARC	cis	rs3126085	0.935	rs10888470	chr1:152200472	T/C	cg26876637	chr1:152193138	HRNR	0.46	5.37	0.33	1.88e-7	Atopic dermatitis;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg11493553	chr7:156993697	UBE3C	0.55	7.69	0.45	4.02e-13	Thyroid stimulating hormone;
SARC	cis	rs9611519	1.000	rs2057070	chr22:41564287	T/C	cg03806693	chr22:41940476	POLR3H	-0.54	-6.1	-0.37	4.49e-9	Neuroticism;
SARC	cis	rs7552404	0.883	rs11161493	chr1:76206254	T/A	cg10523679	chr1:76189770	ACADM	0.51	6.92	0.41	4.41e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6977660	0.652	rs10486362	chr7:19755224	A/G	cg05791153	chr7:19748676	TWISTNB	-0.89	-7.32	-0.43	4.08e-12	Thyroid stimulating hormone;
SARC	cis	rs459571	0.959	rs416390	chr9:136908549	C/G	cg13789015	chr9:136890014	NCRNA00094	-0.64	-8.64	-0.49	8.97e-16	Platelet distribution width;
SARC	cis	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg12463550	chr7:65579703	CRCP	0.66	5.09	0.32	7.42e-7	Diabetic kidney disease;
SARC	cis	rs35110281	0.805	rs4818855	chr21:45038951	C/T	cg01579765	chr21:45077557	HSF2BP	-0.29	-4.87	-0.3	2.03e-6	Mean corpuscular volume;
SARC	cis	rs568617	0.903	rs601863	chr11:65646557	C/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.47	-5.47	-0.34	1.15e-7	Crohn's disease;
SARC	cis	rs9393692	0.875	rs2142703	chr6:26289605	A/G	cg00631329	chr6:26305371	NA	-0.63	-9.18	-0.52	2.34e-17	Educational attainment;
SARC	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg16606324	chr3:10149918	C3orf24	0.49	4.82	0.3	2.56e-6	Alzheimer's disease;
SARC	cis	rs7829975	0.560	rs17154599	chr8:8551418	C/T	cg06636001	chr8:8085503	FLJ10661	-0.43	-5.38	-0.33	1.82e-7	Mood instability;
SARC	cis	rs4727027	0.745	rs10952801	chr7:148864757	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	5.58	0.34	6.53e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs12908161	1.000	rs35808647	chr15:85377441	G/A	cg17507749	chr15:85114479	UBE2QP1	0.56	6.39	0.39	8.72e-10	Schizophrenia;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg24379599	chr1:186369020	OCLM;C1orf27;MIR548F1	0.47	6.81	0.41	8.32e-11	Thyroid stimulating hormone;
SARC	cis	rs995000	0.965	rs12116574	chr1:63037837	C/T	cg06896770	chr1:63153194	DOCK7	1.0	15.5	0.71	1.02e-37	Triglyceride levels;
SARC	cis	rs1707322	0.686	rs1250	chr1:46094027	A/G	cg06784218	chr1:46089804	CCDC17	0.41	7.15	0.42	1.13e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg18252515	chr7:66147081	NA	-1.34	-11.77	-0.61	2.12e-25	Diabetic kidney disease;
SARC	cis	rs11718455	0.883	rs6795366	chr3:44005735	C/T	cg21419209	chr3:44054225	NA	-0.41	-5.09	-0.32	7.32e-7	Coronary artery disease;
SARC	cis	rs12142240	0.659	rs1984491	chr1:46858607	T/G	cg14993813	chr1:46806288	NSUN4	-0.52	-5.56	-0.34	7.46e-8	Menopause (age at onset);
SARC	cis	rs1008375	0.966	rs10489036	chr4:17697687	A/G	cg16339924	chr4:17578868	LAP3	0.56	6.85	0.41	6.33e-11	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs11997175	0.574	rs12156280	chr8:33650277	C/T	ch.8.33884649F	chr8:33765107	NA	0.5	6.63	0.4	2.28e-10	Body mass index;
SARC	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2273669	0.915	rs3734650	chr6:109295017	A/G	cg01304950	chr6:109416612	SESN1;C6orf182	0.54	4.79	0.3	3e-6	Prostate cancer;
SARC	cis	rs889312	0.500	rs832566	chr5:56151744	C/T	cg14703610	chr5:56206110	C5orf35	0.52	6.45	0.39	6.44e-10	Breast cancer;Breast cancer (early onset);
SARC	cis	rs3008870	0.755	rs11208974	chr1:67398119	A/T	cg02640540	chr1:67518911	SLC35D1	0.45	5.19	0.32	4.55e-7	Lymphocyte percentage of white cells;
SARC	cis	rs10089	1.000	rs4836360	chr5:127458161	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.82	10.13	0.55	3.25e-20	Ileal carcinoids;
SARC	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg03161606	chr19:29218774	NA	0.47	6.76	0.4	1.09e-10	Methadone dose in opioid dependence;
SARC	cis	rs7223966	1.000	rs752621	chr17:61901880	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	7.5	0.44	1.3e-12	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1062177	0.855	rs6896664	chr5:151265274	A/G	cg00977110	chr5:151150581	G3BP1	0.56	5.84	0.36	1.77e-8	Preschool internalizing problems;
SARC	cis	rs11122272	0.705	rs2491411	chr1:231533448	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.28	-0.56	1.11e-20	Hemoglobin concentration;
SARC	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg13206674	chr6:150067644	NUP43	0.43	5.61	0.34	5.83e-8	Lung cancer;
SARC	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg16049864	chr8:95962084	TP53INP1	-0.47	-7.53	-0.44	1.08e-12	Type 2 diabetes;
SARC	cis	rs8014204	0.836	rs7150254	chr14:75299101	G/A	cg17347104	chr14:75034677	LTBP2	-0.45	-5.72	-0.35	3.29e-8	Caffeine consumption;
SARC	cis	rs2463822	1.000	rs2513749	chr11:62105391	C/T	cg06239285	chr11:62104954	ASRGL1	0.88	9.32	0.52	9.26e-18	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.45	5.57	0.34	6.93e-8	Tonsillectomy;
SARC	cis	rs28795989	0.795	rs4696779	chr4:7919375	T/C	cg18538662	chr4:7941764	AFAP1	0.39	4.84	0.3	2.37e-6	Intraocular pressure;
SARC	cis	rs9462027	0.628	rs998278	chr6:34765584	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.93	-0.36	1.08e-8	Systemic lupus erythematosus;
SARC	cis	rs748404	0.660	rs2439845	chr15:43722610	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	5.75	0.35	2.76e-8	Lung cancer;
SARC	cis	rs2777491	0.915	rs7178777	chr15:41634588	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.74	-10.99	-0.58	6.61e-23	Ulcerative colitis;
SARC	cis	rs4803468	1.000	rs3810174	chr19:41904165	C/T	cg09537434	chr19:41945824	ATP5SL	-0.93	-15.79	-0.72	1.15e-38	Height;
SARC	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg00933542	chr6:150070202	PCMT1	-0.35	-6.03	-0.37	6.33e-9	Lung cancer;
SARC	trans	rs3780486	0.713	rs3780489	chr9:33129844	G/T	cg20290983	chr6:43655470	MRPS18A	1.15	22.78	0.83	3.27e-61	IgG glycosylation;
SARC	cis	rs9815354	1.000	rs1717001	chr3:41934949	G/A	cg03022575	chr3:42003672	ULK4	-0.56	-5.45	-0.34	1.28e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg16339924	chr4:17578868	LAP3	0.67	9.04	0.51	6.02e-17	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg25427524	chr10:38739819	LOC399744	-0.58	-9.22	-0.52	1.78e-17	Extrinsic epigenetic age acceleration;
SARC	cis	rs10463554	0.963	rs34771	chr5:102450417	G/A	cg23492399	chr5:102201601	PAM	-0.51	-5.64	-0.35	4.99e-8	Parkinson's disease;
SARC	cis	rs79349575	0.715	rs55724082	chr17:47017879	G/A	cg16584676	chr17:46985605	UBE2Z	0.55	6.66	0.4	1.91e-10	Type 2 diabetes;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg19460391	chr5:86709603	CCNH	0.54	7.6	0.45	7.34e-13	Thyroid stimulating hormone;
SARC	cis	rs9527	0.590	rs2066322	chr10:104909339	T/G	cg04362960	chr10:104952993	NT5C2	0.42	4.93	0.31	1.56e-6	Arsenic metabolism;
SARC	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg11764359	chr7:65958608	NA	-0.85	-11.0	-0.58	6.31e-23	Aortic root size;
SARC	cis	rs453301	0.658	rs6986044	chr8:8874786	G/C	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.55	-0.44	9.88e-13	Joint mobility (Beighton score);
SARC	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg18876405	chr7:65276391	NA	0.71	9.04	0.51	6.42e-17	Aortic root size;
SARC	cis	rs9393692	0.905	rs9366649	chr6:26329103	A/T	cg00631329	chr6:26305371	NA	0.63	9.28	0.52	1.18e-17	Educational attainment;
SARC	cis	rs7712401	0.601	rs34348084	chr5:122335114	A/G	cg19412675	chr5:122181750	SNX24	-0.43	-5.43	-0.34	1.41e-7	Mean platelet volume;
SARC	cis	rs17376456	0.877	rs7736620	chr5:93305762	C/T	cg21475434	chr5:93447410	FAM172A	0.85	7.72	0.45	3.4e-13	Diabetic retinopathy;
SARC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg02675527	chr2:114030824	PAX8;LOC440839	-0.33	-4.79	-0.3	2.94e-6	Lymphocyte counts;
SARC	cis	rs918629	0.761	rs3777173	chr5:95281353	C/T	cg16656078	chr5:95278638	ELL2	-0.73	-8.34	-0.48	6.35e-15	IgG glycosylation;
SARC	cis	rs12824058	0.831	rs4759653	chr12:130812604	T/C	cg26677194	chr12:130822605	PIWIL1	0.54	7.41	0.44	2.25e-12	Menopause (age at onset);
SARC	cis	rs4911253	0.527	rs853859	chr20:31402269	A/G	cg13636640	chr20:31349939	DNMT3B	0.65	8.73	0.5	5.02e-16	Lymphocyte counts;
SARC	cis	rs7772486	0.743	rs1292339	chr6:145967086	C/T	cg05347473	chr6:146136440	FBXO30	-0.51	-6.99	-0.42	2.79e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1395	0.778	rs6709602	chr2:27405497	C/T	cg21747090	chr2:27597821	SNX17	-0.48	-5.72	-0.35	3.32e-8	Blood metabolite levels;
SARC	cis	rs7584330	0.554	rs880931	chr2:238396741	G/A	cg08992911	chr2:238395768	MLPH	0.68	5.64	0.35	4.84e-8	Prostate cancer;
SARC	cis	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg07777115	chr5:623756	CEP72	-0.64	-5.75	-0.35	2.75e-8	Obesity-related traits;
SARC	cis	rs9911578	0.900	rs717828	chr17:56535932	A/G	cg12560992	chr17:57184187	TRIM37	0.81	10.79	0.58	2.83e-22	Intelligence (multi-trait analysis);
SARC	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg00450029	chr8:599525	NA	0.78	6.08	0.37	4.81e-9	IgG glycosylation;
SARC	cis	rs6732160	0.588	rs10192654	chr2:73370882	A/T	cg01422370	chr2:73384389	NA	-0.38	-5.82	-0.36	1.92e-8	Intelligence (multi-trait analysis);
SARC	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg16479474	chr6:28041457	NA	0.36	5.25	0.33	3.43e-7	Depression;
SARC	cis	rs7296418	0.961	rs1790121	chr12:123604492	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-5.61	-0.35	5.58e-8	Platelet count;
SARC	cis	rs870825	0.616	rs10428373	chr4:185639002	A/T	cg04058563	chr4:185651563	MLF1IP	0.81	11.3	0.6	6.58e-24	Blood protein levels;
SARC	cis	rs736801	0.780	rs11951091	chr5:131786595	G/A	cg07395648	chr5:131743802	NA	-0.42	-4.74	-0.3	3.64e-6	Breast cancer;Mosquito bite size;
SARC	cis	rs6598163	0.517	rs11246827	chr12:132296423	G/A	cg07389463	chr12:132296394	NA	0.49	7.62	0.45	6.23e-13	Migraine;
SARC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	9.17	0.52	2.52e-17	Prudent dietary pattern;
SARC	cis	rs4713118	0.869	rs9295743	chr6:27715102	G/C	cg17221315	chr6:27791827	HIST1H4J	0.49	5.33	0.33	2.26e-7	Parkinson's disease;
SARC	cis	rs28669119	0.778	rs585950	chr5:88099671	C/T	cg18498987	chr5:88179539	MEF2C	-0.52	-5.35	-0.33	2.12e-7	Schizophrenia;
SARC	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg11987759	chr7:65425863	GUSB	0.47	5.81	0.36	2.05e-8	Aortic root size;
SARC	cis	rs3820928	0.904	rs2396431	chr2:227765488	G/A	cg05526886	chr2:227700861	RHBDD1	-0.51	-6.08	-0.37	4.82e-9	Pulmonary function;
SARC	cis	rs9393692	0.645	rs766406	chr6:26319588	G/T	cg00631329	chr6:26305371	NA	-0.67	-8.66	-0.49	8.02e-16	Educational attainment;
SARC	cis	rs9393777	0.513	rs9368450	chr6:26652489	A/C	cg12826209	chr6:26865740	GUSBL1	0.66	5.95	0.36	9.98e-9	Intelligence (multi-trait analysis);
SARC	cis	rs2075371	0.674	rs11771785	chr7:134013249	A/G	cg00033643	chr7:134001901	SLC35B4	-0.43	-5.17	-0.32	5.02e-7	Mean platelet volume;
SARC	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg20607798	chr8:58055168	NA	0.48	4.74	0.3	3.75e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs796364	0.950	rs188146	chr2:200750444	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.8	7.14	0.42	1.17e-11	Schizophrenia;
SARC	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg04166393	chr7:2884313	GNA12	0.53	6.08	0.37	4.88e-9	Height;
SARC	cis	rs7927771	0.524	rs12421563	chr11:47780222	G/A	cg10504702	chr11:47789108	FNBP4	-0.43	-5.62	-0.35	5.45e-8	Subjective well-being;
SARC	cis	rs9815354	1.000	rs7622259	chr3:41881351	A/T	cg03022575	chr3:42003672	ULK4	0.56	5.29	0.33	2.81e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs743757	1.000	rs743757	chr3:50476378	C/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.52	-4.93	-0.31	1.6e-6	Diastolic blood pressure;
SARC	cis	rs17376456	0.569	rs10076965	chr5:93094972	G/A	cg21475434	chr5:93447410	FAM172A	0.61	5.95	0.36	9.98e-9	Diabetic retinopathy;
SARC	cis	rs3087591	0.960	rs10512433	chr17:29600564	T/C	cg24425628	chr17:29625626	OMG;NF1	0.54	6.77	0.41	1.02e-10	Hip circumference;
SARC	cis	rs3857536	0.813	rs6931701	chr6:66940905	T/C	cg07460842	chr6:66804631	NA	-0.51	-5.83	-0.36	1.86e-8	Blood trace element (Cu levels);
SARC	cis	rs7208859	0.623	rs6505207	chr17:29076571	T/C	cg13385521	chr17:29058706	SUZ12P	0.88	7.94	0.46	8.37e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs7216064	1.000	rs7223930	chr17:65842186	G/A	cg12091567	chr17:66097778	LOC651250	-0.74	-8.17	-0.47	1.97e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	11.35	0.6	4.58e-24	Platelet count;
SARC	cis	rs11190604	0.767	rs10883490	chr10:102194775	C/T	cg07080220	chr10:102295463	HIF1AN	0.72	8.28	0.48	9.7e-15	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs7772486	0.623	rs9485021	chr6:146068797	A/G	cg23711669	chr6:146136114	FBXO30	-0.8	-13.09	-0.65	9.94e-30	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12824058	0.831	rs12322456	chr12:130813594	A/G	cg24838063	chr12:130822603	PIWIL1	0.64	9.05	0.51	5.92e-17	Menopause (age at onset);
SARC	cis	rs17401966	0.838	rs61775887	chr1:10284733	T/C	cg15208524	chr1:10270712	KIF1B	0.47	5.59	0.34	6.49e-8	Hepatocellular carcinoma;
SARC	cis	rs10165862	0.572	rs11674212	chr2:73911180	C/T	cg20560298	chr2:73613845	ALMS1	-0.48	-5.43	-0.33	1.45e-7	Intelligence (multi-trait analysis);
SARC	cis	rs950776	0.714	rs615470	chr15:78885988	T/C	cg22563815	chr15:78856949	CHRNA5	-0.32	-5.24	-0.32	3.54e-7	Sudden cardiac arrest;
SARC	cis	rs7927592	0.546	rs497261	chr11:68192244	T/C	cg01657329	chr11:68192670	LRP5	-0.41	-5.5	-0.34	9.88e-8	Total body bone mineral density;
SARC	cis	rs10979	1.000	rs9376762	chr6:143887248	G/A	cg25407410	chr6:143891975	LOC285740	-0.62	-8.34	-0.48	6.73e-15	Hypospadias;
SARC	cis	rs3741151	1.000	rs111882289	chr11:73053714	T/C	cg17517138	chr11:73019481	ARHGEF17	0.89	6.36	0.38	1.04e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg11987759	chr7:65425863	GUSB	0.47	5.77	0.35	2.51e-8	Aortic root size;
SARC	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg08219700	chr8:58056026	NA	0.61	6.36	0.38	1.05e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9660992	0.736	rs1180734	chr1:205255438	A/G	cg07972983	chr1:205091412	RBBP5	0.5	6.35	0.38	1.09e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-6.41	-0.39	8.19e-10	Bipolar disorder;
SARC	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg00684032	chr4:1343700	KIAA1530	0.39	5.52	0.34	8.95e-8	Obesity-related traits;
SARC	cis	rs2228479	0.702	rs2074963	chr16:89877269	T/C	cg12064134	chr16:90016061	DEF8	-0.61	-5.07	-0.32	8.04e-7	Skin colour saturation;
SARC	cis	rs4268898	0.662	rs2303296	chr2:24432839	A/G	cg26838691	chr2:24397539	C2orf84	-0.54	-6.2	-0.38	2.54e-9	Asthma;
SARC	trans	rs56279505	0.629	rs17526590	chr4:100269045	G/A	cg18024358	chr1:3420815	MEGF6	-0.83	-6.4	-0.39	8.29e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6665290	0.935	rs1929864	chr1:227195500	T/G	cg10327440	chr1:227177885	CDC42BPA	-1.1	-25.51	-0.86	2.16e-69	Myeloid white cell count;
SARC	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg13607699	chr17:42295918	UBTF	-0.58	-7.08	-0.42	1.71e-11	Total body bone mineral density;
SARC	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg16479474	chr6:28041457	NA	0.36	5.68	0.35	4.05e-8	Depression;
SARC	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg01341218	chr17:43662625	NA	0.69	8.24	0.48	1.22e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg17178900	chr1:205818956	PM20D1	0.67	9.97	0.55	1.01e-19	Menarche (age at onset);
SARC	cis	rs736408	0.583	rs2710323	chr3:52815905	T/C	cg18404041	chr3:52824283	ITIH1	-0.39	-5.88	-0.36	1.4e-8	Bipolar disorder;
SARC	cis	rs12477438	0.834	rs1563108	chr2:99701153	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.95	-14.53	-0.69	1.68e-34	Chronic sinus infection;
SARC	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg20607798	chr8:58055168	NA	0.56	5.43	0.34	1.4e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg16479474	chr6:28041457	NA	0.35	5.25	0.33	3.38e-7	Parkinson's disease;
SARC	cis	rs963731	0.649	rs6725356	chr2:39238395	C/G	cg04010122	chr2:39346883	SOS1	1.19	6.25	0.38	1.97e-9	Corticobasal degeneration;
SARC	trans	rs61931739	0.517	rs10844727	chr12:34017435	C/T	cg13010199	chr12:38710504	ALG10B	0.66	8.89	0.5	1.66e-16	Morning vs. evening chronotype;
SARC	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg05025164	chr4:1340916	KIAA1530	0.86	11.0	0.58	5.98e-23	Longevity;
SARC	cis	rs9457247	0.534	rs12055488	chr6:167379570	A/G	cg23791538	chr6:167370224	RNASET2	0.67	9.62	0.53	1.15e-18	Crohn's disease;
SARC	cis	rs617791	0.678	rs551659	chr11:65749645	C/T	cg26695010	chr11:65641043	EFEMP2	-0.54	-6.9	-0.41	4.86e-11	Breast cancer;
SARC	cis	rs9303401	0.614	rs34941454	chr17:57102742	T/G	cg25039879	chr17:56429692	SUPT4H1	0.56	4.98	0.31	1.22e-6	Cognitive test performance;
SARC	cis	rs3087591	1.000	rs12948444	chr17:29443614	A/G	cg24425628	chr17:29625626	OMG;NF1	0.56	7.06	0.42	1.87e-11	Hip circumference;
SARC	cis	rs30380	0.632	rs27640	chr5:96127905	T/C	cg16492584	chr5:96139282	ERAP1	-0.48	-5.52	-0.34	8.89e-8	Cerebrospinal fluid biomarker levels;
SARC	cis	rs4128725	0.925	rs12410729	chr1:159414034	T/C	cg25076881	chr1:159409836	OR10J1	0.4	4.79	0.3	2.95e-6	Select biomarker traits;
SARC	cis	rs7520050	0.966	rs11211234	chr1:46438787	C/A	cg24296786	chr1:45957014	TESK2	0.38	4.87	0.3	2.02e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg13880726	chr7:1868755	MAD1L1	0.49	6.02	0.37	6.81e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs7681440	0.775	rs6848181	chr4:90807252	T/C	cg06632027	chr4:90757378	SNCA	0.41	5.73	0.35	3.07e-8	Dementia with Lewy bodies;
SARC	cis	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg11995313	chr8:8860691	ERI1	-0.41	-5.16	-0.32	5.41e-7	Mood instability;
SARC	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg05861140	chr6:150128134	PCMT1	-0.41	-5.17	-0.32	5.01e-7	Lung cancer;
SARC	cis	rs2204008	0.902	rs11520218	chr12:38223227	G/A	cg13010199	chr12:38710504	ALG10B	0.78	10.64	0.57	8.61e-22	Bladder cancer;
SARC	cis	rs9309473	0.607	rs4641966	chr2:73590806	G/A	cg20560298	chr2:73613845	ALMS1	-0.59	-7.42	-0.44	2.2e-12	Metabolite levels;
SARC	cis	rs6570726	0.935	rs406343	chr6:145874388	A/G	cg05220968	chr6:146057943	EPM2A	-0.3	-5.09	-0.32	7.23e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2777491	1.000	rs316605	chr15:41771591	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.82	-12.15	-0.62	1.24e-26	Ulcerative colitis;
SARC	trans	rs61931739	0.534	rs2636072	chr12:34062386	C/T	cg13010199	chr12:38710504	ALG10B	0.66	8.76	0.5	4.04e-16	Morning vs. evening chronotype;
SARC	cis	rs10992471	0.627	rs10820980	chr9:95253342	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.4	-0.33	1.65e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs1468333	0.567	rs11567983	chr5:137647947	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.66	8.04	0.47	4.63e-14	Resting heart rate;
SARC	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	11.02	0.59	5.23e-23	Alzheimer's disease;
SARC	cis	rs6807306	1.000	rs9836628	chr3:167383631	G/A	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.52	5.42	0.33	1.52e-7	Mean platelet volume;
SARC	cis	rs2361718	0.967	rs2361719	chr17:78103403	A/G	cg27427491	chr17:78079615	GAA	0.29	4.86	0.3	2.18e-6	Yeast infection;
SARC	cis	rs854765	0.654	rs11078400	chr17:17757728	A/G	cg04398451	chr17:18023971	MYO15A	0.45	6.53	0.39	4.06e-10	Total body bone mineral density;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg04768002	chr7:97937117	BAIAP2L1	0.49	6.63	0.4	2.37e-10	Electrocardiographic conduction measures;
SARC	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg00629941	chr15:75287862	SCAMP5	0.39	4.74	0.3	3.77e-6	Breast cancer;
SARC	cis	rs3820928	0.874	rs7563644	chr2:227846932	A/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-6.64	-0.4	2.16e-10	Pulmonary function;
SARC	cis	rs7937682	0.556	rs7108048	chr11:111352299	T/C	cg09085632	chr11:111637200	PPP2R1B	0.44	5.11	0.32	6.72e-7	Primary sclerosing cholangitis;
SARC	cis	rs911555	0.723	rs6575982	chr14:103862681	G/A	cg24130564	chr14:104152367	KLC1	0.49	5.74	0.35	2.96e-8	Intelligence (multi-trait analysis);
SARC	trans	rs12310956	0.510	rs2054867	chr12:33835462	C/G	cg13010199	chr12:38710504	ALG10B	-0.6	-7.91	-0.46	1.05e-13	Morning vs. evening chronotype;
SARC	cis	rs17666538	1.000	rs17666538	chr8:566207	T/C	cg13264159	chr8:625131	ERICH1	0.74	4.74	0.3	3.66e-6	IgG glycosylation;
SARC	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg06108461	chr20:60628389	TAF4	-0.99	-13.55	-0.66	3.12e-31	Body mass index;
SARC	cis	rs8072100	0.701	rs8078309	chr17:45774072	T/C	cg08085267	chr17:45401833	C17orf57	-0.45	-5.33	-0.33	2.3e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs7005606	1.000	rs3802160	chr8:32404629	A/G	cg14488905	chr8:32406789	NRG1	0.45	6.31	0.38	1.42e-9	Hirschsprung disease;
SARC	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg04546413	chr19:29218101	NA	0.64	8.99	0.51	8.9e-17	Methadone dose in opioid dependence;
SARC	cis	rs5758511	0.514	rs5751222	chr22:42517922	T/A	cg00645731	chr22:42541494	CYP2D7P1	0.42	6.04	0.37	6.11e-9	Birth weight;
SARC	cis	rs826838	0.967	rs11183514	chr12:38760744	A/T	cg13010199	chr12:38710504	ALG10B	0.81	11.63	0.61	6.07e-25	Heart rate;
SARC	cis	rs10492096	0.898	rs12426815	chr12:6580314	A/G	cg13857086	chr12:6580257	VAMP1	0.6	6.16	0.37	3.23e-9	Hip geometry;
SARC	cis	rs763121	0.785	rs6001203	chr22:39099602	T/C	cg21395723	chr22:39101663	GTPBP1	0.56	6.73	0.4	1.29e-10	Menopause (age at onset);
SARC	cis	rs73086581	1.000	rs6052196	chr20:3945824	T/C	cg02187196	chr20:3869020	PANK2	0.67	6.46	0.39	6.21e-10	Response to antidepressants in depression;
SARC	cis	rs6542838	0.611	rs7423519	chr2:99518319	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-5.71	-0.35	3.5e-8	Fear of minor pain;
SARC	cis	rs6912958	0.702	rs6906769	chr6:88235949	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-7.22	-0.43	7.23e-12	Monocyte percentage of white cells;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg13229655	chr1:10532570	DFFA	0.77	6.68	0.4	1.76e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg18252515	chr7:66147081	NA	-0.42	-4.72	-0.3	4.03e-6	Aortic root size;
SARC	cis	rs7647973	0.925	rs4955439	chr3:49245645	G/T	cg06212747	chr3:49208901	KLHDC8B	-0.62	-6.38	-0.39	9.48e-10	Menarche (age at onset);
SARC	cis	rs8014204	1.000	rs8014374	chr14:75322914	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.73	-10.7	-0.57	5.22e-22	Caffeine consumption;
SARC	cis	rs826838	0.651	rs1843896	chr12:38612913	G/C	cg26384229	chr12:38710491	ALG10B	0.75	10.15	0.55	2.81e-20	Heart rate;
SARC	cis	rs7843479	0.601	rs3824338	chr8:21864540	A/C	cg17168535	chr8:21777572	XPO7	0.84	12.62	0.64	3.64e-28	Mean corpuscular volume;
SARC	cis	rs11700980	0.636	rs17797032	chr21:30265585	G/A	cg24692254	chr21:30365293	RNF160	-0.65	-4.94	-0.31	1.51e-6	QRS complex (12-leadsum);
SARC	cis	rs7914558	1.000	rs7071373	chr10:104771922	A/G	cg04362960	chr10:104952993	NT5C2	0.45	5.6	0.34	5.97e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg24209194	chr3:40518798	ZNF619	0.63	8.04	0.47	4.48e-14	Renal cell carcinoma;
SARC	cis	rs7937682	0.883	rs486038	chr11:111465963	A/C	cg22437258	chr11:111473054	SIK2	0.76	9.87	0.54	2.07e-19	Primary sclerosing cholangitis;
SARC	cis	rs9790314	0.846	rs899275	chr3:161042104	T/C	cg03342759	chr3:160939853	NMD3	-0.72	-9.75	-0.54	4.56e-19	Morning vs. evening chronotype;
SARC	cis	rs2594989	0.895	rs2594980	chr3:11381387	C/T	cg00170343	chr3:11313890	ATG7	0.57	6.28	0.38	1.67e-9	Circulating chemerin levels;
SARC	cis	rs858239	0.600	rs13438188	chr7:23144197	C/T	cg23682824	chr7:23144976	KLHL7	-0.7	-9.47	-0.53	3.4e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	7.7	0.45	3.9e-13	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg06420487	chr17:61919686	SMARCD2	0.45	5.01	0.31	1.05e-6	Height;
SARC	cis	rs7829975	0.573	rs7842359	chr8:8797078	T/G	cg08975724	chr8:8085496	FLJ10661	-0.39	-4.76	-0.3	3.41e-6	Mood instability;
SARC	cis	rs273218	0.573	rs10513033	chr5:53333477	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.86	-9.22	-0.52	1.8e-17	Migraine;
SARC	cis	rs722599	0.748	rs61978932	chr14:75342954	C/T	cg08847533	chr14:75593920	NEK9	-0.41	-4.73	-0.3	3.83e-6	IgG glycosylation;
SARC	cis	rs3741151	0.686	rs11822984	chr11:73261467	A/C	cg17517138	chr11:73019481	ARHGEF17	0.82	6.28	0.38	1.65e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs72945132	0.882	rs7121012	chr11:70214421	A/T	cg00319359	chr11:70116639	PPFIA1	0.7	6.72	0.4	1.37e-10	Coronary artery disease;
SARC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg23602909	chr7:157956050	PTPRN2	-0.44	-8.24	-0.47	1.27e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
SARC	cis	rs10512697	0.803	rs34007257	chr5:3576503	C/T	cg19473799	chr5:3511975	NA	-0.67	-5.12	-0.32	6.47e-7	Immune response to smallpox vaccine (IL-6);
SARC	trans	rs12310956	0.532	rs10844712	chr12:33961022	G/A	cg13010199	chr12:38710504	ALG10B	0.64	8.44	0.48	3.44e-15	Morning vs. evening chronotype;
SARC	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg20102877	chr2:27665638	KRTCAP3	-0.36	-5.03	-0.31	9.71e-7	Total body bone mineral density;
SARC	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg26874164	chr19:58962979	ZNF324B	0.51	6.71	0.4	1.49e-10	Uric acid clearance;
SARC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg13397359	chr6:42928475	GNMT	-0.57	-7.96	-0.46	7.43e-14	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg02725872	chr8:58115012	NA	-0.34	-5.37	-0.33	1.91e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2916247	1.000	rs34711026	chr8:93029914	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.66	-6.55	-0.39	3.67e-10	Intelligence (multi-trait analysis);
SARC	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.01	-17.51	-0.75	2.16e-44	Chronic sinus infection;
SARC	cis	rs17376456	0.877	rs10052428	chr5:93476530	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.29	0.33	2.81e-7	Diabetic retinopathy;
SARC	cis	rs6121246	0.609	rs6060955	chr20:30385071	A/G	cg13852791	chr20:30311386	BCL2L1	0.82	9.97	0.55	1.02e-19	Mean corpuscular hemoglobin;
SARC	trans	rs453301	0.624	rs330056	chr8:9089695	A/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.76	-0.4	1.1e-10	Joint mobility (Beighton score);
SARC	cis	rs6088813	1.000	rs735531	chr20:33947730	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	-0.46	-5.51	-0.34	9.28e-8	Height;
SARC	cis	rs2721811	0.738	rs2521759	chr7:24764655	C/G	cg17569154	chr7:24781545	DFNA5	0.42	5.71	0.35	3.39e-8	Depressive symptoms (multi-trait analysis);
SARC	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg11987759	chr7:65425863	GUSB	-0.51	-6.03	-0.37	6.33e-9	Aortic root size;
SARC	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg08280861	chr8:58055591	NA	0.6	5.71	0.35	3.4e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2153535	0.580	rs6597334	chr6:8504779	C/T	cg23788917	chr6:8435910	SLC35B3	0.64	8.3	0.48	8.36e-15	Motion sickness;
SARC	cis	rs1113500	0.787	rs4571989	chr1:108631344	G/A	cg06207961	chr1:108661230	NA	0.38	4.91	0.31	1.74e-6	Growth-regulated protein alpha levels;
SARC	cis	rs3820928	0.874	rs10210963	chr2:227821845	A/G	cg11843606	chr2:227700838	RHBDD1	-0.56	-7.08	-0.42	1.64e-11	Pulmonary function;
SARC	cis	rs5167	0.743	rs57204168	chr19:45496776	A/G	cg13119609	chr19:45449297	APOC2	0.38	5.76	0.35	2.64e-8	Blood protein levels;
SARC	cis	rs10791097	0.748	rs2282579	chr11:130735482	C/T	cg12179176	chr11:130786555	SNX19	0.75	11.39	0.6	3.62e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	5.9	0.36	1.26e-8	Prudent dietary pattern;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg27203090	chr3:33138513	GLB1;TMPPE	-0.48	-6.23	-0.38	2.11e-9	Neuroticism;
SARC	cis	rs4891159	0.790	rs77878087	chr18:74116337	G/A	cg24786174	chr18:74118243	ZNF516	-0.68	-9.89	-0.54	1.79e-19	Longevity;
SARC	cis	rs10504073	0.647	rs55920380	chr8:50026353	G/A	cg00325661	chr8:49890786	NA	0.54	7.25	0.43	6.1e-12	Blood metabolite ratios;
SARC	cis	rs748404	0.697	rs473016	chr15:43558823	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.41	5.09	0.32	7.44e-7	Lung cancer;
SARC	cis	rs6088580	0.634	rs945673	chr20:32964265	C/A	cg08999081	chr20:33150536	PIGU	-0.42	-6.43	-0.39	7.29e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs9788721	0.836	rs7181486	chr15:78741618	C/T	cg06917634	chr15:78832804	PSMA4	0.5	5.48	0.34	1.08e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs4713118	0.513	rs149945	chr6:28002853	T/C	cg26450541	chr6:28235208	ZNF187	0.46	4.86	0.3	2.14e-6	Parkinson's disease;
SARC	cis	rs7246657	0.941	rs12982333	chr19:37794724	A/G	cg23950597	chr19:37808831	NA	-0.51	-4.71	-0.3	4.19e-6	Coronary artery calcification;
SARC	cis	rs3733585	0.624	rs76574510	chr4:9953252	T/A	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.94	-0.36	1.06e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	trans	rs2727020	0.576	rs11040223	chr11:49034633	G/T	cg15704280	chr7:45808275	SEPT13	-0.56	-7.84	-0.46	1.62e-13	Coronary artery disease;
SARC	cis	rs10791323	0.604	rs2851116	chr11:133705759	G/A	cg14349672	chr11:133703707	NA	-0.4	-5.81	-0.36	2.04e-8	Childhood ear infection;
SARC	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg18876405	chr7:65276391	NA	0.49	6.04	0.37	6e-9	Aortic root size;
SARC	cis	rs7766436	0.885	rs7773749	chr6:22587190	C/G	cg13666174	chr6:22585274	NA	-0.62	-8.03	-0.47	4.96e-14	Coronary artery disease;
SARC	cis	rs6089584	0.586	rs4925216	chr20:60599923	G/A	cg13770153	chr20:60521292	NA	-0.4	-5.69	-0.35	3.71e-8	Body mass index;
SARC	cis	rs8523	0.715	rs12665478	chr6:11080825	G/A	cg13562911	chr6:11044106	ELOVL2	0.46	6.11	0.37	4.05e-9	Red blood cell fatty acid levels;
SARC	cis	rs3784262	0.669	rs12915989	chr15:58315736	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.32	-4.82	-0.3	2.58e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg10480950	chr6:5067127	NA	-0.5	-6.27	-0.38	1.69e-9	Height;
SARC	cis	rs12142240	0.698	rs6429599	chr1:46827871	G/A	cg14993813	chr1:46806288	NSUN4	-0.53	-5.62	-0.35	5.48e-8	Menopause (age at onset);
SARC	cis	rs9457247	1.000	rs404222	chr6:167402150	G/A	cg07741184	chr6:167504864	NA	0.3	5.68	0.35	4e-8	Crohn's disease;
SARC	cis	rs6570726	1.000	rs386678	chr6:145869010	A/G	cg05347473	chr6:146136440	FBXO30	0.48	6.4	0.39	8.51e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2288912	0.807	rs10423208	chr19:45453656	G/A	cg10169327	chr19:45448959	APOC2	0.31	5.11	0.32	6.83e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs826838	0.935	rs1843639	chr12:39178919	C/A	cg13010199	chr12:38710504	ALG10B	0.75	9.97	0.55	9.86e-20	Heart rate;
SARC	trans	rs208520	0.690	rs12198745	chr6:66722598	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.06	14.21	0.68	2.05e-33	Exhaled nitric oxide output;
SARC	cis	rs34172651	0.917	rs12599643	chr16:24832693	C/T	cg00152838	chr16:24741724	TNRC6A	-0.42	-5.15	-0.32	5.52e-7	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg11987759	chr7:65425863	GUSB	-0.47	-6.27	-0.38	1.7e-9	Aortic root size;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg21393986	chr3:196159244	UBXN7	0.5	6.26	0.38	1.84e-9	Lung adenocarcinoma;
SARC	cis	rs752010	0.714	rs7552928	chr1:42086664	C/T	cg06885757	chr1:42089581	HIVEP3	0.43	6.68	0.4	1.7e-10	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs523522	0.962	rs603574	chr12:120998443	A/G	cg12219531	chr12:120966889	COQ5	0.83	11.11	0.59	2.8e-23	High light scatter reticulocyte count;
SARC	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg04944784	chr2:26401820	FAM59B	0.49	6.32	0.38	1.3e-9	Gut microbiome composition (summer);
SARC	cis	rs7914558	1.000	rs7081075	chr10:104929191	C/T	cg04362960	chr10:104952993	NT5C2	0.4	4.8	0.3	2.83e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg11062466	chr8:58055876	NA	-0.52	-5.38	-0.33	1.84e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs4794202	0.523	rs11871969	chr17:45992622	C/T	cg23391107	chr17:45924227	SP6	-0.52	-5.17	-0.32	5.14e-7	Alzheimer's disease (cognitive decline);
SARC	trans	rs11634851	0.966	rs2627323	chr15:81021383	A/G	cg04669574	chr12:50297945	FAIM2	-0.49	-6.51	-0.39	4.46e-10	Systolic blood pressure;
SARC	cis	rs673253	0.662	rs11210869	chr1:44026040	A/G	cg10881128	chr1:44031826	PTPRF	0.38	4.88	0.3	1.98e-6	Intelligence (multi-trait analysis);
SARC	cis	rs763121	0.962	rs2071887	chr22:38879010	A/T	cg06022373	chr22:39101656	GTPBP1	0.68	8.26	0.48	1.06e-14	Menopause (age at onset);
SARC	cis	rs918629	0.530	rs3777201	chr5:95234630	G/T	cg16656078	chr5:95278638	ELL2	-0.56	-6.74	-0.4	1.23e-10	IgG glycosylation;
SARC	cis	rs8005677	1.000	rs8006409	chr14:23396511	A/G	cg01529538	chr14:23388837	RBM23	0.5	6.12	0.37	3.94e-9	Cognitive ability (multi-trait analysis);
SARC	cis	rs11651000	0.625	rs58067360	chr17:45819587	G/C	cg03474202	chr17:45855739	NA	-0.39	-6.07	-0.37	5.05e-9	IgG glycosylation;
SARC	cis	rs11690935	0.959	rs6758704	chr2:172655097	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.98	-15.52	-0.71	8.81e-38	Schizophrenia;
SARC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg26338869	chr17:61819248	STRADA	0.8	10.65	0.57	7.56e-22	Prudent dietary pattern;
SARC	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg13393036	chr8:95962371	TP53INP1	-0.36	-6.18	-0.38	2.83e-9	Type 2 diabetes;
SARC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg06873352	chr17:61820015	STRADA	0.51	6.49	0.39	5.04e-10	Prudent dietary pattern;
SARC	cis	rs1044826	0.642	rs295470	chr3:139213903	A/G	cg15131784	chr3:139108705	COPB2	0.4	5.13	0.32	6.1e-7	Obesity-related traits;
SARC	cis	rs11770686	0.967	rs6969861	chr7:75328707	T/C	cg17787366	chr7:75369077	HIP1	0.43	5.32	0.33	2.48e-7	Essential tremor;
SARC	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg17971929	chr21:40555470	PSMG1	0.99	14.16	0.68	2.89e-33	Cognitive function;
SARC	cis	rs9916302	0.706	rs8073907	chr17:37424149	C/T	cg20243544	chr17:37824526	PNMT	0.55	5.89	0.36	1.35e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs4555082	0.957	rs8022526	chr14:105756485	A/G	cg13114125	chr14:105738426	BRF1	-0.75	-10.96	-0.58	8.41e-23	Mean platelet volume;Platelet distribution width;
SARC	cis	rs4642101	0.737	rs9877165	chr3:12828497	C/T	cg24848339	chr3:12840334	CAND2	0.31	4.72	0.3	3.98e-6	QRS complex (12-leadsum);
SARC	cis	rs7089973	0.966	rs36089581	chr10:116623059	G/C	cg08188268	chr10:116634841	FAM160B1	0.36	5.21	0.32	4.25e-7	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs7980687	0.628	rs1727332	chr12:123718301	C/T	cg05973401	chr12:123451056	ABCB9	0.54	6.11	0.37	4.09e-9	Height;Educational attainment;Head circumference (infant);
SARC	cis	rs6138458	0.626	rs6050261	chr20:25014206	C/T	cg26195577	chr20:24973756	C20orf3	0.68	7.83	0.46	1.69e-13	Blood protein levels;
SARC	cis	rs1008375	0.966	rs10939736	chr4:17581617	T/A	cg27347728	chr4:17578864	LAP3	0.49	6.06	0.37	5.46e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7395581	0.959	rs326222	chr11:47259668	A/G	cg25783544	chr11:47291846	MADD	-0.45	-5.03	-0.31	9.69e-7	HDL cholesterol;
SARC	cis	rs6871536	0.951	rs2706401	chr5:131881605	G/C	cg11797159	chr5:131991491	NA	0.37	4.82	0.3	2.64e-6	Asthma (childhood onset);
SARC	cis	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg05623727	chr3:50126028	RBM5	0.33	5.0	0.31	1.14e-6	Intelligence (multi-trait analysis);
SARC	cis	rs6088590	0.710	rs6059992	chr20:33282275	T/C	cg24642439	chr20:33292090	TP53INP2	0.72	9.87	0.54	2.04e-19	Coronary artery disease;
SARC	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.8	11.38	0.6	3.84e-24	Total body bone mineral density;
SARC	cis	rs607987	0.871	rs60968445	chr11:30274837	A/T	cg06241208	chr11:30344200	C11orf46	0.41	4.9	0.31	1.79e-6	Body mass index;
SARC	cis	rs2204008	0.837	rs11180821	chr12:38242843	A/G	cg13010199	chr12:38710504	ALG10B	0.78	10.65	0.57	7.82e-22	Bladder cancer;
SARC	cis	rs1878931	0.696	rs35175748	chr16:3445427	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	1.0	18.33	0.77	4.5e-47	Body mass index (adult);
SARC	cis	rs6752107	0.967	rs3816234	chr2:234185999	G/A	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.47	6.18	0.38	2.79e-9	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs6500395	0.926	rs11645193	chr16:48594229	C/T	cg04672837	chr16:48644449	N4BP1	0.42	5.54	0.34	8.04e-8	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs6912958	0.935	rs6454629	chr6:88165515	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-5.6	-0.34	5.9e-8	Monocyte percentage of white cells;
SARC	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg10435706	chr6:150039699	LATS1	0.36	4.8	0.3	2.88e-6	Lung cancer;
SARC	cis	rs910316	1.000	rs175512	chr14:75523382	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.57	-8.07	-0.47	3.72e-14	Height;
SARC	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg02951883	chr7:2050386	MAD1L1	0.42	5.35	0.33	2.11e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs17666538	0.585	rs6559065	chr8:623156	G/C	cg23958373	chr8:599963	NA	0.72	6.01	0.37	7.05e-9	IgG glycosylation;
SARC	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg15857475	chr8:145742913	RECQL4;LRRC14	0.78	11.32	0.6	5.84e-24	Age at first birth;
SARC	cis	rs1055129	0.560	rs2666003	chr17:73942976	G/A	cg06969265	chr17:73775802	H3F3B	0.45	5.54	0.34	8.04e-8	White matter hyperintensity burden;
SARC	cis	rs9640161	0.830	rs35635199	chr7:150063342	C/T	cg17279839	chr7:150038598	RARRES2	0.35	4.95	0.31	1.44e-6	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs9814567	0.762	rs13071852	chr3:134223217	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.52	5.58	0.34	6.53e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg08219700	chr8:58056026	NA	0.6	5.78	0.35	2.43e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs708547	0.647	rs1718830	chr4:57888510	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.56	6.81	0.41	8.08e-11	Response to bleomycin (chromatid breaks);
SARC	cis	rs2415984	0.562	rs4306423	chr14:46915671	G/A	cg14871534	chr14:47121158	RPL10L	0.38	5.18	0.32	4.75e-7	Number of children ever born;
SARC	cis	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg22496380	chr5:211416	CCDC127	-0.79	-8.83	-0.5	2.64e-16	Breast cancer;
SARC	cis	rs7560272	0.538	rs12619258	chr2:73935915	G/T	cg20560298	chr2:73613845	ALMS1	0.42	5.64	0.35	4.92e-8	Schizophrenia;
SARC	cis	rs9486719	0.843	rs2205754	chr6:96843134	T/C	cg06623918	chr6:96969491	KIAA0776	0.75	7.39	0.44	2.65e-12	Migraine;Coronary artery disease;
SARC	cis	rs796364	0.806	rs112486506	chr2:201073947	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.61	-4.82	-0.3	2.64e-6	Schizophrenia;
SARC	cis	rs910316	0.763	rs735452	chr14:75497984	A/G	cg23033748	chr14:75592666	NEK9	-0.35	-4.89	-0.3	1.9e-6	Height;
SARC	cis	rs11122272	0.735	rs2491416	chr1:231547335	T/C	cg06096015	chr1:231504339	EGLN1	-0.37	-5.46	-0.34	1.21e-7	Hemoglobin concentration;
SARC	cis	rs6062302	0.522	rs13043255	chr20:62218916	C/G	cg16989086	chr20:62203971	PRIC285	0.48	4.76	0.3	3.38e-6	Glioblastoma;
SARC	cis	rs9325144	0.647	rs12227834	chr12:38849246	G/C	cg13010199	chr12:38710504	ALG10B	-0.48	-6.03	-0.37	6.33e-9	Morning vs. evening chronotype;
SARC	cis	rs7625806	0.931	rs9840792	chr3:38106932	T/C	cg15121877	chr3:38081287	DLEC1	0.35	4.74	0.3	3.73e-6	Carotid intima media thickness;
SARC	cis	rs3857067	0.506	rs282450	chr4:95139598	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.47	-7.07	-0.42	1.74e-11	QT interval;
SARC	cis	rs71636778	0.631	rs71636788	chr1:27186485	T/C	cg04852280	chr1:26496234	ZNF593	0.51	4.72	0.3	4.1e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs1355223	0.583	rs2941044	chr11:34867444	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.77	11.23	0.59	1.17e-23	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs1699337	0.930	rs1373641	chr3:12402474	C/T	cg04748988	chr3:12329223	PPARG	0.4	5.38	0.33	1.78e-7	Cholesterol, total;
SARC	cis	rs1050631	0.564	rs681757	chr18:33744766	A/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.55	6.75	0.4	1.2e-10	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs6752107	0.935	rs10199278	chr2:234160669	C/G	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.49	6.8	0.41	8.8e-11	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg11301795	chr4:187892539	NA	-0.7	-10.35	-0.56	6.76e-21	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs2727020	0.553	rs61904166	chr11:49581461	T/C	cg03929089	chr4:120376271	NA	-0.76	-11.4	-0.6	3.26e-24	Coronary artery disease;
SARC	cis	rs2075371	0.863	rs1646638	chr7:134008706	T/C	cg20476274	chr7:133979776	SLC35B4	0.53	6.96	0.41	3.39e-11	Mean platelet volume;
SARC	trans	rs6894249	1.000	rs6894249	chr5:131797547	A/G	cg11565042	chr2:105858730	GPR45	-0.45	-6.3	-0.38	1.48e-9	Asthma;
SARC	cis	rs60695258	0.726	rs1471251	chr4:87976359	A/T	cg11209507	chr4:87813803	C4orf36	-0.41	-5.6	-0.34	5.89e-8	Hematocrit;
SARC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.11	-19.65	-0.79	2.38e-51	Prudent dietary pattern;
SARC	cis	rs3087591	0.659	rs2214538	chr17:29636570	C/T	cg24425628	chr17:29625626	OMG;NF1	0.44	5.65	0.35	4.68e-8	Hip circumference;
SARC	cis	rs8180040	0.966	rs7651762	chr3:47470484	G/A	cg27129171	chr3:47204927	SETD2	-0.67	-9.58	-0.53	1.56e-18	Colorectal cancer;
SARC	cis	rs9911578	0.967	rs8075786	chr17:56819216	T/C	cg12560992	chr17:57184187	TRIM37	0.88	12.14	0.62	1.31e-26	Intelligence (multi-trait analysis);
SARC	cis	rs1707322	0.963	rs12076580	chr1:46258159	G/A	cg03146154	chr1:46216737	IPP	0.5	5.99	0.37	7.86e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg07701084	chr6:150067640	NUP43	0.41	5.29	0.33	2.81e-7	Lung cancer;
SARC	cis	rs6504340	0.600	rs2325946	chr17:46584631	G/C	cg04904318	chr17:46607828	HOXB1	0.4	4.98	0.31	1.22e-6	Primary tooth development (number of teeth);
SARC	cis	rs524281	0.648	rs10896089	chr11:65936292	A/G	cg14036092	chr11:66035641	RAB1B	-0.51	-5.48	-0.34	1.1e-7	Electroencephalogram traits;
SARC	cis	rs80130819	0.748	rs2732455	chr12:48677995	C/T	cg24011408	chr12:48396354	COL2A1	0.53	5.81	0.36	2.02e-8	Prostate cancer;
SARC	cis	rs9660992	0.674	rs72745221	chr1:205262337	G/A	cg00857998	chr1:205179979	DSTYK	0.43	4.99	0.31	1.2e-6	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg11987759	chr7:65425863	GUSB	0.5	6.22	0.38	2.29e-9	Aortic root size;
SARC	cis	rs6963495	0.818	rs56165465	chr7:105180384	C/T	cg19920283	chr7:105172520	RINT1	0.69	6.11	0.37	4.2e-9	Bipolar disorder (body mass index interaction);
SARC	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg25894440	chr7:65020034	NA	-0.74	-5.55	-0.34	7.66e-8	Diabetic kidney disease;
SARC	trans	rs61931739	0.853	rs7137146	chr12:34102394	G/A	cg26384229	chr12:38710491	ALG10B	-0.54	-7.17	-0.43	9.71e-12	Morning vs. evening chronotype;
SARC	cis	rs7917772	0.503	rs11191347	chr10:104351617	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	8.77	0.5	3.71e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs273218	1.000	rs156442	chr5:53373029	T/C	ch.5.1024479R	chr5:53302184	ARL15	0.67	7.28	0.43	5.05e-12	Migraine;
SARC	cis	rs7465272	0.530	rs10103161	chr8:143738571	A/G	cg10596483	chr8:143751796	JRK	0.56	7.24	0.43	6.37e-12	Bipolar disorder and schizophrenia;
SARC	cis	rs933688	0.938	rs6866923	chr5:90669352	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.02	13.01	0.65	1.93e-29	Smoking behavior;
SARC	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg13175981	chr1:150552382	MCL1	-0.54	-6.9	-0.41	4.97e-11	Tonsillectomy;
SARC	cis	rs2250402	0.510	rs2898984	chr15:40324075	G/C	cg01081584	chr15:40268610	EIF2AK4	-0.69	-5.88	-0.36	1.42e-8	Corneal curvature;
SARC	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg11062466	chr8:58055876	NA	0.54	5.56	0.34	7.55e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2304069	0.695	rs6866298	chr5:149439588	A/G	cg12661370	chr5:149340060	SLC26A2	0.52	5.41	0.33	1.54e-7	HIV-1 control;
SARC	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg01017244	chr2:74357527	NA	0.52	6.43	0.39	7.15e-10	Gestational age at birth (maternal effect);
SARC	cis	rs4268898	0.931	rs60716082	chr2:24526265	T/A	cg06627628	chr2:24431161	ITSN2	-0.67	-9.63	-0.53	1.11e-18	Asthma;
SARC	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg21724239	chr8:58056113	NA	0.58	6.14	0.37	3.49e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2361710	0.704	rs4889979	chr17:78121707	T/A	cg23534315	chr17:78082725	GAA	0.33	5.03	0.31	9.61e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
SARC	cis	rs34172651	0.917	rs7204281	chr16:24784475	C/T	cg00152838	chr16:24741724	TNRC6A	-0.51	-6.22	-0.38	2.26e-9	Intelligence (multi-trait analysis);
SARC	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg05234568	chr11:5960015	NA	-0.41	-5.45	-0.34	1.26e-7	DNA methylation (variation);
SARC	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg11843238	chr5:131593191	PDLIM4	-0.41	-5.07	-0.32	8.08e-7	Breast cancer;
SARC	cis	rs7772486	0.597	rs6912351	chr6:146264071	T/C	cg23711669	chr6:146136114	FBXO30	-0.86	-12.14	-0.62	1.29e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6456156	0.792	rs10946213	chr6:167516095	A/G	cg07741184	chr6:167504864	NA	-0.36	-7.11	-0.42	1.42e-11	Primary biliary cholangitis;
SARC	cis	rs3126085	0.735	rs4845744	chr1:152185095	T/A	cg26876637	chr1:152193138	HRNR	0.47	5.39	0.33	1.7e-7	Atopic dermatitis;
SARC	cis	rs9814567	1.000	rs13081688	chr3:134259954	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	7.08	0.42	1.73e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg13880726	chr7:1868755	MAD1L1	0.52	6.2	0.38	2.6e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg10130564	chr11:117069849	TAGLN	-0.22	-4.88	-0.3	1.99e-6	Blood protein levels;
SARC	trans	rs2727020	0.595	rs10839286	chr11:49497063	C/A	cg03929089	chr4:120376271	NA	-0.8	-12.03	-0.62	2.92e-26	Coronary artery disease;
SARC	cis	rs1420338	0.967	rs2192874	chr7:34144916	G/A	cg01275685	chr7:34179230	BMPER	-0.43	-5.29	-0.33	2.78e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
SARC	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	7.38	0.44	2.86e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg12311346	chr5:56204834	C5orf35	-0.58	-6.01	-0.37	7.24e-9	Initial pursuit acceleration;
SARC	cis	rs6912958	0.559	rs242279	chr6:88048191	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.34	5.91	0.36	1.2e-8	Monocyte percentage of white cells;
SARC	cis	rs7615952	0.515	rs7630575	chr3:125682330	A/G	cg05084668	chr3:125655381	ALG1L	-0.59	-6.07	-0.37	5.15e-9	Blood pressure (smoking interaction);
SARC	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.95	11.92	0.62	6.96e-26	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs2976388	0.609	rs2585153	chr8:143785345	G/A	cg06565975	chr8:143823917	SLURP1	0.32	5.53	0.34	8.54e-8	Urinary tract infection frequency;
SARC	cis	rs910316	0.789	rs4899552	chr14:75667921	C/A	cg06637938	chr14:75390232	RPS6KL1	-0.48	-6.47	-0.39	5.76e-10	Height;
SARC	cis	rs112591243	0.685	rs2839362	chr21:48024626	G/A	cg10657630	chr21:48055338	PRMT2	0.79	5.19	0.32	4.59e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs6918586	0.658	rs198856	chr6:26102708	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.45	-5.81	-0.36	2.08e-8	Schizophrenia;
SARC	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg12311346	chr5:56204834	C5orf35	-0.39	-4.76	-0.3	3.46e-6	Coronary artery disease;
SARC	cis	rs7772486	0.790	rs1062068	chr6:146207465	A/G	cg23711669	chr6:146136114	FBXO30	0.81	13.09	0.65	1.05e-29	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	10.89	0.58	1.4e-22	Alzheimer's disease;
SARC	cis	rs2180341	1.000	rs9401950	chr6:127655485	C/T	cg24812749	chr6:127587940	RNF146	0.98	13.14	0.65	7.1e-30	Breast cancer;
SARC	cis	rs524281	0.773	rs2236652	chr11:66002681	G/A	cg14036092	chr11:66035641	RAB1B	-0.59	-6.28	-0.38	1.67e-9	Electroencephalogram traits;
SARC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg26338869	chr17:61819248	STRADA	0.8	10.64	0.57	8.58e-22	Prudent dietary pattern;
SARC	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.06	17.7	0.76	5.38e-45	Height;
SARC	trans	rs61931739	0.500	rs11053211	chr12:34464334	T/C	cg13010199	chr12:38710504	ALG10B	0.75	10.59	0.57	1.21e-21	Morning vs. evening chronotype;
SARC	cis	rs9354308	0.899	rs2814094	chr6:66536275	G/T	cg07460842	chr6:66804631	NA	-0.49	-5.58	-0.34	6.74e-8	Metabolite levels;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg15447715	chr7:150725397	ABCB8	0.54	7.22	0.43	7.35e-12	Lung adenocarcinoma;
SARC	cis	rs72945132	0.882	rs7937984	chr11:70144254	C/T	cg05964544	chr11:70165517	PPFIA1	-0.61	-5.87	-0.36	1.5e-8	Coronary artery disease;
SARC	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg12419862	chr22:24373484	LOC391322	0.72	8.41	0.48	4.03e-15	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs3820928	1.000	rs10193316	chr2:227777650	A/G	cg05526886	chr2:227700861	RHBDD1	-0.5	-6.11	-0.37	4.13e-9	Pulmonary function;
SARC	cis	rs8141529	0.748	rs1318025	chr22:29283757	C/T	cg15103426	chr22:29168792	CCDC117	0.63	8.2	0.47	1.63e-14	Lymphocyte counts;
SARC	cis	rs929354	0.742	rs7806775	chr7:156947199	A/G	cg05182265	chr7:156933206	UBE3C	-0.34	-5.19	-0.32	4.49e-7	Body mass index;
SARC	cis	rs4565302	1.000	rs62397045	chr6:38391668	C/T	cg26053840	chr6:38644662	GLO1	-0.49	-4.93	-0.31	1.56e-6	Mammographic density;
SARC	cis	rs9818758	0.607	rs9311439	chr3:49310408	A/G	cg01304814	chr3:48885189	PRKAR2A	0.65	5.29	0.33	2.75e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg26335602	chr6:28129616	ZNF389	0.52	5.65	0.35	4.72e-8	Depression;
SARC	cis	rs9487051	0.872	rs9487032	chr6:109605323	G/T	cg01475377	chr6:109611718	NA	-0.43	-6.13	-0.37	3.68e-9	Reticulocyte fraction of red cells;
SARC	cis	rs7937682	0.883	rs553632	chr11:111462897	C/T	cg22437258	chr11:111473054	SIK2	0.76	9.87	0.54	2.07e-19	Primary sclerosing cholangitis;
SARC	cis	rs2273669	0.667	rs12202145	chr6:109357829	A/G	cg05315195	chr6:109294784	ARMC2	-0.63	-5.7	-0.35	3.6e-8	Prostate cancer;
SARC	cis	rs9905704	0.708	rs304263	chr17:56749941	C/T	cg12560992	chr17:57184187	TRIM37	0.41	4.73	0.3	3.82e-6	Testicular germ cell tumor;
SARC	cis	rs9747201	1.000	rs9303020	chr17:80163247	C/T	cg17462356	chr17:80056334	FASN	-0.45	-5.11	-0.32	6.83e-7	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs3091242	0.933	rs1534954	chr1:25761924	A/T	cg27572855	chr1:25598939	RHD	0.53	8.85	0.5	2.23e-16	Erythrocyte sedimentation rate;
SARC	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg11987759	chr7:65425863	GUSB	-0.6	-7.96	-0.46	7.64e-14	Aortic root size;
SARC	cis	rs1468333	0.565	rs4507481	chr5:137573073	G/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.73	8.04	0.47	4.53e-14	Resting heart rate;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg26444995	chr2:198670187	PLCL1	-0.58	-6.71	-0.4	1.48e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs3768617	0.510	rs6424884	chr1:183065904	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.59	0.57	1.23e-21	Fuchs's corneal dystrophy;
SARC	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.08	21.69	0.82	8.01e-58	Chronic sinus infection;
SARC	cis	rs6840360	1.000	rs7439465	chr4:152594814	C/T	cg22705602	chr4:152727874	NA	0.36	6.07	0.37	5.04e-9	Intelligence (multi-trait analysis);
SARC	cis	rs6449957	0.639	rs251398	chr5:67509801	C/T	cg23036683	chr5:67512108	NA	-0.42	-5.23	-0.32	3.82e-7	Cleft lip with or without cleft palate;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg22281935	chr2:162934111	NA	-0.45	-6.24	-0.38	2.08e-9	Chemerin levels;
SARC	cis	rs16866061	0.515	rs3738951	chr2:225368321	A/G	cg22509189	chr2:225307070	NA	-0.41	-5.27	-0.33	3.07e-7	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	cis	rs4718428	0.607	rs66954441	chr7:66369209	T/C	cg12165864	chr7:66369176	NA	-0.47	-5.2	-0.32	4.29e-7	Corneal structure;
SARC	cis	rs1008375	0.932	rs10029173	chr4:17659598	C/T	cg27347728	chr4:17578864	LAP3	-0.44	-5.47	-0.34	1.18e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg03354898	chr7:1950403	MAD1L1	-0.38	-5.36	-0.33	1.99e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg13939156	chr17:80058883	NA	0.35	5.43	0.34	1.39e-7	Life satisfaction;
SARC	cis	rs2439831	0.850	rs28590651	chr15:44113016	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.74	7.2	0.43	8.19e-12	Lung cancer in ever smokers;
SARC	cis	rs80130819	0.748	rs2732458	chr12:48758281	A/G	cg05342945	chr12:48394962	COL2A1	-0.5	-5.38	-0.33	1.82e-7	Prostate cancer;
SARC	cis	rs6430585	0.528	rs115553816	chr2:136692893	G/A	cg07169764	chr2:136633963	MCM6	1.05	13.64	0.67	1.55e-31	Corneal structure;
SARC	cis	rs2153535	0.580	rs2327051	chr6:8441150	A/G	cg07606381	chr6:8435919	SLC35B3	-0.8	-11.06	-0.59	4.01e-23	Motion sickness;
SARC	cis	rs2273669	0.667	rs6651000	chr6:109281411	G/T	cg01304950	chr6:109416612	SESN1;C6orf182	0.6	4.78	0.3	3.07e-6	Prostate cancer;
SARC	cis	rs2304069	0.545	rs12153714	chr5:149395254	A/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.44	4.94	0.31	1.46e-6	HIV-1 control;
SARC	cis	rs2120243	0.572	rs6803628	chr3:157125584	G/A	cg24825693	chr3:157122686	VEPH1	-0.45	-6.29	-0.38	1.58e-9	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs6840360	0.615	rs6836249	chr4:152465829	T/G	cg22705602	chr4:152727874	NA	-0.42	-6.51	-0.39	4.59e-10	Intelligence (multi-trait analysis);
SARC	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg08859206	chr1:53392774	SCP2	-0.4	-5.82	-0.36	1.89e-8	Monocyte count;
SARC	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.6	-7.51	-0.44	1.25e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs72781680	0.904	rs72796340	chr2:24143622	T/A	cg06627628	chr2:24431161	ITSN2	-0.68	-6.44	-0.39	6.58e-10	Lymphocyte counts;
SARC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg22105103	chr4:187893119	NA	0.5	6.85	0.41	6.42e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg02841227	chr6:26021843	HIST1H4A	0.38	4.72	0.3	4.14e-6	Blood metabolite levels;
SARC	cis	rs4242434	0.892	rs11776549	chr8:22493124	C/T	cg03733263	chr8:22462867	KIAA1967	1.03	14.56	0.69	1.4e-34	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs7681440	0.583	rs2737035	chr4:90777213	C/T	cg06632027	chr4:90757378	SNCA	-0.47	-5.81	-0.36	2.03e-8	Dementia with Lewy bodies;
SARC	trans	rs7359257	1.000	rs7359257	chr15:67702907	A/C	cg14397500	chr7:2214759	MAD1L1	-0.4	-6.24	-0.38	2.08e-9	Menarche (age at onset);
SARC	cis	rs854765	0.663	rs16960744	chr17:17755259	A/G	cg05444541	chr17:17804740	TOM1L2	0.3	5.08	0.32	7.59e-7	Total body bone mineral density;
SARC	cis	rs1355223	0.872	rs7112608	chr11:34699269	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-5.7	-0.35	3.54e-8	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs921968	0.565	rs1079177	chr2:219605929	G/A	cg02176678	chr2:219576539	TTLL4	-0.33	-5.02	-0.31	1.05e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs738322	0.967	rs6001038	chr22:38570585	A/G	cg25457927	chr22:38595422	NA	-0.29	-5.95	-0.36	9.77e-9	Cutaneous nevi;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg01364769	chr10:22607608	COMMD3	0.5	6.99	0.42	2.93e-11	Thyroid stimulating hormone;
SARC	cis	rs666930	0.967	rs637868	chr1:120257110	A/G	cg19096424	chr1:120255104	PHGDH	0.55	7.52	0.44	1.18e-12	Breast cancer;
SARC	cis	rs11675119	0.517	rs12619851	chr2:3492747	T/C	cg15541040	chr2:3486749	NA	-0.44	-5.55	-0.34	7.91e-8	Neurofibrillary tangles;
SARC	cis	rs597583	0.806	rs12224853	chr11:117394822	A/G	cg27161313	chr11:117392002	DSCAML1	0.31	4.87	0.3	2.04e-6	Putamen volume;
SARC	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-4.91	-0.31	1.71e-6	Total body bone mineral density;
SARC	cis	rs7980687	0.596	rs1727319	chr12:123701353	T/C	cg05973401	chr12:123451056	ABCB9	0.55	6.36	0.38	1.04e-9	Height;Educational attainment;Head circumference (infant);
SARC	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg07701084	chr6:150067640	NUP43	0.41	5.39	0.33	1.75e-7	Lung cancer;
SARC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg27588902	chr6:42928151	GNMT	-0.37	-5.73	-0.35	3.11e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs11605924	0.819	rs12805422	chr11:45839889	G/A	ch.11.939596F	chr11:45881766	CRY2	-0.47	-5.73	-0.35	3.04e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg03647317	chr4:187891568	NA	-0.35	-4.95	-0.31	1.39e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg09373136	chr17:61933544	TCAM1	0.39	5.47	0.34	1.17e-7	Prudent dietary pattern;
SARC	cis	rs910316	0.737	rs398896	chr14:75482827	C/A	cg08847533	chr14:75593920	NEK9	-0.8	-11.35	-0.6	4.52e-24	Height;
SARC	cis	rs60752752	0.777	rs3006479	chr1:153355594	C/T	cg26882115	chr1:153603048	S100A1;S100A13	-0.63	-4.83	-0.3	2.49e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs2120019	0.567	rs12385940	chr15:75168162	C/T	cg17294928	chr15:75287854	SCAMP5	-0.88	-9.07	-0.51	5.23e-17	Blood trace element (Zn levels);
SARC	cis	rs6840258	0.825	rs79998318	chr4:87954166	A/G	cg11209507	chr4:87813803	C4orf36	0.44	4.74	0.3	3.7e-6	Mean corpuscular volume;Basophil percentage of granulocytes;
SARC	cis	rs3796352	1.000	rs9874517	chr3:53128371	A/G	cg27565382	chr3:53032988	SFMBT1	0.7	5.0	0.31	1.14e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2273669	0.667	rs17070136	chr6:109350550	T/C	cg05315195	chr6:109294784	ARMC2	-0.64	-5.7	-0.35	3.68e-8	Prostate cancer;
SARC	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg07701084	chr6:150067640	NUP43	0.41	5.39	0.33	1.75e-7	Lung cancer;
SARC	cis	rs7568458	0.846	rs10179195	chr2:85762761	A/G	cg17127132	chr2:85788382	GGCX	0.46	6.26	0.38	1.84e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg14870128	chr10:70931312	VPS26A	0.52	7.32	0.43	3.9e-12	Thyroid stimulating hormone;
SARC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg17178900	chr1:205818956	PM20D1	0.65	9.62	0.53	1.12e-18	Menarche (age at onset);
SARC	cis	rs2050392	0.624	rs2489842	chr10:30721991	T/C	cg25182066	chr10:30743637	MAP3K8	0.43	5.8	0.36	2.17e-8	Inflammatory bowel disease;
SARC	cis	rs3793683	0.928	rs2148666	chr10:134553785	A/G	cg27286337	chr10:134555280	INPP5A	0.88	15.12	0.7	1.85e-36	Migraine;
SARC	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg22875332	chr1:76189707	ACADM	0.49	6.72	0.4	1.38e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9354308	1.000	rs9342503	chr6:66565436	A/G	cg07460842	chr6:66804631	NA	-0.46	-5.31	-0.33	2.52e-7	Metabolite levels;
SARC	cis	rs7945705	0.846	rs4929911	chr11:8816495	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.37	4.83	0.3	2.52e-6	Hemoglobin concentration;
SARC	cis	rs6752107	0.967	rs3816234	chr2:234185999	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.49	6.21	0.38	2.4e-9	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg16049864	chr8:95962084	TP53INP1	-0.55	-8.88	-0.5	1.89e-16	Type 2 diabetes;
SARC	cis	rs6582630	0.555	rs61932279	chr12:38349096	C/T	cg14851346	chr12:38532713	NA	-0.45	-5.31	-0.33	2.61e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9790314	1.000	rs336543	chr3:161061080	C/T	cg04691961	chr3:161091175	C3orf57	0.79	11.91	0.62	7.42e-26	Morning vs. evening chronotype;
SARC	cis	rs2718058	0.583	rs2722248	chr7:37845286	G/T	cg15028436	chr7:37888078	TXNDC3	0.39	4.92	0.31	1.62e-6	Alzheimer's disease (late onset);
SARC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg26338869	chr17:61819248	STRADA	0.8	10.69	0.57	5.79e-22	Prudent dietary pattern;
SARC	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.97e-8	Aortic root size;
SARC	cis	rs116095464	0.558	rs7714335	chr5:263513	T/C	cg22496380	chr5:211416	CCDC127	-0.86	-8.77	-0.5	3.82e-16	Breast cancer;
SARC	cis	rs2204008	0.659	rs4002655	chr12:38169881	T/G	cg13010199	chr12:38710504	ALG10B	0.78	10.64	0.57	8.11e-22	Bladder cancer;
SARC	cis	rs4727027	0.901	rs12671341	chr7:148805282	T/C	cg23583168	chr7:148888333	NA	-0.74	-10.37	-0.56	5.62e-21	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs710216	0.843	rs844501	chr1:43440783	G/A	cg03128534	chr1:43423976	SLC2A1	0.56	5.65	0.35	4.73e-8	Red cell distribution width;
SARC	trans	rs877282	1.000	rs12775643	chr10:773242	G/A	cg22713356	chr15:30763199	NA	1.02	10.31	0.56	8.65e-21	Uric acid levels;
SARC	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.78	7.59	0.45	7.81e-13	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs12995491	0.933	rs7590305	chr2:88513131	C/T	cg04511125	chr2:88470314	THNSL2	-0.38	-5.78	-0.35	2.41e-8	Response to metformin (IC50);
SARC	cis	rs5753618	0.561	rs9606831	chr22:31732512	C/T	cg02404636	chr22:31891804	SFI1	0.48	5.21	0.32	4.09e-7	Colorectal cancer;
SARC	cis	rs4555082	0.834	rs11849607	chr14:105745383	G/A	cg06808227	chr14:105710500	BRF1	-0.51	-6.53	-0.39	4.14e-10	Mean platelet volume;Platelet distribution width;
SARC	cis	rs9815354	0.767	rs73830585	chr3:42003698	T/A	cg03022575	chr3:42003672	ULK4	0.68	5.89	0.36	1.34e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs11711311	1.000	rs12636577	chr3:113497507	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	8.69	0.49	6.43e-16	IgG glycosylation;
SARC	cis	rs6964587	0.967	rs2299235	chr7:91627500	C/T	cg17063962	chr7:91808500	NA	0.95	15.95	0.72	3.35e-39	Breast cancer;
SARC	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.88	14.28	0.68	1.16e-33	Age at first birth;
SARC	cis	rs4319547	0.741	rs4758663	chr12:122939483	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.54	-6.26	-0.38	1.86e-9	Body mass index;
SARC	cis	rs929354	0.713	rs6946660	chr7:156948648	T/C	cg05182265	chr7:156933206	UBE3C	-0.34	-5.19	-0.32	4.49e-7	Body mass index;
SARC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.0	12.28	0.63	4.69e-27	Platelet count;
SARC	cis	rs9581943	0.967	rs7993114	chr13:28476277	A/G	cg17352152	chr13:28491409	NA	0.38	5.12	0.32	6.54e-7	Pancreatic cancer;
SARC	cis	rs1472147	0.955	rs3736614	chr7:128509048	T/G	cg00260937	chr7:128520193	KCP	0.41	4.73	0.3	3.83e-6	Calcium levels;
SARC	cis	rs11677370	0.561	rs11687254	chr2:3830906	C/T	cg17052675	chr2:3827356	NA	-0.44	-5.11	-0.32	6.78e-7	Type 2 diabetes;
SARC	cis	rs9807989	0.839	rs1420099	chr2:102980543	C/G	cg09003973	chr2:102972529	NA	0.41	5.64	0.35	4.86e-8	Asthma;
SARC	cis	rs710216	0.843	rs710220	chr1:43415346	G/T	cg07803811	chr1:43423981	SLC2A1	0.56	6.02	0.37	6.85e-9	Red cell distribution width;
SARC	cis	rs3733585	0.673	rs4312757	chr4:9956145	T/A	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.95	-0.36	9.9e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg02034447	chr16:89574710	SPG7	0.51	6.79	0.41	8.97e-11	Multiple myeloma (IgH translocation);
SARC	cis	rs11785400	1.000	rs4484678	chr8:143730796	A/G	cg24634471	chr8:143751801	JRK	0.67	8.93	0.5	1.34e-16	Schizophrenia;
SARC	cis	rs9896933	0.832	rs75552659	chr17:80804630	G/A	cg15664640	chr17:80829946	TBCD	-0.51	-6.14	-0.37	3.52e-9	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
SARC	cis	rs910316	0.712	rs175074	chr14:75504454	G/A	cg08847533	chr14:75593920	NEK9	-0.84	-12.53	-0.63	7.13e-28	Height;
SARC	trans	rs61931739	0.635	rs1525895	chr12:33966496	A/G	cg26384229	chr12:38710491	ALG10B	0.57	7.5	0.44	1.3e-12	Morning vs. evening chronotype;
SARC	cis	rs7149337	0.869	rs7159770	chr14:51691835	G/A	cg23942311	chr14:51606299	NA	0.33	5.87	0.36	1.47e-8	Cancer;
SARC	cis	rs1707322	0.964	rs6697830	chr1:46290477	C/A	cg06784218	chr1:46089804	CCDC17	0.33	5.76	0.35	2.66e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs477692	0.612	rs58103386	chr10:131319958	C/A	cg14263093	chr10:131365266	MGMT	0.4	5.68	0.35	3.99e-8	Response to temozolomide;
SARC	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg07701084	chr6:150067640	NUP43	0.4	5.32	0.33	2.4e-7	Lung cancer;
SARC	cis	rs7208859	0.623	rs8067035	chr17:29102188	T/C	cg13385521	chr17:29058706	SUZ12P	0.84	7.1	0.42	1.53e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg16680214	chr1:154839983	KCNN3	-0.38	-6.06	-0.37	5.53e-9	Prostate cancer;
SARC	cis	rs7092929	0.883	rs611890	chr10:3585733	T/C	cg14308648	chr10:3568949	NA	0.51	5.13	0.32	6.16e-7	Coronary artery calcification;
SARC	cis	rs67460515	0.892	rs4856703	chr3:161047720	G/T	cg04691961	chr3:161091175	C3orf57	-0.49	-6.15	-0.37	3.36e-9	Parkinson's disease;
SARC	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg08859206	chr1:53392774	SCP2	-0.37	-5.34	-0.33	2.22e-7	Monocyte count;
SARC	cis	rs637571	0.522	rs556643	chr11:65733289	C/T	cg26695010	chr11:65641043	EFEMP2	-0.56	-7.46	-0.44	1.72e-12	Eosinophil percentage of white cells;
SARC	cis	rs798554	0.704	rs798513	chr7:2782493	C/T	cg04166393	chr7:2884313	GNA12	0.47	5.77	0.35	2.52e-8	Height;
SARC	cis	rs9462027	0.585	rs2814976	chr6:34576237	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-6.08	-0.37	4.94e-9	Systemic lupus erythematosus;
SARC	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.75	-0.45	2.91e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs9818758	0.607	rs35673421	chr3:49139406	G/A	cg01304814	chr3:48885189	PRKAR2A	0.62	5.01	0.31	1.07e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs6142102	0.961	rs4911393	chr20:32570926	A/G	cg24642439	chr20:33292090	TP53INP2	0.44	4.81	0.3	2.69e-6	Skin pigmentation;
SARC	cis	rs11249608	0.590	rs36051170	chr5:178447971	T/C	cg21905437	chr5:178450457	ZNF879	0.57	7.62	0.45	6.21e-13	Pubertal anthropometrics;
SARC	cis	rs11252926	0.966	rs11252923	chr10:566195	G/A	cg08603382	chr10:743973	NA	-0.56	-7.06	-0.42	1.95e-11	Psychosis in Alzheimer's disease;
SARC	cis	rs644799	0.710	rs11021311	chr11:95505227	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	13.92	0.67	1.84e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs11122272	0.735	rs2790873	chr1:231539685	A/G	cg06096015	chr1:231504339	EGLN1	0.38	5.58	0.34	6.56e-8	Hemoglobin concentration;
SARC	cis	rs2046867	0.818	rs62249863	chr3:72868666	G/C	cg25664220	chr3:72788482	NA	-0.29	-4.77	-0.3	3.27e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
SARC	cis	rs3862260	0.509	rs10802124	chr1:120164252	G/A	cg16322792	chr1:120165303	ZNF697	0.29	6.09	0.37	4.51e-9	Systemic lupus erythematosus;
SARC	cis	rs6061231	0.837	rs6121558	chr20:60961365	A/G	cg22601191	chr20:60968625	CABLES2	0.4	5.02	0.31	1.02e-6	Colorectal cancer;
SARC	cis	rs2070488	0.804	rs6764551	chr3:38460305	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	12.38	0.63	2.24e-27	Electrocardiographic conduction measures;
SARC	cis	rs1832871	0.711	rs9459887	chr6:158696479	C/T	cg07165851	chr6:158734300	TULP4	0.51	6.18	0.38	2.85e-9	Height;
SARC	cis	rs17514846	0.565	rs2521498	chr15:91442152	A/T	cg05469396	chr15:91419421	FURIN	-0.37	-5.41	-0.33	1.58e-7	Coronary artery disease;
SARC	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg16405210	chr4:1374714	KIAA1530	-0.54	-6.68	-0.4	1.72e-10	Longevity;
SARC	cis	rs1215050	0.765	rs471500	chr4:98714820	T/C	cg05340658	chr4:99064831	C4orf37	0.44	5.85	0.36	1.62e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg10523679	chr1:76189770	ACADM	0.51	6.86	0.41	6.1e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6089584	0.526	rs6089316	chr20:60627552	C/T	cg13770153	chr20:60521292	NA	-0.38	-5.41	-0.33	1.53e-7	Body mass index;
SARC	cis	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg00409905	chr10:38381863	ZNF37A	-0.5	-6.9	-0.41	4.93e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs6570726	0.935	rs385185	chr6:145814992	A/G	cg23711669	chr6:146136114	FBXO30	0.78	11.91	0.62	7.29e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs62432291	0.681	rs439126	chr6:159656632	T/C	cg14500486	chr6:159655392	FNDC1	-0.63	-6.31	-0.38	1.42e-9	Joint mobility (Beighton score);
SARC	cis	rs3845702	0.736	rs115569960	chr2:180848214	C/T	cg01881094	chr2:180872142	CWC22	1.15	9.79	0.54	3.65e-19	Schizophrenia;
SARC	cis	rs6981523	0.500	rs4412337	chr8:11072020	C/T	cg21775007	chr8:11205619	TDH	0.44	5.49	0.34	1.06e-7	Neuroticism;
SARC	cis	rs796364	0.906	rs1658810	chr2:200816382	C/T	cg23649088	chr2:200775458	C2orf69	0.62	5.83	0.36	1.8e-8	Schizophrenia;
SARC	cis	rs10754283	0.967	rs7528433	chr1:90114071	T/C	cg21401794	chr1:90099060	LRRC8C	0.59	8.09	0.47	3.24e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs8180040	0.966	rs11719877	chr3:47425473	C/T	cg27129171	chr3:47204927	SETD2	0.66	9.12	0.51	3.55e-17	Colorectal cancer;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg10284115	chr3:15841404	ANKRD28	0.46	6.47	0.39	5.65e-10	Thyroid stimulating hormone;
SARC	cis	rs10504073	0.584	rs11784268	chr8:49956339	T/G	cg00325661	chr8:49890786	NA	0.52	6.78	0.41	9.87e-11	Blood metabolite ratios;
SARC	cis	rs12048904	0.505	rs11166511	chr1:101240686	G/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.54	-5.67	-0.35	4.13e-8	Multiple sclerosis;
SARC	cis	rs35110281	0.807	rs2838328	chr21:45023234	G/C	cg21573476	chr21:45109991	RRP1B	-0.5	-7.44	-0.44	1.94e-12	Mean corpuscular volume;
SARC	cis	rs13314892	0.764	rs58711181	chr3:69880552	C/T	cg17445875	chr3:69859618	MITF	-0.48	-5.12	-0.32	6.53e-7	QRS complex (12-leadsum);
SARC	cis	rs765787	0.530	rs16941017	chr15:45543281	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.41	-5.04	-0.31	9.29e-7	Uric acid levels;
SARC	trans	rs2727020	0.894	rs11040333	chr11:49346332	G/A	cg15704280	chr7:45808275	SEPT13	-0.74	-9.61	-0.53	1.21e-18	Coronary artery disease;
SARC	cis	rs1018836	0.892	rs10103198	chr8:91579436	A/T	cg16814680	chr8:91681699	NA	-0.71	-10.74	-0.58	4.04e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs7923609	0.841	rs2163188	chr10:65314711	G/C	cg01631684	chr10:65280961	REEP3	0.35	4.72	0.3	4.06e-6	Educational attainment;Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs10979	1.000	rs3748072	chr6:143889757	C/T	cg25407410	chr6:143891975	LOC285740	-0.64	-8.68	-0.49	6.88e-16	Hypospadias;
SARC	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg26335602	chr6:28129616	ZNF389	0.52	5.65	0.35	4.72e-8	Depression;
SARC	cis	rs4737010	0.644	rs506763	chr8:41612487	C/T	cg08923054	chr8:41654455	ANK1	-0.4	-4.87	-0.3	2.08e-6	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
SARC	cis	rs858239	0.601	rs4140959	chr7:23170776	C/T	cg23682824	chr7:23144976	KLHL7	0.73	9.83	0.54	2.64e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg06221963	chr1:154839813	KCNN3	-0.51	-8.13	-0.47	2.53e-14	Prostate cancer;
SARC	trans	rs629535	0.748	rs58675625	chr8:70034924	T/C	cg21567404	chr3:27674614	NA	1.04	13.82	0.67	3.98e-32	Dupuytren's disease;
SARC	cis	rs7520050	0.807	rs6656279	chr1:46124088	C/G	cg06784218	chr1:46089804	CCDC17	0.26	4.75	0.3	3.53e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs6565681	0.760	rs9901680	chr17:78378088	A/G	cg15383979	chr17:78362278	RNF213;LOC100294362	-0.58	-4.81	-0.3	2.72e-6	Moyamoya disease;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg20668222	chr19:44258614	C19orf61	0.69	6.98	0.42	3.08e-11	Lung cancer in ever smokers;
SARC	cis	rs11785400	0.793	rs4403386	chr8:143736770	C/G	cg10596483	chr8:143751796	JRK	0.56	7.2	0.43	8.42e-12	Schizophrenia;
SARC	cis	rs9815354	0.812	rs17216919	chr3:41888938	G/C	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2204008	0.837	rs11611861	chr12:38357459	A/G	cg26384229	chr12:38710491	ALG10B	0.87	12.69	0.64	2.17e-28	Bladder cancer;
SARC	cis	rs734999	0.572	rs3748816	chr1:2526746	A/G	cg18854424	chr1:2615690	NA	0.33	5.22	0.32	3.88e-7	Ulcerative colitis;
SARC	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg17376030	chr22:41985996	PMM1	-0.79	-9.86	-0.54	2.19e-19	Vitiligo;
SARC	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg07701084	chr6:150067640	NUP43	0.4	5.24	0.32	3.57e-7	Lung cancer;
SARC	cis	rs7223966	1.000	rs11658175	chr17:61923838	G/A	cg00588841	chr17:61851480	DDX42;CCDC47	-0.62	-6.7	-0.4	1.51e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs818427	0.964	rs519397	chr5:112229688	T/C	cg07820702	chr5:112228657	REEP5	-0.52	-5.75	-0.35	2.75e-8	Total body bone mineral density;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg21829265	chr6:56911139	KIAA1586	0.53	7.03	0.42	2.24e-11	Electrocardiographic conduction measures;
SARC	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg24531977	chr5:56204891	C5orf35	-0.51	-5.22	-0.32	3.89e-7	Initial pursuit acceleration;
SARC	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg16479474	chr6:28041457	NA	0.36	5.27	0.33	3.04e-7	Depression;
SARC	cis	rs453301	0.686	rs11785819	chr8:8870378	T/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.2	-0.38	2.52e-9	Joint mobility (Beighton score);
SARC	cis	rs1008375	1.000	rs7694020	chr4:17682597	C/T	cg02297831	chr4:17616191	MED28	0.4	4.95	0.31	1.4e-6	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7726839	0.540	rs7558	chr5:660491	C/T	cg14541582	chr5:601475	NA	-0.4	-5.03	-0.31	9.91e-7	Obesity-related traits;
SARC	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg24209194	chr3:40518798	ZNF619	0.65	8.16	0.47	2.04e-14	Renal cell carcinoma;
SARC	cis	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg22857025	chr5:266934	NA	-0.96	-11.29	-0.59	7.39e-24	Breast cancer;
SARC	cis	rs7044106	0.762	rs7849566	chr9:123460769	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	8.57	0.49	1.46e-15	Hip circumference adjusted for BMI;
SARC	cis	rs9398803	0.865	rs1490388	chr6:126835655	C/T	cg19875578	chr6:126661172	C6orf173	0.63	8.53	0.49	1.82e-15	Male-pattern baldness;
SARC	trans	rs8073060	0.544	rs9912939	chr17:34005264	T/G	cg19694781	chr19:47549865	TMEM160	-0.71	-6.97	-0.42	3.32e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs3106136	0.527	rs2632410	chr4:95149507	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.47	-7.05	-0.42	2.06e-11	Capecitabine sensitivity;
SARC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.08	18.74	0.78	2.02e-48	Prudent dietary pattern;
SARC	cis	rs6912958	0.781	rs7761814	chr6:88188309	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.51	-6.85	-0.41	6.69e-11	Monocyte percentage of white cells;
SARC	cis	rs2486288	0.656	rs6493144	chr15:45573489	C/G	cg15395560	chr15:45543142	SLC28A2	-0.29	-5.48	-0.34	1.11e-7	Glomerular filtration rate;
SARC	cis	rs11098499	0.954	rs2389802	chr4:120325732	C/A	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs7824557	0.737	rs2293855	chr8:11177410	G/A	cg21775007	chr8:11205619	TDH	0.54	6.56	0.39	3.52e-10	Retinal vascular caliber;
SARC	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg08859206	chr1:53392774	SCP2	-0.38	-5.42	-0.33	1.47e-7	Monocyte count;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg25121125	chr3:64674314	ADAMTS9	-0.58	-6.23	-0.38	2.14e-9	Lung cancer in ever smokers;
SARC	cis	rs9457247	0.565	rs2239824	chr6:167511799	T/A	cg23791538	chr6:167370224	RNASET2	-0.48	-6.08	-0.37	4.93e-9	Crohn's disease;
SARC	cis	rs9467773	0.523	rs2498399	chr6:26706544	T/C	cg11502198	chr6:26597334	ABT1	0.59	7.33	0.43	3.81e-12	Intelligence (multi-trait analysis);
SARC	cis	rs7589342	0.929	rs13024715	chr2:106433950	A/G	cg14210321	chr2:106509881	NCK2	-0.46	-5.36	-0.33	2e-7	Addiction;
SARC	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg14983838	chr19:29218262	NA	0.77	10.53	0.57	1.83e-21	Methadone dose in opioid dependence;
SARC	cis	rs4481887	0.927	rs9651176	chr1:248447343	A/G	cg13385794	chr1:248469461	NA	0.35	5.38	0.33	1.83e-7	Common traits (Other);
SARC	cis	rs644799	1.000	rs514170	chr11:95556696	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.68	9.17	0.51	2.6e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs11098499	0.863	rs10009626	chr4:120470005	T/C	cg24375607	chr4:120327624	NA	0.42	4.92	0.31	1.64e-6	Corneal astigmatism;
SARC	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg27266027	chr21:40555129	PSMG1	0.48	5.18	0.32	4.79e-7	Cognitive function;
SARC	cis	rs7772486	0.597	rs1970306	chr6:146154543	A/G	cg05347473	chr6:146136440	FBXO30	0.69	9.58	0.53	1.54e-18	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2180341	0.782	rs4487601	chr6:127723521	A/G	cg27446573	chr6:127587934	RNF146	0.79	10.81	0.58	2.49e-22	Breast cancer;
SARC	cis	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg14541582	chr5:601475	NA	-0.41	-5.13	-0.32	6e-7	Obesity-related traits;
SARC	cis	rs7833790	0.660	rs67666182	chr8:82772037	A/G	cg27398817	chr8:82754497	SNX16	0.42	5.31	0.33	2.58e-7	Diastolic blood pressure;
SARC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg04267008	chr7:1944627	MAD1L1	-0.56	-6.44	-0.39	6.59e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs763121	0.853	rs4821808	chr22:39065739	A/G	cg21395723	chr22:39101663	GTPBP1	0.52	5.81	0.36	2.02e-8	Menopause (age at onset);
SARC	cis	rs28374715	0.681	rs8037574	chr15:41630770	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.95	-14.73	-0.69	3.62e-35	Ulcerative colitis;
SARC	cis	rs875971	0.825	rs59466412	chr7:65565358	A/G	cg18252515	chr7:66147081	NA	0.48	5.13	0.32	6.09e-7	Aortic root size;
SARC	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg17077180	chr1:38461687	NA	0.31	5.61	0.34	5.79e-8	Coronary artery disease;
SARC	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg08280861	chr8:58055591	NA	0.67	5.25	0.33	3.4e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6429082	0.755	rs291370	chr1:235693041	A/G	cg26050004	chr1:235667680	B3GALNT2	0.65	8.52	0.49	1.94e-15	Adiposity;
SARC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.8	10.34	0.56	6.97e-21	Prudent dietary pattern;
SARC	cis	rs9527	0.567	rs6584539	chr10:104879402	G/C	cg04362960	chr10:104952993	NT5C2	0.43	4.94	0.31	1.47e-6	Arsenic metabolism;
SARC	cis	rs422249	0.504	rs174538	chr11:61560081	G/A	cg19610905	chr11:61596333	FADS2	-0.41	-4.85	-0.3	2.28e-6	Trans fatty acid levels;
SARC	cis	rs57502260	0.679	rs72936524	chr11:68275898	G/A	cg20283391	chr11:68216788	NA	-0.52	-4.72	-0.3	4.05e-6	Total body bone mineral density (age 45-60);
SARC	cis	rs6546550	0.901	rs7419837	chr2:70146625	T/C	cg02498382	chr2:70120550	SNRNP27	-0.33	-5.36	-0.33	1.99e-7	Prevalent atrial fibrillation;
SARC	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg07636037	chr3:49044803	WDR6	0.91	15.45	0.71	1.54e-37	Menarche (age at onset);
SARC	cis	rs3812831	0.662	rs407531	chr13:114929218	G/A	cg06611532	chr13:114900021	NA	0.34	5.73	0.35	3.16e-8	Schizophrenia;
SARC	cis	rs5167	0.533	rs55778858	chr19:45485465	G/A	cg13119609	chr19:45449297	APOC2	0.39	5.53	0.34	8.77e-8	Blood protein levels;
SARC	trans	rs61931739	0.534	rs2667447	chr12:34133468	C/A	cg26384229	chr12:38710491	ALG10B	0.77	11.06	0.59	4.04e-23	Morning vs. evening chronotype;
SARC	cis	rs1580019	0.563	rs896137	chr7:32579345	G/T	cg06627557	chr7:32535165	LSM5;AVL9	0.96	15.94	0.72	3.65e-39	Cognitive ability;
SARC	cis	rs9858542	0.953	rs9824092	chr3:49674147	C/G	cg03060546	chr3:49711283	APEH	-0.66	-8.29	-0.48	9.28e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs7772486	0.686	rs9376961	chr6:146048737	C/T	cg05347473	chr6:146136440	FBXO30	0.48	6.5	0.39	4.93e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs870825	0.929	rs871254	chr4:185589226	G/C	cg04058563	chr4:185651563	MLF1IP	0.82	9.06	0.51	5.59e-17	Blood protein levels;
SARC	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg19077165	chr18:44547161	KATNAL2	0.52	7.39	0.44	2.58e-12	Personality dimensions;
SARC	cis	rs2120019	1.000	rs34237279	chr15:75361121	A/G	cg09165964	chr15:75287851	SCAMP5	-0.91	-13.65	-0.67	1.4e-31	Blood trace element (Zn levels);
SARC	cis	rs12893668	0.703	rs7148456	chr14:104028270	C/T	cg26031613	chr14:104095156	KLC1	0.52	5.75	0.35	2.86e-8	Reticulocyte count;
SARC	cis	rs7626444	0.625	rs2669638	chr3:196477398	T/G	cg12930392	chr3:196481615	PAK2	0.26	5.14	0.32	5.89e-7	Monocyte count;
SARC	cis	rs34779708	0.966	rs12773647	chr10:35440327	A/G	cg03585969	chr10:35415529	CREM	0.38	4.77	0.3	3.24e-6	Inflammatory bowel disease;Crohn's disease;
SARC	trans	rs1994135	0.594	rs10772096	chr12:33732869	A/G	cg26384229	chr12:38710491	ALG10B	0.59	7.17	0.43	9.69e-12	Resting heart rate;
SARC	cis	rs3219474	0.502	rs41343546	chr1:45908263	A/G	cg24296786	chr1:45957014	TESK2	-0.69	-5.1	-0.32	6.94e-7	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	trans	rs13325613	0.915	rs35117954	chr3:46338831	A/G	cg03618215	chr12:133365750	GOLGA3	-1.27	-6.34	-0.38	1.2e-9	Monocyte count;
SARC	cis	rs10791097	0.694	rs4937581	chr11:130740335	T/C	cg09137382	chr11:130731461	NA	0.31	4.77	0.3	3.2e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	trans	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg00938859	chr5:1591904	SDHAP3	0.79	7.62	0.45	6.43e-13	Breast cancer;
SARC	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg19660806	chr8:588740	NA	0.54	4.9	0.31	1.82e-6	IgG glycosylation;
SARC	cis	rs4319547	0.915	rs11058402	chr12:122981053	A/G	cg23029597	chr12:123009494	RSRC2	-0.41	-5.13	-0.32	6.22e-7	Body mass index;
SARC	cis	rs3768617	0.706	rs6678517	chr1:183002639	A/G	cg13390022	chr1:182993471	LAMC1	0.35	5.25	0.33	3.4e-7	Fuchs's corneal dystrophy;
SARC	cis	rs854765	0.583	rs8075965	chr17:17853180	A/T	cg04398451	chr17:18023971	MYO15A	-0.4	-5.51	-0.34	9.71e-8	Total body bone mineral density;
SARC	cis	rs896543	0.702	rs12692188	chr2:237495929	A/G	cg25295825	chr2:237489920	CXCR7	0.47	5.5	0.34	9.81e-8	Alcohol dependence (age at onset);
SARC	cis	rs11971779	0.616	rs7784192	chr7:139039649	T/C	cg23387468	chr7:139079360	LUC7L2	0.33	4.71	0.3	4.2e-6	Diisocyanate-induced asthma;
SARC	cis	rs3733585	0.673	rs7376948	chr4:9954708	G/A	cg11266682	chr4:10021025	SLC2A9	-0.36	-6.21	-0.38	2.41e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs634534	0.622	rs552130	chr11:65732800	T/C	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.42	-5.22	-0.32	3.92e-7	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs17253792	0.915	rs77252471	chr14:56178075	C/T	cg01858014	chr14:56050164	KTN1	-0.62	-4.86	-0.3	2.19e-6	Putamen volume;
SARC	cis	rs6088590	0.687	rs6088582	chr20:33286798	G/A	cg08999081	chr20:33150536	PIGU	0.43	6.48	0.39	5.51e-10	Coronary artery disease;
SARC	cis	rs11148252	0.532	rs9536262	chr13:53303074	A/C	cg00495681	chr13:53174319	NA	-0.34	-4.86	-0.3	2.2e-6	Lewy body disease;
SARC	cis	rs2549003	1.000	rs9282763	chr5:131822133	T/C	cg21138405	chr5:131827807	IRF1	0.27	5.32	0.33	2.4e-7	Asthma (sex interaction);
SARC	cis	rs10046574	0.831	rs77693675	chr7:135142402	T/C	cg27474649	chr7:135195673	CNOT4	0.87	7.2	0.43	8.45e-12	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg13880726	chr7:1868755	MAD1L1	0.5	5.93	0.36	1.06e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs763121	0.853	rs2205802	chr22:39046327	T/C	cg21395723	chr22:39101663	GTPBP1	0.58	6.67	0.4	1.85e-10	Menopause (age at onset);
SARC	cis	rs7819412	0.521	rs10110684	chr8:11039159	G/C	cg21775007	chr8:11205619	TDH	-0.45	-5.73	-0.35	3.05e-8	Triglycerides;
SARC	cis	rs7772486	0.625	rs9390355	chr6:146112942	C/T	cg05347473	chr6:146136440	FBXO30	-0.51	-7.16	-0.42	1.05e-11	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg04226542	chr12:64173449	TMEM5	0.48	6.43	0.39	7.31e-10	Tetralogy of Fallot;
SARC	cis	rs6088580	0.634	rs6087587	chr20:33058628	G/T	cg08999081	chr20:33150536	PIGU	0.44	6.63	0.4	2.27e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs79349575	0.870	rs12941262	chr17:46967037	T/A	cg07967210	chr17:47022446	SNF8	0.38	4.86	0.3	2.19e-6	Type 2 diabetes;
SARC	cis	rs6981523	0.553	rs2409730	chr8:11060638	C/A	cg12395012	chr8:11607386	GATA4	0.31	5.29	0.33	2.82e-7	Neuroticism;
SARC	cis	rs546131	0.928	rs483976	chr11:34840167	C/G	cg06937548	chr11:34938143	PDHX;APIP	0.48	6.3	0.38	1.45e-9	Lung disease severity in cystic fibrosis;
SARC	cis	rs208515	0.525	rs12191500	chr6:66668681	A/G	cg07460842	chr6:66804631	NA	0.97	11.01	0.58	5.72e-23	Exhaled nitric oxide levels;
SARC	cis	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg08975724	chr8:8085496	FLJ10661	0.55	7.05	0.42	2.03e-11	Mood instability;
SARC	cis	rs9325144	0.723	rs11169519	chr12:39177441	G/A	cg13010199	chr12:38710504	ALG10B	-0.5	-6.0	-0.37	7.53e-9	Morning vs. evening chronotype;
SARC	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg13126279	chr21:47581558	C21orf56	-0.46	-5.6	-0.34	6.01e-8	Testicular germ cell tumor;
SARC	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg03575189	chr17:44344142	NA	-0.53	-5.2	-0.32	4.37e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7149337	0.836	rs35345236	chr14:51671817	T/C	cg23942311	chr14:51606299	NA	0.34	6.01	0.37	6.94e-9	Cancer;
SARC	cis	rs9291683	0.554	rs7668175	chr4:10125782	T/C	cg11266682	chr4:10021025	SLC2A9	-0.37	-6.66	-0.4	1.93e-10	Bone mineral density;
SARC	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg21171335	chr12:122356390	WDR66	0.37	6.0	0.37	7.43e-9	Mean corpuscular volume;
SARC	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg11764359	chr7:65958608	NA	0.86	12.33	0.63	3.29e-27	Aortic root size;
SARC	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg17971929	chr21:40555470	PSMG1	0.95	13.28	0.66	2.35e-30	Cognitive function;
SARC	cis	rs7520050	0.898	rs785502	chr1:46581444	T/C	cg06784218	chr1:46089804	CCDC17	-0.26	-4.82	-0.3	2.56e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs7674212	0.865	rs13149311	chr4:103977700	C/T	cg16532752	chr4:104119610	CENPE	-0.41	-4.75	-0.3	3.52e-6	Type 2 diabetes;
SARC	cis	rs370915	0.542	rs1425953	chr4:187833652	A/C	cg10295955	chr4:187884368	NA	-0.43	-5.13	-0.32	6.02e-7	Gout;
SARC	cis	rs7595412	1.000	rs1379018	chr2:199083827	T/C	cg00208931	chr2:198669586	PLCL1	-0.59	-4.82	-0.3	2.55e-6	Hip bone size;
SARC	cis	rs208520	0.754	rs851592	chr6:66875175	G/T	cg07460842	chr6:66804631	NA	-1.12	-15.16	-0.7	1.35e-36	Exhaled nitric oxide output;
SARC	cis	rs7223966	1.000	rs11657306	chr17:61704822	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	4.82	0.3	2.54e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs651907	0.557	rs3094296	chr3:101400167	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.49	5.81	0.36	2.07e-8	Colorectal cancer;
SARC	cis	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg20965017	chr5:231967	SDHA	-0.55	-5.28	-0.33	2.98e-7	Breast cancer;
SARC	cis	rs853679	0.723	rs1736904	chr6:28219270	G/A	cg26450541	chr6:28235208	ZNF187	0.47	4.92	0.31	1.6e-6	Depression;
SARC	cis	rs7208859	0.573	rs73267872	chr17:29067207	T/C	cg13385521	chr17:29058706	SUZ12P	0.84	7.31	0.43	4.29e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9326248	0.817	rs6589598	chr11:117002403	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.58	6.2	0.38	2.49e-9	Blood protein levels;
SARC	cis	rs3762637	1.000	rs10934602	chr3:122223182	A/C	cg24169773	chr3:122142474	KPNA1	0.58	6.02	0.37	6.65e-9	LDL cholesterol levels;
SARC	cis	rs7843479	0.601	rs878873	chr8:21834581	T/C	cg17168535	chr8:21777572	XPO7	0.85	13.01	0.65	1.88e-29	Mean corpuscular volume;
SARC	cis	rs1318878	0.519	rs73055272	chr12:15427487	G/T	cg08258403	chr12:15378311	NA	0.47	6.61	0.4	2.53e-10	Intelligence (multi-trait analysis);
SARC	cis	rs1729951	0.575	rs835642	chr3:136703365	A/T	cg15507776	chr3:136538369	TMEM22	0.49	5.34	0.33	2.18e-7	Neuroticism;
SARC	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg00933542	chr6:150070202	PCMT1	0.32	5.55	0.34	7.78e-8	Lung cancer;
SARC	cis	rs477692	0.549	rs7098548	chr10:131455028	A/G	cg05714579	chr10:131428358	MGMT	-0.4	-5.0	-0.31	1.15e-6	Response to temozolomide;
SARC	cis	rs9660992	0.686	rs1668870	chr1:205239031	C/G	cg00857998	chr1:205179979	DSTYK	0.52	6.31	0.38	1.41e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs10504229	0.724	rs72649117	chr8:58037639	A/G	cg20607798	chr8:58055168	NA	0.56	5.26	0.33	3.25e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1023500	0.573	rs4822088	chr22:42470589	G/C	cg04733989	chr22:42467013	NAGA	0.77	10.92	0.58	1.11e-22	Schizophrenia;
SARC	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg01475735	chr3:40494733	NA	-0.44	-4.99	-0.31	1.2e-6	Renal cell carcinoma;
SARC	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg08859206	chr1:53392774	SCP2	0.39	5.65	0.35	4.74e-8	Monocyte count;
SARC	cis	rs6582630	0.555	rs12828034	chr12:38274249	C/T	cg26384229	chr12:38710491	ALG10B	-0.59	-7.37	-0.43	2.93e-12	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs943466	1.000	rs61662306	chr6:33746697	G/A	cg04676172	chr6:33757040	LEMD2	0.49	5.12	0.32	6.32e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
SARC	cis	rs57994353	0.861	rs13301660	chr9:139340802	C/T	cg13611204	chr9:139324423	INPP5E	-0.28	-4.88	-0.3	1.98e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs459571	0.804	rs448918	chr9:136885979	G/A	cg13789015	chr9:136890014	NCRNA00094	0.64	9.0	0.51	8.35e-17	Platelet distribution width;
SARC	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg18876405	chr7:65276391	NA	-0.46	-5.18	-0.32	4.8e-7	Aortic root size;
SARC	cis	rs735539	0.521	rs1810717	chr13:21412235	A/G	cg16922012	chr13:21400325	XPO4	-0.43	-5.9	-0.36	1.28e-8	Dental caries;
SARC	cis	rs11864453	0.826	rs2240243	chr16:72137561	A/G	cg16558253	chr16:72132732	DHX38	0.55	8.75	0.5	4.28e-16	Fibrinogen levels;
SARC	cis	rs7552404	0.731	rs2029683	chr1:76341643	T/G	cg10523679	chr1:76189770	ACADM	-0.44	-5.32	-0.33	2.39e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7917772	0.636	rs7894154	chr10:104524647	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-6.38	-0.39	9.19e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs1707322	0.721	rs4564187	chr1:46166861	G/C	cg03146154	chr1:46216737	IPP	0.53	6.35	0.38	1.12e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg11225247	chr11:86086489	CCDC81	0.45	6.39	0.39	8.9e-10	Thyroid stimulating hormone;
SARC	cis	rs9677476	0.863	rs12465477	chr2:232073282	G/A	cg23338755	chr2:231921595	PSMD1	0.48	5.68	0.35	4.02e-8	Food antigen IgG levels;
SARC	cis	rs763121	0.524	rs760645	chr22:39032270	C/T	cg06022373	chr22:39101656	GTPBP1	0.57	6.8	0.41	8.52e-11	Menopause (age at onset);
SARC	cis	rs6840360	0.615	rs12503677	chr4:152610543	A/G	cg22705602	chr4:152727874	NA	-0.51	-8.91	-0.5	1.49e-16	Intelligence (multi-trait analysis);
SARC	cis	rs2235544	0.541	rs928442	chr1:54473488	C/G	cg10336722	chr1:54665764	CYB5RL;MRPL37	0.39	4.79	0.3	2.98e-6	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
SARC	cis	rs1580019	0.587	rs10951338	chr7:32560089	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.54	6.98	0.42	2.96e-11	Cognitive ability;
SARC	cis	rs12600053	0.687	rs8063190	chr16:84849280	C/T	cg09249803	chr16:84846936	NA	0.36	5.37	0.33	1.88e-7	Asthma (childhood onset);
SARC	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg18252515	chr7:66147081	NA	-1.31	-11.71	-0.61	3.25e-25	Diabetic kidney disease;
SARC	cis	rs9875589	0.509	rs1586514	chr3:14050157	G/A	cg19554555	chr3:13937349	NA	-0.4	-5.22	-0.32	4.03e-7	Ovarian reserve;
SARC	cis	rs1018836	0.923	rs62526886	chr8:91627676	G/A	cg16814680	chr8:91681699	NA	-0.85	-13.93	-0.67	1.75e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs2050392	0.517	rs687036	chr10:30761249	G/A	cg25182066	chr10:30743637	MAP3K8	0.43	6.04	0.37	6.09e-9	Inflammatory bowel disease;
SARC	cis	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.41	-5.1	-0.32	6.94e-7	Eosinophil percentage of white cells;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg17841838	chr19:3626645	C19orf29	0.76	6.33	0.38	1.23e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs67460515	0.892	rs11929238	chr3:161045937	A/T	cg04691961	chr3:161091175	C3orf57	-0.49	-6.15	-0.37	3.36e-9	Parkinson's disease;
SARC	cis	rs8084125	0.832	rs7238522	chr18:74948730	A/C	cg26065057	chr18:74961000	GALR1	-0.47	-4.83	-0.3	2.51e-6	Obesity-related traits;
SARC	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg05368731	chr17:41323189	NBR1	0.79	9.6	0.53	1.34e-18	Menopause (age at onset);
SARC	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg16401346	chr18:48724009	MEX3C	-0.45	-6.44	-0.39	6.75e-10	Parental extreme longevity (95 years and older);
SARC	cis	rs240764	0.621	rs11155623	chr6:101184373	A/G	cg09795085	chr6:101329169	ASCC3	-0.5	-6.59	-0.4	2.98e-10	Neuroticism;
SARC	cis	rs1371867	0.726	rs1660333	chr8:101309989	A/G	cg11906718	chr8:101322791	RNF19A	0.67	8.68	0.49	6.82e-16	Atrioventricular conduction;
SARC	cis	rs11249608	0.600	rs13359570	chr5:178449249	T/G	cg21905437	chr5:178450457	ZNF879	0.57	7.66	0.45	5.07e-13	Pubertal anthropometrics;
SARC	cis	rs11098499	0.662	rs13108589	chr4:120268102	G/C	cg09307838	chr4:120376055	NA	0.82	11.31	0.6	6.46e-24	Corneal astigmatism;
SARC	cis	rs1784581	0.588	rs7752870	chr6:162422510	T/C	cg17173639	chr6:162384350	PARK2	0.51	6.48	0.39	5.48e-10	Itch intensity from mosquito bite;
SARC	cis	rs2777491	1.000	rs66538814	chr15:41685917	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.74	-10.93	-0.58	1.01e-22	Ulcerative colitis;
SARC	cis	rs1580019	0.537	rs7804609	chr7:32558094	A/C	cg07520158	chr7:32535189	LSM5;AVL9	0.62	8.19	0.47	1.68e-14	Cognitive ability;
SARC	cis	rs13191362	1.000	rs34653853	chr6:163114362	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.4	4.97	0.31	1.29e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs12478296	1.000	rs57603292	chr2:243028537	G/A	cg06360820	chr2:242988706	NA	-0.63	-4.99	-0.31	1.17e-6	Obesity-related traits;
SARC	cis	rs11098499	0.588	rs2389874	chr4:120554991	A/G	cg09307838	chr4:120376055	NA	-0.7	-9.69	-0.54	6.96e-19	Corneal astigmatism;
SARC	cis	rs367615	0.552	rs2963023	chr5:108730070	C/T	cg17395555	chr5:108820864	NA	-0.34	-4.88	-0.3	1.93e-6	Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs1355223	0.583	rs2915179	chr11:34871943	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.77	10.99	0.58	6.63e-23	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg20887711	chr4:1340912	KIAA1530	0.55	6.6	0.4	2.79e-10	Longevity;
SARC	cis	rs10463554	0.963	rs26262	chr5:102545163	T/G	cg23492399	chr5:102201601	PAM	-0.52	-5.64	-0.35	4.88e-8	Parkinson's disease;
SARC	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg13206674	chr6:150067644	NUP43	0.42	5.41	0.33	1.59e-7	Lung cancer;
SARC	trans	rs208520	0.690	rs851467	chr6:66802721	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-14.36	-0.69	6.28e-34	Exhaled nitric oxide output;
SARC	cis	rs1971762	0.563	rs10219725	chr12:54080865	T/G	cg06632207	chr12:54070931	ATP5G2	0.44	5.78	0.35	2.35e-8	Height;
SARC	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg05863683	chr7:1912471	MAD1L1	0.32	4.75	0.3	3.53e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs6545883	0.862	rs1880866	chr2:61698972	G/C	cg15711740	chr2:61764176	XPO1	-0.42	-5.06	-0.31	8.65e-7	Tuberculosis;
SARC	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs11997175	0.766	rs60855034	chr8:33684732	G/A	ch.8.33884649F	chr8:33765107	NA	0.56	7.55	0.44	9.51e-13	Body mass index;
SARC	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-9.87	-0.54	1.98e-19	Chronic sinus infection;
SARC	cis	rs1580019	0.961	rs4320456	chr7:32496003	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.73	9.78	0.54	3.93e-19	Cognitive ability;
SARC	cis	rs830998	0.756	rs4613240	chr2:170122613	T/C	cg07181881	chr2:170591239	KLHL23	-0.36	-5.12	-0.32	6.54e-7	Anorexia nervosa;
SARC	cis	rs2180341	0.782	rs4487601	chr6:127723521	A/G	cg24812749	chr6:127587940	RNF146	0.76	10.11	0.55	3.65e-20	Breast cancer;
SARC	cis	rs4595586	0.525	rs12809307	chr12:39365927	A/G	cg26384229	chr12:38710491	ALG10B	0.51	6.25	0.38	1.9e-9	Morning vs. evening chronotype;
SARC	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg16434002	chr17:42200994	HDAC5	0.42	5.17	0.32	4.92e-7	Total body bone mineral density;
SARC	cis	rs1267303	1.000	rs1267303	chr1:46990457	A/G	cg25110126	chr1:46999211	NA	0.68	8.15	0.47	2.26e-14	Monobrow;
SARC	cis	rs7412746	0.658	rs11589458	chr1:150792616	A/G	cg10589385	chr1:150898437	SETDB1	0.41	5.45	0.34	1.29e-7	Melanoma;
SARC	cis	rs7614311	0.731	rs3774719	chr3:63950338	C/A	cg22134162	chr3:63841271	THOC7	-0.45	-4.89	-0.3	1.9e-6	Lung function (FVC);Lung function (FEV1);
SARC	cis	rs11711311	1.000	rs34475696	chr3:113458293	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.69	8.9	0.5	1.64e-16	IgG glycosylation;
SARC	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg06221963	chr1:154839813	KCNN3	0.45	7.08	0.42	1.65e-11	Prostate cancer;
SARC	trans	rs7824557	0.767	rs4559208	chr8:11153925	C/G	cg06636001	chr8:8085503	FLJ10661	0.56	6.79	0.41	9.11e-11	Retinal vascular caliber;
SARC	cis	rs854765	0.583	rs8070722	chr17:17813562	C/T	cg05444541	chr17:17804740	TOM1L2	-0.3	-5.12	-0.32	6.26e-7	Total body bone mineral density;
SARC	cis	rs6580649	0.941	rs7312326	chr12:48480643	G/A	cg05342945	chr12:48394962	COL2A1	0.55	5.91	0.36	1.22e-8	Lung cancer;
SARC	cis	rs7312933	0.558	rs11181422	chr12:42718552	G/A	cg19980929	chr12:42632907	YAF2	-0.45	-6.73	-0.4	1.27e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg11366901	chr6:160182831	ACAT2	1.02	10.76	0.58	3.62e-22	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs2303759	0.709	rs10411679	chr19:49826480	A/T	cg24324837	chr19:49891574	CCDC155	0.4	4.78	0.3	3.11e-6	Multiple sclerosis;
SARC	cis	rs950169	0.763	rs35372971	chr15:84941795	G/A	cg24253500	chr15:84953950	NA	0.36	5.13	0.32	6.06e-7	Schizophrenia;
SARC	cis	rs7552404	0.731	rs1689275	chr1:76409655	T/C	cg10523679	chr1:76189770	ACADM	-0.43	-5.15	-0.32	5.52e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs11166927	0.934	rs7015426	chr8:140802688	C/G	cg16909799	chr8:140841666	TRAPPC9	0.35	4.81	0.3	2.68e-6	Pediatric non-alcoholic fatty liver disease activity score;
SARC	cis	rs2204008	0.744	rs66474616	chr12:38461564	G/A	cg13010199	chr12:38710504	ALG10B	0.77	10.35	0.56	6.77e-21	Bladder cancer;
SARC	cis	rs1030877	1.000	rs1030877	chr2:105910513	G/A	cg02079111	chr2:105885981	TGFBRAP1	0.61	9.13	0.51	3.41e-17	Obesity-related traits;
SARC	cis	rs9457247	0.967	rs2757054	chr6:167380501	A/G	cg07741184	chr6:167504864	NA	-0.29	-5.5	-0.34	1.02e-7	Crohn's disease;
SARC	cis	rs7106204	0.748	rs6484032	chr11:24237153	C/A	ch.11.24196551F	chr11:24239977	NA	0.55	5.69	0.35	3.81e-8	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs4891159	0.505	rs680253	chr18:74167427	A/C	cg24786174	chr18:74118243	ZNF516	-0.67	-10.29	-0.56	9.94e-21	Longevity;
SARC	cis	rs78320035	1.000	rs78343926	chr1:168113710	C/T	cg17113809	chr1:168148080	TIPRL	1.11	6.58	0.4	3e-10	Red cell distribution width;
SARC	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg10018233	chr7:150070692	REPIN1	0.72	9.4	0.52	5.31e-18	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs995000	0.931	rs746735	chr1:63113511	C/A	cg06896770	chr1:63153194	DOCK7	-0.92	-13.8	-0.67	4.64e-32	Triglyceride levels;
SARC	cis	rs7824557	0.806	rs6601573	chr8:11094751	A/G	cg21775007	chr8:11205619	TDH	-0.46	-5.47	-0.34	1.15e-7	Retinal vascular caliber;
SARC	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	cg03212183	chr16:81565917	CMIP	0.47	6.28	0.38	1.64e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs137603	0.644	rs137620	chr22:39709776	T/C	cg01093212	chr22:39715156	SNORD43;RPL3	-0.53	-6.15	-0.37	3.31e-9	Primary biliary cholangitis;
SARC	cis	rs2694528	0.686	rs7729652	chr5:59872414	A/G	cg11474532	chr5:59995715	DEPDC1B	0.86	6.09	0.37	4.71e-9	Parkinson's disease;
SARC	cis	rs6582630	0.555	rs11181657	chr12:38381858	T/C	cg26384229	chr12:38710491	ALG10B	-0.85	-12.82	-0.64	7.82e-29	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9790314	0.905	rs7613358	chr3:160949296	T/C	cg04691961	chr3:161091175	C3orf57	-0.68	-9.41	-0.52	4.89e-18	Morning vs. evening chronotype;
SARC	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg11987759	chr7:65425863	GUSB	0.47	5.82	0.36	1.9e-8	Aortic root size;
SARC	cis	rs2425143	1.000	rs11907811	chr20:34428078	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-6.13	-0.37	3.78e-9	Blood protein levels;
SARC	cis	rs1953600	0.870	rs2245168	chr10:81921918	T/C	cg00277334	chr10:82204260	NA	-0.34	-4.91	-0.31	1.75e-6	Sarcoidosis;
SARC	cis	rs796364	1.000	rs281783	chr2:200751582	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.64	0.4	2.24e-10	Schizophrenia;
SARC	cis	rs896623	0.639	rs6820363	chr4:122082935	G/C	cg19463078	chr4:122099598	TNIP3	-0.33	-4.79	-0.3	2.97e-6	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs1853207	1.000	rs117756203	chr10:96601144	G/A	cg02737782	chr1:8014393	NA	-0.95	-6.37	-0.39	1.01e-9	Blood metabolite levels;
SARC	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg20965017	chr5:231967	SDHA	0.54	5.32	0.33	2.4e-7	Breast cancer;
SARC	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg04267008	chr7:1944627	MAD1L1	-0.5	-5.62	-0.35	5.57e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs6582630	0.555	rs11613249	chr12:38519339	T/C	cg26384229	chr12:38710491	ALG10B	0.85	12.57	0.64	5.28e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2016266	0.684	rs4759021	chr12:53714868	G/A	cg26875137	chr12:53738046	NA	-0.43	-5.39	-0.33	1.69e-7	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6871536	1.000	rs3798134	chr5:131965179	C/T	cg11797159	chr5:131991491	NA	0.37	4.79	0.3	2.93e-6	Asthma (childhood onset);
SARC	cis	rs11098499	0.863	rs13136462	chr4:120543173	C/T	cg09307838	chr4:120376055	NA	0.84	11.41	0.6	2.94e-24	Corneal astigmatism;
SARC	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg18252515	chr7:66147081	NA	1.34	11.82	0.61	1.44e-25	Diabetic kidney disease;
SARC	cis	rs6578185	0.782	rs6578184	chr8:142453003	A/G	cg07762003	chr8:142452454	FLJ43860	-0.31	-5.38	-0.33	1.77e-7	Endometriosis;
SARC	trans	rs7615952	1.000	rs9289275	chr3:125648659	A/T	cg07211511	chr3:129823064	LOC729375	-0.95	-10.37	-0.56	5.8e-21	Blood pressure (smoking interaction);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg09438491	chr8:30890902	WRN;PURG	-0.79	-6.94	-0.41	3.8e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs72781680	1.000	rs7588286	chr2:24071427	A/G	cg08917208	chr2:24149416	ATAD2B	0.79	7.6	0.45	7.14e-13	Lymphocyte counts;
SARC	cis	rs41271473	0.500	rs4606285	chr1:228887544	G/T	cg10167378	chr1:228756711	NA	0.39	5.04	0.31	9.52e-7	Chronic lymphocytic leukemia;
SARC	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg20573242	chr4:122745356	CCNA2	0.67	8.46	0.48	2.95e-15	Type 2 diabetes;
SARC	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg25894440	chr7:65020034	NA	0.73	5.51	0.34	9.25e-8	Diabetic kidney disease;
SARC	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg15857475	chr8:145742913	RECQL4;LRRC14	0.7	10.07	0.55	5.02e-20	Age at first birth;
SARC	cis	rs288326	0.561	rs76829215	chr2:183894452	A/G	cg09997497	chr2:183902928	NCKAP1	0.74	5.1	0.32	6.97e-7	Blood protein levels;
SARC	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg22168489	chr12:122356033	WDR66	0.64	9.82	0.54	2.82e-19	Mean corpuscular volume;
SARC	cis	rs933688	0.759	rs1423593	chr5:90752351	T/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.99	12.1	0.62	1.83e-26	Smoking behavior;
SARC	cis	rs858239	0.539	rs6955969	chr7:23186699	C/T	cg23682824	chr7:23144976	KLHL7	0.71	9.25	0.52	1.44e-17	Cerebrospinal fluid biomarker levels;
SARC	cis	rs1448094	0.512	rs1349063	chr12:86264237	C/T	cg02569458	chr12:86230093	RASSF9	0.38	5.32	0.33	2.47e-7	Major depressive disorder;
SARC	cis	rs11209002	0.522	rs2224502	chr1:67539439	A/G	cg02640540	chr1:67518911	SLC35D1	0.59	6.66	0.4	1.99e-10	Crohn's disease;
SARC	cis	rs9420	0.884	rs673344	chr11:57657141	G/A	cg23127183	chr11:57508653	C11orf31	0.58	6.38	0.39	9.46e-10	Schizophrenia;
SARC	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg05025164	chr4:1340916	KIAA1530	-0.44	-5.09	-0.32	7.23e-7	Obesity-related traits;
SARC	cis	rs17270561	0.636	rs9348696	chr6:25781938	A/G	cg16482183	chr6:26056742	HIST1H1C	0.5	6.31	0.38	1.38e-9	Iron status biomarkers;
SARC	cis	rs7481584	0.581	rs515481	chr11:3047184	A/G	cg05729581	chr11:3078854	CARS	0.57	7.42	0.44	2.13e-12	Calcium levels;
SARC	cis	rs6121246	0.542	rs75694362	chr20:30450708	T/C	cg13852791	chr20:30311386	BCL2L1	0.73	5.99	0.37	7.92e-9	Mean corpuscular hemoglobin;
SARC	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg13175981	chr1:150552382	MCL1	-0.55	-6.9	-0.41	4.92e-11	Tonsillectomy;
SARC	cis	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg06636001	chr8:8085503	FLJ10661	0.61	7.83	0.46	1.67e-13	Mood instability;
SARC	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg13699009	chr12:122356056	WDR66	0.58	8.83	0.5	2.57e-16	Mean corpuscular volume;
SARC	cis	rs7666738	0.791	rs34088022	chr4:99001508	G/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg18876405	chr7:65276391	NA	-0.45	-5.13	-0.32	6.15e-7	Aortic root size;
SARC	cis	rs2304069	0.545	rs12153714	chr5:149395254	A/G	cg12661370	chr5:149340060	SLC26A2	0.55	6.38	0.39	9.62e-10	HIV-1 control;
SARC	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg22683308	chr4:1340831	KIAA1530	0.44	5.43	0.33	1.44e-7	Longevity;
SARC	cis	rs478304	0.654	rs7947604	chr11:65442059	G/C	cg27068330	chr11:65405492	SIPA1	-0.44	-5.21	-0.32	4.21e-7	Acne (severe);
SARC	cis	rs4481887	0.741	rs6682953	chr1:248535626	T/C	cg00666640	chr1:248458726	OR2T12	0.34	5.97	0.36	8.87e-9	Common traits (Other);
SARC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.97	12.03	0.62	3.06e-26	Platelet count;
SARC	cis	rs11608355	1.000	rs10850135	chr12:109866528	C/A	cg19025524	chr12:109796872	NA	-0.4	-5.13	-0.32	6.06e-7	Neuroticism;
SARC	trans	rs2898290	0.622	rs7829381	chr8:11344573	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.33	-0.43	3.7e-12	Systolic blood pressure;
SARC	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.42	-5.02	-0.31	1.02e-6	Renal function-related traits (BUN);
SARC	cis	rs7647973	0.626	rs11709734	chr3:49745235	G/A	cg03060546	chr3:49711283	APEH	0.61	6.47	0.39	5.6e-10	Menarche (age at onset);
SARC	cis	rs2304069	0.545	rs13168011	chr5:149392377	C/T	cg12661370	chr5:149340060	SLC26A2	0.56	6.54	0.39	3.93e-10	HIV-1 control;
SARC	cis	rs11235843	0.636	rs6592531	chr11:73412354	C/T	cg18195628	chr11:73498948	MRPL48	-0.58	-5.94	-0.36	1.01e-8	Hand grip strength;
SARC	cis	rs2204008	0.805	rs4589389	chr12:37946120	C/A	cg13010199	chr12:38710504	ALG10B	-0.67	-9.08	-0.51	4.77e-17	Bladder cancer;
SARC	cis	rs13314892	0.764	rs57634646	chr3:69860488	G/A	cg17445875	chr3:69859618	MITF	-0.49	-5.1	-0.32	6.98e-7	QRS complex (12-leadsum);
SARC	cis	rs2013441	1.000	rs3850784	chr17:20185030	A/G	cg13482628	chr17:19912719	NA	-0.48	-6.3	-0.38	1.49e-9	Obesity-related traits;
SARC	cis	rs798554	0.686	rs7777484	chr7:2814271	A/G	cg04166393	chr7:2884313	GNA12	0.41	4.97	0.31	1.32e-6	Height;
SARC	cis	rs3617	0.573	rs4687680	chr3:52907372	G/A	cg18404041	chr3:52824283	ITIH1	-0.34	-4.95	-0.31	1.44e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs11098499	0.913	rs10006304	chr4:120124305	A/G	cg09307838	chr4:120376055	NA	0.83	11.09	0.59	3.13e-23	Corneal astigmatism;
SARC	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg22875332	chr1:76189707	ACADM	0.46	6.34	0.38	1.17e-9	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6696846	0.777	rs6664397	chr1:205051871	C/T	cg07972983	chr1:205091412	RBBP5	0.46	5.81	0.36	2.07e-8	Red blood cell count;
SARC	cis	rs72781680	0.898	rs72782137	chr2:24047805	C/T	cg06627628	chr2:24431161	ITSN2	-0.67	-6.37	-0.38	1.02e-9	Lymphocyte counts;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg01757534	chr6:91006597	BACH2	-0.77	-6.38	-0.39	9.42e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2050392	0.624	rs303435	chr10:30731491	T/C	cg25182066	chr10:30743637	MAP3K8	0.41	5.65	0.35	4.55e-8	Inflammatory bowel disease;
SARC	cis	rs9894429	0.646	rs7220310	chr17:79606056	C/A	cg10661904	chr17:79619235	PDE6G	-0.46	-6.51	-0.39	4.68e-10	Eye color traits;
SARC	trans	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.59	-0.49	1.24e-15	Retinal vascular caliber;
SARC	cis	rs6840360	0.550	rs6535806	chr4:152483906	G/A	cg22705602	chr4:152727874	NA	-0.41	-6.47	-0.39	5.71e-10	Intelligence (multi-trait analysis);
SARC	cis	rs28655083	1.000	rs11863397	chr16:77060388	T/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.41	-5.76	-0.35	2.61e-8	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg17357984	chr19:532039	CDC34	0.45	6.24	0.38	1.99e-9	Cancer;
SARC	cis	rs9323205	0.765	rs2999387	chr14:51652986	C/G	cg23942311	chr14:51606299	NA	-0.32	-5.45	-0.34	1.3e-7	Cancer;
SARC	cis	rs8114671	0.562	rs4911449	chr20:33512236	T/G	cg24642439	chr20:33292090	TP53INP2	0.49	5.96	0.36	9.13e-9	Height;
SARC	cis	rs617791	0.530	rs55947178	chr11:65754230	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.57	6.91	0.41	4.47e-11	Breast cancer;
SARC	trans	rs1814175	0.559	rs1818892	chr11:49863084	C/A	cg15704280	chr7:45808275	SEPT13	-0.87	-13.81	-0.67	4.37e-32	Height;
SARC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg16132339	chr22:24313637	DDTL;DDT	0.38	4.78	0.3	3.13e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs17376456	0.569	rs7729807	chr5:93104089	C/T	cg21475434	chr5:93447410	FAM172A	0.6	5.83	0.36	1.8e-8	Diabetic retinopathy;
SARC	cis	rs4148883	0.675	rs10015824	chr4:100074544	C/G	cg12011299	chr4:100065546	ADH4	0.37	7.04	0.42	2.19e-11	Alcohol dependence;
SARC	cis	rs1419980	0.673	rs12366473	chr12:7728270	G/C	cg10578777	chr12:7781093	NA	0.63	6.7	0.4	1.58e-10	HDL cholesterol levels;
SARC	cis	rs8141529	0.529	rs2269578	chr22:29196843	G/C	cg02153584	chr22:29168773	CCDC117	0.66	6.58	0.4	3.11e-10	Lymphocyte counts;
SARC	cis	rs72781680	0.898	rs12620558	chr2:23936022	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	8.58	0.49	1.32e-15	Lymphocyte counts;
SARC	cis	rs36051895	0.664	rs9695933	chr9:5153104	C/T	cg02405213	chr9:5042618	JAK2	-0.45	-5.39	-0.33	1.72e-7	Pediatric autoimmune diseases;
SARC	cis	rs17376456	0.877	rs12374488	chr5:93481407	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.02	0.31	1.01e-6	Diabetic retinopathy;
SARC	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg23205692	chr1:25664452	TMEM50A	-0.44	-5.32	-0.33	2.45e-7	Erythrocyte sedimentation rate;
SARC	cis	rs2832270	0.562	rs8133819	chr21:30458754	T/C	cg24692254	chr21:30365293	RNF160	-0.66	-5.52	-0.34	8.95e-8	Response to mTOR inhibitor (everolimus);
SARC	cis	rs4268898	0.560	rs78711174	chr2:24496531	G/A	cg06627628	chr2:24431161	ITSN2	-0.82	-9.82	-0.54	2.93e-19	Asthma;
SARC	cis	rs853679	0.599	rs149943	chr6:28002388	G/A	cg19592336	chr6:28129416	ZNF389	0.66	5.07	0.31	8.27e-7	Depression;
SARC	cis	rs2933343	0.621	rs6764682	chr3:128568383	G/A	cg24203234	chr3:128598194	ACAD9	-0.58	-7.13	-0.42	1.27e-11	IgG glycosylation;
SARC	cis	rs7264396	0.563	rs6060569	chr20:34290731	C/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	5.69	0.35	3.71e-8	Total cholesterol levels;
SARC	cis	rs31872	0.678	rs702390	chr5:140442209	G/A	cg19650706	chr5:140594406	PCDHB13	-0.5	-6.06	-0.37	5.38e-9	Visceral adipose tissue adjusted for BMI;
SARC	cis	rs12682352	0.715	rs332039	chr8:8723651	C/G	cg08975724	chr8:8085496	FLJ10661	0.45	5.67	0.35	4.29e-8	Neuroticism;
SARC	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg21724239	chr8:58056113	NA	0.59	5.81	0.36	2.06e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6121246	0.529	rs6060134	chr20:30176794	A/G	cg21427119	chr20:30132790	HM13	-0.49	-5.31	-0.33	2.51e-7	Mean corpuscular hemoglobin;
SARC	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg27286337	chr10:134555280	INPP5A	0.64	7.79	0.45	2.17e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs13082711	0.911	rs6789539	chr3:27444076	T/A	cg02860705	chr3:27208620	NA	0.45	6.03	0.37	6.45e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	trans	rs12660691	0.685	rs9398917	chr6:130014226	G/A	cg06036239	chr1:59234929	NA	-0.73	-6.23	-0.38	2.14e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
SARC	cis	rs7945705	0.875	rs10769947	chr11:8758114	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.39	5.42	0.33	1.51e-7	Hemoglobin concentration;
SARC	cis	rs3540	0.533	rs2256110	chr15:90971036	T/C	cg22089800	chr15:90895588	ZNF774	0.68	8.71	0.5	5.78e-16	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs7666738	0.830	rs17027225	chr4:99028564	C/T	cg05340658	chr4:99064831	C4orf37	0.66	9.02	0.51	7.14e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs899997	0.773	rs11072784	chr15:78966058	T/C	cg04896959	chr15:78267971	NA	0.44	4.82	0.3	2.57e-6	Coronary artery disease or large artery stroke;
SARC	cis	rs2288912	0.872	rs9304646	chr19:45450408	T/C	cg09555818	chr19:45449301	APOC2	0.57	9.04	0.51	6.2e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs826838	0.586	rs10880753	chr12:38628147	C/A	cg13010199	chr12:38710504	ALG10B	-0.52	-6.43	-0.39	7.18e-10	Heart rate;
SARC	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.95	11.92	0.62	6.96e-26	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs7727544	0.661	rs273900	chr5:131694606	G/A	cg07395648	chr5:131743802	NA	-0.42	-4.95	-0.31	1.45e-6	Blood metabolite levels;
SARC	cis	rs9303401	1.000	rs9904677	chr17:56873025	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.7	8.27	0.48	1.01e-14	Cognitive test performance;
SARC	cis	rs9828933	0.626	rs73119018	chr3:63975328	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.82	-6.57	-0.4	3.33e-10	Type 2 diabetes;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg00559967	chr16:89557017	ANKRD11	0.49	6.32	0.38	1.33e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs644799	0.610	rs1255179	chr11:95472097	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.49	6.06	0.37	5.57e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs12479064	0.604	rs11893359	chr2:99954608	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.64	-7.9	-0.46	1.07e-13	Chronic sinus infection;
SARC	cis	rs17854409	0.803	rs1063246	chr20:61472116	G/A	cg05147244	chr20:61493195	TCFL5	0.94	6.03	0.37	6.42e-9	Obesity-related traits;
SARC	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg22105103	chr4:187893119	NA	0.5	6.87	0.41	5.84e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.45	-5.41	-0.33	1.53e-7	Bipolar disorder;
SARC	cis	rs9815354	0.761	rs12186051	chr3:41836919	G/A	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs7937682	0.632	rs4936834	chr11:111764017	T/A	cg09085632	chr11:111637200	PPP2R1B	0.82	10.82	0.58	2.27e-22	Primary sclerosing cholangitis;
SARC	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg06221963	chr1:154839813	KCNN3	-0.51	-8.17	-0.47	1.9e-14	Prostate cancer;
SARC	cis	rs9467773	1.000	rs28558133	chr6:26531433	G/C	cg12292205	chr6:26970375	C6orf41	0.45	5.43	0.34	1.41e-7	Intelligence (multi-trait analysis);
SARC	cis	rs67478160	0.634	rs1955660	chr14:104229985	C/T	cg08213375	chr14:104286397	PPP1R13B	0.26	4.76	0.3	3.34e-6	Schizophrenia;
SARC	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-7.95	-0.46	7.82e-14	Chronic sinus infection;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg18845984	chr7:148936732	ZNF212	0.49	6.26	0.38	1.88e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	trans	rs1814175	0.817	rs28502006	chr11:50049930	T/C	cg03929089	chr4:120376271	NA	-0.89	-14.58	-0.69	1.16e-34	Height;
SARC	cis	rs11756659	0.653	rs199729	chr6:25949915	C/T	cg00631329	chr6:26305371	NA	-0.51	-5.3	-0.33	2.74e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;Red cell distribution width;
SARC	cis	rs2228479	0.850	rs62052711	chr16:89855100	C/A	cg00800038	chr16:89945340	TCF25	-0.79	-5.47	-0.34	1.19e-7	Skin colour saturation;
SARC	cis	rs7772486	0.875	rs2492855	chr6:146296926	A/G	cg05347473	chr6:146136440	FBXO30	0.44	5.97	0.36	8.7e-9	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs1814175	0.904	rs1846289	chr11:49620253	G/A	cg03929089	chr4:120376271	NA	-0.85	-13.28	-0.66	2.49e-30	Height;
SARC	cis	rs7894051	1.000	rs11101721	chr10:135190358	C/G	cg24905316	chr10:135186343	ECHS1	0.6	5.04	0.31	9.53e-7	Lifespan;
SARC	cis	rs11758351	0.734	rs56220351	chr6:26206884	A/G	cg01420254	chr6:26195488	NA	0.54	4.94	0.31	1.47e-6	Gout;Renal underexcretion gout;
SARC	cis	rs709400	0.663	rs72708893	chr14:103929535	G/A	cg12935359	chr14:103987150	CKB	-0.39	-5.71	-0.35	3.38e-8	Body mass index;
SARC	cis	rs2749592	0.550	rs7081464	chr10:37883937	C/T	cg00409905	chr10:38381863	ZNF37A	0.53	7.28	0.43	5.13e-12	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs11581859	0.613	rs11810907	chr1:99201772	T/C	cg20286094	chr1:99190917	SNX7	-0.42	-4.95	-0.31	1.43e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs9325144	0.647	rs35138700	chr12:38804474	C/T	cg13010199	chr12:38710504	ALG10B	-0.49	-6.32	-0.38	1.33e-9	Morning vs. evening chronotype;
SARC	cis	rs981844	0.775	rs17371468	chr4:154759826	G/C	cg14289246	chr4:154710475	SFRP2	0.61	6.97	0.42	3.21e-11	Response to statins (LDL cholesterol change);
SARC	cis	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg05623727	chr3:50126028	RBM5	-0.34	-5.19	-0.32	4.52e-7	Intelligence (multi-trait analysis);
SARC	cis	rs910316	0.737	rs175072	chr14:75502827	T/C	cg08847533	chr14:75593920	NEK9	-0.84	-12.53	-0.63	7.13e-28	Height;
SARC	cis	rs992157	0.735	rs2271541	chr2:219082119	G/T	cg20019365	chr2:219134978	PNKD;AAMP	0.67	9.33	0.52	8.55e-18	Colorectal cancer;
SARC	cis	rs9303401	0.625	rs10515159	chr17:56802693	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	12.31	0.63	3.57e-27	Cognitive test performance;
SARC	cis	rs1707322	0.717	rs28752166	chr1:46213309	G/A	cg03146154	chr1:46216737	IPP	0.52	6.29	0.38	1.56e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.53	6.34	0.38	1.2e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2976388	0.578	rs3758081	chr8:143824373	A/G	cg06565975	chr8:143823917	SLURP1	-0.31	-4.77	-0.3	3.22e-6	Urinary tract infection frequency;
SARC	cis	rs7412746	0.611	rs2256355	chr1:150811794	A/G	cg13175981	chr1:150552382	MCL1	-0.55	-6.85	-0.41	6.4e-11	Melanoma;
SARC	cis	rs6430585	0.528	rs16832205	chr2:136684632	G/A	cg07169764	chr2:136633963	MCM6	1.05	13.66	0.67	1.29e-31	Corneal structure;
SARC	cis	rs6446731	0.636	rs2157092	chr4:3273092	G/C	cg06533319	chr4:3265114	C4orf44	-0.33	-5.36	-0.33	1.97e-7	Mean platelet volume;
SARC	cis	rs34779708	0.931	rs35848945	chr10:35287561	G/T	cg03585969	chr10:35415529	CREM	0.4	4.99	0.31	1.18e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs6582630	0.679	rs10785514	chr12:38573689	T/C	cg13010199	chr12:38710504	ALG10B	0.52	6.58	0.4	3.01e-10	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs35213789	0.768	rs7786073	chr7:69351413	C/T	cg10619644	chr7:69149951	AUTS2	0.39	4.77	0.3	3.3e-6	Childhood ear infection;
SARC	cis	rs709400	0.663	rs11623869	chr14:103883633	G/T	cg12935359	chr14:103987150	CKB	-0.41	-5.91	-0.36	1.21e-8	Body mass index;
SARC	cis	rs2576037	0.796	rs2571030	chr18:44573854	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.49	6.5	0.39	4.85e-10	Personality dimensions;
SARC	cis	rs9831754	0.704	rs6774325	chr3:78458727	G/A	cg06138941	chr3:78371609	NA	-0.55	-6.6	-0.4	2.79e-10	Calcium levels;
SARC	cis	rs1355223	0.867	rs1869360	chr11:34698590	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-5.41	-0.33	1.56e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg17376030	chr22:41985996	PMM1	0.64	7.79	0.45	2.15e-13	Vitiligo;
SARC	cis	rs6580649	1.000	rs6580647	chr12:48403229	G/T	cg24011408	chr12:48396354	COL2A1	-0.55	-6.45	-0.39	6.23e-10	Lung cancer;
SARC	cis	rs1003719	0.788	rs2835593	chr21:38465873	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.63	9.05	0.51	5.67e-17	Eye color traits;
SARC	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg09359103	chr1:154839909	KCNN3	-0.38	-5.86	-0.36	1.56e-8	Prostate cancer;
SARC	cis	rs870825	0.616	rs28500698	chr4:185627746	A/C	cg04058563	chr4:185651563	MLF1IP	0.81	11.25	0.59	9.68e-24	Blood protein levels;
SARC	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2439831	1.000	rs2467739	chr15:43740196	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.81	8.44	0.48	3.49e-15	Lung cancer in ever smokers;
SARC	cis	rs6696846	0.765	rs61822565	chr1:205077332	T/C	cg07972983	chr1:205091412	RBBP5	0.58	7.58	0.44	8.02e-13	Red blood cell count;
SARC	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg16405210	chr4:1374714	KIAA1530	-0.42	-4.74	-0.3	3.78e-6	Obesity-related traits;
SARC	cis	rs1062177	1.000	rs2964571	chr5:151171256	C/T	cg00977110	chr5:151150581	G3BP1	0.58	5.92	0.36	1.14e-8	Preschool internalizing problems;
SARC	cis	rs526231	0.543	rs34779	chr5:102452768	A/G	cg23492399	chr5:102201601	PAM	-0.51	-5.55	-0.34	7.77e-8	Primary biliary cholangitis;
SARC	cis	rs7546668	0.640	rs3820071	chr1:15808767	G/A	cg21858823	chr1:15850916	CASP9	0.48	5.81	0.36	2.02e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs7264396	0.836	rs6058282	chr20:34212590	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.16	-0.42	1.05e-11	Total cholesterol levels;
SARC	cis	rs7647973	0.710	rs6446284	chr3:49616997	A/G	cg13072238	chr3:49761600	GMPPB	-0.61	-5.33	-0.33	2.34e-7	Menarche (age at onset);
SARC	cis	rs4319547	0.688	rs10744287	chr12:123077485	T/A	cg05707623	chr12:122985044	ZCCHC8	-0.5	-6.43	-0.39	6.99e-10	Body mass index;
SARC	cis	rs910316	0.737	rs108622	chr14:75481908	A/G	cg08847533	chr14:75593920	NEK9	-0.8	-11.33	-0.6	5.42e-24	Height;
SARC	cis	rs10463316	0.894	rs1876619	chr5:150744773	G/C	cg03212797	chr5:150827313	SLC36A1	-0.47	-5.74	-0.35	3.01e-8	Metabolite levels (Pyroglutamine);
SARC	cis	rs459571	0.959	rs455381	chr9:136905577	C/A	cg13789015	chr9:136890014	NCRNA00094	0.63	8.51	0.49	2.11e-15	Platelet distribution width;
SARC	cis	rs2011503	1.000	rs8110171	chr19:19560063	C/T	cg03709012	chr19:19516395	GATAD2A	0.64	5.69	0.35	3.77e-8	Bipolar disorder;
SARC	cis	rs2439831	1.000	rs550239	chr15:43720197	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	8.09	0.47	3.35e-14	Lung cancer in ever smokers;
SARC	cis	rs13161895	1.000	rs3719	chr5:179435118	T/C	cg06664874	chr5:179499304	RNF130	-0.49	-4.78	-0.3	3.14e-6	LDL cholesterol;
SARC	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg19901468	chr14:105411992	AHNAK2	0.72	10.57	0.57	1.37e-21	Rheumatoid arthritis;
SARC	cis	rs11711311	1.000	rs9863050	chr3:113508888	C/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	8.4	0.48	4.47e-15	IgG glycosylation;
SARC	cis	rs7666738	0.925	rs34423396	chr4:99049031	T/A	cg05340658	chr4:99064831	C4orf37	0.57	7.16	0.42	1.02e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7647973	0.710	rs34890793	chr3:49619493	C/T	cg06212747	chr3:49208901	KLHDC8B	0.74	6.68	0.4	1.72e-10	Menarche (age at onset);
SARC	cis	rs9660992	0.710	rs1172111	chr1:205232980	C/T	cg21545522	chr1:205238299	TMCC2	0.44	6.14	0.37	3.43e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs910316	0.967	rs1071989	chr14:75564659	G/T	cg08847533	chr14:75593920	NEK9	0.93	15.86	0.72	6.47e-39	Height;
SARC	cis	rs1348850	0.526	rs2178017	chr2:178374788	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.69	6.26	0.38	1.81e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7130144	0.541	rs7941653	chr11:130460365	C/A	cg26307797	chr11:130446613	NA	-0.7	-5.78	-0.35	2.33e-8	Urate levels in lean individuals;
SARC	cis	rs13326165	0.585	rs73088783	chr3:52305286	C/T	cg16894138	chr3:53270350	TKT	-0.53	-4.9	-0.31	1.81e-6	HDL cholesterol;HDL cholesterol levels;
SARC	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg06212747	chr3:49208901	KLHDC8B	0.71	9.75	0.54	4.8e-19	Parkinson's disease;
SARC	cis	rs9486715	0.830	rs1475748	chr6:97034143	T/C	cg06623918	chr6:96969491	KIAA0776	-0.94	-14.49	-0.69	2.36e-34	Headache;
SARC	cis	rs1707322	1.000	rs4660331	chr1:46458783	A/C	cg06784218	chr1:46089804	CCDC17	0.35	6.17	0.37	2.98e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9393692	0.645	rs28446029	chr6:26305801	C/G	cg05868516	chr6:26286170	HIST1H4H	0.48	5.59	0.34	6.36e-8	Educational attainment;
SARC	cis	rs273218	1.000	rs168861	chr5:53377310	T/C	ch.5.1024479R	chr5:53302184	ARL15	0.67	7.37	0.43	2.93e-12	Migraine;
SARC	cis	rs76419734	0.510	rs17036102	chr4:106603098	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	-0.78	-9.67	-0.54	8e-19	Post bronchodilator FEV1;
SARC	cis	rs362272	0.545	rs2236052	chr4:3318413	C/T	cg06533319	chr4:3265114	C4orf44	0.3	4.82	0.3	2.6e-6	Serum sulfate level;
SARC	cis	rs344364	0.511	rs2982447	chr16:1947413	C/T	cg26617929	chr16:1858877	NA	0.72	6.01	0.37	7.06e-9	Glomerular filtration rate in chronic kidney disease;
SARC	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.34	-4.93	-0.31	1.59e-6	Total body bone mineral density;
SARC	cis	rs12200560	0.505	rs211162	chr6:97067344	G/A	cg06623918	chr6:96969491	KIAA0776	0.45	5.01	0.31	1.08e-6	Coronary heart disease;
SARC	trans	rs17685	0.712	rs2158867	chr7:75815141	C/A	cg19862616	chr7:65841803	NCRNA00174	0.61	7.57	0.44	8.42e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs6840360	0.593	rs4696287	chr4:152606723	C/T	cg22705602	chr4:152727874	NA	-0.49	-8.46	-0.48	2.88e-15	Intelligence (multi-trait analysis);
SARC	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg25703541	chr22:24373054	LOC391322	-0.81	-10.85	-0.58	1.86e-22	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs763121	0.853	rs5750664	chr22:39072769	C/T	cg14440974	chr22:39074834	NA	-0.33	-4.77	-0.3	3.24e-6	Menopause (age at onset);
SARC	cis	rs793571	0.688	rs7179399	chr15:59165527	T/C	cg05156742	chr15:59063176	FAM63B	-0.52	-6.02	-0.37	6.81e-9	Schizophrenia;
SARC	cis	rs2404602	0.647	rs12910081	chr15:77022959	G/C	cg15268244	chr15:77196840	NA	0.42	4.87	0.3	2.06e-6	Blood metabolite levels;
SARC	cis	rs9436747	0.605	rs7542824	chr1:65945965	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	-0.43	-5.37	-0.33	1.92e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24688577	chr20:48807332	CEBPB	-0.55	-6.6	-0.4	2.71e-10	Fibrinogen levels;
SARC	cis	rs9790314	0.502	rs7647118	chr3:161016165	T/C	cg17135325	chr3:160939158	NMD3	0.62	7.85	0.46	1.51e-13	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs2204008	0.684	rs11514164	chr12:38036494	C/T	cg26384229	chr12:38710491	ALG10B	0.87	12.37	0.63	2.36e-27	Bladder cancer;
SARC	cis	rs10489202	0.583	rs201539	chr1:167995407	A/G	cg17859187	chr1:168147929	TIPRL	0.4	4.93	0.31	1.59e-6	Schizophrenia;
SARC	cis	rs9911578	1.000	rs8079774	chr17:56908188	A/G	cg12560992	chr17:57184187	TRIM37	0.85	11.82	0.61	1.41e-25	Intelligence (multi-trait analysis);
SARC	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg05863683	chr7:1912471	MAD1L1	0.34	4.81	0.3	2.68e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs3812831	0.695	rs3118895	chr13:114931742	G/A	cg08824895	chr13:115047677	UPF3A	0.51	6.66	0.4	1.92e-10	Schizophrenia;
SARC	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg00933542	chr6:150070202	PCMT1	0.3	5.19	0.32	4.66e-7	Lung cancer;
SARC	trans	rs208520	0.609	rs208436	chr6:66897470	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.77	-9.25	-0.52	1.52e-17	Exhaled nitric oxide output;
SARC	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg18252515	chr7:66147081	NA	-0.63	-6.76	-0.41	1.07e-10	Aortic root size;
SARC	cis	rs9815354	0.812	rs73071208	chr3:41978738	A/T	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.47	-5.52	-0.34	9.12e-8	Renal function-related traits (BUN);
SARC	trans	rs7824557	0.510	rs1435274	chr8:11235910	G/A	cg06636001	chr8:8085503	FLJ10661	-0.62	-8.28	-0.48	9.58e-15	Retinal vascular caliber;
SARC	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg18876405	chr7:65276391	NA	0.46	5.64	0.35	4.78e-8	Aortic root size;
SARC	cis	rs7408868	1.000	rs8107180	chr19:15275430	T/C	cg14696996	chr19:15285081	NOTCH3	1.05	8.52	0.49	1.95e-15	Pulse pressure;
SARC	cis	rs11676348	0.846	rs4674259	chr2:218991005	C/T	cg00012203	chr2:219082015	ARPC2	-0.55	-7.33	-0.43	3.71e-12	Ulcerative colitis;
SARC	trans	rs61931739	0.635	rs1852225	chr12:33963004	C/T	cg13010199	chr12:38710504	ALG10B	0.5	6.42	0.39	7.45e-10	Morning vs. evening chronotype;
SARC	cis	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg07274523	chr3:49395745	GPX1	0.47	5.09	0.32	7.24e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	trans	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.56	-7.41	-0.44	2.25e-12	Intelligence (multi-trait analysis);
SARC	cis	rs2153535	0.580	rs6941670	chr6:8446346	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	7.4	0.44	2.51e-12	Motion sickness;
SARC	cis	rs137699	1.000	rs5757632	chr22:39756097	A/C	cg24399712	chr22:39784796	NA	-0.34	-4.98	-0.31	1.27e-6	IgG glycosylation;
SARC	cis	rs3753242	1.000	rs3753242	chr1:2069681	A/G	cg11518257	chr1:1310775	AURKAIP1	-0.71	-5.18	-0.32	4.79e-7	Response to antipsychotic treatment in schizophrenia (reasoning);
SARC	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg11764359	chr7:65958608	NA	0.88	12.58	0.64	4.89e-28	Aortic root size;
SARC	cis	rs4971059	0.629	rs12904	chr1:155106697	G/A	cg22049894	chr1:155113146	DPM3	0.39	4.83	0.3	2.5e-6	Breast cancer;
SARC	cis	rs2730245	0.527	rs62476464	chr7:158698063	C/T	cg24397884	chr7:158709396	WDR60	1.17	10.66	0.57	7.23e-22	Height;
SARC	cis	rs2486288	0.656	rs7167146	chr15:45571386	A/G	cg15395560	chr15:45543142	SLC28A2	-0.31	-5.62	-0.35	5.52e-8	Glomerular filtration rate;
SARC	cis	rs9325144	0.560	rs11183046	chr12:38655270	A/T	cg13010199	chr12:38710504	ALG10B	-0.56	-6.97	-0.42	3.3e-11	Morning vs. evening chronotype;
SARC	cis	rs11122272	0.735	rs2739516	chr1:231505527	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs4880487	0.888	rs10794730	chr10:1247022	C/T	cg03183215	chr10:1252341	ADARB2	-0.31	-5.68	-0.35	4.07e-8	Migraine;
SARC	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg12463550	chr7:65579703	CRCP	-0.49	-5.6	-0.34	6.14e-8	Aortic root size;
SARC	cis	rs9354308	0.868	rs9345692	chr6:66544714	T/A	cg07460842	chr6:66804631	NA	-0.45	-5.23	-0.32	3.77e-7	Metabolite levels;
SARC	cis	rs4253772	0.530	rs715518	chr22:46754177	C/G	cg24881330	chr22:46731750	TRMU	0.68	4.76	0.3	3.33e-6	LDL cholesterol;Cholesterol, total;
SARC	trans	rs61931739	0.500	rs11053167	chr12:34387092	A/C	cg13010199	chr12:38710504	ALG10B	0.81	11.4	0.6	3.32e-24	Morning vs. evening chronotype;
SARC	cis	rs1983170	0.778	rs906241	chr1:92012154	G/T	cg25838465	chr1:92012736	NA	-0.55	-6.25	-0.38	1.89e-9	Eosinophil percentage of white cells;
SARC	cis	rs2997447	0.846	rs3008235	chr1:26408409	T/C	cg19633962	chr1:26362018	EXTL1	-0.57	-5.32	-0.33	2.38e-7	QRS complex (12-leadsum);
SARC	cis	rs10754283	0.934	rs6661282	chr1:90119992	C/T	cg21401794	chr1:90099060	LRRC8C	0.59	8.25	0.48	1.19e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs9818758	0.545	rs9853352	chr3:49813258	C/T	cg00383909	chr3:49044727	WDR6	-0.67	-5.98	-0.36	8.48e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs17376456	0.825	rs13182631	chr5:93115701	A/G	cg25358565	chr5:93447407	FAM172A	1.17	12.03	0.62	3.11e-26	Diabetic retinopathy;
SARC	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg17376030	chr22:41985996	PMM1	0.72	8.46	0.48	3.01e-15	Vitiligo;
SARC	cis	rs2916247	0.954	rs4506267	chr8:93079246	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.67	-7.15	-0.42	1.1e-11	Intelligence (multi-trait analysis);
SARC	cis	rs6582630	0.615	rs12821226	chr12:38546406	C/T	cg14851346	chr12:38532713	NA	-0.44	-5.31	-0.33	2.5e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6500602	0.727	rs11644481	chr16:4581002	T/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.33	5.39	0.33	1.76e-7	Schizophrenia;
SARC	cis	rs2230307	0.536	rs490669	chr1:100484430	C/T	cg24955406	chr1:100503596	HIAT1	0.7	6.8	0.41	8.56e-11	Carotid intima media thickness;
SARC	cis	rs2288073	0.896	rs13404513	chr2:24410780	G/A	cg06627628	chr2:24431161	ITSN2	-0.63	-7.66	-0.45	4.86e-13	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs6546550	0.901	rs6546553	chr2:70111711	C/A	cg02498382	chr2:70120550	SNRNP27	-0.33	-5.17	-0.32	4.93e-7	Prevalent atrial fibrillation;
SARC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg06873352	chr17:61820015	STRADA	0.53	6.88	0.41	5.32e-11	Prudent dietary pattern;
SARC	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg16405210	chr4:1374714	KIAA1530	-0.51	-6.07	-0.37	5.28e-9	Obesity-related traits;
SARC	cis	rs6840360	0.593	rs1429559	chr4:152681952	A/G	cg22705602	chr4:152727874	NA	-0.48	-8.46	-0.48	3.02e-15	Intelligence (multi-trait analysis);
SARC	cis	rs865483	0.860	rs853228	chr17:35799889	G/T	cg06561646	chr17:35873369	DUSP14	-0.48	-6.21	-0.38	2.4e-9	Monocyte count;
SARC	cis	rs4927850	0.958	rs2044599	chr3:195736740	G/A	cg12696929	chr3:195401817	SDHAP2	0.39	5.09	0.32	7.38e-7	Pancreatic cancer;
SARC	cis	rs3764563	1.000	rs623675	chr19:15705115	G/A	cg20725493	chr19:15740067	CYP4F8	0.67	4.74	0.3	3.69e-6	Inflammatory biomarkers;
SARC	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg08859206	chr1:53392774	SCP2	0.48	6.6	0.4	2.77e-10	Monocyte count;
SARC	cis	rs6545883	0.895	rs2442029	chr2:61679552	G/T	cg15711740	chr2:61764176	XPO1	-0.44	-5.2	-0.32	4.31e-7	Tuberculosis;
SARC	cis	rs554111	0.593	rs4654906	chr1:21509642	A/T	cg04902671	chr1:21058625	SH2D5	-0.45	-5.5	-0.34	9.85e-8	Facial morphology (factor 17, height of vermillion upper lip);
SARC	trans	rs1945213	0.694	rs11227113	chr11:55828024	C/T	cg15704280	chr7:45808275	SEPT13	0.68	6.97	0.42	3.19e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9818758	0.607	rs34326553	chr3:49134429	A/G	cg01304814	chr3:48885189	PRKAR2A	0.64	5.14	0.32	5.75e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs722599	0.748	rs17102884	chr14:75374899	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.39	-4.78	-0.3	3.06e-6	IgG glycosylation;
SARC	cis	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg25185518	chr4:146403942	SMAD1	0.44	5.17	0.32	5.09e-7	Height;
SARC	cis	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg22496380	chr5:211416	CCDC127	-0.88	-9.28	-0.52	1.21e-17	Breast cancer;
SARC	cis	rs9487051	0.676	rs6568568	chr6:109597048	C/T	cg01475377	chr6:109611718	NA	-0.35	-5.08	-0.32	7.8e-7	Reticulocyte fraction of red cells;
SARC	cis	rs11025559	0.812	rs10766678	chr11:20507180	A/G	cg19653624	chr11:20408972	PRMT3	-0.59	-6.6	-0.4	2.74e-10	Pursuit maintenance gain;
SARC	cis	rs4074493	1.000	rs4378192	chr1:231173379	C/T	cg22172038	chr1:231176991	FAM89A	0.33	4.87	0.3	2.1e-6	Carotid plaque burden (smoking interaction);
SARC	cis	rs4763879	0.778	rs1056151	chr12:9851023	T/A	cg27502298	chr12:9555721	NA	0.45	4.92	0.31	1.61e-6	Type 1 diabetes;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg12882762	chr14:53196687	STYX	0.62	6.38	0.39	9.33e-10	Lung cancer in ever smokers;
SARC	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg07701084	chr6:150067640	NUP43	0.41	5.41	0.33	1.54e-7	Lung cancer;
SARC	cis	rs17376456	0.877	rs10064520	chr5:93427358	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.73	0.35	3.03e-8	Diabetic retinopathy;
SARC	cis	rs2723064	0.516	rs2901749	chr2:65292570	G/T	cg20592124	chr2:65290738	CEP68	0.38	4.84	0.3	2.34e-6	Atrial fibrillation;
SARC	cis	rs2425143	0.908	rs6060625	chr20:34414318	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.82	-6.49	-0.39	5.19e-10	Blood protein levels;
SARC	cis	rs611744	0.647	rs1379336	chr8:109276606	G/T	cg21045802	chr8:109455806	TTC35	0.61	7.54	0.44	1.06e-12	Dupuytren's disease;
SARC	cis	rs4073582	0.595	rs801737	chr11:65928193	T/C	cg14036092	chr11:66035641	RAB1B	0.6	8.39	0.48	4.67e-15	Gout;
SARC	cis	rs76419734	1.000	rs113767110	chr4:106599814	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.76	4.89	0.31	1.87e-6	Post bronchodilator FEV1;
SARC	cis	rs1801251	1.000	rs12987513	chr2:233622066	A/G	cg25237894	chr2:233734115	C2orf82	0.37	4.96	0.31	1.36e-6	Coronary artery disease;
SARC	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.44	4.99	0.31	1.19e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg12463550	chr7:65579703	CRCP	0.65	4.8	0.3	2.87e-6	Gout;
SARC	cis	rs911263	0.603	rs12889949	chr14:68774854	T/G	cg18825221	chr14:68749962	RAD51L1	0.42	7.57	0.44	8.76e-13	Primary biliary cholangitis;
SARC	cis	rs1008375	0.931	rs2109519	chr4:17695453	A/G	cg27347728	chr4:17578864	LAP3	0.45	5.73	0.35	3.04e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg03709012	chr19:19516395	GATAD2A	1.01	17.45	0.75	3.42e-44	Tonsillectomy;
SARC	cis	rs7666738	0.830	rs28878289	chr4:98855181	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.59	0.49	1.24e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10979	0.928	rs6924967	chr6:143906235	C/T	cg25407410	chr6:143891975	LOC285740	-0.62	-8.27	-0.48	1.01e-14	Hypospadias;
SARC	cis	rs4595586	0.546	rs10876163	chr12:39244915	G/A	cg13010199	chr12:38710504	ALG10B	0.56	6.63	0.4	2.26e-10	Morning vs. evening chronotype;
SARC	cis	rs524281	0.773	rs10791861	chr11:66008470	G/A	cg14036092	chr11:66035641	RAB1B	-0.59	-6.28	-0.38	1.67e-9	Electroencephalogram traits;
SARC	cis	rs9790314	0.586	rs34727114	chr3:161138929	A/C	cg03342759	chr3:160939853	NMD3	-0.57	-7.04	-0.42	2.12e-11	Morning vs. evening chronotype;
SARC	cis	rs11874712	1.000	rs1800637	chr18:43670190	T/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.46	5.5	0.34	1.02e-7	Migraine - clinic-based;
SARC	cis	rs910316	1.000	rs4903275	chr14:75512509	C/T	cg08847533	chr14:75593920	NEK9	0.94	15.54	0.71	7.32e-38	Height;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg20340149	chr2:122407145	CLASP1	0.48	6.38	0.39	9.41e-10	Chemerin levels;
SARC	cis	rs910316	1.000	rs10873275	chr14:75531460	A/T	cg06637938	chr14:75390232	RPS6KL1	0.56	8.03	0.47	4.68e-14	Height;
SARC	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg19223190	chr17:80058835	NA	-0.45	-6.47	-0.39	5.67e-10	Life satisfaction;
SARC	cis	rs7447593	0.518	rs4074995	chr5:176797343	C/T	cg17509989	chr5:176798049	RGS14	0.78	11.66	0.61	4.79e-25	Urinary electrolytes (magnesium/calcium ratio);
SARC	cis	rs9902453	0.899	rs1979572	chr17:28511978	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.49	6.34	0.38	1.15e-9	Coffee consumption (cups per day);
SARC	cis	rs7191439	0.589	rs11076699	chr16:88756812	A/C	cg27087555	chr16:88793112	FAM38A	0.96	6.48	0.39	5.31e-10	Plateletcrit;
SARC	cis	rs11734570	0.581	rs73808504	chr4:38600593	T/C	cg18361445	chr4:38666374	KLF3;FLJ13197	0.61	6.63	0.4	2.3e-10	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs4253772	0.591	rs6007747	chr22:46657261	A/G	cg24881330	chr22:46731750	TRMU	0.64	6.96	0.41	3.45e-11	LDL cholesterol;Cholesterol, total;
SARC	cis	rs7917772	0.582	rs10786684	chr10:104323028	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.5	-6.76	-0.4	1.1e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs7113850	0.541	rs76005477	chr11:24233322	G/A	ch.11.24196551F	chr11:24239977	NA	0.76	5.48	0.34	1.12e-7	Bone fracture in osteoporosis;
SARC	cis	rs2197308	0.565	rs12809769	chr12:37909968	C/T	cg26384229	chr12:38710491	ALG10B	0.9	13.3	0.66	2.04e-30	Morning vs. evening chronotype;
SARC	cis	rs6964587	0.839	rs9656002	chr7:91475007	A/G	cg17063962	chr7:91808500	NA	-0.85	-12.07	-0.62	2.18e-26	Breast cancer;
SARC	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.73	10.4	0.56	4.57e-21	Menarche (age at onset);
SARC	cis	rs6604026	0.656	rs2811591	chr1:93363951	C/A	cg17283838	chr1:93427260	FAM69A	-0.42	-4.75	-0.3	3.59e-6	Multiple sclerosis;
SARC	cis	rs6580649	0.941	rs7310579	chr12:48427523	G/A	cg24011408	chr12:48396354	COL2A1	-0.51	-5.5	-0.34	9.93e-8	Lung cancer;
SARC	cis	rs240764	0.717	rs1039032	chr6:101161931	T/C	cg09795085	chr6:101329169	ASCC3	-0.47	-5.95	-0.36	9.73e-9	Neuroticism;
SARC	cis	rs7944584	0.655	rs11039183	chr11:47346940	G/A	cg20307385	chr11:47447363	PSMC3	0.61	7.58	0.44	8.15e-13	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	trans	rs11039798	0.623	rs588700	chr11:48449889	T/C	cg15704280	chr7:45808275	SEPT13	-0.62	-6.25	-0.38	1.97e-9	Axial length;
SARC	cis	rs17376456	0.825	rs10079708	chr5:93261796	G/C	cg21475434	chr5:93447410	FAM172A	0.86	7.72	0.45	3.37e-13	Diabetic retinopathy;
SARC	cis	rs7674212	0.541	rs2720471	chr4:104023840	A/G	cg16532752	chr4:104119610	CENPE	-0.48	-6.0	-0.37	7.5e-9	Type 2 diabetes;
SARC	cis	rs10992471	0.603	rs10820968	chr9:95106443	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.49	-0.34	1.06e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs3820928	0.874	rs7423610	chr2:227836262	A/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-6.73	-0.4	1.27e-10	Pulmonary function;
SARC	cis	rs4917300	0.606	rs1388797	chr8:143096908	G/C	cg06573787	chr8:143070187	NA	0.38	5.28	0.33	2.98e-7	Amyotrophic lateral sclerosis;
SARC	cis	rs412050	0.502	rs8136405	chr22:22148021	A/C	cg17089214	chr22:22089827	YPEL1	0.76	6.58	0.4	3.04e-10	Attention deficit hyperactivity disorder;
SARC	cis	rs11719291	0.833	rs11715835	chr3:48770732	C/T	cg00383909	chr3:49044727	WDR6	0.76	6.43	0.39	7.35e-10	Cognitive function;
SARC	cis	rs2153535	0.580	rs9379206	chr6:8458021	C/A	cg07606381	chr6:8435919	SLC35B3	0.75	10.66	0.57	7.43e-22	Motion sickness;
SARC	cis	rs9322193	0.566	rs4870118	chr6:150245013	G/A	cg11878867	chr6:150167359	LRP11	0.4	5.02	0.31	1.02e-6	Lung cancer;
SARC	trans	rs17685	0.736	rs4732594	chr7:75753273	T/C	cg19862616	chr7:65841803	NCRNA00174	0.62	7.72	0.45	3.44e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs11098499	0.954	rs7654587	chr4:120388406	C/T	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs854765	0.547	rs8075189	chr17:17901946	C/G	cg04398451	chr17:18023971	MYO15A	-0.44	-6.34	-0.38	1.18e-9	Total body bone mineral density;
SARC	cis	rs72945132	0.619	rs34552378	chr11:70243208	C/T	cg05964544	chr11:70165517	PPFIA1	-0.61	-5.96	-0.36	9.22e-9	Coronary artery disease;
SARC	cis	rs79349575	0.783	rs318096	chr17:46975370	G/A	cg16584676	chr17:46985605	UBE2Z	0.55	6.66	0.4	1.97e-10	Type 2 diabetes;
SARC	cis	rs6752107	0.935	rs11690131	chr2:234148383	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.47	6.17	0.37	2.92e-9	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs5753618	0.561	rs2413047	chr22:31666026	A/G	cg13145458	chr22:31556086	RNF185	0.47	5.05	0.31	8.76e-7	Colorectal cancer;
SARC	cis	rs7582180	0.629	rs12617779	chr2:100937707	G/A	cg14675211	chr2:100938903	LONRF2	0.51	7.68	0.45	4.44e-13	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg24829409	chr8:58192753	C8orf71	-0.63	-5.96	-0.36	9.37e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg09455208	chr3:40491958	NA	0.41	6.29	0.38	1.53e-9	Renal cell carcinoma;
SARC	cis	rs2075371	0.796	rs1646645	chr7:134012232	G/T	cg11752832	chr7:134001865	SLC35B4	-0.62	-8.32	-0.48	7.28e-15	Mean platelet volume;
SARC	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.39	-4.92	-0.31	1.64e-6	Blood metabolite levels;
SARC	cis	rs9300255	0.568	rs1621194	chr12:123651018	T/C	cg05973401	chr12:123451056	ABCB9	0.54	6.17	0.37	3e-9	Neutrophil percentage of white cells;
SARC	cis	rs2486288	0.656	rs12910009	chr15:45572408	A/G	cg15395560	chr15:45543142	SLC28A2	0.3	5.78	0.35	2.41e-8	Glomerular filtration rate;
SARC	cis	rs11098499	0.865	rs10032158	chr4:120391632	C/T	cg09307838	chr4:120376055	NA	0.9	12.45	0.63	1.34e-27	Corneal astigmatism;
SARC	cis	rs7659604	0.540	rs10012775	chr4:122676878	T/C	cg19671926	chr4:122722719	EXOSC9	0.55	6.99	0.42	2.87e-11	Type 2 diabetes;
SARC	cis	rs933688	1.000	rs6862125	chr5:90724598	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.1	13.87	0.67	2.73e-32	Smoking behavior;
SARC	cis	rs1562975	0.722	rs4593211	chr4:109457433	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.44	5.19	0.32	4.53e-7	Height;
SARC	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg15242686	chr22:24348715	GSTTP1	-0.46	-5.73	-0.35	3.04e-8	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs17023223	0.537	rs2765532	chr1:119591546	T/C	cg05756136	chr1:119680316	WARS2	-0.45	-5.44	-0.34	1.35e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	-0.48	-4.8	-0.3	2.78e-6	Lung function (FEV1/FVC);
SARC	cis	rs10791097	0.967	rs10791099	chr11:130718813	G/C	cg12179176	chr11:130786555	SNX19	0.61	8.51	0.49	2.08e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg19078903	chr1:21112721	HP1BP3	0.49	6.42	0.39	7.4e-10	Lung adenocarcinoma;
SARC	cis	rs6540556	0.769	rs627670	chr1:209929299	G/A	cg05527609	chr1:210001259	C1orf107	0.52	5.26	0.33	3.28e-7	Red blood cell count;
SARC	cis	rs644799	0.965	rs1944080	chr11:95503636	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	9.43	0.53	4.29e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs1008375	0.898	rs4698620	chr4:17587361	C/T	cg27347728	chr4:17578864	LAP3	0.49	6.06	0.37	5.46e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7824557	0.583	rs2263512	chr8:11233419	T/G	cg21775007	chr8:11205619	TDH	-0.63	-8.37	-0.48	5.21e-15	Retinal vascular caliber;
SARC	cis	rs7582720	1.000	rs75324925	chr2:203698300	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	7.5	0.44	1.36e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg27286337	chr10:134555280	INPP5A	0.71	8.16	0.47	2.03e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs8064024	0.508	rs2037912	chr16:4933939	G/C	cg08329684	chr16:4932620	PPL	-0.45	-7.11	-0.42	1.45e-11	Cancer;
SARC	cis	rs736408	0.561	rs2276815	chr3:52853747	C/G	cg18404041	chr3:52824283	ITIH1	-0.47	-5.94	-0.36	1.04e-8	Bipolar disorder;
SARC	cis	rs6545883	0.965	rs766447	chr2:61735569	C/T	cg15711740	chr2:61764176	XPO1	-0.42	-5.27	-0.33	3.03e-7	Tuberculosis;
SARC	cis	rs6912958	0.781	rs985764	chr6:88215206	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.43	-0.34	1.41e-7	Monocyte percentage of white cells;
SARC	cis	rs9640161	0.742	rs2159236	chr7:150017214	A/G	cg17279839	chr7:150038598	RARRES2	0.46	6.49	0.39	5.07e-10	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs57994353	0.897	rs12551527	chr9:139358425	C/G	cg14169450	chr9:139327907	INPP5E	0.42	5.42	0.33	1.48e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs7829975	0.840	rs555617	chr8:8592845	C/G	cg08975724	chr8:8085496	FLJ10661	-0.48	-5.67	-0.35	4.26e-8	Mood instability;
SARC	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg24633833	chr3:10029261	TMEM111	0.49	4.74	0.3	3.7e-6	Alzheimer's disease;
SARC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg20102877	chr2:27665638	KRTCAP3	-0.38	-5.53	-0.34	8.45e-8	Total body bone mineral density;
SARC	cis	rs9790314	0.967	rs460165	chr3:161087710	G/A	cg03342759	chr3:160939853	NMD3	-0.59	-7.59	-0.45	7.67e-13	Morning vs. evening chronotype;
SARC	cis	rs9916302	0.904	rs6503507	chr17:37525274	C/T	cg15445000	chr17:37608096	MED1	-0.43	-5.22	-0.32	3.92e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg06074448	chr4:187884817	NA	-0.37	-5.07	-0.32	8.2e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7560272	0.529	rs2421672	chr2:73955540	G/A	cg20560298	chr2:73613845	ALMS1	0.44	5.86	0.36	1.55e-8	Schizophrenia;
SARC	cis	rs9303401	0.614	rs34900851	chr17:56566399	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.05	11.4	0.6	3.25e-24	Cognitive test performance;
SARC	cis	rs9788721	0.836	rs17484235	chr15:78761414	C/G	cg06917634	chr15:78832804	PSMA4	-0.51	-5.31	-0.33	2.57e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg24110177	chr3:50126178	RBM5	0.57	7.83	0.46	1.71e-13	Intelligence (multi-trait analysis);
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg16177875	chr15:49102732	CEP152	0.48	6.3	0.38	1.51e-9	Lung adenocarcinoma;
SARC	trans	rs1814175	0.619	rs10769623	chr11:49865926	C/T	cg15704280	chr7:45808275	SEPT13	-0.88	-13.91	-0.67	1.97e-32	Height;
SARC	trans	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg06437703	chr8:37914619	EIF4EBP1	-0.56	-6.62	-0.4	2.51e-10	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2985684	0.846	rs10150624	chr14:50051565	A/G	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.45	4.93	0.31	1.57e-6	Carotid intima media thickness;
SARC	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.39	-4.85	-0.3	2.26e-6	Lymphocyte counts;
SARC	trans	rs7824557	0.724	rs2251473	chr8:11177126	C/A	cg08975724	chr8:8085496	FLJ10661	0.54	6.81	0.41	8.42e-11	Retinal vascular caliber;
SARC	cis	rs3741404	0.620	rs882147	chr11:63976689	T/A	cg18225595	chr11:63971243	STIP1	0.47	7.28	0.43	5.15e-12	Platelet count;
SARC	cis	rs7712401	0.601	rs446782	chr5:122341868	C/T	cg19412675	chr5:122181750	SNX24	-0.43	-5.43	-0.34	1.41e-7	Mean platelet volume;
SARC	cis	rs861020	0.527	rs614662	chr1:209962419	C/T	cg05527609	chr1:210001259	C1orf107	0.39	4.84	0.3	2.31e-6	Orofacial clefts;
SARC	cis	rs17376456	0.825	rs12716454	chr5:93272279	A/C	cg21475434	chr5:93447410	FAM172A	0.85	7.51	0.44	1.22e-12	Diabetic retinopathy;
SARC	cis	rs4481887	0.741	rs6682957	chr1:248535639	T/G	cg13385794	chr1:248469461	NA	0.34	5.48	0.34	1.09e-7	Common traits (Other);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg02570102	chr7:76256837	POMZP3;LOC100133091	0.53	6.5	0.39	4.72e-10	Breast cancer;
SARC	trans	rs7980799	0.654	rs10844618	chr12:33625010	A/G	cg13010199	chr12:38710504	ALG10B	-0.53	-6.3	-0.38	1.46e-9	Heart rate;Heart rate variability traits (RMSSD);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg07990511	chr6:36853609	C6orf89	-0.57	-6.37	-0.39	9.81e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs6456156	0.792	rs10946212	chr6:167515947	C/G	cg07741184	chr6:167504864	NA	0.37	7.24	0.43	6.33e-12	Primary biliary cholangitis;
SARC	cis	rs897984	0.520	rs4889536	chr16:30871755	G/T	cg02466173	chr16:30829666	NA	0.41	5.12	0.32	6.39e-7	Dementia with Lewy bodies;
SARC	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg22834771	chr12:69754056	YEATS4	-0.44	-5.78	-0.35	2.43e-8	Blood protein levels;
SARC	cis	rs5753037	0.585	rs249401	chr22:30216168	C/T	cg01021169	chr22:30184971	ASCC2	-0.52	-7.16	-0.42	1.02e-11	Type 1 diabetes;
SARC	cis	rs9300255	0.739	rs1402275	chr12:123750895	A/G	cg05973401	chr12:123451056	ABCB9	0.45	4.94	0.31	1.48e-6	Neutrophil percentage of white cells;
SARC	cis	rs2153535	0.601	rs9502719	chr6:8541032	A/G	cg21535247	chr6:8435926	SLC35B3	0.55	6.83	0.41	7.48e-11	Motion sickness;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg07194689	chr5:102455941	GIN1	0.64	6.51	0.39	4.66e-10	Lung cancer in ever smokers;
SARC	cis	rs2073499	0.872	rs2282751	chr3:50291785	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.52	-7.16	-0.42	1.08e-11	Schizophrenia;
SARC	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg09839136	chr7:766187	HEATR2;PRKAR1B	0.59	5.1	0.32	7e-7	Cerebrospinal P-tau181p levels;
SARC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg20607798	chr8:58055168	NA	0.58	5.55	0.34	7.69e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs12148488	0.816	rs4886655	chr15:75385568	C/T	cg09165964	chr15:75287851	SCAMP5	0.54	7.21	0.43	7.62e-12	Caffeine consumption;
SARC	cis	rs7681440	0.835	rs6532198	chr4:90798870	C/T	cg06632027	chr4:90757378	SNCA	0.41	5.73	0.35	3.07e-8	Dementia with Lewy bodies;
SARC	cis	rs504918	0.556	rs4678105	chr3:124000265	A/G	cg05766129	chr3:123988013	KALRN	-0.3	-4.84	-0.3	2.41e-6	Schizophrenia;
SARC	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg05368731	chr17:41323189	NBR1	0.8	9.59	0.53	1.43e-18	Menopause (age at onset);
SARC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.26	0.52	1.39e-17	Prudent dietary pattern;
SARC	cis	rs3106136	0.649	rs28463907	chr4:95302595	A/G	cg11021082	chr4:95130006	SMARCAD1	0.33	4.91	0.31	1.73e-6	Capecitabine sensitivity;
SARC	cis	rs7296418	0.961	rs4148862	chr12:123568619	A/C	cg16085171	chr12:123569118	PITPNM2	-0.4	-5.05	-0.31	8.86e-7	Platelet count;
SARC	cis	rs7937682	0.889	rs497111	chr11:111499512	G/A	cg22437258	chr11:111473054	SIK2	0.74	10.03	0.55	6.36e-20	Primary sclerosing cholangitis;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg07874155	chr5:138089656	CTNNA1	0.53	6.6	0.4	2.75e-10	Breast cancer;
SARC	cis	rs7586879	0.639	rs4077678	chr2:25122840	C/G	cg04586622	chr2:25135609	ADCY3	0.31	5.25	0.33	3.47e-7	Body mass index;
SARC	trans	rs7824557	0.564	rs2736295	chr8:11234780	C/G	cg15556689	chr8:8085844	FLJ10661	0.53	6.9	0.41	4.88e-11	Retinal vascular caliber;
SARC	cis	rs3617	0.539	rs11922975	chr3:52936763	C/T	cg18404041	chr3:52824283	ITIH1	0.34	4.79	0.3	2.95e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs6120849	0.707	rs752075	chr20:33591591	C/A	cg24642439	chr20:33292090	TP53INP2	0.57	5.54	0.34	7.99e-8	Protein C levels;
SARC	cis	rs9611519	0.542	rs8139770	chr22:41416181	C/T	cg17376030	chr22:41985996	PMM1	0.38	4.78	0.3	3.07e-6	Neuroticism;
SARC	trans	rs11098499	0.821	rs28665282	chr4:120384186	C/T	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	cis	rs3857536	0.904	rs4336428	chr6:66901840	C/T	cg07460842	chr6:66804631	NA	-0.41	-4.81	-0.3	2.75e-6	Blood trace element (Cu levels);
SARC	cis	rs62064224	0.905	rs9891969	chr17:30627085	C/T	cg18200150	chr17:30822561	MYO1D	0.32	4.82	0.3	2.6e-6	Schizophrenia;
SARC	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg11766577	chr21:47581405	C21orf56	-0.41	-5.04	-0.31	9.45e-7	Testicular germ cell tumor;
SARC	cis	rs72781680	0.611	rs7602797	chr2:24318148	C/T	cg06627628	chr2:24431161	ITSN2	-0.5	-5.32	-0.33	2.45e-7	Lymphocyte counts;
SARC	cis	rs644799	0.710	rs3017756	chr11:95537358	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.6	7.87	0.46	1.29e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs870825	0.616	rs28618216	chr4:185648998	T/C	cg04058563	chr4:185651563	MLF1IP	0.8	11.35	0.6	4.56e-24	Blood protein levels;
SARC	cis	rs4727443	0.769	rs2301806	chr7:99580907	C/G	cg22004693	chr7:99632812	ZKSCAN1	0.66	8.83	0.5	2.56e-16	Interstitial lung disease;
SARC	cis	rs9549367	0.789	rs9549715	chr13:113908240	G/C	cg18105134	chr13:113819100	PROZ	-0.38	-5.69	-0.35	3.81e-8	Platelet distribution width;
SARC	cis	rs9398803	0.966	rs9388487	chr6:126678268	G/T	cg19875578	chr6:126661172	C6orf173	0.6	8.27	0.48	1.04e-14	Male-pattern baldness;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg22384366	chr3:178867004	PIK3CA	0.55	7.3	0.43	4.54e-12	Breast cancer;
SARC	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg24829409	chr8:58192753	C8orf71	-0.57	-5.14	-0.32	5.91e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs8016982	0.674	rs759939	chr14:81663453	G/C	cg01989461	chr14:81687754	GTF2A1	0.76	11.46	0.6	2.06e-24	Schizophrenia;
SARC	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg11843238	chr5:131593191	PDLIM4	0.38	5.38	0.33	1.85e-7	Breast cancer;
SARC	cis	rs2916247	1.000	rs28728418	chr8:93061878	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.58	-5.95	-0.36	1e-8	Intelligence (multi-trait analysis);
SARC	cis	rs4925386	0.681	rs2427295	chr20:60927431	G/A	cg24112000	chr20:60950667	NA	-0.36	-5.26	-0.33	3.26e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs17253792	0.822	rs8013831	chr14:56172898	G/A	cg01858014	chr14:56050164	KTN1	-0.64	-5.22	-0.32	4.02e-7	Putamen volume;
SARC	cis	rs4737010	0.501	rs55694640	chr8:41649439	T/G	cg08923054	chr8:41654455	ANK1	0.7	8.28	0.48	9.94e-15	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
SARC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.51	6.71	0.4	1.44e-10	Lymphocyte counts;
SARC	cis	rs2463822	1.000	rs2463820	chr11:62112290	A/T	cg06239285	chr11:62104954	ASRGL1	0.85	8.5	0.49	2.25e-15	Chronic obstructive pulmonary disease-related biomarkers;
SARC	trans	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.72	-10.29	-0.56	9.96e-21	Intelligence (multi-trait analysis);
SARC	cis	rs36051895	0.632	rs10974993	chr9:5182159	C/T	cg02405213	chr9:5042618	JAK2	-0.45	-5.29	-0.33	2.77e-7	Pediatric autoimmune diseases;
SARC	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg13206674	chr6:150067644	NUP43	0.46	6.1	0.37	4.29e-9	Lung cancer;
SARC	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg26681399	chr22:41777847	TEF	0.43	4.89	0.3	1.92e-6	Vitiligo;
SARC	trans	rs561341	0.739	rs9906455	chr17:30215669	G/A	cg20587970	chr11:113659929	NA	0.71	7.11	0.42	1.4e-11	Hip circumference adjusted for BMI;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg25048202	chr15:66993412	SMAD6	0.49	6.46	0.39	5.88e-10	Chemerin levels;
SARC	cis	rs7674212	0.541	rs2720448	chr4:104030589	C/T	cg16532752	chr4:104119610	CENPE	-0.48	-5.9	-0.36	1.3e-8	Type 2 diabetes;
SARC	cis	rs2576037	0.901	rs2060416	chr18:44576240	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.49	6.5	0.39	4.78e-10	Personality dimensions;
SARC	cis	rs372883	0.506	rs2832300	chr21:30749315	A/G	cg08807101	chr21:30365312	RNF160	0.53	6.65	0.4	2.06e-10	Pancreatic cancer;
SARC	cis	rs3809863	0.602	rs7225700	chr17:45391804	T/C	cg08085267	chr17:45401833	C17orf57	-0.54	-6.7	-0.4	1.57e-10	Glaucoma (primary open-angle);
SARC	cis	rs2204008	0.744	rs11514358	chr12:38255526	G/A	cg26384229	chr12:38710491	ALG10B	0.91	13.64	0.67	1.61e-31	Bladder cancer;
SARC	cis	rs1355223	1.000	rs11607300	chr11:34759319	C/T	cg18508148	chr11:34937573	PDHX;APIP	-0.45	-5.73	-0.35	3.06e-8	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs67460515	0.563	rs35914913	chr3:160826561	A/G	cg04691961	chr3:161091175	C3orf57	-0.41	-4.88	-0.3	1.97e-6	Parkinson's disease;
SARC	cis	rs6598163	0.564	rs12319878	chr12:132289989	C/T	cg07389463	chr12:132296394	NA	0.41	6.27	0.38	1.7e-9	Migraine;
SARC	cis	rs9303401	0.580	rs12946396	chr17:57164195	T/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	10.67	0.57	6.72e-22	Cognitive test performance;
SARC	cis	rs11770686	0.967	rs2240138	chr7:75341871	T/A	cg17787366	chr7:75369077	HIP1	0.41	5.13	0.32	6.19e-7	Essential tremor;
SARC	cis	rs7726839	0.540	rs72707016	chr5:665148	A/G	cg14541582	chr5:601475	NA	-0.42	-5.04	-0.31	9.43e-7	Obesity-related traits;
SARC	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg06028808	chr11:68637592	NA	0.42	5.4	0.33	1.62e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg07665352	chr10:5135453	AKR1C3	0.6	8.69	0.49	6.51e-16	Thyroid stimulating hormone;
SARC	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	10.79	0.58	2.79e-22	Alzheimer's disease;
SARC	cis	rs1564271	0.506	rs1148163	chr10:26929671	G/C	cg13837822	chr10:26931731	LOC731789	0.51	7.47	0.44	1.6e-12	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
SARC	cis	rs7264396	0.563	rs1970577	chr20:34336737	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	5.32	0.33	2.49e-7	Total cholesterol levels;
SARC	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.39	0.44	2.61e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7647973	1.000	rs12583	chr3:49571462	G/T	cg07636037	chr3:49044803	WDR6	-0.75	-8.37	-0.48	5.47e-15	Menarche (age at onset);
SARC	cis	rs2153535	0.505	rs1335629	chr6:8491863	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	8.2	0.47	1.57e-14	Motion sickness;
SARC	cis	rs10791097	0.694	rs10791103	chr11:130757161	G/A	cg12179176	chr11:130786555	SNX19	0.77	11.69	0.61	3.82e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg26335602	chr6:28129616	ZNF389	0.51	5.56	0.34	7.41e-8	Parkinson's disease;
SARC	cis	rs1578862	0.966	rs61838689	chr1:247485117	T/C	cg22704608	chr1:247479546	ZNF496	-0.33	-4.75	-0.3	3.61e-6	Monocyte percentage of white cells;
SARC	cis	rs6693567	0.545	rs4446975	chr1:150456169	C/T	cg09579323	chr1:150459698	TARS2	0.39	5.1	0.32	6.9e-7	Migraine;
SARC	cis	rs72781680	0.821	rs72790329	chr2:24129277	A/G	cg06627628	chr2:24431161	ITSN2	-0.57	-5.88	-0.36	1.42e-8	Lymphocyte counts;
SARC	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg21724239	chr8:58056113	NA	0.62	6.38	0.39	9.6e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs62408225	0.722	rs10944481	chr6:90917314	A/G	cg06866423	chr6:90926672	BACH2	-0.32	-5.2	-0.32	4.28e-7	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs9355610	0.609	rs62436424	chr6:167374258	A/G	cg23791538	chr6:167370224	RNASET2	0.54	6.19	0.38	2.63e-9	Graves' disease;
SARC	cis	rs3768617	0.811	rs34721094	chr1:183051521	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	8.19	0.47	1.72e-14	Fuchs's corneal dystrophy;
SARC	cis	rs1008375	1.000	rs10019856	chr4:17615742	T/A	cg02297831	chr4:17616191	MED28	0.51	6.6	0.4	2.75e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1270639	0.778	rs2906930	chr7:157446453	T/C	cg13357408	chr7:157437802	PTPRN2	0.45	4.85	0.3	2.21e-6	Colorectal cancer;
SARC	cis	rs3126085	0.935	rs55942250	chr1:152251914	G/A	cg26876637	chr1:152193138	HRNR	-0.5	-5.46	-0.34	1.22e-7	Atopic dermatitis;
SARC	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg13206674	chr6:150067644	NUP43	0.47	6.14	0.37	3.61e-9	Lung cancer;
SARC	cis	rs870825	0.616	rs10025167	chr4:185649551	A/C	cg04058563	chr4:185651563	MLF1IP	0.8	11.35	0.6	4.56e-24	Blood protein levels;
SARC	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg18404041	chr3:52824283	ITIH1	-0.38	-5.59	-0.34	6.45e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2273669	0.504	rs117426315	chr6:109450464	G/A	cg05315195	chr6:109294784	ARMC2	-0.6	-5.03	-0.31	9.76e-7	Prostate cancer;
SARC	cis	rs9325144	0.768	rs11168750	chr12:38992710	C/A	cg26384229	chr12:38710491	ALG10B	-0.63	-7.63	-0.45	5.99e-13	Morning vs. evening chronotype;
SARC	cis	rs2832191	0.791	rs2832179	chr21:30480366	C/T	cg24692254	chr21:30365293	RNF160	-0.92	-13.86	-0.67	2.95e-32	Dental caries;
SARC	cis	rs7927592	0.956	rs11228256	chr11:68251460	G/A	cg01657329	chr11:68192670	LRP5	-0.41	-5.09	-0.32	7.55e-7	Total body bone mineral density;
SARC	cis	rs3106136	0.681	rs11721714	chr4:95310717	C/G	cg11021082	chr4:95130006	SMARCAD1	0.32	4.86	0.3	2.19e-6	Capecitabine sensitivity;
SARC	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg01448562	chr3:133502909	NA	0.49	7.1	0.42	1.48e-11	Iron status biomarkers;
SARC	cis	rs7520050	0.807	rs5021934	chr1:46109304	A/G	cg06784218	chr1:46089804	CCDC17	-0.26	-4.75	-0.3	3.49e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs7520050	0.931	rs11211213	chr1:46342517	G/A	cg24296786	chr1:45957014	TESK2	0.39	4.97	0.31	1.32e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs208520	0.690	rs207082	chr6:66773796	G/A	cg07460842	chr6:66804631	NA	-1.07	-14.63	-0.69	7.8e-35	Exhaled nitric oxide output;
SARC	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg06221963	chr1:154839813	KCNN3	-0.46	-6.97	-0.42	3.3e-11	Prostate cancer;
SARC	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.89	12.64	0.64	3.1e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	9.77	0.54	4.16e-19	Platelet count;
SARC	cis	rs963731	0.522	rs1454222	chr2:39215895	C/A	cg04010122	chr2:39346883	SOS1	-1.07	-6.23	-0.38	2.13e-9	Corticobasal degeneration;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg26313233	chr2:114415511	NA	-0.51	-6.61	-0.4	2.59e-10	Electrocardiographic conduction measures;
SARC	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.41	0.44	2.36e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs865483	0.895	rs853229	chr17:35800919	A/G	cg06561646	chr17:35873369	DUSP14	-0.48	-6.21	-0.38	2.4e-9	Monocyte count;
SARC	cis	rs950776	0.752	rs7182583	chr15:78899210	G/C	cg06917634	chr15:78832804	PSMA4	0.75	10.08	0.55	4.51e-20	Sudden cardiac arrest;
SARC	cis	rs2230307	0.505	rs482873	chr1:100589757	C/T	cg24955406	chr1:100503596	HIAT1	-0.73	-7.23	-0.43	6.91e-12	Carotid intima media thickness;
SARC	cis	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg25427524	chr10:38739819	LOC399744	-0.55	-8.85	-0.5	2.26e-16	Extrinsic epigenetic age acceleration;
SARC	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg11987759	chr7:65425863	GUSB	-0.6	-8.07	-0.47	3.81e-14	Aortic root size;
SARC	cis	rs2486288	0.656	rs8039354	chr15:45551756	A/G	cg26924012	chr15:45694286	SPATA5L1	0.45	5.57	0.34	6.93e-8	Glomerular filtration rate;
SARC	cis	rs748404	0.690	rs2244981	chr15:43752751	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	5.54	0.34	8.19e-8	Lung cancer;
SARC	cis	rs6062302	0.522	rs3810492	chr20:62219740	G/A	cg16989086	chr20:62203971	PRIC285	0.47	4.74	0.3	3.7e-6	Glioblastoma;
SARC	cis	rs9359856	0.510	rs4053618	chr6:90459454	G/A	cg13799429	chr6:90582589	CASP8AP2	0.53	4.79	0.3	3.04e-6	Bipolar disorder;
SARC	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg02711726	chr17:80685570	FN3KRP	-0.56	-6.95	-0.41	3.65e-11	Glycated hemoglobin levels;
SARC	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg04772025	chr11:68637568	NA	-0.48	-6.14	-0.37	3.46e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9303280	0.901	rs12936231	chr17:38029120	C/G	cg20243544	chr17:37824526	PNMT	0.45	6.08	0.37	4.84e-9	Self-reported allergy;
SARC	cis	rs35306767	0.953	rs11253517	chr10:970524	A/G	cg18964960	chr10:1102726	WDR37	-0.56	-5.54	-0.34	7.98e-8	Eosinophil percentage of granulocytes;
SARC	cis	rs6570726	1.000	rs441477	chr6:145848243	C/T	cg23711669	chr6:146136114	FBXO30	0.77	11.8	0.61	1.68e-25	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs61931739	0.817	rs1687002	chr12:34170263	T/C	cg13010199	chr12:38710504	ALG10B	0.58	7.67	0.45	4.77e-13	Morning vs. evening chronotype;
SARC	cis	rs7264396	0.563	rs2066066	chr20:34329359	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-6.82	-0.41	7.98e-11	Total cholesterol levels;
SARC	cis	rs9916302	0.904	rs602688	chr17:37439496	C/T	cg20243544	chr17:37824526	PNMT	0.56	6.93	0.41	4.16e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs9430161	0.611	rs2095920	chr1:11033457	T/A	cg27631724	chr1:11040367	C1orf127	0.33	4.71	0.3	4.2e-6	Ewing sarcoma;
SARC	cis	rs992157	0.798	rs4996257	chr2:219162836	C/T	cg00012203	chr2:219082015	ARPC2	0.66	9.49	0.53	2.96e-18	Colorectal cancer;
SARC	cis	rs2985684	0.846	rs11157693	chr14:50048426	T/C	cg04989706	chr14:50066350	PPIL5	-0.54	-5.95	-0.36	9.73e-9	Carotid intima media thickness;
SARC	cis	rs79349575	0.783	rs4793995	chr17:47019399	A/C	cg07967210	chr17:47022446	SNF8	0.38	4.77	0.3	3.2e-6	Type 2 diabetes;
SARC	cis	rs11098499	0.731	rs9995026	chr4:120490499	T/A	cg24375607	chr4:120327624	NA	0.42	4.92	0.31	1.64e-6	Corneal astigmatism;
SARC	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg16405210	chr4:1374714	KIAA1530	-0.54	-6.78	-0.41	9.58e-11	Longevity;
SARC	cis	rs1046896	0.562	rs9912684	chr17:80873067	C/T	cg02711726	chr17:80685570	FN3KRP	-0.54	-6.47	-0.39	5.68e-10	Glycated hemoglobin levels;
SARC	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg23172400	chr8:95962367	TP53INP1	-0.33	-5.76	-0.35	2.59e-8	Type 2 diabetes;
SARC	cis	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg12463550	chr7:65579703	CRCP	0.65	5.03	0.31	9.96e-7	Diabetic kidney disease;
SARC	cis	rs62158211	0.691	rs1964463	chr2:114069021	C/T	cg17784749	chr2:114082611	LOC440839	-0.58	-5.99	-0.37	7.81e-9	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
SARC	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg00933542	chr6:150070202	PCMT1	0.3	5.1	0.32	7.1e-7	Lung cancer;
SARC	cis	rs11676348	0.714	rs4674254	chr2:218986077	T/C	cg00012203	chr2:219082015	ARPC2	-0.55	-7.32	-0.43	3.92e-12	Ulcerative colitis;
SARC	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg11890956	chr21:40555474	PSMG1	1.17	19.37	0.79	1.93e-50	Cognitive function;
SARC	cis	rs9790314	0.560	rs1450521	chr3:161091237	C/A	cg03342759	chr3:160939853	NMD3	-0.57	-7.12	-0.42	1.36e-11	Morning vs. evening chronotype;
SARC	cis	rs11098499	0.644	rs10009566	chr4:120558608	A/G	cg09307838	chr4:120376055	NA	0.74	10.14	0.55	2.94e-20	Corneal astigmatism;
SARC	cis	rs2777491	0.874	rs7161772	chr15:41611066	A/T	cg01768344	chr15:41576519	LOC729082	0.44	4.9	0.31	1.76e-6	Ulcerative colitis;
SARC	cis	rs8072100	0.713	rs2292346	chr17:45455473	G/A	cg08085267	chr17:45401833	C17orf57	-0.44	-5.11	-0.32	6.82e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs6088813	1.000	rs6087703	chr20:33996433	T/C	cg14752227	chr20:34000481	UQCC	-0.37	-4.72	-0.3	4.02e-6	Height;
SARC	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg24209194	chr3:40518798	ZNF619	0.66	8.11	0.47	2.86e-14	Renal cell carcinoma;
SARC	cis	rs11122272	0.735	rs2572251	chr1:231514243	C/T	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs9399135	0.967	rs11756988	chr6:135347595	A/G	cg24558204	chr6:135376177	HBS1L	0.45	6.07	0.37	5.25e-9	Red blood cell count;
SARC	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg16606324	chr3:10149918	C3orf24	0.49	5.04	0.31	9.35e-7	Alzheimer's disease;
SARC	cis	rs6138458	1.000	rs7268095	chr20:24972333	C/T	cg26195577	chr20:24973756	C20orf3	0.9	10.0	0.55	8.31e-20	Blood protein levels;
SARC	cis	rs981844	0.816	rs62325145	chr4:154725687	G/C	cg14289246	chr4:154710475	SFRP2	0.58	6.32	0.38	1.31e-9	Response to statins (LDL cholesterol change);
SARC	cis	rs1448094	0.781	rs7959093	chr12:86335502	C/A	cg02569458	chr12:86230093	RASSF9	0.41	5.86	0.36	1.53e-8	Major depressive disorder;
SARC	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg04277193	chr17:41438351	NA	0.44	4.86	0.3	2.18e-6	Menopause (age at onset);
SARC	trans	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg06636001	chr8:8085503	FLJ10661	0.62	9.06	0.51	5.31e-17	Neuroticism;
SARC	trans	rs453301	0.624	rs330056	chr8:9089695	A/T	cg21775007	chr8:11205619	TDH	-0.51	-6.47	-0.39	5.64e-10	Joint mobility (Beighton score);
SARC	cis	rs7980687	0.657	rs2851447	chr12:123665113	G/C	cg05973401	chr12:123451056	ABCB9	0.55	6.38	0.39	9.28e-10	Height;Educational attainment;Head circumference (infant);
SARC	cis	rs12142240	0.698	rs17361833	chr1:46828700	A/G	cg14993813	chr1:46806288	NSUN4	-0.53	-5.62	-0.35	5.48e-8	Menopause (age at onset);
SARC	cis	rs1050631	0.564	rs1625385	chr18:33717364	C/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.59	7.17	0.43	9.66e-12	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg06221963	chr1:154839813	KCNN3	-0.44	-6.48	-0.39	5.46e-10	Prostate cancer;
SARC	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-9.87	-0.54	1.98e-19	Chronic sinus infection;
SARC	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg04772025	chr11:68637568	NA	0.55	7.0	0.42	2.72e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs920590	0.758	rs17091534	chr8:19670651	C/T	cg03894339	chr8:19674705	INTS10	0.58	6.87	0.41	5.68e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs7438	0.506	rs7687728	chr4:170474244	C/T	cg07701716	chr4:170533879	NEK1	0.39	4.73	0.3	3.93e-6	Schizophrenia;
SARC	cis	rs2439831	0.681	rs999047	chr15:43688916	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.75	7.82	0.46	1.88e-13	Lung cancer in ever smokers;
SARC	cis	rs637571	0.522	rs566590	chr11:65754062	C/T	cg26695010	chr11:65641043	EFEMP2	-0.55	-7.08	-0.42	1.66e-11	Eosinophil percentage of white cells;
SARC	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg04944784	chr2:26401820	FAM59B	0.59	7.88	0.46	1.25e-13	Gut microbiome composition (summer);
SARC	cis	rs9486719	0.843	rs2472875	chr6:96844691	G/A	cg06623918	chr6:96969491	KIAA0776	0.75	7.39	0.44	2.65e-12	Migraine;Coronary artery disease;
SARC	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg18876405	chr7:65276391	NA	-0.43	-4.88	-0.3	1.96e-6	Aortic root size;
SARC	cis	rs743757	1.000	rs9835537	chr3:50464335	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.54	5.08	0.32	7.67e-7	Diastolic blood pressure;
SARC	cis	rs1707322	0.721	rs4660314	chr1:46229885	T/C	cg03146154	chr1:46216737	IPP	0.5	5.91	0.36	1.19e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.05	0.37	5.62e-9	Height;
SARC	cis	rs35213789	0.727	rs563740	chr7:69168149	G/A	cg10619644	chr7:69149951	AUTS2	-0.44	-5.72	-0.35	3.2e-8	Childhood ear infection;
SARC	cis	rs9398803	0.673	rs1262557	chr6:127054588	C/T	cg19875578	chr6:126661172	C6orf173	-0.63	-8.61	-0.49	1.11e-15	Male-pattern baldness;
SARC	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs3733585	0.673	rs7375587	chr4:9954758	A/T	cg11266682	chr4:10021025	SLC2A9	0.35	5.91	0.36	1.18e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	trans	rs8073060	0.559	rs10438814	chr17:34007065	A/G	cg19694781	chr19:47549865	TMEM160	-0.7	-6.92	-0.41	4.32e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs2153535	0.601	rs9406160	chr6:8464907	A/C	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	cis	rs7666738	0.606	rs28625338	chr4:99076996	A/G	cg05340658	chr4:99064831	C4orf37	0.47	5.94	0.36	1.03e-8	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg00409905	chr10:38381863	ZNF37A	-0.55	-7.96	-0.46	7.61e-14	Extrinsic epigenetic age acceleration;
SARC	cis	rs9916302	0.706	rs9944459	chr17:37484185	T/C	cg20243544	chr17:37824526	PNMT	-0.54	-5.81	-0.36	1.99e-8	Glomerular filtration rate (creatinine);
SARC	trans	rs61931739	0.824	rs406753	chr12:34117408	A/G	cg13010199	chr12:38710504	ALG10B	0.56	7.61	0.45	6.69e-13	Morning vs. evening chronotype;
SARC	cis	rs910187	0.605	rs8124995	chr20:45811788	G/T	cg27589058	chr20:45804311	EYA2	-0.3	-4.79	-0.3	2.93e-6	Migraine;
SARC	cis	rs41271473	0.950	rs72751907	chr1:228867648	C/T	cg16512390	chr1:228756714	NA	0.5	4.95	0.31	1.43e-6	Chronic lymphocytic leukemia;
SARC	cis	rs2976388	0.967	rs2585183	chr8:143766059	C/G	cg06565975	chr8:143823917	SLURP1	-0.29	-4.89	-0.31	1.87e-6	Urinary tract infection frequency;
SARC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg09033563	chr22:24373618	LOC391322	0.44	4.94	0.31	1.5e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1957429	0.901	rs1951490	chr14:65346957	G/T	cg23373153	chr14:65346875	NA	1.07	11.42	0.6	2.73e-24	Pediatric areal bone mineral density (radius);
SARC	cis	rs6426558	0.537	rs2670462	chr1:227432923	C/G	cg10327440	chr1:227177885	CDC42BPA	-0.42	-4.91	-0.31	1.71e-6	Neutrophil percentage of white cells;
SARC	cis	rs453301	0.686	rs11785634	chr8:8892597	G/T	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.98	-0.46	6.67e-14	Joint mobility (Beighton score);
SARC	cis	rs9309473	1.000	rs6724782	chr2:73679990	T/A	cg20560298	chr2:73613845	ALMS1	-0.51	-6.12	-0.37	3.98e-9	Metabolite levels;
SARC	cis	rs754466	0.605	rs10824578	chr10:79578244	G/C	cg17075019	chr10:79541650	NA	-0.81	-12.57	-0.64	5.15e-28	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2282802	0.685	rs1347143	chr5:139669386	A/G	cg26211634	chr5:139558579	C5orf32	-0.37	-4.95	-0.31	1.45e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9818758	0.607	rs11716445	chr3:49406095	C/T	cg07636037	chr3:49044803	WDR6	-0.7	-5.32	-0.33	2.4e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs6424115	0.830	rs2503000	chr1:24197898	C/G	cg09473613	chr1:24152604	HMGCL	0.33	4.75	0.3	3.49e-6	Immature fraction of reticulocytes;
SARC	cis	rs35110281	0.667	rs4819285	chr21:45118970	C/T	cg01579765	chr21:45077557	HSF2BP	0.36	5.81	0.36	2e-8	Mean corpuscular volume;
SARC	cis	rs7553864	1.000	rs4551570	chr1:87614019	C/A	cg18153957	chr1:87613403	LOC339524	-0.47	-5.55	-0.34	7.8e-8	Smoking behavior;
SARC	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg24399712	chr22:39784796	NA	-0.44	-5.66	-0.35	4.44e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs2486288	0.656	rs11632419	chr15:45557456	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.46	-5.68	-0.35	4.03e-8	Glomerular filtration rate;
SARC	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg20607798	chr8:58055168	NA	0.56	4.81	0.3	2.72e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs72781680	0.611	rs55905755	chr2:24330264	T/C	cg06627628	chr2:24431161	ITSN2	-0.56	-5.85	-0.36	1.7e-8	Lymphocyte counts;
SARC	cis	rs7666738	0.830	rs9884501	chr4:98893721	A/C	cg05340658	chr4:99064831	C4orf37	0.65	8.69	0.49	6.41e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6831352	0.734	rs3018046	chr4:100030388	C/T	cg12011299	chr4:100065546	ADH4	0.28	4.83	0.3	2.47e-6	Alcohol dependence;
SARC	cis	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg00745463	chr17:30367425	LRRC37B	-0.69	-5.28	-0.33	2.96e-7	Hip circumference adjusted for BMI;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg24185116	chr15:52044314	LYSMD2;TMOD2	-0.71	-6.36	-0.38	1.07e-9	Autism spectrum disorder or schizophrenia;
SARC	trans	rs9951602	0.512	rs9955812	chr18:76650954	T/A	cg02800362	chr5:177631904	HNRNPAB	0.71	9.0	0.51	8.26e-17	Obesity-related traits;
SARC	cis	rs1865760	1.000	rs9467636	chr6:25919549	A/C	cg17691542	chr6:26056736	HIST1H1C	0.58	7.11	0.42	1.4e-11	Height;
SARC	cis	rs4969178	0.832	rs4969185	chr17:76398157	G/C	cg20026190	chr17:76395443	PGS1	0.4	5.34	0.33	2.16e-7	HDL cholesterol levels;
SARC	cis	rs6570726	0.935	rs428659	chr6:145827039	T/C	cg05220968	chr6:146057943	EPM2A	-0.29	-4.99	-0.31	1.19e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs921968	0.565	rs35358516	chr2:219625723	A/C	cg02176678	chr2:219576539	TTLL4	-0.32	-4.88	-0.3	2e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs477692	1.000	rs538969	chr10:131410608	C/T	cg05714579	chr10:131428358	MGMT	0.62	8.05	0.47	4.28e-14	Response to temozolomide;
SARC	cis	rs1003719	0.715	rs2251952	chr21:38559711	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.6	-8.74	-0.5	4.74e-16	Eye color traits;
SARC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.57	7.46	0.44	1.67e-12	Lymphocyte counts;
SARC	cis	rs1008375	0.897	rs4334752	chr4:17615430	C/T	cg16339924	chr4:17578868	LAP3	0.67	8.8	0.5	3.12e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2124969	0.562	rs13393480	chr2:161058790	G/T	cg03641300	chr2:160917029	PLA2R1	-0.42	-5.67	-0.35	4.23e-8	Waist circumference adjusted for body mass index;
SARC	cis	rs2072499	0.966	rs11587860	chr1:156156951	G/C	cg25208724	chr1:156163844	SLC25A44	0.88	11.65	0.61	4.97e-25	Testicular germ cell tumor;
SARC	cis	rs17376456	0.825	rs12716453	chr5:93271697	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	5.84	0.36	1.75e-8	Diabetic retinopathy;
SARC	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg22920501	chr2:26401640	FAM59B	-0.56	-7.03	-0.42	2.22e-11	Gut microbiome composition (summer);
SARC	cis	rs55871839	0.684	rs7002967	chr8:59816806	T/A	cg07426533	chr8:59803705	TOX	-0.4	-5.12	-0.32	6.32e-7	Pneumonia;
SARC	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg03264133	chr6:25882463	NA	-0.53	-7.36	-0.43	3.06e-12	Intelligence (multi-trait analysis);
SARC	cis	rs2760061	0.583	rs708118	chr1:228201801	A/G	cg02753203	chr1:228287806	NA	-0.79	-11.56	-0.6	9.94e-25	Diastolic blood pressure;
SARC	cis	rs2486288	0.656	rs2461705	chr15:45570241	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.56	-6.93	-0.41	3.98e-11	Glomerular filtration rate;
SARC	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg11890956	chr21:40555474	PSMG1	1.17	19.52	0.79	6.04e-51	Cognitive function;
SARC	cis	rs721399	0.542	rs10085931	chr8:18245449	A/G	cg18736775	chr8:18248649	NAT2	-0.6	-6.93	-0.41	4.1e-11	Blood metabolite levels;
SARC	cis	rs611744	0.781	rs75534351	chr8:109118714	A/T	cg21045802	chr8:109455806	TTC35	0.42	4.9	0.31	1.83e-6	Dupuytren's disease;
SARC	cis	rs9899728	0.572	rs4365317	chr17:73059820	C/G	cg27626185	chr17:73056755	KCTD2	-0.52	-5.07	-0.31	8.26e-7	Alzheimer's disease or small vessel stroke;
SARC	cis	rs3617	0.573	rs6795646	chr3:52922621	C/T	cg18404041	chr3:52824283	ITIH1	0.33	4.79	0.3	2.93e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs2658782	0.654	rs2605623	chr11:93249359	A/G	cg15737290	chr11:93063684	CCDC67	0.76	8.75	0.5	4.29e-16	Pulmonary function decline;
SARC	cis	rs6918586	0.594	rs198842	chr6:26111448	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.46	-5.84	-0.36	1.71e-8	Schizophrenia;
SARC	cis	rs9309473	0.687	rs11126399	chr2:73613341	G/A	cg20560298	chr2:73613845	ALMS1	-0.51	-6.5	-0.39	4.91e-10	Metabolite levels;
SARC	cis	rs11235843	0.602	rs1830069	chr11:73433229	C/G	cg18195628	chr11:73498948	MRPL48	-0.61	-5.99	-0.37	7.93e-9	Hand grip strength;
SARC	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg19223190	chr17:80058835	NA	-0.43	-6.02	-0.37	6.57e-9	Life satisfaction;
SARC	cis	rs2180341	0.538	rs4577822	chr6:127712911	T/G	cg24812749	chr6:127587940	RNF146	0.46	5.58	0.34	6.82e-8	Breast cancer;
SARC	cis	rs9916302	0.904	rs11078898	chr17:37536480	A/G	cg15445000	chr17:37608096	MED1	-0.42	-5.03	-0.31	9.68e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg08045932	chr20:61659980	NA	0.5	6.84	0.41	7.06e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs965469	1.000	rs6051751	chr20:3310049	G/C	cg25506879	chr20:3388711	C20orf194	-0.5	-5.08	-0.32	7.88e-7	IFN-related cytopenia;
SARC	cis	rs933688	1.000	rs10073935	chr5:90742188	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	12.61	0.64	3.86e-28	Smoking behavior;
SARC	cis	rs2576037	0.901	rs2571021	chr18:44583498	A/G	cg15049968	chr18:44337910	ST8SIA5	0.33	5.27	0.33	3.03e-7	Personality dimensions;
SARC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg06873352	chr17:61820015	STRADA	0.54	6.99	0.42	2.8e-11	Prudent dietary pattern;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg25989856	chr13:111365705	ING1	-0.68	-4.91	-0.31	1.69e-6	Obesity-related traits;
SARC	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg02725872	chr8:58115012	NA	-0.36	-6.5	-0.39	4.94e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1865760	0.566	rs2794720	chr6:26087202	G/C	cg16482183	chr6:26056742	HIST1H1C	0.47	5.91	0.36	1.22e-8	Height;
SARC	trans	rs11098499	0.908	rs7696649	chr4:120322177	G/A	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.52e-12	Corneal astigmatism;
SARC	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg00933542	chr6:150070202	PCMT1	0.33	5.78	0.35	2.38e-8	Lung cancer;
SARC	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg06028808	chr11:68637592	NA	0.45	5.82	0.36	1.93e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs6582630	0.560	rs11504462	chr12:38440379	G/A	cg14851346	chr12:38532713	NA	-0.45	-5.41	-0.33	1.59e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg24675658	chr1:53192096	ZYG11B	0.57	8.08	0.47	3.54e-14	Monocyte count;
SARC	cis	rs1153858	1.000	rs12441971	chr15:45671957	A/T	cg21132104	chr15:45694354	SPATA5L1	0.78	11.01	0.59	5.55e-23	Homoarginine levels;
SARC	cis	rs7429990	0.965	rs1550914	chr3:47995168	A/C	cg11946769	chr3:48343235	NME6	0.46	5.31	0.33	2.61e-7	Educational attainment (years of education);
SARC	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	7.79	0.45	2.25e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs113835537	0.529	rs75685325	chr11:66235242	A/G	cg24851651	chr11:66362959	CCS	0.39	4.72	0.3	4.07e-6	Airway imaging phenotypes;
SARC	cis	rs7647973	0.626	rs1586827	chr3:49671224	T/C	cg13072238	chr3:49761600	GMPPB	-0.6	-6.04	-0.37	6.04e-9	Menarche (age at onset);
SARC	cis	rs11098499	0.954	rs11098525	chr4:120390152	G/A	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs2997447	0.706	rs61776573	chr1:26429356	A/C	cg19633962	chr1:26362018	EXTL1	-0.67	-5.8	-0.36	2.1e-8	QRS complex (12-leadsum);
SARC	cis	rs611744	0.967	rs2600614	chr8:109198079	T/A	cg21045802	chr8:109455806	TTC35	0.45	5.32	0.33	2.41e-7	Dupuytren's disease;
SARC	cis	rs11711311	1.000	rs9811200	chr3:113531180	A/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	8.51	0.49	2.2e-15	IgG glycosylation;
SARC	cis	rs7709909	0.755	rs2081853	chr5:79964349	G/T	cg04186980	chr5:79953697	MSH3	0.37	4.77	0.3	3.27e-6	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
SARC	cis	rs17095355	0.901	rs12240333	chr10:111743972	T/A	cg00817464	chr10:111662876	XPNPEP1	-0.42	-4.73	-0.3	3.84e-6	Biliary atresia;
SARC	cis	rs2952156	0.920	rs9303274	chr17:37836353	T/C	cg20243544	chr17:37824526	PNMT	0.56	7.3	0.43	4.38e-12	Asthma;
SARC	cis	rs9733	0.791	rs11800059	chr1:150651175	C/T	cg13175981	chr1:150552382	MCL1	0.65	8.99	0.51	8.45e-17	Tonsillectomy;
SARC	cis	rs7481584	0.626	rs2071103	chr11:3040087	C/T	cg08508325	chr11:3079039	CARS	0.24	5.39	0.33	1.71e-7	Calcium levels;
SARC	cis	rs2624839	0.704	rs11919418	chr3:50233215	T/G	cg19755318	chr3:50243323	SLC38A3	-0.3	-5.17	-0.32	4.97e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9341808	0.754	rs6907729	chr6:81004922	A/T	cg08355045	chr6:80787529	NA	-0.36	-5.71	-0.35	3.43e-8	Sitting height ratio;
SARC	cis	rs9916302	0.904	rs634365	chr17:37436966	C/T	cg00129232	chr17:37814104	STARD3	-0.53	-6.61	-0.4	2.53e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.43	6.61	0.4	2.53e-10	Schizophrenia;
SARC	cis	rs16866061	0.962	rs3845840	chr2:225359100	G/A	cg12698349	chr2:225449008	CUL3	0.69	9.9	0.54	1.63e-19	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	cis	rs240764	0.746	rs240141	chr6:101084946	G/A	cg09795085	chr6:101329169	ASCC3	0.45	5.66	0.35	4.33e-8	Neuroticism;
SARC	cis	rs7247513	0.897	rs12979146	chr19:12717904	C/T	cg04657146	chr19:12876947	HOOK2	0.4	4.76	0.3	3.34e-6	Bipolar disorder;
SARC	cis	rs17600642	0.724	rs72814547	chr10:72458069	C/T	cg18679544	chr10:72432482	ADAMTS14	0.46	4.79	0.3	2.91e-6	Bipolar disorder;
SARC	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg05861140	chr6:150128134	PCMT1	-0.4	-5.23	-0.32	3.84e-7	Lung cancer;
SARC	cis	rs9291683	0.632	rs11734786	chr4:10041499	A/C	cg11266682	chr4:10021025	SLC2A9	0.4	7.23	0.43	6.87e-12	Bone mineral density;
SARC	cis	rs17125944	0.505	rs3783447	chr14:53191647	G/A	cg00686598	chr14:53173677	PSMC6	1.33	9.1	0.51	4.11e-17	Alzheimer's disease (late onset);
SARC	cis	rs2439831	0.681	rs540388	chr15:43606494	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.08	12.41	0.63	1.78e-27	Lung cancer in ever smokers;
SARC	trans	rs4295623	0.585	rs13259242	chr8:11593033	T/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.43	-0.44	2e-12	Morning vs. evening chronotype;
SARC	cis	rs911555	0.723	rs12894652	chr14:103926024	A/G	cg12935359	chr14:103987150	CKB	0.39	5.34	0.33	2.22e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6964587	0.967	rs41371748	chr7:91708219	A/G	cg17063962	chr7:91808500	NA	0.9	13.17	0.65	5.58e-30	Breast cancer;
SARC	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg00933542	chr6:150070202	PCMT1	0.3	5.15	0.32	5.66e-7	Lung cancer;
SARC	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg22496380	chr5:211416	CCDC127	-0.84	-8.6	-0.49	1.19e-15	Breast cancer;
SARC	trans	rs9354308	0.966	rs1909533	chr6:66565658	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.57	6.71	0.4	1.42e-10	Metabolite levels;
SARC	cis	rs7760949	0.889	rs9475806	chr6:13934527	A/G	cg27413430	chr6:13925136	RNF182	0.43	4.96	0.31	1.35e-6	Mean corpuscular hemoglobin concentration;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	ch.7.592198R	chr7:23385684	IGF2BP3	0.78	6.33	0.38	1.25e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6430585	0.941	rs7589832	chr2:136504101	A/C	cg07169764	chr2:136633963	MCM6	0.81	11.19	0.59	1.57e-23	Corneal structure;
SARC	cis	rs709400	0.628	rs11622320	chr14:103912194	A/T	cg26031613	chr14:104095156	KLC1	0.81	11.64	0.61	5.37e-25	Body mass index;
SARC	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg09699651	chr6:150184138	LRP11	0.51	6.49	0.39	5.13e-10	Lung cancer;
SARC	cis	rs2832191	0.791	rs2832199	chr21:30498501	G/A	cg08807101	chr21:30365312	RNF160	-0.81	-11.21	-0.59	1.33e-23	Dental caries;
SARC	cis	rs3741798	1.000	rs17375328	chr12:12485292	T/C	cg08615371	chr12:12503544	MANSC1	0.8	5.96	0.36	9.13e-9	Cerebrospinal fluid biomarker levels;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg24040382	chr1:224622855	WDR26	-0.51	-6.77	-0.41	1.04e-10	Schizophrenia;
SARC	cis	rs9326248	0.559	rs1269329	chr11:116755041	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.63	7.78	0.45	2.35e-13	Blood protein levels;
SARC	cis	rs112591243	0.685	rs80124066	chr21:47912913	A/G	cg10657630	chr21:48055338	PRMT2	0.76	4.83	0.3	2.52e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs5753618	0.509	rs5753500	chr22:31578879	A/G	cg13145458	chr22:31556086	RNF185	0.46	5.11	0.32	6.76e-7	Colorectal cancer;
SARC	cis	rs854765	0.618	rs9908017	chr17:17774422	C/T	cg05444541	chr17:17804740	TOM1L2	0.3	5.15	0.32	5.62e-7	Total body bone mineral density;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg02724903	chr13:114260339	TFDP1	-0.51	-6.41	-0.39	7.82e-10	Height;
SARC	cis	rs921968	0.591	rs13421421	chr2:219519286	A/G	cg02176678	chr2:219576539	TTLL4	0.36	5.66	0.35	4.32e-8	Mean corpuscular hemoglobin concentration;
SARC	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg11987759	chr7:65425863	GUSB	-0.47	-6.27	-0.38	1.7e-9	Aortic root size;
SARC	trans	rs459571	0.920	rs433402	chr9:136898627	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.59	-6.66	-0.4	1.98e-10	Platelet distribution width;
SARC	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg10207240	chr12:122356781	WDR66	-0.32	-5.59	-0.34	6.36e-8	Mean corpuscular volume;
SARC	cis	rs1865760	0.602	rs2157050	chr6:26020431	C/T	cg18357526	chr6:26021779	HIST1H4A	0.46	5.76	0.35	2.65e-8	Height;
SARC	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg08975724	chr8:8085496	FLJ10661	0.46	5.77	0.35	2.55e-8	Mood instability;
SARC	cis	rs10992471	0.580	rs7030920	chr9:95122952	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.49	-0.34	1.06e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg04317338	chr11:64019027	PLCB3	0.84	9.15	0.51	2.99e-17	Mean platelet volume;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg14963812	chr3:15251896	CAPN7	0.47	6.67	0.4	1.87e-10	Thyroid stimulating hormone;
SARC	cis	rs13082711	0.554	rs674798	chr3:27332302	G/T	cg02860705	chr3:27208620	NA	0.47	6.26	0.38	1.86e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	12.37	0.63	2.38e-27	Chronic sinus infection;
SARC	cis	rs11638352	1.000	rs2957581	chr15:44410082	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.77	-5.83	-0.36	1.82e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg25036284	chr2:26402008	FAM59B	0.46	5.7	0.35	3.59e-8	Gut microbiome composition (summer);
SARC	cis	rs7447927	0.950	rs13153461	chr5:138852369	G/A	cg26929925	chr5:138714136	SLC23A1	0.43	5.7	0.35	3.57e-8	Esophageal squamous cell carcinoma;
SARC	cis	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg15556689	chr8:8085844	FLJ10661	0.43	5.1	0.32	7.09e-7	Mood instability;
SARC	cis	rs73206853	0.688	rs73191809	chr12:110907639	T/A	cg10860002	chr12:110842031	ANAPC7	0.67	5.13	0.32	6.07e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg12463550	chr7:65579703	CRCP	0.5	5.9	0.36	1.27e-8	Aortic root size;
SARC	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg15921436	chr17:44337874	NA	0.54	5.36	0.33	2.02e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg03060546	chr3:49711283	APEH	-0.63	-7.48	-0.44	1.51e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs4430311	0.622	rs10927060	chr1:243875989	A/G	cg21452805	chr1:244014465	NA	-0.44	-5.71	-0.35	3.37e-8	Post-traumatic stress disorder (asjusted for relatedness);
SARC	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg11890956	chr21:40555474	PSMG1	-0.7	-9.13	-0.51	3.28e-17	Menarche (age at onset);
SARC	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg22875332	chr1:76189707	ACADM	0.5	7.17	0.42	1.01e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6570726	0.791	rs441290	chr6:145883183	A/G	cg23711669	chr6:146136114	FBXO30	0.77	12.3	0.63	3.91e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1190552	0.846	rs4906212	chr14:102981595	A/G	cg10241871	chr14:102965420	TECPR2	0.42	4.91	0.31	1.75e-6	Blood protein levels;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg27571351	chr10:17619364	NA	0.47	6.56	0.39	3.37e-10	Breast cancer;
SARC	cis	rs4689388	0.853	rs13103357	chr4:6294544	A/G	cg00701064	chr4:6280414	WFS1	0.54	8.58	0.49	1.38e-15	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs3126085	0.935	rs4534386	chr1:152251714	A/G	cg03465714	chr1:152285911	FLG	-0.46	-5.55	-0.34	7.61e-8	Atopic dermatitis;
SARC	cis	rs6121246	0.529	rs6060171	chr20:30183269	C/T	cg21427119	chr20:30132790	HM13	-0.48	-5.27	-0.33	3.16e-7	Mean corpuscular hemoglobin;
SARC	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg12311346	chr5:56204834	C5orf35	-0.57	-5.94	-0.36	1.02e-8	Initial pursuit acceleration;
SARC	cis	rs514406	0.505	rs269293	chr1:53187767	A/C	cg24675658	chr1:53192096	ZYG11B	-0.65	-9.6	-0.53	1.36e-18	Monocyte count;
SARC	cis	rs75920871	0.588	rs7119185	chr11:116886096	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.49	-5.01	-0.31	1.05e-6	Subjective well-being;
SARC	cis	rs4727027	0.727	rs1568944	chr7:148873497	A/T	cg23583168	chr7:148888333	NA	-0.73	-9.54	-0.53	1.97e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs9790314	0.690	rs6783085	chr3:160830929	A/G	cg03342759	chr3:160939853	NMD3	-0.57	-7.22	-0.43	7.37e-12	Morning vs. evening chronotype;
SARC	cis	rs11700980	0.636	rs61735765	chr21:30255347	C/A	cg24692254	chr21:30365293	RNF160	-0.65	-4.92	-0.31	1.61e-6	QRS complex (12-leadsum);
SARC	cis	rs9303401	0.614	rs12948536	chr17:56580413	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.05	11.45	0.6	2.24e-24	Cognitive test performance;
SARC	cis	rs35110281	0.782	rs1454651	chr21:45012476	A/G	cg01579765	chr21:45077557	HSF2BP	-0.36	-6.03	-0.37	6.31e-9	Mean corpuscular volume;
SARC	cis	rs13401104	0.796	rs1349754	chr2:237119714	G/C	cg19324714	chr2:237145437	ASB18	0.57	5.93	0.36	1.1e-8	Educational attainment;
SARC	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg13175981	chr1:150552382	MCL1	-0.48	-5.97	-0.36	8.78e-9	Tonsillectomy;
SARC	cis	rs240764	0.635	rs12664707	chr6:100919579	A/C	cg09795085	chr6:101329169	ASCC3	-0.4	-4.93	-0.31	1.54e-6	Neuroticism;
SARC	cis	rs1971762	0.583	rs1527068	chr12:54088688	A/G	cg06632207	chr12:54070931	ATP5G2	0.43	5.7	0.35	3.6e-8	Height;
SARC	cis	rs57502260	0.704	rs72936570	chr11:68307139	A/G	cg20283391	chr11:68216788	NA	-0.54	-4.85	-0.3	2.23e-6	Total body bone mineral density (age 45-60);
SARC	cis	rs6058796	1.000	rs6087409	chr20:31257552	A/G	cg13636640	chr20:31349939	DNMT3B	0.56	4.94	0.31	1.48e-6	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg08280861	chr8:58055591	NA	0.57	5.1	0.32	6.94e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs950027	0.620	rs1719245	chr15:45623782	T/C	cg26924012	chr15:45694286	SPATA5L1	0.51	6.47	0.39	5.74e-10	Response to fenofibrate (adiponectin levels);
SARC	cis	rs2070488	0.930	rs928813	chr3:38528537	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	13.62	0.67	1.79e-31	Electrocardiographic conduction measures;
SARC	cis	rs78456975	1.000	rs28742145	chr2:1562671	T/C	cg01028140	chr2:1542097	TPO	-0.5	-4.97	-0.31	1.3e-6	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs796364	0.806	rs10445792	chr2:201078821	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-5.91	-0.36	1.21e-8	Schizophrenia;
SARC	cis	rs12995491	0.933	rs13023008	chr2:88530933	G/A	cg04511125	chr2:88470314	THNSL2	-0.39	-5.73	-0.35	3.04e-8	Response to metformin (IC50);
SARC	cis	rs926392	0.896	rs7268772	chr20:37684501	A/G	cg16355469	chr20:37678765	NA	0.58	7.48	0.44	1.52e-12	Dialysis-related mortality;
SARC	cis	rs2072499	0.966	rs6427304	chr1:156156789	A/G	cg24450063	chr1:156163899	SLC25A44	1.15	20.02	0.8	1.55e-52	Testicular germ cell tumor;
SARC	cis	rs4836694	0.574	rs67899211	chr9:132935614	G/A	cg05251000	chr9:132935664	FREQ	0.39	5.19	0.32	4.68e-7	Alzheimer's disease (cognitive decline);
SARC	cis	rs832540	0.830	rs252907	chr5:56120646	G/A	cg14703610	chr5:56206110	C5orf35	0.5	6.16	0.37	3.1e-9	Coronary artery disease;
SARC	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg23172400	chr8:95962367	TP53INP1	-0.31	-5.36	-0.33	2.02e-7	Type 2 diabetes;
SARC	cis	rs6696846	0.791	rs7520752	chr1:205054114	C/T	cg00857998	chr1:205179979	DSTYK	-0.48	-6.23	-0.38	2.19e-9	Red blood cell count;
SARC	cis	rs3008870	0.785	rs10889651	chr1:67463513	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.59	-7.48	-0.44	1.54e-12	Lymphocyte percentage of white cells;
SARC	cis	rs5167	0.504	rs7257476	chr19:45453165	C/T	cg09555818	chr19:45449301	APOC2	0.56	8.96	0.51	1.05e-16	Blood protein levels;
SARC	cis	rs4268898	0.560	rs78711174	chr2:24496531	G/A	cg26838691	chr2:24397539	C2orf84	-0.5	-5.66	-0.35	4.46e-8	Asthma;
SARC	cis	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg12463550	chr7:65579703	CRCP	0.66	5.04	0.31	9.57e-7	Gout;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg16714616	chr20:40247229	CHD6	-0.94	-8.16	-0.47	2.03e-14	Autism spectrum disorder or schizophrenia;
SARC	cis	rs10046574	0.764	rs56257080	chr7:135128104	A/C	cg27474649	chr7:135195673	CNOT4	0.8	6.48	0.39	5.52e-10	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs10089	0.552	rs56718459	chr5:127546214	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.61	6.56	0.39	3.41e-10	Ileal carcinoids;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg20474699	chr14:102976161	ANKRD9	0.54	6.67	0.4	1.83e-10	Breast cancer;
SARC	cis	rs910316	0.789	rs175457	chr14:75584507	C/T	cg23033748	chr14:75592666	NEK9	-0.35	-4.83	-0.3	2.51e-6	Height;
SARC	cis	rs13256369	1.000	rs13256369	chr8:8577379	T/C	cg18904891	chr8:8559673	CLDN23	0.48	5.52	0.34	8.89e-8	Obesity-related traits;
SARC	trans	rs61931739	0.890	rs694706	chr12:34135323	T/C	cg26384229	chr12:38710491	ALG10B	0.58	7.84	0.46	1.65e-13	Morning vs. evening chronotype;
SARC	cis	rs17384381	1.000	rs17384381	chr1:85897570	C/G	cg16011679	chr1:85725395	C1orf52	0.62	5.95	0.36	9.64e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7584330	0.744	rs72620822	chr2:238379582	C/T	cg11271282	chr2:238384023	NA	0.5	5.11	0.32	6.82e-7	Prostate cancer;
SARC	cis	rs6120849	0.754	rs6120797	chr20:33606002	G/A	cg06115741	chr20:33292138	TP53INP2	0.54	5.16	0.32	5.3e-7	Protein C levels;
SARC	cis	rs644799	0.687	rs3748252	chr11:95519195	A/T	cg25478527	chr11:95522999	CEP57;FAM76B	-0.56	-7.4	-0.44	2.42e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs10911232	0.507	rs9787327	chr1:182978459	A/G	cg13390022	chr1:182993471	LAMC1	0.33	5.06	0.31	8.36e-7	Hypertriglyceridemia;
SARC	cis	rs7931462	0.655	rs6483208	chr11:92705844	A/C	cg19185133	chr11:93474120	C11orf54;TAF1D	0.63	4.97	0.31	1.28e-6	DNA methylation (parent-of-origin);
SARC	cis	rs7927592	0.913	rs7118897	chr11:68360680	G/A	cg01657329	chr11:68192670	LRP5	-0.42	-5.01	-0.31	1.06e-6	Total body bone mineral density;
SARC	cis	rs11638352	1.000	rs2615287	chr15:44415993	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.77	-5.84	-0.36	1.78e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	trans	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg07211511	chr3:129823064	LOC729375	-0.62	-6.7	-0.4	1.55e-10	Blood pressure (smoking interaction);
SARC	trans	rs2018683	0.707	rs7799357	chr7:28970118	A/G	cg19402173	chr7:128379420	CALU	-0.52	-6.81	-0.41	8.23e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs1691799	0.836	rs1168334	chr12:66760972	A/G	cg16791601	chr12:66731901	HELB	-0.71	-10.79	-0.58	2.86e-22	White blood cell count (basophil);
SARC	cis	rs6831352	0.918	rs13110176	chr4:100062430	C/T	cg12011299	chr4:100065546	ADH4	0.36	5.85	0.36	1.65e-8	Alcohol dependence;
SARC	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-15.56	-0.71	6.72e-38	Chronic sinus infection;
SARC	cis	rs9896052	0.533	rs7406173	chr17:73454563	G/A	cg04121983	chr17:73511085	CASKIN2	0.44	5.01	0.31	1.06e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs7566780	0.694	rs1430055	chr2:16680789	C/T	cg09580478	chr2:16689509	NA	0.42	6.02	0.37	6.7e-9	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs9902453	0.967	rs7212741	chr17:28322941	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	6.86	0.41	6.11e-11	Coffee consumption (cups per day);
SARC	cis	rs2933343	0.729	rs1680780	chr3:128612659	G/C	cg25356066	chr3:128598488	ACAD9	0.74	9.72	0.54	5.9e-19	IgG glycosylation;
SARC	cis	rs7772486	0.790	rs9403749	chr6:146162239	A/G	cg23711669	chr6:146136114	FBXO30	0.9	15.44	0.71	1.66e-37	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7927771	0.800	rs12146565	chr11:47398963	G/A	cg20307385	chr11:47447363	PSMC3	-0.56	-7.04	-0.42	2.12e-11	Subjective well-being;
SARC	trans	rs3808502	0.503	rs34190028	chr8:11417150	G/T	cg06636001	chr8:8085503	FLJ10661	-0.66	-9.32	-0.52	9.31e-18	Neuroticism;
SARC	cis	rs6484504	0.576	rs2616792	chr11:31324298	T/G	cg26647111	chr11:31128758	NA	0.39	5.0	0.31	1.11e-6	Red blood cell count;
SARC	cis	rs7520050	0.966	rs1707340	chr1:46514942	T/C	cg06784218	chr1:46089804	CCDC17	-0.28	-5.08	-0.32	7.58e-7	Red blood cell count;Reticulocyte count;
SARC	cis	rs2204008	0.640	rs11520199	chr12:38211026	T/C	cg26384229	chr12:38710491	ALG10B	0.88	12.94	0.65	3.26e-29	Bladder cancer;
SARC	cis	rs11785400	0.793	rs4736367	chr8:143742477	G/A	cg24634471	chr8:143751801	JRK	0.59	7.45	0.44	1.83e-12	Schizophrenia;
SARC	cis	rs36715	1.000	rs251213	chr5:127545605	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	7.19	0.43	8.57e-12	Breast cancer;
SARC	cis	rs6088813	0.925	rs4353719	chr20:33977349	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	-0.45	-5.39	-0.33	1.71e-7	Height;
SARC	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg15448220	chr1:150897856	SETDB1	0.47	6.25	0.38	1.94e-9	Tonsillectomy;
SARC	cis	rs72781680	1.000	rs7581107	chr2:24173565	C/T	cg08917208	chr2:24149416	ATAD2B	0.79	7.54	0.44	1.05e-12	Lymphocyte counts;
SARC	cis	rs36051895	0.632	rs7047795	chr9:5181467	C/T	cg02405213	chr9:5042618	JAK2	-0.43	-4.96	-0.31	1.34e-6	Pediatric autoimmune diseases;
SARC	cis	rs4836694	0.517	rs1017112	chr9:132936804	A/G	cg05251000	chr9:132935664	FREQ	0.38	4.93	0.31	1.59e-6	Alzheimer's disease (cognitive decline);
SARC	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.45	-5.59	-0.34	6.28e-8	Systemic lupus erythematosus;
SARC	cis	rs4803468	1.000	rs878082	chr19:41897674	G/A	cg08477640	chr19:41863820	B9D2	0.43	5.52	0.34	9.2e-8	Height;
SARC	cis	rs6459788	0.585	rs6950818	chr7:157235364	C/G	cg03453431	chr7:157225567	NA	-0.5	-7.54	-0.44	1.06e-12	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	trans	rs629535	0.679	rs62511660	chr8:70157089	G/A	cg21567404	chr3:27674614	NA	-0.92	-9.79	-0.54	3.53e-19	Dupuytren's disease;
SARC	cis	rs9467711	0.606	rs2235251	chr6:26431982	C/T	cg12826209	chr6:26865740	GUSBL1	0.8	4.91	0.31	1.73e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs57506017	0.585	rs6460898	chr7:12252893	A/G	cg23422036	chr7:12250390	TMEM106B	0.49	6.49	0.39	5.19e-10	Neuroticism;
SARC	cis	rs10794720	0.867	rs78029387	chr10:1138589	C/T	cg08668510	chr10:1095578	IDI1	0.84	5.04	0.31	9.54e-7	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;
SARC	cis	rs6933660	0.646	rs6911456	chr6:151778934	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.78	11.29	0.59	7.44e-24	Menarche (age at onset);
SARC	cis	rs10492096	0.947	rs61918020	chr12:6605514	C/T	cg13857086	chr12:6580257	VAMP1	0.69	6.85	0.41	6.6e-11	Hip geometry;
SARC	trans	rs561341	1.000	rs15654	chr17:30326360	A/C	cg20587970	chr11:113659929	NA	-1.34	-13.79	-0.67	4.87e-32	Hip circumference adjusted for BMI;
SARC	cis	rs6964587	0.773	rs62467797	chr7:91889722	G/A	cg17063962	chr7:91808500	NA	0.92	12.8	0.64	8.92e-29	Breast cancer;
SARC	cis	rs62344088	1.000	rs6898413	chr5:173927	A/C	cg20965017	chr5:231967	SDHA	-0.85	-5.79	-0.35	2.26e-8	Asthma (childhood onset);
SARC	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg25894440	chr7:65020034	NA	-0.72	-5.46	-0.34	1.2e-7	Diabetic kidney disease;
SARC	cis	rs826838	0.616	rs4418873	chr12:38625473	C/A	cg26384229	chr12:38710491	ALG10B	0.6	7.81	0.46	1.9e-13	Heart rate;
SARC	cis	rs3818285	0.556	rs944966	chr10:111658334	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.52	-6.83	-0.41	7.38e-11	Superior crus of antihelix expression;
SARC	cis	rs67460515	0.563	rs34630898	chr3:160827038	A/G	cg03342759	chr3:160939853	NMD3	-0.62	-7.49	-0.44	1.46e-12	Parkinson's disease;
SARC	cis	rs6793245	0.810	rs9843500	chr3:38588095	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.47	-5.42	-0.33	1.47e-7	QT interval;
SARC	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.72	7.12	0.42	1.31e-11	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs8067545	0.750	rs4925080	chr17:19991838	T/A	cg13482628	chr17:19912719	NA	0.56	7.3	0.43	4.57e-12	Schizophrenia;
SARC	cis	rs12754538	0.648	rs7524437	chr1:8856603	A/G	cg13785123	chr1:8931135	ENO1	-0.51	-6.15	-0.37	3.27e-9	Subjective well-being;
SARC	cis	rs765787	0.505	rs11630884	chr15:45532246	C/T	cg24006582	chr15:45444508	DUOX1	-0.56	-7.49	-0.44	1.4e-12	Uric acid levels;
SARC	trans	rs9325144	0.647	rs17518186	chr12:38883665	T/C	cg23762105	chr12:34175262	ALG10	0.49	6.41	0.39	7.87e-10	Morning vs. evening chronotype;
SARC	cis	rs7659604	0.540	rs10024878	chr4:122665451	C/G	cg19671926	chr4:122722719	EXOSC9	0.54	6.69	0.4	1.6e-10	Type 2 diabetes;
SARC	cis	rs644799	0.511	rs1016030	chr11:95472693	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.54	6.45	0.39	6.29e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg25427524	chr10:38739819	LOC399744	-0.53	-8.32	-0.48	7.33e-15	Extrinsic epigenetic age acceleration;
SARC	cis	rs3126085	0.935	rs11204943	chr1:152203906	A/C	cg26876637	chr1:152193138	HRNR	0.46	5.37	0.33	1.88e-7	Atopic dermatitis;
SARC	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg18252515	chr7:66147081	NA	-0.44	-4.75	-0.3	3.5e-6	Aortic root size;
SARC	cis	rs2439831	1.000	rs7173487	chr15:43750239	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.75	6.99	0.42	2.8e-11	Lung cancer in ever smokers;
SARC	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg11987759	chr7:65425863	GUSB	-0.47	-6.27	-0.38	1.7e-9	Aortic root size;
SARC	cis	rs9291683	0.588	rs35438220	chr4:9999398	C/T	cg00071950	chr4:10020882	SLC2A9	0.39	6.11	0.37	4.06e-9	Bone mineral density;
SARC	cis	rs6912958	0.754	rs10755484	chr6:88244648	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.42	-0.33	1.52e-7	Monocyte percentage of white cells;
SARC	cis	rs7818688	0.697	rs3802192	chr8:95987471	C/T	cg13393036	chr8:95962371	TP53INP1	0.39	4.77	0.3	3.24e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs2425143	0.908	rs58448091	chr20:34325470	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-5.62	-0.35	5.31e-8	Blood protein levels;
SARC	cis	rs2075371	1.000	rs2544213	chr7:133982867	G/C	cg20476274	chr7:133979776	SLC35B4	0.63	8.69	0.49	6.33e-16	Mean platelet volume;
SARC	cis	rs11105298	0.891	rs11105312	chr12:89920733	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.53	-5.33	-0.33	2.3e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs2228479	0.541	rs9922515	chr16:89954138	G/C	cg06558623	chr16:89946397	TCF25	0.72	6.36	0.38	1.06e-9	Skin colour saturation;
SARC	cis	rs72781680	0.716	rs6718631	chr2:24036086	A/G	cg06627628	chr2:24431161	ITSN2	0.53	5.54	0.34	8.29e-8	Lymphocyte counts;
SARC	cis	rs11191193	0.710	rs10883701	chr10:103747138	G/A	cg15320455	chr10:103880129	LDB1	0.57	5.93	0.36	1.09e-8	Educational attainment;
SARC	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg13395646	chr4:1353034	KIAA1530	-0.52	-6.19	-0.38	2.7e-9	Obesity-related traits;
SARC	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-4.79	-0.3	2.95e-6	Total body bone mineral density;
SARC	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg11890956	chr21:40555474	PSMG1	1.18	19.81	0.79	7.29e-52	Cognitive function;
SARC	cis	rs8031584	0.541	rs2955797	chr15:31210981	A/G	cg08109568	chr15:31115862	NA	0.43	5.75	0.35	2.82e-8	Huntington's disease progression;
SARC	cis	rs477692	0.699	rs578932	chr10:131370724	C/A	cg05714579	chr10:131428358	MGMT	0.57	7.3	0.43	4.38e-12	Response to temozolomide;
SARC	cis	rs2658782	0.789	rs56091149	chr11:93073640	A/C	cg15737290	chr11:93063684	CCDC67	-0.73	-7.57	-0.44	8.84e-13	Pulmonary function decline;
SARC	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg26335602	chr6:28129616	ZNF389	0.54	5.96	0.36	9.19e-9	Depression;
SARC	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg05025164	chr4:1340916	KIAA1530	-0.45	-5.3	-0.33	2.7e-7	Obesity-related traits;
SARC	cis	rs9398803	0.651	rs4895813	chr6:126975786	G/T	cg19875578	chr6:126661172	C6orf173	0.63	8.72	0.5	5.35e-16	Male-pattern baldness;
SARC	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg24209194	chr3:40518798	ZNF619	0.66	7.95	0.46	8.01e-14	Renal cell carcinoma;
SARC	cis	rs6430585	0.528	rs309167	chr2:136669264	C/T	cg07169764	chr2:136633963	MCM6	1.02	13.4	0.66	9.47e-31	Corneal structure;
SARC	cis	rs883565	0.718	rs1112438	chr3:39152345	G/A	cg26331595	chr3:39149181	GORASP1;TTC21A	0.56	6.4	0.39	8.44e-10	Handedness;
SARC	cis	rs28374715	0.783	rs11635269	chr15:41570710	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.1	-17.3	-0.75	1.09e-43	Ulcerative colitis;
SARC	cis	rs67478160	0.609	rs6576003	chr14:104291330	C/A	cg01849466	chr14:104193079	ZFYVE21	-0.36	-4.91	-0.31	1.68e-6	Schizophrenia;
SARC	cis	rs34172651	0.917	rs8049667	chr16:24773524	G/A	cg04756594	chr16:24857601	SLC5A11	0.37	5.89	0.36	1.36e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7264396	0.635	rs6058344	chr20:34475038	A/G	cg12579300	chr20:34535607	PHF20	-0.41	-4.85	-0.3	2.31e-6	Total cholesterol levels;
SARC	cis	rs826838	0.616	rs7977357	chr12:38626008	C/G	cg14851346	chr12:38532713	NA	-0.44	-5.32	-0.33	2.39e-7	Heart rate;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg06973293	chr4:77135005	SCARB2	0.49	6.49	0.39	5.17e-10	Thyroid stimulating hormone;
SARC	cis	rs1448094	0.512	rs11117060	chr12:86250788	G/T	cg02569458	chr12:86230093	RASSF9	-0.38	-5.25	-0.33	3.35e-7	Major depressive disorder;
SARC	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg03806693	chr22:41940476	POLR3H	-0.94	-13.09	-0.65	1.01e-29	Vitiligo;
SARC	cis	rs9660180	0.967	rs12040325	chr1:1702436	G/A	cg13866156	chr1:1669148	SLC35E2	-0.62	-9.22	-0.52	1.82e-17	Body mass index;
SARC	cis	rs6580649	1.000	rs10783227	chr12:48400617	C/T	cg24011408	chr12:48396354	COL2A1	0.53	6.01	0.37	6.97e-9	Lung cancer;
SARC	cis	rs7429990	0.803	rs11714518	chr3:48156635	T/C	cg11946769	chr3:48343235	NME6	-0.46	-5.46	-0.34	1.24e-7	Educational attainment (years of education);
SARC	cis	rs7044106	0.791	rs10984997	chr9:123481206	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	9.43	0.53	4.3e-18	Hip circumference adjusted for BMI;
SARC	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg05872129	chr22:39784769	NA	-0.42	-5.96	-0.36	9.07e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7766436	0.845	rs1342207	chr6:22587762	G/A	cg13666174	chr6:22585274	NA	-0.61	-7.9	-0.46	1.12e-13	Coronary artery disease;
SARC	cis	rs372883	0.613	rs1153289	chr21:30686212	G/T	cg08807101	chr21:30365312	RNF160	-0.59	-7.54	-0.44	1.07e-12	Pancreatic cancer;
SARC	cis	rs4253772	0.637	rs8135997	chr22:46651366	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.64	6.81	0.41	8.27e-11	LDL cholesterol;Cholesterol, total;
SARC	cis	rs523522	0.962	rs12814055	chr12:120987391	G/A	cg12219531	chr12:120966889	COQ5	0.83	11.21	0.59	1.28e-23	High light scatter reticulocyte count;
SARC	cis	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg03213289	chr20:61660250	NA	0.46	6.43	0.39	7.22e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs9457247	0.967	rs1187532	chr6:167382020	G/A	cg23791538	chr6:167370224	RNASET2	-0.63	-8.74	-0.5	4.81e-16	Crohn's disease;
SARC	cis	rs34172651	0.917	rs7204281	chr16:24784475	C/T	cg00339695	chr16:24857497	SLC5A11	0.32	5.14	0.32	5.75e-7	Intelligence (multi-trait analysis);
SARC	cis	rs780094	0.585	rs3739095	chr2:27556721	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.31	-4.96	-0.31	1.38e-6	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg00800038	chr16:89945340	TCF25	-0.76	-5.12	-0.32	6.35e-7	Skin colour saturation;
SARC	trans	rs1814175	0.645	rs28634872	chr11:50042175	T/A	cg03929089	chr4:120376271	NA	-0.83	-11.84	-0.61	1.24e-25	Height;
SARC	cis	rs208520	0.955	rs12216176	chr6:67005130	G/T	cg07460842	chr6:66804631	NA	0.86	9.68	0.54	7.47e-19	Exhaled nitric oxide output;
SARC	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg16606324	chr3:10149918	C3orf24	0.48	4.75	0.3	3.56e-6	Alzheimer's disease;
SARC	cis	rs9329221	0.620	rs6601427	chr8:10156025	A/G	cg27411982	chr8:10470053	RP1L1	-0.34	-5.92	-0.36	1.17e-8	Neuroticism;
SARC	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg18357526	chr6:26021779	HIST1H4A	0.46	5.89	0.36	1.34e-8	Blood metabolite levels;
SARC	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg27572855	chr1:25598939	RHD	0.56	9.69	0.54	7.1e-19	Erythrocyte sedimentation rate;
SARC	trans	rs17685	0.712	rs11770149	chr7:75791644	G/A	cg19862616	chr7:65841803	NCRNA00174	0.6	7.43	0.44	2.09e-12	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg20887711	chr4:1340912	KIAA1530	0.41	4.74	0.3	3.79e-6	Obesity-related traits;
SARC	cis	rs6430585	0.528	rs75753154	chr2:136665711	T/C	cg07169764	chr2:136633963	MCM6	1.06	16.23	0.73	3.95e-40	Corneal structure;
SARC	cis	rs3806843	0.676	rs778594	chr5:140027304	T/C	cg16577123	chr5:140027231	NDUFA2;IK	-0.46	-5.33	-0.33	2.27e-7	Depressive symptoms (multi-trait analysis);
SARC	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg14343924	chr8:8086146	FLJ10661	-0.39	-4.76	-0.3	3.33e-6	Mood instability;
SARC	cis	rs3091242	0.900	rs35345536	chr1:25766488	A/G	cg02931644	chr1:25747376	RHCE	0.43	6.99	0.42	2.89e-11	Erythrocyte sedimentation rate;
SARC	cis	rs3799379	0.550	rs9467736	chr6:26380032	A/G	cg12826209	chr6:26865740	GUSBL1	0.51	5.56	0.34	7.2e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2658782	0.950	rs2446061	chr11:93149277	C/T	cg15737290	chr11:93063684	CCDC67	0.71	7.57	0.44	8.4e-13	Pulmonary function decline;
SARC	cis	rs4975709	0.610	rs6886669	chr5:1867830	T/C	cg12288994	chr5:1860383	NA	0.35	5.64	0.35	4.85e-8	Cardiovascular disease risk factors;
SARC	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.75	7.2	0.43	8.46e-12	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs526821	0.574	rs11230156	chr11:55334809	A/G	cg04317927	chr11:55418816	OR4S2	0.41	6.08	0.37	4.98e-9	Pediatric bone mineral density (spine);
SARC	cis	rs72781680	0.784	rs72798406	chr2:24180144	T/C	cg08917208	chr2:24149416	ATAD2B	0.58	6.01	0.37	7.09e-9	Lymphocyte counts;
SARC	cis	rs6951245	0.507	rs10227709	chr7:1180515	T/G	cg24642844	chr7:1081250	C7orf50	-0.37	-4.89	-0.3	1.9e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs12973672	1.000	rs8101606	chr19:35774556	A/C	cg12095397	chr19:35769544	USF2	0.38	5.16	0.32	5.26e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs763121	0.962	rs138703	chr22:39132748	C/T	cg21395723	chr22:39101663	GTPBP1	0.43	5.04	0.31	9.54e-7	Menopause (age at onset);
SARC	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg13877915	chr19:58951672	ZNF132	0.63	9.35	0.52	7.26e-18	Uric acid clearance;
SARC	cis	rs477895	1.000	rs34292685	chr11:64049021	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	6.12	0.37	4.02e-9	Mean platelet volume;
SARC	cis	rs12142240	0.628	rs56126529	chr1:46808860	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-5.45	-0.34	1.28e-7	Menopause (age at onset);
SARC	cis	rs2354432	0.607	rs9661159	chr1:146757923	G/A	cg25205988	chr1:146714368	CHD1L	-1.0	-7.56	-0.44	9.4e-13	Mitochondrial DNA levels;
SARC	cis	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg18252515	chr7:66147081	NA	1.43	12.98	0.65	2.35e-29	Gout;
SARC	cis	rs10461617	0.512	rs7715746	chr5:56048837	C/T	cg24549020	chr5:56110836	MAP3K1	0.68	7.54	0.44	1.05e-12	Type 2 diabetes;
SARC	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2180341	0.842	rs7739679	chr6:127545428	G/A	cg24812749	chr6:127587940	RNF146	0.96	10.94	0.58	9.28e-23	Breast cancer;
SARC	cis	rs17401966	0.894	rs11587309	chr1:10446596	G/T	cg15208524	chr1:10270712	KIF1B	0.51	6.11	0.37	4.05e-9	Hepatocellular carcinoma;
SARC	cis	rs1865760	0.566	rs9295688	chr6:26084217	G/A	cg16482183	chr6:26056742	HIST1H1C	0.47	5.91	0.36	1.22e-8	Height;
SARC	cis	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.45	-5.7	-0.35	3.56e-8	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs9393692	0.875	rs2142703	chr6:26289605	A/G	cg13736514	chr6:26305472	NA	-0.63	-8.83	-0.5	2.64e-16	Educational attainment;
SARC	cis	rs5167	0.504	rs4803781	chr19:45459671	C/T	cg13119609	chr19:45449297	APOC2	0.54	9.26	0.52	1.42e-17	Blood protein levels;
SARC	cis	rs11225247	0.772	rs34104132	chr11:102232160	T/G	cg11690896	chr11:102217788	BIRC2	0.72	5.19	0.32	4.65e-7	Vein graft stenosis in coronary artery bypass grafting;
SARC	cis	rs7945705	0.719	rs2012680	chr11:8996059	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-7.04	-0.42	2.17e-11	Hemoglobin concentration;
SARC	cis	rs2916247	1.000	rs6986808	chr8:93024393	A/C	cg10183463	chr8:93005414	RUNX1T1	-0.58	-6.16	-0.37	3.17e-9	Intelligence (multi-trait analysis);
SARC	cis	rs9815354	1.000	rs2128834	chr3:41862645	A/G	cg03022575	chr3:42003672	ULK4	0.6	5.74	0.35	2.87e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6582630	0.502	rs7311700	chr12:38463232	T/A	cg13010199	chr12:38710504	ALG10B	0.77	10.35	0.56	6.77e-21	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs72945132	0.882	rs11235739	chr11:70132780	C/T	cg05964544	chr11:70165517	PPFIA1	-0.56	-5.53	-0.34	8.56e-8	Coronary artery disease;
SARC	cis	rs35110281	0.744	rs8131027	chr21:45104908	G/C	cg21573476	chr21:45109991	RRP1B	-0.55	-7.76	-0.45	2.59e-13	Mean corpuscular volume;
SARC	cis	rs9300255	0.602	rs1716160	chr12:123700225	C/T	cg00376283	chr12:123451042	ABCB9	0.55	6.53	0.39	4.09e-10	Neutrophil percentage of white cells;
SARC	cis	rs2762353	0.526	rs12215823	chr6:25726074	G/C	cg17691542	chr6:26056736	HIST1H1C	0.45	5.6	0.34	6.09e-8	Blood metabolite levels;
SARC	cis	rs10504073	0.609	rs17644494	chr8:50019679	T/C	cg00325661	chr8:49890786	NA	0.5	6.87	0.41	5.8200000000000003e-11	Blood metabolite ratios;
SARC	cis	rs9757252	0.580	rs7649317	chr3:86964949	C/T	cg12894142	chr3:86979205	NA	0.31	4.81	0.3	2.68e-6	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs2070997	0.702	rs3780284	chr9:133733961	A/G	cg11464064	chr9:133710261	ABL1	0.57	5.12	0.32	6.31e-7	Response to amphetamines;
SARC	cis	rs11690935	0.632	rs62184165	chr2:172558328	A/G	cg13550731	chr2:172543902	DYNC1I2	0.65	9.18	0.52	2.37e-17	Schizophrenia;
SARC	cis	rs9640161	0.830	rs17173682	chr7:150059602	A/G	cg21361702	chr7:150065534	REPIN1	0.61	7.27	0.43	5.37e-12	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.41	0.44	2.36e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2486288	0.656	rs1719236	chr15:45577783	G/T	cg21132104	chr15:45694354	SPATA5L1	-0.51	-5.98	-0.36	8.49e-9	Glomerular filtration rate;
SARC	cis	rs7944584	0.511	rs10838731	chr11:47607135	C/T	cg20307385	chr11:47447363	PSMC3	0.78	11.18	0.59	1.58e-23	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs1008375	0.931	rs4479701	chr4:17571496	G/A	cg27347728	chr4:17578864	LAP3	0.45	5.53	0.34	8.67e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7659604	1.000	rs35224452	chr4:122664677	C/T	cg19671926	chr4:122722719	EXOSC9	-0.49	-6.06	-0.37	5.48e-9	Type 2 diabetes;
SARC	cis	rs9549260	0.712	rs9532564	chr13:41160579	C/G	cg21288729	chr13:41239152	FOXO1	0.56	5.33	0.33	2.33e-7	Red blood cell count;
SARC	cis	rs10197940	0.662	rs10173699	chr2:152281561	C/G	cg19508488	chr2:152266495	RIF1	-0.51	-5.48	-0.34	1.08e-7	Lung cancer;
SARC	cis	rs910316	1.000	rs4903284	chr14:75592483	G/C	cg08847533	chr14:75593920	NEK9	0.91	15.37	0.71	2.71e-37	Height;
SARC	cis	rs986417	0.748	rs10136486	chr14:60946111	C/T	cg27398547	chr14:60952738	C14orf39	1.02	9.63	0.53	1.06e-18	Gut microbiota (bacterial taxa);
SARC	cis	rs9916302	0.706	rs57933226	chr17:37412829	C/T	cg07936489	chr17:37558343	FBXL20	-0.74	-8.82	-0.5	2.72e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs7512552	0.839	rs698916	chr1:150388385	A/G	cg15654264	chr1:150340011	RPRD2	0.39	4.94	0.31	1.51e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	trans	rs2727020	0.619	rs1829979	chr11:49436875	T/G	cg15704280	chr7:45808275	SEPT13	-0.71	-8.16	-0.47	2.03e-14	Coronary artery disease;
SARC	cis	rs137603	0.644	rs470082	chr22:39715140	C/T	cg01093212	chr22:39715156	SNORD43;RPL3	-0.52	-6.14	-0.37	3.49e-9	Primary biliary cholangitis;
SARC	cis	rs651907	0.557	rs11924013	chr3:101366698	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	6.42	0.39	7.42e-10	Colorectal cancer;
SARC	cis	rs7223966	1.000	rs11079509	chr17:61762148	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.53	-5.45	-0.34	1.26e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs240764	0.658	rs9390681	chr6:101218994	A/T	cg09795085	chr6:101329169	ASCC3	-0.44	-5.64	-0.35	4.9e-8	Neuroticism;
SARC	cis	rs1697139	0.583	rs6895853	chr5:66541427	T/C	cg11553311	chr5:66541588	NA	0.3	4.81	0.3	2.77e-6	Breast cancer;
SARC	cis	rs9291683	0.588	rs35866697	chr4:10018604	C/A	cg11266682	chr4:10021025	SLC2A9	0.41	7.37	0.43	2.9e-12	Bone mineral density;
SARC	cis	rs11585357	0.947	rs72646789	chr1:17610030	C/T	cg08277548	chr1:17600880	PADI3	-0.49	-5.34	-0.33	2.2e-7	Hair shape;
SARC	trans	rs7395662	0.591	rs11039776	chr11:48516706	G/A	cg15704280	chr7:45808275	SEPT13	-0.5	-6.77	-0.41	1.04e-10	HDL cholesterol;
SARC	cis	rs8072100	0.666	rs9913014	chr17:45460189	C/T	cg08085267	chr17:45401833	C17orf57	-0.44	-5.11	-0.32	6.82e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs17376456	0.825	rs17372057	chr5:93071916	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.73	6.87	0.41	5.77e-11	Diabetic retinopathy;
SARC	cis	rs854765	0.618	rs8066982	chr17:17851377	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.43	5.52	0.34	9.04e-8	Total body bone mineral density;
SARC	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg06713675	chr4:122721982	EXOSC9	-0.5	-6.59	-0.4	2.96e-10	Type 2 diabetes;
SARC	cis	rs12824058	0.831	rs4759657	chr12:130815818	G/A	cg26677194	chr12:130822605	PIWIL1	0.55	7.69	0.45	4.13e-13	Menopause (age at onset);
SARC	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg08888412	chr16:72127639	DHX38;TXNL4B	-0.49	-6.33	-0.38	1.23e-9	Thyroid cancer;
SARC	cis	rs61935443	0.720	rs892493	chr12:95283943	T/C	cg21533806	chr12:95267307	NA	0.71	8.6	0.49	1.19e-15	Schizophrenia;
SARC	cis	rs12142240	0.698	rs56063031	chr1:46825433	C/T	cg00530320	chr1:46809349	NSUN4	0.57	6.79	0.41	9.05e-11	Menopause (age at onset);
SARC	cis	rs12142240	0.698	rs1135459	chr1:46815930	C/T	cg10495392	chr1:46806563	NSUN4	0.65	6.83	0.41	7.25e-11	Menopause (age at onset);
SARC	cis	rs11509880	0.543	rs10950393	chr7:12263546	T/C	cg23422036	chr7:12250390	TMEM106B	0.49	6.41	0.39	8.02e-10	Coronary artery disease;
SARC	cis	rs9399135	0.967	rs17638970	chr6:135320063	A/G	cg24558204	chr6:135376177	HBS1L	0.45	6.11	0.37	4.1e-9	Red blood cell count;
SARC	cis	rs78487399	0.808	rs13431070	chr2:43721954	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.52	5.02	0.31	1.03e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs5753618	0.561	rs2073857	chr22:31658281	A/G	cg07713946	chr22:31675144	LIMK2	-0.37	-5.15	-0.32	5.57e-7	Colorectal cancer;
SARC	cis	rs7949030	0.596	rs11231138	chr11:62316195	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.45	6.71	0.4	1.48e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg01475735	chr3:40494733	NA	0.48	5.29	0.33	2.89e-7	Renal cell carcinoma;
SARC	cis	rs7666738	0.830	rs6854902	chr4:99033416	T/G	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs908922	0.584	rs10888500	chr1:152532749	G/A	cg09873164	chr1:152488093	CRCT1	0.6	7.71	0.45	3.7e-13	Hair morphology;
SARC	cis	rs8064299	0.967	rs878905	chr17:72769411	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.54	6.69	0.4	1.68e-10	Monocyte count;
SARC	trans	rs561341	1.000	rs508192	chr17:30315147	C/T	cg20587970	chr11:113659929	NA	1.29	13.27	0.66	2.53e-30	Hip circumference adjusted for BMI;
SARC	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg18305652	chr10:134549665	INPP5A	0.34	5.21	0.32	4.14e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs9457247	1.000	rs2769347	chr6:167371737	T/A	cg23791538	chr6:167370224	RNASET2	0.63	8.74	0.5	4.61e-16	Crohn's disease;
SARC	cis	rs501120	1.000	rs522293	chr10:44756703	G/A	cg09554077	chr10:44749378	NA	0.48	6.49	0.39	5.12e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs2204008	0.660	rs2874343	chr12:38239096	C/T	cg26384229	chr12:38710491	ALG10B	0.91	13.61	0.67	1.95e-31	Bladder cancer;
SARC	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16773899	chr5:83680326	EDIL3	0.44	6.26	0.38	1.86e-9	Parkinson's disease;
SARC	cis	rs4689388	0.926	rs4458523	chr4:6289986	G/T	cg00701064	chr4:6280414	WFS1	-0.57	-9.27	-0.52	1.3e-17	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs79149102	0.649	rs78315681	chr15:75098912	C/G	cg09165964	chr15:75287851	SCAMP5	-0.86	-4.93	-0.31	1.57e-6	Lung cancer;
SARC	cis	rs981844	0.666	rs7691303	chr4:154684198	T/C	cg14289246	chr4:154710475	SFRP2	-0.61	-7.18	-0.43	9.42e-12	Response to statins (LDL cholesterol change);
SARC	cis	rs3857536	0.740	rs7745163	chr6:66889936	A/G	cg07460842	chr6:66804631	NA	-0.6	-7.16	-0.42	1.02e-11	Blood trace element (Cu levels);
SARC	cis	rs9790314	0.659	rs13066683	chr3:160847410	A/G	cg04691961	chr3:161091175	C3orf57	-0.62	-8.47	-0.49	2.77e-15	Morning vs. evening chronotype;
SARC	cis	rs17666538	1.000	rs73177066	chr8:585750	C/T	cg19660806	chr8:588740	NA	-0.61	-4.82	-0.3	2.62e-6	IgG glycosylation;
SARC	cis	rs9443189	0.570	rs567903	chr6:76327851	C/T	cg01950844	chr6:76311363	SENP6	0.8	7.51	0.44	1.24e-12	Prostate cancer;
SARC	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg20607798	chr8:58055168	NA	0.61	5.41	0.33	1.57e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs33912345	0.669	rs1268619	chr14:60897631	G/A	cg27398547	chr14:60952738	C14orf39	-0.39	-4.82	-0.3	2.62e-6	Glaucoma (high intraocular pressure);
SARC	cis	rs6060717	0.536	rs11167279	chr20:34509107	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-5.72	-0.35	3.27e-8	Hip circumference adjusted for BMI;
SARC	cis	rs9790314	1.000	rs1382428	chr3:161032386	A/C	cg04691961	chr3:161091175	C3orf57	-0.79	-11.61	-0.61	7e-25	Morning vs. evening chronotype;
SARC	cis	rs11122272	0.735	rs2486733	chr1:231531465	C/T	cg06096015	chr1:231504339	EGLN1	0.38	5.7	0.35	3.54e-8	Hemoglobin concentration;
SARC	cis	rs72781680	0.898	rs17462670	chr2:24026579	T/C	cg06627628	chr2:24431161	ITSN2	-0.66	-6.27	-0.38	1.69e-9	Lymphocyte counts;
SARC	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9790314	0.704	rs4618258	chr3:160869129	G/C	cg04691961	chr3:161091175	C3orf57	-0.53	-6.8	-0.41	8.8e-11	Morning vs. evening chronotype;
SARC	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg18404041	chr3:52824283	ITIH1	-0.44	-6.7	-0.4	1.58e-10	Bipolar disorder;
SARC	cis	rs2304069	0.909	rs10038824	chr5:149369776	G/A	cg10852222	chr5:149380144	HMGXB3;TIGD6	-0.6	-5.92	-0.36	1.14e-8	HIV-1 control;
SARC	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg23985595	chr17:80112537	CCDC57	-0.32	-4.78	-0.3	3.08e-6	Life satisfaction;
SARC	cis	rs4974559	0.947	rs28540746	chr4:1352954	G/A	cg02980000	chr4:1222292	CTBP1	0.63	4.79	0.3	2.91e-6	Systolic blood pressure;
SARC	cis	rs1538970	1.000	rs4660853	chr1:45849090	C/T	cg05343316	chr1:45956843	TESK2	0.66	7.74	0.45	3.03e-13	Platelet count;
SARC	cis	rs875971	0.545	rs2420612	chr7:66001812	G/A	cg11764359	chr7:65958608	NA	0.63	6.11	0.37	4.11e-9	Aortic root size;
SARC	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs10506458	0.915	rs998506	chr12:63400017	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.77	-6.81	-0.41	8.36e-11	Hemostatic factors and hematological phenotypes;
SARC	cis	rs6964587	0.967	rs7783414	chr7:91785957	C/T	cg17063962	chr7:91808500	NA	0.97	17.15	0.75	3.53e-43	Breast cancer;
SARC	trans	rs61931739	0.929	rs1490110	chr12:34091605	A/G	cg26384229	chr12:38710491	ALG10B	-0.54	-7.21	-0.43	7.99e-12	Morning vs. evening chronotype;
SARC	cis	rs41271473	1.000	rs6701241	chr1:228868477	C/G	cg16512390	chr1:228756714	NA	0.5	4.99	0.31	1.19e-6	Chronic lymphocytic leukemia;
SARC	cis	rs11578119	0.933	rs72709774	chr1:170470628	A/C	cg09767346	chr1:170501363	GORAB	0.4	4.74	0.3	3.8e-6	Male-pattern baldness;
SARC	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg02788857	chr8:22132959	PIWIL2	0.34	4.8	0.3	2.83e-6	Hypertriglyceridemia;
SARC	cis	rs526231	0.511	rs45518833	chr5:102342990	T/C	cg23492399	chr5:102201601	PAM	-0.51	-5.77	-0.35	2.47e-8	Primary biliary cholangitis;
SARC	cis	rs7818345	1.000	rs7833166	chr8:19294634	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.38	5.2	0.32	4.38e-7	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs66887589	0.967	rs6844263	chr4:120433807	A/G	cg09307838	chr4:120376055	NA	0.53	7.32	0.43	4.09e-12	Diastolic blood pressure;
SARC	cis	rs4713118	0.539	rs200951	chr6:27835930	A/G	cg17221315	chr6:27791827	HIST1H4J	0.48	5.53	0.34	8.62e-8	Parkinson's disease;
SARC	cis	rs12477438	0.539	rs12999417	chr2:99865548	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.03	-19.9	-0.79	3.69e-52	Chronic sinus infection;
SARC	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg07701084	chr6:150067640	NUP43	0.39	5.15	0.32	5.56e-7	Lung cancer;
SARC	cis	rs9398803	0.661	rs9375449	chr6:126963807	T/C	cg20229609	chr6:126660872	C6orf173	0.37	5.39	0.33	1.74e-7	Male-pattern baldness;
SARC	cis	rs6088590	0.965	rs6058108	chr20:33288655	A/G	cg24642439	chr20:33292090	TP53INP2	0.87	12.82	0.64	7.89e-29	Coronary artery disease;
SARC	cis	rs2985684	1.000	rs1952012	chr14:50098896	T/A	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.47	4.91	0.31	1.69e-6	Carotid intima media thickness;
SARC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.5	0.57	2.27e-21	Prudent dietary pattern;
SARC	cis	rs12594515	1.000	rs11855509	chr15:45995474	C/T	cg14863074	chr15:45997064	NA	0.34	5.18	0.32	4.84e-7	Waist circumference;Weight;
SARC	trans	rs56279505	0.690	rs62305761	chr4:100286694	G/A	cg18024358	chr1:3420815	MEGF6	-0.79	-6.28	-0.38	1.61e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg10523679	chr1:76189770	ACADM	0.52	6.76	0.4	1.1e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg18252515	chr7:66147081	NA	-1.29	-11.43	-0.6	2.57e-24	Diabetic kidney disease;
SARC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.61	7.89	0.46	1.19e-13	Lymphocyte counts;
SARC	cis	rs240764	0.658	rs12202621	chr6:101220056	C/A	cg09795085	chr6:101329169	ASCC3	-0.44	-5.64	-0.35	4.9e-8	Neuroticism;
SARC	cis	rs72781680	1.000	rs17762782	chr2:24126493	A/G	cg06627628	chr2:24431161	ITSN2	-0.65	-6.25	-0.38	1.93e-9	Lymphocyte counts;
SARC	cis	rs67460515	0.527	rs34221255	chr3:160854123	T/C	cg03342759	chr3:160939853	NMD3	-0.58	-7.09	-0.42	1.59e-11	Parkinson's disease;
SARC	cis	rs400736	0.671	rs863171	chr1:7992615	A/G	cg25007680	chr1:8021821	PARK7	0.4	5.27	0.33	3.07e-7	Response to antidepressants and depression;
SARC	cis	rs67311347	1.000	rs897117	chr3:40437294	C/T	cg09455208	chr3:40491958	NA	-0.42	-6.65	-0.4	2.01e-10	Renal cell carcinoma;
SARC	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg21724239	chr8:58056113	NA	0.61	5.93	0.36	1.1e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2997447	0.846	rs12067677	chr1:26411971	C/T	cg19633962	chr1:26362018	EXTL1	-0.6	-5.76	-0.35	2.59e-8	QRS complex (12-leadsum);
SARC	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg06074448	chr4:187884817	NA	-0.37	-5.07	-0.32	8.2e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2576037	0.796	rs2571020	chr18:44584189	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.68	-9.85	-0.54	2.35e-19	Personality dimensions;
SARC	cis	rs6088580	0.634	rs6059835	chr20:33020141	A/G	cg24642439	chr20:33292090	TP53INP2	0.67	8.56	0.49	1.53e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs9325144	0.555	rs4882359	chr12:38726679	T/C	cg10518543	chr12:38710700	ALG10B	0.38	4.77	0.3	3.2e-6	Morning vs. evening chronotype;
SARC	cis	rs892961	0.899	rs72896162	chr17:75412521	A/G	cg05865280	chr17:75406074	SEPT9	0.57	8.47	0.48	2.87e-15	Airflow obstruction;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg25785679	chr19:49496701	GYS1;RUVBL2	0.51	6.91	0.41	4.66e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs7246657	0.943	rs9676967	chr19:37928089	G/C	cg23950597	chr19:37808831	NA	-0.57	-5.67	-0.35	4.24e-8	Coronary artery calcification;
SARC	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg16325326	chr1:53192061	ZYG11B	-0.9	-15.45	-0.71	1.53e-37	Monocyte count;
SARC	cis	rs8072100	0.790	rs34200664	chr17:45744652	C/T	cg08085267	chr17:45401833	C17orf57	0.41	4.85	0.3	2.22e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg13264159	chr8:625131	ERICH1	-0.61	-4.8	-0.3	2.84e-6	IgG glycosylation;
SARC	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.63	7.49	0.44	1.38e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9309473	1.000	rs10179134	chr2:73637519	A/G	cg20560298	chr2:73613845	ALMS1	-0.51	-6.14	-0.37	3.56e-9	Metabolite levels;
SARC	cis	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg25894440	chr7:65020034	NA	-0.74	-5.72	-0.35	3.18e-8	Diabetic kidney disease;
SARC	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	9.56	0.53	1.74e-18	Platelet count;
SARC	cis	rs7044106	0.791	rs4837792	chr9:123483559	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	6.22	0.38	2.33e-9	Hip circumference adjusted for BMI;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg26313233	chr2:114415511	NA	-0.56	-6.86	-0.41	6.23e-11	Height;
SARC	cis	rs10791097	0.629	rs11222361	chr11:130731424	T/G	cg09137382	chr11:130731461	NA	0.37	5.65	0.35	4.6e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs644799	0.965	rs602512	chr11:95561682	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	9.22	0.52	1.86e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7520050	0.902	rs4626927	chr1:46248645	C/T	cg24296786	chr1:45957014	TESK2	0.42	5.32	0.33	2.45e-7	Red blood cell count;Reticulocyte count;
SARC	cis	rs554111	0.660	rs1985278	chr1:21091861	G/T	cg04902671	chr1:21058625	SH2D5	0.48	5.66	0.35	4.39e-8	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg02475777	chr4:1388615	CRIPAK	-0.56	-6.35	-0.38	1.12e-9	Longevity;
SARC	cis	rs11792861	0.926	rs7870597	chr9:111871864	T/C	cg13535736	chr9:111863775	C9orf5	-0.4	-4.89	-0.31	1.87e-6	Menarche (age at onset);
SARC	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg23982607	chr1:1823379	GNB1	-0.65	-10.96	-0.58	8.46e-23	Body mass index;
SARC	cis	rs7772486	0.714	rs1883365	chr6:146076749	C/T	cg23711669	chr6:146136114	FBXO30	-0.8	-12.99	-0.65	2.13e-29	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg11987759	chr7:65425863	GUSB	0.43	5.52	0.34	8.84e-8	Aortic root size;
SARC	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg03060546	chr3:49711283	APEH	0.42	5.24	0.32	3.51e-7	Parkinson's disease;
SARC	cis	rs1878931	0.535	rs10852706	chr16:3412582	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.61	6.67	0.4	1.86e-10	Body mass index (adult);
SARC	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg24399712	chr22:39784796	NA	-0.44	-5.83	-0.36	1.83e-8	Intelligence (multi-trait analysis);
SARC	cis	rs4742903	0.509	rs12379563	chr9:106956786	G/A	cg14250997	chr9:106856677	SMC2	0.39	4.87	0.3	2.03e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs7644634	0.559	rs2301041	chr3:105429793	C/T	cg23051926	chr3:105466016	CBLB	0.47	5.33	0.33	2.27e-7	Itch intensity from mosquito bite;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg19257979	chr20:37101387	RALGAPB	-0.51	-6.3	-0.38	1.5e-9	Breast cancer;
SARC	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-15.32	-0.71	4.02e-37	Chronic sinus infection;
SARC	cis	rs763121	1.000	rs138464	chr22:38906432	C/T	cg21395723	chr22:39101663	GTPBP1	-0.51	-6.13	-0.37	3.79e-9	Menopause (age at onset);
SARC	trans	rs629535	0.734	rs659430	chr8:70009988	A/G	cg21567404	chr3:27674614	NA	0.9	12.4	0.63	1.9e-27	Dupuytren's disease;
SARC	cis	rs11770686	0.766	rs10954377	chr7:75337644	A/G	cg17787366	chr7:75369077	HIP1	0.43	5.38	0.33	1.81e-7	Essential tremor;
SARC	cis	rs2845885	0.793	rs3751120	chr11:63884453	C/T	cg05555928	chr11:63887634	MACROD1	-0.61	-6.49	-0.39	5.15e-10	Body mass index;
SARC	cis	rs17270561	0.609	rs7769908	chr6:25760539	G/A	cg17691542	chr6:26056736	HIST1H1C	0.57	7.0	0.42	2.78e-11	Iron status biomarkers;
SARC	cis	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg12463550	chr7:65579703	CRCP	0.69	5.24	0.32	3.57e-7	Diabetic kidney disease;
SARC	cis	rs4820539	1.000	rs5759598	chr22:23480962	T/G	cg14186256	chr22:23484241	RTDR1	0.83	12.97	0.65	2.57e-29	Bone mineral density;
SARC	cis	rs2354432	0.556	rs72710311	chr1:146698256	A/G	cg25205988	chr1:146714368	CHD1L	-1.03	-7.52	-0.44	1.21e-12	Mitochondrial DNA levels;
SARC	cis	rs7727544	0.735	rs272867	chr5:131681057	G/A	cg24060327	chr5:131705240	SLC22A5	-0.66	-8.27	-0.48	1.05e-14	Blood metabolite levels;
SARC	cis	rs6831352	0.734	rs1453872	chr4:100022482	G/A	cg13256891	chr4:100009986	ADH5	0.59	7.65	0.45	5.16e-13	Alcohol dependence;
SARC	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	5.07	0.32	8.17e-7	Personality dimensions;
SARC	cis	rs11792861	0.816	rs7027263	chr9:111699569	G/A	cg13535736	chr9:111863775	C9orf5	-0.4	-4.94	-0.31	1.48e-6	Menarche (age at onset);
SARC	cis	rs1707322	0.721	rs11211181	chr1:46236800	C/T	cg03146154	chr1:46216737	IPP	0.46	5.54	0.34	8.02e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs910316	0.967	rs2024653	chr14:75595154	G/A	cg06637938	chr14:75390232	RPS6KL1	0.5	7.13	0.42	1.25e-11	Height;
SARC	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg11987759	chr7:65425863	GUSB	-0.47	-6.27	-0.38	1.7e-9	Aortic root size;
SARC	cis	rs4727027	0.899	rs7791496	chr7:148863674	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	5.6	0.34	5.95e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs4742903	0.527	rs7042705	chr9:106863047	C/T	cg14250997	chr9:106856677	SMC2	0.47	5.93	0.36	1.1e-8	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs11122272	0.735	rs973253	chr1:231520874	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs7651039	0.619	rs7640807	chr3:15685137	A/G	cg16303742	chr3:15540471	COLQ	0.5	7.97	0.46	6.87e-14	Coronary heart disease;
SARC	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg24250549	chr1:154909240	PMVK	0.8	11.93	0.62	6.49e-26	Prostate cancer;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg12950624	chr19:46000154	RTN2	0.48	6.35	0.38	1.12e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs75064307	0.834	rs4855560	chr3:108116129	G/C	cg03329597	chr3:108125523	MYH15	0.47	4.81	0.3	2.73e-6	Intelligence (multi-trait analysis);
SARC	cis	rs3106136	0.814	rs10020236	chr4:95277993	A/G	cg11021082	chr4:95130006	SMARCAD1	0.34	5.39	0.33	1.7e-7	Capecitabine sensitivity;
SARC	cis	rs7589728	1.000	rs11893832	chr2:88507537	G/C	cg04511125	chr2:88470314	THNSL2	0.69	6.2	0.38	2.61e-9	Plasma clusterin levels;
SARC	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg18876405	chr7:65276391	NA	-0.73	-9.55	-0.53	1.88e-18	Aortic root size;
SARC	cis	rs372883	0.648	rs2832297	chr21:30742996	A/C	cg24692254	chr21:30365293	RNF160	0.62	8.04	0.47	4.63e-14	Pancreatic cancer;
SARC	cis	rs2439831	0.867	rs28415933	chr15:43635800	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	8.32	0.48	7.2e-15	Lung cancer in ever smokers;
SARC	cis	rs17376456	0.825	rs55947981	chr5:93278104	G/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	5.77	0.35	2.56e-8	Diabetic retinopathy;
SARC	trans	rs9302817	0.882	rs9927421	chr16:6165126	G/T	cg26270738	chr6:83777272	DOPEY1	-0.65	-6.3	-0.38	1.48e-9	Body mass index;
SARC	cis	rs7712401	0.601	rs246271	chr5:122212822	A/G	cg19412675	chr5:122181750	SNX24	0.41	5.24	0.32	3.51e-7	Mean platelet volume;
SARC	cis	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg06558623	chr16:89946397	TCF25	0.91	6.43	0.39	7.15e-10	Skin colour saturation;
SARC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg06074448	chr4:187884817	NA	0.42	5.54	0.34	8.22e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2070997	0.607	rs3808821	chr9:133712801	G/T	cg11464064	chr9:133710261	ABL1	-0.69	-6.74	-0.4	1.23e-10	Response to amphetamines;
SARC	cis	rs7917772	0.636	rs7088981	chr10:104520423	T/C	ch.10.2196322F	chr10:104248062	ACTR1A	-0.46	-5.39	-0.33	1.76e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs6582630	0.519	rs10880576	chr12:38497693	T/C	cg13010199	chr12:38710504	ALG10B	0.72	9.81	0.54	3.1400000000000002e-19	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs4819052	0.766	rs4819035	chr21:46645715	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	5.41	0.33	1.52e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6665290	0.669	rs3738725	chr1:227174210	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.02	-20.74	-0.81	7.78e-55	Myeloid white cell count;
SARC	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg02475777	chr4:1388615	CRIPAK	0.64	7.22	0.43	7.39e-12	Longevity;
SARC	trans	rs9329221	0.683	rs3105738	chr8:9889914	A/T	cg06636001	chr8:8085503	FLJ10661	-0.68	-9.82	-0.54	2.79e-19	Neuroticism;
SARC	cis	rs9790314	0.779	rs1599376	chr3:160900533	C/G	cg03342759	chr3:160939853	NMD3	-0.47	-5.63	-0.35	5.17e-8	Morning vs. evening chronotype;
SARC	cis	rs2075371	0.966	rs1646646	chr7:133996905	G/T	cg20476274	chr7:133979776	SLC35B4	0.62	8.43	0.48	3.74e-15	Mean platelet volume;
SARC	cis	rs3733585	0.699	rs6449157	chr4:9960442	G/A	cg11266682	chr4:10021025	SLC2A9	-0.36	-6.07	-0.37	5.06e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs6696846	0.765	rs4394715	chr1:205108393	T/G	cg07972983	chr1:205091412	RBBP5	0.58	7.65	0.45	5.31e-13	Red blood cell count;
SARC	cis	rs3862260	0.509	rs7552885	chr1:120164966	C/T	cg16322792	chr1:120165303	ZNF697	0.29	6.09	0.37	4.51e-9	Systemic lupus erythematosus;
SARC	cis	rs60752752	0.852	rs3006485	chr1:153357021	C/T	cg26882115	chr1:153603048	S100A1;S100A13	-0.6	-4.77	-0.3	3.23e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs17021463	0.902	rs2016483	chr4:95229039	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.45	-6.69	-0.4	1.66e-10	Testicular germ cell tumor;
SARC	cis	rs34779708	0.966	rs11599606	chr10:35406626	G/A	cg03585969	chr10:35415529	CREM	0.42	5.17	0.32	5.03e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs1008375	1.000	rs13106338	chr4:17676871	G/T	cg02297831	chr4:17616191	MED28	-0.45	-5.6	-0.34	6.02e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs793571	0.536	rs7183336	chr15:58966236	C/T	cg05156742	chr15:59063176	FAM63B	0.66	7.54	0.44	1.03e-12	Schizophrenia;
SARC	cis	rs9790314	1.000	rs6441373	chr3:161026717	T/G	cg03342759	chr3:160939853	NMD3	-0.59	-7.36	-0.43	3.23e-12	Morning vs. evening chronotype;
SARC	cis	rs2380220	0.576	rs4368819	chr6:96031109	T/G	cg07718321	chr6:96025334	MANEA	0.48	5.25	0.33	3.43e-7	Behavioural disinhibition (generation interaction);
SARC	cis	rs2239547	0.522	rs9844736	chr3:52931971	T/G	cg11645453	chr3:52864694	ITIH4	-0.31	-4.82	-0.3	2.63e-6	Schizophrenia;
SARC	cis	rs2735413	0.918	rs4309408	chr16:78071507	G/A	cg04733911	chr16:78082701	NA	-0.3	-5.44	-0.34	1.34e-7	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs10489202	0.632	rs203781	chr1:167880518	A/C	cg17859187	chr1:168147929	TIPRL	0.39	4.83	0.3	2.51e-6	Schizophrenia;
SARC	cis	rs3087591	1.000	rs2905791	chr17:29472888	T/C	cg24425628	chr17:29625626	OMG;NF1	0.53	6.55	0.39	3.57e-10	Hip circumference;
SARC	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	trans	rs2727020	0.513	rs10839307	chr11:49609843	A/C	cg15704280	chr7:45808275	SEPT13	-0.9	-14.55	-0.69	1.46e-34	Coronary artery disease;
SARC	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg16405210	chr4:1374714	KIAA1530	-0.51	-5.91	-0.36	1.19e-8	Obesity-related traits;
SARC	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-8.76	-0.5	4.15e-16	Alzheimer's disease;
SARC	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.46	5.27	0.33	3.13e-7	Renal function-related traits (BUN);
SARC	trans	rs7752643	0.601	rs1158059	chr6:84264333	C/T	cg14512089	chr1:160771850	LY9	0.32	6.67	0.4	1.81e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg13939156	chr17:80058883	NA	-0.44	-6.86	-0.41	6.12e-11	Life satisfaction;
SARC	cis	rs13392177	0.637	rs61041183	chr2:219056380	G/A	cg00012203	chr2:219082015	ARPC2	0.71	10.03	0.55	6.74e-20	Pyoderma gangrenosum in inflammatory bowel disease;
SARC	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg21747090	chr2:27597821	SNX17	-0.5	-6.9	-0.41	4.8e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs752010	0.530	rs10789401	chr1:42081111	A/G	cg06885757	chr1:42089581	HIVEP3	0.56	8.11	0.47	2.83e-14	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg09699651	chr6:150184138	LRP11	0.39	4.87	0.3	2.04e-6	Lung cancer;
SARC	cis	rs9916302	0.605	rs12938099	chr17:37612910	T/G	cg00129232	chr17:37814104	STARD3	-0.58	-6.13	-0.37	3.66e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs12971120	0.891	rs3764510	chr18:72166846	A/G	cg26446133	chr18:72167187	CNDP2	-0.51	-7.23	-0.43	6.87e-12	Refractive error;
SARC	cis	rs11645898	0.935	rs4788605	chr16:72154682	G/T	cg14768367	chr16:72042858	DHODH	-0.63	-5.72	-0.35	3.21e-8	Blood protein levels;
SARC	trans	rs1109861	0.593	rs658681	chr10:11218580	A/G	cg18242990	chr7:2884021	GNA12	0.47	6.25	0.38	1.88e-9	Urinary albumin-to-creatinine ratio;
SARC	cis	rs2439831	0.867	rs2251844	chr15:43836478	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.95	9.07	0.51	4.97e-17	Lung cancer in ever smokers;
SARC	cis	rs6582630	0.537	rs8189533	chr12:38391068	A/G	cg26384229	chr12:38710491	ALG10B	0.93	13.39	0.66	1.08e-30	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs7426380	0.712	rs6753814	chr2:56034990	C/G	cg07953400	chr16:619759	PIGQ	-0.51	-6.41	-0.39	8.2e-10	Intraocular pressure;
SARC	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg13395646	chr4:1353034	KIAA1530	-0.6	-7.09	-0.42	1.59e-11	Obesity-related traits;
SARC	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.8	12.11	0.62	1.68e-26	Total body bone mineral density;
SARC	cis	rs8058578	1.000	rs56656810	chr16:30788759	C/A	cg02466173	chr16:30829666	NA	-0.46	-6.02	-0.37	6.83e-9	Multiple myeloma;
SARC	cis	rs920590	0.796	rs7820520	chr8:19634864	A/G	cg01411142	chr8:19674711	INTS10	-0.44	-5.11	-0.32	6.8e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs2204008	0.583	rs12307593	chr12:38317803	A/G	cg13010199	chr12:38710504	ALG10B	0.49	5.94	0.36	1.05e-8	Bladder cancer;
SARC	cis	rs17001868	0.614	rs61467436	chr22:40736713	T/C	cg07138101	chr22:40742427	ADSL	0.54	5.94	0.36	1.01e-8	Mammographic density (dense area);
SARC	trans	rs1814175	0.645	rs28538913	chr11:50040718	C/T	cg03929089	chr4:120376271	NA	-0.81	-11.64	-0.61	5.33e-25	Height;
SARC	trans	rs6964833	0.935	rs34630792	chr7:74061197	G/C	cg07504079	chr7:72649617	NCF1B	-0.6	-6.53	-0.39	4.09e-10	Menarche (age at onset);
SARC	cis	rs7927592	0.513	rs556442	chr11:68192690	G/A	cg01657329	chr11:68192670	LRP5	0.41	5.8	0.36	2.14e-8	Total body bone mineral density;
SARC	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg06634786	chr22:41940651	POLR3H	-0.59	-7.0	-0.42	2.72e-11	Vitiligo;
SARC	cis	rs2742234	0.590	rs2503848	chr10:43672785	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.4	-4.74	-0.3	3.67e-6	Hirschsprung disease;
SARC	cis	rs13064447	0.967	rs55668390	chr3:12766020	C/G	cg05775895	chr3:12838266	CAND2	0.39	5.03	0.31	9.86e-7	Major depression and alcohol dependence;
SARC	cis	rs55823223	0.648	rs11869977	chr17:73857382	C/G	cg08125733	chr17:73851984	WBP2	0.63	6.94	0.41	3.89e-11	Psoriasis;
SARC	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-7.83	-0.46	1.71e-13	Alzheimer's disease;
SARC	cis	rs7829975	0.501	rs74345345	chr8:8578435	C/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-5.28	-0.33	2.99e-7	Mood instability;
SARC	cis	rs74181299	0.784	rs2723085	chr2:65297359	C/G	cg20592124	chr2:65290738	CEP68	0.47	6.82	0.41	7.72e-11	Pulse pressure;
SARC	cis	rs1348850	0.793	rs13027299	chr2:178455501	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.63	7.41	0.44	2.26e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg22307029	chr19:49891270	CCDC155	0.63	7.52	0.44	1.21e-12	Multiple sclerosis;
SARC	cis	rs832540	0.629	rs10055224	chr5:56081201	C/T	cg12311346	chr5:56204834	C5orf35	0.4	4.91	0.31	1.7e-6	Coronary artery disease;
SARC	cis	rs738322	0.967	rs133024	chr22:38574066	C/T	cg25457927	chr22:38595422	NA	0.29	6.14	0.37	3.51e-9	Cutaneous nevi;
SARC	cis	rs17739167	0.569	rs6493015	chr15:42225260	G/T	cg20935245	chr15:42234343	EHD4	0.46	6.05	0.37	5.63e-9	Monocyte count;
SARC	cis	rs617791	0.530	rs735942	chr11:65749337	A/G	cg26695010	chr11:65641043	EFEMP2	0.53	6.39	0.39	8.77e-10	Breast cancer;
SARC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg06873352	chr17:61820015	STRADA	0.54	6.89	0.41	5.28e-11	Prudent dietary pattern;
SARC	cis	rs13161895	1.000	rs34603792	chr5:179459287	A/G	cg06664874	chr5:179499304	RNF130	0.5	4.85	0.3	2.26e-6	LDL cholesterol;
SARC	cis	rs41264869	0.689	rs12039805	chr1:205107793	G/A	cg21643547	chr1:205240462	TMCC2	0.46	5.08	0.32	7.62e-7	Blood protein levels;
SARC	cis	rs17384381	0.953	rs3768223	chr1:85809183	T/C	cg16011679	chr1:85725395	C1orf52	0.62	5.57	0.34	6.96e-8	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs1814175	0.650	rs6486000	chr11:49659090	T/A	cg15704280	chr7:45808275	SEPT13	-0.82	-12.05	-0.62	2.56e-26	Height;
SARC	cis	rs897080	0.515	rs1085495	chr2:44608982	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.6	0.4	2.69e-10	Height;
SARC	cis	rs1018836	0.923	rs10956748	chr8:91621537	T/A	cg16814680	chr8:91681699	NA	-0.85	-13.99	-0.68	1.06e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	trans	rs7937682	0.924	rs513425	chr11:111504861	C/T	cg18187862	chr3:45730750	SACM1L	0.55	6.96	0.41	3.46e-11	Primary sclerosing cholangitis;
SARC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.11	0.37	4.11e-9	Prudent dietary pattern;
SARC	cis	rs73086581	0.947	rs55794220	chr20:3956402	C/T	cg02187196	chr20:3869020	PANK2	0.67	6.43	0.39	7.22e-10	Response to antidepressants in depression;
SARC	cis	rs72781680	0.898	rs12619592	chr2:23971415	C/A	cg06627628	chr2:24431161	ITSN2	-0.63	-6.02	-0.37	6.87e-9	Lymphocyte counts;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg07032309	chr8:103668104	KLF10	0.49	6.59	0.4	2.93e-10	Chemerin levels;
SARC	cis	rs4727027	0.865	rs13236754	chr7:148845773	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	5.44	0.34	1.35e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs72634258	0.503	rs697675	chr1:7838113	A/C	cg26816564	chr1:7831052	VAMP3	0.58	5.28	0.33	2.98e-7	Inflammatory bowel disease;
SARC	cis	rs722599	0.748	rs20578	chr14:75367807	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.38	-4.75	-0.3	3.52e-6	IgG glycosylation;
SARC	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg14773178	chr5:1868261	NA	0.33	5.32	0.33	2.47e-7	Cardiovascular disease risk factors;
SARC	cis	rs7940866	0.803	rs10894307	chr11:130876350	G/A	cg12179176	chr11:130786555	SNX19	0.68	9.31	0.52	9.55e-18	Schizophrenia;
SARC	cis	rs7084402	0.967	rs1649027	chr10:60280911	T/G	cg07615347	chr10:60278583	BICC1	-0.6	-8.82	-0.5	2.78e-16	Refractive error;
SARC	cis	rs11693319	1.000	rs67113930	chr2:179741348	A/G	cg17765952	chr2:179737173	CCDC141	0.61	6.82	0.41	7.64e-11	Blood pressure measurement (cold pressor test);
SARC	cis	rs11687170	1.000	rs11687170	chr2:237058144	T/C	cg19324714	chr2:237145437	ASB18	0.5	4.96	0.31	1.38e-6	Educational attainment;Educational attainment (years of education);
SARC	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg06558623	chr16:89946397	TCF25	0.85	7.28	0.43	5.23e-12	Skin colour saturation;
SARC	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg25952890	chr19:58913133	NA	0.35	5.05	0.31	8.77e-7	Uric acid clearance;
SARC	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg05861140	chr6:150128134	PCMT1	-0.38	-4.92	-0.31	1.61e-6	Lung cancer;
SARC	cis	rs6542838	0.609	rs13028500	chr2:99528296	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.43	-5.29	-0.33	2.77e-7	Fear of minor pain;
SARC	cis	rs7395581	0.918	rs326214	chr11:47298360	G/A	cg25783544	chr11:47291846	MADD	-0.44	-5.03	-0.31	9.76e-7	HDL cholesterol;
SARC	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.46	0.39	6.12e-10	Bipolar disorder;
SARC	cis	rs2180341	1.000	rs9375499	chr6:127618072	T/C	cg27446573	chr6:127587934	RNF146	1.02	14.46	0.69	2.89e-34	Breast cancer;
SARC	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.44	-5.47	-0.34	1.18e-7	Blood metabolite levels;
SARC	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg11843238	chr5:131593191	PDLIM4	0.39	5.49	0.34	1.06e-7	Breast cancer;
SARC	cis	rs9309473	0.950	rs6546859	chr2:73842055	C/A	cg07208825	chr2:73871855	ALMS1P	0.34	5.11	0.32	6.68e-7	Metabolite levels;
SARC	cis	rs2576037	0.796	rs2571033	chr18:44578552	C/T	cg15049968	chr18:44337910	ST8SIA5	0.33	5.43	0.34	1.39e-7	Personality dimensions;
SARC	trans	rs79976124	0.842	rs1548154	chr6:66624910	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	7.88	0.46	1.28e-13	Type 2 diabetes;
SARC	cis	rs10504229	0.679	rs1596142	chr8:58032406	G/A	cg21724239	chr8:58056113	NA	0.6	6.2	0.38	2.51e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs8058578	1.000	rs8048448	chr16:30692208	T/C	cg00531865	chr16:30841666	NA	-0.51	-5.79	-0.35	2.28e-8	Multiple myeloma;
SARC	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg24250549	chr1:154909240	PMVK	0.83	12.07	0.62	2.27e-26	Prostate cancer;
SARC	cis	rs9814567	1.000	rs1534025	chr3:134313304	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	6.89	0.41	5.31e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	trans	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-10.59	-0.57	1.18e-21	Intelligence (multi-trait analysis);
SARC	cis	rs763121	0.853	rs9607566	chr22:39075434	C/G	cg06022373	chr22:39101656	GTPBP1	0.84	10.32	0.56	8.51e-21	Menopause (age at onset);
SARC	cis	rs2486288	0.656	rs6493143	chr15:45570781	G/T	cg15395560	chr15:45543142	SLC28A2	0.32	6.17	0.37	2.98e-9	Glomerular filtration rate;
SARC	cis	rs2075371	0.932	rs2544215	chr7:133987896	T/C	cg00033643	chr7:134001901	SLC35B4	0.4	4.85	0.3	2.25e-6	Mean platelet volume;
SARC	cis	rs9486719	0.843	rs2499796	chr6:96848364	A/G	cg18709589	chr6:96969512	KIAA0776	0.51	4.74	0.3	3.71e-6	Migraine;Coronary artery disease;
SARC	cis	rs8077889	0.956	rs58242860	chr17:41847300	T/C	cg26893861	chr17:41843967	DUSP3	0.79	9.11	0.51	3.8e-17	Triglycerides;
SARC	trans	rs7829975	0.511	rs1401390	chr8:8136410	C/T	cg16141378	chr3:129829833	LOC729375	-0.58	-7.16	-0.42	1.05e-11	Mood instability;
SARC	cis	rs2011503	1.000	rs80007081	chr19:19626734	A/G	cg03709012	chr19:19516395	GATAD2A	0.6	5.29	0.33	2.8e-7	Bipolar disorder;
SARC	cis	rs2120019	0.567	rs8029351	chr15:75177237	A/C	cg12414181	chr15:75287860	SCAMP5	-0.5	-4.78	-0.3	3.09e-6	Blood trace element (Zn levels);
SARC	cis	rs6815814	0.898	rs73236616	chr4:38789675	G/A	cg09316306	chr4:38807337	TLR1	0.51	5.25	0.33	3.47e-7	Breast cancer;
SARC	cis	rs1185460	0.934	rs1006195	chr11:118958869	A/C	cg23280166	chr11:118938394	VPS11	-0.69	-9.75	-0.54	4.78e-19	Coronary artery disease;
SARC	cis	rs73036520	0.560	rs346750	chr19:45737218	G/T	cg01416317	chr19:45737208	EXOC3L2	-0.33	-5.05	-0.31	9.12e-7	Monocyte percentage of white cells;
SARC	cis	rs2120243	0.539	rs988588	chr3:157054016	C/G	cg24825693	chr3:157122686	VEPH1	-0.49	-6.71	-0.4	1.48e-10	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs2952156	0.883	rs1495100	chr17:37832279	C/T	cg00129232	chr17:37814104	STARD3	-0.7	-9.93	-0.55	1.3e-19	Asthma;
SARC	cis	rs7582720	1.000	rs72936323	chr2:204050474	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	7.88	0.46	1.21e-13	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs4319547	0.656	rs7397299	chr12:122821649	G/T	cg23029597	chr12:123009494	RSRC2	-0.42	-5.32	-0.33	2.48e-7	Body mass index;
SARC	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg08280861	chr8:58055591	NA	0.6	5.85	0.36	1.67e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2239547	0.522	rs2581779	chr3:53056199	T/C	cg11645453	chr3:52864694	ITIH4	-0.31	-4.92	-0.31	1.67e-6	Schizophrenia;
SARC	cis	rs13343954	0.518	rs2216594	chr19:33533258	G/A	cg17764715	chr19:33622953	WDR88	0.52	6.94	0.41	3.84e-11	Colorectal cancer;
SARC	cis	rs912057	0.671	rs1024246	chr6:6743505	A/T	cg06612196	chr6:6737390	NA	0.64	9.82	0.54	2.78e-19	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs11608355	0.515	rs61941631	chr12:109935475	C/T	cg05360138	chr12:110035743	NA	0.92	9.39	0.52	5.78e-18	Neuroticism;
SARC	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg00149659	chr3:10157352	C3orf10	0.68	6.73	0.4	1.3e-10	Alzheimer's disease;
SARC	trans	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.1	-0.42	1.51e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs7586879	0.639	rs3903070	chr2:25123463	C/G	cg04586622	chr2:25135609	ADCY3	0.32	5.49	0.34	1.04e-7	Body mass index;
SARC	cis	rs1348850	0.526	rs10930802	chr2:178460095	A/G	cg23306229	chr2:178417860	TTC30B	0.89	8.94	0.51	1.2e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs72945132	0.882	rs7123602	chr11:70181489	C/T	cg05964544	chr11:70165517	PPFIA1	-0.58	-5.71	-0.35	3.48e-8	Coronary artery disease;
SARC	cis	rs15676	0.783	rs2417126	chr9:131562457	C/T	cg00228799	chr9:131580591	ENDOG	-0.56	-7.09	-0.42	1.59e-11	Blood metabolite levels;
SARC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.34	5.09	0.32	7.47e-7	Bipolar disorder;
SARC	cis	rs6565180	0.888	rs12447833	chr16:30390314	T/C	cg17640201	chr16:30407289	ZNF48	0.94	13.85	0.67	3.21e-32	Tonsillectomy;
SARC	cis	rs9858542	0.903	rs11921590	chr3:49644193	T/C	cg03060546	chr3:49711283	APEH	-0.66	-8.31	-0.48	7.68e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg19761014	chr17:28927070	LRRC37B2	0.6	4.83	0.3	2.5e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs7635838	0.859	rs7632040	chr3:11427455	A/G	cg00170343	chr3:11313890	ATG7	0.62	8.34	0.48	6.52e-15	HDL cholesterol;
SARC	cis	rs7647973	0.626	rs9870858	chr3:49769071	C/T	cg13072238	chr3:49761600	GMPPB	-0.61	-6.24	-0.38	2.08e-9	Menarche (age at onset);
SARC	cis	rs10883723	0.773	rs2296578	chr10:104240974	C/G	ch.10.2196322F	chr10:104248062	ACTR1A	0.57	7.42	0.44	2.21e-12	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg21724239	chr8:58056113	NA	0.57	5.88	0.36	1.41e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs896854	0.517	rs10112447	chr8:95955701	C/T	cg16049864	chr8:95962084	TP53INP1	-0.33	-4.91	-0.31	1.75e-6	Type 2 diabetes;
SARC	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg13699009	chr12:122356056	WDR66	-0.59	-9.54	-0.53	2.05e-18	Mean corpuscular volume;
SARC	cis	rs6835098	0.923	rs9997477	chr4:174112543	C/T	cg08422745	chr4:174089978	GALNT7	-0.71	-9.22	-0.52	1.86e-17	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs10174077	0.874	rs10186656	chr2:152475938	T/G	cg19508488	chr2:152266495	RIF1	0.48	5.6	0.34	6.14e-8	Squamous cell lung carcinoma;
SARC	cis	rs2991971	0.967	rs7526665	chr1:46005832	G/T	cg24296786	chr1:45957014	TESK2	0.67	9.54	0.53	2.04e-18	High light scatter reticulocyte count;
SARC	cis	rs478304	0.651	rs4930319	chr11:65555458	G/C	cg26695010	chr11:65641043	EFEMP2	0.41	4.87	0.3	2.05e-6	Acne (severe);
SARC	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2952156	0.920	rs2517955	chr17:37843681	C/T	cg20243544	chr17:37824526	PNMT	0.55	7.13	0.42	1.27e-11	Asthma;
SARC	cis	rs9457247	0.967	rs1794694	chr6:167404751	T/C	cg23791538	chr6:167370224	RNASET2	-0.63	-8.74	-0.5	4.69e-16	Crohn's disease;
SARC	cis	rs7582720	1.000	rs7560547	chr2:203757916	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.31	0.43	4.24e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs9611519	1.000	rs9611519	chr22:41613188	C/T	cg17376030	chr22:41985996	PMM1	0.5	6.07	0.37	5.23e-9	Neuroticism;
SARC	cis	rs12311304	0.965	rs7965989	chr12:15361715	G/T	cg08258403	chr12:15378311	NA	0.48	7.64	0.45	5.65e-13	Behavioural disinhibition (generation interaction);
SARC	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg19223190	chr17:80058835	NA	0.44	6.19	0.38	2.67e-9	Life satisfaction;
SARC	cis	rs1059312	0.966	rs7135968	chr12:129280066	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.5	7.08	0.42	1.69e-11	Systemic lupus erythematosus;
SARC	cis	rs698813	0.851	rs698804	chr2:44699720	A/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	5.56	0.34	7.4e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs11122272	0.668	rs1538664	chr1:231555295	C/T	cg06096015	chr1:231504339	EGLN1	0.38	5.8	0.36	2.18e-8	Hemoglobin concentration;
SARC	cis	rs7712401	0.601	rs390234	chr5:122331523	A/G	cg19412675	chr5:122181750	SNX24	-0.43	-5.43	-0.34	1.41e-7	Mean platelet volume;
SARC	cis	rs11770686	0.666	rs2285870	chr7:75310630	A/G	cg17787366	chr7:75369077	HIP1	0.39	4.85	0.3	2.28e-6	Essential tremor;
SARC	cis	rs7084402	1.000	rs1427204	chr10:60267640	A/C	cg07615347	chr10:60278583	BICC1	-0.6	-8.5	-0.49	2.31e-15	Refractive error;
SARC	cis	rs7824557	0.836	rs765731	chr8:11121498	T/A	cg21775007	chr8:11205619	TDH	-0.52	-6.18	-0.38	2.85e-9	Retinal vascular caliber;
SARC	cis	rs1865721	0.804	rs3745084	chr18:73142510	T/G	cg26385618	chr18:73139727	C18orf62	-0.38	-5.24	-0.32	3.6e-7	Intelligence;
SARC	cis	rs765787	0.530	rs11636367	chr15:45535862	A/G	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.81e-6	Uric acid levels;
SARC	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.7	6.85	0.41	6.51e-11	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs854765	0.547	rs2955353	chr17:17948979	T/C	cg05444541	chr17:17804740	TOM1L2	0.3	4.9	0.31	1.76e-6	Total body bone mineral density;
SARC	cis	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg07777115	chr5:623756	CEP72	-0.62	-5.56	-0.34	7.5e-8	Obesity-related traits;
SARC	cis	rs910316	0.967	rs11159121	chr14:75666029	A/T	cg11812906	chr14:75593930	NEK9	-0.81	-12.64	-0.64	3.15e-28	Height;
SARC	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg20607798	chr8:58055168	NA	0.56	5.47	0.34	1.18e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs4927850	0.794	rs13070153	chr3:195741185	A/T	cg12923728	chr3:195709715	SDHAP1	-0.7	-7.82	-0.46	1.85e-13	Pancreatic cancer;
SARC	cis	rs10875746	0.951	rs4760690	chr12:48563653	G/A	cg27446233	chr12:48516484	PFKM	-0.4	-4.73	-0.3	3.97e-6	Longevity (90 years and older);
SARC	cis	rs2072499	0.833	rs2251636	chr1:156202809	G/C	cg24450063	chr1:156163899	SLC25A44	1.0	14.0	0.68	9.7e-33	Testicular germ cell tumor;
SARC	cis	rs4713118	0.869	rs4713121	chr6:27722064	T/C	cg17221315	chr6:27791827	HIST1H4J	0.51	5.46	0.34	1.23e-7	Parkinson's disease;
SARC	cis	rs6988636	1.000	rs59834873	chr8:124188824	G/T	cg23067535	chr8:124195133	FAM83A	-0.69	-5.46	-0.34	1.24e-7	Urinary uromodulin levels;
SARC	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg21747090	chr2:27597821	SNX17	-0.54	-7.59	-0.45	7.45e-13	Total body bone mineral density;
SARC	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg17376030	chr22:41985996	PMM1	-0.71	-9.05	-0.51	5.92e-17	Vitiligo;
SARC	cis	rs7772486	0.790	rs4280983	chr6:146280790	G/C	cg23711669	chr6:146136114	FBXO30	-0.84	-13.41	-0.66	9.02e-31	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs910316	0.737	rs175510	chr14:75524839	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.51	-6.93	-0.41	4.15e-11	Height;
SARC	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	15.0	0.7	4.66e-36	Chronic sinus infection;
SARC	cis	rs7084402	0.967	rs7098326	chr10:60276906	C/T	cg07615347	chr10:60278583	BICC1	-0.6	-8.8	-0.5	3.04e-16	Refractive error;
SARC	cis	rs2425143	1.000	rs11699690	chr20:34271774	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.13	0.32	6.04e-7	Blood protein levels;
SARC	cis	rs4595586	0.545	rs6580893	chr12:39371885	G/T	cg26384229	chr12:38710491	ALG10B	0.51	6.25	0.38	1.9e-9	Morning vs. evening chronotype;
SARC	cis	rs9831754	0.756	rs1512476	chr3:78434219	G/A	cg06138941	chr3:78371609	NA	-0.54	-6.43	-0.39	7.35e-10	Calcium levels;
SARC	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg00800038	chr16:89945340	TCF25	-0.68	-5.39	-0.33	1.76e-7	Skin colour saturation;
SARC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg09373136	chr17:61933544	TCAM1	-0.44	-5.93	-0.36	1.11e-8	Prudent dietary pattern;
SARC	cis	rs10489525	0.583	rs6691374	chr1:115642818	T/C	cg01522456	chr1:115632236	TSPAN2	0.7	7.97	0.46	7.14e-14	Autism;
SARC	cis	rs9400467	0.537	rs73530952	chr6:111486242	G/A	cg15721981	chr6:111408429	SLC16A10	0.66	5.67	0.35	4.24e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs9818758	0.607	rs5030795	chr3:49141116	C/T	cg07636037	chr3:49044803	WDR6	-0.74	-6.89	-0.41	5.07e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs611744	0.647	rs7015513	chr8:109262570	A/C	cg21045802	chr8:109455806	TTC35	0.58	7.24	0.43	6.65e-12	Dupuytren's disease;
SARC	cis	rs9393777	0.513	rs9368451	chr6:26654333	A/G	cg12826209	chr6:26865740	GUSBL1	0.66	5.94	0.36	1.02e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2180341	0.842	rs7739679	chr6:127545428	G/A	cg27446573	chr6:127587934	RNF146	1.02	12.13	0.62	1.43e-26	Breast cancer;
SARC	cis	rs7772486	0.790	rs6570723	chr6:146151230	A/T	cg05347473	chr6:146136440	FBXO30	0.5	7.02	0.42	2.44e-11	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs11781622	0.945	rs1873708	chr8:24375783	T/C	cg17078393	chr1:32717002	LCK	-0.41	-6.27	-0.38	1.73e-9	White matter integrity;
SARC	cis	rs12311304	1.000	rs11056404	chr12:15378291	C/T	cg08258403	chr12:15378311	NA	0.48	7.39	0.44	2.62e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs9381040	0.631	rs13216201	chr6:41162060	G/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.45	-5.13	-0.32	6.08e-7	Alzheimer's disease (late onset);
SARC	cis	rs4509693	1.000	rs4244340	chr10:102499268	G/C	cg15234845	chr10:102496500	NA	0.32	4.86	0.3	2.13e-6	Alzheimer's disease;
SARC	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg11247378	chr22:39784982	NA	-0.32	-5.11	-0.32	6.64e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg00149659	chr3:10157352	C3orf10	0.66	6.11	0.37	4.1e-9	Alzheimer's disease;
SARC	cis	rs9400467	0.506	rs12192617	chr6:111490275	A/G	cg15721981	chr6:111408429	SLC16A10	0.66	5.67	0.35	4.24e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg03161606	chr19:29218774	NA	0.5	7.26	0.43	5.59e-12	Methadone dose in opioid dependence;
SARC	cis	rs9650657	0.504	rs10109167	chr8:11033525	C/T	cg21775007	chr8:11205619	TDH	-0.44	-5.49	-0.34	1.03e-7	Neuroticism;
SARC	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg07061783	chr6:25882402	NA	-0.42	-4.9	-0.31	1.78e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7633857	0.512	rs1374787	chr3:160700144	C/T	cg17135325	chr3:160939158	NMD3	0.4	4.82	0.3	2.54e-6	Educational attainment (years of education);
SARC	trans	rs4834272	0.556	rs7673053	chr4:113302869	G/T	cg04861380	chr7:150497663	TMEM176B;TMEM176A	0.47	6.58	0.4	3.03e-10	Body mass index;
SARC	cis	rs950880	0.710	rs4851570	chr2:103006387	A/G	cg03938978	chr2:103052716	IL18RAP	-0.34	-4.84	-0.3	2.36e-6	Serum protein levels (sST2);
SARC	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg11644478	chr21:40555479	PSMG1	1.02	13.02	0.65	1.69e-29	Cognitive function;
SARC	cis	rs6580649	1.000	rs3825404	chr12:48399931	A/G	cg05342945	chr12:48394962	COL2A1	-0.52	-5.68	-0.35	4.02e-8	Lung cancer;
SARC	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg12463550	chr7:65579703	CRCP	0.48	5.79	0.35	2.23e-8	Aortic root size;
SARC	cis	rs7582180	0.726	rs4438499	chr2:100876789	A/G	cg14675211	chr2:100938903	LONRF2	-0.37	-5.14	-0.32	5.78e-7	Intelligence (multi-trait analysis);
SARC	cis	rs616402	0.527	rs11584327	chr1:10578791	T/C	cg07384165	chr1:10488281	NA	-0.4	-5.3	-0.33	2.74e-7	Breast size;
SARC	cis	rs9858542	0.953	rs9814873	chr3:49454112	A/G	cg07274523	chr3:49395745	GPX1	0.52	5.99	0.37	7.85e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs7208859	0.573	rs79505916	chr17:29062326	C/T	cg13385521	chr17:29058706	SUZ12P	0.83	7.19	0.43	8.8e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs17253792	0.822	rs10139905	chr14:56170031	T/C	cg01858014	chr14:56050164	KTN1	-0.64	-5.22	-0.32	4.02e-7	Putamen volume;
SARC	cis	rs17401966	0.931	rs3748577	chr1:10357406	C/T	cg15208524	chr1:10270712	KIF1B	-0.52	-6.24	-0.38	2.1e-9	Hepatocellular carcinoma;
SARC	cis	rs12586317	0.547	rs10134907	chr14:35499211	A/C	cg26967526	chr14:35346199	BAZ1A	-0.57	-5.71	-0.35	3.4e-8	Psoriasis;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg22993892	chr15:65579119	PARP16	0.52	6.55	0.39	3.57e-10	Lung adenocarcinoma;
SARC	cis	rs12135062	0.851	rs2651927	chr1:3101762	A/C	cg21609526	chr1:3105151	PRDM16	-0.38	-6.56	-0.39	3.41e-10	Migraine;
SARC	cis	rs2120019	1.000	rs12898259	chr15:75369780	G/A	cg09165964	chr15:75287851	SCAMP5	-0.87	-13.08	-0.65	1.1e-29	Blood trace element (Zn levels);
SARC	cis	rs2576037	0.901	rs6507719	chr18:44581310	A/T	cg19077165	chr18:44547161	KATNAL2	0.47	6.54	0.39	3.79e-10	Personality dimensions;
SARC	cis	rs79976124	0.837	rs11751145	chr6:66642039	T/C	cg07460842	chr6:66804631	NA	0.62	6.9	0.41	4.82e-11	Type 2 diabetes;
SARC	cis	rs7005380	0.581	rs869340	chr8:120932612	T/C	cg21744203	chr8:120868354	DSCC1	0.46	5.29	0.33	2.79e-7	Interstitial lung disease;
SARC	cis	rs7027203	0.828	rs4744287	chr9:96585567	A/G	cg13679303	chr9:96623674	NA	0.36	5.18	0.32	4.89e-7	DNA methylation (variation);
SARC	cis	rs1371867	0.810	rs1692004	chr8:101247320	T/C	cg11906718	chr8:101322791	RNF19A	-0.69	-8.63	-0.49	9.47e-16	Atrioventricular conduction;
SARC	cis	rs2933343	1.000	rs789232	chr3:128603080	T/G	cg25356066	chr3:128598488	ACAD9	0.6	6.91	0.41	4.64e-11	IgG glycosylation;
SARC	cis	rs6500602	0.627	rs3848372	chr16:4587875	C/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.36	5.76	0.35	2.63e-8	Schizophrenia;
SARC	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg26681399	chr22:41777847	TEF	-0.48	-5.2	-0.32	4.3e-7	Vitiligo;
SARC	cis	rs11734570	0.509	rs13114193	chr4:38571346	T/G	cg18361445	chr4:38666374	KLF3;FLJ13197	-0.37	-4.76	-0.3	3.34e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg24829409	chr8:58192753	C8orf71	-0.65	-6.15	-0.37	3.28e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7429990	0.965	rs7619882	chr3:47984824	A/G	cg11946769	chr3:48343235	NME6	0.45	5.12	0.32	6.44e-7	Educational attainment (years of education);
SARC	cis	rs1018836	0.828	rs7006279	chr8:91605364	A/G	cg16814680	chr8:91681699	NA	-0.76	-11.96	-0.62	5.1e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs9788721	1.000	rs9788721	chr15:78802869	C/T	cg06917634	chr15:78832804	PSMA4	0.52	5.61	0.34	5.85e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs7246865	0.531	rs8103913	chr19:17166229	G/C	cg16202187	chr19:17186497	HAUS8;MYO9B	0.41	4.92	0.31	1.62e-6	Reticulocyte fraction of red cells;
SARC	cis	rs477692	0.673	rs579952	chr10:131356084	A/T	cg14263093	chr10:131365266	MGMT	-0.34	-4.79	-0.3	2.98e-6	Response to temozolomide;
SARC	cis	rs733592	0.965	rs1978161	chr12:48467721	A/G	cg05342945	chr12:48394962	COL2A1	0.39	4.73	0.3	3.81e-6	Plateletcrit;
SARC	cis	rs11711311	0.668	rs11718061	chr3:113341826	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.57	-7.26	-0.43	5.66e-12	IgG glycosylation;
SARC	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg22857025	chr5:266934	NA	-1.09	-11.97	-0.62	4.86e-26	Breast cancer;
SARC	trans	rs208515	0.525	rs9453538	chr6:66668508	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	11.5	0.6	1.56e-24	Exhaled nitric oxide levels;
SARC	cis	rs2204008	0.505	rs11182550	chr12:38570061	A/T	cg13010199	chr12:38710504	ALG10B	0.53	6.65	0.4	2.11e-10	Bladder cancer;
SARC	cis	rs2976388	0.609	rs2717550	chr8:143787808	T/A	cg06565975	chr8:143823917	SLURP1	0.31	5.36	0.33	2.03e-7	Urinary tract infection frequency;
SARC	cis	rs2439831	1.000	rs7173487	chr15:43750239	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.0	9.21	0.52	1.95e-17	Lung cancer in ever smokers;
SARC	cis	rs41264869	0.567	rs6670870	chr1:205155177	A/T	cg21643547	chr1:205240462	TMCC2	0.43	4.82	0.3	2.59e-6	Blood protein levels;
SARC	cis	rs651907	0.557	rs13066768	chr3:101486920	A/T	cg12386194	chr3:101231763	SENP7	-0.49	-5.79	-0.35	2.29e-8	Colorectal cancer;
SARC	cis	rs9462027	0.583	rs6937784	chr6:34644276	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.89	-0.36	1.36e-8	Systemic lupus erythematosus;
SARC	cis	rs6087990	0.836	rs2424909	chr20:31361861	T/C	cg13636640	chr20:31349939	DNMT3B	0.81	12.82	0.64	8.15e-29	Ulcerative colitis;
SARC	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-8.56	-0.49	1.58e-15	Chronic sinus infection;
SARC	cis	rs35146811	0.586	rs6946168	chr7:99598286	C/T	cg22004693	chr7:99632812	ZKSCAN1	-0.44	-4.72	-0.3	4.12e-6	Coronary artery disease;
SARC	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg00684032	chr4:1343700	KIAA1530	0.33	4.91	0.31	1.73e-6	Obesity-related traits;
SARC	cis	rs2228479	0.850	rs57267516	chr16:89903552	G/A	cg12064134	chr16:90016061	DEF8	-0.55	-4.82	-0.3	2.54e-6	Skin colour saturation;
SARC	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg19223190	chr17:80058835	NA	0.43	5.96	0.36	9.3e-9	Life satisfaction;
SARC	cis	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg06212747	chr3:49208901	KLHDC8B	0.53	6.7	0.4	1.54e-10	Resting heart rate;
SARC	cis	rs12681288	0.823	rs2701905	chr8:1003482	T/C	cg04851639	chr8:1020857	NA	-0.27	-4.81	-0.3	2.65e-6	Schizophrenia;
SARC	cis	rs7666738	0.962	rs2865991	chr4:99067369	C/A	cg05340658	chr4:99064831	C4orf37	0.56	6.81	0.41	8.3e-11	Colonoscopy-negative controls vs population controls;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg00477776	chr10:423907	DIP2C	0.51	6.94	0.41	3.75e-11	Thyroid stimulating hormone;
SARC	cis	rs1018836	0.608	rs6982329	chr8:91467488	A/G	cg16814680	chr8:91681699	NA	-0.65	-9.31	-0.52	9.93e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs760805	0.932	rs1005734	chr1:25262022	C/A	cg22509179	chr1:25234806	RUNX3	-0.53	-7.34	-0.43	3.62e-12	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs6088590	0.735	rs6060001	chr20:33294353	C/T	cg08999081	chr20:33150536	PIGU	-0.37	-5.7	-0.35	3.55e-8	Coronary artery disease;
SARC	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg24399712	chr22:39784796	NA	-0.43	-5.75	-0.35	2.75e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7829975	0.522	rs6601689	chr8:8172283	C/T	cg06636001	chr8:8085503	FLJ10661	0.57	7.1	0.42	1.46e-11	Mood instability;
SARC	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg13393036	chr8:95962371	TP53INP1	-0.37	-6.17	-0.37	2.92e-9	Type 2 diabetes;
SARC	cis	rs12421382	0.659	rs1439518	chr11:109382921	T/G	cg27471124	chr11:109292789	C11orf87	0.37	5.04	0.31	9.33e-7	Schizophrenia;
SARC	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.48	6.0	0.37	7.52e-9	Tonsillectomy;
SARC	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg18252515	chr7:66147081	NA	0.45	4.85	0.3	2.27e-6	Aortic root size;
SARC	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg25072359	chr17:41440525	NA	0.49	5.72	0.35	3.19e-8	Menopause (age at onset);
SARC	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.49	5.41	0.33	1.57e-7	Renal function-related traits (BUN);
SARC	cis	rs2153535	0.580	rs9505450	chr6:8469902	C/T	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg08280861	chr8:58055591	NA	0.61	5.81	0.36	2.02e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9916302	0.706	rs4795385	chr17:37733148	A/G	cg00129232	chr17:37814104	STARD3	0.59	6.22	0.38	2.33e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs13177718	0.908	rs7713158	chr5:108179300	G/A	cg20423064	chr5:108166851	FER	-0.83	-5.53	-0.34	8.64e-8	Height;
SARC	cis	rs4481887	0.927	rs4341391	chr1:248475720	A/G	cg00666640	chr1:248458726	OR2T12	0.31	5.19	0.32	4.61e-7	Common traits (Other);
SARC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg02475777	chr4:1388615	CRIPAK	0.62	7.17	0.43	9.81e-12	Longevity;
SARC	cis	rs9916302	0.706	rs7503377	chr17:37708841	A/G	cg07936489	chr17:37558343	FBXL20	-0.77	-8.18	-0.47	1.85e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs3106136	0.967	rs8026	chr4:95212185	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.39	-6.06	-0.37	5.47e-9	Capecitabine sensitivity;
SARC	cis	rs1707322	1.000	rs785484	chr1:46574015	T/C	cg06784218	chr1:46089804	CCDC17	-0.36	-6.28	-0.38	1.61e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg00031303	chr3:195681400	NA	0.5	5.76	0.35	2.67e-8	Pancreatic cancer;
SARC	cis	rs8141529	0.719	rs6005916	chr22:29233342	T/C	cg02153584	chr22:29168773	CCDC117	0.79	11.88	0.61	9.3e-26	Lymphocyte counts;
SARC	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg15448220	chr1:150897856	SETDB1	0.47	6.25	0.38	1.94e-9	Tonsillectomy;
SARC	cis	rs7249142	0.549	rs741706	chr19:19281672	C/T	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.23	4.85	0.3	2.23e-6	IgG glycosylation;
SARC	trans	rs3780486	0.813	rs3780488	chr9:33133812	T/C	cg20290983	chr6:43655470	MRPS18A	1.15	22.21	0.82	1.95e-59	IgG glycosylation;
SARC	cis	rs72634258	0.842	rs4325151	chr1:8168917	T/A	cg00042356	chr1:8021962	PARK7	-0.63	-5.88	-0.36	1.42e-8	Inflammatory bowel disease;
SARC	cis	rs796364	1.000	rs166845	chr2:200823360	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.78	7.57	0.44	8.72e-13	Schizophrenia;
SARC	cis	rs698833	0.886	rs1056865	chr2:44546741	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.63	7.52	0.44	1.16e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs16854884	0.586	rs6782789	chr3:143746691	G/A	cg06585982	chr3:143692056	C3orf58	0.7	9.83	0.54	2.77e-19	Economic and political preferences (feminism/equality);
SARC	cis	rs9419702	0.568	rs7920966	chr10:133555185	G/T	cg23460707	chr10:133558971	NA	0.35	5.04	0.31	9.4e-7	Survival in rectal cancer;
SARC	cis	rs73206853	0.841	rs73191816	chr12:110918564	G/A	cg10860002	chr12:110842031	ANAPC7	0.64	5.1	0.32	7.2e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs7027203	0.576	rs4424329	chr9:96560806	G/C	cg14598338	chr9:96623480	NA	0.34	4.79	0.3	2.96e-6	DNA methylation (variation);
SARC	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg12419862	chr22:24373484	LOC391322	-0.99	-16.49	-0.73	5.26e-41	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs951366	0.531	rs12030754	chr1:205678043	G/C	cg24503407	chr1:205819492	PM20D1	-0.42	-4.78	-0.3	3.09e-6	Menarche (age at onset);
SARC	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg19723775	chr5:179050963	HNRNPH1	0.44	5.73	0.35	3.04e-8	Lung cancer;
SARC	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.52	5.99	0.37	7.87e-9	Renal function-related traits (BUN);
SARC	cis	rs2370759	1.000	rs16933177	chr10:32565705	G/A	cg05361325	chr10:32636312	EPC1	-0.75	-6.58	-0.4	3.1e-10	Sexual dysfunction (female);
SARC	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg11062466	chr8:58055876	NA	0.61	5.75	0.35	2.74e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9346455	1.000	rs12055385	chr6:71996789	G/A	cg27238071	chr6:71998145	OGFRL1	0.58	4.75	0.3	3.54e-6	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
SARC	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs9611519	0.567	rs8141730	chr22:41473061	A/G	cg17376030	chr22:41985996	PMM1	0.4	5.0	0.31	1.14e-6	Neuroticism;
SARC	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg24642844	chr7:1081250	C7orf50	-0.57	-6.05	-0.37	5.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.35	0.52	7.64e-18	Prudent dietary pattern;
SARC	cis	rs35213789	0.853	rs7809321	chr7:69271349	G/T	cg10619644	chr7:69149951	AUTS2	0.37	4.77	0.3	3.21e-6	Childhood ear infection;
SARC	cis	rs710216	0.718	rs841851	chr1:43401829	A/G	cg03128534	chr1:43423976	SLC2A1	0.6	5.64	0.35	4.83e-8	Red cell distribution width;
SARC	cis	rs6084875	0.733	rs6037959	chr20:4741723	A/G	cg05143360	chr20:4741328	NA	0.4	4.86	0.3	2.18e-6	Systemic lupus erythematosus;
SARC	cis	rs9309473	0.898	rs6546851	chr2:73833283	C/T	cg20560298	chr2:73613845	ALMS1	-0.45	-5.23	-0.32	3.79e-7	Metabolite levels;
SARC	cis	rs1944866	0.764	rs11223927	chr11:134525648	A/G	cg24140030	chr11:133938757	JAM3	-0.65	-4.73	-0.3	3.83e-6	Myopia (pathological);
SARC	cis	rs11122272	0.701	rs2749702	chr1:231523808	A/G	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs7666738	0.830	rs1869082	chr4:98841254	T/A	cg05340658	chr4:99064831	C4orf37	0.66	8.76	0.5	4.2e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1348850	0.632	rs13009207	chr2:178501632	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.51	5.8	0.36	2.18e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9398803	0.897	rs9398804	chr6:126703390	T/A	cg19875578	chr6:126661172	C6orf173	0.58	7.82	0.46	1.83e-13	Male-pattern baldness;
SARC	cis	rs11098499	0.909	rs9994810	chr4:120381590	A/G	cg09307838	chr4:120376055	NA	0.92	13.13	0.65	7.35e-30	Corneal astigmatism;
SARC	cis	rs2120019	0.508	rs8030528	chr15:75171825	C/T	cg00629941	chr15:75287862	SCAMP5	-0.56	-5.29	-0.33	2.84e-7	Blood trace element (Zn levels);
SARC	cis	rs13077101	0.530	rs6787364	chr3:120437310	A/C	cg24332942	chr3:120408071	RABL3	-0.36	-4.76	-0.3	3.38e-6	Obesity-related traits;
SARC	cis	rs8038465	0.592	rs58443257	chr15:73930707	A/T	cg15420318	chr15:73925796	NPTN	0.63	7.27	0.43	5.37e-12	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6728642	0.831	rs10496325	chr2:97683329	C/T	cg26665480	chr2:98280029	ACTR1B	0.62	6.11	0.37	4.24e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg04944784	chr2:26401820	FAM59B	-0.51	-6.18	-0.38	2.82e-9	Gut microbiome composition (summer);
SARC	cis	rs13191362	1.000	rs66534429	chr6:163003322	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.57	5.51	0.34	9.61e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs3796352	1.000	rs34943350	chr3:53012888	C/T	cg15956490	chr3:53032818	SFMBT1	0.85	5.45	0.34	1.27e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs1018836	0.923	rs7840846	chr8:91565501	T/A	cg16814680	chr8:91681699	NA	-0.82	-12.94	-0.65	3.26e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs74417235	0.517	rs13179034	chr5:154059487	C/A	cg08754654	chr5:154026448	NA	0.48	4.8	0.3	2.86e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
SARC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg10295955	chr4:187884368	NA	-1.04	-18.25	-0.77	8.52e-47	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs9329221	0.537	rs6986911	chr8:9978523	C/T	cg06636001	chr8:8085503	FLJ10661	0.53	7.23	0.43	6.85e-12	Neuroticism;
SARC	cis	rs4319547	1.000	rs7309390	chr12:123110422	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.59	-6.98	-0.42	3.05e-11	Body mass index;
SARC	cis	rs6545883	0.524	rs2694618	chr2:61536984	A/G	cg16430332	chr2:61389173	C2orf74	0.33	4.77	0.3	3.24e-6	Tuberculosis;
SARC	cis	rs6570726	0.846	rs7762536	chr6:145923145	T/C	cg05220968	chr6:146057943	EPM2A	-0.28	-4.8	-0.3	2.86e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs397969	0.596	rs9901294	chr17:19888501	G/A	cg13482628	chr17:19912719	NA	0.43	4.77	0.3	3.19e-6	Platelet count;
SARC	cis	rs6971211	0.605	rs754468	chr7:155671147	T/G	cg14601210	chr7:155671264	NA	0.27	5.18	0.32	4.72e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs1801251	1.000	rs67013068	chr2:233608253	G/C	cg25237894	chr2:233734115	C2orf82	0.36	4.79	0.3	2.95e-6	Coronary artery disease;
SARC	cis	rs1113500	0.862	rs2336129	chr1:108640669	A/G	cg06207961	chr1:108661230	NA	-0.48	-6.38	-0.39	9.63e-10	Growth-regulated protein alpha levels;
SARC	cis	rs3087591	1.000	rs2953015	chr17:29495341	A/G	cg24425628	chr17:29625626	OMG;NF1	0.52	6.42	0.39	7.47e-10	Hip circumference;
SARC	cis	rs7223966	0.618	rs9906903	chr17:61634508	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	5.27	0.33	3.05e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6901004	0.935	rs1150078	chr6:111560301	C/T	cg15721981	chr6:111408429	SLC16A10	0.41	4.82	0.3	2.55e-6	Blood metabolite levels;
SARC	cis	rs1983891	1.000	rs1983891	chr6:41536427	A/G	cg15051332	chr6:41514432	FOXP4	-0.53	-5.82	-0.36	1.93e-8	Prostate cancer;
SARC	cis	rs6952808	0.635	rs6952727	chr7:1947958	A/G	cg05863683	chr7:1912471	MAD1L1	0.37	5.69	0.35	3.83e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs2842992	0.714	rs2475564	chr6:160123673	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.76	7.49	0.44	1.45e-12	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg26119090	chr2:26468346	HADHA;HADHB	0.95	13.96	0.67	1.32e-32	Gut microbiome composition (summer);
SARC	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg08219700	chr8:58056026	NA	0.57	5.51	0.34	9.69e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs62432291	0.681	rs2501177	chr6:159655593	C/T	cg14500486	chr6:159655392	FNDC1	-0.62	-6.03	-0.37	6.44e-9	Joint mobility (Beighton score);
SARC	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg14664628	chr15:75095509	CSK	-0.42	-4.97	-0.31	1.29e-6	Breast cancer;
SARC	cis	rs2377585	0.706	rs73053851	chr12:8839377	C/G	cg03761649	chr12:8850719	RIMKLB	0.46	4.72	0.3	4.16e-6	Reticulocyte fraction of red cells;
SARC	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.45	5.06	0.31	8.38e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs950027	0.620	rs35861938	chr15:45637343	T/C	cg26924012	chr15:45694286	SPATA5L1	0.53	6.74	0.4	1.2e-10	Response to fenofibrate (adiponectin levels);
SARC	cis	rs1008375	0.966	rs6839660	chr4:17667987	C/T	cg02297831	chr4:17616191	MED28	0.41	5.22	0.32	4.04e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs15676	0.783	rs4837316	chr9:131577450	A/G	cg00228799	chr9:131580591	ENDOG	0.61	7.73	0.45	3.12e-13	Blood metabolite levels;
SARC	cis	rs77106637	0.858	rs7109575	chr11:72463435	G/A	cg03713592	chr11:72463424	ARAP1	1.09	10.42	0.56	4.16e-21	Type 2 diabetes;
SARC	cis	rs2075371	1.000	rs2598288	chr7:133977304	A/T	cg00033643	chr7:134001901	SLC35B4	0.41	4.98	0.31	1.25e-6	Mean platelet volume;
SARC	cis	rs12586317	0.620	rs8021414	chr14:35581480	T/A	cg05294307	chr14:35346193	BAZ1A	-0.48	-4.93	-0.31	1.59e-6	Psoriasis;
SARC	cis	rs2295359	0.892	rs72676058	chr1:67627681	C/A	cg12940439	chr1:67600707	NA	0.48	6.77	0.41	1.06e-10	Psoriasis;
SARC	cis	rs10752881	1.000	rs12028732	chr1:182985525	G/C	cg13390022	chr1:182993471	LAMC1	0.35	5.24	0.32	3.63e-7	Colorectal cancer;
SARC	cis	rs295137	0.752	rs10931892	chr2:201104997	C/T	cg23649088	chr2:200775458	C2orf69	-0.48	-6.75	-0.4	1.15e-10	Asthma (bronchodilator response);
SARC	cis	rs7772486	0.764	rs7745696	chr6:146162829	T/C	cg23711669	chr6:146136114	FBXO30	0.8	13.38	0.66	1.12e-30	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.68	-8.9	-0.5	1.61e-16	Prudent dietary pattern;
SARC	cis	rs2204008	0.592	rs2320501	chr12:38145285	T/G	cg13010199	chr12:38710504	ALG10B	0.74	9.8	0.54	3.21e-19	Bladder cancer;
SARC	cis	rs35146811	0.844	rs4424195	chr7:99642745	A/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.4	4.91	0.31	1.72e-6	Coronary artery disease;
SARC	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg09359103	chr1:154839909	KCNN3	-0.41	-6.78	-0.41	9.8e-11	Prostate cancer;
SARC	cis	rs288326	0.561	rs77318535	chr2:183857319	C/T	cg09997497	chr2:183902928	NCKAP1	0.74	5.1	0.32	6.97e-7	Blood protein levels;
SARC	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg11062466	chr8:58055876	NA	0.54	5.56	0.34	7.55e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9389248	0.690	rs2294321	chr6:135253048	T/G	cg22676075	chr6:135203613	NA	-0.44	-5.63	-0.35	5.08e-8	High light scatter reticulocyte percentage of red cells;
SARC	cis	rs9303401	0.527	rs12939313	chr17:56755616	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.08	11.1	0.59	2.97e-23	Cognitive test performance;
SARC	cis	rs2016266	0.855	rs6580941	chr12:53662199	T/C	cg26875137	chr12:53738046	NA	0.42	5.55	0.34	7.9e-8	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs4654899	0.828	rs6668591	chr1:21066557	A/G	cg04902671	chr1:21058625	SH2D5	-0.4	-4.76	-0.3	3.38e-6	Superior frontal gyrus grey matter volume;
SARC	cis	rs7712401	0.525	rs193541	chr5:122253304	C/T	cg19412675	chr5:122181750	SNX24	0.37	4.98	0.31	1.23e-6	Mean platelet volume;
SARC	cis	rs8180040	0.764	rs13061071	chr3:47138708	G/A	cg27129171	chr3:47204927	SETD2	0.67	9.41	0.52	5.06e-18	Colorectal cancer;
SARC	cis	rs11122272	0.735	rs2808602	chr1:231537303	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.08	-0.55	4.68e-20	Hemoglobin concentration;
SARC	cis	rs7106204	0.688	rs7131103	chr11:24219299	A/G	ch.11.24196551F	chr11:24239977	NA	0.69	6.38	0.39	9.41e-10	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs4430311	0.723	rs897959	chr1:243897774	C/T	cg21452805	chr1:244014465	NA	-0.38	-4.97	-0.31	1.3e-6	Post-traumatic stress disorder (asjusted for relatedness);
SARC	cis	rs9323205	0.765	rs2999386	chr14:51652628	G/T	cg23942311	chr14:51606299	NA	0.3	5.03	0.31	9.99e-7	Cancer;
SARC	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg12463550	chr7:65579703	CRCP	-0.7	-5.31	-0.33	2.51e-7	Diabetic kidney disease;
SARC	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg24250549	chr1:154909240	PMVK	0.78	11.26	0.59	8.87e-24	Prostate cancer;
SARC	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.31	-4.86	-0.3	2.17e-6	Total body bone mineral density;
SARC	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg19077165	chr18:44547161	KATNAL2	-0.45	-6.15	-0.37	3.37e-9	Personality dimensions;
SARC	cis	rs2908197	0.737	rs6978009	chr7:75992234	A/C	cg22830091	chr7:75961684	YWHAG	0.34	5.03	0.31	9.86e-7	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs7927592	0.913	rs12363722	chr11:68236291	A/C	cg01657329	chr11:68192670	LRP5	-0.41	-4.99	-0.31	1.18e-6	Total body bone mineral density;
SARC	cis	rs3008870	0.959	rs2985816	chr1:67387750	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.93	11.49	0.6	1.62e-24	Lymphocyte percentage of white cells;
SARC	cis	rs9487051	0.714	rs1546722	chr6:109625797	A/G	cg01475377	chr6:109611718	NA	-0.38	-5.43	-0.34	1.38e-7	Reticulocyte fraction of red cells;
SARC	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.44	5.51	0.34	9.56e-8	Tonsillectomy;
SARC	cis	rs4253772	0.530	rs6008662	chr22:46713917	G/A	cg24881330	chr22:46731750	TRMU	0.8	8.03	0.47	4.72e-14	LDL cholesterol;Cholesterol, total;
SARC	cis	rs9473924	0.505	rs7753025	chr6:50858352	A/C	cg14470998	chr6:50812995	TFAP2B	0.77	7.24	0.43	6.59e-12	Body mass index;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg23975846	chr7:2638680	IQCE	-0.5	-6.58	-0.4	3.1e-10	Electrocardiographic conduction measures;
SARC	cis	rs7220711	0.934	rs9909172	chr17:41787521	T/C	cg26893861	chr17:41843967	DUSP3	0.4	5.06	0.31	8.37e-7	Bone mineral density (spine);Bone mineral density (hip);
SARC	cis	rs10504229	0.679	rs1442125	chr8:58036258	A/C	cg21724239	chr8:58056113	NA	-0.58	-5.85	-0.36	1.64e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg22920501	chr2:26401640	FAM59B	-0.59	-7.9	-0.46	1.1e-13	Gut microbiome composition (summer);
SARC	cis	rs17253792	0.822	rs17832365	chr14:56153531	C/G	cg01858014	chr14:56050164	KTN1	-0.63	-4.8	-0.3	2.82e-6	Putamen volume;
SARC	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg02725872	chr8:58115012	NA	-0.27	-4.77	-0.3	3.27e-6	Developmental language disorder (linguistic errors);
SARC	trans	rs877282	0.947	rs957642	chr10:773966	C/T	cg22713356	chr15:30763199	NA	0.96	10.22	0.56	1.74e-20	Uric acid levels;
SARC	cis	rs6088590	1.000	rs6120708	chr20:33335526	G/A	cg06115741	chr20:33292138	TP53INP2	0.57	6.91	0.41	4.71e-11	Coronary artery disease;
SARC	cis	rs2415984	0.562	rs12882684	chr14:46931802	C/T	cg14871534	chr14:47121158	RPL10L	0.39	5.41	0.33	1.54e-7	Number of children ever born;
SARC	cis	rs9916302	0.904	rs8068427	chr17:37511517	G/A	cg00129232	chr17:37814104	STARD3	0.58	7.24	0.43	6.36e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg19723775	chr5:179050963	HNRNPH1	-0.4	-5.09	-0.32	7.23e-7	Lung cancer;
SARC	cis	rs1865760	0.622	rs9295685	chr6:26071725	G/C	cg10373733	chr6:25993375	NA	0.41	4.9	0.31	1.79e-6	Height;
SARC	cis	rs9527	0.590	rs3861984	chr10:104916980	T/C	cg04362960	chr10:104952993	NT5C2	0.45	5.32	0.33	2.46e-7	Arsenic metabolism;
SARC	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg26818010	chr10:134567672	INPP5A	-0.55	-6.14	-0.37	3.58e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs6570726	1.000	rs6570699	chr6:145920732	G/A	cg23711669	chr6:146136114	FBXO30	0.75	10.98	0.58	7.18e-23	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs8017423	0.935	rs7154695	chr14:90795705	C/G	cg20276874	chr14:90721474	PSMC1	-0.36	-4.86	-0.3	2.12e-6	Mortality in heart failure;
SARC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg05839201	chr16:30194815	CORO1A	0.56	6.28	0.38	1.6e-9	Myopia (pathological);
SARC	cis	rs11874712	1.000	rs2298787	chr18:43669980	T/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.46	5.5	0.34	1.02e-7	Migraine - clinic-based;
SARC	cis	rs2070488	1.000	rs13074025	chr3:38455704	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	14.45	0.69	3.18e-34	Electrocardiographic conduction measures;
SARC	cis	rs78487399	0.710	rs17031000	chr2:43758625	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-4.81	-0.3	2.67e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs35160687	0.842	rs10200526	chr2:86527599	G/A	cg10973622	chr2:86423274	IMMT	0.38	4.89	0.31	1.86e-6	Night sleep phenotypes;
SARC	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg21782813	chr7:2030301	MAD1L1	0.35	5.54	0.34	8.11e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs12479064	0.724	rs6748200	chr2:100080895	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.65	-8.02	-0.47	5.01e-14	Chronic sinus infection;
SARC	cis	rs910187	0.678	rs6124965	chr20:45812957	T/G	cg27589058	chr20:45804311	EYA2	-0.29	-4.76	-0.3	3.41e-6	Migraine;
SARC	cis	rs1023500	0.573	rs6002592	chr22:42476754	A/C	cg04733989	chr22:42467013	NAGA	-0.77	-10.92	-0.58	1.11e-22	Schizophrenia;
SARC	cis	rs9796	0.553	rs7171437	chr15:41315168	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.54	-7.27	-0.43	5.34e-12	Menopause (age at onset);
SARC	cis	rs6088590	1.000	rs6119524	chr20:33373813	C/T	cg06115741	chr20:33292138	TP53INP2	0.57	6.83	0.41	7.46e-11	Coronary artery disease;
SARC	cis	rs9788682	0.747	rs11072766	chr15:78771546	C/T	cg24631222	chr15:78858424	CHRNA5	0.74	9.03	0.51	6.53e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs3845702	1.000	rs10497555	chr2:180864967	A/G	cg01881094	chr2:180872142	CWC22	0.6	5.42	0.33	1.52e-7	Schizophrenia;
SARC	cis	rs11190604	0.767	rs7392696	chr10:102182141	G/A	cg07080220	chr10:102295463	HIF1AN	0.72	8.21	0.47	1.47e-14	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs1008375	1.000	rs1121089	chr4:17676476	C/A	cg02297831	chr4:17616191	MED28	0.43	5.37	0.33	1.89e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9858542	0.537	rs9873994	chr3:49359943	T/C	cg00383909	chr3:49044727	WDR6	0.55	5.85	0.36	1.65e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs9640161	0.711	rs60268791	chr7:150023800	G/T	cg17279839	chr7:150038598	RARRES2	0.49	7.39	0.44	2.64e-12	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs6570726	0.846	rs9376954	chr6:145943737	T/A	cg23711669	chr6:146136114	FBXO30	0.77	12.35	0.63	2.82e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	6.08	0.37	4.98e-9	Prudent dietary pattern;
SARC	cis	rs11098499	0.754	rs1814813	chr4:120258207	G/T	cg09307838	chr4:120376055	NA	-0.79	-10.98	-0.58	7e-23	Corneal astigmatism;
SARC	cis	rs936229	0.861	rs7180484	chr15:75115416	G/T	cg14664628	chr15:75095509	CSK	1.05	15.14	0.7	1.57e-36	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs1371867	0.846	rs959022	chr8:101295992	T/A	cg11906718	chr8:101322791	RNF19A	0.69	8.92	0.5	1.36e-16	Atrioventricular conduction;
SARC	cis	rs6570726	0.967	rs6903252	chr6:145922777	A/G	cg05347473	chr6:146136440	FBXO30	0.48	6.52	0.39	4.29e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs910316	0.967	rs11159116	chr14:75550584	G/T	cg11812906	chr14:75593930	NEK9	0.87	13.73	0.67	7.71e-32	Height;
SARC	cis	rs10911232	0.507	rs2151669	chr1:183055398	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.33	0.56	7.51e-21	Hypertriglyceridemia;
SARC	cis	rs7523050	0.554	rs34086470	chr1:109485991	C/A	cg08274380	chr1:109419600	GPSM2	1.08	7.98	0.46	6.45e-14	Fat distribution (HIV);
SARC	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.75	8.78	0.5	3.52e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7568458	0.684	rs1048740	chr2:85764966	A/T	cg02493740	chr2:85810744	VAMP5	-0.41	-5.16	-0.32	5.4e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs782590	0.807	rs782572	chr2:55912120	T/C	cg18811423	chr2:55921094	PNPT1	0.78	11.89	0.61	8.85e-26	Metabolic syndrome;
SARC	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg18404041	chr3:52824283	ITIH1	-0.44	-6.64	-0.4	2.2e-10	Bipolar disorder;
SARC	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.59	-7.69	-0.45	4.07e-13	Mean platelet volume;
SARC	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg13393036	chr8:95962371	TP53INP1	-0.36	-6.21	-0.38	2.38e-9	Type 2 diabetes;
SARC	cis	rs2731664	0.792	rs2630763	chr5:176901005	T/A	cg23176889	chr5:176863531	GRK6	-0.59	-8.85	-0.5	2.22e-16	Intelligence (multi-trait analysis);
SARC	cis	rs1707322	0.821	rs10749857	chr1:46248143	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.49	0.39	5.05e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9914988	0.943	rs12951232	chr17:27132638	G/C	cg20469991	chr17:27169893	C17orf63	-0.5	-5.25	-0.33	3.36e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs4555082	0.750	rs2816650	chr14:105708343	C/T	cg10792982	chr14:105748885	BRF1	0.54	8.16	0.47	2.12e-14	Mean platelet volume;Platelet distribution width;
SARC	cis	rs6912958	0.781	rs4464759	chr6:88282621	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-6.75	-0.4	1.15e-10	Monocyte percentage of white cells;
SARC	trans	rs12310956	0.510	rs10743832	chr12:33884146	A/C	cg13010199	chr12:38710504	ALG10B	0.56	7.31	0.43	4.33e-12	Morning vs. evening chronotype;
SARC	cis	rs10979	0.557	rs9376768	chr6:143909492	C/T	cg25407410	chr6:143891975	LOC285740	-0.5	-5.83	-0.36	1.81e-8	Hypospadias;
SARC	trans	rs2018683	1.000	rs4719962	chr7:28999237	G/A	cg19402173	chr7:128379420	CALU	-0.74	-10.3	-0.56	9.65e-21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	trans	rs11250098	0.574	rs7015168	chr8:10772210	G/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.31	-0.38	1.42e-9	Morning vs. evening chronotype;
SARC	cis	rs7659604	0.540	rs10001092	chr4:122677177	C/T	cg19671926	chr4:122722719	EXOSC9	0.55	6.99	0.42	2.87e-11	Type 2 diabetes;
SARC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg04234412	chr22:24373322	LOC391322	-0.53	-6.26	-0.38	1.88e-9	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs4713118	0.869	rs7776351	chr6:27726731	A/G	cg17221315	chr6:27791827	HIST1H4J	-0.45	-4.75	-0.3	3.54e-6	Parkinson's disease;
SARC	cis	rs7917772	0.636	rs7088981	chr10:104520423	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-6.43	-0.39	7.05e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs36051895	0.623	rs6476955	chr9:5256533	C/G	cg02405213	chr9:5042618	JAK2	-0.41	-4.98	-0.31	1.23e-6	Pediatric autoimmune diseases;
SARC	cis	rs6964587	0.692	rs6953256	chr7:91575417	C/T	cg17063962	chr7:91808500	NA	-0.81	-11.92	-0.62	7.07e-26	Breast cancer;
SARC	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg09455208	chr3:40491958	NA	0.38	5.51	0.34	9.51e-8	Renal cell carcinoma;
SARC	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg20891558	chr2:74357851	NA	0.72	9.7	0.54	6.83e-19	Gestational age at birth (maternal effect);
SARC	cis	rs13191362	1.000	rs13209728	chr6:162997533	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.56	5.41	0.33	1.53e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2832191	0.636	rs8131295	chr21:30516819	A/T	cg24692254	chr21:30365293	RNF160	-0.69	-8.2	-0.47	1.57e-14	Dental caries;
SARC	cis	rs35995292	0.500	rs8180877	chr7:38931258	G/A	cg19327137	chr7:38886074	VPS41	0.49	7.24	0.43	6.36e-12	Subjective well-being (multi-trait analysis);
SARC	cis	rs4808199	1.000	rs17288409	chr19:19504167	T/C	cg03709012	chr19:19516395	GATAD2A	1.16	13.1	0.65	9.21e-30	Nonalcoholic fatty liver disease;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg00014112	chr2:127413530	GYPC	-0.61	-6.88	-0.41	5.6e-11	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg27541892	chr1:1571801	CDK11B	0.41	5.56	0.34	7.31e-8	Body mass index;
SARC	cis	rs2073499	0.873	rs6446202	chr3:50219991	C/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.62	5.26	0.33	3.19e-7	Schizophrenia;
SARC	cis	rs7561273	0.586	rs116650625	chr2:24353212	C/G	cg07265300	chr2:24346000	PFN4;LOC375190	-0.42	-4.72	-0.3	4.01e-6	Quantitative traits;
SARC	cis	rs9948	0.655	rs6751132	chr2:97405866	T/C	cg01990225	chr2:97406019	LMAN2L	-0.81	-6.17	-0.37	2.99e-9	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs9325144	0.555	rs6582576	chr12:38701230	C/T	cg10518543	chr12:38710700	ALG10B	-0.38	-4.75	-0.3	3.52e-6	Morning vs. evening chronotype;
SARC	trans	rs1910358	0.554	rs10057796	chr5:23759746	C/T	cg02790967	chr7:7607022	MIOS	0.55	6.45	0.39	6.51e-10	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs10876993	0.928	rs2640631	chr12:58067532	A/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.46	-5.88	-0.36	1.39e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs1569175	0.522	rs3094771	chr2:200886058	A/G	cg23649088	chr2:200775458	C2orf69	-0.63	-5.37	-0.33	1.91e-7	Response to treatment for acute lymphoblastic leukemia;
SARC	cis	rs2370759	0.898	rs113412621	chr10:32579306	C/T	cg18270830	chr10:32634957	EPC1	0.66	5.81	0.36	2.07e-8	Sexual dysfunction (female);
SARC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg02725872	chr8:58115012	NA	-0.31	-4.78	-0.3	3.09e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2153535	0.580	rs1360054	chr6:8520377	C/A	cg23788917	chr6:8435910	SLC35B3	0.64	8.66	0.49	7.75e-16	Motion sickness;
SARC	cis	rs2439831	0.867	rs2584702	chr15:43684914	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.78	8.26	0.48	1.12e-14	Lung cancer in ever smokers;
SARC	cis	rs950169	1.000	rs11638394	chr15:84778928	G/A	cg17507749	chr15:85114479	UBE2QP1	0.75	9.2	0.52	2.12e-17	Schizophrenia;
SARC	cis	rs2295359	0.892	rs12029362	chr1:67624231	G/A	cg12940439	chr1:67600707	NA	0.48	6.84	0.41	7.05e-11	Psoriasis;
SARC	cis	rs2153535	0.580	rs9406171	chr6:8515362	T/C	cg21535247	chr6:8435926	SLC35B3	0.57	7.21	0.43	7.67e-12	Motion sickness;
SARC	cis	rs9790314	0.663	rs7632423	chr3:160738728	A/G	cg04691961	chr3:161091175	C3orf57	0.56	7.73	0.45	3.1400000000000003e-13	Morning vs. evening chronotype;
SARC	cis	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg24110177	chr3:50126178	RBM5	0.38	4.86	0.3	2.11e-6	Intelligence (multi-trait analysis);
SARC	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg25934064	chr3:52569026	NT5DC2	0.31	4.81	0.3	2.66e-6	Intelligence (multi-trait analysis);
SARC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.8	10.24	0.56	1.52e-20	Prudent dietary pattern;
SARC	cis	rs7223966	1.000	rs7223966	chr17:61893398	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	7.32	0.43	3.91e-12	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs17270561	0.609	rs2154218	chr6:25776290	T/C	cg16482183	chr6:26056742	HIST1H1C	0.5	6.07	0.37	5.24e-9	Iron status biomarkers;
SARC	cis	rs9300255	0.537	rs1716182	chr12:123686127	A/C	cg00376283	chr12:123451042	ABCB9	0.55	6.53	0.39	4.09e-10	Neutrophil percentage of white cells;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg11419670	chr3:57310747	ASB14	0.49	7.18	0.43	9.23e-12	Thyroid stimulating hormone;
SARC	cis	rs3126085	0.935	rs12401851	chr1:152259022	T/C	cg26876637	chr1:152193138	HRNR	-0.5	-5.67	-0.35	4.16e-8	Atopic dermatitis;
SARC	cis	rs1670533	1.000	rs6858612	chr4:1053353	C/T	cg27284194	chr4:1044797	NA	0.45	4.82	0.3	2.57e-6	Recombination rate (females);
SARC	cis	rs709400	0.628	rs2273699	chr14:103923475	A/G	cg26031613	chr14:104095156	KLC1	0.82	11.98	0.62	4.37e-26	Body mass index;
SARC	cis	rs115842765	0.557	rs9357409	chr6:43184641	A/C	cg10864404	chr6:43395769	NA	-0.83	-5.05	-0.31	9.11e-7	PR interval in Tripanosoma cruzi seropositivity;
SARC	cis	rs7312933	0.703	rs11181380	chr12:42616040	A/T	cg19980929	chr12:42632907	YAF2	0.44	5.91	0.36	1.21e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs1843834	0.539	rs2047135	chr2:225427302	G/C	cg22509189	chr2:225307070	NA	-0.68	-8.55	-0.49	1.62e-15	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg14541582	chr5:601475	NA	-0.41	-5.02	-0.31	1e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs11674184	0.714	rs16857668	chr2:11723110	G/A	cg07314298	chr2:11723111	GREB1	-0.51	-6.81	-0.41	8.15e-11	Endometriosis;
SARC	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg12463550	chr7:65579703	CRCP	-0.46	-4.88	-0.3	2.01e-6	Aortic root size;
SARC	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg05896524	chr21:47604654	C21orf56	-0.52	-6.39	-0.39	8.78e-10	Testicular germ cell tumor;
SARC	cis	rs6582630	0.519	rs8189618	chr12:38276281	A/C	cg13010199	chr12:38710504	ALG10B	0.81	11.31	0.6	6.15e-24	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs61931739	0.500	rs7955247	chr12:34126580	G/A	cg13010199	chr12:38710504	ALG10B	0.77	10.4	0.56	4.63e-21	Morning vs. evening chronotype;
SARC	cis	rs9733	0.744	rs2089081	chr1:150800117	T/C	cg13175981	chr1:150552382	MCL1	0.61	8.31	0.48	7.74e-15	Tonsillectomy;
SARC	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg06212747	chr3:49208901	KLHDC8B	0.72	9.69	0.54	7.02e-19	Parkinson's disease;
SARC	cis	rs7395581	0.959	rs7129661	chr11:47268550	T/G	cg25783544	chr11:47291846	MADD	0.47	5.01	0.31	1.08e-6	HDL cholesterol;
SARC	cis	rs7011049	1.000	rs72640868	chr8:53843812	C/A	cg26025543	chr8:53854495	NA	0.6	5.43	0.34	1.42e-7	Systolic blood pressure;
SARC	cis	rs4268898	0.610	rs34216622	chr2:24463445	G/C	cg26838691	chr2:24397539	C2orf84	-0.5	-5.72	-0.35	3.26e-8	Asthma;
SARC	cis	rs7617773	0.780	rs13067450	chr3:48337206	C/T	cg11946769	chr3:48343235	NME6	0.76	9.72	0.54	5.94e-19	Coronary artery disease;
SARC	trans	rs61931739	0.500	rs7484658	chr12:34515879	A/G	cg13010199	chr12:38710504	ALG10B	0.76	10.85	0.58	1.77e-22	Morning vs. evening chronotype;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg18368637	chr6:144179905	LTV1	-0.79	-6.46	-0.39	5.94e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg04944784	chr2:26401820	FAM59B	-0.48	-6.01	-0.37	7.08e-9	Gut microbiome composition (summer);
SARC	cis	rs854765	0.534	rs7207461	chr17:17949789	T/G	cg04398451	chr17:18023971	MYO15A	0.47	6.55	0.39	3.55e-10	Total body bone mineral density;
SARC	cis	rs10911251	0.546	rs3359	chr1:183112041	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.68	9.85	0.54	2.31e-19	Colorectal cancer;
SARC	cis	rs2439831	0.681	rs7175434	chr15:43628542	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	8.94	0.51	1.22e-16	Lung cancer in ever smokers;
SARC	cis	rs7223966	1.000	rs9899788	chr17:61756384	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.45	5.03	0.31	9.75e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs210138	1.000	rs210144	chr6:33547430	G/A	cg07679836	chr6:33548423	BAK1	0.48	5.65	0.35	4.74e-8	Testicular germ cell tumor;
SARC	cis	rs1497406	0.744	rs4537547	chr1:16510798	C/T	cg06365898	chr1:16533907	ARHGEF19	-0.43	-5.6	-0.34	6.11e-8	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs79149102	0.579	rs7182286	chr15:75293839	A/G	cg17294928	chr15:75287854	SCAMP5	-0.99	-8.87	-0.5	1.91e-16	Lung cancer;
SARC	cis	rs12042938	0.600	rs823163	chr1:231771108	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.53	7.43	0.44	2.05e-12	Neuranatomic and neurocognitive phenotypes;
SARC	cis	rs11731606	0.508	rs12108452	chr4:95300688	A/C	cg20625393	chr4:95128694	SMARCAD1	0.49	4.89	0.31	1.86e-6	Mean platelet volume;
SARC	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs78456975	0.943	rs13385274	chr2:1576791	A/T	cg12573674	chr2:1569213	NA	-0.57	-5.17	-0.32	4.92e-7	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs3733585	0.673	rs4235347	chr4:9951956	C/T	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.39	-0.33	1.76e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs35110281	0.627	rs7282704	chr21:44966253	A/G	cg21573476	chr21:45109991	RRP1B	-0.41	-5.87	-0.36	1.48e-8	Mean corpuscular volume;
SARC	cis	rs561341	1.000	rs550264	chr17:30317540	G/T	cg00745463	chr17:30367425	LRRC37B	-0.69	-5.5	-0.34	1.01e-7	Hip circumference adjusted for BMI;
SARC	cis	rs5758659	0.652	rs133335	chr22:42416056	C/T	cg04733989	chr22:42467013	NAGA	-0.45	-5.94	-0.36	1.01e-8	Cognitive function;
SARC	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.51	4.77	0.3	3.29e-6	Lung function (FEV1/FVC);
SARC	cis	rs9818758	0.556	rs9880309	chr3:49304329	G/C	cg01304814	chr3:48885189	PRKAR2A	0.65	5.29	0.33	2.75e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs7208859	0.673	rs9898858	chr17:29156211	A/T	cg13385521	chr17:29058706	SUZ12P	0.87	7.83	0.46	1.76e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs34779708	0.966	rs1478463	chr10:35473035	G/A	cg03585969	chr10:35415529	CREM	0.41	5.17	0.32	5.07e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.63	-6.5	-0.39	4.87e-10	Platelet count;
SARC	cis	rs10493773	0.502	rs12061951	chr1:86081453	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.48	-6.57	-0.4	3.33e-10	Urate levels in overweight individuals;
SARC	trans	rs2727020	0.617	rs7102702	chr11:49401125	T/G	cg15704280	chr7:45808275	SEPT13	-0.77	-9.92	-0.54	1.39e-19	Coronary artery disease;
SARC	cis	rs425277	1.000	rs436045	chr1:2071556	A/G	cg21442419	chr1:2182373	SKI	0.52	6.55	0.39	3.7e-10	Height;
SARC	cis	rs765787	0.530	rs11854689	chr15:45516052	A/G	cg25801113	chr15:45476975	SHF	0.28	4.72	0.3	4.06e-6	Uric acid levels;
SARC	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg11890956	chr21:40555474	PSMG1	-1.06	-16.1	-0.73	1.07e-39	Cognitive function;
SARC	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg24250549	chr1:154909240	PMVK	0.84	12.26	0.63	5.46e-27	Prostate cancer;
SARC	cis	rs10504229	0.679	rs16921677	chr8:58052431	T/C	cg08219700	chr8:58056026	NA	0.6	6.01	0.37	6.93e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs11098499	0.863	rs2170276	chr4:120485824	A/C	cg09307838	chr4:120376055	NA	0.91	12.25	0.63	5.66e-27	Corneal astigmatism;
SARC	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg11644478	chr21:40555479	PSMG1	-0.56	-6.72	-0.4	1.39e-10	Menarche (age at onset);
SARC	cis	rs9325144	0.560	rs61929893	chr12:38653366	G/A	cg13010199	chr12:38710504	ALG10B	-0.56	-6.97	-0.42	3.3e-11	Morning vs. evening chronotype;
SARC	cis	rs9398803	0.865	rs9398805	chr6:126726295	C/T	cg19875578	chr6:126661172	C6orf173	0.6	8.06	0.47	3.87e-14	Male-pattern baldness;
SARC	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg17221315	chr6:27791827	HIST1H4J	0.48	5.2	0.32	4.26e-7	Parkinson's disease;
SARC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	19.22	0.78	5.86e-50	Prudent dietary pattern;
SARC	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg00684032	chr4:1343700	KIAA1530	0.38	5.52	0.34	9.14e-8	Obesity-related traits;
SARC	cis	rs11770686	0.905	rs1052	chr7:75340234	C/T	cg17787366	chr7:75369077	HIP1	0.43	5.34	0.33	2.18e-7	Essential tremor;
SARC	cis	rs11585357	0.947	rs3003441	chr1:17611869	C/T	cg08277548	chr1:17600880	PADI3	0.46	5.32	0.33	2.47e-7	Hair shape;
SARC	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg04518342	chr5:131593106	PDLIM4	0.35	5.06	0.31	8.48e-7	Breast cancer;
SARC	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg20848291	chr7:100343083	ZAN	-0.67	-7.5	-0.44	1.31e-12	Other erythrocyte phenotypes;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg12950624	chr19:46000154	RTN2	-0.58	-7.65	-0.45	5.12e-13	Gallstone disease;
SARC	cis	rs4689388	0.853	rs13108780	chr4:6294630	A/G	cg25554036	chr4:6271136	WFS1	0.39	6.42	0.39	7.48e-10	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs2242194	0.844	rs11264295	chr1:154987526	C/T	cg03351412	chr1:154909251	PMVK	0.47	5.73	0.35	3.02e-8	Schizophrenia;
SARC	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg08280861	chr8:58055591	NA	-0.58	-5.22	-0.32	3.96e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg12000995	chr2:27665139	KRTCAP3	-0.32	-4.99	-0.31	1.19e-6	Total body bone mineral density;
SARC	cis	rs6910061	1.000	rs9468415	chr6:11100885	T/A	cg27233058	chr6:11094804	LOC221710	0.58	5.56	0.34	7.5e-8	Diabetic kidney disease;
SARC	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg00800038	chr16:89945340	TCF25	-0.69	-5.1	-0.32	7.05e-7	Skin colour saturation;
SARC	cis	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg08975724	chr8:8085496	FLJ10661	0.4	5.21	0.32	4.11e-7	Joint mobility (Beighton score);
SARC	cis	rs738322	0.967	rs4380	chr22:38569529	T/C	cg25457927	chr22:38595422	NA	-0.29	-6.01	-0.37	7.09e-9	Cutaneous nevi;
SARC	cis	rs9486719	1.000	rs12213426	chr6:96896035	T/C	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.01	-0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs861020	0.630	rs657861	chr1:210006884	C/G	cg23166289	chr1:210001082	C1orf107	0.39	4.74	0.3	3.66e-6	Orofacial clefts;
SARC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg06873352	chr17:61820015	STRADA	0.53	6.85	0.41	6.67e-11	Prudent dietary pattern;
SARC	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg11878867	chr6:150167359	LRP11	-0.34	-4.72	-0.3	4.01e-6	Lung cancer;
SARC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg26338869	chr17:61819248	STRADA	0.81	10.95	0.58	8.96e-23	Prudent dietary pattern;
SARC	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg19223190	chr17:80058835	NA	-0.43	-6.02	-0.37	6.61e-9	Life satisfaction;
SARC	cis	rs9790314	0.663	rs778642	chr3:160705819	A/G	cg04691961	chr3:161091175	C3orf57	-0.57	-7.9	-0.46	1.11e-13	Morning vs. evening chronotype;
SARC	cis	rs763121	0.853	rs10135	chr22:39082174	C/T	cg06022373	chr22:39101656	GTPBP1	-0.88	-11.87	-0.61	1.03e-25	Menopause (age at onset);
SARC	cis	rs2204008	0.837	rs11172728	chr12:38070042	C/A	cg13010199	chr12:38710504	ALG10B	0.73	9.7	0.54	6.65e-19	Bladder cancer;
SARC	cis	rs4803468	1.000	rs1043413	chr19:41939297	C/G	cg09537434	chr19:41945824	ATP5SL	0.98	17.27	0.75	1.43e-43	Height;
SARC	cis	rs7084402	0.967	rs1658469	chr10:60292402	C/T	cg07615347	chr10:60278583	BICC1	-0.68	-9.57	-0.53	1.6e-18	Refractive error;
SARC	cis	rs6964587	0.541	rs6947170	chr7:91451471	A/G	cg17063962	chr7:91808500	NA	0.69	9.83	0.54	2.67e-19	Breast cancer;
SARC	cis	rs6963495	0.818	rs73192113	chr7:105169603	C/T	cg19920283	chr7:105172520	RINT1	0.67	5.76	0.35	2.59e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs7555523	0.778	rs4233408	chr1:165712960	G/A	cg24409356	chr1:165738333	TMCO1	0.61	5.27	0.33	3.06e-7	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	cis	rs11264799	0.626	rs2758688	chr1:157607377	A/G	cg18268488	chr1:157545234	FCRL4	0.29	4.79	0.3	3.03e-6	IgA nephropathy;
SARC	cis	rs9467773	1.000	rs6922824	chr6:26553815	C/G	cg11502198	chr6:26597334	ABT1	-0.46	-5.6	-0.34	6.1e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2832191	0.671	rs2409332	chr21:30512779	G/A	cg24692254	chr21:30365293	RNF160	-0.67	-8.06	-0.47	3.93e-14	Dental caries;
SARC	cis	rs5753618	0.561	rs2283881	chr22:31638932	G/A	cg07713946	chr22:31675144	LIMK2	-0.38	-5.24	-0.32	3.6e-7	Colorectal cancer;
SARC	cis	rs600231	0.708	rs682845	chr11:65254201	A/G	cg17120908	chr11:65337727	SSSCA1	-0.41	-5.31	-0.33	2.51e-7	Bone mineral density;
SARC	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg18252515	chr7:66147081	NA	0.43	4.77	0.3	3.3e-6	Aortic root size;
SARC	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg09035930	chr12:129282057	SLC15A4	0.56	8.07	0.47	3.67e-14	Systemic lupus erythematosus;
SARC	cis	rs1784581	0.855	rs1790002	chr6:162384397	G/T	cg17173639	chr6:162384350	PARK2	-0.78	-10.89	-0.58	1.37e-22	Itch intensity from mosquito bite;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg21352959	chr17:62340143	TEX2	-0.68	-8.06	-0.47	3.96e-14	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg17178900	chr1:205818956	PM20D1	0.67	9.7	0.54	6.81e-19	Menarche (age at onset);
SARC	cis	rs929354	0.772	rs1182360	chr7:157020550	C/G	cg05182265	chr7:156933206	UBE3C	-0.31	-4.83	-0.3	2.52e-6	Body mass index;
SARC	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	14.77	0.7	2.69e-35	Chronic sinus infection;
SARC	cis	rs4742903	1.000	rs10820603	chr9:106877939	G/A	cg14250997	chr9:106856677	SMC2	0.53	7.04	0.42	2.18e-11	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs10504229	0.679	rs72649131	chr8:58054288	G/T	cg08280861	chr8:58055591	NA	0.58	5.29	0.33	2.86e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs3087591	0.960	rs1124918	chr17:29492423	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.52	-6.66	-0.4	2e-10	Hip circumference;
SARC	cis	rs6570726	0.935	rs390252	chr6:145856896	A/G	cg23711669	chr6:146136114	FBXO30	0.78	12.0	0.62	3.86e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs644799	0.710	rs522536	chr11:95528714	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.6	7.87	0.46	1.29e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9916302	0.861	rs33933929	chr17:37426441	A/C	cg15445000	chr17:37608096	MED1	0.42	5.16	0.32	5.18e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg25072359	chr17:41440525	NA	0.48	5.59	0.34	6.37e-8	Menopause (age at onset);
SARC	cis	rs7552404	0.961	rs211710	chr1:76109038	G/A	cg03433033	chr1:76189801	ACADM	-0.54	-7.35	-0.43	3.41e-12	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs1348850	0.645	rs7571386	chr2:178442687	A/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.54	5.78	0.35	2.33e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg06221963	chr1:154839813	KCNN3	-0.44	-6.52	-0.39	4.32e-10	Prostate cancer;
SARC	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg24633833	chr3:10029261	TMEM111	0.52	5.0	0.31	1.13e-6	Alzheimer's disease;
SARC	cis	rs3820928	0.874	rs2396452	chr2:227838040	T/G	cg11843606	chr2:227700838	RHBDD1	-0.57	-7.24	-0.43	6.33e-12	Pulmonary function;
SARC	cis	rs13191362	0.688	rs73035006	chr6:162997083	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.49	0.34	1.04e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs858239	0.601	rs11982002	chr7:23163270	C/T	cg23682824	chr7:23144976	KLHL7	0.75	10.17	0.55	2.43e-20	Cerebrospinal fluid biomarker levels;
SARC	cis	rs734999	0.545	rs10910105	chr1:2538209	G/A	cg18854424	chr1:2615690	NA	0.32	5.04	0.31	9.14e-7	Ulcerative colitis;
SARC	cis	rs79149102	0.522	rs6495119	chr15:74934440	T/C	cg09165964	chr15:75287851	SCAMP5	-0.59	-4.82	-0.3	2.61e-6	Lung cancer;
SARC	cis	rs30380	0.506	rs469735	chr5:96130014	T/C	cg16492584	chr5:96139282	ERAP1	-0.47	-5.29	-0.33	2.78e-7	Cerebrospinal fluid biomarker levels;
SARC	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg24642844	chr7:1081250	C7orf50	-0.39	-5.39	-0.33	1.69e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs6815814	0.731	rs11735251	chr4:38773057	T/A	cg06935464	chr4:38784597	TLR10	0.5	5.19	0.32	4.66e-7	Breast cancer;
SARC	cis	rs9916302	0.706	rs584377	chr17:37460128	G/A	cg20243544	chr17:37824526	PNMT	-0.56	-6.02	-0.37	6.66e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.79	8.2	0.47	1.63e-14	Platelet count;
SARC	cis	rs7647973	0.626	rs12715437	chr3:49751856	T/C	cg07636037	chr3:49044803	WDR6	0.62	6.3	0.38	1.44e-9	Menarche (age at onset);
SARC	cis	rs921968	0.643	rs524012	chr2:219433273	T/G	cg02176678	chr2:219576539	TTLL4	0.36	5.52	0.34	9.16e-8	Mean corpuscular hemoglobin concentration;
SARC	cis	rs1580019	0.961	rs766657	chr7:32499510	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.44	5.18	0.32	4.9e-7	Cognitive ability;
SARC	cis	rs16854884	0.837	rs6804060	chr3:143804040	C/T	cg06585982	chr3:143692056	C3orf58	0.6	7.77	0.45	2.56e-13	Economic and political preferences (feminism/equality);
SARC	cis	rs9303401	0.573	rs62081879	chr17:57181524	C/T	cg25039879	chr17:56429692	SUPT4H1	0.62	5.66	0.35	4.43e-8	Cognitive test performance;
SARC	cis	rs3858526	0.883	rs10769320	chr11:5932831	G/C	cg02574844	chr11:5959923	NA	-0.42	-5.26	-0.33	3.27e-7	DNA methylation (variation);
SARC	cis	rs9300255	0.507	rs1727302	chr12:123632930	G/A	cg00376283	chr12:123451042	ABCB9	0.59	7.05	0.42	2.03e-11	Neutrophil percentage of white cells;
SARC	cis	rs709400	1.000	rs8018979	chr14:104109087	G/A	cg26031613	chr14:104095156	KLC1	1.0	18.96	0.78	4.13e-49	Body mass index;
SARC	cis	rs72781680	0.898	rs72790310	chr2:24116716	C/T	cg08917208	chr2:24149416	ATAD2B	0.79	7.51	0.44	1.25e-12	Lymphocyte counts;
SARC	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg13206674	chr6:150067644	NUP43	0.45	5.86	0.36	1.53e-8	Lung cancer;
SARC	cis	rs17376456	0.877	rs10476526	chr5:93461916	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	6.14	0.37	3.45e-9	Diabetic retinopathy;
SARC	cis	rs9921222	0.500	rs11648673	chr16:377794	G/A	cg12437481	chr16:420112	MRPL28	-0.45	-6.04	-0.37	6.04e-9	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs4792901	0.797	rs118013810	chr17:41626144	C/A	cg22562494	chr17:41607896	ETV4	-0.33	-5.3	-0.33	2.63e-7	Dupuytren's disease;
SARC	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg12310025	chr6:25882481	NA	0.52	6.75	0.4	1.16e-10	Blood metabolite levels;
SARC	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg11952622	chr19:58962976	ZNF324B	0.54	7.05	0.42	1.97e-11	Uric acid clearance;
SARC	cis	rs611744	0.507	rs1579924	chr8:109324884	G/T	cg21045802	chr8:109455806	TTC35	0.67	8.08	0.47	3.48e-14	Dupuytren's disease;
SARC	cis	rs10489202	1.000	rs34058770	chr1:168057399	C/A	cg24449463	chr1:168025552	DCAF6	-0.62	-6.72	-0.4	1.37e-10	Schizophrenia;
SARC	cis	rs11874712	0.899	rs11664764	chr18:43675364	T/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.46	5.49	0.34	1.06e-7	Migraine - clinic-based;
SARC	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg21747090	chr2:27597821	SNX17	-0.56	-7.82	-0.46	1.86e-13	Total body bone mineral density;
SARC	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	12.51	0.63	8.38e-28	Chronic sinus infection;
SARC	cis	rs8133932	0.813	rs75761084	chr21:47057422	C/A	cg11214348	chr21:47283868	PCBP3	-0.44	-4.77	-0.3	3.19e-6	Schizophrenia;
SARC	trans	rs61931739	0.517	rs1843737	chr12:34015305	A/G	cg26384229	chr12:38710491	ALG10B	0.72	10.18	0.55	2.19e-20	Morning vs. evening chronotype;
SARC	cis	rs3087591	0.708	rs3785956	chr17:29647707	C/A	cg24425628	chr17:29625626	OMG;NF1	0.43	5.56	0.34	7.2e-8	Hip circumference;
SARC	cis	rs425277	0.606	rs3128295	chr1:2068480	C/T	cg04315214	chr1:2043799	PRKCZ	0.29	4.72	0.3	4.09e-6	Height;
SARC	trans	rs1814175	0.817	rs28525029	chr11:50045815	A/G	cg03929089	chr4:120376271	NA	-0.86	-13.59	-0.66	2.32e-31	Height;
SARC	cis	rs17376456	0.877	rs10057814	chr5:93399092	C/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	5.98	0.36	8.47e-9	Diabetic retinopathy;
SARC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg01238044	chr22:24384105	GSTT1	0.69	8.74	0.5	4.52e-16	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg20891283	chr12:69753455	YEATS4	0.66	9.54	0.53	2.01e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs1448094	0.842	rs10863155	chr12:86446416	T/C	cg02569458	chr12:86230093	RASSF9	-0.41	-6.05	-0.37	5.65e-9	Major depressive disorder;
SARC	cis	rs710216	0.957	rs12041787	chr1:43432275	G/C	cg22176566	chr1:43424700	SLC2A1	0.52	5.12	0.32	6.46e-7	Red cell distribution width;
SARC	cis	rs1007738	0.507	rs7940240	chr11:47203068	T/C	cg03339077	chr11:47165057	C11orf49	-0.42	-5.08	-0.32	7.8e-7	Bone mineral density (hip);
SARC	cis	rs10875746	0.904	rs10875750	chr12:48545630	C/T	cg26205652	chr12:48591994	NA	0.57	6.23	0.38	2.14e-9	Longevity (90 years and older);
SARC	cis	rs6450176	0.564	rs374050	chr5:53331646	C/G	ch.5.1024479R	chr5:53302184	ARL15	-0.55	-6.23	-0.38	2.21e-9	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs2425143	1.000	rs6060588	chr20:34337480	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.68	5.65	0.35	4.66e-8	Blood protein levels;
SARC	trans	rs36093844	0.800	rs79276445	chr11:85587827	G/T	cg15359163	chr5:122429178	PRDM6	-0.54	-6.44	-0.39	6.72e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs9894429	0.646	rs6565612	chr17:79602820	C/T	cg18240062	chr17:79603768	NPLOC4	-0.63	-7.83	-0.46	1.74e-13	Eye color traits;
SARC	cis	rs9325144	0.600	rs1825807	chr12:38737007	T/C	cg13010199	chr12:38710504	ALG10B	0.55	7.0	0.42	2.74e-11	Morning vs. evening chronotype;
SARC	cis	rs6120849	0.754	rs6087667	chr20:33651887	A/G	cg24642439	chr20:33292090	TP53INP2	0.57	5.36	0.33	1.99e-7	Protein C levels;
SARC	cis	rs11112613	0.818	rs117644588	chr12:106022040	G/C	cg03607813	chr12:105948248	NA	0.46	4.79	0.3	2.97e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.75	7.37	0.43	2.91e-12	Platelet count;
SARC	cis	rs2073499	0.872	rs7642692	chr3:50222693	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.63	5.52	0.34	8.97e-8	Schizophrenia;
SARC	cis	rs1976403	0.659	rs10799699	chr1:21820961	C/T	cg21906605	chr1:21766650	NBPF3	0.46	6.2	0.38	2.59e-9	Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs950776	0.593	rs588765	chr15:78865425	T/C	cg17108064	chr15:78857060	CHRNA5	-0.29	-4.94	-0.31	1.48e-6	Sudden cardiac arrest;
SARC	cis	rs7953249	0.807	rs7970695	chr12:121423376	G/A	cg25281562	chr12:121454272	C12orf43	-0.43	-5.18	-0.32	4.69e-7	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs1349547	0.510	rs11998440	chr8:39497960	G/A	cg12140000	chr8:38554703	NA	0.31	4.74	0.3	3.71e-6	HIV-1 susceptibility;
SARC	cis	rs965469	1.000	rs6051790	chr20:3342994	C/T	cg25506879	chr20:3388711	C20orf194	-0.47	-4.74	-0.3	3.66e-6	IFN-related cytopenia;
SARC	cis	rs10985070	0.507	rs12551347	chr9:123936594	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.39	4.94	0.31	1.5e-6	Rheumatoid arthritis;
SARC	cis	rs12762955	0.529	rs2387213	chr10:1051420	C/T	cg18964960	chr10:1102726	WDR37	0.56	6.63	0.4	2.27e-10	Response to angiotensin II receptor blocker therapy;
SARC	cis	rs4803468	0.967	rs3213860	chr19:41920211	T/C	cg08477640	chr19:41863820	B9D2	0.45	5.68	0.35	3.94e-8	Height;
SARC	cis	rs11098499	0.954	rs6848389	chr4:120402622	A/G	cg24375607	chr4:120327624	NA	0.42	5.03	0.31	9.61e-7	Corneal astigmatism;
SARC	cis	rs2404602	0.647	rs11072631	chr15:77132909	T/C	cg15268244	chr15:77196840	NA	0.43	5.01	0.31	1.07e-6	Blood metabolite levels;
SARC	trans	rs11098499	0.954	rs11729521	chr4:120416788	T/C	cg25214090	chr10:38739885	LOC399744	0.58	7.32	0.43	3.92e-12	Corneal astigmatism;
SARC	cis	rs10504073	0.584	rs7823690	chr8:49943831	G/A	cg00325661	chr8:49890786	NA	0.51	6.78	0.41	9.76e-11	Blood metabolite ratios;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg23516660	chr17:73761301	GALK1	0.49	6.48	0.39	5.26e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg09373136	chr17:61933544	TCAM1	0.45	6.09	0.37	4.67e-9	Prudent dietary pattern;
SARC	cis	rs8016982	0.633	rs7141288	chr14:81710232	C/A	cg01989461	chr14:81687754	GTF2A1	0.73	10.87	0.58	1.55e-22	Schizophrenia;
SARC	cis	rs67311347	1.000	rs66841330	chr3:40531123	G/A	cg01475735	chr3:40494733	NA	-0.44	-5.05	-0.31	8.74e-7	Renal cell carcinoma;
SARC	cis	rs6879260	1.000	rs1035411	chr5:179729519	A/G	cg02891314	chr5:179741120	GFPT2	-0.49	-5.87	-0.36	1.49e-8	Height;
SARC	cis	rs7769051	0.708	rs9483514	chr6:133228716	G/A	cg22852734	chr6:133119734	C6orf192	0.87	7.91	0.46	1.06e-13	Type 2 diabetes nephropathy;
SARC	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2200578	0.841	rs116668293	chr2:99596991	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.59	5.78	0.35	2.43e-8	IgG glycosylation;
SARC	cis	rs3741151	0.686	rs7938391	chr11:73221957	A/G	cg17517138	chr11:73019481	ARHGEF17	0.74	6.52	0.39	4.31e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs240764	0.658	rs4840148	chr6:101182500	G/A	cg09795085	chr6:101329169	ASCC3	-0.49	-6.42	-0.39	7.54e-10	Neuroticism;
SARC	cis	rs72949976	0.584	rs12467619	chr2:214022933	T/C	cg08319019	chr2:214017104	IKZF2	0.48	6.52	0.39	4.34e-10	Lung cancer;Squamous cell lung carcinoma;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg12089543	chr22:46646381	C22orf40	0.55	7.75	0.45	2.8e-13	Thyroid stimulating hormone;
SARC	cis	rs265548	0.538	rs36688	chr19:17911212	A/C	cg16744531	chr19:17905626	B3GNT3	0.38	4.75	0.3	3.52e-6	Tumor biomarkers;
SARC	cis	rs7659604	0.540	rs28394772	chr4:122678543	C/T	cg19671926	chr4:122722719	EXOSC9	0.55	6.98	0.42	3.02e-11	Type 2 diabetes;
SARC	cis	rs644799	0.931	rs496305	chr11:95567035	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.67	8.98	0.51	9.33e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs17376456	0.877	rs28633397	chr5:93447048	A/G	cg25358565	chr5:93447407	FAM172A	1.31	15.17	0.7	1.33e-36	Diabetic retinopathy;
SARC	cis	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg12463550	chr7:65579703	CRCP	0.69	5.23	0.32	3.81e-7	Diabetic kidney disease;
SARC	cis	rs923375	0.533	rs923376	chr17:3393086	A/G	cg16505927	chr17:3375209	SPATA22	0.38	5.27	0.33	3.04e-7	Myopia (pathological);
SARC	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.33	-4.93	-0.31	1.54e-6	Total body bone mineral density;
SARC	cis	rs8180040	0.587	rs62246398	chr3:47066203	A/C	cg27129171	chr3:47204927	SETD2	-0.68	-9.18	-0.52	2.42e-17	Colorectal cancer;
SARC	cis	rs10892173	0.703	rs1014034	chr11:117661734	G/C	cg07621104	chr11:117668040	DSCAML1	0.37	4.84	0.3	2.39e-6	Myopia;
SARC	cis	rs7633857	0.512	rs1868109	chr3:160682500	G/A	cg17135325	chr3:160939158	NMD3	0.42	5.02	0.31	1.03e-6	Educational attainment (years of education);
SARC	cis	rs36051895	0.623	rs7027871	chr9:5236822	C/G	cg02405213	chr9:5042618	JAK2	0.41	4.73	0.3	3.87e-6	Pediatric autoimmune diseases;
SARC	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.68	6.6	0.4	2.68e-10	Platelet count;
SARC	cis	rs1113500	1.000	rs1777483	chr1:108609408	A/C	cg06207961	chr1:108661230	NA	-0.42	-5.45	-0.34	1.27e-7	Growth-regulated protein alpha levels;
SARC	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg12463550	chr7:65579703	CRCP	-0.45	-5.42	-0.33	1.48e-7	Aortic root size;
SARC	cis	rs9807989	0.839	rs9808453	chr2:102971306	C/A	cg09003973	chr2:102972529	NA	0.41	5.6	0.34	6.11e-8	Asthma;
SARC	cis	rs9309473	0.904	rs78450880	chr2:73821381	T/G	cg20560298	chr2:73613845	ALMS1	-0.47	-5.66	-0.35	4.51e-8	Metabolite levels;
SARC	cis	rs7264396	0.790	rs6579255	chr20:34219496	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.55	5.58	0.34	6.74e-8	Total cholesterol levels;
SARC	cis	rs77956314	0.515	rs4238051	chr12:117366299	A/G	cg02017074	chr12:117425053	FBXW8	0.55	6.71	0.4	1.5e-10	Subcortical brain region volumes;Hippocampal volume;
SARC	cis	rs611744	0.625	rs11779824	chr8:109278689	G/A	cg21045802	chr8:109455806	TTC35	0.62	7.68	0.45	4.34e-13	Dupuytren's disease;
SARC	cis	rs6600671	0.899	rs2319971	chr1:121226982	A/C	cg02905065	chr1:120837955	FAM72B	0.4	4.82	0.3	2.63e-6	Hip geometry;
SARC	trans	rs7359257	0.935	rs56108040	chr15:67707833	G/C	cg14397500	chr7:2214759	MAD1L1	-0.41	-6.25	-0.38	1.95e-9	Menarche (age at onset);
SARC	cis	rs3741404	0.609	rs687581	chr11:63871533	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.75	-9.14	-0.51	3.17e-17	Platelet count;
SARC	cis	rs10512697	0.803	rs13177899	chr5:3578923	T/C	cg19473799	chr5:3511975	NA	-0.68	-4.86	-0.3	2.11e-6	Immune response to smallpox vaccine (IL-6);
SARC	cis	rs71636778	0.722	rs12729652	chr1:27046982	G/A	cg04852280	chr1:26496234	ZNF593	0.54	4.73	0.3	3.9e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs832540	0.898	rs2662024	chr5:56257515	T/C	cg14703610	chr5:56206110	C5orf35	-0.49	-5.83	-0.36	1.8e-8	Coronary artery disease;
SARC	cis	rs8180040	0.522	rs749512	chr3:47035900	C/T	cg27129171	chr3:47204927	SETD2	-0.69	-9.12	-0.51	3.56e-17	Colorectal cancer;
SARC	cis	rs7586879	0.593	rs11689543	chr2:25130440	A/T	cg04586622	chr2:25135609	ADCY3	0.31	5.29	0.33	2.8e-7	Body mass index;
SARC	cis	rs9325144	0.647	rs12822023	chr12:39097964	T/C	cg26384229	chr12:38710491	ALG10B	-0.59	-7.67	-0.45	4.79e-13	Morning vs. evening chronotype;
SARC	cis	rs96067	0.772	rs6664471	chr1:36606757	A/G	cg24686825	chr1:36642396	MAP7D1	-0.46	-5.28	-0.33	2.9e-7	Corneal structure;
SARC	cis	rs11997175	0.646	rs4463379	chr8:33692719	G/A	ch.8.33884649F	chr8:33765107	NA	0.63	8.6	0.49	1.21e-15	Body mass index;
SARC	cis	rs6088580	0.567	rs6088520	chr20:33132364	A/G	cg24642439	chr20:33292090	TP53INP2	-0.56	-6.84	-0.41	6.79e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg21724239	chr8:58056113	NA	0.69	5.98	0.36	8.45e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs17376456	0.877	rs10065056	chr5:93380123	G/T	cg21475434	chr5:93447410	FAM172A	0.87	7.91	0.46	1.06e-13	Diabetic retinopathy;
SARC	cis	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg26859690	chr20:3869672	PANK2	0.34	4.74	0.3	3.68e-6	Immature fraction of reticulocytes;
SARC	cis	rs8523	0.901	rs2295600	chr6:10962250	A/G	cg13562911	chr6:11044106	ELOVL2	0.44	5.82	0.36	1.9e-8	Red blood cell fatty acid levels;
SARC	cis	rs35213789	0.853	rs1014417	chr7:69311506	G/A	cg10619644	chr7:69149951	AUTS2	0.36	4.72	0.3	4.16e-6	Childhood ear infection;
SARC	cis	rs12478296	0.901	rs67951957	chr2:243004901	A/G	cg06360820	chr2:242988706	NA	-0.7	-6.64	-0.4	2.21e-10	Obesity-related traits;
SARC	trans	rs61931739	0.533	rs4270002	chr12:34313126	G/T	cg26384229	chr12:38710491	ALG10B	0.63	8.31	0.48	7.71e-15	Morning vs. evening chronotype;
SARC	cis	rs8072100	0.840	rs12452796	chr17:45479733	G/T	cg08085267	chr17:45401833	C17orf57	0.4	4.82	0.3	2.59e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs1707322	0.963	rs10789484	chr1:46406978	G/C	cg06784218	chr1:46089804	CCDC17	0.34	5.97	0.36	8.98e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg13778778	chr20:35808076	C20orf132;RPN2	0.84	7.04	0.42	2.09e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs12022452	0.556	rs12037288	chr1:40996297	G/A	cg25568243	chr1:40974465	DEM1	0.56	5.09	0.32	7.32e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs751728	0.544	rs2281820	chr6:33768897	A/G	cg25922239	chr6:33757077	LEMD2	0.54	6.69	0.4	1.63e-10	Crohn's disease;
SARC	cis	rs10752881	1.000	rs10737235	chr1:182971816	T/C	cg13390022	chr1:182993471	LAMC1	0.33	5.06	0.31	8.52e-7	Colorectal cancer;
SARC	cis	rs2354432	0.660	rs10751415	chr1:146830785	T/A	cg25205988	chr1:146714368	CHD1L	0.96	7.4	0.44	2.45e-12	Mitochondrial DNA levels;
SARC	cis	rs1163251	0.902	rs627707	chr1:120217133	C/G	cg19096424	chr1:120255104	PHGDH	0.53	6.2	0.38	2.58e-9	Blood metabolite levels;
SARC	trans	rs6600671	0.934	rs11249431	chr1:121286203	A/G	cg00646200	chr1:148855367	NA	-0.5	-6.8	-0.41	8.72e-11	Hip geometry;
SARC	cis	rs9905704	0.647	rs12940492	chr17:56954655	C/G	cg12560992	chr17:57184187	TRIM37	0.42	5.16	0.32	5.26e-7	Testicular germ cell tumor;
SARC	cis	rs10504229	0.593	rs58647001	chr8:58025132	G/A	cg20607798	chr8:58055168	NA	0.54	5.03	0.31	9.65e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs826838	1.000	rs11183747	chr12:38822595	A/G	cg13010199	chr12:38710504	ALG10B	-0.76	-10.96	-0.58	7.91e-23	Heart rate;
SARC	cis	rs9911578	1.000	rs1971659	chr17:57004787	A/G	cg05425664	chr17:57184151	TRIM37	-0.67	-8.32	-0.48	7.53e-15	Intelligence (multi-trait analysis);
SARC	cis	rs6546550	0.935	rs4241261	chr2:70063660	A/G	cg02498382	chr2:70120550	SNRNP27	-0.39	-6.69	-0.4	1.68e-10	Prevalent atrial fibrillation;
SARC	trans	rs56279505	0.629	rs33988198	chr4:100268132	A/C	cg18024358	chr1:3420815	MEGF6	-0.83	-6.4	-0.39	8.29e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4557101	0.798	rs11710509	chr3:73535672	A/G	cg24173753	chr3:73529447	PDZRN3	0.41	6.1	0.37	4.4e-9	QT interval;
SARC	cis	rs2290159	0.706	rs6442319	chr3:12647029	G/A	cg23032965	chr3:12705835	RAF1	0.77	8.56	0.49	1.52e-15	Cholesterol, total;
SARC	cis	rs780096	0.526	rs11682621	chr2:27749669	G/A	cg22903471	chr2:27725779	GCKR	-0.47	-6.93	-0.41	4.04e-11	Total body bone mineral density;
SARC	cis	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg03060546	chr3:49711283	APEH	0.69	7.41	0.44	2.36e-12	Menarche (age at onset);
SARC	cis	rs11608355	0.515	rs11610558	chr12:109925865	C/T	cg05360138	chr12:110035743	NA	0.93	9.49	0.53	2.87e-18	Neuroticism;
SARC	cis	rs9296095	0.632	rs6914422	chr6:33534880	A/G	cg14003231	chr6:33640908	ITPR3	-0.3	-4.91	-0.31	1.71e-6	Platelet count;
SARC	trans	rs629535	0.814	rs62513381	chr8:70110991	T/C	cg21567404	chr3:27674614	NA	-1.08	-14.03	-0.68	8.18e-33	Dupuytren's disease;
SARC	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg26818010	chr10:134567672	INPP5A	-0.62	-6.69	-0.4	1.67e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs11583043	0.546	rs6688545	chr1:101590335	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.45	4.97	0.31	1.28e-6	Ulcerative colitis;Inflammatory bowel disease;
SARC	trans	rs7824557	0.836	rs1435278	chr8:11123029	G/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-6.76	-0.4	1.11e-10	Retinal vascular caliber;
SARC	cis	rs8014204	0.804	rs2241274	chr14:75251331	G/A	cg17347104	chr14:75034677	LTBP2	-0.4	-4.93	-0.31	1.57e-6	Caffeine consumption;
SARC	cis	rs2985684	1.000	rs2985696	chr14:50094913	C/A	cg04989706	chr14:50066350	PPIL5	-0.56	-5.87	-0.36	1.52e-8	Carotid intima media thickness;
SARC	cis	rs10513788	0.756	rs4859218	chr3:182065295	C/T	cg05977900	chr3:182512126	ATP11B	0.47	4.73	0.3	3.89e-6	Cognitive function;
SARC	cis	rs6871536	1.000	rs6894017	chr5:131952398	G/A	cg11797159	chr5:131991491	NA	0.37	4.9	0.31	1.79e-6	Asthma (childhood onset);
SARC	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg12463550	chr7:65579703	CRCP	0.5	5.9	0.36	1.27e-8	Aortic root size;
SARC	cis	rs9322817	0.691	rs2034821	chr6:105219537	C/T	cg02098413	chr6:105308735	HACE1	-0.39	-6.13	-0.37	3.8e-9	Thyroid stimulating hormone;
SARC	cis	rs7223966	1.000	rs8064261	chr17:61705212	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	6.85	0.41	6.67e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg10374962	chr7:1011985	COX19	-0.44	-4.75	-0.3	3.61e-6	Bronchopulmonary dysplasia;
SARC	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg13939156	chr17:80058883	NA	0.41	6.27	0.38	1.7e-9	Life satisfaction;
SARC	cis	rs6546550	0.867	rs4852349	chr2:70076954	A/T	cg02498382	chr2:70120550	SNRNP27	-0.4	-6.74	-0.4	1.23e-10	Prevalent atrial fibrillation;
SARC	cis	rs9467773	0.838	rs3734540	chr6:26463321	A/C	cg11502198	chr6:26597334	ABT1	0.48	5.55	0.34	7.61e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9309473	1.000	rs7572722	chr2:73724675	T/C	cg20560298	chr2:73613845	ALMS1	-0.53	-6.31	-0.38	1.37e-9	Metabolite levels;
SARC	cis	rs11098499	0.954	rs9685777	chr4:120365965	C/A	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	cis	rs3733585	0.648	rs13103497	chr4:9979262	A/G	cg11266682	chr4:10021025	SLC2A9	0.38	6.4	0.39	8.65e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs9858542	0.953	rs9827021	chr3:49514764	C/A	cg03060546	chr3:49711283	APEH	-0.57	-7.03	-0.42	2.31e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs6696846	0.740	rs11240369	chr1:205115099	G/A	cg21545522	chr1:205238299	TMCC2	0.36	5.07	0.32	8.01e-7	Red blood cell count;
SARC	cis	rs62064224	0.791	rs11656289	chr17:30761160	T/C	cg25809561	chr17:30822961	MYO1D	0.39	5.81	0.36	2.04e-8	Schizophrenia;
SARC	cis	rs9916302	0.555	rs12940193	chr17:37652178	T/G	cg20243544	chr17:37824526	PNMT	0.56	6.6	0.4	2.7e-10	Glomerular filtration rate (creatinine);
SARC	trans	rs9650657	0.707	rs10098699	chr8:10676756	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.13	-0.42	1.24e-11	Neuroticism;
SARC	cis	rs4319547	0.656	rs3817011	chr12:122819566	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.56	-6.53	-0.39	4.11e-10	Body mass index;
SARC	cis	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg03212797	chr5:150827313	SLC36A1	-0.52	-6.04	-0.37	6.02e-9	Metabolite levels (Pyroglutamine);
SARC	cis	rs17539620	0.534	rs6557363	chr6:154827813	A/G	cg20019720	chr6:154832845	CNKSR3	0.42	5.12	0.32	6.29e-7	Lipoprotein (a) levels;
SARC	cis	rs2153535	0.504	rs9328472	chr6:8470848	G/A	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	cis	rs9389248	0.690	rs6939543	chr6:135255143	A/G	cg22676075	chr6:135203613	NA	-0.43	-5.56	-0.34	7.3900000000000007e-08	High light scatter reticulocyte percentage of red cells;
SARC	cis	rs7412746	0.621	rs7518156	chr1:150945794	A/C	cg13175981	chr1:150552382	MCL1	-0.53	-6.4	-0.39	8.4e-10	Melanoma;
SARC	cis	rs6484504	0.512	rs7940020	chr11:31366453	T/G	cg26647111	chr11:31128758	NA	0.38	4.92	0.31	1.6e-6	Red blood cell count;
SARC	cis	rs3796352	1.000	rs35737577	chr3:53002557	G/C	cg27565382	chr3:53032988	SFMBT1	0.83	5.63	0.35	5.15e-8	Immune reponse to smallpox (secreted IL-2);
SARC	trans	rs1493916	1.000	rs1493916	chr18:31392577	T/G	cg27147174	chr7:100797783	AP1S1	-0.59	-7.67	-0.45	4.8e-13	Life satisfaction;
SARC	cis	rs9911578	0.967	rs8075786	chr17:56819216	T/C	cg05425664	chr17:57184151	TRIM37	-0.66	-8.17	-0.47	1.99e-14	Intelligence (multi-trait analysis);
SARC	cis	rs818427	0.865	rs1093611	chr5:112218476	A/T	cg07820702	chr5:112228657	REEP5	0.51	5.76	0.35	2.65e-8	Total body bone mineral density;
SARC	cis	rs2013441	1.000	rs2526458	chr17:20092200	C/T	cg13482628	chr17:19912719	NA	-0.48	-6.16	-0.37	3.1e-9	Obesity-related traits;
SARC	cis	rs11190604	0.767	rs4919459	chr10:102200371	C/T	cg07080220	chr10:102295463	HIF1AN	0.69	7.95	0.46	8.18e-14	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs9527	0.615	rs36045108	chr10:104697929	G/A	cg04362960	chr10:104952993	NT5C2	0.41	4.87	0.3	2.1e-6	Arsenic metabolism;
SARC	cis	rs4711350	0.911	rs9461907	chr6:33726990	A/C	cg18005901	chr6:33739558	LEMD2	-0.46	-5.03	-0.31	9.82e-7	Schizophrenia;
SARC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	20.81	0.81	4.58e-55	Prudent dietary pattern;
SARC	cis	rs7523050	0.643	rs7522324	chr1:109399644	T/C	cg08274380	chr1:109419600	GPSM2	1.07	8.3	0.48	8.22e-15	Fat distribution (HIV);
SARC	cis	rs6580649	0.941	rs757556	chr12:48502493	C/T	cg05342945	chr12:48394962	COL2A1	0.52	5.62	0.35	5.38e-8	Lung cancer;
SARC	cis	rs1420338	0.933	rs731844	chr7:34150264	C/T	cg01275685	chr7:34179230	BMPER	-0.45	-5.53	-0.34	8.62e-8	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
SARC	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg22618164	chr12:122356400	WDR66	-0.43	-7.03	-0.42	2.29e-11	Mean corpuscular volume;
SARC	cis	rs2280018	0.581	rs7404524	chr16:15129158	A/G	cg27102117	chr16:15229624	NA	0.49	6.28	0.38	1.62e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.33	4.9	0.31	1.79e-6	Hemoglobin concentration;
SARC	cis	rs10911251	0.527	rs1537520	chr1:183084229	C/T	cg13390022	chr1:182993471	LAMC1	0.33	4.87	0.3	2.02e-6	Colorectal cancer;
SARC	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg11168104	chr5:1857477	NA	-0.34	-4.98	-0.31	1.21e-6	Cardiovascular disease risk factors;
SARC	trans	rs9929218	0.911	rs4783686	chr16:68834156	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.51	-6.4	-0.39	8.57e-10	Colorectal cancer;
SARC	cis	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg00409905	chr10:38381863	ZNF37A	0.49	6.89	0.41	5.19e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs9894429	0.646	rs6565609	chr17:79592267	G/A	cg18240062	chr17:79603768	NPLOC4	0.61	7.41	0.44	2.25e-12	Eye color traits;
SARC	cis	rs1784581	0.928	rs1789995	chr6:162396518	C/T	cg17173639	chr6:162384350	PARK2	-0.77	-10.9	-0.58	1.23e-22	Itch intensity from mosquito bite;
SARC	cis	rs9467773	1.000	rs10946835	chr6:26533757	C/T	cg11502198	chr6:26597334	ABT1	0.46	5.53	0.34	8.38e-8	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg18876405	chr7:65276391	NA	-0.45	-5.04	-0.31	9.18e-7	Aortic root size;
SARC	cis	rs67460515	0.859	rs7610800	chr3:161002582	C/T	cg04691961	chr3:161091175	C3orf57	-0.47	-5.79	-0.35	2.29e-8	Parkinson's disease;
SARC	cis	rs6450176	0.597	rs1541682	chr5:53304401	C/T	ch.5.1024479R	chr5:53302184	ARL15	-1.08	-12.5	-0.63	9.17e-28	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs9815354	0.767	rs73071238	chr3:41992243	A/G	cg03022575	chr3:42003672	ULK4	0.71	6.14	0.37	3.48e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg16479474	chr6:28041457	NA	0.37	5.37	0.33	1.94e-7	Depression;
SARC	cis	rs1545257	0.537	rs12988283	chr2:24642086	G/C	cg06627628	chr2:24431161	ITSN2	-0.56	-7.13	-0.42	1.23e-11	Sjögren's syndrome;
SARC	cis	rs5758659	0.652	rs133313	chr22:42401749	G/T	cg04733989	chr22:42467013	NAGA	0.5	6.73	0.4	1.29e-10	Cognitive function;
SARC	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.33	-5.14	-0.32	5.92e-7	Longevity;Endometriosis;
SARC	cis	rs6484504	0.576	rs158139	chr11:31216076	C/T	cg26647111	chr11:31128758	NA	-0.38	-5.04	-0.31	9.49e-7	Red blood cell count;
SARC	cis	rs533123	0.877	rs1042114	chr1:29138975	G/T	cg08366446	chr1:29138936	OPRD1	0.84	6.75	0.4	1.13e-10	Schizophrenia;
SARC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.43	0.56	3.8e-21	Prudent dietary pattern;
SARC	cis	rs4742903	0.904	rs1507512	chr9:107004948	A/G	cg14250997	chr9:106856677	SMC2	0.37	4.71	0.3	4.18e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs2239547	0.607	rs9836178	chr3:52925403	T/C	cg11645453	chr3:52864694	ITIH4	-0.31	-4.72	-0.3	4.16e-6	Schizophrenia;
SARC	cis	rs9393777	0.513	rs9348728	chr6:26634436	G/A	cg12826209	chr6:26865740	GUSBL1	0.63	5.67	0.35	4.21e-8	Intelligence (multi-trait analysis);
SARC	cis	rs77372450	0.636	rs6860257	chr5:156995869	G/A	cg23851860	chr5:157002805	ADAM19	0.51	4.84	0.3	2.41e-6	Bipolar disorder (body mass index interaction);
SARC	cis	rs908922	0.676	rs6687126	chr1:152530894	T/G	cg09873164	chr1:152488093	CRCT1	0.61	7.84	0.46	1.6e-13	Hair morphology;
SARC	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	12.49	0.63	9.23e-28	Personality dimensions;
SARC	cis	rs9916302	0.752	rs9901219	chr17:37558369	T/G	cg15445000	chr17:37608096	MED1	-0.45	-5.16	-0.32	5.24e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs11249608	0.548	rs6601007	chr5:178455796	G/C	cg01312482	chr5:178451176	ZNF879	-0.35	-4.75	-0.3	3.49e-6	Pubertal anthropometrics;
SARC	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg11890956	chr21:40555474	PSMG1	-1.17	-19.71	-0.79	1.56e-51	Cognitive function;
SARC	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-5.59	-0.34	6.45e-8	Bipolar disorder;
SARC	cis	rs896854	0.530	rs10956934	chr8:95992473	C/A	cg16049864	chr8:95962084	TP53INP1	-0.47	-7.49	-0.44	1.4e-12	Type 2 diabetes;
SARC	cis	rs9487051	0.676	rs6913093	chr6:109636205	T/C	cg01475377	chr6:109611718	NA	-0.37	-5.23	-0.32	3.7e-7	Reticulocyte fraction of red cells;
SARC	cis	rs1707322	0.721	rs11211149	chr1:46112218	T/C	cg06784218	chr1:46089804	CCDC17	0.36	6.25	0.38	1.97e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg16405210	chr4:1374714	KIAA1530	0.53	6.38	0.39	9.66e-10	Obesity-related traits;
SARC	cis	rs1018836	0.923	rs2157607	chr8:91600268	A/G	cg16814680	chr8:91681699	NA	-0.86	-13.92	-0.67	1.78e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs2645694	0.626	rs2703136	chr4:77828957	T/A	cg03477792	chr4:77819574	ANKRD56	0.46	6.8	0.41	8.69e-11	Emphysema distribution in smoking;
SARC	cis	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg06636001	chr8:8085503	FLJ10661	0.62	8.57	0.49	1.47e-15	Mood instability;
SARC	cis	rs617791	0.508	rs10791837	chr11:65774596	C/T	cg26695010	chr11:65641043	EFEMP2	0.57	6.97	0.42	3.26e-11	Breast cancer;
SARC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg06074448	chr4:187884817	NA	-0.43	-5.9	-0.36	1.29e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2228479	0.850	rs34033205	chr16:89922959	G/T	cg00800038	chr16:89945340	TCF25	-0.82	-5.8	-0.35	2.19e-8	Skin colour saturation;
SARC	cis	rs4555082	0.834	rs11622165	chr14:105759761	C/A	cg10792982	chr14:105748885	BRF1	0.57	8.34	0.48	6.72e-15	Mean platelet volume;Platelet distribution width;
SARC	cis	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg07636037	chr3:49044803	WDR6	0.5	5.78	0.35	2.36e-8	Resting heart rate;
SARC	cis	rs2806561	0.765	rs1738468	chr1:23510850	T/G	cg12483005	chr1:23474871	LUZP1	0.43	5.75	0.35	2.73e-8	Height;
SARC	cis	rs3762637	0.882	rs9856011	chr3:122093570	G/A	cg24169773	chr3:122142474	KPNA1	-0.56	-5.52	-0.34	9.04e-8	LDL cholesterol levels;
SARC	cis	rs6484504	0.553	rs2183484	chr11:31259370	G/A	cg02090638	chr11:31391270	DNAJC24;DCDC1	-0.42	-5.29	-0.33	2.83e-7	Red blood cell count;
SARC	trans	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg00938859	chr5:1591904	SDHAP3	0.74	6.91	0.41	4.61e-11	Breast cancer;
SARC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg04234412	chr22:24373322	LOC391322	-0.49	-5.74	-0.35	2.88e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs4481887	0.927	rs12039929	chr1:248482018	G/A	cg00666640	chr1:248458726	OR2T12	0.33	5.37	0.33	1.94e-7	Common traits (Other);
SARC	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg04944784	chr2:26401820	FAM59B	-0.6	-7.95	-0.46	8.14e-14	Gut microbiome composition (summer);
SARC	cis	rs2073300	0.609	rs17830281	chr20:23350525	C/T	cg12062639	chr20:23401060	NAPB	1.02	6.96	0.41	3.51e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg00152838	chr16:24741724	TNRC6A	-0.59	-6.4	-0.39	8.34e-10	Intelligence (multi-trait analysis);
SARC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg20887711	chr4:1340912	KIAA1530	-0.78	-9.95	-0.55	1.16e-19	Longevity;
SARC	cis	rs9815354	0.953	rs1716694	chr3:41986399	G/T	cg03022575	chr3:42003672	ULK4	-0.59	-5.87	-0.36	1.5e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs939574	1.000	rs2071385	chr2:220118782	T/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.65	5.47	0.34	1.19e-7	Platelet distribution width;
SARC	cis	rs9840812	0.680	rs17252498	chr3:136014198	A/C	cg15507776	chr3:136538369	TMEM22	-0.54	-5.29	-0.33	2.86e-7	Fibrinogen levels;
SARC	cis	rs6686643	0.762	rs61800372	chr1:165611981	T/C	cg19407955	chr1:165599744	MGST3	-0.58	-6.0	-0.37	7.61e-9	Total ventricular volume;
SARC	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg22126266	chr1:180199560	LHX4	0.46	6.76	0.4	1.08e-10	Cancer;
SARC	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.43	-6.57	-0.4	3.32e-10	Total body bone mineral density;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg12812760	chr12:53645951	MFSD5	0.78	6.53	0.39	4.03e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1008375	0.966	rs3733576	chr4:17586703	T/C	cg02297831	chr4:17616191	MED28	0.48	5.93	0.36	1.06e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6430585	0.591	rs309170	chr2:136672775	C/T	cg07169764	chr2:136633963	MCM6	0.99	13.0	0.65	2.07e-29	Corneal structure;
SARC	cis	rs3126085	0.935	rs4326625	chr1:152223996	C/T	cg26876637	chr1:152193138	HRNR	0.48	5.62	0.35	5.34e-8	Atopic dermatitis;
SARC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.69	-8.89	-0.5	1.72e-16	Longevity;Endometriosis;
SARC	cis	rs11785400	0.793	rs4467920	chr8:143736846	C/T	cg24634471	chr8:143751801	JRK	0.59	7.62	0.45	6.34e-13	Schizophrenia;
SARC	cis	rs9309711	0.544	rs9752130	chr2:3488502	A/G	cg15541040	chr2:3486749	NA	-0.45	-5.75	-0.35	2.73e-8	Neurofibrillary tangles;
SARC	cis	rs10089	0.951	rs1864923	chr5:127420843	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.83	9.89	0.54	1.7e-19	Ileal carcinoids;
SARC	cis	rs1707322	1.000	rs6682683	chr1:46342337	A/G	cg06784218	chr1:46089804	CCDC17	0.35	6.11	0.37	4.24e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7084402	0.967	rs11006171	chr10:60278487	C/T	cg07615347	chr10:60278583	BICC1	-0.56	-8.15	-0.47	2.22e-14	Refractive error;
SARC	cis	rs7044106	0.791	rs4836831	chr9:123496570	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	6.68	0.4	1.74e-10	Hip circumference adjusted for BMI;
SARC	cis	rs12458462	0.665	rs2035085	chr18:77485280	C/T	cg11879182	chr18:77439856	CTDP1	0.88	12.58	0.64	4.9e-28	Monocyte count;
SARC	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg24250549	chr1:154909240	PMVK	0.83	12.22	0.62	7.36e-27	Prostate cancer;
SARC	cis	rs13161895	0.818	rs114211674	chr5:179484518	A/C	cg06664874	chr5:179499304	RNF130	0.62	5.65	0.35	4.6e-8	LDL cholesterol;
SARC	cis	rs7666738	0.800	rs2865988	chr4:99067807	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.71	0.5	5.54e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs17741873	0.836	rs2254266	chr10:75601688	T/C	cg07699608	chr10:75541558	CHCHD1	0.49	4.9	0.31	1.77e-6	Paclitaxel disposition in epithelial ovarian cancer;
SARC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg26338869	chr17:61819248	STRADA	0.79	10.66	0.57	7e-22	Prudent dietary pattern;
SARC	cis	rs1003719	0.715	rs6517405	chr21:38560334	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.29	-0.52	1.11e-17	Eye color traits;
SARC	cis	rs9291683	0.588	rs34501273	chr4:9996996	C/T	cg11266682	chr4:10021025	SLC2A9	0.43	7.79	0.45	2.22e-13	Bone mineral density;
SARC	cis	rs8067545	0.750	rs36077949	chr17:19985782	C/T	cg13482628	chr17:19912719	NA	0.53	7.12	0.42	1.36e-11	Schizophrenia;
SARC	cis	rs3008870	0.920	rs3008865	chr1:67402838	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.9	11.08	0.59	3.48e-23	Lymphocyte percentage of white cells;
SARC	cis	rs4555082	0.915	rs28594491	chr14:105758018	G/A	cg13114125	chr14:105738426	BRF1	-0.8	-11.27	-0.59	8.29e-24	Mean platelet volume;Platelet distribution width;
SARC	cis	rs6570726	0.577	rs867056	chr6:145784805	A/C	cg23711669	chr6:146136114	FBXO30	-0.82	-11.53	-0.6	1.25e-24	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2120243	0.539	rs2124497	chr3:157120259	T/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.39	4.96	0.31	1.37e-6	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs6977660	0.652	rs12673842	chr7:19747437	T/C	cg07541023	chr7:19748670	TWISTNB	0.97	7.63	0.45	5.81e-13	Thyroid stimulating hormone;
SARC	cis	rs6988636	0.901	rs62521825	chr8:124185786	C/A	cg23067535	chr8:124195133	FAM83A	-0.64	-5.3	-0.33	2.72e-7	Urinary uromodulin levels;
SARC	cis	rs8031584	0.918	rs34331396	chr15:31248736	C/G	cg14298792	chr15:30685198	CHRFAM7A	-0.46	-4.93	-0.31	1.53e-6	Huntington's disease progression;
SARC	cis	rs367615	0.506	rs246102	chr5:108699695	C/G	cg17395555	chr5:108820864	NA	-0.34	-4.92	-0.31	1.62e-6	Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs920590	0.573	rs12547934	chr8:19680736	T/C	cg01411142	chr8:19674711	INTS10	-0.46	-5.36	-0.33	1.98e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs1008375	1.000	rs10939740	chr4:17617490	T/C	cg02297831	chr4:17616191	MED28	0.48	6.22	0.38	2.25e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4141404	0.577	rs2413045	chr22:31665862	A/G	cg13145458	chr22:31556086	RNF185	0.59	4.75	0.3	3.52e-6	Paclitaxel-induced neuropathy;
SARC	cis	rs57994353	0.897	rs35526483	chr9:139364940	G/A	cg14169450	chr9:139327907	INPP5E	0.42	5.41	0.33	1.54e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg05863683	chr7:1912471	MAD1L1	-0.33	-4.98	-0.31	1.25e-6	Bipolar disorder and schizophrenia;
SARC	trans	rs9354308	0.899	rs2814094	chr6:66536275	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.57	-6.69	-0.4	1.68e-10	Metabolite levels;
SARC	cis	rs11578119	0.933	rs7512094	chr1:170408985	A/C	cg09767346	chr1:170501363	GORAB	0.41	4.84	0.3	2.41e-6	Male-pattern baldness;
SARC	cis	rs6901004	0.803	rs1322214	chr6:111480045	T/A	cg15721981	chr6:111408429	SLC16A10	-0.44	-5.32	-0.33	2.39e-7	Blood metabolite levels;
SARC	cis	rs17270561	0.609	rs1892248	chr6:25768914	C/T	cg17691542	chr6:26056736	HIST1H1C	0.58	6.97	0.42	3.27e-11	Iron status biomarkers;
SARC	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg07701084	chr6:150067640	NUP43	0.4	5.37	0.33	1.91e-7	Lung cancer;
SARC	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	15.35	0.71	3.17e-37	Chronic sinus infection;
SARC	cis	rs644799	0.672	rs61902245	chr11:95517737	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.92	15.79	0.72	1.09e-38	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs6582630	0.638	rs12424222	chr12:38548273	C/T	cg13010199	chr12:38710504	ALG10B	-0.49	-6.1	-0.37	4.44e-9	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg01490102	chr1:68698453	GPR177	0.59	7.45	0.44	1.79e-12	Breast cancer;
SARC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg26338869	chr17:61819248	STRADA	0.8	10.7	0.57	5.44e-22	Prudent dietary pattern;
SARC	cis	rs9650657	0.515	rs6601560	chr8:10950866	T/C	cg21775007	chr8:11205619	TDH	-0.47	-5.82	-0.36	1.9e-8	Neuroticism;
SARC	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg00290607	chr11:67383545	NA	-0.54	-7.5	-0.44	1.34e-12	Mean corpuscular volume;
SARC	cis	rs2000999	0.515	rs2854956	chr16:72115238	A/T	cg16558253	chr16:72132732	DHX38	-0.58	-9.1	-0.51	4.16e-17	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
SARC	cis	rs7662987	0.517	rs2851286	chr4:100014976	A/G	cg12011299	chr4:100065546	ADH4	-0.32	-5.08	-0.32	7.69e-7	Smoking initiation;
SARC	cis	rs607987	0.841	rs515997	chr11:30267038	T/C	cg06241208	chr11:30344200	C11orf46	-0.41	-4.96	-0.31	1.34e-6	Body mass index;
SARC	cis	rs11758351	1.000	rs111596617	chr6:26191678	A/T	cg23601095	chr6:26197514	HIST1H3D	0.63	5.43	0.34	1.4e-7	Gout;Renal underexcretion gout;
SARC	cis	rs2273669	0.915	rs6907937	chr6:109293898	T/G	cg01304950	chr6:109416612	SESN1;C6orf182	0.54	4.81	0.3	2.77e-6	Prostate cancer;
SARC	cis	rs9341808	0.718	rs12203867	chr6:80820833	G/T	cg08355045	chr6:80787529	NA	0.34	5.48	0.34	1.09e-7	Sitting height ratio;
SARC	cis	rs9660992	0.573	rs7368327	chr1:205214792	C/T	cg07972983	chr1:205091412	RBBP5	0.54	6.8	0.41	8.75e-11	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs72772090	0.710	rs1559085	chr5:96078702	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.57	-4.88	-0.3	1.95e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7659604	0.540	rs11734075	chr4:122695685	C/T	cg19671926	chr4:122722719	EXOSC9	0.65	8.55	0.49	1.66e-15	Type 2 diabetes;
SARC	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.58	7.13	0.42	1.25e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9435341	0.965	rs1335055	chr1:107624563	A/G	cg09367891	chr1:107599246	PRMT6	0.65	8.05	0.47	4.28e-14	Facial morphology (factor 21, depth of nasal alae);
SARC	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg08219700	chr8:58056026	NA	0.59	6.28	0.38	1.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg07234876	chr8:600039	NA	0.78	6.49	0.39	4.98e-10	IgG glycosylation;
SARC	cis	rs17023223	0.537	rs2765531	chr1:119585497	A/G	cg05756136	chr1:119680316	WARS2	-0.45	-5.44	-0.34	1.35e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs513349	1.000	rs210145	chr6:33547440	G/C	cg07679836	chr6:33548423	BAK1	0.34	4.94	0.31	1.5e-6	Platelet count;
SARC	cis	rs8014204	0.806	rs11159104	chr14:75293374	A/G	cg17347104	chr14:75034677	LTBP2	-0.42	-5.22	-0.32	3.9e-7	Caffeine consumption;
SARC	cis	rs7772486	0.641	rs2748489	chr6:146331287	T/G	cg23711669	chr6:146136114	FBXO30	0.76	10.36	0.56	6.45e-21	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9487051	1.000	rs1008084	chr6:109626965	G/A	cg01475377	chr6:109611718	NA	-0.41	-5.71	-0.35	3.51e-8	Reticulocyte fraction of red cells;
SARC	cis	rs1124769	0.871	rs17646461	chr15:51158110	C/T	cg21246271	chr15:51200259	AP4E1	-0.59	-5.47	-0.34	1.16e-7	Cognitive performance;
SARC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.73	7.01	0.42	2.53e-11	Platelet count;
SARC	cis	rs9392918	0.934	rs13216054	chr6:7718590	C/T	cg23089261	chr6:7723385	NA	-0.38	-5.14	-0.32	5.78e-7	Height;
SARC	cis	rs7633770	0.786	rs950190	chr3:46683377	C/T	cg11219411	chr3:46661640	NA	0.43	7.06	0.42	1.85e-11	Coronary artery disease;
SARC	cis	rs644799	1.000	rs509720	chr11:95562771	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.68	9.17	0.51	2.6e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs4304924	0.500	rs2281856	chr13:79207644	C/T	cg01819759	chr13:79234251	RNF219	-0.38	-4.74	-0.3	3.77e-6	Large artery stroke;
SARC	cis	rs3784262	1.000	rs7178497	chr15:58240333	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.36	-5.21	-0.32	4.06e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs559928	0.606	rs55942618	chr11:63936005	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	5.12	0.32	6.44e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs8062405	0.824	rs153106	chr16:28526897	T/C	cg08761264	chr16:28874980	SH2B1	-0.42	-4.76	-0.3	3.43e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs9911578	0.967	rs6503890	chr17:57064167	A/G	cg05425664	chr17:57184151	TRIM37	-0.65	-8.0	-0.46	5.75e-14	Intelligence (multi-trait analysis);
SARC	cis	rs703842	1.000	rs11172351	chr12:58213485	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.78	11.29	0.59	7.05e-24	Multiple sclerosis;
SARC	cis	rs2933343	0.700	rs883602	chr3:128653952	A/G	cg24203234	chr3:128598194	ACAD9	0.63	8.07	0.47	3.74e-14	IgG glycosylation;
SARC	cis	rs6009527	0.752	rs7286232	chr22:49568490	A/G	cg12746016	chr22:49560550	NA	0.32	5.74	0.35	2.88e-8	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
SARC	cis	rs2486288	0.656	rs2413768	chr15:45561984	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.52	-6.43	-0.39	7.16e-10	Glomerular filtration rate;
SARC	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg08280861	chr8:58055591	NA	0.6	5.28	0.33	2.92e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs201673768	1	rs201673768	chr12:48699606	TGTTTTGTTTTG/T	cg21466736	chr12:48725269	NA	-0.35	-6.21	-0.38	2.39e-9	Platelet count;
SARC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg14159672	chr1:205819179	PM20D1	-0.75	-12.22	-0.63	7.14e-27	Monocyte percentage of white cells;
SARC	cis	rs634534	0.622	rs593525	chr11:65727799	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.73	10.11	0.55	3.7e-20	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	9.84	0.54	2.52e-19	Platelet count;
SARC	cis	rs6942407	0.546	rs4140847	chr7:86783263	A/T	cg02420886	chr7:86849541	C7orf23	0.72	6.32	0.38	1.3e-9	Food allergy;
SARC	cis	rs4891159	0.584	rs689878	chr18:74152017	C/T	cg24786174	chr18:74118243	ZNF516	0.72	11.85	0.61	1.11e-25	Longevity;
SARC	cis	rs6500602	0.727	rs2160567	chr16:4535557	C/T	cg08645402	chr16:4508243	NA	0.39	5.11	0.32	6.64e-7	Schizophrenia;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg04749066	chr2:192746843	NA	-0.81	-6.75	-0.4	1.15e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs858239	0.600	rs10488077	chr7:23144182	A/T	cg23682824	chr7:23144976	KLHL7	0.66	8.8	0.5	3.22e-16	Cerebrospinal fluid biomarker levels;
SARC	cis	rs5758659	1.000	rs5751255	chr22:42648408	C/T	cg15128208	chr22:42549153	NA	-0.37	-5.37	-0.33	1.86e-7	Cognitive function;
SARC	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg13175981	chr1:150552382	MCL1	-0.53	-6.81	-0.41	8.15e-11	Tonsillectomy;
SARC	cis	rs854765	0.583	rs8078105	chr17:17853782	T/C	cg05444541	chr17:17804740	TOM1L2	-0.29	-4.82	-0.3	2.56e-6	Total body bone mineral density;
SARC	cis	rs4132509	1.000	rs2125230	chr1:243885848	A/G	cg21452805	chr1:244014465	NA	-0.64	-7.43	-0.44	1.99e-12	RR interval (heart rate);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg18737844	chr2:162285454	NA	0.59	8.7	0.5	6.17e-16	Thyroid stimulating hormone;
SARC	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg09359103	chr1:154839909	KCNN3	0.46	7.71	0.45	3.53e-13	Prostate cancer;
SARC	cis	rs72781680	0.948	rs72781652	chr2:24213754	G/A	cg08917208	chr2:24149416	ATAD2B	0.79	7.65	0.45	5.14e-13	Lymphocyte counts;
SARC	cis	rs9296095	0.948	rs75080135	chr6:33552707	A/C	cg14003231	chr6:33640908	ITPR3	0.4	6.14	0.37	3.53e-9	Platelet count;
SARC	cis	rs7666738	0.791	rs2081622	chr4:98927369	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs965469	1.000	rs2092990	chr20:3346338	C/T	cg25506879	chr20:3388711	C20orf194	-0.47	-4.74	-0.3	3.66e-6	IFN-related cytopenia;
SARC	cis	rs73198271	0.694	rs113694763	chr8:8647076	C/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-4.97	-0.31	1.3e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs3857536	0.776	rs2040593	chr6:66944076	G/A	cg07460842	chr6:66804631	NA	-0.45	-5.16	-0.32	5.28e-7	Blood trace element (Cu levels);
SARC	trans	rs61931739	0.534	rs11052983	chr12:34045787	C/A	cg13010199	chr12:38710504	ALG10B	0.67	9.1	0.51	4.09e-17	Morning vs. evening chronotype;
SARC	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.95	-15.34	-0.71	3.43e-37	Chronic sinus infection;
SARC	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg21724239	chr8:58056113	NA	0.66	6.2	0.38	2.55e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs757081	0.671	rs214090	chr11:17297161	C/T	cg15432903	chr11:17409602	KCNJ11	-0.38	-4.85	-0.3	2.28e-6	Systolic blood pressure;
SARC	cis	rs35213789	0.791	rs589983	chr7:69184148	G/T	cg10619644	chr7:69149951	AUTS2	-0.34	-4.74	-0.3	3.73e-6	Childhood ear infection;
SARC	cis	rs2043112	1.000	rs13165709	chr5:38971865	A/G	cg04869206	chr5:39074266	RICTOR	0.49	5.95	0.36	9.51e-9	Obesity-related traits;
SARC	cis	rs10927875	0.632	rs10927864	chr1:16165661	C/G	cg21385522	chr1:16154831	NA	-0.93	-13.85	-0.67	3.21e-32	Dilated cardiomyopathy;
SARC	cis	rs1865760	0.625	rs9393681	chr6:26008260	A/G	cg18357526	chr6:26021779	HIST1H4A	0.39	4.93	0.31	1.59e-6	Height;
SARC	cis	rs1904096	0.506	rs12511433	chr4:95162425	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.48	-7.29	-0.43	4.93e-12	Type 2 diabetes;
SARC	cis	rs470119	1.000	rs131801	chr22:50966634	G/T	cg12969734	chr22:50962224	SCO2	0.51	6.84	0.41	6.78e-11	Mean corpuscular hemoglobin;
SARC	cis	rs2576037	0.796	rs2576034	chr18:44588548	G/A	cg19077165	chr18:44547161	KATNAL2	0.49	6.99	0.42	2.92e-11	Personality dimensions;
SARC	cis	rs13314892	0.840	rs62250978	chr3:69840659	T/C	cg17445875	chr3:69859618	MITF	-0.45	-4.76	-0.3	3.46e-6	QRS complex (12-leadsum);
SARC	cis	rs7819412	0.740	rs11250119	chr8:11037034	C/T	cg12395012	chr8:11607386	GATA4	0.29	4.81	0.3	2.71e-6	Triglycerides;
SARC	cis	rs611744	0.967	rs686251	chr8:109198907	C/A	cg21045802	chr8:109455806	TTC35	0.44	5.23	0.32	3.81e-7	Dupuytren's disease;
SARC	cis	rs2832191	0.791	rs2832186	chr21:30484151	A/C	cg24692254	chr21:30365293	RNF160	-0.95	-14.57	-0.69	1.24e-34	Dental caries;
SARC	cis	rs6120849	0.707	rs6088690	chr20:33633326	A/G	cg24642439	chr20:33292090	TP53INP2	0.57	5.48	0.34	1.1e-7	Protein C levels;
SARC	cis	rs735396	0.770	rs2464196	chr12:121435427	G/A	cg02403541	chr12:121454288	C12orf43	0.85	12.54	0.63	6.59e-28	N-glycan levels;
SARC	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg03517284	chr6:25882590	NA	-0.44	-5.87	-0.36	1.49e-8	Intelligence (multi-trait analysis);
SARC	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg06618935	chr21:46677482	NA	-0.41	-5.33	-0.33	2.32e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7264396	0.563	rs2225950	chr20:34333015	C/G	cg01084648	chr20:34329383	RBM39	0.57	5.0	0.31	1.13e-6	Total cholesterol levels;
SARC	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg08677398	chr8:58056175	NA	0.42	5.06	0.31	8.49e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs12079745	0.826	rs12070626	chr1:169097156	T/C	cg09363564	chr1:169337483	NME7;BLZF1	-0.67	-4.93	-0.31	1.59e-6	QT interval;
SARC	cis	rs7659604	0.605	rs2071486	chr4:122740162	C/T	cg19748678	chr4:122722346	EXOSC9	0.66	8.0	0.46	5.88e-14	Type 2 diabetes;
SARC	cis	rs7647973	0.588	rs9883000	chr3:49667691	A/G	cg06212747	chr3:49208901	KLHDC8B	0.56	5.77	0.35	2.53e-8	Menarche (age at onset);
SARC	cis	rs1865760	0.865	rs1541987	chr6:25950397	A/G	cg16482183	chr6:26056742	HIST1H1C	-0.5	-6.38	-0.39	9.59e-10	Height;
SARC	cis	rs12142240	0.698	rs13374893	chr1:46843800	A/G	cg10495392	chr1:46806563	NSUN4	0.65	6.88	0.41	5.6e-11	Menopause (age at onset);
SARC	trans	rs1814175	0.615	rs11040654	chr11:49939485	T/G	cg15704280	chr7:45808275	SEPT13	-0.88	-14.0	-0.68	1.02e-32	Height;
SARC	cis	rs7659604	0.689	rs59131059	chr4:122666357	C/T	cg19748678	chr4:122722346	EXOSC9	0.41	4.96	0.31	1.38e-6	Type 2 diabetes;
SARC	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg03517284	chr6:25882590	NA	0.5	6.6	0.4	2.72e-10	Blood metabolite levels;
SARC	cis	rs926938	0.543	rs360600	chr1:115388116	T/C	cg12756093	chr1:115239321	AMPD1	0.38	5.05	0.31	8.81e-7	Autism;
SARC	cis	rs2354432	0.505	rs7551766	chr1:146858964	A/G	cg25205988	chr1:146714368	CHD1L	-0.94	-6.82	-0.41	7.96e-11	Mitochondrial DNA levels;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg08020962	chr6:80714156	TTK	-0.5	-6.39	-0.39	8.82e-10	Schizophrenia;
SARC	cis	rs11122272	0.735	rs2486735	chr1:231521778	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs918629	0.567	rs2548594	chr5:95244414	C/T	cg16656078	chr5:95278638	ELL2	-0.52	-6.65	-0.4	2.06e-10	IgG glycosylation;
SARC	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg06618935	chr21:46677482	NA	-0.4	-5.4	-0.33	1.63e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.42	-5.23	-0.32	3.77e-7	Gut microbiome composition (summer);
SARC	cis	rs35110281	0.837	rs2838341	chr21:45076443	A/G	cg21573476	chr21:45109991	RRP1B	-0.49	-7.27	-0.43	5.41e-12	Mean corpuscular volume;
SARC	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg08219700	chr8:58056026	NA	0.6	5.81	0.36	2.06e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7178909	0.872	rs3867167	chr15:90433790	T/C	cg19708238	chr15:90437601	AP3S2	0.58	7.47	0.44	1.59e-12	Common traits (Other);
SARC	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg21724239	chr8:58056113	NA	0.61	5.93	0.36	1.1e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9457247	0.715	rs6923582	chr6:167437162	T/A	cg23791538	chr6:167370224	RNASET2	-0.5	-6.51	-0.39	4.5e-10	Crohn's disease;
SARC	cis	rs9303401	0.734	rs8073316	chr17:57211381	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.68	-7.97	-0.46	7.15e-14	Cognitive test performance;
SARC	cis	rs7829975	0.508	rs1594437	chr8:8825875	T/C	cg15556689	chr8:8085844	FLJ10661	0.5	6.03	0.37	6.4e-9	Mood instability;
SARC	cis	rs9787249	0.957	rs12239844	chr1:40217258	T/C	cg02773041	chr1:40204384	PPIE	0.53	6.42	0.39	7.6e-10	Blood protein levels;
SARC	cis	rs2290159	0.752	rs73130368	chr3:12667374	C/T	cg23032965	chr3:12705835	RAF1	0.78	8.68	0.49	6.81e-16	Cholesterol, total;
SARC	cis	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg07777115	chr5:623756	CEP72	-0.6	-5.35	-0.33	2.06e-7	Obesity-related traits;
SARC	cis	rs2228479	0.850	rs1800344	chr16:89816367	T/G	cg00800038	chr16:89945340	TCF25	-0.74	-5.14	-0.32	5.75e-7	Skin colour saturation;
SARC	cis	rs918629	0.530	rs967546	chr5:95232551	G/A	cg16656078	chr5:95278638	ELL2	-0.59	-7.01	-0.42	2.52e-11	IgG glycosylation;
SARC	cis	rs9612	0.950	rs346546	chr19:44256910	T/C	cg08581076	chr19:44259116	C19orf61	0.64	7.92	0.46	9.53e-14	Exhaled nitric oxide output;
SARC	cis	rs2832191	0.791	rs28633762	chr21:30500070	C/T	cg24692254	chr21:30365293	RNF160	-0.84	-11.9	-0.61	8.25e-26	Dental caries;
SARC	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg17971929	chr21:40555470	PSMG1	0.86	11.22	0.59	1.26e-23	Cognitive function;
SARC	cis	rs9788682	0.633	rs2656070	chr15:78730252	A/G	cg06917634	chr15:78832804	PSMA4	0.54	5.53	0.34	8.53e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg00152838	chr16:24741724	TNRC6A	-0.58	-6.11	-0.37	4.1e-9	Intelligence (multi-trait analysis);
SARC	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg06028808	chr11:68637592	NA	0.46	5.89	0.36	1.35e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs807669	0.934	rs762523	chr22:19180589	A/G	cg02655711	chr22:19163373	SLC25A1	0.55	7.51	0.44	1.28e-12	Metabolite levels;
SARC	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg22496380	chr5:211416	CCDC127	-0.88	-9.35	-0.52	7.72e-18	Breast cancer;
SARC	cis	rs9303401	0.659	rs35828828	chr17:56718205	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.09	12.51	0.63	8.33e-28	Cognitive test performance;
SARC	cis	rs818427	0.858	rs469727	chr5:112242968	A/G	cg07820702	chr5:112228657	REEP5	0.45	4.9	0.31	1.81e-6	Total body bone mineral density;
SARC	cis	rs2304069	0.695	rs6866298	chr5:149439588	A/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.5	5.12	0.32	6.5e-7	HIV-1 control;
SARC	cis	rs4268898	0.662	rs2303292	chr2:24432138	C/T	cg06627628	chr2:24431161	ITSN2	-0.84	-10.12	-0.55	3.39e-20	Asthma;
SARC	cis	rs17600642	0.672	rs72814553	chr10:72460524	C/T	cg19779893	chr10:72451501	ADAMTS14	-0.39	-6.09	-0.37	4.57e-9	Bipolar disorder;
SARC	cis	rs9810089	0.903	rs7432375	chr3:136288405	G/A	cg15507776	chr3:136538369	TMEM22	0.44	4.75	0.3	3.63e-6	Gestational age at birth (child effect);
SARC	cis	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg24110177	chr3:50126178	RBM5	-0.4	-5.06	-0.31	8.7e-7	Intelligence (multi-trait analysis);
SARC	cis	rs754466	0.580	rs1054608	chr10:79543308	T/G	cg17075019	chr10:79541650	NA	-0.86	-14.24	-0.68	1.64e-33	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg12419862	chr22:24373484	LOC391322	0.76	8.66	0.49	8.14e-16	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	trans	rs10085978	0.604	rs11167128	chr8:143225883	A/G	cg12997958	chr17:18161617	FLII	0.47	6.35	0.38	1.1e-9	Mosquito bite size;
SARC	cis	rs6738485	0.601	rs7566680	chr2:106851657	G/A	cg16099169	chr2:106886729	NA	-0.4	-5.12	-0.32	6.45e-7	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
SARC	cis	rs748404	0.631	rs2412781	chr15:43667900	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.5	-5.84	-0.36	1.79e-8	Lung cancer;
SARC	cis	rs6860806	0.507	rs2631371	chr5:131703691	G/A	cg24060327	chr5:131705240	SLC22A5	0.72	8.58	0.49	1.36e-15	Breast cancer;
SARC	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.16	-0.37	3.16e-9	Mood instability;
SARC	cis	rs2303759	0.830	rs7257053	chr19:49894456	C/G	cg24324837	chr19:49891574	CCDC155	0.42	5.34	0.33	2.16e-7	Multiple sclerosis;
SARC	cis	rs240764	0.658	rs4840155	chr6:101253942	G/T	cg09795085	chr6:101329169	ASCC3	-0.42	-5.39	-0.33	1.76e-7	Neuroticism;
SARC	cis	rs4423214	0.625	rs78685409	chr11:71137383	T/C	cg05163923	chr11:71159392	DHCR7	-0.6	-6.97	-0.42	3.14e-11	Vitamin D levels;
SARC	cis	rs910316	0.763	rs13712	chr14:75483812	T/C	cg11812906	chr14:75593930	NEK9	0.79	11.0	0.58	5.99e-23	Height;
SARC	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg11987759	chr7:65425863	GUSB	0.6	7.71	0.45	3.68e-13	Aortic root size;
SARC	cis	rs67460515	0.563	rs1585481	chr3:160901481	C/T	cg03342759	chr3:160939853	NMD3	-0.65	-8.04	-0.47	4.55e-14	Parkinson's disease;
SARC	cis	rs3126085	1.000	rs12567463	chr1:152180128	T/A	cg09127314	chr1:152161683	NA	-0.42	-4.77	-0.3	3.2e-6	Atopic dermatitis;
SARC	cis	rs4417855	0.762	rs3774309	chr3:187445197	A/G	cg08969912	chr3:187456781	BCL6	-0.48	-5.46	-0.34	1.2e-7	Granulocyte percentage of myeloid white cells;
SARC	trans	rs12554020	0.786	rs56073019	chr9:96253451	C/T	cg26442883	chr16:49686662	ZNF423	0.56	6.24	0.38	2.1e-9	Schizophrenia;
SARC	cis	rs4713675	0.584	rs560111	chr6:33706277	C/T	cg15676125	chr6:33679581	C6orf125	0.5	6.13	0.37	3.8e-9	Plateletcrit;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg00387170	chr6:41514002	FOXP4	-0.75	-6.38	-0.39	9.42e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs826838	1.000	rs10880826	chr12:38672787	G/C	cg26384229	chr12:38710491	ALG10B	0.93	14.67	0.69	5.99e-35	Heart rate;
SARC	cis	rs765787	0.530	rs4774542	chr15:45526026	A/C	cg24006582	chr15:45444508	DUOX1	0.46	5.94	0.36	1.04e-8	Uric acid levels;
SARC	cis	rs1662342	0.736	rs4404166	chr18:3285657	C/G	cg14211874	chr18:3262499	MYL12B	-0.68	-5.43	-0.34	1.39e-7	QRS duration;
SARC	cis	rs995000	0.931	rs6587976	chr1:62945631	C/T	cg06896770	chr1:63153194	DOCK7	0.95	14.44	0.69	3.41e-34	Triglyceride levels;
SARC	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg13628971	chr7:2884303	GNA12	0.58	6.79	0.41	9.4e-11	Height;
SARC	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg04267008	chr7:1944627	MAD1L1	-0.65	-7.35	-0.43	3.33e-12	Bipolar disorder and schizophrenia;
SARC	cis	rs1105228	0.592	rs4504451	chr6:165676648	C/A	cg20535254	chr6:165714960	C6orf118	-0.35	-4.84	-0.3	2.4e-6	Number of pregnancies;Number of children;
SARC	cis	rs1003719	0.788	rs60447195	chr21:38448600	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.67	9.98	0.55	9.34e-20	Eye color traits;
SARC	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg18357526	chr6:26021779	HIST1H4A	0.57	6.26	0.38	1.84e-9	Urate levels;
SARC	cis	rs7808935	0.628	rs9791862	chr7:27950760	G/A	cg05786569	chr7:27702416	HIBADH	0.69	7.53	0.44	1.08e-12	Prostate cancer;
SARC	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg23758822	chr17:41437982	NA	0.84	10.47	0.57	2.81e-21	Menopause (age at onset);
SARC	cis	rs7617773	0.514	rs11130166	chr3:48388056	A/G	cg11946769	chr3:48343235	NME6	0.54	6.64	0.4	2.13e-10	Coronary artery disease;
SARC	cis	rs2439831	1.000	rs690002	chr15:43729349	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.08	11.12	0.59	2.58e-23	Lung cancer in ever smokers;
SARC	cis	rs8031584	0.958	rs1043742	chr15:31232581	A/C	cg14829155	chr15:31115871	NA	-0.42	-5.18	-0.32	4.85e-7	Huntington's disease progression;
SARC	cis	rs13191362	0.872	rs73020362	chr6:163005737	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.49	0.34	1.04e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs11098499	0.722	rs17595727	chr4:120262074	C/T	cg09307838	chr4:120376055	NA	-0.77	-10.88	-0.58	1.51e-22	Corneal astigmatism;
SARC	cis	rs11583043	0.918	rs3850453	chr1:101408933	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.46	5.7	0.35	3.64e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs8114671	0.562	rs7266550	chr20:33495510	C/T	cg07148914	chr20:33460835	GGT7	0.42	5.09	0.32	7.24e-7	Height;
SARC	cis	rs5167	0.781	rs909134	chr19:45493061	T/C	cg10169327	chr19:45448959	APOC2	0.31	4.98	0.31	1.27e-6	Blood protein levels;
SARC	cis	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg24110177	chr3:50126178	RBM5	-0.41	-5.16	-0.32	5.4e-7	Intelligence (multi-trait analysis);
SARC	cis	rs3771570	0.901	rs62190407	chr2:242405772	G/A	cg21155796	chr2:242212141	HDLBP	0.53	5.36	0.33	1.99e-7	Prostate cancer;
SARC	cis	rs460214	0.528	rs6517474	chr21:40023133	G/A	cg12884169	chr21:40033163	ERG	-0.35	-5.02	-0.31	1.01e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs12701220	0.817	rs59471534	chr7:1085224	G/A	cg02733842	chr7:1102375	C7orf50	-0.5	-6.46	-0.39	6.19e-10	Bronchopulmonary dysplasia;
SARC	cis	rs738322	0.967	rs4383	chr22:38570927	C/G	cg25457927	chr22:38595422	NA	-0.29	-5.95	-0.36	9.77e-9	Cutaneous nevi;
SARC	cis	rs5750854	0.503	rs5757752	chr22:40025237	G/C	cg10455938	chr22:40058150	CACNA1I	0.43	5.08	0.32	7.7300000000000005e-07	Intelligence (multi-trait analysis);
SARC	cis	rs2529049	0.537	rs2711115	chr7:24691155	A/G	cg17569154	chr7:24781545	DFNA5	0.5	7.27	0.43	5.31e-12	Urate levels in obese individuals;
SARC	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg03060546	chr3:49711283	APEH	-0.45	-5.69	-0.35	3.8e-8	Parkinson's disease;
SARC	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg00908189	chr16:619842	PIGQ	0.84	12.16	0.62	1.13e-26	Height;
SARC	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg07701084	chr6:150067640	NUP43	0.42	5.66	0.35	4.38e-8	Lung cancer;
SARC	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg08859206	chr1:53392774	SCP2	0.38	5.43	0.34	1.38e-7	Monocyte count;
SARC	cis	rs11098499	0.821	rs3775852	chr4:120454556	A/G	cg24375607	chr4:120327624	NA	0.42	4.9	0.31	1.76e-6	Corneal astigmatism;
SARC	cis	rs911555	0.755	rs8016676	chr14:103904842	C/A	cg24130564	chr14:104152367	KLC1	0.49	5.75	0.35	2.83e-8	Intelligence (multi-trait analysis);
SARC	cis	rs11153147	0.649	rs10456863	chr6:109299092	A/T	cg05315195	chr6:109294784	ARMC2	-0.59	-5.33	-0.33	2.32e-7	Mean corpuscular volume;
SARC	cis	rs2486288	0.656	rs6493144	chr15:45573489	C/G	cg21132104	chr15:45694354	SPATA5L1	0.53	6.64	0.4	2.14e-10	Glomerular filtration rate;
SARC	cis	rs3771570	0.901	rs3771585	chr2:242400723	G/A	cg21155796	chr2:242212141	HDLBP	0.55	5.58	0.34	6.75e-8	Prostate cancer;
SARC	cis	rs7312933	0.501	rs3810793	chr12:42729407	C/T	cg19980929	chr12:42632907	YAF2	0.47	6.83	0.41	7.11e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg25036284	chr2:26402008	FAM59B	-0.43	-5.4	-0.33	1.67e-7	Gut microbiome composition (summer);
SARC	cis	rs6912958	0.781	rs7757636	chr6:88256092	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.42	-0.33	1.5e-7	Monocyte percentage of white cells;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg25655799	chr10:79397930	KCNMA1	-0.79	-6.49	-0.39	5.08e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9788682	0.747	rs6495308	chr15:78907656	A/G	cg06917634	chr15:78832804	PSMA4	-0.47	-5.31	-0.33	2.55e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg17971929	chr21:40555470	PSMG1	0.95	11.4	0.6	3.35e-24	Cognitive function;
SARC	cis	rs208520	1.000	rs12193164	chr6:66978962	C/T	cg07460842	chr6:66804631	NA	0.9	10.32	0.56	8.16e-21	Exhaled nitric oxide output;
SARC	cis	rs8114671	0.967	rs4911472	chr20:33775377	T/A	cg24642439	chr20:33292090	TP53INP2	0.5	5.64	0.35	4.85e-8	Height;
SARC	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg05861140	chr6:150128134	PCMT1	-0.41	-5.28	-0.33	2.97e-7	Lung cancer;
SARC	cis	rs2153535	0.580	rs2327060	chr6:8447111	G/A	cg21535247	chr6:8435926	SLC35B3	0.56	6.93	0.41	4.07e-11	Motion sickness;
SARC	cis	rs2916247	0.954	rs7841406	chr8:93156120	A/C	cg10183463	chr8:93005414	RUNX1T1	-0.46	-5.09	-0.32	7.44e-7	Intelligence (multi-trait analysis);
SARC	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg14784868	chr12:69753453	YEATS4	0.63	8.77	0.5	3.92e-16	Cerebrospinal fluid biomarker levels;
SARC	cis	rs10876993	0.789	rs1689600	chr12:58049645	A/T	cg18357645	chr12:58087776	OS9	0.47	6.11	0.37	4.09e-9	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs4566357	0.695	rs11892058	chr2:227951063	C/T	cg11843606	chr2:227700838	RHBDD1	-0.41	-4.95	-0.31	1.4e-6	Coronary artery disease;
SARC	cis	rs2865126	0.743	rs1941550	chr18:10747590	T/C	cg21165219	chr18:10698044	FAM38B	-0.47	-4.74	-0.3	3.71e-6	Metabolite levels (5-HIAA/ MHPG Ratio);
SARC	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg14343924	chr8:8086146	FLJ10661	0.45	5.6	0.34	6.07e-8	Mood instability;
SARC	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg11764359	chr7:65958608	NA	0.79	9.88	0.54	1.93e-19	Aortic root size;
SARC	cis	rs7666738	0.606	rs28481322	chr4:99086638	T/C	cg05340658	chr4:99064831	C4orf37	0.47	5.95	0.36	9.8e-9	Colonoscopy-negative controls vs population controls;
SARC	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg11764359	chr7:65958608	NA	-0.67	-7.96	-0.46	7.7e-14	Aortic root size;
SARC	cis	rs568617	0.626	rs10896050	chr11:65577516	G/T	cg14036092	chr11:66035641	RAB1B	-0.46	-5.01	-0.31	1.08e-6	Crohn's disease;
SARC	cis	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg12463550	chr7:65579703	CRCP	0.69	5.23	0.32	3.81e-7	Diabetic kidney disease;
SARC	cis	rs1153858	1.000	rs28679834	chr15:45616206	C/T	cg15395560	chr15:45543142	SLC28A2	-0.27	-4.85	-0.3	2.25e-6	Homoarginine levels;
SARC	cis	rs11225247	0.881	rs7114048	chr11:102253780	C/T	cg11690896	chr11:102217788	BIRC2	0.77	5.44	0.34	1.33e-7	Vein graft stenosis in coronary artery bypass grafting;
SARC	trans	rs208520	0.955	rs12202599	chr6:67001573	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.83	9.29	0.52	1.12e-17	Exhaled nitric oxide output;
SARC	cis	rs523522	0.962	rs4767904	chr12:120930798	T/G	cg12219531	chr12:120966889	COQ5	0.82	11.15	0.59	1.99e-23	High light scatter reticulocyte count;
SARC	cis	rs6963495	0.745	rs55906043	chr7:105165367	T/G	cg13798780	chr7:105162888	PUS7	0.61	5.61	0.34	5.84e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs710216	0.957	rs3806401	chr1:43426212	G/T	cg22176566	chr1:43424700	SLC2A1	-0.55	-5.29	-0.33	2.84e-7	Red cell distribution width;
SARC	cis	rs6582630	0.572	rs1969363	chr12:38514872	A/G	cg26384229	chr12:38710491	ALG10B	0.72	9.62	0.53	1.13e-18	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7937682	0.632	rs11214029	chr11:111761230	C/T	cg22437258	chr11:111473054	SIK2	-0.48	-5.25	-0.33	3.38e-7	Primary sclerosing cholangitis;
SARC	cis	rs2652834	1.000	rs4344684	chr15:63397318	C/T	cg05507819	chr15:63340323	TPM1	0.55	5.37	0.33	1.89e-7	HDL cholesterol;
SARC	cis	rs56161922	0.749	rs3738469	chr1:207818422	G/A	cg11752769	chr1:207818423	CR1L	-0.58	-4.72	-0.3	3.99e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
SARC	cis	rs13191362	0.872	rs13196631	chr6:163001588	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.57	5.38	0.33	1.85e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs6963495	0.818	rs73192126	chr7:105175415	T/C	cg19920283	chr7:105172520	RINT1	0.68	5.85	0.36	1.65e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg09373136	chr17:61933544	TCAM1	-0.45	-6.2	-0.38	2.48e-9	Prudent dietary pattern;
SARC	cis	rs12079745	0.590	rs76692040	chr1:169295689	T/C	cg09363564	chr1:169337483	NME7;BLZF1	-0.98	-5.82	-0.36	1.95e-8	QT interval;
SARC	cis	rs11578119	0.933	rs12130086	chr1:170483041	T/A	cg09767346	chr1:170501363	GORAB	0.4	4.73	0.3	3.91e-6	Male-pattern baldness;
SARC	cis	rs1008375	1.000	rs10011865	chr4:17645710	G/A	cg02297831	chr4:17616191	MED28	0.5	6.47	0.39	5.82e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs459571	1.000	rs459571	chr9:136912626	C/T	cg01294253	chr9:136912663	BRD3	0.4	5.07	0.32	8.02e-7	Platelet distribution width;
SARC	trans	rs11165623	0.792	rs13375510	chr1:96920723	A/G	cg10631902	chr5:14652156	NA	-0.47	-7.72	-0.45	3.33e-13	Hip circumference;Waist circumference;
SARC	cis	rs2354432	0.607	rs1890039	chr1:146681951	T/C	cg25205988	chr1:146714368	CHD1L	1.06	8.87	0.5	2.02e-16	Mitochondrial DNA levels;
SARC	cis	rs6063312	0.518	rs6122718	chr20:47346225	A/G	cg18078177	chr20:47281410	PREX1	-0.52	-6.45	-0.39	6.51e-10	Tonometry;
SARC	cis	rs4720575	0.868	rs7779776	chr7:47092914	C/G	cg00036614	chr7:47093842	NA	-0.43	-6.09	-0.37	4.56e-9	Angiotensin-converting enzyme inhibitor intolerance;
SARC	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.0	12.67	0.64	2.43e-28	Smoking behavior;
SARC	cis	rs910316	0.763	rs1548807	chr14:75479582	T/G	cg06637938	chr14:75390232	RPS6KL1	0.47	6.32	0.38	1.32e-9	Height;
SARC	cis	rs11249608	0.511	rs58827878	chr5:178481936	C/G	cg01312482	chr5:178451176	ZNF879	-0.42	-5.19	-0.32	4.59e-7	Pubertal anthropometrics;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg02798621	chr6:82462430	FAM46A	0.51	6.31	0.38	1.38e-9	Breast cancer;
SARC	cis	rs698833	0.532	rs2616444	chr2:44605518	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.64	7.74	0.45	3.1e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs7666738	0.716	rs11097615	chr4:99092773	T/C	cg05340658	chr4:99064831	C4orf37	0.6	7.76	0.45	2.62e-13	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs12597458	0.789	rs7186207	chr16:72035359	C/T	cg16558253	chr16:72132732	DHX38	-0.33	-5.06	-0.31	8.67e-7	Prostate cancer;
SARC	cis	rs16854884	0.657	rs34683397	chr3:143723559	C/T	cg06585982	chr3:143692056	C3orf58	0.63	8.44	0.48	3.36e-15	Economic and political preferences (feminism/equality);
SARC	cis	rs3106136	0.967	rs2632399	chr4:95153741	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.97	-0.36	8.92e-9	Capecitabine sensitivity;
SARC	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg22974920	chr21:40686053	BRWD1	0.44	4.78	0.3	3.17e-6	Cognitive function;
SARC	cis	rs14978	1.000	rs11974384	chr7:12256540	A/G	cg23422036	chr7:12250390	TMEM106B	0.41	4.72	0.3	4.03e-6	Response to amphetamines;
SARC	cis	rs6120849	0.754	rs6120819	chr20:33653038	T/C	cg24642439	chr20:33292090	TP53INP2	0.58	5.48	0.34	1.12e-7	Protein C levels;
SARC	cis	rs34172651	0.917	rs1075987	chr16:24794957	G/A	cg00339695	chr16:24857497	SLC5A11	0.29	4.82	0.3	2.61e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2204008	0.729	rs114133083	chr12:38182923	G/C	cg26384229	chr12:38710491	ALG10B	-0.68	-8.83	-0.5	2.6e-16	Bladder cancer;
SARC	cis	rs854765	0.583	rs11869536	chr17:17826528	T/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	9.82	0.54	2.79e-19	Total body bone mineral density;
SARC	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg16680214	chr1:154839983	KCNN3	-0.38	-5.98	-0.36	8.29e-9	Prostate cancer;
SARC	cis	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg12463550	chr7:65579703	CRCP	0.68	5.21	0.32	4.1e-7	Diabetic kidney disease;
SARC	cis	rs2797685	1.000	rs2859390	chr1:7847529	A/G	cg00864860	chr1:7907996	UTS2	-0.37	-5.23	-0.32	3.82e-7	Crohn's disease;
SARC	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg27266027	chr21:40555129	PSMG1	-0.51	-5.61	-0.34	5.8e-8	Cognitive function;
SARC	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg10876282	chr6:28092338	ZSCAN16	0.46	4.78	0.3	3.05e-6	Parkinson's disease;
SARC	trans	rs804280	0.509	rs13276433	chr8:11783036	A/G	cg06636001	chr8:8085503	FLJ10661	0.51	6.63	0.4	2.27e-10	Myopia (pathological);
SARC	cis	rs17376456	0.825	rs13155452	chr5:93164449	C/T	cg21475434	chr5:93447410	FAM172A	-0.77	-6.58	-0.4	3.05e-10	Diabetic retinopathy;
SARC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg26338869	chr17:61819248	STRADA	0.81	10.84	0.58	1.98e-22	Prudent dietary pattern;
SARC	cis	rs7520050	0.966	rs4073846	chr1:46462881	C/T	cg24296786	chr1:45957014	TESK2	-0.38	-4.78	-0.3	3.06e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs2273669	0.667	rs4527738	chr6:109309150	T/C	cg05315195	chr6:109294784	ARMC2	-0.6	-5.51	-0.34	9.42e-8	Prostate cancer;
SARC	cis	rs10752881	1.000	rs12028740	chr1:182985581	G/A	cg13390022	chr1:182993471	LAMC1	0.35	5.24	0.32	3.63e-7	Colorectal cancer;
SARC	cis	rs8016982	0.674	rs11159494	chr14:81667611	G/C	cg01989461	chr14:81687754	GTF2A1	0.76	11.63	0.61	5.78e-25	Schizophrenia;
SARC	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg01475735	chr3:40494733	NA	-0.49	-5.41	-0.33	1.57e-7	Renal cell carcinoma;
SARC	cis	rs8013055	0.846	rs10139744	chr14:105974696	G/A	cg19700328	chr14:106028568	NA	-0.62	-8.6	-0.49	1.17e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
SARC	cis	rs7927592	0.913	rs7925275	chr11:68290433	T/C	cg01657329	chr11:68192670	LRP5	-0.4	-4.91	-0.31	1.71e-6	Total body bone mineral density;
SARC	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg18252515	chr7:66147081	NA	0.44	4.75	0.3	3.5e-6	Aortic root size;
SARC	cis	rs7833986	0.501	rs72653959	chr8:56996516	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.73	7.37	0.43	2.98e-12	Height;
SARC	cis	rs9660992	0.710	rs1668873	chr1:205235990	G/A	cg07972983	chr1:205091412	RBBP5	0.56	6.88	0.41	5.35e-11	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg25072359	chr17:41440525	NA	0.48	5.55	0.34	7.82e-8	Menopause (age at onset);
SARC	cis	rs1865760	0.532	rs2794719	chr6:26088890	T/G	cg10373733	chr6:25993375	NA	0.46	5.55	0.34	7.87e-8	Height;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg14036097	chr4:190862158	FRG1	0.49	6.71	0.4	1.47e-10	Height;
SARC	cis	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg06636001	chr8:8085503	FLJ10661	0.7	9.55	0.53	1.85e-18	Neuroticism;
SARC	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	10.56	0.57	1.49e-21	Alzheimer's disease;
SARC	cis	rs6570726	0.791	rs7765675	chr6:145915077	A/C	cg05347473	chr6:146136440	FBXO30	0.54	7.32	0.43	4.05e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg24675658	chr1:53192096	ZYG11B	-0.66	-9.72	-0.54	5.63e-19	Monocyte count;
SARC	cis	rs7481584	0.624	rs412842	chr11:3047448	A/G	cg08508325	chr11:3079039	CARS	0.23	5.13	0.32	6.14e-7	Calcium levels;
SARC	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg20607798	chr8:58055168	NA	0.61	5.41	0.33	1.57e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9790314	1.000	rs189270	chr3:161063504	T/C	cg03342759	chr3:160939853	NMD3	-0.6	-7.56	-0.44	9.33e-13	Morning vs. evening chronotype;
SARC	cis	rs11098499	1.000	rs13116504	chr4:120209412	A/C	cg09307838	chr4:120376055	NA	0.84	11.53	0.6	1.21e-24	Corneal astigmatism;
SARC	cis	rs61935443	0.501	rs10745697	chr12:95193867	G/A	cg21533806	chr12:95267307	NA	0.38	4.79	0.3	3.03e-6	Schizophrenia;
SARC	cis	rs6582630	0.512	rs11182667	chr12:38588392	C/A	cg26384229	chr12:38710491	ALG10B	-0.61	-7.7	-0.45	3.75e-13	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs473651	0.935	rs483166	chr2:239346641	C/T	cg18131467	chr2:239335373	ASB1	-0.95	-15.69	-0.72	2.4e-38	Multiple system atrophy;
SARC	cis	rs4803468	1.000	rs11670668	chr19:41920454	G/C	cg09537434	chr19:41945824	ATP5SL	-0.98	-17.48	-0.75	2.73e-44	Height;
SARC	cis	rs524281	0.861	rs9645684	chr11:65907964	G/A	cg14036092	chr11:66035641	RAB1B	-0.52	-5.52	-0.34	9.09e-8	Electroencephalogram traits;
SARC	cis	rs4595586	0.545	rs12812262	chr12:39392567	T/A	cg26384229	chr12:38710491	ALG10B	0.5	6.12	0.37	3.98e-9	Morning vs. evening chronotype;
SARC	cis	rs12971120	0.891	rs4891557	chr18:72170299	C/T	cg25817165	chr18:72167213	CNDP2	-0.53	-7.55	-0.44	1.01e-12	Refractive error;
SARC	cis	rs9303401	0.632	rs7502541	chr17:57241019	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.64	7.68	0.45	4.5e-13	Cognitive test performance;
SARC	cis	rs1008375	1.000	rs10939743	chr4:17662731	G/A	cg27347728	chr4:17578864	LAP3	0.45	5.54	0.34	8.28e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg18230493	chr5:56204884	C5orf35	-0.56	-4.87	-0.3	2.08e-6	Initial pursuit acceleration;
SARC	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg09699651	chr6:150184138	LRP11	0.51	6.28	0.38	1.68e-9	Testicular germ cell tumor;
SARC	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg27541892	chr1:1571801	CDK11B	0.41	5.5	0.34	9.74e-8	Body mass index;
SARC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	19.51	0.79	6.64e-51	Prudent dietary pattern;
SARC	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg16325326	chr1:53192061	ZYG11B	-0.98	-18.42	-0.77	2.28e-47	Monocyte count;
SARC	cis	rs3087591	0.919	rs2012581	chr17:29560800	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.46	-5.63	-0.35	5.27e-8	Hip circumference;
SARC	cis	rs8114671	0.562	rs4911450	chr20:33512406	C/T	cg24642439	chr20:33292090	TP53INP2	0.47	5.6	0.34	6.15e-8	Height;
SARC	cis	rs526231	0.543	rs17154913	chr5:102328490	C/G	cg23492399	chr5:102201601	PAM	-0.52	-6.36	-0.38	1.03e-9	Primary biliary cholangitis;
SARC	cis	rs7589728	0.514	rs78204719	chr2:88460747	G/C	cg04511125	chr2:88470314	THNSL2	0.76	7.15	0.42	1.11e-11	Plasma clusterin levels;
SARC	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg09373136	chr17:61933544	TCAM1	0.39	5.47	0.34	1.17e-7	Prudent dietary pattern;
SARC	cis	rs11098499	0.954	rs12508504	chr4:120410607	A/C	cg09307838	chr4:120376055	NA	0.9	12.61	0.64	4.01e-28	Corneal astigmatism;
SARC	cis	rs1018836	0.884	rs7008765	chr8:91632589	C/T	cg16814680	chr8:91681699	NA	-0.84	-13.82	-0.67	4.04e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg26338869	chr17:61819248	STRADA	0.76	10.21	0.56	1.87e-20	Prudent dietary pattern;
SARC	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg21017887	chr14:105400489	NA	0.52	7.49	0.44	1.38e-12	Rheumatoid arthritis;
SARC	cis	rs11098499	1.000	rs7659194	chr4:120207147	T/G	cg09307838	chr4:120376055	NA	0.83	11.28	0.59	7.86e-24	Corneal astigmatism;
SARC	cis	rs4268898	0.662	rs9784114	chr2:24437517	C/T	cg26838691	chr2:24397539	C2orf84	-0.53	-6.14	-0.37	3.56e-9	Asthma;
SARC	cis	rs10465746	0.746	rs6663949	chr1:84452853	T/C	cg10977910	chr1:84465055	TTLL7	0.45	5.55	0.34	7.56e-8	Obesity-related traits;
SARC	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.53	5.2	0.32	4.4e-7	Lung function (FEV1/FVC);
SARC	trans	rs17066873	1.000	rs35649611	chr13:77468054	A/G	cg21804574	chr18:76126700	NA	0.93	6.69	0.4	1.64e-10	Pharmacokinetics of antiepileptic drugs in severe mental disorder (concentration drug ratio);
SARC	cis	rs9916302	0.904	rs612194	chr17:37442707	T/A	cg07936489	chr17:37558343	FBXL20	0.69	9.22	0.52	1.82e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs4742903	1.000	rs2274724	chr9:106860568	C/T	cg14250997	chr9:106856677	SMC2	0.52	6.85	0.41	6.65e-11	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs6060960	0.537	rs6089119	chr20:30514161	T/G	cg09796376	chr20:30640595	HCK	0.51	4.79	0.3	2.98e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
SARC	cis	rs11190604	0.945	rs2495746	chr10:102328270	T/C	cg07080220	chr10:102295463	HIF1AN	0.76	9.07	0.51	5.12e-17	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs7666738	0.830	rs11941844	chr4:99042722	A/T	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9303280	0.837	rs907092	chr17:37922259	A/G	cg00129232	chr17:37814104	STARD3	0.4	5.11	0.32	6.57e-7	Self-reported allergy;
SARC	cis	rs11077998	0.840	rs9894993	chr17:80481088	T/C	cg10255544	chr17:80519551	FOXK2	0.44	6.24	0.38	2.08e-9	Reticulocyte fraction of red cells;
SARC	cis	rs6963495	0.818	rs73190202	chr7:105166510	A/G	cg13798780	chr7:105162888	PUS7	0.6	5.56	0.34	7.22e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs748404	0.631	rs8042688	chr15:43638525	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.39	4.8	0.3	2.84e-6	Lung cancer;
SARC	cis	rs7395581	0.959	rs901746	chr11:47260319	A/G	cg25783544	chr11:47291846	MADD	0.47	5.12	0.32	6.53e-7	HDL cholesterol;
SARC	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg18225595	chr11:63971243	STIP1	0.57	8.43	0.48	3.59e-15	Platelet count;
SARC	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg17554472	chr22:41940697	POLR3H	-0.43	-4.75	-0.3	3.54e-6	Vitiligo;
SARC	cis	rs36051895	0.658	rs10975029	chr9:5251068	T/C	cg02405213	chr9:5042618	JAK2	-0.4	-4.85	-0.3	2.25e-6	Pediatric autoimmune diseases;
SARC	cis	rs981844	1.000	rs72731669	chr4:154662464	G/A	cg14289246	chr4:154710475	SFRP2	0.59	6.74	0.4	1.25e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs11718455	0.883	rs2372579	chr3:44034003	A/T	cg08738300	chr3:44038990	NA	0.52	5.67	0.35	4.18e-8	Coronary artery disease;
SARC	cis	rs1580019	0.961	rs1580021	chr7:32497702	T/G	cg14728415	chr7:32535168	LSM5;AVL9	0.43	5.04	0.31	9.3e-7	Cognitive ability;
SARC	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg13395646	chr4:1353034	KIAA1530	-0.42	-4.99	-0.31	1.19e-6	Obesity-related traits;
SARC	cis	rs735396	1.000	rs2259816	chr12:121435587	A/C	cg15155738	chr12:121454335	C12orf43	-0.5	-6.08	-0.37	4.9e-9	N-glycan levels;
SARC	cis	rs4819052	0.565	rs35776291	chr21:46706142	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.53	6.49	0.39	5.23e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs17079247	1.000	rs9566017	chr13:85664694	C/T	ch.13.84760847R	chr13:85862846	NA	-0.57	-4.82	-0.3	2.59e-6	Bipolar disorder (mania);
SARC	cis	rs7666738	0.830	rs2114425	chr4:99023967	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.88	0.5	1.84e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs595982	0.559	rs17206700	chr19:49361255	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.64	-7.16	-0.42	1.08e-11	Red cell distribution width;
SARC	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg18357526	chr6:26021779	HIST1H4A	0.86	11.21	0.59	1.34e-23	Intelligence (multi-trait analysis);
SARC	cis	rs72945132	0.882	rs61177215	chr11:70129534	G/A	cg05964544	chr11:70165517	PPFIA1	-0.6	-5.85	-0.36	1.66e-8	Coronary artery disease;
SARC	cis	rs8017423	0.765	rs8017170	chr14:90721849	T/A	cg20276874	chr14:90721474	PSMC1	-0.39	-5.47	-0.34	1.18e-7	Mortality in heart failure;
SARC	cis	rs34375054	0.660	rs12578446	chr12:125605887	A/G	cg25124228	chr12:125621409	AACS	-0.51	-5.45	-0.34	1.27e-7	Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs7635838	0.718	rs2594981	chr3:11380638	C/G	cg00170343	chr3:11313890	ATG7	0.62	8.57	0.49	1.45e-15	HDL cholesterol;
SARC	cis	rs3796352	0.667	rs9831977	chr3:52854140	T/G	cg27565382	chr3:53032988	SFMBT1	0.77	5.43	0.34	1.4e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.66	-7.62	-0.45	6.27e-13	Gut microbiome composition (summer);
SARC	cis	rs7772486	0.790	rs2254283	chr6:146204289	T/C	cg23711669	chr6:146136114	FBXO30	0.79	12.61	0.64	4e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs5753618	0.583	rs5749270	chr22:31812853	C/T	cg02404636	chr22:31891804	SFI1	0.49	5.17	0.32	4.93e-7	Colorectal cancer;
SARC	cis	rs7208859	0.673	rs9914271	chr17:29232625	G/A	cg13385521	chr17:29058706	SUZ12P	0.85	7.23	0.43	7.08e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs950776	0.518	rs4887063	chr15:78839715	C/T	cg22563815	chr15:78856949	CHRNA5	-0.43	-6.82	-0.41	7.64e-11	Sudden cardiac arrest;
SARC	cis	rs9818758	0.607	rs11706189	chr3:49210833	C/A	cg00383909	chr3:49044727	WDR6	0.71	6.37	0.39	9.81e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs13166103	0.657	rs10513147	chr5:57716976	G/T	cg10487770	chr5:57879443	RAB3C	0.52	5.46	0.34	1.19e-7	Type 2 diabetes (age of onset);
SARC	cis	rs6121246	0.529	rs6058196	chr20:30194714	A/T	cg21427119	chr20:30132790	HM13	-0.48	-5.29	-0.33	2.84e-7	Mean corpuscular hemoglobin;
SARC	cis	rs244731	1.000	rs244731	chr5:176539679	C/T	cg16006841	chr5:176797999	RGS14	0.55	6.21	0.38	2.35e-9	Urate levels in lean individuals;
SARC	cis	rs4803455	0.565	rs1025497	chr19:41871254	A/G	cg14132834	chr19:41945861	ATP5SL	-0.41	-5.24	-0.32	3.68e-7	Migraine;Coronary artery disease;
SARC	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	15.02	0.7	4.1e-36	Chronic sinus infection;
SARC	cis	rs9393692	0.875	rs9393690	chr6:26271713	A/T	cg05868516	chr6:26286170	HIST1H4H	0.57	7.57	0.44	8.39e-13	Educational attainment;
SARC	cis	rs881375	0.935	rs7034390	chr9:123646488	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.41	4.83	0.3	2.51e-6	Rheumatoid arthritis;
SARC	trans	rs890100	0.801	rs10189319	chr2:56706672	C/G	cg26233084	chr5:15510258	FBXL7	-0.31	-6.34	-0.38	1.19e-9	Gut microbiome composition (summer);
SARC	cis	rs4481887	1.000	rs4360555	chr1:248468591	G/T	cg00666640	chr1:248458726	OR2T12	0.38	6.42	0.39	7.43e-10	Common traits (Other);
SARC	cis	rs7666738	0.830	rs17550610	chr4:99008273	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg20891283	chr12:69753455	YEATS4	0.54	7.43	0.44	2.09e-12	Blood protein levels;
SARC	cis	rs4699052	0.963	rs11943325	chr4:104178393	T/C	cg16532752	chr4:104119610	CENPE	-0.4	-4.71	-0.3	4.17e-6	Testicular germ cell tumor;
SARC	cis	rs16976116	0.901	rs28589609	chr15:55503630	C/T	cg11288833	chr15:55489084	RSL24D1	0.61	5.91	0.36	1.19e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6964587	0.839	rs17731846	chr7:91440342	A/G	cg17063962	chr7:91808500	NA	0.84	11.7	0.61	3.6e-25	Breast cancer;
SARC	cis	rs798554	0.660	rs2644295	chr7:2860217	A/C	cg13628971	chr7:2884303	GNA12	0.44	5.45	0.34	1.26e-7	Height;
SARC	cis	rs9393777	0.513	rs9368447	chr6:26646674	A/C	cg12826209	chr6:26865740	GUSBL1	0.66	5.87	0.36	1.47e-8	Intelligence (multi-trait analysis);
SARC	cis	rs5758511	0.637	rs5751244	chr22:42617411	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.45	6.83	0.41	7.41e-11	Birth weight;
SARC	cis	rs8060686	0.844	rs7196076	chr16:67887494	T/A	cg09117114	chr16:67998030	SLC12A4	-0.53	-4.76	-0.3	3.45e-6	HDL cholesterol;Metabolic syndrome;
SARC	cis	rs7772486	0.719	rs702317	chr6:146005010	C/T	cg23711669	chr6:146136114	FBXO30	-0.87	-14.73	-0.69	3.63e-35	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4128725	1.000	rs4399156	chr1:159338072	G/A	cg25076881	chr1:159409836	OR10J1	0.4	4.78	0.3	3.04e-6	Select biomarker traits;
SARC	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg03351412	chr1:154909251	PMVK	0.56	6.72	0.4	1.37e-10	Prostate cancer;
SARC	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs763121	0.853	rs5750652	chr22:39048316	A/G	cg06022373	chr22:39101656	GTPBP1	0.92	12.73	0.64	1.6e-28	Menopause (age at onset);
SARC	cis	rs834603	0.575	rs865031	chr7:47448640	A/C	cg23694490	chr7:47445681	TNS3	-0.34	-6.21	-0.38	2.42e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs10489202	0.583	rs203777	chr1:167876616	C/T	cg24449463	chr1:168025552	DCAF6	-0.66	-8.57	-0.49	1.47e-15	Schizophrenia;
SARC	cis	rs7582180	0.669	rs4455176	chr2:100876629	T/A	cg14675211	chr2:100938903	LONRF2	0.35	4.93	0.31	1.56e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2011503	0.941	rs56135441	chr19:19371370	A/T	cg03709012	chr19:19516395	GATAD2A	0.61	5.54	0.34	8.2e-8	Bipolar disorder;
SARC	cis	rs7647973	0.626	rs1996663	chr3:49878264	C/G	cg06212747	chr3:49208901	KLHDC8B	-0.58	-5.78	-0.35	2.34e-8	Menarche (age at onset);
SARC	cis	rs8180040	1.000	rs295428	chr3:47359262	G/T	cg27129171	chr3:47204927	SETD2	0.67	9.38	0.52	5.96e-18	Colorectal cancer;
SARC	cis	rs2380220	0.541	rs9285413	chr6:96023439	G/A	cg07718321	chr6:96025334	MANEA	0.49	5.31	0.33	2.6e-7	Behavioural disinhibition (generation interaction);
SARC	cis	rs9398803	0.687	rs4626447	chr6:126964675	G/A	cg19875578	chr6:126661172	C6orf173	0.63	8.7	0.5	5.9e-16	Male-pattern baldness;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg24828496	chr2:163009887	GCG	0.54	7.92	0.46	9.39e-14	Thyroid stimulating hormone;
SARC	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.68	7.44	0.44	1.97e-12	Age-related macular degeneration (geographic atrophy);
SARC	trans	rs9329221	0.683	rs555200	chr8:9888729	A/G	cg21775007	chr8:11205619	TDH	-0.5	-6.43	-0.39	7.32e-10	Neuroticism;
SARC	trans	rs11098499	0.863	rs2291185	chr4:120434833	C/A	cg25214090	chr10:38739885	LOC399744	0.57	7.35	0.43	3.31e-12	Corneal astigmatism;
SARC	cis	rs7149337	0.805	rs71422017	chr14:51612417	A/T	cg23942311	chr14:51606299	NA	0.3	5.51	0.34	9.46e-8	Cancer;
SARC	cis	rs1865760	0.566	rs9379825	chr6:26083871	C/A	cg18357526	chr6:26021779	HIST1H4A	0.41	4.98	0.31	1.23e-6	Height;
SARC	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs501120	1.000	rs670056	chr10:44753375	C/T	cg09554077	chr10:44749378	NA	0.48	6.67	0.4	1.85e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs703842	1.000	rs10747783	chr12:58176614	T/C	cg00677455	chr12:58241039	CTDSP2	0.51	6.64	0.4	2.18e-10	Multiple sclerosis;
SARC	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg11987759	chr7:65425863	GUSB	-0.48	-6.54	-0.39	3.9e-10	Aortic root size;
SARC	trans	rs12310956	0.510	rs10743832	chr12:33884146	A/C	cg26384229	chr12:38710491	ALG10B	0.61	8.04	0.47	4.53e-14	Morning vs. evening chronotype;
SARC	cis	rs3771395	1.000	rs3771396	chr2:71132952	G/A	cg21294935	chr2:71128538	VAX2	0.65	5.41	0.33	1.55e-7	Corneal astigmatism;
SARC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg12419862	chr22:24373484	LOC391322	0.8	11.02	0.59	5.2e-23	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2933343	0.679	rs1091938	chr3:128637025	T/C	cg25356066	chr3:128598488	ACAD9	0.73	9.45	0.53	3.8e-18	IgG glycosylation;
SARC	cis	rs709400	0.628	rs12879085	chr14:103874420	G/A	cg26031613	chr14:104095156	KLC1	-0.76	-10.64	-0.57	8.34e-22	Body mass index;
SARC	cis	rs11098499	0.954	rs10006525	chr4:120408931	T/G	cg24375607	chr4:120327624	NA	0.42	4.96	0.31	1.35e-6	Corneal astigmatism;
SARC	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg04518342	chr5:131593106	PDLIM4	0.44	5.7	0.35	3.64e-8	Breast cancer;
SARC	cis	rs4427176	0.714	rs11784181	chr8:9479926	C/T	cg21625330	chr8:9911636	MSRA	0.62	4.92	0.31	1.62e-6	Mosquito bite size;
SARC	cis	rs561341	0.556	rs542244	chr17:30307242	T/C	cg00745463	chr17:30367425	LRRC37B	-0.67	-5.32	-0.33	2.4e-7	Hip circumference adjusted for BMI;
SARC	cis	rs2273669	0.667	rs12154092	chr6:109313303	C/T	cg05315195	chr6:109294784	ARMC2	-0.59	-5.45	-0.34	1.28e-7	Prostate cancer;
SARC	cis	rs2050392	0.590	rs694346	chr10:30711929	C/T	cg25182066	chr10:30743637	MAP3K8	0.42	5.75	0.35	2.85e-8	Inflammatory bowel disease;
SARC	cis	rs17376456	0.877	rs10059630	chr5:93459807	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.79	0.35	2.3e-8	Diabetic retinopathy;
SARC	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg00152838	chr16:24741724	TNRC6A	0.49	5.08	0.32	7.59e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2204008	0.774	rs11520237	chr12:38266978	G/A	cg26384229	chr12:38710491	ALG10B	0.91	13.79	0.67	4.83e-32	Bladder cancer;
SARC	trans	rs61931739	0.500	rs11513287	chr12:34584351	G/A	cg26384229	chr12:38710491	ALG10B	0.91	13.72	0.67	8.65e-32	Morning vs. evening chronotype;
SARC	cis	rs7089973	0.610	rs17721905	chr10:116731596	A/G	cg08188268	chr10:116634841	FAM160B1	0.42	5.67	0.35	4.29e-8	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs9341808	0.754	rs1324121	chr6:80946077	A/G	cg08355045	chr6:80787529	NA	0.33	5.34	0.33	2.24e-7	Sitting height ratio;
SARC	cis	rs6570726	0.791	rs427128	chr6:145865917	T/C	cg05347473	chr6:146136440	FBXO30	0.54	7.45	0.44	1.8e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg00149659	chr3:10157352	C3orf10	0.76	7.19	0.43	8.87e-12	Alzheimer's disease;
SARC	cis	rs2075371	0.796	rs35440439	chr7:134006094	C/T	cg11752832	chr7:134001865	SLC35B4	0.55	6.91	0.41	4.6e-11	Mean platelet volume;
SARC	cis	rs4595586	0.545	rs6580892	chr12:39370237	G/C	cg13010199	chr12:38710504	ALG10B	0.4	4.75	0.3	3.57e-6	Morning vs. evening chronotype;
SARC	cis	rs854765	0.505	rs4506969	chr17:17899839	A/G	cg05444541	chr17:17804740	TOM1L2	-0.3	-4.86	-0.3	2.17e-6	Total body bone mineral density;
SARC	cis	rs854765	0.562	rs2955381	chr17:17945500	G/C	cg05444541	chr17:17804740	TOM1L2	0.3	4.89	0.31	1.85e-6	Total body bone mineral density;
SARC	cis	rs7644634	0.649	rs9816486	chr3:105403685	A/G	cg23051926	chr3:105466016	CBLB	0.47	5.96	0.36	9.14e-9	Itch intensity from mosquito bite;
SARC	cis	rs12701220	0.553	rs34062359	chr7:1139076	C/T	cg10374962	chr7:1011985	COX19	-0.45	-4.74	-0.3	3.77e-6	Bronchopulmonary dysplasia;
SARC	cis	rs17376456	0.825	rs35426871	chr5:93291613	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.65	5.87	0.36	1.46e-8	Diabetic retinopathy;
SARC	cis	rs11785400	1.000	rs11780221	chr8:143748215	T/A	cg24634471	chr8:143751801	JRK	0.67	8.76	0.5	4.06e-16	Schizophrenia;
SARC	cis	rs6545883	0.929	rs10173974	chr2:61748900	C/G	cg15711740	chr2:61764176	XPO1	-0.42	-5.21	-0.32	4.16e-7	Tuberculosis;
SARC	cis	rs6665290	0.545	rs6426584	chr1:227374949	A/T	cg10327440	chr1:227177885	CDC42BPA	-0.89	-13.41	-0.66	9.18e-31	Myeloid white cell count;
SARC	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg16606324	chr3:10149918	C3orf24	0.5	5.01	0.31	1.08e-6	Alzheimer's disease;
SARC	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.87	12.36	0.63	2.47e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs12824058	0.737	rs11060829	chr12:130814996	G/T	cg23887609	chr12:130822674	PIWIL1	0.38	5.31	0.33	2.54e-7	Menopause (age at onset);
SARC	cis	rs4742903	0.527	rs1450673	chr9:106944775	G/A	cg14250997	chr9:106856677	SMC2	0.39	4.83	0.3	2.51e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg05025164	chr4:1340916	KIAA1530	0.49	6.02	0.37	6.81e-9	Longevity;
SARC	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg18404041	chr3:52824283	ITIH1	-0.44	-6.59	-0.4	2.9e-10	Bipolar disorder;
SARC	cis	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg21775007	chr8:11205619	TDH	0.64	8.43	0.48	3.66e-15	Retinal vascular caliber;
SARC	trans	rs11165623	0.564	rs7541109	chr1:96995960	C/A	cg10631902	chr5:14652156	NA	-0.42	-6.49	-0.39	5.21e-10	Hip circumference;Waist circumference;
SARC	cis	rs9309473	0.950	rs1052162	chr2:73829372	A/G	cg20560298	chr2:73613845	ALMS1	0.46	5.68	0.35	4e-8	Metabolite levels;
SARC	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.44	-5.6	-0.34	5.98e-8	Intelligence (multi-trait analysis);
SARC	cis	rs10791323	0.536	rs4937842	chr11:133734542	C/G	cg15485101	chr11:133734466	NA	-0.35	-5.58	-0.34	6.58e-8	Childhood ear infection;
SARC	cis	rs11122272	0.735	rs2749717	chr1:231489353	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-9.95	-0.55	1.14e-19	Hemoglobin concentration;
SARC	cis	rs17030434	0.906	rs5020754	chr4:154670444	T/C	cg14289246	chr4:154710475	SFRP2	-0.66	-6.6	-0.4	2.78e-10	Electrocardiographic conduction measures;
SARC	cis	rs6568686	0.577	rs174400	chr6:111922979	A/G	cg15721981	chr6:111408429	SLC16A10	0.68	5.6	0.34	6.11e-8	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs4988958	0.565	rs10206291	chr2:103038863	T/C	cg03938978	chr2:103052716	IL18RAP	0.32	5.12	0.32	6.49e-7	Asthma (childhood onset);
SARC	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg24675658	chr1:53192096	ZYG11B	0.67	9.85	0.54	2.29e-19	Monocyte count;
SARC	cis	rs1395	0.744	rs62130709	chr2:27505782	C/T	cg22903471	chr2:27725779	GCKR	-0.39	-4.75	-0.3	3.51e-6	Blood metabolite levels;
SARC	cis	rs9430161	0.611	rs34032547	chr1:11034374	C/G	cg02454025	chr1:11042201	C1orf127	0.87	12.08	0.62	2.04e-26	Ewing sarcoma;
SARC	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg22535103	chr8:58192502	C8orf71	-0.73	-7.24	-0.43	6.52e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs858239	0.932	rs1637190	chr7:23269065	A/G	cg23682824	chr7:23144976	KLHL7	0.6	7.6	0.45	7.02e-13	Cerebrospinal fluid biomarker levels;
SARC	cis	rs11264799	0.520	rs849817	chr1:157542045	G/A	cg18268488	chr1:157545234	FCRL4	0.32	5.75	0.35	2.73e-8	IgA nephropathy;
SARC	cis	rs2073300	0.609	rs2281428	chr20:23400050	C/T	cg12062639	chr20:23401060	NAPB	1.01	6.99	0.42	2.92e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs7017697	0.642	rs3927029	chr8:19681933	G/A	cg03894339	chr8:19674705	INTS10	-0.6	-6.85	-0.41	6.36e-11	Breast cancer;
SARC	cis	rs7236492	0.683	rs59828426	chr18:77204397	T/C	cg15644404	chr18:77186268	NFATC1	-0.56	-6.05	-0.37	5.85e-9	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs7829975	0.514	rs2976926	chr8:8261624	T/C	cg06636001	chr8:8085503	FLJ10661	0.63	7.83	0.46	1.67e-13	Mood instability;
SARC	cis	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg11608241	chr8:8085544	FLJ10661	-0.42	-5.04	-0.31	9.27e-7	Joint mobility (Beighton score);
SARC	cis	rs858239	0.537	rs10279691	chr7:23228387	A/G	cg23682824	chr7:23144976	KLHL7	0.66	8.44	0.48	3.4e-15	Cerebrospinal fluid biomarker levels;
SARC	cis	rs1580019	0.961	rs766660	chr7:32499077	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.44	5.18	0.32	4.9e-7	Cognitive ability;
SARC	trans	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg19312536	chr1:154540535	CHRNB2	0.44	6.48	0.39	5.44e-10	Immature fraction of reticulocytes;
SARC	cis	rs6831352	0.569	rs4140388	chr4:100065734	G/C	cg13256891	chr4:100009986	ADH5	0.46	6.04	0.37	5.9e-9	Alcohol dependence;
SARC	cis	rs920590	0.679	rs4577973	chr8:19658017	A/G	cg17834443	chr8:19674713	INTS10	0.42	5.23	0.32	3.7e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs4423214	0.879	rs1792283	chr11:71135136	T/C	cg05163923	chr11:71159392	DHCR7	-0.48	-5.39	-0.33	1.74e-7	Vitamin D levels;
SARC	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg21782813	chr7:2030301	MAD1L1	0.4	6.22	0.38	2.26e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg22105103	chr4:187893119	NA	0.5	6.83	0.41	7.16e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11509880	0.606	rs1990621	chr7:12283873	C/G	cg23422036	chr7:12250390	TMEM106B	0.48	6.35	0.38	1.12e-9	Coronary artery disease;
SARC	cis	rs7819412	0.527	rs7821914	chr8:10805015	A/G	cg00262122	chr8:11665843	FDFT1	-0.43	-5.32	-0.33	2.42e-7	Triglycerides;
SARC	cis	rs870825	0.616	rs7683537	chr4:185631998	T/C	cg04058563	chr4:185651563	MLF1IP	0.83	11.16	0.59	1.91e-23	Blood protein levels;
SARC	cis	rs3733585	0.673	rs4560411	chr4:9953361	A/G	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.39	-0.33	1.76e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs72781680	0.611	rs56113233	chr2:24341085	A/C	cg08917208	chr2:24149416	ATAD2B	0.61	6.31	0.38	1.4e-9	Lymphocyte counts;
SARC	cis	rs13161895	1.000	rs4129403	chr5:179476610	A/G	cg06664874	chr5:179499304	RNF130	0.51	4.76	0.3	3.39e-6	LDL cholesterol;
SARC	cis	rs763121	0.889	rs2267390	chr22:38889657	C/T	cg06022373	chr22:39101656	GTPBP1	0.92	11.78	0.61	2e-25	Menopause (age at onset);
SARC	cis	rs7772486	0.658	rs4895683	chr6:146113654	T/A	cg23711669	chr6:146136114	FBXO30	-0.8	-13.15	-0.65	6.6e-30	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg23172400	chr8:95962367	TP53INP1	-0.33	-5.76	-0.35	2.59e-8	Type 2 diabetes;
SARC	cis	rs11687170	0.882	rs56087190	chr2:237053914	G/A	cg19324714	chr2:237145437	ASB18	0.49	4.93	0.31	1.54e-6	Educational attainment;Educational attainment (years of education);
SARC	cis	rs2153535	0.623	rs2152346	chr6:8454652	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	6.54	0.39	3.96e-10	Motion sickness;
SARC	cis	rs2153535	0.580	rs1335628	chr6:8491742	A/T	cg21535247	chr6:8435926	SLC35B3	0.57	7.26	0.43	5.7e-12	Motion sickness;
SARC	cis	rs6704644	1.000	rs72982325	chr2:234434414	C/T	cg27060346	chr2:234359958	DGKD	-0.6	-4.74	-0.3	3.65e-6	Bilirubin levels;
SARC	cis	rs34421088	0.559	rs12386974	chr8:11400628	C/G	cg21775007	chr8:11205619	TDH	0.39	4.85	0.3	2.26e-6	Neuroticism;
SARC	cis	rs7481584	0.624	rs428726	chr11:3046201	G/A	cg05729581	chr11:3078854	CARS	0.58	7.61	0.45	6.65e-13	Calcium levels;
SARC	cis	rs6580649	0.941	rs10492080	chr12:48501411	A/G	cg24011408	chr12:48396354	COL2A1	-0.47	-5.34	-0.33	2.22e-7	Lung cancer;
SARC	cis	rs11718455	0.961	rs3846068	chr3:44029835	G/A	cg08738300	chr3:44038990	NA	0.49	5.42	0.33	1.51e-7	Coronary artery disease;
SARC	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg02795432	chr2:204193336	ABI2	0.48	6.36	0.38	1.03e-9	Chemerin levels;
SARC	cis	rs1348850	0.632	rs12467363	chr2:178502512	C/T	cg23306229	chr2:178417860	TTC30B	0.51	5.74	0.35	3e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg03033257	chr22:50311977	ALG12;CRELD2	0.61	5.8	0.36	2.1e-8	Schizophrenia;
SARC	cis	rs1419980	0.630	rs2377089	chr12:7737325	T/C	cg10578777	chr12:7781093	NA	0.56	5.93	0.36	1.1e-8	HDL cholesterol levels;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg26074535	chr5:134094528	DDX46	0.52	6.28	0.38	1.61e-9	Blood pressure;
SARC	cis	rs6500602	0.592	rs3747585	chr16:4519140	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.37	6.09	0.37	4.7e-9	Schizophrenia;
SARC	cis	rs8020289	0.560	rs4903492	chr14:77264528	G/A	cg23436960	chr14:77239540	VASH1	-0.32	-4.81	-0.3	2.72e-6	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg03722871	chr13:111527030	NA	-0.77	-5.57	-0.34	7.13e-8	Obesity-related traits;
SARC	cis	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg24110177	chr3:50126178	RBM5	0.54	7.23	0.43	7.07e-12	Intelligence (multi-trait analysis);
SARC	cis	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg24110177	chr3:50126178	RBM5	0.4	5.07	0.32	7.98e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6570726	0.905	rs406799	chr6:145821837	G/C	cg23711669	chr6:146136114	FBXO30	0.78	11.91	0.62	7.29e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs17376456	0.877	rs114256265	chr5:93473130	T/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.65	5.87	0.36	1.49e-8	Diabetic retinopathy;
SARC	cis	rs12200560	0.505	rs211164	chr6:97068140	G/T	cg06623918	chr6:96969491	KIAA0776	0.45	5.07	0.32	8.15e-7	Coronary heart disease;
SARC	cis	rs6910061	0.830	rs41270602	chr6:11094690	G/T	cg27233058	chr6:11094804	LOC221710	0.6	5.45	0.34	1.31e-7	Diabetic kidney disease;
SARC	cis	rs9325144	0.600	rs10748442	chr12:38732939	A/T	cg10518543	chr12:38710700	ALG10B	0.38	4.78	0.3	3.1e-6	Morning vs. evening chronotype;
SARC	cis	rs4642101	0.669	rs1467026	chr3:12830775	G/A	cg05775895	chr3:12838266	CAND2	0.71	10.51	0.57	2.1e-21	QRS complex (12-leadsum);
SARC	cis	rs524281	0.773	rs7951079	chr11:65980550	C/T	cg14036092	chr11:66035641	RAB1B	-0.54	-5.3	-0.33	2.67e-7	Electroencephalogram traits;
SARC	cis	rs9462027	0.606	rs12201281	chr6:34681091	T/C	cg07306190	chr6:34760872	UHRF1BP1	0.42	6.01	0.37	7.25e-9	Systemic lupus erythematosus;
SARC	trans	rs4834272	0.662	rs12507761	chr4:113305623	A/G	cg04861380	chr7:150497663	TMEM176B;TMEM176A	-0.45	-6.24	-0.38	2.1e-9	Body mass index;
SARC	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg09455208	chr3:40491958	NA	0.4	5.88	0.36	1.39e-8	Renal cell carcinoma;
SARC	cis	rs28829049	0.597	rs12563386	chr1:19455205	T/C	cg13387374	chr1:19411106	UBR4	0.45	5.26	0.33	3.33e-7	QRS duration in Tripanosoma cruzi seropositivity;
SARC	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg18876405	chr7:65276391	NA	-0.44	-4.93	-0.31	1.56e-6	Aortic root size;
SARC	cis	rs611744	0.967	rs702802	chr8:109218238	G/A	cg21045802	chr8:109455806	TTC35	0.46	5.48	0.34	1.09e-7	Dupuytren's disease;
SARC	cis	rs6991838	0.806	rs35024820	chr8:66463531	C/T	cg13398993	chr8:66546079	ARMC1	0.41	5.05	0.31	8.76e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7772486	0.712	rs1292335	chr6:145967877	G/T	cg05347473	chr6:146136440	FBXO30	0.46	6.07	0.37	5.07e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11121022	0.965	rs11121021	chr1:7835699	G/A	cg09696653	chr1:7765353	CAMTA1	0.39	5.37	0.33	1.92e-7	Morning vs. evening chronotype;
SARC	cis	rs6582630	0.599	rs11181807	chr12:38403763	G/A	cg26384229	chr12:38710491	ALG10B	-0.57	-7.04	-0.42	2.19e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs17666538	0.585	rs6559064	chr8:623061	G/A	cg23958373	chr8:599963	NA	0.72	6.01	0.37	7.05e-9	IgG glycosylation;
SARC	cis	rs6580649	0.941	rs1968071	chr12:48489357	A/G	cg05342945	chr12:48394962	COL2A1	0.57	6.32	0.38	1.29e-9	Lung cancer;
SARC	cis	rs6772849	0.930	rs4857916	chr3:128376014	C/G	cg08795948	chr3:128337044	NA	0.55	7.82	0.46	1.85e-13	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs2295359	0.824	rs12060309	chr1:67604219	T/C	cg12940439	chr1:67600707	NA	0.48	6.54	0.39	3.78e-10	Psoriasis;
SARC	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-9.68	-0.54	7.76e-19	Chronic sinus infection;
SARC	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg03161606	chr19:29218774	NA	0.48	6.87	0.41	5.87e-11	Methadone dose in opioid dependence;
SARC	cis	rs1568889	0.938	rs1464898	chr11:28034748	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	10.16	0.55	2.68e-20	Bipolar disorder;
SARC	cis	rs995000	0.931	rs12037659	chr1:62923863	C/T	cg06896770	chr1:63153194	DOCK7	1.0	15.96	0.72	2.95e-39	Triglyceride levels;
SARC	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg10523679	chr1:76189770	ACADM	0.51	6.63	0.4	2.26e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs1371867	0.764	rs1020171	chr8:101288610	T/C	cg11906718	chr8:101322791	RNF19A	0.71	9.25	0.52	1.54e-17	Atrioventricular conduction;
SARC	cis	rs17270561	0.609	rs9356986	chr6:25739119	T/C	cg17691542	chr6:26056736	HIST1H1C	0.58	7.09	0.42	1.6e-11	Iron status biomarkers;
SARC	cis	rs4605213	0.869	rs8079266	chr17:49246726	A/C	cg00965052	chr17:49230932	NME1;NME1-NME2	0.44	5.02	0.31	1.05e-6	Height;
SARC	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg16405210	chr4:1374714	KIAA1530	-0.53	-6.55	-0.39	3.63e-10	Obesity-related traits;
SARC	cis	rs1468333	0.592	rs4074484	chr5:137576017	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.73	8.04	0.47	4.4e-14	Resting heart rate;
SARC	cis	rs7044106	0.762	rs7044226	chr9:123466328	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	4.99	0.31	1.2e-6	Hip circumference adjusted for BMI;
SARC	cis	rs2721811	0.512	rs6952491	chr7:24590979	A/C	cg17569154	chr7:24781545	DFNA5	-0.36	-4.75	-0.3	3.54e-6	Depressive symptoms (multi-trait analysis);
SARC	cis	rs617791	0.530	rs10896073	chr11:65762814	T/C	cg09783858	chr11:65769428	EIF1AD;BANF1	0.6	7.43	0.44	2.03e-12	Breast cancer;
SARC	cis	rs7582180	0.629	rs4851308	chr2:100971865	C/A	cg14675211	chr2:100938903	LONRF2	0.52	7.79	0.45	2.26e-13	Intelligence (multi-trait analysis);
SARC	cis	rs9894429	0.966	rs6565601	chr17:79580173	C/T	cg18240062	chr17:79603768	NPLOC4	0.71	9.81	0.54	3.03e-19	Eye color traits;
SARC	cis	rs4720575	0.839	rs10255464	chr7:47097043	A/G	cg00036614	chr7:47093842	NA	-0.45	-6.3	-0.38	1.49e-9	Angiotensin-converting enzyme inhibitor intolerance;
SARC	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg02018176	chr4:1364513	KIAA1530	0.35	5.0	0.31	1.11e-6	Obesity-related traits;
SARC	trans	rs12310956	0.510	rs10129020	chr12:33858936	T/G	cg13010199	chr12:38710504	ALG10B	0.6	7.64	0.45	5.53e-13	Morning vs. evening chronotype;
SARC	cis	rs6908034	0.505	rs76391302	chr6:19819116	G/A	cg02682789	chr6:19804855	NA	0.68	5.49	0.34	1.03e-7	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs9611519	0.580	rs8138349	chr22:41412723	C/T	cg03806693	chr22:41940476	POLR3H	-0.59	-7.95	-0.46	8.04e-14	Neuroticism;
SARC	cis	rs7246760	0.737	rs57296518	chr19:9819950	A/G	cg16876255	chr19:9731953	ZNF561	0.74	4.85	0.3	2.24e-6	Pursuit maintenance gain;
SARC	cis	rs2882877	0.648	rs35209105	chr2:190395060	T/C	cg21926118	chr2:190387206	NA	-0.41	-5.17	-0.32	5.03e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs2486288	0.656	rs8024620	chr15:45574329	C/T	cg15395560	chr15:45543142	SLC28A2	0.3	5.78	0.35	2.41e-8	Glomerular filtration rate;
SARC	cis	rs10197940	0.662	rs4335940	chr2:152275304	A/G	cg19508488	chr2:152266495	RIF1	-0.47	-5.19	-0.32	4.48e-7	Lung cancer;
SARC	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg03806693	chr22:41940476	POLR3H	0.85	11.76	0.61	2.34e-25	Vitiligo;
SARC	cis	rs2013441	1.000	rs2158473	chr17:20139090	T/C	cg13482628	chr17:19912719	NA	-0.47	-6.2	-0.38	2.57e-9	Obesity-related traits;
SARC	cis	rs6120849	0.707	rs6120799	chr20:33614955	T/C	cg24642439	chr20:33292090	TP53INP2	0.57	5.48	0.34	1.1e-7	Protein C levels;
SARC	cis	rs6570726	0.935	rs12663211	chr6:145818427	G/A	cg05220968	chr6:146057943	EPM2A	-0.29	-4.83	-0.3	2.44e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11122272	0.705	rs2572260	chr1:231486189	T/C	cg06096015	chr1:231504339	EGLN1	0.38	5.64	0.35	4.9e-8	Hemoglobin concentration;
SARC	cis	rs910316	1.000	rs175426	chr14:75624134	C/T	cg11812906	chr14:75593930	NEK9	-0.84	-12.68	-0.64	2.23e-28	Height;
SARC	cis	rs36051895	0.632	rs1590803	chr9:5177533	T/C	cg02405213	chr9:5042618	JAK2	-0.45	-5.42	-0.33	1.48e-7	Pediatric autoimmune diseases;
SARC	trans	rs61931739	0.517	rs7139189	chr12:34319757	T/C	cg13010199	chr12:38710504	ALG10B	0.64	8.56	0.49	1.52e-15	Morning vs. evening chronotype;
SARC	cis	rs929354	0.772	rs10230895	chr7:157007038	T/C	cg05182265	chr7:156933206	UBE3C	-0.31	-4.81	-0.3	2.7e-6	Body mass index;
SARC	cis	rs3796352	1.000	rs3806692	chr3:53080987	C/G	cg07884673	chr3:53033167	SFMBT1	0.69	4.89	0.31	1.88e-6	Immune reponse to smallpox (secreted IL-2);
SARC	trans	rs61931739	0.635	rs10743837	chr12:33982162	A/G	cg26384229	chr12:38710491	ALG10B	0.61	7.87	0.46	1.33e-13	Morning vs. evening chronotype;
SARC	cis	rs9611198	0.792	rs5757727	chr22:39963173	G/A	cg10455938	chr22:40058150	CACNA1I	0.38	4.79	0.3	2.97e-6	Schizophrenia;
SARC	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg24642844	chr7:1081250	C7orf50	-0.57	-6.05	-0.37	5.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs9818758	0.607	rs34566463	chr3:49245077	T/C	cg00383909	chr3:49044727	WDR6	0.67	5.93	0.36	1.07e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs796364	1.000	rs4410273	chr2:200818258	T/C	cg23649088	chr2:200775458	C2orf69	0.63	5.86	0.36	1.59e-8	Schizophrenia;
SARC	cis	rs9291683	0.704	rs11726271	chr4:10098192	G/A	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.63	-0.35	5.23e-8	Bone mineral density;
SARC	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg03576123	chr11:487126	PTDSS2	-1.15	-11.85	-0.61	1.13e-25	Body mass index;
SARC	cis	rs9290065	0.538	rs6809206	chr3:160755708	G/A	cg04691961	chr3:161091175	C3orf57	-0.5	-6.24	-0.38	2.09e-9	Kawasaki disease;
SARC	cis	rs1670533	0.932	rs2248083	chr4:1052166	A/C	cg27284194	chr4:1044797	NA	0.46	4.77	0.3	3.23e-6	Recombination rate (females);
SARC	cis	rs11190604	1.000	rs2495734	chr10:102338686	G/A	cg07080220	chr10:102295463	HIF1AN	0.76	8.67	0.49	7.54e-16	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs11249608	0.548	rs6875473	chr5:178451387	C/A	cg21905437	chr5:178450457	ZNF879	0.58	7.92	0.46	9.53e-14	Pubertal anthropometrics;
SARC	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	11.03	0.59	4.93e-23	Alzheimer's disease;
SARC	cis	rs36051895	0.658	rs10974914	chr9:5014332	C/T	cg02405213	chr9:5042618	JAK2	-0.5	-6.04	-0.37	6.12e-9	Pediatric autoimmune diseases;
SARC	cis	rs3845702	0.736	rs6433816	chr2:180809317	G/C	cg01881094	chr2:180872142	CWC22	-1.12	-9.33	-0.52	8.56e-18	Schizophrenia;
SARC	cis	rs1144333	0.510	rs1144328	chr1:76266601	G/A	cg03433033	chr1:76189801	ACADM	-0.58	-4.75	-0.3	3.54e-6	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs1570884	0.516	rs7334387	chr13:50172133	T/A	cg03651054	chr13:50194643	NA	0.3	4.77	0.3	3.21e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs208520	0.754	rs1100989	chr6:66880532	G/A	cg07460842	chr6:66804631	NA	-1.12	-15.12	-0.7	1.91e-36	Exhaled nitric oxide output;
SARC	cis	rs55871839	0.533	rs1375193	chr8:59846943	T/C	cg07426533	chr8:59803705	TOX	0.48	5.4	0.33	1.64e-7	Pneumonia;
SARC	cis	rs12421382	0.636	rs1371329	chr11:109382725	G/T	cg27471124	chr11:109292789	C11orf87	-0.4	-5.56	-0.34	7.48e-8	Schizophrenia;
SARC	cis	rs12479064	0.604	rs11893359	chr2:99954608	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.56	-6.52	-0.39	4.31e-10	Chronic sinus infection;
SARC	cis	rs9359856	0.673	rs2039053	chr6:90303760	G/A	cg13799429	chr6:90582589	CASP8AP2	0.55	4.85	0.3	2.31e-6	Bipolar disorder;
SARC	cis	rs7937682	0.814	rs1619652	chr11:111469757	G/A	cg22437258	chr11:111473054	SIK2	0.74	9.59	0.53	1.4e-18	Primary sclerosing cholangitis;
SARC	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.08	21.36	0.81	8.63e-57	Chronic sinus infection;
SARC	cis	rs611744	0.810	rs672161	chr8:109164182	G/A	cg21045802	chr8:109455806	TTC35	0.51	6.27	0.38	1.69e-9	Dupuytren's disease;
SARC	cis	rs992157	0.798	rs7587220	chr2:219160864	C/A	cg13835894	chr2:219148914	PNKD;TMBIM1	-0.29	-4.76	-0.3	3.38e-6	Colorectal cancer;
SARC	cis	rs11718455	0.960	rs35711021	chr3:44004791	G/A	cg21419209	chr3:44054225	NA	-0.41	-5.02	-0.31	1.02e-6	Coronary artery disease;
SARC	cis	rs9815354	0.855	rs73071261	chr3:42003369	C/A	cg03022575	chr3:42003672	ULK4	0.68	5.89	0.36	1.34e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg13175981	chr1:150552382	MCL1	-0.54	-6.82	-0.41	7.54e-11	Tonsillectomy;
SARC	trans	rs1814175	0.817	rs7109440	chr11:49966296	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-18.43	-0.77	2.07e-47	Height;
SARC	cis	rs9896933	0.778	rs80112422	chr17:80827719	G/T	cg15664640	chr17:80829946	TBCD	-0.48	-5.53	-0.34	8.66e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
SARC	cis	rs611744	0.901	rs673981	chr8:109191917	G/A	cg21045802	chr8:109455806	TTC35	0.44	5.3	0.33	2.64e-7	Dupuytren's disease;
SARC	cis	rs897080	0.515	rs696595	chr2:44682692	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	5.76	0.35	2.61e-8	Height;
SARC	cis	rs2295359	0.892	rs4655687	chr1:67649946	C/T	cg12940439	chr1:67600707	NA	0.47	6.74	0.4	1.25e-10	Psoriasis;
SARC	cis	rs950169	0.922	rs12915832	chr15:85111457	C/T	cg03959625	chr15:84868606	LOC388152	0.36	4.96	0.31	1.35e-6	Schizophrenia;
SARC	cis	rs6772849	0.775	rs9828414	chr3:128412717	C/T	cg01163369	chr3:128370232	RPN1	-0.35	-4.89	-0.31	1.86e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs61935443	0.720	rs10859780	chr12:95282601	T/C	cg21533806	chr12:95267307	NA	0.71	8.64	0.49	9.29e-16	Schizophrenia;
SARC	cis	rs1008375	0.932	rs2302391	chr4:17660237	T/C	cg02297831	chr4:17616191	MED28	0.46	5.84	0.36	1.71e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2075371	0.611	rs13235296	chr7:134019192	A/G	cg11752832	chr7:134001865	SLC35B4	-0.53	-6.76	-0.41	1.07e-10	Mean platelet volume;
SARC	cis	rs2836633	0.929	rs2836602	chr21:40039169	A/T	cg12884169	chr21:40033163	ERG	-0.47	-8.45	-0.48	3.1e-15	Coronary artery disease;
SARC	cis	rs240764	0.680	rs239234	chr6:101101234	G/A	cg09795085	chr6:101329169	ASCC3	0.42	5.31	0.33	2.58e-7	Neuroticism;
SARC	cis	rs2073300	0.609	rs6137930	chr20:23376732	G/A	cg12062639	chr20:23401060	NAPB	0.95	6.5	0.39	4.74e-10	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs651907	0.557	rs34457525	chr3:101435225	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	6.37	0.39	9.84e-10	Colorectal cancer;
SARC	cis	rs72653721	0.838	rs10498676	chr6:11026999	C/T	cg13562911	chr6:11044106	ELOVL2	0.55	6.2	0.38	2.61e-9	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	cis	rs9398803	0.636	rs864938	chr6:127022804	A/T	cg19875578	chr6:126661172	C6orf173	-0.62	-8.64	-0.49	9.14e-16	Male-pattern baldness;
SARC	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg22903657	chr4:1355424	KIAA1530	-0.42	-5.73	-0.35	3.1e-8	Obesity-related traits;
SARC	cis	rs1348850	0.526	rs2218575	chr2:178368997	C/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	5.87	0.36	1.5e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg17971929	chr21:40555470	PSMG1	-0.85	-11.03	-0.59	4.95e-23	Cognitive function;
SARC	cis	rs6570726	0.689	rs411785	chr6:145888398	G/A	cg05347473	chr6:146136440	FBXO30	0.52	7.09	0.42	1.63e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9322817	0.583	rs6571202	chr6:105182644	G/T	cg02098413	chr6:105308735	HACE1	-0.39	-6.09	-0.37	4.54e-9	Thyroid stimulating hormone;
SARC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg06873352	chr17:61820015	STRADA	0.55	6.87	0.41	5.69e-11	Prudent dietary pattern;
SARC	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg04944784	chr2:26401820	FAM59B	0.6	7.95	0.46	8.14e-14	Gut microbiome composition (summer);
SARC	cis	rs8084125	1.000	rs62105176	chr18:74949427	A/G	cg05528293	chr18:74961138	GALR1	0.53	4.75	0.3	3.63e-6	Obesity-related traits;
SARC	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	11.25	0.59	1.01e-23	Platelet count;
SARC	trans	rs7824557	0.564	rs2572399	chr8:11234520	A/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.67	-0.49	7.61e-16	Retinal vascular caliber;
SARC	trans	rs10929925	0.522	rs12468840	chr2:6159861	A/C	cg25116709	chr5:122426797	PRDM6	-0.43	-6.5	-0.39	4.94e-10	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
SARC	cis	rs11122272	0.735	rs2739507	chr1:231527329	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.95	-0.55	1.19e-19	Hemoglobin concentration;
SARC	cis	rs7727544	0.684	rs611084	chr5:131709739	A/C	cg07395648	chr5:131743802	NA	0.42	4.93	0.31	1.57e-6	Blood metabolite levels;
SARC	cis	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.58	-0.44	8.13e-13	Extrinsic epigenetic age acceleration;
SARC	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg22968622	chr17:43663579	NA	0.83	10.46	0.57	3.08e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7089973	0.641	rs17795104	chr10:116739531	T/A	cg08188268	chr10:116634841	FAM160B1	0.39	5.11	0.32	6.78e-7	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	trans	rs1814175	0.817	rs7483795	chr11:49704930	G/A	cg15704280	chr7:45808275	SEPT13	-0.96	-18.05	-0.76	3.68e-46	Height;
SARC	cis	rs739401	0.611	rs402276	chr11:3051404	C/G	cg20651018	chr11:3035856	CARS	-0.46	-7.09	-0.42	1.55e-11	Longevity;
SARC	cis	rs858239	0.539	rs2141306	chr7:23191664	G/A	cg23682824	chr7:23144976	KLHL7	0.74	9.66	0.53	8.86e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs2594989	0.943	rs6784861	chr3:11465568	T/C	cg00170343	chr3:11313890	ATG7	0.6	5.62	0.35	5.48e-8	Circulating chemerin levels;
SARC	cis	rs3820928	0.874	rs1320407	chr2:227867385	G/T	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.66	-0.35	4.32e-8	Pulmonary function;
SARC	cis	rs62064224	0.702	rs2302277	chr17:30791509	C/G	cg18200150	chr17:30822561	MYO1D	0.46	7.32	0.43	3.93e-12	Schizophrenia;
SARC	cis	rs9911578	0.967	rs2611781	chr17:56703124	C/G	cg12560992	chr17:57184187	TRIM37	0.82	10.91	0.58	1.15e-22	Intelligence (multi-trait analysis);
SARC	cis	rs10782582	0.593	rs11801414	chr1:76124517	G/A	cg03433033	chr1:76189801	ACADM	-0.4	-5.26	-0.33	3.33e-7	Daytime sleep phenotypes;
SARC	cis	rs7927592	0.956	rs11228269	chr11:68289796	A/G	cg01657329	chr11:68192670	LRP5	-0.41	-5.08	-0.32	7.81e-7	Total body bone mineral density;
SARC	cis	rs995000	0.931	rs1168021	chr1:63009900	A/G	cg06896770	chr1:63153194	DOCK7	-0.89	-13.16	-0.65	6e-30	Triglyceride levels;
SARC	cis	rs9640161	0.789	rs1464751	chr7:150021282	C/T	cg17279839	chr7:150038598	RARRES2	0.48	6.85	0.41	6.5e-11	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs9443189	1.000	rs6906615	chr6:76489774	A/G	cg01950844	chr6:76311363	SENP6	0.72	6.33	0.38	1.28e-9	Prostate cancer;
SARC	cis	rs4253772	0.550	rs739164	chr22:46684558	C/T	cg24881330	chr22:46731750	TRMU	-0.73	-7.29	-0.43	4.84e-12	LDL cholesterol;Cholesterol, total;
SARC	cis	rs9611519	0.929	rs9611466	chr22:41426299	A/T	cg17376030	chr22:41985996	PMM1	0.5	5.96	0.36	9.12e-9	Neuroticism;
SARC	cis	rs735539	0.521	rs513795	chr13:21427448	T/C	cg16922012	chr13:21400325	XPO4	-0.44	-6.08	-0.37	4.98e-9	Dental caries;
SARC	cis	rs72848980	0.706	rs11191732	chr10:105331761	G/A	cg00126946	chr10:105363258	SH3PXD2A	0.49	6.21	0.38	2.41e-9	White matter hyperintensity burden;
SARC	cis	rs751728	0.687	rs9357164	chr6:33761021	T/C	cg25922239	chr6:33757077	LEMD2	0.57	7.53	0.44	1.1e-12	Crohn's disease;
SARC	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg10589385	chr1:150898437	SETDB1	0.4	5.36	0.33	2.01e-7	Melanoma;
SARC	cis	rs6714710	0.580	rs1838797	chr2:98454572	G/C	cg26665480	chr2:98280029	ACTR1B	0.49	6.63	0.4	2.34e-10	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs12824058	0.831	rs4759653	chr12:130812604	T/C	cg23887609	chr12:130822674	PIWIL1	0.37	5.15	0.32	5.52e-7	Menopause (age at onset);
SARC	cis	rs12479064	0.724	rs2305352	chr2:100015124	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.46	-5.22	-0.32	3.96e-7	Chronic sinus infection;
SARC	cis	rs6088580	0.634	rs4911152	chr20:32955024	T/C	cg08999081	chr20:33150536	PIGU	-0.42	-6.5	-0.39	4.71e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs7481584	0.924	rs12805661	chr11:3020740	C/T	cg25174290	chr11:3078921	CARS	-0.51	-6.5	-0.39	4.84e-10	Calcium levels;
SARC	cis	rs763121	0.853	rs6001214	chr22:39149155	C/T	cg06022373	chr22:39101656	GTPBP1	0.88	11.22	0.59	1.24e-23	Menopause (age at onset);
SARC	cis	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg11266682	chr4:10021025	SLC2A9	0.41	7.52	0.44	1.15e-12	Bone mineral density;
SARC	cis	rs7412746	0.622	rs11552229	chr1:150783985	T/C	cg10589385	chr1:150898437	SETDB1	0.4	5.41	0.33	1.59e-7	Melanoma;
SARC	cis	rs10463316	0.894	rs6579865	chr5:150762335	A/C	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.28	-0.33	2.89e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs2069757	0.561	rs77143352	chr5:131985990	A/T	cg11797159	chr5:131991491	NA	0.38	4.99	0.31	1.17e-6	Hodgkin's lymphoma;
SARC	cis	rs2832191	0.720	rs4643617	chr21:30485278	T/C	cg08807101	chr21:30365312	RNF160	-0.84	-11.99	-0.62	3.98e-26	Dental caries;
SARC	cis	rs9840812	0.769	rs1279425	chr3:136006984	T/C	cg15507776	chr3:136538369	TMEM22	0.44	4.78	0.3	3.15e-6	Fibrinogen levels;
SARC	cis	rs314370	0.951	rs17881696	chr7:100493359	G/A	cg10426581	chr7:100472382	SRRT	0.58	6.13	0.37	3.78e-9	Resting heart rate;
SARC	cis	rs9388451	0.772	rs1268064	chr6:126042578	G/A	cg06289844	chr6:126071538	HEY2	-0.37	-6.07	-0.37	5.24e-9	Brugada syndrome;
SARC	cis	rs3741151	1.000	rs61037777	chr11:73046663	A/G	cg17517138	chr11:73019481	ARHGEF17	0.78	6.8	0.41	8.74e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs2908197	0.788	rs6465111	chr7:75991378	A/G	cg22830091	chr7:75961684	YWHAG	-0.36	-5.32	-0.33	2.39e-7	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs10782582	0.609	rs2029682	chr1:76341619	T/C	cg10523679	chr1:76189770	ACADM	-0.39	-4.88	-0.3	1.93e-6	Daytime sleep phenotypes;
SARC	cis	rs7412746	0.566	rs2864871	chr1:150766964	T/C	cg13175981	chr1:150552382	MCL1	-0.49	-5.85	-0.36	1.65e-8	Melanoma;
SARC	cis	rs698833	0.926	rs1067347	chr2:44672165	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.6	-6.97	-0.42	3.15e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs9905704	0.647	rs6503888	chr17:57028126	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.39	-4.72	-0.3	4.13e-6	Testicular germ cell tumor;
SARC	cis	rs6772849	1.000	rs9848975	chr3:128311983	T/C	cg08795948	chr3:128337044	NA	0.36	4.81	0.3	2.66e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs27434	0.583	rs34759	chr5:96153133	T/C	cg16492584	chr5:96139282	ERAP1	-0.56	-6.96	-0.42	3.35e-11	Ankylosing spondylitis;
SARC	cis	rs367943	1.000	rs348962	chr5:112819086	C/T	cg12552261	chr5:112820674	MCC	0.45	5.13	0.32	6.02e-7	Type 2 diabetes;
SARC	cis	rs3008870	1.000	rs3008894	chr1:67377739	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.92	10.96	0.58	7.9399999999999994e-23	Lymphocyte percentage of white cells;
SARC	cis	rs11687170	0.882	rs56236451	chr2:237056840	A/G	cg19324714	chr2:237145437	ASB18	0.49	4.87	0.3	2.09e-6	Educational attainment;Educational attainment (years of education);
SARC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg07092213	chr7:1199455	ZFAND2A	-0.45	-6.01	-0.37	7.24e-9	Longevity;Endometriosis;
SARC	cis	rs9868809	0.772	rs9812200	chr3:48695667	A/G	cg06212747	chr3:49208901	KLHDC8B	0.52	4.76	0.3	3.42e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs1476670	0.710	rs753637	chr1:44508927	A/G	cg09470012	chr1:44509516	NA	0.4	5.05	0.31	8.75e-7	Eotaxin levels;
SARC	cis	rs10752881	1.000	rs12126434	chr1:182988414	A/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.71	-10.77	-0.58	3.33e-22	Colorectal cancer;
SARC	cis	rs9815354	1.000	rs73071329	chr3:41810539	G/A	cg03022575	chr3:42003672	ULK4	0.58	5.62	0.35	5.37e-8	Pulse pressure;Diastolic blood pressure;
SARC	trans	rs10519937	1.000	rs74381320	chr5:126740835	A/G	cg26526953	chr19:1921199	SCAMP4	0.6	6.26	0.38	1.79e-9	IgG glycosylation;
SARC	cis	rs3126085	0.935	rs4361987	chr1:152229701	A/G	cg26876637	chr1:152193138	HRNR	0.45	5.21	0.32	4.17e-7	Atopic dermatitis;
SARC	trans	rs1814175	0.616	rs1794131	chr11:49904194	A/G	cg03929089	chr4:120376271	NA	-0.81	-11.76	-0.61	2.25e-25	Height;
SARC	cis	rs10464366	0.544	rs4355688	chr7:39158402	C/T	cg15212455	chr7:39170539	POU6F2	0.39	4.96	0.31	1.34e-6	IgG glycosylation;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg04152151	chr2:149215884	MBD5	0.49	7.04	0.42	2.2e-11	Thyroid stimulating hormone;
SARC	cis	rs763121	0.889	rs4820335	chr22:38935927	C/G	cg21395723	chr22:39101663	GTPBP1	-0.48	-5.6	-0.34	5.93e-8	Menopause (age at onset);
SARC	trans	rs208520	0.661	rs150263	chr6:66777620	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.06	-14.43	-0.69	3.67e-34	Exhaled nitric oxide output;
SARC	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg13206674	chr6:150067644	NUP43	0.46	6.1	0.37	4.29e-9	Lung cancer;
SARC	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.56	6.84	0.41	6.86e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1538970	0.924	rs1494812	chr1:45876999	C/T	cg05343316	chr1:45956843	TESK2	0.72	8.62	0.49	1.01e-15	Platelet count;
SARC	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg26335602	chr6:28129616	ZNF389	0.47	5.48	0.34	1.1e-7	Depression;
SARC	cis	rs981844	1.000	rs62325093	chr4:154669733	G/A	cg14289246	chr4:154710475	SFRP2	0.58	6.57	0.4	3.23e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs34779708	0.966	rs34296409	chr10:35404613	C/G	cg03585969	chr10:35415529	CREM	0.42	5.17	0.32	5.03e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs10752881	1.000	rs12028740	chr1:182985581	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.7	0.57	5.56e-22	Colorectal cancer;
SARC	cis	rs9581943	0.967	rs9554193	chr13:28471366	G/A	cg17352152	chr13:28491409	NA	0.39	5.18	0.32	4.71e-7	Pancreatic cancer;
SARC	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.46	-4.94	-0.31	1.51e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg25894440	chr7:65020034	NA	0.79	5.96	0.36	9.49e-9	Diabetic kidney disease;
SARC	cis	rs2290159	0.800	rs6792773	chr3:12668726	C/T	cg23032965	chr3:12705835	RAF1	0.78	8.68	0.49	6.81e-16	Cholesterol, total;
SARC	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg22875332	chr1:76189707	ACADM	0.45	5.83	0.36	1.86e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg05623727	chr3:50126028	RBM5	0.35	5.17	0.32	5.14e-7	Body mass index;
SARC	cis	rs3796352	1.000	rs71301804	chr3:53073314	C/A	cg27565382	chr3:53032988	SFMBT1	0.86	6.3	0.38	1.49e-9	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs933688	1.000	rs10041402	chr5:90738948	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.0	12.59	0.64	4.38e-28	Smoking behavior;
SARC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg24101359	chr6:42928495	GNMT	0.4	5.51	0.34	9.3e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.36	-4.92	-0.31	1.61e-6	Personality dimensions;
SARC	trans	rs1814175	0.653	rs10839480	chr11:50034556	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-18.52	-0.77	1.06e-47	Height;
SARC	cis	rs11718455	0.921	rs1404482	chr3:43997282	A/G	cg08738300	chr3:44038990	NA	0.54	6.08	0.37	4.83e-9	Coronary artery disease;
SARC	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg26335602	chr6:28129616	ZNF389	0.52	5.94	0.36	1.04e-8	Depression;
SARC	cis	rs910316	0.763	rs12588981	chr14:75460561	A/G	cg23033748	chr14:75592666	NEK9	0.37	5.04	0.31	9.4e-7	Height;
SARC	cis	rs472402	0.905	rs531241	chr5:6637380	C/T	cg10789808	chr5:6633262	NSUN2;SRD5A1	0.38	4.8	0.3	2.79e-6	Response to amphetamines;
SARC	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg16325326	chr1:53192061	ZYG11B	-0.75	-10.61	-0.57	1.06e-21	Monocyte count;
SARC	cis	rs9324022	0.929	rs59488041	chr14:101180041	T/A	cg18089426	chr14:101175970	NA	0.57	5.61	0.35	5.62e-8	Plateletcrit;
SARC	cis	rs11098499	0.863	rs3775845	chr4:120432447	T/C	cg24375607	chr4:120327624	NA	0.42	4.9	0.31	1.77e-6	Corneal astigmatism;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg15568225	chr1:40537438	CAP1	-0.47	-6.57	-0.4	3.19e-10	Chemerin levels;
SARC	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.45	6.82	0.41	7.71e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs8044995	0.563	rs3785116	chr16:68372730	G/A	cg09835421	chr16:68378352	PRMT7	-0.66	-5.97	-0.36	8.81e-9	Schizophrenia;
SARC	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	11.03	0.59	4.93e-23	Alzheimer's disease;
SARC	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg24209194	chr3:40518798	ZNF619	0.66	8.04	0.47	4.42e-14	Renal cell carcinoma;
SARC	cis	rs6704644	0.527	rs72980361	chr2:234359375	A/G	cg27060346	chr2:234359958	DGKD	-0.81	-4.99	-0.31	1.16e-6	Bilirubin levels;
SARC	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.49	-5.75	-0.35	2.8e-8	Renal function-related traits (BUN);
SARC	cis	rs11190604	1.000	rs3750630	chr10:102275780	A/G	cg07080220	chr10:102295463	HIF1AN	0.76	9.08	0.51	4.83e-17	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg05861140	chr6:150128134	PCMT1	-0.42	-5.44	-0.34	1.32e-7	Lung cancer;
SARC	cis	rs72781680	1.000	rs17762102	chr2:24085606	A/G	cg06627628	chr2:24431161	ITSN2	-0.66	-6.47	-0.39	5.57e-10	Lymphocyte counts;
SARC	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg08859206	chr1:53392774	SCP2	0.39	5.68	0.35	3.99e-8	Monocyte count;
SARC	cis	rs1865760	0.566	rs9295686	chr6:26081983	G/C	cg17691542	chr6:26056736	HIST1H1C	0.52	6.41	0.39	8.05e-10	Height;
SARC	cis	rs1348850	0.651	rs4893821	chr2:178229352	A/G	cg23306229	chr2:178417860	TTC30B	-0.41	-4.85	-0.3	2.28e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2180341	0.814	rs9401958	chr6:127736357	T/G	cg24812749	chr6:127587940	RNF146	0.79	10.11	0.55	3.71e-20	Breast cancer;
SARC	cis	rs3106136	0.967	rs3106135	chr4:95138308	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.97	-0.36	8.92e-9	Capecitabine sensitivity;
SARC	cis	rs644799	0.648	rs1255178	chr11:95471908	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.58	7.37	0.43	3e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs12971120	0.891	rs2278158	chr18:72178300	G/T	cg25817165	chr18:72167213	CNDP2	-0.5	-6.78	-0.41	9.71e-11	Refractive error;
SARC	cis	rs2439831	0.867	rs689616	chr15:43761901	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.04	11.03	0.59	4.93e-23	Lung cancer in ever smokers;
SARC	cis	rs918629	0.679	rs3822750	chr5:95276260	C/A	cg16656078	chr5:95278638	ELL2	-0.59	-6.98	-0.42	3.12e-11	IgG glycosylation;
SARC	cis	rs9381040	0.610	rs4140579	chr6:41041752	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.42	-4.79	-0.3	2.96e-6	Alzheimer's disease (late onset);
SARC	cis	rs1707322	0.827	rs10890347	chr1:46242332	A/T	cg03146154	chr1:46216737	IPP	-0.42	-5.19	-0.32	4.56e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7246760	0.867	rs16981648	chr19:9804424	A/C	cg16876255	chr19:9731953	ZNF561	0.76	4.76	0.3	3.41e-6	Pursuit maintenance gain;
SARC	cis	rs73206853	0.614	rs117546059	chr12:110508632	T/C	cg08946844	chr12:110511112	NA	0.65	5.11	0.32	6.68e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg19223190	chr17:80058835	NA	0.45	6.2	0.38	2.59e-9	Life satisfaction;
SARC	cis	rs9987353	0.519	rs2929465	chr8:9064002	C/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.67	-0.45	4.77e-13	Recombination measurement;
SARC	cis	rs992157	0.835	rs2045434	chr2:219144498	A/G	cg00012203	chr2:219082015	ARPC2	-0.63	-9.14	-0.51	3.16e-17	Colorectal cancer;
SARC	cis	rs9807989	0.507	rs1420094	chr2:103015687	C/T	cg03938978	chr2:103052716	IL18RAP	0.31	5.02	0.31	1.04e-6	Asthma;
SARC	cis	rs12545109	1.000	rs12545109	chr8:57313906	A/C	cg21220214	chr8:57350948	NA	-0.44	-5.16	-0.32	5.3e-7	Obesity-related traits;
SARC	cis	rs344364	0.511	rs1742464	chr16:1947335	A/G	cg26617929	chr16:1858877	NA	0.71	6.08	0.37	4.86e-9	Glomerular filtration rate in chronic kidney disease;
SARC	cis	rs11874712	0.933	rs8097521	chr18:43666952	C/A	cg25174615	chr18:43684699	ATP5A1;HAUS1	0.4	4.75	0.3	3.52e-6	Migraine - clinic-based;
SARC	cis	rs2370759	1.000	rs11597888	chr10:32635834	G/A	cg01819863	chr10:32635814	EPC1	1.01	9.93	0.55	1.3e-19	Sexual dysfunction (female);
SARC	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	7.36	0.43	3.13e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg24247472	chr17:46908838	CALCOCO2	-0.58	-6.52	-0.39	4.31e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg11764359	chr7:65958608	NA	0.59	7.09	0.42	1.56e-11	Aortic root size;
SARC	cis	rs4742903	0.875	rs10820609	chr9:106907332	G/A	cg14250997	chr9:106856677	SMC2	0.47	6.1	0.37	4.35e-9	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs2354432	0.607	rs9782976	chr1:146825049	A/G	cg25205988	chr1:146714368	CHD1L	0.85	7.95	0.46	8.01e-14	Mitochondrial DNA levels;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg06226095	chr4:146540576	MMAA	-0.48	-6.34	-0.38	1.18e-9	Chemerin levels;
SARC	cis	rs11155671	0.517	rs9397058	chr6:150207249	C/T	cg00933542	chr6:150070202	PCMT1	0.29	4.91	0.31	1.73e-6	Testicular germ cell tumor;
SARC	cis	rs892961	0.899	rs35217221	chr17:75412385	G/A	cg05865280	chr17:75406074	SEPT9	0.55	8.17	0.47	1.99e-14	Airflow obstruction;
SARC	cis	rs1048238	0.506	rs848209	chr1:16256007	T/C	cg21385522	chr1:16154831	NA	-0.44	-5.31	-0.33	2.56e-7	Systolic blood pressure;
SARC	cis	rs2066819	1.000	rs2695789	chr12:56694261	C/A	cg26734620	chr12:56694298	CS	-0.86	-6.37	-0.39	1.01e-9	Psoriasis vulgaris;
SARC	cis	rs4803468	1.000	rs284654	chr19:41928724	G/A	cg08477640	chr19:41863820	B9D2	0.4	4.95	0.31	1.41e-6	Height;
SARC	cis	rs752010	0.714	rs7515948	chr1:42079046	T/G	cg06885757	chr1:42089581	HIVEP3	0.4	6.14	0.37	3.53e-9	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs918629	0.530	rs1057963	chr5:95235748	G/C	cg16656078	chr5:95278638	ELL2	-0.56	-6.9	-0.41	4.77e-11	IgG glycosylation;
SARC	cis	rs6933660	0.512	rs13198669	chr6:151799924	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.67	-5.85	-0.36	1.68e-8	Menarche (age at onset);
SARC	cis	rs8067545	0.611	rs2703803	chr17:20107069	G/T	cg13482628	chr17:19912719	NA	-0.52	-6.72	-0.4	1.37e-10	Schizophrenia;
SARC	cis	rs7197653	0.667	rs12599876	chr16:68393405	C/T	cg09835421	chr16:68378352	PRMT7	-0.59	-4.9	-0.31	1.77e-6	Magnesium levels;
SARC	cis	rs986417	0.748	rs4141684	chr14:61069351	C/T	cg27398547	chr14:60952738	C14orf39	0.76	7.2	0.43	8.42e-12	Gut microbiota (bacterial taxa);
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24382680	chr15:80351977	ZFAND6	0.51	6.35	0.38	1.15e-9	Fibrinogen levels;
SARC	cis	rs1346751	0.512	rs1346748	chr2:16614171	G/A	cg09580478	chr2:16689509	NA	0.45	4.96	0.31	1.37e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
SARC	cis	rs7044106	0.791	rs10760116	chr9:123494681	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	6.55	0.39	3.57e-10	Hip circumference adjusted for BMI;
SARC	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg24060327	chr5:131705240	SLC22A5	-0.73	-8.99	-0.51	8.97e-17	Breast cancer;
SARC	cis	rs3796352	1.000	rs60942590	chr3:53016421	G/A	cg07884673	chr3:53033167	SFMBT1	0.77	5.03	0.31	1e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs12586317	0.653	rs4981287	chr14:35828198	G/A	cg26967526	chr14:35346199	BAZ1A	-0.49	-5.11	-0.32	6.76e-7	Psoriasis;
SARC	cis	rs9815354	1.000	rs6803652	chr3:41824556	A/G	cg03022575	chr3:42003672	ULK4	0.58	5.67	0.35	4.28e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg11890956	chr21:40555474	PSMG1	-1.04	-16.33	-0.73	1.73e-40	Cognitive function;
SARC	cis	rs7589342	0.929	rs2060036	chr2:106436101	G/A	cg14210321	chr2:106509881	NCK2	-0.46	-5.36	-0.33	2e-7	Addiction;
SARC	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg06028808	chr11:68637592	NA	0.48	6.23	0.38	2.15e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs1843834	0.505	rs4674911	chr2:225345254	A/G	cg22509189	chr2:225307070	NA	-0.71	-9.04	-0.51	6.4e-17	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs798554	0.567	rs2527695	chr7:2858267	T/G	cg04166393	chr7:2884313	GNA12	0.45	5.49	0.34	1.03e-7	Height;
SARC	cis	rs9457247	1.000	rs376574	chr6:167389956	A/T	cg23791538	chr6:167370224	RNASET2	-0.62	-8.66	-0.49	8.17e-16	Crohn's disease;
SARC	cis	rs6704644	0.932	rs11686188	chr2:234451630	C/T	cg27060346	chr2:234359958	DGKD	-0.59	-4.99	-0.31	1.17e-6	Bilirubin levels;
SARC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	18.64	0.77	4.57e-48	Prudent dietary pattern;
SARC	cis	rs11997175	0.766	rs4442096	chr8:33691039	T/C	ch.8.33884649F	chr8:33765107	NA	0.56	7.59	0.45	7.78e-13	Body mass index;
SARC	cis	rs11731606	0.508	rs28501313	chr4:95281023	G/A	cg00507259	chr4:95128692	SMARCAD1	0.57	5.42	0.33	1.47e-7	Mean platelet volume;
SARC	cis	rs7647973	0.925	rs6808036	chr3:49236439	T/G	cg06212747	chr3:49208901	KLHDC8B	0.61	6.48	0.39	5.53e-10	Menarche (age at onset);
SARC	cis	rs6582630	0.555	rs11182193	chr12:38474090	C/G	cg26384229	chr12:38710491	ALG10B	0.84	12.0	0.62	3.64e-26	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg07636037	chr3:49044803	WDR6	0.98	17.2	0.75	2.35e-43	Parkinson's disease;
SARC	cis	rs7223966	1.000	rs7209758	chr17:61913621	C/T	cg26338869	chr17:61819248	STRADA	0.49	5.32	0.33	2.41e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs72781680	0.848	rs715646	chr2:24010566	G/A	cg08917208	chr2:24149416	ATAD2B	0.75	7.09	0.42	1.56e-11	Lymphocyte counts;
SARC	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg04317338	chr11:64019027	PLCB3	0.55	6.36	0.38	1.07e-9	Platelet count;
SARC	cis	rs524281	0.814	rs10896093	chr11:65958411	C/G	cg14036092	chr11:66035641	RAB1B	-0.5	-5.37	-0.33	1.89e-7	Electroencephalogram traits;
SARC	cis	rs941408	1.000	rs1736180	chr19:2796021	C/T	cg00079169	chr19:2811669	THOP1	0.44	4.99	0.31	1.17e-6	Total cholesterol levels;
SARC	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg24209194	chr3:40518798	ZNF619	0.66	8.06	0.47	4.07e-14	Renal cell carcinoma;
SARC	cis	rs8114671	0.562	rs6087641	chr20:33467717	T/C	cg08999081	chr20:33150536	PIGU	0.32	4.78	0.3	3.14e-6	Height;
SARC	cis	rs921968	0.643	rs62191565	chr2:219482017	C/T	cg02176678	chr2:219576539	TTLL4	0.4	5.99	0.37	8.05e-9	Mean corpuscular hemoglobin concentration;
SARC	cis	rs6430585	0.528	rs7606267	chr2:136668123	T/C	cg07169764	chr2:136633963	MCM6	1.06	16.23	0.73	3.95e-40	Corneal structure;
SARC	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-15.18	-0.71	1.17e-36	Chronic sinus infection;
SARC	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg20965017	chr5:231967	SDHA	-0.55	-5.26	-0.33	3.23e-7	Breast cancer;
SARC	cis	rs617791	0.678	rs551659	chr11:65749645	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.85	12.63	0.64	3.35e-28	Breast cancer;
SARC	trans	rs61931739	0.817	rs11833948	chr12:34276942	G/T	cg26384229	chr12:38710491	ALG10B	0.61	7.99	0.46	6.3e-14	Morning vs. evening chronotype;
SARC	cis	rs4780401	0.755	rs7194034	chr16:11770777	A/G	cg01061890	chr16:11836724	TXNDC11	-0.47	-6.06	-0.37	5.35e-9	Rheumatoid arthritis;
SARC	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg22903471	chr2:27725779	GCKR	-0.5	-7.52	-0.44	1.15e-12	Total body bone mineral density;
SARC	cis	rs2153535	0.601	rs7738877	chr6:8542230	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	10.4	0.56	4.69e-21	Motion sickness;
SARC	cis	rs7829975	0.572	rs28730413	chr8:8795447	A/C	cg15556689	chr8:8085844	FLJ10661	-0.4	-4.89	-0.31	1.88e-6	Mood instability;
SARC	cis	rs7772486	0.790	rs3924499	chr6:146232978	A/T	cg05347473	chr6:146136440	FBXO30	-0.48	-6.55	-0.39	3.55e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg07777115	chr5:623756	CEP72	-0.56	-4.9	-0.31	1.77e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs6495122	0.532	rs2470890	chr15:75047426	C/T	cg14664628	chr15:75095509	CSK	-0.74	-8.85	-0.5	2.21e-16	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	cis	rs6910061	0.830	rs68037813	chr6:11110985	G/C	cg27233058	chr6:11094804	LOC221710	0.62	5.53	0.34	8.6e-8	Diabetic kidney disease;
SARC	cis	rs9303401	0.659	rs62083410	chr17:56964386	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.05	11.76	0.61	2.3e-25	Cognitive test performance;
SARC	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg03433033	chr1:76189801	ACADM	0.55	7.8	0.45	2.08e-13	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg21782813	chr7:2030301	MAD1L1	-0.37	-5.88	-0.36	1.42e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs4481887	0.861	rs4295906	chr1:248429861	C/T	cg13385794	chr1:248469461	NA	0.34	4.98	0.31	1.23e-6	Common traits (Other);
SARC	cis	rs921968	0.541	rs634590	chr2:219372768	C/A	cg02176678	chr2:219576539	TTLL4	0.46	7.12	0.42	1.33e-11	Mean corpuscular hemoglobin concentration;
SARC	cis	rs7264396	0.563	rs7268195	chr20:34339854	G/A	cg01084648	chr20:34329383	RBM39	0.57	5.0	0.31	1.13e-6	Total cholesterol levels;
SARC	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg17971929	chr21:40555470	PSMG1	-0.87	-11.46	-0.6	2.09e-24	Cognitive function;
SARC	cis	rs57506017	0.540	rs1019309	chr7:12251671	T/A	cg23422036	chr7:12250390	TMEM106B	0.49	6.44	0.39	6.91e-10	Neuroticism;
SARC	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg26335602	chr6:28129616	ZNF389	0.52	5.84	0.36	1.75e-8	Depression;
SARC	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg12310025	chr6:25882481	NA	0.51	6.48	0.39	5.47e-10	Intelligence (multi-trait analysis);
SARC	trans	rs6815916	1.000	rs56151114	chr4:182553414	T/G	cg13864546	chr1:2310327	MORN1	0.68	6.41	0.39	7.98e-10	Venous thromboembolism (SNP x SNP interaction);
SARC	trans	rs12967884	0.892	rs4799204	chr18:76559622	G/A	cg10946435	chr1:154843044	KCNN3	0.57	6.26	0.38	1.79e-9	Subcutaneous adipose tissue;
SARC	cis	rs926938	0.618	rs516985	chr1:115495011	G/A	cg12756093	chr1:115239321	AMPD1	0.38	4.88	0.3	1.95e-6	Autism;
SARC	cis	rs11638352	1.000	rs2706481	chr15:44406317	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	-0.75	-5.73	-0.35	3.08e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg04157308	chr12:19459301	PLEKHA5	0.48	6.64	0.4	2.12e-10	Thyroid stimulating hormone;
SARC	cis	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg12395012	chr8:11607386	GATA4	-0.28	-4.71	-0.3	4.2e-6	Retinal vascular caliber;
SARC	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg02297831	chr4:17616191	MED28	0.51	6.63	0.4	2.36e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg06136555	chr12:112123888	ACAD10;BRAP	0.48	6.25	0.38	1.98e-9	Chemerin levels;
SARC	cis	rs6500395	0.735	rs16946340	chr16:48667717	G/A	cg04672837	chr16:48644449	N4BP1	0.39	5.23	0.32	3.7e-7	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs11687170	0.882	rs4349292	chr2:237062211	A/G	cg19324714	chr2:237145437	ASB18	0.47	4.73	0.3	3.82e-6	Educational attainment;Educational attainment (years of education);
SARC	cis	rs2073499	1.000	rs79499880	chr3:50259551	A/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.64	5.63	0.35	5.2e-8	Schizophrenia;
SARC	trans	rs4332037	0.539	rs57148375	chr7:2025001	G/C	cg11693508	chr17:37793320	STARD3	0.66	6.61	0.4	2.58e-10	Bipolar disorder;
SARC	cis	rs17023223	0.537	rs12086549	chr1:119614337	A/T	cg05756136	chr1:119680316	WARS2	0.47	5.37	0.33	1.91e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs11166927	0.548	rs4736099	chr8:140828745	T/C	cg16909799	chr8:140841666	TRAPPC9	-0.39	-5.32	-0.33	2.45e-7	Pediatric non-alcoholic fatty liver disease activity score;
SARC	cis	rs4789693	1.000	rs4789693	chr17:80421870	A/C	cg23652146	chr17:80417115	NARF	0.45	5.2	0.32	4.33e-7	Glucocorticoid-induced osteonecrosis;
SARC	cis	rs3008870	0.755	rs6657065	chr1:67384639	T/G	cg02640540	chr1:67518911	SLC35D1	0.44	5.01	0.31	1.07e-6	Lymphocyte percentage of white cells;
SARC	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg00149659	chr3:10157352	C3orf10	0.69	6.44	0.39	6.6e-10	Alzheimer's disease;
SARC	cis	rs7666738	0.830	rs4440224	chr4:99044924	G/A	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs3820928	0.874	rs116652884	chr2:227902285	C/T	cg05526886	chr2:227700861	RHBDD1	-0.51	-5.98	-0.36	8.23e-9	Pulmonary function;
SARC	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg08677398	chr8:58056175	NA	0.42	4.99	0.31	1.2e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs8067545	0.603	rs10083830	chr17:19965883	G/A	cg13482628	chr17:19912719	NA	0.53	6.68	0.4	1.69e-10	Schizophrenia;
SARC	cis	rs1062177	1.000	rs12518722	chr5:151231460	A/G	cg00977110	chr5:151150581	G3BP1	0.58	5.7	0.35	3.52e-8	Preschool internalizing problems;
SARC	trans	rs9505118	0.733	rs7748736	chr6:7302035	C/T	cg09552510	chr11:58980665	MPEG1	0.39	6.37	0.39	1.02e-9	Type 2 diabetes;
SARC	cis	rs9467711	0.651	rs13200797	chr6:26122957	G/A	cg21479132	chr6:26055353	NA	0.97	6.74	0.4	1.21e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs4794106	0.792	rs11365	chr17:48211533	T/G	cg13127421	chr17:48202128	SAMD14	-0.57	-7.8	-0.46	2.05e-13	Temporomandibular joint disorder;
SARC	cis	rs7824557	0.564	rs2572392	chr8:11235605	T/G	cg21775007	chr8:11205619	TDH	-0.65	-8.62	-0.49	1.05e-15	Retinal vascular caliber;
SARC	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg05313129	chr8:58192883	C8orf71	-0.55	-6.16	-0.37	3.13e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9457247	0.765	rs9295385	chr6:167448181	A/G	cg23791538	chr6:167370224	RNASET2	-0.49	-6.04	-0.37	6.14e-9	Crohn's disease;
SARC	cis	rs1048238	0.846	rs945417	chr1:16344625	C/G	cg21385522	chr1:16154831	NA	0.51	6.13	0.37	3.79e-9	Systolic blood pressure;
SARC	cis	rs4268898	0.662	rs56006260	chr2:24409903	A/G	cg26838691	chr2:24397539	C2orf84	-0.54	-6.27	-0.38	1.75e-9	Asthma;
SARC	cis	rs17384381	1.000	rs12118950	chr1:85864519	T/C	cg16011679	chr1:85725395	C1orf52	0.61	5.77	0.35	2.49e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg16680214	chr1:154839983	KCNN3	-0.35	-5.56	-0.34	7.22e-8	Prostate cancer;
SARC	cis	rs6088813	1.000	rs2425065	chr20:33926268	A/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.44	5.35	0.33	2.07e-7	Height;
SARC	cis	rs1008375	0.898	rs4698623	chr4:17594702	T/C	cg27347728	chr4:17578864	LAP3	0.46	5.51	0.34	9.63e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs3540	0.960	rs10083661	chr15:91022339	G/A	cg22089800	chr15:90895588	ZNF774	0.5	5.61	0.35	5.61e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs10504229	0.679	rs16921606	chr8:58034477	A/C	cg20607798	chr8:58055168	NA	0.51	4.76	0.3	3.41e-6	Developmental language disorder (linguistic errors);
SARC	trans	rs9427116	0.502	rs12125166	chr1:154582129	A/G	cg04295991	chr13:21348012	N6AMT2	-0.5	-6.42	-0.39	7.48e-10	Blood protein levels;
SARC	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.49	-0.39	4.99e-10	Total body bone mineral density;
SARC	cis	rs7589342	0.628	rs10496403	chr2:106419622	T/G	cg16077055	chr2:106428750	NCK2	0.32	5.42	0.33	1.46e-7	Addiction;
SARC	cis	rs17095355	1.000	rs12570820	chr10:111732507	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.43	-4.8	-0.3	2.88e-6	Biliary atresia;
SARC	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs6815814	0.851	rs4129009	chr4:38774889	T/C	cg02016764	chr4:38805732	TLR1	-0.44	-4.8	-0.3	2.81e-6	Breast cancer;
SARC	cis	rs2295359	1.000	rs11209007	chr1:67619345	C/G	cg11235152	chr1:67600687	NA	0.47	7.07	0.42	1.84e-11	Psoriasis;
SARC	cis	rs1003719	0.715	rs762139	chr21:38568475	A/T	cg01262913	chr21:38580486	DSCR9	0.37	5.15	0.32	5.55e-7	Eye color traits;
SARC	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-9.14	-0.51	3.2e-17	Alzheimer's disease;
SARC	trans	rs61931739	0.534	rs1211286	chr12:34135581	T/C	cg13010199	chr12:38710504	ALG10B	0.7	9.6	0.53	1.32e-18	Morning vs. evening chronotype;
SARC	cis	rs1568889	1.000	rs61889054	chr11:28333000	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.72	9.27	0.52	1.34e-17	Bipolar disorder;
SARC	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg23758822	chr17:41437982	NA	0.89	11.4	0.6	3.19e-24	Menopause (age at onset);
SARC	cis	rs2710642	0.962	rs7557501	chr2:63086639	C/T	cg17519650	chr2:63277830	OTX1	0.39	4.92	0.31	1.63e-6	LDL cholesterol levels;LDL cholesterol;
SARC	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg20607798	chr8:58055168	NA	0.61	5.32	0.33	2.38e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7223966	1.000	rs2854219	chr17:61942682	C/T	cg26338869	chr17:61819248	STRADA	0.51	5.32	0.33	2.48e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1003719	1.000	rs2835608	chr21:38493455	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.66	9.04	0.51	6.33e-17	Eye color traits;
SARC	cis	rs1153858	1.000	rs4627277	chr15:45652768	C/A	cg14582100	chr15:45693742	SPATA5L1	0.35	4.82	0.3	2.64e-6	Homoarginine levels;
SARC	cis	rs9653442	0.777	rs6732141	chr2:100743492	G/C	cg22139774	chr2:100720529	AFF3	-0.29	-4.98	-0.31	1.23e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
SARC	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg05793240	chr7:2802953	GNA12	-0.37	-5.23	-0.32	3.77e-7	Height;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg21818540	chr2:45406573	NA	0.44	6.34	0.38	1.2e-9	Thyroid stimulating hormone;
SARC	cis	rs922107	0.738	rs12124338	chr1:90053167	A/G	cg15422784	chr1:90023713	LRRC8B	-0.32	-4.73	-0.3	3.82e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
SARC	cis	rs7178572	0.568	rs1493700	chr15:77629060	T/C	cg22256960	chr15:77711686	NA	-0.52	-5.82	-0.36	1.97e-8	Type 2 diabetes;
SARC	trans	rs7980799	0.682	rs1601006	chr12:33629519	C/T	cg26384229	chr12:38710491	ALG10B	-0.6	-7.32	-0.43	4.01e-12	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs4332037	0.530	rs62434669	chr7:1866946	G/A	cg13880726	chr7:1868755	MAD1L1	-0.53	-4.77	-0.3	3.28e-6	Bipolar disorder;
SARC	cis	rs1008375	0.931	rs10019482	chr4:17578079	G/A	cg27347728	chr4:17578864	LAP3	0.49	6.06	0.37	5.41e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2235642	0.717	rs2236269	chr16:1652614	T/A	cg09065629	chr16:1709722	CRAMP1L	0.38	5.28	0.33	3.03e-7	Coronary artery disease;
SARC	cis	rs2952156	0.920	rs2517958	chr17:37838751	G/A	cg00129232	chr17:37814104	STARD3	-0.71	-10.04	-0.55	6.16e-20	Asthma;
SARC	cis	rs17102884	0.506	rs4899540	chr14:75403408	G/A	cg08847533	chr14:75593920	NEK9	-0.44	-5.45	-0.34	1.29e-7	Neuroticism;
SARC	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg08280861	chr8:58055591	NA	0.61	5.81	0.36	2.02e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs11098499	0.954	rs3733523	chr4:120423719	C/T	cg25214090	chr10:38739885	LOC399744	0.58	7.47	0.44	1.63e-12	Corneal astigmatism;
SARC	cis	rs933688	1.000	rs6867219	chr5:90718008	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.03	13.23	0.65	3.53e-30	Smoking behavior;
SARC	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg12463550	chr7:65579703	CRCP	0.48	5.21	0.32	4.06e-7	Aortic root size;
SARC	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg17971929	chr21:40555470	PSMG1	0.98	13.6	0.67	2.19e-31	Cognitive function;
SARC	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg21724239	chr8:58056113	NA	0.6	6.37	0.38	1.03e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2130392	0.926	rs1107907	chr4:185620108	G/T	cg04058563	chr4:185651563	MLF1IP	0.39	5.61	0.35	5.58e-8	Kawasaki disease;
SARC	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	11.04	0.59	4.42e-23	Platelet count;
SARC	cis	rs35110281	0.715	rs2838353	chr21:45119228	C/T	cg01579765	chr21:45077557	HSF2BP	-0.35	-5.77	-0.35	2.55e-8	Mean corpuscular volume;
SARC	cis	rs79149102	0.649	rs1531162	chr15:75111984	C/T	cg17294928	chr15:75287854	SCAMP5	-0.83	-5.15	-0.32	5.54e-7	Lung cancer;
SARC	cis	rs1580019	0.523	rs13236410	chr7:32690663	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.64	8.39	0.48	4.62e-15	Cognitive ability;
SARC	cis	rs72717009	0.825	rs7529225	chr1:161479352	G/A	cg23840854	chr1:161414152	NA	-0.54	-5.04	-0.31	9.44e-7	Rheumatoid arthritis;
SARC	cis	rs17270561	0.609	rs1937131	chr6:25744831	A/T	cg17691542	chr6:26056736	HIST1H1C	-0.58	-6.92	-0.41	4.32e-11	Iron status biomarkers;
SARC	cis	rs9916302	0.904	rs2338797	chr17:37548241	G/A	cg07936489	chr17:37558343	FBXL20	0.69	9.09	0.51	4.37e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs1971762	0.563	rs11170645	chr12:54079080	G/T	cg06632207	chr12:54070931	ATP5G2	0.43	5.56	0.34	7.42e-8	Height;
SARC	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg21782813	chr7:2030301	MAD1L1	0.35	5.55	0.34	7.61e-8	Autism spectrum disorder or schizophrenia;
SARC	cis	rs4481887	1.000	rs4244178	chr1:248468441	A/G	cg01631408	chr1:248437212	OR2T33	-0.41	-5.13	-0.32	6.07e-7	Common traits (Other);
SARC	cis	rs1401999	0.565	rs4912515	chr3:183653718	A/G	cg01324343	chr3:183735012	ABCC5	0.49	8.84	0.5	2.34e-16	Anterior chamber depth;
SARC	cis	rs7089973	0.628	rs11196953	chr10:116607707	A/G	cg08188268	chr10:116634841	FAM160B1	0.28	4.79	0.3	3.02e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs920590	0.717	rs62496675	chr8:19635733	A/T	cg17834443	chr8:19674713	INTS10	0.47	5.73	0.35	3.09e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs16866061	1.000	rs2047134	chr2:225347713	A/C	cg12698349	chr2:225449008	CUL3	0.73	9.67	0.54	8.39e-19	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg08645402	chr16:4508243	NA	0.39	4.84	0.3	2.39e-6	Schizophrenia;
SARC	cis	rs11792861	0.619	rs2289480	chr9:111705501	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.8	10.63	0.57	9.05e-22	Menarche (age at onset);
SARC	cis	rs7327064	0.510	rs9547542	chr13:36953523	C/T	cg13455704	chr13:36871754	C13orf38	0.54	6.39	0.39	8.96e-10	Economic and political preferences;
SARC	cis	rs3820928	0.904	rs6735069	chr2:227893660	A/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-6.55	-0.39	3.62e-10	Pulmonary function;
SARC	trans	rs11098499	0.913	rs10010696	chr4:120164303	T/C	cg25214090	chr10:38739885	LOC399744	0.53	6.89	0.41	5.09e-11	Corneal astigmatism;
SARC	cis	rs7617773	0.817	rs11720622	chr3:48246679	G/A	cg11946769	chr3:48343235	NME6	0.64	8.51	0.49	2.16e-15	Coronary artery disease;
SARC	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg19318889	chr4:1322082	MAEA	0.4	4.9	0.31	1.78e-6	Longevity;
SARC	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg11168104	chr5:1857477	NA	-0.35	-5.1	-0.32	7.07e-7	Cardiovascular disease risk factors;
SARC	cis	rs9916302	0.904	rs10221223	chr17:37489100	T/G	cg00129232	chr17:37814104	STARD3	0.58	7.24	0.43	6.36e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs2273669	0.915	rs6928200	chr6:109294164	A/C	cg01304950	chr6:109416612	SESN1;C6orf182	0.54	4.74	0.3	3.75e-6	Prostate cancer;
SARC	cis	rs7084402	0.967	rs1626606	chr10:60328088	C/T	cg07615347	chr10:60278583	BICC1	0.58	8.58	0.49	1.36e-15	Refractive error;
SARC	cis	rs933688	0.759	rs1423593	chr5:90752351	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	12.54	0.63	6.75e-28	Smoking behavior;
SARC	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.72	-7.58	-0.44	8e-13	Platelet count;
SARC	cis	rs7223966	1.000	rs9901112	chr17:61730617	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.53	-5.4	-0.33	1.62e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2153535	0.562	rs6901765	chr6:8455436	A/T	cg23788917	chr6:8435910	SLC35B3	0.63	8.29	0.48	8.89e-15	Motion sickness;
SARC	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg06618935	chr21:46677482	NA	0.37	5.04	0.31	9.17e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2239547	0.657	rs6445538	chr3:52874288	T/C	cg18404041	chr3:52824283	ITIH1	-0.41	-5.06	-0.31	8.32e-7	Schizophrenia;
SARC	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg22535103	chr8:58192502	C8orf71	-0.73	-7.24	-0.43	6.52e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs11098499	1.000	rs6837898	chr4:120179154	C/T	cg24375607	chr4:120327624	NA	0.4	4.86	0.3	2.12e-6	Corneal astigmatism;
SARC	cis	rs4563143	0.502	rs73029061	chr19:29283980	T/A	cg12756686	chr19:29218302	NA	0.66	8.44	0.48	3.35e-15	Methadone dose in opioid dependence;
SARC	cis	rs2180341	0.889	rs9321074	chr6:127618019	G/A	cg27446573	chr6:127587934	RNF146	1.02	14.46	0.69	2.89e-34	Breast cancer;
SARC	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg00149659	chr3:10157352	C3orf10	0.69	6.9	0.41	4.76e-11	Alzheimer's disease;
SARC	cis	rs6867032	0.527	rs4975777	chr5:1973324	G/T	cg26168224	chr5:2018326	NA	-0.59	-6.76	-0.4	1.13e-10	Gut microbiome composition (winter);
SARC	cis	rs6430585	0.528	rs309162	chr2:136690783	T/A	cg07169764	chr2:136633963	MCM6	1.04	15.9	0.72	4.76e-39	Corneal structure;
SARC	cis	rs2952156	0.920	rs8078228	chr17:37834998	C/T	cg07936489	chr17:37558343	FBXL20	-0.4	-5.28	-0.33	2.89e-7	Asthma;
SARC	trans	rs7937682	1.000	rs9734135	chr11:111536190	G/A	cg18187862	chr3:45730750	SACM1L	0.55	6.86	0.41	6.12e-11	Primary sclerosing cholangitis;
SARC	cis	rs67311347	0.503	rs11719968	chr3:40241600	G/T	cg24209194	chr3:40518798	ZNF619	0.51	6.11	0.37	4.09e-9	Renal cell carcinoma;
SARC	cis	rs7223966	0.921	rs3020612	chr17:61960878	C/T	cg26338869	chr17:61819248	STRADA	0.5	5.64	0.35	5.01e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1059312	1.000	rs9738216	chr12:129281788	C/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.49	6.98	0.42	3.02e-11	Systemic lupus erythematosus;
SARC	cis	rs9325144	0.577	rs12314639	chr12:39119869	T/C	cg13010199	chr12:38710504	ALG10B	-0.51	-6.33	-0.38	1.25e-9	Morning vs. evening chronotype;
SARC	cis	rs6942407	0.649	rs6952384	chr7:86859551	T/C	cg02420886	chr7:86849541	C7orf23	0.61	5.35	0.33	2.13e-7	Food allergy;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg02085815	chr4:128802010	PLK4	-0.78	-6.44	-0.39	6.8e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9902453	0.904	rs9894893	chr17:28270350	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	6.94	0.41	3.77e-11	Coffee consumption (cups per day);
SARC	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.7	9.53	0.53	2.13e-18	Menarche (age at onset);
SARC	cis	rs2486288	0.656	rs12910009	chr15:45572408	A/G	cg19305227	chr15:45544335	SLC28A2	0.3	5.63	0.35	5.06e-8	Glomerular filtration rate;
SARC	cis	rs9916302	0.784	rs4795382	chr17:37700860	A/G	cg15445000	chr17:37608096	MED1	0.42	4.93	0.31	1.59e-6	Glomerular filtration rate (creatinine);
SARC	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg22433210	chr17:43662623	NA	-0.95	-11.27	-0.59	8.48e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.4	0.39	8.38e-10	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg12463550	chr7:65579703	CRCP	-0.49	-5.28	-0.33	2.93e-7	Aortic root size;
SARC	cis	rs12545912	0.770	rs7822700	chr8:9540854	C/G	cg21625330	chr8:9911636	MSRA	0.44	4.81	0.3	2.74e-6	Multiple myeloma (hyperdiploidy);
SARC	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg19761014	chr17:28927070	LRRC37B2	0.57	5.38	0.33	1.82e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg03239202	chr2:68694299	FBXO48;APLF	-0.51	-6.41	-0.39	7.88e-10	Schizophrenia;
SARC	cis	rs1949733	0.959	rs2688242	chr4:8429943	T/G	cg13073564	chr4:8508604	NA	-0.43	-6.66	-0.4	2e-10	Response to antineoplastic agents;
SARC	cis	rs787274	0.718	rs4979178	chr9:115644335	G/C	cg13803584	chr9:115635662	SNX30	-0.71	-5.69	-0.35	3.76e-8	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg20573242	chr4:122745356	CCNA2	0.66	8.64	0.49	9.26e-16	Type 2 diabetes;
SARC	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg13877915	chr19:58951672	ZNF132	0.63	9.11	0.51	3.83e-17	Uric acid clearance;
SARC	cis	rs17376456	0.877	rs12153506	chr5:93360953	T/G	cg21475434	chr5:93447410	FAM172A	0.87	7.91	0.46	1.06e-13	Diabetic retinopathy;
SARC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.03	0.37	6.28e-9	Prudent dietary pattern;
SARC	cis	rs9309473	1.000	rs10207220	chr2:73785046	G/C	cg20560298	chr2:73613845	ALMS1	-0.48	-5.92	-0.36	1.14e-8	Metabolite levels;
SARC	cis	rs3768617	0.510	rs7525917	chr1:183065406	A/G	cg13390022	chr1:182993471	LAMC1	0.32	4.8	0.3	2.79e-6	Fuchs's corneal dystrophy;
SARC	cis	rs10982256	1.000	rs4979413	chr9:117259548	A/G	cg15903421	chr9:117267460	DFNB31	-0.38	-5.01	-0.31	1.1e-6	Bipolar disorder;
SARC	cis	rs7667	0.846	rs12405176	chr1:19757506	G/C	cg15311933	chr1:19638897	PQLC2;AKR7A2	-0.43	-4.87	-0.3	2.04e-6	Crohn's disease and psoriasis;
SARC	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg03806693	chr22:41940476	POLR3H	-0.98	-13.6	-0.67	2.18e-31	Vitiligo;
SARC	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg04277193	chr17:41438351	NA	0.45	4.87	0.3	2.03e-6	Menopause (age at onset);
SARC	cis	rs11252926	0.673	rs7096559	chr10:499188	C/T	cg16386425	chr10:429943	DIP2C	-0.46	-5.31	-0.33	2.6e-7	Psychosis in Alzheimer's disease;
SARC	cis	rs10463316	0.832	rs246484	chr5:150730938	T/C	cg03212797	chr5:150827313	SLC36A1	-0.54	-6.65	-0.4	2.08e-10	Metabolite levels (Pyroglutamine);
SARC	cis	rs9914988	0.778	rs9907192	chr17:27122426	C/G	cg20469991	chr17:27169893	C17orf63	-0.5	-5.21	-0.32	4.1e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.52	5.99	0.37	7.81e-9	Renal function-related traits (BUN);
SARC	cis	rs6669008	1.000	rs6669008	chr1:114166561	A/G	cg26035817	chr1:114414802	PTPN22	0.48	5.66	0.35	4.36e-8	Bacteremia;
SARC	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg16606324	chr3:10149918	C3orf24	0.54	5.34	0.33	2.22e-7	Alzheimer's disease;
SARC	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg03709012	chr19:19516395	GATAD2A	0.96	15.32	0.71	4.24e-37	Tonsillectomy;
SARC	cis	rs1045529	0.524	rs34251783	chr8:8891376	T/C	cg11995313	chr8:8860691	ERI1	0.43	5.54	0.34	8.09e-8	Myopia;Myopia (pathological);
SARC	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.65	6.06	0.37	5.29e-9	Platelet count;
SARC	cis	rs1707322	0.963	rs11211229	chr1:46400517	A/C	cg06784218	chr1:46089804	CCDC17	0.34	5.97	0.36	8.98e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs10493773	0.532	rs12064199	chr1:86187073	A/T	cg17807903	chr1:86174739	ZNHIT6	-0.6	-9.63	-0.53	1.06e-18	Urate levels in overweight individuals;
SARC	cis	rs2370759	1.000	rs78959390	chr10:32616346	C/T	cg01819863	chr10:32635814	EPC1	1.02	10.19	0.56	2.06e-20	Sexual dysfunction (female);
SARC	cis	rs820218	1.000	rs820134	chr17:73674105	G/A	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.59	7.18	0.43	9.35e-12	Rotator cuff tears;
SARC	cis	rs1580019	0.563	rs764483	chr7:32578150	A/T	cg06627557	chr7:32535165	LSM5;AVL9	0.95	15.89	0.72	5e-39	Cognitive ability;
SARC	cis	rs35213789	0.887	rs6959766	chr7:69252380	C/A	cg10619644	chr7:69149951	AUTS2	0.44	5.79	0.35	2.25e-8	Childhood ear infection;
SARC	cis	rs12311304	0.965	rs10846159	chr12:15363407	A/G	cg08258403	chr12:15378311	NA	0.48	7.48	0.44	1.49e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg08280861	chr8:58055591	NA	0.6	5.28	0.33	2.92e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg05382772	chr11:65686513	DRAP1;C11orf68	0.51	6.33	0.38	1.24e-9	Breast cancer;
SARC	cis	rs709400	1.000	rs10135248	chr14:104122310	T/C	cg12935359	chr14:103987150	CKB	-0.32	-4.86	-0.3	2.15e-6	Body mass index;
SARC	cis	rs2204008	0.837	rs12146734	chr12:38237079	A/G	cg26384229	chr12:38710491	ALG10B	0.92	13.59	0.66	2.33e-31	Bladder cancer;
SARC	cis	rs3820928	0.935	rs12151597	chr2:227859224	A/G	cg05526886	chr2:227700861	RHBDD1	-0.49	-5.87	-0.36	1.5e-8	Pulmonary function;
SARC	cis	rs8031584	0.672	rs17815726	chr15:31313252	C/G	cg19680485	chr15:31195859	MTMR15	0.53	5.3	0.33	2.74e-7	Huntington's disease progression;
SARC	cis	rs9325144	0.560	rs2387923	chr12:38662677	G/A	cg26384229	chr12:38710491	ALG10B	-0.66	-8.86	-0.5	2.06e-16	Morning vs. evening chronotype;
SARC	cis	rs13256369	0.802	rs12681925	chr8:8561649	G/A	cg17143192	chr8:8559678	CLDN23	0.51	5.59	0.34	6.36e-8	Obesity-related traits;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg10114235	chr6:169449059	NA	0.46	7.16	0.42	1.02e-11	Thyroid stimulating hormone;
SARC	trans	rs9329221	0.686	rs35840352	chr8:10239807	A/G	cg06636001	chr8:8085503	FLJ10661	0.59	7.1	0.42	1.53e-11	Neuroticism;
SARC	cis	rs7666738	0.791	rs13111960	chr4:98976851	C/T	cg05340658	chr4:99064831	C4orf37	0.64	8.6	0.49	1.18e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs3768617	0.868	rs2296299	chr1:183104013	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.6	8.33	0.48	7.01e-15	Fuchs's corneal dystrophy;
SARC	cis	rs2380220	1.000	rs9632496	chr6:95976450	C/G	cg07718321	chr6:96025334	MANEA	0.5	5.13	0.32	6.06e-7	Behavioural disinhibition (generation interaction);
SARC	trans	rs61931739	0.817	rs10743842	chr12:34306859	C/T	cg13010199	chr12:38710504	ALG10B	0.57	7.48	0.44	1.49e-12	Morning vs. evening chronotype;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg15888849	chr15:76094525	NA	0.47	6.37	0.39	1e-9	Thyroid stimulating hormone;
SARC	cis	rs9467773	1.000	rs2393670	chr6:26535541	A/G	cg12292205	chr6:26970375	C6orf41	0.45	5.43	0.34	1.41e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7937682	0.889	rs578022	chr11:111490552	G/T	cg22437258	chr11:111473054	SIK2	0.74	10.24	0.56	1.44e-20	Primary sclerosing cholangitis;
SARC	cis	rs3741798	1.000	rs55865572	chr12:12497333	T/C	cg08615371	chr12:12503544	MANSC1	0.68	5.43	0.34	1.43e-7	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9810089	0.835	rs654237	chr3:136068699	T/C	cg15507776	chr3:136538369	TMEM22	0.44	5.0	0.31	1.15e-6	Gestational age at birth (child effect);
SARC	cis	rs6728642	1.000	rs7593754	chr2:97607544	C/T	cg26665480	chr2:98280029	ACTR1B	-0.54	-4.76	-0.3	3.33e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs4742903	0.527	rs2417497	chr9:106951832	A/G	cg14250997	chr9:106856677	SMC2	0.39	4.85	0.3	2.3e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs6840360	0.517	rs4399967	chr4:152729312	T/A	cg22705602	chr4:152727874	NA	0.48	8.55	0.49	1.68e-15	Intelligence (multi-trait analysis);
SARC	cis	rs76419734	1.000	rs72669978	chr4:106520852	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.76	4.81	0.3	2.74e-6	Post bronchodilator FEV1;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg07893544	chr4:55991782	KDR	-0.46	-6.45	-0.39	6.54e-10	Schizophrenia;
SARC	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg12016809	chr21:47604291	C21orf56	0.42	5.09	0.32	7.29e-7	Testicular germ cell tumor;
SARC	cis	rs4713118	0.513	rs156734	chr6:28007357	A/C	cg26450541	chr6:28235208	ZNF187	0.49	5.12	0.32	6.54e-7	Parkinson's disease;
SARC	cis	rs10752881	1.000	rs10752881	chr1:182973491	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.64	0.57	8.27e-22	Colorectal cancer;
SARC	cis	rs2153535	0.580	rs4451187	chr6:8473910	C/T	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	cis	rs11690935	0.655	rs12997093	chr2:172564438	A/G	cg13550731	chr2:172543902	DYNC1I2	0.67	9.34	0.52	8.03e-18	Schizophrenia;
SARC	cis	rs7224737	1.000	rs9915255	chr17:40284191	C/T	cg20291162	chr17:40259547	DHX58	-0.33	-4.86	-0.3	2.2e-6	Fibrinogen levels;
SARC	cis	rs10088262	0.629	rs6990565	chr8:124785645	C/A	cg02993010	chr8:124780839	FAM91A1	-0.76	-8.67	-0.49	7.48e-16	Pancreatic cancer;
SARC	cis	rs57561814	0.655	rs6461660	chr7:22742134	T/C	cg26061582	chr7:22766209	IL6	0.92	7.73	0.45	3.15e-13	Tonsillectomy;
SARC	cis	rs6121246	0.529	rs41310803	chr20:30452709	A/G	cg13852791	chr20:30311386	BCL2L1	0.59	5.15	0.32	5.43e-7	Mean corpuscular hemoglobin;
SARC	cis	rs11718455	1.000	rs1524885	chr3:44031847	G/A	cg21419209	chr3:44054225	NA	-0.4	-4.79	-0.3	2.99e-6	Coronary artery disease;
SARC	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg10523679	chr1:76189770	ACADM	-0.5	-6.72	-0.4	1.36e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs1008375	1.000	rs1008375	chr4:17682834	T/C	cg02297831	chr4:17616191	MED28	0.44	5.56	0.34	7.19e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg11764359	chr7:65958608	NA	-0.65	-7.77	-0.45	2.42e-13	Aortic root size;
SARC	cis	rs524281	0.773	rs11227413	chr11:65883696	G/A	cg14036092	chr11:66035641	RAB1B	-0.49	-5.12	-0.32	6.33e-7	Electroencephalogram traits;
SARC	cis	rs7582720	1.000	rs77268589	chr2:203751981	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.31	0.43	4.24e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs9400467	0.537	rs55643604	chr6:111490648	T/G	cg15721981	chr6:111408429	SLC16A10	0.68	5.85	0.36	1.63e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs1185460	0.967	rs1184902	chr11:118945337	A/G	cg01677386	chr11:118938358	VPS11	-0.42	-5.02	-0.31	1.05e-6	Coronary artery disease;
SARC	cis	rs17376456	0.877	rs9314092	chr5:93326362	A/G	cg21475434	chr5:93447410	FAM172A	0.83	7.36	0.43	3.11e-12	Diabetic retinopathy;
SARC	cis	rs3733585	0.781	rs13103879	chr4:9972879	T/C	cg11266682	chr4:10021025	SLC2A9	-0.37	-6.6	-0.4	2.74e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg06074448	chr4:187884817	NA	-0.37	-5.06	-0.31	8.5e-7	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg27219598	chr4:148538521	TMEM184C	0.49	6.32	0.38	1.32e-9	Chemerin levels;
SARC	cis	rs6840360	0.571	rs11932059	chr4:152524496	G/A	cg22705602	chr4:152727874	NA	-0.43	-6.66	-0.4	1.91e-10	Intelligence (multi-trait analysis);
SARC	cis	rs722599	0.748	rs61978932	chr14:75342954	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.4	-5.01	-0.31	1.1e-6	IgG glycosylation;
SARC	cis	rs7769051	1.000	rs12204027	chr6:133122831	A/G	cg22852734	chr6:133119734	C6orf192	1.04	10.29	0.56	1.05e-20	Type 2 diabetes nephropathy;
SARC	cis	rs9393692	0.905	rs7769028	chr6:26267568	C/T	cg00631329	chr6:26305371	NA	-0.62	-9.05	-0.51	5.98e-17	Educational attainment;
SARC	cis	rs9916302	0.784	rs4795382	chr17:37700860	A/G	cg00129232	chr17:37814104	STARD3	-0.63	-7.73	-0.45	3.25e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs79839061	0.656	rs11726912	chr4:887868	A/C	cg07828340	chr4:882639	GAK	0.78	6.45	0.39	6.41e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7633770	0.643	rs11130102	chr3:46689567	G/C	cg11219411	chr3:46661640	NA	-0.39	-5.91	-0.36	1.22e-8	Coronary artery disease;
SARC	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	5.69	0.35	3.71e-8	Bipolar disorder;
SARC	cis	rs3791556	0.898	rs3791549	chr2:240109024	A/G	cg03281426	chr2:240109471	HDAC4	-0.38	-4.93	-0.31	1.53e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs2834188	0.924	rs2409487	chr21:34684958	C/T	cg14352951	chr21:34696688	IFNAR1	0.45	5.57	0.34	7.04e-8	Narcolepsy;
SARC	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg08280861	chr8:58055591	NA	0.61	5.96	0.36	9.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10875746	0.951	rs4760689	chr12:48563644	G/A	cg26205652	chr12:48591994	NA	0.53	5.91	0.36	1.19e-8	Longevity (90 years and older);
SARC	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.43	-5.98	-0.36	8.45e-9	Personality dimensions;
SARC	cis	rs2204008	0.774	rs11495520	chr12:38060605	T/G	cg13010199	chr12:38710504	ALG10B	0.78	10.73	0.57	4.45e-22	Bladder cancer;
SARC	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg06212747	chr3:49208901	KLHDC8B	0.51	6.27	0.38	1.78e-9	Resting heart rate;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg01308931	chr2:120517826	PTPN4	0.5	6.69	0.4	1.62e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg13939156	chr17:80058883	NA	-0.4	-6.27	-0.38	1.77e-9	Life satisfaction;
SARC	cis	rs11098499	0.909	rs1809406	chr4:120377122	G/A	cg09307838	chr4:120376055	NA	0.92	13.13	0.65	7.35e-30	Corneal astigmatism;
SARC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg05165339	chr4:1420672	NA	-0.26	-5.65	-0.35	4.55e-8	Longevity;
SARC	cis	rs11718455	0.960	rs11920021	chr3:44000856	T/C	cg08738300	chr3:44038990	NA	0.54	5.95	0.36	9.6e-9	Coronary artery disease;
SARC	cis	rs1570884	0.516	rs7334387	chr13:50172133	T/A	cg08779649	chr13:50194554	NA	0.36	6.27	0.38	1.76e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs9815354	0.812	rs73081372	chr3:41917993	C/T	cg03022575	chr3:42003672	ULK4	0.67	5.47	0.34	1.17e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9905704	0.647	rs11659035	chr17:56966052	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.4	-4.83	-0.3	2.52e-6	Testicular germ cell tumor;
SARC	cis	rs55871839	0.684	rs4738729	chr8:59808617	T/C	cg07426533	chr8:59803705	TOX	-0.45	-6.04	-0.37	5.98e-9	Pneumonia;
SARC	cis	rs11585357	0.947	rs6666990	chr1:17611520	G/A	cg08277548	chr1:17600880	PADI3	0.44	5.14	0.32	5.92e-7	Hair shape;
SARC	cis	rs9916302	0.904	rs6503519	chr17:37706578	A/G	cg07936489	chr17:37558343	FBXL20	-0.68	-8.8	-0.5	3.12e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg24549020	chr5:56110836	MAP3K1	-0.47	-5.21	-0.32	4.15e-7	Initial pursuit acceleration;
SARC	cis	rs2011503	1.000	rs2965184	chr19:19545428	C/T	cg15839431	chr19:19639596	YJEFN3	0.49	4.85	0.3	2.28e-6	Bipolar disorder;
SARC	cis	rs2816062	0.813	rs2816053	chr1:18895819	A/G	cg18795169	chr1:18902165	NA	-0.78	-12.69	-0.64	2.13e-28	Urate levels in lean individuals;
SARC	cis	rs17376456	0.825	rs10057130	chr5:93282557	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	5.75	0.35	2.81e-8	Diabetic retinopathy;
SARC	cis	rs8053891	0.855	rs6499553	chr16:71996715	C/T	cg16558253	chr16:72132732	DHX38	-0.41	-5.31	-0.33	2.5e-7	Coronary artery disease;
SARC	cis	rs1981331	0.609	rs59121565	chr21:48043023	A/G	cg17243659	chr21:48055224	PRMT2	0.78	4.73	0.3	3.88e-6	Cerebrospinal fluid t-tau:AB1-42 ratio;
SARC	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg14582100	chr15:45693742	SPATA5L1	0.35	4.89	0.31	1.87e-6	Homoarginine levels;
SARC	cis	rs6582630	0.598	rs12823134	chr12:38514347	T/A	cg14851346	chr12:38532713	NA	-0.42	-5.12	-0.32	6.26e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7647973	0.626	rs6809879	chr3:49834571	A/G	cg07636037	chr3:49044803	WDR6	-0.69	-6.78	-0.41	9.78e-11	Menarche (age at onset);
SARC	cis	rs66573146	0.634	rs56097119	chr4:7018692	C/G	cg15105060	chr4:7024189	TBC1D14	-0.67	-4.81	-0.3	2.72e-6	Granulocyte percentage of myeloid white cells;
SARC	cis	rs2273669	0.667	rs11153154	chr6:109357324	G/T	cg05315195	chr6:109294784	ARMC2	-0.63	-5.7	-0.35	3.6e-8	Prostate cancer;
SARC	cis	rs644799	1.000	rs557079	chr11:95530125	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	14.15	0.68	3.08e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs708547	0.647	rs781666	chr4:57830981	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.49	5.95	0.36	9.73e-9	Response to bleomycin (chromatid breaks);
SARC	cis	rs7772486	0.764	rs2265471	chr6:146220250	G/A	cg23711669	chr6:146136114	FBXO30	0.8	12.6	0.64	4.27e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4481887	1.000	rs4244179	chr1:248470984	T/A	cg00666640	chr1:248458726	OR2T12	0.37	6.23	0.38	2.17e-9	Common traits (Other);
SARC	cis	rs2635047	0.638	rs2317324	chr18:44628687	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.39	-4.71	-0.3	4.17e-6	Educational attainment;
SARC	cis	rs4810685	0.526	rs6018685	chr20:46410809	A/G	cg08288986	chr20:46415360	SULF2	-0.54	-6.25	-0.38	1.97e-9	Attention deficit hyperactivity disorder (time to onset);
SARC	cis	rs7772486	0.790	rs2265474	chr6:146182092	G/A	cg05347473	chr6:146136440	FBXO30	0.56	7.87	0.46	1.34e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6977660	0.714	rs4719587	chr7:19828174	C/G	cg05791153	chr7:19748676	TWISTNB	0.54	4.91	0.31	1.75e-6	Thyroid stimulating hormone;
SARC	cis	rs11997175	0.583	rs17780153	chr8:33789161	A/G	ch.8.33884649F	chr8:33765107	NA	0.46	5.87	0.36	1.51e-8	Body mass index;
SARC	cis	rs9359856	0.510	rs4235839	chr6:90472410	A/G	cg13799429	chr6:90582589	CASP8AP2	0.53	4.79	0.3	3.04e-6	Bipolar disorder;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg24717964	chr20:61477008	DPH3B;TCFL5	0.54	6.7	0.4	1.54e-10	Breast cancer;
SARC	cis	rs870825	0.616	rs4594761	chr4:185643002	A/C	cg04058563	chr4:185651563	MLF1IP	0.81	11.52	0.6	1.31e-24	Blood protein levels;
SARC	cis	rs854765	0.583	rs8075965	chr17:17853180	A/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.43	5.52	0.34	9.04e-8	Total body bone mineral density;
SARC	cis	rs11687170	0.816	rs56102535	chr2:237053791	G/A	cg19324714	chr2:237145437	ASB18	0.48	4.81	0.3	2.69e-6	Educational attainment;Educational attainment (years of education);
SARC	cis	rs1580019	0.713	rs2167274	chr7:32524844	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.48	6.0	0.37	7.35e-9	Cognitive ability;
SARC	trans	rs877282	0.945	rs17293517	chr10:778770	C/T	cg22713356	chr15:30763199	NA	1.06	10.7	0.57	5.26e-22	Uric acid levels;
SARC	cis	rs748404	0.660	rs690512	chr15:43717678	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.4	4.78	0.3	3.13e-6	Lung cancer;
SARC	cis	rs4319547	0.774	rs7954006	chr12:123131824	A/C	cg05707623	chr12:122985044	ZCCHC8	0.57	6.65	0.4	2.07e-10	Body mass index;
SARC	cis	rs3008870	1.000	rs2755244	chr1:67484470	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.9	-10.93	-0.58	1.01e-22	Lymphocyte percentage of white cells;
SARC	cis	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg00745463	chr17:30367425	LRRC37B	-0.62	-5.04	-0.31	9.23e-7	Hip circumference adjusted for BMI;
SARC	trans	rs79976124	0.837	rs11751145	chr6:66642039	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	8.09	0.47	3.18e-14	Type 2 diabetes;
SARC	cis	rs1707322	1.000	rs785493	chr1:46584859	A/G	cg06784218	chr1:46089804	CCDC17	-0.35	-6.01	-0.37	7.21e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg27572855	chr1:25598939	RHD	0.54	9.4	0.52	5.29e-18	Plateletcrit;Mean corpuscular volume;
SARC	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg21747090	chr2:27597821	SNX17	-0.51	-7.08	-0.42	1.71e-11	Total body bone mineral density;
SARC	trans	rs61931739	0.534	rs1817761	chr12:34105719	C/T	cg13010199	chr12:38710504	ALG10B	0.77	10.37	0.56	5.83e-21	Morning vs. evening chronotype;
SARC	cis	rs17376456	0.825	rs28705226	chr5:93233135	T/C	cg21475434	chr5:93447410	FAM172A	0.84	7.5	0.44	1.35e-12	Diabetic retinopathy;
SARC	cis	rs1057239	0.739	rs1014554	chr1:175133626	A/G	cg08873628	chr1:175162347	KIAA0040	0.34	4.85	0.3	2.26e-6	Diastolic blood pressure;
SARC	cis	rs9325144	0.650	rs6582631	chr12:38744135	T/C	cg04568710	chr12:38710424	ALG10B	0.4	4.94	0.31	1.51e-6	Morning vs. evening chronotype;
SARC	cis	rs832540	0.931	rs1445996	chr5:56235548	C/T	cg14703610	chr5:56206110	C5orf35	-0.53	-6.81	-0.41	8.1e-11	Coronary artery disease;
SARC	cis	rs6964587	1.000	rs6974607	chr7:91750116	G/A	cg17063962	chr7:91808500	NA	0.95	15.35	0.71	3.17e-37	Breast cancer;
SARC	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg18876405	chr7:65276391	NA	-0.44	-5.0	-0.31	1.13e-6	Aortic root size;
SARC	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg10295955	chr4:187884368	NA	-1.06	-19.9	-0.79	3.6e-52	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11098499	0.754	rs878372	chr4:120238780	A/C	cg09307838	chr4:120376055	NA	0.81	11.15	0.59	2.11e-23	Corneal astigmatism;
SARC	cis	rs12971120	0.891	rs3794955	chr18:72174827	C/T	cg26446133	chr18:72167187	CNDP2	-0.47	-6.39	-0.39	8.94e-10	Refractive error;
SARC	trans	rs988913	0.957	rs9475098	chr6:54833177	A/G	cg03849851	chr6:166980629	RPS6KA2	0.37	6.23	0.38	2.12e-9	Menarche (age at onset);
SARC	cis	rs10779751	0.879	rs7543400	chr1:11283964	C/G	cg08854313	chr1:11322531	MTOR	0.91	14.39	0.69	5.22e-34	Body mass index;
SARC	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg07701084	chr6:150067640	NUP43	0.41	5.49	0.34	1.04e-7	Lung cancer;
SARC	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg03709012	chr19:19516395	GATAD2A	1.04	18.03	0.76	4.51e-46	Tonsillectomy;
SARC	cis	rs12971120	0.947	rs8083001	chr18:72165058	A/G	cg26446133	chr18:72167187	CNDP2	-0.51	-9.52	-0.53	2.34e-18	Refractive error;
SARC	cis	rs3858526	0.796	rs9645652	chr11:5944264	C/T	cg13902645	chr11:5959945	NA	-0.44	-5.08	-0.32	7.57e-7	DNA methylation (variation);
SARC	cis	rs2549003	1.000	rs2549007	chr5:131826875	T/C	cg21138405	chr5:131827807	IRF1	-0.28	-5.54	-0.34	8.04e-8	Asthma (sex interaction);
SARC	cis	rs3737883	1.000	rs11579558	chr1:203032038	G/T	cg03900565	chr1:203031815	PPFIA4	0.34	5.36	0.33	2e-7	Early onset atrial fibrillation;
SARC	cis	rs9894429	0.608	rs8477	chr17:79618059	C/T	cg18240062	chr17:79603768	NPLOC4	0.59	7.07	0.42	1.82e-11	Eye color traits;
SARC	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg03351412	chr1:154909251	PMVK	0.6	7.8	0.45	2.08e-13	Prostate cancer;
SARC	cis	rs7666738	0.800	rs12163918	chr4:98835794	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.76	0.5	4.2e-16	Colonoscopy-negative controls vs population controls;
SARC	trans	rs61931739	0.500	rs12832312	chr12:34031199	G/A	cg26384229	chr12:38710491	ALG10B	0.86	12.5	0.63	9.09e-28	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg21724239	chr8:58056113	NA	0.61	6.43	0.39	7.16e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs35110281	0.686	rs162399	chr21:44950020	G/A	cg21573476	chr21:45109991	RRP1B	-0.52	-7.87	-0.46	1.3e-13	Mean corpuscular volume;
SARC	cis	rs6912958	0.712	rs4706294	chr6:88317675	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-5.71	-0.35	3.51e-8	Monocyte percentage of white cells;
SARC	cis	rs57244997	0.582	rs73030424	chr6:162434298	T/A	cg17173639	chr6:162384350	PARK2	-0.48	-4.9	-0.31	1.8e-6	Mosquito bite size;
SARC	cis	rs9436747	0.615	rs6691346	chr1:66046397	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.48	4.94	0.31	1.48e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	trans	rs6601450	0.579	rs11775625	chr8:10272439	C/T	cg06636001	chr8:8085503	FLJ10661	0.52	6.65	0.4	2.11e-10	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs637571	0.584	rs594689	chr11:65635559	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.53	-7.09	-0.42	1.62e-11	Eosinophil percentage of white cells;
SARC	cis	rs3008870	0.755	rs10789219	chr1:67417742	A/C	cg02640540	chr1:67518911	SLC35D1	0.46	5.26	0.33	3.29e-7	Lymphocyte percentage of white cells;
SARC	cis	rs1559088	0.948	rs7247748	chr19:33594023	T/C	cg17764715	chr19:33622953	WDR88	0.5	6.75	0.4	1.18e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs12142240	0.692	rs7529674	chr1:46818508	T/C	cg10495392	chr1:46806563	NSUN4	0.65	6.83	0.41	7.25e-11	Menopause (age at onset);
SARC	cis	rs1348850	0.598	rs12616259	chr2:178503803	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.49	5.59	0.34	6.21e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7000551	0.715	rs1879793	chr8:22313986	G/A	cg12081754	chr8:22256438	SLC39A14	0.6	8.45	0.48	3.15e-15	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs2502731	0.539	rs3003609	chr9:130984755	A/G	cg13642260	chr9:130955380	CIZ1	-0.37	-5.0	-0.31	1.13e-6	Attention deficit hyperactivity disorder;
SARC	cis	rs6456156	0.586	rs9457266	chr6:167482555	T/C	cg07741184	chr6:167504864	NA	0.36	6.99	0.42	2.83e-11	Primary biliary cholangitis;
SARC	cis	rs6952808	0.929	rs2280550	chr7:1976556	G/A	cg21782813	chr7:2030301	MAD1L1	0.42	6.37	0.39	1.01e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs16866061	1.000	rs12470077	chr2:225334971	T/C	cg12698349	chr2:225449008	CUL3	0.71	10.59	0.57	1.16e-21	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	cis	rs2228479	0.850	rs12597296	chr16:89822331	C/T	cg06558623	chr16:89946397	TCF25	0.88	6.21	0.38	2.39e-9	Skin colour saturation;
SARC	cis	rs3754214	0.857	rs488271	chr1:150284534	A/G	cg09579323	chr1:150459698	TARS2	-0.41	-5.26	-0.33	3.34e-7	Cerebrospinal fluid biomarker levels;
SARC	trans	rs1814175	0.817	rs10839397	chr11:49857074	C/T	cg15704280	chr7:45808275	SEPT13	-0.96	-18.1	-0.76	2.52e-46	Height;
SARC	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg13866156	chr1:1669148	SLC35E2	-0.5	-7.13	-0.42	1.29e-11	Body mass index;
SARC	cis	rs9650657	0.655	rs10093774	chr8:10703293	C/T	cg21775007	chr8:11205619	TDH	0.47	5.87	0.36	1.51e-8	Neuroticism;
SARC	cis	rs981844	0.683	rs2405423	chr4:154749823	C/A	cg14289246	chr4:154710475	SFRP2	-0.45	-5.36	-0.33	1.96e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs11676348	0.811	rs13027120	chr2:219020914	C/T	cg00012203	chr2:219082015	ARPC2	0.54	7.38	0.44	2.72e-12	Ulcerative colitis;
SARC	cis	rs6121246	0.697	rs7269866	chr20:30232504	G/A	cg13852791	chr20:30311386	BCL2L1	0.81	8.61	0.49	1.11e-15	Mean corpuscular hemoglobin;
SARC	cis	rs7769051	0.711	rs9493436	chr6:133088275	T/C	cg22852734	chr6:133119734	C6orf192	1.06	10.42	0.56	4.01e-21	Type 2 diabetes nephropathy;
SARC	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.95	11.98	0.62	4.49e-26	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs35110281	0.805	rs8131005	chr21:45041954	T/C	cg21573476	chr21:45109991	RRP1B	-0.52	-7.79	-0.45	2.14e-13	Mean corpuscular volume;
SARC	cis	rs6835098	1.000	rs6826412	chr4:174109622	C/T	cg08422745	chr4:174089978	GALNT7	-0.73	-9.31	-0.52	9.57e-18	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs4820539	1.000	rs916585	chr22:23469438	G/A	cg14186256	chr22:23484241	RTDR1	0.9	14.69	0.69	4.95e-35	Bone mineral density;
SARC	cis	rs10504073	0.647	rs10504072	chr8:49993083	G/A	cg00325661	chr8:49890786	NA	0.54	7.22	0.43	7.43e-12	Blood metabolite ratios;
SARC	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg24829409	chr8:58192753	C8orf71	-0.56	-6.16	-0.37	3.12e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg04944784	chr2:26401820	FAM59B	-0.41	-5.52	-0.34	9.19e-8	Gut microbiome composition (summer);
SARC	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg01448562	chr3:133502909	NA	-0.45	-6.65	-0.4	2.08e-10	Iron status biomarkers;
SARC	cis	rs2227564	0.830	rs2675667	chr10:75683832	G/A	cg16540259	chr10:75572220	NDST2	0.35	4.74	0.3	3.71e-6	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs2236918	1.000	rs1635515	chr1:242017009	A/G	cg17736920	chr1:242011382	EXO1	0.78	11.12	0.59	2.59e-23	Menopause (age at onset);
SARC	cis	rs7552404	0.924	rs3818855	chr1:76198785	C/T	cg03433033	chr1:76189801	ACADM	0.51	7.58	0.44	8.36e-13	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9399137	0.507	rs4580893	chr6:135297662	G/A	cg22676075	chr6:135203613	NA	0.38	4.83	0.3	2.5e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg24503407	chr1:205819492	PM20D1	-0.41	-4.76	-0.3	3.37e-6	Parkinson's disease;
SARC	cis	rs6867032	0.958	rs4975797	chr5:2015573	G/A	cg26168224	chr5:2018326	NA	0.92	14.86	0.7	1.4e-35	Gut microbiome composition (winter);
SARC	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg10207240	chr12:122356781	WDR66	0.29	5.03	0.31	9.79e-7	Mean corpuscular volume;
SARC	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg01475735	chr3:40494733	NA	-0.46	-5.15	-0.32	5.56e-7	Renal cell carcinoma;
SARC	cis	rs7220711	0.967	rs2342315	chr17:41786382	T/C	cg26893861	chr17:41843967	DUSP3	0.4	5.07	0.32	8.08e-7	Bone mineral density (spine);Bone mineral density (hip);
SARC	cis	rs6121246	0.529	rs6060296	chr20:30198480	T/C	cg21427119	chr20:30132790	HM13	-0.45	-4.98	-0.31	1.23e-6	Mean corpuscular hemoglobin;
SARC	cis	rs4727027	0.899	rs7791496	chr7:148863674	C/G	cg23583168	chr7:148888333	NA	-0.74	-11.07	-0.59	3.61e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs875971	0.545	rs73148639	chr7:65855329	A/T	cg11764359	chr7:65958608	NA	0.68	6.86	0.41	6.19e-11	Aortic root size;
SARC	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.98	10.58	0.57	1.26e-21	Platelet count;
SARC	cis	rs2238126	0.941	rs1894307	chr12:12005720	C/T	cg00261552	chr12:12764894	CREBL2	0.54	5.0	0.31	1.15e-6	Colorectal cancer;
SARC	cis	rs8177253	0.530	rs8177177	chr3:133463195	A/G	cg16414030	chr3:133502952	NA	-0.36	-4.89	-0.3	1.91e-6	Iron status biomarkers;
SARC	cis	rs9329221	0.905	rs4610752	chr8:10248962	A/G	cg21775007	chr8:11205619	TDH	-0.4	-4.89	-0.31	1.88e-6	Neuroticism;
SARC	cis	rs12421382	0.778	rs12804063	chr11:109495509	C/T	cg27471124	chr11:109292789	C11orf87	-0.5	-6.48	-0.39	5.37e-10	Schizophrenia;
SARC	cis	rs2120243	0.533	rs1392798	chr3:157056287	A/G	cg24825693	chr3:157122686	VEPH1	0.42	5.88	0.36	1.39e-8	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs28669119	0.749	rs244750	chr5:88147192	T/C	cg18498987	chr5:88179539	MEF2C	0.56	5.19	0.32	4.63e-7	Schizophrenia;
SARC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.42	-6.42	-0.39	7.6e-10	Total body bone mineral density;
SARC	cis	rs9436747	0.714	rs1186403	chr1:66000533	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.52	-5.72	-0.35	3.23e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg07777115	chr5:623756	CEP72	-0.55	-4.75	-0.3	3.5e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs7086627	0.515	rs10887899	chr10:82210214	G/A	cg01528321	chr10:82214614	TSPAN14	0.57	8.21	0.47	1.55e-14	Post bronchodilator FEV1;
SARC	cis	rs28829049	0.597	rs2313509	chr1:19437860	C/T	cg13387374	chr1:19411106	UBR4	0.45	5.3	0.33	2.64e-7	QRS duration in Tripanosoma cruzi seropositivity;
SARC	cis	rs951366	0.531	rs12030754	chr1:205678043	G/C	cg14893161	chr1:205819251	PM20D1	-0.45	-4.98	-0.31	1.23e-6	Menarche (age at onset);
SARC	cis	rs4073582	0.595	rs801734	chr11:65931216	T/C	cg14036092	chr11:66035641	RAB1B	0.6	8.44	0.48	3.49e-15	Gout;
SARC	cis	rs7666738	0.830	rs1426669	chr4:98945534	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.44	-5.14	-0.32	5.82e-7	Renal function-related traits (BUN);
SARC	cis	rs6570726	0.935	rs425717	chr6:145838620	A/T	cg05347473	chr6:146136440	FBXO30	0.48	6.42	0.39	7.51e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg08280861	chr8:58055591	NA	0.57	5.1	0.32	6.94e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg24675658	chr1:53192096	ZYG11B	-0.62	-8.4	-0.48	4.27e-15	Monocyte count;
SARC	cis	rs11098499	0.675	rs11098534	chr4:120556772	T/G	cg09307838	chr4:120376055	NA	0.77	10.4	0.56	4.59e-21	Corneal astigmatism;
SARC	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6570726	0.935	rs442254	chr6:145849118	T/C	cg05220968	chr6:146057943	EPM2A	-0.29	-5.04	-0.31	9.48e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2832077	0.527	rs2738953	chr21:30238363	G/C	cg03476357	chr21:30257390	N6AMT1	0.65	7.35	0.43	3.38e-12	Cognitive test performance;
SARC	cis	rs60871478	0.898	rs4720929	chr7:808009	T/C	cg05535760	chr7:792225	HEATR2	0.78	8.06	0.47	3.86e-14	Cerebrospinal P-tau181p levels;
SARC	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg27266027	chr21:40555129	PSMG1	-0.52	-5.71	-0.35	3.39e-8	Cognitive function;
SARC	cis	rs2408955	0.522	rs973398	chr12:48491048	A/G	cg24011408	chr12:48396354	COL2A1	-0.41	-5.02	-0.31	1.04e-6	Glycated hemoglobin levels;
SARC	cis	rs10463554	0.927	rs257316	chr5:102422443	A/G	cg23492399	chr5:102201601	PAM	0.52	5.82	0.36	1.96e-8	Parkinson's disease;
SARC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.44	0.53	4.08e-18	Prudent dietary pattern;
SARC	cis	rs2908197	0.737	rs2109857	chr7:75963169	T/C	cg07849177	chr7:76178544	LOC100133091	-0.43	-4.92	-0.31	1.66e-6	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs6570726	0.935	rs449377	chr6:145852437	C/G	cg23711669	chr6:146136114	FBXO30	0.79	12.24	0.63	6.3e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg07777115	chr5:623756	CEP72	-0.67	-6.08	-0.37	4.88e-9	Obesity-related traits;
SARC	cis	rs9818758	0.607	rs9837625	chr3:49215966	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.74	-6.42	-0.39	7.64e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs7246657	0.943	rs8111782	chr19:37867904	A/G	cg23950597	chr19:37808831	NA	-0.62	-6.05	-0.37	5.66e-9	Coronary artery calcification;
SARC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg06873352	chr17:61820015	STRADA	0.54	6.99	0.42	2.8e-11	Prudent dietary pattern;
SARC	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.92	9.71	0.54	6.22e-19	Platelet count;
SARC	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.44	-5.76	-0.35	2.62e-8	Gut microbiome composition (summer);
SARC	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg22800045	chr5:56110881	MAP3K1	0.74	7.82	0.46	1.86e-13	Initial pursuit acceleration;
SARC	cis	rs2061333	0.557	rs28539456	chr19:44607547	G/T	cg18700516	chr19:44507157	ZNF230	-0.56	-5.28	-0.33	3.01e-7	Alzheimer's disease;
SARC	cis	rs4243830	0.737	rs11122085	chr1:6597861	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	1.04	10.25	0.56	1.37e-20	Body mass index;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg25192619	chr6:37467404	C6orf129	0.48	6.24	0.38	2.04e-9	Chemerin levels;
SARC	cis	rs36051895	0.554	rs7856773	chr9:5204705	T/C	cg02405213	chr9:5042618	JAK2	-0.43	-4.84	-0.3	2.37e-6	Pediatric autoimmune diseases;
SARC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg27588902	chr6:42928151	GNMT	-0.38	-5.67	-0.35	4.2e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs854765	0.583	rs9635697	chr17:17870394	T/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	9.72	0.54	5.87e-19	Total body bone mineral density;
SARC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg11494091	chr17:61959527	GH2	0.53	7.83	0.46	1.75e-13	Prudent dietary pattern;
SARC	cis	rs865483	0.860	rs853220	chr17:35787666	C/T	cg06561646	chr17:35873369	DUSP14	-0.48	-6.22	-0.38	2.24e-9	Monocyte count;
SARC	cis	rs9818758	0.607	rs34823813	chr3:49749976	G/A	cg07636037	chr3:49044803	WDR6	-0.74	-6.37	-0.39	9.72e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg07636037	chr3:49044803	WDR6	0.99	17.47	0.75	3.09e-44	Parkinson's disease;
SARC	cis	rs2663905	1.000	rs2663905	chr15:81359137	G/A	cg09888468	chr15:81410853	NA	-0.38	-4.81	-0.3	2.76e-6	QT interval (drug interaction);
SARC	trans	rs17685	0.753	rs4728550	chr7:75670988	C/A	cg19862616	chr7:65841803	NCRNA00174	-0.62	-7.88	-0.46	1.22e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs10046574	0.561	rs9656457	chr7:135202254	T/A	cg27474649	chr7:135195673	CNOT4	0.84	7.94	0.46	8.38e-14	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs10861342	1.000	rs1345095	chr12:105471577	C/T	cg23923672	chr12:105501055	KIAA1033	0.71	5.16	0.32	5.37e-7	IgG glycosylation;
SARC	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg08048268	chr3:133502702	NA	-0.49	-6.49	-0.39	5.16e-10	Iron status biomarkers;
SARC	cis	rs3820928	0.874	rs12467261	chr2:227888838	T/C	cg05526886	chr2:227700861	RHBDD1	-0.49	-5.75	-0.35	2.85e-8	Pulmonary function;
SARC	cis	rs9612	1.000	rs9612	chr19:44235517	A/G	cg07522664	chr19:44259120	C19orf61	0.48	5.53	0.34	8.46e-8	Exhaled nitric oxide output;
SARC	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg20607798	chr8:58055168	NA	0.55	4.8	0.3	2.84e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg21144161	chr5:423903	AHRR	0.31	4.84	0.3	2.39e-6	Cystic fibrosis severity;
SARC	cis	rs1008375	1.000	rs4698648	chr4:17692715	C/G	cg02297831	chr4:17616191	MED28	0.39	4.86	0.3	2.14e-6	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs611744	0.967	rs650437	chr8:109210927	T/G	cg21045802	chr8:109455806	TTC35	0.45	5.32	0.33	2.41e-7	Dupuytren's disease;
SARC	cis	rs5753618	0.504	rs5753659	chr22:31893613	A/G	cg02404636	chr22:31891804	SFI1	0.52	5.61	0.34	5.86e-8	Colorectal cancer;
SARC	cis	rs6570726	0.902	rs9390326	chr6:145791222	A/G	cg23711669	chr6:146136114	FBXO30	-0.71	-10.61	-0.57	1.07e-21	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7481584	0.961	rs12797969	chr11:3019216	C/T	cg08508325	chr11:3079039	CARS	0.22	4.87	0.3	2.02e-6	Calcium levels;
SARC	trans	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg21659725	chr3:3221576	CRBN	-0.78	-11.73	-0.61	2.87e-25	Intelligence (multi-trait analysis);
SARC	cis	rs2430386	1.000	rs2430386	chr2:63178111	C/T	cg17519650	chr2:63277830	OTX1	0.47	6.33	0.38	1.28e-9	Prostate cancer;
SARC	cis	rs8072100	0.576	rs12948299	chr17:45403057	T/C	cg08085267	chr17:45401833	C17orf57	-0.6	-6.92	-0.41	4.27e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	trans	rs9951602	0.512	rs58352488	chr18:76651113	T/A	cg02800362	chr5:177631904	HNRNPAB	0.71	9.0	0.51	8.26e-17	Obesity-related traits;
SARC	cis	rs76419734	1.000	rs72673860	chr4:106762900	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.77	5.19	0.32	4.53e-7	Post bronchodilator FEV1;
SARC	cis	rs4588572	0.643	rs7716529	chr5:77738637	A/T	cg11547950	chr5:77652471	NA	-0.41	-5.07	-0.32	8.22e-7	Triglycerides;
SARC	cis	rs72945132	0.714	rs115143889	chr11:70150122	G/T	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.59	-0.34	6.41e-8	Coronary artery disease;
SARC	cis	rs5015933	0.801	rs7848571	chr9:128141206	A/T	cg14078157	chr9:128172775	NA	-0.32	-4.77	-0.3	3.32e-6	Body mass index;
SARC	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg10883421	chr6:151773342	RMND1;C6orf211	-0.78	-11.61	-0.61	7.04e-25	Menarche (age at onset);
SARC	cis	rs10823500	0.777	rs10762348	chr10:71952322	C/A	cg04118878	chr10:71993077	PPA1	0.55	6.1	0.37	4.38e-9	Blood protein levels;
SARC	cis	rs7246657	0.943	rs3745765	chr19:37854235	G/T	cg23950597	chr19:37808831	NA	-0.54	-5.47	-0.34	1.15e-7	Coronary artery calcification;
SARC	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg23758822	chr17:41437982	NA	0.89	11.4	0.6	3.2e-24	Menopause (age at onset);
SARC	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg22903471	chr2:27725779	GCKR	-0.46	-6.83	-0.41	7.4e-11	Total body bone mineral density;
SARC	cis	rs2916247	0.954	rs1160821	chr8:93105771	C/G	cg10183463	chr8:93005414	RUNX1T1	-0.63	-6.93	-0.41	3.98e-11	Intelligence (multi-trait analysis);
SARC	cis	rs898097	0.841	rs2271918	chr17:80861206	A/G	cg15369054	chr17:80825471	TBCD	0.52	6.82	0.41	7.64e-11	Breast cancer;
SARC	cis	rs11122272	0.735	rs2486733	chr1:231531465	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.08	-0.55	4.68e-20	Hemoglobin concentration;
SARC	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg00933542	chr6:150070202	PCMT1	-0.31	-5.26	-0.33	3.24e-7	Lung cancer;
SARC	cis	rs2997447	0.739	rs72884784	chr1:26432246	G/A	cg19633962	chr1:26362018	EXTL1	-0.57	-5.05	-0.31	8.95e-7	QRS complex (12-leadsum);
SARC	cis	rs7769051	0.614	rs76404165	chr6:133235936	T/G	cg07930552	chr6:133119739	C6orf192	0.88	5.23	0.32	3.73e-7	Type 2 diabetes nephropathy;
SARC	cis	rs13314892	0.764	rs59487570	chr3:69860905	T/G	cg17445875	chr3:69859618	MITF	-0.48	-4.98	-0.31	1.23e-6	QRS complex (12-leadsum);
SARC	cis	rs920590	0.721	rs61180388	chr8:19670214	G/C	cg01411142	chr8:19674711	INTS10	0.52	5.97	0.36	8.87e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs8031584	0.918	rs1425292	chr15:31285422	G/A	cg14829155	chr15:31115871	NA	-0.4	-4.84	-0.3	2.34e-6	Huntington's disease progression;
SARC	cis	rs7712401	0.601	rs246269	chr5:122256741	T/C	cg19412675	chr5:122181750	SNX24	0.4	5.1	0.32	6.88e-7	Mean platelet volume;
SARC	cis	rs920590	0.643	rs2083641	chr8:19660217	A/C	cg17834443	chr8:19674713	INTS10	0.49	6.05	0.37	5.74e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-9.61	-0.53	1.21e-18	Chronic sinus infection;
SARC	cis	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg07777115	chr5:623756	CEP72	-0.56	-4.9	-0.31	1.77e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg24110177	chr3:50126178	RBM5	-0.55	-7.28	-0.43	5.15e-12	Intelligence (multi-trait analysis);
SARC	cis	rs796364	0.901	rs13030683	chr2:201061535	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.49	4.9	0.31	1.77e-6	Schizophrenia;
SARC	cis	rs7582720	1.000	rs72934765	chr2:203758551	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.32	0.43	4.07e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs9682041	0.935	rs11923053	chr3:170095281	T/C	cg11886554	chr3:170076028	SKIL	1.03	8.2	0.47	1.65e-14	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs9388451	0.839	rs9321054	chr6:126079968	A/G	cg06289844	chr6:126071538	HEY2	-0.35	-5.71	-0.35	3.35e-8	Brugada syndrome;
SARC	cis	rs2061333	1.000	rs4508518	chr19:44611420	A/G	cg18700516	chr19:44507157	ZNF230	-0.52	-5.08	-0.32	7.7e-7	Alzheimer's disease;
SARC	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg18876405	chr7:65276391	NA	0.7	8.68	0.49	6.76e-16	Aortic root size;
SARC	cis	rs6912958	0.525	rs586771	chr6:88064971	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.78	12.24	0.63	6.5e-27	Monocyte percentage of white cells;
SARC	cis	rs7945705	0.902	rs7930026	chr11:9013639	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.44	6.08	0.37	4.77e-9	Hemoglobin concentration;
SARC	cis	rs1044826	1.000	rs973691	chr3:139197858	G/C	cg15131784	chr3:139108705	COPB2	0.45	5.19	0.32	4.69e-7	Obesity-related traits;
SARC	cis	rs4595586	0.545	rs12828866	chr12:39391925	C/A	cg26384229	chr12:38710491	ALG10B	0.5	6.12	0.37	3.98e-9	Morning vs. evening chronotype;
SARC	cis	rs11690935	0.959	rs10803863	chr2:172535337	T/C	cg13550731	chr2:172543902	DYNC1I2	0.99	15.2	0.71	1.05e-36	Schizophrenia;
SARC	trans	rs208520	1.000	rs208536	chr6:66963440	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.82	-8.94	-0.51	1.2e-16	Exhaled nitric oxide output;
SARC	cis	rs11711311	1.000	rs9811353	chr3:113483979	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	8.71	0.5	5.64e-16	IgG glycosylation;
SARC	cis	rs2276314	0.857	rs28431958	chr18:33578401	T/G	cg19628046	chr18:33552617	C18orf21	0.6	6.0	0.37	7.31e-9	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg24209194	chr3:40518798	ZNF619	0.58	7.1	0.42	1.52e-11	Renal cell carcinoma;
SARC	cis	rs6546550	0.933	rs6546554	chr2:70135706	G/A	cg02498382	chr2:70120550	SNRNP27	-0.32	-5.13	-0.32	6.02e-7	Prevalent atrial fibrillation;
SARC	cis	rs131777	0.575	rs131760	chr22:51011936	T/C	cg25309564	chr22:51001381	C22orf41	0.53	6.62	0.4	2.5e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs9322817	0.691	rs4591886	chr6:105249970	G/C	cg02098413	chr6:105308735	HACE1	-0.38	-5.91	-0.36	1.18e-8	Thyroid stimulating hormone;
SARC	cis	rs11585357	0.793	rs11588418	chr1:17616445	A/G	cg08277548	chr1:17600880	PADI3	-0.46	-5.18	-0.32	4.9e-7	Hair shape;
SARC	cis	rs2204008	0.837	rs34381557	chr12:38181983	T/C	cg26384229	chr12:38710491	ALG10B	0.88	12.94	0.65	3.26e-29	Bladder cancer;
SARC	cis	rs9303401	0.614	rs34920953	chr17:56589406	G/A	cg25039879	chr17:56429692	SUPT4H1	0.64	5.96	0.36	9.19e-9	Cognitive test performance;
SARC	cis	rs9916302	0.904	rs7501488	chr17:37576417	T/G	cg20243544	chr17:37824526	PNMT	0.56	6.64	0.4	2.19e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs1865760	0.566	rs9379825	chr6:26083871	C/A	cg10373733	chr6:25993375	NA	0.45	5.43	0.34	1.4e-7	Height;
SARC	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg27286337	chr10:134555280	INPP5A	0.69	8.16	0.47	2.04e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg22105103	chr4:187893119	NA	0.5	6.77	0.41	1.05e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6840360	0.571	rs4696102	chr4:152529658	C/T	cg22705602	chr4:152727874	NA	-0.44	-6.8	-0.41	8.48e-11	Intelligence (multi-trait analysis);
SARC	cis	rs9341808	0.718	rs7740627	chr6:80916347	A/G	cg08355045	chr6:80787529	NA	0.33	5.32	0.33	2.48e-7	Sitting height ratio;
SARC	trans	rs877282	0.898	rs12356709	chr10:763365	A/G	cg22713356	chr15:30763199	NA	1.03	9.99	0.55	8.97e-20	Uric acid levels;
SARC	cis	rs7944584	0.588	rs2697923	chr11:47363215	G/T	cg20307385	chr11:47447363	PSMC3	-0.61	-7.96	-0.46	7.56e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs10504073	0.669	rs4493917	chr8:50015846	C/T	cg00325661	chr8:49890786	NA	0.54	7.39	0.44	2.67e-12	Blood metabolite ratios;
SARC	cis	rs2153535	0.580	rs9393021	chr6:8466123	A/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs6426558	0.537	rs6692080	chr1:227390162	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.43	-4.99	-0.31	1.17e-6	Neutrophil percentage of white cells;
SARC	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg26681399	chr22:41777847	TEF	0.48	5.33	0.33	2.31e-7	Vitiligo;
SARC	cis	rs17253792	0.822	rs10137340	chr14:56050989	A/G	cg01858014	chr14:56050164	KTN1	-0.71	-5.52	-0.34	8.83e-8	Putamen volume;
SARC	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	9.33	0.52	8.88e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs3087591	0.960	rs8067021	chr17:29555078	T/A	cg24425628	chr17:29625626	OMG;NF1	-0.48	-5.84	-0.36	1.75e-8	Hip circumference;
SARC	cis	rs365132	1.000	rs35977534	chr5:176335231	T/C	cg16309518	chr5:176445507	NA	-0.45	-5.97	-0.36	8.59e-9	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs9911578	1.000	rs12449365	chr17:56600660	C/G	cg12560992	chr17:57184187	TRIM37	-0.81	-10.81	-0.58	2.5e-22	Intelligence (multi-trait analysis);
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg02707280	chr19:44617674	ZNF225	0.5	6.33	0.38	1.22e-9	Electrocardiographic conduction measures;
SARC	cis	rs7582180	0.629	rs4851295	chr2:100945605	T/C	cg14675211	chr2:100938903	LONRF2	0.51	7.63	0.45	6.1e-13	Intelligence (multi-trait analysis);
SARC	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg09359103	chr1:154839909	KCNN3	-0.46	-7.8	-0.46	2e-13	Prostate cancer;
SARC	cis	rs13401104	0.796	rs72620807	chr2:237114205	T/G	cg19324714	chr2:237145437	ASB18	0.57	5.91	0.36	1.22e-8	Educational attainment;
SARC	cis	rs2011503	1.000	rs1989867	chr19:19447470	A/G	cg03709012	chr19:19516395	GATAD2A	-0.64	-5.71	-0.35	3.37e-8	Bipolar disorder;
SARC	trans	rs1814175	0.645	rs1851850	chr11:50012168	G/A	cg15704280	chr7:45808275	SEPT13	-0.91	-14.68	-0.69	5.63e-35	Height;
SARC	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg17376030	chr22:41985996	PMM1	-0.64	-8.25	-0.48	1.19e-14	Vitiligo;
SARC	cis	rs4595586	0.545	rs7308161	chr12:39363459	A/G	cg26384229	chr12:38710491	ALG10B	0.5	6.18	0.38	2.83e-9	Morning vs. evening chronotype;
SARC	cis	rs4794202	0.618	rs4794224	chr17:45957463	C/T	cg23391107	chr17:45924227	SP6	-0.47	-5.14	-0.32	5.83e-7	Alzheimer's disease (cognitive decline);
SARC	cis	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg02487422	chr3:49467188	NICN1	0.51	6.83	0.41	7.34e-11	Resting heart rate;
SARC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg04066115	chr4:140374523	RAB33B	0.58	6.56	0.39	3.54e-10	Myopia (pathological);
SARC	cis	rs2115630	0.754	rs12595321	chr15:85331269	G/A	cg12501888	chr15:85177176	SCAND2	-0.43	-5.04	-0.31	9.19e-7	P wave terminal force;
SARC	cis	rs11574514	1.000	rs1073632	chr16:68248607	G/A	cg01866162	chr16:67596514	CTCF	1.12	6.54	0.39	3.87e-10	Crohn's disease;
SARC	cis	rs3106136	0.901	rs17376488	chr4:95226548	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.89	-0.36	1.35e-8	Capecitabine sensitivity;
SARC	cis	rs7223966	0.655	rs7209961	chr17:61633705	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	5.23	0.32	3.86e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9810259	0.614	rs17793951	chr3:12370737	A/G	cg04748988	chr3:12329223	PPARG	-0.41	-5.1	-0.32	7.11e-7	Platelet count;
SARC	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg24642844	chr7:1081250	C7orf50	-0.39	-5.14	-0.32	5.72e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs2732480	0.500	rs11168464	chr12:48602115	C/T	cg24011408	chr12:48396354	COL2A1	0.47	5.42	0.33	1.52e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs514024	0.729	rs557630	chr9:130491998	C/T	cg13643465	chr9:130375613	STXBP1	-0.46	-5.64	-0.35	5.01e-8	Eating disorders (purging via substances);
SARC	cis	rs12303914	0.802	rs1600126	chr12:10470029	T/G	cg16417563	chr12:10365564	GABARAPL1	0.39	4.73	0.3	3.97e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg07234876	chr8:600039	NA	0.75	6.36	0.38	1.06e-9	IgG glycosylation;
SARC	cis	rs55823223	0.702	rs3785437	chr17:73906222	G/T	cg02397686	chr17:73851076	WBP2	0.59	4.95	0.31	1.4e-6	Psoriasis;
SARC	cis	rs9420	0.961	rs11606396	chr11:57435211	C/T	cg19752551	chr11:57585705	CTNND1	-0.5	-6.77	-0.41	1.02e-10	Schizophrenia;
SARC	cis	rs910316	1.000	rs12889472	chr14:75543979	A/G	cg06637938	chr14:75390232	RPS6KL1	0.52	7.32	0.43	4.06e-12	Height;
SARC	cis	rs9894429	0.608	rs7406219	chr17:79609410	G/T	cg18240062	chr17:79603768	NPLOC4	0.59	7.14	0.42	1.19e-11	Eye color traits;
SARC	cis	rs858239	0.699	rs1881201	chr7:23194013	C/T	cg23682824	chr7:23144976	KLHL7	-0.59	-7.3	-0.43	4.61e-12	Cerebrospinal fluid biomarker levels;
SARC	cis	rs4924590	0.550	rs1426889	chr15:42231658	C/T	cg20935245	chr15:42234343	EHD4	-0.47	-6.02	-0.37	6.79e-9	Lymphocyte percentage of white cells;Sum basophil neutrophil counts;Granulocyte count;
SARC	cis	rs838147	0.844	rs8111399	chr19:49247963	G/T	cg13540341	chr19:49222985	MAMSTR	0.28	4.73	0.3	3.83e-6	Dietary macronutrient intake;
SARC	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg02863842	chr19:45349685	PVRL2	-0.47	-6.5	-0.39	4.9e-10	Thyroid cancer;
SARC	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg06108461	chr20:60628389	TAF4	-0.89	-11.84	-0.61	1.21e-25	Body mass index;
SARC	cis	rs11602339	1	rs11602339	chr11:47761471	C/T	cg20307385	chr11:47447363	PSMC3	-0.47	-5.61	-0.35	5.63e-8	Body mass index;
SARC	cis	rs7264396	0.623	rs6060507	chr20:34198334	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	5.39	0.33	1.76e-7	Total cholesterol levels;
SARC	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg12064134	chr16:90016061	DEF8	-0.57	-4.78	-0.3	3.14e-6	Skin colour saturation;
SARC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg13397359	chr6:42928475	GNMT	0.64	9.06	0.51	5.6e-17	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg00409905	chr10:38381863	ZNF37A	0.52	7.36	0.43	3.09e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs9902453	0.542	rs3809789	chr17:27955761	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.45	5.45	0.34	1.28e-7	Coffee consumption (cups per day);
SARC	cis	rs12908161	0.959	rs34028043	chr15:85231585	G/A	cg17507749	chr15:85114479	UBE2QP1	0.58	6.68	0.4	1.77e-10	Schizophrenia;
SARC	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg12463550	chr7:65579703	CRCP	0.51	5.79	0.35	2.3e-8	Aortic root size;
SARC	cis	rs2235544	0.565	rs620907	chr1:54468166	T/G	cg10336722	chr1:54665764	CYB5RL;MRPL37	-0.38	-4.74	-0.3	3.66e-6	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
SARC	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg17376030	chr22:41985996	PMM1	-0.71	-8.94	-0.51	1.26e-16	Vitiligo;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24007300	chr15:42264860	EHD4	-0.55	-6.83	-0.41	7.26e-11	Smoking initiation;
SARC	cis	rs10411936	0.720	rs4808513	chr19:16580498	G/C	cg10248733	chr19:16607483	C19orf44;CALR3	0.58	7.03	0.42	2.32e-11	White blood cell count;Multiple sclerosis;
SARC	cis	rs1865760	0.865	rs10946800	chr6:25957773	C/T	cg18357526	chr6:26021779	HIST1H4A	0.4	4.92	0.31	1.62e-6	Height;
SARC	cis	rs5758659	0.714	rs2284087	chr22:42485671	T/C	cg15128208	chr22:42549153	NA	0.36	5.19	0.32	4.66e-7	Cognitive function;
SARC	cis	rs9875589	0.509	rs6768383	chr3:14076952	G/A	cg19554555	chr3:13937349	NA	-0.38	-4.87	-0.3	2.08e-6	Ovarian reserve;
SARC	cis	rs3785574	0.705	rs2665856	chr17:61982721	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	-1.02	-14.22	-0.68	1.93e-33	Height;
SARC	trans	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg21659725	chr3:3221576	CRBN	-0.79	-11.89	-0.61	8.28e-26	Intelligence (multi-trait analysis);
SARC	cis	rs2228479	0.850	rs11639788	chr16:89807543	G/A	cg00800038	chr16:89945340	TCF25	-0.74	-5.08	-0.32	7.86e-7	Skin colour saturation;
SARC	cis	rs6424115	0.965	rs2502986	chr1:24135292	G/T	cg15997130	chr1:24165203	NA	0.48	6.64	0.4	2.2e-10	Immature fraction of reticulocytes;
SARC	cis	rs208520	0.690	rs176289	chr6:66766522	C/T	cg07460842	chr6:66804631	NA	-1.08	-14.49	-0.69	2.31e-34	Exhaled nitric oxide output;
SARC	cis	rs2952156	0.684	rs881844	chr17:37810218	C/G	cg00129232	chr17:37814104	STARD3	-0.79	-11.56	-0.6	1.03e-24	Asthma;
SARC	cis	rs3784262	0.934	rs4646611	chr15:58265083	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.39	-5.96	-0.36	9.48e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs9815354	1.000	rs73081353	chr3:41906448	T/A	cg03022575	chr3:42003672	ULK4	0.67	5.73	0.35	3.13e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg13397359	chr6:42928475	GNMT	0.6	8.16	0.47	2.12e-14	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg18252515	chr7:66147081	NA	-0.62	-6.59	-0.4	2.98e-10	Aortic root size;
SARC	cis	rs651907	0.535	rs12631513	chr3:101517476	A/C	cg12386194	chr3:101231763	SENP7	0.47	5.38	0.33	1.77e-7	Colorectal cancer;
SARC	cis	rs7512552	0.839	rs11577600	chr1:150407443	G/A	cg15654264	chr1:150340011	RPRD2	0.39	5.09	0.32	7.25e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs7568458	0.636	rs11126995	chr2:85792408	A/T	cg02493740	chr2:85810744	VAMP5	-0.42	-5.32	-0.33	2.47e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs2354432	0.607	rs4950310	chr1:146659964	A/G	cg25205988	chr1:146714368	CHD1L	0.98	7.29	0.43	4.79e-12	Mitochondrial DNA levels;
SARC	cis	rs12044355	0.827	rs16854783	chr1:231827371	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-7.64	-0.45	5.51e-13	Alzheimer's disease;
SARC	cis	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg09783858	chr11:65769428	EIF1AD;BANF1	0.44	5.53	0.34	8.4e-8	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs4253772	0.530	rs9615989	chr22:46803774	A/T	cg18190219	chr22:46762943	CELSR1	-0.69	-5.53	-0.34	8.44e-8	LDL cholesterol;Cholesterol, total;
SARC	cis	rs2115630	0.967	rs28595395	chr15:85334952	T/C	cg12501888	chr15:85177176	SCAND2	-0.48	-5.79	-0.35	2.21e-8	P wave terminal force;
SARC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg08719467	chr1:146714230	CHD1L	0.47	6.45	0.39	6.3e-10	Colonoscopy-negative controls vs population controls;
SARC	cis	rs35110281	0.666	rs2236665	chr21:45108987	C/A	cg01579765	chr21:45077557	HSF2BP	-0.38	-6.03	-0.37	6.45e-9	Mean corpuscular volume;
SARC	cis	rs3771570	1.000	rs60209440	chr2:242260340	G/C	cg21155796	chr2:242212141	HDLBP	0.68	5.89	0.36	1.31e-8	Prostate cancer;
SARC	cis	rs6912958	0.512	rs910563	chr6:88058885	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.75	11.82	0.61	1.41e-25	Monocyte percentage of white cells;
SARC	cis	rs1046896	1.000	rs1046896	chr17:80685533	A/G	cg02711726	chr17:80685570	FN3KRP	0.67	8.38	0.48	5.06e-15	Glycated hemoglobin levels;
SARC	cis	rs854765	0.547	rs8069811	chr17:17922280	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.64	9.45	0.53	3.79e-18	Total body bone mineral density;
SARC	cis	rs9359856	0.564	rs72915904	chr6:90421412	C/A	cg13799429	chr6:90582589	CASP8AP2	-0.58	-4.73	-0.3	3.81e-6	Bipolar disorder;
SARC	cis	rs4481887	1.000	rs4306162	chr1:248468509	C/T	cg01631408	chr1:248437212	OR2T33	-0.42	-5.3	-0.33	2.68e-7	Common traits (Other);
SARC	cis	rs2898681	0.580	rs41279517	chr4:53729771	T/C	cg00338735	chr4:53728038	RASL11B	0.49	5.01	0.31	1.08e-6	Optic nerve measurement (cup area);
SARC	trans	rs61931739	0.500	rs10844846	chr12:34394611	C/G	cg26384229	chr12:38710491	ALG10B	0.84	12.77	0.64	1.2e-28	Morning vs. evening chronotype;
SARC	cis	rs17039065	0.920	rs12508024	chr4:109413413	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	-0.64	-5.18	-0.32	4.9e-7	Gut microbiome composition (summer);
SARC	cis	rs986417	0.892	rs74060153	chr14:60794488	T/A	cg27398547	chr14:60952738	C14orf39	-1.06	-8.79	-0.5	3.34e-16	Gut microbiota (bacterial taxa);
SARC	trans	rs7937682	0.824	rs510866	chr11:111484113	A/C	cg18187862	chr3:45730750	SACM1L	0.55	6.98	0.42	3.04e-11	Primary sclerosing cholangitis;
SARC	cis	rs7592578	0.679	rs4287794	chr2:191327147	T/C	cg25963032	chr2:191064776	C2orf88	-0.45	-5.02	-0.31	1.01e-6	Diastolic blood pressure;
SARC	trans	rs9395865	0.520	rs6903708	chr6:53332940	A/G	cg24045482	chr1:876993	SAMD11	-0.51	-6.58	-0.4	3.07e-10	Electroencephalographic traits in alcoholism;
SARC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg23034840	chr1:205782522	SLC41A1	0.61	7.95	0.46	8.15e-14	Menarche (age at onset);
SARC	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg04267008	chr7:1944627	MAD1L1	-0.49	-5.6	-0.34	5.94e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs12142240	0.698	rs4372193	chr1:46853233	G/T	cg10495392	chr1:46806563	NSUN4	0.65	6.88	0.41	5.6e-11	Menopause (age at onset);
SARC	cis	rs34172651	0.917	rs11642302	chr16:24770856	G/A	cg00152838	chr16:24741724	TNRC6A	-0.43	-5.36	-0.33	2.02e-7	Intelligence (multi-trait analysis);
SARC	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-4.79	-0.3	3.03e-6	Total body bone mineral density;
SARC	trans	rs66573146	0.572	rs66611116	chr4:6953270	A/G	cg07817883	chr1:32538562	TMEM39B	1.07	8.38	0.48	5.02e-15	Granulocyte percentage of myeloid white cells;
SARC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg11494091	chr17:61959527	GH2	-0.49	-7.09	-0.42	1.56e-11	Prudent dietary pattern;
SARC	cis	rs10465746	0.935	rs11807807	chr1:84424071	C/T	cg10977910	chr1:84465055	TTLL7	0.38	4.73	0.3	3.84e-6	Obesity-related traits;
SARC	cis	rs2370759	1.000	rs79578760	chr10:32611264	C/A	cg18270830	chr10:32634957	EPC1	0.7	6.34	0.38	1.17e-9	Sexual dysfunction (female);
SARC	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg04944784	chr2:26401820	FAM59B	-0.48	-5.99	-0.37	7.95e-9	Gut microbiome composition (summer);
SARC	cis	rs1348850	0.914	rs4893938	chr2:178250095	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.67	8.56	0.49	1.54e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9393777	0.623	rs7756567	chr6:26481642	T/G	cg12826209	chr6:26865740	GUSBL1	0.81	7.39	0.44	2.59e-12	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7089973	0.604	rs765173	chr10:116601675	C/T	cg03647239	chr10:116582469	FAM160B1	0.55	7.31	0.43	4.15e-12	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs7043114	0.525	rs1053441	chr9:95147840	T/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.49	-0.34	1.03e-7	Height;
SARC	cis	rs796364	0.760	rs1569178	chr2:201024512	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.6	-4.91	-0.31	1.71e-6	Schizophrenia;
SARC	cis	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg20965017	chr5:231967	SDHA	-0.52	-4.84	-0.3	2.37e-6	Breast cancer;
SARC	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg11764359	chr7:65958608	NA	-0.67	-7.97	-0.46	7.1e-14	Aortic root size;
SARC	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg08645402	chr16:4508243	NA	0.41	5.29	0.33	2.78e-7	Schizophrenia;
SARC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg07308232	chr7:1071921	C7orf50	-0.46	-5.69	-0.35	3.88e-8	Longevity;Endometriosis;
SARC	cis	rs2180341	0.855	rs4308584	chr6:127714874	A/G	cg27446573	chr6:127587934	RNF146	0.77	10.14	0.55	2.92e-20	Breast cancer;
SARC	cis	rs9397240	0.789	rs9383751	chr6:155615791	C/T	cg07943832	chr6:155568918	TIAM2	-0.58	-5.61	-0.34	5.72e-8	Life satisfaction;
SARC	cis	rs2153535	0.580	rs7743686	chr6:8526111	A/G	cg21535247	chr6:8435926	SLC35B3	0.51	6.48	0.39	5.5e-10	Motion sickness;
SARC	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg18876405	chr7:65276391	NA	-0.45	-5.06	-0.31	8.39e-7	Aortic root size;
SARC	cis	rs4481887	1.000	rs4244174	chr1:248467956	A/G	cg00666640	chr1:248458726	OR2T12	0.38	6.42	0.39	7.43e-10	Common traits (Other);
SARC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.5	-8.01	-0.46	5.59e-14	Longevity;Endometriosis;
SARC	cis	rs79057730	0.599	rs4721086	chr7:821123	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.66	5.14	0.32	5.77e-7	Initial pursuit acceleration;
SARC	cis	rs12142240	0.660	rs72886903	chr1:46813860	C/T	cg00530320	chr1:46809349	NSUN4	0.57	6.92	0.41	4.4e-11	Menopause (age at onset);
SARC	cis	rs17376456	0.569	rs7702348	chr5:93065683	A/G	cg25358565	chr5:93447407	FAM172A	-0.84	-9.18	-0.52	2.41e-17	Diabetic retinopathy;
SARC	cis	rs3796352	0.667	rs3755805	chr3:52866299	G/A	cg15956490	chr3:53032818	SFMBT1	0.85	5.53	0.34	8.75e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs858239	0.899	rs10085838	chr7:23298415	C/A	cg23682824	chr7:23144976	KLHL7	0.57	7.13	0.42	1.26e-11	Cerebrospinal fluid biomarker levels;
SARC	cis	rs10465746	0.780	rs1324486	chr1:84384825	A/G	cg10977910	chr1:84465055	TTLL7	-0.49	-6.01	-0.37	7.28e-9	Obesity-related traits;
SARC	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg20607798	chr8:58055168	NA	0.65	5.61	0.35	5.68e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg19223190	chr17:80058835	NA	0.44	6.19	0.38	2.67e-9	Life satisfaction;
SARC	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs13082711	0.522	rs480238	chr3:27347577	A/T	cg02860705	chr3:27208620	NA	0.45	5.93	0.36	1.1e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs4900538	0.855	rs1190537	chr14:102887816	C/T	cg18135206	chr14:102964638	TECPR2	-0.6	-7.7	-0.45	3.93e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg22834771	chr12:69754056	YEATS4	-0.45	-5.89	-0.36	1.33e-8	Blood protein levels;
SARC	cis	rs9463078	0.665	rs227849	chr6:44698708	C/T	cg25276700	chr6:44698697	NA	0.29	4.85	0.3	2.26e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
SARC	cis	rs754466	0.606	rs55854323	chr10:79589904	C/T	cg17075019	chr10:79541650	NA	-0.8	-12.42	-0.63	1.58e-27	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs870825	0.549	rs28542773	chr4:185617935	A/G	cg04058563	chr4:185651563	MLF1IP	0.82	11.42	0.6	2.8e-24	Blood protein levels;
SARC	cis	rs6429082	0.764	rs291369	chr1:235691913	T/C	cg26050004	chr1:235667680	B3GALNT2	0.68	8.04	0.47	4.42e-14	Adiposity;
SARC	cis	rs9768139	0.708	rs11771764	chr7:158119871	A/G	cg25566285	chr7:158114605	PTPRN2	0.31	5.12	0.32	6.49e-7	Calcium levels;
SARC	trans	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg17830980	chr10:43048298	ZNF37B	-0.51	-6.99	-0.42	2.83e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs995000	0.965	rs10889352	chr1:63099023	T/C	cg06896770	chr1:63153194	DOCK7	0.98	15.08	0.7	2.62e-36	Triglyceride levels;
SARC	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg23172400	chr8:95962367	TP53INP1	-0.31	-5.38	-0.33	1.8e-7	Type 2 diabetes;
SARC	cis	rs7824557	0.751	rs2099456	chr8:11127001	A/C	cg09130043	chr8:11561283	GATA4	-0.33	-4.82	-0.3	2.56e-6	Retinal vascular caliber;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg24035352	chr4:151937399	LRBA	0.63	6.48	0.39	5.51e-10	Lung cancer in ever smokers;
SARC	cis	rs8180040	0.966	rs12486969	chr3:47429003	G/C	cg27129171	chr3:47204927	SETD2	-0.68	-9.36	-0.52	7.02e-18	Colorectal cancer;
SARC	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg22535103	chr8:58192502	C8orf71	-0.8	-9.15	-0.51	2.94e-17	Developmental language disorder (linguistic errors);
SARC	cis	rs3892630	0.824	rs2287882	chr19:33332952	C/T	cg22980127	chr19:33182716	NUDT19	0.87	7.86	0.46	1.4e-13	Red blood cell traits;
SARC	cis	rs738322	0.726	rs5750561	chr22:38595260	A/T	cg25457927	chr22:38595422	NA	0.38	8.44	0.48	3.45e-15	Cutaneous nevi;
SARC	cis	rs10916814	0.610	rs10799641	chr1:20897250	G/A	cg24502330	chr1:20914028	CDA	-0.29	-5.1	-0.32	7.19e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg05863683	chr7:1912471	MAD1L1	0.36	5.52	0.34	8.93e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs896854	0.738	rs1713669	chr8:95958637	C/G	cg13393036	chr8:95962371	TP53INP1	-0.3	-4.94	-0.31	1.49e-6	Type 2 diabetes;
SARC	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg10523679	chr1:76189770	ACADM	0.53	6.81	0.41	8.11e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs793571	0.502	rs411007	chr15:59078502	G/C	cg05156742	chr15:59063176	FAM63B	0.81	12.66	0.64	2.71e-28	Schizophrenia;
SARC	cis	rs910316	1.000	rs8017642	chr14:75590822	G/A	cg08847533	chr14:75593920	NEK9	0.93	15.38	0.71	2.57e-37	Height;
SARC	cis	rs2933343	0.700	rs789240	chr3:128630635	T/C	cg24203234	chr3:128598194	ACAD9	0.63	8.01	0.46	5.49e-14	IgG glycosylation;
SARC	cis	rs77372450	0.636	rs73814834	chr5:157024459	A/G	cg23851860	chr5:157002805	ADAM19	0.49	4.75	0.3	3.58e-6	Bipolar disorder (body mass index interaction);
SARC	cis	rs763121	0.813	rs4821807	chr22:39065582	A/G	cg06022373	chr22:39101656	GTPBP1	0.84	10.33	0.56	7.63e-21	Menopause (age at onset);
SARC	cis	rs7216064	1.000	rs55939964	chr17:65869297	G/A	cg12091567	chr17:66097778	LOC651250	-0.64	-6.45	-0.39	6.56e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs9818758	0.607	rs80170003	chr3:48951640	T/C	cg00383909	chr3:49044727	WDR6	0.78	6.71	0.4	1.43e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs9902453	0.808	rs10445400	chr17:28183059	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	7.2	0.43	8.24e-12	Coffee consumption (cups per day);
SARC	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg18876405	chr7:65276391	NA	-0.45	-5.14	-0.32	5.94e-7	Aortic root size;
SARC	cis	rs1904096	0.506	rs10034781	chr4:95169682	A/C	cg11021082	chr4:95130006	SMARCAD1	0.48	7.03	0.42	2.24e-11	Type 2 diabetes;
SARC	trans	rs9929218	0.551	rs3785133	chr16:68728611	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.81	13.61	0.67	2.02e-31	Colorectal cancer;
SARC	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg11987759	chr7:65425863	GUSB	0.56	7.39	0.44	2.55e-12	Aortic root size;
SARC	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg18252515	chr7:66147081	NA	-1.29	-11.2	-0.59	1.41e-23	Diabetic kidney disease;
SARC	cis	rs7647973	1.000	rs2177268	chr3:49439725	A/T	cg06212747	chr3:49208901	KLHDC8B	-0.56	-5.75	-0.35	2.8e-8	Menarche (age at onset);
SARC	cis	rs13034020	0.522	rs4564760	chr2:61248575	T/C	cg18625361	chr2:61244694	PEX13;PUS10	0.67	5.94	0.36	1.04e-8	Hodgkin's lymphoma;
SARC	cis	rs4268898	0.662	rs72795832	chr2:24441855	C/A	cg26838691	chr2:24397539	C2orf84	-0.5	-5.74	-0.35	2.99e-8	Asthma;
SARC	cis	rs9381107	1.000	rs9349190	chr6:9462881	T/A	cg14735645	chr6:9486422	NA	-0.43	-4.74	-0.3	3.74e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg11987759	chr7:65425863	GUSB	-0.48	-6.54	-0.39	3.9e-10	Aortic root size;
SARC	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg03806693	chr22:41940476	POLR3H	-0.94	-12.91	-0.65	4.06e-29	Vitiligo;
SARC	cis	rs400736	0.930	rs2745722	chr1:8056669	G/A	cg25007680	chr1:8021821	PARK7	0.5	6.57	0.4	3.17e-10	Response to antidepressants and depression;
SARC	trans	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg21659725	chr3:3221576	CRBN	-0.51	-6.63	-0.4	2.31e-10	Intelligence (multi-trait analysis);
SARC	cis	rs4253772	0.638	rs6007845	chr22:46718417	A/T	cg24881330	chr22:46731750	TRMU	-0.79	-7.78	-0.45	2.3e-13	LDL cholesterol;Cholesterol, total;
SARC	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg24250549	chr1:154909240	PMVK	0.83	12.01	0.62	3.64e-26	Prostate cancer;
SARC	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg07701084	chr6:150067640	NUP43	0.38	5.13	0.32	6.14e-7	Lung cancer;
SARC	trans	rs561341	0.556	rs41290963	chr17:30396390	C/T	cg20587970	chr11:113659929	NA	-1.4	-11.71	-0.61	3.25e-25	Hip circumference adjusted for BMI;
SARC	cis	rs6700896	0.931	rs10789193	chr1:66129646	A/T	cg04111102	chr1:66153794	NA	0.36	5.66	0.35	4.49e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg15202954	chr13:102068996	NALCN	-0.47	-6.4	-0.39	8.65e-10	Chemerin levels;
SARC	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg19223190	chr17:80058835	NA	-0.4	-5.56	-0.34	7.43e-8	Life satisfaction;
SARC	cis	rs698813	0.604	rs7565928	chr2:44489956	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	6.16	0.37	3.21e-9	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs11630290	0.592	rs1912048	chr15:64155974	G/A	cg12036633	chr15:63758958	NA	0.47	4.93	0.31	1.54e-6	Iris characteristics;
SARC	cis	rs78545713	1.000	rs114970164	chr6:26241993	G/C	cg00631329	chr6:26305371	NA	-0.73	-6.4	-0.39	8.56e-10	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs826838	0.616	rs7977357	chr12:38626008	C/G	cg26384229	chr12:38710491	ALG10B	-0.59	-7.54	-0.44	1.04e-12	Heart rate;
SARC	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg24642844	chr7:1081250	C7orf50	-0.6	-6.12	-0.37	4.02e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs9840812	0.592	rs12489577	chr3:136213145	C/T	cg15507776	chr3:136538369	TMEM22	0.5	5.6	0.34	5.96e-8	Fibrinogen levels;
SARC	cis	rs9393692	0.846	rs7771202	chr6:26279907	A/G	cg13736514	chr6:26305472	NA	-0.61	-8.57	-0.49	1.42e-15	Educational attainment;
SARC	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg18357526	chr6:26021779	HIST1H4A	0.84	11.58	0.6	8.4e-25	Intelligence (multi-trait analysis);
SARC	cis	rs6912958	0.667	rs7746545	chr6:88090225	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	10.52	0.57	1.94e-21	Monocyte percentage of white cells;
SARC	trans	rs62103177	1.000	rs62103177	chr18:77624479	G/A	cg05926928	chr17:57297772	GDPD1	1.08	9.41	0.52	5.04e-18	Opioid sensitivity;
SARC	cis	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg07777115	chr5:623756	CEP72	-0.57	-5.12	-0.32	6.42e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs4466137	0.953	rs974023	chr5:83014848	T/C	cg16102102	chr5:83017553	HAPLN1	-0.76	-9.36	-0.52	6.85e-18	Prostate cancer;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg18450072	chr4:40058936	LOC344967;N4BP2	0.51	6.8	0.41	8.75e-11	Chemerin levels;
SARC	cis	rs17539620	0.506	rs62432749	chr6:154839219	G/A	cg20019720	chr6:154832845	CNKSR3	0.41	4.83	0.3	2.48e-6	Lipoprotein (a) levels;
SARC	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg22974920	chr21:40686053	BRWD1	-0.45	-4.87	-0.3	2.08e-6	Cognitive function;
SARC	cis	rs911263	0.603	rs1956525	chr14:68799859	G/A	cg18825221	chr14:68749962	RAD51L1	0.4	7.07	0.42	1.78e-11	Primary biliary cholangitis;
SARC	cis	rs2120019	0.938	rs1867150	chr15:75321139	T/C	cg12414181	chr15:75287860	SCAMP5	-0.48	-5.53	-0.34	8.36e-8	Blood trace element (Zn levels);
SARC	cis	rs1559088	0.947	rs10403238	chr19:33552405	A/G	cg27124370	chr19:33622961	WDR88	0.41	5.16	0.32	5.18e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs7587476	0.906	rs3768713	chr2:215637505	G/A	cg11970703	chr2:215861251	ABCA12	-0.38	-5.69	-0.35	3.85e-8	Neuroblastoma;
SARC	cis	rs9457247	0.663	rs12526548	chr6:167431147	C/T	cg23791538	chr6:167370224	RNASET2	-0.51	-6.88	-0.41	5.56e-11	Crohn's disease;
SARC	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg25894440	chr7:65020034	NA	0.75	5.67	0.35	4.23e-8	Diabetic kidney disease;
SARC	cis	rs600231	0.508	rs11227201	chr11:65242548	G/A	cg17120908	chr11:65337727	SSSCA1	-0.45	-4.99	-0.31	1.17e-6	Bone mineral density;
SARC	cis	rs2439831	0.867	rs2278860	chr15:43659046	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-1.06	-11.65	-0.61	5.27e-25	Lung cancer in ever smokers;
SARC	cis	rs12681288	0.823	rs2701905	chr8:1003482	T/C	cg15309053	chr8:964076	NA	0.42	7.05	0.42	2e-11	Schizophrenia;
SARC	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg11644478	chr21:40555479	PSMG1	0.98	11.55	0.6	1.05e-24	Cognitive function;
SARC	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg11141652	chr22:24348549	GSTTP1	-0.47	-5.12	-0.32	6.45e-7	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg24250549	chr1:154909240	PMVK	0.61	7.98	0.46	6.59e-14	Prostate cancer;
SARC	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg11764359	chr7:65958608	NA	-0.8	-10.02	-0.55	6.95e-20	Aortic root size;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg10302505	chr8:128748092	MYC	0.52	7.01	0.42	2.61e-11	Tetralogy of Fallot;
SARC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg26668828	chr6:292823	DUSP22	-0.65	-8.37	-0.48	5.39e-15	Menopause (age at onset);
SARC	cis	rs11098499	0.863	rs10019674	chr4:120443489	C/T	cg24375607	chr4:120327624	NA	-0.42	-4.98	-0.31	1.26e-6	Corneal astigmatism;
SARC	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg26850624	chr5:429559	AHRR	-0.31	-4.77	-0.3	3.21e-6	Cystic fibrosis severity;
SARC	cis	rs9467773	0.572	rs62394558	chr6:26604650	G/A	cg11502198	chr6:26597334	ABT1	0.62	7.6	0.45	7.21e-13	Intelligence (multi-trait analysis);
SARC	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg22968622	chr17:43663579	NA	0.83	10.46	0.57	3.08e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg27588902	chr6:42928151	GNMT	-0.38	-5.67	-0.35	4.2e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs57506017	0.540	rs1435524	chr7:12262801	G/A	cg23422036	chr7:12250390	TMEM106B	0.49	6.41	0.39	8.02e-10	Neuroticism;
SARC	cis	rs938682	0.555	rs8192478	chr15:78910462	A/G	cg24631222	chr15:78858424	CHRNA5	0.56	7.03	0.42	2.29e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
SARC	cis	rs10791097	0.694	rs2155749	chr11:130751094	G/T	cg09137382	chr11:130731461	NA	0.32	4.98	0.31	1.22e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08677398	chr8:58056175	NA	0.39	5.38	0.33	1.82e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg16479474	chr6:28041457	NA	-0.35	-5.03	-0.31	9.76e-7	Parkinson's disease;
SARC	cis	rs7621025	0.500	rs1965107	chr3:136648643	T/A	cg15507776	chr3:136538369	TMEM22	0.94	10.83	0.58	2.09e-22	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
SARC	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.48	5.3	0.33	2.72e-7	Renal function-related traits (BUN);
SARC	cis	rs67311347	0.869	rs7646899	chr3:40366982	A/G	cg09455208	chr3:40491958	NA	0.38	5.93	0.36	1.1e-8	Renal cell carcinoma;
SARC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg16132339	chr22:24313637	DDTL;DDT	-0.38	-4.76	-0.3	3.41e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9985766	0.959	rs28806288	chr4:151048211	A/G	cg05926478	chr4:151174724	DCLK2	-0.49	-4.83	-0.3	2.46e-6	Coronary artery disease;Myocardial infarction;
SARC	cis	rs6545883	0.931	rs12713437	chr2:61722904	C/T	cg15711740	chr2:61764176	XPO1	-0.43	-5.27	-0.33	3.14e-7	Tuberculosis;
SARC	cis	rs611744	0.967	rs613644	chr8:109188994	G/A	cg21045802	chr8:109455806	TTC35	0.44	5.3	0.33	2.64e-7	Dupuytren's disease;
SARC	cis	rs7296418	0.663	rs28450974	chr12:123861420	G/A	cg00376283	chr12:123451042	ABCB9	0.59	7.29	0.43	4.67e-12	Platelet count;
SARC	trans	rs7937682	0.883	rs512669	chr11:111467893	G/A	cg18187862	chr3:45730750	SACM1L	0.53	6.28	0.38	1.69e-9	Primary sclerosing cholangitis;
SARC	cis	rs611744	0.967	rs628843	chr8:109196115	C/G	cg21045802	chr8:109455806	TTC35	0.44	5.3	0.33	2.63e-7	Dupuytren's disease;
SARC	cis	rs797680	0.681	rs4847406	chr1:93758450	C/T	cg01538778	chr1:93646459	TMED5;CCDC18	0.41	4.94	0.31	1.52e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
SARC	cis	rs751728	1.000	rs11752297	chr6:33735154	G/C	cg25922239	chr6:33757077	LEMD2	0.8	10.67	0.57	6.89e-22	Crohn's disease;
SARC	trans	rs629535	0.547	rs72654095	chr8:70120770	A/G	cg21567404	chr3:27674614	NA	-0.96	-10.86	-0.58	1.6400000000000001e-22	Dupuytren's disease;
SARC	cis	rs12451471	0.559	rs12452263	chr17:78079310	T/C	cg24585782	chr17:78113791	EIF4A3	-0.53	-6.04	-0.37	5.92e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
SARC	cis	rs9462027	0.628	rs2814992	chr6:34617144	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-6.01	-0.37	7.15e-9	Systemic lupus erythematosus;
SARC	cis	rs6991838	0.584	rs35941313	chr8:66499733	G/T	cg13398993	chr8:66546079	ARMC1	-0.62	-8.31	-0.48	7.89e-15	Intelligence (multi-trait analysis);
SARC	cis	rs6582630	0.574	rs12146797	chr12:38436499	T/C	cg13010199	chr12:38710504	ALG10B	0.75	10.24	0.56	1.42e-20	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs11676348	0.935	rs2230054	chr2:219000310	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.5	-6.57	-0.4	3.32e-10	Ulcerative colitis;
SARC	cis	rs10489525	1.000	rs10489525	chr1:115263685	A/G	cg01522456	chr1:115632236	TSPAN2	-0.47	-5.69	-0.35	3.78e-8	Autism;
SARC	cis	rs3741151	1.000	rs74776668	chr11:73065909	G/A	cg17517138	chr11:73019481	ARHGEF17	0.97	6.83	0.41	7.16e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs3796352	1.000	rs13076033	chr3:52898427	T/C	cg27565382	chr3:53032988	SFMBT1	0.98	6.63	0.4	2.25e-10	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2929278	0.617	rs663214	chr15:44113782	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.43	-4.83	-0.3	2.5e-6	Schizophrenia;
SARC	cis	rs7818688	0.697	rs77402106	chr8:95970484	C/T	cg13393036	chr8:95962371	TP53INP1	0.43	5.13	0.32	6.08e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs6831352	0.703	rs2602862	chr4:100033221	A/G	cg12011299	chr4:100065546	ADH4	0.28	4.8	0.3	2.86e-6	Alcohol dependence;
SARC	cis	rs921968	0.565	rs7580147	chr2:219643036	A/G	cg02176678	chr2:219576539	TTLL4	-0.33	-5.09	-0.32	7.49e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs796364	0.901	rs13030683	chr2:201061535	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.56	5.72	0.35	3.22e-8	Schizophrenia;
SARC	cis	rs509477	1.000	rs7240845	chr18:32574960	G/C	cg23791764	chr18:32556832	MAPRE2	-0.55	-6.51	-0.39	4.66e-10	Cerebrospinal fluid AB1-42 levels;
SARC	cis	rs763014	0.931	rs7199839	chr16:636126	T/C	cg07343612	chr16:622815	PIGQ	-0.53	-7.2	-0.43	8.25e-12	Height;
SARC	cis	rs78487399	0.808	rs17030889	chr2:43702829	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-5.28	-0.33	2.9e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs3771570	0.901	rs62190415	chr2:242426692	A/G	cg21155796	chr2:242212141	HDLBP	0.61	6.09	0.37	4.68e-9	Prostate cancer;
SARC	cis	rs9341808	0.519	rs660888	chr6:80983212	A/T	cg08355045	chr6:80787529	NA	0.34	5.15	0.32	5.56e-7	Sitting height ratio;
SARC	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.46	-5.76	-0.35	2.59e-8	Gut microbiome composition (summer);
SARC	cis	rs11758351	1.000	rs17598927	chr6:26184640	C/G	cg23601095	chr6:26197514	HIST1H3D	-0.67	-5.51	-0.34	9.25e-8	Gout;Renal underexcretion gout;
SARC	cis	rs6005807	0.543	rs2235432	chr22:29169420	T/G	cg02153584	chr22:29168773	CCDC117	0.67	5.38	0.33	1.78e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
SARC	cis	rs78132593	0.723	rs34593358	chr1:150686633	A/T	cg13175981	chr1:150552382	MCL1	0.47	4.99	0.31	1.2e-6	High light scatter reticulocyte count;
SARC	cis	rs9296092	0.517	rs55683509	chr6:33471077	A/G	cg13560919	chr6:33536144	NA	-0.44	-5.07	-0.32	8.23e-7	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	trans	rs1814175	0.817	rs80244685	chr11:49763292	C/A	cg15704280	chr7:45808275	SEPT13	-0.86	-13.47	-0.66	5.71e-31	Height;
SARC	cis	rs644799	0.965	rs607039	chr11:95547086	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	15.35	0.71	3.21e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg13628971	chr7:2884303	GNA12	0.64	7.45	0.44	1.85e-12	Height;
SARC	cis	rs6735179	0.958	rs10048704	chr2:1777819	G/C	cg08534653	chr2:1747700	PXDN	0.41	4.86	0.3	2.18e-6	Response to antipsychotic treatment;
SARC	cis	rs13256369	0.802	rs12153	chr8:8560909	G/C	cg17143192	chr8:8559678	CLDN23	0.52	5.81	0.36	2.07e-8	Obesity-related traits;
SARC	cis	rs4718428	0.705	rs4718422	chr7:66359269	A/G	cg12165864	chr7:66369176	NA	-0.46	-5.17	-0.32	5.1e-7	Corneal structure;
SARC	cis	rs9796	0.621	rs2578655	chr15:41462809	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.52	-7.43	-0.44	2.01e-12	Menopause (age at onset);
SARC	cis	rs12477438	1.000	rs6732980	chr2:99921613	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-10.11	-0.55	3.61e-20	Chronic sinus infection;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25465019	chr1:87794181	LMO4	0.58	7.36	0.43	3.06e-12	Fibrinogen levels;
SARC	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg24549020	chr5:56110836	MAP3K1	-0.55	-4.81	-0.3	2.72e-6	Initial pursuit acceleration;
SARC	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg03647317	chr4:187891568	NA	0.37	5.33	0.33	2.28e-7	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg08800530	chr5:175788722	KIAA1191	-0.5	-6.46	-0.39	5.96e-10	Neuroticism;
SARC	trans	rs3779273	0.748	rs4236580	chr7:77835256	T/C	cg05596911	chr5:118502651	DMXL1	-0.58	-7.36	-0.43	3.17e-12	Body mass index;
SARC	cis	rs4423214	0.569	rs4944044	chr11:71120213	G/A	cg05163923	chr11:71159392	DHCR7	0.46	6.33	0.38	1.25e-9	Vitamin D levels;
SARC	cis	rs854765	0.505	rs4506969	chr17:17899839	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.43	5.28	0.33	2.98e-7	Total body bone mineral density;
SARC	cis	rs9840812	0.861	rs684773	chr3:135956305	A/C	cg15507776	chr3:136538369	TMEM22	0.48	4.93	0.31	1.57e-6	Fibrinogen levels;
SARC	cis	rs7727544	0.606	rs72795121	chr5:131638324	T/A	cg24060327	chr5:131705240	SLC22A5	-0.42	-5.0	-0.31	1.12e-6	Blood metabolite levels;
SARC	cis	rs6693567	0.565	rs10888578	chr1:150260993	A/G	cg09579323	chr1:150459698	TARS2	-0.38	-4.85	-0.3	2.27e-6	Migraine;
SARC	cis	rs73206853	0.841	rs73191818	chr12:110918721	T/G	cg10860002	chr12:110842031	ANAPC7	0.62	4.94	0.31	1.5e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs7772486	0.790	rs4280983	chr6:146280790	G/C	cg05347473	chr6:146136440	FBXO30	-0.5	-6.8	-0.41	8.81e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3087591	0.960	rs4435317	chr17:29436512	G/C	cg24425628	chr17:29625626	OMG;NF1	0.56	7.04	0.42	2.11e-11	Hip circumference;
SARC	cis	rs6570726	0.791	rs4335004	chr6:145904764	G/A	cg05347473	chr6:146136440	FBXO30	0.55	7.51	0.44	1.24e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs317689	0.876	rs547332	chr12:69743639	C/G	cg14784868	chr12:69753453	YEATS4	0.45	5.15	0.32	5.45e-7	Response to diuretic therapy;
SARC	cis	rs9811216	0.958	rs9876206	chr3:169517436	C/T	cg14222479	chr3:169487675	ARPM1	0.42	5.16	0.32	5.4e-7	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs244731	0.959	rs6872021	chr5:176610012	G/A	cg16006841	chr5:176797999	RGS14	-0.57	-6.8	-0.41	8.92e-11	Urate levels in lean individuals;
SARC	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21284376	chr1:72748601	NEGR1	0.57	7.68	0.45	4.32e-13	Parkinson's disease;
SARC	trans	rs3942852	0.806	rs1875696	chr11:48133526	G/A	cg15704280	chr7:45808275	SEPT13	-0.57	-6.59	-0.4	2.83e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs2153535	0.553	rs2984099	chr6:8637274	C/T	cg21535247	chr6:8435926	SLC35B3	-0.65	-7.69	-0.45	4.1e-13	Motion sickness;
SARC	cis	rs35955747	0.902	rs11703927	chr22:31644964	G/A	cg13145458	chr22:31556086	RNF185	0.43	5.36	0.33	2.05e-7	Neutrophil count;Sum basophil neutrophil counts;
SARC	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg11366901	chr6:160182831	ACAT2	1.0	10.28	0.56	1.08e-20	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs9902453	0.904	rs7218379	chr17:28402737	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.23	-0.43	7.03e-12	Coffee consumption (cups per day);
SARC	cis	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg09021430	chr5:549028	NA	-0.43	-5.7	-0.35	3.58e-8	Obesity-related traits;
SARC	cis	rs12980942	0.591	rs2304232	chr19:41762525	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.59	4.81	0.3	2.69e-6	Coronary artery disease;
SARC	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg13699009	chr12:122356056	WDR66	-0.54	-8.58	-0.49	1.37e-15	Mean corpuscular volume;
SARC	cis	rs7264396	0.790	rs12480622	chr20:34234620	T/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	5.92	0.36	1.17e-8	Total cholesterol levels;
SARC	cis	rs17376456	0.825	rs6865441	chr5:93284746	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.67	0.35	4.28e-8	Diabetic retinopathy;
SARC	cis	rs3733585	0.699	rs7683283	chr4:9969974	T/C	cg00071950	chr4:10020882	SLC2A9	-0.37	-5.57	-0.34	6.89e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg11890956	chr21:40555474	PSMG1	-1.05	-16.08	-0.73	1.19e-39	Cognitive function;
SARC	cis	rs6807306	1.000	rs6444553	chr3:167435492	A/G	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.53	5.3	0.33	2.67e-7	Mean platelet volume;
SARC	cis	rs6570726	1.000	rs374464	chr6:145846679	A/C	cg05220968	chr6:146057943	EPM2A	-0.29	-4.88	-0.3	2.01e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3218477	0.925	rs79343405	chr7:152371024	T/G	cg06618968	chr7:152373420	XRCC2	-0.71	-4.73	-0.3	3.96e-6	Mean platelet volume;
SARC	cis	rs2777491	0.874	rs7161772	chr15:41611066	A/T	cg18705301	chr15:41695430	NDUFAF1	-0.74	-10.89	-0.58	1.32e-22	Ulcerative colitis;
SARC	cis	rs6772849	0.775	rs67105978	chr3:128415180	C/A	cg08795948	chr3:128337044	NA	0.53	7.03	0.42	2.21e-11	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg11987759	chr7:65425863	GUSB	-0.5	-6.19	-0.38	2.62e-9	Aortic root size;
SARC	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg11987759	chr7:65425863	GUSB	-0.6	-8.13	-0.47	2.6e-14	Aortic root size;
SARC	cis	rs7949030	1.000	rs2956993	chr11:62406162	G/T	cg13298116	chr11:62369859	EML3;MTA2	-0.42	-6.19	-0.38	2.63e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs710216	0.879	rs710218	chr1:43427218	A/T	cg07803811	chr1:43423981	SLC2A1	0.58	6.49	0.39	5e-10	Red cell distribution width;
SARC	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-6.34	-0.38	1.17e-9	Personality dimensions;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg09297334	chr8:71520303	TRAM1	-0.9	-7.49	-0.44	1.45e-12	Autism spectrum disorder or schizophrenia;
SARC	cis	rs5758659	0.653	rs133383	chr22:42473603	C/T	cg15128208	chr22:42549153	NA	-0.37	-5.21	-0.32	4.22e-7	Cognitive function;
SARC	cis	rs7572733	0.555	rs6434953	chr2:198929693	A/G	cg00792783	chr2:198669748	PLCL1	0.43	4.85	0.3	2.25e-6	Dermatomyositis;
SARC	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg23758822	chr17:41437982	NA	0.88	11.19	0.59	1.55e-23	Menopause (age at onset);
SARC	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg16405210	chr4:1374714	KIAA1530	-0.49	-5.85	-0.36	1.67e-8	Obesity-related traits;
SARC	cis	rs1318878	0.565	rs73055297	chr12:15460015	T/C	cg08258403	chr12:15378311	NA	0.48	6.73	0.4	1.29e-10	Intelligence (multi-trait analysis);
SARC	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.48	0.44	1.54e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7223966	1.000	rs28463311	chr17:61919643	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	7.5	0.44	1.3e-12	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7481584	0.581	rs399565	chr11:3061780	C/T	cg20651018	chr11:3035856	CARS	0.39	5.77	0.35	2.49e-8	Calcium levels;
SARC	cis	rs524281	0.861	rs580891	chr11:65954681	A/C	cg14036092	chr11:66035641	RAB1B	-0.56	-5.94	-0.36	1.05e-8	Electroencephalogram traits;
SARC	cis	rs10886503	0.546	rs10787975	chr10:121267261	T/G	cg17804342	chr10:121271663	RGS10	0.46	4.89	0.31	1.85e-6	Obstetric antiphospholipid syndrome;
SARC	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg11987759	chr7:65425863	GUSB	0.5	6.55	0.39	3.66e-10	Aortic root size;
SARC	cis	rs1018836	0.923	rs2187982	chr8:91556317	G/T	cg16814680	chr8:91681699	NA	-0.77	-12.58	-0.64	4.95e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.37	-0.43	3.03e-12	Gut microbiome composition (summer);
SARC	cis	rs763121	0.853	rs5757226	chr22:39070550	T/C	cg06022373	chr22:39101656	GTPBP1	0.86	10.88	0.58	1.41e-22	Menopause (age at onset);
SARC	cis	rs73206853	0.541	rs11837455	chr12:110505621	C/A	cg08946844	chr12:110511112	NA	0.67	4.93	0.31	1.54e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-5.45	-0.34	1.28e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs10416265	0.527	rs6510337	chr19:33545701	C/T	cg17764715	chr19:33622953	WDR88	0.57	7.81	0.46	1.95e-13	Bone properties (heel);
SARC	cis	rs7824557	0.602	rs7816636	chr8:11205654	T/A	cg21775007	chr8:11205619	TDH	0.67	8.67	0.49	7.48e-16	Retinal vascular caliber;
SARC	cis	rs763121	0.853	rs3747172	chr22:39067524	A/G	cg06022373	chr22:39101656	GTPBP1	0.86	10.88	0.58	1.41e-22	Menopause (age at onset);
SARC	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg12463550	chr7:65579703	CRCP	0.5	5.94	0.36	1.01e-8	Aortic root size;
SARC	cis	rs6582630	0.537	rs35336822	chr12:38346251	T/C	cg26384229	chr12:38710491	ALG10B	0.88	12.87	0.64	5.59e-29	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2228479	0.850	rs12597299	chr16:89822364	C/A	cg00800038	chr16:89945340	TCF25	-0.74	-5.14	-0.32	5.75e-7	Skin colour saturation;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg11673304	chr2:208490091	FAM119A	0.49	6.3	0.38	1.5e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs1691799	0.836	rs1184552	chr12:66756215	A/G	cg16791601	chr12:66731901	HELB	-0.7	-10.52	-0.57	1.93e-21	White blood cell count (basophil);
SARC	cis	rs7819412	0.561	rs2001328	chr8:10987199	T/C	cg21775007	chr8:11205619	TDH	-0.43	-5.39	-0.33	1.69e-7	Triglycerides;
SARC	cis	rs17253792	0.822	rs79022053	chr14:56071721	A/G	cg01858014	chr14:56050164	KTN1	-0.71	-5.63	-0.35	5.25e-8	Putamen volume;
SARC	cis	rs787274	1.000	rs2796037	chr9:115511826	C/T	cg13803584	chr9:115635662	SNX30	0.77	5.6	0.34	6.11e-8	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg18404041	chr3:52824283	ITIH1	-0.43	-6.53	-0.39	4.04e-10	Bipolar disorder;
SARC	cis	rs9894429	1.000	rs9894429	chr17:79596811	C/T	cg10661904	chr17:79619235	PDE6G	-0.34	-4.76	-0.3	3.45e-6	Eye color traits;
SARC	cis	rs709400	0.628	rs3783394	chr14:103858673	G/A	cg26031613	chr14:104095156	KLC1	0.81	11.72	0.61	3.08e-25	Body mass index;
SARC	cis	rs6714710	0.603	rs12995673	chr2:98409046	G/A	cg26665480	chr2:98280029	ACTR1B	0.55	7.47	0.44	1.64e-12	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs3106136	0.743	rs6847767	chr4:95276951	C/G	cg11021082	chr4:95130006	SMARCAD1	0.34	5.22	0.32	3.91e-7	Capecitabine sensitivity;
SARC	cis	rs6089584	0.566	rs6061972	chr20:60610245	C/T	cg13770153	chr20:60521292	NA	-0.38	-5.59	-0.34	6.44e-8	Body mass index;
SARC	cis	rs7084402	0.967	rs1649041	chr10:60328782	T/C	cg07615347	chr10:60278583	BICC1	0.58	8.58	0.49	1.36e-15	Refractive error;
SARC	cis	rs2370759	1.000	rs2225152	chr10:32574759	T/C	cg18270830	chr10:32634957	EPC1	0.66	5.81	0.36	2.07e-8	Sexual dysfunction (female);
SARC	cis	rs7584330	0.910	rs7606177	chr2:238394913	G/C	cg11271282	chr2:238384023	NA	0.44	5.16	0.32	5.19e-7	Prostate cancer;
SARC	cis	rs6912958	0.605	rs2754247	chr6:88383571	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.47	-6.0	-0.37	7.42e-9	Monocyte percentage of white cells;
SARC	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg19774624	chr17:42201019	HDAC5	-0.78	-11.4	-0.6	3.33e-24	Total body bone mineral density;
SARC	cis	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.48	-0.49	2.54e-15	Mood instability;
SARC	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg03709012	chr19:19516395	GATAD2A	0.95	14.76	0.7	2.9e-35	Tonsillectomy;
SARC	cis	rs9436747	0.748	rs1171262	chr1:66001746	A/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.53	-5.19	-0.32	4.49e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg12463550	chr7:65579703	CRCP	0.66	5.08	0.32	7.79e-7	Diabetic kidney disease;
SARC	cis	rs9300255	0.537	rs10772993	chr12:123644714	A/G	cg05973401	chr12:123451056	ABCB9	0.57	5.47	0.34	1.17e-7	Neutrophil percentage of white cells;
SARC	cis	rs73206853	0.620	rs73194023	chr12:111137940	G/A	cg10860002	chr12:110842031	ANAPC7	0.64	5.04	0.31	9.17e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs7712401	0.601	rs2910136	chr5:122254017	C/T	cg19412675	chr5:122181750	SNX24	-0.4	-5.14	-0.32	5.87e-7	Mean platelet volume;
SARC	cis	rs60752752	0.852	rs2916215	chr1:153353451	G/T	cg26882115	chr1:153603048	S100A1;S100A13	-0.63	-4.83	-0.3	2.49e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg17971929	chr21:40555470	PSMG1	0.98	13.63	0.67	1.68e-31	Cognitive function;
SARC	cis	rs9435341	0.965	rs6669831	chr1:107608607	G/A	cg09367891	chr1:107599246	PRMT6	-0.63	-7.76	-0.45	2.65e-13	Facial morphology (factor 21, depth of nasal alae);
SARC	cis	rs240764	0.658	rs12212435	chr6:101196080	T/C	cg09795085	chr6:101329169	ASCC3	-0.49	-6.42	-0.39	7.72e-10	Neuroticism;
SARC	cis	rs73001065	0.818	rs58847337	chr19:19726022	G/A	cg03709012	chr19:19516395	GATAD2A	0.85	5.8	0.36	2.1e-8	LDL cholesterol;
SARC	cis	rs2290402	0.536	rs56307842	chr4:854232	T/C	cg00846425	chr4:957561	DGKQ	-0.42	-4.89	-0.31	1.84e-6	Type 2 diabetes;
SARC	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg10523679	chr1:76189770	ACADM	0.51	6.45	0.39	6.48e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs34172651	0.917	rs200529	chr16:24758502	T/C	cg00152838	chr16:24741724	TNRC6A	0.41	5.09	0.32	7.35e-7	Intelligence (multi-trait analysis);
SARC	cis	rs17376456	0.778	rs10440717	chr5:93424852	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	6.14	0.37	3.45e-9	Diabetic retinopathy;
SARC	cis	rs6847149	0.929	rs10857002	chr4:110773433	A/C	cg07850274	chr4:110748770	RRH	0.49	5.46	0.34	1.24e-7	Exercise treadmill test traits;
SARC	cis	rs7582720	1.000	rs75141346	chr2:203685119	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.71	7.13	0.42	1.29e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs7178572	1.000	rs11633054	chr15:77747276	A/G	cg22256960	chr15:77711686	NA	-0.56	-6.67	-0.4	1.86e-10	Type 2 diabetes;
SARC	cis	rs3087591	0.960	rs9903754	chr17:29634468	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.54	-6.65	-0.4	2.07e-10	Hip circumference;
SARC	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9486719	0.857	rs4486027	chr6:96911886	T/C	cg18709589	chr6:96969512	KIAA0776	-0.48	-5.14	-0.32	5.86e-7	Migraine;Coronary artery disease;
SARC	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg15049968	chr18:44337910	ST8SIA5	-0.35	-5.58	-0.34	6.5e-8	Personality dimensions;
SARC	cis	rs10892173	0.904	rs10892172	chr11:117672474	C/A	cg21640587	chr11:117668038	DSCAML1	0.53	7.47	0.44	1.61e-12	Myopia;
SARC	cis	rs17376456	0.877	rs17316137	chr5:93456577	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.92	0.36	1.13e-8	Diabetic retinopathy;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg02780181	chr11:6704622	MRPL17	0.48	6.31	0.38	1.41e-9	Chemerin levels;
SARC	cis	rs6570726	0.870	rs370653	chr6:145823642	G/A	cg23711669	chr6:146136114	FBXO30	0.78	11.86	0.61	1.04e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9457247	0.740	rs10946204	chr6:167451129	T/C	cg23791538	chr6:167370224	RNASET2	-0.56	-7.26	-0.43	5.7e-12	Crohn's disease;
SARC	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg26039829	chr8:22132926	PIWIL2	0.48	6.79	0.41	9.09e-11	Hypertriglyceridemia;
SARC	cis	rs9788682	1.000	rs57064725	chr15:78833036	C/A	cg24631222	chr15:78858424	CHRNA5	0.72	9.65	0.53	9.3e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs1878931	0.580	rs4785932	chr16:3410456	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.9	14.28	0.68	1.14e-33	Body mass index (adult);
SARC	trans	rs11098499	1.000	rs10029750	chr4:120172543	A/G	cg25214090	chr10:38739885	LOC399744	0.52	6.84	0.41	6.85e-11	Corneal astigmatism;
SARC	cis	rs4308124	0.708	rs7585313	chr2:111975203	A/G	cg04571233	chr2:111982156	NA	-0.51	-5.99	-0.37	7.96e-9	Vitiligo;
SARC	trans	rs7980799	0.591	rs10844614	chr12:33605702	A/C	cg26384229	chr12:38710491	ALG10B	-0.59	-7.0	-0.42	2.63e-11	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs7568458	0.905	rs10187424	chr2:85794297	T/C	cg02493740	chr2:85810744	VAMP5	-0.33	-4.81	-0.3	2.77e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs11191193	0.686	rs10883695	chr10:103690999	G/A	cg15320455	chr10:103880129	LDB1	0.54	5.86	0.36	1.55e-8	Educational attainment;
SARC	cis	rs950169	0.960	rs35159785	chr15:84804014	G/A	cg17507749	chr15:85114479	UBE2QP1	0.75	8.75	0.5	4.29e-16	Schizophrenia;
SARC	cis	rs7592578	0.599	rs62180992	chr2:191285732	A/G	cg10560079	chr2:191398806	TMEM194B	-0.7	-7.69	-0.45	4.22e-13	Diastolic blood pressure;
SARC	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.59e-6	Depression;
SARC	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg07701084	chr6:150067640	NUP43	0.4	5.26	0.33	3.33e-7	Lung cancer;
SARC	cis	rs12971120	0.685	rs34780792	chr18:72173278	G/A	cg26446133	chr18:72167187	CNDP2	-0.51	-7.08	-0.42	1.7e-11	Refractive error;
SARC	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg00933542	chr6:150070202	PCMT1	0.3	5.08	0.32	7.56e-7	Lung cancer;
SARC	cis	rs9916302	0.706	rs4794808	chr17:37531916	C/T	cg15445000	chr17:37608096	MED1	-0.45	-4.85	-0.3	2.29e-6	Glomerular filtration rate (creatinine);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg24507384	chr2:210385137	MAP2	0.44	6.99	0.42	2.8e-11	Thyroid stimulating hormone;
SARC	cis	rs9420	0.961	rs10896647	chr11:57571883	C/T	cg19752551	chr11:57585705	CTNND1	-0.53	-7.1	-0.42	1.48e-11	Schizophrenia;
SARC	cis	rs4804155	0.590	rs17766692	chr19:11342599	C/T	cg00586551	chr19:11347513	LOC55908;DOCK6	0.72	7.05	0.42	2.06e-11	HDL cholesterol;Total cholesterol levels;
SARC	cis	rs10483809	0.659	rs9944146	chr14:68766811	G/A	cg18825221	chr14:68749962	RAD51L1	-0.42	-4.72	-0.3	4.09e-6	Circulating chromogranin peptide levels;
SARC	cis	rs2834188	0.889	rs2040108	chr21:34676158	T/C	cg04842828	chr21:34696676	IFNAR1	0.4	4.79	0.3	3.03e-6	Narcolepsy;
SARC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg06873352	chr17:61820015	STRADA	0.51	6.57	0.4	3.22e-10	Prudent dietary pattern;
SARC	cis	rs9470366	0.527	rs10807170	chr6:36629444	C/T	cg08179530	chr6:36648295	CDKN1A	-0.65	-8.76	-0.5	4.2e-16	QRS duration;
SARC	cis	rs4499344	0.730	rs259286	chr19:33164759	C/T	cg22980127	chr19:33182716	NUDT19	-0.43	-4.84	-0.3	2.33e-6	Mean platelet volume;
SARC	cis	rs17270561	0.636	rs4145218	chr6:25746083	G/A	cg17691542	chr6:26056736	HIST1H1C	0.61	7.36	0.43	3.06e-12	Iron status biomarkers;
SARC	cis	rs3126085	0.935	rs11204941	chr1:152203343	A/G	cg26876637	chr1:152193138	HRNR	0.48	5.6	0.34	6.08e-8	Atopic dermatitis;
SARC	cis	rs7586879	0.639	rs13407913	chr2:25097644	A/G	cg04586622	chr2:25135609	ADCY3	0.31	5.34	0.33	2.17e-7	Body mass index;
SARC	cis	rs3733585	0.631	rs3822236	chr4:10119961	T/G	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.1	-0.32	7.04e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs3741151	0.686	rs11235809	chr11:73290163	A/G	cg17517138	chr11:73019481	ARHGEF17	0.68	5.57	0.34	7.09e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs1865760	1.000	rs9348698	chr6:25929689	T/A	cg10373733	chr6:25993375	NA	0.41	4.85	0.3	2.22e-6	Height;
SARC	cis	rs644799	1.000	rs627568	chr11:95569253	A/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.67	9.02	0.51	7.06e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs11785400	1.000	rs11780221	chr8:143748215	T/A	cg10596483	chr8:143751796	JRK	0.64	8.48	0.49	2.68e-15	Schizophrenia;
SARC	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg25036284	chr2:26402008	FAM59B	0.46	5.73	0.35	3.07e-8	Gut microbiome composition (summer);
SARC	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg05863683	chr7:1912471	MAD1L1	0.34	5.06	0.31	8.45e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs950169	0.922	rs12912934	chr15:85114447	C/T	cg03959625	chr15:84868606	LOC388152	0.36	4.91	0.31	1.71e-6	Schizophrenia;
SARC	cis	rs1707322	0.721	rs56255771	chr1:46224319	C/T	cg06784218	chr1:46089804	CCDC17	0.4	7.02	0.42	2.42e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs10464366	0.544	rs2280667	chr7:39172228	A/C	cg15212455	chr7:39170539	POU6F2	0.4	5.24	0.32	3.62e-7	IgG glycosylation;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg19596177	chr12:95611375	FGD6;VEZT	0.51	6.41	0.39	8.06e-10	Height;
SARC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.86	12.82	0.64	8.22e-29	Prudent dietary pattern;
SARC	cis	rs2180341	0.782	rs6912006	chr6:127722631	C/T	cg24812749	chr6:127587940	RNF146	0.61	7.76	0.45	2.71e-13	Breast cancer;
SARC	trans	rs1814175	0.817	rs7929173	chr11:49944007	T/C	cg15704280	chr7:45808275	SEPT13	-0.97	-17.77	-0.76	3.05e-45	Height;
SARC	cis	rs11122272	0.735	rs2808591	chr1:231523421	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs67311347	0.866	rs56331709	chr3:40356558	A/C	cg09455208	chr3:40491958	NA	0.4	6.33	0.38	1.24e-9	Renal cell carcinoma;
SARC	cis	rs7662987	0.517	rs2602865	chr4:100034841	T/C	cg12011299	chr4:100065546	ADH4	0.33	5.53	0.34	8.55e-8	Smoking initiation;
SARC	cis	rs501120	0.810	rs510785	chr10:44749990	C/A	cg09554077	chr10:44749378	NA	0.46	6.47	0.39	5.63e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs796364	0.625	rs4673837	chr2:201131159	A/G	cg23649088	chr2:200775458	C2orf69	0.61	6.18	0.38	2.83e-9	Schizophrenia;
SARC	cis	rs2228479	0.557	rs2293584	chr16:89888686	C/G	cg12064134	chr16:90016061	DEF8	-0.55	-4.8	-0.3	2.8e-6	Skin colour saturation;
SARC	cis	rs6504663	0.558	rs7627	chr17:48552154	G/C	cg03611598	chr17:48586076	MYCBPAP	0.5	5.4	0.33	1.64e-7	Visceral fat;
SARC	cis	rs6570726	0.846	rs9399559	chr6:145945778	C/T	cg23711669	chr6:146136114	FBXO30	0.77	12.31	0.63	3.69e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg08219700	chr8:58056026	NA	0.62	5.81	0.36	2.04e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg00800038	chr16:89945340	TCF25	-0.74	-5.14	-0.32	5.79e-7	Skin colour saturation;
SARC	cis	rs920590	0.796	rs11778257	chr8:19634598	A/T	cg01411142	chr8:19674711	INTS10	0.43	5.05	0.31	9.07e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs7412746	0.611	rs9661876	chr1:150910911	C/T	cg10589385	chr1:150898437	SETDB1	0.4	5.31	0.33	2.54e-7	Melanoma;
SARC	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.72	10.22	0.56	1.71e-20	Menarche (age at onset);
SARC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg21856205	chr7:94953877	PON1	-0.35	-5.65	-0.35	4.57e-8	Paraoxonase activity;
SARC	cis	rs8114671	0.562	rs2378294	chr20:33500378	G/A	cg24642439	chr20:33292090	TP53INP2	0.5	6.11	0.37	4.08e-9	Height;
SARC	cis	rs9326248	0.861	rs4938348	chr11:117021877	G/C	cg01368799	chr11:117014884	PAFAH1B2	0.57	5.58	0.34	6.79e-8	Blood protein levels;
SARC	cis	rs7635838	0.684	rs2606758	chr3:11353064	G/A	cg00170343	chr3:11313890	ATG7	0.64	8.83	0.5	2.64e-16	HDL cholesterol;
SARC	cis	rs7084402	0.967	rs1649066	chr10:60305916	G/C	cg07615347	chr10:60278583	BICC1	0.59	8.61	0.49	1.12e-15	Refractive error;
SARC	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2239547	0.562	rs2581810	chr3:52960859	C/T	cg11645453	chr3:52864694	ITIH4	-0.31	-4.71	-0.3	4.17e-6	Schizophrenia;
SARC	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.63e-10	Life satisfaction;
SARC	cis	rs2204008	0.811	rs2139752	chr12:38370398	C/T	cg13010199	chr12:38710504	ALG10B	0.78	10.75	0.58	3.67e-22	Bladder cancer;
SARC	cis	rs861020	0.630	rs616544	chr1:210007368	T/C	cg23166289	chr1:210001082	C1orf107	0.39	4.74	0.3	3.66e-6	Orofacial clefts;
SARC	cis	rs6831352	0.589	rs2602836	chr4:100014805	C/T	cg13256891	chr4:100009986	ADH5	-0.72	-11.33	-0.6	5.38e-24	Alcohol dependence;
SARC	cis	rs778371	1.000	rs11535	chr2:233743532	G/C	cg16596103	chr2:233749413	NGEF	0.36	5.18	0.32	4.69e-7	Schizophrenia;
SARC	cis	rs1550582	0.917	rs7831961	chr8:135507060	C/G	cg17885191	chr8:135476712	NA	-0.59	-6.63	-0.4	2.25e-10	Educational attainment;
SARC	cis	rs4243830	0.850	rs2063806	chr1:6610382	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.87	-8.42	-0.48	3.98e-15	Body mass index;
SARC	cis	rs751728	0.585	rs9380381	chr6:33771070	C/T	cg25922239	chr6:33757077	LEMD2	0.65	7.73	0.45	3.25e-13	Crohn's disease;
SARC	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg03433033	chr1:76189801	ACADM	0.47	6.54	0.39	3.92e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6674176	0.696	rs4448553	chr1:44411589	A/G	cg13606994	chr1:44402422	ARTN	-0.34	-5.61	-0.34	5.85e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs7937682	0.737	rs518294	chr11:111424716	A/T	cg22437258	chr11:111473054	SIK2	0.56	7.34	0.43	3.54e-12	Primary sclerosing cholangitis;
SARC	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg13126279	chr21:47581558	C21orf56	0.51	6.24	0.38	2.08e-9	Testicular germ cell tumor;
SARC	cis	rs7208859	0.623	rs28556733	chr17:29083945	T/G	cg13385521	chr17:29058706	SUZ12P	0.89	7.89	0.46	1.18e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs7408868	0.831	rs7245850	chr19:15274585	A/C	cg14696996	chr19:15285081	NOTCH3	1.06	8.7	0.5	6.14e-16	Pulse pressure;
SARC	cis	rs17376456	0.877	rs10061080	chr5:93420559	A/G	cg25358565	chr5:93447407	FAM172A	1.24	14.28	0.68	1.21e-33	Diabetic retinopathy;
SARC	cis	rs453301	0.686	rs13252797	chr8:8861430	A/G	cg08975724	chr8:8085496	FLJ10661	0.44	5.59	0.34	6.32e-8	Joint mobility (Beighton score);
SARC	cis	rs1318878	0.639	rs1034504	chr12:15514827	A/G	cg08258403	chr12:15378311	NA	0.5	6.84	0.41	6.85e-11	Intelligence (multi-trait analysis);
SARC	cis	rs3857067	0.806	rs12513267	chr4:95109545	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.04	-0.31	9.48e-7	QT interval;
SARC	cis	rs2204008	0.693	rs12372025	chr12:38202028	G/A	cg13010199	chr12:38710504	ALG10B	0.78	10.64	0.57	8.61e-22	Bladder cancer;
SARC	cis	rs9911578	0.967	rs7214892	chr17:57065401	G/A	cg12560992	chr17:57184187	TRIM37	0.84	11.59	0.6	8.22e-25	Intelligence (multi-trait analysis);
SARC	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	8.66	0.49	7.78e-16	Mean platelet volume;
SARC	cis	rs72781680	0.821	rs17038360	chr2:24095798	A/G	cg08917208	chr2:24149416	ATAD2B	0.61	6.43	0.39	7.08e-10	Lymphocyte counts;
SARC	cis	rs9527	0.615	rs10883810	chr10:104727224	A/C	cg04362960	chr10:104952993	NT5C2	0.42	4.98	0.31	1.23e-6	Arsenic metabolism;
SARC	cis	rs7659604	0.605	rs67772833	chr4:122723106	G/A	cg19748678	chr4:122722346	EXOSC9	0.58	6.99	0.42	2.93e-11	Type 2 diabetes;
SARC	cis	rs6901004	0.772	rs191632	chr6:111544882	C/T	cg15721981	chr6:111408429	SLC16A10	-0.42	-5.11	-0.32	6.68e-7	Blood metabolite levels;
SARC	cis	rs9788682	0.706	rs924840	chr15:78731808	A/T	cg24631222	chr15:78858424	CHRNA5	0.74	9.17	0.52	2.54e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs4800452	0.826	rs9949705	chr18:20745345	A/G	cg13313047	chr18:20735648	CABLES1	-0.49	-5.49	-0.34	1.04e-7	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
SARC	cis	rs6933660	0.512	rs13202634	chr6:151800630	C/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.59	5.14	0.32	5.82e-7	Menarche (age at onset);
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg08582827	chr6:90529665	MDN1	0.5	6.28	0.38	1.64e-9	Lung adenocarcinoma;
SARC	cis	rs4792901	0.959	rs55955027	chr17:41621156	T/A	cg22562494	chr17:41607896	ETV4	-0.33	-5.3	-0.33	2.63e-7	Dupuytren's disease;
SARC	cis	rs4268898	0.662	rs17789375	chr2:24502554	G/T	cg26838691	chr2:24397539	C2orf84	-0.51	-5.81	-0.36	2.06e-8	Asthma;
SARC	trans	rs561341	0.714	rs474455	chr17:30312465	A/T	cg20587970	chr11:113659929	NA	-1.25	-12.81	-0.64	8.62e-29	Hip circumference adjusted for BMI;
SARC	cis	rs8114671	0.836	rs13042358	chr20:33634479	G/A	cg08999081	chr20:33150536	PIGU	-0.34	-4.89	-0.31	1.86e-6	Height;
SARC	cis	rs4561483	0.801	rs251723	chr16:11953080	G/C	cg08843971	chr16:11963173	GSPT1	-0.44	-5.55	-0.34	7.78e-8	Testicular germ cell tumor;
SARC	cis	rs739401	0.527	rs418832	chr11:3072236	C/T	cg25174290	chr11:3078921	CARS	0.59	8.33	0.48	6.94e-15	Longevity;
SARC	cis	rs6665290	0.870	rs1045289	chr1:227178713	C/T	cg14016676	chr1:227182615	CDC42BPA	0.34	5.03	0.31	1e-6	Myeloid white cell count;
SARC	cis	rs4853012	0.887	rs6737314	chr2:74339586	A/G	cg19729930	chr2:74357872	NA	0.74	10.88	0.58	1.48e-22	Gestational age at birth (maternal effect);
SARC	cis	rs10875746	0.669	rs10875792	chr12:48697423	T/A	cg26205652	chr12:48591994	NA	0.46	4.92	0.31	1.61e-6	Longevity (90 years and older);
SARC	cis	rs3106136	0.649	rs11097426	chr4:95309450	G/A	cg11021082	chr4:95130006	SMARCAD1	0.33	4.9	0.31	1.78e-6	Capecitabine sensitivity;
SARC	cis	rs7615952	0.611	rs9681518	chr3:125615130	A/G	cg05084668	chr3:125655381	ALG1L	-0.88	-8.41	-0.48	4.06e-15	Blood pressure (smoking interaction);
SARC	cis	rs7772486	0.686	rs9376956	chr6:145949844	T/C	cg23711669	chr6:146136114	FBXO30	0.77	12.31	0.63	3.69e-27	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs7824557	0.510	rs2736297	chr8:11234885	C/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.82	-0.5	2.8e-16	Retinal vascular caliber;
SARC	cis	rs1483890	0.723	rs6549207	chr3:69412018	T/G	cg22125112	chr3:69402811	FRMD4B	0.28	4.72	0.3	4.05e-6	Resting heart rate;
SARC	cis	rs10791097	0.629	rs11222361	chr11:130731424	T/G	cg12179176	chr11:130786555	SNX19	0.67	9.34	0.52	8.15e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs11690935	0.959	rs7608403	chr2:172646765	A/C	cg13550731	chr2:172543902	DYNC1I2	-0.99	-15.74	-0.72	1.58e-38	Schizophrenia;
SARC	cis	rs11155671	0.530	rs9371215	chr6:150194298	C/T	cg09699651	chr6:150184138	LRP11	0.56	6.84	0.41	6.96e-11	Testicular germ cell tumor;
SARC	cis	rs3126085	0.935	rs12730241	chr1:152274016	G/A	cg09127314	chr1:152161683	NA	-0.44	-4.75	-0.3	3.55e-6	Atopic dermatitis;
SARC	cis	rs7937682	0.562	rs10891276	chr11:111370415	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.59	-7.99	-0.46	6.39e-14	Primary sclerosing cholangitis;
SARC	cis	rs3768617	0.510	rs1886501	chr1:183095234	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.82e-21	Fuchs's corneal dystrophy;
SARC	cis	rs7617773	0.539	rs13094496	chr3:48387050	G/C	cg11946769	chr3:48343235	NME6	0.55	6.69	0.4	1.62e-10	Coronary artery disease;
SARC	cis	rs367943	1.000	rs348929	chr5:112814883	T/A	cg12552261	chr5:112820674	MCC	-0.45	-5.19	-0.32	4.65e-7	Type 2 diabetes;
SARC	cis	rs611744	0.905	rs677031	chr8:109152068	G/A	cg21045802	chr8:109455806	TTC35	0.42	4.94	0.31	1.47e-6	Dupuytren's disease;
SARC	cis	rs2070677	0.935	rs4384343	chr10:135422545	G/C	cg20169779	chr10:135381914	SYCE1	-0.56	-6.9	-0.41	4.74e-11	Gout;
SARC	cis	rs7296418	0.885	rs1790104	chr12:123709409	C/T	cg00376283	chr12:123451042	ABCB9	0.61	7.56	0.44	9.45e-13	Platelet count;
SARC	cis	rs425277	1.000	rs262651	chr1:2091397	A/G	cg21442419	chr1:2182373	SKI	-0.52	-6.62	-0.4	2.44e-10	Height;
SARC	cis	rs17270561	0.609	rs4712964	chr6:25740822	A/T	cg16482183	chr6:26056742	HIST1H1C	0.43	5.08	0.32	7.69e-7	Iron status biomarkers;
SARC	cis	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg01579765	chr21:45077557	HSF2BP	-0.37	-6.22	-0.38	2.3e-9	Mean corpuscular volume;
SARC	cis	rs11626933	0.959	rs8005973	chr14:90774951	C/T	cg14092571	chr14:90743983	NA	-0.62	-8.94	-0.51	1.21e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs2292864	1.000	rs2292864	chr17:45367681	C/T	cg18085866	chr17:45331354	ITGB3	-0.68	-5.68	-0.35	4.04e-8	Left atrial antero-posterior diameter;
SARC	cis	rs3540	0.554	rs4244879	chr15:91066915	C/T	cg22089800	chr15:90895588	ZNF774	-0.61	-7.61	-0.45	6.63e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs1200821	0.529	rs4934856	chr10:37807847	T/C	cg25427524	chr10:38739819	LOC399744	0.46	6.89	0.41	5.13e-11	Hemostatic factors and hematological phenotypes;
SARC	cis	rs72781680	0.898	rs17462433	chr2:24012758	T/C	cg06627628	chr2:24431161	ITSN2	-0.66	-6.26	-0.38	1.83e-9	Lymphocyte counts;
SARC	cis	rs1448094	0.933	rs11117102	chr12:86312720	A/C	cg02569458	chr12:86230093	RASSF9	0.39	5.61	0.34	5.7e-8	Major depressive disorder;
SARC	cis	rs4423214	1.000	rs12793530	chr11:71161656	G/A	cg05163923	chr11:71159392	DHCR7	0.65	8.64	0.49	9.29e-16	Vitamin D levels;
SARC	cis	rs9815354	0.812	rs59476821	chr3:41946481	A/G	cg03022575	chr3:42003672	ULK4	0.7	5.7	0.35	3.66e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs7296418	0.636	rs11057261	chr12:123797567	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.39	-5.25	-0.33	3.49e-7	Platelet count;
SARC	trans	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg20587970	chr11:113659929	NA	-0.97	-9.65	-0.53	9.11e-19	Hip circumference adjusted for BMI;
SARC	cis	rs12421382	0.614	rs12420249	chr11:109390254	T/G	cg16359550	chr11:109292809	C11orf87	0.34	5.19	0.32	4.5e-7	Schizophrenia;
SARC	cis	rs7819412	0.540	rs2409726	chr8:11043138	T/C	cg21775007	chr8:11205619	TDH	-0.47	-5.95	-0.36	9.59e-9	Triglycerides;
SARC	cis	rs9457247	0.905	rs453184	chr6:167387404	A/C	cg07741184	chr6:167504864	NA	0.29	5.49	0.34	1.04e-7	Crohn's disease;
SARC	cis	rs4742903	0.935	rs1413341	chr9:106973013	C/T	cg14250997	chr9:106856677	SMC2	0.42	5.3	0.33	2.74e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs9291683	0.632	rs7679916	chr4:10042160	C/T	cg00071950	chr4:10020882	SLC2A9	0.39	6.29	0.38	1.52e-9	Bone mineral density;
SARC	cis	rs2841233	0.692	rs2028416	chr14:105348552	C/T	cg01147727	chr14:105363015	KIAA0284	-0.37	-6.55	-0.39	3.57e-10	IgG glycosylation;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg17233202	chr15:82338518	MEX3B	-0.47	-6.36	-0.38	1.07e-9	Schizophrenia;
SARC	cis	rs7246657	0.943	rs713256	chr19:37865365	C/T	cg14683738	chr19:37701593	ZNF585B	0.52	4.71	0.3	4.2e-6	Coronary artery calcification;
SARC	cis	rs2070488	0.965	rs35553573	chr3:38441439	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	14.15	0.68	3.31e-33	Electrocardiographic conduction measures;
SARC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg24101359	chr6:42928495	GNMT	0.43	5.98	0.36	8.24e-9	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs2303745	0.544	rs12710308	chr19:17395879	T/A	cg22549504	chr19:17448937	GTPBP3	0.48	4.94	0.31	1.46e-6	Systemic lupus erythematosus;
SARC	cis	rs1215050	0.791	rs6813619	chr4:98830768	C/T	cg05340658	chr4:99064831	C4orf37	-0.44	-5.89	-0.36	1.32e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg26335602	chr6:28129616	ZNF389	0.47	5.49	0.34	1.03e-7	Cardiac Troponin-T levels;
SARC	cis	rs734999	0.550	rs2985855	chr1:2531372	A/C	cg20673091	chr1:2541236	MMEL1	-0.33	-5.09	-0.32	7.54e-7	Ulcerative colitis;
SARC	cis	rs9303280	0.901	rs2290400	chr17:38066240	A/G	cg19468946	chr17:37922297	IKZF3	-0.29	-4.77	-0.3	3.25e-6	Self-reported allergy;
SARC	cis	rs9896052	0.614	rs34042490	chr17:73452956	T/C	cg27037648	chr17:73511087	CASKIN2	0.42	4.79	0.3	3.03e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs6598955	0.724	rs10902737	chr1:26635716	G/A	cg21300267	chr1:26547059	NA	-0.25	-4.73	-0.3	3.95e-6	Obesity-related traits;
SARC	cis	rs796364	1.000	rs769949	chr2:200729558	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.58	0.4	3.11e-10	Schizophrenia;
SARC	cis	rs709400	0.628	rs7150317	chr14:103921691	C/G	cg12935359	chr14:103987150	CKB	-0.4	-5.9	-0.36	1.24e-8	Body mass index;
SARC	cis	rs5753618	0.561	rs2040533	chr22:31679110	G/C	cg00478049	chr22:31556069	RNF185	0.43	4.75	0.3	3.54e-6	Colorectal cancer;
SARC	cis	rs734999	0.545	rs12752515	chr1:2564465	T/C	cg18854424	chr1:2615690	NA	-0.32	-5.11	-0.32	6.74e-7	Ulcerative colitis;
SARC	trans	rs9650657	0.501	rs3021500	chr8:11023997	G/C	cg08975724	chr8:8085496	FLJ10661	-0.55	-7.04	-0.42	2.14e-11	Neuroticism;
SARC	cis	rs876084	0.505	rs11988495	chr8:121128487	A/G	cg06265175	chr8:121136014	COL14A1	0.56	7.24	0.43	6.63e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg12923728	chr3:195709715	SDHAP1	-0.69	-8.57	-0.49	1.4e-15	Pancreatic cancer;
SARC	cis	rs13390159	1.000	rs13390159	chr2:237156549	G/A	cg19324714	chr2:237145437	ASB18	0.49	4.85	0.3	2.28e-6	Response to statin therapy;
SARC	cis	rs1784581	0.802	rs2156747	chr6:162430000	C/G	cg17173639	chr6:162384350	PARK2	-0.63	-8.53	-0.49	1.84e-15	Itch intensity from mosquito bite;
SARC	cis	rs2529049	0.537	rs2721799	chr7:24691332	T/C	cg17569154	chr7:24781545	DFNA5	0.5	7.22	0.43	7.42e-12	Urate levels in obese individuals;
SARC	cis	rs2153535	0.580	rs2327056	chr6:8443305	C/T	cg21535247	chr6:8435926	SLC35B3	0.56	7.01	0.42	2.6e-11	Motion sickness;
SARC	cis	rs17376456	0.569	rs6556839	chr5:93206292	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.53	-5.53	-0.34	8.42e-8	Diabetic retinopathy;
SARC	cis	rs6815814	0.950	rs5743560	chr4:38806200	G/T	cg09316306	chr4:38807337	TLR1	0.5	5.16	0.32	5.23e-7	Breast cancer;
SARC	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg05861140	chr6:150128134	PCMT1	-0.39	-5.12	-0.32	6.36e-7	Lung cancer;
SARC	cis	rs7927592	0.763	rs596494	chr11:68251054	T/G	cg01657329	chr11:68192670	LRP5	-0.36	-5.06	-0.31	8.4e-7	Total body bone mineral density;
SARC	cis	rs6772849	0.930	rs9813197	chr3:128369104	G/A	cg01163369	chr3:128370232	RPN1	-0.34	-4.94	-0.31	1.47e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs6693567	0.565	rs1260398	chr1:150279876	T/C	cg09579323	chr1:150459698	TARS2	-0.41	-5.26	-0.33	3.34e-7	Migraine;
SARC	cis	rs2153535	0.580	rs6902001	chr6:8477055	T/G	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	cis	rs644799	0.542	rs10831418	chr11:95468828	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.68	8.69	0.49	6.62e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg21659725	chr3:3221576	CRBN	-0.53	-6.84	-0.41	7.03e-11	Intelligence (multi-trait analysis);
SARC	cis	rs7020830	0.898	rs12554874	chr9:37073902	C/T	cg14294708	chr9:37120828	ZCCHC7	1.14	21.54	0.82	2.29e-57	Schizophrenia;
SARC	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg13114125	chr14:105738426	BRF1	0.82	12.23	0.63	6.95e-27	Mean platelet volume;Platelet distribution width;
SARC	trans	rs9650657	0.801	rs4841437	chr8:10596795	T/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.77	-0.41	1.06e-10	Neuroticism;
SARC	cis	rs3772130	0.564	rs35178434	chr3:121595936	G/A	cg20356878	chr3:121714668	ILDR1	0.4	6.31	0.38	1.42e-9	Cognitive performance;
SARC	cis	rs2288073	0.965	rs10173949	chr2:24410256	A/C	cg06627628	chr2:24431161	ITSN2	-0.63	-7.66	-0.45	4.86e-13	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs7474896	0.616	rs2474561	chr10:38373544	C/T	cg25427524	chr10:38739819	LOC399744	-0.5	-5.36	-0.33	2.01e-7	Obesity (extreme);
SARC	cis	rs11792861	0.890	rs3087979	chr9:111781779	T/C	cg13535736	chr9:111863775	C9orf5	-0.39	-4.82	-0.3	2.61e-6	Menarche (age at onset);
SARC	cis	rs911555	0.755	rs2273702	chr14:103918182	C/G	cg26031613	chr14:104095156	KLC1	-0.41	-4.76	-0.3	3.34e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2276314	0.947	rs16967319	chr18:33573525	A/G	cg19628046	chr18:33552617	C18orf21	0.61	6.06	0.37	5.57e-9	Endometriosis;Drug-induced torsades de pointes;
SARC	trans	rs61931739	0.500	rs12146843	chr12:34451738	T/G	cg26384229	chr12:38710491	ALG10B	0.84	12.56	0.64	5.71e-28	Morning vs. evening chronotype;
SARC	cis	rs8114671	0.662	rs3761143	chr20:33545745	C/T	cg07148914	chr20:33460835	GGT7	0.42	5.09	0.32	7.54e-7	Height;
SARC	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg12463550	chr7:65579703	CRCP	0.47	5.16	0.32	5.3e-7	Aortic root size;
SARC	cis	rs7712401	0.601	rs30054	chr5:122301999	A/G	cg19412675	chr5:122181750	SNX24	0.4	5.13	0.32	5.98e-7	Mean platelet volume;
SARC	trans	rs10771431	0.597	rs7976807	chr12:9352459	G/A	cg27600084	chr12:12264075	NA	0.51	6.66	0.4	1.93e-10	Breast size;
SARC	cis	rs4481887	0.830	rs4916126	chr1:248466604	G/A	cg13385794	chr1:248469461	NA	0.36	5.57	0.34	7.1e-8	Common traits (Other);
SARC	cis	rs4481887	1.000	rs4306162	chr1:248468509	C/T	cg00666640	chr1:248458726	OR2T12	0.38	6.42	0.39	7.43e-10	Common traits (Other);
SARC	cis	rs11711311	1.000	rs9828099	chr3:113518402	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	8.69	0.49	6.43e-16	IgG glycosylation;
SARC	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg03806693	chr22:41940476	POLR3H	0.83	11.73	0.61	2.8e-25	Vitiligo;
SARC	cis	rs4919087	0.962	rs3814164	chr10:98982749	G/A	cg25902810	chr10:99078978	FRAT1	0.45	5.52	0.34	8.9e-8	Monocyte count;
SARC	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	12.2	0.62	8.46e-27	Alzheimer's disease;
SARC	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg05368731	chr17:41323189	NBR1	0.81	9.93	0.55	1.35e-19	Menopause (age at onset);
SARC	cis	rs7216064	0.532	rs3890640	chr17:66053028	C/T	cg12091567	chr17:66097778	LOC651250	0.96	12.88	0.64	5.09e-29	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs765787	0.530	rs28396110	chr15:45536909	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.67e-7	Uric acid levels;
SARC	cis	rs1801251	1.000	rs6745879	chr2:233590007	A/G	cg25237894	chr2:233734115	C2orf82	0.39	5.08	0.32	7.72e-7	Coronary artery disease;
SARC	trans	rs208520	1.000	rs12190187	chr6:66973207	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	9.16	0.51	2.69e-17	Exhaled nitric oxide output;
SARC	cis	rs11098499	0.954	rs10031665	chr4:120422852	T/C	cg09307838	chr4:120376055	NA	0.93	12.73	0.64	1.6e-28	Corneal astigmatism;
SARC	cis	rs1707322	0.686	rs1541131	chr1:46084934	G/A	cg06784218	chr1:46089804	CCDC17	-0.38	-6.76	-0.4	1.12e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs858239	0.862	rs1728292	chr7:23263474	C/G	cg23682824	chr7:23144976	KLHL7	0.56	6.98	0.42	3e-11	Cerebrospinal fluid biomarker levels;
SARC	cis	rs2228479	1.000	rs12596492	chr16:89957169	T/G	cg06558623	chr16:89946397	TCF25	0.89	6.28	0.38	1.67e-9	Skin colour saturation;
SARC	cis	rs896854	0.738	rs481887	chr8:95967838	A/G	cg09323728	chr8:95962352	TP53INP1	0.29	4.77	0.3	3.27e-6	Type 2 diabetes;
SARC	cis	rs8180040	0.966	rs57346147	chr3:47410564	C/G	cg27129171	chr3:47204927	SETD2	-0.66	-9.21	-0.52	1.91e-17	Colorectal cancer;
SARC	cis	rs672059	1.000	rs544352	chr1:183157546	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.51	6.92	0.41	4.32e-11	Hypertriglyceridemia;
SARC	cis	rs3617	0.625	rs11922961	chr3:52868610	T/C	cg18404041	chr3:52824283	ITIH1	0.38	5.56	0.34	7.4e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs9462027	0.630	rs9469871	chr6:34745007	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.84	-0.36	1.71e-8	Systemic lupus erythematosus;
SARC	cis	rs4481887	0.962	rs6686911	chr1:248476969	T/C	cg00666640	chr1:248458726	OR2T12	0.39	6.45	0.39	6.29e-10	Common traits (Other);
SARC	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg05234568	chr11:5960015	NA	0.49	6.82	0.41	7.58e-11	DNA methylation (variation);
SARC	cis	rs62432291	0.681	rs378547	chr6:159662525	A/G	cg14500486	chr6:159655392	FNDC1	0.5	5.09	0.32	7.22e-7	Joint mobility (Beighton score);
SARC	cis	rs4319547	0.614	rs10846764	chr12:122874297	T/C	cg05707623	chr12:122985044	ZCCHC8	0.57	6.41	0.39	7.89e-10	Body mass index;
SARC	cis	rs2439831	0.571	rs2470121	chr15:43937618	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	7.52	0.44	1.19e-12	Lung cancer in ever smokers;
SARC	cis	rs17376456	0.597	rs7708175	chr5:93381182	A/G	cg25358565	chr5:93447407	FAM172A	-0.86	-10.12	-0.55	3.48e-20	Diabetic retinopathy;
SARC	cis	rs2463822	0.687	rs118012228	chr11:62155914	G/A	cg06239285	chr11:62104954	ASRGL1	-0.85	-8.1	-0.47	3.09e-14	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg24642844	chr7:1081250	C7orf50	-0.6	-6.12	-0.37	4.02e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs13161895	0.887	rs1103811	chr5:179413168	G/A	cg02702477	chr5:179499311	RNF130	0.5	5.11	0.32	6.75e-7	LDL cholesterol;
SARC	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg24209194	chr3:40518798	ZNF619	0.58	7.22	0.43	7.36e-12	Renal cell carcinoma;
SARC	cis	rs9398803	0.687	rs9401897	chr6:126940641	A/G	cg20229609	chr6:126660872	C6orf173	0.37	5.39	0.33	1.74e-7	Male-pattern baldness;
SARC	cis	rs7312933	0.528	rs10880238	chr12:42489613	A/G	cg01256987	chr12:42539512	GXYLT1	-0.41	-6.1	-0.37	4.43e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs9682041	0.696	rs9872796	chr3:170099393	T/G	cg11886554	chr3:170076028	SKIL	1.07	8.49	0.49	2.41e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs9341808	0.539	rs2490253	chr6:80895870	T/C	cg08355045	chr6:80787529	NA	0.37	5.86	0.36	1.58e-8	Sitting height ratio;
SARC	cis	rs9326248	0.559	rs609177	chr11:116770517	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.56	7.16	0.42	1.02e-11	Blood protein levels;
SARC	cis	rs6542838	0.702	rs6419564	chr2:99534113	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-6.01	-0.37	7.05e-9	Fear of minor pain;
SARC	cis	rs12311304	1.000	rs12309210	chr12:15388361	T/C	cg08258403	chr12:15378311	NA	0.46	7.17	0.43	9.75e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs7615952	0.688	rs9754526	chr3:125542866	C/A	cg05084668	chr3:125655381	ALG1L	-0.49	-5.2	-0.32	4.31e-7	Blood pressure (smoking interaction);
SARC	cis	rs2288073	0.965	rs6545340	chr2:24422269	C/G	cg26838691	chr2:24397539	C2orf84	-0.54	-6.73	-0.4	1.34e-10	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs9467773	0.620	rs2451731	chr6:26624822	A/C	cg11502198	chr6:26597334	ABT1	0.62	8.54	0.49	1.78e-15	Intelligence (multi-trait analysis);
SARC	cis	rs4243830	0.850	rs4908910	chr1:6599362	T/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.01	-9.9	-0.54	1.61e-19	Body mass index;
SARC	trans	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg20587970	chr11:113659929	NA	-1.01	-10.18	-0.55	2.18e-20	Hip circumference adjusted for BMI;
SARC	cis	rs3106136	0.872	rs2059605	chr4:95255212	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.4	-6.25	-0.38	1.89e-9	Capecitabine sensitivity;
SARC	cis	rs10752881	1.000	rs10737236	chr1:182988608	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.69	-9.92	-0.55	1.39e-19	Colorectal cancer;
SARC	cis	rs4970988	0.787	rs1532770	chr1:150725335	G/T	cg13175981	chr1:150552382	MCL1	-0.55	-6.66	-0.4	1.91e-10	Urate levels;
SARC	cis	rs1707322	0.752	rs28812624	chr1:46203736	T/A	cg03146154	chr1:46216737	IPP	0.52	6.3	0.38	1.44e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7428	0.502	rs3184781	chr2:85549527	T/C	cg03728395	chr2:85555865	TGOLN2	-0.45	-6.3	-0.38	1.47e-9	Ear protrusion;
SARC	cis	rs1419980	0.673	rs1978284	chr12:7771151	G/A	cg10578777	chr12:7781093	NA	0.56	6.01	0.37	6.92e-9	HDL cholesterol levels;
SARC	cis	rs7824557	0.606	rs2736273	chr8:11199938	C/A	cg21775007	chr8:11205619	TDH	0.68	9.06	0.51	5.44e-17	Retinal vascular caliber;
SARC	cis	rs79149102	0.579	rs6495146	chr15:75367630	A/T	cg17294928	chr15:75287854	SCAMP5	-0.89	-8.14	-0.47	2.42e-14	Lung cancer;
SARC	cis	rs10992471	0.528	rs3780347	chr9:95266812	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.42	-4.77	-0.3	3.18e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs3741151	0.773	rs7945825	chr11:73287140	G/C	cg17517138	chr11:73019481	ARHGEF17	0.9	6.41	0.39	8.1e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs6089584	1.000	rs6089585	chr20:60564395	G/A	cg06108461	chr20:60628389	TAF4	-0.91	-11.92	-0.62	7.02e-26	Body mass index;
SARC	cis	rs57506017	0.585	rs5011434	chr7:12268717	C/T	cg23422036	chr7:12250390	TMEM106B	0.45	5.87	0.36	1.46e-8	Neuroticism;
SARC	cis	rs2380220	1.000	rs2380220	chr6:95967412	T/C	cg07718321	chr6:96025334	MANEA	0.49	5.01	0.31	1.1e-6	Behavioural disinhibition (generation interaction);
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg23074799	chr7:18126459	NA	-0.49	-6.67	-0.4	1.8e-10	Schizophrenia;
SARC	cis	rs10979	1.000	rs9321923	chr6:143897206	A/G	cg25407410	chr6:143891975	LOC285740	-0.64	-8.78	-0.5	3.67e-16	Hypospadias;
SARC	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg17971929	chr21:40555470	PSMG1	0.99	13.79	0.67	4.84e-32	Cognitive function;
SARC	trans	rs2727020	0.636	rs11040368	chr11:49453602	C/A	cg15704280	chr7:45808275	SEPT13	-0.86	-14.03	-0.68	7.69e-33	Coronary artery disease;
SARC	cis	rs9457247	0.534	rs4710154	chr6:167394634	A/T	cg23791538	chr6:167370224	RNASET2	0.65	9.29	0.52	1.15e-17	Crohn's disease;
SARC	cis	rs9611519	0.808	rs5751074	chr22:41665722	G/A	cg03806693	chr22:41940476	POLR3H	-0.65	-8.52	-0.49	2.03e-15	Neuroticism;
SARC	cis	rs933688	0.532	rs11740007	chr5:90545498	C/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.5	-5.63	-0.35	5.27e-8	Smoking behavior;
SARC	cis	rs11574514	1.000	rs76177657	chr16:68023790	C/T	cg01866162	chr16:67596514	CTCF	1.03	6.53	0.39	3.97e-10	Crohn's disease;
SARC	cis	rs854765	0.547	rs12150369	chr17:17911014	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.46	5.99	0.37	7.81e-9	Total body bone mineral density;
SARC	cis	rs6831352	0.959	rs1139490	chr4:100045141	C/T	cg13256891	chr4:100009986	ADH5	0.67	9.14	0.51	3.21e-17	Alcohol dependence;
SARC	cis	rs2361718	0.933	rs8077849	chr17:78104137	C/T	cg06718696	chr17:78121285	EIF4A3	0.49	5.6	0.34	5.87e-8	Yeast infection;
SARC	cis	rs4253772	0.530	rs113258957	chr22:46663678	G/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.63	4.82	0.3	2.63e-6	LDL cholesterol;Cholesterol, total;
SARC	cis	rs11676348	0.712	rs11687434	chr2:218945143	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.43	-5.5	-0.34	9.85e-8	Ulcerative colitis;
SARC	cis	rs6089584	1.000	rs6089583	chr20:60563624	G/A	cg13770153	chr20:60521292	NA	-0.55	-7.78	-0.45	2.37e-13	Body mass index;
SARC	cis	rs2013441	1.000	rs2526462	chr17:20079460	A/T	cg13482628	chr17:19912719	NA	-0.48	-6.15	-0.37	3.36e-9	Obesity-related traits;
SARC	cis	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg01579765	chr21:45077557	HSF2BP	-0.38	-6.46	-0.39	5.93e-10	Mean corpuscular volume;
SARC	cis	rs9790314	0.535	rs4679922	chr3:160642984	T/C	cg04691961	chr3:161091175	C3orf57	0.61	8.4	0.48	4.46e-15	Morning vs. evening chronotype;
SARC	cis	rs6060960	0.537	rs6087787	chr20:30452089	G/A	cg09796376	chr20:30640595	HCK	0.55	4.9	0.31	1.83e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
SARC	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg19223190	chr17:80058835	NA	-0.43	-6.02	-0.37	6.57e-9	Life satisfaction;
SARC	cis	rs7584330	0.826	rs72620825	chr2:238381243	G/A	cg14458575	chr2:238380390	NA	0.57	6.11	0.37	4.14e-9	Prostate cancer;
SARC	cis	rs11874712	1.000	rs11082509	chr18:43655010	G/A	cg25174615	chr18:43684699	ATP5A1;HAUS1	0.4	4.75	0.3	3.52e-6	Migraine - clinic-based;
SARC	cis	rs6484504	0.625	rs10835766	chr11:31374329	C/A	cg19308365	chr11:31391254	DNAJC24;DCDC1	0.38	4.78	0.3	3.12e-6	Red blood cell count;
SARC	cis	rs13008686	1	rs13008686	chr2:227339461	T/G	cg03426602	chr2:227312417	NA	-0.38	-4.72	-0.3	4.03e-6	Breast cancer;
SARC	trans	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.35	-0.38	1.09e-9	Neuroticism;
SARC	cis	rs72781680	0.611	rs55788848	chr2:24268721	C/T	cg08917208	chr2:24149416	ATAD2B	0.66	6.39	0.39	8.72e-10	Lymphocyte counts;
SARC	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg11764359	chr7:65958608	NA	-0.83	-11.09	-0.59	3.13e-23	Aortic root size;
SARC	cis	rs10782582	0.569	rs4549990	chr1:76125075	A/G	cg10523679	chr1:76189770	ACADM	-0.41	-5.1	-0.32	6.96e-7	Daytime sleep phenotypes;
SARC	cis	rs4820294	1.000	rs78974622	chr22:38059925	A/C	cg21798802	chr22:38057573	PDXP	0.34	5.09	0.32	7.39e-7	Fat distribution (HIV);
SARC	cis	rs2286885	1.000	rs10819169	chr9:129249625	C/T	cg14319473	chr9:129242481	FAM125B	0.39	4.89	0.31	1.87e-6	Intraocular pressure;
SARC	cis	rs11792861	0.926	rs72607163	chr9:111803128	G/T	cg13535736	chr9:111863775	C9orf5	-0.39	-4.79	-0.3	2.93e-6	Menarche (age at onset);
SARC	cis	rs4478037	0.822	rs9825335	chr3:33123292	A/C	cg19404215	chr3:33155277	CRTAP	0.53	4.74	0.3	3.69e-6	Major depressive disorder;
SARC	cis	rs10046574	0.908	rs997530	chr7:135054147	T/C	cg27474649	chr7:135195673	CNOT4	0.83	6.42	0.39	7.53e-10	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs10876993	0.928	rs2640631	chr12:58067532	A/T	cg18357645	chr12:58087776	OS9	0.44	5.77	0.35	2.53e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs459571	0.959	rs2073818	chr9:136918662	C/A	cg13789015	chr9:136890014	NCRNA00094	0.61	8.48	0.49	2.57e-15	Platelet distribution width;
SARC	cis	rs12216125	0.549	rs9358905	chr6:26077839	T/A	cg17691542	chr6:26056736	HIST1H1C	0.48	5.87	0.36	1.48e-8	Iron status biomarkers;
SARC	cis	rs4595586	0.525	rs4441057	chr12:39420620	T/A	cg26384229	chr12:38710491	ALG10B	0.55	6.14	0.37	3.48e-9	Morning vs. evening chronotype;
SARC	cis	rs10463316	0.817	rs12653378	chr5:150802366	A/G	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.29	-0.33	2.79e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs6540556	0.682	rs2282741	chr1:209900609	G/C	cg05527609	chr1:210001259	C1orf107	-0.54	-5.6	-0.34	6.1e-8	Red blood cell count;
SARC	cis	rs35995292	0.963	rs2893567	chr7:38902934	A/G	cg19327137	chr7:38886074	VPS41	0.36	5.1	0.32	7e-7	Subjective well-being (multi-trait analysis);
SARC	cis	rs34779708	0.931	rs10466072	chr10:35402756	C/T	cg03585969	chr10:35415529	CREM	0.4	5.08	0.32	7.56e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs9790314	0.934	rs9290074	chr3:160997823	T/C	cg03342759	chr3:160939853	NMD3	-0.61	-7.73	-0.45	3.22e-13	Morning vs. evening chronotype;
SARC	cis	rs62432291	0.681	rs419836	chr6:159659481	C/T	cg14500486	chr6:159655392	FNDC1	-0.64	-6.37	-0.39	9.75e-10	Joint mobility (Beighton score);
SARC	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.41	-6.22	-0.38	2.33e-9	Menopause (age at onset);
SARC	cis	rs986417	0.901	rs1884095	chr14:61017024	C/G	cg27398547	chr14:60952738	C14orf39	0.97	8.83	0.5	2.58e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs2832191	1.000	rs2832190	chr21:30488226	G/A	cg24692254	chr21:30365293	RNF160	-0.77	-10.72	-0.57	4.73e-22	Dental caries;
SARC	cis	rs9914544	0.545	rs7212905	chr17:18774271	A/G	cg25390199	chr17:18761479	PRPSAP2	0.42	5.46	0.34	1.19e-7	Educational attainment (years of education);
SARC	cis	rs35213789	0.562	rs2533454	chr7:69057091	C/A	cg10619644	chr7:69149951	AUTS2	-0.34	-4.88	-0.3	1.96e-6	Childhood ear infection;
SARC	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg07701084	chr6:150067640	NUP43	0.45	5.49	0.34	1.02e-7	Lung cancer;
SARC	cis	rs4803468	1.000	rs284649	chr19:41926838	C/T	cg09537434	chr19:41945824	ATP5SL	-0.98	-17.13	-0.75	3.95e-43	Height;
SARC	cis	rs4792901	0.959	rs2293015	chr17:41621999	G/A	cg22562494	chr17:41607896	ETV4	-0.33	-5.3	-0.33	2.63e-7	Dupuytren's disease;
SARC	cis	rs735539	0.563	rs9579950	chr13:21347384	G/A	cg16922012	chr13:21400325	XPO4	-0.43	-5.68	-0.35	3.9e-8	Dental caries;
SARC	cis	rs10504229	0.593	rs74760806	chr8:58024785	C/T	cg21724239	chr8:58056113	NA	0.67	6.68	0.4	1.76e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs17376456	0.877	rs13173952	chr5:93307557	A/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.54	0.34	8.17e-8	Diabetic retinopathy;
SARC	cis	rs7949030	1.000	rs2956993	chr11:62406162	G/T	cg11742103	chr11:62369870	EML3;MTA2	-0.38	-5.57	-0.34	7.12e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs2228479	0.619	rs77847775	chr16:89896243	C/T	cg06558623	chr16:89946397	TCF25	0.91	6.5	0.39	4.78e-10	Skin colour saturation;
SARC	cis	rs9487051	0.872	rs9487034	chr6:109605899	A/G	cg01475377	chr6:109611718	NA	-0.4	-5.85	-0.36	1.69e-8	Reticulocyte fraction of red cells;
SARC	cis	rs6594499	0.564	rs12518884	chr5:110452223	A/G	cg04022379	chr5:110408740	TSLP	0.61	7.97	0.46	7.25e-14	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs9886651	0.905	rs10110243	chr8:128805020	A/G	cg24514600	chr8:128805414	PVT1	-0.43	-5.6	-0.34	6e-8	Epithelial ovarian cancer;Serous invasive ovarian cancer;
SARC	cis	rs11676348	0.846	rs13009946	chr2:219007752	A/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.5	-6.58	-0.4	3.06e-10	Ulcerative colitis;
SARC	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg18876405	chr7:65276391	NA	-0.43	-4.75	-0.3	3.58e-6	Aortic root size;
SARC	cis	rs2439831	1.000	rs689754	chr15:43775895	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.05	9.76	0.54	4.27e-19	Lung cancer in ever smokers;
SARC	cis	rs1448094	0.512	rs11832992	chr12:86240790	T/C	cg02569458	chr12:86230093	RASSF9	0.39	5.45	0.34	1.26e-7	Major depressive disorder;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14787155	chr3:108308533	DZIP3;KIAA1524	0.47	6.27	0.38	1.72e-9	Smoking initiation;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg01820584	chr4:52735830	DCUN1D4	0.47	6.36	0.38	1.03e-9	Thyroid stimulating hormone;
SARC	cis	rs6964587	1.000	rs2299240	chr7:91654618	A/G	cg17063962	chr7:91808500	NA	0.96	16.55	0.74	3.39e-41	Breast cancer;
SARC	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg26681399	chr22:41777847	TEF	0.47	5.14	0.32	5.91e-7	Vitiligo;
SARC	cis	rs8180040	0.764	rs13062022	chr3:47169375	G/A	cg02527881	chr3:46936655	PTH1R	-0.31	-4.89	-0.3	1.91e-6	Colorectal cancer;
SARC	cis	rs7209700	0.574	rs3851806	chr17:45350919	G/C	cg18085866	chr17:45331354	ITGB3	-0.53	-5.0	-0.31	1.13e-6	IgG glycosylation;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg04270405	chr13:111367185	ING1	-0.76	-5.74	-0.35	2.9e-8	Obesity-related traits;
SARC	cis	rs12579753	0.789	rs35448307	chr12:82165817	A/G	cg07988820	chr12:82153109	PPFIA2	-0.58	-6.86	-0.41	6.21e-11	Resting heart rate;
SARC	cis	rs4642101	0.669	rs1467026	chr3:12830775	G/A	cg24848339	chr3:12840334	CAND2	0.4	6.06	0.37	5.44e-9	QRS complex (12-leadsum);
SARC	cis	rs7197653	0.748	rs2279538	chr16:68397106	C/G	cg09835421	chr16:68378352	PRMT7	-0.67	-6.3	-0.38	1.45e-9	Magnesium levels;
SARC	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg26335602	chr6:28129616	ZNF389	0.48	5.47	0.34	1.17e-7	Cardiac Troponin-T levels;
SARC	cis	rs7264396	0.943	rs6060448	chr20:34112192	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.41	4.75	0.3	3.59e-6	Total cholesterol levels;
SARC	cis	rs2153535	0.580	rs4960413	chr6:8438466	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg11987759	chr7:65425863	GUSB	0.45	5.98	0.36	8.46e-9	Aortic root size;
SARC	cis	rs67478160	0.595	rs12879501	chr14:104272634	G/T	cg26031613	chr14:104095156	KLC1	-0.4	-4.79	-0.3	3e-6	Schizophrenia;
SARC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg09373136	chr17:61933544	TCAM1	-0.44	-5.99	-0.37	7.99e-9	Prudent dietary pattern;
SARC	cis	rs7481584	0.669	rs12793371	chr11:3034709	A/G	cg08508325	chr11:3079039	CARS	0.23	5.17	0.32	4.92e-7	Calcium levels;
SARC	cis	rs9398803	0.830	rs2039735	chr6:126745076	T/C	cg19875578	chr6:126661172	C6orf173	0.59	7.98	0.46	6.62e-14	Male-pattern baldness;
SARC	cis	rs7465272	1.000	rs35476574	chr8:143683784	C/A	cg10596483	chr8:143751796	JRK	0.55	5.93	0.36	1.09e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.18	0.38	2.83e-9	Intelligence (multi-trait analysis);
SARC	cis	rs2439831	0.681	rs511673	chr15:43618863	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.81	9.01	0.51	7.46e-17	Lung cancer in ever smokers;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg23551132	chr14:32030686	NUBPL	0.59	7.75	0.45	2.8e-13	Breast cancer;
SARC	cis	rs16976116	0.901	rs2899580	chr15:55491571	A/G	cg11288833	chr15:55489084	RSL24D1	0.63	6.09	0.37	4.66e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs13095912	0.962	rs34505819	chr3:185340721	C/T	cg11274856	chr3:185301563	NA	0.35	4.84	0.3	2.34e-6	Systolic blood pressure;
SARC	cis	rs6963495	0.872	rs73190193	chr7:105164852	A/G	cg19920283	chr7:105172520	RINT1	0.65	5.48	0.34	1.09e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs10089	1.000	rs1560636	chr5:127447987	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.82	10.24	0.56	1.51e-20	Ileal carcinoids;
SARC	cis	rs67311347	1.000	rs12638199	chr3:40475285	A/G	cg09455208	chr3:40491958	NA	0.41	6.58	0.4	3.11e-10	Renal cell carcinoma;
SARC	cis	rs9457247	1.000	rs408040	chr6:167398903	A/T	cg23791538	chr6:167370224	RNASET2	-0.63	-8.73	-0.5	4.84e-16	Crohn's disease;
SARC	cis	rs9470366	0.816	rs1321311	chr6:36622900	C/A	cg08179530	chr6:36648295	CDKN1A	0.54	5.97	0.36	8.64e-9	QRS duration;
SARC	cis	rs6728642	0.803	rs11891458	chr2:97632450	G/T	cg26665480	chr2:98280029	ACTR1B	-0.66	-6.52	-0.39	4.35e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs6696846	0.765	rs4394715	chr1:205108393	T/G	cg21545522	chr1:205238299	TMCC2	0.35	4.91	0.31	1.73e-6	Red blood cell count;
SARC	cis	rs7843479	0.562	rs6988010	chr8:21859084	G/A	cg17168535	chr8:21777572	XPO7	0.84	12.74	0.64	1.43e-28	Mean corpuscular volume;
SARC	cis	rs477692	0.673	rs7909964	chr10:131338714	T/C	cg05714579	chr10:131428358	MGMT	0.55	7.19	0.43	8.58e-12	Response to temozolomide;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg16347018	chr20:57607424	ATP5E	0.51	6.94	0.41	3.83e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs7937682	0.632	rs10891297	chr11:111770150	C/T	cg22437258	chr11:111473054	SIK2	-0.48	-5.51	-0.34	9.29e-8	Primary sclerosing cholangitis;
SARC	cis	rs13191362	1.000	rs73035025	chr6:163000988	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.49	0.34	1.04e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs7681440	0.583	rs2619367	chr4:90767095	A/C	cg06632027	chr4:90757378	SNCA	-0.46	-5.74	-0.35	2.87e-8	Dementia with Lewy bodies;
SARC	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.35	-0.43	3.34e-12	Gut microbiome composition (summer);
SARC	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg20965017	chr5:231967	SDHA	-0.58	-5.73	-0.35	3.14e-8	Breast cancer;
SARC	cis	rs9503598	0.636	rs7775474	chr6:3468224	T/C	cg00476032	chr6:3446245	SLC22A23	0.38	6.01	0.37	7.15e-9	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
SARC	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg12756686	chr19:29218302	NA	0.51	6.19	0.38	2.64e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs17270561	0.609	rs9379788	chr6:25742759	A/C	cg17691542	chr6:26056736	HIST1H1C	0.61	7.36	0.43	3.06e-12	Iron status biomarkers;
SARC	cis	rs3796352	1.000	rs36090694	chr3:53010742	T/C	cg07884673	chr3:53033167	SFMBT1	0.81	5.1	0.32	7.18e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs3733585	0.699	rs17245723	chr4:9962218	A/T	cg11266682	chr4:10021025	SLC2A9	-0.37	-6.31	-0.38	1.4e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg26850624	chr5:429559	AHRR	-0.31	-4.77	-0.3	3.21e-6	Cystic fibrosis severity;
SARC	cis	rs3126085	0.935	rs11584340	chr1:152285930	G/A	cg03465714	chr1:152285911	FLG	0.48	5.59	0.34	6.32e-8	Atopic dermatitis;
SARC	cis	rs2834188	0.557	rs2834186	chr21:34686753	C/T	cg04842828	chr21:34696676	IFNAR1	0.4	5.01	0.31	1.07e-6	Narcolepsy;
SARC	cis	rs66887589	0.720	rs11724758	chr4:120239878	G/A	cg09307838	chr4:120376055	NA	0.56	7.53	0.44	1.11e-12	Diastolic blood pressure;
SARC	cis	rs13191362	0.935	rs13219926	chr6:163004213	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.49	0.34	1.04e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2073300	0.609	rs6137936	chr20:23385232	C/T	cg12062639	chr20:23401060	NAPB	1.02	6.94	0.41	3.78e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.03	12.36	0.63	2.47e-27	Platelet count;
SARC	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg00149659	chr3:10157352	C3orf10	0.67	6.18	0.38	2.79e-9	Alzheimer's disease;
SARC	cis	rs9905704	0.647	rs2036730	chr17:57038282	A/G	cg12560992	chr17:57184187	TRIM37	0.4	4.73	0.3	3.81e-6	Testicular germ cell tumor;
SARC	cis	rs899997	1.000	rs7182694	chr15:79045030	C/T	cg04896959	chr15:78267971	NA	0.45	5.38	0.33	1.77e-7	Coronary artery disease or large artery stroke;
SARC	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg06108461	chr20:60628389	TAF4	-0.87	-11.65	-0.61	5.28e-25	Body mass index;
SARC	cis	rs17270561	0.636	rs6456697	chr6:25741434	A/G	cg16482183	chr6:26056742	HIST1H1C	0.43	5.08	0.32	7.76e-7	Iron status biomarkers;
SARC	cis	rs6568686	0.679	rs7776184	chr6:111809918	G/A	cg15721981	chr6:111408429	SLC16A10	-0.6	-4.85	-0.3	2.22e-6	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	trans	rs1814175	0.727	rs2140597	chr11:49873946	G/A	cg15704280	chr7:45808275	SEPT13	-0.96	-18.05	-0.76	3.72e-46	Height;
SARC	cis	rs11225247	0.772	rs34296997	chr11:102238607	A/G	cg11690896	chr11:102217788	BIRC2	0.72	5.15	0.32	5.67e-7	Vein graft stenosis in coronary artery bypass grafting;
SARC	cis	rs4595586	0.545	rs7136002	chr12:39369168	G/A	cg13010199	chr12:38710504	ALG10B	0.4	4.75	0.3	3.57e-6	Morning vs. evening chronotype;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg13300911	chr15:42119951	JMJD7;MAPKBP1;JMJD7-PLA2G4B	0.5	6.64	0.4	2.17e-10	Breast cancer;
SARC	cis	rs362296	0.698	rs3135171	chr4:3261127	A/G	cg06533319	chr4:3265114	C4orf44	0.34	5.15	0.32	5.57e-7	Parental longevity (mother's age at death);
SARC	cis	rs6430585	0.528	rs895285	chr2:136710554	A/G	cg07169764	chr2:136633963	MCM6	1.02	13.66	0.67	1.37e-31	Corneal structure;
SARC	cis	rs13191362	0.935	rs34603926	chr6:163266793	A/T	cg18825119	chr6:163149453	PACRG;PARK2	0.37	5.14	0.32	5.82e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs1018836	0.544	rs2339154	chr8:91459316	T/C	cg16814680	chr8:91681699	NA	-0.58	-7.79	-0.45	2.27e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg14019146	chr3:50243930	SLC38A3	-0.33	-5.07	-0.32	8.02e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7953249	0.618	rs7954039	chr12:121398654	A/C	cg15155738	chr12:121454335	C12orf43	-0.45	-5.48	-0.34	1.13e-7	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs2239547	0.522	rs6770957	chr3:52995416	T/C	cg11645453	chr3:52864694	ITIH4	0.37	5.78	0.35	2.37e-8	Schizophrenia;
SARC	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg11987759	chr7:65425863	GUSB	0.49	5.98	0.36	8.43e-9	Aortic root size;
SARC	cis	rs6963495	0.818	rs6961863	chr7:105180953	C/T	cg13798780	chr7:105162888	PUS7	0.57	5.32	0.33	2.48e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs9790314	1.000	rs4350933	chr3:160955879	G/T	cg04691961	chr3:161091175	C3orf57	-0.75	-10.8	-0.58	2.59e-22	Morning vs. evening chronotype;
SARC	cis	rs11764590	0.724	rs1533829	chr7:2082841	A/G	cg21782813	chr7:2030301	MAD1L1	-0.32	-4.91	-0.31	1.72e-6	Neuroticism;
SARC	cis	rs17376456	0.825	rs17374166	chr5:93238655	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.66	0.35	4.4e-8	Diabetic retinopathy;
SARC	cis	rs796364	0.616	rs7574313	chr2:200681040	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.55	4.74	0.3	3.76e-6	Schizophrenia;
SARC	cis	rs4478037	0.749	rs72856153	chr3:33111182	T/G	cg19404215	chr3:33155277	CRTAP	0.75	6.29	0.38	1.51e-9	Major depressive disorder;
SARC	cis	rs2832077	0.506	rs10222093	chr21:30163518	T/C	cg08807101	chr21:30365312	RNF160	-0.5	-5.46	-0.34	1.21e-7	Cognitive test performance;
SARC	cis	rs908922	0.676	rs1572533	chr1:152509742	T/C	cg09873164	chr1:152488093	CRCT1	0.65	8.72	0.5	5.41e-16	Hair morphology;
SARC	cis	rs9581943	0.933	rs61652270	chr13:28461726	C/T	cg17352152	chr13:28491409	NA	0.4	5.28	0.33	2.9e-7	Pancreatic cancer;
SARC	cis	rs79349575	0.811	rs80032154	chr17:47014992	C/A	cg16584676	chr17:46985605	UBE2Z	0.55	6.58	0.4	3.12e-10	Type 2 diabetes;
SARC	cis	rs1570884	0.740	rs12146924	chr13:50134358	T/C	cg08779649	chr13:50194554	NA	0.33	5.41	0.33	1.59e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs7264396	0.563	rs6060558	chr20:34271092	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-6.52	-0.39	4.2e-10	Total cholesterol levels;
SARC	cis	rs72945132	0.769	rs11235754	chr11:70136092	C/T	cg00319359	chr11:70116639	PPFIA1	0.68	6.37	0.39	1.01e-9	Coronary artery disease;
SARC	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg05896524	chr21:47604654	C21orf56	0.42	5.04	0.31	9.35e-7	Testicular germ cell tumor;
SARC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.71	9.63	0.53	1.05e-18	Lymphocyte counts;
SARC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.71	9.8	0.54	3.2e-19	Lymphocyte counts;
SARC	cis	rs548181	0.536	rs503288	chr11:125461787	C/T	cg03464685	chr11:125439445	EI24	-1.07	-10.12	-0.55	3.46e-20	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs7481584	0.564	rs7948848	chr11:2981896	G/A	cg05729581	chr11:3078854	CARS	0.4	5.28	0.33	2.92e-7	Calcium levels;
SARC	cis	rs9487051	0.676	rs6568566	chr6:109596792	G/A	cg01475377	chr6:109611718	NA	-0.35	-5.08	-0.32	7.8e-7	Reticulocyte fraction of red cells;
SARC	cis	rs12681366	0.683	rs2470739	chr8:95401922	G/A	cg26464482	chr8:95565502	KIAA1429	-0.44	-5.42	-0.33	1.49e-7	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg02463440	chr8:22132932	PIWIL2	0.47	6.68	0.4	1.75e-10	Hypertriglyceridemia;
SARC	cis	rs1008375	1.000	rs2872958	chr4:17665032	A/G	cg02297831	chr4:17616191	MED28	0.42	5.25	0.33	3.43e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg04756594	chr16:24857601	SLC5A11	-0.48	-6.16	-0.37	3.08e-9	Intelligence (multi-trait analysis);
SARC	cis	rs4423214	1.000	rs4944946	chr11:71159429	G/A	cg24826892	chr11:71159390	DHCR7	0.46	5.58	0.34	6.59e-8	Vitamin D levels;
SARC	trans	rs4076764	0.958	rs6688181	chr1:163384193	C/T	cg21344215	chr2:27851972	GPN1;CCDC121	-0.51	-6.73	-0.4	1.3100000000000001e-10	Motion sickness;
SARC	cis	rs6582630	0.576	rs2222345	chr12:38356020	G/A	cg14851346	chr12:38532713	NA	-0.47	-5.64	-0.35	4.98e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2075371	1.000	rs2244700	chr7:133987374	A/G	cg11752832	chr7:134001865	SLC35B4	0.59	7.66	0.45	5e-13	Mean platelet volume;
SARC	cis	rs854765	0.724	rs62072049	chr17:17906520	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.42	5.55	0.34	7.93e-8	Total body bone mineral density;
SARC	cis	rs5753618	0.509	rs5749224	chr22:31558549	C/T	cg07713946	chr22:31675144	LIMK2	-0.38	-5.49	-0.34	1.07e-7	Colorectal cancer;
SARC	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg03433033	chr1:76189801	ACADM	0.53	7.72	0.45	3.49e-13	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7582720	1.000	rs72932558	chr2:203847325	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs11997175	0.516	rs6981283	chr8:33619363	A/G	ch.8.33884649F	chr8:33765107	NA	0.51	6.49	0.39	5.05e-10	Body mass index;
SARC	trans	rs208520	0.507	rs9453585	chr6:66796668	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-21.67	-0.82	9.44e-58	Exhaled nitric oxide output;
SARC	cis	rs1401999	1.000	rs1402002	chr3:183642794	A/G	cg01324343	chr3:183735012	ABCC5	0.66	13.4	0.66	9.97e-31	Anterior chamber depth;
SARC	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.56	6.38	0.39	9.44e-10	Renal function-related traits (BUN);
SARC	cis	rs7824557	0.767	rs17797443	chr8:11164012	T/C	cg21775007	chr8:11205619	TDH	0.52	6.18	0.38	2.84e-9	Retinal vascular caliber;
SARC	cis	rs2280018	1.000	rs2280018	chr16:15150833	A/C	cg07549590	chr16:15018862	NA	-0.37	-5.19	-0.32	4.54e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs524281	0.861	rs918299	chr11:65927607	C/T	cg14036092	chr11:66035641	RAB1B	-0.5	-5.4	-0.33	1.63e-7	Electroencephalogram traits;
SARC	cis	rs17376456	0.935	rs10036891	chr5:93171738	T/A	cg21475434	chr5:93447410	FAM172A	0.77	5.76	0.35	2.7e-8	Diabetic retinopathy;
SARC	cis	rs7523050	0.730	rs67312582	chr1:109423976	A/G	cg08274380	chr1:109419600	GPSM2	1.1	8.68	0.49	6.9e-16	Fat distribution (HIV);
SARC	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg22875332	chr1:76189707	ACADM	-0.49	-7.02	-0.42	2.36e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	trans	rs7395662	0.534	rs12418219	chr11:48988091	G/T	cg15704280	chr7:45808275	SEPT13	-0.55	-7.46	-0.44	1.65e-12	HDL cholesterol;
SARC	cis	rs9916302	0.706	rs7503081	chr17:37482673	A/G	cg00129232	chr17:37814104	STARD3	0.53	5.7	0.35	3.69e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.97e-8	Aortic root size;
SARC	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg23205692	chr1:25664452	TMEM50A	0.39	4.78	0.3	3.11e-6	Erythrocyte sedimentation rate;
SARC	cis	rs6500395	0.962	rs9937134	chr16:48577683	T/A	cg04672837	chr16:48644449	N4BP1	0.42	5.51	0.34	9.57e-8	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs17376456	0.877	rs9314095	chr5:93425495	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.71	0.35	3.39e-8	Diabetic retinopathy;
SARC	cis	rs12586317	0.620	rs17103042	chr14:35575428	T/C	cg05294307	chr14:35346193	BAZ1A	-0.48	-4.93	-0.31	1.59e-6	Psoriasis;
SARC	cis	rs17376456	0.825	rs7715562	chr5:93222034	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.62	-5.59	-0.34	6.43e-8	Diabetic retinopathy;
SARC	cis	rs999943	0.846	rs9348923	chr6:33617924	C/T	cg14003231	chr6:33640908	ITPR3	0.52	8.57	0.49	1.47e-15	Obesity (extreme);
SARC	cis	rs10513788	0.665	rs2129825	chr3:181991271	T/C	cg05977900	chr3:182512126	ATP11B	0.48	5.01	0.31	1.08e-6	Cognitive function;
SARC	cis	rs9296092	0.517	rs11751684	chr6:33528739	G/T	cg13560919	chr6:33536144	NA	-0.52	-6.13	-0.37	3.77e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs6963495	0.818	rs55691539	chr7:105165774	T/C	cg19920283	chr7:105172520	RINT1	0.66	5.62	0.35	5.45e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs7586879	0.639	rs2033653	chr2:25103446	C/T	cg01884057	chr2:25150051	NA	-0.28	-4.77	-0.3	3.27e-6	Body mass index;
SARC	cis	rs2439831	0.867	rs2447196	chr15:43893818	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.81	-7.86	-0.46	1.41e-13	Lung cancer in ever smokers;
SARC	cis	rs9287719	0.967	rs6744599	chr2:10747013	C/G	cg03983476	chr2:10830698	NOL10	0.34	4.93	0.31	1.54e-6	Prostate cancer;
SARC	cis	rs2370759	1.000	rs76998371	chr10:32631785	A/G	cg01819863	chr10:32635814	EPC1	1.01	9.93	0.55	1.3e-19	Sexual dysfunction (female);
SARC	cis	rs1865760	0.532	rs1061482	chr6:26086699	G/T	cg16482183	chr6:26056742	HIST1H1C	0.45	5.53	0.34	8.79e-8	Height;
SARC	trans	rs61931739	0.517	rs1817760	chr12:34106060	A/G	cg26384229	chr12:38710491	ALG10B	0.87	12.44	0.63	1.37e-27	Morning vs. evening chronotype;
SARC	cis	rs67311347	0.544	rs13062243	chr3:40336789	G/A	cg09455208	chr3:40491958	NA	0.3	5.01	0.31	1.08e-6	Renal cell carcinoma;
SARC	cis	rs12617721	0.718	rs1857746	chr2:99017358	A/G	cg18455616	chr2:99124870	INPP4A	0.42	4.73	0.3	3.82e-6	Bipolar disorder with mood-incongruent psychosis;
SARC	cis	rs9916302	0.861	rs10491129	chr17:37461643	T/G	cg00129232	chr17:37814104	STARD3	0.6	7.33	0.43	3.84e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs7772486	0.624	rs9485018	chr6:146025731	T/C	cg23711669	chr6:146136114	FBXO30	-0.8	-12.52	-0.63	7.4e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4803468	0.967	rs4803461	chr19:41908871	G/A	cg14132834	chr19:41945861	ATP5SL	-0.55	-7.38	-0.44	2.72e-12	Height;
SARC	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg19223190	chr17:80058835	NA	0.45	6.29	0.38	1.57e-9	Life satisfaction;
SARC	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.64	-7.64	-0.45	5.46e-13	Gut microbiome composition (summer);
SARC	cis	rs425277	0.917	rs262656	chr1:2088754	A/C	cg24578937	chr1:2090814	PRKCZ	0.31	5.87	0.36	1.47e-8	Height;
SARC	cis	rs6866344	0.697	rs11739893	chr5:178127837	G/A	cg10224037	chr5:178157518	ZNF354A	0.99	11.95	0.62	5.67e-26	Neutrophil percentage of white cells;
SARC	cis	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg08975724	chr8:8085496	FLJ10661	0.55	6.57	0.4	3.19e-10	Mood instability;
SARC	cis	rs2288073	1.000	rs6708328	chr2:24412413	A/G	cg06627628	chr2:24431161	ITSN2	-0.62	-7.6	-0.45	7.41e-13	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs9467773	1.000	rs11756120	chr6:26529808	G/C	cg11502198	chr6:26597334	ABT1	0.46	5.53	0.34	8.38e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg18357526	chr6:26021779	HIST1H4A	0.44	5.47	0.34	1.17e-7	Blood metabolite levels;
SARC	cis	rs2242116	0.734	rs4683294	chr3:46979013	C/G	cg02527881	chr3:46936655	PTH1R	0.35	5.32	0.33	2.45e-7	Birth weight;
SARC	cis	rs1865760	0.588	rs9467658	chr6:26010881	T/G	cg16482183	chr6:26056742	HIST1H1C	0.48	6.26	0.38	1.83e-9	Height;
SARC	cis	rs7312933	0.558	rs61926593	chr12:42818912	C/T	cg19980929	chr12:42632907	YAF2	0.47	6.63	0.4	2.27e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs17345786	0.906	rs55710435	chr3:101180330	G/A	cg12386194	chr3:101231763	SENP7	0.81	9.48	0.53	3.02e-18	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4268898	0.662	rs35624938	chr2:24576651	T/C	cg06627628	chr2:24431161	ITSN2	-0.84	-10.13	-0.55	3.11e-20	Asthma;
SARC	cis	rs6570726	0.846	rs6570700	chr6:145931552	A/G	cg23711669	chr6:146136114	FBXO30	0.77	12.16	0.62	1.17e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3768617	0.706	rs4129858	chr1:183004334	A/G	cg13390022	chr1:182993471	LAMC1	0.35	5.13	0.32	6.09e-7	Fuchs's corneal dystrophy;
SARC	cis	rs72781680	0.898	rs72786278	chr2:24063243	C/T	cg08917208	chr2:24149416	ATAD2B	0.78	7.43	0.44	2.09e-12	Lymphocyte counts;
SARC	cis	rs4128725	1.000	rs11265193	chr1:159401656	G/T	cg25076881	chr1:159409836	OR10J1	0.4	4.8	0.3	2.86e-6	Select biomarker traits;
SARC	cis	rs11225247	0.772	rs35569122	chr11:102232348	C/T	cg11690896	chr11:102217788	BIRC2	0.73	5.21	0.32	4.15e-7	Vein graft stenosis in coronary artery bypass grafting;
SARC	cis	rs950169	0.922	rs62021167	chr15:85118051	T/A	cg24253500	chr15:84953950	NA	0.37	5.31	0.33	2.59e-7	Schizophrenia;
SARC	cis	rs7246657	0.508	rs10419845	chr19:37491192	G/T	cg23950597	chr19:37808831	NA	-0.55	-4.86	-0.3	2.17e-6	Coronary artery calcification;
SARC	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.42	-5.2	-0.32	4.29e-7	Tonsillectomy;
SARC	cis	rs7624766	0.778	rs7634342	chr3:160485789	G/A	cg22637730	chr3:160473554	PPM1L	0.44	5.75	0.35	2.73e-8	Response to methotrexate in rheumatoid arthritis;
SARC	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg13877915	chr19:58951672	ZNF132	0.66	9.73	0.54	5.2e-19	Uric acid clearance;
SARC	cis	rs10911232	0.507	rs10797833	chr1:183044067	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.1	0.55	3.88e-20	Hypertriglyceridemia;
SARC	cis	rs4702	0.611	rs11539637	chr15:91428290	C/T	cg05469396	chr15:91419421	FURIN	0.44	5.96	0.36	9.29e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg13206674	chr6:150067644	NUP43	0.43	5.27	0.33	3.12e-7	Lung cancer;
SARC	cis	rs2797685	1.000	rs707472	chr1:7906008	A/C	cg00864860	chr1:7907996	UTS2	0.36	5.14	0.32	5.88e-7	Crohn's disease;
SARC	cis	rs2997447	0.761	rs17257113	chr1:26449595	G/A	cg19633962	chr1:26362018	EXTL1	-0.56	-5.06	-0.31	8.55e-7	QRS complex (12-leadsum);
SARC	cis	rs2153535	0.562	rs6901765	chr6:8455436	A/T	cg07606381	chr6:8435919	SLC35B3	0.75	10.67	0.57	6.5600000000000005e-22	Motion sickness;
SARC	cis	rs9640161	0.830	rs6722	chr7:150068933	T/C	cg17279839	chr7:150038598	RARRES2	0.38	6.14	0.37	3.44e-9	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs6088590	0.561	rs6059918	chr20:33150503	C/T	cg24642439	chr20:33292090	TP53INP2	0.66	8.51	0.49	2.13e-15	Coronary artery disease;
SARC	cis	rs73635312	0.850	rs78741571	chr10:8947079	G/A	cg24467326	chr10:9646929	NA	0.56	4.87	0.3	2.02e-6	Basal cell carcinoma;
SARC	cis	rs2652834	0.950	rs2729789	chr15:63400345	G/A	cg05507819	chr15:63340323	TPM1	0.54	5.37	0.33	1.94e-7	HDL cholesterol;
SARC	cis	rs854765	0.619	rs6502636	chr17:17983817	A/T	cg04398451	chr17:18023971	MYO15A	-0.56	-8.2	-0.47	1.64e-14	Total body bone mineral density;
SARC	cis	rs55883249	1.000	rs57234614	chr2:9756379	T/C	cg23886495	chr2:9695866	ADAM17	0.69	6.9	0.41	4.82e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	trans	rs11039798	0.545	rs7118670	chr11:48532056	C/T	cg15704280	chr7:45808275	SEPT13	0.63	6.43	0.39	7.11e-10	Axial length;
SARC	cis	rs9916302	0.731	rs11868030	chr17:37650332	A/G	cg00129232	chr17:37814104	STARD3	-0.64	-7.93	-0.46	8.9e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs9443189	0.762	rs2748943	chr6:76435543	C/T	cg01950844	chr6:76311363	SENP6	-0.85	-8.05	-0.47	4.11e-14	Prostate cancer;
SARC	cis	rs9513627	0.833	rs73556146	chr13:100116920	A/G	cg25919922	chr13:100150906	NA	-0.76	-5.44	-0.34	1.33e-7	Obesity-related traits;
SARC	cis	rs9462027	0.628	rs2764198	chr6:34706128	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.88	-0.36	1.39e-8	Systemic lupus erythematosus;
SARC	cis	rs694739	0.595	rs11606015	chr11:64136877	C/G	cg02228329	chr11:64053129	BAD;GPR137	0.52	5.66	0.35	4.51e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs918629	0.567	rs2270554	chr5:95246134	G/T	cg16656078	chr5:95278638	ELL2	0.52	6.55	0.39	3.74e-10	IgG glycosylation;
SARC	cis	rs847851	0.798	rs2140418	chr6:34975415	T/C	cg17149859	chr6:34856158	ANKS1A;TAF11	0.44	4.72	0.3	3.99e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1971762	0.583	rs7979659	chr12:54086579	A/G	cg06632207	chr12:54070931	ATP5G2	0.45	5.85	0.36	1.64e-8	Height;
SARC	cis	rs79349575	0.715	rs55724082	chr17:47017879	G/A	cg07967210	chr17:47022446	SNF8	0.38	4.77	0.3	3.2e-6	Type 2 diabetes;
SARC	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg04546413	chr19:29218101	NA	0.63	8.52	0.49	2.01e-15	Methadone dose in opioid dependence;
SARC	cis	rs1483890	0.723	rs6807930	chr3:69411662	C/T	cg22125112	chr3:69402811	FRMD4B	0.29	4.78	0.3	3.12e-6	Resting heart rate;
SARC	cis	rs11098499	0.863	rs1383533	chr4:120434576	G/A	cg24375607	chr4:120327624	NA	0.42	4.9	0.31	1.76e-6	Corneal astigmatism;
SARC	cis	rs11608355	0.515	rs1045263	chr12:109974191	A/G	cg05360138	chr12:110035743	NA	0.9	9.41	0.52	4.84e-18	Neuroticism;
SARC	cis	rs634534	0.622	rs552130	chr11:65732800	T/C	cg26695010	chr11:65641043	EFEMP2	-0.55	-7.26	-0.43	5.91e-12	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs35110281	0.720	rs162375	chr21:44927015	C/T	cg01579765	chr21:45077557	HSF2BP	0.38	6.45	0.39	6.34e-10	Mean corpuscular volume;
SARC	cis	rs71277158	0.688	rs73879180	chr3:169874968	T/C	cg04067573	chr3:169899625	PHC3	0.56	4.77	0.3	3.18e-6	Prostate cancer;
SARC	cis	rs11969893	0.649	rs9390699	chr6:101306502	C/G	cg12253828	chr6:101329408	ASCC3	0.95	7.16	0.42	1.06e-11	Economic and political preferences (immigration/crime);
SARC	cis	rs34779708	0.966	rs12260130	chr10:35467671	C/T	cg03585969	chr10:35415529	CREM	0.39	4.98	0.31	1.23e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs7481584	0.624	rs397919	chr11:3063094	A/C	cg20651018	chr11:3035856	CARS	0.39	5.8	0.36	2.13e-8	Calcium levels;
SARC	cis	rs10911232	0.507	rs4397624	chr1:183053131	C/T	cg13390022	chr1:182993471	LAMC1	0.33	5.06	0.31	8.41e-7	Hypertriglyceridemia;
SARC	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg12756686	chr19:29218302	NA	-0.59	-6.61	-0.4	2.52e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs9611565	0.921	rs8137373	chr22:41729216	A/G	cg03806693	chr22:41940476	POLR3H	0.75	10.11	0.55	3.8e-20	Vitiligo;
SARC	cis	rs17270561	0.666	rs4711099	chr6:25741809	C/G	cg17691542	chr6:26056736	HIST1H1C	0.61	7.36	0.43	3.06e-12	Iron status biomarkers;
SARC	cis	rs1790761	0.667	rs1254123	chr11:67334812	T/C	cg24690094	chr11:67383802	NA	0.33	4.84	0.3	2.36e-6	Mean corpuscular volume;
SARC	cis	rs7103648	0.630	rs7934481	chr11:47883337	C/T	cg10504702	chr11:47789108	FNBP4	0.76	9.89	0.54	1.81e-19	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs12586317	0.547	rs2383693	chr14:35500205	A/C	cg26967526	chr14:35346199	BAZ1A	-0.57	-5.71	-0.35	3.4e-8	Psoriasis;
SARC	cis	rs899997	0.731	rs58717592	chr15:79030417	T/C	cg04896959	chr15:78267971	NA	-0.5	-5.04	-0.31	9.23e-7	Coronary artery disease or large artery stroke;
SARC	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-15.46	-0.71	1.39e-37	Chronic sinus infection;
SARC	cis	rs7582180	0.629	rs11685406	chr2:100946638	A/G	cg14675211	chr2:100938903	LONRF2	0.51	7.57	0.44	8.42e-13	Intelligence (multi-trait analysis);
SARC	cis	rs8044995	0.563	rs55968019	chr16:68398111	G/A	cg05110241	chr16:68378359	PRMT7	-0.64	-6.19	-0.38	2.64e-9	Schizophrenia;
SARC	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg14983838	chr19:29218262	NA	0.77	10.52	0.57	2e-21	Methadone dose in opioid dependence;
SARC	cis	rs8064299	0.597	rs4789098	chr17:72781292	C/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.75	9.78	0.54	3.74e-19	Monocyte count;
SARC	cis	rs57506017	0.585	rs5011437	chr7:12268792	A/T	cg23422036	chr7:12250390	TMEM106B	0.45	5.87	0.36	1.46e-8	Neuroticism;
SARC	cis	rs79349575	0.783	rs15563	chr17:47005193	A/G	cg16584676	chr17:46985605	UBE2Z	0.51	6.17	0.37	2.94e-9	Type 2 diabetes;
SARC	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.91	11.07	0.59	3.6e-23	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs8072100	0.576	rs7216112	chr17:45406345	C/T	cg25173405	chr17:45401733	C17orf57	0.44	4.77	0.3	3.21e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs67311347	0.868	rs10865895	chr3:40378677	C/T	cg09455208	chr3:40491958	NA	0.4	6.16	0.37	3.1e-9	Renal cell carcinoma;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg21542574	chr22:46726517	GTSE1	-0.48	-6.4	-0.39	8.45e-10	Electrocardiographic conduction measures;
SARC	cis	rs11792861	0.962	rs3829084	chr9:111801724	C/G	cg13535736	chr9:111863775	C9orf5	0.41	4.99	0.31	1.19e-6	Menarche (age at onset);
SARC	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg21724239	chr8:58056113	NA	0.65	5.93	0.36	1.1e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9296092	0.538	rs9461881	chr6:33520041	C/T	cg13560919	chr6:33536144	NA	-0.5	-6.31	-0.38	1.38e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg10523679	chr1:76189770	ACADM	0.54	7.07	0.42	1.81e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs35110281	0.712	rs167930	chr21:44946625	G/A	cg01579765	chr21:45077557	HSF2BP	-0.31	-5.37	-0.33	1.88e-7	Mean corpuscular volume;
SARC	cis	rs1873147	1.000	rs12443295	chr15:63313666	C/T	cg05507819	chr15:63340323	TPM1	-0.47	-5.13	-0.32	6.15e-7	Orofacial clefts;
SARC	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg26335602	chr6:28129616	ZNF389	0.53	5.91	0.36	1.2e-8	Depression;
SARC	cis	rs3796352	1.000	rs61172708	chr3:52996052	T/G	cg15956490	chr3:53032818	SFMBT1	0.79	5.18	0.32	4.85e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2075371	0.966	rs2544214	chr7:133985736	G/A	cg00033643	chr7:134001901	SLC35B4	0.4	4.85	0.3	2.25e-6	Mean platelet volume;
SARC	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg04518342	chr5:131593106	PDLIM4	0.4	5.47	0.34	1.16e-7	Acylcarnitine levels;
SARC	cis	rs36051895	0.659	rs12336577	chr9:5063690	T/A	cg02405213	chr9:5042618	JAK2	-0.47	-5.44	-0.34	1.38e-7	Pediatric autoimmune diseases;
SARC	cis	rs798554	0.660	rs2644296	chr7:2859061	A/T	cg13628971	chr7:2884303	GNA12	0.45	5.75	0.35	2.8e-8	Height;
SARC	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg27266027	chr21:40555129	PSMG1	0.51	5.64	0.35	4.81e-8	Cognitive function;
SARC	cis	rs12477438	0.666	rs10179910	chr2:99658503	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-7.96	-0.46	7.66e-14	Chronic sinus infection;
SARC	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg20102877	chr2:27665638	KRTCAP3	-0.38	-5.37	-0.33	1.88e-7	Total body bone mineral density;
SARC	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg07701084	chr6:150067640	NUP43	0.41	5.39	0.33	1.75e-7	Lung cancer;
SARC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg10963375	chr1:205815865	PM20D1	0.33	5.06	0.31	8.41e-7	Menarche (age at onset);
SARC	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg13012494	chr21:47604986	C21orf56	0.44	5.06	0.31	8.32e-7	Testicular germ cell tumor;
SARC	cis	rs4974559	0.947	rs28437782	chr4:1355062	A/G	cg02980000	chr4:1222292	CTBP1	0.63	4.81	0.3	2.73e-6	Systolic blood pressure;
SARC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg24846343	chr22:24311635	DDTL	-0.44	-6.17	-0.37	3.01e-9	Liver enzyme levels (gamma-glutamyl transferase);
SARC	trans	rs62103177	0.525	rs1835410	chr18:77702025	T/C	cg05926928	chr17:57297772	GDPD1	-0.69	-6.34	-0.38	1.17e-9	Opioid sensitivity;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg18758298	chr6:167040735	RPS6KA2	-0.54	-6.81	-0.41	8.41e-11	Height;
SARC	cis	rs6061231	0.798	rs2427308	chr20:60969451	C/T	cg24112000	chr20:60950667	NA	-0.36	-5.14	-0.32	5.68e-7	Colorectal cancer;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04785418	chr12:42538813	GXYLT1	-0.51	-6.52	-0.39	4.42e-10	Smoking initiation;
SARC	cis	rs6964587	1.000	rs2285333	chr7:91667692	T/G	cg17063962	chr7:91808500	NA	0.95	16.02	0.72	1.87e-39	Breast cancer;
SARC	trans	rs9836270	1.000	rs9836270	chr3:131916996	G/T	cg12178287	chr19:17631836	PGLS	0.47	6.38	0.39	9.57e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9640161	0.742	rs2108852	chr7:150019628	T/C	cg21361702	chr7:150065534	REPIN1	0.47	4.94	0.31	1.49e-6	Blood protein levels;Circulating chemerin levels;
SARC	trans	rs9329221	0.619	rs591346	chr8:9818065	C/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.26	-0.38	1.87e-9	Neuroticism;
SARC	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg18357526	chr6:26021779	HIST1H4A	0.72	9.98	0.55	9.4e-20	Intelligence (multi-trait analysis);
SARC	cis	rs10782582	0.592	rs7513194	chr1:76382664	A/C	cg03433033	chr1:76189801	ACADM	0.39	5.16	0.32	5.38e-7	Daytime sleep phenotypes;
SARC	cis	rs4243830	0.850	rs13513	chr1:6585804	C/T	cg04093404	chr1:6614507	TAS1R1;NOL9	0.58	5.08	0.32	7.58e-7	Body mass index;
SARC	cis	rs7551222	0.714	rs4951404	chr1:204541342	G/C	cg20240347	chr1:204465584	NA	-0.29	-4.91	-0.31	1.75e-6	Schizophrenia;
SARC	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg13939156	chr17:80058883	NA	-0.43	-6.63	-0.4	2.35e-10	Life satisfaction;
SARC	cis	rs3741151	0.686	rs7125598	chr11:73160589	C/T	cg17517138	chr11:73019481	ARHGEF17	-0.67	-5.61	-0.34	5.85e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs6424115	0.830	rs3003333	chr1:24194014	A/T	cg15997130	chr1:24165203	NA	-0.41	-5.48	-0.34	1.12e-7	Immature fraction of reticulocytes;
SARC	cis	rs709400	0.663	rs8015918	chr14:103942991	A/G	cg26031613	chr14:104095156	KLC1	0.82	11.97	0.62	4.77e-26	Body mass index;
SARC	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg04756594	chr16:24857601	SLC5A11	0.42	5.6	0.34	5.94e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg09508770	chr1:107684255	NTNG1	-0.48	-6.51	-0.39	4.54e-10	Electrocardiographic conduction measures;
SARC	trans	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg06532184	chr4:16227813	FLJ39653;TAPT1	0.46	6.49	0.39	5.17e-10	Immature fraction of reticulocytes;
SARC	cis	rs4319547	0.656	rs6488951	chr12:122873928	A/G	cg23029597	chr12:123009494	RSRC2	-0.43	-5.29	-0.33	2.85e-7	Body mass index;
SARC	cis	rs8044995	0.706	rs73612697	chr16:68162016	G/A	cg27539214	chr16:67997921	SLC12A4	-0.51	-4.86	-0.3	2.14e-6	Schizophrenia;
SARC	cis	rs7666738	0.830	rs28497822	chr4:98906873	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.53	0.49	1.88e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7666738	0.753	rs1527520	chr4:98929164	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg22433210	chr17:43662623	NA	-0.94	-11.19	-0.59	1.56e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs4481887	0.893	rs4297335	chr1:248473421	C/T	cg01631408	chr1:248437212	OR2T33	-0.38	-4.92	-0.31	1.67e-6	Common traits (Other);
SARC	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.29	0.38	1.55e-9	Bipolar disorder;
SARC	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.79	-8.56	-0.49	1.53e-15	Alzheimer's disease;
SARC	trans	rs1814175	0.645	rs4625470	chr11:49983769	T/C	cg15704280	chr7:45808275	SEPT13	-0.89	-14.17	-0.68	2.8e-33	Height;
SARC	cis	rs67460515	0.529	rs6795586	chr3:160897701	A/C	cg03342759	chr3:160939853	NMD3	-0.52	-6.18	-0.38	2.78e-9	Parkinson's disease;
SARC	cis	rs35213789	0.853	rs2851500	chr7:69110413	A/G	cg10619644	chr7:69149951	AUTS2	-0.43	-5.77	-0.35	2.54e-8	Childhood ear infection;
SARC	cis	rs12802200	0.561	rs7940600	chr11:572105	A/G	cg16486109	chr11:613632	IRF7	0.36	5.02	0.31	1.02e-6	Systemic lupus erythematosus;
SARC	cis	rs6545977	0.531	rs2539981	chr2:63104904	T/C	cg17519650	chr2:63277830	OTX1	0.48	6.43	0.39	7.2e-10	Prostate cancer;
SARC	cis	rs6060717	0.528	rs73905955	chr20:34332938	A/G	cg01084648	chr20:34329383	RBM39	0.62	4.92	0.31	1.63e-6	Hip circumference adjusted for BMI;
SARC	cis	rs74417235	0.684	rs7723610	chr5:154053349	A/C	cg17344516	chr5:154026930	NA	0.5	5.17	0.32	5.03e-7	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
SARC	cis	rs13166103	0.657	rs719429	chr5:57710748	C/T	cg10487770	chr5:57879443	RAB3C	0.52	5.46	0.34	1.19e-7	Type 2 diabetes (age of onset);
SARC	cis	rs950027	0.549	rs9920634	chr15:45596546	G/T	cg21132104	chr15:45694354	SPATA5L1	-0.53	-6.28	-0.38	1.64e-9	Response to fenofibrate (adiponectin levels);
SARC	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg02725872	chr8:58115012	NA	-0.37	-6.55	-0.39	3.71e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7944584	0.632	rs11039159	chr11:47294021	G/T	cg20307385	chr11:47447363	PSMC3	0.56	6.95	0.41	3.66e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs876084	0.505	rs7459865	chr8:121115611	A/T	cg06265175	chr8:121136014	COL14A1	0.57	7.35	0.43	3.37e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs526821	0.532	rs578067	chr11:55313690	T/G	cg04317927	chr11:55418816	OR4S2	0.39	5.7	0.35	3.69e-8	Pediatric bone mineral density (spine);
SARC	cis	rs4699052	1.000	rs7661702	chr4:104140129	C/G	cg16532752	chr4:104119610	CENPE	-0.42	-5.08	-0.32	7.67e-7	Testicular germ cell tumor;
SARC	trans	rs453301	0.624	rs330060	chr8:9090902	A/G	cg06636001	chr8:8085503	FLJ10661	-0.71	-9.82	-0.54	2.86e-19	Joint mobility (Beighton score);
SARC	cis	rs752010	0.619	rs7539238	chr1:42113572	A/C	cg06885757	chr1:42089581	HIVEP3	0.45	6.35	0.38	1.13e-9	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs7592578	0.679	rs62181019	chr2:191325414	A/G	cg27211696	chr2:191398769	TMEM194B	-0.51	-5.5	-0.34	9.76e-8	Diastolic blood pressure;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg04940515	chr1:76251865	SNORD45C;RABGGTB	0.48	6.32	0.38	1.34e-9	Lung adenocarcinoma;
SARC	cis	rs9392653	1.000	rs9392651	chr6:5071059	T/C	cg00563771	chr6:5110810	LYRM4	-0.46	-5.2	-0.32	4.42e-7	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs11581859	0.613	rs12406053	chr1:99223508	C/T	cg20286094	chr1:99190917	SNX7	-0.43	-5.06	-0.31	8.5e-7	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs7572733	0.534	rs1435568	chr2:198762879	T/C	cg00792783	chr2:198669748	PLCL1	0.42	4.78	0.3	3.08e-6	Dermatomyositis;
SARC	cis	rs6570726	0.935	rs371744	chr6:145841024	C/T	cg05347473	chr6:146136440	FBXO30	0.48	6.45	0.39	6.38e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11608355	0.545	rs9943764	chr12:109905720	G/A	cg05360138	chr12:110035743	NA	0.92	9.68	0.54	7.88e-19	Neuroticism;
SARC	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg08219700	chr8:58056026	NA	0.62	6.52	0.39	4.28e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2276314	0.857	rs28396546	chr18:33639024	T/C	cg05985134	chr18:33552581	C18orf21	0.64	6.81	0.41	8.17e-11	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs2624839	0.704	rs11919418	chr3:50233215	T/G	cg14019146	chr3:50243930	SLC38A3	-0.45	-7.43	-0.44	2.1e-12	Intelligence (multi-trait analysis);
SARC	cis	rs9715521	0.677	rs4490528	chr4:59854572	T/G	cg11281224	chr4:60001000	NA	-0.46	-5.9	-0.36	1.29e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs10752881	1.000	rs6658501	chr1:182991417	C/T	cg13390022	chr1:182993471	LAMC1	-0.33	-5.08	-0.32	7.87e-7	Colorectal cancer;
SARC	cis	rs7130144	0.541	rs1950119	chr11:130462002	A/T	cg26307797	chr11:130446613	NA	0.65	5.59	0.34	6.31e-8	Urate levels in lean individuals;
SARC	cis	rs2635047	0.967	rs7242978	chr18:44633424	G/T	cg19077165	chr18:44547161	KATNAL2	0.35	4.74	0.3	3.75e-6	Educational attainment;
SARC	cis	rs72945132	0.882	rs56368190	chr11:70204328	T/G	cg05964544	chr11:70165517	PPFIA1	-0.57	-5.46	-0.34	1.19e-7	Coronary artery disease;
SARC	cis	rs7561273	0.565	rs6545275	chr2:24331860	A/G	cg08917208	chr2:24149416	ATAD2B	0.45	4.93	0.31	1.55e-6	Quantitative traits;
SARC	cis	rs6988636	1.000	rs62521826	chr8:124186668	C/T	cg23067535	chr8:124195133	FAM83A	-0.64	-5.3	-0.33	2.72e-7	Urinary uromodulin levels;
SARC	cis	rs208520	0.754	rs12204635	chr6:66740779	C/A	cg07460842	chr6:66804631	NA	1.04	13.88	0.67	2.45e-32	Exhaled nitric oxide output;
SARC	cis	rs9325144	0.560	rs12424821	chr12:38649951	C/T	cg26384229	chr12:38710491	ALG10B	-0.63	-8.12	-0.47	2.64e-14	Morning vs. evening chronotype;
SARC	cis	rs9815354	1.000	rs17063599	chr3:41861676	C/T	cg03022575	chr3:42003672	ULK4	0.57	5.32	0.33	2.38e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs17539620	0.534	rs76931320	chr6:154833508	G/A	cg20019720	chr6:154832845	CNKSR3	0.43	5.0	0.31	1.1e-6	Lipoprotein (a) levels;
SARC	cis	rs7824557	0.836	rs1435278	chr8:11123029	G/T	cg21775007	chr8:11205619	TDH	-0.53	-6.11	-0.37	4.11e-9	Retinal vascular caliber;
SARC	cis	rs2816062	0.813	rs742485	chr1:18900943	A/T	cg18795169	chr1:18902165	NA	-0.82	-13.16	-0.65	6.07e-30	Urate levels in lean individuals;
SARC	cis	rs73001065	0.711	rs58489806	chr19:19456917	C/T	cg03709012	chr19:19516395	GATAD2A	1.03	6.29	0.38	1.52e-9	LDL cholesterol;
SARC	cis	rs1707322	0.721	rs10789468	chr1:46124558	A/G	cg03146154	chr1:46216737	IPP	0.49	5.96	0.36	9.12e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs644799	0.562	rs1254989	chr11:95508121	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	11.3	0.6	6.72e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs897080	0.514	rs1067376	chr2:44648361	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.68	0.4	1.78e-10	Height;
SARC	cis	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg05623727	chr3:50126028	RBM5	0.35	5.24	0.32	3.53e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg06558623	chr16:89946397	TCF25	0.98	7.65	0.45	5.42e-13	Skin colour saturation;
SARC	cis	rs62344088	1.000	rs28409618	chr5:160289	C/T	cg22496380	chr5:211416	CCDC127	-0.76	-4.98	-0.31	1.25e-6	Asthma (childhood onset);
SARC	cis	rs7246657	0.943	rs1015848	chr19:37945274	A/C	cg23950597	chr19:37808831	NA	-0.63	-6.05	-0.37	5.72e-9	Coronary artery calcification;
SARC	cis	rs72781680	0.821	rs11894756	chr2:24170214	A/G	cg08917208	chr2:24149416	ATAD2B	-0.58	-6.03	-0.37	6.48e-9	Lymphocyte counts;
SARC	cis	rs2204008	0.811	rs8189445	chr12:38276295	T/C	cg13010199	chr12:38710504	ALG10B	0.81	11.31	0.6	6.15e-24	Bladder cancer;
SARC	cis	rs7103648	0.864	rs12801188	chr11:47388214	G/A	cg10504702	chr11:47789108	FNBP4	0.56	6.74	0.4	1.24e-10	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs2227564	0.729	rs2688615	chr10:75651499	C/G	cg16540259	chr10:75572220	NDST2	0.35	4.97	0.31	1.29e-6	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs6500395	1.000	rs9936004	chr16:48566088	A/G	cg04672837	chr16:48644449	N4BP1	0.47	6.2	0.38	2.57e-9	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg21782813	chr7:2030301	MAD1L1	0.48	7.54	0.44	1.07e-12	Bipolar disorder and schizophrenia;
SARC	cis	rs6484504	0.600	rs1323738	chr11:31344898	T/C	cg26647111	chr11:31128758	NA	0.38	4.83	0.3	2.53e-6	Red blood cell count;
SARC	cis	rs12950390	0.530	rs16947058	chr17:45825186	A/G	cg03474202	chr17:45855739	NA	0.39	6.39	0.39	9.18e-10	IgG glycosylation;
SARC	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg12463550	chr7:65579703	CRCP	0.48	5.49	0.34	1.05e-7	Aortic root size;
SARC	cis	rs10089	0.953	rs1036171	chr5:127402798	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	10.39	0.56	4.9e-21	Ileal carcinoids;
SARC	cis	rs4253772	0.530	rs6008623	chr22:46710024	G/A	cg24881330	chr22:46731750	TRMU	0.73	5.96	0.36	9.42e-9	LDL cholesterol;Cholesterol, total;
SARC	cis	rs7246657	0.943	rs3760825	chr19:37945601	C/T	cg23950597	chr19:37808831	NA	-0.57	-5.68	-0.35	3.9e-8	Coronary artery calcification;
SARC	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg22535103	chr8:58192502	C8orf71	-0.57	-6.02	-0.37	6.72e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg14983838	chr19:29218262	NA	0.76	10.52	0.57	2.03e-21	Methadone dose in opioid dependence;
SARC	cis	rs2303745	0.589	rs751599	chr19:17396549	A/G	cg04248312	chr19:17393744	ANKLE1	-0.6	-7.75	-0.45	2.9e-13	Systemic lupus erythematosus;
SARC	cis	rs2197308	0.692	rs1904964	chr12:37933241	T/A	cg13010199	chr12:38710504	ALG10B	0.79	10.99	0.58	6.6e-23	Morning vs. evening chronotype;
SARC	cis	rs3020736	0.500	rs4147640	chr22:42485292	T/C	cg15557168	chr22:42548783	NA	0.35	4.8	0.3	2.85e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2985684	0.894	rs2883436	chr14:50013822	T/C	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.54	5.88	0.36	1.43e-8	Carotid intima media thickness;
SARC	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg21782813	chr7:2030301	MAD1L1	0.32	4.88	0.3	1.98e-6	Schizophrenia;
SARC	trans	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg00377133	chr18:3247815	MYL12A	0.47	6.3	0.38	1.45e-9	Immature fraction of reticulocytes;
SARC	trans	rs1814175	0.791	rs7395713	chr11:49877887	A/G	cg15704280	chr7:45808275	SEPT13	-0.97	-18.12	-0.76	2.26e-46	Height;
SARC	cis	rs9300255	0.602	rs2682434	chr12:123694724	C/T	cg05973401	chr12:123451056	ABCB9	0.52	5.89	0.36	1.34e-8	Neutrophil percentage of white cells;
SARC	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	8.71	0.5	5.56e-16	Alzheimer's disease;
SARC	cis	rs2439831	0.702	rs3759791	chr15:44090798	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.93	8.22	0.47	1.42e-14	Lung cancer in ever smokers;
SARC	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg00152838	chr16:24741724	TNRC6A	0.59	6.45	0.39	6.37e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs870825	0.860	rs55974219	chr4:185600733	G/A	cg04058563	chr4:185651563	MLF1IP	0.8	9.84	0.54	2.51e-19	Blood protein levels;
SARC	cis	rs933688	1.000	rs10059163	chr5:90742444	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.04	13.23	0.66	3.43e-30	Smoking behavior;
SARC	cis	rs17030434	0.784	rs72617459	chr4:154661686	T/C	cg14289246	chr4:154710475	SFRP2	-0.49	-5.65	-0.35	4.77e-8	Electrocardiographic conduction measures;
SARC	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg11987759	chr7:65425863	GUSB	0.49	6.01	0.37	7.13e-9	Aortic root size;
SARC	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg16325326	chr1:53192061	ZYG11B	0.93	17.19	0.75	2.5e-43	Monocyte count;
SARC	cis	rs7772486	0.754	rs702318	chr6:146005873	G/T	cg05347473	chr6:146136440	FBXO30	-0.56	-7.82	-0.46	1.85e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg08564027	chr20:61660810	NA	0.76	11.57	0.6	9.45e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs57994353	0.828	rs11146021	chr9:139327858	A/G	cg13611204	chr9:139324423	INPP5E	0.28	4.8	0.3	2.87e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg16479474	chr6:28041457	NA	0.37	5.44	0.34	1.37e-7	Depression;
SARC	cis	rs7552167	1.000	rs7552167	chr1:24518643	A/G	cg01960748	chr1:24522592	NA	-0.46	-4.83	-0.3	2.49e-6	Psoriasis vulgaris;
SARC	cis	rs854765	0.547	rs2955372	chr17:17970229	T/C	cg04398451	chr17:18023971	MYO15A	0.46	6.49	0.39	5.04e-10	Total body bone mineral density;
SARC	cis	rs2228479	0.764	rs11641201	chr16:89983276	T/C	cg12064134	chr16:90016061	DEF8	-0.48	-5.07	-0.32	8e-7	Skin colour saturation;
SARC	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg24675658	chr1:53192096	ZYG11B	0.77	11.27	0.59	8.41e-24	Monocyte count;
SARC	cis	rs1448094	0.512	rs11117061	chr12:86250916	G/A	cg02569458	chr12:86230093	RASSF9	0.36	5.06	0.31	8.66e-7	Major depressive disorder;
SARC	cis	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg09021430	chr5:549028	NA	-0.45	-5.7	-0.35	3.69e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs6446731	0.734	rs10937921	chr4:3276491	C/T	cg06533319	chr4:3265114	C4orf44	-0.34	-5.58	-0.34	6.49e-8	Mean platelet volume;
SARC	cis	rs2072499	0.966	rs2984615	chr1:156165317	G/C	cg25208724	chr1:156163844	SLC25A44	0.93	12.69	0.64	2.13e-28	Testicular germ cell tumor;
SARC	cis	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg08045932	chr20:61659980	NA	0.5	6.95	0.41	3.66e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs34779708	0.966	rs7913615	chr10:35422957	T/G	cg03585969	chr10:35415529	CREM	0.38	4.8	0.3	2.84e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.93	9.13	0.51	3.44e-17	Platelet count;
SARC	cis	rs10752881	0.743	rs10737244	chr1:183098417	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.66e-21	Colorectal cancer;
SARC	cis	rs820218	0.687	rs820150	chr17:73615962	T/C	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.5	6.21	0.38	2.37e-9	Rotator cuff tears;
SARC	cis	rs910316	0.967	rs4903292	chr14:75656245	A/G	cg08847533	chr14:75593920	NEK9	0.85	12.44	0.63	1.44e-27	Height;
SARC	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg12292205	chr6:26970375	C6orf41	0.52	5.85	0.36	1.66e-8	Autism spectrum disorder or schizophrenia;
SARC	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg08219700	chr8:58056026	NA	0.46	4.96	0.31	1.34e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs477692	0.569	rs871028	chr10:131293478	C/T	cg05714579	chr10:131428358	MGMT	-0.58	-7.82	-0.46	1.88e-13	Response to temozolomide;
SARC	cis	rs17428076	0.514	rs3821095	chr2:172684006	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.49	-6.37	-0.39	9.87e-10	Myopia;
SARC	cis	rs3768617	0.510	rs6424889	chr1:183091796	G/C	cg13390022	chr1:182993471	LAMC1	0.32	4.83	0.3	2.44e-6	Fuchs's corneal dystrophy;
SARC	cis	rs80130819	0.688	rs10783233	chr12:48590899	C/G	cg24011408	chr12:48396354	COL2A1	0.54	6.04	0.37	6.13e-9	Prostate cancer;
SARC	cis	rs34375054	0.525	rs7133006	chr12:125606123	G/A	cg25124228	chr12:125621409	AACS	-0.63	-7.93	-0.46	9.35e-14	Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs10752881	1.000	rs6697739	chr1:182983333	A/C	cg13390022	chr1:182993471	LAMC1	0.34	5.17	0.32	5.11e-7	Colorectal cancer;
SARC	cis	rs262150	0.851	rs2730249	chr7:158767628	A/G	cg04111992	chr7:158790115	NA	0.37	5.03	0.31	9.93e-7	Facial morphology (factor 20);
SARC	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	9.84	0.54	2.45e-19	Alzheimer's disease;
SARC	cis	rs7000551	0.725	rs2461486	chr8:22392008	T/C	cg12081754	chr8:22256438	SLC39A14	0.57	7.81	0.46	1.89e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs9341808	0.718	rs9343971	chr6:80882056	C/T	cg08355045	chr6:80787529	NA	0.34	5.54	0.34	8.01e-8	Sitting height ratio;
SARC	cis	rs17345786	1.000	rs58907984	chr3:101305170	T/G	cg12386194	chr3:101231763	SENP7	0.72	8.59	0.49	1.26e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs5758659	0.714	rs2413668	chr22:42505841	G/A	cg04733989	chr22:42467013	NAGA	-0.5	-6.1	-0.37	4.31e-9	Cognitive function;
SARC	cis	rs908922	0.676	rs1123567	chr1:152516023	G/A	cg09873164	chr1:152488093	CRCT1	0.64	8.56	0.49	1.51e-15	Hair morphology;
SARC	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg03351412	chr1:154909251	PMVK	0.62	7.85	0.46	1.49e-13	Prostate cancer;
SARC	cis	rs981844	0.807	rs56053818	chr4:154638126	T/A	cg14289246	chr4:154710475	SFRP2	0.44	4.92	0.31	1.61e-6	Response to statins (LDL cholesterol change);
SARC	cis	rs300703	0.935	rs7568664	chr2:280939	A/G	cg21211680	chr2:198530	NA	0.58	5.4	0.33	1.61e-7	Blood protein levels;
SARC	cis	rs1881797	0.872	rs12404733	chr1:247690417	A/C	cg11166453	chr1:247681781	NA	0.43	4.82	0.3	2.59e-6	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs818427	0.964	rs151978	chr5:112234498	T/G	cg07820702	chr5:112228657	REEP5	-0.49	-5.31	-0.33	2.6e-7	Total body bone mineral density;
SARC	cis	rs9814567	1.000	rs9883753	chr3:134247231	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.1	-0.42	1.49e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9660992	0.624	rs72745217	chr1:205261482	C/G	cg07972983	chr1:205091412	RBBP5	0.51	5.95	0.36	9.86e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg11062466	chr8:58055876	NA	0.56	5.69	0.35	3.79e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg03452623	chr4:187889614	NA	-0.76	-11.22	-0.59	1.21e-23	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7937682	0.562	rs527847	chr11:111369132	A/C	cg22437258	chr11:111473054	SIK2	-0.44	-5.36	-0.33	2.04e-7	Primary sclerosing cholangitis;
SARC	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	-0.78	-7.69	-0.45	4.18e-13	Platelet count;
SARC	cis	rs8028182	0.636	rs8034317	chr15:75764343	G/A	cg20655648	chr15:75932815	IMP3	0.63	7.57	0.44	8.89e-13	Sudden cardiac arrest;
SARC	cis	rs4803468	1.000	rs10417997	chr19:41902361	G/A	cg14132834	chr19:41945861	ATP5SL	-0.55	-7.35	-0.43	3.36e-12	Height;
SARC	cis	rs1707322	1.000	rs4134387	chr1:46395158	A/T	cg03146154	chr1:46216737	IPP	0.5	6.0	0.37	7.46e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9393692	0.645	rs766407	chr6:26319534	T/C	cg13736514	chr6:26305472	NA	-0.7	-9.04	-0.51	6.22e-17	Educational attainment;
SARC	cis	rs6669543	0.917	rs6674320	chr1:161979841	C/T	cg10810183	chr1:161993987	OLFML2B	0.44	4.72	0.3	4.02e-6	QT interval;
SARC	cis	rs7937682	0.883	rs568038	chr11:111432161	A/C	cg22437258	chr11:111473054	SIK2	-0.78	-9.75	-0.54	4.83e-19	Primary sclerosing cholangitis;
SARC	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg00933542	chr6:150070202	PCMT1	-0.32	-5.08	-0.32	7.64e-7	Lung cancer;
SARC	cis	rs1707322	0.717	rs1972410	chr1:46080947	G/T	cg06784218	chr1:46089804	CCDC17	0.38	6.44	0.39	6.87e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs3784262	1.000	rs1372368	chr15:58297363	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.39	-5.88	-0.36	1.44e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs240764	0.817	rs239207	chr6:101137765	A/C	cg09795085	chr6:101329169	ASCC3	0.45	5.86	0.36	1.53e-8	Neuroticism;
SARC	trans	rs11098499	0.909	rs11723839	chr4:120299673	G/A	cg25214090	chr10:38739885	LOC399744	0.57	7.43	0.44	2.01e-12	Corneal astigmatism;
SARC	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg09359103	chr1:154839909	KCNN3	-0.43	-6.96	-0.42	3.33e-11	Prostate cancer;
SARC	cis	rs73206853	0.764	rs56128816	chr12:110775609	T/C	cg10860002	chr12:110842031	ANAPC7	0.62	4.8	0.3	2.84e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs11097912	0.632	rs7669212	chr4:107186712	G/A	cg09646026	chr4:107269030	AIMP1	-0.44	-4.83	-0.3	2.49e-6	Airflow obstruction;
SARC	cis	rs17023223	0.537	rs66715579	chr1:119725432	G/A	cg05756136	chr1:119680316	WARS2	-0.49	-5.62	-0.35	5.47e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs910316	1.000	rs2268617	chr14:75608728	G/A	cg23033748	chr14:75592666	NEK9	0.36	5.05	0.31	8.75e-7	Height;
SARC	cis	rs12458462	0.851	rs3859317	chr18:77443093	A/C	cg11879182	chr18:77439856	CTDP1	0.9	13.28	0.66	2.5e-30	Monocyte count;
SARC	cis	rs1448094	0.967	rs7301496	chr12:86321212	A/C	cg02569458	chr12:86230093	RASSF9	0.4	5.75	0.35	2.77e-8	Major depressive disorder;
SARC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg13397359	chr6:42928475	GNMT	-0.58	-8.1	-0.47	3.17e-14	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs11785400	0.793	rs7459963	chr8:143737129	C/T	cg24634471	chr8:143751801	JRK	0.58	7.37	0.43	3.02e-12	Schizophrenia;
SARC	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs2727020	0.553	rs3862350	chr11:49595912	A/C	cg15704280	chr7:45808275	SEPT13	-0.83	-13.5	-0.66	4.59e-31	Coronary artery disease;
SARC	cis	rs11864453	0.826	rs6499559	chr16:72132064	G/C	cg01557791	chr16:72042693	DHODH	-0.65	-9.15	-0.51	2.88e-17	Fibrinogen levels;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg23103367	chr13:60970259	TDRD3	-0.52	-7.06	-0.42	1.93e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg18695750	chr6:71135534	FAM135A	0.5	6.91	0.41	4.54e-11	Thyroid stimulating hormone;
SARC	cis	rs698813	0.851	rs698807	chr2:44701659	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	5.33	0.33	2.29e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg16479474	chr6:28041457	NA	0.36	5.45	0.34	1.25e-7	Depression;
SARC	cis	rs4808199	0.947	rs2163804	chr19:19575965	G/A	cg03709012	chr19:19516395	GATAD2A	1.2	13.19	0.65	4.79e-30	Nonalcoholic fatty liver disease;
SARC	cis	rs3126085	0.935	rs1496050	chr1:152163549	T/C	cg03465714	chr1:152285911	FLG	-0.47	-5.56	-0.34	7.45e-8	Atopic dermatitis;
SARC	cis	rs56116382	0.604	rs9858428	chr3:49877585	G/T	cg03060546	chr3:49711283	APEH	-0.61	-4.77	-0.3	3.24e-6	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
SARC	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	12.61	0.64	3.79e-28	Platelet count;
SARC	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg13206674	chr6:150067644	NUP43	0.43	5.66	0.35	4.37e-8	Lung cancer;
SARC	cis	rs2075423	1.000	rs2075423	chr1:214154719	A/C	cg24083324	chr1:214162604	PROX1	0.43	5.89	0.36	1.36e-8	Type 2 diabetes;
SARC	cis	rs2191566	0.576	rs370809	chr19:44493830	C/T	cg20607764	chr19:44506953	ZNF230	0.42	4.8	0.3	2.86e-6	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg07701084	chr6:150067640	NUP43	0.44	5.64	0.35	4.79e-8	Lung cancer;
SARC	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg27266027	chr21:40555129	PSMG1	-0.48	-5.28	-0.33	3.01e-7	Cognitive function;
SARC	cis	rs4481887	1.000	rs10788775	chr1:248471945	C/G	cg00666640	chr1:248458726	OR2T12	0.38	6.28	0.38	1.62e-9	Common traits (Other);
SARC	cis	rs9640161	0.789	rs1464753	chr7:150021350	G/C	cg10018233	chr7:150070692	REPIN1	0.71	9.29	0.52	1.16e-17	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs2645424	0.604	rs9644756	chr8:11715100	A/T	cg21281001	chr8:11725306	CTSB	0.45	5.55	0.34	7.87e-8	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
SARC	cis	rs8072100	0.817	rs9892497	chr17:45545919	G/A	cg08085267	chr17:45401833	C17orf57	-0.49	-5.93	-0.36	1.11e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg07701084	chr6:150067640	NUP43	0.38	5.04	0.31	9.56e-7	Lung cancer;
SARC	cis	rs7566780	0.575	rs4240228	chr2:16688759	G/T	cg09580478	chr2:16689509	NA	0.51	6.35	0.38	1.12e-9	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs12079745	1.000	rs79478286	chr1:169127908	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.87	-5.68	-0.35	4.08e-8	QT interval;
SARC	cis	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg11764359	chr7:65958608	NA	0.67	6.58	0.4	3e-10	Aortic root size;
SARC	cis	rs453301	0.658	rs6983877	chr8:8904639	T/C	cg11995313	chr8:8860691	ERI1	0.46	5.94	0.36	1.05e-8	Joint mobility (Beighton score);
SARC	cis	rs34779708	0.966	rs35146199	chr10:35460939	T/C	cg03585969	chr10:35415529	CREM	0.39	4.81	0.3	2.67e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs6582630	0.560	rs11504462	chr12:38440379	G/A	cg13010199	chr12:38710504	ALG10B	-0.48	-5.86	-0.36	1.56e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6700896	0.931	rs1892534	chr1:66105944	C/T	cg04111102	chr1:66153794	NA	0.33	5.05	0.31	8.85e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.78	11.83	0.61	1.32e-25	Personality dimensions;
SARC	cis	rs7553864	0.614	rs1886634	chr1:87614821	C/T	cg18153957	chr1:87613403	LOC339524	0.42	4.83	0.3	2.44e-6	Smoking behavior;
SARC	cis	rs4453791	0.505	rs35752744	chr3:38926290	T/C	cg26331595	chr3:39149181	GORASP1;TTC21A	0.45	4.79	0.3	2.95e-6	Social communication problems;
SARC	cis	rs9486719	0.857	rs4265039	chr6:96878929	T/C	cg18709589	chr6:96969512	KIAA0776	0.51	5.53	0.34	8.52e-8	Migraine;Coronary artery disease;
SARC	cis	rs896854	0.738	rs509594	chr8:95967156	C/G	cg09323728	chr8:95962352	TP53INP1	0.29	4.76	0.3	3.33e-6	Type 2 diabetes;
SARC	cis	rs7592578	0.679	rs59929070	chr2:191327852	A/G	cg25963032	chr2:191064776	C2orf88	-0.44	-4.92	-0.31	1.66e-6	Diastolic blood pressure;
SARC	cis	rs4926611	0.698	rs4307514	chr1:54060248	T/C	cg08927728	chr1:54059983	GLIS1	0.31	5.07	0.32	8.05e-7	Hand grip strength;
SARC	cis	rs11122272	0.706	rs2749710	chr1:231535112	A/C	cg06096015	chr1:231504339	EGLN1	-0.4	-6.05	-0.37	5.83e-9	Hemoglobin concentration;
SARC	cis	rs2180341	0.960	rs7751865	chr6:127683040	G/A	cg24812749	chr6:127587940	RNF146	1.01	13.14	0.65	6.91e-30	Breast cancer;
SARC	cis	rs10927875	0.894	rs10927878	chr1:16319957	C/T	cg21385522	chr1:16154831	NA	-0.7	-9.09	-0.51	4.39e-17	Dilated cardiomyopathy;
SARC	cis	rs1865760	1.000	rs3830057	chr6:25918510	G/T	cg16482183	chr6:26056742	HIST1H1C	0.5	6.24	0.38	2.01e-9	Height;
SARC	cis	rs854765	0.533	rs2955354	chr17:17948716	G/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.41	-5.13	-0.32	6.16e-7	Total body bone mineral density;
SARC	cis	rs7740797	0.818	rs3087697	chr6:155133742	C/G	cg02865717	chr6:155053990	RBM16	-0.35	-5.09	-0.32	7.22e-7	Colorectal or endometrial cancer;
SARC	cis	rs7264396	0.563	rs1970577	chr20:34336737	A/G	cg01084648	chr20:34329383	RBM39	0.57	5.0	0.31	1.13e-6	Total cholesterol levels;
SARC	cis	rs1185460	0.967	rs4545564	chr11:118937518	T/C	cg23280166	chr11:118938394	VPS11	0.81	12.29	0.63	4.3e-27	Coronary artery disease;
SARC	cis	rs10870270	0.830	rs11146269	chr10:133761820	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.84	-10.59	-0.57	1.24e-21	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-9.66	-0.53	8.5e-19	Chronic sinus infection;
SARC	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg24633833	chr3:10029261	TMEM111	0.52	5.25	0.33	3.43e-7	Alzheimer's disease;
SARC	cis	rs950169	0.922	rs11633534	chr15:85124642	C/T	cg17507749	chr15:85114479	UBE2QP1	0.79	9.37	0.52	6.69e-18	Schizophrenia;
SARC	cis	rs2204008	0.580	rs11174421	chr12:38105138	A/G	cg26384229	chr12:38710491	ALG10B	0.85	10.75	0.58	3.82e-22	Bladder cancer;
SARC	cis	rs1865760	0.929	rs1436307	chr6:25939723	C/T	cg10373733	chr6:25993375	NA	0.41	4.85	0.3	2.27e-6	Height;
SARC	cis	rs7843479	1.000	rs2306641	chr8:21833965	A/G	cg17168535	chr8:21777572	XPO7	-0.61	-7.82	-0.46	1.8e-13	Mean corpuscular volume;
SARC	cis	rs7264396	1.000	rs224429	chr20:34152018	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.46	-5.34	-0.33	2.16e-7	Total cholesterol levels;
SARC	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg07701084	chr6:150067640	NUP43	0.39	5.21	0.32	4.25e-7	Lung cancer;
SARC	cis	rs2204008	0.627	rs10878488	chr12:38148666	G/A	cg26384229	chr12:38710491	ALG10B	0.89	12.84	0.64	6.93e-29	Bladder cancer;
SARC	cis	rs10982256	1.000	rs4979413	chr9:117259548	A/G	cg21159778	chr9:117266918	DFNB31	-0.33	-4.93	-0.31	1.55e-6	Bipolar disorder;
SARC	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg03806693	chr22:41940476	POLR3H	-0.95	-13.04	-0.65	1.49e-29	Vitiligo;
SARC	cis	rs1691799	0.899	rs1168317	chr12:66746225	C/T	cg16791601	chr12:66731901	HELB	-0.72	-10.86	-0.58	1.68e-22	White blood cell count (basophil);
SARC	cis	rs7408868	0.908	rs10418660	chr19:15278635	A/G	cg14696996	chr19:15285081	NOTCH3	1.01	8.87	0.5	1.93e-16	Pulse pressure;
SARC	cis	rs568617	1.000	rs693824	chr11:65654783	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.47	5.45	0.34	1.31e-7	Crohn's disease;
SARC	cis	rs611744	0.870	rs57723916	chr8:109191433	A/T	cg21045802	chr8:109455806	TTC35	0.44	5.3	0.33	2.64e-7	Dupuytren's disease;
SARC	cis	rs9768139	0.935	rs116290351	chr7:158119712	T/A	cg25566285	chr7:158114605	PTPRN2	-0.31	-5.28	-0.33	2.95e-7	Calcium levels;
SARC	cis	rs2479724	0.846	rs2254805	chr6:41846110	T/G	cg17623882	chr6:41773611	USP49	-0.46	-5.56	-0.34	7.45e-8	Menarche (age at onset);
SARC	cis	rs9325144	0.555	rs2387843	chr12:38711203	T/C	cg26384229	chr12:38710491	ALG10B	0.61	8.26	0.48	1.11e-14	Morning vs. evening chronotype;
SARC	trans	rs11039798	0.565	rs7118675	chr11:48532063	C/A	cg15704280	chr7:45808275	SEPT13	0.63	6.42	0.39	7.76e-10	Axial length;
SARC	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg01341218	chr17:43662625	NA	1.02	11.73	0.61	2.77e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs1144333	0.655	rs58722308	chr1:76423525	A/G	cg03433033	chr1:76189801	ACADM	0.62	5.09	0.32	7.45e-7	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs3741151	0.773	rs17244616	chr11:73293112	C/T	cg17517138	chr11:73019481	ARHGEF17	0.92	6.64	0.4	2.15e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs712039	0.652	rs853227	chr17:35797529	C/T	cg16670864	chr17:35848621	DUSP14	0.44	4.84	0.3	2.41e-6	Tuberculosis;
SARC	cis	rs1865760	1.000	rs12209482	chr6:25909229	T/G	cg10373733	chr6:25993375	NA	0.46	5.54	0.34	8.23e-8	Height;
SARC	cis	rs13161895	1.000	rs34027780	chr5:179478891	C/A	cg02702477	chr5:179499311	RNF130	0.69	6.75	0.4	1.18e-10	LDL cholesterol;
SARC	cis	rs7959452	0.535	rs4761228	chr12:69682327	G/A	cg20891283	chr12:69753455	YEATS4	0.41	5.44	0.34	1.37e-7	Blood protein levels;
SARC	cis	rs735396	0.770	rs2259820	chr12:121435342	C/T	cg04422896	chr12:121454269	C12orf43	0.39	4.74	0.3	3.75e-6	N-glycan levels;
SARC	trans	rs9329221	0.741	rs534523	chr8:9884999	C/G	cg21775007	chr8:11205619	TDH	-0.5	-6.44	-0.39	6.89e-10	Neuroticism;
SARC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg24846343	chr22:24311635	DDTL	-0.45	-5.86	-0.36	1.59e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs763121	0.925	rs9611008	chr22:39098787	T/C	cg06022373	chr22:39101656	GTPBP1	0.82	10.89	0.58	1.36e-22	Menopause (age at onset);
SARC	cis	rs16854884	1.000	rs16854886	chr3:143781492	A/G	cg06585982	chr3:143692056	C3orf58	0.55	6.67	0.4	1.89e-10	Economic and political preferences (feminism/equality);
SARC	cis	rs35213789	0.839	rs17462837	chr7:69548090	A/G	cg10619644	chr7:69149951	AUTS2	0.41	5.07	0.32	8.06e-7	Childhood ear infection;
SARC	cis	rs601339	0.938	rs1696345	chr12:123183060	T/G	cg18578876	chr12:123200353	GPR109B	0.43	4.84	0.3	2.42e-6	Adiponectin levels;
SARC	cis	rs9921222	1.000	rs10794639	chr16:377367	A/G	cg26913058	chr16:419975	MRPL28	-0.31	-5.8	-0.35	2.19e-8	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs11608355	1.000	rs10774695	chr12:109868040	G/A	cg19025524	chr12:109796872	NA	-0.41	-5.28	-0.33	2.98e-7	Neuroticism;
SARC	cis	rs644799	1.000	rs627568	chr11:95569253	A/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	14.73	0.69	3.74e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9398803	0.678	rs9372841	chr6:126898541	A/G	cg19875578	chr6:126661172	C6orf173	0.63	8.7	0.5	5.9e-16	Male-pattern baldness;
SARC	cis	rs6732160	0.613	rs58317144	chr2:73388153	C/T	cg01422370	chr2:73384389	NA	0.36	5.48	0.34	1.1e-7	Intelligence (multi-trait analysis);
SARC	cis	rs8133932	0.724	rs11701249	chr21:47050714	G/A	cg11214348	chr21:47283868	PCBP3	-0.46	-5.03	-0.31	9.63e-7	Schizophrenia;
SARC	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg26513180	chr16:89883248	FANCA	-0.87	-12.52	-0.63	7.77e-28	Vitiligo;
SARC	cis	rs9682041	0.696	rs6786542	chr3:170105378	C/T	cg11886554	chr3:170076028	SKIL	0.84	7.76	0.45	2.72e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs995000	0.899	rs1002687	chr1:62963737	G/A	cg06896770	chr1:63153194	DOCK7	-0.89	-12.97	-0.65	2.48e-29	Triglyceride levels;
SARC	cis	rs6570726	0.935	rs422540	chr6:145837815	G/T	cg05220968	chr6:146057943	EPM2A	-0.29	-4.99	-0.31	1.19e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6582630	0.599	rs1589392	chr12:38418535	G/C	cg14851346	chr12:38532713	NA	-0.47	-5.67	-0.35	4.25e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9818758	0.607	rs71324929	chr3:49044713	C/T	cg00383909	chr3:49044727	WDR6	0.77	6.38	0.39	9.45e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg26338869	chr17:61819248	STRADA	0.8	10.72	0.57	4.8e-22	Prudent dietary pattern;
SARC	cis	rs79149102	0.737	rs16973172	chr15:75156944	G/A	cg09165964	chr15:75287851	SCAMP5	-1.07	-6.68	-0.4	1.76e-10	Lung cancer;
SARC	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg27266027	chr21:40555129	PSMG1	0.48	5.13	0.32	6.16e-7	Cognitive function;
SARC	cis	rs1008375	0.872	rs6831115	chr4:17640463	A/G	cg27347728	chr4:17578864	LAP3	0.47	5.94	0.36	1.01e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs8054556	0.751	rs11642430	chr16:30045789	C/G	cg06015834	chr16:30021696	DOC2A	-0.37	-4.96	-0.31	1.36e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2952156	0.883	rs8077172	chr17:37834977	G/T	cg07936489	chr17:37558343	FBXL20	-0.4	-5.28	-0.33	2.89e-7	Asthma;
SARC	cis	rs1580019	0.844	rs1901202	chr7:32503724	A/T	cg06627557	chr7:32535165	LSM5;AVL9	0.79	11.02	0.59	5.12e-23	Cognitive ability;
SARC	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg13206674	chr6:150067644	NUP43	0.46	5.95	0.36	9.77e-9	Lung cancer;
SARC	cis	rs8031584	0.958	rs3512	chr15:31235005	G/C	cg08109568	chr15:31115862	NA	-0.46	-5.7	-0.35	3.66e-8	Huntington's disease progression;
SARC	cis	rs1797081	1.000	rs812426	chr10:16857133	C/G	cg23933602	chr10:16859644	RSU1	0.95	17.84	0.76	1.79e-45	Platelet distribution width;
SARC	cis	rs1008375	0.897	rs2315554	chr4:17660407	T/C	cg16339924	chr4:17578868	LAP3	0.66	8.5	0.49	2.25e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg03188948	chr7:1209495	NA	0.59	5.8	0.36	2.19e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs4268898	0.552	rs11125444	chr2:24367205	G/T	cg26838691	chr2:24397539	C2orf84	0.38	5.05	0.31	9.11e-7	Asthma;
SARC	cis	rs11649653	0.502	rs62057232	chr16:30820866	T/C	cg02466173	chr16:30829666	NA	0.34	4.8	0.3	2.82e-6	Triglycerides;
SARC	cis	rs6815814	0.950	rs11722889	chr4:38810975	C/T	cg09316306	chr4:38807337	TLR1	0.5	5.22	0.32	3.93e-7	Breast cancer;
SARC	cis	rs7944584	0.563	rs61895112	chr11:47560433	T/C	cg20307385	chr11:47447363	PSMC3	0.71	9.01	0.51	7.6e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs74417235	0.684	rs13179358	chr5:154059746	C/A	cg08754654	chr5:154026448	NA	0.48	4.8	0.3	2.86e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
SARC	cis	rs112591243	0.685	rs2839323	chr21:47978421	G/A	cg10657630	chr21:48055338	PRMT2	0.83	5.47	0.34	1.15e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs854765	0.583	rs8065416	chr17:17851162	C/T	cg05444541	chr17:17804740	TOM1L2	-0.29	-4.82	-0.3	2.56e-6	Total body bone mineral density;
SARC	cis	rs2204008	0.628	rs10876106	chr12:37990767	A/G	cg26384229	chr12:38710491	ALG10B	0.86	12.42	0.63	1.62e-27	Bladder cancer;
SARC	cis	rs6121246	0.529	rs58757492	chr20:30181425	G/A	cg13852791	chr20:30311386	BCL2L1	0.68	5.9	0.36	1.27e-8	Mean corpuscular hemoglobin;
SARC	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.82	10.75	0.58	3.66e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9818758	0.505	rs67286839	chr3:49265744	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.72	-6.16	-0.37	3.16e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs2652822	0.525	rs8037296	chr15:63516759	A/G	cg02713581	chr15:63449717	RPS27L	0.53	6.39	0.39	8.7e-10	Metabolic traits;
SARC	cis	rs6831352	0.918	rs17218141	chr4:100055908	T/C	cg13256891	chr4:100009986	ADH5	-0.64	-8.0	-0.46	5.7e-14	Alcohol dependence;
SARC	cis	rs9916302	0.706	rs7503377	chr17:37708841	A/G	cg00129232	chr17:37814104	STARD3	-0.56	-5.45	-0.34	1.31e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs751728	1.000	rs2296748	chr6:33745071	C/T	cg15252951	chr6:33757062	LEMD2	0.59	6.84	0.41	6.79e-11	Crohn's disease;
SARC	cis	rs73157695	0.929	rs78131185	chr21:47330224	G/A	cg00682050	chr21:47343716	PCBP3	-0.42	-4.87	-0.3	2.02e-6	Myopia;
SARC	cis	rs10504073	0.584	rs62507182	chr8:49942500	C/A	cg00325661	chr8:49890786	NA	0.52	6.95	0.41	3.55e-11	Blood metabolite ratios;
SARC	cis	rs9911578	0.813	rs8066773	chr17:56601552	A/G	cg12560992	chr17:57184187	TRIM37	0.73	8.84	0.5	2.34e-16	Intelligence (multi-trait analysis);
SARC	cis	rs9926296	0.744	rs164746	chr16:89709019	C/T	cg26513180	chr16:89883248	FANCA	-0.49	-5.96	-0.36	9.41e-9	Vitiligo;
SARC	cis	rs3087591	1.000	rs6505235	chr17:29688603	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.5	-6.06	-0.37	5.34e-9	Hip circumference;
SARC	cis	rs60871478	1.000	rs62432252	chr7:802886	C/G	cg19087971	chr7:751233	PRKAR1B	-0.42	-4.75	-0.3	3.52e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs6582630	0.519	rs1607868	chr12:38385512	G/T	cg26384229	chr12:38710491	ALG10B	0.87	12.86	0.64	5.77e-29	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs7824557	0.564	rs12547100	chr8:11242632	G/A	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.6	-0.49	1.19e-15	Retinal vascular caliber;
SARC	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg17294928	chr15:75287854	SCAMP5	0.49	6.23	0.38	2.15e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	cis	rs9494145	0.531	rs9399136	chr6:135402339	T/C	cg22676075	chr6:135203613	NA	0.41	4.72	0.3	4.07e-6	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
SARC	cis	rs910316	1.000	rs4903289	chr14:75623988	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.5	-7.08	-0.42	1.66e-11	Height;
SARC	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg21442419	chr1:2182373	SKI	-0.48	-6.25	-0.38	1.91e-9	Height;
SARC	cis	rs2273669	0.915	rs1080945	chr6:109304694	A/G	cg05315195	chr6:109294784	ARMC2	-0.5	-4.94	-0.31	1.46e-6	Prostate cancer;
SARC	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg03576123	chr11:487126	PTDSS2	-1.14	-11.6	-0.6	7.51e-25	Body mass index;
SARC	cis	rs9612	1.000	rs28373139	chr19:44246706	A/G	cg07522664	chr19:44259120	C19orf61	0.48	5.41	0.33	1.56e-7	Exhaled nitric oxide output;
SARC	cis	rs11608355	0.545	rs2302704	chr12:109898797	A/G	cg05360138	chr12:110035743	NA	0.92	9.65	0.53	9.69e-19	Neuroticism;
SARC	cis	rs1843834	0.539	rs2068244	chr2:225440011	A/G	cg12698349	chr2:225449008	CUL3	-0.67	-8.25	-0.48	1.16e-14	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs933688	1.000	rs12656350	chr5:90751343	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.97	12.01	0.62	3.57e-26	Smoking behavior;
SARC	cis	rs113835537	0.597	rs4576	chr11:66331000	A/G	cg24851651	chr11:66362959	CCS	0.4	5.08	0.32	7.77e-7	Airway imaging phenotypes;
SARC	cis	rs11098499	0.663	rs9996501	chr4:120238918	C/A	cg09307838	chr4:120376055	NA	0.84	11.54	0.6	1.15e-24	Corneal astigmatism;
SARC	cis	rs10416265	0.527	rs7508599	chr19:33546512	A/T	cg17764715	chr19:33622953	WDR88	0.57	7.77	0.45	2.56e-13	Bone properties (heel);
SARC	cis	rs6429082	0.608	rs4659836	chr1:235564412	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.6	-7.17	-0.43	9.57e-12	Adiposity;
SARC	cis	rs694739	0.541	rs61886926	chr11:64133552	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.52	5.61	0.35	5.69e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs2228479	0.850	rs17233497	chr16:89815152	G/A	cg00800038	chr16:89945340	TCF25	-0.79	-5.27	-0.33	3.06e-7	Skin colour saturation;
SARC	cis	rs3106136	0.778	rs1593554	chr4:95278501	C/T	cg11021082	chr4:95130006	SMARCAD1	0.33	5.12	0.32	6.34e-7	Capecitabine sensitivity;
SARC	cis	rs2204008	0.837	rs11612397	chr12:38357455	T/C	cg26384229	chr12:38710491	ALG10B	0.87	12.69	0.64	2.17e-28	Bladder cancer;
SARC	cis	rs3820928	0.874	rs7563644	chr2:227846932	A/G	cg05526886	chr2:227700861	RHBDD1	-0.56	-6.71	-0.4	1.44e-10	Pulmonary function;
SARC	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.54	7.03	0.42	2.22e-11	Menarche (age at onset);
SARC	cis	rs4727027	0.933	rs12704062	chr7:148827865	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	5.49	0.34	1.03e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs7769051	1.000	rs9399041	chr6:133096233	T/G	cg07930552	chr6:133119739	C6orf192	0.94	8.67	0.49	7.39e-16	Type 2 diabetes nephropathy;
SARC	cis	rs546131	0.928	rs572690	chr11:34833614	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.47	5.66	0.35	4.32e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg27588902	chr6:42928151	GNMT	-0.38	-5.86	-0.36	1.56e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg00152838	chr16:24741724	TNRC6A	-0.61	-6.27	-0.38	1.7e-9	Intelligence (multi-trait analysis);
SARC	cis	rs9916302	0.706	rs584377	chr17:37460128	G/A	cg15445000	chr17:37608096	MED1	-0.45	-4.92	-0.31	1.62e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs6570726	0.935	rs428659	chr6:145827039	T/C	cg05347473	chr6:146136440	FBXO30	0.48	6.42	0.39	7.51e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs17376456	0.569	rs17083377	chr5:93164870	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.53	5.6	0.34	6.09e-8	Diabetic retinopathy;
SARC	cis	rs9796	0.727	rs12101934	chr15:41353079	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.5	-6.78	-0.41	9.9e-11	Menopause (age at onset);
SARC	cis	rs7772486	0.754	rs9497419	chr6:146142609	T/C	cg05347473	chr6:146136440	FBXO30	0.51	7.22	0.43	7.1e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7027203	0.717	rs7869328	chr9:96588782	A/G	cg14598338	chr9:96623480	NA	-0.54	-7.67	-0.45	4.73e-13	DNA methylation (variation);
SARC	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg24829409	chr8:58192753	C8orf71	-0.57	-5.2	-0.32	4.43e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg23022344	chr1:24969466	SRRM1	0.52	6.28	0.38	1.6e-9	Breast cancer;
SARC	cis	rs11997175	0.766	rs7387133	chr8:33727045	C/G	ch.8.33884649F	chr8:33765107	NA	-0.59	-8.19	-0.47	1.71e-14	Body mass index;
SARC	cis	rs6912958	1.000	rs9450701	chr6:88173167	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.62	-8.56	-0.49	1.54e-15	Monocyte percentage of white cells;
SARC	cis	rs11697848	1.000	rs2284647	chr20:48526749	A/C	cg17849948	chr20:48532315	SPATA2	0.87	5.2	0.32	4.3e-7	Systemic lupus erythematosus;
SARC	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg06108461	chr20:60628389	TAF4	0.59	6.2	0.38	2.52e-9	Obesity-related traits;
SARC	cis	rs9814567	1.000	rs9809619	chr3:134280948	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.04	-0.42	2.19e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs7546668	0.640	rs4661634	chr1:15808289	C/T	cg18192808	chr1:15853278	DNAJC16	0.44	5.13	0.32	6.23e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs2288073	0.965	rs6545338	chr2:24422156	C/T	cg26838691	chr2:24397539	C2orf84	-0.54	-6.66	-0.4	1.92e-10	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs765787	0.530	rs55771002	chr15:45541566	T/C	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.51e-10	Uric acid levels;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg15318396	chr21:38593284	NA	-0.55	-6.6	-0.4	2.67e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.95	-14.1	-0.68	4.59e-33	Chronic sinus infection;
SARC	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg22800045	chr5:56110881	MAP3K1	-0.56	-5.46	-0.34	1.24e-7	Initial pursuit acceleration;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg14618681	chr20:32273893	E2F1	0.49	6.63	0.4	2.36e-10	Tetralogy of Fallot;
SARC	cis	rs7412746	0.658	rs4537557	chr1:150734436	A/G	cg15448220	chr1:150897856	SETDB1	0.47	6.07	0.37	5.12e-9	Melanoma;
SARC	cis	rs7408868	0.656	rs1043997	chr19:15292437	T/C	cg14696996	chr19:15285081	NOTCH3	0.57	5.95	0.36	9.69e-9	Pulse pressure;
SARC	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg18225595	chr11:63971243	STIP1	-0.45	-5.57	-0.34	6.85e-8	Mean platelet volume;
SARC	cis	rs3540	0.960	rs11853271	chr15:91025830	C/T	cg22089800	chr15:90895588	ZNF774	0.48	5.41	0.33	1.56e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs9733	0.536	rs10888385	chr1:150574302	T/C	cg13175981	chr1:150552382	MCL1	0.64	8.26	0.48	1.09e-14	Tonsillectomy;
SARC	cis	rs8064024	0.625	rs960006	chr16:4911195	T/C	cg08329684	chr16:4932620	PPL	0.35	5.44	0.34	1.38e-7	Cancer;
SARC	cis	rs523522	0.962	rs10849758	chr12:120971149	C/T	cg27279351	chr12:120934652	DYNLL1	0.73	9.05	0.51	5.73e-17	High light scatter reticulocyte count;
SARC	cis	rs4481887	1.000	rs4360553	chr1:248467092	A/G	cg01631408	chr1:248437212	OR2T33	-0.44	-5.68	-0.35	3.91e-8	Common traits (Other);
SARC	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg24642844	chr7:1081250	C7orf50	-0.38	-5.24	-0.32	3.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs2120243	0.572	rs2305620	chr3:157127586	C/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.39	4.94	0.31	1.5e-6	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs4803468	1.000	rs8105833	chr19:41896145	G/A	cg09537434	chr19:41945824	ATP5SL	-0.93	-15.92	-0.72	4.27e-39	Height;
SARC	cis	rs2841277	0.676	rs4264326	chr14:105411700	A/G	cg14403583	chr14:105418241	AHNAK2	-0.57	-7.36	-0.43	3.15e-12	Rheumatoid arthritis;
SARC	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg01570182	chr17:44337453	NA	0.88	9.99	0.55	8.93e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7520050	0.778	rs2991985	chr1:46080530	T/C	cg06784218	chr1:46089804	CCDC17	-0.26	-4.72	-0.3	4.01e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs3772130	0.545	rs7340674	chr3:121574215	T/C	cg20356878	chr3:121714668	ILDR1	0.39	6.05	0.37	5.6e-9	Cognitive performance;
SARC	cis	rs73206853	0.841	rs73206883	chr12:110849549	A/G	cg10860002	chr12:110842031	ANAPC7	0.62	4.95	0.31	1.4e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg09721380	chr16:69140530	HAS3	0.52	6.66	0.4	1.92e-10	Breast cancer;
SARC	cis	rs644799	1.000	rs564675	chr11:95561873	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.9	14.03	0.68	7.82e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs10927875	0.632	rs6677321	chr1:16149301	A/C	cg21385522	chr1:16154831	NA	-0.92	-13.13	-0.65	7.32e-30	Dilated cardiomyopathy;
SARC	cis	rs6840360	0.615	rs7669761	chr4:152609304	G/A	cg22705602	chr4:152727874	NA	-0.48	-8.39	-0.48	4.63e-15	Intelligence (multi-trait analysis);
SARC	cis	rs4742903	0.904	rs7028408	chr9:106859811	G/A	cg21169611	chr9:106856078	SMC2	0.39	4.83	0.3	2.52e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs1552244	0.882	rs56125067	chr3:9984130	T/G	cg00149659	chr3:10157352	C3orf10	0.66	5.93	0.36	1.07e-8	Alzheimer's disease;
SARC	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg02733842	chr7:1102375	C7orf50	0.59	7.58	0.44	8.29e-13	Bronchopulmonary dysplasia;
SARC	cis	rs7429990	0.965	rs34750113	chr3:47986392	C/T	cg11946769	chr3:48343235	NME6	0.46	5.11	0.32	6.78e-7	Educational attainment (years of education);
SARC	cis	rs17384381	0.953	rs12130145	chr1:85828970	G/C	cg16011679	chr1:85725395	C1orf52	0.65	5.87	0.36	1.46e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs17376456	0.877	rs12716460	chr5:93416733	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.66	5.95	0.36	9.82e-9	Diabetic retinopathy;
SARC	cis	rs9300255	0.596	rs10773002	chr12:123746961	A/T	cg05973401	chr12:123451056	ABCB9	-0.49	-5.41	-0.33	1.54e-7	Neutrophil percentage of white cells;
SARC	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg13939156	chr17:80058883	NA	0.4	6.25	0.38	1.92e-9	Life satisfaction;
SARC	cis	rs9341808	0.667	rs2505929	chr6:80834208	A/G	cg08355045	chr6:80787529	NA	0.36	5.76	0.35	2.63e-8	Sitting height ratio;
SARC	cis	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg15556689	chr8:8085844	FLJ10661	-0.39	-4.9	-0.31	1.82e-6	Mood instability;
SARC	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg20891558	chr2:74357851	NA	0.71	9.66	0.53	8.55e-19	Gestational age at birth (maternal effect);
SARC	cis	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg11995313	chr8:8860691	ERI1	-0.4	-4.96	-0.31	1.37e-6	Mood instability;
SARC	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.98	-16.17	-0.73	6.02e-40	Chronic sinus infection;
SARC	cis	rs17376456	1.000	rs13185608	chr5:93509688	T/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.2	0.32	4.33e-7	Diabetic retinopathy;
SARC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg23131131	chr22:24373011	LOC391322	-0.42	-4.77	-0.3	3.26e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg07636037	chr3:49044803	WDR6	0.48	5.65	0.35	4.66e-8	Resting heart rate;
SARC	cis	rs2933343	0.621	rs789249	chr3:128578453	T/C	cg24203234	chr3:128598194	ACAD9	0.63	8.12	0.47	2.7e-14	IgG glycosylation;
SARC	cis	rs6459788	0.585	rs6950818	chr7:157235364	C/G	cg22987457	chr7:157211561	NA	0.38	4.94	0.31	1.48e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs9916302	0.904	rs7210488	chr17:37539819	T/G	cg15445000	chr17:37608096	MED1	-0.42	-5.08	-0.32	7.81e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs62344088	0.590	rs58563514	chr5:177837	C/T	cg22496380	chr5:211416	CCDC127	-0.73	-5.45	-0.34	1.28e-7	Asthma (childhood onset);
SARC	cis	rs9473924	0.505	rs2817416	chr6:50809777	T/C	cg14470998	chr6:50812995	TFAP2B	0.7	6.29	0.38	1.6e-9	Body mass index;
SARC	cis	rs778371	0.723	rs6704763	chr2:233592487	C/T	cg16596103	chr2:233749413	NGEF	-0.39	-6.2	-0.38	2.6e-9	Schizophrenia;
SARC	cis	rs2120019	0.567	rs68036747	chr15:75203200	A/C	cg17294928	chr15:75287854	SCAMP5	-0.9	-9.36	-0.52	6.9e-18	Blood trace element (Zn levels);
SARC	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg20120463	chr17:44301886	NA	0.32	5.03	0.31	9.89e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg22800045	chr5:56110881	MAP3K1	0.74	7.92	0.46	9.76e-14	Initial pursuit acceleration;
SARC	trans	rs7937682	0.855	rs521947	chr11:111492616	A/G	cg18187862	chr3:45730750	SACM1L	0.55	6.99	0.42	2.93e-11	Primary sclerosing cholangitis;
SARC	cis	rs2153535	0.580	rs9406174	chr6:8516764	T/C	cg07606381	chr6:8435919	SLC35B3	0.77	10.87	0.58	1.55e-22	Motion sickness;
SARC	cis	rs7043114	0.507	rs10820971	chr9:95161740	G/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.49	-0.34	1.05e-7	Height;
SARC	cis	rs1904096	0.506	rs13434570	chr4:95168019	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.47	-7.07	-0.42	1.74e-11	Type 2 diabetes;
SARC	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg16479474	chr6:28041457	NA	0.35	5.15	0.32	5.48e-7	Cardiac Troponin-T levels;
SARC	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg20102877	chr2:27665638	KRTCAP3	-0.34	-4.75	-0.3	3.62e-6	Total body bone mineral density;
SARC	cis	rs8067545	0.750	rs28666381	chr17:19984809	C/G	cg13482628	chr17:19912719	NA	0.53	7.11	0.42	1.41e-11	Schizophrenia;
SARC	cis	rs7582720	1.000	rs72932553	chr2:203842661	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs9436747	0.641	rs12042877	chr1:66053148	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.48	4.94	0.31	1.47e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg23034840	chr1:205782522	SLC41A1	0.79	8.69	0.49	6.64e-16	Prostate-specific antigen levels;
SARC	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg12463550	chr7:65579703	CRCP	0.65	4.98	0.31	1.22e-6	Diabetic kidney disease;
SARC	cis	rs4803455	0.565	rs2241713	chr19:41869468	C/G	cg14132834	chr19:41945861	ATP5SL	0.41	5.17	0.32	5.12e-7	Migraine;Coronary artery disease;
SARC	cis	rs7731783	1	rs7731783	chr5:177060312	T/C	cg15051221	chr5:177434457	FAM153C	0.36	4.87	0.3	2.11e-6	Methadone dose in opioid dependence;
SARC	cis	rs7772486	0.727	rs6941429	chr6:145952283	G/A	cg05347473	chr6:146136440	FBXO30	0.55	7.7	0.45	3.9e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs854765	0.647	rs741782	chr17:18019712	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.38	4.74	0.3	3.74e-6	Total body bone mineral density;
SARC	cis	rs2658782	0.615	rs2605615	chr11:93233068	G/A	cg15737290	chr11:93063684	CCDC67	0.74	8.72	0.5	5.19e-16	Pulmonary function decline;
SARC	cis	rs514406	0.505	rs436363	chr1:53172163	T/C	cg24675658	chr1:53192096	ZYG11B	-0.66	-9.73	-0.54	5.31e-19	Monocyte count;
SARC	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg23758822	chr17:41437982	NA	0.9	11.51	0.6	1.45e-24	Menopause (age at onset);
SARC	cis	rs7927771	1.000	rs12421210	chr11:47779586	C/T	cg20307385	chr11:47447363	PSMC3	-0.47	-5.59	-0.34	6.3e-8	Subjective well-being;
SARC	cis	rs4423214	0.840	rs2017686	chr11:71187061	C/G	cg05163923	chr11:71159392	DHCR7	-0.6	-7.21	-0.43	7.58e-12	Vitamin D levels;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg22618487	chr12:16064282	DERA	0.49	6.58	0.4	3.01e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs10489525	0.528	rs360604	chr1:115390019	G/A	cg01522456	chr1:115632236	TSPAN2	-0.44	-5.31	-0.33	2.51e-7	Autism;
SARC	cis	rs9302635	0.513	rs8044555	chr16:72152755	T/C	cg01557791	chr16:72042693	DHODH	-0.58	-6.47	-0.39	5.6e-10	Blood protein levels;
SARC	cis	rs6696846	0.749	rs6692170	chr1:205074019	G/A	cg07972983	chr1:205091412	RBBP5	0.55	6.99	0.42	2.92e-11	Red blood cell count;
SARC	cis	rs875971	0.964	rs160635	chr7:65528918	T/C	cg12463550	chr7:65579703	CRCP	0.43	5.05	0.31	8.85e-7	Aortic root size;
SARC	cis	rs35306767	0.903	rs11253488	chr10:922482	G/C	cg20503657	chr10:835505	NA	0.81	7.68	0.45	4.27e-13	Eosinophil percentage of granulocytes;
SARC	cis	rs748404	0.697	rs1814323	chr15:43563237	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.45	-5.65	-0.35	4.61e-8	Lung cancer;
SARC	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg25072359	chr17:41440525	NA	0.52	6.18	0.38	2.83e-9	Menopause (age at onset);
SARC	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg13866156	chr1:1669148	SLC35E2	-0.61	-9.21	-0.52	1.93e-17	Body mass index;
SARC	cis	rs2236918	0.710	rs2797602	chr1:242029206	G/T	cg17736920	chr1:242011382	EXO1	0.64	8.55	0.49	1.63e-15	Menopause (age at onset);
SARC	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg26335602	chr6:28129616	ZNF389	0.55	5.95	0.36	9.89e-9	Parkinson's disease;
SARC	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg19901468	chr14:105411992	AHNAK2	-0.73	-10.79	-0.58	2.74e-22	Rheumatoid arthritis;
SARC	cis	rs2075371	0.897	rs1643102	chr7:133999983	T/A	cg11752832	chr7:134001865	SLC35B4	0.56	7.1	0.42	1.47e-11	Mean platelet volume;
SARC	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg27541892	chr1:1571801	CDK11B	0.4	5.47	0.34	1.19e-7	Body mass index;
SARC	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg16434002	chr17:42200994	HDAC5	-0.4	-4.87	-0.3	2.05e-6	Total body bone mineral density;
SARC	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs1348850	0.554	rs11679519	chr2:178432110	C/T	cg23306229	chr2:178417860	TTC30B	0.8	8.78	0.5	3.56e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	trans	rs2018683	0.707	rs2057957	chr7:28974626	A/C	cg19402173	chr7:128379420	CALU	0.49	6.3	0.38	1.44e-9	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs12135062	0.755	rs1553287	chr1:3101277	G/A	cg21609526	chr1:3105151	PRDM16	-0.41	-6.74	-0.4	1.22e-10	Migraine;
SARC	cis	rs3771570	1.000	rs7557535	chr2:242206555	T/C	cg21155796	chr2:242212141	HDLBP	0.69	5.96	0.36	9.37e-9	Prostate cancer;
SARC	cis	rs739401	0.611	rs2301140	chr11:3022629	C/T	cg08508325	chr11:3079039	CARS	-0.31	-7.32	-0.43	4.11e-12	Longevity;
SARC	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg10523679	chr1:76189770	ACADM	-0.43	-5.31	-0.33	2.61e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg24531977	chr5:56204891	C5orf35	-0.55	-5.6	-0.34	6.11e-8	Initial pursuit acceleration;
SARC	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg19223190	chr17:80058835	NA	0.48	6.6	0.4	2.8e-10	Life satisfaction;
SARC	cis	rs5758659	0.714	rs5751216	chr22:42508937	G/T	cg04733989	chr22:42467013	NAGA	-0.49	-6.08	-0.37	4.9e-9	Cognitive function;
SARC	cis	rs2732480	0.557	rs2634682	chr12:48732943	T/C	cg21466736	chr12:48725269	NA	-0.33	-5.13	-0.32	6.07e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg06108461	chr20:60628389	TAF4	-0.92	-12.75	-0.64	1.37e-28	Body mass index;
SARC	cis	rs2075371	0.933	rs2544201	chr7:133963561	C/G	cg20476274	chr7:133979776	SLC35B4	0.58	7.66	0.45	4.83e-13	Mean platelet volume;
SARC	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg15049968	chr18:44337910	ST8SIA5	0.33	5.2	0.32	4.27e-7	Personality dimensions;
SARC	cis	rs317689	0.680	rs315140	chr12:69790780	A/T	cg14784868	chr12:69753453	YEATS4	0.47	5.27	0.33	3.17e-7	Response to diuretic therapy;
SARC	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg00149659	chr3:10157352	C3orf10	0.74	6.77	0.41	1.01e-10	Alzheimer's disease;
SARC	cis	rs9393692	0.905	rs34916901	chr6:26286149	G/T	cg05868516	chr6:26286170	HIST1H4H	0.57	7.51	0.44	1.25e-12	Educational attainment;
SARC	cis	rs780094	0.528	rs1728918	chr2:27635463	C/T	cg03023068	chr2:27486122	SLC30A3	0.43	5.44	0.34	1.36e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg04899180	chr1:45266286	PLK3	0.47	6.43	0.39	7.22e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs6580649	0.941	rs72644841	chr12:48411987	A/G	cg24011408	chr12:48396354	COL2A1	-0.5	-5.52	-0.34	9.09e-8	Lung cancer;
SARC	cis	rs3733585	0.673	rs4455410	chr4:9953297	C/T	cg11266682	chr4:10021025	SLC2A9	0.36	6.13	0.37	3.65e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs10464366	0.746	rs62442210	chr7:39146328	G/T	cg15212455	chr7:39170539	POU6F2	0.44	5.34	0.33	2.16e-7	IgG glycosylation;
SARC	trans	rs2396442	1.000	rs2256819	chr6:45418402	A/G	cg17932484	chr13:24463526	MIPEP;PCOTH	-0.55	-6.32	-0.38	1.31e-9	Left ventricle wall thickness;
SARC	cis	rs6545883	0.965	rs6734830	chr2:61731112	G/A	cg15711740	chr2:61764176	XPO1	-0.42	-5.17	-0.32	5.02e-7	Tuberculosis;
SARC	cis	rs7828089	1.000	rs7828089	chr8:22264334	T/G	cg12081754	chr8:22256438	SLC39A14	0.44	5.71	0.35	3.4e-8	Verbal declarative memory;
SARC	cis	rs9487051	0.837	rs4403290	chr6:109611583	A/T	cg01475377	chr6:109611718	NA	-0.41	-5.9	-0.36	1.25e-8	Reticulocyte fraction of red cells;
SARC	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.62	7.52	0.44	1.14e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg00933542	chr6:150070202	PCMT1	0.31	5.31	0.33	2.6e-7	Lung cancer;
SARC	cis	rs28374715	0.662	rs8038983	chr15:41473316	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.0	-14.01	-0.68	9.56e-33	Ulcerative colitis;
SARC	cis	rs151234	0.800	rs231972	chr16:28538336	A/C	cg01378222	chr16:28622494	SULT1A1	-0.46	-5.41	-0.33	1.59e-7	Platelet distribution width;
SARC	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg24675658	chr1:53192096	ZYG11B	0.6	8.35	0.48	6.02e-15	Monocyte count;
SARC	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg20891283	chr12:69753455	YEATS4	0.68	9.72	0.54	5.85e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs2304069	0.545	rs11167492	chr5:149403101	G/A	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.46	5.13	0.32	5.96e-7	HIV-1 control;
SARC	cis	rs4243830	1.000	rs41278014	chr1:6579653	G/C	cg22792644	chr1:6614718	TAS1R1;NOL9	1.03	8.42	0.48	3.89e-15	Body mass index;
SARC	cis	rs10870270	0.956	rs10781555	chr10:133745720	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.82	-10.71	-0.57	4.89e-22	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs921968	0.608	rs678814	chr2:219359287	T/C	cg02176678	chr2:219576539	TTLL4	0.36	5.53	0.34	8.72e-8	Mean corpuscular hemoglobin concentration;
SARC	cis	rs35123781	0.696	rs904612	chr5:139070952	G/A	cg10513866	chr5:139070639	NA	0.35	4.73	0.3	3.82e-6	Schizophrenia;
SARC	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-6.63	-0.4	2.33e-10	Personality dimensions;
SARC	cis	rs6964587	0.626	rs34404183	chr7:91551249	T/C	cg17063962	chr7:91808500	NA	-0.76	-10.93	-0.58	1.04e-22	Breast cancer;
SARC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.09	13.12	0.65	8.31e-30	Platelet count;
SARC	cis	rs72945132	0.825	rs7941965	chr11:70213182	T/C	cg05964544	chr11:70165517	PPFIA1	-0.56	-5.5	-0.34	1.01e-7	Coronary artery disease;
SARC	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg21782813	chr7:2030301	MAD1L1	0.48	7.75	0.45	2.91e-13	Bipolar disorder and schizophrenia;
SARC	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg26119090	chr2:26468346	HADHA;HADHB	0.95	13.96	0.67	1.32e-32	Gut microbiome composition (summer);
SARC	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.59	0.34	6.34e-8	Bipolar disorder;
SARC	cis	rs9814567	0.964	rs12492930	chr3:134222722	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-7.03	-0.42	2.3e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs7647973	0.626	rs62262722	chr3:49769419	G/C	cg03060546	chr3:49711283	APEH	-0.6	-5.58	-0.34	6.83e-8	Menarche (age at onset);
SARC	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg19346786	chr7:2764209	NA	-0.33	-4.84	-0.3	2.41e-6	Height;
SARC	cis	rs8053891	0.756	rs12708921	chr16:71999589	G/A	cg16558253	chr16:72132732	DHX38	-0.37	-4.82	-0.3	2.58e-6	Coronary artery disease;
SARC	cis	rs4808199	0.843	rs10402308	chr19:19657500	G/A	cg03709012	chr19:19516395	GATAD2A	1.07	12.48	0.63	1.02e-27	Nonalcoholic fatty liver disease;
SARC	cis	rs787274	0.867	rs1711744	chr9:115453484	A/T	cg13803584	chr9:115635662	SNX30	-0.73	-5.88	-0.36	1.43e-8	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg13206674	chr6:150067644	NUP43	0.39	5.2	0.32	4.3e-7	Lung cancer;
SARC	cis	rs67366981	0.800	rs55939042	chr14:77691186	T/A	cg06779847	chr14:77687015	TMEM63C	-0.54	-6.07	-0.37	5.18e-9	Obsessive-compulsive symptoms;
SARC	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg13395646	chr4:1353034	KIAA1530	-0.55	-6.53	-0.39	4.15e-10	Obesity-related traits;
SARC	cis	rs79149102	0.649	rs76516943	chr15:75127539	C/A	cg17294928	chr15:75287854	SCAMP5	-0.99	-5.66	-0.35	4.52e-8	Lung cancer;
SARC	cis	rs7412746	0.553	rs59337856	chr1:150746406	G/T	cg10589385	chr1:150898437	SETDB1	0.4	5.31	0.33	2.53e-7	Melanoma;
SARC	cis	rs4148883	0.675	rs28762430	chr4:100119257	C/A	cg12011299	chr4:100065546	ADH4	0.36	6.71	0.4	1.43e-10	Alcohol dependence;
SARC	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg19223190	chr17:80058835	NA	0.44	6.16	0.37	3.21e-9	Life satisfaction;
SARC	cis	rs7937682	0.793	rs4581484	chr11:111415822	G/A	cg22437258	chr11:111473054	SIK2	-0.5	-6.13	-0.37	3.73e-9	Primary sclerosing cholangitis;
SARC	cis	rs208520	0.770	rs1342960	chr6:66883514	T/C	cg07460842	chr6:66804631	NA	-1.06	-13.6	-0.67	2.2e-31	Exhaled nitric oxide output;
SARC	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg20102877	chr2:27665638	KRTCAP3	-0.34	-4.77	-0.3	3.27e-6	Total body bone mineral density;
SARC	cis	rs6500395	1.000	rs9925406	chr16:48671436	C/A	cg04672837	chr16:48644449	N4BP1	0.47	6.24	0.38	2.05e-9	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs7264396	0.790	rs6058297	chr20:34271861	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	5.78	0.35	2.33e-8	Total cholesterol levels;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg06861343	chr3:52739491	GLT8D1;SPCS1	-0.79	-6.55	-0.39	3.54e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9916302	0.706	rs439537	chr17:37734482	T/C	cg07936489	chr17:37558343	FBXL20	-0.74	-8.47	-0.49	2.71e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs6735179	0.688	rs2382564	chr2:1763701	A/G	cg08534653	chr2:1747700	PXDN	0.38	4.77	0.3	3.24e-6	Response to antipsychotic treatment;
SARC	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg26681399	chr22:41777847	TEF	0.47	5.14	0.32	5.91e-7	Vitiligo;
SARC	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg10207240	chr12:122356781	WDR66	0.3	5.03	0.31	9.7e-7	Mean corpuscular volume;
SARC	cis	rs9843304	0.721	rs13062142	chr3:149201983	C/T	cg08667024	chr3:149219783	TM4SF4	-0.36	-5.3	-0.33	2.64e-7	Gallstone disease;
SARC	cis	rs523522	0.962	rs12814055	chr12:120987391	G/A	cg27279351	chr12:120934652	DYNLL1	0.72	8.87	0.5	2.02e-16	High light scatter reticulocyte count;
SARC	cis	rs6815814	0.950	rs3924112	chr4:38795810	C/T	cg06935464	chr4:38784597	TLR10	0.61	6.0	0.37	7.64e-9	Breast cancer;
SARC	cis	rs7412746	0.658	rs2864869	chr1:150734655	G/A	cg13175981	chr1:150552382	MCL1	-0.46	-5.51	-0.34	9.58e-8	Melanoma;
SARC	cis	rs854765	0.663	rs4925120	chr17:17754633	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.39	-5.11	-0.32	6.71e-7	Total body bone mineral density;
SARC	cis	rs7020830	0.858	rs1492714	chr9:37141259	T/C	cg14294708	chr9:37120828	ZCCHC7	1.13	20.57	0.8	2.61e-54	Schizophrenia;
SARC	cis	rs12586317	0.508	rs10134914	chr14:35425012	T/G	cg05294307	chr14:35346193	BAZ1A	-0.46	-5.07	-0.32	8.11e-7	Psoriasis;
SARC	cis	rs9300255	0.568	rs1047158	chr12:123644056	C/A	cg05973401	chr12:123451056	ABCB9	0.53	6.13	0.37	3.64e-9	Neutrophil percentage of white cells;
SARC	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg26513180	chr16:89883248	FANCA	0.91	16.79	0.74	5.45e-42	Vitiligo;
SARC	cis	rs79149102	0.579	rs12592477	chr15:75292699	C/T	cg09165964	chr15:75287851	SCAMP5	-1.03	-9.15	-0.51	2.86e-17	Lung cancer;
SARC	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.65	-6.91	-0.41	4.63e-11	Platelet count;
SARC	cis	rs898097	0.691	rs7222745	chr17:80907253	C/T	cg20578329	chr17:80767326	TBCD	-0.34	-4.77	-0.3	3.31e-6	Breast cancer;
SARC	cis	rs7223966	0.881	rs3020608	chr17:61979993	C/A	cg00588841	chr17:61851480	DDX42;CCDC47	-0.65	-6.75	-0.4	1.18e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs11581859	0.613	rs9727624	chr1:99191980	T/C	cg20286094	chr1:99190917	SNX7	-0.42	-4.93	-0.31	1.55e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs4900538	0.855	rs1209151	chr14:102893756	C/T	cg18135206	chr14:102964638	TECPR2	-0.6	-7.79	-0.45	2.15e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs2075671	0.903	rs11979818	chr7:100293639	A/G	cg03098644	chr7:100410630	EPHB4	-0.46	-5.06	-0.31	8.36e-7	Other erythrocyte phenotypes;
SARC	cis	rs6676180	0.555	rs12060730	chr1:119770702	A/G	cg05756136	chr1:119680316	WARS2	-0.39	-5.31	-0.33	2.58e-7	Monobrow;
SARC	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg11987759	chr7:65425863	GUSB	0.5	6.21	0.38	2.36e-9	Aortic root size;
SARC	trans	rs2243123	0.602	rs2133310	chr3:159716352	A/G	cg00122254	chr1:46769320	LRRC41;UQCRH	0.49	6.27	0.38	1.75e-9	Multiple sclerosis;
SARC	cis	rs6840360	0.615	rs4696097	chr4:152479765	C/T	cg22705602	chr4:152727874	NA	0.39	6.0	0.37	7.37e-9	Intelligence (multi-trait analysis);
SARC	cis	rs1044826	0.642	rs6439860	chr3:139175797	A/G	cg15131784	chr3:139108705	COPB2	0.41	5.13	0.32	6.12e-7	Obesity-related traits;
SARC	cis	rs73206853	0.563	rs7960761	chr12:111164415	T/C	cg10860002	chr12:110842031	ANAPC7	0.58	4.92	0.31	1.67e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs9858542	0.953	rs6446272	chr3:49463287	G/A	cg07274523	chr3:49395745	GPX1	0.53	6.13	0.37	3.68e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs9462027	0.628	rs2814942	chr6:34644261	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.98	-0.36	8.35e-9	Systemic lupus erythematosus;
SARC	cis	rs11122272	0.735	rs11122280	chr1:231519816	T/C	cg06096015	chr1:231504339	EGLN1	0.38	5.65	0.35	4.55e-8	Hemoglobin concentration;
SARC	cis	rs7582180	0.629	rs4850927	chr2:100969067	A/G	cg14675211	chr2:100938903	LONRF2	0.53	7.98	0.46	6.48e-14	Intelligence (multi-trait analysis);
SARC	cis	rs55794721	0.509	rs12027110	chr1:25775682	A/T	cg27572855	chr1:25598939	RHD	0.54	9.03	0.51	6.46e-17	Plateletcrit;Mean corpuscular volume;
SARC	cis	rs1008375	0.898	rs10008445	chr4:17593978	G/T	cg02297831	chr4:17616191	MED28	0.51	6.39	0.39	8.91e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs898097	0.841	rs8180	chr17:80901036	C/G	cg20578329	chr17:80767326	TBCD	0.44	6.03	0.37	6.52e-9	Breast cancer;
SARC	cis	rs4808199	0.689	rs12979148	chr19:19406869	T/C	cg03709012	chr19:19516395	GATAD2A	1.01	7.89	0.46	1.14e-13	Nonalcoholic fatty liver disease;
SARC	cis	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg11764359	chr7:65958608	NA	-0.67	-7.78	-0.45	2.36e-13	Aortic root size;
SARC	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg18252515	chr7:66147081	NA	-0.47	-5.3	-0.33	2.71e-7	Aortic root size;
SARC	cis	rs17270561	0.609	rs4711094	chr6:25706174	T/A	cg17691542	chr6:26056736	HIST1H1C	0.57	7.11	0.42	1.37e-11	Iron status biomarkers;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg26546862	chr10:70288128	SLC25A16	0.49	6.72	0.4	1.37e-10	Thyroid stimulating hormone;
SARC	cis	rs897080	0.552	rs1067320	chr2:44633122	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.7	0.4	1.59e-10	Height;
SARC	cis	rs7216064	1.000	rs2365468	chr17:65841318	C/T	cg12091567	chr17:66097778	LOC651250	-0.75	-8.31	-0.48	8.1e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs2180341	0.920	rs1073932	chr6:127682009	G/T	cg17762328	chr6:126965162	NA	-0.43	-4.77	-0.3	3.22e-6	Breast cancer;
SARC	cis	rs12586317	0.620	rs28870452	chr14:35536878	C/A	cg16230307	chr14:35515116	FAM177A1	0.93	10.88	0.58	1.49e-22	Psoriasis;
SARC	cis	rs3784262	0.669	rs4646603	chr15:58290024	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.34	-5.09	-0.32	7.23e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs847851	0.617	rs3807051	chr6:34922439	T/C	cg13137465	chr6:34857473	ANKS1A	0.59	4.77	0.3	3.21e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg22800045	chr5:56110881	MAP3K1	0.74	7.83	0.46	1.74e-13	Initial pursuit acceleration;
SARC	cis	rs113835537	0.597	rs3737525	chr11:66306355	A/G	cg24851651	chr11:66362959	CCS	0.39	4.83	0.3	2.52e-6	Airway imaging phenotypes;
SARC	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg20607798	chr8:58055168	NA	0.63	5.75	0.35	2.8e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1468333	1.000	rs17171770	chr5:137514815	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.77	10.19	0.56	2.09e-20	Resting heart rate;
SARC	cis	rs11098499	0.909	rs9759478	chr4:120367998	G/A	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg21724239	chr8:58056113	NA	0.61	5.93	0.36	1.1e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10513788	0.665	rs1565181	chr3:181992910	T/C	cg05977900	chr3:182512126	ATP11B	0.47	4.97	0.31	1.3e-6	Cognitive function;
SARC	cis	rs6688363	0.943	rs1016732	chr1:160086968	A/G	cg01023271	chr1:160068607	IGSF8	0.53	4.96	0.31	1.34e-6	Response to antipsychotic treatment;
SARC	cis	rs1448094	0.933	rs10779218	chr12:86320053	A/G	cg02569458	chr12:86230093	RASSF9	0.4	5.75	0.35	2.84e-8	Major depressive disorder;
SARC	cis	rs7666738	0.800	rs28427190	chr4:98989106	A/G	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9303401	0.659	rs62083362	chr17:56846464	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	11.56	0.6	9.91e-25	Cognitive test performance;
SARC	trans	rs2727020	0.513	rs10839307	chr11:49609843	A/C	cg03929089	chr4:120376271	NA	-0.82	-11.94	-0.62	5.69e-26	Coronary artery disease;
SARC	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg22549504	chr19:17448937	GTPBP3	-0.5	-5.08	-0.32	7.59e-7	Systemic lupus erythematosus;
SARC	cis	rs9843304	0.528	rs9880421	chr3:149183359	C/T	cg08667024	chr3:149219783	TM4SF4	0.42	6.26	0.38	1.81e-9	Gallstone disease;
SARC	cis	rs3796352	0.892	rs2581807	chr3:53088844	G/A	cg27565382	chr3:53032988	SFMBT1	-0.74	-5.81	-0.36	2.06e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg24675658	chr1:53192096	ZYG11B	-0.58	-8.1	-0.47	3.11e-14	Monocyte count;
SARC	cis	rs2050392	0.517	rs7096279	chr10:30759608	C/T	cg25182066	chr10:30743637	MAP3K8	0.48	7.03	0.42	2.28e-11	Inflammatory bowel disease;
SARC	trans	rs11722228	0.508	rs2241473	chr4:10085949	G/A	cg26043149	chr18:55253948	FECH	0.7	7.91	0.46	1.04e-13	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs72781680	0.898	rs17462558	chr2:24020812	T/C	cg08917208	chr2:24149416	ATAD2B	0.76	7.11	0.42	1.4e-11	Lymphocyte counts;
SARC	cis	rs4595586	0.545	rs7980848	chr12:39375166	G/C	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	cis	rs2153535	0.580	rs2183112	chr6:8528212	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	6.53	0.39	4.11e-10	Motion sickness;
SARC	cis	rs3791556	0.898	rs3828222	chr2:240109568	A/G	cg03281426	chr2:240109471	HDAC4	-0.42	-5.5	-0.34	9.88e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs1008375	0.843	rs59112113	chr4:17685336	A/T	cg02297831	chr4:17616191	MED28	0.39	4.89	0.3	1.92e-6	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2486288	0.656	rs11632752	chr15:45551140	A/G	cg15395560	chr15:45543142	SLC28A2	0.29	5.63	0.35	5.17e-8	Glomerular filtration rate;
SARC	cis	rs644799	0.526	rs568120	chr11:95578734	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	9.81	0.54	3.13e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7647973	1.000	rs9862534	chr3:49598064	A/G	cg06212747	chr3:49208901	KLHDC8B	0.56	6.13	0.37	3.66e-9	Menarche (age at onset);
SARC	cis	rs7089973	0.584	rs6585300	chr10:116639889	A/C	cg03647239	chr10:116582469	FAM160B1	0.51	6.5	0.39	4.73e-10	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs10782582	0.609	rs1770882	chr1:76411549	G/A	cg03433033	chr1:76189801	ACADM	-0.42	-5.37	-0.33	1.94e-7	Daytime sleep phenotypes;
SARC	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.69	9.19	0.52	2.21e-17	Menarche (age at onset);
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg05920870	chr7:100205729	PCOLCE	0.44	6.25	0.38	1.91e-9	Schizophrenia;
SARC	cis	rs367943	1.000	rs348961	chr5:112819944	A/C	cg12552261	chr5:112820674	MCC	-0.46	-4.98	-0.31	1.25e-6	Type 2 diabetes;
SARC	cis	rs9325144	0.555	rs6582576	chr12:38701230	C/T	cg13010199	chr12:38710504	ALG10B	-0.52	-6.56	-0.39	3.39e-10	Morning vs. evening chronotype;
SARC	cis	rs9818758	0.607	rs73084135	chr3:49272218	A/G	cg01304814	chr3:48885189	PRKAR2A	0.66	5.4	0.33	1.68e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs7626444	0.625	rs1798636	chr3:196476604	G/A	cg12930392	chr3:196481615	PAK2	0.25	5.0	0.31	1.13e-6	Monocyte count;
SARC	cis	rs11608355	0.515	rs4766606	chr12:109934390	C/G	cg05360138	chr12:110035743	NA	0.92	9.39	0.52	5.78e-18	Neuroticism;
SARC	cis	rs17253792	0.822	rs79262019	chr14:56092704	A/G	cg01858014	chr14:56050164	KTN1	-0.67	-5.11	-0.32	6.86e-7	Putamen volume;
SARC	cis	rs9467711	0.606	rs2076030	chr6:26426856	G/A	cg12826209	chr6:26865740	GUSBL1	0.8	4.91	0.31	1.73e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs634534	0.622	rs593525	chr11:65727799	T/C	cg04055107	chr11:65626734	MUS81;CFL1	0.45	5.68	0.35	4.01e-8	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs17376456	0.877	rs10066791	chr5:93350255	G/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.86	0.36	1.59e-8	Diabetic retinopathy;
SARC	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg19223190	chr17:80058835	NA	-0.43	-6.02	-0.37	6.57e-9	Life satisfaction;
SARC	cis	rs57024841	0.562	rs7862602	chr9:139840471	G/T	cg00693599	chr9:139836323	FBXW5	0.34	5.62	0.35	5.5e-8	Beta-trace protein levels;
SARC	cis	rs2380220	0.574	rs9374322	chr6:95998994	G/A	cg04719120	chr6:96025338	MANEA	0.54	6.06	0.37	5.45e-9	Behavioural disinhibition (generation interaction);
SARC	cis	rs6701037	1.000	rs6425323	chr1:175125036	C/T	cg00321850	chr1:175162397	KIAA0040	-0.34	-5.02	-0.31	1.03e-6	Alcohol dependence;
SARC	trans	rs61931739	0.500	rs4436630	chr12:34394200	C/T	cg13010199	chr12:38710504	ALG10B	0.75	10.67	0.57	6.59e-22	Morning vs. evening chronotype;
SARC	cis	rs4595586	0.545	rs6580888	chr12:39369704	C/T	cg13010199	chr12:38710504	ALG10B	0.4	4.75	0.3	3.57e-6	Morning vs. evening chronotype;
SARC	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg13939156	chr17:80058883	NA	-0.44	-6.62	-0.4	2.41e-10	Life satisfaction;
SARC	cis	rs1707322	0.963	rs4630155	chr1:46257110	G/C	cg06784218	chr1:46089804	CCDC17	0.37	6.45	0.39	6.38e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-8.64	-0.49	9.09e-16	Chronic sinus infection;
SARC	cis	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg03060546	chr3:49711283	APEH	0.59	7.38	0.44	2.86e-12	Resting heart rate;
SARC	cis	rs11997175	0.603	rs7016580	chr8:33824135	G/A	ch.8.33884649F	chr8:33765107	NA	0.45	5.63	0.35	5.22e-8	Body mass index;
SARC	cis	rs7520050	0.966	rs12021587	chr1:46472759	G/T	cg24296786	chr1:45957014	TESK2	0.39	4.92	0.31	1.62e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs1691799	0.899	rs903589	chr12:66745835	C/T	cg16791601	chr12:66731901	HELB	-0.73	-11.13	-0.59	2.38e-23	White blood cell count (basophil);
SARC	cis	rs9388451	0.626	rs2875881	chr6:126072853	C/G	cg05901451	chr6:126070800	HEY2	-0.52	-6.49	-0.39	5.23e-10	Brugada syndrome;
SARC	cis	rs7255436	0.965	rs11666233	chr19:8452045	G/T	cg10174797	chr19:8464628	RAB11B	0.43	6.21	0.38	2.37e-9	HDL cholesterol;
SARC	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg07636037	chr3:49044803	WDR6	0.91	15.5	0.71	1.03e-37	Menarche (age at onset);
SARC	cis	rs4243830	0.737	rs925744	chr1:6615695	C/T	cg04093404	chr1:6614507	TAS1R1;NOL9	0.61	5.15	0.32	5.47e-7	Body mass index;
SARC	cis	rs7833986	0.534	rs17814089	chr8:56965563	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	-0.7	-7.14	-0.42	1.18e-11	Height;
SARC	cis	rs1048238	0.818	rs2017577	chr1:16350123	C/G	cg21385522	chr1:16154831	NA	0.51	6.18	0.38	2.79e-9	Systolic blood pressure;
SARC	cis	rs2279817	0.863	rs12749985	chr1:18026004	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.47	-5.41	-0.33	1.59e-7	Neuroticism;
SARC	cis	rs12142240	0.698	rs72890727	chr1:46860237	G/A	cg00530320	chr1:46809349	NSUN4	0.57	7.0	0.42	2.74e-11	Menopause (age at onset);
SARC	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg20818283	chr2:191399100	TMEM194B	0.44	5.67	0.35	4.29e-8	Pulse pressure;
SARC	trans	rs7824557	0.545	rs2572380	chr8:11237477	A/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-8.14	-0.47	2.44e-14	Retinal vascular caliber;
SARC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg09373136	chr17:61933544	TCAM1	-0.44	-6.08	-0.37	4.86e-9	Prudent dietary pattern;
SARC	cis	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg05623727	chr3:50126028	RBM5	-0.34	-5.29	-0.33	2.77e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg27266027	chr21:40555129	PSMG1	0.51	5.61	0.34	5.84e-8	Cognitive function;
SARC	cis	rs910316	0.763	rs175036	chr14:75464295	C/T	cg08847533	chr14:75593920	NEK9	-0.86	-13.01	-0.65	1.95e-29	Height;
SARC	cis	rs35110281	0.591	rs162366	chr21:44935383	C/T	cg01579765	chr21:45077557	HSF2BP	0.33	5.52	0.34	8.9e-8	Mean corpuscular volume;
SARC	cis	rs1707322	0.655	rs3014240	chr1:46089225	C/G	cg03146154	chr1:46216737	IPP	-0.51	-6.1	-0.37	4.4e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg20887711	chr4:1340912	KIAA1530	-0.62	-7.23	-0.43	6.96e-12	Obesity-related traits;
SARC	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg08564027	chr20:61660810	NA	0.75	11.74	0.61	2.63e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs2180341	1.000	rs6569479	chr6:127606588	A/G	cg17762328	chr6:126965162	NA	-0.44	-5.03	-0.31	9.94e-7	Breast cancer;
SARC	cis	rs7937682	0.961	rs491937	chr11:111494947	A/T	cg22437258	chr11:111473054	SIK2	0.72	9.91	0.54	1.54e-19	Primary sclerosing cholangitis;
SARC	cis	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg00071950	chr4:10020882	SLC2A9	0.39	6.31	0.38	1.4e-9	Bone mineral density;
SARC	cis	rs3892630	0.620	rs10413279	chr19:33182746	A/G	cg22980127	chr19:33182716	NUDT19	1.14	12.14	0.62	1.33e-26	Red blood cell traits;
SARC	cis	rs425277	1.000	rs385039	chr1:2077409	C/T	cg21442419	chr1:2182373	SKI	0.55	7.03	0.42	2.31e-11	Height;
SARC	cis	rs9788721	0.630	rs77681598	chr15:78906103	C/A	cg17108064	chr15:78857060	CHRNA5	-0.28	-4.87	-0.3	2.04e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs1008375	0.932	rs12500947	chr4:17603424	C/T	cg16339924	chr4:17578868	LAP3	0.64	8.34	0.48	6.37e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.33	-5.0	-0.31	1.11e-6	Total body bone mineral density;
SARC	cis	rs7044106	0.734	rs12553070	chr9:123485266	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.74	0.54	4.92e-19	Hip circumference adjusted for BMI;
SARC	cis	rs7084402	0.905	rs1649031	chr10:60279742	G/A	cg07615347	chr10:60278583	BICC1	-0.6	-8.82	-0.5	2.78e-16	Refractive error;
SARC	cis	rs10504229	0.679	rs4737454	chr8:58033965	A/T	cg08280861	chr8:58055591	NA	0.57	5.28	0.33	3.01e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs372883	0.648	rs11088117	chr21:30737816	G/C	cg24692254	chr21:30365293	RNF160	0.6	7.59	0.45	7.51e-13	Pancreatic cancer;
SARC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg11494091	chr17:61959527	GH2	0.53	7.79	0.45	2.17e-13	Prudent dietary pattern;
SARC	cis	rs2594989	0.780	rs2443706	chr3:11550505	C/G	cg00170343	chr3:11313890	ATG7	0.54	5.54	0.34	8.24e-8	Circulating chemerin levels;
SARC	cis	rs796364	0.806	rs6743396	chr2:200860138	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.77	6.78	0.41	9.78e-11	Schizophrenia;
SARC	cis	rs4742903	0.509	rs6479223	chr9:106921023	T/C	cg14250997	chr9:106856677	SMC2	0.41	5.02	0.31	1.01e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs2472297	1.000	rs2472297	chr15:75027880	A/G	cg10253484	chr15:75165896	SCAMP2	0.75	7.85	0.46	1.49e-13	Caffeine metabolism (plasma 1,3,7-trimethylxanthine (caffeine) level);Coffee consumption (cups per day);Coffee consumption;Caffeine metabolism (plasma 1,3-dimethylxanthine (theophylline) level);Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
SARC	trans	rs11098499	0.818	rs12498599	chr4:120468503	C/T	cg25214090	chr10:38739885	LOC399744	0.57	7.25	0.43	6.27e-12	Corneal astigmatism;
SARC	cis	rs12142240	0.698	rs68083747	chr1:46807416	T/G	cg10495392	chr1:46806563	NSUN4	0.65	6.96	0.41	3.41e-11	Menopause (age at onset);
SARC	cis	rs526231	0.543	rs158244	chr5:102410766	G/C	cg23492399	chr5:102201601	PAM	-0.5	-5.43	-0.34	1.41e-7	Primary biliary cholangitis;
SARC	cis	rs11690935	0.838	rs10432423	chr2:172753295	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.81	-11.3	-0.6	6.67e-24	Schizophrenia;
SARC	cis	rs708547	0.836	rs1718882	chr4:57859533	C/G	cg14719990	chr4:57843890	C4orf14;POLR2B	0.44	5.35	0.33	2.09e-7	Response to bleomycin (chromatid breaks);
SARC	cis	rs9300255	0.602	rs941305	chr12:123715266	T/C	cg00376283	chr12:123451042	ABCB9	0.52	6.03	0.37	6.37e-9	Neutrophil percentage of white cells;
SARC	cis	rs9303401	0.659	rs36093395	chr17:56957357	C/T	cg25039879	chr17:56429692	SUPT4H1	0.62	5.77	0.35	2.46e-8	Cognitive test performance;
SARC	cis	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg01579765	chr21:45077557	HSF2BP	-0.38	-6.46	-0.39	5.92e-10	Mean corpuscular volume;
SARC	trans	rs208520	1.000	rs12212063	chr6:66985148	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.76	8.66	0.49	7.77e-16	Exhaled nitric oxide output;
SARC	trans	rs7944735	0.507	rs7934659	chr11:48066374	C/T	cg15704280	chr7:45808275	SEPT13	0.62	7.12	0.42	1.32e-11	Intraocular pressure;
SARC	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg07061783	chr6:25882402	NA	-0.41	-4.8	-0.3	2.86e-6	Intelligence (multi-trait analysis);
SARC	cis	rs981844	0.712	rs6535957	chr4:154749862	C/A	cg14289246	chr4:154710475	SFRP2	-0.45	-5.36	-0.33	1.96e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg19223190	chr17:80058835	NA	-0.38	-5.26	-0.33	3.18e-7	Life satisfaction;
SARC	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg18404041	chr3:52824283	ITIH1	-0.39	-5.98	-0.36	8.45e-9	Electroencephalogram traits;
SARC	cis	rs11122272	0.735	rs2572253	chr1:231512768	C/A	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs362296	0.661	rs3121420	chr4:3264210	T/C	cg06533319	chr4:3265114	C4orf44	0.33	5.49	0.34	1.05e-7	Parental longevity (mother's age at death);
SARC	cis	rs763121	0.814	rs5757212	chr22:39053757	G/C	cg06022373	chr22:39101656	GTPBP1	0.92	12.73	0.64	1.6e-28	Menopause (age at onset);
SARC	cis	rs4795419	1	rs4795419	chr17:38166003	G/A	cg17467752	chr17:38218738	THRA	0.47	5.94	0.36	1.01e-8	Monocyte percentage of white cells;
SARC	cis	rs876084	0.505	rs7815878	chr8:121103137	C/T	cg06265175	chr8:121136014	COL14A1	0.57	7.53	0.44	1.1e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs2439831	0.702	rs9989313	chr15:44152817	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.93	8.14	0.47	2.39e-14	Lung cancer in ever smokers;
SARC	cis	rs1003719	0.680	rs2835620	chr21:38505581	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-9.13	-0.51	3.35e-17	Eye color traits;
SARC	cis	rs644799	0.526	rs542509	chr11:95641602	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	10.08	0.55	4.64e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7296418	0.675	rs1879379	chr12:123727443	G/A	cg00376283	chr12:123451042	ABCB9	0.57	7.1	0.42	1.53e-11	Platelet count;
SARC	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg22903657	chr4:1355424	KIAA1530	-0.41	-5.73	-0.35	3.07e-8	Obesity-related traits;
SARC	cis	rs7927771	0.832	rs896816	chr11:47394338	T/C	cg20307385	chr11:47447363	PSMC3	0.54	6.8	0.41	8.92e-11	Subjective well-being;
SARC	cis	rs7219021	0.705	rs12939844	chr17:47025559	T/A	cg16584676	chr17:46985605	UBE2Z	-0.5	-5.78	-0.35	2.33e-8	Schizophrenia or bipolar disorder;
SARC	cis	rs10911251	0.508	rs2245784	chr1:183107665	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.68	9.86	0.54	2.24e-19	Colorectal cancer;
SARC	cis	rs3784262	0.740	rs12917536	chr15:58288247	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.34	-4.95	-0.31	1.43e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs910316	1.000	rs11623413	chr14:75588824	C/T	cg11812906	chr14:75593930	NEK9	-0.89	-14.24	-0.68	1.54e-33	Height;
SARC	cis	rs2303745	0.589	rs8103523	chr19:17398269	A/G	cg22549504	chr19:17448937	GTPBP3	0.49	4.92	0.31	1.65e-6	Systemic lupus erythematosus;
SARC	trans	rs66573146	0.831	rs66645969	chr4:6985614	G/A	cg07817883	chr1:32538562	TMEM39B	1.32	8.69	0.49	6.42e-16	Granulocyte percentage of myeloid white cells;
SARC	cis	rs10089	1.000	rs73337363	chr5:127483597	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.81	10.17	0.55	2.39e-20	Ileal carcinoids;
SARC	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg00149659	chr3:10157352	C3orf10	1.05	9.18	0.52	2.39e-17	Alzheimer's disease;
SARC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg20607798	chr8:58055168	NA	0.58	5.57	0.34	6.9e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg00149659	chr3:10157352	C3orf10	1.07	9.51	0.53	2.45e-18	Alzheimer's disease;
SARC	cis	rs9354308	0.868	rs9363457	chr6:66549080	G/A	cg07460842	chr6:66804631	NA	-0.42	-4.85	-0.3	2.27e-6	Metabolite levels;
SARC	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg11494091	chr17:61959527	GH2	0.35	5.0	0.31	1.15e-6	Height;
SARC	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg18252515	chr7:66147081	NA	-1.25	-10.99	-0.58	6.44e-23	Diabetic kidney disease;
SARC	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg24250549	chr1:154909240	PMVK	0.83	12.22	0.62	7.36e-27	Prostate cancer;
SARC	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs2730245	1.000	rs2252502	chr7:158738634	G/C	cg24397884	chr7:158709396	WDR60	-1.05	-15.87	-0.72	6.01e-39	Height;
SARC	cis	rs9790314	0.695	rs7630763	chr3:160864865	T/C	cg03342759	chr3:160939853	NMD3	-0.56	-7.15	-0.42	1.14e-11	Morning vs. evening chronotype;
SARC	cis	rs8102137	1.000	rs3218036	chr19:30305684	A/G	cg27475126	chr19:30303651	CCNE1	0.35	4.98	0.31	1.25e-6	Bladder cancer;
SARC	cis	rs524281	0.817	rs10791849	chr11:65890597	T/A	cg14036092	chr11:66035641	RAB1B	-0.47	-4.82	-0.3	2.57e-6	Electroencephalogram traits;
SARC	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg17971929	chr21:40555470	PSMG1	0.99	13.54	0.66	3.33e-31	Cognitive function;
SARC	cis	rs854765	0.547	rs2955377	chr17:17932818	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.42	5.26	0.33	3.22e-7	Total body bone mineral density;
SARC	cis	rs7914558	0.899	rs7913682	chr10:104684392	T/A	cg04362960	chr10:104952993	NT5C2	0.41	4.92	0.31	1.65e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs11608355	0.515	rs12831026	chr12:109903651	C/T	cg05360138	chr12:110035743	NA	0.92	9.68	0.54	7.88e-19	Neuroticism;
SARC	cis	rs9467773	0.620	rs9461275	chr6:26590801	C/T	cg12292205	chr6:26970375	C6orf41	0.43	5.37	0.33	1.88e-7	Intelligence (multi-trait analysis);
SARC	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg25036284	chr2:26402008	FAM59B	-0.46	-5.7	-0.35	3.59e-8	Gut microbiome composition (summer);
SARC	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.97e-8	Aortic root size;
SARC	cis	rs4689388	0.890	rs4342257	chr4:6290037	G/C	cg00701064	chr4:6280414	WFS1	0.54	8.77	0.5	3.71e-16	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg20965017	chr5:231967	SDHA	-0.56	-5.3	-0.33	2.71e-7	Breast cancer;
SARC	cis	rs892961	0.867	rs1079354	chr17:75415713	C/T	cg05865280	chr17:75406074	SEPT9	0.54	7.71	0.45	3.65e-13	Airflow obstruction;
SARC	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg22535103	chr8:58192502	C8orf71	-0.69	-8.19	-0.47	1.68e-14	Developmental language disorder (linguistic errors);
SARC	cis	rs66573146	1.000	rs56074877	chr4:6990374	C/T	cg00086871	chr4:6988644	TBC1D14	0.86	5.15	0.32	5.57e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs9790314	0.967	rs463928	chr3:161087734	A/T	cg03342759	chr3:160939853	NMD3	-0.59	-7.59	-0.45	7.67e-13	Morning vs. evening chronotype;
SARC	cis	rs10911232	0.507	rs12037585	chr1:183000041	G/T	cg13390022	chr1:182993471	LAMC1	0.33	4.97	0.31	1.31e-6	Hypertriglyceridemia;
SARC	cis	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg24110177	chr3:50126178	RBM5	-0.55	-7.28	-0.43	5.15e-12	Intelligence (multi-trait analysis);
SARC	cis	rs9640161	0.750	rs11538922	chr7:150035183	C/T	cg17279839	chr7:150038598	RARRES2	0.48	6.36	0.38	1.04e-9	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs73206853	0.619	rs112148402	chr12:111171493	T/C	cg10860002	chr12:110842031	ANAPC7	0.58	4.92	0.31	1.67e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs6504663	0.596	rs7208018	chr17:48557863	C/T	cg00901687	chr17:48585270	MYCBPAP	-0.53	-6.13	-0.37	3.81e-9	Visceral fat;
SARC	cis	rs918629	1.000	rs3777164	chr5:95293261	C/T	cg16656078	chr5:95278638	ELL2	-0.51	-6.24	-0.38	2.05e-9	IgG glycosylation;
SARC	cis	rs9682041	0.627	rs10936625	chr3:170094908	G/T	cg11886554	chr3:170076028	SKIL	-0.59	-5.86	-0.36	1.53e-8	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg11494091	chr17:61959527	GH2	0.54	8.06	0.47	4.05e-14	Prudent dietary pattern;
SARC	cis	rs7945705	0.846	rs2742540	chr11:8899528	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.37	5.28	0.33	2.94e-7	Hemoglobin concentration;
SARC	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg24829409	chr8:58192753	C8orf71	0.7	6.62	0.4	2.46e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs12824058	0.831	rs4759451	chr12:130812739	G/A	cg24838063	chr12:130822603	PIWIL1	0.63	8.93	0.5	1.34e-16	Menopause (age at onset);
SARC	cis	rs11711311	1.000	rs9854504	chr3:113532381	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	7.86	0.46	1.45e-13	IgG glycosylation;
SARC	cis	rs453301	0.686	rs28665409	chr8:8869277	G/A	cg11995313	chr8:8860691	ERI1	0.47	5.81	0.36	2.06e-8	Joint mobility (Beighton score);
SARC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg21548813	chr6:291882	DUSP22	0.63	8.28	0.48	9.8e-15	Menopause (age at onset);
SARC	cis	rs35213789	0.768	rs17140980	chr7:69325931	A/G	cg10619644	chr7:69149951	AUTS2	0.39	4.83	0.3	2.49e-6	Childhood ear infection;
SARC	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg11366901	chr6:160182831	ACAT2	0.64	6.65	0.4	2.1e-10	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	cis	rs9467773	0.873	rs9295698	chr6:26566099	T/A	cg11502198	chr6:26597334	ABT1	0.51	6.28	0.38	1.68e-9	Intelligence (multi-trait analysis);
SARC	cis	rs11690935	0.550	rs6730085	chr2:172864845	C/A	cg13550731	chr2:172543902	DYNC1I2	0.53	6.74	0.4	1.23e-10	Schizophrenia;
SARC	cis	rs1549118	0.595	rs28613643	chr14:78332161	G/A	cg23188588	chr14:78226832	SNW1;C14orf178	-0.48	-5.03	-0.31	9.7e-7	Resting heart rate;
SARC	cis	rs9916302	0.808	rs12947281	chr17:37652210	G/T	cg20243544	chr17:37824526	PNMT	0.56	6.6	0.4	2.7e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg05036130	chr6:150231994	NA	0.27	4.73	0.3	3.84e-6	Testicular germ cell tumor;
SARC	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg27266027	chr21:40555129	PSMG1	0.51	5.54	0.34	8.25e-8	Cognitive function;
SARC	cis	rs2153535	0.580	rs1889715	chr6:8443475	G/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.62	0.49	1.02e-15	Motion sickness;
SARC	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.94	-14.38	-0.69	5.48e-34	Height;
SARC	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg10295955	chr4:187884368	NA	-1.07	-20.18	-0.8	4.55e-53	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg03185022	chr7:2884158	GNA12	-0.48	-5.38	-0.33	1.77e-7	Height;
SARC	cis	rs611744	0.934	rs624311	chr8:109204437	A/G	cg21045802	chr8:109455806	TTC35	0.44	5.23	0.32	3.81e-7	Dupuytren's disease;
SARC	cis	rs477692	0.569	rs1771448	chr10:131296201	A/G	cg05714579	chr10:131428358	MGMT	-0.56	-7.45	-0.44	1.78e-12	Response to temozolomide;
SARC	cis	rs6908034	0.607	rs12529148	chr6:19806797	G/C	cg02682789	chr6:19804855	NA	0.69	5.41	0.33	1.53e-7	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg11750080	chr17:74379913	SPHK1	-0.64	-6.4	-0.39	8.35e-10	Lung cancer in ever smokers;
SARC	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.44	0.44	1.97e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg11766577	chr21:47581405	C21orf56	-0.45	-5.47	-0.34	1.16e-7	Testicular germ cell tumor;
SARC	cis	rs7659604	1.000	rs35224452	chr4:122664677	C/T	cg20573242	chr4:122745356	CCNA2	0.44	5.78	0.35	2.34e-8	Type 2 diabetes;
SARC	cis	rs918629	0.530	rs3777203	chr5:95234377	C/T	cg16656078	chr5:95278638	ELL2	-0.59	-7.01	-0.42	2.52e-11	IgG glycosylation;
SARC	cis	rs7551222	0.749	rs6594018	chr1:204568152	A/G	cg20240347	chr1:204465584	NA	-0.27	-4.93	-0.31	1.58e-6	Schizophrenia;
SARC	cis	rs12971120	0.891	rs12605820	chr18:72167802	G/A	cg25817165	chr18:72167213	CNDP2	-0.54	-7.68	-0.45	4.39e-13	Refractive error;
SARC	cis	rs9443189	0.570	rs9341532	chr6:76403674	A/G	cg01950844	chr6:76311363	SENP6	0.86	8.18	0.47	1.82e-14	Prostate cancer;
SARC	cis	rs6062302	0.522	rs3761126	chr20:62252044	C/T	cg09650180	chr20:62225654	GMEB2	-0.44	-5.23	-0.32	3.69e-7	Glioblastoma;
SARC	cis	rs4588572	0.643	rs1864173	chr5:77691158	C/T	cg11547950	chr5:77652471	NA	0.4	4.89	0.31	1.88e-6	Triglycerides;
SARC	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg13939156	chr17:80058883	NA	-0.41	-6.37	-0.39	1e-9	Life satisfaction;
SARC	cis	rs17666538	1.000	rs61064968	chr8:587933	T/C	cg07234876	chr8:600039	NA	-0.86	-6.74	-0.4	1.24e-10	IgG glycosylation;
SARC	cis	rs950776	0.695	rs1878399	chr15:78912003	G/C	cg06917634	chr15:78832804	PSMA4	-0.79	-11.5	-0.6	1.54e-24	Sudden cardiac arrest;
SARC	cis	rs9790314	0.521	rs2122527	chr3:161091636	G/A	cg17135325	chr3:160939158	NMD3	0.49	6.21	0.38	2.38e-9	Morning vs. evening chronotype;
SARC	cis	rs3733585	0.638	rs13145554	chr4:9979589	C/T	cg11266682	chr4:10021025	SLC2A9	0.37	6.24	0.38	2.03e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs2075671	0.903	rs11983334	chr7:100302434	C/T	cg20848291	chr7:100343083	ZAN	-0.65	-7.21	-0.43	7.81e-12	Other erythrocyte phenotypes;
SARC	cis	rs17376456	0.825	rs28705226	chr5:93233135	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.74	0.35	3.01e-8	Diabetic retinopathy;
SARC	cis	rs12711979	0.509	rs13005405	chr2:3826324	C/T	cg17052675	chr2:3827356	NA	-0.55	-8.26	-0.48	1.1e-14	Itch intensity from mosquito bite adjusted by bite size;
SARC	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg17971929	chr21:40555470	PSMG1	-0.57	-7.13	-0.42	1.23e-11	Menarche (age at onset);
SARC	cis	rs9660992	0.674	rs1151785	chr1:205232299	C/T	cg00857998	chr1:205179979	DSTYK	0.52	6.33	0.38	1.28e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs4253772	0.550	rs6008613	chr22:46707924	G/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.61	5.02	0.31	1.05e-6	LDL cholesterol;Cholesterol, total;
SARC	cis	rs11150038	0.826	rs9926583	chr16:78087730	C/T	cg04733911	chr16:78082701	NA	-0.42	-4.82	-0.3	2.63e-6	Colorectal or endometrial cancer;
SARC	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg22903657	chr4:1355424	KIAA1530	-0.33	-4.73	-0.3	3.82e-6	Longevity;
SARC	cis	rs950027	1.000	rs950027	chr15:45801035	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.51	-6.09	-0.37	4.64e-9	Response to fenofibrate (adiponectin levels);
SARC	cis	rs7084402	0.967	rs7094882	chr10:60276829	C/T	cg07615347	chr10:60278583	BICC1	-0.6	-8.78	-0.5	3.54e-16	Refractive error;
SARC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg24101359	chr6:42928495	GNMT	0.49	6.85	0.41	6.62e-11	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs651907	0.557	rs34376498	chr3:101480156	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	6.21	0.38	2.46e-9	Colorectal cancer;
SARC	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg17211192	chr8:82754475	SNX16	-0.51	-6.44	-0.39	6.6e-10	Diastolic blood pressure;
SARC	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg26839252	chr6:160211577	TCP1;MRPL18	0.68	7.44	0.44	1.97e-12	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs1003719	0.679	rs1133001	chr21:38512956	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.33	-0.52	8.73e-18	Eye color traits;
SARC	cis	rs896854	0.738	rs481887	chr8:95967838	A/G	cg13393036	chr8:95962371	TP53INP1	0.31	5.09	0.32	7.4e-7	Type 2 diabetes;
SARC	cis	rs2250402	0.510	rs7535	chr15:40328575	G/C	cg20255370	chr15:40268687	EIF2AK4	-0.7	-5.88	-0.36	1.44e-8	Corneal curvature;
SARC	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg06212747	chr3:49208901	KLHDC8B	0.65	8.63	0.49	9.91e-16	Parkinson's disease;
SARC	cis	rs2153535	0.580	rs1360054	chr6:8520377	C/A	cg07606381	chr6:8435919	SLC35B3	0.76	11.08	0.59	3.38e-23	Motion sickness;
SARC	cis	rs7615952	0.599	rs12486459	chr3:125741465	T/G	cg05084668	chr3:125655381	ALG1L	-0.49	-5.14	-0.32	5.75e-7	Blood pressure (smoking interaction);
SARC	cis	rs17666538	0.710	rs1703941	chr8:658447	G/A	cg07234876	chr8:600039	NA	0.83	6.3	0.38	1.51e-9	IgG glycosylation;
SARC	cis	rs11719291	0.833	rs73080361	chr3:48832146	G/A	cg01304814	chr3:48885189	PRKAR2A	0.84	6.62	0.4	2.39e-10	Cognitive function;
SARC	trans	rs9329221	0.905	rs13254263	chr8:10255181	A/G	cg06636001	chr8:8085503	FLJ10661	-0.68	-9.26	-0.52	1.37e-17	Neuroticism;
SARC	cis	rs2645694	0.569	rs11097584	chr4:77836059	C/T	cg06046430	chr4:77819534	ANKRD56	0.53	5.14	0.32	5.89e-7	Emphysema distribution in smoking;
SARC	cis	rs12079745	0.793	rs12063863	chr1:169269557	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.84	-5.25	-0.33	3.45e-7	QT interval;
SARC	cis	rs13401104	0.796	rs12464503	chr2:237113007	C/T	cg19324714	chr2:237145437	ASB18	0.6	6.15	0.37	3.32e-9	Educational attainment;
SARC	cis	rs6582630	0.533	rs4103689	chr12:38702980	A/C	cg13010199	chr12:38710504	ALG10B	0.55	7.29	0.43	4.66e-12	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7582720	1.000	rs72934735	chr2:203740010	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.28	0.43	5.16e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs7000551	0.715	rs34649162	chr8:22314730	T/C	cg12081754	chr8:22256438	SLC39A14	0.61	8.7	0.5	5.91e-16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg02841227	chr6:26021843	HIST1H4A	-0.46	-5.45	-0.34	1.27e-7	Intelligence (multi-trait analysis);
SARC	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg15595755	chr5:1867978	NA	0.49	6.56	0.39	3.46e-10	Cardiovascular disease risk factors;
SARC	cis	rs708547	0.647	rs12621	chr4:57897570	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.58	7.13	0.42	1.27e-11	Response to bleomycin (chromatid breaks);
SARC	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.16	-0.42	1.04e-11	Gut microbiome composition (summer);
SARC	cis	rs2180341	0.566	rs982306	chr6:127777039	T/C	cg27446573	chr6:127587934	RNF146	0.65	7.78	0.45	2.4e-13	Breast cancer;
SARC	cis	rs6991838	0.733	rs13281981	chr8:66523884	T/C	cg13398993	chr8:66546079	ARMC1	0.4	5.05	0.31	8.75e-7	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg14926445	chr8:58193284	C8orf71	-0.42	-4.76	-0.3	3.45e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs77106637	0.929	rs74333814	chr11:72457487	C/T	cg03713592	chr11:72463424	ARAP1	1.09	10.13	0.55	3.17e-20	Type 2 diabetes;
SARC	cis	rs9400467	0.506	rs12205046	chr6:111619620	G/A	cg15721981	chr6:111408429	SLC16A10	0.7	5.87	0.36	1.48e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs4144743	1.000	rs34182248	chr17:45321359	T/C	cg18085866	chr17:45331354	ITGB3	-0.73	-7.35	-0.43	3.42e-12	Body mass index;
SARC	cis	rs9326248	0.581	rs7120963	chr11:116830261	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.61	-7.65	-0.45	5.44e-13	Blood protein levels;
SARC	cis	rs870825	0.860	rs72689297	chr4:185600957	A/T	cg04058563	chr4:185651563	MLF1IP	0.8	9.84	0.54	2.51e-19	Blood protein levels;
SARC	cis	rs72945132	0.882	rs7935969	chr11:70194175	G/A	cg05964544	chr11:70165517	PPFIA1	-0.56	-5.46	-0.34	1.22e-7	Coronary artery disease;
SARC	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg23205692	chr1:25664452	TMEM50A	0.39	4.89	0.3	1.92e-6	Erythrocyte sedimentation rate;
SARC	cis	rs317689	0.718	rs315122	chr12:69771073	G/T	cg14784868	chr12:69753453	YEATS4	0.46	5.12	0.32	6.4e-7	Response to diuretic therapy;
SARC	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg05368731	chr17:41323189	NBR1	0.64	6.66	0.4	1.96e-10	Menopause (age at onset);
SARC	trans	rs9395865	0.501	rs2067833	chr6:53330356	A/G	cg00120998	chr16:67881473	CENPT;NUTF2	-0.52	-6.38	-0.39	9.3e-10	Electroencephalographic traits in alcoholism;
SARC	cis	rs2230307	0.656	rs531174	chr1:100485988	G/T	cg24955406	chr1:100503596	HIAT1	0.69	5.59	0.34	6.48e-8	Carotid intima media thickness;
SARC	cis	rs9303401	0.659	rs34382037	chr17:56643550	G/T	cg25039879	chr17:56429692	SUPT4H1	0.67	6.21	0.38	2.4e-9	Cognitive test performance;
SARC	cis	rs7590368	0.926	rs12623588	chr2:10957612	C/G	cg25617230	chr2:10952979	PDIA6	-0.47	-4.91	-0.31	1.71e-6	Educational attainment (years of education);
SARC	cis	rs9653442	0.835	rs11694875	chr2:100732845	A/G	cg22139774	chr2:100720529	AFF3	0.27	4.83	0.3	2.46e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
SARC	cis	rs8060686	0.668	rs255056	chr16:68016185	G/C	cg27539214	chr16:67997921	SLC12A4	-0.54	-5.51	-0.34	9.66e-8	HDL cholesterol;Metabolic syndrome;
SARC	cis	rs9325144	0.555	rs1843867	chr12:38703855	A/G	cg10518543	chr12:38710700	ALG10B	-0.39	-4.86	-0.3	2.12e-6	Morning vs. evening chronotype;
SARC	trans	rs9388451	0.874	rs13209968	chr6:126089285	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.57	-7.41	-0.44	2.33e-12	Brugada syndrome;
SARC	cis	rs3845702	1.000	rs3768837	chr2:180835792	T/A	cg01881094	chr2:180872142	CWC22	-0.74	-6.83	-0.41	7.39e-11	Schizophrenia;
SARC	trans	rs988958	0.883	rs12329065	chr2:42303587	G/T	cg02435573	chr1:94712239	NA	0.49	6.44	0.39	6.91e-10	Hypospadias;
SARC	cis	rs698833	0.962	rs786406	chr2:44735953	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.65	-7.89	-0.46	1.14e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs1568889	1.000	rs10767693	chr11:28093926	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.87	14.82	0.7	1.86e-35	Bipolar disorder;
SARC	cis	rs798554	0.567	rs1182190	chr7:2869391	A/G	cg04166393	chr7:2884313	GNA12	0.4	4.85	0.3	2.3e-6	Height;
SARC	cis	rs7582180	0.663	rs6542930	chr2:100944383	T/A	cg14675211	chr2:100938903	LONRF2	0.49	7.08	0.42	1.73e-11	Intelligence (multi-trait analysis);
SARC	cis	rs6582630	0.555	rs8189479	chr12:38308240	C/T	cg13010199	chr12:38710504	ALG10B	-0.53	-6.37	-0.39	9.86e-10	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg06896619	chr17:61851486	DDX42;CCDC47	-0.44	-5.05	-0.31	8.82e-7	Prudent dietary pattern;
SARC	cis	rs1797081	0.967	rs780632	chr10:16861400	A/G	cg23933602	chr10:16859644	RSU1	-0.95	-18.71	-0.77	2.57e-48	Platelet distribution width;
SARC	cis	rs3857536	0.904	rs9363544	chr6:66898799	C/T	cg07460842	chr6:66804631	NA	-0.43	-5.18	-0.32	4.82e-7	Blood trace element (Cu levels);
SARC	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.41	-4.79	-0.3	2.93e-6	Renal function-related traits (BUN);
SARC	cis	rs13161895	0.941	rs3797764	chr5:179439345	A/G	cg04265672	chr5:179402240	RNF130	0.52	5.15	0.32	5.48e-7	LDL cholesterol;
SARC	cis	rs4243830	0.737	rs11122088	chr1:6603677	T/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.01	-9.9	-0.54	1.61e-19	Body mass index;
SARC	cis	rs765787	0.530	rs55771002	chr15:45541566	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.67e-7	Uric acid levels;
SARC	cis	rs6484504	0.553	rs7113880	chr11:31279557	A/G	cg19308365	chr11:31391254	DNAJC24;DCDC1	-0.38	-4.76	-0.3	3.4e-6	Red blood cell count;
SARC	cis	rs12421382	0.659	rs979603	chr11:109384996	A/G	cg27471124	chr11:109292789	C11orf87	-0.34	-4.79	-0.3	3.02e-6	Schizophrenia;
SARC	cis	rs10782582	0.593	rs115291524	chr1:76141811	A/G	cg03433033	chr1:76189801	ACADM	-0.38	-4.78	-0.3	3.11e-6	Daytime sleep phenotypes;
SARC	cis	rs12586317	0.620	rs12437439	chr14:35585669	C/A	cg16230307	chr14:35515116	FAM177A1	0.99	11.22	0.59	1.25e-23	Psoriasis;
SARC	cis	rs11190604	0.767	rs10883479	chr10:102162860	A/G	cg07080220	chr10:102295463	HIF1AN	0.69	7.57	0.44	8.81e-13	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs11758351	0.866	rs77889957	chr6:26207435	A/G	cg01420254	chr6:26195488	NA	0.53	4.82	0.3	2.63e-6	Gout;Renal underexcretion gout;
SARC	cis	rs74181299	0.648	rs1050676	chr2:65310831	A/T	cg20592124	chr2:65290738	CEP68	-0.35	-4.76	-0.3	3.33e-6	Pulse pressure;
SARC	cis	rs2295359	0.892	rs10789224	chr1:67605134	C/T	cg03340356	chr1:67600835	NA	-0.36	-4.88	-0.3	1.97e-6	Psoriasis;
SARC	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg19223190	chr17:80058835	NA	0.43	6.04	0.37	6.11e-9	Life satisfaction;
SARC	cis	rs7762018	0.607	rs3800544	chr6:170058374	C/T	cg13015042	chr6:170102002	WDR27;C6orf120	0.73	5.34	0.33	2.25e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs66725070	1	rs66725070	chr15:58267416	GACAT/G	cg12031962	chr15:58353849	ALDH1A2	-0.37	-5.63	-0.35	5.26e-8	Barrett's esophagus;
SARC	cis	rs6426558	0.559	rs2813947	chr1:227459413	G/T	cg10327440	chr1:227177885	CDC42BPA	0.43	5.04	0.31	9.53e-7	Neutrophil percentage of white cells;
SARC	cis	rs9309473	0.632	rs11885217	chr2:73553208	A/G	cg20560298	chr2:73613845	ALMS1	-0.59	-6.84	-0.41	6.88e-11	Metabolite levels;
SARC	cis	rs1420338	0.967	rs10271544	chr7:34147159	C/T	cg01275685	chr7:34179230	BMPER	-0.43	-5.22	-0.32	4.01e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
SARC	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg03806693	chr22:41940476	POLR3H	-0.94	-13.03	-0.65	1.64e-29	Vitiligo;
SARC	cis	rs9467711	0.591	rs6913795	chr6:25848025	T/C	cg21479132	chr6:26055353	NA	0.78	5.0	0.31	1.1e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1570884	0.536	rs1359541	chr13:50158939	A/G	cg03651054	chr13:50194643	NA	0.31	5.1	0.32	7e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg11494091	chr17:61959527	GH2	0.53	7.96	0.46	7.52e-14	Prudent dietary pattern;
SARC	cis	rs8038465	0.571	rs7176654	chr15:73999006	C/T	cg15420318	chr15:73925796	NPTN	-0.46	-5.57	-0.34	6.84e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1348850	0.574	rs4893835	chr2:178442592	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.51	5.25	0.33	3.36e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs6582630	0.519	rs4002438	chr12:38484880	C/T	cg13010199	chr12:38710504	ALG10B	0.75	10.21	0.56	1.79e-20	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs3020736	0.519	rs5996116	chr22:42517492	G/A	cg04733989	chr22:42467013	NAGA	-0.76	-10.57	-0.57	1.4e-21	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6933660	0.646	rs9383899	chr6:151781022	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.78	11.29	0.59	7.44e-24	Menarche (age at onset);
SARC	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg17376030	chr22:41985996	PMM1	0.77	9.44	0.53	4.03e-18	Vitiligo;
SARC	cis	rs274567	0.602	rs272853	chr5:131688561	A/G	cg04518342	chr5:131593106	PDLIM4	0.4	5.32	0.33	2.44e-7	Blood metabolite levels;
SARC	cis	rs7020830	0.789	rs17408112	chr9:37114065	A/G	cg14294708	chr9:37120828	ZCCHC7	1.15	21.94	0.82	1.27e-58	Schizophrenia;
SARC	cis	rs2832077	0.527	rs2705690	chr21:30239245	T/A	cg24692254	chr21:30365293	RNF160	0.56	6.19	0.38	2.73e-9	Cognitive test performance;
SARC	cis	rs2204008	0.774	rs3910796	chr12:38230660	G/T	cg13010199	chr12:38710504	ALG10B	0.78	10.64	0.57	8.61e-22	Bladder cancer;
SARC	cis	rs7666738	0.688	rs35739409	chr4:98576934	C/T	cg05340658	chr4:99064831	C4orf37	0.49	5.13	0.32	6.14e-7	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10267417	0.514	rs2072184	chr7:19748883	A/G	cg05791153	chr7:19748676	TWISTNB	0.96	10.11	0.55	3.6e-20	Night sleep phenotypes;
SARC	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.05	0.37	5.62e-9	Height;
SARC	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg23248424	chr5:179741104	GFPT2	-0.48	-5.95	-0.36	1e-8	Height;
SARC	cis	rs11155671	0.530	rs6939761	chr6:150210994	T/C	cg00933542	chr6:150070202	PCMT1	0.29	4.81	0.3	2.77e-6	Testicular germ cell tumor;
SARC	cis	rs7772486	0.558	rs9376965	chr6:146130055	G/A	cg23711669	chr6:146136114	FBXO30	0.85	12.58	0.64	5.01e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7520050	0.966	rs785503	chr1:46595868	T/C	cg06784218	chr1:46089804	CCDC17	-0.26	-4.82	-0.3	2.56e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs7772486	0.712	rs6570726	chr6:146159460	T/C	cg23711669	chr6:146136114	FBXO30	0.77	11.44	0.6	2.5e-24	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7223966	0.921	rs2006123	chr17:61958669	G/T	cg00588841	chr17:61851480	DDX42;CCDC47	-0.58	-6.39	-0.39	8.85e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs372883	0.597	rs2018956	chr21:30736622	C/A	cg08807101	chr21:30365312	RNF160	0.52	6.52	0.39	4.26e-10	Pancreatic cancer;
SARC	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	5.29	0.33	2.82e-7	Electroencephalogram traits;
SARC	cis	rs9467773	0.649	rs2145318	chr6:26496603	T/A	cg11502198	chr6:26597334	ABT1	0.45	5.33	0.33	2.36e-7	Intelligence (multi-trait analysis);
SARC	cis	rs193541	0.593	rs154517	chr5:122189825	A/T	cg19412675	chr5:122181750	SNX24	0.51	6.64	0.4	2.16e-10	Glucose homeostasis traits;
SARC	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg11987759	chr7:65425863	GUSB	-0.48	-6.04	-0.37	5.99e-9	Aortic root size;
SARC	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg10150615	chr22:24372951	LOC391322	-0.42	-4.72	-0.3	4.14e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs17001868	0.568	rs73167007	chr22:40734241	G/C	cg07138101	chr22:40742427	ADSL	0.54	5.94	0.36	1.01e-8	Mammographic density (dense area);
SARC	trans	rs1814175	0.519	rs3913237	chr11:49551828	G/A	cg03929089	chr4:120376271	NA	0.7	7.93	0.46	9.2e-14	Height;
SARC	cis	rs12142240	0.698	rs61519400	chr1:46855298	A/G	cg00530320	chr1:46809349	NSUN4	0.57	7.0	0.42	2.74e-11	Menopause (age at onset);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg17861791	chr1:113162073	ST7L;CAPZA1	0.49	6.5	0.39	4.7e-10	Chemerin levels;
SARC	cis	rs7829975	0.540	rs2976909	chr8:8346690	C/T	cg15556689	chr8:8085844	FLJ10661	-0.38	-4.81	-0.3	2.7e-6	Mood instability;
SARC	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs10463554	0.926	rs3776858	chr5:102357494	A/G	cg23492399	chr5:102201601	PAM	-0.47	-5.16	-0.32	5.2e-7	Parkinson's disease;
SARC	cis	rs854765	0.505	rs4506969	chr17:17899839	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	9.57	0.53	1.66e-18	Total body bone mineral density;
SARC	cis	rs6120849	0.754	rs3746435	chr20:33587198	G/C	cg06115741	chr20:33292138	TP53INP2	0.56	5.36	0.33	1.95e-7	Protein C levels;
SARC	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg22903657	chr4:1355424	KIAA1530	-0.43	-5.93	-0.36	1.11e-8	Obesity-related traits;
SARC	trans	rs9325144	0.505	rs10785560	chr12:38636622	C/T	cg23762105	chr12:34175262	ALG10	-0.5	-6.27	-0.38	1.71e-9	Morning vs. evening chronotype;
SARC	cis	rs72781680	1.000	rs56104215	chr2:24133590	T/C	cg08917208	chr2:24149416	ATAD2B	0.79	7.64	0.45	5.66e-13	Lymphocyte counts;
SARC	cis	rs3741151	0.892	rs76854106	chr11:73027110	G/A	cg17517138	chr11:73019481	ARHGEF17	0.93	7.21	0.43	7.58e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs6582630	0.519	rs4406888	chr12:38293312	A/C	cg26384229	chr12:38710491	ALG10B	0.87	12.86	0.64	6.01e-29	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7635838	0.617	rs346074	chr3:11294310	T/C	cg00170343	chr3:11313890	ATG7	0.76	10.3	0.56	9.72e-21	HDL cholesterol;
SARC	cis	rs4478037	0.822	rs77355992	chr3:33107518	T/C	cg19404215	chr3:33155277	CRTAP	0.79	5.97	0.36	8.6e-9	Major depressive disorder;
SARC	cis	rs3092073	0.624	rs11696623	chr20:44580380	C/T	cg27529037	chr20:44575021	PCIF1	0.39	6.09	0.37	4.74e-9	Intelligence (multi-trait analysis);
SARC	cis	rs17345786	0.906	rs72940399	chr3:101122575	A/T	cg11279151	chr3:101281821	RG9MTD1	-0.45	-4.75	-0.3	3.57e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2916247	1.000	rs1443559	chr8:92997242	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.63	-6.33	-0.38	1.23e-9	Intelligence (multi-trait analysis);
SARC	cis	rs9768139	0.733	rs13309363	chr7:158122179	C/A	cg25566285	chr7:158114605	PTPRN2	0.32	5.26	0.33	3.33e-7	Calcium levels;
SARC	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg08280861	chr8:58055591	NA	0.68	5.67	0.35	4.12e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg16743903	chr16:89593216	SPG7	-0.4	-5.33	-0.33	2.3e-7	Multiple myeloma (IgH translocation);
SARC	cis	rs12709013	0.636	rs8044542	chr16:58799524	T/C	cg04273148	chr16:57808038	KIFC3	0.32	4.72	0.3	4.08e-6	Blood metabolite ratios;
SARC	cis	rs6121246	0.529	rs6060118	chr20:30171209	T/C	cg13852791	chr20:30311386	BCL2L1	0.66	5.71	0.35	3.41e-8	Mean corpuscular hemoglobin;
SARC	cis	rs9611519	0.929	rs926914	chr22:41418154	C/T	cg17376030	chr22:41985996	PMM1	0.49	5.8	0.36	2.16e-8	Neuroticism;
SARC	cis	rs1545257	0.537	rs11125582	chr2:24646213	C/T	cg06627628	chr2:24431161	ITSN2	-0.54	-6.83	-0.41	7.18e-11	Sjögren's syndrome;
SARC	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg18252515	chr7:66147081	NA	-1.28	-10.91	-0.58	1.21e-22	Diabetic kidney disease;
SARC	cis	rs6496667	1.000	rs6496665	chr15:90891615	G/A	cg22089800	chr15:90895588	ZNF774	0.52	4.85	0.3	2.22e-6	Rheumatoid arthritis;
SARC	cis	rs2228479	0.717	rs2286392	chr16:89809549	A/G	cg00800038	chr16:89945340	TCF25	-0.66	-5.1	-0.32	7.1e-7	Skin colour saturation;
SARC	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg00938859	chr5:1591904	SDHAP3	0.74	7.18	0.43	9.17e-12	Breast cancer;
SARC	cis	rs10992471	0.576	rs9409664	chr9:95070095	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.41	-4.95	-0.31	1.42e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs9457247	1.000	rs421214	chr6:167396629	A/G	cg07741184	chr6:167504864	NA	0.29	5.55	0.34	7.6e-8	Crohn's disease;
SARC	cis	rs2032447	0.613	rs6456708	chr6:26032847	G/C	cg18357526	chr6:26021779	HIST1H4A	0.53	6.92	0.41	4.23e-11	Intelligence (multi-trait analysis);
SARC	cis	rs7726839	0.794	rs10053310	chr5:595661	C/G	cg16447950	chr5:562315	NA	-0.42	-4.81	-0.3	2.74e-6	Obesity-related traits;
SARC	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg01570182	chr17:44337453	NA	0.83	9.45	0.53	3.8e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	trans	rs459571	0.920	rs2520094	chr9:136919985	A/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.62	-7.07	-0.42	1.79e-11	Platelet distribution width;
SARC	cis	rs2153535	0.580	rs2152348	chr6:8474301	C/A	cg23788917	chr6:8435910	SLC35B3	0.64	8.63	0.49	9.85e-16	Motion sickness;
SARC	trans	rs9329221	0.537	rs12678797	chr8:9978919	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.9	-0.41	4.95e-11	Neuroticism;
SARC	cis	rs9911578	0.839	rs1871751	chr17:57190368	A/G	cg05425664	chr17:57184151	TRIM37	-0.56	-7.01	-0.42	2.52e-11	Intelligence (multi-trait analysis);
SARC	cis	rs4803468	1.000	rs878082	chr19:41897674	G/A	cg14132834	chr19:41945861	ATP5SL	-0.56	-7.49	-0.44	1.38e-12	Height;
SARC	cis	rs13077101	0.927	rs9849411	chr3:120472208	T/C	cg24332942	chr3:120408071	RABL3	-0.37	-4.76	-0.3	3.33e-6	Obesity-related traits;
SARC	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg04277193	chr17:41438351	NA	0.43	4.85	0.3	2.25e-6	Menopause (age at onset);
SARC	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg05861140	chr6:150128134	PCMT1	-0.42	-5.44	-0.34	1.32e-7	Lung cancer;
SARC	cis	rs4253772	0.637	rs9627402	chr22:46702586	C/T	cg24881330	chr22:46731750	TRMU	0.66	5.58	0.34	6.79e-8	LDL cholesterol;Cholesterol, total;
SARC	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg12463550	chr7:65579703	CRCP	0.69	5.24	0.32	3.54e-7	Diabetic kidney disease;
SARC	cis	rs10911232	0.507	rs4652769	chr1:183009196	T/C	cg13390022	chr1:182993471	LAMC1	0.35	5.35	0.33	2.11e-7	Hypertriglyceridemia;
SARC	cis	rs4243830	0.850	rs4908910	chr1:6599362	T/A	cg05709478	chr1:6581295	PLEKHG5	-0.48	-4.8	-0.3	2.87e-6	Body mass index;
SARC	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg11987759	chr7:65425863	GUSB	0.62	8.25	0.48	1.17e-14	Aortic root size;
SARC	cis	rs2115630	0.967	rs7171167	chr15:85239123	A/T	cg12501888	chr15:85177176	SCAND2	-0.48	-5.78	-0.35	2.42e-8	P wave terminal force;
SARC	cis	rs9290065	0.519	rs6441346	chr3:160709229	C/T	cg04691961	chr3:161091175	C3orf57	-0.49	-6.32	-0.38	1.31e-9	Kawasaki disease;
SARC	cis	rs818427	0.896	rs458451	chr5:112224331	T/C	cg07820702	chr5:112228657	REEP5	-0.46	-5.23	-0.32	3.82e-7	Total body bone mineral density;
SARC	cis	rs17376456	1.000	rs34068652	chr5:93563319	G/A	cg25358565	chr5:93447407	FAM172A	1.31	14.86	0.7	1.39e-35	Diabetic retinopathy;
SARC	cis	rs12497850	1.000	rs6788650	chr3:48749543	T/C	cg07636037	chr3:49044803	WDR6	0.91	14.97	0.7	6.07e-36	Parkinson's disease;
SARC	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg10591111	chr5:226296	SDHA	-0.56	-5.05	-0.31	9.04e-7	Breast cancer;
SARC	cis	rs9400467	0.537	rs73528998	chr6:111445630	C/T	cg15721981	chr6:111408429	SLC16A10	0.67	5.78	0.35	2.37e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs9467773	0.620	rs9461276	chr6:26595168	T/C	cg12292205	chr6:26970375	C6orf41	0.43	5.36	0.33	2.03e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1784581	0.674	rs1784592	chr6:162387365	T/A	cg17173639	chr6:162384350	PARK2	-0.61	-7.87	-0.46	1.32e-13	Itch intensity from mosquito bite;
SARC	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg09033563	chr22:24373618	LOC391322	-0.41	-4.73	-0.3	3.86e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2327429	0.858	rs12524865	chr6:134196674	C/A	cg25632230	chr6:134101081	NA	-0.44	-5.23	-0.32	3.81e-7	Coronary artery disease;
SARC	cis	rs9902453	0.808	rs56088359	chr17:28173659	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	7.13	0.42	1.28e-11	Coffee consumption (cups per day);
SARC	cis	rs2153535	0.553	rs2984099	chr6:8637274	C/T	cg07606381	chr6:8435919	SLC35B3	-0.84	-11.12	-0.59	2.6e-23	Motion sickness;
SARC	trans	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg06437703	chr8:37914619	EIF4EBP1	-0.65	-8.63	-0.49	9.71e-16	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs10875746	0.859	rs12305647	chr12:48582961	T/C	cg26205652	chr12:48591994	NA	0.47	5.44	0.34	1.33e-7	Longevity (90 years and older);
SARC	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg25405998	chr7:65216604	CCT6P1	0.52	6.15	0.37	3.25e-9	Calcium levels;
SARC	cis	rs2908197	0.662	rs917423	chr7:75984717	A/G	cg07849177	chr7:76178544	LOC100133091	-0.43	-4.89	-0.31	1.86e-6	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs1580019	0.523	rs13236410	chr7:32690663	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.98	17.06	0.75	6.7e-43	Cognitive ability;
SARC	cis	rs2439831	0.867	rs45585139	chr15:43700427	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.05	9.23	0.52	1.67e-17	Lung cancer in ever smokers;
SARC	cis	rs72781680	1.000	rs12616899	chr2:24165235	A/G	cg06627628	chr2:24431161	ITSN2	-0.69	-6.48	-0.39	5.36e-10	Lymphocyte counts;
SARC	cis	rs7617773	0.817	rs745116	chr3:48272536	T/G	cg11946769	chr3:48343235	NME6	0.72	9.61	0.53	1.24e-18	Coronary artery disease;
SARC	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg06212747	chr3:49208901	KLHDC8B	0.51	6.24	0.38	2.01e-9	Resting heart rate;
SARC	cis	rs10979	1.000	rs12212011	chr6:143894694	C/A	cg25407410	chr6:143891975	LOC285740	-0.64	-8.78	-0.5	3.67e-16	Hypospadias;
SARC	trans	rs10767455	1.000	rs16914608	chr11:25794091	C/T	cg05791779	chr3:126452023	CHCHD6	0.43	6.26	0.38	1.87e-9	QRS interval (sulfonylurea treatment interaction);
SARC	cis	rs7824557	0.628	rs7831346	chr8:11193530	C/T	cg21775007	chr8:11205619	TDH	0.65	8.35	0.48	6.14e-15	Retinal vascular caliber;
SARC	cis	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg09021430	chr5:549028	NA	-0.44	-5.45	-0.34	1.26e-7	Obesity-related traits;
SARC	cis	rs17030434	1.000	rs952211	chr4:154717816	A/G	cg14289246	chr4:154710475	SFRP2	-0.58	-4.79	-0.3	2.99e-6	Electrocardiographic conduction measures;
SARC	cis	rs7762018	0.941	rs4716387	chr6:170136777	G/C	cg13891659	chr6:170190454	C6orf122;C6orf208	0.54	4.77	0.3	3.29e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs7700895	0.702	rs6890954	chr5:95229429	T/C	cg16656078	chr5:95278638	ELL2	-0.56	-6.73	-0.4	1.3e-10	IgG glycosylation;
SARC	cis	rs9467773	0.620	rs2504600	chr6:26648334	C/A	cg11502198	chr6:26597334	ABT1	0.63	8.46	0.48	2.95e-15	Intelligence (multi-trait analysis);
SARC	cis	rs9486719	1.000	rs12191653	chr6:96903898	T/C	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.01	-0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs2486288	0.656	rs11632724	chr15:45550791	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.45	-5.57	-0.34	7.07e-8	Glomerular filtration rate;
SARC	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg06108461	chr20:60628389	TAF4	-0.92	-12.72	-0.64	1.71e-28	Body mass index;
SARC	cis	rs1707322	1.000	rs9793167	chr1:46446800	G/A	cg03146154	chr1:46216737	IPP	0.45	5.41	0.33	1.57e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7103648	0.643	rs12365079	chr11:47696596	A/T	cg10504702	chr11:47789108	FNBP4	0.72	9.37	0.52	6.58e-18	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs2425143	0.908	rs11697087	chr20:34427583	G/A	cg01084648	chr20:34329383	RBM39	0.71	4.77	0.3	3.25e-6	Blood protein levels;
SARC	cis	rs7223966	0.921	rs6504186	chr17:61863932	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	7.24	0.43	6.65e-12	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg12564285	chr5:131593104	PDLIM4	0.35	5.25	0.33	3.46e-7	Breast cancer;
SARC	cis	rs76917914	0.820	rs7020081	chr9:100823360	C/A	cg03040243	chr9:100819229	NANS	0.71	7.68	0.45	4.3e-13	Immature fraction of reticulocytes;
SARC	cis	rs7772486	0.754	rs6932863	chr6:146021255	A/T	cg23711669	chr6:146136114	FBXO30	-0.91	-15.91	-0.72	4.41e-39	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg11494091	chr17:61959527	GH2	-0.55	-8.43	-0.48	3.55e-15	Prudent dietary pattern;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg19448109	chr4:57301998	PAICS;PPAT	0.47	6.24	0.38	2.1e-9	Chemerin levels;
SARC	cis	rs9660992	0.710	rs1768587	chr1:205236432	C/T	cg21545522	chr1:205238299	TMCC2	0.49	6.83	0.41	7.36e-11	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs6752107	1.000	rs34123137	chr2:234167881	T/A	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.5	6.74	0.4	1.23e-10	Crohn's disease;Inflammatory bowel disease;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg01805784	chr5:176873808	PRR7	0.47	6.36	0.38	1.08e-9	Thyroid stimulating hormone;
SARC	cis	rs7552404	0.731	rs1689275	chr1:76409655	T/C	cg03433033	chr1:76189801	ACADM	-0.43	-5.43	-0.34	1.41e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs12541335	0.615	rs4872464	chr8:22153381	G/A	cg18135555	chr8:22132992	PIWIL2	0.39	5.72	0.35	3.21e-8	Hypertriglyceridemia;
SARC	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg11062466	chr8:58055876	NA	0.54	5.56	0.34	7.55e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg11987759	chr7:65425863	GUSB	0.54	6.99	0.42	2.9e-11	Aortic root size;
SARC	trans	rs17685	0.753	rs3757593	chr7:75678735	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.62	-7.88	-0.46	1.22e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg24110177	chr3:50126178	RBM5	-0.62	-8.08	-0.47	3.46e-14	Body mass index;
SARC	cis	rs2735413	0.958	rs11150034	chr16:78066369	G/A	cg04733911	chr16:78082701	NA	-0.28	-4.96	-0.31	1.34e-6	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs908922	0.676	rs7550769	chr1:152531213	G/A	cg09873164	chr1:152488093	CRCT1	0.61	7.84	0.46	1.6e-13	Hair morphology;
SARC	trans	rs8073060	0.586	rs225264	chr17:33961335	A/G	cg19694781	chr19:47549865	TMEM160	-0.68	-6.84	-0.41	7.09e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs17253792	0.545	rs12893610	chr14:56016347	C/T	cg01858014	chr14:56050164	KTN1	-0.71	-4.84	-0.3	2.35e-6	Putamen volume;
SARC	cis	rs6964587	1.000	rs11971885	chr7:91674807	T/C	cg17063962	chr7:91808500	NA	0.96	16.4	0.73	1.04e-40	Breast cancer;
SARC	cis	rs7223966	1.000	rs9895920	chr17:61852719	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	6.93	0.41	4.01e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg18357526	chr6:26021779	HIST1H4A	0.58	6.74	0.4	1.24e-10	Intelligence (multi-trait analysis);
SARC	cis	rs16976116	0.901	rs28589384	chr15:55494366	A/G	cg11288833	chr15:55489084	RSL24D1	0.63	6.13	0.37	3.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2832077	0.527	rs2705690	chr21:30239245	T/A	cg03476357	chr21:30257390	N6AMT1	0.65	7.33	0.43	3.66e-12	Cognitive test performance;
SARC	cis	rs9911578	1.000	rs9892062	chr17:56976981	G/A	cg05425664	chr17:57184151	TRIM37	-0.67	-8.33	-0.48	7.15e-15	Intelligence (multi-trait analysis);
SARC	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.78	-0.5	3.56e-16	Alzheimer's disease;
SARC	cis	rs7953249	0.618	rs7954039	chr12:121398654	A/C	cg25281562	chr12:121454272	C12orf43	-0.45	-5.38	-0.33	1.84e-7	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs3091242	0.809	rs660129	chr1:25727438	C/T	cg23205692	chr1:25664452	TMEM50A	0.4	4.82	0.3	2.58e-6	Erythrocyte sedimentation rate;
SARC	cis	rs2153535	0.580	rs1119688	chr6:8460850	T/C	cg21535247	chr6:8435926	SLC35B3	0.54	6.67	0.4	1.8e-10	Motion sickness;
SARC	cis	rs10791097	0.967	rs10750450	chr11:130719061	G/T	cg12179176	chr11:130786555	SNX19	0.61	8.51	0.49	2.15e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs7300001	0.667	rs7298716	chr12:110506181	A/T	cg08946844	chr12:110511112	NA	0.66	4.83	0.3	2.45e-6	Headache;
SARC	cis	rs12472274	0.646	rs35468889	chr2:239090959	G/A	cg17459225	chr2:239074497	NA	0.61	6.42	0.39	7.51e-10	Phospholipid levels (plasma);
SARC	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg17178900	chr1:205818956	PM20D1	0.48	5.5	0.34	9.82e-8	Prostate-specific antigen levels;
SARC	cis	rs6570726	0.905	rs419575	chr6:145840174	A/G	cg05347473	chr6:146136440	FBXO30	0.48	6.42	0.39	7.51e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg22875332	chr1:76189707	ACADM	0.41	5.36	0.33	1.98e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg27266027	chr21:40555129	PSMG1	0.48	5.2	0.32	4.41e-7	Cognitive function;
SARC	cis	rs748404	0.631	rs2467745	chr15:43722742	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.4	4.78	0.3	3.13e-6	Lung cancer;
SARC	cis	rs3796352	0.892	rs9756317	chr3:53088815	T/C	cg15956490	chr3:53032818	SFMBT1	-0.68	-5.16	-0.32	5.24e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs9859260	0.710	rs34906439	chr3:195779706	A/G	cg03462622	chr3:195777018	TFRC	-0.46	-5.4	-0.33	1.65e-7	Mean corpuscular volume;
SARC	cis	rs9788682	0.747	rs11637630	chr15:78899719	G/A	cg24631222	chr15:78858424	CHRNA5	-0.72	-9.81	-0.54	3.04e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs2268241	0.877	rs17887186	chr21:34779202	G/A	cg14850771	chr21:34775459	IFNGR2	0.97	9.33	0.52	8.64e-18	Obesity-related traits;
SARC	cis	rs523522	0.962	rs10774549	chr12:120891172	C/T	cg12219531	chr12:120966889	COQ5	0.81	10.48	0.57	2.58e-21	High light scatter reticulocyte count;
SARC	trans	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg21659725	chr3:3221576	CRBN	-0.54	-7.06	-0.42	1.85e-11	Intelligence (multi-trait analysis);
SARC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg06873352	chr17:61820015	STRADA	-0.57	-7.43	-0.44	2.1e-12	Prudent dietary pattern;
SARC	trans	rs1600249	0.562	rs17153419	chr8:11394233	C/T	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.48	-0.39	5.39e-10	Rheumatoid arthritis;
SARC	cis	rs9300255	0.537	rs1716182	chr12:123686127	A/C	cg05973401	chr12:123451056	ABCB9	0.52	5.89	0.36	1.34e-8	Neutrophil percentage of white cells;
SARC	cis	rs4481887	0.927	rs4381224	chr1:248456826	A/T	cg01631408	chr1:248437212	OR2T33	-0.43	-5.43	-0.34	1.39e-7	Common traits (Other);
SARC	trans	rs9388451	0.839	rs9321054	chr6:126079968	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.57	7.3	0.43	4.63e-12	Brugada syndrome;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg22548015	chr20:30539544	PDRG1	0.49	6.65	0.4	2.07e-10	Thyroid stimulating hormone;
SARC	cis	rs13256369	0.950	rs1522839	chr8:8580453	C/T	cg18904891	chr8:8559673	CLDN23	0.48	5.47	0.34	1.15e-7	Obesity-related traits;
SARC	cis	rs554111	0.613	rs3816455	chr1:21191430	A/G	cg04902671	chr1:21058625	SH2D5	0.44	5.37	0.33	1.89e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs7246657	0.943	rs10405407	chr19:37839164	C/T	cg23950597	chr19:37808831	NA	-0.54	-5.47	-0.34	1.15e-7	Coronary artery calcification;
SARC	cis	rs7481584	0.961	rs729662	chr11:3028140	G/A	cg08508325	chr11:3079039	CARS	0.23	4.85	0.3	2.3e-6	Calcium levels;
SARC	cis	rs7408868	0.908	rs4809028	chr19:15273231	A/G	cg14696996	chr19:15285081	NOTCH3	1.06	8.68	0.49	6.85e-16	Pulse pressure;
SARC	cis	rs193541	0.617	rs2045628	chr5:122095154	C/T	cg19412675	chr5:122181750	SNX24	0.43	5.56	0.34	7.52e-8	Glucose homeostasis traits;
SARC	cis	rs73001065	0.688	rs59148799	chr19:19484008	A/G	cg03709012	chr19:19516395	GATAD2A	1.13	8.38	0.48	4.94e-15	LDL cholesterol;
SARC	cis	rs77633900	0.614	rs280013	chr15:76978139	C/T	cg21673338	chr15:77095150	SCAPER	0.77	6.45	0.39	6.52e-10	Non-glioblastoma glioma;Glioma;
SARC	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	11.65	0.61	4.98e-25	Alzheimer's disease;
SARC	cis	rs4481887	0.636	rs6672981	chr1:248407200	C/T	cg13385794	chr1:248469461	NA	0.37	5.01	0.31	1.09e-6	Common traits (Other);
SARC	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg21782813	chr7:2030301	MAD1L1	0.37	5.75	0.35	2.72e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs67460515	0.527	rs34221255	chr3:160854123	T/C	cg04691961	chr3:161091175	C3orf57	-0.43	-5.22	-0.32	3.97e-7	Parkinson's disease;
SARC	cis	rs2576037	0.796	rs2576043	chr18:44573476	C/G	cg19077165	chr18:44547161	KATNAL2	0.44	6.05	0.37	5.58e-9	Personality dimensions;
SARC	cis	rs5753037	0.653	rs131266	chr22:30145717	G/T	cg01021169	chr22:30184971	ASCC2	-0.46	-6.45	-0.39	6.32e-10	Type 1 diabetes;
SARC	cis	rs7560272	0.501	rs11891140	chr2:73944084	A/G	cg20560298	chr2:73613845	ALMS1	0.44	5.89	0.36	1.33e-8	Schizophrenia;
SARC	cis	rs6685188	0.925	rs12752037	chr1:205661614	A/C	cg23034840	chr1:205782522	SLC41A1	-0.44	-4.75	-0.3	3.63e-6	White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs12681288	0.550	rs72507624	chr8:961324	G/A	cg15309053	chr8:964076	NA	0.46	7.54	0.44	1.03e-12	Schizophrenia;
SARC	cis	rs10504229	0.679	rs16921687	chr8:58053514	T/C	cg22535103	chr8:58192502	C8orf71	-0.59	-5.94	-0.36	1.03e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7666738	0.830	rs35644814	chr4:98886111	G/C	cg05340658	chr4:99064831	C4orf37	0.65	8.56	0.49	1.54e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg08219700	chr8:58056026	NA	0.59	6.27	0.38	1.76e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7566780	0.575	rs7605502	chr2:16689951	A/T	cg09580478	chr2:16689509	NA	0.51	6.35	0.38	1.12e-9	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs365132	1.000	rs353464	chr5:176403023	A/G	cg16309518	chr5:176445507	NA	-0.47	-6.07	-0.37	5.23e-9	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs911555	0.755	rs10148970	chr14:103892000	G/A	cg12935359	chr14:103987150	CKB	-0.38	-5.24	-0.32	3.57e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1043515	0.748	rs11653487	chr17:36942631	A/G	cg09592244	chr17:37024020	NA	-0.38	-4.96	-0.31	1.37e-6	Height;
SARC	cis	rs7647973	0.626	rs4855849	chr3:49653378	A/G	cg03060546	chr3:49711283	APEH	0.67	7.1	0.42	1.54e-11	Menarche (age at onset);
SARC	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.66	0.35	4.44e-8	Bipolar disorder;
SARC	cis	rs9303542	0.625	rs8064626	chr17:46567851	G/A	cg04904318	chr17:46607828	HOXB1	-0.47	-5.46	-0.34	1.23e-7	Ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs2635047	0.638	rs12968552	chr18:44702502	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	6.29	0.38	1.52e-9	Educational attainment;
SARC	cis	rs2046867	0.818	rs1502757	chr3:72864161	C/T	cg25664220	chr3:72788482	NA	-0.3	-4.89	-0.3	1.92e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
SARC	cis	rs453301	0.658	rs9329175	chr8:8866661	C/T	cg11608241	chr8:8085544	FLJ10661	-0.39	-4.82	-0.3	2.54e-6	Joint mobility (Beighton score);
SARC	cis	rs7089973	0.604	rs11196941	chr10:116596258	A/G	cg08188268	chr10:116634841	FAM160B1	0.28	4.83	0.3	2.46e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs2228479	0.850	rs62056061	chr16:89901767	G/A	cg00800038	chr16:89945340	TCF25	-0.82	-5.77	-0.35	2.46e-8	Skin colour saturation;
SARC	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg12463550	chr7:65579703	CRCP	0.49	5.85	0.36	1.63e-8	Aortic root size;
SARC	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg24642844	chr7:1081250	C7orf50	-0.59	-6.24	-0.38	2.07e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs9381040	0.655	rs7775972	chr6:41038116	A/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.46	-5.23	-0.32	3.74e-7	Alzheimer's disease (late onset);
SARC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg09060608	chr5:178986726	RUFY1	-0.34	-4.98	-0.31	1.24e-6	Lung cancer;
SARC	cis	rs10927875	0.662	rs698893	chr1:16302982	C/T	cg21385522	chr1:16154831	NA	0.47	5.65	0.35	4.69e-8	Dilated cardiomyopathy;
SARC	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	12.5	0.63	8.96e-28	Chronic sinus infection;
SARC	cis	rs10791323	0.572	rs4353292	chr11:133742656	A/G	cg13461336	chr11:133711254	SPATA19	-0.28	-5.08	-0.32	7.71e-7	Childhood ear infection;
SARC	cis	rs9916302	0.851	rs12936646	chr17:37647450	A/T	cg20243544	chr17:37824526	PNMT	0.57	6.79	0.41	9.01e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs1580019	0.587	rs7806941	chr7:32553319	G/T	cg14728415	chr7:32535168	LSM5;AVL9	0.54	6.92	0.41	4.21e-11	Cognitive ability;
SARC	cis	rs12681366	0.537	rs10956914	chr8:95483723	G/T	cg13257157	chr8:95487014	RAD54B	-0.4	-4.85	-0.3	2.3e-6	Nonsyndromic cleft lip with cleft palate;
SARC	trans	rs10838798	0.523	rs2019093	chr11:48196553	G/A	cg15704280	chr7:45808275	SEPT13	-0.48	-6.59	-0.4	2.99e-10	Height;
SARC	cis	rs908922	0.676	rs6587681	chr1:152512135	C/T	cg09873164	chr1:152488093	CRCT1	0.65	8.66	0.49	7.93e-16	Hair morphology;
SARC	cis	rs9815354	0.909	rs6794477	chr3:41920401	C/T	cg03022575	chr3:42003672	ULK4	-0.54	-5.12	-0.32	6.5e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs11719291	0.667	rs9877542	chr3:48748545	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.57	-5.27	-0.33	3.12e-7	Cognitive function;
SARC	cis	rs7312933	0.531	rs2708059	chr12:42851008	C/T	cg19980929	chr12:42632907	YAF2	-0.47	-6.96	-0.41	3.39e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs13314892	0.764	rs62251026	chr3:69862376	T/C	cg17445875	chr3:69859618	MITF	-0.49	-5.1	-0.32	6.98e-7	QRS complex (12-leadsum);
SARC	cis	rs9916302	0.851	rs11870631	chr17:37645129	C/T	cg07936489	chr17:37558343	FBXL20	-0.69	-9.02	-0.51	7.36e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs8180040	0.966	rs3736177	chr3:47451411	C/T	cg27129171	chr3:47204927	SETD2	-0.68	-9.44	-0.53	4.02e-18	Colorectal cancer;
SARC	cis	rs703842	1.000	rs11172351	chr12:58213485	C/T	cg00677455	chr12:58241039	CTDSP2	0.51	6.61	0.4	2.63e-10	Multiple sclerosis;
SARC	cis	rs9875589	0.509	rs11128679	chr3:14075245	C/T	cg19554555	chr3:13937349	NA	-0.4	-5.16	-0.32	5.29e-7	Ovarian reserve;
SARC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg07308232	chr7:1071921	C7orf50	-0.68	-8.81	-0.5	2.99e-16	Longevity;Endometriosis;
SARC	cis	rs7552404	0.727	rs11161626	chr1:76260837	C/T	cg03433033	chr1:76189801	ACADM	0.47	5.97	0.36	8.59e-9	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg15966229	chr18:44337664	ST8SIA5	-0.37	-4.88	-0.3	1.95e-6	Personality dimensions;
SARC	trans	rs4282339	0.868	rs2974433	chr5:168268387	A/G	cg14217793	chr9:139072310	NA	-0.34	-6.34	-0.38	1.21e-9	Height;
SARC	cis	rs818427	0.927	rs461424	chr5:112229903	G/A	cg07820702	chr5:112228657	REEP5	-0.46	-4.89	-0.3	1.92e-6	Total body bone mineral density;
SARC	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg20607798	chr8:58055168	NA	0.57	5.25	0.33	3.35e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.45	5.26	0.33	3.24e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	trans	rs208520	0.909	rs62414639	chr6:67023706	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.82	8.32	0.48	7.56e-15	Exhaled nitric oxide output;
SARC	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg12379764	chr21:47803548	PCNT	0.54	5.68	0.35	3.98e-8	Testicular germ cell tumor;
SARC	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg08859206	chr1:53392774	SCP2	0.39	5.53	0.34	8.44e-8	Monocyte count;
SARC	cis	rs12464559	0.522	rs7583060	chr2:152620943	C/A	cg01189475	chr2:152685088	ARL5A	0.59	4.91	0.31	1.73e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg06713675	chr4:122721982	EXOSC9	-0.5	-6.6	-0.4	2.74e-10	Type 2 diabetes;
SARC	cis	rs4906332	0.868	rs4900578	chr14:103926010	A/T	cg26031613	chr14:104095156	KLC1	-0.49	-5.74	-0.35	2.88e-8	Coronary artery disease;
SARC	cis	rs6121246	1.000	rs6121246	chr20:30433352	C/T	cg13852791	chr20:30311386	BCL2L1	0.83	8.8	0.5	3.18e-16	Mean corpuscular hemoglobin;
SARC	cis	rs7264396	0.623	rs6060507	chr20:34198334	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-7.09	-0.42	1.58e-11	Total cholesterol levels;
SARC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.62	-7.58	-0.44	8.28e-13	Longevity;Endometriosis;
SARC	cis	rs7772486	0.806	rs2253648	chr6:146199296	G/A	cg05347473	chr6:146136440	FBXO30	0.52	7.23	0.43	7.03e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg22105103	chr4:187893119	NA	0.45	5.94	0.36	1.05e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7927592	0.763	rs11822059	chr11:68300822	T/G	cg01657329	chr11:68192670	LRP5	-0.37	-5.21	-0.32	4.14e-7	Total body bone mineral density;
SARC	cis	rs3796352	1.000	rs2336541	chr3:52974630	G/C	cg15956490	chr3:53032818	SFMBT1	0.79	5.18	0.32	4.85e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2439831	0.850	rs12441861	chr15:44060883	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	8.49	0.49	2.43e-15	Lung cancer in ever smokers;
SARC	cis	rs12579753	1.000	rs11115015	chr12:82174543	T/C	cg07988820	chr12:82153109	PPFIA2	-0.58	-6.76	-0.41	1.09e-10	Resting heart rate;
SARC	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg06634786	chr22:41940651	POLR3H	-0.58	-7.0	-0.42	2.79e-11	Vitiligo;
SARC	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg08280861	chr8:58055591	NA	0.7	5.85	0.36	1.64e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs13256369	0.951	rs13260947	chr8:8565883	A/G	cg17143192	chr8:8559678	CLDN23	0.52	5.81	0.36	2.04e-8	Obesity-related traits;
SARC	cis	rs7208859	0.725	rs7210904	chr17:29170205	G/A	cg13385521	chr17:29058706	SUZ12P	0.77	6.89	0.41	5.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9916302	0.904	rs801420	chr17:37466103	C/G	cg00129232	chr17:37814104	STARD3	0.59	7.27	0.43	5.32e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs4332037	0.707	rs62435132	chr7:1891315	C/T	cg12591125	chr7:1885375	MAD1L1	0.5	5.26	0.33	3.25e-7	Bipolar disorder;
SARC	cis	rs7520050	0.966	rs6669522	chr1:46397941	A/G	cg24296786	chr1:45957014	TESK2	0.39	4.9	0.31	1.77e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg18252515	chr7:66147081	NA	-0.65	-6.88	-0.41	5.34e-11	Aortic root size;
SARC	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	21.28	0.81	1.52e-56	Chronic sinus infection;
SARC	cis	rs2997447	0.739	rs60141220	chr1:26395741	G/A	cg19633962	chr1:26362018	EXTL1	-0.56	-4.84	-0.3	2.4e-6	QRS complex (12-leadsum);
SARC	trans	rs12310956	0.510	rs4931743	chr12:33867588	T/C	cg26384229	chr12:38710491	ALG10B	0.62	8.27	0.48	1.02e-14	Morning vs. evening chronotype;
SARC	cis	rs910316	0.935	rs2268620	chr14:75640403	G/A	cg23033748	chr14:75592666	NEK9	-0.37	-5.08	-0.32	7.85e-7	Height;
SARC	cis	rs1062177	0.826	rs2053063	chr5:151166764	T/C	cg00977110	chr5:151150581	G3BP1	0.6	6.13	0.37	3.76e-9	Preschool internalizing problems;
SARC	cis	rs7824557	0.545	rs2572380	chr8:11237477	A/G	cg21775007	chr8:11205619	TDH	-0.63	-8.39	-0.48	4.56e-15	Retinal vascular caliber;
SARC	cis	rs4481887	0.927	rs10749651	chr1:248472930	T/C	cg01631408	chr1:248437212	OR2T33	-0.39	-5.06	-0.31	8.56e-7	Common traits (Other);
SARC	cis	rs1707322	0.963	rs10789478	chr1:46350506	C/T	cg03146154	chr1:46216737	IPP	0.51	6.21	0.38	2.4e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7429990	0.932	rs936428	chr3:48167281	A/G	cg11946769	chr3:48343235	NME6	-0.46	-5.46	-0.34	1.24e-7	Educational attainment (years of education);
SARC	cis	rs72781680	1.000	rs72781648	chr2:24210333	T/C	cg08917208	chr2:24149416	ATAD2B	0.78	7.62	0.45	6.31e-13	Lymphocyte counts;
SARC	cis	rs16976116	0.704	rs7183895	chr15:55513712	G/A	cg11288833	chr15:55489084	RSL24D1	0.52	5.22	0.32	4.03e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1865760	0.622	rs9968910	chr6:26072095	A/C	cg10373733	chr6:25993375	NA	0.5	5.64	0.35	4.8e-8	Height;
SARC	cis	rs4595586	0.545	rs1562729	chr12:39406179	T/G	cg26384229	chr12:38710491	ALG10B	0.5	6.12	0.37	3.98e-9	Morning vs. evening chronotype;
SARC	cis	rs7727544	0.660	rs2631361	chr5:131707380	C/A	cg24060327	chr5:131705240	SLC22A5	0.71	9.13	0.51	3.28e-17	Blood metabolite levels;
SARC	cis	rs6088580	0.634	rs2378133	chr20:32919505	C/G	cg24642439	chr20:33292090	TP53INP2	-0.67	-8.52	-0.49	1.97e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs12791968	0.765	rs12790121	chr11:45001089	G/A	cg11846598	chr11:44996168	LOC221122	-0.33	-4.78	-0.3	3.04e-6	Inhibitory control;
SARC	cis	rs1355223	0.583	rs2956074	chr11:34864880	T/C	cg18508148	chr11:34937573	PDHX;APIP	0.53	6.98	0.42	3.05e-11	Systemic lupus erythematosus and Systemic sclerosis;
SARC	trans	rs1814175	0.558	rs5025146	chr11:49795724	C/G	cg03929089	chr4:120376271	NA	-0.84	-12.3	-0.63	4.13e-27	Height;
SARC	cis	rs360798	0.643	rs6705692	chr2:62815912	C/T	cg16915676	chr2:62734870	TMEM17	-0.53	-5.57	-0.34	6.99e-8	Coronary artery disease;
SARC	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.73	8.8	0.5	3.1e-16	Height;
SARC	cis	rs7223966	1.000	rs992416	chr17:61745905	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.51	-5.36	-0.33	2e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs826838	0.904	rs10880981	chr12:38763911	G/A	cg13010199	chr12:38710504	ALG10B	0.81	11.63	0.61	6.07e-25	Heart rate;
SARC	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg11062466	chr8:58055876	NA	0.52	5.39	0.33	1.76e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs3812111	0.510	rs1931892	chr6:116594511	A/C	cg18828861	chr6:116576566	TSPYL4	0.33	4.84	0.3	2.4e-6	Age-related macular degeneration;
SARC	cis	rs6138458	1.000	rs1977540	chr20:24900290	G/T	cg26195577	chr20:24973756	C20orf3	-0.86	-9.47	-0.53	3.25e-18	Blood protein levels;
SARC	cis	rs4642101	1.000	rs7650482	chr3:12841804	A/G	cg05775895	chr3:12838266	CAND2	0.7	9.99	0.55	8.44e-20	QRS complex (12-leadsum);
SARC	cis	rs986417	0.786	rs1254273	chr14:60843581	C/A	cg27398547	chr14:60952738	C14orf39	-1.0	-8.65	-0.49	8.38e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs79976124	0.879	rs12214239	chr6:66636059	A/G	cg07460842	chr6:66804631	NA	0.62	6.67	0.4	1.89e-10	Type 2 diabetes;
SARC	cis	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg18252515	chr7:66147081	NA	-1.27	-10.81	-0.58	2.36e-22	Diabetic kidney disease;
SARC	cis	rs73242632	1.000	rs28623722	chr4:57895764	A/G	cg20415529	chr4:57845134	POLR2B;C4orf14	1.07	6.6	0.4	2.74e-10	Congenital heart disease (maternal effect);
SARC	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6089584	1.000	rs6089580	chr20:60558976	G/A	cg06108461	chr20:60628389	TAF4	-0.91	-11.96	-0.62	5.27e-26	Body mass index;
SARC	cis	rs8180040	0.800	rs62248905	chr3:47274082	A/G	cg27129171	chr3:47204927	SETD2	-0.73	-9.54	-0.53	1.96e-18	Colorectal cancer;
SARC	cis	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg05623727	chr3:50126028	RBM5	-0.35	-5.1	-0.32	7.18e-7	Body mass index;
SARC	cis	rs11581859	0.613	rs6674890	chr1:99231152	A/T	cg20286094	chr1:99190917	SNX7	0.43	5.13	0.32	6.12e-7	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg17971929	chr21:40555470	PSMG1	-0.58	-7.36	-0.43	3.15e-12	Menarche (age at onset);
SARC	cis	rs2230307	0.536	rs522696	chr1:100476662	G/A	cg24955406	chr1:100503596	HIAT1	0.71	7.03	0.42	2.28e-11	Carotid intima media thickness;
SARC	cis	rs2425143	0.514	rs8114246	chr20:34581979	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-4.94	-0.31	1.48e-6	Blood protein levels;
SARC	cis	rs9790314	0.905	rs7632797	chr3:161002694	C/T	cg03342759	chr3:160939853	NMD3	0.62	7.95	0.46	7.8500000000000006e-14	Morning vs. evening chronotype;
SARC	cis	rs7178572	0.568	rs1191196	chr15:77646504	C/T	cg22256960	chr15:77711686	NA	0.49	5.38	0.33	1.83e-7	Type 2 diabetes;
SARC	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.71	7.02	0.42	2.35e-11	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs9611519	0.639	rs7290458	chr22:41476337	C/T	cg17376030	chr22:41985996	PMM1	-0.39	-4.89	-0.31	1.87e-6	Neuroticism;
SARC	cis	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg05623727	chr3:50126028	RBM5	-0.34	-5.19	-0.32	4.52e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7429990	0.965	rs34380889	chr3:47947182	C/T	cg11946769	chr3:48343235	NME6	0.45	5.16	0.32	5.26e-7	Educational attainment (years of education);
SARC	cis	rs7223966	1.000	rs8076717	chr17:61850301	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.46	-4.8	-0.3	2.86e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg11266682	chr4:10021025	SLC2A9	0.41	7.29	0.43	4.75e-12	Bone mineral density;
SARC	cis	rs10752881	0.967	rs4652758	chr1:182975100	T/C	cg13390022	chr1:182993471	LAMC1	0.33	5.06	0.31	8.36e-7	Colorectal cancer;
SARC	cis	rs1185460	0.967	rs1786141	chr11:118938315	C/T	cg23280166	chr11:118938394	VPS11	0.82	12.84	0.64	6.84e-29	Coronary artery disease;
SARC	cis	rs3812111	0.510	rs9387390	chr6:116584080	T/C	cg18828861	chr6:116576566	TSPYL4	0.33	4.85	0.3	2.21e-6	Age-related macular degeneration;
SARC	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg24399712	chr22:39784796	NA	-0.43	-5.72	-0.35	3.32e-8	Intelligence (multi-trait analysis);
SARC	cis	rs8014204	0.836	rs11159099	chr14:75235397	A/G	cg17347104	chr14:75034677	LTBP2	-0.43	-5.35	-0.33	2.09e-7	Caffeine consumption;
SARC	cis	rs427394	0.659	rs274675	chr5:6755319	C/T	cg10857441	chr5:6722123	POLS	-0.34	-5.04	-0.31	9.35e-7	Menopause (age at onset);
SARC	cis	rs2354432	0.607	rs1530335	chr1:146685288	T/C	cg25205988	chr1:146714368	CHD1L	1.06	8.87	0.5	2.02e-16	Mitochondrial DNA levels;
SARC	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg26335602	chr6:28129616	ZNF389	0.51	5.56	0.34	7.41e-8	Parkinson's disease;
SARC	cis	rs7084402	0.935	rs11006192	chr10:60343638	T/C	cg07615347	chr10:60278583	BICC1	0.54	7.67	0.45	4.55e-13	Refractive error;
SARC	cis	rs8067545	0.611	rs2526476	chr17:20134289	C/T	cg13482628	chr17:19912719	NA	-0.56	-7.2	-0.43	8.41e-12	Schizophrenia;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg10158133	chr10:75488242	BMS1P4	-0.74	-6.48	-0.39	5.46e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9902453	0.934	rs4343336	chr17:28488236	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	6.77	0.41	1.05e-10	Coffee consumption (cups per day);
SARC	cis	rs6667605	0.527	rs6673993	chr1:2552071	T/C	cg18854424	chr1:2615690	NA	0.31	5.0	0.31	1.11e-6	Inflammatory bowel disease;Ulcerative colitis;
SARC	cis	rs9462027	0.628	rs7745097	chr6:34794434	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-6.1	-0.37	4.37e-9	Systemic lupus erythematosus;
SARC	cis	rs9916302	0.706	rs11657153	chr17:37699729	A/G	cg07936489	chr17:37558343	FBXL20	-0.74	-8.58	-0.49	1.37e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg00933542	chr6:150070202	PCMT1	0.33	5.89	0.36	1.32e-8	Lung cancer;
SARC	cis	rs2624839	0.630	rs2624841	chr3:50198415	C/T	cg24110177	chr3:50126178	RBM5	-0.51	-6.36	-0.38	1.03e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7639513	0.767	rs7617041	chr3:12709167	A/G	cg23032965	chr3:12705835	RAF1	0.85	12.42	0.63	1.59e-27	Itch intensity from mosquito bite;
SARC	cis	rs7264396	0.563	rs2425081	chr20:34299733	C/A	cg01084648	chr20:34329383	RBM39	0.56	4.93	0.31	1.57e-6	Total cholesterol levels;
SARC	cis	rs7246760	0.609	rs57889827	chr19:9777459	T/C	cg16876255	chr19:9731953	ZNF561	0.84	5.14	0.32	5.8e-7	Pursuit maintenance gain;
SARC	cis	rs7246657	0.882	rs28623164	chr19:37913453	G/A	cg23950597	chr19:37808831	NA	-0.57	-5.67	-0.35	4.24e-8	Coronary artery calcification;
SARC	cis	rs3784262	0.564	rs34958088	chr15:58328332	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.32	-4.79	-0.3	2.98e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs8058578	0.887	rs28421305	chr16:30838128	G/A	cg02466173	chr16:30829666	NA	-0.45	-5.99	-0.37	7.82e-9	Multiple myeloma;
SARC	cis	rs79349575	0.749	rs519537	chr17:46971140	G/A	cg07967210	chr17:47022446	SNF8	0.38	4.78	0.3	3.07e-6	Type 2 diabetes;
SARC	trans	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg08986653	chr3:40498475	RPL14	-0.66	-6.42	-0.39	7.65e-10	Cutaneous psoriasis;
SARC	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg24675658	chr1:53192096	ZYG11B	0.78	11.25	0.59	9.77e-24	Monocyte count;
SARC	cis	rs754466	0.651	rs11002317	chr10:79617648	G/A	cg17075019	chr10:79541650	NA	-0.78	-12.5	-0.63	8.75e-28	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7246657	1.000	rs10426297	chr19:37798373	A/G	cg23950597	chr19:37808831	NA	-0.51	-4.71	-0.3	4.19e-6	Coronary artery calcification;
SARC	cis	rs2806561	0.765	rs1997866	chr1:23512524	A/G	cg12483005	chr1:23474871	LUZP1	0.45	5.9	0.36	1.26e-8	Height;
SARC	cis	rs739401	0.611	rs2071104	chr11:3036933	G/T	cg20651018	chr11:3035856	CARS	-0.45	-6.9	-0.41	4.89e-11	Longevity;
SARC	cis	rs1865760	0.566	rs9358902	chr6:26058570	C/G	cg10373733	chr6:25993375	NA	0.4	4.81	0.3	2.66e-6	Height;
SARC	cis	rs8058578	1.000	rs8051050	chr16:30687909	A/G	cg02466173	chr16:30829666	NA	-0.42	-5.43	-0.34	1.4e-7	Multiple myeloma;
SARC	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg18404041	chr3:52824283	ITIH1	0.38	5.75	0.35	2.78e-8	Bipolar disorder;
SARC	cis	rs9392918	0.600	rs6915280	chr6:7694263	A/T	cg23089261	chr6:7723385	NA	0.44	5.48	0.34	1.11e-7	Height;
SARC	cis	rs10791323	0.569	rs5019134	chr11:133713082	G/C	cg15485101	chr11:133734466	NA	0.33	5.07	0.32	8.08e-7	Childhood ear infection;
SARC	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg27170947	chr2:26402098	FAM59B	-0.37	-4.83	-0.3	2.52e-6	Gut microbiome composition (summer);
SARC	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg26354017	chr1:205819088	PM20D1	0.43	4.79	0.3	3.03e-6	Parkinson's disease;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg06452419	chr17:55938940	NA	-0.5	-6.41	-0.39	7.89e-10	Height;
SARC	trans	rs9929218	0.953	rs3114411	chr16:68734591	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.62	7.43	0.44	2.08e-12	Colorectal cancer;
SARC	cis	rs2594989	0.943	rs2454502	chr3:11499331	T/C	cg00170343	chr3:11313890	ATG7	0.53	5.24	0.32	3.62e-7	Circulating chemerin levels;
SARC	cis	rs644799	0.601	rs662168	chr11:95586982	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.44	5.59	0.34	6.24e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs4566357	0.595	rs1320406	chr2:227920474	C/T	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.71	-0.35	3.45e-8	Coronary artery disease;
SARC	cis	rs11711311	0.824	rs35952547	chr3:113352501	G/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.61	7.42	0.44	2.17e-12	IgG glycosylation;
SARC	cis	rs7582180	0.700	rs11685293	chr2:100976502	A/C	cg14675211	chr2:100938903	LONRF2	0.49	7.34	0.43	3.49e-12	Intelligence (multi-trait analysis);
SARC	cis	rs3733585	0.699	rs13328050	chr4:9951120	G/T	cg11266682	chr4:10021025	SLC2A9	-0.36	-6.24	-0.38	2.01e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs3126085	0.877	rs4457589	chr1:152247860	T/C	cg03465714	chr1:152285911	FLG	-0.45	-5.45	-0.34	1.25e-7	Atopic dermatitis;
SARC	cis	rs11098499	0.575	rs907205	chr4:120238664	G/C	cg09307838	chr4:120376055	NA	0.81	11.01	0.58	5.67e-23	Corneal astigmatism;
SARC	cis	rs926392	0.666	rs912179	chr20:37710775	G/A	cg16355469	chr20:37678765	NA	0.63	8.07	0.47	3.84e-14	Dialysis-related mortality;
SARC	cis	rs765787	0.530	rs13329228	chr15:45533017	C/T	cg25801113	chr15:45476975	SHF	0.3	4.89	0.31	1.84e-6	Uric acid levels;
SARC	cis	rs2327429	0.858	rs1832181	chr6:134186165	C/G	cg25632230	chr6:134101081	NA	-0.46	-5.5	-0.34	9.97e-8	Coronary artery disease;
SARC	cis	rs6700896	0.897	rs7541434	chr1:66168499	A/C	cg04111102	chr1:66153794	NA	-0.35	-5.3	-0.33	2.72e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs721399	0.706	rs6997340	chr8:18286997	C/T	cg18736775	chr8:18248649	NAT2	-0.4	-5.49	-0.34	1.06e-7	Blood metabolite levels;
SARC	cis	rs62244186	0.659	rs9873072	chr3:44516496	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.48	5.82	0.36	1.96e-8	Depressive symptoms;
SARC	cis	rs12130219	0.500	rs4845737	chr1:152177539	G/A	cg09127314	chr1:152161683	NA	0.39	5.11	0.32	6.82e-7	Inflammatory skin disease;
SARC	trans	rs11098499	0.955	rs1511019	chr4:120166007	T/G	cg25214090	chr10:38739885	LOC399744	0.52	6.91	0.41	4.65e-11	Corneal astigmatism;
SARC	cis	rs11718455	0.921	rs11130020	chr3:44009459	C/T	cg21419209	chr3:44054225	NA	-0.46	-5.59	-0.34	6.38e-8	Coronary artery disease;
SARC	cis	rs2486288	0.656	rs11637838	chr15:45550657	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.45	-5.51	-0.34	9.44e-8	Glomerular filtration rate;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg01852244	chr16:47494711	PHKB;ITFG1	0.58	6.35	0.38	1.12e-9	Lung cancer in ever smokers;
SARC	cis	rs7084402	0.967	rs1658427	chr10:60331504	G/A	cg07615347	chr10:60278583	BICC1	0.57	8.41	0.48	4.23e-15	Refractive error;
SARC	cis	rs2075371	0.965	rs1862049	chr7:133978344	A/T	cg11752832	chr7:134001865	SLC35B4	0.58	7.6	0.45	7.27e-13	Mean platelet volume;
SARC	cis	rs36051895	0.659	rs4495487	chr9:5072798	T/C	cg02405213	chr9:5042618	JAK2	-0.44	-5.08	-0.32	7.75e-7	Pediatric autoimmune diseases;
SARC	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg05368731	chr17:41323189	NBR1	0.79	9.83	0.54	2.62e-19	Menopause (age at onset);
SARC	cis	rs9921222	1.000	rs9921222	chr16:375782	A/G	cg12437481	chr16:420112	MRPL28	0.47	7.7	0.45	3.82e-13	Bone mineral density (spine);Bone mineral density;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg15319206	chr6:159065938	DYNLT1	-0.51	-6.43	-0.39	7.24e-10	Height;
SARC	cis	rs79149102	0.649	rs3743486	chr15:75113958	C/G	cg17294928	chr15:75287854	SCAMP5	-0.82	-4.95	-0.31	1.42e-6	Lung cancer;
SARC	cis	rs6545883	0.860	rs13023037	chr2:61620989	C/T	cg15711740	chr2:61764176	XPO1	0.42	5.05	0.31	8.78e-7	Tuberculosis;
SARC	cis	rs4906332	1.000	rs8004780	chr14:103853360	A/C	cg26031613	chr14:104095156	KLC1	-0.55	-6.53	-0.39	4.17e-10	Coronary artery disease;
SARC	cis	rs870825	0.616	rs35533356	chr4:185639134	A/G	cg04058563	chr4:185651563	MLF1IP	0.83	11.51	0.6	1.47e-24	Blood protein levels;
SARC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg10862848	chr6:42927986	GNMT	-0.45	-7.51	-0.44	1.22e-12	Alzheimer's disease in APOE e4+ carriers;
SARC	trans	rs12486865	0.500	rs7619048	chr3:99927237	G/A	cg21934772	chr13:110198949	NA	0.5	7.16	0.42	1.06e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs12369635	1.000	rs11060121	chr12:129564206	C/T	cg01909103	chr12:129572610	TMEM132D	-0.65	-6.34	-0.38	1.2e-9	Schizophrenia (inflammation and infection response interaction);
SARC	cis	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg20965017	chr5:231967	SDHA	-0.55	-5.26	-0.33	3.23e-7	Breast cancer;
SARC	cis	rs5167	0.504	rs4803781	chr19:45459671	C/T	cg10169327	chr19:45448959	APOC2	0.34	5.75	0.35	2.72e-8	Blood protein levels;
SARC	cis	rs6088580	0.634	rs6058070	chr20:33103521	G/C	cg24642439	chr20:33292090	TP53INP2	0.66	8.68	0.49	6.79e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs72781680	1.000	rs72781654	chr2:24218099	T/C	cg08917208	chr2:24149416	ATAD2B	0.55	5.79	0.35	2.21e-8	Lymphocyte counts;
SARC	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.33	0.38	1.23e-9	Height;
SARC	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg05535760	chr7:792225	HEATR2	0.83	8.23	0.47	1.36e-14	Cerebrospinal P-tau181p levels;
SARC	cis	rs3126085	0.935	rs1552995	chr1:152171427	A/G	cg26876637	chr1:152193138	HRNR	0.48	5.51	0.34	9.32e-8	Atopic dermatitis;
SARC	cis	rs4148883	0.689	rs1800760	chr4:100065626	A/T	cg12011299	chr4:100065546	ADH4	0.39	7.25	0.43	6.16e-12	Alcohol dependence;
SARC	cis	rs4481887	0.888	rs12042602	chr1:248482053	C/T	cg01631408	chr1:248437212	OR2T33	-0.37	-4.73	-0.3	3.98e-6	Common traits (Other);
SARC	cis	rs13191362	1.000	rs13212608	chr6:163032128	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.57	5.48	0.34	1.09e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs7000551	0.725	rs2469756	chr8:22360423	G/A	cg12081754	chr8:22256438	SLC39A14	0.54	7.64	0.45	5.6e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs6672530	0.518	rs4653850	chr1:227737888	C/T	cg26340147	chr1:227730820	NA	0.33	4.74	0.3	3.79e-6	Hip circumference adjusted for BMI;
SARC	cis	rs9790314	0.687	rs62280331	chr3:160682092	C/A	cg04691961	chr3:161091175	C3orf57	0.58	7.63	0.45	6.1e-13	Morning vs. evening chronotype;
SARC	cis	rs963731	0.579	rs72909662	chr2:39335328	C/T	cg04010122	chr2:39346883	SOS1	0.85	5.49	0.34	1.03e-7	Corticobasal degeneration;
SARC	cis	rs9486715	0.867	rs3849199	chr6:97049191	T/C	cg18709589	chr6:96969512	KIAA0776	-0.6	-7.48	-0.44	1.55e-12	Headache;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg01865825	chr16:850240	GNG13	0.62	6.47	0.39	5.69e-10	Lung cancer in ever smokers;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg04052832	chr13:111220199	NA	-0.59	-5.37	-0.33	1.86e-7	Obesity-related traits;
SARC	trans	rs61931739	0.500	rs11053198	chr12:34444013	G/C	cg26384229	chr12:38710491	ALG10B	0.84	12.56	0.64	5.71e-28	Morning vs. evening chronotype;
SARC	cis	rs7937682	0.883	rs12366001	chr11:111433916	A/G	cg09085632	chr11:111637200	PPP2R1B	0.88	12.68	0.64	2.22e-28	Primary sclerosing cholangitis;
SARC	cis	rs4481887	0.927	rs7521689	chr1:248435831	G/T	cg01631408	chr1:248437212	OR2T33	-0.45	-5.62	-0.35	5.33e-8	Common traits (Other);
SARC	cis	rs2370759	1.000	rs2225152	chr10:32574759	T/C	cg01819863	chr10:32635814	EPC1	1.02	9.93	0.55	1.37e-19	Sexual dysfunction (female);
SARC	cis	rs734999	0.572	rs4310388	chr1:2507415	G/T	cg00980319	chr1:2560884	MMEL1	-0.35	-4.8	-0.3	2.83e-6	Ulcerative colitis;
SARC	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.83	8.49	0.49	2.52e-15	Age-related macular degeneration (geographic atrophy);
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg17925329	chr14:105676908	BRF1	0.49	6.69	0.4	1.62e-10	Neuroticism;
SARC	cis	rs72945132	0.607	rs67767222	chr11:70121610	T/A	cg00319359	chr11:70116639	PPFIA1	0.68	6.37	0.39	1.01e-9	Coronary artery disease;
SARC	cis	rs568617	1.000	rs641018	chr11:65655393	G/C	cg26695010	chr11:65641043	EFEMP2	-0.49	-5.75	-0.35	2.82e-8	Crohn's disease;
SARC	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg18876405	chr7:65276391	NA	0.69	8.46	0.48	3e-15	Aortic root size;
SARC	cis	rs10463554	0.927	rs34825	chr5:102439318	T/C	cg23492399	chr5:102201601	PAM	-0.52	-5.72	-0.35	3.2e-8	Parkinson's disease;
SARC	cis	rs920590	0.721	rs67989257	chr8:19660278	G/A	cg03894339	chr8:19674705	INTS10	0.54	6.35	0.38	1.09e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs2985684	0.901	rs7146248	chr14:50112067	C/T	cg04989706	chr14:50066350	PPIL5	-0.59	-6.19	-0.38	2.74e-9	Carotid intima media thickness;
SARC	cis	rs4242434	0.927	rs3735901	chr8:22462374	T/C	cg03733263	chr8:22462867	KIAA1967	1.03	17.02	0.74	9.12e-43	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg11062466	chr8:58055876	NA	0.6	6.1	0.37	4.46e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1348850	0.632	rs13008833	chr2:178514439	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.48	5.57	0.34	6.88e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg11905131	chr22:24372483	LOC391322	-0.5	-5.62	-0.35	5.45e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs12545109	0.800	rs1440762	chr8:57410708	C/T	cg19413350	chr8:57351067	NA	-0.43	-5.36	-0.33	1.97e-7	Obesity-related traits;
SARC	cis	rs6963495	0.818	rs117887993	chr7:105193837	T/G	cg13798780	chr7:105162888	PUS7	0.57	5.23	0.32	3.86e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.08	22.63	0.83	9.78e-61	Chronic sinus infection;
SARC	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg03452623	chr4:187889614	NA	-0.76	-12.04	-0.62	2.83e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg15966229	chr18:44337664	ST8SIA5	-0.38	-5.03	-0.31	9.88e-7	Personality dimensions;
SARC	cis	rs9309473	0.519	rs4852951	chr2:73869796	C/G	cg20560298	chr2:73613845	ALMS1	0.51	6.9	0.41	4.74e-11	Metabolite levels;
SARC	cis	rs9611565	0.525	rs9611548	chr22:41704143	G/T	cg03806693	chr22:41940476	POLR3H	-0.74	-9.43	-0.53	4.34e-18	Vitiligo;
SARC	cis	rs12478296	1.000	rs55777943	chr2:243040686	T/C	cg06360820	chr2:242988706	NA	-0.61	-4.83	-0.3	2.49e-6	Obesity-related traits;
SARC	cis	rs7769051	0.803	rs12193474	chr6:133186168	T/C	cg07930552	chr6:133119739	C6orf192	0.86	6.61	0.4	2.6e-10	Type 2 diabetes nephropathy;
SARC	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg07636037	chr3:49044803	WDR6	1.0	17.57	0.75	1.37e-44	Parkinson's disease;
SARC	cis	rs9790314	1.000	rs6775627	chr3:160953609	A/G	cg04691961	chr3:161091175	C3orf57	-0.79	-11.72	-0.61	3.09e-25	Morning vs. evening chronotype;
SARC	cis	rs921968	0.541	rs4674310	chr2:219318078	T/C	cg02176678	chr2:219576539	TTLL4	-0.5	-7.57	-0.44	8.87e-13	Mean corpuscular hemoglobin concentration;
SARC	cis	rs10875746	0.903	rs11168418	chr12:48515754	C/A	cg27446233	chr12:48516484	PFKM	-0.41	-4.79	-0.3	2.92e-6	Longevity (90 years and older);
SARC	cis	rs7249142	0.562	rs10418053	chr19:19287164	A/G	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.24	4.94	0.31	1.49e-6	IgG glycosylation;
SARC	trans	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg00938859	chr5:1591904	SDHAP3	0.8	7.32	0.43	4.05e-12	Breast cancer;
SARC	cis	rs4588572	0.602	rs10059672	chr5:77673317	G/C	cg11547950	chr5:77652471	NA	0.41	4.92	0.31	1.66e-6	Triglycerides;
SARC	cis	rs73206853	0.764	rs970228	chr12:111070169	G/C	cg10860002	chr12:110842031	ANAPC7	0.59	5.08	0.32	7.77e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg22105103	chr4:187893119	NA	0.5	6.84	0.41	7.11e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.46	5.77	0.35	2.54e-8	Gut microbiome composition (summer);
SARC	cis	rs11608355	0.960	rs3742021	chr12:109883117	T/C	cg05360138	chr12:110035743	NA	0.42	4.78	0.3	3.14e-6	Neuroticism;
SARC	cis	rs2273669	0.667	rs7767882	chr6:109334971	C/A	cg05315195	chr6:109294784	ARMC2	-0.63	-5.7	-0.35	3.6e-8	Prostate cancer;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg02172857	chr6:80247368	LCA5	-0.48	-6.39	-0.39	8.72e-10	Thyroid stimulating hormone;
SARC	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg11366901	chr6:160182831	ACAT2	1.02	10.79	0.58	2.78e-22	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs2075371	0.796	rs35440439	chr7:134006094	C/T	cg20476274	chr7:133979776	SLC35B4	0.53	6.76	0.41	1.07e-10	Mean platelet volume;
SARC	cis	rs12142240	0.738	rs41293275	chr1:46806429	A/T	cg00530320	chr1:46809349	NSUN4	0.55	6.69	0.4	1.61e-10	Menopause (age at onset);
SARC	cis	rs1920116	0.778	rs16854453	chr3:169559234	G/A	cg08193579	chr3:169529701	LRRC34	0.39	4.73	0.3	3.81e-6	Glioma (high-grade);
SARC	cis	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg25894440	chr7:65020034	NA	-0.74	-5.55	-0.34	7.85e-8	Diabetic kidney disease;
SARC	cis	rs6087990	0.748	rs4911255	chr20:31357580	A/T	cg13636640	chr20:31349939	DNMT3B	0.79	12.51	0.63	8.28e-28	Ulcerative colitis;
SARC	cis	rs4800452	0.826	rs4800455	chr18:20748733	A/G	cg13313047	chr18:20735648	CABLES1	-0.42	-5.11	-0.32	6.69e-7	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
SARC	cis	rs9503598	0.644	rs9503593	chr6:3430787	T/C	cg00476032	chr6:3446245	SLC22A23	0.32	4.79	0.3	2.97e-6	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
SARC	cis	rs73206853	0.620	rs28720928	chr12:111126609	C/T	cg10860002	chr12:110842031	ANAPC7	0.58	4.96	0.31	1.38e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs6665290	0.904	rs7541033	chr1:227188371	C/A	cg10327440	chr1:227177885	CDC42BPA	-1.09	-25.24	-0.86	1.33e-68	Myeloid white cell count;
SARC	cis	rs2730245	0.527	rs842700	chr7:158697565	G/A	cg24397884	chr7:158709396	WDR60	1.11	9.86	0.54	2.1e-19	Height;
SARC	cis	rs1008375	1.000	rs917665	chr4:17668504	A/C	cg27347728	chr4:17578864	LAP3	-0.39	-4.74	-0.3	3.72e-6	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1843834	0.539	rs6749402	chr2:225443901	T/G	cg22509189	chr2:225307070	NA	-0.66	-8.05	-0.47	4.12e-14	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs2153535	0.606	rs11243253	chr6:8380193	T/C	cg23788917	chr6:8435910	SLC35B3	-0.66	-8.51	-0.49	2.09e-15	Motion sickness;
SARC	cis	rs1451375	0.617	rs9942686	chr7:50596381	G/A	cg18232548	chr7:50535776	DDC	0.49	5.02	0.31	1.01e-6	Malaria;
SARC	cis	rs2235642	0.821	rs2281236	chr16:1603576	G/A	cg09065629	chr16:1709722	CRAMP1L	0.37	5.1	0.32	7.14e-7	Coronary artery disease;
SARC	cis	rs4319547	0.915	rs7314638	chr12:122983460	A/G	cg23029597	chr12:123009494	RSRC2	-0.41	-5.13	-0.32	6.22e-7	Body mass index;
SARC	cis	rs10779751	1.000	rs1010447	chr1:11269796	A/G	cg08854313	chr1:11322531	MTOR	0.76	10.6	0.57	1.11e-21	Body mass index;
SARC	cis	rs796364	0.806	rs203769	chr2:200900866	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.73	-6.16	-0.37	3.17e-9	Schizophrenia;
SARC	cis	rs9815354	1.000	rs1716644	chr3:41968028	A/G	cg03022575	chr3:42003672	ULK4	-0.61	-5.67	-0.35	4.25e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs1865760	0.622	rs9295685	chr6:26071725	G/C	cg17691542	chr6:26056736	HIST1H1C	0.52	6.35	0.38	1.09e-9	Height;
SARC	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-5.96	-0.36	9.37e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs67460515	0.563	rs11717272	chr3:160810355	A/G	cg17135325	chr3:160939158	NMD3	0.63	7.58	0.44	8.39e-13	Parkinson's disease;
SARC	cis	rs244731	0.959	rs3105419	chr5:176551396	G/C	cg17509989	chr5:176798049	RGS14	0.68	8.23	0.47	1.37e-14	Urate levels in lean individuals;
SARC	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg27121462	chr16:89883253	FANCA	-0.52	-7.12	-0.42	1.33e-11	Vitiligo;
SARC	cis	rs1783925	1.000	rs1615640	chr11:125308076	C/G	cg03464685	chr11:125439445	EI24	0.43	5.03	0.31	9.97e-7	Formal thought disorder in schizophrenia;
SARC	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg11987759	chr7:65425863	GUSB	-0.47	-6.27	-0.38	1.7e-9	Aortic root size;
SARC	cis	rs899997	0.906	rs62010552	chr15:78987686	T/C	cg04896959	chr15:78267971	NA	-0.5	-6.08	-0.37	4.77e-9	Coronary artery disease or large artery stroke;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg01221484	chr19:58920079	ZNF584	0.51	6.94	0.41	3.85e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs2425143	1.000	rs6060642	chr20:34449840	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-5.96	-0.36	9.2e-9	Blood protein levels;
SARC	cis	rs7582180	0.790	rs4851288	chr2:100920451	T/C	cg14675211	chr2:100938903	LONRF2	0.52	7.51	0.44	1.22e-12	Intelligence (multi-trait analysis);
SARC	cis	rs76419734	1.000	rs11726094	chr4:106773387	G/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.77	5.19	0.32	4.53e-7	Post bronchodilator FEV1;
SARC	cis	rs6545883	0.894	rs2694643	chr2:61604383	A/G	cg15711740	chr2:61764176	XPO1	-0.4	-4.81	-0.3	2.68e-6	Tuberculosis;
SARC	cis	rs75229567	0.618	rs11177848	chr12:70180892	A/G	cg10114359	chr12:70132523	RAB3IP	1.24	8.2	0.47	1.65e-14	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
SARC	cis	rs11583043	0.958	rs11583674	chr1:101396560	C/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.44	5.39	0.33	1.69e-7	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs17376456	0.569	rs7736892	chr5:93205597	G/A	cg25358565	chr5:93447407	FAM172A	-0.95	-10.7	-0.57	5.21e-22	Diabetic retinopathy;
SARC	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg12064134	chr16:90016061	DEF8	0.56	4.84	0.3	2.35e-6	Skin colour saturation;
SARC	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg21782813	chr7:2030301	MAD1L1	0.4	6.23	0.38	2.12e-9	Bipolar disorder and schizophrenia;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg12799086	chr7:99724835	MBLAC1	-0.81	-6.93	-0.41	4.11e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs13095912	1.000	rs6784948	chr3:185342787	C/T	cg11274856	chr3:185301563	NA	0.35	4.79	0.3	2.91e-6	Systolic blood pressure;
SARC	cis	rs920590	0.643	rs3855754	chr8:19659499	C/G	cg03894339	chr8:19674705	INTS10	0.44	5.33	0.33	2.26e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs10782582	0.609	rs2881785	chr1:76318096	T/C	cg10523679	chr1:76189770	ACADM	-0.42	-5.17	-0.32	5.07e-7	Daytime sleep phenotypes;
SARC	cis	rs2486288	0.656	rs1706770	chr15:45575062	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.53	-6.45	-0.39	6.44e-10	Glomerular filtration rate;
SARC	cis	rs735396	1.000	rs1169313	chr12:121442670	C/T	cg02403541	chr12:121454288	C12orf43	-0.69	-9.15	-0.51	2.89e-17	N-glycan levels;
SARC	cis	rs6964587	0.621	rs38798	chr7:92044539	C/A	cg17063962	chr7:91808500	NA	-0.73	-9.84	-0.54	2.51e-19	Breast cancer;
SARC	cis	rs5760092	0.755	rs11090298	chr22:24262061	G/A	cg16132339	chr22:24313637	DDTL;DDT	-0.41	-4.87	-0.3	2.07e-6	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs1865760	0.593	rs9393676	chr6:25936944	G/A	cg17691542	chr6:26056736	HIST1H1C	0.58	7.29	0.43	4.71e-12	Height;
SARC	cis	rs11122272	0.637	rs2808593	chr1:231524228	G/T	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg03351412	chr1:154909251	PMVK	0.59	7.45	0.44	1.77e-12	Prostate cancer;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg12632569	chr7:107686951	LAMB4	0.48	6.43	0.39	7.14e-10	Thyroid stimulating hormone;
SARC	cis	rs10870270	0.912	rs7079991	chr10:133736130	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.8	-10.37	-0.56	5.78e-21	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.69	8.62	0.49	1.06e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs7980799	0.682	rs10844612	chr12:33603676	T/C	cg26384229	chr12:38710491	ALG10B	-0.61	-7.6	-0.45	7.38e-13	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs9346455	0.881	rs9354993	chr6:72030526	A/G	cg27238071	chr6:71998145	OGFRL1	0.58	4.82	0.3	2.56e-6	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
SARC	cis	rs986417	0.901	rs8020867	chr14:61093246	A/T	cg27398547	chr14:60952738	C14orf39	0.72	6.69	0.4	1.68e-10	Gut microbiota (bacterial taxa);
SARC	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.54e-6	Parkinson's disease;
SARC	cis	rs55879323	1	rs55879323	chr1:152168740	C/T	cg26320663	chr1:152161521	NA	0.44	5.41	0.33	1.6e-7	Inflammatory skin disease;
SARC	cis	rs7937682	0.632	rs11214015	chr11:111719417	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.79	-10.66	-0.57	7.38e-22	Primary sclerosing cholangitis;
SARC	cis	rs7264396	0.690	rs2425164	chr20:34434916	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.51	5.02	0.31	1.02e-6	Total cholesterol levels;
SARC	cis	rs728616	0.867	rs7893241	chr10:81954338	C/T	cg05935833	chr10:81318306	SFTPA2	-0.55	-5.06	-0.31	8.36e-7	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg11062466	chr8:58055876	NA	0.6	5.71	0.35	3.44e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs12701220	0.803	rs12701432	chr7:1052453	C/T	cg02733842	chr7:1102375	C7orf50	-0.59	-7.03	-0.42	2.23e-11	Bronchopulmonary dysplasia;
SARC	cis	rs6700896	0.931	rs12043644	chr1:66147348	A/G	cg04111102	chr1:66153794	NA	0.37	5.65	0.35	4.78e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs870825	0.929	rs1405940	chr4:185591481	A/G	cg04058563	chr4:185651563	MLF1IP	0.81	9.28	0.52	1.2e-17	Blood protein levels;
SARC	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg04277193	chr17:41438351	NA	0.44	4.82	0.3	2.59e-6	Menopause (age at onset);
SARC	cis	rs3749237	0.595	rs4955412	chr3:49418168	A/C	cg02487422	chr3:49467188	NICN1	0.5	6.51	0.39	4.57e-10	Resting heart rate;
SARC	cis	rs35160687	0.901	rs12714179	chr2:86514958	T/C	cg10973622	chr2:86423274	IMMT	0.38	4.9	0.31	1.77e-6	Night sleep phenotypes;
SARC	cis	rs10484885	0.824	rs72921954	chr6:90586656	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.61	-5.23	-0.32	3.71e-7	QRS interval (sulfonylurea treatment interaction);
SARC	cis	rs1018836	0.923	rs4735268	chr8:91629715	C/T	cg16814680	chr8:91681699	NA	-0.8	-12.73	-0.64	1.6e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs2180341	1.000	rs6569477	chr6:127589302	T/A	cg17762328	chr6:126965162	NA	-0.43	-4.86	-0.3	2.18e-6	Breast cancer;
SARC	cis	rs858239	0.665	rs858305	chr7:23242830	C/G	cg23682824	chr7:23144976	KLHL7	-0.63	-8.34	-0.48	6.55e-15	Cerebrospinal fluid biomarker levels;
SARC	cis	rs524281	0.814	rs10896098	chr11:65968416	G/A	cg14036092	chr11:66035641	RAB1B	-0.49	-5.18	-0.32	4.9e-7	Electroencephalogram traits;
SARC	cis	rs7223966	0.960	rs8082651	chr17:61675292	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	5.92	0.36	1.17e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg26354017	chr1:205819088	PM20D1	0.85	13.15	0.65	6.59e-30	Menarche (age at onset);
SARC	cis	rs34172651	0.876	rs1862451	chr16:24803620	A/G	cg04756594	chr16:24857601	SLC5A11	0.38	5.93	0.36	1.09e-8	Intelligence (multi-trait analysis);
SARC	cis	rs3617	0.625	rs7652667	chr3:52866535	C/A	cg18404041	chr3:52824283	ITIH1	0.37	5.42	0.33	1.5e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg03185022	chr7:2884158	GNA12	0.45	4.88	0.3	1.99e-6	Height;
SARC	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg16680214	chr1:154839983	KCNN3	0.35	5.64	0.35	4.8e-8	Prostate cancer;
SARC	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	27.17	0.87	3.61e-74	Chronic sinus infection;
SARC	cis	rs897080	0.515	rs1067362	chr2:44660112	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	5.82	0.36	1.89e-8	Height;
SARC	cis	rs11792861	0.926	rs72607174	chr9:111899132	A/T	cg13535736	chr9:111863775	C9orf5	-0.4	-4.87	-0.3	2.09e-6	Menarche (age at onset);
SARC	cis	rs10463316	0.779	rs6896444	chr5:150777357	T/G	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.32	-0.33	2.46e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs17401966	0.838	rs12139981	chr1:10390696	T/C	cg15208524	chr1:10270712	KIF1B	0.48	5.77	0.35	2.49e-8	Hepatocellular carcinoma;
SARC	cis	rs72945132	0.882	rs56176527	chr11:70162513	A/G	cg00319359	chr11:70116639	PPFIA1	0.67	6.08	0.37	4.85e-9	Coronary artery disease;
SARC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-4.93	-0.31	1.59e-6	Total body bone mineral density;
SARC	cis	rs870825	0.616	rs7667449	chr4:185641711	T/C	cg04058563	chr4:185651563	MLF1IP	0.83	11.69	0.61	3.86e-25	Blood protein levels;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg00866556	chr1:29449356	TMEM200B	0.45	6.31	0.38	1.39e-9	Schizophrenia;
SARC	cis	rs12887734	0.524	rs4906364	chr14:104214342	C/G	cg26031613	chr14:104095156	KLC1	-0.48	-5.55	-0.34	7.72e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	cis	rs17376456	0.935	rs13156002	chr5:93508931	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.49	0.34	1.03e-7	Diabetic retinopathy;
SARC	cis	rs7224737	1.000	rs9903204	chr17:40288062	G/A	cg20291162	chr17:40259547	DHX58	-0.33	-4.79	-0.3	2.95e-6	Fibrinogen levels;
SARC	cis	rs11098499	0.954	rs13133522	chr4:120324424	A/T	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs4728302	0.559	rs7779409	chr7:133158475	A/G	cg10665199	chr7:133106180	EXOC4	0.41	5.22	0.32	4.05e-7	Intelligence;Intelligence (multi-trait analysis);
SARC	cis	rs9467711	0.932	rs11966360	chr6:26316982	A/G	cg12826209	chr6:26865740	GUSBL1	0.55	4.85	0.3	2.24e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs941408	1.000	rs1736176	chr19:2790394	G/A	cg06609049	chr19:2785107	THOP1	0.81	10.32	0.56	8.29e-21	Total cholesterol levels;
SARC	cis	rs4891159	0.790	rs10514217	chr18:74144939	A/G	cg24786174	chr18:74118243	ZNF516	-0.5	-6.16	-0.37	3.18e-9	Longevity;
SARC	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg04772025	chr11:68637568	NA	0.48	5.81	0.36	1.99e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs67311347	0.544	rs12635762	chr3:40332759	C/T	cg09455208	chr3:40491958	NA	-0.3	-4.96	-0.31	1.34e-6	Renal cell carcinoma;
SARC	cis	rs79149102	0.579	rs61166993	chr15:75306644	C/A	cg17294928	chr15:75287854	SCAMP5	-1.01	-9.31	-0.52	1e-17	Lung cancer;
SARC	cis	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg05623727	chr3:50126028	RBM5	-0.33	-4.99	-0.31	1.21e-6	Intelligence (multi-trait analysis);
SARC	cis	rs4478037	0.822	rs9875140	chr3:33117068	T/A	cg19404215	chr3:33155277	CRTAP	0.77	6.06	0.37	5.3e-9	Major depressive disorder;
SARC	cis	rs6570726	0.935	rs408723	chr6:145838535	A/G	cg05220968	chr6:146057943	EPM2A	-0.29	-4.99	-0.31	1.19e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs13191362	1.000	rs13193282	chr6:163015442	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.57	5.47	0.34	1.16e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg27170947	chr2:26402098	FAM59B	-0.37	-4.8	-0.3	2.79e-6	Gut microbiome composition (summer);
SARC	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg18876405	chr7:65276391	NA	0.49	6.07	0.37	5.21e-9	Aortic root size;
SARC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg10295955	chr4:187884368	NA	1.03	18.88	0.78	7.43e-49	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs17270561	0.609	rs1165211	chr6:25800922	T/C	cg17691542	chr6:26056736	HIST1H1C	0.45	5.49	0.34	1.07e-7	Iron status biomarkers;
SARC	cis	rs2273669	0.504	rs1539596	chr6:109408428	C/G	cg05315195	chr6:109294784	ARMC2	-0.6	-5.02	-0.31	1.01e-6	Prostate cancer;
SARC	cis	rs751728	0.638	rs4713686	chr6:33787506	C/T	cg25922239	chr6:33757077	LEMD2	0.57	6.55	0.39	3.74e-10	Crohn's disease;
SARC	cis	rs2777491	0.874	rs28716108	chr15:41655523	G/C	cg01768344	chr15:41576519	LOC729082	0.45	4.72	0.3	4.07e-6	Ulcerative colitis;
SARC	cis	rs4595586	0.545	rs1400284	chr12:39400419	G/A	cg26384229	chr12:38710491	ALG10B	0.5	6.12	0.37	3.98e-9	Morning vs. evening chronotype;
SARC	cis	rs473651	0.935	rs472357	chr2:239355454	A/G	cg18131467	chr2:239335373	ASB1	-0.96	-16.5	-0.73	4.72e-41	Multiple system atrophy;
SARC	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg21724239	chr8:58056113	NA	0.58	5.75	0.35	2.75e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.66	-0.4	1.89e-10	Joint mobility (Beighton score);
SARC	cis	rs9399137	0.507	rs6904897	chr6:135382980	T/G	cg24558204	chr6:135376177	HBS1L	0.64	8.26	0.48	1.11e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg16479474	chr6:28041457	NA	0.37	5.25	0.33	3.45e-7	Parkinson's disease;
SARC	cis	rs11608355	0.521	rs7976839	chr12:109830534	C/A	cg19025524	chr12:109796872	NA	-0.42	-6.34	-0.38	1.18e-9	Neuroticism;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg23898175	chr11:118796425	NA	-0.83	-6.8	-0.41	8.75e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	5.77	0.35	2.56e-8	Bipolar disorder;
SARC	cis	rs5769765	0.740	rs2103932	chr22:50272515	A/G	cg03033257	chr22:50311977	ALG12;CRELD2	-0.56	-5.8	-0.36	2.15e-8	Schizophrenia;
SARC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg26338869	chr17:61819248	STRADA	0.69	9.4	0.52	5.38e-18	Prudent dietary pattern;
SARC	cis	rs9457247	0.967	rs2769346	chr6:167370999	A/G	cg07741184	chr6:167504864	NA	-0.3	-5.62	-0.35	5.44e-8	Crohn's disease;
SARC	cis	rs10791097	0.935	rs4601795	chr11:130729430	T/C	cg12179176	chr11:130786555	SNX19	0.61	8.18	0.47	1.83e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg24642844	chr7:1081250	C7orf50	-0.59	-6.25	-0.38	1.98e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	trans	rs11098499	1.000	rs35643470	chr4:120184948	T/C	cg25214090	chr10:38739885	LOC399744	0.53	7.05	0.42	1.98e-11	Corneal astigmatism;
SARC	cis	rs1707322	0.963	rs12076580	chr1:46258159	G/A	cg06784218	chr1:46089804	CCDC17	0.37	6.45	0.39	6.38e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4481887	1.000	rs10888352	chr1:248451965	G/A	cg00666640	chr1:248458726	OR2T12	0.35	5.73	0.35	3.14e-8	Common traits (Other);
SARC	cis	rs6665290	0.870	rs1045289	chr1:227178713	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.07	-25.78	-0.86	3.44e-70	Myeloid white cell count;
SARC	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.75	10.93	0.58	1.02e-22	Personality dimensions;
SARC	cis	rs4919044	0.599	rs10882124	chr10:94665826	A/G	cg05127821	chr10:94822908	CYP26C1	-0.74	-6.03	-0.37	6.22e-9	Coronary artery disease;
SARC	cis	rs6687430	0.543	rs7512495	chr1:10631237	C/T	cg17425144	chr1:10567563	PEX14	0.35	5.15	0.32	5.65e-7	Hand grip strength;
SARC	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg06618935	chr21:46677482	NA	-0.43	-5.56	-0.34	7.38e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs986417	0.818	rs10142842	chr14:61085205	C/T	cg27398547	chr14:60952738	C14orf39	-0.75	-7.11	-0.42	1.43e-11	Gut microbiota (bacterial taxa);
SARC	cis	rs9513627	1.000	rs4294655	chr13:100216696	A/G	cg25919922	chr13:100150906	NA	0.65	4.74	0.3	3.75e-6	Obesity-related traits;
SARC	cis	rs11098499	0.865	rs28634456	chr4:120375778	A/G	cg24375607	chr4:120327624	NA	0.39	4.73	0.3	3.96e-6	Corneal astigmatism;
SARC	cis	rs12142240	0.698	rs72677596	chr1:46833930	C/T	cg14993813	chr1:46806288	NSUN4	-0.51	-5.2	-0.32	4.45e-7	Menopause (age at onset);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg15968925	chr6:97671391	MIR548H3;C6orf167	0.45	6.43	0.39	7.13e-10	Thyroid stimulating hormone;
SARC	cis	rs6500395	0.962	rs7499213	chr16:48680597	T/C	cg04672837	chr16:48644449	N4BP1	0.43	5.73	0.35	3.16e-8	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs7729447	0.776	rs58529247	chr5:32693889	C/T	cg16267343	chr5:32710456	NPR3	0.65	8.59	0.49	1.24e-15	Blood pressure;
SARC	trans	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg00262122	chr8:11665843	FDFT1	0.5	6.47	0.39	5.65e-10	Neuroticism;
SARC	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg21724239	chr8:58056113	NA	0.45	4.88	0.3	1.99e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs9815354	0.761	rs57638657	chr3:41809238	G/C	cg03022575	chr3:42003672	ULK4	0.72	5.99	0.37	7.83e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2075371	0.932	rs2544215	chr7:133987896	T/C	cg20476274	chr7:133979776	SLC35B4	0.62	8.41	0.48	4.17e-15	Mean platelet volume;
SARC	cis	rs240764	0.817	rs239204	chr6:101135580	T/C	cg09795085	chr6:101329169	ASCC3	0.45	5.76	0.35	2.58e-8	Neuroticism;
SARC	cis	rs7582180	0.614	rs1530031	chr2:101009326	T/C	cg14675211	chr2:100938903	LONRF2	0.53	8.03	0.47	4.93e-14	Intelligence (multi-trait analysis);
SARC	trans	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg00938859	chr5:1591904	SDHAP3	0.69	7.04	0.42	2.16e-11	Breast cancer;
SARC	cis	rs9796	0.870	rs3986311	chr15:41264339	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.42	-5.8	-0.36	2.17e-8	Menopause (age at onset);
SARC	cis	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg18876405	chr7:65276391	NA	0.67	7.78	0.45	2.35e-13	Aortic root size;
SARC	cis	rs34779708	0.931	rs11010125	chr10:35502953	A/G	cg03585969	chr10:35415529	CREM	0.38	4.79	0.3	3e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs9788721	0.592	rs28564957	chr15:78906107	C/A	cg24631222	chr15:78858424	CHRNA5	0.4	5.27	0.33	3.05e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs36051895	0.623	rs6476952	chr9:5236924	T/C	cg02405213	chr9:5042618	JAK2	-0.42	-4.94	-0.31	1.47e-6	Pediatric autoimmune diseases;
SARC	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg13206674	chr6:150067644	NUP43	0.42	5.41	0.33	1.59e-7	Lung cancer;
SARC	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.56	5.46	0.34	1.24e-7	Lung function (FEV1/FVC);
SARC	cis	rs9815354	0.951	rs9868066	chr3:41794161	T/A	cg03022575	chr3:42003672	ULK4	0.59	5.69	0.35	3.85e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg15448220	chr1:150897856	SETDB1	0.46	6.02	0.37	6.66e-9	Tonsillectomy;
SARC	cis	rs2075371	0.933	rs2244548	chr7:133986234	A/G	cg00033643	chr7:134001901	SLC35B4	0.4	4.85	0.3	2.25e-6	Mean platelet volume;
SARC	cis	rs9354308	0.809	rs9345693	chr6:66550984	T/C	cg07460842	chr6:66804631	NA	-0.42	-4.84	-0.3	2.36e-6	Metabolite levels;
SARC	cis	rs4742903	0.509	rs4743697	chr9:106959800	G/C	cg14250997	chr9:106856677	SMC2	0.39	4.87	0.3	2.03e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs7927771	0.864	rs3781627	chr11:47441472	T/A	cg20135002	chr11:47629003	NA	0.3	4.78	0.3	3.07e-6	Subjective well-being;
SARC	cis	rs60871478	0.735	rs62432241	chr7:795360	G/A	cg05535760	chr7:792225	HEATR2	0.81	7.07	0.42	1.77e-11	Cerebrospinal P-tau181p levels;
SARC	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg00149659	chr3:10157352	C3orf10	0.66	6.6	0.4	2.82e-10	Alzheimer's disease;
SARC	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	10.04	0.55	6.12e-20	Platelet count;
SARC	cis	rs6998277	0.830	rs12543046	chr8:103603809	A/G	cg10187029	chr8:103597600	NA	-0.87	-12.32	-0.63	3.52e-27	Migraine;
SARC	cis	rs7766436	0.813	rs7773580	chr6:22587114	C/T	cg13666174	chr6:22585274	NA	-0.61	-7.82	-0.46	1.85e-13	Coronary artery disease;
SARC	cis	rs892961	0.932	rs7224442	chr17:75413439	A/G	cg05865280	chr17:75406074	SEPT9	0.57	8.47	0.48	2.87e-15	Airflow obstruction;
SARC	cis	rs1185460	0.967	rs2509121	chr11:118928253	C/T	cg23280166	chr11:118938394	VPS11	0.78	11.41	0.6	2.96e-24	Coronary artery disease;
SARC	cis	rs3008870	1.000	rs3008871	chr1:67419089	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.93	-11.07	-0.59	3.61e-23	Lymphocyte percentage of white cells;
SARC	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg16405210	chr4:1374714	KIAA1530	-0.49	-5.74	-0.35	2.86e-8	Obesity-related traits;
SARC	cis	rs2933343	1.000	rs1680784	chr3:128644458	A/G	cg25356066	chr3:128598488	ACAD9	0.62	6.96	0.41	3.44e-11	IgG glycosylation;
SARC	cis	rs1401999	1.000	rs6767013	chr3:183680102	G/A	cg01324343	chr3:183735012	ABCC5	0.67	13.43	0.66	7.75e-31	Anterior chamber depth;
SARC	cis	rs67460515	0.892	rs7610985	chr3:161062848	G/A	cg04691961	chr3:161091175	C3orf57	-0.51	-6.32	-0.38	1.34e-9	Parkinson's disease;
SARC	cis	rs7520050	0.931	rs6698247	chr1:46371486	C/T	cg24296786	chr1:45957014	TESK2	0.38	4.82	0.3	2.54e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs7959452	0.684	rs11177615	chr12:69754189	G/A	cg20891283	chr12:69753455	YEATS4	0.54	7.32	0.43	4.03e-12	Blood protein levels;
SARC	cis	rs2070997	0.592	rs7858778	chr9:133679656	A/G	cg11464064	chr9:133710261	ABL1	0.53	4.82	0.3	2.54e-6	Response to amphetamines;
SARC	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.63e-10	Life satisfaction;
SARC	cis	rs17666538	1.000	rs61122136	chr8:585027	G/C	cg02524346	chr8:600233	NA	-0.94	-7.06	-0.42	1.89e-11	IgG glycosylation;
SARC	cis	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg08975724	chr8:8085496	FLJ10661	0.61	7.98	0.46	6.69e-14	Mood instability;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg06894723	chr13:110398142	NA	0.57	4.72	0.3	4.06e-6	Obesity-related traits;
SARC	cis	rs10463316	0.894	rs10042030	chr5:150768028	T/C	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.27	-0.33	3.06e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg09263875	chr16:632152	PIGQ	0.54	8.23	0.47	1.31e-14	Height;
SARC	cis	rs7914558	1.000	rs7094843	chr10:104806654	A/C	cg04362960	chr10:104952993	NT5C2	0.42	5.08	0.32	7.7300000000000005e-07	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs9828933	0.678	rs704366	chr3:63871648	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	0.56	5.2	0.32	4.28e-7	Type 2 diabetes;
SARC	cis	rs10492096	1.000	rs11064210	chr12:6576721	C/T	cg13857086	chr12:6580257	VAMP1	0.76	7.77	0.45	2.46e-13	Hip geometry;
SARC	cis	rs1797885	0.510	rs2442820	chr3:12599196	G/C	cg05775895	chr3:12838266	CAND2	0.36	4.72	0.3	4e-6	Immature fraction of reticulocytes;
SARC	cis	rs9916302	0.904	rs4794813	chr17:37670994	A/T	cg07936489	chr17:37558343	FBXL20	-0.69	-9.07	-0.51	5.16e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs6426558	0.621	rs7521639	chr1:227223736	T/C	cg10327440	chr1:227177885	CDC42BPA	0.67	9.57	0.53	1.66e-18	Neutrophil percentage of white cells;
SARC	cis	rs6679356	0.865	rs17129794	chr1:67794918	A/C	cg09018107	chr1:67798929	IL12RB2	0.36	4.78	0.3	3.12e-6	Primary biliary cholangitis;
SARC	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg13206674	chr6:150067644	NUP43	0.43	5.23	0.32	3.81e-7	Lung cancer;
SARC	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg05896524	chr21:47604654	C21orf56	0.4	4.83	0.3	2.45e-6	Testicular germ cell tumor;
SARC	cis	rs9309473	1.000	rs7580825	chr2:73635148	G/A	cg20560298	chr2:73613845	ALMS1	-0.51	-6.15	-0.37	3.3e-9	Metabolite levels;
SARC	cis	rs9790314	0.846	rs4856738	chr3:160986637	C/G	cg03342759	chr3:160939853	NMD3	-0.71	-9.5	-0.53	2.6e-18	Morning vs. evening chronotype;
SARC	cis	rs950027	0.549	rs12909409	chr15:45608582	T/G	cg21132104	chr15:45694354	SPATA5L1	-0.51	-6.33	-0.38	1.26e-9	Response to fenofibrate (adiponectin levels);
SARC	cis	rs2594989	0.733	rs9876898	chr3:11567961	T/C	cg00170343	chr3:11313890	ATG7	-0.6	-6.81	-0.41	8e-11	Circulating chemerin levels;
SARC	cis	rs7582180	0.638	rs9973536	chr2:100942243	C/T	cg14675211	chr2:100938903	LONRF2	0.47	6.77	0.41	1.01e-10	Intelligence (multi-trait analysis);
SARC	cis	rs17001868	0.568	rs2280790	chr22:40745181	T/C	cg07138101	chr22:40742427	ADSL	0.56	6.02	0.37	6.77e-9	Mammographic density (dense area);
SARC	cis	rs7312774	0.618	rs4964500	chr12:107320788	T/C	cg16260113	chr12:107380972	MTERFD3	0.96	7.56	0.44	8.96e-13	Severe influenza A (H1N1) infection;
SARC	cis	rs11864453	0.786	rs1050362	chr16:72130815	C/A	cg01557791	chr16:72042693	DHODH	-0.65	-9.09	-0.51	4.3e-17	Fibrinogen levels;
SARC	cis	rs9486719	1.000	rs11153023	chr6:96968525	C/T	cg06623918	chr6:96969491	KIAA0776	-0.71	-7.61	-0.45	6.91e-13	Migraine;Coronary artery disease;
SARC	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg24209194	chr3:40518798	ZNF619	0.67	8.13	0.47	2.49e-14	Renal cell carcinoma;
SARC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg15242686	chr22:24348715	GSTTP1	-0.42	-5.34	-0.33	2.21e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9796	0.561	rs7173086	chr15:41509288	A/T	cg18705301	chr15:41695430	NDUFAF1	-0.54	-7.65	-0.45	5.17e-13	Menopause (age at onset);
SARC	cis	rs4713675	0.565	rs9394161	chr6:33669793	G/C	cg15676125	chr6:33679581	C6orf125	0.52	6.35	0.38	1.12e-9	Plateletcrit;
SARC	cis	rs1468333	0.694	rs7719684	chr5:137614085	C/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.78	10.58	0.57	1.28e-21	Resting heart rate;
SARC	cis	rs7044106	0.791	rs10985004	chr9:123484937	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	7.12	0.42	1.35e-11	Hip circumference adjusted for BMI;
SARC	cis	rs7772486	0.720	rs991507	chr6:146023609	G/A	cg05347473	chr6:146136440	FBXO30	-0.54	-7.5	-0.44	1.36e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg00933542	chr6:150070202	PCMT1	0.32	5.46	0.34	1.23e-7	Lung cancer;
SARC	cis	rs9910055	0.529	rs368328	chr17:42170289	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	-0.48	-5.6	-0.34	6.06e-8	Total body bone mineral density;
SARC	cis	rs2645694	0.626	rs2703119	chr4:77823640	C/T	cg18351406	chr4:77819688	ANKRD56	0.44	6.25	0.38	1.9e-9	Emphysema distribution in smoking;
SARC	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg00149659	chr3:10157352	C3orf10	0.7	6.89	0.41	5.14e-11	Alzheimer's disease;
SARC	cis	rs6570726	0.791	rs365747	chr6:145866784	C/T	cg23711669	chr6:146136114	FBXO30	0.87	14.71	0.69	4.26e-35	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2735413	0.711	rs12921476	chr16:78079846	G/C	cg04733911	chr16:78082701	NA	-0.33	-5.08	-0.32	7.87e-7	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs6701037	1.000	rs6701037	chr1:175120079	G/T	cg00321850	chr1:175162397	KIAA0040	0.34	5.25	0.33	3.39e-7	Alcohol dependence;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14242958	chr11:101785693	KIAA1377;ANGPTL5	-0.52	-6.24	-0.38	2.04e-9	Fibrinogen levels;
SARC	cis	rs9372253	0.645	rs7753212	chr6:110700229	T/C	cg19196401	chr6:110721138	DDO	-0.39	-5.19	-0.32	4.59e-7	Platelet distribution width;
SARC	cis	rs6831352	0.879	rs67311928	chr4:100048999	A/G	cg12011299	chr4:100065546	ADH4	-0.34	-5.66	-0.35	4.44e-8	Alcohol dependence;
SARC	cis	rs240764	0.687	rs239248	chr6:101088315	T/A	cg09795085	chr6:101329169	ASCC3	0.45	5.77	0.35	2.52e-8	Neuroticism;
SARC	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg06028808	chr11:68637592	NA	0.48	6.23	0.38	2.15e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg21634602	chr5:112073570	APC	0.5	6.34	0.38	1.21e-9	Breast cancer;
SARC	cis	rs7824557	0.564	rs12547100	chr8:11242632	G/A	cg00262122	chr8:11665843	FDFT1	-0.41	-4.95	-0.31	1.4e-6	Retinal vascular caliber;
SARC	cis	rs75920871	0.588	rs6589587	chr11:116875338	T/G	cg01368799	chr11:117014884	PAFAH1B2	-0.48	-4.96	-0.31	1.34e-6	Subjective well-being;
SARC	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg07701084	chr6:150067640	NUP43	0.43	5.55	0.34	7.81e-8	Lung cancer;
SARC	cis	rs1707322	1.000	rs7539800	chr1:46262129	C/G	cg03146154	chr1:46216737	IPP	-0.51	-6.2	-0.38	2.52e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg21280719	chr6:42927975	GNMT	-0.46	-7.97	-0.46	7.21e-14	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs28386778	0.700	rs4968672	chr17:62011352	G/A	cg06873352	chr17:61820015	STRADA	-0.44	-5.46	-0.34	1.22e-7	Prudent dietary pattern;
SARC	cis	rs912057	0.797	rs1294430	chr6:6744698	A/G	cg06612196	chr6:6737390	NA	0.64	9.32	0.52	9.03e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs9868809	0.881	rs7620853	chr3:48666503	G/A	cg07636037	chr3:49044803	WDR6	-0.73	-6.64	-0.4	2.23e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs709400	0.628	rs2273700	chr14:103923414	A/G	cg12935359	chr14:103987150	CKB	-0.39	-5.79	-0.35	2.27e-8	Body mass index;
SARC	cis	rs1185460	1.000	rs1784305	chr11:118942048	G/A	cg23280166	chr11:118938394	VPS11	0.78	11.31	0.6	6.38e-24	Coronary artery disease;
SARC	cis	rs1983891	0.955	rs2025645	chr6:41519654	A/G	cg15051332	chr6:41514432	FOXP4	0.57	6.28	0.38	1.66e-9	Prostate cancer;
SARC	cis	rs4295623	0.531	rs2898295	chr8:11595969	C/T	cg25393495	chr8:12034317	NA	-0.3	-4.74	-0.3	3.7e-6	Morning vs. evening chronotype;
SARC	cis	rs12979813	1.000	rs17001244	chr19:11340057	C/T	cg00586551	chr19:11347513	LOC55908;DOCK6	-0.39	-4.76	-0.3	3.38e-6	HDL cholesterol;
SARC	cis	rs4481887	0.927	rs12044126	chr1:248481952	T/C	cg00666640	chr1:248458726	OR2T12	0.33	5.48	0.34	1.12e-7	Common traits (Other);
SARC	cis	rs9398803	0.698	rs1262550	chr6:127078110	A/C	cg19875578	chr6:126661172	C6orf173	-0.6	-8.29	-0.48	8.89e-15	Male-pattern baldness;
SARC	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg11987759	chr7:65425863	GUSB	-0.46	-6.14	-0.37	3.47e-9	Aortic root size;
SARC	cis	rs6598955	0.950	rs6700455	chr1:26545864	T/C	cg04990556	chr1:26633338	UBXN11	0.67	8.56	0.49	1.51e-15	Obesity-related traits;
SARC	cis	rs17270561	0.666	rs9356987	chr6:25739187	C/A	cg17691542	chr6:26056736	HIST1H1C	0.58	7.09	0.42	1.6e-11	Iron status biomarkers;
SARC	cis	rs2832191	0.716	rs7284006	chr21:30475186	T/A	cg24692254	chr21:30365293	RNF160	1.04	18.74	0.78	2.03e-48	Dental caries;
SARC	cis	rs11190604	0.943	rs7085261	chr10:102209811	G/A	cg07080220	chr10:102295463	HIF1AN	0.78	9.58	0.53	1.56e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg19223190	chr17:80058835	NA	0.4	5.47	0.34	1.15e-7	Life satisfaction;
SARC	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg05896524	chr21:47604654	C21orf56	0.4	4.86	0.3	2.18e-6	Testicular germ cell tumor;
SARC	cis	rs6696846	0.791	rs11240352	chr1:205051711	C/G	cg21643547	chr1:205240462	TMCC2	0.55	7.6	0.45	7.09e-13	Red blood cell count;
SARC	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg19723775	chr5:179050963	HNRNPH1	0.42	5.09	0.32	7.5e-7	Lung cancer;
SARC	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg19671926	chr4:122722719	EXOSC9	-0.6	-6.69	-0.4	1.64e-10	Type 2 diabetes;
SARC	cis	rs1200821	0.529	rs2505707	chr10:37801254	T/C	cg00409905	chr10:38381863	ZNF37A	-0.47	-6.45	-0.39	6.54e-10	Hemostatic factors and hematological phenotypes;
SARC	cis	rs7592578	0.679	rs62181019	chr2:191325414	A/G	cg10560079	chr2:191398806	TMEM194B	-0.73	-8.34	-0.48	6.35e-15	Diastolic blood pressure;
SARC	cis	rs36051895	0.632	rs10815166	chr9:5149920	T/G	cg02405213	chr9:5042618	JAK2	-0.47	-5.62	-0.35	5.56e-8	Pediatric autoimmune diseases;
SARC	trans	rs6044112	0.784	rs6080293	chr20:16516914	T/C	cg09086761	chr11:62369541	MTA2	-0.73	-6.39	-0.39	8.86e-10	Response to taxane treatment (docetaxel);
SARC	cis	rs1371867	0.846	rs1692006	chr8:101252462	C/T	cg11906718	chr8:101322791	RNF19A	-0.68	-8.7	-0.5	6.18e-16	Atrioventricular conduction;
SARC	cis	rs3087591	0.683	rs4368212	chr17:29639263	C/T	cg24425628	chr17:29625626	OMG;NF1	0.43	5.67	0.35	4.31e-8	Hip circumference;
SARC	cis	rs3781913	1.000	rs11235558	chr11:72373798	A/G	cg03713592	chr11:72463424	ARAP1	-0.41	-5.12	-0.32	6.34e-7	Rheumatoid arthritis;
SARC	cis	rs273218	1.000	rs156380	chr5:53378450	T/C	ch.5.1024479R	chr5:53302184	ARL15	0.67	7.16	0.42	1.03e-11	Migraine;
SARC	cis	rs6693567	0.545	rs5011187	chr1:150422761	T/C	cg09579323	chr1:150459698	TARS2	0.44	5.62	0.35	5.5e-8	Migraine;
SARC	cis	rs17270561	0.609	rs1185976	chr6:25822363	A/G	cg16482183	chr6:26056742	HIST1H1C	-0.52	-7.01	-0.42	2.5e-11	Iron status biomarkers;
SARC	cis	rs4423214	1.000	rs12790010	chr11:71170653	T/C	cg24826892	chr11:71159390	DHCR7	0.44	5.61	0.35	5.6e-8	Vitamin D levels;
SARC	cis	rs9814567	1.000	rs13089966	chr3:134279197	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	6.99	0.42	2.88e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs2303759	0.830	rs7257053	chr19:49894456	C/G	cg22590775	chr19:49891494	CCDC155	0.51	6.01	0.37	7.16e-9	Multiple sclerosis;
SARC	cis	rs9486715	1.000	rs9486715	chr6:97059769	A/C	cg18709589	chr6:96969512	KIAA0776	-0.63	-7.67	-0.45	4.71e-13	Headache;
SARC	cis	rs8141529	0.529	rs5752790	chr22:29152965	G/A	cg15103426	chr22:29168792	CCDC117	0.58	5.66	0.35	4.42e-8	Lymphocyte counts;
SARC	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg16606324	chr3:10149918	C3orf24	0.49	4.82	0.3	2.56e-6	Alzheimer's disease;
SARC	cis	rs17401966	0.931	rs4846205	chr1:10310214	A/T	cg15208524	chr1:10270712	KIF1B	0.49	5.84	0.36	1.75e-8	Hepatocellular carcinoma;
SARC	cis	rs9790314	0.750	rs6765270	chr3:160899974	A/G	cg03342759	chr3:160939853	NMD3	-0.49	-5.84	-0.36	1.71e-8	Morning vs. evening chronotype;
SARC	cis	rs2120243	0.533	rs34263112	chr3:157056048	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.42	5.6	0.34	6.1e-8	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs6714710	0.580	rs57681139	chr2:98454473	C/T	cg26665480	chr2:98280029	ACTR1B	0.49	6.63	0.4	2.34e-10	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs2273669	1.000	rs2273669	chr6:109285189	A/G	cg01304950	chr6:109416612	SESN1;C6orf182	0.54	4.74	0.3	3.75e-6	Prostate cancer;
SARC	cis	rs6840360	0.571	rs12648420	chr4:152543434	G/C	cg22705602	chr4:152727874	NA	-0.42	-6.62	-0.4	2.46e-10	Intelligence (multi-trait analysis);
SARC	cis	rs14403	0.874	rs884808	chr1:243653439	C/T	cg24496088	chr1:243650228	SDCCAG8	-0.44	-5.09	-0.32	7.35e-7	Schizophrenia;
SARC	cis	rs9467711	0.651	rs17586784	chr6:25935227	C/A	cg21479132	chr6:26055353	NA	0.83	5.14	0.32	5.94e-7	Autism spectrum disorder or schizophrenia;
SARC	cis	rs607987	0.836	rs4267043	chr11:30293769	T/A	cg06241208	chr11:30344200	C11orf46	0.42	5.14	0.32	5.9e-7	Body mass index;
SARC	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg21724239	chr8:58056113	NA	0.6	6.37	0.38	1.03e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7945705	0.818	rs2742552	chr11:8876852	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.45	-6.37	-0.38	1.02e-9	Hemoglobin concentration;
SARC	cis	rs4595586	0.545	rs7976609	chr12:39394317	T/C	cg26384229	chr12:38710491	ALG10B	0.5	6.12	0.37	3.98e-9	Morning vs. evening chronotype;
SARC	cis	rs9399135	0.967	rs2183709	chr6:135377091	C/T	cg24558204	chr6:135376177	HBS1L	0.47	6.3	0.38	1.44e-9	Red blood cell count;
SARC	cis	rs875971	0.867	rs13227219	chr7:65844062	T/A	cg11987759	chr7:65425863	GUSB	-0.46	-6.08	-0.37	4.95e-9	Aortic root size;
SARC	cis	rs523522	0.962	rs3893104	chr12:120903936	G/A	cg27279351	chr12:120934652	DYNLL1	0.7	8.37	0.48	5.29e-15	High light scatter reticulocyte count;
SARC	cis	rs3741404	0.574	rs638227	chr11:63871549	T/C	cg04317338	chr11:64019027	PLCB3	0.48	5.52	0.34	9.17e-8	Platelet count;
SARC	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg06713675	chr4:122721982	EXOSC9	-0.53	-7.18	-0.43	9.25e-12	Type 2 diabetes;
SARC	cis	rs3008870	0.755	rs2755242	chr1:67479598	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.59	7.6	0.45	7e-13	Lymphocyte percentage of white cells;
SARC	cis	rs9392918	0.531	rs927415	chr6:7698384	T/C	cg23089261	chr6:7723385	NA	0.53	6.76	0.4	1.11e-10	Height;
SARC	cis	rs8067354	0.830	rs2453913	chr17:57860150	G/T	cg13753209	chr17:57696993	CLTC	0.51	6.24	0.38	1.99e-9	Hemoglobin concentration;
SARC	cis	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg21573476	chr21:45109991	RRP1B	-0.56	-8.21	-0.47	1.56e-14	Mean corpuscular volume;
SARC	cis	rs75804782	0.641	rs72987321	chr2:239352765	T/G	cg21699342	chr2:239360505	ASB1	-0.58	-4.81	-0.3	2.68e-6	Morning vs. evening chronotype;Chronotype;
SARC	cis	rs2273669	1.000	rs2273669	chr6:109285189	A/G	cg05315195	chr6:109294784	ARMC2	-0.48	-4.78	-0.3	3.15e-6	Prostate cancer;
SARC	cis	rs4919044	0.756	rs7073161	chr10:94826465	C/G	cg05127821	chr10:94822908	CYP26C1	0.61	5.24	0.32	3.61e-7	Coronary artery disease;
SARC	trans	rs7815944	1.000	rs7815944	chr8:129427518	A/G	cg17342469	chr22:46473074	NA	0.67	7.26	0.43	5.77e-12	Atopic dermatitis;
SARC	trans	rs9329221	0.683	rs4598253	chr8:9890304	A/T	cg08975724	chr8:8085496	FLJ10661	-0.53	-7.11	-0.42	1.43e-11	Neuroticism;
SARC	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.62	7.68	0.45	4.32e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs826838	0.967	rs1352122	chr12:39130885	G/A	cg26384229	chr12:38710491	ALG10B	-0.76	-11.59	-0.6	7.97e-25	Heart rate;
SARC	cis	rs3126085	0.935	rs2338430	chr1:152214420	C/T	cg03465714	chr1:152285911	FLG	0.43	5.22	0.32	3.94e-7	Atopic dermatitis;
SARC	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg24399712	chr22:39784796	NA	-0.44	-6.04	-0.37	6.14e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7770848	1	rs7770848	chr6:44769237	A/C	cg23165752	chr6:44215591	HSP90AB1	0.57	4.88	0.3	2.01e-6	Asthma (childhood onset);
SARC	cis	rs526821	0.595	rs551665	chr11:55343268	G/A	cg04317927	chr11:55418816	OR4S2	0.41	6.09	0.37	4.71e-9	Pediatric bone mineral density (spine);
SARC	cis	rs11608355	0.545	rs2302705	chr12:109898716	C/T	cg05360138	chr12:110035743	NA	0.92	9.65	0.53	9.69e-19	Neuroticism;
SARC	cis	rs754466	0.580	rs10824573	chr10:79540969	T/C	cg17075019	chr10:79541650	NA	-0.84	-13.37	-0.66	1.23e-30	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9916302	0.851	rs6503518	chr17:37660469	A/G	cg07936489	chr17:37558343	FBXL20	-0.69	-8.92	-0.5	1.4e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs7223966	1.000	rs11657306	chr17:61704822	G/A	cg26338869	chr17:61819248	STRADA	0.42	4.86	0.3	2.13e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs963731	0.649	rs78905728	chr2:39339241	G/T	cg04010122	chr2:39346883	SOS1	1.11	6.38	0.39	9.36e-10	Corticobasal degeneration;
SARC	cis	rs28669119	0.778	rs674747	chr5:88079010	G/T	cg18498987	chr5:88179539	MEF2C	-0.52	-5.36	-0.33	1.97e-7	Schizophrenia;
SARC	cis	rs3815700	1.000	rs7260624	chr19:33096562	A/G	cg24916020	chr19:33096688	ANKRD27	0.56	5.66	0.35	4.43e-8	Eosinophilic esophagitis;
SARC	cis	rs62344088	0.590	rs60845955	chr5:185094	C/T	cg22857025	chr5:266934	NA	-0.87	-6.51	-0.39	4.53e-10	Asthma (childhood onset);
SARC	cis	rs7727544	0.735	rs272881	chr5:131669264	G/A	cg24060327	chr5:131705240	SLC22A5	-0.68	-8.77	-0.5	3.9e-16	Blood metabolite levels;
SARC	cis	rs1215050	0.791	rs2658477	chr4:98850993	G/A	cg05340658	chr4:99064831	C4orf37	-0.44	-5.88	-0.36	1.44e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs1348850	0.526	rs935426	chr2:178369433	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	5.87	0.36	1.5e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs4253772	0.591	rs9627324	chr22:46656511	A/G	cg24881330	chr22:46731750	TRMU	0.62	6.86	0.41	6.14e-11	LDL cholesterol;Cholesterol, total;
SARC	cis	rs1055129	0.655	rs8067076	chr17:73837142	G/T	cg06969265	chr17:73775802	H3F3B	-0.42	-4.88	-0.3	1.93e-6	White matter hyperintensity burden;
SARC	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	9.09	0.51	4.5e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7833790	0.724	rs6473309	chr8:82707880	A/G	cg06027949	chr8:82754900	SNX16	-0.48	-6.09	-0.37	4.51e-9	Diastolic blood pressure;
SARC	cis	rs4819052	0.679	rs28623526	chr21:46712324	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.61	7.48	0.44	1.55e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7824557	0.815	rs958648	chr8:11103895	A/G	cg21775007	chr8:11205619	TDH	-0.4	-4.72	-0.3	4.01e-6	Retinal vascular caliber;
SARC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg23131131	chr22:24373011	LOC391322	-0.48	-5.15	-0.32	5.55e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg20891558	chr2:74357851	NA	0.67	9.08	0.51	4.83e-17	Gestational age at birth (maternal effect);
SARC	cis	rs4595586	0.545	rs1375796	chr12:39410592	G/T	cg26384229	chr12:38710491	ALG10B	0.49	5.74	0.35	2.97e-8	Morning vs. evening chronotype;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg22394521	chr20:61569754	DIDO1;C20orf11	0.46	6.25	0.38	1.98e-9	Tetralogy of Fallot;
SARC	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs11190604	1.000	rs2495737	chr10:102338344	T/C	cg07080220	chr10:102295463	HIF1AN	0.77	8.99	0.51	8.89e-17	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs9831754	0.856	rs9824624	chr3:78407182	G/A	cg06138941	chr3:78371609	NA	-0.58	-6.79	-0.41	9.42e-11	Calcium levels;
SARC	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg00885506	chr9:116102792	WDR31	-0.54	-6.87	-0.41	5.87e-11	Thyroid cancer;
SARC	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg00933542	chr6:150070202	PCMT1	0.31	5.42	0.33	1.47e-7	Lung cancer;
SARC	cis	rs933688	1.000	rs10474353	chr5:90732285	A/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.06	13.26	0.66	2.82e-30	Smoking behavior;
SARC	trans	rs11767400	0.745	rs11763594	chr7:122186753	G/A	cg04856042	chr3:115752704	LSAMP	0.44	6.38	0.39	9.39e-10	Menarche (age at onset);
SARC	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg11890956	chr21:40555474	PSMG1	-1.04	-16.09	-0.73	1.15e-39	Cognitive function;
SARC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg09858108	chr8:58055024	NA	0.45	5.54	0.34	8.21e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2228479	0.702	rs62056100	chr16:89939753	C/T	cg12064134	chr16:90016061	DEF8	-0.56	-4.79	-0.3	3.02e-6	Skin colour saturation;
SARC	cis	rs1580019	0.885	rs1610141	chr7:32498435	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.79	10.97	0.58	7.64e-23	Cognitive ability;
SARC	cis	rs12044355	0.827	rs16854779	chr1:231827318	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-7.26	-0.43	5.69e-12	Alzheimer's disease;
SARC	cis	rs2303759	0.626	rs12982246	chr19:49801169	A/G	cg22590775	chr19:49891494	CCDC155	0.46	5.2	0.32	4.43e-7	Multiple sclerosis;
SARC	cis	rs57221529	0.563	rs4957057	chr5:569230	C/G	cg09021430	chr5:549028	NA	-0.5	-6.59	-0.4	2.93e-10	Lung disease severity in cystic fibrosis;
SARC	cis	rs78487399	0.731	rs13395302	chr2:43706350	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-5.3	-0.33	2.7e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg08859206	chr1:53392774	SCP2	-0.39	-5.61	-0.34	5.86e-8	Monocyte count;
SARC	cis	rs9858542	0.953	rs6779524	chr3:49450449	C/T	cg03060546	chr3:49711283	APEH	-0.57	-7.1	-0.42	1.51e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg16486109	chr11:613632	IRF7	0.45	6.04	0.37	6.13e-9	Systemic lupus erythematosus;
SARC	cis	rs3820928	0.874	rs10167086	chr2:227792729	A/T	cg05526886	chr2:227700861	RHBDD1	0.54	6.58	0.4	3e-10	Pulmonary function;
SARC	cis	rs7523050	0.643	rs12736534	chr1:109399934	T/C	cg08274380	chr1:109419600	GPSM2	1.07	8.3	0.48	8.22e-15	Fat distribution (HIV);
SARC	cis	rs2073300	0.609	rs6137917	chr20:23360369	G/A	cg16736954	chr20:23401023	NAPB	0.79	4.95	0.31	1.44e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg25894440	chr7:65020034	NA	-0.76	-5.73	-0.35	3.11e-8	Diabetic kidney disease;
SARC	cis	rs1475911	1.000	rs55645900	chr21:43515728	G/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.39	-4.84	-0.3	2.41e-6	IgG glycosylation;
SARC	cis	rs4805272	0.539	rs1075733	chr19:29324460	C/T	cg12756686	chr19:29218302	NA	0.58	6.7	0.4	1.58e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs6120849	0.754	rs3746446	chr20:33574765	T/C	cg06115741	chr20:33292138	TP53INP2	0.55	5.31	0.33	2.6e-7	Protein C levels;
SARC	cis	rs3106136	0.546	rs7685121	chr4:95175682	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.48	-7.26	-0.43	5.65e-12	Capecitabine sensitivity;
SARC	cis	rs765787	0.530	rs4238376	chr15:45541887	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.67e-7	Uric acid levels;
SARC	cis	rs228437	1.000	rs985122	chr6:134931300	A/G	cg24504307	chr6:134963096	NA	0.54	6.3	0.38	1.47e-9	Melanoma;
SARC	cis	rs7208859	0.673	rs11653955	chr17:29033292	C/A	cg13385521	chr17:29058706	SUZ12P	0.88	7.12	0.42	1.33e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs72781680	0.716	rs2712071	chr2:23990419	A/G	cg08917208	chr2:24149416	ATAD2B	0.64	6.35	0.38	1.14e-9	Lymphocyte counts;
SARC	trans	rs800082	0.698	rs800070	chr3:144346614	A/T	cg24215973	chr2:240111563	HDAC4	-0.53	-6.37	-0.39	1.02e-9	Smoking behavior;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg07300030	chr2:165698022	COBLL1	-0.46	-6.28	-0.38	1.68e-9	Neuroticism;
SARC	cis	rs1580019	0.813	rs2044839	chr7:32500805	A/C	cg06627557	chr7:32535165	LSM5;AVL9	0.79	10.8	0.58	2.71e-22	Cognitive ability;
SARC	cis	rs1580019	0.961	rs6949851	chr7:32493807	T/G	cg14728415	chr7:32535168	LSM5;AVL9	0.41	4.73	0.3	3.88e-6	Cognitive ability;
SARC	cis	rs2721195	0.845	rs3757966	chr8:145744618	G/A	cg26752003	chr8:145688521	CYHR1	-0.56	-7.42	-0.44	2.21e-12	Age at first birth;
SARC	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg04277193	chr17:41438351	NA	0.45	4.9	0.31	1.83e-6	Menopause (age at onset);
SARC	cis	rs9303401	1.000	rs6503882	chr17:56915761	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.67	7.82	0.46	1.81e-13	Cognitive test performance;
SARC	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.97e-8	Aortic root size;
SARC	cis	rs892961	0.932	rs7224116	chr17:75413177	A/G	cg05865280	chr17:75406074	SEPT9	0.57	8.47	0.48	2.87e-15	Airflow obstruction;
SARC	cis	rs911263	0.603	rs61985136	chr14:68769199	C/T	cg18825221	chr14:68749962	RAD51L1	0.41	7.36	0.43	3.14e-12	Primary biliary cholangitis;
SARC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg27588902	chr6:42928151	GNMT	-0.37	-5.68	-0.35	3.92e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs1707322	1.000	rs11211223	chr1:46380605	C/T	cg06784218	chr1:46089804	CCDC17	0.34	5.94	0.36	1.03e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs56235845	0.694	rs6875461	chr5:176754665	C/T	cg17509989	chr5:176798049	RGS14	-0.56	-7.71	-0.45	3.52e-13	Hemoglobin concentration;Hematocrit;
SARC	cis	rs10870270	1.000	rs3935905	chr10:133758262	A/C	cg26149184	chr10:133730230	NA	0.45	5.06	0.31	8.52e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg03806693	chr22:41940476	POLR3H	-0.95	-13.2	-0.65	4.55e-30	Vitiligo;
SARC	cis	rs7847628	0.587	rs3793638	chr9:123582697	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.94	14.66	0.69	6.4e-35	Birth weight;
SARC	cis	rs9300255	0.739	rs1969354	chr12:123741776	T/C	cg05973401	chr12:123451056	ABCB9	0.44	4.86	0.3	2.19e-6	Neutrophil percentage of white cells;
SARC	cis	rs1707322	0.721	rs10789470	chr1:46158331	T/G	cg03146154	chr1:46216737	IPP	0.53	6.35	0.38	1.12e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs12079745	1.000	rs12084964	chr1:169113282	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.69	-4.87	-0.3	2.06e-6	QT interval;
SARC	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg22920501	chr2:26401640	FAM59B	0.61	8.19	0.47	1.71e-14	Gut microbiome composition (summer);
SARC	cis	rs4481887	0.927	rs4244181	chr1:248471118	A/G	cg13385794	chr1:248469461	NA	0.36	5.46	0.34	1.19e-7	Common traits (Other);
SARC	cis	rs7568458	0.777	rs12473819	chr2:85773061	A/G	cg17127132	chr2:85788382	GGCX	0.45	6.04	0.37	6.15e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs4906332	1.000	rs17680085	chr14:103953154	T/C	cg26031613	chr14:104095156	KLC1	-0.49	-5.76	-0.35	2.64e-8	Coronary artery disease;
SARC	cis	rs8044868	0.893	rs12929749	chr16:72168241	T/G	cg16558253	chr16:72132732	DHX38	-0.35	-4.84	-0.3	2.34e-6	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
SARC	cis	rs826838	0.616	rs2200605	chr12:38624088	G/A	cg26384229	chr12:38710491	ALG10B	0.61	7.92	0.46	9.43e-14	Heart rate;
SARC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.68	-8.73	-0.5	5.01e-16	Prudent dietary pattern;
SARC	trans	rs208520	1.000	rs72882100	chr6:66981495	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.83	9.35	0.52	7.46e-18	Exhaled nitric oxide output;
SARC	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg15052019	chr19:19431593	KIAA0892;SF4	-0.4	-4.83	-0.3	2.51e-6	Tonsillectomy;
SARC	cis	rs651907	0.557	rs62284198	chr3:101474699	G/A	cg12386194	chr3:101231763	SENP7	0.47	5.62	0.35	5.38e-8	Colorectal cancer;
SARC	cis	rs6912958	0.781	rs2325064	chr6:88224467	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-5.79	-0.35	2.32e-8	Monocyte percentage of white cells;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg17347471	chr5:52405518	MOCS2	0.52	6.28	0.38	1.68e-9	Blood pressure;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15185286	chr6:143381675	AIG1	-0.49	-6.32	-0.38	1.32e-9	Smoking initiation;
SARC	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg00684032	chr4:1343700	KIAA1530	0.33	4.79	0.3	2.93e-6	Obesity-related traits;
SARC	cis	rs911555	0.755	rs7148567	chr14:103882234	C/T	cg12935359	chr14:103987150	CKB	-0.38	-5.24	-0.32	3.57e-7	Intelligence (multi-trait analysis);
SARC	trans	rs208520	1.000	rs12192261	chr6:66985268	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.83	9.35	0.52	7.46e-18	Exhaled nitric oxide output;
SARC	cis	rs35110281	0.782	rs4818856	chr21:45043495	A/G	cg01579765	chr21:45077557	HSF2BP	-0.38	-6.46	-0.39	5.92e-10	Mean corpuscular volume;
SARC	cis	rs9660992	0.639	rs1151786	chr1:205227760	G/C	cg07972983	chr1:205091412	RBBP5	0.58	7.06	0.42	1.85e-11	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs832540	0.593	rs252912	chr5:56195792	C/T	cg14703610	chr5:56206110	C5orf35	0.46	5.19	0.32	4.49e-7	Coronary artery disease;
SARC	cis	rs1865760	0.865	rs1541987	chr6:25950397	A/G	cg10373733	chr6:25993375	NA	-0.39	-4.74	-0.3	3.75e-6	Height;
SARC	cis	rs897080	0.552	rs1067384	chr2:44644554	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.58	6.68	0.4	1.75e-10	Height;
SARC	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.42	-6.42	-0.39	7.71e-10	Total body bone mineral density;
SARC	cis	rs9291683	0.527	rs73212848	chr4:10093299	T/C	cg11266682	chr4:10021025	SLC2A9	-0.46	-8.13	-0.47	2.51e-14	Bone mineral density;
SARC	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg05861140	chr6:150128134	PCMT1	-0.39	-4.86	-0.3	2.15e-6	Lung cancer;
SARC	cis	rs7712401	0.562	rs246267	chr5:122256104	A/T	cg19412675	chr5:122181750	SNX24	0.4	5.1	0.32	6.88e-7	Mean platelet volume;
SARC	cis	rs9325144	0.647	rs4616077	chr12:39092364	T/C	cg26384229	chr12:38710491	ALG10B	-0.6	-7.79	-0.45	2.19e-13	Morning vs. evening chronotype;
SARC	cis	rs10883723	0.810	rs13287	chr10:104240438	A/G	ch.10.2196322F	chr10:104248062	ACTR1A	0.57	7.22	0.43	7.35e-12	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs11711311	1.000	rs7622403	chr3:113472434	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.68	-8.82	-0.5	2.81e-16	IgG glycosylation;
SARC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg23131131	chr22:24373011	LOC391322	-0.46	-4.98	-0.31	1.23e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6598955	0.694	rs6659387	chr1:26634307	G/A	cg04990556	chr1:26633338	UBXN11	-0.61	-8.35	-0.48	6.02e-15	Obesity-related traits;
SARC	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg03806693	chr22:41940476	POLR3H	-0.85	-11.53	-0.6	1.25e-24	Vitiligo;
SARC	cis	rs1559088	0.749	rs10405757	chr19:33616526	C/A	cg17764715	chr19:33622953	WDR88	0.51	6.75	0.4	1.19e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs7264396	0.563	rs6060567	chr20:34288250	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-7.26	-0.43	5.75e-12	Total cholesterol levels;
SARC	cis	rs703842	1.000	rs2069502	chr12:58144665	A/G	cg00677455	chr12:58241039	CTDSP2	-0.49	-6.18	-0.38	2.85e-9	Multiple sclerosis;
SARC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg16405210	chr4:1374714	KIAA1530	-0.89	-12.6	-0.64	4.2e-28	Longevity;
SARC	cis	rs4555082	0.794	rs2735829	chr14:105708472	C/T	cg10792982	chr14:105748885	BRF1	0.54	8.13	0.47	2.49e-14	Mean platelet volume;Platelet distribution width;
SARC	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg17221315	chr6:27791827	HIST1H4J	0.47	5.14	0.32	5.95e-7	Parkinson's disease;
SARC	cis	rs2204008	0.599	rs2320526	chr12:38220405	T/A	cg13010199	chr12:38710504	ALG10B	0.73	9.63	0.53	1.11e-18	Bladder cancer;
SARC	cis	rs10463554	0.963	rs17154953	chr5:102355261	A/G	cg23492399	chr5:102201601	PAM	-0.45	-5.14	-0.32	5.85e-7	Parkinson's disease;
SARC	cis	rs9398803	0.687	rs9375450	chr6:126985351	G/A	cg19875578	chr6:126661172	C6orf173	0.63	8.74	0.5	4.8e-16	Male-pattern baldness;
SARC	trans	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg00938859	chr5:1591904	SDHAP3	0.8	7.69	0.45	4.07e-13	Breast cancer;
SARC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.12	0.37	3.96e-9	Prudent dietary pattern;
SARC	trans	rs7824557	0.583	rs4448232	chr8:11231354	G/T	cg06636001	chr8:8085503	FLJ10661	0.6	7.87	0.46	1.35e-13	Retinal vascular caliber;
SARC	cis	rs4975616	0.869	rs421284	chr5:1325590	T/C	cg26373071	chr5:1325741	CLPTM1L	0.31	5.16	0.32	5.29e-7	Lung cancer;
SARC	cis	rs7635838	0.892	rs9814907	chr3:11438645	G/A	cg00170343	chr3:11313890	ATG7	0.61	8.29	0.48	8.94e-15	HDL cholesterol;
SARC	cis	rs6582630	0.560	rs12315134	chr12:38419857	T/A	cg13010199	chr12:38710504	ALG10B	-0.49	-5.93	-0.36	1.11e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs611744	0.901	rs2348801	chr8:109167337	C/T	cg21045802	chr8:109455806	TTC35	0.45	5.45	0.34	1.28e-7	Dupuytren's disease;
SARC	cis	rs9914988	0.537	rs28448745	chr17:27188296	A/C	cg20469991	chr17:27169893	C17orf63	0.53	4.9	0.31	1.83e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs2997447	0.761	rs2783639	chr1:26429437	C/G	cg19633962	chr1:26362018	EXTL1	0.64	6.2	0.38	2.5e-9	QRS complex (12-leadsum);
SARC	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg12463550	chr7:65579703	CRCP	0.66	5.08	0.32	7.79e-7	Diabetic kidney disease;
SARC	trans	rs61931739	0.500	rs12371415	chr12:34521362	C/T	cg26384229	chr12:38710491	ALG10B	0.92	13.49	0.66	4.79e-31	Morning vs. evening chronotype;
SARC	cis	rs16854884	0.586	rs11914731	chr3:143725594	A/G	cg06585982	chr3:143692056	C3orf58	0.7	9.83	0.54	2.77e-19	Economic and political preferences (feminism/equality);
SARC	cis	rs79149102	0.579	rs6495138	chr15:75304692	A/G	cg09165964	chr15:75287851	SCAMP5	-0.96	-8.95	-0.51	1.14e-16	Lung cancer;
SARC	cis	rs2032447	0.613	rs6456708	chr6:26032847	G/C	cg17691542	chr6:26056736	HIST1H1C	0.46	5.7	0.35	3.65e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9611519	0.929	rs9611474	chr22:41434858	G/A	cg17376030	chr22:41985996	PMM1	0.5	6.06	0.37	5.45e-9	Neuroticism;
SARC	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg05368731	chr17:41323189	NBR1	0.78	9.25	0.52	1.46e-17	Menopause (age at onset);
SARC	cis	rs11098499	0.863	rs34308924	chr4:120481431	T/C	cg24375607	chr4:120327624	NA	0.42	4.92	0.31	1.64e-6	Corneal astigmatism;
SARC	trans	rs1973993	0.691	rs4000303	chr1:96913765	A/G	cg10631902	chr5:14652156	NA	0.51	8.93	0.5	1.31e-16	Weight;
SARC	trans	rs877282	1.000	rs71494928	chr10:769134	A/G	cg22713356	chr15:30763199	NA	1.04	9.91	0.54	1.51e-19	Uric acid levels;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg08881067	chr5:74062846	NSA2;GFM2	-0.47	-6.29	-0.38	1.56e-9	Neuroticism;
SARC	cis	rs9948	0.655	rs62152785	chr2:97459403	A/T	cg01990225	chr2:97406019	LMAN2L	-1.0	-7.3	-0.43	4.63e-12	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs34779708	0.931	rs34375045	chr10:35362356	A/C	cg03585969	chr10:35415529	CREM	0.38	4.72	0.3	4.02e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs6570726	0.902	rs4895678	chr6:145935510	C/T	cg05347473	chr6:146136440	FBXO30	0.48	6.33	0.38	1.24e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2180341	1.000	rs6569479	chr6:127606588	A/G	cg24812749	chr6:127587940	RNF146	0.94	12.14	0.62	1.37e-26	Breast cancer;
SARC	cis	rs7923609	0.811	rs10822181	chr10:65325126	G/A	cg01631684	chr10:65280961	REEP3	0.36	4.76	0.3	3.36e-6	Educational attainment;Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs9911578	0.835	rs9889419	chr17:56473259	C/T	cg05425664	chr17:57184151	TRIM37	-0.62	-7.5	-0.44	1.32e-12	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg22535103	chr8:58192502	C8orf71	-0.57	-6.03	-0.37	6.4e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs76419734	1.000	rs17036125	chr4:106623674	A/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.82	5.06	0.31	8.65e-7	Post bronchodilator FEV1;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg05902063	chr12:96794315	CDK17	-0.5	-6.28	-0.38	1.6e-9	Schizophrenia;
SARC	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg17971929	chr21:40555470	PSMG1	0.98	13.68	0.67	1.14e-31	Cognitive function;
SARC	trans	rs12460587	0.587	rs10415150	chr19:52604625	C/G	cg05614176	chr13:113242512	TUBGCP3	0.52	6.79	0.41	9.33e-11	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
SARC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg12419862	chr22:24373484	LOC391322	-0.65	-7.78	-0.45	2.34e-13	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9581857	0.725	rs9581853	chr13:28016236	T/C	cg01674679	chr13:27998804	GTF3A	-0.63	-4.97	-0.31	1.32e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	cis	rs8180040	0.620	rs2305635	chr3:47043622	G/A	cg27129171	chr3:47204927	SETD2	-0.72	-9.56	-0.53	1.72e-18	Colorectal cancer;
SARC	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.47	-5.62	-0.35	5.47e-8	Calcium levels;
SARC	cis	rs7223966	1.000	rs2854223	chr17:61939014	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.46	5.04	0.31	9.41e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg03575189	chr17:44344142	NA	-0.57	-5.54	-0.34	8.35e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	trans	rs2691273	0.530	rs2569430	chr19:51609586	C/T	cg08253363	chr19:16529096	EPS15L1	0.48	6.32	0.38	1.34e-9	Blood protein levels;
SARC	trans	rs2664588	0.741	rs12479809	chr20:46621697	C/G	cg05508447	chr12:133264322	PXMP2;POLE	0.53	6.27	0.38	1.71e-9	Cerebrospinal fluid AB1-42 levels;
SARC	cis	rs854765	0.547	rs9913277	chr17:17919749	G/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.42	5.42	0.33	1.47e-7	Total body bone mineral density;
SARC	cis	rs2749592	0.550	rs4934881	chr10:37914346	A/C	cg00409905	chr10:38381863	ZNF37A	0.55	7.68	0.45	4.31e-13	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs2933343	0.951	rs1055128	chr3:128591048	C/T	cg24203234	chr3:128598194	ACAD9	0.53	5.85	0.36	1.62e-8	IgG glycosylation;
SARC	cis	rs854765	0.583	rs4925123	chr17:17784374	A/G	cg04398451	chr17:18023971	MYO15A	0.4	5.79	0.35	2.28e-8	Total body bone mineral density;
SARC	trans	rs56279505	0.581	rs62307318	chr4:100267023	G/A	cg21156590	chr1:3420848	MEGF6	-0.83	-6.41	-0.39	8.04e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg26335602	chr6:28129616	ZNF389	0.52	5.94	0.36	1.04e-8	Depression;
SARC	cis	rs9467711	0.591	rs17586553	chr6:25928775	C/T	cg08501292	chr6:25962987	TRIM38	0.7	4.87	0.3	2.02e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7317038	1.000	rs7317038	chr13:114012898	C/T	cg24344662	chr13:114018021	GRTP1	-0.47	-5.94	-0.36	1.03e-8	Mean platelet volume;
SARC	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg08109568	chr15:31115862	NA	0.52	6.65	0.4	2.06e-10	Huntington's disease progression;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg12950624	chr19:46000154	RTN2	0.61	8.48	0.49	2.61e-15	Tetralogy of Fallot;
SARC	cis	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg11608241	chr8:8085544	FLJ10661	-0.39	-4.73	-0.3	3.81e-6	Joint mobility (Beighton score);
SARC	cis	rs10911363	0.592	rs2702182	chr1:183516440	C/T	cg09173681	chr1:183549694	NCF2	0.33	5.41	0.33	1.56e-7	Systemic lupus erythematosus;
SARC	cis	rs617791	0.508	rs747526	chr11:65776071	C/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.61	7.62	0.45	6.54e-13	Breast cancer;
SARC	cis	rs208520	0.690	rs12198745	chr6:66722598	T/C	cg07460842	chr6:66804631	NA	1.06	14.26	0.68	1.34e-33	Exhaled nitric oxide output;
SARC	cis	rs10463554	0.927	rs34813	chr5:102433409	G/A	cg23492399	chr5:102201601	PAM	-0.52	-5.68	-0.35	3.99e-8	Parkinson's disease;
SARC	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg22168489	chr12:122356033	WDR66	0.63	9.94	0.55	1.22e-19	Mean corpuscular volume;
SARC	cis	rs1483890	0.723	rs12631128	chr3:69411416	G/T	cg22125112	chr3:69402811	FRMD4B	0.29	4.78	0.3	3.12e-6	Resting heart rate;
SARC	cis	rs11112613	0.609	rs6539218	chr12:105934875	C/T	cg03607813	chr12:105948248	NA	0.4	4.83	0.3	2.46e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg21144161	chr5:423903	AHRR	0.31	4.87	0.3	2.05e-6	Cystic fibrosis severity;
SARC	cis	rs7681440	0.538	rs2619351	chr4:90747704	A/G	cg06632027	chr4:90757378	SNCA	-0.43	-5.32	-0.33	2.4e-7	Dementia with Lewy bodies;
SARC	cis	rs11997175	0.572	rs7836230	chr8:33623250	T/C	ch.8.33884649F	chr8:33765107	NA	0.51	6.49	0.39	5.05e-10	Body mass index;
SARC	cis	rs55883249	1.000	rs10495571	chr2:9736066	A/G	cg23886495	chr2:9695866	ADAM17	0.66	7.17	0.43	9.79e-12	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs459571	1.000	rs2810489	chr9:136922700	C/T	cg01294253	chr9:136912663	BRD3	0.43	5.6	0.34	6.05e-8	Platelet distribution width;
SARC	cis	rs73206853	0.698	rs73194015	chr12:111116651	C/T	cg10860002	chr12:110842031	ANAPC7	0.63	5.29	0.33	2.83e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs2073300	0.609	rs77673953	chr20:23398794	G/C	cg16736954	chr20:23401023	NAPB	0.77	4.79	0.3	2.96e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs2760061	0.624	rs10442629	chr1:228191070	T/A	cg02753203	chr1:228287806	NA	0.76	10.5	0.57	2.35e-21	Diastolic blood pressure;
SARC	cis	rs2204008	0.639	rs7311462	chr12:38278130	G/A	cg26384229	chr12:38710491	ALG10B	0.91	13.64	0.67	1.61e-31	Bladder cancer;
SARC	cis	rs854765	0.583	rs7207043	chr17:17819188	A/G	cg04398451	chr17:18023971	MYO15A	-0.37	-5.29	-0.33	2.76e-7	Total body bone mineral density;
SARC	cis	rs2463822	0.844	rs2513737	chr11:62119495	G/C	cg06239285	chr11:62104954	ASRGL1	0.89	9.16	0.51	2.79e-17	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs11608355	0.545	rs36094325	chr12:109911542	A/T	cg05360138	chr12:110035743	NA	0.93	9.74	0.54	4.9e-19	Neuroticism;
SARC	cis	rs9911578	1.000	rs4793950	chr17:56593111	T/C	cg05425664	chr17:57184151	TRIM37	0.65	7.92	0.46	9.82e-14	Intelligence (multi-trait analysis);
SARC	cis	rs17376456	1.000	rs67150649	chr5:93292377	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.67	6.17	0.37	3e-9	Diabetic retinopathy;
SARC	cis	rs11155671	0.530	rs9397420	chr6:150206781	C/T	cg09217309	chr6:150244204	RAET1G	-0.37	-4.87	-0.3	2.08e-6	Testicular germ cell tumor;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg21568731	chr6:80714280	TTK	0.55	6.98	0.42	3.07e-11	Breast cancer;
SARC	cis	rs17253792	0.822	rs79921041	chr14:56090779	T/C	cg01858014	chr14:56050164	KTN1	-0.67	-5.11	-0.32	6.86e-7	Putamen volume;
SARC	cis	rs2228479	0.850	rs1800355	chr16:89813194	C/T	cg00800038	chr16:89945340	TCF25	-0.74	-5.1	-0.32	7.19e-7	Skin colour saturation;
SARC	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg17376030	chr22:41985996	PMM1	-0.8	-10.14	-0.55	2.93e-20	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs2652834	1.000	rs2652838	chr15:63396088	A/G	cg05507819	chr15:63340323	TPM1	0.55	5.52	0.34	9.16e-8	HDL cholesterol;
SARC	cis	rs3806843	0.676	rs2245643	chr5:140029780	C/T	cg16577123	chr5:140027231	NDUFA2;IK	-0.47	-5.73	-0.35	3.03e-8	Depressive symptoms (multi-trait analysis);
SARC	cis	rs7618915	0.798	rs353547	chr3:52268866	A/G	cg18404041	chr3:52824283	ITIH1	0.37	5.38	0.33	1.78e-7	Bipolar disorder;
SARC	cis	rs1348850	0.632	rs12471621	chr2:178502353	T/C	cg23306229	chr2:178417860	TTC30B	0.51	5.79	0.35	2.23e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs6121246	0.567	rs6060344	chr20:30207316	A/G	cg21427119	chr20:30132790	HM13	-0.48	-5.19	-0.32	4.57e-7	Mean corpuscular hemoglobin;
SARC	cis	rs4680	0.737	rs4646312	chr22:19948337	C/T	cg07194846	chr22:19930177	COMT;TXNRD2	-0.39	-5.09	-0.32	7.48e-7	Blood metabolite levels;
SARC	trans	rs66573146	1.000	rs7686168	chr4:6986057	C/A	cg07817883	chr1:32538562	TMEM39B	1.52	9.1	0.51	4.22e-17	Granulocyte percentage of myeloid white cells;
SARC	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg12463550	chr7:65579703	CRCP	0.49	5.82	0.36	1.92e-8	Aortic root size;
SARC	cis	rs6867032	1.000	rs28392808	chr5:2013477	A/G	cg26168224	chr5:2018326	NA	0.95	15.92	0.72	4.09e-39	Gut microbiome composition (winter);
SARC	cis	rs2180341	0.920	rs6906717	chr6:127596782	C/A	cg17762328	chr6:126965162	NA	-0.46	-5.28	-0.33	3.01e-7	Breast cancer;
SARC	cis	rs17270561	1.000	rs17270561	chr6:25820439	A/C	cg16482183	chr6:26056742	HIST1H1C	-0.54	-5.76	-0.35	2.66e-8	Iron status biomarkers;
SARC	cis	rs2797685	1.000	rs697691	chr1:7885354	A/G	cg00864860	chr1:7907996	UTS2	-0.36	-5.05	-0.31	8.92e-7	Crohn's disease;
SARC	cis	rs6570726	0.791	rs10457788	chr6:145921136	T/A	cg23711669	chr6:146136114	FBXO30	0.88	14.59	0.69	1.08e-34	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg06074448	chr4:187884817	NA	-0.41	-5.39	-0.33	1.76e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs17376456	0.569	rs2045020	chr5:93224466	T/C	cg25358565	chr5:93447407	FAM172A	-0.99	-11.66	-0.61	4.63e-25	Diabetic retinopathy;
SARC	cis	rs644799	0.710	rs523153	chr11:95570961	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.58	7.6	0.45	7.14e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs17079247	1.000	rs61960240	chr13:85765007	T/C	ch.13.84760847R	chr13:85862846	NA	-0.57	-5.02	-0.31	1.05e-6	Bipolar disorder (mania);
SARC	cis	rs12079745	0.793	rs12081030	chr1:169350003	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.81	-5.31	-0.33	2.62e-7	QT interval;
SARC	cis	rs2730245	0.636	rs2657382	chr7:158650941	G/A	cg14689365	chr7:158441557	NCAPG2	0.43	4.73	0.3	3.92e-6	Height;
SARC	cis	rs2479724	0.875	rs2253961	chr6:41827011	A/G	cg17623882	chr6:41773611	USP49	-0.44	-5.5	-0.34	9.92e-8	Menarche (age at onset);
SARC	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg13939156	chr17:80058883	NA	-0.42	-6.48	-0.39	5.51e-10	Life satisfaction;
SARC	cis	rs8067545	0.611	rs9893832	chr17:20038273	A/G	cg13482628	chr17:19912719	NA	0.52	6.81	0.41	8.45e-11	Schizophrenia;
SARC	cis	rs12586317	0.586	rs2295103	chr14:35515920	C/G	cg16230307	chr14:35515116	FAM177A1	0.95	11.21	0.59	1.3e-23	Psoriasis;
SARC	cis	rs4555082	0.874	rs113291192	chr14:105738181	C/T	cg13114125	chr14:105738426	BRF1	-0.8	-11.66	-0.61	4.88e-25	Mean platelet volume;Platelet distribution width;
SARC	cis	rs228437	1.000	rs228448	chr6:134903308	C/T	cg24504307	chr6:134963096	NA	0.48	5.5	0.34	1.01e-7	Melanoma;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg06661924	chr1:65613383	AK3L1	-0.8	-6.67	-0.4	1.81e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg20607798	chr8:58055168	NA	0.66	5.15	0.32	5.52e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg17221315	chr6:27791827	HIST1H4J	0.47	5.39	0.33	1.71e-7	Depression;
SARC	cis	rs6456156	0.586	rs6909180	chr6:167460537	A/G	cg23791538	chr6:167370224	RNASET2	-0.52	-6.79	-0.41	9.49e-11	Primary biliary cholangitis;
SARC	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-8.38	-0.48	5.14e-15	Mood instability;
SARC	cis	rs12142240	0.698	rs68191463	chr1:46808695	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-5.45	-0.34	1.28e-7	Menopause (age at onset);
SARC	cis	rs2115630	1.000	rs6496441	chr15:85363348	A/G	cg12501888	chr15:85177176	SCAND2	-0.46	-5.76	-0.35	2.61e-8	P wave terminal force;
SARC	cis	rs11583043	1.000	rs2391573	chr1:101489698	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.49	5.45	0.34	1.25e-7	Ulcerative colitis;Inflammatory bowel disease;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg12615137	chr3:87040286	VGLL3	-0.77	-6.49	-0.39	5.16e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2718058	0.606	rs2722273	chr7:37808298	T/C	cg15028436	chr7:37888078	TXNDC3	0.39	4.96	0.31	1.33e-6	Alzheimer's disease (late onset);
SARC	cis	rs4481887	0.927	rs4564179	chr1:248472422	T/C	cg01631408	chr1:248437212	OR2T33	-0.39	-5.06	-0.31	8.56e-7	Common traits (Other);
SARC	cis	rs6570726	0.764	rs451108	chr6:145844309	T/C	cg05347473	chr6:146136440	FBXO30	0.54	7.49	0.44	1.41e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs2070488	0.931	rs6599212	chr3:38558906	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.82	-13.07	-0.65	1.18e-29	Electrocardiographic conduction measures;
SARC	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg19671926	chr4:122722719	EXOSC9	-0.51	-5.88	-0.36	1.44e-8	Type 2 diabetes;
SARC	cis	rs4253772	0.591	rs6007732	chr22:46652303	A/T	cg24881330	chr22:46731750	TRMU	0.64	6.8	0.41	8.87e-11	LDL cholesterol;Cholesterol, total;
SARC	cis	rs448720	0.811	rs399408	chr15:68183851	G/A	cg05925327	chr15:68127851	NA	-0.36	-5.3	-0.33	2.7e-7	Cognitive performance;
SARC	cis	rs9788682	0.747	rs16969894	chr15:78776456	C/T	cg24631222	chr15:78858424	CHRNA5	0.74	8.96	0.51	1.06e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs13191362	1.000	rs34725898	chr6:163127302	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.4	5.05	0.31	8.87e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2718058	0.564	rs1450176	chr7:37756528	T/C	cg24998770	chr7:37888106	TXNDC3	-0.32	-5.0	-0.31	1.13e-6	Alzheimer's disease (late onset);
SARC	cis	rs12477438	1.000	rs12466388	chr2:99916538	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-6.6	-0.4	2.72e-10	Chronic sinus infection;
SARC	cis	rs5753037	0.585	rs5752962	chr22:30188245	A/C	cg01021169	chr22:30184971	ASCC2	-0.52	-7.36	-0.43	3.08e-12	Type 1 diabetes;
SARC	cis	rs2730245	0.593	rs842699	chr7:158663404	T/A	cg24397884	chr7:158709396	WDR60	0.72	8.95	0.51	1.13e-16	Height;
SARC	cis	rs9527	0.544	rs3781280	chr10:104863843	T/G	cg04362960	chr10:104952993	NT5C2	0.41	4.75	0.3	3.54e-6	Arsenic metabolism;
SARC	cis	rs920590	0.560	rs7823457	chr8:19671334	G/A	cg03894339	chr8:19674705	INTS10	-0.41	-4.9	-0.31	1.83e-6	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	5.12	0.32	6.4e-7	Personality dimensions;
SARC	cis	rs854765	0.693	rs9907287	chr17:17774118	C/T	cg04398451	chr17:18023971	MYO15A	0.46	6.58	0.4	3.15e-10	Total body bone mineral density;
SARC	cis	rs926392	0.965	rs6129166	chr20:37688825	T/C	cg16355469	chr20:37678765	NA	0.57	7.3	0.43	4.62e-12	Dialysis-related mortality;
SARC	cis	rs11792861	0.926	rs72607172	chr9:111876523	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.67	7.79	0.45	2.25e-13	Menarche (age at onset);
SARC	cis	rs634534	0.622	rs531612	chr11:65705432	C/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.44	-5.49	-0.34	1.05e-7	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs62344088	1.000	rs73022563	chr5:140813	G/T	cg20965017	chr5:231967	SDHA	-0.84	-4.8	-0.3	2.89e-6	Asthma (childhood onset);
SARC	trans	rs6600671	0.967	rs4844613	chr1:121173773	T/C	cg00646200	chr1:148855367	NA	0.53	7.48	0.44	1.48e-12	Hip geometry;
SARC	cis	rs7589342	0.862	rs6745887	chr2:106468039	G/A	cg14210321	chr2:106509881	NCK2	-0.48	-5.54	-0.34	8.2e-8	Addiction;
SARC	cis	rs2120019	0.938	rs35911108	chr15:75322179	G/A	cg09165964	chr15:75287851	SCAMP5	-0.95	-14.5	-0.69	2.24e-34	Blood trace element (Zn levels);
SARC	cis	rs6733011	0.578	rs10181972	chr2:99497284	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-5.37	-0.33	1.94e-7	Bipolar disorder;
SARC	cis	rs918629	0.679	rs12055287	chr5:95272428	G/C	cg16656078	chr5:95278638	ELL2	-0.66	-7.39	-0.44	2.61e-12	IgG glycosylation;
SARC	cis	rs12545109	0.800	rs1992122	chr8:57409467	A/G	cg21220214	chr8:57350948	NA	-0.41	-4.78	-0.3	3.04e-6	Obesity-related traits;
SARC	cis	rs722599	0.715	rs61978928	chr14:75321714	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.39	-4.89	-0.3	1.91e-6	IgG glycosylation;
SARC	cis	rs1003719	1.000	rs1003719	chr21:38491095	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.66	9.07	0.51	5e-17	Eye color traits;
SARC	cis	rs9660992	0.573	rs1172161	chr1:205206495	C/T	cg00857998	chr1:205179979	DSTYK	0.51	6.31	0.38	1.39e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs986417	1.000	rs1018531	chr14:60970844	C/T	cg27398547	chr14:60952738	C14orf39	1.02	9.63	0.53	1.06e-18	Gut microbiota (bacterial taxa);
SARC	cis	rs6912958	0.781	rs2273129	chr6:88182439	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.51	-6.82	-0.41	7.6e-11	Monocyte percentage of white cells;
SARC	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs4372836	0.729	rs10174533	chr2:28968928	G/A	cg09522027	chr2:28974177	PPP1CB	0.35	4.73	0.3	3.86e-6	Body mass index;
SARC	cis	rs17376456	0.597	rs11135401	chr5:93365716	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.47	-5.15	-0.32	5.54e-7	Diabetic retinopathy;
SARC	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg24675658	chr1:53192096	ZYG11B	-0.58	-7.91	-0.46	1.05e-13	Monocyte count;
SARC	cis	rs1865760	0.622	rs10946807	chr6:26079638	T/C	cg17691542	chr6:26056736	HIST1H1C	0.66	7.85	0.46	1.55e-13	Height;
SARC	cis	rs4595586	0.545	rs12827197	chr12:39404362	C/T	cg26384229	chr12:38710491	ALG10B	0.5	6.12	0.37	3.98e-9	Morning vs. evening chronotype;
SARC	cis	rs9467711	0.591	rs9461223	chr6:25918335	T/C	cg21479132	chr6:26055353	NA	0.75	4.75	0.3	3.62e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9527	0.590	rs11191547	chr10:104843148	C/T	cg04362960	chr10:104952993	NT5C2	0.41	4.83	0.3	2.48e-6	Arsenic metabolism;
SARC	cis	rs17376456	0.569	rs7735009	chr5:93260865	T/C	cg25358565	chr5:93447407	FAM172A	-0.85	-10.11	-0.55	3.64e-20	Diabetic retinopathy;
SARC	cis	rs35213789	0.762	rs2851514	chr7:69145211	A/C	cg10619644	chr7:69149951	AUTS2	-0.36	-4.95	-0.31	1.44e-6	Childhood ear infection;
SARC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg22105103	chr4:187893119	NA	-0.44	-5.93	-0.36	1.09e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2486288	0.656	rs2271438	chr15:45557468	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.46	-5.68	-0.35	4.03e-8	Glomerular filtration rate;
SARC	cis	rs9457247	1.000	rs389946	chr6:167407268	T/C	cg07741184	chr6:167504864	NA	0.29	5.59	0.34	6.4e-8	Crohn's disease;
SARC	cis	rs2235642	0.787	rs2235646	chr16:1601287	A/G	cg09065629	chr16:1709722	CRAMP1L	0.35	4.93	0.31	1.55e-6	Coronary artery disease;
SARC	cis	rs12142240	0.660	rs6679080	chr1:46819779	A/T	cg00530320	chr1:46809349	NSUN4	0.57	6.92	0.41	4.4e-11	Menopause (age at onset);
SARC	trans	rs10506458	1.000	rs1495013	chr12:63428188	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.73	-6.79	-0.41	9.13e-11	Hemostatic factors and hematological phenotypes;
SARC	cis	rs72781680	0.664	rs2712076	chr2:23993366	T/C	cg06627628	chr2:24431161	ITSN2	-0.54	-5.59	-0.34	6.44e-8	Lymphocyte counts;
SARC	cis	rs6912958	0.703	rs6903219	chr6:88096498	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.74	11.04	0.59	4.41e-23	Monocyte percentage of white cells;
SARC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg18876405	chr7:65276391	NA	-0.58	-7.33	-0.43	3.77e-12	Calcium levels;
SARC	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg10560079	chr2:191398806	TMEM194B	-0.64	-8.76	-0.5	4.21e-16	Pulse pressure;
SARC	cis	rs7639513	0.767	rs9861271	chr3:12707620	A/C	cg23032965	chr3:12705835	RAF1	0.85	12.42	0.63	1.59e-27	Itch intensity from mosquito bite;
SARC	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg20891558	chr2:74357851	NA	0.68	9.49	0.53	2.9e-18	Gestational age at birth (maternal effect);
SARC	cis	rs7953249	0.618	rs7954039	chr12:121398654	A/C	cg02403541	chr12:121454288	C12orf43	-0.73	-9.74	-0.54	4.87e-19	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.87	11.99	0.62	3.96e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs1003719	0.788	rs2835605	chr21:38490734	T/A	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.95	0.51	1.17e-16	Eye color traits;
SARC	trans	rs9650657	0.769	rs2116094	chr8:10598822	C/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.61	-0.4	2.54e-10	Neuroticism;
SARC	cis	rs2153535	0.580	rs6421948	chr6:8531020	T/C	cg21535247	chr6:8435926	SLC35B3	0.54	6.86	0.41	6.27e-11	Motion sickness;
SARC	cis	rs668210	0.793	rs1204011	chr11:65741086	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.61	-5.89	-0.36	1.34e-8	Cerebrospinal fluid biomarker levels;
SARC	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg18252515	chr7:66147081	NA	-1.29	-11.04	-0.59	4.48e-23	Diabetic kidney disease;
SARC	cis	rs908922	0.676	rs11205031	chr1:152527662	C/T	cg09873164	chr1:152488093	CRCT1	0.61	7.96	0.46	7.66e-14	Hair morphology;
SARC	cis	rs1670533	1.000	rs6599278	chr4:1058798	C/T	cg27284194	chr4:1044797	NA	0.46	4.76	0.3	3.38e-6	Recombination rate (females);
SARC	cis	rs1322639	0.531	rs11751421	chr6:169574993	T/C	cg04662567	chr6:169592167	NA	0.39	5.22	0.32	4.01e-7	Pulse pressure;
SARC	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg07061783	chr6:25882402	NA	-0.38	-4.8	-0.3	2.83e-6	Intelligence (multi-trait analysis);
SARC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.13	0.8	7.01e-53	Prudent dietary pattern;
SARC	cis	rs7712401	0.601	rs448505	chr5:122336690	T/C	cg19412675	chr5:122181750	SNX24	-0.42	-5.38	-0.33	1.84e-7	Mean platelet volume;
SARC	cis	rs959260	0.557	rs4788887	chr17:73323876	C/G	cg14668889	chr17:73230827	NUP85	-0.56	-7.15	-0.42	1.1e-11	Systemic lupus erythematosus;
SARC	cis	rs79349575	0.783	rs12602933	chr17:47029280	G/C	cg16584676	chr17:46985605	UBE2Z	0.55	6.58	0.4	3.01e-10	Type 2 diabetes;
SARC	cis	rs7644634	0.559	rs7615317	chr3:105430251	C/T	cg23051926	chr3:105466016	CBLB	0.47	5.25	0.33	3.43e-7	Itch intensity from mosquito bite;
SARC	cis	rs7208859	0.623	rs78071511	chr17:29128154	C/T	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs6545883	0.929	rs1900572	chr2:61650715	T/G	cg15711740	chr2:61764176	XPO1	0.43	5.22	0.32	3.94e-7	Tuberculosis;
SARC	trans	rs10929925	0.545	rs4670031	chr2:6158286	C/T	cg25116709	chr5:122426797	PRDM6	-0.42	-6.32	-0.38	1.33e-9	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
SARC	cis	rs7666738	0.546	rs3911415	chr4:98692401	T/A	cg05340658	chr4:99064831	C4orf37	0.6	7.3	0.43	4.4e-12	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10189230	0.643	rs2710503	chr2:222374699	C/G	cg14652038	chr2:222343519	EPHA4	-0.39	-5.16	-0.32	5.29e-7	Urate levels in lean individuals;
SARC	cis	rs9788721	0.967	rs2036527	chr15:78851615	G/A	cg18825076	chr15:78729989	IREB2	-0.45	-5.42	-0.33	1.5e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg20965017	chr5:231967	SDHA	-0.57	-5.57	-0.34	7.12e-8	Breast cancer;
SARC	cis	rs9393692	0.627	rs2179517	chr6:26198845	G/C	cg00631329	chr6:26305371	NA	-0.56	-7.62	-0.45	6.26e-13	Educational attainment;
SARC	cis	rs2204008	0.774	rs11615665	chr12:38328162	T/A	cg13010199	chr12:38710504	ALG10B	0.77	10.47	0.57	2.87e-21	Bladder cancer;
SARC	cis	rs3762637	0.941	rs6788746	chr3:122106743	G/A	cg24169773	chr3:122142474	KPNA1	-0.57	-5.61	-0.35	5.6e-8	LDL cholesterol levels;
SARC	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg14784868	chr12:69753453	YEATS4	0.51	6.77	0.41	1.04e-10	Blood protein levels;
SARC	cis	rs9309711	0.666	rs6767	chr2:3483205	C/T	cg15506890	chr2:3487001	NA	-0.46	-6.14	-0.37	3.59e-9	Neurofibrillary tangles;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg12536451	chr10:99496852	ZFYVE27	0.57	7.11	0.42	1.42e-11	Breast cancer;
SARC	cis	rs4660261	0.526	rs2040950	chr1:44315113	G/C	cg09903430	chr1:44172605	ST3GAL3	0.36	4.75	0.3	3.62e-6	Intelligence (multi-trait analysis);
SARC	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg16325326	chr1:53192061	ZYG11B	0.72	10.07	0.55	5e-20	Monocyte count;
SARC	cis	rs3764563	0.735	rs62106282	chr19:15727124	T/C	cg20725493	chr19:15740067	CYP4F8	-0.66	-4.91	-0.31	1.7e-6	Inflammatory biomarkers;
SARC	cis	rs7944584	0.563	rs61895112	chr11:47560433	T/C	cg10504702	chr11:47789108	FNBP4	0.64	7.51	0.44	1.26e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg23939001	chr4:940644	TMEM175	0.45	7.21	0.43	7.88e-12	Sjögren's syndrome;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg27457105	chr17:36003574	DDX52	0.51	6.32	0.38	1.34e-9	Breast cancer;
SARC	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg20607798	chr8:58055168	NA	0.67	5.56	0.34	7.23e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg03709012	chr19:19516395	GATAD2A	1.0	17.43	0.75	3.97e-44	Tonsillectomy;
SARC	cis	rs11122272	0.735	rs2491407	chr1:231518928	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs7465272	1.000	rs35868630	chr8:143685933	G/A	cg24634471	chr8:143751801	JRK	0.6	6.53	0.39	4.13e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs2013441	1.000	rs2703804	chr17:20107195	T/C	cg13482628	chr17:19912719	NA	-0.45	-5.89	-0.36	1.35e-8	Obesity-related traits;
SARC	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg14820908	chr5:178986412	RUFY1	-0.36	-5.15	-0.32	5.43e-7	Lung cancer;
SARC	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg19748678	chr4:122722346	EXOSC9	0.79	10.01	0.55	7.61e-20	Type 2 diabetes;
SARC	cis	rs6912958	0.630	rs4707377	chr6:88280332	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-6.8	-0.41	8.58e-11	Monocyte percentage of white cells;
SARC	cis	rs36051895	0.659	rs11999076	chr9:5037694	C/T	cg02405213	chr9:5042618	JAK2	-0.56	-6.62	-0.4	2.4e-10	Pediatric autoimmune diseases;
SARC	cis	rs1691799	0.899	rs1168303	chr12:66738586	A/G	cg16791601	chr12:66731901	HELB	-0.71	-10.67	-0.57	6.75e-22	White blood cell count (basophil);
SARC	cis	rs12368653	0.525	rs1564374	chr12:58010163	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.41	-5.43	-0.34	1.41e-7	Multiple sclerosis;
SARC	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg25072359	chr17:41440525	NA	0.47	5.38	0.33	1.84e-7	Menopause (age at onset);
SARC	cis	rs8077889	0.871	rs11079838	chr17:41898971	G/A	cg26893861	chr17:41843967	DUSP3	0.86	10.74	0.58	4.09e-22	Triglycerides;
SARC	cis	rs2204008	0.550	rs11495600	chr12:38126654	C/T	cg26384229	chr12:38710491	ALG10B	0.88	12.94	0.65	3.26e-29	Bladder cancer;
SARC	cis	rs2204008	0.818	rs1589389	chr12:38416041	G/A	cg13010199	chr12:38710504	ALG10B	-0.69	-9.42	-0.53	4.76e-18	Bladder cancer;
SARC	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg11987759	chr7:65425863	GUSB	0.51	6.48	0.39	5.42e-10	Aortic root size;
SARC	cis	rs5753618	0.561	rs737684	chr22:31659827	C/G	cg02404636	chr22:31891804	SFI1	-0.49	-5.24	-0.32	3.53e-7	Colorectal cancer;
SARC	cis	rs2486288	0.539	rs2433601	chr15:45716425	T/C	cg21132104	chr15:45694354	SPATA5L1	0.54	6.72	0.4	1.41e-10	Glomerular filtration rate;
SARC	cis	rs992157	0.735	rs13392177	chr2:219112956	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.65	-9.05	-0.51	5.97e-17	Colorectal cancer;
SARC	cis	rs910316	0.810	rs77939209	chr14:75670070	A/G	cg11812906	chr14:75593930	NEK9	-0.8	-11.44	-0.6	2.38e-24	Height;
SARC	cis	rs4481887	1.000	rs7511706	chr1:248467360	G/A	cg00666640	chr1:248458726	OR2T12	0.38	6.42	0.39	7.43e-10	Common traits (Other);
SARC	cis	rs2304069	1.000	rs7737689	chr5:149396159	C/A	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.57	6.08	0.37	4.86e-9	HIV-1 control;
SARC	cis	rs826838	0.967	rs11183622	chr12:38792849	T/C	cg13010199	chr12:38710504	ALG10B	0.79	11.26	0.59	8.77e-24	Heart rate;
SARC	cis	rs4742903	0.967	rs10512325	chr9:106861191	C/T	cg14250997	chr9:106856677	SMC2	0.53	7.08	0.42	1.68e-11	High-grade serous ovarian cancer;Breast cancer;
SARC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg24883574	chr7:127225343	GCC1	0.54	6.74	0.4	1.21e-10	Myopia (pathological);
SARC	cis	rs3749237	1.000	rs2291542	chr3:49751585	C/T	cg07636037	chr3:49044803	WDR6	0.48	5.57	0.34	7.15e-8	Resting heart rate;
SARC	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg22433210	chr17:43662623	NA	-0.95	-11.34	-0.6	4.92e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs12216125	0.554	rs6942196	chr6:26072804	A/G	cg17691542	chr6:26056736	HIST1H1C	0.53	6.52	0.39	4.23e-10	Iron status biomarkers;
SARC	cis	rs7223966	0.515	rs2727315	chr17:61961458	C/T	cg26338869	chr17:61819248	STRADA	0.46	4.93	0.31	1.59e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6493487	0.512	rs34874493	chr15:51312751	G/A	cg02338191	chr15:51200825	AP4E1	0.53	4.83	0.3	2.44e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs6831352	0.959	rs1139490	chr4:100045141	C/T	cg12011299	chr4:100065546	ADH4	0.32	5.82	0.36	1.93e-8	Alcohol dependence;
SARC	cis	rs6669919	0.553	rs7546343	chr1:211671801	C/T	cg10512769	chr1:211675356	NA	-0.38	-6.01	-0.37	6.96e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg18404041	chr3:52824283	ITIH1	-0.42	-6.27	-0.38	1.73e-9	Bipolar disorder;
SARC	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg08564027	chr20:61660810	NA	0.76	11.8	0.61	1.69e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs501120	0.657	rs646890	chr10:44741710	C/T	cg09554077	chr10:44749378	NA	0.4	5.08	0.32	7.67e-7	Coronary artery disease;Coronary heart disease;
SARC	cis	rs13191362	0.935	rs116735807	chr6:163010615	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.5	0.34	1.01e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs62344088	0.590	rs2115276	chr5:169829	C/G	cg20965017	chr5:231967	SDHA	-0.84	-5.71	-0.35	3.34e-8	Asthma (childhood onset);
SARC	trans	rs10506458	0.915	rs12426308	chr12:63405778	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.71	-6.49	-0.39	4.99e-10	Hemostatic factors and hematological phenotypes;
SARC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg13397359	chr6:42928475	GNMT	0.57	7.95	0.46	8.25e-14	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg17328964	chr8:145687451	CYHR1	-0.45	-5.97	-0.36	8.64e-9	Age at first birth;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg04597389	chr17:79935740	ASPSCR1	0.47	6.3	0.38	1.5e-9	Tetralogy of Fallot;
SARC	cis	rs2276314	1.000	rs9304153	chr18:33562150	T/C	cg05985134	chr18:33552581	C18orf21	0.66	6.88	0.41	5.4e-11	Endometriosis;Drug-induced torsades de pointes;
SARC	trans	rs9952991	0.654	rs35923716	chr18:12885577	A/G	cg17491449	chr4:3344154	RGS12	-0.6	-6.58	-0.4	3.1e-10	Inflammatory skin disease;
SARC	cis	rs1707322	0.752	rs11211169	chr1:46166709	A/G	cg06784218	chr1:46089804	CCDC17	0.36	6.24	0.38	2.03e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2439831	0.702	rs2788	chr15:44064886	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	7.74	0.45	3.01e-13	Lung cancer in ever smokers;
SARC	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg03709012	chr19:19516395	GATAD2A	0.93	13.36	0.66	1.35e-30	Tonsillectomy;
SARC	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg06212747	chr3:49208901	KLHDC8B	0.76	11.04	0.59	4.57e-23	Menarche (age at onset);
SARC	cis	rs6909752	0.651	rs34930763	chr6:22557915	C/G	cg13666174	chr6:22585274	NA	-0.43	-4.89	-0.31	1.85e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg23492582	chr20:55926133	RAE1	-0.77	-6.32	-0.38	1.3e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg13647721	chr17:30228624	UTP6	0.59	4.74	0.3	3.78e-6	Hip circumference adjusted for BMI;
SARC	trans	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg00656289	chr6:158653327	NA	0.45	6.35	0.38	1.11e-9	Immature fraction of reticulocytes;
SARC	cis	rs35213789	0.878	rs12698853	chr7:69580978	A/G	cg10619644	chr7:69149951	AUTS2	-0.42	-5.21	-0.32	4.23e-7	Childhood ear infection;
SARC	cis	rs4660306	1.000	rs7522705	chr1:45992300	C/G	cg24296786	chr1:45957014	TESK2	-0.55	-6.4	-0.39	8.35e-10	Homocysteine levels;
SARC	cis	rs3812831	0.695	rs7995986	chr13:114938802	A/G	cg06611532	chr13:114900021	NA	0.32	5.47	0.34	1.17e-7	Schizophrenia;
SARC	cis	rs796364	0.806	rs203767	chr2:200902411	G/A	cg23649088	chr2:200775458	C2orf69	-0.64	-5.54	-0.34	8.17e-8	Schizophrenia;
SARC	cis	rs7615952	0.688	rs17334074	chr3:125540460	A/G	cg05084668	chr3:125655381	ALG1L	0.46	5.05	0.31	9.03e-7	Blood pressure (smoking interaction);
SARC	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg07636037	chr3:49044803	WDR6	0.99	17.55	0.75	1.7e-44	Parkinson's disease;
SARC	cis	rs16854884	0.632	rs4446205	chr3:143682607	A/G	cg06585982	chr3:143692056	C3orf58	0.64	8.38	0.48	4.87e-15	Economic and political preferences (feminism/equality);
SARC	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg27532560	chr4:187881888	NA	-0.37	-5.04	-0.31	9.14e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2120019	0.938	rs8030089	chr15:75290377	C/T	cg17294928	chr15:75287854	SCAMP5	-1.02	-15.03	-0.7	3.73e-36	Blood trace element (Zn levels);
SARC	cis	rs3806843	0.676	rs2569159	chr5:140030710	C/T	cg16577123	chr5:140027231	NDUFA2;IK	-0.45	-5.3	-0.33	2.65e-7	Depressive symptoms (multi-trait analysis);
SARC	cis	rs11645898	0.872	rs55955726	chr16:72213691	G/C	cg14768367	chr16:72042858	DHODH	-0.55	-5.2	-0.32	4.42e-7	Blood protein levels;
SARC	cis	rs1707322	0.963	rs10890373	chr1:46393755	A/C	cg03146154	chr1:46216737	IPP	0.48	5.9	0.36	1.28e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs13191362	1.000	rs35754151	chr6:163074867	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.74	6.47	0.39	5.62e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs9346455	1.000	rs60555932	chr6:71990896	A/T	cg27238071	chr6:71998145	OGFRL1	0.59	4.8	0.3	2.82e-6	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
SARC	trans	rs1961637	0.603	rs1550423	chr2:223885812	C/T	cg26634885	chr17:43209687	PLCD3;ACBD4	-0.48	-6.27	-0.38	1.73e-9	Oropharynx cancer;
SARC	cis	rs9611519	0.507	rs12484525	chr22:41443877	G/C	cg03806693	chr22:41940476	POLR3H	-0.6	-7.86	-0.46	1.38e-13	Neuroticism;
SARC	cis	rs7474896	0.526	rs1208633	chr10:38156873	A/C	cg25427524	chr10:38739819	LOC399744	0.52	6.36	0.38	1.04e-9	Obesity (extreme);
SARC	cis	rs6981523	0.553	rs11783890	chr8:11056388	T/C	cg12395012	chr8:11607386	GATA4	0.31	5.03	0.31	9.84e-7	Neuroticism;
SARC	cis	rs7474896	0.515	rs594594	chr10:38307723	A/G	cg00409905	chr10:38381863	ZNF37A	0.45	4.96	0.31	1.37e-6	Obesity (extreme);
SARC	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg16339924	chr4:17578868	LAP3	0.68	9.1	0.51	4.11e-17	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.41	-6.35	-0.38	1.14e-9	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	trans	rs61931739	0.517	rs7486246	chr12:34526419	T/G	cg13010199	chr12:38710504	ALG10B	0.78	11.07	0.59	3.76e-23	Morning vs. evening chronotype;
SARC	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.52	-6.49	-0.39	5.02e-10	Bipolar disorder;
SARC	trans	rs2727020	0.729	rs588458	chr11:49214048	C/A	cg15704280	chr7:45808275	SEPT13	0.86	13.33	0.66	1.66e-30	Coronary artery disease;
SARC	cis	rs2228479	0.850	rs11639906	chr16:89798183	T/C	cg00800038	chr16:89945340	TCF25	-0.7	-4.71	-0.3	4.18e-6	Skin colour saturation;
SARC	cis	rs2976388	1.000	rs2717562	chr8:143776668	T/C	cg06565975	chr8:143823917	SLURP1	-0.28	-4.73	-0.3	3.82e-6	Urinary tract infection frequency;
SARC	cis	rs1448094	0.791	rs10863110	chr12:86328523	T/C	cg02569458	chr12:86230093	RASSF9	0.41	5.83	0.36	1.88e-8	Major depressive disorder;
SARC	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg11987759	chr7:65425863	GUSB	-0.57	-7.33	-0.43	3.85e-12	Aortic root size;
SARC	cis	rs2486288	0.539	rs2433601	chr15:45716425	T/C	cg26924012	chr15:45694286	SPATA5L1	0.52	6.44	0.39	6.66e-10	Glomerular filtration rate;
SARC	cis	rs7582720	0.943	rs72932560	chr2:203847417	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs7223966	1.000	rs6504182	chr17:61823672	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.56	-6.45	-0.39	6.38e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg13939156	chr17:80058883	NA	-0.44	-6.84	-0.41	6.85e-11	Life satisfaction;
SARC	cis	rs1949733	1.000	rs1949733	chr4:8503359	C/T	cg11789530	chr4:8429930	ACOX3	-0.84	-11.35	-0.6	4.58e-24	Response to antineoplastic agents;
SARC	cis	rs3741404	0.584	rs645461	chr11:63893694	C/T	cg04317338	chr11:64019027	PLCB3	-0.45	-5.43	-0.33	1.44e-7	Platelet count;
SARC	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg12463550	chr7:65579703	CRCP	0.51	5.75	0.35	2.75e-8	Aortic root size;
SARC	cis	rs9660992	0.573	rs1172158	chr1:205208948	G/A	cg00857998	chr1:205179979	DSTYK	0.51	6.31	0.38	1.39e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs9894429	0.634	rs11655346	chr17:79572399	A/G	cg10661904	chr17:79619235	PDE6G	0.43	6.08	0.37	4.85e-9	Eye color traits;
SARC	cis	rs6570726	0.791	rs9399558	chr6:145911730	T/C	cg05347473	chr6:146136440	FBXO30	0.54	7.32	0.43	4.05e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7011049	1.000	rs77668788	chr8:53856407	C/T	cg26025543	chr8:53854495	NA	0.6	5.37	0.33	1.91e-7	Systolic blood pressure;
SARC	cis	rs2290402	0.536	rs73207790	chr4:865430	G/A	cg00846425	chr4:957561	DGKQ	-0.42	-4.93	-0.31	1.57e-6	Type 2 diabetes;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg26651188	chr12:7092012	LPCAT3	0.45	6.33	0.38	1.24e-9	Thyroid stimulating hormone;
SARC	cis	rs3106136	0.609	rs28696050	chr4:95136630	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.33	-4.78	-0.3	3.13e-6	Capecitabine sensitivity;
SARC	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg17376030	chr22:41985996	PMM1	-0.69	-8.72	-0.5	5.23e-16	Vitiligo;
SARC	cis	rs7666738	0.830	rs28417716	chr4:98864859	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.59	0.49	1.24e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs780096	0.778	rs780094	chr2:27741237	C/T	cg12000995	chr2:27665139	KRTCAP3	0.29	4.92	0.31	1.65e-6	Total body bone mineral density;
SARC	cis	rs1707322	1.000	rs11211243	chr1:46455433	G/C	cg06784218	chr1:46089804	CCDC17	0.35	6.07	0.37	5.11e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg05368731	chr17:41323189	NBR1	0.81	9.93	0.55	1.35e-19	Menopause (age at onset);
SARC	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg06618935	chr21:46677482	NA	-0.41	-5.36	-0.33	2.03e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9443189	0.570	rs485906	chr6:76300550	A/C	cg01950844	chr6:76311363	SENP6	0.83	7.62	0.45	6.44e-13	Prostate cancer;
SARC	cis	rs9788682	0.747	rs3743078	chr15:78894759	C/G	cg24631222	chr15:78858424	CHRNA5	-0.67	-9.07	-0.51	5.22e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.82	-12.2	-0.62	8.75e-27	Personality dimensions;
SARC	cis	rs1865760	0.566	rs9348706	chr6:26065481	G/C	cg17691542	chr6:26056736	HIST1H1C	0.53	6.58	0.4	3.06e-10	Height;
SARC	cis	rs10911232	0.507	rs10911231	chr1:183051745	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.35	0.56	6.82e-21	Hypertriglyceridemia;
SARC	cis	rs8058578	1.000	rs7204278	chr16:30730274	A/G	cg00531865	chr16:30841666	NA	-0.54	-6.18	-0.38	2.9e-9	Multiple myeloma;
SARC	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg11987759	chr7:65425863	GUSB	-0.58	-7.8	-0.46	2.07e-13	Aortic root size;
SARC	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg05368731	chr17:41323189	NBR1	0.66	8.14	0.47	2.36e-14	Menopause (age at onset);
SARC	cis	rs11969893	0.850	rs3734351	chr6:101307131	C/T	cg12253828	chr6:101329408	ASCC3	1.25	7.81	0.46	1.91e-13	Economic and political preferences (immigration/crime);
SARC	cis	rs986417	0.901	rs4640083	chr14:61097779	G/A	cg27398547	chr14:60952738	C14orf39	0.87	7.55	0.44	9.83e-13	Gut microbiota (bacterial taxa);
SARC	cis	rs10870270	1.000	rs10430617	chr10:133748889	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.47	-5.58	-0.34	6.64e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs7512552	0.780	rs55823828	chr1:150467296	G/C	cg15654264	chr1:150340011	RPRD2	0.38	4.79	0.3	3.02e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg11608241	chr8:8085544	FLJ10661	0.46	5.46	0.34	1.21e-7	Systolic blood pressure;
SARC	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	12.85	0.64	6.39e-29	Platelet count;
SARC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg07414643	chr4:187882934	NA	0.45	6.47	0.39	5.68e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12079745	0.793	rs3737683	chr1:169438180	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.85	-5.08	-0.32	7.7e-7	QT interval;
SARC	cis	rs11098499	0.954	rs66506550	chr4:120371445	T/A	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs7727544	0.684	rs2631363	chr5:131707095	A/G	cg07395648	chr5:131743802	NA	0.42	4.92	0.31	1.62e-6	Blood metabolite levels;
SARC	cis	rs477692	1.000	rs7475154	chr10:131440584	C/T	cg05714579	chr10:131428358	MGMT	-0.56	-7.28	-0.43	5.23e-12	Response to temozolomide;
SARC	cis	rs6998277	1.000	rs35155104	chr8:103646559	G/T	cg10187029	chr8:103597600	NA	0.66	6.64	0.4	2.17e-10	Migraine;
SARC	cis	rs2742234	0.590	rs2503863	chr10:43667398	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.4	-4.74	-0.3	3.67e-6	Hirschsprung disease;
SARC	trans	rs1814175	0.817	rs1390676	chr11:50056778	C/T	cg03929089	chr4:120376271	NA	-0.88	-14.35	-0.68	6.73e-34	Height;
SARC	cis	rs6580649	0.941	rs1793931	chr12:48396505	G/T	cg05342945	chr12:48394962	COL2A1	-0.55	-5.66	-0.35	4.54e-8	Lung cancer;
SARC	cis	rs7208859	0.673	rs11654331	chr17:29165017	A/G	cg13385521	chr17:29058706	SUZ12P	0.86	7.3	0.43	4.51e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs2120243	0.598	rs1500916	chr3:157088042	C/G	cg24825693	chr3:157122686	VEPH1	-0.44	-5.97	-0.36	8.67e-9	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs6540556	0.834	rs6700223	chr1:209935031	G/A	cg23920097	chr1:209922102	NA	-0.56	-6.64	-0.4	2.17e-10	Red blood cell count;
SARC	cis	rs2016266	0.784	rs6421176	chr12:53654052	A/G	cg26875137	chr12:53738046	NA	0.41	5.2	0.32	4.35e-7	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs734999	0.545	rs7368105	chr1:2556548	C/T	cg20673091	chr1:2541236	MMEL1	0.32	4.98	0.31	1.23e-6	Ulcerative colitis;
SARC	cis	rs1003719	0.612	rs2835652	chr21:38557408	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.29	-0.52	1.11e-17	Eye color traits;
SARC	trans	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg06437703	chr8:37914619	EIF4EBP1	0.62	7.26	0.43	5.6e-12	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs7027203	0.797	rs3996254	chr9:96591239	A/G	cg13679303	chr9:96623674	NA	-0.34	-4.9	-0.31	1.79e-6	DNA methylation (variation);
SARC	cis	rs10861342	0.892	rs11112378	chr12:105514033	A/G	cg23923672	chr12:105501055	KIAA1033	0.7	5.14	0.32	5.77e-7	IgG glycosylation;
SARC	cis	rs959260	0.623	rs4542691	chr17:73326965	T/C	cg07104495	chr17:73266070	MIF4GD	-0.33	-4.91	-0.31	1.74e-6	Systemic lupus erythematosus;
SARC	cis	rs6570726	0.791	rs9376945	chr6:145828080	T/A	cg23711669	chr6:146136114	FBXO30	0.87	14.58	0.69	1.18e-34	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4742903	0.904	rs1507514	chr9:106986114	T/C	cg14250997	chr9:106856677	SMC2	0.4	4.96	0.31	1.33e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs9818758	0.607	rs9880088	chr3:49178990	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.69	-5.85	-0.36	1.61e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs2116941	1.000	rs2033493	chr19:10340854	A/C	cg01850179	chr19:10340795	S1PR2	-0.66	-8.09	-0.47	3.26e-14	Pulse pressure;
SARC	cis	rs1270639	0.722	rs6950817	chr7:157439636	A/G	cg13357408	chr7:157437802	PTPRN2	0.46	4.93	0.31	1.6e-6	Colorectal cancer;
SARC	cis	rs2180341	1.000	rs3798853	chr6:127636823	C/T	cg24812749	chr6:127587940	RNF146	-0.95	-12.23	-0.63	6.66e-27	Breast cancer;
SARC	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg07061783	chr6:25882402	NA	-0.44	-5.34	-0.33	2.21e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1348850	0.837	rs4243388	chr2:178284604	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.7	8.98	0.51	9.48e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7264396	0.635	rs6060688	chr20:34516731	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.51	-5.28	-0.33	3.03e-7	Total cholesterol levels;
SARC	cis	rs13082711	0.911	rs57317249	chr3:27515854	A/C	cg02860705	chr3:27208620	NA	0.41	5.38	0.33	1.78e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg13770153	chr20:60521292	NA	-0.54	-7.26	-0.43	5.59e-12	Body mass index;
SARC	cis	rs67311347	0.544	rs9814779	chr3:40340431	T/C	cg24209194	chr3:40518798	ZNF619	0.47	6.31	0.38	1.38e-9	Renal cell carcinoma;
SARC	cis	rs7216064	1.000	rs12602912	chr17:65870073	C/T	cg12091567	chr17:66097778	LOC651250	-0.64	-6.45	-0.39	6.56e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs9790314	0.779	rs1599376	chr3:160900533	C/G	cg04691961	chr3:161091175	C3orf57	-0.7	-9.56	-0.53	1.72e-18	Morning vs. evening chronotype;
SARC	trans	rs1865760	0.929	rs9461224	chr6:25936402	G/T	cg26788993	chr3:159706828	IL12A	-0.53	-6.4	-0.39	8.23e-10	Height;
SARC	cis	rs2180341	1.000	rs9321073	chr6:127609691	C/T	cg17762328	chr6:126965162	NA	-0.45	-5.1	-0.32	7.15e-7	Breast cancer;
SARC	cis	rs11608355	0.515	rs34038572	chr12:109901657	A/G	cg05360138	chr12:110035743	NA	0.92	9.65	0.53	9.69e-19	Neuroticism;
SARC	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg20887711	chr4:1340912	KIAA1530	-0.62	-7.28	-0.43	5.1e-12	Obesity-related traits;
SARC	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg24642844	chr7:1081250	C7orf50	-0.59	-6.11	-0.37	4.26e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs6866344	0.598	rs34703961	chr5:178147874	A/G	cg10224037	chr5:178157518	ZNF354A	0.97	12.66	0.64	2.68e-28	Neutrophil percentage of white cells;
SARC	cis	rs7412746	0.658	rs2089082	chr1:150800090	T/G	cg15448220	chr1:150897856	SETDB1	0.48	6.3	0.38	1.5e-9	Melanoma;
SARC	cis	rs3126085	0.935	rs2184950	chr1:152272776	T/C	cg26876637	chr1:152193138	HRNR	-0.43	-4.75	-0.3	3.54e-6	Atopic dermatitis;
SARC	cis	rs78487399	0.808	rs77527404	chr2:43678387	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-5.01	-0.31	1.08e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg06018095	chr13:46550134	ZC3H13	-0.54	-6.55	-0.39	3.6e-10	Alcohol dependence;
SARC	cis	rs861020	0.606	rs2184919	chr1:210000015	C/T	cg05527609	chr1:210001259	C1orf107	-0.72	-8.83	-0.5	2.56e-16	Orofacial clefts;
SARC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg25894440	chr7:65020034	NA	0.42	4.77	0.3	3.19e-6	Calcium levels;
SARC	cis	rs2832077	0.943	rs2832100	chr21:30175628	A/C	cg03476357	chr21:30257390	N6AMT1	-0.51	-4.91	-0.31	1.71e-6	Cognitive test performance;
SARC	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg27266027	chr21:40555129	PSMG1	0.47	5.13	0.32	6.03e-7	Cognitive function;
SARC	cis	rs9527	0.590	rs7910900	chr10:104829898	C/T	cg04362960	chr10:104952993	NT5C2	0.42	4.96	0.31	1.38e-6	Arsenic metabolism;
SARC	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.83	-12.06	-0.62	2.37e-26	Gut microbiome composition (summer);
SARC	cis	rs6910061	0.830	rs9461493	chr6:11120770	C/T	cg27233058	chr6:11094804	LOC221710	0.61	5.41	0.33	1.53e-7	Diabetic kidney disease;
SARC	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg09757709	chr11:93464721	SNORA32;SNORD6;SNORA25	-0.51	-6.25	-0.38	1.98e-9	Brain structure;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg23087020	chr1:167190262	POU2F1	-0.74	-6.25	-0.38	1.91e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg02463440	chr8:22132932	PIWIL2	0.47	6.67	0.4	1.84e-10	Hypertriglyceridemia;
SARC	cis	rs7560272	0.501	rs6750494	chr2:73946496	G/A	cg20560298	chr2:73613845	ALMS1	0.43	5.73	0.35	3.08e-8	Schizophrenia;
SARC	trans	rs12310956	0.532	rs11052933	chr12:33969881	G/A	cg13010199	chr12:38710504	ALG10B	0.75	10.16	0.55	2.58e-20	Morning vs. evening chronotype;
SARC	cis	rs3784262	0.669	rs4646595	chr15:58302341	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.35	-5.29	-0.33	2.85e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg16414030	chr3:133502952	NA	-0.39	-5.34	-0.33	2.18e-7	Iron status biomarkers;
SARC	cis	rs2253017	0.723	rs2818989	chr13:21386851	A/C	cg16922012	chr13:21400325	XPO4	-0.43	-6.1	-0.37	4.42e-9	PR segment;
SARC	cis	rs7617480	0.544	rs6442129	chr3:48735256	T/C	cg07636037	chr3:49044803	WDR6	0.77	8.22	0.47	1.38e-14	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs6831352	0.703	rs2602854	chr4:100028651	C/T	cg13256891	chr4:100009986	ADH5	0.6	7.84	0.46	1.5700000000000001e-13	Alcohol dependence;
SARC	cis	rs1153858	1.000	rs1365610	chr15:45694610	C/T	cg15395560	chr15:45543142	SLC28A2	-0.26	-4.76	-0.3	3.41e-6	Homoarginine levels;
SARC	cis	rs611744	0.608	rs612744	chr8:109245991	G/A	cg21045802	chr8:109455806	TTC35	0.6	7.54	0.44	1.02e-12	Dupuytren's disease;
SARC	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg18876405	chr7:65276391	NA	-0.47	-5.29	-0.33	2.84e-7	Aortic root size;
SARC	cis	rs11864453	0.963	rs7185215	chr16:72034864	T/C	cg01557791	chr16:72042693	DHODH	-0.67	-9.24	-0.52	1.58e-17	Fibrinogen levels;
SARC	cis	rs11785400	1.000	rs7002932	chr8:143738816	C/A	cg10596483	chr8:143751796	JRK	0.64	8.65	0.49	8.4e-16	Schizophrenia;
SARC	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg26924012	chr15:45694286	SPATA5L1	0.78	10.98	0.58	7.1e-23	Homoarginine levels;
SARC	cis	rs12579753	0.879	rs11115010	chr12:82165895	G/T	cg07988820	chr12:82153109	PPFIA2	-0.58	-6.92	-0.41	4.35e-11	Resting heart rate;
SARC	cis	rs10911232	0.507	rs10737239	chr1:183030170	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.11	0.55	3.72e-20	Hypertriglyceridemia;
SARC	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg05340658	chr4:99064831	C4orf37	0.54	6.53	0.39	3.97e-10	Colonoscopy-negative controls vs population controls;
SARC	cis	rs3796352	1.000	rs13091844	chr3:53010271	C/T	cg27565382	chr3:53032988	SFMBT1	0.76	5.34	0.33	2.25e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg18876405	chr7:65276391	NA	0.71	9.35	0.52	7.69e-18	Aortic root size;
SARC	cis	rs4906332	1.000	rs7155822	chr14:103922390	A/G	cg26031613	chr14:104095156	KLC1	-0.47	-5.51	-0.34	9.59e-8	Coronary artery disease;
SARC	cis	rs4974559	0.739	rs2335937	chr4:1321516	C/A	cg02980000	chr4:1222292	CTBP1	0.65	4.98	0.31	1.23e-6	Systolic blood pressure;
SARC	cis	rs6582630	0.512	rs11182667	chr12:38588392	C/A	cg13010199	chr12:38710504	ALG10B	-0.53	-6.55	-0.39	3.64e-10	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg22875332	chr1:76189707	ACADM	-0.44	-5.62	-0.35	5.51e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg05793240	chr7:2802953	GNA12	-0.38	-5.48	-0.34	1.12e-7	Height;
SARC	cis	rs77956314	0.515	rs10850741	chr12:117432004	A/G	cg02017074	chr12:117425053	FBXW8	0.59	7.25	0.43	6.05e-12	Subcortical brain region volumes;Hippocampal volume;
SARC	cis	rs2439831	0.717	rs2470132	chr15:43835481	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	9.0	0.51	8.02e-17	Lung cancer in ever smokers;
SARC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg08280861	chr8:58055591	NA	0.61	5.94	0.36	1.01e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg15556689	chr8:8085844	FLJ10661	0.61	8.01	0.46	5.6e-14	Neuroticism;
SARC	cis	rs8095374	0.935	rs11082513	chr18:43747153	C/T	cg25174615	chr18:43684699	ATP5A1;HAUS1	0.46	5.37	0.33	1.91e-7	Clinical laboratory measurements;
SARC	cis	rs459571	0.804	rs448918	chr9:136885979	G/A	cg01294253	chr9:136912663	BRD3	0.4	5.16	0.32	5.25e-7	Platelet distribution width;
SARC	cis	rs7927771	0.800	rs35996350	chr11:47389223	A/G	cg20307385	chr11:47447363	PSMC3	-0.57	-7.13	-0.42	1.23e-11	Subjective well-being;
SARC	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	ch.11.2136200F	chr11:103819223	PDGFD	0.5	6.42	0.39	7.58e-10	Brain structure;
SARC	cis	rs11098499	0.618	rs28491261	chr4:120294900	C/A	cg09307838	chr4:120376055	NA	0.9	12.64	0.64	3.03e-28	Corneal astigmatism;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg01493318	chr18:8705700	NA	-0.86	-7.27	-0.43	5.41e-12	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6674176	0.696	rs4448553	chr1:44411589	A/G	cg13246856	chr1:44399776	ARTN	0.3	4.88	0.3	1.97e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs7940866	0.801	rs10894296	chr11:130840433	T/G	cg12179176	chr11:130786555	SNX19	0.66	8.79	0.5	3.43e-16	Schizophrenia;
SARC	cis	rs7917772	0.636	rs2863718	chr10:104519631	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-6.43	-0.39	7.05e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	trans	rs1814175	0.817	rs6486044	chr11:49982718	C/T	cg03929089	chr4:120376271	NA	-0.89	-14.59	-0.69	1.1e-34	Height;
SARC	cis	rs12922317	0.681	rs2869492	chr16:12071341	T/C	cg09319797	chr16:12061715	TNFRSF17	0.4	6.41	0.39	7.86e-10	Schizophrenia;
SARC	cis	rs2832191	0.636	rs8131283	chr21:30516796	A/G	cg24692254	chr21:30365293	RNF160	-0.69	-8.17	-0.47	1.91e-14	Dental caries;
SARC	cis	rs6904897	0.563	rs4896117	chr6:135229400	T/C	cg12549451	chr6:135224345	NA	-0.42	-5.71	-0.35	3.35e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs17376456	1.000	rs10514382	chr5:93566534	G/A	cg25358565	chr5:93447407	FAM172A	1.34	14.09	0.68	5.05e-33	Diabetic retinopathy;
SARC	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.44	6.76	0.41	1.07e-10	Schizophrenia;
SARC	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg05313129	chr8:58192883	C8orf71	-0.52	-5.96	-0.36	9.41e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1790761	0.632	rs625978	chr11:67344664	C/T	cg24690094	chr11:67383802	NA	0.37	5.5	0.34	1.01e-7	Mean corpuscular volume;
SARC	cis	rs3741151	0.892	rs2027763	chr11:73035799	A/G	cg17517138	chr11:73019481	ARHGEF17	0.69	6.35	0.38	1.11e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs9303401	0.614	rs56284918	chr17:57178838	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.97	10.17	0.55	2.42e-20	Cognitive test performance;
SARC	cis	rs10848704	1.000	rs10848704	chr12:2882544	A/G	cg19995117	chr12:2880862	NA	-0.35	-5.37	-0.33	1.92e-7	Quantitative traits;
SARC	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	11.31	0.6	6.28e-24	Alzheimer's disease;
SARC	cis	rs2841233	0.791	rs2028415	chr14:105349220	T/G	cg01147727	chr14:105363015	KIAA0284	-0.46	-7.36	-0.43	3.16e-12	IgG glycosylation;
SARC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg15383120	chr6:291909	DUSP22	-0.6	-8.01	-0.46	5.43e-14	Menopause (age at onset);
SARC	cis	rs12545109	0.917	rs1370304	chr8:57322822	G/C	cg19413350	chr8:57351067	NA	-0.43	-5.08	-0.32	7.69e-7	Obesity-related traits;
SARC	cis	rs6964587	0.967	rs34040612	chr7:91798916	G/T	cg17063962	chr7:91808500	NA	0.97	15.94	0.72	3.58e-39	Breast cancer;
SARC	cis	rs1045529	0.524	rs34251783	chr8:8891376	T/C	cg08975724	chr8:8085496	FLJ10661	-0.48	-6.2	-0.38	2.51e-9	Myopia;Myopia (pathological);
SARC	cis	rs9911578	1.000	rs2567905	chr17:56782297	T/C	cg12560992	chr17:57184187	TRIM37	0.83	11.23	0.59	1.1e-23	Intelligence (multi-trait analysis);
SARC	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg20887711	chr4:1340912	KIAA1530	0.41	5.0	0.31	1.12e-6	Longevity;
SARC	cis	rs2276314	0.802	rs58906216	chr18:33630297	T/C	cg19628046	chr18:33552617	C18orf21	0.58	6.01	0.37	7.22e-9	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs1421811	0.509	rs7733428	chr5:32689850	G/A	cg16267343	chr5:32710456	NPR3	0.85	11.11	0.59	2.81e-23	Blood pressure;
SARC	cis	rs9309473	1.000	rs6753344	chr2:73653138	C/T	cg20560298	chr2:73613845	ALMS1	0.44	5.45	0.34	1.29e-7	Metabolite levels;
SARC	cis	rs820218	0.886	rs1093994	chr17:73614794	A/G	cg01592526	chr17:73663357	RECQL5;SAP30BP	-0.59	-7.37	-0.43	3.03e-12	Rotator cuff tears;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg01443832	chr7:29725145	LOC646762	-0.8	-6.66	-0.4	1.94e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs477692	0.629	rs945231	chr10:131294827	A/G	cg14263093	chr10:131365266	MGMT	0.35	4.85	0.3	2.26e-6	Response to temozolomide;
SARC	cis	rs523522	0.962	rs2393590	chr12:120913900	G/A	cg27279351	chr12:120934652	DYNLL1	0.71	8.66	0.49	8.19e-16	High light scatter reticulocyte count;
SARC	cis	rs7647973	1.000	rs3448	chr3:49396751	T/C	cg06212747	chr3:49208901	KLHDC8B	0.56	5.75	0.35	2.8e-8	Menarche (age at onset);
SARC	cis	rs6977660	0.714	rs12666488	chr7:19788403	G/A	cg07541023	chr7:19748670	TWISTNB	0.75	6.86	0.41	6.1e-11	Thyroid stimulating hormone;
SARC	cis	rs10089	0.951	rs736969	chr5:127466347	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	10.26	0.56	1.31e-20	Ileal carcinoids;
SARC	cis	rs787274	1.000	rs10739373	chr9:115593239	G/A	cg13803584	chr9:115635662	SNX30	-0.83	-5.03	-0.31	9.96e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs6058796	1.000	rs6087963	chr20:31249144	G/C	cg13636640	chr20:31349939	DNMT3B	0.55	4.82	0.3	2.65e-6	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
SARC	trans	rs9427116	0.502	rs12125166	chr1:154582129	A/G	cg24334809	chr2:178483498	TTC30A	-0.51	-6.26	-0.38	1.8e-9	Blood protein levels;
SARC	cis	rs2933343	1.000	rs789232	chr3:128603080	T/G	cg24203234	chr3:128598194	ACAD9	0.53	5.93	0.36	1.11e-8	IgG glycosylation;
SARC	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg26116260	chr4:7069785	GRPEL1	0.92	11.57	0.6	9e-25	Monocyte percentage of white cells;
SARC	cis	rs9902453	0.817	rs1842026	chr17:28188111	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	7.39	0.44	2.64e-12	Coffee consumption (cups per day);
SARC	cis	rs9818758	0.607	rs5030795	chr3:49141116	C/T	cg12468774	chr3:49236860	CCDC36	0.46	4.88	0.3	1.93e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg17971929	chr21:40555470	PSMG1	-0.57	-7.2	-0.43	8.13e-12	Menarche (age at onset);
SARC	cis	rs9788721	0.900	rs4243084	chr15:78911672	G/C	cg18825076	chr15:78729989	IREB2	-0.41	-5.01	-0.31	1.06e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs67460515	0.500	rs9860537	chr3:160660500	G/T	cg03342759	chr3:160939853	NMD3	0.52	5.85	0.36	1.66e-8	Parkinson's disease;
SARC	cis	rs28374715	0.532	rs28477406	chr15:41642036	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.19	-18.12	-0.76	2.14e-46	Ulcerative colitis;
SARC	cis	rs2797160	0.967	rs1777224	chr6:126019527	T/C	cg05901451	chr6:126070800	HEY2	0.42	5.01	0.31	1.09e-6	Endometrial cancer;
SARC	cis	rs60843830	0.964	rs17713879	chr2:254215	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.65	9.4	0.52	5.47e-18	Spherical equivalent (joint analysis main effects and education interaction);
SARC	cis	rs9296092	0.538	rs35381461	chr6:33519751	T/C	cg13560919	chr6:33536144	NA	-0.5	-6.31	-0.38	1.38e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs7614311	0.636	rs73117057	chr3:63915689	A/G	cg22134162	chr3:63841271	THOC7	-0.46	-4.91	-0.31	1.69e-6	Lung function (FVC);Lung function (FEV1);
SARC	cis	rs7769051	0.522	rs57176306	chr6:133142168	C/T	cg07930552	chr6:133119739	C6orf192	1.0	6.0	0.37	7.59e-9	Type 2 diabetes nephropathy;
SARC	cis	rs2806561	0.704	rs588387	chr1:23523689	A/G	cg12483005	chr1:23474871	LUZP1	0.47	6.11	0.37	4.05e-9	Height;
SARC	cis	rs6582630	0.555	rs1829583	chr12:38423161	T/C	cg13010199	chr12:38710504	ALG10B	-0.69	-9.46	-0.53	3.49e-18	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs8114671	0.967	rs1577924	chr20:33784288	C/G	cg24642439	chr20:33292090	TP53INP2	-0.49	-5.61	-0.34	5.74e-8	Height;
SARC	cis	rs780094	0.585	rs7586601	chr2:27584666	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.32	-4.91	-0.31	1.7e-6	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs9300255	0.602	rs2695478	chr12:123689521	C/T	cg05973401	chr12:123451056	ABCB9	0.54	5.16	0.32	5.32e-7	Neutrophil percentage of white cells;
SARC	cis	rs4711350	0.765	rs943473	chr6:33743651	G/C	cg13859433	chr6:33739653	LEMD2	-0.33	-4.73	-0.3	3.91e-6	Schizophrenia;
SARC	cis	rs6938	0.563	rs12917376	chr15:75116167	C/T	cg09165964	chr15:75287851	SCAMP5	0.6	8.35	0.48	5.92e-15	Breast cancer;
SARC	cis	rs6665290	0.904	rs6664955	chr1:227183434	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.08	-24.92	-0.85	1.15e-67	Myeloid white cell count;
SARC	trans	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg00938859	chr5:1591904	SDHAP3	0.81	7.82	0.46	1.86e-13	Breast cancer;
SARC	cis	rs9790314	0.540	rs9844862	chr3:161076188	G/A	cg04691961	chr3:161091175	C3orf57	-0.57	-7.49	-0.44	1.43e-12	Morning vs. evening chronotype;
SARC	cis	rs2463822	0.688	rs7121684	chr11:62162389	T/C	cg06239285	chr11:62104954	ASRGL1	-0.83	-7.84	-0.46	1.64e-13	Chronic obstructive pulmonary disease-related biomarkers;
SARC	trans	rs1814175	0.588	rs1721994	chr11:49914050	G/A	cg03929089	chr4:120376271	NA	-0.81	-11.69	-0.61	3.89e-25	Height;
SARC	cis	rs7264396	0.790	rs2425125	chr20:34330954	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.55	-5.65	-0.35	4.63e-8	Total cholesterol levels;
SARC	cis	rs4423214	0.592	rs3829251	chr11:71194559	G/A	cg05163923	chr11:71159392	DHCR7	-0.57	-5.75	-0.35	2.85e-8	Vitamin D levels;
SARC	cis	rs77633900	0.614	rs2585730	chr15:76989344	A/G	cg21673338	chr15:77095150	SCAPER	-0.77	-6.45	-0.39	6.52e-10	Non-glioblastoma glioma;Glioma;
SARC	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg04166393	chr7:2884313	GNA12	0.63	7.41	0.44	2.36e-12	Height;
SARC	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg11987759	chr7:65425863	GUSB	-0.58	-7.98	-0.46	6.46e-14	Aortic root size;
SARC	cis	rs12142240	0.698	rs72886907	chr1:46814265	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-5.47	-0.34	1.13e-7	Menopause (age at onset);
SARC	cis	rs9660992	0.674	rs72745219	chr1:205262271	G/A	cg21545522	chr1:205238299	TMCC2	0.46	6.07	0.37	5.05e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs2075371	1.000	rs7486	chr7:133975183	A/G	cg20476274	chr7:133979776	SLC35B4	0.6	8.19	0.47	1.7e-14	Mean platelet volume;
SARC	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg14664628	chr15:75095509	CSK	-0.47	-5.9	-0.36	1.29e-8	Breast cancer;
SARC	cis	rs12931792	0.712	rs2887799	chr16:30163833	G/A	cg17640201	chr16:30407289	ZNF48	0.57	7.33	0.43	3.73e-12	Tonsillectomy;
SARC	cis	rs6504663	0.558	rs2412325	chr17:48546232	G/C	cg00901687	chr17:48585270	MYCBPAP	0.43	5.06	0.31	8.47e-7	Visceral fat;
SARC	cis	rs9916302	0.706	rs7503377	chr17:37708841	A/G	cg20243544	chr17:37824526	PNMT	0.52	4.94	0.31	1.48e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg26335602	chr6:28129616	ZNF389	0.53	5.91	0.36	1.2e-8	Depression;
SARC	cis	rs6714710	0.603	rs13023980	chr2:98502987	T/C	cg26665480	chr2:98280029	ACTR1B	0.51	6.91	0.41	4.71e-11	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs4713118	0.513	rs149962	chr6:28015918	G/A	cg26335602	chr6:28129616	ZNF389	0.45	5.11	0.32	6.68e-7	Parkinson's disease;
SARC	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg05025164	chr4:1340916	KIAA1530	-0.45	-5.16	-0.32	5.26e-7	Obesity-related traits;
SARC	cis	rs1008375	0.932	rs6844593	chr4:17659039	T/C	cg27347728	chr4:17578864	LAP3	0.49	6.19	0.38	2.73e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg18404041	chr3:52824283	ITIH1	-0.38	-5.68	-0.35	3.93e-8	Bipolar disorder;
SARC	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg23958373	chr8:599963	NA	0.73	5.56	0.34	7.33e-8	IgG glycosylation;
SARC	cis	rs4986172	0.726	rs12051846	chr17:43226887	A/G	cg27395066	chr17:43221220	ACBD4	0.39	5.09	0.32	7.43e-7	Height;
SARC	cis	rs7940866	0.740	rs2162060	chr11:130830763	A/G	cg12179176	chr11:130786555	SNX19	0.65	8.77	0.5	3.88e-16	Schizophrenia;
SARC	cis	rs2380220	0.938	rs6923253	chr6:95970141	C/G	cg23517279	chr6:96025343	MANEA	0.54	5.6	0.34	6.03e-8	Behavioural disinhibition (generation interaction);
SARC	trans	rs2727020	0.688	rs4929894	chr11:49196333	G/C	cg03929089	chr4:120376271	NA	-0.73	-9.99	-0.55	8.44e-20	Coronary artery disease;
SARC	trans	rs61931739	0.517	rs34760282	chr12:34153711	G/T	cg26384229	chr12:38710491	ALG10B	0.83	12.13	0.62	1.42e-26	Morning vs. evening chronotype;
SARC	cis	rs854765	0.619	rs6502636	chr17:17983817	A/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.4	4.98	0.31	1.24e-6	Total body bone mineral density;
SARC	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg24675658	chr1:53192096	ZYG11B	-0.61	-8.47	-0.49	2.72e-15	Monocyte count;
SARC	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.44	5.06	0.31	8.39e-7	Renal function-related traits (BUN);
SARC	cis	rs5769765	0.542	rs5770720	chr22:50253101	A/G	cg03033257	chr22:50311977	ALG12;CRELD2	-0.54	-4.75	-0.3	3.58e-6	Schizophrenia;
SARC	cis	rs11718455	0.960	rs34179760	chr3:44002303	A/G	cg08738300	chr3:44038990	NA	0.54	5.91	0.36	1.18e-8	Coronary artery disease;
SARC	cis	rs6582630	0.519	rs11495376	chr12:38284957	A/C	cg26384229	chr12:38710491	ALG10B	0.87	12.86	0.64	6.01e-29	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs453301	0.658	rs13271797	chr8:8885954	G/A	cg15556689	chr8:8085844	FLJ10661	-0.53	-7.1	-0.42	1.5e-11	Joint mobility (Beighton score);
SARC	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg06618935	chr21:46677482	NA	-0.39	-5.23	-0.32	3.74e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1707322	1.000	rs785490	chr1:46577124	T/C	cg03146154	chr1:46216737	IPP	-0.48	-5.6	-0.34	6.03e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6448317	0.906	rs4053966	chr4:24901466	A/G	cg21108841	chr4:24914750	CCDC149	-0.52	-6.07	-0.37	5.21e-9	Heschl's gyrus morphology;
SARC	cis	rs9322817	0.691	rs1455935	chr6:105230312	C/G	cg02098413	chr6:105308735	HACE1	-0.39	-6.13	-0.37	3.69e-9	Thyroid stimulating hormone;
SARC	cis	rs6570726	0.846	rs7773939	chr6:145927384	C/T	cg23711669	chr6:146136114	FBXO30	-0.79	-12.2	-0.62	8.76e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4728302	0.608	rs10254118	chr7:133158353	T/A	cg10665199	chr7:133106180	EXOC4	0.41	5.23	0.32	3.74e-7	Intelligence;Intelligence (multi-trait analysis);
SARC	cis	rs10876993	0.890	rs774888	chr12:58036506	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.46	-5.89	-0.36	1.37e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs7662987	0.517	rs2602877	chr4:100039847	T/A	cg13256891	chr4:100009986	ADH5	0.68	8.61	0.49	1.13e-15	Smoking initiation;
SARC	cis	rs9660992	0.710	rs1668873	chr1:205235990	G/A	cg19090574	chr1:205240910	TMCC2	-0.39	-4.85	-0.3	2.29e-6	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs7191439	0.858	rs11076702	chr16:88774569	A/C	cg27087555	chr16:88793112	FAM38A	-1.09	-7.44	-0.44	1.93e-12	Plateletcrit;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg01481569	chr12:29673649	TMTC1	0.45	6.34	0.38	1.16e-9	Thyroid stimulating hormone;
SARC	cis	rs2415984	0.562	rs34386313	chr14:46908479	C/T	cg14871534	chr14:47121158	RPL10L	0.38	5.09	0.32	7.22e-7	Number of children ever born;
SARC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.42	0.53	4.71e-18	Prudent dietary pattern;
SARC	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg05313129	chr8:58192883	C8orf71	-0.62	-6.34	-0.38	1.18e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10193935	1.000	rs10210866	chr2:42387879	A/G	cg27598129	chr2:42591480	NA	-0.36	-5.02	-0.31	1.01e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs67460515	0.892	rs7648279	chr3:160979646	G/A	cg17135325	chr3:160939158	NMD3	0.61	7.72	0.45	3.44e-13	Parkinson's disease;
SARC	cis	rs568617	1.000	rs641018	chr11:65655393	G/C	cg04055107	chr11:65626734	MUS81;CFL1	0.47	5.45	0.34	1.31e-7	Crohn's disease;
SARC	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg18404041	chr3:52824283	ITIH1	-0.43	-6.53	-0.39	4.04e-10	Bipolar disorder;
SARC	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg04267008	chr7:1944627	MAD1L1	-0.62	-6.84	-0.41	6.97e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs754466	0.651	rs10824583	chr10:79619402	C/T	cg17075019	chr10:79541650	NA	0.79	12.36	0.63	2.5e-27	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1448094	0.549	rs4919770	chr12:86238050	G/T	cg02569458	chr12:86230093	RASSF9	0.41	5.9	0.36	1.28e-8	Major depressive disorder;
SARC	cis	rs1669338	0.588	rs3846135	chr3:3195574	C/T	cg16797762	chr3:3221439	CRBN	-0.91	-9.37	-0.52	6.43e-18	White matter integrity;
SARC	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs3799379	0.550	rs2072804	chr6:26391190	G/A	cg12826209	chr6:26865740	GUSBL1	0.52	5.82	0.36	1.89e-8	Intelligence (multi-trait analysis);
SARC	cis	rs4805272	0.539	rs1422212	chr19:29330191	T/A	cg12756686	chr19:29218302	NA	0.57	6.47	0.39	5.88e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs2197308	0.765	rs7295711	chr12:37903631	C/T	cg13010199	chr12:38710504	ALG10B	0.8	11.02	0.59	5.3e-23	Morning vs. evening chronotype;
SARC	trans	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg26001467	chr14:21979675	METTL3	-0.64	-6.23	-0.38	2.15e-9	Cutaneous psoriasis;
SARC	cis	rs2908197	0.713	rs2961037	chr7:75952212	G/T	cg07849177	chr7:76178544	LOC100133091	-0.43	-5.0	-0.31	1.13e-6	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs2303745	0.589	rs7246262	chr19:17392483	C/G	cg04248312	chr19:17393744	ANKLE1	-0.61	-8.03	-0.47	4.94e-14	Systemic lupus erythematosus;
SARC	cis	rs7766436	0.614	rs12660581	chr6:22564435	C/T	cg13666174	chr6:22585274	NA	-0.56	-5.86	-0.36	1.59e-8	Coronary artery disease;
SARC	cis	rs7523050	0.730	rs72984614	chr1:109435848	T/C	cg08274380	chr1:109419600	GPSM2	1.1	8.68	0.49	6.9e-16	Fat distribution (HIV);
SARC	cis	rs9399135	0.967	rs7750300	chr6:135350950	C/G	cg24558204	chr6:135376177	HBS1L	0.45	6.09	0.37	4.73e-9	Red blood cell count;
SARC	cis	rs6446731	0.517	rs2071671	chr4:3269787	C/G	cg06533319	chr4:3265114	C4orf44	0.31	4.9	0.31	1.81e-6	Mean platelet volume;
SARC	cis	rs6546550	0.901	rs6725425	chr2:70150674	T/C	cg02498382	chr2:70120550	SNRNP27	-0.33	-5.36	-0.33	1.99e-7	Prevalent atrial fibrillation;
SARC	cis	rs933688	0.941	rs6452954	chr5:90735692	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	13.36	0.66	1.29e-30	Smoking behavior;
SARC	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs874628	0.576	rs72999466	chr19:18248499	C/T	cg00493341	chr19:18228948	MAST3	0.47	4.91	0.31	1.69e-6	Multiple sclerosis;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg23010344	chr1:228871301	RHOU	0.49	6.43	0.39	6.96e-10	Chemerin levels;
SARC	trans	rs11165623	0.564	rs12752866	chr1:97000181	T/C	cg10631902	chr5:14652156	NA	-0.43	-6.54	-0.39	3.89e-10	Hip circumference;Waist circumference;
SARC	trans	rs3780486	0.757	rs10758189	chr9:33125804	A/G	cg04842962	chr6:43655489	MRPS18A	1.08	20.01	0.8	1.71e-52	IgG glycosylation;
SARC	trans	rs2727020	0.553	rs10839295	chr11:49527345	A/C	cg15704280	chr7:45808275	SEPT13	-0.81	-12.97	-0.65	2.65e-29	Coronary artery disease;
SARC	cis	rs981844	0.857	rs62325142	chr4:154717790	A/G	cg14289246	chr4:154710475	SFRP2	0.65	6.97	0.42	3.28e-11	Response to statins (LDL cholesterol change);
SARC	cis	rs7011049	0.908	rs11986701	chr8:53833480	G/T	cg26025543	chr8:53854495	NA	0.6	5.47	0.34	1.15e-7	Systolic blood pressure;
SARC	cis	rs1267303	0.675	rs7519040	chr1:46986641	A/G	cg25110126	chr1:46999211	NA	0.69	7.8	0.45	2.1e-13	Monobrow;
SARC	cis	rs2708377	0.858	rs117212341	chr12:11282556	C/G	cg27345534	chr12:11509583	PRB1	0.5	4.75	0.3	3.59e-6	Bitter taste perception;
SARC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	10.46	0.57	2.97e-21	Platelet count;
SARC	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg26335602	chr6:28129616	ZNF389	0.55	5.95	0.36	9.89e-9	Parkinson's disease;
SARC	cis	rs9810089	0.708	rs711977	chr3:136227387	G/A	cg15507776	chr3:136538369	TMEM22	0.44	4.84	0.3	2.32e-6	Gestational age at birth (child effect);
SARC	cis	rs7086627	0.515	rs4933390	chr10:82213081	A/C	cg00277334	chr10:82204260	NA	-0.57	-9.48	-0.53	3.15e-18	Post bronchodilator FEV1;
SARC	cis	rs6753739	0.871	rs6436114	chr2:220002834	A/C	cg24212621	chr2:219920517	IHH	0.35	4.86	0.3	2.17e-6	Height;
SARC	cis	rs9896933	0.778	rs80112422	chr17:80827719	G/T	cg20578329	chr17:80767326	TBCD	-0.72	-8.22	-0.47	1.43e-14	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
SARC	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg17221315	chr6:27791827	HIST1H4J	0.46	5.08	0.32	7.89e-7	Cardiac Troponin-T levels;
SARC	cis	rs6963495	0.556	rs711433	chr7:105153191	A/G	cg19920283	chr7:105172520	RINT1	-0.56	-5.77	-0.35	2.45e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs748404	0.631	rs6493083	chr15:43637985	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.39	4.72	0.3	4.1e-6	Lung cancer;
SARC	cis	rs10078	0.528	rs2434697	chr5:466811	T/C	cg26072250	chr5:443457	EXOC3;C5orf55	0.67	5.56	0.34	7.48e-8	Fat distribution (HIV);
SARC	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	10.38	0.56	5.22e-21	Platelet count;
SARC	cis	rs2387326	0.717	rs10829337	chr10:129943548	T/C	cg16087940	chr10:129947807	NA	-0.44	-5.48	-0.34	1.08e-7	Select biomarker traits;
SARC	cis	rs4319547	0.614	rs10846764	chr12:122874297	T/C	cg23029597	chr12:123009494	RSRC2	0.43	5.29	0.33	2.85e-7	Body mass index;
SARC	cis	rs13006833	0.739	rs291468	chr2:191188119	A/G	cg25963032	chr2:191064776	C2orf88	0.38	5.3	0.33	2.66e-7	Urinary metabolites;
SARC	cis	rs2075371	1.000	rs2241334	chr7:133979225	C/G	cg00033643	chr7:134001901	SLC35B4	0.43	5.21	0.32	4.06e-7	Mean platelet volume;
SARC	cis	rs703842	0.964	rs2014886	chr12:58177437	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.78	11.25	0.59	9.62e-24	Multiple sclerosis;
SARC	cis	rs2952156	0.920	rs2517953	chr17:37841211	G/C	cg00129232	chr17:37814104	STARD3	-0.72	-10.03	-0.55	6.39e-20	Asthma;
SARC	cis	rs7246657	0.943	rs10426666	chr19:37828514	C/G	cg23950597	chr19:37808831	NA	-0.6	-5.85	-0.36	1.67e-8	Coronary artery calcification;
SARC	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg19660806	chr8:588740	NA	0.58	5.07	0.31	8.3e-7	IgG glycosylation;
SARC	cis	rs7618915	1.000	rs3852064	chr3:52349412	G/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.35	4.99	0.31	1.16e-6	Bipolar disorder;
SARC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.62	-0.4	2.4e-10	Total body bone mineral density;
SARC	cis	rs654950	0.806	rs1535505	chr1:42026152	A/G	cg06885757	chr1:42089581	HIVEP3	0.36	5.03	0.31	9.65e-7	Airway imaging phenotypes;
SARC	cis	rs9291683	0.546	rs6829727	chr4:10051672	A/C	cg11266682	chr4:10021025	SLC2A9	0.41	7.07	0.42	1.84e-11	Bone mineral density;
SARC	cis	rs7264396	0.836	rs6088880	chr20:34165582	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	0.46	5.17	0.32	5.07e-7	Total cholesterol levels;
SARC	cis	rs7089973	0.836	rs7895551	chr10:116625481	C/T	cg08188268	chr10:116634841	FAM160B1	0.37	5.89	0.36	1.33e-8	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg03806693	chr22:41940476	POLR3H	0.83	11.81	0.61	1.51e-25	Vitiligo;
SARC	cis	rs3784262	1.000	rs4646638	chr15:58248783	C/T	cg12031962	chr15:58353849	ALDH1A2	0.42	6.27	0.38	1.73e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs870825	0.860	rs60022249	chr4:185600772	T/C	cg04058563	chr4:185651563	MLF1IP	0.75	9.34	0.52	8.15e-18	Blood protein levels;
SARC	cis	rs7551222	0.752	rs12566957	chr1:204556958	C/T	cg20240347	chr1:204465584	NA	-0.28	-5.09	-0.32	7.36e-7	Schizophrenia;
SARC	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg11764359	chr7:65958608	NA	0.86	12.33	0.63	3.29e-27	Aortic root size;
SARC	cis	rs4481887	0.741	rs11488133	chr1:248548380	T/C	cg13385794	chr1:248469461	NA	0.32	5.29	0.33	2.81e-7	Common traits (Other);
SARC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.46	0.57	3.1e-21	Prudent dietary pattern;
SARC	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg25072359	chr17:41440525	NA	0.51	6.03	0.37	6.45e-9	Menopause (age at onset);
SARC	cis	rs36051895	0.623	rs2146040	chr9:5260039	C/G	cg02405213	chr9:5042618	JAK2	0.4	4.74	0.3	3.68e-6	Pediatric autoimmune diseases;
SARC	cis	rs7312933	0.558	rs1796384	chr12:42780568	G/A	cg19980929	chr12:42632907	YAF2	-0.47	-6.9	-0.41	4.76e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs11122272	0.735	rs2790882	chr1:231532783	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.72	10.9	0.58	1.23e-22	Hemoglobin concentration;
SARC	trans	rs1994135	0.669	rs10844628	chr12:33697065	T/C	cg13010199	chr12:38710504	ALG10B	0.6	7.18	0.43	9.39e-12	Resting heart rate;
SARC	cis	rs1348850	0.567	rs1527401	chr2:178522104	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.41	4.82	0.3	2.57e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	trans	rs9354308	0.899	rs2802058	chr6:66550787	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.57	6.66	0.4	1.92e-10	Metabolite levels;
SARC	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg02951883	chr7:2050386	MAD1L1	-0.42	-5.38	-0.33	1.78e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs35110281	0.600	rs11089092	chr21:45120994	A/C	cg01579765	chr21:45077557	HSF2BP	-0.36	-5.83	-0.36	1.82e-8	Mean corpuscular volume;
SARC	cis	rs760805	1.000	rs3845302	chr1:25259884	C/G	cg22509179	chr1:25234806	RUNX3	-0.49	-6.92	-0.41	4.31e-11	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs9341808	0.718	rs10943696	chr6:80901272	C/G	cg08355045	chr6:80787529	NA	0.33	5.33	0.33	2.26e-7	Sitting height ratio;
SARC	cis	rs6484504	0.576	rs11031320	chr11:31242545	C/T	cg26647111	chr11:31128758	NA	-0.4	-5.19	-0.32	4.56e-7	Red blood cell count;
SARC	trans	rs7395662	0.591	rs4882085	chr11:48504569	C/G	cg15704280	chr7:45808275	SEPT13	-0.47	-6.26	-0.38	1.8e-9	HDL cholesterol;
SARC	cis	rs2865116	0.816	rs7785437	chr7:68952450	T/C	cg10619644	chr7:69149951	AUTS2	0.34	4.76	0.3	3.33e-6	Positive affect;
SARC	cis	rs8180040	0.934	rs62260710	chr3:47564462	C/G	cg27129171	chr3:47204927	SETD2	-0.69	-9.52	-0.53	2.3e-18	Colorectal cancer;
SARC	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg17158414	chr2:27665306	KRTCAP3	0.41	6.82	0.41	7.91e-11	Total body bone mineral density;
SARC	trans	rs61931739	0.534	rs12372557	chr12:34363843	C/T	cg13010199	chr12:38710504	ALG10B	0.79	10.85	0.58	1.88e-22	Morning vs. evening chronotype;
SARC	cis	rs7424096	0.613	rs17332671	chr2:37244124	C/G	cg14987922	chr2:37194071	STRN	0.57	6.53	0.39	4.01e-10	High light scatter reticulocyte percentage of red cells;
SARC	cis	rs453301	0.686	rs10217044	chr8:8894752	A/G	cg11608241	chr8:8085544	FLJ10661	-0.42	-5.35	-0.33	2.12e-7	Joint mobility (Beighton score);
SARC	cis	rs7666738	0.830	rs28485415	chr4:99060340	G/A	cg05340658	chr4:99064831	C4orf37	0.64	8.66	0.49	7.7e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2153535	0.580	rs1577466	chr6:8444192	T/C	cg21535247	chr6:8435926	SLC35B3	0.57	7.07	0.42	1.77e-11	Motion sickness;
SARC	cis	rs858239	0.600	rs6967475	chr7:23128982	C/T	cg23682824	chr7:23144976	KLHL7	0.71	9.45	0.53	3.74e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs7940866	0.834	rs1594821	chr11:130835883	C/T	cg12179176	chr11:130786555	SNX19	0.64	8.39	0.48	4.74e-15	Schizophrenia;
SARC	cis	rs7703051	0.513	rs59014134	chr5:74589385	C/T	cg19683494	chr5:74908142	NA	0.53	5.59	0.34	6.36e-8	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
SARC	cis	rs57920188	0.535	rs7412438	chr1:4095581	C/G	cg20703997	chr1:4087676	NA	0.52	5.49	0.34	1.05e-7	Interleukin-17 levels;
SARC	cis	rs7666738	0.830	rs13148363	chr4:98847498	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.58	0.49	1.36e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs5997397	0.934	rs6005864	chr22:29157487	A/G	cg15103426	chr22:29168792	CCDC117	-0.52	-6.73	-0.4	1.34e-10	Red cell distribution width;
SARC	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg25894440	chr7:65020034	NA	-0.68	-5.14	-0.32	5.9e-7	Diabetic kidney disease;
SARC	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg24060327	chr5:131705240	SLC22A5	-0.47	-5.55	-0.34	7.73e-8	Acylcarnitine levels;
SARC	cis	rs2594989	0.943	rs2454509	chr3:11489653	C/T	cg00170343	chr3:11313890	ATG7	-0.48	-4.76	-0.3	3.45e-6	Circulating chemerin levels;
SARC	cis	rs2806561	0.828	rs604030	chr1:23518227	T/C	cg12483005	chr1:23474871	LUZP1	0.44	5.86	0.36	1.6e-8	Height;
SARC	cis	rs113835537	0.529	rs117112180	chr11:66293273	A/G	cg24851651	chr11:66362959	CCS	0.38	4.78	0.3	3.12e-6	Airway imaging phenotypes;
SARC	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg08859206	chr1:53392774	SCP2	-0.36	-5.21	-0.32	4.21e-7	Monocyte count;
SARC	cis	rs7681440	0.904	rs28403500	chr4:90769729	T/G	cg02192967	chr4:90758406	SNCA	0.36	5.13	0.32	6.11e-7	Dementia with Lewy bodies;
SARC	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-6.33	-0.38	1.26e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg12310025	chr6:25882481	NA	-0.47	-5.98	-0.37	8.13e-9	Intelligence (multi-trait analysis);
SARC	trans	rs1493916	0.905	rs34910379	chr18:31400047	A/G	cg27147174	chr7:100797783	AP1S1	-0.55	-6.98	-0.42	2.96e-11	Life satisfaction;
SARC	cis	rs2916247	1.000	rs7827887	chr8:93026374	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.54	-5.79	-0.35	2.26e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	5.73	0.35	3.02e-8	Bipolar disorder;
SARC	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg24060327	chr5:131705240	SLC22A5	-0.49	-5.88	-0.36	1.43e-8	Acylcarnitine levels;
SARC	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg13628971	chr7:2884303	GNA12	0.63	7.67	0.45	4.54e-13	Height;
SARC	cis	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg00800038	chr16:89945340	TCF25	-0.67	-4.82	-0.3	2.63e-6	Skin colour saturation;
SARC	cis	rs881375	0.967	rs876445	chr9:123677102	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	4.77	0.3	3.2e-6	Rheumatoid arthritis;
SARC	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	8.97	0.51	1.03e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs9929218	0.954	rs112225541	chr16:68755165	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.64	-8.11	-0.47	2.95e-14	Colorectal cancer;
SARC	cis	rs9290065	0.519	rs7616249	chr3:160679422	T/C	cg04691961	chr3:161091175	C3orf57	-0.5	-6.48	-0.39	5.35e-10	Kawasaki disease;
SARC	cis	rs9398803	0.687	rs9375450	chr6:126985351	G/A	cg20229609	chr6:126660872	C6orf173	0.37	5.3	0.33	2.63e-7	Male-pattern baldness;
SARC	trans	rs9395865	0.501	rs2067833	chr6:53330356	A/G	cg24837744	chr17:7620647	NA	-0.51	-6.49	-0.39	5e-10	Electroencephalographic traits in alcoholism;
SARC	cis	rs9325144	0.555	rs1825806	chr12:38692547	G/A	cg13010199	chr12:38710504	ALG10B	0.56	7.33	0.43	3.73e-12	Morning vs. evening chronotype;
SARC	cis	rs79149102	0.579	rs58068887	chr15:75286140	G/A	cg17294928	chr15:75287854	SCAMP5	-0.99	-8.81	-0.5	2.87e-16	Lung cancer;
SARC	cis	rs12586317	0.547	rs60152856	chr14:35421373	G/A	cg26967526	chr14:35346199	BAZ1A	-0.68	-6.64	-0.4	2.18e-10	Psoriasis;
SARC	cis	rs11722228	0.522	rs12504600	chr4:10067138	C/A	cg11266682	chr4:10021025	SLC2A9	0.34	4.9	0.31	1.78e-6	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs6429082	0.689	rs10802803	chr1:235709610	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.56	-6.33	-0.38	1.27e-9	Adiposity;
SARC	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg13206674	chr6:150067644	NUP43	0.42	5.53	0.34	8.65e-8	Lung cancer;
SARC	cis	rs2180341	0.566	rs982306	chr6:127777039	T/C	cg24812749	chr6:127587940	RNF146	0.67	7.95	0.46	7.87e-14	Breast cancer;
SARC	cis	rs7766436	0.767	rs6456497	chr6:22603559	G/A	cg13666174	chr6:22585274	NA	-0.51	-7.11	-0.42	1.42e-11	Coronary artery disease;
SARC	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg03517284	chr6:25882590	NA	0.47	6.27	0.38	1.78e-9	Blood metabolite levels;
SARC	cis	rs9300255	0.602	rs1626899	chr12:123708063	A/G	cg05973401	chr12:123451056	ABCB9	0.49	5.44	0.34	1.37e-7	Neutrophil percentage of white cells;
SARC	cis	rs4794202	0.836	rs4794204	chr17:45937787	G/A	cg23391107	chr17:45924227	SP6	-0.52	-4.79	-0.3	3e-6	Alzheimer's disease (cognitive decline);
SARC	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg09263875	chr16:632152	PIGQ	0.54	8.34	0.48	6.32e-15	Height;
SARC	cis	rs16937	0.711	rs10751431	chr1:205128059	C/T	cg21643547	chr1:205240462	TMCC2	-0.43	-5.3	-0.33	2.67e-7	Schizophrenia;
SARC	cis	rs2046867	0.866	rs2244246	chr3:72789191	G/A	cg25664220	chr3:72788482	NA	0.26	4.76	0.3	3.38e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
SARC	cis	rs698833	0.892	rs698831	chr2:44731117	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.68	8.26	0.48	1.11e-14	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	trans	rs2018683	1.000	rs2018683	chr7:29014195	G/T	cg19402173	chr7:128379420	CALU	-0.69	-9.36	-0.52	6.95e-18	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs7274811	0.711	rs184110	chr20:31981432	G/A	cg21523528	chr20:32077966	CBFA2T2	-0.43	-5.2	-0.32	4.37e-7	Height;
SARC	cis	rs6500602	0.702	rs3761680	chr16:4524060	C/A	cg08645402	chr16:4508243	NA	0.46	6.14	0.37	3.5e-9	Schizophrenia;
SARC	cis	rs1559088	0.847	rs7254758	chr19:33608047	T/A	cg03563238	chr19:33554763	RHPN2	-0.26	-4.73	-0.3	3.82e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs317689	0.718	rs315122	chr12:69771073	G/T	cg20891283	chr12:69753455	YEATS4	0.49	5.56	0.34	7.44e-8	Response to diuretic therapy;
SARC	cis	rs2033711	0.811	rs9304814	chr19:58951811	C/A	cg03735888	chr19:58951602	ZNF132	0.42	5.42	0.33	1.47e-7	Uric acid clearance;
SARC	cis	rs1107366	0.593	rs12635766	chr3:125930021	T/C	cg01346077	chr3:125931526	NA	0.39	5.43	0.34	1.43e-7	Metabolite levels;
SARC	cis	rs7833790	0.632	rs6473308	chr8:82707708	G/A	cg17211192	chr8:82754475	SNX16	-0.5	-6.35	-0.38	1.13e-9	Diastolic blood pressure;
SARC	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg07308232	chr7:1071921	C7orf50	-0.41	-4.95	-0.31	1.4e-6	Longevity;Endometriosis;
SARC	cis	rs9914988	0.778	rs4794837	chr17:27110024	T/C	cg20469991	chr17:27169893	C17orf63	-0.5	-5.21	-0.32	4.1e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs6831352	0.918	rs2851248	chr4:100045974	A/G	cg12011299	chr4:100065546	ADH4	0.32	5.4	0.33	1.67e-7	Alcohol dependence;
SARC	cis	rs709400	0.859	rs7154948	chr14:104022944	C/T	cg26031613	chr14:104095156	KLC1	1.02	19.85	0.79	5.44e-52	Body mass index;
SARC	cis	rs17376456	0.877	rs10078194	chr5:93364310	A/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	6.12	0.37	3.99e-9	Diabetic retinopathy;
SARC	cis	rs6835098	1.000	rs6814857	chr4:174082805	T/A	cg08422745	chr4:174089978	GALNT7	-0.72	-9.29	-0.52	1.15e-17	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs9807989	0.507	rs3213732	chr2:102998279	A/G	cg03938978	chr2:103052716	IL18RAP	0.32	5.17	0.32	5.14e-7	Asthma;
SARC	cis	rs4253772	0.550	rs9615951	chr22:46728056	C/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.62	4.92	0.31	1.62e-6	LDL cholesterol;Cholesterol, total;
SARC	cis	rs9457247	0.602	rs9459854	chr6:167465882	C/T	cg23791538	chr6:167370224	RNASET2	-0.53	-6.99	-0.42	2.88e-11	Crohn's disease;
SARC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg11965913	chr1:205819406	PM20D1	0.89	14.27	0.68	1.31e-33	Menarche (age at onset);
SARC	cis	rs2228479	0.850	rs62056069	chr16:89912000	C/T	cg00800038	chr16:89945340	TCF25	-0.82	-5.8	-0.35	2.19e-8	Skin colour saturation;
SARC	cis	rs11626933	1.000	rs61989986	chr14:90739180	G/A	cg14092571	chr14:90743983	NA	-0.64	-9.09	-0.51	4.58e-17	Gut microbiota (bacterial taxa);
SARC	cis	rs6981523	0.553	rs11783890	chr8:11056388	T/C	cg21775007	chr8:11205619	TDH	-0.44	-5.41	-0.33	1.57e-7	Neuroticism;
SARC	cis	rs9443189	0.570	rs6931578	chr6:76272310	C/T	cg01950844	chr6:76311363	SENP6	0.88	8.08	0.47	3.47e-14	Prostate cancer;
SARC	cis	rs35213789	0.760	rs10950191	chr7:69031759	A/C	cg10619644	chr7:69149951	AUTS2	0.39	5.01	0.31	1.06e-6	Childhood ear infection;
SARC	cis	rs1983170	0.736	rs11164909	chr1:92002506	T/C	cg25838465	chr1:92012736	NA	0.57	5.86	0.36	1.61e-8	Eosinophil percentage of white cells;
SARC	cis	rs6088580	0.609	rs6059844	chr20:33036482	A/G	cg24642439	chr20:33292090	TP53INP2	0.63	8.11	0.47	2.95e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs13314892	0.728	rs62252234	chr3:69890474	T/G	cg17445875	chr3:69859618	MITF	-0.48	-4.95	-0.31	1.45e-6	QRS complex (12-leadsum);
SARC	cis	rs1018836	0.892	rs13267237	chr8:91550820	T/C	cg16814680	chr8:91681699	NA	-0.73	-11.51	-0.6	1.48e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05988158	chr22:51021418	CHKB-CPT1B;CHKB;LOC100144603	-0.57	-7.19	-0.43	8.56e-12	Smoking initiation;
SARC	cis	rs11992186	0.597	rs77717027	chr8:8591632	T/C	cg06636001	chr8:8085503	FLJ10661	-0.44	-5.34	-0.33	2.23e-7	Neuroticism;
SARC	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg17509989	chr5:176798049	RGS14	-0.71	-9.95	-0.55	1.11e-19	Urinary electrolytes (magnesium/calcium ratio);
SARC	cis	rs6912958	0.874	rs2103764	chr6:88157392	T/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.57	-0.34	6.94e-8	Monocyte percentage of white cells;
SARC	cis	rs7949030	0.754	rs36104523	chr11:62395740	A/T	cg22862634	chr11:62369728	EML3;MTA2	-0.49	-7.32	-0.43	3.97e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs936229	0.626	rs3765066	chr15:75140854	G/A	cg14664628	chr15:75095509	CSK	-0.77	-9.51	-0.53	2.52e-18	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg22903471	chr2:27725779	GCKR	-0.48	-7.29	-0.43	4.87e-12	Total body bone mineral density;
SARC	cis	rs12780845	0.540	rs10904903	chr10:17238336	T/A	cg11116878	chr10:17243438	TRDMT1	0.4	5.1	0.32	6.95e-7	Homocysteine levels;
SARC	cis	rs9467773	0.583	rs2498380	chr6:26643996	C/G	cg12292205	chr6:26970375	C6orf41	-0.4	-4.97	-0.31	1.32e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9611519	0.929	rs13055800	chr22:41440424	G/A	cg03806693	chr22:41940476	POLR3H	-0.6	-7.69	-0.45	4.15e-13	Neuroticism;
SARC	cis	rs2120019	1.000	rs2083731	chr15:75368538	A/C	cg12414181	chr15:75287860	SCAMP5	-0.43	-5.01	-0.31	1.07e-6	Blood trace element (Zn levels);
SARC	cis	rs2075371	0.897	rs1643102	chr7:133999983	T/A	cg00033643	chr7:134001901	SLC35B4	0.42	5.06	0.31	8.4e-7	Mean platelet volume;
SARC	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg22974920	chr21:40686053	BRWD1	-0.46	-4.99	-0.31	1.2e-6	Cognitive function;
SARC	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg11168104	chr5:1857477	NA	-0.35	-5.04	-0.31	9.25e-7	Cardiovascular disease risk factors;
SARC	cis	rs300703	0.935	rs4241316	chr2:252197	A/G	cg21211680	chr2:198530	NA	-0.55	-5.37	-0.33	1.94e-7	Blood protein levels;
SARC	cis	rs57561814	0.655	rs58879058	chr7:22741822	T/C	cg26061582	chr7:22766209	IL6	1.09	8.43	0.48	3.71e-15	Tonsillectomy;
SARC	cis	rs2439831	1.000	rs2264239	chr15:43765533	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	8.41	0.48	4.06e-15	Lung cancer in ever smokers;
SARC	cis	rs526231	0.578	rs42860	chr5:102428118	G/T	cg23492399	chr5:102201601	PAM	-0.47	-5.21	-0.32	4.1e-7	Primary biliary cholangitis;
SARC	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg26335602	chr6:28129616	ZNF389	0.47	5.43	0.34	1.42e-7	Cardiac Troponin-T levels;
SARC	cis	rs35110281	0.748	rs4997353	chr21:45002329	A/C	cg01579765	chr21:45077557	HSF2BP	-0.31	-5.29	-0.33	2.85e-7	Mean corpuscular volume;
SARC	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg08045932	chr20:61659980	NA	0.5	6.84	0.41	7.06e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs9875589	0.915	rs62234597	chr3:13963780	G/A	cg19554555	chr3:13937349	NA	0.52	6.63	0.4	2.3e-10	Ovarian reserve;
SARC	cis	rs9479482	0.935	rs563278	chr6:150364427	G/C	cg03788504	chr6:150331562	NA	-0.34	-5.51	-0.34	9.33e-8	Alopecia areata;
SARC	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-10.15	-0.55	2.87e-20	Chronic sinus infection;
SARC	cis	rs9831754	0.756	rs6548554	chr3:78423185	C/T	cg06138941	chr3:78371609	NA	-0.57	-6.89	-0.41	5.02e-11	Calcium levels;
SARC	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	12.23	0.63	6.97e-27	Chronic sinus infection;
SARC	cis	rs7191439	0.674	rs4782430	chr16:88792047	A/G	cg27087555	chr16:88793112	FAM38A	-1.16	-10.22	-0.56	1.66e-20	Plateletcrit;
SARC	cis	rs9815354	0.812	rs73073355	chr3:41842332	G/A	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9858542	0.953	rs34588335	chr3:49407660	G/C	cg03060546	chr3:49711283	APEH	-0.57	-7.14	-0.42	1.19e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs425277	0.958	rs7546523	chr1:2043792	G/A	cg21442419	chr1:2182373	SKI	-0.47	-5.71	-0.35	3.39e-8	Height;
SARC	cis	rs708547	0.575	rs6847086	chr4:57791864	A/G	cg24291500	chr4:57773398	REST	-0.31	-4.97	-0.31	1.31e-6	Response to bleomycin (chromatid breaks);
SARC	trans	rs3780486	0.881	rs10738906	chr9:33135634	T/C	cg20290983	chr6:43655470	MRPS18A	1.14	22.08	0.82	4.97e-59	IgG glycosylation;
SARC	cis	rs7917772	0.582	rs10786680	chr10:104317192	A/G	ch.10.2196322F	chr10:104248062	ACTR1A	0.43	5.77	0.35	2.53e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs3136441	1.000	rs61337452	chr11:46728966	T/C	cg25783544	chr11:47291846	MADD	0.65	4.82	0.3	2.6e-6	HDL cholesterol;
SARC	cis	rs2070677	0.736	rs4498943	chr10:135422505	A/T	cg20169779	chr10:135381914	SYCE1	0.49	5.67	0.35	4.16e-8	Gout;
SARC	cis	rs74181299	0.712	rs2241160	chr2:65291546	A/G	cg20592124	chr2:65290738	CEP68	0.58	9.26	0.52	1.41e-17	Pulse pressure;
SARC	cis	rs9303280	0.901	rs9901146	chr17:38043343	G/A	cg20243544	chr17:37824526	PNMT	0.43	5.8	0.35	2.2e-8	Self-reported allergy;
SARC	cis	rs1153858	0.621	rs1719237	chr15:45579822	G/A	cg21132104	chr15:45694354	SPATA5L1	0.73	9.4	0.52	5.47e-18	Homoarginine levels;
SARC	cis	rs950776	0.518	rs12910100	chr15:78822667	C/T	cg17108064	chr15:78857060	CHRNA5	0.29	4.93	0.31	1.56e-6	Sudden cardiac arrest;
SARC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg24503407	chr1:205819492	PM20D1	0.9	16.0	0.72	2.21e-39	Menarche (age at onset);
SARC	cis	rs7940866	0.774	rs2162059	chr11:130831224	C/T	cg12179176	chr11:130786555	SNX19	0.66	9.62	0.53	1.17e-18	Schizophrenia;
SARC	cis	rs950776	0.616	rs6495307	chr15:78890321	C/T	cg17108064	chr15:78857060	CHRNA5	0.3	5.35	0.33	2.05e-7	Sudden cardiac arrest;
SARC	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg11843238	chr5:131593191	PDLIM4	0.39	5.57	0.34	7.14e-8	Breast cancer;
SARC	cis	rs4128725	1.000	rs4551589	chr1:159351032	T/A	cg25076881	chr1:159409836	OR10J1	0.4	4.78	0.3	3.04e-6	Select biomarker traits;
SARC	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg20102877	chr2:27665638	KRTCAP3	-0.35	-4.92	-0.31	1.65e-6	Total body bone mineral density;
SARC	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg16405210	chr4:1374714	KIAA1530	-0.48	-5.62	-0.35	5.44e-8	Obesity-related traits;
SARC	cis	rs3768617	0.510	rs10911249	chr1:183080690	G/A	cg13390022	chr1:182993471	LAMC1	0.32	4.88	0.3	1.95e-6	Fuchs's corneal dystrophy;
SARC	cis	rs12458462	0.892	rs12456692	chr18:77482189	C/T	cg11879182	chr18:77439856	CTDP1	0.85	12.23	0.63	6.91e-27	Monocyte count;
SARC	cis	rs7264396	0.563	rs6060560	chr20:34278890	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-6.46	-0.39	6.12e-10	Total cholesterol levels;
SARC	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg18364779	chr6:26104403	HIST1H4C	0.42	5.04	0.31	9.29e-7	Intelligence (multi-trait analysis);
SARC	cis	rs4718428	0.705	rs13231140	chr7:66361618	C/G	cg18252515	chr7:66147081	NA	-0.56	-6.17	-0.37	3.06e-9	Corneal structure;
SARC	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs12142240	0.698	rs7525309	chr1:46809025	G/T	cg10495392	chr1:46806563	NSUN4	0.64	6.76	0.4	1.09e-10	Menopause (age at onset);
SARC	cis	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg07274523	chr3:49395745	GPX1	0.49	5.34	0.33	2.25e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs17376456	0.877	rs10062711	chr5:93348659	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.68	0.35	3.93e-8	Diabetic retinopathy;
SARC	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg16680214	chr1:154839983	KCNN3	-0.36	-5.72	-0.35	3.2e-8	Prostate cancer;
SARC	cis	rs2522056	1.000	rs62385693	chr5:131773674	T/C	cg24060327	chr5:131705240	SLC22A5	0.6	6.31	0.38	1.43e-9	Lymphocyte counts;Fibrinogen;
SARC	cis	rs2153535	0.580	rs7753192	chr6:8482637	G/A	cg21535247	chr6:8435926	SLC35B3	0.55	6.97	0.42	3.17e-11	Motion sickness;
SARC	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg19223190	chr17:80058835	NA	0.44	6.19	0.38	2.67e-9	Life satisfaction;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg07136949	chr6:7986672	MGC26597	-0.76	-6.59	-0.4	2.92e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2153535	0.563	rs6942177	chr6:8534460	A/G	cg21535247	chr6:8435926	SLC35B3	-0.51	-6.43	-0.39	6.96e-10	Motion sickness;
SARC	cis	rs10791323	0.582	rs2723613	chr11:133706696	G/A	cg14349672	chr11:133703707	NA	-0.39	-5.58	-0.34	6.71e-8	Childhood ear infection;
SARC	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.95	13.96	0.67	1.32e-32	Gut microbiome composition (summer);
SARC	cis	rs7582720	1.000	rs72934767	chr2:203766563	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.31	0.43	4.24e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs7769051	0.522	rs56908272	chr6:133102165	G/C	cg22852734	chr6:133119734	C6orf192	1.27	7.96	0.46	7.63e-14	Type 2 diabetes nephropathy;
SARC	cis	rs1865760	0.865	rs4478388	chr6:25953633	A/G	cg17691542	chr6:26056736	HIST1H1C	0.58	7.29	0.43	4.67e-12	Height;
SARC	cis	rs34172651	0.876	rs1862451	chr16:24803620	A/G	cg00152838	chr16:24741724	TNRC6A	-0.5	-6.03	-0.37	6.52e-9	Intelligence (multi-trait analysis);
SARC	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg00149659	chr3:10157352	C3orf10	0.66	6.6	0.4	2.82e-10	Alzheimer's disease;
SARC	cis	rs9902453	1.000	rs7207021	chr17:28400516	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.52	-6.88	-0.41	5.46e-11	Coffee consumption (cups per day);
SARC	cis	rs9902453	0.904	rs4077465	chr17:28300144	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	6.95	0.41	3.58e-11	Coffee consumption (cups per day);
SARC	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.58	7.08	0.42	1.69e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs67460515	0.500	rs1345156	chr3:160649272	G/T	cg17135325	chr3:160939158	NMD3	-0.51	-5.91	-0.36	1.22e-8	Parkinson's disease;
SARC	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg03161606	chr19:29218774	NA	0.48	6.87	0.41	5.87e-11	Methadone dose in opioid dependence;
SARC	cis	rs151227923	1	rs151227923	chr7:155106564	C/T	cg04811098	chr7:155088454	INSIG1	0.33	4.86	0.3	2.11e-6	Stem cell growth factor beta levels;
SARC	cis	rs9611519	0.894	rs4821998	chr22:41468273	C/G	cg03806693	chr22:41940476	POLR3H	-0.59	-7.37	-0.43	2.88e-12	Neuroticism;
SARC	cis	rs6088580	0.624	rs6120645	chr20:33025171	C/T	cg08999081	chr20:33150536	PIGU	0.44	6.58	0.4	3.05e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg04267008	chr7:1944627	MAD1L1	-0.51	-5.79	-0.35	2.24e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg21280719	chr6:42927975	GNMT	-0.47	-8.15	-0.47	2.19e-14	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs735396	0.770	rs1169301	chr12:121431300	C/T	cg02403541	chr12:121454288	C12orf43	0.84	12.08	0.62	2.05e-26	N-glycan levels;
SARC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg22903471	chr2:27725779	GCKR	-0.47	-7.13	-0.42	1.23e-11	Total body bone mineral density;
SARC	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg11644478	chr21:40555479	PSMG1	1.03	14.57	0.69	1.33e-34	Cognitive function;
SARC	cis	rs9790314	0.540	rs9844862	chr3:161076188	G/A	cg17135325	chr3:160939158	NMD3	0.52	6.53	0.39	4.14e-10	Morning vs. evening chronotype;
SARC	cis	rs735396	0.595	rs1169279	chr12:121455873	C/T	cg15155738	chr12:121454335	C12orf43	0.54	7.12	0.42	1.34e-11	N-glycan levels;
SARC	cis	rs1348850	0.597	rs13014417	chr2:178417835	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.55	5.89	0.36	1.37e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs76419734	1.000	rs72671885	chr4:106668546	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.76	5.11	0.32	6.56e-7	Post bronchodilator FEV1;
SARC	cis	rs6570726	0.905	rs388728	chr6:145816419	T/C	cg23711669	chr6:146136114	FBXO30	0.78	11.91	0.62	7.29e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1348850	0.874	rs1348848	chr2:178358233	A/C	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.69	-8.81	-0.5	2.99e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs17666538	1.000	rs59631161	chr8:587808	G/T	cg00450029	chr8:599525	NA	-0.69	-5.42	-0.33	1.49e-7	IgG glycosylation;
SARC	cis	rs11792861	0.926	rs11788825	chr9:111829757	T/G	cg13535736	chr9:111863775	C9orf5	-0.37	-4.74	-0.3	3.73e-6	Menarche (age at onset);
SARC	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.33	5.02	0.31	1.01e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2594989	0.943	rs2454508	chr3:11493232	T/C	cg00170343	chr3:11313890	ATG7	0.53	5.2	0.32	4.43e-7	Circulating chemerin levels;
SARC	cis	rs17401966	0.931	rs17410217	chr1:10371854	A/G	cg15208524	chr1:10270712	KIF1B	0.54	6.5	0.39	4.71e-10	Hepatocellular carcinoma;
SARC	trans	rs1814175	0.745	rs7483456	chr11:49774613	C/T	cg03929089	chr4:120376271	NA	-0.9	-14.53	-0.69	1.76e-34	Height;
SARC	cis	rs17376456	0.569	rs7732578	chr5:93410244	C/T	cg21475434	chr5:93447410	FAM172A	-0.6	-6.27	-0.38	1.73e-9	Diabetic retinopathy;
SARC	cis	rs523522	0.962	rs10849759	chr12:120994488	T/A	cg12219531	chr12:120966889	COQ5	0.83	11.11	0.59	2.8e-23	High light scatter reticulocyte count;
SARC	cis	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg12463550	chr7:65579703	CRCP	0.68	5.09	0.32	7.53e-7	Gout;
SARC	cis	rs13401104	0.531	rs12469569	chr2:237113376	T/C	cg19324714	chr2:237145437	ASB18	0.57	5.91	0.36	1.22e-8	Educational attainment;
SARC	cis	rs1483890	0.642	rs9825845	chr3:69404572	C/A	cg22125112	chr3:69402811	FRMD4B	0.3	4.94	0.31	1.5e-6	Resting heart rate;
SARC	cis	rs3892630	0.588	rs7245709	chr19:33242755	C/T	cg22980127	chr19:33182716	NUDT19	1.09	11.51	0.6	1.46e-24	Red blood cell traits;
SARC	cis	rs2236918	1.000	rs1629051	chr1:242026344	A/G	cg17736920	chr1:242011382	EXO1	-0.77	-10.74	-0.58	4.03e-22	Menopause (age at onset);
SARC	cis	rs2425143	1.000	rs57963833	chr20:34344225	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-5.75	-0.35	2.72e-8	Blood protein levels;
SARC	trans	rs61931739	0.658	rs4476006	chr12:34237154	A/C	cg13010199	chr12:38710504	ALG10B	0.52	6.96	0.41	3.38e-11	Morning vs. evening chronotype;
SARC	cis	rs9660992	0.674	rs72745221	chr1:205262337	G/A	cg21643547	chr1:205240462	TMCC2	-0.58	-7.18	-0.43	9.34e-12	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs36051895	0.559	rs72701682	chr9:5208025	A/G	cg02405213	chr9:5042618	JAK2	-0.43	-4.92	-0.31	1.65e-6	Pediatric autoimmune diseases;
SARC	cis	rs6597981	0.675	rs4963120	chr11:825777	A/G	cg01741372	chr11:783889	NA	-0.38	-5.78	-0.35	2.43e-8	Breast cancer;
SARC	cis	rs9906944	0.742	rs4073893	chr17:47118523	A/G	cg16584676	chr17:46985605	UBE2Z	-0.44	-5.3	-0.33	2.67e-7	Intelligence (multi-trait analysis);Body fat percentage;
SARC	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg24060327	chr5:131705240	SLC22A5	-0.69	-8.21	-0.47	1.53e-14	Breast cancer;
SARC	cis	rs9300255	0.544	rs1790100	chr12:123656725	G/T	cg00376283	chr12:123451042	ABCB9	0.58	6.82	0.41	7.75e-11	Neutrophil percentage of white cells;
SARC	cis	rs7647973	0.626	rs4855833	chr3:49657441	A/G	cg06212747	chr3:49208901	KLHDC8B	0.58	5.8	0.36	2.18e-8	Menarche (age at onset);
SARC	cis	rs11608355	1.000	rs9669684	chr12:109860644	C/T	cg05360138	chr12:110035743	NA	0.43	4.8	0.3	2.86e-6	Neuroticism;
SARC	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg21782813	chr7:2030301	MAD1L1	0.4	6.37	0.39	9.86e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs3820928	0.874	rs1917127	chr2:227895125	A/G	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.67	-0.35	4.12e-8	Pulmonary function;
SARC	cis	rs17376456	0.877	rs12716456	chr5:93397557	A/G	cg21475434	chr5:93447410	FAM172A	0.87	7.91	0.46	1.06e-13	Diabetic retinopathy;
SARC	cis	rs6570726	0.935	rs421690	chr6:145834594	A/C	cg23711669	chr6:146136114	FBXO30	0.78	11.86	0.61	1.04e-25	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg02910180	chr11:71955299	PHOX2A	-0.79	-6.36	-0.38	1.04e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7432375	0.580	rs4678442	chr3:136532971	A/G	cg15507776	chr3:136538369	TMEM22	0.62	7.7	0.45	3.93e-13	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	cis	rs6963495	0.818	rs818621	chr7:105173029	T/C	cg13798780	chr7:105162888	PUS7	0.48	4.84	0.3	2.34e-6	Bipolar disorder (body mass index interaction);
SARC	cis	rs9818758	0.607	rs12715434	chr3:49295025	G/C	cg07636037	chr3:49044803	WDR6	-0.75	-6.53	-0.39	4.11e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	trans	rs79976124	0.879	rs10944856	chr6:66636960	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	7.73	0.45	3.16e-13	Type 2 diabetes;
SARC	cis	rs1152591	0.811	rs1255986	chr14:64655161	A/G	cg23250157	chr14:64679961	SYNE2	-0.53	-7.83	-0.46	1.76e-13	Atrial fibrillation;
SARC	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg12756686	chr19:29218302	NA	0.66	8.87	0.5	1.98e-16	Methadone dose in opioid dependence;
SARC	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg13395646	chr4:1353034	KIAA1530	-0.41	-5.03	-0.31	9.6e-7	Longevity;
SARC	cis	rs7772486	0.558	rs702322	chr6:146007166	G/A	cg05347473	chr6:146136440	FBXO30	-0.7	-9.9	-0.54	1.64e-19	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs67311347	0.544	rs9821440	chr3:40342347	T/C	cg09455208	chr3:40491958	NA	0.28	4.76	0.3	3.33e-6	Renal cell carcinoma;
SARC	cis	rs7592578	0.771	rs1128723	chr2:191366707	A/G	cg27211696	chr2:191398769	TMEM194B	-0.53	-5.62	-0.35	5.32e-8	Diastolic blood pressure;
SARC	cis	rs10504229	0.593	rs58647001	chr8:58025132	G/A	cg08219700	chr8:58056026	NA	0.62	6.47	0.39	5.78e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7412746	0.658	rs10305711	chr1:150802996	T/C	cg13175981	chr1:150552382	MCL1	-0.5	-6.07	-0.37	5.23e-9	Melanoma;
SARC	cis	rs6089584	0.566	rs11699442	chr20:60623268	A/G	cg23262073	chr20:60523788	NA	-0.35	-5.37	-0.33	1.89e-7	Body mass index;
SARC	trans	rs9325144	0.555	rs1825806	chr12:38692547	G/A	cg23762105	chr12:34175262	ALG10	-0.53	-7.07	-0.42	1.81e-11	Morning vs. evening chronotype;
SARC	cis	rs7236492	0.627	rs76032846	chr18:77198322	G/A	cg15644404	chr18:77186268	NFATC1	-0.68	-6.77	-0.41	1.05e-10	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-5.46	-0.34	1.24e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs709400	0.567	rs28496120	chr14:103897899	C/T	cg26031613	chr14:104095156	KLC1	0.8	11.29	0.59	7.41e-24	Body mass index;
SARC	cis	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg07274523	chr3:49395745	GPX1	0.49	5.43	0.34	1.43e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg22800045	chr5:56110881	MAP3K1	0.74	7.82	0.46	1.86e-13	Initial pursuit acceleration;
SARC	cis	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg12463550	chr7:65579703	CRCP	-0.68	-5.09	-0.32	7.53e-7	Gout;
SARC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.68	-8.95	-0.51	1.11e-16	Longevity;Endometriosis;
SARC	cis	rs10870270	1.000	rs11146324	chr10:133767445	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.48	-5.47	-0.34	1.17e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs7760949	0.963	rs9396248	chr6:13906360	A/G	cg27413430	chr6:13925136	RNF182	0.41	5.0	0.31	1.12e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs910316	0.967	rs4903285	chr14:75609268	A/T	cg08847533	chr14:75593920	NEK9	0.92	15.69	0.72	2.33e-38	Height;
SARC	cis	rs739401	0.595	rs6578305	chr11:3001120	C/T	cg05729581	chr11:3078854	CARS	-0.53	-7.0	-0.42	2.64e-11	Longevity;
SARC	cis	rs6667605	0.527	rs4422947	chr1:2539590	C/T	cg20673091	chr1:2541236	MMEL1	0.33	5.11	0.32	6.61e-7	Inflammatory bowel disease;Ulcerative colitis;
SARC	cis	rs9309473	0.748	rs2421552	chr2:73758803	C/T	cg20560298	chr2:73613845	ALMS1	-0.55	-6.58	-0.4	2.99e-10	Metabolite levels;
SARC	cis	rs6912958	0.754	rs1051131	chr6:88221546	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-5.79	-0.35	2.32e-8	Monocyte percentage of white cells;
SARC	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg05896524	chr21:47604654	C21orf56	-0.59	-7.2	-0.43	8.45e-12	Testicular germ cell tumor;
SARC	cis	rs17401966	1.000	rs12402052	chr1:10318652	C/G	cg15208524	chr1:10270712	KIF1B	0.58	6.52	0.39	4.26e-10	Hepatocellular carcinoma;
SARC	cis	rs9467773	0.967	rs9295694	chr6:26512994	A/T	cg12292205	chr6:26970375	C6orf41	0.44	5.46	0.34	1.24e-7	Intelligence (multi-trait analysis);
SARC	cis	rs926392	0.965	rs6129167	chr20:37689228	C/T	cg16355469	chr20:37678765	NA	-0.58	-7.52	-0.44	1.19e-12	Dialysis-related mortality;
SARC	cis	rs3741404	0.620	rs2236647	chr11:63964605	A/G	cg18225595	chr11:63971243	STIP1	-0.43	-6.77	-0.41	1.02e-10	Platelet count;
SARC	cis	rs1318878	0.639	rs1157937	chr12:15515239	A/G	cg08258403	chr12:15378311	NA	0.47	6.59	0.4	2.89e-10	Intelligence (multi-trait analysis);
SARC	cis	rs787274	1.000	rs2796028	chr9:115528755	T/C	cg13803584	chr9:115635662	SNX30	-0.83	-5.03	-0.31	9.96e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.44	-5.51	-0.34	9.58e-8	Blood metabolite levels;
SARC	cis	rs5753618	0.583	rs9606843	chr22:31853371	A/C	cg02404636	chr22:31891804	SFI1	0.5	5.43	0.34	1.39e-7	Colorectal cancer;
SARC	cis	rs10782582	0.609	rs1770889	chr1:76401166	A/G	cg10523679	chr1:76189770	ACADM	-0.42	-5.15	-0.32	5.66e-7	Daytime sleep phenotypes;
SARC	cis	rs6582630	0.502	rs11181475	chr12:38348922	G/A	cg13010199	chr12:38710504	ALG10B	0.78	10.79	0.58	2.78e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1355223	0.902	rs865070	chr11:34742497	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-5.3	-0.33	2.7e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	trans	rs2727020	0.675	rs7929401	chr11:49350832	C/A	cg15704280	chr7:45808275	SEPT13	-0.64	-7.19	-0.43	8.91e-12	Coronary artery disease;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg14150915	chr11:66056828	YIF1A	0.5	6.46	0.39	5.92e-10	Schizophrenia;
SARC	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg16606324	chr3:10149918	C3orf24	0.48	5.07	0.32	8.2e-7	Alzheimer's disease;
SARC	cis	rs2204008	0.502	rs2387275	chr12:38142836	G/A	cg13010199	chr12:38710504	ALG10B	0.8	10.84	0.58	1.98e-22	Bladder cancer;
SARC	cis	rs8141529	0.600	rs916332	chr22:29308414	C/T	cg02153584	chr22:29168773	CCDC117	0.68	7.35	0.43	3.28e-12	Lymphocyte counts;
SARC	cis	rs854765	0.534	rs7207461	chr17:17949789	T/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.41	-5.13	-0.32	6.16e-7	Total body bone mineral density;
SARC	cis	rs2153535	0.580	rs2327061	chr6:8447231	G/C	cg07606381	chr6:8435919	SLC35B3	0.79	11.42	0.6	2.9e-24	Motion sickness;
SARC	cis	rs2075371	1.000	rs2075372	chr7:133984432	C/T	cg00033643	chr7:134001901	SLC35B4	0.4	4.85	0.3	2.25e-6	Mean platelet volume;
SARC	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.39	-0.56	4.87e-21	Chronic sinus infection;
SARC	cis	rs34779708	0.931	rs7099593	chr10:35366878	A/C	cg03585969	chr10:35415529	CREM	0.39	4.97	0.31	1.32e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs7551222	0.634	rs12139477	chr1:204553104	A/C	cg20240347	chr1:204465584	NA	-0.3	-5.38	-0.33	1.81e-7	Schizophrenia;
SARC	cis	rs4919087	0.748	rs701815	chr10:98975893	A/C	cg25902810	chr10:99078978	FRAT1	-0.56	-6.52	-0.39	4.36e-10	Monocyte count;
SARC	cis	rs9398803	0.865	rs9385401	chr6:126789472	C/T	cg19875578	chr6:126661172	C6orf173	0.63	8.55	0.49	1.64e-15	Male-pattern baldness;
SARC	cis	rs7772486	0.754	rs2328709	chr6:146106819	A/G	cg23711669	chr6:146136114	FBXO30	-0.91	-16.14	-0.73	7.78e-40	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7595412	1.000	rs6730300	chr2:199025596	A/G	cg00208931	chr2:198669586	PLCL1	0.68	5.01	0.31	1.07e-6	Hip bone size;
SARC	cis	rs509477	0.718	rs273358	chr18:32596784	C/T	cg23791764	chr18:32556832	MAPRE2	0.39	4.87	0.3	2.02e-6	Cerebrospinal fluid AB1-42 levels;
SARC	cis	rs7937682	0.575	rs7930208	chr11:111741463	T/C	cg09085632	chr11:111637200	PPP2R1B	0.78	10.3	0.56	9.89e-21	Primary sclerosing cholangitis;
SARC	cis	rs80130819	0.748	rs7953726	chr12:48611757	A/G	cg05342945	chr12:48394962	COL2A1	-0.5	-5.25	-0.33	3.42e-7	Prostate cancer;
SARC	cis	rs950776	0.518	rs11630349	chr15:78824608	C/T	cg17108064	chr15:78857060	CHRNA5	0.29	4.93	0.31	1.56e-6	Sudden cardiac arrest;
SARC	cis	rs950169	0.650	rs12902052	chr15:85125838	A/T	cg17507749	chr15:85114479	UBE2QP1	0.79	9.37	0.52	6.69e-18	Schizophrenia;
SARC	cis	rs13191362	0.688	rs73025321	chr6:162974896	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.59	5.11	0.32	6.66e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg20102877	chr2:27665638	KRTCAP3	0.38	5.35	0.33	2.06e-7	Total body bone mineral density;
SARC	cis	rs6570726	0.791	rs422099	chr6:145806936	C/T	cg23711669	chr6:146136114	FBXO30	0.87	14.49	0.69	2.32e-34	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs5750830	0.594	rs5757647	chr22:39775047	C/A	cg05872129	chr22:39784769	NA	-0.46	-6.67	-0.4	1.81e-10	Intelligence (multi-trait analysis);
SARC	cis	rs6977660	0.714	rs10251774	chr7:19790489	T/C	cg07541023	chr7:19748670	TWISTNB	0.75	6.72	0.4	1.35e-10	Thyroid stimulating hormone;
SARC	cis	rs6088590	1.000	rs55753039	chr20:33394940	C/T	cg06115741	chr20:33292138	TP53INP2	0.59	7.14	0.42	1.17e-11	Coronary artery disease;
SARC	cis	rs7582720	0.943	rs115628302	chr2:203690047	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.71	7.33	0.43	3.68e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs1707322	1.000	rs4539075	chr1:46358010	C/T	cg06784218	chr1:46089804	CCDC17	0.34	6.03	0.37	6.51e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2204008	0.811	rs4882300	chr12:38415224	A/T	cg13010199	chr12:38710504	ALG10B	-0.7	-9.58	-0.53	1.53e-18	Bladder cancer;
SARC	cis	rs8067545	0.611	rs7216599	chr17:20015600	G/C	cg13482628	chr17:19912719	NA	0.52	6.66	0.4	1.93e-10	Schizophrenia;
SARC	trans	rs1814175	0.817	rs7947526	chr11:49983654	T/C	cg03929089	chr4:120376271	NA	-0.88	-14.13	-0.68	3.73e-33	Height;
SARC	cis	rs12824058	0.831	rs4759452	chr12:130812799	G/A	cg24838063	chr12:130822603	PIWIL1	0.63	8.93	0.5	1.34e-16	Menopause (age at onset);
SARC	cis	rs11098499	0.863	rs7678400	chr4:120461957	G/A	cg09307838	chr4:120376055	NA	0.93	12.66	0.64	2.64e-28	Corneal astigmatism;
SARC	cis	rs7553864	0.667	rs1886633	chr1:87610356	G/A	cg17420885	chr1:87600446	LOC339524	-0.35	-4.79	-0.3	3.04e-6	Smoking behavior;
SARC	cis	rs7264396	1.000	rs224433	chr20:34153850	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.46	-5.23	-0.32	3.81e-7	Total cholesterol levels;
SARC	cis	rs7894051	1.000	rs11101721	chr10:135190358	C/G	cg20534287	chr10:135191450	PAOX	0.62	5.05	0.31	8.94e-7	Lifespan;
SARC	cis	rs35146811	0.586	rs1076237	chr7:99585441	A/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.42	5.06	0.31	8.68e-7	Coronary artery disease;
SARC	cis	rs67311347	0.956	rs11714871	chr3:40428938	T/G	cg09455208	chr3:40491958	NA	0.4	6.22	0.38	2.26e-9	Renal cell carcinoma;
SARC	cis	rs8114671	0.742	rs6058161	chr20:33620026	C/T	cg24642439	chr20:33292090	TP53INP2	-0.51	-5.99	-0.37	8.05e-9	Height;
SARC	cis	rs9436747	0.704	rs10789184	chr1:66036962	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.51	4.73	0.3	3.82e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs8031584	0.918	rs61997140	chr15:31277312	A/G	cg08109568	chr15:31115862	NA	-0.47	-5.85	-0.36	1.69e-8	Huntington's disease progression;
SARC	cis	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg25894440	chr7:65020034	NA	-0.73	-5.54	-0.34	8.32e-8	Diabetic kidney disease;
SARC	cis	rs2439831	0.850	rs7169988	chr15:44060435	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.81	7.61	0.45	6.95e-13	Lung cancer in ever smokers;
SARC	cis	rs9393692	0.905	rs9393694	chr6:26279296	T/C	cg05868516	chr6:26286170	HIST1H4H	0.56	7.37	0.43	2.9e-12	Educational attainment;
SARC	cis	rs1865760	0.713	rs9461229	chr6:25992279	G/T	cg17691542	chr6:26056736	HIST1H1C	0.51	6.58	0.4	3e-10	Height;
SARC	cis	rs9309711	0.666	rs4321399	chr2:3481659	G/A	cg15541040	chr2:3486749	NA	-0.41	-5.48	-0.34	1.12e-7	Neurofibrillary tangles;
SARC	cis	rs9814567	1.000	rs9876658	chr3:134179453	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.49	6.39	0.39	9.08e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs7178572	0.568	rs1823100	chr15:77402744	C/T	cg22256960	chr15:77711686	NA	-0.52	-5.55	-0.34	7.69e-8	Type 2 diabetes;
SARC	cis	rs11168187	0.843	rs12819759	chr12:48115086	T/G	cg12761788	chr12:48120090	P11	0.36	4.77	0.3	3.28e-6	Vertical cup-disc ratio;
SARC	cis	rs7000551	0.689	rs2469753	chr8:22383225	T/C	cg12081754	chr8:22256438	SLC39A14	0.56	7.88	0.46	1.24e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs10754283	0.967	rs6698273	chr1:90106791	T/A	cg21401794	chr1:90099060	LRRC8C	0.59	8.09	0.47	3.24e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs2120019	0.935	rs34913788	chr15:75372617	A/C	cg09165964	chr15:75287851	SCAMP5	-0.87	-13.08	-0.65	1.1e-29	Blood trace element (Zn levels);
SARC	cis	rs763121	0.853	rs5757211	chr22:39051705	C/T	cg06022373	chr22:39101656	GTPBP1	0.9	11.56	0.6	9.96e-25	Menopause (age at onset);
SARC	trans	rs6815916	0.619	rs11726894	chr4:182554008	C/T	cg13864546	chr1:2310327	MORN1	0.68	6.41	0.39	7.98e-10	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs11098499	0.909	rs28571712	chr4:120375980	G/A	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	cis	rs7647973	0.925	rs6446257	chr3:49253492	A/G	cg07636037	chr3:49044803	WDR6	-0.7	-7.55	-0.44	9.75e-13	Menarche (age at onset);
SARC	cis	rs1030877	0.515	rs2679893	chr2:105909554	A/G	cg02079111	chr2:105885981	TGFBRAP1	0.54	6.25	0.38	1.89e-9	Obesity-related traits;
SARC	cis	rs453301	0.658	rs6983877	chr8:8904639	T/C	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.98	-0.42	2.96e-11	Joint mobility (Beighton score);
SARC	cis	rs2239547	0.522	rs6445550	chr3:52983434	G/A	cg22484793	chr3:52261325	TLR9	0.34	4.72	0.3	4.05e-6	Schizophrenia;
SARC	cis	rs11719291	0.504	rs71324924	chr3:48865444	G/A	cg07636037	chr3:49044803	WDR6	-0.73	-6.45	-0.39	6.39e-10	Cognitive function;
SARC	cis	rs34421088	0.548	rs2618443	chr8:11384556	A/G	cg21775007	chr8:11205619	TDH	-0.38	-4.85	-0.3	2.24e-6	Neuroticism;
SARC	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.46	-5.76	-0.35	2.65e-8	Intelligence (multi-trait analysis);
SARC	cis	rs4481887	0.893	rs6702113	chr1:248486151	T/C	cg01631408	chr1:248437212	OR2T33	-0.39	-4.89	-0.31	1.84e-6	Common traits (Other);
SARC	cis	rs1976403	0.659	rs10799699	chr1:21820961	C/T	cg17800788	chr1:21766015	NBPF3	0.31	5.11	0.32	6.57e-7	Liver enzyme levels (alkaline phosphatase);
SARC	trans	rs61931739	0.534	rs1486886	chr12:34043619	C/T	cg13010199	chr12:38710504	ALG10B	0.66	9.05	0.51	5.8e-17	Morning vs. evening chronotype;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg21749200	chr2:179328668	FKBP7;MIR548N	0.52	7.62	0.45	6.5e-13	Thyroid stimulating hormone;
SARC	trans	rs12310956	0.532	rs10844712	chr12:33961022	G/A	cg26384229	chr12:38710491	ALG10B	0.74	10.25	0.56	1.36e-20	Morning vs. evening chronotype;
SARC	cis	rs7666738	0.830	rs13115356	chr4:98933171	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6568686	0.577	rs383515	chr6:111916668	C/T	cg15721981	chr6:111408429	SLC16A10	0.63	5.19	0.32	4.61e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg04317338	chr11:64019027	PLCB3	0.61	7.07	0.42	1.84e-11	Platelet count;
SARC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg10150615	chr22:24372951	LOC391322	-0.44	-4.89	-0.3	1.9e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs427394	0.632	rs169285	chr5:6736587	G/C	cg10857441	chr5:6722123	POLS	-0.33	-4.89	-0.31	1.89e-6	Menopause (age at onset);
SARC	cis	rs7829975	0.577	rs940030	chr8:8546928	A/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-5.25	-0.33	3.41e-7	Mood instability;
SARC	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg18357526	chr6:26021779	HIST1H4A	0.9	12.67	0.64	2.53e-28	Intelligence (multi-trait analysis);
SARC	cis	rs738321	0.701	rs4821754	chr22:38581503	A/G	cg25457927	chr22:38595422	NA	0.29	5.05	0.31	9.11e-7	Breast cancer;
SARC	cis	rs9467773	1.000	rs12526680	chr6:26550954	A/G	cg11502198	chr6:26597334	ABT1	0.46	5.59	0.34	6.35e-8	Intelligence (multi-trait analysis);
SARC	trans	rs61931739	0.890	rs814663	chr12:34106338	C/T	cg13010199	chr12:38710504	ALG10B	0.56	7.47	0.44	1.57e-12	Morning vs. evening chronotype;
SARC	cis	rs897080	0.515	rs786405	chr2:44710367	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	6.24	0.38	2.06e-9	Height;
SARC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg02018176	chr4:1364513	KIAA1530	0.65	9.87	0.54	1.99e-19	Longevity;
SARC	cis	rs4319547	0.695	rs4758662	chr12:122924778	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.59	-6.6	-0.4	2.68e-10	Body mass index;
SARC	cis	rs4713118	0.662	rs149901	chr6:27965503	C/T	cg17221315	chr6:27791827	HIST1H4J	0.48	4.94	0.31	1.47e-6	Parkinson's disease;
SARC	cis	rs820218	0.926	rs1661744	chr17:73647138	C/T	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.68	9.27	0.52	1.33e-17	Rotator cuff tears;
SARC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.62	-6.69	-0.4	1.66e-10	Platelet count;
SARC	cis	rs10979	1.000	rs9373394	chr6:143890776	A/G	cg25407410	chr6:143891975	LOC285740	-0.64	-8.68	-0.49	6.88e-16	Hypospadias;
SARC	cis	rs9457247	0.534	rs933243	chr6:167403873	A/C	cg23791538	chr6:167370224	RNASET2	-0.64	-8.84	-0.5	2.45e-16	Crohn's disease;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg11422861	chr22:30821626	MTP18	0.51	6.53	0.39	4.05e-10	Breast cancer;
SARC	cis	rs17270561	0.609	rs3778272	chr6:25767661	G/A	cg17691542	chr6:26056736	HIST1H1C	0.57	7.0	0.42	2.78e-11	Iron status biomarkers;
SARC	cis	rs854765	0.623	rs9893690	chr17:17753846	A/T	cg16928487	chr17:17741425	SREBF1	0.25	5.27	0.33	3.15e-7	Total body bone mineral density;
SARC	cis	rs9354308	0.868	rs2351729	chr6:66537291	A/G	cg07460842	chr6:66804631	NA	-0.46	-5.34	-0.33	2.23e-7	Metabolite levels;
SARC	cis	rs6582630	0.513	rs11181246	chr12:38302670	C/T	cg13010199	chr12:38710504	ALG10B	0.78	10.82	0.58	2.18e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6456156	0.586	rs7742305	chr6:167485723	C/T	cg07741184	chr6:167504864	NA	0.36	6.99	0.42	2.83e-11	Primary biliary cholangitis;
SARC	cis	rs710216	0.917	rs900837	chr1:43412793	A/G	cg07803811	chr1:43423981	SLC2A1	-0.55	-5.55	-0.34	7.61e-8	Red cell distribution width;
SARC	cis	rs2467099	0.786	rs1463486	chr17:73943942	G/A	cg23806715	chr17:73775811	H3F3B	0.55	5.56	0.34	7.42e-8	Systolic blood pressure;
SARC	cis	rs7412746	0.658	rs12405726	chr1:150956128	G/A	cg13175981	chr1:150552382	MCL1	-0.49	-5.54	-0.34	8e-8	Melanoma;
SARC	cis	rs9611519	0.894	rs9611486	chr22:41458784	C/G	cg03806693	chr22:41940476	POLR3H	-0.58	-7.09	-0.42	1.57e-11	Neuroticism;
SARC	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg26681399	chr22:41777847	TEF	0.45	5.01	0.31	1.1e-6	Vitiligo;
SARC	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg15049968	chr18:44337910	ST8SIA5	-0.35	-5.42	-0.33	1.49e-7	Personality dimensions;
SARC	cis	rs992157	0.735	rs10932765	chr2:219099484	T/C	cg00012203	chr2:219082015	ARPC2	0.85	13.86	0.67	2.84e-32	Colorectal cancer;
SARC	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg06028808	chr11:68637592	NA	0.43	5.59	0.34	6.45e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs12950390	1.000	rs12950390	chr17:45830948	A/G	cg03474202	chr17:45855739	NA	-0.43	-6.21	-0.38	2.41e-9	IgG glycosylation;
SARC	cis	rs1215050	0.791	rs503863	chr4:98707663	T/C	cg05340658	chr4:99064831	C4orf37	0.44	5.85	0.36	1.62e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg05863683	chr7:1912471	MAD1L1	0.37	5.45	0.34	1.28e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg05313129	chr8:58192883	C8orf71	-0.62	-6.34	-0.38	1.18e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs72781680	1.000	rs72781643	chr2:24208746	G/A	cg06627628	chr2:24431161	ITSN2	-0.7	-6.78	-0.41	9.65e-11	Lymphocyte counts;
SARC	cis	rs9303401	0.614	rs2333409	chr17:57139134	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.99	10.09	0.55	4.14e-20	Cognitive test performance;
SARC	cis	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg05084668	chr3:125655381	ALG1L	-0.46	-4.83	-0.3	2.46e-6	Blood pressure (smoking interaction);
SARC	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg01475735	chr3:40494733	NA	-0.46	-5.03	-0.31	9.7e-7	Renal cell carcinoma;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg10386194	chr1:200642383	NA	0.49	7.14	0.42	1.21e-11	Thyroid stimulating hormone;
SARC	cis	rs34779708	0.931	rs2001893	chr10:35300623	G/A	cg03585969	chr10:35415529	CREM	0.4	5.0	0.31	1.1e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs910316	0.726	rs175040	chr14:75469555	A/G	cg23033748	chr14:75592666	NEK9	-0.38	-5.24	-0.32	3.62e-7	Height;
SARC	cis	rs57083693	0.536	rs10745911	chr12:101695105	T/C	cg22051763	chr12:101673672	UTP20	-0.45	-5.37	-0.33	1.89e-7	Alcohol dependence (age at onset);
SARC	cis	rs9815354	0.767	rs79323474	chr3:42000973	C/T	cg03022575	chr3:42003672	ULK4	0.71	6.03	0.37	6.5e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2463822	0.583	rs72917379	chr11:62026112	T/C	cg06239285	chr11:62104954	ASRGL1	-0.88	-7.97	-0.46	7.26e-14	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg25894440	chr7:65020034	NA	0.78	5.89	0.36	1.34e-8	Diabetic kidney disease;
SARC	cis	rs2180341	0.782	rs6912006	chr6:127722631	C/T	cg27446573	chr6:127587934	RNF146	0.64	8.49	0.49	2.43e-15	Breast cancer;
SARC	cis	rs12681288	0.676	rs62488537	chr8:1011962	A/C	cg15309053	chr8:964076	NA	0.44	7.11	0.42	1.37e-11	Schizophrenia;
SARC	cis	rs2180341	0.960	rs6900074	chr6:127685893	A/G	cg17762328	chr6:126965162	NA	-0.44	-4.87	-0.3	2.06e-6	Breast cancer;
SARC	cis	rs3126085	0.877	rs12116736	chr1:152167062	C/T	cg03465714	chr1:152285911	FLG	-0.47	-5.56	-0.34	7.45e-8	Atopic dermatitis;
SARC	cis	rs6912958	0.874	rs2103764	chr6:88157392	T/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.62	-8.69	-0.49	6.48e-16	Monocyte percentage of white cells;
SARC	cis	rs2997447	0.846	rs61775428	chr1:26409126	G/C	cg19633962	chr1:26362018	EXTL1	-0.67	-5.76	-0.35	2.71e-8	QRS complex (12-leadsum);
SARC	cis	rs709400	0.663	rs62007683	chr14:103894071	G/T	cg26031613	chr14:104095156	KLC1	0.81	11.42	0.6	2.88e-24	Body mass index;
SARC	cis	rs981844	0.775	rs62323977	chr4:154746141	G/A	cg14289246	chr4:154710475	SFRP2	0.58	6.52	0.39	4.33e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg21724239	chr8:58056113	NA	0.58	5.69	0.35	3.74e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs3812831	0.643	rs7322339	chr13:114929726	C/A	cg08824895	chr13:115047677	UPF3A	0.51	6.75	0.4	1.18e-10	Schizophrenia;
SARC	cis	rs1044826	0.518	rs295488	chr3:139239323	C/T	cg15131784	chr3:139108705	COPB2	0.46	5.71	0.35	3.41e-8	Obesity-related traits;
SARC	cis	rs10088262	0.540	rs6988602	chr8:124788502	C/T	cg20713898	chr8:124780851	FAM91A1	0.67	6.88	0.41	5.41e-11	Pancreatic cancer;
SARC	cis	rs7582720	1.000	rs72926787	chr2:203818299	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg07636037	chr3:49044803	WDR6	0.99	17.23	0.75	1.85e-43	Parkinson's disease;
SARC	cis	rs7659604	0.791	rs57316471	chr4:122663939	A/G	cg06713675	chr4:122721982	EXOSC9	-0.4	-5.57	-0.34	6.88e-8	Type 2 diabetes;
SARC	cis	rs6495122	0.501	rs12101482	chr15:75344784	A/T	cg17294928	chr15:75287854	SCAMP5	-0.51	-6.56	-0.39	3.49e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	cis	rs6669008	1.000	rs1891969	chr1:114185855	C/A	cg26035817	chr1:114414802	PTPN22	0.44	5.21	0.32	4.25e-7	Bacteremia;
SARC	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg24250549	chr1:154909240	PMVK	0.77	10.8	0.58	2.67e-22	Prostate cancer;
SARC	cis	rs9902453	0.845	rs2321331	chr17:28025528	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	7.08	0.42	1.73e-11	Coffee consumption (cups per day);
SARC	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg07701084	chr6:150067640	NUP43	0.41	5.39	0.33	1.75e-7	Lung cancer;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg15618797	chr5:140419947	NA	-0.46	-6.46	-0.39	5.94e-10	Thyroid stimulating hormone;
SARC	trans	rs629535	0.862	rs2178955	chr8:70045303	C/T	cg21567404	chr3:27674614	NA	1.04	13.82	0.67	3.98e-32	Dupuytren's disease;
SARC	cis	rs7296418	0.518	rs28825193	chr12:123878262	T/C	cg05973401	chr12:123451056	ABCB9	0.46	5.29	0.33	2.84e-7	Platelet count;
SARC	cis	rs782590	0.967	rs782592	chr2:55843875	T/A	cg18811423	chr2:55921094	PNPT1	0.57	7.54	0.44	1.02e-12	Metabolic syndrome;
SARC	cis	rs7667	0.841	rs12027702	chr1:19747103	G/T	cg15311933	chr1:19638897	PQLC2;AKR7A2	-0.46	-5.42	-0.33	1.5e-7	Crohn's disease and psoriasis;
SARC	cis	rs4926611	0.863	rs2141083	chr1:54082352	C/T	cg08927728	chr1:54059983	GLIS1	0.3	5.05	0.31	8.76e-7	Hand grip strength;
SARC	trans	rs6894249	1.000	rs6894249	chr5:131797547	A/G	cg01056358	chr6:166858118	RPS6KA2	-0.44	-6.25	-0.38	1.98e-9	Asthma;
SARC	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg18252515	chr7:66147081	NA	-1.34	-12.05	-0.62	2.51e-26	Diabetic kidney disease;
SARC	cis	rs6580649	0.941	rs4141065	chr12:48523499	G/A	cg05342945	chr12:48394962	COL2A1	0.51	5.42	0.33	1.5e-7	Lung cancer;
SARC	cis	rs7223966	0.961	rs112709843	chr17:61836936	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	7.0	0.42	2.73e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs10489202	0.909	rs61809580	chr1:168091602	A/C	cg24449463	chr1:168025552	DCAF6	-0.51	-5.28	-0.33	2.95e-7	Schizophrenia;
SARC	cis	rs5167	0.504	rs3760629	chr19:45458146	A/C	cg09555818	chr19:45449301	APOC2	0.52	8.09	0.47	3.32e-14	Blood protein levels;
SARC	cis	rs12142240	0.698	rs45449893	chr1:46859024	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-5.56	-0.34	7.46e-8	Menopause (age at onset);
SARC	cis	rs10089	0.904	rs2195921	chr5:127489754	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.79	9.78	0.54	3.86e-19	Ileal carcinoids;
SARC	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg07701084	chr6:150067640	NUP43	0.41	5.27	0.33	3.18e-7	Lung cancer;
SARC	cis	rs459571	0.916	rs467303	chr9:136904835	C/T	cg13789015	chr9:136890014	NCRNA00094	0.64	8.82	0.5	2.73e-16	Platelet distribution width;
SARC	cis	rs826838	0.616	rs4619214	chr12:38614704	C/A	cg26384229	chr12:38710491	ALG10B	0.6	7.81	0.46	1.9e-13	Heart rate;
SARC	cis	rs738322	0.935	rs2413503	chr22:38568944	A/T	cg25457927	chr22:38595422	NA	-0.28	-5.78	-0.35	2.42e-8	Cutaneous nevi;
SARC	trans	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg00938859	chr5:1591904	SDHAP3	0.79	7.64	0.45	5.49e-13	Breast cancer;
SARC	cis	rs35123781	0.696	rs4912755	chr5:139070651	A/G	cg10513866	chr5:139070639	NA	0.36	4.85	0.3	2.23e-6	Schizophrenia;
SARC	cis	rs7412746	0.611	rs3768018	chr1:150723747	T/C	cg10589385	chr1:150898437	SETDB1	0.4	5.19	0.32	4.6e-7	Melanoma;
SARC	cis	rs9815354	1.000	rs6599175	chr3:41786009	C/T	cg03022575	chr3:42003672	ULK4	-0.57	-5.58	-0.34	6.7e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg09021430	chr5:549028	NA	-0.43	-5.66	-0.35	4.45e-8	Obesity-related traits;
SARC	cis	rs4906332	0.811	rs2021965	chr14:103997248	C/A	cg19000871	chr14:103996768	TRMT61A	0.4	4.91	0.31	1.74e-6	Coronary artery disease;
SARC	cis	rs9473924	0.505	rs9296644	chr6:50828247	G/A	cg14470998	chr6:50812995	TFAP2B	0.69	6.41	0.39	7.9e-10	Body mass index;
SARC	cis	rs7582180	0.627	rs6542947	chr2:100999647	C/G	cg14675211	chr2:100938903	LONRF2	-0.54	-7.88	-0.46	1.24e-13	Intelligence (multi-trait analysis);
SARC	cis	rs34172651	0.917	rs2112786	chr16:24778944	C/T	cg04756594	chr16:24857601	SLC5A11	0.35	5.78	0.35	2.42e-8	Intelligence (multi-trait analysis);
SARC	cis	rs5167	0.781	rs909134	chr19:45493061	T/C	cg13119609	chr19:45449297	APOC2	0.39	5.99	0.37	7.88e-9	Blood protein levels;
SARC	cis	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg11266682	chr4:10021025	SLC2A9	0.4	7.18	0.43	9.44e-12	Bone mineral density;
SARC	trans	rs877282	0.853	rs12777155	chr10:754731	G/C	cg22713356	chr15:30763199	NA	0.99	9.88	0.54	1.92e-19	Uric acid levels;
SARC	cis	rs15676	0.783	rs2280843	chr9:131585069	A/G	cg00228799	chr9:131580591	ENDOG	0.62	7.81	0.46	1.94e-13	Blood metabolite levels;
SARC	cis	rs1008375	1.000	rs7654345	chr4:17691796	A/G	cg02297831	chr4:17616191	MED28	0.39	4.86	0.3	2.14e-6	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs208520	0.633	rs79679034	chr6:66701724	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.09	14.54	0.69	1.67e-34	Exhaled nitric oxide output;
SARC	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg05025164	chr4:1340916	KIAA1530	-0.45	-5.17	-0.32	4.98e-7	Obesity-related traits;
SARC	cis	rs2342371	0.720	rs61345811	chr3:196143030	C/T	cg15048948	chr3:196158458	UBXN7	0.63	7.67	0.45	4.65e-13	Fat distribution (HIV);
SARC	cis	rs721399	0.924	rs1961456	chr8:18255709	A/G	cg18736775	chr8:18248649	NAT2	-0.43	-5.56	-0.34	7.38e-8	Blood metabolite levels;
SARC	cis	rs7512552	0.809	rs698923	chr1:150379159	G/A	cg15654264	chr1:150340011	RPRD2	0.37	4.77	0.3	3.25e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg16680214	chr1:154839983	KCNN3	-0.33	-5.22	-0.32	3.96e-7	Prostate cancer;
SARC	trans	rs61931739	0.534	rs1387789	chr12:34056304	C/A	cg26384229	chr12:38710491	ALG10B	0.74	10.39	0.56	4.97e-21	Morning vs. evening chronotype;
SARC	cis	rs11190604	0.943	rs7900678	chr10:102229016	T/C	cg07080220	chr10:102295463	HIF1AN	0.76	9.07	0.51	5.2e-17	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg03033257	chr22:50311977	ALG12;CRELD2	0.62	5.92	0.36	1.16e-8	Schizophrenia;
SARC	cis	rs829883	0.622	rs7302630	chr12:98959577	C/A	cg25150519	chr12:98850993	NA	-0.6	-7.28	-0.43	5.15e-12	Colorectal adenoma (advanced);
SARC	cis	rs4148883	0.629	rs2602899	chr4:100010128	C/T	cg13256891	chr4:100009986	ADH5	0.61	8.2	0.47	1.61e-14	Alcohol dependence;
SARC	cis	rs2652834	1.000	rs2729784	chr15:63402735	T/C	cg05507819	chr15:63340323	TPM1	0.55	5.44	0.34	1.38e-7	HDL cholesterol;
SARC	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg08219700	chr8:58056026	NA	0.61	6.35	0.38	1.13e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7666738	0.830	rs115279324	chr4:99042114	T/C	cg05340658	chr4:99064831	C4orf37	0.64	8.6	0.49	1.18e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7666738	0.830	rs4699588	chr4:98973789	A/G	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6540556	0.634	rs11485195	chr1:209891738	T/C	cg05527609	chr1:210001259	C1orf107	-0.56	-5.25	-0.33	3.45e-7	Red blood cell count;
SARC	cis	rs10752881	1.000	rs10797800	chr1:182969828	C/A	cg13390022	chr1:182993471	LAMC1	0.33	4.99	0.31	1.19e-6	Colorectal cancer;
SARC	cis	rs9389248	0.708	rs7750574	chr6:135350932	G/C	cg22676075	chr6:135203613	NA	0.39	4.97	0.31	1.29e-6	High light scatter reticulocyte percentage of red cells;
SARC	cis	rs76419734	0.558	rs59936741	chr4:106518916	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.66	5.52	0.34	8.88e-8	Post bronchodilator FEV1;
SARC	cis	rs34779708	0.931	rs11592404	chr10:35273476	G/A	cg03585969	chr10:35415529	CREM	0.39	4.9	0.31	1.82e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs4319547	0.915	rs3803005	chr12:123110654	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.59	-7.0	-0.42	2.72e-11	Body mass index;
SARC	cis	rs9457247	0.967	rs1211447	chr6:167381979	C/T	cg23791538	chr6:167370224	RNASET2	-0.63	-8.74	-0.5	4.81e-16	Crohn's disease;
SARC	cis	rs9916302	0.904	rs588193	chr17:37440439	A/C	cg20243544	chr17:37824526	PNMT	-0.56	-6.91	-0.41	4.55e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg19223190	chr17:80058835	NA	0.44	6.19	0.38	2.67e-9	Life satisfaction;
SARC	cis	rs1008375	0.966	rs10939755	chr4:17693755	T/C	cg16339924	chr4:17578868	LAP3	0.54	6.84	0.41	6.93e-11	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs950776	0.722	rs471889	chr15:78870235	T/C	cg22563815	chr15:78856949	CHRNA5	-0.34	-5.26	-0.33	3.29e-7	Sudden cardiac arrest;
SARC	cis	rs617219	0.737	rs12655567	chr5:78465698	C/G	cg24856658	chr5:78533917	JMY	-0.31	-5.04	-0.31	9.52e-7	Betaine levels in individuals undergoing cardiac evaluation;
SARC	cis	rs1348850	0.526	rs935426	chr2:178369433	T/C	cg23306229	chr2:178417860	TTC30B	0.79	7.68	0.45	4.31e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg04277193	chr17:41438351	NA	0.45	4.75	0.3	3.52e-6	Menopause (age at onset);
SARC	cis	rs4563143	0.514	rs73029081	chr19:29295583	C/G	cg04546413	chr19:29218101	NA	0.59	6.99	0.42	2.87e-11	Methadone dose in opioid dependence;
SARC	cis	rs10088262	0.629	rs12541177	chr8:124800273	G/T	cg15047889	chr8:124780837	FAM91A1	-0.66	-7.32	-0.43	3.96e-12	Pancreatic cancer;
SARC	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg11764359	chr7:65958608	NA	-0.77	-9.36	-0.52	6.84e-18	Aortic root size;
SARC	cis	rs4660261	0.526	rs2906458	chr1:44336389	A/G	cg12908607	chr1:44402522	ARTN	0.31	5.47	0.34	1.18e-7	Intelligence (multi-trait analysis);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg12952179	chr4:111866981	NA	-0.53	-6.46	-0.39	5.99e-10	Height;
SARC	cis	rs2504916	1.000	rs2504938	chr6:160824754	C/T	cg20340146	chr6:160172821	WTAP	0.47	4.73	0.3	3.93e-6	Response to hepatitis C treatment;
SARC	cis	rs8180040	0.966	rs13059519	chr3:47539969	C/T	cg27129171	chr3:47204927	SETD2	0.68	9.31	0.52	9.8e-18	Colorectal cancer;
SARC	cis	rs208520	0.802	rs1342959	chr6:66883329	A/G	cg07460842	chr6:66804631	NA	-1.06	-13.6	-0.67	2.2e-31	Exhaled nitric oxide output;
SARC	cis	rs9393777	0.513	rs9379895	chr6:26592707	A/G	cg12292205	chr6:26970375	C6orf41	-0.52	-4.79	-0.3	3.03e-6	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs16866061	1.000	rs1568750	chr2:225342597	A/T	cg12698349	chr2:225449008	CUL3	0.71	10.27	0.56	1.22e-20	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	cis	rs11190604	1.000	rs6584383	chr10:102303065	C/G	cg07080220	chr10:102295463	HIF1AN	0.82	9.49	0.53	2.87e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs992157	0.835	rs10932768	chr2:219146199	T/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.69	-10.09	-0.55	4.32e-20	Colorectal cancer;
SARC	cis	rs9399137	0.507	rs4896128	chr6:135349756	A/G	cg24558204	chr6:135376177	HBS1L	-0.63	-8.1	-0.47	3.03e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs28829049	0.861	rs67113006	chr1:19376566	A/G	cg13387374	chr1:19411106	UBR4	0.42	4.82	0.3	2.55e-6	QRS duration in Tripanosoma cruzi seropositivity;
SARC	cis	rs1355223	0.583	rs2915178	chr11:34878051	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.76	10.7	0.57	5.31e-22	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs11945232	1.000	rs28609242	chr4:88342497	T/C	cg23841344	chr4:88312519	HSD17B11	-0.57	-7.48	-0.44	1.47e-12	Intelligence (multi-trait analysis);
SARC	cis	rs9398803	0.687	rs1269195	chr6:127031550	C/T	cg19875578	chr6:126661172	C6orf173	-0.64	-8.9	-0.5	1.56e-16	Male-pattern baldness;
SARC	cis	rs9325144	0.532	rs12812406	chr12:38719802	G/A	cg13010199	chr12:38710504	ALG10B	-0.55	-7.03	-0.42	2.26e-11	Morning vs. evening chronotype;
SARC	cis	rs981844	1.000	rs2606335	chr4:154656536	T/C	cg14289246	chr4:154710475	SFRP2	0.58	6.64	0.4	2.14e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs12950390	0.853	rs8071192	chr17:45856141	A/G	cg24803719	chr17:45855879	NA	-0.47	-7.73	-0.45	3.29e-13	IgG glycosylation;
SARC	cis	rs2153535	0.580	rs4639392	chr6:8446547	A/G	cg07606381	chr6:8435919	SLC35B3	0.77	11.05	0.59	4.23e-23	Motion sickness;
SARC	cis	rs9790314	0.791	rs6809256	chr3:161026513	G/A	cg03342759	chr3:160939853	NMD3	-0.72	-9.71	-0.54	6.02e-19	Morning vs. evening chronotype;
SARC	cis	rs7914558	1.000	rs10883824	chr10:104812897	A/G	cg04362960	chr10:104952993	NT5C2	0.4	4.9	0.31	1.81e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs10189230	0.967	rs1367241	chr2:222353413	G/A	cg14652038	chr2:222343519	EPHA4	0.45	6.05	0.37	5.72e-9	Urate levels in lean individuals;
SARC	cis	rs3126085	0.935	rs4845745	chr1:152185184	C/T	cg26876637	chr1:152193138	HRNR	0.47	5.39	0.33	1.7e-7	Atopic dermatitis;
SARC	cis	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg13647721	chr17:30228624	UTP6	0.63	5.59	0.34	6.33e-8	Hip circumference adjusted for BMI;
SARC	cis	rs453301	0.686	rs3989373	chr8:8911308	G/T	cg06636001	chr8:8085503	FLJ10661	-0.64	-8.77	-0.5	3.89e-16	Joint mobility (Beighton score);
SARC	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg06634786	chr22:41940651	POLR3H	-0.55	-6.48	-0.39	5.55e-10	Vitiligo;
SARC	cis	rs2404602	0.692	rs8037005	chr15:76951109	C/T	cg22467129	chr15:76604101	ETFA	-0.37	-4.8	-0.3	2.89e-6	Blood metabolite levels;
SARC	cis	rs599083	0.530	rs576118	chr11:68177708	C/T	cg01657329	chr11:68192670	LRP5	0.47	6.32	0.38	1.3e-9	Bone mineral density (spine);
SARC	cis	rs11971779	0.774	rs6467838	chr7:139043501	A/G	cg23387468	chr7:139079360	LUC7L2	0.33	4.71	0.3	4.2e-6	Diisocyanate-induced asthma;
SARC	cis	rs11764590	0.724	rs55669426	chr7:2090129	G/C	cg21782813	chr7:2030301	MAD1L1	-0.31	-4.82	-0.3	2.54e-6	Neuroticism;
SARC	cis	rs9436747	0.641	rs12038998	chr1:66049128	C/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.46	4.77	0.3	3.31e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs509477	0.718	rs273342	chr18:32604956	G/A	cg23791764	chr18:32556832	MAPRE2	0.42	5.15	0.32	5.43e-7	Cerebrospinal fluid AB1-42 levels;
SARC	cis	rs748404	0.631	rs12905772	chr15:43648444	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.39	4.8	0.3	2.89e-6	Lung cancer;
SARC	cis	rs694739	1.000	rs11231757	chr11:64106317	C/T	cg26898376	chr11:64110657	CCDC88B	0.34	4.8	0.3	2.86e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs2952156	0.920	rs2517953	chr17:37841211	G/C	cg07936489	chr17:37558343	FBXL20	-0.44	-5.66	-0.35	4.38e-8	Asthma;
SARC	cis	rs10982256	0.774	rs10759712	chr9:117253434	G/A	cg15903421	chr9:117267460	DFNB31	0.39	4.98	0.31	1.21e-6	Bipolar disorder;
SARC	cis	rs10504229	0.679	rs16921683	chr8:58053270	T/C	cg21724239	chr8:58056113	NA	0.58	5.9	0.36	1.27e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg26335602	chr6:28129616	ZNF389	-0.47	-5.39	-0.33	1.7e-7	Depression;
SARC	cis	rs35306767	0.623	rs72760943	chr10:1143104	G/A	cg18964960	chr10:1102726	WDR37	0.7	6.81	0.41	8.36e-11	Eosinophil percentage of granulocytes;
SARC	cis	rs9398803	0.830	rs1490387	chr6:126834083	C/A	cg20229609	chr6:126660872	C6orf173	0.4	5.79	0.35	2.23e-8	Male-pattern baldness;
SARC	cis	rs2228479	0.850	rs11639906	chr16:89798183	T/C	cg06558623	chr16:89946397	TCF25	0.85	5.77	0.35	2.46e-8	Skin colour saturation;
SARC	cis	rs36051895	0.623	rs12351715	chr9:5262349	A/G	cg02405213	chr9:5042618	JAK2	-0.43	-5.05	-0.31	8.79e-7	Pediatric autoimmune diseases;
SARC	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg18404041	chr3:52824283	ITIH1	-0.43	-6.45	-0.39	6.24e-10	Bipolar disorder;
SARC	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg10523679	chr1:76189770	ACADM	0.52	6.88	0.41	5.36e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs17739167	0.550	rs6493014	chr15:42225008	A/G	cg20935245	chr15:42234343	EHD4	-0.45	-6.11	-0.37	4.11e-9	Monocyte count;
SARC	cis	rs826838	0.967	rs7970069	chr12:38810631	T/C	cg26384229	chr12:38710491	ALG10B	0.93	15.06	0.7	3.05e-36	Heart rate;
SARC	cis	rs2197308	0.765	rs12230545	chr12:37927114	C/T	cg26384229	chr12:38710491	ALG10B	-0.8	-11.47	-0.6	1.94e-24	Morning vs. evening chronotype;
SARC	cis	rs6062302	0.522	rs914558	chr20:62216976	A/G	cg09650180	chr20:62225654	GMEB2	-0.47	-5.61	-0.35	5.66e-8	Glioblastoma;
SARC	cis	rs1348850	0.632	rs10167783	chr2:178519041	G/A	cg22681709	chr2:178499509	PDE11A	-0.41	-5.7	-0.35	3.69e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg11878867	chr6:150167359	LRP11	-0.34	-4.72	-0.3	4.01e-6	Lung cancer;
SARC	cis	rs950776	0.714	rs17408276	chr15:78881618	T/C	cg17108064	chr15:78857060	CHRNA5	0.31	5.13	0.32	6.07e-7	Sudden cardiac arrest;
SARC	cis	rs7833790	0.660	rs10091077	chr8:82705464	A/G	cg27398817	chr8:82754497	SNX16	-0.43	-5.06	-0.31	8.66e-7	Diastolic blood pressure;
SARC	cis	rs11025559	0.643	rs11025570	chr11:20481109	T/A	cg19653624	chr11:20408972	PRMT3	-0.74	-7.11	-0.42	1.45e-11	Pursuit maintenance gain;
SARC	cis	rs2562456	0.755	rs1879234	chr19:21704479	T/G	cg00806126	chr19:22604979	ZNF98	0.48	4.95	0.31	1.42e-6	Pain;
SARC	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs7412746	0.658	rs11582281	chr1:150826831	T/C	cg15448220	chr1:150897856	SETDB1	0.49	6.23	0.38	2.12e-9	Melanoma;
SARC	cis	rs910316	0.789	rs12894419	chr14:75471802	C/T	cg11812906	chr14:75593930	NEK9	0.81	11.35	0.6	4.62e-24	Height;
SARC	cis	rs7824557	0.527	rs11785394	chr8:11238029	C/T	cg21775007	chr8:11205619	TDH	-0.59	-7.57	-0.44	8.9e-13	Retinal vascular caliber;
SARC	cis	rs10754283	0.967	rs7523046	chr1:90109499	G/A	cg21401794	chr1:90099060	LRRC8C	0.58	8.02	0.46	5.22e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs9467773	0.596	rs2451751	chr6:26646714	T/C	cg11502198	chr6:26597334	ABT1	0.63	8.46	0.48	2.95e-15	Intelligence (multi-trait analysis);
SARC	cis	rs473651	0.904	rs62196716	chr2:239356977	C/G	cg18131467	chr2:239335373	ASB1	0.99	17.08	0.75	6.06e-43	Multiple system atrophy;
SARC	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg04944784	chr2:26401820	FAM59B	-0.5	-6.27	-0.38	1.76e-9	Gut microbiome composition (summer);
SARC	cis	rs950776	0.518	rs4243083	chr15:78833830	C/G	cg06917634	chr15:78832804	PSMA4	-0.9	-14.17	-0.68	2.83e-33	Sudden cardiac arrest;
SARC	cis	rs6570726	0.764	rs4263604	chr6:145916697	A/G	cg05347473	chr6:146136440	FBXO30	0.54	7.45	0.44	1.85e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3820928	0.874	rs1320407	chr2:227867385	G/T	cg11843606	chr2:227700838	RHBDD1	-0.49	-6.01	-0.37	7.25e-9	Pulmonary function;
SARC	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg00933542	chr6:150070202	PCMT1	0.3	5.14	0.32	5.77e-7	Lung cancer;
SARC	cis	rs4141404	0.851	rs5749222	chr22:31556759	C/G	cg13145458	chr22:31556086	RNF185	0.53	6.48	0.39	5.52e-10	Paclitaxel-induced neuropathy;
SARC	cis	rs7819412	0.740	rs7844536	chr8:11034028	A/G	cg21775007	chr8:11205619	TDH	-0.47	-5.89	-0.36	1.31e-8	Triglycerides;
SARC	cis	rs637571	0.565	rs633800	chr11:65638719	G/A	cg26695010	chr11:65641043	EFEMP2	0.77	11.65	0.61	5.06e-25	Eosinophil percentage of white cells;
SARC	cis	rs4713118	0.513	rs149945	chr6:28002853	T/C	cg26335602	chr6:28129616	ZNF389	0.45	5.29	0.33	2.85e-7	Parkinson's disease;
SARC	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.32	-4.72	-0.3	4.14e-6	Menopause (age at onset);
SARC	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg05861140	chr6:150128134	PCMT1	-0.39	-4.86	-0.3	2.15e-6	Lung cancer;
SARC	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg16414030	chr3:133502952	NA	-0.4	-5.35	-0.33	2.06e-7	Iron status biomarkers;
SARC	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg11062466	chr8:58055876	NA	0.58	5.76	0.35	2.59e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg16606324	chr3:10149918	C3orf24	0.53	5.05	0.31	8.92e-7	Alzheimer's disease;
SARC	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg26513180	chr16:89883248	FANCA	-0.6	-8.19	-0.47	1.78e-14	Vitiligo;
SARC	cis	rs2153535	0.580	rs7742689	chr6:8452433	C/A	cg07606381	chr6:8435919	SLC35B3	0.78	11.13	0.59	2.34e-23	Motion sickness;
SARC	cis	rs6752107	1.000	rs6431654	chr2:234161769	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.46	6.26	0.38	1.82e-9	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs1949733	0.701	rs2631754	chr4:8449233	A/G	cg13073564	chr4:8508604	NA	-0.44	-7.02	-0.42	2.42e-11	Response to antineoplastic agents;
SARC	cis	rs1003719	1.000	rs2835607	chr21:38491973	T/G	cg10648535	chr21:38446584	PIGP;TTC3	0.66	9.07	0.51	5.21e-17	Eye color traits;
SARC	cis	rs748404	0.660	rs509306	chr15:43715171	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	5.72	0.35	3.27e-8	Lung cancer;
SARC	cis	rs73198271	0.562	rs79296712	chr8:8659978	G/A	cg01851573	chr8:8652454	MFHAS1	0.46	5.72	0.35	3.33e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	trans	rs116095464	0.558	rs10056628	chr5:279512	G/A	cg00938859	chr5:1591904	SDHAP3	0.77	6.38	0.39	9.4e-10	Breast cancer;
SARC	trans	rs208520	1.000	rs12209225	chr6:66996443	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	9.32	0.52	9.16e-18	Exhaled nitric oxide output;
SARC	cis	rs1957429	0.572	rs3813421	chr14:65347239	G/A	cg23373153	chr14:65346875	NA	1.07	11.5	0.6	1.51e-24	Pediatric areal bone mineral density (radius);
SARC	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg07636037	chr3:49044803	WDR6	0.99	17.38	0.75	5.99e-44	Parkinson's disease;
SARC	cis	rs62344088	0.744	rs76038312	chr5:229005	A/G	cg22857025	chr5:266934	NA	-1.11	-6.92	-0.41	4.26e-11	Asthma (childhood onset);
SARC	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg25072359	chr17:41440525	NA	0.54	6.6	0.4	2.74e-10	Menopause (age at onset);
SARC	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.65	7.6	0.45	7.34e-13	Gut microbiome composition (summer);
SARC	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.35	-0.43	3.24e-12	Gut microbiome composition (summer);
SARC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.36	0.8	1.22e-53	Prudent dietary pattern;
SARC	cis	rs2290159	0.800	rs55762590	chr3:12689451	C/T	cg23032965	chr3:12705835	RAF1	0.78	8.76	0.5	4.18e-16	Cholesterol, total;
SARC	cis	rs7000551	0.715	rs12544074	chr8:22338378	A/G	cg12081754	chr8:22256438	SLC39A14	0.59	8.31	0.48	8.02e-15	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	trans	rs61931739	0.534	rs7313137	chr12:34010231	T/G	cg26384229	chr12:38710491	ALG10B	0.85	12.17	0.62	1.1e-26	Morning vs. evening chronotype;
SARC	cis	rs11122272	0.735	rs2790889	chr1:231520240	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs796364	0.806	rs11688168	chr2:200916004	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.67	-5.68	-0.35	4.06e-8	Schizophrenia;
SARC	cis	rs933688	0.938	rs10063683	chr5:90714595	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.02	12.84	0.64	6.81e-29	Smoking behavior;
SARC	cis	rs57994353	0.861	rs3812591	chr9:139341612	C/T	cg14169450	chr9:139327907	INPP5E	-0.42	-5.27	-0.33	3.17e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs9816226	0.591	rs74607912	chr3:185818559	G/A	cg00760338	chr3:185826511	ETV5	-0.87	-8.54	-0.49	1.76e-15	Obesity;Body mass index;
SARC	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg24549020	chr5:56110836	MAP3K1	0.81	8.35	0.48	6.22e-15	Initial pursuit acceleration;
SARC	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg23262073	chr20:60523788	NA	-0.45	-6.76	-0.41	1.07e-10	Body mass index;
SARC	cis	rs80130819	0.748	rs2732477	chr12:48700282	C/T	cg05342945	chr12:48394962	COL2A1	0.52	5.44	0.34	1.33e-7	Prostate cancer;
SARC	cis	rs2288884	0.943	rs1433089	chr19:52506985	T/C	cg24794228	chr19:52391166	ZNF577	0.44	4.74	0.3	3.71e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
SARC	cis	rs9325144	0.505	rs901635	chr12:38646572	A/C	cg26384229	chr12:38710491	ALG10B	-0.72	-9.71	-0.54	6.05e-19	Morning vs. evening chronotype;
SARC	cis	rs75920871	0.588	rs1815788	chr11:116834971	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.47	-4.93	-0.31	1.54e-6	Subjective well-being;
SARC	cis	rs733592	1.000	rs1859440	chr12:48427329	T/C	cg24011408	chr12:48396354	COL2A1	-0.49	-6.53	-0.39	4.15e-10	Plateletcrit;
SARC	cis	rs2070488	0.804	rs13094715	chr3:38504430	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	12.62	0.64	3.63e-28	Electrocardiographic conduction measures;
SARC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg05552183	chr6:42928497	GNMT	0.53	7.21	0.43	7.59e-12	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg00825309	chr19:58991885	ZNF446	-0.55	-7.61	-0.45	6.74e-13	Uric acid clearance;
SARC	cis	rs1144333	0.655	rs4949681	chr1:76409828	C/T	cg03433033	chr1:76189801	ACADM	0.64	5.21	0.32	4.14e-7	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs898097	1.000	rs898097	chr17:80904310	C/T	cg20578329	chr17:80767326	TBCD	0.43	5.98	0.36	8.39e-9	Breast cancer;
SARC	cis	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg20965017	chr5:231967	SDHA	-0.57	-5.59	-0.34	6.35e-8	Breast cancer;
SARC	cis	rs7599312	0.517	rs10192988	chr2:213407782	T/G	cg20637307	chr2:213403960	ERBB4	0.8	12.12	0.62	1.53e-26	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg03709012	chr19:19516395	GATAD2A	0.96	15.22	0.71	8.65e-37	Tonsillectomy;
SARC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg06873352	chr17:61820015	STRADA	-0.55	-7.11	-0.42	1.45e-11	Prudent dietary pattern;
SARC	cis	rs3741404	0.594	rs11231704	chr11:63898182	C/T	cg05555928	chr11:63887634	MACROD1	0.46	7.94	0.46	8.41e-14	Platelet count;
SARC	cis	rs55871839	0.708	rs10098750	chr8:59813205	T/G	cg07426533	chr8:59803705	TOX	-0.43	-5.77	-0.35	2.51e-8	Pneumonia;
SARC	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg05861140	chr6:150128134	PCMT1	-0.41	-5.07	-0.32	8.13e-7	Lung cancer;
SARC	cis	rs112591243	0.685	rs2839341	chr21:47990008	A/G	cg10657630	chr21:48055338	PRMT2	-0.84	-5.61	-0.34	5.84e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	trans	rs561341	0.714	rs75861674	chr17:30304317	A/G	cg20587970	chr11:113659929	NA	-1.26	-12.92	-0.65	3.84e-29	Hip circumference adjusted for BMI;
SARC	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg26338869	chr17:61819248	STRADA	-0.79	-10.23	-0.56	1.56e-20	Prudent dietary pattern;
SARC	cis	rs16976116	0.619	rs4774750	chr15:55466155	G/A	cg17854078	chr15:55489399	RSL24D1	-0.6	-5.19	-0.32	4.57e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7824557	0.736	rs35392635	chr8:11164349	G/C	cg21775007	chr8:11205619	TDH	0.52	6.18	0.38	2.79e-9	Retinal vascular caliber;
SARC	cis	rs7727544	0.735	rs4705933	chr5:131678412	G/A	cg24060327	chr5:131705240	SLC22A5	-0.66	-8.27	-0.48	1.05e-14	Blood metabolite levels;
SARC	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg15921436	chr17:44337874	NA	0.52	5.14	0.32	5.87e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs2013441	0.931	rs4925089	chr17:20064784	A/T	cg13482628	chr17:19912719	NA	0.48	6.15	0.37	3.36e-9	Obesity-related traits;
SARC	cis	rs6493487	0.512	rs80355962	chr15:51142997	C/T	cg02338191	chr15:51200825	AP4E1	0.54	5.08	0.32	7.71e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs6088580	0.634	rs6088512	chr20:33095891	G/A	cg08999081	chr20:33150536	PIGU	0.43	6.75	0.4	1.14e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs2075371	1.000	rs2505	chr7:133979552	C/T	cg00033643	chr7:134001901	SLC35B4	0.4	4.91	0.31	1.68e-6	Mean platelet volume;
SARC	cis	rs9291683	0.588	rs13121211	chr4:9999539	A/G	cg11266682	chr4:10021025	SLC2A9	0.41	7.24	0.43	6.62e-12	Bone mineral density;
SARC	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg13939156	chr17:80058883	NA	-0.41	-6.35	-0.38	1.11e-9	Life satisfaction;
SARC	cis	rs9914988	0.778	rs35398767	chr17:27122960	A/T	cg20469991	chr17:27169893	C17orf63	-0.5	-5.21	-0.32	4.1e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs2075371	0.933	rs431306	chr7:133955974	A/T	cg20476274	chr7:133979776	SLC35B4	0.61	8.42	0.48	3.85e-15	Mean platelet volume;
SARC	cis	rs703842	0.964	rs10431552	chr12:58178148	G/A	cg00677455	chr12:58241039	CTDSP2	0.51	6.64	0.4	2.18e-10	Multiple sclerosis;
SARC	cis	rs17666538	1.000	rs57255985	chr8:574131	C/T	cg19660806	chr8:588740	NA	-0.65	-5.03	-0.31	9.99e-7	IgG glycosylation;
SARC	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg20607798	chr8:58055168	NA	0.65	5.61	0.35	5.68e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.43	5.87	0.36	1.51e-8	Personality dimensions;
SARC	cis	rs9291683	0.595	rs11731110	chr4:10037346	T/C	cg00071950	chr4:10020882	SLC2A9	0.4	6.29	0.38	1.54e-9	Bone mineral density;
SARC	cis	rs6582630	0.555	rs34730221	chr12:38405140	C/T	cg13010199	chr12:38710504	ALG10B	-0.71	-9.66	-0.53	9.06e-19	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg03709012	chr19:19516395	GATAD2A	-0.96	-15.51	-0.71	9.48e-38	Tonsillectomy;
SARC	cis	rs72717009	0.825	rs61802846	chr1:161473873	A/C	cg23840854	chr1:161414152	NA	-0.54	-5.07	-0.32	8.2e-7	Rheumatoid arthritis;
SARC	cis	rs6598955	0.543	rs6690461	chr1:26543097	T/A	cg04990556	chr1:26633338	UBXN11	0.76	7.72	0.45	3.49e-13	Obesity-related traits;
SARC	cis	rs9916302	0.904	rs585961	chr17:37444036	G/A	cg15445000	chr17:37608096	MED1	-0.44	-5.34	-0.33	2.19e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs2228479	0.618	rs34689166	chr16:89860697	C/T	cg00800038	chr16:89945340	TCF25	-0.8	-5.6	-0.34	6.15e-8	Skin colour saturation;
SARC	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg06108461	chr20:60628389	TAF4	-0.92	-12.42	-0.63	1.61e-27	Body mass index;
SARC	cis	rs2304069	0.817	rs216132	chr5:149431259	C/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	-0.54	-5.51	-0.34	9.59e-8	HIV-1 control;
SARC	cis	rs10197940	0.662	rs72860233	chr2:152289767	G/A	cg19508488	chr2:152266495	RIF1	0.51	5.46	0.34	1.19e-7	Lung cancer;
SARC	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.8	-11.06	-0.59	4.06e-23	Chronic sinus infection;
SARC	cis	rs7223966	1.000	rs8081541	chr17:61812483	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	6.88	0.41	5.45e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg16405210	chr4:1374714	KIAA1530	-0.94	-12.78	-0.64	1.05e-28	Longevity;
SARC	cis	rs9486719	0.843	rs2499793	chr6:96846402	A/C	cg06623918	chr6:96969491	KIAA0776	0.75	7.39	0.44	2.65e-12	Migraine;Coronary artery disease;
SARC	cis	rs72781680	0.898	rs72796396	chr2:24178154	G/A	cg08917208	chr2:24149416	ATAD2B	0.79	7.55	0.44	9.78e-13	Lymphocyte counts;
SARC	cis	rs10876993	0.826	rs1678534	chr12:58057435	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.49	-6.3	-0.38	1.44e-9	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs7208859	0.673	rs73277978	chr17:29191449	A/G	cg13385521	chr17:29058706	SUZ12P	0.86	7.34	0.43	3.54e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs10782582	0.609	rs79835994	chr1:76287508	G/T	cg03433033	chr1:76189801	ACADM	-0.38	-4.78	-0.3	3.04e-6	Daytime sleep phenotypes;
SARC	cis	rs2153535	0.580	rs9406170	chr6:8514153	T/C	cg21535247	chr6:8435926	SLC35B3	0.58	7.25	0.43	6.2e-12	Motion sickness;
SARC	cis	rs7552404	0.696	rs1417405	chr1:76457797	T/C	cg03433033	chr1:76189801	ACADM	0.45	5.21	0.32	4.18e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg11987759	chr7:65425863	GUSB	0.49	6.01	0.37	7.24e-9	Aortic root size;
SARC	trans	rs10100465	0.596	rs218009	chr8:118716275	A/G	cg02235641	chr8:67687675	SGK3	0.66	7.02	0.42	2.47e-11	Leprosy;
SARC	cis	rs2070488	0.965	rs9829192	chr3:38569463	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.81	-12.96	-0.65	2.79e-29	Electrocardiographic conduction measures;
SARC	cis	rs8017423	0.967	rs8016385	chr14:90721946	G/A	cg20276874	chr14:90721474	PSMC1	-0.39	-5.47	-0.34	1.18e-7	Mortality in heart failure;
SARC	cis	rs6542838	0.671	rs6752025	chr2:99505699	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.41	-5.11	-0.32	6.71e-7	Fear of minor pain;
SARC	cis	rs8070128	0.597	rs4635395	chr17:17882087	G/A	cg04398451	chr17:18023971	MYO15A	-0.43	-5.59	-0.34	6.32e-8	Total body bone mineral density;
SARC	cis	rs965469	1.000	rs6051736	chr20:3296898	T/C	cg25506879	chr20:3388711	C20orf194	-0.52	-5.25	-0.33	3.39e-7	IFN-related cytopenia;
SARC	cis	rs6450176	0.585	rs255761	chr5:53321956	G/T	ch.5.1024479R	chr5:53302184	ARL15	-0.72	-8.2	-0.47	1.62e-14	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs11997175	1.000	rs7464996	chr8:33770925	G/T	ch.8.33884649F	chr8:33765107	NA	0.58	8.15	0.47	2.3e-14	Body mass index;
SARC	cis	rs2180341	0.883	rs9388568	chr6:127690694	C/A	cg17762328	chr6:126965162	NA	-0.45	-4.98	-0.31	1.21e-6	Breast cancer;
SARC	cis	rs12367572	0.965	rs1506678	chr12:45249492	A/G	cg04608330	chr12:45269318	NELL2	-0.42	-5.49	-0.34	1.07e-7	Gut microbiome composition (summer);
SARC	cis	rs9486715	0.838	rs9386576	chr6:96954717	C/T	cg06623918	chr6:96969491	KIAA0776	0.89	12.91	0.65	3.96e-29	Headache;
SARC	cis	rs2303745	0.544	rs6512181	chr19:17399213	T/G	cg04248312	chr19:17393744	ANKLE1	-0.59	-7.56	-0.44	9.06e-13	Systemic lupus erythematosus;
SARC	cis	rs881375	0.967	rs3761849	chr9:123690957	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	5.31	0.33	2.55e-7	Rheumatoid arthritis;
SARC	cis	rs3820928	0.904	rs6735069	chr2:227893660	A/G	cg05526886	chr2:227700861	RHBDD1	-0.47	-5.48	-0.34	1.08e-7	Pulmonary function;
SARC	cis	rs870825	0.616	rs1401362	chr4:185643775	G/A	cg04058563	chr4:185651563	MLF1IP	0.81	11.52	0.6	1.31e-24	Blood protein levels;
SARC	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg22974920	chr21:40686053	BRWD1	0.45	4.91	0.31	1.69e-6	Cognitive function;
SARC	cis	rs6545883	0.929	rs1186707	chr2:61673520	C/A	cg15711740	chr2:61764176	XPO1	-0.43	-5.12	-0.32	6.3e-7	Tuberculosis;
SARC	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg12564285	chr5:131593104	PDLIM4	-0.45	-6.09	-0.37	4.51e-9	Breast cancer;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg04519918	chr16:57278807	ARL2BP	-0.52	-6.36	-0.38	1.08e-9	Breast cancer;
SARC	cis	rs9911578	1.000	rs7207693	chr17:57016525	C/T	cg05425664	chr17:57184151	TRIM37	-0.67	-8.32	-0.48	7.53e-15	Intelligence (multi-trait analysis);
SARC	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg03185022	chr7:2884158	GNA12	0.45	4.75	0.3	3.61e-6	Height;
SARC	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg00800038	chr16:89945340	TCF25	-0.76	-5.06	-0.31	8.3e-7	Skin colour saturation;
SARC	cis	rs4372836	0.741	rs4563180	chr2:29093695	C/G	cg09522027	chr2:28974177	PPP1CB	-0.35	-4.73	-0.3	3.81e-6	Body mass index;
SARC	cis	rs9325144	0.600	rs61931871	chr12:38829889	G/A	cg13010199	chr12:38710504	ALG10B	-0.5	-6.36	-0.38	1.05e-9	Morning vs. evening chronotype;
SARC	cis	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg05623727	chr3:50126028	RBM5	-0.33	-4.99	-0.31	1.19e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg05896524	chr21:47604654	C21orf56	0.42	5.04	0.31	9.35e-7	Testicular germ cell tumor;
SARC	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg12064134	chr16:90016061	DEF8	-0.56	-4.83	-0.3	2.51e-6	Skin colour saturation;
SARC	cis	rs2180341	0.814	rs6569488	chr6:127726256	C/T	cg27446573	chr6:127587934	RNF146	0.8	10.39	0.56	4.87e-21	Breast cancer;
SARC	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg25036284	chr2:26402008	FAM59B	0.47	5.61	0.35	5.68e-8	Gut microbiome composition (summer);
SARC	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg11987759	chr7:65425863	GUSB	-0.6	-7.96	-0.46	7.49e-14	Aortic root size;
SARC	cis	rs9640161	0.830	rs17173703	chr7:150068620	C/T	cg17279839	chr7:150038598	RARRES2	0.34	4.74	0.3	3.79e-6	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.78	-0.5	3.56e-16	Alzheimer's disease;
SARC	cis	rs9858542	0.953	rs9853683	chr3:49512588	A/G	cg03060546	chr3:49711283	APEH	-0.58	-7.13	-0.42	1.28e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs965469	1.000	rs2281497	chr20:3258874	G/A	cg25506879	chr20:3388711	C20orf194	-0.48	-4.87	-0.3	2.04e-6	IFN-related cytopenia;
SARC	cis	rs12908161	1.000	rs58416181	chr15:85264461	G/A	cg17507749	chr15:85114479	UBE2QP1	0.59	6.75	0.4	1.18e-10	Schizophrenia;
SARC	cis	rs7000551	0.689	rs2449339	chr8:22387981	G/A	cg12081754	chr8:22256438	SLC39A14	0.56	7.89	0.46	1.2e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs77372450	0.636	rs11465233	chr5:157001953	T/A	cg23851860	chr5:157002805	ADAM19	0.52	4.98	0.31	1.23e-6	Bipolar disorder (body mass index interaction);
SARC	trans	rs804280	0.542	rs36100659	chr8:11791653	A/T	cg06636001	chr8:8085503	FLJ10661	0.5	6.28	0.38	1.64e-9	Myopia (pathological);
SARC	cis	rs12142240	0.698	rs17361833	chr1:46828700	A/G	cg10495392	chr1:46806563	NSUN4	0.64	6.83	0.41	7.39e-11	Menopause (age at onset);
SARC	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.6	-6.31	-0.38	1.42e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs1348850	0.874	rs13013752	chr2:178456862	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.63	7.7	0.45	3.95e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs13191362	1.000	rs71567659	chr6:163001736	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.57	5.38	0.33	1.85e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs7412746	0.611	rs4970931	chr1:150910727	G/A	cg15448220	chr1:150897856	SETDB1	0.52	6.89	0.41	5.25e-11	Melanoma;
SARC	cis	rs2404602	0.536	rs7165025	chr15:76766434	G/A	cg22467129	chr15:76604101	ETFA	-0.37	-4.89	-0.31	1.87e-6	Blood metabolite levels;
SARC	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg05793240	chr7:2802953	GNA12	0.36	5.27	0.33	3.06e-7	Height;
SARC	trans	rs7395662	0.571	rs4881998	chr11:48525186	C/T	cg15704280	chr7:45808275	SEPT13	-0.49	-6.66	-0.4	1.97e-10	HDL cholesterol;
SARC	cis	rs2549003	1.000	rs2070722	chr5:131824486	A/C	cg21138405	chr5:131827807	IRF1	0.26	5.13	0.32	6.24e-7	Asthma (sex interaction);
SARC	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg09455208	chr3:40491958	NA	-0.37	-5.53	-0.34	8.71e-8	Renal cell carcinoma;
SARC	trans	rs61931739	0.534	rs1843733	chr12:34047626	T/C	cg13010199	chr12:38710504	ALG10B	0.68	9.39	0.52	5.53e-18	Morning vs. evening chronotype;
SARC	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg09165964	chr15:75287851	SCAMP5	0.5	6.62	0.4	2.48e-10	Breast cancer;
SARC	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg00684032	chr4:1343700	KIAA1530	0.4	5.85	0.36	1.65e-8	Obesity-related traits;
SARC	cis	rs6831352	0.840	rs17817868	chr4:100060623	C/T	cg12011299	chr4:100065546	ADH4	-0.35	-5.75	-0.35	2.8e-8	Alcohol dependence;
SARC	cis	rs13082711	0.863	rs66743193	chr3:27471958	G/A	cg02860705	chr3:27208620	NA	0.48	6.09	0.37	4.52e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs7223966	1.000	rs8075422	chr17:61804686	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	6.69	0.4	1.61e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6570726	0.905	rs452770	chr6:145847162	T/C	cg23711669	chr6:146136114	FBXO30	0.78	12.08	0.62	2.13e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs561341	0.714	rs55925849	chr17:30253085	C/T	cg00745463	chr17:30367425	LRRC37B	-0.66	-4.95	-0.31	1.41e-6	Hip circumference adjusted for BMI;
SARC	trans	rs61931739	0.500	rs11524949	chr12:34435551	C/T	cg26384229	chr12:38710491	ALG10B	0.92	13.78	0.67	5.56e-32	Morning vs. evening chronotype;
SARC	cis	rs2933343	0.859	rs789247	chr3:128580585	C/A	cg25356066	chr3:128598488	ACAD9	0.58	6.61	0.4	2.65e-10	IgG glycosylation;
SARC	cis	rs9325144	0.600	rs2171405	chr12:38741030	G/T	cg13010199	chr12:38710504	ALG10B	-0.54	-6.87	-0.41	5.92e-11	Morning vs. evening chronotype;
SARC	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg18876405	chr7:65276391	NA	0.74	9.42	0.53	4.63e-18	Aortic root size;
SARC	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg15921436	chr17:44337874	NA	0.49	4.94	0.31	1.47e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7208859	0.673	rs28588622	chr17:29245699	G/A	cg13385521	chr17:29058706	SUZ12P	0.91	7.48	0.44	1.49e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs796364	1.000	rs1658807	chr2:200767512	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.75	6.97	0.42	3.27e-11	Schizophrenia;
SARC	cis	rs644799	0.710	rs11021309	chr11:95501898	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.87	14.28	0.68	1.16e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs477692	0.625	rs4751104	chr10:131405358	G/A	cg05714579	chr10:131428358	MGMT	-0.62	-8.34	-0.48	6.48e-15	Response to temozolomide;
SARC	cis	rs10885997	0.678	rs7072157	chr10:118395377	C/T	cg08406102	chr10:119292130	EMX2OS	-0.3	-4.85	-0.3	2.3e-6	Phospholipid levels (plasma);
SARC	cis	rs453301	0.658	rs9650616	chr8:8869199	T/G	cg11608241	chr8:8085544	FLJ10661	-0.44	-5.33	-0.33	2.27e-7	Joint mobility (Beighton score);
SARC	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg21782813	chr7:2030301	MAD1L1	0.37	5.71	0.35	3.47e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg02725872	chr8:58115012	NA	-0.34	-5.37	-0.33	1.91e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7870753	0.838	rs7037607	chr9:99244798	G/A	cg25260653	chr9:99212216	HABP4	0.51	4.77	0.3	3.21e-6	Height;
SARC	cis	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg15145296	chr3:125709740	NA	-0.49	-4.88	-0.3	1.98e-6	Blood pressure (smoking interaction);
SARC	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg00933542	chr6:150070202	PCMT1	0.33	5.63	0.35	5.13e-8	Lung cancer;
SARC	cis	rs9359856	0.636	rs9294440	chr6:90308666	C/G	cg13799429	chr6:90582589	CASP8AP2	0.56	4.96	0.31	1.33e-6	Bipolar disorder;
SARC	cis	rs208520	0.837	rs208498	chr6:66931560	G/A	cg07460842	chr6:66804631	NA	-0.9	-10.66	-0.57	7.23e-22	Exhaled nitric oxide output;
SARC	cis	rs6942407	0.744	rs10244350	chr7:86863278	A/G	cg02420886	chr7:86849541	C7orf23	0.56	5.1	0.32	6.96e-7	Food allergy;
SARC	cis	rs765787	0.530	rs11855435	chr15:45522117	G/A	cg25801113	chr15:45476975	SHF	0.31	5.12	0.32	6.38e-7	Uric acid levels;
SARC	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg07636037	chr3:49044803	WDR6	0.91	15.5	0.71	1.03e-37	Menarche (age at onset);
SARC	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg11644478	chr21:40555479	PSMG1	-0.53	-6.5	-0.39	4.93e-10	Menarche (age at onset);
SARC	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg22800045	chr5:56110881	MAP3K1	0.72	6.58	0.4	3.02e-10	Initial pursuit acceleration;
SARC	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.8	7.81	0.46	1.89e-13	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs9911578	1.000	rs8067571	chr17:56868856	C/T	cg12560992	chr17:57184187	TRIM37	0.89	12.39	0.63	2.03e-27	Intelligence (multi-trait analysis);
SARC	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg05890377	chr2:74357713	NA	0.57	7.07	0.42	1.79e-11	Gestational age at birth (maternal effect);
SARC	cis	rs6570726	1.000	rs951143	chr6:145932576	C/T	cg05347473	chr6:146136440	FBXO30	0.47	6.16	0.37	3.21e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs5995756	0.666	rs3788567	chr22:40006035	G/T	cg10455938	chr22:40058150	CACNA1I	0.43	5.12	0.32	6.52e-7	Autism spectrum disorder or schizophrenia;
SARC	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg11062466	chr8:58055876	NA	0.65	6.02	0.37	6.69e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs8044868	0.530	rs12446480	chr16:72056757	A/G	cg16558253	chr16:72132732	DHX38	-0.41	-6.09	-0.37	4.59e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
SARC	cis	rs112591243	0.685	rs78463142	chr21:47964481	A/G	cg10657630	chr21:48055338	PRMT2	0.82	5.2	0.32	4.39e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs8114671	0.933	rs6087683	chr20:33774444	C/T	cg24642439	chr20:33292090	TP53INP2	0.5	5.64	0.35	4.85e-8	Height;
SARC	trans	rs897080	0.516	rs1067361	chr2:44661217	G/C	cg19364021	chr13:53776396	NA	0.47	6.27	0.38	1.77e-9	Height;
SARC	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg18252515	chr7:66147081	NA	0.54	5.88	0.36	1.4e-8	Aortic root size;
SARC	cis	rs7633857	0.512	rs13098529	chr3:160657053	A/G	cg03342759	chr3:160939853	NMD3	-0.5	-5.94	-0.36	1.05e-8	Educational attainment (years of education);
SARC	cis	rs1707322	0.785	rs10890348	chr1:46242423	G/T	cg03146154	chr1:46216737	IPP	0.5	6.14	0.37	3.54e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs96067	0.805	rs6425966	chr1:36611287	C/T	cg24686825	chr1:36642396	MAP7D1	0.57	6.89	0.41	5.17e-11	Corneal structure;
SARC	cis	rs7223966	1.000	rs56057198	chr17:61733332	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.53	-5.42	-0.33	1.51e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs79349575	0.749	rs46521	chr17:46988529	A/G	cg16584676	chr17:46985605	UBE2Z	0.53	6.42	0.39	7.58e-10	Type 2 diabetes;
SARC	cis	rs13082711	0.911	rs35605663	chr3:27515754	C/T	cg02860705	chr3:27208620	NA	0.45	5.72	0.35	3.27e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg11764359	chr7:65958608	NA	0.76	8.96	0.51	1.07e-16	Aortic root size;
SARC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg09373136	chr17:61933544	TCAM1	-0.44	-5.99	-0.37	7.94e-9	Prudent dietary pattern;
SARC	cis	rs2732480	0.538	rs1387259	chr12:48703522	C/T	cg24011408	chr12:48396354	COL2A1	-0.45	-5.23	-0.32	3.75e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	trans	rs61931739	0.534	rs2636082	chr12:34061848	T/A	cg13010199	chr12:38710504	ALG10B	0.65	8.83	0.5	2.52e-16	Morning vs. evening chronotype;
SARC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg22903471	chr2:27725779	GCKR	-0.49	-7.42	-0.44	2.21e-12	Total body bone mineral density;
SARC	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg06873352	chr17:61820015	STRADA	-0.45	-5.8	-0.36	2.16e-8	Prudent dietary pattern;
SARC	cis	rs854765	0.583	rs5002487	chr17:17832460	A/G	cg05444541	chr17:17804740	TOM1L2	-0.32	-5.62	-0.35	5.49e-8	Total body bone mineral density;
SARC	cis	rs4713118	0.513	rs149958	chr6:28013617	A/C	cg26335602	chr6:28129616	ZNF389	0.44	4.96	0.31	1.34e-6	Parkinson's disease;
SARC	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg22535103	chr8:58192502	C8orf71	-0.62	-6.29	-0.38	1.53e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7561149	0.570	rs6731864	chr2:179736006	T/G	cg17765952	chr2:179737173	CCDC141	-0.47	-6.51	-0.39	4.49e-10	QT interval;
SARC	cis	rs17376456	0.825	rs55947981	chr5:93278104	G/T	cg21475434	chr5:93447410	FAM172A	0.85	7.57	0.44	8.53e-13	Diabetic retinopathy;
SARC	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg11764359	chr7:65958608	NA	0.88	12.58	0.64	4.89e-28	Aortic root size;
SARC	cis	rs6570726	0.791	rs4335004	chr6:145904764	G/A	cg23711669	chr6:146136114	FBXO30	0.89	14.72	0.69	3.93e-35	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs208520	0.874	rs208481	chr6:66922636	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.93	-11.11	-0.59	2.7e-23	Exhaled nitric oxide output;
SARC	cis	rs6138458	0.701	rs6138474	chr20:25012427	T/A	cg26195577	chr20:24973756	C20orf3	0.68	8.18	0.47	1.88e-14	Blood protein levels;
SARC	cis	rs7824557	0.628	rs7815802	chr8:11190647	G/C	cg21775007	chr8:11205619	TDH	0.66	8.45	0.48	3.11e-15	Retinal vascular caliber;
SARC	cis	rs2777491	0.915	rs7165675	chr15:41614704	T/C	cg01768344	chr15:41576519	LOC729082	0.44	4.9	0.31	1.76e-6	Ulcerative colitis;
SARC	cis	rs198851	0.915	rs112370520	chr6:26036092	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.4	-5.14	-0.32	5.84e-7	Red cell distribution width;High light scatter reticulocyte percentage of red cells;Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs478304	0.580	rs11606947	chr11:65508237	A/C	cg26695010	chr11:65641043	EFEMP2	0.4	4.91	0.31	1.71e-6	Acne (severe);
SARC	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg04944784	chr2:26401820	FAM59B	0.61	8.14	0.47	2.36e-14	Gut microbiome composition (summer);
SARC	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg11764359	chr7:65958608	NA	-0.63	-7.24	-0.43	6.66e-12	Aortic root size;
SARC	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg22590775	chr19:49891494	CCDC155	0.53	6.19	0.38	2.68e-9	Multiple sclerosis;
SARC	cis	rs6570726	0.967	rs418662	chr6:145848832	A/C	cg05347473	chr6:146136440	FBXO30	0.47	6.44	0.39	6.8e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7223966	1.000	rs16947042	chr17:61766457	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.57	-6.67	-0.4	1.87e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2075671	0.855	rs62483567	chr7:100286435	G/A	cg20848291	chr7:100343083	ZAN	-0.67	-7.37	-0.44	2.87e-12	Other erythrocyte phenotypes;
SARC	cis	rs12586317	0.553	rs78124218	chr14:35570606	G/A	cg05294307	chr14:35346193	BAZ1A	-0.48	-4.88	-0.3	1.93e-6	Psoriasis;
SARC	cis	rs4595586	0.545	rs2218762	chr12:39397762	G/A	cg26384229	chr12:38710491	ALG10B	0.5	6.14	0.37	3.61e-9	Morning vs. evening chronotype;
SARC	cis	rs2425143	1.000	rs2425141	chr20:34350123	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	5.19	0.32	4.53e-7	Blood protein levels;
SARC	cis	rs1057510	0.858	rs66627071	chr12:6705380	C/T	cg19104830	chr12:7342086	PEX5	0.59	4.79	0.3	2.99e-6	Myopia (pathological);
SARC	cis	rs2948294	0.524	rs13270062	chr8:8112650	C/A	cg15556689	chr8:8085844	FLJ10661	0.43	4.87	0.3	2.05e-6	Red cell distribution width;
SARC	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg11764359	chr7:65958608	NA	0.77	9.51	0.53	2.44e-18	Aortic root size;
SARC	cis	rs738322	0.934	rs133019	chr22:38573035	A/G	cg25457927	chr22:38595422	NA	-0.3	-6.35	-0.38	1.11e-9	Cutaneous nevi;
SARC	cis	rs6062509	0.732	rs6062304	chr20:62351539	A/T	cg27236539	chr20:62289627	RTEL1	0.52	5.86	0.36	1.59e-8	Prostate cancer;
SARC	cis	rs4727027	0.933	rs917123	chr7:148848358	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	5.73	0.35	3.05e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs2075371	0.673	rs35290398	chr7:134011773	C/T	cg20476274	chr7:133979776	SLC35B4	0.46	5.67	0.35	4.17e-8	Mean platelet volume;
SARC	cis	rs7917772	0.636	rs2486757	chr10:104535145	C/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.49	5.62	0.35	5.48e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg25072359	chr17:41440525	NA	0.53	6.28	0.38	1.61e-9	Menopause (age at onset);
SARC	cis	rs9527	0.568	rs12772775	chr10:104702999	C/A	cg04362960	chr10:104952993	NT5C2	0.41	4.77	0.3	3.32e-6	Arsenic metabolism;
SARC	cis	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg18252515	chr7:66147081	NA	-1.42	-13.07	-0.65	1.16e-29	Gout;
SARC	cis	rs920590	0.502	rs7816670	chr8:19634556	C/G	cg03894339	chr8:19674705	INTS10	0.44	5.4	0.33	1.67e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.43	5.03	0.31	9.61e-7	Renal function-related traits (BUN);
SARC	cis	rs9420	0.784	rs10896656	chr11:57668941	C/G	cg23127183	chr11:57508653	C11orf31	-0.54	-5.39	-0.33	1.72e-7	Schizophrenia;
SARC	cis	rs11025559	0.631	rs11025571	chr11:20482801	C/G	cg19653624	chr11:20408972	PRMT3	0.73	7.24	0.43	6.44e-12	Pursuit maintenance gain;
SARC	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg03188948	chr7:1209495	NA	0.6	5.17	0.32	5.04e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs2635047	1.000	rs2684818	chr18:44712965	C/T	cg19077165	chr18:44547161	KATNAL2	-0.37	-5.01	-0.31	1.1e-6	Educational attainment;
SARC	cis	rs116979167	0.575	rs67661063	chr7:105187259	T/G	cg19920283	chr7:105172520	RINT1	0.56	5.7	0.35	3.62e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.48	-6.03	-0.37	6.29e-9	Lymphocyte counts;
SARC	cis	rs763121	0.853	rs5757204	chr22:39046700	A/C	cg06022373	chr22:39101656	GTPBP1	0.9	11.56	0.6	9.96e-25	Menopause (age at onset);
SARC	cis	rs10489202	1.000	rs7523437	chr1:168029365	A/G	cg24449463	chr1:168025552	DCAF6	-0.63	-6.96	-0.42	3.33e-11	Schizophrenia;
SARC	cis	rs4479964	0.605	rs17755156	chr6:129962301	G/C	cg27192990	chr6:129479024	LAMA2	0.29	4.77	0.3	3.2e-6	Gut microbiome composition (summer);
SARC	cis	rs11155671	0.530	rs7763849	chr6:150206380	C/T	cg00933542	chr6:150070202	PCMT1	0.3	4.94	0.31	1.51e-6	Testicular germ cell tumor;
SARC	cis	rs523522	0.962	rs4766966	chr12:120942911	G/C	cg12219531	chr12:120966889	COQ5	0.82	11.15	0.59	1.99e-23	High light scatter reticulocyte count;
SARC	cis	rs9611519	0.828	rs4822008	chr22:41539206	C/G	cg17376030	chr22:41985996	PMM1	0.47	5.33	0.33	2.31e-7	Neuroticism;
SARC	cis	rs854765	0.575	rs2955357	chr17:17946401	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.44	-5.62	-0.35	5.51e-8	Total body bone mineral density;
SARC	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg22800045	chr5:56110881	MAP3K1	0.76	8.02	0.47	5.09e-14	Initial pursuit acceleration;
SARC	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg11644478	chr21:40555479	PSMG1	-0.88	-11.37	-0.6	3.97e-24	Cognitive function;
SARC	cis	rs10876993	0.928	rs1689596	chr12:58053029	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.46	-5.84	-0.36	1.76e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs10463554	0.963	rs11242485	chr5:102382034	G/A	cg23492399	chr5:102201601	PAM	-0.51	-5.65	-0.35	4.78e-8	Parkinson's disease;
SARC	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg08677398	chr8:58056175	NA	0.44	5.25	0.33	3.38e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg22535103	chr8:58192502	C8orf71	-0.66	-5.85	-0.36	1.65e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2645694	0.532	rs2645706	chr4:77829606	A/C	cg03477792	chr4:77819574	ANKRD56	0.46	6.77	0.41	1.01e-10	Emphysema distribution in smoking;
SARC	cis	rs2290159	0.800	rs11711419	chr3:12667784	A/T	cg23032965	chr3:12705835	RAF1	0.78	8.68	0.49	6.81e-16	Cholesterol, total;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg07049977	chr2:37458536	CEBPZ;C2orf56	0.5	6.29	0.38	1.58e-9	Height;
SARC	cis	rs4148883	0.504	rs4585310	chr4:100120233	T/C	cg13256891	chr4:100009986	ADH5	-0.53	-7.15	-0.42	1.11e-11	Alcohol dependence;
SARC	cis	rs7666738	0.830	rs11723283	chr4:99001617	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6952809	0.532	rs10272548	chr7:2439467	G/A	cg23289794	chr7:2394357	EIF3B	-0.73	-6.94	-0.41	3.78e-11	Multiple sclerosis;
SARC	trans	rs1994135	0.692	rs1816958	chr12:33695066	A/T	cg26384229	chr12:38710491	ALG10B	0.69	8.33	0.48	6.93e-15	Resting heart rate;
SARC	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg13206674	chr6:150067644	NUP43	0.39	5.08	0.32	7.86e-7	Lung cancer;
SARC	cis	rs35110281	0.633	rs4819292	chr21:45125223	A/G	cg21573476	chr21:45109991	RRP1B	-0.58	-7.94	-0.46	8.3e-14	Mean corpuscular volume;
SARC	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-15.51	-0.71	9.76e-38	Chronic sinus infection;
SARC	cis	rs17021463	0.726	rs62320444	chr4:95261251	C/T	cg11021082	chr4:95130006	SMARCAD1	0.42	6.01	0.37	7.21e-9	Testicular germ cell tumor;
SARC	cis	rs754466	0.606	rs11002306	chr10:79591519	A/T	cg17075019	chr10:79541650	NA	-0.79	-12.65	-0.64	2.89e-28	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs4851254	0.920	rs11689956	chr2:100795329	T/C	cg17356467	chr2:100759845	AFF3	0.28	4.73	0.3	3.9e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9787249	0.915	rs58589165	chr1:40213670	A/T	cg02773041	chr1:40204384	PPIE	0.53	6.46	0.39	6.11e-10	Blood protein levels;
SARC	cis	rs3741151	1.000	rs74795285	chr11:73033387	A/G	cg17517138	chr11:73019481	ARHGEF17	1.0	7.64	0.45	5.48e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg13206674	chr6:150067644	NUP43	0.41	5.37	0.33	1.95e-7	Lung cancer;
SARC	cis	rs957448	1.000	rs7829886	chr8:95497388	T/A	cg26464482	chr8:95565502	KIAA1429	0.42	4.78	0.3	3.18e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs12984174	0.752	rs388159	chr19:18141996	C/T	cg21649277	chr19:18117794	ARRDC2	0.64	6.03	0.37	6.23e-9	Pulmonary function in asthmatics;
SARC	cis	rs4727027	0.635	rs12111923	chr7:148885877	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.48	5.44	0.34	1.38e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs2276314	0.947	rs3898595	chr18:33565885	T/A	cg05985134	chr18:33552581	C18orf21	0.71	7.71	0.45	3.59e-13	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs7247513	0.639	rs12984441	chr19:12760287	A/C	cg04657146	chr19:12876947	HOOK2	0.43	5.22	0.32	3.91e-7	Bipolar disorder;
SARC	cis	rs6998277	0.830	rs6468838	chr8:103609336	T/C	cg10187029	chr8:103597600	NA	0.87	12.28	0.63	4.67e-27	Migraine;
SARC	cis	rs10791323	0.569	rs1119851	chr11:133742842	T/C	cg15485101	chr11:133734466	NA	0.32	5.14	0.32	5.92e-7	Childhood ear infection;
SARC	cis	rs35110281	0.633	rs4819289	chr21:45120237	A/G	cg21573476	chr21:45109991	RRP1B	-0.57	-8.02	-0.47	5.15e-14	Mean corpuscular volume;
SARC	cis	rs2658782	0.951	rs72972364	chr11:93122128	C/T	cg15737290	chr11:93063684	CCDC67	-0.71	-6.81	-0.41	8.42e-11	Pulmonary function decline;
SARC	cis	rs910316	0.737	rs28687415	chr14:75495482	T/C	cg11812906	chr14:75593930	NEK9	0.77	10.34	0.56	7.35e-21	Height;
SARC	cis	rs6997458	0.742	rs4566	chr8:86361082	G/T	cg21346043	chr8:86351067	CA3	-0.34	-4.81	-0.3	2.67e-6	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg21724239	chr8:58056113	NA	0.61	5.93	0.36	1.1e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg11494091	chr17:61959527	GH2	-0.59	-9.63	-0.53	1.07e-18	Prudent dietary pattern;
SARC	cis	rs1163251	0.902	rs639761	chr1:120217558	G/A	cg19096424	chr1:120255104	PHGDH	0.53	6.2	0.38	2.56e-9	Blood metabolite levels;
SARC	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg27347728	chr4:17578864	LAP3	0.48	6.1	0.37	4.5e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs17030434	0.906	rs12641631	chr4:154665279	A/G	cg14289246	chr4:154710475	SFRP2	-0.66	-6.49	-0.39	5.15e-10	Electrocardiographic conduction measures;
SARC	cis	rs9392918	0.935	rs7745400	chr6:7697544	C/T	cg23089261	chr6:7723385	NA	0.37	4.89	0.3	1.9e-6	Height;
SARC	cis	rs6807306	1.000	rs2420024	chr3:167369129	A/G	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.53	5.36	0.33	2.02e-7	Mean platelet volume;
SARC	cis	rs1707322	1.000	rs10890353	chr1:46298383	G/T	cg06784218	chr1:46089804	CCDC17	0.33	5.77	0.35	2.45e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs3762637	0.941	rs9837149	chr3:122230845	G/C	cg24169773	chr3:122142474	KPNA1	-0.56	-5.67	-0.35	4.18e-8	LDL cholesterol levels;
SARC	cis	rs72781680	0.898	rs72782136	chr2:24047344	A/G	cg08917208	chr2:24149416	ATAD2B	0.78	7.41	0.44	2.26e-12	Lymphocyte counts;
SARC	cis	rs8114671	0.662	rs3761143	chr20:33545745	C/T	cg24642439	chr20:33292090	TP53INP2	0.45	5.39	0.33	1.75e-7	Height;
SARC	cis	rs2153535	0.580	rs1932279	chr6:8473653	T/C	cg23788917	chr6:8435910	SLC35B3	0.64	8.39	0.48	4.57e-15	Motion sickness;
SARC	cis	rs554111	1.000	rs554111	chr1:21042300	C/G	cg04902671	chr1:21058625	SH2D5	-0.43	-4.78	-0.3	3.13e-6	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg14829155	chr15:31115871	NA	-0.47	-5.64	-0.35	4.92e-8	Huntington's disease progression;
SARC	trans	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg08975724	chr8:8085496	FLJ10661	0.52	6.98	0.42	2.96e-11	Neuroticism;
SARC	cis	rs1371867	0.875	rs1660320	chr8:101337579	A/C	cg11906718	chr8:101322791	RNF19A	0.68	8.66	0.49	7.89e-16	Atrioventricular conduction;
SARC	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg11987759	chr7:65425863	GUSB	0.47	5.82	0.36	1.9e-8	Aortic root size;
SARC	cis	rs5753618	0.561	rs737887	chr22:31696615	A/G	cg00478049	chr22:31556069	RNF185	0.44	4.79	0.3	2.95e-6	Colorectal cancer;
SARC	cis	rs77669868	0.929	rs3782004	chr11:114070250	T/C	cg01914181	chr11:114070210	ZBTB16	0.45	5.57	0.34	7.16e-8	Monocyte percentage of white cells;
SARC	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6991838	0.584	rs4388482	chr8:66496203	T/G	cg13398993	chr8:66546079	ARMC1	-0.62	-8.31	-0.48	7.89e-15	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg21724239	chr8:58056113	NA	0.69	5.98	0.36	8.45e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs651907	0.557	rs3094296	chr3:101400167	A/G	cg12386194	chr3:101231763	SENP7	0.49	5.71	0.35	3.39e-8	Colorectal cancer;
SARC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg02353165	chr6:42928485	GNMT	0.6	8.36	0.48	5.72e-15	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg05623727	chr3:50126028	RBM5	0.34	5.19	0.32	4.52e-7	Intelligence (multi-trait analysis);
SARC	cis	rs11249608	0.548	rs7733072	chr5:178456007	A/G	cg21905437	chr5:178450457	ZNF879	0.57	7.79	0.45	2.21e-13	Pubertal anthropometrics;
SARC	cis	rs9611519	0.780	rs9611546	chr22:41698542	C/G	cg03806693	chr22:41940476	POLR3H	-0.73	-9.4	-0.52	5.31e-18	Neuroticism;
SARC	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg08219700	chr8:58056026	NA	0.5	5.18	0.32	4.76e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9911578	0.967	rs9894274	chr17:56977919	G/A	cg12560992	chr17:57184187	TRIM37	0.85	11.57	0.6	9.08e-25	Intelligence (multi-trait analysis);
SARC	cis	rs10870270	1.000	rs10430617	chr10:133748889	T/C	cg26149184	chr10:133730230	NA	0.46	5.18	0.32	4.84e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs7582720	1.000	rs72926791	chr2:203822891	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs9815354	1.000	rs1716685	chr3:41925301	C/T	cg03022575	chr3:42003672	ULK4	0.54	5.23	0.32	3.83e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg03033257	chr22:50311977	ALG12;CRELD2	0.61	5.8	0.36	2.1e-8	Schizophrenia;
SARC	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg04518342	chr5:131593106	PDLIM4	-0.39	-5.28	-0.33	3e-7	Acylcarnitine levels;
SARC	cis	rs12142240	0.698	rs72677594	chr1:46824371	A/C	cg00530320	chr1:46809349	NSUN4	0.57	6.79	0.41	9.05e-11	Menopause (age at onset);
SARC	cis	rs9341808	0.718	rs2179842	chr6:80979053	T/C	cg08355045	chr6:80787529	NA	0.35	5.67	0.35	4.22e-8	Sitting height ratio;
SARC	cis	rs17826219	0.706	rs57698184	chr17:29064918	T/C	cg13385521	chr17:29058706	SUZ12P	0.88	7.94	0.46	8.37e-14	Body mass index;
SARC	cis	rs986417	0.892	rs8012339	chr14:60797545	T/G	cg27398547	chr14:60952738	C14orf39	-1.06	-8.79	-0.5	3.34e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs16976116	0.951	rs28706531	chr15:55477072	G/A	cg17854078	chr15:55489399	RSL24D1	0.65	6.63	0.4	2.32e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg09699651	chr6:150184138	LRP11	0.43	5.28	0.33	3e-7	Lung cancer;
SARC	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg11764359	chr7:65958608	NA	0.75	8.49	0.49	2.41e-15	Aortic root size;
SARC	cis	rs11191193	0.686	rs11191157	chr10:103703929	G/A	cg15320455	chr10:103880129	LDB1	0.53	5.68	0.35	3.98e-8	Educational attainment;
SARC	cis	rs4268898	0.662	rs2288074	chr2:24413595	C/T	cg06627628	chr2:24431161	ITSN2	-0.81	-9.52	-0.53	2.35e-18	Asthma;
SARC	cis	rs1348850	0.574	rs4893834	chr2:178442288	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.51	-4.81	-0.3	2.73e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg02353165	chr6:42928485	GNMT	0.62	8.62	0.49	1.04e-15	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs2228479	0.557	rs57071566	chr16:89889327	T/G	cg12064134	chr16:90016061	DEF8	-0.55	-4.8	-0.3	2.8e-6	Skin colour saturation;
SARC	cis	rs11716531	0.537	rs7626646	chr3:27268316	G/T	cg02860705	chr3:27208620	NA	0.57	7.02	0.42	2.45e-11	Diastolic blood pressure;
SARC	trans	rs9395865	0.520	rs6903708	chr6:53332940	A/G	cg03226554	chr1:28573817	NA	-0.5	-6.31	-0.38	1.41e-9	Electroencephalographic traits in alcoholism;
SARC	trans	rs3780486	0.874	rs10813955	chr9:33141791	C/T	cg20290983	chr6:43655470	MRPS18A	1.14	21.64	0.82	1.13e-57	IgG glycosylation;
SARC	cis	rs1018836	0.923	rs4735256	chr8:91612145	C/G	cg16814680	chr8:91681699	NA	-0.85	-13.84	-0.67	3.51e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs13161895	1.000	rs34027780	chr5:179478891	C/A	cg06664874	chr5:179499304	RNF130	0.53	5.12	0.32	6.46e-7	LDL cholesterol;
SARC	cis	rs2466076	0.503	rs17721043	chr8:32436875	C/T	cg14488905	chr8:32406789	NRG1	0.46	5.23	0.32	3.81e-7	Thyroid cancer;
SARC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg10862848	chr6:42927986	GNMT	-0.42	-6.54	-0.39	3.75e-10	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg15847926	chr7:2749597	AMZ1	-0.3	-4.91	-0.31	1.73e-6	Height;
SARC	trans	rs11039798	0.588	rs10437592	chr11:48598859	G/T	cg15704280	chr7:45808275	SEPT13	0.62	6.47	0.39	5.79e-10	Axial length;
SARC	cis	rs113835537	0.529	rs11550299	chr11:66254085	G/T	cg24851651	chr11:66362959	CCS	0.38	4.79	0.3	2.98e-6	Airway imaging phenotypes;
SARC	trans	rs503734	0.643	rs2317749	chr3:101121980	C/T	cg04233747	chr5:145214971	PRELID2	-0.52	-6.72	-0.4	1.37e-10	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs7917772	0.582	rs10786685	chr10:104323103	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.47	5.75	0.35	2.75e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs4568518	0.869	rs12699945	chr7:18037804	T/G	cg00911873	chr7:18067463	PRPS1L1	-0.33	-4.72	-0.3	4.15e-6	Measles;
SARC	cis	rs6582630	0.599	rs8189525	chr12:38424982	A/C	cg26384229	chr12:38710491	ALG10B	0.55	6.87	0.41	5.75e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7223966	1.000	rs55868506	chr17:61851686	T/G	cg26338869	chr17:61819248	STRADA	0.45	4.85	0.3	2.23e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs916888	0.610	rs199530	chr17:44836653	C/T	cg15921436	chr17:44337874	NA	-0.46	-5.24	-0.32	3.64e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs1865760	0.566	rs9358904	chr6:26068566	C/T	cg10373733	chr6:25993375	NA	0.41	5.0	0.31	1.12e-6	Height;
SARC	cis	rs4423214	1.000	rs11600860	chr11:71164019	T/C	cg24826892	chr11:71159390	DHCR7	0.44	5.3	0.33	2.74e-7	Vitamin D levels;
SARC	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg23172400	chr8:95962367	TP53INP1	-0.3	-5.26	-0.33	3.24e-7	Type 2 diabetes;
SARC	trans	rs1493916	0.967	rs1389532	chr18:31392323	C/T	cg27147174	chr7:100797783	AP1S1	-0.59	-7.68	-0.45	4.3e-13	Life satisfaction;
SARC	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg08677398	chr8:58056175	NA	0.44	5.25	0.33	3.38e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2836974	0.544	rs8128919	chr21:40711862	C/T	cg11644478	chr21:40555479	PSMG1	0.66	8.33	0.48	6.89e-15	Cognitive function;
SARC	cis	rs7044106	0.762	rs4837790	chr9:123446325	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	5.51	0.34	9.39e-8	Hip circumference adjusted for BMI;
SARC	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg04166393	chr7:2884313	GNA12	-0.54	-6.27	-0.38	1.75e-9	Height;
SARC	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg26681399	chr22:41777847	TEF	0.48	5.3	0.33	2.72e-7	Vitiligo;
SARC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg24846343	chr22:24311635	DDTL	0.36	5.03	0.31	9.97e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9457247	0.905	rs377232	chr6:167409638	C/A	cg07741184	chr6:167504864	NA	0.3	5.77	0.35	2.5e-8	Crohn's disease;
SARC	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg11247378	chr22:39784982	NA	-0.33	-5.33	-0.33	2.32e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs4808199	0.894	rs10418051	chr19:19397789	C/T	cg03709012	chr19:19516395	GATAD2A	1.03	10.57	0.57	1.4e-21	Nonalcoholic fatty liver disease;
SARC	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg24209194	chr3:40518798	ZNF619	0.58	7.17	0.43	9.89e-12	Renal cell carcinoma;
SARC	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg11247378	chr22:39784982	NA	-0.32	-5.18	-0.32	4.84e-7	Intelligence (multi-trait analysis);
SARC	cis	rs11168351	0.864	rs12228750	chr12:48496997	G/A	cg24011408	chr12:48396354	COL2A1	-0.42	-5.15	-0.32	5.63e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs7829975	0.711	rs1039916	chr8:8685854	A/G	cg14343924	chr8:8086146	FLJ10661	0.43	5.35	0.33	2.15e-7	Mood instability;
SARC	cis	rs9393692	0.905	rs9393694	chr6:26279296	T/C	cg00631329	chr6:26305371	NA	-0.58	-8.36	-0.48	5.54e-15	Educational attainment;
SARC	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.33	-5.0	-0.31	1.11e-6	Total body bone mineral density;
SARC	cis	rs3126085	0.877	rs868304	chr1:152178568	G/A	cg26876637	chr1:152193138	HRNR	0.49	5.61	0.35	5.67e-8	Atopic dermatitis;
SARC	cis	rs9902453	0.765	rs2447935	chr17:28057524	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.54	-7.09	-0.42	1.61e-11	Coffee consumption (cups per day);
SARC	cis	rs6570726	0.837	rs419991	chr6:145864212	C/T	cg05220968	chr6:146057943	EPM2A	-0.3	-5.08	-0.32	7.76e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9896933	0.830	rs607544	chr17:80768760	C/G	cg15664640	chr17:80829946	TBCD	-0.43	-5.41	-0.33	1.53e-7	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
SARC	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg07414643	chr4:187882934	NA	0.5	7.52	0.44	1.18e-12	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg23731901	chr1:167906689	BRP44;DCAF6	-0.46	-6.26	-0.38	1.86e-9	Neuroticism;
SARC	cis	rs12421382	0.659	rs60143378	chr11:109385513	T/C	cg16359550	chr11:109292809	C11orf87	0.36	5.28	0.33	2.9e-7	Schizophrenia;
SARC	cis	rs909341	0.537	rs12481497	chr20:62385541	G/A	cg14758556	chr20:62440591	NA	0.51	5.01	0.31	1.07e-6	Atopic dermatitis;
SARC	cis	rs910316	1.000	rs4899546	chr14:75594946	G/C	cg08847533	chr14:75593920	NEK9	0.92	15.52	0.71	9.06e-38	Height;
SARC	cis	rs929354	0.742	rs7807556	chr7:156934329	T/C	cg05182265	chr7:156933206	UBE3C	-0.35	-5.29	-0.33	2.85e-7	Body mass index;
SARC	cis	rs67133203	0.606	rs11169736	chr12:51566657	G/T	cg15029631	chr12:52078762	SCN8A	-0.42	-4.9	-0.31	1.79e-6	Urinary tract infection frequency;
SARC	cis	rs11608355	0.576	rs1477117	chr12:109888779	A/G	cg05360138	chr12:110035743	NA	-0.88	-8.46	-0.48	3.03e-15	Neuroticism;
SARC	cis	rs709400	0.663	rs11628213	chr14:103952453	A/C	cg12935359	chr14:103987150	CKB	-0.39	-5.71	-0.35	3.38e-8	Body mass index;
SARC	trans	rs11039798	0.623	rs7294273	chr11:48705374	T/C	cg15704280	chr7:45808275	SEPT13	0.64	6.41	0.39	8.11e-10	Axial length;
SARC	cis	rs17270561	0.609	rs3922842	chr6:25736564	T/C	cg17691542	chr6:26056736	HIST1H1C	0.58	7.09	0.42	1.6e-11	Iron status biomarkers;
SARC	cis	rs1580019	0.562	rs4720064	chr7:32559638	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.54	6.96	0.41	3.39e-11	Cognitive ability;
SARC	cis	rs10789491	1.000	rs12794	chr1:47141718	T/C	cg15501359	chr1:47185051	KIAA0494	0.73	7.91	0.46	1.01e-13	Response to hepatitis C treatment;
SARC	cis	rs7727544	0.684	rs274567	chr5:131714409	C/T	cg24060327	chr5:131705240	SLC22A5	0.68	8.97	0.51	1e-16	Blood metabolite levels;
SARC	cis	rs4792901	0.918	rs12603164	chr17:41618566	C/G	cg22562494	chr17:41607896	ETV4	-0.31	-5.11	-0.32	6.62e-7	Dupuytren's disease;
SARC	cis	rs16870629	0.564	rs326050	chr5:1002620	C/T	cg18655438	chr5:1077845	SLC12A7	0.36	4.74	0.3	3.76e-6	QT interval;
SARC	cis	rs9916302	0.861	rs11078912	chr17:37671490	A/G	cg00129232	chr17:37814104	STARD3	-0.65	-7.57	-0.44	8.73e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs2115536	1.000	rs11072871	chr15:80197931	T/C	cg00225070	chr15:80189496	MTHFS	0.66	8.8	0.5	3.07e-16	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
SARC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.0	0.79	1.72e-52	Prudent dietary pattern;
SARC	cis	rs7824557	0.564	rs11782430	chr8:11226071	A/G	cg21775007	chr8:11205619	TDH	-0.64	-8.38	-0.48	5e-15	Retinal vascular caliber;
SARC	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg20120463	chr17:44301886	NA	0.32	5.03	0.31	9.89e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	5.01	0.31	1.08e-6	Personality dimensions;
SARC	cis	rs4481887	0.893	rs10158180	chr1:248481423	C/T	cg00666640	chr1:248458726	OR2T12	0.33	5.54	0.34	7.95e-8	Common traits (Other);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg04989395	chr3:170167033	NA	0.48	6.53	0.39	4.04e-10	Thyroid stimulating hormone;
SARC	cis	rs11166927	0.524	rs10092101	chr8:140830697	C/T	cg16909799	chr8:140841666	TRAPPC9	-0.37	-5.19	-0.32	4.59e-7	Pediatric non-alcoholic fatty liver disease activity score;
SARC	cis	rs7615952	0.546	rs11711150	chr3:125315663	C/T	cg21696256	chr3:125484277	NA	-0.4	-4.74	-0.3	3.78e-6	Blood pressure (smoking interaction);
SARC	cis	rs3758785	0.596	rs2096762	chr11:94114673	T/C	cg13023536	chr11:94226537	MRE11A;ANKRD49	-0.42	-5.41	-0.33	1.58e-7	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
SARC	trans	rs2727020	0.704	rs4144700	chr11:49370834	C/A	cg15704280	chr7:45808275	SEPT13	-0.82	-13.26	-0.66	2.83e-30	Coronary artery disease;
SARC	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg25072359	chr17:41440525	NA	0.51	6.26	0.38	1.8e-9	Menopause (age at onset);
SARC	cis	rs67311347	0.544	rs13098483	chr3:40342743	G/C	cg24209194	chr3:40518798	ZNF619	0.46	6.19	0.38	2.67e-9	Renal cell carcinoma;
SARC	cis	rs710216	0.843	rs2297972	chr1:43418026	C/T	cg22176566	chr1:43424700	SLC2A1	-0.48	-5.11	-0.32	6.63e-7	Red cell distribution width;
SARC	cis	rs8064299	0.597	rs2016126	chr17:72784932	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.79	10.63	0.57	8.79e-22	Monocyte count;
SARC	cis	rs17376456	0.877	rs7734897	chr5:93305402	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.65	6.1	0.37	4.49e-9	Diabetic retinopathy;
SARC	cis	rs76419734	1.000	rs72671869	chr4:106658658	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.84	5.42	0.33	1.51e-7	Post bronchodilator FEV1;
SARC	cis	rs11792861	0.781	rs72607158	chr9:111763010	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.73	8.54	0.49	1.78e-15	Menarche (age at onset);
SARC	cis	rs854765	0.575	rs7207821	chr17:17891781	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.66	9.58	0.53	1.57e-18	Total body bone mineral density;
SARC	cis	rs834603	0.546	rs869170	chr7:47484299	C/T	cg23694490	chr7:47445681	TNS3	-0.3	-5.34	-0.33	2.23e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg04944784	chr2:26401820	FAM59B	0.6	7.95	0.46	8.14e-14	Gut microbiome composition (summer);
SARC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg26338869	chr17:61819248	STRADA	0.78	10.49	0.57	2.48e-21	Prudent dietary pattern;
SARC	cis	rs763121	0.853	rs5757208	chr22:39049230	A/C	cg21395723	chr22:39101663	GTPBP1	0.58	6.67	0.4	1.85e-10	Menopause (age at onset);
SARC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.94	10.27	0.56	1.22e-20	Platelet count;
SARC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg08219700	chr8:58056026	NA	0.62	6.56	0.4	3.37e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs5753618	0.561	rs1858821	chr22:31676454	T/C	cg02404636	chr22:31891804	SFI1	-0.49	-5.22	-0.32	3.99e-7	Colorectal cancer;
SARC	cis	rs981844	0.689	rs6835372	chr4:154682056	T/C	cg14289246	chr4:154710475	SFRP2	-0.59	-6.98	-0.42	3.05e-11	Response to statins (LDL cholesterol change);
SARC	cis	rs834603	0.735	rs7801481	chr7:47447215	A/T	cg23694490	chr7:47445681	TNS3	-0.36	-6.61	-0.4	2.63e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg05861140	chr6:150128134	PCMT1	-0.44	-5.72	-0.35	3.18e-8	Lung cancer;
SARC	cis	rs796364	0.806	rs78037592	chr2:201105734	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.65	-5.17	-0.32	5.15e-7	Schizophrenia;
SARC	cis	rs2130392	1.000	rs2130392	chr4:185639169	A/G	cg04058563	chr4:185651563	MLF1IP	0.33	4.79	0.3	2.91e-6	Kawasaki disease;
SARC	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg11301795	chr4:187892539	NA	-0.7	-10.27	-0.56	1.18e-20	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2380220	0.606	rs4571572	chr6:96004823	T/C	cg15832292	chr6:96025679	MANEA	0.52	5.77	0.35	2.51e-8	Behavioural disinhibition (generation interaction);
SARC	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg11742103	chr11:62369870	EML3;MTA2	0.38	5.02	0.31	1.02e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs6772849	0.804	rs4857920	chr3:128407623	C/T	cg08795948	chr3:128337044	NA	0.53	6.94	0.41	3.87e-11	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs4906332	1.000	rs35862113	chr14:103857229	G/T	cg26031613	chr14:104095156	KLC1	-0.54	-6.31	-0.38	1.36e-9	Coronary artery disease;
SARC	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg11987759	chr7:65425863	GUSB	0.52	6.57	0.4	3.27e-10	Aortic root size;
SARC	cis	rs79149102	0.579	rs59303424	chr15:75370014	G/A	cg17294928	chr15:75287854	SCAMP5	-0.89	-8.16	-0.47	2.15e-14	Lung cancer;
SARC	cis	rs240764	0.658	rs7746961	chr6:101215244	A/G	cg09795085	chr6:101329169	ASCC3	-0.44	-5.64	-0.35	4.87e-8	Neuroticism;
SARC	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.73	8.72	0.5	5.4e-16	Height;
SARC	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg11987759	chr7:65425863	GUSB	0.48	5.72	0.35	3.19e-8	Aortic root size;
SARC	cis	rs709400	1.000	rs56660916	chr14:104126137	G/T	cg26031613	chr14:104095156	KLC1	0.99	18.61	0.77	5.65e-48	Body mass index;
SARC	cis	rs568617	1.000	rs641018	chr11:65655393	G/C	cg00576331	chr11:65640516	EFEMP2	-0.46	-5.41	-0.33	1.53e-7	Crohn's disease;
SARC	cis	rs3857536	0.813	rs1029400	chr6:66952385	A/G	cg07460842	chr6:66804631	NA	-0.45	-5.07	-0.32	8.17e-7	Blood trace element (Cu levels);
SARC	cis	rs858239	0.600	rs61292332	chr7:23131862	C/T	cg23682824	chr7:23144976	KLHL7	0.71	9.42	0.53	4.53e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs7582180	0.607	rs1530029	chr2:100968205	C/T	cg14675211	chr2:100938903	LONRF2	0.52	7.58	0.44	8.36e-13	Intelligence (multi-trait analysis);
SARC	trans	rs1994135	0.669	rs10844629	chr12:33697096	T/A	cg13010199	chr12:38710504	ALG10B	0.6	7.18	0.43	9.39e-12	Resting heart rate;
SARC	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.9	14.25	0.68	1.49e-33	Chronic sinus infection;
SARC	cis	rs7617773	0.676	rs13060020	chr3:48372646	C/T	cg11946769	chr3:48343235	NME6	0.76	9.57	0.53	1.61e-18	Coronary artery disease;
SARC	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg18876405	chr7:65276391	NA	0.69	8.53	0.49	1.85e-15	Aortic root size;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg00011122	chr16:11439027	C16orf75	-0.48	-6.36	-0.38	1.08e-9	Height;
SARC	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg12373951	chr3:133503437	NA	0.36	5.19	0.32	4.64e-7	Iron status biomarkers;
SARC	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg10351095	chr21:47802916	PCNT	-0.41	-4.73	-0.3	3.93e-6	Testicular germ cell tumor;
SARC	cis	rs9815354	0.904	rs6776724	chr3:41841270	A/G	cg03022575	chr3:42003672	ULK4	0.56	5.41	0.33	1.59e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9354352	0.967	rs9354351	chr6:66696271	G/A	cg07460842	chr6:66804631	NA	0.59	7.69	0.45	4.08e-13	Initial pursuit acceleration in psychotic disorders;
SARC	cis	rs62432291	0.681	rs7757530	chr6:159647929	G/A	cg14500486	chr6:159655392	FNDC1	0.62	6.09	0.37	4.52e-9	Joint mobility (Beighton score);
SARC	cis	rs1707322	1.000	rs7553924	chr1:46352624	T/C	cg03146154	chr1:46216737	IPP	0.47	5.69	0.35	3.76e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7044106	0.718	rs10616	chr9:123363533	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	8.97	0.51	1.03e-16	Hip circumference adjusted for BMI;
SARC	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg06713675	chr4:122721982	EXOSC9	-0.51	-6.63	-0.4	2.26e-10	Type 2 diabetes;
SARC	cis	rs77633900	0.614	rs2439993	chr15:76861532	G/A	cg21673338	chr15:77095150	SCAPER	-0.75	-6.24	-0.38	2.08e-9	Non-glioblastoma glioma;Glioma;
SARC	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg15448220	chr1:150897856	SETDB1	-0.43	-5.68	-0.35	3.97e-8	Tonsillectomy;
SARC	cis	rs57920188	0.535	rs12129515	chr1:4094101	G/A	cg20703997	chr1:4087676	NA	0.5	5.35	0.33	2.07e-7	Interleukin-17 levels;
SARC	cis	rs9388451	0.626	rs1268074	chr6:126107791	G/C	cg05901451	chr6:126070800	HEY2	-0.5	-6.4	-0.39	8.44e-10	Brugada syndrome;
SARC	cis	rs881375	0.967	rs2416805	chr9:123676482	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	4.77	0.3	3.2e-6	Rheumatoid arthritis;
SARC	cis	rs8013055	0.846	rs8003942	chr14:105971670	A/G	cg19700328	chr14:106028568	NA	-0.6	-8.51	-0.49	2.19e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
SARC	cis	rs644799	0.710	rs3748253	chr11:95519506	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.85	13.62	0.67	1.77e-31	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7937682	0.883	rs512669	chr11:111467893	G/A	cg22437258	chr11:111473054	SIK2	0.76	9.86	0.54	2.22e-19	Primary sclerosing cholangitis;
SARC	cis	rs2153535	0.580	rs9328479	chr6:8519646	A/G	cg07606381	chr6:8435919	SLC35B3	0.77	10.9	0.58	1.28e-22	Motion sickness;
SARC	cis	rs709400	0.930	rs2274268	chr14:104029378	C/G	cg24130564	chr14:104152367	KLC1	-0.38	-4.87	-0.3	2.09e-6	Body mass index;
SARC	cis	rs1018836	0.892	rs1476428	chr8:91555603	G/T	cg16814680	chr8:91681699	NA	-0.74	-11.18	-0.59	1.59e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs787274	1.000	rs1361720	chr9:115535579	G/A	cg13803584	chr9:115635662	SNX30	-0.79	-6.14	-0.37	3.47e-9	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs853679	0.628	rs9368560	chr6:28159960	T/C	cg16479474	chr6:28041457	NA	0.35	5.0	0.31	1.12e-6	Depression;
SARC	cis	rs9811216	1.000	rs12630450	chr3:169480204	A/G	cg14222479	chr3:169487675	ARPM1	0.42	5.06	0.31	8.35e-7	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs17539620	0.624	rs62432736	chr6:154834401	A/G	cg17771515	chr6:154831774	CNKSR3	0.53	5.06	0.31	8.7e-7	Lipoprotein (a) levels;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg18321423	chr7:133084947	EXOC4	0.47	6.53	0.39	3.98e-10	Thyroid stimulating hormone;
SARC	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg06713675	chr4:122721982	EXOSC9	-0.5	-7.07	-0.42	1.79e-11	Type 2 diabetes;
SARC	cis	rs3741151	0.773	rs73544729	chr11:73183418	G/T	cg17517138	chr11:73019481	ARHGEF17	0.91	6.7	0.4	1.55e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs734999	0.588	rs2985859	chr1:2532416	T/C	cg18854424	chr1:2615690	NA	-0.32	-5.03	-0.31	9.77e-7	Ulcerative colitis;
SARC	trans	rs9929218	0.551	rs3785135	chr16:68728976	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-12.82	-0.64	7.75e-29	Colorectal cancer;
SARC	cis	rs7412746	0.658	rs6658066	chr1:150918937	T/G	cg15448220	chr1:150897856	SETDB1	0.5	6.48	0.39	5.51e-10	Melanoma;
SARC	cis	rs2652822	0.901	rs4775622	chr15:63408179	A/C	cg02713581	chr15:63449717	RPS27L	0.69	9.27	0.52	1.33e-17	Metabolic traits;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg00131899	chr4:110481302	CCDC109B	0.76	6.51	0.39	4.45e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg04772025	chr11:68637568	NA	0.51	6.24	0.38	2.01e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg11764359	chr7:65958608	NA	0.59	7.1	0.42	1.51e-11	Aortic root size;
SARC	cis	rs9341808	0.754	rs9361591	chr6:80953255	C/A	cg08355045	chr6:80787529	NA	0.34	5.52	0.34	9.1e-8	Sitting height ratio;
SARC	cis	rs1185460	1.000	rs4614	chr11:118952371	A/G	cg23280166	chr11:118938394	VPS11	0.74	9.11	0.51	3.76e-17	Coronary artery disease;
SARC	cis	rs1348850	1.000	rs1348850	chr2:178418575	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.67	8.28	0.48	9.42e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7589342	0.501	rs13429800	chr2:106441002	C/T	cg16077055	chr2:106428750	NCK2	0.25	4.73	0.3	3.94e-6	Addiction;
SARC	cis	rs7539542	0.556	rs2275734	chr1:202887295	C/T	cg08940984	chr1:202857613	RABIF	0.39	5.23	0.32	3.84e-7	Mean platelet volume;
SARC	cis	rs1864585	0.520	rs73209921	chr8:10707724	C/T	cg21775007	chr8:11205619	TDH	-0.49	-4.86	-0.3	2.19e-6	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
SARC	cis	rs9682041	0.569	rs4955724	chr3:170146532	A/G	cg11886554	chr3:170076028	SKIL	0.83	7.64	0.45	5.62e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs11191270	0.554	rs11191253	chr10:104066507	A/T	cg15320455	chr10:103880129	LDB1	1.04	9.01	0.51	7.39e-17	Intelligence (multi-trait analysis);
SARC	cis	rs16976116	0.901	rs28508034	chr15:55499010	T/C	cg17854078	chr15:55489399	RSL24D1	0.66	6.53	0.39	4.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4427176	0.652	rs7833036	chr8:9472952	G/T	cg21625330	chr8:9911636	MSRA	-0.63	-4.92	-0.31	1.63e-6	Mosquito bite size;
SARC	cis	rs2777491	0.574	rs316616	chr15:41746276	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.16	-18.81	-0.78	1.21e-48	Ulcerative colitis;
SARC	trans	rs61931739	0.500	rs3924704	chr12:34557833	C/T	cg26384229	chr12:38710491	ALG10B	0.89	13.28	0.66	2.37e-30	Morning vs. evening chronotype;
SARC	cis	rs4144743	0.759	rs34251886	chr17:45320299	G/T	cg18085866	chr17:45331354	ITGB3	-0.79	-7.08	-0.42	1.65e-11	Body mass index;
SARC	cis	rs11719291	0.915	rs11557629	chr3:48732223	G/A	cg07636037	chr3:49044803	WDR6	-0.74	-7.11	-0.42	1.39e-11	Cognitive function;
SARC	cis	rs1707322	1.000	rs4660336	chr1:46487976	T/C	cg03146154	chr1:46216737	IPP	-0.46	-5.59	-0.34	6.36e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs12545109	0.800	rs1992122	chr8:57409467	A/G	cg19413350	chr8:57351067	NA	-0.44	-5.41	-0.33	1.55e-7	Obesity-related traits;
SARC	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg19774624	chr17:42201019	HDAC5	-0.85	-13.37	-0.66	1.21e-30	Total body bone mineral density;
SARC	cis	rs12145833	0.596	rs12026068	chr1:243440352	A/G	cg02356786	chr1:243265016	LOC731275	0.77	6.3	0.38	1.43e-9	Obesity (early onset extreme);
SARC	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	5.9	0.36	1.24e-8	Electroencephalogram traits;
SARC	cis	rs6089584	0.546	rs6061978	chr20:60615604	C/T	cg06108461	chr20:60628389	TAF4	-0.67	-8.84	-0.5	2.33e-16	Body mass index;
SARC	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg19671926	chr4:122722719	EXOSC9	-0.6	-6.7	-0.4	1.51e-10	Type 2 diabetes;
SARC	cis	rs9815354	1.000	rs28733681	chr3:41863444	C/A	cg03022575	chr3:42003672	ULK4	0.57	5.33	0.33	2.34e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs3126085	0.877	rs1552996	chr1:152171104	C/A	cg26876637	chr1:152193138	HRNR	0.48	5.51	0.34	9.32e-8	Atopic dermatitis;
SARC	cis	rs9790314	0.605	rs2593812	chr3:160703069	T/G	cg04691961	chr3:161091175	C3orf57	0.59	7.98	0.46	6.76e-14	Morning vs. evening chronotype;
SARC	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg11987759	chr7:65425863	GUSB	0.47	5.74	0.35	2.99e-8	Aortic root size;
SARC	cis	rs9372253	1.000	rs9374170	chr6:110712991	A/G	cg00083206	chr6:110721305	DDO	-0.37	-4.8	-0.3	2.88e-6	Platelet distribution width;
SARC	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg06420487	chr17:61919686	SMARCD2	0.43	4.79	0.3	2.93e-6	Height;
SARC	trans	rs561341	0.609	rs11658984	chr17:30186612	C/T	cg20587970	chr11:113659929	NA	0.68	6.54	0.39	3.95e-10	Hip circumference adjusted for BMI;
SARC	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg11644478	chr21:40555479	PSMG1	-0.54	-6.51	-0.39	4.53e-10	Menarche (age at onset);
SARC	cis	rs6977660	0.714	rs17141884	chr7:19790280	A/G	cg05791153	chr7:19748676	TWISTNB	-0.73	-6.44	-0.39	6.73e-10	Thyroid stimulating hormone;
SARC	cis	rs13314892	0.764	rs56764448	chr3:69860504	A/G	cg17445875	chr3:69859618	MITF	-0.48	-4.98	-0.31	1.23e-6	QRS complex (12-leadsum);
SARC	cis	rs10464366	0.544	rs9639812	chr7:39192058	C/T	cg18850127	chr7:39170497	POU6F2	0.37	4.8	0.3	2.82e-6	IgG glycosylation;
SARC	cis	rs35306767	0.903	rs7077278	chr10:911291	A/G	cg26597838	chr10:835615	NA	-0.84	-8.3	-0.48	8.49e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs2273669	0.915	rs6908104	chr6:109293973	T/C	cg05315195	chr6:109294784	ARMC2	-0.49	-4.82	-0.3	2.57e-6	Prostate cancer;
SARC	cis	rs9902453	0.740	rs2628189	chr17:28088813	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.29	-0.43	4.67e-12	Coffee consumption (cups per day);
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg09074817	chr6:87866051	ZNF292	-0.48	-6.68	-0.4	1.74e-10	Schizophrenia;
SARC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg26338869	chr17:61819248	STRADA	-0.75	-9.48	-0.53	3.04e-18	Prudent dietary pattern;
SARC	cis	rs13401104	0.796	rs12466147	chr2:237110404	T/A	cg19324714	chr2:237145437	ASB18	0.57	5.6	0.34	5.92e-8	Educational attainment;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg24513067	chr10:54080151	NA	0.46	6.25	0.38	1.93e-9	Thyroid stimulating hormone;
SARC	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg17221315	chr6:27791827	HIST1H4J	0.46	4.83	0.3	2.53e-6	Depression;
SARC	cis	rs453301	0.686	rs6987107	chr8:8893581	A/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.94	-0.41	3.93e-11	Joint mobility (Beighton score);
SARC	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg18252515	chr7:66147081	NA	-0.57	-6.11	-0.37	4.17e-9	Aortic root size;
SARC	cis	rs7592578	0.882	rs61117285	chr2:191468986	G/C	cg10560079	chr2:191398806	TMEM194B	-0.81	-9.2	-0.52	2.1e-17	Diastolic blood pressure;
SARC	cis	rs6060717	0.610	rs2794382	chr20:34613651	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-4.8	-0.3	2.89e-6	Hip circumference adjusted for BMI;
SARC	cis	rs10876993	0.928	rs2640629	chr12:58065448	C/T	cg18357645	chr12:58087776	OS9	0.52	7.04	0.42	2.09e-11	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs7927771	0.832	rs1542321	chr11:47379615	G/A	cg20307385	chr11:47447363	PSMC3	0.57	6.94	0.41	3.79e-11	Subjective well-being;
SARC	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg17971929	chr21:40555470	PSMG1	-0.59	-7.4	-0.44	2.44e-12	Menarche (age at onset);
SARC	cis	rs17539620	0.519	rs4077066	chr6:154838448	C/G	cg17771515	chr6:154831774	CNKSR3	0.52	5.02	0.31	1.01e-6	Lipoprotein (a) levels;
SARC	cis	rs12497850	1.000	rs4858828	chr3:48724811	C/T	cg03060546	chr3:49711283	APEH	0.42	5.19	0.32	4.51e-7	Parkinson's disease;
SARC	cis	rs155076	1.000	rs261406	chr13:21855854	G/A	cg06138931	chr13:21896616	NA	-0.39	-5.06	-0.31	8.68e-7	White matter hyperintensity burden;
SARC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg20887711	chr4:1340912	KIAA1530	0.61	7.52	0.44	1.15e-12	Longevity;
SARC	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	10.54	0.57	1.68e-21	Platelet count;
SARC	cis	rs765787	0.530	rs4544188	chr15:45535393	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.67e-7	Uric acid levels;
SARC	cis	rs11574514	1.000	rs28490940	chr16:68010262	G/C	cg01866162	chr16:67596514	CTCF	0.92	5.56	0.34	7.47e-8	Crohn's disease;
SARC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg03354898	chr7:1950403	MAD1L1	0.39	5.46	0.34	1.24e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs787274	0.718	rs10739379	chr9:115640976	C/G	cg13803584	chr9:115635662	SNX30	-0.88	-6.2	-0.38	2.5e-9	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs4689388	0.856	rs4308430	chr4:6294095	A/G	cg14416269	chr4:6271139	WFS1	0.32	4.86	0.3	2.2e-6	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs2481665	0.765	rs2481678	chr1:62634020	T/C	cg18591186	chr1:62594603	INADL	-0.53	-7.16	-0.42	1.03e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs995000	0.931	rs1168132	chr1:63133468	T/A	cg06896770	chr1:63153194	DOCK7	-0.89	-13.48	-0.66	5.31e-31	Triglyceride levels;
SARC	trans	rs61931739	0.534	rs4365131	chr12:34053308	T/C	cg13010199	chr12:38710504	ALG10B	0.65	8.81	0.5	2.96e-16	Morning vs. evening chronotype;
SARC	cis	rs27434	0.583	rs151953	chr5:96157648	C/G	cg16492584	chr5:96139282	ERAP1	-0.54	-6.6	-0.4	2.79e-10	Ankylosing spondylitis;
SARC	cis	rs3820928	0.605	rs4675124	chr2:227802354	G/A	cg11843606	chr2:227700838	RHBDD1	-0.57	-7.64	-0.45	5.59e-13	Pulmonary function;
SARC	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg22920501	chr2:26401640	FAM59B	-0.54	-6.99	-0.42	2.87e-11	Gut microbiome composition (summer);
SARC	cis	rs1941023	0.503	rs894591	chr11:60132647	T/C	cg08716584	chr11:60157161	MS4A7	-0.4	-6.86	-0.41	6.09e-11	Congenital heart disease (maternal effect);
SARC	cis	rs4803468	1.000	rs3816037	chr19:41918009	C/T	cg09537434	chr19:41945824	ATP5SL	-0.98	-17.56	-0.75	1.59e-44	Height;
SARC	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.62	7.47	0.44	1.59e-12	Gut microbiome composition (summer);
SARC	cis	rs74181299	0.750	rs58342673	chr2:65347584	T/C	cg20592124	chr2:65290738	CEP68	-0.39	-5.45	-0.34	1.3e-7	Pulse pressure;
SARC	cis	rs7223966	0.960	rs2319990	chr17:61705397	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.53	-6.02	-0.37	6.74e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.97	12.03	0.62	3.02e-26	Platelet count;
SARC	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg17971929	chr21:40555470	PSMG1	-0.86	-11.43	-0.6	2.59e-24	Cognitive function;
SARC	cis	rs10489202	1.000	rs34192847	chr1:168064317	A/T	cg24449463	chr1:168025552	DCAF6	-0.6	-6.62	-0.4	2.4e-10	Schizophrenia;
SARC	cis	rs1348850	1.000	rs1348850	chr2:178418575	A/G	cg23306229	chr2:178417860	TTC30B	0.57	6.57	0.4	3.3e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7772486	0.686	rs2092263	chr6:146029687	G/A	cg05347473	chr6:146136440	FBXO30	-0.5	-6.89	-0.41	5.27e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs17209837	1.000	rs2302386	chr7:87091944	A/G	cg00919237	chr7:87102261	ABCB4	-0.47	-4.96	-0.31	1.38e-6	Gallbladder cancer;
SARC	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg26681399	chr22:41777847	TEF	0.47	5.13	0.32	6.11e-7	Vitiligo;
SARC	cis	rs4642101	0.765	rs6791647	chr3:12826425	C/T	cg12400702	chr3:12838781	CAND2	0.25	5.07	0.32	8.02e-7	QRS complex (12-leadsum);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg08793511	chr2:227698065	NA	0.46	6.44	0.39	6.83e-10	Thyroid stimulating hormone;
SARC	cis	rs1707322	0.752	rs11211147	chr1:46110094	A/G	cg06784218	chr1:46089804	CCDC17	0.36	6.15	0.37	3.35e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9430161	0.645	rs12081186	chr1:11034195	T/C	cg02454025	chr1:11042201	C1orf127	0.87	12.08	0.62	2.04e-26	Ewing sarcoma;
SARC	cis	rs910316	1.000	rs9805979	chr14:75566209	G/A	cg08847533	chr14:75593920	NEK9	0.93	15.86	0.72	6.47e-39	Height;
SARC	cis	rs10463554	0.889	rs34775	chr5:102451276	C/T	cg23492399	chr5:102201601	PAM	-0.52	-5.72	-0.35	3.2e-8	Parkinson's disease;
SARC	trans	rs1814175	0.754	rs28593359	chr11:50042357	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-18.68	-0.77	3.33e-48	Height;
SARC	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg19223190	chr17:80058835	NA	-0.47	-6.67	-0.4	1.81e-10	Life satisfaction;
SARC	cis	rs9814567	1.000	rs9827987	chr3:134272621	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.08	-0.42	1.73e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs838147	0.534	rs2638280	chr19:49209318	G/A	cg07051648	chr19:49177693	NTN5;SEC1	-0.4	-5.19	-0.32	4.68e-7	Dietary macronutrient intake;
SARC	cis	rs5167	0.583	rs7252480	chr19:45458925	C/T	cg09555818	chr19:45449301	APOC2	0.38	5.01	0.31	1.09e-6	Blood protein levels;
SARC	cis	rs67460515	0.892	rs34896809	chr3:161059804	C/T	cg04691961	chr3:161091175	C3orf57	-0.49	-6.13	-0.37	3.72e-9	Parkinson's disease;
SARC	cis	rs7552404	0.961	rs1767458	chr1:76219155	A/G	cg22875332	chr1:76189707	ACADM	0.39	5.43	0.34	1.41e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs4481887	0.927	rs6689193	chr1:248482900	T/A	cg00666640	chr1:248458726	OR2T12	0.33	5.48	0.34	1.12e-7	Common traits (Other);
SARC	cis	rs6088813	1.000	rs6088823	chr20:33994265	G/T	cg14752227	chr20:34000481	UQCC	-0.37	-4.72	-0.3	4.02e-6	Height;
SARC	cis	rs9896052	0.625	rs11656558	chr17:73440437	T/C	cg25649188	chr17:73499917	CASKIN2	0.49	5.52	0.34	8.94e-8	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs7582180	0.602	rs7585582	chr2:100998030	G/C	cg14675211	chr2:100938903	LONRF2	0.54	7.9	0.46	1.07e-13	Intelligence (multi-trait analysis);
SARC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg14159672	chr1:205819179	PM20D1	0.84	14.08	0.68	5.36e-33	Menarche (age at onset);
SARC	cis	rs1707322	0.752	rs11211173	chr1:46219376	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.37	0.38	1.03e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs17376456	0.877	rs10055340	chr5:93317644	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.65	6.1	0.37	4.49e-9	Diabetic retinopathy;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg17607973	chr7:100027408	MEPCE;ZCWPW1	-0.57	-6.47	-0.39	5.84e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	7.77	0.45	2.56e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs13191362	0.935	rs34709632	chr6:163048380	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.6	5.17	0.32	4.96e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	trans	rs61931739	0.500	rs3922568	chr12:34560107	A/C	cg26384229	chr12:38710491	ALG10B	0.85	12.6	0.64	4.07e-28	Morning vs. evening chronotype;
SARC	cis	rs9486719	0.947	rs12213375	chr6:96902134	A/G	cg06623918	chr6:96969491	KIAA0776	-0.72	-7.58	-0.44	8.24e-13	Migraine;Coronary artery disease;
SARC	cis	rs7582720	1.000	rs6435169	chr2:203753016	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.31	0.43	4.24e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg02733842	chr7:1102375	C7orf50	-0.5	-6.03	-0.37	6.44e-9	Bronchopulmonary dysplasia;
SARC	cis	rs6981523	0.553	rs2409730	chr8:11060638	C/A	cg21775007	chr8:11205619	TDH	-0.43	-5.38	-0.33	1.8e-7	Neuroticism;
SARC	cis	rs600231	0.706	rs3782091	chr11:65336483	G/T	cg17120908	chr11:65337727	SSSCA1	0.52	6.5	0.39	4.78e-10	Bone mineral density;
SARC	cis	rs41278232	0.557	rs817347	chr20:62609394	G/A	cg07620230	chr20:62328084	TNFRSF6B	0.34	4.78	0.3	3.09e-6	Tonsillectomy;
SARC	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg11878867	chr6:150167359	LRP11	-0.35	-4.81	-0.3	2.76e-6	Lung cancer;
SARC	cis	rs7829975	0.514	rs2920983	chr8:8268063	G/C	cg15556689	chr8:8085844	FLJ10661	0.52	6.2	0.38	2.55e-9	Mood instability;
SARC	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg01475735	chr3:40494733	NA	0.48	5.48	0.34	1.09e-7	Renal cell carcinoma;
SARC	cis	rs2191566	0.960	rs11083732	chr19:44520743	T/C	cg20607764	chr19:44506953	ZNF230	-0.49	-5.66	-0.35	4.34e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9650657	0.504	rs10108347	chr8:11033517	G/C	cg12395012	chr8:11607386	GATA4	0.3	5.05	0.31	9.03e-7	Neuroticism;
SARC	trans	rs8020941	0.585	rs78662326	chr14:97501843	G/A	cg05136476	chr3:53190709	NA	-0.64	-6.44	-0.39	6.85e-10	Diabetic kidney disease;
SARC	cis	rs9487051	0.837	rs6568561	chr6:109592909	A/G	cg01475377	chr6:109611718	NA	-0.41	-5.84	-0.36	1.73e-8	Reticulocyte fraction of red cells;
SARC	cis	rs986417	1.000	rs1254323	chr14:60908378	G/A	cg27398547	chr14:60952738	C14orf39	-1.03	-9.75	-0.54	4.8e-19	Gut microbiota (bacterial taxa);
SARC	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg02931644	chr1:25747376	RHCE	0.47	8.0	0.46	5.85e-14	Erythrocyte sedimentation rate;
SARC	cis	rs4588572	0.606	rs4290994	chr5:77742253	C/T	cg18281939	chr5:77783895	LHFPL2	0.34	4.75	0.3	3.62e-6	Triglycerides;
SARC	trans	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg07211511	chr3:129823064	LOC729375	-0.61	-6.56	-0.39	3.4e-10	Blood pressure (smoking interaction);
SARC	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg02733842	chr7:1102375	C7orf50	-0.6	-7.43	-0.44	2.05e-12	Bronchopulmonary dysplasia;
SARC	cis	rs10979	0.931	rs9484770	chr6:143896758	A/G	cg25407410	chr6:143891975	LOC285740	-0.64	-8.78	-0.5	3.67e-16	Hypospadias;
SARC	trans	rs17685	0.725	rs6947068	chr7:75662056	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.62	-7.89	-0.46	1.19e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs734999	0.588	rs2843401	chr1:2528133	T/C	cg20673091	chr1:2541236	MMEL1	-0.33	-5.13	-0.32	5.98e-7	Ulcerative colitis;
SARC	cis	rs1797081	1.000	rs2603807	chr10:16872797	A/G	cg23933602	chr10:16859644	RSU1	0.96	19.22	0.78	5.87e-50	Platelet distribution width;
SARC	trans	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.72	-10.33	-0.56	7.71e-21	Intelligence (multi-trait analysis);
SARC	cis	rs4969178	0.965	rs12451791	chr17:76397343	G/A	cg02836325	chr17:76403955	PGS1	0.33	5.01	0.31	1.07e-6	HDL cholesterol levels;
SARC	cis	rs12596210	0.925	rs12596328	chr16:54037485	C/T	cg00542139	chr16:53088674	CHD9	0.58	4.73	0.3	3.87e-6	Sex hormone-binding globulin levels;
SARC	cis	rs4588572	0.643	rs9293747	chr5:77705567	A/G	cg11547950	chr5:77652471	NA	-0.42	-5.09	-0.32	7.32e-7	Triglycerides;
SARC	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg12311346	chr5:56204834	C5orf35	0.75	7.43	0.44	2e-12	Initial pursuit acceleration;
SARC	cis	rs17685	0.753	rs2302435	chr7:75676987	G/A	cg07335156	chr7:75947820	NA	-0.39	-4.72	-0.3	3.98e-6	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs7829975	0.539	rs883647	chr8:8569724	G/A	cg06636001	chr8:8085503	FLJ10661	-0.49	-5.82	-0.36	1.92e-8	Mood instability;
SARC	cis	rs2276314	1.000	rs58054756	chr18:33554053	G/C	cg05985134	chr18:33552581	C18orf21	0.74	8.03	0.47	4.88e-14	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs72848980	1.000	rs72848976	chr10:105312536	G/A	cg00126946	chr10:105363258	SH3PXD2A	0.41	5.06	0.31	8.57e-7	White matter hyperintensity burden;
SARC	cis	rs6121246	0.821	rs115585940	chr20:30317902	T/C	cg13852791	chr20:30311386	BCL2L1	0.85	8.56	0.49	1.58e-15	Mean corpuscular hemoglobin;
SARC	cis	rs41271473	0.526	rs942853	chr1:228730949	G/T	cg16512390	chr1:228756714	NA	0.61	5.58	0.34	6.79e-8	Chronic lymphocytic leukemia;
SARC	cis	rs7246657	0.943	rs13343502	chr19:37962292	C/T	cg23950597	chr19:37808831	NA	-0.61	-5.89	-0.36	1.36e-8	Coronary artery calcification;
SARC	cis	rs7647973	0.626	rs1463728	chr3:49647404	T/A	cg13072238	chr3:49761600	GMPPB	-0.63	-5.58	-0.34	6.78e-8	Menarche (age at onset);
SARC	cis	rs1707322	1.000	rs4660332	chr1:46461418	T/A	cg03146154	chr1:46216737	IPP	0.5	6.1	0.37	4.45e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg01238044	chr22:24384105	GSTT1	-0.81	-11.31	-0.6	6.25e-24	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg13939156	chr17:80058883	NA	-0.4	-6.26	-0.38	1.79e-9	Life satisfaction;
SARC	cis	rs11583043	0.793	rs3903905	chr1:101420957	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.48	6.03	0.37	6.33e-9	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs6580649	0.883	rs879242	chr12:48503301	T/C	cg24011408	chr12:48396354	COL2A1	-0.47	-5.28	-0.33	2.92e-7	Lung cancer;
SARC	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg03351412	chr1:154909251	PMVK	0.58	7.06	0.42	1.87e-11	Prostate cancer;
SARC	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	-0.96	-10.49	-0.57	2.37e-21	Platelet count;
SARC	cis	rs4427176	0.561	rs62489419	chr8:9662973	C/T	cg21625330	chr8:9911636	MSRA	-0.67	-5.47	-0.34	1.16e-7	Mosquito bite size;
SARC	cis	rs7084402	0.967	rs1427197	chr10:60275150	A/G	cg07615347	chr10:60278583	BICC1	-0.57	-8.4	-0.48	4.36e-15	Refractive error;
SARC	cis	rs752010	0.806	rs4457567	chr1:42091407	C/T	cg06885757	chr1:42089581	HIVEP3	0.4	6.2	0.38	2.59e-9	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs372883	0.624	rs1153286	chr21:30684383	A/G	cg24692254	chr21:30365293	RNF160	-0.61	-7.97	-0.46	7.14e-14	Pancreatic cancer;
SARC	trans	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.1	-0.42	1.51e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs11785400	0.890	rs13279182	chr8:143720544	A/G	cg24634471	chr8:143751801	JRK	0.68	8.96	0.51	1.05e-16	Schizophrenia;
SARC	cis	rs16858210	0.520	rs12636861	chr3:183549788	T/C	cg03417191	chr3:183542750	MAP6D1	-0.54	-4.86	-0.3	2.16e-6	Menopause (age at onset);
SARC	cis	rs6450176	0.904	rs6889847	chr5:53303452	G/C	ch.5.1024479R	chr5:53302184	ARL15	-0.68	-8.06	-0.47	3.96e-14	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs7945705	0.837	rs2742474	chr11:9002089	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-7.07	-0.42	1.82e-11	Hemoglobin concentration;
SARC	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.47	0.34	1.15e-7	Bipolar disorder;
SARC	cis	rs2180341	0.781	rs7760652	chr6:127572096	A/G	cg27446573	chr6:127587934	RNF146	0.89	12.75	0.64	1.4e-28	Breast cancer;
SARC	cis	rs1865760	0.551	rs9461230	chr6:26019240	G/C	cg18357526	chr6:26021779	HIST1H4A	0.47	5.96	0.36	9.18e-9	Height;
SARC	cis	rs3820928	0.874	rs7605032	chr2:227847630	T/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-6.68	-0.4	1.7e-10	Pulmonary function;
SARC	cis	rs10927875	0.541	rs1739844	chr1:16343322	T/C	cg21385522	chr1:16154831	NA	0.55	6.64	0.4	2.24e-10	Dilated cardiomyopathy;
SARC	cis	rs7927592	0.731	rs2840367	chr11:68302101	G/A	cg01657329	chr11:68192670	LRP5	0.37	5.16	0.32	5.37e-7	Total body bone mineral density;
SARC	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.1	20.6	0.8	2.17e-54	Chronic sinus infection;
SARC	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg08280861	chr8:58055591	NA	0.58	5.63	0.35	5.17e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg06074448	chr4:187884817	NA	-0.38	-5.18	-0.32	4.72e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs526231	0.543	rs34801	chr5:102426513	T/A	cg23492399	chr5:102201601	PAM	-0.53	-5.73	-0.35	3.04e-8	Primary biliary cholangitis;
SARC	cis	rs6912958	0.535	rs448580	chr6:88040399	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.7	10.02	0.55	7.25e-20	Monocyte percentage of white cells;
SARC	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg03709012	chr19:19516395	GATAD2A	-1.02	-17.9	-0.76	1.2e-45	Tonsillectomy;
SARC	cis	rs6840360	0.571	rs6833814	chr4:152539679	A/G	cg22705602	chr4:152727874	NA	-0.44	-6.78	-0.41	9.81e-11	Intelligence (multi-trait analysis);
SARC	cis	rs67478160	0.619	rs12886363	chr14:104273786	T/C	cg08213375	chr14:104286397	PPP1R13B	0.27	4.78	0.3	3.04e-6	Schizophrenia;
SARC	cis	rs8180040	0.800	rs11920354	chr3:47262246	C/A	cg27129171	chr3:47204927	SETD2	-0.73	-9.78	-0.54	3.7e-19	Colorectal cancer;
SARC	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg09455208	chr3:40491958	NA	0.38	5.77	0.35	2.56e-8	Renal cell carcinoma;
SARC	cis	rs1215050	0.818	rs6532703	chr4:98777486	A/T	cg05340658	chr4:99064831	C4orf37	0.41	5.22	0.32	3.99e-7	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs9948	0.655	rs62156213	chr2:97399100	T/C	cg01990225	chr2:97406019	LMAN2L	-0.94	-6.38	-0.39	9.49e-10	Erectile dysfunction and prostate cancer treatment;
SARC	trans	rs3808502	0.526	rs7843987	chr8:11422130	T/C	cg06636001	chr8:8085503	FLJ10661	-0.66	-9.17	-0.51	2.55e-17	Neuroticism;
SARC	cis	rs6696846	0.777	rs6664397	chr1:205051871	C/T	cg21545522	chr1:205238299	TMCC2	0.34	4.86	0.3	2.18e-6	Red blood cell count;
SARC	cis	rs4689388	0.819	rs12649341	chr4:6294759	G/A	cg00701064	chr4:6280414	WFS1	0.54	8.58	0.49	1.38e-15	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs12908161	0.959	rs2175567	chr15:85200946	C/G	cg17507749	chr15:85114479	UBE2QP1	0.59	6.83	0.41	7.29e-11	Schizophrenia;
SARC	cis	rs17376456	0.877	rs9314099	chr5:93447375	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	6.14	0.37	3.45e-9	Diabetic retinopathy;
SARC	trans	rs11669910	1	rs11669910	chr19:45741333	A/T	cg23345151	chr18:77292947	NA	0.43	6.37	0.39	9.96e-10	Sum eosinophil basophil counts;
SARC	cis	rs5997397	1.000	rs5997397	chr22:29154455	A/G	cg15103426	chr22:29168792	CCDC117	0.54	6.97	0.42	3.2e-11	Red cell distribution width;
SARC	cis	rs896854	0.738	rs2515226	chr8:95965743	G/A	cg13393036	chr8:95962371	TP53INP1	0.31	5.06	0.31	8.67e-7	Type 2 diabetes;
SARC	cis	rs36051895	0.695	rs7045000	chr9:5015143	G/A	cg02405213	chr9:5042618	JAK2	-0.5	-5.89	-0.36	1.34e-8	Pediatric autoimmune diseases;
SARC	cis	rs2180341	1.000	rs6569480	chr6:127621748	A/G	cg17762328	chr6:126965162	NA	-0.43	-4.96	-0.31	1.33e-6	Breast cancer;
SARC	cis	rs910316	1.000	rs12889472	chr14:75543979	A/G	cg08847533	chr14:75593920	NEK9	0.94	16.08	0.73	1.26e-39	Height;
SARC	cis	rs4588572	0.643	rs10440686	chr5:77688331	A/G	cg11547950	chr5:77652471	NA	0.4	4.83	0.3	2.43e-6	Triglycerides;
SARC	cis	rs11864453	0.826	rs6499559	chr16:72132064	G/C	cg16558253	chr16:72132732	DHX38	-0.59	-9.77	-0.54	4.03e-19	Fibrinogen levels;
SARC	trans	rs208520	0.739	rs1935894	chr6:66891434	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-12.78	-0.64	1.05e-28	Exhaled nitric oxide output;
SARC	cis	rs66573146	0.831	rs1048009	chr4:6988677	G/A	cg15105060	chr4:7024189	TBC1D14	-0.63	-4.81	-0.3	2.75e-6	Granulocyte percentage of myeloid white cells;
SARC	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg13206674	chr6:150067644	NUP43	0.4	5.24	0.32	3.53e-7	Lung cancer;
SARC	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg01475735	chr3:40494733	NA	-0.47	-5.11	-0.32	6.66e-7	Renal cell carcinoma;
SARC	cis	rs7264396	0.563	rs11698796	chr20:34248134	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.72	0.35	3.18e-8	Total cholesterol levels;
SARC	cis	rs7727544	0.735	rs274557	chr5:131721204	T/C	cg24060327	chr5:131705240	SLC22A5	0.69	8.96	0.51	1.06e-16	Blood metabolite levels;
SARC	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg04277193	chr17:41438351	NA	0.44	4.73	0.3	3.83e-6	Menopause (age at onset);
SARC	trans	rs12310956	0.515	rs115836245	chr12:33951369	T/C	cg26384229	chr12:38710491	ALG10B	0.73	10.2	0.56	1.96e-20	Morning vs. evening chronotype;
SARC	cis	rs9341808	0.500	rs2223873	chr6:81048288	A/G	cg08355045	chr6:80787529	NA	0.33	5.22	0.32	3.93e-7	Sitting height ratio;
SARC	cis	rs6582630	0.576	rs3900594	chr12:38272429	C/T	cg26384229	chr12:38710491	ALG10B	-0.6	-7.56	-0.44	9.4e-13	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs8078723	0.901	rs709591	chr17:38175561	T/A	cg17467752	chr17:38218738	THRA	0.47	5.96	0.36	9.44e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs6424115	0.800	rs4649123	chr1:24197696	A/G	cg15997130	chr1:24165203	NA	0.42	5.74	0.35	2.93e-8	Immature fraction of reticulocytes;
SARC	trans	rs7824557	0.527	rs2572446	chr8:11239565	C/T	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.72	-0.45	3.43e-13	Retinal vascular caliber;
SARC	cis	rs17376456	0.825	rs10053405	chr5:93275403	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.68	-5.78	-0.35	2.44e-8	Diabetic retinopathy;
SARC	cis	rs17376456	0.877	rs34184666	chr5:93444584	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.89	0.36	1.36e-8	Diabetic retinopathy;
SARC	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg04518342	chr5:131593106	PDLIM4	0.42	5.49	0.34	1.07e-7	Breast cancer;
SARC	cis	rs1670533	0.697	rs658846	chr4:1084723	G/C	cg16405210	chr4:1374714	KIAA1530	-0.54	-5.09	-0.32	7.26e-7	Recombination rate (females);
SARC	cis	rs9487051	0.872	rs9386793	chr6:109610002	C/A	cg01475377	chr6:109611718	NA	-0.42	-5.98	-0.36	8.23e-9	Reticulocyte fraction of red cells;
SARC	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg11890956	chr21:40555474	PSMG1	-1.04	-15.32	-0.71	4.23e-37	Cognitive function;
SARC	cis	rs2342371	0.565	rs13084212	chr3:196212211	G/T	cg15048948	chr3:196158458	UBXN7	-0.41	-5.3	-0.33	2.75e-7	Fat distribution (HIV);
SARC	cis	rs12681288	0.823	rs2701909	chr8:1003057	A/G	cg04851639	chr8:1020857	NA	-0.27	-4.85	-0.3	2.27e-6	Schizophrenia;
SARC	cis	rs73198271	0.562	rs964772	chr8:8651306	A/G	cg01851573	chr8:8652454	MFHAS1	0.41	5.12	0.32	6.33e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs75229567	0.618	rs11177849	chr12:70182473	C/T	cg10114359	chr12:70132523	RAB3IP	-1.08	-7.34	-0.43	3.6e-12	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
SARC	cis	rs11098499	0.789	rs1980024	chr4:120253047	C/T	cg09307838	chr4:120376055	NA	0.81	11.03	0.59	4.84e-23	Corneal astigmatism;
SARC	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg24642844	chr7:1081250	C7orf50	-0.59	-6.05	-0.37	5.79e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	trans	rs61931739	0.749	rs11053093	chr12:34231095	A/G	cg13010199	chr12:38710504	ALG10B	0.52	6.97	0.42	3.17e-11	Morning vs. evening chronotype;
SARC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg15242686	chr22:24348715	GSTTP1	0.4	5.18	0.32	4.9e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9611519	0.761	rs35445172	chr22:41660301	G/A	cg17376030	chr22:41985996	PMM1	0.53	6.68	0.4	1.73e-10	Neuroticism;
SARC	cis	rs4481887	0.927	rs7555310	chr1:248487638	A/G	cg00666640	chr1:248458726	OR2T12	0.37	6.02	0.37	6.83e-9	Common traits (Other);
SARC	cis	rs1475911	0.656	rs9980065	chr21:43528072	G/A	cg19766460	chr21:43528205	UMODL1;C21orf128	0.72	8.11	0.47	2.97e-14	IgG glycosylation;
SARC	cis	rs7084402	0.902	rs10763557	chr10:60341515	C/T	cg07615347	chr10:60278583	BICC1	0.58	8.34	0.48	6.61e-15	Refractive error;
SARC	cis	rs36051895	0.659	rs12351277	chr9:5061405	A/C	cg02405213	chr9:5042618	JAK2	-0.46	-5.17	-0.32	4.97e-7	Pediatric autoimmune diseases;
SARC	cis	rs6450176	1.000	rs5024170	chr5:53300827	C/A	ch.5.1024479R	chr5:53302184	ARL15	-0.67	-7.75	-0.45	2.78e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs826838	0.967	rs11183022	chr12:38652519	G/A	cg13010199	chr12:38710504	ALG10B	0.82	11.85	0.61	1.17e-25	Heart rate;
SARC	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg07701084	chr6:150067640	NUP43	0.41	5.4	0.33	1.62e-7	Lung cancer;
SARC	cis	rs17401966	1.000	rs17396382	chr1:10290268	T/C	cg15208524	chr1:10270712	KIF1B	0.59	6.35	0.38	1.09e-9	Hepatocellular carcinoma;
SARC	cis	rs910316	0.763	rs175016	chr14:75459633	C/T	cg23033748	chr14:75592666	NEK9	-0.38	-5.17	-0.32	5.16e-7	Height;
SARC	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg19077165	chr18:44547161	KATNAL2	-0.52	-6.97	-0.42	3.18e-11	Personality dimensions;
SARC	cis	rs9818758	0.607	rs9990153	chr3:49291883	C/T	cg00383909	chr3:49044727	WDR6	0.7	6.17	0.37	3.06e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs2439831	0.867	rs2899082	chr15:43656043	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.08	11.58	0.6	8.71e-25	Lung cancer in ever smokers;
SARC	cis	rs6570726	0.935	rs384806	chr6:145814889	C/G	cg05220968	chr6:146057943	EPM2A	-0.29	-4.83	-0.3	2.44e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10080237	0.564	rs2490224	chr6:80809833	G/A	cg08355045	chr6:80787529	NA	0.36	5.54	0.34	8.04e-8	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
SARC	cis	rs9902453	0.967	rs55748380	chr17:28469782	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	6.52	0.39	4.21e-10	Coffee consumption (cups per day);
SARC	cis	rs2439831	0.850	rs694985	chr15:43813387	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.01	10.03	0.55	6.75e-20	Lung cancer in ever smokers;
SARC	cis	rs9611519	0.590	rs4821980	chr22:41415479	C/G	cg03806693	chr22:41940476	POLR3H	-0.59	-7.95	-0.46	8.04e-14	Neuroticism;
SARC	cis	rs7833790	1.000	rs1463259	chr8:82737745	A/G	cg27398817	chr8:82754497	SNX16	-0.5	-5.72	-0.35	3.19e-8	Diastolic blood pressure;
SARC	cis	rs1018836	0.923	rs4735230	chr8:91574184	G/C	cg16814680	chr8:91681699	NA	-0.82	-12.94	-0.65	3.26e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg04458869	chr2:169312687	LASS6	0.52	6.62	0.4	2.46e-10	Breast cancer;
SARC	cis	rs6831352	0.918	rs2602895	chr4:100045840	C/T	cg13256891	chr4:100009986	ADH5	0.66	8.4	0.48	4.51e-15	Alcohol dependence;
SARC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg10862848	chr6:42927986	GNMT	-0.45	-7.35	-0.43	3.39e-12	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg23758822	chr17:41437982	NA	0.86	10.56	0.57	1.52e-21	Menopause (age at onset);
SARC	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg13939156	chr17:80058883	NA	0.4	6.09	0.37	4.56e-9	Life satisfaction;
SARC	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg16479474	chr6:28041457	NA	0.37	5.25	0.33	3.45e-7	Parkinson's disease;
SARC	cis	rs7208859	0.623	rs73271842	chr17:29137155	T/C	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs75229567	0.717	rs17107156	chr12:70234066	A/G	cg10114359	chr12:70132523	RAB3IP	-0.82	-6.21	-0.38	2.44e-9	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
SARC	cis	rs9309473	0.950	rs73947808	chr2:73721250	A/C	cg20560298	chr2:73613845	ALMS1	-0.53	-6.11	-0.37	4.22e-9	Metabolite levels;
SARC	cis	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg25427524	chr10:38739819	LOC399744	-0.52	-8.25	-0.48	1.17e-14	Extrinsic epigenetic age acceleration;
SARC	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.97e-8	Aortic root size;
SARC	cis	rs12908161	1.000	rs60957376	chr15:85280792	T/G	cg17507749	chr15:85114479	UBE2QP1	0.56	6.49	0.39	5e-10	Schizophrenia;
SARC	cis	rs9392918	0.600	rs2146064	chr6:7704133	T/C	cg23089261	chr6:7723385	NA	0.51	6.64	0.4	2.19e-10	Height;
SARC	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg08109568	chr15:31115862	NA	0.54	6.97	0.42	3.21e-11	Huntington's disease progression;
SARC	cis	rs17376456	0.542	rs2084916	chr5:93194961	A/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.49	-4.92	-0.31	1.66e-6	Diabetic retinopathy;
SARC	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg18252515	chr7:66147081	NA	0.56	6.02	0.37	6.73e-9	Aortic root size;
SARC	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg11764359	chr7:65958608	NA	0.76	8.78	0.5	3.62e-16	Aortic root size;
SARC	cis	rs472402	0.580	rs11738248	chr5:6657494	C/T	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.44	-5.33	-0.33	2.31e-7	Response to amphetamines;
SARC	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg00149659	chr3:10157352	C3orf10	0.69	6.44	0.39	6.6e-10	Alzheimer's disease;
SARC	cis	rs9943753	0.508	rs7958071	chr12:109836089	G/A	cg19025524	chr12:109796872	NA	-0.39	-5.66	-0.35	4.53e-8	HDL cholesterol;
SARC	trans	rs9987353	0.830	rs4841114	chr8:9129698	A/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-6.31	-0.38	1.39e-9	Recombination measurement;
SARC	cis	rs72781680	0.582	rs72783611	chr2:24291445	C/T	cg08917208	chr2:24149416	ATAD2B	0.61	6.31	0.38	1.42e-9	Lymphocyte counts;
SARC	cis	rs6545883	0.929	rs7606167	chr2:61742654	C/G	cg15711740	chr2:61764176	XPO1	-0.43	-5.36	-0.33	1.97e-7	Tuberculosis;
SARC	cis	rs2204008	0.641	rs2387810	chr12:38368875	G/T	cg13010199	chr12:38710504	ALG10B	0.78	10.75	0.58	3.67e-22	Bladder cancer;
SARC	cis	rs9788682	1.000	rs7181245	chr15:78814389	C/T	cg06917634	chr15:78832804	PSMA4	-0.58	-6.68	-0.4	1.73e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg24250549	chr1:154909240	PMVK	0.77	10.97	0.58	7.82e-23	Prostate cancer;
SARC	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg05872129	chr22:39784769	NA	0.42	5.77	0.35	2.57e-8	Intelligence (multi-trait analysis);
SARC	cis	rs1008375	0.966	rs2010053	chr4:17583806	A/C	cg16339924	chr4:17578868	LAP3	0.69	9.17	0.51	2.59e-17	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs72781680	0.898	rs12619525	chr2:23999565	G/C	cg06627628	chr2:24431161	ITSN2	-0.67	-6.35	-0.38	1.14e-9	Lymphocyte counts;
SARC	cis	rs17270561	0.609	rs4712968	chr6:25760344	T/C	cg16482183	chr6:26056742	HIST1H1C	0.48	5.95	0.36	9.58e-9	Iron status biomarkers;
SARC	cis	rs7520050	0.966	rs7522601	chr1:46419021	G/A	cg24296786	chr1:45957014	TESK2	0.38	4.87	0.3	2.02e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs3120667	0.790	rs3753444	chr1:152387867	C/G	cg26876637	chr1:152193138	HRNR	-0.48	-4.84	-0.3	2.34e-6	Eating disorders;
SARC	cis	rs2204008	0.743	rs2132212	chr12:38039405	G/A	cg26384229	chr12:38710491	ALG10B	0.79	11.35	0.6	4.69e-24	Bladder cancer;
SARC	cis	rs6459788	0.934	rs10251462	chr7:157258183	C/G	cg03453431	chr7:157225567	NA	-0.41	-5.97	-0.36	8.63e-9	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs57506017	0.585	rs10950395	chr7:12264467	T/C	cg23422036	chr7:12250390	TMEM106B	0.47	6.04	0.37	6.04e-9	Neuroticism;
SARC	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.43	-6.47	-0.39	5.79e-10	Total body bone mineral density;
SARC	cis	rs7633770	0.643	rs59048074	chr3:46689155	C/T	cg11219411	chr3:46661640	NA	-0.4	-6.17	-0.37	3.05e-9	Coronary artery disease;
SARC	cis	rs796364	0.951	rs10931888	chr2:201022952	T/G	cg23649088	chr2:200775458	C2orf69	-0.62	-6.03	-0.37	6.4e-9	Schizophrenia;
SARC	cis	rs9398803	0.865	rs1538172	chr6:126748493	A/G	cg19875578	chr6:126661172	C6orf173	0.6	8.07	0.47	3.8e-14	Male-pattern baldness;
SARC	cis	rs3020736	0.500	rs6002597	chr22:42488160	C/A	cg15557168	chr22:42548783	NA	0.36	4.92	0.31	1.61e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs763121	0.889	rs6001209	chr22:39121252	C/T	cg06022373	chr22:39101656	GTPBP1	-0.85	-10.8	-0.58	2.53e-22	Menopause (age at onset);
SARC	cis	rs11252926	0.673	rs816620	chr10:645916	A/G	cg08603382	chr10:743973	NA	-0.51	-6.61	-0.4	2.58e-10	Psychosis in Alzheimer's disease;
SARC	cis	rs2016266	0.896	rs3741663	chr12:53664015	G/A	cg26875137	chr12:53738046	NA	0.37	5.2	0.32	4.42e-7	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg27170947	chr2:26402098	FAM59B	0.37	4.8	0.3	2.79e-6	Gut microbiome composition (summer);
SARC	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg18404041	chr3:52824283	ITIH1	-0.44	-6.63	-0.4	2.38e-10	Bipolar disorder;
SARC	cis	rs2963155	0.518	rs6196	chr5:142661490	A/G	cg17617527	chr5:142782415	NR3C1	0.89	6.8	0.41	8.69e-11	Breast cancer;
SARC	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg00149659	chr3:10157352	C3orf10	0.74	7.28	0.43	5.18e-12	Alzheimer's disease;
SARC	cis	rs911555	0.504	rs8021368	chr14:104074810	G/A	cg24130564	chr14:104152367	KLC1	-0.7	-9.78	-0.54	3.82e-19	Intelligence (multi-trait analysis);
SARC	cis	rs35110281	0.715	rs2838320	chr21:44995037	A/G	cg01579765	chr21:45077557	HSF2BP	-0.35	-5.86	-0.36	1.56e-8	Mean corpuscular volume;
SARC	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.77	7.62	0.45	6.49e-13	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs459571	0.959	rs460888	chr9:136913123	C/G	cg01294253	chr9:136912663	BRD3	0.4	5.14	0.32	5.9e-7	Platelet distribution width;
SARC	cis	rs7584330	0.657	rs10211024	chr2:238353776	A/T	cg14458575	chr2:238380390	NA	0.51	6.09	0.37	4.74e-9	Prostate cancer;
SARC	cis	rs10911232	0.507	rs10752888	chr1:182993751	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.64	0.57	8.13e-22	Hypertriglyceridemia;
SARC	cis	rs9341808	0.718	rs9448893	chr6:80837239	A/G	cg08355045	chr6:80787529	NA	0.34	5.49	0.34	1.02e-7	Sitting height ratio;
SARC	cis	rs10504073	0.584	rs4873304	chr8:49922733	G/A	cg00325661	chr8:49890786	NA	0.52	6.9	0.41	4.88e-11	Blood metabolite ratios;
SARC	cis	rs4144743	0.641	rs67696888	chr17:45355116	A/G	cg18085866	chr17:45331354	ITGB3	-0.72	-6.81	-0.41	8.24e-11	Body mass index;
SARC	cis	rs3126085	0.935	rs4845745	chr1:152185184	C/T	cg03465714	chr1:152285911	FLG	-0.46	-5.5	-0.34	1e-7	Atopic dermatitis;
SARC	cis	rs2213920	0.619	rs6478174	chr9:118252779	C/T	cg13918206	chr9:118159781	DEC1	0.84	6.55	0.39	3.71e-10	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs2832191	0.740	rs2012645	chr21:30445961	G/A	cg08807101	chr21:30365312	RNF160	0.89	13.68	0.67	1.14e-31	Dental caries;
SARC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.8	10.5	0.57	2.27e-21	Prudent dietary pattern;
SARC	cis	rs6840360	0.615	rs62329085	chr4:152470237	G/A	cg22705602	chr4:152727874	NA	-0.42	-6.55	-0.39	3.67e-10	Intelligence (multi-trait analysis);
SARC	cis	rs5758659	0.714	rs7245	chr22:42481849	G/A	cg04733989	chr22:42467013	NAGA	-0.49	-5.79	-0.35	2.26e-8	Cognitive function;
SARC	cis	rs2273669	0.667	rs6918331	chr6:109317394	C/G	cg05315195	chr6:109294784	ARMC2	-0.6	-5.47	-0.34	1.13e-7	Prostate cancer;
SARC	cis	rs12545912	0.820	rs61176710	chr8:9485899	G/A	cg21625330	chr8:9911636	MSRA	0.52	4.93	0.31	1.55e-6	Multiple myeloma (hyperdiploidy);
SARC	cis	rs7020830	0.898	rs6476617	chr9:37200103	G/A	cg14294708	chr9:37120828	ZCCHC7	1.14	21.46	0.81	4.03e-57	Schizophrenia;
SARC	cis	rs1800469	1.000	rs1982072	chr19:41864509	T/A	cg09537434	chr19:41945824	ATP5SL	-0.54	-6.33	-0.38	1.22e-9	Colorectal cancer;
SARC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.46	0.57	3.12e-21	Prudent dietary pattern;
SARC	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs11718455	0.921	rs35872933	chr3:44028515	T/G	cg08738300	chr3:44038990	NA	0.51	5.63	0.35	5.13e-8	Coronary artery disease;
SARC	cis	rs3740540	0.530	rs10751598	chr10:126290951	A/G	cg04949429	chr10:126290192	LHPP	-0.38	-5.51	-0.34	9.29e-8	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9916302	0.904	rs6503519	chr17:37706578	A/G	cg00129232	chr17:37814104	STARD3	-0.63	-7.71	-0.45	3.69e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs8072100	0.607	rs9894594	chr17:45461383	A/G	cg08085267	chr17:45401833	C17orf57	-0.42	-4.86	-0.3	2.16e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs9457247	1.000	rs439553	chr6:167391212	A/G	cg23791538	chr6:167370224	RNASET2	-0.55	-7.55	-0.44	9.64e-13	Crohn's disease;
SARC	cis	rs11718455	0.960	rs1852037	chr3:44003720	G/T	cg08738300	chr3:44038990	NA	-0.57	-6.31	-0.38	1.4e-9	Coronary artery disease;
SARC	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg16680214	chr1:154839983	KCNN3	-0.39	-6.05	-0.37	5.8e-9	Prostate cancer;
SARC	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.39	0.44	2.61e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs3762637	1.000	rs55853677	chr3:122140616	G/A	cg24169773	chr3:122142474	KPNA1	-0.56	-5.7	-0.35	3.6e-8	LDL cholesterol levels;
SARC	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg00431813	chr7:1051703	C7orf50	-0.33	-5.0	-0.31	1.14e-6	Longevity;Endometriosis;
SARC	trans	rs7615952	0.512	rs1077621	chr3:125819799	A/G	cg07211511	chr3:129823064	LOC729375	-0.61	-6.58	-0.4	3.12e-10	Blood pressure (smoking interaction);
SARC	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg00800038	chr16:89945340	TCF25	-0.66	-5.63	-0.35	5.07e-8	Skin colour saturation;
SARC	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg11764359	chr7:65958608	NA	-0.78	-9.63	-0.53	1.11e-18	Aortic root size;
SARC	cis	rs8058578	1.000	rs2289442	chr16:30739919	A/G	cg02466173	chr16:30829666	NA	-0.39	-5.23	-0.32	3.78e-7	Multiple myeloma;
SARC	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.9	-0.5	1.61e-16	Alzheimer's disease;
SARC	cis	rs9916302	0.706	rs6503504	chr17:37514412	A/G	cg15445000	chr17:37608096	MED1	-0.46	-5.04	-0.31	9.46e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs4423214	0.959	rs12800438	chr11:71171003	G/A	cg24826892	chr11:71159390	DHCR7	0.48	6.16	0.37	3.09e-9	Vitamin D levels;
SARC	cis	rs854765	0.547	rs4365348	chr17:17912548	C/T	cg04398451	chr17:18023971	MYO15A	-0.44	-6.2	-0.38	2.5e-9	Total body bone mineral density;
SARC	cis	rs35110281	0.805	rs8131005	chr21:45041954	T/C	cg01579765	chr21:45077557	HSF2BP	-0.3	-5.03	-0.31	9.71e-7	Mean corpuscular volume;
SARC	cis	rs4975616	0.804	rs457130	chr5:1336178	A/T	cg07493874	chr5:1342172	CLPTM1L	-0.5	-6.58	-0.4	3.12e-10	Lung cancer;
SARC	trans	rs2486950	0.797	rs2486071	chr1:203196479	A/C	cg08259168	chr1:78509494	NA	-0.4	-6.33	-0.38	1.23e-9	Blood protein levels;
SARC	cis	rs1008375	0.966	rs6449313	chr4:17588320	A/G	cg02297831	chr4:17616191	MED28	0.51	6.46	0.39	6.08e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs911555	0.570	rs11625397	chr14:104027557	A/G	cg24130564	chr14:104152367	KLC1	0.63	9.02	0.51	7.27e-17	Intelligence (multi-trait analysis);
SARC	cis	rs10927875	0.632	rs10927863	chr1:16165247	C/A	cg07117364	chr1:16154769	NA	-0.46	-5.64	-0.35	4.94e-8	Dilated cardiomyopathy;
SARC	cis	rs2635047	1.000	rs2684818	chr18:44712965	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	6.63	0.4	2.32e-10	Educational attainment;
SARC	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg24549020	chr5:56110836	MAP3K1	0.53	5.83	0.36	1.82e-8	Initial pursuit acceleration;
SARC	cis	rs1864585	0.619	rs73209922	chr8:10708509	A/G	cg21775007	chr8:11205619	TDH	-0.48	-4.78	-0.3	3.09e-6	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
SARC	cis	rs7937682	0.889	rs484013	chr11:111495779	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.89	-14.08	-0.68	5.44e-33	Primary sclerosing cholangitis;
SARC	cis	rs80130819	0.688	rs7313023	chr12:48584179	T/C	cg24011408	chr12:48396354	COL2A1	0.54	6.03	0.37	6.51e-9	Prostate cancer;
SARC	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg24549020	chr5:56110836	MAP3K1	0.81	8.43	0.48	3.58e-15	Initial pursuit acceleration;
SARC	cis	rs6977660	0.714	rs10486365	chr7:19801364	A/G	cg07541023	chr7:19748670	TWISTNB	0.69	6.49	0.39	5.06e-10	Thyroid stimulating hormone;
SARC	cis	rs4243830	1.000	rs12047931	chr1:6587614	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	1.02	7.83	0.46	1.72e-13	Body mass index;
SARC	cis	rs3820928	1.000	rs3820928	chr2:227773466	A/G	cg05526886	chr2:227700861	RHBDD1	-0.47	-5.56	-0.34	7.44e-8	Pulmonary function;
SARC	cis	rs12754538	0.611	rs12093157	chr1:8791894	C/T	cg13785123	chr1:8931135	ENO1	-0.47	-5.86	-0.36	1.55e-8	Subjective well-being;
SARC	cis	rs7644634	0.624	rs34520191	chr3:105387224	T/G	cg23051926	chr3:105466016	CBLB	0.47	5.84	0.36	1.71e-8	Itch intensity from mosquito bite;
SARC	cis	rs7953249	0.502	rs1169294	chr12:121426594	G/A	cg15155738	chr12:121454335	C12orf43	0.48	5.9	0.36	1.31e-8	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs9325144	0.647	rs12231313	chr12:39101929	C/T	cg26384229	chr12:38710491	ALG10B	-0.6	-7.74	-0.45	2.98e-13	Morning vs. evening chronotype;
SARC	cis	rs1062177	1.000	rs973529	chr5:151188158	T/C	cg00977110	chr5:151150581	G3BP1	0.57	5.51	0.34	9.34e-8	Preschool internalizing problems;
SARC	cis	rs854765	0.618	rs8066982	chr17:17851377	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	9.85	0.54	2.34e-19	Total body bone mineral density;
SARC	cis	rs2180341	0.711	rs4371861	chr6:127568447	G/T	cg24812749	chr6:127587940	RNF146	0.65	8.71	0.5	5.82e-16	Breast cancer;
SARC	cis	rs986417	0.818	rs4901993	chr14:61081453	G/A	cg27398547	chr14:60952738	C14orf39	0.76	7.12	0.42	1.31e-11	Gut microbiota (bacterial taxa);
SARC	cis	rs12142240	0.659	rs17361873	chr1:46832686	A/G	cg10495392	chr1:46806563	NSUN4	0.64	6.83	0.41	7.39e-11	Menopause (age at onset);
SARC	cis	rs854765	0.583	rs7213225	chr17:17869111	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.43	5.44	0.34	1.33e-7	Total body bone mineral density;
SARC	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg25036284	chr2:26402008	FAM59B	0.46	5.7	0.35	3.59e-8	Gut microbiome composition (summer);
SARC	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg25072359	chr17:41440525	NA	0.5	5.94	0.36	1.04e-8	Menopause (age at onset);
SARC	cis	rs2854207	0.505	rs2466957	chr17:61961230	G/C	cg00588841	chr17:61851480	DDX42;CCDC47	-0.56	-5.98	-0.36	8.15e-9	Height;
SARC	cis	rs72634258	0.554	rs35123409	chr1:7878568	C/T	cg05338066	chr1:7812865	CAMTA1	0.67	5.57	0.34	6.91e-8	Inflammatory bowel disease;
SARC	cis	rs9549367	0.789	rs9577220	chr13:113908294	T/A	cg18105134	chr13:113819100	PROZ	-0.36	-5.48	-0.34	1.11e-7	Platelet distribution width;
SARC	cis	rs17376456	0.877	rs7734897	chr5:93305402	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.54	0.34	8.17e-8	Diabetic retinopathy;
SARC	cis	rs9790314	0.586	rs11710086	chr3:161125858	A/T	cg03342759	chr3:160939853	NMD3	-0.58	-7.16	-0.42	1.05e-11	Morning vs. evening chronotype;
SARC	trans	rs61931739	0.500	rs9705909	chr12:34576419	G/C	cg26384229	chr12:38710491	ALG10B	0.91	13.72	0.67	8.65e-32	Morning vs. evening chronotype;
SARC	cis	rs422249	0.512	rs174576	chr11:61603510	C/A	cg19610905	chr11:61596333	FADS2	-0.4	-4.86	-0.3	2.19e-6	Trans fatty acid levels;
SARC	cis	rs3087591	0.708	rs2525563	chr17:29647908	T/G	cg24425628	chr17:29625626	OMG;NF1	0.43	5.54	0.34	8.02e-8	Hip circumference;
SARC	cis	rs11758351	0.789	rs2069020	chr6:26205500	C/T	cg01420254	chr6:26195488	NA	0.56	5.01	0.31	1.05e-6	Gout;Renal underexcretion gout;
SARC	cis	rs11190604	0.767	rs77838250	chr10:102180090	T/G	cg07080220	chr10:102295463	HIF1AN	0.72	8.21	0.47	1.47e-14	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs9581857	0.685	rs9319370	chr13:28042493	G/T	cg01674679	chr13:27998804	GTF3A	-0.64	-4.86	-0.3	2.19e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	trans	rs7819412	0.691	rs73198970	chr8:11040216	T/C	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.66	-0.4	1.96e-10	Triglycerides;
SARC	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg18876405	chr7:65276391	NA	0.49	6.04	0.37	6e-9	Aortic root size;
SARC	cis	rs11792861	0.926	rs17628095	chr9:111889172	A/G	cg13535736	chr9:111863775	C9orf5	0.4	4.98	0.31	1.24e-6	Menarche (age at onset);
SARC	cis	rs35110281	0.641	rs9983670	chr21:45083425	A/G	cg01579765	chr21:45077557	HSF2BP	-0.39	-6.37	-0.39	9.85e-10	Mean corpuscular volume;
SARC	trans	rs10506458	0.915	rs1463821	chr12:63402875	C/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	0.74	6.73	0.4	1.3100000000000001e-10	Hemostatic factors and hematological phenotypes;
SARC	cis	rs244731	0.959	rs3105419	chr5:176551396	G/C	cg16006841	chr5:176797999	RGS14	0.56	6.57	0.4	3.21e-10	Urate levels in lean individuals;
SARC	cis	rs13314892	0.764	rs62252182	chr3:69881433	A/G	cg17445875	chr3:69859618	MITF	-0.49	-5.13	-0.32	6.2e-7	QRS complex (12-leadsum);
SARC	cis	rs2481665	0.806	rs55725347	chr1:62538252	G/A	cg18591186	chr1:62594603	INADL	-0.55	-7.36	-0.43	3.19e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs6570726	0.902	rs973855	chr6:145781850	C/T	cg23711669	chr6:146136114	FBXO30	-0.73	-10.94	-0.58	9.57e-23	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs763121	0.853	rs3761454	chr22:39066820	C/T	cg14440974	chr22:39074834	NA	-0.34	-5.01	-0.31	1.08e-6	Menopause (age at onset);
SARC	cis	rs9547692	0.938	rs12020196	chr13:37469191	G/C	cg01493522	chr13:37497338	NA	-0.44	-4.88	-0.3	1.93e-6	Coronary artery disease;
SARC	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg24549020	chr5:56110836	MAP3K1	0.81	8.4	0.48	4.37e-15	Initial pursuit acceleration;
SARC	cis	rs208520	1.000	rs12209225	chr6:66996443	G/T	cg07460842	chr6:66804631	NA	0.9	10.25	0.56	1.39e-20	Exhaled nitric oxide output;
SARC	cis	rs12579753	0.830	rs12825476	chr12:82238350	G/A	cg07988820	chr12:82153109	PPFIA2	-0.52	-6.07	-0.37	5.24e-9	Resting heart rate;
SARC	cis	rs2153535	0.580	rs4960412	chr6:8438261	G/C	cg07606381	chr6:8435919	SLC35B3	0.78	11.09	0.59	3.11e-23	Motion sickness;
SARC	cis	rs9400467	0.537	rs9647629	chr6:111501484	C/T	cg15721981	chr6:111408429	SLC16A10	0.67	5.65	0.35	4.66e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg12463550	chr7:65579703	CRCP	0.48	5.24	0.32	3.65e-7	Aortic root size;
SARC	trans	rs36093844	0.752	rs1445505	chr11:85584722	A/G	cg27065003	chr5:122429449	PRDM6	-0.55	-6.46	-0.39	5.9e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs3781913	0.675	rs907853	chr11:72354028	C/A	cg03713592	chr11:72463424	ARAP1	-0.41	-4.92	-0.31	1.64e-6	Rheumatoid arthritis;
SARC	cis	rs72781680	1.000	rs72781631	chr2:24195064	G/A	cg08917208	chr2:24149416	ATAD2B	0.78	7.51	0.44	1.29e-12	Lymphocyte counts;
SARC	cis	rs12478296	1.000	rs7603984	chr2:243047294	A/G	cg06360820	chr2:242988706	NA	-0.6	-4.75	-0.3	3.61e-6	Obesity-related traits;
SARC	trans	rs7824557	0.564	rs13260727	chr8:11232860	A/G	cg06636001	chr8:8085503	FLJ10661	0.58	7.58	0.44	8.3e-13	Retinal vascular caliber;
SARC	cis	rs721399	1.000	rs721399	chr8:18259366	C/T	cg18736775	chr8:18248649	NAT2	0.42	5.56	0.34	7.33e-8	Blood metabolite levels;
SARC	cis	rs9818758	0.607	rs11716445	chr3:49406095	C/T	cg00383909	chr3:49044727	WDR6	0.8	6.24	0.38	2.06e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs9300255	0.602	rs2851438	chr12:123643689	T/C	cg00376283	chr12:123451042	ABCB9	0.58	6.9	0.41	4.89e-11	Neutrophil percentage of white cells;
SARC	trans	rs9329221	0.623	rs34487437	chr8:10243803	G/A	cg06636001	chr8:8085503	FLJ10661	0.61	7.3	0.43	4.49e-12	Neuroticism;
SARC	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs35306767	0.903	rs12254002	chr10:929133	A/G	cg20503657	chr10:835505	NA	-0.74	-7.4	-0.44	2.49e-12	Eosinophil percentage of granulocytes;
SARC	cis	rs826838	0.904	rs1554550	chr12:39208889	G/A	cg13010199	chr12:38710504	ALG10B	0.73	9.35	0.52	7.67e-18	Heart rate;
SARC	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg18876405	chr7:65276391	NA	0.71	8.86	0.5	2.03e-16	Aortic root size;
SARC	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg12463550	chr7:65579703	CRCP	0.71	5.37	0.33	1.9e-7	Diabetic kidney disease;
SARC	cis	rs2519796	0.531	rs2519109	chr9:136807770	A/G	cg13040392	chr9:136075393	NA	-0.4	-4.75	-0.3	3.48e-6	Hematocrit;Hemoglobin concentration;
SARC	cis	rs6831352	0.879	rs17218003	chr4:100054723	G/C	cg12011299	chr4:100065546	ADH4	-0.34	-5.74	-0.35	2.95e-8	Alcohol dependence;
SARC	cis	rs6866344	0.568	rs10516147	chr5:178094484	A/G	cg03877680	chr5:178157825	ZNF354A	0.79	8.73	0.5	4.86e-16	Neutrophil percentage of white cells;
SARC	cis	rs2380220	0.606	rs7747776	chr6:96005852	C/T	cg15832292	chr6:96025679	MANEA	0.54	6.01	0.37	7.04e-9	Behavioural disinhibition (generation interaction);
SARC	cis	rs6964587	0.773	rs17757926	chr7:91987702	T/C	cg17063962	chr7:91808500	NA	0.91	12.91	0.65	3.93e-29	Breast cancer;
SARC	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg23221052	chr5:179740743	GFPT2	-0.54	-6.75	-0.4	1.13e-10	Height;
SARC	cis	rs1707322	0.752	rs11211171	chr1:46168642	A/G	cg03146154	chr1:46216737	IPP	0.52	6.28	0.38	1.6e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg05368731	chr17:41323189	NBR1	0.77	9.18	0.52	2.34e-17	Menopause (age at onset);
SARC	cis	rs72781680	0.611	rs36052574	chr2:24306587	A/C	cg06627628	chr2:24431161	ITSN2	-0.56	-5.86	-0.36	1.57e-8	Lymphocyte counts;
SARC	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg11764359	chr7:65958608	NA	0.86	12.33	0.63	3.29e-27	Aortic root size;
SARC	cis	rs941408	0.515	rs1736188	chr19:2782368	A/G	cg00079169	chr19:2811669	THOP1	0.45	5.0	0.31	1.14e-6	Total cholesterol levels;
SARC	cis	rs10751667	0.600	rs1128413	chr11:1010694	C/T	cg17559110	chr11:984447	AP2A2	-0.38	-4.88	-0.3	1.96e-6	Alzheimer's disease (late onset);
SARC	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg10523679	chr1:76189770	ACADM	0.52	6.89	0.41	5.02e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs4595586	0.525	rs7968458	chr12:39377139	C/A	cg26384229	chr12:38710491	ALG10B	0.52	6.32	0.38	1.29e-9	Morning vs. evening chronotype;
SARC	cis	rs6069325	0.529	rs6024210	chr20:54139554	A/G	cg06877860	chr20:55043471	C20orf43	-0.5	-4.78	-0.3	3.16e-6	Motion sickness;
SARC	trans	rs607987	0.967	rs605765	chr11:30217503	C/T	cg16771474	chr7:7776115	NA	0.49	6.55	0.39	3.65e-10	Body mass index;
SARC	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.61e-6	Depression;
SARC	cis	rs72945132	0.882	rs7129843	chr11:70180381	G/A	cg05964544	chr11:70165517	PPFIA1	-0.57	-5.54	-0.34	8.15e-8	Coronary artery disease;
SARC	cis	rs7089973	0.584	rs4752322	chr10:116613258	A/C	cg03647239	chr10:116582469	FAM160B1	0.54	6.99	0.42	2.89e-11	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs7617773	0.817	rs11710861	chr3:48297560	C/T	cg11946769	chr3:48343235	NME6	0.7	9.38	0.52	6.06e-18	Coronary artery disease;
SARC	cis	rs7959452	0.535	rs7135092	chr12:69658330	T/C	cg14784868	chr12:69753453	YEATS4	0.41	5.46	0.34	1.2e-7	Blood protein levels;
SARC	cis	rs3617	0.559	rs11915546	chr3:52866845	A/C	cg04865290	chr3:52927548	TMEM110	0.35	5.07	0.32	8.25e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs7044106	0.762	rs10760110	chr9:123412563	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.67	-8.35	-0.48	6.2e-15	Hip circumference adjusted for BMI;
SARC	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg22875332	chr1:76189707	ACADM	-0.46	-5.64	-0.35	4.84e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs735396	0.770	rs1169301	chr12:121431300	C/T	cg25281562	chr12:121454272	C12orf43	0.55	6.78	0.41	9.79e-11	N-glycan levels;
SARC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg03452623	chr4:187889614	NA	-0.76	-11.88	-0.61	9e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs950027	0.549	rs1719250	chr15:45609773	A/G	cg19305227	chr15:45544335	SLC28A2	-0.28	-5.24	-0.32	3.64e-7	Response to fenofibrate (adiponectin levels);
SARC	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg27347728	chr4:17578864	LAP3	0.49	6.13	0.37	3.8e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs78545713	0.649	rs11757549	chr6:26231608	G/A	cg00631329	chr6:26305371	NA	-0.71	-5.17	-0.32	5.09e-7	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs748404	0.697	rs546170	chr15:43564849	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	5.66	0.35	4.54e-8	Lung cancer;
SARC	cis	rs1728785	1.000	rs1170434	chr16:68606590	A/G	cg02972257	chr16:68554789	NA	-0.5	-5.9	-0.36	1.28e-8	Ulcerative colitis;
SARC	cis	rs11098499	0.954	rs6822679	chr4:120402702	A/C	cg09307838	chr4:120376055	NA	0.93	12.78	0.64	1.08e-28	Corneal astigmatism;
SARC	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg06028605	chr16:24865363	SLC5A11	-0.36	-5.16	-0.32	5.36e-7	Intelligence (multi-trait analysis);
SARC	cis	rs5753618	0.539	rs1034588	chr22:31616301	A/G	cg00478049	chr22:31556069	RNF185	0.45	4.78	0.3	3.06e-6	Colorectal cancer;
SARC	cis	rs668210	0.793	rs506873	chr11:65767215	A/C	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.51	-5.39	-0.33	1.69e-7	Cerebrospinal fluid biomarker levels;
SARC	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg08280861	chr8:58055591	NA	0.61	5.81	0.36	2.02e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg15506890	chr2:3487001	NA	-0.46	-6.17	-0.37	2.98e-9	Neurofibrillary tangles;
SARC	cis	rs9462027	0.517	rs2744973	chr6:34580221	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.73	-0.35	3.01e-8	Systemic lupus erythematosus;
SARC	cis	rs2153535	0.580	rs6914276	chr6:8450435	A/T	cg07606381	chr6:8435919	SLC35B3	-0.75	-10.51	-0.57	2.12e-21	Motion sickness;
SARC	cis	rs12444795	0.855	rs12445265	chr16:4924160	A/G	cg06965925	chr16:4818988	NA	0.38	4.81	0.3	2.75e-6	Cancer;
SARC	cis	rs11098499	0.580	rs12509234	chr4:120319434	T/C	cg09307838	chr4:120376055	NA	0.9	12.37	0.63	2.31e-27	Corneal astigmatism;
SARC	cis	rs25645	0.823	rs12453334	chr17:38153473	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.39	7.17	0.43	9.86e-12	Myeloid white cell count;
SARC	cis	rs12893668	0.616	rs58033365	chr14:104030901	T/C	cg26031613	chr14:104095156	KLC1	-0.51	-5.42	-0.33	1.48e-7	Reticulocyte count;
SARC	trans	rs11098499	0.954	rs7654587	chr4:120388406	C/T	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg18225595	chr11:63971243	STIP1	0.51	7.52	0.44	1.21e-12	Platelet count;
SARC	cis	rs6430585	0.583	rs4988201	chr2:136618507	A/G	cg07169764	chr2:136633963	MCM6	1.09	16.65	0.74	1.55e-41	Corneal structure;
SARC	cis	rs3768617	0.510	rs10797844	chr1:183082067	C/T	cg13390022	chr1:182993471	LAMC1	0.32	4.88	0.3	1.95e-6	Fuchs's corneal dystrophy;
SARC	cis	rs4481887	1.000	rs4244182	chr1:248471174	A/G	cg00666640	chr1:248458726	OR2T12	0.37	6.18	0.38	2.86e-9	Common traits (Other);
SARC	trans	rs36093844	0.615	rs77258124	chr11:85578081	G/A	cg15359163	chr5:122429178	PRDM6	-0.53	-6.38	-0.39	9.19e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs17021463	0.872	rs34181160	chr4:95275157	T/G	cg11021082	chr4:95130006	SMARCAD1	0.41	5.86	0.36	1.58e-8	Testicular germ cell tumor;
SARC	cis	rs1707322	0.964	rs785483	chr1:46559171	T/C	cg03146154	chr1:46216737	IPP	-0.48	-5.66	-0.35	4.54e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2425143	1.000	rs1890470	chr20:34357008	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-6.34	-0.38	1.19e-9	Blood protein levels;
SARC	trans	rs7937682	0.814	rs1784788	chr11:111486136	T/G	cg18187862	chr3:45730750	SACM1L	0.56	7.02	0.42	2.34e-11	Primary sclerosing cholangitis;
SARC	cis	rs12681288	0.676	rs35389636	chr8:1010613	G/T	cg04851639	chr8:1020857	NA	-0.3	-5.02	-0.31	1e-6	Schizophrenia;
SARC	cis	rs2242194	0.816	rs6671688	chr1:154994265	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.36	6.24	0.38	2.04e-9	Schizophrenia;
SARC	cis	rs4843747	0.671	rs72818576	chr16:88111019	C/G	cg01573921	chr16:88061006	BANP	-0.45	-4.83	-0.3	2.45e-6	Menopause (age at onset);
SARC	cis	rs9816226	0.591	rs77805826	chr3:185798025	C/T	cg00760338	chr3:185826511	ETV5	-0.77	-7.62	-0.45	6.27e-13	Obesity;Body mass index;
SARC	cis	rs2228479	0.557	rs11641726	chr16:89891619	G/A	cg06558623	chr16:89946397	TCF25	0.93	6.63	0.4	2.29e-10	Skin colour saturation;
SARC	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg21724239	chr8:58056113	NA	0.6	6.18	0.38	2.83e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg19901468	chr14:105411992	AHNAK2	-0.73	-10.79	-0.58	2.74e-22	Rheumatoid arthritis;
SARC	cis	rs1538970	0.962	rs3219489	chr1:45797505	C/G	cg05343316	chr1:45956843	TESK2	0.71	7.66	0.45	4.82e-13	Platelet count;
SARC	cis	rs10461617	0.617	rs6874733	chr5:56069600	A/G	cg22800045	chr5:56110881	MAP3K1	0.61	6.87	0.41	5.73e-11	Type 2 diabetes;
SARC	cis	rs2594989	0.943	rs346073	chr3:11298181	G/A	cg00170343	chr3:11313890	ATG7	0.66	6.12	0.37	3.95e-9	Circulating chemerin levels;
SARC	cis	rs6840360	0.550	rs4696289	chr4:152621237	C/T	cg22705602	chr4:152727874	NA	-0.48	-7.27	-0.43	5.51e-12	Intelligence (multi-trait analysis);
SARC	cis	rs6088813	0.922	rs4911493	chr20:33960799	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.43	-5.2	-0.32	4.33e-7	Height;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg22879676	chr17:81009871	B3GNTL1	0.63	6.42	0.39	7.64e-10	Lung cancer in ever smokers;
SARC	cis	rs9902453	0.904	rs9897794	chr17:28296327	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	7.3	0.43	4.39e-12	Coffee consumption (cups per day);
SARC	cis	rs8072100	0.570	rs9905073	chr17:45468296	G/A	cg08085267	chr17:45401833	C17orf57	-0.42	-4.86	-0.3	2.16e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs870825	0.616	rs4443323	chr4:185629805	C/A	cg04058563	chr4:185651563	MLF1IP	0.83	11.25	0.59	9.69e-24	Blood protein levels;
SARC	cis	rs7914558	1.000	rs7899084	chr10:104872547	A/T	cg04362960	chr10:104952993	NT5C2	0.41	4.82	0.3	2.61e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs3087591	0.881	rs2905804	chr17:29519995	T/C	cg24425628	chr17:29625626	OMG;NF1	0.54	6.64	0.4	2.14e-10	Hip circumference;
SARC	cis	rs992157	0.775	rs7559428	chr2:219150238	A/G	cg00012203	chr2:219082015	ARPC2	-0.64	-9.25	-0.52	1.52e-17	Colorectal cancer;
SARC	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.78	-0.5	3.56e-16	Alzheimer's disease;
SARC	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	10.73	0.58	4.39e-22	Platelet count;
SARC	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg07061783	chr6:25882402	NA	-0.42	-5.09	-0.32	7.23e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6570726	0.791	rs9373464	chr6:145907167	T/C	cg05347473	chr6:146136440	FBXO30	0.53	7.41	0.44	2.36e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1355223	0.583	rs2956076	chr11:34874124	T/C	cg18508148	chr11:34937573	PDHX;APIP	0.49	6.22	0.38	2.25e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg16016165	chr17:28257073	EFCAB5;SSH2	-0.46	-6.5	-0.39	4.93e-10	Thyroid stimulating hormone;
SARC	cis	rs1008375	1.000	rs11724495	chr4:17621310	G/A	cg27347728	chr4:17578864	LAP3	0.47	5.8	0.36	2.18e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs11250098	0.642	rs4841460	chr8:10789493	C/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.55	-0.39	3.62e-10	Morning vs. evening chronotype;
SARC	cis	rs1707322	0.896	rs809774	chr1:46560244	T/A	cg03146154	chr1:46216737	IPP	-0.48	-5.84	-0.36	1.79e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7626444	0.625	rs2686596	chr3:196475119	T/C	cg12930392	chr3:196481615	PAK2	0.25	5.02	0.31	1.04e-6	Monocyte count;
SARC	cis	rs918629	0.567	rs56219066	chr5:95242931	T/C	cg16656078	chr5:95278638	ELL2	-0.55	-6.87	-0.41	5.64e-11	IgG glycosylation;
SARC	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-7.61	-0.45	6.63e-13	Chronic sinus infection;
SARC	cis	rs1008375	1.000	rs555	chr4:17625658	A/G	cg27347728	chr4:17578864	LAP3	0.47	5.78	0.35	2.4e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1355223	0.506	rs7947848	chr11:34866220	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.25	-0.38	1.89e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	trans	rs2727020	0.658	rs1851992	chr11:49438110	C/T	cg15704280	chr7:45808275	SEPT13	-0.86	-14.14	-0.68	3.47e-33	Coronary artery disease;
SARC	cis	rs11711311	1.000	rs28394480	chr3:113485143	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	8.71	0.5	5.64e-16	IgG glycosylation;
SARC	cis	rs2243480	0.522	rs778717	chr7:65848151	G/C	cg18252515	chr7:66147081	NA	-1.1	-7.22	-0.43	7.46e-12	Diabetic kidney disease;
SARC	cis	rs3733585	0.699	rs2018643	chr4:9947121	C/T	cg00071950	chr4:10020882	SLC2A9	0.39	6.12	0.37	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	trans	rs2727020	0.796	rs7131672	chr11:49274421	A/C	cg03929089	chr4:120376271	NA	0.68	7.8	0.46	2.02e-13	Coronary artery disease;
SARC	cis	rs9890032	0.520	rs2321926	chr17:29041552	T/C	cg13385521	chr17:29058706	SUZ12P	0.52	5.62	0.35	5.44e-8	Hip circumference adjusted for BMI;
SARC	cis	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg06558623	chr16:89946397	TCF25	0.89	6.23	0.38	2.14e-9	Skin colour saturation;
SARC	cis	rs11690935	0.877	rs72890834	chr2:172835802	G/T	cg13550731	chr2:172543902	DYNC1I2	-0.99	-15.5	-0.71	1.04e-37	Schizophrenia;
SARC	cis	rs6456042	1.000	rs6456040	chr6:166534636	T/C	cg11088901	chr6:166572345	T	-0.33	-4.83	-0.3	2.47e-6	Asthma;
SARC	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	12.03	0.62	3.06e-26	Chronic sinus infection;
SARC	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg01316550	chr5:56110833	MAP3K1	0.53	4.88	0.3	1.95e-6	Initial pursuit acceleration;
SARC	cis	rs2153535	0.580	rs6921964	chr6:8446395	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	8.24	0.48	1.22e-14	Motion sickness;
SARC	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.76	11.45	0.6	2.16e-24	Menarche (age at onset);
SARC	cis	rs28374715	0.681	rs28712264	chr15:41588797	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.1	-17.23	-0.75	1.94e-43	Ulcerative colitis;
SARC	cis	rs6138458	1.000	rs227658	chr20:24932028	A/G	cg26195577	chr20:24973756	C20orf3	0.89	9.49	0.53	2.94e-18	Blood protein levels;
SARC	cis	rs12142240	0.698	rs67142569	chr1:46828460	C/T	cg00530320	chr1:46809349	NSUN4	0.58	7.07	0.42	1.78e-11	Menopause (age at onset);
SARC	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg13206674	chr6:150067644	NUP43	-0.45	-5.84	-0.36	1.78e-8	Lung cancer;
SARC	cis	rs698833	0.518	rs4953085	chr2:44554724	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.7	7.94	0.46	8.62e-14	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs3741151	0.686	rs61516411	chr11:73302768	T/C	cg17517138	chr11:73019481	ARHGEF17	0.7	5.83	0.36	1.88e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs7568458	0.684	rs60012532	chr2:85752474	A/C	cg23752985	chr2:85803571	VAMP8	0.4	5.28	0.33	2.89e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs6449957	0.801	rs921792	chr5:67465803	C/T	cg23036683	chr5:67512108	NA	0.55	6.24	0.38	2.09e-9	Cleft lip with or without cleft palate;
SARC	cis	rs1008375	0.966	rs6449325	chr4:17699509	C/T	cg16339924	chr4:17578868	LAP3	-0.52	-6.42	-0.39	7.35e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6121246	0.529	rs6060195	chr20:30185638	C/T	cg13852791	chr20:30311386	BCL2L1	0.68	5.91	0.36	1.2e-8	Mean corpuscular hemoglobin;
SARC	cis	rs6493487	0.512	rs11856129	chr15:51172604	T/C	cg02338191	chr15:51200825	AP4E1	0.55	5.09	0.32	7.27e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs9400467	0.537	rs1891387	chr6:111462290	A/G	cg15721981	chr6:111408429	SLC16A10	0.64	5.67	0.35	4.19e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs3845702	1.000	rs3845702	chr2:180848488	A/C	cg01881094	chr2:180872142	CWC22	0.69	6.72	0.4	1.36e-10	Schizophrenia;
SARC	cis	rs10876993	0.890	rs12302350	chr12:58062589	T/G	cg18357645	chr12:58087776	OS9	0.44	5.81	0.36	2.01e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs4969178	1.000	rs7212201	chr17:76393896	C/A	cg02836325	chr17:76403955	PGS1	0.32	4.99	0.31	1.17e-6	HDL cholesterol levels;
SARC	cis	rs17023223	0.537	rs2765542	chr1:119560326	T/A	cg05756136	chr1:119680316	WARS2	-0.49	-5.82	-0.36	1.96e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs888194	0.587	rs6606711	chr12:109849297	A/G	cg05360138	chr12:110035743	NA	0.4	5.08	0.32	7.65e-7	Neuroticism;
SARC	cis	rs10463554	0.892	rs158252	chr5:102406250	A/G	cg23492399	chr5:102201601	PAM	-0.51	-5.67	-0.35	4.23e-8	Parkinson's disease;
SARC	cis	rs17401966	0.867	rs12403443	chr1:10423988	A/G	cg15208524	chr1:10270712	KIF1B	0.6	6.58	0.4	3.14e-10	Hepatocellular carcinoma;
SARC	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg12463550	chr7:65579703	CRCP	0.71	5.36	0.33	2.02e-7	Diabetic kidney disease;
SARC	cis	rs72945132	0.882	rs7118156	chr11:70142922	T/C	cg00319359	chr11:70116639	PPFIA1	0.67	6.08	0.37	4.85e-9	Coronary artery disease;
SARC	cis	rs1057510	0.929	rs10849492	chr12:6720795	A/G	cg12392916	chr12:6772545	ING4	0.5	4.99	0.31	1.18e-6	Myopia (pathological);
SARC	cis	rs986417	1.000	rs2351175	chr14:61066730	C/T	cg27398547	chr14:60952738	C14orf39	0.87	7.44	0.44	1.96e-12	Gut microbiota (bacterial taxa);
SARC	cis	rs72781680	0.898	rs79023848	chr2:24038174	C/A	cg06627628	chr2:24431161	ITSN2	-0.71	-6.47	-0.39	5.57e-10	Lymphocyte counts;
SARC	cis	rs9341808	0.538	rs620147	chr6:80992090	G/A	cg08355045	chr6:80787529	NA	-0.34	-5.13	-0.32	5.96e-7	Sitting height ratio;
SARC	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg17294928	chr15:75287854	SCAMP5	0.46	5.88	0.36	1.44e-8	Breast cancer;
SARC	cis	rs9858542	0.951	rs1800668	chr3:49395757	G/A	cg07274523	chr3:49395745	GPX1	0.53	6.25	0.38	1.94e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs8114671	0.773	rs3746438	chr20:33584289	C/T	cg07148914	chr20:33460835	GGT7	-0.41	-4.96	-0.31	1.35e-6	Height;
SARC	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.69	8.81	0.5	2.92e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg06108461	chr20:60628389	TAF4	-0.92	-12.7	-0.64	1.92e-28	Body mass index;
SARC	cis	rs2204008	0.777	rs2387813	chr12:38382091	A/C	cg26384229	chr12:38710491	ALG10B	0.87	12.85	0.64	6.2e-29	Bladder cancer;
SARC	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg22974920	chr21:40686053	BRWD1	0.45	4.84	0.3	2.36e-6	Cognitive function;
SARC	cis	rs950027	0.620	rs1145084	chr15:45675440	G/A	cg21132104	chr15:45694354	SPATA5L1	0.55	7.05	0.42	1.96e-11	Response to fenofibrate (adiponectin levels);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg13203223	chr12:49319398	FKBP11	0.5	6.56	0.39	3.47e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs9811216	1.000	rs1920122	chr3:169506141	C/T	cg14222479	chr3:169487675	ARPM1	0.42	5.22	0.32	4.03e-7	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs1008375	1.000	rs11947857	chr4:17691047	T/C	cg27347728	chr4:17578864	LAP3	-0.5	-6.09	-0.37	4.58e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2153535	0.580	rs6910742	chr6:8448328	G/A	cg21535247	chr6:8435926	SLC35B3	0.57	7.24	0.43	6.41e-12	Motion sickness;
SARC	cis	rs10911232	0.524	rs4652773	chr1:183054827	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.33	0.56	7.51e-21	Hypertriglyceridemia;
SARC	cis	rs6912958	0.781	rs6940150	chr6:88287114	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-6.8	-0.41	8.58e-11	Monocyte percentage of white cells;
SARC	cis	rs12367572	0.965	rs11182706	chr12:45223339	T/C	cg04608330	chr12:45269318	NELL2	-0.47	-5.87	-0.36	1.47e-8	Gut microbiome composition (summer);
SARC	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg16479474	chr6:28041457	NA	0.36	5.29	0.33	2.82e-7	Depression;
SARC	cis	rs9381040	1.000	rs9381040	chr6:41154650	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.48	-5.45	-0.34	1.29e-7	Alzheimer's disease (late onset);
SARC	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.46	-5.72	-0.35	3.33e-8	Gut microbiome composition (summer);
SARC	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	trans	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg00938859	chr5:1591904	SDHAP3	0.79	7.66	0.45	5.1e-13	Breast cancer;
SARC	cis	rs9323205	0.871	rs8008599	chr14:51670057	A/G	cg23942311	chr14:51606299	NA	0.32	4.93	0.31	1.59e-6	Cancer;
SARC	cis	rs2439831	1.000	rs2444250	chr15:43785051	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.05	10.85	0.58	1.78e-22	Lung cancer in ever smokers;
SARC	cis	rs9467711	0.591	rs72834617	chr6:25999175	G/A	cg21479132	chr6:26055353	NA	0.94	6.28	0.38	1.62e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1008375	0.966	rs4698642	chr4:17679174	A/T	cg16339924	chr4:17578868	LAP3	0.64	8.37	0.48	5.39e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1048257	0.682	rs2582514	chr14:105413204	G/T	cg19901468	chr14:105411992	AHNAK2	-0.72	-10.4	-0.56	4.64e-21	Systemic lupus erythematosus;
SARC	cis	rs12701220	0.817	rs59471534	chr7:1085224	G/A	cg26769984	chr7:1090371	C7orf50	0.47	5.4	0.33	1.66e-7	Bronchopulmonary dysplasia;
SARC	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg17971929	chr21:40555470	PSMG1	-0.59	-7.52	-0.44	1.19e-12	Menarche (age at onset);
SARC	cis	rs9814567	1.000	rs2370578	chr3:134199612	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-7.08	-0.42	1.68e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg10186232	chr5:64920368	C5orf44;TRIM23	-0.47	-6.3	-0.38	1.49e-9	Neuroticism;
SARC	cis	rs2115630	0.645	rs3825878	chr15:85174755	C/T	cg12501888	chr15:85177176	SCAND2	-0.49	-6.0	-0.37	7.62e-9	P wave terminal force;
SARC	cis	rs910316	1.000	rs13099	chr14:75599155	G/A	cg08847533	chr14:75593920	NEK9	-0.87	-13.72	-0.67	8.2e-32	Height;
SARC	cis	rs10484885	0.752	rs72921948	chr6:90582560	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.72	-7.7	-0.45	3.95e-13	QRS interval (sulfonylurea treatment interaction);
SARC	cis	rs1801251	1.000	rs1801251	chr2:233633460	G/A	cg25237894	chr2:233734115	C2orf82	0.37	4.8	0.3	2.81e-6	Coronary artery disease;
SARC	cis	rs80130819	0.688	rs2468945	chr12:48652414	G/A	cg05342945	chr12:48394962	COL2A1	-0.53	-5.69	-0.35	3.7e-8	Prostate cancer;
SARC	cis	rs10089	1.000	rs7713877	chr5:127428825	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.83	10.35	0.56	6.5e-21	Ileal carcinoids;
SARC	cis	rs11997175	0.624	rs4733460	chr8:33675169	T/C	ch.8.33884649F	chr8:33765107	NA	0.61	8.19	0.47	1.73e-14	Body mass index;
SARC	cis	rs2834188	1.000	rs1018742	chr21:34686381	A/G	cg04842828	chr21:34696676	IFNAR1	0.4	4.72	0.3	4e-6	Narcolepsy;
SARC	cis	rs9323205	0.798	rs2999392	chr14:51655145	A/G	cg23942311	chr14:51606299	NA	-0.3	-4.87	-0.3	2.06e-6	Cancer;
SARC	cis	rs7769051	0.808	rs1467404	chr6:133090141	A/G	cg07930552	chr6:133119739	C6orf192	-0.9	-8.12	-0.47	2.79e-14	Type 2 diabetes nephropathy;
SARC	cis	rs79349575	0.749	rs8182364	chr17:47018025	A/G	cg16584676	chr17:46985605	UBE2Z	0.55	6.66	0.4	1.91e-10	Type 2 diabetes;
SARC	cis	rs9341808	0.754	rs9352817	chr6:81025879	T/G	cg08355045	chr6:80787529	NA	0.37	6.0	0.37	7.65e-9	Sitting height ratio;
SARC	trans	rs2727020	0.930	rs1164688	chr11:49290604	C/G	cg15704280	chr7:45808275	SEPT13	0.78	10.68	0.57	6.21e-22	Coronary artery disease;
SARC	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	11.0	0.58	5.97e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9616064	0.557	rs9615397	chr22:47049086	C/T	cg05621596	chr22:47072043	GRAMD4	-0.6	-8.19	-0.47	1.7e-14	Urate levels in obese individuals;
SARC	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg13880726	chr7:1868755	MAD1L1	0.52	6.2	0.38	2.6e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs8016982	0.674	rs2288499	chr14:81660997	C/T	cg01989461	chr14:81687754	GTF2A1	0.76	11.46	0.6	2.06e-24	Schizophrenia;
SARC	cis	rs35213789	0.878	rs1476105	chr7:69562563	A/G	cg10619644	chr7:69149951	AUTS2	0.42	5.12	0.32	6.39e-7	Childhood ear infection;
SARC	cis	rs6088580	0.634	rs2225837	chr20:33005634	C/T	cg24642439	chr20:33292090	TP53INP2	-0.68	-8.73	-0.5	4.96e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs57506017	0.628	rs2302635	chr7:12270625	G/A	cg23422036	chr7:12250390	TMEM106B	0.45	5.87	0.36	1.49e-8	Neuroticism;
SARC	cis	rs8077889	0.871	rs9893111	chr17:41915767	G/A	cg26893861	chr17:41843967	DUSP3	0.78	9.18	0.52	2.4e-17	Triglycerides;
SARC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	10.64	0.57	8.51e-22	Platelet count;
SARC	cis	rs9527	0.590	rs34104646	chr10:104896078	T/A	cg04362960	chr10:104952993	NT5C2	0.44	5.15	0.32	5.58e-7	Arsenic metabolism;
SARC	trans	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg17830980	chr10:43048298	ZNF37B	-0.53	-6.89	-0.41	5.26e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs17376456	0.877	rs7734897	chr5:93305402	G/A	cg25358565	chr5:93447407	FAM172A	1.28	14.54	0.69	1.6e-34	Diabetic retinopathy;
SARC	cis	rs10463316	0.894	rs10062856	chr5:150768196	C/G	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.26	-0.33	3.23e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg12463550	chr7:65579703	CRCP	-0.52	-5.53	-0.34	8.79e-8	Aortic root size;
SARC	cis	rs78487399	0.808	rs7581586	chr2:43668176	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-5.69	-0.35	3.78e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs4820539	0.902	rs737846	chr22:23460669	A/G	cg14186256	chr22:23484241	RTDR1	0.89	14.28	0.68	1.14e-33	Bone mineral density;
SARC	cis	rs62064224	0.902	rs17732573	chr17:30627664	C/T	cg18200150	chr17:30822561	MYO1D	-0.33	-4.9	-0.31	1.81e-6	Schizophrenia;
SARC	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg00149659	chr3:10157352	C3orf10	0.68	6.38	0.39	9.46e-10	Alzheimer's disease;
SARC	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg21017887	chr14:105400489	NA	0.52	7.49	0.44	1.38e-12	Rheumatoid arthritis;
SARC	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg16434002	chr17:42200994	HDAC5	0.4	4.84	0.3	2.36e-6	Total body bone mineral density;
SARC	cis	rs9660992	0.573	rs12140422	chr1:205187981	G/A	cg07972983	chr1:205091412	RBBP5	0.56	6.91	0.41	4.7e-11	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs8014204	0.836	rs8021280	chr14:75290018	C/G	cg06637938	chr14:75390232	RPS6KL1	0.68	9.72	0.54	5.66e-19	Caffeine consumption;
SARC	trans	rs330048	0.545	rs10503387	chr8:9150525	C/T	cg06636001	chr8:8085503	FLJ10661	0.59	7.04	0.42	2.16e-11	Systemic lupus erythematosus;
SARC	cis	rs1983891	1.000	rs9381082	chr6:41542214	T/C	cg15051332	chr6:41514432	FOXP4	0.52	5.68	0.35	3.94e-8	Prostate cancer;
SARC	cis	rs449789	0.817	rs1875814	chr6:159720266	G/A	cg14500486	chr6:159655392	FNDC1	-0.44	-5.02	-0.31	1.01e-6	Pulse pressure;
SARC	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	7.0	0.42	2.71e-11	Height;
SARC	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg11644478	chr21:40555479	PSMG1	-0.9	-11.53	-0.6	1.29e-24	Cognitive function;
SARC	cis	rs4664308	0.935	rs6744567	chr2:160933781	C/G	cg03641300	chr2:160917029	PLA2R1	-0.71	-9.54	-0.53	2.02e-18	Idiopathic membranous nephropathy;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg14489159	chr17:29421766	NF1	0.67	6.98	0.42	3.11e-11	Lung cancer in ever smokers;
SARC	cis	rs7103648	0.966	rs874896	chr11:47418953	C/G	cg10504702	chr11:47789108	FNBP4	0.57	7.47	0.44	1.61e-12	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs17376456	0.825	rs10061377	chr5:93174513	T/C	cg21475434	chr5:93447410	FAM172A	0.81	6.71	0.4	1.49e-10	Diabetic retinopathy;
SARC	cis	rs13144136	0.687	rs12499294	chr4:10654086	T/C	cg10242279	chr4:10666415	CLNK	-0.42	-6.82	-0.41	7.86e-11	Resistance to antihypertensive treatment in hypertension;
SARC	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	11.05	0.59	4.24e-23	Platelet count;
SARC	cis	rs28655083	0.956	rs1485792	chr16:77100439	G/T	cg01504555	chr16:77246968	SYCE1L	-0.37	-4.72	-0.3	4.03e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg16479474	chr6:28041457	NA	-0.37	-5.68	-0.35	4.02e-8	Depression;
SARC	cis	rs7412746	0.634	rs3754212	chr1:150738200	A/G	cg10589385	chr1:150898437	SETDB1	0.39	5.06	0.31	8.47e-7	Melanoma;
SARC	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg18876405	chr7:65276391	NA	0.47	5.29	0.33	2.88e-7	Aortic root size;
SARC	trans	rs877282	0.853	rs11595507	chr10:756703	C/T	cg22713356	chr15:30763199	NA	0.99	9.88	0.54	1.92e-19	Uric acid levels;
SARC	cis	rs6963495	0.818	rs73190181	chr7:105162907	A/C	cg19920283	chr7:105172520	RINT1	0.65	5.48	0.34	1.09e-7	Bipolar disorder (body mass index interaction);
SARC	trans	rs11722228	0.549	rs62288521	chr4:10099772	G/A	cg26043149	chr18:55253948	FECH	0.7	7.87	0.46	1.35e-13	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg09455208	chr3:40491958	NA	0.36	5.33	0.33	2.36e-7	Renal cell carcinoma;
SARC	cis	rs1790761	0.667	rs658768	chr11:67337808	G/A	cg24690094	chr11:67383802	NA	0.37	5.52	0.34	8.98e-8	Mean corpuscular volume;
SARC	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg27266027	chr21:40555129	PSMG1	0.5	5.48	0.34	1.12e-7	Cognitive function;
SARC	cis	rs734999	0.588	rs3748819	chr1:2524966	C/T	cg18854424	chr1:2615690	NA	0.34	5.46	0.34	1.2e-7	Ulcerative colitis;
SARC	cis	rs7412746	0.658	rs7526489	chr1:150726238	C/T	cg15448220	chr1:150897856	SETDB1	0.47	6.03	0.37	6.23e-9	Melanoma;
SARC	cis	rs709400	0.628	rs4906321	chr14:103878882	C/T	cg26031613	chr14:104095156	KLC1	0.72	9.54	0.53	2.02e-18	Body mass index;
SARC	trans	rs9354308	0.868	rs9363457	chr6:66549080	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.53	-6.32	-0.38	1.32e-9	Metabolite levels;
SARC	cis	rs11792861	0.926	rs7870597	chr9:111871864	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.69	7.9	0.46	1.08e-13	Menarche (age at onset);
SARC	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg11644478	chr21:40555479	PSMG1	1.04	14.48	0.69	2.48e-34	Cognitive function;
SARC	cis	rs1552244	0.554	rs3846169	chr3:9997054	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.46	5.63	0.35	5.2100000000000003e-08	Alzheimer's disease;
SARC	cis	rs35213789	0.887	rs2851504	chr7:69113006	A/C	cg10619644	chr7:69149951	AUTS2	0.41	5.46	0.34	1.19e-7	Childhood ear infection;
SARC	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg00933542	chr6:150070202	PCMT1	0.3	4.75	0.3	3.56e-6	Lung cancer;
SARC	cis	rs4664308	0.935	rs58354887	chr2:160927112	C/T	cg03641300	chr2:160917029	PLA2R1	-0.7	-9.51	-0.53	2.41e-18	Idiopathic membranous nephropathy;
SARC	cis	rs7927592	0.913	rs11228293	chr11:68384646	T/C	cg01657329	chr11:68192670	LRP5	-0.44	-5.23	-0.32	3.81e-7	Total body bone mineral density;
SARC	cis	rs6840360	1.000	rs6535811	chr4:152598992	C/T	cg22705602	chr4:152727874	NA	-0.38	-6.54	-0.39	3.91e-10	Intelligence (multi-trait analysis);
SARC	cis	rs10752881	1.000	rs6697739	chr1:182983333	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.72	10.87	0.58	1.56e-22	Colorectal cancer;
SARC	cis	rs9814567	0.964	rs6772406	chr3:134210183	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-6.96	-0.41	3.44e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs7937682	0.921	rs10891280	chr11:111433609	A/T	cg22437258	chr11:111473054	SIK2	-0.71	-9.22	-0.52	1.78e-17	Primary sclerosing cholangitis;
SARC	cis	rs2836950	0.772	rs62222988	chr21:40569508	T/C	cg11890956	chr21:40555474	PSMG1	-0.57	-6.97	-0.42	3.18e-11	Menarche (age at onset);
SARC	cis	rs751728	0.664	rs943478	chr6:33750940	T/A	cg25922239	chr6:33757077	LEMD2	0.58	7.64	0.45	5.71e-13	Crohn's disease;
SARC	cis	rs9398803	0.723	rs853983	chr6:127046153	G/A	cg19875578	chr6:126661172	C6orf173	-0.64	-8.82	-0.5	2.75e-16	Male-pattern baldness;
SARC	cis	rs1003719	0.646	rs9985082	chr21:38501021	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-9.12	-0.51	3.7e-17	Eye color traits;
SARC	cis	rs9486719	1.000	rs2971608	chr6:97039757	T/C	cg06623918	chr6:96969491	KIAA0776	-0.78	-9.59	-0.53	1.44e-18	Migraine;Coronary artery disease;
SARC	cis	rs7587476	0.736	rs62202002	chr2:215690600	T/C	cg04530015	chr2:215796436	ABCA12	-0.41	-6.7	-0.4	1.56e-10	Neuroblastoma;
SARC	cis	rs9818758	0.607	rs12185979	chr3:49651970	C/G	cg00383909	chr3:49044727	WDR6	0.78	5.01	0.31	1.06e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg11987759	chr7:65425863	GUSB	0.5	6.21	0.38	2.36e-9	Aortic root size;
SARC	cis	rs6121246	0.542	rs6059761	chr20:30110522	G/C	cg13852791	chr20:30311386	BCL2L1	0.64	5.74	0.35	2.93e-8	Mean corpuscular hemoglobin;
SARC	cis	rs959260	0.614	rs930297	chr17:73404537	C/T	cg00200289	chr17:73401734	GRB2	-0.6	-5.51	-0.34	9.51e-8	Systemic lupus erythematosus;
SARC	cis	rs10513432	0.826	rs1371098	chr3:152552197	C/T	cg04845053	chr3:152552877	P2RY1	0.81	4.73	0.3	3.96e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg24633833	chr3:10029261	TMEM111	0.51	5.09	0.32	7.27e-7	Alzheimer's disease;
SARC	cis	rs9858542	0.953	rs9853683	chr3:49512588	A/G	cg07274523	chr3:49395745	GPX1	0.53	6.1	0.37	4.27e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs7566780	0.725	rs4347841	chr2:16702165	C/T	cg09580478	chr2:16689509	NA	0.46	5.32	0.33	2.42e-7	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs74181299	0.855	rs2723066	chr2:65279321	T/G	cg20592124	chr2:65290738	CEP68	0.45	6.51	0.39	4.49e-10	Pulse pressure;
SARC	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6570726	0.935	rs413916	chr6:145831400	T/C	cg23711669	chr6:146136114	FBXO30	0.8	12.14	0.62	1.3e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6450176	0.909	rs6884760	chr5:53293077	T/A	ch.5.1024479R	chr5:53302184	ARL15	-0.65	-7.35	-0.43	3.24e-12	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	trans	rs1814175	0.817	rs10839358	chr11:49770972	G/A	cg03929089	chr4:120376271	NA	-0.9	-14.53	-0.69	1.76e-34	Height;
SARC	cis	rs1568889	1.000	rs12804198	chr11:28143114	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.71	9.16	0.51	2.71e-17	Bipolar disorder;
SARC	cis	rs3892630	0.588	rs7248798	chr19:33303684	G/T	cg22980127	chr19:33182716	NUDT19	1.0	10.76	0.58	3.52e-22	Red blood cell traits;
SARC	trans	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.73	10.46	0.57	2.95e-21	Intelligence (multi-trait analysis);
SARC	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg18357526	chr6:26021779	HIST1H4A	0.89	12.34	0.63	2.86e-27	Intelligence (multi-trait analysis);
SARC	trans	rs208520	0.754	rs851594	chr6:66876695	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.09	-14.31	-0.68	9.05e-34	Exhaled nitric oxide output;
SARC	cis	rs6450176	0.909	rs10940353	chr5:53299959	A/C	ch.5.1024479R	chr5:53302184	ARL15	-0.66	-7.6	-0.45	7.06e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs7264396	0.563	rs2425071	chr20:34292961	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	0.76	7.48	0.44	1.47e-12	Total cholesterol levels;
SARC	cis	rs9868809	0.881	rs2286652	chr3:48689192	G/A	cg07636037	chr3:49044803	WDR6	-0.72	-6.38	-0.39	9.5e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	trans	rs66573146	1.000	rs28729690	chr4:6962061	C/T	cg07817883	chr1:32538562	TMEM39B	1.43	9.06	0.51	5.43e-17	Granulocyte percentage of myeloid white cells;
SARC	cis	rs9326248	0.520	rs74830	chr11:117090558	C/T	cg20270762	chr11:117014891	PAFAH1B2	-0.43	-5.1	-0.32	7.14e-7	Blood protein levels;
SARC	cis	rs9858542	0.953	rs3811697	chr3:49590770	C/T	cg07274523	chr3:49395745	GPX1	0.51	6.0	0.37	7.32e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg24250549	chr1:154909240	PMVK	0.74	9.76	0.54	4.32e-19	Prostate cancer;
SARC	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg02463440	chr8:22132932	PIWIL2	0.47	6.67	0.4	1.84e-10	Hypertriglyceridemia;
SARC	cis	rs7523050	0.730	rs41279678	chr1:109440215	G/A	cg08274380	chr1:109419600	GPSM2	1.08	8.3	0.48	8.49e-15	Fat distribution (HIV);
SARC	cis	rs920590	0.560	rs7823457	chr8:19671334	G/A	cg17834443	chr8:19674713	INTS10	-0.51	-6.4	-0.39	8.53e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs56011263	0.687	rs4690187	chr4:703813	C/T	cg05835009	chr4:710272	PCGF3	0.57	6.61	0.4	2.61e-10	White blood cell count;
SARC	cis	rs739401	0.572	rs404629	chr11:3077025	A/G	cg05729581	chr11:3078854	CARS	-0.51	-6.73	-0.4	1.3e-10	Longevity;
SARC	cis	rs7617773	0.832	rs6775114	chr3:48182620	G/C	cg11946769	chr3:48343235	NME6	-0.52	-6.38	-0.39	9.29e-10	Coronary artery disease;
SARC	cis	rs7044106	0.762	rs1886337	chr9:123443776	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	8.99	0.51	9.01e-17	Hip circumference adjusted for BMI;
SARC	cis	rs6912958	0.582	rs242285	chr6:88070743	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.78	11.3	0.59	6.83e-24	Monocyte percentage of white cells;
SARC	cis	rs1008375	1.000	rs4698198	chr4:17656536	G/A	cg02297831	chr4:17616191	MED28	0.49	6.31	0.38	1.39e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4819052	0.788	rs13049700	chr21:46701909	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	7.49	0.44	1.41e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs12586317	0.547	rs115019197	chr14:35503764	G/A	cg26967526	chr14:35346199	BAZ1A	-0.57	-5.64	-0.35	4.92e-8	Psoriasis;
SARC	cis	rs6120849	0.754	rs6087666	chr20:33640242	G/A	cg06115741	chr20:33292138	TP53INP2	0.54	5.16	0.32	5.3e-7	Protein C levels;
SARC	cis	rs2153535	0.547	rs9502720	chr6:8541362	C/A	cg21535247	chr6:8435926	SLC35B3	0.55	6.83	0.41	7.48e-11	Motion sickness;
SARC	cis	rs2933343	0.729	rs1680794	chr3:128620390	A/G	cg24203234	chr3:128598194	ACAD9	0.64	8.09	0.47	3.31e-14	IgG glycosylation;
SARC	trans	rs11165623	0.792	rs9437609	chr1:96977961	A/C	cg10631902	chr5:14652156	NA	-0.47	-7.61	-0.45	6.81e-13	Hip circumference;Waist circumference;
SARC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.93	10.56	0.57	1.51e-21	Platelet count;
SARC	cis	rs6570726	0.791	rs448939	chr6:145808320	T/C	cg05347473	chr6:146136440	FBXO30	0.49	6.75	0.4	1.16e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7223966	1.000	rs11079508	chr17:61750066	T/C	cg00588841	chr17:61851480	DDX42;CCDC47	-0.61	-6.68	-0.4	1.76e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7149337	0.717	rs4309324	chr14:51606336	A/T	cg23942311	chr14:51606299	NA	-0.33	-5.47	-0.34	1.15e-7	Cancer;
SARC	cis	rs35110281	0.837	rs2838342	chr21:45077865	G/A	cg01579765	chr21:45077557	HSF2BP	-0.32	-5.3	-0.33	2.69e-7	Mean corpuscular volume;
SARC	cis	rs765787	0.530	rs2899379	chr15:45534799	C/T	cg24006582	chr15:45444508	DUOX1	0.46	5.76	0.35	2.63e-8	Uric acid levels;
SARC	cis	rs1044826	0.913	rs9860521	chr3:139214559	A/G	cg15131784	chr3:139108705	COPB2	0.47	5.34	0.33	2.23e-7	Obesity-related traits;
SARC	cis	rs6582630	0.555	rs4601853	chr12:38435569	G/A	cg13010199	chr12:38710504	ALG10B	0.75	10.24	0.56	1.42e-20	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs17376456	0.597	rs10064158	chr5:93095186	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.56	5.82	0.36	1.96e-8	Diabetic retinopathy;
SARC	trans	rs10506458	0.915	rs56321182	chr12:63392023	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.74	-6.3	-0.38	1.51e-9	Hemostatic factors and hematological phenotypes;
SARC	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.76	8.3	0.48	8.42e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg06636001	chr8:8085503	FLJ10661	0.66	8.86	0.5	2.08e-16	Mood instability;
SARC	cis	rs1784581	0.588	rs9295180	chr6:162420579	T/C	cg17173639	chr6:162384350	PARK2	0.51	6.48	0.39	5.29e-10	Itch intensity from mosquito bite;
SARC	cis	rs2629540	0.847	rs12762597	chr10:126387043	G/A	cg08799069	chr10:126477246	METTL10	0.6	6.55	0.39	3.54e-10	Cocaine dependence;
SARC	cis	rs9715521	0.935	rs34361458	chr4:59838192	C/A	cg11281224	chr4:60001000	NA	-0.42	-5.31	-0.33	2.54e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs72781680	1.000	rs72781634	chr2:24199102	C/T	cg08917208	chr2:24149416	ATAD2B	0.78	7.62	0.45	6.31e-13	Lymphocyte counts;
SARC	cis	rs7587476	0.784	rs13026390	chr2:215687075	C/T	cg04530015	chr2:215796436	ABCA12	0.4	6.72	0.4	1.39e-10	Neuroblastoma;
SARC	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg13880726	chr7:1868755	MAD1L1	0.6	7.16	0.42	1.06e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs7208859	0.623	rs9898084	chr17:29082334	C/G	cg13385521	chr17:29058706	SUZ12P	0.89	7.75	0.45	2.86e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9467773	1.000	rs6940053	chr6:26562122	C/T	cg12292205	chr6:26970375	C6orf41	0.45	5.35	0.33	2.05e-7	Intelligence (multi-trait analysis);
SARC	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg16325326	chr1:53192061	ZYG11B	-0.92	-15.75	-0.72	1.52e-38	Monocyte count;
SARC	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg11890956	chr21:40555474	PSMG1	1.18	19.81	0.79	6.98e-52	Cognitive function;
SARC	cis	rs2760061	0.599	rs849903	chr1:228137659	T/C	cg02753203	chr1:228287806	NA	-0.53	-7.28	-0.43	5.16e-12	Diastolic blood pressure;
SARC	cis	rs1790761	0.692	rs638140	chr11:67333858	G/C	cg24690094	chr11:67383802	NA	0.37	5.45	0.34	1.25e-7	Mean corpuscular volume;
SARC	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg16680214	chr1:154839983	KCNN3	-0.37	-5.85	-0.36	1.69e-8	Prostate cancer;
SARC	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg00149659	chr3:10157352	C3orf10	0.78	7.3	0.43	4.52e-12	Alzheimer's disease;
SARC	cis	rs644799	0.965	rs11021313	chr11:95506907	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	15.46	0.71	1.39e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg13647721	chr17:30228624	UTP6	-0.68	-5.45	-0.34	1.3e-7	Hip circumference adjusted for BMI;
SARC	cis	rs17376456	0.825	rs72786702	chr5:93254656	A/C	cg25358565	chr5:93447407	FAM172A	1.29	14.23	0.68	1.68e-33	Diabetic retinopathy;
SARC	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg10435706	chr6:150039699	LATS1	0.36	4.8	0.3	2.88e-6	Lung cancer;
SARC	cis	rs2832077	0.527	rs2705690	chr21:30239245	T/A	cg08807101	chr21:30365312	RNF160	0.5	5.43	0.34	1.41e-7	Cognitive test performance;
SARC	trans	rs629535	0.862	rs598548	chr8:70032438	C/T	cg21567404	chr3:27674614	NA	1.05	14.23	0.68	1.78e-33	Dupuytren's disease;
SARC	trans	rs561341	1.000	rs501957	chr17:30314504	C/T	cg20587970	chr11:113659929	NA	-1.36	-13.83	-0.67	3.63e-32	Hip circumference adjusted for BMI;
SARC	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg13175981	chr1:150552382	MCL1	-0.54	-6.9	-0.41	4.97e-11	Tonsillectomy;
SARC	cis	rs6088580	0.634	rs6059896	chr20:33111783	T/C	cg24642439	chr20:33292090	TP53INP2	0.66	8.68	0.49	6.79e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs561341	0.769	rs559228	chr17:30294527	T/C	cg00745463	chr17:30367425	LRRC37B	-0.68	-5.23	-0.32	3.82e-7	Hip circumference adjusted for BMI;
SARC	cis	rs7395581	0.918	rs3816725	chr11:47305669	T/G	cg25783544	chr11:47291846	MADD	0.5	5.54	0.34	8.15e-8	HDL cholesterol;
SARC	cis	rs1348850	1.000	rs3927978	chr2:178443854	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.67	-8.27	-0.48	1.01e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	11.6	0.61	7.26e-25	Alzheimer's disease;
SARC	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg17971929	chr21:40555470	PSMG1	-0.86	-11.37	-0.6	3.96e-24	Cognitive function;
SARC	cis	rs1215050	0.755	rs783958	chr4:98893836	A/T	cg05340658	chr4:99064831	C4orf37	-0.44	-5.92	-0.36	1.12e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	trans	rs10085978	0.604	rs10104197	chr8:143235315	C/G	cg12891252	chr10:43902500	HNRNPF	0.52	6.24	0.38	2.05e-9	Mosquito bite size;
SARC	trans	rs11165623	0.564	rs6593612	chr1:97002041	C/A	cg10631902	chr5:14652156	NA	-0.42	-6.36	-0.38	1.04e-9	Hip circumference;Waist circumference;
SARC	trans	rs1910358	0.554	rs10057796	chr5:23759746	C/T	cg10386045	chr7:14029680	ETV1	0.54	6.27	0.38	1.74e-9	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs4242434	0.889	rs7817772	chr8:22539316	A/G	cg03733263	chr8:22462867	KIAA1967	-0.96	-14.87	-0.7	1.33e-35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg22535103	chr8:58192502	C8orf71	0.73	7.23	0.43	6.8e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg12463550	chr7:65579703	CRCP	-0.5	-5.55	-0.34	7.9e-8	Aortic root size;
SARC	cis	rs1707322	0.752	rs11211145	chr1:46108491	A/C	cg03146154	chr1:46216737	IPP	0.49	5.57	0.34	7.11e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.1	20.93	0.81	1.96e-55	Chronic sinus infection;
SARC	cis	rs4423214	1.000	rs3750997	chr11:71158841	A/C	cg24826892	chr11:71159390	DHCR7	0.5	6.38	0.39	9.38e-10	Vitamin D levels;
SARC	cis	rs12893668	0.703	rs34186780	chr14:104027595	T/G	cg26031613	chr14:104095156	KLC1	-0.46	-4.73	-0.3	3.97e-6	Reticulocyte count;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg20293685	chr10:35363893	CUL2	0.48	6.46	0.39	6.05e-10	Thyroid stimulating hormone;
SARC	cis	rs9398803	0.687	rs9482757	chr6:126923877	A/C	cg19875578	chr6:126661172	C6orf173	0.6	8.22	0.47	1.39e-14	Male-pattern baldness;
SARC	cis	rs1865721	0.804	rs7243462	chr18:73147998	A/T	cg26385618	chr18:73139727	C18orf62	-0.37	-5.04	-0.31	9.47e-7	Intelligence;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg14414971	chr7:3340979	SDK1	0.48	6.29	0.38	1.58e-9	Schizophrenia;
SARC	cis	rs16976116	0.901	rs7172108	chr15:55501551	C/G	cg17854078	chr15:55489399	RSL24D1	0.66	6.53	0.39	4.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs11098499	1.000	rs10029750	chr4:120172543	A/G	cg09307838	chr4:120376055	NA	0.85	11.66	0.61	4.75e-25	Corneal astigmatism;
SARC	cis	rs3809566	0.963	rs12148057	chr15:63331509	A/T	cg05507819	chr15:63340323	TPM1	0.53	5.96	0.36	9.21e-9	Platelet count;
SARC	cis	rs3749237	0.595	rs1464567	chr3:49459252	C/G	cg02487422	chr3:49467188	NICN1	-0.49	-6.14	-0.37	3.53e-9	Resting heart rate;
SARC	cis	rs6665290	0.904	rs12409428	chr1:227189969	T/C	cg14016676	chr1:227182615	CDC42BPA	0.37	5.33	0.33	2.31e-7	Myeloid white cell count;
SARC	cis	rs8114671	0.967	rs6142321	chr20:33788474	G/A	cg24642439	chr20:33292090	TP53INP2	-0.48	-5.52	-0.34	8.89e-8	Height;
SARC	cis	rs10861342	1.000	rs10861337	chr12:105452442	G/A	cg23923672	chr12:105501055	KIAA1033	0.71	5.12	0.32	6.36e-7	IgG glycosylation;
SARC	cis	rs12142240	0.698	rs72677589	chr1:46817770	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-5.39	-0.33	1.72e-7	Menopause (age at onset);
SARC	cis	rs9420	0.961	rs708228	chr11:57585662	C/T	cg19752551	chr11:57585705	CTNND1	-0.53	-7.13	-0.42	1.28e-11	Schizophrenia;
SARC	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg05861140	chr6:150128134	PCMT1	-0.38	-4.81	-0.3	2.68e-6	Lung cancer;
SARC	cis	rs17539620	0.624	rs7770107	chr6:154836862	A/G	cg17771515	chr6:154831774	CNKSR3	0.53	5.07	0.32	8.2e-7	Lipoprotein (a) levels;
SARC	cis	rs7937682	0.562	rs955744	chr11:111374334	C/T	cg22437258	chr11:111473054	SIK2	-0.39	-4.83	-0.3	2.47e-6	Primary sclerosing cholangitis;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg27248875	chr13:111534506	ANKRD10	0.72	5.5	0.34	1.02e-7	Obesity-related traits;
SARC	cis	rs3126085	0.935	rs3126062	chr1:152272352	G/A	cg26876637	chr1:152193138	HRNR	-0.44	-5.02	-0.31	1.04e-6	Atopic dermatitis;
SARC	cis	rs9905704	0.647	rs11650809	chr17:56972741	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.4	-4.83	-0.3	2.52e-6	Testicular germ cell tumor;
SARC	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg05861140	chr6:150128134	PCMT1	-0.41	-5.41	-0.33	1.53e-7	Lung cancer;
SARC	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg14773178	chr5:1868261	NA	0.31	4.95	0.31	1.45e-6	Cardiovascular disease risk factors;
SARC	cis	rs9400467	0.537	rs73528983	chr6:111433641	A/G	cg15721981	chr6:111408429	SLC16A10	0.67	5.78	0.35	2.37e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs1355223	0.867	rs1869360	chr11:34698590	C/T	cg18508148	chr11:34937573	PDHX;APIP	-0.43	-5.47	-0.34	1.17e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs796364	0.806	rs6743396	chr2:200860138	T/C	cg23649088	chr2:200775458	C2orf69	0.6	5.35	0.33	2.08e-7	Schizophrenia;
SARC	cis	rs611744	0.538	rs13257548	chr8:109273185	G/A	cg21045802	chr8:109455806	TTC35	0.59	7.76	0.45	2.71e-13	Dupuytren's disease;
SARC	cis	rs7291412	1.000	rs7291412	chr22:46459132	G/T	cg09693106	chr22:46449821	C22orf26;LOC150381	0.34	4.88	0.3	1.95e-6	Dupuytren's disease;Subjective well-being;
SARC	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg17376030	chr22:41985996	PMM1	0.62	7.75	0.45	2.75e-13	Vitiligo;
SARC	cis	rs116095464	0.558	rs10065239	chr5:275288	C/T	cg22496380	chr5:211416	CCDC127	-0.95	-8.7	-0.5	6.1e-16	Breast cancer;
SARC	cis	rs72781680	0.846	rs72782114	chr2:24025740	G/A	cg08917208	chr2:24149416	ATAD2B	0.76	7.11	0.42	1.4e-11	Lymphocyte counts;
SARC	cis	rs4689388	0.890	rs4342257	chr4:6290037	G/C	cg25554036	chr4:6271136	WFS1	0.41	6.66	0.4	1.96e-10	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs9682041	0.866	rs6444926	chr3:170133235	T/C	cg11886554	chr3:170076028	SKIL	1.06	8.61	0.49	1.14e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg04135372	chr2:99061383	INPP4A	0.49	6.28	0.38	1.61e-9	Height;
SARC	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg21782813	chr7:2030301	MAD1L1	0.44	7.09	0.42	1.56e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg04166393	chr7:2884313	GNA12	0.6	6.86	0.41	5.97e-11	Height;
SARC	cis	rs9341808	0.587	rs3805859	chr6:81048946	C/A	cg08355045	chr6:80787529	NA	0.33	5.18	0.32	4.81e-7	Sitting height ratio;
SARC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.72	-9.3	-0.52	1.08e-17	Prudent dietary pattern;
SARC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg10862848	chr6:42927986	GNMT	-0.42	-6.54	-0.39	3.75e-10	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg14517863	chr17:44321492	NA	0.42	6.16	0.37	3.14e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs853679	1.000	rs853678	chr6:28297313	T/A	cg26450541	chr6:28235208	ZNF187	0.62	5.19	0.32	4.64e-7	Depression;
SARC	cis	rs6582630	0.576	rs4882372	chr12:38356609	C/A	cg26384229	chr12:38710491	ALG10B	-0.57	-7.1	-0.42	1.54e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs5167	0.566	rs35080293	chr19:45496624	T/G	cg10169327	chr19:45448959	APOC2	0.33	4.96	0.31	1.37e-6	Blood protein levels;
SARC	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg11366901	chr6:160182831	ACAT2	0.98	9.94	0.55	1.26e-19	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs11880706	0.831	rs3795009	chr19:6088820	T/C	cg18109231	chr19:6110877	RFX2	0.68	4.77	0.3	3.18e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs9913156	0.707	rs9902000	chr17:4582426	A/C	cg19197139	chr17:4613644	ARRB2	-0.76	-8.76	-0.5	4.06e-16	Lymphocyte counts;
SARC	cis	rs617791	0.530	rs10896073	chr11:65762814	T/C	cg26695010	chr11:65641043	EFEMP2	0.57	7.02	0.42	2.47e-11	Breast cancer;
SARC	cis	rs7647973	0.593	rs1799844	chr3:49847642	G/A	cg03060546	chr3:49711283	APEH	-0.62	-6.06	-0.37	5.29e-9	Menarche (age at onset);
SARC	cis	rs1568889	0.938	rs12795971	chr11:28355104	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.72	9.58	0.53	1.48e-18	Bipolar disorder;
SARC	cis	rs826838	1.000	rs11168676	chr12:38977304	A/G	cg13010199	chr12:38710504	ALG10B	0.77	10.62	0.57	9.98e-22	Heart rate;
SARC	cis	rs1008375	0.931	rs979823	chr4:17700176	G/A	cg27347728	chr4:17578864	LAP3	0.46	5.75	0.35	2.73e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9392918	0.622	rs6908257	chr6:7706089	A/G	cg23089261	chr6:7723385	NA	0.51	6.42	0.39	7.63e-10	Height;
SARC	cis	rs1055129	0.537	rs2467100	chr17:73949038	C/G	cg06969265	chr17:73775802	H3F3B	0.45	5.53	0.34	8.67e-8	White matter hyperintensity burden;
SARC	cis	rs6450176	0.633	rs391448	chr5:53332323	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.6	-6.9	-0.41	4.79e-11	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs9303280	0.806	rs36095411	chr17:38031865	T/G	cg19468946	chr17:37922297	IKZF3	-0.29	-4.76	-0.3	3.4e-6	Self-reported allergy;
SARC	cis	rs35306767	0.903	rs12264711	chr10:929525	T/C	cg26597838	chr10:835615	NA	0.82	8.53	0.49	1.84e-15	Eosinophil percentage of granulocytes;
SARC	trans	rs9354352	0.791	rs4710306	chr6:66700271	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.63	-8.15	-0.47	2.3e-14	Initial pursuit acceleration in psychotic disorders;
SARC	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg12463550	chr7:65579703	CRCP	-0.49	-5.34	-0.33	2.21e-7	Aortic root size;
SARC	cis	rs6570726	0.935	rs369458	chr6:145812809	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.48	0.39	5.27e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs668210	0.643	rs549334	chr11:65774659	C/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.71	7.57	0.44	8.83e-13	Cerebrospinal fluid biomarker levels;
SARC	cis	rs829883	0.872	rs1641641	chr12:98896018	A/C	cg25150519	chr12:98850993	NA	0.71	9.49	0.53	2.82e-18	Colorectal adenoma (advanced);
SARC	cis	rs6426558	0.537	rs6662583	chr1:227383889	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.41	-4.78	-0.3	3.15e-6	Neutrophil percentage of white cells;
SARC	cis	rs950027	0.787	rs1153845	chr15:45724729	C/T	cg15395560	chr15:45543142	SLC28A2	0.26	4.72	0.3	4.02e-6	Response to fenofibrate (adiponectin levels);
SARC	cis	rs8051517	1.000	rs71395854	chr16:68401392	G/A	cg01866162	chr16:67596514	CTCF	1.1	6.2	0.38	2.57e-9	Blood protein levels;
SARC	cis	rs9650657	0.515	rs7820860	chr8:10950396	C/G	cg21775007	chr8:11205619	TDH	-0.47	-5.85	-0.36	1.63e-8	Neuroticism;
SARC	cis	rs9916302	0.706	rs8067511	chr17:37611352	C/T	cg00129232	chr17:37814104	STARD3	-0.55	-5.69	-0.35	3.71e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg21171335	chr12:122356390	WDR66	0.47	7.55	0.44	9.81e-13	Mean corpuscular volume;
SARC	cis	rs11077998	1.000	rs11077998	chr17:80483946	C/G	cg10255544	chr17:80519551	FOXK2	-0.45	-6.38	-0.39	9.65e-10	Reticulocyte fraction of red cells;
SARC	cis	rs448720	1.000	rs7172137	chr15:68204357	A/C	cg05925327	chr15:68127851	NA	-0.32	-4.82	-0.3	2.64e-6	Cognitive performance;
SARC	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg25072359	chr17:41440525	NA	-0.44	-5.52	-0.34	8.95e-8	Menopause (age at onset);
SARC	trans	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg17712092	chr4:129076599	LARP1B	0.68	9.23	0.52	1.71e-17	Breast cancer;
SARC	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg20891283	chr12:69753455	YEATS4	0.68	9.8	0.54	3.26e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs3862030	0.720	rs11593526	chr10:104228017	G/T	ch.10.2196322F	chr10:104248062	ACTR1A	-0.48	-6.64	-0.4	2.16e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
SARC	trans	rs12310956	0.510	rs7302434	chr12:33886819	G/A	cg13010199	chr12:38710504	ALG10B	0.56	7.21	0.43	7.74e-12	Morning vs. evening chronotype;
SARC	cis	rs9325144	0.534	rs1843866	chr12:38703160	G/T	cg13010199	chr12:38710504	ALG10B	0.55	7.2	0.43	8.24e-12	Morning vs. evening chronotype;
SARC	cis	rs7927592	0.913	rs11228287	chr11:68349754	A/G	cg01657329	chr11:68192670	LRP5	-0.43	-5.11	-0.32	6.59e-7	Total body bone mineral density;
SARC	trans	rs208520	0.526	rs9354366	chr6:66788559	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.11	-22.05	-0.82	5.76e-59	Exhaled nitric oxide output;
SARC	cis	rs770189	0.955	rs244755	chr5:88095785	A/G	cg18498987	chr5:88179539	MEF2C	0.39	4.99	0.31	1.2e-6	Tonometry;
SARC	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg26513180	chr16:89883248	FANCA	0.94	16.53	0.73	3.88e-41	Vitiligo;
SARC	cis	rs2463822	0.925	rs1881535	chr11:62121623	C/T	cg06239285	chr11:62104954	ASRGL1	0.89	9.16	0.51	2.79e-17	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs7927771	1.000	rs10838748	chr11:47716381	T/G	cg05585544	chr11:47624801	NA	-0.38	-5.11	-0.32	6.55e-7	Subjective well-being;
SARC	cis	rs2273669	0.915	rs3734650	chr6:109295017	A/G	cg05315195	chr6:109294784	ARMC2	-0.48	-4.79	-0.3	2.96e-6	Prostate cancer;
SARC	cis	rs497273	0.553	rs508595	chr12:121198891	C/G	cg02403541	chr12:121454288	C12orf43	0.45	5.35	0.33	2.08e-7	Systemic lupus erythematosus;
SARC	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg23262073	chr20:60523788	NA	-0.45	-6.57	-0.4	3.3e-10	Body mass index;
SARC	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg04277193	chr17:41438351	NA	0.44	4.82	0.3	2.59e-6	Menopause (age at onset);
SARC	cis	rs2228479	0.867	rs62056110	chr16:89946388	A/C	cg06558623	chr16:89946397	TCF25	0.98	8.13	0.47	2.6e-14	Skin colour saturation;
SARC	cis	rs477692	0.563	rs7079165	chr10:131430240	G/A	cg05714579	chr10:131428358	MGMT	-0.61	-7.95	-0.46	7.76e-14	Response to temozolomide;
SARC	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg13395646	chr4:1353034	KIAA1530	-0.42	-5.22	-0.32	3.94e-7	Longevity;
SARC	cis	rs858239	0.539	rs4377861	chr7:23185969	C/T	cg23682824	chr7:23144976	KLHL7	0.66	8.16	0.47	2.05e-14	Cerebrospinal fluid biomarker levels;
SARC	cis	rs17270561	0.609	rs4145216	chr6:25743559	G/A	cg17691542	chr6:26056736	HIST1H1C	0.61	7.36	0.43	3.06e-12	Iron status biomarkers;
SARC	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg03433033	chr1:76189801	ACADM	0.54	7.42	0.44	2.19e-12	Blood metabolite levels;Acylcarnitine levels;
SARC	trans	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.52	6.62	0.4	2.42e-10	Intelligence (multi-trait analysis);
SARC	cis	rs1953600	0.870	rs2788295	chr10:81941007	C/G	cg00277334	chr10:82204260	NA	0.36	5.29	0.33	2.85e-7	Sarcoidosis;
SARC	cis	rs12142240	0.698	rs17361915	chr1:46847321	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-5.56	-0.34	7.46e-8	Menopause (age at onset);
SARC	cis	rs17376456	0.542	rs35672980	chr5:93284877	A/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.47	-5.34	-0.33	2.24e-7	Diabetic retinopathy;
SARC	cis	rs11785693	0.862	rs62491168	chr8:4982290	A/T	cg26367366	chr8:4980734	NA	0.69	6.19	0.38	2.75e-9	Neuroticism (multi-trait analysis);Neuroticism;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg07504288	chr2:175870204	CHN1	0.52	7.06	0.42	1.9e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs11792861	0.926	rs7470160	chr9:111844246	C/A	cg13535736	chr9:111863775	C9orf5	-0.41	-5.07	-0.32	8.04e-7	Menarche (age at onset);
SARC	cis	rs11225247	0.772	rs61895376	chr11:102227892	A/G	cg11690896	chr11:102217788	BIRC2	0.72	5.19	0.32	4.65e-7	Vein graft stenosis in coronary artery bypass grafting;
SARC	cis	rs73206853	0.764	rs76142162	chr12:110884307	C/G	cg10860002	chr12:110842031	ANAPC7	0.64	5.11	0.32	6.75e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs950776	0.518	rs12910978	chr15:78810017	A/G	cg22563815	chr15:78856949	CHRNA5	0.41	6.71	0.4	1.49e-10	Sudden cardiac arrest;
SARC	cis	rs9914988	0.887	rs34644886	chr17:27168327	T/C	cg20469991	chr17:27169893	C17orf63	-0.49	-4.91	-0.31	1.73e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg12050434	chr12:43030949	NA	0.51	6.55	0.39	3.73e-10	Breast cancer;
SARC	cis	rs1153858	0.943	rs8038342	chr15:45651537	T/C	cg21132104	chr15:45694354	SPATA5L1	0.77	10.99	0.58	6.68e-23	Homoarginine levels;
SARC	cis	rs8114671	0.562	rs6088636	chr20:33469746	C/T	cg24642439	chr20:33292090	TP53INP2	0.49	6.08	0.37	4.84e-9	Height;
SARC	cis	rs1008375	1.000	rs2058337	chr4:17678649	C/T	cg27347728	chr4:17578864	LAP3	0.46	5.69	0.35	3.88e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg01475735	chr3:40494733	NA	-0.47	-5.21	-0.32	4.06e-7	Renal cell carcinoma;
SARC	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg06420487	chr17:61919686	SMARCD2	0.43	4.76	0.3	3.33e-6	Height;
SARC	trans	rs1422110	0.515	rs1155791	chr5:85417582	A/C	cg01787110	chr1:109008453	NBPF6	0.45	6.37	0.39	9.76e-10	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs11098499	0.644	rs2389880	chr4:120559870	T/A	cg09307838	chr4:120376055	NA	0.78	10.53	0.57	1.83e-21	Corneal astigmatism;
SARC	cis	rs9398803	0.865	rs1361108	chr6:126767600	C/T	cg19875578	chr6:126661172	C6orf173	0.62	8.51	0.49	2.2e-15	Male-pattern baldness;
SARC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg06873352	chr17:61820015	STRADA	0.53	6.82	0.41	7.72e-11	Prudent dietary pattern;
SARC	cis	rs4481887	0.854	rs4534423	chr1:248474993	G/C	cg13385794	chr1:248469461	NA	0.36	5.43	0.34	1.4e-7	Common traits (Other);
SARC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg20102877	chr2:27665638	KRTCAP3	-0.37	-5.25	-0.33	3.44e-7	Total body bone mineral density;
SARC	cis	rs941408	1.000	rs1640273	chr19:2803227	C/T	cg00079169	chr19:2811669	THOP1	0.46	5.05	0.31	8.92e-7	Total cholesterol levels;
SARC	cis	rs11997175	0.624	rs4355732	chr8:33676920	A/C	ch.8.33884649F	chr8:33765107	NA	0.61	8.17	0.47	2.01e-14	Body mass index;
SARC	cis	rs77669868	0.929	rs3782007	chr11:114066438	A/G	cg01914181	chr11:114070210	ZBTB16	-0.46	-5.85	-0.36	1.69e-8	Monocyte percentage of white cells;
SARC	cis	rs7223966	0.921	rs34699959	chr17:61960720	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-5.91	-0.36	1.23e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs936229	0.798	rs1869959	chr15:75147332	A/C	cg14664628	chr15:75095509	CSK	-0.97	-12.9	-0.65	4.35e-29	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs72781680	0.560	rs72781698	chr2:24271506	C/T	cg08917208	chr2:24149416	ATAD2B	0.66	6.39	0.39	8.72e-10	Lymphocyte counts;
SARC	cis	rs12950390	0.853	rs11655336	chr17:45858836	A/G	cg03474202	chr17:45855739	NA	0.42	6.69	0.4	1.63e-10	IgG glycosylation;
SARC	cis	rs9858542	0.903	rs35999162	chr3:49597230	C/G	cg07274523	chr3:49395745	GPX1	0.51	5.99	0.37	7.84e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs9916302	0.851	rs7220650	chr17:37487168	A/G	cg20243544	chr17:37824526	PNMT	-0.54	-6.54	-0.39	3.94e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg11644478	chr21:40555479	PSMG1	1.04	14.42	0.69	4.01e-34	Cognitive function;
SARC	cis	rs12200560	0.505	rs60879781	chr6:97075466	A/T	cg06623918	chr6:96969491	KIAA0776	0.45	5.12	0.32	6.36e-7	Coronary heart disease;
SARC	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg13175981	chr1:150552382	MCL1	-0.54	-6.82	-0.41	7.54e-11	Tonsillectomy;
SARC	cis	rs7635838	1.000	rs7635838	chr3:11412604	A/G	cg00170343	chr3:11313890	ATG7	0.51	6.64	0.4	2.15e-10	HDL cholesterol;
SARC	cis	rs16976116	0.901	rs56328329	chr15:55502977	A/T	cg17854078	chr15:55489399	RSL24D1	0.66	6.53	0.39	4.18e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4803468	1.000	rs2241711	chr19:41911980	T/C	cg08477640	chr19:41863820	B9D2	0.46	5.85	0.36	1.64e-8	Height;
SARC	cis	rs72792276	0.908	rs3828656	chr5:127487535	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.68	6.18	0.38	2.85e-9	Red cell distribution width;
SARC	cis	rs2204008	0.658	rs11181310	chr12:38315963	C/A	cg26384229	chr12:38710491	ALG10B	0.85	12.26	0.63	5.36e-27	Bladder cancer;
SARC	cis	rs9399137	0.507	rs11154791	chr6:135379148	A/G	cg24558204	chr6:135376177	HBS1L	0.65	8.35	0.48	6.09e-15	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs2112347	0.502	rs34342	chr5:74934213	A/C	cg19683494	chr5:74908142	NA	-0.54	-4.96	-0.31	1.37e-6	Body mass index (joint analysis main effects and smoking interaction);Waist circumference;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Hip circumference;Body mass index;Body mass index in physically active individuals;Obesity;
SARC	cis	rs4969178	0.965	rs16971105	chr17:76393975	G/T	cg20026190	chr17:76395443	PGS1	0.39	5.24	0.32	3.6e-7	HDL cholesterol levels;
SARC	trans	rs561341	0.882	rs563539	chr17:30307958	A/G	cg20587970	chr11:113659929	NA	-1.22	-12.4	-0.63	1.95e-27	Hip circumference adjusted for BMI;
SARC	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg15320075	chr8:145703422	NA	0.6	8.29	0.48	8.75e-15	Age at first birth;
SARC	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg10435706	chr6:150039699	LATS1	0.36	4.81	0.3	2.7e-6	Lung cancer;
SARC	trans	rs208520	0.526	rs9363522	chr6:66816642	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-21.5	-0.82	3.05e-57	Exhaled nitric oxide output;
SARC	cis	rs10870270	0.830	rs11146269	chr10:133761820	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.49	-5.64	-0.35	4.83e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg00933542	chr6:150070202	PCMT1	0.31	5.37	0.33	1.91e-7	Lung cancer;
SARC	cis	rs12912251	1.000	rs12903120	chr15:38988097	G/T	cg01338139	chr15:38987640	C15orf53	-0.46	-5.42	-0.33	1.52e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
SARC	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg04944784	chr2:26401820	FAM59B	-0.47	-5.78	-0.35	2.43e-8	Gut microbiome composition (summer);
SARC	cis	rs854765	0.647	rs721669	chr17:18005073	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.43	5.3	0.33	2.73e-7	Total body bone mineral density;
SARC	cis	rs4853036	0.951	rs10185266	chr2:70152407	C/G	cg02498382	chr2:70120550	SNRNP27	-0.38	-5.19	-0.32	4.55e-7	Colorectal or endometrial cancer;
SARC	cis	rs698833	0.561	rs696597	chr2:44722553	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	5.2	0.32	4.41e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg09359103	chr1:154839909	KCNN3	-0.43	-7.0	-0.42	2.72e-11	Prostate cancer;
SARC	cis	rs2011503	1.000	rs75667002	chr19:19592232	T/A	cg03709012	chr19:19516395	GATAD2A	0.63	5.55	0.34	7.94e-8	Bipolar disorder;
SARC	cis	rs2033732	0.706	rs12679039	chr8:85064095	G/A	cg05716166	chr8:85095498	RALYL	0.47	5.62	0.35	5.51e-8	Body mass index;
SARC	cis	rs2645694	0.626	rs2703120	chr4:77822470	G/A	cg10057126	chr4:77819792	ANKRD56	0.43	6.51	0.39	4.5e-10	Emphysema distribution in smoking;
SARC	cis	rs12347191	0.500	rs907579	chr9:100622723	G/T	cg13688889	chr9:100608707	NA	-0.48	-5.01	-0.31	1.08e-6	Orofacial clefts;
SARC	cis	rs2882667	0.652	rs6596463	chr5:138444926	A/G	cg04439458	chr5:138467593	SIL1	-0.28	-5.04	-0.31	9.23e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs4481887	0.927	rs4578248	chr1:248434069	G/A	cg13385794	chr1:248469461	NA	0.32	4.8	0.3	2.87e-6	Common traits (Other);
SARC	cis	rs2073300	0.609	rs74809795	chr20:23372383	A/C	cg12062639	chr20:23401060	NAPB	0.95	6.5	0.39	4.74e-10	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg13206674	chr6:150067644	NUP43	0.45	5.86	0.36	1.53e-8	Lung cancer;
SARC	cis	rs7940866	0.809	rs2324317	chr11:130877142	T/C	cg12179176	chr11:130786555	SNX19	0.62	8.24	0.48	1.24e-14	Schizophrenia;
SARC	trans	rs7824557	0.527	rs10109537	chr8:11239640	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.39	-0.39	8.91e-10	Retinal vascular caliber;
SARC	cis	rs6582630	0.532	rs1589394	chr12:38419700	A/C	cg13010199	chr12:38710504	ALG10B	0.6	7.51	0.44	1.23e-12	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs10992471	0.603	rs1121978	chr9:95140351	T/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.49	-0.34	1.06e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	trans	rs9929218	0.551	rs7201437	chr16:68727130	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.8	13.0	0.65	2.04e-29	Colorectal cancer;
SARC	cis	rs4727443	0.966	rs66748925	chr7:99589843	A/G	cg22004693	chr7:99632812	ZKSCAN1	0.62	8.03	0.47	4.9e-14	Interstitial lung disease;
SARC	cis	rs8044868	0.530	rs2287999	chr16:72059149	A/G	cg16558253	chr16:72132732	DHX38	-0.41	-6.11	-0.37	4.2e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
SARC	trans	rs637571	0.522	rs649000	chr11:65742933	T/C	cg17712092	chr4:129076599	LARP1B	0.68	9.06	0.51	5.54e-17	Eosinophil percentage of white cells;
SARC	cis	rs8027181	0.959	rs11631352	chr15:73086473	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	-0.4	-5.34	-0.33	2.21e-7	Triglyceride levels;
SARC	trans	rs561341	0.883	rs2074102	chr17:30228884	G/A	cg20587970	chr11:113659929	NA	-1.03	-9.65	-0.53	9.56e-19	Hip circumference adjusted for BMI;
SARC	cis	rs6138458	1.000	rs6114981	chr20:24974401	C/T	cg26195577	chr20:24973756	C20orf3	-0.91	-9.96	-0.55	1.07e-19	Blood protein levels;
SARC	cis	rs921968	0.584	rs2305833	chr2:219305404	G/C	cg02176678	chr2:219576539	TTLL4	0.36	5.45	0.34	1.28e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs1152591	0.729	rs1255988	chr14:64657684	C/A	cg23250157	chr14:64679961	SYNE2	0.51	7.6	0.45	7.13e-13	Atrial fibrillation;
SARC	cis	rs9309473	1.000	rs2421555	chr2:73816955	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-5.47	-0.34	1.18e-7	Metabolite levels;
SARC	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	11.0	0.58	6.29e-23	Alzheimer's disease;
SARC	cis	rs854765	0.547	rs7209003	chr17:17907393	T/A	cg04398451	chr17:18023971	MYO15A	-0.44	-6.34	-0.38	1.18e-9	Total body bone mineral density;
SARC	cis	rs7524258	0.868	rs6577428	chr1:7314655	C/T	cg07173049	chr1:7289937	CAMTA1	-0.34	-6.41	-0.39	8.21e-10	Tourette's syndrome or obsessive-compulsive disorder;
SARC	cis	rs1348850	0.519	rs10201883	chr2:178471407	T/C	cg23306229	chr2:178417860	TTC30B	0.78	7.28	0.43	4.99e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7552404	0.727	rs61770533	chr1:76306490	C/G	cg03433033	chr1:76189801	ACADM	0.48	6.01	0.37	7.13e-9	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs8141529	0.748	rs6005936	chr22:29289250	T/C	cg15103426	chr22:29168792	CCDC117	0.67	8.7	0.5	6.02e-16	Lymphocyte counts;
SARC	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg26681399	chr22:41777847	TEF	-0.49	-5.29	-0.33	2.77e-7	Vitiligo;
SARC	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg23758822	chr17:41437982	NA	0.89	11.22	0.59	1.19e-23	Menopause (age at onset);
SARC	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg22903657	chr4:1355424	KIAA1530	-0.33	-4.85	-0.3	2.23e-6	Longevity;
SARC	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg11644478	chr21:40555479	PSMG1	-0.89	-11.4	-0.6	3.15e-24	Cognitive function;
SARC	cis	rs796364	0.951	rs11675980	chr2:201051150	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.62	-6.28	-0.38	1.65e-9	Schizophrenia;
SARC	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9818758	0.607	rs113186424	chr3:49272726	T/C	cg00383909	chr3:49044727	WDR6	0.67	5.88	0.36	1.39e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg03709012	chr19:19516395	GATAD2A	1.02	17.93	0.76	9.26e-46	Tonsillectomy;
SARC	cis	rs2204008	0.806	rs11520229	chr12:38246448	C/A	cg13010199	chr12:38710504	ALG10B	0.81	11.31	0.6	6.33e-24	Bladder cancer;
SARC	cis	rs11758351	1.000	rs16891397	chr6:26200256	C/T	cg23601095	chr6:26197514	HIST1H3D	0.62	5.38	0.33	1.8e-7	Gout;Renal underexcretion gout;
SARC	trans	rs9650657	0.707	rs7814757	chr8:10675188	T/C	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.66	-0.4	1.99e-10	Neuroticism;
SARC	cis	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg05084668	chr3:125655381	ALG1L	-0.47	-4.89	-0.31	1.88e-6	Blood pressure (smoking interaction);
SARC	cis	rs7481584	0.624	rs413368	chr11:3047646	C/G	cg05729581	chr11:3078854	CARS	0.57	7.42	0.44	2.13e-12	Calcium levels;
SARC	cis	rs634534	0.622	rs501353	chr11:65739549	T/G	cg04055107	chr11:65626734	MUS81;CFL1	0.45	5.63	0.35	5.04e-8	Sum eosinophil basophil counts;Eosinophil counts;
SARC	trans	rs11119805	0.649	rs11119816	chr1:211999488	A/G	cg02708296	chr12:69633319	CPSF6	-0.73	-8.0	-0.46	5.69e-14	Stearic acid (18:0) levels;
SARC	cis	rs7551222	0.752	rs16853958	chr1:204528344	A/C	cg20240347	chr1:204465584	NA	-0.33	-5.89	-0.36	1.36e-8	Schizophrenia;
SARC	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7474896	0.583	rs7071147	chr10:38003376	T/C	cg00409905	chr10:38381863	ZNF37A	-0.44	-4.82	-0.3	2.59e-6	Obesity (extreme);
SARC	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg03999130	chr15:45571217	NA	0.39	5.09	0.32	7.55e-7	Homoarginine levels;
SARC	cis	rs12478296	0.901	rs9653611	chr2:243006956	C/G	cg06360820	chr2:242988706	NA	-0.64	-6.02	-0.37	6.73e-9	Obesity-related traits;
SARC	cis	rs79149102	0.649	rs75985113	chr15:75379312	C/T	cg09165964	chr15:75287851	SCAMP5	-0.94	-8.14	-0.47	2.42e-14	Lung cancer;
SARC	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg11764359	chr7:65958608	NA	0.66	7.83	0.46	1.7e-13	Aortic root size;
SARC	cis	rs2463822	0.858	rs2463836	chr11:62126494	A/G	cg06239285	chr11:62104954	ASRGL1	0.89	9.16	0.51	2.79e-17	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs1559088	0.600	rs7259117	chr19:33550113	G/T	cg27124370	chr19:33622961	WDR88	0.47	6.11	0.37	4.15e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs3126085	0.935	rs12726613	chr1:152185500	C/G	cg03465714	chr1:152285911	FLG	0.46	5.5	0.34	1e-7	Atopic dermatitis;
SARC	cis	rs9457247	0.566	rs10946207	chr6:167456036	C/T	cg07741184	chr6:167504864	NA	0.36	6.9	0.41	4.89e-11	Crohn's disease;
SARC	cis	rs3126085	0.935	rs41267154	chr1:152286367	C/A	cg26876637	chr1:152193138	HRNR	-0.5	-5.58	-0.34	6.59e-8	Atopic dermatitis;
SARC	cis	rs6545883	0.718	rs3771260	chr2:61762384	G/T	cg15711740	chr2:61764176	XPO1	-0.43	-5.29	-0.33	2.77e-7	Tuberculosis;
SARC	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	11.03	0.59	4.93e-23	Alzheimer's disease;
SARC	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg03709012	chr19:19516395	GATAD2A	1.01	17.32	0.75	9.53e-44	Tonsillectomy;
SARC	cis	rs147144681	1	rs147144681	chr15:78900908	C/T	cg06917634	chr15:78832804	PSMA4	-0.54	-5.81	-0.36	2.03e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs748404	0.697	rs471122	chr15:43558574	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.53	-6.32	-0.38	1.28e-9	Lung cancer;
SARC	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.74	8.77	0.5	3.94e-16	Height;
SARC	cis	rs7666738	0.830	rs10029849	chr4:99059362	T/C	cg05340658	chr4:99064831	C4orf37	0.64	8.66	0.49	7.7e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs992157	0.835	rs10932769	chr2:219147245	T/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.69	-10.09	-0.55	4.32e-20	Colorectal cancer;
SARC	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg13849007	chr1:1677539	SLC35E2	0.37	4.81	0.3	2.66e-6	Body mass index;
SARC	cis	rs6089584	0.527	rs927589	chr20:60606363	A/G	cg13770153	chr20:60521292	NA	-0.38	-5.42	-0.33	1.46e-7	Body mass index;
SARC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.35	0.52	7.64e-18	Prudent dietary pattern;
SARC	cis	rs1865760	0.566	rs1800702	chr6:26086463	C/G	cg10373733	chr6:25993375	NA	0.45	5.43	0.34	1.4e-7	Height;
SARC	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg06221963	chr1:154839813	KCNN3	-0.5	-8.07	-0.47	3.68e-14	Prostate cancer;
SARC	cis	rs73198271	0.562	rs35432123	chr8:8671018	G/T	cg01851573	chr8:8652454	MFHAS1	0.41	5.03	0.31	9.96e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs9611565	0.802	rs9611577	chr22:41793090	T/G	cg17376030	chr22:41985996	PMM1	0.61	7.6	0.45	7.09e-13	Vitiligo;
SARC	cis	rs6570726	1.000	rs1935615	chr6:145921117	G/T	cg05347473	chr6:146136440	FBXO30	0.48	6.33	0.38	1.26e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7953249	1.000	rs7953249	chr12:121403724	A/G	cg02403541	chr12:121454288	C12orf43	0.55	7.09	0.42	1.62e-11	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs637571	0.522	rs493899	chr11:65747952	A/C	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.43	-5.36	-0.33	1.97e-7	Eosinophil percentage of white cells;
SARC	cis	rs13256369	0.802	rs11249888	chr8:8564934	T/C	cg17143192	chr8:8559678	CLDN23	0.52	5.83	0.36	1.82e-8	Obesity-related traits;
SARC	cis	rs4925386	0.765	rs6142737	chr20:60919800	C/G	cg24112000	chr20:60950667	NA	-0.35	-5.42	-0.33	1.51e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
SARC	trans	rs12310956	0.532	rs11052922	chr12:33957476	A/G	cg13010199	chr12:38710504	ALG10B	0.65	8.64	0.49	8.85e-16	Morning vs. evening chronotype;
SARC	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg24642844	chr7:1081250	C7orf50	-0.49	-5.45	-0.34	1.29e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs2303745	0.589	rs6512182	chr19:17399476	G/T	cg04248312	chr19:17393744	ANKLE1	-0.59	-7.56	-0.44	9.06e-13	Systemic lupus erythematosus;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg26878734	chr2:176793622	KIAA1715	0.51	7.08	0.42	1.65e-11	Thyroid stimulating hormone;
SARC	cis	rs4742903	0.935	rs726203	chr9:106906437	A/G	cg14250997	chr9:106856677	SMC2	0.49	6.43	0.39	7.06e-10	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs3126085	0.935	rs1858478	chr1:152257457	C/T	cg03465714	chr1:152285911	FLG	0.45	5.45	0.34	1.25e-7	Atopic dermatitis;
SARC	cis	rs12421382	0.659	rs11600110	chr11:109392438	A/G	cg27471124	chr11:109292789	C11orf87	0.39	5.36	0.33	2.04e-7	Schizophrenia;
SARC	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.76	-7.99	-0.46	6.06e-14	Platelet count;
SARC	cis	rs11122272	0.735	rs2486727	chr1:231539245	A/G	cg06096015	chr1:231504339	EGLN1	0.38	5.59	0.34	6.18e-8	Hemoglobin concentration;
SARC	cis	rs796364	0.806	rs1605900	chr2:200870197	C/G	cg23649088	chr2:200775458	C2orf69	0.6	5.36	0.33	2.03e-7	Schizophrenia;
SARC	trans	rs11098499	0.909	rs28632018	chr4:120386730	T/C	cg25214090	chr10:38739885	LOC399744	0.57	7.4	0.44	2.42e-12	Corneal astigmatism;
SARC	cis	rs7560272	0.538	rs4852975	chr2:73932465	C/T	cg20560298	chr2:73613845	ALMS1	0.46	6.09	0.37	4.55e-9	Schizophrenia;
SARC	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	8.82	0.5	2.77e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2120243	0.539	rs988587	chr3:157054271	A/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.41	4.93	0.31	1.58e-6	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs76419734	1.000	rs11733124	chr4:106677541	A/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.77	5.11	0.32	6.62e-7	Post bronchodilator FEV1;
SARC	cis	rs10791323	0.604	rs2853115	chr11:133707908	C/T	cg14349672	chr11:133703707	NA	0.39	5.71	0.35	3.51e-8	Childhood ear infection;
SARC	cis	rs13418717	0.793	rs7425345	chr2:127640396	C/T	cg25501666	chr2:127640322	NA	0.81	5.29	0.33	2.83e-7	Heart failure;
SARC	cis	rs11608355	0.846	rs35393419	chr12:109881809	C/T	cg05360138	chr12:110035743	NA	0.68	7.11	0.42	1.43e-11	Neuroticism;
SARC	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg11890956	chr21:40555474	PSMG1	-0.7	-9.3	-0.52	1.06e-17	Menarche (age at onset);
SARC	cis	rs7666738	0.515	rs13131874	chr4:98779183	A/G	cg05340658	chr4:99064831	C4orf37	0.59	7.24	0.43	6.56e-12	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1387259	0.859	rs2054905	chr12:48687951	A/G	cg24011408	chr12:48396354	COL2A1	0.48	5.6	0.34	5.92e-8	Obstructive sleep apnea trait (apnea hypopnea index);
SARC	cis	rs2204008	0.837	rs10876019	chr12:37985477	C/T	cg26384229	chr12:38710491	ALG10B	0.89	13.14	0.65	7.28e-30	Bladder cancer;
SARC	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg02951883	chr7:2050386	MAD1L1	-0.48	-6.11	-0.37	4.1e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs11997175	0.520	rs6994803	chr8:33817796	A/G	ch.8.33884649F	chr8:33765107	NA	0.46	5.97	0.36	8.86e-9	Body mass index;
SARC	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg08975724	chr8:8085496	FLJ10661	0.47	6.12	0.37	4.04e-9	Mood instability;
SARC	cis	rs73198271	0.740	rs964771	chr8:8650939	A/G	cg06636001	chr8:8085503	FLJ10661	0.51	5.59	0.34	6.22e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.85	12.17	0.62	1.09e-26	Chronic sinus infection;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	ch.21.33444458F	chr21:34522588	NA	-0.54	-6.34	-0.38	1.2e-9	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs7829975	0.514	rs2976926	chr8:8261624	T/C	cg15556689	chr8:8085844	FLJ10661	0.53	6.27	0.38	1.71e-9	Mood instability;
SARC	cis	rs11997175	0.679	rs10954935	chr8:33670379	C/G	ch.8.33884649F	chr8:33765107	NA	0.43	5.47	0.34	1.14e-7	Body mass index;
SARC	cis	rs28795989	0.795	rs17770447	chr4:7903572	T/C	cg18538662	chr4:7941764	AFAP1	-0.42	-5.38	-0.33	1.79e-7	Intraocular pressure;
SARC	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg07167872	chr1:205819463	PM20D1	0.41	4.75	0.3	3.59e-6	Parkinson's disease;
SARC	cis	rs9910055	0.530	rs7222349	chr17:42304644	C/T	cg19774624	chr17:42201019	HDAC5	-0.47	-6.3	-0.38	1.5e-9	Total body bone mineral density;
SARC	cis	rs9467773	0.620	rs2101582	chr6:26622734	C/T	cg11502198	chr6:26597334	ABT1	0.63	8.62	0.49	1.06e-15	Intelligence (multi-trait analysis);
SARC	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.35	-0.43	3.34e-12	Gut microbiome composition (summer);
SARC	cis	rs910316	0.967	rs11624893	chr14:75660124	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.5	-6.87	-0.41	5.71e-11	Height;
SARC	cis	rs7843479	0.930	rs2054713	chr8:21840534	A/G	cg17168535	chr8:21777572	XPO7	0.65	8.39	0.48	4.71e-15	Mean corpuscular volume;
SARC	cis	rs1008375	0.932	rs2302394	chr4:17641188	A/G	cg16339924	chr4:17578868	LAP3	0.66	8.74	0.5	4.73e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2239547	0.522	rs6773040	chr3:52935428	C/A	cg18404041	chr3:52824283	ITIH1	0.4	5.0	0.31	1.14e-6	Schizophrenia;
SARC	trans	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.11	-0.42	1.41e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs4642101	0.686	rs9822382	chr3:12828828	T/G	cg12400702	chr3:12838781	CAND2	-0.27	-5.44	-0.34	1.36e-7	QRS complex (12-leadsum);
SARC	cis	rs9303401	0.659	rs34468504	chr17:56648277	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.09	12.25	0.63	5.64e-27	Cognitive test performance;
SARC	cis	rs4481887	0.927	rs4244185	chr1:248486913	A/G	cg13385794	chr1:248469461	NA	0.34	5.11	0.32	6.55e-7	Common traits (Other);
SARC	cis	rs2011503	1.000	rs78176666	chr19:19636702	T/C	cg03709012	chr19:19516395	GATAD2A	0.6	5.29	0.33	2.8e-7	Bipolar disorder;
SARC	cis	rs9796	0.674	rs6492978	chr15:41317702	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.41	-5.73	-0.35	3.06e-8	Menopause (age at onset);
SARC	cis	rs6582630	0.537	rs1829579	chr12:38420555	A/G	cg13010199	chr12:38710504	ALG10B	0.75	10.24	0.56	1.42e-20	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7481584	0.624	rs511990	chr11:3052936	A/G	cg08508325	chr11:3079039	CARS	0.23	5.13	0.32	5.98e-7	Calcium levels;
SARC	trans	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg20587970	chr11:113659929	NA	-0.95	-9.49	-0.53	2.77e-18	Hip circumference adjusted for BMI;
SARC	cis	rs651907	0.557	rs62284198	chr3:101474699	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	6.48	0.39	5.38e-10	Colorectal cancer;
SARC	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg22903471	chr2:27725779	GCKR	0.57	8.96	0.51	1.04e-16	Total body bone mineral density;
SARC	cis	rs7666738	0.830	rs7659420	chr4:98878714	G/C	cg05340658	chr4:99064831	C4orf37	0.65	8.72	0.5	5.23e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs3859192	0.537	rs12309	chr17:38175462	C/T	cg17467752	chr17:38218738	THRA	-0.38	-4.79	-0.3	2.94e-6	White blood cell count;
SARC	cis	rs981844	0.775	rs62323979	chr4:154752935	T/C	cg14289246	chr4:154710475	SFRP2	0.58	6.57	0.4	3.22e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg18404041	chr3:52824283	ITIH1	-0.44	-6.58	-0.4	3.05e-10	Bipolar disorder;
SARC	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg25703541	chr22:24373054	LOC391322	-0.96	-15.52	-0.71	8.95e-38	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs910316	1.000	rs3742778	chr14:75538217	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.55	-8.06	-0.47	4.02e-14	Height;
SARC	cis	rs965469	0.895	rs6037592	chr20:3392950	T/G	cg25506879	chr20:3388711	C20orf194	-0.56	-5.74	-0.35	2.99e-8	IFN-related cytopenia;
SARC	trans	rs36093844	0.800	rs17817331	chr11:85595338	A/G	cg15359163	chr5:122429178	PRDM6	0.53	6.67	0.4	1.85e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs17376456	0.597	rs11135401	chr5:93365716	G/A	cg21475434	chr5:93447410	FAM172A	-0.59	-6.31	-0.38	1.39e-9	Diabetic retinopathy;
SARC	cis	rs28829049	0.570	rs12060125	chr1:19391108	A/G	cg13387374	chr1:19411106	UBR4	-0.42	-5.04	-0.31	9.32e-7	QRS duration in Tripanosoma cruzi seropositivity;
SARC	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg16680214	chr1:154839983	KCNN3	-0.37	-5.95	-0.36	9.76e-9	Prostate cancer;
SARC	cis	rs7626444	0.625	rs1403101	chr3:196485074	G/A	cg12930392	chr3:196481615	PAK2	0.25	4.9	0.31	1.79e-6	Monocyte count;
SARC	cis	rs6121246	0.697	rs6088856	chr20:30226543	C/G	cg13852791	chr20:30311386	BCL2L1	0.77	7.92	0.46	9.79e-14	Mean corpuscular hemoglobin;
SARC	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg04518342	chr5:131593106	PDLIM4	0.42	5.76	0.35	2.64e-8	Acylcarnitine levels;
SARC	cis	rs10782582	0.593	rs11578480	chr1:76208989	T/G	cg10523679	chr1:76189770	ACADM	-0.45	-5.49	-0.34	1.03e-7	Daytime sleep phenotypes;
SARC	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg19223190	chr17:80058835	NA	0.44	6.09	0.37	4.51e-9	Life satisfaction;
SARC	cis	rs3923518	1.000	rs13080116	chr3:38907223	T/C	cg15678707	chr3:39149194	GORASP1;TTC21A	0.48	5.24	0.32	3.55e-7	Migraine;
SARC	cis	rs7552404	0.924	rs1611823	chr1:76221706	T/G	cg10523679	chr1:76189770	ACADM	0.44	5.92	0.36	1.16e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7223966	1.000	rs7220821	chr17:61704147	G/A	cg00588841	chr17:61851480	DDX42;CCDC47	-0.59	-6.87	-0.41	5.81e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg06221963	chr1:154839813	KCNN3	-0.49	-8.06	-0.47	3.92e-14	Prostate cancer;
SARC	cis	rs11245387	0.633	rs2086945	chr10:126543993	C/T	cg08799069	chr10:126477246	METTL10	0.46	5.49	0.34	1.02e-7	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	cis	rs3126085	0.932	rs72696991	chr1:152250235	T/C	cg26876637	chr1:152193138	HRNR	-0.5	-5.14	-0.32	5.95e-7	Atopic dermatitis;
SARC	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg04546413	chr19:29218101	NA	0.63	8.42	0.48	3.93e-15	Methadone dose in opioid dependence;
SARC	cis	rs4689388	0.926	rs4308429	chr4:6294001	A/G	cg25554036	chr4:6271136	WFS1	0.39	6.42	0.39	7.48e-10	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs72781680	0.716	rs2551334	chr2:24000396	G/A	cg06627628	chr2:24431161	ITSN2	-0.54	-5.53	-0.34	8.36e-8	Lymphocyte counts;
SARC	cis	rs13161895	1.000	rs35135297	chr5:179469532	T/C	cg02702477	chr5:179499311	RNF130	0.65	6.2	0.38	2.6e-9	LDL cholesterol;
SARC	cis	rs861020	0.771	rs654470	chr1:210014093	A/T	cg09163369	chr1:210001066	C1orf107	0.49	4.93	0.31	1.58e-6	Orofacial clefts;
SARC	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/C	cg03060546	chr3:49711283	APEH	0.41	5.12	0.32	6.46e-7	Parkinson's disease;
SARC	cis	rs6087990	0.735	rs2424928	chr20:31388636	T/C	cg13636640	chr20:31349939	DNMT3B	0.77	12.01	0.62	3.49e-26	Ulcerative colitis;
SARC	trans	rs1973993	0.567	rs2800433	chr1:96998126	T/A	cg10631902	chr5:14652156	NA	0.45	7.56	0.44	9.09e-13	Weight;
SARC	cis	rs6138458	1.000	rs227615	chr20:24908721	T/C	cg26195577	chr20:24973756	C20orf3	0.87	9.5	0.53	2.73e-18	Blood protein levels;
SARC	cis	rs7772486	0.686	rs1569540	chr6:146069112	A/G	cg05347473	chr6:146136440	FBXO30	-0.52	-7.24	-0.43	6.47e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg03806693	chr22:41940476	POLR3H	-0.91	-11.84	-0.61	1.24e-25	Vitiligo;
SARC	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg01316550	chr5:56110833	MAP3K1	0.53	4.81	0.3	2.74e-6	Initial pursuit acceleration;
SARC	cis	rs17376456	0.569	rs10050364	chr5:93064127	T/C	cg21475434	chr5:93447410	FAM172A	0.65	6.38	0.39	9.35e-10	Diabetic retinopathy;
SARC	cis	rs11191270	0.590	rs12569901	chr10:104025410	C/G	cg15320455	chr10:103880129	LDB1	0.97	8.86	0.5	2.1e-16	Intelligence (multi-trait analysis);
SARC	cis	rs992157	0.710	rs10169718	chr2:219103580	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.66	-9.15	-0.51	2.86e-17	Colorectal cancer;
SARC	cis	rs7727544	0.606	rs17622208	chr5:131717050	G/A	cg24060327	chr5:131705240	SLC22A5	-0.45	-5.3	-0.33	2.64e-7	Blood metabolite levels;
SARC	cis	rs10791097	0.694	rs7940027	chr11:130745591	A/G	cg12179176	chr11:130786555	SNX19	0.75	11.37	0.6	3.98e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs11098499	0.954	rs12502423	chr4:120424172	A/C	cg24375607	chr4:120327624	NA	0.41	4.86	0.3	2.12e-6	Corneal astigmatism;
SARC	cis	rs9549367	0.713	rs3024776	chr13:113827075	A/G	cg18105134	chr13:113819100	PROZ	0.49	7.28	0.43	5.13e-12	Platelet distribution width;
SARC	cis	rs1865760	0.566	rs2032449	chr6:26026599	G/C	cg16482183	chr6:26056742	HIST1H1C	0.47	5.95	0.36	9.65e-9	Height;
SARC	trans	rs1814175	0.558	rs5025146	chr11:49795724	C/G	cg15704280	chr7:45808275	SEPT13	-0.88	-13.89	-0.67	2.29e-32	Height;
SARC	cis	rs2070488	0.965	rs2051216	chr3:38562288	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.82	-13.16	-0.65	5.94e-30	Electrocardiographic conduction measures;
SARC	cis	rs7481584	0.624	rs369461	chr11:3061992	A/G	cg25174290	chr11:3078921	CARS	-0.59	-8.45	-0.48	3.26e-15	Calcium levels;
SARC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg11905131	chr22:24372483	LOC391322	-0.52	-5.69	-0.35	3.83e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	trans	rs12310956	0.510	rs7302434	chr12:33886819	G/A	cg26384229	chr12:38710491	ALG10B	0.6	7.93	0.46	9.37e-14	Morning vs. evening chronotype;
SARC	cis	rs7666738	0.830	rs10014986	chr4:99000687	A/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7937682	0.793	rs7130440	chr11:111417779	A/G	cg09085632	chr11:111637200	PPP2R1B	0.65	8.61	0.49	1.07e-15	Primary sclerosing cholangitis;
SARC	cis	rs7824557	0.564	rs2572400	chr8:11234367	T/G	cg21775007	chr8:11205619	TDH	-0.64	-8.54	-0.49	1.75e-15	Retinal vascular caliber;
SARC	cis	rs2361718	0.521	rs2361724	chr17:78099114	G/A	cg23534315	chr17:78082725	GAA	0.43	5.36	0.33	2.01e-7	Yeast infection;
SARC	cis	rs854765	0.547	rs28537385	chr17:17902135	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.42	5.28	0.33	2.95e-7	Total body bone mineral density;
SARC	cis	rs8067545	0.616	rs203470	chr17:19858626	C/T	cg04132472	chr17:19861366	AKAP10	0.4	5.25	0.33	3.35e-7	Schizophrenia;
SARC	cis	rs916888	0.610	rs199453	chr17:44800946	C/T	cg15921436	chr17:44337874	NA	0.46	5.33	0.33	2.27e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs12960119	0.764	rs2169000	chr18:23605526	A/G	cg05533124	chr18:24443298	AQP4	0.45	4.9	0.31	1.81e-6	Rhegmatogenous retinal detachment;
SARC	cis	rs7223966	0.883	rs2955250	chr17:61959740	C/T	cg00588841	chr17:61851480	DDX42;CCDC47	-0.56	-6.13	-0.37	3.75e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg10523679	chr1:76189770	ACADM	-0.5	-6.48	-0.39	5.32e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg21782813	chr7:2030301	MAD1L1	0.43	6.88	0.41	5.32e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs9875589	0.509	rs1906538	chr3:14014169	C/T	cg19554555	chr3:13937349	NA	-0.4	-5.22	-0.32	4.03e-7	Ovarian reserve;
SARC	cis	rs722599	0.961	rs2359239	chr14:75326771	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.49	-6.47	-0.39	5.72e-10	IgG glycosylation;
SARC	cis	rs1355223	0.902	rs680727	chr11:34704446	A/C	cg18508148	chr11:34937573	PDHX;APIP	0.4	5.23	0.32	3.82e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	7.08	0.42	1.69e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7005380	0.531	rs13263147	chr8:120907469	T/A	cg21744203	chr8:120868354	DSCC1	-0.48	-5.03	-0.31	9.79e-7	Interstitial lung disease;
SARC	trans	rs9650657	0.648	rs7833945	chr8:10700266	T/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.06	-0.42	1.85e-11	Neuroticism;
SARC	trans	rs208520	1.000	rs208520	chr6:66952828	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.76	-8.44	-0.48	3.38e-15	Exhaled nitric oxide output;
SARC	cis	rs11122272	0.735	rs2790890	chr1:231514567	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-9.79	-0.54	3.66e-19	Hemoglobin concentration;
SARC	cis	rs11098499	0.874	rs9995277	chr4:120108603	G/A	cg09307838	chr4:120376055	NA	0.82	11.06	0.59	3.96e-23	Corneal astigmatism;
SARC	trans	rs1814175	0.645	rs28447324	chr11:50046629	C/A	cg03929089	chr4:120376271	NA	-0.81	-11.64	-0.61	5.33e-25	Height;
SARC	cis	rs763014	0.838	rs4984670	chr16:641044	A/G	cg07343612	chr16:622815	PIGQ	-0.53	-7.24	-0.43	6.31e-12	Height;
SARC	cis	rs9486719	1.000	rs2971603	chr6:97035418	C/T	cg18709589	chr6:96969512	KIAA0776	-0.51	-5.64	-0.35	4.81e-8	Migraine;Coronary artery disease;
SARC	cis	rs7666738	0.724	rs28451676	chr4:98966990	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs739401	0.572	rs404629	chr11:3077025	A/G	cg25174290	chr11:3078921	CARS	0.59	8.42	0.48	3.88e-15	Longevity;
SARC	cis	rs9911578	1.000	rs304296	chr17:56834229	G/T	cg12560992	chr17:57184187	TRIM37	0.88	12.06	0.62	2.46e-26	Intelligence (multi-trait analysis);
SARC	cis	rs870825	0.616	rs4386643	chr4:185624281	A/T	cg04058563	chr4:185651563	MLF1IP	0.82	11.42	0.6	2.8e-24	Blood protein levels;
SARC	cis	rs9309711	0.623	rs4641971	chr2:3481857	A/C	cg08493051	chr2:3487164	NA	0.43	5.49	0.34	1.03e-7	Neurofibrillary tangles;
SARC	cis	rs7312933	0.584	rs7974654	chr12:42630466	C/A	cg19980929	chr12:42632907	YAF2	0.47	6.76	0.4	1.1e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs796364	0.806	rs78527234	chr2:200913453	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.68	-5.72	-0.35	3.32e-8	Schizophrenia;
SARC	trans	rs11098499	0.738	rs34566984	chr4:120361270	G/A	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	cis	rs9303401	0.659	rs12602389	chr17:56779778	G/A	cg25039879	chr17:56429692	SUPT4H1	0.68	6.4	0.39	8.57e-10	Cognitive test performance;
SARC	trans	rs11098499	0.604	rs12642411	chr4:120580525	T/C	cg25214090	chr10:38739885	LOC399744	0.5	6.36	0.38	1.04e-9	Corneal astigmatism;
SARC	cis	rs959260	0.623	rs4542691	chr17:73326965	T/C	cg14668889	chr17:73230827	NUP85	-0.58	-7.25	-0.43	5.98e-12	Systemic lupus erythematosus;
SARC	cis	rs672059	1.000	rs546183	chr1:183157753	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.51	6.92	0.41	4.32e-11	Hypertriglyceridemia;
SARC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg26354017	chr1:205819088	PM20D1	-0.84	-11.92	-0.62	6.79e-26	Menarche (age at onset);
SARC	cis	rs9788721	0.640	rs1394371	chr15:78724469	C/T	cg18825076	chr15:78729989	IREB2	-0.51	-5.86	-0.36	1.54e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs2439831	0.850	rs60883262	chr15:44076503	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	8.6	0.49	1.17e-15	Lung cancer in ever smokers;
SARC	cis	rs7666738	0.830	rs6832568	chr4:98994061	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs17270561	0.609	rs9358887	chr6:25759406	G/T	cg17691542	chr6:26056736	HIST1H1C	0.58	7.12	0.42	1.31e-11	Iron status biomarkers;
SARC	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.46	-5.77	-0.35	2.54e-8	Gut microbiome composition (summer);
SARC	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg00933542	chr6:150070202	PCMT1	0.31	5.24	0.32	3.56e-7	Lung cancer;
SARC	cis	rs12142240	0.698	rs17413701	chr1:46818452	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-5.46	-0.34	1.22e-7	Menopause (age at onset);
SARC	cis	rs2228479	0.850	rs62056102	chr16:89941438	T/C	cg06558623	chr16:89946397	TCF25	0.88	6.16	0.37	3.08e-9	Skin colour saturation;
SARC	cis	rs9660992	0.710	rs55671824	chr1:205249814	G/A	cg21643547	chr1:205240462	TMCC2	-0.63	-8.04	-0.47	4.47e-14	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs4727027	0.866	rs35599790	chr7:148806012	C/T	cg23583168	chr7:148888333	NA	-0.75	-10.62	-0.57	9.78e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs763121	0.849	rs12004	chr22:38877461	T/G	cg21395723	chr22:39101663	GTPBP1	0.6	6.81	0.41	8.15e-11	Menopause (age at onset);
SARC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.72	7.45	0.44	1.79e-12	Platelet count;
SARC	cis	rs9473924	0.505	rs55653665	chr6:50812984	T/C	cg14470998	chr6:50812995	TFAP2B	0.68	6.01	0.37	7e-9	Body mass index;
SARC	cis	rs3806933	0.522	rs11241095	chr5:110439509	A/G	cg04022379	chr5:110408740	TSLP	0.7	8.8	0.5	3.22e-16	Eosinophilic esophagitis;
SARC	cis	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg14541582	chr5:601475	NA	-0.4	-5.05	-0.31	9.11e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs4742903	0.935	rs7853727	chr9:106990048	T/G	cg14250997	chr9:106856677	SMC2	0.39	4.93	0.31	1.53e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs12950390	0.853	rs17773010	chr17:45858297	C/T	cg03474202	chr17:45855739	NA	-0.43	-6.74	-0.4	1.22e-10	IgG glycosylation;
SARC	trans	rs11098499	0.909	rs79704848	chr4:120309351	T/A	cg25214090	chr10:38739885	LOC399744	0.55	7.14	0.42	1.15e-11	Corneal astigmatism;
SARC	cis	rs9790314	0.695	rs7637086	chr3:160836822	T/C	cg03342759	chr3:160939853	NMD3	-0.57	-7.22	-0.43	7.37e-12	Morning vs. evening chronotype;
SARC	cis	rs6981523	0.553	rs11783045	chr8:11056175	A/G	cg21775007	chr8:11205619	TDH	-0.42	-5.18	-0.32	4.77e-7	Neuroticism;
SARC	cis	rs2290159	0.706	rs7643321	chr3:12663233	A/G	cg23032965	chr3:12705835	RAF1	0.73	7.3	0.43	4.42e-12	Cholesterol, total;
SARC	cis	rs9303401	0.614	rs3087762	chr17:56568680	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.05	11.4	0.6	3.25e-24	Cognitive test performance;
SARC	cis	rs2235544	0.565	rs676562	chr1:54468638	C/G	cg10336722	chr1:54665764	CYB5RL;MRPL37	-0.39	-4.78	-0.3	3.15e-6	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
SARC	cis	rs1729951	0.575	rs12494558	chr3:136678781	C/G	cg15507776	chr3:136538369	TMEM22	0.52	5.76	0.35	2.66e-8	Neuroticism;
SARC	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	12.02	0.62	3.23e-26	Chronic sinus infection;
SARC	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg19223190	chr17:80058835	NA	-0.42	-5.73	-0.35	3.09e-8	Life satisfaction;
SARC	cis	rs11025523	1.000	rs11025523	chr11:20378124	A/G	cg19653624	chr11:20408972	PRMT3	0.52	4.87	0.3	2.1e-6	Obesity-related traits;
SARC	cis	rs7635838	0.596	rs13353463	chr3:11260221	T/C	cg00170343	chr3:11313890	ATG7	0.67	8.8	0.5	3.08e-16	HDL cholesterol;
SARC	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg23149560	chr2:74406255	MOBKL1B	0.48	4.76	0.3	3.33e-6	Gestational age at birth (maternal effect);
SARC	cis	rs11690935	0.959	rs6745143	chr2:172650382	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.98	-15.52	-0.71	8.81e-38	Schizophrenia;
SARC	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg12705353	chr12:122356852	WDR66	0.4	5.76	0.35	2.7e-8	Mean corpuscular volume;
SARC	cis	rs829883	0.934	rs249814	chr12:98892964	A/G	cg25150519	chr12:98850993	NA	0.71	9.49	0.53	2.82e-18	Colorectal adenoma (advanced);
SARC	cis	rs2404602	0.552	rs11634428	chr15:77084582	T/C	cg15268244	chr15:77196840	NA	0.44	4.87	0.3	2.04e-6	Blood metabolite levels;
SARC	cis	rs72781680	0.898	rs56303870	chr2:24086944	G/A	cg08917208	chr2:24149416	ATAD2B	0.75	7.33	0.43	3.77e-12	Lymphocyte counts;
SARC	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg11764359	chr7:65958608	NA	-0.79	-9.74	-0.54	5.08e-19	Aortic root size;
SARC	cis	rs8017423	0.967	rs11844225	chr14:90726676	G/A	cg20276874	chr14:90721474	PSMC1	-0.38	-5.31	-0.33	2.59e-7	Mortality in heart failure;
SARC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg18099408	chr3:52552593	STAB1	-0.4	-5.24	-0.32	3.56e-7	Electroencephalogram traits;
SARC	cis	rs1355223	0.902	rs1258468	chr11:34729731	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.32	-0.33	2.4e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs7089973	0.836	rs12765350	chr10:116635305	G/A	cg08188268	chr10:116634841	FAM160B1	0.36	5.74	0.35	2.86e-8	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs612683	0.517	rs3767832	chr1:100943100	A/G	cg06223162	chr1:101003688	GPR88	-0.25	-4.82	-0.3	2.64e-6	Breast cancer;
SARC	cis	rs10782582	0.632	rs11810154	chr1:76239973	C/G	cg10523679	chr1:76189770	ACADM	-0.44	-5.39	-0.33	1.71e-7	Daytime sleep phenotypes;
SARC	cis	rs11690935	0.959	rs10204501	chr2:172588865	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.99	-15.92	-0.72	4.25e-39	Schizophrenia;
SARC	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg12016809	chr21:47604291	C21orf56	-0.47	-5.63	-0.35	5.24e-8	Testicular germ cell tumor;
SARC	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg08859206	chr1:53392774	SCP2	0.36	5.22	0.32	3.96e-7	Monocyte count;
SARC	cis	rs9486715	1.000	rs6902835	chr6:97063005	C/G	cg18709589	chr6:96969512	KIAA0776	-0.57	-7.01	-0.42	2.48e-11	Headache;
SARC	cis	rs3743266	0.507	rs11637887	chr15:60765216	C/T	cg22293140	chr15:60689852	ANXA2	-0.53	-4.77	-0.3	3.27e-6	Menarche (age at onset);
SARC	cis	rs2594989	0.895	rs2442789	chr3:11540188	C/T	cg00170343	chr3:11313890	ATG7	0.54	5.36	0.33	2.01e-7	Circulating chemerin levels;
SARC	cis	rs9436747	0.740	rs1171265	chr1:66003252	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	-0.45	-5.13	-0.32	6.2e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs10465746	0.780	rs12145258	chr1:84401211	G/A	cg10977910	chr1:84465055	TTLL7	0.42	5.08	0.32	7.71e-7	Obesity-related traits;
SARC	cis	rs651907	0.557	rs13069443	chr3:101373305	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	6.18	0.38	2.83e-9	Colorectal cancer;
SARC	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg03575189	chr17:44344142	NA	0.61	5.84	0.36	1.78e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs950776	0.593	rs481134	chr15:78877563	C/T	cg22563815	chr15:78856949	CHRNA5	0.38	6.42	0.39	7.56e-10	Sudden cardiac arrest;
SARC	cis	rs155076	1.000	rs261430	chr13:21865242	C/T	cg25811766	chr13:21894605	NA	-0.53	-5.62	-0.35	5.32e-8	White matter hyperintensity burden;
SARC	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	7.38	0.44	2.71e-12	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs10936632	0.755	rs10804839	chr3:170071783	A/T	cg11886554	chr3:170076028	SKIL	0.39	4.83	0.3	2.51e-6	Prostate cancer;
SARC	cis	rs208520	0.909	rs55813840	chr6:67012508	A/C	cg07460842	chr6:66804631	NA	0.84	8.59	0.49	1.29e-15	Exhaled nitric oxide output;
SARC	cis	rs761746	0.960	rs5998035	chr22:31939612	G/A	cg15162869	chr22:32027605	PISD	-0.35	-4.91	-0.31	1.73e-6	Intelligence;
SARC	cis	rs67460515	0.529	rs11712713	chr3:160852471	A/G	cg04691961	chr3:161091175	C3orf57	-0.44	-5.29	-0.33	2.76e-7	Parkinson's disease;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg08265790	chr5:141704696	SPRY4	0.52	6.98	0.42	3.11e-11	Tetralogy of Fallot;
SARC	trans	rs7824557	0.688	rs2572397	chr8:11176403	G/A	cg08975724	chr8:8085496	FLJ10661	0.53	6.74	0.4	1.21e-10	Retinal vascular caliber;
SARC	cis	rs921968	0.612	rs573555	chr2:219348888	A/C	cg02176678	chr2:219576539	TTLL4	0.38	5.67	0.35	4.21e-8	Mean corpuscular hemoglobin concentration;
SARC	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg11965913	chr1:205819406	PM20D1	-0.49	-6.15	-0.37	3.36e-9	Menarche (age at onset);
SARC	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.59e-6	Depression;
SARC	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg11608241	chr8:8085544	FLJ10661	0.43	5.2	0.32	4.46e-7	Neuroticism;
SARC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.33	-5.0	-0.31	1.11e-6	Total body bone mineral density;
SARC	cis	rs10504229	0.871	rs56048296	chr8:58163781	C/T	cg22535103	chr8:58192502	C8orf71	-0.69	-8.38	-0.48	5.16e-15	Developmental language disorder (linguistic errors);
SARC	cis	rs7582180	0.663	rs10199518	chr2:100946041	G/A	cg14675211	chr2:100938903	LONRF2	0.5	7.44	0.44	1.93e-12	Intelligence (multi-trait analysis);
SARC	cis	rs7312933	0.510	rs10880223	chr12:42413443	G/A	cg01256987	chr12:42539512	GXYLT1	-0.39	-5.72	-0.35	3.21e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.48	5.98	0.36	8.29e-9	Tonsillectomy;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg12578182	chr17:41132637	AARSD1;RUNDC1	0.51	6.64	0.4	2.17e-10	Lung adenocarcinoma;
SARC	cis	rs1538970	1.000	rs4660852	chr1:45848931	A/C	cg05343316	chr1:45956843	TESK2	-0.69	-8.29	-0.48	9.29e-15	Platelet count;
SARC	cis	rs9916302	0.605	rs12938099	chr17:37612910	T/G	cg07936489	chr17:37558343	FBXL20	-0.75	-8.63	-0.49	9.98e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs60871478	0.541	rs56964970	chr7:910791	G/C	cg05535760	chr7:792225	HEATR2	-0.74	-6.86	-0.41	6.16e-11	Cerebrospinal P-tau181p levels;
SARC	cis	rs17095355	1.000	rs12246851	chr10:111726340	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.42	-4.76	-0.3	3.35e-6	Biliary atresia;
SARC	cis	rs4900538	0.963	rs1190554	chr14:102918686	T/C	cg18135206	chr14:102964638	TECPR2	0.66	9.0	0.51	8.08e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs12824058	0.831	rs11608406	chr12:130805866	G/C	cg26677194	chr12:130822605	PIWIL1	0.52	6.96	0.42	3.35e-11	Menopause (age at onset);
SARC	cis	rs1707322	0.721	rs6429575	chr1:46134216	G/C	cg06784218	chr1:46089804	CCDC17	0.36	6.25	0.38	1.93e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg05623727	chr3:50126028	RBM5	0.33	5.03	0.31	9.66e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6952808	0.609	rs34967784	chr7:1949507	T/G	cg21782813	chr7:2030301	MAD1L1	0.36	5.63	0.35	5.22e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs35851103	0.507	rs6601649	chr8:11857317	A/G	cg03403963	chr8:11986501	LOC392196;FAM66D	-0.35	-5.06	-0.31	8.56e-7	Neuroticism;
SARC	cis	rs13108904	0.604	rs13103860	chr4:1320120	G/A	cg22903657	chr4:1355424	KIAA1530	-0.39	-5.27	-0.33	3.06e-7	Obesity-related traits;
SARC	cis	rs739401	0.611	rs12284275	chr11:3024384	T/C	cg05729581	chr11:3078854	CARS	-0.49	-6.25	-0.38	1.89e-9	Longevity;
SARC	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg13126279	chr21:47581558	C21orf56	0.44	5.38	0.33	1.78e-7	Testicular germ cell tumor;
SARC	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg25072359	chr17:41440525	NA	0.5	5.87	0.36	1.46e-8	Menopause (age at onset);
SARC	cis	rs6088580	0.634	rs6059866	chr20:33075810	A/C	cg24642439	chr20:33292090	TP53INP2	0.65	7.99	0.46	6.06e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs6867913	0.951	rs4912799	chr5:141453720	G/C	cg15672022	chr5:141805772	NA	-0.35	-4.86	-0.3	2.19e-6	Asthma;
SARC	cis	rs12291225	0.753	rs1431374	chr11:14303975	T/C	cg19336497	chr11:14380999	RRAS2	-0.41	-6.86	-0.41	6.02e-11	Sense of smell;
SARC	cis	rs67311347	1.000	rs6795475	chr3:40489281	A/G	cg24209194	chr3:40518798	ZNF619	0.61	7.89	0.46	1.2e-13	Renal cell carcinoma;
SARC	cis	rs881375	0.967	rs10435844	chr9:123668199	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	4.87	0.3	2.03e-6	Rheumatoid arthritis;
SARC	cis	rs2251381	0.722	rs2776252	chr21:30531705	G/A	cg08807101	chr21:30365312	RNF160	0.77	10.21	0.56	1.76e-20	Selective IgA deficiency;
SARC	cis	rs9916302	0.904	rs4239222	chr17:37696235	A/C	cg07936489	chr17:37558343	FBXL20	0.67	8.7	0.5	5.94e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs12142240	0.698	rs41294476	chr1:46818374	C/A	cg10495392	chr1:46806563	NSUN4	0.65	6.83	0.41	7.25e-11	Menopause (age at onset);
SARC	cis	rs4132509	0.793	rs6694738	chr1:243715210	C/A	cg21452805	chr1:244014465	NA	0.57	5.61	0.34	5.84e-8	RR interval (heart rate);
SARC	cis	rs11025559	0.796	rs11603462	chr11:20412180	C/A	cg19653624	chr11:20408972	PRMT3	-0.56	-6.23	-0.38	2.2e-9	Pursuit maintenance gain;
SARC	cis	rs883565	0.569	rs784515	chr3:39163848	C/T	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.43	-5.06	-0.31	8.5e-7	Handedness;
SARC	cis	rs6977660	0.714	rs17141882	chr7:19790217	C/T	cg05791153	chr7:19748676	TWISTNB	0.73	6.43	0.39	7.21e-10	Thyroid stimulating hormone;
SARC	cis	rs826838	0.967	rs12823908	chr12:38845686	T/C	cg13010199	chr12:38710504	ALG10B	0.78	11.08	0.59	3.29e-23	Heart rate;
SARC	cis	rs4889855	0.556	rs11651818	chr17:78530300	A/G	cg17956530	chr17:78667699	RPTOR	0.42	4.85	0.3	2.26e-6	Fractional excretion of uric acid;
SARC	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs317689	0.918	rs581911	chr12:69738293	C/T	cg14784868	chr12:69753453	YEATS4	0.44	4.75	0.3	3.55e-6	Response to diuretic therapy;
SARC	cis	rs9322193	0.516	rs1999632	chr6:150187873	C/T	cg11878867	chr6:150167359	LRP11	-0.45	-5.14	-0.32	5.71e-7	Lung cancer;
SARC	cis	rs9913156	0.793	rs55682338	chr17:4582183	G/A	cg00122941	chr17:4613640	ARRB2	0.86	9.5	0.53	2.69e-18	Lymphocyte counts;
SARC	cis	rs4481887	0.772	rs4916127	chr1:248466615	A/G	cg00666640	chr1:248458726	OR2T12	0.37	6.3	0.38	1.43e-9	Common traits (Other);
SARC	cis	rs10504073	0.647	rs28685207	chr8:50003484	A/G	cg00325661	chr8:49890786	NA	0.5	6.85	0.41	6.69e-11	Blood metabolite ratios;
SARC	cis	rs7959452	0.503	rs7300266	chr12:69654187	A/G	cg14784868	chr12:69753453	YEATS4	0.39	5.1	0.32	6.94e-7	Blood protein levels;
SARC	cis	rs17345786	1.000	rs3804775	chr3:101306507	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.46	5.06	0.31	8.47e-7	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2276314	0.857	rs28791905	chr18:33602213	G/A	cg05985134	chr18:33552581	C18orf21	0.67	6.91	0.41	4.5e-11	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg26769984	chr7:1090371	C7orf50	0.52	5.29	0.33	2.8e-7	Bronchopulmonary dysplasia;
SARC	cis	rs9419702	0.568	rs7920966	chr10:133555185	G/T	cg04492858	chr10:133558786	NA	0.31	4.86	0.3	2.18e-6	Survival in rectal cancer;
SARC	cis	rs1008375	1.000	rs10939738	chr4:17604295	G/C	cg16339924	chr4:17578868	LAP3	0.67	8.83	0.5	2.6e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2204008	0.720	rs11180923	chr12:38255172	A/T	cg26384229	chr12:38710491	ALG10B	0.91	13.79	0.67	4.83e-32	Bladder cancer;
SARC	cis	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg07777115	chr5:623756	CEP72	-0.62	-5.56	-0.34	7.5e-8	Obesity-related traits;
SARC	cis	rs4141404	0.923	rs2413046	chr22:31665909	C/A	cg02404636	chr22:31891804	SFI1	-0.49	-5.24	-0.32	3.53e-7	Paclitaxel-induced neuropathy;
SARC	cis	rs6690583	0.623	rs893620	chr1:85425821	T/C	cg22153463	chr1:85462885	MCOLN2	0.71	6.83	0.41	7.4e-11	Serum sulfate level;
SARC	cis	rs11264799	0.603	rs2208751	chr1:157590928	G/T	cg18268488	chr1:157545234	FCRL4	-0.29	-4.85	-0.3	2.3e-6	IgA nephropathy;
SARC	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg03452623	chr4:187889614	NA	-0.77	-12.14	-0.62	1.32e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs986417	1.000	rs1254265	chr14:60840478	T/C	cg27398547	chr14:60952738	C14orf39	-0.99	-8.56	-0.49	1.56e-15	Gut microbiota (bacterial taxa);
SARC	cis	rs2197308	0.605	rs2387437	chr12:37919367	T/C	cg26384229	chr12:38710491	ALG10B	0.87	12.53	0.63	6.93e-28	Morning vs. evening chronotype;
SARC	cis	rs9359856	0.564	rs10484885	chr6:90395016	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.58	-4.73	-0.3	3.81e-6	Bipolar disorder;
SARC	cis	rs10504073	0.669	rs62507253	chr8:50028836	C/T	cg00325661	chr8:49890786	NA	0.53	7.16	0.42	1.02e-11	Blood metabolite ratios;
SARC	cis	rs2562456	0.917	rs10420016	chr19:21688602	C/G	cg00806126	chr19:22604979	ZNF98	0.47	4.85	0.3	2.27e-6	Pain;
SARC	cis	rs2153535	0.580	rs6597327	chr6:8482157	G/A	cg21535247	chr6:8435926	SLC35B3	0.55	6.97	0.42	3.17e-11	Motion sickness;
SARC	cis	rs13082711	0.911	rs13089870	chr3:27447626	C/T	cg02860705	chr3:27208620	NA	0.44	5.8	0.36	2.18e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs2559856	1.000	rs2695291	chr12:102087543	G/A	cg12924262	chr12:102091054	CHPT1	0.57	7.73	0.45	3.16e-13	Blood protein levels;
SARC	cis	rs2624839	0.704	rs13064381	chr3:50233317	C/T	cg24110177	chr3:50126178	RBM5	-0.57	-7.21	-0.43	7.59e-12	Intelligence (multi-trait analysis);
SARC	cis	rs2952156	0.920	rs12940986	chr17:37836581	A/G	cg07936489	chr17:37558343	FBXL20	0.44	5.7	0.35	3.53e-8	Asthma;
SARC	cis	rs820218	0.728	rs820151	chr17:73615983	G/A	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.5	6.21	0.38	2.37e-9	Rotator cuff tears;
SARC	cis	rs6696846	0.765	rs4394715	chr1:205108393	T/G	cg00857998	chr1:205179979	DSTYK	0.5	6.5	0.39	4.78e-10	Red blood cell count;
SARC	cis	rs7772486	0.790	rs2243665	chr6:146208120	A/C	cg23711669	chr6:146136114	FBXO30	0.79	11.99	0.62	3.98e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3099143	0.901	rs28405838	chr15:77226053	C/G	cg21673338	chr15:77095150	SCAPER	-0.68	-5.37	-0.33	1.91e-7	Recalcitrant atopic dermatitis;
SARC	cis	rs6815814	0.950	rs45588337	chr4:38807328	A/G	cg09316306	chr4:38807337	TLR1	0.5	5.16	0.32	5.23e-7	Breast cancer;
SARC	trans	rs13325613	0.915	rs34289272	chr3:46263244	C/T	cg12387106	chr12:133178249	NA	0.84	6.58	0.4	3e-10	Monocyte count;
SARC	cis	rs7208859	0.673	rs3816780	chr17:29161358	C/T	cg13385521	chr17:29058706	SUZ12P	0.81	6.78	0.41	9.67e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs1348850	0.750	rs55792594	chr2:178496468	C/T	cg23306229	chr2:178417860	TTC30B	0.5	5.51	0.34	9.6e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg09847027	chr10:28885431	WAC	0.51	6.84	0.41	6.72e-11	Thyroid stimulating hormone;
SARC	cis	rs910316	1.000	rs4322591	chr14:75600697	C/T	cg11812906	chr14:75593930	NEK9	0.87	13.87	0.67	2.61e-32	Height;
SARC	cis	rs6088590	0.965	rs13040449	chr20:33358901	T/A	cg24642439	chr20:33292090	TP53INP2	0.88	12.31	0.63	3.67e-27	Coronary artery disease;
SARC	cis	rs3796352	0.686	rs1560333	chr3:53138254	T/C	cg15956490	chr3:53032818	SFMBT1	-0.65	-4.81	-0.3	2.73e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs155076	1.000	rs261423	chr13:21852331	A/C	cg06138931	chr13:21896616	NA	-0.38	-4.98	-0.31	1.25e-6	White matter hyperintensity burden;
SARC	cis	rs7945705	0.818	rs2742537	chr11:8908389	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-6.9	-0.41	4.97e-11	Hemoglobin concentration;
SARC	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.58	5.5	0.34	9.77e-8	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg04267008	chr7:1944627	MAD1L1	-0.57	-6.45	-0.39	6.46e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2073300	0.609	rs6137938	chr20:23389127	C/G	cg16736954	chr20:23401023	NAPB	0.76	4.83	0.3	2.53e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs6580649	0.883	rs4760621	chr12:48561262	A/G	cg24011408	chr12:48396354	COL2A1	0.47	5.39	0.33	1.72e-7	Lung cancer;
SARC	cis	rs3820928	0.839	rs12151848	chr2:227859326	G/A	cg11843606	chr2:227700838	RHBDD1	-0.5	-6.12	-0.37	3.84e-9	Pulmonary function;
SARC	cis	rs898097	0.841	rs11656358	chr17:80853956	G/A	cg20578329	chr17:80767326	TBCD	-0.5	-6.83	-0.41	7.24e-11	Breast cancer;
SARC	cis	rs12586317	0.531	rs60049741	chr14:35719842	G/A	cg16230307	chr14:35515116	FAM177A1	0.44	5.32	0.33	2.47e-7	Psoriasis;
SARC	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg21782813	chr7:2030301	MAD1L1	0.37	5.92	0.36	1.14e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs11122272	0.735	rs2011357	chr1:231480208	A/G	cg06096015	chr1:231504339	EGLN1	0.38	5.57	0.34	6.88e-8	Hemoglobin concentration;
SARC	cis	rs7833790	0.700	rs28390260	chr8:82769175	A/T	cg06027949	chr8:82754900	SNX16	0.49	6.12	0.37	4.01e-9	Diastolic blood pressure;
SARC	cis	rs7044106	0.762	rs10760107	chr9:123383630	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.68	8.53	0.49	1.86e-15	Hip circumference adjusted for BMI;
SARC	cis	rs818427	0.555	rs410701	chr5:112206416	G/A	cg07820702	chr5:112228657	REEP5	0.43	4.77	0.3	3.21e-6	Total body bone mineral density;
SARC	cis	rs10911363	0.573	rs2761580	chr1:183516989	A/T	cg09173681	chr1:183549694	NCF2	0.31	5.02	0.31	1.02e-6	Systemic lupus erythematosus;
SARC	cis	rs13191362	1.000	rs67025553	chr6:163011552	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.5	0.34	1.01e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs6840360	1.000	rs4696291	chr4:152631637	G/A	cg22705602	chr4:152727874	NA	-0.38	-6.56	-0.4	3.37e-10	Intelligence (multi-trait analysis);
SARC	cis	rs4969178	0.965	rs8071884	chr17:76398058	C/G	cg02836325	chr17:76403955	PGS1	0.32	4.81	0.3	2.66e-6	HDL cholesterol levels;
SARC	cis	rs7246657	0.882	rs13345148	chr19:37819631	A/G	cg23950597	chr19:37808831	NA	-0.54	-5.46	-0.34	1.24e-7	Coronary artery calcification;
SARC	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg21724239	chr8:58056113	NA	0.57	6.08	0.37	4.82e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4481887	0.927	rs4551626	chr1:248489128	G/T	cg00666640	chr1:248458726	OR2T12	0.35	5.75	0.35	2.83e-8	Common traits (Other);
SARC	cis	rs2197308	0.667	rs11181073	chr12:37898543	A/G	cg26384229	chr12:38710491	ALG10B	0.88	12.62	0.64	3.66e-28	Morning vs. evening chronotype;
SARC	cis	rs5758659	0.652	rs5751195	chr22:42380001	A/C	cg04733989	chr22:42467013	NAGA	0.47	6.35	0.38	1.14e-9	Cognitive function;
SARC	cis	rs911555	0.755	rs34411783	chr14:103900639	G/A	cg12935359	chr14:103987150	CKB	0.41	5.51	0.34	9.4e-8	Intelligence (multi-trait analysis);
SARC	cis	rs611744	0.647	rs2848620	chr8:109249551	G/T	cg21045802	chr8:109455806	TTC35	0.6	7.65	0.45	5.26e-13	Dupuytren's disease;
SARC	cis	rs10791097	0.667	rs2155358	chr11:130740357	T/C	cg09137382	chr11:130731461	NA	0.31	4.77	0.3	3.2e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg09320746	chr13:44361019	ENOX1	0.49	6.25	0.38	1.91e-9	Lung adenocarcinoma;
SARC	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg08280861	chr8:58055591	NA	0.6	5.28	0.33	2.92e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs3815700	1.000	rs7247420	chr19:33096786	G/A	cg02997394	chr19:33096574	ANKRD27	0.77	8.21	0.47	1.53e-14	Eosinophilic esophagitis;
SARC	cis	rs7084402	0.967	rs1658419	chr10:60332812	A/C	cg07615347	chr10:60278583	BICC1	0.58	8.47	0.49	2.76e-15	Refractive error;
SARC	cis	rs7429990	0.896	rs34448818	chr3:47841312	G/A	cg11946769	chr3:48343235	NME6	0.69	6.86	0.41	6.28e-11	Educational attainment (years of education);
SARC	cis	rs929354	0.772	rs3802124	chr7:156970609	G/A	cg05182265	chr7:156933206	UBE3C	-0.33	-5.08	-0.32	7.67e-7	Body mass index;
SARC	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg09373136	chr17:61933544	TCAM1	0.37	5.05	0.31	8.87e-7	Prudent dietary pattern;
SARC	cis	rs8070128	0.637	rs4925133	chr17:17884801	A/G	cg04398451	chr17:18023971	MYO15A	-0.43	-5.76	-0.35	2.69e-8	Total body bone mineral density;
SARC	cis	rs6690583	0.573	rs75119114	chr1:85451385	A/C	cg22153463	chr1:85462885	MCOLN2	0.72	6.96	0.42	3.33e-11	Serum sulfate level;
SARC	trans	rs1941687	0.563	rs7238931	chr18:31334993	G/A	cg27147174	chr7:100797783	AP1S1	-0.51	-6.48	-0.39	5.35e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
SARC	cis	rs708547	0.836	rs1315005	chr4:57858237	C/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.52	-6.3	-0.38	1.5e-9	Response to bleomycin (chromatid breaks);
SARC	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg25894440	chr7:65020034	NA	0.78	5.89	0.36	1.34e-8	Diabetic kidney disease;
SARC	cis	rs763121	0.785	rs5750646	chr22:39013830	T/C	cg21395723	chr22:39101663	GTPBP1	0.54	6.34	0.38	1.15e-9	Menopause (age at onset);
SARC	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg13939156	chr17:80058883	NA	-0.44	-6.88	-0.41	5.45e-11	Life satisfaction;
SARC	cis	rs6977660	0.598	rs72591445	chr7:19773035	G/A	cg07541023	chr7:19748670	TWISTNB	0.93	8.12	0.47	2.77e-14	Thyroid stimulating hormone;
SARC	cis	rs7568458	0.811	rs3755015	chr2:85764041	G/A	cg17127132	chr2:85788382	GGCX	0.46	6.21	0.38	2.36e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs7666738	0.830	rs13118892	chr4:98968497	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4808199	0.947	rs4808960	chr19:19574277	G/C	cg03709012	chr19:19516395	GATAD2A	1.2	13.19	0.65	4.79e-30	Nonalcoholic fatty liver disease;
SARC	cis	rs16854884	0.657	rs16854772	chr3:143703890	A/G	cg06585982	chr3:143692056	C3orf58	0.66	8.63	0.49	9.64e-16	Economic and political preferences (feminism/equality);
SARC	cis	rs9443189	0.950	rs6453845	chr6:76576527	G/T	cg01950844	chr6:76311363	SENP6	-0.74	-6.34	-0.38	1.17e-9	Prostate cancer;
SARC	cis	rs2380220	1.000	rs9400318	chr6:95972381	T/A	cg23517279	chr6:96025343	MANEA	0.55	5.65	0.35	4.55e-8	Behavioural disinhibition (generation interaction);
SARC	cis	rs7659604	0.846	rs35986491	chr4:122664528	A/T	cg19748678	chr4:122722346	EXOSC9	0.42	5.2	0.32	4.29e-7	Type 2 diabetes;
SARC	cis	rs3126085	0.935	rs12407156	chr1:152295942	A/G	cg26876637	chr1:152193138	HRNR	-0.51	-5.23	-0.32	3.81e-7	Atopic dermatitis;
SARC	trans	rs9650657	0.740	rs34653170	chr8:10676542	G/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.13	-0.42	1.24e-11	Neuroticism;
SARC	cis	rs739401	0.595	rs6578304	chr11:2998279	A/G	cg25174290	chr11:3078921	CARS	-0.56	-7.86	-0.46	1.43e-13	Longevity;
SARC	cis	rs79976124	0.797	rs79522358	chr6:66641140	C/G	cg07460842	chr6:66804631	NA	0.62	6.73	0.4	1.27e-10	Type 2 diabetes;
SARC	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg05368731	chr17:41323189	NBR1	-0.74	-9.01	-0.51	7.59e-17	Menopause (age at onset);
SARC	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg04772025	chr11:68637568	NA	0.49	6.22	0.38	2.32e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg19680485	chr15:31195859	MTMR15	0.52	6.08	0.37	4.75e-9	Huntington's disease progression;
SARC	cis	rs7116495	1.000	rs2250866	chr11:71804513	A/G	cg10381502	chr11:71823885	C11orf51	-0.78	-4.87	-0.3	2.08e-6	Severe influenza A (H1N1) infection;
SARC	cis	rs742614	0.905	rs6057924	chr20:32474571	T/C	cg06304546	chr20:32448765	NA	-0.42	-5.09	-0.32	7.21e-7	Stearic acid (18:0) levels;
SARC	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg00684032	chr4:1343700	KIAA1530	0.34	4.85	0.3	2.3e-6	Obesity-related traits;
SARC	cis	rs9300255	0.596	rs10734900	chr12:123743445	G/A	cg00376283	chr12:123451042	ABCB9	0.51	5.73	0.35	3.04e-8	Neutrophil percentage of white cells;
SARC	cis	rs11792861	0.926	rs58795279	chr9:111851902	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.68	7.84	0.46	1.59e-13	Menarche (age at onset);
SARC	cis	rs8058578	0.887	rs28421305	chr16:30838128	G/A	cg00531865	chr16:30841666	NA	-0.47	-5.23	-0.32	3.71e-7	Multiple myeloma;
SARC	cis	rs6456156	0.846	rs204293	chr6:167514481	T/C	cg07741184	chr6:167504864	NA	0.34	6.25	0.38	1.9e-9	Primary biliary cholangitis;
SARC	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg05368731	chr17:41323189	NBR1	0.71	8.3	0.48	8.49e-15	Menopause (age at onset);
SARC	cis	rs6121246	0.647	rs6088855	chr20:30225792	C/T	cg13852791	chr20:30311386	BCL2L1	0.79	8.07	0.47	3.83e-14	Mean corpuscular hemoglobin;
SARC	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg06108461	chr20:60628389	TAF4	-0.98	-13.24	-0.66	3.22e-30	Body mass index;
SARC	cis	rs10752881	1.000	rs10797810	chr1:182980950	C/T	cg13390022	chr1:182993471	LAMC1	0.33	5.06	0.31	8.36e-7	Colorectal cancer;
SARC	cis	rs1005277	0.522	rs9418276	chr10:37940116	G/T	cg00409905	chr10:38381863	ZNF37A	-0.53	-7.23	-0.43	6.71e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs300703	0.935	rs10167992	chr2:263270	C/T	cg21211680	chr2:198530	NA	-0.45	-4.81	-0.3	2.68e-6	Blood protein levels;
SARC	trans	rs1814175	0.817	rs28525029	chr11:50045815	A/G	cg15704280	chr7:45808275	SEPT13	-0.97	-18.06	-0.76	3.38e-46	Height;
SARC	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg08219700	chr8:58056026	NA	0.6	5.71	0.35	3.49e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2635047	0.625	rs1836259	chr18:44732389	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	6.25	0.38	1.95e-9	Educational attainment;
SARC	cis	rs7044106	0.791	rs2416799	chr9:123480866	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	6.11	0.37	4.14e-9	Hip circumference adjusted for BMI;
SARC	cis	rs17376456	0.877	rs12374488	chr5:93481407	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.61	5.12	0.32	6.49e-7	Diabetic retinopathy;
SARC	cis	rs7833986	0.501	rs2976018	chr8:57014752	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.73	7.47	0.44	1.56e-12	Height;
SARC	cis	rs9462027	0.628	rs7769961	chr6:34760162	G/C	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.85	-0.36	1.63e-8	Systemic lupus erythematosus;
SARC	cis	rs7647973	0.626	rs62260720	chr3:49853796	T/A	cg06212747	chr3:49208901	KLHDC8B	-0.59	-5.94	-0.36	1.01e-8	Menarche (age at onset);
SARC	cis	rs5753037	0.585	rs7954	chr22:30184950	A/G	cg01021169	chr22:30184971	ASCC2	-0.54	-7.65	-0.45	5.39e-13	Type 1 diabetes;
SARC	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg04518342	chr5:131593106	PDLIM4	0.42	5.76	0.35	2.64e-8	Acylcarnitine levels;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg20073376	chr20:37146256	RALGAPB	0.49	6.61	0.4	2.66e-10	Thyroid stimulating hormone;
SARC	cis	rs2180341	0.961	rs3798857	chr6:127659473	A/T	cg27446573	chr6:127587934	RNF146	1.04	14.77	0.7	2.87e-35	Breast cancer;
SARC	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg11764359	chr7:65958608	NA	-0.67	-8.0	-0.46	5.66e-14	Cotinine glucuronidation;
SARC	cis	rs367615	0.660	rs10061221	chr5:108839038	C/T	cg17395555	chr5:108820864	NA	0.49	7.02	0.42	2.45e-11	Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs4803468	0.934	rs2317131	chr19:41885151	C/T	cg08477640	chr19:41863820	B9D2	0.46	6.01	0.37	7.09e-9	Height;
SARC	cis	rs3733585	0.699	rs4276278	chr4:9948870	T/C	cg00071950	chr4:10020882	SLC2A9	-0.39	-6.14	-0.37	3.49e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg17839359	chr5:82770619	VCAN	-0.47	-6.46	-0.39	6.19e-10	Chemerin levels;
SARC	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg19346786	chr7:2764209	NA	-0.37	-5.46	-0.34	1.21e-7	Height;
SARC	cis	rs7607369	0.714	rs2272190	chr2:219609995	G/C	cg02176678	chr2:219576539	TTLL4	-0.32	-4.94	-0.31	1.48e-6	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs2295359	1.000	rs11209006	chr1:67619259	T/G	cg12940439	chr1:67600707	NA	0.43	6.65	0.4	2.04e-10	Psoriasis;
SARC	cis	rs3859192	0.599	rs2227319	chr17:38170845	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.39	7.15	0.42	1.1e-11	White blood cell count;
SARC	cis	rs807669	0.548	rs885978	chr22:19198226	A/G	cg02655711	chr22:19163373	SLC25A1	0.49	6.97	0.42	3.22e-11	Metabolite levels;
SARC	cis	rs912057	0.601	rs1294405	chr6:6737591	A/G	cg06612196	chr6:6737390	NA	0.76	13.08	0.65	1.12e-29	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs698833	0.852	rs698768	chr2:44576549	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.69	8.67	0.49	7.3e-16	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs6088590	0.965	rs6120730	chr20:33385102	G/C	cg06115741	chr20:33292138	TP53INP2	0.58	6.92	0.41	4.28e-11	Coronary artery disease;
SARC	cis	rs9790314	0.812	rs7631479	chr3:161139566	C/T	cg03342759	chr3:160939853	NMD3	-0.5	-6.35	-0.38	1.09e-9	Morning vs. evening chronotype;
SARC	cis	rs3008870	0.701	rs2815367	chr1:67500762	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.62	8.03	0.47	4.73e-14	Lymphocyte percentage of white cells;
SARC	cis	rs6121246	0.523	rs6060286	chr20:30197663	C/A	cg13852791	chr20:30311386	BCL2L1	0.68	5.91	0.36	1.2e-8	Mean corpuscular hemoglobin;
SARC	cis	rs3796352	1.000	rs34244302	chr3:53102236	C/G	cg27565382	chr3:53032988	SFMBT1	1.0	6.88	0.41	5.55e-11	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs8028182	0.725	rs8024276	chr15:75699523	G/A	cg20655648	chr15:75932815	IMP3	0.69	5.17	0.32	4.93e-7	Sudden cardiac arrest;
SARC	trans	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg17830980	chr10:43048298	ZNF37B	-0.5	-6.57	-0.4	3.19e-10	Extrinsic epigenetic age acceleration;
SARC	cis	rs3820928	0.874	rs2177594	chr2:227836239	C/G	cg05526886	chr2:227700861	RHBDD1	-0.56	-6.76	-0.4	1.09e-10	Pulmonary function;
SARC	cis	rs2425143	1.000	rs28685274	chr20:34358527	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	5.19	0.32	4.57e-7	Blood protein levels;
SARC	trans	rs61931739	0.500	rs35030191	chr12:34548865	C/T	cg26384229	chr12:38710491	ALG10B	0.92	13.82	0.67	4.07e-32	Morning vs. evening chronotype;
SARC	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg13877915	chr19:58951672	ZNF132	0.44	5.09	0.32	7.33e-7	Mean platelet volume;
SARC	cis	rs710216	1.000	rs710216	chr1:43428757	A/G	cg03128534	chr1:43423976	SLC2A1	0.66	6.61	0.4	2.59e-10	Red cell distribution width;
SARC	cis	rs6840360	0.571	rs62327275	chr4:152548238	G/T	cg22705602	chr4:152727874	NA	-0.44	-6.84	-0.41	7.02e-11	Intelligence (multi-trait analysis);
SARC	cis	rs9858542	0.953	rs11711485	chr3:49491983	G/T	cg03060546	chr3:49711283	APEH	-0.57	-6.95	-0.41	3.59e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs7582720	0.731	rs10207567	chr2:203714973	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.49	5.2	0.32	4.4e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs1728785	1.000	rs1170428	chr16:68603988	C/A	cg02972257	chr16:68554789	NA	-0.5	-5.86	-0.36	1.53e-8	Ulcerative colitis;
SARC	cis	rs17826219	0.561	rs11655876	chr17:29017150	G/A	cg13385521	chr17:29058706	SUZ12P	0.9	7.79	0.45	2.14e-13	Body mass index;
SARC	cis	rs926392	0.666	rs35166252	chr20:37695601	C/T	cg16355469	chr20:37678765	NA	0.73	9.6	0.53	1.35e-18	Dialysis-related mortality;
SARC	cis	rs950776	0.695	rs8025188	chr15:78912278	C/G	cg24631222	chr15:78858424	CHRNA5	0.4	5.32	0.33	2.49e-7	Sudden cardiac arrest;
SARC	cis	rs13401104	0.796	rs11887959	chr2:237114894	C/T	cg19324714	chr2:237145437	ASB18	0.58	6.21	0.38	2.42e-9	Educational attainment;
SARC	cis	rs7666738	0.830	rs9994346	chr4:99037986	A/G	cg05340658	chr4:99064831	C4orf37	0.63	8.25	0.48	1.14e-14	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg02951883	chr7:2050386	MAD1L1	-0.48	-6.11	-0.37	4.1e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg17221315	chr6:27791827	HIST1H4J	0.47	5.22	0.32	3.95e-7	Depression;
SARC	cis	rs959260	0.925	rs9747801	chr17:73396572	C/T	cg14668889	chr17:73230827	NUP85	-0.43	-4.78	-0.3	3.07e-6	Systemic lupus erythematosus;
SARC	cis	rs28374715	0.532	rs3204853	chr15:41689166	C/A	cg18705301	chr15:41695430	NDUFAF1	-1.17	-18.57	-0.77	7.77e-48	Ulcerative colitis;
SARC	cis	rs2014572	0.967	rs11667407	chr19:57763122	C/T	cg24459738	chr19:57751996	ZNF805	-0.45	-5.13	-0.32	5.99e-7	Hyperactive-impulsive symptoms;
SARC	cis	rs617219	0.574	rs3930426	chr5:78597535	C/T	cg24856658	chr5:78533917	JMY	0.3	4.78	0.3	3.09e-6	Betaine levels in individuals undergoing cardiac evaluation;
SARC	cis	rs734999	0.545	rs7364820	chr1:2556709	G/A	cg20673091	chr1:2541236	MMEL1	0.32	4.98	0.31	1.23e-6	Ulcerative colitis;
SARC	cis	rs2273669	0.667	rs7759014	chr6:109351125	A/G	cg05315195	chr6:109294784	ARMC2	-0.63	-5.7	-0.35	3.6e-8	Prostate cancer;
SARC	cis	rs6815814	0.950	rs66922907	chr4:38812537	A/G	cg02016764	chr4:38805732	TLR1	-0.41	-4.76	-0.3	3.33e-6	Breast cancer;
SARC	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg12311346	chr5:56204834	C5orf35	-0.58	-5.92	-0.36	1.14e-8	Initial pursuit acceleration;
SARC	cis	rs9790314	0.723	rs12631850	chr3:160883062	C/T	cg04691961	chr3:161091175	C3orf57	0.57	7.54	0.44	1.06e-12	Morning vs. evening chronotype;
SARC	cis	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.8	-0.46	2.01e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs35213789	0.768	rs6961164	chr7:69406854	A/G	cg10619644	chr7:69149951	AUTS2	0.37	4.8	0.3	2.89e-6	Childhood ear infection;
SARC	cis	rs1153858	1.000	rs12439274	chr15:45636667	A/G	cg03999130	chr15:45571217	NA	0.39	5.03	0.31	9.87e-7	Homoarginine levels;
SARC	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg26554054	chr8:600488	NA	0.58	4.82	0.3	2.64e-6	IgG glycosylation;
SARC	cis	rs28374715	0.662	rs1554445	chr15:41503198	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.96	-12.97	-0.65	2.54e-29	Ulcerative colitis;
SARC	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg22535103	chr8:58192502	C8orf71	-0.72	-6.63	-0.4	2.34e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7659604	1.000	rs7659604	chr4:122665514	A/G	cg20573242	chr4:122745356	CCNA2	-0.44	-5.72	-0.35	3.23e-8	Type 2 diabetes;
SARC	cis	rs7843479	0.601	rs10866827	chr8:21801141	G/A	cg17168535	chr8:21777572	XPO7	0.89	13.93	0.67	1.73e-32	Mean corpuscular volume;
SARC	cis	rs9894429	0.646	rs9905639	chr17:79614154	A/G	cg10661904	chr17:79619235	PDE6G	-0.43	-6.13	-0.37	3.72e-9	Eye color traits;
SARC	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg11890956	chr21:40555474	PSMG1	1.17	19.29	0.78	3.44e-50	Cognitive function;
SARC	cis	rs9815354	1.000	rs73081364	chr3:41913616	G/C	cg03022575	chr3:42003672	ULK4	0.67	5.73	0.35	3.13e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9486715	0.867	rs1855533	chr6:97050265	T/C	cg06623918	chr6:96969491	KIAA0776	-0.94	-14.57	-0.69	1.25e-34	Headache;
SARC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.46	0.8	5.92e-54	Prudent dietary pattern;
SARC	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg24399712	chr22:39784796	NA	-0.43	-5.79	-0.35	2.26e-8	Intelligence (multi-trait analysis);
SARC	cis	rs763121	0.853	rs5757204	chr22:39046700	A/C	cg21395723	chr22:39101663	GTPBP1	0.58	6.67	0.4	1.85e-10	Menopause (age at onset);
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg15659093	chr11:66278037	BBS1	-0.52	-6.52	-0.39	4.35e-10	Gallstone disease;
SARC	cis	rs3784262	0.669	rs4646555	chr15:58355345	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.35	-5.19	-0.32	4.66e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs1580019	0.961	rs1580022	chr7:32497712	C/A	cg14728415	chr7:32535168	LSM5;AVL9	0.43	5.04	0.31	9.3e-7	Cognitive ability;
SARC	cis	rs995000	0.965	rs10789116	chr1:63042738	A/G	cg06896770	chr1:63153194	DOCK7	1.0	15.5	0.71	1.02e-37	Triglyceride levels;
SARC	cis	rs1008375	1.000	rs7673500	chr4:17621383	C/T	cg16339924	chr4:17578868	LAP3	0.68	8.92	0.5	1.42e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs9329221	0.619	rs591346	chr8:9818065	C/T	cg21775007	chr8:11205619	TDH	-0.57	-7.36	-0.43	3.08e-12	Neuroticism;
SARC	cis	rs7772486	0.686	rs7744014	chr6:146123818	G/A	cg05347473	chr6:146136440	FBXO30	0.51	7.16	0.42	1.03e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4481887	0.962	rs10788768	chr1:248456027	G/A	cg01631408	chr1:248437212	OR2T33	-0.43	-5.55	-0.34	7.73e-8	Common traits (Other);
SARC	cis	rs16854884	0.741	rs55909524	chr3:143794734	T/C	cg06585982	chr3:143692056	C3orf58	0.6	7.88	0.46	1.21e-13	Economic and political preferences (feminism/equality);
SARC	cis	rs1865760	1.000	rs9467636	chr6:25919549	A/C	cg10373733	chr6:25993375	NA	0.46	5.51	0.34	9.61e-8	Height;
SARC	cis	rs9394841	0.667	rs9367112	chr6:41769920	T/C	cg08135965	chr6:41755394	TOMM6	0.62	6.55	0.39	3.7e-10	Mean corpuscular hemoglobin;Red cell distribution width;
SARC	cis	rs614226	0.516	rs1794748	chr12:120953758	A/G	cg01236616	chr12:121019343	POP5	1.27	18.35	0.77	4.03e-47	Type 1 diabetes nephropathy;
SARC	cis	rs2304069	0.954	rs6861548	chr5:149384680	A/G	cg12661370	chr5:149340060	SLC26A2	0.59	5.65	0.35	4.64e-8	HIV-1 control;
SARC	cis	rs10982256	0.905	rs4979417	chr9:117263878	C/T	cg15903421	chr9:117267460	DFNB31	-0.36	-4.9	-0.31	1.78e-6	Bipolar disorder;
SARC	cis	rs295140	0.837	rs12474914	chr2:201130210	A/G	cg05691004	chr2:201170426	SPATS2L	0.35	4.98	0.31	1.24e-6	QT interval;
SARC	cis	rs9303401	0.614	rs34900851	chr17:56566399	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.05	11.45	0.6	2.3e-24	Cognitive test performance;
SARC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg26338869	chr17:61819248	STRADA	0.78	10.34	0.56	7.03e-21	Prudent dietary pattern;
SARC	cis	rs10849605	0.737	rs6489769	chr12:1072965	C/T	cg02055889	chr12:1059459	RAD52	0.43	6.07	0.37	5.13e-9	Lung cancer;
SARC	cis	rs2153535	0.580	rs6918391	chr6:8461178	A/C	cg23788917	chr6:8435910	SLC35B3	0.62	8.19	0.47	1.77e-14	Motion sickness;
SARC	cis	rs12477438	0.953	rs3851334	chr2:99794704	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.9	-10.49	-0.57	2.37e-21	Chronic sinus infection;
SARC	cis	rs7681440	0.904	rs35424815	chr4:90767877	C/T	cg02192967	chr4:90758406	SNCA	0.36	5.13	0.32	6.11e-7	Dementia with Lewy bodies;
SARC	trans	rs61931739	0.500	rs11053246	chr12:34516620	C/T	cg13010199	chr12:38710504	ALG10B	0.82	11.58	0.6	8.37e-25	Morning vs. evening chronotype;
SARC	cis	rs1580019	0.844	rs1584615	chr7:32503258	G/C	cg06627557	chr7:32535165	LSM5;AVL9	0.79	10.96	0.58	8.21e-23	Cognitive ability;
SARC	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	7.88	0.46	1.28e-13	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs6893300	0.524	rs12522926	chr5:179214818	G/A	cg14593053	chr5:179126677	CANX	0.5	7.05	0.42	2.04e-11	Resting heart rate;
SARC	cis	rs2777491	0.872	rs7163649	chr15:41586798	A/G	cg01768344	chr15:41576519	LOC729082	0.43	4.82	0.3	2.56e-6	Ulcerative colitis;
SARC	cis	rs9359856	0.510	rs17294495	chr6:90445753	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.53	-4.85	-0.3	2.25e-6	Bipolar disorder;
SARC	cis	rs12142240	0.698	rs6690075	chr1:46819848	G/A	cg10495392	chr1:46806563	NSUN4	0.65	6.83	0.41	7.25e-11	Menopause (age at onset);
SARC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.45	0.53	3.64e-18	Prudent dietary pattern;
SARC	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg05863683	chr7:1912471	MAD1L1	0.37	5.65	0.35	4.55e-8	Bipolar disorder and schizophrenia;
SARC	trans	rs12310956	0.532	rs7955514	chr12:33978737	G/A	cg26384229	chr12:38710491	ALG10B	0.85	12.42	0.63	1.57e-27	Morning vs. evening chronotype;
SARC	cis	rs2985684	0.894	rs4900928	chr14:50020817	A/G	cg04989706	chr14:50066350	PPIL5	-0.5	-5.59	-0.34	6.21e-8	Carotid intima media thickness;
SARC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.13	0.37	3.73e-9	Prudent dietary pattern;
SARC	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg12463550	chr7:65579703	CRCP	0.47	5.16	0.32	5.3e-7	Aortic root size;
SARC	cis	rs2228479	0.702	rs12600047	chr16:89831630	G/A	cg00800038	chr16:89945340	TCF25	-0.75	-4.91	-0.31	1.75e-6	Skin colour saturation;
SARC	cis	rs10870270	0.956	rs4131689	chr10:133744328	A/C	cg26149184	chr10:133730230	NA	-0.47	-5.41	-0.33	1.55e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg18876405	chr7:65276391	NA	0.49	6.05	0.37	5.7e-9	Aortic root size;
SARC	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.1	20.49	0.8	5e-54	Chronic sinus infection;
SARC	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg19223190	chr17:80058835	NA	-0.43	-6.02	-0.37	6.61e-9	Life satisfaction;
SARC	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg02725872	chr8:58115012	NA	-0.37	-6.55	-0.39	3.71e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg05313129	chr8:58192883	C8orf71	-0.51	-5.95	-0.36	9.74e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7824557	0.603	rs2250028	chr8:11213589	T/G	cg21775007	chr8:11205619	TDH	0.65	8.62	0.49	1.02e-15	Retinal vascular caliber;
SARC	cis	rs2153535	0.580	rs4960421	chr6:8459292	C/T	cg21535247	chr6:8435926	SLC35B3	0.52	6.55	0.39	3.66e-10	Motion sickness;
SARC	cis	rs2011503	1.000	rs8105642	chr19:19558468	G/A	cg03709012	chr19:19516395	GATAD2A	0.64	5.69	0.35	3.77e-8	Bipolar disorder;
SARC	cis	rs3733585	0.699	rs7694997	chr4:9947811	A/G	cg11266682	chr4:10021025	SLC2A9	-0.38	-6.49	-0.39	5.19e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs9381040	0.655	rs9381031	chr6:41044957	A/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.43	-4.9	-0.31	1.78e-6	Alzheimer's disease (late onset);
SARC	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg12463550	chr7:65579703	CRCP	0.5	5.9	0.36	1.27e-8	Aortic root size;
SARC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg06873352	chr17:61820015	STRADA	0.5	6.44	0.39	6.63e-10	Prudent dietary pattern;
SARC	cis	rs6545883	0.894	rs6739427	chr2:61452879	T/C	cg15711740	chr2:61764176	XPO1	0.39	4.76	0.3	3.34e-6	Tuberculosis;
SARC	cis	rs67460515	0.892	rs4856703	chr3:161047720	G/T	cg17135325	chr3:160939158	NMD3	0.62	7.9	0.46	1.08e-13	Parkinson's disease;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg15150615	chr19:45681664	BLOC1S3;TRAPPC6A	-0.64	-6.6	-0.4	2.79e-10	Lung cancer in ever smokers;
SARC	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg00684032	chr4:1343700	KIAA1530	0.42	6.29	0.38	1.58e-9	Obesity-related traits;
SARC	cis	rs1348850	0.914	rs9789582	chr2:178330173	C/G	cg23306229	chr2:178417860	TTC30B	0.55	6.44	0.39	6.63e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7106204	0.668	rs7119198	chr11:24218267	A/G	ch.11.24196551F	chr11:24239977	NA	0.59	6.29	0.38	1.52e-9	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs4727027	0.933	rs12154382	chr7:148862284	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	5.63	0.35	5.08e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs1953600	0.870	rs1049550	chr10:81926702	G/A	cg00277334	chr10:82204260	NA	-0.36	-5.28	-0.33	2.93e-7	Sarcoidosis;
SARC	cis	rs9324022	0.722	rs72698709	chr14:101165747	C/T	cg18089426	chr14:101175970	NA	0.59	4.82	0.3	2.57e-6	Plateletcrit;
SARC	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg00684032	chr4:1343700	KIAA1530	0.38	5.55	0.34	7.9e-8	Obesity-related traits;
SARC	cis	rs6456042	0.965	rs3099294	chr6:166530992	T/C	cg11088901	chr6:166572345	T	-0.35	-5.1	-0.32	7.02e-7	Asthma;
SARC	cis	rs7582180	0.652	rs11687864	chr2:100946993	T/A	cg14675211	chr2:100938903	LONRF2	0.5	7.33	0.43	3.67e-12	Intelligence (multi-trait analysis);
SARC	cis	rs861020	0.771	rs674804	chr1:210014603	C/G	cg05527609	chr1:210001259	C1orf107	1.04	12.62	0.64	3.52e-28	Orofacial clefts;
SARC	cis	rs7829975	0.660	rs10093926	chr8:8549020	A/C	cg08975724	chr8:8085496	FLJ10661	-0.44	-5.42	-0.33	1.49e-7	Mood instability;
SARC	cis	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg12257692	chr3:49977190	RBM6	-0.27	-4.86	-0.3	2.21e-6	Body mass index;
SARC	cis	rs7582180	0.629	rs11123826	chr2:100936276	G/T	cg14675211	chr2:100938903	LONRF2	-0.51	-7.85	-0.46	1.55e-13	Intelligence (multi-trait analysis);
SARC	cis	rs8141529	0.529	rs2236141	chr22:29137870	C/T	cg15103426	chr22:29168792	CCDC117	0.59	5.61	0.34	5.72e-8	Lymphocyte counts;
SARC	cis	rs711245	0.573	rs7570763	chr2:36800589	A/C	cg09467607	chr2:36825704	FEZ2	-0.59	-8.01	-0.46	5.58e-14	Height;
SARC	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.66	6.17	0.37	3.05e-9	Platelet count;
SARC	trans	rs3780486	0.505	rs10217267	chr9:33146528	T/C	cg20290983	chr6:43655470	MRPS18A	0.9	12.82	0.64	8.23e-29	IgG glycosylation;
SARC	cis	rs67460515	0.596	rs35589595	chr3:160930984	G/A	cg17135325	chr3:160939158	NMD3	0.68	8.66	0.49	7.95e-16	Parkinson's disease;
SARC	cis	rs751728	1.000	rs2395449	chr6:33728755	T/A	cg15252951	chr6:33757062	LEMD2	0.56	6.47	0.39	5.78e-10	Crohn's disease;
SARC	cis	rs1371867	0.875	rs1125706	chr8:101326739	T/A	cg11906718	chr8:101322791	RNF19A	0.71	9.12	0.51	3.68e-17	Atrioventricular conduction;
SARC	cis	rs4919694	1.000	rs12246689	chr10:104817031	C/T	cg04362960	chr10:104952993	NT5C2	0.65	5.49	0.34	1.03e-7	Arsenic metabolism;
SARC	cis	rs807669	0.869	rs807672	chr22:19157819	C/G	cg02655711	chr22:19163373	SLC25A1	0.36	5.18	0.32	4.75e-7	Metabolite levels;
SARC	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.45	-5.59	-0.34	6.28e-8	Systemic lupus erythematosus;
SARC	trans	rs11098499	0.865	rs11098513	chr4:120316075	A/G	cg25214090	chr10:38739885	LOC399744	0.55	7.1	0.42	1.51e-11	Corneal astigmatism;
SARC	cis	rs4332037	0.950	rs10267593	chr7:1937261	G/A	cg23422044	chr7:1970798	MAD1L1	-0.41	-4.74	-0.3	3.73e-6	Bipolar disorder;
SARC	cis	rs459571	0.959	rs378740	chr9:136890876	C/A	cg13789015	chr9:136890014	NCRNA00094	0.64	8.85	0.5	2.19e-16	Platelet distribution width;
SARC	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.77	7.62	0.45	6.49e-13	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs1048238	0.506	rs1262788	chr1:16215608	G/C	cg21385522	chr1:16154831	NA	-0.47	-5.86	-0.36	1.57e-8	Systolic blood pressure;
SARC	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg11987759	chr7:65425863	GUSB	0.48	5.88	0.36	1.42e-8	Aortic root size;
SARC	cis	rs5769765	0.773	rs6520065	chr22:50294470	A/T	cg03033257	chr22:50311977	ALG12;CRELD2	0.52	5.34	0.33	2.17e-7	Schizophrenia;
SARC	cis	rs995000	0.895	rs1168124	chr1:63139730	C/T	cg06896770	chr1:63153194	DOCK7	-0.9	-13.43	-0.66	7.78e-31	Triglyceride levels;
SARC	cis	rs34311866	0.808	rs62294491	chr4:969111	C/T	cg07828340	chr4:882639	GAK	0.69	5.45	0.34	1.31e-7	Parkinson's disease;
SARC	cis	rs4689388	0.889	rs4629534	chr4:6294124	G/T	cg14416269	chr4:6271139	WFS1	0.32	4.85	0.3	2.23e-6	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs12541335	0.536	rs4266653	chr8:22169087	A/G	cg18135555	chr8:22132992	PIWIL2	0.41	6.15	0.37	3.32e-9	Hypertriglyceridemia;
SARC	cis	rs950776	0.518	rs12914694	chr15:78814444	G/A	cg22563815	chr15:78856949	CHRNA5	0.41	6.78	0.41	9.54e-11	Sudden cardiac arrest;
SARC	cis	rs9611565	1.000	rs5751086	chr22:41768862	C/T	cg06634786	chr22:41940651	POLR3H	-0.39	-5.02	-0.31	1.02e-6	Vitiligo;
SARC	cis	rs965469	0.947	rs7274193	chr20:3329750	C/T	cg25506879	chr20:3388711	C20orf194	-0.52	-5.34	-0.33	2.2e-7	IFN-related cytopenia;
SARC	cis	rs9790314	0.723	rs10936223	chr3:160884313	C/A	cg04691961	chr3:161091175	C3orf57	-0.57	-7.57	-0.44	8.51e-13	Morning vs. evening chronotype;
SARC	cis	rs4720575	1.000	rs7791050	chr7:47086452	T/C	cg00036614	chr7:47093842	NA	-0.43	-6.05	-0.37	5.62e-9	Angiotensin-converting enzyme inhibitor intolerance;
SARC	cis	rs6424115	0.830	rs6672157	chr1:24198840	C/G	cg15997130	chr1:24165203	NA	0.41	5.43	0.34	1.39e-7	Immature fraction of reticulocytes;
SARC	cis	rs3812049	1.000	rs3812049	chr5:127418850	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.88	9.67	0.54	7.93e-19	Lymphocyte counts;Red cell distribution width;
SARC	cis	rs950169	0.919	rs12915589	chr15:84734464	T/C	cg24253500	chr15:84953950	NA	0.35	5.04	0.31	9.53e-7	Schizophrenia;
SARC	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg11062466	chr8:58055876	NA	0.61	5.75	0.35	2.74e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6582630	0.538	rs7971292	chr12:38498151	A/G	cg14851346	chr12:38532713	NA	-0.46	-5.61	-0.34	5.84e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs3087591	0.922	rs2341348	chr17:29534867	C/T	cg24425628	chr17:29625626	OMG;NF1	0.47	5.71	0.35	3.41e-8	Hip circumference;
SARC	cis	rs9300255	0.602	rs11057192	chr12:123693420	T/C	cg05973401	chr12:123451056	ABCB9	0.52	5.89	0.36	1.34e-8	Neutrophil percentage of white cells;
SARC	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg08048268	chr3:133502702	NA	-0.43	-5.82	-0.36	1.9e-8	Iron status biomarkers;
SARC	trans	rs1814175	0.715	rs7479622	chr11:49673340	T/G	cg15704280	chr7:45808275	SEPT13	-0.93	-16.48	-0.73	5.53e-41	Height;
SARC	cis	rs3741151	0.773	rs73543000	chr11:73151774	T/C	cg17517138	chr11:73019481	ARHGEF17	0.91	6.74	0.4	1.22e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	trans	rs10825741	0.825	rs12269201	chr10:57927404	C/T	cg12948920	chr4:8609706	CPZ	0.53	6.31	0.38	1.38e-9	Night sleep phenotypes;
SARC	cis	rs2303745	0.589	rs8103523	chr19:17398269	A/G	cg04248312	chr19:17393744	ANKLE1	-0.6	-7.75	-0.45	2.78e-13	Systemic lupus erythematosus;
SARC	trans	rs2071426	0.959	rs11572139	chr10:96808886	A/G	cg25426716	chr5:125695699	GRAMD3	0.47	6.27	0.38	1.7e-9	Blood metabolite levels;
SARC	cis	rs6912958	0.684	rs2787893	chr6:88387359	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.46	-5.95	-0.36	9.51e-9	Monocyte percentage of white cells;
SARC	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg25811766	chr13:21894605	NA	0.68	8.89	0.5	1.76e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs4713118	0.662	rs149900	chr6:28014597	C/T	cg17221315	chr6:27791827	HIST1H4J	0.51	5.14	0.32	5.69e-7	Parkinson's disease;
SARC	cis	rs4727027	0.800	rs12530946	chr7:148887942	A/G	cg23583168	chr7:148888333	NA	-0.89	-14.2	-0.68	2.14e-33	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs6815814	0.808	rs11721824	chr4:38767749	G/A	cg02016764	chr4:38805732	TLR1	-0.44	-4.8	-0.3	2.81e-6	Breast cancer;
SARC	cis	rs8027181	0.797	rs8033580	chr15:72994968	C/A	cg25996835	chr15:72978165	BBS4;HIGD2B	0.39	5.14	0.32	5.85e-7	Triglyceride levels;
SARC	cis	rs7000551	0.689	rs12545909	chr8:22310052	A/G	cg12081754	chr8:22256438	SLC39A14	-0.55	-7.65	-0.45	5.19e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs796364	1.000	rs769950	chr2:200730028	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.8	7.11	0.42	1.4e-11	Schizophrenia;
SARC	cis	rs4969178	0.965	rs8077859	chr17:76386335	C/T	cg20026190	chr17:76395443	PGS1	0.4	5.33	0.33	2.37e-7	HDL cholesterol levels;
SARC	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg11247378	chr22:39784982	NA	-0.32	-5.19	-0.32	4.61e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg27572855	chr1:25598939	RHD	0.54	9.04	0.51	6.32e-17	Plateletcrit;Mean corpuscular volume;
SARC	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg24829409	chr8:58192753	C8orf71	-0.65	-6.15	-0.37	3.28e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10979	0.557	rs9403517	chr6:143909400	T/C	cg25407410	chr6:143891975	LOC285740	-0.52	-6.03	-0.37	6.39e-9	Hypospadias;
SARC	cis	rs1318878	1.000	rs1318878	chr12:15543479	C/A	cg08258403	chr12:15378311	NA	0.46	6.09	0.37	4.58e-9	Intelligence (multi-trait analysis);
SARC	cis	rs9911578	0.805	rs1811202	chr17:56454435	T/G	cg12560992	chr17:57184187	TRIM37	-0.78	-9.63	-0.53	1.08e-18	Intelligence (multi-trait analysis);
SARC	cis	rs5771242	0.518	rs7290465	chr22:50679758	C/T	cg16473166	chr22:50639996	SELO	-0.53	-5.65	-0.35	4.74e-8	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
SARC	cis	rs11785400	0.793	rs4587307	chr8:143738529	G/A	cg10596483	chr8:143751796	JRK	0.55	7.01	0.42	2.59e-11	Schizophrenia;
SARC	cis	rs60843830	0.633	rs1078763	chr2:113763	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	-0.51	-6.99	-0.42	2.9e-11	Spherical equivalent (joint analysis main effects and education interaction);
SARC	cis	rs16976116	0.803	rs7168737	chr15:55501344	T/C	cg17854078	chr15:55489399	RSL24D1	0.66	6.53	0.39	4.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7223966	0.515	rs2727315	chr17:61961458	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.53	-5.41	-0.33	1.57e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs920590	0.549	rs10749625	chr8:19635117	T/C	cg17834443	chr8:19674713	INTS10	0.39	4.77	0.3	3.19e-6	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs4774830	0.744	rs62045229	chr15:56280869	G/C	cg24530489	chr15:56299380	NA	-0.91	-5.14	-0.32	5.81e-7	Delta-5 desaturase activity;
SARC	cis	rs9948	0.655	rs57582887	chr2:97406354	A/C	cg01990225	chr2:97406019	LMAN2L	-0.94	-6.38	-0.39	9.49e-10	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs10089	1.000	rs6887847	chr5:127473807	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.8	9.86	0.54	2.11e-19	Ileal carcinoids;
SARC	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg27170947	chr2:26402098	FAM59B	0.38	4.86	0.3	2.16e-6	Gut microbiome composition (summer);
SARC	cis	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.43	-5.37	-0.33	1.86e-7	Breast cancer;
SARC	cis	rs9302635	0.513	rs8061459	chr16:72156063	C/T	cg16558253	chr16:72132732	DHX38	-0.53	-6.83	-0.41	7.18e-11	Blood protein levels;
SARC	cis	rs4423214	0.592	rs10898211	chr11:71210677	T/C	cg05163923	chr11:71159392	DHCR7	-0.48	-4.86	-0.3	2.16e-6	Vitamin D levels;
SARC	cis	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg00800038	chr16:89945340	TCF25	-0.74	-5.14	-0.32	5.75e-7	Skin colour saturation;
SARC	cis	rs79149102	0.579	rs78434425	chr15:75304754	C/T	cg00629941	chr15:75287862	SCAMP5	-0.73	-5.2	-0.32	4.37e-7	Lung cancer;
SARC	cis	rs911555	0.755	rs1116095	chr14:103931879	A/G	cg24130564	chr14:104152367	KLC1	0.49	5.77	0.35	2.48e-8	Intelligence (multi-trait analysis);
SARC	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg24675658	chr1:53192096	ZYG11B	0.58	8.09	0.47	3.22e-14	Monocyte count;
SARC	cis	rs12042938	0.600	rs1094656	chr1:231773675	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.55	7.59	0.45	7.5e-13	Neuranatomic and neurocognitive phenotypes;
SARC	cis	rs981844	0.775	rs62324020	chr4:154763851	G/A	cg14289246	chr4:154710475	SFRP2	0.61	6.97	0.42	3.21e-11	Response to statins (LDL cholesterol change);
SARC	cis	rs77741769	0.764	rs11065332	chr12:121360959	G/A	cg02403541	chr12:121454288	C12orf43	0.46	5.16	0.32	5.26e-7	Mean corpuscular volume;
SARC	cis	rs7106204	0.764	rs58215218	chr11:24234720	G/T	ch.11.24196551F	chr11:24239977	NA	0.7	5.19	0.32	4.65e-7	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg19077165	chr18:44547161	KATNAL2	-0.51	-7.09	-0.42	1.58e-11	Personality dimensions;
SARC	cis	rs13082711	0.640	rs35903173	chr3:27287751	T/C	cg02860705	chr3:27208620	NA	0.75	8.58	0.49	1.38e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs71636778	0.722	rs12746395	chr1:27168188	G/C	cg04852280	chr1:26496234	ZNF593	0.55	5.2	0.32	4.31e-7	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs6815814	0.950	rs114719937	chr4:38808585	G/C	cg09316306	chr4:38807337	TLR1	0.5	5.16	0.32	5.23e-7	Breast cancer;
SARC	cis	rs1843834	0.929	rs4674934	chr2:225516468	A/T	cg12698349	chr2:225449008	CUL3	-0.37	-4.87	-0.3	2.08e-6	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg17376030	chr22:41985996	PMM1	0.77	9.06	0.51	5.44e-17	Vitiligo;
SARC	cis	rs1545257	0.505	rs12988810	chr2:24635093	G/T	cg06627628	chr2:24431161	ITSN2	-0.56	-7.21	-0.43	7.53e-12	Sjögren's syndrome;
SARC	cis	rs6901004	0.771	rs6900781	chr6:111422856	T/A	cg15721981	chr6:111408429	SLC16A10	-0.44	-5.31	-0.33	2.6e-7	Blood metabolite levels;
SARC	cis	rs67311347	1.000	rs1466236	chr3:40462162	C/T	cg24209194	chr3:40518798	ZNF619	0.63	8.26	0.48	1.07e-14	Renal cell carcinoma;
SARC	cis	rs6991838	0.806	rs11777025	chr8:66463673	A/C	cg13398993	chr8:66546079	ARMC1	-0.4	-4.94	-0.31	1.47e-6	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg20607798	chr8:58055168	NA	0.67	5.56	0.34	7.23e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6782228	0.527	rs2712371	chr3:128346214	G/A	cg08795948	chr3:128337044	NA	0.36	4.92	0.31	1.62e-6	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
SARC	cis	rs9487051	0.802	rs6910696	chr6:109592329	A/T	cg01475377	chr6:109611718	NA	-0.42	-6.01	-0.37	7.17e-9	Reticulocyte fraction of red cells;
SARC	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg12463550	chr7:65579703	CRCP	-0.5	-5.48	-0.34	1.09e-7	Aortic root size;
SARC	cis	rs9398803	0.865	rs4565329	chr6:126752798	A/G	cg20229609	chr6:126660872	C6orf173	-0.37	-5.4	-0.33	1.61e-7	Male-pattern baldness;
SARC	cis	rs9309473	1.000	rs13431267	chr2:73782200	A/G	cg20560298	chr2:73613845	ALMS1	-0.48	-5.92	-0.36	1.14e-8	Metabolite levels;
SARC	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg22974920	chr21:40686053	BRWD1	0.45	4.88	0.3	1.94e-6	Cognitive function;
SARC	cis	rs9393777	0.528	rs9467989	chr6:27064275	C/T	cg12826209	chr6:26865740	GUSBL1	0.64	6.25	0.38	1.9e-9	Intelligence (multi-trait analysis);
SARC	cis	rs116095464	0.558	rs10060089	chr5:205565	G/A	cg22496380	chr5:211416	CCDC127	-0.9	-8.06	-0.47	3.98e-14	Breast cancer;
SARC	cis	rs9398803	0.584	rs3850234	chr6:127001534	T/G	cg20229609	chr6:126660872	C6orf173	0.37	5.25	0.33	3.38e-7	Male-pattern baldness;
SARC	cis	rs72781680	0.784	rs12616678	chr2:24181159	G/T	cg06627628	chr2:24431161	ITSN2	-0.57	-6.07	-0.37	5.07e-9	Lymphocyte counts;
SARC	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg05025164	chr4:1340916	KIAA1530	0.46	5.4	0.33	1.65e-7	Obesity-related traits;
SARC	cis	rs7772486	0.790	rs6570724	chr6:146151283	T/C	cg05347473	chr6:146136440	FBXO30	0.5	7.02	0.42	2.44e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg22903657	chr4:1355424	KIAA1530	-0.35	-4.74	-0.3	3.76e-6	Obesity-related traits;
SARC	cis	rs17376456	0.569	rs10076965	chr5:93094972	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.56	5.82	0.36	1.96e-8	Diabetic retinopathy;
SARC	cis	rs5753618	0.583	rs5753615	chr22:31828027	T/C	cg13145458	chr22:31556086	RNF185	-0.45	-4.79	-0.3	2.92e-6	Colorectal cancer;
SARC	cis	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg06212747	chr3:49208901	KLHDC8B	0.53	6.71	0.4	1.45e-10	Resting heart rate;
SARC	cis	rs6740322	0.857	rs11690012	chr2:43542480	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-6.41	-0.39	7.87e-10	Coronary artery disease;
SARC	cis	rs9916302	0.904	rs7501488	chr17:37576417	T/G	cg07936489	chr17:37558343	FBXL20	-0.69	-9.17	-0.52	2.52e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs1035144	0.713	rs2284730	chr14:81464901	T/C	cg06600135	chr14:81408086	NA	0.46	5.7	0.35	3.56e-8	Male sexual orientation;
SARC	cis	rs2854207	0.505	rs2466957	chr17:61961230	G/C	cg26338869	chr17:61819248	STRADA	0.48	5.27	0.33	3.12e-7	Height;
SARC	cis	rs10911232	0.507	rs10797819	chr1:183006911	A/G	cg13390022	chr1:182993471	LAMC1	0.35	5.35	0.33	2.11e-7	Hypertriglyceridemia;
SARC	cis	rs17001868	0.568	rs3788579	chr22:40742989	T/C	cg07138101	chr22:40742427	ADSL	0.55	6.07	0.37	5.15e-9	Mammographic density (dense area);
SARC	cis	rs11190604	0.806	rs11190510	chr10:102157175	G/A	cg07080220	chr10:102295463	HIF1AN	0.7	7.66	0.45	5.04e-13	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs9467773	1.000	rs6930120	chr6:26555484	A/G	cg12292205	chr6:26970375	C6orf41	0.46	5.51	0.34	9.65e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9291683	0.509	rs10939671	chr4:10050815	T/C	cg11266682	chr4:10021025	SLC2A9	0.42	7.45	0.44	1.84e-12	Bone mineral density;
SARC	cis	rs2011503	0.943	rs8100927	chr19:19643636	C/G	cg03709012	chr19:19516395	GATAD2A	0.6	5.29	0.33	2.8e-7	Bipolar disorder;
SARC	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg11764359	chr7:65958608	NA	0.73	8.52	0.49	1.99e-15	Aortic root size;
SARC	cis	rs3820928	0.935	rs113195824	chr2:227769139	A/G	cg11843606	chr2:227700838	RHBDD1	-0.55	-6.88	-0.41	5.4e-11	Pulmonary function;
SARC	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg18357526	chr6:26021779	HIST1H4A	0.84	11.11	0.59	2.76e-23	Intelligence (multi-trait analysis);
SARC	cis	rs1355223	0.507	rs11032903	chr11:34876176	C/T	cg11622362	chr11:34938112	PDHX;APIP	0.45	5.88	0.36	1.42e-8	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg14019146	chr3:50243930	SLC38A3	0.3	4.74	0.3	3.79e-6	Body mass index;
SARC	trans	rs12310956	0.532	rs11052930	chr12:33964824	A/G	cg13010199	chr12:38710504	ALG10B	0.74	9.95	0.55	1.17e-19	Morning vs. evening chronotype;
SARC	cis	rs295140	0.773	rs13007517	chr2:201129729	C/T	cg05691004	chr2:201170426	SPATS2L	0.35	4.98	0.31	1.24e-6	QT interval;
SARC	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg10351095	chr21:47802916	PCNT	-0.4	-4.72	-0.3	3.98e-6	Testicular germ cell tumor;
SARC	cis	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg00409905	chr10:38381863	ZNF37A	-0.58	-8.19	-0.47	1.73e-14	Extrinsic epigenetic age acceleration;
SARC	cis	rs6963495	0.818	rs73190187	chr7:105164401	A/T	cg19920283	chr7:105172520	RINT1	0.65	5.48	0.34	1.09e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs12142240	0.698	rs12385697	chr1:46818898	T/C	cg00530320	chr1:46809349	NSUN4	0.57	6.92	0.41	4.4e-11	Menopause (age at onset);
SARC	cis	rs9436747	0.680	rs1171264	chr1:66003014	C/G	cg14976592	chr1:65886160	LEPROT;LEPR	-0.52	-5.1	-0.32	7.17e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg27266027	chr21:40555129	PSMG1	0.5	5.4	0.33	1.68e-7	Cognitive function;
SARC	cis	rs11581859	0.613	rs12404259	chr1:99197741	C/T	cg20286094	chr1:99190917	SNX7	-0.42	-4.99	-0.31	1.2e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg14019146	chr3:50243930	SLC38A3	-0.31	-4.85	-0.3	2.29e-6	Body mass index;
SARC	cis	rs9487051	0.676	rs1829694	chr6:109593860	G/T	cg01475377	chr6:109611718	NA	-0.35	-5.08	-0.32	7.66e-7	Reticulocyte fraction of red cells;
SARC	cis	rs2404602	0.716	rs2164101	chr15:76749117	A/G	cg22467129	chr15:76604101	ETFA	-0.37	-4.92	-0.31	1.63e-6	Blood metabolite levels;
SARC	trans	rs2727020	0.729	rs6485965	chr11:49166730	C/T	cg15704280	chr7:45808275	SEPT13	0.76	11.53	0.6	1.21e-24	Coronary artery disease;
SARC	cis	rs2425143	1.000	rs8115150	chr20:34397189	G/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.66	5.23	0.32	3.86e-7	Blood protein levels;
SARC	cis	rs7647973	0.626	rs1078341	chr3:49685592	A/G	cg03060546	chr3:49711283	APEH	0.64	6.81	0.41	8.37e-11	Menarche (age at onset);
SARC	cis	rs10782582	0.632	rs77099976	chr1:76240524	T/C	cg10523679	chr1:76189770	ACADM	-0.42	-5.08	-0.32	7.9e-7	Daytime sleep phenotypes;
SARC	cis	rs3931020	0.657	rs277376	chr1:75242246	G/T	cg10128416	chr1:75198403	TYW3;CRYZ	-0.53	-5.6	-0.34	5.86e-8	Resistin levels;
SARC	trans	rs9325144	0.671	rs7486919	chr12:38767997	A/G	cg23762105	chr12:34175262	ALG10	0.49	6.35	0.38	1.1e-9	Morning vs. evening chronotype;
SARC	cis	rs11098699	0.821	rs11734868	chr4:124211544	A/G	cg09941581	chr4:124220074	SPATA5	0.39	4.78	0.3	3.07e-6	Mosquito bite size;
SARC	trans	rs9951602	0.512	rs61021837	chr18:76648210	A/C	cg02800362	chr5:177631904	HNRNPAB	0.72	9.23	0.52	1.67e-17	Obesity-related traits;
SARC	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	8.71	0.5	5.56e-16	Alzheimer's disease;
SARC	cis	rs9814567	1.000	rs4423809	chr3:134300107	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	6.89	0.41	5.31e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	trans	rs877282	0.853	rs11595510	chr10:756757	C/G	cg22713356	chr15:30763199	NA	0.99	10.0	0.55	8.07e-20	Uric acid levels;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg09439260	chr3:16645784	DAZL	-0.52	-6.42	-0.39	7.56e-10	Alcohol dependence;
SARC	cis	rs986417	0.892	rs11622577	chr14:60814981	A/T	cg27398547	chr14:60952738	C14orf39	-0.99	-8.65	-0.49	8.48e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg23758822	chr17:41437982	NA	0.88	11.24	0.59	1.04e-23	Menopause (age at onset);
SARC	trans	rs7824557	0.564	rs6601584	chr8:11232343	C/G	cg06636001	chr8:8085503	FLJ10661	-0.64	-8.45	-0.48	3.21e-15	Retinal vascular caliber;
SARC	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.39	-4.86	-0.3	2.17e-6	Lymphocyte counts;
SARC	cis	rs7700895	0.691	rs3777183	chr5:95263735	G/A	cg16656078	chr5:95278638	ELL2	-0.55	-6.58	-0.4	3.16e-10	IgG glycosylation;
SARC	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg11764359	chr7:65958608	NA	0.76	9.06	0.51	5.44e-17	Aortic root size;
SARC	cis	rs829883	0.724	rs3168521	chr12:98908547	C/T	cg25150519	chr12:98850993	NA	-0.67	-8.36	-0.48	5.73e-15	Colorectal adenoma (advanced);
SARC	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg08280861	chr8:58055591	NA	0.61	5.96	0.36	9.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs3796352	1.000	rs11707780	chr3:53084326	A/G	cg15956490	chr3:53032818	SFMBT1	-0.61	-4.74	-0.3	3.78e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg21171335	chr12:122356390	WDR66	0.38	5.8	0.35	2.2e-8	Mean corpuscular volume;
SARC	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg14664628	chr15:75095509	CSK	-0.45	-5.45	-0.34	1.28e-7	Breast cancer;
SARC	cis	rs2120019	0.938	rs2120020	chr15:75316845	T/C	cg00629941	chr15:75287862	SCAMP5	-0.7	-8.32	-0.48	7.66e-15	Blood trace element (Zn levels);
SARC	cis	rs10416265	0.528	rs3826906	chr19:33620897	C/T	cg17764715	chr19:33622953	WDR88	0.46	4.82	0.3	2.57e-6	Bone properties (heel);
SARC	cis	rs7103648	0.897	rs2278890	chr11:47399602	G/A	cg20307385	chr11:47447363	PSMC3	0.79	11.5	0.6	1.5e-24	Diastolic blood pressure;Systolic blood pressure;
SARC	trans	rs61931739	0.963	rs59195137	chr12:34091838	G/A	cg13010199	chr12:38710504	ALG10B	-0.53	-6.59	-0.4	2.93e-10	Morning vs. evening chronotype;
SARC	cis	rs412050	0.501	rs78329092	chr22:22126203	C/T	cg17089214	chr22:22089827	YPEL1	0.8	6.92	0.41	4.43e-11	Attention deficit hyperactivity disorder;
SARC	cis	rs1707322	0.717	rs12023439	chr1:46104636	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.16	0.37	3.19e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs60594510	1	rs60594510	chr12:110594503	C/T	cg10860002	chr12:110842031	ANAPC7	0.64	5.15	0.32	5.62e-7	Intelligence (multi-trait analysis);
SARC	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg04166393	chr7:2884313	GNA12	-0.54	-6.38	-0.39	9.49e-10	Height;
SARC	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg21724239	chr8:58056113	NA	0.59	5.39	0.33	1.72e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg12463550	chr7:65579703	CRCP	0.68	5.14	0.32	5.82e-7	Gout;
SARC	cis	rs4805272	0.539	rs11883172	chr19:29318536	C/T	cg12756686	chr19:29218302	NA	0.59	6.66	0.4	1.94e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs35849525	0.776	rs7615318	chr3:49987475	C/T	cg24110177	chr3:50126178	RBM5	-0.51	-5.7	-0.35	3.66e-8	Intelligence (multi-trait analysis);
SARC	cis	rs637571	0.544	rs617791	chr11:65702523	C/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.49	7.22	0.43	7.49e-12	Eosinophil percentage of white cells;
SARC	cis	rs1005277	0.522	rs289645	chr10:37943642	T/C	cg25427524	chr10:38739819	LOC399744	-0.5	-7.16	-0.42	1.07e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs912057	0.833	rs1294418	chr6:6742185	A/G	cg06612196	chr6:6737390	NA	0.65	9.45	0.53	3.79e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs9790314	0.934	rs9290074	chr3:160997823	T/C	cg04691961	chr3:161091175	C3orf57	-0.79	-11.72	-0.61	3.09e-25	Morning vs. evening chronotype;
SARC	cis	rs7843479	0.965	rs878872	chr8:21834567	A/G	cg17168535	chr8:21777572	XPO7	0.61	7.74	0.45	3.05e-13	Mean corpuscular volume;
SARC	cis	rs478304	0.651	rs948494	chr11:65552118	G/A	cg26695010	chr11:65641043	EFEMP2	0.4	4.81	0.3	2.75e-6	Acne (severe);
SARC	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.34	-4.96	-0.31	1.39e-6	Longevity;Endometriosis;
SARC	cis	rs4805272	0.512	rs66830923	chr19:29321277	C/T	cg12756686	chr19:29218302	NA	0.59	6.56	0.39	3.5e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg22862634	chr11:62369728	EML3;MTA2	0.54	8.17	0.47	1.9e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg24503407	chr1:205819492	PM20D1	0.81	12.89	0.65	4.82e-29	Menarche (age at onset);
SARC	cis	rs9322817	0.625	rs2499655	chr6:105307435	G/A	cg02098413	chr6:105308735	HACE1	0.38	5.9	0.36	1.25e-8	Thyroid stimulating hormone;
SARC	cis	rs4975616	0.836	rs13178866	chr5:1323212	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.59	-8.78	-0.5	3.65e-16	Lung cancer;
SARC	cis	rs6964587	0.904	rs2023785	chr7:91547369	C/A	cg17063962	chr7:91808500	NA	-0.9	-13.21	-0.65	4.26e-30	Breast cancer;
SARC	cis	rs6963495	0.769	rs11556986	chr7:105177041	A/T	cg13798780	chr7:105162888	PUS7	0.58	5.39	0.33	1.75e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs1707322	0.964	rs785483	chr1:46559171	T/C	cg06784218	chr1:46089804	CCDC17	-0.36	-6.21	-0.38	2.44e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs155076	1.000	rs598754	chr13:21845010	C/A	cg06138931	chr13:21896616	NA	-0.39	-5.08	-0.32	7.88e-7	White matter hyperintensity burden;
SARC	cis	rs6700896	0.500	rs4655754	chr1:66114747	C/T	cg04111102	chr1:66153794	NA	-0.46	-4.93	-0.31	1.54e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs240764	0.717	rs239215	chr6:101147426	A/G	cg09795085	chr6:101329169	ASCC3	0.45	5.64	0.35	4.86e-8	Neuroticism;
SARC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg05552183	chr6:42928497	GNMT	0.57	7.76	0.45	2.71e-13	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs4727027	0.870	rs1568945	chr7:148874112	T/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.54	6.51	0.39	4.46e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs8180040	0.932	rs62246474	chr3:47398130	C/T	cg27129171	chr3:47204927	SETD2	-0.7	-9.86	-0.54	2.2e-19	Colorectal cancer;
SARC	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg21747090	chr2:27597821	SNX17	-0.54	-7.53	-0.44	1.12e-12	Menopause (age at onset);
SARC	cis	rs920590	0.796	rs7820505	chr8:19634829	A/G	cg17834443	chr8:19674713	INTS10	-0.47	-5.58	-0.34	6.68e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg04944784	chr2:26401820	FAM59B	0.64	8.27	0.48	1.03e-14	Gut microbiome composition (summer);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg21559469	chr19:19431446	KIAA0892;SF4	0.51	6.25	0.38	1.93e-9	Breast cancer;
SARC	cis	rs7582720	1.000	rs72932791	chr2:203700870	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	7.55	0.44	1e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	trans	rs7824557	0.564	rs13274106	chr8:11233958	A/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.84	-0.41	6.96e-11	Retinal vascular caliber;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg02070114	chr5:139555300	C5orf32	0.48	6.43	0.39	7.01e-10	Chemerin levels;
SARC	cis	rs9747201	1.000	rs9303020	chr17:80163247	C/T	cg09264619	chr17:80180166	NA	-0.51	-6.09	-0.37	4.63e-9	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs17376456	0.825	rs13161885	chr5:93071242	A/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.71	6.57	0.4	3.3e-10	Diabetic retinopathy;
SARC	cis	rs8180040	0.620	rs6414435	chr3:47121140	A/G	cg27129171	chr3:47204927	SETD2	0.7	9.56	0.53	1.79e-18	Colorectal cancer;
SARC	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.7	8.39	0.48	4.66e-15	Height;
SARC	cis	rs7264396	0.563	rs2425084	chr20:34301871	C/T	cg01084648	chr20:34329383	RBM39	0.55	4.83	0.3	2.5e-6	Total cholesterol levels;
SARC	cis	rs910316	1.000	rs876402	chr14:75601862	C/T	cg23033748	chr14:75592666	NEK9	-0.37	-5.13	-0.32	6.2e-7	Height;
SARC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg11062466	chr8:58055876	NA	0.67	6.06	0.37	5.55e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1008375	1.000	rs7661631	chr4:17679751	T/C	cg27347728	chr4:17578864	LAP3	-0.49	-6.07	-0.37	5.07e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-4.92	-0.31	1.61e-6	Total body bone mineral density;
SARC	cis	rs1318878	0.565	rs11056437	chr12:15500105	T/C	cg08258403	chr12:15378311	NA	0.51	7.08	0.42	1.68e-11	Intelligence (multi-trait analysis);
SARC	cis	rs60733400	0.817	rs4648657	chr1:2560735	A/G	cg00980319	chr1:2560884	MMEL1	0.34	4.83	0.3	2.42e-6	Multiple sclerosis;
SARC	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg03060546	chr3:49711283	APEH	0.44	5.6	0.34	6.04e-8	Parkinson's disease;
SARC	cis	rs12973672	1.000	rs12973672	chr19:35767866	A/G	cg12095397	chr19:35769544	USF2	0.37	4.75	0.3	3.5e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs861020	0.630	rs685248	chr1:210008367	C/G	cg23166289	chr1:210001082	C1orf107	0.39	4.72	0.3	4.09e-6	Orofacial clefts;
SARC	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg07701084	chr6:150067640	NUP43	0.37	4.9	0.31	1.82e-6	Lung cancer;
SARC	cis	rs116095464	1.000	rs10475185	chr5:306981	C/T	cg22496380	chr5:211416	CCDC127	-0.93	-6.16	-0.37	3.21e-9	Breast cancer;
SARC	cis	rs7264396	0.563	rs2425120	chr20:34324456	A/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	5.68	0.35	4.03e-8	Total cholesterol levels;
SARC	cis	rs9612	1.000	rs28446957	chr19:44246600	T/A	cg08581076	chr19:44259116	C19orf61	0.74	9.18	0.52	2.36e-17	Exhaled nitric oxide output;
SARC	cis	rs9807841	0.592	rs2742313	chr19:10799750	T/C	cg17710535	chr19:10819994	QTRT1	0.44	5.23	0.32	3.72e-7	Inflammatory skin disease;
SARC	cis	rs7712401	0.601	rs35334805	chr5:122335261	G/A	cg19412675	chr5:122181750	SNX24	-0.43	-5.43	-0.34	1.41e-7	Mean platelet volume;
SARC	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg02951883	chr7:2050386	MAD1L1	-0.42	-5.43	-0.34	1.41e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs2425143	1.000	rs111597121	chr20:34371913	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	5.04	0.31	9.36e-7	Blood protein levels;
SARC	cis	rs356220	0.656	rs181490	chr4:90635033	A/G	cg06632027	chr4:90757378	SNCA	0.39	5.0	0.31	1.13e-6	Parkinson's disease;
SARC	cis	rs4975616	0.773	rs414965	chr5:1324121	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.47	-6.2	-0.38	2.56e-9	Lung cancer;
SARC	cis	rs6598955	0.543	rs61608823	chr1:26555090	G/A	cg04990556	chr1:26633338	UBXN11	0.76	7.81	0.46	1.92e-13	Obesity-related traits;
SARC	cis	rs897984	0.683	rs9932572	chr16:30841642	A/G	cg02466173	chr16:30829666	NA	-0.55	-8.01	-0.46	5.6e-14	Dementia with Lewy bodies;
SARC	cis	rs7824557	0.564	rs2437152	chr8:11235497	G/A	cg21775007	chr8:11205619	TDH	-0.65	-8.62	-0.49	1.05e-15	Retinal vascular caliber;
SARC	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg09699651	chr6:150184138	LRP11	0.49	5.83	0.36	1.84e-8	Lung cancer;
SARC	cis	rs8180040	0.701	rs11130111	chr3:47009805	C/T	cg27129171	chr3:47204927	SETD2	0.65	8.91	0.5	1.47e-16	Colorectal cancer;
SARC	trans	rs643955	0.611	rs35044612	chr8:9864980	T/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.2	-0.43	8.42e-12	Systemic lupus erythematosus;
SARC	cis	rs826838	1.000	rs4768328	chr12:39129315	C/T	cg13010199	chr12:38710504	ALG10B	-0.63	-8.88	-0.5	1.87e-16	Heart rate;
SARC	cis	rs11583043	0.874	rs6577219	chr1:101415707	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.48	5.98	0.36	8.33e-9	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs1538970	0.884	rs781232	chr1:45890399	C/T	cg05343316	chr1:45956843	TESK2	-0.73	-8.41	-0.48	4.11e-15	Platelet count;
SARC	cis	rs874628	0.686	rs11666281	chr19:18234588	C/T	cg00493341	chr19:18228948	MAST3	0.49	5.38	0.33	1.81e-7	Multiple sclerosis;
SARC	trans	rs1814175	0.645	rs28445479	chr11:50047999	A/G	cg15704280	chr7:45808275	SEPT13	-0.89	-14.15	-0.68	3.23e-33	Height;
SARC	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg13256598	chr4:5624571	EVC2	-0.53	-6.32	-0.38	1.29e-9	Alcohol dependence;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg11905814	chr11:46639029	KIAA0652;HARBI1	0.47	6.29	0.38	1.52e-9	Chemerin levels;
SARC	cis	rs501120	1.000	rs534079	chr10:44752558	G/T	cg09554077	chr10:44749378	NA	0.48	6.67	0.4	1.85e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs4889855	0.530	rs8072592	chr17:78615361	A/C	cg17956530	chr17:78667699	RPTOR	0.46	5.42	0.33	1.47e-7	Fractional excretion of uric acid;
SARC	cis	rs7937682	0.632	rs7112886	chr11:111743232	T/C	cg22437258	chr11:111473054	SIK2	-0.48	-5.55	-0.34	7.6e-8	Primary sclerosing cholangitis;
SARC	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg09359103	chr1:154839909	KCNN3	-0.46	-7.73	-0.45	3.23e-13	Prostate cancer;
SARC	cis	rs6772849	0.804	rs9832430	chr3:128412897	C/T	cg08795948	chr3:128337044	NA	0.52	6.78	0.41	9.85e-11	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs10932679	0.532	rs2712162	chr2:217661788	C/T	cg05032264	chr2:217675019	NA	-0.51	-5.94	-0.36	1.02e-8	Pulse pressure;
SARC	cis	rs2486288	0.656	rs11632777	chr15:45551045	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.45	-5.57	-0.34	7.07e-8	Glomerular filtration rate;
SARC	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg08859206	chr1:53392774	SCP2	-0.39	-5.55	-0.34	7.87e-8	Monocyte count;
SARC	cis	rs6582630	0.638	rs61931383	chr12:38513845	G/A	cg13010199	chr12:38710504	ALG10B	-0.47	-5.87	-0.36	1.5e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs10489202	0.632	rs202268	chr1:167927339	T/C	cg24449463	chr1:168025552	DCAF6	-0.69	-9.35	-0.52	7.57e-18	Schizophrenia;
SARC	cis	rs4588572	0.643	rs35299318	chr5:77668322	A/C	cg11547950	chr5:77652471	NA	0.41	4.84	0.3	2.36e-6	Triglycerides;
SARC	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg20120463	chr17:44301886	NA	-0.36	-5.55	-0.34	7.6e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs4974559	0.895	rs28493051	chr4:1331030	A/C	cg02980000	chr4:1222292	CTBP1	0.56	5.51	0.34	9.35e-8	Systolic blood pressure;
SARC	cis	rs12145833	0.538	rs10754798	chr1:243309958	A/G	cg02356786	chr1:243265016	LOC731275	-0.78	-6.63	-0.4	2.29e-10	Obesity (early onset extreme);
SARC	cis	rs282587	0.597	rs12876520	chr13:113393566	C/G	cg02820901	chr13:113351484	ATP11A	-0.5	-4.83	-0.3	2.51e-6	Glycated hemoglobin levels;
SARC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg16405210	chr4:1374714	KIAA1530	-0.86	-11.51	-0.6	1.42e-24	Longevity;
SARC	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	13.55	0.66	3.05e-31	Chronic sinus infection;
SARC	cis	rs9457247	1.000	rs400837	chr6:167411008	T/C	cg23791538	chr6:167370224	RNASET2	-0.6	-8.22	-0.47	1.39e-14	Crohn's disease;
SARC	cis	rs9372253	1.000	rs9384740	chr6:110716207	G/A	cg01119278	chr6:110721349	DDO	-0.37	-4.82	-0.3	2.61e-6	Platelet distribution width;
SARC	cis	rs1784581	0.651	rs1784593	chr6:162386096	A/T	cg17173639	chr6:162384350	PARK2	-0.61	-7.84	-0.46	1.6e-13	Itch intensity from mosquito bite;
SARC	cis	rs9457247	1.000	rs364283	chr6:167383750	C/T	cg07741184	chr6:167504864	NA	0.3	5.6	0.34	5.86e-8	Crohn's disease;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg01888592	chr5:6714537	POLS	0.52	6.88	0.41	5.32e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs7529073	0.683	rs340882	chr1:214145731	C/G	cg24083324	chr1:214162604	PROX1	0.33	4.73	0.3	3.92e-6	Schizophrenia;
SARC	trans	rs1814175	0.645	rs11040699	chr11:50023798	C/G	cg03929089	chr4:120376271	NA	-0.82	-11.88	-0.61	9.03e-26	Height;
SARC	cis	rs2832077	0.506	rs10222093	chr21:30163518	T/C	cg24692254	chr21:30365293	RNF160	-0.54	-5.84	-0.36	1.78e-8	Cognitive test performance;
SARC	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg15448220	chr1:150897856	SETDB1	-0.46	-6.25	-0.38	1.89e-9	Tonsillectomy;
SARC	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg10589385	chr1:150898437	SETDB1	0.41	5.52	0.34	9.02e-8	Melanoma;
SARC	cis	rs7000551	0.751	rs2100291	chr8:22374551	C/T	cg12081754	chr8:22256438	SLC39A14	0.57	8.02	0.47	5.08e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg13206674	chr6:150067644	NUP43	0.41	5.4	0.33	1.66e-7	Lung cancer;
SARC	cis	rs9902453	0.866	rs4795529	chr17:28443549	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	6.93	0.41	4.08e-11	Coffee consumption (cups per day);
SARC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg09436375	chr6:42928200	GNMT	-0.36	-5.62	-0.35	5.3e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs3126085	0.877	rs11204968	chr1:152250211	A/T	cg26876637	chr1:152193138	HRNR	0.45	5.21	0.32	4.07e-7	Atopic dermatitis;
SARC	trans	rs61931739	0.500	rs10844844	chr12:34380350	G/T	cg26384229	chr12:38710491	ALG10B	0.88	13.1	0.65	9.7e-30	Morning vs. evening chronotype;
SARC	cis	rs9811216	0.917	rs28626343	chr3:169526272	T/C	cg14222479	chr3:169487675	ARPM1	0.44	5.09	0.32	7.53e-7	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
SARC	trans	rs9388451	0.839	rs3966775	chr6:126067655	C/A	cg05039488	chr6:79577232	IRAK1BP1	-0.58	-7.41	-0.44	2.27e-12	Brugada syndrome;
SARC	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg22683308	chr4:1340831	KIAA1530	0.42	5.08	0.32	7.75e-7	Longevity;
SARC	cis	rs35955747	0.902	rs12167361	chr22:31696278	G/C	cg13145458	chr22:31556086	RNF185	0.39	4.83	0.3	2.45e-6	Neutrophil count;Sum basophil neutrophil counts;
SARC	cis	rs8014204	1.000	rs8014204	chr14:75322794	A/G	cg17347104	chr14:75034677	LTBP2	-0.41	-4.96	-0.31	1.34e-6	Caffeine consumption;
SARC	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg12463550	chr7:65579703	CRCP	-0.51	-5.52	-0.34	8.92e-8	Aortic root size;
SARC	cis	rs13314892	0.764	rs55946371	chr3:69871412	G/A	cg17445875	chr3:69859618	MITF	-0.49	-5.12	-0.32	6.44e-7	QRS complex (12-leadsum);
SARC	cis	rs796364	0.760	rs55906940	chr2:201049386	A/G	cg23649088	chr2:200775458	C2orf69	-0.64	-5.67	-0.35	4.17e-8	Schizophrenia;
SARC	cis	rs2242194	0.844	rs11264295	chr1:154987526	C/T	cg24250549	chr1:154909240	PMVK	0.53	6.58	0.4	3.15e-10	Schizophrenia;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg15113064	chr3:124774855	HEG1	0.53	7.22	0.43	7.42e-12	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg08280861	chr8:58055591	NA	0.61	5.88	0.36	1.43e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6752107	1.000	rs6431654	chr2:234161769	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.47	6.1	0.37	4.48e-9	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs3796352	0.881	rs35385050	chr3:52997945	C/A	cg07884673	chr3:53033167	SFMBT1	0.8	4.95	0.31	1.43e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs760805	1.000	rs61774728	chr1:25258867	G/C	cg22509179	chr1:25234806	RUNX3	-0.5	-6.97	-0.42	3.32e-11	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs4481887	0.927	rs10749646	chr1:248429719	A/G	cg00666640	chr1:248458726	OR2T12	-0.39	-6.4	-0.39	8.63e-10	Common traits (Other);
SARC	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg07701084	chr6:150067640	NUP43	0.41	5.4	0.33	1.62e-7	Lung cancer;
SARC	cis	rs7769051	1.000	rs6934161	chr6:133124077	C/T	cg07930552	chr6:133119739	C6orf192	-0.91	-8.36	-0.48	5.85e-15	Type 2 diabetes nephropathy;
SARC	cis	rs11578119	0.843	rs113019901	chr1:170543775	T/C	cg09767346	chr1:170501363	GORAB	0.44	5.19	0.32	4.61e-7	Male-pattern baldness;
SARC	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg03351412	chr1:154909251	PMVK	0.65	8.34	0.48	6.47e-15	Prostate cancer;
SARC	cis	rs7829975	0.633	rs2979181	chr8:8323088	A/T	cg08975724	chr8:8085496	FLJ10661	0.54	7.2	0.43	8.11e-12	Mood instability;
SARC	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg24642844	chr7:1081250	C7orf50	-0.6	-6.14	-0.37	3.53e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs17270561	0.609	rs9393662	chr6:25739670	T/C	cg17691542	chr6:26056736	HIST1H1C	0.58	7.09	0.42	1.6e-11	Iron status biomarkers;
SARC	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg26335602	chr6:28129616	ZNF389	0.53	5.88	0.36	1.43e-8	Depression;
SARC	cis	rs10078	0.515	rs1053299	chr5:470760	G/A	cg07599136	chr5:415885	AHRR	0.67	5.93	0.36	1.08e-8	Fat distribution (HIV);
SARC	trans	rs1814175	0.817	rs10839318	chr11:49657511	G/C	cg15704280	chr7:45808275	SEPT13	-0.97	-17.82	-0.76	2.12e-45	Height;
SARC	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg08677398	chr8:58056175	NA	0.44	5.24	0.32	3.59e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9790314	0.645	rs9879687	chr3:160874938	A/G	cg03342759	chr3:160939853	NMD3	-0.61	-7.9	-0.46	1.07e-13	Morning vs. evening chronotype;
SARC	cis	rs9814567	0.727	rs4435681	chr3:134344435	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.49	-6.36	-0.38	1.04e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs7818345	0.967	rs4412390	chr8:19270143	A/T	cg11303988	chr8:19266685	CSGALNACT1	-0.41	-5.53	-0.34	8.54e-8	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs9911578	1.000	rs9901114	chr17:56575208	G/A	cg05425664	chr17:57184151	TRIM37	0.63	7.7	0.45	3.86e-13	Intelligence (multi-trait analysis);
SARC	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	8.67	0.49	7.61e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7412746	0.646	rs10399947	chr1:150861960	G/A	cg10589385	chr1:150898437	SETDB1	0.39	5.16	0.32	5.3e-7	Melanoma;
SARC	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg06212747	chr3:49208901	KLHDC8B	0.65	8.64	0.49	9.19e-16	Parkinson's disease;
SARC	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg21016266	chr12:122356598	WDR66	0.34	5.27	0.33	3.1e-7	Mean corpuscular volume;
SARC	cis	rs1008375	0.872	rs6831115	chr4:17640463	A/G	cg02297831	chr4:17616191	MED28	0.5	6.49	0.39	5.05e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg13939156	chr17:80058883	NA	-0.44	-6.93	-0.41	3.98e-11	Life satisfaction;
SARC	cis	rs7568458	0.684	rs3731828	chr2:85806266	C/T	cg02493740	chr2:85810744	VAMP5	-0.42	-5.23	-0.32	3.85e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs3796352	0.881	rs13100714	chr3:53074824	T/G	cg15956490	chr3:53032818	SFMBT1	0.76	5.33	0.33	2.28e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs11997175	0.646	rs4612298	chr8:33713451	G/A	ch.8.33884649F	chr8:33765107	NA	0.63	8.6	0.49	1.21e-15	Body mass index;
SARC	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	5.38	0.33	1.86e-7	Personality dimensions;
SARC	cis	rs30380	0.632	rs26489	chr5:96133427	C/T	cg16492584	chr5:96139282	ERAP1	-0.48	-5.5	-0.34	1.02e-7	Cerebrospinal fluid biomarker levels;
SARC	trans	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.49	-0.49	2.52e-15	Triglycerides;
SARC	cis	rs7412746	0.611	rs36008098	chr1:150856806	G/A	cg10589385	chr1:150898437	SETDB1	0.39	5.11	0.32	6.62e-7	Melanoma;
SARC	cis	rs9473924	0.580	rs66462826	chr6:50814877	C/A	cg14470998	chr6:50812995	TFAP2B	0.66	6.02	0.37	6.73e-9	Body mass index;
SARC	cis	rs1153858	0.621	rs2413769	chr15:45561868	A/C	cg03999130	chr15:45571217	NA	0.4	4.94	0.31	1.47e-6	Homoarginine levels;
SARC	cis	rs9815354	0.812	rs766286	chr3:41838329	G/A	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg27170947	chr2:26402098	FAM59B	0.37	4.8	0.3	2.79e-6	Gut microbiome composition (summer);
SARC	cis	rs9816226	1.000	rs55835921	chr3:185831474	T/C	cg00760338	chr3:185826511	ETV5	-0.86	-9.67	-0.53	8.46e-19	Obesity;Body mass index;
SARC	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg19774624	chr17:42201019	HDAC5	0.63	8.07	0.47	3.79e-14	Total body bone mineral density;
SARC	cis	rs6840258	0.607	rs56023922	chr4:87916086	A/C	cg11209507	chr4:87813803	C4orf36	0.47	4.76	0.3	3.33e-6	Mean corpuscular volume;Basophil percentage of granulocytes;
SARC	cis	rs2072499	0.778	rs2247476	chr1:156190280	C/A	cg25208724	chr1:156163844	SLC25A44	0.74	8.1	0.47	3.01e-14	Testicular germ cell tumor;
SARC	cis	rs1448094	0.512	rs57278040	chr12:86237886	A/G	cg00310523	chr12:86230176	RASSF9	0.3	4.89	0.3	1.92e-6	Major depressive disorder;
SARC	cis	rs501120	1.000	rs607760	chr10:44756236	A/G	cg09554077	chr10:44749378	NA	0.48	6.62	0.4	2.45e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs7412746	0.658	rs11581757	chr1:150892244	A/G	cg10589385	chr1:150898437	SETDB1	0.42	5.64	0.35	4.91e-8	Melanoma;
SARC	cis	rs56011263	0.687	rs4690186	chr4:703607	G/A	cg05835009	chr4:710272	PCGF3	0.57	6.67	0.4	1.89e-10	White blood cell count;
SARC	cis	rs35362007	0.530	rs10484053	chr14:96011645	C/T	cg02940042	chr14:96000874	GLRX5;SNHG10;SCARNA13	0.62	5.36	0.33	1.99e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs11658309	1	rs11658309	chr17:17762247	T/G	cg04398451	chr17:18023971	MYO15A	0.44	6.29	0.38	1.53e-9	Strep throat;
SARC	cis	rs6831352	0.879	rs36034266	chr4:100061388	T/C	cg12011299	chr4:100065546	ADH4	-0.34	-5.67	-0.35	4.2e-8	Alcohol dependence;
SARC	cis	rs2997447	0.761	rs61776586	chr1:26438933	T/C	cg19633962	chr1:26362018	EXTL1	-0.57	-5.02	-0.31	1.01e-6	QRS complex (12-leadsum);
SARC	cis	rs9486719	0.901	rs760619	chr6:96857431	A/G	cg06623918	chr6:96969491	KIAA0776	0.71	7.44	0.44	1.87e-12	Migraine;Coronary artery disease;
SARC	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg04234412	chr22:24373322	LOC391322	-0.52	-6.26	-0.38	1.87e-9	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs11025559	1.000	rs11025559	chr11:20443875	A/G	cg04101203	chr11:20408940	PRMT3	0.48	5.21	0.32	4.14e-7	Pursuit maintenance gain;
SARC	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg05332525	chr7:65337924	VKORC1L1	0.43	4.82	0.3	2.57e-6	Calcium levels;
SARC	cis	rs9527	0.590	rs7087040	chr10:104799668	G/A	cg04362960	chr10:104952993	NT5C2	0.42	5.05	0.31	8.8e-7	Arsenic metabolism;
SARC	cis	rs4595586	0.679	rs5017082	chr12:39314564	A/C	cg26384229	chr12:38710491	ALG10B	-0.41	-5.06	-0.31	8.65e-7	Morning vs. evening chronotype;
SARC	cis	rs4588572	0.686	rs2362823	chr5:77693623	A/G	cg11547950	chr5:77652471	NA	0.4	4.89	0.31	1.85e-6	Triglycerides;
SARC	cis	rs7635838	0.718	rs2594991	chr3:11362704	G/A	cg00170343	chr3:11313890	ATG7	0.65	8.89	0.5	1.67e-16	HDL cholesterol;
SARC	cis	rs765787	0.530	rs4774542	chr15:45526026	A/C	cg26924012	chr15:45694286	SPATA5L1	0.4	4.88	0.3	2e-6	Uric acid levels;
SARC	cis	rs739401	0.527	rs423236	chr11:3065916	C/T	cg25174290	chr11:3078921	CARS	0.58	8.35	0.48	6.11e-15	Longevity;
SARC	cis	rs1144333	0.655	rs1417402	chr1:76437196	C/T	cg03433033	chr1:76189801	ACADM	0.65	5.36	0.33	2.02e-7	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs10911251	0.546	rs10911267	chr1:183115323	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.68	9.8	0.54	3.36e-19	Colorectal cancer;
SARC	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg12463550	chr7:65579703	CRCP	0.51	5.74	0.35	2.94e-8	Aortic root size;
SARC	cis	rs7582180	0.629	rs11123827	chr2:100951248	C/G	cg14675211	chr2:100938903	LONRF2	0.51	7.63	0.45	6.1e-13	Intelligence (multi-trait analysis);
SARC	cis	rs826838	1.000	rs55828987	chr12:39056421	A/C	cg26384229	chr12:38710491	ALG10B	0.9	14.09	0.68	5e-33	Heart rate;
SARC	cis	rs362296	0.698	rs3095083	chr4:3263499	G/A	cg06533319	chr4:3265114	C4orf44	0.35	5.72	0.35	3.31e-8	Parental longevity (mother's age at death);
SARC	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg21433313	chr16:3507492	NAT15	-0.34	-5.06	-0.31	8.63e-7	Tuberculosis;
SARC	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg22535103	chr8:58192502	C8orf71	-0.79	-9.1	-0.51	4.23e-17	Developmental language disorder (linguistic errors);
SARC	cis	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg03060546	chr3:49711283	APEH	0.69	7.41	0.44	2.36e-12	Menarche (age at onset);
SARC	cis	rs2985684	1.000	rs3007030	chr14:50086563	C/T	cg04989706	chr14:50066350	PPIL5	-0.57	-6.06	-0.37	5.38e-9	Carotid intima media thickness;
SARC	trans	rs1814175	0.867	rs7926002	chr11:49616018	A/G	cg15704280	chr7:45808275	SEPT13	-0.88	-14.83	-0.7	1.76e-35	Height;
SARC	cis	rs7044106	0.762	rs1530370	chr9:123424552	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	8.45	0.48	3.16e-15	Hip circumference adjusted for BMI;
SARC	cis	rs36051895	0.632	rs12340617	chr9:5164492	G/C	cg02405213	chr9:5042618	JAK2	-0.41	-4.87	-0.3	2.06e-6	Pediatric autoimmune diseases;
SARC	cis	rs765787	0.530	rs12323957	chr15:45490773	C/T	cg24006582	chr15:45444508	DUOX1	0.54	6.57	0.4	3.24e-10	Uric acid levels;
SARC	cis	rs4481887	0.927	rs10157089	chr1:248488157	A/G	cg01631408	chr1:248437212	OR2T33	-0.39	-4.89	-0.31	1.84e-6	Common traits (Other);
SARC	cis	rs9388451	0.874	rs1159974	chr6:126090277	C/T	cg05901451	chr6:126070800	HEY2	0.68	9.54	0.53	1.99e-18	Brugada syndrome;
SARC	cis	rs9814567	1.000	rs6763093	chr3:134254995	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	7.08	0.42	1.73e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs3892630	0.878	rs11878394	chr19:33205844	G/C	cg22980127	chr19:33182716	NUDT19	1.02	8.88	0.5	1.79e-16	Red blood cell traits;
SARC	cis	rs9341808	0.754	rs6916405	chr6:81024188	C/T	cg08355045	chr6:80787529	NA	0.37	5.82	0.36	1.96e-8	Sitting height ratio;
SARC	cis	rs7923609	0.783	rs4746203	chr10:65323997	G/T	cg01631684	chr10:65280961	REEP3	0.36	4.76	0.3	3.36e-6	Educational attainment;Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs3768617	0.510	rs10797852	chr1:183101302	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.44	0.56	3.45e-21	Fuchs's corneal dystrophy;
SARC	cis	rs10752881	1.000	rs10797807	chr1:182978873	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.76	0.58	3.38e-22	Colorectal cancer;
SARC	trans	rs61931739	0.500	rs7955933	chr12:34473608	A/G	cg13010199	chr12:38710504	ALG10B	0.73	10.16	0.55	2.53e-20	Morning vs. evening chronotype;
SARC	cis	rs9902453	0.904	rs12103671	chr17:28408217	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.56	-7.3	-0.43	4.44e-12	Coffee consumption (cups per day);
SARC	cis	rs6964587	0.605	rs6956022	chr7:91553199	A/G	cg17063962	chr7:91808500	NA	-0.78	-11.2	-0.59	1.44e-23	Breast cancer;
SARC	trans	rs7824557	0.736	rs10107010	chr8:11132712	C/A	cg06636001	chr8:8085503	FLJ10661	-0.61	-7.39	-0.44	2.62e-12	Retinal vascular caliber;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg18860136	chr19:14359707	NA	0.49	6.39	0.39	8.71e-10	Thyroid stimulating hormone;
SARC	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg16479474	chr6:28041457	NA	0.35	5.12	0.32	6.32e-7	Parkinson's disease;
SARC	cis	rs9503598	0.636	rs6596976	chr6:3466022	C/T	cg00476032	chr6:3446245	SLC22A23	0.4	6.28	0.38	1.67e-9	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
SARC	cis	rs372883	0.638	rs371432	chr21:30710876	G/A	cg24692254	chr21:30365293	RNF160	-0.64	-7.93	-0.46	8.93e-14	Pancreatic cancer;
SARC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg11494091	chr17:61959527	GH2	-0.54	-8.04	-0.47	4.4e-14	Prudent dietary pattern;
SARC	cis	rs6456156	0.524	rs6934043	chr6:167466449	C/T	cg23791538	chr6:167370224	RNASET2	-0.52	-6.79	-0.41	9.49e-11	Primary biliary cholangitis;
SARC	cis	rs854765	0.647	rs741782	chr17:18019712	T/C	cg23370820	chr17:17987590	NA	-0.26	-5.07	-0.32	8.2e-7	Total body bone mineral density;
SARC	cis	rs61935443	0.562	rs11107791	chr12:95316374	G/A	cg21533806	chr12:95267307	NA	0.68	7.71	0.45	3.63e-13	Schizophrenia;
SARC	cis	rs11098499	0.863	rs7669520	chr4:120515278	T/C	cg09307838	chr4:120376055	NA	0.91	12.21	0.62	7.81e-27	Corneal astigmatism;
SARC	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg13849007	chr1:1677539	SLC35E2	-0.38	-4.89	-0.31	1.86e-6	Body mass index;
SARC	cis	rs7551222	0.714	rs930947	chr1:204541197	G/A	cg20240347	chr1:204465584	NA	-0.29	-4.91	-0.31	1.75e-6	Schizophrenia;
SARC	cis	rs2377585	0.653	rs7976729	chr12:8848685	A/G	cg03761649	chr12:8850719	RIMKLB	0.45	4.84	0.3	2.39e-6	Reticulocyte fraction of red cells;
SARC	cis	rs78320035	0.737	rs115959320	chr1:168159811	G/A	cg17113809	chr1:168148080	TIPRL	1.25	6.64	0.4	2.22e-10	Red cell distribution width;
SARC	cis	rs1318878	0.519	rs56195914	chr12:15503405	A/G	cg08258403	chr12:15378311	NA	0.5	6.98	0.42	3.13e-11	Intelligence (multi-trait analysis);
SARC	cis	rs9486719	0.857	rs2971606	chr6:97043025	C/G	cg18709589	chr6:96969512	KIAA0776	-0.49	-5.51	-0.34	9.41e-8	Migraine;Coronary artery disease;
SARC	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg12648201	chr2:27665141	KRTCAP3	-0.32	-4.72	-0.3	3.99e-6	Total body bone mineral density;
SARC	cis	rs7520050	0.966	rs1768803	chr1:46546208	T/C	cg06784218	chr1:46089804	CCDC17	-0.26	-4.82	-0.3	2.57e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs1008375	0.868	rs6816286	chr4:17698088	A/G	cg27347728	chr4:17578864	LAP3	0.44	5.67	0.35	4.13e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9486719	1.000	rs4343922	chr6:96876903	C/T	cg06623918	chr6:96969491	KIAA0776	0.73	8.33	0.48	6.81e-15	Migraine;Coronary artery disease;
SARC	cis	rs11105298	0.891	rs4842662	chr12:89933446	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.56	-5.62	-0.35	5.51e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs9388451	0.626	rs3734637	chr6:126081319	G/T	cg05901451	chr6:126070800	HEY2	-0.51	-6.56	-0.39	3.46e-10	Brugada syndrome;
SARC	cis	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg25809561	chr17:30822961	MYO1D	-0.37	-5.22	-0.32	3.92e-7	Schizophrenia;
SARC	cis	rs854765	0.583	rs8070722	chr17:17813562	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.66	9.77	0.54	3.98e-19	Total body bone mineral density;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17157498	chr19:1383493	NDUFS7	-0.5	-6.24	-0.38	2.07e-9	Smoking initiation;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg19778582	chr5:7900364	MTRR	0.48	6.89	0.41	5.02e-11	Thyroid stimulating hormone;
SARC	cis	rs4619890	0.510	rs28562959	chr4:7873174	T/C	cg18538662	chr4:7941764	AFAP1	-0.38	-4.9	-0.31	1.83e-6	Glaucoma (primary open-angle);
SARC	cis	rs3771570	1.000	rs57196672	chr2:242235193	G/A	cg21155796	chr2:242212141	HDLBP	0.64	5.24	0.32	3.65e-7	Prostate cancer;
SARC	cis	rs36051895	0.589	rs62543573	chr9:5201675	A/G	cg02405213	chr9:5042618	JAK2	-0.41	-4.75	-0.3	3.59e-6	Pediatric autoimmune diseases;
SARC	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.47	-5.08	-0.32	7.61e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg27286337	chr10:134555280	INPP5A	0.71	8.17	0.47	2.02e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs11581859	0.613	rs12071100	chr1:99198989	A/G	cg20286094	chr1:99190917	SNX7	0.41	4.85	0.3	2.24e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.72	8.47	0.49	2.82e-15	Height;
SARC	cis	rs2011503	0.943	rs1529745	chr19:19517325	C/G	cg03709012	chr19:19516395	GATAD2A	0.63	5.38	0.33	1.77e-7	Bipolar disorder;
SARC	trans	rs2727020	0.729	rs4980439	chr11:49342246	G/C	cg03929089	chr4:120376271	NA	-0.73	-10.71	-0.57	4.96e-22	Coronary artery disease;
SARC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg22903471	chr2:27725779	GCKR	-0.49	-7.42	-0.44	2.21e-12	Total body bone mineral density;
SARC	cis	rs2290405	0.527	rs7663192	chr4:923947	T/C	cg04824913	chr4:887549	GAK	0.57	7.0	0.42	2.73e-11	Systemic sclerosis;
SARC	cis	rs1008375	0.932	rs10009933	chr4:17670107	A/C	cg02297831	chr4:17616191	MED28	0.43	5.37	0.33	1.92e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7607369	0.714	rs1344643	chr2:219584975	G/C	cg02176678	chr2:219576539	TTLL4	-0.47	-7.49	-0.44	1.38e-12	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.65	-7.61	-0.45	6.58e-13	Gut microbiome composition (summer);
SARC	trans	rs17685	0.753	rs6951808	chr7:75772413	A/G	cg19862616	chr7:65841803	NCRNA00174	0.63	7.95	0.46	8.05e-14	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg11062466	chr8:58055876	NA	-0.6	-5.82	-0.36	1.97e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg12873037	chr17:79205369	C17orf56	0.48	6.27	0.38	1.71e-9	Schizophrenia;
SARC	cis	rs3870371	0.955	rs10091828	chr8:122697607	T/A	cg21781600	chr8:122651575	HAS2;HAS2AS	0.48	5.32	0.33	2.41e-7	Periodontal disease-related phenotypes;
SARC	cis	rs2283831	1.000	rs12169970	chr22:26967163	C/T	cg20674067	chr22:26567893	SEZ6L	-0.33	-5.01	-0.31	1.07e-6	Anti-saccade response;
SARC	cis	rs9486719	0.947	rs12194971	chr6:96911073	T/C	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.01	-0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs7587476	0.954	rs3768708	chr2:215645046	C/T	cg11970703	chr2:215861251	ABCA12	0.34	5.34	0.33	2.22e-7	Neuroblastoma;
SARC	cis	rs208520	0.690	rs207112	chr6:66792092	C/T	cg07460842	chr6:66804631	NA	-1.08	-15.02	-0.7	4.17e-36	Exhaled nitric oxide output;
SARC	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs734999	0.545	rs6666788	chr1:2567500	A/G	cg18854424	chr1:2615690	NA	-0.33	-5.24	-0.32	3.61e-7	Ulcerative colitis;
SARC	cis	rs1124769	0.957	rs12443062	chr15:51372727	C/T	cg21246271	chr15:51200259	AP4E1	-0.52	-4.86	-0.3	2.19e-6	Cognitive performance;
SARC	cis	rs709400	0.832	rs10145755	chr14:104121984	C/T	cg26031613	chr14:104095156	KLC1	0.99	18.61	0.77	5.65e-48	Body mass index;
SARC	cis	rs4664308	0.692	rs10497213	chr2:160963603	G/A	cg03641300	chr2:160917029	PLA2R1	-0.52	-6.84	-0.41	6.76e-11	Idiopathic membranous nephropathy;
SARC	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg26116260	chr4:7069785	GRPEL1	0.94	11.97	0.62	4.65e-26	Monocyte percentage of white cells;
SARC	cis	rs7208487	0.684	rs12449852	chr17:37632088	A/G	cg07936489	chr17:37558343	FBXL20	-0.76	-8.48	-0.49	2.64e-15	Primary biliary cholangitis;Glomerular filtration rate in non diabetics (creatinine);
SARC	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg22920501	chr2:26401640	FAM59B	-0.55	-7.13	-0.42	1.27e-11	Gut microbiome composition (summer);
SARC	cis	rs78320035	1.000	rs7552213	chr1:168137725	G/T	cg17113809	chr1:168148080	TIPRL	-1.1	-6.39	-0.39	8.82e-10	Red cell distribution width;
SARC	trans	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg20587970	chr11:113659929	NA	-1.31	-13.7	-0.67	9.62e-32	Hip circumference adjusted for BMI;
SARC	cis	rs7833986	0.501	rs2953911	chr8:56948009	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.75	7.44	0.44	1.88e-12	Height;
SARC	cis	rs1163251	0.837	rs592762	chr1:120247355	A/G	cg19096424	chr1:120255104	PHGDH	0.59	6.95	0.41	3.61e-11	Blood metabolite levels;
SARC	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg22903471	chr2:27725779	GCKR	-0.47	-6.86	-0.41	6.08e-11	Total body bone mineral density;
SARC	cis	rs2439831	0.867	rs2255051	chr15:43846161	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.95	9.15	0.51	3.04e-17	Lung cancer in ever smokers;
SARC	cis	rs7223966	0.960	rs2854222	chr17:61939015	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.46	5.04	0.31	9.41e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2153535	0.580	rs7741456	chr6:8452424	G/A	cg21535247	chr6:8435926	SLC35B3	0.55	6.84	0.41	6.72e-11	Motion sickness;
SARC	trans	rs61931739	0.534	rs4931772	chr12:34044590	G/A	cg13010199	chr12:38710504	ALG10B	0.66	9.05	0.51	5.8e-17	Morning vs. evening chronotype;
SARC	cis	rs191220855	1	rs191220855	chr2:200778130	A/G	cg17644776	chr2:200775616	C2orf69	-0.54	-5.16	-0.32	5.21e-7	Chickenpox;
SARC	cis	rs910316	0.967	rs1071989	chr14:75564659	G/T	cg11812906	chr14:75593930	NEK9	0.87	13.66	0.67	1.39e-31	Height;
SARC	cis	rs1163251	0.902	rs487081	chr1:120217389	G/A	cg19096424	chr1:120255104	PHGDH	0.53	6.2	0.38	2.58e-9	Blood metabolite levels;
SARC	cis	rs11687170	0.882	rs6758305	chr2:237056684	C/T	cg19324714	chr2:237145437	ASB18	0.49	4.89	0.31	1.89e-6	Educational attainment;Educational attainment (years of education);
SARC	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg17376030	chr22:41985996	PMM1	0.68	8.1	0.47	3.04e-14	Vitiligo;
SARC	cis	rs2013441	1.000	rs2703816	chr17:20118887	A/G	cg13482628	chr17:19912719	NA	-0.46	-6.0	-0.37	7.43e-9	Obesity-related traits;
SARC	trans	rs6815916	1.000	rs62339493	chr4:182553085	A/G	cg13864546	chr1:2310327	MORN1	0.67	6.36	0.38	1.06e-9	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs2760061	0.583	rs708123	chr1:228220495	A/G	cg01200585	chr1:228362443	C1orf69	0.45	5.91	0.36	1.23e-8	Diastolic blood pressure;
SARC	cis	rs870825	0.929	rs1405939	chr4:185591444	C/T	cg04058563	chr4:185651563	MLF1IP	0.76	7.73	0.45	3.23e-13	Blood protein levels;
SARC	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg03264133	chr6:25882463	NA	-0.52	-6.81	-0.41	8.04e-11	Intelligence (multi-trait analysis);
SARC	cis	rs9815354	1.000	rs9838965	chr3:41927938	C/T	cg03022575	chr3:42003672	ULK4	-0.56	-5.38	-0.33	1.81e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2204008	0.774	rs11616004	chr12:38278822	G/A	cg13010199	chr12:38710504	ALG10B	0.81	11.31	0.6	6.33e-24	Bladder cancer;
SARC	cis	rs9467773	0.620	rs2451732	chr6:26622904	A/T	cg12292205	chr6:26970375	C6orf41	-0.44	-5.55	-0.34	7.69e-8	Intelligence (multi-trait analysis);
SARC	cis	rs209489	1.000	rs209489	chr6:53177678	A/C	cg13709529	chr6:54001895	C6orf142	0.54	4.86	0.3	2.19e-6	Survival in colorectal cancer (distant metastatic);
SARC	cis	rs2985684	1.000	rs2224949	chr14:50096560	A/G	cg04989706	chr14:50066350	PPIL5	0.51	5.41	0.33	1.58e-7	Carotid intima media thickness;
SARC	trans	rs1814175	0.817	rs1794164	chr11:49899610	T/C	cg03929089	chr4:120376271	NA	-0.89	-14.51	-0.69	2.05e-34	Height;
SARC	cis	rs1799949	0.602	rs8176199	chr17:41230524	T/G	cg23758822	chr17:41437982	NA	0.85	8.75	0.5	4.48e-16	Menopause (age at onset);
SARC	cis	rs4588572	0.643	rs10043115	chr5:77692019	T/C	cg11547950	chr5:77652471	NA	0.4	4.93	0.31	1.55e-6	Triglycerides;
SARC	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg16405210	chr4:1374714	KIAA1530	-0.4	-4.82	-0.3	2.64e-6	Obesity-related traits;
SARC	trans	rs9354308	0.899	rs2802057	chr6:66548093	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.57	6.66	0.4	1.92e-10	Metabolite levels;
SARC	cis	rs10463554	1.000	rs3776864	chr5:102327868	A/C	cg23492399	chr5:102201601	PAM	-0.53	-6.54	-0.39	3.94e-10	Parkinson's disease;
SARC	cis	rs2055942	0.639	rs3792211	chr4:46994495	G/T	cg09812070	chr4:46995689	GABRA4	0.44	5.92	0.36	1.14e-8	Type 2 diabetes;
SARC	cis	rs2153535	0.580	rs915350	chr6:8443486	A/G	cg21535247	chr6:8435926	SLC35B3	0.56	7.01	0.42	2.6e-11	Motion sickness;
SARC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg09033563	chr22:24373618	LOC391322	-0.46	-5.59	-0.34	6.27e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs11098499	0.954	rs1546505	chr4:120241224	A/G	cg24375607	chr4:120327624	NA	0.4	4.82	0.3	2.59e-6	Corneal astigmatism;
SARC	cis	rs9916302	0.904	rs755500	chr17:37409865	C/T	cg07936489	chr17:37558343	FBXL20	-0.69	-9.46	-0.53	3.44e-18	Glomerular filtration rate (creatinine);
SARC	cis	rs1878931	0.624	rs28089	chr16:3446937	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.68	-7.32	-0.43	4.1e-12	Body mass index (adult);
SARC	cis	rs734999	0.549	rs3828154	chr1:2524943	G/A	cg20673091	chr1:2541236	MMEL1	0.33	5.13	0.32	6.14e-7	Ulcerative colitis;
SARC	cis	rs2180341	0.960	rs7766942	chr6:127691323	G/T	cg27446573	chr6:127587934	RNF146	1.06	14.81	0.7	2.04e-35	Breast cancer;
SARC	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg03060546	chr3:49711283	APEH	0.75	11.17	0.59	1.7e-23	Resting heart rate;
SARC	cis	rs4972806	0.849	rs2071581	chr2:177026148	G/T	cg13092806	chr2:177043255	NA	0.39	5.06	0.31	8.55e-7	IgG glycosylation;
SARC	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	cis	rs875971	1.000	rs1144895	chr7:65541307	C/G	cg18876405	chr7:65276391	NA	-0.47	-5.68	-0.35	3.99e-8	Aortic root size;
SARC	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg23758822	chr17:41437982	NA	0.88	10.75	0.58	3.78e-22	Menopause (age at onset);
SARC	cis	rs9290065	0.519	rs6774203	chr3:160705217	G/T	cg04691961	chr3:161091175	C3orf57	-0.49	-6.12	-0.37	3.86e-9	Kawasaki disease;
SARC	cis	rs3768617	0.706	rs8179460	chr1:183056222	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.66	9.31	0.52	1e-17	Fuchs's corneal dystrophy;
SARC	cis	rs79149102	0.737	rs113915655	chr15:75219722	T/C	cg09165964	chr15:75287851	SCAMP5	-1.12	-7.07	-0.42	1.76e-11	Lung cancer;
SARC	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg09359103	chr1:154839909	KCNN3	-0.48	-8.05	-0.47	4.18e-14	Prostate cancer;
SARC	cis	rs8067354	0.645	rs2102507	chr17:57875907	A/G	cg02344993	chr17:57696989	CLTC	0.67	7.01	0.42	2.54e-11	Hemoglobin concentration;
SARC	cis	rs9818758	0.607	rs66991555	chr3:49228643	A/G	cg03060546	chr3:49711283	APEH	-0.55	-4.85	-0.3	2.25e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg11317459	chr13:21872234	NA	1.1	16.11	0.73	9.5e-40	White matter hyperintensity burden;
SARC	cis	rs826838	0.806	rs826873	chr12:39121305	G/A	cg26384229	chr12:38710491	ALG10B	-0.82	-12.51	-0.63	8.48e-28	Heart rate;
SARC	cis	rs1371867	0.846	rs1788182	chr8:101334620	C/T	cg11906718	chr8:101322791	RNF19A	0.66	8.65	0.49	8.33e-16	Atrioventricular conduction;
SARC	cis	rs1729951	0.575	rs35289288	chr3:136680568	C/T	cg15507776	chr3:136538369	TMEM22	0.51	5.73	0.35	3.12e-8	Neuroticism;
SARC	cis	rs7178572	0.568	rs12901739	chr15:77395491	C/T	cg22256960	chr15:77711686	NA	-0.52	-5.58	-0.34	6.58e-8	Type 2 diabetes;
SARC	cis	rs4268898	0.662	rs72795824	chr2:24435837	T/C	cg26838691	chr2:24397539	C2orf84	-0.54	-6.2	-0.38	2.54e-9	Asthma;
SARC	cis	rs9768139	0.611	rs12698211	chr7:158119623	G/A	cg25566285	chr7:158114605	PTPRN2	0.31	5.19	0.32	4.68e-7	Calcium levels;
SARC	cis	rs2120243	0.572	rs2305620	chr3:157127586	C/T	cg24825693	chr3:157122686	VEPH1	-0.49	-6.86	-0.41	6.24e-11	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs9916302	0.861	rs4795377	chr17:37669056	C/T	cg15445000	chr17:37608096	MED1	0.4	4.74	0.3	3.8e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs7223966	1.000	rs9903897	chr17:61716705	T/A	cg00588841	chr17:61851480	DDX42;CCDC47	-0.59	-6.74	-0.4	1.2e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg06713675	chr4:122721982	EXOSC9	-0.5	-6.59	-0.4	2.96e-10	Type 2 diabetes;
SARC	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg06634786	chr22:41940651	POLR3H	0.55	6.33	0.38	1.24e-9	Vitiligo;
SARC	cis	rs9790314	0.871	rs466626	chr3:161103629	A/C	cg03342759	chr3:160939853	NMD3	-0.59	-7.35	-0.43	3.25e-12	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg02725872	chr8:58115012	NA	-0.36	-6.12	-0.37	3.91e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg18225595	chr11:63971243	STIP1	0.43	5.15	0.32	5.43e-7	Mean platelet volume;
SARC	trans	rs1973993	0.967	rs10489741	chr1:96942406	G/A	cg10631902	chr5:14652156	NA	0.44	7.47	0.44	1.61e-12	Weight;
SARC	cis	rs2276314	1.000	rs4573997	chr18:33552568	C/T	cg19628046	chr18:33552617	C18orf21	0.57	5.97	0.36	8.95e-9	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs8523	0.901	rs1570069	chr6:11017825	A/G	cg13562911	chr6:11044106	ELOVL2	0.36	4.79	0.3	2.99e-6	Red blood cell fatty acid levels;
SARC	cis	rs7953249	0.656	rs1732391	chr12:121392341	C/T	cg15155738	chr12:121454335	C12orf43	-0.45	-5.41	-0.33	1.6e-7	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs6546550	0.900	rs2054047	chr2:70117421	A/C	cg02498382	chr2:70120550	SNRNP27	-0.36	-5.85	-0.36	1.62e-8	Prevalent atrial fibrillation;
SARC	cis	rs1865760	0.865	rs9467652	chr6:25959127	A/G	cg18357526	chr6:26021779	HIST1H4A	0.4	4.92	0.31	1.63e-6	Height;
SARC	cis	rs7084402	0.967	rs1649032	chr10:60279701	T/C	cg07615347	chr10:60278583	BICC1	-0.6	-8.82	-0.5	2.78e-16	Refractive error;
SARC	cis	rs7635838	0.617	rs347587	chr3:11287155	A/G	cg00170343	chr3:11313890	ATG7	-0.73	-9.85	-0.54	2.4e-19	HDL cholesterol;
SARC	cis	rs17384381	1.000	rs12132677	chr1:85879613	A/C	cg16011679	chr1:85725395	C1orf52	0.6	5.63	0.35	5.18e-8	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg27379232	chr7:6694978	NA	0.48	6.27	0.38	1.69e-9	Schizophrenia;
SARC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg20304750	chr12:124821387	NCOR2	0.47	6.26	0.38	1.86e-9	HDL cholesterol;
SARC	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg16414030	chr3:133502952	NA	-0.38	-4.76	-0.3	3.36e-6	Iron status biomarkers;
SARC	cis	rs6665290	0.904	rs1045252	chr1:227181555	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.06	-24.69	-0.85	5.75e-67	Myeloid white cell count;
SARC	cis	rs4803468	1.000	rs1473248	chr19:41923314	C/T	cg09537434	chr19:41945824	ATP5SL	0.98	17.69	0.76	5.69e-45	Height;
SARC	cis	rs918629	0.530	rs13361837	chr5:95250478	T/G	cg16656078	chr5:95278638	ELL2	-0.54	-6.75	-0.4	1.16e-10	IgG glycosylation;
SARC	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.61	5.14	0.32	5.75e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg08640168	chr5:138273197	NA	-0.46	-6.49	-0.39	5.11e-10	Chemerin levels;
SARC	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg12463550	chr7:65579703	CRCP	0.47	5.29	0.33	2.79e-7	Aortic root size;
SARC	cis	rs10791323	0.575	rs4489760	chr11:133732265	A/T	cg13461336	chr11:133711254	SPATA19	-0.28	-5.17	-0.32	5.03e-7	Childhood ear infection;
SARC	cis	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg24110177	chr3:50126178	RBM5	0.39	5.04	0.31	9.18e-7	Intelligence (multi-trait analysis);
SARC	cis	rs67460515	0.531	rs1585483	chr3:160843111	G/A	cg17135325	chr3:160939158	NMD3	0.61	7.47	0.44	1.59e-12	Parkinson's disease;
SARC	cis	rs11687170	0.816	rs55880022	chr2:237061032	T/G	cg19324714	chr2:237145437	ASB18	0.47	4.73	0.3	3.82e-6	Educational attainment;Educational attainment (years of education);
SARC	cis	rs4466137	0.645	rs6894022	chr5:82982945	T/C	cg16102102	chr5:83017553	HAPLN1	-0.62	-8.37	-0.48	5.2e-15	Prostate cancer;
SARC	cis	rs7833790	0.724	rs4739627	chr8:82734657	A/G	cg06027949	chr8:82754900	SNX16	-0.48	-6.1	-0.37	4.28e-9	Diastolic blood pressure;
SARC	cis	rs7159888	0.510	rs10047879	chr14:65760543	C/A	cg15999311	chr14:65749247	NA	0.34	5.39	0.33	1.69e-7	IgG glycosylation;N-glycan levels;
SARC	cis	rs2836950	0.545	rs2836949	chr21:40602456	C/A	cg11890956	chr21:40555474	PSMG1	-0.71	-9.02	-0.51	7.19e-17	Menarche (age at onset);
SARC	cis	rs76419734	1.000	rs4373160	chr4:106648641	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.84	5.56	0.34	7.44e-8	Post bronchodilator FEV1;
SARC	trans	rs3942852	0.774	rs10838813	chr11:48186969	C/A	cg03929089	chr4:120376271	NA	-0.6	-6.75	-0.4	1.13e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs7829975	0.567	rs6601273	chr8:8796519	T/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.94	-0.41	3.75e-11	Mood instability;
SARC	cis	rs7666738	0.830	rs36028444	chr4:98968635	G/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg17691542	chr6:26056736	HIST1H1C	0.51	6.37	0.39	9.72e-10	Height;
SARC	cis	rs7666738	0.791	rs12233867	chr4:98950233	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	5.69	0.35	3.71e-8	Bipolar disorder;
SARC	cis	rs9916302	0.768	rs11078900	chr17:37614641	C/T	cg15445000	chr17:37608096	MED1	0.41	4.81	0.3	2.69e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg14893161	chr1:205819251	PM20D1	0.99	18.24	0.77	9.22e-47	Menarche (age at onset);
SARC	cis	rs55823223	0.618	rs11867339	chr17:73862093	A/G	cg06969265	chr17:73775802	H3F3B	0.67	7.08	0.42	1.69e-11	Psoriasis;
SARC	cis	rs12950390	0.893	rs4239165	chr17:45847272	A/T	cg24803719	chr17:45855879	NA	-0.48	-7.99	-0.46	6.27e-14	IgG glycosylation;
SARC	trans	rs931812	0.825	rs35515344	chr8:101896769	C/G	cg20993868	chr7:22813445	NA	0.46	6.38	0.39	9.51e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs7178909	0.872	rs61345389	chr15:90435885	T/C	cg19708238	chr15:90437601	AP3S2	0.62	8.41	0.48	4.15e-15	Common traits (Other);
SARC	cis	rs9303401	0.659	rs12944971	chr17:56988801	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.09	11.64	0.61	5.59e-25	Cognitive test performance;
SARC	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg18252515	chr7:66147081	NA	-1.22	-10.67	-0.57	6.88e-22	Diabetic kidney disease;
SARC	cis	rs2204008	0.902	rs11520218	chr12:38223227	G/A	cg26384229	chr12:38710491	ALG10B	0.88	12.94	0.65	3.26e-29	Bladder cancer;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg11295902	chr11:64546368	SF1	0.5	6.46	0.39	5.95e-10	Blood pressure;
SARC	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg16479474	chr6:28041457	NA	0.37	5.39	0.33	1.73e-7	Depression;
SARC	cis	rs3820928	0.874	rs11685983	chr2:227799853	A/G	cg05526886	chr2:227700861	RHBDD1	-0.54	-6.54	-0.39	3.76e-10	Pulmonary function;
SARC	cis	rs10779751	0.734	rs2486920	chr1:11125050	T/C	cg08854313	chr1:11322531	MTOR	0.81	11.17	0.59	1.77e-23	Body mass index;
SARC	cis	rs7818382	0.967	rs7812465	chr8:96050557	C/T	cg16049864	chr8:95962084	TP53INP1	0.32	5.15	0.32	5.51e-7	Alzheimer's disease (late onset);
SARC	trans	rs10862219	0.963	rs7954341	chr12:81419397	G/A	cg03835158	chr8:52773607	PCMTD1	-0.5	-6.84	-0.41	7.03e-11	Neuroticism;
SARC	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	13.57	0.66	2.58e-31	Chronic sinus infection;
SARC	cis	rs3540	0.533	rs2601197	chr15:90940059	C/A	cg22089800	chr15:90895588	ZNF774	0.66	7.94	0.46	8.39e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs2361710	0.668	rs2304855	chr17:78118266	T/A	cg20811857	chr17:78079795	GAA	-0.32	-5.19	-0.32	4.48e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
SARC	cis	rs1784581	0.674	rs1789996	chr6:162391895	T/C	cg17173639	chr6:162384350	PARK2	-0.58	-7.54	-0.44	1.06e-12	Itch intensity from mosquito bite;
SARC	cis	rs35110281	0.681	rs162343	chr21:44957072	A/G	cg01579765	chr21:45077557	HSF2BP	-0.32	-5.41	-0.33	1.57e-7	Mean corpuscular volume;
SARC	cis	rs10791323	0.511	rs4937837	chr11:133731134	T/C	cg14349672	chr11:133703707	NA	-0.34	-5.04	-0.31	9.17e-7	Childhood ear infection;
SARC	cis	rs7208859	0.673	rs2470251	chr17:29095061	T/C	cg13385521	chr17:29058706	SUZ12P	0.84	7.73	0.45	3.25e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs8067545	0.720	rs9916675	chr17:19900168	A/G	cg13482628	chr17:19912719	NA	0.55	6.96	0.41	3.51e-11	Schizophrenia;
SARC	cis	rs3733585	0.664	rs17245436	chr4:9958169	A/G	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.82	-0.36	1.92e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	5.93	0.36	1.09e-8	Prudent dietary pattern;
SARC	cis	rs546131	0.928	rs552627	chr11:34826680	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.49	6.24	0.38	2e-9	Lung disease severity in cystic fibrosis;
SARC	cis	rs12142240	0.698	rs55971480	chr1:46823206	G/T	cg10495392	chr1:46806563	NSUN4	0.65	6.8	0.41	8.89e-11	Menopause (age at onset);
SARC	cis	rs6910061	1.000	rs9468446	chr6:11118718	C/T	cg27233058	chr6:11094804	LOC221710	0.6	5.98	0.36	8.44e-9	Diabetic kidney disease;
SARC	cis	rs920590	0.500	rs7819535	chr8:19689058	A/G	cg17834443	chr8:19674713	INTS10	0.55	4.75	0.3	3.52e-6	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs1505368	0.567	rs972491	chr2:213316573	A/G	cg16329650	chr2:213403929	ERBB4	-0.46	-6.16	-0.37	3.11e-9	Symmetrical dimethylarginine levels;
SARC	trans	rs61931739	0.500	rs7310576	chr12:34474735	T/C	cg26384229	chr12:38710491	ALG10B	0.81	11.76	0.61	2.27e-25	Morning vs. evening chronotype;
SARC	cis	rs35213789	1.000	rs763759	chr7:69291567	C/T	cg10619644	chr7:69149951	AUTS2	0.46	5.74	0.35	2.99e-8	Childhood ear infection;
SARC	cis	rs8064299	0.597	rs2166703	chr17:72781812	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.8	10.94	0.58	9.14e-23	Monocyte count;
SARC	cis	rs6539267	0.741	rs35816179	chr12:106693710	T/C	cg02476566	chr12:106696527	TCP11L2	0.5	5.17	0.32	5.05e-7	Tourette syndrome;
SARC	cis	rs7937682	0.562	rs7938620	chr11:111366844	G/A	cg22437258	chr11:111473054	SIK2	-0.4	-4.78	-0.3	3.17e-6	Primary sclerosing cholangitis;
SARC	cis	rs8114671	0.967	rs3746427	chr20:33730464	A/G	cg24642439	chr20:33292090	TP53INP2	0.55	6.51	0.39	4.49e-10	Height;
SARC	cis	rs9916302	0.851	rs12936646	chr17:37647450	A/T	cg00129232	chr17:37814104	STARD3	-0.65	-8.06	-0.47	4e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs6582630	0.519	rs8189609	chr12:38281408	A/G	cg13010199	chr12:38710504	ALG10B	0.81	11.31	0.6	6.33e-24	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7582720	1.000	rs72934706	chr2:203707752	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	7.55	0.44	1e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg08975724	chr8:8085496	FLJ10661	0.51	6.37	0.39	1.01e-9	Mood instability;
SARC	cis	rs10779751	0.770	rs10864490	chr1:11236410	A/C	cg08854313	chr1:11322531	MTOR	0.8	10.5	0.57	2.37e-21	Body mass index;
SARC	cis	rs9470366	0.535	rs762624	chr6:36645588	A/C	cg08179530	chr6:36648295	CDKN1A	0.74	9.01	0.51	7.85e-17	QRS duration;
SARC	cis	rs911555	0.755	rs2756132	chr14:103967820	C/G	cg24130564	chr14:104152367	KLC1	0.52	6.01	0.37	7.26e-9	Intelligence (multi-trait analysis);
SARC	cis	rs73206853	0.841	rs3759382	chr12:110889483	G/A	cg10860002	chr12:110842031	ANAPC7	0.63	4.98	0.31	1.22e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs995000	0.931	rs1168042	chr1:62974150	A/T	cg06896770	chr1:63153194	DOCK7	-0.89	-12.89	-0.65	4.52e-29	Triglyceride levels;
SARC	cis	rs10982256	0.782	rs62555200	chr9:117247642	T/C	cg21159778	chr9:117266918	DFNB31	0.35	4.89	0.3	1.91e-6	Bipolar disorder;
SARC	cis	rs270601	0.817	rs460089	chr5:131629772	C/G	cg12564285	chr5:131593104	PDLIM4	0.41	5.36	0.33	2e-7	Acylcarnitine levels;
SARC	cis	rs796364	0.760	rs56285751	chr2:200919836	C/T	cg23649088	chr2:200775458	C2orf69	-0.6	-5.29	-0.33	2.77e-7	Schizophrenia;
SARC	cis	rs11098499	0.722	rs10006192	chr4:120263022	T/C	cg09307838	chr4:120376055	NA	0.75	10.43	0.56	3.87e-21	Corneal astigmatism;
SARC	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	20.88	0.81	2.79e-55	Chronic sinus infection;
SARC	cis	rs9400467	0.537	rs73528979	chr6:111430404	G/A	cg15721981	chr6:111408429	SLC16A10	0.66	5.64	0.35	4.81e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg15448220	chr1:150897856	SETDB1	0.48	6.53	0.39	4.09e-10	Tonsillectomy;
SARC	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg00933542	chr6:150070202	PCMT1	0.32	5.46	0.34	1.23e-7	Lung cancer;
SARC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg23131131	chr22:24373011	LOC391322	-0.49	-5.3	-0.33	2.64e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2011503	0.941	rs76944848	chr19:19417512	C/T	cg03709012	chr19:19516395	GATAD2A	0.65	5.5	0.34	9.91e-8	Bipolar disorder;
SARC	cis	rs10197940	0.662	rs10175134	chr2:152299355	G/A	cg19508488	chr2:152266495	RIF1	0.5	5.29	0.33	2.77e-7	Lung cancer;
SARC	cis	rs2387326	0.767	rs12264157	chr10:129943271	G/A	cg16087940	chr10:129947807	NA	-0.47	-5.74	-0.35	3e-8	Select biomarker traits;
SARC	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg17376030	chr22:41985996	PMM1	-0.63	-7.77	-0.45	2.42e-13	Vitiligo;
SARC	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg23758822	chr17:41437982	NA	0.9	11.39	0.6	3.52e-24	Menopause (age at onset);
SARC	cis	rs4481887	0.830	rs4916126	chr1:248466604	G/A	cg00666640	chr1:248458726	OR2T12	0.37	6.3	0.38	1.43e-9	Common traits (Other);
SARC	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg12463550	chr7:65579703	CRCP	0.7	5.31	0.33	2.6e-7	Diabetic kidney disease;
SARC	cis	rs72687362	0.581	rs12544947	chr8:143345477	A/T	cg01869618	chr8:143397339	TSNARE1	-0.37	-4.85	-0.3	2.26e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7223966	1.000	rs8075273	chr17:61728881	G/T	cg22842932	chr17:61959568	GH2	-0.39	-5.04	-0.31	9.5e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg08219700	chr8:58056026	NA	0.59	6.29	0.38	1.55e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs732765	0.909	rs709887	chr14:75369379	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.45	-5.26	-0.33	3.31e-7	Non-small cell lung cancer;
SARC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.33	-4.95	-0.31	1.4e-6	Total body bone mineral density;
SARC	cis	rs568617	0.903	rs601863	chr11:65646557	C/A	cg00576331	chr11:65640516	EFEMP2	0.47	5.45	0.34	1.27e-7	Crohn's disease;
SARC	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg24324837	chr19:49891574	CCDC155	0.42	5.27	0.33	3.03e-7	Multiple sclerosis;
SARC	cis	rs11608355	0.515	rs12579916	chr12:109924528	T/G	cg05360138	chr12:110035743	NA	0.93	9.49	0.53	2.87e-18	Neuroticism;
SARC	cis	rs1153858	1.000	rs11852800	chr15:45639131	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.77	-10.77	-0.58	3.25e-22	Homoarginine levels;
SARC	cis	rs820218	0.798	rs9909259	chr17:73648366	G/A	cg01592526	chr17:73663357	RECQL5;SAP30BP	-0.58	-7.65	-0.45	5.27e-13	Rotator cuff tears;
SARC	cis	rs875971	0.867	rs13227219	chr7:65844062	T/A	cg18876405	chr7:65276391	NA	0.49	5.9	0.36	1.29e-8	Aortic root size;
SARC	cis	rs734999	0.505	rs4278312	chr1:2539555	A/G	cg18854424	chr1:2615690	NA	0.32	5.12	0.32	6.25e-7	Ulcerative colitis;
SARC	cis	rs6831352	0.760	rs1311616	chr4:100012303	T/G	cg12011299	chr4:100065546	ADH4	0.32	5.24	0.32	3.6e-7	Alcohol dependence;
SARC	cis	rs3816788	0.837	rs6557640	chr8:21771731	A/T	cg17168535	chr8:21777572	XPO7	0.8	10.83	0.58	2.17e-22	Lung cancer in ever smokers;
SARC	cis	rs11098499	0.863	rs7664986	chr4:120429952	A/C	cg24375607	chr4:120327624	NA	0.41	4.79	0.3	2.97e-6	Corneal astigmatism;
SARC	cis	rs4932217	0.693	rs208824	chr15:89927560	A/G	cg03745604	chr15:89905304	NA	0.35	4.92	0.31	1.64e-6	Height;
SARC	cis	rs9457247	0.508	rs6918286	chr6:167505829	C/T	cg23791538	chr6:167370224	RNASET2	-0.4	-4.97	-0.31	1.32e-6	Crohn's disease;
SARC	cis	rs12311304	0.901	rs9787991	chr12:15417022	C/T	cg08258403	chr12:15378311	NA	0.43	6.72	0.4	1.37e-10	Behavioural disinhibition (generation interaction);
SARC	cis	rs7666738	0.830	rs6852015	chr4:99054373	C/A	cg05340658	chr4:99064831	C4orf37	0.65	8.85	0.5	2.24e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg16606324	chr3:10149918	C3orf24	0.5	5.01	0.31	1.08e-6	Alzheimer's disease;
SARC	cis	rs611744	0.934	rs1668178	chr8:109191700	A/G	cg21045802	chr8:109455806	TTC35	0.44	5.3	0.33	2.64e-7	Dupuytren's disease;
SARC	cis	rs7216064	1.000	rs9897982	chr17:65879592	G/T	cg12091567	chr17:66097778	LOC651250	-0.71	-7.78	-0.45	2.38e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	trans	rs61931739	0.513	rs10743833	chr12:33897481	C/T	cg26384229	chr12:38710491	ALG10B	0.59	7.63	0.45	5.83e-13	Morning vs. evening chronotype;
SARC	cis	rs10782582	0.593	rs77208152	chr1:76124255	T/C	cg03433033	chr1:76189801	ACADM	-0.4	-5.26	-0.33	3.33e-7	Daytime sleep phenotypes;
SARC	cis	rs113835537	0.597	rs7939759	chr11:66337964	C/T	cg24851651	chr11:66362959	CCS	0.41	5.28	0.33	2.93e-7	Airway imaging phenotypes;
SARC	cis	rs7944584	0.563	rs2280231	chr11:47600438	C/T	cg10504702	chr11:47789108	FNBP4	0.65	7.72	0.45	3.37e-13	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg03647317	chr4:187891568	NA	-0.36	-5.22	-0.32	3.98e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7223966	1.000	rs9903897	chr17:61716705	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.48	-5.22	-0.32	3.92e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs473651	0.740	rs502349	chr2:239318389	C/T	cg21699342	chr2:239360505	ASB1	0.39	5.64	0.35	4.93e-8	Multiple system atrophy;
SARC	cis	rs67311347	0.544	rs9868700	chr3:40345408	G/A	cg09455208	chr3:40491958	NA	0.28	4.74	0.3	3.73e-6	Renal cell carcinoma;
SARC	cis	rs17125944	0.505	rs2295826	chr14:53174923	C/T	cg13660082	chr14:53194042	PSMC6	0.71	5.14	0.32	5.92e-7	Alzheimer's disease (late onset);
SARC	cis	rs2498796	0.712	rs4983546	chr14:105214479	T/C	cg07523784	chr14:105186699	NA	-0.34	-4.92	-0.31	1.61e-6	Endometrial cancer;Endometrial endometrioid carcinoma;
SARC	cis	rs6540556	0.723	rs6540550	chr1:209925251	A/G	cg23920097	chr1:209922102	NA	-0.6	-6.87	-0.41	5.79e-11	Red blood cell count;
SARC	cis	rs4253772	0.637	rs6008357	chr22:46652104	T/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.64	6.81	0.41	8.27e-11	LDL cholesterol;Cholesterol, total;
SARC	cis	rs2816062	1.000	rs2816062	chr1:18903902	G/A	cg18795169	chr1:18902165	NA	-0.79	-12.15	-0.62	1.25e-26	Urate levels in lean individuals;
SARC	cis	rs7100689	0.516	rs10887711	chr10:82034842	A/G	cg01528321	chr10:82214614	TSPAN14	0.57	7.44	0.44	1.93e-12	Post bronchodilator FEV1;
SARC	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-6.82	-0.41	7.94e-11	Personality dimensions;
SARC	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-8.85	-0.5	2.28e-16	Alzheimer's disease;
SARC	cis	rs7714584	1.000	rs17800886	chr5:150309539	C/G	cg22134413	chr5:150180641	NA	0.81	6.82	0.41	7.88e-11	Crohn's disease;
SARC	cis	rs2228479	0.618	rs34689166	chr16:89860697	C/T	cg06558623	chr16:89946397	TCF25	0.94	6.6	0.4	2.67e-10	Skin colour saturation;
SARC	cis	rs7592578	0.537	rs62180982	chr2:191264485	G/T	cg27211696	chr2:191398769	TMEM194B	-0.48	-5.07	-0.31	8.26e-7	Diastolic blood pressure;
SARC	cis	rs6591182	0.504	rs7116712	chr11:65372518	A/G	cg27068330	chr11:65405492	SIPA1	-0.42	-5.09	-0.32	7.27e-7	Non-alcoholic fatty liver disease histology (lobular);
SARC	cis	rs950169	0.922	rs11638445	chr15:85137694	C/A	cg24253500	chr15:84953950	NA	0.37	5.25	0.33	3.35e-7	Schizophrenia;
SARC	cis	rs9810089	0.868	rs4630889	chr3:136278251	T/C	cg15507776	chr3:136538369	TMEM22	0.43	4.73	0.3	3.89e-6	Gestational age at birth (child effect);
SARC	cis	rs9916302	0.904	rs55689507	chr17:37404436	G/C	cg00129232	chr17:37814104	STARD3	-0.6	-7.39	-0.44	2.57e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg20607798	chr8:58055168	NA	0.6	5.34	0.33	2.19e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg08219700	chr8:58056026	NA	0.49	5.47	0.34	1.14e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9381040	1.000	rs2093396	chr6:41155000	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.45	-5.31	-0.33	2.53e-7	Alzheimer's disease (late onset);
SARC	cis	rs9300255	0.602	rs1727294	chr12:123616514	A/G	cg05973401	chr12:123451056	ABCB9	0.56	6.37	0.39	1e-9	Neutrophil percentage of white cells;
SARC	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg05368731	chr17:41323189	NBR1	0.79	9.45	0.53	3.89e-18	Menopause (age at onset);
SARC	cis	rs7106204	0.748	rs12293729	chr11:24224679	A/G	ch.11.24196551F	chr11:24239977	NA	0.55	5.9	0.36	1.28e-8	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs1348850	0.914	rs2121430	chr2:178318375	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.49	5.72	0.35	3.27e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs4660306	0.961	rs4660867	chr1:45986484	A/G	cg24296786	chr1:45957014	TESK2	0.58	6.79	0.41	9.22e-11	Homocysteine levels;
SARC	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg06108461	chr20:60628389	TAF4	-0.92	-12.69	-0.64	2.14e-28	Body mass index;
SARC	cis	rs7223966	1.000	rs15637	chr17:61772050	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.57	-6.67	-0.4	1.87e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7246760	0.867	rs2287843	chr19:9769913	G/A	cg16876255	chr19:9731953	ZNF561	0.84	5.15	0.32	5.66e-7	Pursuit maintenance gain;
SARC	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg21782813	chr7:2030301	MAD1L1	0.34	5.34	0.33	2.21e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs6665290	0.545	rs6426584	chr1:227374949	A/T	cg14016676	chr1:227182615	CDC42BPA	0.37	4.93	0.31	1.56e-6	Myeloid white cell count;
SARC	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg20965017	chr5:231967	SDHA	-0.56	-5.3	-0.33	2.71e-7	Breast cancer;
SARC	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg11062466	chr8:58055876	NA	0.53	5.53	0.34	8.39e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg08859206	chr1:53392774	SCP2	-0.42	-6.12	-0.37	3.91e-9	Monocyte count;
SARC	cis	rs611744	0.967	rs695028	chr8:109239324	T/C	cg21045802	chr8:109455806	TTC35	0.46	5.43	0.34	1.38e-7	Dupuytren's disease;
SARC	cis	rs710216	0.917	rs900834	chr1:43412343	A/G	cg03128534	chr1:43423976	SLC2A1	-0.66	-6.77	-0.41	1.03e-10	Red cell distribution width;
SARC	cis	rs4891159	0.757	rs11665518	chr18:74147054	C/T	cg24786174	chr18:74118243	ZNF516	-0.64	-8.9	-0.5	1.57e-16	Longevity;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg08941850	chr5:43066475	NA	-0.52	-6.31	-0.38	1.36e-9	Schizophrenia;
SARC	cis	rs568617	0.953	rs1151519	chr11:65645831	G/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.47	-5.47	-0.34	1.15e-7	Crohn's disease;
SARC	cis	rs36051895	0.623	rs7025005	chr9:5261794	T/C	cg02405213	chr9:5042618	JAK2	-0.45	-5.19	-0.32	4.68e-7	Pediatric autoimmune diseases;
SARC	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg04772025	chr11:68637568	NA	0.5	6.12	0.37	3.95e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7833986	0.501	rs2667999	chr8:56950474	T/C	cg26371346	chr8:56986568	SNORD54;RPS20	0.74	7.44	0.44	1.97e-12	Height;
SARC	cis	rs6138458	0.546	rs6050118	chr20:24891895	C/T	cg26195577	chr20:24973756	C20orf3	-0.78	-7.08	-0.42	1.65e-11	Blood protein levels;
SARC	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg00149659	chr3:10157352	C3orf10	0.74	7.17	0.43	9.81e-12	Alzheimer's disease;
SARC	cis	rs9303401	0.573	rs35104446	chr17:57180234	A/C	cg25039879	chr17:56429692	SUPT4H1	0.58	5.22	0.32	3.88e-7	Cognitive test performance;
SARC	cis	rs2273669	0.915	rs67708237	chr6:109292058	G/A	cg05315195	chr6:109294784	ARMC2	-0.48	-4.78	-0.3	3.15e-6	Prostate cancer;
SARC	cis	rs4242434	0.819	rs55776566	chr8:22469492	T/C	cg03733263	chr8:22462867	KIAA1967	0.93	15.42	0.71	1.92e-37	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg13628971	chr7:2884303	GNA12	0.51	6.11	0.37	4.21e-9	Height;
SARC	cis	rs2120019	1.000	rs12910644	chr15:75358388	A/G	cg09165964	chr15:75287851	SCAMP5	-0.93	-13.7	-0.67	1.01e-31	Blood trace element (Zn levels);
SARC	cis	rs9916302	0.904	rs612194	chr17:37442707	T/A	cg15445000	chr17:37608096	MED1	-0.42	-5.16	-0.32	5.18e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs12579753	0.719	rs4418885	chr12:82275845	A/T	cg07988820	chr12:82153109	PPFIA2	-0.44	-5.31	-0.33	2.58e-7	Resting heart rate;
SARC	cis	rs36051895	0.659	rs1576271	chr9:5039652	A/C	cg02405213	chr9:5042618	JAK2	-0.56	-6.18	-0.38	2.85e-9	Pediatric autoimmune diseases;
SARC	trans	rs1814175	0.745	rs7483456	chr11:49774613	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-18.04	-0.76	3.96e-46	Height;
SARC	cis	rs2191566	1.000	rs2356549	chr19:44511202	A/T	cg20607764	chr19:44506953	ZNF230	-0.44	-5.03	-0.31	9.91e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs7681440	0.583	rs2583987	chr4:90760221	A/C	cg06632027	chr4:90757378	SNCA	-0.44	-5.61	-0.35	5.66e-8	Dementia with Lewy bodies;
SARC	cis	rs854765	0.583	rs11869536	chr17:17826528	T/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.43	5.67	0.35	4.18e-8	Total body bone mineral density;
SARC	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.47	-5.87	-0.36	1.51e-8	Intelligence (multi-trait analysis);
SARC	cis	rs12079745	1.000	rs12081562	chr1:169176266	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.8	-5.08	-0.32	7.68e-7	QT interval;
SARC	cis	rs9911578	1.000	rs2079703	chr17:56603978	G/A	cg05425664	chr17:57184151	TRIM37	0.65	8.02	0.46	5.23e-14	Intelligence (multi-trait analysis);
SARC	cis	rs911555	0.504	rs745079	chr14:104073551	G/A	cg26031613	chr14:104095156	KLC1	0.59	7.78	0.45	2.35e-13	Intelligence (multi-trait analysis);
SARC	cis	rs524281	0.647	rs2302883	chr11:65824994	T/C	cg14036092	chr11:66035641	RAB1B	-0.6	-6.9	-0.41	4.76e-11	Electroencephalogram traits;
SARC	cis	rs5753618	0.583	rs7287267	chr22:31748415	C/T	cg13145458	chr22:31556086	RNF185	-0.46	-5.06	-0.31	8.58e-7	Colorectal cancer;
SARC	cis	rs826838	0.709	rs4882355	chr12:38721462	A/T	cg13010199	chr12:38710504	ALG10B	0.57	7.4	0.44	2.45e-12	Heart rate;
SARC	cis	rs910316	1.000	rs4903281	chr14:75554361	G/C	cg11812906	chr14:75593930	NEK9	0.89	13.69	0.67	1.05e-31	Height;
SARC	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.49	7.2	0.43	8.31e-12	Systemic lupus erythematosus;
SARC	cis	rs1062177	0.906	rs2964573	chr5:151160122	A/T	cg00977110	chr5:151150581	G3BP1	0.63	6.33	0.38	1.22e-9	Preschool internalizing problems;
SARC	cis	rs10927875	0.557	rs1572381	chr1:16344494	G/A	cg21385522	chr1:16154831	NA	0.54	6.45	0.39	6.22e-10	Dilated cardiomyopathy;
SARC	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg22535103	chr8:58192502	C8orf71	-0.66	-8.07	-0.47	3.7e-14	Developmental language disorder (linguistic errors);
SARC	cis	rs7931462	0.655	rs6483208	chr11:92705844	A/C	cg16027622	chr11:93517359	MED17	0.64	4.95	0.31	1.43e-6	DNA methylation (parent-of-origin);
SARC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.57	0.57	1.43e-21	Prudent dietary pattern;
SARC	cis	rs7666738	0.830	rs7657490	chr4:99043973	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4689388	0.750	rs10001190	chr4:6284633	C/T	cg25554036	chr4:6271136	WFS1	-0.34	-5.17	-0.32	4.95e-7	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs8067545	0.611	rs12936443	chr17:20033446	T/G	cg13482628	chr17:19912719	NA	0.53	6.99	0.42	2.87e-11	Schizophrenia;
SARC	cis	rs1920116	0.778	rs9831336	chr3:169558373	C/G	cg08193579	chr3:169529701	LRRC34	-0.39	-4.75	-0.3	3.56e-6	Glioma (high-grade);
SARC	cis	rs1797081	0.967	rs780633	chr10:16863161	C/T	cg23933602	chr10:16859644	RSU1	0.99	20.32	0.8	1.65e-53	Platelet distribution width;
SARC	cis	rs9761603	0.570	rs61326094	chr4:138412210	C/T	cg12033966	chr4:138453416	PCDH18	0.56	7.41	0.44	2.32e-12	Diastolic blood pressure;
SARC	cis	rs1153858	1.000	rs4775909	chr15:45643042	T/C	cg14582100	chr15:45693742	SPATA5L1	0.36	5.01	0.31	1.1e-6	Homoarginine levels;
SARC	cis	rs861020	0.630	rs627069	chr1:210004613	C/G	cg05527609	chr1:210001259	C1orf107	0.78	10.12	0.55	3.37e-20	Orofacial clefts;
SARC	cis	rs9814567	1.000	rs11706117	chr3:134212526	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-7.22	-0.43	7.32e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs367943	1.000	rs348941	chr5:112824166	G/C	cg12552261	chr5:112820674	MCC	-0.46	-5.2	-0.32	4.33e-7	Type 2 diabetes;
SARC	cis	rs6570726	1.000	rs455109	chr6:145872665	C/T	cg23711669	chr6:146136114	FBXO30	0.74	11.07	0.59	3.76e-23	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs17030434	0.953	rs12639885	chr4:154700374	G/A	cg14289246	chr4:154710475	SFRP2	-0.8	-7.97	-0.46	7.13e-14	Electrocardiographic conduction measures;
SARC	cis	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg00745463	chr17:30367425	LRRC37B	-0.69	-5.28	-0.33	2.96e-7	Hip circumference adjusted for BMI;
SARC	cis	rs7949030	1.000	rs2956993	chr11:62406162	G/T	cg22862634	chr11:62369728	EML3;MTA2	-0.46	-6.72	-0.4	1.35e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs57506017	0.585	rs1990622	chr7:12283787	A/G	cg23422036	chr7:12250390	TMEM106B	0.48	6.35	0.38	1.12e-9	Neuroticism;
SARC	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg14784868	chr12:69753453	YEATS4	0.5	6.67	0.4	1.88e-10	Blood protein levels;
SARC	cis	rs9916302	0.904	rs7221875	chr17:37543328	G/A	cg15445000	chr17:37608096	MED1	-0.4	-4.85	-0.3	2.22e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs7552404	0.924	rs2275378	chr1:76198436	T/C	cg10523679	chr1:76189770	ACADM	0.51	7.07	0.42	1.75e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg12042659	chr19:58951599	ZNF132	0.41	5.49	0.34	1.03e-7	Uric acid clearance;
SARC	trans	rs877282	0.898	rs2004478	chr10:770709	C/A	cg22713356	chr15:30763199	NA	1.03	9.96	0.55	1.07e-19	Uric acid levels;
SARC	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg25894440	chr7:65020034	NA	-0.73	-5.54	-0.34	8.11e-8	Diabetic kidney disease;
SARC	cis	rs9987353	0.544	rs2929469	chr8:9062656	T/G	cg15556689	chr8:8085844	FLJ10661	0.48	5.96	0.36	9.31e-9	Recombination measurement;
SARC	cis	rs2120019	1.000	rs2083731	chr15:75368538	A/C	cg00629941	chr15:75287862	SCAMP5	-0.61	-7.28	-0.43	5.2e-12	Blood trace element (Zn levels);
SARC	cis	rs865483	0.861	rs1063215	chr17:35874936	A/G	cg06561646	chr17:35873369	DUSP14	-0.51	-6.54	-0.39	3.94e-10	Monocyte count;
SARC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg09373136	chr17:61933544	TCAM1	-0.44	-6.08	-0.37	4.86e-9	Prudent dietary pattern;
SARC	trans	rs1814175	0.616	rs1722020	chr11:49904189	G/A	cg03929089	chr4:120376271	NA	-0.81	-11.68	-0.61	4.04e-25	Height;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg24410064	chr7:7222050	C1GALT1	-0.62	-7.18	-0.43	9.23e-12	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs4727027	0.833	rs2107846	chr7:148832774	G/A	cg23583168	chr7:148888333	NA	-0.74	-11.29	-0.59	7.1e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs9325144	0.534	rs1843866	chr12:38703160	G/T	cg10518543	chr12:38710700	ALG10B	0.38	4.81	0.3	2.67e-6	Morning vs. evening chronotype;
SARC	cis	rs11098499	0.954	rs7681544	chr4:120411255	T/C	cg09307838	chr4:120376055	NA	0.93	12.73	0.64	1.6e-28	Corneal astigmatism;
SARC	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg04267008	chr7:1944627	MAD1L1	-0.67	-8.22	-0.47	1.4e-14	Bipolar disorder and schizophrenia;
SARC	cis	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg14541582	chr5:601475	NA	-0.4	-4.8	-0.3	2.85e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs950776	0.616	rs3743077	chr15:78894896	C/T	cg22563815	chr15:78856949	CHRNA5	0.39	6.42	0.39	7.65e-10	Sudden cardiac arrest;
SARC	cis	rs1448094	0.967	rs2044617	chr12:86324089	T/C	cg02569458	chr12:86230093	RASSF9	0.4	5.8	0.36	2.17e-8	Major depressive disorder;
SARC	trans	rs916888	0.647	rs199524	chr17:44848438	G/T	cg22433210	chr17:43662623	NA	-0.75	-8.46	-0.48	2.89e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg12564285	chr5:131593104	PDLIM4	0.44	6.15	0.37	3.4e-9	Breast cancer;
SARC	cis	rs11677370	0.561	rs10191326	chr2:3827524	G/C	cg17052675	chr2:3827356	NA	-0.48	-5.47	-0.34	1.14e-7	Type 2 diabetes;
SARC	cis	rs8180040	1.000	rs1024037	chr3:47318449	C/A	cg27129171	chr3:47204927	SETD2	-0.7	-9.7	-0.54	6.56e-19	Colorectal cancer;
SARC	trans	rs11098499	0.865	rs28845498	chr4:120405186	G/A	cg25214090	chr10:38739885	LOC399744	0.57	7.33	0.43	3.83e-12	Corneal astigmatism;
SARC	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg08219700	chr8:58056026	NA	0.47	4.84	0.3	2.39e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs2295359	1.000	rs4655684	chr1:67611772	A/G	cg12940439	chr1:67600707	NA	-0.45	-7.04	-0.42	2.17e-11	Psoriasis;
SARC	cis	rs17270561	0.609	rs4712965	chr6:25742022	G/T	cg16482183	chr6:26056742	HIST1H1C	0.43	5.08	0.32	7.76e-7	Iron status biomarkers;
SARC	cis	rs7296418	0.961	rs1790106	chr12:123591596	G/T	cg00376283	chr12:123451042	ABCB9	0.69	8.98	0.51	9.17e-17	Platelet count;
SARC	cis	rs425277	0.958	rs262660	chr1:2086757	A/G	cg21442419	chr1:2182373	SKI	-0.53	-6.71	-0.4	1.44e-10	Height;
SARC	cis	rs7582720	0.943	rs72932583	chr2:203869847	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	7.36	0.43	3.09e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs1865721	0.771	rs727893	chr18:73136931	G/A	cg26385618	chr18:73139727	C18orf62	-0.39	-5.44	-0.34	1.34e-7	Intelligence;
SARC	cis	rs734999	0.588	rs4648562	chr1:2535613	C/A	cg20673091	chr1:2541236	MMEL1	0.34	5.25	0.33	3.46e-7	Ulcerative colitis;
SARC	cis	rs6578185	0.810	rs3935446	chr8:142452954	C/T	cg07762003	chr8:142452454	FLJ43860	-0.3	-5.34	-0.33	2.18e-7	Endometriosis;
SARC	cis	rs992157	0.866	rs2292554	chr2:219146868	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.69	-10.0	-0.55	8.07e-20	Colorectal cancer;
SARC	cis	rs9916302	0.851	rs4390625	chr17:37620347	A/G	cg20243544	chr17:37824526	PNMT	0.56	6.73	0.4	1.32e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs7598759	0.712	rs6740474	chr2:232331831	A/G	cg19187155	chr2:232395269	NMUR1	0.6	8.52	0.49	2e-15	Noise-induced hearing loss;
SARC	cis	rs367615	0.552	rs3828603	chr5:108712068	G/C	cg17395555	chr5:108820864	NA	-0.34	-4.8	-0.3	2.9e-6	Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs7851660	0.967	rs13288000	chr9:100608980	A/G	cg13688889	chr9:100608707	NA	-0.37	-4.79	-0.3	2.93e-6	Strep throat;
SARC	cis	rs112591243	0.685	rs2839338	chr21:47987984	C/T	cg10657630	chr21:48055338	PRMT2	0.73	5.31	0.33	2.57e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs412050	0.895	rs240065	chr22:22296119	C/T	cg17089214	chr22:22089827	YPEL1	0.55	5.17	0.32	5.1e-7	Attention deficit hyperactivity disorder;
SARC	cis	rs1865760	0.532	rs9295687	chr6:26082710	T/C	cg10373733	chr6:25993375	NA	0.45	5.43	0.34	1.4e-7	Height;
SARC	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg16049864	chr8:95962084	TP53INP1	-0.48	-7.83	-0.46	1.72e-13	Type 2 diabetes;
SARC	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg04944784	chr2:26401820	FAM59B	-0.48	-5.94	-0.36	1.01e-8	Gut microbiome composition (summer);
SARC	cis	rs7937682	0.889	rs12360825	chr11:111528786	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.97	-16.26	-0.73	3.06e-40	Primary sclerosing cholangitis;
SARC	trans	rs1814175	0.817	rs12277258	chr11:49940216	T/C	cg15704280	chr7:45808275	SEPT13	-0.98	-18.3	-0.77	5.62e-47	Height;
SARC	cis	rs7712401	0.715	rs401226	chr5:122347726	G/A	cg19412675	chr5:122181750	SNX24	-0.41	-5.26	-0.33	3.18e-7	Mean platelet volume;
SARC	cis	rs12188164	0.543	rs2672722	chr5:453567	G/A	cg16584290	chr5:462447	EXOC3	0.43	6.65	0.4	2.05e-10	Cystic fibrosis severity;
SARC	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg11644478	chr21:40555479	PSMG1	1.05	14.99	0.7	5.25e-36	Cognitive function;
SARC	cis	rs12681288	0.862	rs7814231	chr8:1021103	A/G	cg15309053	chr8:964076	NA	0.41	6.91	0.41	4.48e-11	Schizophrenia;
SARC	cis	rs826838	0.616	rs1601746	chr12:38626195	G/T	cg26384229	chr12:38710491	ALG10B	-0.61	-8.09	-0.47	3.31e-14	Heart rate;
SARC	cis	rs9303401	0.704	rs740605	chr17:56604811	C/T	cg05425664	chr17:57184151	TRIM37	-0.42	-5.05	-0.31	8.85e-7	Cognitive test performance;
SARC	trans	rs9354308	0.774	rs10155672	chr6:66538447	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.56	-6.64	-0.4	2.18e-10	Metabolite levels;
SARC	cis	rs3540	0.597	rs10152221	chr15:91047664	A/G	cg22089800	chr15:90895588	ZNF774	-0.59	-7.63	-0.45	5.79e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg22800045	chr5:56110881	MAP3K1	0.74	7.83	0.46	1.74e-13	Initial pursuit acceleration;
SARC	cis	rs17209837	1.000	rs59616301	chr7:87118407	T/C	cg00919237	chr7:87102261	ABCB4	-0.45	-4.76	-0.3	3.48e-6	Gallbladder cancer;
SARC	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	7.78	0.45	2.33e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg06873352	chr17:61820015	STRADA	0.53	6.79	0.41	9.06e-11	Prudent dietary pattern;
SARC	cis	rs7626444	0.647	rs844546	chr3:196475274	T/G	cg12930392	chr3:196481615	PAK2	0.25	5.02	0.31	1.01e-6	Monocyte count;
SARC	cis	rs7681440	0.583	rs2583966	chr4:90741519	G/A	cg06632027	chr4:90757378	SNCA	-0.42	-5.23	-0.32	3.81e-7	Dementia with Lewy bodies;
SARC	cis	rs1728785	1.000	rs1728784	chr16:68591156	T/A	cg02972257	chr16:68554789	NA	-0.47	-5.58	-0.34	6.79e-8	Ulcerative colitis;
SARC	cis	rs1035144	0.506	rs2371416	chr14:81275672	A/T	cg06600135	chr14:81408086	NA	-0.47	-5.34	-0.33	2.23e-7	Male sexual orientation;
SARC	cis	rs7904368	0.806	rs6602161	chr10:16862280	A/G	cg23933602	chr10:16859644	RSU1	0.55	5.66	0.35	4.54e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs1865760	1.000	rs2071298	chr6:25914901	G/A	cg17691542	chr6:26056736	HIST1H1C	0.56	6.83	0.41	7.18e-11	Height;
SARC	cis	rs16976116	0.901	rs8031949	chr15:55492724	A/G	cg11288833	chr15:55489084	RSL24D1	0.62	5.99	0.37	7.85e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9309473	0.950	rs6745480	chr2:73840055	C/T	cg07208825	chr2:73871855	ALMS1P	0.34	5.02	0.31	1.05e-6	Metabolite levels;
SARC	cis	rs826838	1.000	rs1843881	chr12:38733706	A/G	cg13010199	chr12:38710504	ALG10B	-0.84	-12.18	-0.62	9.99e-27	Heart rate;
SARC	cis	rs6831352	0.734	rs2851259	chr4:100033986	C/T	cg12011299	chr4:100065546	ADH4	0.28	4.8	0.3	2.86e-6	Alcohol dependence;
SARC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg11301795	chr4:187892539	NA	-0.69	-10.19	-0.56	2.09e-20	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7659604	0.517	rs6856996	chr4:122671271	C/T	cg19748678	chr4:122722346	EXOSC9	0.6	6.75	0.4	1.15e-10	Type 2 diabetes;
SARC	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg15049968	chr18:44337910	ST8SIA5	-0.33	-5.2	-0.32	4.31e-7	Personality dimensions;
SARC	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg25072359	chr17:41440525	NA	0.51	6.08	0.37	4.92e-9	Menopause (age at onset);
SARC	cis	rs6782228	0.527	rs2811491	chr3:128353950	C/A	cg08795948	chr3:128337044	NA	0.36	4.81	0.3	2.75e-6	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
SARC	cis	rs765787	0.530	rs4442750	chr15:45535328	G/T	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.51e-10	Uric acid levels;
SARC	cis	rs826838	0.934	rs10875647	chr12:38856995	G/A	cg13010199	chr12:38710504	ALG10B	0.78	11.08	0.59	3.29e-23	Heart rate;
SARC	cis	rs6088580	0.634	rs6059887	chr20:33101102	C/G	cg24642439	chr20:33292090	TP53INP2	0.68	8.88	0.5	1.87e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs3768617	0.510	rs7414273	chr1:183075017	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.17	0.55	2.42e-20	Fuchs's corneal dystrophy;
SARC	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg18305652	chr10:134549665	INPP5A	0.36	5.1	0.32	7.09e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs34172651	0.876	rs1862451	chr16:24803620	A/G	cg06028605	chr16:24865363	SLC5A11	0.27	4.75	0.3	3.56e-6	Intelligence (multi-trait analysis);
SARC	cis	rs854765	0.583	rs9890341	chr17:17823175	G/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.43	5.67	0.35	4.18e-8	Total body bone mineral density;
SARC	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg04317338	chr11:64019027	PLCB3	0.79	8.31	0.48	8.09e-15	Mean platelet volume;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg26635845	chr20:61426715	C20orf20	-0.6	-6.68	-0.4	1.73e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs10845606	1.000	rs10845605	chr12:12833468	T/C	cg09462578	chr12:12878428	APOLD1	-0.55	-5.37	-0.33	1.86e-7	Systemic lupus erythematosus;
SARC	cis	rs11098499	0.775	rs10029303	chr4:120286755	T/A	cg09307838	chr4:120376055	NA	0.83	11.82	0.61	1.46e-25	Corneal astigmatism;
SARC	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg21782813	chr7:2030301	MAD1L1	0.35	5.54	0.34	8.11e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs11574514	1.000	rs117298895	chr16:67883262	C/A	cg01866162	chr16:67596514	CTCF	1.11	6.4	0.39	8.22e-10	Crohn's disease;
SARC	cis	rs9303280	0.901	rs883770	chr17:38063381	C/T	cg00129232	chr17:37814104	STARD3	-0.37	-4.84	-0.3	2.37e-6	Self-reported allergy;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg20842997	chr4:39529386	UGDH	0.48	6.3	0.38	1.49e-9	Thyroid stimulating hormone;
SARC	cis	rs10979	0.557	rs9390120	chr6:143909411	A/G	cg25407410	chr6:143891975	LOC285740	-0.52	-6.03	-0.37	6.39e-9	Hypospadias;
SARC	cis	rs7666738	0.830	rs2865981	chr4:99031493	G/A	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs72945132	0.882	rs55915603	chr11:70210067	G/T	cg00319359	chr11:70116639	PPFIA1	0.68	6.1	0.37	4.34e-9	Coronary artery disease;
SARC	cis	rs763121	0.819	rs8137829	chr22:39061030	G/A	cg14440974	chr22:39074834	NA	-0.34	-4.89	-0.3	1.9e-6	Menopause (age at onset);
SARC	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.69	7.33	0.43	3.78e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg11266682	chr4:10021025	SLC2A9	0.41	7.29	0.43	4.75e-12	Bone mineral density;
SARC	cis	rs7208859	0.623	rs7217984	chr17:29092766	G/A	cg13385521	chr17:29058706	SUZ12P	0.9	7.81	0.46	1.96e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg18252515	chr7:66147081	NA	-1.42	-13.08	-0.65	1.15e-29	Diabetic kidney disease;
SARC	cis	rs2506889	0.553	rs17035189	chr1:10597024	A/G	cg07384165	chr1:10488281	NA	-0.42	-5.61	-0.35	5.61e-8	Breast cancer;
SARC	cis	rs787274	0.557	rs980345	chr9:115670823	T/C	cg13803584	chr9:115635662	SNX30	-0.89	-5.06	-0.31	8.53e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs449789	0.857	rs606833	chr6:159717776	T/A	cg14500486	chr6:159655392	FNDC1	-0.44	-5.02	-0.31	1.01e-6	Pulse pressure;
SARC	cis	rs1957429	0.520	rs230718	chr14:65318943	A/G	cg23373153	chr14:65346875	NA	-0.65	-5.4	-0.33	1.64e-7	Pediatric areal bone mineral density (radius);
SARC	cis	rs425277	1.000	rs381664	chr1:2088104	A/G	cg24578937	chr1:2090814	PRKCZ	0.31	5.87	0.36	1.47e-8	Height;
SARC	cis	rs4727027	0.933	rs6961605	chr7:148870108	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	5.7	0.35	3.62e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs9394841	0.646	rs9471676	chr6:41815192	C/T	cg08135965	chr6:41755394	TOMM6	0.62	6.62	0.4	2.43e-10	Mean corpuscular hemoglobin;Red cell distribution width;
SARC	cis	rs734999	0.549	rs3828154	chr1:2524943	G/A	cg18854424	chr1:2615690	NA	0.33	5.22	0.32	3.88e-7	Ulcerative colitis;
SARC	cis	rs17376456	0.569	rs10057664	chr5:93182274	C/T	cg25358565	chr5:93447407	FAM172A	-0.94	-10.61	-0.57	1.05e-21	Diabetic retinopathy;
SARC	cis	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg25427524	chr10:38739819	LOC399744	-0.53	-8.46	-0.48	2.95e-15	Extrinsic epigenetic age acceleration;
SARC	cis	rs1580019	0.587	rs7805311	chr7:32558302	A/G	cg14728415	chr7:32535168	LSM5;AVL9	-0.51	-6.37	-0.39	9.9e-10	Cognitive ability;
SARC	cis	rs3126085	0.935	rs7533529	chr1:152176871	T/C	cg26876637	chr1:152193138	HRNR	0.48	5.43	0.34	1.38e-7	Atopic dermatitis;
SARC	cis	rs7561528	0.501	rs57724183	chr2:127883905	A/C	cg12632573	chr2:127783243	NA	0.67	6.1	0.37	4.44e-9	Alzheimer's disease;Alzheimer's disease (late onset);
SARC	cis	rs4605213	0.649	rs8077566	chr17:49333241	T/G	cg00965052	chr17:49230932	NME1;NME1-NME2	-0.5	-5.1	-0.32	7.01e-7	Height;
SARC	cis	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg00745463	chr17:30367425	LRRC37B	-0.69	-5.25	-0.33	3.39e-7	Hip circumference adjusted for BMI;
SARC	cis	rs11711311	0.868	rs13091621	chr3:113481977	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	8.34	0.48	6.69e-15	IgG glycosylation;
SARC	cis	rs13144136	0.687	rs11723092	chr4:10651891	G/A	cg10242279	chr4:10666415	CLNK	-0.42	-6.93	-0.41	4.09e-11	Resistance to antihypertensive treatment in hypertension;
SARC	cis	rs11190604	1.000	rs9420797	chr10:102331147	C/T	cg07510080	chr10:102295549	HIF1AN	0.45	4.93	0.31	1.55e-6	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs2712184	0.868	rs1548946	chr2:217665368	C/T	cg05032264	chr2:217675019	NA	-0.61	-8.42	-0.48	3.95e-15	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
SARC	cis	rs12200560	0.505	rs211173	chr6:97070804	C/T	cg06623918	chr6:96969491	KIAA0776	0.43	4.85	0.3	2.21e-6	Coronary heart disease;
SARC	cis	rs1008375	1.000	rs13106338	chr4:17676871	G/T	cg27347728	chr4:17578864	LAP3	-0.49	-6.06	-0.37	5.54e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg00933542	chr6:150070202	PCMT1	0.33	5.68	0.35	4.05e-8	Lung cancer;
SARC	cis	rs2916247	1.000	rs6987763	chr8:93028518	G/C	cg10183463	chr8:93005414	RUNX1T1	-0.58	-6.05	-0.37	5.83e-9	Intelligence (multi-trait analysis);
SARC	cis	rs2404602	0.716	rs56216512	chr15:76686936	T/C	cg26408565	chr15:76604113	ETFA	-0.36	-4.77	-0.3	3.27e-6	Blood metabolite levels;
SARC	cis	rs5417	0.689	rs55868524	chr17:7170665	G/A	cg25256661	chr17:7137939	DVL2	-0.68	-10.19	-0.56	2.16e-20	Diastolic blood pressure;
SARC	cis	rs4713675	0.709	rs626156	chr6:33670482	A/G	cg15676125	chr6:33679581	C6orf125	-0.42	-5.09	-0.32	7.48e-7	Plateletcrit;
SARC	cis	rs3008870	1.000	rs2065001	chr1:67486509	C/G	cg08660285	chr1:67390436	MIER1;WDR78	0.9	10.4	0.56	4.53e-21	Lymphocyte percentage of white cells;
SARC	cis	rs57506017	0.585	rs6966757	chr7:12265952	A/T	cg23422036	chr7:12250390	TMEM106B	0.46	5.95	0.36	1e-8	Neuroticism;
SARC	cis	rs6930083	0.527	rs9470367	chr6:36626932	G/C	cg08179530	chr6:36648295	CDKN1A	-0.75	-10.36	-0.56	6.44e-21	Coronary artery disease;
SARC	cis	rs1568889	1.000	rs12802157	chr11:28060285	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	10.33	0.56	7.9e-21	Bipolar disorder;
SARC	cis	rs6831352	0.918	rs2851247	chr4:100046091	C/G	cg12011299	chr4:100065546	ADH4	-0.36	-5.81	-0.36	2.05e-8	Alcohol dependence;
SARC	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.93	-15.0	-0.7	4.62e-36	Chronic sinus infection;
SARC	cis	rs78487399	0.808	rs6731980	chr2:43703183	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-5.13	-0.32	6.24e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs7666738	0.606	rs3846447	chr4:99099907	G/A	cg05340658	chr4:99064831	C4orf37	0.47	5.84	0.36	1.77e-8	Colonoscopy-negative controls vs population controls;
SARC	cis	rs910316	1.000	rs7156105	chr14:75541954	C/A	cg11812906	chr14:75593930	NEK9	0.89	14.16	0.68	2.96e-33	Height;
SARC	cis	rs11155671	0.517	rs9397058	chr6:150207249	C/T	cg09699651	chr6:150184138	LRP11	0.51	6.55	0.39	3.7e-10	Testicular germ cell tumor;
SARC	cis	rs3820928	0.904	rs10188570	chr2:227792540	G/A	cg05526886	chr2:227700861	RHBDD1	-0.45	-4.85	-0.3	2.21e-6	Pulmonary function;
SARC	cis	rs2486288	0.656	rs11639420	chr15:45559268	A/C	cg21132104	chr15:45694354	SPATA5L1	-0.52	-6.5	-0.39	4.85e-10	Glomerular filtration rate;
SARC	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg05025164	chr4:1340916	KIAA1530	0.44	5.33	0.33	2.29e-7	Obesity-related traits;
SARC	cis	rs820218	0.926	rs820204	chr17:73639951	G/C	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.66	9.05	0.51	5.73e-17	Rotator cuff tears;
SARC	cis	rs12220238	1.000	rs11000931	chr10:75984800	A/C	cg19889307	chr10:75911429	ADK;AP3M1	-0.54	-5.32	-0.33	2.4e-7	Soluble interleukin-2 receptor subunit alpha;
SARC	cis	rs57994353	0.793	rs33982662	chr9:139324737	C/A	cg13611204	chr9:139324423	INPP5E	-0.28	-4.88	-0.3	1.94e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs9612	1.000	rs7246677	chr19:44248625	G/A	cg08581076	chr19:44259116	C19orf61	0.72	9.1	0.51	4.27e-17	Exhaled nitric oxide output;
SARC	cis	rs11608355	0.515	rs7971160	chr12:109946751	T/A	cg05360138	chr12:110035743	NA	0.92	9.39	0.52	5.78e-18	Neuroticism;
SARC	cis	rs921968	0.565	rs7595901	chr2:219606931	A/G	cg02176678	chr2:219576539	TTLL4	-0.33	-4.95	-0.31	1.42e-6	Mean corpuscular hemoglobin concentration;
SARC	trans	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.08	-0.42	1.69e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs10463316	0.894	rs3846712	chr5:150759813	C/A	cg03212797	chr5:150827313	SLC36A1	-0.44	-5.19	-0.32	4.68e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg27266027	chr21:40555129	PSMG1	0.49	5.39	0.33	1.7e-7	Cognitive function;
SARC	cis	rs6429082	0.738	rs2131921	chr1:235705157	C/T	cg26050004	chr1:235667680	B3GALNT2	0.51	5.38	0.33	1.8e-7	Adiposity;
SARC	cis	rs10463554	0.824	rs427430	chr5:102432024	G/A	cg23492399	chr5:102201601	PAM	-0.52	-5.77	-0.35	2.46e-8	Parkinson's disease;
SARC	cis	rs9325144	0.723	rs11169535	chr12:39183494	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-7.64	-0.45	5.71e-13	Morning vs. evening chronotype;
SARC	cis	rs2718798	1	rs2718798	chr3:133492088	A/C	cg01448562	chr3:133502909	NA	-0.32	-4.92	-0.31	1.63e-6	Ankle injury;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg26778584	chr3:149691960	NA	0.47	6.64	0.4	2.23e-10	Thyroid stimulating hormone;
SARC	cis	rs9388451	0.626	rs9385383	chr6:126086290	G/T	cg05901451	chr6:126070800	HEY2	-0.54	-6.99	-0.42	2.79e-11	Brugada syndrome;
SARC	cis	rs7647973	1.000	rs6446262	chr3:49401153	T/C	cg06212747	chr3:49208901	KLHDC8B	0.57	5.57	0.34	7.17e-8	Menarche (age at onset);
SARC	cis	rs8114671	0.869	rs1407202	chr20:33651967	C/T	cg24642439	chr20:33292090	TP53INP2	-0.53	-6.22	-0.38	2.24e-9	Height;
SARC	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs950027	0.620	rs1617634	chr15:45615578	A/G	cg15395560	chr15:45543142	SLC28A2	-0.27	-5.07	-0.32	8.01e-7	Response to fenofibrate (adiponectin levels);
SARC	cis	rs8114671	0.562	rs4911164	chr20:33479488	G/C	cg07148914	chr20:33460835	GGT7	0.44	5.41	0.33	1.58e-7	Height;
SARC	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg27286337	chr10:134555280	INPP5A	0.68	8.18	0.47	1.89e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs2153535	0.541	rs1414353	chr6:8485642	C/G	cg21535247	chr6:8435926	SLC35B3	0.57	7.24	0.43	6.48e-12	Motion sickness;
SARC	trans	rs9650657	0.504	rs6601566	chr8:11042974	G/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.19	-0.43	8.77e-12	Neuroticism;
SARC	cis	rs9487051	0.676	rs1608042	chr6:109595631	G/A	cg01475377	chr6:109611718	NA	-0.35	-5.08	-0.32	7.8e-7	Reticulocyte fraction of red cells;
SARC	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.51	-6.21	-0.38	2.43e-9	Renal function-related traits (BUN);
SARC	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.43	0.44	1.98e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs9325144	0.600	rs1825807	chr12:38737007	T/C	cg23762105	chr12:34175262	ALG10	-0.55	-7.11	-0.42	1.4e-11	Morning vs. evening chronotype;
SARC	cis	rs9303401	0.659	rs1864754	chr17:56688789	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	-1.09	-12.5	-0.63	8.96e-28	Cognitive test performance;
SARC	trans	rs2727020	0.595	rs10839286	chr11:49497063	C/A	cg15704280	chr7:45808275	SEPT13	-0.87	-14.4	-0.69	4.67e-34	Coronary artery disease;
SARC	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg19223190	chr17:80058835	NA	-0.43	-6.02	-0.37	6.57e-9	Life satisfaction;
SARC	cis	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg05623727	chr3:50126028	RBM5	-0.35	-5.14	-0.32	5.92e-7	Body mass index;
SARC	cis	rs7599312	0.534	rs7607373	chr2:213409719	G/A	cg16329650	chr2:213403929	ERBB4	0.67	9.91	0.54	1.56e-19	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg17221315	chr6:27791827	HIST1H4J	0.46	4.83	0.3	2.53e-6	Depression;
SARC	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg02487422	chr3:49467188	NICN1	0.5	6.72	0.4	1.41e-10	Resting heart rate;
SARC	cis	rs7909074	1.000	rs12777258	chr10:45394961	A/G	cg04218760	chr10:45406644	TMEM72	0.27	5.19	0.32	4.48e-7	Mean corpuscular volume;
SARC	trans	rs6964833	0.935	rs7795281	chr7:74122854	A/G	cg07504079	chr7:72649617	NCF1B	-0.59	-6.38	-0.39	9.35e-10	Menarche (age at onset);
SARC	cis	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg14343924	chr8:8086146	FLJ10661	0.41	4.83	0.3	2.46e-6	Mood instability;
SARC	cis	rs2535633	0.631	rs9823697	chr3:53002150	A/G	cg05564831	chr3:52568323	NT5DC2	0.29	4.81	0.3	2.73e-6	Body mass index;
SARC	cis	rs13256369	0.774	rs13248423	chr8:8577602	C/G	cg18904891	chr8:8559673	CLDN23	0.41	4.73	0.3	3.87e-6	Obesity-related traits;
SARC	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg17221315	chr6:27791827	HIST1H4J	0.47	5.1	0.32	6.88e-7	Parkinson's disease;
SARC	cis	rs1348850	0.507	rs10186934	chr2:178425998	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.71	6.39	0.39	8.86e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg02711726	chr17:80685570	FN3KRP	0.43	5.92	0.36	1.12e-8	Glycated hemoglobin levels;
SARC	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg18876405	chr7:65276391	NA	0.46	5.11	0.32	6.58e-7	Aortic root size;
SARC	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	11.4	0.6	3.36e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs344364	0.518	rs1657129	chr16:1945826	G/A	cg26617929	chr16:1858877	NA	-0.71	-6.06	-0.37	5.5e-9	Glomerular filtration rate in chronic kidney disease;
SARC	cis	rs1707322	1.000	rs4660903	chr1:46457601	A/G	cg03146154	chr1:46216737	IPP	0.46	5.59	0.34	6.25e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg17221315	chr6:27791827	HIST1H4J	0.51	5.28	0.33	2.97e-7	Parkinson's disease;
SARC	cis	rs6089584	1.000	rs6142910	chr20:60562181	C/A	cg06108461	chr20:60628389	TAF4	-0.91	-11.96	-0.62	5.27e-26	Body mass index;
SARC	cis	rs9916302	0.821	rs412430	chr17:37737094	C/G	cg15445000	chr17:37608096	MED1	0.43	4.89	0.31	1.87e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg00933542	chr6:150070202	PCMT1	0.32	5.35	0.33	2.06e-7	Lung cancer;
SARC	cis	rs13256369	0.950	rs13270006	chr8:8574197	C/A	cg18904891	chr8:8559673	CLDN23	0.48	5.53	0.34	8.72e-8	Obesity-related traits;
SARC	cis	rs1018836	0.608	rs6992512	chr8:91477936	C/A	cg16814680	chr8:91681699	NA	-0.65	-9.19	-0.52	2.2e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs1003719	0.788	rs1155787	chr21:38448069	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.67	9.98	0.55	9.34e-20	Eye color traits;
SARC	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.43	-5.28	-0.33	2.92e-7	Tonsillectomy;
SARC	cis	rs950776	0.593	rs6495306	chr15:78865893	C/T	cg22563815	chr15:78856949	CHRNA5	-0.39	-6.46	-0.39	6.18e-10	Sudden cardiac arrest;
SARC	cis	rs2228479	0.850	rs79244293	chr16:89896220	T/C	cg00800038	chr16:89945340	TCF25	-0.82	-5.9	-0.36	1.27e-8	Skin colour saturation;
SARC	cis	rs2976388	0.647	rs2082801	chr8:143786461	A/G	cg06565975	chr8:143823917	SLURP1	0.31	5.51	0.34	9.56e-8	Urinary tract infection frequency;
SARC	cis	rs12142240	0.698	rs7515598	chr1:46818479	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-5.46	-0.34	1.22e-7	Menopause (age at onset);
SARC	cis	rs66887589	0.967	rs2892869	chr4:120521297	T/C	cg09307838	chr4:120376055	NA	-0.53	-7.23	-0.43	6.96e-12	Diastolic blood pressure;
SARC	cis	rs2635047	0.935	rs2461247	chr18:44698537	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.54	7.07	0.42	1.75e-11	Educational attainment;
SARC	cis	rs950776	0.518	rs2869055	chr15:78822388	G/C	cg22563815	chr15:78856949	CHRNA5	-0.38	-6.37	-0.38	1.01e-9	Sudden cardiac arrest;
SARC	cis	rs6991838	0.584	rs7459944	chr8:66478275	T/C	cg13398993	chr8:66546079	ARMC1	-0.62	-8.11	-0.47	2.85e-14	Intelligence (multi-trait analysis);
SARC	cis	rs11874712	1.000	rs9944637	chr18:43655239	G/A	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	6.35	0.38	1.14e-9	Migraine - clinic-based;
SARC	cis	rs9457247	0.871	rs1811121	chr6:167403539	T/C	cg07741184	chr6:167504864	NA	0.29	5.55	0.34	7.65e-8	Crohn's disease;
SARC	cis	rs6141769	0.542	rs6057632	chr20:31319841	A/G	cg13636640	chr20:31349939	DNMT3B	-0.44	-4.74	-0.3	3.69e-6	Subjective well-being;
SARC	cis	rs3820928	0.874	rs10195072	chr2:227794452	G/A	cg11843606	chr2:227700838	RHBDD1	-0.57	-7.16	-0.42	1.02e-11	Pulmonary function;
SARC	cis	rs611744	0.967	rs662591	chr8:109211358	C/T	cg21045802	chr8:109455806	TTC35	0.46	5.41	0.33	1.57e-7	Dupuytren's disease;
SARC	cis	rs72945132	0.619	rs61887436	chr11:70243337	C/T	cg05964544	chr11:70165517	PPFIA1	-0.66	-6.26	-0.38	1.83e-9	Coronary artery disease;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg13096721	chr1:51185450	FAF1	0.47	6.46	0.39	6.06e-10	Thyroid stimulating hormone;
SARC	cis	rs67311347	1.000	rs6599102	chr3:40468406	G/A	cg09455208	chr3:40491958	NA	0.41	6.59	0.4	2.89e-10	Renal cell carcinoma;
SARC	cis	rs7223966	1.000	rs11870797	chr17:61804622	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-5.86	-0.36	1.6e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1371867	0.875	rs1371868	chr8:101330267	C/T	cg11906718	chr8:101322791	RNF19A	0.71	9.13	0.51	3.37e-17	Atrioventricular conduction;
SARC	cis	rs7666738	0.830	rs34244876	chr4:99031336	G/A	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs28374715	0.532	rs28535540	chr15:41659277	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.19	-20.27	-0.8	2.49e-53	Ulcerative colitis;
SARC	cis	rs7647973	0.626	rs4855882	chr3:49715354	G/T	cg07636037	chr3:49044803	WDR6	0.58	5.5	0.34	9.83e-8	Menarche (age at onset);
SARC	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg22903471	chr2:27725779	GCKR	-0.46	-6.77	-0.41	1.06e-10	Total body bone mineral density;
SARC	trans	rs1814175	0.817	rs11040474	chr11:49708441	G/A	cg03929089	chr4:120376271	NA	-0.9	-14.72	-0.69	3.94e-35	Height;
SARC	cis	rs1976403	0.633	rs1697422	chr1:21821897	T/C	cg00786952	chr1:21763130	NA	0.33	5.46	0.34	1.2e-7	Liver enzyme levels (alkaline phosphatase);
SARC	trans	rs9929218	1.000	rs12921546	chr16:68780069	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.63	-8.09	-0.47	3.32e-14	Colorectal cancer;
SARC	trans	rs9329221	0.521	rs17693945	chr8:10106010	C/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.67	-0.45	4.72e-13	Neuroticism;
SARC	cis	rs1113500	0.966	rs11185249	chr1:108611646	C/A	cg06207961	chr1:108661230	NA	0.44	5.7	0.35	3.59e-8	Growth-regulated protein alpha levels;
SARC	cis	rs25645	0.800	rs34003767	chr17:38194296	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.38	6.88	0.41	5.33e-11	Myeloid white cell count;
SARC	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg16479474	chr6:28041457	NA	0.37	5.48	0.34	1.11e-7	Depression;
SARC	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.41	-0.44	2.32e-12	Gut microbiome composition (summer);
SARC	cis	rs9916302	0.904	rs13341996	chr17:37536862	C/T	cg20243544	chr17:37824526	PNMT	-0.55	-6.74	-0.4	1.24e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg12463550	chr7:65579703	CRCP	0.7	5.7	0.35	3.54e-8	Diabetic kidney disease;
SARC	trans	rs1814175	0.645	rs11040702	chr11:50024827	C/T	cg03929089	chr4:120376271	NA	-0.82	-11.88	-0.61	9.03e-26	Height;
SARC	cis	rs8180040	0.739	rs12488225	chr3:47235107	G/A	cg27129171	chr3:47204927	SETD2	0.68	9.61	0.53	1.28e-18	Colorectal cancer;
SARC	cis	rs4481887	1.000	rs10888351	chr1:248451608	G/A	cg01631408	chr1:248437212	OR2T33	-0.4	-5.08	-0.32	7.86e-7	Common traits (Other);
SARC	cis	rs13256369	0.708	rs11249886	chr8:8562021	T/A	cg17143192	chr8:8559678	CLDN23	0.52	5.83	0.36	1.86e-8	Obesity-related traits;
SARC	cis	rs9341808	0.652	rs2505940	chr6:80851191	T/C	cg08355045	chr6:80787529	NA	0.36	5.78	0.35	2.35e-8	Sitting height ratio;
SARC	cis	rs9325144	0.581	rs6582564	chr12:38671282	G/A	cg13010199	chr12:38710504	ALG10B	-0.57	-7.39	-0.44	2.57e-12	Morning vs. evening chronotype;
SARC	cis	rs1008375	0.966	rs3796813	chr4:17591648	A/G	cg27347728	chr4:17578864	LAP3	0.49	6.0	0.37	7.68e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2153535	0.542	rs9393012	chr6:8439809	G/A	cg07606381	chr6:8435919	SLC35B3	0.78	11.09	0.59	3.11e-23	Motion sickness;
SARC	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg21782813	chr7:2030301	MAD1L1	0.34	5.25	0.33	3.42e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs7927771	0.524	rs10838771	chr11:47831332	A/G	cg10504702	chr11:47789108	FNBP4	-0.43	-5.53	-0.34	8.63e-8	Subjective well-being;
SARC	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg24675658	chr1:53192096	ZYG11B	0.65	9.27	0.52	1.34e-17	Monocyte count;
SARC	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg24209194	chr3:40518798	ZNF619	0.58	7.14	0.42	1.16e-11	Renal cell carcinoma;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg24431586	chr2:161340734	RBMS1	0.47	6.27	0.38	1.7e-9	Thyroid stimulating hormone;
SARC	cis	rs11785400	1.000	rs4736342	chr8:143735190	A/G	cg10596483	chr8:143751796	JRK	0.64	8.4	0.48	4.51e-15	Schizophrenia;
SARC	cis	rs9916302	0.821	rs12938268	chr17:37572139	G/A	cg00129232	chr17:37814104	STARD3	-0.62	-7.59	-0.45	7.62e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs2730245	0.527	rs712197	chr7:158660846	C/G	cg24397884	chr7:158709396	WDR60	1.1	9.71	0.54	6.03e-19	Height;
SARC	cis	rs12681366	0.708	rs2515156	chr8:95379186	G/A	cg26464482	chr8:95565502	KIAA1429	-0.45	-5.54	-0.34	8.16e-8	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs7582720	1.000	rs114520702	chr2:203697092	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	7.48	0.44	1.5e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs12200782	0.505	rs9295696	chr6:26550288	C/T	cg11502198	chr6:26597334	ABT1	0.71	7.72	0.45	3.45e-13	Small cell lung carcinoma;
SARC	cis	rs1961456	0.542	rs10095159	chr8:18244684	G/A	cg18736775	chr8:18248649	NAT2	-0.59	-6.73	-0.4	1.28e-10	Total cholesterol levels;
SARC	cis	rs17666538	0.792	rs58523286	chr8:675683	C/T	cg00450029	chr8:599525	NA	-0.87	-5.64	-0.35	5.01e-8	IgG glycosylation;
SARC	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg24675658	chr1:53192096	ZYG11B	0.6	8.35	0.48	6.02e-15	Monocyte count;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg15522984	chr1:182991683	LAMC1	-0.49	-6.62	-0.4	2.46e-10	Tetralogy of Fallot;
SARC	cis	rs2742234	0.590	rs2505553	chr10:43681251	G/T	cg15436174	chr10:43711423	RASGEF1A	-0.4	-4.74	-0.3	3.67e-6	Hirschsprung disease;
SARC	cis	rs7824557	0.679	rs10110008	chr8:11133736	G/T	cg21775007	chr8:11205619	TDH	-0.55	-6.57	-0.4	3.17e-10	Retinal vascular caliber;
SARC	cis	rs826838	0.616	rs10880754	chr12:38628154	C/T	cg14851346	chr12:38532713	NA	-0.43	-5.2	-0.32	4.3e-7	Heart rate;
SARC	cis	rs11770686	0.967	rs6957776	chr7:75328671	C/G	cg17787366	chr7:75369077	HIP1	0.43	5.32	0.33	2.48e-7	Essential tremor;
SARC	cis	rs9611565	1.000	rs5751086	chr22:41768862	C/T	cg03806693	chr22:41940476	POLR3H	-0.71	-10.07	-0.55	4.83e-20	Vitiligo;
SARC	cis	rs3008870	0.727	rs11208971	chr1:67383901	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.61	7.79	0.45	2.19e-13	Lymphocyte percentage of white cells;
SARC	cis	rs7666738	0.830	rs991168	chr4:98928293	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs950169	1.000	rs62026530	chr15:84775840	G/T	cg24253500	chr15:84953950	NA	0.37	5.4	0.33	1.67e-7	Schizophrenia;
SARC	cis	rs76419734	0.558	rs11735330	chr4:106521870	T/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.67	5.78	0.35	2.34e-8	Post bronchodilator FEV1;
SARC	cis	rs6121246	0.529	rs6060144	chr20:30178624	A/G	cg13852791	chr20:30311386	BCL2L1	0.63	4.89	0.31	1.84e-6	Mean corpuscular hemoglobin;
SARC	cis	rs9303401	0.659	rs8074016	chr17:56840587	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.04	11.52	0.6	1.32e-24	Cognitive test performance;
SARC	cis	rs72634258	0.572	rs66692705	chr1:7938565	T/C	cg05338066	chr1:7812865	CAMTA1	0.52	4.78	0.3	3.06e-6	Inflammatory bowel disease;
SARC	trans	rs66573146	0.572	rs68169399	chr4:6952491	T/A	cg07817883	chr1:32538562	TMEM39B	1.07	8.38	0.48	5.02e-15	Granulocyte percentage of myeloid white cells;
SARC	cis	rs11105298	0.685	rs117578503	chr12:89836672	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.49	-4.93	-0.31	1.57e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg11266682	chr4:10021025	SLC2A9	0.41	7.32	0.43	3.99e-12	Bone mineral density;
SARC	cis	rs4919087	0.715	rs13439	chr10:99006083	C/T	cg25902810	chr10:99078978	FRAT1	-0.51	-6.06	-0.37	5.52e-9	Monocyte count;
SARC	cis	rs12579753	0.917	rs12316644	chr12:82205497	C/T	cg07988820	chr12:82153109	PPFIA2	0.5	5.97	0.36	8.92e-9	Resting heart rate;
SARC	cis	rs4319547	0.737	rs4758646	chr12:122946507	G/A	cg23029597	chr12:123009494	RSRC2	-0.38	-4.84	-0.3	2.35e-6	Body mass index;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg12933587	chr20:62496506	TPD52L2	-0.51	-6.28	-0.38	1.66e-9	Schizophrenia;
SARC	trans	rs2727020	0.576	rs61885308	chr11:49343363	G/A	cg15704280	chr7:45808275	SEPT13	-0.66	-9.51	-0.53	2.45e-18	Coronary artery disease;
SARC	cis	rs4268898	0.722	rs2288072	chr2:24390517	G/A	cg06627628	chr2:24431161	ITSN2	0.54	7.13	0.42	1.24e-11	Asthma;
SARC	cis	rs1348850	0.668	rs6734426	chr2:178493770	C/T	cg23306229	chr2:178417860	TTC30B	0.62	6.66	0.4	1.98e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg00933542	chr6:150070202	PCMT1	0.33	5.67	0.35	4.23e-8	Lung cancer;
SARC	cis	rs6121246	0.529	rs2889528	chr20:30210021	C/T	cg13852791	chr20:30311386	BCL2L1	0.64	5.64	0.35	4.79e-8	Mean corpuscular hemoglobin;
SARC	cis	rs9682041	0.668	rs6784631	chr3:170100476	T/C	cg11886554	chr3:170076028	SKIL	1.14	8.99	0.51	8.63e-17	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs6456156	0.586	rs12528323	chr6:167461645	A/G	cg07741184	chr6:167504864	NA	0.35	6.83	0.41	7.46e-11	Primary biliary cholangitis;
SARC	cis	rs6834538	0.597	rs2029211	chr4:113488134	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.54	7.26	0.43	5.74e-12	Free thyroxine concentration;
SARC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg23131131	chr22:24373011	LOC391322	0.46	4.95	0.31	1.42e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs11155671	0.530	rs4869764	chr6:150211828	T/C	cg00933542	chr6:150070202	PCMT1	0.29	4.81	0.3	2.77e-6	Testicular germ cell tumor;
SARC	cis	rs72781680	1.000	rs17763442	chr2:24255991	C/T	cg08917208	chr2:24149416	ATAD2B	0.88	8.28	0.48	9.36e-15	Lymphocyte counts;
SARC	cis	rs11874712	0.932	rs34907121	chr18:43677793	G/A	cg25174615	chr18:43684699	ATP5A1;HAUS1	0.42	4.9	0.31	1.76e-6	Migraine - clinic-based;
SARC	cis	rs6835098	0.961	rs11737748	chr4:174130503	T/C	cg08422745	chr4:174089978	GALNT7	0.75	9.58	0.53	1.53e-18	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs13191362	1.000	rs13220181	chr6:163004401	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.57	5.51	0.34	9.61e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs1568889	1.000	rs66857704	chr11:28212346	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.72	9.27	0.52	1.34e-17	Bipolar disorder;
SARC	cis	rs1008375	1.000	rs11947857	chr4:17691047	T/C	cg16339924	chr4:17578868	LAP3	-0.64	-7.92	-0.46	9.66e-14	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-6.42	-0.39	7.39e-10	Personality dimensions;
SARC	cis	rs2734839	0.537	rs11214603	chr11:113279922	G/A	cg14159747	chr11:113255604	NA	0.35	4.97	0.31	1.3e-6	Information processing speed;
SARC	cis	rs9790314	1.000	rs336583	chr3:161081981	A/T	cg04691961	chr3:161091175	C3orf57	0.81	11.75	0.61	2.43e-25	Morning vs. evening chronotype;
SARC	cis	rs9420	0.809	rs11600169	chr11:57464945	T/A	cg23127183	chr11:57508653	C11orf31	-0.55	-6.27	-0.38	1.73e-9	Schizophrenia;
SARC	cis	rs950776	0.745	rs3743075	chr15:78909452	T/C	cg22563815	chr15:78856949	CHRNA5	-0.31	-4.83	-0.3	2.44e-6	Sudden cardiac arrest;
SARC	cis	rs208520	0.526	rs6455072	chr6:66797215	A/G	cg07460842	chr6:66804631	NA	-1.12	-22.38	-0.83	5.7e-60	Exhaled nitric oxide output;
SARC	cis	rs4803468	0.967	rs4803462	chr19:41908936	T/A	cg09537434	chr19:41945824	ATP5SL	-0.95	-16.2	-0.73	4.76e-40	Height;
SARC	cis	rs9457247	0.967	rs2149092	chr6:167372978	C/T	cg23791538	chr6:167370224	RNASET2	0.63	8.74	0.5	4.74e-16	Crohn's disease;
SARC	cis	rs1124376	0.935	rs6550307	chr3:20097885	G/A	cg05072819	chr3:20081367	KAT2B	0.5	4.82	0.3	2.62e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs9430161	0.611	rs12081181	chr1:11034165	T/G	cg02454025	chr1:11042201	C1orf127	0.85	12.06	0.62	2.33e-26	Ewing sarcoma;
SARC	cis	rs3820928	0.904	rs4414671	chr2:227816200	T/A	cg05526886	chr2:227700861	RHBDD1	-0.53	-6.52	-0.39	4.25e-10	Pulmonary function;
SARC	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg05368731	chr17:41323189	NBR1	0.79	9.6	0.53	1.33e-18	Menopause (age at onset);
SARC	cis	rs11098499	0.909	rs2127821	chr4:120394535	T/C	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	cis	rs6500395	0.775	rs1968902	chr16:48663974	A/G	cg04672837	chr16:48644449	N4BP1	0.41	5.63	0.35	5.04e-8	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs1044826	0.642	rs9859864	chr3:139091219	G/T	cg15131784	chr3:139108705	COPB2	-0.4	-5.04	-0.31	9.19e-7	Obesity-related traits;
SARC	cis	rs13314892	0.764	rs6802804	chr3:69862105	A/C	cg17445875	chr3:69859618	MITF	-0.48	-5.05	-0.31	8.78e-7	QRS complex (12-leadsum);
SARC	cis	rs921968	0.643	rs1344645	chr2:219538019	A/C	cg02176678	chr2:219576539	TTLL4	0.34	5.06	0.31	8.34e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs2439831	0.850	rs28891769	chr15:44072860	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	8.62	0.49	1.07e-15	Lung cancer in ever smokers;
SARC	cis	rs1008375	0.898	rs4698623	chr4:17594702	T/C	cg02297831	chr4:17616191	MED28	0.46	5.7	0.35	3.63e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs881375	0.967	rs10739579	chr9:123694788	C/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	5.44	0.34	1.33e-7	Rheumatoid arthritis;
SARC	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg21724239	chr8:58056113	NA	0.69	6.35	0.38	1.11e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9400467	0.506	rs12207199	chr6:111525906	G/A	cg15721981	chr6:111408429	SLC16A10	0.66	5.63	0.35	5.13e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs8031584	0.958	rs34909055	chr15:31284170	C/T	cg08109568	chr15:31115862	NA	-0.45	-5.71	-0.35	3.34e-8	Huntington's disease progression;
SARC	cis	rs9843304	0.837	rs9289788	chr3:149207934	T/C	cg08667024	chr3:149219783	TM4SF4	0.37	5.97	0.36	8.89e-9	Gallstone disease;
SARC	cis	rs1355223	0.525	rs7129517	chr11:34872236	A/C	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-5.39	-0.33	1.74e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs4780401	0.539	rs62040604	chr16:11803641	G/A	cg01061890	chr16:11836724	TXNDC11	-0.58	-8.07	-0.47	3.83e-14	Rheumatoid arthritis;
SARC	cis	rs9818758	0.607	rs73084135	chr3:49272218	A/G	cg00383909	chr3:49044727	WDR6	0.76	6.57	0.4	3.29e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs1971762	1.000	rs1971762	chr12:54058238	C/T	cg06632207	chr12:54070931	ATP5G2	0.43	4.97	0.31	1.29e-6	Height;
SARC	cis	rs6450176	1.000	rs67473746	chr5:53296730	G/C	ch.5.1024479R	chr5:53302184	ARL15	-0.67	-7.71	-0.45	3.58e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg02725872	chr8:58115012	NA	-0.37	-6.55	-0.39	3.71e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs787274	1.000	rs787296	chr9:115541703	A/G	cg13803584	chr9:115635662	SNX30	-0.83	-5.06	-0.31	8.34e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg18364779	chr6:26104403	HIST1H4C	-0.42	-5.23	-0.32	3.82e-7	Intelligence (multi-trait analysis);
SARC	cis	rs12681366	0.708	rs2450554	chr8:95343780	A/G	cg26464482	chr8:95565502	KIAA1429	0.46	5.6	0.34	6.05e-8	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs2816062	0.721	rs2816047	chr1:18893728	A/C	cg18795169	chr1:18902165	NA	-0.76	-12.0	-0.62	3.71e-26	Urate levels in lean individuals;
SARC	cis	rs7681440	0.606	rs2737012	chr4:90745707	G/A	cg06632027	chr4:90757378	SNCA	-0.44	-5.44	-0.34	1.36e-7	Dementia with Lewy bodies;
SARC	cis	rs742320	0.756	rs4984925	chr16:839996	T/C	cg03433313	chr16:819064	MIR662	-0.42	-5.52	-0.34	8.8e-8	Mean corpuscular volume;
SARC	trans	rs61931739	0.500	rs11052966	chr12:34019826	C/T	cg26384229	chr12:38710491	ALG10B	0.74	10.49	0.57	2.46e-21	Morning vs. evening chronotype;
SARC	cis	rs569214	0.763	rs538181	chr8:27476815	C/T	cg04264299	chr8:27491209	SCARA3	-0.43	-4.88	-0.3	1.99e-6	Alzheimer's disease;
SARC	cis	rs17345786	1.000	rs3762729	chr3:101308874	C/T	cg12386194	chr3:101231763	SENP7	0.72	8.53	0.49	1.82e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs910316	0.783	rs11850751	chr14:75590113	A/T	cg06637938	chr14:75390232	RPS6KL1	0.49	6.94	0.41	3.82e-11	Height;
SARC	cis	rs911555	0.755	rs12435516	chr14:103954404	T/C	cg24130564	chr14:104152367	KLC1	0.49	5.77	0.35	2.48e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9814567	1.000	rs62271515	chr3:134300507	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-6.93	-0.41	4.14e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs8114671	0.562	rs959829	chr20:33346047	T/C	cg07148914	chr20:33460835	GGT7	-0.43	-5.35	-0.33	2.08e-7	Height;
SARC	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg12463550	chr7:65579703	CRCP	0.72	5.37	0.33	1.91e-7	Diabetic kidney disease;
SARC	cis	rs3764563	0.799	rs7249233	chr19:15723591	T/C	cg20725493	chr19:15740067	CYP4F8	-0.65	-4.85	-0.3	2.24e-6	Inflammatory biomarkers;
SARC	cis	rs9916302	0.706	rs4795375	chr17:37662932	T/C	cg20243544	chr17:37824526	PNMT	0.53	5.45	0.34	1.28e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.88	-13.07	-0.65	1.23e-29	Prudent dietary pattern;
SARC	cis	rs3870371	0.637	rs4540414	chr8:122689288	C/T	cg21781600	chr8:122651575	HAS2;HAS2AS	0.49	5.85	0.36	1.62e-8	Periodontal disease-related phenotypes;
SARC	cis	rs7043114	0.525	rs6479417	chr9:95064562	G/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-5.47	-0.34	1.16e-7	Height;
SARC	cis	rs6088580	0.505	rs6142219	chr20:33256345	G/A	cg07148914	chr20:33460835	GGT7	-0.42	-5.16	-0.32	5.4e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs858239	0.600	rs7776644	chr7:23119307	C/T	cg23682824	chr7:23144976	KLHL7	0.72	9.51	0.53	2.46e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs611744	0.967	rs686265	chr8:109199763	A/G	cg21045802	chr8:109455806	TTC35	0.44	5.23	0.32	3.81e-7	Dupuytren's disease;
SARC	cis	rs11792861	0.926	rs1333344	chr9:111776224	C/T	cg13535736	chr9:111863775	C9orf5	-0.38	-4.71	-0.3	4.18e-6	Menarche (age at onset);
SARC	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg21747090	chr2:27597821	SNX17	-0.55	-7.63	-0.45	5.82e-13	Total body bone mineral density;
SARC	cis	rs1559088	0.803	rs10405770	chr19:33616549	C/T	cg17764715	chr19:33622953	WDR88	0.51	6.75	0.4	1.19e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs1580019	0.587	rs9638880	chr7:32552401	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.53	6.91	0.41	4.63e-11	Cognitive ability;
SARC	cis	rs10752881	1.000	rs12403189	chr1:182983832	G/C	cg13390022	chr1:182993471	LAMC1	0.34	5.17	0.32	5.11e-7	Colorectal cancer;
SARC	cis	rs7312774	0.881	rs79048355	chr12:107311169	G/T	cg16260113	chr12:107380972	MTERFD3	0.71	6.09	0.37	4.65e-9	Severe influenza A (H1N1) infection;
SARC	cis	rs1832871	0.711	rs9459904	chr6:158700982	C/T	cg07165851	chr6:158734300	TULP4	0.51	6.18	0.38	2.85e-9	Height;
SARC	cis	rs9905704	0.813	rs304269	chr17:56802059	A/G	cg12560992	chr17:57184187	TRIM37	-0.45	-5.22	-0.32	3.92e-7	Testicular germ cell tumor;
SARC	cis	rs1559088	0.847	rs3760891	chr19:33599708	C/T	cg17764715	chr19:33622953	WDR88	0.5	6.91	0.41	4.61e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs1800469	1.000	rs2241714	chr19:41869392	C/T	cg08477640	chr19:41863820	B9D2	-0.7	-9.34	-0.52	8.24e-18	Colorectal cancer;
SARC	trans	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg17830980	chr10:43048298	ZNF37B	-0.52	-6.91	-0.41	4.56e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs12497850	0.931	rs11920534	chr3:48937761	G/T	cg03060546	chr3:49711283	APEH	0.45	5.75	0.35	2.81e-8	Parkinson's disease;
SARC	cis	rs7772486	0.754	rs6932863	chr6:146021255	A/T	cg05347473	chr6:146136440	FBXO30	-0.56	-7.82	-0.46	1.84e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs35110281	0.774	rs9978811	chr21:44998683	C/T	cg21573476	chr21:45109991	RRP1B	-0.47	-6.81	-0.41	8.35e-11	Mean corpuscular volume;
SARC	cis	rs6582630	0.519	rs8189561	chr12:38296178	G/A	cg26384229	chr12:38710491	ALG10B	0.87	12.86	0.64	6.01e-29	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs3820928	0.605	rs13410141	chr2:227805529	A/G	cg11843606	chr2:227700838	RHBDD1	-0.56	-7.51	-0.44	1.23e-12	Pulmonary function;
SARC	trans	rs2727020	0.566	rs10839234	chr11:49185524	C/T	cg15704280	chr7:45808275	SEPT13	-0.8	-12.11	-0.62	1.61e-26	Coronary artery disease;
SARC	cis	rs2153535	0.580	rs9393023	chr6:8469994	T/G	cg21535247	chr6:8435926	SLC35B3	0.54	6.79	0.41	9.19e-11	Motion sickness;
SARC	cis	rs9916302	0.904	rs57399933	chr17:37551189	A/G	cg20243544	chr17:37824526	PNMT	-0.55	-6.58	-0.4	3.1e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg11764359	chr7:65958608	NA	0.78	10.15	0.55	2.84e-20	Aortic root size;
SARC	cis	rs2221894	0.506	rs74783515	chr8:28848539	G/T	cg07962641	chr8:28805897	HMBOX1	-0.78	-7.69	-0.45	4.02e-13	Obesity-related traits;
SARC	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg27347728	chr4:17578864	LAP3	0.49	6.1	0.37	4.34e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs8084125	1.000	rs72978665	chr18:74953641	A/G	cg07390210	chr18:74961196	GALR1	0.55	6.3	0.38	1.48e-9	Obesity-related traits;
SARC	cis	rs11690935	0.885	rs6750058	chr2:172786909	G/T	cg13550731	chr2:172543902	DYNC1I2	-0.94	-13.63	-0.67	1.74e-31	Schizophrenia;
SARC	cis	rs870825	0.929	rs55746424	chr4:185589603	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	9.4	0.52	5.18e-18	Blood protein levels;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg23740897	chr7:2195739	MAD1L1	-0.45	-6.31	-0.38	1.41e-9	Electrocardiographic conduction measures;
SARC	cis	rs6087990	0.735	rs2424915	chr20:31378448	C/T	cg13636640	chr20:31349939	DNMT3B	0.8	12.73	0.64	1.55e-28	Ulcerative colitis;
SARC	cis	rs4722166	0.695	rs7808122	chr7:22798080	A/G	cg26061582	chr7:22766209	IL6	0.45	5.16	0.32	5.3e-7	Lung cancer;
SARC	cis	rs4481887	0.708	rs28729425	chr1:248563027	T/C	cg13385794	chr1:248469461	NA	0.33	5.45	0.34	1.31e-7	Common traits (Other);
SARC	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg08677398	chr8:58056175	NA	0.42	5.14	0.32	5.77e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg22920501	chr2:26401640	FAM59B	-0.54	-7.03	-0.42	2.22e-11	Gut microbiome composition (summer);
SARC	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.77	7.59	0.45	7.63e-13	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs4268898	0.931	rs7603997	chr2:24524958	C/T	cg06627628	chr2:24431161	ITSN2	-0.67	-9.63	-0.53	1.11e-18	Asthma;
SARC	cis	rs1691799	0.867	rs1168341	chr12:66759080	G/C	cg16791601	chr12:66731901	HELB	-0.72	-10.84	-0.58	2.01e-22	White blood cell count (basophil);
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg27665823	chr16:460516	DECR2	0.51	6.26	0.38	1.85e-9	Schizophrenia;
SARC	cis	rs7408868	0.764	rs45504393	chr19:15277010	A/G	cg14696996	chr19:15285081	NOTCH3	1.02	8.7	0.5	6e-16	Pulse pressure;
SARC	cis	rs72634258	0.786	rs7514098	chr1:8177632	G/A	cg00042356	chr1:8021962	PARK7	0.64	5.92	0.36	1.16e-8	Inflammatory bowel disease;
SARC	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg09699651	chr6:150184138	LRP11	0.41	5.11	0.32	6.6e-7	Lung cancer;
SARC	cis	rs10904908	1.000	rs10795465	chr10:17260525	C/T	cg01003015	chr10:17271136	VIM	-0.42	-5.21	-0.32	4.22e-7	Total cholesterol levels;Cholesterol, total;
SARC	cis	rs67311347	0.577	rs2371129	chr3:40248393	C/T	cg24209194	chr3:40518798	ZNF619	-0.45	-5.34	-0.33	2.22e-7	Renal cell carcinoma;
SARC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg06873352	chr17:61820015	STRADA	0.52	6.57	0.4	3.29e-10	Prudent dietary pattern;
SARC	cis	rs11097912	0.632	rs3805405	chr4:107238885	T/C	cg09646026	chr4:107269030	AIMP1	-0.45	-4.87	-0.3	2.08e-6	Airflow obstruction;
SARC	cis	rs992157	0.735	rs13388024	chr2:219097773	A/G	cg00012203	chr2:219082015	ARPC2	0.85	13.75	0.67	6.88e-32	Colorectal cancer;
SARC	cis	rs3126085	0.935	rs3126091	chr1:152307338	T/C	cg03465714	chr1:152285911	FLG	0.46	5.5	0.34	1.02e-7	Atopic dermatitis;
SARC	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg11644478	chr21:40555479	PSMG1	1.03	14.49	0.69	2.39e-34	Cognitive function;
SARC	cis	rs9899728	0.764	rs9660	chr17:73038746	A/G	cg27626185	chr17:73056755	KCTD2	-0.58	-4.73	-0.3	3.89e-6	Alzheimer's disease or small vessel stroke;
SARC	cis	rs943466	1.000	rs6933174	chr6:33751003	G/A	cg04676172	chr6:33757040	LEMD2	0.45	4.78	0.3	3.1e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
SARC	cis	rs9300255	0.620	rs7313483	chr12:123726834	C/T	cg05973401	chr12:123451056	ABCB9	0.47	5.18	0.32	4.77e-7	Neutrophil percentage of white cells;
SARC	cis	rs11098499	0.954	rs13145352	chr4:120409963	C/T	cg09307838	chr4:120376055	NA	-0.8	-10.16	-0.55	2.62e-20	Corneal astigmatism;
SARC	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg03709012	chr19:19516395	GATAD2A	1.01	17.32	0.75	9.53e-44	Tonsillectomy;
SARC	cis	rs2439831	0.681	rs2444036	chr15:43694108	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	10.74	0.58	4.05e-22	Lung cancer in ever smokers;
SARC	cis	rs6901004	0.803	rs9320360	chr6:111462272	G/T	cg15721981	chr6:111408429	SLC16A10	-0.44	-5.4	-0.33	1.6e-7	Blood metabolite levels;
SARC	cis	rs6665290	0.904	rs3768425	chr1:227178127	A/G	cg14016676	chr1:227182615	CDC42BPA	0.34	5.03	0.31	1e-6	Myeloid white cell count;
SARC	cis	rs36051895	0.664	rs1034072	chr9:5088903	T/A	cg02405213	chr9:5042618	JAK2	-0.45	-5.34	-0.33	2.25e-7	Pediatric autoimmune diseases;
SARC	cis	rs11155671	0.530	rs2342767	chr6:150209717	C/G	cg09699651	chr6:150184138	LRP11	0.52	6.59	0.4	2.86e-10	Testicular germ cell tumor;
SARC	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg21747090	chr2:27597821	SNX17	-0.52	-7.08	-0.42	1.67e-11	Total body bone mineral density;
SARC	cis	rs9309473	1.000	rs7564890	chr2:73641853	T/C	cg20560298	chr2:73613845	ALMS1	-0.45	-5.57	-0.34	6.95e-8	Metabolite levels;
SARC	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs503734	0.643	rs2317749	chr3:101121980	C/T	cg19452782	chr3:101232218	SENP7	-0.41	-5.24	-0.32	3.61e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs1355223	0.902	rs1539250	chr11:34742775	C/T	cg18508148	chr11:34937573	PDHX;APIP	-0.38	-4.83	-0.3	2.46e-6	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs7224737	0.750	rs12325861	chr17:40289412	T/C	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-0.5	-4.73	-0.3	3.85e-6	Fibrinogen levels;
SARC	cis	rs3758785	0.586	rs481597	chr11:94070016	A/C	cg13023536	chr11:94226537	MRE11A;ANKRD49	-0.46	-6.01	-0.37	7.27e-9	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
SARC	cis	rs10197940	0.624	rs17270233	chr2:152372420	A/G	cg19508488	chr2:152266495	RIF1	0.52	5.69	0.35	3.75e-8	Lung cancer;
SARC	cis	rs73242632	0.881	rs73242633	chr4:57920066	C/T	cg20415529	chr4:57845134	POLR2B;C4orf14	0.94	6.0	0.37	7.3e-9	Congenital heart disease (maternal effect);
SARC	cis	rs3768617	0.510	rs4491025	chr1:183065183	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.65	0.57	7.77e-22	Fuchs's corneal dystrophy;
SARC	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	8.95	0.51	1.15e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7727544	0.507	rs9791170	chr5:131569627	A/G	cg24060327	chr5:131705240	SLC22A5	-0.43	-5.24	-0.32	3.52e-7	Blood metabolite levels;
SARC	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg22496380	chr5:211416	CCDC127	-0.87	-8.86	-0.5	2.06e-16	Breast cancer;
SARC	cis	rs7223966	1.000	rs28463311	chr17:61919643	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-4.97	-0.31	1.29e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg22875332	chr1:76189707	ACADM	0.5	7.17	0.42	1.01e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6580649	0.941	rs78649179	chr12:48508196	T/A	cg05342945	chr12:48394962	COL2A1	0.52	5.62	0.35	5.38e-8	Lung cancer;
SARC	cis	rs10028773	0.515	rs9994488	chr4:120587781	C/T	cg09307838	chr4:120376055	NA	0.72	10.26	0.56	1.24e-20	Educational attainment;
SARC	cis	rs12912251	0.591	rs3102118	chr15:39003475	A/C	cg01338139	chr15:38987640	C15orf53	0.5	4.88	0.3	2.01e-6	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
SARC	cis	rs138491296	1	rs138491296	chr17:27961561	GATTATT/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.44	-5.24	-0.32	3.55e-7	White blood cell count;
SARC	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg08859206	chr1:53392774	SCP2	0.42	6.01	0.37	7.26e-9	Monocyte count;
SARC	trans	rs11174478	0.500	rs2128275	chr12:40421985	A/C	cg17715141	chr4:182609697	NA	-0.41	-6.26	-0.38	1.82e-9	Insomnia;
SARC	cis	rs10870270	1.000	rs11146338	chr10:133770291	C/G	cg26149184	chr10:133730230	NA	0.46	5.05	0.31	9e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg10295955	chr4:187884368	NA	1.05	18.1	0.76	2.48e-46	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6831352	0.918	rs7670241	chr4:100059619	G/T	cg12011299	chr4:100065546	ADH4	-0.34	-5.74	-0.35	2.95e-8	Alcohol dependence;
SARC	cis	rs651907	0.557	rs12629954	chr3:101360623	C/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	6.29	0.38	1.57e-9	Colorectal cancer;
SARC	cis	rs9640161	0.659	rs7806429	chr7:150013393	A/G	cg21361702	chr7:150065534	REPIN1	0.43	4.88	0.3	1.95e-6	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs9457247	0.902	rs34560498	chr6:167395862	A/G	cg07741184	chr6:167504864	NA	0.29	5.55	0.34	7.66e-8	Crohn's disease;
SARC	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg03647317	chr4:187891568	NA	-0.36	-5.3	-0.33	2.65e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs274567	0.501	rs272856	chr5:131687081	G/C	cg12564285	chr5:131593104	PDLIM4	0.43	5.87	0.36	1.49e-8	Blood metabolite levels;
SARC	cis	rs9457247	0.967	rs402191	chr6:167405553	T/C	cg07741184	chr6:167504864	NA	0.29	5.55	0.34	7.72e-8	Crohn's disease;
SARC	cis	rs9303401	0.659	rs714959	chr17:56628601	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.1	11.87	0.61	1.01e-25	Cognitive test performance;
SARC	trans	rs11098499	0.863	rs34868248	chr4:120442430	A/G	cg25214090	chr10:38739885	LOC399744	0.57	7.35	0.43	3.31e-12	Corneal astigmatism;
SARC	cis	rs2072499	0.554	rs1052067	chr1:156206121	C/T	cg25208724	chr1:156163844	SLC25A44	0.61	6.0	0.37	7.68e-9	Testicular germ cell tumor;
SARC	cis	rs6964587	0.620	rs6967588	chr7:91643402	G/T	cg17063962	chr7:91808500	NA	0.84	12.83	0.64	7.58e-29	Breast cancer;
SARC	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.65	8.2	0.47	1.6e-14	Chronic sinus infection;
SARC	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	11.03	0.59	4.93e-23	Alzheimer's disease;
SARC	cis	rs2153535	0.580	rs7742794	chr6:8459723	C/A	cg07606381	chr6:8435919	SLC35B3	0.75	10.66	0.57	7.43e-22	Motion sickness;
SARC	cis	rs12421382	0.659	rs11213103	chr11:109385935	A/G	cg16359550	chr11:109292809	C11orf87	0.35	5.08	0.32	7.67e-7	Schizophrenia;
SARC	cis	rs3820928	1.000	rs9288617	chr2:227762815	G/C	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.83	-0.36	1.82e-8	Pulmonary function;
SARC	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg08280861	chr8:58055591	NA	0.63	7.33	0.43	3.73e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs6840360	0.615	rs55932132	chr4:152463897	G/T	cg22705602	chr4:152727874	NA	-0.42	-6.51	-0.39	4.59e-10	Intelligence (multi-trait analysis);
SARC	trans	rs4834272	0.556	rs7673053	chr4:113302869	G/T	cg19336959	chr7:150497703	TMEM176B;TMEM176A	0.44	6.25	0.38	1.9e-9	Body mass index;
SARC	cis	rs9430161	0.579	rs11121667	chr1:11038476	C/T	cg27631724	chr1:11040367	C1orf127	0.43	6.64	0.4	2.15e-10	Ewing sarcoma;
SARC	cis	rs9916302	0.904	rs6503503	chr17:37514373	G/A	cg20243544	chr17:37824526	PNMT	-0.56	-6.92	-0.41	4.39e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs6089584	0.566	rs11699442	chr20:60623268	A/G	cg06108461	chr20:60628389	TAF4	-0.7	-9.08	-0.51	4.74e-17	Body mass index;
SARC	cis	rs9868809	0.772	rs9836462	chr3:48712791	C/T	cg06212747	chr3:49208901	KLHDC8B	0.62	5.46	0.34	1.22e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs6933660	0.683	rs8180642	chr6:151756612	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.67	9.24	0.52	1.61e-17	Menarche (age at onset);
SARC	cis	rs7772486	0.622	rs1292333	chr6:145982344	C/T	cg05347473	chr6:146136440	FBXO30	-0.5	-6.95	-0.41	3.67e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10046574	0.831	rs17403220	chr7:135191705	A/G	cg27474649	chr7:135195673	CNOT4	0.87	7.13	0.42	1.25e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg08219700	chr8:58056026	NA	0.63	6.34	0.38	1.19e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2594989	0.887	rs7640360	chr3:11584889	T/G	cg00170343	chr3:11313890	ATG7	-0.59	-5.89	-0.36	1.37e-8	Circulating chemerin levels;
SARC	cis	rs7824557	0.564	rs13260727	chr8:11232860	A/G	cg21775007	chr8:11205619	TDH	0.58	7.43	0.44	2.04e-12	Retinal vascular caliber;
SARC	cis	rs10078	0.559	rs2671891	chr5:456386	A/G	cg24955955	chr5:415729	AHRR	0.72	6.54	0.39	3.84e-10	Fat distribution (HIV);
SARC	cis	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg07777115	chr5:623756	CEP72	-0.56	-4.81	-0.3	2.68e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs12621445	1	rs12621445	chr2:24154964	C/T	cg08917208	chr2:24149416	ATAD2B	0.93	8.7	0.5	6.18e-16	Immature fraction of reticulocytes;
SARC	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg16049864	chr8:95962084	TP53INP1	-0.47	-7.69	-0.45	4.13e-13	Type 2 diabetes;
SARC	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg05313129	chr8:58192883	C8orf71	-0.62	-6.34	-0.38	1.18e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2292864	0.764	rs36046953	chr17:45381791	A/G	cg18085866	chr17:45331354	ITGB3	-0.81	-6.02	-0.37	6.66e-9	Left atrial antero-posterior diameter;
SARC	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg05896524	chr21:47604654	C21orf56	0.42	5.04	0.31	9.35e-7	Testicular germ cell tumor;
SARC	cis	rs501120	0.850	rs642222	chr10:44770473	A/G	cg09554077	chr10:44749378	NA	0.48	6.64	0.4	2.12e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs10870270	0.913	rs115236491	chr10:133766855	T/G	cg17892150	chr10:133769511	PPP2R2D	-0.83	-10.33	-0.56	7.55e-21	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs765787	0.530	rs12440321	chr15:45529385	G/A	cg24006582	chr15:45444508	DUOX1	0.45	5.62	0.35	5.53e-8	Uric acid levels;
SARC	cis	rs7666738	0.830	rs28795113	chr4:98951331	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9457247	1.000	rs406095	chr6:167409087	C/T	cg07741184	chr6:167504864	NA	0.3	5.6	0.34	5.91e-8	Crohn's disease;
SARC	cis	rs9640161	0.702	rs11765692	chr7:150026567	C/T	cg21361702	chr7:150065534	REPIN1	0.5	5.39	0.33	1.76e-7	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs11997175	0.522	rs10954930	chr8:33588352	C/T	ch.8.33884649F	chr8:33765107	NA	0.48	6.0	0.37	7.45e-9	Body mass index;
SARC	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg04772025	chr11:68637568	NA	0.48	6.1	0.37	4.46e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7216064	0.953	rs2086744	chr17:65849275	C/G	cg12091567	chr17:66097778	LOC651250	-0.66	-6.72	-0.4	1.39e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs79349575	0.783	rs4793998	chr17:47019899	C/T	cg07967210	chr17:47022446	SNF8	0.38	4.77	0.3	3.2e-6	Type 2 diabetes;
SARC	cis	rs478304	0.718	rs1144789	chr11:65389631	A/G	cg27068330	chr11:65405492	SIPA1	0.41	5.09	0.32	7.55e-7	Acne (severe);
SARC	cis	rs778371	0.874	rs938575	chr2:233768788	G/A	cg16596103	chr2:233749413	NGEF	0.36	5.11	0.32	6.7e-7	Schizophrenia;
SARC	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg22683308	chr4:1340831	KIAA1530	0.45	5.34	0.33	2.23e-7	Longevity;
SARC	cis	rs10752881	1.000	rs4402094	chr1:182986441	G/A	cg13390022	chr1:182993471	LAMC1	0.35	5.24	0.32	3.63e-7	Colorectal cancer;
SARC	cis	rs9322193	0.607	rs4870078	chr6:150201812	A/G	cg05036130	chr6:150231994	NA	-0.32	-4.9	-0.31	1.81e-6	Lung cancer;
SARC	cis	rs274567	0.501	rs272855	chr5:131687175	C/T	cg04518342	chr5:131593106	PDLIM4	0.42	5.31	0.33	2.54e-7	Blood metabolite levels;
SARC	cis	rs17376456	0.825	rs28610997	chr5:93248374	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	5.75	0.35	2.81e-8	Diabetic retinopathy;
SARC	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg11644478	chr21:40555479	PSMG1	-0.57	-7.04	-0.42	2.19e-11	Menarche (age at onset);
SARC	cis	rs2153535	0.580	rs6421949	chr6:8531769	G/A	cg23788917	chr6:8435910	SLC35B3	0.64	8.64	0.49	9.33e-16	Motion sickness;
SARC	cis	rs7197653	0.748	rs8063446	chr16:68344363	A/C	cg09835421	chr16:68378352	PRMT7	-0.68	-5.68	-0.35	4.1e-8	Magnesium levels;
SARC	cis	rs9916302	0.904	rs679995	chr17:37441679	A/T	cg00129232	chr17:37814104	STARD3	0.58	7.22	0.43	7.41e-12	Glomerular filtration rate (creatinine);
SARC	trans	rs1814175	0.546	rs1614397	chr11:49913384	G/C	cg03929089	chr4:120376271	NA	-0.89	-14.5	-0.69	2.16e-34	Height;
SARC	cis	rs2795502	1.000	rs2185717	chr10:43343875	G/A	cg20628663	chr10:43360327	NA	0.48	6.48	0.39	5.49e-10	Blood protein levels;
SARC	cis	rs6540556	0.859	rs11119341	chr1:209940675	A/G	cg23920097	chr1:209922102	NA	0.53	5.82	0.36	1.93e-8	Red blood cell count;
SARC	cis	rs6058796	1.000	rs9636547	chr20:31262033	T/A	cg13636640	chr20:31349939	DNMT3B	0.56	4.94	0.31	1.52e-6	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs1348850	0.632	rs13009207	chr2:178501632	A/G	cg23306229	chr2:178417860	TTC30B	0.5	5.48	0.34	1.11e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7772486	0.790	rs10223507	chr6:146285204	C/A	cg05347473	chr6:146136440	FBXO30	-0.46	-6.24	-0.38	1.99e-9	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.51	6.46	0.39	6.05e-10	Intelligence (multi-trait analysis);
SARC	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg13866156	chr1:1669148	SLC35E2	-0.62	-9.13	-0.51	3.38e-17	Body mass index;
SARC	cis	rs546131	0.890	rs496558	chr11:34826425	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.45	5.6	0.34	6.15e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs17376456	0.569	rs2924374	chr5:93151141	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.5	-5.05	-0.31	8.79e-7	Diabetic retinopathy;
SARC	trans	rs7815944	1.000	rs7815944	chr8:129427518	A/G	cg25487405	chr22:46473039	NA	0.59	6.61	0.4	2.63e-10	Atopic dermatitis;
SARC	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg26513180	chr16:89883248	FANCA	-0.72	-4.82	-0.3	2.57e-6	Skin colour saturation;
SARC	cis	rs17376456	0.569	rs6879620	chr5:93119893	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.56	-5.87	-0.36	1.47e-8	Diabetic retinopathy;
SARC	cis	rs7945705	0.791	rs6484484	chr11:8817206	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.36	4.94	0.31	1.48e-6	Hemoglobin concentration;
SARC	cis	rs12586317	0.534	rs1568200	chr14:35419592	C/T	cg05294307	chr14:35346193	BAZ1A	-0.46	-5.09	-0.32	7.22e-7	Psoriasis;
SARC	cis	rs1707322	0.752	rs4660313	chr1:46110841	A/G	cg06784218	chr1:46089804	CCDC17	-0.36	-6.24	-0.38	2e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1153858	1.000	rs56806728	chr15:45637814	A/G	cg26924012	chr15:45694286	SPATA5L1	0.76	10.58	0.57	1.3e-21	Homoarginine levels;
SARC	cis	rs796364	0.806	rs203765	chr2:200903020	G/A	cg23649088	chr2:200775458	C2orf69	-0.66	-5.82	-0.36	1.97e-8	Schizophrenia;
SARC	cis	rs41271473	0.526	rs10916344	chr1:228737489	C/T	cg16512390	chr1:228756714	NA	0.68	6.84	0.41	6.75e-11	Chronic lymphocytic leukemia;
SARC	cis	rs17666538	0.901	rs73177064	chr8:585293	C/G	cg19660806	chr8:588740	NA	-0.61	-4.82	-0.3	2.62e-6	IgG glycosylation;
SARC	cis	rs1865760	0.786	rs1436308	chr6:25939567	T/G	cg16482183	chr6:26056742	HIST1H1C	0.53	6.73	0.4	1.3100000000000001e-10	Height;
SARC	cis	rs2153535	0.542	rs9393012	chr6:8439809	G/A	cg21535247	chr6:8435926	SLC35B3	0.56	7.01	0.42	2.6e-11	Motion sickness;
SARC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.41	-6.88	-0.41	5.61e-11	Total body bone mineral density;
SARC	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg16325326	chr1:53192061	ZYG11B	0.87	16.01	0.72	2.1e-39	Monocyte count;
SARC	cis	rs2832191	0.720	rs7277028	chr21:30494604	T/C	cg24692254	chr21:30365293	RNF160	-0.88	-12.46	-0.63	1.2e-27	Dental caries;
SARC	cis	rs965469	1.000	rs2236104	chr20:3277602	C/A	cg25506879	chr20:3388711	C20orf194	-0.5	-5.04	-0.31	9.42e-7	IFN-related cytopenia;
SARC	cis	rs11651000	0.625	rs2074190	chr17:45811210	A/G	cg24803719	chr17:45855879	NA	-0.45	-7.14	-0.42	1.15e-11	IgG glycosylation;
SARC	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.73	-7.32	-0.43	3.94e-12	Platelet count;
SARC	cis	rs4319547	0.626	rs11057882	chr12:122875046	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.57	-6.41	-0.39	7.89e-10	Body mass index;
SARC	cis	rs7666738	0.830	rs28729647	chr4:99059552	T/C	cg05340658	chr4:99064831	C4orf37	0.64	8.66	0.49	7.7e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg07701084	chr6:150067640	NUP43	0.4	5.37	0.33	1.91e-7	Lung cancer;
SARC	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg03709012	chr19:19516395	GATAD2A	1.01	17.96	0.76	7.55e-46	Tonsillectomy;
SARC	cis	rs9341808	0.754	rs10806185	chr6:80954511	G/A	cg08355045	chr6:80787529	NA	0.34	5.5	0.34	9.89e-8	Sitting height ratio;
SARC	trans	rs747334	0.846	rs7897603	chr10:92708759	C/G	cg03368787	chr6:35480625	TULP1	-0.42	-6.45	-0.39	6.38e-10	Fibroblast growth factor basic levels;
SARC	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg10295955	chr4:187884368	NA	1.05	19.64	0.79	2.62e-51	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.63	-6.73	-0.4	1.29e-10	Platelet count;
SARC	cis	rs6088590	0.931	rs6088624	chr20:33436852	T/A	cg24642439	chr20:33292090	TP53INP2	0.85	11.56	0.6	1.02e-24	Coronary artery disease;
SARC	cis	rs2718058	0.639	rs2718036	chr7:37775288	T/A	cg15028436	chr7:37888078	TXNDC3	0.37	5.11	0.32	6.64e-7	Alzheimer's disease (late onset);
SARC	trans	rs2727020	0.521	rs7946190	chr11:49521964	T/A	cg15704280	chr7:45808275	SEPT13	0.7	8.13	0.47	2.52e-14	Coronary artery disease;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg08929612	chr5:1320685	CLPTM1L	0.46	6.64	0.4	2.19e-10	Schizophrenia;
SARC	cis	rs782590	0.967	rs11125579	chr2:55739804	T/C	cg18811423	chr2:55921094	PNPT1	0.75	10.86	0.58	1.68e-22	Metabolic syndrome;
SARC	cis	rs17270561	0.666	rs9356987	chr6:25739187	C/A	cg16482183	chr6:26056742	HIST1H1C	0.43	5.22	0.32	3.92e-7	Iron status biomarkers;
SARC	cis	rs523522	0.885	rs524735	chr12:121022099	T/C	cg27279351	chr12:120934652	DYNLL1	0.71	8.72	0.5	5.43e-16	High light scatter reticulocyte count;
SARC	cis	rs4727027	0.901	rs1534197	chr7:148771970	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	5.84	0.36	1.7e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs4148883	0.603	rs1893883	chr4:100124716	C/G	cg12011299	chr4:100065546	ADH4	0.34	6.19	0.38	2.64e-9	Alcohol dependence;
SARC	trans	rs9325144	0.555	rs2387847	chr12:38687434	C/T	cg23762105	chr12:34175262	ALG10	-0.52	-6.97	-0.42	3.32e-11	Morning vs. evening chronotype;
SARC	cis	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg03060546	chr3:49711283	APEH	0.6	7.49	0.44	1.41e-12	Resting heart rate;
SARC	cis	rs73206853	0.688	rs60971459	chr12:110702051	G/A	cg10860002	chr12:110842031	ANAPC7	0.63	5.1	0.32	6.94e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	trans	rs61931739	0.534	rs1843733	chr12:34047626	T/C	cg26384229	chr12:38710491	ALG10B	0.76	10.94	0.58	9.15e-23	Morning vs. evening chronotype;
SARC	cis	rs9515201	0.627	rs9521730	chr13:111031180	C/T	cg05272587	chr13:111038400	COL4A2	-0.37	-5.45	-0.34	1.25e-7	White matter hyperintensity burden;
SARC	cis	rs459571	0.959	rs461462	chr9:136911272	C/T	cg01294253	chr9:136912663	BRD3	0.39	5.13	0.32	6.07e-7	Platelet distribution width;
SARC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg16405210	chr4:1374714	KIAA1530	0.82	10.9	0.58	1.23e-22	Longevity;
SARC	cis	rs2976388	0.506	rs2572902	chr8:143791387	A/G	cg06565975	chr8:143823917	SLURP1	0.3	5.24	0.32	3.65e-7	Urinary tract infection frequency;
SARC	cis	rs2439831	1.000	rs2439831	chr15:43784475	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.1	11.11	0.59	2.71e-23	Lung cancer in ever smokers;
SARC	cis	rs7937682	0.889	rs10749984	chr11:111492861	T/C	cg22437258	chr11:111473054	SIK2	0.74	10.24	0.56	1.44e-20	Primary sclerosing cholangitis;
SARC	cis	rs11651000	0.625	rs4794067	chr17:45808828	T/C	cg24803719	chr17:45855879	NA	-0.44	-6.87	-0.41	5.8e-11	IgG glycosylation;
SARC	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg04756594	chr16:24857601	SLC5A11	-0.45	-6.31	-0.38	1.39e-9	Intelligence (multi-trait analysis);
SARC	cis	rs6772849	0.930	rs6768344	chr3:128373556	G/A	cg01163369	chr3:128370232	RPN1	-0.34	-4.98	-0.31	1.23e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs2439831	0.867	rs2447208	chr15:43933895	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	7.5	0.44	1.33e-12	Lung cancer in ever smokers;
SARC	cis	rs3820928	0.874	rs10933163	chr2:227815286	A/G	cg11843606	chr2:227700838	RHBDD1	-0.56	-7.12	-0.42	1.33e-11	Pulmonary function;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg18671773	chr5:141016477	RELL2;HDAC3	0.54	7.28	0.43	5.18e-12	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs9815354	0.767	rs73073342	chr3:41839455	A/C	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2735413	0.846	rs12923626	chr16:78080139	A/C	cg04733911	chr16:78082701	NA	-0.3	-5.45	-0.34	1.29e-7	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg08048268	chr3:133502702	NA	0.44	5.95	0.36	9.98e-9	Iron status biomarkers;
SARC	cis	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg08564027	chr20:61660810	NA	0.76	11.57	0.6	9.45e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg09373136	chr17:61933544	TCAM1	-0.45	-6.13	-0.37	3.74e-9	Prudent dietary pattern;
SARC	cis	rs9911578	0.904	rs7209253	chr17:56908987	C/T	cg12560992	chr17:57184187	TRIM37	0.86	12.1	0.62	1.84e-26	Intelligence (multi-trait analysis);
SARC	trans	rs9388451	0.874	rs3734634	chr6:126111800	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.6	-7.78	-0.45	2.28e-13	Brugada syndrome;
SARC	cis	rs9788682	0.748	rs637137	chr15:78873976	T/A	cg06917634	chr15:78832804	PSMA4	-0.51	-5.7	-0.35	3.63e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	trans	rs9354308	0.899	rs2814099	chr6:66555130	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.56	6.65	0.4	2.11e-10	Metabolite levels;
SARC	cis	rs3008870	0.755	rs2815355	chr1:67485034	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.59	7.6	0.45	7e-13	Lymphocyte percentage of white cells;
SARC	cis	rs3126085	0.877	rs4415568	chr1:152181207	G/A	cg26876637	chr1:152193138	HRNR	0.49	5.61	0.35	5.67e-8	Atopic dermatitis;
SARC	cis	rs5753618	0.561	rs5749265	chr22:31796897	A/C	cg07713946	chr22:31675144	LIMK2	0.35	4.88	0.3	1.94e-6	Colorectal cancer;
SARC	cis	rs6988636	0.818	rs73339658	chr8:124173007	A/G	cg23067535	chr8:124195133	FAM83A	-0.73	-5.1	-0.32	6.93e-7	Urinary uromodulin levels;
SARC	cis	rs6582630	0.555	rs11181684	chr12:38388000	T/C	cg26384229	chr12:38710491	ALG10B	0.87	12.85	0.64	6.2e-29	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs4713118	0.869	rs9461400	chr6:27700559	A/G	cg17221315	chr6:27791827	HIST1H4J	0.49	5.29	0.33	2.77e-7	Parkinson's disease;
SARC	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg03060546	chr3:49711283	APEH	0.42	5.23	0.32	3.86e-7	Parkinson's disease;
SARC	cis	rs35110281	0.807	rs6518301	chr21:45016818	T/C	cg01579765	chr21:45077557	HSF2BP	-0.34	-5.82	-0.36	1.89e-8	Mean corpuscular volume;
SARC	cis	rs7843479	0.965	rs1484162	chr8:21831385	A/G	cg17168535	chr8:21777572	XPO7	0.64	8.21	0.47	1.55e-14	Mean corpuscular volume;
SARC	cis	rs526231	0.511	rs17154965	chr5:102359566	C/A	cg23492399	chr5:102201601	PAM	-0.51	-5.56	-0.34	7.44e-8	Primary biliary cholangitis;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg13976866	chr7:128696069	LOC286016;TNPO3	0.53	6.32	0.38	1.35e-9	Blood pressure;
SARC	cis	rs9611519	0.603	rs4821999	chr22:41470001	A/G	cg17376030	chr22:41985996	PMM1	0.4	5.01	0.31	1.07e-6	Neuroticism;
SARC	cis	rs7762018	0.556	rs78233989	chr6:170102041	C/G	cg13015042	chr6:170102002	WDR27;C6orf120	0.68	4.81	0.3	2.73e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg06831761	chr7:104885108	SRPK2	-0.76	-6.37	-0.39	1.02e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg14541582	chr5:601475	NA	-0.4	-4.8	-0.3	2.85e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs9790314	0.875	rs336582	chr3:161082659	C/T	cg04691961	chr3:161091175	C3orf57	-0.76	-11.31	-0.6	6.12e-24	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg08280861	chr8:58055591	NA	0.71	5.78	0.35	2.38e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	5.62	0.35	5.51e-8	Electroencephalogram traits;
SARC	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.64	5.35	0.33	2.11e-7	Initial pursuit acceleration;
SARC	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg24633833	chr3:10029261	TMEM111	0.52	5.25	0.33	3.43e-7	Alzheimer's disease;
SARC	cis	rs4423214	1.000	rs12807718	chr11:71171170	T/C	cg24826892	chr11:71159390	DHCR7	0.48	6.16	0.37	3.09e-9	Vitamin D levels;
SARC	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg13393036	chr8:95962371	TP53INP1	-0.36	-6.0	-0.37	7.6e-9	Type 2 diabetes;
SARC	cis	rs6909279	0.648	rs6919923	chr6:151849670	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	-0.49	-6.32	-0.38	1.29e-9	Bone mineral density;
SARC	cis	rs6500602	0.793	rs4785964	chr16:4484613	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.38	5.47	0.34	1.17e-7	Schizophrenia;
SARC	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg22920501	chr2:26401640	FAM59B	0.58	7.38	0.44	2.75e-12	Gut microbiome composition (summer);
SARC	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg05332525	chr7:65337924	VKORC1L1	0.43	4.83	0.3	2.44e-6	Aortic root size;
SARC	cis	rs2242116	0.796	rs2290546	chr3:46965197	C/G	cg02527881	chr3:46936655	PTH1R	-0.39	-5.98	-0.36	8.15e-9	Birth weight;
SARC	cis	rs2985684	0.901	rs2354448	chr14:50098296	G/A	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.47	4.91	0.31	1.69e-6	Carotid intima media thickness;
SARC	cis	rs9303401	0.659	rs35082010	chr17:56936867	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.05	11.76	0.61	2.3e-25	Cognitive test performance;
SARC	cis	rs4243830	0.737	rs56036909	chr1:6608503	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.93	8.91	0.5	1.52e-16	Body mass index;
SARC	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg21442419	chr1:2182373	SKI	-0.46	-5.99	-0.37	8.01e-9	Height;
SARC	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg20887711	chr4:1340912	KIAA1530	0.55	6.74	0.4	1.22e-10	Longevity;
SARC	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg11247378	chr22:39784982	NA	-0.33	-5.27	-0.33	3.08e-7	Intelligence (multi-trait analysis);
SARC	cis	rs4727027	0.933	rs10238826	chr7:148830888	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	5.58	0.34	6.5e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs11098499	0.779	rs10011097	chr4:120310359	T/G	cg09160332	chr4:120329925	NA	-0.33	-4.77	-0.3	3.27e-6	Corneal astigmatism;
SARC	cis	rs11792861	0.816	rs28361111	chr9:111761012	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.73	8.54	0.49	1.78e-15	Menarche (age at onset);
SARC	cis	rs4481887	1.000	rs4579792	chr1:248463742	C/T	cg00666640	chr1:248458726	OR2T12	-0.32	-5.43	-0.34	1.38e-7	Common traits (Other);
SARC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg26354017	chr1:205819088	PM20D1	0.84	13.08	0.65	1.13e-29	Menarche (age at onset);
SARC	cis	rs4595586	0.545	rs12813151	chr12:39363405	C/G	cg26384229	chr12:38710491	ALG10B	-0.53	-6.29	-0.38	1.58e-9	Morning vs. evening chronotype;
SARC	cis	rs12142240	0.698	rs17361812	chr1:46814008	C/T	cg00530320	chr1:46809349	NSUN4	0.57	6.92	0.41	4.4e-11	Menopause (age at onset);
SARC	cis	rs67460515	0.527	rs34221255	chr3:160854123	T/C	cg17135325	chr3:160939158	NMD3	0.58	7.22	0.43	7.29e-12	Parkinson's disease;
SARC	cis	rs11098499	0.863	rs13134665	chr4:120426430	T/C	cg09307838	chr4:120376055	NA	0.9	11.88	0.61	9.34e-26	Corneal astigmatism;
SARC	cis	rs9322817	0.669	rs4079063	chr6:105266118	A/G	cg02098413	chr6:105308735	HACE1	-0.38	-5.91	-0.36	1.18e-8	Thyroid stimulating hormone;
SARC	cis	rs4853036	1.000	rs35002543	chr2:70091299	A/G	cg02498382	chr2:70120550	SNRNP27	-0.39	-5.15	-0.32	5.5e-7	Colorectal or endometrial cancer;
SARC	cis	rs2985684	0.846	rs4476096	chr14:50019391	A/C	cg04989706	chr14:50066350	PPIL5	-0.51	-5.72	-0.35	3.29e-8	Carotid intima media thickness;
SARC	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	16.89	0.74	2.57e-42	Height;
SARC	trans	rs9354308	0.838	rs9354305	chr6:66542891	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.53	-6.32	-0.38	1.32e-9	Metabolite levels;
SARC	cis	rs4853036	1.000	rs62134006	chr2:70050641	T/C	cg02498382	chr2:70120550	SNRNP27	-0.42	-5.7	-0.35	3.53e-8	Colorectal or endometrial cancer;
SARC	cis	rs4742903	0.509	rs10991115	chr9:106896111	C/T	cg14250997	chr9:106856677	SMC2	0.48	5.97	0.36	8.92e-9	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs9788682	0.747	rs2938671	chr15:78732754	A/G	cg06917634	chr15:78832804	PSMA4	0.52	5.4	0.33	1.62e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs10870270	1.000	rs4880250	chr10:133773919	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.83	-10.33	-0.56	7.55e-21	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs478304	0.654	rs1074156	chr11:65458169	G/T	cg27068330	chr11:65405492	SIPA1	-0.44	-4.95	-0.31	1.43e-6	Acne (severe);
SARC	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg24642844	chr7:1081250	C7orf50	-0.59	-6.21	-0.38	2.41e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg13264159	chr8:625131	ERICH1	-0.73	-5.17	-0.32	5.06e-7	IgG glycosylation;
SARC	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.82	-12.58	-0.64	5.02e-28	Personality dimensions;
SARC	cis	rs854765	0.654	rs11078400	chr17:17757728	A/G	cg16928487	chr17:17741425	SREBF1	0.23	4.87	0.3	2.1e-6	Total body bone mineral density;
SARC	cis	rs2463822	0.669	rs72919475	chr11:62042361	T/A	cg06239285	chr11:62104954	ASRGL1	-0.85	-7.9	-0.46	1.08e-13	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs1003719	0.788	rs2835578	chr21:38457671	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.65	9.46	0.53	3.43e-18	Eye color traits;
SARC	cis	rs875971	0.528	rs801213	chr7:66014918	C/T	cg11764359	chr7:65958608	NA	-0.62	-6.06	-0.37	5.55e-9	Aortic root size;
SARC	cis	rs3762637	0.941	rs74467988	chr3:122083140	C/T	cg24169773	chr3:122142474	KPNA1	-0.58	-5.7	-0.35	3.66e-8	LDL cholesterol levels;
SARC	cis	rs9902453	0.900	rs56195309	chr17:28453753	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	6.52	0.39	4.21e-10	Coffee consumption (cups per day);
SARC	cis	rs889312	0.923	rs12697152	chr5:56025716	A/G	cg14703610	chr5:56206110	C5orf35	-0.41	-4.89	-0.3	1.91e-6	Breast cancer;Breast cancer (early onset);
SARC	cis	rs908922	0.887	rs4845783	chr1:152492559	G/A	cg09873164	chr1:152488093	CRCT1	0.7	8.23	0.47	1.34e-14	Hair morphology;
SARC	cis	rs2651899	0.902	rs1736522	chr1:3080940	C/G	cg22674798	chr1:3096360	PRDM16	0.23	4.74	0.3	3.68e-6	Migraine;
SARC	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg03709012	chr19:19516395	GATAD2A	0.99	16.93	0.74	1.88e-42	Tonsillectomy;
SARC	cis	rs4481887	0.893	rs10788774	chr1:248471712	T/C	cg00666640	chr1:248458726	OR2T12	0.38	6.28	0.38	1.62e-9	Common traits (Other);
SARC	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg11062466	chr8:58055876	NA	0.53	5.16	0.32	5.35e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1865721	0.804	rs72977816	chr18:73146779	A/T	cg26385618	chr18:73139727	C18orf62	-0.37	-5.1	-0.32	7.13e-7	Intelligence;
SARC	cis	rs796364	0.715	rs77089299	chr2:201116853	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.82	-6.02	-0.37	6.71e-9	Schizophrenia;
SARC	cis	rs11792861	0.781	rs2297581	chr9:111755008	C/T	cg13535736	chr9:111863775	C9orf5	-0.38	-4.72	-0.3	4.03e-6	Menarche (age at onset);
SARC	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg15790184	chr11:494944	RNH1	0.38	4.72	0.3	4.05e-6	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs9341808	0.690	rs9343970	chr6:80881289	C/G	cg08355045	chr6:80787529	NA	0.34	5.54	0.34	8.01e-8	Sitting height ratio;
SARC	cis	rs2498796	0.727	rs4983543	chr14:105212399	T/C	cg07523784	chr14:105186699	NA	-0.37	-5.28	-0.33	2.95e-7	Endometrial cancer;Endometrial endometrioid carcinoma;
SARC	cis	rs10791097	0.547	rs3829271	chr11:130753912	T/A	cg12179176	chr11:130786555	SNX19	0.72	10.29	0.56	1.01e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs9660992	0.710	rs1172111	chr1:205232980	C/T	cg19090574	chr1:205240910	TMCC2	-0.4	-4.99	-0.31	1.18e-6	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg27170947	chr2:26402098	FAM59B	0.37	4.8	0.3	2.79e-6	Gut microbiome composition (summer);
SARC	cis	rs3820928	0.874	rs2229812	chr2:227896886	C/T	cg11843606	chr2:227700838	RHBDD1	-0.55	-6.84	-0.41	6.81e-11	Pulmonary function;
SARC	cis	rs36051895	0.659	rs7859390	chr9:5062473	A/T	cg02405213	chr9:5042618	JAK2	-0.46	-5.32	-0.33	2.41e-7	Pediatric autoimmune diseases;
SARC	cis	rs9948	0.529	rs62156208	chr2:97383686	A/G	cg01990225	chr2:97406019	LMAN2L	-1.0	-7.24	-0.43	6.58e-12	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg12463550	chr7:65579703	CRCP	0.71	5.32	0.33	2.41e-7	Diabetic kidney disease;
SARC	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg11644478	chr21:40555479	PSMG1	-1.0	-14.14	-0.68	3.46e-33	Cognitive function;
SARC	cis	rs1318878	0.565	rs16910770	chr12:15505731	C/T	cg08258403	chr12:15378311	NA	0.46	6.63	0.4	2.32e-10	Intelligence (multi-trait analysis);
SARC	cis	rs6510489	0.527	rs10419824	chr19:35956014	G/A	cg05711131	chr19:36231948	TMEM149	-0.47	-4.89	-0.31	1.86e-6	Bipolar disorder;
SARC	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg06028808	chr11:68637592	NA	0.51	6.12	0.37	3.92e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs4900538	0.855	rs72698602	chr14:102880454	T/C	cg18135206	chr14:102964638	TECPR2	-0.62	-8.04	-0.47	4.59e-14	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs6484504	0.600	rs2761593	chr11:31326752	G/T	cg26647111	chr11:31128758	NA	0.4	5.13	0.32	6.02e-7	Red blood cell count;
SARC	cis	rs8038465	0.622	rs2509	chr15:73859488	A/T	cg15420318	chr15:73925796	NPTN	-0.56	-6.44	-0.39	6.88e-10	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs10489202	1.000	rs7535138	chr1:167931462	T/G	cg24449463	chr1:168025552	DCAF6	-0.65	-7.05	-0.42	2.04e-11	Schizophrenia;
SARC	cis	rs11098499	0.954	rs11722872	chr4:120233030	G/C	cg09160332	chr4:120329925	NA	-0.34	-4.75	-0.3	3.62e-6	Corneal astigmatism;
SARC	cis	rs798554	0.634	rs6970963	chr7:2821271	C/T	cg04166393	chr7:2884313	GNA12	0.43	5.28	0.33	2.94e-7	Height;
SARC	cis	rs7666738	0.791	rs1559860	chr4:99024422	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2439831	0.541	rs12440854	chr15:43610672	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.13	10.17	0.55	2.44e-20	Lung cancer in ever smokers;
SARC	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg05861140	chr6:150128134	PCMT1	-0.39	-5.08	-0.32	7.83e-7	Lung cancer;
SARC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.98	11.32	0.6	5.83e-24	Platelet count;
SARC	cis	rs6604026	0.656	rs949915	chr1:93369774	A/G	cg17283838	chr1:93427260	FAM69A	-0.42	-4.75	-0.3	3.59e-6	Multiple sclerosis;
SARC	cis	rs9325144	0.560	rs7314632	chr12:38636979	C/T	cg14851346	chr12:38532713	NA	-0.39	-4.84	-0.3	2.35e-6	Morning vs. evening chronotype;
SARC	trans	rs2898290	0.622	rs4840567	chr8:11347625	A/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.81	-0.46	1.89e-13	Systolic blood pressure;
SARC	trans	rs55704346	0.515	rs7682177	chr4:25205654	A/G	cg21101356	chr14:34420266	EGLN3	0.48	6.29	0.38	1.58e-9	Tonsillectomy;
SARC	cis	rs10089	1.000	rs2054444	chr5:127493206	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.78	-9.56	-0.53	1.74e-18	Ileal carcinoids;
SARC	cis	rs710216	0.957	rs12041787	chr1:43432275	G/C	cg07803811	chr1:43423981	SLC2A1	0.52	5.15	0.32	5.57e-7	Red cell distribution width;
SARC	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg16434002	chr17:42200994	HDAC5	-0.43	-5.42	-0.33	1.52e-7	Total body bone mineral density;
SARC	cis	rs12545109	0.800	rs2576592	chr8:57419357	A/C	cg21220214	chr8:57350948	NA	-0.4	-4.84	-0.3	2.37e-6	Obesity-related traits;
SARC	cis	rs2304069	1.000	rs2304069	chr5:149406733	G/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.9	9.99	0.55	8.71e-20	HIV-1 control;
SARC	cis	rs10089	1.000	rs17764954	chr5:127514436	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	8.49	0.49	2.52e-15	Ileal carcinoids;
SARC	cis	rs7005380	0.581	rs9297607	chr8:120937071	G/A	cg21744203	chr8:120868354	DSCC1	0.45	5.29	0.33	2.75e-7	Interstitial lung disease;
SARC	cis	rs9359856	0.564	rs17735590	chr6:90330268	G/C	cg13799429	chr6:90582589	CASP8AP2	-0.66	-5.24	-0.32	3.59e-7	Bipolar disorder;
SARC	cis	rs10089	1.000	rs13357268	chr5:127423051	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.85	10.53	0.57	1.79e-21	Ileal carcinoids;
SARC	cis	rs2635047	0.875	rs2251948	chr18:44681356	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.54	7.39	0.44	2.65e-12	Educational attainment;
SARC	cis	rs7615952	0.599	rs60847438	chr3:125746005	T/C	cg15145296	chr3:125709740	NA	-0.49	-4.81	-0.3	2.68e-6	Blood pressure (smoking interaction);
SARC	cis	rs1003719	0.715	rs7280251	chr21:38567911	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-8.99	-0.51	8.94e-17	Eye color traits;
SARC	trans	rs7709377	0.951	rs2112570	chr5:115547594	C/G	cg01136335	chr5:68629714	NA	-0.54	-6.44	-0.39	6.79e-10	Metabolite levels  (X-11787);
SARC	cis	rs6693567	0.545	rs2133129	chr1:150355537	T/C	cg09579323	chr1:150459698	TARS2	0.46	5.84	0.36	1.74e-8	Migraine;
SARC	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg05861140	chr6:150128134	PCMT1	-0.38	-4.93	-0.31	1.54e-6	Lung cancer;
SARC	cis	rs2816062	0.786	rs735946	chr1:18901323	T/C	cg10574377	chr1:18908098	NA	0.34	4.82	0.3	2.54e-6	Urate levels in lean individuals;
SARC	cis	rs6866344	0.570	rs1071882	chr5:178136040	C/T	cg10224037	chr5:178157518	ZNF354A	1.03	14.72	0.69	4.05e-35	Neutrophil percentage of white cells;
SARC	cis	rs1832871	0.683	rs56197409	chr6:158684338	A/G	cg07165851	chr6:158734300	TULP4	0.55	6.67	0.4	1.82e-10	Height;
SARC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg22105103	chr4:187893119	NA	0.5	6.86	0.41	6.16e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4805272	0.512	rs765484	chr19:29344663	A/G	cg04546413	chr19:29218101	NA	0.44	4.85	0.3	2.28e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs9682041	0.696	rs10936627	chr3:170104406	C/T	cg11886554	chr3:170076028	SKIL	0.84	7.76	0.45	2.72e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs6690583	0.623	rs12042018	chr1:85436937	T/C	cg22153463	chr1:85462885	MCOLN2	0.7	6.7	0.4	1.54e-10	Serum sulfate level;
SARC	cis	rs9393692	0.905	rs1124999	chr6:26287043	G/T	cg13736514	chr6:26305472	NA	-0.62	-8.55	-0.49	1.7e-15	Educational attainment;
SARC	cis	rs2404602	0.716	rs56216512	chr15:76686936	T/C	cg22467129	chr15:76604101	ETFA	-0.37	-4.83	-0.3	2.49e-6	Blood metabolite levels;
SARC	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	7.84	0.46	1.59e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-4.91	-0.31	1.71e-6	Total body bone mineral density;
SARC	cis	rs7647973	0.961	rs7626076	chr3:49298139	G/A	cg07636037	chr3:49044803	WDR6	0.73	7.96	0.46	7.73e-14	Menarche (age at onset);
SARC	cis	rs5753618	0.509	rs2079431	chr22:31564334	C/T	cg07713946	chr22:31675144	LIMK2	-0.38	-5.48	-0.34	1.09e-7	Colorectal cancer;
SARC	trans	rs1814175	0.647	rs4881649	chr11:49845560	A/G	cg03929089	chr4:120376271	NA	-0.74	-10.74	-0.58	3.91e-22	Height;
SARC	cis	rs10489202	0.954	rs3820399	chr1:168062053	C/T	cg24449463	chr1:168025552	DCAF6	-0.61	-6.83	-0.41	7.27e-11	Schizophrenia;
SARC	cis	rs10463316	0.832	rs246482	chr5:150731857	C/G	cg03212797	chr5:150827313	SLC36A1	-0.51	-6.11	-0.37	4.23e-9	Metabolite levels (Pyroglutamine);
SARC	cis	rs6991838	0.584	rs4737748	chr8:66525865	C/T	cg13398993	chr8:66546079	ARMC1	0.62	8.19	0.47	1.72e-14	Intelligence (multi-trait analysis);
SARC	cis	rs7520050	0.931	rs785472	chr1:46518288	T/A	cg24296786	chr1:45957014	TESK2	0.37	4.75	0.3	3.61e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs10870270	0.957	rs3753008	chr10:133785129	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.77	-9.64	-0.53	9.87e-19	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs9815354	1.000	rs17063649	chr3:41863406	C/T	cg03022575	chr3:42003672	ULK4	0.57	5.33	0.33	2.34e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg03213289	chr20:61660250	NA	0.46	6.43	0.39	7.22e-10	Prostate cancer (SNP x SNP interaction);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg12344600	chr6:89769123	NA	-0.56	-6.96	-0.41	3.38e-11	Height;
SARC	cis	rs1003719	0.667	rs3753073	chr21:38466615	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.54	7.37	0.43	3.01e-12	Eye color traits;
SARC	cis	rs9486719	1.000	rs2472884	chr6:96863965	C/T	cg06623918	chr6:96969491	KIAA0776	0.73	8.01	0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs6963495	0.818	rs73190158	chr7:105153943	T/C	cg13798780	chr7:105162888	PUS7	0.6	5.5	0.34	9.98e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs4803468	1.000	rs284651	chr19:41928336	T/C	cg08477640	chr19:41863820	B9D2	0.43	5.45	0.34	1.28e-7	Height;
SARC	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg11644478	chr21:40555479	PSMG1	-1.05	-15.0	-0.7	4.65e-36	Cognitive function;
SARC	cis	rs17376456	0.825	rs13164315	chr5:93147421	A/G	cg21475434	chr5:93447410	FAM172A	0.78	6.63	0.4	2.34e-10	Diabetic retinopathy;
SARC	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg11764359	chr7:65958608	NA	-0.83	-11.1	-0.59	2.96e-23	Aortic root size;
SARC	cis	rs9467773	1.000	rs1884949	chr6:26568067	G/A	cg12292205	chr6:26970375	C6orf41	0.45	5.43	0.33	1.45e-7	Intelligence (multi-trait analysis);
SARC	cis	rs155076	1.000	rs261431	chr13:21865738	A/G	cg25811766	chr13:21894605	NA	0.46	5.05	0.31	8.99e-7	White matter hyperintensity burden;
SARC	cis	rs6911965	0.641	rs16889387	chr6:24485736	T/C	cg20631270	chr6:24437470	GPLD1	0.51	4.82	0.3	2.59e-6	Hematological and biochemical traits;
SARC	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg25072359	chr17:41440525	NA	0.48	5.62	0.35	5.43e-8	Menopause (age at onset);
SARC	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg17221315	chr6:27791827	HIST1H4J	0.51	5.21	0.32	4.16e-7	Parkinson's disease;
SARC	cis	rs55823223	0.503	rs9906971	chr17:73848477	A/G	cg23806715	chr17:73775811	H3F3B	0.46	5.03	0.31	9.68e-7	Psoriasis;
SARC	cis	rs7851660	0.967	rs6478437	chr9:100607497	A/G	cg13688889	chr9:100608707	NA	-0.36	-4.72	-0.3	3.99e-6	Strep throat;
SARC	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	8.54	0.49	1.71e-15	Alzheimer's disease;
SARC	cis	rs453301	0.686	rs2409120	chr8:8882571	G/C	cg11995313	chr8:8860691	ERI1	0.41	5.28	0.33	3e-7	Joint mobility (Beighton score);
SARC	cis	rs1371867	0.875	rs1660311	chr8:101330579	C/T	cg11906718	chr8:101322791	RNF19A	0.71	9.13	0.51	3.37e-17	Atrioventricular conduction;
SARC	cis	rs7633770	0.965	rs6804112	chr3:46686248	C/T	cg11219411	chr3:46661640	NA	0.44	7.04	0.42	2.11e-11	Coronary artery disease;
SARC	cis	rs208520	1.000	rs208527	chr6:66957209	A/C	cg07460842	chr6:66804631	NA	-0.86	-9.56	-0.53	1.79e-18	Exhaled nitric oxide output;
SARC	cis	rs12497850	0.931	rs7616815	chr3:48779715	C/T	cg07636037	chr3:49044803	WDR6	0.95	16.07	0.72	1.33e-39	Parkinson's disease;
SARC	cis	rs11651000	0.857	rs16947078	chr17:45825500	A/G	cg24803719	chr17:45855879	NA	-0.5	-7.39	-0.44	2.54e-12	IgG glycosylation;
SARC	cis	rs17376456	0.690	rs6892055	chr5:93113023	A/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.71	6.58	0.4	3.13e-10	Diabetic retinopathy;
SARC	cis	rs9916302	0.768	rs11078900	chr17:37614641	C/T	cg20243544	chr17:37824526	PNMT	0.55	6.43	0.39	7.19e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs4481887	0.741	rs28589987	chr1:248564785	T/C	cg00666640	chr1:248458726	OR2T12	0.32	5.56	0.34	7.24e-8	Common traits (Other);
SARC	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg06420487	chr17:61919686	SMARCD2	0.43	4.9	0.31	1.8e-6	Height;
SARC	cis	rs883565	0.792	rs1274958	chr3:39184959	C/T	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.53	-5.78	-0.35	2.34e-8	Handedness;
SARC	cis	rs208515	0.560	rs207084	chr6:66776966	T/C	cg07460842	chr6:66804631	NA	-1.1	-21.35	-0.81	9.4e-57	Exhaled nitric oxide levels;
SARC	cis	rs4820539	1.000	rs2267002	chr22:23456702	T/C	cg14186256	chr22:23484241	RTDR1	0.88	14.21	0.68	2.08e-33	Bone mineral density;
SARC	cis	rs73815153	1.000	rs7731337	chr5:180433264	C/T	cg21012711	chr5:179921286	CNOT6	0.93	5.43	0.33	1.45e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	trans	rs11098499	0.954	rs7656252	chr4:120404268	T/C	cg25214090	chr10:38739885	LOC399744	0.57	7.33	0.43	3.83e-12	Corneal astigmatism;
SARC	trans	rs7819412	0.595	rs2409712	chr8:10986837	A/C	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.95	-0.46	7.82e-14	Triglycerides;
SARC	cis	rs10197940	0.662	rs2432945	chr2:152278414	T/C	cg19508488	chr2:152266495	RIF1	0.47	5.19	0.32	4.48e-7	Lung cancer;
SARC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.82	10.9	0.58	1.28e-22	Prudent dietary pattern;
SARC	cis	rs7412746	0.611	rs4970985	chr1:150887442	C/T	cg15448220	chr1:150897856	SETDB1	-0.5	-6.52	-0.39	4.28e-10	Melanoma;
SARC	cis	rs12142240	0.698	rs6679898	chr1:46820589	A/C	cg10495392	chr1:46806563	NSUN4	0.65	6.8	0.41	8.89e-11	Menopause (age at onset);
SARC	cis	rs995000	0.899	rs1184865	chr1:62973795	A/G	cg06896770	chr1:63153194	DOCK7	-0.85	-12.42	-0.63	1.6e-27	Triglyceride levels;
SARC	cis	rs796364	0.762	rs13030712	chr2:200973569	G/A	cg23649088	chr2:200775458	C2orf69	0.73	8.81	0.5	2.83e-16	Schizophrenia;
SARC	cis	rs11785400	0.963	rs9771845	chr8:143726577	C/G	cg24634471	chr8:143751801	JRK	0.67	8.93	0.5	1.34e-16	Schizophrenia;
SARC	cis	rs10870270	1.000	rs10870232	chr10:133738537	T/G	cg08754478	chr10:133766260	PPP2R2D	-0.45	-5.37	-0.33	1.93e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs9896933	0.832	rs79103992	chr17:80855483	G/A	cg20578329	chr17:80767326	TBCD	-0.74	-8.33	-0.48	6.76e-15	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
SARC	cis	rs2303745	0.589	rs7246262	chr19:17392483	C/G	cg22549504	chr19:17448937	GTPBP3	0.48	4.88	0.3	1.94e-6	Systemic lupus erythematosus;
SARC	cis	rs7712401	0.525	rs246312	chr5:122269455	G/A	cg19412675	chr5:122181750	SNX24	0.41	5.21	0.32	4.23e-7	Mean platelet volume;
SARC	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg23172400	chr8:95962367	TP53INP1	-0.31	-5.38	-0.33	1.83e-7	Type 2 diabetes;
SARC	cis	rs17270561	0.609	rs3778272	chr6:25767661	G/A	cg16482183	chr6:26056742	HIST1H1C	0.48	5.95	0.36	9.58e-9	Iron status biomarkers;
SARC	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg12564285	chr5:131593104	PDLIM4	0.35	5.22	0.32	3.93e-7	Breast cancer;
SARC	cis	rs826838	0.754	rs2387920	chr12:38626351	A/G	cg13010199	chr12:38710504	ALG10B	0.8	11.21	0.59	1.3e-23	Heart rate;
SARC	cis	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg24110177	chr3:50126178	RBM5	0.57	7.78	0.45	2.32e-13	Intelligence (multi-trait analysis);
SARC	cis	rs870825	0.587	rs35377170	chr4:185639728	T/C	cg04058563	chr4:185651563	MLF1IP	0.79	11.24	0.59	1.03e-23	Blood protein levels;
SARC	cis	rs2832077	0.527	rs2142375	chr21:30223742	G/A	cg08807101	chr21:30365312	RNF160	-0.55	-6.29	-0.38	1.53e-9	Cognitive test performance;
SARC	cis	rs2228479	0.717	rs12917681	chr16:89810941	C/A	cg06558623	chr16:89946397	TCF25	0.87	6.94	0.41	3.78e-11	Skin colour saturation;
SARC	cis	rs17376456	0.825	rs10058331	chr5:93279115	T/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.57	0.34	6.9e-8	Diabetic retinopathy;
SARC	cis	rs6450176	0.538	rs12186486	chr5:53306549	T/A	ch.5.1024479R	chr5:53302184	ARL15	-1.07	-12.4	-0.63	1.83e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs9911578	1.000	rs6503887	chr17:56993320	T/C	cg05425664	chr17:57184151	TRIM37	-0.67	-8.33	-0.48	7.15e-15	Intelligence (multi-trait analysis);
SARC	cis	rs9650657	0.644	rs3808603	chr8:10698218	T/C	cg21775007	chr8:11205619	TDH	-0.4	-4.97	-0.31	1.32e-6	Neuroticism;
SARC	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg04166393	chr7:2884313	GNA12	0.42	5.19	0.32	4.53e-7	Height;
SARC	cis	rs142518269	1	rs142518269	chr2:24087095	G/A	cg06627628	chr2:24431161	ITSN2	-0.69	-6.52	-0.39	4.34e-10	Mean corpuscular hemoglobin;
SARC	cis	rs10197940	0.624	rs6724796	chr2:152412813	C/T	cg19508488	chr2:152266495	RIF1	0.5	5.65	0.35	4.63e-8	Lung cancer;
SARC	cis	rs6963495	0.818	rs1721498	chr7:105178819	A/C	cg13798780	chr7:105162888	PUS7	-0.47	-4.96	-0.31	1.36e-6	Bipolar disorder (body mass index interaction);
SARC	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.37	-4.85	-0.3	2.26e-6	Bronchopulmonary dysplasia;
SARC	cis	rs6456156	1.000	rs6456156	chr6:167522300	T/C	cg07741184	chr6:167504864	NA	0.3	5.4	0.33	1.66e-7	Primary biliary cholangitis;
SARC	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg26617929	chr16:1858877	NA	-0.74	-6.67	-0.4	1.81e-10	Ankle injury;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17696629	chr8:94713190	FAM92A1	-0.52	-6.37	-0.39	9.85e-10	Fibrinogen levels;
SARC	cis	rs1056053	0.514	rs3127329	chr6:166572362	G/A	cg11088901	chr6:166572345	T	-0.42	-5.51	-0.34	9.35e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs7000551	0.556	rs6998780	chr8:22254639	C/T	cg12081754	chr8:22256438	SLC39A14	0.83	11.4	0.6	3.29e-24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	trans	rs1814175	0.817	rs28594987	chr11:50045181	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-18.68	-0.77	3.33e-48	Height;
SARC	cis	rs2073499	1.000	rs78020607	chr3:50254624	A/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.61	5.35	0.33	2.09e-7	Schizophrenia;
SARC	cis	rs6598955	1.000	rs6598955	chr1:26619649	C/T	cg04990556	chr1:26633338	UBXN11	0.69	8.69	0.49	6.69e-16	Obesity-related traits;
SARC	cis	rs1008375	1.000	rs2058337	chr4:17678649	C/T	cg02297831	chr4:17616191	MED28	0.44	5.54	0.34	8.24e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6582630	0.519	rs12819814	chr12:38332568	G/C	cg13010199	chr12:38710504	ALG10B	0.79	10.84	0.58	1.95e-22	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg12041069	chr6:45341222	RUNX2;SUPT3H	0.52	6.71	0.4	1.44e-10	Thyroid stimulating hormone;
SARC	cis	rs7727544	0.660	rs274563	chr5:131717859	C/A	cg07395648	chr5:131743802	NA	0.41	4.91	0.31	1.73e-6	Blood metabolite levels;
SARC	trans	rs62103177	0.810	rs3902996	chr18:77630571	A/G	cg05926928	chr17:57297772	GDPD1	1.1	9.27	0.52	1.3e-17	Opioid sensitivity;
SARC	cis	rs9325144	0.647	rs11169222	chr12:39105210	C/T	cg26384229	chr12:38710491	ALG10B	-0.6	-7.74	-0.45	2.98e-13	Morning vs. evening chronotype;
SARC	cis	rs6060717	0.536	rs8125966	chr20:34511823	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-5.72	-0.35	3.27e-8	Hip circumference adjusted for BMI;
SARC	cis	rs3820928	1.000	rs7592387	chr2:227777095	A/G	cg05526886	chr2:227700861	RHBDD1	-0.5	-6.14	-0.37	3.52e-9	Pulmonary function;
SARC	cis	rs34172651	0.917	rs11074654	chr16:24813743	A/G	cg06028605	chr16:24865363	SLC5A11	0.27	4.85	0.3	2.21e-6	Intelligence (multi-trait analysis);
SARC	cis	rs514024	0.700	rs553083	chr9:130491483	C/T	cg13643465	chr9:130375613	STXBP1	0.42	5.21	0.32	4.08e-7	Eating disorders (purging via substances);
SARC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg13494126	chr7:1908745	MAD1L1	0.52	6.4	0.39	8.51e-10	Hepatitis;
SARC	cis	rs7565124	0.909	rs6747472	chr2:20252007	C/T	cg23821541	chr2:20251993	LAPTM4A	0.49	4.74	0.3	3.73e-6	Major depressive disorder;
SARC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.98	10.35	0.56	6.92e-21	Platelet count;
SARC	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg02841227	chr6:26021843	HIST1H4A	0.61	7.0	0.42	2.72e-11	Intelligence (multi-trait analysis);
SARC	cis	rs7326068	0.610	rs7995798	chr13:21338432	C/T	cg16922012	chr13:21400325	XPO4	-0.44	-5.71	-0.35	3.42e-8	Schizophrenia, bipolar disorder and depression (combined);
SARC	cis	rs739401	0.611	rs3782069	chr11:3033275	G/A	cg25174290	chr11:3078921	CARS	0.57	7.91	0.46	1.01e-13	Longevity;
SARC	cis	rs16854884	0.770	rs1530478	chr3:143819553	C/T	cg06585982	chr3:143692056	C3orf58	0.6	8.3	0.48	8.66e-15	Economic and political preferences (feminism/equality);
SARC	cis	rs11574514	1.000	rs79407301	chr16:67717264	G/A	cg01866162	chr16:67596514	CTCF	1.13	6.68	0.4	1.7e-10	Crohn's disease;
SARC	cis	rs3771570	0.901	rs55811034	chr2:242406245	C/T	cg21155796	chr2:242212141	HDLBP	0.64	5.98	0.36	8.5e-9	Prostate cancer;
SARC	cis	rs11190604	0.943	rs2495744	chr10:102329409	C/T	cg07080220	chr10:102295463	HIF1AN	0.84	10.14	0.55	2.9e-20	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs12155623	0.834	rs16939055	chr8:49824013	T/G	cg06076277	chr8:49783056	NA	0.3	4.99	0.31	1.2e-6	Sudden cardiac arrest;
SARC	cis	rs79349575	0.749	rs2270574	chr17:47022270	C/T	cg07967210	chr17:47022446	SNF8	0.38	4.77	0.3	3.2e-6	Type 2 diabetes;
SARC	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg11987759	chr7:65425863	GUSB	0.49	6.39	0.39	8.71e-10	Aortic root size;
SARC	cis	rs11864453	0.826	rs2072142	chr16:72132713	C/T	cg16558253	chr16:72132732	DHX38	-0.59	-9.65	-0.53	9.16e-19	Fibrinogen levels;
SARC	cis	rs11574514	1.000	rs8058835	chr16:67814865	C/T	cg01866162	chr16:67596514	CTCF	0.81	5.42	0.33	1.47e-7	Crohn's disease;
SARC	cis	rs7944735	0.817	rs7924699	chr11:47893120	A/T	cg03393444	chr11:47293049	MADD	0.32	5.27	0.33	3.1e-7	Intraocular pressure;
SARC	cis	rs7208859	0.623	rs7208441	chr17:29143863	C/T	cg13385521	chr17:29058706	SUZ12P	0.9	7.55	0.44	9.53e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs2282802	0.660	rs2436390	chr5:139586501	G/A	cg26211634	chr5:139558579	C5orf32	-0.37	-4.81	-0.3	2.69e-6	Intelligence (multi-trait analysis);
SARC	cis	rs1538970	0.962	rs9429076	chr1:45819489	A/G	cg16078521	chr1:45672383	ZSWIM5	0.45	4.88	0.3	2.01e-6	Platelet count;
SARC	cis	rs7103648	0.966	rs896817	chr11:47394305	A/G	cg10504702	chr11:47789108	FNBP4	-0.56	-6.83	-0.41	7.46e-11	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2115630	1.000	rs4633690	chr15:85361960	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.44	-5.36	-0.33	1.98e-7	P wave terminal force;
SARC	cis	rs7560272	0.538	rs35767294	chr2:73922834	A/G	cg20560298	chr2:73613845	ALMS1	0.46	6.12	0.37	4e-9	Schizophrenia;
SARC	cis	rs73086581	1.000	rs14047	chr20:3914215	G/A	cg02187196	chr20:3869020	PANK2	0.65	6.3	0.38	1.5e-9	Response to antidepressants in depression;
SARC	cis	rs13314892	0.764	rs7647742	chr3:69857303	A/C	cg17445875	chr3:69859618	MITF	-0.48	-5.1	-0.32	6.92e-7	QRS complex (12-leadsum);
SARC	cis	rs9467773	1.000	rs2208331	chr6:26507319	A/G	cg11502198	chr6:26597334	ABT1	0.48	5.98	0.36	8.37e-9	Intelligence (multi-trait analysis);
SARC	cis	rs9322193	1.000	rs58189451	chr6:149921388	G/A	cg13206674	chr6:150067644	NUP43	0.42	5.33	0.33	2.26e-7	Lung cancer;
SARC	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg19680485	chr15:31195859	MTMR15	0.56	6.34	0.38	1.21e-9	Huntington's disease progression;
SARC	cis	rs9302635	0.513	rs8061459	chr16:72156063	C/T	cg01557791	chr16:72042693	DHODH	-0.58	-6.46	-0.39	5.93e-10	Blood protein levels;
SARC	cis	rs1215050	0.791	rs1215049	chr4:98848280	C/T	cg05340658	chr4:99064831	C4orf37	0.44	5.95	0.36	9.78e-9	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs7560272	0.512	rs13015885	chr2:73920482	G/T	cg20560298	chr2:73613845	ALMS1	0.47	6.3	0.38	1.43e-9	Schizophrenia;
SARC	cis	rs62283056	0.512	rs4568307	chr4:6284965	A/G	cg00701064	chr4:6280414	WFS1	0.5	7.07	0.42	1.76e-11	Cisplatin-induced ototoxicity;
SARC	cis	rs12348691	0.503	rs7046645	chr9:100617375	T/C	cg13688889	chr9:100608707	NA	-0.47	-5.0	-0.31	1.15e-6	Alopecia areata;
SARC	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg17221315	chr6:27791827	HIST1H4J	0.47	5.56	0.34	7.45e-8	Cardiac Troponin-T levels;
SARC	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-9.54	-0.53	2.07e-18	Alzheimer's disease;
SARC	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.72	6.85	0.41	6.4e-11	Platelet count;
SARC	cis	rs8014204	1.000	rs8014204	chr14:75322794	A/G	cg06637938	chr14:75390232	RPS6KL1	0.72	10.11	0.55	3.84e-20	Caffeine consumption;
SARC	cis	rs763121	0.776	rs4820346	chr22:39125074	C/G	cg06022373	chr22:39101656	GTPBP1	-0.77	-10.15	-0.55	2.71e-20	Menopause (age at onset);
SARC	cis	rs9309473	0.948	rs10170849	chr2:73747932	G/A	cg20560298	chr2:73613845	ALMS1	-0.49	-5.91	-0.36	1.22e-8	Metabolite levels;
SARC	cis	rs35110281	0.837	rs12627667	chr21:45071396	A/C	cg21573476	chr21:45109991	RRP1B	-0.49	-7.14	-0.42	1.16e-11	Mean corpuscular volume;
SARC	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg17971929	chr21:40555470	PSMG1	-0.58	-7.16	-0.42	1.04e-11	Menarche (age at onset);
SARC	cis	rs66573146	0.831	rs66645969	chr4:6985614	G/A	cg00086871	chr4:6988644	TBC1D14	0.89	5.27	0.33	3.06e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs9399137	0.507	rs11759062	chr6:135381248	A/C	cg22676075	chr6:135203613	NA	0.4	5.01	0.31	1.09e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg03806693	chr22:41940476	POLR3H	-0.86	-11.82	-0.61	1.44e-25	Vitiligo;
SARC	cis	rs4911259	0.513	rs6057665	chr20:31463460	A/G	cg13636640	chr20:31349939	DNMT3B	-0.67	-9.22	-0.52	1.84e-17	Inflammatory bowel disease;
SARC	cis	rs5758659	0.714	rs5758574	chr22:42481400	G/C	cg15128208	chr22:42549153	NA	0.36	5.19	0.32	4.57e-7	Cognitive function;
SARC	cis	rs1697139	0.583	rs1428474	chr5:66544015	C/A	cg11553311	chr5:66541588	NA	0.3	4.79	0.3	3.03e-6	Breast cancer;
SARC	trans	rs656319	0.586	rs35013996	chr8:9947145	A/G	cg06636001	chr8:8085503	FLJ10661	-0.64	-7.87	-0.46	1.37e-13	Myopia (pathological);
SARC	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg22535103	chr8:58192502	C8orf71	-0.59	-6.21	-0.38	2.35e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs5769765	0.913	rs8135071	chr22:50299587	T/C	cg03033257	chr22:50311977	ALG12;CRELD2	0.52	5.4	0.33	1.65e-7	Schizophrenia;
SARC	cis	rs1395	0.778	rs2580761	chr2:27426362	G/A	cg21747090	chr2:27597821	SNX17	-0.49	-5.79	-0.35	2.29e-8	Blood metabolite levels;
SARC	cis	rs2075555	0.632	rs62062993	chr17:48254577	G/T	cg06769994	chr17:48288538	NA	0.49	5.02	0.31	1.04e-6	Breast cancer;
SARC	cis	rs72634258	0.945	rs17523802	chr1:8021740	G/A	cg00042356	chr1:8021962	PARK7	0.79	7.16	0.42	1.06e-11	Inflammatory bowel disease;
SARC	cis	rs2288073	0.965	rs10469924	chr2:24416230	G/A	cg06627628	chr2:24431161	ITSN2	-0.65	-7.91	-0.46	1.05e-13	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs6582630	0.519	rs11495699	chr12:38286219	G/T	cg26384229	chr12:38710491	ALG10B	0.93	14.05	0.68	6.61e-33	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9677476	0.863	rs12465438	chr2:232073106	G/A	cg23338755	chr2:231921595	PSMD1	0.46	5.47	0.34	1.15e-7	Food antigen IgG levels;
SARC	cis	rs751728	0.965	rs2296743	chr6:33740025	C/T	cg15252951	chr6:33757062	LEMD2	0.6	7.1	0.42	1.5e-11	Crohn's disease;
SARC	cis	rs1920116	0.778	rs34058457	chr3:169554741	G/T	cg08193579	chr3:169529701	LRRC34	0.42	4.95	0.31	1.44e-6	Glioma (high-grade);
SARC	cis	rs2455601	0.671	rs10840135	chr11:8879794	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.39	-4.82	-0.3	2.56e-6	Schizophrenia;
SARC	cis	rs72781680	0.846	rs72780198	chr2:24014883	T/A	cg08917208	chr2:24149416	ATAD2B	0.75	7.09	0.42	1.56e-11	Lymphocyte counts;
SARC	cis	rs3892630	0.824	rs12327732	chr19:33221767	C/T	cg22980127	chr19:33182716	NUDT19	1.01	8.64	0.49	9.08e-16	Red blood cell traits;
SARC	cis	rs7818345	1.000	rs4392916	chr8:19309355	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.39	5.23	0.32	3.82e-7	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	11.07	0.59	3.59e-23	Alzheimer's disease;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg16978871	chr7:139026114	C7orf55	-0.55	-6.39	-0.39	9.12e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs9815354	0.953	rs11717170	chr3:42002811	G/C	cg03022575	chr3:42003672	ULK4	-0.56	-5.43	-0.33	1.44e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs4718428	0.705	rs4717328	chr7:66352665	T/C	cg12165864	chr7:66369176	NA	-0.45	-4.9	-0.31	1.82e-6	Corneal structure;
SARC	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.48	5.43	0.34	1.39e-7	Renal function-related traits (BUN);
SARC	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg19346786	chr7:2764209	NA	-0.38	-5.67	-0.35	4.21e-8	Height;
SARC	cis	rs6752107	1.000	rs3828309	chr2:234180410	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	-0.5	-6.29	-0.38	1.53e-9	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg13206674	chr6:150067644	NUP43	0.41	5.37	0.33	1.95e-7	Lung cancer;
SARC	cis	rs17376456	0.877	rs28539612	chr5:93499099	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.61	5.12	0.32	6.49e-7	Diabetic retinopathy;
SARC	cis	rs12579753	0.917	rs10862361	chr12:82197946	T/C	cg07988820	chr12:82153109	PPFIA2	-0.52	-6.11	-0.37	4.18e-9	Resting heart rate;
SARC	cis	rs3768617	0.510	rs7525917	chr1:183065406	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.41	0.56	4.46e-21	Fuchs's corneal dystrophy;
SARC	cis	rs10227331	1.000	rs10255520	chr7:157292087	C/T	cg04156418	chr7:157293606	NA	0.47	8.08	0.47	3.5e-14	Inattentive symptoms;
SARC	cis	rs7839435	0.666	rs11777131	chr8:27453762	C/T	cg01579299	chr8:27450062	NA	0.55	5.8	0.36	2.19e-8	Lung adenocarcinoma;
SARC	cis	rs2204008	0.846	rs2030416	chr12:38465118	A/G	cg13010199	chr12:38710504	ALG10B	-0.69	-9.44	-0.53	4.09e-18	Bladder cancer;
SARC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg10295955	chr4:187884368	NA	-1.07	-20.16	-0.8	5.35e-53	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504073	0.669	rs62507251	chr8:50028524	T/G	cg00325661	chr8:49890786	NA	0.54	7.22	0.43	7.1e-12	Blood metabolite ratios;
SARC	cis	rs10779751	0.734	rs7533211	chr1:11132965	G/C	cg04508216	chr1:11107452	MASP2	0.34	4.83	0.3	2.45e-6	Body mass index;
SARC	cis	rs13314892	0.689	rs62252230	chr3:69888682	C/T	cg17445875	chr3:69859618	MITF	-0.48	-4.95	-0.31	1.45e-6	QRS complex (12-leadsum);
SARC	trans	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.57	7.4	0.44	2.4e-12	Intelligence (multi-trait analysis);
SARC	cis	rs10078	0.848	rs890985	chr5:479746	C/G	cg08916839	chr5:415575	AHRR	0.52	5.47	0.34	1.17e-7	Fat distribution (HIV);
SARC	cis	rs2404602	0.647	rs11852395	chr15:77087785	T/C	cg15268244	chr15:77196840	NA	0.43	5.03	0.31	9.79e-7	Blood metabolite levels;
SARC	cis	rs3857536	0.813	rs1891600	chr6:66941645	G/C	cg07460842	chr6:66804631	NA	-0.51	-5.83	-0.36	1.86e-8	Blood trace element (Cu levels);
SARC	trans	rs561341	0.714	rs7218466	chr17:30263314	A/G	cg20587970	chr11:113659929	NA	-0.99	-9.9	-0.54	1.65e-19	Hip circumference adjusted for BMI;
SARC	trans	rs208520	0.690	rs207094	chr6:66799009	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-14.36	-0.69	6.28e-34	Exhaled nitric oxide output;
SARC	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg03650068	chr1:25596491	NA	0.32	4.91	0.31	1.68e-6	Erythrocyte sedimentation rate;
SARC	cis	rs4900538	0.927	rs8005804	chr14:102957803	A/G	cg18135206	chr14:102964638	TECPR2	0.67	9.03	0.51	6.65e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs7566780	0.575	rs4383328	chr2:16693124	A/T	cg09580478	chr2:16689509	NA	0.51	6.35	0.38	1.12e-9	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs7666738	0.830	rs35951881	chr4:98999474	A/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg00684032	chr4:1343700	KIAA1530	0.33	4.91	0.31	1.73e-6	Obesity-related traits;
SARC	cis	rs1018836	0.608	rs10111060	chr8:91491152	T/C	cg16814680	chr8:91681699	NA	-0.66	-9.56	-0.53	1.79e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg05623727	chr3:50126028	RBM5	0.33	4.99	0.31	1.21e-6	Intelligence (multi-trait analysis);
SARC	cis	rs910316	1.000	rs1043674	chr14:75549370	T/C	cg11812906	chr14:75593930	NEK9	0.89	14.1	0.68	4.63e-33	Height;
SARC	cis	rs2933343	0.649	rs789216	chr3:128594503	A/C	cg24203234	chr3:128598194	ACAD9	0.63	8.04	0.47	4.56e-14	IgG glycosylation;
SARC	cis	rs6446731	0.593	rs7656026	chr4:3273625	G/C	cg06533319	chr4:3265114	C4orf44	-0.33	-5.28	-0.33	3e-7	Mean platelet volume;
SARC	cis	rs4970988	0.556	rs6695123	chr1:150563483	T/C	cg13175981	chr1:150552382	MCL1	0.5	5.95	0.36	9.96e-9	Urate levels;
SARC	cis	rs9309473	1.000	rs62151652	chr2:73700131	A/C	cg20560298	chr2:73613845	ALMS1	-0.53	-6.3	-0.38	1.51e-9	Metabolite levels;
SARC	cis	rs10744422	1.000	rs10847869	chr12:123328359	C/G	cg25930673	chr12:123319894	HIP1R	-0.65	-5.06	-0.31	8.53e-7	Schizophrenia;
SARC	cis	rs6688613	0.579	rs4657609	chr1:166839174	G/A	cg07049167	chr1:166818506	POGK	0.47	4.81	0.3	2.69e-6	Refractive astigmatism;
SARC	cis	rs10791323	0.575	rs4489760	chr11:133732265	A/T	cg14349672	chr11:133703707	NA	-0.33	-5.1	-0.32	7.18e-7	Childhood ear infection;
SARC	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg26335602	chr6:28129616	ZNF389	0.48	5.53	0.34	8.67e-8	Parkinson's disease;
SARC	cis	rs10892173	0.566	rs10892174	chr11:117672565	A/C	cg21640587	chr11:117668038	DSCAML1	0.71	10.24	0.56	1.5e-20	Myopia;
SARC	cis	rs13144136	0.748	rs4697774	chr4:10670461	A/G	cg10242279	chr4:10666415	CLNK	-0.35	-5.5	-0.34	9.83e-8	Resistance to antihypertensive treatment in hypertension;
SARC	cis	rs3796352	0.892	rs35076015	chr3:53026366	C/T	cg15956490	chr3:53032818	SFMBT1	0.87	5.73	0.35	3.14e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs11098499	0.954	rs10008459	chr4:120394231	T/C	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	trans	rs10862219	0.964	rs11114701	chr12:81430698	C/A	cg03835158	chr8:52773607	PCMTD1	-0.48	-6.55	-0.39	3.71e-10	Neuroticism;
SARC	cis	rs6665290	0.935	rs12409755	chr1:227196949	A/T	cg14016676	chr1:227182615	CDC42BPA	0.39	5.58	0.34	6.82e-8	Myeloid white cell count;
SARC	cis	rs950880	0.710	rs2270298	chr2:102992079	A/G	cg03938978	chr2:103052716	IL18RAP	-0.34	-4.85	-0.3	2.22e-6	Serum protein levels (sST2);
SARC	cis	rs508618	0.731	rs576462	chr1:231544607	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-6.43	-0.39	6.97e-10	Red blood cell count;
SARC	cis	rs77372450	0.636	rs10072471	chr5:157022207	G/C	cg23851860	chr5:157002805	ADAM19	0.5	4.86	0.3	2.16e-6	Bipolar disorder (body mass index interaction);
SARC	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.98	-11.84	-0.61	1.2e-25	Alzheimer's disease;
SARC	cis	rs2832191	1.000	rs2832191	chr21:30489300	A/C	cg08807101	chr21:30365312	RNF160	-0.72	-10.09	-0.55	4.22e-20	Dental caries;
SARC	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.98	11.28	0.59	7.83e-24	Platelet count;
SARC	cis	rs1003719	0.788	rs7276917	chr21:38451334	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.65	9.46	0.53	3.52e-18	Eye color traits;
SARC	cis	rs9916302	0.904	rs7208274	chr17:37513796	C/T	cg07936489	chr17:37558343	FBXL20	0.68	9.16	0.51	2.78e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs12142240	0.660	rs7520497	chr1:46824919	C/A	cg00530320	chr1:46809349	NSUN4	0.57	6.79	0.41	9.05e-11	Menopause (age at onset);
SARC	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg03806693	chr22:41940476	POLR3H	-0.94	-13.14	-0.65	7.11e-30	Vitiligo;
SARC	cis	rs748404	0.660	rs689767	chr15:43722077	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.4	4.78	0.3	3.13e-6	Lung cancer;
SARC	cis	rs9303401	0.659	rs36093395	chr17:56957357	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.05	11.76	0.61	2.3e-25	Cognitive test performance;
SARC	cis	rs9859260	0.710	rs41298097	chr3:195779155	C/T	cg03462622	chr3:195777018	TFRC	-0.46	-5.4	-0.33	1.65e-7	Mean corpuscular volume;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg23850707	chr15:55582494	RAB27A	-0.51	-6.35	-0.38	1.14e-9	Schizophrenia;
SARC	cis	rs72781680	0.898	rs72786278	chr2:24063243	C/T	cg06627628	chr2:24431161	ITSN2	-0.67	-6.45	-0.39	6.22e-10	Lymphocyte counts;
SARC	trans	rs2055729	0.645	rs6989793	chr8:9744650	A/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-6.48	-0.39	5.28e-10	Multiple myeloma (hyperdiploidy);
SARC	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.28	-0.52	1.19e-17	Developmental language disorder (linguistic errors);
SARC	cis	rs2635047	0.542	rs11082567	chr18:44769820	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.4	5.02	0.31	1.02e-6	Educational attainment;
SARC	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg08859206	chr1:53392774	SCP2	-0.41	-6.04	-0.37	5.95e-9	Monocyte count;
SARC	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg04277193	chr17:41438351	NA	0.45	4.86	0.3	2.15e-6	Menopause (age at onset);
SARC	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg05368731	chr17:41323189	NBR1	0.79	9.57	0.53	1.59e-18	Menopause (age at onset);
SARC	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.43	-4.95	-0.31	1.41e-6	Renal function-related traits (BUN);
SARC	cis	rs10870270	0.956	rs67378218	chr10:133752420	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.47	-5.48	-0.34	1.09e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg06558623	chr16:89946397	TCF25	-0.91	-6.42	-0.39	7.65e-10	Skin colour saturation;
SARC	cis	rs595982	0.702	rs623520	chr19:49369943	A/G	cg03707168	chr19:49379127	PPP1R15A	0.43	5.81	0.36	2.02e-8	Red cell distribution width;
SARC	cis	rs10100465	0.596	rs218009	chr8:118716275	A/G	cg26579311	chr8:119124103	EXT1	0.62	6.26	0.38	1.83e-9	Leprosy;
SARC	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg25072359	chr17:41440525	NA	0.5	5.76	0.35	2.67e-8	Menopause (age at onset);
SARC	cis	rs523522	0.962	rs55848094	chr12:120966659	G/A	cg27279351	chr12:120934652	DYNLL1	0.73	9.05	0.51	5.73e-17	High light scatter reticulocyte count;
SARC	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg18225595	chr11:63971243	STIP1	0.47	6.83	0.41	7.52e-11	Platelet count;
SARC	cis	rs9309473	0.948	rs10183818	chr2:73714556	A/G	cg20560298	chr2:73613845	ALMS1	-0.58	-6.53	-0.39	4.19e-10	Metabolite levels;
SARC	cis	rs17125944	0.686	rs2296495	chr14:53379878	G/A	cg00686598	chr14:53173677	PSMC6	0.84	5.83	0.36	1.87e-8	Alzheimer's disease (late onset);
SARC	cis	rs6752107	1.000	rs2241878	chr2:234183718	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.5	6.36	0.38	1.05e-9	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs73206853	0.698	rs1018133	chr12:111121302	G/C	cg10860002	chr12:110842031	ANAPC7	0.58	5.03	0.31	9.89e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs10782582	0.609	rs112431348	chr1:76275571	A/G	cg10523679	chr1:76189770	ACADM	-0.41	-5.04	-0.31	9.42e-7	Daytime sleep phenotypes;
SARC	cis	rs59918340	0.764	rs3824234	chr8:142229370	T/C	cg16341495	chr8:142228727	SLC45A4	-0.37	-5.22	-0.32	3.96e-7	Immature fraction of reticulocytes;
SARC	cis	rs79149102	0.579	rs3812946	chr15:75288610	G/C	cg00629941	chr15:75287862	SCAMP5	-0.8	-5.78	-0.35	2.41e-8	Lung cancer;
SARC	cis	rs9436747	0.618	rs1171266	chr1:66003824	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	-0.52	-5.52	-0.34	8.87e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs7833790	0.963	rs72686466	chr8:82758928	G/T	cg27398817	chr8:82754497	SNX16	0.52	5.64	0.35	5e-8	Diastolic blood pressure;
SARC	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg03351412	chr1:154909251	PMVK	0.61	8.06	0.47	4.02e-14	Prostate cancer;
SARC	cis	rs2153535	0.580	rs2225765	chr6:8481785	A/G	cg23788917	chr6:8435910	SLC35B3	0.64	8.36	0.48	5.74e-15	Motion sickness;
SARC	cis	rs72945132	0.882	rs7116191	chr11:70159781	G/A	cg05964544	chr11:70165517	PPFIA1	-0.61	-5.87	-0.36	1.5e-8	Coronary artery disease;
SARC	trans	rs1973993	0.691	rs11165623	chr1:96893000	G/A	cg10631902	chr5:14652156	NA	0.52	8.96	0.51	1.07e-16	Weight;
SARC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.63	-0.4	2.28e-10	Total body bone mineral density;
SARC	cis	rs709400	1.000	rs61995780	chr14:104120612	A/G	cg26031613	chr14:104095156	KLC1	0.98	17.74	0.76	4.02e-45	Body mass index;
SARC	cis	rs9457247	1.000	rs408087	chr6:167398952	C/T	cg23791538	chr6:167370224	RNASET2	-0.57	-7.85	-0.46	1.5e-13	Crohn's disease;
SARC	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg26513180	chr16:89883248	FANCA	0.72	4.79	0.3	2.92e-6	Skin colour saturation;
SARC	cis	rs6964587	1.000	rs7781066	chr7:91691946	G/T	cg17063962	chr7:91808500	NA	0.94	15.98	0.72	2.68e-39	Breast cancer;
SARC	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.0	-17.55	-0.75	1.68e-44	Chronic sinus infection;
SARC	cis	rs7633857	0.512	rs733948	chr3:160652784	C/G	cg04691961	chr3:161091175	C3orf57	-0.48	-5.96	-0.36	9.34e-9	Educational attainment (years of education);
SARC	cis	rs2652834	0.851	rs4238372	chr15:63351488	G/A	cg05507819	chr15:63340323	TPM1	0.62	6.34	0.38	1.19e-9	HDL cholesterol;
SARC	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.42	5.21	0.32	4.07e-7	Electroencephalogram traits;
SARC	trans	rs9329221	0.532	rs2062333	chr8:9981149	A/G	cg06636001	chr8:8085503	FLJ10661	0.49	6.66	0.4	1.96e-10	Neuroticism;
SARC	cis	rs73242632	1.000	rs114513553	chr4:57858458	G/A	cg20415529	chr4:57845134	POLR2B;C4orf14	1.07	6.63	0.4	2.37e-10	Congenital heart disease (maternal effect);
SARC	cis	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg13072238	chr3:49761600	GMPPB	-0.42	-5.54	-0.34	8.33e-8	Intelligence (multi-trait analysis);
SARC	cis	rs13034020	0.522	rs13017457	chr2:61248645	G/A	cg18625361	chr2:61244694	PEX13;PUS10	0.71	6.07	0.37	5.05e-9	Hodgkin's lymphoma;
SARC	cis	rs10411936	0.720	rs2885706	chr19:16582937	C/A	cg10248733	chr19:16607483	C19orf44;CALR3	0.58	7.03	0.42	2.32e-11	White blood cell count;Multiple sclerosis;
SARC	cis	rs1865760	0.516	rs9393684	chr6:26075531	G/C	cg02841227	chr6:26021843	HIST1H4A	0.38	4.73	0.3	3.97e-6	Height;
SARC	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg05313129	chr8:58192883	C8orf71	-0.54	-6.29	-0.38	1.54e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg03929089	chr4:120376271	NA	0.82	10.17	0.55	2.36e-20	Height;
SARC	cis	rs3782089	1.000	rs11600543	chr11:65298939	G/A	cg00206168	chr11:65308501	LTBP3	0.93	5.59	0.34	6.42e-8	Height;
SARC	cis	rs1957429	0.901	rs1957434	chr14:65349909	C/T	cg23373153	chr14:65346875	NA	1.07	11.5	0.6	1.53e-24	Pediatric areal bone mineral density (radius);
SARC	cis	rs11630290	0.806	rs10519220	chr15:64047120	C/T	cg12036633	chr15:63758958	NA	0.49	4.82	0.3	2.63e-6	Iris characteristics;
SARC	cis	rs6964587	1.000	rs56072181	chr7:91690457	A/G	cg17063962	chr7:91808500	NA	0.96	16.21	0.73	4.33e-40	Breast cancer;
SARC	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg11764359	chr7:65958608	NA	-0.76	-9.35	-0.52	7.72e-18	Aortic root size;
SARC	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg09165964	chr15:75287851	SCAMP5	0.49	6.5	0.39	4.73e-10	Breast cancer;
SARC	cis	rs9467773	0.967	rs9467775	chr6:26513435	G/A	cg11502198	chr6:26597334	ABT1	0.47	5.93	0.36	1.1e-8	Intelligence (multi-trait analysis);
SARC	cis	rs67460515	0.500	rs9822435	chr3:160748068	A/T	cg03342759	chr3:160939853	NMD3	-0.54	-6.28	-0.38	1.68e-9	Parkinson's disease;
SARC	cis	rs11249608	0.703	rs7726601	chr5:178444713	A/G	cg21905437	chr5:178450457	ZNF879	-0.51	-6.9	-0.41	4.86e-11	Pubertal anthropometrics;
SARC	cis	rs3213545	0.676	rs1179998	chr12:121483653	G/A	cg02403541	chr12:121454288	C12orf43	0.63	7.89	0.46	1.17e-13	Subjective well-being;Cardiovascular disease risk factors;
SARC	cis	rs7447593	0.518	rs4074995	chr5:176797343	C/T	cg16006841	chr5:176797999	RGS14	0.71	10.08	0.55	4.7e-20	Urinary electrolytes (magnesium/calcium ratio);
SARC	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg21747090	chr2:27597821	SNX17	-0.55	-7.56	-0.44	9.03e-13	Total body bone mineral density;
SARC	cis	rs35306767	0.903	rs11253467	chr10:901244	A/G	cg20503657	chr10:835505	NA	0.88	8.4	0.48	4.51e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs3815700	1.000	rs8108840	chr19:33094452	A/C	cg02997394	chr19:33096574	ANKRD27	0.75	7.75	0.45	2.86e-13	Eosinophilic esophagitis;
SARC	cis	rs7712401	0.601	rs36180885	chr5:122356403	C/A	cg19412675	chr5:122181750	SNX24	-0.47	-6.11	-0.37	4.15e-9	Mean platelet volume;
SARC	cis	rs1018836	0.923	rs11784529	chr8:91640956	C/A	cg16814680	chr8:91681699	NA	-0.82	-13.31	-0.66	1.88e-30	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs826838	1.000	rs10506122	chr12:38699232	A/G	cg13010199	chr12:38710504	ALG10B	0.82	11.82	0.61	1.5e-25	Heart rate;
SARC	cis	rs2153535	0.580	rs6941771	chr6:8494452	T/G	cg23788917	chr6:8435910	SLC35B3	0.64	8.41	0.48	4.24e-15	Motion sickness;
SARC	cis	rs9400467	0.537	rs12212282	chr6:111524838	T/C	cg15721981	chr6:111408429	SLC16A10	0.66	5.63	0.35	5.13e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg05861140	chr6:150128134	PCMT1	-0.4	-5.19	-0.32	4.55e-7	Lung cancer;
SARC	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg11301795	chr4:187892539	NA	-0.7	-10.49	-0.57	2.5e-21	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6503863	1	rs6503863	chr17:56517034	G/A	cg05425664	chr17:57184151	TRIM37	-0.4	-4.82	-0.3	2.54e-6	Intelligence (multi-trait analysis);
SARC	cis	rs854765	0.583	rs4925126	chr17:17798633	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.68	10.1	0.55	3.9e-20	Total body bone mineral density;
SARC	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg18404041	chr3:52824283	ITIH1	-0.41	-6.16	-0.37	3.21e-9	Bipolar disorder;
SARC	cis	rs2952156	0.959	rs1495102	chr17:37832093	T/C	cg00129232	chr17:37814104	STARD3	-0.69	-9.54	-0.53	2.01e-18	Asthma;
SARC	cis	rs6088590	1.000	rs2180276	chr20:33360785	T/A	cg24642439	chr20:33292090	TP53INP2	0.89	12.63	0.64	3.35e-28	Coronary artery disease;
SARC	cis	rs9916302	0.861	rs9903363	chr17:37499604	C/G	cg07936489	chr17:37558343	FBXL20	0.68	9.16	0.51	2.78e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.77	-11.19	-0.59	1.54e-23	Total body bone mineral density;
SARC	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg11764359	chr7:65958608	NA	0.66	7.91	0.46	1.04e-13	Aortic root size;
SARC	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-4.83	-0.3	2.49e-6	Total body bone mineral density;
SARC	cis	rs7264396	0.512	rs2425072	chr20:34293686	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	5.83	0.36	1.8e-8	Total cholesterol levels;
SARC	cis	rs13082711	0.595	rs17317435	chr3:27339326	A/G	cg02860705	chr3:27208620	NA	0.67	8.05	0.47	4.3e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs2070488	0.804	rs13092473	chr3:38458958	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.81	12.47	0.63	1.15e-27	Electrocardiographic conduction measures;
SARC	cis	rs918629	0.567	rs1057964	chr5:95235627	T/C	cg16656078	chr5:95278638	ELL2	-0.51	-6.41	-0.39	8e-10	IgG glycosylation;
SARC	cis	rs6815814	0.861	rs28393318	chr4:38784267	A/G	cg06935464	chr4:38784597	TLR10	0.51	5.66	0.35	4.39e-8	Breast cancer;
SARC	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg11987759	chr7:65425863	GUSB	-0.58	-7.99	-0.46	6.34e-14	Aortic root size;
SARC	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	25.79	0.86	3.31e-70	Chronic sinus infection;
SARC	cis	rs17209837	1.000	rs2302385	chr7:87091826	T/C	cg00919237	chr7:87102261	ABCB4	-0.47	-4.96	-0.31	1.38e-6	Gallbladder cancer;
SARC	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg08280861	chr8:58055591	NA	0.69	5.78	0.35	2.33e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1008375	1.000	rs4698200	chr4:17657051	G/A	cg27347728	chr4:17578864	LAP3	0.48	5.93	0.36	1.07e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs282587	0.569	rs378432	chr13:113398048	A/C	cg02820901	chr13:113351484	ATP11A	-0.5	-4.92	-0.31	1.65e-6	Glycated hemoglobin levels;
SARC	cis	rs35110281	0.720	rs162400	chr21:44950305	A/C	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.13	-0.37	3.66e-9	Mean corpuscular volume;
SARC	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg23172400	chr8:95962367	TP53INP1	-0.32	-5.56	-0.34	7.49e-8	Type 2 diabetes;
SARC	cis	rs5167	0.743	rs57204168	chr19:45496776	A/G	cg09555818	chr19:45449301	APOC2	0.39	5.62	0.35	5.52e-8	Blood protein levels;
SARC	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg23758822	chr17:41437982	NA	0.86	10.56	0.57	1.52e-21	Menopause (age at onset);
SARC	cis	rs6665290	0.901	rs68087483	chr1:227202668	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.08	-24.08	-0.84	3.84e-65	Myeloid white cell count;
SARC	cis	rs931812	0.691	rs884488	chr8:101898523	C/G	cg07585502	chr8:101912084	NA	-0.4	-5.21	-0.32	4.2e-7	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs4713118	0.513	rs202908	chr6:28011551	C/G	cg26335602	chr6:28129616	ZNF389	0.45	5.24	0.32	3.68e-7	Parkinson's disease;
SARC	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.35	-4.88	-0.3	1.93e-6	Personality dimensions;
SARC	cis	rs7829975	0.500	rs7841082	chr8:8168987	C/T	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.07	-0.37	5.25e-9	Mood instability;
SARC	cis	rs2197308	0.565	rs4123923	chr12:37857684	T/C	cg13010199	chr12:38710504	ALG10B	0.81	11.19	0.59	1.53e-23	Morning vs. evening chronotype;
SARC	cis	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg03060546	chr3:49711283	APEH	0.77	11.26	0.59	8.94e-24	Resting heart rate;
SARC	trans	rs9329221	0.905	rs4433149	chr8:10249268	A/T	cg06636001	chr8:8085503	FLJ10661	-0.68	-9.18	-0.52	2.4e-17	Neuroticism;
SARC	cis	rs941873	0.868	rs4980063	chr10:81105844	A/T	cg09469691	chr10:81107165	PPIF	0.6	9.03	0.51	6.8e-17	Height;
SARC	cis	rs10875746	0.951	rs4760689	chr12:48563644	G/A	cg27446233	chr12:48516484	PFKM	-0.41	-4.77	-0.3	3.19e-6	Longevity (90 years and older);
SARC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg26338869	chr17:61819248	STRADA	0.81	10.89	0.58	1.38e-22	Prudent dietary pattern;
SARC	cis	rs861020	0.563	rs61820640	chr1:210041297	G/T	cg05527609	chr1:210001259	C1orf107	-0.75	-7.44	-0.44	1.95e-12	Orofacial clefts;
SARC	cis	rs55882075	0.723	rs56227602	chr5:179179472	A/G	cg14593053	chr5:179126677	CANX	0.5	7.07	0.42	1.76e-11	Monocyte percentage of white cells;
SARC	trans	rs1814175	0.645	rs11040671	chr11:49958776	G/A	cg03929089	chr4:120376271	NA	-0.82	-11.88	-0.61	9.2e-26	Height;
SARC	cis	rs2315504	0.509	rs2240076	chr17:39035615	C/T	cg05063374	chr17:38953512	KRT28	-0.28	-4.74	-0.3	3.73e-6	Height;
SARC	cis	rs7208859	0.673	rs9896095	chr17:29187497	A/G	cg13385521	chr17:29058706	SUZ12P	0.86	7.34	0.43	3.54e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs2710642	0.962	rs7567923	chr2:63085848	C/T	cg17519650	chr2:63277830	OTX1	-0.4	-5.05	-0.31	9.01e-7	LDL cholesterol levels;LDL cholesterol;
SARC	cis	rs910316	1.000	rs2098297	chr14:75619118	G/T	cg23033748	chr14:75592666	NEK9	-0.36	-5.06	-0.31	8.66e-7	Height;
SARC	cis	rs4803468	0.967	rs3745290	chr19:41890003	C/T	cg14132834	chr19:41945861	ATP5SL	-0.56	-7.54	-0.44	1.04e-12	Height;
SARC	cis	rs9300255	0.602	rs4372492	chr12:123697357	T/C	cg00376283	chr12:123451042	ABCB9	0.55	6.53	0.39	4.09e-10	Neutrophil percentage of white cells;
SARC	cis	rs11098499	0.863	rs13140391	chr4:120503437	A/G	cg24375607	chr4:120327624	NA	0.42	4.92	0.31	1.64e-6	Corneal astigmatism;
SARC	cis	rs698833	0.852	rs698761	chr2:44547574	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.66	-8.34	-0.48	6.36e-15	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs1153858	1.000	rs56669689	chr15:45637729	A/C	cg21132104	chr15:45694354	SPATA5L1	0.78	11.03	0.59	4.99e-23	Homoarginine levels;
SARC	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg22496380	chr5:211416	CCDC127	-0.84	-8.6	-0.49	1.19e-15	Breast cancer;
SARC	trans	rs1910358	0.554	rs10057796	chr5:23759746	C/T	cg25944700	chr8:23386623	SLC25A37	0.56	6.53	0.39	4.03e-10	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs9916302	0.861	rs8081033	chr17:37506650	A/G	cg00129232	chr17:37814104	STARD3	0.59	7.31	0.43	4.18e-12	Glomerular filtration rate (creatinine);
SARC	trans	rs7652995	1.000	rs1009640	chr3:186735096	C/T	cg01166399	chr6:119346816	FAM184A	-0.65	-6.4	-0.39	8.24e-10	IgG glycosylation;
SARC	cis	rs3780378	0.967	rs7023146	chr9:5040163	G/A	cg02405213	chr9:5042618	JAK2	-0.44	-5.39	-0.33	1.75e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
SARC	cis	rs920590	0.758	rs2898491	chr8:19661883	C/T	cg17834443	chr8:19674713	INTS10	0.58	7.0	0.42	2.74e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg11494091	chr17:61959527	GH2	0.54	8.07	0.47	3.82e-14	Prudent dietary pattern;
SARC	cis	rs9894429	0.716	rs7405578	chr17:79588306	C/A	cg18240062	chr17:79603768	NPLOC4	0.88	13.51	0.66	4.09e-31	Eye color traits;
SARC	cis	rs698833	0.542	rs13418572	chr2:44705614	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	6.56	0.39	3.49e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg09699651	chr6:150184138	LRP11	0.38	4.73	0.3	3.96e-6	Lung cancer;
SARC	cis	rs4268898	0.636	rs72787385	chr2:24585820	G/A	cg26838691	chr2:24397539	C2orf84	-0.53	-6.17	-0.37	3.02e-9	Asthma;
SARC	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs74544699	1.000	rs11574450	chr4:74847111	A/C	cg02530824	chr4:74847766	PF4	0.77	4.73	0.3	3.91e-6	Growth-regulated protein alpha levels;
SARC	cis	rs17376456	0.825	rs10038831	chr5:93124115	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.73	6.78	0.41	1.01e-10	Diabetic retinopathy;
SARC	cis	rs2882877	0.621	rs2119070	chr2:190372919	C/T	cg21926118	chr2:190387206	NA	0.41	5.16	0.32	5.19e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs7833986	0.501	rs72653948	chr8:56955689	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.73	7.38	0.44	2.71e-12	Height;
SARC	cis	rs897080	0.515	rs1067398	chr2:44678882	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	6.3	0.38	1.48e-9	Height;
SARC	cis	rs3784262	0.669	rs4646579	chr15:58329528	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.34	-5.02	-0.31	1.02e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs57506017	0.540	rs1435525	chr7:12262717	T/C	cg23422036	chr7:12250390	TMEM106B	0.49	6.41	0.39	8.02e-10	Neuroticism;
SARC	cis	rs1345301	1.000	rs1345302	chr2:102873369	A/G	cg12451869	chr2:102867685	NA	0.39	5.5	0.34	1e-7	Waist circumference;
SARC	cis	rs9303280	0.806	rs8069176	chr17:38057197	G/A	cg20243544	chr17:37824526	PNMT	0.41	5.45	0.34	1.27e-7	Self-reported allergy;
SARC	cis	rs9457247	0.602	rs12209395	chr6:167463914	C/T	cg07741184	chr6:167504864	NA	0.36	6.89	0.41	5.23e-11	Crohn's disease;
SARC	trans	rs17685	0.712	rs1859792	chr7:75789264	T/C	cg19862616	chr7:65841803	NCRNA00174	0.6	7.41	0.44	2.25e-12	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.97	11.59	0.6	7.87e-25	Platelet count;
SARC	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-5.43	-0.33	1.44e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs1153858	1.000	rs12437840	chr15:45669055	C/A	cg26924012	chr15:45694286	SPATA5L1	0.79	11.28	0.59	7.91e-24	Homoarginine levels;
SARC	trans	rs56279505	0.629	rs11499823	chr4:100274749	A/G	cg21156590	chr1:3420848	MEGF6	-0.83	-6.41	-0.39	8.04e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs3820928	0.874	rs10174073	chr2:227794944	A/G	cg05526886	chr2:227700861	RHBDD1	-0.54	-6.64	-0.4	2.13e-10	Pulmonary function;
SARC	cis	rs7220401	0.512	rs71371126	chr17:28002642	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.51	-5.63	-0.35	5.04e-8	Coronary artery disease;
SARC	cis	rs11786130	1.000	rs10956401	chr8:129002419	G/A	cg01765152	chr8:129005526	PVT1	-0.48	-8.11	-0.47	2.83e-14	Eosinophil counts;Sum eosinophil basophil counts;
SARC	cis	rs9341808	0.529	rs9352826	chr6:81059371	C/T	cg08355045	chr6:80787529	NA	0.32	4.94	0.31	1.5e-6	Sitting height ratio;
SARC	cis	rs12142240	0.698	rs67276232	chr1:46825484	T/G	cg10495392	chr1:46806563	NSUN4	0.65	6.8	0.41	8.89e-11	Menopause (age at onset);
SARC	cis	rs11098499	0.863	rs10004484	chr4:120442428	C/T	cg09160332	chr4:120329925	NA	-0.35	-4.82	-0.3	2.63e-6	Corneal astigmatism;
SARC	cis	rs736408	0.608	rs2239547	chr3:52855229	T/C	cg18404041	chr3:52824283	ITIH1	-0.47	-5.99	-0.37	7.83e-9	Bipolar disorder;
SARC	cis	rs1018836	0.564	rs7821994	chr8:91700916	C/T	cg16814680	chr8:91681699	NA	-1.02	-21.34	-0.81	9.8e-57	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs8180040	0.932	rs12489046	chr3:47527683	T/G	cg27129171	chr3:47204927	SETD2	0.67	9.29	0.52	1.1e-17	Colorectal cancer;
SARC	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	6.55	0.39	3.75e-10	Calcium levels;
SARC	cis	rs7617773	0.780	rs11720026	chr3:48377921	T/C	cg11946769	chr3:48343235	NME6	0.77	9.66	0.53	8.6e-19	Coronary artery disease;
SARC	trans	rs1973993	0.967	rs6679458	chr1:96946253	G/T	cg10631902	chr5:14652156	NA	0.46	7.89	0.46	1.18e-13	Weight;
SARC	cis	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg05084668	chr3:125655381	ALG1L	-0.49	-5.22	-0.32	4.02e-7	Blood pressure (smoking interaction);
SARC	cis	rs17270561	0.609	rs4712964	chr6:25740822	A/T	cg17691542	chr6:26056736	HIST1H1C	0.61	7.26	0.43	5.59e-12	Iron status biomarkers;
SARC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg21280719	chr6:42927975	GNMT	-0.44	-7.46	-0.44	1.75e-12	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs9400467	0.506	rs12200641	chr6:111622758	C/T	cg15721981	chr6:111408429	SLC16A10	0.69	5.85	0.36	1.67e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs7587476	0.784	rs13032278	chr2:215698034	G/A	cg11970703	chr2:215861251	ABCA12	-0.32	-4.96	-0.31	1.39e-6	Neuroblastoma;
SARC	cis	rs981844	0.712	rs11099915	chr4:154743624	A/G	cg14289246	chr4:154710475	SFRP2	-0.45	-5.2	-0.32	4.33e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs2228479	0.717	rs12917681	chr16:89810941	C/A	cg00800038	chr16:89945340	TCF25	-0.66	-5.1	-0.32	7.1e-7	Skin colour saturation;
SARC	cis	rs7927771	1.000	rs7105282	chr11:47805614	C/A	cg20307385	chr11:47447363	PSMC3	-0.47	-5.59	-0.34	6.3e-8	Subjective well-being;
SARC	cis	rs1953600	0.870	rs2573353	chr10:81940917	A/C	cg00277334	chr10:82204260	NA	-0.37	-5.31	-0.33	2.56e-7	Sarcoidosis;
SARC	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.38	4.94	0.31	1.51e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs1920116	0.778	rs12489230	chr3:169558821	C/T	cg08193579	chr3:169529701	LRRC34	0.39	4.73	0.3	3.81e-6	Glioma (high-grade);
SARC	cis	rs12347191	0.500	rs925485	chr9:100619561	G/C	cg13688889	chr9:100608707	NA	-0.48	-5.07	-0.32	8.16e-7	Orofacial clefts;
SARC	trans	rs17685	0.753	rs4728586	chr7:75802869	T/C	cg19862616	chr7:65841803	NCRNA00174	0.64	8.02	0.47	5e-14	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs41264869	0.628	rs12048453	chr1:205134987	T/C	cg21643547	chr1:205240462	TMCC2	0.49	5.3	0.33	2.67e-7	Blood protein levels;
SARC	cis	rs2412459	0.831	rs6492924	chr15:40272391	G/A	cg16127683	chr15:40268777	EIF2AK4	-0.66	-6.31	-0.38	1.39e-9	Response to haloperidol in psychosis;
SARC	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	16.67	0.74	1.37e-41	Height;
SARC	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-9.15	-0.51	2.85e-17	Alzheimer's disease;
SARC	cis	rs34375054	0.525	rs1080910	chr12:125608492	T/C	cg25124228	chr12:125621409	AACS	-0.63	-7.87	-0.46	1.33e-13	Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs7937682	0.889	rs1784785	chr11:111483306	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.88	-13.97	-0.68	1.3e-32	Primary sclerosing cholangitis;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg24495234	chr15:48483217	CTXN2	-0.47	-6.98	-0.42	3.04e-11	Thyroid stimulating hormone;
SARC	cis	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg25894440	chr7:65020034	NA	-0.74	-5.72	-0.35	3.18e-8	Diabetic kidney disease;
SARC	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg26116260	chr4:7069785	GRPEL1	0.87	10.28	0.56	1.07e-20	Monocyte percentage of white cells;
SARC	cis	rs16976116	0.851	rs28393427	chr15:55490981	A/G	cg17854078	chr15:55489399	RSL24D1	0.66	6.46	0.39	6.14e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2645694	0.626	rs2703122	chr4:77821418	A/C	cg18351406	chr4:77819688	ANKRD56	0.45	6.31	0.38	1.37e-9	Emphysema distribution in smoking;
SARC	cis	rs7666738	0.830	rs1834645	chr4:98979593	T/A	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg13393036	chr8:95962371	TP53INP1	-0.38	-6.4	-0.39	8.54e-10	Type 2 diabetes;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg07236798	chr8:131455818	NA	0.49	6.33	0.38	1.27e-9	Chemerin levels;
SARC	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg00933542	chr6:150070202	PCMT1	0.34	5.95	0.36	9.85e-9	Lung cancer;
SARC	trans	rs491567	0.711	rs17549749	chr15:53960628	G/A	cg03570417	chr12:132312461	MMP17	-0.47	-6.23	-0.38	2.11e-9	Chronic kidney disease;Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);
SARC	cis	rs1538970	0.669	rs3219476	chr1:45802670	A/C	cg05343316	chr1:45956843	TESK2	-0.58	-6.83	-0.41	7.12e-11	Platelet count;
SARC	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg27266027	chr21:40555129	PSMG1	-0.41	-4.8	-0.3	2.87e-6	Menarche (age at onset);
SARC	cis	rs651907	0.557	rs35850993	chr3:101437433	A/G	cg12386194	chr3:101231763	SENP7	0.48	5.72	0.35	3.26e-8	Colorectal cancer;
SARC	cis	rs11676348	0.791	rs6726126	chr2:218952233	G/A	cg00012203	chr2:219082015	ARPC2	-0.51	-6.82	-0.41	7.56e-11	Ulcerative colitis;
SARC	cis	rs9547692	1.000	rs2147168	chr13:37467503	A/C	cg01493522	chr13:37497338	NA	-0.43	-4.75	-0.3	3.57e-6	Coronary artery disease;
SARC	cis	rs734999	0.545	rs7368072	chr1:2556125	C/T	cg20673091	chr1:2541236	MMEL1	0.32	4.86	0.3	2.13e-6	Ulcerative colitis;
SARC	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg21856205	chr7:94953877	PON1	0.36	5.66	0.35	4.47e-8	Paraoxonase activity;
SARC	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg19223190	chr17:80058835	NA	0.43	6.05	0.37	5.62e-9	Life satisfaction;
SARC	cis	rs28374715	0.783	rs11630656	chr15:41570909	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.11	-17.03	-0.74	8.33e-43	Ulcerative colitis;
SARC	trans	rs9354308	1.000	rs9354308	chr6:66565353	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.54	6.36	0.38	1.07e-9	Metabolite levels;
SARC	cis	rs9443189	1.000	rs3822957	chr6:76607280	A/G	cg01950844	chr6:76311363	SENP6	-0.76	-6.47	-0.39	5.79e-10	Prostate cancer;
SARC	cis	rs17125944	0.615	rs2357945	chr14:53318434	A/G	cg00686598	chr14:53173677	PSMC6	-0.63	-4.88	-0.3	2e-6	Alzheimer's disease (late onset);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg07781988	chr4:87927978	AFF1	0.53	6.93	0.41	3.98e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs7635838	0.892	rs9836167	chr3:11493392	C/T	cg00170343	chr3:11313890	ATG7	0.61	8.27	0.48	1.02e-14	HDL cholesterol;
SARC	cis	rs6484504	0.576	rs158144	chr11:31211795	A/C	cg02090638	chr11:31391270	DNAJC24;DCDC1	-0.37	-4.74	-0.3	3.77e-6	Red blood cell count;
SARC	trans	rs7824557	0.767	rs17797443	chr8:11164012	T/C	cg06636001	chr8:8085503	FLJ10661	0.57	6.9	0.41	4.91e-11	Retinal vascular caliber;
SARC	cis	rs7267979	0.706	rs6037069	chr20:25234166	C/T	cg03522245	chr20:25566470	NINL	0.34	4.75	0.3	3.48e-6	Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs4144743	0.528	rs16941802	chr17:45355353	C/G	cg18085866	chr17:45331354	ITGB3	0.78	6.67	0.4	1.83e-10	Body mass index;
SARC	cis	rs1707322	0.964	rs12067716	chr1:46434428	T/A	cg06784218	chr1:46089804	CCDC17	0.36	6.35	0.38	1.12e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg26338869	chr17:61819248	STRADA	0.8	10.72	0.57	4.8e-22	Prudent dietary pattern;
SARC	cis	rs9443189	1.000	rs6903077	chr6:76503045	A/G	cg01950844	chr6:76311363	SENP6	0.65	5.7	0.35	3.65e-8	Prostate cancer;
SARC	cis	rs6669543	0.797	rs4656347	chr1:161996062	T/C	cg10810183	chr1:161993987	OLFML2B	0.47	5.51	0.34	9.47e-8	QT interval;
SARC	trans	rs35833281	1.000	rs3122170	chr6:55058998	C/A	cg19977494	chr7:128431264	CCDC136	0.71	6.57	0.4	3.25e-10	Morning vs. evening chronotype;
SARC	cis	rs35110281	0.712	rs1454648	chr21:45053815	C/T	cg01579765	chr21:45077557	HSF2BP	-0.37	-6.2	-0.38	2.59e-9	Mean corpuscular volume;
SARC	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.46	5.21	0.32	4.2e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs11785693	0.862	rs11774842	chr8:4979769	A/C	cg26367366	chr8:4980734	NA	0.69	6.19	0.38	2.67e-9	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs240764	0.658	rs7740783	chr6:101263516	C/T	cg09795085	chr6:101329169	ASCC3	0.45	5.83	0.36	1.81e-8	Neuroticism;
SARC	cis	rs10489202	0.634	rs11582396	chr1:168077636	C/T	cg24449463	chr1:168025552	DCAF6	-0.57	-7.26	-0.43	5.7e-12	Schizophrenia;
SARC	cis	rs7520050	0.966	rs10749860	chr1:46328210	C/G	cg24296786	chr1:45957014	TESK2	0.39	4.92	0.31	1.63e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs2228479	0.850	rs62054224	chr16:89892071	C/T	cg12064134	chr16:90016061	DEF8	-0.56	-4.79	-0.3	2.91e-6	Skin colour saturation;
SARC	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg04944784	chr2:26401820	FAM59B	0.62	8.05	0.47	4.32e-14	Gut microbiome composition (summer);
SARC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg24503407	chr1:205819492	PM20D1	0.88	14.96	0.7	6.55e-36	Menarche (age at onset);
SARC	cis	rs4253772	0.591	rs6008384	chr22:46655948	T/C	cg24881330	chr22:46731750	TRMU	0.62	6.86	0.41	6.14e-11	LDL cholesterol;Cholesterol, total;
SARC	cis	rs11581859	0.587	rs12726679	chr1:99202634	G/T	cg20286094	chr1:99190917	SNX7	-0.42	-4.89	-0.31	1.86e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs1008375	0.931	rs6837181	chr4:17701253	A/C	cg16339924	chr4:17578868	LAP3	0.54	6.92	0.41	4.22e-11	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	15.14	0.7	1.58e-36	Chronic sinus infection;
SARC	cis	rs854765	0.583	rs5002487	chr17:17832460	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.39	5.13	0.32	6.07e-7	Total body bone mineral density;
SARC	cis	rs113835537	0.529	rs2305532	chr11:66298594	C/T	cg24851651	chr11:66362959	CCS	0.38	4.78	0.3	3.11e-6	Airway imaging phenotypes;
SARC	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-7.85	-0.46	1.56e-13	Alzheimer's disease;
SARC	cis	rs8031584	0.679	rs34017474	chr15:31230611	T/C	cg19680485	chr15:31195859	MTMR15	-0.56	-6.95	-0.41	3.64e-11	Huntington's disease progression;
SARC	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs67311347	1.000	rs56992941	chr3:40472434	A/T	cg24209194	chr3:40518798	ZNF619	0.63	8.24	0.48	1.22e-14	Renal cell carcinoma;
SARC	cis	rs4144743	1.000	rs72823473	chr17:45321775	A/T	cg18085866	chr17:45331354	ITGB3	-0.72	-7.34	-0.43	3.59e-12	Body mass index;
SARC	cis	rs4481887	0.927	rs4381224	chr1:248456826	A/T	cg13385794	chr1:248469461	NA	0.33	5.04	0.31	9.35e-7	Common traits (Other);
SARC	cis	rs1707322	0.752	rs3811436	chr1:46125880	T/C	cg03146154	chr1:46216737	IPP	0.52	6.25	0.38	1.92e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4919087	0.590	rs1253396	chr10:99045230	C/T	cg25902810	chr10:99078978	FRAT1	-0.55	-6.3	-0.38	1.51e-9	Monocyte count;
SARC	cis	rs2012796	0.785	rs61986599	chr14:81860917	G/A	cg02996355	chr14:81879375	NA	0.53	5.86	0.36	1.61e-8	Night sleep phenotypes;
SARC	trans	rs3734266	0.702	rs2296362	chr6:34802999	A/G	cg27444414	chr1:184122874	NA	0.6	6.53	0.39	3.99e-10	Systemic lupus erythematosus;
SARC	cis	rs1003719	0.788	rs4817849	chr21:38469796	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.63	9.05	0.51	5.67e-17	Eye color traits;
SARC	cis	rs2115630	0.967	rs10438428	chr15:85330745	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.46	-5.46	-0.34	1.24e-7	P wave terminal force;
SARC	cis	rs13266463	0.898	rs13267784	chr8:143394915	C/T	cg16886403	chr8:143471632	TSNARE1	0.38	4.72	0.3	4.14e-6	Schizophrenia;
SARC	cis	rs796364	0.806	rs11674293	chr2:201026743	G/A	cg23649088	chr2:200775458	C2orf69	-0.64	-5.65	-0.35	4.56e-8	Schizophrenia;
SARC	cis	rs244731	1.000	rs244731	chr5:176539679	C/T	cg17509989	chr5:176798049	RGS14	0.66	7.74	0.45	2.97e-13	Urate levels in lean individuals;
SARC	cis	rs1943345	0.556	rs555586	chr11:82911879	C/T	cg07047830	chr11:82868014	PCF11	0.46	5.83	0.36	1.81e-8	Obesity-related traits;
SARC	cis	rs7666738	0.791	rs10856933	chr4:98958542	C/A	cg05340658	chr4:99064831	C4orf37	0.66	9.0	0.51	8.07e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs854765	0.520	rs7219324	chr17:17909775	C/T	cg04398451	chr17:18023971	MYO15A	0.48	6.5	0.39	4.94e-10	Total body bone mineral density;
SARC	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg07061783	chr6:25882402	NA	-0.42	-5.12	-0.32	6.28e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7959452	0.535	rs2305641	chr12:69646914	C/T	cg20891283	chr12:69753455	YEATS4	0.37	4.95	0.31	1.41e-6	Blood protein levels;
SARC	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.03	12.03	0.62	3.06e-26	Alzheimer's disease;
SARC	cis	rs847851	0.630	rs9462021	chr6:34758640	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.85	-0.36	1.63e-8	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2070433	0.706	rs2268524	chr21:47838700	C/T	cg12379764	chr21:47803548	PCNT	0.55	4.76	0.3	3.35e-6	Lymphocyte counts;
SARC	cis	rs6429082	0.627	rs2016437	chr1:235539355	T/G	cg26050004	chr1:235667680	B3GALNT2	-0.6	-6.91	-0.41	4.68e-11	Adiposity;
SARC	cis	rs12134245	0.755	rs11164928	chr1:92012678	G/A	cg21854759	chr1:92012499	NA	-0.39	-5.15	-0.32	5.65e-7	Breast cancer;
SARC	cis	rs796364	0.806	rs34381014	chr2:200916403	C/T	cg23649088	chr2:200775458	C2orf69	-0.6	-5.29	-0.33	2.77e-7	Schizophrenia;
SARC	cis	rs698833	0.562	rs13402006	chr2:44726040	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	7.03	0.42	2.31e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs7412746	0.634	rs12096831	chr1:150864113	T/G	cg10589385	chr1:150898437	SETDB1	0.41	5.5	0.34	1e-7	Melanoma;
SARC	trans	rs208520	0.955	rs9345808	chr6:67008262	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	7.66	0.45	5.02e-13	Exhaled nitric oxide output;
SARC	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	7.77	0.45	2.56e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg07701084	chr6:150067640	NUP43	0.4	5.11	0.32	6.81e-7	Lung cancer;
SARC	cis	rs7712401	0.715	rs6859163	chr5:122354920	A/G	cg19412675	chr5:122181750	SNX24	-0.42	-5.3	-0.33	2.65e-7	Mean platelet volume;
SARC	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg23758822	chr17:41437982	NA	-0.88	-11.22	-0.59	1.2e-23	Menopause (age at onset);
SARC	cis	rs2239815	0.515	rs5752810	chr22:29225523	G/A	cg15103426	chr22:29168792	CCDC117	0.62	6.39	0.39	8.8e-10	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
SARC	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg04287289	chr16:89883240	FANCA	0.84	13.6	0.67	2.13e-31	Vitiligo;
SARC	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg22875332	chr1:76189707	ACADM	0.44	5.84	0.36	1.73e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9875589	0.509	rs6783645	chr3:14024542	T/C	cg19554555	chr3:13937349	NA	-0.4	-5.14	-0.32	5.95e-7	Ovarian reserve;
SARC	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg03575189	chr17:44344142	NA	-0.52	-5.07	-0.32	7.99e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	trans	rs561341	1.000	rs546748	chr17:30324293	A/C	cg20587970	chr11:113659929	NA	-1.02	-10.23	-0.56	1.63e-20	Hip circumference adjusted for BMI;
SARC	cis	rs3782089	0.744	rs11545200	chr11:65319751	G/A	cg21890820	chr11:65308645	LTBP3	0.88	5.53	0.34	8.52e-8	Height;
SARC	trans	rs9523762	0.577	rs9516124	chr13:93354797	A/G	cg13458596	chr1:150208665	ANP32E	0.47	6.4	0.39	8.52e-10	Multiple sclerosis;
SARC	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg11168104	chr5:1857477	NA	-0.34	-4.93	-0.31	1.54e-6	Cardiovascular disease risk factors;
SARC	cis	rs1448094	0.967	rs2121892	chr12:86324556	G/T	cg02569458	chr12:86230093	RASSF9	0.4	5.8	0.36	2.17e-8	Major depressive disorder;
SARC	cis	rs7647973	0.626	rs1996664	chr3:49878395	A/G	cg03060546	chr3:49711283	APEH	-0.65	-6.91	-0.41	4.67e-11	Menarche (age at onset);
SARC	cis	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg25427524	chr10:38739819	LOC399744	-0.61	-9.78	-0.54	3.87e-19	Extrinsic epigenetic age acceleration;
SARC	cis	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg02487422	chr3:49467188	NICN1	0.5	6.83	0.41	7.5e-11	Resting heart rate;
SARC	cis	rs2656056	1	rs2656056	chr15:78722519	T/C	cg06917634	chr15:78832804	PSMA4	0.53	5.34	0.33	2.16e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
SARC	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg12463550	chr7:65579703	CRCP	0.5	5.9	0.36	1.27e-8	Aortic root size;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg11158760	chr3:61237270	FHIT	-0.48	-6.58	-0.4	3.01e-10	Schizophrenia;
SARC	cis	rs9467711	0.591	rs34791189	chr6:26035806	G/A	cg21479132	chr6:26055353	NA	1.0	7.34	0.43	3.61e-12	Autism spectrum disorder or schizophrenia;
SARC	cis	rs909674	0.731	rs6001594	chr22:39837472	C/T	cg05872129	chr22:39784769	NA	-0.4	-5.38	-0.33	1.78e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs6545883	0.965	rs1562308	chr2:61768421	A/C	cg15711740	chr2:61764176	XPO1	-0.45	-5.48	-0.34	1.09e-7	Tuberculosis;
SARC	cis	rs7818688	0.697	rs11779698	chr8:95979764	C/G	cg13393036	chr8:95962371	TP53INP1	0.4	4.85	0.3	2.27e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs7595412	1.000	rs75488195	chr2:199046126	C/T	cg00208931	chr2:198669586	PLCL1	0.7	4.77	0.3	3.22e-6	Hip bone size;
SARC	cis	rs4253772	0.744	rs1134224	chr22:46633371	A/T	cg24881330	chr22:46731750	TRMU	0.52	5.9	0.36	1.27e-8	LDL cholesterol;Cholesterol, total;
SARC	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg16606324	chr3:10149918	C3orf24	-0.53	-5.18	-0.32	4.71e-7	Alzheimer's disease;
SARC	cis	rs17600642	0.724	rs72814540	chr10:72452788	G/A	cg19779893	chr10:72451501	ADAMTS14	-0.38	-5.85	-0.36	1.62e-8	Bipolar disorder;
SARC	cis	rs6570726	0.738	rs6917199	chr6:145918320	G/A	cg23711669	chr6:146136114	FBXO30	0.88	14.58	0.69	1.2e-34	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg16405210	chr4:1374714	KIAA1530	-0.42	-4.86	-0.3	2.13e-6	Obesity-related traits;
SARC	cis	rs10876993	0.928	rs1689592	chr12:58057773	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.47	-5.96	-0.36	9.04e-9	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs7412746	0.658	rs2089082	chr1:150800090	T/G	cg13175981	chr1:150552382	MCL1	-0.5	-6.13	-0.37	3.73e-9	Melanoma;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg26101560	chr11:118889209	TRAPPC4;RPS25	-0.83	-6.94	-0.41	3.93e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1707322	0.716	rs28375469	chr1:46195375	T/C	cg06784218	chr1:46089804	CCDC17	0.36	6.29	0.38	1.55e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7000551	0.715	rs1879792	chr8:22314029	C/A	cg12081754	chr8:22256438	SLC39A14	0.61	8.54	0.49	1.8e-15	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs4481887	0.927	rs4390209	chr1:248472613	A/T	cg13385794	chr1:248469461	NA	0.35	5.45	0.34	1.29e-7	Common traits (Other);
SARC	cis	rs4481887	0.927	rs7555310	chr1:248487638	A/G	cg01631408	chr1:248437212	OR2T33	-0.39	-4.89	-0.31	1.84e-6	Common traits (Other);
SARC	trans	rs34421088	0.560	rs2467520	chr8:11398953	T/C	cg06636001	chr8:8085503	FLJ10661	-0.65	-9.0	-0.51	8.05e-17	Neuroticism;
SARC	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10464366	0.560	rs11763728	chr7:39145862	C/T	cg18850127	chr7:39170497	POU6F2	0.4	5.86	0.36	1.58e-8	IgG glycosylation;
SARC	cis	rs2749592	0.918	rs11011388	chr10:38155210	C/T	cg25427524	chr10:38739819	LOC399744	0.46	5.48	0.34	1.12e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs7582180	0.627	rs4149523	chr2:101007039	T/C	cg14675211	chr2:100938903	LONRF2	0.54	7.89	0.46	1.16e-13	Intelligence (multi-trait analysis);
SARC	cis	rs2635047	0.967	rs2668779	chr18:44742066	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.56	7.23	0.43	6.92e-12	Educational attainment;
SARC	cis	rs1707322	0.717	rs1135812	chr1:46095272	T/C	cg06784218	chr1:46089804	CCDC17	0.37	6.39	0.39	8.81e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs36051895	0.695	rs62541534	chr9:5028921	C/G	cg02405213	chr9:5042618	JAK2	-0.52	-5.67	-0.35	4.2e-8	Pediatric autoimmune diseases;
SARC	trans	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg21659725	chr3:3221576	CRBN	-0.81	-12.46	-0.63	1.19e-27	Intelligence (multi-trait analysis);
SARC	cis	rs7408868	1.000	rs7249525	chr19:15277309	G/A	cg14696996	chr19:15285081	NOTCH3	1.01	8.54	0.49	1.78e-15	Pulse pressure;
SARC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.51	-0.39	4.62e-10	Total body bone mineral density;
SARC	cis	rs11025559	0.812	rs10766678	chr11:20507180	A/G	cg04101203	chr11:20408940	PRMT3	-0.49	-5.25	-0.33	3.47e-7	Pursuit maintenance gain;
SARC	trans	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg06437703	chr8:37914619	EIF4EBP1	-0.54	-6.52	-0.39	4.39e-10	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2425143	1.000	rs74785978	chr20:34373234	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-5.89	-0.36	1.33e-8	Blood protein levels;
SARC	cis	rs2115630	0.875	rs8039472	chr15:85361644	A/G	cg17507749	chr15:85114479	UBE2QP1	-0.54	-6.37	-0.39	9.94e-10	P wave terminal force;
SARC	trans	rs877282	0.853	rs7092652	chr10:756109	G/A	cg22713356	chr15:30763199	NA	0.99	9.88	0.54	1.92e-19	Uric acid levels;
SARC	cis	rs6570726	0.846	rs446031	chr6:145885592	C/T	cg05347473	chr6:146136440	FBXO30	0.51	7.03	0.42	2.22e-11	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15884202	chr7:158649092	WDR60	-0.52	-6.44	-0.39	6.85e-10	Smoking initiation;
SARC	cis	rs72781680	0.898	rs72796152	chr2:23933626	G/A	cg08917208	chr2:24149416	ATAD2B	0.83	7.61	0.45	6.76e-13	Lymphocyte counts;
SARC	cis	rs881375	0.678	rs10739581	chr9:123696871	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	6.65	0.4	2.01e-10	Rheumatoid arthritis;
SARC	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.51e-10	Life satisfaction;
SARC	cis	rs2668423	0.501	rs502121	chr19:1387299	T/C	cg02639931	chr19:1387894	NDUFS7	-0.47	-8.23	-0.47	1.34e-14	Nonalcoholic fatty liver disease;
SARC	cis	rs796364	0.806	rs10931890	chr2:201102055	C/T	cg23649088	chr2:200775458	C2orf69	-0.67	-5.89	-0.36	1.36e-8	Schizophrenia;
SARC	cis	rs28655083	0.956	rs4088757	chr16:77071545	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	0.36	5.08	0.32	7.92e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9788682	0.747	rs28480606	chr15:78762313	A/G	cg06917634	chr15:78832804	PSMA4	-0.53	-5.5	-0.34	1.02e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs4319547	0.774	rs7295105	chr12:123124225	G/A	cg23029597	chr12:123009494	RSRC2	-0.45	-5.86	-0.36	1.53e-8	Body mass index;
SARC	cis	rs8028182	0.636	rs8036758	chr15:75817562	G/A	cg20655648	chr15:75932815	IMP3	0.64	7.38	0.44	2.83e-12	Sudden cardiac arrest;
SARC	cis	rs11734570	0.548	rs11943642	chr4:38572266	A/G	cg18361445	chr4:38666374	KLF3;FLJ13197	-0.41	-5.3	-0.33	2.63e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg05036130	chr6:150231994	NA	0.29	5.08	0.32	7.92e-7	Testicular germ cell tumor;
SARC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg21747090	chr2:27597821	SNX17	-0.55	-7.68	-0.45	4.44e-13	Total body bone mineral density;
SARC	cis	rs2997447	0.748	rs2783640	chr1:26430447	T/C	cg19633962	chr1:26362018	EXTL1	-0.6	-5.23	-0.32	3.73e-7	QRS complex (12-leadsum);
SARC	cis	rs826838	0.967	rs1684415	chr12:39130099	T/C	cg26384229	chr12:38710491	ALG10B	-0.76	-11.59	-0.6	7.97e-25	Heart rate;
SARC	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg11965913	chr1:205819406	PM20D1	0.5	6.45	0.39	6.22e-10	Menarche (age at onset);
SARC	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.94	10.04	0.55	5.91e-20	Platelet count;
SARC	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg24633833	chr3:10029261	TMEM111	0.52	5.25	0.33	3.43e-7	Alzheimer's disease;
SARC	cis	rs2137920	0.680	rs2255253	chr10:50219565	C/G	cg09419352	chr10:50604330	NA	0.42	4.82	0.3	2.61e-6	Migraine with aura;
SARC	cis	rs6840360	0.593	rs1429558	chr4:152685406	A/T	cg22705602	chr4:152727874	NA	-0.48	-8.52	-0.49	2.01e-15	Intelligence (multi-trait analysis);
SARC	cis	rs4481887	0.893	rs7515080	chr1:248494073	A/G	cg13385794	chr1:248469461	NA	0.36	5.35	0.33	2.06e-7	Common traits (Other);
SARC	cis	rs11785400	0.793	rs13248524	chr8:143739343	T/C	cg24634471	chr8:143751801	JRK	0.59	7.45	0.44	1.83e-12	Schizophrenia;
SARC	cis	rs10911251	0.528	rs2147584	chr1:183074764	T/C	cg13390022	chr1:182993471	LAMC1	0.32	4.78	0.3	3.07e-6	Colorectal cancer;
SARC	cis	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg13647721	chr17:30228624	UTP6	0.67	5.96	0.36	9.32e-9	Hip circumference adjusted for BMI;
SARC	cis	rs2916247	0.909	rs11785983	chr8:93049466	A/T	cg10183463	chr8:93005414	RUNX1T1	-0.58	-6.03	-0.37	6.49e-9	Intelligence (multi-trait analysis);
SARC	cis	rs62012628	0.527	rs12438008	chr15:79084680	C/T	cg22753661	chr15:79092743	ADAMTS7	-0.41	-4.94	-0.31	1.48e-6	Diastolic blood pressure;
SARC	cis	rs7246657	0.943	rs10420754	chr19:37959372	C/G	cg23950597	chr19:37808831	NA	-0.56	-5.66	-0.35	4.38e-8	Coronary artery calcification;
SARC	cis	rs6696846	0.715	rs61822659	chr1:205142847	G/A	cg21545522	chr1:205238299	TMCC2	0.35	4.74	0.3	3.73e-6	Red blood cell count;
SARC	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg05793240	chr7:2802953	GNA12	-0.36	-5.21	-0.32	4.17e-7	Height;
SARC	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg10560079	chr2:191398806	TMEM194B	0.63	9.03	0.51	6.6e-17	Pulse pressure;
SARC	trans	rs561341	1.000	rs68140514	chr17:30335781	T/C	cg20587970	chr11:113659929	NA	-1.19	-12.14	-0.62	1.36e-26	Hip circumference adjusted for BMI;
SARC	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg00800038	chr16:89945340	TCF25	-0.79	-5.45	-0.34	1.26e-7	Skin colour saturation;
SARC	cis	rs9868809	0.505	rs35064573	chr3:48740280	C/A	cg03060546	chr3:49711283	APEH	-0.51	-4.75	-0.3	3.52e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs8114671	0.562	rs6087641	chr20:33467717	T/C	cg07148914	chr20:33460835	GGT7	0.43	5.34	0.33	2.16e-7	Height;
SARC	cis	rs9733	0.744	rs3754211	chr1:150951857	G/A	cg13175981	chr1:150552382	MCL1	-0.55	-7.29	-0.43	4.85e-12	Tonsillectomy;
SARC	cis	rs9625935	0.518	rs9625870	chr22:30261219	C/T	cg01021169	chr22:30184971	ASCC2	-0.39	-5.17	-0.32	5.09e-7	Tonsillectomy;
SARC	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.95	14.46	0.69	3.03e-34	Chronic sinus infection;
SARC	cis	rs77372450	0.551	rs6874196	chr5:157045634	C/G	cg05585991	chr5:157099197	C5orf52	0.54	5.38	0.33	1.85e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs911186	0.947	rs9379962	chr6:27145311	C/T	cg12826209	chr6:26865740	GUSBL1	0.7	6.74	0.4	1.21e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs79149102	0.579	rs6495146	chr15:75367630	A/T	cg09165964	chr15:75287851	SCAMP5	-0.87	-8.18	-0.47	1.86e-14	Lung cancer;
SARC	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg03806693	chr22:41940476	POLR3H	-0.86	-11.92	-0.62	7.02e-26	Vitiligo;
SARC	cis	rs67460515	0.892	rs16832082	chr3:161043571	A/G	cg17135325	chr3:160939158	NMD3	0.63	7.96	0.46	7.58e-14	Parkinson's disease;
SARC	cis	rs4803455	0.565	rs1025497	chr19:41871254	A/G	cg09537434	chr19:41945824	ATP5SL	-0.66	-9.07	-0.51	5.06e-17	Migraine;Coronary artery disease;
SARC	cis	rs1953600	0.870	rs2573370	chr10:81951366	C/T	cg00277334	chr10:82204260	NA	0.36	5.29	0.33	2.85e-7	Sarcoidosis;
SARC	cis	rs12586317	0.547	rs10145723	chr14:35460954	G/A	cg26967526	chr14:35346199	BAZ1A	-0.57	-5.71	-0.35	3.4e-8	Psoriasis;
SARC	cis	rs916888	0.610	rs199438	chr17:44791643	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.54	6.3	0.38	1.45e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	trans	rs7980799	0.716	rs10161311	chr12:33623204	G/A	cg26384229	chr12:38710491	ALG10B	-0.63	-7.84	-0.46	1.59e-13	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs6831352	0.918	rs2213035	chr4:100064233	G/A	cg13256891	chr4:100009986	ADH5	-0.66	-8.03	-0.47	4.84e-14	Alcohol dependence;
SARC	cis	rs7617773	0.780	rs4541431	chr3:48365218	G/C	cg11946769	chr3:48343235	NME6	0.77	9.81	0.54	2.97e-19	Coronary artery disease;
SARC	cis	rs2055729	0.507	rs814424	chr8:9942924	C/T	cg12345456	chr8:9911630	MSRA	0.6	5.83	0.36	1.88e-8	Multiple myeloma (hyperdiploidy);
SARC	cis	rs995000	0.965	rs1179765	chr1:63010110	G/C	cg06896770	chr1:63153194	DOCK7	-0.89	-13.16	-0.65	6e-30	Triglyceride levels;
SARC	cis	rs13256369	0.756	rs13280759	chr8:8562995	G/T	cg17143192	chr8:8559678	CLDN23	0.51	5.67	0.35	4.18e-8	Obesity-related traits;
SARC	cis	rs12579753	0.956	rs34747993	chr12:82217777	C/T	cg07988820	chr12:82153109	PPFIA2	-0.54	-6.04	-0.37	6.17e-9	Resting heart rate;
SARC	cis	rs2882877	0.648	rs35000023	chr2:190375710	G/T	cg21926118	chr2:190387206	NA	-0.42	-5.25	-0.33	3.46e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg07701084	chr6:150067640	NUP43	0.42	5.51	0.34	9.26e-8	Lung cancer;
SARC	cis	rs3857067	0.806	rs7654919	chr4:95136164	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.15	-0.32	5.47e-7	QT interval;
SARC	cis	rs67311347	0.911	rs6773917	chr3:40469254	G/T	cg09455208	chr3:40491958	NA	0.42	6.69	0.4	1.63e-10	Renal cell carcinoma;
SARC	cis	rs644799	0.965	rs10831425	chr11:95500628	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.68	9.43	0.53	4.19e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2011503	1.000	rs2965181	chr19:19512317	C/T	cg15839431	chr19:19639596	YJEFN3	-0.5	-4.9	-0.31	1.78e-6	Bipolar disorder;
SARC	trans	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg00938859	chr5:1591904	SDHAP3	0.74	7.18	0.43	9.17e-12	Breast cancer;
SARC	cis	rs9399137	0.507	rs11759062	chr6:135381248	A/C	cg24558204	chr6:135376177	HBS1L	0.64	8.17	0.47	1.9e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs9300255	0.602	rs2851435	chr12:123712416	G/A	cg00376283	chr12:123451042	ABCB9	0.54	5.2	0.32	4.4e-7	Neutrophil percentage of white cells;
SARC	cis	rs9556958	0.708	rs4772092	chr13:99166614	A/G	cg07423050	chr13:99094983	FARP1	-0.3	-4.74	-0.3	3.73e-6	Educational attainment (years of education);
SARC	cis	rs9325144	0.600	rs12297194	chr12:38735803	A/G	cg26384229	chr12:38710491	ALG10B	-0.59	-7.69	-0.45	3.99e-13	Morning vs. evening chronotype;
SARC	cis	rs12912251	1.000	rs12901215	chr15:38992893	G/A	cg01338139	chr15:38987640	C15orf53	-0.45	-5.14	-0.32	5.84e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
SARC	cis	rs72781680	0.898	rs17762651	chr2:24115922	A/G	cg08917208	chr2:24149416	ATAD2B	0.79	7.51	0.44	1.25e-12	Lymphocyte counts;
SARC	cis	rs8084125	0.832	rs62105175	chr18:74948498	T/C	cg07390210	chr18:74961196	GALR1	0.56	6.38	0.39	9.37e-10	Obesity-related traits;
SARC	cis	rs926938	0.584	rs1299780	chr1:115366014	G/A	cg12756093	chr1:115239321	AMPD1	0.38	4.98	0.31	1.21e-6	Autism;
SARC	cis	rs7818688	0.697	rs78777150	chr8:95984411	C/G	cg13393036	chr8:95962371	TP53INP1	0.4	4.84	0.3	2.34e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	trans	rs877282	1.000	rs34257857	chr10:772993	C/A	cg22713356	chr15:30763199	NA	1.04	10.32	0.56	8.5e-21	Uric acid levels;
SARC	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg10110953	chr20:30865763	KIF3B	-0.49	-6.27	-0.38	1.74e-9	Parental extreme longevity (95 years and older);
SARC	cis	rs7582180	0.629	rs11686799	chr2:100956055	C/G	cg14675211	chr2:100938903	LONRF2	0.51	7.5	0.44	1.37e-12	Intelligence (multi-trait analysis);
SARC	cis	rs11608355	1.000	rs3742020	chr12:109883254	T/C	cg05360138	chr12:110035743	NA	0.43	4.9	0.31	1.84e-6	Neuroticism;
SARC	cis	rs965469	0.947	rs1854834	chr20:3376619	C/T	cg25506879	chr20:3388711	C20orf194	-0.52	-5.36	-0.33	1.96e-7	IFN-related cytopenia;
SARC	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg16479474	chr6:28041457	NA	0.36	5.45	0.34	1.25e-7	Parkinson's disease;
SARC	cis	rs2997447	0.846	rs12069719	chr1:26411918	A/G	cg19633962	chr1:26362018	EXTL1	-0.65	-6.28	-0.38	1.64e-9	QRS complex (12-leadsum);
SARC	cis	rs1448094	0.512	rs4540904	chr12:86235472	A/G	cg02569458	chr12:86230093	RASSF9	0.4	5.6	0.34	5.98e-8	Major depressive disorder;
SARC	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg20965017	chr5:231967	SDHA	-0.55	-5.26	-0.33	3.23e-7	Breast cancer;
SARC	cis	rs9715521	0.677	rs11944208	chr4:59860652	G/A	cg11281224	chr4:60001000	NA	-0.48	-5.97	-0.36	8.74e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs10489525	0.599	rs17033129	chr1:115611539	C/T	cg01522456	chr1:115632236	TSPAN2	0.43	4.92	0.31	1.6e-6	Autism;
SARC	cis	rs11122272	0.766	rs2486732	chr1:231531476	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-9.98	-0.55	9.08e-20	Hemoglobin concentration;
SARC	cis	rs2439831	0.681	rs478104	chr15:43594900	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.07	12.32	0.63	3.43e-27	Lung cancer in ever smokers;
SARC	cis	rs66573146	0.572	rs66611116	chr4:6953270	A/G	cg26116260	chr4:7069785	GRPEL1	-0.68	-5.02	-0.31	1.04e-6	Granulocyte percentage of myeloid white cells;
SARC	cis	rs10461617	0.541	rs7715822	chr5:56043600	G/T	cg22800045	chr5:56110881	MAP3K1	0.69	6.41	0.39	8.13e-10	Type 2 diabetes;
SARC	cis	rs72717009	0.778	rs9427400	chr1:161477204	C/T	cg23840854	chr1:161414152	NA	-0.54	-5.07	-0.32	8.2e-7	Rheumatoid arthritis;
SARC	cis	rs7589342	0.628	rs11886675	chr2:106409118	G/T	cg16077055	chr2:106428750	NCK2	0.32	5.51	0.34	9.69e-8	Addiction;
SARC	cis	rs10056811	0.538	rs4703645	chr5:74361140	A/G	cg06933384	chr5:74808293	COL4A3BP;POLK	0.48	4.99	0.31	1.2e-6	Coronary artery disease;
SARC	cis	rs2235544	0.565	rs633697	chr1:54468760	A/G	cg10336722	chr1:54665764	CYB5RL;MRPL37	-0.38	-4.74	-0.3	3.66e-6	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
SARC	cis	rs6121246	0.529	rs6060142	chr20:30178028	A/G	cg21427119	chr20:30132790	HM13	-0.44	-4.87	-0.3	2.08e-6	Mean corpuscular hemoglobin;
SARC	cis	rs854765	0.505	rs2955358	chr17:17946623	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.66	-9.79	-0.54	3.5e-19	Total body bone mineral density;
SARC	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg26119090	chr2:26468346	HADHA;HADHB	0.97	14.18	0.68	2.59e-33	Gut microbiome composition (summer);
SARC	cis	rs6426558	0.502	rs2813965	chr1:227445733	A/G	cg10327440	chr1:227177885	CDC42BPA	0.45	5.3	0.33	2.72e-7	Neutrophil percentage of white cells;
SARC	cis	rs2227631	0.505	rs4729662	chr7:100765559	C/T	cg18465962	chr7:100767262	NA	0.58	7.19	0.43	8.92e-12	Plasminogen activator inhibitor type 1 levels (PAI-1);
SARC	cis	rs12044355	0.927	rs12040182	chr1:231839165	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.51	6.71	0.4	1.47e-10	Alzheimer's disease;
SARC	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg17971929	chr21:40555470	PSMG1	0.98	13.42	0.66	8.46e-31	Cognitive function;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg13150344	chr11:67889062	CHKA	0.52	6.92	0.41	4.42e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg24549020	chr5:56110836	MAP3K1	-0.49	-5.38	-0.33	1.77e-7	Initial pursuit acceleration;
SARC	cis	rs7385804	0.761	rs507392	chr7:100319936	G/A	cg20848291	chr7:100343083	ZAN	0.41	5.04	0.31	9.28e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
SARC	cis	rs7666738	0.546	rs1813970	chr4:98887167	A/G	cg05340658	chr4:99064831	C4orf37	-0.57	-6.87	-0.41	5.94e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs17376456	0.542	rs2043979	chr5:93120782	T/A	cg25358565	chr5:93447407	FAM172A	-0.81	-8.91	-0.5	1.48e-16	Diabetic retinopathy;
SARC	cis	rs6446731	0.593	rs2858083	chr4:3272331	T/A	cg06533319	chr4:3265114	C4orf44	-0.32	-5.22	-0.32	3.99e-7	Mean platelet volume;
SARC	cis	rs995000	0.931	rs630144	chr1:62918864	A/G	cg06896770	chr1:63153194	DOCK7	0.9	13.85	0.67	3.23e-32	Triglyceride levels;
SARC	cis	rs9291683	0.588	rs17246745	chr4:9994583	T/C	cg00071950	chr4:10020882	SLC2A9	0.4	6.33	0.38	1.25e-9	Bone mineral density;
SARC	cis	rs62064224	0.560	rs12162135	chr17:30805795	A/C	cg25809561	chr17:30822961	MYO1D	0.42	6.16	0.37	3.09e-9	Schizophrenia;
SARC	cis	rs9549260	0.564	rs6563844	chr13:41298190	T/C	cg21288729	chr13:41239152	FOXO1	0.45	5.21	0.32	4.1e-7	Red blood cell count;
SARC	cis	rs1483890	0.723	rs12629224	chr3:69411188	T/C	cg22125112	chr3:69402811	FRMD4B	0.29	4.81	0.3	2.77e-6	Resting heart rate;
SARC	cis	rs208520	0.507	rs7755710	chr6:66783355	G/A	cg07460842	chr6:66804631	NA	-1.12	-22.84	-0.83	2.24e-61	Exhaled nitric oxide output;
SARC	cis	rs28374715	0.662	rs72737786	chr15:41500361	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.98	-13.66	-0.67	1.34e-31	Ulcerative colitis;
SARC	cis	rs2712184	0.655	rs1003622	chr2:217653608	A/G	cg05032264	chr2:217675019	NA	-0.52	-6.75	-0.4	1.19e-10	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
SARC	cis	rs6696846	0.765	rs61822619	chr1:205090885	C/G	cg21643547	chr1:205240462	TMCC2	-0.59	-7.94	-0.46	8.31e-14	Red blood cell count;
SARC	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg11764359	chr7:65958608	NA	0.86	12.33	0.63	3.29e-27	Aortic root size;
SARC	cis	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg20362242	chr5:692897	TPPP	0.53	4.73	0.3	3.87e-6	Obesity-related traits;
SARC	cis	rs7149337	0.869	rs10137445	chr14:51694416	G/A	cg23942311	chr14:51606299	NA	0.33	5.88	0.36	1.39e-8	Cancer;
SARC	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg20607798	chr8:58055168	NA	0.66	5.7	0.35	3.62e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	5.42	0.33	1.47e-7	Bipolar disorder;
SARC	cis	rs7666738	0.830	rs6843777	chr4:98866635	T/A	cg05340658	chr4:99064831	C4orf37	0.65	8.59	0.49	1.24e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2239547	0.563	rs4687560	chr3:52898121	T/G	cg18404041	chr3:52824283	ITIH1	-0.42	-5.04	-0.31	9.56e-7	Schizophrenia;
SARC	cis	rs854765	0.522	rs63721860	chr17:17829576	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.41	5.28	0.33	3e-7	Total body bone mineral density;
SARC	cis	rs16854884	0.582	rs34402874	chr3:143643249	T/A	cg06585982	chr3:143692056	C3orf58	0.67	8.65	0.49	8.32e-16	Economic and political preferences (feminism/equality);
SARC	trans	rs7922314	0.571	rs61282002	chr10:64738038	C/T	cg25304107	chr2:177017331	HOXD4	-0.78	-6.29	-0.38	1.52e-9	Cutaneous psoriasis;
SARC	cis	rs1865760	0.865	rs9467650	chr6:25958235	A/G	cg17691542	chr6:26056736	HIST1H1C	0.59	7.43	0.44	2.07e-12	Height;
SARC	cis	rs5167	0.781	rs2075619	chr19:45495682	A/G	cg13119609	chr19:45449297	APOC2	0.39	5.99	0.37	7.88e-9	Blood protein levels;
SARC	cis	rs34172651	0.917	rs2059134	chr16:24816492	C/T	cg06028605	chr16:24865363	SLC5A11	-0.28	-4.88	-0.3	1.94e-6	Intelligence (multi-trait analysis);
SARC	cis	rs708547	0.874	rs1401190	chr4:57885174	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.68	8.04	0.47	4.51e-14	Response to bleomycin (chromatid breaks);
SARC	cis	rs17600642	1.000	rs17600642	chr10:72462994	G/T	cg19779893	chr10:72451501	ADAMTS14	-0.41	-6.33	-0.38	1.23e-9	Bipolar disorder;
SARC	cis	rs3092073	0.624	rs34293711	chr20:44587186	C/T	cg27529037	chr20:44575021	PCIF1	0.36	5.76	0.35	2.66e-8	Intelligence (multi-trait analysis);
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg25590640	chr22:38005350	GGA1	-0.73	-7.88	-0.46	1.27e-13	Lung cancer in ever smokers;
SARC	cis	rs1018836	0.892	rs11776824	chr8:91553256	T/C	cg16814680	chr8:91681699	NA	-0.72	-11.28	-0.59	8.03e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs12681366	0.659	rs2470735	chr8:95415898	C/T	cg26464482	chr8:95565502	KIAA1429	-0.44	-5.5	-0.34	1.01e-7	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs60871478	1.000	rs62432253	chr7:802928	A/G	cg09839136	chr7:766187	HEATR2;PRKAR1B	0.56	4.79	0.3	3.02e-6	Cerebrospinal P-tau181p levels;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg02122052	chr13:46550203	ZC3H13	-0.51	-6.31	-0.38	1.41e-9	Alcohol dependence;
SARC	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs72945132	0.882	rs72949076	chr11:70217695	T/C	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.74	-0.35	2.91e-8	Coronary artery disease;
SARC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg24846343	chr22:24311635	DDTL	0.47	6.24	0.38	2.02e-9	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs8114671	0.562	rs6088621	chr20:33418740	C/T	cg24642439	chr20:33292090	TP53INP2	0.56	6.81	0.41	8.02e-11	Height;
SARC	cis	rs6088590	0.931	rs6088624	chr20:33436852	T/A	cg06115741	chr20:33292138	TP53INP2	0.57	6.72	0.4	1.38e-10	Coronary artery disease;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg24414182	chr19:54370948	MYADM	-0.5	-6.43	-0.39	7.12e-10	Gallstone disease;
SARC	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg11890956	chr21:40555474	PSMG1	1.16	19.69	0.79	1.79e-51	Cognitive function;
SARC	cis	rs752010	1.000	rs752010	chr1:42093015	C/T	cg06885757	chr1:42089581	HIVEP3	0.34	5.39	0.33	1.7e-7	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs9513627	0.920	rs73556201	chr13:100128753	C/G	cg25919922	chr13:100150906	NA	-0.64	-4.81	-0.3	2.66e-6	Obesity-related traits;
SARC	cis	rs76419734	0.510	rs7659526	chr4:106621643	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	9.36	0.52	7e-18	Post bronchodilator FEV1;
SARC	cis	rs7560272	0.538	rs12052539	chr2:73937153	C/T	cg20560298	chr2:73613845	ALMS1	-0.41	-5.41	-0.33	1.53e-7	Schizophrenia;
SARC	cis	rs2073499	0.935	rs3755832	chr3:50305234	G/A	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.59	5.35	0.33	2.09e-7	Schizophrenia;
SARC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg06896619	chr17:61851486	DDX42;CCDC47	-0.42	-4.89	-0.31	1.84e-6	Prudent dietary pattern;
SARC	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg18252515	chr7:66147081	NA	-1.33	-11.84	-0.61	1.22e-25	Diabetic kidney disease;
SARC	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg11987759	chr7:65425863	GUSB	-0.51	-6.09	-0.37	4.69e-9	Aortic root size;
SARC	cis	rs440932	1.000	rs365309	chr8:9026940	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.42	-0.39	7.4e-10	High light scatter reticulocyte percentage of red cells;
SARC	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg18357526	chr6:26021779	HIST1H4A	-0.43	-5.44	-0.34	1.34e-7	Blood metabolite levels;
SARC	cis	rs9790314	0.704	rs4618258	chr3:160869129	G/C	cg17135325	chr3:160939158	NMD3	0.4	4.75	0.3	3.5e-6	Morning vs. evening chronotype;
SARC	cis	rs9916302	0.904	rs2338797	chr17:37548241	G/A	cg20243544	chr17:37824526	PNMT	-0.55	-6.61	-0.4	2.63e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs8017423	0.967	rs2277514	chr14:90723059	T/C	cg20276874	chr14:90721474	PSMC1	-0.39	-5.49	-0.34	1.06e-7	Mortality in heart failure;
SARC	cis	rs6831352	0.879	rs1984362	chr4:100070973	G/A	cg13256891	chr4:100009986	ADH5	-0.64	-7.74	-0.45	2.95e-13	Alcohol dependence;
SARC	cis	rs7666738	0.830	rs6832209	chr4:98994120	A/G	cg05340658	chr4:99064831	C4orf37	0.64	8.6	0.49	1.18e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4664308	1.000	rs2175416	chr2:160904021	G/A	cg03641300	chr2:160917029	PLA2R1	-0.67	-8.98	-0.51	9.07e-17	Idiopathic membranous nephropathy;
SARC	cis	rs7635838	0.819	rs7637414	chr3:11522228	C/G	cg00170343	chr3:11313890	ATG7	0.62	8.75	0.5	4.31e-16	HDL cholesterol;
SARC	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg03806693	chr22:41940476	POLR3H	0.84	11.81	0.61	1.54e-25	Vitiligo;
SARC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg26338869	chr17:61819248	STRADA	0.81	10.8	0.58	2.65e-22	Prudent dietary pattern;
SARC	cis	rs3857067	0.806	rs4693002	chr4:95115302	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.32	-4.83	-0.3	2.43e-6	QT interval;
SARC	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg11890956	chr21:40555474	PSMG1	-1.06	-15.66	-0.72	3.13e-38	Cognitive function;
SARC	cis	rs9916302	0.706	rs9890198	chr17:37457480	A/C	cg00129232	chr17:37814104	STARD3	0.52	5.48	0.34	1.09e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg09373136	chr17:61933544	TCAM1	-0.45	-6.13	-0.37	3.79e-9	Prudent dietary pattern;
SARC	trans	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg17830980	chr10:43048298	ZNF37B	-0.51	-6.71	-0.4	1.5e-10	Extrinsic epigenetic age acceleration;
SARC	cis	rs6429082	0.905	rs12405889	chr1:235597252	A/C	cg26050004	chr1:235667680	B3GALNT2	-0.45	-5.96	-0.36	9.46e-9	Adiposity;
SARC	cis	rs7020830	0.505	rs12553878	chr9:37095705	C/T	cg14294708	chr9:37120828	ZCCHC7	0.86	12.11	0.62	1.71e-26	Schizophrenia;
SARC	cis	rs858239	0.539	rs7791200	chr7:23182121	A/T	cg23682824	chr7:23144976	KLHL7	0.72	9.36	0.52	7.22e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs2985684	0.948	rs2883437	chr14:50031666	A/G	cg04989706	chr14:50066350	PPIL5	-0.53	-5.84	-0.36	1.76e-8	Carotid intima media thickness;
SARC	cis	rs6088590	1.000	rs6120708	chr20:33335526	G/A	cg08999081	chr20:33150536	PIGU	0.34	4.92	0.31	1.63e-6	Coronary artery disease;
SARC	cis	rs1348850	0.632	rs13008857	chr2:178514468	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.48	5.57	0.34	6.88e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1023500	0.573	rs133382	chr22:42471774	C/T	cg15557168	chr22:42548783	NA	-0.35	-4.82	-0.3	2.56e-6	Schizophrenia;
SARC	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-9.17	-0.52	2.53e-17	Alzheimer's disease;
SARC	cis	rs7264396	0.635	rs6058375	chr20:34531997	T/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.49	4.81	0.3	2.7e-6	Total cholesterol levels;
SARC	cis	rs8005677	1.000	rs11157930	chr14:23403171	T/G	cg01529538	chr14:23388837	RBM23	0.43	5.2	0.32	4.41e-7	Cognitive ability (multi-trait analysis);
SARC	cis	rs1322639	0.574	rs9689193	chr6:169588074	A/G	cg03254818	chr6:169586852	NA	0.7	7.06	0.42	1.92e-11	Pulse pressure;
SARC	cis	rs9911578	0.874	rs302874	chr17:56767996	A/G	cg12560992	chr17:57184187	TRIM37	0.85	11.66	0.61	4.61e-25	Intelligence (multi-trait analysis);
SARC	cis	rs7552404	0.961	rs1767458	chr1:76219155	A/G	cg10523679	chr1:76189770	ACADM	0.44	5.92	0.36	1.16e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2153535	0.505	rs9405395	chr6:8468622	T/A	cg23788917	chr6:8435910	SLC35B3	0.61	7.97	0.46	7e-14	Motion sickness;
SARC	cis	rs12458462	0.665	rs2035085	chr18:77485280	C/T	cg23301140	chr18:77439876	CTDP1	0.65	8.29	0.48	9.04e-15	Monocyte count;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg25742201	chr17:35306863	AATF	-0.57	-6.38	-0.39	9.23e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs7223966	1.000	rs9891018	chr17:61827856	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	6.98	0.42	3.04e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2718058	0.613	rs2718037	chr7:37777846	G/C	cg24998770	chr7:37888106	TXNDC3	0.3	4.72	0.3	4.01e-6	Alzheimer's disease (late onset);
SARC	trans	rs10085978	0.583	rs10100233	chr8:143235054	G/C	cg12891252	chr10:43902500	HNRNPF	0.53	6.44	0.39	6.65e-10	Mosquito bite size;
SARC	cis	rs7336332	0.598	rs45622135	chr13:28011594	T/C	cg01674679	chr13:27998804	GTF3A	-0.53	-4.93	-0.31	1.54e-6	Weight;
SARC	cis	rs3096299	0.606	rs8052103	chr16:89541243	A/T	cg03648679	chr16:89555682	ANKRD11	-0.42	-4.84	-0.3	2.37e-6	Multiple myeloma (IgH translocation);
SARC	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.39	-4.77	-0.3	3.23e-6	Lymphocyte counts;
SARC	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.19	-0.56	2.08e-20	Chronic sinus infection;
SARC	cis	rs6570726	0.935	rs429306	chr6:145827016	T/C	cg05347473	chr6:146136440	FBXO30	0.48	6.42	0.39	7.51e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3768617	0.510	rs10797837	chr1:183075121	C/G	cg13390022	chr1:182993471	LAMC1	0.32	4.78	0.3	3.07e-6	Fuchs's corneal dystrophy;
SARC	cis	rs3857536	0.813	rs2093253	chr6:66937702	A/G	cg07460842	chr6:66804631	NA	-0.51	-5.83	-0.36	1.86e-8	Blood trace element (Cu levels);
SARC	cis	rs9818758	0.607	rs13077498	chr3:49313978	C/T	cg07636037	chr3:49044803	WDR6	-0.75	-6.54	-0.39	3.94e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs72781680	0.898	rs72788218	chr2:24090435	C/T	cg08917208	chr2:24149416	ATAD2B	0.77	7.59	0.45	7.54e-13	Lymphocyte counts;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg10057817	chr7:121701410	PTPRZ1	0.46	6.32	0.38	1.29e-9	Thyroid stimulating hormone;
SARC	cis	rs2033732	0.826	rs2196617	chr8:85089394	G/A	cg05716166	chr8:85095498	RALYL	0.55	7.07	0.42	1.78e-11	Body mass index;
SARC	cis	rs798554	0.610	rs2644304	chr7:2878779	T/C	cg04166393	chr7:2884313	GNA12	0.41	5.14	0.32	5.84e-7	Height;
SARC	cis	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg08045932	chr20:61659980	NA	0.5	6.84	0.41	7.06e-11	Prostate cancer (SNP x SNP interaction);
SARC	trans	rs561341	1.000	rs1557731	chr17:30321567	T/G	cg20587970	chr11:113659929	NA	-1.22	-12.41	-0.63	1.8e-27	Hip circumference adjusted for BMI;
SARC	cis	rs13256369	0.851	rs13254997	chr8:8563753	G/C	cg18904891	chr8:8559673	CLDN23	0.49	5.49	0.34	1.04e-7	Obesity-related traits;
SARC	cis	rs6540556	0.723	rs12086634	chr1:209880259	T/G	cg05527609	chr1:210001259	C1orf107	-0.59	-5.49	-0.34	1.06e-7	Red blood cell count;
SARC	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.38	-4.78	-0.3	3.08e-6	Lymphocyte counts;
SARC	cis	rs9788682	0.948	rs34664138	chr15:78831624	T/G	cg24631222	chr15:78858424	CHRNA5	0.77	10.35	0.56	6.66e-21	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg12463550	chr7:65579703	CRCP	-0.49	-5.34	-0.33	2.21e-7	Aortic root size;
SARC	cis	rs9987353	0.566	rs6998368	chr8:9070288	G/C	cg15556689	chr8:8085844	FLJ10661	-0.45	-5.41	-0.33	1.56e-7	Recombination measurement;
SARC	cis	rs7762018	0.607	rs79728466	chr6:170046405	T/C	cg19338460	chr6:170058176	WDR27	-0.78	-5.16	-0.32	5.37e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg07343612	chr16:622815	PIGQ	-0.59	-8.34	-0.48	6.46e-15	Height;
SARC	cis	rs11122272	0.735	rs2474630	chr1:231535335	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.28	-0.56	1.12e-20	Hemoglobin concentration;
SARC	cis	rs6088813	1.000	rs6088815	chr20:33976474	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	-0.43	-5.24	-0.32	3.67e-7	Height;
SARC	cis	rs79349575	0.783	rs62078370	chr17:47026836	G/C	cg07967210	chr17:47022446	SNF8	0.37	4.71	0.3	4.19e-6	Type 2 diabetes;
SARC	cis	rs5417	0.662	rs12601936	chr17:7172609	A/G	cg13768953	chr17:7114967	DLG4	0.31	5.02	0.31	1.03e-6	Diastolic blood pressure;
SARC	trans	rs747334	0.846	rs7897603	chr10:92708759	C/G	cg05788437	chr3:197476880	FYTTD1;KIAA0226	-0.51	-7.15	-0.42	1.11e-11	Fibroblast growth factor basic levels;
SARC	cis	rs1348850	0.668	rs6734683	chr2:178494012	C/G	cg23306229	chr2:178417860	TTC30B	0.6	6.59	0.4	2.94e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs10875746	0.855	rs10875730	chr12:48427875	A/T	cg26205652	chr12:48591994	NA	0.53	5.62	0.35	5.3e-8	Longevity (90 years and older);
SARC	cis	rs7937682	0.562	rs12275761	chr11:111367083	T/A	cg09085632	chr11:111637200	PPP2R1B	0.56	7.24	0.43	6.52e-12	Primary sclerosing cholangitis;
SARC	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg08219700	chr8:58056026	NA	0.62	6.52	0.39	4.28e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7583236	0.500	rs7601899	chr2:70335973	C/G	cg01613454	chr2:70366299	NA	0.53	5.25	0.33	3.37e-7	Obesity-related traits;
SARC	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg25894440	chr7:65020034	NA	-0.77	-5.67	-0.35	4.23e-8	Diabetic kidney disease;
SARC	cis	rs6570726	0.764	rs76635693	chr6:145834070	T/C	cg05347473	chr6:146136440	FBXO30	0.53	7.29	0.43	4.79e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs986417	0.901	rs1950310	chr14:60988526	T/A	cg27398547	chr14:60952738	C14orf39	1.0	9.54	0.53	1.95e-18	Gut microbiota (bacterial taxa);
SARC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg01238044	chr22:24384105	GSTT1	0.6	6.85	0.41	6.53e-11	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs4481887	0.830	rs9662041	chr1:248484701	A/T	cg00666640	chr1:248458726	OR2T12	0.35	5.74	0.35	2.9e-8	Common traits (Other);
SARC	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg23985595	chr17:80112537	CCDC57	-0.32	-4.78	-0.3	3.08e-6	Life satisfaction;
SARC	cis	rs1580019	0.587	rs9638880	chr7:32552401	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.61	8.07	0.47	3.62e-14	Cognitive ability;
SARC	trans	rs877282	1.000	rs12779159	chr10:772143	T/C	cg22713356	chr15:30763199	NA	1.05	10.11	0.55	3.81e-20	Uric acid levels;
SARC	cis	rs1008375	1.000	rs4235388	chr4:17682030	G/A	cg16339924	chr4:17578868	LAP3	0.64	8.44	0.48	3.47e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6762477	0.748	rs11714799	chr3:50217899	T/G	cg24110177	chr3:50126178	RBM5	0.48	6.17	0.37	2.95e-9	Menarche (age at onset);
SARC	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg17221315	chr6:27791827	HIST1H4J	0.45	4.74	0.3	3.76e-6	Depression;
SARC	cis	rs9326248	1.000	rs4938344	chr11:117003749	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.55	6.1	0.37	4.48e-9	Blood protein levels;
SARC	cis	rs9916302	0.904	rs7223438	chr17:37521355	T/C	cg07936489	chr17:37558343	FBXL20	0.69	9.3	0.52	1.02e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs208520	1.000	rs12200490	chr6:66976084	G/A	cg07460842	chr6:66804631	NA	0.88	9.83	0.54	2.6e-19	Exhaled nitric oxide output;
SARC	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg25894440	chr7:65020034	NA	-0.76	-5.81	-0.36	2.02e-8	Diabetic kidney disease;
SARC	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg12463550	chr7:65579703	CRCP	0.66	5.08	0.32	7.79e-7	Diabetic kidney disease;
SARC	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg18230493	chr5:56204884	C5orf35	0.54	4.99	0.31	1.2e-6	Initial pursuit acceleration;
SARC	cis	rs7086627	0.515	rs1870147	chr10:82212541	A/T	cg01528321	chr10:82214614	TSPAN14	0.59	8.42	0.48	3.8e-15	Post bronchodilator FEV1;
SARC	cis	rs6088590	0.561	rs6087605	chr20:33180624	G/T	cg08999081	chr20:33150536	PIGU	0.45	6.82	0.41	7.78e-11	Coronary artery disease;
SARC	cis	rs7829975	0.660	rs10093926	chr8:8549020	A/C	cg15556689	chr8:8085844	FLJ10661	-0.46	-5.67	-0.35	4.16e-8	Mood instability;
SARC	cis	rs1348850	0.567	rs880897	chr2:178532503	C/T	cg22681709	chr2:178499509	PDE11A	-0.36	-5.18	-0.32	4.87e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg23758822	chr17:41437982	NA	0.9	11.46	0.6	2.14e-24	Menopause (age at onset);
SARC	trans	rs9388451	0.626	rs3799708	chr6:126078530	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.61	-8.09	-0.47	3.2e-14	Brugada syndrome;
SARC	cis	rs7300001	0.667	rs7302441	chr12:110506468	T/C	cg08946844	chr12:110511112	NA	0.66	4.83	0.3	2.45e-6	Headache;
SARC	cis	rs5758659	0.714	rs133376	chr22:42466905	C/T	cg04692870	chr22:42525206	CYP2D6	0.35	4.72	0.3	4.08e-6	Cognitive function;
SARC	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg16405210	chr4:1374714	KIAA1530	-0.49	-5.75	-0.35	2.77e-8	Obesity-related traits;
SARC	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg19077165	chr18:44547161	KATNAL2	-0.52	-7.17	-0.42	1.01e-11	Personality dimensions;
SARC	cis	rs9640161	0.789	rs13223702	chr7:150058968	G/A	cg10018233	chr7:150070692	REPIN1	0.66	8.78	0.5	3.54e-16	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg18876405	chr7:65276391	NA	0.7	8.81	0.5	3e-16	Aortic root size;
SARC	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg06634786	chr22:41940651	POLR3H	-0.58	-6.95	-0.41	3.64e-11	Vitiligo;
SARC	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg12705353	chr12:122356852	WDR66	-0.33	-4.88	-0.3	2e-6	Mean corpuscular volume;
SARC	cis	rs796364	0.865	rs769948	chr2:200728475	C/A	cg23649088	chr2:200775458	C2orf69	0.59	5.34	0.33	2.23e-7	Schizophrenia;
SARC	cis	rs4689388	0.889	rs4629534	chr4:6294124	G/T	cg25554036	chr4:6271136	WFS1	0.39	6.33	0.38	1.25e-9	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	trans	rs2727020	0.681	rs2866362	chr11:49379316	A/G	cg03929089	chr4:120376271	NA	-0.76	-11.22	-0.59	1.21e-23	Coronary artery disease;
SARC	cis	rs12479064	0.724	rs737094	chr2:100089078	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-5.69	-0.35	3.83e-8	Chronic sinus infection;
SARC	cis	rs146009840	1	rs146009840	chr15:78906177	A/T	cg06917634	chr15:78832804	PSMA4	-0.57	-5.86	-0.36	1.53e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs2073300	0.609	rs56334525	chr20:23365812	A/G	cg16736954	chr20:23401023	NAPB	0.79	4.99	0.31	1.16e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs17376456	0.877	rs10050465	chr5:93349963	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.84	0.36	1.77e-8	Diabetic retinopathy;
SARC	cis	rs4974559	0.740	rs11933854	chr4:1315172	G/A	cg02980000	chr4:1222292	CTBP1	0.56	5.29	0.33	2.84e-7	Systolic blood pressure;
SARC	cis	rs742614	0.533	rs6087526	chr20:32398295	A/C	cg06304546	chr20:32448765	NA	-0.59	-7.57	-0.44	8.66e-13	Stearic acid (18:0) levels;
SARC	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg24060327	chr5:131705240	SLC22A5	-0.74	-9.06	-0.51	5.55e-17	Breast cancer;
SARC	cis	rs10791097	0.748	rs4937580	chr11:130734270	T/C	cg12179176	chr11:130786555	SNX19	0.74	11.27	0.59	8.51e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs9815354	1.000	rs7650227	chr3:41794937	T/G	cg03022575	chr3:42003672	ULK4	0.59	5.75	0.35	2.71e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs858239	1.000	rs199348	chr7:23293098	C/A	cg23682824	chr7:23144976	KLHL7	0.56	6.95	0.41	3.71e-11	Cerebrospinal fluid biomarker levels;
SARC	cis	rs10089	1.000	rs72794396	chr5:127501386	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	8.65	0.49	8.41e-16	Ileal carcinoids;
SARC	cis	rs1878931	0.501	rs4785934	chr16:3419934	G/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.74	9.54	0.53	2.07e-18	Body mass index (adult);
SARC	cis	rs17095355	1.000	rs12259261	chr10:111725145	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.42	-4.76	-0.3	3.35e-6	Biliary atresia;
SARC	cis	rs992157	0.835	rs12987180	chr2:219144089	G/A	cg00012203	chr2:219082015	ARPC2	-0.63	-9.14	-0.51	3.16e-17	Colorectal cancer;
SARC	cis	rs35213789	0.878	rs7796592	chr7:69554128	G/A	cg10619644	chr7:69149951	AUTS2	0.43	5.16	0.32	5.39e-7	Childhood ear infection;
SARC	trans	rs61931739	0.534	rs7138522	chr12:34039762	G/A	cg26384229	chr12:38710491	ALG10B	0.85	12.34	0.63	2.98e-27	Morning vs. evening chronotype;
SARC	cis	rs9300255	0.537	rs1727334	chr12:123714236	A/G	cg05973401	chr12:123451056	ABCB9	0.47	5.29	0.33	2.84e-7	Neutrophil percentage of white cells;
SARC	cis	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg01579765	chr21:45077557	HSF2BP	-0.38	-6.46	-0.39	5.93e-10	Mean corpuscular volume;
SARC	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg23758822	chr17:41437982	NA	0.88	11.19	0.59	1.55e-23	Menopause (age at onset);
SARC	cis	rs7647973	0.626	rs62260723	chr3:49872124	T/C	cg03060546	chr3:49711283	APEH	-0.66	-6.95	-0.41	3.73e-11	Menarche (age at onset);
SARC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg26338869	chr17:61819248	STRADA	0.8	10.67	0.57	6.8e-22	Prudent dietary pattern;
SARC	trans	rs61931739	0.500	rs11053282	chr12:34561151	T/C	cg13010199	chr12:38710504	ALG10B	0.83	11.69	0.61	3.9e-25	Morning vs. evening chronotype;
SARC	cis	rs2486288	0.656	rs10519018	chr15:45549265	C/T	cg15395560	chr15:45543142	SLC28A2	0.29	5.57	0.34	6.84e-8	Glomerular filtration rate;
SARC	cis	rs1023500	0.573	rs13057094	chr22:42470317	T/C	cg04733989	chr22:42467013	NAGA	0.76	10.19	0.56	2.03e-20	Schizophrenia;
SARC	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg19987790	chr17:43696684	MGC57346	0.48	6.3	0.38	1.45e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg08280861	chr8:58055591	NA	0.61	5.81	0.36	2.02e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2204008	0.806	rs3922574	chr12:38329069	C/T	cg26384229	chr12:38710491	ALG10B	0.87	12.52	0.63	7.53e-28	Bladder cancer;
SARC	cis	rs3859192	0.599	rs2302777	chr17:38179492	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.39	7.37	0.43	3e-12	White blood cell count;
SARC	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg03709012	chr19:19516395	GATAD2A	1.03	18.4	0.77	2.65e-47	Tonsillectomy;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg19470508	chr3:44803154	KIF15;KIAA1143	0.53	6.98	0.42	3.08e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg18252515	chr7:66147081	NA	-1.34	-11.93	-0.62	6.47e-26	Diabetic kidney disease;
SARC	cis	rs2273669	0.915	rs10872027	chr6:109289540	T/C	cg01304950	chr6:109416612	SESN1;C6orf182	0.55	4.84	0.3	2.4e-6	Prostate cancer;
SARC	cis	rs6120849	0.950	rs6088732	chr20:33744134	A/G	cg24642439	chr20:33292090	TP53INP2	-0.49	-4.93	-0.31	1.59e-6	Protein C levels;
SARC	cis	rs2288884	0.541	rs72483948	chr19:52474921	C/G	cg24732339	chr19:52471368	ZNF350	-0.59	-5.26	-0.33	3.2e-7	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
SARC	cis	rs17023223	0.537	rs2361273	chr1:119603700	A/T	cg05756136	chr1:119680316	WARS2	-0.43	-5.03	-0.31	9.81e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	trans	rs7819412	0.540	rs11777355	chr8:11044689	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.73	-0.4	1.28e-10	Triglycerides;
SARC	cis	rs12022452	0.506	rs6673386	chr1:41011879	C/G	cg25568243	chr1:40974465	DEM1	0.54	5.3	0.33	2.68e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs4727027	0.933	rs6464940	chr7:148826309	G/T	cg23583168	chr7:148888333	NA	-0.73	-10.69	-0.57	5.97e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	trans	rs12310956	0.531	rs10772110	chr12:33841755	A/G	cg26384229	chr12:38710491	ALG10B	0.6	7.19	0.43	8.94e-12	Morning vs. evening chronotype;
SARC	cis	rs72781680	0.821	rs72796361	chr2:24160689	A/T	cg06627628	chr2:24431161	ITSN2	-0.57	-5.91	-0.36	1.21e-8	Lymphocyte counts;
SARC	cis	rs1580019	0.534	rs13237495	chr7:32560687	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.53	6.85	0.41	6.69e-11	Cognitive ability;
SARC	cis	rs7044106	0.718	rs1981021	chr9:123388393	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	5.52	0.34	9.03e-8	Hip circumference adjusted for BMI;
SARC	cis	rs7829975	0.511	rs2976902	chr8:8341105	T/G	cg08975724	chr8:8085496	FLJ10661	0.5	6.72	0.4	1.37e-10	Mood instability;
SARC	cis	rs6456156	0.742	rs1331299	chr6:167533467	A/G	cg07741184	chr6:167504864	NA	0.27	5.26	0.33	3.2e-7	Primary biliary cholangitis;
SARC	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	-0.46	-5.55	-0.34	7.73e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs2115536	0.730	rs12898642	chr15:80182050	T/C	cg00225070	chr15:80189496	MTHFS	0.55	7.2	0.43	8.17e-12	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
SARC	cis	rs6815814	0.904	rs3924113	chr4:38796255	G/T	cg02016764	chr4:38805732	TLR1	-0.43	-4.73	-0.3	3.9e-6	Breast cancer;
SARC	cis	rs2777491	0.668	rs2026946	chr15:41789704	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.73	-9.97	-0.55	9.9e-20	Ulcerative colitis;
SARC	trans	rs208515	0.525	rs12204706	chr6:66669930	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.97	-11.29	-0.59	7.12e-24	Exhaled nitric oxide levels;
SARC	cis	rs6728642	0.572	rs7574488	chr2:97599618	T/C	cg26665480	chr2:98280029	ACTR1B	-0.72	-7.6	-0.45	7.19e-13	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs600231	0.708	rs1784860	chr11:65240712	C/A	cg17120908	chr11:65337727	SSSCA1	-0.43	-5.47	-0.34	1.13e-7	Bone mineral density;
SARC	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.06	0.37	5.52e-9	Height;
SARC	cis	rs1348850	0.567	rs3821006	chr2:178537694	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.43	5.02	0.31	1.02e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs763121	1.000	rs763121	chr22:38879940	C/T	cg21395723	chr22:39101663	GTPBP1	-0.42	-4.86	-0.3	2.15e-6	Menopause (age at onset);
SARC	cis	rs11731606	0.508	rs9307140	chr4:95288670	G/C	cg20625393	chr4:95128694	SMARCAD1	0.57	5.53	0.34	8.43e-8	Mean platelet volume;
SARC	cis	rs1448094	0.872	rs7975457	chr12:86410404	C/T	cg02569458	chr12:86230093	RASSF9	0.38	5.64	0.35	4.8e-8	Major depressive disorder;
SARC	cis	rs11190604	1.000	rs10883509	chr10:102296461	C/T	cg07080220	chr10:102295463	HIF1AN	0.78	8.66	0.49	8.06e-16	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs9470366	0.883	rs9462207	chr6:36627599	T/C	cg08179530	chr6:36648295	CDKN1A	0.56	5.83	0.36	1.88e-8	QRS duration;
SARC	cis	rs7635838	0.892	rs9874535	chr3:11463730	A/G	cg00170343	chr3:11313890	ATG7	0.63	8.51	0.49	2.13e-15	HDL cholesterol;
SARC	cis	rs2635047	0.811	rs17785603	chr18:44769534	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	6.57	0.4	3.27e-10	Educational attainment;
SARC	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg11890956	chr21:40555474	PSMG1	-0.72	-9.56	-0.53	1.82e-18	Menarche (age at onset);
SARC	cis	rs796364	0.950	rs56155997	chr2:200768491	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.7	-5.94	-0.36	1.04e-8	Schizophrenia;
SARC	cis	rs6582630	0.593	rs7134006	chr12:38596245	A/C	cg13010199	chr12:38710504	ALG10B	0.71	9.71	0.54	6.4e-19	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs8078723	0.714	rs12940405	chr17:38143768	C/T	cg17467752	chr17:38218738	THRA	-0.38	-4.91	-0.31	1.69e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs28830936	0.510	rs7174099	chr15:42099059	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.47	-7.55	-0.44	9.93e-13	Diastolic blood pressure;
SARC	cis	rs67460515	0.892	rs4856757	chr3:160999418	A/T	cg03342759	chr3:160939853	NMD3	-0.71	-9.02	-0.51	7.27e-17	Parkinson's disease;
SARC	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg00149659	chr3:10157352	C3orf10	0.64	5.91	0.36	1.22e-8	Alzheimer's disease;
SARC	cis	rs1348850	0.747	rs1047884	chr2:178488281	C/G	cg23306229	chr2:178417860	TTC30B	0.45	4.73	0.3	3.93e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1580019	0.961	rs1868776	chr7:32494435	G/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.74	-10.01	-0.55	7.5e-20	Cognitive ability;
SARC	cis	rs854765	0.583	rs4414547	chr17:17859052	G/T	cg05444541	chr17:17804740	TOM1L2	-0.29	-4.82	-0.3	2.56e-6	Total body bone mineral density;
SARC	cis	rs2228479	0.618	rs17233623	chr16:89811209	C/T	cg06558623	chr16:89946397	TCF25	0.87	6.93	0.41	4.02e-11	Skin colour saturation;
SARC	cis	rs7666738	0.830	rs6532715	chr4:99016792	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.9	0.5	1.65e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg10295955	chr4:187884368	NA	-1.07	-19.85	-0.79	5.42e-52	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3087591	1.000	rs12939853	chr17:29455021	G/A	cg24425628	chr17:29625626	OMG;NF1	0.56	7.12	0.42	1.32e-11	Hip circumference;
SARC	cis	rs66887589	1.000	rs66887589	chr4:120509279	T/C	cg09307838	chr4:120376055	NA	-0.53	-7.16	-0.42	1.04e-11	Diastolic blood pressure;
SARC	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.51	7.88	0.46	1.29e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs72781680	0.898	rs56315094	chr2:23941952	T/C	cg06627628	chr2:24431161	ITSN2	-0.66	-6.25	-0.38	1.94e-9	Lymphocyte counts;
SARC	cis	rs17376456	0.877	rs10078194	chr5:93364310	A/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.76	0.35	2.64e-8	Diabetic retinopathy;
SARC	cis	rs950169	0.922	rs62028133	chr15:84919375	A/C	cg24253500	chr15:84953950	NA	0.36	5.19	0.32	4.54e-7	Schizophrenia;
SARC	cis	rs17376456	0.825	rs6865441	chr5:93284746	G/A	cg25358565	chr5:93447407	FAM172A	1.3	14.17	0.68	2.82e-33	Diabetic retinopathy;
SARC	cis	rs114858855	1.000	rs17070656	chr6:109828712	A/C	cg26835506	chr6:109038353	NA	-0.63	-5.17	-0.32	5.02e-7	Plasma trimethylamine N-oxide levels;
SARC	cis	rs6912958	0.678	rs9450744	chr6:88280529	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.43	-0.34	1.42e-7	Monocyte percentage of white cells;
SARC	cis	rs11098499	0.779	rs10016060	chr4:120298412	A/G	cg09160332	chr4:120329925	NA	-0.33	-4.77	-0.3	3.27e-6	Corneal astigmatism;
SARC	cis	rs9611519	0.780	rs2235852	chr22:41661154	G/T	cg03806693	chr22:41940476	POLR3H	-0.59	-7.58	-0.44	8.16e-13	Neuroticism;
SARC	cis	rs6733011	0.582	rs2280256	chr2:99449174	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.43	-5.4	-0.33	1.62e-7	Bipolar disorder;
SARC	cis	rs72653721	0.730	rs56074859	chr6:11044089	C/T	cg13562911	chr6:11044106	ELOVL2	0.59	6.7	0.4	1.56e-10	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	cis	rs10789491	1.000	rs1545206	chr1:47185082	C/G	cg15501359	chr1:47185051	KIAA0494	0.76	7.9	0.46	1.11e-13	Response to hepatitis C treatment;
SARC	cis	rs4727027	0.933	rs13225884	chr7:148857795	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.43	5.36	0.33	2.05e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg02297831	chr4:17616191	MED28	0.5	6.46	0.39	6.17e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs9650657	0.707	rs6984744	chr8:10616265	A/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.64	-0.4	2.2e-10	Neuroticism;
SARC	cis	rs2562456	0.917	rs2562466	chr19:21714204	C/T	cg00806126	chr19:22604979	ZNF98	0.47	4.88	0.3	1.97e-6	Pain;
SARC	cis	rs644799	0.542	rs10831415	chr11:95466159	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.49	5.67	0.35	4.2e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg13175981	chr1:150552382	MCL1	-0.48	-5.97	-0.36	8.78e-9	Tonsillectomy;
SARC	cis	rs71277158	0.688	rs9757709	chr3:169906407	T/G	cg04067573	chr3:169899625	PHC3	0.57	4.81	0.3	2.73e-6	Prostate cancer;
SARC	cis	rs11098499	0.913	rs11098496	chr4:120167466	C/G	cg09307838	chr4:120376055	NA	0.85	11.65	0.61	4.92e-25	Corneal astigmatism;
SARC	cis	rs763121	0.819	rs5750658	chr22:39060917	C/T	cg06022373	chr22:39101656	GTPBP1	0.91	11.32	0.6	5.9e-24	Menopause (age at onset);
SARC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg06074448	chr4:187884817	NA	-0.38	-4.93	-0.31	1.58e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6690583	0.623	rs2083283	chr1:85439996	C/A	cg22153463	chr1:85462885	MCOLN2	0.68	6.45	0.39	6.5e-10	Serum sulfate level;
SARC	cis	rs79149102	0.579	rs2304904	chr15:75315975	G/A	cg00629941	chr15:75287862	SCAMP5	-0.77	-5.68	-0.35	3.98e-8	Lung cancer;
SARC	cis	rs10465746	0.682	rs882897	chr1:84426049	A/T	cg10977910	chr1:84465055	TTLL7	0.42	5.07	0.32	8.12e-7	Obesity-related traits;
SARC	cis	rs2115536	0.704	rs2163005	chr15:80194480	A/G	cg01843524	chr15:80216276	C15orf37;ST20	0.42	4.96	0.31	1.38e-6	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
SARC	cis	rs3796352	1.000	rs13078971	chr3:53103645	G/C	cg27565382	chr3:53032988	SFMBT1	1.0	6.88	0.41	5.58e-11	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs986417	0.818	rs12883272	chr14:61015153	A/G	cg27398547	chr14:60952738	C14orf39	0.97	8.83	0.5	2.63e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs4481887	0.893	rs7515080	chr1:248494073	A/G	cg00666640	chr1:248458726	OR2T12	0.4	6.58	0.4	3.1e-10	Common traits (Other);
SARC	cis	rs72781680	0.678	rs11125293	chr2:24102423	A/G	cg08917208	chr2:24149416	ATAD2B	0.63	6.63	0.4	2.37e-10	Lymphocyte counts;
SARC	cis	rs6121246	0.697	rs6060446	chr20:30231637	T/C	cg13852791	chr20:30311386	BCL2L1	0.82	8.92	0.5	1.38e-16	Mean corpuscular hemoglobin;
SARC	cis	rs12579753	0.879	rs1987116	chr12:82156478	G/A	cg07988820	chr12:82153109	PPFIA2	-0.59	-7.09	-0.42	1.6e-11	Resting heart rate;
SARC	cis	rs9419702	0.568	rs7093241	chr10:133556596	G/A	cg04492858	chr10:133558786	NA	0.31	5.0	0.31	1.1e-6	Survival in rectal cancer;
SARC	cis	rs2273669	0.667	rs75942063	chr6:109352545	G/A	cg05315195	chr6:109294784	ARMC2	-0.64	-5.7	-0.35	3.68e-8	Prostate cancer;
SARC	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg18252515	chr7:66147081	NA	-1.34	-11.86	-0.61	1.09e-25	Diabetic kidney disease;
SARC	cis	rs9435341	0.965	rs3108680	chr1:107572997	T/C	cg09367891	chr1:107599246	PRMT6	0.64	8.4	0.48	4.52e-15	Facial morphology (factor 21, depth of nasal alae);
SARC	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg11764359	chr7:65958608	NA	0.86	12.35	0.63	2.72e-27	Aortic root size;
SARC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg01238044	chr22:24384105	GSTT1	-0.72	-9.29	-0.52	1.1e-17	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1865760	0.865	rs9467647	chr6:25957642	A/G	cg16482183	chr6:26056742	HIST1H1C	0.52	6.69	0.4	1.63e-10	Height;
SARC	cis	rs4727027	0.680	rs6464941	chr7:148826352	A/G	cg23583168	chr7:148888333	NA	-0.72	-9.68	-0.54	7.42e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs4319547	0.910	rs6416298	chr12:123002143	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.62	-6.98	-0.42	3e-11	Body mass index;
SARC	cis	rs8044995	0.636	rs117761434	chr16:68254196	G/A	cg27539214	chr16:67997921	SLC12A4	-0.53	-4.99	-0.31	1.19e-6	Schizophrenia;
SARC	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg18252515	chr7:66147081	NA	0.46	4.94	0.31	1.46e-6	Aortic root size;
SARC	cis	rs2594989	0.943	rs901865	chr3:11300707	T/C	cg00170343	chr3:11313890	ATG7	0.67	6.52	0.39	4.2e-10	Circulating chemerin levels;
SARC	cis	rs2718058	0.630	rs2722292	chr7:37824581	A/G	cg15028436	chr7:37888078	TXNDC3	0.4	5.01	0.31	1.08e-6	Alzheimer's disease (late onset);
SARC	cis	rs11785400	0.642	rs4256574	chr8:143725705	C/T	cg24634471	chr8:143751801	JRK	0.6	7.74	0.45	2.98e-13	Schizophrenia;
SARC	cis	rs9457247	1.000	rs365189	chr6:167384545	G/A	cg23791538	chr6:167370224	RNASET2	-0.63	-8.74	-0.5	4.81e-16	Crohn's disease;
SARC	cis	rs765787	0.530	rs2899381	chr15:45529630	C/T	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.51e-10	Uric acid levels;
SARC	cis	rs763121	0.853	rs138709	chr22:39139216	C/G	cg06022373	chr22:39101656	GTPBP1	0.87	12.0	0.62	3.86e-26	Menopause (age at onset);
SARC	cis	rs6963495	0.818	rs73190158	chr7:105153943	T/C	cg19920283	chr7:105172520	RINT1	0.65	5.53	0.34	8.62e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs79149102	0.579	rs7167415	chr15:75302570	C/T	cg17294928	chr15:75287854	SCAMP5	-1.01	-9.17	-0.52	2.56e-17	Lung cancer;
SARC	cis	rs11608355	0.515	rs6606727	chr12:109941450	T/A	cg05360138	chr12:110035743	NA	0.92	9.39	0.52	5.78e-18	Neuroticism;
SARC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg07167872	chr1:205819463	PM20D1	0.73	11.51	0.6	1.46e-24	Menarche (age at onset);
SARC	cis	rs7772486	0.790	rs1062068	chr6:146207465	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.68	0.4	1.72e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7582720	1.000	rs72934737	chr2:203740798	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.28	0.43	5.16e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	trans	rs3779273	0.776	rs4730110	chr7:77832149	T/C	cg05596911	chr5:118502651	DMXL1	-0.53	-6.56	-0.39	3.49e-10	Body mass index;
SARC	cis	rs7408868	0.611	rs11669982	chr19:15292366	C/T	cg14696996	chr19:15285081	NOTCH3	0.57	5.95	0.36	9.69e-9	Pulse pressure;
SARC	cis	rs11098499	0.569	rs55845118	chr4:120290913	T/C	cg09307838	chr4:120376055	NA	0.83	11.82	0.61	1.46e-25	Corneal astigmatism;
SARC	cis	rs709400	0.627	rs55859054	chr14:103953666	T/A	cg26031613	chr14:104095156	KLC1	0.81	11.39	0.6	3.44e-24	Body mass index;
SARC	cis	rs4555082	0.872	rs7153832	chr14:105730563	G/T	cg13114125	chr14:105738426	BRF1	-0.8	-11.92	-0.62	6.63e-26	Mean platelet volume;Platelet distribution width;
SARC	cis	rs2072438	0.503	rs4837810	chr9:123881199	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.41	5.27	0.33	3.09e-7	Rheumatoid arthritis;
SARC	cis	rs5417	0.662	rs12601936	chr17:7172609	A/G	cg14660024	chr17:7154518	C17orf81;DULLARD	0.36	5.05	0.31	8.73e-7	Diastolic blood pressure;
SARC	cis	rs1707322	1.000	rs946527	chr1:46485970	C/T	cg06784218	chr1:46089804	CCDC17	0.34	5.9	0.36	1.26e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs13082711	0.513	rs7612102	chr3:27372826	A/G	cg02860705	chr3:27208620	NA	-0.53	-6.77	-0.41	1.01e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs7264396	0.836	rs6058276	chr20:34187728	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-5.97	-0.36	8.56e-9	Total cholesterol levels;
SARC	cis	rs9486719	0.947	rs2472908	chr6:96875998	A/T	cg06623918	chr6:96969491	KIAA0776	0.73	8.01	0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg27598017	chr4:104119803	CENPE	0.49	6.39	0.39	8.98e-10	Lung adenocarcinoma;
SARC	cis	rs2832077	0.689	rs2832052	chr21:30130073	G/C	cg24692254	chr21:30365293	RNF160	-0.46	-4.78	-0.3	3.06e-6	Cognitive test performance;
SARC	cis	rs2070488	0.775	rs4679066	chr3:38568527	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.77	-11.43	-0.6	2.52e-24	Electrocardiographic conduction measures;
SARC	cis	rs1865760	0.827	rs9461227	chr6:25960815	C/T	cg10373733	chr6:25993375	NA	0.39	4.79	0.3	3.01e-6	Height;
SARC	cis	rs10504229	0.679	rs2218271	chr8:58052446	T/A	cg22535103	chr8:58192502	C8orf71	-0.57	-5.68	-0.35	4.09e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs3812831	0.654	rs6560933	chr13:114937294	A/G	cg06611532	chr13:114900021	NA	-0.3	-4.92	-0.31	1.63e-6	Schizophrenia;
SARC	cis	rs3020736	0.500	rs8143153	chr22:42515637	G/C	cg15557168	chr22:42548783	NA	0.36	4.94	0.31	1.51e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg26338869	chr17:61819248	STRADA	0.78	10.49	0.57	2.48e-21	Prudent dietary pattern;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg26774410	chr16:30780246	RNF40	-0.46	-6.26	-0.38	1.85e-9	Chemerin levels;
SARC	trans	rs747334	0.846	rs7897603	chr10:92708759	C/G	cg14008834	chr4:24472254	NA	-0.49	-6.55	-0.39	3.71e-10	Fibroblast growth factor basic levels;
SARC	cis	rs7264396	0.563	rs6060570	chr20:34291166	A/C	cg01084648	chr20:34329383	RBM39	0.56	4.93	0.31	1.57e-6	Total cholesterol levels;
SARC	cis	rs2414059	0.518	rs3098171	chr15:50771511	C/G	cg05456662	chr15:50716270	USP8	-0.39	-4.81	-0.3	2.7e-6	QT interval;
SARC	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	8.89	0.5	1.67e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9858542	0.903	rs17080528	chr3:49389842	C/T	cg03060546	chr3:49711283	APEH	-0.57	-7.09	-0.42	1.55e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs4253772	0.678	rs1053332	chr22:46640179	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.51	5.42	0.33	1.51e-7	LDL cholesterol;Cholesterol, total;
SARC	cis	rs9462027	0.628	rs6937132	chr6:34799221	T/A	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-6.14	-0.37	3.58e-9	Systemic lupus erythematosus;
SARC	cis	rs9513627	1.000	rs4466950	chr13:100166875	G/T	cg25919922	chr13:100150906	NA	0.63	4.85	0.3	2.26e-6	Obesity-related traits;
SARC	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg04772025	chr11:68637568	NA	0.49	6.27	0.38	1.72e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs2425143	1.000	rs74785978	chr20:34373234	G/C	cg01084648	chr20:34329383	RBM39	0.63	4.75	0.3	3.49e-6	Blood protein levels;
SARC	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg15541040	chr2:3486749	NA	-0.46	-6.2	-0.38	2.49e-9	Neurofibrillary tangles;
SARC	cis	rs2075371	0.527	rs1862046	chr7:134023524	T/C	cg11752832	chr7:134001865	SLC35B4	0.53	6.47	0.39	5.56e-10	Mean platelet volume;
SARC	cis	rs10463554	0.892	rs11952337	chr5:102263747	G/C	cg23492399	chr5:102201601	PAM	-0.47	-5.59	-0.34	6.48e-8	Parkinson's disease;
SARC	cis	rs1215050	0.740	rs1214994	chr4:99035577	C/T	cg05340658	chr4:99064831	C4orf37	0.48	6.49	0.39	5.21e-10	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg11987759	chr7:65425863	GUSB	-0.5	-6.05	-0.37	5.67e-9	Aortic root size;
SARC	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg10523679	chr1:76189770	ACADM	0.45	5.83	0.36	1.79e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg14077847	chr17:57184164	TRIM37	-0.49	-6.46	-0.39	6.16e-10	Thyroid cancer;
SARC	cis	rs4974559	0.947	rs28540746	chr4:1352954	G/A	cg09010372	chr4:1323433	MAEA	-0.47	-4.72	-0.3	3.99e-6	Systolic blood pressure;
SARC	trans	rs66573146	1.000	rs28384174	chr4:6961107	G/T	cg07817883	chr1:32538562	TMEM39B	1.43	9.06	0.51	5.43e-17	Granulocyte percentage of myeloid white cells;
SARC	cis	rs9329221	0.935	rs3750311	chr8:10283602	C/A	cg21775007	chr8:11205619	TDH	-0.45	-5.49	-0.34	1.05e-7	Neuroticism;
SARC	cis	rs6088590	0.582	rs6059909	chr20:33139691	C/A	cg08999081	chr20:33150536	PIGU	0.45	6.82	0.41	7.83e-11	Coronary artery disease;
SARC	cis	rs1569175	1.000	rs2189471	chr2:200924202	G/A	cg23649088	chr2:200775458	C2orf69	-0.89	-4.95	-0.31	1.46e-6	Response to treatment for acute lymphoblastic leukemia;
SARC	cis	rs36051895	0.659	rs12343867	chr9:5074189	T/C	cg02405213	chr9:5042618	JAK2	-0.45	-5.19	-0.32	4.67e-7	Pediatric autoimmune diseases;
SARC	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg03161606	chr19:29218774	NA	0.47	6.7	0.4	1.55e-10	Methadone dose in opioid dependence;
SARC	cis	rs1018836	0.884	rs2073640	chr8:91594853	A/G	cg16814680	chr8:91681699	NA	-0.81	-13.2	-0.65	4.37e-30	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs1865760	0.534	rs2032444	chr6:26046744	T/G	cg10373733	chr6:25993375	NA	0.49	5.49	0.34	1.07e-7	Height;
SARC	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.43	-5.38	-0.33	1.82e-7	Lymphocyte counts;
SARC	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg12463550	chr7:65579703	CRCP	0.48	5.24	0.32	3.65e-7	Aortic root size;
SARC	cis	rs9814567	1.000	rs9989967	chr3:134238964	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-7.06	-0.42	1.94e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs11581859	0.613	rs12732234	chr1:99210267	C/A	cg20286094	chr1:99190917	SNX7	-0.43	-5.21	-0.32	4.23e-7	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs1707322	0.752	rs28623463	chr1:46170758	A/C	cg06784218	chr1:46089804	CCDC17	0.36	6.24	0.38	2.03e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg07414643	chr4:187882934	NA	0.5	7.55	0.44	1e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6088580	0.542	rs6059882	chr20:33090167	T/C	cg08999081	chr20:33150536	PIGU	0.43	6.69	0.4	1.65e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs10465746	0.780	rs1570691	chr1:84370393	A/C	cg10977910	chr1:84465055	TTLL7	0.39	4.79	0.3	2.91e-6	Obesity-related traits;
SARC	cis	rs2050392	0.630	rs303428	chr10:30739058	C/T	cg25182066	chr10:30743637	MAP3K8	-0.41	-5.53	-0.34	8.55e-8	Inflammatory bowel disease;
SARC	cis	rs12586317	0.557	rs72664863	chr14:35643588	C/T	cg16230307	chr14:35515116	FAM177A1	0.46	5.72	0.35	3.19e-8	Psoriasis;
SARC	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg14298792	chr15:30685198	CHRFAM7A	-0.51	-5.74	-0.35	2.96e-8	Huntington's disease progression;
SARC	cis	rs1707322	0.682	rs12041197	chr1:46104464	T/C	cg03146154	chr1:46216737	IPP	0.51	6.11	0.37	4.04e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs8017423	0.967	rs11624725	chr14:90713609	G/T	cg20276874	chr14:90721474	PSMC1	0.37	5.15	0.32	5.48e-7	Mortality in heart failure;
SARC	cis	rs13108904	0.604	rs13103860	chr4:1320120	G/A	cg00684032	chr4:1343700	KIAA1530	0.46	6.59	0.4	2.97e-10	Obesity-related traits;
SARC	cis	rs7584330	0.737	rs7584314	chr2:238361089	C/T	cg14458575	chr2:238380390	NA	0.46	5.73	0.35	3.03e-8	Prostate cancer;
SARC	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg03709012	chr19:19516395	GATAD2A	1.0	17.3	0.75	1.07e-43	Tonsillectomy;
SARC	cis	rs897080	0.515	rs1067333	chr2:44626710	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.62	7.48	0.44	1.52e-12	Height;
SARC	cis	rs8016982	0.963	rs7149672	chr14:81657336	A/G	cg01989461	chr14:81687754	GTF2A1	0.56	6.73	0.4	1.32e-10	Schizophrenia;
SARC	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg18876405	chr7:65276391	NA	-0.65	-8.09	-0.47	3.26e-14	Aortic root size;
SARC	cis	rs35110281	0.807	rs2838326	chr21:45014315	C/T	cg01579765	chr21:45077557	HSF2BP	-0.31	-5.28	-0.33	3.01e-7	Mean corpuscular volume;
SARC	cis	rs1580019	0.813	rs2044839	chr7:32500805	A/C	cg14728415	chr7:32535168	LSM5;AVL9	0.43	5.06	0.31	8.61e-7	Cognitive ability;
SARC	trans	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg02368765	chr17:38219085	THRA	0.47	6.59	0.4	2.88e-10	Immature fraction of reticulocytes;
SARC	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg07701084	chr6:150067640	NUP43	0.42	5.54	0.34	8.2e-8	Lung cancer;
SARC	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg14893161	chr1:205819251	PM20D1	0.5	5.57	0.34	7.03e-8	Parkinson's disease;
SARC	cis	rs13401104	0.796	rs72620810	chr2:237117697	A/G	cg19324714	chr2:237145437	ASB18	0.57	5.71	0.35	3.46e-8	Educational attainment;
SARC	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	5.35	0.33	2.05e-7	Tonsillectomy;
SARC	cis	rs73206853	0.620	rs55845219	chr12:111164875	C/T	cg10860002	chr12:110842031	ANAPC7	0.6	5.04	0.31	9.5e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	trans	rs61931739	0.500	rs7298322	chr12:34445489	A/T	cg26384229	chr12:38710491	ALG10B	0.84	12.56	0.64	5.71e-28	Morning vs. evening chronotype;
SARC	cis	rs2645694	0.626	rs2703140	chr4:77830057	C/G	cg03477792	chr4:77819574	ANKRD56	0.46	6.8	0.41	8.69e-11	Emphysema distribution in smoking;
SARC	cis	rs11785400	0.793	rs13248524	chr8:143739343	T/C	cg10596483	chr8:143751796	JRK	0.55	7.01	0.42	2.59e-11	Schizophrenia;
SARC	cis	rs7512552	0.839	rs3896342	chr1:150411312	T/C	cg15654264	chr1:150340011	RPRD2	0.39	5.02	0.31	1.03e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs8005677	0.962	rs34917191	chr14:23387628	T/C	cg01529538	chr14:23388837	RBM23	0.46	5.72	0.35	3.25e-8	Cognitive ability (multi-trait analysis);
SARC	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.53	-6.75	-0.4	1.15e-10	Lymphocyte counts;
SARC	cis	rs10489202	0.608	rs10918827	chr1:168077044	A/G	cg24449463	chr1:168025552	DCAF6	0.57	7.56	0.44	9.4e-13	Schizophrenia;
SARC	cis	rs73206853	0.534	rs12302069	chr12:110512359	A/G	cg08946844	chr12:110511112	NA	0.62	4.92	0.31	1.61e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs4927850	1.000	rs6799572	chr3:195740408	C/T	cg12696929	chr3:195401817	SDHAP2	0.38	5.07	0.32	7.95e-7	Pancreatic cancer;
SARC	cis	rs1707322	0.691	rs11211175	chr1:46220884	C/G	cg06784218	chr1:46089804	CCDC17	0.37	6.43	0.39	7.15e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg06618935	chr21:46677482	NA	-0.41	-5.39	-0.33	1.72e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs11971779	0.680	rs4398844	chr7:139043139	G/A	cg23387468	chr7:139079360	LUC7L2	0.33	4.74	0.3	3.76e-6	Diisocyanate-induced asthma;
SARC	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg13206674	chr6:150067644	NUP43	0.44	5.75	0.35	2.76e-8	Lung cancer;
SARC	cis	rs4466137	0.830	rs6886442	chr5:82973210	A/C	cg16102102	chr5:83017553	HAPLN1	0.68	8.93	0.5	1.3e-16	Prostate cancer;
SARC	cis	rs10791097	0.694	rs4370948	chr11:130755700	A/C	cg12179176	chr11:130786555	SNX19	0.76	11.33	0.6	5.46e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs2153219	1.000	rs2789495	chr6:149763956	C/T	cg18043157	chr6:150390308	ULBP3	-0.54	-5.01	-0.31	1.05e-6	Coronary artery disease;
SARC	cis	rs4481887	0.893	rs28579823	chr1:248506881	C/T	cg01631408	chr1:248437212	OR2T33	-0.45	-6.05	-0.37	5.83e-9	Common traits (Other);
SARC	cis	rs7255045	0.788	rs8111370	chr19:12948864	G/T	cg21491176	chr19:12958399	MAST1	-0.35	-5.01	-0.31	1.1e-6	Mean corpuscular volume;
SARC	cis	rs67460515	0.500	rs9812507	chr3:160723393	G/A	cg04691961	chr3:161091175	C3orf57	-0.44	-5.4	-0.33	1.6e-7	Parkinson's disease;
SARC	cis	rs4713675	0.565	rs3818524	chr6:33660695	G/C	cg15676125	chr6:33679581	C6orf125	0.53	6.45	0.39	6.28e-10	Plateletcrit;
SARC	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg22168489	chr12:122356033	WDR66	0.62	9.82	0.54	2.9e-19	Mean corpuscular volume;
SARC	cis	rs7582180	0.701	rs4622752	chr2:100892018	A/G	cg14675211	chr2:100938903	LONRF2	-0.4	-5.41	-0.33	1.53e-7	Intelligence (multi-trait analysis);
SARC	cis	rs11122272	0.735	rs2808584	chr1:231512925	A/G	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg10207240	chr12:122356781	WDR66	0.33	5.61	0.34	5.72e-8	Mean platelet volume;
SARC	cis	rs9303401	0.659	rs17741087	chr17:56550300	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.05	11.45	0.6	2.3e-24	Cognitive test performance;
SARC	cis	rs4595586	0.545	rs12821810	chr12:39375858	T/C	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	cis	rs17376456	0.825	rs7715562	chr5:93222034	C/T	cg21475434	chr5:93447410	FAM172A	-0.82	-7.29	-0.43	4.77e-12	Diabetic retinopathy;
SARC	cis	rs6866344	0.697	rs17184344	chr5:178129281	A/G	cg03877680	chr5:178157825	ZNF354A	1.02	12.35	0.63	2.73e-27	Neutrophil percentage of white cells;
SARC	cis	rs10463554	0.927	rs158403	chr5:102415768	C/G	cg23492399	chr5:102201601	PAM	-0.5	-5.58	-0.34	6.68e-8	Parkinson's disease;
SARC	cis	rs7772486	0.754	rs702306	chr6:145991029	T/C	cg23711669	chr6:146136114	FBXO30	-0.85	-14.3	-0.68	1.03e-33	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2043112	0.964	rs13166875	chr5:38996638	A/G	cg04869206	chr5:39074266	RICTOR	0.51	6.18	0.38	2.79e-9	Obesity-related traits;
SARC	cis	rs9818758	0.607	rs55873331	chr3:49597055	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.66	-5.3	-0.33	2.64e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	trans	rs459571	0.635	rs379471	chr9:136890649	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.58	-6.58	-0.4	3.15e-10	Platelet distribution width;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg23411876	chr7:140396886	LOC100134713;NDUFB2	-0.73	-7.6	-0.45	7.3e-13	Lung cancer in ever smokers;
SARC	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg02725872	chr8:58115012	NA	-0.33	-5.0	-0.31	1.13e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg04267008	chr7:1944627	MAD1L1	-0.6	-6.99	-0.42	2.83e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg25894440	chr7:65020034	NA	-0.74	-5.64	-0.35	4.95e-8	Diabetic kidney disease;
SARC	cis	rs3008870	0.755	rs1925409	chr1:67365089	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.57	-7.26	-0.43	5.63e-12	Lymphocyte percentage of white cells;
SARC	cis	rs6964587	0.869	rs11769294	chr7:91549937	C/T	cg17063962	chr7:91808500	NA	0.85	12.7	0.64	1.91e-28	Breast cancer;
SARC	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg17221315	chr6:27791827	HIST1H4J	0.45	4.89	0.31	1.89e-6	Cardiac Troponin-T levels;
SARC	cis	rs2070997	0.816	rs6597642	chr9:133725767	C/T	cg03924115	chr9:133768966	QRFP	0.5	6.0	0.37	7.31e-9	Response to amphetamines;
SARC	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	12.32	0.63	3.5e-27	Personality dimensions;
SARC	cis	rs208515	0.525	rs12193034	chr6:66677866	C/T	cg07460842	chr6:66804631	NA	0.96	11.01	0.59	5.47e-23	Exhaled nitric oxide levels;
SARC	cis	rs5753618	0.561	rs5753521	chr22:31638027	T/C	cg07713946	chr22:31675144	LIMK2	-0.38	-5.24	-0.32	3.54e-7	Colorectal cancer;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg17468841	chr3:105588020	CBLB	0.54	6.56	0.39	3.4e-10	Blood pressure;
SARC	cis	rs2048656	0.501	rs7464185	chr8:9460995	G/A	cg21625330	chr8:9911636	MSRA	-0.51	-4.88	-0.3	1.94e-6	Schizophrenia;
SARC	cis	rs526231	0.511	rs17154942	chr5:102352718	C/T	cg23492399	chr5:102201601	PAM	0.52	5.88	0.36	1.43e-8	Primary biliary cholangitis;
SARC	cis	rs8067545	0.641	rs203479	chr17:19829311	T/C	cg13482628	chr17:19912719	NA	0.54	6.84	0.41	6.97e-11	Schizophrenia;
SARC	cis	rs7927592	0.913	rs10896329	chr11:68250029	A/G	cg01657329	chr11:68192670	LRP5	-0.41	-4.96	-0.31	1.37e-6	Total body bone mineral density;
SARC	cis	rs80130819	0.688	rs6580660	chr12:48588112	T/C	cg24011408	chr12:48396354	COL2A1	0.55	6.09	0.37	4.73e-9	Prostate cancer;
SARC	cis	rs282587	0.597	rs450351	chr13:113394987	C/T	cg02820901	chr13:113351484	ATP11A	-0.5	-4.83	-0.3	2.51e-6	Glycated hemoglobin levels;
SARC	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	12.14	0.62	1.32e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs3749237	0.595	rs4955412	chr3:49418168	A/C	cg03060546	chr3:49711283	APEH	0.75	10.72	0.57	4.68e-22	Resting heart rate;
SARC	trans	rs7927370	1.000	rs56299119	chr11:55328348	A/T	cg07162727	chr16:4848039	ROGDI	0.83	6.4	0.39	8.25e-10	Systemic lupus erythematosus;
SARC	cis	rs35306767	0.623	rs36051896	chr10:1155747	T/C	cg18964960	chr10:1102726	WDR37	0.69	6.84	0.41	6.95e-11	Eosinophil percentage of granulocytes;
SARC	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.68	6.83	0.41	7.48e-11	Platelet count;
SARC	cis	rs8114671	0.562	rs6088621	chr20:33418740	C/T	cg07148914	chr20:33460835	GGT7	0.42	4.94	0.31	1.49e-6	Height;
SARC	cis	rs11997175	0.574	rs4364597	chr8:33653729	G/C	ch.8.33884649F	chr8:33765107	NA	0.48	6.45	0.39	6.25e-10	Body mass index;
SARC	cis	rs3020736	0.500	rs5996110	chr22:42493767	A/G	cg15557168	chr22:42548783	NA	0.35	4.8	0.3	2.85e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs710216	0.917	rs2297977	chr1:43415288	G/T	cg03128534	chr1:43423976	SLC2A1	0.65	6.77	0.41	1.04e-10	Red cell distribution width;
SARC	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.84	8.77	0.5	3.82e-16	Mean platelet volume;
SARC	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg08859206	chr1:53392774	SCP2	-0.44	-6.28	-0.38	1.6e-9	Monocyte count;
SARC	cis	rs637571	0.522	rs491973	chr11:65727301	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.58	9.2	0.52	2.11e-17	Eosinophil percentage of white cells;
SARC	cis	rs425277	1.000	rs1401138	chr1:2063149	C/T	cg24578937	chr1:2090814	PRKCZ	0.32	5.93	0.36	1.11e-8	Height;
SARC	cis	rs113835537	0.529	rs17495838	chr11:66196265	T/C	cg24851651	chr11:66362959	CCS	0.4	4.82	0.3	2.61e-6	Airway imaging phenotypes;
SARC	cis	rs6752107	1.000	rs13009506	chr2:234175706	A/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	-0.47	-6.48	-0.39	5.45e-10	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs11626933	0.851	rs2282031	chr14:90730943	A/G	cg14092571	chr14:90743983	NA	-0.53	-8.05	-0.47	4.2e-14	Gut microbiota (bacterial taxa);
SARC	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg18404041	chr3:52824283	ITIH1	-0.43	-6.43	-0.39	7.24e-10	Bipolar disorder;
SARC	cis	rs7654585	0.645	rs6828416	chr4:25933273	C/T	cg10409131	chr4:25915609	C4orf52	0.58	7.65	0.45	5.36e-13	Obesity-related traits;
SARC	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg02718654	chr19:40971802	SPTBN4;BLVRB	-0.55	-7.19	-0.43	8.83e-12	Parental extreme longevity (95 years and older);
SARC	cis	rs4727027	0.933	rs9718383	chr7:148857624	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.45	-5.52	-0.34	8.84e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs9788721	1.000	rs9788721	chr15:78802869	C/T	cg18825076	chr15:78729989	IREB2	0.43	5.17	0.32	5.13e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs2204008	0.774	rs11514062	chr12:38332297	A/C	cg13010199	chr12:38710504	ALG10B	0.77	10.22	0.56	1.71e-20	Bladder cancer;
SARC	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg25894440	chr7:65020034	NA	0.78	5.89	0.36	1.34e-8	Diabetic kidney disease;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg22848982	chr1:3697631	LRRC47	0.49	6.93	0.41	4.14e-11	Schizophrenia;
SARC	cis	rs4253772	0.550	rs6007761	chr22:46670394	C/T	cg24881330	chr22:46731750	TRMU	-0.62	-6.53	-0.39	4.14e-10	LDL cholesterol;Cholesterol, total;
SARC	cis	rs9814567	0.752	rs1880378	chr3:134330709	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.51	-6.61	-0.4	2.53e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs9788682	0.747	rs7177514	chr15:78907406	C/G	cg24631222	chr15:78858424	CHRNA5	0.71	9.74	0.54	4.9e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg06713675	chr4:122721982	EXOSC9	-0.53	-7.18	-0.43	9.25e-12	Type 2 diabetes;
SARC	cis	rs1448094	0.545	rs11117077	chr12:86277317	A/G	cg02569458	chr12:86230093	RASSF9	0.41	5.58	0.34	6.67e-8	Major depressive disorder;
SARC	cis	rs763121	0.785	rs5750646	chr22:39013830	T/C	cg06022373	chr22:39101656	GTPBP1	0.87	11.59	0.6	8.09e-25	Menopause (age at onset);
SARC	cis	rs73198271	0.740	rs10103163	chr8:8650675	T/C	cg06636001	chr8:8085503	FLJ10661	-0.48	-5.4	-0.33	1.65e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs908922	0.676	rs2146120	chr1:152504200	A/T	cg09873164	chr1:152488093	CRCT1	0.71	9.03	0.51	6.79e-17	Hair morphology;
SARC	cis	rs2997447	0.792	rs61775432	chr1:26416376	A/G	cg19633962	chr1:26362018	EXTL1	-0.67	-5.66	-0.35	4.41e-8	QRS complex (12-leadsum);
SARC	cis	rs6598955	0.670	rs10902734	chr1:26617923	G/T	cg04990556	chr1:26633338	UBXN11	0.59	8.16	0.47	2.04e-14	Obesity-related traits;
SARC	cis	rs9787249	0.957	rs7518431	chr1:40214944	C/T	cg19912559	chr1:40204330	PPIE	-0.4	-4.81	-0.3	2.67e-6	Blood protein levels;
SARC	cis	rs9399135	0.967	rs6569990	chr6:135365818	C/T	cg22676075	chr6:135203613	NA	0.34	4.75	0.3	3.59e-6	Red blood cell count;
SARC	cis	rs9911578	0.835	rs3744093	chr17:56492800	T/C	cg05425664	chr17:57184151	TRIM37	0.62	7.31	0.43	4.14e-12	Intelligence (multi-trait analysis);
SARC	cis	rs4642101	0.765	rs9872103	chr3:12827452	G/T	cg24848339	chr3:12840334	CAND2	0.32	4.92	0.31	1.63e-6	QRS complex (12-leadsum);
SARC	cis	rs2645694	0.626	rs12502590	chr4:77823642	G/A	cg10057126	chr4:77819792	ANKRD56	0.45	6.87	0.41	5.84e-11	Emphysema distribution in smoking;
SARC	cis	rs2645694	0.626	rs12502590	chr4:77823642	G/A	cg03477792	chr4:77819574	ANKRD56	0.5	7.62	0.45	6.49e-13	Emphysema distribution in smoking;
SARC	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg26924012	chr15:45694286	SPATA5L1	0.77	10.99	0.58	6.8e-23	Homoarginine levels;
SARC	cis	rs11997175	0.550	rs6468206	chr8:33780878	A/C	ch.8.33884649F	chr8:33765107	NA	0.44	5.79	0.35	2.29e-8	Body mass index;
SARC	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg26513180	chr16:89883248	FANCA	0.74	4.78	0.3	3.11e-6	Skin colour saturation;
SARC	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg16680214	chr1:154839983	KCNN3	-0.36	-5.61	-0.34	5.7e-8	Prostate cancer;
SARC	cis	rs6963495	0.606	rs6969426	chr7:105147150	G/A	cg13798780	chr7:105162888	PUS7	0.61	5.75	0.35	2.79e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs80130819	0.688	rs2732475	chr12:48700754	G/C	cg24011408	chr12:48396354	COL2A1	0.52	5.89	0.36	1.32e-8	Prostate cancer;
SARC	cis	rs2997447	0.846	rs3008231	chr1:26402023	A/G	cg19633962	chr1:26362018	EXTL1	-0.57	-5.3	-0.33	2.69e-7	QRS complex (12-leadsum);
SARC	cis	rs67460515	0.563	rs73023235	chr3:160864123	G/A	cg04691961	chr3:161091175	C3orf57	-0.42	-5.01	-0.31	1.07e-6	Parkinson's disease;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg26877631	chr10:21823297	MLLT10	-0.5	-6.27	-0.38	1.69e-9	Schizophrenia;
SARC	cis	rs1059312	1.000	rs7136092	chr12:129280164	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.48	-5.86	-0.36	1.56e-8	Systemic lupus erythematosus;
SARC	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.95	13.39	0.66	1.09e-30	Gut microbiome composition (summer);
SARC	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg21644426	chr2:191273491	MFSD6	-0.5	-6.67	-0.4	1.8e-10	Pulse pressure;
SARC	cis	rs67460515	0.892	rs11711413	chr3:160998910	C/G	cg17135325	chr3:160939158	NMD3	0.63	7.94	0.46	8.49e-14	Parkinson's disease;
SARC	cis	rs2731664	0.756	rs4976695	chr5:176862963	T/A	cg23176889	chr5:176863531	GRK6	-0.56	-8.21	-0.47	1.53e-14	Intelligence (multi-trait analysis);
SARC	cis	rs7666738	0.830	rs34135615	chr4:99001325	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4975616	0.869	rs452932	chr5:1330253	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.58	-8.61	-0.49	1.11e-15	Lung cancer;
SARC	cis	rs1008375	0.897	rs4334752	chr4:17615430	C/T	cg27347728	chr4:17578864	LAP3	0.45	5.51	0.34	9.39e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs2727020	0.514	rs4980444	chr11:49550764	T/A	cg03929089	chr4:120376271	NA	-0.75	-11.2	-0.59	1.4e-23	Coronary artery disease;
SARC	cis	rs9400467	0.537	rs78080415	chr6:111537016	T/C	cg15721981	chr6:111408429	SLC16A10	0.68	5.72	0.35	3.24e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg22484793	chr3:52261325	TLR9	0.29	4.8	0.3	2.81e-6	Bipolar disorder;
SARC	cis	rs3540	0.597	rs12708583	chr15:91050271	C/T	cg22089800	chr15:90895588	ZNF774	0.6	7.79	0.45	2.26e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg08859206	chr1:53392774	SCP2	0.39	5.65	0.35	4.74e-8	Monocyte count;
SARC	cis	rs11098499	0.909	rs79026312	chr4:120440677	C/A	cg09307838	chr4:120376055	NA	0.92	12.26	0.63	5.54e-27	Corneal astigmatism;
SARC	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg20607798	chr8:58055168	NA	0.72	5.84	0.36	1.71e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7586879	0.593	rs10198356	chr2:25130592	A/G	cg04586622	chr2:25135609	ADCY3	0.31	5.18	0.32	4.82e-7	Body mass index;
SARC	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-8.27	-0.48	1.05e-14	Chronic sinus infection;
SARC	cis	rs6964587	1.000	rs7806184	chr7:91601978	A/G	cg17063962	chr7:91808500	NA	0.95	15.95	0.72	3.15e-39	Breast cancer;
SARC	cis	rs2204008	0.527	rs1315367	chr12:38177487	G/T	cg14851346	chr12:38532713	NA	-0.43	-5.14	-0.32	5.87e-7	Bladder cancer;
SARC	cis	rs10916814	0.588	rs4571937	chr1:20897033	G/A	cg24502330	chr1:20914028	CDA	-0.3	-5.16	-0.32	5.26e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs7429990	0.965	rs35689209	chr3:48119763	A/G	cg11946769	chr3:48343235	NME6	-0.46	-5.32	-0.33	2.46e-7	Educational attainment (years of education);
SARC	cis	rs6807306	1.000	rs6444571	chr3:167439397	T/C	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.55	5.46	0.34	1.22e-7	Mean platelet volume;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg26336277	chr3:197476294	FYTTD1;KIAA0226	-0.55	-6.96	-0.41	3.35e-11	Gallstone disease;
SARC	cis	rs4481887	1.000	rs4457616	chr1:248492198	A/G	cg00666640	chr1:248458726	OR2T12	0.4	6.64	0.4	2.15e-10	Common traits (Other);
SARC	cis	rs473651	0.904	rs508274	chr2:239337723	G/A	cg21699342	chr2:239360505	ASB1	0.49	7.2	0.43	8.26e-12	Multiple system atrophy;
SARC	cis	rs9814567	1.000	rs9850015	chr3:134269541	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.08	-0.42	1.73e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs9467773	1.000	rs9461259	chr6:26504835	C/A	cg11502198	chr6:26597334	ABT1	0.48	5.98	0.36	8.37e-9	Intelligence (multi-trait analysis);
SARC	cis	rs9303401	0.659	rs35928756	chr17:56702652	C/T	cg25039879	chr17:56429692	SUPT4H1	0.69	6.55	0.39	3.71e-10	Cognitive test performance;
SARC	cis	rs8028182	0.636	rs62027181	chr15:75839952	A/G	cg20655648	chr15:75932815	IMP3	0.61	7.17	0.43	9.98e-12	Sudden cardiac arrest;
SARC	cis	rs9344	0.806	rs2450255	chr11:69452358	T/C	cg26123414	chr11:69490316	ORAOV1	-0.37	-4.91	-0.31	1.68e-6	Immunoglobulin light chain (AL) amyloidosis (kidney involvement);Immunoglobulin light chain (AL) amyloidosis (serum Ig light chain only lambda/kappa based profile);Immunoglobulin light chain (AL) amyloidosis;Immunoglobulin light chain (AL) amyloidosis (heart involvement);Immunoglobulin light chain (AL) amyloidosis (serum Ig light chain only lambda based profile);Immunoglobulin light chain (AL) amyloidosis (serum Ig lambda profile);
SARC	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg11742103	chr11:62369870	EML3;MTA2	0.4	6.21	0.38	2.44e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg03806693	chr22:41940476	POLR3H	-0.83	-11.48	-0.6	1.82e-24	Vitiligo;
SARC	cis	rs6942407	0.744	rs6980450	chr7:86861201	C/G	cg02420886	chr7:86849541	C7orf23	0.57	5.11	0.32	6.79e-7	Food allergy;
SARC	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg08219700	chr8:58056026	NA	0.49	5.01	0.31	1.07e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	5.08	0.32	7.65e-7	Personality dimensions;
SARC	cis	rs5753037	0.543	rs140119	chr22:30138149	A/T	cg01021169	chr22:30184971	ASCC2	-0.51	-6.85	-0.41	6.42e-11	Type 1 diabetes;
SARC	cis	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg00800038	chr16:89945340	TCF25	-0.79	-5.44	-0.34	1.32e-7	Skin colour saturation;
SARC	cis	rs11847263	0.525	rs1256536	chr14:65762476	A/G	cg15999311	chr14:65749247	NA	0.34	5.39	0.33	1.69e-7	IgG monogalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG digalactosylation phenotypes (multivariate analysis);IgG monosialylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG glycosylation;
SARC	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg10295955	chr4:187884368	NA	1.1	21.07	0.81	6.88e-56	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7766436	0.885	rs10946567	chr6:22581302	T/C	cg13666174	chr6:22585274	NA	-0.6	-7.74	-0.45	3.04e-13	Coronary artery disease;
SARC	cis	rs8141529	0.748	rs1318026	chr22:29283518	A/G	cg15103426	chr22:29168792	CCDC117	0.66	8.64	0.49	9.17e-16	Lymphocyte counts;
SARC	cis	rs73206853	0.764	rs56838584	chr12:110666136	A/G	cg10860002	chr12:110842031	ANAPC7	0.64	5.24	0.32	3.54e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs6964587	0.967	rs10279943	chr7:91587477	G/C	cg17063962	chr7:91808500	NA	0.95	15.95	0.72	3.15e-39	Breast cancer;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg19372772	chr2:264904	ACP1;SH3YL1	0.51	6.47	0.39	5.63e-10	Lung adenocarcinoma;
SARC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg01516881	chr6:292596	DUSP22	-0.63	-7.84	-0.46	1.62e-13	Menopause (age at onset);
SARC	trans	rs1941687	0.524	rs6507062	chr18:31374197	G/C	cg27147174	chr7:100797783	AP1S1	-0.55	-6.89	-0.41	5.07e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
SARC	cis	rs240764	0.594	rs9403997	chr6:101163433	A/C	cg09795085	chr6:101329169	ASCC3	0.4	4.94	0.31	1.46e-6	Neuroticism;
SARC	cis	rs2011503	1.000	rs11669558	chr19:19655670	C/T	cg03709012	chr19:19516395	GATAD2A	0.59	5.12	0.32	6.49e-7	Bipolar disorder;
SARC	cis	rs2652834	0.861	rs4774472	chr15:63353760	C/A	cg05507819	chr15:63340323	TPM1	0.67	6.97	0.42	3.27e-11	HDL cholesterol;
SARC	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	11.57	0.6	9.26e-25	Alzheimer's disease;
SARC	cis	rs883565	0.569	rs1298712	chr3:39169693	A/G	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.47	-5.56	-0.34	7.19e-8	Handedness;
SARC	cis	rs12893668	0.703	rs729438	chr14:104092789	A/G	cg24130564	chr14:104152367	KLC1	0.45	5.32	0.33	2.49e-7	Reticulocyte count;
SARC	cis	rs2153535	0.580	rs6597337	chr6:8531652	C/T	cg07606381	chr6:8435919	SLC35B3	0.76	10.99	0.58	6.38e-23	Motion sickness;
SARC	cis	rs2718058	0.519	rs2598054	chr7:37884640	C/T	cg15028436	chr7:37888078	TXNDC3	0.44	5.63	0.35	5.06e-8	Alzheimer's disease (late onset);
SARC	cis	rs9815354	0.812	rs17217746	chr3:41926021	A/G	cg03022575	chr3:42003672	ULK4	0.69	5.65	0.35	4.69e-8	Pulse pressure;Diastolic blood pressure;
SARC	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg22968622	chr17:43663579	NA	1.01	12.58	0.64	4.83e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg21171335	chr12:122356390	WDR66	0.4	6.03	0.37	6.46e-9	Mean corpuscular volume;
SARC	cis	rs9916302	0.706	rs4795358	chr17:37573065	A/C	cg20243544	chr17:37824526	PNMT	0.54	5.61	0.35	5.69e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs1153858	1.000	rs4774579	chr15:45651803	G/A	cg21132104	chr15:45694354	SPATA5L1	0.77	10.99	0.58	6.68e-23	Homoarginine levels;
SARC	cis	rs2204008	0.837	rs4432085	chr12:38181146	C/T	cg13010199	chr12:38710504	ALG10B	0.78	10.64	0.57	8.61e-22	Bladder cancer;
SARC	cis	rs6866344	0.568	rs10516147	chr5:178094484	A/G	cg10224037	chr5:178157518	ZNF354A	0.83	9.49	0.53	2.94e-18	Neutrophil percentage of white cells;
SARC	cis	rs6674176	0.628	rs2301993	chr1:44426025	G/A	cg12908607	chr1:44402522	ARTN	-0.37	-6.32	-0.38	1.32e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs7779181	0.556	rs7780609	chr7:32341916	G/A	cg16719466	chr7:32338569	NA	-0.62	-5.45	-0.34	1.3e-7	Body mass index;
SARC	cis	rs4780401	0.678	rs7193441	chr16:11764821	C/T	cg01061890	chr16:11836724	TXNDC11	-0.45	-5.84	-0.36	1.76e-8	Rheumatoid arthritis;
SARC	cis	rs950776	0.714	rs17408276	chr15:78881618	T/C	cg06917634	chr15:78832804	PSMA4	0.78	10.51	0.57	2.16e-21	Sudden cardiac arrest;
SARC	cis	rs4242434	0.819	rs751680	chr8:22475627	G/A	cg03733263	chr8:22462867	KIAA1967	0.98	16.31	0.73	2.12e-40	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs7681440	0.904	rs28750169	chr4:90774303	A/G	cg02192967	chr4:90758406	SNCA	0.37	5.26	0.33	3.22e-7	Dementia with Lewy bodies;
SARC	cis	rs7005606	0.874	rs4733128	chr8:32406602	C/T	cg14488905	chr8:32406789	NRG1	0.45	6.31	0.38	1.42e-9	Hirschsprung disease;
SARC	cis	rs698813	0.674	rs6544753	chr2:44501895	A/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	6.1	0.37	4.46e-9	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs765787	0.530	rs11854690	chr15:45516016	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.43	-5.39	-0.33	1.73e-7	Uric acid levels;
SARC	cis	rs1008375	0.898	rs7670500	chr4:17586957	A/G	cg02297831	chr4:17616191	MED28	0.49	6.22	0.38	2.31e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	16.13	0.73	8.11e-40	Chronic sinus infection;
SARC	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg24531977	chr5:56204891	C5orf35	-0.48	-5.06	-0.31	8.51e-7	Initial pursuit acceleration;
SARC	cis	rs12042938	0.622	rs11122318	chr1:231806852	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.56	7.31	0.43	4.23e-12	Neuranatomic and neurocognitive phenotypes;
SARC	cis	rs9309473	0.500	rs4852952	chr2:73869907	T/C	cg20560298	chr2:73613845	ALMS1	0.46	6.14	0.37	3.44e-9	Metabolite levels;
SARC	cis	rs2228479	0.702	rs17177891	chr16:89799950	C/T	cg06558623	chr16:89946397	TCF25	0.86	5.86	0.36	1.55e-8	Skin colour saturation;
SARC	cis	rs7560272	0.502	rs13013228	chr2:73925216	G/A	cg20560298	chr2:73613845	ALMS1	0.46	6.12	0.37	4e-9	Schizophrenia;
SARC	cis	rs3733585	0.673	rs4459990	chr4:9954005	T/C	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.94	-0.36	1.06e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs9393692	0.905	rs9358919	chr6:26287862	C/T	cg00631329	chr6:26305371	NA	-0.6	-8.58	-0.49	1.31e-15	Educational attainment;
SARC	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg23758822	chr17:41437982	NA	0.89	11.4	0.6	3.2e-24	Menopause (age at onset);
SARC	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg08280861	chr8:58055591	NA	-0.57	-4.87	-0.3	2.1e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs73198271	0.601	rs11997731	chr8:8649848	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-5.58	-0.34	6.53e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg05872129	chr22:39784769	NA	-0.44	-6.19	-0.38	2.72e-9	Intelligence (multi-trait analysis);
SARC	cis	rs2549003	1.000	rs9282761	chr5:131822224	T/C	cg21138405	chr5:131827807	IRF1	0.27	5.32	0.33	2.4e-7	Asthma (sex interaction);
SARC	cis	rs7566780	0.516	rs7566990	chr2:16668723	T/C	cg09580478	chr2:16689509	NA	0.55	6.82	0.41	7.65e-11	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs10504229	0.679	rs1596142	chr8:58032406	G/A	cg20607798	chr8:58055168	NA	0.57	5.29	0.33	2.84e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9921222	0.521	rs62032884	chr16:363415	C/T	cg12437481	chr16:420112	MRPL28	-0.39	-5.22	-0.32	3.88e-7	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg19223190	chr17:80058835	NA	0.44	6.19	0.38	2.67e-9	Life satisfaction;
SARC	cis	rs56116382	0.605	rs12715435	chr3:49338992	G/A	cg00383909	chr3:49044727	WDR6	0.54	5.5	0.34	1.02e-7	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
SARC	cis	rs4481887	0.893	rs6702113	chr1:248486151	T/C	cg00666640	chr1:248458726	OR2T12	0.37	6.02	0.37	6.83e-9	Common traits (Other);
SARC	cis	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg08564027	chr20:61660810	NA	0.76	11.57	0.6	9.45e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs10463554	0.892	rs17154859	chr5:102290912	A/C	cg23492399	chr5:102201601	PAM	0.46	5.55	0.34	7.85e-8	Parkinson's disease;
SARC	cis	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg20965017	chr5:231967	SDHA	-0.55	-5.26	-0.33	3.23e-7	Breast cancer;
SARC	cis	rs7481584	0.624	rs449466	chr11:3047603	C/T	cg25174290	chr11:3078921	CARS	-0.59	-8.27	-0.48	1.02e-14	Calcium levels;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg12048536	chr14:76044591	FLVCR2	0.51	6.75	0.4	1.15e-10	Tetralogy of Fallot;
SARC	cis	rs7953249	0.656	rs2243616	chr12:121406370	G/T	cg25281562	chr12:121454272	C12orf43	-0.48	-5.9	-0.36	1.29e-8	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs10078	0.559	rs2671891	chr5:456386	A/G	cg26072250	chr5:443457	EXOC3;C5orf55	0.69	5.77	0.35	2.52e-8	Fat distribution (HIV);
SARC	cis	rs35110281	0.715	rs2838353	chr21:45119228	C/T	cg21573476	chr21:45109991	RRP1B	-0.58	-8.57	-0.49	1.48e-15	Mean corpuscular volume;
SARC	trans	rs61931739	0.534	rs4086956	chr12:34105047	A/T	cg13010199	chr12:38710504	ALG10B	0.67	8.91	0.5	1.51e-16	Morning vs. evening chronotype;
SARC	trans	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.74	-0.4	1.25e-10	Neuroticism;
SARC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg22105103	chr4:187893119	NA	0.47	6.14	0.37	3.5e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6908034	0.607	rs112824001	chr6:19804691	C/T	cg02682789	chr6:19804855	NA	0.71	5.1	0.32	7.14e-7	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs10992471	0.756	rs1121979	chr9:95140218	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-6.69	-0.4	1.67e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs7552404	0.691	rs61770550	chr1:76366966	C/T	cg10523679	chr1:76189770	ACADM	0.45	5.29	0.33	2.83e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg26681399	chr22:41777847	TEF	0.43	4.92	0.31	1.67e-6	Vitiligo;
SARC	cis	rs3540	0.618	rs2301832	chr15:91040725	A/T	cg22089800	chr15:90895588	ZNF774	-0.64	-8.11	-0.47	2.88e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs787274	1.000	rs7041965	chr9:115598341	T/G	cg13803584	chr9:115635662	SNX30	-0.83	-5.03	-0.31	9.96e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs921968	0.643	rs524902	chr2:219433357	A/C	cg02176678	chr2:219576539	TTLL4	0.37	5.49	0.34	1.02e-7	Mean corpuscular hemoglobin concentration;
SARC	trans	rs9929218	1.000	rs12443730	chr16:68804342	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.52	-6.72	-0.4	1.36e-10	Colorectal cancer;
SARC	cis	rs995000	0.929	rs12038768	chr1:63040728	G/T	cg06896770	chr1:63153194	DOCK7	1.0	15.5	0.71	1.02e-37	Triglyceride levels;
SARC	cis	rs11792861	0.962	rs72607161	chr9:111792640	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.68	7.78	0.45	2.34e-13	Menarche (age at onset);
SARC	cis	rs4423214	1.000	rs11606631	chr11:71164121	C/A	cg05163923	chr11:71159392	DHCR7	0.65	8.66	0.49	8.18e-16	Vitamin D levels;
SARC	cis	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg14541582	chr5:601475	NA	-0.39	-4.92	-0.31	1.66e-6	Obesity-related traits;
SARC	cis	rs4889855	0.556	rs74003969	chr17:78526212	C/T	cg17956530	chr17:78667699	RPTOR	0.43	4.87	0.3	2.1e-6	Fractional excretion of uric acid;
SARC	cis	rs1729951	0.575	rs16844325	chr3:136678161	C/G	cg15507776	chr3:136538369	TMEM22	0.52	5.76	0.35	2.66e-8	Neuroticism;
SARC	cis	rs9486719	1.000	rs4077932	chr6:96905144	C/T	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.01	-0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	trans	rs7613875	0.580	rs3774745	chr3:50204745	C/T	cg21659725	chr3:3221576	CRBN	-0.5	-6.28	-0.38	1.66e-9	Body mass index;
SARC	cis	rs6696846	0.515	rs6593924	chr1:205110452	A/G	cg21643547	chr1:205240462	TMCC2	-0.48	-5.88	-0.36	1.43e-8	Red blood cell count;
SARC	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg16606324	chr3:10149918	C3orf24	0.48	5.04	0.31	9.53e-7	Alzheimer's disease;
SARC	cis	rs7786877	0.723	rs10487157	chr7:100214487	C/G	cg20848291	chr7:100343083	ZAN	-0.61	-6.11	-0.37	4.08e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs6964587	0.692	rs10236483	chr7:91797296	A/C	cg17063962	chr7:91808500	NA	0.8	12.31	0.63	3.7e-27	Breast cancer;
SARC	trans	rs34421088	0.559	rs12386974	chr8:11400628	C/G	cg15556689	chr8:8085844	FLJ10661	0.52	6.79	0.41	9.01e-11	Neuroticism;
SARC	cis	rs7224737	1.000	rs9889640	chr17:40293497	C/T	cg20291162	chr17:40259547	DHX58	-0.33	-4.85	-0.3	2.24e-6	Fibrinogen levels;
SARC	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg04267008	chr7:1944627	MAD1L1	-0.57	-6.46	-0.39	6.21e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg11366901	chr6:160182831	ACAT2	-0.59	-6.03	-0.37	6.53e-9	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs35213789	0.768	rs12698816	chr7:69386161	T/C	cg10619644	chr7:69149951	AUTS2	0.38	4.78	0.3	3.15e-6	Childhood ear infection;
SARC	cis	rs2011503	1.000	rs4808968	chr19:19644402	C/T	cg03709012	chr19:19516395	GATAD2A	0.6	5.29	0.33	2.8e-7	Bipolar disorder;
SARC	cis	rs3733585	0.605	rs56178126	chr4:10123581	C/T	cg00071950	chr4:10020882	SLC2A9	-0.4	-5.85	-0.36	1.65e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs11874712	1.000	rs1800637	chr18:43670190	T/C	cg25174615	chr18:43684699	ATP5A1;HAUS1	0.4	4.75	0.3	3.52e-6	Migraine - clinic-based;
SARC	cis	rs13191362	1.000	rs34653853	chr6:163114362	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.74	6.43	0.39	7.21e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs7772486	0.754	rs697053	chr6:145989807	T/C	cg05347473	chr6:146136440	FBXO30	-0.55	-7.63	-0.45	5.87e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2213920	0.522	rs9284057	chr9:118241947	C/T	cg13918206	chr9:118159781	DEC1	0.45	4.86	0.3	2.13e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs14978	0.958	rs12699335	chr7:12277020	T/C	cg23422036	chr7:12250390	TMEM106B	0.42	4.87	0.3	2.08e-6	Response to amphetamines;
SARC	cis	rs8141529	0.732	rs5762788	chr22:29174770	G/T	cg15103426	chr22:29168792	CCDC117	0.66	8.9	0.5	1.63e-16	Lymphocyte counts;
SARC	cis	rs2290402	0.536	rs45486093	chr4:875671	T/C	cg00846425	chr4:957561	DGKQ	-0.43	-5.02	-0.31	1.02e-6	Type 2 diabetes;
SARC	cis	rs35110281	0.626	rs10854486	chr21:45118280	G/T	cg01579765	chr21:45077557	HSF2BP	-0.33	-5.19	-0.32	4.66e-7	Mean corpuscular volume;
SARC	cis	rs10911232	0.507	rs7515822	chr1:183037803	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.1	0.55	3.88e-20	Hypertriglyceridemia;
SARC	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg12463550	chr7:65579703	CRCP	-0.7	-5.31	-0.33	2.51e-7	Diabetic kidney disease;
SARC	cis	rs6570726	0.516	rs10484700	chr6:145728933	C/T	cg23711669	chr6:146136114	FBXO30	0.57	7.61	0.45	6.82e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg08859206	chr1:53392774	SCP2	-0.39	-5.59	-0.34	6.49e-8	Monocyte count;
SARC	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.77	11.13	0.59	2.33e-23	Personality dimensions;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg26567249	chr8:97247842	UQCRB	-0.62	-7.09	-0.42	1.55e-11	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs2213920	0.679	rs7860135	chr9:118242257	G/A	cg13918206	chr9:118159781	DEC1	0.74	5.9	0.36	1.26e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	0.77	7.93	0.46	8.91e-14	Alzheimer's disease;
SARC	cis	rs2842992	0.747	rs4709378	chr6:160227435	G/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.81	7.45	0.44	1.82e-12	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.39	-4.76	-0.3	3.4e-6	Lymphocyte counts;
SARC	cis	rs644799	0.648	rs1255176	chr11:95471465	A/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.48	5.94	0.36	1.02e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs929354	0.772	rs1182365	chr7:157017255	A/T	cg05182265	chr7:156933206	UBE3C	0.31	4.79	0.3	2.93e-6	Body mass index;
SARC	cis	rs7481584	0.961	rs729662	chr11:3028140	G/A	cg05729581	chr11:3078854	CARS	0.48	5.78	0.35	2.34e-8	Calcium levels;
SARC	cis	rs3126085	0.935	rs1390487	chr1:152194601	G/A	cg26876637	chr1:152193138	HRNR	0.5	5.75	0.35	2.83e-8	Atopic dermatitis;
SARC	cis	rs7635838	0.859	rs9875414	chr3:11453559	A/G	cg00170343	chr3:11313890	ATG7	0.63	8.5	0.49	2.28e-15	HDL cholesterol;
SARC	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg20965017	chr5:231967	SDHA	-0.56	-5.3	-0.33	2.71e-7	Breast cancer;
SARC	cis	rs6456042	0.893	rs3099312	chr6:166557339	T/C	cg11088901	chr6:166572345	T	-0.34	-4.87	-0.3	2.03e-6	Asthma;
SARC	cis	rs9916302	0.851	rs11078907	chr17:37662954	C/T	cg00129232	chr17:37814104	STARD3	-0.64	-7.93	-0.46	8.9e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs17376456	0.877	rs28418572	chr5:93144161	A/C	cg25358565	chr5:93447407	FAM172A	1.2	12.22	0.62	7.24e-27	Diabetic retinopathy;
SARC	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg18230493	chr5:56204884	C5orf35	0.59	5.39	0.33	1.74e-7	Initial pursuit acceleration;
SARC	cis	rs9397240	0.841	rs9384309	chr6:155620226	G/C	cg07943832	chr6:155568918	TIAM2	-0.56	-5.45	-0.34	1.31e-7	Life satisfaction;
SARC	cis	rs826838	1.000	rs826891	chr12:39100824	A/G	cg13010199	chr12:38710504	ALG10B	-0.65	-9.26	-0.52	1.44e-17	Heart rate;
SARC	cis	rs2070488	0.636	rs2284817	chr3:38510388	A/G	cg27533700	chr3:38537683	EXOG	-0.42	-5.26	-0.33	3.3e-7	Electrocardiographic conduction measures;
SARC	cis	rs7659604	0.540	rs9995322	chr4:122675642	G/A	cg19671926	chr4:122722719	EXOSC9	0.55	6.99	0.42	2.87e-11	Type 2 diabetes;
SARC	cis	rs3093024	1.000	rs3093023	chr6:167534290	A/G	cg23791538	chr6:167370224	RNASET2	0.38	4.75	0.3	3.49e-6	Rheumatoid arthritis;
SARC	cis	rs7647973	0.731	rs9831648	chr3:49214303	G/T	cg06212747	chr3:49208901	KLHDC8B	0.85	9.02	0.51	7.23e-17	Menarche (age at onset);
SARC	trans	rs208520	0.690	rs2144081	chr6:66824972	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-13.6	-0.67	2.17e-31	Exhaled nitric oxide output;
SARC	cis	rs11574514	1.000	rs117875362	chr16:67909448	C/T	cg01866162	chr16:67596514	CTCF	1.11	6.4	0.39	8.22e-10	Crohn's disease;
SARC	cis	rs17001868	0.568	rs760700	chr22:40800071	C/T	cg07138101	chr22:40742427	ADSL	-0.52	-5.78	-0.35	2.36e-8	Mammographic density (dense area);
SARC	cis	rs7223966	1.000	rs113134232	chr17:61715461	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	6.38	0.39	9.28e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs5753037	0.615	rs131279	chr22:30155251	G/C	cg01021169	chr22:30184971	ASCC2	-0.45	-6.31	-0.38	1.39e-9	Type 1 diabetes;
SARC	cis	rs1865760	0.566	rs9467672	chr6:26083904	C/T	cg17691542	chr6:26056736	HIST1H1C	0.52	6.41	0.39	8.05e-10	Height;
SARC	cis	rs7552404	0.691	rs1770890	chr1:76401117	A/G	cg03433033	chr1:76189801	ACADM	-0.45	-5.6	-0.34	6.03e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7666738	0.830	rs13125537	chr4:98978428	A/G	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs858239	0.600	rs10237755	chr7:23131564	A/G	cg23682824	chr7:23144976	KLHL7	0.71	9.6	0.53	1.34e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg22875332	chr1:76189707	ACADM	0.49	6.62	0.4	2.42e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs477692	0.647	rs11016853	chr10:131443990	A/G	cg05714579	chr10:131428358	MGMT	-0.58	-7.5	-0.44	1.36e-12	Response to temozolomide;
SARC	cis	rs751728	0.605	rs1535950	chr6:33785827	A/G	cg15252951	chr6:33757062	LEMD2	0.44	5.02	0.31	1.01e-6	Crohn's disease;
SARC	cis	rs13144136	0.687	rs13128842	chr4:10661991	T/A	cg10242279	chr4:10666415	CLNK	-0.45	-7.56	-0.44	8.99e-13	Resistance to antihypertensive treatment in hypertension;
SARC	cis	rs7011049	0.908	rs79560601	chr8:53853614	C/T	cg26025543	chr8:53854495	NA	0.61	5.41	0.33	1.53e-7	Systolic blood pressure;
SARC	cis	rs62064224	0.791	rs72811096	chr17:30647302	A/T	cg25809561	chr17:30822961	MYO1D	0.37	5.28	0.33	2.92e-7	Schizophrenia;
SARC	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg12463550	chr7:65579703	CRCP	-0.47	-5.28	-0.33	3.03e-7	Aortic root size;
SARC	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg11987759	chr7:65425863	GUSB	-0.58	-7.98	-0.46	6.46e-14	Calcium levels;
SARC	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg05863683	chr7:1912471	MAD1L1	0.34	4.89	0.31	1.88e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs6500395	1.000	rs1486411	chr16:48587083	T/C	cg04672837	chr16:48644449	N4BP1	0.44	5.82	0.36	1.9e-8	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs7681440	0.517	rs2619352	chr4:90747709	C/T	cg06632027	chr4:90757378	SNCA	-0.43	-5.32	-0.33	2.4e-7	Dementia with Lewy bodies;
SARC	cis	rs1008375	0.966	rs6839660	chr4:17667987	C/T	cg27347728	chr4:17578864	LAP3	0.45	5.6	0.34	6.06e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg02733842	chr7:1102375	C7orf50	-0.43	-5.4	-0.33	1.64e-7	Bronchopulmonary dysplasia;
SARC	cis	rs7586879	0.681	rs6705446	chr2:25118608	T/C	cg04586622	chr2:25135609	ADCY3	0.33	5.67	0.35	4.12e-8	Body mass index;
SARC	cis	rs986417	0.901	rs10151423	chr14:60996667	A/G	cg27398547	chr14:60952738	C14orf39	1.01	9.69	0.54	6.93e-19	Gut microbiota (bacterial taxa);
SARC	cis	rs9796	0.866	rs692155	chr15:41407061	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.45	-6.13	-0.37	3.66e-9	Menopause (age at onset);
SARC	cis	rs9462027	0.628	rs2814968	chr6:34713138	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.4	-5.7	-0.35	3.67e-8	Systemic lupus erythematosus;
SARC	cis	rs4595586	0.545	rs12812750	chr12:39363258	C/T	cg13010199	chr12:38710504	ALG10B	0.41	4.76	0.3	3.46e-6	Morning vs. evening chronotype;
SARC	cis	rs1044826	1.000	rs34623690	chr3:139194385	A/G	cg15131784	chr3:139108705	COPB2	0.45	5.19	0.32	4.69e-7	Obesity-related traits;
SARC	cis	rs7103648	1.000	rs12292911	chr11:47449072	C/T	cg10504702	chr11:47789108	FNBP4	0.6	7.66	0.45	5.03e-13	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs7224737	1.000	rs7219220	chr17:40294280	T/C	cg20291162	chr17:40259547	DHX58	-0.33	-4.87	-0.3	2.1e-6	Fibrinogen levels;
SARC	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	7.77	0.45	2.56e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.49	5.63	0.35	5.2e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs2645694	0.626	rs2703143	chr4:77830441	A/G	cg06046430	chr4:77819534	ANKRD56	0.48	6.83	0.41	7.24e-11	Emphysema distribution in smoking;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg05382772	chr11:65686513	DRAP1;C11orf68	0.57	6.99	0.42	2.87e-11	Blood pressure;
SARC	cis	rs17023223	0.537	rs1057991	chr1:119575170	C/A	cg05756136	chr1:119680316	WARS2	-0.45	-5.44	-0.34	1.35e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs12824058	0.831	rs11616174	chr12:130814503	A/G	cg24838063	chr12:130822603	PIWIL1	0.63	9.04	0.51	6.29e-17	Menopause (age at onset);
SARC	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	10.86	0.58	1.6400000000000001e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7647973	0.626	rs9829155	chr3:49817450	T/C	cg03060546	chr3:49711283	APEH	-0.63	-6.63	-0.4	2.28e-10	Menarche (age at onset);
SARC	cis	rs7149242	0.696	rs7141210	chr14:101182470	T/C	cg18089426	chr14:101175970	NA	-0.42	-5.86	-0.36	1.58e-8	Platelet count;
SARC	cis	rs5167	0.506	rs7257916	chr19:45482884	T/C	cg09555818	chr19:45449301	APOC2	-0.61	-9.96	-0.55	1.07e-19	Blood protein levels;
SARC	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg12463550	chr7:65579703	CRCP	-0.49	-5.83	-0.36	1.79e-8	Aortic root size;
SARC	cis	rs13256369	0.755	rs12680167	chr8:8562467	A/G	cg17143192	chr8:8559678	CLDN23	0.52	5.75	0.35	2.75e-8	Obesity-related traits;
SARC	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs617219	0.613	rs10072296	chr5:78594870	T/C	cg24856658	chr5:78533917	JMY	0.3	4.75	0.3	3.55e-6	Betaine levels in individuals undergoing cardiac evaluation;
SARC	cis	rs3857536	0.813	rs6903678	chr6:66931208	C/T	cg07460842	chr6:66804631	NA	0.44	5.22	0.32	4e-7	Blood trace element (Cu levels);
SARC	cis	rs6582630	0.519	rs11495376	chr12:38284957	A/C	cg13010199	chr12:38710504	ALG10B	0.79	11.02	0.59	5.26e-23	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7582180	0.652	rs11675901	chr2:100951189	G/A	cg14675211	chr2:100938903	LONRF2	0.51	7.48	0.44	1.49e-12	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	11.64	0.61	5.7e-25	Alzheimer's disease;
SARC	cis	rs2635047	0.638	rs1434529	chr18:44730142	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	6.13	0.37	3.75e-9	Educational attainment;
SARC	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg21017887	chr14:105400489	NA	0.53	7.5	0.44	1.3e-12	Rheumatoid arthritis;
SARC	cis	rs1483890	1.000	rs1483890	chr3:69410725	A/G	cg22125112	chr3:69402811	FRMD4B	0.3	5.05	0.31	9.04e-7	Resting heart rate;
SARC	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg09455208	chr3:40491958	NA	0.37	5.56	0.34	7.43e-8	Renal cell carcinoma;
SARC	trans	rs2727020	0.553	rs4103567	chr11:49255389	C/T	cg03929089	chr4:120376271	NA	-0.55	-7.38	-0.44	2.78e-12	Coronary artery disease;
SARC	cis	rs5758511	0.680	rs1107553	chr22:42667473	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.44	6.5	0.39	4.73e-10	Birth weight;
SARC	cis	rs9611565	0.525	rs9611548	chr22:41704143	G/T	cg17376030	chr22:41985996	PMM1	0.59	7.12	0.42	1.3e-11	Vitiligo;
SARC	cis	rs1448094	0.522	rs12313658	chr12:86271063	C/T	cg02569458	chr12:86230093	RASSF9	0.39	5.38	0.33	1.81e-7	Major depressive disorder;
SARC	cis	rs9911578	0.967	rs4076229	chr17:56937256	C/T	cg05425664	chr17:57184151	TRIM37	-0.65	-8.01	-0.46	5.44e-14	Intelligence (multi-trait analysis);
SARC	cis	rs2762353	0.526	rs3936052	chr6:25715534	A/G	cg17691542	chr6:26056736	HIST1H1C	0.42	5.22	0.32	3.97e-7	Blood metabolite levels;
SARC	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg07701084	chr6:150067640	NUP43	0.4	5.37	0.33	1.91e-7	Lung cancer;
SARC	trans	rs9354308	0.933	rs12203567	chr6:66589062	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.58	6.82	0.41	7.77e-11	Metabolite levels;
SARC	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg03351412	chr1:154909251	PMVK	0.62	7.91	0.46	1.03e-13	Prostate cancer;
SARC	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg22903657	chr4:1355424	KIAA1530	-0.36	-4.86	-0.3	2.14e-6	Obesity-related traits;
SARC	cis	rs1957429	0.808	rs9783609	chr14:65352282	A/G	cg23373153	chr14:65346875	NA	1.08	11.73	0.61	2.72e-25	Pediatric areal bone mineral density (radius);
SARC	cis	rs7666738	0.830	rs9998682	chr4:98939009	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	trans	rs8073060	0.586	rs225257	chr17:33956625	G/A	cg19694781	chr19:47549865	TMEM160	-0.68	-6.84	-0.41	7.09e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs12824058	0.831	rs11616174	chr12:130814503	A/G	cg23887609	chr12:130822674	PIWIL1	0.38	5.18	0.32	4.7e-7	Menopause (age at onset);
SARC	cis	rs26232	0.521	rs3776855	chr5:102358815	A/C	cg23492399	chr5:102201601	PAM	-0.49	-5.48	-0.34	1.12e-7	Rheumatoid arthritis;
SARC	cis	rs6456156	0.586	rs2345753	chr6:167484344	T/A	cg07741184	chr6:167504864	NA	0.36	6.99	0.42	2.83e-11	Primary biliary cholangitis;
SARC	cis	rs1059312	1.000	rs2291350	chr12:129283711	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.5	-6.13	-0.37	3.67e-9	Systemic lupus erythematosus;
SARC	cis	rs10463554	0.857	rs34376	chr5:102401113	C/T	cg23492399	chr5:102201601	PAM	-0.52	-5.7	-0.35	3.64e-8	Parkinson's disease;
SARC	cis	rs9285223	1.000	rs9317088	chr13:23136136	A/G	cg08083251	chr13:23309930	NA	-0.48	-5.09	-0.32	7.33e-7	Idiopathic osteonecrosis of the femoral head;
SARC	cis	rs986417	0.892	rs8017336	chr14:60798682	G/A	cg27398547	chr14:60952738	C14orf39	-1.07	-8.71	-0.5	5.72e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs7568458	0.837	rs3770098	chr2:85805367	C/A	cg23752985	chr2:85803571	VAMP8	0.34	4.99	0.31	1.18e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs7296418	0.961	rs949143	chr12:123595163	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.42	-5.71	-0.35	3.47e-8	Platelet count;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg24311251	chr13:44453387	CCDC122;C13orf31	0.62	6.49	0.39	5.12e-10	Lung cancer in ever smokers;
SARC	cis	rs8028182	0.636	rs12708519	chr15:75803200	T/C	cg20655648	chr15:75932815	IMP3	0.64	7.41	0.44	2.38e-12	Sudden cardiac arrest;
SARC	cis	rs297755	0.675	rs297765	chr20:4487111	A/G	cg14606382	chr20:4573199	NA	0.48	5.68	0.35	4.03e-8	Current cigarettes per day in chronic obstructive pulmonary disease;
SARC	cis	rs826838	0.967	rs1719856	chr12:39127201	C/T	cg26384229	chr12:38710491	ALG10B	-0.76	-11.59	-0.6	7.97e-25	Heart rate;
SARC	cis	rs4595586	0.545	rs4411311	chr12:39363612	C/G	cg26384229	chr12:38710491	ALG10B	0.51	6.25	0.38	1.9e-9	Morning vs. evening chronotype;
SARC	cis	rs9354308	0.932	rs1938061	chr6:66545581	A/C	cg07460842	chr6:66804631	NA	-0.47	-5.39	-0.33	1.73e-7	Metabolite levels;
SARC	cis	rs6463523	0.815	rs66886645	chr7:763853	C/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.9	13.81	0.67	4.25e-32	Subjective well-being;
SARC	cis	rs763121	0.853	rs2267394	chr22:39101633	T/C	cg06022373	chr22:39101656	GTPBP1	0.9	12.47	0.63	1.14e-27	Menopause (age at onset);
SARC	cis	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg24110177	chr3:50126178	RBM5	-0.6	-7.89	-0.46	1.18e-13	Intelligence (multi-trait analysis);
SARC	cis	rs3784262	0.669	rs12595180	chr15:58332541	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.34	-5.12	-0.32	6.35e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg04671591	chr1:147400503	GPR89B	-0.49	-6.4	-0.39	8.69e-10	Electrocardiographic conduction measures;
SARC	cis	rs66573146	0.831	rs66645969	chr4:6985614	G/A	cg15105060	chr4:7024189	TBC1D14	-0.69	-4.91	-0.31	1.71e-6	Granulocyte percentage of myeloid white cells;
SARC	cis	rs7833790	0.654	rs6415652	chr8:82702257	G/A	cg27398817	chr8:82754497	SNX16	-0.43	-5.12	-0.32	6.29e-7	Diastolic blood pressure;
SARC	cis	rs995000	0.931	rs1168015	chr1:62996046	C/G	cg06896770	chr1:63153194	DOCK7	-0.9	-13.61	-0.67	2e-31	Triglyceride levels;
SARC	cis	rs2795502	1.000	rs1581702	chr10:43344246	G/A	cg20628663	chr10:43360327	NA	0.48	6.48	0.39	5.49e-10	Blood protein levels;
SARC	cis	rs9733	0.818	rs7520022	chr1:150659173	C/G	cg13175981	chr1:150552382	MCL1	0.63	8.7	0.5	6.18e-16	Tonsillectomy;
SARC	cis	rs9303401	0.538	rs10515155	chr17:56481944	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.04	10.77	0.58	3.36e-22	Cognitive test performance;
SARC	cis	rs67311347	0.955	rs11717036	chr3:40379578	G/T	cg24209194	chr3:40518798	ZNF619	-0.61	-7.95	-0.46	7.99e-14	Renal cell carcinoma;
SARC	cis	rs710216	0.843	rs710214	chr1:43439282	C/T	cg03128534	chr1:43423976	SLC2A1	0.57	5.68	0.35	3.91e-8	Red cell distribution width;
SARC	cis	rs8031584	0.958	rs11637469	chr15:31238783	T/C	cg19680485	chr15:31195859	MTMR15	-0.52	-5.95	-0.36	9.62e-9	Huntington's disease progression;
SARC	cis	rs13191362	1.000	rs68144677	chr6:163149024	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.75	6.38	0.39	9.54e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs734999	0.545	rs28690427	chr1:2571823	A/G	cg00980319	chr1:2560884	MMEL1	0.36	4.99	0.31	1.19e-6	Ulcerative colitis;
SARC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg19318889	chr4:1322082	MAEA	0.45	5.46	0.34	1.23e-7	Longevity;
SARC	cis	rs240764	0.658	rs10872628	chr6:101176349	A/G	cg09795085	chr6:101329169	ASCC3	-0.51	-6.74	-0.4	1.25e-10	Neuroticism;
SARC	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-6.79	-0.41	9.33e-11	Personality dimensions;
SARC	cis	rs778371	0.697	rs2344613	chr2:233603065	C/G	cg20388707	chr2:233749442	NGEF	-0.34	-4.89	-0.31	1.85e-6	Schizophrenia;
SARC	cis	rs2228479	0.850	rs11647174	chr16:89958538	G/A	cg06558623	chr16:89946397	TCF25	0.89	6.28	0.38	1.67e-9	Skin colour saturation;
SARC	cis	rs17826219	0.585	rs8064302	chr17:28724938	G/A	cg13385521	chr17:29058706	SUZ12P	-0.58	-4.95	-0.31	1.42e-6	Body mass index;
SARC	cis	rs4713118	0.699	rs200969	chr6:27859453	T/C	cg17221315	chr6:27791827	HIST1H4J	0.51	5.06	0.31	8.59e-7	Parkinson's disease;
SARC	cis	rs3008870	1.000	rs12137403	chr1:67437043	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.87	-10.59	-0.57	1.19e-21	Lymphocyte percentage of white cells;
SARC	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg24531977	chr5:56204891	C5orf35	-0.55	-5.07	-0.32	8.23e-7	Type 2 diabetes;
SARC	cis	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg00071950	chr4:10020882	SLC2A9	0.41	6.61	0.4	2.57e-10	Bone mineral density;
SARC	cis	rs10979	1.000	rs13198159	chr6:143891953	C/T	cg25407410	chr6:143891975	LOC285740	-0.65	-8.8	-0.5	3.12e-16	Hypospadias;
SARC	cis	rs3824867	0.920	rs7130693	chr11:47452321	T/C	cg20307385	chr11:47447363	PSMC3	-0.48	-5.3	-0.33	2.72e-7	Mean corpuscular hemoglobin;
SARC	cis	rs854765	0.562	rs2955381	chr17:17945500	G/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.41	-5.13	-0.32	6.16e-7	Total body bone mineral density;
SARC	cis	rs17253792	0.730	rs77079997	chr14:56155250	A/G	cg01858014	chr14:56050164	KTN1	-0.63	-5.07	-0.32	8.22e-7	Putamen volume;
SARC	cis	rs9834373	0.553	rs9818134	chr3:78495979	A/C	cg06138941	chr3:78371609	NA	0.34	4.72	0.3	4.11e-6	Protein quantitative trait loci;
SARC	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg25894440	chr7:65020034	NA	0.73	5.94	0.36	1.06e-8	Diabetic kidney disease;
SARC	cis	rs2742234	0.541	rs11238479	chr10:43717423	C/T	cg15436174	chr10:43711423	RASGEF1A	0.43	5.01	0.31	1.08e-6	Hirschsprung disease;
SARC	cis	rs11585357	0.895	rs72633823	chr1:17630779	G/A	cg08277548	chr1:17600880	PADI3	-0.46	-5.38	-0.33	1.85e-7	Hair shape;
SARC	cis	rs854765	0.647	rs854767	chr17:18018263	A/C	cg23370820	chr17:17987590	NA	0.26	5.18	0.32	4.72e-7	Total body bone mineral density;
SARC	cis	rs2952156	0.883	rs2517960	chr17:37846521	T/C	cg20243544	chr17:37824526	PNMT	0.55	7.13	0.42	1.27e-11	Asthma;
SARC	cis	rs11871801	0.517	rs35635959	chr17:40772288	T/C	cg20126647	chr17:40714003	COASY	0.5	5.57	0.34	7.04e-8	Crohn's disease;
SARC	cis	rs6909279	0.678	rs6557143	chr6:151848611	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	-0.45	-5.85	-0.36	1.66e-8	Bone mineral density;
SARC	cis	rs2354432	0.607	rs12402309	chr1:146721983	T/A	cg25205988	chr1:146714368	CHD1L	-1.04	-7.58	-0.44	8.14e-13	Mitochondrial DNA levels;
SARC	cis	rs9790314	0.846	rs7636941	chr3:160993928	A/G	cg03342759	chr3:160939853	NMD3	-0.73	-9.93	-0.55	1.29e-19	Morning vs. evening chronotype;
SARC	cis	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg22496380	chr5:211416	CCDC127	-0.88	-9.28	-0.52	1.21e-17	Breast cancer;
SARC	cis	rs2370759	0.945	rs10508773	chr10:32575444	C/T	cg05361325	chr10:32636312	EPC1	-0.74	-6.51	-0.39	4.62e-10	Sexual dysfunction (female);
SARC	cis	rs3087591	0.708	rs1129506	chr17:29646032	G/A	cg24425628	chr17:29625626	OMG;NF1	0.46	5.94	0.36	1.03e-8	Hip circumference;
SARC	cis	rs11719291	0.915	rs9834996	chr3:48754877	G/T	cg03060546	chr3:49711283	APEH	-0.51	-4.76	-0.3	3.43e-6	Cognitive function;
SARC	cis	rs6570726	0.935	rs110289	chr6:145865176	C/G	cg05347473	chr6:146136440	FBXO30	0.49	6.58	0.4	3.04e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7582180	0.614	rs1530030	chr2:101009600	G/A	cg14675211	chr2:100938903	LONRF2	0.53	7.93	0.46	8.91e-14	Intelligence (multi-trait analysis);
SARC	cis	rs7568458	0.846	rs6705971	chr2:85761417	G/T	cg17127132	chr2:85788382	GGCX	-0.46	-6.24	-0.38	2.1e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs6456156	0.792	rs9366089	chr6:167512896	A/G	cg07741184	chr6:167504864	NA	0.36	6.89	0.41	5.09e-11	Primary biliary cholangitis;
SARC	cis	rs17345786	1.000	rs58907984	chr3:101305170	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.48	5.33	0.33	2.29e-7	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6088813	1.000	rs6142360	chr20:33960486	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	-0.45	-5.44	-0.34	1.34e-7	Height;
SARC	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg27286337	chr10:134555280	INPP5A	0.62	8.1	0.47	3.03e-14	Migraine;
SARC	cis	rs6088590	1.000	rs6088595	chr20:33358499	T/A	cg24642439	chr20:33292090	TP53INP2	0.83	10.74	0.58	3.92e-22	Coronary artery disease;
SARC	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg00339695	chr16:24857497	SLC5A11	0.42	5.67	0.35	4.31e-8	Intelligence (multi-trait analysis);
SARC	trans	rs1493916	0.870	rs1389531	chr18:31386616	C/T	cg27147174	chr7:100797783	AP1S1	-0.58	-7.34	-0.43	3.53e-12	Life satisfaction;
SARC	cis	rs6831352	0.918	rs13110176	chr4:100062430	C/T	cg13256891	chr4:100009986	ADH5	0.66	8.03	0.47	4.87e-14	Alcohol dependence;
SARC	cis	rs36051895	0.659	rs12343065	chr9:5083533	C/T	cg02405213	chr9:5042618	JAK2	-0.46	-5.31	-0.33	2.51e-7	Pediatric autoimmune diseases;
SARC	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.91	-14.54	-0.69	1.6e-34	Chronic sinus infection;
SARC	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg08859206	chr1:53392774	SCP2	0.37	5.43	0.34	1.4e-7	Monocyte count;
SARC	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg22903657	chr4:1355424	KIAA1530	-0.35	-4.9	-0.31	1.81e-6	Obesity-related traits;
SARC	cis	rs710216	0.917	rs900836	chr1:43412727	T/C	cg07803811	chr1:43423981	SLC2A1	-0.55	-5.55	-0.34	7.61e-8	Red cell distribution width;
SARC	cis	rs4891159	0.790	rs683306	chr18:74112473	C/G	cg24786174	chr18:74118243	ZNF516	-0.66	-9.57	-0.53	1.67e-18	Longevity;
SARC	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.93	-12.63	-0.64	3.37e-28	Gut microbiome composition (summer);
SARC	cis	rs2594989	0.837	rs2922348	chr3:11309784	T/C	cg00170343	chr3:11313890	ATG7	0.63	5.78	0.35	2.36e-8	Circulating chemerin levels;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg09732432	chr5:61602737	KIF2A	-0.76	-6.37	-0.39	1.01e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2361710	0.668	rs4889830	chr17:78114528	G/A	cg23534315	chr17:78082725	GAA	0.33	5.1	0.32	7.02e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
SARC	cis	rs55823223	0.564	rs4572466	chr17:73846314	A/C	cg14829360	chr17:73884958	NA	-0.6	-8.09	-0.47	3.27e-14	Psoriasis;
SARC	cis	rs2976388	1.000	rs2572910	chr8:143770135	C/G	cg06565975	chr8:143823917	SLURP1	-0.27	-4.75	-0.3	3.52e-6	Urinary tract infection frequency;
SARC	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg26681399	chr22:41777847	TEF	-0.43	-4.85	-0.3	2.24e-6	Vitiligo;
SARC	cis	rs7412746	0.658	rs6658066	chr1:150918937	T/G	cg13175981	chr1:150552382	MCL1	-0.49	-5.89	-0.36	1.34e-8	Melanoma;
SARC	cis	rs7296418	0.961	rs11613937	chr12:123520071	C/T	cg05973401	chr12:123451056	ABCB9	0.6	7.15	0.42	1.12e-11	Platelet count;
SARC	cis	rs10128251	0.625	rs9424204	chr10:5726376	C/G	cg11519256	chr10:5708881	ASB13	0.4	4.73	0.3	3.97e-6	Childhood ear infection;
SARC	cis	rs6665290	0.901	rs61834001	chr1:227197411	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.09	-25.55	-0.86	1.65e-69	Myeloid white cell count;
SARC	cis	rs7326068	0.610	rs4769134	chr13:21438871	G/A	cg16922012	chr13:21400325	XPO4	-0.44	-6.17	-0.37	2.92e-9	Schizophrenia, bipolar disorder and depression (combined);
SARC	cis	rs35213789	0.887	rs1468588	chr7:69105656	T/C	cg10619644	chr7:69149951	AUTS2	-0.43	-5.77	-0.35	2.54e-8	Childhood ear infection;
SARC	cis	rs2301436	0.512	rs6925969	chr6:167501738	C/A	cg07741184	chr6:167504864	NA	0.38	7.27	0.43	5.43e-12	Crohn's disease;
SARC	trans	rs9929218	0.817	rs3114400	chr16:68719430	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.68	-8.66	-0.49	8.07e-16	Colorectal cancer;
SARC	cis	rs8180040	0.627	rs6442059	chr3:47187075	C/G	cg27129171	chr3:47204927	SETD2	0.69	9.4	0.52	5.41e-18	Colorectal cancer;
SARC	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg19346786	chr7:2764209	NA	-0.36	-5.37	-0.33	1.89e-7	Height;
SARC	cis	rs3106136	0.967	rs2306803	chr4:95161996	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.35	-5.41	-0.33	1.59e-7	Capecitabine sensitivity;
SARC	cis	rs4268898	0.636	rs9636438	chr2:24460566	C/T	cg06627628	chr2:24431161	ITSN2	0.8	9.86	0.54	2.18e-19	Asthma;
SARC	trans	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.85	-0.41	6.45e-11	Retinal vascular caliber;
SARC	cis	rs11122272	0.701	rs2883799	chr1:231531166	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.08	-0.55	4.68e-20	Hemoglobin concentration;
SARC	cis	rs10870270	0.956	rs10870293	chr10:133771413	G/A	cg26149184	chr10:133730230	NA	0.46	5.03	0.31	9.78e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs2834188	0.924	rs2040107	chr21:34675962	C/G	cg04842828	chr21:34696676	IFNAR1	-0.42	-4.98	-0.31	1.21e-6	Narcolepsy;
SARC	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg26335602	chr6:28129616	ZNF389	0.52	5.78	0.35	2.41e-8	Depression;
SARC	cis	rs2075371	1.000	rs2598288	chr7:133977304	A/T	cg11752832	chr7:134001865	SLC35B4	0.57	7.45	0.44	1.81e-12	Mean platelet volume;
SARC	cis	rs986417	0.818	rs10151839	chr14:60980688	T/G	cg27398547	chr14:60952738	C14orf39	1.0	9.03	0.51	6.84e-17	Gut microbiota (bacterial taxa);
SARC	cis	rs7818688	0.697	rs78088250	chr8:95972718	G/A	cg13393036	chr8:95962371	TP53INP1	0.41	4.81	0.3	2.65e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg18876405	chr7:65276391	NA	-0.43	-5.3	-0.33	2.69e-7	Aortic root size;
SARC	cis	rs1008375	0.932	rs11938710	chr4:17670664	G/C	cg02297831	chr4:17616191	MED28	-0.42	-5.24	-0.32	3.61e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6089584	0.927	rs11697597	chr20:60584748	C/T	cg06108461	chr20:60628389	TAF4	-0.89	-11.73	-0.61	2.85e-25	Body mass index;
SARC	cis	rs11583043	0.575	rs12759611	chr1:101587145	T/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.45	4.98	0.31	1.26e-6	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs514024	0.735	rs2039205	chr9:130375643	G/C	cg13643465	chr9:130375613	STXBP1	0.44	5.53	0.34	8.77e-8	Eating disorders (purging via substances);
SARC	cis	rs9858542	0.953	rs9821311	chr3:49543656	C/T	cg03060546	chr3:49711283	APEH	-0.57	-7.03	-0.42	2.31e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg01577475	chr2:114033581	PAX8;LOC440839	-0.36	-5.43	-0.33	1.45e-7	Lymphocyte counts;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg07379550	chr1:227204743	CDC42BPA	-0.49	-6.6	-0.4	2.79e-10	Alcohol dependence;
SARC	cis	rs2011503	0.882	rs10423874	chr19:19359500	C/G	cg03709012	chr19:19516395	GATAD2A	0.58	5.35	0.33	2.09e-7	Bipolar disorder;
SARC	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg18252515	chr7:66147081	NA	0.46	4.94	0.31	1.46e-6	Aortic root size;
SARC	cis	rs2439831	1.000	rs689826	chr15:43749916	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.04	10.73	0.58	4.38e-22	Lung cancer in ever smokers;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg21749200	chr2:179328668	FKBP7;MIR548N	-0.5	-6.33	-0.38	1.27e-9	Alcohol dependence;
SARC	cis	rs453301	0.686	rs6601280	chr8:8909236	A/T	cg06636001	chr8:8085503	FLJ10661	0.51	6.5	0.39	4.84e-10	Joint mobility (Beighton score);
SARC	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg03351412	chr1:154909251	PMVK	0.4	4.85	0.3	2.25e-6	Prostate cancer;
SARC	cis	rs6570726	0.902	rs373321	chr6:145854150	T/A	cg23711669	chr6:146136114	FBXO30	0.78	12.0	0.62	3.86e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg03213289	chr20:61660250	NA	0.46	6.37	0.39	9.75e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg03060546	chr3:49711283	APEH	0.43	5.35	0.33	2.13e-7	Parkinson's disease;
SARC	cis	rs1865760	1.000	rs7739966	chr6:25906040	T/C	cg10373733	chr6:25993375	NA	0.46	5.54	0.34	8.23e-8	Height;
SARC	cis	rs637571	0.522	rs538954	chr11:65756808	A/G	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.41	-5.16	-0.32	5.35e-7	Eosinophil percentage of white cells;
SARC	cis	rs6088580	0.634	rs1205334	chr20:32930369	T/C	cg08999081	chr20:33150536	PIGU	-0.45	-6.78	-0.41	9.96e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs7712401	0.601	rs246265	chr5:122254950	C/T	cg19412675	chr5:122181750	SNX24	0.41	5.24	0.32	3.56e-7	Mean platelet volume;
SARC	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg07167872	chr1:205819463	PM20D1	0.4	4.73	0.3	3.91e-6	Parkinson's disease;
SARC	cis	rs2370759	1.000	rs7910776	chr10:32639093	C/T	cg05361325	chr10:32636312	EPC1	-0.62	-5.5	-0.34	9.84e-8	Sexual dysfunction (female);
SARC	cis	rs9326248	1.000	rs7946257	chr11:117053165	A/G	cg10130564	chr11:117069849	TAGLN	0.26	5.49	0.34	1.07e-7	Blood protein levels;
SARC	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg11890956	chr21:40555474	PSMG1	1.17	19.32	0.78	2.72e-50	Cognitive function;
SARC	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg05025164	chr4:1340916	KIAA1530	-0.45	-5.28	-0.33	2.98e-7	Obesity-related traits;
SARC	cis	rs6088580	0.634	rs6088483	chr20:32984714	T/A	cg24642439	chr20:33292090	TP53INP2	-0.65	-8.43	-0.48	3.57e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	15.35	0.71	3.17e-37	Chronic sinus infection;
SARC	cis	rs11719291	0.833	rs11713694	chr3:48833615	G/T	cg07636037	chr3:49044803	WDR6	-0.73	-6.45	-0.39	6.39e-10	Cognitive function;
SARC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg24846343	chr22:24311635	DDTL	0.5	7.32	0.43	4.07e-12	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6424115	0.708	rs11803575	chr1:24182348	A/T	cg15997130	chr1:24165203	NA	-0.43	-5.18	-0.32	4.84e-7	Immature fraction of reticulocytes;
SARC	trans	rs75246769	1.000	rs76279338	chr7:145445523	T/A	cg00210271	chr12:54088934	NA	-0.47	-6.25	-0.38	1.93e-9	Facial morphology (factor 10, width of nasal floor);
SARC	cis	rs568617	0.716	rs17854357	chr11:65601560	G/C	cg00576331	chr11:65640516	EFEMP2	-0.53	-5.07	-0.32	8.13e-7	Crohn's disease;
SARC	cis	rs1707322	0.691	rs61784799	chr1:46177748	A/G	cg06784218	chr1:46089804	CCDC17	-0.36	-6.13	-0.37	3.75e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7937682	0.961	rs7119563	chr11:111543916	T/A	cg09085632	chr11:111637200	PPP2R1B	0.95	15.57	0.71	6.1e-38	Primary sclerosing cholangitis;
SARC	cis	rs1448094	0.817	rs7973694	chr12:86335589	A/G	cg02569458	chr12:86230093	RASSF9	0.42	5.89	0.36	1.31e-8	Major depressive disorder;
SARC	cis	rs1018836	0.786	rs10086401	chr8:91572818	C/T	cg16814680	chr8:91681699	NA	-0.74	-11.43	-0.6	2.58e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs10504073	0.584	rs115370638	chr8:49916452	A/G	cg00325661	chr8:49890786	NA	0.51	6.82	0.41	7.54e-11	Blood metabolite ratios;
SARC	cis	rs920590	0.643	rs7012694	chr8:19662732	C/T	cg03894339	chr8:19674705	INTS10	0.43	5.24	0.32	3.59e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg17376030	chr22:41985996	PMM1	-0.73	-9.06	-0.51	5.59e-17	Vitiligo;
SARC	cis	rs761746	0.960	rs4820979	chr22:31914399	A/G	cg15823100	chr22:32027580	PISD	0.35	5.09	0.32	7.48e-7	Intelligence;
SARC	cis	rs4891159	0.790	rs72975930	chr18:74144645	G/A	cg24786174	chr18:74118243	ZNF516	-0.64	-8.97	-0.51	9.84e-17	Longevity;
SARC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.63	-0.4	2.28e-10	Total body bone mineral density;
SARC	cis	rs67460515	0.596	rs4856700	chr3:160922951	A/C	cg03342759	chr3:160939853	NMD3	-0.65	-8.08	-0.47	3.4e-14	Parkinson's disease;
SARC	cis	rs2130392	0.962	rs7660116	chr4:185626542	G/A	cg04058563	chr4:185651563	MLF1IP	0.33	4.88	0.3	1.93e-6	Kawasaki disease;
SARC	trans	rs2727020	0.731	rs10450572	chr11:49281073	T/C	cg03929089	chr4:120376271	NA	0.77	11.48	0.6	1.77e-24	Coronary artery disease;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg10579128	chr15:59225866	SLTM	0.5	6.64	0.4	2.17e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs709400	0.628	rs7150317	chr14:103921691	C/G	cg26031613	chr14:104095156	KLC1	0.82	11.92	0.62	6.67e-26	Body mass index;
SARC	cis	rs10904908	0.733	rs359299	chr10:17334378	G/A	cg01003015	chr10:17271136	VIM	0.4	4.78	0.3	3.06e-6	Total cholesterol levels;Cholesterol, total;
SARC	cis	rs7829975	0.572	rs28730413	chr8:8795447	A/C	cg14343924	chr8:8086146	FLJ10661	-0.41	-4.99	-0.31	1.19e-6	Mood instability;
SARC	cis	rs2204008	0.811	rs11520277	chr12:38359611	G/A	cg13010199	chr12:38710504	ALG10B	0.78	10.79	0.58	2.78e-22	Bladder cancer;
SARC	cis	rs8078723	1.000	rs4795412	chr17:38150604	C/T	cg17467752	chr17:38218738	THRA	0.47	6.01	0.37	7.01e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs6674970	0.932	rs12569193	chr1:151115186	C/T	cg11822372	chr1:151115635	SEMA6C	0.4	4.9	0.31	1.83e-6	Childhood ear infection;
SARC	cis	rs7727544	0.684	rs274560	chr5:131719450	T/C	cg24060327	chr5:131705240	SLC22A5	0.72	9.37	0.52	6.54e-18	Blood metabolite levels;
SARC	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg24633833	chr3:10029261	TMEM111	0.51	5.09	0.32	7.27e-7	Alzheimer's disease;
SARC	cis	rs7766436	0.524	rs6938780	chr6:22556791	C/A	cg13666174	chr6:22585274	NA	-0.58	-6.03	-0.37	6.46e-9	Coronary artery disease;
SARC	trans	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg21659725	chr3:3221576	CRBN	0.53	6.83	0.41	7.25e-11	Intelligence (multi-trait analysis);
SARC	cis	rs796364	0.806	rs79333757	chr2:200915716	T/C	cg23649088	chr2:200775458	C2orf69	-0.6	-5.29	-0.33	2.77e-7	Schizophrenia;
SARC	cis	rs8017423	0.904	rs7147212	chr14:90697809	A/C	cg20276874	chr14:90721474	PSMC1	-0.36	-5.04	-0.31	9.28e-7	Mortality in heart failure;
SARC	cis	rs28829049	0.597	rs2066002	chr1:19504300	G/A	cg13387374	chr1:19411106	UBR4	0.45	5.34	0.33	2.21e-7	QRS duration in Tripanosoma cruzi seropositivity;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg22027408	chr19:12902453	JUNB	0.59	6.24	0.38	2.03e-9	Lung cancer in ever smokers;
SARC	cis	rs7590720	0.840	rs705648	chr2:216933792	C/T	cg12620499	chr2:216877984	MREG	0.55	7.34	0.43	3.57e-12	Alcohol dependence;
SARC	cis	rs637571	0.584	rs594689	chr11:65635559	G/A	cg26695010	chr11:65641043	EFEMP2	0.78	11.89	0.61	8.87e-26	Eosinophil percentage of white cells;
SARC	cis	rs1448094	0.556	rs11610627	chr12:86167752	C/T	cg02569458	chr12:86230093	RASSF9	0.37	5.03	0.31	9.77e-7	Major depressive disorder;
SARC	cis	rs910316	0.763	rs175450	chr14:75590340	G/A	cg11812906	chr14:75593930	NEK9	-0.76	-10.57	-0.57	1.42e-21	Height;
SARC	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg03264133	chr6:25882463	NA	-0.41	-5.27	-0.33	3.09e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.75	7.35	0.43	3.25e-12	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs2997457	0.515	rs2992068	chr1:26275548	A/C	cg24596570	chr1:26146463	FAM54B;LOC646471	-0.51	-4.81	-0.3	2.74e-6	Facial morphology (factor 16);
SARC	cis	rs11098499	0.909	rs10002083	chr4:120311152	C/T	cg09307838	chr4:120376055	NA	0.91	12.88	0.65	4.9e-29	Corneal astigmatism;
SARC	cis	rs9985766	0.959	rs6848344	chr4:151049132	G/T	cg05926478	chr4:151174724	DCLK2	-0.49	-4.83	-0.3	2.46e-6	Coronary artery disease;Myocardial infarction;
SARC	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg11987759	chr7:65425863	GUSB	-0.47	-6.27	-0.38	1.7e-9	Aortic root size;
SARC	cis	rs55823223	0.646	rs74410877	chr17:73832384	C/T	cg14829360	chr17:73884958	NA	-0.61	-5.64	-0.35	4.92e-8	Psoriasis;
SARC	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7647973	1.000	rs13096474	chr3:49443081	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.56	-5.91	-0.36	1.22e-8	Menarche (age at onset);
SARC	cis	rs11225247	0.881	rs12277594	chr11:102257415	A/C	cg11690896	chr11:102217788	BIRC2	0.77	5.37	0.33	1.93e-7	Vein graft stenosis in coronary artery bypass grafting;
SARC	cis	rs9486719	0.947	rs72932805	chr6:96902933	T/G	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.01	-0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs910316	0.967	rs4899545	chr14:75568138	A/G	cg08847533	chr14:75593920	NEK9	0.94	16.27	0.73	2.77e-40	Height;
SARC	cis	rs911555	0.574	rs34251103	chr14:103860063	A/G	cg24130564	chr14:104152367	KLC1	0.49	5.83	0.36	1.8e-8	Intelligence (multi-trait analysis);
SARC	cis	rs6456156	0.819	rs4709148	chr6:167521676	T/C	cg07741184	chr6:167504864	NA	0.28	5.07	0.32	8.02e-7	Primary biliary cholangitis;
SARC	cis	rs9300255	0.602	rs941305	chr12:123715266	T/C	cg05973401	chr12:123451056	ABCB9	0.47	5.29	0.33	2.84e-7	Neutrophil percentage of white cells;
SARC	cis	rs9487051	0.676	rs2884013	chr6:109599952	C/T	cg01475377	chr6:109611718	NA	-0.35	-5.16	-0.32	5.41e-7	Reticulocyte fraction of red cells;
SARC	cis	rs918629	0.798	rs6898399	chr5:95289398	A/G	cg16656078	chr5:95278638	ELL2	-0.64	-7.74	-0.45	3.03e-13	IgG glycosylation;
SARC	cis	rs1153858	0.943	rs28605551	chr15:45641720	C/T	cg03999130	chr15:45571217	NA	0.39	4.99	0.31	1.16e-6	Homoarginine levels;
SARC	cis	rs9309473	0.898	rs7587577	chr2:73832786	C/T	cg20560298	chr2:73613845	ALMS1	-0.48	-5.71	-0.35	3.51e-8	Metabolite levels;
SARC	cis	rs16854884	0.770	rs7621093	chr3:143814542	C/G	cg06585982	chr3:143692056	C3orf58	0.58	6.87	0.41	5.96e-11	Economic and political preferences (feminism/equality);
SARC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg03452623	chr4:187889614	NA	-0.76	-11.9	-0.61	7.83e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg02725872	chr8:58115012	NA	-0.36	-6.12	-0.37	3.91e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg11987759	chr7:65425863	GUSB	0.62	8.25	0.48	1.17e-14	Aortic root size;
SARC	trans	rs7819412	0.805	rs2409710	chr8:10979821	A/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-8.76	-0.5	4.03e-16	Triglycerides;
SARC	cis	rs17021463	0.902	rs34465979	chr4:95257554	C/A	cg11021082	chr4:95130006	SMARCAD1	0.42	6.44	0.39	6.67e-10	Testicular germ cell tumor;
SARC	cis	rs7662987	0.517	rs2851265	chr4:100029684	A/G	cg13256891	chr4:100009986	ADH5	0.66	8.22	0.47	1.42e-14	Smoking initiation;
SARC	trans	rs9329221	0.741	rs534523	chr8:9884999	C/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-9.14	-0.51	3.16e-17	Neuroticism;
SARC	cis	rs959260	0.557	rs12946365	chr17:73317644	C/T	cg14668889	chr17:73230827	NUP85	-0.57	-7.24	-0.43	6.48e-12	Systemic lupus erythematosus;
SARC	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg20607798	chr8:58055168	NA	0.61	5.41	0.33	1.57e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7582720	1.000	rs72932554	chr2:203845828	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs12134245	0.747	rs35654098	chr1:92001452	T/A	cg02896835	chr1:92012615	NA	-0.52	-7.15	-0.42	1.09e-11	Breast cancer;
SARC	cis	rs7635838	0.785	rs904475	chr3:11535417	G/A	cg00170343	chr3:11313890	ATG7	0.6	8.21	0.47	1.55e-14	HDL cholesterol;
SARC	cis	rs2559856	0.967	rs7970837	chr12:102081576	A/G	cg12924262	chr12:102091054	CHPT1	0.58	7.62	0.45	6.2800000000000005e-13	Blood protein levels;
SARC	cis	rs10752881	0.875	rs10797825	chr1:183024581	G/A	cg13390022	chr1:182993471	LAMC1	0.36	5.41	0.33	1.6e-7	Colorectal cancer;
SARC	cis	rs2439831	1.000	rs561863	chr15:43761352	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.04	11.03	0.59	4.93e-23	Lung cancer in ever smokers;
SARC	trans	rs61931739	0.500	rs7306053	chr12:34510848	T/G	cg13010199	chr12:38710504	ALG10B	0.76	10.85	0.58	1.77e-22	Morning vs. evening chronotype;
SARC	trans	rs61931739	0.517	rs1817760	chr12:34106060	A/G	cg13010199	chr12:38710504	ALG10B	0.77	10.37	0.56	5.83e-21	Morning vs. evening chronotype;
SARC	cis	rs950027	0.620	rs1145077	chr15:45683795	A/C	cg26924012	chr15:45694286	SPATA5L1	-0.49	-6.04	-0.37	6.12e-9	Response to fenofibrate (adiponectin levels);
SARC	cis	rs16937	0.662	rs10900468	chr1:205163057	A/G	cg21643547	chr1:205240462	TMCC2	-0.4	-4.91	-0.31	1.71e-6	Schizophrenia;
SARC	cis	rs9309473	0.950	rs10198549	chr2:73794404	A/G	cg20560298	chr2:73613845	ALMS1	-0.48	-5.92	-0.36	1.14e-8	Metabolite levels;
SARC	cis	rs4589502	0.512	rs7183242	chr15:67096658	A/G	cg12317470	chr15:67143691	NA	0.67	8.2	0.47	1.65e-14	Lung cancer (smoking interaction);
SARC	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg12463550	chr7:65579703	CRCP	0.71	5.37	0.33	1.9e-7	Diabetic kidney disease;
SARC	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.49	7.46	0.44	1.66e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs12824058	0.831	rs1390849	chr12:130811547	A/G	cg23887609	chr12:130822674	PIWIL1	0.37	5.15	0.32	5.48e-7	Menopause (age at onset);
SARC	cis	rs644799	0.542	rs10831418	chr11:95468828	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	6.28	0.38	1.65e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg24549020	chr5:56110836	MAP3K1	0.81	8.4	0.48	4.37e-15	Initial pursuit acceleration;
SARC	cis	rs10463316	0.862	rs13354553	chr5:150758128	G/A	cg03212797	chr5:150827313	SLC36A1	-0.5	-6.04	-0.37	6.08e-9	Metabolite levels (Pyroglutamine);
SARC	cis	rs2865116	0.851	rs6957902	chr7:68938618	C/T	cg10619644	chr7:69149951	AUTS2	0.34	4.73	0.3	3.84e-6	Positive affect;
SARC	cis	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg05623727	chr3:50126028	RBM5	-0.35	-5.46	-0.34	1.2e-7	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg11764359	chr7:65958608	NA	-0.78	-9.67	-0.54	8.24e-19	Aortic root size;
SARC	trans	rs2018683	0.707	rs917216	chr7:28971472	A/G	cg19402173	chr7:128379420	CALU	-0.52	-6.74	-0.4	1.23e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs11625487	0.609	rs17824567	chr14:77976450	G/T	cg16049707	chr14:77965284	ISM2	0.67	5.32	0.33	2.43e-7	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
SARC	cis	rs644799	0.862	rs1150361	chr11:95633805	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.63	7.88	0.46	1.23e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7681440	0.606	rs2583973	chr4:90747499	C/T	cg06632027	chr4:90757378	SNCA	-0.46	-5.76	-0.35	2.61e-8	Dementia with Lewy bodies;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg10667969	chr3:149181941	NA	0.53	6.55	0.39	3.74e-10	Breast cancer;
SARC	cis	rs2304069	0.954	rs1469691	chr5:149386716	G/A	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.68	6.62	0.4	2.45e-10	HIV-1 control;
SARC	cis	rs6542838	0.704	rs13011428	chr2:99528305	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-6.02	-0.37	6.86e-9	Fear of minor pain;
SARC	trans	rs9354308	0.868	rs6907911	chr6:66555683	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.55	-6.64	-0.4	2.16e-10	Metabolite levels;
SARC	cis	rs11098499	0.954	rs6838814	chr4:120392443	G/A	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs3204270	0.639	rs62077183	chr17:79658940	C/A	cg26965718	chr17:79658957	HGS	-0.63	-5.16	-0.32	5.23e-7	Dental caries;
SARC	cis	rs6693567	0.565	rs7513182	chr1:150442612	A/G	cg09579323	chr1:150459698	TARS2	-0.44	-5.58	-0.34	6.5e-8	Migraine;
SARC	cis	rs8114671	0.836	rs734308	chr20:33572096	A/G	cg24642439	chr20:33292090	TP53INP2	-0.5	-5.77	-0.35	2.47e-8	Height;
SARC	cis	rs820218	0.546	rs1661675	chr17:73725304	C/G	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.61	6.92	0.41	4.43e-11	Rotator cuff tears;
SARC	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg03735888	chr19:58951602	ZNF132	0.41	5.48	0.34	1.08e-7	Uric acid clearance;
SARC	cis	rs60871478	1.000	rs4397290	chr7:828493	T/C	cg05535760	chr7:792225	HEATR2	-0.78	-8.04	-0.47	4.64e-14	Cerebrospinal P-tau181p levels;
SARC	cis	rs523522	0.962	rs4767914	chr12:120993817	C/T	cg12219531	chr12:120966889	COQ5	0.84	11.3	0.59	6.84e-24	High light scatter reticulocyte count;
SARC	trans	rs877282	0.755	rs2486578	chr10:785227	C/T	cg22713356	chr15:30763199	NA	-0.9	-9.41	-0.52	4.93e-18	Uric acid levels;
SARC	cis	rs73206853	0.841	rs74503171	chr12:111061652	A/G	cg10860002	chr12:110842031	ANAPC7	0.59	4.99	0.31	1.18e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs7659604	0.539	rs72680779	chr4:122797263	C/T	cg06713675	chr4:122721982	EXOSC9	-0.52	-6.64	-0.4	2.19e-10	Type 2 diabetes;
SARC	cis	rs943466	1.000	rs55775340	chr6:33751784	C/G	cg04676172	chr6:33757040	LEMD2	0.47	5.07	0.32	8.19e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
SARC	cis	rs79349575	0.783	rs4794003	chr17:47029904	C/T	cg07967210	chr17:47022446	SNF8	0.37	4.71	0.3	4.19e-6	Type 2 diabetes;
SARC	cis	rs4713118	0.662	rs175954	chr6:28011585	A/G	cg17221315	chr6:27791827	HIST1H4J	0.49	5.05	0.31	9.12e-7	Parkinson's disease;
SARC	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg01475735	chr3:40494733	NA	-0.46	-5.16	-0.32	5.33e-7	Renal cell carcinoma;
SARC	cis	rs7043114	0.563	rs10820988	chr9:95317008	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.5	-6.01	-0.37	7.11e-9	Height;
SARC	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg16405210	chr4:1374714	KIAA1530	-0.91	-12.83	-0.64	7.64e-29	Longevity;
SARC	cis	rs4481887	1.000	rs10888351	chr1:248451608	G/A	cg13385794	chr1:248469461	NA	0.32	4.79	0.3	3e-6	Common traits (Other);
SARC	cis	rs8008758	1.000	rs8013718	chr14:101689506	C/T	cg26224664	chr14:101693935	NA	-0.39	-6.07	-0.37	5.1e-9	Body mass index (alcohol intake interaction);
SARC	cis	rs9916302	0.752	rs6503513	chr17:37561613	A/G	cg15445000	chr17:37608096	MED1	-0.45	-5.18	-0.32	4.76e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs228769	0.673	rs375677	chr17:42108974	A/C	cg09913183	chr17:42254507	C17orf65;ASB16	-0.45	-4.94	-0.31	1.49e-6	Bone mineral density (hip);Bone mineral density (spine);
SARC	cis	rs7647973	0.593	rs59684465	chr3:49874246	C/T	cg07636037	chr3:49044803	WDR6	-0.63	-6.45	-0.39	6.52e-10	Menarche (age at onset);
SARC	cis	rs4595586	0.545	rs925829	chr12:39364167	A/G	cg26384229	chr12:38710491	ALG10B	0.51	6.25	0.38	1.9e-9	Morning vs. evening chronotype;
SARC	cis	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg18252515	chr7:66147081	NA	-1.29	-11.49	-0.6	1.7e-24	Diabetic kidney disease;
SARC	cis	rs281408	0.559	rs204248	chr19:49216224	G/C	cg13540341	chr19:49222985	MAMSTR	0.32	5.32	0.33	2.39e-7	Urinary metabolites (H-NMR features);
SARC	cis	rs2916247	1.000	rs4477079	chr8:93059038	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.62	-6.55	-0.39	3.56e-10	Intelligence (multi-trait analysis);
SARC	cis	rs1443512	0.755	rs1373160	chr12:54340383	A/G	cg17410650	chr12:54324560	NA	-0.32	-5.08	-0.32	7.91e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
SARC	trans	rs7937682	0.889	rs1789355	chr11:111499718	T/C	cg18187862	chr3:45730750	SACM1L	0.57	7.11	0.42	1.45e-11	Primary sclerosing cholangitis;
SARC	cis	rs4430311	0.723	rs12144546	chr1:243883877	T/G	cg21452805	chr1:244014465	NA	-0.45	-5.82	-0.36	1.94e-8	Post-traumatic stress disorder (asjusted for relatedness);
SARC	trans	rs11710567	0.684	rs13088826	chr3:57841858	G/A	cg01127878	chr19:42811035	PRR19	-0.44	-6.31	-0.38	1.42e-9	Granulocyte percentage of myeloid white cells;
SARC	cis	rs8067545	0.616	rs203465	chr17:19810720	T/G	cg13482628	chr17:19912719	NA	0.53	6.71	0.4	1.43e-10	Schizophrenia;
SARC	cis	rs9911578	1.000	rs2643119	chr17:56827760	G/T	cg12560992	chr17:57184187	TRIM37	0.88	12.14	0.62	1.31e-26	Intelligence (multi-trait analysis);
SARC	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg24549020	chr5:56110836	MAP3K1	0.8	8.12	0.47	2.63e-14	Initial pursuit acceleration;
SARC	cis	rs240764	0.853	rs12374612	chr6:100955752	C/T	cg09795085	chr6:101329169	ASCC3	-0.44	-5.76	-0.35	2.64e-8	Neuroticism;
SARC	cis	rs10789491	1.000	rs10749863	chr1:47174328	C/T	cg15501359	chr1:47185051	KIAA0494	0.74	8.1	0.47	3.14e-14	Response to hepatitis C treatment;
SARC	cis	rs875971	0.793	rs460678	chr7:65527200	C/G	cg11987759	chr7:65425863	GUSB	-0.47	-6.32	-0.38	1.32e-9	Aortic root size;
SARC	cis	rs6565180	0.962	rs6565183	chr16:30382755	T/C	cg17640201	chr16:30407289	ZNF48	-1.0	-17.4	-0.75	5.23e-44	Tonsillectomy;
SARC	trans	rs11098499	0.954	rs6849171	chr4:120409549	G/A	cg25214090	chr10:38739885	LOC399744	0.54	6.99	0.42	2.81e-11	Corneal astigmatism;
SARC	trans	rs1814175	0.817	rs11518158	chr11:49985633	G/T	cg15704280	chr7:45808275	SEPT13	-0.97	-18.55	-0.77	9.01e-48	Height;
SARC	cis	rs6088580	0.634	rs6142153	chr20:32968747	C/G	cg08999081	chr20:33150536	PIGU	-0.43	-6.58	-0.4	3.15e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs13082711	0.554	rs9310843	chr3:27371260	A/G	cg02860705	chr3:27208620	NA	0.5	6.77	0.41	1.03e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs9916302	0.706	rs6503504	chr17:37514412	A/G	cg07936489	chr17:37558343	FBXL20	0.76	9.12	0.51	3.63e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg04317338	chr11:64019027	PLCB3	0.57	6.57	0.4	3.23e-10	Platelet count;
SARC	cis	rs4925386	1.000	rs6089351	chr20:60916153	G/A	cg22633769	chr20:60982531	CABLES2	-0.47	-5.16	-0.32	5.17e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs1395	0.744	rs11126936	chr2:27483101	A/C	cg22903471	chr2:27725779	GCKR	0.36	4.71	0.3	4.18e-6	Blood metabolite levels;
SARC	cis	rs1401999	1.000	rs6802849	chr3:183698943	A/C	cg01324343	chr3:183735012	ABCC5	0.66	13.29	0.66	2.23e-30	Anterior chamber depth;
SARC	cis	rs9467711	0.591	rs13195692	chr6:26044373	C/T	cg21479132	chr6:26055353	NA	0.99	7.28	0.43	5.04e-12	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg11644478	chr21:40555479	PSMG1	1.03	14.5	0.69	2.22e-34	Cognitive function;
SARC	cis	rs9916302	0.904	rs10852933	chr17:37698194	G/T	cg15445000	chr17:37608096	MED1	0.42	4.93	0.31	1.59e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs6570726	0.791	rs425999	chr6:145819370	C/A	cg23711669	chr6:146136114	FBXO30	0.87	14.62	0.69	8.73e-35	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg06028605	chr16:24865363	SLC5A11	0.37	5.71	0.35	3.35e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs4253772	0.637	rs3087501	chr22:46647909	A/G	cg24881330	chr22:46731750	TRMU	0.62	6.65	0.4	2.09e-10	LDL cholesterol;Cholesterol, total;
SARC	cis	rs2997447	0.706	rs2783712	chr1:26429344	A/C	cg19633962	chr1:26362018	EXTL1	-0.6	-5.61	-0.34	5.75e-8	QRS complex (12-leadsum);
SARC	cis	rs7681440	0.746	rs10001067	chr4:90818216	C/G	cg02192967	chr4:90758406	SNCA	0.38	5.21	0.32	4.14e-7	Dementia with Lewy bodies;
SARC	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.77	10.87	0.58	1.61e-22	Personality dimensions;
SARC	cis	rs17376456	0.877	rs114256265	chr5:93473130	T/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	5.71	0.35	3.5e-8	Diabetic retinopathy;
SARC	cis	rs10463316	0.817	rs6877498	chr5:150802876	C/T	cg03212797	chr5:150827313	SLC36A1	-0.44	-5.18	-0.32	4.82e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs1538970	0.924	rs3790582	chr1:45887288	T/C	cg05343316	chr1:45956843	TESK2	0.72	8.49	0.49	2.49e-15	Platelet count;
SARC	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg12564285	chr5:131593104	PDLIM4	-0.4	-5.68	-0.35	3.94e-8	Acylcarnitine levels;
SARC	cis	rs34172651	0.917	rs200538	chr16:24735736	C/T	cg06028605	chr16:24865363	SLC5A11	-0.27	-4.74	-0.3	3.67e-6	Intelligence (multi-trait analysis);
SARC	cis	rs921943	0.554	rs163132	chr5:78285921	A/G	cg26802063	chr5:78281964	ARSB	0.55	5.92	0.36	1.17e-8	Blood and toenail selenium levels;Blood trace element (Se levels);
SARC	cis	rs7598759	0.712	rs10933372	chr2:232332325	G/A	cg19187155	chr2:232395269	NMUR1	0.6	8.52	0.49	2e-15	Noise-induced hearing loss;
SARC	cis	rs4727027	0.933	rs12704063	chr7:148827909	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	5.49	0.34	1.03e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg18252515	chr7:66147081	NA	-1.26	-11.14	-0.59	2.14e-23	Diabetic kidney disease;
SARC	trans	rs7937682	0.889	rs2850247	chr11:111637202	C/A	cg18187862	chr3:45730750	SACM1L	-0.6	-7.34	-0.43	3.56e-12	Primary sclerosing cholangitis;
SARC	cis	rs3126085	0.935	rs4511111	chr1:152211624	C/G	cg03465714	chr1:152285911	FLG	0.46	4.86	0.3	2.16e-6	Atopic dermatitis;
SARC	cis	rs6912958	0.703	rs12207825	chr6:88098292	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.74	11.02	0.59	5.35e-23	Monocyte percentage of white cells;
SARC	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg11644478	chr21:40555479	PSMG1	-0.87	-11.27	-0.59	8.6e-24	Cognitive function;
SARC	cis	rs708547	0.581	rs10020462	chr4:57825593	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.51	-5.74	-0.35	2.92e-8	Response to bleomycin (chromatid breaks);
SARC	cis	rs28374715	0.528	rs7181982	chr15:41623020	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.17	-19.16	-0.78	8.85e-50	Ulcerative colitis;
SARC	cis	rs1448094	0.740	rs4919774	chr12:86337560	G/T	cg02569458	chr12:86230093	RASSF9	0.44	6.26	0.38	1.86e-9	Major depressive disorder;
SARC	cis	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg00745463	chr17:30367425	LRRC37B	-0.69	-5.28	-0.33	2.96e-7	Hip circumference adjusted for BMI;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg25517427	chr17:12921477	ELAC2	0.48	6.42	0.39	7.49e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	8.97	0.51	1.03e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs804280	0.560	rs10503426	chr8:11589383	A/C	cg02569740	chr8:10878898	XKR6	0.35	4.83	0.3	2.45e-6	Myopia (pathological);
SARC	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg06420487	chr17:61919686	SMARCD2	0.49	5.71	0.35	3.46e-8	Height;
SARC	cis	rs709400	0.832	rs10145755	chr14:104121984	C/T	cg12935359	chr14:103987150	CKB	-0.33	-4.97	-0.31	1.28e-6	Body mass index;
SARC	cis	rs2658782	0.547	rs3020064	chr11:93060851	A/G	cg15737290	chr11:93063684	CCDC67	0.97	13.52	0.66	3.84e-31	Pulmonary function decline;
SARC	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs3733585	0.725	rs10939636	chr4:9972640	T/G	cg11266682	chr4:10021025	SLC2A9	-0.39	-6.73	-0.4	1.34e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs2235642	0.505	rs56359342	chr16:1654948	G/A	cg09065629	chr16:1709722	CRAMP1L	0.41	5.22	0.32	4.02e-7	Coronary artery disease;
SARC	cis	rs526231	0.575	rs10463990	chr5:102317418	G/A	cg23492399	chr5:102201601	PAM	-0.52	-6.38	-0.39	9.62e-10	Primary biliary cholangitis;
SARC	cis	rs11583043	0.831	rs6667818	chr1:101412313	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.48	5.98	0.36	8.33e-9	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs2933343	0.700	rs2624910	chr3:128650275	G/C	cg24203234	chr3:128598194	ACAD9	0.63	8.04	0.47	4.5e-14	IgG glycosylation;
SARC	cis	rs77372450	0.636	rs10052322	chr5:157014420	C/A	cg23851860	chr5:157002805	ADAM19	0.52	4.85	0.3	2.28e-6	Bipolar disorder (body mass index interaction);
SARC	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg24675658	chr1:53192096	ZYG11B	-0.6	-8.37	-0.48	5.41e-15	Monocyte count;
SARC	trans	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg21659725	chr3:3221576	CRBN	-0.79	-11.96	-0.62	5.19e-26	Intelligence (multi-trait analysis);
SARC	cis	rs208515	0.525	rs10944870	chr6:66687757	G/C	cg07460842	chr6:66804631	NA	0.96	11.01	0.59	5.47e-23	Exhaled nitric oxide levels;
SARC	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg27266027	chr21:40555129	PSMG1	-0.41	-4.84	-0.3	2.37e-6	Menarche (age at onset);
SARC	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg19774624	chr17:42201019	HDAC5	-0.79	-11.34	-0.6	5.09e-24	Total body bone mineral density;
SARC	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg21724239	chr8:58056113	NA	0.64	6.5	0.39	4.82e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9640161	0.663	rs1916932	chr7:150021644	T/C	cg21361702	chr7:150065534	REPIN1	0.46	4.98	0.31	1.22e-6	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs921968	0.643	rs4674320	chr2:219510768	A/G	cg02176678	chr2:219576539	TTLL4	0.35	5.26	0.33	3.2e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs9818758	0.505	rs11716159	chr3:49631585	G/A	cg01304814	chr3:48885189	PRKAR2A	0.65	5.07	0.31	8.26e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-9.17	-0.51	2.59e-17	Alzheimer's disease;
SARC	cis	rs8031584	0.505	rs2959036	chr15:31219742	T/G	cg14829155	chr15:31115871	NA	0.42	5.74	0.35	2.93e-8	Huntington's disease progression;
SARC	cis	rs8064299	0.597	rs7210318	chr17:72783385	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.8	10.84	0.58	2.02e-22	Monocyte count;
SARC	cis	rs698833	0.509	rs10178209	chr2:44770193	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.4	5.13	0.32	6.23e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	16.73	0.74	8.77e-42	Height;
SARC	cis	rs698833	0.926	rs786626	chr2:44604066	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.67	8.52	0.49	1.96e-15	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs10416265	0.527	rs7246814	chr19:33538414	G/T	cg27124370	chr19:33622961	WDR88	0.46	5.93	0.36	1.11e-8	Bone properties (heel);
SARC	cis	rs7551222	0.749	rs6594019	chr1:204568610	T/C	cg20240347	chr1:204465584	NA	-0.27	-5.05	-0.31	8.77e-7	Schizophrenia;
SARC	cis	rs7772486	0.720	rs1890171	chr6:146072114	T/C	cg05347473	chr6:146136440	FBXO30	-0.56	-7.82	-0.46	1.87e-13	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs1814175	0.867	rs7926002	chr11:49616018	A/G	cg03929089	chr4:120376271	NA	-0.8	-12.01	-0.62	3.56e-26	Height;
SARC	cis	rs9747201	0.962	rs62079995	chr17:80076624	C/T	cg09264619	chr17:80180166	NA	0.5	5.53	0.34	8.42e-8	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs1348850	0.526	rs10803912	chr2:178407176	A/C	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.67	-6.51	-0.39	4.49e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7537052	0.646	rs6680302	chr1:36653540	C/T	cg24686825	chr1:36642396	MAP7D1	-0.65	-8.73	-0.5	5.13e-16	Schizophrenia;
SARC	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg18357526	chr6:26021779	HIST1H4A	0.63	7.9	0.46	1.1e-13	Intelligence (multi-trait analysis);
SARC	cis	rs2425143	1.000	rs6058303	chr20:34290281	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.66	5.36	0.33	2.01e-7	Blood protein levels;
SARC	cis	rs7560272	0.501	rs17350188	chr2:73964842	C/G	cg20560298	chr2:73613845	ALMS1	-0.43	-5.63	-0.35	5.22e-8	Schizophrenia;
SARC	cis	rs11122272	0.735	rs2739518	chr1:231537633	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.08	-0.55	4.68e-20	Hemoglobin concentration;
SARC	cis	rs981844	1.000	rs62325092	chr4:154668674	T/C	cg14289246	chr4:154710475	SFRP2	0.57	6.43	0.39	7.08e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs11734570	0.581	rs73811714	chr4:38588327	T/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.59	6.32	0.38	1.29e-9	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs72781680	0.898	rs12623316	chr2:24087857	A/G	cg06627628	chr2:24431161	ITSN2	-0.65	-6.37	-0.39	9.72e-10	Lymphocyte counts;
SARC	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	20.34	0.8	1.48e-53	Chronic sinus infection;
SARC	trans	rs561341	0.714	rs55925849	chr17:30253085	C/T	cg20587970	chr11:113659929	NA	-1.35	-13.04	-0.65	1.55e-29	Hip circumference adjusted for BMI;
SARC	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg27572855	chr1:25598939	RHD	-0.5	-8.71	-0.5	5.72e-16	Erythrocyte sedimentation rate;
SARC	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2562456	0.876	rs11085468	chr19:21751889	C/T	cg00455402	chr19:21769736	NA	-0.37	-4.72	-0.3	4.05e-6	Pain;
SARC	cis	rs17401966	0.931	rs10492972	chr1:10353112	A/G	cg15208524	chr1:10270712	KIF1B	0.48	5.74	0.35	2.99e-8	Hepatocellular carcinoma;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg22384366	chr3:178867004	PIK3CA	-0.76	-6.54	-0.39	3.81e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs12898370	0.651	rs11634056	chr15:77539914	G/A	cg17802220	chr15:77601643	NA	-0.43	-4.8	-0.3	2.85e-6	Risky sexual behaviors (alcohol dependence interaction);
SARC	cis	rs2997447	0.706	rs1414419	chr1:26430501	C/T	cg19633962	chr1:26362018	EXTL1	-0.58	-5.22	-0.32	3.87e-7	QRS complex (12-leadsum);
SARC	cis	rs9858542	0.953	rs9862080	chr3:49674458	A/G	cg07274523	chr3:49395745	GPX1	0.49	5.61	0.35	5.68e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs2576037	0.899	rs2246877	chr18:44577005	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.63	-8.3	-0.48	8.67e-15	Personality dimensions;
SARC	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg22903657	chr4:1355424	KIAA1530	-0.36	-4.83	-0.3	2.46e-6	Obesity-related traits;
SARC	cis	rs765787	0.530	rs11855435	chr15:45522117	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.41	-4.9	-0.31	1.82e-6	Uric acid levels;
SARC	cis	rs7582720	1.000	rs72932557	chr2:203846817	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs6540556	0.643	rs2236903	chr1:209883480	A/T	cg23920097	chr1:209922102	NA	-0.45	-4.99	-0.31	1.2e-6	Red blood cell count;
SARC	cis	rs7582720	1.000	rs72936847	chr2:203774748	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.26	0.43	5.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs57506017	0.585	rs3807865	chr7:12250402	A/G	cg23422036	chr7:12250390	TMEM106B	-0.53	-6.81	-0.41	8.36e-11	Neuroticism;
SARC	cis	rs796364	0.715	rs78988795	chr2:201095739	G/A	cg23649088	chr2:200775458	C2orf69	-0.67	-5.27	-0.33	3.13e-7	Schizophrenia;
SARC	cis	rs883565	0.543	rs784496	chr3:39179536	A/G	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.44	-5.07	-0.32	7.92e-7	Handedness;
SARC	cis	rs1056053	0.514	rs3099269	chr6:166572242	T/A	cg11088901	chr6:166572345	T	-0.42	-5.51	-0.34	9.35e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs7208859	0.623	rs73269913	chr17:29092183	T/C	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.06e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9462027	0.628	rs66506671	chr6:34777149	T/A	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.87	-0.36	1.52e-8	Systemic lupus erythematosus;
SARC	cis	rs3126085	0.935	rs1353436	chr1:152172658	G/A	cg09127314	chr1:152161683	NA	0.43	4.87	0.3	2.06e-6	Atopic dermatitis;
SARC	cis	rs6964587	1.000	rs12540055	chr7:91707921	A/G	cg17063962	chr7:91808500	NA	0.93	15.5	0.71	1.02e-37	Breast cancer;
SARC	cis	rs705471	0.762	rs7919625	chr10:3669970	A/G	cg14308648	chr10:3568949	NA	0.54	7.22	0.43	7.16e-12	Capecitabine sensitivity;
SARC	cis	rs6120849	0.518	rs11696652	chr20:33637060	T/G	cg06115741	chr20:33292138	TP53INP2	0.54	5.16	0.32	5.3e-7	Protein C levels;
SARC	trans	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.55	-7.21	-0.43	7.87e-12	Intelligence (multi-trait analysis);
SARC	cis	rs6449957	0.966	rs73126520	chr5:67475425	C/T	cg23036683	chr5:67512108	NA	0.55	6.42	0.39	7.66e-10	Cleft lip with or without cleft palate;
SARC	cis	rs13161895	0.818	rs114211674	chr5:179484518	A/C	cg02702477	chr5:179499311	RNF130	0.75	6.89	0.41	5.23e-11	LDL cholesterol;
SARC	cis	rs6582630	0.513	rs11181246	chr12:38302670	C/T	cg26384229	chr12:38710491	ALG10B	0.87	12.74	0.64	1.45e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1153858	1.000	rs4774579	chr15:45651803	G/A	cg03999130	chr15:45571217	NA	0.39	4.97	0.31	1.27e-6	Homoarginine levels;
SARC	trans	rs35833281	1.000	rs3122154	chr6:55078458	A/G	cg19977494	chr7:128431264	CCDC136	0.73	6.97	0.42	3.14e-11	Morning vs. evening chronotype;
SARC	cis	rs10463316	0.894	rs4099170	chr5:150766583	G/A	cg03212797	chr5:150827313	SLC36A1	-0.44	-5.26	-0.33	3.34e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs4443100	0.670	rs3788338	chr22:23412058	G/A	cg14186256	chr22:23484241	RTDR1	0.53	5.59	0.34	6.28e-8	Serum parathyroid hormone levels;
SARC	cis	rs870825	0.698	rs66462315	chr4:185623917	C/T	cg04058563	chr4:185651563	MLF1IP	0.82	11.42	0.6	2.8e-24	Blood protein levels;
SARC	cis	rs4713118	0.629	rs172165	chr6:28020814	T/G	cg26335602	chr6:28129616	ZNF389	0.5	5.28	0.33	2.95e-7	Parkinson's disease;
SARC	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg16479474	chr6:28041457	NA	0.37	5.44	0.34	1.37e-7	Depression;
SARC	cis	rs1209950	1.000	rs1209950	chr21:40173528	A/G	cg01359822	chr21:40176597	ETS2	-0.34	-5.43	-0.34	1.4e-7	Non-small cell lung cancer (survival);
SARC	cis	rs4253772	0.550	rs738444	chr22:46721088	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.75	7.47	0.44	1.58e-12	LDL cholesterol;Cholesterol, total;
SARC	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.61	5.11	0.32	6.64e-7	Initial pursuit acceleration;
SARC	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg02951883	chr7:2050386	MAD1L1	0.38	4.84	0.3	2.4e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs9818758	0.607	rs35060561	chr3:49255503	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.73	-6.32	-0.38	1.35e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	trans	rs12554020	0.686	rs56275034	chr9:96325756	G/T	cg26442883	chr16:49686662	ZNF423	0.61	6.58	0.4	3.01e-10	Schizophrenia;
SARC	cis	rs8044995	0.563	rs7190134	chr16:68381516	A/G	cg05110241	chr16:68378359	PRMT7	0.68	6.58	0.4	3.04e-10	Schizophrenia;
SARC	cis	rs8180040	0.966	rs2291298	chr3:47555142	C/A	cg27129171	chr3:47204927	SETD2	0.67	9.07	0.51	5.19e-17	Colorectal cancer;
SARC	cis	rs137699	1.000	rs137703	chr22:39750241	A/G	cg24399712	chr22:39784796	NA	-0.33	-4.72	-0.3	4.02e-6	IgG glycosylation;
SARC	cis	rs4319547	1.000	rs9705654	chr12:123083508	T/C	cg23029597	chr12:123009494	RSRC2	-0.39	-5.04	-0.31	9.25e-7	Body mass index;
SARC	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg13628971	chr7:2884303	GNA12	0.52	6.18	0.38	2.89e-9	Height;
SARC	cis	rs11785400	1.000	rs3824208	chr8:143743653	C/G	cg10596483	chr8:143751796	JRK	0.64	8.65	0.49	8.4e-16	Schizophrenia;
SARC	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg23758822	chr17:41437982	NA	0.87	10.68	0.57	6.32e-22	Menopause (age at onset);
SARC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.76	7.32	0.43	3.95e-12	Platelet count;
SARC	cis	rs240764	0.531	rs1070990	chr6:101264412	T/A	cg09795085	chr6:101329169	ASCC3	0.49	6.46	0.39	5.88e-10	Neuroticism;
SARC	cis	rs4253772	0.550	rs9615951	chr22:46728056	C/A	cg24881330	chr22:46731750	TRMU	0.73	5.92	0.36	1.12e-8	LDL cholesterol;Cholesterol, total;
SARC	cis	rs897080	0.515	rs1067359	chr2:44661997	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	6.15	0.37	3.4e-9	Height;
SARC	cis	rs2153535	0.580	rs9378552	chr6:8463748	G/A	cg21535247	chr6:8435926	SLC35B3	0.54	6.78	0.41	1e-10	Motion sickness;
SARC	cis	rs11792861	0.926	rs11788825	chr9:111829757	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.68	8.1	0.47	3.15e-14	Menarche (age at onset);
SARC	cis	rs981844	0.712	rs1456397	chr4:154744554	C/G	cg14289246	chr4:154710475	SFRP2	0.45	5.32	0.33	2.4e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg23758822	chr17:41437982	NA	0.9	11.51	0.6	1.45e-24	Menopause (age at onset);
SARC	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg17376030	chr22:41985996	PMM1	0.75	9.44	0.53	3.97e-18	Vitiligo;
SARC	cis	rs7555523	0.887	rs4657477	chr1:165736175	C/T	cg19769164	chr1:165738335	TMCO1	0.56	4.71	0.3	4.17e-6	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg07930192	chr7:1003750	NA	0.39	5.13	0.32	6.17e-7	Longevity;Endometriosis;
SARC	cis	rs4689388	0.890	rs4481292	chr4:6298375	C/T	cg14416269	chr4:6271139	WFS1	0.33	5.09	0.32	7.43e-7	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.6	0.53	1.32e-18	Prudent dietary pattern;
SARC	cis	rs3733585	0.699	rs4408959	chr4:9948868	C/T	cg00071950	chr4:10020882	SLC2A9	-0.39	-6.14	-0.37	3.49e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs12079745	0.590	rs10919151	chr1:169334096	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.94	-5.6	-0.34	5.87e-8	QT interval;
SARC	cis	rs6732160	0.588	rs2043100	chr2:73374096	T/C	cg01422370	chr2:73384389	NA	0.37	5.72	0.35	3.22e-8	Intelligence (multi-trait analysis);
SARC	cis	rs10911232	0.507	rs4652769	chr1:183009196	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.34	0.56	7.2e-21	Hypertriglyceridemia;
SARC	cis	rs826838	1.000	rs1684416	chr12:39130301	G/A	cg26384229	chr12:38710491	ALG10B	-0.76	-11.59	-0.6	7.97e-25	Heart rate;
SARC	cis	rs4969178	0.932	rs3744219	chr17:76400236	G/A	cg20026190	chr17:76395443	PGS1	0.4	5.37	0.33	1.86e-7	HDL cholesterol levels;
SARC	cis	rs8031584	0.958	rs11637469	chr15:31238783	T/C	cg14829155	chr15:31115871	NA	-0.42	-5.28	-0.33	2.91e-7	Huntington's disease progression;
SARC	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.49	7.46	0.44	1.66e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs6088580	0.524	rs6088565	chr20:33254986	A/C	cg24642439	chr20:33292090	TP53INP2	-0.54	-6.48	-0.39	5.33e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs17401966	0.964	rs34215045	chr1:10361679	G/A	cg15208524	chr1:10270712	KIF1B	0.6	6.68	0.4	1.75e-10	Hepatocellular carcinoma;
SARC	cis	rs2832191	0.791	rs2832182	chr21:30481612	G/A	cg24692254	chr21:30365293	RNF160	-0.92	-13.86	-0.67	2.95e-32	Dental caries;
SARC	cis	rs2278491	0.528	rs4514005	chr8:117782385	C/T	cg23513447	chr8:117778558	UTP23	-0.49	-5.27	-0.33	3.08e-7	Body mass index;
SARC	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg11814155	chr7:99998594	ZCWPW1	0.44	4.73	0.3	3.84e-6	Platelet count;
SARC	cis	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg21573476	chr21:45109991	RRP1B	-0.55	-8.27	-0.48	1.01e-14	Mean corpuscular volume;
SARC	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg03354898	chr7:1950403	MAD1L1	-0.36	-4.73	-0.3	3.89e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs858239	0.863	rs274054	chr7:23390467	G/C	cg23682824	chr7:23144976	KLHL7	0.59	7.33	0.43	3.65e-12	Cerebrospinal fluid biomarker levels;
SARC	cis	rs694739	0.628	rs11606081	chr11:64137875	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.52	5.66	0.35	4.51e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs644799	1.000	rs474442	chr11:95583995	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.89	14.25	0.68	1.44e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs1371867	0.846	rs1788191	chr8:101260844	C/T	cg11906718	chr8:101322791	RNF19A	-0.73	-9.48	-0.53	3.01e-18	Atrioventricular conduction;
SARC	cis	rs9815354	0.812	rs55748698	chr3:41805233	G/A	cg03022575	chr3:42003672	ULK4	0.72	5.99	0.37	7.83e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg26039829	chr8:22132926	PIWIL2	0.46	6.68	0.4	1.75e-10	Hypertriglyceridemia;
SARC	cis	rs7084402	0.967	rs1649023	chr10:60285820	C/T	cg07615347	chr10:60278583	BICC1	0.59	8.65	0.49	8.68e-16	Refractive error;
SARC	cis	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg25427524	chr10:38739819	LOC399744	0.56	8.2	0.47	1.65e-14	Extrinsic epigenetic age acceleration;
SARC	cis	rs9303280	0.628	rs12939565	chr17:38038389	A/T	cg20243544	chr17:37824526	PNMT	0.44	5.88	0.36	1.39e-8	Self-reported allergy;
SARC	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg18876405	chr7:65276391	NA	-0.47	-5.29	-0.33	2.84e-7	Aortic root size;
SARC	cis	rs7465272	1.000	rs7017842	chr8:143685116	G/A	cg24634471	chr8:143751801	JRK	0.59	6.34	0.38	1.17e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs526231	0.578	rs59323174	chr5:102267869	T/C	cg23492399	chr5:102201601	PAM	-0.44	-5.25	-0.32	3.5e-7	Primary biliary cholangitis;
SARC	cis	rs41271473	0.526	rs28593014	chr1:228743576	G/A	cg16512390	chr1:228756714	NA	0.62	5.63	0.35	5.27e-8	Chronic lymphocytic leukemia;
SARC	cis	rs709400	0.663	rs3742458	chr14:103950368	A/G	cg26031613	chr14:104095156	KLC1	0.82	11.93	0.62	6.36e-26	Body mass index;
SARC	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg08280861	chr8:58055591	NA	0.61	5.96	0.36	9.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg26338869	chr17:61819248	STRADA	0.8	10.85	0.58	1.86e-22	Prudent dietary pattern;
SARC	cis	rs2380220	0.606	rs4571572	chr6:96004823	T/C	cg04719120	chr6:96025338	MANEA	0.59	6.71	0.4	1.46e-10	Behavioural disinhibition (generation interaction);
SARC	cis	rs8016982	0.633	rs9944085	chr14:81717620	A/T	cg01989461	chr14:81687754	GTF2A1	-0.72	-11.0	-0.58	6.17e-23	Schizophrenia;
SARC	cis	rs10448080	0.879	rs240946	chr8:28568905	A/G	cg04440597	chr8:28573618	EXTL3	0.38	4.74	0.3	3.66e-6	Height;
SARC	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg11987759	chr7:65425863	GUSB	0.48	5.76	0.35	2.66e-8	Aortic root size;
SARC	cis	rs6582630	0.555	rs10785454	chr12:38476260	C/T	cg26384229	chr12:38710491	ALG10B	0.84	12.0	0.62	3.64e-26	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2120019	1.000	rs7162900	chr15:75368017	T/C	cg17294928	chr15:75287854	SCAMP5	-0.9	-13.23	-0.66	3.44e-30	Blood trace element (Zn levels);
SARC	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg01448562	chr3:133502909	NA	0.58	9.11	0.51	3.77e-17	Iron status biomarkers;
SARC	cis	rs17345786	0.798	rs4257518	chr3:101281709	C/T	cg11279151	chr3:101281821	RG9MTD1	0.45	5.34	0.33	2.22e-7	Colonoscopy-negative controls vs population controls;
SARC	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg18876405	chr7:65276391	NA	0.47	5.31	0.33	2.53e-7	Aortic root size;
SARC	cis	rs3741404	0.609	rs641378	chr11:63869493	T/C	cg04317338	chr11:64019027	PLCB3	0.48	5.52	0.34	8.86e-8	Platelet count;
SARC	cis	rs453301	0.658	rs6986044	chr8:8874786	G/C	cg08975724	chr8:8085496	FLJ10661	-0.45	-5.72	-0.35	3.3e-8	Joint mobility (Beighton score);
SARC	cis	rs8180040	0.620	rs1811652	chr3:47208698	C/G	cg27129171	chr3:47204927	SETD2	-0.69	-9.43	-0.53	4.2e-18	Colorectal cancer;
SARC	trans	rs3734266	0.702	rs13205210	chr6:34831856	T/C	cg08157914	chr7:2646478	IQCE	0.53	6.29	0.38	1.52e-9	Systemic lupus erythematosus;
SARC	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	11.07	0.59	3.59e-23	Alzheimer's disease;
SARC	cis	rs898097	0.578	rs2380173	chr17:80909157	G/T	cg02711726	chr17:80685570	FN3KRP	0.45	6.39	0.39	9.15e-10	Breast cancer;
SARC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg02592271	chr2:27665507	KRTCAP3	-0.42	-6.42	-0.39	7.6e-10	Total body bone mineral density;
SARC	cis	rs6545883	0.894	rs778144	chr2:61583128	A/C	cg15711740	chr2:61764176	XPO1	0.4	4.84	0.3	2.33e-6	Tuberculosis;
SARC	cis	rs743757	1.000	rs2236954	chr3:50425177	C/A	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.53	4.98	0.31	1.22e-6	Diastolic blood pressure;
SARC	cis	rs2832191	0.716	rs2692625	chr21:30446360	C/G	cg24692254	chr21:30365293	RNF160	1.03	18.22	0.77	1.07e-46	Dental caries;
SARC	cis	rs9916302	0.752	rs6503513	chr17:37561613	A/G	cg20243544	chr17:37824526	PNMT	-0.58	-6.53	-0.39	4.08e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs10911232	0.507	rs10737239	chr1:183030170	A/C	cg13390022	chr1:182993471	LAMC1	0.34	5.19	0.32	4.61e-7	Hypertriglyceridemia;
SARC	cis	rs2250402	0.510	rs2291621	chr15:40324837	C/T	cg10636054	chr15:40330586	SRP14	0.92	6.99	0.42	2.82e-11	Corneal curvature;
SARC	cis	rs3087591	1.000	rs2107360	chr17:29697901	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.49	-6.02	-0.37	6.6e-9	Hip circumference;
SARC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.81	8.6	0.49	1.18e-15	Platelet count;
SARC	cis	rs2635047	1.000	rs9304341	chr18:44670263	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.54	7.36	0.43	3.12e-12	Educational attainment;
SARC	cis	rs7599312	0.534	rs10180824	chr2:213407975	G/A	cg20637307	chr2:213403960	ERBB4	0.8	12.22	0.62	7.34e-27	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs12824058	0.831	rs55726136	chr12:130810312	G/A	cg24838063	chr12:130822603	PIWIL1	0.63	8.94	0.51	1.25e-16	Menopause (age at onset);
SARC	cis	rs4713118	0.826	rs2893929	chr6:27738732	A/T	cg17221315	chr6:27791827	HIST1H4J	0.56	5.75	0.35	2.84e-8	Parkinson's disease;
SARC	cis	rs6570726	0.791	rs1509214	chr6:145784606	A/C	cg05347473	chr6:146136440	FBXO30	-0.5	-6.74	-0.4	1.23e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9815354	0.812	rs73069292	chr3:41973963	T/C	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg14517863	chr17:44321492	NA	0.42	6.25	0.38	1.93e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.31	-0.43	4.36e-12	Gut microbiome composition (summer);
SARC	cis	rs13166103	0.571	rs11957466	chr5:57765340	C/T	cg10487770	chr5:57879443	RAB3C	0.53	5.48	0.34	1.1e-7	Type 2 diabetes (age of onset);
SARC	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg02788857	chr8:22132959	PIWIL2	0.37	5.36	0.33	2.03e-7	Hypertriglyceridemia;
SARC	cis	rs4974559	0.744	rs10024529	chr4:1363886	G/A	cg02980000	chr4:1222292	CTBP1	0.71	5.08	0.32	7.87e-7	Systolic blood pressure;
SARC	cis	rs9715521	0.900	rs6551646	chr4:59824827	A/G	cg11281224	chr4:60001000	NA	-0.39	-4.9	-0.31	1.77e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg04277193	chr17:41438351	NA	0.46	4.97	0.31	1.3e-6	Menopause (age at onset);
SARC	cis	rs8017423	0.967	rs7151776	chr14:90724803	A/G	cg20276874	chr14:90721474	PSMC1	-0.4	-5.6	-0.34	6.01e-8	Mortality in heart failure;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg17350441	chr10:88389642	NA	0.51	7.1	0.42	1.49e-11	Thyroid stimulating hormone;
SARC	cis	rs763121	0.853	rs5750652	chr22:39048316	A/G	cg21395723	chr22:39101663	GTPBP1	0.58	6.91	0.41	4.55e-11	Menopause (age at onset);
SARC	cis	rs11690935	0.959	rs10204502	chr2:172588866	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.99	-15.92	-0.72	4.25e-39	Schizophrenia;
SARC	cis	rs1395	0.744	rs4665962	chr2:27515105	A/G	cg21747090	chr2:27597821	SNX17	-0.54	-6.29	-0.38	1.55e-9	Blood metabolite levels;
SARC	cis	rs611744	0.967	rs682007	chr8:109210326	G/C	cg21045802	chr8:109455806	TTC35	0.45	5.32	0.33	2.41e-7	Dupuytren's disease;
SARC	cis	rs8060686	0.920	rs73594556	chr16:67925435	G/A	cg27539214	chr16:67997921	SLC12A4	-0.54	-5.11	-0.32	6.76e-7	HDL cholesterol;Metabolic syndrome;
SARC	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg09839136	chr7:766187	HEATR2;PRKAR1B	0.59	5.1	0.32	7e-7	Cerebrospinal P-tau181p levels;
SARC	cis	rs6840360	0.533	rs4696297	chr4:152725838	T/G	cg22705602	chr4:152727874	NA	0.47	8.15	0.47	2.28e-14	Intelligence (multi-trait analysis);
SARC	cis	rs9790314	1.000	rs336548	chr3:161058412	T/C	cg04691961	chr3:161091175	C3orf57	-0.79	-11.99	-0.62	4.04e-26	Morning vs. evening chronotype;
SARC	cis	rs1707322	1.000	rs34446427	chr1:46417655	A/C	cg06784218	chr1:46089804	CCDC17	0.34	5.98	0.36	8.31e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7598759	0.675	rs6727530	chr2:232332058	T/C	cg19187155	chr2:232395269	NMUR1	0.6	8.52	0.49	2e-15	Noise-induced hearing loss;
SARC	cis	rs4332037	1.000	rs6947019	chr7:1950337	G/A	cg23422044	chr7:1970798	MAD1L1	-0.47	-5.04	-0.31	9.32e-7	Bipolar disorder;
SARC	cis	rs2180341	0.883	rs7760748	chr6:127690062	C/T	cg24812749	chr6:127587940	RNF146	1.02	13.46	0.66	6.06e-31	Breast cancer;
SARC	cis	rs13006833	0.739	rs12693568	chr2:191202637	A/G	cg25963032	chr2:191064776	C2orf88	0.38	5.3	0.33	2.71e-7	Urinary metabolites;
SARC	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg13393036	chr8:95962371	TP53INP1	-0.35	-5.92	-0.36	1.15e-8	Type 2 diabetes;
SARC	trans	rs56341938	0.757	rs1420465	chr3:168715138	C/G	cg08633923	chr1:236959181	MTR	-0.51	-6.39	-0.39	9.14e-10	Lung function (FEV1/FVC);
SARC	trans	rs7824557	0.767	rs28507159	chr8:11166076	C/T	cg06636001	chr8:8085503	FLJ10661	0.57	6.98	0.42	3.02e-11	Retinal vascular caliber;
SARC	cis	rs2153535	0.580	rs1928184	chr6:8532108	T/A	cg07606381	chr6:8435919	SLC35B3	0.76	11.06	0.59	4.01e-23	Motion sickness;
SARC	cis	rs7481584	1.000	rs12786344	chr11:3021392	G/A	cg05729581	chr11:3078854	CARS	0.47	5.78	0.35	2.42e-8	Calcium levels;
SARC	cis	rs6693567	0.565	rs12731296	chr1:150411787	A/G	cg09579323	chr1:150459698	TARS2	0.44	5.58	0.34	6.5e-8	Migraine;
SARC	cis	rs6754311	0.551	rs6739713	chr2:136488978	A/G	cg07169764	chr2:136633963	MCM6	0.46	5.55	0.34	7.73e-8	Mosquito bite size;
SARC	cis	rs6493487	0.512	rs12907367	chr15:51265986	A/G	cg02338191	chr15:51200825	AP4E1	0.55	5.09	0.32	7.52e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs4595586	0.525	rs7313120	chr12:39388027	A/G	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	trans	rs17221829	0.733	rs11018668	chr11:89356178	C/T	cg21763952	chr12:111051697	TCTN1	-0.46	-6.24	-0.38	2.02e-9	Anxiety in major depressive disorder;
SARC	cis	rs926938	0.527	rs11084	chr1:115537933	A/G	cg12756093	chr1:115239321	AMPD1	0.38	4.71	0.3	4.16e-6	Autism;
SARC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.42	0.8	8.36e-54	Prudent dietary pattern;
SARC	trans	rs4866650	0.803	rs16869638	chr5:2448538	A/G	cg18888710	chr2:10917862	ATP6V1C2	-0.84	-6.27	-0.38	1.77e-9	Left inferior lateral ventricle volume (Cerebrospinal fluid biomarker status interaction);
SARC	cis	rs6840360	0.593	rs2089811	chr4:152685171	C/T	cg22705602	chr4:152727874	NA	0.48	8.47	0.49	2.74e-15	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg11062466	chr8:58055876	NA	0.53	5.48	0.34	1.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg22834771	chr12:69754056	YEATS4	-0.48	-6.29	-0.38	1.55e-9	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9911578	0.967	rs12944948	chr17:56951474	A/G	cg12560992	chr17:57184187	TRIM37	0.86	11.82	0.61	1.41e-25	Intelligence (multi-trait analysis);
SARC	cis	rs7927592	0.913	rs12284933	chr11:68319489	G/A	cg01657329	chr11:68192670	LRP5	-0.41	-4.82	-0.3	2.55e-6	Total body bone mineral density;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg05330668	chr14:24836090	NFATC4	0.52	6.54	0.39	3.95e-10	Breast cancer;
SARC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	20.42	0.8	8.12e-54	Prudent dietary pattern;
SARC	cis	rs35110281	0.667	rs4819286	chr21:45120121	G/A	cg01579765	chr21:45077557	HSF2BP	-0.36	-5.79	-0.35	2.3e-8	Mean corpuscular volume;
SARC	cis	rs710216	0.843	rs10890232	chr1:43416514	C/T	cg07803811	chr1:43423981	SLC2A1	0.58	6.43	0.39	6.97e-10	Red cell distribution width;
SARC	cis	rs1920116	0.778	rs12494201	chr3:169559856	T/C	cg08193579	chr3:169529701	LRRC34	0.39	4.72	0.3	3.98e-6	Glioma (high-grade);
SARC	cis	rs735539	0.593	rs2818997	chr13:21369315	C/T	cg16922012	chr13:21400325	XPO4	-0.39	-5.56	-0.34	7.31e-8	Dental caries;
SARC	cis	rs9790314	1.000	rs336590	chr3:161079583	G/A	cg04691961	chr3:161091175	C3orf57	-0.79	-11.68	-0.61	4.15e-25	Morning vs. evening chronotype;
SARC	cis	rs6582630	0.615	rs12821226	chr12:38546406	C/T	cg26384229	chr12:38710491	ALG10B	-0.59	-7.56	-0.44	9.4e-13	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs4713118	0.869	rs10214440	chr6:27702440	A/C	cg17221315	chr6:27791827	HIST1H4J	0.48	5.27	0.33	3.04e-7	Parkinson's disease;
SARC	cis	rs1538970	0.884	rs61788261	chr1:45899114	G/A	cg05343316	chr1:45956843	TESK2	0.78	8.92	0.5	1.44e-16	Platelet count;
SARC	cis	rs2204008	0.540	rs1283306	chr12:38153778	C/A	cg13010199	chr12:38710504	ALG10B	-0.63	-7.89	-0.46	1.16e-13	Bladder cancer;
SARC	cis	rs526231	0.543	rs4386712	chr5:102369234	T/C	cg23492399	chr5:102201601	PAM	-0.51	-5.58	-0.34	6.63e-8	Primary biliary cholangitis;
SARC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.95	11.02	0.59	5.25e-23	Platelet count;
SARC	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg27266027	chr21:40555129	PSMG1	-0.44	-4.86	-0.3	2.15e-6	Cognitive function;
SARC	cis	rs6060717	0.654	rs6058347	chr20:34483781	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.52	4.99	0.31	1.18e-6	Hip circumference adjusted for BMI;
SARC	cis	rs9868809	0.764	rs2633958	chr3:48635432	A/G	cg00383909	chr3:49044727	WDR6	-0.64	-5.0	-0.31	1.11e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs858239	0.601	rs6948469	chr7:23174766	G/T	cg23682824	chr7:23144976	KLHL7	0.72	9.69	0.54	7.06e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs7937682	0.883	rs472465	chr11:111468962	C/T	cg22437258	chr11:111473054	SIK2	0.76	9.87	0.54	2.07e-19	Primary sclerosing cholangitis;
SARC	cis	rs75804782	0.557	rs3769118	chr2:239342542	C/G	cg21699342	chr2:239360505	ASB1	-0.59	-5.9	-0.36	1.29e-8	Morning vs. evening chronotype;Chronotype;
SARC	cis	rs1784581	0.651	rs1784589	chr6:162389571	A/G	cg17173639	chr6:162384350	PARK2	-0.6	-7.76	-0.45	2.69e-13	Itch intensity from mosquito bite;
SARC	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.94	10.04	0.55	5.91e-20	Platelet count;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg23555592	chr10:91174309	IFIT5	-0.52	-7.05	-0.42	2.02e-11	Thyroid stimulating hormone;
SARC	cis	rs6003958	1	rs6003958	chr22:24264089	T/G	cg01238044	chr22:24384105	GSTT1	0.68	7.29	0.43	4.68e-12	S-phenylmercapturic acid levels in smokers;
SARC	cis	rs1865760	0.622	rs9968910	chr6:26072095	A/C	cg16482183	chr6:26056742	HIST1H1C	0.55	6.5	0.39	4.74e-10	Height;
SARC	cis	rs4660261	0.562	rs3011223	chr1:44318286	T/C	cg12908607	chr1:44402522	ARTN	-0.33	-5.78	-0.35	2.44e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7659604	0.502	rs10212738	chr4:122675724	G/A	cg19671926	chr4:122722719	EXOSC9	0.55	6.99	0.42	2.87e-11	Type 2 diabetes;
SARC	cis	rs3857536	0.776	rs6941904	chr6:66931042	A/G	cg07460842	chr6:66804631	NA	-0.51	-5.86	-0.36	1.59e-8	Blood trace element (Cu levels);
SARC	cis	rs7561273	0.586	rs13418279	chr2:24349218	G/T	cg07265300	chr2:24346000	PFN4;LOC375190	-0.42	-4.77	-0.3	3.26e-6	Quantitative traits;
SARC	cis	rs62244186	0.566	rs55901755	chr3:44834707	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.56	7.3	0.43	4.39e-12	Depressive symptoms;
SARC	cis	rs3808502	0.526	rs11783065	chr8:11417257	A/G	cg21775007	chr8:11205619	TDH	-0.43	-5.52	-0.34	9.04e-8	Neuroticism;
SARC	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg21724239	chr8:58056113	NA	0.62	6.01	0.37	7.26e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2635047	0.638	rs13381713	chr18:44669499	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	6.56	0.39	3.5e-10	Educational attainment;
SARC	cis	rs10861342	1.000	rs11112359	chr12:105471661	C/A	cg23923672	chr12:105501055	KIAA1033	0.73	5.3	0.33	2.67e-7	IgG glycosylation;
SARC	cis	rs9640161	0.702	rs1962004	chr7:150020381	G/A	cg17279839	chr7:150038598	RARRES2	0.49	6.55	0.39	3.57e-10	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs2370759	1.000	rs2769241	chr10:32556229	T/C	cg01819863	chr10:32635814	EPC1	-0.98	-9.49	-0.53	2.92e-18	Sexual dysfunction (female);
SARC	cis	rs6570726	0.764	rs9403731	chr6:145907937	G/A	cg05347473	chr6:146136440	FBXO30	0.52	7.22	0.43	7.41e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg08280861	chr8:58055591	NA	0.61	5.96	0.36	9.44e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs11098499	0.954	rs13113483	chr4:120309039	C/T	cg25214090	chr10:38739885	LOC399744	0.55	7.14	0.42	1.15e-11	Corneal astigmatism;
SARC	cis	rs742614	0.533	rs6059499	chr20:32447920	C/T	cg06304546	chr20:32448765	NA	0.57	7.48	0.44	1.53e-12	Stearic acid (18:0) levels;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg17704177	chr6:36562212	SFRS3	-0.59	-6.81	-0.41	8.03e-11	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg11644478	chr21:40555479	PSMG1	-0.86	-10.93	-0.58	1.01e-22	Cognitive function;
SARC	cis	rs59918340	0.764	rs4961258	chr8:142232878	A/G	cg23750338	chr8:142222470	SLC45A4	-0.29	-4.72	-0.3	4.09e-6	Immature fraction of reticulocytes;
SARC	cis	rs362296	0.698	rs3095082	chr4:3263617	C/A	cg06533319	chr4:3265114	C4orf44	0.32	5.17	0.32	5.08e-7	Parental longevity (mother's age at death);
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg00645897	chr1:46713442	RAD54L	0.5	6.87	0.41	5.89e-11	Tetralogy of Fallot;
SARC	cis	rs1957429	0.520	rs72625645	chr14:65343431	G/C	cg23373153	chr14:65346875	NA	-0.82	-5.71	-0.35	3.45e-8	Pediatric areal bone mineral density (radius);
SARC	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg03351412	chr1:154909251	PMVK	0.64	8.15	0.47	2.17e-14	Prostate cancer;
SARC	cis	rs1448094	0.967	rs10746357	chr12:86341044	A/T	cg02569458	chr12:86230093	RASSF9	0.4	5.85	0.36	1.68e-8	Major depressive disorder;
SARC	cis	rs10463554	0.927	rs6862616	chr5:102246038	T/C	cg23492399	chr5:102201601	PAM	-0.47	-5.54	-0.34	8.17e-8	Parkinson's disease;
SARC	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.69	7.21	0.43	7.94e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs4959677	0.901	rs6920875	chr6:2478975	C/T	cg04780909	chr6:1610669	FOXC1	-0.38	-4.77	-0.3	3.29e-6	Orthostatic hypotension;
SARC	cis	rs8064024	0.538	rs12446456	chr16:4922201	C/T	cg08329684	chr16:4932620	PPL	0.41	6.57	0.4	3.22e-10	Cancer;
SARC	trans	rs11722228	0.508	rs3756227	chr4:10087995	C/A	cg26043149	chr18:55253948	FECH	0.69	7.81	0.46	1.91e-13	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs10936602	0.520	rs3732451	chr3:169558025	C/T	cg27020690	chr3:169482358	NA	0.39	4.94	0.31	1.47e-6	Renal cell carcinoma;
SARC	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg03650068	chr1:25596491	NA	0.32	4.98	0.31	1.23e-6	Erythrocyte sedimentation rate;
SARC	cis	rs1113500	0.933	rs61797344	chr1:108622580	C/T	cg06207961	chr1:108661230	NA	0.45	5.93	0.36	1.1e-8	Growth-regulated protein alpha levels;
SARC	cis	rs7264396	0.635	rs6121102	chr20:34544274	A/G	cg12579300	chr20:34535607	PHF20	-0.41	-4.8	-0.3	2.84e-6	Total cholesterol levels;
SARC	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg19077165	chr18:44547161	KATNAL2	-0.52	-7.29	-0.43	4.74e-12	Personality dimensions;
SARC	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg26335602	chr6:28129616	ZNF389	0.53	5.88	0.36	1.43e-8	Depression;
SARC	cis	rs9291683	0.552	rs3796832	chr4:10015865	C/T	cg00071950	chr4:10020882	SLC2A9	0.39	6.25	0.38	1.95e-9	Bone mineral density;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg08916340	chr10:112631462	LOC282997;PDCD4	0.54	6.82	0.41	7.6e-11	Height;
SARC	cis	rs1153858	1.000	rs4534782	chr15:45652933	G/A	cg26924012	chr15:45694286	SPATA5L1	0.78	11.14	0.59	2.18e-23	Homoarginine levels;
SARC	trans	rs61931739	0.500	rs73103774	chr12:34482279	C/T	cg13010199	chr12:38710504	ALG10B	0.82	11.59	0.6	7.91e-25	Morning vs. evening chronotype;
SARC	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg12463550	chr7:65579703	CRCP	-0.7	-5.34	-0.33	2.21e-7	Diabetic kidney disease;
SARC	cis	rs1057510	0.790	rs2259931	chr12:6719894	T/C	cg06495803	chr12:6553489	CD27;LOC678655	0.43	4.71	0.3	4.19e-6	Myopia (pathological);
SARC	cis	rs78320035	1.000	rs79655597	chr1:168095842	A/C	cg17113809	chr1:168148080	TIPRL	1.1	6.38	0.39	9.57e-10	Red cell distribution width;
SARC	trans	rs3780486	0.846	rs7850878	chr9:33126570	A/G	cg04842962	chr6:43655489	MRPS18A	1.1	20.6	0.8	2.08e-54	IgG glycosylation;
SARC	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg13206674	chr6:150067644	NUP43	0.46	6.03	0.37	6.45e-9	Lung cancer;
SARC	cis	rs7833986	0.941	rs13278255	chr8:57067975	C/T	cg26371346	chr8:56986568	SNORD54;RPS20	0.57	4.96	0.31	1.35e-6	Height;
SARC	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg18252515	chr7:66147081	NA	0.59	6.34	0.38	1.17e-9	Aortic root size;
SARC	cis	rs1008375	0.932	rs6845288	chr4:17665498	A/T	cg16339924	chr4:17578868	LAP3	-0.62	-7.82	-0.46	1.84e-13	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs9929218	1.000	rs9937664	chr16:68784603	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.63	-8.1	-0.47	3.05e-14	Colorectal cancer;
SARC	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg07701084	chr6:150067640	NUP43	-0.4	-4.77	-0.3	3.22e-6	Lung cancer;
SARC	cis	rs10464366	0.517	rs13231075	chr7:39174806	G/T	cg18850127	chr7:39170497	POU6F2	0.4	5.28	0.33	2.91e-7	IgG glycosylation;
SARC	cis	rs5753037	0.585	rs249396	chr22:30213972	T/G	cg01021169	chr22:30184971	ASCC2	-0.54	-7.48	-0.44	1.49e-12	Type 1 diabetes;
SARC	cis	rs7584330	0.744	rs10929235	chr2:238380272	A/G	cg14458575	chr2:238380390	NA	0.56	6.22	0.38	2.27e-9	Prostate cancer;
SARC	cis	rs10504073	0.647	rs4873312	chr8:49991145	A/G	cg00325661	chr8:49890786	NA	0.54	7.22	0.43	7.43e-12	Blood metabolite ratios;
SARC	cis	rs7216064	1.000	rs2046323	chr17:65849927	T/G	cg12091567	chr17:66097778	LOC651250	-0.66	-6.72	-0.4	1.39e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg26839252	chr6:160211577	TCP1;MRPL18	-0.53	-4.91	-0.31	1.71e-6	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs708547	0.874	rs1718868	chr4:57881215	G/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.46	-5.07	-0.32	8.1e-7	Response to bleomycin (chromatid breaks);
SARC	cis	rs72634258	0.554	rs12723500	chr1:7857374	G/C	cg26816564	chr1:7831052	VAMP3	0.57	4.93	0.31	1.57e-6	Inflammatory bowel disease;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg26979339	chr12:107168153	RIC8B	-0.78	-6.31	-0.38	1.43e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs10845606	1.000	rs10845606	chr12:12834894	G/T	cg04607235	chr12:12878440	APOLD1	-0.53	-5.3	-0.33	2.73e-7	Systemic lupus erythematosus;
SARC	cis	rs6665290	0.904	rs1045287	chr1:227178962	C/T	cg14016676	chr1:227182615	CDC42BPA	-0.34	-5.09	-0.32	7.55e-7	Myeloid white cell count;
SARC	cis	rs6540556	0.723	rs12120361	chr1:209913473	A/C	cg23920097	chr1:209922102	NA	-0.51	-5.38	-0.33	1.79e-7	Red blood cell count;
SARC	cis	rs12893668	0.703	rs34026011	chr14:104050883	G/A	cg26031613	chr14:104095156	KLC1	-0.58	-6.43	-0.39	7.34e-10	Reticulocyte count;
SARC	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	10.48	0.57	2.62e-21	Alzheimer's disease;
SARC	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg11764359	chr7:65958608	NA	0.88	12.58	0.64	4.89e-28	Aortic root size;
SARC	cis	rs11997175	0.625	rs11991490	chr8:33595407	T/C	ch.8.33884649F	chr8:33765107	NA	0.49	6.32	0.38	1.29e-9	Body mass index;
SARC	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg17971929	chr21:40555470	PSMG1	0.96	11.84	0.61	1.25e-25	Cognitive function;
SARC	cis	rs453301	0.686	rs28482034	chr8:8869664	G/A	cg11608241	chr8:8085544	FLJ10661	-0.44	-5.48	-0.34	1.08e-7	Joint mobility (Beighton score);
SARC	cis	rs7819412	0.505	rs17782536	chr8:11021682	A/G	cg21775007	chr8:11205619	TDH	-0.45	-5.7	-0.35	3.64e-8	Triglycerides;
SARC	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg18876405	chr7:65276391	NA	0.7	8.68	0.49	6.76e-16	Aortic root size;
SARC	cis	rs763121	0.853	rs3747170	chr22:39067331	G/A	cg21395723	chr22:39101663	GTPBP1	0.53	5.94	0.36	1.03e-8	Menopause (age at onset);
SARC	cis	rs3857536	0.813	rs7768944	chr6:66951088	C/T	cg07460842	chr6:66804631	NA	-0.45	-5.19	-0.32	4.5e-7	Blood trace element (Cu levels);
SARC	cis	rs8031584	0.541	rs2959037	chr15:31218164	T/C	cg14829155	chr15:31115871	NA	0.42	5.74	0.35	2.93e-8	Huntington's disease progression;
SARC	cis	rs7727544	0.684	rs2516788	chr5:131715565	G/C	cg07395648	chr5:131743802	NA	0.42	4.96	0.31	1.37e-6	Blood metabolite levels;
SARC	cis	rs920590	0.758	rs17091534	chr8:19670651	C/T	cg01411142	chr8:19674711	INTS10	0.51	6.03	0.37	6.35e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs8058578	0.832	rs3812999	chr16:30773605	G/T	cg02466173	chr16:30829666	NA	-0.43	-5.56	-0.34	7.41e-8	Multiple myeloma;
SARC	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg22875332	chr1:76189707	ACADM	0.49	6.8	0.41	8.49e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs11786130	1.000	rs10956403	chr8:129007207	A/G	cg01765152	chr8:129005526	PVT1	-0.5	-8.35	-0.48	6.21e-15	Eosinophil counts;Sum eosinophil basophil counts;
SARC	trans	rs11098499	0.909	rs7659501	chr4:120371552	G/T	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	cis	rs642803	0.527	rs1647570	chr11:65568256	A/T	cg08755490	chr11:65554678	OVOL1	-0.42	-5.21	-0.32	4.16e-7	Urate levels;
SARC	cis	rs501120	1.000	rs607363	chr10:44761623	A/G	cg09554077	chr10:44749378	NA	0.48	6.45	0.39	6.48e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs7412746	0.658	rs59024312	chr1:150909005	T/G	cg15448220	chr1:150897856	SETDB1	0.51	6.65	0.4	2.02e-10	Melanoma;
SARC	cis	rs10911232	0.507	rs10911231	chr1:183051745	T/A	cg13390022	chr1:182993471	LAMC1	0.33	5.06	0.31	8.41e-7	Hypertriglyceridemia;
SARC	cis	rs7246657	0.943	rs10417844	chr19:37837587	C/T	cg23950597	chr19:37808831	NA	-0.54	-5.47	-0.34	1.15e-7	Coronary artery calcification;
SARC	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs67460515	0.892	rs11711695	chr3:161057593	A/G	cg04691961	chr3:161091175	C3orf57	-0.49	-6.15	-0.37	3.31e-9	Parkinson's disease;
SARC	cis	rs9807989	0.811	rs11688568	chr2:102969949	C/T	cg09003973	chr2:102972529	NA	0.41	5.57	0.34	7.03e-8	Asthma;
SARC	cis	rs12451471	0.620	rs11150846	chr17:78098520	C/T	cg06718696	chr17:78121285	EIF4A3	0.85	9.96	0.55	1.04e-19	Plateletcrit;Mean corpuscular hemoglobin concentration;
SARC	cis	rs4481887	0.538	rs4916117	chr1:248387187	G/C	cg13385794	chr1:248469461	NA	0.37	4.96	0.31	1.37e-6	Common traits (Other);
SARC	cis	rs28374715	0.662	rs72737792	chr15:41515589	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.99	-14.16	-0.68	3.03e-33	Ulcerative colitis;
SARC	cis	rs7772486	0.790	rs9376971	chr6:146259505	C/T	cg23711669	chr6:146136114	FBXO30	-0.8	-12.47	-0.63	1.13e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.91	11.07	0.59	3.6e-23	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs31872	0.526	rs810277	chr5:140452494	A/G	cg19650706	chr5:140594406	PCDHB13	-0.5	-6.05	-0.37	5.83e-9	Visceral adipose tissue adjusted for BMI;
SARC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.67	9.0	0.51	8.01e-17	Lymphocyte counts;
SARC	cis	rs7264396	0.563	rs3827029	chr20:34332784	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.68	6.88	0.41	5.33e-11	Total cholesterol levels;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg07595554	chr1:17380588	SDHB	-0.78	-6.5	-0.39	4.86e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg20607798	chr8:58055168	NA	0.61	5.41	0.33	1.57e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg00152838	chr16:24741724	TNRC6A	0.56	6.05	0.37	5.83e-9	Intelligence (multi-trait analysis);
SARC	cis	rs12908161	1.000	rs12912388	chr15:85344550	T/A	cg17507749	chr15:85114479	UBE2QP1	0.54	6.28	0.38	1.68e-9	Schizophrenia;
SARC	cis	rs12682352	0.652	rs1567398	chr8:8726804	A/C	cg08975724	chr8:8085496	FLJ10661	-0.42	-5.21	-0.32	4.2e-7	Neuroticism;
SARC	cis	rs1957429	0.614	rs380741	chr14:65322027	C/T	cg23373153	chr14:65346875	NA	-0.66	-5.52	-0.34	9.09e-8	Pediatric areal bone mineral density (radius);
SARC	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg08219700	chr8:58056026	NA	0.72	6.73	0.4	1.34e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9303401	0.659	rs34556735	chr17:56694447	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	11.52	0.6	1.34e-24	Cognitive test performance;
SARC	cis	rs13191362	0.935	rs35537826	chr6:163145867	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.38	4.94	0.31	1.46e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs10791097	0.765	rs10894269	chr11:130722789	C/T	cg12179176	chr11:130786555	SNX19	0.63	8.78	0.5	3.64e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs62244186	0.541	rs62244226	chr3:44831831	G/A	cg15687855	chr3:44754131	ZNF502	-0.34	-5.12	-0.32	6.44e-7	Depressive symptoms;
SARC	cis	rs4481887	0.538	rs6697831	chr1:248392205	C/T	cg13385794	chr1:248469461	NA	0.38	5.06	0.31	8.48e-7	Common traits (Other);
SARC	cis	rs7666738	0.830	rs10470893	chr4:99038756	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06996869	chr11:93474705	C11orf54;TAF1D	-0.55	-7.02	-0.42	2.41e-11	Smoking initiation;
SARC	cis	rs73086581	0.838	rs11906481	chr20:4028706	C/T	cg02187196	chr20:3869020	PANK2	0.51	4.82	0.3	2.56e-6	Response to antidepressants in depression;
SARC	cis	rs9341808	0.628	rs1892475	chr6:80862213	T/C	cg08355045	chr6:80787529	NA	0.37	5.81	0.36	2.01e-8	Sitting height ratio;
SARC	cis	rs17376456	0.825	rs17314797	chr5:93234845	T/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.66	0.35	4.4e-8	Diabetic retinopathy;
SARC	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg18357526	chr6:26021779	HIST1H4A	0.46	5.89	0.36	1.34e-8	Blood metabolite levels;
SARC	cis	rs7223966	1.000	rs16947042	chr17:61766457	T/G	cg26338869	chr17:61819248	STRADA	0.44	5.14	0.32	5.82e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs17221829	0.733	rs11018668	chr11:89356178	C/T	cg10002837	chr19:36545633	WDR62;THAP8	0.46	6.29	0.38	1.54e-9	Anxiety in major depressive disorder;
SARC	cis	rs12477438	0.765	rs6722164	chr2:99561527	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-7.89	-0.46	1.19e-13	Chronic sinus infection;
SARC	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg15352829	chr14:105391018	PLD4	-0.33	-6.33	-0.38	1.24e-9	Rheumatoid arthritis;
SARC	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg11890956	chr21:40555474	PSMG1	-1.04	-15.98	-0.72	2.56e-39	Cognitive function;
SARC	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg05861140	chr6:150128134	PCMT1	-0.36	-4.79	-0.3	2.99e-6	Lung cancer;
SARC	cis	rs6060717	0.536	rs8125966	chr20:34511823	A/G	cg01084648	chr20:34329383	RBM39	0.62	4.73	0.3	3.89e-6	Hip circumference adjusted for BMI;
SARC	cis	rs58785573	0.504	rs3860067	chr4:38611905	T/C	cg18361445	chr4:38666374	KLF3;FLJ13197	0.4	5.07	0.32	8.18e-7	Lymphocyte percentage of white cells;
SARC	cis	rs3815700	0.920	rs10424732	chr19:33096487	C/T	cg24916020	chr19:33096688	ANKRD27	0.58	5.64	0.35	4.8e-8	Eosinophilic esophagitis;
SARC	cis	rs9467773	0.844	rs2393669	chr6:26503873	C/T	cg11502198	chr6:26597334	ABT1	0.48	5.98	0.36	8.37e-9	Intelligence (multi-trait analysis);
SARC	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg26119090	chr2:26468346	HADHA;HADHB	0.97	14.18	0.68	2.59e-33	Gut microbiome composition (summer);
SARC	cis	rs6580649	0.941	rs11609399	chr12:48501161	A/T	cg24011408	chr12:48396354	COL2A1	-0.47	-5.34	-0.33	2.22e-7	Lung cancer;
SARC	cis	rs2070488	0.896	rs11914389	chr3:38527215	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.83	13.5	0.66	4.6e-31	Electrocardiographic conduction measures;
SARC	cis	rs11225247	0.764	rs11225237	chr11:102250527	A/G	cg11690896	chr11:102217788	BIRC2	0.77	5.37	0.33	1.93e-7	Vein graft stenosis in coronary artery bypass grafting;
SARC	cis	rs12368653	0.591	rs1552842	chr12:58012163	A/G	cg00677455	chr12:58241039	CTDSP2	0.4	5.41	0.33	1.59e-7	Multiple sclerosis;
SARC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.36	0.8	1.22e-53	Prudent dietary pattern;
SARC	cis	rs763121	0.853	rs926299	chr22:39095698	C/G	cg21395723	chr22:39101663	GTPBP1	0.56	6.73	0.4	1.29e-10	Menopause (age at onset);
SARC	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg11764359	chr7:65958608	NA	-0.87	-12.29	-0.63	4.37e-27	Aortic root size;
SARC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.55	-9.61	-0.53	1.28e-18	Longevity;Endometriosis;
SARC	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg02725872	chr8:58115012	NA	-0.34	-5.37	-0.33	1.91e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs651907	0.535	rs34648996	chr3:101511202	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.48	5.61	0.34	5.72e-8	Colorectal cancer;
SARC	trans	rs208520	0.837	rs208486	chr6:66926255	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-11.15	-0.59	1.99e-23	Exhaled nitric oxide output;
SARC	cis	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg25427524	chr10:38739819	LOC399744	-0.52	-8.23	-0.47	1.32e-14	Extrinsic epigenetic age acceleration;
SARC	cis	rs72945132	0.660	rs12292191	chr11:70122426	T/C	cg00319359	chr11:70116639	PPFIA1	0.68	6.35	0.38	1.14e-9	Coronary artery disease;
SARC	cis	rs765787	0.530	rs1706837	chr15:45519036	A/G	cg24006582	chr15:45444508	DUOX1	-0.49	-6.43	-0.39	7.33e-10	Uric acid levels;
SARC	cis	rs910316	0.934	rs8006587	chr14:75664939	A/G	cg08847533	chr14:75593920	NEK9	0.84	13.26	0.66	2.75e-30	Height;
SARC	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg23172400	chr8:95962367	TP53INP1	-0.35	-5.98	-0.36	8.43e-9	Type 2 diabetes;
SARC	cis	rs6700896	0.931	rs7531867	chr1:66107546	A/G	cg04111102	chr1:66153794	NA	-0.35	-5.39	-0.33	1.76e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs6912958	0.712	rs2246113	chr6:88410050	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.3	-4.94	-0.31	1.47e-6	Monocyte percentage of white cells;
SARC	cis	rs4423214	1.000	rs11600569	chr11:71173747	C/G	cg05163923	chr11:71159392	DHCR7	0.64	8.91	0.5	1.48e-16	Vitamin D levels;
SARC	cis	rs1401999	1.000	rs6443926	chr3:183706630	A/C	cg01324343	chr3:183735012	ABCC5	0.66	13.09	0.65	1.05e-29	Anterior chamber depth;
SARC	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg22535103	chr8:58192502	C8orf71	-0.73	-7.24	-0.43	6.52e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs17125944	1.000	rs17125924	chr14:53391680	A/G	cg00686598	chr14:53173677	PSMC6	0.88	6.29	0.38	1.54e-9	Alzheimer's disease (late onset);
SARC	cis	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg07636037	chr3:49044803	WDR6	0.48	5.56	0.34	7.3900000000000007e-08	Resting heart rate;
SARC	cis	rs6060717	0.536	rs2425104	chr20:34312346	C/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.68	5.54	0.34	7.96e-8	Hip circumference adjusted for BMI;
SARC	cis	rs1034435	0.543	rs5768672	chr22:48882605	C/T	cg05992904	chr22:48892994	FAM19A5	-0.43	-5.24	-0.32	3.63e-7	Late-onset Alzheimer's disease;
SARC	cis	rs910316	1.000	rs11159117	chr14:75584867	C/T	cg06637938	chr14:75390232	RPS6KL1	0.5	7.03	0.42	2.2e-11	Height;
SARC	cis	rs9329289	0.510	rs28579610	chr10:2546080	C/A	cg15501526	chr10:2543763	NA	0.37	5.68	0.35	4.03e-8	Age-related hearing impairment;
SARC	cis	rs11209002	0.567	rs2815385	chr1:67542083	A/G	cg02640540	chr1:67518911	SLC35D1	0.57	6.27	0.38	1.78e-9	Crohn's disease;
SARC	cis	rs2115630	0.691	rs2292462	chr15:85200754	G/T	cg17507749	chr15:85114479	UBE2QP1	-0.52	-6.15	-0.37	3.4e-9	P wave terminal force;
SARC	cis	rs477692	0.792	rs12762024	chr10:131441055	G/C	cg05714579	chr10:131428358	MGMT	-0.62	-8.48	-0.49	2.62e-15	Response to temozolomide;
SARC	cis	rs9322817	0.691	rs2499664	chr6:105301484	C/G	cg02098413	chr6:105308735	HACE1	0.38	5.9	0.36	1.25e-8	Thyroid stimulating hormone;
SARC	cis	rs939574	0.676	rs10166888	chr2:220136836	G/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.5	-5.1	-0.32	6.91e-7	Platelet distribution width;
SARC	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg19748678	chr4:122722346	EXOSC9	0.76	9.43	0.53	4.18e-18	Type 2 diabetes;
SARC	cis	rs10870270	1.000	rs10870270	chr10:133754334	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.84	-11.02	-0.59	5.29e-23	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs2120019	1.000	rs12898259	chr15:75369780	G/A	cg00629941	chr15:75287862	SCAMP5	-0.6	-7.27	-0.43	5.46e-12	Blood trace element (Zn levels);
SARC	cis	rs7937682	0.564	rs11600652	chr11:111754368	A/T	cg09085632	chr11:111637200	PPP2R1B	0.77	10.41	0.56	4.37e-21	Primary sclerosing cholangitis;
SARC	cis	rs73206853	0.686	rs73194018	chr12:111127697	G/A	cg10860002	chr12:110842031	ANAPC7	0.65	5.39	0.33	1.69e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs9611519	0.964	rs5995992	chr22:41487218	T/C	cg17376030	chr22:41985996	PMM1	0.52	6.11	0.37	4.2e-9	Neuroticism;
SARC	cis	rs7223966	1.000	rs11079511	chr17:61858537	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.51	-5.14	-0.32	5.69e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2387326	0.717	rs10829343	chr10:129944496	T/C	cg16087940	chr10:129947807	NA	-0.45	-5.74	-0.35	2.98e-8	Select biomarker traits;
SARC	cis	rs9486719	0.947	rs12208556	chr6:96903486	C/T	cg06623918	chr6:96969491	KIAA0776	-0.75	-8.23	-0.47	1.36e-14	Migraine;Coronary artery disease;
SARC	cis	rs7644634	0.559	rs2301037	chr3:105430849	C/T	cg23051926	chr3:105466016	CBLB	0.47	5.23	0.32	3.84e-7	Itch intensity from mosquito bite;
SARC	cis	rs12545109	0.879	rs2576580	chr8:57365828	G/C	cg19413350	chr8:57351067	NA	-0.45	-4.92	-0.31	1.61e-6	Obesity-related traits;
SARC	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg11764359	chr7:65958608	NA	0.86	12.33	0.63	3.29e-27	Aortic root size;
SARC	cis	rs6088580	0.634	rs6120644	chr20:33023810	G/A	cg08999081	chr20:33150536	PIGU	0.44	6.59	0.4	2.97e-10	Glomerular filtration rate (creatinine);
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg23165545	chr3:49449548	TCTA;RHOA	0.54	6.43	0.39	7.02e-10	Blood pressure;
SARC	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg22484793	chr3:52261325	TLR9	0.3	4.87	0.3	2.05e-6	Bipolar disorder;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg09975659	chr16:88050166	BANP	0.51	6.45	0.39	6.57e-10	Schizophrenia;
SARC	cis	rs698833	0.509	rs12475963	chr2:44766595	T/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.4	5.0	0.31	1.11e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs73086581	1.000	rs6107386	chr20:3972756	A/C	cg02187196	chr20:3869020	PANK2	0.58	5.45	0.34	1.28e-7	Response to antidepressants in depression;
SARC	trans	rs1941687	0.526	rs9959347	chr18:31316169	C/T	cg27147174	chr7:100797783	AP1S1	-0.48	-6.32	-0.38	1.31e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
SARC	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.41	-6.36	-0.38	1.04e-9	Total body bone mineral density;
SARC	cis	rs9290065	0.538	rs9860182	chr3:160768962	T/C	cg04691961	chr3:161091175	C3orf57	-0.51	-6.45	-0.39	6.32e-10	Kawasaki disease;
SARC	trans	rs9951602	0.512	rs7234283	chr18:76640552	T/G	cg02800362	chr5:177631904	HNRNPAB	0.68	8.61	0.49	1.13e-15	Obesity-related traits;
SARC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg20102877	chr2:27665638	KRTCAP3	-0.37	-5.25	-0.33	3.44e-7	Total body bone mineral density;
SARC	cis	rs8067354	0.645	rs9899611	chr17:57832190	A/G	cg02344993	chr17:57696989	CLTC	0.65	6.7	0.4	1.55e-10	Hemoglobin concentration;
SARC	cis	rs3741404	0.665	rs594461	chr11:63872543	A/G	cg18225595	chr11:63971243	STIP1	0.39	5.55	0.34	7.79e-8	Platelet count;
SARC	cis	rs6696846	0.729	rs72757512	chr1:205079203	G/A	cg21643547	chr1:205240462	TMCC2	-0.58	-7.73	-0.45	3.19e-13	Red blood cell count;
SARC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	11.05	0.59	4.18e-23	Platelet count;
SARC	cis	rs7824557	0.564	rs2736302	chr8:11236419	T/C	cg21775007	chr8:11205619	TDH	-0.65	-8.62	-0.49	1.01e-15	Retinal vascular caliber;
SARC	cis	rs2236918	1.000	rs2995544	chr1:242020495	C/T	cg17736920	chr1:242011382	EXO1	0.77	10.68	0.57	6.15e-22	Menopause (age at onset);
SARC	cis	rs1046896	0.553	rs1044661	chr17:80901020	G/A	cg22027946	chr17:80790580	TBCD;ZNF750	0.39	4.85	0.3	2.29e-6	Glycated hemoglobin levels;
SARC	cis	rs6762	0.692	rs5030778	chr11:836008	T/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.59	-7.66	-0.45	4.83e-13	Mean platelet volume;
SARC	cis	rs1348850	0.567	rs880898	chr2:178532470	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.42	4.89	0.31	1.88e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg18876405	chr7:65276391	NA	0.49	6.04	0.37	6e-9	Aortic root size;
SARC	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg19223190	chr17:80058835	NA	-0.4	-5.56	-0.34	7.43e-8	Life satisfaction;
SARC	cis	rs2242194	0.816	rs6671688	chr1:154994265	T/C	cg24250549	chr1:154909240	PMVK	0.51	6.41	0.39	8.05e-10	Schizophrenia;
SARC	cis	rs80130819	0.591	rs17122651	chr12:48496660	C/T	cg05342945	chr12:48394962	COL2A1	0.55	5.95	0.36	9.68e-9	Prostate cancer;
SARC	cis	rs4280164	0.945	rs4366641	chr14:24771101	C/T	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.58	-5.46	-0.34	1.24e-7	Parent of origin effect on language impairment (paternal);
SARC	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg03264133	chr6:25882463	NA	-0.4	-5.21	-0.32	4.17e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7617773	0.779	rs77957078	chr3:48331286	G/C	cg11946769	chr3:48343235	NME6	0.74	9.44	0.53	3.99e-18	Coronary artery disease;
SARC	cis	rs2197308	0.594	rs9705810	chr12:37895003	G/A	cg13010199	chr12:38710504	ALG10B	-0.69	-9.1	-0.51	4.16e-17	Morning vs. evening chronotype;
SARC	cis	rs733592	0.931	rs765260	chr12:48431936	C/T	cg21466736	chr12:48725269	NA	0.29	5.1	0.32	7.18e-7	Plateletcrit;
SARC	cis	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg25894440	chr7:65020034	NA	-0.74	-5.72	-0.35	3.18e-8	Diabetic kidney disease;
SARC	cis	rs10744422	0.858	rs12426809	chr12:123327143	C/T	cg25930673	chr12:123319894	HIP1R	-0.65	-5.06	-0.31	8.53e-7	Schizophrenia;
SARC	cis	rs7312933	0.558	rs7965743	chr12:42736822	A/G	cg19980929	chr12:42632907	YAF2	-0.44	-6.49	-0.39	4.97e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs11785400	1.000	rs6997670	chr8:143737915	G/A	cg10596483	chr8:143751796	JRK	0.64	8.65	0.49	8.4e-16	Schizophrenia;
SARC	cis	rs9916302	0.904	rs7503069	chr17:37697128	C/G	cg00129232	chr17:37814104	STARD3	-0.63	-7.73	-0.45	3.25e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs6963495	0.818	rs73192115	chr7:105169605	T/A	cg13798780	chr7:105162888	PUS7	0.6	5.55	0.34	7.84e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs9399137	0.507	rs61738647	chr6:135282735	T/C	cg24558204	chr6:135376177	HBS1L	0.62	8.18	0.47	1.85e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg11062466	chr8:58055876	NA	0.61	5.75	0.35	2.74e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs79349575	0.783	rs12601858	chr17:47017477	T/C	cg07967210	chr17:47022446	SNF8	0.38	4.77	0.3	3.2e-6	Type 2 diabetes;
SARC	cis	rs826838	0.967	rs980572	chr12:39127673	A/C	cg13010199	chr12:38710504	ALG10B	0.67	9.3	0.52	1.04e-17	Heart rate;
SARC	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg19223190	chr17:80058835	NA	0.46	6.43	0.39	7.11e-10	Life satisfaction;
SARC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg10963375	chr1:205815865	PM20D1	0.32	4.74	0.3	3.75e-6	Menarche (age at onset);
SARC	cis	rs6121246	0.529	rs6058152	chr20:30178107	G/A	cg13852791	chr20:30311386	BCL2L1	0.68	5.9	0.36	1.27e-8	Mean corpuscular hemoglobin;
SARC	cis	rs11190604	0.945	rs11190553	chr10:102207959	T/C	cg07080220	chr10:102295463	HIF1AN	0.78	9.58	0.53	1.56e-18	Palmitoleic acid (16:1n-7) levels;
SARC	trans	rs61931739	0.890	rs694706	chr12:34135323	T/C	cg13010199	chr12:38710504	ALG10B	0.55	7.39	0.44	2.68e-12	Morning vs. evening chronotype;
SARC	trans	rs561341	0.882	rs16967101	chr17:30377162	A/G	cg20587970	chr11:113659929	NA	-0.99	-10.27	-0.56	1.21e-20	Hip circumference adjusted for BMI;
SARC	cis	rs1707322	0.896	rs785512	chr1:46534543	A/G	cg06784218	chr1:46089804	CCDC17	-0.37	-6.31	-0.38	1.39e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs12579753	0.879	rs7958657	chr12:82135067	G/A	cg07988820	chr12:82153109	PPFIA2	-0.6	-7.03	-0.42	2.3e-11	Resting heart rate;
SARC	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.99	11.62	0.61	6.3e-25	Platelet count;
SARC	trans	rs3780486	1.000	rs3780486	chr9:33139453	C/T	cg04842962	chr6:43655489	MRPS18A	0.95	13.01	0.65	1.96e-29	IgG glycosylation;
SARC	cis	rs1355223	0.902	rs704744	chr11:34736561	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.34	-0.33	2.21e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs4595586	0.545	rs1303886	chr12:39366876	G/A	cg13010199	chr12:38710504	ALG10B	0.4	4.75	0.3	3.57e-6	Morning vs. evening chronotype;
SARC	cis	rs12472274	0.817	rs12621791	chr2:239104061	G/A	cg17459225	chr2:239074497	NA	0.63	7.57	0.44	8.62e-13	Phospholipid levels (plasma);
SARC	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.9	-0.5	1.61e-16	Alzheimer's disease;
SARC	cis	rs9790314	0.637	rs778643	chr3:160706041	G/A	cg04691961	chr3:161091175	C3orf57	-0.57	-7.9	-0.46	1.11e-13	Morning vs. evening chronotype;
SARC	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg12064134	chr16:90016061	DEF8	-0.49	-5.16	-0.32	5.36e-7	Skin colour saturation;
SARC	cis	rs12477438	0.834	rs1563108	chr2:99701153	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-9.53	-0.53	2.11e-18	Chronic sinus infection;
SARC	cis	rs9814567	1.000	rs6785027	chr3:134211649	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.54	6.76	0.4	1.11e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs698833	0.926	rs1067394	chr2:44638123	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.71	9.31	0.52	1.01e-17	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs4808199	0.947	rs2099333	chr19:19605963	C/T	cg03709012	chr19:19516395	GATAD2A	1.2	13.13	0.65	7.72e-30	Nonalcoholic fatty liver disease;
SARC	cis	rs2425143	1.000	rs733609	chr20:34393074	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-6.37	-0.39	9.75e-10	Blood protein levels;
SARC	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg02034447	chr16:89574710	SPG7	0.51	6.98	0.42	3.1e-11	Multiple myeloma (IgH translocation);
SARC	cis	rs2204008	0.540	rs1672425	chr12:38122842	G/A	cg26384229	chr12:38710491	ALG10B	-0.67	-8.68	-0.49	6.85e-16	Bladder cancer;
SARC	trans	rs61931739	0.500	rs11052994	chr12:34065843	C/T	cg13010199	chr12:38710504	ALG10B	0.77	10.36	0.56	6.42e-21	Morning vs. evening chronotype;
SARC	cis	rs4808199	1.000	rs60321073	chr19:19499598	A/G	cg03709012	chr19:19516395	GATAD2A	1.18	13.13	0.65	7.56e-30	Nonalcoholic fatty liver disease;
SARC	cis	rs1451375	0.617	rs2060763	chr7:50542359	G/A	cg18232548	chr7:50535776	DDC	-0.5	-4.93	-0.31	1.57e-6	Malaria;
SARC	cis	rs78456975	1.000	rs72776298	chr2:1570163	C/G	cg01028140	chr2:1542097	TPO	-0.48	-4.86	-0.3	2.2e-6	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs35110281	0.776	rs9983763	chr21:44990578	A/G	cg01579765	chr21:45077557	HSF2BP	0.38	6.27	0.38	1.77e-9	Mean corpuscular volume;
SARC	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg01448562	chr3:133502909	NA	-0.45	-6.56	-0.39	3.43e-10	Iron status biomarkers;
SARC	cis	rs9916302	0.706	rs667193	chr17:37448835	T/C	cg00129232	chr17:37814104	STARD3	0.54	5.76	0.35	2.7e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs3784262	0.740	rs8032572	chr15:58311280	A/G	cg12031962	chr15:58353849	ALDH1A2	0.33	4.85	0.3	2.29e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg06221963	chr1:154839813	KCNN3	-0.46	-7.05	-0.42	1.99e-11	Prostate cancer;
SARC	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg07701084	chr6:150067640	NUP43	0.47	5.87	0.36	1.5e-8	Lung cancer;
SARC	cis	rs6582630	0.555	rs11182202	chr12:38476451	C/G	cg13010199	chr12:38710504	ALG10B	0.75	10.21	0.56	1.79e-20	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6738485	0.507	rs72819611	chr2:106845912	G/A	cg15412446	chr2:106886593	NA	-0.57	-5.82	-0.36	1.93e-8	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
SARC	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.46	-5.55	-0.34	7.73e-8	Tonsillectomy;
SARC	cis	rs2486288	0.656	rs12911861	chr15:45566718	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.56	-7.07	-0.42	1.74e-11	Glomerular filtration rate;
SARC	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg23958373	chr8:599963	NA	0.73	6.04	0.37	5.89e-9	IgG glycosylation;
SARC	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg24399712	chr22:39784796	NA	0.43	5.9	0.36	1.25e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs11608355	0.521	rs6606704	chr12:109814036	T/C	cg19025524	chr12:109796872	NA	-0.42	-6.22	-0.38	2.29e-9	Neuroticism;
SARC	cis	rs16976116	0.806	rs117064453	chr15:55492319	T/A	cg11288833	chr15:55489084	RSL24D1	0.65	6.14	0.37	3.54e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7953249	0.807	rs7970695	chr12:121423376	G/A	cg02403541	chr12:121454288	C12orf43	-0.58	-7.33	-0.43	3.75e-12	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs4689388	0.890	rs3821941	chr4:6286954	A/G	cg25554036	chr4:6271136	WFS1	0.43	6.97	0.42	3.25e-11	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs1981331	0.609	rs57896262	chr21:48028188	C/T	cg23283320	chr21:48055893	PRMT2	0.95	5.63	0.35	5.29e-8	Cerebrospinal fluid t-tau:AB1-42 ratio;
SARC	cis	rs35306767	0.855	rs2050944	chr10:918910	T/C	cg26597838	chr10:835615	NA	0.84	8.43	0.48	3.6e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs2075371	1.000	rs2075371	chr7:133984127	A/G	cg11752832	chr7:134001865	SLC35B4	0.56	7.26	0.43	5.74e-12	Mean platelet volume;
SARC	cis	rs12545109	0.879	rs2670015	chr8:57376607	T/A	cg19413350	chr8:57351067	NA	-0.45	-4.92	-0.31	1.61e-6	Obesity-related traits;
SARC	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg13393036	chr8:95962371	TP53INP1	-0.35	-5.88	-0.36	1.39e-8	Type 2 diabetes;
SARC	cis	rs6087990	0.965	rs2424903	chr20:31349315	C/T	cg13636640	chr20:31349939	DNMT3B	0.81	12.89	0.65	4.57e-29	Ulcerative colitis;
SARC	cis	rs2652822	0.525	rs12148434	chr15:63510114	A/G	cg02713581	chr15:63449717	RPS27L	0.53	6.39	0.39	8.7e-10	Metabolic traits;
SARC	cis	rs4481887	0.927	rs6587445	chr1:248440915	A/G	cg00666640	chr1:248458726	OR2T12	0.33	5.41	0.33	1.56e-7	Common traits (Other);
SARC	cis	rs7106204	0.748	rs4382909	chr11:24236618	C/T	ch.11.24196551F	chr11:24239977	NA	0.55	5.69	0.35	3.81e-8	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs3771570	1.000	rs56363214	chr2:242227157	A/G	cg21155796	chr2:242212141	HDLBP	0.65	5.84	0.36	1.77e-8	Prostate cancer;
SARC	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg13206674	chr6:150067644	NUP43	0.53	6.79	0.41	9.39e-11	Lung cancer;
SARC	cis	rs2594989	0.565	rs7621843	chr3:11603229	T/G	cg00170343	chr3:11313890	ATG7	-0.53	-5.49	-0.34	1.07e-7	Circulating chemerin levels;
SARC	cis	rs3733585	0.673	rs7377578	chr4:9952775	T/C	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.39	-0.33	1.76e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs4901847	0.933	rs12886425	chr14:58564485	G/A	cg15908186	chr14:58618357	C14orf37	0.52	5.89	0.36	1.38e-8	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs4253772	0.530	rs6008616	chr22:46707954	A/G	cg24881330	chr22:46731750	TRMU	0.67	5.7	0.35	3.53e-8	LDL cholesterol;Cholesterol, total;
SARC	cis	rs1832871	0.711	rs9457264	chr6:158689367	G/A	cg07165851	chr6:158734300	TULP4	0.54	6.56	0.39	3.5e-10	Height;
SARC	cis	rs6426558	0.502	rs2813970	chr1:227410637	C/T	cg10327440	chr1:227177885	CDC42BPA	0.45	5.31	0.33	2.55e-7	Neutrophil percentage of white cells;
SARC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg16145915	chr7:1198662	ZFAND2A	0.34	5.13	0.32	6.08e-7	Longevity;Endometriosis;
SARC	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9916302	0.851	rs11078904	chr17:37650569	G/A	cg00129232	chr17:37814104	STARD3	-0.64	-7.93	-0.46	8.9e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs6840360	0.615	rs2406973	chr4:152608339	G/T	cg22705602	chr4:152727874	NA	0.48	8.45	0.48	3.08e-15	Intelligence (multi-trait analysis);
SARC	cis	rs1707322	1.000	rs6676982	chr1:46275401	A/T	cg06784218	chr1:46089804	CCDC17	0.33	5.76	0.35	2.66e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7589342	0.929	rs1465640	chr2:106439103	C/T	cg16077055	chr2:106428750	NCK2	0.39	7.27	0.43	5.44e-12	Addiction;
SARC	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg16049864	chr8:95962084	TP53INP1	-0.47	-7.62	-0.45	6.44e-13	Type 2 diabetes;
SARC	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg16325326	chr1:53192061	ZYG11B	-0.85	-14.04	-0.68	7.45e-33	Monocyte count;
SARC	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs11122272	0.732	rs999010	chr1:231495316	A/G	cg06096015	chr1:231504339	EGLN1	0.36	5.43	0.34	1.41e-7	Hemoglobin concentration;
SARC	cis	rs4790333	0.967	rs2002863	chr17:2269769	C/T	cg02569219	chr17:2266849	SGSM2	0.45	5.73	0.35	3.04e-8	Proinsulin levels;
SARC	cis	rs2806561	0.765	rs1738469	chr1:23511407	G/C	cg12483005	chr1:23474871	LUZP1	0.43	5.66	0.35	4.44e-8	Height;
SARC	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg00933542	chr6:150070202	PCMT1	-0.3	-4.98	-0.31	1.24e-6	Lung cancer;
SARC	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg24675658	chr1:53192096	ZYG11B	0.6	8.35	0.48	6.25e-15	Monocyte count;
SARC	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg11843238	chr5:131593191	PDLIM4	-0.41	-5.06	-0.31	8.31e-7	Breast cancer;
SARC	cis	rs4820539	0.966	rs2267000	chr22:23455366	A/G	cg14186256	chr22:23484241	RTDR1	0.85	13.48	0.66	5.29e-31	Bone mineral density;
SARC	cis	rs7027203	1.000	rs13288708	chr9:96509653	T/C	cg14598338	chr9:96623480	NA	0.51	6.85	0.41	6.38e-11	DNA methylation (variation);
SARC	cis	rs11098499	0.909	rs35165976	chr4:120325630	G/A	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs8064024	0.650	rs12926178	chr16:4905915	C/T	cg08329684	chr16:4932620	PPL	-0.36	-5.73	-0.35	3.12e-8	Cancer;
SARC	cis	rs12142240	0.698	rs17361763	chr1:46810670	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-5.45	-0.34	1.28e-7	Menopause (age at onset);
SARC	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.23e-9	Life satisfaction;
SARC	cis	rs10875746	0.903	rs12313404	chr12:48492048	T/A	cg26205652	chr12:48591994	NA	0.56	6.05	0.37	5.72e-9	Longevity (90 years and older);
SARC	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg05793240	chr7:2802953	GNA12	-0.35	-5.08	-0.32	7.6e-7	Height;
SARC	cis	rs11997175	0.597	rs6988880	chr8:33594504	C/T	ch.8.33884649F	chr8:33765107	NA	0.48	6.05	0.37	5.66e-9	Body mass index;
SARC	cis	rs1832871	0.711	rs9459829	chr6:158680799	C/T	cg07165851	chr6:158734300	TULP4	0.55	6.67	0.4	1.8e-10	Height;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg14092536	chr9:130889808	LOC389791;PTGES2	0.48	6.25	0.38	1.93e-9	Chemerin levels;
SARC	cis	rs2952156	0.920	rs2517955	chr17:37843681	C/T	cg00129232	chr17:37814104	STARD3	-0.72	-10.03	-0.55	6.39e-20	Asthma;
SARC	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg04277193	chr17:41438351	NA	0.45	4.85	0.3	2.21e-6	Menopause (age at onset);
SARC	cis	rs9815354	0.638	rs111465678	chr3:41864405	C/A	cg03022575	chr3:42003672	ULK4	0.57	5.32	0.33	2.38e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9420	0.816	rs674094	chr11:57665336	A/C	cg23127183	chr11:57508653	C11orf31	0.58	6.14	0.37	3.45e-9	Schizophrenia;
SARC	cis	rs12479064	0.724	rs10496336	chr2:99996165	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.45	-5.24	-0.32	3.62e-7	Chronic sinus infection;
SARC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07856758	chr19:37861652	ZNF527	0.62	6.64	0.4	2.17e-10	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs10875746	0.859	rs4760695	chr12:48591848	A/G	cg26205652	chr12:48591994	NA	0.48	5.48	0.34	1.12e-7	Longevity (90 years and older);
SARC	cis	rs7296418	0.699	rs1109559	chr12:123757861	C/T	cg00376283	chr12:123451042	ABCB9	0.59	7.28	0.43	5.15e-12	Platelet count;
SARC	cis	rs6840360	0.593	rs867800	chr4:152691470	T/C	cg22705602	chr4:152727874	NA	-0.5	-8.96	-0.51	1.1e-16	Intelligence (multi-trait analysis);
SARC	cis	rs12311304	1.000	rs7297771	chr12:15376420	A/G	cg08258403	chr12:15378311	NA	0.48	7.15	0.42	1.1e-11	Behavioural disinhibition (generation interaction);
SARC	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg22683308	chr4:1340831	KIAA1530	0.42	5.1	0.32	6.93e-7	Longevity;
SARC	cis	rs735539	0.521	rs9552280	chr13:21365361	T/A	cg16922012	chr13:21400325	XPO4	-0.42	-5.72	-0.35	3.22e-8	Dental caries;
SARC	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.44	5.93	0.36	1.1e-8	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs2933343	0.700	rs1680778	chr3:128614185	A/C	cg24203234	chr3:128598194	ACAD9	0.64	7.98	0.46	6.78e-14	IgG glycosylation;
SARC	cis	rs7520050	0.966	rs785520	chr1:46568836	T/C	cg06784218	chr1:46089804	CCDC17	-0.26	-4.82	-0.3	2.56e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs513349	0.964	rs210139	chr6:33543409	A/C	cg07679836	chr6:33548423	BAK1	0.33	4.76	0.3	3.44e-6	Platelet count;
SARC	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg18867708	chr6:26865862	GUSBL1	0.43	4.82	0.3	2.64e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2180341	0.960	rs7745944	chr6:127709574	A/G	cg24812749	chr6:127587940	RNF146	1.04	13.46	0.66	6.15e-31	Breast cancer;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg15676060	chr5:82372786	XRCC4;TMEM167A	-0.47	-6.26	-0.38	1.84e-9	Thyroid stimulating hormone;
SARC	cis	rs2153535	0.580	rs1577471	chr6:8485905	T/A	cg23788917	chr6:8435910	SLC35B3	0.62	8.05	0.47	4.27e-14	Motion sickness;
SARC	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg16479474	chr6:28041457	NA	0.37	5.47	0.34	1.17e-7	Depression;
SARC	cis	rs9902453	0.904	rs12951836	chr17:28410277	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.21	-0.43	7.73e-12	Coffee consumption (cups per day);
SARC	cis	rs7772486	0.790	rs6570723	chr6:146151230	A/T	cg23711669	chr6:146136114	FBXO30	0.8	13.21	0.65	4.21e-30	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs72653721	0.713	rs60197525	chr6:11053289	T/C	cg13562911	chr6:11044106	ELOVL2	0.59	6.63	0.4	2.35e-10	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg13395646	chr4:1353034	KIAA1530	-0.46	-5.41	-0.33	1.52e-7	Obesity-related traits;
SARC	cis	rs2997447	0.655	rs12094933	chr1:26374779	T/C	cg19633962	chr1:26362018	EXTL1	-0.76	-7.76	-0.45	2.59e-13	QRS complex (12-leadsum);
SARC	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg10435706	chr6:150039699	LATS1	0.37	4.87	0.3	2.04e-6	Lung cancer;
SARC	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg04267008	chr7:1944627	MAD1L1	-0.61	-7.01	-0.42	2.52e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg16479474	chr6:28041457	NA	0.37	5.25	0.33	3.45e-7	Parkinson's disease;
SARC	cis	rs1218582	0.651	rs4845396	chr1:154828409	A/G	cg24250549	chr1:154909240	PMVK	-0.55	-7.25	-0.43	6.16e-12	Prostate cancer;
SARC	cis	rs12142240	0.731	rs6658556	chr1:46844180	A/C	cg00530320	chr1:46809349	NSUN4	0.58	6.84	0.41	7e-11	Menopause (age at onset);
SARC	cis	rs3091242	0.902	rs36003018	chr1:25784318	A/G	cg27572855	chr1:25598939	RHD	-0.54	-9.26	-0.52	1.44e-17	Erythrocyte sedimentation rate;
SARC	cis	rs3087591	0.708	rs4794887	chr17:29649696	G/A	cg24425628	chr17:29625626	OMG;NF1	0.42	5.36	0.33	1.98e-7	Hip circumference;
SARC	cis	rs7552404	0.691	rs61770550	chr1:76366966	C/T	cg03433033	chr1:76189801	ACADM	0.46	5.64	0.35	4.81e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs453301	0.686	rs3895823	chr8:8873646	T/C	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.48	-0.39	5.34e-10	Joint mobility (Beighton score);
SARC	cis	rs78487399	0.808	rs13409687	chr2:43701151	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-5.13	-0.32	6.24e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs9303401	0.614	rs34920953	chr17:56589406	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.06	11.67	0.61	4.53e-25	Cognitive test performance;
SARC	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg03433033	chr1:76189801	ACADM	0.51	6.88	0.41	5.5e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9916302	0.808	rs12947281	chr17:37652210	G/T	cg07936489	chr17:37558343	FBXL20	-0.68	-8.92	-0.5	1.43e-16	Glomerular filtration rate (creatinine);
SARC	trans	rs208520	0.690	rs851464	chr6:66839802	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-13.77	-0.67	5.95e-32	Exhaled nitric oxide output;
SARC	cis	rs7647973	0.626	rs11720705	chr3:49753788	A/G	cg03060546	chr3:49711283	APEH	0.61	6.47	0.39	5.6e-10	Menarche (age at onset);
SARC	cis	rs11608355	0.515	rs7311488	chr12:109930905	C/G	cg05360138	chr12:110035743	NA	-0.93	-9.57	-0.53	1.66e-18	Neuroticism;
SARC	cis	rs17270561	0.609	rs1317510	chr6:25778924	T/C	cg16482183	chr6:26056742	HIST1H1C	0.5	6.08	0.37	4.77e-9	Iron status biomarkers;
SARC	cis	rs7481584	0.624	rs436580	chr11:3063961	T/G	cg25174290	chr11:3078921	CARS	-0.57	-8.04	-0.47	4.52e-14	Calcium levels;
SARC	cis	rs950027	0.620	rs872192	chr15:45614502	A/G	cg26924012	chr15:45694286	SPATA5L1	0.52	6.52	0.39	4.28e-10	Response to fenofibrate (adiponectin levels);
SARC	cis	rs861020	0.606	rs695140	chr1:210005061	G/A	cg05527609	chr1:210001259	C1orf107	0.78	10.12	0.55	3.37e-20	Orofacial clefts;
SARC	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg20120463	chr17:44301886	NA	-0.36	-5.59	-0.34	6.48e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg18252515	chr7:66147081	NA	-1.22	-11.86	-0.61	1.07e-25	Diabetic kidney disease;
SARC	cis	rs3733585	0.673	rs4467564	chr4:9953472	G/T	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.94	-0.36	1.06e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.72	7.81	0.46	1.89e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs12477438	0.715	rs7586608	chr2:99558017	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-14.96	-0.7	6.61e-36	Chronic sinus infection;
SARC	cis	rs77106637	1.000	rs11602858	chr11:72615069	C/G	cg03713592	chr11:72463424	ARAP1	0.93	7.93	0.46	9.33e-14	Type 2 diabetes;
SARC	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg10792982	chr14:105748885	BRF1	-0.55	-8.25	-0.48	1.19e-14	Mean platelet volume;Platelet distribution width;
SARC	cis	rs2304069	0.954	rs2340463	chr5:149409294	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.94	10.22	0.56	1.73e-20	HIV-1 control;
SARC	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg19223190	chr17:80058835	NA	0.45	6.35	0.38	1.13e-9	Life satisfaction;
SARC	cis	rs2200578	1.000	rs60025964	chr2:99880577	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.63	5.96	0.36	9.14e-9	IgG glycosylation;
SARC	cis	rs739401	0.566	rs7931504	chr11:3026712	C/T	cg25174290	chr11:3078921	CARS	0.57	7.93	0.46	9.24e-14	Longevity;
SARC	cis	rs892961	0.932	rs3987886	chr17:75414980	A/G	cg05865280	chr17:75406074	SEPT9	0.53	7.72	0.45	3.32e-13	Airflow obstruction;
SARC	cis	rs2304069	0.779	rs245081	chr5:149356075	G/T	cg12661370	chr5:149340060	SLC26A2	0.62	6.86	0.41	6.22e-11	HIV-1 control;
SARC	cis	rs6570726	0.935	rs454370	chr6:145846729	T/G	cg23711669	chr6:146136114	FBXO30	0.78	12.08	0.62	2.13e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2832077	0.689	rs2832055	chr21:30132382	C/G	cg03476357	chr21:30257390	N6AMT1	0.5	5.03	0.31	9.61e-7	Cognitive test performance;
SARC	cis	rs6912958	0.781	rs7750207	chr6:88303967	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.54	-0.34	8.32e-8	Monocyte percentage of white cells;
SARC	cis	rs898097	0.841	rs2271918	chr17:80861206	A/G	cg20578329	chr17:80767326	TBCD	-0.54	-7.0	-0.42	2.66e-11	Breast cancer;
SARC	cis	rs7667	1.000	rs3790767	chr1:19698546	A/C	cg15311933	chr1:19638897	PQLC2;AKR7A2	-0.48	-5.53	-0.34	8.43e-8	Crohn's disease and psoriasis;
SARC	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg06420487	chr17:61919686	SMARCD2	0.45	4.93	0.31	1.59e-6	Height;
SARC	cis	rs36051895	0.664	rs10115518	chr9:5094559	T/C	cg02405213	chr9:5042618	JAK2	-0.47	-5.65	-0.35	4.63e-8	Pediatric autoimmune diseases;
SARC	cis	rs870825	0.616	rs10428373	chr4:185639002	A/G	cg21366198	chr4:185655624	MLF1IP	-0.71	-7.54	-0.44	1.01e-12	Blood protein levels;
SARC	cis	rs9420	0.961	rs12807250	chr11:57600285	C/T	cg19752551	chr11:57585705	CTNND1	-0.52	-7.11	-0.42	1.39e-11	Schizophrenia;
SARC	cis	rs9399135	1.000	rs11754265	chr6:135356216	C/G	cg22676075	chr6:135203613	NA	0.34	4.75	0.3	3.6e-6	Red blood cell count;
SARC	cis	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg09021430	chr5:549028	NA	-0.43	-5.68	-0.35	3.92e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs995000	0.931	rs1748200	chr1:63046039	T/C	cg06896770	chr1:63153194	DOCK7	-0.89	-13.19	-0.65	4.67e-30	Triglyceride levels;
SARC	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-7.06	-0.42	1.87e-11	Gut microbiome composition (summer);
SARC	cis	rs9660992	0.700	rs1172125	chr1:205258442	A/T	cg19090574	chr1:205240910	TMCC2	-0.37	-4.82	-0.3	2.62e-6	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs422249	0.512	rs174574	chr11:61600342	A/C	cg19610905	chr11:61596333	FADS2	0.39	4.73	0.3	3.85e-6	Trans fatty acid levels;
SARC	cis	rs9611519	0.566	rs4821981	chr22:41415644	A/C	cg03806693	chr22:41940476	POLR3H	0.6	7.78	0.45	2.31e-13	Neuroticism;
SARC	cis	rs6121246	0.560	rs6088854	chr20:30225357	G/A	cg13852791	chr20:30311386	BCL2L1	0.86	7.84	0.46	1.6e-13	Mean corpuscular hemoglobin;
SARC	cis	rs17376456	0.825	rs34592268	chr5:93232751	G/C	cg21475434	chr5:93447410	FAM172A	0.84	7.5	0.44	1.35e-12	Diabetic retinopathy;
SARC	cis	rs11098499	0.615	rs28850368	chr4:120554313	G/A	cg09307838	chr4:120376055	NA	0.76	10.28	0.56	1.08e-20	Corneal astigmatism;
SARC	cis	rs72781680	0.898	rs17462558	chr2:24020812	T/C	cg06627628	chr2:24431161	ITSN2	-0.66	-6.27	-0.38	1.69e-9	Lymphocyte counts;
SARC	cis	rs7264396	0.515	rs2425134	chr20:34339439	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	5.29	0.33	2.87e-7	Total cholesterol levels;
SARC	trans	rs57994514	0.524	rs16936872	chr8:71192380	A/G	cg04828133	chr7:155259845	NA	0.96	6.59	0.4	2.87e-10	Intelligence (multi-trait analysis);
SARC	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg10589385	chr1:150898437	SETDB1	-0.37	-4.98	-0.31	1.21e-6	Tonsillectomy;
SARC	cis	rs8180040	0.966	rs13075233	chr3:47420627	T/C	cg27129171	chr3:47204927	SETD2	0.66	9.06	0.51	5.37e-17	Colorectal cancer;
SARC	cis	rs7587476	0.784	rs13008641	chr2:215698033	T/C	cg11970703	chr2:215861251	ABCA12	-0.32	-4.96	-0.31	1.39e-6	Neuroblastoma;
SARC	cis	rs9420	0.961	rs11606396	chr11:57435211	C/T	cg23127183	chr11:57508653	C11orf31	-0.56	-6.37	-0.38	1.02e-9	Schizophrenia;
SARC	cis	rs3935695	0.796	rs10185293	chr2:239918946	A/G	cg09163117	chr2:239148697	HES6	0.51	5.48	0.34	1.12e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs3099143	1.000	rs35645941	chr15:77140302	C/T	cg21673338	chr15:77095150	SCAPER	-0.6	-4.99	-0.31	1.18e-6	Recalcitrant atopic dermatitis;
SARC	cis	rs17376456	0.569	rs11135397	chr5:93214975	G/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.51	5.35	0.33	2.11e-7	Diabetic retinopathy;
SARC	cis	rs11098499	0.863	rs13134665	chr4:120426430	T/C	cg24375607	chr4:120327624	NA	0.41	4.79	0.3	2.97e-6	Corneal astigmatism;
SARC	trans	rs1814175	0.708	rs10839464	chr11:49981386	T/C	cg15704280	chr7:45808275	SEPT13	-0.89	-14.17	-0.68	2.8e-33	Height;
SARC	cis	rs1395	0.710	rs2083363	chr2:27475318	G/C	cg21747090	chr2:27597821	SNX17	-0.46	-5.62	-0.35	5.42e-8	Blood metabolite levels;
SARC	cis	rs4727027	0.870	rs1105261	chr7:148794442	T/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	5.69	0.35	3.73e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs2191566	1.000	rs369106	chr19:44506930	C/T	cg20607764	chr19:44506953	ZNF230	0.53	6.21	0.38	2.38e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg16405210	chr4:1374714	KIAA1530	-0.95	-13.12	-0.65	8.2e-30	Longevity;
SARC	cis	rs4481887	0.962	rs10788769	chr1:248457426	C/T	cg01631408	chr1:248437212	OR2T33	-0.43	-5.55	-0.34	7.73e-8	Common traits (Other);
SARC	cis	rs8038465	0.615	rs6495075	chr15:73981005	A/G	cg15420318	chr15:73925796	NPTN	0.5	5.79	0.35	2.25e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg03812994	chr10:81205453	ZCCHC24	-0.52	-6.47	-0.39	5.73e-10	Height;
SARC	cis	rs1865760	0.566	rs4529296	chr6:26083135	C/G	cg17691542	chr6:26056736	HIST1H1C	0.52	6.41	0.39	8.05e-10	Height;
SARC	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg13298116	chr11:62369859	EML3;MTA2	0.45	7.08	0.42	1.7e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs2425143	1.000	rs113203744	chr20:34253656	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.13	0.32	6.04e-7	Blood protein levels;
SARC	cis	rs9341808	0.754	rs6918172	chr6:81019242	A/G	cg08355045	chr6:80787529	NA	0.36	5.75	0.35	2.76e-8	Sitting height ratio;
SARC	cis	rs8141529	0.588	rs10222249	chr22:29257147	A/G	cg02153584	chr22:29168773	CCDC117	0.67	8.43	0.48	3.58e-15	Lymphocyte counts;
SARC	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg22920501	chr2:26401640	FAM59B	-0.6	-7.95	-0.46	8.18e-14	Gut microbiome composition (summer);
SARC	cis	rs7429990	0.866	rs3732529	chr3:47970109	C/T	cg11946769	chr3:48343235	NME6	0.44	5.06	0.31	8.47e-7	Educational attainment (years of education);
SARC	cis	rs911555	0.723	rs7144010	chr14:103869869	G/A	cg24130564	chr14:104152367	KLC1	0.47	5.41	0.33	1.56e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7833790	1.000	rs7460277	chr8:82709777	T/C	cg27398817	chr8:82754497	SNX16	-0.51	-5.66	-0.35	4.33e-8	Diastolic blood pressure;
SARC	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg09699651	chr6:150184138	LRP11	0.39	4.87	0.3	2.04e-6	Lung cancer;
SARC	cis	rs9807989	0.765	rs9807962	chr2:102971664	A/G	cg09003973	chr2:102972529	NA	0.41	5.6	0.34	6.11e-8	Asthma;
SARC	cis	rs6679356	0.906	rs56194793	chr1:67790598	T/C	cg09018107	chr1:67798929	IL12RB2	0.42	5.15	0.32	5.45e-7	Primary biliary cholangitis;
SARC	cis	rs10992471	0.756	rs3758229	chr9:95078852	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-6.04	-0.37	6.1e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs2273669	0.667	rs11751295	chr6:109334458	C/G	cg05315195	chr6:109294784	ARMC2	-0.63	-5.73	-0.35	3.16e-8	Prostate cancer;
SARC	cis	rs10089	0.953	rs6887674	chr5:127531183	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.81	9.2	0.52	2.03e-17	Ileal carcinoids;
SARC	cis	rs921968	0.541	rs1863704	chr2:219562675	C/T	cg02176678	chr2:219576539	TTLL4	-0.5	-7.6	-0.45	7.14e-13	Mean corpuscular hemoglobin concentration;
SARC	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs12545109	0.800	rs1467123	chr8:57418870	C/T	cg19413350	chr8:57351067	NA	-0.43	-5.4	-0.33	1.67e-7	Obesity-related traits;
SARC	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg05234568	chr11:5960015	NA	-0.39	-5.36	-0.33	2e-7	DNA methylation (variation);
SARC	cis	rs703842	1.000	rs1875124	chr12:58196802	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.77	11.14	0.59	2.16e-23	Multiple sclerosis;
SARC	cis	rs2153219	0.786	rs75384733	chr6:149763109	C/T	cg18043157	chr6:150390308	ULBP3	-0.64	-4.73	-0.3	3.92e-6	Coronary artery disease;
SARC	cis	rs10193935	0.786	rs13399052	chr2:42385151	G/A	cg27598129	chr2:42591480	NA	-0.36	-5.02	-0.31	1.01e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7824557	0.767	rs11250127	chr8:11170209	G/A	cg21775007	chr8:11205619	TDH	0.51	6.01	0.37	7.21e-9	Retinal vascular caliber;
SARC	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg24642844	chr7:1081250	C7orf50	-0.53	-5.81	-0.36	2.01e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg05368731	chr17:41323189	NBR1	0.76	9.29	0.52	1.14e-17	Menopause (age at onset);
SARC	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg18876405	chr7:65276391	NA	-0.72	-9.18	-0.52	2.4e-17	Aortic root size;
SARC	cis	rs826838	0.616	rs9668847	chr12:38614669	C/T	cg26384229	chr12:38710491	ALG10B	0.6	7.81	0.46	1.9e-13	Heart rate;
SARC	cis	rs4713118	0.513	rs156734	chr6:28007357	A/C	cg26335602	chr6:28129616	ZNF389	0.45	5.25	0.33	3.39e-7	Parkinson's disease;
SARC	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg11644478	chr21:40555479	PSMG1	-0.57	-6.87	-0.41	5.64e-11	Menarche (age at onset);
SARC	cis	rs2153535	0.580	rs1335641	chr6:8487860	G/T	cg23788917	chr6:8435910	SLC35B3	0.62	8.09	0.47	3.25e-14	Motion sickness;
SARC	cis	rs708547	0.836	rs1277287	chr4:57853147	C/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.54	-6.2	-0.38	2.53e-9	Response to bleomycin (chromatid breaks);
SARC	cis	rs950169	0.922	rs4842940	chr15:84831225	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.78	-9.21	-0.52	1.98e-17	Schizophrenia;
SARC	cis	rs7223966	0.883	rs2727317	chr17:61961302	C/T	cg00588841	chr17:61851480	DDX42;CCDC47	-0.58	-6.39	-0.39	8.85e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6121246	0.567	rs6058197	chr20:30194899	A/G	cg21427119	chr20:30132790	HM13	-0.48	-5.29	-0.33	2.84e-7	Mean corpuscular hemoglobin;
SARC	cis	rs7520050	0.553	rs2993263	chr1:46021630	A/G	cg24296786	chr1:45957014	TESK2	-0.57	-7.69	-0.45	4.22e-13	Red blood cell count;Reticulocyte count;
SARC	cis	rs10191773	0.535	rs11123133	chr2:112965023	G/A	cg07905836	chr2:113190072	RGPD8;RGPD5	0.94	8.39	0.48	4.68e-15	Yeast infection;
SARC	cis	rs36051895	0.659	rs72699590	chr9:5041690	C/G	cg02405213	chr9:5042618	JAK2	-0.56	-6.58	-0.4	3.12e-10	Pediatric autoimmune diseases;
SARC	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg27266027	chr21:40555129	PSMG1	-0.53	-5.93	-0.36	1.08e-8	Cognitive function;
SARC	cis	rs6484504	0.576	rs158144	chr11:31211795	A/C	cg26647111	chr11:31128758	NA	-0.39	-5.14	-0.32	5.72e-7	Red blood cell count;
SARC	trans	rs61931739	0.534	rs1705757	chr12:34091637	A/G	cg26384229	chr12:38710491	ALG10B	0.74	10.14	0.55	2.95e-20	Morning vs. evening chronotype;
SARC	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg11764359	chr7:65958608	NA	0.88	12.58	0.64	4.89e-28	Aortic root size;
SARC	cis	rs6831352	0.918	rs35784540	chr4:100061692	T/A	cg13256891	chr4:100009986	ADH5	-0.66	-8.16	-0.47	2.08e-14	Alcohol dependence;
SARC	cis	rs1865760	0.964	rs6932113	chr6:25913098	C/T	cg16482183	chr6:26056742	HIST1H1C	0.49	6.15	0.37	3.37e-9	Height;
SARC	cis	rs9815354	1.000	rs9847006	chr3:41755359	T/C	cg03022575	chr3:42003672	ULK4	0.57	5.34	0.33	2.22e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2658782	0.789	rs2658773	chr11:93126914	A/G	cg15737290	chr11:93063684	CCDC67	0.72	7.55	0.44	9.6e-13	Pulmonary function decline;
SARC	cis	rs2933343	0.729	rs1680785	chr3:128644816	C/T	cg25356066	chr3:128598488	ACAD9	0.7	9.29	0.52	1.17e-17	IgG glycosylation;
SARC	cis	rs8523	0.804	rs9295763	chr6:11045192	G/C	cg13562911	chr6:11044106	ELOVL2	0.48	6.46	0.39	6.21e-10	Red blood cell fatty acid levels;
SARC	cis	rs2153535	0.505	rs1737583	chr6:8536812	G/A	cg07606381	chr6:8435919	SLC35B3	0.77	10.82	0.58	2.19e-22	Motion sickness;
SARC	cis	rs9916302	0.904	rs801420	chr17:37466103	C/G	cg20243544	chr17:37824526	PNMT	-0.55	-6.64	-0.4	2.19e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs6448317	0.954	rs13139649	chr4:24922007	C/A	cg21108841	chr4:24914750	CCDC149	-0.57	-5.99	-0.37	7.91e-9	Heschl's gyrus morphology;
SARC	cis	rs7551222	0.691	rs4951077	chr1:204482262	G/A	cg20240347	chr1:204465584	NA	-0.35	-6.18	-0.38	2.78e-9	Schizophrenia;
SARC	cis	rs10911232	0.507	rs10797829	chr1:183033228	C/T	cg13390022	chr1:182993471	LAMC1	-0.34	-5.1	-0.32	7.06e-7	Hypertriglyceridemia;
SARC	cis	rs13040088	0.872	rs2295481	chr20:61574727	C/T	cg23096297	chr20:61557774	DIDO1	0.92	9.75	0.54	4.65e-19	Menopause (age at onset);
SARC	cis	rs734999	0.505	rs10797437	chr1:2539006	T/C	cg18854424	chr1:2615690	NA	0.32	5.15	0.32	5.59e-7	Ulcerative colitis;
SARC	cis	rs7223966	1.000	rs6504182	chr17:61823672	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.47	-5.1	-0.32	6.94e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs1853207	1.000	rs75645849	chr10:96698970	T/G	cg02737782	chr1:8014393	NA	-0.92	-6.65	-0.4	2.03e-10	Blood metabolite levels;
SARC	cis	rs11809207	0.523	rs2802343	chr1:26498570	T/C	cg00300879	chr1:26503847	CNKSR1	0.31	4.86	0.3	2.16e-6	Height;
SARC	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg13298116	chr11:62369859	EML3;MTA2	0.47	7.48	0.44	1.48e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg01341218	chr17:43662625	NA	0.96	11.21	0.59	1.27e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9815354	0.767	rs73071337	chr3:41822518	G/C	cg03022575	chr3:42003672	ULK4	0.71	5.89	0.36	1.34e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs7615952	0.546	rs4428131	chr3:125346479	C/T	cg05084668	chr3:125655381	ALG1L	-0.52	-4.8	-0.3	2.87e-6	Blood pressure (smoking interaction);
SARC	cis	rs644799	1.000	rs10831431	chr11:95510089	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	15.14	0.7	1.65e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg18404041	chr3:52824283	ITIH1	-0.43	-6.58	-0.4	3.15e-10	Bipolar disorder;
SARC	cis	rs883565	0.610	rs4676600	chr3:39157011	A/G	cg26331595	chr3:39149181	GORASP1;TTC21A	0.44	5.24	0.32	3.57e-7	Handedness;
SARC	cis	rs240764	0.853	rs12191199	chr6:101008093	C/T	cg09795085	chr6:101329169	ASCC3	-0.45	-5.84	-0.36	1.78e-8	Neuroticism;
SARC	cis	rs4925386	1.000	rs4925382	chr20:60918542	G/C	cg24112000	chr20:60950667	NA	0.33	5.32	0.33	2.46e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs72781680	1.000	rs17712391	chr2:24245659	C/T	cg06627628	chr2:24431161	ITSN2	-0.71	-6.92	-0.41	4.26e-11	Lymphocyte counts;
SARC	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg11062466	chr8:58055876	NA	0.67	6.06	0.37	5.41e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6582630	0.538	rs7971292	chr12:38498151	A/G	cg13010199	chr12:38710504	ALG10B	-0.49	-6.1	-0.37	4.41e-9	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs12912251	0.947	rs7165988	chr15:38988815	C/G	cg01338139	chr15:38987640	C15orf53	-0.46	-5.41	-0.33	1.6e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
SARC	cis	rs34891900	0.507	rs5992088	chr22:18135912	C/T	cg19898043	chr22:18121309	BCL2L13	-0.67	-7.55	-0.44	9.77e-13	Sum neutrophil eosinophil counts;
SARC	cis	rs7428	0.527	rs4459734	chr2:85547429	G/T	cg03728395	chr2:85555865	TGOLN2	-0.48	-6.62	-0.4	2.49e-10	Ear protrusion;
SARC	cis	rs7614311	0.681	rs73130565	chr3:63887135	T/C	cg22134162	chr3:63841271	THOC7	-0.46	-4.95	-0.31	1.44e-6	Lung function (FVC);Lung function (FEV1);
SARC	cis	rs3126085	0.935	rs11584340	chr1:152285930	G/A	cg26876637	chr1:152193138	HRNR	-0.5	-5.61	-0.34	5.74e-8	Atopic dermatitis;
SARC	cis	rs9896933	0.832	rs79103992	chr17:80855483	G/A	cg15664640	chr17:80829946	TBCD	-0.51	-5.95	-0.36	1e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
SARC	cis	rs6542838	0.582	rs6542845	chr2:99537600	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-4.84	-0.3	2.39e-6	Fear of minor pain;
SARC	cis	rs1008375	1.000	rs55939327	chr4:17642937	T/A	cg02297831	chr4:17616191	MED28	0.5	6.47	0.39	5.62e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg12463550	chr7:65579703	CRCP	0.48	5.79	0.35	2.23e-8	Aortic root size;
SARC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg09373136	chr17:61933544	TCAM1	0.4	5.58	0.34	6.61e-8	Prudent dietary pattern;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg08699355	chr12:80328999	PPP1R12A	0.49	6.38	0.39	9.34e-10	Chemerin levels;
SARC	cis	rs11613048	0.897	rs1973268	chr12:30323342	C/G	cg12718339	chr12:29936407	TMTC1	-0.37	-5.09	-0.32	7.33e-7	Major depressive disorder;
SARC	cis	rs4713118	0.513	rs156738	chr6:28014025	G/C	cg16479474	chr6:28041457	NA	0.33	4.95	0.31	1.43e-6	Parkinson's disease;
SARC	cis	rs1153858	1.000	rs10519022	chr15:45663684	C/T	cg15395560	chr15:45543142	SLC28A2	0.27	5.0	0.31	1.15e-6	Homoarginine levels;
SARC	cis	rs2404602	0.716	rs12917430	chr15:76674360	T/C	cg22467129	chr15:76604101	ETFA	-0.37	-4.85	-0.3	2.31e-6	Blood metabolite levels;
SARC	cis	rs4308124	0.708	rs10178095	chr2:111972516	C/T	cg04571233	chr2:111982156	NA	-0.51	-5.96	-0.36	9.39e-9	Vitiligo;
SARC	trans	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg07211511	chr3:129823064	LOC729375	-0.56	-6.45	-0.39	6.56e-10	Blood pressure (smoking interaction);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg21581312	chr15:35529473	LOC723972	-0.88	-7.46	-0.44	1.66e-12	Autism spectrum disorder or schizophrenia;
SARC	cis	rs561341	1.000	rs554078	chr17:30330109	A/C	cg00745463	chr17:30367425	LRRC37B	-0.63	-5.09	-0.32	7.39e-7	Hip circumference adjusted for BMI;
SARC	cis	rs10779751	0.734	rs2039840	chr1:11125866	G/A	cg08854313	chr1:11322531	MTOR	0.82	11.26	0.59	8.86e-24	Body mass index;
SARC	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg11764359	chr7:65958608	NA	0.88	12.58	0.64	4.89e-28	Aortic root size;
SARC	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-9.59	-0.53	1.42e-18	Chronic sinus infection;
SARC	cis	rs1707322	1.000	rs12403666	chr1:46431621	G/A	cg03146154	chr1:46216737	IPP	0.46	5.5	0.34	9.8e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs8067545	0.641	rs169412	chr17:19851875	G/T	cg13482628	chr17:19912719	NA	0.52	6.51	0.39	4.67e-10	Schizophrenia;
SARC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg03452623	chr4:187889614	NA	-0.81	-12.96	-0.65	2.81e-29	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs449789	0.857	rs4708817	chr6:159720640	A/G	cg14500486	chr6:159655392	FNDC1	-0.44	-5.02	-0.31	1.03e-6	Pulse pressure;
SARC	cis	rs7551222	0.752	rs4951075	chr1:204464446	C/A	cg20240347	chr1:204465584	NA	-0.34	-5.9	-0.36	1.27e-8	Schizophrenia;
SARC	cis	rs67460515	0.563	rs6772723	chr3:160895074	C/G	cg04691961	chr3:161091175	C3orf57	-0.4	-4.84	-0.3	2.33e-6	Parkinson's disease;
SARC	cis	rs7644634	0.559	rs7652702	chr3:105433359	G/A	cg23051926	chr3:105466016	CBLB	0.47	5.27	0.33	3.18e-7	Itch intensity from mosquito bite;
SARC	cis	rs8067545	0.641	rs860335	chr17:19837679	A/G	cg13482628	chr17:19912719	NA	0.5	6.2	0.38	2.51e-9	Schizophrenia;
SARC	cis	rs9388451	0.587	rs1739385	chr6:126099939	G/A	cg06289844	chr6:126071538	HEY2	0.33	5.16	0.32	5.17e-7	Brugada syndrome;
SARC	cis	rs514406	0.505	rs427319	chr1:53178807	T/G	cg16325326	chr1:53192061	ZYG11B	0.94	17.9	0.76	1.15e-45	Monocyte count;
SARC	cis	rs950169	0.614	rs765524	chr15:84681782	G/T	cg24253500	chr15:84953950	NA	0.35	4.99	0.31	1.2e-6	Schizophrenia;
SARC	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg00149659	chr3:10157352	C3orf10	0.7	6.89	0.41	5.14e-11	Alzheimer's disease;
SARC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.99	12.23	0.63	6.97e-27	Platelet count;
SARC	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.46	-5.85	-0.36	1.65e-8	Personality dimensions;
SARC	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg25894440	chr7:65020034	NA	-0.75	-5.77	-0.35	2.56e-8	Diabetic kidney disease;
SARC	cis	rs9467711	0.591	rs13206501	chr6:26110148	T/C	cg21479132	chr6:26055353	NA	0.93	7.0	0.42	2.7e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.42	5.23	0.32	3.74e-7	Tonsillectomy;
SARC	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg24531977	chr5:56204891	C5orf35	0.67	6.4	0.39	8.28e-10	Initial pursuit acceleration;
SARC	cis	rs7246657	0.943	rs8109632	chr19:37931125	A/T	cg23950597	chr19:37808831	NA	-0.57	-5.67	-0.35	4.24e-8	Coronary artery calcification;
SARC	cis	rs7709909	0.720	rs6864512	chr5:79985947	A/C	cg04186980	chr5:79953697	MSH3	0.35	4.72	0.3	4.12e-6	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
SARC	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg18252515	chr7:66147081	NA	0.48	5.14	0.32	5.72e-7	Aortic root size;
SARC	cis	rs4141404	0.818	rs5997897	chr22:31570436	G/A	cg00478049	chr22:31556069	RNF185	0.38	4.91	0.31	1.68e-6	Paclitaxel-induced neuropathy;
SARC	cis	rs7178572	0.568	rs4243045	chr15:77455914	A/C	cg22256960	chr15:77711686	NA	-0.5	-5.56	-0.34	7.45e-8	Type 2 diabetes;
SARC	cis	rs62490346	1.000	rs62490346	chr8:10227910	C/T	cg21775007	chr8:11205619	TDH	0.68	5.23	0.32	3.76e-7	Chickenpox;
SARC	trans	rs459571	0.959	rs410876	chr9:136893867	C/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.58	-6.52	-0.39	4.38e-10	Platelet distribution width;
SARC	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.7	6.84	0.41	6.96e-11	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs7568458	0.870	rs6757263	chr2:85803542	A/G	cg17127132	chr2:85788382	GGCX	0.47	6.26	0.38	1.87e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg11764359	chr7:65958608	NA	0.77	9.44	0.53	3.99e-18	Aortic root size;
SARC	cis	rs9660992	0.710	rs1668864	chr1:205248799	T/C	cg00857998	chr1:205179979	DSTYK	0.5	5.98	0.36	8.28e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs2228479	0.850	rs17232630	chr16:89851179	C/T	cg00800038	chr16:89945340	TCF25	-0.79	-5.47	-0.34	1.19e-7	Skin colour saturation;
SARC	cis	rs3762637	0.941	rs9873842	chr3:122135331	A/T	cg24169773	chr3:122142474	KPNA1	-0.55	-5.56	-0.34	7.29e-8	LDL cholesterol levels;
SARC	cis	rs698833	0.886	rs4953091	chr2:44565266	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	-0.63	-8.39	-0.48	4.73e-15	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg00933542	chr6:150070202	PCMT1	0.32	5.36	0.33	2.01e-7	Lung cancer;
SARC	cis	rs13326165	0.585	rs61644644	chr3:52307496	T/C	cg16894138	chr3:53270350	TKT	-0.54	-4.87	-0.3	2.02e-6	HDL cholesterol;HDL cholesterol levels;
SARC	cis	rs6912958	0.712	rs2787927	chr6:88412786	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.3	-4.96	-0.31	1.34e-6	Monocyte percentage of white cells;
SARC	cis	rs918629	0.530	rs3777185	chr5:95259862	C/T	cg16656078	chr5:95278638	ELL2	-0.57	-7.05	-0.42	2.06e-11	IgG glycosylation;
SARC	cis	rs6732160	0.588	rs2043099	chr2:73374156	G/A	cg01422370	chr2:73384389	NA	0.37	5.72	0.35	3.22e-8	Intelligence (multi-trait analysis);
SARC	cis	rs4642101	0.793	rs6799179	chr3:12829095	A/C	cg24848339	chr3:12840334	CAND2	0.33	4.99	0.31	1.17e-6	QRS complex (12-leadsum);
SARC	cis	rs73206853	0.764	rs73191817	chr12:110918673	G/A	cg10860002	chr12:110842031	ANAPC7	0.63	5.03	0.31	9.77e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs35110281	0.693	rs3819161	chr21:45092653	A/G	cg21573476	chr21:45109991	RRP1B	-0.6	-8.09	-0.47	3.3e-14	Mean corpuscular volume;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg00278692	chr10:93683737	BTAF1	0.48	6.6	0.4	2.8e-10	Chemerin levels;
SARC	cis	rs514024	0.700	rs10118731	chr9:130418652	G/A	cg13643465	chr9:130375613	STXBP1	0.51	6.47	0.39	5.64e-10	Eating disorders (purging via substances);
SARC	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg07701084	chr6:150067640	NUP43	0.42	5.56	0.34	7.28e-8	Lung cancer;
SARC	cis	rs7937682	1.000	rs7128353	chr11:111538875	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.99	-17.18	-0.75	2.74e-43	Primary sclerosing cholangitis;
SARC	cis	rs7429990	0.965	rs319685	chr3:47931984	C/A	cg11946769	chr3:48343235	NME6	0.45	5.16	0.32	5.26e-7	Educational attainment (years of education);
SARC	cis	rs2075371	1.000	rs1421485	chr7:133985181	C/T	cg11752832	chr7:134001865	SLC35B4	0.56	7.26	0.43	5.74e-12	Mean platelet volume;
SARC	cis	rs7927592	0.513	rs630225	chr11:68194611	A/C	cg01657329	chr11:68192670	LRP5	-0.38	-5.09	-0.32	7.35e-7	Total body bone mineral density;
SARC	cis	rs3540	0.533	rs4932342	chr15:90982923	C/T	cg22089800	chr15:90895588	ZNF774	0.68	8.75	0.5	4.27e-16	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs864537	0.676	rs1773561	chr1:167421951	C/T	cg09179987	chr1:167433047	CD247	0.38	6.13	0.37	3.81e-9	Celiac disease or Rheumatoid arthritis;Celiac disease;
SARC	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg13271783	chr10:134563150	INPP5A	-0.38	-4.97	-0.31	1.28e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs41433250	1	rs41433250	chr13:31495835	A/G	cg07636088	chr13:31734946	HSPH1	-0.66	-4.76	-0.3	3.4e-6	Influenza A (H1N1) infection;Mild influenza (H1N1) infection;
SARC	cis	rs912057	0.582	rs1294412	chr6:6739854	A/G	cg06612196	chr6:6737390	NA	0.76	12.9	0.65	4.42e-29	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs1355223	0.902	rs7121272	chr11:34752562	T/G	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-5.65	-0.35	4.73e-8	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs9902453	0.967	rs60176674	chr17:28479854	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	6.6	0.4	2.71e-10	Coffee consumption (cups per day);
SARC	cis	rs72781680	0.898	rs72780191	chr2:24007122	T/C	cg08917208	chr2:24149416	ATAD2B	0.92	8.74	0.5	4.71e-16	Lymphocyte counts;
SARC	cis	rs3126085	0.935	rs7531094	chr1:152176850	A/G	cg09127314	chr1:152161683	NA	0.43	4.85	0.3	2.24e-6	Atopic dermatitis;
SARC	cis	rs4727027	0.901	rs1534197	chr7:148771970	T/C	cg23583168	chr7:148888333	NA	-0.73	-10.28	-0.56	1.1e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-8.75	-0.5	4.39e-16	Alzheimer's disease;
SARC	cis	rs2070677	0.935	rs12261048	chr10:135407923	A/G	cg20169779	chr10:135381914	SYCE1	-0.53	-6.44	-0.39	6.93e-10	Gout;
SARC	cis	rs929596	0.606	rs7604115	chr2:234658116	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.36	-5.07	-0.32	8.18e-7	Total bilirubin levels in HIV-1 infection;
SARC	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	5.68	0.35	3.9e-8	Bipolar disorder;
SARC	cis	rs10504073	0.647	rs4873314	chr8:50011656	A/C	cg00325661	chr8:49890786	NA	0.54	7.3	0.43	4.46e-12	Blood metabolite ratios;
SARC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	9.13	0.51	3.43e-17	Prudent dietary pattern;
SARC	cis	rs796364	0.512	rs1653290	chr2:201078165	A/T	cg23649088	chr2:200775458	C2orf69	0.74	7.28	0.43	5e-12	Schizophrenia;
SARC	cis	rs17376456	0.877	rs12153501	chr5:93360866	T/G	cg21475434	chr5:93447410	FAM172A	0.87	7.91	0.46	1.06e-13	Diabetic retinopathy;
SARC	cis	rs6121246	0.529	rs6060174	chr20:30183538	G/A	cg13852791	chr20:30311386	BCL2L1	0.68	5.91	0.36	1.2e-8	Mean corpuscular hemoglobin;
SARC	cis	rs2439831	0.867	rs11856184	chr15:43919162	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	7.5	0.44	1.35e-12	Lung cancer in ever smokers;
SARC	cis	rs829883	0.646	rs249838	chr12:98874749	C/G	cg25150519	chr12:98850993	NA	0.39	5.09	0.32	7.51e-7	Colorectal adenoma (advanced);
SARC	cis	rs818427	0.964	rs35726351	chr5:112217737	G/A	cg07820702	chr5:112228657	REEP5	-0.45	-4.98	-0.31	1.22e-6	Total body bone mineral density;
SARC	cis	rs526821	0.789	rs10896993	chr11:55303410	A/G	cg04317927	chr11:55418816	OR4S2	0.35	4.91	0.31	1.73e-6	Pediatric bone mineral density (spine);
SARC	cis	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg14541582	chr5:601475	NA	-0.39	-4.91	-0.31	1.71e-6	Obesity-related traits;
SARC	cis	rs17376456	1.000	rs13154249	chr5:93550508	C/T	cg25358565	chr5:93447407	FAM172A	1.35	14.25	0.68	1.48e-33	Diabetic retinopathy;
SARC	cis	rs412050	0.895	rs2329886	chr22:22298474	G/A	cg17089214	chr22:22089827	YPEL1	0.54	5.0	0.31	1.13e-6	Attention deficit hyperactivity disorder;
SARC	trans	rs11781622	0.945	rs1907751	chr8:24373809	C/T	cg17078393	chr1:32717002	LCK	-0.41	-6.27	-0.38	1.73e-9	White matter integrity;
SARC	cis	rs6138458	1.000	rs227624	chr20:24911562	T/C	cg26195577	chr20:24973756	C20orf3	0.88	9.75	0.54	4.69e-19	Blood protein levels;
SARC	cis	rs9309473	0.500	rs12472502	chr2:73859184	C/T	cg20560298	chr2:73613845	ALMS1	0.51	7.0	0.42	2.76e-11	Metabolite levels;
SARC	cis	rs4742903	1.000	rs4743687	chr9:106856910	C/T	cg14250997	chr9:106856677	SMC2	0.53	6.94	0.41	3.96e-11	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg27266027	chr21:40555129	PSMG1	0.48	5.24	0.32	3.52e-7	Cognitive function;
SARC	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg21442419	chr1:2182373	SKI	0.46	5.8	0.36	2.17e-8	Height;
SARC	cis	rs9399135	0.935	rs949547	chr6:135343499	C/G	cg24558204	chr6:135376177	HBS1L	0.45	6.07	0.37	5.25e-9	Red blood cell count;
SARC	cis	rs4846217	1.000	rs6694081	chr1:10443560	G/A	cg19092837	chr1:10271724	KIF1B	0.41	5.4	0.33	1.64e-7	Platelet count;
SARC	trans	rs629535	0.783	rs658407	chr8:70035247	T/C	cg21567404	chr3:27674614	NA	1.04	13.82	0.67	3.98e-32	Dupuytren's disease;
SARC	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg22496380	chr5:211416	CCDC127	-0.88	-9.55	-0.53	1.95e-18	Breast cancer;
SARC	cis	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg21573476	chr21:45109991	RRP1B	-0.54	-8.06	-0.47	3.94e-14	Mean corpuscular volume;
SARC	cis	rs921968	0.541	rs647990	chr2:219441428	T/C	cg02176678	chr2:219576539	TTLL4	0.47	7.13	0.42	1.28e-11	Mean corpuscular hemoglobin concentration;
SARC	cis	rs10504073	0.584	rs17642664	chr8:49942945	A/G	cg00325661	chr8:49890786	NA	0.52	6.95	0.41	3.55e-11	Blood metabolite ratios;
SARC	cis	rs874628	0.851	rs4808762	chr19:18326222	T/C	cg13670957	chr19:18329801	PDE4C	0.5	5.64	0.35	4.96e-8	Multiple sclerosis;
SARC	cis	rs4619890	0.528	rs28417050	chr4:7883077	T/C	cg18538662	chr4:7941764	AFAP1	-0.4	-5.22	-0.32	3.94e-7	Glaucoma (primary open-angle);
SARC	cis	rs9790314	0.663	rs9811594	chr3:160745935	A/G	cg04691961	chr3:161091175	C3orf57	-0.58	-8.03	-0.47	4.76e-14	Morning vs. evening chronotype;
SARC	cis	rs9302635	0.816	rs7202323	chr16:72217113	T/G	cg16558253	chr16:72132732	DHX38	-0.51	-6.16	-0.37	3.17e-9	Blood protein levels;
SARC	cis	rs2425143	1.000	rs6060578	chr20:34305445	C/T	cg01084648	chr20:34329383	RBM39	0.63	4.86	0.3	2.17e-6	Blood protein levels;
SARC	cis	rs3741404	0.560	rs12362602	chr11:63908660	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.65	-8.33	-0.48	6.79e-15	Platelet count;
SARC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	8.99	0.51	8.59e-17	Prudent dietary pattern;
SARC	cis	rs7659604	0.521	rs10001697	chr4:122677737	G/T	cg19671926	chr4:122722719	EXOSC9	0.55	6.99	0.42	2.87e-11	Type 2 diabetes;
SARC	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg17554472	chr22:41940697	POLR3H	-0.45	-5.1	-0.32	6.91e-7	Vitiligo;
SARC	cis	rs523522	0.962	rs3213565	chr12:120992401	C/T	cg12219531	chr12:120966889	COQ5	0.83	11.21	0.59	1.28e-23	High light scatter reticulocyte count;
SARC	cis	rs2153535	0.580	rs7767780	chr6:8453462	A/G	cg21535247	chr6:8435926	SLC35B3	0.57	7.22	0.43	7.46e-12	Motion sickness;
SARC	cis	rs9467773	0.967	rs6932865	chr6:26540166	C/A	cg12292205	chr6:26970375	C6orf41	0.45	5.42	0.33	1.45e-7	Intelligence (multi-trait analysis);
SARC	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.82	10.82	0.58	2.22e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9790314	0.690	rs9860738	chr3:160843290	G/A	cg04691961	chr3:161091175	C3orf57	-0.56	-7.35	-0.43	3.27e-12	Morning vs. evening chronotype;
SARC	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg11764359	chr7:65958608	NA	-0.72	-8.41	-0.48	4.1e-15	Aortic root size;
SARC	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.91	-13.37	-0.66	1.27e-30	Gut microbiome composition (summer);
SARC	cis	rs9556958	0.527	rs9517313	chr13:99105892	C/G	cg07423050	chr13:99094983	FARP1	0.44	6.36	0.38	1.08e-9	Educational attainment (years of education);
SARC	cis	rs6840360	1.000	rs6817586	chr4:152643184	G/A	cg22705602	chr4:152727874	NA	-0.37	-6.44	-0.39	6.63e-10	Intelligence (multi-trait analysis);
SARC	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.6	8.1	0.47	3.12e-14	Menarche (age at onset);
SARC	cis	rs8141529	0.509	rs7287124	chr22:29239157	A/G	cg15103426	chr22:29168792	CCDC117	0.6	7.12	0.42	1.3e-11	Lymphocyte counts;
SARC	cis	rs9309473	0.898	rs10209517	chr2:73845392	C/G	cg20560298	chr2:73613845	ALMS1	-0.43	-5.25	-0.33	3.37e-7	Metabolite levels;
SARC	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg04166393	chr7:2884313	GNA12	0.64	7.62	0.45	6.2e-13	Height;
SARC	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.81	12.34	0.63	2.86e-27	Menarche (age at onset);
SARC	trans	rs1814175	0.791	rs1722011	chr11:49899340	G/C	cg15704280	chr7:45808275	SEPT13	-0.98	-18.29	-0.77	5.97e-47	Height;
SARC	cis	rs7553864	1.000	rs4626859	chr1:87614020	G/A	cg18153957	chr1:87613403	LOC339524	-0.45	-5.27	-0.33	3.17e-7	Smoking behavior;
SARC	cis	rs2370759	1.000	rs11599522	chr10:32568434	G/C	cg01819863	chr10:32635814	EPC1	1.01	9.93	0.55	1.36e-19	Sexual dysfunction (female);
SARC	cis	rs2425143	1.000	rs1970357	chr20:34339200	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.69	-5.78	-0.35	2.35e-8	Blood protein levels;
SARC	cis	rs2115536	0.692	rs6495450	chr15:80162499	C/A	cg00225070	chr15:80189496	MTHFS	0.52	6.71	0.4	1.43e-10	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
SARC	cis	rs2075371	0.796	rs35440439	chr7:134006094	C/T	cg00033643	chr7:134001901	SLC35B4	0.46	5.55	0.34	7.68e-8	Mean platelet volume;
SARC	cis	rs2213920	0.620	rs7852799	chr9:118188696	T/C	cg13918206	chr9:118159781	DEC1	0.79	6.26	0.38	1.82e-9	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs9902453	1.000	rs59274738	chr17:28437635	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	6.71	0.4	1.5e-10	Coffee consumption (cups per day);
SARC	trans	rs2637266	1.000	rs2637266	chr10:78331318	C/T	cg00377332	chr3:45761250	SACM1L	0.45	7.11	0.42	1.39e-11	Pulmonary function;
SARC	cis	rs1003719	0.762	rs9975361	chr21:38450025	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.67	9.98	0.55	9.34e-20	Eye color traits;
SARC	cis	rs113835537	0.529	rs17580784	chr11:66214859	T/A	cg24851651	chr11:66362959	CCS	0.39	4.74	0.3	3.72e-6	Airway imaging phenotypes;
SARC	cis	rs7927771	1.000	rs12419692	chr11:47624714	A/C	cg20307385	chr11:47447363	PSMC3	0.49	5.86	0.36	1.55e-8	Subjective well-being;
SARC	trans	rs561341	0.941	rs2428341	chr17:30317295	C/T	cg20587970	chr11:113659929	NA	-1.02	-10.23	-0.56	1.63e-20	Hip circumference adjusted for BMI;
SARC	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg26769984	chr7:1090371	C7orf50	0.52	5.29	0.33	2.8e-7	Bronchopulmonary dysplasia;
SARC	cis	rs2721195	0.626	rs59464125	chr8:145857786	G/A	cg26752003	chr8:145688521	CYHR1	0.46	5.73	0.35	3.11e-8	Age at first birth;
SARC	cis	rs17376456	0.569	rs17083377	chr5:93164870	C/G	cg21475434	chr5:93447410	FAM172A	0.57	5.65	0.35	4.7e-8	Diabetic retinopathy;
SARC	cis	rs10463316	0.832	rs246486	chr5:150727880	C/T	cg03212797	chr5:150827313	SLC36A1	0.47	5.72	0.35	3.23e-8	Metabolite levels (Pyroglutamine);
SARC	cis	rs9796	0.654	rs2947489	chr15:41459576	T/A	cg18705301	chr15:41695430	NDUFAF1	0.54	7.58	0.44	8.27e-13	Menopause (age at onset);
SARC	cis	rs6991838	0.806	rs13262793	chr8:66461897	T/C	cg13398993	chr8:66546079	ARMC1	0.42	5.13	0.32	6e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg09436375	chr6:42928200	GNMT	-0.37	-5.91	-0.36	1.23e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs11785400	0.793	rs2976400	chr8:143743611	G/A	cg10596483	chr8:143751796	JRK	0.55	7.07	0.42	1.76e-11	Schizophrenia;
SARC	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg00908189	chr16:619842	PIGQ	0.85	12.65	0.64	2.89e-28	Height;
SARC	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg05896524	chr21:47604654	C21orf56	0.59	7.17	0.43	9.64e-12	Testicular germ cell tumor;
SARC	trans	rs4295623	0.585	rs13259242	chr8:11593033	T/G	cg08975724	chr8:8085496	FLJ10661	-0.54	-6.78	-0.41	9.66e-11	Morning vs. evening chronotype;
SARC	cis	rs4889855	0.556	rs4890039	chr17:78517883	C/T	cg17956530	chr17:78667699	RPTOR	0.42	4.8	0.3	2.87e-6	Fractional excretion of uric acid;
SARC	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.49	6.04	0.37	5.96e-9	Gut microbiome composition (summer);
SARC	trans	rs629535	0.783	rs538832	chr8:70033817	A/G	cg21567404	chr3:27674614	NA	1.04	13.82	0.67	3.98e-32	Dupuytren's disease;
SARC	trans	rs3857536	0.740	rs7763555	chr6:66889930	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.6	-7.14	-0.42	1.16e-11	Blood trace element (Cu levels);
SARC	cis	rs12762955	0.561	rs11253567	chr10:1054444	A/G	cg18964960	chr10:1102726	WDR37	0.54	6.4	0.39	8.54e-10	Response to angiotensin II receptor blocker therapy;
SARC	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg06618935	chr21:46677482	NA	-0.4	-5.31	-0.33	2.61e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9325144	0.555	rs1825806	chr12:38692547	G/A	cg26384229	chr12:38710491	ALG10B	0.6	8.03	0.47	4.66e-14	Morning vs. evening chronotype;
SARC	trans	rs61931739	0.534	rs7965503	chr12:34199349	A/G	cg13010199	chr12:38710504	ALG10B	0.74	10.02	0.55	6.94e-20	Morning vs. evening chronotype;
SARC	cis	rs751728	1.000	rs9380378	chr6:33765479	T/C	cg25922239	chr6:33757077	LEMD2	0.77	10.08	0.55	4.69e-20	Crohn's disease;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08841425	chr10:112679110	NCRNA00081;SHOC2	-0.52	-6.35	-0.38	1.09e-9	Fibrinogen levels;
SARC	trans	rs61931739	0.534	rs11053072	chr12:34202399	A/C	cg13010199	chr12:38710504	ALG10B	0.74	10.02	0.55	6.89e-20	Morning vs. evening chronotype;
SARC	cis	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg15145296	chr3:125709740	NA	-0.48	-4.73	-0.3	3.92e-6	Blood pressure (smoking interaction);
SARC	cis	rs1580019	0.665	rs34147895	chr7:32531796	G/C	cg06627557	chr7:32535165	LSM5;AVL9	0.95	15.76	0.72	1.4e-38	Cognitive ability;
SARC	cis	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg18252515	chr7:66147081	NA	1.43	12.98	0.65	2.35e-29	Gout;
SARC	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg13607699	chr17:42295918	UBTF	0.49	5.9	0.36	1.25e-8	Total body bone mineral density;
SARC	cis	rs9916302	0.706	rs9909304	chr17:37500508	G/T	cg20243544	chr17:37824526	PNMT	-0.54	-5.81	-0.36	1.99e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs926392	0.640	rs1007913	chr20:37693592	G/A	cg16355469	chr20:37678765	NA	0.71	9.33	0.52	8.44e-18	Dialysis-related mortality;
SARC	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg05025164	chr4:1340916	KIAA1530	0.47	5.46	0.34	1.22e-7	Obesity-related traits;
SARC	cis	rs4595586	0.545	rs6580895	chr12:39372011	C/T	cg13010199	chr12:38710504	ALG10B	-0.41	-4.91	-0.31	1.69e-6	Morning vs. evening chronotype;
SARC	cis	rs4588572	0.643	rs6453391	chr5:77755035	T/C	cg11547950	chr5:77652471	NA	-0.41	-5.03	-0.31	9.75e-7	Triglycerides;
SARC	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg12705353	chr12:122356852	WDR66	0.4	5.76	0.35	2.7e-8	Mean corpuscular volume;
SARC	cis	rs12142240	0.698	rs1053628	chr1:46827769	C/T	cg00530320	chr1:46809349	NSUN4	0.58	7.07	0.42	1.78e-11	Menopause (age at onset);
SARC	cis	rs995000	0.839	rs1168034	chr1:62963914	G/C	cg06896770	chr1:63153194	DOCK7	-0.89	-12.97	-0.65	2.48e-29	Triglyceride levels;
SARC	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg25072359	chr17:41440525	NA	0.54	6.55	0.39	3.69e-10	Menopause (age at onset);
SARC	cis	rs13191362	0.935	rs34934114	chr6:163082480	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.69	6.04	0.37	5.94e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs11122272	0.735	rs2749711	chr1:231537543	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.97	-0.55	1.02e-19	Hemoglobin concentration;
SARC	cis	rs7615952	0.673	rs3811677	chr3:125648080	G/A	cg05084668	chr3:125655381	ALG1L	-0.68	-6.76	-0.41	1.08e-10	Blood pressure (smoking interaction);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg26582338	chr3:155523741	C3orf33	-0.86	-7.12	-0.42	1.35e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs3737883	1.000	rs2270543	chr1:203030685	T/C	cg03900565	chr1:203031815	PPFIA4	0.34	5.27	0.33	3.15e-7	Early onset atrial fibrillation;
SARC	cis	rs1008375	0.966	rs4698621	chr4:17587565	C/T	cg16339924	chr4:17578868	LAP3	0.69	9.17	0.51	2.59e-17	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs11574514	1.000	rs79972507	chr16:68282777	G/A	cg01866162	chr16:67596514	CTCF	1.12	6.56	0.39	3.49e-10	Crohn's disease;
SARC	cis	rs9398803	0.865	rs4422634	chr6:126806676	A/G	cg20229609	chr6:126660872	C6orf173	0.37	5.28	0.33	2.92e-7	Male-pattern baldness;
SARC	cis	rs1215050	0.791	rs165239	chr4:98682549	C/T	cg05340658	chr4:99064831	C4orf37	0.43	5.77	0.35	2.56e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs6831352	0.819	rs2851274	chr4:100025866	G/C	cg13256891	chr4:100009986	ADH5	0.61	8.4	0.48	4.33e-15	Alcohol dependence;
SARC	cis	rs5753037	0.543	rs140126	chr22:30147038	A/G	cg01021169	chr22:30184971	ASCC2	-0.48	-6.34	-0.38	1.18e-9	Type 1 diabetes;
SARC	cis	rs11770686	0.659	rs4518599	chr7:75297622	C/T	cg07211516	chr7:75296079	HIP1	0.35	4.74	0.3	3.73e-6	Essential tremor;
SARC	cis	rs367943	1.000	rs2248930	chr5:112811119	G/T	cg12552261	chr5:112820674	MCC	-0.45	-5.19	-0.32	4.65e-7	Type 2 diabetes;
SARC	cis	rs2857078	0.720	rs9906669	chr17:42305706	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.43	5.75	0.35	2.77e-8	Red cell distribution width;Reticulocyte count;
SARC	cis	rs17376456	0.877	rs10044066	chr5:93437580	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	6.14	0.37	3.45e-9	Diabetic retinopathy;
SARC	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg05313129	chr8:58192883	C8orf71	-0.62	-6.37	-0.39	9.92e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg05313129	chr8:58192883	C8orf71	-0.62	-6.34	-0.38	1.18e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs950169	0.922	rs12911223	chr15:84831671	G/A	cg17507749	chr15:85114479	UBE2QP1	-0.78	-9.21	-0.52	1.98e-17	Schizophrenia;
SARC	cis	rs9916302	0.904	rs8065879	chr17:37515978	G/A	cg00129232	chr17:37814104	STARD3	0.59	7.31	0.43	4.18e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg26335602	chr6:28129616	ZNF389	0.53	5.88	0.36	1.43e-8	Depression;
SARC	cis	rs4713118	0.629	rs172165	chr6:28020814	T/G	cg17221315	chr6:27791827	HIST1H4J	0.52	5.27	0.33	3.1e-7	Parkinson's disease;
SARC	cis	rs6142102	0.923	rs6057961	chr20:32573811	A/G	cg24642439	chr20:33292090	TP53INP2	0.43	4.73	0.3	3.88e-6	Skin pigmentation;
SARC	cis	rs1005277	0.522	rs289643	chr10:37941494	T/G	cg00409905	chr10:38381863	ZNF37A	-0.53	-7.08	-0.42	1.65e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs9916302	0.680	rs2271308	chr17:37817482	T/C	cg00129232	chr17:37814104	STARD3	-0.73	-10.25	-0.56	1.4e-20	Glomerular filtration rate (creatinine);
SARC	cis	rs9916302	0.706	rs4794808	chr17:37531916	C/T	cg20243544	chr17:37824526	PNMT	-0.55	-5.86	-0.36	1.56e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg15448220	chr1:150897856	SETDB1	0.47	6.25	0.38	1.94e-9	Tonsillectomy;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg26332194	chr12:45610695	ANO6;PLEKHA9	0.48	6.37	0.39	9.86e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs9388451	0.626	rs1935983	chr6:126068914	C/T	cg05901451	chr6:126070800	HEY2	-0.52	-6.43	-0.39	7.08e-10	Brugada syndrome;
SARC	cis	rs7582180	0.739	rs10195793	chr2:100925803	A/G	cg14675211	chr2:100938903	LONRF2	0.51	7.37	0.44	2.87e-12	Intelligence (multi-trait analysis);
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04538470	chr21:38445379	PIGP;TTC3	-0.5	-6.38	-0.39	9.5e-10	Smoking initiation;
SARC	cis	rs9547692	1.000	rs9531991	chr13:37470945	A/G	cg01493522	chr13:37497338	NA	-0.45	-4.77	-0.3	3.22e-6	Coronary artery disease;
SARC	cis	rs12682352	0.602	rs1473029	chr8:8668917	A/C	cg08975724	chr8:8085496	FLJ10661	0.43	5.23	0.32	3.76e-7	Neuroticism;
SARC	cis	rs5753037	0.586	rs140120	chr22:30138548	T/C	cg01021169	chr22:30184971	ASCC2	-0.46	-6.4	-0.39	8.28e-10	Type 1 diabetes;
SARC	cis	rs7208859	0.573	rs8070182	chr17:29135594	A/C	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg14582100	chr15:45693742	SPATA5L1	0.34	4.76	0.3	3.36e-6	Homoarginine levels;
SARC	cis	rs2916247	1.000	rs7825562	chr8:93022696	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.58	-5.83	-0.36	1.88e-8	Intelligence (multi-trait analysis);
SARC	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg05793240	chr7:2802953	GNA12	-0.37	-5.42	-0.33	1.47e-7	Height;
SARC	cis	rs6834538	0.964	rs2087110	chr4:113411791	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.43	5.3	0.33	2.68e-7	Free thyroxine concentration;
SARC	cis	rs6930083	0.527	rs9470367	chr6:36626932	G/C	cg00292029	chr6:36703127	NA	0.31	4.71	0.3	4.2e-6	Coronary artery disease;
SARC	cis	rs9831754	0.906	rs7621811	chr3:78388816	G/A	cg06138941	chr3:78371609	NA	-0.59	-6.97	-0.42	3.31e-11	Calcium levels;
SARC	cis	rs524281	0.861	rs10791855	chr11:65963737	A/G	cg14036092	chr11:66035641	RAB1B	-0.49	-5.25	-0.33	3.43e-7	Electroencephalogram traits;
SARC	cis	rs10927875	0.726	rs1763603	chr1:16339809	T/C	cg21385522	chr1:16154831	NA	0.72	9.16	0.51	2.72e-17	Dilated cardiomyopathy;
SARC	cis	rs9790314	0.690	rs7617204	chr3:160821969	A/G	cg04691961	chr3:161091175	C3orf57	-0.56	-7.44	-0.44	1.94e-12	Morning vs. evening chronotype;
SARC	cis	rs113835537	0.529	rs11227501	chr11:66274072	T/C	cg24851651	chr11:66362959	CCS	0.37	4.72	0.3	4.11e-6	Airway imaging phenotypes;
SARC	cis	rs4595586	0.525	rs4450203	chr12:39381493	T/G	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	cis	rs1957429	0.901	rs7141985	chr14:65345670	C/T	cg23373153	chr14:65346875	NA	1.1	10.67	0.57	6.5600000000000005e-22	Pediatric areal bone mineral density (radius);
SARC	cis	rs8016982	0.698	rs8021385	chr14:81704682	G/A	cg01989461	chr14:81687754	GTF2A1	0.73	10.76	0.58	3.41e-22	Schizophrenia;
SARC	cis	rs8014204	0.550	rs2302832	chr14:75137664	T/C	cg17347104	chr14:75034677	LTBP2	-0.47	-6.16	-0.37	3.14e-9	Caffeine consumption;
SARC	cis	rs7592578	0.882	rs7569128	chr2:191446691	C/A	cg10560079	chr2:191398806	TMEM194B	0.84	9.54	0.53	2.05e-18	Diastolic blood pressure;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg22302626	chr19:10196930	C19orf66	0.78	6.71	0.4	1.45e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9635726	0.638	rs2952155	chr17:37861718	T/C	cg00129232	chr17:37814104	STARD3	-0.64	-7.59	-0.45	7.55e-13	Primary biliary cholangitis;
SARC	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg13175981	chr1:150552382	MCL1	-0.54	-6.9	-0.41	4.97e-11	Tonsillectomy;
SARC	cis	rs477692	0.569	rs10764882	chr10:131306496	C/G	cg05714579	chr10:131428358	MGMT	0.56	7.61	0.45	6.62e-13	Response to temozolomide;
SARC	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg22974920	chr21:40686053	BRWD1	0.47	5.09	0.32	7.44e-7	Cognitive function;
SARC	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg15847926	chr7:2749597	AMZ1	-0.3	-4.95	-0.31	1.41e-6	Height;
SARC	cis	rs7552404	0.545	rs12748741	chr1:76351193	A/G	cg10523679	chr1:76189770	ACADM	-0.43	-5.27	-0.33	3.11e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6901004	1.000	rs6901004	chr6:111554822	C/G	cg15721981	chr6:111408429	SLC16A10	0.43	5.13	0.32	6.17e-7	Blood metabolite levels;
SARC	cis	rs7481584	0.624	rs80871	chr11:3049843	A/C	cg20651018	chr11:3035856	CARS	0.41	6.12	0.37	4.01e-9	Calcium levels;
SARC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg07414643	chr4:187882934	NA	0.5	7.5	0.44	1.34e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs735396	0.770	rs2464196	chr12:121435427	G/A	cg25281562	chr12:121454272	C12orf43	0.57	7.09	0.42	1.62e-11	N-glycan levels;
SARC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.28	0.8	2.29e-53	Prudent dietary pattern;
SARC	cis	rs36051895	0.626	rs10283563	chr9:5075603	C/T	cg02405213	chr9:5042618	JAK2	-0.45	-5.23	-0.32	3.84e-7	Pediatric autoimmune diseases;
SARC	cis	rs4423214	0.879	rs12803256	chr11:71132868	A/G	cg24826892	chr11:71159390	DHCR7	0.39	4.75	0.3	3.61e-6	Vitamin D levels;
SARC	cis	rs2439831	0.850	rs3862142	chr15:44064806	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	8.62	0.49	1.07e-15	Lung cancer in ever smokers;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg10452522	chr19:34663544	LSM14A	0.52	6.83	0.41	7.29e-11	Lung adenocarcinoma;
SARC	cis	rs3126085	0.935	rs3126072	chr1:152279729	C/T	cg03465714	chr1:152285911	FLG	0.48	5.58	0.34	6.64e-8	Atopic dermatitis;
SARC	cis	rs7772486	0.558	rs9376965	chr6:146130055	G/A	cg05347473	chr6:146136440	FBXO30	0.72	10.09	0.55	4.19e-20	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6001982	0.510	rs55844816	chr22:40803112	C/T	cg07138101	chr22:40742427	ADSL	0.55	4.96	0.31	1.37e-6	Breast cancer;
SARC	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs17685	0.725	rs4476928	chr7:75642107	C/A	cg19862616	chr7:65841803	NCRNA00174	-0.61	-7.58	-0.44	7.94e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg21226059	chr5:178986404	RUFY1	0.37	5.35	0.33	2.1e-7	Lung cancer;
SARC	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-5.56	-0.34	7.49e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs1728785	1.000	rs864742	chr16:68575309	T/C	cg02972257	chr16:68554789	NA	-0.43	-5.08	-0.32	7.6e-7	Ulcerative colitis;
SARC	cis	rs9322817	0.691	rs4504502	chr6:105325332	A/G	cg02098413	chr6:105308735	HACE1	0.38	5.92	0.36	1.17e-8	Thyroid stimulating hormone;
SARC	cis	rs6668108	1	rs6668108	chr1:165691320	A/G	cg24409356	chr1:165738333	TMCO1	0.84	6.65	0.4	2.03e-10	Intraocular pressure;
SARC	cis	rs889312	0.500	rs866223	chr5:56125353	A/G	cg14703610	chr5:56206110	C5orf35	0.51	6.44	0.39	6.61e-10	Breast cancer;Breast cancer (early onset);
SARC	cis	rs370915	0.542	rs1000060	chr4:187839499	G/A	cg10295955	chr4:187884368	NA	-0.43	-5.14	-0.32	5.92e-7	Gout;
SARC	cis	rs13336428	0.730	rs28653458	chr16:1525850	T/C	cg07835181	chr16:1525278	CLCN7	0.7	10.68	0.57	6.45e-22	Bone mineral density;
SARC	cis	rs9400467	0.506	rs12195578	chr6:111614786	C/T	cg15721981	chr6:111408429	SLC16A10	0.66	5.64	0.35	4.95e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs854765	0.522	rs63721860	chr17:17829576	T/C	cg04398451	chr17:18023971	MYO15A	-0.42	-5.89	-0.36	1.36e-8	Total body bone mineral density;
SARC	cis	rs1538970	0.847	rs1771550	chr1:45883565	C/T	cg05343316	chr1:45956843	TESK2	-0.69	-8.25	-0.48	1.15e-14	Platelet count;
SARC	cis	rs2404602	0.622	rs9635380	chr15:77103479	A/G	cg15268244	chr15:77196840	NA	0.41	4.76	0.3	3.33e-6	Blood metabolite levels;
SARC	cis	rs9325144	0.647	rs12231313	chr12:39101929	C/T	cg13010199	chr12:38710504	ALG10B	-0.52	-6.47	-0.39	5.68e-10	Morning vs. evening chronotype;
SARC	cis	rs9457247	0.534	rs4710149	chr6:167386346	T/C	cg23791538	chr6:167370224	RNASET2	0.65	9.29	0.52	1.15e-17	Crohn's disease;
SARC	cis	rs7712401	0.715	rs6880480	chr5:122354726	T/A	cg19412675	chr5:122181750	SNX24	-0.39	-4.92	-0.31	1.62e-6	Mean platelet volume;
SARC	cis	rs611744	0.967	rs662714	chr8:109221659	C/A	cg21045802	chr8:109455806	TTC35	0.46	5.43	0.34	1.38e-7	Dupuytren's disease;
SARC	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg08219700	chr8:58056026	NA	0.62	6.25	0.38	1.96e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg15556689	chr8:8085844	FLJ10661	0.46	5.97	0.36	8.68e-9	Mood instability;
SARC	cis	rs5760092	0.755	rs6003959	chr22:24264395	C/T	cg09033563	chr22:24373618	LOC391322	0.53	5.62	0.35	5.39e-8	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs761746	0.739	rs5753690	chr22:31950005	C/T	cg15162869	chr22:32027605	PISD	-0.41	-5.21	-0.32	4.07e-7	Intelligence;
SARC	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg11644478	chr21:40555479	PSMG1	-0.57	-6.92	-0.41	4.41e-11	Menarche (age at onset);
SARC	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1153858	1.000	rs1346268	chr15:45673029	T/C	cg21132104	chr15:45694354	SPATA5L1	0.78	11.01	0.59	5.55e-23	Homoarginine levels;
SARC	cis	rs11252926	0.604	rs2050970	chr10:515870	C/T	cg08603382	chr10:743973	NA	0.42	5.67	0.35	4.25e-8	Psychosis in Alzheimer's disease;
SARC	cis	rs4568518	0.869	rs12155371	chr7:18036164	T/C	cg00911873	chr7:18067463	PRPS1L1	-0.33	-4.72	-0.3	4.08e-6	Measles;
SARC	cis	rs9858542	0.903	rs11917431	chr3:49644012	C/T	cg03060546	chr3:49711283	APEH	-0.66	-8.31	-0.48	7.68e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs12681366	0.663	rs2921389	chr8:95466366	G/A	cg13257157	chr8:95487014	RAD54B	0.39	4.92	0.31	1.65e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs561341	0.714	rs474455	chr17:30312465	A/T	cg00745463	chr17:30367425	LRRC37B	-0.6	-4.81	-0.3	2.67e-6	Hip circumference adjusted for BMI;
SARC	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg00800038	chr16:89945340	TCF25	-0.79	-5.45	-0.34	1.26e-7	Skin colour saturation;
SARC	cis	rs4722166	0.630	rs1829927	chr7:22779918	G/A	cg26061582	chr7:22766209	IL6	0.57	6.29	0.38	1.52e-9	Lung cancer;
SARC	cis	rs9467773	1.000	rs3736782	chr6:26505403	C/A	cg11502198	chr6:26597334	ABT1	0.48	5.98	0.36	8.37e-9	Intelligence (multi-trait analysis);
SARC	trans	rs3780486	0.505	rs10813959	chr9:33166234	C/T	cg04842962	chr6:43655489	MRPS18A	-0.8	-10.87	-0.58	1.61e-22	IgG glycosylation;
SARC	cis	rs8072100	0.744	rs34537623	chr17:45530203	A/G	cg08085267	chr17:45401833	C17orf57	-0.4	-4.81	-0.3	2.66e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg26554054	chr8:600488	NA	0.61	5.09	0.32	7.48e-7	IgG glycosylation;
SARC	cis	rs14978	0.628	rs4721060	chr7:12267552	G/A	cg23422036	chr7:12250390	TMEM106B	0.44	5.64	0.35	4.85e-8	Response to amphetamines;
SARC	cis	rs7438	0.551	rs12499239	chr4:170525701	G/A	cg07701716	chr4:170533879	NEK1	0.39	4.79	0.3	2.99e-6	Schizophrenia;
SARC	cis	rs2486288	0.656	rs6493143	chr15:45570781	G/T	cg21132104	chr15:45694354	SPATA5L1	-0.54	-6.81	-0.41	8.2e-11	Glomerular filtration rate;
SARC	cis	rs3008870	1.000	rs2985797	chr1:67431499	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.97	-11.51	-0.6	1.4e-24	Lymphocyte percentage of white cells;
SARC	trans	rs629535	0.814	rs488231	chr8:70064993	T/C	cg21567404	chr3:27674614	NA	1.05	13.33	0.66	1.68e-30	Dupuytren's disease;
SARC	cis	rs2180341	0.814	rs6919082	chr6:127737888	T/G	cg27446573	chr6:127587934	RNF146	0.79	10.02	0.55	6.91e-20	Breast cancer;
SARC	cis	rs7945705	0.747	rs2568045	chr11:9004060	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-7.2	-0.43	8.12e-12	Hemoglobin concentration;
SARC	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg14773178	chr5:1868261	NA	0.3	4.71	0.3	4.17e-6	Cardiovascular disease risk factors;
SARC	cis	rs710216	0.917	rs4660691	chr1:43417150	T/G	cg03128534	chr1:43423976	SLC2A1	-0.65	-6.8	-0.41	8.59e-11	Red cell distribution width;
SARC	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg22920501	chr2:26401640	FAM59B	-0.63	-8.67	-0.49	7.53e-16	Gut microbiome composition (summer);
SARC	cis	rs12022452	0.591	rs1001400	chr1:40998902	A/G	cg25568243	chr1:40974465	DEM1	0.56	5.09	0.32	7.32e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg21171335	chr12:122356390	WDR66	0.38	5.8	0.35	2.2e-8	Mean corpuscular volume;
SARC	cis	rs9640161	0.830	rs17173702	chr7:150068605	G/A	cg17279839	chr7:150038598	RARRES2	0.34	4.74	0.3	3.79e-6	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs7740797	0.764	rs3800005	chr6:155113108	T/C	cg02865717	chr6:155053990	RBM16	-0.33	-4.74	-0.3	3.7e-6	Colorectal or endometrial cancer;
SARC	cis	rs7927771	0.864	rs3781625	chr11:47443080	T/C	cg20307385	chr11:47447363	PSMC3	-0.59	-7.4	-0.44	2.48e-12	Subjective well-being;
SARC	trans	rs10862219	1.000	rs10862219	chr12:81430043	T/C	cg03835158	chr8:52773607	PCMTD1	-0.48	-6.55	-0.39	3.71e-10	Neuroticism;
SARC	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg06420487	chr17:61919686	SMARCD2	0.43	4.79	0.3	2.93e-6	Height;
SARC	cis	rs933688	1.000	rs889213	chr5:90682151	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.02	12.97	0.65	2.47e-29	Smoking behavior;
SARC	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7872515	0.887	rs10820937	chr9:94840206	T/C	cg01248375	chr9:94877805	SPTLC1	0.66	5.96	0.36	9.26e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs4853036	0.672	rs6759494	chr2:70030905	A/G	cg02498382	chr2:70120550	SNRNP27	-0.36	-4.95	-0.31	1.42e-6	Colorectal or endometrial cancer;
SARC	cis	rs6942407	0.592	rs6958626	chr7:86751525	A/G	cg02420886	chr7:86849541	C7orf23	0.59	5.41	0.33	1.55e-7	Food allergy;
SARC	cis	rs2658782	0.507	rs4457713	chr11:93037430	C/T	cg15737290	chr11:93063684	CCDC67	0.95	12.94	0.65	3.25e-29	Pulmonary function decline;
SARC	cis	rs6570726	0.935	rs12663205	chr6:145818378	G/A	cg05220968	chr6:146057943	EPM2A	-0.29	-4.83	-0.3	2.44e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.94	9.83	0.54	2.7e-19	Platelet count;
SARC	cis	rs9790314	0.875	rs336582	chr3:161082659	C/T	cg03342759	chr3:160939853	NMD3	-0.63	-8.26	-0.48	1.09e-14	Morning vs. evening chronotype;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg11458134	chr5:102091118	NA	-0.75	-6.36	-0.38	1.05e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs16976116	0.901	rs2899582	chr15:55491734	T/C	cg17854078	chr15:55489399	RSL24D1	0.66	6.46	0.39	6.14e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs734999	0.588	rs867435	chr1:2523706	C/T	cg18854424	chr1:2615690	NA	0.33	5.14	0.32	5.86e-7	Ulcerative colitis;
SARC	cis	rs1580019	0.961	rs3801328	chr7:32496930	T/C	cg14728415	chr7:32535168	LSM5;AVL9	0.43	5.04	0.31	9.3e-7	Cognitive ability;
SARC	cis	rs7566780	0.602	rs1430056	chr2:16684144	T/C	cg09580478	chr2:16689509	NA	0.57	7.0	0.42	2.78e-11	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-7.01	-0.42	2.58e-11	Gut microbiome composition (summer);
SARC	cis	rs2652822	0.935	rs7162825	chr15:63439186	A/G	cg02713581	chr15:63449717	RPS27L	-0.71	-9.75	-0.54	4.57e-19	Metabolic traits;
SARC	cis	rs13161895	0.941	rs3797764	chr5:179439345	A/G	cg02702477	chr5:179499311	RNF130	-0.65	-6.46	-0.39	5.92e-10	LDL cholesterol;
SARC	cis	rs526231	0.543	rs257310	chr5:102418853	C/T	cg23492399	chr5:102201601	PAM	-0.5	-5.49	-0.34	1.05e-7	Primary biliary cholangitis;
SARC	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg26818010	chr10:134567672	INPP5A	-0.53	-6.17	-0.37	3.08e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs7043114	0.507	rs2007837	chr9:95189767	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.81	-0.36	2.07e-8	Height;
SARC	cis	rs17125944	0.686	rs7149638	chr14:53346931	T/C	cg00686598	chr14:53173677	PSMC6	-0.66	-4.82	-0.3	2.64e-6	Alzheimer's disease (late onset);
SARC	cis	rs9911578	0.967	rs11079354	chr17:56594460	G/A	cg12560992	chr17:57184187	TRIM37	-0.81	-10.81	-0.58	2.5e-22	Intelligence (multi-trait analysis);
SARC	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg24250549	chr1:154909240	PMVK	0.83	12.22	0.62	7.36e-27	Prostate cancer;
SARC	cis	rs10463554	0.927	rs257304	chr5:102416818	C/G	cg23492399	chr5:102201601	PAM	-0.46	-5.11	-0.32	6.71e-7	Parkinson's disease;
SARC	cis	rs7683537	0.501	rs2171838	chr4:185667404	A/G	cg04058563	chr4:185651563	MLF1IP	-0.55	-6.9	-0.41	4.99e-11	Systemic lupus erythematosus;
SARC	cis	rs7824557	0.564	rs7834572	chr8:11236685	C/T	cg21775007	chr8:11205619	TDH	-0.65	-8.62	-0.49	1.01e-15	Retinal vascular caliber;
SARC	cis	rs2425143	0.598	rs2425118	chr20:34324098	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-7.01	-0.42	2.5e-11	Blood protein levels;
SARC	cis	rs2933343	0.700	rs2624910	chr3:128650275	G/C	cg25356066	chr3:128598488	ACAD9	0.7	9.18	0.52	2.39e-17	IgG glycosylation;
SARC	cis	rs7523050	0.730	rs72984612	chr1:109434826	T/C	cg08274380	chr1:109419600	GPSM2	1.1	8.68	0.49	6.9e-16	Fat distribution (HIV);
SARC	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg02951883	chr7:2050386	MAD1L1	0.41	5.26	0.33	3.2e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs2075371	0.796	rs7780583	chr7:133960716	C/G	cg20476274	chr7:133979776	SLC35B4	0.57	7.41	0.44	2.28e-12	Mean platelet volume;
SARC	cis	rs2073300	0.609	rs79250740	chr20:23417165	G/A	cg16736954	chr20:23401023	NAPB	0.77	4.77	0.3	3.22e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs72945132	0.882	rs7950916	chr11:70210001	T/C	cg05964544	chr11:70165517	PPFIA1	-0.56	-5.37	-0.33	1.93e-7	Coronary artery disease;
SARC	cis	rs2952156	0.920	rs1565920	chr17:37831613	G/A	cg00129232	chr17:37814104	STARD3	-0.7	-10.07	-0.55	5.04e-20	Asthma;
SARC	cis	rs2228479	0.850	rs45524643	chr16:89815824	G/A	cg26513180	chr16:89883248	FANCA	0.72	4.79	0.3	2.99e-6	Skin colour saturation;
SARC	cis	rs17666538	0.591	rs2878547	chr8:603416	G/A	cg02524346	chr8:600233	NA	0.65	5.56	0.34	7.53e-8	IgG glycosylation;
SARC	cis	rs5758511	0.689	rs5758691	chr22:42668504	G/C	cg00645731	chr22:42541494	CYP2D7P1	0.45	6.73	0.4	1.33e-10	Birth weight;
SARC	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.5	-5.81	-0.36	2.07e-8	Blood metabolite levels;
SARC	cis	rs7216064	0.953	rs4791300	chr17:65930772	A/G	cg12091567	chr17:66097778	LOC651250	-0.75	-8.29	-0.48	9.02e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg16060330	chr2:173369204	ITGA6	0.43	6.83	0.41	7.22e-11	Thyroid stimulating hormone;
SARC	trans	rs8073060	0.660	rs58266733	chr17:34003812	A/T	cg19694781	chr19:47549865	TMEM160	-0.7	-6.92	-0.41	4.32e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg07167872	chr1:205819463	PM20D1	0.68	10.77	0.58	3.2e-22	Monocyte percentage of white cells;
SARC	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg24060327	chr5:131705240	SLC22A5	0.45	5.5	0.34	1.01e-7	Acylcarnitine levels;
SARC	cis	rs6665290	0.935	rs17528667	chr1:227201770	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.08	-24.68	-0.85	6e-67	Myeloid white cell count;
SARC	cis	rs1865760	0.566	rs9366634	chr6:26072396	C/G	cg16482183	chr6:26056742	HIST1H1C	0.48	6.08	0.37	4.98e-9	Height;
SARC	cis	rs7178909	0.933	rs7183156	chr15:90445446	A/G	cg19708238	chr15:90437601	AP3S2	0.55	7.07	0.42	1.82e-11	Common traits (Other);
SARC	cis	rs4427176	0.579	rs62489391	chr8:9656272	G/A	cg21625330	chr8:9911636	MSRA	-0.67	-5.23	-0.32	3.75e-7	Mosquito bite size;
SARC	cis	rs17376456	0.877	rs12716460	chr5:93416733	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	6.02	0.37	6.6e-9	Diabetic retinopathy;
SARC	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.39	-4.76	-0.3	3.4e-6	Lymphocyte counts;
SARC	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	12.6	0.64	4.08e-28	Chronic sinus infection;
SARC	cis	rs8114671	0.562	rs2064454	chr20:33496169	C/T	cg07148914	chr20:33460835	GGT7	0.47	5.76	0.35	2.59e-8	Height;
SARC	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg02524346	chr8:600233	NA	0.67	4.99	0.31	1.19e-6	IgG glycosylation;
SARC	cis	rs6088580	0.634	rs6059890	chr20:33101653	G/C	cg24642439	chr20:33292090	TP53INP2	0.66	8.58	0.49	1.39e-15	Glomerular filtration rate (creatinine);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg05707844	chr2:37383994	EIF2AK2	0.5	6.45	0.39	6.43e-10	Height;
SARC	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg27286337	chr10:134555280	INPP5A	0.68	8.37	0.48	5.29e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs2425143	1.000	rs113203744	chr20:34253656	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-5.75	-0.35	2.78e-8	Blood protein levels;
SARC	cis	rs193541	0.593	rs1035372	chr5:122169448	C/A	cg19412675	chr5:122181750	SNX24	0.49	6.34	0.38	1.21e-9	Glucose homeostasis traits;
SARC	cis	rs6964587	0.967	rs12538325	chr7:91757479	A/G	cg17063962	chr7:91808500	NA	0.96	15.4	0.71	2.28e-37	Breast cancer;
SARC	cis	rs6831352	0.918	rs29001199	chr4:100053891	A/G	cg13256891	chr4:100009986	ADH5	-0.63	-7.87	-0.46	1.31e-13	Alcohol dependence;
SARC	cis	rs4253772	0.550	rs6007830	chr22:46711323	C/T	cg24881330	chr22:46731750	TRMU	0.67	5.53	0.34	8.72e-8	LDL cholesterol;Cholesterol, total;
SARC	cis	rs2204008	0.701	rs3898237	chr12:38219714	A/G	cg26384229	chr12:38710491	ALG10B	0.88	12.86	0.64	5.78e-29	Bladder cancer;
SARC	cis	rs4689388	0.824	rs4467645	chr4:6294305	C/T	cg25554036	chr4:6271136	WFS1	0.39	6.39	0.39	8.98e-10	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs9840812	0.567	rs2655008	chr3:136123775	A/T	cg15507776	chr3:136538369	TMEM22	0.53	6.07	0.37	5.25e-9	Fibrinogen levels;
SARC	cis	rs722599	0.748	rs2300599	chr14:75359441	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.43	-5.46	-0.34	1.24e-7	IgG glycosylation;
SARC	cis	rs7264396	0.635	rs6058351	chr20:34486093	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.51	5.2	0.32	4.33e-7	Total cholesterol levels;
SARC	cis	rs7588746	0.621	rs10497859	chr2:201144446	G/A	cg23649088	chr2:200775458	C2orf69	-0.5	-5.91	-0.36	1.18e-8	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs12497850	1.000	rs4858828	chr3:48724811	C/T	cg07636037	chr3:49044803	WDR6	0.92	14.86	0.7	1.41e-35	Parkinson's disease;
SARC	cis	rs6121246	0.954	rs6089093	chr20:30421459	C/T	cg13852791	chr20:30311386	BCL2L1	0.86	9.12	0.51	3.55e-17	Mean corpuscular hemoglobin;
SARC	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg11062466	chr8:58055876	NA	0.58	5.62	0.35	5.37e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs910316	1.000	rs12889309	chr14:75593902	C/T	cg23033748	chr14:75592666	NEK9	0.37	5.3	0.33	2.73e-7	Height;
SARC	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg16405210	chr4:1374714	KIAA1530	-0.47	-5.53	-0.34	8.44e-8	Obesity-related traits;
SARC	cis	rs6834538	0.597	rs4834291	chr4:113482718	C/T	cg05166686	chr4:113558556	LARP7;C4orf21	0.55	7.32	0.43	4.09e-12	Free thyroxine concentration;
SARC	cis	rs7208859	0.623	rs11650982	chr17:29129955	A/G	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs12145833	1.000	rs76473275	chr1:243460555	T/C	cg02356786	chr1:243265016	LOC731275	0.68	5.99	0.37	8.06e-9	Obesity (early onset extreme);
SARC	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg18404041	chr3:52824283	ITIH1	0.46	6.77	0.41	1.03e-10	Bipolar disorder;
SARC	cis	rs75804782	0.520	rs72987319	chr2:239351143	C/T	cg21699342	chr2:239360505	ASB1	-0.58	-4.79	-0.3	2.96e-6	Morning vs. evening chronotype;Chronotype;
SARC	cis	rs6674176	0.628	rs3791119	chr1:44431362	C/G	cg13606994	chr1:44402422	ARTN	-0.33	-5.42	-0.33	1.48e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg13393036	chr8:95962371	TP53INP1	-0.31	-5.32	-0.33	2.4e-7	Type 2 diabetes;
SARC	cis	rs2230307	0.831	rs473688	chr1:100492867	A/G	cg24955406	chr1:100503596	HIAT1	0.71	4.78	0.3	3.15e-6	Carotid intima media thickness;
SARC	cis	rs11532322	1	rs11532322	chr12:123731423	A/G	cg05973401	chr12:123451056	ABCB9	0.51	5.88	0.36	1.44e-8	Schizophrenia;
SARC	cis	rs3733585	0.648	rs35954357	chr4:9978758	G/C	cg00071950	chr4:10020882	SLC2A9	0.38	5.81	0.36	2.04e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs2180341	1.000	rs2326567	chr6:127606160	G/A	cg27446573	chr6:127587934	RNF146	1.01	14.22	0.68	1.88e-33	Breast cancer;
SARC	cis	rs1448094	0.802	rs7397730	chr12:86416212	T/C	cg02569458	chr12:86230093	RASSF9	0.38	5.68	0.35	4.02e-8	Major depressive disorder;
SARC	cis	rs17384381	0.861	rs12736004	chr1:85901367	G/A	cg16011679	chr1:85725395	C1orf52	0.59	5.48	0.34	1.08e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7647973	1.000	rs13322887	chr3:49555583	G/A	cg07636037	chr3:49044803	WDR6	-0.75	-8.43	-0.48	3.58e-15	Menarche (age at onset);
SARC	cis	rs11122272	0.735	rs10489610	chr1:231517765	C/A	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs870825	0.616	rs7692104	chr4:185650895	T/G	cg04058563	chr4:185651563	MLF1IP	0.8	11.37	0.6	3.9e-24	Blood protein levels;
SARC	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.0	-17.04	-0.74	7.98e-43	Chronic sinus infection;
SARC	cis	rs9467711	0.651	rs71557316	chr6:26072981	G/A	cg21479132	chr6:26055353	NA	0.88	6.1	0.37	4.35e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7588746	0.571	rs10931896	chr2:201148076	C/T	cg23649088	chr2:200775458	C2orf69	-0.5	-5.91	-0.36	1.18e-8	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs910316	0.839	rs35977276	chr14:75637359	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.51	-6.73	-0.4	1.3100000000000001e-10	Height;
SARC	cis	rs6545883	0.540	rs11687956	chr2:61851342	T/C	cg15711740	chr2:61764176	XPO1	0.45	5.59	0.34	6.29e-8	Tuberculosis;
SARC	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg23205692	chr1:25664452	TMEM50A	0.44	5.38	0.33	1.8e-7	Erythrocyte sedimentation rate;
SARC	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg06634786	chr22:41940651	POLR3H	-0.51	-6.15	-0.37	3.43e-9	Vitiligo;
SARC	cis	rs6088590	0.561	rs6059932	chr20:33175466	C/T	cg24642439	chr20:33292090	TP53INP2	0.66	8.51	0.49	2.12e-15	Coronary artery disease;
SARC	cis	rs4253772	0.637	rs9627350	chr22:46663017	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.64	7.09	0.42	1.61e-11	LDL cholesterol;Cholesterol, total;
SARC	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	10.51	0.57	2.07e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs995000	0.965	rs3913007	chr1:62921586	T/C	cg06896770	chr1:63153194	DOCK7	1.0	15.96	0.72	2.95e-39	Triglyceride levels;
SARC	cis	rs7617773	0.817	rs11709691	chr3:48303669	A/G	cg11946769	chr3:48343235	NME6	0.71	9.08	0.51	4.84e-17	Coronary artery disease;
SARC	cis	rs6912958	1.000	rs2207144	chr6:88150816	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.62	-8.71	-0.5	5.53e-16	Monocyte percentage of white cells;
SARC	cis	rs11711311	1.000	rs2305545	chr3:113499733	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	8.58	0.49	1.31e-15	IgG glycosylation;
SARC	cis	rs751728	0.965	rs9394168	chr6:33759701	T/A	cg15252951	chr6:33757062	LEMD2	0.58	6.86	0.41	6.27e-11	Crohn's disease;
SARC	cis	rs2153535	0.580	rs9406164	chr6:8470048	C/T	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	cis	rs6693567	0.565	rs1262432	chr1:150371839	C/A	cg09579323	chr1:150459698	TARS2	0.46	5.8	0.36	2.11e-8	Migraine;
SARC	cis	rs9896933	0.775	rs79299098	chr17:80830944	G/A	cg15664640	chr17:80829946	TBCD	-0.49	-5.54	-0.34	7.95e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
SARC	cis	rs765787	0.530	rs11854689	chr15:45516052	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.43	-5.39	-0.33	1.73e-7	Uric acid levels;
SARC	cis	rs1549118	0.595	rs28613643	chr14:78332161	G/A	cg21497246	chr14:78225524	SNW1;C14orf178	0.51	5.35	0.33	2.15e-7	Resting heart rate;
SARC	cis	rs1468333	0.507	rs13361619	chr5:137648679	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.66	8.04	0.47	4.63e-14	Resting heart rate;
SARC	cis	rs7772486	0.754	rs697055	chr6:146003790	C/G	cg05347473	chr6:146136440	FBXO30	0.56	7.88	0.46	1.27e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs826838	1.000	rs1963562	chr12:38662896	C/T	cg13010199	chr12:38710504	ALG10B	0.82	11.85	0.61	1.17e-25	Heart rate;
SARC	cis	rs55986470	0.763	rs6713788	chr2:239456932	T/A	cg18131467	chr2:239335373	ASB1	-0.51	-4.82	-0.3	2.55e-6	Chronotype;
SARC	cis	rs7712401	0.791	rs6872932	chr5:122145636	A/G	cg19412675	chr5:122181750	SNX24	0.39	5.2	0.32	4.4e-7	Mean platelet volume;
SARC	cis	rs9549260	0.755	rs3892360	chr13:41184078	C/G	cg21288729	chr13:41239152	FOXO1	0.65	8.69	0.49	6.57e-16	Red blood cell count;
SARC	cis	rs7523050	0.642	rs12044219	chr1:109481236	T/C	cg08274380	chr1:109419600	GPSM2	0.87	7.17	0.43	9.68e-12	Fat distribution (HIV);
SARC	cis	rs7264396	0.563	rs6060580	chr20:34310512	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	5.69	0.35	3.71e-8	Total cholesterol levels;
SARC	cis	rs8072100	0.713	rs57427906	chr17:45494014	G/A	cg08085267	chr17:45401833	C17orf57	-0.44	-5.18	-0.32	4.76e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs11676348	0.818	rs6436031	chr2:218979259	T/C	cg00012203	chr2:219082015	ARPC2	-0.55	-7.32	-0.43	3.96e-12	Ulcerative colitis;
SARC	cis	rs2288912	0.872	rs9304646	chr19:45450408	T/C	cg10169327	chr19:45448959	APOC2	0.33	5.33	0.33	2.28e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	trans	rs8020941	0.585	rs77109381	chr14:97497205	C/T	cg05136476	chr3:53190709	NA	-0.63	-6.39	-0.39	8.99e-10	Diabetic kidney disease;
SARC	cis	rs11155671	0.530	rs7768626	chr6:150207962	G/T	cg00933542	chr6:150070202	PCMT1	0.29	4.91	0.31	1.73e-6	Testicular germ cell tumor;
SARC	cis	rs4427176	0.561	rs62489425	chr8:9669078	C/T	cg21625330	chr8:9911636	MSRA	-0.69	-5.47	-0.34	1.17e-7	Mosquito bite size;
SARC	cis	rs6570726	1.000	rs373778	chr6:145873252	C/T	cg05347473	chr6:146136440	FBXO30	0.48	6.48	0.39	5.34e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs62432291	0.764	rs436743	chr6:159655102	A/G	cg14500486	chr6:159655392	FNDC1	-0.62	-6.03	-0.37	6.44e-9	Joint mobility (Beighton score);
SARC	cis	rs453301	0.658	rs9650616	chr8:8869199	T/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-5.86	-0.36	1.61e-8	Joint mobility (Beighton score);
SARC	cis	rs11155671	0.530	rs6939761	chr6:150210994	T/C	cg05036130	chr6:150231994	NA	0.28	4.87	0.3	2.04e-6	Testicular germ cell tumor;
SARC	cis	rs7044106	0.762	rs1547268	chr9:123408688	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	4.97	0.31	1.33e-6	Hip circumference adjusted for BMI;
SARC	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg24562565	chr11:27494352	LGR4	-0.5	-6.55	-0.39	3.62e-10	Thyroid cancer;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg21205276	chr9:95056231	IARS;SNORA84	0.51	6.39	0.39	9.13e-10	Breast cancer;
SARC	trans	rs7927370	1.000	rs56063920	chr11:55326249	A/G	cg07162727	chr16:4848039	ROGDI	0.83	6.4	0.39	8.25e-10	Systemic lupus erythematosus;
SARC	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg11764359	chr7:65958608	NA	-0.64	-7.11	-0.42	1.42e-11	Aortic root size;
SARC	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.36	-5.44	-0.34	1.36e-7	Total body bone mineral density;
SARC	cis	rs6088580	0.634	rs6142159	chr20:32993035	G/A	cg24642439	chr20:33292090	TP53INP2	-0.66	-8.58	-0.49	1.36e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg11766577	chr21:47581405	C21orf56	-0.43	-4.98	-0.31	1.21e-6	Testicular germ cell tumor;
SARC	cis	rs34172651	0.876	rs7186893	chr16:24806420	G/T	cg00339695	chr16:24857497	SLC5A11	0.31	4.98	0.31	1.24e-6	Intelligence (multi-trait analysis);
SARC	cis	rs1707322	1.000	rs1768817	chr1:46514534	C/G	cg06784218	chr1:46089804	CCDC17	-0.38	-6.82	-0.41	7.8e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg05623727	chr3:50126028	RBM5	0.35	5.16	0.32	5.22e-7	Body mass index;
SARC	cis	rs6570726	1.000	rs404229	chr6:145868200	G/A	cg23711669	chr6:146136114	FBXO30	0.74	11.07	0.59	3.66e-23	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg11301795	chr4:187892539	NA	-0.69	-10.28	-0.56	1.14e-20	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs634534	0.563	rs470192	chr11:65724291	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.58	9.2	0.52	2.11e-17	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs56235845	0.694	rs4532376	chr5:176774403	G/A	cg17509989	chr5:176798049	RGS14	0.59	7.87	0.46	1.34e-13	Hemoglobin concentration;Hematocrit;
SARC	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg19346786	chr7:2764209	NA	-0.37	-5.51	-0.34	9.7e-8	Height;
SARC	cis	rs743757	0.878	rs6786523	chr3:50524221	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.58	-5.44	-0.34	1.37e-7	Diastolic blood pressure;
SARC	cis	rs7000551	0.700	rs2461491	chr8:22361252	C/T	cg12081754	chr8:22256438	SLC39A14	-0.5	-7.0	-0.42	2.79e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs11690935	0.959	rs7562356	chr2:172626611	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.0	-15.74	-0.72	1.64e-38	Schizophrenia;
SARC	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg06221963	chr1:154839813	KCNN3	0.37	5.71	0.35	3.4e-8	Schizophrenia;
SARC	cis	rs2070433	0.539	rs2839312	chr21:47958225	T/C	cg12379764	chr21:47803548	PCNT	0.52	5.64	0.35	4.98e-8	Lymphocyte counts;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg17610734	chr5:167913534	RARS	0.46	6.25	0.38	1.89e-9	Lung adenocarcinoma;
SARC	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg12310025	chr6:25882481	NA	-0.39	-5.12	-0.32	6.33e-7	Intelligence (multi-trait analysis);
SARC	cis	rs12142240	0.698	rs17361819	chr1:46828109	A/G	cg00530320	chr1:46809349	NSUN4	0.58	7.07	0.42	1.78e-11	Menopause (age at onset);
SARC	cis	rs2816062	0.786	rs2816055	chr1:18898248	A/G	cg10574377	chr1:18908098	NA	0.35	5.09	0.32	7.47e-7	Urate levels in lean individuals;
SARC	cis	rs11792861	0.888	rs11794648	chr9:111829792	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	7.35	0.43	3.25e-12	Menarche (age at onset);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg06383531	chr19:4471622	HDGF2	-0.52	-6.65	-0.4	2.03e-10	Breast cancer;
SARC	cis	rs6088580	0.634	rs6142153	chr20:32968747	C/G	cg24642439	chr20:33292090	TP53INP2	-0.66	-8.63	-0.49	9.96e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs7607369	0.574	rs12990478	chr2:219667463	T/A	cg02176678	chr2:219576539	TTLL4	-0.38	-5.72	-0.35	3.26e-8	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs4660306	1.000	rs1044717	chr1:45976587	A/G	cg24296786	chr1:45957014	TESK2	0.56	6.59	0.4	2.85e-10	Homocysteine levels;
SARC	cis	rs4713118	0.739	rs2893931	chr6:27748010	G/A	cg17221315	chr6:27791827	HIST1H4J	0.47	5.1	0.32	6.97e-7	Parkinson's disease;
SARC	cis	rs1949733	0.655	rs2631736	chr4:8478421	C/G	cg13073564	chr4:8508604	NA	0.45	7.26	0.43	5.84e-12	Response to antineoplastic agents;
SARC	cis	rs12145833	0.679	rs12048498	chr1:243550647	G/A	cg02356786	chr1:243265016	LOC731275	0.64	4.73	0.3	3.83e-6	Obesity (early onset extreme);
SARC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.36	-5.16	-0.32	5.31e-7	Longevity;Endometriosis;
SARC	cis	rs7932354	0.528	rs10466478	chr11:47162604	A/C	cg03339077	chr11:47165057	C11orf49	-0.5	-7.11	-0.42	1.42e-11	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg18402987	chr7:1209562	NA	0.4	5.1	0.32	6.88e-7	Longevity;Endometriosis;
SARC	cis	rs2033732	0.596	rs1550212	chr8:85057433	C/T	cg05716166	chr8:85095498	RALYL	0.47	5.63	0.35	5.1e-8	Body mass index;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg24485466	chr1:200589999	KIF14	-0.91	-7.82	-0.46	1.85e-13	Autism spectrum disorder or schizophrenia;
SARC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg01171360	chr6:293285	DUSP22	0.58	7.53	0.44	1.07e-12	Menopause (age at onset);
SARC	cis	rs734999	0.588	rs3001837	chr1:2532506	G/A	cg18854424	chr1:2615690	NA	-0.32	-5.03	-0.31	9.77e-7	Ulcerative colitis;
SARC	cis	rs7084402	0.967	rs1658468	chr10:60292664	A/G	cg07615347	chr10:60278583	BICC1	0.61	8.99	0.51	8.95e-17	Refractive error;
SARC	cis	rs6570726	0.791	rs446362	chr6:145878716	G/T	cg23711669	chr6:146136114	FBXO30	0.87	14.68	0.69	5.43e-35	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7647973	0.626	rs4855833	chr3:49657441	A/G	cg07636037	chr3:49044803	WDR6	0.65	6.58	0.4	3.01e-10	Menarche (age at onset);
SARC	cis	rs7179456	0.544	rs2555357	chr15:59087115	A/G	cg05156742	chr15:59063176	FAM63B	0.83	13.14	0.65	6.96e-30	Asperger disorder;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg22144486	chr17:8529207	MYH10	0.47	6.72	0.4	1.39e-10	Thyroid stimulating hormone;
SARC	cis	rs2731664	0.819	rs449351	chr5:176872591	T/C	cg23176889	chr5:176863531	GRK6	-0.57	-8.6	-0.49	1.16e-15	Intelligence (multi-trait analysis);
SARC	cis	rs950169	0.881	rs34117475	chr15:85108443	T/C	cg24253500	chr15:84953950	NA	0.36	5.18	0.32	4.86e-7	Schizophrenia;
SARC	cis	rs7766436	0.885	rs1954272	chr6:22586499	A/G	cg13666174	chr6:22585274	NA	-0.61	-7.82	-0.46	1.85e-13	Coronary artery disease;
SARC	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg00933542	chr6:150070202	PCMT1	0.31	5.36	0.33	2.04e-7	Lung cancer;
SARC	cis	rs1448094	0.817	rs7972773	chr12:86340774	A/C	cg02569458	chr12:86230093	RASSF9	0.41	5.9	0.36	1.26e-8	Major depressive disorder;
SARC	cis	rs76419734	0.702	rs72673888	chr4:106808181	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.9	5.07	0.32	8.26e-7	Post bronchodilator FEV1;
SARC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg21724239	chr8:58056113	NA	0.61	6.43	0.39	7.16e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1256061	0.603	rs1256037	chr14:64743301	G/A	cg23250157	chr14:64679961	SYNE2	0.46	6.37	0.38	1.02e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs9911578	0.835	rs9889419	chr17:56473259	C/T	cg12560992	chr17:57184187	TRIM37	0.72	9.15	0.51	2.97e-17	Intelligence (multi-trait analysis);
SARC	cis	rs2295359	0.824	rs4655679	chr1:67599657	A/G	cg12940439	chr1:67600707	NA	-0.47	-6.65	-0.4	2.08e-10	Psoriasis;
SARC	cis	rs8054556	0.787	rs3814877	chr16:30042677	G/T	cg06015834	chr16:30021696	DOC2A	-0.37	-5.1	-0.32	7.03e-7	Autism spectrum disorder or schizophrenia;
SARC	cis	rs4718428	0.705	rs11028	chr7:66276217	T/C	cg18876405	chr7:65276391	NA	0.47	5.32	0.33	2.4e-7	Corneal structure;
SARC	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg00152838	chr16:24741724	TNRC6A	0.6	6.3	0.38	1.44e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	trans	rs459571	1.000	rs456207	chr9:136911140	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.61	-7.08	-0.42	1.64e-11	Platelet distribution width;
SARC	cis	rs10484885	0.878	rs111664889	chr6:90566427	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.61	-5.23	-0.32	3.71e-7	QRS interval (sulfonylurea treatment interaction);
SARC	cis	rs11690935	0.959	rs6724337	chr2:172735329	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.97	-14.62	-0.69	8.72e-35	Schizophrenia;
SARC	cis	rs13161895	1.000	rs17079968	chr5:179443423	C/T	cg02702477	chr5:179499311	RNF130	0.67	6.69	0.4	1.61e-10	LDL cholesterol;
SARC	cis	rs155076	1.000	rs658244	chr13:21850976	T/C	cg14456004	chr13:21872349	NA	-0.99	-12.42	-0.63	1.65e-27	White matter hyperintensity burden;
SARC	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg11890956	chr21:40555474	PSMG1	-1.04	-16.0	-0.72	2.22e-39	Cognitive function;
SARC	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg22535103	chr8:58192502	C8orf71	-0.59	-6.06	-0.37	5.57e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1008375	0.931	rs6449326	chr4:17699790	G/T	cg27347728	chr4:17578864	LAP3	0.44	5.67	0.35	4.13e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs11690935	0.959	rs10206062	chr2:172577276	A/T	cg13550731	chr2:172543902	DYNC1I2	-0.99	-15.91	-0.72	4.3e-39	Schizophrenia;
SARC	cis	rs7592578	0.508	rs62180987	chr2:191267173	A/G	cg25963032	chr2:191064776	C2orf88	-0.47	-5.48	-0.34	1.1e-7	Diastolic blood pressure;
SARC	cis	rs7429990	0.965	rs1060407	chr3:47958037	G/T	cg11946769	chr3:48343235	NME6	0.47	5.19	0.32	4.67e-7	Educational attainment (years of education);
SARC	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg02725872	chr8:58115012	NA	-0.34	-5.37	-0.33	1.91e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg11266682	chr4:10021025	SLC2A9	0.41	7.29	0.43	4.75e-12	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg18876405	chr7:65276391	NA	-0.44	-4.83	-0.3	2.43e-6	Aortic root size;
SARC	cis	rs12586317	0.511	rs113770696	chr14:35444383	C/T	cg26967526	chr14:35346199	BAZ1A	-0.57	-5.7	-0.35	3.53e-8	Psoriasis;
SARC	cis	rs1957429	0.614	rs73279833	chr14:65352523	A/G	cg23373153	chr14:65346875	NA	-0.96	-7.36	-0.43	3.09e-12	Pediatric areal bone mineral density (radius);
SARC	cis	rs7587476	0.861	rs3768716	chr2:215635794	T/C	cg11970703	chr2:215861251	ABCA12	-0.39	-5.66	-0.35	4.36e-8	Neuroblastoma;
SARC	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg22800045	chr5:56110881	MAP3K1	0.73	7.85	0.46	1.52e-13	Initial pursuit acceleration;
SARC	cis	rs10916814	0.632	rs10916818	chr1:20897425	C/T	cg24502330	chr1:20914028	CDA	-0.29	-5.1	-0.32	7.19e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs7020830	0.861	rs6476622	chr9:37308049	T/A	cg14294708	chr9:37120828	ZCCHC7	1.11	19.6	0.79	3.52e-51	Schizophrenia;
SARC	cis	rs9818758	0.545	rs11717978	chr3:48969036	T/A	cg00383909	chr3:49044727	WDR6	0.75	6.7	0.4	1.54e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs708547	0.874	rs1401190	chr4:57885174	T/C	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.46	-5.04	-0.31	9.18e-7	Response to bleomycin (chromatid breaks);
SARC	cis	rs17376456	0.542	rs6556833	chr5:93104707	T/C	cg21475434	chr5:93447410	FAM172A	0.53	5.26	0.33	3.31e-7	Diabetic retinopathy;
SARC	cis	rs61935443	0.720	rs10859784	chr12:95288926	G/A	cg21533806	chr12:95267307	NA	0.68	8.12	0.47	2.73e-14	Schizophrenia;
SARC	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg22168489	chr12:122356033	WDR66	0.65	9.65	0.53	9.34e-19	Mean corpuscular volume;
SARC	cis	rs3767633	0.800	rs2341479	chr1:161885352	C/A	cg09175582	chr1:161736000	ATF6	0.57	5.35	0.33	2.07e-7	IgG glycosylation;
SARC	cis	rs7626444	0.543	rs843528	chr3:196480335	G/A	cg12930392	chr3:196481615	PAK2	0.25	4.98	0.31	1.25e-6	Monocyte count;
SARC	cis	rs1215050	0.740	rs700739	chr4:99022546	A/G	cg05340658	chr4:99064831	C4orf37	-0.5	-6.81	-0.41	8.42e-11	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs832540	0.931	rs331499	chr5:56210923	C/T	cg14703610	chr5:56206110	C5orf35	0.51	6.6	0.4	2.77e-10	Coronary artery disease;
SARC	cis	rs2839186	0.585	rs2839154	chr21:47637760	C/T	cg05896524	chr21:47604654	C21orf56	-0.44	-5.45	-0.34	1.28e-7	Testicular germ cell tumor;
SARC	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg01570182	chr17:44337453	NA	0.87	9.72	0.54	5.66e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs703842	1.000	rs10783847	chr12:58196447	G/A	cg00677455	chr12:58241039	CTDSP2	0.53	6.94	0.41	3.93e-11	Multiple sclerosis;
SARC	cis	rs8180040	0.545	rs9311403	chr3:47138878	T/C	cg27129171	chr3:47204927	SETD2	0.69	9.53	0.53	2.14e-18	Colorectal cancer;
SARC	cis	rs9457247	0.565	rs2239823	chr6:167512131	T/C	cg23791538	chr6:167370224	RNASET2	-0.5	-6.27	-0.38	1.72e-9	Crohn's disease;
SARC	cis	rs9300255	0.596	rs10734901	chr12:123743447	G/A	cg05973401	chr12:123451056	ABCB9	0.48	5.24	0.32	3.53e-7	Neutrophil percentage of white cells;
SARC	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg19077165	chr18:44547161	KATNAL2	-0.51	-7.1	-0.42	1.46e-11	Personality dimensions;
SARC	cis	rs7592578	0.771	rs12052514	chr2:191378170	C/T	cg27211696	chr2:191398769	TMEM194B	-0.56	-5.87	-0.36	1.47e-8	Diastolic blood pressure;
SARC	cis	rs709400	0.567	rs11624343	chr14:103859156	T/A	cg12935359	chr14:103987150	CKB	-0.39	-5.69	-0.35	3.88e-8	Body mass index;
SARC	cis	rs6594499	0.872	rs10055177	chr5:110450584	T/G	cg04022379	chr5:110408740	TSLP	0.5	6.27	0.38	1.78e-9	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs2342371	0.848	rs13092653	chr3:196200188	C/T	cg15048948	chr3:196158458	UBXN7	-0.51	-6.22	-0.38	2.23e-9	Fat distribution (HIV);
SARC	cis	rs6570726	0.967	rs9497316	chr6:145792387	G/T	cg05347473	chr6:146136440	FBXO30	-0.45	-6.12	-0.37	3.98e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs765787	0.530	rs1648287	chr15:45516956	T/C	cg25801113	chr15:45476975	SHF	0.29	4.85	0.3	2.27e-6	Uric acid levels;
SARC	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg22535103	chr8:58192502	C8orf71	-0.57	-6.12	-0.37	4.03e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9457247	1.000	rs400176	chr6:167406238	T/C	cg07741184	chr6:167504864	NA	0.29	5.61	0.34	5.85e-8	Crohn's disease;
SARC	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-9.22	-0.52	1.78e-17	Alzheimer's disease;
SARC	cis	rs17384381	1.000	rs1608536	chr1:85885836	C/T	cg16011679	chr1:85725395	C1orf52	0.61	5.66	0.35	4.32e-8	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs10506458	1.000	rs10506458	chr12:63445092	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.76	-6.86	-0.41	6.12e-11	Hemostatic factors and hematological phenotypes;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg13553498	chr12:9821986	CLEC2D	0.48	6.78	0.41	9.83e-11	Thyroid stimulating hormone;
SARC	cis	rs6089584	0.508	rs6061988	chr20:60626300	C/T	cg13770153	chr20:60521292	NA	-0.38	-5.41	-0.33	1.53e-7	Body mass index;
SARC	cis	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg21573476	chr21:45109991	RRP1B	-0.55	-8.3	-0.48	8.51e-15	Mean corpuscular volume;
SARC	cis	rs1355223	0.552	rs2421743	chr11:34882840	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.79	11.52	0.6	1.37e-24	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs1707322	1.000	rs11211235	chr1:46440375	G/A	cg03146154	chr1:46216737	IPP	0.45	5.41	0.33	1.57e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs73376981	0.732	rs9378846	chr6:471640	A/G	cg03622371	chr11:73000436	P2RY6	-0.53	-6.35	-0.38	1.1e-9	Plantar warts;
SARC	cis	rs10197940	0.686	rs12616688	chr2:152242099	C/G	cg19508488	chr2:152266495	RIF1	0.54	6.11	0.37	4.23e-9	Lung cancer;
SARC	trans	rs7819412	0.775	rs11773990	chr8:10935082	T/C	cg08975724	chr8:8085496	FLJ10661	-0.58	-7.79	-0.45	2.2e-13	Triglycerides;
SARC	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.88	13.38	0.66	1.12e-30	Subjective well-being;
SARC	cis	rs933688	0.938	rs7708782	chr5:90718517	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.02	12.84	0.64	6.81e-29	Smoking behavior;
SARC	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg14517863	chr17:44321492	NA	0.38	5.6	0.34	5.96e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs735539	0.521	rs2585897	chr13:21398979	A/G	cg16922012	chr13:21400325	XPO4	0.4	5.43	0.34	1.42e-7	Dental caries;
SARC	cis	rs798554	0.591	rs1713913	chr7:2895627	C/T	cg04166393	chr7:2884313	GNA12	0.49	5.89	0.36	1.36e-8	Height;
SARC	cis	rs546131	0.614	rs35264793	chr11:34834844	G/C	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-4.83	-0.3	2.52e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs7264396	0.563	rs2425132	chr20:34338390	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.55	5.18	0.32	4.9e-7	Total cholesterol levels;
SARC	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg25072359	chr17:41440525	NA	0.51	6.13	0.37	3.66e-9	Menopause (age at onset);
SARC	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg22168489	chr12:122356033	WDR66	0.73	11.62	0.61	6.31e-25	Mean corpuscular volume;
SARC	cis	rs910316	1.000	rs10142626	chr14:75555636	A/T	cg06637938	chr14:75390232	RPS6KL1	0.54	7.72	0.45	3.41e-13	Height;
SARC	cis	rs7582180	0.563	rs4851304	chr2:100963871	C/T	cg14675211	chr2:100938903	LONRF2	0.51	7.51	0.44	1.24e-12	Intelligence (multi-trait analysis);
SARC	cis	rs1691799	0.867	rs1168356	chr12:66750469	A/G	cg16791601	chr12:66731901	HELB	-0.74	-11.14	-0.59	2.2e-23	White blood cell count (basophil);
SARC	trans	rs9427116	0.502	rs12125166	chr1:154582129	A/G	cg07222414	chr1:98550994	NA	-0.49	-6.4	-0.39	8.22e-10	Blood protein levels;
SARC	cis	rs6456156	0.766	rs150112	chr6:167509878	C/T	cg07741184	chr6:167504864	NA	-0.34	-6.71	-0.4	1.48e-10	Primary biliary cholangitis;
SARC	cis	rs11098499	0.722	rs10025925	chr4:120271744	A/T	cg09307838	chr4:120376055	NA	0.75	10.26	0.56	1.31e-20	Corneal astigmatism;
SARC	cis	rs796364	0.539	rs6738494	chr2:200697058	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.61	4.92	0.31	1.64e-6	Schizophrenia;
SARC	cis	rs1008375	1.000	rs2872959	chr4:17677163	G/A	cg02297831	chr4:17616191	MED28	-0.45	-5.6	-0.34	6.02e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs3796352	0.892	rs58515094	chr3:52995575	C/T	cg15956490	chr3:53032818	SFMBT1	0.79	5.18	0.32	4.85e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs7000551	0.663	rs11778844	chr8:22335170	C/T	cg12081754	chr8:22256438	SLC39A14	0.57	8.05	0.47	4.17e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs6087990	0.769	rs17123658	chr20:31390840	C/A	cg13636640	chr20:31349939	DNMT3B	0.78	12.03	0.62	3.1e-26	Ulcerative colitis;
SARC	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg25072359	chr17:41440525	NA	-0.53	-6.42	-0.39	7.61e-10	Menopause (age at onset);
SARC	cis	rs4919087	0.748	rs701810	chr10:98974849	C/T	cg25902810	chr10:99078978	FRAT1	-0.54	-6.11	-0.37	4.04e-9	Monocyte count;
SARC	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg16482183	chr6:26056742	HIST1H1C	0.41	4.72	0.3	4.04e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7084402	0.967	rs1658422	chr10:60331758	G/T	cg07615347	chr10:60278583	BICC1	0.58	8.44	0.48	3.3e-15	Refractive error;
SARC	cis	rs7633857	0.532	rs9858335	chr3:160760146	A/G	cg03342759	chr3:160939853	NMD3	-0.56	-7.16	-0.42	1.03e-11	Educational attainment (years of education);
SARC	trans	rs3779273	0.776	rs1829989	chr7:77830751	A/C	cg05596911	chr5:118502651	DMXL1	-0.57	-7.35	-0.43	3.38e-12	Body mass index;
SARC	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg16414030	chr3:133502952	NA	-0.39	-5.16	-0.32	5.23e-7	Iron status biomarkers;
SARC	cis	rs7098414	0.511	rs10466236	chr10:82149717	C/T	cg01528321	chr10:82214614	TSPAN14	-0.57	-8.09	-0.47	3.22e-14	Post bronchodilator FEV1;
SARC	cis	rs763121	0.853	rs5757162	chr22:38993370	C/T	cg21395723	chr22:39101663	GTPBP1	0.56	6.25	0.38	1.91e-9	Menopause (age at onset);
SARC	cis	rs6456156	0.586	rs7761977	chr6:167485678	A/G	cg07741184	chr6:167504864	NA	0.36	6.99	0.42	2.83e-11	Primary biliary cholangitis;
SARC	cis	rs9916302	0.904	rs13341996	chr17:37536862	C/T	cg07936489	chr17:37558343	FBXL20	0.69	9.32	0.52	9.49e-18	Glomerular filtration rate (creatinine);
SARC	cis	rs6449957	0.639	rs40419	chr5:67515602	T/C	cg23036683	chr5:67512108	NA	0.42	5.05	0.31	9.09e-7	Cleft lip with or without cleft palate;
SARC	cis	rs3091242	0.900	rs1811832	chr1:25753565	G/A	cg02931644	chr1:25747376	RHCE	0.45	7.43	0.44	2.02e-12	Erythrocyte sedimentation rate;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg15628953	chr12:64238424	SRGAP1	0.51	6.37	0.39	1.02e-9	Height;
SARC	cis	rs4128725	1.000	rs4656820	chr1:159368937	T/C	cg25076881	chr1:159409836	OR10J1	0.4	4.78	0.3	3.16e-6	Select biomarker traits;
SARC	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg00149659	chr3:10157352	C3orf10	1.07	9.51	0.53	2.45e-18	Alzheimer's disease;
SARC	cis	rs34779708	0.931	rs11593858	chr10:35381373	G/A	cg03585969	chr10:35415529	CREM	0.41	4.98	0.31	1.21e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs9902453	1.000	rs9896062	chr17:28357047	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.53	-6.96	-0.41	3.52e-11	Coffee consumption (cups per day);
SARC	cis	rs13418410	0.539	rs1545399	chr2:33843801	A/G	cg04131969	chr2:33951647	MYADML	-0.65	-9.46	-0.53	3.51e-18	Non-response to antidepressants and depression;
SARC	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.82	11.13	0.59	2.28e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs11581859	0.613	rs12024504	chr1:99199734	G/T	cg20286094	chr1:99190917	SNX7	-0.42	-4.93	-0.31	1.55e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs9486719	1.000	rs12205728	chr6:96891838	T/C	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.01	-0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs4073405	0.584	rs7395357	chr11:45308862	A/T	cg04573976	chr11:45942176	GYLTL1B	-0.27	-4.77	-0.3	3.24e-6	Schizophrenia;
SARC	cis	rs13256369	1.000	rs13271966	chr8:8575472	T/C	cg17143192	chr8:8559678	CLDN23	0.51	5.77	0.35	2.5e-8	Obesity-related traits;
SARC	cis	rs6088580	0.524	rs6088560	chr20:33228549	T/C	cg07148914	chr20:33460835	GGT7	-0.4	-4.86	-0.3	2.19e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs16976116	0.901	rs28433503	chr15:55499857	T/C	cg11288833	chr15:55489084	RSL24D1	0.63	6.13	0.37	3.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs3126085	0.935	rs4845426	chr1:152195359	A/G	cg26876637	chr1:152193138	HRNR	0.46	5.4	0.33	1.62e-7	Atopic dermatitis;
SARC	cis	rs11190604	1.000	rs10883502	chr10:102238343	T/G	cg07080220	chr10:102295463	HIF1AN	0.76	8.87	0.5	1.92e-16	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs11583043	0.957	rs6667932	chr1:101503755	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.49	5.54	0.34	8.1e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs4718428	0.705	rs10267335	chr7:66403220	G/T	cg12165864	chr7:66369176	NA	-0.47	-5.21	-0.32	4.18e-7	Corneal structure;
SARC	cis	rs829883	0.659	rs11109517	chr12:98921574	A/C	cg25150519	chr12:98850993	NA	0.59	7.2	0.43	8.24e-12	Colorectal adenoma (advanced);
SARC	trans	rs1814175	0.817	rs6486044	chr11:49982718	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-18.54	-0.77	9.52e-48	Height;
SARC	cis	rs1003719	0.715	rs2835667	chr21:38579914	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.17	-0.52	2.52e-17	Eye color traits;
SARC	cis	rs11583043	0.831	rs6667818	chr1:101412313	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	5.99	0.37	7.88e-9	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs477895	1.000	rs34292685	chr11:64049021	C/T	cg02228329	chr11:64053129	BAD;GPR137	-0.57	-4.85	-0.3	2.24e-6	Mean platelet volume;
SARC	cis	rs427394	1.000	rs274672	chr5:6744176	G/A	cg10857441	chr5:6722123	POLS	-0.33	-5.18	-0.32	4.77e-7	Menopause (age at onset);
SARC	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg18252515	chr7:66147081	NA	0.45	4.8	0.3	2.87e-6	Aortic root size;
SARC	cis	rs4737010	0.501	rs7000282	chr8:41647493	A/C	cg17182837	chr8:41585554	ANK1	-0.45	-4.9	-0.31	1.76e-6	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
SARC	cis	rs193541	0.545	rs112390044	chr5:122312002	A/C	cg19412675	chr5:122181750	SNX24	-0.43	-5.38	-0.33	1.79e-7	Glucose homeostasis traits;
SARC	cis	rs6963495	0.519	rs3892297	chr7:105152173	G/A	cg19920283	chr7:105172520	RINT1	0.62	5.15	0.32	5.67e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs12048904	0.964	rs3188491	chr1:101338482	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.4	5.05	0.31	9.06e-7	Multiple sclerosis;
SARC	cis	rs7223966	1.000	rs8068603	chr17:61755211	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.45	5.03	0.31	9.75e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs4713675	0.565	rs60704560	chr6:33713300	C/T	cg15676125	chr6:33679581	C6orf125	0.58	7.14	0.42	1.15e-11	Plateletcrit;
SARC	cis	rs9660992	0.674	rs12122105	chr1:205256818	C/T	cg21545522	chr1:205238299	TMCC2	0.48	6.57	0.4	3.2e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs10979	1.000	rs10979	chr6:143890039	G/A	cg25407410	chr6:143891975	LOC285740	-0.64	-8.68	-0.49	6.88e-16	Hypospadias;
SARC	trans	rs12310956	0.532	rs11608842	chr12:33951121	C/T	cg13010199	chr12:38710504	ALG10B	0.7	9.25	0.52	1.46e-17	Morning vs. evening chronotype;
SARC	cis	rs453301	0.606	rs7462373	chr8:8899318	G/C	cg06636001	chr8:8085503	FLJ10661	-0.61	-8.47	-0.49	2.86e-15	Joint mobility (Beighton score);
SARC	cis	rs41264869	0.600	rs12048416	chr1:205134829	T/C	cg21643547	chr1:205240462	TMCC2	0.49	5.3	0.33	2.67e-7	Blood protein levels;
SARC	cis	rs9914544	0.545	rs12451200	chr17:18778493	A/G	cg25390199	chr17:18761479	PRPSAP2	0.47	6.14	0.37	3.58e-9	Educational attainment (years of education);
SARC	cis	rs72781680	0.678	rs11125293	chr2:24102423	A/G	cg06627628	chr2:24431161	ITSN2	-0.57	-6.05	-0.37	5.8e-9	Lymphocyte counts;
SARC	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg06221963	chr1:154839813	KCNN3	-0.51	-8.24	-0.47	1.27e-14	Prostate cancer;
SARC	cis	rs7772486	0.790	rs9399571	chr6:146282061	A/G	cg23711669	chr6:146136114	FBXO30	-0.8	-12.38	-0.63	2.12e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10782582	0.609	rs56159153	chr1:76353498	T/G	cg03433033	chr1:76189801	ACADM	-0.39	-5.03	-0.31	1e-6	Daytime sleep phenotypes;
SARC	cis	rs8005677	0.962	rs8003934	chr14:23401142	A/G	cg01529538	chr14:23388837	RBM23	0.44	5.32	0.33	2.46e-7	Cognitive ability (multi-trait analysis);
SARC	cis	rs10985070	0.504	rs2296077	chr9:123944943	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	5.09	0.32	7.44e-7	Rheumatoid arthritis;
SARC	cis	rs793571	0.590	rs673813	chr15:59077171	A/T	cg05156742	chr15:59063176	FAM63B	0.72	9.8	0.54	3.29e-19	Schizophrenia;
SARC	cis	rs4664308	0.935	rs4637057	chr2:160950161	G/T	cg03641300	chr2:160917029	PLA2R1	-0.71	-9.8	-0.54	3.36e-19	Idiopathic membranous nephropathy;
SARC	cis	rs4906332	1.000	rs17617307	chr14:103904965	C/G	cg26031613	chr14:104095156	KLC1	-0.48	-5.66	-0.35	4.45e-8	Coronary artery disease;
SARC	cis	rs7520050	0.966	rs1707340	chr1:46514942	T/C	cg24296786	chr1:45957014	TESK2	0.37	4.75	0.3	3.61e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs7044106	0.791	rs4617229	chr9:123480696	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.72	9.61	0.53	1.26e-18	Hip circumference adjusted for BMI;
SARC	cis	rs477692	0.603	rs10829602	chr10:131326790	G/A	cg05714579	chr10:131428358	MGMT	0.59	7.67	0.45	4.62e-13	Response to temozolomide;
SARC	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg03806693	chr22:41940476	POLR3H	0.87	11.92	0.62	6.82e-26	Vitiligo;
SARC	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg18225595	chr11:63971243	STIP1	0.52	7.45	0.44	1.8e-12	Platelet count;
SARC	cis	rs921968	0.573	rs684776	chr2:219324016	T/C	cg02176678	chr2:219576539	TTLL4	0.47	7.22	0.43	7.28e-12	Mean corpuscular hemoglobin concentration;
SARC	cis	rs14978	0.605	rs4721064	chr7:12284378	G/A	cg23422036	chr7:12250390	TMEM106B	0.47	6.26	0.38	1.84e-9	Response to amphetamines;
SARC	cis	rs1008375	0.932	rs4698630	chr4:17614692	C/G	cg16339924	chr4:17578868	LAP3	0.62	8.04	0.47	4.65e-14	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs76419734	0.850	rs17036090	chr4:106593574	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	-0.82	-5.18	-0.32	4.88e-7	Post bronchodilator FEV1;
SARC	cis	rs950776	0.518	rs952215	chr15:78819153	C/T	cg06917634	chr15:78832804	PSMA4	-0.91	-14.01	-0.68	9.41e-33	Sudden cardiac arrest;
SARC	cis	rs11785400	1.000	rs13265663	chr8:143732255	A/C	cg10596483	chr8:143751796	JRK	0.64	8.54	0.49	1.8e-15	Schizophrenia;
SARC	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg11062466	chr8:58055876	NA	0.54	5.56	0.34	7.55e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs798554	0.660	rs2527687	chr7:2838485	G/A	cg13628971	chr7:2884303	GNA12	0.47	5.79	0.35	2.24e-8	Height;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg26918105	chr5:41928727	FBXO4	-0.52	-6.25	-0.38	1.96e-9	Alcohol dependence;
SARC	cis	rs28795989	0.795	rs938604	chr4:7904363	G/A	cg18538662	chr4:7941764	AFAP1	-0.41	-5.09	-0.32	7.46e-7	Intraocular pressure;
SARC	cis	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg21775007	chr8:11205619	TDH	0.58	7.66	0.45	5.11e-13	Retinal vascular caliber;
SARC	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.63	7.75	0.45	2.76e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4132509	1.000	rs2168812	chr1:243777066	G/A	cg21452805	chr1:244014465	NA	0.49	5.4	0.33	1.62e-7	RR interval (heart rate);
SARC	cis	rs9818758	0.556	rs9813813	chr3:49207093	T/A	cg00383909	chr3:49044727	WDR6	0.75	6.65	0.4	2.01e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs965469	0.843	rs6051842	chr20:3397434	T/C	cg25506879	chr20:3388711	C20orf194	-0.57	-5.92	-0.36	1.16e-8	IFN-related cytopenia;
SARC	cis	rs11697848	1.000	rs55999915	chr20:48453736	A/C	cg17849948	chr20:48532315	SPATA2	0.8	4.84	0.3	2.32e-6	Systemic lupus erythematosus;
SARC	cis	rs422249	0.512	rs174568	chr11:61593816	C/T	cg19610905	chr11:61596333	FADS2	-0.4	-4.77	-0.3	3.29e-6	Trans fatty acid levels;
SARC	cis	rs2153535	0.601	rs9505472	chr6:8538765	T/C	cg23788917	chr6:8435910	SLC35B3	0.64	8.4	0.48	4.5e-15	Motion sickness;
SARC	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg04944784	chr2:26401820	FAM59B	0.6	7.95	0.46	8.14e-14	Gut microbiome composition (summer);
SARC	cis	rs1865760	0.566	rs2032445	chr6:26044812	T/A	cg17691542	chr6:26056736	HIST1H1C	0.54	6.73	0.4	1.3e-10	Height;
SARC	cis	rs8180040	0.726	rs1463393	chr3:46994987	G/A	cg27129171	chr3:47204927	SETD2	-0.69	-9.82	-0.54	2.82e-19	Colorectal cancer;
SARC	cis	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg14541582	chr5:601475	NA	-0.39	-4.8	-0.3	2.89e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs9790314	1.000	rs336593	chr3:161076431	T/C	cg03342759	chr3:160939853	NMD3	-0.59	-7.53	-0.44	1.13e-12	Morning vs. evening chronotype;
SARC	cis	rs2180341	0.855	rs4308584	chr6:127714874	A/G	cg24812749	chr6:127587940	RNF146	0.78	10.09	0.55	4.29e-20	Breast cancer;
SARC	cis	rs208520	0.690	rs12202401	chr6:66760544	A/G	cg07460842	chr6:66804631	NA	1.09	14.57	0.69	1.28e-34	Exhaled nitric oxide output;
SARC	cis	rs11122272	0.701	rs2491402	chr1:231494338	T/C	cg06096015	chr1:231504339	EGLN1	0.36	5.37	0.33	1.92e-7	Hemoglobin concentration;
SARC	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg16479474	chr6:28041457	NA	0.37	5.25	0.33	3.45e-7	Parkinson's disease;
SARC	trans	rs12967884	0.892	rs9963498	chr18:76550928	C/G	cg10946435	chr1:154843044	KCNN3	0.55	6.51	0.39	4.49e-10	Subcutaneous adipose tissue;
SARC	cis	rs4718428	0.705	rs11028	chr7:66276217	T/C	cg18252515	chr7:66147081	NA	-0.57	-6.22	-0.38	2.33e-9	Corneal structure;
SARC	cis	rs2645694	0.626	rs2703119	chr4:77823640	C/T	cg03477792	chr4:77819574	ANKRD56	0.5	7.62	0.45	6.49e-13	Emphysema distribution in smoking;
SARC	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg13939156	chr17:80058883	NA	0.4	6.37	0.39	9.76e-10	Life satisfaction;
SARC	cis	rs2071426	0.959	rs11572139	chr10:96808886	A/G	cg17180012	chr10:97666929	C10orf131	-0.45	-5.41	-0.33	1.58e-7	Blood metabolite levels;
SARC	cis	rs9902453	0.765	rs1531553	chr17:28066752	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.54	-7.14	-0.42	1.19e-11	Coffee consumption (cups per day);
SARC	cis	rs7589342	0.566	rs7589589	chr2:106391154	C/G	cg16077055	chr2:106428750	NCK2	0.32	6.16	0.37	3.09e-9	Addiction;
SARC	cis	rs10911251	0.528	rs4652779	chr1:183104552	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.67	9.78	0.54	3.82e-19	Colorectal cancer;
SARC	cis	rs9916302	0.904	rs600010	chr17:37433517	T/C	cg15445000	chr17:37608096	MED1	0.42	5.16	0.32	5.37e-7	Glomerular filtration rate (creatinine);
SARC	trans	rs1865760	0.929	rs9461224	chr6:25936402	G/T	cg27024417	chr1:32645813	TXLNA	-0.58	-7.14	-0.42	1.16e-11	Height;
SARC	trans	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg21659725	chr3:3221576	CRBN	0.52	6.74	0.4	1.23e-10	Intelligence (multi-trait analysis);
SARC	trans	rs1814175	0.817	rs10839351	chr11:49758153	C/T	cg03929089	chr4:120376271	NA	-0.91	-14.89	-0.7	1.07e-35	Height;
SARC	cis	rs829661	0.512	rs11676852	chr2:30792898	A/C	cg12454169	chr2:30669597	LCLAT1	-0.44	-5.63	-0.35	5.27e-8	Midgestational circulating levels of PBDEs (fetal genetic effect);
SARC	cis	rs708547	0.766	rs781545	chr4:57732025	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.56	-5.85	-0.36	1.62e-8	Response to bleomycin (chromatid breaks);
SARC	cis	rs11651000	0.625	rs11079786	chr17:45805916	A/G	cg24803719	chr17:45855879	NA	0.43	6.8	0.41	8.88e-11	IgG glycosylation;
SARC	cis	rs12545109	0.800	rs1530218	chr8:57407864	C/G	cg19413350	chr8:57351067	NA	-0.43	-4.77	-0.3	3.18e-6	Obesity-related traits;
SARC	cis	rs13095912	1.000	rs13100229	chr3:185343200	C/T	cg11274856	chr3:185301563	NA	0.35	4.84	0.3	2.34e-6	Systolic blood pressure;
SARC	cis	rs9486719	1.000	rs9486719	chr6:97060124	G/A	cg06623918	chr6:96969491	KIAA0776	-0.79	-8.9	-0.5	1.63e-16	Migraine;Coronary artery disease;
SARC	cis	rs57083693	0.518	rs7975348	chr12:101701930	T/C	cg22051763	chr12:101673672	UTP20	-0.45	-5.37	-0.33	1.89e-7	Alcohol dependence (age at onset);
SARC	cis	rs6540556	0.954	rs6540555	chr1:209936571	A/G	cg23920097	chr1:209922102	NA	-0.62	-6.99	-0.42	2.92e-11	Red blood cell count;
SARC	cis	rs11168187	0.843	rs7976708	chr12:48116255	A/G	cg12761788	chr12:48120090	P11	0.36	4.76	0.3	3.43e-6	Vertical cup-disc ratio;
SARC	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg12463550	chr7:65579703	CRCP	-0.7	-5.31	-0.33	2.51e-7	Diabetic kidney disease;
SARC	cis	rs17376456	0.569	rs2045019	chr5:93201971	C/T	cg25358565	chr5:93447407	FAM172A	-0.95	-10.78	-0.58	3.13e-22	Diabetic retinopathy;
SARC	cis	rs9462027	0.606	rs2814979	chr6:34578425	G/C	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.98	-0.36	8.49e-9	Systemic lupus erythematosus;
SARC	cis	rs11098499	0.913	rs35271032	chr4:120156659	C/T	cg09307838	chr4:120376055	NA	0.86	11.6	0.61	7.28e-25	Corneal astigmatism;
SARC	cis	rs2153535	0.580	rs9505448	chr6:8459804	A/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.04e-14	Motion sickness;
SARC	cis	rs2075371	0.966	rs2544214	chr7:133985736	G/A	cg11752832	chr7:134001865	SLC35B4	0.57	7.43	0.44	1.99e-12	Mean platelet volume;
SARC	cis	rs9640161	0.830	rs3757425	chr7:150067640	A/C	cg21361702	chr7:150065534	REPIN1	0.55	6.84	0.41	6.84e-11	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg05084668	chr3:125655381	ALG1L	-0.5	-5.61	-0.35	5.57e-8	Blood pressure (smoking interaction);
SARC	trans	rs629535	0.862	rs655028	chr8:70049047	T/C	cg21567404	chr3:27674614	NA	1.04	13.82	0.67	3.98e-32	Dupuytren's disease;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06771923	chr16:23607815	NDUFAB1	-0.53	-6.59	-0.4	2.84e-10	Smoking initiation;
SARC	cis	rs9790314	0.613	rs56665329	chr3:160590858	T/A	cg04691961	chr3:161091175	C3orf57	0.58	7.94	0.46	8.59e-14	Morning vs. evening chronotype;
SARC	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg25072359	chr17:41440525	NA	0.51	6.08	0.37	4.92e-9	Menopause (age at onset);
SARC	trans	rs3780486	0.801	rs3780495	chr9:33125942	A/C	cg04842962	chr6:43655489	MRPS18A	1.1	20.32	0.8	1.73e-53	IgG glycosylation;
SARC	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg18252515	chr7:66147081	NA	0.59	6.25	0.38	1.92e-9	Aortic root size;
SARC	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg07701084	chr6:150067640	NUP43	0.4	5.29	0.33	2.78e-7	Lung cancer;
SARC	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	11.35	0.6	4.58e-24	Platelet count;
SARC	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	5.41	0.33	1.59e-7	Tonsillectomy;
SARC	cis	rs6964587	0.934	rs7811328	chr7:91720931	A/T	cg17063962	chr7:91808500	NA	0.94	15.98	0.72	2.68e-39	Breast cancer;
SARC	cis	rs9790314	0.818	rs6797066	chr3:161008725	T/A	cg03342759	chr3:160939853	NMD3	-0.74	-9.94	-0.55	1.25e-19	Morning vs. evening chronotype;
SARC	cis	rs10046574	0.561	rs6966294	chr7:135196479	G/A	cg27474649	chr7:135195673	CNOT4	0.85	7.94	0.46	8.44e-14	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs9790314	0.560	rs4856701	chr3:161044106	G/T	cg04691961	chr3:161091175	C3orf57	-0.57	-7.58	-0.44	8.01e-13	Morning vs. evening chronotype;
SARC	cis	rs1318878	0.565	rs12317051	chr12:15428939	A/G	cg08258403	chr12:15378311	NA	0.46	6.75	0.4	1.15e-10	Intelligence (multi-trait analysis);
SARC	trans	rs3780486	0.713	rs3780489	chr9:33129844	G/T	cg04842962	chr6:43655489	MRPS18A	1.1	20.63	0.8	1.68e-54	IgG glycosylation;
SARC	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg03351412	chr1:154909251	PMVK	0.57	7.11	0.42	1.37e-11	Prostate cancer;
SARC	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg05896524	chr21:47604654	C21orf56	0.42	5.04	0.31	9.35e-7	Testicular germ cell tumor;
SARC	cis	rs651907	0.535	rs9830943	chr3:101428899	T/G	cg12386194	chr3:101231763	SENP7	0.49	5.77	0.35	2.57e-8	Colorectal cancer;
SARC	cis	rs6546324	0.580	rs1430785	chr2:67869292	A/G	cg18237512	chr2:67827392	NA	-0.46	-5.72	-0.35	3.3e-8	Endometriosis;
SARC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg11494091	chr17:61959527	GH2	0.54	8.07	0.47	3.81e-14	Prudent dietary pattern;
SARC	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg21724239	chr8:58056113	NA	0.6	6.37	0.38	1.03e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1448094	0.842	rs10863159	chr12:86459140	T/C	cg02569458	chr12:86230093	RASSF9	-0.39	-5.72	-0.35	3.24e-8	Major depressive disorder;
SARC	cis	rs9790314	0.846	rs9834659	chr3:160980947	A/C	cg03342759	chr3:160939853	NMD3	-0.73	-9.94	-0.55	1.26e-19	Morning vs. evening chronotype;
SARC	cis	rs6866344	0.697	rs61247551	chr5:178133503	G/A	cg10224037	chr5:178157518	ZNF354A	1.0	12.53	0.63	7.04e-28	Neutrophil percentage of white cells;
SARC	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg22800045	chr5:56110881	MAP3K1	0.41	4.96	0.31	1.36e-6	Coronary artery disease;
SARC	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg02592271	chr2:27665507	KRTCAP3	-0.41	-6.22	-0.38	2.33e-9	Menopause (age at onset);
SARC	cis	rs2734839	0.537	rs1554929	chr11:113278764	C/T	cg14159747	chr11:113255604	NA	0.36	5.23	0.32	3.78e-7	Information processing speed;
SARC	cis	rs11098499	0.697	rs28655325	chr4:120372999	A/G	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg06027949	chr8:82754900	SNX16	0.5	6.16	0.37	3.23e-9	Diastolic blood pressure;
SARC	cis	rs5995756	0.666	rs5750857	chr22:40000221	A/C	cg10455938	chr22:40058150	CACNA1I	-0.45	-5.25	-0.33	3.43e-7	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg25072359	chr17:41440525	NA	0.48	5.62	0.35	5.43e-8	Menopause (age at onset);
SARC	cis	rs561341	0.943	rs508566	chr17:30289861	G/C	cg00745463	chr17:30367425	LRRC37B	-0.65	-4.97	-0.31	1.32e-6	Hip circumference adjusted for BMI;
SARC	cis	rs9443189	0.570	rs276684	chr6:76427065	A/G	cg01950844	chr6:76311363	SENP6	-0.83	-7.46	-0.44	1.72e-12	Prostate cancer;
SARC	cis	rs8078723	0.933	rs4794822	chr17:38156712	C/T	cg17467752	chr17:38218738	THRA	0.46	5.89	0.36	1.35e-8	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs3126085	1.000	rs12567463	chr1:152180128	T/A	cg26876637	chr1:152193138	HRNR	-0.47	-5.27	-0.33	3.16e-7	Atopic dermatitis;
SARC	cis	rs2290416	0.892	rs61652493	chr8:144669164	G/A	cg10810860	chr8:144639591	GSDMD	-0.7	-4.72	-0.3	4.08e-6	Attention deficit hyperactivity disorder;
SARC	cis	rs7011049	1.000	rs28867471	chr8:53838179	C/T	cg26025543	chr8:53854495	NA	0.61	5.51	0.34	9.53e-8	Systolic blood pressure;
SARC	cis	rs7429990	0.965	rs11709289	chr3:47806649	G/A	cg11946769	chr3:48343235	NME6	0.69	6.81	0.41	8.42e-11	Educational attainment (years of education);
SARC	cis	rs4853036	0.723	rs3732268	chr2:70046262	G/A	cg02498382	chr2:70120550	SNRNP27	-0.44	-5.27	-0.33	3.13e-7	Colorectal or endometrial cancer;
SARC	cis	rs3812111	0.510	rs9372456	chr6:116592956	A/G	cg18828861	chr6:116576566	TSPYL4	0.33	4.85	0.3	2.21e-6	Age-related macular degeneration;
SARC	cis	rs7647973	1.000	rs11928090	chr3:49604904	G/A	cg06212747	chr3:49208901	KLHDC8B	0.55	5.83	0.36	1.82e-8	Menarche (age at onset);
SARC	cis	rs6831352	0.879	rs7434491	chr4:100069847	G/C	cg12011299	chr4:100065546	ADH4	-0.32	-5.09	-0.32	7.33e-7	Alcohol dependence;
SARC	cis	rs6669919	0.530	rs11587621	chr1:211668400	C/T	cg10512769	chr1:211675356	NA	0.35	5.66	0.35	4.44e-8	Intelligence (multi-trait analysis);
SARC	cis	rs4595586	0.545	rs11615584	chr12:39409350	C/G	cg26384229	chr12:38710491	ALG10B	0.51	5.96	0.36	9.35e-9	Morning vs. evening chronotype;
SARC	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg22857025	chr5:266934	NA	-1.06	-11.8	-0.61	1.74e-25	Breast cancer;
SARC	cis	rs9902453	0.904	rs12952179	chr17:28412687	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.08	-0.42	1.73e-11	Coffee consumption (cups per day);
SARC	trans	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg21659725	chr3:3221576	CRBN	-0.65	-6.44	-0.39	6.75e-10	Menarche (age at onset);
SARC	cis	rs6809651	0.524	rs12638263	chr3:185795855	A/C	cg00760338	chr3:185826511	ETV5	-0.76	-9.74	-0.54	5.04e-19	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
SARC	cis	rs7264396	0.623	rs11698601	chr20:34205035	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-7.25	-0.43	6.02e-12	Total cholesterol levels;
SARC	cis	rs12249377	0.519	rs10785972	chr10:92593800	C/T	cg14313238	chr10:92632228	RPP30	0.43	5.11	0.32	6.56e-7	White matter microstructure (global fractional anisotropy);
SARC	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg03806693	chr22:41940476	POLR3H	0.85	11.77	0.61	2.15e-25	Vitiligo;
SARC	cis	rs708547	0.874	rs1713984	chr4:57886493	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.65	7.36	0.43	3.1e-12	Response to bleomycin (chromatid breaks);
SARC	cis	rs9359856	0.636	rs1179896	chr6:90318610	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.57	-5.1	-0.32	7.13e-7	Bipolar disorder;
SARC	cis	rs13082711	0.522	rs551621	chr3:27336325	G/C	cg02860705	chr3:27208620	NA	0.47	6.26	0.38	1.86e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.5	0.39	4.96e-10	Bipolar disorder;
SARC	cis	rs72792276	1.000	rs3805603	chr5:127451581	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	5.52	0.34	8.98e-8	Red cell distribution width;
SARC	cis	rs734999	0.588	rs745368	chr1:2524205	C/T	cg20673091	chr1:2541236	MMEL1	0.34	5.19	0.32	4.64e-7	Ulcerative colitis;
SARC	trans	rs656319	0.513	rs17746245	chr8:9981686	A/C	cg06636001	chr8:8085503	FLJ10661	0.53	6.93	0.41	3.99e-11	Myopia (pathological);
SARC	cis	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg24110177	chr3:50126178	RBM5	-0.38	-4.87	-0.3	2.11e-6	Intelligence (multi-trait analysis);
SARC	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg11764359	chr7:65958608	NA	-0.75	-8.8	-0.5	3.11e-16	Aortic root size;
SARC	cis	rs7945718	0.967	rs12291695	chr11:12795662	A/G	ch.11.340609R	chr11:12831013	TEAD1	0.39	4.89	0.3	1.91e-6	Educational attainment (years of education);
SARC	cis	rs3741151	1.000	rs75912489	chr11:73073846	G/A	cg17517138	chr11:73019481	ARHGEF17	0.99	7.01	0.42	2.57e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs2276314	0.857	rs28431958	chr18:33578401	T/G	cg05985134	chr18:33552581	C18orf21	0.67	6.66	0.4	1.97e-10	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs1348850	0.958	rs1548067	chr2:178462914	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.59	7.13	0.42	1.22e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg12564285	chr5:131593104	PDLIM4	0.42	6.18	0.38	2.9e-9	Acylcarnitine levels;
SARC	cis	rs752010	0.905	rs2038977	chr1:42094659	A/G	cg06885757	chr1:42089581	HIVEP3	0.46	7.37	0.43	2.91e-12	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs710216	0.917	rs710223	chr1:43411038	C/G	cg03128534	chr1:43423976	SLC2A1	0.68	6.87	0.41	5.9e-11	Red cell distribution width;
SARC	cis	rs7621025	0.664	rs6439657	chr3:136494639	C/T	cg15507776	chr3:136538369	TMEM22	-0.56	-6.34	-0.38	1.16e-9	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
SARC	cis	rs2153535	0.580	rs6941670	chr6:8446346	G/A	cg07606381	chr6:8435919	SLC35B3	0.8	11.47	0.6	2e-24	Motion sickness;
SARC	cis	rs2370759	1.000	rs2769241	chr10:32556229	T/C	cg05361325	chr10:32636312	EPC1	0.7	6.04	0.37	6.03e-9	Sexual dysfunction (female);
SARC	trans	rs2727020	0.619	rs11040300	chr11:49269984	C/A	cg03929089	chr4:120376271	NA	0.68	7.8	0.46	2.02e-13	Coronary artery disease;
SARC	cis	rs8067354	0.645	rs56236317	chr17:57822125	C/T	cg13753209	chr17:57696993	CLTC	0.67	7.24	0.43	6.46e-12	Hemoglobin concentration;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg21980954	chr13:111141868	COL4A2	0.91	7.07	0.42	1.77e-11	Obesity-related traits;
SARC	cis	rs10876993	0.928	rs1689586	chr12:58079586	A/T	cg18357645	chr12:58087776	OS9	0.52	7.12	0.42	1.36e-11	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg12463550	chr7:65579703	CRCP	-0.7	-5.33	-0.33	2.35e-7	Diabetic kidney disease;
SARC	cis	rs2735413	0.918	rs34094825	chr16:78081392	G/C	cg04733911	chr16:78082701	NA	-0.3	-5.47	-0.34	1.17e-7	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg00800038	chr16:89945340	TCF25	-0.74	-5.11	-0.32	6.78e-7	Skin colour saturation;
SARC	cis	rs1957429	0.901	rs3813423	chr14:65347475	C/A	cg23373153	chr14:65346875	NA	1.07	11.5	0.6	1.53e-24	Pediatric areal bone mineral density (radius);
SARC	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg17221315	chr6:27791827	HIST1H4J	0.51	5.28	0.33	2.97e-7	Parkinson's disease;
SARC	cis	rs67311347	1.000	rs6795475	chr3:40489281	A/G	cg09455208	chr3:40491958	NA	0.42	6.71	0.4	1.48e-10	Renal cell carcinoma;
SARC	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg13206674	chr6:150067644	NUP43	0.53	6.82	0.41	7.64e-11	Lung cancer;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg04597389	chr17:79935740	ASPSCR1	0.75	6.36	0.38	1.07e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs5417	0.662	rs12601936	chr17:7172609	A/G	cg25750800	chr17:7185070	SLC2A4	-0.41	-5.19	-0.32	4.64e-7	Diastolic blood pressure;
SARC	cis	rs854765	0.663	rs4925120	chr17:17754633	C/T	cg04398451	chr17:18023971	MYO15A	0.42	6.12	0.37	4.02e-9	Total body bone mineral density;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg11980410	chr1:145397667	NA	0.48	6.26	0.38	1.85e-9	Lung adenocarcinoma;
SARC	cis	rs35110281	0.712	rs162345	chr21:44954155	T/G	cg21573476	chr21:45109991	RRP1B	-0.44	-6.39	-0.39	8.77e-10	Mean corpuscular volume;
SARC	cis	rs10028773	0.556	rs4473640	chr4:120260437	G/A	cg09307838	chr4:120376055	NA	0.75	10.4	0.56	4.7e-21	Educational attainment;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg18422875	chr5:113697897	KCNN2	-0.48	-6.91	-0.41	4.64e-11	Electrocardiographic conduction measures;
SARC	cis	rs55962025	0.842	rs362271	chr4:3235518	C/T	cg06533319	chr4:3265114	C4orf44	0.36	5.29	0.33	2.86e-7	Parental longevity (mother's age at death);
SARC	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg05368731	chr17:41323189	NBR1	0.79	9.6	0.53	1.34e-18	Menopause (age at onset);
SARC	cis	rs1707322	0.682	rs3014241	chr1:46087879	A/G	cg06784218	chr1:46089804	CCDC17	-0.39	-6.73	-0.4	1.29e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9814567	1.000	rs7611611	chr3:134307877	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-6.93	-0.41	4.14e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs10979	1.000	rs6570565	chr6:143899531	C/T	cg25407410	chr6:143891975	LOC285740	-0.63	-8.4	-0.48	4.35e-15	Hypospadias;
SARC	cis	rs546131	0.642	rs34191151	chr11:34850509	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-4.76	-0.3	3.42e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs3762637	1.000	rs9968189	chr3:122175136	G/A	cg24169773	chr3:122142474	KPNA1	-0.56	-5.73	-0.35	3.07e-8	LDL cholesterol levels;
SARC	cis	rs9399137	0.507	rs13197750	chr6:135312380	G/A	cg22676075	chr6:135203613	NA	0.38	4.84	0.3	2.32e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg16339924	chr4:17578868	LAP3	0.67	9.12	0.51	3.53e-17	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1552244	0.882	rs56125067	chr3:9984130	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.75	-7.43	-0.44	2.03e-12	Alzheimer's disease;
SARC	cis	rs9462027	0.628	rs9462015	chr6:34739726	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.85	-0.36	1.69e-8	Systemic lupus erythematosus;
SARC	cis	rs10463316	0.894	rs6579863	chr5:150761946	A/T	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.28	-0.33	2.89e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.39	-5.25	-0.32	3.5e-7	Intelligence (multi-trait analysis);
SARC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg02018176	chr4:1364513	KIAA1530	0.64	9.29	0.52	1.14e-17	Longevity;
SARC	cis	rs7659604	1.000	rs6816071	chr4:122665185	G/A	cg19748678	chr4:122722346	EXOSC9	0.41	5.05	0.31	9e-7	Type 2 diabetes;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg25428156	chr4:119556601	NA	0.41	6.36	0.38	1.06e-9	Schizophrenia;
SARC	cis	rs9902453	0.757	rs12453308	chr17:28441604	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	6.52	0.39	4.2e-10	Coffee consumption (cups per day);
SARC	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg05313129	chr8:58192883	C8orf71	-0.52	-6.3	-0.38	1.47e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs11190604	1.000	rs10883512	chr10:102308516	A/G	cg07080220	chr10:102295463	HIF1AN	0.82	10.46	0.57	3.11e-21	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.46	0.57	3.12e-21	Prudent dietary pattern;
SARC	cis	rs473651	1.000	rs473651	chr2:239335401	A/C	cg00800569	chr2:239229395	TRAF3IP1	0.4	4.79	0.3	3.03e-6	Multiple system atrophy;
SARC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.91	10.42	0.56	4.02e-21	Platelet count;
SARC	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg06108461	chr20:60628389	TAF4	-1.01	-13.86	-0.67	2.84e-32	Body mass index;
SARC	cis	rs9296092	0.538	rs3916674	chr6:33522975	C/T	cg13560919	chr6:33536144	NA	-0.49	-5.95	-0.36	9.74e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs6714710	0.603	rs956039	chr2:98416848	C/A	cg26665480	chr2:98280029	ACTR1B	0.55	7.42	0.44	2.2e-12	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs7017697	0.507	rs10112790	chr8:19684414	A/T	cg01411142	chr8:19674711	INTS10	-0.45	-4.78	-0.3	3.17e-6	Breast cancer;
SARC	cis	rs11676348	0.846	rs11677534	chr2:219007060	T/C	cg00012203	chr2:219082015	ARPC2	-0.51	-6.77	-0.41	1.02e-10	Ulcerative colitis;
SARC	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg03452623	chr4:187889614	NA	-0.82	-13.89	-0.67	2.29e-32	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs854765	0.583	rs7213225	chr17:17869111	T/C	cg05444541	chr17:17804740	TOM1L2	-0.3	-4.88	-0.3	1.96e-6	Total body bone mineral density;
SARC	cis	rs11077998	0.967	rs12185229	chr17:80499065	G/C	cg10255544	chr17:80519551	FOXK2	0.44	6.45	0.39	6.37e-10	Reticulocyte fraction of red cells;
SARC	cis	rs3540	0.597	rs4620932	chr15:91036569	G/A	cg22089800	chr15:90895588	ZNF774	0.66	8.46	0.48	3e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg11366901	chr6:160182831	ACAT2	0.95	9.81	0.54	3.13e-19	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs9296092	0.517	rs55963187	chr6:33523778	G/C	cg13560919	chr6:33536144	NA	-0.49	-5.95	-0.36	9.74e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	9.71	0.54	6.14e-19	Platelet count;
SARC	cis	rs4689388	0.926	rs5018647	chr4:6292799	A/C	cg14416269	chr4:6271139	WFS1	0.32	4.98	0.31	1.23e-6	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs10927875	0.793	rs1763619	chr1:16326935	A/G	cg21385522	chr1:16154831	NA	0.7	9.19	0.52	2.2e-17	Dilated cardiomyopathy;
SARC	cis	rs7666738	0.830	rs13108422	chr4:99059267	G/A	cg05340658	chr4:99064831	C4orf37	0.63	8.37	0.48	5.34e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9354308	0.933	rs55672811	chr6:66571730	G/A	cg07460842	chr6:66804631	NA	0.49	5.59	0.34	6.34e-8	Metabolite levels;
SARC	cis	rs2859741	0.967	rs592520	chr1:37513503	G/C	cg09363841	chr1:37513479	NA	-0.3	-5.48	-0.34	1.1e-7	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
SARC	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg12667521	chr19:29218732	NA	0.39	5.26	0.33	3.27e-7	Methadone dose in opioid dependence;
SARC	cis	rs8014204	0.804	rs35641442	chr14:75207263	G/A	cg17347104	chr14:75034677	LTBP2	-0.44	-5.47	-0.34	1.13e-7	Caffeine consumption;
SARC	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg00825309	chr19:58991885	ZNF446	-0.56	-7.78	-0.45	2.29e-13	Uric acid clearance;
SARC	cis	rs6582630	0.555	rs10880602	chr12:38505660	T/C	cg26384229	chr12:38710491	ALG10B	0.83	12.22	0.62	7.27e-27	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2439831	0.850	rs3825783	chr15:44102309	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	8.2	0.47	1.62e-14	Lung cancer in ever smokers;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg03651852	chr6:52285170	EFHC1	0.5	6.38	0.39	9.63e-10	Chemerin levels;
SARC	cis	rs7429990	0.965	rs7430913	chr3:48032357	G/T	cg11946769	chr3:48343235	NME6	-0.45	-5.24	-0.32	3.64e-7	Educational attainment (years of education);
SARC	cis	rs883565	0.531	rs813668	chr3:39180867	G/T	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.55	-6.3	-0.38	1.48e-9	Handedness;
SARC	cis	rs5753618	0.561	rs5753543	chr22:31685458	G/A	cg02404636	chr22:31891804	SFI1	-0.48	-5.15	-0.32	5.56e-7	Colorectal cancer;
SARC	cis	rs910316	0.737	rs175080	chr14:75513828	G/A	cg11812906	chr14:75593930	NEK9	-0.78	-10.69	-0.57	5.69e-22	Height;
SARC	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg08280861	chr8:58055591	NA	0.59	5.8	0.36	2.12e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1355223	1.000	rs11602909	chr11:34768003	T/C	cg18508148	chr11:34937573	PDHX;APIP	-0.43	-5.53	-0.34	8.42e-8	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs7727544	0.735	rs2631370	chr5:131703776	T/C	cg07395648	chr5:131743802	NA	0.42	4.94	0.31	1.49e-6	Blood metabolite levels;
SARC	cis	rs1045902	0.532	rs10185579	chr2:73456342	C/T	cg06642617	chr2:73461528	CCT7;C2orf7	0.4	4.79	0.3	2.96e-6	Intelligence (multi-trait analysis);
SARC	cis	rs28795989	0.795	rs34179701	chr4:7916182	T/C	cg18538662	chr4:7941764	AFAP1	0.44	5.56	0.34	7.38e-8	Intraocular pressure;
SARC	cis	rs72634258	0.786	rs9434993	chr1:8179744	G/C	cg00042356	chr1:8021962	PARK7	0.59	5.52	0.34	9.08e-8	Inflammatory bowel disease;
SARC	cis	rs9527	0.501	rs12244388	chr10:104640052	G/A	cg15744005	chr10:104629667	AS3MT	-0.27	-4.85	-0.3	2.25e-6	Arsenic metabolism;
SARC	trans	rs13240504	0.557	rs2066902	chr7:126181047	A/T	cg14121234	chr10:696332	DIP2C;C10orf108	-0.61	-6.32	-0.38	1.34e-9	Anti-saccade response;
SARC	cis	rs854765	0.583	rs10048206	chr17:17866897	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.43	5.52	0.34	9.04e-8	Total body bone mineral density;
SARC	cis	rs79349575	0.783	rs17708633	chr17:47011620	C/G	cg07967210	chr17:47022446	SNF8	0.38	4.77	0.3	3.2e-6	Type 2 diabetes;
SARC	cis	rs992157	0.835	rs2292551	chr2:219143229	G/A	cg00012203	chr2:219082015	ARPC2	-0.63	-9.14	-0.51	3.16e-17	Colorectal cancer;
SARC	cis	rs2153535	0.580	rs9378554	chr6:8488468	C/T	cg23788917	chr6:8435910	SLC35B3	0.62	8.09	0.47	3.25e-14	Motion sickness;
SARC	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.32	-4.85	-0.3	2.23e-6	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	trans	rs208520	0.909	rs60604603	chr6:67022955	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.82	8.32	0.48	7.56e-15	Exhaled nitric oxide output;
SARC	cis	rs597539	0.727	rs632984	chr11:68620271	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	10.15	0.55	2.76e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg05861140	chr6:150128134	PCMT1	-0.38	-4.85	-0.3	2.22e-6	Lung cancer;
SARC	cis	rs7659604	0.539	rs72680779	chr4:122797263	C/T	cg19671926	chr4:122722719	EXOSC9	-0.55	-5.94	-0.36	1.02e-8	Type 2 diabetes;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg14459420	chr2:55459779	RPS27A;C2orf63	-0.55	-6.96	-0.41	3.52e-11	Gallstone disease;
SARC	cis	rs9388451	0.874	rs13209968	chr6:126089285	G/C	cg06289844	chr6:126071538	HEY2	0.35	5.72	0.35	3.26e-8	Brugada syndrome;
SARC	cis	rs7246657	1.000	rs12709812	chr19:37794850	A/G	cg14683738	chr19:37701593	ZNF585B	-0.61	-5.73	-0.35	3.16e-8	Coronary artery calcification;
SARC	cis	rs4268898	0.679	rs2551181	chr2:24437548	C/T	cg06627628	chr2:24431161	ITSN2	0.68	8.34	0.48	6.7e-15	Asthma;
SARC	cis	rs7089973	0.604	rs2420066	chr10:116583897	A/G	cg08188268	chr10:116634841	FAM160B1	0.28	4.76	0.3	3.41e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs874628	0.851	rs12461072	chr19:18330592	C/G	cg13670957	chr19:18329801	PDE4C	0.5	5.78	0.35	2.34e-8	Multiple sclerosis;
SARC	cis	rs13401104	0.686	rs72620812	chr2:237118765	C/T	cg19324714	chr2:237145437	ASB18	0.57	5.66	0.35	4.32e-8	Educational attainment;
SARC	cis	rs7246865	0.510	rs3816550	chr19:17173487	A/G	cg16202187	chr19:17186497	HAUS8;MYO9B	0.39	4.77	0.3	3.2e-6	Reticulocyte fraction of red cells;
SARC	cis	rs4808199	0.948	rs968525	chr19:19459215	C/T	cg03709012	chr19:19516395	GATAD2A	1.07	11.44	0.6	2.34e-24	Nonalcoholic fatty liver disease;
SARC	cis	rs72945132	0.882	rs6592552	chr11:70223831	A/T	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.62	-0.35	5.51e-8	Coronary artery disease;
SARC	cis	rs7551222	0.752	rs4951398	chr1:204531876	T/C	cg20240347	chr1:204465584	NA	-0.32	-5.63	-0.35	5.29e-8	Schizophrenia;
SARC	cis	rs8067354	0.645	rs2665400	chr17:57880201	G/A	cg13753209	chr17:57696993	CLTC	0.68	7.55	0.44	9.66e-13	Hemoglobin concentration;
SARC	cis	rs7103648	0.695	rs11039290	chr11:47572279	G/A	cg10504702	chr11:47789108	FNBP4	0.7	9.21	0.52	1.89e-17	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs5753618	0.561	rs2078803	chr22:31652852	G/A	cg02404636	chr22:31891804	SFI1	-0.49	-5.29	-0.33	2.85e-7	Colorectal cancer;
SARC	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg05861140	chr6:150128134	PCMT1	-0.44	-5.72	-0.35	3.18e-8	Lung cancer;
SARC	cis	rs425277	0.958	rs262687	chr1:2117155	G/A	cg24578937	chr1:2090814	PRKCZ	0.28	5.06	0.31	8.52e-7	Height;
SARC	cis	rs2645694	0.626	rs2703115	chr4:77824442	C/T	cg10057126	chr4:77819792	ANKRD56	0.42	6.44	0.39	6.72e-10	Emphysema distribution in smoking;
SARC	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg03806693	chr22:41940476	POLR3H	0.89	11.67	0.61	4.48e-25	Vitiligo;
SARC	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg12463550	chr7:65579703	CRCP	0.5	5.9	0.36	1.27e-8	Aortic root size;
SARC	cis	rs12711979	0.765	rs13028529	chr2:3825467	C/T	cg17052675	chr2:3827356	NA	-0.32	-4.73	-0.3	3.87e-6	Itch intensity from mosquito bite adjusted by bite size;
SARC	cis	rs35306767	0.903	rs34847097	chr10:902252	A/T	cg26597838	chr10:835615	NA	0.83	8.49	0.49	2.51e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg16132339	chr22:24313637	DDTL;DDT	0.43	5.56	0.34	7.24e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	trans	rs561341	1.000	rs561341	chr17:30316385	T/G	cg20587970	chr11:113659929	NA	-1.33	-13.84	-0.67	3.43e-32	Hip circumference adjusted for BMI;
SARC	cis	rs765787	0.530	rs28756676	chr15:45540360	G/A	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.81e-6	Uric acid levels;
SARC	cis	rs4242434	0.857	rs11777808	chr8:22462755	A/C	cg03733263	chr8:22462867	KIAA1967	1.04	18.34	0.77	4.34e-47	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs1215050	0.740	rs2695464	chr4:98980929	T/C	cg05340658	chr4:99064831	C4orf37	-0.47	-6.34	-0.38	1.17e-9	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs7481584	0.624	rs421196	chr11:3048582	T/G	cg25174290	chr11:3078921	CARS	-0.6	-8.35	-0.48	6.26e-15	Calcium levels;
SARC	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg10435706	chr6:150039699	LATS1	0.36	4.8	0.3	2.88e-6	Lung cancer;
SARC	cis	rs6815814	0.950	rs4540055	chr4:38803255	A/T	cg06935464	chr4:38784597	TLR10	0.55	5.83	0.36	1.89e-8	Breast cancer;
SARC	cis	rs6912958	0.558	rs7741825	chr6:88327338	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-5.74	-0.35	2.99e-8	Monocyte percentage of white cells;
SARC	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg09323728	chr8:95962352	TP53INP1	-0.29	-4.96	-0.31	1.35e-6	Type 2 diabetes;
SARC	cis	rs11166927	0.870	rs11166930	chr8:140824621	A/G	cg16909799	chr8:140841666	TRAPPC9	-0.37	-5.22	-0.32	3.95e-7	Pediatric non-alcoholic fatty liver disease activity score;
SARC	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg27211696	chr2:191398769	TMEM194B	0.51	7.06	0.42	1.95e-11	Pulse pressure;
SARC	cis	rs7617773	0.539	rs13087050	chr3:48392800	C/T	cg11946769	chr3:48343235	NME6	0.56	7.01	0.42	2.55e-11	Coronary artery disease;
SARC	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs920590	0.758	rs1907799	chr8:19664668	A/G	cg17834443	chr8:19674713	INTS10	-0.59	-7.3	-0.43	4.51e-12	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs4713118	0.597	rs172166	chr6:28020820	C/G	cg26335602	chr6:28129616	ZNF389	0.5	5.28	0.33	2.95e-7	Parkinson's disease;
SARC	cis	rs4803468	1.000	rs2569754	chr19:41936734	A/G	cg14132834	chr19:41945861	ATP5SL	-0.57	-7.45	-0.44	1.81e-12	Height;
SARC	cis	rs9398803	0.865	rs9401883	chr6:126797111	A/G	cg19875578	chr6:126661172	C6orf173	0.63	8.55	0.49	1.64e-15	Male-pattern baldness;
SARC	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg26818010	chr10:134567672	INPP5A	-0.53	-5.98	-0.36	8.39e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs7264396	0.563	rs7268195	chr20:34339854	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-6.71	-0.4	1.47e-10	Total cholesterol levels;
SARC	cis	rs644799	0.710	rs523153	chr11:95570961	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	13.31	0.66	1.91e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs4073582	0.595	rs708471	chr11:65931008	A/G	cg14036092	chr11:66035641	RAB1B	0.59	8.36	0.48	5.75e-15	Gout;
SARC	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg01341218	chr17:43662625	NA	1.0	11.35	0.6	4.76e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs2153535	0.580	rs915350	chr6:8443486	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg13902645	chr11:5959945	NA	-0.44	-6.07	-0.37	5.24e-9	DNA methylation (variation);
SARC	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg11644478	chr21:40555479	PSMG1	0.57	6.83	0.41	7.38e-11	Menarche (age at onset);
SARC	cis	rs870825	0.860	rs72689277	chr4:185593699	G/A	cg04058563	chr4:185651563	MLF1IP	0.81	9.73	0.54	5.47e-19	Blood protein levels;
SARC	cis	rs10193935	0.901	rs871045	chr2:42609431	G/C	cg27598129	chr2:42591480	NA	-0.38	-5.3	-0.33	2.71e-7	Colonoscopy-negative controls vs population controls;
SARC	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.33	-5.05	-0.31	9.12e-7	Total body bone mineral density;
SARC	cis	rs12545109	0.775	rs10093388	chr8:57318799	C/T	cg09654669	chr8:57350985	NA	-0.42	-5.44	-0.34	1.32e-7	Obesity-related traits;
SARC	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2908197	0.653	rs2961034	chr7:75961550	T/C	cg22830091	chr7:75961684	YWHAG	-0.35	-5.22	-0.32	3.98e-7	3-hydroxypropylmercapturic acid levels in smokers;
SARC	trans	rs3780486	0.522	rs10217770	chr9:33146393	C/A	cg04842962	chr6:43655489	MRPS18A	0.84	11.5	0.6	1.57e-24	IgG glycosylation;
SARC	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg24829409	chr8:58192753	C8orf71	-0.57	-6.07	-0.37	5.19e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg08859206	chr1:53392774	SCP2	0.42	6.01	0.37	7.26e-9	Monocyte count;
SARC	cis	rs526231	0.543	rs152134	chr5:102512447	C/G	cg23492399	chr5:102201601	PAM	-0.51	-5.58	-0.34	6.54e-8	Primary biliary cholangitis;
SARC	cis	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg22496380	chr5:211416	CCDC127	-0.88	-9.32	-0.52	9.29e-18	Breast cancer;
SARC	trans	rs9329221	0.683	rs4598253	chr8:9890304	A/T	cg06636001	chr8:8085503	FLJ10661	-0.69	-10.02	-0.55	7.04e-20	Neuroticism;
SARC	cis	rs1371867	0.846	rs1788189	chr8:101249762	G/T	cg11906718	chr8:101322791	RNF19A	-0.66	-8.51	-0.49	2.08e-15	Atrioventricular conduction;
SARC	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg03264133	chr6:25882463	NA	0.43	5.86	0.36	1.55e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg09699651	chr6:150184138	LRP11	0.39	4.98	0.31	1.26e-6	Lung cancer;
SARC	cis	rs7937682	1.000	rs10789843	chr11:111576158	C/T	cg22437258	chr11:111473054	SIK2	-0.71	-9.31	-0.52	9.9e-18	Primary sclerosing cholangitis;
SARC	cis	rs10463554	1.000	rs6596529	chr5:102317042	C/T	cg23492399	chr5:102201601	PAM	-0.49	-5.97	-0.36	8.73e-9	Parkinson's disease;
SARC	cis	rs2204008	0.575	rs10444564	chr12:38043782	T/C	cg13010199	chr12:38710504	ALG10B	0.78	10.69	0.57	5.8e-22	Bladder cancer;
SARC	cis	rs2072499	1.000	rs2540173	chr1:156188214	A/G	cg24450063	chr1:156163899	SLC25A44	1.14	19.4	0.79	1.5e-50	Testicular germ cell tumor;
SARC	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg23758822	chr17:41437982	NA	0.88	11.19	0.59	1.55e-23	Menopause (age at onset);
SARC	cis	rs6963495	0.556	rs818474	chr7:105155243	A/T	cg19920283	chr7:105172520	RINT1	0.55	5.6	0.34	6.11e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg03709012	chr19:19516395	GATAD2A	1.03	18.37	0.77	3.25e-47	Tonsillectomy;
SARC	cis	rs57994353	0.600	rs11145974	chr9:139316744	A/G	cg14169450	chr9:139327907	INPP5E	-0.44	-5.1	-0.32	7.01e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs2204008	0.743	rs2127952	chr12:37995364	G/T	cg13010199	chr12:38710504	ALG10B	0.74	9.81	0.54	3.15e-19	Bladder cancer;
SARC	cis	rs910316	1.000	rs3742780	chr14:75505008	G/C	cg11812906	chr14:75593930	NEK9	0.9	13.39	0.66	1.0500000000000001e-30	Height;
SARC	cis	rs2050392	0.624	rs303450	chr10:30725337	C/A	cg25182066	chr10:30743637	MAP3K8	0.43	5.8	0.36	2.17e-8	Inflammatory bowel disease;
SARC	cis	rs861020	0.630	rs627069	chr1:210004613	C/G	cg23166289	chr1:210001082	C1orf107	0.39	4.74	0.3	3.66e-6	Orofacial clefts;
SARC	cis	rs72945132	0.638	rs11236127	chr11:70241536	G/C	cg00319359	chr11:70116639	PPFIA1	0.58	5.4	0.33	1.63e-7	Coronary artery disease;
SARC	cis	rs1008375	0.898	rs10008445	chr4:17593978	G/T	cg16339924	chr4:17578868	LAP3	0.68	8.85	0.5	2.27e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs35213789	0.562	rs6974900	chr7:69032990	A/T	cg10619644	chr7:69149951	AUTS2	0.36	5.08	0.32	7.67e-7	Childhood ear infection;
SARC	cis	rs1865760	0.566	rs1539183	chr6:26075051	G/C	cg18357526	chr6:26021779	HIST1H4A	0.41	4.99	0.31	1.2e-6	Height;
SARC	cis	rs6672530	0.518	rs12070036	chr1:227819514	C/T	cg26340147	chr1:227730820	NA	-0.33	-4.83	-0.3	2.46e-6	Hip circumference adjusted for BMI;
SARC	cis	rs7560272	0.588	rs4852965	chr2:73911169	T/C	cg20560298	chr2:73613845	ALMS1	0.46	6.21	0.38	2.39e-9	Schizophrenia;
SARC	cis	rs4481887	0.927	rs10127803	chr1:248476196	A/T	cg01631408	chr1:248437212	OR2T33	-0.39	-5.06	-0.31	8.56e-7	Common traits (Other);
SARC	cis	rs7666738	0.830	rs2865949	chr4:99039967	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6696846	0.749	rs11578293	chr1:205070178	T/C	cg21545522	chr1:205238299	TMCC2	0.37	5.0	0.31	1.12e-6	Red blood cell count;
SARC	cis	rs10752881	1.000	rs12035773	chr1:182985716	A/G	cg13390022	chr1:182993471	LAMC1	0.35	5.24	0.32	3.63e-7	Colorectal cancer;
SARC	cis	rs9389248	0.500	rs116273677	chr6:135339135	A/C	cg24558204	chr6:135376177	HBS1L	0.46	6.08	0.37	4.87e-9	High light scatter reticulocyte percentage of red cells;
SARC	cis	rs7672847	0.547	rs4692727	chr4:170352325	A/C	cg00846720	chr4:170533756	NEK1	-0.59	-4.86	-0.3	2.15e-6	Subjective well-being;
SARC	cis	rs16870629	1.000	rs16870629	chr5:1015063	C/T	cg17097710	chr5:1061055	SLC12A7	-0.47	-6.09	-0.37	4.53e-9	QT interval;
SARC	cis	rs1008375	0.863	rs4698632	chr4:17614894	T/C	cg02297831	chr4:17616191	MED28	0.49	6.27	0.38	1.74e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2952156	0.876	rs903504	chr17:37829570	C/G	cg00129232	chr17:37814104	STARD3	-0.7	-9.9	-0.54	1.66e-19	Asthma;
SARC	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg08280861	chr8:58055591	NA	0.58	5.13	0.32	6.06e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg06618935	chr21:46677482	NA	-0.41	-5.46	-0.34	1.2e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7681440	0.904	rs10004413	chr4:90769479	T/C	cg02192967	chr4:90758406	SNCA	0.36	5.13	0.32	6.11e-7	Dementia with Lewy bodies;
SARC	cis	rs6540556	0.769	rs10157973	chr1:209924425	C/T	cg23920097	chr1:209922102	NA	-0.6	-6.87	-0.41	5.79e-11	Red blood cell count;
SARC	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.58	0.34	6.55e-8	Bipolar disorder;
SARC	cis	rs7932354	0.502	rs10769244	chr11:47182368	A/G	cg03339077	chr11:47165057	C11orf49	0.44	6.02	0.37	6.59e-9	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs36051895	0.589	rs11790596	chr9:5198335	T/C	cg02405213	chr9:5042618	JAK2	-0.44	-5.19	-0.32	4.62e-7	Pediatric autoimmune diseases;
SARC	cis	rs12421382	0.616	rs2357795	chr11:109381135	C/T	cg16359550	chr11:109292809	C11orf87	0.34	5.11	0.32	6.73e-7	Schizophrenia;
SARC	cis	rs708547	0.599	rs2948348	chr4:57848772	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.63	8.62	0.49	1.06e-15	Response to bleomycin (chromatid breaks);
SARC	cis	rs9316337	0.933	rs9509670	chr13:21953885	T/G	cg18095732	chr13:22033692	ZDHHC20	0.38	4.86	0.3	2.13e-6	Schizophrenia;
SARC	trans	rs1493916	1.000	rs11081827	chr18:31390228	C/A	cg27147174	chr7:100797783	AP1S1	-0.61	-7.97	-0.46	6.99e-14	Life satisfaction;
SARC	cis	rs66573146	1.000	rs67405518	chr4:6965930	C/T	cg00086871	chr4:6988644	TBC1D14	0.91	5.07	0.32	8.14e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs1153858	1.000	rs7169587	chr15:45640379	A/G	cg03999130	chr15:45571217	NA	0.39	4.99	0.31	1.16e-6	Homoarginine levels;
SARC	cis	rs2985684	0.895	rs4900940	chr14:50075310	A/C	cg04989706	chr14:50066350	PPIL5	-0.57	-6.13	-0.37	3.65e-9	Carotid intima media thickness;
SARC	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg14403583	chr14:105418241	AHNAK2	-0.58	-7.63	-0.45	5.95e-13	Rheumatoid arthritis;
SARC	cis	rs61869271	0.692	rs61869274	chr10:116742329	G/A	cg08188268	chr10:116634841	FAM160B1	0.4	5.17	0.32	5.02e-7	Tonsillectomy;
SARC	cis	rs7644634	0.531	rs3772536	chr3:105407311	G/A	cg23051926	chr3:105466016	CBLB	0.48	5.45	0.34	1.26e-7	Itch intensity from mosquito bite;
SARC	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg16680214	chr1:154839983	KCNN3	-0.34	-5.15	-0.32	5.41e-7	Prostate cancer;
SARC	cis	rs6500602	0.647	rs4786514	chr16:4576798	A/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.37	6.0	0.37	7.41e-9	Schizophrenia;
SARC	cis	rs2832077	0.527	rs9980449	chr21:30224889	G/C	cg03476357	chr21:30257390	N6AMT1	-0.55	-6.17	-0.37	3.07e-9	Cognitive test performance;
SARC	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg15448220	chr1:150897856	SETDB1	0.47	6.25	0.38	1.95e-9	Tonsillectomy;
SARC	cis	rs4481887	0.893	rs10788774	chr1:248471712	T/C	cg01631408	chr1:248437212	OR2T33	-0.44	-5.49	-0.34	1.03e-7	Common traits (Other);
SARC	cis	rs3870371	1.000	rs12334795	chr8:122692531	A/C	cg21781600	chr8:122651575	HAS2;HAS2AS	-0.48	-5.41	-0.33	1.55e-7	Periodontal disease-related phenotypes;
SARC	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.7	6.38	0.39	9.24e-10	Platelet count;
SARC	cis	rs524281	0.861	rs7942894	chr11:65976525	T/C	cg14036092	chr11:66035641	RAB1B	-0.51	-5.44	-0.34	1.38e-7	Electroencephalogram traits;
SARC	cis	rs2797160	1.000	rs9491471	chr6:125991715	C/T	cg05901451	chr6:126070800	HEY2	-0.4	-4.82	-0.3	2.63e-6	Endometrial cancer;
SARC	cis	rs9388451	0.626	rs3734637	chr6:126081319	G/T	cg06289844	chr6:126071538	HEY2	0.31	4.91	0.31	1.69e-6	Brugada syndrome;
SARC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	5.98	0.36	8.43e-9	Prudent dietary pattern;
SARC	cis	rs10189230	0.967	rs13002861	chr2:222352859	T/G	cg14652038	chr2:222343519	EPHA4	0.44	5.79	0.35	2.31e-8	Urate levels in lean individuals;
SARC	cis	rs9303401	0.659	rs12948133	chr17:56673602	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	12.29	0.63	4.25e-27	Cognitive test performance;
SARC	cis	rs2985684	1.000	rs2147712	chr14:50091684	G/A	cg04989706	chr14:50066350	PPIL5	-0.56	-5.95	-0.36	9.65e-9	Carotid intima media thickness;
SARC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	6.1	0.37	4.5e-9	Prudent dietary pattern;
SARC	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg11987759	chr7:65425863	GUSB	0.57	7.56	0.44	9.26e-13	Aortic root size;
SARC	cis	rs4595586	0.545	rs1356265	chr12:39403696	A/G	cg26384229	chr12:38710491	ALG10B	0.47	5.93	0.36	1.07e-8	Morning vs. evening chronotype;
SARC	cis	rs2204008	0.684	rs11514164	chr12:38036494	C/T	cg13010199	chr12:38710504	ALG10B	0.74	9.74	0.54	4.89e-19	Bladder cancer;
SARC	cis	rs2242116	0.796	rs7645278	chr3:46974100	A/C	cg02527881	chr3:46936655	PTH1R	-0.37	-5.57	-0.34	7.18e-8	Birth weight;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg25346576	chr17:28443852	CCDC55;MIR423	-0.62	-7.06	-0.42	1.88e-11	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs9457247	0.765	rs1060404	chr6:167429467	A/G	cg23791538	chr6:167370224	RNASET2	-0.53	-6.9	-0.41	4.78e-11	Crohn's disease;
SARC	trans	rs1994135	0.692	rs7958788	chr12:33692179	T/C	cg13010199	chr12:38710504	ALG10B	0.61	7.26	0.43	5.87e-12	Resting heart rate;
SARC	cis	rs7223966	1.000	rs9901112	chr17:61730617	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.62	-6.53	-0.39	4.01e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.38	4.71	0.3	4.2e-6	Tonsillectomy;
SARC	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg15049968	chr18:44337910	ST8SIA5	-0.35	-5.5	-0.34	9.97e-8	Personality dimensions;
SARC	cis	rs735396	0.694	rs2264750	chr12:121450165	C/T	cg15155738	chr12:121454335	C12orf43	0.52	6.59	0.4	2.84e-10	N-glycan levels;
SARC	cis	rs6964587	1.000	rs6951972	chr7:91689446	T/G	cg17063962	chr7:91808500	NA	0.96	16.21	0.73	4.33e-40	Breast cancer;
SARC	cis	rs7520050	0.966	rs4660321	chr1:46366760	A/G	cg24296786	chr1:45957014	TESK2	0.38	4.82	0.3	2.56e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs5758511	0.596	rs55644935	chr22:42666069	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.43	6.47	0.39	5.63e-10	Birth weight;
SARC	cis	rs35661897	1.000	rs35661897	chr2:227333838	A/G	cg03426602	chr2:227312417	NA	-0.56	-5.19	-0.32	4.56e-7	Urinary tract infection frequency;
SARC	cis	rs2549003	1.000	rs2070728	chr5:131819977	C/T	cg21138405	chr5:131827807	IRF1	0.27	5.33	0.33	2.26e-7	Asthma (sex interaction);
SARC	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg09359103	chr1:154839909	KCNN3	-0.47	-7.99	-0.46	6.06e-14	Prostate cancer;
SARC	cis	rs4253772	0.550	rs739164	chr22:46684558	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.71	-7.02	-0.42	2.47e-11	LDL cholesterol;Cholesterol, total;
SARC	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg04944784	chr2:26401820	FAM59B	-0.6	-7.94	-0.46	8.49e-14	Gut microbiome composition (summer);
SARC	cis	rs7666738	0.606	rs10006414	chr4:99101401	T/C	cg05340658	chr4:99064831	C4orf37	0.47	5.86	0.36	1.54e-8	Colonoscopy-negative controls vs population controls;
SARC	cis	rs55823223	0.648	rs11867560	chr17:73857206	A/G	cg23806715	chr17:73775811	H3F3B	0.56	5.81	0.36	2.02e-8	Psoriasis;
SARC	cis	rs10464366	0.746	rs12674262	chr7:39141728	G/T	cg18850127	chr7:39170497	POU6F2	0.45	5.45	0.34	1.28e-7	IgG glycosylation;
SARC	cis	rs17095355	1.000	rs11194941	chr10:111744810	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.42	-4.76	-0.3	3.33e-6	Biliary atresia;
SARC	cis	rs769267	0.864	rs7245983	chr19:19657632	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	5.3	0.33	2.65e-7	Tonsillectomy;
SARC	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg06618935	chr21:46677482	NA	-0.39	-5.23	-0.32	3.74e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2011503	1.000	rs2965179	chr19:19512755	G/A	cg03709012	chr19:19516395	GATAD2A	0.65	5.63	0.35	5.07e-8	Bipolar disorder;
SARC	cis	rs2204008	0.837	rs1589395	chr12:38420405	C/T	cg13010199	chr12:38710504	ALG10B	0.75	10.24	0.56	1.42e-20	Bladder cancer;
SARC	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg19346786	chr7:2764209	NA	-0.42	-6.12	-0.37	3.97e-9	Height;
SARC	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg11062466	chr8:58055876	NA	0.54	5.56	0.34	7.55e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1401999	1.000	rs1402003	chr3:183642879	C/T	cg01324343	chr3:183735012	ABCC5	0.67	13.54	0.66	3.46e-31	Anterior chamber depth;
SARC	cis	rs11651753	0.561	rs35336840	chr17:45966108	A/G	cg02219949	chr17:45927392	SP6	0.35	4.82	0.3	2.6e-6	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	cis	rs1008375	1.000	rs13106338	chr4:17676871	G/T	cg16339924	chr4:17578868	LAP3	-0.65	-8.51	-0.49	2.15e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9393777	0.513	rs6924727	chr6:26491234	A/G	cg12826209	chr6:26865740	GUSBL1	0.8	7.81	0.46	1.9e-13	Intelligence (multi-trait analysis);
SARC	cis	rs7084402	0.934	rs1593673	chr10:60294170	C/T	cg07615347	chr10:60278583	BICC1	0.6	8.91	0.5	1.45e-16	Refractive error;
SARC	cis	rs7520050	0.966	rs12409773	chr1:46358831	A/G	cg24296786	chr1:45957014	TESK2	0.38	4.82	0.3	2.56e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs9790314	0.521	rs1450522	chr3:161077630	A/G	cg04691961	chr3:161091175	C3orf57	-0.51	-6.34	-0.38	1.15e-9	Morning vs. evening chronotype;
SARC	cis	rs9902453	0.967	rs56129908	chr17:28421382	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	6.7	0.4	1.52e-10	Coffee consumption (cups per day);
SARC	cis	rs13161895	1.000	rs248318	chr5:179430530	C/T	cg06664874	chr5:179499304	RNF130	0.49	4.78	0.3	3.14e-6	LDL cholesterol;
SARC	cis	rs8014204	0.604	rs2159906	chr14:75390912	G/T	cg08847533	chr14:75593920	NEK9	0.52	6.12	0.37	3.88e-9	Caffeine consumption;
SARC	cis	rs7772486	0.686	rs9399565	chr6:146081906	G/T	cg23711669	chr6:146136114	FBXO30	-0.79	-12.62	-0.64	3.68e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3815700	1.000	rs7248273	chr19:33096816	C/T	cg02997394	chr19:33096574	ANKRD27	0.78	7.58	0.44	8.38e-13	Eosinophilic esophagitis;
SARC	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-10.79	-0.58	2.85e-22	Chronic sinus infection;
SARC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.45	-6.02	-0.37	6.6e-9	Longevity;Endometriosis;
SARC	cis	rs79149102	0.579	rs9788648	chr15:75300284	A/G	cg09165964	chr15:75287851	SCAMP5	-0.95	-8.86	-0.5	2.03e-16	Lung cancer;
SARC	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg14517863	chr17:44321492	NA	0.43	6.27	0.38	1.73e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs4481887	0.927	rs10888344	chr1:248446655	T/C	cg00666640	chr1:248458726	OR2T12	0.34	5.62	0.35	5.47e-8	Common traits (Other);
SARC	trans	rs61931739	0.892	rs61931711	chr12:34045374	C/T	cg26384229	chr12:38710491	ALG10B	-0.58	-7.27	-0.43	5.33e-12	Morning vs. evening chronotype;
SARC	cis	rs11758351	1.000	rs79264785	chr6:26194121	C/T	cg01420254	chr6:26195488	NA	0.55	4.8	0.3	2.79e-6	Gout;Renal underexcretion gout;
SARC	cis	rs9807841	0.592	rs11085743	chr19:10759442	G/A	cg17710535	chr19:10819994	QTRT1	0.4	4.81	0.3	2.7e-6	Inflammatory skin disease;
SARC	cis	rs2075371	0.933	rs2544181	chr7:133944934	C/T	cg11752832	chr7:134001865	SLC35B4	0.53	6.75	0.4	1.17e-10	Mean platelet volume;
SARC	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg19680485	chr15:31195859	MTMR15	0.58	6.91	0.41	4.67e-11	Huntington's disease progression;
SARC	cis	rs796364	1.000	rs1704186	chr2:200769539	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.88	0.41	5.54e-11	Schizophrenia;
SARC	cis	rs9790314	0.747	rs7619011	chr3:160855676	A/G	cg04691961	chr3:161091175	C3orf57	-0.61	-8.31	-0.48	7.84e-15	Morning vs. evening chronotype;
SARC	cis	rs7833790	0.632	rs6473308	chr8:82707708	G/A	cg27398817	chr8:82754497	SNX16	-0.43	-5.5	-0.34	1.02e-7	Diastolic blood pressure;
SARC	cis	rs826838	0.510	rs10876149	chr12:39228083	C/G	cg26384229	chr12:38710491	ALG10B	-0.73	-9.31	-0.52	9.77e-18	Heart rate;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg20099018	chr17:40169396	DNAJC7;NKIRAS2	0.5	6.33	0.38	1.27e-9	Breast cancer;
SARC	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg11843238	chr5:131593191	PDLIM4	0.38	5.06	0.31	8.42e-7	Blood metabolite levels;
SARC	cis	rs3126085	0.935	rs1552993	chr1:152171483	A/G	cg09127314	chr1:152161683	NA	0.43	4.87	0.3	2.06e-6	Atopic dermatitis;
SARC	cis	rs5753618	0.509	rs5753500	chr22:31578879	A/G	cg02404636	chr22:31891804	SFI1	-0.5	-5.52	-0.34	8.94e-8	Colorectal cancer;
SARC	cis	rs1559088	0.948	rs10406916	chr19:33590093	G/A	cg27124370	chr19:33622961	WDR88	0.44	5.86	0.36	1.6e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs617791	0.508	rs10791837	chr11:65774596	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.61	7.57	0.44	8.74e-13	Breast cancer;
SARC	cis	rs12545109	1.000	rs12545109	chr8:57313906	A/C	cg09654669	chr8:57350985	NA	-0.41	-5.17	-0.32	4.97e-7	Obesity-related traits;
SARC	cis	rs10781543	0.776	rs4378078	chr9:139375962	A/G	cg14169450	chr9:139327907	INPP5E	0.43	6.23	0.38	2.19e-9	Monocyte percentage of white cells;
SARC	cis	rs2991971	0.934	rs11580609	chr1:45975856	C/G	cg24296786	chr1:45957014	TESK2	0.65	9.36	0.52	6.96e-18	High light scatter reticulocyte count;
SARC	cis	rs7654585	1.000	rs4692025	chr4:25949759	A/C	cg10409131	chr4:25915609	C4orf52	-0.52	-6.62	-0.4	2.4e-10	Obesity-related traits;
SARC	cis	rs2153535	0.601	rs7741024	chr6:8530313	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	6.53	0.39	4.11e-10	Motion sickness;
SARC	cis	rs2153535	0.601	rs2327054	chr6:8443130	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	7.31	0.43	4.24e-12	Motion sickness;
SARC	cis	rs7633857	0.512	rs2376477	chr3:160700699	G/T	cg03342759	chr3:160939853	NMD3	-0.5	-6.17	-0.37	2.98e-9	Educational attainment (years of education);
SARC	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg20887711	chr4:1340912	KIAA1530	0.59	7.45	0.44	1.8e-12	Longevity;
SARC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg11141652	chr22:24348549	GSTTP1	0.4	4.9	0.31	1.76e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2624839	0.704	rs12632110	chr3:50224225	A/G	cg24110177	chr3:50126178	RBM5	0.44	5.55	0.34	7.56e-8	Intelligence (multi-trait analysis);
SARC	cis	rs4900538	0.855	rs72698597	chr14:102868633	C/T	cg18135206	chr14:102964638	TECPR2	-0.61	-7.88	-0.46	1.21e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg05368731	chr17:41323189	NBR1	0.6	7.05	0.42	1.99e-11	Menopause (age at onset);
SARC	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.55	-5.65	-0.35	4.57e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg00149659	chr3:10157352	C3orf10	0.69	6.44	0.39	6.6e-10	Alzheimer's disease;
SARC	cis	rs9303401	0.659	rs17822807	chr17:56687190	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.08	11.88	0.61	9.17e-26	Cognitive test performance;
SARC	cis	rs17539620	0.534	rs11541339	chr6:154831643	G/C	cg17771515	chr6:154831774	CNKSR3	0.52	5.13	0.32	5.97e-7	Lipoprotein (a) levels;
SARC	cis	rs12142240	0.698	rs1475388	chr1:46816465	G/A	cg10495392	chr1:46806563	NSUN4	0.65	6.83	0.41	7.25e-11	Menopause (age at onset);
SARC	cis	rs523522	0.962	rs4767914	chr12:120993817	C/T	cg27279351	chr12:120934652	DYNLL1	0.72	8.89	0.5	1.7e-16	High light scatter reticulocyte count;
SARC	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg05896524	chr21:47604654	C21orf56	0.54	6.64	0.4	2.21e-10	Testicular germ cell tumor;
SARC	cis	rs9467711	0.516	rs1324088	chr6:25841122	C/T	cg21479132	chr6:26055353	NA	0.59	4.73	0.3	3.91e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1559088	0.546	rs11881543	chr19:33559372	T/G	cg27124370	chr19:33622961	WDR88	0.46	5.91	0.36	1.22e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg06028605	chr16:24865363	SLC5A11	-0.39	-6.17	-0.37	3.04e-9	Intelligence (multi-trait analysis);
SARC	trans	rs12967884	0.892	rs1567548	chr18:76563678	G/A	cg10946435	chr1:154843044	KCNN3	0.57	6.31	0.38	1.38e-9	Subcutaneous adipose tissue;
SARC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg22535103	chr8:58192502	C8orf71	-0.59	-6.21	-0.38	2.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10979	0.597	rs9484776	chr6:143906325	T/C	cg25407410	chr6:143891975	LOC285740	-0.53	-6.14	-0.37	3.61e-9	Hypospadias;
SARC	cis	rs6686643	0.868	rs9333461	chr1:165618320	G/T	cg19407955	chr1:165599744	MGST3	-0.51	-5.62	-0.35	5.41e-8	Total ventricular volume;
SARC	cis	rs62229266	0.647	rs59397717	chr21:37451725	C/T	cg12218747	chr21:37451666	NA	-0.37	-5.25	-0.33	3.46e-7	Mitral valve prolapse;
SARC	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg15049968	chr18:44337910	ST8SIA5	-0.32	-4.91	-0.31	1.69e-6	Personality dimensions;
SARC	cis	rs360798	0.512	rs2710640	chr2:63144305	A/G	cg17519650	chr2:63277830	OTX1	0.43	5.44	0.34	1.36e-7	Coronary artery disease;
SARC	cis	rs1549118	0.560	rs11848126	chr14:78318268	T/C	cg21497246	chr14:78225524	SNW1;C14orf178	0.49	5.04	0.31	9.25e-7	Resting heart rate;
SARC	cis	rs4750440	0.642	rs1574583	chr10:14026870	C/G	cg27542038	chr10:14027202	FRMD4A	-0.35	-4.89	-0.31	1.86e-6	Adiponectin levels;
SARC	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg21782813	chr7:2030301	MAD1L1	0.35	5.28	0.33	2.92e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs995000	0.931	rs10789114	chr1:63034222	T/C	cg06896770	chr1:63153194	DOCK7	1.0	15.49	0.71	1.15e-37	Triglyceride levels;
SARC	cis	rs4727027	0.899	rs6464942	chr7:148826368	T/C	cg23583168	chr7:148888333	NA	-0.73	-10.69	-0.57	5.97e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs3768617	0.510	rs10797851	chr1:183098001	A/G	cg13390022	chr1:182993471	LAMC1	0.31	4.79	0.3	3.01e-6	Fuchs's corneal dystrophy;
SARC	cis	rs2354432	0.607	rs7553584	chr1:146693429	A/G	cg25205988	chr1:146714368	CHD1L	-1.06	-8.87	-0.5	1.98e-16	Mitochondrial DNA levels;
SARC	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg07701084	chr6:150067640	NUP43	0.43	5.54	0.34	8.17e-8	Lung cancer;
SARC	cis	rs36051895	0.622	rs12335546	chr9:5072182	C/T	cg02405213	chr9:5042618	JAK2	-0.45	-5.38	-0.33	1.85e-7	Pediatric autoimmune diseases;
SARC	cis	rs12145833	1.000	rs61833916	chr1:243469946	C/T	cg02356786	chr1:243265016	LOC731275	0.67	5.71	0.35	3.4e-8	Obesity (early onset extreme);
SARC	cis	rs12022452	0.544	rs11208423	chr1:41029614	T/C	cg25568243	chr1:40974465	DEM1	0.53	5.17	0.32	5.09e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs13427251	0.903	rs6746402	chr2:100150443	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.65	-8.79	-0.5	3.28e-16	Chronic sinus infection;
SARC	cis	rs7681440	0.583	rs2619363	chr4:90759047	G/T	cg06632027	chr4:90757378	SNCA	-0.44	-5.61	-0.35	5.66e-8	Dementia with Lewy bodies;
SARC	cis	rs4722166	0.630	rs12537614	chr7:22789551	C/G	cg26061582	chr7:22766209	IL6	0.52	5.82	0.36	1.91e-8	Lung cancer;
SARC	cis	rs8114671	0.562	rs6088646	chr20:33505937	T/C	cg08999081	chr20:33150536	PIGU	0.32	4.72	0.3	3.99e-6	Height;
SARC	cis	rs9916302	0.904	rs7503069	chr17:37697128	C/G	cg20243544	chr17:37824526	PNMT	0.53	6.17	0.37	2.93e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs7223966	1.000	rs7211213	chr17:61769456	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.46	5.15	0.32	5.66e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs1853207	1.000	rs10509677	chr10:96576110	T/C	cg02737782	chr1:8014393	NA	-0.95	-6.37	-0.39	1.01e-9	Blood metabolite levels;
SARC	cis	rs79149102	0.579	rs74025863	chr15:75284161	T/C	cg09165964	chr15:75287851	SCAMP5	-0.95	-8.68	-0.49	7.05e-16	Lung cancer;
SARC	cis	rs7944584	0.551	rs12224672	chr11:47500400	C/T	cg20307385	chr11:47447363	PSMC3	0.72	9.39	0.52	5.84e-18	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs9879311	0.966	rs775018	chr3:10400145	A/G	cg11030744	chr3:10328490	GHRL;GHRLOS	0.5	6.13	0.37	3.72e-9	Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	cis	rs2997447	0.761	rs2802314	chr1:26431337	T/C	cg19633962	chr1:26362018	EXTL1	-0.58	-5.22	-0.32	3.87e-7	QRS complex (12-leadsum);
SARC	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg02951883	chr7:2050386	MAD1L1	-0.51	-6.7	-0.4	1.59e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs6807306	1.000	rs9817126	chr3:167397840	A/G	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.53	5.16	0.32	5.39e-7	Mean platelet volume;
SARC	cis	rs554111	0.613	rs1567128	chr1:21404653	G/A	cg04902671	chr1:21058625	SH2D5	0.44	5.36	0.33	2.05e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs27434	0.561	rs35134	chr5:96159523	A/G	cg16492584	chr5:96139282	ERAP1	-0.57	-7.12	-0.42	1.31e-11	Ankylosing spondylitis;
SARC	cis	rs76419734	1.000	rs72671896	chr4:106685825	C/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.81	5.48	0.34	1.08e-7	Post bronchodilator FEV1;
SARC	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg07701084	chr6:150067640	NUP43	0.4	5.28	0.33	2.96e-7	Lung cancer;
SARC	cis	rs7582180	0.663	rs4850930	chr2:100990955	T/C	cg14675211	chr2:100938903	LONRF2	0.54	7.89	0.46	1.21e-13	Intelligence (multi-trait analysis);
SARC	cis	rs734999	0.505	rs10910107	chr1:2539181	C/T	cg18854424	chr1:2615690	NA	0.32	5.15	0.32	5.59e-7	Ulcerative colitis;
SARC	cis	rs12579753	0.917	rs11115029	chr12:82202219	C/G	cg07988820	chr12:82153109	PPFIA2	-0.52	-6.11	-0.37	4.18e-9	Resting heart rate;
SARC	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg00933542	chr6:150070202	PCMT1	0.31	5.36	0.33	1.98e-7	Lung cancer;
SARC	cis	rs753778	0.602	rs9792	chr8:142205237	C/T	cg18755752	chr8:142205143	DENND3	0.53	7.72	0.45	3.48e-13	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg13939156	chr17:80058883	NA	-0.42	-6.5	-0.39	4.76e-10	Life satisfaction;
SARC	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg13206674	chr6:150067644	NUP43	0.42	5.41	0.33	1.59e-7	Lung cancer;
SARC	cis	rs9911578	1.000	rs12453459	chr17:56624291	C/T	cg05425664	chr17:57184151	TRIM37	0.65	7.99	0.46	6.09e-14	Intelligence (multi-trait analysis);
SARC	cis	rs832540	0.931	rs832399	chr5:56222358	A/T	cg14703610	chr5:56206110	C5orf35	0.52	6.59	0.4	2.89e-10	Coronary artery disease;
SARC	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg21782813	chr7:2030301	MAD1L1	0.45	7.16	0.42	1.04e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs9393813	0.967	rs1883403	chr6:27350329	G/A	cg11502198	chr6:26597334	ABT1	0.39	4.74	0.3	3.79e-6	Bipolar disorder;
SARC	cis	rs614226	0.872	rs787827	chr12:120937794	A/G	cg01236616	chr12:121019343	POP5	1.26	18.25	0.77	8.39e-47	Type 1 diabetes nephropathy;
SARC	cis	rs6570726	0.875	rs1883407	chr6:145823432	T/C	cg23711669	chr6:146136114	FBXO30	0.76	11.32	0.6	5.68e-24	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7084402	0.934	rs1649021	chr10:60286028	C/T	cg07615347	chr10:60278583	BICC1	0.6	8.82	0.5	2.75e-16	Refractive error;
SARC	cis	rs7005606	0.870	rs2466077	chr8:32432753	G/T	cg14488905	chr8:32406789	NRG1	-0.44	-6.05	-0.37	5.87e-9	Hirschsprung disease;
SARC	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.51	-5.86	-0.36	1.57e-8	Systemic lupus erythematosus;
SARC	cis	rs1832871	0.672	rs9457361	chr6:158771750	G/A	cg07165851	chr6:158734300	TULP4	0.53	6.34	0.38	1.16e-9	Height;
SARC	cis	rs12142240	0.659	rs17361873	chr1:46832686	A/G	cg00530320	chr1:46809349	NSUN4	0.58	7.07	0.42	1.78e-11	Menopause (age at onset);
SARC	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg22903471	chr2:27725779	GCKR	-0.47	-6.88	-0.41	5.54e-11	Total body bone mineral density;
SARC	cis	rs113835537	0.935	rs75863187	chr11:66443461	G/A	cg24851651	chr11:66362959	CCS	0.47	4.97	0.31	1.29e-6	Airway imaging phenotypes;
SARC	cis	rs9843304	0.546	rs9847773	chr3:149217816	C/T	cg08667024	chr3:149219783	TM4SF4	0.47	7.15	0.42	1.1e-11	Gallstone disease;
SARC	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg08219700	chr8:58056026	NA	0.59	6.3	0.38	1.51e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1865760	0.516	rs9379819	chr6:26049819	A/C	cg10373733	chr6:25993375	NA	0.39	4.85	0.3	2.22e-6	Height;
SARC	cis	rs3784262	1.000	rs11855259	chr15:58249377	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.42	-6.3	-0.38	1.46e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg13175981	chr1:150552382	MCL1	0.47	5.88	0.36	1.39e-8	Tonsillectomy;
SARC	cis	rs2295359	1.000	rs4655684	chr1:67611772	A/G	cg08029281	chr1:67600428	NA	-0.39	-5.59	-0.34	6.24e-8	Psoriasis;
SARC	cis	rs7847628	0.587	rs10760117	chr9:123586737	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	9.41	0.52	5.05e-18	Birth weight;
SARC	cis	rs796364	0.951	rs971232	chr2:200792881	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.76	6.88	0.41	5.42e-11	Schizophrenia;
SARC	cis	rs28647808	0.881	rs4962139	chr9:136267869	C/T	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	-0.76	-5.94	-0.36	1.03e-8	Blood protein levels;
SARC	cis	rs7223966	1.000	rs8075257	chr17:61728750	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.53	-5.69	-0.35	3.8e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2645694	0.532	rs2645706	chr4:77829606	A/C	cg10057126	chr4:77819792	ANKRD56	0.41	6.1	0.37	4.4e-9	Emphysema distribution in smoking;
SARC	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	10.98	0.58	6.89e-23	Platelet count;
SARC	cis	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg13072238	chr3:49761600	GMPPB	-0.41	-5.39	-0.33	1.7e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9916302	0.904	rs8068427	chr17:37511517	G/A	cg20243544	chr17:37824526	PNMT	-0.56	-6.92	-0.41	4.39e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs425277	1.000	rs262676	chr1:2078482	T/A	cg24578937	chr1:2090814	PRKCZ	0.31	5.85	0.36	1.63e-8	Height;
SARC	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	13.6	0.67	2.11e-31	Chronic sinus infection;
SARC	cis	rs11098499	0.863	rs1480940	chr4:120457682	T/C	cg09307838	chr4:120376055	NA	0.92	12.49	0.63	9.35e-28	Corneal astigmatism;
SARC	cis	rs6912958	0.500	rs9342104	chr6:87798512	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-5.46	-0.34	1.23e-7	Monocyte percentage of white cells;
SARC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	11.15	0.59	2.1e-23	Platelet count;
SARC	cis	rs6088813	1.000	rs6060401	chr20:34005214	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	-0.43	-5.18	-0.32	4.75e-7	Height;
SARC	cis	rs16854884	0.586	rs4616638	chr3:143735423	A/T	cg06585982	chr3:143692056	C3orf58	-0.69	-9.52	-0.53	2.29e-18	Economic and political preferences (feminism/equality);
SARC	cis	rs155076	0.702	rs482731	chr13:21846075	G/A	cg06138931	chr13:21896616	NA	-0.39	-5.08	-0.32	7.88e-7	White matter hyperintensity burden;
SARC	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg17158414	chr2:27665306	KRTCAP3	0.4	6.51	0.39	4.62e-10	Total body bone mineral density;
SARC	cis	rs9462027	0.628	rs7752522	chr6:34760583	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.93	-0.36	1.11e-8	Systemic lupus erythematosus;
SARC	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg22535103	chr8:58192502	C8orf71	-0.53	-5.3	-0.33	2.73e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9470366	1.000	rs9470366	chr6:36625562	C/T	cg08179530	chr6:36648295	CDKN1A	0.57	5.87	0.36	1.47e-8	QRS duration;
SARC	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.46	5.49	0.34	1.06e-7	Calcium levels;
SARC	cis	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg24110177	chr3:50126178	RBM5	0.55	7.39	0.44	2.64e-12	Intelligence (multi-trait analysis);
SARC	cis	rs7772486	0.790	rs2253880	chr6:146200774	T/C	cg23711669	chr6:146136114	FBXO30	0.8	13.13	0.65	7.67e-30	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg08280861	chr8:58055591	NA	0.61	5.96	0.36	9.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1044826	1.000	rs2349059	chr3:139176932	C/T	cg15131784	chr3:139108705	COPB2	0.45	5.19	0.32	4.6e-7	Obesity-related traits;
SARC	cis	rs1983891	0.643	rs3800284	chr6:41558365	G/C	cg15051332	chr6:41514432	FOXP4	0.48	5.09	0.32	7.39e-7	Prostate cancer;
SARC	cis	rs34245846	0.769	rs12084791	chr1:154824973	A/G	cg24250549	chr1:154909240	PMVK	-0.45	-4.87	-0.3	2.11e-6	Atrial fibrillation;
SARC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg11301795	chr4:187892539	NA	-0.7	-10.58	-0.57	1.27e-21	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg13628971	chr7:2884303	GNA12	0.53	6.25	0.38	1.98e-9	Height;
SARC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.79	8.2	0.47	1.63e-14	Platelet count;
SARC	cis	rs11997175	0.546	rs11775414	chr8:33615826	A/G	ch.8.33884649F	chr8:33765107	NA	0.51	6.49	0.39	5.05e-10	Body mass index;
SARC	cis	rs7666738	0.830	rs1426672	chr4:98923984	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6540556	0.769	rs6540552	chr1:209927710	C/T	cg05527609	chr1:210001259	C1orf107	0.49	5.04	0.31	9.23e-7	Red blood cell count;
SARC	cis	rs7524258	0.900	rs7551574	chr1:7314363	G/T	cg07173049	chr1:7289937	CAMTA1	0.34	6.64	0.4	2.14e-10	Tourette's syndrome or obsessive-compulsive disorder;
SARC	cis	rs11792861	0.816	rs11791845	chr9:111683898	G/A	cg13535736	chr9:111863775	C9orf5	-0.38	-4.78	-0.3	3.16e-6	Menarche (age at onset);
SARC	cis	rs6964587	1.000	rs1063243	chr7:91726927	A/C	cg17063962	chr7:91808500	NA	0.96	16.55	0.73	3.46e-41	Breast cancer;
SARC	cis	rs2732480	0.557	rs2634682	chr12:48732943	T/C	cg24011408	chr12:48396354	COL2A1	0.42	4.99	0.31	1.17e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg27572855	chr1:25598939	RHD	0.55	9.59	0.53	1.43e-18	Erythrocyte sedimentation rate;
SARC	cis	rs11608355	1.000	rs11066523	chr12:109851899	A/G	cg19025524	chr12:109796872	NA	0.39	5.04	0.31	9.53e-7	Neuroticism;
SARC	cis	rs9325144	0.555	rs61929925	chr12:38698828	C/A	cg13010199	chr12:38710504	ALG10B	-0.54	-6.97	-0.42	3.24e-11	Morning vs. evening chronotype;
SARC	cis	rs7223966	1.000	rs9912201	chr17:61763208	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	6.74	0.4	1.2e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2529049	0.560	rs2954558	chr7:24736636	T/C	cg17569154	chr7:24781545	DFNA5	0.47	6.79	0.41	9.44e-11	Urate levels in obese individuals;
SARC	cis	rs5762813	0.561	rs5752811	chr22:29225592	C/G	cg02153584	chr22:29168773	CCDC117	-0.66	-6.7	-0.4	1.55e-10	Hematocrit;Hemoglobin concentration;
SARC	cis	rs72945132	0.882	rs6592554	chr11:70226040	G/A	cg05964544	chr11:70165517	PPFIA1	-0.58	-5.82	-0.36	1.94e-8	Coronary artery disease;
SARC	cis	rs35306767	0.953	rs1539174	chr10:974870	C/G	cg25019033	chr10:957182	NA	-0.47	-4.84	-0.3	2.4e-6	Eosinophil percentage of granulocytes;
SARC	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg17971929	chr21:40555470	PSMG1	-0.86	-11.41	-0.6	2.97e-24	Cognitive function;
SARC	cis	rs6500602	0.702	rs9929475	chr16:4540885	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.35	-5.69	-0.35	3.84e-8	Schizophrenia;
SARC	cis	rs155076	1.000	rs598754	chr13:21845010	C/A	cg14456004	chr13:21872349	NA	-1.0	-12.77	-0.64	1.13e-28	White matter hyperintensity burden;
SARC	cis	rs4148883	0.675	rs10000357	chr4:100099942	G/C	cg12011299	chr4:100065546	ADH4	0.36	6.77	0.41	1.03e-10	Alcohol dependence;
SARC	cis	rs3087591	0.922	rs2905788	chr17:29480295	C/T	cg24425628	chr17:29625626	OMG;NF1	0.54	6.71	0.4	1.47e-10	Hip circumference;
SARC	cis	rs8114671	0.836	rs6142280	chr20:33622242	A/C	cg08999081	chr20:33150536	PIGU	-0.34	-4.92	-0.31	1.67e-6	Height;
SARC	cis	rs561341	1.000	rs55959993	chr17:30254771	C/G	cg00745463	chr17:30367425	LRRC37B	-0.66	-4.98	-0.31	1.24e-6	Hip circumference adjusted for BMI;
SARC	cis	rs10489202	0.513	rs4657731	chr1:168081255	C/T	cg24449463	chr1:168025552	DCAF6	-0.58	-7.75	-0.45	2.77e-13	Schizophrenia;
SARC	cis	rs2816062	0.786	rs2745317	chr1:18896552	G/A	cg10574377	chr1:18908098	NA	0.35	5.05	0.31	8.83e-7	Urate levels in lean individuals;
SARC	cis	rs79149102	0.579	rs12594117	chr15:75323648	C/G	cg17294928	chr15:75287854	SCAMP5	-1.09	-9.42	-0.53	4.6e-18	Lung cancer;
SARC	cis	rs7296418	0.961	rs10773921	chr12:123541606	C/T	cg05973401	chr12:123451056	ABCB9	0.58	7.02	0.42	2.4e-11	Platelet count;
SARC	cis	rs11645898	0.935	rs4788614	chr16:72188828	C/T	cg14768367	chr16:72042858	DHODH	0.63	5.73	0.35	3.11e-8	Blood protein levels;
SARC	cis	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg12463550	chr7:65579703	CRCP	0.68	5.21	0.32	4.1e-7	Diabetic kidney disease;
SARC	cis	rs11690935	0.959	rs6759575	chr2:172689068	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.97	-14.9	-0.7	9.87e-36	Schizophrenia;
SARC	cis	rs6728515	0.541	rs72848089	chr2:23728727	C/G	cg04881095	chr2:23870823	KLHL29	-0.61	-4.77	-0.3	3.32e-6	Conotruncal heart defects (maternal effects);
SARC	cis	rs6430585	0.583	rs3769001	chr2:136626078	A/G	cg07169764	chr2:136633963	MCM6	1.1	16.25	0.73	3.2e-40	Corneal structure;
SARC	cis	rs933688	0.509	rs2973472	chr5:90519496	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.46	-5.25	-0.32	3.5e-7	Smoking behavior;
SARC	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.98	10.78	0.58	2.93e-22	Platelet count;
SARC	cis	rs2529049	0.628	rs2721806	chr7:24780053	C/T	cg17569154	chr7:24781545	DFNA5	0.43	5.77	0.35	2.46e-8	Urate levels in obese individuals;
SARC	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg16414030	chr3:133502952	NA	-0.46	-6.12	-0.37	3.98e-9	Iron status biomarkers;
SARC	cis	rs26232	0.583	rs26434	chr5:102363402	C/T	cg23492399	chr5:102201601	PAM	0.49	5.44	0.34	1.37e-7	Rheumatoid arthritis;
SARC	cis	rs35110281	0.837	rs2838336	chr21:45071741	A/G	cg01579765	chr21:45077557	HSF2BP	0.33	5.57	0.34	7.04e-8	Mean corpuscular volume;
SARC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.51	6.64	0.4	2.14e-10	Lymphocyte counts;
SARC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg05552183	chr6:42928497	GNMT	0.52	7.11	0.42	1.41e-11	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs7945705	0.818	rs2653613	chr11:8879105	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.45	-6.44	-0.39	6.85e-10	Hemoglobin concentration;
SARC	cis	rs2153535	0.541	rs9392222	chr6:8467649	G/A	cg21535247	chr6:8435926	SLC35B3	0.54	6.79	0.41	9.19e-11	Motion sickness;
SARC	cis	rs8042680	0.522	rs8026678	chr15:91562005	A/G	cg08919649	chr15:91565780	VPS33B	0.43	5.34	0.33	2.21e-7	Type 2 diabetes;
SARC	cis	rs992157	0.835	rs10932768	chr2:219146199	T/A	cg00012203	chr2:219082015	ARPC2	-0.64	-9.13	-0.51	3.49e-17	Colorectal cancer;
SARC	cis	rs9948	0.786	rs62152765	chr2:97440420	G/A	cg01990225	chr2:97406019	LMAN2L	-0.96	-6.95	-0.41	3.73e-11	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.47	5.23	0.32	3.86e-7	Renal function-related traits (BUN);
SARC	trans	rs1814175	0.754	rs7103235	chr11:49699191	A/G	cg15704280	chr7:45808275	SEPT13	-0.87	-12.88	-0.64	5.02e-29	Height;
SARC	cis	rs4595586	0.545	rs6580896	chr12:39372223	C/T	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	cis	rs356220	0.632	rs356224	chr4:90643623	A/G	cg06632027	chr4:90757378	SNCA	0.4	5.01	0.31	1.07e-6	Parkinson's disease;
SARC	cis	rs995000	0.931	rs11208000	chr1:63108374	A/G	cg06896770	chr1:63153194	DOCK7	0.9	13.49	0.66	5.04e-31	Triglyceride levels;
SARC	cis	rs9611565	0.877	rs3817999	chr22:41747717	A/G	cg17376030	chr22:41985996	PMM1	-0.51	-6.45	-0.39	6.25e-10	Vitiligo;
SARC	trans	rs3780486	0.846	rs6476399	chr9:33123013	A/G	cg04842962	chr6:43655489	MRPS18A	1.09	20.79	0.81	5.31e-55	IgG glycosylation;
SARC	cis	rs7246657	0.943	rs2126977	chr19:37995747	C/G	cg23950597	chr19:37808831	NA	0.55	5.48	0.34	1.08e-7	Coronary artery calcification;
SARC	cis	rs73001065	0.901	rs73004933	chr19:19675696	C/T	cg03709012	chr19:19516395	GATAD2A	0.83	5.33	0.33	2.31e-7	LDL cholesterol;
SARC	trans	rs61931739	0.500	rs11519123	chr12:34436478	A/G	cg13010199	chr12:38710504	ALG10B	0.75	10.66	0.57	7.34e-22	Morning vs. evening chronotype;
SARC	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	10.68	0.57	6.06e-22	Platelet count;
SARC	cis	rs6831352	0.918	rs13133633	chr4:100058697	C/G	cg13256891	chr4:100009986	ADH5	-0.64	-8.0	-0.46	5.7e-14	Alcohol dependence;
SARC	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg27347728	chr4:17578864	LAP3	0.48	6.1	0.37	4.5e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg22535103	chr8:58192502	C8orf71	-0.83	-9.52	-0.53	2.3e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg25767906	chr1:53392781	SCP2	0.32	4.83	0.3	2.47e-6	Monocyte count;
SARC	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg18404041	chr3:52824283	ITIH1	-0.43	-6.44	-0.39	6.8e-10	Bipolar disorder;
SARC	cis	rs7674212	0.570	rs2126470	chr4:104061762	T/C	cg16532752	chr4:104119610	CENPE	-0.44	-5.43	-0.34	1.43e-7	Type 2 diabetes;
SARC	cis	rs6500602	0.826	rs7205189	chr16:4460114	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.34	4.99	0.31	1.2e-6	Schizophrenia;
SARC	cis	rs10490913	0.806	rs2010654	chr10:120165167	A/T	cg23160142	chr10:120154512	NA	-0.4	-6.02	-0.37	6.68e-9	Cancer;
SARC	cis	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg22857025	chr5:266934	NA	-1.05	-11.39	-0.6	3.61e-24	Breast cancer;
SARC	cis	rs362272	0.524	rs3129334	chr4:3368526	T/C	cg08741688	chr4:3415352	RGS12	-0.47	-5.77	-0.35	2.5e-8	Serum sulfate level;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg20522707	chr17:28995014	NA	0.51	6.35	0.38	1.11e-9	Breast cancer;
SARC	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg11062466	chr8:58055876	NA	0.63	5.36	0.33	1.99e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9325144	0.872	rs11183390	chr12:38729942	G/T	cg13010199	chr12:38710504	ALG10B	-0.44	-5.0	-0.31	1.13e-6	Morning vs. evening chronotype;
SARC	cis	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg00800038	chr16:89945340	TCF25	-0.74	-5.14	-0.32	5.79e-7	Skin colour saturation;
SARC	cis	rs34311866	0.752	rs11725653	chr4:963397	C/T	cg07828340	chr4:882639	GAK	0.7	5.49	0.34	1.04e-7	Parkinson's disease;
SARC	trans	rs208520	0.690	rs207119	chr6:66786408	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.06	-14.41	-0.69	4.36e-34	Exhaled nitric oxide output;
SARC	cis	rs854765	0.693	rs35451946	chr17:17764061	C/G	cg04398451	chr17:18023971	MYO15A	0.44	6.29	0.38	1.53e-9	Total body bone mineral density;
SARC	cis	rs17376456	0.757	rs1031424	chr5:93139706	G/C	cg25358565	chr5:93447407	FAM172A	1.18	12.38	0.63	2.25e-27	Diabetic retinopathy;
SARC	cis	rs9672608	0.687	rs5019044	chr15:78796282	T/A	cg06917634	chr15:78832804	PSMA4	-0.54	-5.47	-0.34	1.17e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs8014204	0.762	rs12889665	chr14:75234830	T/G	cg06637938	chr14:75390232	RPS6KL1	0.58	8.09	0.47	3.18e-14	Caffeine consumption;
SARC	cis	rs7819412	0.838	rs3021494	chr8:10983534	A/G	cg12395012	chr8:11607386	GATA4	0.29	4.76	0.3	3.34e-6	Triglycerides;
SARC	cis	rs3126085	0.935	rs11204981	chr1:152298212	C/T	cg26876637	chr1:152193138	HRNR	-0.54	-6.09	-0.37	4.64e-9	Atopic dermatitis;
SARC	cis	rs644799	0.687	rs11021318	chr11:95522996	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.97	16.72	0.74	9.23e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs1322639	0.614	rs7751131	chr6:169578710	G/A	cg04662567	chr6:169592167	NA	-0.52	-5.22	-0.32	3.9e-7	Pulse pressure;
SARC	cis	rs2075371	0.933	rs1421480	chr7:133958114	A/C	cg20476274	chr7:133979776	SLC35B4	0.61	8.32	0.48	7.38e-15	Mean platelet volume;
SARC	cis	rs7429990	0.965	rs4392441	chr3:48077701	C/T	cg11946769	chr3:48343235	NME6	-0.45	-5.28	-0.33	2.92e-7	Educational attainment (years of education);
SARC	cis	rs11122272	0.735	rs2790891	chr1:231513190	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08462292	chr1:97188168	PTBP2	-0.64	-8.63	-0.49	9.52e-16	Smoking initiation;
SARC	cis	rs561341	1.000	rs561341	chr17:30316385	T/G	cg00745463	chr17:30367425	LRRC37B	-0.67	-5.32	-0.33	2.4e-7	Hip circumference adjusted for BMI;
SARC	cis	rs6693567	0.545	rs1313568	chr1:150344180	C/G	cg09579323	chr1:150459698	TARS2	0.46	5.86	0.36	1.55e-8	Migraine;
SARC	cis	rs67478160	0.643	rs11160762	chr14:104255083	A/G	cg01849466	chr14:104193079	ZFYVE21	0.35	4.84	0.3	2.37e-6	Schizophrenia;
SARC	cis	rs12421382	0.593	rs2357793	chr11:109389353	A/T	cg16359550	chr11:109292809	C11orf87	0.34	5.14	0.32	5.73e-7	Schizophrenia;
SARC	cis	rs17376456	0.569	rs6556834	chr5:93123067	C/T	cg21475434	chr5:93447410	FAM172A	-0.59	-5.8	-0.36	2.17e-8	Diabetic retinopathy;
SARC	cis	rs7833790	0.963	rs1451997	chr8:82774053	A/T	cg27398817	chr8:82754497	SNX16	0.51	5.57	0.34	6.89e-8	Diastolic blood pressure;
SARC	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg12310025	chr6:25882481	NA	-0.45	-5.8	-0.35	2.2e-8	Intelligence (multi-trait analysis);
SARC	cis	rs11098499	0.954	rs1480931	chr4:120395809	G/T	cg24375607	chr4:120327624	NA	0.4	4.84	0.3	2.39e-6	Corneal astigmatism;
SARC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg02353165	chr6:42928485	GNMT	0.62	8.53	0.49	1.86e-15	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs6665290	0.669	rs3768419	chr1:227173477	C/G	cg14016676	chr1:227182615	CDC42BPA	0.34	4.86	0.3	2.19e-6	Myeloid white cell count;
SARC	trans	rs11098499	0.954	rs10006706	chr4:120409152	A/G	cg25214090	chr10:38739885	LOC399744	0.55	7.02	0.42	2.39e-11	Corneal astigmatism;
SARC	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg19346786	chr7:2764209	NA	-0.38	-5.54	-0.34	7.97e-8	Height;
SARC	cis	rs9290065	0.558	rs9846254	chr3:160770370	C/T	cg17135325	chr3:160939158	NMD3	0.41	4.88	0.3	1.95e-6	Kawasaki disease;
SARC	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg18252515	chr7:66147081	NA	-1.33	-11.96	-0.62	5.03e-26	Diabetic kidney disease;
SARC	cis	rs9790314	0.582	rs6796201	chr3:160634313	A/G	cg04691961	chr3:161091175	C3orf57	0.57	7.89	0.46	1.18e-13	Morning vs. evening chronotype;
SARC	cis	rs6088590	1.000	rs6087625	chr20:33342477	A/G	cg24642439	chr20:33292090	TP53INP2	-0.86	-12.12	-0.62	1.54e-26	Coronary artery disease;
SARC	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg11890956	chr21:40555474	PSMG1	0.71	9.13	0.51	3.33e-17	Menarche (age at onset);
SARC	cis	rs826838	0.616	rs7966266	chr12:38626138	G/A	cg13010199	chr12:38710504	ALG10B	-0.52	-6.43	-0.39	7.32e-10	Heart rate;
SARC	cis	rs6762477	0.748	rs3755831	chr3:50228767	G/T	cg24110177	chr3:50126178	RBM5	0.49	6.39	0.39	9.15e-10	Menarche (age at onset);
SARC	cis	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg25427524	chr10:38739819	LOC399744	-0.53	-8.46	-0.48	2.95e-15	Extrinsic epigenetic age acceleration;
SARC	cis	rs1832871	0.672	rs6899322	chr6:158753669	G/T	cg07165851	chr6:158734300	TULP4	0.54	6.45	0.39	6.46e-10	Height;
SARC	trans	rs10506458	0.915	rs998505	chr12:63400018	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.77	-6.81	-0.41	8.36e-11	Hemostatic factors and hematological phenotypes;
SARC	cis	rs6772849	0.931	rs60825080	chr3:128384834	G/T	cg08795948	chr3:128337044	NA	0.55	7.58	0.44	8.25e-13	Monocyte percentage of white cells;Monocyte count;
SARC	trans	rs2727020	0.595	rs10466496	chr11:49501514	C/T	cg03929089	chr4:120376271	NA	-0.8	-12.03	-0.62	2.92e-26	Coronary artery disease;
SARC	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	13.12	0.65	8.35e-30	Chronic sinus infection;
SARC	cis	rs2439831	0.702	rs7171750	chr15:44025858	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.97	8.38	0.48	4.89e-15	Lung cancer in ever smokers;
SARC	cis	rs637571	0.522	rs493899	chr11:65747952	A/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.58	9.11	0.51	3.83e-17	Eosinophil percentage of white cells;
SARC	cis	rs3733585	0.588	rs6449154	chr4:9956404	C/T	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.39	-0.33	1.73e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg24642844	chr7:1081250	C7orf50	-0.57	-6.05	-0.37	5.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs6840360	0.967	rs17027798	chr4:152597540	A/G	cg22705602	chr4:152727874	NA	-0.36	-6.14	-0.37	3.6e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg10589385	chr1:150898437	SETDB1	0.39	5.11	0.32	6.82e-7	Melanoma;
SARC	cis	rs9326248	0.581	rs10892061	chr11:116886114	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.66	8.4	0.48	4.4e-15	Blood protein levels;
SARC	trans	rs7824557	0.564	rs2572400	chr8:11234367	T/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.67	-0.49	7.61e-16	Retinal vascular caliber;
SARC	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-8.85	-0.5	2.2e-16	Alzheimer's disease;
SARC	cis	rs698833	0.501	rs10194161	chr2:44507213	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.43	-5.4	-0.33	1.62e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg08300343	chr19:50432802	NUP62;IL4I1;ATF5	0.49	6.37	0.39	9.94e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg11754314	chr11:67121010	POLD4;LOC100130987	0.49	6.35	0.38	1.12e-9	Chemerin levels;
SARC	cis	rs6138458	1.000	rs6114988	chr20:24977586	C/T	cg26195577	chr20:24973756	C20orf3	0.91	9.89	0.54	1.77e-19	Blood protein levels;
SARC	cis	rs1538970	0.962	rs3219472	chr1:45804050	A/G	cg05343316	chr1:45956843	TESK2	-0.66	-7.44	-0.44	1.89e-12	Platelet count;
SARC	cis	rs55962025	0.883	rs3121419	chr4:3232257	C/T	cg06533319	chr4:3265114	C4orf44	0.34	5.04	0.31	9.43e-7	Parental longevity (mother's age at death);
SARC	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.5	6.34	0.38	1.19e-9	Lymphocyte counts;
SARC	cis	rs838147	0.844	rs12611211	chr19:49248331	G/A	cg13540341	chr19:49222985	MAMSTR	0.28	4.73	0.3	3.83e-6	Dietary macronutrient intake;
SARC	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg16479474	chr6:28041457	NA	0.37	5.44	0.34	1.37e-7	Depression;
SARC	cis	rs992157	0.560	rs7605980	chr2:219100869	C/G	cg20019365	chr2:219134978	PNKD;AAMP	0.57	7.67	0.45	4.66e-13	Colorectal cancer;
SARC	cis	rs16944613	0.541	rs7494949	chr15:91090394	C/G	cg26821196	chr15:91095069	CRTC3	0.55	5.69	0.35	3.74e-8	Colorectal cancer;
SARC	cis	rs735539	0.593	rs35584557	chr13:21366557	T/C	cg16922012	chr13:21400325	XPO4	-0.39	-5.47	-0.34	1.18e-7	Dental caries;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg06879406	chr19:797398	PTBP1	0.49	6.5	0.39	4.94e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs763121	0.853	rs5750669	chr22:39080638	T/A	cg21395723	chr22:39101663	GTPBP1	0.53	5.85	0.36	1.63e-8	Menopause (age at onset);
SARC	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7666738	0.830	rs13112131	chr4:98976784	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2921036	0.529	rs2979192	chr8:8338147	C/T	cg06636001	chr8:8085503	FLJ10661	0.64	7.99	0.46	6.1e-14	Neuroticism;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg25141894	chr1:115164619	DENND2C	0.47	6.37	0.39	9.71e-10	Thyroid stimulating hormone;
SARC	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg22875332	chr1:76189707	ACADM	-0.42	-5.53	-0.34	8.5e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs5769765	1.000	rs768618	chr22:50286827	G/A	cg03033257	chr22:50311977	ALG12;CRELD2	0.54	5.55	0.34	7.94e-8	Schizophrenia;
SARC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg06873352	chr17:61820015	STRADA	0.54	7.14	0.42	1.16e-11	Prudent dietary pattern;
SARC	cis	rs66887589	0.934	rs4834792	chr4:120555696	T/A	cg09307838	chr4:120376055	NA	-0.54	-7.45	-0.44	1.82e-12	Diastolic blood pressure;
SARC	cis	rs8114671	0.562	rs2273683	chr20:33509523	C/T	cg07148914	chr20:33460835	GGT7	0.48	5.87	0.36	1.47e-8	Height;
SARC	trans	rs1814175	0.645	rs7115592	chr11:50013243	A/G	cg15704280	chr7:45808275	SEPT13	-0.9	-14.33	-0.68	7.84e-34	Height;
SARC	cis	rs765787	0.530	rs12906537	chr15:45520061	T/C	cg24006582	chr15:45444508	DUOX1	0.44	5.42	0.33	1.52e-7	Uric acid levels;
SARC	trans	rs11165623	0.602	rs4619021	chr1:97025910	T/C	cg10631902	chr5:14652156	NA	-0.42	-6.3	-0.38	1.45e-9	Hip circumference;Waist circumference;
SARC	cis	rs9790314	0.934	rs461638	chr3:161103166	A/G	cg04691961	chr3:161091175	C3orf57	-0.78	-11.64	-0.61	5.46e-25	Morning vs. evening chronotype;
SARC	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg24060327	chr5:131705240	SLC22A5	0.74	8.74	0.5	4.83e-16	Breast cancer;
SARC	cis	rs664172	1	rs664172	chr15:78862762	G/A	cg24631222	chr15:78858424	CHRNA5	0.74	9.91	0.54	1.51e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.35	-5.73	-0.35	3.12e-8	Total body bone mineral density;
SARC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg11301795	chr4:187892539	NA	0.74	10.8	0.58	2.56e-22	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs854765	0.693	rs35451946	chr17:17764061	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.64	-9.44	-0.53	4.07e-18	Total body bone mineral density;
SARC	cis	rs10504229	0.724	rs72649117	chr8:58037639	A/G	cg08280861	chr8:58055591	NA	0.52	4.85	0.3	2.24e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	5.57	0.34	6.89e-8	Personality dimensions;
SARC	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-8.85	-0.5	2.28e-16	Alzheimer's disease;
SARC	cis	rs2916247	0.954	rs6992101	chr8:93152048	C/A	cg10183463	chr8:93005414	RUNX1T1	0.56	5.82	0.36	1.93e-8	Intelligence (multi-trait analysis);
SARC	cis	rs4970988	0.527	rs12067556	chr1:150614535	G/A	cg15448220	chr1:150897856	SETDB1	0.48	5.98	0.36	8.33e-9	Urate levels;
SARC	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg19723775	chr5:179050963	HNRNPH1	0.41	5.08	0.32	7.56e-7	Lung cancer;
SARC	cis	rs3204955	0.802	rs11578766	chr1:116246678	G/A	cg20810993	chr1:116250018	CASQ2	-0.51	-5.11	-0.32	6.66e-7	Itch intensity from mosquito bite adjusted by bite size;
SARC	cis	rs870825	0.616	rs2696037	chr4:185610940	C/T	cg04058563	chr4:185651563	MLF1IP	-0.77	-10.32	-0.56	8.46e-21	Blood protein levels;
SARC	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.68	-9.13	-0.51	3.49e-17	Parkinson's disease;
SARC	cis	rs8114671	1.000	rs8114671	chr20:33789142	C/A	cg24642439	chr20:33292090	TP53INP2	-0.49	-5.66	-0.35	4.42e-8	Height;
SARC	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg11494091	chr17:61959527	GH2	-0.34	-4.85	-0.3	2.3e-6	Height;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg07027685	chr9:95055737	IARS;SNORA84	0.87	7.33	0.43	3.86e-12	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1707322	0.963	rs4660900	chr1:46419605	T/C	cg03146154	chr1:46216737	IPP	0.46	5.5	0.34	9.8e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.48	5.61	0.35	5.6e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs3768617	1.000	rs2027077	chr1:183073453	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.58	7.78	0.45	2.38e-13	Fuchs's corneal dystrophy;
SARC	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg05535760	chr7:792225	HEATR2	0.83	8.23	0.47	1.36e-14	Cerebrospinal P-tau181p levels;
SARC	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg27572855	chr1:25598939	RHD	0.55	9.51	0.53	2.45e-18	Erythrocyte sedimentation rate;
SARC	cis	rs12142240	0.698	rs72677594	chr1:46824371	A/C	cg10495392	chr1:46806563	NSUN4	0.65	6.8	0.41	8.89e-11	Menopause (age at onset);
SARC	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg08219700	chr8:58056026	NA	0.57	5.23	0.32	3.82e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg04944784	chr2:26401820	FAM59B	0.61	8.06	0.47	4.03e-14	Gut microbiome composition (summer);
SARC	cis	rs2153535	0.580	rs7741403	chr6:8530578	C/T	cg23788917	chr6:8435910	SLC35B3	-0.58	-7.68	-0.45	4.3e-13	Motion sickness;
SARC	cis	rs4332037	0.576	rs62434668	chr7:1866901	G/A	cg13880726	chr7:1868755	MAD1L1	-0.53	-4.77	-0.3	3.28e-6	Bipolar disorder;
SARC	cis	rs751837	0.932	rs8021471	chr14:103486375	C/T	cg02938407	chr14:103486904	CDC42BPB	0.53	5.29	0.33	2.82e-7	Large B-cell lymphoma;
SARC	cis	rs3126085	0.935	rs74129461	chr1:152285099	C/T	cg03465714	chr1:152285911	FLG	0.49	5.62	0.35	5.45e-8	Atopic dermatitis;
SARC	cis	rs8067545	0.611	rs2526486	chr17:20101626	T/G	cg13482628	chr17:19912719	NA	-0.53	-6.85	-0.41	6.35e-11	Schizophrenia;
SARC	cis	rs1153858	1.000	rs1346268	chr15:45673029	T/C	cg26924012	chr15:45694286	SPATA5L1	0.79	11.28	0.59	7.91e-24	Homoarginine levels;
SARC	cis	rs2370759	1.000	rs77165999	chr10:32577131	T/C	cg01819863	chr10:32635814	EPC1	1.01	9.89	0.54	1.71e-19	Sexual dysfunction (female);
SARC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08280861	chr8:58055591	NA	0.67	7.83	0.46	1.73e-13	Developmental language disorder (linguistic errors);
SARC	cis	rs4975616	0.843	rs4975615	chr5:1315343	C/T	cg06550200	chr5:1325588	CLPTM1L	0.44	6.39	0.39	9.18e-10	Lung cancer;
SARC	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg09165964	chr15:75287851	SCAMP5	0.53	7.03	0.42	2.31e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	cis	rs7223966	1.000	rs8066719	chr17:61825764	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	7.12	0.42	1.33e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2204008	0.747	rs11514040	chr12:38201040	G/A	cg13010199	chr12:38710504	ALG10B	0.78	10.64	0.57	8.61e-22	Bladder cancer;
SARC	cis	rs17023223	0.509	rs10923740	chr1:119600287	C/T	cg05756136	chr1:119680316	WARS2	-0.46	-5.33	-0.33	2.37e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs11675119	0.517	rs12619851	chr2:3492747	T/C	cg10845886	chr2:3471009	TTC15	-0.37	-4.74	-0.3	3.78e-6	Neurofibrillary tangles;
SARC	cis	rs73198271	0.562	rs75525911	chr8:8659359	C/A	cg01851573	chr8:8652454	MFHAS1	0.46	5.72	0.35	3.33e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs3617	0.573	rs2336667	chr3:52916363	C/T	cg05564831	chr3:52568323	NT5DC2	-0.27	-4.76	-0.3	3.43e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs3020264	0.586	rs3020265	chr8:6488921	A/G	cg06565184	chr8:6479163	MCPH1	-0.47	-5.75	-0.35	2.8e-8	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);
SARC	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg10560079	chr2:191398806	TMEM194B	-0.63	-8.96	-0.51	1.04e-16	Pulse pressure;
SARC	trans	rs9929218	0.551	rs6499193	chr16:68727069	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.79	13.27	0.66	2.6e-30	Colorectal cancer;
SARC	cis	rs709400	0.658	rs72708874	chr14:103899251	T/G	cg12935359	chr14:103987150	CKB	-0.4	-5.83	-0.36	1.85e-8	Body mass index;
SARC	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg18876405	chr7:65276391	NA	0.71	9.19	0.52	2.26e-17	Calcium levels;
SARC	cis	rs523522	0.962	rs12309824	chr12:120990582	A/C	cg27279351	chr12:120934652	DYNLL1	0.72	8.87	0.5	2.02e-16	High light scatter reticulocyte count;
SARC	cis	rs11122272	0.735	rs2790885	chr1:231529925	C/T	cg06096015	chr1:231504339	EGLN1	0.39	5.81	0.36	1.99e-8	Hemoglobin concentration;
SARC	cis	rs748404	0.587	rs9920879	chr15:43639770	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.41	4.93	0.31	1.55e-6	Lung cancer;
SARC	cis	rs4919087	0.715	rs946981	chr10:98995076	A/G	cg25902810	chr10:99078978	FRAT1	-0.53	-6.03	-0.37	6.25e-9	Monocyte count;
SARC	cis	rs34172651	0.917	rs17771137	chr16:24792242	G/A	cg00152838	chr16:24741724	TNRC6A	-0.5	-6.14	-0.37	3.59e-9	Intelligence (multi-trait analysis);
SARC	cis	rs12291225	0.679	rs11023178	chr11:14310282	G/A	cg19336497	chr11:14380999	RRAS2	-0.41	-6.93	-0.41	4.05e-11	Sense of smell;
SARC	cis	rs875971	0.545	rs73152714	chr7:65999628	G/A	cg11764359	chr7:65958608	NA	0.64	6.4	0.39	8.5e-10	Aortic root size;
SARC	cis	rs2721811	0.701	rs2721808	chr7:24744309	C/A	cg17569154	chr7:24781545	DFNA5	0.45	6.28	0.38	1.61e-9	Depressive symptoms (multi-trait analysis);
SARC	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg03806693	chr22:41940476	POLR3H	0.88	12.2	0.62	8.17e-27	Vitiligo;
SARC	cis	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg05623727	chr3:50126028	RBM5	-0.33	-5.0	-0.31	1.15e-6	Intelligence (multi-trait analysis);
SARC	cis	rs1318878	1.000	rs60023910	chr12:15546774	A/G	cg08258403	chr12:15378311	NA	0.46	6.07	0.37	5.26e-9	Intelligence (multi-trait analysis);
SARC	cis	rs6062302	0.522	rs3761126	chr20:62252044	C/T	cg16989086	chr20:62203971	PRIC285	0.48	4.77	0.3	3.28e-6	Glioblastoma;
SARC	cis	rs7044106	0.791	rs10818473	chr9:123484155	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	6.08	0.37	4.87e-9	Hip circumference adjusted for BMI;
SARC	cis	rs7223966	1.000	rs3817181	chr17:61776538	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	6.76	0.4	1.1e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2273669	0.667	rs76201299	chr6:109344975	T/G	cg05315195	chr6:109294784	ARMC2	-0.64	-5.7	-0.35	3.68e-8	Prostate cancer;
SARC	cis	rs28374715	0.681	rs28728213	chr15:41653602	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.97	-15.4	-0.71	2.15e-37	Ulcerative colitis;
SARC	cis	rs4887067	1	rs4887067	chr15:78886947	G/A	cg18825076	chr15:78729989	IREB2	-0.45	-5.11	-0.32	6.56e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs739401	0.572	rs7111857	chr11:3068106	A/G	cg08508325	chr11:3079039	CARS	0.33	8.01	0.46	5.52e-14	Longevity;
SARC	cis	rs2594989	0.943	rs4684070	chr3:11437551	A/G	cg00170343	chr3:11313890	ATG7	0.6	5.9	0.36	1.24e-8	Circulating chemerin levels;
SARC	cis	rs826838	0.900	rs1403523	chr12:39130570	T/A	cg26384229	chr12:38710491	ALG10B	-0.76	-11.59	-0.6	7.97e-25	Heart rate;
SARC	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.38	6.22	0.38	2.27e-9	Schizophrenia;
SARC	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg26335602	chr6:28129616	ZNF389	0.52	5.94	0.36	1.04e-8	Parkinson's disease;
SARC	cis	rs35160687	0.787	rs10186289	chr2:86512988	G/A	cg10973622	chr2:86423274	IMMT	0.41	5.55	0.34	7.64e-8	Night sleep phenotypes;
SARC	cis	rs2180341	0.596	rs12215298	chr6:127676833	C/T	cg27446573	chr6:127587934	RNF146	0.7	8.84	0.5	2.33e-16	Breast cancer;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg03956680	chr2:64067521	UGP2	-0.52	-6.99	-0.42	2.83e-11	Chemerin levels;
SARC	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.43	-6.56	-0.39	3.5e-10	Total body bone mineral density;
SARC	cis	rs3126085	0.935	rs4845750	chr1:152201217	A/G	cg03465714	chr1:152285911	FLG	-0.43	-4.99	-0.31	1.16e-6	Atopic dermatitis;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg25509121	chr17:61851092	DDX42;CCDC47	0.55	7.01	0.42	2.5e-11	Breast cancer;
SARC	cis	rs72634258	0.699	rs12128234	chr1:8170219	T/C	cg00042356	chr1:8021962	PARK7	-0.64	-5.96	-0.36	9.12e-9	Inflammatory bowel disease;
SARC	cis	rs2505675	0.665	rs234932	chr6:2220520	C/T	cg16550324	chr6:2245327	GMDS	0.45	5.32	0.33	2.42e-7	Tuberculosis;
SARC	trans	rs2727020	0.729	rs6485965	chr11:49166730	C/T	cg03929089	chr4:120376271	NA	0.67	9.28	0.52	1.23e-17	Coronary artery disease;
SARC	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg17376030	chr22:41985996	PMM1	0.56	6.77	0.41	1.06e-10	Vitiligo;
SARC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg14893161	chr1:205819251	PM20D1	0.61	8.23	0.47	1.32e-14	Menarche (age at onset);
SARC	trans	rs1994135	0.617	rs12821909	chr12:33723466	T/C	cg13010199	chr12:38710504	ALG10B	0.76	8.97	0.51	1e-16	Resting heart rate;
SARC	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg01475735	chr3:40494733	NA	-0.49	-5.64	-0.35	4.98e-8	Renal cell carcinoma;
SARC	trans	rs9951602	0.573	rs8098953	chr18:76648734	A/G	cg02800362	chr5:177631904	HNRNPAB	0.72	9.15	0.51	2.93e-17	Obesity-related traits;
SARC	trans	rs61931739	0.817	rs10743841	chr12:34252870	T/C	cg26384229	chr12:38710491	ALG10B	0.58	7.89	0.46	1.2e-13	Morning vs. evening chronotype;
SARC	cis	rs2594989	1.000	rs2606740	chr3:11392441	G/A	cg00170343	chr3:11313890	ATG7	0.55	4.97	0.31	1.29e-6	Circulating chemerin levels;
SARC	cis	rs7712401	0.562	rs364723	chr5:122326464	A/G	cg19412675	chr5:122181750	SNX24	-0.43	-5.43	-0.34	1.41e-7	Mean platelet volume;
SARC	cis	rs11645898	0.935	rs11641721	chr16:72155241	G/A	cg14768367	chr16:72042858	DHODH	-0.63	-5.72	-0.35	3.21e-8	Blood protein levels;
SARC	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs11651000	0.857	rs57171311	chr17:45826168	A/G	cg24803719	chr17:45855879	NA	-0.51	-7.39	-0.44	2.56e-12	IgG glycosylation;
SARC	cis	rs2404602	0.647	rs4312276	chr15:77164361	T/C	cg15268244	chr15:77196840	NA	0.45	5.17	0.32	4.93e-7	Blood metabolite levels;
SARC	cis	rs6964587	0.869	rs55811257	chr7:91484799	T/A	cg17063962	chr7:91808500	NA	-0.92	-13.66	-0.67	1.33e-31	Breast cancer;
SARC	cis	rs9640161	0.789	rs6964110	chr7:150041836	A/C	cg17279839	chr7:150038598	RARRES2	0.39	5.64	0.35	4.87e-8	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.65	0.4	2.07e-10	Height;
SARC	cis	rs11122272	0.766	rs2790872	chr1:231540543	A/T	cg06096015	chr1:231504339	EGLN1	0.37	5.44	0.34	1.35e-7	Hemoglobin concentration;
SARC	trans	rs11165623	0.564	rs7555035	chr1:96996026	T/C	cg10631902	chr5:14652156	NA	-0.42	-6.49	-0.39	5.21e-10	Hip circumference;Waist circumference;
SARC	cis	rs898097	0.841	rs12453162	chr17:80859971	C/T	cg15664640	chr17:80829946	TBCD	-0.55	-8.23	-0.47	1.31e-14	Breast cancer;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg00570896	chr1:51443449	NA	0.49	6.45	0.39	6.56e-10	Chemerin levels;
SARC	cis	rs16854884	0.558	rs60367530	chr3:143719294	G/A	cg06585982	chr3:143692056	C3orf58	0.65	8.64	0.49	9.03e-16	Economic and political preferences (feminism/equality);
SARC	cis	rs11190604	1.000	rs9420797	chr10:102331147	C/T	cg14256752	chr10:102295592	HIF1AN	0.44	5.05	0.31	8.75e-7	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs944802	0.929	rs10965269	chr9:22162061	A/G	cg00491127	chr9:22154101	NA	-0.52	-5.45	-0.34	1.25e-7	White blood cell count;
SARC	cis	rs1707322	1.000	rs10890350	chr1:46262378	G/A	cg03146154	chr1:46216737	IPP	0.48	5.79	0.35	2.24e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg16434002	chr17:42200994	HDAC5	-0.49	-6.23	-0.38	2.18e-9	Total body bone mineral density;
SARC	cis	rs593982	0.777	rs534414	chr11:65475515	A/G	cg08755490	chr11:65554678	OVOL1	0.86	8.47	0.49	2.72e-15	Atopic dermatitis;
SARC	cis	rs9788721	0.836	rs17405217	chr15:78731149	C/T	cg18825076	chr15:78729989	IREB2	-0.55	-6.72	-0.4	1.35e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs6732160	0.809	rs13387480	chr2:73371007	C/T	cg01422370	chr2:73384389	NA	0.31	5.19	0.32	4.56e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2228479	0.718	rs11645376	chr16:89912281	G/C	cg06558623	chr16:89946397	TCF25	0.93	6.61	0.4	2.59e-10	Skin colour saturation;
SARC	cis	rs7914558	1.000	rs7911789	chr10:104756374	T/C	cg04362960	chr10:104952993	NT5C2	0.44	5.51	0.34	9.66e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs6060717	0.536	rs6060683	chr20:34507921	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	4.95	0.31	1.42e-6	Hip circumference adjusted for BMI;
SARC	cis	rs7772486	0.774	rs6930181	chr6:146180974	A/T	cg23711669	chr6:146136114	FBXO30	-0.78	-12.34	-0.63	3.03e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9902453	0.817	rs2729435	chr17:28121532	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.23	-0.43	6.84e-12	Coffee consumption (cups per day);
SARC	cis	rs17376456	0.569	rs1349711	chr5:93179032	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.47	-4.88	-0.3	1.98e-6	Diabetic retinopathy;
SARC	cis	rs72781680	0.898	rs72786279	chr2:24063266	C/T	cg06627628	chr2:24431161	ITSN2	-0.67	-6.45	-0.39	6.22e-10	Lymphocyte counts;
SARC	cis	rs2070488	0.775	rs2051213	chr3:38560254	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.77	11.46	0.6	2.12e-24	Electrocardiographic conduction measures;
SARC	cis	rs9487051	0.676	rs9400268	chr6:109600550	C/T	cg01475377	chr6:109611718	NA	-0.35	-5.19	-0.32	4.61e-7	Reticulocyte fraction of red cells;
SARC	cis	rs16854884	0.632	rs4535221	chr3:143658607	A/G	cg06585982	chr3:143692056	C3orf58	0.66	8.87	0.5	1.91e-16	Economic and political preferences (feminism/equality);
SARC	cis	rs2549003	1.000	rs2070727	chr5:131820275	C/A	cg21138405	chr5:131827807	IRF1	0.27	5.33	0.33	2.26e-7	Asthma (sex interaction);
SARC	cis	rs3008870	0.629	rs12742428	chr1:67426487	A/G	cg02640540	chr1:67518911	SLC35D1	0.46	5.26	0.33	3.29e-7	Lymphocyte percentage of white cells;
SARC	cis	rs950169	0.840	rs2896002	chr15:84945121	A/G	cg17507749	chr15:85114479	UBE2QP1	0.78	9.47	0.53	3.37e-18	Schizophrenia;
SARC	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg13175981	chr1:150552382	MCL1	-0.51	-6.19	-0.38	2.67e-9	Melanoma;
SARC	cis	rs11690935	0.959	rs35391289	chr2:172634983	A/C	cg13550731	chr2:172543902	DYNC1I2	-0.99	-15.59	-0.71	5.05e-38	Schizophrenia;
SARC	cis	rs4595586	0.545	rs4142846	chr12:39395140	C/T	cg26384229	chr12:38710491	ALG10B	0.45	5.64	0.35	5.01e-8	Morning vs. evening chronotype;
SARC	cis	rs17376456	0.825	rs74825443	chr5:93254973	T/C	cg21475434	chr5:93447410	FAM172A	0.86	7.72	0.45	3.37e-13	Diabetic retinopathy;
SARC	cis	rs9341808	0.718	rs1324123	chr6:80932894	G/A	cg08355045	chr6:80787529	NA	0.34	5.3	0.33	2.67e-7	Sitting height ratio;
SARC	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg18252515	chr7:66147081	NA	-1.31	-11.71	-0.61	3.25e-25	Diabetic kidney disease;
SARC	cis	rs9828933	0.882	rs3733127	chr3:63988174	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.7	-5.69	-0.35	3.77e-8	Type 2 diabetes;
SARC	cis	rs7223966	1.000	rs7223672	chr17:61720565	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.26	0.38	1.87e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2985684	0.841	rs12894785	chr14:50049755	G/C	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.46	4.98	0.31	1.25e-6	Carotid intima media thickness;
SARC	cis	rs12142240	0.698	rs10158130	chr1:46822600	T/C	cg10495392	chr1:46806563	NSUN4	0.65	6.8	0.41	8.89e-11	Menopause (age at onset);
SARC	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg23982607	chr1:1823379	GNB1	-0.66	-11.09	-0.59	3.07e-23	Body mass index;
SARC	cis	rs12579753	1.000	rs12821073	chr12:82183260	G/T	cg07988820	chr12:82153109	PPFIA2	-0.53	-6.3	-0.38	1.44e-9	Resting heart rate;
SARC	cis	rs4780401	0.933	rs4780396	chr16:11816671	G/A	cg01061890	chr16:11836724	TXNDC11	-0.52	-6.78	-0.41	9.59e-11	Rheumatoid arthritis;
SARC	cis	rs1707322	0.663	rs3935296	chr1:46180470	T/C	cg06784218	chr1:46089804	CCDC17	-0.36	-6.17	-0.37	2.95e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg18370025	chr7:2749541	AMZ1	-0.29	-4.71	-0.3	4.18e-6	Height;
SARC	cis	rs3818285	0.515	rs12258440	chr10:111676799	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.54	-7.21	-0.43	7.9e-12	Superior crus of antihelix expression;
SARC	cis	rs734999	0.545	rs9970196	chr1:2574078	T/C	cg00980319	chr1:2560884	MMEL1	0.36	5.03	0.31	9.59e-7	Ulcerative colitis;
SARC	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs11719291	0.833	rs11715835	chr3:48770732	C/T	cg01304814	chr3:48885189	PRKAR2A	0.63	4.99	0.31	1.21e-6	Cognitive function;
SARC	cis	rs4763879	0.865	rs4763839	chr12:9882700	T/A	cg27502298	chr12:9555721	NA	0.46	5.02	0.31	1.03e-6	Type 1 diabetes;
SARC	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg13395646	chr4:1353034	KIAA1530	-0.49	-5.9	-0.36	1.25e-8	Obesity-related traits;
SARC	cis	rs965604	1.000	rs1964678	chr15:78754000	A/G	cg24631222	chr15:78858424	CHRNA5	-0.47	-6.07	-0.37	5.16e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	trans	rs7937682	0.774	rs59921976	chr11:111473088	G/A	cg18187862	chr3:45730750	SACM1L	0.52	6.48	0.39	5.44e-10	Primary sclerosing cholangitis;
SARC	cis	rs9894429	0.505	rs35570626	chr17:79611084	A/G	cg18240062	chr17:79603768	NPLOC4	0.58	7.04	0.42	2.14e-11	Eye color traits;
SARC	cis	rs708547	0.874	rs1614251	chr4:57891386	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.46	-4.97	-0.31	1.28e-6	Response to bleomycin (chromatid breaks);
SARC	cis	rs55883249	0.958	rs17362734	chr2:9730208	A/G	cg23886495	chr2:9695866	ADAM17	0.69	6.98	0.42	3.12e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	trans	rs9329221	0.678	rs560638	chr8:9882767	A/G	cg08975724	chr8:8085496	FLJ10661	-0.53	-7.0	-0.42	2.78e-11	Neuroticism;
SARC	cis	rs17001868	0.568	rs9607701	chr22:40739116	A/G	cg07138101	chr22:40742427	ADSL	0.54	5.94	0.36	1.01e-8	Mammographic density (dense area);
SARC	cis	rs9815354	1.000	rs73079321	chr3:41863910	C/T	cg03022575	chr3:42003672	ULK4	0.57	5.32	0.33	2.38e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9398803	0.713	rs4621657	chr6:126896227	G/A	cg20229609	chr6:126660872	C6orf173	0.35	5.07	0.31	8.26e-7	Male-pattern baldness;
SARC	cis	rs35213789	0.534	rs41859	chr7:69006876	G/A	cg10619644	chr7:69149951	AUTS2	0.35	4.98	0.31	1.26e-6	Childhood ear infection;
SARC	cis	rs17331151	0.573	rs11718060	chr3:52875546	G/A	cg04865290	chr3:52927548	TMEM110	-0.65	-5.66	-0.35	4.33e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs6952808	0.635	rs6952727	chr7:1947958	A/G	cg04267008	chr7:1944627	MAD1L1	-0.48	-5.48	-0.34	1.1e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs9398803	0.687	rs1538956	chr6:126964026	G/T	cg19875578	chr6:126661172	C6orf173	0.63	8.7	0.5	5.9e-16	Male-pattern baldness;
SARC	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg11987759	chr7:65425863	GUSB	-0.46	-6.23	-0.38	2.15e-9	Aortic root size;
SARC	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg25072359	chr17:41440525	NA	0.51	6.08	0.37	4.92e-9	Menopause (age at onset);
SARC	cis	rs3018712	0.532	rs2513281	chr11:68417094	A/G	cg01657329	chr11:68192670	LRP5	0.59	5.33	0.33	2.3e-7	Total body bone mineral density;
SARC	cis	rs10911232	0.507	rs10911230	chr1:183051118	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.35	0.56	6.82e-21	Hypertriglyceridemia;
SARC	cis	rs10791097	0.694	rs876641	chr11:130752040	A/C	cg09137382	chr11:130731461	NA	0.32	4.94	0.31	1.5e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs10511378	1.000	rs1520115	chr3:118182377	C/T	cg14856641	chr3:118959468	B4GALT4	-0.45	-4.78	-0.3	3.11e-6	Obesity-related traits;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg19695842	chr20:19997930	NAA20	0.48	6.42	0.39	7.73e-10	Chemerin levels;
SARC	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg05313129	chr8:58192883	C8orf71	-0.62	-6.34	-0.38	1.18e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs74417235	0.639	rs2396994	chr5:154052750	A/T	cg08754654	chr5:154026448	NA	-0.48	-4.78	-0.3	3.06e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
SARC	cis	rs9894429	0.646	rs8079963	chr17:79603285	C/T	cg18240062	chr17:79603768	NPLOC4	0.6	7.4	0.44	2.41e-12	Eye color traits;
SARC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.63	-0.4	2.28e-10	Total body bone mineral density;
SARC	cis	rs9300255	0.699	rs11057204	chr12:123725827	T/C	cg00376283	chr12:123451042	ABCB9	0.52	5.98	0.36	8.35e-9	Neutrophil percentage of white cells;
SARC	cis	rs11509153	0.687	rs3800845	chr7:12264151	C/G	cg23422036	chr7:12250390	TMEM106B	0.42	5.37	0.33	1.94e-7	Residual cognition;
SARC	cis	rs356220	0.656	rs356216	chr4:90636708	T/C	cg06632027	chr4:90757378	SNCA	0.39	4.95	0.31	1.42e-6	Parkinson's disease;
SARC	cis	rs7552404	0.924	rs1313071	chr1:76195542	C/G	cg22875332	chr1:76189707	ACADM	0.4	5.79	0.35	2.25e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg13175981	chr1:150552382	MCL1	-0.54	-6.9	-0.41	4.97e-11	Tonsillectomy;
SARC	cis	rs9303401	0.573	rs34717648	chr17:56886624	T/A	cg25039879	chr17:56429692	SUPT4H1	0.64	6.07	0.37	5.22e-9	Cognitive test performance;
SARC	cis	rs9420	0.884	rs644883	chr11:57663522	C/G	cg23127183	chr11:57508653	C11orf31	0.56	6.27	0.38	1.75e-9	Schizophrenia;
SARC	cis	rs9486719	1.000	rs4839837	chr6:96908706	G/A	cg06623918	chr6:96969491	KIAA0776	0.74	8.09	0.47	3.28e-14	Migraine;Coronary artery disease;
SARC	cis	rs11098499	0.955	rs1511018	chr4:120161580	G/T	cg24375607	chr4:120327624	NA	0.4	4.86	0.3	2.12e-6	Corneal astigmatism;
SARC	cis	rs8114671	0.562	rs8117491	chr20:33510120	T/C	cg24642439	chr20:33292090	TP53INP2	0.46	5.52	0.34	9.03e-8	Height;
SARC	trans	rs2727020	0.636	rs10839275	chr11:49438962	T/A	cg03929089	chr4:120376271	NA	-0.79	-11.77	-0.61	2.09e-25	Coronary artery disease;
SARC	cis	rs62012628	0.527	rs12438008	chr15:79084680	C/T	cg00639195	chr15:79103007	ADAMTS7	0.57	6.11	0.37	4.25e-9	Diastolic blood pressure;
SARC	cis	rs1008375	0.966	rs3733581	chr4:17695206	C/G	cg27347728	chr4:17578864	LAP3	-0.51	-6.21	-0.38	2.44e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2075371	0.897	rs1646702	chr7:134000177	C/G	cg20476274	chr7:133979776	SLC35B4	0.63	8.51	0.49	2.17e-15	Mean platelet volume;
SARC	cis	rs7666738	0.830	rs10010223	chr4:99021758	G/A	cg05340658	chr4:99064831	C4orf37	0.66	9.04	0.51	6.35e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1707322	0.896	rs785518	chr1:46568422	A/T	cg06784218	chr1:46089804	CCDC17	-0.35	-6.16	-0.37	3.23e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs11098499	0.697	rs10020027	chr4:120381879	G/C	cg09307838	chr4:120376055	NA	0.92	13.13	0.65	7.35e-30	Corneal astigmatism;
SARC	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg18404041	chr3:52824283	ITIH1	-0.47	-7.14	-0.42	1.2e-11	Bipolar disorder;
SARC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg09373136	chr17:61933544	TCAM1	-0.44	-6.07	-0.37	5.09e-9	Prudent dietary pattern;
SARC	cis	rs6840360	1.000	rs751012	chr4:152602247	A/C	cg22705602	chr4:152727874	NA	-0.38	-6.54	-0.39	3.91e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7727544	0.735	rs2569266	chr5:131706791	T/C	cg24060327	chr5:131705240	SLC22A5	0.67	8.51	0.49	2.12e-15	Blood metabolite levels;
SARC	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	11.19	0.59	1.55e-23	Platelet count;
SARC	trans	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg00938859	chr5:1591904	SDHAP3	-0.8	-8.04	-0.47	4.42e-14	Breast cancer;
SARC	trans	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg15136797	chr2:86851071	RNF103	0.45	6.24	0.38	2.03e-9	Immature fraction of reticulocytes;
SARC	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg21724239	chr8:58056113	NA	0.6	6.37	0.38	1.03e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs754466	0.580	rs10430530	chr10:79582812	T/C	cg17075019	chr10:79541650	NA	-0.8	-12.51	-0.63	7.99e-28	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs910316	0.763	rs175016	chr14:75459633	C/T	cg11812906	chr14:75593930	NEK9	-0.78	-10.88	-0.58	1.42e-22	Height;
SARC	cis	rs137603	1.000	rs137607	chr22:39695505	G/A	cg01093212	chr22:39715156	SNORD43;RPL3	-0.43	-5.19	-0.32	4.51e-7	Primary biliary cholangitis;
SARC	cis	rs2304069	0.909	rs10038824	chr5:149369776	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.74	-7.75	-0.45	2.84e-13	HIV-1 control;
SARC	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg05368731	chr17:41323189	NBR1	0.77	9.32	0.52	9.34e-18	Menopause (age at onset);
SARC	trans	rs459571	0.959	rs460888	chr9:136913123	C/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.62	-7.11	-0.42	1.44e-11	Platelet distribution width;
SARC	cis	rs7029536	0.551	rs10987639	chr9:130172485	G/A	cg09445097	chr9:130186736	ZNF79	0.53	4.97	0.31	1.27e-6	Metabolite levels (HVA);
SARC	cis	rs9291683	0.507	rs3796837	chr4:10011321	C/G	cg11266682	chr4:10021025	SLC2A9	0.4	6.95	0.41	3.71e-11	Bone mineral density;
SARC	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg23758822	chr17:41437982	NA	0.81	10.2	0.56	1.91e-20	Menopause (age at onset);
SARC	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg08923669	chr16:420230	MRPL28	-0.4	-6.08	-0.37	4.88e-9	Bone mineral density (spine);Bone mineral density;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg14515211	chr4:174292111	SAP30	0.5	6.38	0.39	9.38e-10	Lung adenocarcinoma;
SARC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.69	0.54	6.99e-19	Prudent dietary pattern;
SARC	cis	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg00409905	chr10:38381863	ZNF37A	-0.55	-7.71	-0.45	3.72e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs1497406	0.744	rs4537547	chr1:16510798	C/T	cg20430773	chr1:16534157	ARHGEF19	-0.52	-7.63	-0.45	6.1e-13	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs11122272	0.735	rs2474623	chr1:231513993	T/C	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	trans	rs988958	0.840	rs10176250	chr2:42303086	C/T	cg02435573	chr1:94712239	NA	-0.5	-6.54	-0.39	3.94e-10	Hypospadias;
SARC	cis	rs11112613	0.775	rs61200462	chr12:105969271	G/A	cg03607813	chr12:105948248	NA	0.52	7.05	0.42	1.98e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs2228479	0.850	rs62056063	chr16:89903680	C/T	cg00800038	chr16:89945340	TCF25	-0.82	-5.77	-0.35	2.46e-8	Skin colour saturation;
SARC	cis	rs611744	0.647	rs689275	chr8:109241822	T/C	cg21045802	chr8:109455806	TTC35	0.6	7.65	0.45	5.11e-13	Dupuytren's disease;
SARC	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.73	10.52	0.57	1.95e-21	Personality dimensions;
SARC	cis	rs826838	0.935	rs11169508	chr12:39173385	C/T	cg13010199	chr12:38710504	ALG10B	0.77	10.36	0.56	6.07e-21	Heart rate;
SARC	cis	rs1003719	0.788	rs4572679	chr21:38453227	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.65	9.46	0.53	3.43e-18	Eye color traits;
SARC	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg11941060	chr3:133502564	NA	-0.35	-4.98	-0.31	1.23e-6	Iron status biomarkers;
SARC	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg24399712	chr22:39784796	NA	-0.43	-5.69	-0.35	3.8e-8	Intelligence (multi-trait analysis);
SARC	cis	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.8	-0.46	2.01e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs2439831	0.681	rs28578454	chr15:43603032	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.04	10.69	0.57	5.75e-22	Lung cancer in ever smokers;
SARC	cis	rs4713675	0.565	rs2274458	chr6:33679596	A/C	cg15676125	chr6:33679581	C6orf125	0.53	6.52	0.39	4.36e-10	Plateletcrit;
SARC	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg06634786	chr22:41940651	POLR3H	-0.63	-7.58	-0.44	8.31e-13	Vitiligo;
SARC	cis	rs7940866	0.801	rs10894300	chr11:130845943	A/G	cg12179176	chr11:130786555	SNX19	0.66	8.75	0.5	4.48e-16	Schizophrenia;
SARC	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg01570182	chr17:44337453	NA	0.84	9.48	0.53	3.08e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs12142240	0.698	rs41294458	chr1:46810304	T/C	cg10495392	chr1:46806563	NSUN4	0.64	6.76	0.4	1.09e-10	Menopause (age at onset);
SARC	cis	rs12586317	0.547	rs4982234	chr14:35460106	T/A	cg26967526	chr14:35346199	BAZ1A	-0.57	-5.71	-0.35	3.4e-8	Psoriasis;
SARC	cis	rs7246657	0.882	rs4803539	chr19:37897522	A/C	cg14683738	chr19:37701593	ZNF585B	0.49	4.76	0.3	3.42e-6	Coronary artery calcification;
SARC	cis	rs288326	0.561	rs77535302	chr2:183870045	T/A	cg09997497	chr2:183902928	NCKAP1	0.74	5.1	0.32	6.97e-7	Blood protein levels;
SARC	cis	rs12497850	1.000	rs12497850	chr3:48748989	G/T	cg07636037	chr3:49044803	WDR6	0.91	14.97	0.7	6.07e-36	Parkinson's disease;
SARC	cis	rs1691799	0.899	rs1168300	chr12:66736467	C/A	cg16791601	chr12:66731901	HELB	-0.71	-10.67	-0.57	6.75e-22	White blood cell count (basophil);
SARC	cis	rs8141529	0.529	rs16987024	chr22:29208975	A/G	cg02153584	chr22:29168773	CCDC117	0.65	6.65	0.4	2.02e-10	Lymphocyte counts;
SARC	cis	rs11608355	0.521	rs6606707	chr12:109830241	T/G	cg19025524	chr12:109796872	NA	-0.42	-6.21	-0.38	2.39e-9	Neuroticism;
SARC	cis	rs6831352	0.819	rs1230155	chr4:99989259	C/T	cg12011299	chr4:100065546	ADH4	0.28	4.97	0.31	1.29e-6	Alcohol dependence;
SARC	cis	rs1865760	0.865	rs9467648	chr6:25957933	T/A	cg18357526	chr6:26021779	HIST1H4A	0.4	4.92	0.31	1.63e-6	Height;
SARC	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg04277193	chr17:41438351	NA	0.44	4.86	0.3	2.18e-6	Menopause (age at onset);
SARC	cis	rs67311347	0.955	rs2123999	chr3:40378738	C/T	cg24209194	chr3:40518798	ZNF619	0.6	7.92	0.46	9.89e-14	Renal cell carcinoma;
SARC	cis	rs611744	0.573	rs629996	chr8:109255206	C/T	cg21045802	chr8:109455806	TTC35	0.63	8.42	0.48	3.81e-15	Dupuytren's disease;
SARC	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg15448220	chr1:150897856	SETDB1	0.47	6.25	0.38	1.94e-9	Tonsillectomy;
SARC	cis	rs2836974	0.583	rs2735307	chr21:40713358	C/T	cg17971929	chr21:40555470	PSMG1	0.62	8.14	0.47	2.43e-14	Cognitive function;
SARC	cis	rs6866344	0.570	rs1132338	chr5:178139442	T/G	cg10224037	chr5:178157518	ZNF354A	0.97	13.61	0.67	1.91e-31	Neutrophil percentage of white cells;
SARC	cis	rs9916302	0.706	rs8075737	chr17:37727316	C/T	cg20243544	chr17:37824526	PNMT	-0.57	-6.34	-0.38	1.15e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs4481887	0.962	rs4244177	chr1:248468279	C/T	cg00666640	chr1:248458726	OR2T12	0.38	6.42	0.39	7.43e-10	Common traits (Other);
SARC	cis	rs66573146	0.656	rs56094305	chr4:6956086	C/T	cg26116260	chr4:7069785	GRPEL1	-0.68	-5.02	-0.31	1.03e-6	Granulocyte percentage of myeloid white cells;
SARC	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	13.12	0.65	8.35e-30	Chronic sinus infection;
SARC	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.46	5.52	0.34	8.94e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs4689388	0.750	rs10001190	chr4:6284633	C/T	cg00701064	chr4:6280414	WFS1	-0.48	-7.15	-0.42	1.14e-11	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.64	-7.8	-0.46	2.04e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs3768617	0.811	rs10797828	chr1:183028430	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	7.93	0.46	9.16e-14	Fuchs's corneal dystrophy;
SARC	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg03806693	chr22:41940476	POLR3H	-0.8	-10.51	-0.57	2.14e-21	Vitiligo;
SARC	cis	rs1865760	0.516	rs9295684	chr6:26069669	T/C	cg16482183	chr6:26056742	HIST1H1C	0.47	6.05	0.37	5.65e-9	Height;
SARC	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg24531977	chr5:56204891	C5orf35	-0.56	-5.38	-0.33	1.8e-7	Type 2 diabetes;
SARC	cis	rs12472274	0.941	rs11677230	chr2:239092054	T/C	cg17459225	chr2:239074497	NA	0.63	7.85	0.46	1.54e-13	Phospholipid levels (plasma);
SARC	cis	rs6570726	0.837	rs636894	chr6:145864122	T/C	cg05220968	chr6:146057943	EPM2A	-0.29	-4.9	-0.31	1.82e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg24112000	chr20:60950667	NA	0.4	6.75	0.4	1.15e-10	Colorectal cancer;
SARC	cis	rs7937682	0.711	rs4938792	chr11:111420936	T/C	cg22437258	chr11:111473054	SIK2	-0.53	-6.77	-0.41	1.05e-10	Primary sclerosing cholangitis;
SARC	cis	rs73157695	0.927	rs9984088	chr21:47343695	T/C	cg00682050	chr21:47343716	PCBP3	-0.44	-5.07	-0.32	7.96e-7	Myopia;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg14290704	chr9:2015039	SMARCA2	-0.5	-6.49	-0.39	5.04e-10	Electrocardiographic conduction measures;
SARC	cis	rs1023500	0.506	rs6002625	chr22:42517689	A/G	cg04733989	chr22:42467013	NAGA	-0.74	-9.8	-0.54	3.28e-19	Schizophrenia;
SARC	cis	rs9640161	0.789	rs1464752	chr7:150021284	C/T	cg10018233	chr7:150070692	REPIN1	0.71	9.29	0.52	1.16e-17	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs10504073	0.584	rs62507210	chr8:49946601	C/T	cg00325661	chr8:49890786	NA	0.52	6.97	0.42	3.24e-11	Blood metabolite ratios;
SARC	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg02725872	chr8:58115012	NA	-0.34	-5.32	-0.33	2.46e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs7922314	0.571	rs61865719	chr10:64741119	C/T	cg25304107	chr2:177017331	HOXD4	-0.82	-6.43	-0.39	7.16e-10	Cutaneous psoriasis;
SARC	cis	rs1949733	1.000	rs1916326	chr4:8500023	G/A	cg13073564	chr4:8508604	NA	0.48	7.9	0.46	1.1e-13	Response to antineoplastic agents;
SARC	cis	rs80282103	0.867	rs7075830	chr10:1091650	G/C	cg08668510	chr10:1095578	IDI1	0.78	5.2	0.32	4.35e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs12079745	0.793	rs12073439	chr1:169284482	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.86	-6.01	-0.37	7.26e-9	QT interval;
SARC	cis	rs9787249	0.957	rs7518431	chr1:40214944	C/T	cg02773041	chr1:40204384	PPIE	-0.53	-6.48	-0.39	5.35e-10	Blood protein levels;
SARC	cis	rs9300255	0.722	rs34997336	chr12:123829116	G/A	cg00376283	chr12:123451042	ABCB9	-0.45	-4.75	-0.3	3.5e-6	Neutrophil percentage of white cells;
SARC	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	8.71	0.5	5.56e-16	Alzheimer's disease;
SARC	cis	rs453301	0.658	rs13271797	chr8:8885954	G/A	cg06636001	chr8:8085503	FLJ10661	-0.62	-8.56	-0.49	1.59e-15	Joint mobility (Beighton score);
SARC	cis	rs7474896	0.522	rs117157955	chr10:37984164	G/T	cg00409905	chr10:38381863	ZNF37A	-0.45	-4.73	-0.3	3.88e-6	Obesity (extreme);
SARC	cis	rs1957429	0.901	rs8008745	chr14:65351593	C/G	cg23373153	chr14:65346875	NA	1.1	11.74	0.61	2.63e-25	Pediatric areal bone mineral density (radius);
SARC	cis	rs9911578	0.935	rs9893351	chr17:57023326	G/A	cg05425664	chr17:57184151	TRIM37	-0.56	-6.85	-0.41	6.33e-11	Intelligence (multi-trait analysis);
SARC	cis	rs11098499	0.863	rs3775847	chr4:120447642	A/C	cg09307838	chr4:120376055	NA	0.91	12.31	0.63	3.63e-27	Corneal astigmatism;
SARC	cis	rs2204008	0.837	rs11169157	chr12:37980047	T/C	cg26384229	chr12:38710491	ALG10B	0.86	12.52	0.63	7.57e-28	Bladder cancer;
SARC	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.5e-10	Life satisfaction;
SARC	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg13072238	chr3:49761600	GMPPB	-0.44	-5.64	-0.35	4.84e-8	Intelligence (multi-trait analysis);
SARC	cis	rs1568889	0.548	rs34906813	chr11:28508819	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.65	6.53	0.39	4.06e-10	Bipolar disorder;
SARC	cis	rs7208859	0.673	rs11080138	chr17:29224542	A/G	cg13385521	chr17:29058706	SUZ12P	0.85	7.23	0.43	7.08e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs13191362	0.938	rs13213746	chr6:163167777	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.59	5.38	0.33	1.84e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9660992	0.508	rs113817010	chr1:205104581	C/A	cg21643547	chr1:205240462	TMCC2	-0.62	-8.45	-0.48	3.25e-15	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs739401	0.611	rs2301140	chr11:3022629	C/T	cg20651018	chr11:3035856	CARS	-0.39	-5.7	-0.35	3.56e-8	Longevity;
SARC	cis	rs7584330	0.744	rs10929234	chr2:238380034	C/G	cg14458575	chr2:238380390	NA	-0.58	-6.5	-0.39	4.72e-10	Prostate cancer;
SARC	cis	rs703842	0.575	rs701006	chr12:58106836	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.48	6.57	0.4	3.17e-10	Multiple sclerosis;
SARC	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg11742103	chr11:62369870	EML3;MTA2	-0.36	-4.81	-0.3	2.71e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs362272	0.545	rs2748447	chr4:3337831	G/A	cg08741688	chr4:3415352	RGS12	-0.49	-6.17	-0.37	3.04e-9	Serum sulfate level;
SARC	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg05313129	chr8:58192883	C8orf71	-0.48	-5.72	-0.35	3.18e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs607987	0.871	rs1933345	chr11:30279268	G/C	cg06241208	chr11:30344200	C11orf46	0.42	5.06	0.31	8.31e-7	Body mass index;
SARC	trans	rs629535	0.748	rs689410	chr8:70037558	G/A	cg21567404	chr3:27674614	NA	1.04	13.82	0.67	3.98e-32	Dupuytren's disease;
SARC	cis	rs708547	0.836	rs1612191	chr4:57724320	A/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.55	-5.85	-0.36	1.66e-8	Response to bleomycin (chromatid breaks);
SARC	cis	rs7927592	0.913	rs10896347	chr11:68353127	G/A	cg01657329	chr11:68192670	LRP5	-0.43	-5.11	-0.32	6.59e-7	Total body bone mineral density;
SARC	cis	rs1003719	0.788	rs2835602	chr21:38469069	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.63	9.05	0.51	5.67e-17	Eye color traits;
SARC	cis	rs7681440	0.904	rs6532193	chr4:90764188	G/A	cg06632027	chr4:90757378	SNCA	0.41	5.88	0.36	1.38e-8	Dementia with Lewy bodies;
SARC	cis	rs2276314	0.857	rs9960670	chr18:33577712	A/G	cg05985134	chr18:33552581	C18orf21	0.65	6.41	0.39	7.91e-10	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs12681366	0.592	rs2450556	chr8:95330332	A/C	cg26464482	chr8:95565502	KIAA1429	-0.46	-5.57	-0.34	7.06e-8	Nonsyndromic cleft lip with cleft palate;
SARC	trans	rs62103177	0.608	rs59300126	chr18:77694439	C/A	cg05926928	chr17:57297772	GDPD1	0.79	7.41	0.44	2.27e-12	Opioid sensitivity;
SARC	cis	rs17685	0.725	rs2302436	chr7:75676988	A/T	cg07335156	chr7:75947820	NA	-0.39	-4.72	-0.3	3.98e-6	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs7647973	0.710	rs6446285	chr3:49626306	G/A	cg13072238	chr3:49761600	GMPPB	-0.71	-5.81	-0.36	2.03e-8	Menarche (age at onset);
SARC	cis	rs798554	0.660	rs2644296	chr7:2859061	A/T	cg04166393	chr7:2884313	GNA12	0.42	5.25	0.33	3.4e-7	Height;
SARC	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg18876405	chr7:65276391	NA	-0.45	-4.94	-0.31	1.46e-6	Aortic root size;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg06870750	chr13:50018044	SETDB2;CAB39L	-0.45	-6.25	-0.38	1.92e-9	Schizophrenia;
SARC	cis	rs12960472	0.666	rs9962166	chr18:52235014	T/A	cg04730925	chr18:51795821	POLI	-0.46	-4.78	-0.3	3.14e-6	Positive affect;
SARC	cis	rs2242116	0.932	rs7646906	chr3:46949379	G/A	cg23352942	chr3:46931381	PTH1R	-0.33	-4.86	-0.3	2.17e-6	Birth weight;
SARC	cis	rs3733585	0.699	rs62294331	chr4:9959889	A/G	cg11266682	chr4:10021025	SLC2A9	-0.35	-6.03	-0.37	6.35e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg24829409	chr8:58192753	C8orf71	-0.62	-5.91	-0.36	1.2e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs870825	0.616	rs1401361	chr4:185643742	G/C	cg04058563	chr4:185651563	MLF1IP	0.81	11.5	0.6	1.55e-24	Blood protein levels;
SARC	cis	rs9840812	0.645	rs13068119	chr3:136206369	A/G	cg15507776	chr3:136538369	TMEM22	-0.55	-5.78	-0.35	2.36e-8	Fibrinogen levels;
SARC	cis	rs73086581	0.524	rs2253977	chr20:3939140	A/G	cg02187196	chr20:3869020	PANK2	-0.45	-5.28	-0.33	2.91e-7	Response to antidepressants in depression;
SARC	cis	rs7621025	0.500	rs4678275	chr3:136653683	C/T	cg15507776	chr3:136538369	TMEM22	0.93	10.75	0.58	3.82e-22	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
SARC	cis	rs6496044	0.591	rs979825	chr15:86080625	A/T	cg10818794	chr15:86012489	AKAP13	-0.39	-4.86	-0.3	2.18e-6	Interstitial lung disease;
SARC	cis	rs17376456	0.569	rs1026279	chr5:93209581	C/A	cg21475434	chr5:93447410	FAM172A	-0.66	-6.54	-0.39	3.76e-10	Diabetic retinopathy;
SARC	cis	rs12931792	0.846	rs9924308	chr16:30154740	C/T	cg17640201	chr16:30407289	ZNF48	-0.63	-8.17	-0.47	1.94e-14	Tonsillectomy;
SARC	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg04944784	chr2:26401820	FAM59B	-0.48	-5.97	-0.36	8.88e-9	Gut microbiome composition (summer);
SARC	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg11878867	chr6:150167359	LRP11	-0.34	-4.75	-0.3	3.64e-6	Lung cancer;
SARC	cis	rs73086581	0.680	rs11908158	chr20:3936672	G/T	cg02187196	chr20:3869020	PANK2	0.62	6.04	0.37	6.05e-9	Response to antidepressants in depression;
SARC	cis	rs365302	0.868	rs381639	chr6:159653635	C/G	cg14500486	chr6:159655392	FNDC1	-0.38	-4.8	-0.3	2.82e-6	Coronary heart disease;
SARC	cis	rs9325144	0.505	rs7138977	chr12:38642109	G/A	cg26384229	chr12:38710491	ALG10B	0.77	10.59	0.57	1.18e-21	Morning vs. evening chronotype;
SARC	cis	rs2976388	0.609	rs2585148	chr8:143796193	C/G	cg06565975	chr8:143823917	SLURP1	0.31	5.41	0.33	1.55e-7	Urinary tract infection frequency;
SARC	cis	rs96067	0.772	rs2231318	chr1:36602943	C/T	cg24686825	chr1:36642396	MAP7D1	-0.52	-5.94	-0.36	1.06e-8	Corneal structure;
SARC	cis	rs2425143	1.000	rs10485510	chr20:34445164	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	4.84	0.3	2.35e-6	Blood protein levels;
SARC	cis	rs9309473	0.687	rs10165862	chr2:73610743	C/T	cg20560298	chr2:73613845	ALMS1	-0.53	-6.78	-0.41	9.67e-11	Metabolite levels;
SARC	cis	rs8017423	0.740	rs7152196	chr14:90703900	G/T	cg20276874	chr14:90721474	PSMC1	-0.37	-5.18	-0.32	4.89e-7	Mortality in heart failure;
SARC	cis	rs7644634	0.649	rs9657914	chr3:105375132	A/G	cg23051926	chr3:105466016	CBLB	0.48	5.96	0.36	9.37e-9	Itch intensity from mosquito bite;
SARC	cis	rs548181	0.736	rs543389	chr11:125464841	A/G	cg03464685	chr11:125439445	EI24	1.08	10.02	0.55	7.14e-20	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg21782813	chr7:2030301	MAD1L1	0.35	5.3	0.33	2.68e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs67311347	0.822	rs9826847	chr3:40345312	A/T	cg24209194	chr3:40518798	ZNF619	0.53	6.8	0.41	8.77e-11	Renal cell carcinoma;
SARC	cis	rs9788721	0.900	rs72740964	chr15:78868636	G/A	cg18825076	chr15:78729989	IREB2	-0.43	-5.04	-0.31	9.16e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg09884257	chr4:6988322	TBC1D14	-0.63	-7.27	-0.43	5.36e-12	Brain volume in infants (cerebrospinal fluid);
SARC	trans	rs9888736	0.501	rs12903499	chr15:47911870	A/G	cg01357263	chr12:122459509	BCL7A	-0.49	-6.26	-0.38	1.82e-9	Body mass index;
SARC	cis	rs787274	1.000	rs4979154	chr9:115555031	A/G	cg13803584	chr9:115635662	SNX30	-0.83	-5.01	-0.31	1.08e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs8058578	1.000	rs2289442	chr16:30739919	A/G	cg00531865	chr16:30841666	NA	-0.5	-5.86	-0.36	1.55e-8	Multiple myeloma;
SARC	cis	rs910316	1.000	rs10146482	chr14:75574087	C/T	cg06637938	chr14:75390232	RPS6KL1	0.51	7.39	0.44	2.65e-12	Height;
SARC	cis	rs7819412	0.668	rs920047	chr8:11087475	C/T	cg21775007	chr8:11205619	TDH	-0.51	-6.42	-0.39	7.73e-10	Triglycerides;
SARC	cis	rs6912958	0.558	rs7741825	chr6:88327338	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.28	-4.85	-0.3	2.25e-6	Monocyte percentage of white cells;
SARC	cis	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg05623727	chr3:50126028	RBM5	-0.35	-5.1	-0.32	7.18e-7	Body mass index;
SARC	cis	rs7481584	0.581	rs515481	chr11:3047184	A/G	cg20651018	chr11:3035856	CARS	0.41	6.08	0.37	4.91e-9	Calcium levels;
SARC	cis	rs7824557	0.767	rs10104728	chr8:11171300	A/G	cg21775007	chr8:11205619	TDH	0.53	6.3	0.38	1.48e-9	Retinal vascular caliber;
SARC	cis	rs2153535	0.580	rs6921036	chr6:8455400	G/A	cg23788917	chr6:8435910	SLC35B3	0.64	8.42	0.48	3.99e-15	Motion sickness;
SARC	cis	rs3796352	1.000	rs36090694	chr3:53010742	T/C	cg12962167	chr3:53033115	SFMBT1	0.81	5.21	0.32	4.08e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs11098499	0.909	rs7681214	chr4:120385320	C/A	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs6696846	0.740	rs11240369	chr1:205115099	G/A	cg21643547	chr1:205240462	TMCC2	-0.59	-8.04	-0.47	4.56e-14	Red blood cell count;
SARC	cis	rs7223966	0.883	rs2955250	chr17:61959740	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.52	-5.59	-0.34	6.24e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.35	-4.78	-0.3	3.1e-6	Personality dimensions;
SARC	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9902453	1.000	rs7223786	chr17:28332107	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.52	-6.74	-0.4	1.21e-10	Coffee consumption (cups per day);
SARC	cis	rs1185460	1.000	rs1185460	chr11:118943433	C/T	cg23280166	chr11:118938394	VPS11	-0.7	-8.88	-0.5	1.81e-16	Coronary artery disease;
SARC	cis	rs2342371	0.599	rs7618690	chr3:196146039	T/C	cg15048948	chr3:196158458	UBXN7	0.62	7.46	0.44	1.67e-12	Fat distribution (HIV);
SARC	cis	rs796364	0.806	rs74771155	chr2:200913743	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-6.62	-0.4	2.51e-10	Schizophrenia;
SARC	cis	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg08045932	chr20:61659980	NA	0.49	6.75	0.4	1.13e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg13939156	chr17:80058883	NA	-0.41	-6.22	-0.38	2.27e-9	Life satisfaction;
SARC	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg21782813	chr7:2030301	MAD1L1	0.31	4.78	0.3	3.09e-6	Schizophrenia;
SARC	cis	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg24110177	chr3:50126178	RBM5	0.58	7.91	0.46	1.04e-13	Intelligence (multi-trait analysis);
SARC	cis	rs6860806	0.507	rs270615	chr5:131641573	G/C	cg11843238	chr5:131593191	PDLIM4	0.39	4.73	0.3	3.97e-6	Breast cancer;
SARC	cis	rs1008375	0.966	rs6825133	chr4:17577776	C/T	cg16339924	chr4:17578868	LAP3	0.69	9.17	0.51	2.59e-17	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1568889	0.641	rs34857148	chr11:28481976	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.7	8.29	0.48	9.01e-15	Bipolar disorder;
SARC	cis	rs35306767	0.903	rs11253475	chr10:907262	C/A	cg20503657	chr10:835505	NA	0.87	8.18	0.47	1.8e-14	Eosinophil percentage of granulocytes;
SARC	cis	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg00800038	chr16:89945340	TCF25	-0.74	-5.08	-0.32	7.86e-7	Skin colour saturation;
SARC	cis	rs9910055	0.502	rs1684662	chr17:42180822	T/A	cg19774624	chr17:42201019	HDAC5	0.55	6.63	0.4	2.34e-10	Total body bone mineral density;
SARC	cis	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg22857025	chr5:266934	NA	-1.06	-11.63	-0.61	5.91e-25	Breast cancer;
SARC	cis	rs55665837	0.583	rs78843135	chr11:14411254	T/G	cg19336497	chr11:14380999	RRAS2	-0.33	-5.69	-0.35	3.82e-8	Vitamin D levels;
SARC	cis	rs3768617	0.510	rs10752904	chr1:183101038	A/G	cg13390022	chr1:182993471	LAMC1	0.31	4.79	0.3	3.01e-6	Fuchs's corneal dystrophy;
SARC	cis	rs2549003	0.966	rs2706386	chr5:131832687	C/T	cg21138405	chr5:131827807	IRF1	-0.29	-5.81	-0.36	2.02e-8	Asthma (sex interaction);
SARC	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg04277193	chr17:41438351	NA	0.45	4.93	0.31	1.59e-6	Menopause (age at onset);
SARC	cis	rs4268898	0.662	rs59996104	chr2:24404064	C/T	cg06627628	chr2:24431161	ITSN2	-0.8	-9.58	-0.53	1.49e-18	Asthma;
SARC	cis	rs6867032	1.000	rs7729761	chr5:2015783	G/T	cg26168224	chr5:2018326	NA	0.92	14.86	0.7	1.4e-35	Gut microbiome composition (winter);
SARC	cis	rs3820928	1.000	rs3820927	chr2:227779191	C/A	cg05526886	chr2:227700861	RHBDD1	-0.53	-6.28	-0.38	1.64e-9	Pulmonary function;
SARC	cis	rs8063160	0.799	rs1805007	chr16:89986117	A/G	cg06173319	chr16:90148775	NA	0.82	4.77	0.3	3.32e-6	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
SARC	cis	rs9399135	0.816	rs4134030	chr6:135354094	G/T	cg22676075	chr6:135203613	NA	0.34	4.76	0.3	3.41e-6	Red blood cell count;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg06719391	chr11:2554330	KCNQ1	-0.57	-6.56	-0.39	3.48e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	5.63	0.35	5.07e-8	Bipolar disorder;
SARC	cis	rs13144136	0.786	rs4309833	chr4:10666766	C/T	cg10242279	chr4:10666415	CLNK	0.34	5.32	0.33	2.4e-7	Resistance to antihypertensive treatment in hypertension;
SARC	cis	rs765787	0.530	rs11070451	chr15:45533541	T/C	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.51e-10	Uric acid levels;
SARC	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg16479474	chr6:28041457	NA	0.36	5.27	0.33	3.04e-7	Depression;
SARC	cis	rs7762018	0.556	rs80250989	chr6:170105553	T/C	cg19338460	chr6:170058176	WDR27	-0.76	-5.36	-0.33	2.02e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs3135718	0.967	rs1219648	chr10:123346190	A/G	cg09772154	chr10:123358284	FGFR2	-0.33	-4.73	-0.3	3.82e-6	Estrogen receptor status in breast cancer;
SARC	cis	rs497273	0.511	rs1151862	chr12:121331285	G/A	cg02403541	chr12:121454288	C12orf43	-0.41	-4.92	-0.31	1.63e-6	Systemic lupus erythematosus;
SARC	cis	rs986417	0.892	rs78026410	chr14:60801142	G/A	cg27398547	chr14:60952738	C14orf39	-1.08	-8.94	-0.51	1.21e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.06	15.83	0.72	8.2e-39	Height;
SARC	cis	rs7481584	0.669	rs12421922	chr11:3035070	A/G	cg25174290	chr11:3078921	CARS	-0.54	-7.49	-0.44	1.44e-12	Calcium levels;
SARC	cis	rs9325144	0.647	rs34963631	chr12:38912260	T/A	cg13010199	chr12:38710504	ALG10B	-0.46	-5.89	-0.36	1.33e-8	Morning vs. evening chronotype;
SARC	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg16680214	chr1:154839983	KCNN3	0.31	4.96	0.31	1.36e-6	Schizophrenia;
SARC	cis	rs9325144	0.555	rs7301258	chr12:38706942	C/T	cg26384229	chr12:38710491	ALG10B	0.62	8.2	0.47	1.59e-14	Morning vs. evening chronotype;
SARC	cis	rs12971120	0.891	rs12608037	chr18:72169395	A/G	cg26446133	chr18:72167187	CNDP2	-0.51	-7.2	-0.43	8.28e-12	Refractive error;
SARC	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg17294928	chr15:75287854	SCAMP5	-0.5	-6.45	-0.39	6.3e-10	Breast cancer;
SARC	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg12463550	chr7:65579703	CRCP	-0.49	-5.36	-0.33	1.98e-7	Aortic root size;
SARC	cis	rs155076	0.938	rs9509630	chr13:21844314	G/A	cg11317459	chr13:21872234	NA	-0.98	-12.36	-0.63	2.52e-27	White matter hyperintensity burden;
SARC	cis	rs637571	0.522	rs550435	chr11:65732651	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.42	-5.23	-0.32	3.77e-7	Eosinophil percentage of white cells;
SARC	cis	rs36051895	0.695	rs10974922	chr9:5028813	C/T	cg02405213	chr9:5042618	JAK2	-0.54	-6.29	-0.38	1.59e-9	Pediatric autoimmune diseases;
SARC	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg03452623	chr4:187889614	NA	-0.78	-11.76	-0.61	2.21e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1355223	0.902	rs7121272	chr11:34752562	T/G	cg18508148	chr11:34937573	PDHX;APIP	-0.4	-5.07	-0.32	8.17e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs2735413	0.918	rs11643649	chr16:78081199	T/C	cg04733911	chr16:78082701	NA	-0.3	-5.47	-0.34	1.14e-7	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs4481887	0.927	rs6689193	chr1:248482900	T/A	cg13385794	chr1:248469461	NA	0.33	5.09	0.32	7.48e-7	Common traits (Other);
SARC	cis	rs9486719	0.843	rs2499787	chr6:96841762	G/C	cg06623918	chr6:96969491	KIAA0776	0.76	7.42	0.44	2.23e-12	Migraine;Coronary artery disease;
SARC	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg26335602	chr6:28129616	ZNF389	0.52	5.84	0.36	1.75e-8	Depression;
SARC	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg06634786	chr22:41940651	POLR3H	-0.57	-6.7	-0.4	1.57e-10	Vitiligo;
SARC	cis	rs3096299	0.582	rs12935119	chr16:89542874	A/T	cg00750074	chr16:89608354	SPG7	-0.35	-5.41	-0.33	1.57e-7	Multiple myeloma (IgH translocation);
SARC	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg11890956	chr21:40555474	PSMG1	1.17	19.44	0.79	1.14e-50	Cognitive function;
SARC	cis	rs3782089	0.546	rs76146604	chr11:65277512	G/T	cg00206168	chr11:65308501	LTBP3	0.91	5.55	0.34	7.64e-8	Height;
SARC	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg23758822	chr17:41437982	NA	0.84	11.14	0.59	2.14e-23	Menopause (age at onset);
SARC	cis	rs4481887	1.000	rs10888358	chr1:248471467	C/A	cg13385794	chr1:248469461	NA	0.36	5.46	0.34	1.19e-7	Common traits (Other);
SARC	cis	rs9487051	0.714	rs9386797	chr6:109632520	C/A	cg01475377	chr6:109611718	NA	-0.37	-5.35	-0.33	2.1e-7	Reticulocyte fraction of red cells;
SARC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg03647317	chr4:187891568	NA	-0.35	-4.94	-0.31	1.46e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs765787	0.505	rs12593605	chr15:45497448	T/A	cg24006582	chr15:45444508	DUOX1	0.53	6.69	0.4	1.61e-10	Uric acid levels;
SARC	cis	rs950027	0.620	rs1145076	chr15:45684508	G/T	cg15395560	chr15:45543142	SLC28A2	-0.27	-5.25	-0.33	3.45e-7	Response to fenofibrate (adiponectin levels);
SARC	cis	rs4619890	0.510	rs7687428	chr4:7889487	T/C	cg18538662	chr4:7941764	AFAP1	-0.42	-5.42	-0.33	1.47e-7	Glaucoma (primary open-angle);
SARC	cis	rs4555082	0.874	rs11622166	chr14:105759763	C/A	cg10792982	chr14:105748885	BRF1	0.57	8.34	0.48	6.72e-15	Mean platelet volume;Platelet distribution width;
SARC	cis	rs1943345	0.556	rs528703	chr11:82926035	G/A	cg07047830	chr11:82868014	PCF11	0.46	5.78	0.35	2.44e-8	Obesity-related traits;
SARC	trans	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg21775007	chr8:11205619	TDH	0.51	6.27	0.38	1.72e-9	Neuroticism;
SARC	cis	rs11098499	0.863	rs7695620	chr4:120452776	G/A	cg09307838	chr4:120376055	NA	0.91	12.31	0.63	3.63e-27	Corneal astigmatism;
SARC	trans	rs9929218	1.000	rs11865026	chr16:68774283	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.62	-8.08	-0.47	3.51e-14	Colorectal cancer;
SARC	cis	rs763121	0.819	rs138700	chr22:39129999	A/G	cg21395723	chr22:39101663	GTPBP1	0.57	6.76	0.4	1.09e-10	Menopause (age at onset);
SARC	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg06108461	chr20:60628389	TAF4	-0.88	-10.85	-0.58	1.77e-22	Body mass index;
SARC	cis	rs2933343	0.553	rs789212	chr3:128686912	A/C	cg25356066	chr3:128598488	ACAD9	0.61	7.63	0.45	5.97e-13	IgG glycosylation;
SARC	cis	rs3106136	0.843	rs1426575	chr4:95260069	G/C	cg11021082	chr4:95130006	SMARCAD1	0.35	5.38	0.33	1.83e-7	Capecitabine sensitivity;
SARC	cis	rs12681288	0.676	rs2701901	chr8:1017816	G/C	cg15309053	chr8:964076	NA	0.45	7.25	0.43	5.92e-12	Schizophrenia;
SARC	cis	rs554111	0.656	rs10916930	chr1:21395357	C/T	cg04902671	chr1:21058625	SH2D5	-0.42	-5.1	-0.32	6.92e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs9858542	0.953	rs67216675	chr3:49493151	G/T	cg07274523	chr3:49395745	GPX1	0.53	6.1	0.37	4.27e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs7666738	0.791	rs2865958	chr4:99040732	G/T	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs362272	0.545	rs2749782	chr4:3339761	A/G	cg08741688	chr4:3415352	RGS12	-0.53	-6.87	-0.41	5.97e-11	Serum sulfate level;
SARC	cis	rs1059312	0.966	rs12370194	chr12:129277250	A/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.47	-5.86	-0.36	1.57e-8	Systemic lupus erythematosus;
SARC	cis	rs2072499	0.750	rs909269	chr1:156192028	C/T	cg25208724	chr1:156163844	SLC25A44	0.74	7.93	0.46	8.92e-14	Testicular germ cell tumor;
SARC	cis	rs899997	1.000	rs7182993	chr15:79045014	G/A	cg04896959	chr15:78267971	NA	0.45	5.38	0.33	1.77e-7	Coronary artery disease or large artery stroke;
SARC	cis	rs9462027	0.628	rs2744944	chr6:34658080	A/C	cg07306190	chr6:34760872	UHRF1BP1	0.42	6.01	0.37	7.1e-9	Systemic lupus erythematosus;
SARC	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg04267008	chr7:1944627	MAD1L1	-0.5	-5.3	-0.33	2.63e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs11871801	0.517	rs665268	chr17:40722029	A/G	cg20126647	chr17:40714003	COASY	0.52	5.68	0.35	3.94e-8	Crohn's disease;
SARC	cis	rs2153535	0.580	rs4960433	chr6:8523697	A/G	cg21535247	chr6:8435926	SLC35B3	0.53	6.77	0.41	1.03e-10	Motion sickness;
SARC	cis	rs1008375	0.897	rs3733577	chr4:17649233	T/G	cg02297831	chr4:17616191	MED28	0.49	6.36	0.38	1.04e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs607987	0.871	rs4359180	chr11:30303443	C/T	cg06241208	chr11:30344200	C11orf46	-0.42	-4.97	-0.31	1.28e-6	Body mass index;
SARC	cis	rs7647973	0.626	rs9824435	chr3:49674343	A/G	cg13072238	chr3:49761600	GMPPB	0.62	6.03	0.37	6.24e-9	Menarche (age at onset);
SARC	cis	rs6582630	0.539	rs8189604	chr12:38308546	G/T	cg26384229	chr12:38710491	ALG10B	-0.6	-7.47	-0.44	1.6e-12	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7246657	0.882	rs6508719	chr19:37877419	A/G	cg23950597	chr19:37808831	NA	-0.56	-5.69	-0.35	3.84e-8	Coronary artery calcification;
SARC	cis	rs3936840	0.752	rs2181343	chr14:102993303	A/C	cg18135206	chr14:102964638	TECPR2	-0.53	-7.22	-0.43	7.46e-12	Plateletcrit;
SARC	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg00825309	chr19:58991885	ZNF446	-0.55	-7.76	-0.45	2.73e-13	Uric acid clearance;
SARC	cis	rs796364	0.806	rs76112266	chr2:201087157	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-6.43	-0.39	7.06e-10	Schizophrenia;
SARC	cis	rs9858542	0.953	rs6779524	chr3:49450449	C/T	cg07274523	chr3:49395745	GPX1	0.53	6.26	0.38	1.84e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs2282802	0.617	rs10477348	chr5:139666906	A/T	cg26211634	chr5:139558579	C5orf32	0.38	4.83	0.3	2.46e-6	Intelligence (multi-trait analysis);
SARC	cis	rs17376456	0.569	rs11948511	chr5:93286601	A/C	cg21475434	chr5:93447410	FAM172A	-0.59	-6.29	-0.38	1.52e-9	Diabetic retinopathy;
SARC	cis	rs6831352	0.918	rs34936974	chr4:100052384	A/G	cg12011299	chr4:100065546	ADH4	0.31	5.3	0.33	2.66e-7	Alcohol dependence;
SARC	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg20607798	chr8:58055168	NA	0.56	5.43	0.34	1.4e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs11122272	0.705	rs2486742	chr1:231507254	G/A	cg06096015	chr1:231504339	EGLN1	0.38	5.75	0.35	2.76e-8	Hemoglobin concentration;
SARC	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg26335602	chr6:28129616	ZNF389	0.5	5.32	0.33	2.45e-7	Parkinson's disease;
SARC	cis	rs9715521	0.867	rs6840137	chr4:59830872	A/G	cg11281224	chr4:60001000	NA	-0.39	-5.02	-0.31	1.01e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs2933343	0.553	rs35979399	chr3:128697313	G/A	cg24203234	chr3:128598194	ACAD9	0.48	5.65	0.35	4.76e-8	IgG glycosylation;
SARC	cis	rs11098499	0.954	rs3733519	chr4:120423448	A/G	cg09307838	chr4:120376055	NA	0.93	12.73	0.64	1.6e-28	Corneal astigmatism;
SARC	cis	rs8027181	0.839	rs4777532	chr15:73041767	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	0.42	5.61	0.34	5.73e-8	Triglyceride levels;
SARC	cis	rs995000	0.868	rs6682423	chr1:63171063	C/T	cg06896770	chr1:63153194	DOCK7	-0.85	-12.94	-0.65	3.09e-29	Triglyceride levels;
SARC	cis	rs7000551	0.527	rs11783730	chr8:22244897	C/T	cg12081754	chr8:22256438	SLC39A14	0.84	11.4	0.6	3.35e-24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg18252515	chr7:66147081	NA	-0.48	-5.24	-0.32	3.55e-7	Aortic root size;
SARC	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg18230493	chr5:56204884	C5orf35	0.6	5.45	0.34	1.3e-7	Initial pursuit acceleration;
SARC	cis	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg08975724	chr8:8085496	FLJ10661	0.5	6.3	0.38	1.5e-9	Mood instability;
SARC	cis	rs57561814	0.510	rs1524107	chr7:22768219	C/T	cg26061582	chr7:22766209	IL6	1.16	9.48	0.53	2.99e-18	Tonsillectomy;
SARC	cis	rs6665290	0.904	rs1045286	chr1:227179037	A/C	cg10327440	chr1:227177885	CDC42BPA	1.07	23.46	0.84	2.82e-63	Myeloid white cell count;
SARC	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.59	5.18	0.32	4.85e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs9611519	0.590	rs4821980	chr22:41415479	C/G	cg06634786	chr22:41940651	POLR3H	-0.38	-4.9	-0.31	1.8e-6	Neuroticism;
SARC	cis	rs9513627	0.834	rs73556197	chr13:100128479	A/G	cg25919922	chr13:100150906	NA	-0.64	-4.81	-0.3	2.66e-6	Obesity-related traits;
SARC	cis	rs7647973	0.731	rs7617480	chr3:49210732	G/T	cg06212747	chr3:49208901	KLHDC8B	-0.8	-8.58	-0.49	1.35e-15	Menarche (age at onset);
SARC	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.75	10.93	0.58	9.87e-23	Personality dimensions;
SARC	cis	rs6060717	0.536	rs11697851	chr20:34524494	T/C	cg01084648	chr20:34329383	RBM39	0.63	4.75	0.3	3.54e-6	Hip circumference adjusted for BMI;
SARC	cis	rs710216	0.917	rs1681859	chr1:43411829	G/A	cg07803811	chr1:43423981	SLC2A1	0.54	5.29	0.33	2.88e-7	Red cell distribution width;
SARC	cis	rs4660306	0.677	rs1691217	chr1:45900190	T/C	cg24296786	chr1:45957014	TESK2	-0.49	-4.82	-0.3	2.57e-6	Homocysteine levels;
SARC	cis	rs7681440	0.606	rs2028535	chr4:90756421	C/G	cg06632027	chr4:90757378	SNCA	0.45	5.74	0.35	3.01e-8	Dementia with Lewy bodies;
SARC	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg05861140	chr6:150128134	PCMT1	-0.44	-5.72	-0.35	3.18e-8	Lung cancer;
SARC	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg08280861	chr8:58055591	NA	0.7	6.12	0.37	3.95e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs3857067	0.806	rs7654565	chr4:95112939	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.05	-0.31	8.98e-7	QT interval;
SARC	cis	rs1421811	0.532	rs72740626	chr5:32692220	G/C	cg16267343	chr5:32710456	NPR3	0.84	11.11	0.59	2.72e-23	Blood pressure;
SARC	cis	rs3762637	1.000	rs76599189	chr3:122124076	G/A	cg24169773	chr3:122142474	KPNA1	-0.58	-5.88	-0.36	1.39e-8	LDL cholesterol levels;
SARC	cis	rs912057	0.526	rs746453	chr6:6734221	C/A	cg06612196	chr6:6737390	NA	0.72	11.94	0.62	6.06e-26	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.92	-13.3	-0.66	2.16e-30	Chronic sinus infection;
SARC	cis	rs6545883	0.929	rs1186710	chr2:61688727	T/A	cg15711740	chr2:61764176	XPO1	-0.43	-5.07	-0.32	8.11e-7	Tuberculosis;
SARC	cis	rs12142240	0.698	rs6695043	chr1:46844530	A/G	cg10495392	chr1:46806563	NSUN4	-0.65	-6.9	-0.41	5e-11	Menopause (age at onset);
SARC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg05863683	chr7:1912471	MAD1L1	0.35	5.31	0.33	2.57e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs2084898	0.506	rs488672	chr11:120047745	A/G	cg07435449	chr11:120005650	TRIM29	-0.34	-5.46	-0.34	1.24e-7	Stroke (pediatric);
SARC	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg26677194	chr12:130822605	PIWIL1	0.55	7.58	0.44	8.36e-13	Menopause (age at onset);
SARC	cis	rs722599	0.748	rs3742783	chr14:75377008	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.39	-4.88	-0.3	1.98e-6	IgG glycosylation;
SARC	trans	rs2396442	1.000	rs2256819	chr6:45418402	A/G	cg12950624	chr19:46000154	RTN2	-0.55	-6.32	-0.38	1.32e-9	Left ventricle wall thickness;
SARC	cis	rs951366	0.531	rs12030754	chr1:205678043	G/C	cg11965913	chr1:205819406	PM20D1	-0.49	-5.53	-0.34	8.41e-8	Menarche (age at onset);
SARC	cis	rs6693567	0.545	rs1694380	chr1:150292341	A/G	cg09579323	chr1:150459698	TARS2	0.42	5.33	0.33	2.27e-7	Migraine;
SARC	cis	rs7546668	0.640	rs6675825	chr1:15811346	C/T	cg18192808	chr1:15853278	DNAJC16	0.43	5.04	0.31	9.55e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs2721811	0.738	rs2521755	chr7:24749223	T/C	cg17569154	chr7:24781545	DFNA5	0.45	6.28	0.38	1.63e-9	Depressive symptoms (multi-trait analysis);
SARC	cis	rs2072499	0.750	rs10159384	chr1:156160822	C/T	cg24450063	chr1:156163899	SLC25A44	1.09	14.4	0.69	4.79e-34	Testicular germ cell tumor;
SARC	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.74	-10.1	-0.55	4.1e-20	Homoarginine levels;
SARC	cis	rs11971779	0.585	rs3922848	chr7:139046210	T/C	cg23387468	chr7:139079360	LUC7L2	0.33	4.71	0.3	4.2e-6	Diisocyanate-induced asthma;
SARC	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg00684032	chr4:1343700	KIAA1530	0.37	5.27	0.33	3.05e-7	Obesity-related traits;
SARC	cis	rs11997175	0.624	rs7016783	chr8:33696831	A/G	ch.8.33884649F	chr8:33765107	NA	0.64	8.73	0.5	5.12e-16	Body mass index;
SARC	cis	rs9325144	0.671	rs12818797	chr12:39019409	A/G	cg26384229	chr12:38710491	ALG10B	-0.62	-8.05	-0.47	4.23e-14	Morning vs. evening chronotype;
SARC	cis	rs7412746	0.611	rs1889741	chr1:150869045	T/C	cg10589385	chr1:150898437	SETDB1	0.4	5.38	0.33	1.8e-7	Melanoma;
SARC	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg24060327	chr5:131705240	SLC22A5	0.73	8.7	0.5	6.08e-16	Breast cancer;
SARC	cis	rs9660992	0.573	rs1172158	chr1:205208948	G/A	cg07972983	chr1:205091412	RBBP5	0.57	7.02	0.42	2.35e-11	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs3857067	0.836	rs12501138	chr4:95098444	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.07	-0.32	8.24e-7	QT interval;
SARC	cis	rs654950	0.934	rs653369	chr1:42002376	A/T	cg06885757	chr1:42089581	HIVEP3	-0.44	-6.22	-0.38	2.27e-9	Airway imaging phenotypes;
SARC	cis	rs2180341	1.000	rs4895822	chr6:127642703	T/C	cg24812749	chr6:127587940	RNF146	0.98	12.95	0.65	2.92e-29	Breast cancer;
SARC	cis	rs6963495	0.745	rs73192152	chr7:105212258	A/C	cg19920283	chr7:105172520	RINT1	0.68	5.77	0.35	2.46e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs7937682	0.961	rs552387	chr11:111490047	T/G	cg09085632	chr11:111637200	PPP2R1B	-0.93	-15.25	-0.71	7.22e-37	Primary sclerosing cholangitis;
SARC	cis	rs6580649	0.941	rs57054831	chr12:48486892	C/T	cg24011408	chr12:48396354	COL2A1	-0.47	-5.38	-0.33	1.78e-7	Lung cancer;
SARC	trans	rs9354352	1.000	rs9354352	chr6:66696272	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.59	7.7	0.45	3.76e-13	Initial pursuit acceleration in psychotic disorders;
SARC	cis	rs10512697	0.803	rs35056798	chr5:3575747	A/G	cg19473799	chr5:3511975	NA	-0.66	-4.86	-0.3	2.16e-6	Immune response to smallpox vaccine (IL-6);
SARC	cis	rs17376456	0.877	rs66696214	chr5:93424533	G/A	cg21475434	chr5:93447410	FAM172A	0.86	7.71	0.45	3.65e-13	Diabetic retinopathy;
SARC	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg18252515	chr7:66147081	NA	-1.34	-11.85	-0.61	1.15e-25	Diabetic kidney disease;
SARC	cis	rs6430585	0.528	rs75667274	chr2:136682486	C/T	cg07169764	chr2:136633963	MCM6	1.05	12.93	0.65	3.43e-29	Corneal structure;
SARC	cis	rs7681440	0.904	rs2301134	chr4:90758945	A/G	cg06632027	chr4:90757378	SNCA	0.42	6.07	0.37	5.2e-9	Dementia with Lewy bodies;
SARC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg01577475	chr2:114033581	PAX8;LOC440839	-0.35	-5.26	-0.33	3.3e-7	Lymphocyte counts;
SARC	cis	rs17401966	1.000	rs35766535	chr1:10284659	T/C	cg15208524	chr1:10270712	KIF1B	0.58	6.65	0.4	2.1e-10	Hepatocellular carcinoma;
SARC	cis	rs709400	0.628	rs7155014	chr14:103863970	C/G	cg26031613	chr14:104095156	KLC1	0.78	11.14	0.59	2.15e-23	Body mass index;
SARC	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg02592271	chr2:27665507	KRTCAP3	-0.41	-6.56	-0.39	3.44e-10	Total body bone mineral density;
SARC	cis	rs7944584	0.563	rs2280231	chr11:47600438	C/T	cg20307385	chr11:47447363	PSMC3	0.71	9.14	0.51	3.21e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs2073300	0.609	rs6137937	chr20:23385419	G/A	cg12062639	chr20:23401060	NAPB	1.02	6.94	0.41	3.78e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg24399712	chr22:39784796	NA	-0.41	-5.44	-0.34	1.34e-7	Intelligence (multi-trait analysis);
SARC	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.43	0.44	1.98e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9486715	0.825	rs211158	chr6:97022938	C/G	cg18709589	chr6:96969512	KIAA0776	-0.57	-7.25	-0.43	6.22e-12	Headache;
SARC	cis	rs4919694	0.572	rs12262258	chr10:104900272	G/A	cg04362960	chr10:104952993	NT5C2	0.58	5.29	0.33	2.79e-7	Arsenic metabolism;
SARC	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg08219700	chr8:58056026	NA	0.6	5.71	0.35	3.49e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs13144136	0.687	rs6850317	chr4:10664294	T/C	cg10242279	chr4:10666415	CLNK	-0.43	-6.99	-0.42	2.83e-11	Resistance to antihypertensive treatment in hypertension;
SARC	cis	rs2645694	0.626	rs2703122	chr4:77821418	A/C	cg10057126	chr4:77819792	ANKRD56	0.44	6.58	0.4	3.1e-10	Emphysema distribution in smoking;
SARC	cis	rs2730245	0.851	rs2657333	chr7:158728743	G/A	cg00815399	chr7:158750607	NA	-0.35	-4.85	-0.3	2.24e-6	Height;
SARC	trans	rs9354308	0.867	rs2802051	chr6:66536403	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.58	6.74	0.4	1.23e-10	Metabolite levels;
SARC	cis	rs7520050	0.966	rs12409773	chr1:46358831	A/G	cg06784218	chr1:46089804	CCDC17	-0.26	-4.89	-0.31	1.85e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs6570726	0.791	rs370112	chr6:145859853	T/G	cg05347473	chr6:146136440	FBXO30	0.54	7.45	0.44	1.8e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg14517863	chr17:44321492	NA	0.4	6.05	0.37	5.77e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs6424115	0.830	rs2503000	chr1:24197898	C/G	cg15997130	chr1:24165203	NA	0.41	5.51	0.34	9.33e-8	Immature fraction of reticulocytes;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg00887444	chr13:31248228	NA	0.49	6.48	0.39	5.5e-10	Lung adenocarcinoma;
SARC	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg02018176	chr4:1364513	KIAA1530	0.33	4.89	0.31	1.88e-6	Longevity;
SARC	cis	rs7589342	0.894	rs6736932	chr2:106444854	A/G	cg16077055	chr2:106428750	NCK2	0.4	7.5	0.44	1.36e-12	Addiction;
SARC	cis	rs7216064	1.000	rs56404791	chr17:65893019	T/G	cg12091567	chr17:66097778	LOC651250	-0.75	-8.29	-0.48	9.02e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs72781680	0.898	rs56303870	chr2:24086944	G/A	cg06627628	chr2:24431161	ITSN2	-0.65	-6.37	-0.39	9.72e-10	Lymphocyte counts;
SARC	cis	rs9815354	1.000	rs9830064	chr3:41881801	T/C	cg03022575	chr3:42003672	ULK4	0.56	5.32	0.33	2.44e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs950169	0.922	rs4338765	chr15:84916836	G/T	cg24253500	chr15:84953950	NA	0.37	5.33	0.33	2.33e-7	Schizophrenia;
SARC	cis	rs7666738	0.962	rs2865950	chr4:99040061	T/C	cg05340658	chr4:99064831	C4orf37	0.57	7.16	0.42	1.02e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1150668	0.796	rs9468372	chr6:28379361	T/A	cg13525197	chr6:28411240	ZSCAN23	-0.44	-5.45	-0.34	1.25e-7	Pubertal anthropometrics;
SARC	cis	rs911555	0.504	rs745079	chr14:104073551	G/A	cg17925084	chr14:104152323	KLC1	0.38	5.33	0.33	2.37e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1008375	0.900	rs4698622	chr4:17589557	C/T	cg02297831	chr4:17616191	MED28	0.46	5.61	0.34	5.71e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs365132	0.875	rs353479	chr5:176372593	C/T	cg16309518	chr5:176445507	NA	-0.46	-5.68	-0.35	3.96e-8	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs9400467	0.506	rs10456872	chr6:111586667	C/T	cg15721981	chr6:111408429	SLC16A10	0.67	5.6	0.34	5.87e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs1018836	0.847	rs35409073	chr8:91648036	G/T	cg16814680	chr8:91681699	NA	-0.86	-14.16	-0.68	2.94e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs6963495	0.818	rs6955796	chr7:105170321	T/G	cg19920283	chr7:105172520	RINT1	0.67	5.76	0.35	2.59e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs6570726	0.902	rs396681	chr6:145853603	T/C	cg05347473	chr6:146136440	FBXO30	0.49	6.57	0.4	3.24e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs55692411	0.517	rs13095697	chr3:50136463	G/A	cg14019146	chr3:50243930	SLC38A3	-0.34	-4.83	-0.3	2.52e-6	Intelligence (multi-trait analysis);
SARC	cis	rs13401104	0.716	rs6737755	chr2:237125171	A/G	cg19324714	chr2:237145437	ASB18	0.55	6.45	0.39	6.57e-10	Educational attainment;
SARC	cis	rs9325144	0.510	rs6582599	chr12:38715965	T/G	cg04568710	chr12:38710424	ALG10B	0.39	4.93	0.31	1.56e-6	Morning vs. evening chronotype;
SARC	trans	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg17830980	chr10:43048298	ZNF37B	-0.5	-6.57	-0.4	3.19e-10	Extrinsic epigenetic age acceleration;
SARC	cis	rs9788682	0.747	rs8042059	chr15:78907859	A/C	cg24631222	chr15:78858424	CHRNA5	0.73	10.1	0.55	4.02e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs6918586	0.658	rs198837	chr6:26113398	A/T	cg18357526	chr6:26021779	HIST1H4A	0.46	5.87	0.36	1.47e-8	Schizophrenia;
SARC	cis	rs6121246	0.529	rs6088814	chr20:30218172	C/T	cg13852791	chr20:30311386	BCL2L1	0.64	5.64	0.35	4.79e-8	Mean corpuscular hemoglobin;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02250680	chr11:58346542	LPXN;ZFP91-CNTF;ZFP91	-0.51	-6.33	-0.38	1.23e-9	Fibrinogen levels;
SARC	cis	rs7208859	0.623	rs11652631	chr17:29060766	A/G	cg13385521	chr17:29058706	SUZ12P	0.84	7.31	0.43	4.29e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg17034360	chr1:68629032	GPR177	0.51	6.25	0.38	1.91e-9	Breast cancer;
SARC	cis	rs10782582	0.609	rs1796810	chr1:76403305	C/T	cg10523679	chr1:76189770	ACADM	-0.44	-5.38	-0.33	1.79e-7	Daytime sleep phenotypes;
SARC	cis	rs6142102	0.961	rs1055857	chr20:32613873	A/G	cg24642439	chr20:33292090	TP53INP2	0.44	4.81	0.3	2.69e-6	Skin pigmentation;
SARC	cis	rs9341808	0.718	rs3805920	chr6:80892745	T/C	cg08355045	chr6:80787529	NA	0.34	5.33	0.33	2.28e-7	Sitting height ratio;
SARC	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg03452623	chr4:187889614	NA	0.77	11.9	0.61	7.76e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6963495	0.818	rs73192149	chr7:105210910	A/G	cg19920283	chr7:105172520	RINT1	0.67	5.72	0.35	3.33e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs73198271	0.729	rs67000451	chr8:8605083	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-4.83	-0.3	2.46e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs17376456	0.877	rs10078194	chr5:93364310	A/C	cg25358565	chr5:93447407	FAM172A	1.3	14.78	0.7	2.47e-35	Diabetic retinopathy;
SARC	cis	rs6088590	1.000	rs2180276	chr20:33360785	T/A	cg06115741	chr20:33292138	TP53INP2	0.57	6.88	0.41	5.45e-11	Coronary artery disease;
SARC	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg25036284	chr2:26402008	FAM59B	-0.46	-5.7	-0.35	3.59e-8	Gut microbiome composition (summer);
SARC	cis	rs5760092	0.755	rs6003959	chr22:24264395	C/T	cg04234412	chr22:24373322	LOC391322	0.59	6.52	0.39	4.44e-10	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg12419862	chr22:24373484	LOC391322	-0.71	-8.68	-0.49	6.99e-16	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs698813	0.756	rs2592196	chr2:44605522	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.64	7.74	0.45	3.1e-13	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs7615952	0.736	rs11921945	chr3:125643719	A/G	cg05084668	chr3:125655381	ALG1L	-0.63	-6.44	-0.39	6.7e-10	Blood pressure (smoking interaction);
SARC	cis	rs1707322	0.717	rs11211161	chr1:46148138	A/C	cg06784218	chr1:46089804	CCDC17	0.36	6.27	0.38	1.72e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	12.76	0.64	1.22e-28	Platelet count;
SARC	cis	rs6570726	0.934	rs9484995	chr6:145781114	T/A	cg05347473	chr6:146136440	FBXO30	-0.46	-6.07	-0.37	5.28e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg08859206	chr1:53392774	SCP2	0.36	5.22	0.32	3.97e-7	Monocyte count;
SARC	cis	rs6901004	0.803	rs354529	chr6:111504655	G/A	cg15721981	chr6:111408429	SLC16A10	-0.44	-5.33	-0.33	2.32e-7	Blood metabolite levels;
SARC	cis	rs709400	0.663	rs7158822	chr14:103887868	C/T	cg26031613	chr14:104095156	KLC1	0.8	11.23	0.59	1.12e-23	Body mass index;
SARC	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg18252515	chr7:66147081	NA	-0.45	-4.97	-0.31	1.28e-6	Aortic root size;
SARC	trans	rs459571	0.959	rs2520099	chr9:136918139	T/C	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.65	-7.63	-0.45	5.87e-13	Platelet distribution width;
SARC	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg02841227	chr6:26021843	HIST1H4A	0.62	7.1	0.42	1.49e-11	Intelligence (multi-trait analysis);
SARC	trans	rs61931739	0.534	rs11052979	chr12:34035774	G/T	cg26384229	chr12:38710491	ALG10B	0.85	12.34	0.63	2.98e-27	Morning vs. evening chronotype;
SARC	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg18876405	chr7:65276391	NA	-0.45	-4.94	-0.31	1.46e-6	Aortic root size;
SARC	cis	rs1267303	0.642	rs7542296	chr1:46998009	A/G	cg25110126	chr1:46999211	NA	0.92	10.26	0.56	1.32e-20	Monobrow;
SARC	cis	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg13072238	chr3:49761600	GMPPB	-0.42	-5.43	-0.34	1.4e-7	Intelligence (multi-trait analysis);
SARC	cis	rs78487399	0.808	rs77791126	chr2:43744050	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-4.74	-0.3	3.73e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs477895	1.000	rs12785488	chr11:64107521	G/A	cg04317338	chr11:64019027	PLCB3	0.65	5.19	0.32	4.53e-7	Mean platelet volume;
SARC	cis	rs11881751	0.868	rs117864137	chr19:4983304	A/G	cg04571196	chr19:4910051	UHRF1	0.46	4.78	0.3	3.15e-6	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg09455208	chr3:40491958	NA	0.4	5.83	0.36	1.84e-8	Renal cell carcinoma;
SARC	cis	rs7647973	0.593	rs7652179	chr3:49808618	T/A	cg03060546	chr3:49711283	APEH	-0.59	-5.76	-0.35	2.6e-8	Menarche (age at onset);
SARC	cis	rs5167	0.566	rs934427	chr19:45478816	T/G	cg10169327	chr19:45448959	APOC2	0.32	4.86	0.3	2.19e-6	Blood protein levels;
SARC	cis	rs7647973	0.588	rs62262675	chr3:49673662	A/G	cg07636037	chr3:49044803	WDR6	-0.6	-5.26	-0.33	3.23e-7	Menarche (age at onset);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg14082963	chr4:89444434	PIGY	-0.6	-7.21	-0.43	7.99e-12	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg11644478	chr21:40555479	PSMG1	1.02	14.57	0.69	1.3e-34	Cognitive function;
SARC	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg01570182	chr17:44337453	NA	-0.82	-9.75	-0.54	4.71e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg05793240	chr7:2802953	GNA12	0.35	5.16	0.32	5.35e-7	Height;
SARC	cis	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg05623727	chr3:50126028	RBM5	-0.32	-4.87	-0.3	2.07e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2276314	0.857	rs62101379	chr18:33584902	G/A	cg19628046	chr18:33552617	C18orf21	0.6	6.05	0.37	5.65e-9	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs858239	0.600	rs28483572	chr7:23131785	A/G	cg23682824	chr7:23144976	KLHL7	0.7	9.38	0.52	5.93e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs12142240	0.698	rs17413694	chr1:46818416	A/C	cg10495392	chr1:46806563	NSUN4	0.65	6.83	0.41	7.25e-11	Menopause (age at onset);
SARC	cis	rs2439831	0.867	rs2470134	chr15:43849886	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.83	-7.76	-0.45	2.69e-13	Lung cancer in ever smokers;
SARC	cis	rs2920503	1.000	rs2920503	chr3:12324230	C/T	cg23514324	chr3:12329213	PPARG	0.64	7.95	0.46	7.94e-14	LDL cholesterol;
SARC	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg17971929	chr21:40555470	PSMG1	0.96	13.06	0.65	1.28e-29	Cognitive function;
SARC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg23131131	chr22:24373011	LOC391322	0.46	4.91	0.31	1.69e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2723064	0.543	rs2080385	chr2:65292762	G/T	cg20592124	chr2:65290738	CEP68	0.43	5.6	0.34	6e-8	Atrial fibrillation;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg07900786	chr7:45151525	TBRG4	-0.58	-6.62	-0.4	2.43e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs611744	0.647	rs7015240	chr8:109262204	G/A	cg21045802	chr8:109455806	TTC35	0.58	7.28	0.43	4.97e-12	Dupuytren's disease;
SARC	cis	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg25894440	chr7:65020034	NA	-0.73	-5.55	-0.34	7.84e-8	Diabetic kidney disease;
SARC	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg22800045	chr5:56110881	MAP3K1	0.71	7.45	0.44	1.83e-12	Initial pursuit acceleration;
SARC	cis	rs1707322	0.721	rs61784800	chr1:46178112	A/G	cg06784218	chr1:46089804	CCDC17	-0.37	-6.38	-0.39	9.21e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg20607798	chr8:58055168	NA	0.71	5.79	0.35	2.29e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10992471	0.756	rs2516568	chr9:95187380	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-6.69	-0.4	1.66e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs524281	1.000	rs547087	chr11:65846264	A/G	cg14036092	chr11:66035641	RAB1B	0.52	5.83	0.36	1.87e-8	Electroencephalogram traits;
SARC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg21747090	chr2:27597821	SNX17	-0.55	-7.68	-0.45	4.44e-13	Total body bone mineral density;
SARC	cis	rs4132509	0.793	rs10927047	chr1:243803677	A/T	cg21452805	chr1:244014465	NA	0.57	5.22	0.32	3.96e-7	RR interval (heart rate);
SARC	cis	rs7264396	0.677	rs6060553	chr20:34267386	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-7.46	-0.44	1.65e-12	Total cholesterol levels;
SARC	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg10523679	chr1:76189770	ACADM	0.54	7.38	0.44	2.73e-12	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs72781680	0.611	rs2303289	chr2:24342242	C/G	cg08917208	chr2:24149416	ATAD2B	-0.59	-6.12	-0.37	4.03e-9	Lymphocyte counts;
SARC	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg15448220	chr1:150897856	SETDB1	0.47	6.22	0.38	2.24e-9	Tonsillectomy;
SARC	cis	rs79149102	0.522	rs11857192	chr15:74822444	A/G	cg09165964	chr15:75287851	SCAMP5	-0.65	-5.04	-0.31	9.56e-7	Lung cancer;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg25969673	chr4:26585760	TBC1D19	0.49	6.42	0.39	7.53e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs911263	0.603	rs8017304	chr14:68785077	A/G	cg18825221	chr14:68749962	RAD51L1	-0.42	-7.2	-0.43	8.29e-12	Primary biliary cholangitis;
SARC	cis	rs7011049	1.000	rs72643600	chr8:53854530	T/G	cg26025543	chr8:53854495	NA	0.6	5.37	0.33	1.91e-7	Systolic blood pressure;
SARC	cis	rs17023223	0.537	rs12081327	chr1:119686358	A/G	cg05756136	chr1:119680316	WARS2	-0.48	-5.55	-0.34	7.84e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs10489202	0.632	rs275143	chr1:168056724	A/G	cg17859187	chr1:168147929	TIPRL	0.4	4.77	0.3	3.24e-6	Schizophrenia;
SARC	cis	rs9747201	1.000	rs4597372	chr17:80175444	G/A	cg09264619	chr17:80180166	NA	-0.53	-5.88	-0.36	1.39e-8	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs34891900	0.507	rs2535679	chr22:18202850	A/G	cg19898043	chr22:18121309	BCL2L13	0.65	7.31	0.43	4.31e-12	Sum neutrophil eosinophil counts;
SARC	cis	rs3126085	0.935	rs6681433	chr1:152277396	T/C	cg03465714	chr1:152285911	FLG	0.48	5.62	0.35	5.42e-8	Atopic dermatitis;
SARC	cis	rs1865760	0.929	rs1436307	chr6:25939723	C/T	cg16482183	chr6:26056742	HIST1H1C	0.53	6.73	0.4	1.3100000000000001e-10	Height;
SARC	cis	rs11785400	0.963	rs4579507	chr8:143733663	C/G	cg10596483	chr8:143751796	JRK	0.64	8.66	0.49	8.21e-16	Schizophrenia;
SARC	cis	rs9291683	0.530	rs6449196	chr4:9973660	C/T	cg00071950	chr4:10020882	SLC2A9	-0.4	-6.37	-0.39	9.82e-10	Bone mineral density;
SARC	cis	rs6088580	0.602	rs6059834	chr20:33019299	A/G	cg24642439	chr20:33292090	TP53INP2	0.67	8.56	0.49	1.53e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg05901451	chr6:126070800	HEY2	-0.68	-9.46	-0.53	3.44e-18	Brugada syndrome;
SARC	cis	rs367943	1.000	rs348931	chr5:112812864	G/C	cg12552261	chr5:112820674	MCC	-0.45	-5.19	-0.32	4.65e-7	Type 2 diabetes;
SARC	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg05368731	chr17:41323189	NBR1	0.81	9.9	0.54	1.66e-19	Menopause (age at onset);
SARC	cis	rs9640161	0.750	rs59211922	chr7:150023790	T/G	cg21361702	chr7:150065534	REPIN1	0.46	4.98	0.31	1.22e-6	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs12586317	0.576	rs2415265	chr14:35630388	A/G	cg16230307	chr14:35515116	FAM177A1	0.5	6.32	0.38	1.31e-9	Psoriasis;
SARC	cis	rs2075371	1.000	rs2598288	chr7:133977304	A/T	cg20476274	chr7:133979776	SLC35B4	0.6	8.19	0.47	1.7e-14	Mean platelet volume;
SARC	cis	rs1568889	1.000	rs7937117	chr11:28370038	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	9.88	0.54	1.89e-19	Bipolar disorder;
SARC	cis	rs870825	0.616	rs6825561	chr4:185615532	A/T	cg04058563	chr4:185651563	MLF1IP	0.82	11.18	0.59	1.58e-23	Blood protein levels;
SARC	cis	rs910187	0.605	rs3787235	chr20:45803522	C/T	cg27589058	chr20:45804311	EYA2	-0.31	-5.0	-0.31	1.1e-6	Migraine;
SARC	cis	rs453301	0.686	rs7017868	chr8:8873293	G/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.23	-0.43	6.77e-12	Joint mobility (Beighton score);
SARC	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg21433313	chr16:3507492	NAT15	0.34	4.86	0.3	2.19e-6	Tuberculosis;
SARC	cis	rs1949733	0.848	rs2255501	chr4:8475014	G/A	cg13073564	chr4:8508604	NA	0.38	5.87	0.36	1.46e-8	Response to antineoplastic agents;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg00832928	chr3:150329458	SELT	-0.84	-7.27	-0.43	5.43e-12	Autism spectrum disorder or schizophrenia;
SARC	trans	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg17830980	chr10:43048298	ZNF37B	0.49	6.68	0.4	1.73e-10	Extrinsic epigenetic age acceleration;
SARC	cis	rs438465	0.580	rs12174595	chr6:169771178	C/A	cg16388071	chr6:169726476	NA	0.55	4.74	0.3	3.77e-6	Corneal astigmatism;
SARC	cis	rs472402	0.580	rs3733773	chr5:6652252	G/A	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.43	-5.14	-0.32	5.69e-7	Response to amphetamines;
SARC	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-5.73	-0.35	3.13e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.39	4.75	0.3	3.55e-6	Tonsillectomy;
SARC	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg02725872	chr8:58115012	NA	-0.34	-5.37	-0.33	1.91e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs3771570	1.000	rs59496049	chr2:242260756	G/C	cg21155796	chr2:242212141	HDLBP	0.58	5.45	0.34	1.25e-7	Prostate cancer;
SARC	cis	rs763512	0.504	rs4573978	chr17:35972014	C/A	cg16670864	chr17:35848621	DUSP14	-0.46	-5.15	-0.32	5.58e-7	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs1034435	0.692	rs6008739	chr22:48892542	T/C	cg05992904	chr22:48892994	FAM19A5	-0.46	-6.76	-0.4	1.1e-10	Late-onset Alzheimer's disease;
SARC	trans	rs7922314	0.571	rs59286975	chr10:64736664	G/A	cg25304107	chr2:177017331	HOXD4	-0.83	-6.46	-0.39	5.88e-10	Cutaneous psoriasis;
SARC	cis	rs7617773	0.746	rs7619865	chr3:48370580	G/A	cg11946769	chr3:48343235	NME6	0.7	9.35	0.52	7.47e-18	Coronary artery disease;
SARC	cis	rs870825	0.616	rs7668009	chr4:185641998	A/C	cg04058563	chr4:185651563	MLF1IP	0.81	11.4	0.6	3.16e-24	Blood protein levels;
SARC	cis	rs262150	1.000	rs262150	chr7:158777934	G/A	cg04111992	chr7:158790115	NA	-0.37	-4.73	-0.3	3.84e-6	Facial morphology (factor 20);
SARC	cis	rs2075371	1.000	rs1421486	chr7:133985196	T/C	cg20476274	chr7:133979776	SLC35B4	0.62	8.41	0.48	4.18e-15	Mean platelet volume;
SARC	cis	rs8014131	0.689	rs1955435	chr14:85987306	G/A	cg10406690	chr14:85995726	FLRT2	0.41	5.21	0.32	4.18e-7	Menarche (age at onset);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg23987548	chr17:73401912	GRB2	0.48	6.35	0.38	1.1e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg11766577	chr21:47581405	C21orf56	0.44	5.14	0.32	5.84e-7	Testicular germ cell tumor;
SARC	cis	rs4919694	0.901	rs113541728	chr10:104716771	A/T	cg04362960	chr10:104952993	NT5C2	0.64	5.42	0.33	1.51e-7	Arsenic metabolism;
SARC	cis	rs1215050	0.740	rs1648568	chr4:98957619	A/G	cg05340658	chr4:99064831	C4orf37	-0.48	-6.55	-0.39	3.7e-10	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs2235642	0.750	rs2755185	chr16:1645827	A/G	cg09065629	chr16:1709722	CRAMP1L	0.36	4.9	0.31	1.8e-6	Coronary artery disease;
SARC	cis	rs7264396	0.563	rs2425114	chr20:34322346	T/C	cg01084648	chr20:34329383	RBM39	0.58	5.03	0.31	9.74e-7	Total cholesterol levels;
SARC	cis	rs14978	1.000	rs12666249	chr7:12260546	C/T	cg23422036	chr7:12250390	TMEM106B	0.42	4.96	0.31	1.39e-6	Response to amphetamines;
SARC	cis	rs3087591	0.639	rs757378	chr17:29722619	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.42	-5.21	-0.32	4.12e-7	Hip circumference;
SARC	cis	rs7103648	0.808	rs7103835	chr11:47461693	G/A	cg20307385	chr11:47447363	PSMC3	0.77	10.31	0.56	8.88e-21	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs7666738	0.830	rs4441757	chr4:98927059	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9682041	1.000	rs6773095	chr3:170082181	A/G	cg11886554	chr3:170076028	SKIL	1.07	8.49	0.49	2.41e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs7681440	0.835	rs6831847	chr4:90785341	A/G	cg02192967	chr4:90758406	SNCA	-0.39	-5.45	-0.34	1.27e-7	Dementia with Lewy bodies;
SARC	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg05313129	chr8:58192883	C8orf71	-0.55	-6.16	-0.37	3.13e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs651907	0.557	rs34181125	chr3:101490278	A/G	cg12386194	chr3:101231763	SENP7	0.48	5.78	0.35	2.39e-8	Colorectal cancer;
SARC	trans	rs9354308	0.932	rs1938061	chr6:66545581	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.56	-6.57	-0.4	3.32e-10	Metabolite levels;
SARC	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.88	-13.07	-0.65	1.23e-29	Prudent dietary pattern;
SARC	cis	rs11039389	1	rs11039389	chr11:47796062	T/C	cg20307385	chr11:47447363	PSMC3	-0.47	-5.72	-0.35	3.19e-8	Neuroticism;
SARC	cis	rs4481887	0.927	rs12731721	chr1:248474210	G/A	cg00666640	chr1:248458726	OR2T12	0.34	5.7	0.35	3.65e-8	Common traits (Other);
SARC	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg05863683	chr7:1912471	MAD1L1	0.37	5.54	0.34	8.08e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs7647973	0.593	rs28535523	chr3:49848414	C/T	cg03060546	chr3:49711283	APEH	-0.66	-6.95	-0.41	3.73e-11	Menarche (age at onset);
SARC	cis	rs9815354	0.812	rs967619	chr3:41876710	C/G	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2153535	0.580	rs2152347	chr6:8474281	A/G	cg23788917	chr6:8435910	SLC35B3	0.64	8.39	0.48	4.57e-15	Motion sickness;
SARC	cis	rs9868809	0.772	rs73078349	chr3:48688114	G/A	cg04581018	chr3:49236808	CCDC36	0.56	4.82	0.3	2.6e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs6912958	0.967	rs6905947	chr6:88161949	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.64	-8.64	-0.49	8.93e-16	Monocyte percentage of white cells;
SARC	cis	rs9814567	0.964	rs3856729	chr3:134200925	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-7.06	-0.42	1.85e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	trans	rs10100465	0.596	rs218009	chr8:118716275	A/G	cg05203659	chr16:12009378	GSPT1	0.63	6.3	0.38	1.5e-9	Leprosy;
SARC	cis	rs7666738	0.830	rs2167892	chr4:99048503	G/C	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6582630	0.572	rs7315897	chr12:38449081	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-6.91	-0.41	4.51e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg13147721	chr7:65941812	NA	-0.52	-4.79	-0.3	3.03e-6	Diabetic kidney disease;
SARC	cis	rs6991838	0.584	rs1053088	chr8:66515783	A/G	cg13398993	chr8:66546079	ARMC1	0.62	8.31	0.48	7.86e-15	Intelligence (multi-trait analysis);
SARC	cis	rs2070488	0.662	rs7373930	chr3:38454931	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.62	7.98	0.46	6.54e-14	Electrocardiographic conduction measures;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg27300238	chr6:21595173	SOX4	-0.82	-6.56	-0.39	3.44e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2070488	0.699	rs6599205	chr3:38529440	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.77	10.95	0.58	8.56e-23	Electrocardiographic conduction measures;
SARC	trans	rs7819412	0.659	rs4073948	chr8:10772644	A/T	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.26	-0.38	1.87e-9	Triglycerides;
SARC	cis	rs995000	0.899	rs10889340	chr1:63012071	A/C	cg06896770	chr1:63153194	DOCK7	-0.9	-13.26	-0.66	2.87e-30	Triglyceride levels;
SARC	cis	rs2153535	0.580	rs7761937	chr6:8459434	A/T	cg07606381	chr6:8435919	SLC35B3	0.77	11.07	0.59	3.76e-23	Motion sickness;
SARC	cis	rs523522	0.962	rs9788155	chr12:120938408	G/A	cg27279351	chr12:120934652	DYNLL1	0.72	8.91	0.5	1.5e-16	High light scatter reticulocyte count;
SARC	cis	rs3540	1.000	rs3540	chr15:91045408	G/A	cg22089800	chr15:90895588	ZNF774	0.49	5.62	0.35	5.36e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs7084402	0.967	rs1649080	chr10:60293294	C/T	cg07615347	chr10:60278583	BICC1	0.61	8.86	0.5	2.05e-16	Refractive error;
SARC	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg16479474	chr6:28041457	NA	0.37	5.25	0.33	3.45e-7	Parkinson's disease;
SARC	trans	rs61931739	0.500	rs11053236	chr12:34507962	C/G	cg26384229	chr12:38710491	ALG10B	0.91	13.59	0.66	2.23e-31	Morning vs. evening chronotype;
SARC	trans	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.62	-8.22	-0.47	1.38e-14	Liver enzyme levels (gamma-glutamyl transferase);
SARC	trans	rs2727020	0.563	rs10769582	chr11:49474040	T/C	cg03929089	chr4:120376271	NA	-0.79	-11.56	-0.6	9.84e-25	Coronary artery disease;
SARC	cis	rs7681440	0.606	rs990088	chr4:90755225	A/G	cg06632027	chr4:90757378	SNCA	-0.44	-5.48	-0.34	1.13e-7	Dementia with Lewy bodies;
SARC	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg03575189	chr17:44344142	NA	0.61	5.9	0.36	1.29e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs2645694	0.626	rs2703121	chr4:77822328	C/G	cg03477792	chr4:77819574	ANKRD56	0.5	7.5	0.44	1.35e-12	Emphysema distribution in smoking;
SARC	cis	rs6450176	1.000	rs6876198	chr5:53303595	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.68	-8.25	-0.48	1.19e-14	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs1059312	0.966	rs12370194	chr12:129277250	A/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.49	7.23	0.43	6.93e-12	Systemic lupus erythematosus;
SARC	trans	rs9325144	0.534	rs4882350	chr12:38686979	A/G	cg23762105	chr12:34175262	ALG10	-0.52	-6.96	-0.41	3.4e-11	Morning vs. evening chronotype;
SARC	cis	rs8180040	0.966	rs11130129	chr3:47489885	G/C	cg27129171	chr3:47204927	SETD2	-0.68	-9.57	-0.53	1.62e-18	Colorectal cancer;
SARC	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	9.09	0.51	4.42e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs12135062	0.901	rs2651928	chr1:3101722	C/T	cg21609526	chr1:3105151	PRDM16	-0.39	-6.59	-0.4	2.89e-10	Migraine;
SARC	cis	rs67460515	1.000	rs67460515	chr3:161068566	T/C	cg03342759	chr3:160939853	NMD3	-0.65	-8.11	-0.47	2.81e-14	Parkinson's disease;
SARC	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-9.15	-0.51	2.85e-17	Alzheimer's disease;
SARC	cis	rs2204008	0.744	rs11181337	chr12:38322083	C/A	cg26384229	chr12:38710491	ALG10B	0.85	11.95	0.62	5.3e-26	Bladder cancer;
SARC	cis	rs9640161	0.742	rs2108852	chr7:150019628	T/C	cg10018233	chr7:150070692	REPIN1	0.68	9.04	0.51	6.03e-17	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs1971762	0.583	rs12810378	chr12:54091838	G/T	cg06632207	chr12:54070931	ATP5G2	0.42	5.43	0.34	1.43e-7	Height;
SARC	cis	rs7474896	0.537	rs1208587	chr10:38207759	A/G	cg25427524	chr10:38739819	LOC399744	0.49	6.15	0.37	3.31e-9	Obesity (extreme);
SARC	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg08219700	chr8:58056026	NA	0.49	5.01	0.31	1.07e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs4453791	0.505	rs35752744	chr3:38926290	T/C	cg15678707	chr3:39149194	GORASP1;TTC21A	0.47	5.09	0.32	7.25e-7	Social communication problems;
SARC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.34	-5.06	-0.31	8.5e-7	Total body bone mineral density;
SARC	cis	rs9300255	0.516	rs6488868	chr12:123799974	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-4.88	-0.3	1.94e-6	Neutrophil percentage of white cells;
SARC	cis	rs2075371	0.863	rs1646635	chr7:134006728	T/C	cg11752832	chr7:134001865	SLC35B4	0.6	7.95	0.46	8.2e-14	Mean platelet volume;
SARC	cis	rs4713118	0.824	rs2092075	chr6:27749330	G/C	cg17221315	chr6:27791827	HIST1H4J	0.47	5.1	0.32	6.97e-7	Parkinson's disease;
SARC	cis	rs12681288	0.676	rs4565481	chr8:1001944	C/T	cg15309053	chr8:964076	NA	0.45	7.41	0.44	2.25e-12	Schizophrenia;
SARC	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.75	7.54	0.44	1.06e-12	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs6088580	0.634	rs1205344	chr20:32918298	G/A	cg24642439	chr20:33292090	TP53INP2	-0.64	-8.35	-0.48	5.99e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs858239	0.601	rs10278700	chr7:23160529	T/C	cg23682824	chr7:23144976	KLHL7	0.74	10.02	0.55	7.18e-20	Cerebrospinal fluid biomarker levels;
SARC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg09373136	chr17:61933544	TCAM1	-0.45	-6.17	-0.37	2.98e-9	Prudent dietary pattern;
SARC	cis	rs9916302	0.645	rs1053651	chr17:37822311	A/C	cg07936489	chr17:37558343	FBXL20	-0.44	-5.62	-0.35	5.3e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs1801251	0.778	rs809639	chr2:233731244	C/G	cg25237894	chr2:233734115	C2orf82	0.33	4.81	0.3	2.74e-6	Coronary artery disease;
SARC	cis	rs870825	0.872	rs12507711	chr4:185571776	C/T	cg04058563	chr4:185651563	MLF1IP	0.62	6.85	0.41	6.63e-11	Blood protein levels;
SARC	cis	rs72781680	0.716	rs17045975	chr2:24099611	A/T	cg08917208	chr2:24149416	ATAD2B	-0.57	-5.88	-0.36	1.43e-8	Lymphocyte counts;
SARC	cis	rs17376456	0.877	rs10052428	chr5:93476530	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.55	0.34	7.72e-8	Diabetic retinopathy;
SARC	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg13206674	chr6:150067644	NUP43	0.41	5.0	0.31	1.14e-6	Lung cancer;
SARC	cis	rs568617	0.859	rs1204650	chr11:65645580	A/C	cg00576331	chr11:65640516	EFEMP2	0.47	5.45	0.34	1.27e-7	Crohn's disease;
SARC	cis	rs607987	0.836	rs1222202	chr11:30336613	G/A	cg06241208	chr11:30344200	C11orf46	-0.39	-4.76	-0.3	3.4e-6	Body mass index;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26002659	chr19:3557856	C19orf28	0.52	6.37	0.39	1.02e-9	Fibrinogen levels;
SARC	cis	rs12681366	0.636	rs1580498	chr8:95425554	C/G	cg26464482	chr8:95565502	KIAA1429	-0.44	-5.42	-0.33	1.52e-7	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs72634258	0.836	rs7545687	chr1:7997183	G/A	cg00042356	chr1:8021962	PARK7	0.87	7.03	0.42	2.33e-11	Inflammatory bowel disease;
SARC	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.39	5.38	0.33	1.85e-7	Personality dimensions;
SARC	cis	rs858239	0.600	rs7784929	chr7:23124277	T/C	cg23682824	chr7:23144976	KLHL7	0.7	9.38	0.52	5.93e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs6815814	0.950	rs73236617	chr4:38793860	C/G	cg09316306	chr4:38807337	TLR1	0.5	5.14	0.32	5.87e-7	Breast cancer;
SARC	cis	rs898097	0.691	rs7222745	chr17:80907253	C/T	cg10494973	chr17:80897199	TBCD	0.42	5.43	0.34	1.39e-7	Breast cancer;
SARC	cis	rs6121246	0.609	rs2149281	chr20:30417918	G/A	cg13852791	chr20:30311386	BCL2L1	0.83	10.32	0.56	8.45e-21	Mean corpuscular hemoglobin;
SARC	cis	rs2531992	0.925	rs2531993	chr16:4014245	A/G	cg05927578	chr16:4029543	ADCY9	0.4	4.73	0.3	3.82e-6	Waist circumference;
SARC	cis	rs9894429	0.634	rs11655346	chr17:79572399	A/G	cg18240062	chr17:79603768	NPLOC4	-0.58	-7.2	-0.43	8.43e-12	Eye color traits;
SARC	cis	rs6864727	1.000	rs2097865	chr5:137245067	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.53	5.86	0.36	1.6e-8	Atrial fibrillation;
SARC	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-5.96	-0.36	9.37e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9911578	1.000	rs1631237	chr17:56734695	A/G	cg05425664	chr17:57184151	TRIM37	-0.68	-8.49	-0.49	2.48e-15	Intelligence (multi-trait analysis);
SARC	cis	rs7666738	0.515	rs28615369	chr4:98896858	C/T	cg05340658	chr4:99064831	C4orf37	0.57	7.07	0.42	1.79e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6456156	0.774	rs6908364	chr6:167527296	C/T	cg07741184	chr6:167504864	NA	-0.27	-5.23	-0.32	3.73e-7	Primary biliary cholangitis;
SARC	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg27266027	chr21:40555129	PSMG1	0.51	5.11	0.32	6.77e-7	Cognitive function;
SARC	cis	rs7833790	0.654	rs6415652	chr8:82702257	G/A	cg17211192	chr8:82754475	SNX16	-0.49	-5.87	-0.36	1.46e-8	Diastolic blood pressure;
SARC	cis	rs9486719	1.000	rs9400016	chr6:96940883	G/T	cg18709589	chr6:96969512	KIAA0776	-0.47	-4.78	-0.3	3.1e-6	Migraine;Coronary artery disease;
SARC	cis	rs7552404	0.696	rs12140121	chr1:76455001	A/G	cg22875332	chr1:76189707	ACADM	0.43	5.1	0.32	6.97e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7824557	0.583	rs2736306	chr8:11239762	A/T	cg21775007	chr8:11205619	TDH	0.63	8.23	0.47	1.33e-14	Retinal vascular caliber;
SARC	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.94	9.94	0.55	1.25e-19	Platelet count;
SARC	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg00431813	chr7:1051703	C7orf50	-0.34	-5.02	-0.31	1.02e-6	Longevity;Endometriosis;
SARC	cis	rs9309473	0.898	rs11126403	chr2:73796923	A/G	cg20560298	chr2:73613845	ALMS1	-0.46	-5.53	-0.34	8.77e-8	Metabolite levels;
SARC	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg20607798	chr8:58055168	NA	0.61	5.41	0.33	1.57e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs807669	0.770	rs807458	chr22:19220648	G/A	cg26795923	chr22:19165960	SLC25A1	0.8	5.04	0.31	9.39e-7	Metabolite levels;
SARC	cis	rs9549260	0.755	rs3900833	chr13:41188292	A/G	cg21288729	chr13:41239152	FOXO1	0.64	8.94	0.51	1.21e-16	Red blood cell count;
SARC	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.5	-5.89	-0.36	1.34e-8	Renal function-related traits (BUN);
SARC	trans	rs11098499	0.954	rs35063680	chr4:120387102	T/C	cg25214090	chr10:38739885	LOC399744	0.56	7.32	0.43	4.04e-12	Corneal astigmatism;
SARC	cis	rs6088580	0.634	rs6120650	chr20:33039973	G/A	cg08999081	chr20:33150536	PIGU	0.44	6.73	0.4	1.3100000000000001e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs2836633	1.000	rs2836633	chr21:40067445	C/T	cg12884169	chr21:40033163	ERG	-0.44	-7.75	-0.45	2.75e-13	Coronary artery disease;
SARC	cis	rs858239	0.669	rs1006709	chr7:23140099	C/T	cg23682824	chr7:23144976	KLHL7	0.67	8.6	0.49	1.19e-15	Cerebrospinal fluid biomarker levels;
SARC	cis	rs73198271	0.960	rs73198290	chr8:8616009	A/T	cg06636001	chr8:8085503	FLJ10661	-0.47	-4.72	-0.3	4.02e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs7766436	0.614	rs16886471	chr6:22567379	C/T	cg13666174	chr6:22585274	NA	-0.56	-5.86	-0.36	1.59e-8	Coronary artery disease;
SARC	cis	rs13191362	1.000	rs35449999	chr6:163023465	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.57	5.47	0.34	1.16e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs8027181	0.804	rs7178130	chr15:72978202	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	-0.42	-5.9	-0.36	1.28e-8	Triglyceride levels;
SARC	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg14517863	chr17:44321492	NA	-0.32	-4.76	-0.3	3.46e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	trans	rs61931739	0.500	rs11053290	chr12:34582392	C/T	cg13010199	chr12:38710504	ALG10B	-0.78	-11.12	-0.59	2.47e-23	Morning vs. evening chronotype;
SARC	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg04511125	chr2:88470314	THNSL2	0.81	7.27	0.43	5.44e-12	Plasma clusterin levels;
SARC	cis	rs2997447	0.595	rs3008425	chr1:26385660	T/C	cg19633962	chr1:26362018	EXTL1	-0.78	-8.07	-0.47	3.8e-14	QRS complex (12-leadsum);
SARC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.6	0.53	1.32e-18	Prudent dietary pattern;
SARC	cis	rs2073499	0.872	rs2239801	chr3:50402309	C/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.58	5.17	0.32	5.09e-7	Schizophrenia;
SARC	cis	rs59724122	0.542	rs28633173	chr8:27446980	A/G	cg01579299	chr8:27450062	NA	0.66	8.18	0.47	1.85e-14	Bipolar disorder lithium response (categorical) or schizophrenia;
SARC	cis	rs3126085	0.867	rs11204948	chr1:152218473	A/G	cg09127314	chr1:152161683	NA	0.46	5.0	0.31	1.12e-6	Atopic dermatitis;
SARC	cis	rs3087591	0.960	rs11080146	chr17:29578724	C/T	cg24425628	chr17:29625626	OMG;NF1	-0.51	-6.3	-0.38	1.43e-9	Hip circumference;
SARC	cis	rs3733346	0.553	rs2290403	chr4:942006	G/A	cg20814179	chr4:940893	TMEM175	0.41	5.9	0.36	1.27e-8	Sjögren's syndrome;
SARC	cis	rs2439831	0.717	rs7165471	chr15:43644788	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.77	7.99	0.46	6.26e-14	Lung cancer in ever smokers;
SARC	cis	rs897984	0.683	rs8050330	chr16:30824970	C/T	cg00531865	chr16:30841666	NA	-0.46	-5.3	-0.33	2.67e-7	Dementia with Lewy bodies;
SARC	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg05793240	chr7:2802953	GNA12	-0.38	-5.18	-0.32	4.7e-7	Height;
SARC	cis	rs7191700	0.644	rs12149160	chr16:11439303	G/T	cg00044050	chr16:11439710	C16orf75	-0.38	-4.8	-0.3	2.83e-6	Multiple sclerosis;
SARC	cis	rs9354308	0.868	rs9363464	chr6:66557759	C/T	cg07460842	chr6:66804631	NA	-0.41	-4.73	-0.3	3.93e-6	Metabolite levels;
SARC	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg21724239	chr8:58056113	NA	0.6	6.37	0.38	1.03e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs477692	0.870	rs532248	chr10:131414156	T/A	cg05714579	chr10:131428358	MGMT	0.58	7.77	0.45	2.43e-13	Response to temozolomide;
SARC	cis	rs7592578	0.882	rs58568707	chr2:191468987	G/A	cg25963032	chr2:191064776	C2orf88	-0.45	-5.04	-0.31	9.14e-7	Diastolic blood pressure;
SARC	cis	rs13082711	0.595	rs6783818	chr3:27361988	C/G	cg02860705	chr3:27208620	NA	0.66	7.95	0.46	7.98e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg03060546	chr3:49711283	APEH	0.44	5.59	0.34	6.23e-8	Parkinson's disease;
SARC	cis	rs7772486	0.558	rs2142978	chr6:146012061	T/C	cg05347473	chr6:146136440	FBXO30	-0.7	-9.9	-0.54	1.64e-19	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6496667	0.533	rs2601206	chr15:90962699	C/T	cg22089800	chr15:90895588	ZNF774	0.42	4.77	0.3	3.3e-6	Rheumatoid arthritis;
SARC	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg07701084	chr6:150067640	NUP43	0.41	5.39	0.33	1.68e-7	Lung cancer;
SARC	cis	rs1348850	0.526	rs78587445	chr2:178461339	G/T	cg23306229	chr2:178417860	TTC30B	-0.88	-8.0	-0.46	6.01e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg05025164	chr4:1340916	KIAA1530	0.44	5.33	0.33	2.3e-7	Obesity-related traits;
SARC	cis	rs2594989	0.943	rs2442780	chr3:11510568	A/G	cg00170343	chr3:11313890	ATG7	0.54	5.29	0.33	2.79e-7	Circulating chemerin levels;
SARC	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg06634786	chr22:41940651	POLR3H	0.54	6.41	0.39	8.14e-10	Vitiligo;
SARC	cis	rs17401966	1.000	rs2275424	chr1:10356562	C/A	cg15208524	chr1:10270712	KIF1B	0.59	6.5	0.39	4.73e-10	Hepatocellular carcinoma;
SARC	cis	rs11097912	0.632	rs12644259	chr4:107151258	A/G	cg09646026	chr4:107269030	AIMP1	0.45	4.94	0.31	1.51e-6	Airflow obstruction;
SARC	cis	rs2072499	0.750	rs909269	chr1:156192028	C/T	cg24450063	chr1:156163899	SLC25A44	1.03	12.68	0.64	2.26e-28	Testicular germ cell tumor;
SARC	cis	rs10979	1.000	rs9403505	chr6:143885841	A/G	cg25407410	chr6:143891975	LOC285740	-0.59	-7.62	-0.45	6.43e-13	Hypospadias;
SARC	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg22508957	chr16:3507546	NAT15	0.38	5.49	0.34	1.05e-7	Tuberculosis;
SARC	cis	rs114858855	1.000	rs1303981	chr6:109879139	C/T	cg26835506	chr6:109038353	NA	-0.61	-4.98	-0.31	1.26e-6	Plasma trimethylamine N-oxide levels;
SARC	cis	rs11098499	0.909	rs28632018	chr4:120386730	T/C	cg24375607	chr4:120327624	NA	0.39	4.72	0.3	4.14e-6	Corneal astigmatism;
SARC	cis	rs12249377	0.519	rs12259060	chr10:92579949	A/G	cg14313238	chr10:92632228	RPP30	0.43	5.1	0.32	7.03e-7	White matter microstructure (global fractional anisotropy);
SARC	cis	rs12545912	0.909	rs4841182	chr8:9470714	C/T	cg21625330	chr8:9911636	MSRA	-0.51	-4.89	-0.31	1.84e-6	Multiple myeloma (hyperdiploidy);
SARC	cis	rs992157	0.796	rs55680399	chr2:219160621	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.62	8.64	0.49	9.35e-16	Colorectal cancer;
SARC	cis	rs698833	0.561	rs698808	chr2:44701901	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	5.08	0.32	7.7e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs2304069	0.545	rs9686746	chr5:149399968	G/A	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.44	4.97	0.31	1.28e-6	HIV-1 control;
SARC	cis	rs6701037	1.000	rs11585617	chr1:175123186	C/G	cg00321850	chr1:175162397	KIAA0040	-0.34	-5.11	-0.32	6.73e-7	Alcohol dependence;
SARC	cis	rs16912285	0.688	rs12284649	chr11:24316260	T/A	ch.11.24196551F	chr11:24239977	NA	0.49	4.74	0.3	3.67e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg19223190	chr17:80058835	NA	-0.45	-6.47	-0.39	5.67e-10	Life satisfaction;
SARC	cis	rs3087591	0.639	rs2342052	chr17:29721011	T/C	cg24425628	chr17:29625626	OMG;NF1	0.39	4.83	0.3	2.43e-6	Hip circumference;
SARC	cis	rs7412746	0.658	rs72704682	chr1:150897677	A/T	cg10589385	chr1:150898437	SETDB1	0.42	5.64	0.35	4.91e-8	Melanoma;
SARC	cis	rs9399135	0.967	rs9321481	chr6:135352648	C/G	cg24558204	chr6:135376177	HBS1L	-0.45	-6.07	-0.37	5.09e-9	Red blood cell count;
SARC	cis	rs1865721	0.728	rs8087297	chr18:73136221	T/A	cg26385618	chr18:73139727	C18orf62	-0.39	-5.44	-0.34	1.34e-7	Intelligence;
SARC	cis	rs9303401	0.580	rs2013166	chr17:56637630	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	11.65	0.61	5.15e-25	Cognitive test performance;
SARC	cis	rs17666538	1.000	rs61122136	chr8:585027	G/C	cg07234876	chr8:600039	NA	-1.0	-7.44	-0.44	1.88e-12	IgG glycosylation;
SARC	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg18876405	chr7:65276391	NA	-0.45	-5.5	-0.34	9.95e-8	Aortic root size;
SARC	cis	rs2304069	0.954	rs4705409	chr5:149414899	A/G	cg12661370	chr5:149340060	SLC26A2	0.6	5.89	0.36	1.33e-8	HIV-1 control;
SARC	cis	rs1797885	0.510	rs2442802	chr3:12608045	A/C	cg05775895	chr3:12838266	CAND2	0.38	4.96	0.31	1.37e-6	Immature fraction of reticulocytes;
SARC	cis	rs2153535	0.580	rs6597337	chr6:8531652	C/T	cg21535247	chr6:8435926	SLC35B3	0.54	6.84	0.41	6.76e-11	Motion sickness;
SARC	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg18252515	chr7:66147081	NA	-1.3	-11.47	-0.6	1.96e-24	Diabetic kidney disease;
SARC	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg21724239	chr8:58056113	NA	0.58	6.22	0.38	2.3e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4742903	0.527	rs1395829	chr9:106954204	C/T	cg14250997	chr9:106856677	SMC2	0.39	4.86	0.3	2.12e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs832540	0.629	rs3309	chr5:56092779	A/T	cg22800045	chr5:56110881	MAP3K1	-0.46	-5.5	-0.34	1.01e-7	Coronary artery disease;
SARC	trans	rs1994135	0.647	rs66542958	chr12:33695385	T/G	cg13010199	chr12:38710504	ALG10B	0.72	8.72	0.5	5.41e-16	Resting heart rate;
SARC	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg08677398	chr8:58056175	NA	0.43	5.05	0.31	8.92e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7169223	0.653	rs3743057	chr15:79089007	T/C	cg06917634	chr15:78832804	PSMA4	-0.49	-5.18	-0.32	4.86e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
SARC	cis	rs7772486	0.790	rs9497435	chr6:146265340	C/A	cg23711669	chr6:146136114	FBXO30	-0.76	-11.77	-0.61	2.12e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7560272	0.501	rs7210	chr2:73957124	A/G	cg20560298	chr2:73613845	ALMS1	0.42	5.62	0.35	5.46e-8	Schizophrenia;
SARC	cis	rs3204955	0.802	rs7541344	chr1:116251926	C/A	cg20810993	chr1:116250018	CASQ2	-0.56	-5.8	-0.36	2.18e-8	Itch intensity from mosquito bite adjusted by bite size;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg12960782	chr5:59996455	DEPDC1B	-0.57	-6.35	-0.38	1.14e-9	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg13206674	chr6:150067644	NUP43	0.53	6.78	0.41	9.67e-11	Lung cancer;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg13597198	chr19:3208049	NCLN	0.47	6.23	0.38	2.14e-9	Schizophrenia;
SARC	cis	rs7621025	0.586	rs12330725	chr3:136412580	A/T	cg15507776	chr3:136538369	TMEM22	-0.43	-4.83	-0.3	2.48e-6	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
SARC	trans	rs11722228	0.521	rs12501336	chr4:10137351	G/A	cg26043149	chr18:55253948	FECH	0.75	9.21	0.52	1.99e-17	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs752092	1.000	rs7182945	chr15:101784223	C/T	cg19997662	chr15:101784653	CHSY1	-0.43	-5.7	-0.35	3.68e-8	Corneal structure;
SARC	cis	rs2882667	0.858	rs2043271	chr5:138459108	A/G	cg04439458	chr5:138467593	SIL1	-0.28	-4.79	-0.3	2.98e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg00149659	chr3:10157352	C3orf10	0.78	7.3	0.43	4.52e-12	Alzheimer's disease;
SARC	cis	rs1971762	0.523	rs3852562	chr12:54085750	T/C	cg06632207	chr12:54070931	ATP5G2	0.44	5.73	0.35	3.16e-8	Height;
SARC	cis	rs7582180	0.629	rs12991172	chr2:100941671	A/G	cg14675211	chr2:100938903	LONRF2	0.51	7.68	0.45	4.44e-13	Intelligence (multi-trait analysis);
SARC	cis	rs72615157	0.539	rs2261360	chr7:99692993	G/T	cg22004693	chr7:99632812	ZKSCAN1	0.75	9.31	0.52	1.02e-17	Lung function (FEV1/FVC);
SARC	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg11764359	chr7:65958608	NA	0.88	12.6	0.64	4.07e-28	Aortic root size;
SARC	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs7859245	0.819	rs10117157	chr9:138490836	T/C	cg01352810	chr12:133707387	ZNF10	0.56	6.75	0.4	1.16e-10	Response to paliperidone in schizophrenia (negative Marder score);
SARC	cis	rs7662987	0.517	rs2851268	chr4:100027878	A/G	cg13256891	chr4:100009986	ADH5	0.66	8.13	0.47	2.55e-14	Smoking initiation;
SARC	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg22433210	chr17:43662623	NA	1.08	12.77	0.64	1.12e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	trans	rs9929218	1.000	rs12448448	chr16:68802516	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.53	-6.69	-0.4	1.6e-10	Colorectal cancer;
SARC	cis	rs10089	0.953	rs72794400	chr5:127516028	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	8.92	0.5	1.4e-16	Ileal carcinoids;
SARC	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.75	8.92	0.5	1.38e-16	Height;
SARC	cis	rs910316	1.000	rs9805979	chr14:75566209	G/A	cg11812906	chr14:75593930	NEK9	0.87	13.66	0.67	1.39e-31	Height;
SARC	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg17221315	chr6:27791827	HIST1H4J	0.45	4.74	0.3	3.76e-6	Depression;
SARC	cis	rs708547	0.836	rs781554	chr4:57717537	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.55	-5.57	-0.34	6.83e-8	Response to bleomycin (chromatid breaks);
SARC	cis	rs2204008	0.720	rs11170774	chr12:38021722	C/T	cg13010199	chr12:38710504	ALG10B	-0.65	-8.71	-0.5	5.89e-16	Bladder cancer;
SARC	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg04166393	chr7:2884313	GNA12	0.45	5.48	0.34	1.08e-7	Height;
SARC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg11494091	chr17:61959527	GH2	0.54	8.15	0.47	2.26e-14	Prudent dietary pattern;
SARC	cis	rs6964587	0.869	rs401	chr7:91527945	T/G	cg17063962	chr7:91808500	NA	-0.91	-14.0	-0.68	9.98e-33	Breast cancer;
SARC	cis	rs4466137	0.830	rs10039752	chr5:82974532	G/A	cg16102102	chr5:83017553	HAPLN1	-0.72	-9.26	-0.52	1.43e-17	Prostate cancer;
SARC	cis	rs1008375	0.900	rs3822235	chr4:17694916	C/T	cg16339924	chr4:17578868	LAP3	-0.52	-6.53	-0.39	4.13e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4891159	0.527	rs690593	chr18:74160408	C/G	cg24786174	chr18:74118243	ZNF516	0.71	11.33	0.6	5.26e-24	Longevity;
SARC	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg09699651	chr6:150184138	LRP11	0.39	4.98	0.31	1.26e-6	Lung cancer;
SARC	cis	rs2233152	0.610	rs10405596	chr19:41314720	C/T	cg07297178	chr19:42193084	CEACAM7	0.39	4.92	0.31	1.62e-6	Kawasaki disease;
SARC	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg26818010	chr10:134567672	INPP5A	-0.6	-6.35	-0.38	1.11e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs7953249	0.791	rs1920792	chr12:121404584	T/C	cg02403541	chr12:121454288	C12orf43	-0.43	-5.17	-0.32	4.96e-7	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	trans	rs12310956	0.532	rs1352209	chr12:33983408	G/A	cg13010199	chr12:38710504	ALG10B	0.65	8.68	0.49	7.12e-16	Morning vs. evening chronotype;
SARC	cis	rs1957429	0.808	rs4899150	chr14:65344400	A/G	cg23373153	chr14:65346875	NA	0.98	9.28	0.52	1.18e-17	Pediatric areal bone mineral density (radius);
SARC	cis	rs4481887	0.861	rs4644528	chr1:248472508	T/A	cg00666640	chr1:248458726	OR2T12	0.34	5.7	0.35	3.65e-8	Common traits (Other);
SARC	cis	rs763121	1.000	rs86796	chr22:38881454	A/C	cg21395723	chr22:39101663	GTPBP1	-0.5	-5.98	-0.36	8.35e-9	Menopause (age at onset);
SARC	cis	rs7247513	0.759	rs73002392	chr19:12768391	G/A	cg11738485	chr19:12877000	HOOK2	0.42	4.96	0.31	1.39e-6	Bipolar disorder;
SARC	cis	rs9467773	1.000	rs9393731	chr6:26529374	C/T	cg11502198	chr6:26597334	ABT1	0.45	5.47	0.34	1.14e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6815814	0.851	rs11466617	chr4:38780471	T/C	cg06935464	chr4:38784597	TLR10	0.63	5.98	0.36	8.46e-9	Breast cancer;
SARC	cis	rs8067545	0.641	rs203481	chr17:19828728	C/T	cg13482628	chr17:19912719	NA	0.54	6.84	0.41	6.97e-11	Schizophrenia;
SARC	cis	rs11122272	0.766	rs2808614	chr1:231550168	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.67	9.91	0.54	1.54e-19	Hemoglobin concentration;
SARC	cis	rs11623869	0.772	rs12587310	chr14:103907286	G/A	cg12935359	chr14:103987150	CKB	0.4	5.87	0.36	1.48e-8	Bone mineral density;
SARC	trans	rs56279505	0.629	rs62307295	chr4:100260545	C/A	cg21156590	chr1:3420848	MEGF6	-0.83	-6.43	-0.39	7.07e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2120019	0.938	rs1867150	chr15:75321139	T/C	cg17294928	chr15:75287854	SCAMP5	-1.01	-15.27	-0.71	6.03e-37	Blood trace element (Zn levels);
SARC	cis	rs2814982	0.605	rs75152896	chr6:34477793	G/A	cg17674042	chr6:34482479	PACSIN1	-0.58	-5.05	-0.31	9.01e-7	Cholesterol, total;Total cholesterol levels;
SARC	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg12463550	chr7:65579703	CRCP	0.48	5.79	0.35	2.23e-8	Aortic root size;
SARC	cis	rs807669	0.548	rs9605957	chr22:19187375	G/A	cg02655711	chr22:19163373	SLC25A1	0.39	5.62	0.35	5.3e-8	Metabolite levels;
SARC	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg24531977	chr5:56204891	C5orf35	-0.56	-5.67	-0.35	4.23e-8	Initial pursuit acceleration;
SARC	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg19318889	chr4:1322082	MAEA	0.4	4.84	0.3	2.37e-6	Longevity;
SARC	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg01475735	chr3:40494733	NA	0.46	5.2	0.32	4.46e-7	Renal cell carcinoma;
SARC	cis	rs9810089	0.835	rs6791611	chr3:136160590	C/G	cg15507776	chr3:136538369	TMEM22	-0.45	-5.06	-0.31	8.46e-7	Gestational age at birth (child effect);
SARC	cis	rs981844	0.740	rs1020702	chr4:154685712	A/C	cg14289246	chr4:154710475	SFRP2	-0.61	-7.18	-0.43	9.54e-12	Response to statins (LDL cholesterol change);
SARC	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg07061783	chr6:25882402	NA	-0.39	-4.94	-0.31	1.49e-6	Intelligence (multi-trait analysis);
SARC	cis	rs11252926	0.565	rs60553947	chr10:474284	T/C	cg16386425	chr10:429943	DIP2C	0.45	5.05	0.31	9.09e-7	Psychosis in Alzheimer's disease;
SARC	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg03709012	chr19:19516395	GATAD2A	1.02	17.74	0.76	4.06e-45	Tonsillectomy;
SARC	cis	rs2180341	0.960	rs6913424	chr6:127707010	A/C	cg27446573	chr6:127587934	RNF146	1.07	14.71	0.69	4.35e-35	Breast cancer;
SARC	cis	rs7772486	0.790	rs9403755	chr6:146231470	C/A	cg23711669	chr6:146136114	FBXO30	-0.79	-12.5	-0.63	8.58e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6542838	0.611	rs13006398	chr2:99522323	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-5.52	-0.34	8.89e-8	Fear of minor pain;
SARC	trans	rs1814175	0.645	rs1722000	chr11:49917928	A/C	cg15704280	chr7:45808275	SEPT13	-0.88	-14.0	-0.68	1.02e-32	Height;
SARC	cis	rs8141529	0.529	rs5762780	chr22:29151760	G/A	cg02153584	chr22:29168773	CCDC117	0.63	6.46	0.39	6.2e-10	Lymphocyte counts;
SARC	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg16680214	chr1:154839983	KCNN3	-0.36	-5.72	-0.35	3.2e-8	Prostate cancer;
SARC	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg26681399	chr22:41777847	TEF	0.47	5.16	0.32	5.3e-7	Vitiligo;
SARC	cis	rs7208859	0.614	rs28758251	chr17:29223312	A/T	cg13385521	chr17:29058706	SUZ12P	0.85	7.23	0.43	7.08e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs2153535	0.580	rs6597326	chr6:8482019	A/C	cg23788917	chr6:8435910	SLC35B3	0.64	8.59	0.49	1.25e-15	Motion sickness;
SARC	cis	rs17539620	0.624	rs871068	chr6:154837514	C/A	cg20019720	chr6:154832845	CNKSR3	0.41	4.84	0.3	2.39e-6	Lipoprotein (a) levels;
SARC	trans	rs9388451	0.626	rs9385383	chr6:126086290	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.62	-8.25	-0.48	1.13e-14	Brugada syndrome;
SARC	cis	rs858239	0.720	rs10227559	chr7:23272144	G/A	cg23682824	chr7:23144976	KLHL7	0.62	7.83	0.46	1.74e-13	Cerebrospinal fluid biomarker levels;
SARC	cis	rs17023223	0.537	rs10923767	chr1:119732347	C/T	cg05756136	chr1:119680316	WARS2	-0.48	-5.67	-0.35	4.28e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs11190604	1.000	rs7084810	chr10:102297546	A/G	cg07080220	chr10:102295463	HIF1AN	0.8	9.44	0.53	3.91e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg24829409	chr8:58192753	C8orf71	-0.54	-6.0	-0.37	7.57e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs2898290	0.617	rs13273172	chr8:11461111	A/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.77	-0.5	3.89e-16	Systolic blood pressure;
SARC	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg27170947	chr2:26402098	FAM59B	0.37	4.8	0.3	2.79e-6	Gut microbiome composition (summer);
SARC	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg18876405	chr7:65276391	NA	-0.71	-9.13	-0.51	3.27e-17	Aortic root size;
SARC	cis	rs7246657	1.000	rs35398388	chr19:37740358	A/G	cg14683738	chr19:37701593	ZNF585B	0.61	5.52	0.34	8.9e-8	Coronary artery calcification;
SARC	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg20102877	chr2:27665638	KRTCAP3	-0.39	-5.41	-0.33	1.54e-7	Total body bone mineral density;
SARC	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg08219700	chr8:58056026	NA	0.6	5.71	0.35	3.49e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs314370	0.951	rs6706	chr7:100471044	C/T	cg10426581	chr7:100472382	SRRT	0.62	6.48	0.39	5.32e-10	Resting heart rate;
SARC	cis	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg05084668	chr3:125655381	ALG1L	-0.49	-5.22	-0.32	4.02e-7	Blood pressure (smoking interaction);
SARC	cis	rs6570726	0.577	rs406868	chr6:145809983	C/T	cg23711669	chr6:146136114	FBXO30	0.82	11.67	0.61	4.44e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3106136	0.967	rs12646184	chr4:95183216	A/G	cg11021082	chr4:95130006	SMARCAD1	0.39	6.08	0.37	4.93e-9	Capecitabine sensitivity;
SARC	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg00149659	chr3:10157352	C3orf10	0.68	6.36	0.38	1.03e-9	Alzheimer's disease;
SARC	cis	rs9911578	1.000	rs391370	chr17:56675050	A/C	cg12560992	chr17:57184187	TRIM37	0.84	11.45	0.6	2.22e-24	Intelligence (multi-trait analysis);
SARC	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg09323728	chr8:95962352	TP53INP1	-0.29	-4.91	-0.31	1.73e-6	Type 2 diabetes;
SARC	cis	rs1355223	0.525	rs10836316	chr11:34874295	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.5	-6.36	-0.38	1.06e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs11764590	0.724	rs1533829	chr7:2082841	A/G	cg24858417	chr7:2057703	MAD1L1	0.41	4.73	0.3	3.97e-6	Neuroticism;
SARC	cis	rs765787	0.530	rs28414644	chr15:45536721	G/C	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.67e-7	Uric acid levels;
SARC	cis	rs6570726	0.935	rs110289	chr6:145865176	C/G	cg23711669	chr6:146136114	FBXO30	0.78	12.0	0.62	3.86e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6964587	1.000	rs35653487	chr7:91745441	C/G	cg17063962	chr7:91808500	NA	0.95	16.04	0.72	1.66e-39	Breast cancer;
SARC	cis	rs2239547	0.522	rs9865094	chr3:52985319	G/C	cg22484793	chr3:52261325	TLR9	-0.34	-4.78	-0.3	3.11e-6	Schizophrenia;
SARC	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg12310025	chr6:25882481	NA	0.54	6.96	0.41	3.42e-11	Blood metabolite levels;
SARC	cis	rs72945132	0.882	rs72947078	chr11:70197542	G/T	cg00319359	chr11:70116639	PPFIA1	0.68	6.1	0.37	4.34e-9	Coronary artery disease;
SARC	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg06618935	chr21:46677482	NA	-0.41	-5.38	-0.33	1.78e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6582630	0.539	rs4882324	chr12:38499180	T/C	cg13010199	chr12:38710504	ALG10B	-0.51	-6.33	-0.38	1.23e-9	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg16405210	chr4:1374714	KIAA1530	-0.56	-6.86	-0.41	6.12e-11	Longevity;
SARC	cis	rs644799	0.710	rs10765771	chr11:95521044	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.95	16.35	0.73	1.52e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg23230018	chr19:36239588	LIN37	-0.61	-6.61	-0.4	2.64e-10	Hepatitis;
SARC	cis	rs7412746	0.611	rs10888391	chr1:150729983	G/A	cg10589385	chr1:150898437	SETDB1	0.4	5.29	0.33	2.88e-7	Melanoma;
SARC	cis	rs6991838	0.584	rs1533285	chr8:66549364	T/C	cg13398993	chr8:66546079	ARMC1	0.62	8.19	0.47	1.72e-14	Intelligence (multi-trait analysis);
SARC	cis	rs11098499	0.909	rs9759478	chr4:120367998	G/A	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs2731664	0.792	rs2630764	chr5:176880085	C/T	cg23176889	chr5:176863531	GRK6	-0.55	-8.26	-0.48	1.12e-14	Intelligence (multi-trait analysis);
SARC	cis	rs4970988	0.556	rs6695123	chr1:150563483	T/C	cg15448220	chr1:150897856	SETDB1	-0.41	-5.06	-0.31	8.69e-7	Urate levels;
SARC	cis	rs2075371	0.863	rs12672691	chr7:133954431	C/T	cg11752832	chr7:134001865	SLC35B4	0.48	5.85	0.36	1.66e-8	Mean platelet volume;
SARC	cis	rs11711311	0.824	rs35341324	chr3:113351719	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.6	7.28	0.43	4.99e-12	IgG glycosylation;
SARC	cis	rs7412746	0.658	rs12090215	chr1:150893660	C/A	cg15448220	chr1:150897856	SETDB1	0.51	6.65	0.4	2.02e-10	Melanoma;
SARC	cis	rs709400	1.000	rs2403205	chr14:104143385	C/T	cg12935359	chr14:103987150	CKB	-0.35	-5.18	-0.32	4.82e-7	Body mass index;
SARC	cis	rs7169223	0.653	rs2904228	chr15:79086099	G/A	cg06917634	chr15:78832804	PSMA4	0.54	5.55	0.34	7.59e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
SARC	cis	rs6604026	0.656	rs12066638	chr1:93375391	C/G	cg17283838	chr1:93427260	FAM69A	-0.42	-4.75	-0.3	3.59e-6	Multiple sclerosis;
SARC	trans	rs7824557	0.591	rs2572452	chr8:11228254	C/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.51	-0.44	1.27e-12	Retinal vascular caliber;
SARC	trans	rs9329221	0.537	rs6601414	chr8:9976748	G/A	cg06636001	chr8:8085503	FLJ10661	0.57	7.73	0.45	3.11e-13	Neuroticism;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg17696234	chr3:38164516	ACAA1	0.46	6.28	0.38	1.68e-9	Neuroticism;
SARC	cis	rs28386778	0.703	rs2286565	chr17:62010232	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	-0.57	-6.7	-0.4	1.58e-10	Prudent dietary pattern;
SARC	cis	rs9398803	0.673	rs1262556	chr6:127054435	G/C	cg20229609	chr6:126660872	C6orf173	-0.34	-4.72	-0.3	4e-6	Male-pattern baldness;
SARC	cis	rs10197940	0.532	rs13425170	chr2:152387112	A/C	cg19508488	chr2:152266495	RIF1	0.47	4.84	0.3	2.37e-6	Lung cancer;
SARC	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg18404041	chr3:52824283	ITIH1	-0.44	-6.59	-0.4	2.82e-10	Bipolar disorder;
SARC	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg06618935	chr21:46677482	NA	-0.41	-5.39	-0.33	1.75e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6540556	0.834	rs11119337	chr1:209934133	A/G	cg23920097	chr1:209922102	NA	-0.58	-6.96	-0.41	3.52e-11	Red blood cell count;
SARC	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg19077165	chr18:44547161	KATNAL2	-0.53	-7.33	-0.43	3.7e-12	Personality dimensions;
SARC	cis	rs703842	1.000	rs1875124	chr12:58196802	A/G	cg00677455	chr12:58241039	CTDSP2	0.51	6.6	0.4	2.73e-10	Multiple sclerosis;
SARC	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg22618164	chr12:122356400	WDR66	0.43	6.93	0.41	4.19e-11	Mean corpuscular volume;
SARC	cis	rs4803468	1.000	rs166925	chr19:41926098	T/C	cg08477640	chr19:41863820	B9D2	0.44	5.61	0.35	5.65e-8	Height;
SARC	cis	rs10752881	0.839	rs2093983	chr1:183094210	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.82e-21	Colorectal cancer;
SARC	cis	rs7662987	0.517	rs2602845	chr4:100023944	T/C	cg13256891	chr4:100009986	ADH5	0.66	8.13	0.47	2.55e-14	Smoking initiation;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26080111	chr7:559651	PDGFA	0.55	6.78	0.41	9.84e-11	Fibrinogen levels;
SARC	cis	rs67311347	1.000	rs67680017	chr3:40533164	C/T	cg09455208	chr3:40491958	NA	0.32	4.89	0.31	1.88e-6	Renal cell carcinoma;
SARC	cis	rs8072100	0.817	rs7213086	chr17:45752310	C/G	cg08085267	chr17:45401833	C17orf57	-0.41	-4.78	-0.3	3.09e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs12421382	0.507	rs11600810	chr11:109356443	G/A	cg27471124	chr11:109292789	C11orf87	0.54	7.07	0.42	1.83e-11	Schizophrenia;
SARC	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg11062466	chr8:58055876	NA	0.54	5.56	0.34	7.55e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1569175	0.655	rs166847	chr2:200840612	A/G	cg23649088	chr2:200775458	C2orf69	-1.0	-6.42	-0.39	7.59e-10	Response to treatment for acute lymphoblastic leukemia;
SARC	cis	rs9457247	0.902	rs366938	chr6:167403538	T/C	cg23791538	chr6:167370224	RNASET2	-0.63	-8.73	-0.5	4.9e-16	Crohn's disease;
SARC	cis	rs6834538	0.597	rs6822451	chr4:113463265	G/A	cg05166686	chr4:113558556	LARP7;C4orf21	0.54	7.33	0.43	3.86e-12	Free thyroxine concentration;
SARC	cis	rs1966248	0.543	rs12193307	chr6:134103250	A/G	cg25632230	chr6:134101081	NA	-0.53	-7.04	-0.42	2.09e-11	Coronary artery disease;
SARC	cis	rs4727027	0.866	rs1358062	chr7:148783743	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	5.6	0.34	6.12e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs9660992	0.710	rs1151787	chr1:205254238	G/A	cg00857998	chr1:205179979	DSTYK	0.49	5.88	0.36	1.39e-8	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs57244997	0.860	rs9458425	chr6:162376946	C/T	cg17173639	chr6:162384350	PARK2	-0.59	-5.65	-0.35	4.67e-8	Mosquito bite size;
SARC	cis	rs17030434	0.906	rs78436201	chr4:154661755	C/A	cg14289246	chr4:154710475	SFRP2	-0.63	-6.39	-0.39	8.95e-10	Electrocardiographic conduction measures;
SARC	cis	rs10791097	0.720	rs6590516	chr11:130733393	G/T	cg12179176	chr11:130786555	SNX19	0.71	10.6	0.57	1.12e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs7223966	1.000	rs8075521	chr17:61804954	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.53	-5.55	-0.34	7.66e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs12421382	0.659	rs56410856	chr11:109382455	T/G	cg16359550	chr11:109292809	C11orf87	0.36	5.14	0.32	5.81e-7	Schizophrenia;
SARC	cis	rs7666738	0.791	rs4699324	chr4:98967496	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg02951883	chr7:2050386	MAD1L1	-0.42	-5.43	-0.34	1.41e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg04267008	chr7:1944627	MAD1L1	-0.49	-5.55	-0.34	7.64e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs9462027	0.540	rs2814951	chr6:34695081	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.91	-0.36	1.19e-8	Systemic lupus erythematosus;
SARC	cis	rs9902453	0.791	rs3115090	chr17:28035014	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	7.06	0.42	1.92e-11	Coffee consumption (cups per day);
SARC	cis	rs3796352	1.000	rs13074524	chr3:52974184	A/G	cg27565382	chr3:53032988	SFMBT1	0.83	5.57	0.34	7.16e-8	Immune reponse to smallpox (secreted IL-2);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg17481046	chr3:40547578	ZNF620	-0.51	-6.48	-0.39	5.33e-10	Breast cancer;
SARC	cis	rs929354	0.772	rs3802118	chr7:156986814	T/C	cg05182265	chr7:156933206	UBE3C	-0.33	-5.02	-0.31	1.03e-6	Body mass index;
SARC	cis	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg22857025	chr5:266934	NA	-1.05	-11.9	-0.61	7.87e-26	Breast cancer;
SARC	cis	rs2290405	0.527	rs4690332	chr4:910520	C/T	cg04824913	chr4:887549	GAK	-0.6	-7.78	-0.45	2.41e-13	Systemic sclerosis;
SARC	cis	rs10751667	0.677	rs11246386	chr11:1044938	C/T	cg11406765	chr11:980039	AP2A2	0.41	5.0	0.31	1.12e-6	Alzheimer's disease (late onset);
SARC	cis	rs7762018	1.000	rs7762018	chr6:170113244	G/T	cg13891659	chr6:170190454	C6orf122;C6orf208	0.52	4.78	0.3	3.16e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg12000995	chr2:27665139	KRTCAP3	-0.3	-4.77	-0.3	3.24e-6	Total body bone mineral density;
SARC	cis	rs2180341	0.782	rs6912750	chr6:127723081	A/T	cg27446573	chr6:127587934	RNF146	0.79	10.81	0.58	2.49e-22	Breast cancer;
SARC	cis	rs2153219	1.000	rs632360	chr6:149757596	C/T	cg18043157	chr6:150390308	ULBP3	-0.53	-5.08	-0.32	7.74e-7	Coronary artery disease;
SARC	cis	rs9393692	0.905	rs7450556	chr6:26299900	C/T	cg13736514	chr6:26305472	NA	-0.65	-9.25	-0.52	1.51e-17	Educational attainment;
SARC	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg26335602	chr6:28129616	ZNF389	0.53	5.91	0.36	1.2e-8	Depression;
SARC	cis	rs11676348	0.808	rs1008563	chr2:219026888	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-5.98	-0.36	8.37e-9	Ulcerative colitis;
SARC	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.23e-9	Life satisfaction;
SARC	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg18357526	chr6:26021779	HIST1H4A	-0.68	-8.71	-0.5	5.81e-16	Intelligence (multi-trait analysis);
SARC	cis	rs9325144	0.647	rs11169189	chr12:39097078	A/T	cg13010199	chr12:38710504	ALG10B	-0.49	-5.98	-0.36	8.55e-9	Morning vs. evening chronotype;
SARC	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.72	-7.24	-0.43	6.52e-12	Platelet count;
SARC	cis	rs12681366	0.573	rs2470740	chr8:95399551	A/T	cg26464482	chr8:95565502	KIAA1429	-0.44	-5.21	-0.32	4.12e-7	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs10779751	0.770	rs2791643	chr1:11207269	C/T	cg08854313	chr1:11322531	MTOR	0.77	10.33	0.56	7.51e-21	Body mass index;
SARC	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg25072359	chr17:41440525	NA	0.5	6.25	0.38	1.98e-9	Menopause (age at onset);
SARC	cis	rs7149337	0.804	rs4131981	chr14:51667504	A/T	cg23942311	chr14:51606299	NA	-0.32	-5.52	-0.34	9.03e-8	Cancer;
SARC	cis	rs17376456	1.000	rs58734583	chr5:93532155	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.47	0.34	1.14e-7	Diabetic retinopathy;
SARC	cis	rs7829975	0.517	rs12542733	chr8:8824858	G/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.55	-0.44	9.76e-13	Mood instability;
SARC	trans	rs2727020	0.619	rs11040300	chr11:49269984	C/A	cg15704280	chr7:45808275	SEPT13	0.64	7.39	0.44	2.59e-12	Coronary artery disease;
SARC	cis	rs941873	0.868	rs2181080	chr10:81121960	A/G	cg09469691	chr10:81107165	PPIF	0.68	9.25	0.52	1.49e-17	Height;
SARC	cis	rs1144333	0.655	rs75578876	chr1:76395586	A/C	cg03433033	chr1:76189801	ACADM	0.64	5.23	0.32	3.71e-7	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg01448562	chr3:133502909	NA	-0.51	-7.85	-0.46	1.48e-13	Iron status biomarkers;
SARC	trans	rs208520	0.955	rs208538	chr6:66964492	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.76	-8.44	-0.48	3.38e-15	Exhaled nitric oxide output;
SARC	cis	rs36051895	0.632	rs10815165	chr9:5149138	T/C	cg02405213	chr9:5042618	JAK2	-0.45	-5.39	-0.33	1.76e-7	Pediatric autoimmune diseases;
SARC	trans	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.55	-7.15	-0.42	1.12e-11	Intelligence (multi-trait analysis);
SARC	cis	rs7178572	0.568	rs12914345	chr15:77670401	A/C	cg22256960	chr15:77711686	NA	-0.53	-5.97	-0.36	8.67e-9	Type 2 diabetes;
SARC	cis	rs1153858	1.000	rs1890565	chr15:45663299	T/C	cg14582100	chr15:45693742	SPATA5L1	0.34	4.71	0.3	4.2e-6	Homoarginine levels;
SARC	cis	rs3857067	0.804	rs6821438	chr4:95091911	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.34	-4.97	-0.31	1.27e-6	QT interval;
SARC	cis	rs2814982	0.605	rs80254589	chr6:34478514	C/T	cg14254433	chr6:34482411	PACSIN1	-0.51	-4.89	-0.31	1.89e-6	Cholesterol, total;Total cholesterol levels;
SARC	cis	rs2295359	0.892	rs11209005	chr1:67618678	A/G	cg12940439	chr1:67600707	NA	0.48	6.86	0.41	6.14e-11	Psoriasis;
SARC	cis	rs708547	0.874	rs781551	chr4:57718406	A/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.55	-5.57	-0.34	6.83e-8	Response to bleomycin (chromatid breaks);
SARC	cis	rs6121246	0.909	rs6087778	chr20:30354142	G/A	cg13852791	chr20:30311386	BCL2L1	0.85	9.09	0.51	4.49e-17	Mean corpuscular hemoglobin;
SARC	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg11843238	chr5:131593191	PDLIM4	-0.4	-4.88	-0.3	1.99e-6	Breast cancer;
SARC	cis	rs1348850	0.632	rs12616288	chr2:178503813	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.49	5.67	0.35	4.13e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs3796352	1.000	rs13069006	chr3:52973305	G/C	cg07884673	chr3:53033167	SFMBT1	0.8	4.95	0.31	1.43e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2635047	1.000	rs2635043	chr18:44679769	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.54	7.39	0.44	2.65e-12	Educational attainment;
SARC	cis	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg21144161	chr5:423903	AHRR	0.31	4.84	0.3	2.39e-6	Cystic fibrosis severity;
SARC	cis	rs9815354	0.812	rs73071328	chr3:41810055	A/C	cg03022575	chr3:42003672	ULK4	0.72	5.99	0.37	7.83e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg23262073	chr20:60523788	NA	-0.38	-5.31	-0.33	2.62e-7	Body mass index;
SARC	cis	rs356220	0.642	rs356172	chr4:90631986	C/T	cg06632027	chr4:90757378	SNCA	0.41	5.44	0.34	1.37e-7	Parkinson's disease;
SARC	cis	rs7617773	0.817	rs11707606	chr3:48237087	A/C	cg11946769	chr3:48343235	NME6	0.72	9.33	0.52	8.45e-18	Coronary artery disease;
SARC	cis	rs1670533	1.000	rs6850784	chr4:1059809	G/A	cg27284194	chr4:1044797	NA	0.45	4.81	0.3	2.67e-6	Recombination rate (females);
SARC	cis	rs2916247	0.865	rs2930536	chr8:93181853	A/G	cg10183463	chr8:93005414	RUNX1T1	0.51	5.2	0.32	4.42e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2070997	0.607	rs2183224	chr9:133665081	G/A	cg11464064	chr9:133710261	ABL1	0.54	5.25	0.33	3.47e-7	Response to amphetamines;
SARC	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg05861140	chr6:150128134	PCMT1	-0.37	-4.88	-0.3	2.01e-6	Lung cancer;
SARC	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.41	-6.7	-0.4	1.56e-10	Total body bone mineral density;
SARC	cis	rs453301	0.719	rs34004903	chr8:8892604	C/T	cg11608241	chr8:8085544	FLJ10661	-0.44	-5.53	-0.34	8.73e-8	Joint mobility (Beighton score);
SARC	cis	rs7712401	0.755	rs3213794	chr5:122161638	A/C	cg19412675	chr5:122181750	SNX24	0.38	5.09	0.32	7.45e-7	Mean platelet volume;
SARC	cis	rs3768617	0.510	rs10737245	chr1:183100884	G/A	cg13390022	chr1:182993471	LAMC1	0.31	4.79	0.3	3.01e-6	Fuchs's corneal dystrophy;
SARC	cis	rs4780401	0.610	rs933574	chr16:11792700	A/C	cg01061890	chr16:11836724	TXNDC11	-0.39	-4.99	-0.31	1.19e-6	Rheumatoid arthritis;
SARC	cis	rs1707322	0.721	rs9793568	chr1:46130373	G/A	cg03146154	chr1:46216737	IPP	0.52	6.32	0.38	1.33e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2354432	0.546	rs7539416	chr1:146881586	C/T	cg25205988	chr1:146714368	CHD1L	0.86	8.58	0.49	1.36e-15	Mitochondrial DNA levels;
SARC	cis	rs17253792	0.822	rs78820104	chr14:56068854	C/T	cg01858014	chr14:56050164	KTN1	-0.67	-5.16	-0.32	5.38e-7	Putamen volume;
SARC	cis	rs4128725	0.778	rs76984433	chr1:159384493	C/T	cg25076881	chr1:159409836	OR10J1	0.49	5.49	0.34	1.07e-7	Select biomarker traits;
SARC	cis	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.66	-8.8	-0.5	3.21e-16	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs2153535	0.580	rs2327062	chr6:8453858	G/A	cg21535247	chr6:8435926	SLC35B3	0.54	6.69	0.4	1.67e-10	Motion sickness;
SARC	cis	rs7769051	0.615	rs12209144	chr6:133191064	A/T	cg07930552	chr6:133119739	C6orf192	0.78	6.21	0.38	2.39e-9	Type 2 diabetes nephropathy;
SARC	cis	rs74181299	0.964	rs2723065	chr2:65279414	A/G	cg20592124	chr2:65290738	CEP68	0.48	7.03	0.42	2.25e-11	Pulse pressure;
SARC	cis	rs1699337	0.702	rs1175544	chr3:12467044	C/T	cg04748988	chr3:12329223	PPARG	-0.37	-4.77	-0.3	3.21e-6	Cholesterol, total;
SARC	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg16606324	chr3:10149918	C3orf24	0.52	5.0	0.31	1.13e-6	Alzheimer's disease;
SARC	cis	rs7833790	0.654	rs7835342	chr8:82698092	A/G	cg27398817	chr8:82754497	SNX16	-0.43	-5.13	-0.32	6.22e-7	Diastolic blood pressure;
SARC	cis	rs3768617	0.811	rs10911232	chr1:183052533	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.62	8.54	0.49	1.71e-15	Fuchs's corneal dystrophy;
SARC	cis	rs9790314	0.967	rs9821201	chr3:160996155	G/C	cg03342759	chr3:160939853	NMD3	-0.61	-7.73	-0.45	3.22e-13	Morning vs. evening chronotype;
SARC	cis	rs4588572	0.644	rs6873144	chr5:77741784	C/T	cg18281939	chr5:77783895	LHFPL2	0.35	4.86	0.3	2.16e-6	Triglycerides;
SARC	cis	rs11098499	0.908	rs2017057	chr4:120257711	A/G	cg09307838	chr4:120376055	NA	0.9	12.29	0.63	4.2e-27	Corneal astigmatism;
SARC	cis	rs644799	0.509	rs580181	chr11:95643040	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.72	9.4	0.52	5.38e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs11792861	0.926	rs75128146	chr9:111833791	G/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.66	7.6	0.45	7.38e-13	Menarche (age at onset);
SARC	cis	rs4803468	1.000	rs2241708	chr19:41912270	C/T	cg14132834	chr19:41945861	ATP5SL	-0.57	-7.52	-0.44	1.2e-12	Height;
SARC	cis	rs9325144	0.602	rs11169100	chr12:39077861	G/T	cg13010199	chr12:38710504	ALG10B	-0.55	-6.97	-0.42	3.17e-11	Morning vs. evening chronotype;
SARC	cis	rs9325144	0.513	rs7977596	chr12:38649067	C/A	cg26384229	chr12:38710491	ALG10B	-0.63	-8.1	-0.47	2.99e-14	Morning vs. evening chronotype;
SARC	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg11366901	chr6:160182831	ACAT2	1.01	10.65	0.57	7.48e-22	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs6061231	0.755	rs11699160	chr20:60958651	T/C	cg22633769	chr20:60982531	CABLES2	0.43	4.78	0.3	3.06e-6	Colorectal cancer;
SARC	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg25767906	chr1:53392781	SCP2	0.32	4.82	0.3	2.65e-6	Monocyte count;
SARC	cis	rs3741404	0.609	rs666497	chr11:63869821	G/C	cg04317338	chr11:64019027	PLCB3	0.48	5.52	0.34	8.86e-8	Platelet count;
SARC	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg11247378	chr22:39784982	NA	-0.32	-5.14	-0.32	5.95e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg23262073	chr20:60523788	NA	-0.39	-5.71	-0.35	3.41e-8	Body mass index;
SARC	cis	rs55823223	0.564	rs936391	chr17:73847799	A/G	cg14829360	chr17:73884958	NA	0.52	6.99	0.42	2.85e-11	Psoriasis;
SARC	cis	rs4969178	0.965	rs8072632	chr17:76397830	T/C	cg02836325	chr17:76403955	PGS1	0.33	5.07	0.32	8.11e-7	HDL cholesterol levels;
SARC	trans	rs61931739	0.534	rs1844526	chr12:34102780	G/A	cg26384229	chr12:38710491	ALG10B	0.87	12.44	0.63	1.37e-27	Morning vs. evening chronotype;
SARC	cis	rs7647973	0.626	rs7637711	chr3:49829653	A/G	cg07636037	chr3:49044803	WDR6	-0.64	-6.68	-0.4	1.75e-10	Menarche (age at onset);
SARC	trans	rs61931739	0.517	rs2101396	chr12:34048927	T/A	cg13010199	chr12:38710504	ALG10B	0.68	9.39	0.52	5.53e-18	Morning vs. evening chronotype;
SARC	cis	rs9815354	1.000	rs1717021	chr3:41983860	A/T	cg03022575	chr3:42003672	ULK4	-0.55	-5.14	-0.32	5.7e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs854765	0.624	rs9899634	chr17:17727943	A/T	cg04398451	chr17:18023971	MYO15A	0.38	5.57	0.34	7.13e-8	Total body bone mineral density;
SARC	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg22433210	chr17:43662623	NA	1.04	12.55	0.64	6.33e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7223966	1.000	rs73337598	chr17:61732576	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.24	0.38	2.07e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2408955	0.561	rs9971924	chr12:48479832	C/G	cg24011408	chr12:48396354	COL2A1	-0.41	-4.95	-0.31	1.46e-6	Glycated hemoglobin levels;
SARC	cis	rs7772486	0.846	rs6908063	chr6:146403618	T/C	cg05347473	chr6:146136440	FBXO30	0.46	6.39	0.39	8.89e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.65	-8.02	-0.47	5.13e-14	Gut microbiome composition (summer);
SARC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg11905131	chr22:24372483	LOC391322	-0.45	-4.97	-0.31	1.3e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6120849	0.754	rs6120797	chr20:33606002	G/A	cg24642439	chr20:33292090	TP53INP2	0.57	5.48	0.34	1.1e-7	Protein C levels;
SARC	cis	rs17739167	0.550	rs17687976	chr15:42234824	A/G	cg20935245	chr15:42234343	EHD4	-0.46	-6.03	-0.37	6.41e-9	Monocyte count;
SARC	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg26335602	chr6:28129616	ZNF389	0.51	5.62	0.35	5.41e-8	Depression;
SARC	cis	rs7760949	0.852	rs9475800	chr6:13932230	A/G	cg27413430	chr6:13925136	RNF182	0.43	5.11	0.32	6.79e-7	Mean corpuscular hemoglobin concentration;
SARC	trans	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg00938859	chr5:1591904	SDHAP3	0.74	6.91	0.41	4.53e-11	Breast cancer;
SARC	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg00149659	chr3:10157352	C3orf10	0.7	6.58	0.4	3.15e-10	Alzheimer's disease;
SARC	cis	rs995000	0.931	rs10159255	chr1:63020816	C/A	cg06896770	chr1:63153194	DOCK7	1.0	15.5	0.71	1.02e-37	Triglyceride levels;
SARC	cis	rs4803468	1.000	rs4803469	chr19:41922775	A/C	cg09537434	chr19:41945824	ATP5SL	-0.98	-17.39	-0.75	5.41e-44	Height;
SARC	cis	rs4642101	0.662	rs4034942	chr3:12836792	C/T	cg24848339	chr3:12840334	CAND2	0.36	5.66	0.35	4.39e-8	QRS complex (12-leadsum);
SARC	cis	rs13095912	1.000	rs9714158	chr3:185328780	C/T	cg11274856	chr3:185301563	NA	0.36	4.98	0.31	1.24e-6	Systolic blood pressure;
SARC	cis	rs4906332	1.000	rs35126287	chr14:103959432	A/G	cg26031613	chr14:104095156	KLC1	-0.49	-5.76	-0.35	2.64e-8	Coronary artery disease;
SARC	cis	rs6430585	0.528	rs2278682	chr2:136743143	G/C	cg07169764	chr2:136633963	MCM6	0.91	11.8	0.61	1.73e-25	Corneal structure;
SARC	cis	rs9911578	1.000	rs6503870	chr17:56659018	C/T	cg12560992	chr17:57184187	TRIM37	0.82	11.2	0.59	1.36e-23	Intelligence (multi-trait analysis);
SARC	trans	rs11088226	0.681	rs9622	chr21:33951068	T/C	cg09050820	chr6:167586206	TCP10L2	0.6	6.73	0.4	1.33e-10	Gastritis;
SARC	cis	rs12903285	1	rs12903285	chr15:78778953	A/G	cg24631222	chr15:78858424	CHRNA5	-0.47	-6.08	-0.37	4.87e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
SARC	trans	rs9870680	0.505	rs1450097	chr3:7545521	C/T	cg14106308	chr3:157217286	VEPH1	-0.41	-6.44	-0.39	6.68e-10	Major depressive disorder (broad);
SARC	cis	rs10463554	0.963	rs12054848	chr5:102380440	C/T	cg23492399	chr5:102201601	PAM	-0.51	-5.65	-0.35	4.78e-8	Parkinson's disease;
SARC	cis	rs7772486	0.754	rs4896838	chr6:146015451	T/C	cg23711669	chr6:146136114	FBXO30	-0.91	-15.89	-0.72	5.29e-39	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9902453	0.868	rs7212162	chr17:28321328	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	7.03	0.42	2.28e-11	Coffee consumption (cups per day);
SARC	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.73	10.55	0.57	1.64e-21	Menarche (age at onset);
SARC	cis	rs9462027	0.606	rs2038841	chr6:34738203	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.85	-0.36	1.69e-8	Systemic lupus erythematosus;
SARC	cis	rs12118280	0.581	rs545593	chr1:108720242	G/A	cg11967332	chr1:108735228	SLC25A24	-0.53	-6.26	-0.38	1.86e-9	Myeloid white cell count;
SARC	trans	rs61931739	0.500	rs12146843	chr12:34451738	T/G	cg13010199	chr12:38710504	ALG10B	0.76	10.71	0.57	5.2e-22	Morning vs. evening chronotype;
SARC	cis	rs11608355	0.515	rs4766476	chr12:109934700	A/G	cg05360138	chr12:110035743	NA	0.92	9.39	0.52	5.78e-18	Neuroticism;
SARC	cis	rs765787	0.530	rs2668737	chr15:45522799	C/T	cg24006582	chr15:45444508	DUOX1	-0.49	-6.49	-0.39	5.13e-10	Uric acid levels;
SARC	cis	rs1971762	0.561	rs4759288	chr12:54084006	T/A	cg06632207	chr12:54070931	ATP5G2	0.44	5.75	0.35	2.78e-8	Height;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg15043926	chr4:26863112	STIM2	0.53	6.98	0.42	2.97e-11	Chemerin levels;
SARC	cis	rs76419734	1.000	rs72671892	chr4:106680363	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.76	4.98	0.31	1.23e-6	Post bronchodilator FEV1;
SARC	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg12373951	chr3:133503437	NA	0.37	5.5	0.34	9.77e-8	Iron status biomarkers;
SARC	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	10.0	0.55	8.19e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs4765905	0.610	rs10774033	chr12:2314426	C/T	cg10668781	chr12:2307325	CACNA1C	-0.31	-4.87	-0.3	2.08e-6	Schizophrenia;
SARC	cis	rs739401	0.611	rs10833048	chr11:3020040	A/G	cg25174290	chr11:3078921	CARS	0.57	8.02	0.46	5.25e-14	Longevity;
SARC	cis	rs9660992	0.573	rs1172147	chr1:205225457	G/A	cg07972983	chr1:205091412	RBBP5	0.54	6.85	0.41	6.63e-11	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs8060686	0.920	rs1124324	chr16:67897487	C/T	cg04539111	chr16:67997858	SLC12A4	-0.51	-4.76	-0.3	3.38e-6	HDL cholesterol;Metabolic syndrome;
SARC	cis	rs11209002	0.956	rs11209000	chr1:67578514	C/G	cg02640540	chr1:67518911	SLC35D1	0.47	4.77	0.3	3.19e-6	Crohn's disease;
SARC	cis	rs7312933	0.585	rs7969814	chr12:42669657	C/G	cg19980929	chr12:42632907	YAF2	0.45	6.54	0.39	3.92e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	trans	rs79976124	0.837	rs74327235	chr6:66648353	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	7.91	0.46	1.06e-13	Type 2 diabetes;
SARC	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg12311346	chr5:56204834	C5orf35	-0.58	-6.02	-0.37	6.85e-9	Initial pursuit acceleration;
SARC	cis	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg11764359	chr7:65958608	NA	0.66	6.45	0.39	6.39e-10	Aortic root size;
SARC	trans	rs6076960	0.684	rs6038408	chr20:6268983	A/C	cg21095983	chr6:86352623	SYNCRIP	0.46	6.52	0.39	4.28e-10	Smooth-surface caries;
SARC	cis	rs3781913	0.675	rs907854	chr11:72353784	C/T	cg03713592	chr11:72463424	ARAP1	-0.4	-4.89	-0.31	1.84e-6	Rheumatoid arthritis;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg09862948	chr1:224177126	NA	-0.44	-6.71	-0.4	1.44e-10	Chemerin levels;
SARC	cis	rs3771570	0.681	rs12151655	chr2:242281438	T/A	cg21155796	chr2:242212141	HDLBP	0.67	5.74	0.35	2.99e-8	Prostate cancer;
SARC	cis	rs936229	1.000	rs936228	chr15:75132164	T/C	cg14664628	chr15:75095509	CSK	-1.03	-13.01	-0.65	1.94e-29	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs6964587	0.677	rs62467839	chr7:91967371	A/G	cg17063962	chr7:91808500	NA	0.83	10.92	0.58	1.08e-22	Breast cancer;
SARC	cis	rs1691799	0.899	rs1168302	chr12:66737518	C/T	cg16791601	chr12:66731901	HELB	-0.71	-10.6	-0.57	1.13e-21	White blood cell count (basophil);
SARC	cis	rs698833	0.638	rs698778	chr2:44740684	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	6.43	0.39	7.13e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs8067354	0.872	rs1295925	chr17:57910263	T/C	cg02344993	chr17:57696989	CLTC	-0.44	-5.13	-0.32	5.97e-7	Hemoglobin concentration;
SARC	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg20607798	chr8:58055168	NA	0.6	5.34	0.33	2.19e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7712401	0.755	rs10900759	chr5:122105080	T/A	cg19412675	chr5:122181750	SNX24	0.37	4.8	0.3	2.83e-6	Mean platelet volume;
SARC	cis	rs7520050	0.902	rs9429088	chr1:46497500	T/A	cg24296786	chr1:45957014	TESK2	0.37	4.74	0.3	3.71e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg06108461	chr20:60628389	TAF4	-0.6	-6.39	-0.39	8.75e-10	Obesity-related traits;
SARC	trans	rs9302817	0.891	rs13332701	chr16:6164745	C/T	cg11733626	chr3:123304043	PTPLB	-0.68	-6.32	-0.38	1.35e-9	Body mass index;
SARC	cis	rs12586317	0.547	rs77262907	chr14:35495734	C/G	cg16230307	chr14:35515116	FAM177A1	1.02	11.85	0.61	1.18e-25	Psoriasis;
SARC	cis	rs9457247	0.612	rs2237273	chr6:167443017	T/C	cg23791538	chr6:167370224	RNASET2	-0.52	-6.78	-0.41	9.64e-11	Crohn's disease;
SARC	cis	rs921968	0.541	rs4674308	chr2:219310483	A/C	cg02176678	chr2:219576539	TTLL4	0.47	7.06	0.42	1.89e-11	Mean corpuscular hemoglobin concentration;
SARC	cis	rs6546550	0.901	rs897120	chr2:70160982	C/T	cg02498382	chr2:70120550	SNRNP27	0.32	5.16	0.32	5.39e-7	Prevalent atrial fibrillation;
SARC	cis	rs6991838	0.584	rs14213	chr8:66514954	C/T	cg13398993	chr8:66546079	ARMC1	0.6	7.94	0.46	8.77e-14	Intelligence (multi-trait analysis);
SARC	cis	rs6912958	0.712	rs7746465	chr6:88348996	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.54	-0.34	8.34e-8	Monocyte percentage of white cells;
SARC	cis	rs9840812	0.769	rs1279840	chr3:136006576	T/C	cg15507776	chr3:136538369	TMEM22	0.45	4.79	0.3	2.91e-6	Fibrinogen levels;
SARC	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.59	-6.26	-0.38	1.83e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs950169	0.579	rs12913054	chr15:84664456	A/G	cg17507749	chr15:85114479	UBE2QP1	0.71	7.47	0.44	1.63e-12	Schizophrenia;
SARC	cis	rs76419734	0.558	rs4324546	chr4:106526987	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	-0.67	-6.33	-0.38	1.24e-9	Post bronchodilator FEV1;
SARC	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs1348850	0.958	rs10497501	chr2:178462299	C/G	cg23306229	chr2:178417860	TTC30B	0.56	6.47	0.39	5.64e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg16325326	chr1:53192061	ZYG11B	0.94	17.79	0.76	2.67e-45	Monocyte count;
SARC	cis	rs6670533	0.571	rs11801912	chr1:24861373	T/C	cg07475527	chr1:24864545	NA	-1.0	-5.65	-0.35	4.76e-8	Fasting blood insulin (BMI interaction);
SARC	cis	rs9916302	0.821	rs1966915	chr17:37425262	A/C	cg07936489	chr17:37558343	FBXL20	-0.69	-9.22	-0.52	1.82e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs918629	0.761	rs6898371	chr5:95289333	A/G	cg16656078	chr5:95278638	ELL2	-0.64	-7.74	-0.45	3.03e-13	IgG glycosylation;
SARC	cis	rs2730245	0.527	rs712199	chr7:158662250	A/G	cg24397884	chr7:158709396	WDR60	1.07	9.61	0.53	1.26e-18	Height;
SARC	cis	rs11170631	0.504	rs12817180	chr12:54035448	A/G	cg06632207	chr12:54070931	ATP5G2	0.59	7.93	0.46	9.35e-14	Height;
SARC	cis	rs9815354	1.000	rs114960066	chr3:41882323	A/G	cg03022575	chr3:42003672	ULK4	0.56	5.29	0.33	2.81e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs1669338	0.588	rs3864049	chr3:3186719	T/G	cg16797762	chr3:3221439	CRBN	-0.94	-9.53	-0.53	2.24e-18	White matter integrity;
SARC	cis	rs3784262	0.869	rs12903792	chr15:58261280	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.37	-5.38	-0.33	1.81e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs9916302	0.706	rs7212621	chr17:37527911	T/G	cg00129232	chr17:37814104	STARD3	0.54	5.79	0.35	2.29e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs3820928	0.874	rs1996998	chr2:227840294	C/A	cg05526886	chr2:227700861	RHBDD1	-0.56	-6.83	-0.41	7.41e-11	Pulmonary function;
SARC	cis	rs35213789	0.839	rs7780640	chr7:69554350	A/C	cg10619644	chr7:69149951	AUTS2	0.42	5.12	0.32	6.39e-7	Childhood ear infection;
SARC	cis	rs7044106	0.762	rs3904197	chr9:123480378	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	9.99	0.55	8.95e-20	Hip circumference adjusted for BMI;
SARC	cis	rs6565180	1.000	rs12930787	chr16:30381303	C/G	cg17640201	chr16:30407289	ZNF48	-0.95	-14.64	-0.69	7.78e-35	Tonsillectomy;
SARC	cis	rs7216064	1.000	rs7223813	chr17:65945840	A/G	cg12091567	chr17:66097778	LOC651250	-0.72	-7.46	-0.44	1.65e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs10489202	0.583	rs201539	chr1:167995407	A/G	cg24449463	chr1:168025552	DCAF6	-0.67	-9.04	-0.51	6.04e-17	Schizophrenia;
SARC	cis	rs477692	0.699	rs471390	chr10:131382825	A/G	cg05714579	chr10:131428358	MGMT	-0.53	-6.72	-0.4	1.36e-10	Response to temozolomide;
SARC	cis	rs9660992	0.573	rs12144980	chr1:205185104	C/T	cg00857998	chr1:205179979	DSTYK	0.53	6.69	0.4	1.63e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs9916302	0.821	rs412430	chr17:37737094	C/G	cg20243544	chr17:37824526	PNMT	0.53	6.07	0.37	5.15e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg22535103	chr8:58192502	C8orf71	-0.59	-6.21	-0.38	2.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9457247	0.663	rs2282861	chr6:167440128	C/T	cg23791538	chr6:167370224	RNASET2	-0.52	-7.03	-0.42	2.23e-11	Crohn's disease;
SARC	cis	rs6665290	0.904	rs6426559	chr1:227195876	T/C	cg14016676	chr1:227182615	CDC42BPA	0.39	5.59	0.34	6.27e-8	Myeloid white cell count;
SARC	cis	rs7937612	0.931	rs12417581	chr11:120216906	T/A	cg15690696	chr11:120217718	ARHGEF12	-0.29	-4.89	-0.3	1.92e-6	Intraocular pressure;
SARC	cis	rs787274	0.867	rs1361719	chr9:115535576	A/G	cg13803584	chr9:115635662	SNX30	-0.79	-6.14	-0.37	3.47e-9	Age-related hearing impairment (SNP x SNP interaction);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg15090727	chr9:113341951	SVEP1	0.46	6.38	0.39	9.29e-10	Breast cancer;
SARC	cis	rs651907	0.535	rs12631513	chr3:101517476	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	5.8	0.36	2.13e-8	Colorectal cancer;
SARC	cis	rs1448094	0.549	rs7297996	chr12:86235899	C/T	cg00310523	chr12:86230176	RASSF9	0.33	5.27	0.33	3.04e-7	Major depressive disorder;
SARC	cis	rs7843479	0.601	rs7220	chr8:21863290	G/A	cg17168535	chr8:21777572	XPO7	0.83	12.59	0.64	4.63e-28	Mean corpuscular volume;
SARC	cis	rs9419702	0.568	rs7075233	chr10:133545170	A/G	cg04492858	chr10:133558786	NA	-0.3	-4.74	-0.3	3.76e-6	Survival in rectal cancer;
SARC	cis	rs7566780	0.693	rs6531160	chr2:16671359	A/G	cg09580478	chr2:16689509	NA	0.49	5.72	0.35	3.34e-8	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs4988958	0.525	rs3771159	chr2:103004958	T/C	cg03938978	chr2:103052716	IL18RAP	0.32	5.16	0.32	5.28e-7	Asthma (childhood onset);
SARC	cis	rs10499694	0.933	rs7778349	chr7:50593157	C/T	cg19499709	chr7:50660583	GRB10	-0.35	-4.79	-0.3	3.01e-6	Body mass index;
SARC	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg27266027	chr21:40555129	PSMG1	-0.53	-5.83	-0.36	1.81e-8	Cognitive function;
SARC	trans	rs7819412	0.775	rs34094119	chr8:10935898	A/G	cg08975724	chr8:8085496	FLJ10661	-0.58	-7.75	-0.45	2.86e-13	Triglycerides;
SARC	cis	rs9309473	1.000	rs10193972	chr2:73717656	A/G	cg20560298	chr2:73613845	ALMS1	-0.5	-6.04	-0.37	6.04e-9	Metabolite levels;
SARC	cis	rs9581857	0.579	rs77187836	chr13:27998646	C/A	cg01674679	chr13:27998804	GTF3A	-0.63	-5.07	-0.32	8.18e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	cis	rs11574514	1.000	rs11865098	chr16:67857436	A/G	cg01866162	chr16:67596514	CTCF	0.98	5.83	0.36	1.81e-8	Crohn's disease;
SARC	cis	rs3859192	0.599	rs34342173	chr17:38161507	T/C	cg17467752	chr17:38218738	THRA	-0.38	-4.77	-0.3	3.31e-6	White blood cell count;
SARC	cis	rs9815354	0.951	rs1619558	chr3:41914213	C/G	cg03022575	chr3:42003672	ULK4	0.55	5.27	0.33	3.16e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9910055	0.502	rs1684662	chr17:42180822	T/A	cg09913183	chr17:42254507	C17orf65;ASB16	-0.43	-5.04	-0.31	9.36e-7	Total body bone mineral density;
SARC	cis	rs11785400	0.762	rs1137522	chr8:143739020	A/C	cg24634471	chr8:143751801	JRK	0.59	7.45	0.44	1.83e-12	Schizophrenia;
SARC	cis	rs4900538	0.855	rs60215817	chr14:102873886	A/G	cg18135206	chr14:102964638	TECPR2	-0.62	-7.96	-0.46	7.73e-14	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs3809566	0.526	rs35829897	chr15:63334688	G/C	cg05507819	chr15:63340323	TPM1	-0.9	-10.13	-0.55	3.24e-20	Platelet count;
SARC	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg26681399	chr22:41777847	TEF	-0.45	-4.94	-0.31	1.47e-6	Vitiligo;
SARC	cis	rs4423214	0.879	rs12803256	chr11:71132868	A/G	cg05163923	chr11:71159392	DHCR7	0.61	7.97	0.46	7.21e-14	Vitamin D levels;
SARC	cis	rs921968	0.643	rs598701	chr2:219387005	C/G	cg02176678	chr2:219576539	TTLL4	-0.35	-5.14	-0.32	5.68e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs1832871	0.672	rs12529235	chr6:158766950	A/G	cg07165851	chr6:158734300	TULP4	0.58	6.78	0.41	9.7e-11	Height;
SARC	cis	rs13191362	1.000	rs35754151	chr6:163074867	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.71	6.15	0.37	3.34e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs763121	0.776	rs4820346	chr22:39125074	C/G	cg21395723	chr22:39101663	GTPBP1	-0.55	-6.67	-0.4	1.87e-10	Menopause (age at onset);
SARC	cis	rs10088262	0.629	rs9918907	chr8:124816862	A/G	cg15047889	chr8:124780837	FAM91A1	-0.65	-7.23	-0.43	6.91e-12	Pancreatic cancer;
SARC	cis	rs10927875	0.832	rs4661342	chr1:16160773	C/G	cg21385522	chr1:16154831	NA	-0.92	-10.9	-0.58	1.23e-22	Dilated cardiomyopathy;
SARC	cis	rs2806561	0.514	rs10917360	chr1:23539010	C/T	cg12483005	chr1:23474871	LUZP1	-0.39	-4.83	-0.3	2.5e-6	Height;
SARC	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg12105361	chr19:10216875	PPAN-P2RY11;SNORD105;PPAN	0.58	7.3	0.43	4.55e-12	Breast cancer;
SARC	cis	rs11581859	0.613	rs9730501	chr1:99204684	A/T	cg20286094	chr1:99190917	SNX7	-0.42	-4.89	-0.31	1.86e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs2204008	0.580	rs1315373	chr12:38179114	T/G	cg14851346	chr12:38532713	NA	-0.43	-5.14	-0.32	5.87e-7	Bladder cancer;
SARC	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.41	5.11	0.32	6.63e-7	Electroencephalogram traits;
SARC	cis	rs617219	0.613	rs16876693	chr5:78628233	A/G	cg24856658	chr5:78533917	JMY	-0.3	-4.74	-0.3	3.68e-6	Betaine levels in individuals undergoing cardiac evaluation;
SARC	cis	rs229541	1.000	rs229540	chr22:37591290	A/C	cg02031638	chr22:36959246	NA	-0.34	-4.81	-0.3	2.66e-6	Type 1 diabetes;
SARC	cis	rs1113500	0.787	rs12047429	chr1:108633239	C/T	cg06207961	chr1:108661230	NA	0.38	5.01	0.31	1.1e-6	Growth-regulated protein alpha levels;
SARC	cis	rs10789491	1.000	rs1890473	chr1:47149794	C/T	cg15501359	chr1:47185051	KIAA0494	0.65	7.15	0.42	1.1e-11	Response to hepatitis C treatment;
SARC	cis	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg13072238	chr3:49761600	GMPPB	-0.58	-5.82	-0.36	1.9e-8	Menarche (age at onset);
SARC	cis	rs4642101	0.640	rs7629354	chr3:12827746	T/G	cg12400702	chr3:12838781	CAND2	-0.26	-5.16	-0.32	5.22e-7	QRS complex (12-leadsum);
SARC	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg22105103	chr4:187893119	NA	0.5	6.47	0.39	5.7e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9814567	0.964	rs4539979	chr3:134287597	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-7.03	-0.42	2.23e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	trans	rs7937682	0.921	rs4534611	chr11:111440425	C/G	cg18187862	chr3:45730750	SACM1L	0.5	6.31	0.38	1.42e-9	Primary sclerosing cholangitis;
SARC	cis	rs11214589	0.620	rs34601878	chr11:113260898	G/A	cg14159747	chr11:113255604	NA	0.37	5.28	0.33	2.97e-7	Neuroticism;
SARC	trans	rs11039798	0.588	rs643668	chr11:48413399	C/G	cg15704280	chr7:45808275	SEPT13	-0.61	-6.42	-0.39	7.75e-10	Axial length;
SARC	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	13.66	0.67	1.39e-31	Chronic sinus infection;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg06030229	chr18:19321133	MIB1	0.55	6.85	0.41	6.48e-11	Breast cancer;
SARC	cis	rs9309473	0.500	rs10865398	chr2:73741497	A/C	cg20560298	chr2:73613845	ALMS1	0.49	6.5	0.39	4.89e-10	Metabolite levels;
SARC	cis	rs4072980	0.524	rs16824514	chr1:38395947	A/T	cg12658694	chr1:38397304	INPP5B	0.61	7.31	0.43	4.22e-12	Coronary artery disease;
SARC	cis	rs1881797	0.872	rs12408686	chr1:247691141	C/T	cg18198730	chr1:247681584	NA	0.5	5.55	0.34	7.72e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs7412746	0.634	rs12409208	chr1:150860055	A/G	cg15448220	chr1:150897856	SETDB1	0.51	6.56	0.39	3.46e-10	Melanoma;
SARC	cis	rs739401	0.967	rs451041	chr11:3060725	C/T	cg08508325	chr11:3079039	CARS	-0.25	-5.9	-0.36	1.27e-8	Longevity;
SARC	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg24642844	chr7:1081250	C7orf50	-0.59	-6.23	-0.38	2.16e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs981844	0.712	rs6535956	chr4:154746001	G/A	cg14289246	chr4:154710475	SFRP2	-0.47	-5.51	-0.34	9.58e-8	Response to statins (LDL cholesterol change);
SARC	cis	rs9462027	0.675	rs9296132	chr6:34777531	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.87	-0.36	1.52e-8	Systemic lupus erythematosus;
SARC	trans	rs561341	0.700	rs2074101	chr17:30228656	G/A	cg20587970	chr11:113659929	NA	-0.59	-6.59	-0.4	2.85e-10	Hip circumference adjusted for BMI;
SARC	cis	rs4919087	1.000	rs4919091	chr10:99088682	A/T	cg25902810	chr10:99078978	FRAT1	-0.47	-5.77	-0.35	2.46e-8	Monocyte count;
SARC	cis	rs2594989	0.733	rs2447605	chr3:11574296	C/G	cg00170343	chr3:11313890	ATG7	-0.56	-6.14	-0.37	3.51e-9	Circulating chemerin levels;
SARC	cis	rs67311347	0.866	rs1454491	chr3:40352647	C/G	cg24209194	chr3:40518798	ZNF619	0.55	7.02	0.42	2.34e-11	Renal cell carcinoma;
SARC	cis	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg22809023	chr3:195622598	TNK2	-0.43	-5.55	-0.34	7.83e-8	Bronchopulmonary dysplasia;
SARC	cis	rs10779751	0.770	rs4845853	chr1:11243470	A/G	cg08854313	chr1:11322531	MTOR	0.87	12.8	0.64	9.47e-29	Body mass index;
SARC	cis	rs918629	0.530	rs10070197	chr5:95241868	T/C	cg16656078	chr5:95278638	ELL2	-0.52	-6.69	-0.4	1.6e-10	IgG glycosylation;
SARC	cis	rs1865760	0.566	rs9295688	chr6:26084217	G/A	cg17691542	chr6:26056736	HIST1H1C	0.52	6.41	0.39	8.05e-10	Height;
SARC	cis	rs1949733	0.598	rs4696838	chr4:8540349	A/G	cg05004818	chr4:8539015	NA	0.37	4.83	0.3	2.51e-6	Response to antineoplastic agents;
SARC	cis	rs2387326	0.717	rs12266400	chr10:129944536	C/G	cg16087940	chr10:129947807	NA	0.45	5.88	0.36	1.4e-8	Select biomarker traits;
SARC	trans	rs2727020	0.556	rs2866365	chr11:49390731	A/G	cg15704280	chr7:45808275	SEPT13	-0.69	-7.74	-0.45	3.03e-13	Coronary artery disease;
SARC	cis	rs910316	1.000	rs175443	chr14:75601963	C/T	cg08847533	chr14:75593920	NEK9	-0.87	-13.82	-0.67	4.1e-32	Height;
SARC	cis	rs17600642	0.672	rs72814528	chr10:72444390	T/C	cg19779893	chr10:72451501	ADAMTS14	-0.36	-5.83	-0.36	1.82e-8	Bipolar disorder;
SARC	cis	rs8114671	0.836	rs6060140	chr20:33566507	G/A	cg24642439	chr20:33292090	TP53INP2	0.5	5.82	0.36	1.95e-8	Height;
SARC	cis	rs12497850	0.931	rs3774628	chr3:48801840	C/T	cg06212747	chr3:49208901	KLHDC8B	0.66	8.87	0.5	1.94e-16	Parkinson's disease;
SARC	cis	rs7937682	0.814	rs1619652	chr11:111469757	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.94	-14.19	-0.68	2.36e-33	Primary sclerosing cholangitis;
SARC	trans	rs9929218	0.953	rs2902323	chr16:68736292	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.66	-8.35	-0.48	6.28e-15	Colorectal cancer;
SARC	cis	rs1153858	0.945	rs7182300	chr15:45634928	G/A	cg14582100	chr15:45693742	SPATA5L1	0.36	5.03	0.31	9.88e-7	Homoarginine levels;
SARC	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg01316550	chr5:56110833	MAP3K1	0.53	4.84	0.3	2.35e-6	Initial pursuit acceleration;
SARC	cis	rs2836950	0.805	rs2836961	chr21:40627020	A/C	cg11644478	chr21:40555479	PSMG1	-0.41	-4.75	-0.3	3.57e-6	Menarche (age at onset);
SARC	cis	rs1348850	0.574	rs2365617	chr2:178421934	C/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.63	6.01	0.37	7.15e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs3733585	0.699	rs7686538	chr4:9948077	C/T	cg11266682	chr4:10021025	SLC2A9	-0.39	-6.69	-0.4	1.62e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs35110281	0.776	rs2838316	chr21:44990036	C/T	cg01579765	chr21:45077557	HSF2BP	-0.35	-5.88	-0.36	1.42e-8	Mean corpuscular volume;
SARC	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.49	5.81	0.36	2e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	trans	rs61931739	0.534	rs1387789	chr12:34056304	C/A	cg13010199	chr12:38710504	ALG10B	0.65	8.86	0.5	2.05e-16	Morning vs. evening chronotype;
SARC	cis	rs12497850	1.000	rs4858798	chr3:48727112	C/T	cg03060546	chr3:49711283	APEH	0.41	5.09	0.32	7.35e-7	Parkinson's disease;
SARC	cis	rs7615952	0.673	rs115942855	chr3:125601960	G/A	cg05084668	chr3:125655381	ALG1L	-0.88	-7.85	-0.46	1.5e-13	Blood pressure (smoking interaction);
SARC	cis	rs12421382	0.659	rs12417251	chr11:109386273	G/T	cg27471124	chr11:109292789	C11orf87	0.39	5.31	0.33	2.52e-7	Schizophrenia;
SARC	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg12463550	chr7:65579703	CRCP	-0.46	-5.13	-0.32	5.95e-7	Aortic root size;
SARC	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg11965913	chr1:205819406	PM20D1	0.42	5.21	0.32	4.1e-7	Menarche (age at onset);
SARC	cis	rs9858542	0.953	rs34363169	chr3:49537712	G/A	cg03060546	chr3:49711283	APEH	-0.59	-7.21	-0.43	7.57e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs9400467	0.506	rs12200758	chr6:111710844	A/G	cg15721981	chr6:111408429	SLC16A10	0.62	5.46	0.34	1.19e-7	Blood metabolite levels;Amino acid levels;
SARC	cis	rs262150	0.851	rs2527224	chr7:158769198	G/A	cg09640425	chr7:158790006	NA	-0.36	-4.86	-0.3	2.17e-6	Facial morphology (factor 20);
SARC	cis	rs55871839	0.684	rs10108037	chr8:59812337	A/C	cg07426533	chr8:59803705	TOX	-0.43	-5.77	-0.35	2.51e-8	Pneumonia;
SARC	cis	rs9359856	0.636	rs1980878	chr6:90314749	A/C	cg13799429	chr6:90582589	CASP8AP2	0.56	4.97	0.31	1.32e-6	Bipolar disorder;
SARC	cis	rs10046574	0.831	rs10279987	chr7:135094763	A/G	cg27474649	chr7:135195673	CNOT4	0.82	6.74	0.4	1.25e-10	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs7412746	0.611	rs12085336	chr1:150775780	A/T	cg13175981	chr1:150552382	MCL1	-0.52	-6.37	-0.39	9.81e-10	Melanoma;
SARC	cis	rs595982	0.559	rs4802516	chr19:49366170	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.65	-7.34	-0.43	3.65e-12	Red cell distribution width;
SARC	cis	rs4481887	0.927	rs4581306	chr1:248476158	C/A	cg01631408	chr1:248437212	OR2T33	-0.39	-5.06	-0.31	8.56e-7	Common traits (Other);
SARC	cis	rs6696846	0.749	rs61822566	chr1:205078660	T/C	cg00857998	chr1:205179979	DSTYK	0.41	4.92	0.31	1.61e-6	Red blood cell count;
SARC	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg04944784	chr2:26401820	FAM59B	-0.51	-6.15	-0.37	3.33e-9	Gut microbiome composition (summer);
SARC	cis	rs66569888	0.632	rs6728600	chr2:106898653	G/T	cg23109721	chr2:106886537	NA	-0.5	-5.05	-0.31	9.05e-7	Facial morphology (factor 23);
SARC	cis	rs57506017	0.606	rs7785087	chr7:12257549	A/G	cg23422036	chr7:12250390	TMEM106B	0.49	6.5	0.39	4.74e-10	Neuroticism;
SARC	cis	rs9818758	0.607	rs35060561	chr3:49255503	T/C	cg00383909	chr3:49044727	WDR6	0.7	6.07	0.37	5.13e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs9733	0.818	rs12130363	chr1:150688596	T/C	cg15448220	chr1:150897856	SETDB1	-0.36	-4.73	-0.3	3.86e-6	Tonsillectomy;
SARC	cis	rs11608355	0.515	rs11613718	chr12:109912332	C/T	cg05360138	chr12:110035743	NA	0.93	9.74	0.54	4.9e-19	Neuroticism;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg01087382	chr6:91297190	MAP3K7	-0.61	-6.91	-0.41	4.6e-11	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs12458462	1.000	rs12458462	chr18:77472436	C/A	cg11879182	chr18:77439856	CTDP1	0.86	12.42	0.63	1.63e-27	Monocyte count;
SARC	cis	rs9814567	1.000	rs9835204	chr3:134261342	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.1	-0.42	1.49e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs909674	0.734	rs5757675	chr22:39838892	G/T	cg24399712	chr22:39784796	NA	-0.44	-5.85	-0.36	1.7e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs3768617	0.510	rs20563	chr1:183085755	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.7	-10.4	-0.56	4.71e-21	Fuchs's corneal dystrophy;
SARC	cis	rs743757	0.938	rs2282753	chr3:50436716	C/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.55	5.12	0.32	6.26e-7	Diastolic blood pressure;
SARC	cis	rs1865760	0.566	rs2032443	chr6:26046802	A/G	cg18357526	chr6:26021779	HIST1H4A	0.42	5.29	0.33	2.85e-7	Height;
SARC	cis	rs9479482	0.789	rs12204988	chr6:150339315	T/G	cg03788504	chr6:150331562	NA	-0.33	-5.42	-0.33	1.48e-7	Alopecia areata;
SARC	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs1493916	0.744	rs7504560	chr18:31312148	A/G	cg27147174	chr7:100797783	AP1S1	-0.53	-6.66	-0.4	1.9e-10	Life satisfaction;
SARC	cis	rs11758351	0.925	rs10452600	chr6:26192502	C/A	cg23601095	chr6:26197514	HIST1H3D	0.63	5.43	0.34	1.4e-7	Gout;Renal underexcretion gout;
SARC	cis	rs9314323	0.862	rs7813520	chr8:26263260	C/T	cg11498726	chr8:26250323	BNIP3L	-0.6	-7.84	-0.46	1.5700000000000001e-13	Red cell distribution width;
SARC	cis	rs9914988	0.943	rs7217547	chr17:27106872	C/G	cg20469991	chr17:27169893	C17orf63	-0.46	-4.82	-0.3	2.64e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs965469	0.895	rs12626130	chr20:3393192	G/T	cg25506879	chr20:3388711	C20orf194	-0.58	-6.04	-0.37	5.95e-9	IFN-related cytopenia;
SARC	cis	rs55665837	0.559	rs9667144	chr11:14421101	C/T	cg19336497	chr11:14380999	RRAS2	0.32	5.3	0.33	2.63e-7	Vitamin D levels;
SARC	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg06873352	chr17:61820015	STRADA	-0.41	-5.35	-0.33	2.06e-7	Prudent dietary pattern;
SARC	cis	rs10779751	0.734	rs1194820	chr1:11129259	A/C	cg04508216	chr1:11107452	MASP2	0.34	4.82	0.3	2.55e-6	Body mass index;
SARC	cis	rs7666738	0.962	rs4699605	chr4:99064379	A/G	cg05340658	chr4:99064831	C4orf37	0.56	6.86	0.41	6.29e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10493773	0.748	rs6576784	chr1:86149476	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.55	-8.51	-0.49	2.11e-15	Urate levels in overweight individuals;
SARC	cis	rs1949733	0.554	rs4259044	chr4:8536188	A/G	cg11789530	chr4:8429930	ACOX3	-0.54	-6.52	-0.39	4.41e-10	Response to antineoplastic agents;
SARC	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg06028605	chr16:24865363	SLC5A11	0.36	5.59	0.34	6.36e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs6772849	0.930	rs6768344	chr3:128373556	G/A	cg08795948	chr3:128337044	NA	0.54	7.59	0.45	7.84e-13	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs796364	0.806	rs203767	chr2:200902411	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-6.47	-0.39	5.62e-10	Schizophrenia;
SARC	cis	rs644799	0.625	rs1255177	chr11:95471495	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	6.2	0.38	2.59e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs6912958	0.712	rs7772561	chr6:88331299	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-6.46	-0.39	6.16e-10	Monocyte percentage of white cells;
SARC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg15242686	chr22:24348715	GSTTP1	-0.42	-5.42	-0.33	1.49e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2963155	0.518	rs9324918	chr5:142767160	T/C	cg17617527	chr5:142782415	NR3C1	0.8	6.36	0.38	1.03e-9	Breast cancer;
SARC	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-8.76	-0.5	4.15e-16	Alzheimer's disease;
SARC	cis	rs7607369	0.559	rs13027908	chr2:219660374	T/C	cg02176678	chr2:219576539	TTLL4	-0.37	-5.73	-0.35	3.02e-8	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs820218	0.886	rs820154	chr17:73616446	A/T	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.57	7.13	0.42	1.24e-11	Rotator cuff tears;
SARC	cis	rs6088813	1.000	rs6087705	chr20:34001250	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	-0.43	-5.23	-0.32	3.69e-7	Height;
SARC	cis	rs1018836	0.774	rs35159732	chr8:91633094	A/G	cg16814680	chr8:91681699	NA	-0.85	-13.63	-0.67	1.67e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.59	7.17	0.43	9.71e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9660992	0.573	rs1172158	chr1:205208948	G/A	cg21545522	chr1:205238299	TMCC2	0.39	5.34	0.33	2.25e-7	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg04944784	chr2:26401820	FAM59B	-0.46	-5.73	-0.35	3.16e-8	Gut microbiome composition (summer);
SARC	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg08280861	chr8:58055591	NA	0.57	4.89	0.31	1.84e-6	Developmental language disorder (linguistic errors);
SARC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	ch.1.3128389F	chr1:160061098	NA	-0.56	-6.37	-0.39	9.81e-10	Hepatitis;
SARC	cis	rs6964587	0.934	rs73226382	chr7:91692760	T/C	cg17063962	chr7:91808500	NA	0.96	16.21	0.73	4.33e-40	Breast cancer;
SARC	cis	rs2130392	0.702	rs12108497	chr4:185571557	C/T	cg14471096	chr4:185570637	CCDC111;CASP3	0.45	5.62	0.35	5.33e-8	Kawasaki disease;
SARC	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg12463550	chr7:65579703	CRCP	0.51	5.74	0.35	2.94e-8	Aortic root size;
SARC	cis	rs4975616	0.869	rs452384	chr5:1330840	T/C	cg26373071	chr5:1325741	CLPTM1L	0.3	4.94	0.31	1.48e-6	Lung cancer;
SARC	cis	rs8054556	0.787	rs12921753	chr16:30018720	C/T	cg06015834	chr16:30021696	DOC2A	-0.36	-4.84	-0.3	2.4e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9399137	0.507	rs11757723	chr6:135291293	C/T	cg24558204	chr6:135376177	HBS1L	0.63	8.1	0.47	3.05e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs6088580	0.668	rs1205337	chr20:32926041	T/A	cg24642439	chr20:33292090	TP53INP2	-0.64	-8.23	-0.47	1.33e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg13939156	chr17:80058883	NA	-0.42	-6.48	-0.39	5.51e-10	Life satisfaction;
SARC	cis	rs6866344	0.598	rs11742156	chr5:178147833	C/T	cg03877680	chr5:178157825	ZNF354A	1.03	13.83	0.67	3.82e-32	Neutrophil percentage of white cells;
SARC	cis	rs7246657	0.882	rs13345148	chr19:37819631	A/G	cg14683738	chr19:37701593	ZNF585B	0.51	4.94	0.31	1.52e-6	Coronary artery calcification;
SARC	cis	rs1564271	0.528	rs2489589	chr10:26983095	A/G	cg13837822	chr10:26931731	LOC731789	0.38	5.45	0.34	1.31e-7	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
SARC	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg16405210	chr4:1374714	KIAA1530	-0.49	-5.85	-0.36	1.67e-8	Obesity-related traits;
SARC	cis	rs875971	1.000	rs2220626	chr7:65546062	C/T	cg12463550	chr7:65579703	CRCP	-0.48	-5.59	-0.34	6.43e-8	Aortic root size;
SARC	cis	rs3768617	0.510	rs2333621	chr1:183090751	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.1	0.55	4.11e-20	Fuchs's corneal dystrophy;
SARC	cis	rs11098499	0.908	rs7696649	chr4:120322177	G/A	cg09307838	chr4:120376055	NA	0.9	12.47	0.63	1.08e-27	Corneal astigmatism;
SARC	trans	rs73191547	0.501	rs6986885	chr8:9978471	G/A	cg06636001	chr8:8085503	FLJ10661	0.52	6.91	0.41	4.61e-11	Schizophrenia;
SARC	cis	rs9818758	0.607	rs9847839	chr3:49289003	T/C	cg07636037	chr3:49044803	WDR6	-0.75	-6.62	-0.4	2.39e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs72945132	0.882	rs6592554	chr11:70226040	G/A	cg00319359	chr11:70116639	PPFIA1	0.67	6.4	0.39	8.28e-10	Coronary artery disease;
SARC	cis	rs2354432	1.000	rs2120003	chr1:146690635	A/G	cg25205988	chr1:146714368	CHD1L	0.86	7.69	0.45	4.15e-13	Mitochondrial DNA levels;
SARC	cis	rs9815354	0.812	rs58360908	chr3:41839837	A/G	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs1538970	0.816	rs868351	chr1:46009818	G/T	cg05343316	chr1:45956843	TESK2	0.79	8.92	0.5	1.4e-16	Platelet count;
SARC	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg24250549	chr1:154909240	PMVK	0.75	10.35	0.56	6.92e-21	Prostate cancer;
SARC	cis	rs765787	0.530	rs4775836	chr15:45537664	T/C	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.51e-10	Uric acid levels;
SARC	cis	rs6484504	0.625	rs7940420	chr11:31366700	T/A	cg26647111	chr11:31128758	NA	0.38	4.99	0.31	1.2e-6	Red blood cell count;
SARC	cis	rs2916247	0.908	rs2996057	chr8:93179864	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.49	-5.33	-0.33	2.35e-7	Intelligence (multi-trait analysis);
SARC	trans	rs1994135	0.617	rs10743824	chr12:33733764	C/T	cg26384229	chr12:38710491	ALG10B	0.59	7.15	0.42	1.09e-11	Resting heart rate;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg27109877	chr18:31158549	ASXL3	-0.8	-6.63	-0.4	2.28e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs3126085	0.935	rs2291770	chr1:152179792	G/C	cg03465714	chr1:152285911	FLG	-0.46	-5.51	-0.34	9.24e-8	Atopic dermatitis;
SARC	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg25894440	chr7:65020034	NA	0.73	5.51	0.34	9.25e-8	Diabetic kidney disease;
SARC	cis	rs72781680	0.898	rs72781639	chr2:24204148	C/G	cg06627628	chr2:24431161	ITSN2	-0.7	-6.78	-0.41	9.65e-11	Lymphocyte counts;
SARC	cis	rs9916302	0.904	rs9894500	chr17:37515735	G/C	cg20243544	chr17:37824526	PNMT	-0.56	-6.92	-0.41	4.39e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg12667521	chr19:29218732	NA	0.4	5.23	0.32	3.73e-7	Methadone dose in opioid dependence;
SARC	cis	rs734999	0.588	rs745368	chr1:2524205	C/T	cg18854424	chr1:2615690	NA	0.33	5.17	0.32	5e-7	Ulcerative colitis;
SARC	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg10435706	chr6:150039699	LATS1	0.37	4.87	0.3	2.04e-6	Lung cancer;
SARC	cis	rs524281	0.861	rs7943911	chr11:65943054	G/A	cg14036092	chr11:66035641	RAB1B	-0.5	-5.46	-0.34	1.23e-7	Electroencephalogram traits;
SARC	cis	rs12220238	1.000	rs12220238	chr10:75952670	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.58	5.82	0.36	1.98e-8	Soluble interleukin-2 receptor subunit alpha;
SARC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg11905131	chr22:24372483	LOC391322	-0.44	-5.04	-0.31	9.56e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs870825	0.520	rs10022842	chr4:185649459	A/G	cg04058563	chr4:185651563	MLF1IP	0.8	11.35	0.6	4.56e-24	Blood protein levels;
SARC	cis	rs7223966	1.000	rs56057198	chr17:61733332	G/A	cg00588841	chr17:61851480	DDX42;CCDC47	-0.64	-6.65	-0.4	2.11e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2032447	0.530	rs9356996	chr6:26008487	C/A	cg03264133	chr6:25882463	NA	-0.44	-6.35	-0.38	1.1e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7819412	0.745	rs6601569	chr8:11073578	C/T	cg21775007	chr8:11205619	TDH	-0.45	-5.64	-0.35	4.83e-8	Triglycerides;
SARC	cis	rs4891159	0.660	rs4891160	chr18:74102135	C/T	cg24786174	chr18:74118243	ZNF516	0.59	9.45	0.53	3.85e-18	Longevity;
SARC	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.76	9.13	0.51	3.45e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6120849	0.754	rs1885116	chr20:33600560	A/G	cg24642439	chr20:33292090	TP53INP2	0.56	5.38	0.33	1.78e-7	Protein C levels;
SARC	cis	rs453301	0.686	rs6601281	chr8:8911004	A/G	cg11608241	chr8:8085544	FLJ10661	-0.45	-5.65	-0.35	4.71e-8	Joint mobility (Beighton score);
SARC	cis	rs765787	0.530	rs12917187	chr15:45538297	A/G	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.81e-6	Uric acid levels;
SARC	cis	rs950169	1.000	rs12916348	chr15:84765527	C/T	cg24253500	chr15:84953950	NA	0.36	5.28	0.33	2.92e-7	Schizophrenia;
SARC	cis	rs17270561	0.609	rs9358877	chr6:25739228	A/G	cg17691542	chr6:26056736	HIST1H1C	0.58	7.09	0.42	1.6e-11	Iron status biomarkers;
SARC	cis	rs7236492	0.630	rs8086439	chr18:77173038	A/G	cg15644404	chr18:77186268	NFATC1	-0.64	-5.07	-0.32	8.22e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs9640161	0.789	rs1464752	chr7:150021284	C/T	cg17279839	chr7:150038598	RARRES2	0.47	6.62	0.4	2.5e-10	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs17125944	0.505	rs77690283	chr14:53233320	C/G	cg00686598	chr14:53173677	PSMC6	1.3	9.0	0.51	8.31e-17	Alzheimer's disease (late onset);
SARC	cis	rs9987353	0.519	rs11779181	chr8:9063027	A/G	cg06636001	chr8:8085503	FLJ10661	0.55	6.91	0.41	4.66e-11	Recombination measurement;
SARC	cis	rs10870270	1.000	rs7898755	chr10:133777122	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.48	-5.41	-0.33	1.56e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg04277193	chr17:41438351	NA	0.43	4.76	0.3	3.33e-6	Menopause (age at onset);
SARC	cis	rs9916302	0.851	rs12936646	chr17:37647450	A/T	cg07936489	chr17:37558343	FBXL20	-0.67	-8.67	-0.49	7.41e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs12249377	0.519	rs12259401	chr10:92594121	T/G	cg14313238	chr10:92632228	RPP30	0.42	5.05	0.31	9.11e-7	White matter microstructure (global fractional anisotropy);
SARC	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	trans	rs890100	0.704	rs7600814	chr2:56643955	A/G	cg26233084	chr5:15510258	FBXL7	0.32	6.59	0.4	2.88e-10	Gut microbiome composition (summer);
SARC	cis	rs3126085	0.935	rs1390487	chr1:152194601	G/A	cg03465714	chr1:152285911	FLG	-0.5	-6.02	-0.37	6.84e-9	Atopic dermatitis;
SARC	cis	rs9291683	0.655	rs55941493	chr4:10100341	G/A	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.57	-0.34	7.11e-8	Bone mineral density;
SARC	cis	rs4481887	0.927	rs7555310	chr1:248487638	A/G	cg13385794	chr1:248469461	NA	0.34	5.1	0.32	6.89e-7	Common traits (Other);
SARC	cis	rs6728642	0.561	rs58984980	chr2:97570759	T/A	cg26665480	chr2:98280029	ACTR1B	-0.64	-5.46	-0.34	1.19e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs7666738	0.716	rs6827474	chr4:99089683	T/G	cg05340658	chr4:99064831	C4orf37	0.6	7.71	0.45	3.59e-13	Colonoscopy-negative controls vs population controls;
SARC	cis	rs17345786	0.906	rs72944107	chr3:101197190	C/T	cg12386194	chr3:101231763	SENP7	0.81	9.43	0.53	4.38e-18	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6598955	0.724	rs4659420	chr1:26614333	G/A	cg21300267	chr1:26547059	NA	-0.25	-4.87	-0.3	2.08e-6	Obesity-related traits;
SARC	cis	rs6933660	0.683	rs8180642	chr6:151756612	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.52	6.67	0.4	1.82e-10	Menarche (age at onset);
SARC	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg21724239	chr8:58056113	NA	0.59	5.52	0.34	8.98e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1707322	0.717	rs1135850	chr1:46093692	G/A	cg03146154	chr1:46216737	IPP	0.51	6.1	0.37	4.4e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9303401	0.659	rs35564417	chr17:56718286	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	12.0	0.62	3.7e-26	Cognitive test performance;
SARC	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs72781680	0.716	rs2712050	chr2:24059408	A/C	cg06627628	chr2:24431161	ITSN2	-0.58	-5.81	-0.36	2.09e-8	Lymphocyte counts;
SARC	cis	rs9814567	0.929	rs1863911	chr3:134205231	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-6.89	-0.41	5.19e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg03806693	chr22:41940476	POLR3H	-0.93	-12.83	-0.64	7.61e-29	Vitiligo;
SARC	cis	rs73635312	0.850	rs17505816	chr10:8990550	C/G	cg24467326	chr10:9646929	NA	0.59	5.07	0.32	8.19e-7	Basal cell carcinoma;
SARC	cis	rs35110281	0.600	rs914198	chr21:45117456	A/C	cg21573476	chr21:45109991	RRP1B	-0.59	-8.34	-0.48	6.49e-15	Mean corpuscular volume;
SARC	cis	rs4727027	0.933	rs6961605	chr7:148870108	G/A	cg23583168	chr7:148888333	NA	-0.73	-10.86	-0.58	1.72e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg05896524	chr21:47604654	C21orf56	0.53	6.5	0.39	4.9e-10	Testicular germ cell tumor;
SARC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg15326887	chr12:64238325	SRGAP1	-0.6	-6.68	-0.4	1.77e-10	Hepatitis;
SARC	cis	rs9814567	1.000	rs9826496	chr3:134224437	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-6.93	-0.41	3.97e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-5.72	-0.35	3.18e-8	Electroencephalogram traits;
SARC	cis	rs526231	0.543	rs34804	chr5:102428239	G/A	cg23492399	chr5:102201601	PAM	-0.48	-4.91	-0.31	1.68e-6	Primary biliary cholangitis;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg06223186	chr7:1544111	INTS1	0.74	6.24	0.38	2.09e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg16479474	chr6:28041457	NA	0.37	5.53	0.34	8.38e-8	Depression;
SARC	trans	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.21	-0.43	7.82e-12	Extrinsic epigenetic age acceleration;
SARC	trans	rs6600671	1.000	rs1856572	chr1:121169579	A/C	cg00646200	chr1:148855367	NA	0.5	6.79	0.41	9.39e-11	Hip geometry;
SARC	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-6.45	-0.39	6.46e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs240764	0.725	rs239193	chr6:101131848	T/C	cg09795085	chr6:101329169	ASCC3	0.37	4.76	0.3	3.35e-6	Neuroticism;
SARC	cis	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg12923728	chr3:195709715	SDHAP1	-0.6	-6.82	-0.41	7.7e-11	Pancreatic cancer;
SARC	cis	rs7666738	0.830	rs10009943	chr4:99021475	G/A	cg05340658	chr4:99064831	C4orf37	0.66	9.04	0.51	6.35e-17	Colonoscopy-negative controls vs population controls;
SARC	trans	rs1814175	0.586	rs10769603	chr11:49688837	T/C	cg03929089	chr4:120376271	NA	-0.8	-11.43	-0.6	2.58e-24	Height;
SARC	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg21782813	chr7:2030301	MAD1L1	0.45	7.14	0.42	1.2e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs4891159	0.548	rs660342	chr18:74130896	C/G	cg24786174	chr18:74118243	ZNF516	0.72	12.17	0.62	1.09e-26	Longevity;
SARC	cis	rs12079745	0.793	rs3753298	chr1:169176899	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.82	-5.25	-0.33	3.41e-7	QT interval;
SARC	cis	rs460214	0.539	rs55819392	chr21:40038207	G/A	cg12884169	chr21:40033163	ERG	-0.35	-4.9	-0.31	1.83e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs2732480	0.577	rs1489108	chr12:48738781	G/A	cg24011408	chr12:48396354	COL2A1	0.43	5.11	0.32	6.81e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs1865760	0.532	rs9295687	chr6:26082710	T/C	cg17691542	chr6:26056736	HIST1H1C	0.52	6.41	0.39	8.05e-10	Height;
SARC	cis	rs473651	0.935	rs540636	chr2:239358341	T/C	cg18131467	chr2:239335373	ASB1	1.0	17.17	0.75	2.97e-43	Multiple system atrophy;
SARC	cis	rs2933343	0.700	rs789238	chr3:128636715	A/G	cg25356066	chr3:128598488	ACAD9	0.7	9.32	0.52	9.22e-18	IgG glycosylation;
SARC	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg15448220	chr1:150897856	SETDB1	0.45	5.99	0.37	7.81e-9	Tonsillectomy;
SARC	cis	rs7772486	0.875	rs2492855	chr6:146296926	A/G	cg23711669	chr6:146136114	FBXO30	0.72	11.0	0.58	6.12e-23	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9650657	0.615	rs12541110	chr8:10695125	A/T	cg21775007	chr8:11205619	TDH	-0.39	-4.82	-0.3	2.58e-6	Neuroticism;
SARC	cis	rs7937682	0.632	rs2070894	chr11:111780837	G/A	cg09085632	chr11:111637200	PPP2R1B	0.8	10.6	0.57	1.09e-21	Primary sclerosing cholangitis;
SARC	cis	rs7264396	0.563	rs6060560	chr20:34278890	T/C	cg01084648	chr20:34329383	RBM39	0.63	5.26	0.33	3.18e-7	Total cholesterol levels;
SARC	cis	rs2921073	0.604	rs2979140	chr8:8267202	T/A	cg15556689	chr8:8085844	FLJ10661	0.49	5.66	0.35	4.45e-8	Parkinson's disease;
SARC	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	21.47	0.82	3.89e-57	Chronic sinus infection;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg25353054	chr22:39101979	GTPBP1	0.52	7.04	0.42	2.19e-11	Tetralogy of Fallot;
SARC	cis	rs1044826	0.692	rs169824	chr3:139235006	G/C	cg15131784	chr3:139108705	COPB2	-0.4	-5.07	-0.32	7.94e-7	Obesity-related traits;
SARC	cis	rs710216	0.917	rs900836	chr1:43412727	T/C	cg03128534	chr1:43423976	SLC2A1	-0.66	-6.84	-0.41	6.75e-11	Red cell distribution width;
SARC	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg13206674	chr6:150067644	NUP43	0.46	5.95	0.36	9.98e-9	Lung cancer;
SARC	cis	rs7296418	0.630	rs7974099	chr12:123771475	A/G	cg00376283	chr12:123451042	ABCB9	0.56	6.88	0.41	5.55e-11	Platelet count;
SARC	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg04317338	chr11:64019027	PLCB3	0.81	8.68	0.49	6.79e-16	Mean platelet volume;
SARC	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg11987759	chr7:65425863	GUSB	-0.4	-5.22	-0.32	4.05e-7	Calcium levels;
SARC	cis	rs4243830	0.737	rs6692747	chr1:6610049	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	1.01	7.84	0.46	1.56e-13	Body mass index;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg02738677	chr3:133265129	NA	0.51	6.23	0.38	2.15e-9	Schizophrenia;
SARC	cis	rs9818758	0.607	rs9837237	chr3:49215583	G/T	cg03060546	chr3:49711283	APEH	-0.56	-4.86	-0.3	2.17e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg08280861	chr8:58055591	NA	0.59	5.25	0.33	3.49e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2997447	0.802	rs72884792	chr1:26436688	G/C	cg19633962	chr1:26362018	EXTL1	-0.57	-5.05	-0.31	8.95e-7	QRS complex (12-leadsum);
SARC	cis	rs79349575	0.811	rs1057897	chr17:47005509	T/G	cg07967210	chr17:47022446	SNF8	0.37	4.73	0.3	3.95e-6	Type 2 diabetes;
SARC	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg12463550	chr7:65579703	CRCP	-0.49	-5.35	-0.33	2.13e-7	Aortic root size;
SARC	cis	rs7106204	0.541	rs75552854	chr11:24231824	G/A	ch.11.24196551F	chr11:24239977	NA	0.73	5.37	0.33	1.91e-7	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs992157	0.798	rs7557709	chr2:219167529	G/A	cg00012203	chr2:219082015	ARPC2	0.63	9.02	0.51	7.03e-17	Colorectal cancer;
SARC	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg11987759	chr7:65425863	GUSB	0.48	6.23	0.38	2.16e-9	Aortic root size;
SARC	cis	rs5167	0.566	rs2075618	chr19:45495668	G/C	cg09555818	chr19:45449301	APOC2	0.38	5.15	0.32	5.62e-7	Blood protein levels;
SARC	cis	rs4800452	0.956	rs4369779	chr18:20735408	T/C	cg13313047	chr18:20735648	CABLES1	-0.45	-4.97	-0.31	1.32e-6	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
SARC	trans	rs56279505	0.630	rs78744403	chr4:100276771	G/A	cg21156590	chr1:3420848	MEGF6	-0.83	-6.41	-0.39	8.04e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2645694	0.626	rs2645708	chr4:77822682	G/A	cg18351406	chr4:77819688	ANKRD56	0.45	6.3	0.38	1.46e-9	Emphysema distribution in smoking;
SARC	cis	rs8024058	0.919	rs2350270	chr15:89171891	C/T	cg00367546	chr15:89165046	AEN	0.44	4.74	0.3	3.71e-6	Night sleep phenotypes;
SARC	cis	rs910316	1.000	rs12589815	chr14:75544101	C/T	cg06637938	chr14:75390232	RPS6KL1	0.55	7.85	0.46	1.54e-13	Height;
SARC	cis	rs3812831	0.654	rs9314900	chr13:114937618	A/C	cg08824895	chr13:115047677	UPF3A	0.44	5.51	0.34	9.55e-8	Schizophrenia;
SARC	cis	rs7945705	0.902	rs2012696	chr11:8995818	A/C	cg21881798	chr11:8931708	C11orf17;ST5	0.46	6.49	0.39	5.18e-10	Hemoglobin concentration;
SARC	cis	rs62432291	0.681	rs400477	chr6:159635943	A/C	cg14500486	chr6:159655392	FNDC1	0.62	6.25	0.38	1.9e-9	Joint mobility (Beighton score);
SARC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.13	0.37	3.78e-9	Prudent dietary pattern;
SARC	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg11941060	chr3:133502564	NA	0.4	5.7	0.35	3.67e-8	Iron status biomarkers;
SARC	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6831352	0.703	rs4235435	chr4:100039578	C/T	cg13256891	chr4:100009986	ADH5	0.6	7.9	0.46	1.09e-13	Alcohol dependence;
SARC	cis	rs6088590	0.561	rs11167239	chr20:33140472	G/A	cg08999081	chr20:33150536	PIGU	0.45	6.82	0.41	7.83e-11	Coronary artery disease;
SARC	cis	rs2153535	0.580	rs1414344	chr6:8471365	C/A	cg23788917	chr6:8435910	SLC35B3	0.64	8.63	0.49	9.85e-16	Motion sickness;
SARC	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	-0.91	-10.0	-0.55	7.84e-20	Platelet count;
SARC	trans	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.63	7.71	0.45	3.55e-13	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs3892630	0.824	rs2287884	chr19:33321447	A/G	cg22980127	chr19:33182716	NUDT19	0.89	7.97	0.46	7.14e-14	Red blood cell traits;
SARC	trans	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	7.04	0.42	2.17e-11	Intelligence (multi-trait analysis);
SARC	cis	rs8014131	0.689	rs1884009	chr14:85987605	G/T	cg10406690	chr14:85995726	FLRT2	0.41	5.35	0.33	2.13e-7	Menarche (age at onset);
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg07583296	chr19:6002914	RFX2	0.47	6.36	0.38	1.09e-9	Schizophrenia;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg11860616	chr5:158712539	UBLCP1	0.47	6.53	0.39	4.12e-10	Thyroid stimulating hormone;
SARC	cis	rs2832191	0.716	rs9983051	chr21:30371890	C/T	cg24692254	chr21:30365293	RNF160	1.03	18.75	0.78	1.91e-48	Dental caries;
SARC	cis	rs8067545	0.611	rs12942568	chr17:20117893	G/T	cg13482628	chr17:19912719	NA	-0.55	-7.28	-0.43	5.23e-12	Schizophrenia;
SARC	cis	rs5753618	0.539	rs2106294	chr22:31645759	C/T	cg02404636	chr22:31891804	SFI1	-0.48	-5.2	-0.32	4.32e-7	Colorectal cancer;
SARC	cis	rs4268898	1.000	rs2303294	chr2:24432620	A/G	cg26838691	chr2:24397539	C2orf84	0.37	4.93	0.31	1.54e-6	Asthma;
SARC	cis	rs763121	0.853	rs3788544	chr22:39064966	C/T	cg21395723	chr22:39101663	GTPBP1	0.51	5.6	0.34	5.97e-8	Menopause (age at onset);
SARC	cis	rs6062509	0.965	rs2315007	chr20:62343845	T/C	cg27236539	chr20:62289627	RTEL1	0.5	5.73	0.35	3.04e-8	Prostate cancer;
SARC	cis	rs870825	0.616	rs7659201	chr4:185632013	G/A	cg04058563	chr4:185651563	MLF1IP	0.83	11.16	0.59	1.91e-23	Blood protein levels;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg08505473	chr14:94255513	PRIMA1	-0.68	-6.46	-0.39	6.03e-10	Autism spectrum disorder or schizophrenia;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg27310163	chr2:113342241	CHCHD5	0.48	6.27	0.38	1.7e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg04546413	chr19:29218101	NA	0.64	8.55	0.49	1.67e-15	Methadone dose in opioid dependence;
SARC	cis	rs2180341	0.961	rs7774468	chr6:127592501	G/C	cg24812749	chr6:127587940	RNF146	0.96	12.56	0.64	5.55e-28	Breast cancer;
SARC	cis	rs6542838	0.673	rs1949424	chr2:99468341	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.44	5.45	0.34	1.27e-7	Fear of minor pain;
SARC	cis	rs9303401	0.659	rs36093395	chr17:56957357	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	11.27	0.59	8.61e-24	Cognitive test performance;
SARC	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg11905131	chr22:24372483	LOC391322	-0.48	-5.42	-0.33	1.48e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6088580	0.634	rs6120644	chr20:33023810	G/A	cg24642439	chr20:33292090	TP53INP2	0.67	8.56	0.49	1.53e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs208520	0.690	rs9345764	chr6:66820597	C/T	cg07460842	chr6:66804631	NA	-1.09	-15.29	-0.71	5.27e-37	Exhaled nitric oxide output;
SARC	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg04944784	chr2:26401820	FAM59B	-0.48	-5.93	-0.36	1.09e-8	Gut microbiome composition (summer);
SARC	cis	rs2070488	1.000	rs7373816	chr3:38490443	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	14.64	0.69	7.76e-35	Electrocardiographic conduction measures;
SARC	cis	rs7428	0.527	rs1554110	chr2:85547963	C/T	cg03728395	chr2:85555865	TGOLN2	-0.48	-6.62	-0.4	2.49e-10	Ear protrusion;
SARC	cis	rs13314892	0.764	rs62251032	chr3:69865127	G/A	cg17445875	chr3:69859618	MITF	-0.49	-5.12	-0.32	6.44e-7	QRS complex (12-leadsum);
SARC	cis	rs62244186	0.520	rs2372828	chr3:44784949	A/G	cg15225532	chr3:44803084	KIF15;KIAA1143	-0.58	-7.66	-0.45	5.04e-13	Depressive symptoms;
SARC	cis	rs8014204	0.762	rs12891131	chr14:75240090	A/G	cg06637938	chr14:75390232	RPS6KL1	0.58	8.09	0.47	3.18e-14	Caffeine consumption;
SARC	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg01017244	chr2:74357527	NA	0.54	6.54	0.39	3.84e-10	Gestational age at birth (maternal effect);
SARC	cis	rs9625935	0.518	rs713718	chr22:30314092	A/C	cg01021169	chr22:30184971	ASCC2	0.4	5.3	0.33	2.66e-7	Tonsillectomy;
SARC	cis	rs8044995	0.563	rs3785116	chr16:68372730	G/A	cg05110241	chr16:68378359	PRMT7	-0.68	-6.38	-0.39	9.2e-10	Schizophrenia;
SARC	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg09033563	chr22:24373618	LOC391322	-0.41	-4.74	-0.3	3.68e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	trans	rs62103177	0.733	rs62096748	chr18:77619699	T/C	cg05926928	chr17:57297772	GDPD1	1.09	9.4	0.52	5.4e-18	Opioid sensitivity;
SARC	cis	rs754466	0.580	rs10762765	chr10:79566407	T/C	cg17075019	chr10:79541650	NA	-0.82	-12.52	-0.63	7.52e-28	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1215050	0.655	rs6842706	chr4:98499037	A/T	cg05340658	chr4:99064831	C4orf37	-0.41	-5.18	-0.32	4.83e-7	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs78456975	1.000	rs6720874	chr2:1580504	A/G	cg12573674	chr2:1569213	NA	-0.52	-4.74	-0.3	3.67e-6	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs2153535	0.580	rs9405390	chr6:8466209	T/G	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	cis	rs2652822	0.509	rs4774478	chr15:63434763	A/G	cg02713581	chr15:63449717	RPS27L	0.53	5.93	0.36	1.07e-8	Metabolic traits;
SARC	trans	rs208520	0.690	rs851459	chr6:66813989	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.04	-14.09	-0.68	5.12e-33	Exhaled nitric oxide output;
SARC	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg00933542	chr6:150070202	PCMT1	0.31	5.16	0.32	5.39e-7	Lung cancer;
SARC	cis	rs1008375	0.902	rs7654332	chr4:17691778	A/T	cg27347728	chr4:17578864	LAP3	0.46	5.74	0.35	2.94e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6500395	0.775	rs1968903	chr16:48664014	C/T	cg04672837	chr16:48644449	N4BP1	0.41	5.63	0.35	5.04e-8	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs12142240	0.659	rs72677602	chr1:46837487	G/A	cg14993813	chr1:46806288	NSUN4	-0.5	-5.13	-0.32	6.01e-7	Menopause (age at onset);
SARC	cis	rs2730245	0.569	rs1188955	chr7:158690866	A/G	cg17136484	chr7:158649327	WDR60	0.49	5.47	0.34	1.15e-7	Height;
SARC	cis	rs3768617	0.510	rs1886500	chr1:183095048	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.82e-21	Fuchs's corneal dystrophy;
SARC	cis	rs9640161	0.789	rs2098053	chr7:150043205	G/A	cg10018233	chr7:150070692	REPIN1	0.63	7.7	0.45	3.96e-13	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs36051895	0.632	rs1581927	chr9:5177462	C/T	cg02405213	chr9:5042618	JAK2	-0.45	-5.42	-0.33	1.48e-7	Pediatric autoimmune diseases;
SARC	cis	rs7644634	0.661	rs1443108	chr3:105422405	A/G	cg23051926	chr3:105466016	CBLB	-0.43	-5.56	-0.34	7.53e-8	Itch intensity from mosquito bite;
SARC	cis	rs3815700	1.000	rs8113165	chr19:33096316	C/T	cg24916020	chr19:33096688	ANKRD27	0.59	5.92	0.36	1.16e-8	Eosinophilic esophagitis;
SARC	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg15049968	chr18:44337910	ST8SIA5	0.39	6.1	0.37	4.38e-9	Personality dimensions;
SARC	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.75	10.82	0.58	2.3e-22	Personality dimensions;
SARC	cis	rs6500395	0.775	rs4277341	chr16:48664387	T/G	cg04672837	chr16:48644449	N4BP1	0.41	5.63	0.35	5.04e-8	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs965469	1.000	rs6051807	chr20:3350485	A/G	cg25506879	chr20:3388711	C20orf194	-0.5	-5.07	-0.32	8.24e-7	IFN-related cytopenia;
SARC	cis	rs735396	1.000	rs2259852	chr12:121434833	G/A	cg25281562	chr12:121454272	C12orf43	0.51	6.11	0.37	4.22e-9	N-glycan levels;
SARC	cis	rs244293	0.765	rs7503269	chr17:53019712	T/C	cg19360675	chr17:53046073	COX11;STXBP4	-0.42	-5.12	-0.32	6.55e-7	Menarche (age at onset);
SARC	cis	rs9457247	0.967	rs86755	chr6:167403108	T/C	cg07741184	chr6:167504864	NA	0.29	5.55	0.34	7.59e-8	Crohn's disease;
SARC	cis	rs735396	0.770	rs1169314	chr12:121443116	A/G	cg25281562	chr12:121454272	C12orf43	0.56	7.08	0.42	1.69e-11	N-glycan levels;
SARC	cis	rs7219014	1	rs7219014	chr17:37624790	A/G	cg15445000	chr17:37608096	MED1	0.42	5.05	0.31	8.76e-7	Urinary metabolites;
SARC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	10.6	0.57	1.08e-21	Platelet count;
SARC	cis	rs834603	0.547	rs834599	chr7:47463842	T/G	cg23694490	chr7:47445681	TNS3	-0.34	-6.12	-0.37	4.01e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	trans	rs459571	0.959	rs2810491	chr9:136923331	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	0.6	6.85	0.41	6.67e-11	Platelet distribution width;
SARC	cis	rs1559088	0.947	rs12461219	chr19:33550633	C/G	cg17764715	chr19:33622953	WDR88	0.48	6.25	0.38	1.95e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs11792861	0.962	rs72607162	chr9:111793719	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.68	7.78	0.45	2.34e-13	Menarche (age at onset);
SARC	cis	rs941408	1.000	rs1640274	chr19:2807375	G/A	cg00079169	chr19:2811669	THOP1	0.49	5.12	0.32	6.31e-7	Total cholesterol levels;
SARC	cis	rs7818345	0.845	rs11785649	chr8:19268233	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.39	4.94	0.31	1.47e-6	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs7940866	0.903	rs1347283	chr11:130868583	T/G	cg12179176	chr11:130786555	SNX19	0.64	8.56	0.49	1.5e-15	Schizophrenia;
SARC	trans	rs7615952	0.515	rs4267608	chr3:125680500	C/T	cg07211511	chr3:129823064	LOC729375	-0.65	-6.78	-0.41	9.85e-11	Blood pressure (smoking interaction);
SARC	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg00933542	chr6:150070202	PCMT1	0.32	5.31	0.33	2.56e-7	Lung cancer;
SARC	cis	rs910316	0.763	rs1548807	chr14:75479582	T/G	cg23033748	chr14:75592666	NEK9	0.38	5.24	0.32	3.63e-7	Height;
SARC	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.62	7.71	0.45	3.55e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6728642	0.908	rs6576996	chr2:97623312	T/C	cg26665480	chr2:98280029	ACTR1B	-0.64	-6.36	-0.38	1.05e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs6582630	0.519	rs12366667	chr12:38332632	C/T	cg13010199	chr12:38710504	ALG10B	0.77	10.69	0.57	5.96e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg00800038	chr16:89945340	TCF25	-0.76	-5.06	-0.31	8.3e-7	Skin colour saturation;
SARC	cis	rs798554	1.000	rs798562	chr7:2757938	C/T	cg13628971	chr7:2884303	GNA12	0.56	6.64	0.4	2.17e-10	Height;
SARC	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg16606324	chr3:10149918	C3orf24	0.49	4.74	0.3	3.74e-6	Alzheimer's disease;
SARC	cis	rs6840360	0.615	rs6858483	chr4:152465509	C/T	cg22705602	chr4:152727874	NA	-0.42	-6.47	-0.39	5.59e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7020830	0.898	rs506981	chr9:37351348	A/T	cg14294708	chr9:37120828	ZCCHC7	-1.1	-20.24	-0.8	2.98e-53	Schizophrenia;
SARC	cis	rs2236918	1.000	rs2526704	chr1:242015820	A/G	cg17736920	chr1:242011382	EXO1	0.79	10.82	0.58	2.22e-22	Menopause (age at onset);
SARC	cis	rs4664308	0.935	rs4520993	chr2:160937673	G/A	cg03641300	chr2:160917029	PLA2R1	-0.71	-9.54	-0.53	2.02e-18	Idiopathic membranous nephropathy;
SARC	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg01017244	chr2:74357527	NA	-0.47	-5.77	-0.35	2.46e-8	Gestational age at birth (maternal effect);
SARC	cis	rs6570726	0.577	rs406868	chr6:145809983	C/T	cg05347473	chr6:146136440	FBXO30	0.72	9.83	0.54	2.58e-19	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.62	5.39	0.33	1.69e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs875971	1.000	rs1167411	chr7:65539264	C/G	cg11764359	chr7:65958608	NA	-0.86	-12.07	-0.62	2.22e-26	Aortic root size;
SARC	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	trans	rs17221829	0.733	rs11018668	chr11:89356178	C/T	cg09724427	chr17:47866462	MYST2	0.47	6.38	0.39	9.63e-10	Anxiety in major depressive disorder;
SARC	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs8051517	1.000	rs34598145	chr16:68378322	C/T	cg01866162	chr16:67596514	CTCF	0.95	5.61	0.35	5.68e-8	Blood protein levels;
SARC	cis	rs57083693	0.518	rs10860711	chr12:101723568	T/G	cg22051763	chr12:101673672	UTP20	-0.46	-5.41	-0.33	1.57e-7	Alcohol dependence (age at onset);
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25261764	chr18:55288998	NARS	-0.52	-6.64	-0.4	2.24e-10	Smoking initiation;
SARC	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg11062466	chr8:58055876	NA	0.63	5.36	0.33	1.99e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1865760	0.964	rs3799373	chr6:25929173	A/C	cg17691542	chr6:26056736	HIST1H1C	0.58	7.04	0.42	2.08e-11	Height;
SARC	cis	rs9916302	0.706	rs801427	chr17:37436711	A/G	cg20243544	chr17:37824526	PNMT	0.59	6.42	0.39	7.75e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs6540556	0.723	rs1999826	chr1:209919275	C/T	cg23920097	chr1:209922102	NA	-0.6	-6.67	-0.4	1.81e-10	Red blood cell count;
SARC	cis	rs11105298	0.891	rs10858906	chr12:89934474	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.55	-5.55	-0.34	7.56e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs35110281	0.805	rs2838318	chr21:44991825	G/A	cg21573476	chr21:45109991	RRP1B	-0.49	-7.16	-0.42	1.07e-11	Mean corpuscular volume;
SARC	cis	rs7617773	0.817	rs35414021	chr3:48293524	G/C	cg11946769	chr3:48343235	NME6	0.72	9.38	0.52	6.3e-18	Coronary artery disease;
SARC	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg24549020	chr5:56110836	MAP3K1	-0.55	-4.82	-0.3	2.65e-6	Initial pursuit acceleration;
SARC	cis	rs1580019	0.587	rs2392069	chr7:32547154	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.98	17.41	0.75	4.7e-44	Cognitive ability;
SARC	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg15448220	chr1:150897856	SETDB1	0.51	6.52	0.39	4.3e-10	Melanoma;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg07476944	chr4:39978140	PDS5A	-0.47	-6.27	-0.38	1.73e-9	Tetralogy of Fallot;
SARC	cis	rs763121	0.626	rs5750643	chr22:39009017	A/G	cg21395723	chr22:39101663	GTPBP1	0.57	6.72	0.4	1.41e-10	Menopause (age at onset);
SARC	cis	rs36051895	0.659	rs62543863	chr9:5085417	C/T	cg02405213	chr9:5042618	JAK2	-0.45	-5.14	-0.32	5.75e-7	Pediatric autoimmune diseases;
SARC	cis	rs9393777	0.557	rs9358949	chr6:26485717	A/C	cg12826209	chr6:26865740	GUSBL1	0.76	6.25	0.38	1.9e-9	Intelligence (multi-trait analysis);
SARC	cis	rs9300255	0.568	rs1790102	chr12:123704890	G/A	cg05973401	chr12:123451056	ABCB9	0.52	5.89	0.36	1.34e-8	Neutrophil percentage of white cells;
SARC	cis	rs6493487	0.512	rs7170815	chr15:51369937	A/G	cg02338191	chr15:51200825	AP4E1	0.5	4.88	0.3	1.96e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg19723775	chr5:179050963	HNRNPH1	-0.4	-5.09	-0.32	7.52e-7	Lung cancer;
SARC	cis	rs4689388	0.824	rs6446482	chr4:6295693	C/G	cg25554036	chr4:6271136	WFS1	0.38	6.12	0.37	3.98e-9	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs73086581	1.000	rs73086540	chr20:3950850	T/C	cg02187196	chr20:3869020	PANK2	0.67	6.4	0.39	8.3e-10	Response to antidepressants in depression;
SARC	cis	rs5769765	0.818	rs8140681	chr22:50292081	C/A	cg03033257	chr22:50311977	ALG12;CRELD2	0.52	5.33	0.33	2.28e-7	Schizophrenia;
SARC	cis	rs11112613	0.713	rs17041546	chr12:105950801	G/T	cg03607813	chr12:105948248	NA	-0.5	-7.15	-0.42	1.09e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs35213789	0.959	rs7781403	chr7:69281631	A/G	cg10619644	chr7:69149951	AUTS2	0.45	5.68	0.35	4.1e-8	Childhood ear infection;
SARC	cis	rs7424096	0.613	rs72873859	chr2:37246738	T/G	cg14987922	chr2:37194071	STRN	0.58	6.57	0.4	3.31e-10	High light scatter reticulocyte percentage of red cells;
SARC	cis	rs6450176	0.564	rs31228	chr5:53325994	C/G	ch.5.1024479R	chr5:53302184	ARL15	-0.55	-6.28	-0.38	1.63e-9	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	trans	rs11039798	0.588	rs7946443	chr11:48545504	G/A	cg15704280	chr7:45808275	SEPT13	0.64	6.57	0.4	3.16e-10	Axial length;
SARC	cis	rs1348850	0.914	rs10170546	chr2:178248790	C/T	cg23306229	chr2:178417860	TTC30B	0.55	6.38	0.39	9.48e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg22903471	chr2:27725779	GCKR	-0.46	-6.78	-0.41	1.01e-10	Menopause (age at onset);
SARC	cis	rs12950390	0.893	rs4239166	chr17:45847329	A/G	cg24803719	chr17:45855879	NA	-0.48	-7.99	-0.46	6.27e-14	IgG glycosylation;
SARC	cis	rs4253772	0.550	rs738444	chr22:46721088	C/T	cg24881330	chr22:46731750	TRMU	0.84	8.71	0.5	5.84e-16	LDL cholesterol;Cholesterol, total;
SARC	cis	rs6582630	0.533	rs2120464	chr12:38280289	A/C	cg26384229	chr12:38710491	ALG10B	0.59	7.59	0.45	7.61e-13	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs12458462	0.892	rs2242175	chr18:77464406	G/A	cg23301140	chr18:77439876	CTDP1	0.61	7.98	0.46	6.82e-14	Monocyte count;
SARC	trans	rs656319	0.513	rs17746227	chr8:9981654	T/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.0	-0.42	2.7e-11	Myopia (pathological);
SARC	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg25894440	chr7:65020034	NA	0.75	5.66	0.35	4.46e-8	Diabetic kidney disease;
SARC	cis	rs921968	0.565	rs7594046	chr2:219624170	A/G	cg02176678	chr2:219576539	TTLL4	0.33	4.97	0.31	1.28e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs9868809	0.505	rs28793701	chr3:48762683	C/G	cg03060546	chr3:49711283	APEH	-0.55	-5.03	-0.31	9.73e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs7829975	0.744	rs2409092	chr8:8682192	A/T	cg06636001	chr8:8085503	FLJ10661	0.64	8.67	0.49	7.57e-16	Mood instability;
SARC	cis	rs240764	0.507	rs9404031	chr6:101211298	T/C	cg09795085	chr6:101329169	ASCC3	0.41	5.02	0.31	1.04e-6	Neuroticism;
SARC	cis	rs7395581	0.918	rs7124955	chr11:47315274	A/T	cg25783544	chr11:47291846	MADD	0.48	5.42	0.33	1.48e-7	HDL cholesterol;
SARC	cis	rs80033912	0.713	rs7629936	chr3:49836707	G/A	cg03060546	chr3:49711283	APEH	0.57	6.16	0.37	3.2e-9	Intelligence (multi-trait analysis);
SARC	trans	rs6651255	0.580	rs12675465	chr8:130786091	T/C	cg14826211	chr2:23747197	KLHL29	0.52	6.43	0.39	7.1e-10	Sciatica caused by lumbar disc herniation (treated with microdiscectomy);
SARC	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg05665937	chr4:1216051	CTBP1	0.35	4.86	0.3	2.18e-6	Obesity-related traits;
SARC	cis	rs12477438	0.520	rs2632276	chr2:99779655	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	15.54	0.71	7.38e-38	Chronic sinus infection;
SARC	cis	rs372883	0.532	rs388707	chr21:30714776	T/C	cg24692254	chr21:30365293	RNF160	-0.49	-6.07	-0.37	5.13e-9	Pancreatic cancer;
SARC	cis	rs9300255	0.602	rs1106240	chr12:123626982	C/T	cg05973401	chr12:123451056	ABCB9	0.51	4.84	0.3	2.35e-6	Neutrophil percentage of white cells;
SARC	cis	rs208520	0.789	rs9351549	chr6:66871851	A/G	cg07460842	chr6:66804631	NA	-1.13	-15.21	-0.71	9.2e-37	Exhaled nitric oxide output;
SARC	cis	rs11098499	0.955	rs7685268	chr4:120162188	G/A	cg09307838	chr4:120376055	NA	0.84	11.55	0.6	1.04e-24	Corneal astigmatism;
SARC	cis	rs35110281	0.807	rs4818850	chr21:45028071	T/G	cg01579765	chr21:45077557	HSF2BP	-0.33	-5.68	-0.35	3.94e-8	Mean corpuscular volume;
SARC	cis	rs1023500	0.551	rs4822076	chr22:42364057	C/T	cg04733989	chr22:42467013	NAGA	0.57	6.97	0.42	3.23e-11	Schizophrenia;
SARC	cis	rs4792901	0.959	rs72833147	chr17:41626578	C/T	cg22562494	chr17:41607896	ETV4	-0.33	-5.31	-0.33	2.53e-7	Dupuytren's disease;
SARC	cis	rs4319547	0.656	rs7135419	chr12:122911861	T/A	cg05707623	chr12:122985044	ZCCHC8	-0.56	-6.29	-0.38	1.57e-9	Body mass index;
SARC	cis	rs79149102	0.579	rs7342601	chr15:75306795	G/T	cg09165964	chr15:75287851	SCAMP5	0.83	8.16	0.47	2.05e-14	Lung cancer;
SARC	cis	rs735539	0.521	rs575063	chr13:21422911	A/C	cg16922012	chr13:21400325	XPO4	-0.42	-5.55	-0.34	7.62e-8	Dental caries;
SARC	cis	rs13314892	0.764	rs6800508	chr3:69870871	C/T	cg17445875	chr3:69859618	MITF	-0.49	-5.12	-0.32	6.44e-7	QRS complex (12-leadsum);
SARC	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg03433033	chr1:76189801	ACADM	-0.52	-7.4	-0.44	2.49e-12	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg13206674	chr6:150067644	NUP43	0.46	6.05	0.37	5.68e-9	Lung cancer;
SARC	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg12311346	chr5:56204834	C5orf35	-0.57	-5.89	-0.36	1.37e-8	Initial pursuit acceleration;
SARC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg03647317	chr4:187891568	NA	-0.4	-5.72	-0.35	3.28e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3767633	0.925	rs4656335	chr1:161822078	A/G	cg09175582	chr1:161736000	ATF6	0.68	5.88	0.36	1.38e-8	IgG glycosylation;
SARC	cis	rs600231	0.719	rs7114809	chr11:65251444	A/G	cg17120908	chr11:65337727	SSSCA1	-0.44	-5.7	-0.35	3.6e-8	Bone mineral density;
SARC	cis	rs9814567	1.000	rs13322305	chr3:134310791	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-6.93	-0.41	4.14e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	8.8	0.5	3.1e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6963495	0.585	rs1706923	chr7:105221097	A/G	cg19920283	chr7:105172520	RINT1	0.49	5.14	0.32	5.86e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs9790314	0.581	rs6772578	chr3:160760851	T/A	cg04691961	chr3:161091175	C3orf57	-0.6	-8.14	-0.47	2.37e-14	Morning vs. evening chronotype;
SARC	cis	rs7005606	1.000	rs2439305	chr8:32429464	C/T	cg14488905	chr8:32406789	NRG1	-0.42	-5.83	-0.36	1.81e-8	Hirschsprung disease;
SARC	cis	rs3768617	0.510	rs7542640	chr1:183063738	G/A	cg13390022	chr1:182993471	LAMC1	0.33	4.94	0.31	1.49e-6	Fuchs's corneal dystrophy;
SARC	cis	rs910316	1.000	rs12589376	chr14:75561152	C/T	cg06637938	chr14:75390232	RPS6KL1	0.54	7.69	0.45	4.04e-13	Height;
SARC	cis	rs637571	0.522	rs491973	chr11:65727301	A/G	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.43	-5.39	-0.33	1.7e-7	Eosinophil percentage of white cells;
SARC	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg18252515	chr7:66147081	NA	-1.28	-11.26	-0.59	9.2e-24	Diabetic kidney disease;
SARC	cis	rs6752107	1.000	rs12994971	chr2:234178453	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.5	6.48	0.39	5.47e-10	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs4242434	0.672	rs900266	chr8:22485295	A/T	cg03733263	chr8:22462867	KIAA1967	0.88	13.9	0.67	2.08e-32	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs10463554	0.927	rs34375	chr5:102401123	C/T	cg23492399	chr5:102201601	PAM	-0.52	-5.7	-0.35	3.64e-8	Parkinson's disease;
SARC	cis	rs2153535	0.547	rs9502720	chr6:8541362	C/A	cg07606381	chr6:8435919	SLC35B3	0.77	11.04	0.59	4.62e-23	Motion sickness;
SARC	trans	rs9354308	0.802	rs2814102	chr6:66523230	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.56	6.52	0.39	4.42e-10	Metabolite levels;
SARC	cis	rs9818758	0.545	rs11717978	chr3:48969036	T/A	cg06212747	chr3:49208901	KLHDC8B	-0.64	-5.46	-0.34	1.22e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs11785400	1.000	rs3735999	chr8:143746069	T/C	cg24634471	chr8:143751801	JRK	0.67	8.88	0.5	1.79e-16	Schizophrenia;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21254277	chr17:61920407	SMARCD2	0.54	6.82	0.41	7.77e-11	Smoking initiation;
SARC	cis	rs4969178	0.965	rs8077859	chr17:76386335	C/T	cg02836325	chr17:76403955	PGS1	0.32	4.84	0.3	2.41e-6	HDL cholesterol levels;
SARC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg09436375	chr6:42928200	GNMT	-0.34	-5.24	-0.32	3.58e-7	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs2228479	0.850	rs62056091	chr16:89930414	G/A	cg12064134	chr16:90016061	DEF8	-0.56	-4.81	-0.3	2.71e-6	Skin colour saturation;
SARC	cis	rs1843834	0.539	rs12694643	chr2:225446603	A/G	cg22509189	chr2:225307070	NA	-0.65	-7.86	-0.46	1.46e-13	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs7647973	0.593	rs59684465	chr3:49874246	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.59	-5.95	-0.36	9.6e-9	Menarche (age at onset);
SARC	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg10589385	chr1:150898437	SETDB1	0.42	5.61	0.34	5.7e-8	Melanoma;
SARC	cis	rs2439831	0.614	rs2467733	chr15:43693328	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	10.74	0.58	4.05e-22	Lung cancer in ever smokers;
SARC	cis	rs10489202	0.632	rs275137	chr1:168051266	A/C	cg24449463	chr1:168025552	DCAF6	0.69	9.37	0.52	6.55e-18	Schizophrenia;
SARC	cis	rs9611565	0.506	rs7364221	chr22:41650190	C/A	cg17376030	chr22:41985996	PMM1	0.58	7.27	0.43	5.44e-12	Vitiligo;
SARC	cis	rs4919694	1.000	rs12257941	chr10:104833161	C/T	cg04362960	chr10:104952993	NT5C2	0.66	5.4	0.33	1.66e-7	Arsenic metabolism;
SARC	cis	rs4689388	0.853	rs1079216	chr4:6282473	T/C	cg00701064	chr4:6280414	WFS1	0.56	8.5	0.49	2.32e-15	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs35110281	0.506	rs13051661	chr21:45111518	A/T	cg21573476	chr21:45109991	RRP1B	-0.53	-7.38	-0.44	2.78e-12	Mean corpuscular volume;
SARC	cis	rs453301	0.686	rs7017868	chr8:8873293	G/A	cg11995313	chr8:8860691	ERI1	0.47	5.93	0.36	1.07e-8	Joint mobility (Beighton score);
SARC	cis	rs73036520	0.958	rs73036517	chr19:45744842	A/G	cg01416317	chr19:45737208	EXOC3L2	0.36	4.82	0.3	2.6e-6	Monocyte percentage of white cells;
SARC	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg19077165	chr18:44547161	KATNAL2	-0.52	-7.29	-0.43	4.74e-12	Personality dimensions;
SARC	cis	rs8072100	0.713	rs9807106	chr17:45457102	G/T	cg08085267	chr17:45401833	C17orf57	-0.42	-4.86	-0.3	2.16e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs3764563	0.935	rs4807958	chr19:15718042	T/C	cg20725493	chr19:15740067	CYP4F8	-0.67	-4.74	-0.3	3.69e-6	Inflammatory biomarkers;
SARC	cis	rs7826238	0.526	rs876955	chr8:8310884	C/G	cg06636001	chr8:8085503	FLJ10661	0.53	5.85	0.36	1.67e-8	Systolic blood pressure;
SARC	trans	rs2727020	0.729	rs2204366	chr11:49349367	A/C	cg15704280	chr7:45808275	SEPT13	0.79	12.82	0.64	8.17e-29	Coronary artery disease;
SARC	cis	rs9457247	1.000	rs385863	chr6:167386615	C/G	cg23791538	chr6:167370224	RNASET2	-0.62	-8.66	-0.49	8.17e-16	Crohn's disease;
SARC	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.35	-5.25	-0.33	3.43e-7	Longevity;Endometriosis;
SARC	cis	rs9303401	0.659	rs16943326	chr17:57050365	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.06	11.87	0.61	9.74e-26	Cognitive test performance;
SARC	cis	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg03213289	chr20:61660250	NA	0.46	6.43	0.39	7.22e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg22800045	chr5:56110881	MAP3K1	-0.64	-7.53	-0.44	1.11e-12	Type 2 diabetes;
SARC	cis	rs7264396	0.563	rs6058296	chr20:34269225	G/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.67	0.35	4.2e-8	Total cholesterol levels;
SARC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg13397359	chr6:42928475	GNMT	0.56	7.86	0.46	1.4e-13	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs3847687	1.000	rs10848269	chr12:131518622	A/G	cg25772418	chr12:131519998	GPR133	-0.32	-4.94	-0.31	1.51e-6	Longevity;
SARC	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg22105103	chr4:187893119	NA	0.49	6.57	0.4	3.25e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2268241	0.938	rs9974603	chr21:34776300	C/A	cg14850771	chr21:34775459	IFNGR2	0.95	9.33	0.52	8.68e-18	Obesity-related traits;
SARC	cis	rs1983170	0.808	rs2219393	chr1:92016577	C/T	cg25838465	chr1:92012736	NA	0.47	5.73	0.35	3.13e-8	Eosinophil percentage of white cells;
SARC	cis	rs9393777	0.623	rs7773938	chr6:26474044	C/T	cg12826209	chr6:26865740	GUSBL1	0.79	7.21	0.43	7.59e-12	Intelligence (multi-trait analysis);
SARC	cis	rs2760061	0.626	rs2796057	chr1:228124414	G/C	cg02753203	chr1:228287806	NA	-0.54	-7.45	-0.44	1.85e-12	Diastolic blood pressure;
SARC	cis	rs1468333	0.897	rs2269957	chr5:137501396	A/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.77	10.43	0.56	3.88e-21	Resting heart rate;
SARC	cis	rs778371	0.697	rs6717048	chr2:233586427	T/C	cg20388707	chr2:233749442	NGEF	-0.35	-5.06	-0.31	8.49e-7	Schizophrenia;
SARC	cis	rs10489202	0.632	rs12410730	chr1:168069477	T/C	cg24449463	chr1:168025552	DCAF6	-0.6	-7.85	-0.46	1.53e-13	Schizophrenia;
SARC	cis	rs911263	0.590	rs1570106	chr14:68813115	A/G	cg18825221	chr14:68749962	RAD51L1	0.4	5.41	0.33	1.54e-7	Primary biliary cholangitis;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg24354784	chr6:26059952	NA	0.46	6.26	0.38	1.81e-9	Thyroid stimulating hormone;
SARC	cis	rs2777491	0.957	rs6493002	chr15:41709195	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.82	-12.26	-0.63	5.57e-27	Ulcerative colitis;
SARC	cis	rs1008375	0.966	rs6832962	chr4:17652133	T/C	cg02297831	chr4:17616191	MED28	0.47	5.95	0.36	9.7e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6815814	0.950	rs113465719	chr4:38808045	A/T	cg06935464	chr4:38784597	TLR10	0.63	6.31	0.38	1.41e-9	Breast cancer;
SARC	cis	rs35110281	0.622	rs9977258	chr21:44976485	G/T	cg21573476	chr21:45109991	RRP1B	-0.45	-6.36	-0.38	1.04e-9	Mean corpuscular volume;
SARC	cis	rs4713118	0.513	rs149941	chr6:28001033	T/C	cg26335602	chr6:28129616	ZNF389	0.45	5.32	0.33	2.42e-7	Parkinson's disease;
SARC	cis	rs11785400	0.793	rs7459963	chr8:143737129	C/T	cg10596483	chr8:143751796	JRK	0.55	6.92	0.41	4.38e-11	Schizophrenia;
SARC	cis	rs1729951	0.546	rs12054218	chr3:136677496	C/G	cg15507776	chr3:136538369	TMEM22	0.51	5.73	0.35	3.12e-8	Neuroticism;
SARC	cis	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg24110177	chr3:50126178	RBM5	0.65	8.8	0.5	3.23e-16	Body mass index;
SARC	cis	rs6732160	0.613	rs10179063	chr2:73385111	T/A	cg01422370	chr2:73384389	NA	0.37	5.71	0.35	3.45e-8	Intelligence (multi-trait analysis);
SARC	cis	rs6840360	0.530	rs11946622	chr4:152486018	C/T	cg22705602	chr4:152727874	NA	-0.45	-6.89	-0.41	5.14e-11	Intelligence (multi-trait analysis);
SARC	cis	rs9790314	0.812	rs2004862	chr3:161135638	C/T	cg03342759	chr3:160939853	NMD3	-0.55	-6.88	-0.41	5.35e-11	Morning vs. evening chronotype;
SARC	cis	rs910316	1.000	rs4899546	chr14:75594946	G/C	cg11812906	chr14:75593930	NEK9	0.88	13.92	0.67	1.88e-32	Height;
SARC	cis	rs60871478	1.000	rs62432250	chr7:801792	C/G	cg05535760	chr7:792225	HEATR2	0.75	7.81	0.46	1.97e-13	Cerebrospinal P-tau181p levels;
SARC	cis	rs17125944	0.615	rs2025633	chr14:53317340	C/T	cg00686598	chr14:53173677	PSMC6	-0.66	-4.96	-0.31	1.36e-6	Alzheimer's disease (late onset);
SARC	cis	rs7808935	0.914	rs11971132	chr7:27985867	G/C	cg05786569	chr7:27702416	HIBADH	0.55	5.64	0.35	4.82e-8	Prostate cancer;
SARC	cis	rs12474201	0.928	rs34186074	chr2:46965010	T/C	cg06386533	chr2:46925753	SOCS5	0.91	14.0	0.68	1.03e-32	Height;
SARC	cis	rs7772486	0.790	rs9497427	chr6:146238302	T/A	cg23711669	chr6:146136114	FBXO30	-0.75	-11.73	-0.61	2.8e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs796364	0.760	rs74993507	chr2:201068684	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.61	-4.81	-0.3	2.72e-6	Schizophrenia;
SARC	cis	rs9843304	0.616	rs4681177	chr3:149203000	G/T	cg08667024	chr3:149219783	TM4SF4	-0.37	-5.27	-0.33	3.05e-7	Gallstone disease;
SARC	cis	rs7666738	0.606	rs13108868	chr4:99083753	C/T	cg05340658	chr4:99064831	C4orf37	0.47	5.95	0.36	9.8e-9	Colonoscopy-negative controls vs population controls;
SARC	cis	rs273218	0.724	rs392714	chr5:53382703	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.5	5.73	0.35	3.03e-8	Migraine;
SARC	cis	rs6450176	0.909	rs66872223	chr5:53292730	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.64	-7.22	-0.43	7.11e-12	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.63	0.53	1.05e-18	Prudent dietary pattern;
SARC	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg03806693	chr22:41940476	POLR3H	-0.88	-11.83	-0.61	1.38e-25	Vitiligo;
SARC	cis	rs1200821	0.535	rs1208783	chr10:37767467	A/G	cg25427524	chr10:38739819	LOC399744	-0.45	-6.64	-0.4	2.17e-10	Hemostatic factors and hematological phenotypes;
SARC	cis	rs72717009	0.825	rs6671753	chr1:161478708	G/A	cg23840854	chr1:161414152	NA	-0.54	-5.07	-0.32	8.2e-7	Rheumatoid arthritis;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg23483656	chr3:64430634	NA	-0.54	-6.79	-0.41	9.24e-11	Alcohol dependence;
SARC	cis	rs9467711	0.606	rs67234939	chr6:26530419	A/G	cg12826209	chr6:26865740	GUSBL1	0.74	5.24	0.32	3.57e-7	Autism spectrum disorder or schizophrenia;
SARC	cis	rs911555	0.570	rs11625397	chr14:104027557	A/G	cg17925084	chr14:104152323	KLC1	-0.35	-5.14	-0.32	5.95e-7	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg11987759	chr7:65425863	GUSB	0.61	8.33	0.48	7.01e-15	Aortic root size;
SARC	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg08859206	chr1:53392774	SCP2	0.41	5.86	0.36	1.6e-8	Monocyte count;
SARC	cis	rs2276314	1.000	rs1789513	chr18:33545630	A/G	cg05985134	chr18:33552581	C18orf21	-0.7	-7.46	-0.44	1.73e-12	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs3733585	0.699	rs10001964	chr4:9959275	C/T	cg11266682	chr4:10021025	SLC2A9	-0.37	-6.31	-0.38	1.4e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs6840360	0.550	rs11723438	chr4:152531801	C/T	cg22705602	chr4:152727874	NA	0.44	6.85	0.41	6.6e-11	Intelligence (multi-trait analysis);
SARC	cis	rs175714	0.845	rs175702	chr14:75971133	G/T	cg01624173	chr14:75981868	NA	-0.51	-6.58	-0.4	3.06e-10	Lymphocyte counts;
SARC	cis	rs651907	0.557	rs17347644	chr3:101547733	C/T	cg12386194	chr3:101231763	SENP7	0.49	5.42	0.33	1.46e-7	Colorectal cancer;
SARC	cis	rs7412746	0.658	rs7528773	chr1:150915875	G/A	cg15448220	chr1:150897856	SETDB1	0.51	6.65	0.4	2.02e-10	Melanoma;
SARC	cis	rs9467773	0.620	rs2504592	chr6:26640951	C/G	cg12292205	chr6:26970375	C6orf41	0.4	4.92	0.31	1.64e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg02841227	chr6:26021843	HIST1H4A	0.64	7.73	0.45	3.25e-13	Intelligence (multi-trait analysis);
SARC	cis	rs7208859	0.673	rs9899525	chr17:29120296	T/A	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs7412746	0.524	rs58304714	chr1:150831561	T/A	cg10589385	chr1:150898437	SETDB1	0.42	5.61	0.34	5.7e-8	Melanoma;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg10573763	chr19:19030094	COPE;DDX49	0.55	6.89	0.41	5.17e-11	Breast cancer;
SARC	cis	rs7169223	0.653	rs1976007	chr15:79085023	T/C	cg06917634	chr15:78832804	PSMA4	-0.49	-5.28	-0.33	2.93e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
SARC	cis	rs17270561	0.609	rs4712959	chr6:25727057	C/T	cg16482183	chr6:26056742	HIST1H1C	0.43	5.25	0.33	3.49e-7	Iron status biomarkers;
SARC	cis	rs950169	0.922	rs11631096	chr15:85100929	G/C	cg17507749	chr15:85114479	UBE2QP1	0.77	9.32	0.52	8.98e-18	Schizophrenia;
SARC	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg25894440	chr7:65020034	NA	-0.72	-5.46	-0.34	1.2e-7	Diabetic kidney disease;
SARC	cis	rs734999	0.545	rs28690427	chr1:2571823	A/G	cg18854424	chr1:2615690	NA	-0.31	-4.8	-0.3	2.87e-6	Ulcerative colitis;
SARC	cis	rs4975616	0.773	rs414965	chr5:1324121	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.52	-7.27	-0.43	5.29e-12	Lung cancer;
SARC	cis	rs533581	0.873	rs555191	chr16:88978850	C/T	cg16701003	chr16:89028210	CBFA2T3	0.47	6.78	0.41	9.78e-11	Social autistic-like traits;
SARC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg23131131	chr22:24373011	LOC391322	-0.42	-4.72	-0.3	4.14e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6582630	0.598	rs11182207	chr12:38477514	T/C	cg14851346	chr12:38532713	NA	-0.49	-5.96	-0.36	9.03e-9	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs3106136	0.967	rs72665658	chr4:95144761	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.97	-0.36	8.92e-9	Capecitabine sensitivity;
SARC	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	6.83	0.41	7.18e-11	Platelet count;
SARC	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.57	5.28	0.33	2.98e-7	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs9640161	0.830	rs3757425	chr7:150067640	A/C	cg17279839	chr7:150038598	RARRES2	0.34	5.32	0.33	2.41e-7	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg12463550	chr7:65579703	CRCP	-0.49	-5.22	-0.32	4.05e-7	Aortic root size;
SARC	cis	rs11122272	0.701	rs2011383	chr1:231479788	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-10.4	-0.56	4.78e-21	Hemoglobin concentration;
SARC	cis	rs7084402	0.967	rs1593672	chr10:60294379	T/C	cg07615347	chr10:60278583	BICC1	0.6	8.63	0.49	9.59e-16	Refractive error;
SARC	cis	rs2439831	0.867	rs2920781	chr15:43924682	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	7.5	0.44	1.35e-12	Lung cancer in ever smokers;
SARC	cis	rs12142240	0.698	rs1053627	chr1:46827728	A/C	cg00530320	chr1:46809349	NSUN4	0.57	6.79	0.41	9.05e-11	Menopause (age at onset);
SARC	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg22968622	chr17:43663579	NA	-0.85	-10.83	-0.58	2.14e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.54	6.14	0.37	3.48e-9	Prudent dietary pattern;
SARC	cis	rs6540556	0.954	rs6685077	chr1:209933331	A/G	cg23920097	chr1:209922102	NA	-0.61	-6.92	-0.41	4.32e-11	Red blood cell count;
SARC	cis	rs67460515	0.567	rs34691229	chr3:160876897	G/T	cg03342759	chr3:160939853	NMD3	-0.65	-7.94	-0.46	8.52e-14	Parkinson's disease;
SARC	cis	rs10504073	0.669	rs818558	chr8:50030855	A/G	cg00325661	chr8:49890786	NA	0.52	7.06	0.42	1.85e-11	Blood metabolite ratios;
SARC	trans	rs61931739	0.500	rs11053203	chr12:34456593	C/T	cg26384229	chr12:38710491	ALG10B	0.92	13.8	0.67	4.45e-32	Morning vs. evening chronotype;
SARC	cis	rs4253772	0.513	rs12171124	chr22:46710693	A/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.61	4.93	0.31	1.6e-6	LDL cholesterol;Cholesterol, total;
SARC	trans	rs1814175	0.791	rs11040513	chr11:49778153	G/C	cg03929089	chr4:120376271	NA	-0.9	-14.53	-0.69	1.76e-34	Height;
SARC	cis	rs7589342	0.628	rs35622044	chr2:106404095	G/A	cg16077055	chr2:106428750	NCK2	0.32	5.41	0.33	1.53e-7	Addiction;
SARC	cis	rs7000551	0.715	rs1530874	chr8:22347777	G/C	cg12081754	chr8:22256438	SLC39A14	0.56	7.82	0.46	1.81e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg11890956	chr21:40555474	PSMG1	1.18	20.06	0.8	1.13e-52	Cognitive function;
SARC	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg27266027	chr21:40555129	PSMG1	-0.5	-5.34	-0.33	2.15e-7	Cognitive function;
SARC	cis	rs2985684	0.901	rs57119148	chr14:50097226	T/C	cg04989706	chr14:50066350	PPIL5	-0.54	-5.75	-0.35	2.75e-8	Carotid intima media thickness;
SARC	cis	rs9309711	0.544	rs9752130	chr2:3488502	A/G	cg08493051	chr2:3487164	NA	-0.42	-5.1	-0.32	7.01e-7	Neurofibrillary tangles;
SARC	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg11644478	chr21:40555479	PSMG1	-0.56	-6.95	-0.41	3.69e-11	Menarche (age at onset);
SARC	cis	rs2953145	0.568	rs2975752	chr2:241521327	A/G	cg07929629	chr2:241523174	NA	0.42	5.3	0.33	2.69e-7	Bipolar disorder;
SARC	cis	rs6495122	0.501	rs6495144	chr15:75343438	T/C	cg09165964	chr15:75287851	SCAMP5	-0.48	-6.39	-0.39	9.11e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.47	0.53	3.34e-18	Prudent dietary pattern;
SARC	cis	rs9487051	0.836	rs9400270	chr6:109607488	G/A	cg01475377	chr6:109611718	NA	-0.41	-5.96	-0.36	9.28e-9	Reticulocyte fraction of red cells;
SARC	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg16434002	chr17:42200994	HDAC5	-0.39	-4.82	-0.3	2.63e-6	Total body bone mineral density;
SARC	cis	rs1832871	0.672	rs7745596	chr6:158732991	T/A	cg07165851	chr6:158734300	TULP4	0.58	6.77	0.41	1.05e-10	Height;
SARC	cis	rs6831352	0.918	rs17218560	chr4:100060794	C/T	cg13256891	chr4:100009986	ADH5	0.58	6.9	0.41	4.95e-11	Alcohol dependence;
SARC	cis	rs9660180	0.620	rs34298494	chr1:1663402	A/C	cg23982607	chr1:1823379	GNB1	0.38	4.82	0.3	2.57e-6	Body mass index;
SARC	cis	rs72781680	1.000	rs72788280	chr2:24095907	A/G	cg06627628	chr2:24431161	ITSN2	-0.66	-6.46	-0.39	5.99e-10	Lymphocyte counts;
SARC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	20.35	0.8	1.32e-53	Prudent dietary pattern;
SARC	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg20607798	chr8:58055168	NA	0.58	5.57	0.34	6.9e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9831754	0.906	rs2089934	chr3:78382448	T/C	cg06138941	chr3:78371609	NA	-0.59	-6.78	-0.41	9.96e-11	Calcium levels;
SARC	cis	rs9914544	0.564	rs9906799	chr17:18795317	A/G	cg25390199	chr17:18761479	PRPSAP2	0.46	6.05	0.37	5.66e-9	Educational attainment (years of education);
SARC	cis	rs2836633	0.929	rs11701577	chr21:40028906	C/T	cg12884169	chr21:40033163	ERG	0.48	8.78	0.5	3.51e-16	Coronary artery disease;
SARC	cis	rs8141529	0.719	rs5762825	chr22:29223642	A/G	cg02153584	chr22:29168773	CCDC117	0.8	11.69	0.61	3.83e-25	Lymphocyte counts;
SARC	cis	rs796364	0.906	rs281789	chr2:200780698	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.76	7.17	0.43	9.92e-12	Schizophrenia;
SARC	cis	rs11731606	0.508	rs12108275	chr4:95298847	T/G	cg00507259	chr4:95128692	SMARCAD1	0.56	5.39	0.33	1.7e-7	Mean platelet volume;
SARC	cis	rs7000551	0.715	rs2443502	chr8:22340499	G/A	cg12081754	chr8:22256438	SLC39A14	0.56	7.77	0.45	2.55e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs6696846	0.765	rs61822619	chr1:205090885	C/G	cg07972983	chr1:205091412	RBBP5	0.57	7.37	0.43	3.03e-12	Red blood cell count;
SARC	cis	rs6728642	0.614	rs113485946	chr2:97866442	T/C	cg26665480	chr2:98280029	ACTR1B	-0.64	-5.07	-0.32	8.2e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg02462569	chr6:150064036	NUP43	-0.4	-5.14	-0.32	5.76e-7	Lung cancer;
SARC	cis	rs2180341	0.814	rs6914131	chr6:127737489	T/C	cg24812749	chr6:127587940	RNF146	0.79	10.11	0.55	3.71e-20	Breast cancer;
SARC	cis	rs7766436	0.961	rs6900627	chr6:22570245	G/A	cg13666174	chr6:22585274	NA	-0.57	-7.22	-0.43	7.26e-12	Coronary artery disease;
SARC	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg02931644	chr1:25747376	RHCE	0.45	7.58	0.44	8.04e-13	Erythrocyte sedimentation rate;
SARC	cis	rs8141529	0.600	rs16986838	chr22:29312578	C/T	cg02153584	chr22:29168773	CCDC117	0.68	7.35	0.43	3.28e-12	Lymphocyte counts;
SARC	cis	rs12824058	0.831	rs11608406	chr12:130805866	G/C	cg23887609	chr12:130822674	PIWIL1	0.4	5.54	0.34	8.1e-8	Menopause (age at onset);
SARC	cis	rs6665290	0.904	rs6426559	chr1:227195876	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.09	-25.43	-0.86	3.74e-69	Myeloid white cell count;
SARC	cis	rs7429990	0.901	rs7374482	chr3:48168390	A/G	cg11946769	chr3:48343235	NME6	-0.46	-5.42	-0.33	1.46e-7	Educational attainment (years of education);
SARC	cis	rs554111	0.656	rs6685914	chr1:21362378	G/A	cg08890418	chr1:21044141	KIF17	-0.36	-4.91	-0.31	1.72e-6	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs4072980	0.545	rs11210870	chr1:38449910	T/C	cg18451016	chr1:38461880	NA	-0.36	-4.86	-0.3	2.11e-6	Coronary artery disease;
SARC	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs1814175	0.791	rs11040472	chr11:49703116	C/T	cg03929089	chr4:120376271	NA	-0.9	-14.71	-0.69	4.3e-35	Height;
SARC	cis	rs807669	0.772	rs809901	chr22:19228736	C/T	cg02655711	chr22:19163373	SLC25A1	0.4	5.58	0.34	6.82e-8	Metabolite levels;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07076661	chr18:9136556	ANKRD12	0.52	6.29	0.38	1.59e-9	Fibrinogen levels;
SARC	cis	rs6088580	0.601	rs6059872	chr20:33082775	C/A	cg08999081	chr20:33150536	PIGU	0.45	6.89	0.41	5.18e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs7662987	0.517	rs1453874	chr4:100022724	G/A	cg13256891	chr4:100009986	ADH5	0.66	8.13	0.47	2.55e-14	Smoking initiation;
SARC	cis	rs1355223	0.583	rs1396880	chr11:34870552	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.73	-10.3	-0.56	9.9e-21	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs644799	0.930	rs587123	chr11:95560539	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	14.98	0.7	5.62e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs807669	0.903	rs807666	chr22:19160549	C/T	cg02655711	chr22:19163373	SLC25A1	0.57	7.97	0.46	6.86e-14	Metabolite levels;
SARC	cis	rs9818758	0.545	rs55921200	chr3:49189316	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.62	-4.73	-0.3	3.86e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs9457247	1.000	rs10946198	chr6:167404432	C/T	cg07741184	chr6:167504864	NA	0.29	5.55	0.34	7.72e-8	Crohn's disease;
SARC	cis	rs3796619	0.503	rs13147452	chr4:1078124	G/A	cg27284194	chr4:1044797	NA	0.6	8.62	0.49	1.02e-15	Recombination rate (males);
SARC	cis	rs1865760	0.566	rs2858993	chr6:26087856	T/A	cg17691542	chr6:26056736	HIST1H1C	0.54	6.62	0.4	2.47e-10	Height;
SARC	cis	rs1538970	1.000	rs61791368	chr1:45867944	T/C	cg05343316	chr1:45956843	TESK2	0.72	8.59	0.49	1.25e-15	Platelet count;
SARC	cis	rs2425143	1.000	rs11700256	chr20:34372941	C/G	cg01084648	chr20:34329383	RBM39	0.63	4.75	0.3	3.49e-6	Blood protein levels;
SARC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg23131131	chr22:24373011	LOC391322	-0.44	-4.73	-0.3	3.96e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg13944838	chr5:179740914	GFPT2	-0.56	-7.25	-0.43	6.06e-12	Height;
SARC	cis	rs2204008	0.837	rs1842599	chr12:37986081	G/A	cg26384229	chr12:38710491	ALG10B	-0.79	-11.35	-0.6	4.71e-24	Bladder cancer;
SARC	cis	rs858239	0.601	rs10263110	chr7:23160551	G/A	cg23682824	chr7:23144976	KLHL7	0.74	10.02	0.55	7.18e-20	Cerebrospinal fluid biomarker levels;
SARC	cis	rs4906332	0.966	rs12894275	chr14:103901424	A/G	cg26031613	chr14:104095156	KLC1	0.46	5.28	0.33	3.02e-7	Coronary artery disease;
SARC	cis	rs2221894	0.506	rs17454230	chr8:28926081	G/T	cg07962641	chr8:28805897	HMBOX1	-0.77	-7.58	-0.44	8.1e-13	Obesity-related traits;
SARC	cis	rs514406	0.505	rs374849	chr1:53185631	G/A	cg24675658	chr1:53192096	ZYG11B	-0.65	-9.6	-0.53	1.36e-18	Monocyte count;
SARC	cis	rs7927771	0.524	rs2290851	chr11:47753370	C/T	cg20307385	chr11:47447363	PSMC3	-0.49	-6.64	-0.4	2.2e-10	Subjective well-being;
SARC	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg12648201	chr2:27665141	KRTCAP3	-0.32	-4.89	-0.31	1.89e-6	Total body bone mineral density;
SARC	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg20607798	chr8:58055168	NA	0.56	5.43	0.34	1.4e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg07234876	chr8:600039	NA	0.85	6.93	0.41	4.13e-11	IgG glycosylation;
SARC	trans	rs3734266	0.702	rs36026951	chr6:34722761	T/C	cg08157914	chr7:2646478	IQCE	0.52	6.24	0.38	2.1e-9	Systemic lupus erythematosus;
SARC	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg16606324	chr3:10149918	C3orf24	0.48	5.04	0.31	9.53e-7	Alzheimer's disease;
SARC	cis	rs1023500	0.505	rs134888	chr22:42674281	C/T	cg04733989	chr22:42467013	NAGA	0.51	6.52	0.39	4.36e-10	Schizophrenia;
SARC	cis	rs7512552	0.839	rs834229	chr1:150384665	G/C	cg15654264	chr1:150340011	RPRD2	0.37	4.77	0.3	3.25e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.76	5.79	0.35	2.26e-8	Initial pursuit acceleration;
SARC	cis	rs9815354	0.812	rs73073229	chr3:42007850	T/C	cg03022575	chr3:42003672	ULK4	0.68	5.89	0.36	1.34e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6582630	0.502	rs3902522	chr12:38271203	T/C	cg26384229	chr12:38710491	ALG10B	0.89	13.06	0.65	1.31e-29	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1003719	0.680	rs8130069	chr21:38552116	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.21	-0.52	1.9e-17	Eye color traits;
SARC	cis	rs6500602	0.727	rs12443748	chr16:4541831	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.34	5.66	0.35	4.43e-8	Schizophrenia;
SARC	cis	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg05623727	chr3:50126028	RBM5	-0.35	-5.08	-0.32	7.92e-7	Body mass index;
SARC	cis	rs7824557	0.603	rs2736278	chr8:11219781	C/T	cg21775007	chr8:11205619	TDH	0.65	8.44	0.48	3.37e-15	Retinal vascular caliber;
SARC	cis	rs2153535	0.542	rs9505465	chr6:8510846	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	7.3	0.43	4.57e-12	Motion sickness;
SARC	trans	rs1814175	0.935	rs11040463	chr11:49685574	C/T	cg03929089	chr4:120376271	NA	-0.86	-13.64	-0.67	1.52e-31	Height;
SARC	cis	rs2732480	0.577	rs2634691	chr12:48708259	G/T	cg21466736	chr12:48725269	NA	-0.32	-4.92	-0.31	1.62e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs17376456	0.877	rs10476599	chr5:93383423	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.68	0.35	3.93e-8	Diabetic retinopathy;
SARC	trans	rs61931739	0.500	rs9795938	chr12:34587739	C/T	cg26384229	chr12:38710491	ALG10B	-0.85	-12.8	-0.64	9.59e-29	Morning vs. evening chronotype;
SARC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	9.07	0.51	5.22e-17	Prudent dietary pattern;
SARC	cis	rs721399	0.719	rs4646257	chr8:18262546	A/G	cg18736775	chr8:18248649	NAT2	0.52	5.95	0.36	9.79e-9	Blood metabolite levels;
SARC	cis	rs10908458	0.743	rs7367207	chr1:155079477	C/T	cg22049894	chr1:155113146	DPM3	0.43	5.52	0.34	8.96e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2290402	0.505	rs17165087	chr4:845841	C/T	cg00846425	chr4:957561	DGKQ	-0.42	-4.86	-0.3	2.12e-6	Type 2 diabetes;
SARC	cis	rs2204008	0.548	rs8189475	chr12:38037115	C/T	cg13010199	chr12:38710504	ALG10B	0.67	8.99	0.51	8.92e-17	Bladder cancer;
SARC	cis	rs6141769	0.542	rs6058833	chr20:31316767	T/G	cg13636640	chr20:31349939	DNMT3B	-0.45	-4.78	-0.3	3.08e-6	Subjective well-being;
SARC	cis	rs7236492	0.515	rs76804350	chr18:77180607	C/T	cg15644404	chr18:77186268	NFATC1	-0.62	-4.83	-0.3	2.47e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs11155671	0.530	rs3823021	chr6:150210999	G/C	cg05036130	chr6:150231994	NA	0.28	4.87	0.3	2.04e-6	Testicular germ cell tumor;
SARC	cis	rs11190604	1.000	rs2489039	chr10:102328036	T/A	cg07080220	chr10:102295463	HIF1AN	0.8	9.54	0.53	2.07e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs9611565	0.570	rs12159188	chr22:42121125	A/T	cg17376030	chr22:41985996	PMM1	-0.64	-8.42	-0.48	3.87e-15	Vitiligo;
SARC	cis	rs3923518	0.956	rs11919589	chr3:38935192	A/G	cg15678707	chr3:39149194	GORASP1;TTC21A	0.47	5.05	0.31	8.93e-7	Migraine;
SARC	trans	rs9951602	0.541	rs12454297	chr18:76654445	A/G	cg02800362	chr5:177631904	HNRNPAB	0.7	8.92	0.5	1.4e-16	Obesity-related traits;
SARC	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg16414030	chr3:133502952	NA	-0.37	-4.77	-0.3	3.31e-6	Iron status biomarkers;
SARC	cis	rs9916302	0.904	rs755500	chr17:37409865	C/T	cg00129232	chr17:37814104	STARD3	-0.59	-7.37	-0.44	2.87e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs7223966	1.000	rs8067431	chr17:61817048	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.52	-5.38	-0.33	1.83e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2404618	0.561	rs4242536	chr8:1477225	A/G	cg13402656	chr8:1511478	DLGAP2	-0.6	-8.81	-0.5	2.84e-16	Lung cancer;
SARC	cis	rs12142240	0.698	rs41294456	chr1:46809782	T/C	cg00530320	chr1:46809349	NSUN4	0.58	7.07	0.42	1.74e-11	Menopause (age at onset);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg06079273	chr8:97247865	UQCRB	0.84	7.31	0.43	4.33e-12	Autism spectrum disorder or schizophrenia;
SARC	cis	rs3540	0.960	rs11857092	chr15:90960115	T/C	cg22089800	chr15:90895588	ZNF774	0.47	5.08	0.32	7.58e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs6582630	0.519	rs1851121	chr12:38389467	T/C	cg26384229	chr12:38710491	ALG10B	0.87	12.79	0.64	1.02e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7772486	0.790	rs2265474	chr6:146182092	G/A	cg23711669	chr6:146136114	FBXO30	0.89	15.2	0.71	1.06e-36	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1144333	0.655	rs17097867	chr1:76471614	C/T	cg03433033	chr1:76189801	ACADM	0.63	5.15	0.32	5.47e-7	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs8072100	0.840	rs1912482	chr17:45454883	G/A	cg08085267	chr17:45401833	C17orf57	-0.41	-4.86	-0.3	2.17e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs1707322	0.721	rs4564187	chr1:46166861	G/C	cg06784218	chr1:46089804	CCDC17	0.36	6.17	0.37	2.95e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	8.87	0.5	1.93e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2011503	0.943	rs10406278	chr19:19494725	A/C	cg15839431	chr19:19639596	YJEFN3	0.5	4.9	0.31	1.78e-6	Bipolar disorder;
SARC	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg11987759	chr7:65425863	GUSB	-0.46	-6.15	-0.37	3.36e-9	Aortic root size;
SARC	cis	rs12142240	0.659	rs72677591	chr1:46818219	T/G	cg14993813	chr1:46806288	NSUN4	-0.52	-5.46	-0.34	1.22e-7	Menopause (age at onset);
SARC	cis	rs6871536	1.000	rs17166050	chr5:131915213	G/A	cg11797159	chr5:131991491	NA	0.38	4.78	0.3	3.13e-6	Asthma (childhood onset);
SARC	trans	rs3942852	0.688	rs10742834	chr11:48169717	G/A	cg15704280	chr7:45808275	SEPT13	-0.62	-7.2	-0.43	8.05e-12	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs362272	0.545	rs3129308	chr4:3309272	C/T	cg06533319	chr4:3265114	C4orf44	-0.31	-4.91	-0.31	1.7e-6	Serum sulfate level;
SARC	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs11770686	0.666	rs2255968	chr7:75310506	C/T	cg17787366	chr7:75369077	HIP1	0.39	4.85	0.3	2.28e-6	Essential tremor;
SARC	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg08219700	chr8:58056026	NA	0.6	5.71	0.35	3.49e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs12101261	0.536	rs724170	chr14:81457940	G/A	cg06600135	chr14:81408086	NA	0.39	4.81	0.3	2.77e-6	Graves' disease;
SARC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg26354017	chr1:205819088	PM20D1	0.83	13.2	0.65	4.37e-30	Menarche (age at onset);
SARC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg06873352	chr17:61820015	STRADA	0.53	6.89	0.41	5.28e-11	Prudent dietary pattern;
SARC	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg25952890	chr19:58913133	NA	0.39	5.57	0.34	6.93e-8	Uric acid clearance;
SARC	cis	rs2295359	1.000	rs4655684	chr1:67611772	A/G	cg03340356	chr1:67600835	NA	-0.32	-4.79	-0.3	2.93e-6	Psoriasis;
SARC	cis	rs826838	1.000	rs11183941	chr12:38851692	G/C	cg13010199	chr12:38710504	ALG10B	0.78	11.08	0.59	3.29e-23	Heart rate;
SARC	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg03060546	chr3:49711283	APEH	0.42	5.24	0.32	3.51e-7	Parkinson's disease;
SARC	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg03806693	chr22:41940476	POLR3H	0.92	12.39	0.63	2.01e-27	Vitiligo;
SARC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg05165339	chr4:1420672	NA	-0.25	-5.4	-0.33	1.62e-7	Longevity;
SARC	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg11644478	chr21:40555479	PSMG1	-0.55	-6.69	-0.4	1.67e-10	Menarche (age at onset);
SARC	cis	rs11098499	0.954	rs6847248	chr4:120225955	A/G	cg09307838	chr4:120376055	NA	0.89	11.73	0.61	2.76e-25	Corneal astigmatism;
SARC	cis	rs9660992	0.626	rs61823972	chr1:205201325	A/C	cg07972983	chr1:205091412	RBBP5	0.56	7.13	0.42	1.25e-11	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs36051895	0.664	rs4593605	chr9:5107278	C/A	cg02405213	chr9:5042618	JAK2	-0.47	-5.56	-0.34	7.52e-8	Pediatric autoimmune diseases;
SARC	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg03517284	chr6:25882590	NA	-0.44	-5.67	-0.35	4.23e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7560272	0.669	rs13008860	chr2:73774019	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-6.13	-0.37	3.64e-9	Schizophrenia;
SARC	cis	rs2916247	1.000	rs13251018	chr8:93053581	G/T	cg10183463	chr8:93005414	RUNX1T1	-0.59	-6.25	-0.38	1.9e-9	Intelligence (multi-trait analysis);
SARC	cis	rs2180341	0.618	rs12529077	chr6:127634244	G/T	cg24812749	chr6:127587940	RNF146	0.59	7.44	0.44	1.98e-12	Breast cancer;
SARC	trans	rs34421088	0.560	rs2618434	chr8:11398865	A/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-9.0	-0.51	8.01e-17	Neuroticism;
SARC	cis	rs2075371	0.932	rs1862052	chr7:133981227	G/A	cg20476274	chr7:133979776	SLC35B4	0.58	7.61	0.45	6.96e-13	Mean platelet volume;
SARC	cis	rs1030877	0.557	rs2278501	chr2:105979506	C/T	cg02079111	chr2:105885981	TGFBRAP1	-0.36	-5.18	-0.32	4.85e-7	Obesity-related traits;
SARC	cis	rs3767633	0.925	rs924777	chr1:161848904	G/A	cg09175582	chr1:161736000	ATF6	0.65	5.5	0.34	9.86e-8	IgG glycosylation;
SARC	cis	rs3820928	1.000	rs6752707	chr2:227766822	C/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-6.68	-0.4	1.72e-10	Pulmonary function;
SARC	cis	rs1448094	0.511	rs10863083	chr12:86226739	C/A	cg00310523	chr12:86230176	RASSF9	0.32	5.07	0.32	8.26e-7	Major depressive disorder;
SARC	cis	rs7246657	0.882	rs6508716	chr19:37819010	T/C	cg14683738	chr19:37701593	ZNF585B	0.51	4.94	0.31	1.52e-6	Coronary artery calcification;
SARC	trans	rs629535	0.911	rs627382	chr8:70014081	C/T	cg21567404	chr3:27674614	NA	-1.06	-14.0	-0.68	9.69e-33	Dupuytren's disease;
SARC	cis	rs2841277	0.741	rs9672139	chr14:105408182	T/G	cg19901468	chr14:105411992	AHNAK2	-0.79	-11.84	-0.61	1.27e-25	Rheumatoid arthritis;
SARC	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg12463550	chr7:65579703	CRCP	0.47	5.31	0.33	2.59e-7	Aortic root size;
SARC	cis	rs4319547	0.956	rs7316149	chr12:123063912	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.66	-7.99	-0.46	6.29e-14	Body mass index;
SARC	cis	rs1800469	1.000	rs2241712	chr19:41869756	C/T	cg14132834	chr19:41945861	ATP5SL	-0.42	-5.06	-0.31	8.67e-7	Colorectal cancer;
SARC	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.77	8.72	0.5	5.3e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4619890	0.510	rs7680747	chr4:7871623	G/A	cg18538662	chr4:7941764	AFAP1	-0.38	-4.76	-0.3	3.37e-6	Glaucoma (primary open-angle);
SARC	cis	rs372883	0.532	rs425989	chr21:30715275	T/C	cg08807101	chr21:30365312	RNF160	-0.48	-5.95	-0.36	9.69e-9	Pancreatic cancer;
SARC	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg22974920	chr21:40686053	BRWD1	0.46	4.9	0.31	1.77e-6	Cognitive function;
SARC	cis	rs73242632	1.000	rs73242632	chr4:57893770	C/A	cg20415529	chr4:57845134	POLR2B;C4orf14	1.07	6.6	0.4	2.74e-10	Congenital heart disease (maternal effect);
SARC	cis	rs2153535	0.580	rs4587214	chr6:8454119	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	8.31	0.48	8.13e-15	Motion sickness;
SARC	cis	rs9486715	0.929	rs7775721	chr6:97056979	C/T	cg18709589	chr6:96969512	KIAA0776	-0.66	-8.29	-0.48	9.16e-15	Headache;
SARC	cis	rs4481887	0.927	rs4523548	chr1:248472399	G/T	cg00666640	chr1:248458726	OR2T12	0.34	5.7	0.35	3.65e-8	Common traits (Other);
SARC	cis	rs9325144	0.647	rs17518186	chr12:38883665	T/C	cg26384229	chr12:38710491	ALG10B	-0.54	-6.98	-0.42	3.03e-11	Morning vs. evening chronotype;
SARC	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg26913058	chr16:419975	MRPL28	-0.37	-6.88	-0.41	5.33e-11	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg18404041	chr3:52824283	ITIH1	-0.39	-5.95	-0.36	9.61e-9	Bipolar disorder;
SARC	cis	rs7481584	0.624	rs12417389	chr11:3035304	G/C	cg20651018	chr11:3035856	CARS	0.4	6.01	0.37	6.93e-9	Calcium levels;
SARC	cis	rs9916302	0.904	rs9898170	chr17:37510092	T/C	cg07936489	chr17:37558343	FBXL20	0.68	9.2	0.52	2.14e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs10085978	0.583	rs13258478	chr8:143235330	C/G	cg24634471	chr8:143751801	JRK	0.46	5.29	0.33	2.88e-7	Mosquito bite size;
SARC	cis	rs9911578	1.000	rs2270097	chr17:56572070	G/A	cg12560992	chr17:57184187	TRIM37	-0.79	-10.42	-0.56	4.08e-21	Intelligence (multi-trait analysis);
SARC	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.41	-6.91	-0.41	4.52e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs12142240	0.698	rs72677594	chr1:46824371	A/C	cg14993813	chr1:46806288	NSUN4	-0.51	-5.34	-0.33	2.19e-7	Menopause (age at onset);
SARC	cis	rs282587	0.569	rs7982564	chr13:113398930	G/A	cg02820901	chr13:113351484	ATP11A	-0.51	-4.98	-0.31	1.23e-6	Glycated hemoglobin levels;
SARC	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg11608241	chr8:8085544	FLJ10661	0.41	5.09	0.32	7.45e-7	Mood instability;
SARC	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg05863683	chr7:1912471	MAD1L1	-0.34	-5.03	-0.31	9.73e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs76917914	1.000	rs4742711	chr9:100780790	G/A	cg03040243	chr9:100819229	NANS	0.58	6.0	0.37	7.32e-9	Immature fraction of reticulocytes;
SARC	cis	rs10463554	0.892	rs34830	chr5:102444053	A/G	cg23492399	chr5:102201601	PAM	-0.52	-5.72	-0.35	3.2e-8	Parkinson's disease;
SARC	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg06420487	chr17:61919686	SMARCD2	0.49	5.71	0.35	3.46e-8	Height;
SARC	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg05890377	chr2:74357713	NA	0.58	7.08	0.42	1.72e-11	Gestational age at birth (maternal effect);
SARC	cis	rs1707322	0.721	rs61784800	chr1:46178112	A/G	cg03146154	chr1:46216737	IPP	-0.5	-6.04	-0.37	6.1e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg20887711	chr4:1340912	KIAA1530	-0.69	-8.31	-0.48	7.94e-15	Longevity;
SARC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg11494091	chr17:61959527	GH2	0.54	8.15	0.47	2.26e-14	Prudent dietary pattern;
SARC	cis	rs6782228	0.606	rs6439135	chr3:128358633	G/A	cg08795948	chr3:128337044	NA	0.37	5.03	0.31	9.66e-7	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
SARC	cis	rs367615	0.512	rs814153	chr5:108667829	A/C	cg17395555	chr5:108820864	NA	0.33	4.76	0.3	3.45e-6	Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs6815814	0.950	rs4540055	chr4:38803255	A/T	cg09316306	chr4:38807337	TLR1	0.46	5.13	0.32	5.95e-7	Breast cancer;
SARC	cis	rs6762	0.550	rs8672	chr11:838634	C/G	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.59	-7.59	-0.45	7.59e-13	Mean platelet volume;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg17107193	chr6:5261438	LYRM4;FARS2	0.52	6.5	0.39	4.82e-10	Height;
SARC	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg11890956	chr21:40555474	PSMG1	1.09	16.3	0.73	2.28e-40	Cognitive function;
SARC	cis	rs7681440	0.874	rs1442154	chr4:90775761	C/G	cg02192967	chr4:90758406	SNCA	0.37	5.26	0.33	3.25e-7	Dementia with Lewy bodies;
SARC	cis	rs2075371	0.897	rs10488428	chr7:133997560	C/T	cg20476274	chr7:133979776	SLC35B4	0.59	7.64	0.45	5.65e-13	Mean platelet volume;
SARC	cis	rs12545912	0.866	rs10503380	chr8:9410495	C/T	cg21625330	chr8:9911636	MSRA	-0.53	-4.99	-0.31	1.2e-6	Multiple myeloma (hyperdiploidy);
SARC	cis	rs7945705	0.869	rs2742471	chr11:9003953	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-7.07	-0.42	1.82e-11	Hemoglobin concentration;
SARC	cis	rs1153858	1.000	rs7181167	chr15:45686236	C/G	cg15395560	chr15:45543142	SLC28A2	-0.27	-4.87	-0.3	2.03e-6	Homoarginine levels;
SARC	cis	rs8014204	0.836	rs11159099	chr14:75235397	A/G	cg06637938	chr14:75390232	RPS6KL1	0.7	10.11	0.55	3.62e-20	Caffeine consumption;
SARC	cis	rs832540	1.000	rs192249	chr5:56197514	C/G	cg14703610	chr5:56206110	C5orf35	0.54	6.73	0.4	1.29e-10	Coronary artery disease;
SARC	cis	rs9325144	0.647	rs12831609	chr12:39051576	C/A	cg26384229	chr12:38710491	ALG10B	-0.62	-8.1	-0.47	3.07e-14	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg11062466	chr8:58055876	NA	0.65	6.15	0.37	3.38e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6860806	0.507	rs270614	chr5:131640813	G/A	cg24060327	chr5:131705240	SLC22A5	-0.72	-8.61	-0.49	1.11e-15	Breast cancer;
SARC	cis	rs17125944	0.615	rs1886786	chr14:53312189	A/T	cg00686598	chr14:53173677	PSMC6	-0.66	-5.02	-0.31	1.05e-6	Alzheimer's disease (late onset);
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11026874	chr17:30368766	LRRC37B	0.54	7.0	0.42	2.64e-11	Smoking initiation;
SARC	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg16479474	chr6:28041457	NA	0.36	5.24	0.32	3.65e-7	Parkinson's disease;
SARC	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg17971929	chr21:40555470	PSMG1	-0.56	-7.07	-0.42	1.81e-11	Menarche (age at onset);
SARC	cis	rs11599315	0.757	rs11250392	chr10:1342543	T/C	cg09624528	chr10:1369823	ADARB2	0.45	6.92	0.41	4.27e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg12373951	chr3:133503437	NA	0.36	5.24	0.32	3.63e-7	Iron status biomarkers;
SARC	cis	rs2153535	0.580	rs9505448	chr6:8459804	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	10.66	0.57	7.43e-22	Motion sickness;
SARC	cis	rs6545883	0.894	rs2177962	chr2:61588070	T/A	cg15711740	chr2:61764176	XPO1	0.41	4.84	0.3	2.32e-6	Tuberculosis;
SARC	cis	rs367615	0.552	rs2963025	chr5:108733256	A/C	cg17395555	chr5:108820864	NA	-0.34	-4.91	-0.31	1.72e-6	Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs62244186	0.715	rs11130032	chr3:44704083	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.43	5.33	0.33	2.36e-7	Depressive symptoms;
SARC	trans	rs11098499	0.863	rs36040693	chr4:120477616	A/G	cg25214090	chr10:38739885	LOC399744	0.57	7.25	0.43	6.27e-12	Corneal astigmatism;
SARC	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg27266027	chr21:40555129	PSMG1	-0.53	-5.93	-0.36	1.08e-8	Cognitive function;
SARC	cis	rs6912958	0.781	rs9450752	chr6:88300013	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-6.8	-0.41	8.58e-11	Monocyte percentage of white cells;
SARC	cis	rs67460515	0.926	rs13062740	chr3:161024208	G/A	cg04691961	chr3:161091175	C3orf57	-0.5	-6.21	-0.38	2.45e-9	Parkinson's disease;
SARC	cis	rs4727027	0.704	rs2888600	chr7:148908562	C/T	cg23583168	chr7:148888333	NA	-0.81	-12.16	-0.62	1.12e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs472402	0.560	rs10065299	chr5:6654489	T/C	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.43	-5.14	-0.32	5.69e-7	Response to amphetamines;
SARC	cis	rs72781680	1.000	rs72781634	chr2:24199102	C/T	cg06627628	chr2:24431161	ITSN2	-0.7	-6.78	-0.41	9.65e-11	Lymphocyte counts;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg13394530	chr9:34612526	C9orf23	0.54	6.99	0.42	2.8e-11	Electrocardiographic conduction measures;
SARC	cis	rs9322193	0.607	rs4869755	chr6:150207483	G/A	cg11878867	chr6:150167359	LRP11	-0.41	-4.85	-0.3	2.26e-6	Lung cancer;
SARC	cis	rs11792861	0.926	rs12683988	chr9:111867290	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.69	7.9	0.46	1.08e-13	Menarche (age at onset);
SARC	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg09455208	chr3:40491958	NA	0.38	5.64	0.35	4.9e-8	Renal cell carcinoma;
SARC	cis	rs1048238	0.506	rs10927867	chr1:16177285	A/G	cg21385522	chr1:16154831	NA	0.46	5.7	0.35	3.62e-8	Systolic blood pressure;
SARC	cis	rs2644899	0.785	rs2604895	chr19:41292263	T/A	cg24958765	chr19:41283667	RAB4B	-0.58	-6.42	-0.39	7.47e-10	Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs11190604	1.000	rs10883511	chr10:102299407	A/G	cg07080220	chr10:102295463	HIF1AN	0.82	9.74	0.54	4.96e-19	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs11711311	0.955	rs12634241	chr3:113397685	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	8.15	0.47	2.29e-14	IgG glycosylation;
SARC	cis	rs2985684	0.901	rs57119148	chr14:50097226	T/C	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.46	4.84	0.3	2.4e-6	Carotid intima media thickness;
SARC	cis	rs4919087	0.545	rs793531	chr10:99041167	G/T	cg25902810	chr10:99078978	FRAT1	-0.54	-5.96	-0.36	9.39e-9	Monocyte count;
SARC	cis	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg00745463	chr17:30367425	LRRC37B	-0.63	-5.05	-0.31	8.97e-7	Hip circumference adjusted for BMI;
SARC	cis	rs365132	0.967	rs58279426	chr5:176448139	T/C	cg16309518	chr5:176445507	NA	-0.44	-5.66	-0.35	4.53e-8	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs4689388	0.853	rs4293850	chr4:6292020	A/C	cg14416269	chr4:6271139	WFS1	0.33	5.08	0.32	7.62e-7	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs1059312	1.000	rs1059312	chr12:129278864	A/G	cg23521905	chr12:129298690	SLC15A4;MGC16384	-0.49	-7.13	-0.42	1.25e-11	Systemic lupus erythematosus;
SARC	trans	rs1814175	0.669	rs11040473	chr11:49703813	C/T	cg15704280	chr7:45808275	SEPT13	-0.81	-13.11	-0.65	9.14e-30	Height;
SARC	cis	rs9902453	0.904	rs9900974	chr17:28364456	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.16	-0.42	1.02e-11	Coffee consumption (cups per day);
SARC	cis	rs11770686	0.766	rs1859292	chr7:75341135	C/T	cg17787366	chr7:75369077	HIP1	0.44	5.44	0.34	1.34e-7	Essential tremor;
SARC	cis	rs11190604	1.000	rs9419897	chr10:102246125	T/C	cg07080220	chr10:102295463	HIF1AN	0.7	8.26	0.48	1.13e-14	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs2011503	0.882	rs72999053	chr19:19375372	G/A	cg03709012	chr19:19516395	GATAD2A	0.64	5.54	0.34	8.09e-8	Bipolar disorder;
SARC	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg04277193	chr17:41438351	NA	0.44	4.73	0.3	3.83e-6	Menopause (age at onset);
SARC	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg13206674	chr6:150067644	NUP43	0.46	6.03	0.37	6.45e-9	Lung cancer;
SARC	cis	rs6690583	0.623	rs12041012	chr1:85515644	G/A	cg22153463	chr1:85462885	MCOLN2	0.68	5.1	0.32	6.91e-7	Serum sulfate level;
SARC	cis	rs2288912	0.807	rs10423208	chr19:45453656	G/A	cg13119609	chr19:45449297	APOC2	0.5	8.42	0.48	3.76e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg19223190	chr17:80058835	NA	0.41	5.71	0.35	3.45e-8	Life satisfaction;
SARC	cis	rs748404	0.650	rs518261	chr15:43573429	A/T	cg12308275	chr15:43558855	TGM5	-0.4	-4.82	-0.3	2.61e-6	Lung cancer;
SARC	cis	rs9300255	0.569	rs1790115	chr12:123620270	C/G	cg00376283	chr12:123451042	ABCB9	0.56	6.52	0.39	4.36e-10	Neutrophil percentage of white cells;
SARC	cis	rs9611565	0.649	rs126092	chr22:42178441	A/G	cg03806693	chr22:41940476	POLR3H	0.75	9.35	0.52	7.29e-18	Vitiligo;
SARC	cis	rs9902453	0.578	rs8073217	chr17:28164263	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	7.14	0.42	1.19e-11	Coffee consumption (cups per day);
SARC	cis	rs193541	0.632	rs7729834	chr5:122122159	A/G	cg19412675	chr5:122181750	SNX24	0.5	6.57	0.4	3.28e-10	Glucose homeostasis traits;
SARC	cis	rs7772486	0.754	rs6906258	chr6:146089356	A/G	cg23711669	chr6:146136114	FBXO30	-0.92	-16.21	-0.73	4.61e-40	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg07648498	chr16:89883185	FANCA	0.43	5.76	0.35	2.63e-8	Vitiligo;
SARC	cis	rs10791097	0.694	rs1050071	chr11:130747231	C/G	cg12179176	chr11:130786555	SNX19	0.77	10.9	0.58	1.28e-22	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs732765	0.819	rs2058920	chr14:75311329	C/T	cg06637938	chr14:75390232	RPS6KL1	0.41	4.73	0.3	3.83e-6	Non-small cell lung cancer;
SARC	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg02951883	chr7:2050386	MAD1L1	-0.43	-5.55	-0.34	7.8e-8	Schizophrenia;
SARC	cis	rs1949733	0.523	rs55977448	chr4:8542918	G/T	cg13073564	chr4:8508604	NA	0.49	7.34	0.43	3.47e-12	Response to antineoplastic agents;
SARC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg11965913	chr1:205819406	PM20D1	0.58	7.72	0.45	3.32e-13	Menarche (age at onset);
SARC	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg20607798	chr8:58055168	NA	0.67	5.26	0.33	3.31e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9790314	0.663	rs61105146	chr3:160651949	T/A	cg03342759	chr3:160939853	NMD3	0.39	4.79	0.3	2.95e-6	Morning vs. evening chronotype;
SARC	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg11644478	chr21:40555479	PSMG1	1.03	12.76	0.64	1.26e-28	Cognitive function;
SARC	cis	rs2204008	0.627	rs1851117	chr12:38398987	G/T	cg26384229	chr12:38710491	ALG10B	0.84	11.73	0.61	2.82e-25	Bladder cancer;
SARC	cis	rs7296418	0.663	rs4553407	chr12:123750748	G/C	cg00376283	chr12:123451042	ABCB9	0.57	6.91	0.41	4.66e-11	Platelet count;
SARC	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg18876405	chr7:65276391	NA	-0.43	-4.72	-0.3	4.13e-6	Aortic root size;
SARC	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg11987759	chr7:65425863	GUSB	-0.49	-6.59	-0.4	2.96e-10	Aortic root size;
SARC	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.74	8.42	0.48	3.76e-15	Height;
SARC	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg12923728	chr3:195709715	SDHAP1	0.65	8.04	0.47	4.62e-14	Pancreatic cancer;
SARC	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg01341218	chr17:43662625	NA	-0.71	-8.25	-0.48	1.15e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs10875746	0.951	rs2286021	chr12:48528220	C/T	cg26205652	chr12:48591994	NA	0.54	5.99	0.37	8.11e-9	Longevity (90 years and older);
SARC	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	9.03	0.51	6.74e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs17345786	0.511	rs12639028	chr3:101346033	G/C	cg12386194	chr3:101231763	SENP7	0.54	6.48	0.39	5.38e-10	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1348850	0.526	rs7607073	chr2:178375065	C/A	cg23306229	chr2:178417860	TTC30B	0.84	7.66	0.45	4.88e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7937682	0.961	rs491937	chr11:111494947	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.93	-15.25	-0.71	7.22e-37	Primary sclerosing cholangitis;
SARC	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg18357526	chr6:26021779	HIST1H4A	0.45	5.67	0.35	4.29e-8	Blood metabolite levels;
SARC	cis	rs73086581	0.687	rs73082600	chr20:3844365	G/A	cg02187196	chr20:3869020	PANK2	0.65	5.71	0.35	3.38e-8	Response to antidepressants in depression;
SARC	cis	rs11608355	0.846	rs4766598	chr12:109853306	A/G	cg05360138	chr12:110035743	NA	0.58	6.16	0.37	3.24e-9	Neuroticism;
SARC	cis	rs763121	0.813	rs4821807	chr22:39065582	A/G	cg14440974	chr22:39074834	NA	-0.33	-4.73	-0.3	3.9e-6	Menopause (age at onset);
SARC	cis	rs11112613	0.713	rs58066965	chr12:105952505	C/G	cg03607813	chr12:105948248	NA	0.54	7.74	0.45	3.01e-13	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg08975724	chr8:8085496	FLJ10661	0.41	5.24	0.32	3.53e-7	Joint mobility (Beighton score);
SARC	trans	rs61931739	0.500	rs10844848	chr12:34409705	A/C	cg13010199	chr12:38710504	ALG10B	0.82	11.43	0.6	2.62e-24	Morning vs. evening chronotype;
SARC	cis	rs11711311	0.955	rs9866806	chr3:113379865	C/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.66	-7.77	-0.45	2.49e-13	IgG glycosylation;
SARC	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg10295955	chr4:187884368	NA	-1.08	-18.18	-0.77	1.39e-46	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7819412	0.595	rs4841500	chr8:10988275	A/G	cg21775007	chr8:11205619	TDH	-0.42	-5.12	-0.32	6.34e-7	Triglycerides;
SARC	cis	rs67311347	0.713	rs4974018	chr3:40307419	G/A	cg24209194	chr3:40518798	ZNF619	0.53	6.57	0.4	3.22e-10	Renal cell carcinoma;
SARC	cis	rs4900538	0.855	rs12587464	chr14:102886561	G/C	cg18135206	chr14:102964638	TECPR2	-0.6	-7.64	-0.45	5.65e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs10791323	0.572	rs1114367	chr11:133737304	G/T	cg13461336	chr11:133711254	SPATA19	-0.28	-5.04	-0.31	9.28e-7	Childhood ear infection;
SARC	cis	rs12134245	0.776	rs12125947	chr1:91990487	T/C	cg02896835	chr1:92012615	NA	-0.52	-7.08	-0.42	1.71e-11	Breast cancer;
SARC	cis	rs637571	0.584	rs659824	chr11:65636509	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.52	-7.06	-0.42	1.86e-11	Eosinophil percentage of white cells;
SARC	cis	rs611744	0.647	rs676654	chr8:109242303	A/G	cg21045802	chr8:109455806	TTC35	0.63	8.0	0.46	5.71e-14	Dupuytren's disease;
SARC	cis	rs9616064	0.531	rs66909472	chr22:47050210	G/A	cg05621596	chr22:47072043	GRAMD4	-0.61	-8.46	-0.48	2.97e-15	Urate levels in obese individuals;
SARC	cis	rs17666538	0.792	rs115204727	chr8:676639	G/A	cg02524346	chr8:600233	NA	-0.9	-5.67	-0.35	4.29e-8	IgG glycosylation;
SARC	cis	rs9911578	1.000	rs11870671	chr17:56605360	A/G	cg12560992	chr17:57184187	TRIM37	-0.81	-10.81	-0.58	2.5e-22	Intelligence (multi-trait analysis);
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg16118148	chr16:4675387	MGRN1	0.5	6.41	0.39	8e-10	Lung adenocarcinoma;
SARC	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg16479474	chr6:28041457	NA	0.37	5.25	0.33	3.45e-7	Parkinson's disease;
SARC	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg06634786	chr22:41940651	POLR3H	-0.5	-5.92	-0.36	1.17e-8	Vitiligo;
SARC	cis	rs12451471	0.500	rs8077056	chr17:78076006	C/T	cg06718696	chr17:78121285	EIF4A3	0.89	10.11	0.55	3.67e-20	Plateletcrit;Mean corpuscular hemoglobin concentration;
SARC	cis	rs62344088	0.590	rs6889904	chr5:177264	A/C	cg22857025	chr5:266934	NA	-0.74	-5.57	-0.34	7.16e-8	Asthma (childhood onset);
SARC	trans	rs11098499	0.908	rs1002152	chr4:120273387	C/A	cg25214090	chr10:38739885	LOC399744	0.55	7.14	0.42	1.15e-11	Corneal astigmatism;
SARC	cis	rs66573146	0.572	rs66734745	chr4:6948765	T/C	cg26116260	chr4:7069785	GRPEL1	-0.68	-5.02	-0.31	1.04e-6	Granulocyte percentage of myeloid white cells;
SARC	cis	rs12579753	0.872	rs7956132	chr12:82178709	A/G	cg07988820	chr12:82153109	PPFIA2	-0.53	-6.27	-0.38	1.7e-9	Resting heart rate;
SARC	cis	rs7647973	0.826	rs9834535	chr3:49378797	A/T	cg06212747	chr3:49208901	KLHDC8B	0.63	6.54	0.39	3.95e-10	Menarche (age at onset);
SARC	cis	rs8067545	0.611	rs2703800	chr17:20086562	C/T	cg13482628	chr17:19912719	NA	0.55	7.25	0.43	5.93e-12	Schizophrenia;
SARC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.7	0.54	6.55e-19	Prudent dietary pattern;
SARC	cis	rs820218	0.886	rs820202	chr17:73636623	G/A	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.66	8.9	0.5	1.58e-16	Rotator cuff tears;
SARC	cis	rs13161895	1.000	rs17079966	chr5:179443190	G/T	cg02702477	chr5:179499311	RNF130	0.69	7.09	0.42	1.63e-11	LDL cholesterol;
SARC	cis	rs11098499	0.954	rs12507964	chr4:120413061	T/A	cg09307838	chr4:120376055	NA	0.93	12.73	0.64	1.6e-28	Corneal astigmatism;
SARC	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg18876405	chr7:65276391	NA	0.69	9.06	0.51	5.41e-17	Calcium levels;
SARC	cis	rs262150	0.503	rs11769917	chr7:158817498	C/T	cg09640425	chr7:158790006	NA	-0.38	-5.43	-0.34	1.41e-7	Facial morphology (factor 20);
SARC	cis	rs7700895	0.737	rs11135442	chr5:95222511	T/C	cg16656078	chr5:95278638	ELL2	-0.55	-6.74	-0.4	1.24e-10	IgG glycosylation;
SARC	trans	rs12310956	0.510	rs1386936	chr12:33875369	G/A	cg26384229	chr12:38710491	ALG10B	0.62	8.27	0.48	1.02e-14	Morning vs. evening chronotype;
SARC	cis	rs7520050	0.807	rs72688483	chr1:46149209	A/G	cg24296786	chr1:45957014	TESK2	-0.45	-5.78	-0.35	2.33e-8	Red blood cell count;Reticulocyte count;
SARC	trans	rs9325144	0.671	rs7306605	chr12:38730471	C/T	cg23762105	chr12:34175262	ALG10	-0.54	-7.07	-0.42	1.83e-11	Morning vs. evening chronotype;
SARC	cis	rs11608355	1.000	rs10774690	chr12:109859682	G/A	cg05360138	chr12:110035743	NA	0.43	4.8	0.3	2.86e-6	Neuroticism;
SARC	cis	rs11690935	0.632	rs9789538	chr2:172618474	G/C	cg13550731	chr2:172543902	DYNC1I2	0.66	9.41	0.52	4.91e-18	Schizophrenia;
SARC	cis	rs7044106	0.762	rs1324473	chr9:123404610	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.7	-8.89	-0.5	1.66e-16	Hip circumference adjusted for BMI;
SARC	cis	rs6429082	0.818	rs696248	chr1:235668511	C/A	cg26050004	chr1:235667680	B3GALNT2	0.66	7.55	0.44	9.59e-13	Adiposity;
SARC	cis	rs2251381	0.750	rs2251186	chr21:30528880	G/A	cg24692254	chr21:30365293	RNF160	0.87	12.41	0.63	1.72e-27	Selective IgA deficiency;
SARC	cis	rs2153535	0.563	rs7739249	chr6:8534590	C/G	cg07606381	chr6:8435919	SLC35B3	0.72	9.68	0.54	7.86e-19	Motion sickness;
SARC	cis	rs10779751	0.770	rs11121696	chr1:11238063	A/G	cg08854313	chr1:11322531	MTOR	-0.78	-9.85	-0.54	2.35e-19	Body mass index;
SARC	cis	rs4121859	1.000	rs17625540	chr11:95184355	A/G	cg00671093	chr11:95522599	CEP57;FAM76B	0.45	4.95	0.31	1.44e-6	Cancer;
SARC	cis	rs7605378	1.000	rs769957	chr2:200695524	A/C	cg23649088	chr2:200775458	C2orf69	0.5	5.81	0.36	2.09e-8	Osteoporosis;
SARC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg26668828	chr6:292823	DUSP22	-0.6	-7.85	-0.46	1.51e-13	Menopause (age at onset);
SARC	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg18252515	chr7:66147081	NA	0.53	5.6	0.34	5.91e-8	Aortic root size;
SARC	cis	rs6831352	0.918	rs4699713	chr4:100060513	C/T	cg12011299	chr4:100065546	ADH4	-0.35	-5.75	-0.35	2.8e-8	Alcohol dependence;
SARC	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg05861140	chr6:150128134	PCMT1	-0.43	-5.48	-0.34	1.12e-7	Lung cancer;
SARC	cis	rs8180040	0.764	rs6794193	chr3:47114904	T/C	cg02527881	chr3:46936655	PTH1R	-0.31	-4.77	-0.3	3.24e-6	Colorectal cancer;
SARC	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg12311346	chr5:56204834	C5orf35	-0.54	-5.5	-0.34	9.74e-8	Initial pursuit acceleration;
SARC	cis	rs7560272	0.682	rs2421546	chr2:73641077	A/C	cg20560298	chr2:73613845	ALMS1	0.51	6.98	0.42	3.05e-11	Schizophrenia;
SARC	cis	rs4742903	0.509	rs10991153	chr9:106953169	C/T	cg14250997	chr9:106856677	SMC2	0.39	4.85	0.3	2.3e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs6546550	0.835	rs3755389	chr2:70119469	T/C	cg02498382	chr2:70120550	SNRNP27	-0.35	-5.57	-0.34	6.86e-8	Prevalent atrial fibrillation;
SARC	cis	rs2816062	0.735	rs2816054	chr1:18896431	C/T	cg10574377	chr1:18908098	NA	0.35	5.05	0.31	8.83e-7	Urate levels in lean individuals;
SARC	cis	rs73001065	0.636	rs28720066	chr19:19572220	G/T	cg03709012	chr19:19516395	GATAD2A	1.15	8.15	0.47	2.3e-14	LDL cholesterol;
SARC	cis	rs1707322	1.000	rs11211219	chr1:46359478	G/C	cg03146154	chr1:46216737	IPP	0.47	5.64	0.35	4.94e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9612	1.000	rs12669	chr19:44235535	G/A	cg08581076	chr19:44259116	C19orf61	0.73	9.33	0.52	8.39e-18	Exhaled nitric oxide output;
SARC	cis	rs3540	0.960	rs4031435	chr15:91015566	G/C	cg22089800	chr15:90895588	ZNF774	0.52	5.91	0.36	1.23e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.59	5.18	0.32	4.85e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs9660992	0.710	rs1172136	chr1:205247097	T/G	cg21545522	chr1:205238299	TMCC2	0.48	6.58	0.4	3.16e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs2228479	0.850	rs62054611	chr16:89817017	T/C	cg00800038	chr16:89945340	TCF25	-0.74	-5.14	-0.32	5.75e-7	Skin colour saturation;
SARC	cis	rs8141529	0.702	rs132536	chr22:29302906	A/G	cg02153584	chr22:29168773	CCDC117	-0.78	-11.33	-0.6	5.58e-24	Lymphocyte counts;
SARC	cis	rs7615952	0.611	rs12488771	chr3:125700526	A/G	cg05084668	chr3:125655381	ALG1L	-0.94	-7.5	-0.44	1.29e-12	Blood pressure (smoking interaction);
SARC	cis	rs965469	0.842	rs6051776	chr20:3332062	T/C	cg25506879	chr20:3388711	C20orf194	-0.53	-5.55	-0.34	7.72e-8	IFN-related cytopenia;
SARC	trans	rs2898290	0.622	rs978804	chr8:11343673	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.33	-0.43	3.83e-12	Systolic blood pressure;
SARC	cis	rs9788682	0.706	rs2568493	chr15:78740233	G/A	cg06917634	chr15:78832804	PSMA4	0.52	5.44	0.34	1.35e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs7589342	1.000	rs7589342	chr2:106433478	C/T	cg16077055	chr2:106428750	NCK2	0.4	7.45	0.44	1.79e-12	Addiction;
SARC	trans	rs2018683	0.677	rs2057956	chr7:28973460	G/A	cg19402173	chr7:128379420	CALU	-0.5	-6.37	-0.39	1.02e-9	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.47	0.44	1.61e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs995000	0.509	rs11207978	chr1:62980512	T/C	cg06896770	chr1:63153194	DOCK7	0.78	7.85	0.46	1.48e-13	Triglyceride levels;
SARC	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg12463550	chr7:65579703	CRCP	-0.5	-5.83	-0.36	1.85e-8	Aortic root size;
SARC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg05564831	chr3:52568323	NT5DC2	0.27	4.88	0.3	1.98e-6	Electroencephalogram traits;
SARC	cis	rs11098699	0.821	rs1562063	chr4:124204110	G/A	cg09941581	chr4:124220074	SPATA5	0.39	4.73	0.3	3.98e-6	Mosquito bite size;
SARC	cis	rs7264396	0.676	rs6060729	chr20:34557004	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	5.3	0.33	2.71e-7	Total cholesterol levels;
SARC	trans	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg17830980	chr10:43048298	ZNF37B	-0.5	-6.57	-0.4	3.19e-10	Extrinsic epigenetic age acceleration;
SARC	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg13395646	chr4:1353034	KIAA1530	-0.6	-7.01	-0.42	2.57e-11	Obesity-related traits;
SARC	cis	rs6977660	0.507	rs72591450	chr7:19775480	A/G	cg05791153	chr7:19748676	TWISTNB	0.9	7.53	0.44	1.1e-12	Thyroid stimulating hormone;
SARC	cis	rs11214589	0.651	rs11214594	chr11:113259332	G/A	cg14159747	chr11:113255604	NA	0.37	5.29	0.33	2.86e-7	Neuroticism;
SARC	cis	rs4481887	0.927	rs7519334	chr1:248472076	C/T	cg13385794	chr1:248469461	NA	0.35	5.39	0.33	1.74e-7	Common traits (Other);
SARC	cis	rs6918586	0.658	rs198809	chr6:26128766	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.44	-5.53	-0.34	8.36e-8	Schizophrenia;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg06896044	chr16:2222637	TRAF7	0.5	6.42	0.39	7.62e-10	Schizophrenia;
SARC	cis	rs10823500	0.640	rs7077538	chr10:71993094	T/G	cg04118878	chr10:71993077	PPA1	0.56	6.02	0.37	6.83e-9	Blood protein levels;
SARC	trans	rs10085978	0.604	rs11167128	chr8:143225883	A/G	cg10589950	chr19:36231534	TMEM149	0.47	6.24	0.38	2.07e-9	Mosquito bite size;
SARC	cis	rs523522	0.923	rs10774553	chr12:120954984	T/C	cg27279351	chr12:120934652	DYNLL1	0.73	9.04	0.51	6.26e-17	High light scatter reticulocyte count;
SARC	cis	rs3126085	0.935	rs11204967	chr1:152249720	A/G	cg26876637	chr1:152193138	HRNR	-0.43	-5.06	-0.31	8.68e-7	Atopic dermatitis;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg04499690	chr3:93781964	NSUN3;DHFRL1	0.47	6.26	0.38	1.85e-9	Lung adenocarcinoma;
SARC	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg11764359	chr7:65958608	NA	0.59	7.1	0.42	1.51e-11	Calcium levels;
SARC	cis	rs7084402	0.875	rs1593671	chr10:60295969	A/T	cg07615347	chr10:60278583	BICC1	0.6	8.91	0.5	1.45e-16	Refractive error;
SARC	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.06	15.83	0.72	8.2e-39	Height;
SARC	trans	rs66573146	1.000	rs66573146	chr4:6984464	C/G	cg07817883	chr1:32538562	TMEM39B	1.52	9.1	0.51	4.22e-17	Granulocyte percentage of myeloid white cells;
SARC	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	5.58	0.34	6.73e-8	Bipolar disorder;
SARC	cis	rs11190604	1.000	rs7079136	chr10:102292709	T/C	cg07080220	chr10:102295463	HIF1AN	0.8	9.6	0.53	1.36e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs9916302	0.904	rs2061338	chr17:37421767	T/C	cg15445000	chr17:37608096	MED1	0.41	5.08	0.32	7.87e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs735396	0.627	rs2264778	chr12:121450354	C/A	cg15155738	chr12:121454335	C12orf43	0.52	6.8	0.41	8.74e-11	N-glycan levels;
SARC	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg24829409	chr8:58192753	C8orf71	-0.6	-6.11	-0.37	4.1e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg00409905	chr10:38381863	ZNF37A	-0.53	-7.55	-0.44	9.57e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg11644478	chr21:40555479	PSMG1	1.05	14.99	0.7	5.25e-36	Cognitive function;
SARC	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7246657	0.941	rs67293224	chr19:37803248	C/T	cg14683738	chr19:37701593	ZNF585B	0.6	5.24	0.32	3.57e-7	Coronary artery calcification;
SARC	cis	rs2153535	0.580	rs915351	chr6:8442793	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.95	11.39	0.6	3.6e-24	Platelet count;
SARC	cis	rs2731664	0.792	rs2630767	chr5:176870700	T/C	cg23176889	chr5:176863531	GRK6	-0.53	-7.69	-0.45	4.12e-13	Intelligence (multi-trait analysis);
SARC	cis	rs76419734	1.000	rs72671853	chr4:106646886	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.84	5.42	0.33	1.51e-7	Post bronchodilator FEV1;
SARC	cis	rs2153535	0.580	rs6597335	chr6:8527714	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	10.6	0.57	1.12e-21	Motion sickness;
SARC	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg12311346	chr5:56204834	C5orf35	-0.58	-5.41	-0.33	1.59e-7	Type 2 diabetes;
SARC	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg20102877	chr2:27665638	KRTCAP3	-0.34	-4.75	-0.3	3.62e-6	Total body bone mineral density;
SARC	cis	rs10875746	0.951	rs10875756	chr12:48562304	C/T	cg27446233	chr12:48516484	PFKM	-0.41	-4.81	-0.3	2.74e-6	Longevity (90 years and older);
SARC	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg17971929	chr21:40555470	PSMG1	0.97	13.53	0.66	3.53e-31	Cognitive function;
SARC	cis	rs8067545	0.611	rs7219908	chr17:20043036	A/G	cg13482628	chr17:19912719	NA	0.52	6.81	0.41	8.45e-11	Schizophrenia;
SARC	cis	rs72945132	0.882	rs72945168	chr11:70131471	G/C	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.78	-0.35	2.39e-8	Coronary artery disease;
SARC	trans	rs7819412	0.645	rs10156356	chr8:11046209	T/C	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.73	-0.45	3.19e-13	Triglycerides;
SARC	cis	rs8114671	0.967	rs2069948	chr20:33762489	C/T	cg24642439	chr20:33292090	TP53INP2	0.51	5.88	0.36	1.44e-8	Height;
SARC	cis	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg13072238	chr3:49761600	GMPPB	-0.42	-5.54	-0.34	8.33e-8	Intelligence (multi-trait analysis);
SARC	cis	rs736801	0.891	rs10900809	chr5:131826322	G/A	cg07395648	chr5:131743802	NA	-0.48	-5.14	-0.32	5.79e-7	Breast cancer;Mosquito bite size;
SARC	cis	rs35661897	0.920	rs12469727	chr2:227301483	A/G	cg03426602	chr2:227312417	NA	0.49	4.74	0.3	3.68e-6	Urinary tract infection frequency;
SARC	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg22920501	chr2:26401640	FAM59B	-0.53	-6.68	-0.4	1.78e-10	Gut microbiome composition (summer);
SARC	cis	rs8141529	0.529	rs73170633	chr22:29160805	C/T	cg15103426	chr22:29168792	CCDC117	0.61	5.8	0.36	2.19e-8	Lymphocyte counts;
SARC	cis	rs7647973	0.626	rs62260720	chr3:49853796	T/A	cg03060546	chr3:49711283	APEH	-0.66	-6.95	-0.41	3.73e-11	Menarche (age at onset);
SARC	cis	rs7923609	0.811	rs12245367	chr10:65321464	C/T	cg01631684	chr10:65280961	REEP3	0.36	4.75	0.3	3.48e-6	Educational attainment;Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs6908034	0.600	rs79733895	chr6:19799541	A/G	cg02682789	chr6:19804855	NA	0.71	5.1	0.32	7.14e-7	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg26769984	chr7:1090371	C7orf50	0.45	4.92	0.31	1.6e-6	Bronchopulmonary dysplasia;
SARC	cis	rs854765	0.583	rs8073001	chr17:17831716	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.63	-9.43	-0.53	4.21e-18	Total body bone mineral density;
SARC	cis	rs1707322	1.000	rs785519	chr1:46568562	C/T	cg06784218	chr1:46089804	CCDC17	-0.35	-6.16	-0.37	3.23e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg11764359	chr7:65958608	NA	-0.66	-7.8	-0.45	2.11e-13	Aortic root size;
SARC	cis	rs1348850	0.526	rs59972556	chr2:178399561	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.57	5.51	0.34	9.65e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2797160	1.000	rs2211420	chr6:125995549	A/G	cg05901451	chr6:126070800	HEY2	-0.41	-4.81	-0.3	2.66e-6	Endometrial cancer;
SARC	cis	rs7617773	0.780	rs77044321	chr3:48349314	C/T	cg11946769	chr3:48343235	NME6	0.76	9.7	0.54	6.55e-19	Coronary artery disease;
SARC	cis	rs11122272	0.525	rs2749713	chr1:231537921	T/C	cg06096015	chr1:231504339	EGLN1	0.38	5.71	0.35	3.4e-8	Hemoglobin concentration;
SARC	cis	rs5997397	0.967	rs5752791	chr22:29153547	A/G	cg02153584	chr22:29168773	CCDC117	-0.55	-7.55	-0.44	9.73e-13	Red cell distribution width;
SARC	cis	rs8141529	0.529	rs5752803	chr22:29205004	G/A	cg02153584	chr22:29168773	CCDC117	0.65	6.65	0.4	2.02e-10	Lymphocyte counts;
SARC	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg19223190	chr17:80058835	NA	-0.43	-6.02	-0.37	6.57e-9	Life satisfaction;
SARC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.46	0.57	3.12e-21	Prudent dietary pattern;
SARC	cis	rs8053891	0.906	rs8047643	chr16:71996498	A/G	cg16558253	chr16:72132732	DHX38	-0.41	-5.31	-0.33	2.5e-7	Coronary artery disease;
SARC	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg09699651	chr6:150184138	LRP11	0.41	5.11	0.32	6.6e-7	Lung cancer;
SARC	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg18305652	chr10:134549665	INPP5A	0.35	5.45	0.34	1.31e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs10489525	0.599	rs2335724	chr1:115608444	T/C	cg01522456	chr1:115632236	TSPAN2	0.45	5.18	0.32	4.89e-7	Autism;
SARC	cis	rs7772486	0.790	rs3924499	chr6:146232978	A/T	cg23711669	chr6:146136114	FBXO30	-0.82	-13.29	-0.66	2.22e-30	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9902453	0.780	rs3115093	chr17:28039755	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	6.9	0.41	4.99e-11	Coffee consumption (cups per day);
SARC	cis	rs526231	0.543	rs62362541	chr5:102322448	G/A	cg23492399	chr5:102201601	PAM	-0.52	-6.6	-0.4	2.74e-10	Primary biliary cholangitis;
SARC	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg04277193	chr17:41438351	NA	0.45	4.93	0.31	1.59e-6	Menopause (age at onset);
SARC	cis	rs6782228	0.606	rs2712381	chr3:128338600	A/C	cg08795948	chr3:128337044	NA	0.36	4.83	0.3	2.44e-6	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
SARC	cis	rs858239	0.632	rs7811903	chr7:23119056	A/G	cg23682824	chr7:23144976	KLHL7	0.74	9.91	0.54	1.48e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg08067268	chr2:26466485	HADHB;HADHA	0.41	5.22	0.32	3.99e-7	Gut microbiome composition (summer);
SARC	cis	rs11240408	1	rs11240408	chr1:205264536	A/T	cg19090574	chr1:205240910	TMCC2	0.39	4.83	0.3	2.47e-6	Platelet count;
SARC	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.67	5.16	0.32	5.21e-7	Initial pursuit acceleration;
SARC	cis	rs9303401	0.659	rs62081316	chr17:56781499	C/T	cg25039879	chr17:56429692	SUPT4H1	0.68	6.4	0.39	8.57e-10	Cognitive test performance;
SARC	cis	rs8114671	0.562	rs6120763	chr20:33506400	C/G	cg24642439	chr20:33292090	TP53INP2	0.49	5.94	0.36	1e-8	Height;
SARC	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-1.11	-11.87	-0.61	9.68e-26	Alzheimer's disease;
SARC	cis	rs3820928	0.692	rs17416354	chr2:227770844	A/G	cg05526886	chr2:227700861	RHBDD1	-0.48	-6.33	-0.38	1.25e-9	Pulmonary function;
SARC	cis	rs12142240	0.698	rs41294478	chr1:46818442	G/A	cg00530320	chr1:46809349	NSUN4	0.57	6.92	0.41	4.4e-11	Menopause (age at onset);
SARC	cis	rs910316	1.000	rs12889309	chr14:75593902	C/T	cg06637938	chr14:75390232	RPS6KL1	0.5	7.15	0.42	1.09e-11	Height;
SARC	cis	rs12681366	0.636	rs2246066	chr8:95419155	G/A	cg26464482	chr8:95565502	KIAA1429	-0.44	-5.5	-0.34	1.01e-7	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs12142240	0.698	rs966907	chr1:46817125	C/G	cg00530320	chr1:46809349	NSUN4	0.57	6.92	0.41	4.4e-11	Menopause (age at onset);
SARC	cis	rs5769765	0.728	rs6520064	chr22:50294469	A/G	cg03033257	chr22:50311977	ALG12;CRELD2	0.52	5.34	0.33	2.17e-7	Schizophrenia;
SARC	cis	rs76419734	0.558	rs11730080	chr4:106521859	C/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.67	5.78	0.35	2.34e-8	Post bronchodilator FEV1;
SARC	cis	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg08564027	chr20:61660810	NA	0.76	11.75	0.61	2.46e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs9916302	0.861	rs8079590	chr17:37426201	T/C	cg07936489	chr17:37558343	FBXL20	-0.68	-9.23	-0.52	1.69e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs16937	0.711	rs10751430	chr1:205107497	A/G	cg00857998	chr1:205179979	DSTYK	0.4	4.72	0.3	4.16e-6	Schizophrenia;
SARC	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg19723775	chr5:179050963	HNRNPH1	0.49	6.41	0.39	7.82e-10	Lung cancer;
SARC	cis	rs761746	0.920	rs5998011	chr22:31889566	T/C	cg15162869	chr22:32027605	PISD	0.43	5.86	0.36	1.6e-8	Intelligence;
SARC	cis	rs11758351	1.000	rs2143346	chr6:26198449	C/G	cg23601095	chr6:26197514	HIST1H3D	-0.66	-5.85	-0.36	1.68e-8	Gout;Renal underexcretion gout;
SARC	cis	rs72945132	0.882	rs57810426	chr11:70230030	G/A	cg00319359	chr11:70116639	PPFIA1	0.68	6.46	0.39	6.04e-10	Coronary artery disease;
SARC	cis	rs870825	0.616	rs28459754	chr4:185636280	C/A	cg04058563	chr4:185651563	MLF1IP	0.84	11.36	0.6	4.49e-24	Blood protein levels;
SARC	cis	rs4595586	0.545	rs4768526	chr12:39402898	A/G	cg26384229	chr12:38710491	ALG10B	0.53	6.13	0.37	3.71e-9	Morning vs. evening chronotype;
SARC	cis	rs17376456	0.877	rs56373208	chr5:93491276	C/A	cg25358565	chr5:93447407	FAM172A	1.36	14.0	0.68	1.04e-32	Diabetic retinopathy;
SARC	trans	rs1814175	0.645	rs11040703	chr11:50024961	C/T	cg15704280	chr7:45808275	SEPT13	-0.9	-14.33	-0.68	7.84e-34	Height;
SARC	cis	rs4713675	0.584	rs4713666	chr6:33679061	A/G	cg15676125	chr6:33679581	C6orf125	0.53	6.52	0.39	4.25e-10	Plateletcrit;
SARC	cis	rs11785400	1.000	rs11785400	chr8:143730456	C/T	cg10596483	chr8:143751796	JRK	0.64	8.46	0.48	2.97e-15	Schizophrenia;
SARC	cis	rs72781680	0.678	rs2551341	chr2:24014778	G/T	cg08917208	chr2:24149416	ATAD2B	0.6	6.04	0.37	6.17e-9	Lymphocyte counts;
SARC	cis	rs2072499	0.966	rs2842869	chr1:156160696	A/G	cg25208724	chr1:156163844	SLC25A44	0.92	12.68	0.64	2.29e-28	Testicular germ cell tumor;
SARC	cis	rs13314892	0.764	rs56927902	chr3:69863476	T/C	cg17445875	chr3:69859618	MITF	-0.49	-5.14	-0.32	5.68e-7	QRS complex (12-leadsum);
SARC	cis	rs9611565	0.592	rs12484467	chr22:41957610	T/C	cg03806693	chr22:41940476	POLR3H	-0.88	-11.12	-0.59	2.47e-23	Vitiligo;
SARC	cis	rs113835537	0.529	rs78999944	chr11:66251228	C/G	cg24851651	chr11:66362959	CCS	0.38	4.79	0.3	2.98e-6	Airway imaging phenotypes;
SARC	cis	rs2806561	0.796	rs1738467	chr1:23506521	C/T	cg12483005	chr1:23474871	LUZP1	0.44	5.73	0.35	3.05e-8	Height;
SARC	cis	rs9303401	0.538	rs12603174	chr17:56489279	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.04	10.67	0.57	6.76e-22	Cognitive test performance;
SARC	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg00933542	chr6:150070202	PCMT1	0.32	5.14	0.32	5.83e-7	Lung cancer;
SARC	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg11644478	chr21:40555479	PSMG1	-0.87	-11.24	-0.59	1.04e-23	Cognitive function;
SARC	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	27.53	0.87	3.44e-75	Chronic sinus infection;
SARC	cis	rs11674184	0.714	rs9789525	chr2:11724580	G/T	cg07314298	chr2:11723111	GREB1	-0.54	-7.12	-0.42	1.31e-11	Endometriosis;
SARC	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg05896524	chr21:47604654	C21orf56	-0.52	-6.45	-0.39	6.47e-10	Testicular germ cell tumor;
SARC	cis	rs763121	0.853	rs8140617	chr22:38970439	A/G	cg21395723	chr22:39101663	GTPBP1	-0.48	-5.1	-0.32	6.93e-7	Menopause (age at onset);
SARC	cis	rs4478037	0.822	rs9817393	chr3:33117069	A/G	cg19404215	chr3:33155277	CRTAP	0.77	6.06	0.37	5.3e-9	Major depressive disorder;
SARC	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg05313129	chr8:58192883	C8orf71	-0.62	-6.33	-0.38	1.26e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.45	-5.63	-0.35	5.14e-8	Gut microbiome composition (summer);
SARC	trans	rs12753816	0.749	rs6688139	chr1:169190655	C/T	cg04371528	chr3:20081516	KAT2B	-0.53	-6.33	-0.38	1.27e-9	Coronary artery disease;
SARC	cis	rs12579753	0.871	rs10862362	chr12:82199383	T/G	cg07988820	chr12:82153109	PPFIA2	-0.52	-6.11	-0.37	4.18e-9	Resting heart rate;
SARC	cis	rs6456156	0.755	rs4710182	chr6:167514061	G/A	cg23791538	chr6:167370224	RNASET2	-0.41	-5.26	-0.33	3.19e-7	Primary biliary cholangitis;
SARC	cis	rs10206020	0.885	rs6720797	chr2:1574340	T/C	cg12573674	chr2:1569213	NA	-0.46	-5.33	-0.33	2.27e-7	IgG glycosylation;
SARC	cis	rs6988636	1.000	rs4282551	chr8:124185916	G/A	cg23067535	chr8:124195133	FAM83A	-0.64	-5.3	-0.33	2.72e-7	Urinary uromodulin levels;
SARC	cis	rs17270561	0.636	rs12194699	chr6:25729229	G/C	cg16482183	chr6:26056742	HIST1H1C	0.43	5.25	0.33	3.49e-7	Iron status biomarkers;
SARC	cis	rs28795989	0.731	rs13139805	chr4:7917053	A/C	cg18538662	chr4:7941764	AFAP1	0.44	5.56	0.34	7.38e-8	Intraocular pressure;
SARC	cis	rs11673344	0.566	rs11666708	chr19:37887110	G/C	cg14683738	chr19:37701593	ZNF585B	0.47	5.55	0.34	7.76e-8	Obesity-related traits;
SARC	cis	rs10876993	0.928	rs2169988	chr12:58071165	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.46	-5.79	-0.35	2.29e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs16978956	0.779	rs6045352	chr20:18327106	C/T	cg12587960	chr20:18033564	OVOL2	-0.28	-4.78	-0.3	3.08e-6	Body mass index;
SARC	cis	rs911555	0.713	rs10162425	chr14:103931621	C/T	cg12935359	chr14:103987150	CKB	-0.37	-5.18	-0.32	4.91e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7666738	1.000	rs880473	chr4:98922596	C/T	cg05340658	chr4:99064831	C4orf37	0.56	6.99	0.42	2.95e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2288884	0.943	rs1433089	chr19:52506985	T/C	cg03562414	chr19:52391078	ZNF577	0.44	4.73	0.3	3.81e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
SARC	cis	rs950027	0.549	rs2899375	chr15:45598335	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.53	-6.45	-0.39	6.53e-10	Response to fenofibrate (adiponectin levels);
SARC	cis	rs62064224	1.000	rs62064224	chr17:30635115	G/A	cg18200150	chr17:30822561	MYO1D	0.44	6.83	0.41	7.22e-11	Schizophrenia;
SARC	trans	rs1814175	0.588	rs1794144	chr11:49918233	A/G	cg03929089	chr4:120376271	NA	-0.81	-11.69	-0.61	3.89e-25	Height;
SARC	cis	rs10911232	0.524	rs10911209	chr1:183013988	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.44	0.56	3.45e-21	Hypertriglyceridemia;
SARC	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg22496380	chr5:211416	CCDC127	-0.88	-9.22	-0.52	1.85e-17	Breast cancer;
SARC	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg03351412	chr1:154909251	PMVK	0.65	8.39	0.48	4.69e-15	Prostate cancer;
SARC	cis	rs7927592	0.956	rs55816191	chr11:68262979	G/T	cg01657329	chr11:68192670	LRP5	-0.39	-5.03	-0.31	9.92e-7	Total body bone mineral density;
SARC	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-9.9	-0.54	1.67e-19	Chronic sinus infection;
SARC	cis	rs11122272	0.638	rs2739514	chr1:231514806	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-9.75	-0.54	4.78e-19	Hemoglobin concentration;
SARC	cis	rs288326	0.561	rs80252162	chr2:183717105	G/A	cg09997497	chr2:183902928	NCKAP1	0.69	4.81	0.3	2.67e-6	Blood protein levels;
SARC	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs2832191	0.597	rs8127842	chr21:30516461	G/A	cg08807101	chr21:30365312	RNF160	-0.7	-8.49	-0.49	2.41e-15	Dental caries;
SARC	cis	rs796364	0.616	rs2030653	chr2:200677625	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.54	4.76	0.3	3.47e-6	Schizophrenia;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg24923678	chr4:3261226	C4orf44	-0.48	-6.28	-0.38	1.63e-9	Height;
SARC	cis	rs616402	0.527	rs2274985	chr1:10573867	G/A	cg07384165	chr1:10488281	NA	-0.4	-5.27	-0.33	3.08e-7	Breast size;
SARC	cis	rs11190604	1.000	rs3750719	chr10:102248950	C/G	cg07080220	chr10:102295463	HIF1AN	0.75	8.35	0.48	5.92e-15	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs9818758	0.607	rs5030795	chr3:49141116	C/T	cg00383909	chr3:49044727	WDR6	0.73	6.77	0.41	1.06e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs9790314	0.695	rs7637086	chr3:160836822	T/C	cg04691961	chr3:161091175	C3orf57	-0.56	-7.35	-0.43	3.29e-12	Morning vs. evening chronotype;
SARC	cis	rs1348850	0.567	rs2222711	chr2:178534110	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.42	5.01	0.31	1.09e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs708547	0.624	rs1718886	chr4:57849251	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.45	-5.6	-0.34	5.97e-8	Response to bleomycin (chromatid breaks);
SARC	cis	rs12142240	0.698	rs17361887	chr1:46834775	A/G	cg00530320	chr1:46809349	NSUN4	0.57	6.77	0.41	1.07e-10	Menopause (age at onset);
SARC	cis	rs12681366	0.708	rs2470731	chr8:95375374	G/A	cg26464482	chr8:95565502	KIAA1429	-0.46	-5.7	-0.35	3.55e-8	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs2075371	1.000	rs378358	chr7:133970628	A/G	cg20476274	chr7:133979776	SLC35B4	0.61	8.45	0.48	3.12e-15	Mean platelet volume;
SARC	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg05025164	chr4:1340916	KIAA1530	0.46	5.21	0.32	4.23e-7	Obesity-related traits;
SARC	cis	rs73086581	0.891	rs55871214	chr20:3965706	A/C	cg02187196	chr20:3869020	PANK2	0.67	6.43	0.39	7.22e-10	Response to antidepressants in depression;
SARC	cis	rs4919694	0.572	rs72846714	chr10:104878454	G/A	cg04362960	chr10:104952993	NT5C2	0.55	4.98	0.31	1.26e-6	Arsenic metabolism;
SARC	cis	rs8180040	0.553	rs7620997	chr3:47214122	C/T	cg27129171	chr3:47204927	SETD2	-0.67	-8.87	-0.5	1.94e-16	Colorectal cancer;
SARC	cis	rs6912958	0.781	rs9450739	chr6:88268271	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.46	-0.34	1.23e-7	Monocyte percentage of white cells;
SARC	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg09699651	chr6:150184138	LRP11	0.39	4.87	0.3	2.04e-6	Lung cancer;
SARC	cis	rs9790314	0.846	rs4856738	chr3:160986637	C/G	cg04691961	chr3:161091175	C3orf57	-0.68	-9.41	-0.52	4.89e-18	Morning vs. evening chronotype;
SARC	cis	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg15556689	chr8:8085844	FLJ10661	0.48	5.99	0.37	7.92e-9	Mood instability;
SARC	cis	rs7582180	0.676	rs10048665	chr2:100933085	A/G	cg14675211	chr2:100938903	LONRF2	0.48	7.03	0.42	2.22e-11	Intelligence (multi-trait analysis);
SARC	cis	rs12754538	0.777	rs12040568	chr1:8727944	G/T	cg13785123	chr1:8931135	ENO1	-0.47	-5.36	-0.33	2.04e-7	Subjective well-being;
SARC	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg01181863	chr3:195395398	SDHAP2	-0.58	-6.59	-0.4	2.89e-10	Pancreatic cancer;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg10976172	chr16:30597528	ZNF785	0.6	6.25	0.38	1.95e-9	Lung cancer in ever smokers;
SARC	cis	rs80130819	0.636	rs4760623	chr12:48619256	A/C	cg05342945	chr12:48394962	COL2A1	-0.5	-5.25	-0.33	3.42e-7	Prostate cancer;
SARC	cis	rs477692	0.789	rs507900	chr10:131398144	A/G	cg05714579	chr10:131428358	MGMT	-0.54	-6.98	-0.42	2.96e-11	Response to temozolomide;
SARC	cis	rs7270101	0.749	rs8120318	chr20:3171710	C/T	cg25506879	chr20:3388711	C20orf194	-0.6	-4.82	-0.3	2.64e-6	Chronic hepatitis C infection;
SARC	cis	rs8064299	0.967	rs3744208	chr17:72767565	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.54	6.7	0.4	1.58e-10	Monocyte count;
SARC	cis	rs2016266	0.784	rs12424778	chr12:53737840	A/T	cg26875137	chr12:53738046	NA	0.42	5.28	0.33	2.99e-7	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs17428076	0.836	rs3770455	chr2:172667895	C/T	cg13550731	chr2:172543902	DYNC1I2	0.44	4.75	0.3	3.64e-6	Myopia;
SARC	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg23262073	chr20:60523788	NA	-0.39	-5.63	-0.35	5.17e-8	Body mass index;
SARC	cis	rs826838	0.585	rs4363678	chr12:38624514	G/A	cg13010199	chr12:38710504	ALG10B	0.52	6.55	0.39	3.57e-10	Heart rate;
SARC	cis	rs3892630	0.878	rs6510277	chr19:33183669	C/A	cg22980127	chr19:33182716	NUDT19	1.06	9.66	0.53	8.5e-19	Red blood cell traits;
SARC	cis	rs1003719	0.715	rs2835613	chr21:38496883	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.22	-0.52	1.8e-17	Eye color traits;
SARC	trans	rs9329221	0.507	rs12678938	chr8:10016969	C/T	cg06636001	chr8:8085503	FLJ10661	-0.63	-7.89	-0.46	1.16e-13	Neuroticism;
SARC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	20.48	0.8	5.33e-54	Prudent dietary pattern;
SARC	cis	rs6831352	0.918	rs6813415	chr4:100048509	T/C	cg13256891	chr4:100009986	ADH5	-0.66	-8.28	-0.48	9.71e-15	Alcohol dependence;
SARC	cis	rs7772486	0.790	rs2256998	chr6:146207657	A/C	cg23711669	chr6:146136114	FBXO30	0.8	12.61	0.64	3.91e-28	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs7859245	1.000	rs7859245	chr9:138490597	A/G	cg02665744	chr19:50223325	NA	-0.56	-7.02	-0.42	2.47e-11	Response to paliperidone in schizophrenia (negative Marder score);
SARC	cis	rs240764	0.697	rs12189562	chr6:101168679	A/G	cg09795085	chr6:101329169	ASCC3	-0.41	-5.21	-0.32	4.21e-7	Neuroticism;
SARC	trans	rs61931739	0.500	rs6488218	chr12:34452587	T/C	cg13010199	chr12:38710504	ALG10B	0.77	11.06	0.59	3.85e-23	Morning vs. evening chronotype;
SARC	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg06713675	chr4:122721982	EXOSC9	-0.5	-6.54	-0.39	3.85e-10	Type 2 diabetes;
SARC	cis	rs7219021	0.705	rs999475	chr17:46988044	C/T	cg16584676	chr17:46985605	UBE2Z	-0.48	-5.7	-0.35	3.52e-8	Schizophrenia or bipolar disorder;
SARC	trans	rs75246769	1.000	rs75880997	chr7:145474018	A/G	cg00210271	chr12:54088934	NA	-0.49	-6.34	-0.38	1.17e-9	Facial morphology (factor 10, width of nasal floor);
SARC	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg13770153	chr20:60521292	NA	-0.53	-7.53	-0.44	1.11e-12	Body mass index;
SARC	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg11764359	chr7:65958608	NA	0.86	12.33	0.63	3.29e-27	Aortic root size;
SARC	cis	rs36051895	0.632	rs62541916	chr9:5151904	C/A	cg02405213	chr9:5042618	JAK2	-0.47	-5.6	-0.34	5.91e-8	Pediatric autoimmune diseases;
SARC	cis	rs11700980	0.636	rs116306600	chr21:30232542	T/C	cg24692254	chr21:30365293	RNF160	-0.62	-4.72	-0.3	4.08e-6	QRS complex (12-leadsum);
SARC	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg07414643	chr4:187882934	NA	0.41	6.01	0.37	7.27e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12930096	0.938	rs8048558	chr16:11678332	G/A	cg07439791	chr16:11680400	LITAF	0.61	5.8	0.36	2.11e-8	QT interval;
SARC	cis	rs1559088	0.744	rs12972060	chr19:33537096	C/T	cg17764715	chr19:33622953	WDR88	-0.42	-5.3	-0.33	2.72e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs6570726	0.791	rs418701	chr6:145889992	C/T	cg05347473	chr6:146136440	FBXO30	0.5	6.92	0.41	4.39e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4588572	0.643	rs6453396	chr5:77785387	T/C	cg11547950	chr5:77652471	NA	-0.42	-5.15	-0.32	5.58e-7	Triglycerides;
SARC	cis	rs9902453	0.817	rs1038089	chr17:28178724	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	7.22	0.43	7.39e-12	Coffee consumption (cups per day);
SARC	cis	rs76419734	1.000	rs11733225	chr4:106705363	C/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.8	5.33	0.33	2.27e-7	Post bronchodilator FEV1;
SARC	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg19671926	chr4:122722719	EXOSC9	-0.55	-6.03	-0.37	6.38e-9	Type 2 diabetes;
SARC	cis	rs3740540	0.507	rs942015	chr10:126289932	G/T	cg04949429	chr10:126290192	LHPP	0.42	5.98	0.36	8.42e-9	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
SARC	trans	rs61931739	0.534	rs7133262	chr12:34279444	G/A	cg26384229	chr12:38710491	ALG10B	0.83	11.69	0.61	3.7e-25	Morning vs. evening chronotype;
SARC	cis	rs60871478	0.636	rs56393680	chr7:885696	A/G	cg05535760	chr7:792225	HEATR2	-0.72	-6.87	-0.41	5.89e-11	Cerebrospinal P-tau181p levels;
SARC	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg12292205	chr6:26970375	C6orf41	0.61	6.89	0.41	5.2e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg27266027	chr21:40555129	PSMG1	0.51	5.5	0.34	9.96e-8	Cognitive function;
SARC	cis	rs6133127	0.671	rs6133129	chr20:4486062	G/T	cg14606382	chr20:4573199	NA	-0.47	-5.12	-0.32	6.49e-7	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
SARC	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg22920501	chr2:26401640	FAM59B	-0.53	-6.61	-0.4	2.55e-10	Gut microbiome composition (summer);
SARC	cis	rs611744	0.967	rs627019	chr8:109222544	G/A	cg21045802	chr8:109455806	TTC35	0.46	5.43	0.34	1.38e-7	Dupuytren's disease;
SARC	cis	rs4481887	1.000	rs4579792	chr1:248463742	C/T	cg01631408	chr1:248437212	OR2T33	0.39	5.01	0.31	1.06e-6	Common traits (Other);
SARC	cis	rs7829975	0.684	rs474892	chr8:8596731	G/T	cg08975724	chr8:8085496	FLJ10661	-0.44	-5.36	-0.33	2.03e-7	Mood instability;
SARC	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg16479474	chr6:28041457	NA	0.37	5.53	0.34	8.38e-8	Depression;
SARC	cis	rs4975616	0.836	rs460073	chr5:1336459	T/C	cg26373071	chr5:1325741	CLPTM1L	0.3	4.81	0.3	2.71e-6	Lung cancer;
SARC	cis	rs4803468	1.000	rs4803468	chr19:41922352	A/G	cg14132834	chr19:41945861	ATP5SL	-0.57	-7.53	-0.44	1.1e-12	Height;
SARC	cis	rs6866344	0.569	rs56027952	chr5:178150181	C/A	cg10224037	chr5:178157518	ZNF354A	1.0	12.69	0.64	2.08e-28	Neutrophil percentage of white cells;
SARC	cis	rs7123876	0.587	rs11600831	chr11:72360220	C/T	cg03713592	chr11:72463424	ARAP1	0.58	5.25	0.33	3.34e-7	Body mass index;
SARC	cis	rs9916302	0.660	rs665413	chr17:37455678	T/A	cg00129232	chr17:37814104	STARD3	0.54	5.76	0.35	2.66e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs9325144	0.534	rs1843887	chr12:38692380	T/C	cg10518543	chr12:38710700	ALG10B	0.38	4.88	0.3	2.01e-6	Morning vs. evening chronotype;
SARC	cis	rs7044106	0.791	rs10984995	chr9:123479210	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	6.28	0.38	1.6e-9	Hip circumference adjusted for BMI;
SARC	cis	rs763121	0.853	rs4821812	chr22:39075235	G/C	cg21395723	chr22:39101663	GTPBP1	0.52	5.79	0.35	2.3e-8	Menopause (age at onset);
SARC	cis	rs8095374	1.000	rs8089153	chr18:43769305	A/G	cg25174615	chr18:43684699	ATP5A1;HAUS1	-0.43	-4.98	-0.31	1.22e-6	Clinical laboratory measurements;
SARC	cis	rs35306767	0.903	rs11253494	chr10:937047	C/T	cg26597838	chr10:835615	NA	0.72	7.47	0.44	1.6e-12	Eosinophil percentage of granulocytes;
SARC	cis	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.63	-0.45	5.88e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs2204008	0.623	rs1663281	chr12:38120936	A/G	cg26384229	chr12:38710491	ALG10B	-0.66	-8.64	-0.49	9.24e-16	Bladder cancer;
SARC	cis	rs60752752	0.852	rs11205280	chr1:153359781	C/A	cg26882115	chr1:153603048	S100A1;S100A13	-0.66	-5.0	-0.31	1.15e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs7113874	0.659	rs12574009	chr11:8519953	G/A	cg09828998	chr11:8703972	RPL27A	0.5	5.27	0.33	3.05e-7	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7617773	0.780	rs13084616	chr3:48339699	A/G	cg11946769	chr3:48343235	NME6	-0.74	-9.51	-0.53	2.53e-18	Coronary artery disease;
SARC	cis	rs763121	0.925	rs5757251	chr22:39100128	G/A	cg06022373	chr22:39101656	GTPBP1	0.73	9.14	0.51	3.23e-17	Menopause (age at onset);
SARC	cis	rs7592578	0.771	rs1128723	chr2:191366707	A/G	cg25963032	chr2:191064776	C2orf88	-0.44	-4.97	-0.31	1.31e-6	Diastolic blood pressure;
SARC	cis	rs6504663	0.558	rs11871603	chr17:48559037	T/G	cg00901687	chr17:48585270	MYCBPAP	0.52	5.97	0.36	9.01e-9	Visceral fat;
SARC	cis	rs9309473	1.000	rs13384952	chr2:73723959	C/T	cg20560298	chr2:73613845	ALMS1	0.66	5.45	0.34	1.3e-7	Metabolite levels;
SARC	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg16479474	chr6:28041457	NA	0.37	5.44	0.34	1.37e-7	Depression;
SARC	cis	rs2153535	0.580	rs1932285	chr6:8477719	T/G	cg07606381	chr6:8435919	SLC35B3	0.76	10.74	0.58	4.06e-22	Motion sickness;
SARC	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg19346786	chr7:2764209	NA	-0.35	-5.16	-0.32	5.36e-7	Height;
SARC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg06873352	chr17:61820015	STRADA	0.53	6.92	0.41	4.3e-11	Prudent dietary pattern;
SARC	cis	rs8005677	1.000	rs2295685	chr14:23398153	A/G	cg01529538	chr14:23388837	RBM23	0.44	5.32	0.33	2.46e-7	Cognitive ability (multi-trait analysis);
SARC	cis	rs2832191	0.765	rs2832162	chr21:30461808	G/A	cg08807101	chr21:30365312	RNF160	0.87	13.17	0.65	5.53e-30	Dental caries;
SARC	cis	rs796364	0.525	rs10931895	chr2:201143242	C/T	cg23649088	chr2:200775458	C2orf69	0.64	6.91	0.41	4.52e-11	Schizophrenia;
SARC	cis	rs9733	0.650	rs1971378	chr1:150597261	C/T	cg18016565	chr1:150552671	MCL1	-0.39	-5.46	-0.34	1.2e-7	Tonsillectomy;
SARC	cis	rs11190604	1.000	rs10883501	chr10:102238326	A/G	cg07080220	chr10:102295463	HIF1AN	0.76	8.87	0.5	1.92e-16	Palmitoleic acid (16:1n-7) levels;
SARC	trans	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg26956263	chr7:140624468	BRAF	-0.72	-6.66	-0.4	1.98e-10	Cutaneous psoriasis;
SARC	cis	rs7617480	0.648	rs10865953	chr3:48759562	C/T	cg07636037	chr3:49044803	WDR6	0.79	8.35	0.48	6.02e-15	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs7717697	0.669	rs13166766	chr5:82731442	T/C	cg19814134	chr5:82768288	VCAN	0.42	4.89	0.31	1.88e-6	Vertical cup-disc ratio;
SARC	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg22903657	chr4:1355424	KIAA1530	0.34	4.8	0.3	2.88e-6	Obesity-related traits;
SARC	cis	rs13427251	0.868	rs1901284	chr2:100146040	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.46	5.65	0.35	4.74e-8	Chronic sinus infection;
SARC	cis	rs4951011	0.706	rs4364935	chr1:203759009	C/T	cg05526099	chr1:203152295	CHI3L1	-0.34	-4.75	-0.3	3.54e-6	Breast cancer;
SARC	cis	rs6582630	0.555	rs7978749	chr12:38527141	G/T	cg26384229	chr12:38710491	ALG10B	0.85	12.55	0.64	6.07e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg08645402	chr16:4508243	NA	-0.42	-5.21	-0.32	4.21e-7	Schizophrenia;
SARC	cis	rs12477438	0.834	rs11903311	chr2:99701807	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.1	-0.47	2.99e-14	Chronic sinus infection;
SARC	cis	rs6714710	0.603	rs11678591	chr2:98541001	T/C	cg26665480	chr2:98280029	ACTR1B	0.49	6.48	0.39	5.33e-10	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg23758822	chr17:41437982	NA	0.81	8.89	0.5	1.68e-16	Menopause (age at onset);
SARC	cis	rs7178909	0.902	rs10459674	chr15:90438295	G/C	cg19708238	chr15:90437601	AP3S2	0.63	8.53	0.49	1.91e-15	Common traits (Other);
SARC	cis	rs4280164	0.945	rs3181384	chr14:24786976	C/T	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.61	-6.01	-0.37	7.06e-9	Parent of origin effect on language impairment (paternal);
SARC	cis	rs7617773	0.780	rs13085251	chr3:48340045	C/T	cg11946769	chr3:48343235	NME6	0.76	9.72	0.54	5.94e-19	Coronary artery disease;
SARC	cis	rs7786808	0.782	rs7787923	chr7:158227312	A/G	cg01191920	chr7:158217561	PTPRN2	-0.4	-7.5	-0.44	1.35e-12	Obesity-related traits;
SARC	cis	rs8084125	0.832	rs62105179	chr18:74950858	A/G	cg19705131	chr18:74961163	GALR1	0.42	4.75	0.3	3.55e-6	Obesity-related traits;
SARC	trans	rs2898290	0.592	rs2736342	chr8:11347289	A/C	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.92	-0.46	9.67e-14	Systolic blood pressure;
SARC	cis	rs1348850	0.526	rs2141157	chr2:178374112	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	5.87	0.36	1.5e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs3733585	0.725	rs10939636	chr4:9972640	T/G	cg00071950	chr4:10020882	SLC2A9	-0.39	-5.96	-0.36	9.44e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs8038734	0.688	rs4776601	chr15:72806425	C/T	cg10943348	chr15:72668568	HEXA;C15orf34	0.62	4.8	0.3	2.81e-6	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs1949733	0.582	rs61258495	chr4:8534017	G/A	cg13073564	chr4:8508604	NA	0.42	6.71	0.4	1.49e-10	Response to antineoplastic agents;
SARC	cis	rs6831352	0.838	rs2851250	chr4:100044113	G/C	cg12011299	chr4:100065546	ADH4	0.34	5.61	0.35	5.65e-8	Alcohol dependence;
SARC	cis	rs79349575	0.783	rs9912829	chr17:46982749	G/C	cg16584676	chr17:46985605	UBE2Z	0.54	6.59	0.4	2.95e-10	Type 2 diabetes;
SARC	cis	rs9733	0.519	rs11800855	chr1:150800995	G/A	cg10589385	chr1:150898437	SETDB1	0.41	5.47	0.34	1.18e-7	Tonsillectomy;
SARC	cis	rs35110281	0.782	rs2051407	chr21:45079245	T/C	cg01579765	chr21:45077557	HSF2BP	-0.38	-6.28	-0.38	1.65e-9	Mean corpuscular volume;
SARC	cis	rs9911578	0.967	rs8082544	chr17:57185807	C/T	cg20303301	chr17:57937339	TUBD1	0.33	4.84	0.3	2.37e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg17971929	chr21:40555470	PSMG1	0.94	11.7	0.61	3.64e-25	Cognitive function;
SARC	cis	rs7615952	0.512	rs34651730	chr3:125358640	T/C	cg21696256	chr3:125484277	NA	-0.35	-5.05	-0.31	8.97e-7	Blood pressure (smoking interaction);
SARC	trans	rs17685	0.753	rs6951943	chr7:75772452	A/G	cg19862616	chr7:65841803	NCRNA00174	0.64	7.97	0.46	7e-14	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg02725872	chr8:58115012	NA	-0.37	-6.45	-0.39	6.34e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs11608355	0.597	rs10850070	chr12:109793882	A/G	cg05360138	chr12:110035743	NA	0.41	4.97	0.31	1.3e-6	Neuroticism;
SARC	cis	rs9814567	0.896	rs7653880	chr3:134345788	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.5	-6.4	-0.39	8.24e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs1048257	0.682	rs2582514	chr14:105413204	G/T	cg21017887	chr14:105400489	NA	0.5	6.93	0.41	4.01e-11	Systemic lupus erythematosus;
SARC	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-7.61	-0.45	6.63e-13	Chronic sinus infection;
SARC	cis	rs4481887	0.927	rs4405158	chr1:248490647	A/C	cg01631408	chr1:248437212	OR2T33	-0.38	-4.74	-0.3	3.75e-6	Common traits (Other);
SARC	cis	rs12142240	0.628	rs56126529	chr1:46808860	C/T	cg00530320	chr1:46809349	NSUN4	0.58	7.07	0.42	1.74e-11	Menopause (age at onset);
SARC	cis	rs2153535	0.580	rs6597332	chr6:8504748	C/G	cg23788917	chr6:8435910	SLC35B3	0.64	8.29	0.48	9.21e-15	Motion sickness;
SARC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.67	6.4	0.39	8.37e-10	Platelet count;
SARC	cis	rs7624766	0.743	rs6781371	chr3:160523671	G/A	cg22637730	chr3:160473554	PPM1L	0.43	5.62	0.35	5.31e-8	Response to methotrexate in rheumatoid arthritis;
SARC	cis	rs9790314	1.000	rs7638668	chr3:161047283	G/A	cg03342759	chr3:160939853	NMD3	-0.57	-7.23	-0.43	6.78e-12	Morning vs. evening chronotype;
SARC	cis	rs4481887	0.927	rs4453081	chr1:248475691	C/G	cg00666640	chr1:248458726	OR2T12	0.32	5.43	0.34	1.42e-7	Common traits (Other);
SARC	trans	rs1493916	1.000	rs990882	chr18:31398180	T/G	cg27147174	chr7:100797783	AP1S1	-0.59	-7.63	-0.45	5.95e-13	Life satisfaction;
SARC	cis	rs6570726	0.967	rs7772286	chr6:145930423	A/T	cg23711669	chr6:146136114	FBXO30	-0.75	-11.52	-0.6	1.34e-24	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12142240	0.698	rs17357711	chr1:46829013	A/G	cg10495392	chr1:46806563	NSUN4	0.64	6.83	0.41	7.39e-11	Menopause (age at onset);
SARC	cis	rs11098499	0.863	rs11933966	chr4:120476715	G/A	cg24375607	chr4:120327624	NA	0.42	4.92	0.31	1.64e-6	Corneal astigmatism;
SARC	cis	rs62244186	0.659	rs7649834	chr3:44503732	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.47	5.78	0.35	2.38e-8	Depressive symptoms;
SARC	cis	rs3796352	1.000	rs71301804	chr3:53073314	C/A	cg07884673	chr3:53033167	SFMBT1	0.77	5.33	0.33	2.35e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs933688	1.000	rs6866191	chr5:90746852	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.98	11.93	0.62	6.27e-26	Smoking behavior;
SARC	cis	rs67311347	0.822	rs11709089	chr3:40351484	C/T	cg09455208	chr3:40491958	NA	0.39	6.1	0.37	4.32e-9	Renal cell carcinoma;
SARC	cis	rs7927592	0.913	rs7116994	chr11:68254627	C/T	cg01657329	chr11:68192670	LRP5	-0.39	-4.97	-0.31	1.31e-6	Total body bone mineral density;
SARC	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg24399712	chr22:39784796	NA	-0.43	-5.64	-0.35	4.86e-8	Intelligence (multi-trait analysis);
SARC	cis	rs11626933	1.000	rs2236402	chr14:90734378	C/G	cg14092571	chr14:90743983	NA	-0.64	-9.25	-0.52	1.53e-17	Gut microbiota (bacterial taxa);
SARC	cis	rs5995756	0.627	rs1008677	chr22:40009336	C/T	cg10455938	chr22:40058150	CACNA1I	0.44	5.25	0.33	3.45e-7	Autism spectrum disorder or schizophrenia;
SARC	cis	rs12709013	0.636	rs11076260	chr16:58783846	A/G	cg04273148	chr16:57808038	KIFC3	0.32	4.72	0.3	4.08e-6	Blood metabolite ratios;
SARC	cis	rs17270561	0.636	rs9379782	chr6:25715023	G/A	cg17691542	chr6:26056736	HIST1H1C	0.56	6.88	0.41	5.58e-11	Iron status biomarkers;
SARC	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg15049968	chr18:44337910	ST8SIA5	-0.33	-5.1	-0.32	7.11e-7	Personality dimensions;
SARC	cis	rs2425143	1.000	rs7264414	chr20:34446826	A/G	cg01084648	chr20:34329383	RBM39	0.64	4.95	0.31	1.44e-6	Blood protein levels;
SARC	cis	rs2204008	0.606	rs6582502	chr12:38543352	C/T	cg13010199	chr12:38710504	ALG10B	-0.51	-6.34	-0.38	1.19e-9	Bladder cancer;
SARC	cis	rs2730245	0.527	rs2527197	chr7:158735260	G/A	cg24397884	chr7:158709396	WDR60	-1.21	-11.91	-0.62	7.55e-26	Height;
SARC	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg18357526	chr6:26021779	HIST1H4A	0.68	8.89	0.5	1.68e-16	Intelligence (multi-trait analysis);
SARC	cis	rs1185460	1.000	rs15818	chr11:118952173	A/G	cg23280166	chr11:118938394	VPS11	0.71	9.19	0.52	2.32e-17	Coronary artery disease;
SARC	cis	rs10128251	0.743	rs2386636	chr10:5712087	G/T	cg09234995	chr10:5726438	C10orf18	0.37	4.72	0.3	4.12e-6	Childhood ear infection;
SARC	trans	rs61931739	0.534	rs11053021	chr12:34111157	C/T	cg13010199	chr12:38710504	ALG10B	0.77	10.36	0.56	6.18e-21	Morning vs. evening chronotype;
SARC	cis	rs7113850	0.541	rs4451727	chr11:24216855	G/C	ch.11.24196551F	chr11:24239977	NA	0.69	6.62	0.4	2.4e-10	Bone fracture in osteoporosis;
SARC	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg18252515	chr7:66147081	NA	-0.46	-4.98	-0.31	1.22e-6	Aortic root size;
SARC	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg16414030	chr3:133502952	NA	-0.41	-5.56	-0.34	7.21e-8	Iron status biomarkers;
SARC	trans	rs656319	0.702	rs587328	chr8:9809722	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.63	-0.4	2.35e-10	Myopia (pathological);
SARC	cis	rs28456	1	rs28456	chr11:61589481	A/G	cg19610905	chr11:61596333	FADS2	-0.41	-4.84	-0.3	2.35e-6	Bipolar disorder;
SARC	cis	rs12188164	0.965	rs56146525	chr5:442571	A/C	cg26850624	chr5:429559	AHRR	-0.31	-4.77	-0.3	3.21e-6	Cystic fibrosis severity;
SARC	cis	rs743757	0.878	rs12494849	chr3:50524558	C/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.54	5.09	0.32	7.49e-7	Diastolic blood pressure;
SARC	cis	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg05901451	chr6:126070800	HEY2	0.65	9.32	0.52	9.27e-18	Brugada syndrome;
SARC	cis	rs4566357	0.615	rs10178260	chr2:227914458	G/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.62	-0.35	5.48e-8	Coronary artery disease;
SARC	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg24531977	chr5:56204891	C5orf35	-0.54	-5.48	-0.34	1.09e-7	Initial pursuit acceleration;
SARC	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg06618935	chr21:46677482	NA	-0.39	-5.2	-0.32	4.34e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg19346786	chr7:2764209	NA	-0.39	-5.49	-0.34	1.05e-7	Height;
SARC	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg16405210	chr4:1374714	KIAA1530	0.5	6.15	0.37	3.4e-9	Obesity-related traits;
SARC	cis	rs8114671	0.839	rs2104084	chr20:33649217	G/C	cg24642439	chr20:33292090	TP53INP2	-0.51	-5.96	-0.36	9.41e-9	Height;
SARC	cis	rs7113850	0.541	rs4367945	chr11:24215605	A/C	ch.11.24196551F	chr11:24239977	NA	0.78	6.16	0.37	3.15e-9	Bone fracture in osteoporosis;
SARC	trans	rs7395662	0.517	rs10454483	chr11:48754997	A/G	cg00717180	chr2:96193071	NA	-0.38	-6.36	-0.38	1.07e-9	HDL cholesterol;
SARC	cis	rs17376456	0.504	rs6898507	chr5:93082343	C/T	cg21475434	chr5:93447410	FAM172A	0.61	5.95	0.36	9.98e-9	Diabetic retinopathy;
SARC	cis	rs10752881	0.935	rs3935221	chr1:182969010	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.33	0.56	7.66e-21	Colorectal cancer;
SARC	cis	rs858239	0.539	rs870476	chr7:23193271	C/T	cg23682824	chr7:23144976	KLHL7	0.72	9.86	0.54	2.16e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg08219700	chr8:58056026	NA	0.69	6.39	0.39	8.93e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg07777115	chr5:623756	CEP72	-0.57	-5.14	-0.32	5.79e-7	Obesity-related traits;
SARC	cis	rs6570726	0.934	rs9484995	chr6:145781114	T/A	cg23711669	chr6:146136114	FBXO30	-0.72	-10.45	-0.56	3.34e-21	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7264396	0.570	rs6060717	chr20:34544647	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.52	5.17	0.32	4.98e-7	Total cholesterol levels;
SARC	cis	rs7546668	1.000	rs4646093	chr1:15821400	G/T	cg21858823	chr1:15850916	CASP9	0.52	6.94	0.41	3.9e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs763121	0.853	rs6001191	chr22:39074452	T/C	cg14440974	chr22:39074834	NA	-0.33	-4.77	-0.3	3.24e-6	Menopause (age at onset);
SARC	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg00149659	chr3:10157352	C3orf10	0.69	6.9	0.41	4.76e-11	Alzheimer's disease;
SARC	cis	rs3781913	0.874	rs11235559	chr11:72374037	C/T	cg03713592	chr11:72463424	ARAP1	-0.4	-4.92	-0.31	1.64e-6	Rheumatoid arthritis;
SARC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg09436375	chr6:42928200	GNMT	-0.36	-5.66	-0.35	4.37e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs9354308	0.901	rs2814121	chr6:66566915	G/C	cg07460842	chr6:66804631	NA	0.49	5.59	0.34	6.34e-8	Metabolite levels;
SARC	cis	rs2204008	0.692	rs11613378	chr12:38213138	T/A	cg13010199	chr12:38710504	ALG10B	0.78	10.64	0.57	8.61e-22	Bladder cancer;
SARC	cis	rs9467603	0.925	rs13199775	chr6:25828782	A/T	cg21479132	chr6:26055353	NA	0.79	5.03	0.31	9.83e-7	Intelligence (multi-trait analysis);
SARC	cis	rs10979	1.000	rs9496678	chr6:143896664	C/A	cg25407410	chr6:143891975	LOC285740	-0.64	-8.78	-0.5	3.67e-16	Hypospadias;
SARC	cis	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg14825384	chr10:115438916	CASP7	0.54	6.73	0.4	1.3e-10	Breast cancer;
SARC	cis	rs7927771	1.000	rs35902101	chr11:47795169	C/T	cg05585544	chr11:47624801	NA	-0.36	-4.82	-0.3	2.59e-6	Subjective well-being;
SARC	cis	rs17173637	1.000	rs73165523	chr7:150530519	G/C	cg26935020	chr7:151217007	RHEB	-0.73	-4.83	-0.3	2.45e-6	HDL cholesterol;HDL cholesterol levels;
SARC	trans	rs61931739	0.620	rs745608	chr12:33711564	A/G	cg26384229	chr12:38710491	ALG10B	0.51	6.26	0.38	1.8e-9	Morning vs. evening chronotype;
SARC	cis	rs1018836	0.786	rs10956736	chr8:91602067	C/T	cg16814680	chr8:91681699	NA	-0.78	-12.4	-0.63	1.85e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs76419734	0.558	rs11721842	chr4:106521846	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.67	5.78	0.35	2.34e-8	Post bronchodilator FEV1;
SARC	cis	rs12216125	0.554	rs6942196	chr6:26072804	A/G	cg16482183	chr6:26056742	HIST1H1C	0.48	6.04	0.37	5.92e-9	Iron status biomarkers;
SARC	cis	rs2075371	0.966	rs2544223	chr7:133995787	A/G	cg20476274	chr7:133979776	SLC35B4	0.62	8.42	0.48	3.76e-15	Mean platelet volume;
SARC	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg27572855	chr1:25598939	RHD	-0.57	-9.82	-0.54	2.8e-19	Erythrocyte sedimentation rate;
SARC	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.63	-6.41	-0.39	8.13e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs9916302	0.904	rs650106	chr17:37451559	A/G	cg00129232	chr17:37814104	STARD3	0.59	7.27	0.43	5.32e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs7647973	0.922	rs6809851	chr3:49309787	C/A	cg06212747	chr3:49208901	KLHDC8B	0.57	5.9	0.36	1.29e-8	Menarche (age at onset);
SARC	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg11764359	chr7:65958608	NA	0.75	9.13	0.51	3.31e-17	Aortic root size;
SARC	cis	rs7829975	0.846	rs6601724	chr8:8544872	C/T	cg08975724	chr8:8085496	FLJ10661	-0.42	-5.2	-0.32	4.4e-7	Mood instability;
SARC	cis	rs10791097	0.694	rs7926167	chr11:130745045	T/C	cg12179176	chr11:130786555	SNX19	0.74	11.09	0.59	3.11e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg03575189	chr17:44344142	NA	0.6	5.68	0.35	3.97e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9325144	0.723	rs3887436	chr12:39189526	A/C	cg26384229	chr12:38710491	ALG10B	-0.61	-7.51	-0.44	1.29e-12	Morning vs. evening chronotype;
SARC	cis	rs3617	0.539	rs9985365	chr3:52953844	A/G	cg18404041	chr3:52824283	ITIH1	0.37	5.31	0.33	2.51e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs2033732	0.706	rs6473525	chr8:85070206	A/G	cg05716166	chr8:85095498	RALYL	0.48	5.76	0.35	2.63e-8	Body mass index;
SARC	cis	rs9922678	0.843	rs41356645	chr16:9945919	C/T	cg00934661	chr16:10775706	TEKT5	-0.28	-4.73	-0.3	3.9e-6	Schizophrenia;
SARC	cis	rs9527	0.545	rs12247514	chr10:104958066	C/A	cg04362960	chr10:104952993	NT5C2	0.43	5.06	0.31	8.57e-7	Arsenic metabolism;
SARC	cis	rs10752881	0.933	rs2027086	chr1:183057933	G/A	cg13390022	chr1:182993471	LAMC1	0.33	5.06	0.31	8.42e-7	Colorectal cancer;
SARC	cis	rs2180341	0.920	rs9401951	chr6:127671632	A/C	cg24812749	chr6:127587940	RNF146	1.01	13.21	0.65	4.13e-30	Breast cancer;
SARC	cis	rs9457247	0.565	rs2038580	chr6:167456490	A/T	cg23791538	chr6:167370224	RNASET2	-0.53	-6.88	-0.41	5.37e-11	Crohn's disease;
SARC	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg11952622	chr19:58962976	ZNF324B	0.56	7.41	0.44	2.34e-12	Uric acid clearance;
SARC	cis	rs9660992	0.573	rs4400674	chr1:205218425	A/C	cg21643547	chr1:205240462	TMCC2	0.56	7.48	0.44	1.55e-12	Mean corpuscular volume;Mean platelet volume;
SARC	trans	rs7980799	0.716	rs10161311	chr12:33623204	G/A	cg13010199	chr12:38710504	ALG10B	-0.53	-6.35	-0.38	1.13e-9	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	12.22	0.62	7.4e-27	Chronic sinus infection;
SARC	cis	rs11249608	0.548	rs13161528	chr5:178452958	C/G	cg21905437	chr5:178450457	ZNF879	0.59	8.22	0.47	1.45e-14	Pubertal anthropometrics;
SARC	cis	rs2764208	0.770	rs112283401	chr6:34797756	G/T	cg07306190	chr6:34760872	UHRF1BP1	-0.4	-5.58	-0.34	6.59e-8	Systemic lupus erythematosus;
SARC	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.36	-4.89	-0.3	1.9e-6	Total body bone mineral density;
SARC	cis	rs7296418	0.961	rs10848428	chr12:123572495	C/T	cg05973401	chr12:123451056	ABCB9	0.58	7.03	0.42	2.25e-11	Platelet count;
SARC	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg13206674	chr6:150067644	NUP43	0.41	4.87	0.3	2.02e-6	Lung cancer;
SARC	cis	rs2153535	1.000	rs11243251	chr6:8368207	G/A	cg07606381	chr6:8435919	SLC35B3	-0.53	-6.64	-0.4	2.24e-10	Motion sickness;
SARC	cis	rs9612	1.000	rs3786954	chr19:44272346	A/G	cg07522664	chr19:44259120	C19orf61	0.47	5.49	0.34	1.03e-7	Exhaled nitric oxide output;
SARC	cis	rs9486719	0.741	rs2049927	chr6:96848958	C/G	cg06623918	chr6:96969491	KIAA0776	-0.7	-6.96	-0.41	3.52e-11	Migraine;Coronary artery disease;
SARC	cis	rs9397240	0.789	rs12213806	chr6:155607953	A/G	cg07943832	chr6:155568918	TIAM2	-0.6	-5.77	-0.35	2.54e-8	Life satisfaction;
SARC	cis	rs10097215	1.000	rs10097215	chr8:2506899	A/G	cg09126794	chr8:1879551	ARHGEF10	0.54	5.19	0.32	4.56e-7	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
SARC	cis	rs2832191	0.740	rs2012645	chr21:30445961	G/A	cg24692254	chr21:30365293	RNF160	1.03	18.22	0.77	1.07e-46	Dental caries;
SARC	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg11987759	chr7:65425863	GUSB	0.48	5.94	0.36	1.06e-8	Aortic root size;
SARC	cis	rs34779708	0.931	rs7923172	chr10:35309367	G/A	cg03585969	chr10:35415529	CREM	0.39	4.98	0.31	1.24e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs10911232	0.507	rs28477876	chr1:183019882	T/C	cg13390022	chr1:182993471	LAMC1	0.36	5.41	0.33	1.56e-7	Hypertriglyceridemia;
SARC	cis	rs870825	0.790	rs12513128	chr4:185576729	G/C	cg04058563	chr4:185651563	MLF1IP	0.78	8.94	0.51	1.21e-16	Blood protein levels;
SARC	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.56	6.41	0.39	7.83e-10	Renal function-related traits (BUN);
SARC	cis	rs698833	0.886	rs2053455	chr2:44550233	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.72	9.52	0.53	2.39e-18	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs78320035	1.000	rs116431876	chr1:168140612	C/T	cg17113809	chr1:168148080	TIPRL	1.32	7.02	0.42	2.39e-11	Red cell distribution width;
SARC	cis	rs910316	1.000	rs7142235	chr14:75559963	T/C	cg08847533	chr14:75593920	NEK9	0.94	16.23	0.73	3.78e-40	Height;
SARC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg07414643	chr4:187882934	NA	0.5	7.63	0.45	6e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9393777	0.623	rs34313099	chr6:26489607	C/T	cg12826209	chr6:26865740	GUSBL1	0.8	7.08	0.42	1.73e-11	Intelligence (multi-trait analysis);
SARC	cis	rs6991838	0.584	rs4737747	chr8:66519259	C/T	cg13398993	chr8:66546079	ARMC1	-0.62	-8.39	-0.48	4.67e-15	Intelligence (multi-trait analysis);
SARC	cis	rs1629083	0.738	rs590580	chr11:118066104	C/T	cg18857871	chr11:118064634	AMICA1	-0.33	-4.8	-0.3	2.8e-6	Lung cancer;
SARC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	9.8	0.54	3.29e-19	Platelet count;
SARC	cis	rs9815354	1.000	rs7617397	chr3:41959037	T/C	cg03022575	chr3:42003672	ULK4	-0.55	-5.26	-0.33	3.22e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg19748678	chr4:122722346	EXOSC9	0.78	9.68	0.54	7.65e-19	Type 2 diabetes;
SARC	cis	rs1949733	0.636	rs16842498	chr4:8539529	C/T	cg05004818	chr4:8539015	NA	0.37	4.83	0.3	2.51e-6	Response to antineoplastic agents;
SARC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg12648201	chr2:27665141	KRTCAP3	-0.33	-5.06	-0.31	8.69e-7	Total body bone mineral density;
SARC	cis	rs898097	0.841	rs4986136	chr17:80865119	A/G	cg15369054	chr17:80825471	TBCD	-0.48	-6.45	-0.39	6.32e-10	Breast cancer;
SARC	trans	rs12310956	0.532	rs10506119	chr12:33963684	A/G	cg26384229	chr12:38710491	ALG10B	0.85	12.3	0.63	4.14e-27	Morning vs. evening chronotype;
SARC	cis	rs4780401	0.588	rs9926666	chr16:11786553	C/T	cg01061890	chr16:11836724	TXNDC11	0.37	4.93	0.31	1.55e-6	Rheumatoid arthritis;
SARC	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.74	10.57	0.57	1.34e-21	Personality dimensions;
SARC	cis	rs523522	0.892	rs4767916	chr12:121024032	T/C	cg27279351	chr12:120934652	DYNLL1	0.72	8.85	0.5	2.22e-16	High light scatter reticulocyte count;
SARC	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg11141652	chr22:24348549	GSTTP1	-0.52	-5.55	-0.34	7.71e-8	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs2070677	0.736	rs4529856	chr10:135414020	C/G	cg20169779	chr10:135381914	SYCE1	-0.5	-5.32	-0.33	2.47e-7	Gout;
SARC	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg12564285	chr5:131593104	PDLIM4	-0.39	-5.35	-0.33	2.14e-7	Breast cancer;
SARC	cis	rs1468333	0.567	rs12514520	chr5:137778068	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.65	7.72	0.45	3.5e-13	Resting heart rate;
SARC	cis	rs2730245	0.527	rs2657362	chr7:158685095	A/G	cg24397884	chr7:158709396	WDR60	1.14	10.19	0.56	2.12e-20	Height;
SARC	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg14895029	chr7:2775587	GNA12	-0.38	-4.73	-0.3	3.84e-6	Height;
SARC	cis	rs2251381	0.778	rs2245021	chr21:30546841	C/T	cg08807101	chr21:30365312	RNF160	0.73	10.09	0.55	4.31e-20	Selective IgA deficiency;
SARC	cis	rs1348850	0.793	rs12990917	chr2:178487259	T/G	cg23306229	chr2:178417860	TTC30B	0.57	6.28	0.38	1.63e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs4481887	0.893	rs10888348	chr1:248448610	C/G	cg00666640	chr1:248458726	OR2T12	0.34	5.63	0.35	5.26e-8	Common traits (Other);
SARC	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg12310025	chr6:25882481	NA	-0.61	-7.72	-0.45	3.51e-13	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7537052	0.669	rs475591	chr1:36642420	T/C	cg24686825	chr1:36642396	MAP7D1	-0.72	-10.02	-0.55	6.87e-20	Schizophrenia;
SARC	cis	rs6964587	1.000	rs2106171	chr7:91750450	A/G	cg17063962	chr7:91808500	NA	0.95	16.04	0.72	1.66e-39	Breast cancer;
SARC	cis	rs12979813	1.000	rs10418759	chr19:11340242	A/G	cg00586551	chr19:11347513	LOC55908;DOCK6	0.42	5.16	0.32	5.4e-7	HDL cholesterol;
SARC	cis	rs2239815	0.515	rs6005917	chr22:29233486	A/G	cg15103426	chr22:29168792	CCDC117	0.63	6.79	0.41	9.47e-11	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
SARC	cis	rs7818345	0.967	rs12679712	chr8:19271032	C/G	cg11303988	chr8:19266685	CSGALNACT1	0.42	5.73	0.35	3.12e-8	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg08219700	chr8:58056026	NA	0.46	4.94	0.31	1.47e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs7179456	0.545	rs585192	chr15:59052210	T/C	cg05156742	chr15:59063176	FAM63B	0.66	8.55	0.49	1.69e-15	Asperger disorder;
SARC	cis	rs6582630	0.615	rs12821226	chr12:38546406	C/T	cg13010199	chr12:38710504	ALG10B	-0.52	-6.47	-0.39	5.77e-10	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs1973993	0.717	rs56209707	chr1:96972973	C/A	cg10631902	chr5:14652156	NA	-0.41	-6.55	-0.39	3.59e-10	Weight;
SARC	cis	rs2933343	1.000	rs1683778	chr3:128644595	A/G	cg24203234	chr3:128598194	ACAD9	0.55	6.04	0.37	6.17e-9	IgG glycosylation;
SARC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg11203670	chr7:100026453	MEPCE;ZCWPW1	0.52	4.88	0.3	1.95e-6	Platelet count;
SARC	cis	rs80282103	0.867	rs13377037	chr10:1068639	C/T	cg08668510	chr10:1095578	IDI1	0.8	5.67	0.35	4.17e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg20891283	chr12:69753455	YEATS4	0.55	7.56	0.44	9.09e-13	Blood protein levels;
SARC	cis	rs1949733	0.598	rs4696838	chr4:8540349	A/G	cg13073564	chr4:8508604	NA	0.51	7.85	0.46	1.52e-13	Response to antineoplastic agents;
SARC	cis	rs7806994	1	rs7806994	chr7:56139505	A/T	cg04783474	chr7:55799845	NA	-0.46	-5.23	-0.32	3.86e-7	PR interval in Tripanosoma cruzi seropositivity;
SARC	cis	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg14541582	chr5:601475	NA	-0.39	-4.95	-0.31	1.45e-6	Obesity-related traits;
SARC	trans	rs629535	0.821	rs660144	chr8:70035629	T/C	cg21567404	chr3:27674614	NA	1.04	13.82	0.67	3.98e-32	Dupuytren's disease;
SARC	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg22535103	chr8:58192502	C8orf71	-0.78	-9.14	-0.51	3.2e-17	Developmental language disorder (linguistic errors);
SARC	cis	rs151450	1	rs151450	chr4:88016514	G/A	cg11209507	chr4:87813803	C4orf36	0.38	4.92	0.31	1.62e-6	Basophil percentage of white cells;
SARC	cis	rs3768617	0.510	rs10458355	chr1:183063993	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.65	0.57	7.77e-22	Fuchs's corneal dystrophy;
SARC	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg22903471	chr2:27725779	GCKR	-0.51	-7.68	-0.45	4.26e-13	Total body bone mineral density;
SARC	cis	rs62432291	0.681	rs435521	chr6:159662638	C/T	cg14500486	chr6:159655392	FNDC1	0.57	5.78	0.35	2.33e-8	Joint mobility (Beighton score);
SARC	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg21724239	chr8:58056113	NA	0.6	6.31	0.38	1.43e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg11266682	chr4:10021025	SLC2A9	0.42	7.66	0.45	4.91e-13	Bone mineral density;
SARC	cis	rs829661	0.532	rs11678346	chr2:30767508	C/T	cg17749961	chr2:30669863	LCLAT1	-0.4	-4.96	-0.31	1.39e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
SARC	cis	rs2276314	1.000	rs62101367	chr18:33550884	C/T	cg19628046	chr18:33552617	C18orf21	0.57	5.93	0.36	1.11e-8	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg05368731	chr17:41323189	NBR1	0.68	8.12	0.47	2.68e-14	Menopause (age at onset);
SARC	cis	rs2120019	1.000	rs12324912	chr15:75361006	G/A	cg17294928	chr15:75287854	SCAMP5	-0.94	-13.59	-0.67	2.25e-31	Blood trace element (Zn levels);
SARC	cis	rs1348850	0.526	rs6718769	chr2:178450909	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.55	5.54	0.34	8.23e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs3858526	0.959	rs61876224	chr11:5952859	G/A	cg02574844	chr11:5959923	NA	-0.43	-5.32	-0.33	2.47e-7	DNA methylation (variation);
SARC	cis	rs1707322	0.681	rs12048866	chr1:46117492	T/G	cg03146154	chr1:46216737	IPP	0.52	6.25	0.38	1.92e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs3540	0.574	rs8035980	chr15:90974390	C/G	cg22089800	chr15:90895588	ZNF774	0.63	8.2	0.47	1.64e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs1580019	0.563	rs13244332	chr7:32537679	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.01	18.92	0.78	5.57e-49	Cognitive ability;
SARC	cis	rs6456156	0.846	rs10946211	chr6:167515489	G/A	cg07741184	chr6:167504864	NA	-0.33	-6.13	-0.37	3.68e-9	Primary biliary cholangitis;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg13482209	chr3:48700475	CELSR3	0.49	6.61	0.4	2.53e-10	Breast cancer;
SARC	cis	rs2576037	0.899	rs2060417	chr18:44576486	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.55	7.13	0.42	1.28e-11	Personality dimensions;
SARC	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg22535103	chr8:58192502	C8orf71	-0.59	-6.21	-0.38	2.35e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2242116	0.932	rs7646906	chr3:46949379	G/A	cg02527881	chr3:46936655	PTH1R	-0.41	-6.69	-0.4	1.63e-10	Birth weight;
SARC	cis	rs11098499	0.722	rs1814814	chr4:120258124	C/G	cg09307838	chr4:120376055	NA	0.79	11.03	0.59	5e-23	Corneal astigmatism;
SARC	cis	rs7520050	0.778	rs12404197	chr1:46232420	G/A	cg24296786	chr1:45957014	TESK2	0.43	5.53	0.34	8.71e-8	Red blood cell count;Reticulocyte count;
SARC	cis	rs34172651	0.917	rs12599643	chr16:24832693	C/T	cg06028605	chr16:24865363	SLC5A11	0.27	4.88	0.3	1.92e-6	Intelligence (multi-trait analysis);
SARC	cis	rs8141529	0.515	rs13056243	chr22:29349306	A/G	cg15103426	chr22:29168792	CCDC117	-0.54	-5.35	-0.33	2.1e-7	Lymphocyte counts;
SARC	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg21747090	chr2:27597821	SNX17	-0.56	-7.9	-0.46	1.13e-13	Menopause (age at onset);
SARC	trans	rs116095464	0.558	rs7714335	chr5:263513	T/C	cg00938859	chr5:1591904	SDHAP3	0.76	7.15	0.42	1.14e-11	Breast cancer;
SARC	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg06212747	chr3:49208901	KLHDC8B	0.6	7.72	0.45	3.45e-13	Parkinson's disease;
SARC	cis	rs6539267	0.741	rs10861572	chr12:106688576	A/G	cg00173435	chr12:106696525	TCP11L2	-0.79	-9.25	-0.52	1.51e-17	Tourette syndrome;
SARC	cis	rs9790314	1.000	rs336543	chr3:161061080	C/T	cg03342759	chr3:160939853	NMD3	0.59	7.56	0.44	9.26e-13	Morning vs. evening chronotype;
SARC	cis	rs208520	1.000	rs12190187	chr6:66973207	T/G	cg07460842	chr6:66804631	NA	0.88	9.81	0.54	3.15e-19	Exhaled nitric oxide output;
SARC	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg18876405	chr7:65276391	NA	-0.44	-5.05	-0.31	8.78e-7	Aortic root size;
SARC	cis	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg18252515	chr7:66147081	NA	-1.27	-11.31	-0.6	6.26e-24	Diabetic kidney disease;
SARC	cis	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg08847533	chr14:75593920	NEK9	0.74	8.91	0.5	1.46e-16	Height;
SARC	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.8	7.92	0.46	9.8e-14	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg18252515	chr7:66147081	NA	-1.29	-11.2	-0.59	1.41e-23	Diabetic kidney disease;
SARC	cis	rs6686643	0.762	rs9333433	chr1:165611455	G/C	cg19407955	chr1:165599744	MGST3	-0.59	-6.08	-0.37	4.85e-9	Total ventricular volume;
SARC	trans	rs10825741	0.825	rs10082436	chr10:57913735	C/T	cg12948920	chr4:8609706	CPZ	0.53	6.29	0.38	1.53e-9	Night sleep phenotypes;
SARC	cis	rs6598955	0.543	rs4585968	chr1:26535146	G/A	cg04990556	chr1:26633338	UBXN11	0.76	7.72	0.45	3.49e-13	Obesity-related traits;
SARC	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg18876405	chr7:65276391	NA	-0.68	-8.73	-0.5	5.03e-16	Aortic root size;
SARC	cis	rs16976116	0.643	rs12440420	chr15:55517432	C/T	cg11288833	chr15:55489084	RSL24D1	-0.51	-4.93	-0.31	1.59e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2303745	0.544	rs6512181	chr19:17399213	T/G	cg10664184	chr19:17420304	DDA1	0.48	4.89	0.3	1.91e-6	Systemic lupus erythematosus;
SARC	cis	rs1059312	0.500	rs12303338	chr12:129276641	C/T	cg09035930	chr12:129282057	SLC15A4	-0.41	-4.91	-0.31	1.74e-6	Systemic lupus erythematosus;
SARC	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg08219700	chr8:58056026	NA	0.49	5.09	0.32	7.4e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs710216	0.917	rs900834	chr1:43412343	A/G	cg07803811	chr1:43423981	SLC2A1	-0.54	-5.42	-0.33	1.45e-7	Red cell distribution width;
SARC	cis	rs8067354	0.645	rs2645491	chr17:57877049	C/T	cg02344993	chr17:57696989	CLTC	0.67	7.01	0.42	2.54e-11	Hemoglobin concentration;
SARC	cis	rs959260	0.623	rs2164244	chr17:73325244	C/T	cg14668889	chr17:73230827	NUP85	-0.57	-7.24	-0.43	6.48e-12	Systemic lupus erythematosus;
SARC	cis	rs9304742	0.683	rs10402714	chr19:53463680	G/A	cg24044776	chr19:53454761	ZNF816A	-0.39	-5.37	-0.33	1.92e-7	Psoriasis;
SARC	cis	rs751728	1.000	rs2296748	chr6:33745071	C/T	cg25922239	chr6:33757077	LEMD2	0.78	10.12	0.55	3.38e-20	Crohn's disease;
SARC	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg14582100	chr15:45693742	SPATA5L1	0.35	4.88	0.3	2.01e-6	Homoarginine levels;
SARC	cis	rs2153535	0.541	rs4637688	chr6:8446501	A/G	cg21535247	chr6:8435926	SLC35B3	0.57	7.04	0.42	2.19e-11	Motion sickness;
SARC	cis	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg09021430	chr5:549028	NA	-0.46	-5.92	-0.36	1.17e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs1865760	0.532	rs2006736	chr6:26086017	C/T	cg10373733	chr6:25993375	NA	0.45	5.43	0.34	1.4e-7	Height;
SARC	cis	rs3008870	0.727	rs2862729	chr1:67500828	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.55	6.69	0.4	1.65e-10	Lymphocyte percentage of white cells;
SARC	cis	rs4243830	1.000	rs41278016	chr1:6584045	C/G	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.69	-4.71	-0.3	4.16e-6	Body mass index;
SARC	cis	rs1790761	0.692	rs674783	chr11:67339076	C/T	cg00290607	chr11:67383545	NA	0.39	5.38	0.33	1.84e-7	Mean corpuscular volume;
SARC	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg05861140	chr6:150128134	PCMT1	-0.42	-5.44	-0.34	1.32e-7	Lung cancer;
SARC	cis	rs12438659	1	rs12438659	chr15:78824924	G/A	cg24631222	chr15:78858424	CHRNA5	0.75	9.98	0.55	9.16e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs78456975	1.000	rs11884854	chr2:1566154	A/G	cg01028140	chr2:1542097	TPO	-0.44	-4.73	-0.3	3.86e-6	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg03264133	chr6:25882463	NA	-0.43	-5.8	-0.36	2.17e-8	Intelligence (multi-trait analysis);
SARC	trans	rs17685	0.753	rs1639617	chr7:75701728	A/G	cg19862616	chr7:65841803	NCRNA00174	0.63	7.83	0.46	1.68e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs6058796	0.892	rs6141780	chr20:31262423	C/G	cg13636640	chr20:31349939	DNMT3B	-0.55	-4.9	-0.31	1.76e-6	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs7481584	0.581	rs420127	chr11:3077990	C/T	cg05729581	chr11:3078854	CARS	0.51	6.59	0.4	2.9e-10	Calcium levels;
SARC	cis	rs77972916	0.611	rs10495899	chr2:43602304	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.58	-6.46	-0.39	6e-10	Granulocyte percentage of myeloid white cells;
SARC	cis	rs11098499	0.863	rs10018280	chr4:120478139	T/G	cg09307838	chr4:120376055	NA	0.91	12.58	0.64	4.84e-28	Corneal astigmatism;
SARC	cis	rs870825	0.929	rs2310102	chr4:185595141	C/G	cg04058563	chr4:185651563	MLF1IP	-0.79	-9.37	-0.52	6.37e-18	Blood protein levels;
SARC	cis	rs7847628	0.550	rs12343516	chr9:123603469	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	9.46	0.53	3.59e-18	Birth weight;
SARC	cis	rs12545109	0.800	rs1553969	chr8:57420187	A/G	cg19413350	chr8:57351067	NA	-0.43	-5.4	-0.33	1.67e-7	Obesity-related traits;
SARC	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg06074448	chr4:187884817	NA	-0.46	-6.48	-0.39	5.32e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2486288	0.656	rs12899058	chr15:45547324	G/A	cg15395560	chr15:45543142	SLC28A2	0.29	5.59	0.34	6.44e-8	Glomerular filtration rate;
SARC	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.5e-10	Life satisfaction;
SARC	cis	rs172166	0.637	rs1225592	chr6:28150242	G/A	cg16479474	chr6:28041457	NA	0.32	5.26	0.33	3.25e-7	Cardiac Troponin-T levels;
SARC	cis	rs1003719	0.762	rs8130846	chr21:38480242	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.95	0.51	1.17e-16	Eye color traits;
SARC	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.41	-6.44	-0.39	6.7e-10	Total body bone mineral density;
SARC	cis	rs921968	0.565	rs2272188	chr2:219612282	C/T	cg02176678	chr2:219576539	TTLL4	0.34	5.21	0.32	4.06e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs3768617	0.510	rs2296294	chr1:183095596	T/C	cg13390022	chr1:182993471	LAMC1	0.31	4.79	0.3	3.01e-6	Fuchs's corneal dystrophy;
SARC	trans	rs747334	0.846	rs7897603	chr10:92708759	C/G	cg11442381	chr3:52312806	WDR82	-0.47	-6.27	-0.38	1.71e-9	Fibroblast growth factor basic levels;
SARC	cis	rs8114671	0.901	rs6119581	chr20:33773689	T/A	cg24642439	chr20:33292090	TP53INP2	0.5	5.64	0.35	4.85e-8	Height;
SARC	cis	rs559928	0.548	rs11231713	chr11:63931849	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	5.12	0.32	6.44e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs6062509	0.811	rs6062498	chr20:62339059	C/G	cg27236539	chr20:62289627	RTEL1	0.51	5.7	0.35	3.61e-8	Prostate cancer;
SARC	cis	rs9790314	1.000	rs456611	chr3:161097268	A/G	cg04691961	chr3:161091175	C3orf57	-0.82	-12.33	-0.63	3.23e-27	Morning vs. evening chronotype;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg13151498	chr3:185541792	IGF2BP2	-0.78	-6.41	-0.39	8.21e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7927771	1.000	rs10838747	chr11:47716324	G/C	cg20307385	chr11:47447363	PSMC3	-0.5	-5.99	-0.37	8.05e-9	Subjective well-being;
SARC	trans	rs3780486	0.874	rs10813955	chr9:33141791	C/T	cg04842962	chr6:43655489	MRPS18A	1.09	19.52	0.79	6.28e-51	IgG glycosylation;
SARC	cis	rs7647973	0.626	rs9830730	chr3:49675875	G/C	cg13072238	chr3:49761600	GMPPB	-0.58	-5.74	-0.35	2.89e-8	Menarche (age at onset);
SARC	cis	rs7208859	0.623	rs56018041	chr17:29059985	G/A	cg13385521	chr17:29058706	SUZ12P	0.89	8.0	0.46	5.9e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs11098499	0.754	rs11098502	chr4:120252063	T/A	cg09307838	chr4:120376055	NA	0.81	11.03	0.59	4.84e-23	Corneal astigmatism;
SARC	cis	rs1185460	0.967	rs1786141	chr11:118938315	C/T	cg01677386	chr11:118938358	VPS11	-0.39	-4.87	-0.3	2.07e-6	Coronary artery disease;
SARC	cis	rs7818688	0.697	rs11776186	chr8:95971968	A/G	cg13393036	chr8:95962371	TP53INP1	0.43	5.07	0.32	8.14e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs8523	0.901	rs4711146	chr6:10961405	T/C	cg13562911	chr6:11044106	ELOVL2	0.4	5.34	0.33	2.25e-7	Red blood cell fatty acid levels;
SARC	cis	rs2242194	0.844	rs11264295	chr1:154987526	C/T	cg16680214	chr1:154839983	KCNN3	-0.33	-5.19	-0.32	4.56e-7	Schizophrenia;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg27377863	chr19:16189693	TPM4	-0.57	-6.53	-0.39	4.03e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs9399135	0.967	rs9376085	chr6:135371224	T/C	cg24558204	chr6:135376177	HBS1L	0.46	6.18	0.38	2.88e-9	Red blood cell count;
SARC	cis	rs4478037	0.555	rs60749629	chr3:33105319	G/A	cg19404215	chr3:33155277	CRTAP	0.84	5.23	0.32	3.7e-7	Major depressive disorder;
SARC	cis	rs7666738	0.830	rs35560671	chr4:99069095	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.71	0.5	5.54e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg13206674	chr6:150067644	NUP43	0.46	5.91	0.36	1.22e-8	Lung cancer;
SARC	trans	rs2018683	0.835	rs7782264	chr7:28978986	A/G	cg19402173	chr7:128379420	CALU	0.61	8.02	0.47	5.03e-14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg08677398	chr8:58056175	NA	0.43	5.09	0.32	7.42e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg13271783	chr10:134563150	INPP5A	-0.41	-5.0	-0.31	1.12e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs2290720	0.896	rs6538983	chr12:101721860	T/C	cg22051763	chr12:101673672	UTP20	-0.42	-4.97	-0.31	1.27e-6	Brain structure (hippocampal volume);
SARC	cis	rs787274	0.850	rs10739378	chr9:115639631	C/T	cg13803584	chr9:115635662	SNX30	-0.9	-6.32	-0.38	1.33e-9	Age-related hearing impairment (SNP x SNP interaction);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg15806518	chr9:127177817	PSMB7	-0.57	-6.43	-0.39	6.99e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg24531977	chr5:56204891	C5orf35	-0.52	-5.22	-0.32	4.03e-7	Initial pursuit acceleration;
SARC	cis	rs748404	0.697	rs505249	chr15:43559960	T/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.55	6.52	0.39	4.37e-10	Lung cancer;
SARC	cis	rs16866061	1.000	rs11688397	chr2:225393173	C/T	cg12698349	chr2:225449008	CUL3	0.71	10.32	0.56	8.14e-21	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	cis	rs3784262	0.669	rs4646594	chr15:58302386	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.34	-5.21	-0.32	4.21e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs11077998	0.967	rs11657886	chr17:80516173	T/C	cg10255544	chr17:80519551	FOXK2	0.47	6.97	0.42	3.2e-11	Reticulocyte fraction of red cells;
SARC	cis	rs4843747	0.708	rs11866437	chr16:88072279	A/G	cg01573921	chr16:88061006	BANP	0.53	5.66	0.35	4.4e-8	Menopause (age at onset);
SARC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg16132339	chr22:24313637	DDTL;DDT	0.38	5.17	0.32	5.01e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7474896	0.537	rs1208591	chr10:38212502	A/T	cg00409905	chr10:38381863	ZNF37A	-0.44	-4.92	-0.31	1.62e-6	Obesity (extreme);
SARC	cis	rs7312774	0.881	rs1822737	chr12:107309175	A/G	cg16260113	chr12:107380972	MTERFD3	0.75	6.62	0.4	2.47e-10	Severe influenza A (H1N1) infection;
SARC	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	12.62	0.64	3.53e-28	Chronic sinus infection;
SARC	cis	rs7647973	0.593	rs9870755	chr3:49809841	A/G	cg13072238	chr3:49761600	GMPPB	-0.58	-5.88	-0.36	1.38e-8	Menarche (age at onset);
SARC	cis	rs2933343	0.761	rs789225	chr3:128600229	G/A	cg24203234	chr3:128598194	ACAD9	0.63	8.11	0.47	2.89e-14	IgG glycosylation;
SARC	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg22920501	chr2:26401640	FAM59B	-0.48	-6.13	-0.37	3.69e-9	Gut microbiome composition (summer);
SARC	cis	rs7937682	0.961	rs11601674	chr11:111634354	C/T	cg22437258	chr11:111473054	SIK2	0.66	8.36	0.48	5.74e-15	Primary sclerosing cholangitis;
SARC	cis	rs11731606	0.508	rs9307140	chr4:95288670	G/C	cg00507259	chr4:95128692	SMARCAD1	0.55	5.3	0.33	2.74e-7	Mean platelet volume;
SARC	cis	rs6788895	1.000	rs34348847	chr3:150501389	C/G	cg09723797	chr3:150481914	SIAH2	0.78	4.89	0.3	1.92e-6	Breast cancer;
SARC	cis	rs7264396	0.635	rs2024854	chr20:34511189	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-7.47	-0.44	1.56e-12	Total cholesterol levels;
SARC	cis	rs7818688	0.697	rs75349998	chr8:95990918	G/A	cg13393036	chr8:95962371	TP53INP1	0.41	4.87	0.3	2.09e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs4727027	0.801	rs12666337	chr7:148796253	C/T	cg23583168	chr7:148888333	NA	-0.74	-10.4	-0.56	4.66e-21	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs10089	1.000	rs62373701	chr5:127416294	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.85	10.15	0.55	2.8e-20	Ileal carcinoids;
SARC	cis	rs2046867	0.862	rs6766747	chr3:72856551	T/C	cg25664220	chr3:72788482	NA	-0.29	-4.78	-0.3	3.09e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
SARC	cis	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg06636001	chr8:8085503	FLJ10661	0.62	8.23	0.47	1.34e-14	Mood instability;
SARC	trans	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg20587970	chr11:113659929	NA	1.0	9.46	0.53	3.42e-18	Hip circumference adjusted for BMI;
SARC	cis	rs7772486	0.686	rs1004752	chr6:146037822	G/A	cg23711669	chr6:146136114	FBXO30	-0.8	-12.65	-0.64	2.79e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-10.45	-0.56	3.26e-21	Chronic sinus infection;
SARC	cis	rs4595586	0.545	rs1156707	chr12:39372451	G/T	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg16479474	chr6:28041457	NA	0.37	5.39	0.33	1.73e-7	Depression;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg08928203	chr11:67888847	CHKA	0.48	6.31	0.38	1.42e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.42	-6.44	-0.39	6.6e-10	Total body bone mineral density;
SARC	cis	rs2070677	0.708	rs12762259	chr10:135350365	C/T	cg20169779	chr10:135381914	SYCE1	0.44	5.76	0.35	2.59e-8	Gout;
SARC	cis	rs965469	1.000	rs6051745	chr20:3307243	T/G	cg25506879	chr20:3388711	C20orf194	-0.5	-5.08	-0.32	7.88e-7	IFN-related cytopenia;
SARC	cis	rs6674176	0.660	rs12726706	chr1:44399942	G/A	cg13606994	chr1:44402422	ARTN	-0.34	-5.6	-0.34	6e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg23936098	chr10:103911881	NOLC1	-0.54	-6.91	-0.41	4.7e-11	Gallstone disease;
SARC	cis	rs9549260	0.727	rs4603422	chr13:41148353	T/C	cg21288729	chr13:41239152	FOXO1	0.64	8.3	0.48	8.42e-15	Red blood cell count;
SARC	cis	rs7617773	0.817	rs6800492	chr3:48323890	G/A	cg11946769	chr3:48343235	NME6	0.69	9.27	0.52	1.29e-17	Coronary artery disease;
SARC	cis	rs79349575	0.783	rs62078370	chr17:47026836	G/C	cg16584676	chr17:46985605	UBE2Z	0.55	6.58	0.4	3.01e-10	Type 2 diabetes;
SARC	cis	rs6964587	1.000	rs10228800	chr7:91610111	T/G	cg17063962	chr7:91808500	NA	0.93	15.52	0.71	8.63e-38	Breast cancer;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg08479976	chr1:90286333	LRRC8D	-0.77	-6.46	-0.39	6.12e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2880765	0.566	rs55899824	chr15:86004091	C/T	cg19183879	chr15:85880815	NA	-0.3	-4.79	-0.3	3.01e-6	Coronary artery disease;
SARC	cis	rs9916302	0.861	rs11078913	chr17:37671714	G/T	cg20243544	chr17:37824526	PNMT	0.56	6.7	0.4	1.58e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg08219700	chr8:58056026	NA	0.51	5.25	0.33	3.36e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg22484793	chr3:52261325	TLR9	0.29	4.73	0.3	3.83e-6	Bipolar disorder;
SARC	cis	rs6942407	0.592	rs1859125	chr7:86752074	C/T	cg02420886	chr7:86849541	C7orf23	0.6	5.44	0.34	1.32e-7	Food allergy;
SARC	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg19077165	chr18:44547161	KATNAL2	0.57	8.11	0.47	2.88e-14	Personality dimensions;
SARC	cis	rs2120019	1.000	rs12324912	chr15:75361006	G/A	cg00629941	chr15:75287862	SCAMP5	-0.61	-7.16	-0.42	1.03e-11	Blood trace element (Zn levels);
SARC	cis	rs8072100	0.811	rs9889709	chr17:45445229	C/T	cg08085267	chr17:45401833	C17orf57	-0.43	-5.24	-0.32	3.66e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs9733	0.650	rs11204680	chr1:150587140	T/G	cg18016565	chr1:150552671	MCL1	-0.39	-5.39	-0.33	1.7e-7	Tonsillectomy;
SARC	cis	rs1707322	0.963	rs34907901	chr1:46405214	T/G	cg06784218	chr1:46089804	CCDC17	0.35	5.99	0.37	7.71e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg25427524	chr10:38739819	LOC399744	-0.54	-8.56	-0.49	1.52e-15	Extrinsic epigenetic age acceleration;
SARC	cis	rs6871536	0.760	rs3091307	chr5:131989136	A/G	cg11797159	chr5:131991491	NA	0.36	4.72	0.3	3.99e-6	Asthma (childhood onset);
SARC	cis	rs12216125	0.554	rs6942196	chr6:26072804	A/G	cg10373733	chr6:25993375	NA	0.42	5.15	0.32	5.67e-7	Iron status biomarkers;
SARC	cis	rs2439831	0.867	rs2614811	chr15:43913487	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.81	7.5	0.44	1.36e-12	Lung cancer in ever smokers;
SARC	cis	rs2718058	0.519	rs2722242	chr7:37873610	A/G	cg24998770	chr7:37888106	TXNDC3	-0.33	-5.06	-0.31	8.57e-7	Alzheimer's disease (late onset);
SARC	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg24675658	chr1:53192096	ZYG11B	0.57	8.08	0.47	3.54e-14	Monocyte count;
SARC	cis	rs2599510	0.744	rs2254106	chr2:32768797	G/A	cg02381751	chr2:32503542	YIPF4	0.52	6.49	0.39	5.18e-10	Interleukin-18 levels;
SARC	cis	rs1976403	0.659	rs10799699	chr1:21820961	C/T	cg00786952	chr1:21763130	NA	0.35	5.79	0.35	2.22e-8	Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs2997447	0.761	rs17257120	chr1:26450101	A/G	cg19633962	chr1:26362018	EXTL1	-0.56	-5.06	-0.31	8.55e-7	QRS complex (12-leadsum);
SARC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.46	0.57	3.12e-21	Prudent dietary pattern;
SARC	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg24060327	chr5:131705240	SLC22A5	-0.72	-8.69	-0.49	6.41e-16	Breast cancer;
SARC	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg27170947	chr2:26402098	FAM59B	0.37	4.8	0.3	2.79e-6	Gut microbiome composition (summer);
SARC	cis	rs9894429	1.000	rs11651264	chr17:79576394	A/G	cg18240062	chr17:79603768	NPLOC4	-0.71	-9.81	-0.54	3.03e-19	Eye color traits;
SARC	cis	rs7681440	0.606	rs2583983	chr4:90753960	C/T	cg06632027	chr4:90757378	SNCA	-0.43	-5.34	-0.33	2.17e-7	Dementia with Lewy bodies;
SARC	cis	rs1008375	0.868	rs6816286	chr4:17698088	A/G	cg16339924	chr4:17578868	LAP3	0.52	6.67	0.4	1.8e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10464366	0.517	rs13231075	chr7:39174806	G/T	cg15212455	chr7:39170539	POU6F2	0.38	4.83	0.3	2.43e-6	IgG glycosylation;
SARC	cis	rs66573146	0.831	rs56081162	chr4:6989718	C/T	cg15105060	chr4:7024189	TBC1D14	-0.69	-4.96	-0.31	1.35e-6	Granulocyte percentage of myeloid white cells;
SARC	cis	rs1408799	0.720	rs12379260	chr9:12723112	G/A	cg05274944	chr9:12693694	TYRP1	0.35	5.23	0.32	3.81e-7	Eye color;Blue vs. green eyes;
SARC	cis	rs427394	0.582	rs274665	chr5:6707981	C/T	cg10857441	chr5:6722123	POLS	-0.32	-4.72	-0.3	4e-6	Menopause (age at onset);
SARC	trans	rs3942852	0.774	rs10838812	chr11:48186924	T/C	cg15704280	chr7:45808275	SEPT13	-0.62	-7.2	-0.43	8.05e-12	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs11719291	0.504	rs34571182	chr3:49209057	T/A	cg00383909	chr3:49044727	WDR6	0.71	6.37	0.39	9.81e-10	Cognitive function;
SARC	cis	rs637571	0.565	rs570387	chr11:65637076	T/C	cg09783858	chr11:65769428	EIF1AD;BANF1	0.38	4.88	0.3	1.94e-6	Eosinophil percentage of white cells;
SARC	cis	rs8141529	0.732	rs5752798	chr22:29181868	A/G	cg02153584	chr22:29168773	CCDC117	0.82	12.64	0.64	3.06e-28	Lymphocyte counts;
SARC	cis	rs1008375	0.900	rs1003413	chr4:17582442	C/T	cg02297831	chr4:17616191	MED28	-0.47	-5.76	-0.35	2.6e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs8072100	0.748	rs9908016	chr17:45551361	G/A	cg08085267	chr17:45401833	C17orf57	-0.49	-6.04	-0.37	6.17e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	trans	rs9929218	0.529	rs11075694	chr16:68730366	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.82	13.71	0.67	9.33e-32	Colorectal cancer;
SARC	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg00933542	chr6:150070202	PCMT1	0.32	5.43	0.33	1.44e-7	Lung cancer;
SARC	cis	rs9733	0.519	rs11800855	chr1:150800995	G/A	cg13175981	chr1:150552382	MCL1	-0.55	-6.85	-0.41	6.4e-11	Tonsillectomy;
SARC	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg21724239	chr8:58056113	NA	0.72	6.49	0.39	5.22e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6598955	0.543	rs79778574	chr1:26538482	A/G	cg04990556	chr1:26633338	UBXN11	0.76	7.72	0.45	3.49e-13	Obesity-related traits;
SARC	cis	rs5758659	0.714	rs6002626	chr22:42517989	C/G	cg15128208	chr22:42549153	NA	0.36	4.97	0.31	1.28e-6	Cognitive function;
SARC	cis	rs4742903	0.904	rs7028408	chr9:106859811	G/A	cg14250997	chr9:106856677	SMC2	0.53	7.08	0.42	1.68e-11	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs9715521	0.900	rs6819160	chr4:59834879	A/G	cg11281224	chr4:60001000	NA	-0.39	-4.95	-0.31	1.45e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs8072100	0.666	rs9913503	chr17:45776330	T/G	cg08085267	chr17:45401833	C17orf57	-0.43	-5.05	-0.31	8.73e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs7824557	0.713	rs6601575	chr8:11097804	A/C	cg16664915	chr8:10907788	XKR6	0.39	5.17	0.32	4.96e-7	Retinal vascular caliber;
SARC	cis	rs9868809	0.772	rs13070798	chr3:48705934	C/T	cg00383909	chr3:49044727	WDR6	-0.55	-5.59	-0.34	6.22e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs4243830	0.850	rs12410405	chr1:6581283	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.89	8.89	0.5	1.73e-16	Body mass index;
SARC	cis	rs2836974	0.544	rs8128919	chr21:40711862	C/T	cg11890956	chr21:40555474	PSMG1	0.76	10.29	0.56	1.04e-20	Cognitive function;
SARC	cis	rs1559088	0.847	rs8100392	chr19:33605933	T/C	cg27124370	chr19:33622961	WDR88	0.43	5.63	0.35	5.15e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs2204008	0.576	rs11519979	chr12:37999413	C/T	cg26384229	chr12:38710491	ALG10B	0.89	13.14	0.65	6.99e-30	Bladder cancer;
SARC	cis	rs933688	1.000	rs11950530	chr5:90688740	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.01	12.94	0.65	3.09e-29	Smoking behavior;
SARC	cis	rs6943931	1.000	rs12532078	chr7:22425998	G/A	cg11052958	chr7:21583226	DNAH11	0.36	5.24	0.32	3.65e-7	Diabetic kidney disease;
SARC	cis	rs7937682	0.602	rs503905	chr11:111390762	G/C	cg22437258	chr11:111473054	SIK2	0.42	5.23	0.32	3.83e-7	Primary sclerosing cholangitis;
SARC	cis	rs524281	0.773	rs2017969	chr11:66039032	G/A	cg14036092	chr11:66035641	RAB1B	-0.59	-6.01	-0.37	7.02e-9	Electroencephalogram traits;
SARC	cis	rs61409971	0.924	rs737522	chr14:93014672	A/G	cg04718702	chr14:93020195	RIN3	-0.37	-4.82	-0.3	2.56e-6	Lymphocyte percentage of white cells;
SARC	cis	rs2153535	0.580	rs7769020	chr6:8457724	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	10.66	0.57	7.43e-22	Motion sickness;
SARC	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	11.4	0.6	3.34e-24	Alzheimer's disease;
SARC	cis	rs1881797	0.932	rs41305741	chr1:247689543	A/G	cg18198730	chr1:247681584	NA	0.49	5.4	0.33	1.66e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs75804782	0.641	rs72987328	chr2:239360097	C/T	cg21699342	chr2:239360505	ASB1	-0.58	-4.86	-0.3	2.2e-6	Morning vs. evening chronotype;Chronotype;
SARC	cis	rs7727544	0.606	rs10060615	chr5:131708877	T/C	cg24060327	chr5:131705240	SLC22A5	-0.43	-5.08	-0.32	7.56e-7	Blood metabolite levels;
SARC	cis	rs4423214	0.547	rs11234030	chr11:71236967	G/A	cg05163923	chr11:71159392	DHCR7	-0.5	-5.01	-0.31	1.06e-6	Vitamin D levels;
SARC	cis	rs1062177	1.000	rs72802204	chr5:151183183	T/C	cg00977110	chr5:151150581	G3BP1	0.58	5.91	0.36	1.24e-8	Preschool internalizing problems;
SARC	cis	rs9818758	0.607	rs34326553	chr3:49134429	A/G	cg00383909	chr3:49044727	WDR6	0.78	6.72	0.4	1.4e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg05793240	chr7:2802953	GNA12	-0.36	-5.21	-0.32	4.22e-7	Height;
SARC	cis	rs2952156	0.920	rs2517958	chr17:37838751	G/A	cg20243544	chr17:37824526	PNMT	0.56	7.21	0.43	7.6e-12	Asthma;
SARC	cis	rs3733585	0.699	rs1079128	chr4:9951221	T/C	cg11266682	chr4:10021025	SLC2A9	-0.34	-5.84	-0.36	1.77e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs9788721	0.902	rs7180002	chr15:78873993	A/T	cg18825076	chr15:78729989	IREB2	-0.44	-5.21	-0.32	4.07e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg18252515	chr7:66147081	NA	0.58	6.24	0.38	2.02e-9	Aortic root size;
SARC	cis	rs7659604	0.540	rs10020581	chr4:122676559	A/C	cg19671926	chr4:122722719	EXOSC9	0.55	6.99	0.42	2.87e-11	Type 2 diabetes;
SARC	cis	rs9303401	0.659	rs62083368	chr17:56878062	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.06	12.04	0.62	2.73e-26	Cognitive test performance;
SARC	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg14773178	chr5:1868261	NA	0.3	4.79	0.3	3.03e-6	Cardiovascular disease risk factors;
SARC	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg22875332	chr1:76189707	ACADM	0.49	6.72	0.4	1.35e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs77372450	0.551	rs955967	chr5:157047715	A/G	cg05585991	chr5:157099197	C5orf52	-0.53	-5.21	-0.32	4.07e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs2303759	0.918	rs9749416	chr19:49885005	G/A	cg22307029	chr19:49891270	CCDC155	0.62	7.47	0.44	1.62e-12	Multiple sclerosis;
SARC	cis	rs2014572	0.967	rs4801452	chr19:57768066	A/G	cg24459738	chr19:57751996	ZNF805	-0.43	-4.9	-0.31	1.83e-6	Hyperactive-impulsive symptoms;
SARC	cis	rs2576037	0.796	rs2576039	chr18:44582148	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.5	6.54	0.39	3.91e-10	Personality dimensions;
SARC	cis	rs6815814	0.898	rs1873195	chr4:38891173	C/T	cg06935464	chr4:38784597	TLR10	0.51	5.09	0.32	7.28e-7	Breast cancer;
SARC	cis	rs6772849	0.930	rs9873888	chr3:128360987	G/A	cg08795948	chr3:128337044	NA	0.55	7.72	0.45	3.52e-13	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg05313129	chr8:58192883	C8orf71	-0.52	-5.96	-0.36	9.41e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9393692	0.905	rs7769028	chr6:26267568	C/T	cg13736514	chr6:26305472	NA	-0.62	-8.7	-0.5	6.1e-16	Educational attainment;
SARC	cis	rs6580649	0.941	rs17122613	chr12:48460016	T/C	cg24011408	chr12:48396354	COL2A1	-0.48	-5.38	-0.33	1.78e-7	Lung cancer;
SARC	trans	rs9354308	0.868	rs6923994	chr6:66555665	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.55	-6.61	-0.4	2.61e-10	Metabolite levels;
SARC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg11494091	chr17:61959527	GH2	0.53	7.98	0.46	6.44e-14	Prudent dietary pattern;
SARC	cis	rs2073300	0.609	rs17830281	chr20:23350525	C/T	cg16736954	chr20:23401023	NAPB	0.78	4.88	0.3	2.01e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs57506017	0.585	rs13230513	chr7:12268243	C/A	cg23422036	chr7:12250390	TMEM106B	0.45	5.87	0.36	1.46e-8	Neuroticism;
SARC	cis	rs2075371	0.897	rs1643033	chr7:134004662	T/C	cg20476274	chr7:133979776	SLC35B4	0.58	7.69	0.45	3.99e-13	Mean platelet volume;
SARC	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg07636037	chr3:49044803	WDR6	0.98	16.79	0.74	5.33e-42	Parkinson's disease;
SARC	cis	rs7647973	0.588	rs9883000	chr3:49667691	A/G	cg07636037	chr3:49044803	WDR6	0.57	5.91	0.36	1.19e-8	Menarche (age at onset);
SARC	cis	rs8044995	0.501	rs7189887	chr16:68353915	C/T	cg09835421	chr16:68378352	PRMT7	-0.64	-5.61	-0.34	5.85e-8	Schizophrenia;
SARC	cis	rs11651753	0.561	rs60580012	chr17:45969808	C/T	cg02219949	chr17:45927392	SP6	0.36	4.95	0.31	1.45e-6	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg18252515	chr7:66147081	NA	-0.65	-6.84	-0.41	7.06e-11	Aortic root size;
SARC	cis	rs7124681	0.584	rs1471712	chr11:47912150	G/A	cg10504702	chr11:47789108	FNBP4	-0.42	-5.35	-0.33	2.12e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
SARC	cis	rs10911232	0.507	rs10797821	chr1:183012559	G/A	cg13390022	chr1:182993471	LAMC1	0.36	5.42	0.33	1.48e-7	Hypertriglyceridemia;
SARC	cis	rs72781680	1.000	rs12616899	chr2:24165235	A/G	cg08917208	chr2:24149416	ATAD2B	0.77	7.19	0.43	8.94e-12	Lymphocyte counts;
SARC	cis	rs112591243	0.685	rs2839282	chr21:47902822	C/G	cg10657630	chr21:48055338	PRMT2	-0.78	-5.14	-0.32	5.84e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs6456156	0.565	rs12529959	chr6:167469292	T/C	cg07741184	chr6:167504864	NA	0.36	7.09	0.42	1.62e-11	Primary biliary cholangitis;
SARC	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg17294928	chr15:75287854	SCAMP5	-0.49	-6.27	-0.38	1.77e-9	Breast cancer;
SARC	cis	rs1976403	0.633	rs1697422	chr1:21821897	T/C	cg17800788	chr1:21766015	NBPF3	0.33	5.52	0.34	9.08e-8	Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs2011503	1.000	rs16996127	chr19:19627310	T/G	cg03709012	chr19:19516395	GATAD2A	0.6	5.33	0.33	2.26e-7	Bipolar disorder;
SARC	cis	rs3820928	0.605	rs7560867	chr2:227780945	C/A	cg11843606	chr2:227700838	RHBDD1	-0.57	-7.51	-0.44	1.26e-12	Pulmonary function;
SARC	cis	rs7954584	0.560	rs745327	chr12:122456524	T/C	cg13699009	chr12:122356056	WDR66	-0.44	-6.09	-0.37	4.69e-9	Mean corpuscular volume;
SARC	trans	rs61931739	0.517	rs10772139	chr12:34186178	A/T	cg13010199	chr12:38710504	ALG10B	0.73	9.71	0.54	6.21e-19	Morning vs. evening chronotype;
SARC	cis	rs6714710	0.603	rs13020776	chr2:98402753	T/A	cg26665480	chr2:98280029	ACTR1B	0.49	6.49	0.39	5.15e-10	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs79976124	0.837	rs74327235	chr6:66648353	T/A	cg07460842	chr6:66804631	NA	0.63	6.82	0.41	7.55e-11	Type 2 diabetes;
SARC	cis	rs950169	0.810	rs2879976	chr15:85109578	G/A	cg24253500	chr15:84953950	NA	0.36	5.18	0.32	4.86e-7	Schizophrenia;
SARC	cis	rs9393777	0.513	rs7759969	chr6:26663096	T/A	cg12826209	chr6:26865740	GUSBL1	0.66	5.89	0.36	1.34e-8	Intelligence (multi-trait analysis);
SARC	cis	rs12594515	1.000	rs12185095	chr15:45994635	G/T	cg14863074	chr15:45997064	NA	0.34	5.11	0.32	6.78e-7	Waist circumference;Weight;
SARC	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg18876405	chr7:65276391	NA	0.71	9.3	0.52	1.09e-17	Calcium levels;
SARC	cis	rs67460515	0.500	rs964533	chr3:160749019	C/A	cg17135325	chr3:160939158	NMD3	0.49	5.91	0.36	1.21e-8	Parkinson's disease;
SARC	cis	rs7089973	0.610	rs34461950	chr10:116728273	C/T	cg08188268	chr10:116634841	FAM160B1	0.42	5.61	0.35	5.63e-8	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.51	6.23	0.38	2.14e-9	Gut microbiome composition (summer);
SARC	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg06634786	chr22:41940651	POLR3H	0.51	5.94	0.36	1.04e-8	Vitiligo;
SARC	cis	rs3784262	1.000	rs11071356	chr15:58240518	T/G	cg12031962	chr15:58353849	ALDH1A2	-0.38	-5.59	-0.34	6.36e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.61	7.4	0.44	2.43e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1371867	0.846	rs1788181	chr8:101334068	C/T	cg11906718	chr8:101322791	RNF19A	0.66	8.65	0.49	8.33e-16	Atrioventricular conduction;
SARC	cis	rs7011049	1.000	rs6988927	chr8:53837496	T/C	cg26025543	chr8:53854495	NA	0.61	5.45	0.34	1.28e-7	Systolic blood pressure;
SARC	cis	rs4972806	0.849	rs2071581	chr2:177026148	G/T	cg03152288	chr2:177042942	NA	0.37	4.75	0.3	3.56e-6	IgG glycosylation;
SARC	cis	rs2115630	0.967	rs12595786	chr15:85336670	T/C	cg17507749	chr15:85114479	UBE2QP1	-0.45	-5.39	-0.33	1.69e-7	P wave terminal force;
SARC	trans	rs11098499	0.954	rs10005644	chr4:120298477	T/C	cg25214090	chr10:38739885	LOC399744	0.55	7.14	0.42	1.15e-11	Corneal astigmatism;
SARC	cis	rs2075371	0.863	rs1421479	chr7:133949345	T/G	cg11752832	chr7:134001865	SLC35B4	0.48	5.85	0.36	1.66e-8	Mean platelet volume;
SARC	cis	rs3741404	0.609	rs635139	chr11:63872210	A/G	cg18225595	chr11:63971243	STIP1	0.4	5.65	0.35	4.71e-8	Platelet count;
SARC	cis	rs9296092	0.517	rs56043172	chr6:33522363	T/G	cg13560919	chr6:33536144	NA	-0.5	-6.31	-0.38	1.38e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg11764359	chr7:65958608	NA	-0.69	-8.08	-0.47	3.43e-14	Aortic root size;
SARC	cis	rs7927771	0.524	rs4539273	chr11:47694699	C/T	cg20307385	chr11:47447363	PSMC3	-0.5	-6.94	-0.41	3.79e-11	Subjective well-being;
SARC	cis	rs6867032	0.958	rs4246754	chr5:2014776	A/C	cg26168224	chr5:2018326	NA	0.84	13.11	0.65	8.77e-30	Gut microbiome composition (winter);
SARC	cis	rs9815354	0.812	rs56983571	chr3:41994473	T/C	cg03022575	chr3:42003672	ULK4	0.72	6.26	0.38	1.79e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg13072238	chr3:49761600	GMPPB	0.46	5.89	0.36	1.34e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7481584	0.626	rs2071103	chr11:3040087	C/T	cg05729581	chr11:3078854	CARS	0.57	7.34	0.43	3.61e-12	Calcium levels;
SARC	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg12292205	chr6:26970375	C6orf41	-0.56	-6.17	-0.37	2.96e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9650315	0.530	rs35399441	chr8:57089431	A/C	cg26371346	chr8:56986568	SNORD54;RPS20	0.49	4.77	0.3	3.31e-6	Height;
SARC	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg08219700	chr8:58056026	NA	-0.57	-5.4	-0.33	1.66e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs11153147	0.649	rs11153145	chr6:109300799	C/T	cg05315195	chr6:109294784	ARMC2	-0.58	-5.25	-0.33	3.41e-7	Mean corpuscular volume;
SARC	cis	rs9398803	0.651	rs979197	chr6:127075696	C/T	cg19875578	chr6:126661172	C6orf173	-0.6	-8.29	-0.48	8.89e-15	Male-pattern baldness;
SARC	cis	rs9316337	0.582	rs2146401	chr13:22018650	C/A	cg21080246	chr13:22033151	ZDHHC20	0.43	5.03	0.31	9.71e-7	Schizophrenia;
SARC	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg09699651	chr6:150184138	LRP11	0.42	5.04	0.31	9.36e-7	Lung cancer;
SARC	cis	rs9487051	0.872	rs9400269	chr6:109606065	C/G	cg01475377	chr6:109611718	NA	-0.41	-5.81	-0.36	2.08e-8	Reticulocyte fraction of red cells;
SARC	cis	rs4718428	0.705	rs28648401	chr7:66367132	T/C	cg18252515	chr7:66147081	NA	-0.56	-6.12	-0.37	3.88e-9	Corneal structure;
SARC	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg11987759	chr7:65425863	GUSB	0.5	6.22	0.38	2.29e-9	Aortic root size;
SARC	cis	rs2228479	0.702	rs62056100	chr16:89939753	C/T	cg06558623	chr16:89946397	TCF25	0.88	6.16	0.37	3.08e-9	Skin colour saturation;
SARC	cis	rs709400	0.663	rs7145113	chr14:103945414	A/G	cg26031613	chr14:104095156	KLC1	0.83	11.96	0.62	5.03e-26	Body mass index;
SARC	cis	rs9787249	0.874	rs12094291	chr1:40226046	G/A	cg24920358	chr1:40204285	PPIE	0.41	4.99	0.31	1.19e-6	Blood protein levels;
SARC	cis	rs6088580	0.634	rs6059824	chr20:33014543	T/C	cg24642439	chr20:33292090	TP53INP2	0.65	8.47	0.49	2.8e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs4971059	0.617	rs12127609	chr1:155133491	G/C	cg22049894	chr1:155113146	DPM3	0.4	4.97	0.31	1.31e-6	Breast cancer;
SARC	trans	rs2018683	0.700	rs13227954	chr7:29017188	A/C	cg19402173	chr7:128379420	CALU	0.55	7.2	0.43	8.04e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs911555	0.755	rs7147664	chr14:103963420	G/A	cg12935359	chr14:103987150	CKB	-0.37	-5.18	-0.32	4.91e-7	Intelligence (multi-trait analysis);
SARC	cis	rs5750830	0.594	rs5757647	chr22:39775047	C/A	cg24399712	chr22:39784796	NA	-0.44	-6.11	-0.37	4.14e-9	Intelligence (multi-trait analysis);
SARC	cis	rs2916247	0.954	rs1484562	chr8:93131247	T/C	cg10183463	chr8:93005414	RUNX1T1	0.5	5.28	0.33	2.93e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg02951883	chr7:2050386	MAD1L1	0.38	4.83	0.3	2.44e-6	Bipolar disorder and schizophrenia;
SARC	trans	rs9388451	0.839	rs4897157	chr6:126102981	A/T	cg05039488	chr6:79577232	IRAK1BP1	-0.57	-7.3	-0.43	4.64e-12	Brugada syndrome;
SARC	cis	rs6860806	0.507	rs270615	chr5:131641573	G/C	cg12564285	chr5:131593104	PDLIM4	0.44	5.98	0.36	8.21e-9	Breast cancer;
SARC	cis	rs2153535	0.580	rs9379213	chr6:8474945	G/A	cg23788917	chr6:8435910	SLC35B3	0.64	8.39	0.48	4.57e-15	Motion sickness;
SARC	cis	rs6542838	0.641	rs4851176	chr2:99534859	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.52	-6.74	-0.4	1.24e-10	Fear of minor pain;
SARC	trans	rs9325144	0.510	rs7952795	chr12:38720686	C/T	cg23762105	chr12:34175262	ALG10	-0.52	-6.82	-0.41	7.91e-11	Morning vs. evening chronotype;
SARC	cis	rs568617	0.768	rs12225345	chr11:65647105	A/G	cg00576331	chr11:65640516	EFEMP2	-0.46	-4.8	-0.3	2.83e-6	Crohn's disease;
SARC	cis	rs858239	0.899	rs1881203	chr7:23292808	T/C	cg23682824	chr7:23144976	KLHL7	0.57	7.19	0.43	8.68e-12	Cerebrospinal fluid biomarker levels;
SARC	cis	rs73206853	0.610	rs73194020	chr12:111131366	G/A	cg10860002	chr12:110842031	ANAPC7	0.63	5.23	0.32	3.79e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs9815354	1.000	rs1716664	chr3:41948378	G/A	cg03022575	chr3:42003672	ULK4	-0.55	-5.22	-0.32	4.05e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs1348850	0.793	rs13027299	chr2:178455501	T/G	cg23306229	chr2:178417860	TTC30B	0.56	6.22	0.38	2.32e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9921222	0.500	rs8046256	chr16:393948	C/T	cg00101154	chr16:420108	MRPL28	-0.57	-7.83	-0.46	1.72e-13	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs7932354	0.528	rs11039105	chr11:47157677	A/T	cg03339077	chr11:47165057	C11orf49	0.41	5.63	0.35	5.18e-8	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg16414030	chr3:133502952	NA	-0.4	-5.45	-0.34	1.25e-7	Iron status biomarkers;
SARC	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg09699651	chr6:150184138	LRP11	0.43	5.28	0.33	2.94e-7	Lung cancer;
SARC	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs11122272	0.735	rs2486746	chr1:231497324	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-10.02	-0.55	6.93e-20	Hemoglobin concentration;
SARC	cis	rs796364	1.000	rs281771	chr2:200812202	A/C	cg23649088	chr2:200775458	C2orf69	-0.62	-5.76	-0.35	2.63e-8	Schizophrenia;
SARC	cis	rs2012796	0.785	rs61986593	chr14:81840659	G/A	cg02996355	chr14:81879375	NA	0.53	5.78	0.35	2.33e-8	Night sleep phenotypes;
SARC	cis	rs6089584	0.507	rs28545731	chr20:60634102	C/T	cg06108461	chr20:60628389	TAF4	-0.67	-8.61	-0.49	1.14e-15	Body mass index;
SARC	cis	rs7659604	0.628	rs3828485	chr4:122722368	G/A	cg19671926	chr4:122722719	EXOSC9	-0.58	-6.49	-0.39	5.21e-10	Type 2 diabetes;
SARC	cis	rs9486719	1.000	rs13210597	chr6:96969694	C/A	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.76	-0.5	3.96e-16	Migraine;Coronary artery disease;
SARC	cis	rs4727027	0.866	rs3927307	chr7:148774869	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	5.97	0.36	8.97e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs1185460	0.967	rs1786685	chr11:118938957	G/A	cg01677386	chr11:118938358	VPS11	-0.39	-4.74	-0.3	3.77e-6	Coronary artery disease;
SARC	cis	rs6981523	0.500	rs4412337	chr8:11072020	C/T	cg12395012	chr8:11607386	GATA4	-0.32	-5.41	-0.33	1.52e-7	Neuroticism;
SARC	cis	rs6121246	0.522	rs6088736	chr20:30195166	C/G	cg21427119	chr20:30132790	HM13	-0.48	-5.29	-0.33	2.84e-7	Mean corpuscular hemoglobin;
SARC	cis	rs67311347	0.544	rs2123998	chr3:40359005	C/G	cg09455208	chr3:40491958	NA	-0.31	-5.12	-0.32	6.29e-7	Renal cell carcinoma;
SARC	trans	rs61931739	0.500	rs3934517	chr12:34451396	T/C	cg13010199	chr12:38710504	ALG10B	0.76	10.71	0.57	5.2e-22	Morning vs. evening chronotype;
SARC	cis	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.42	-5.15	-0.32	5.58e-7	Eosinophil percentage of white cells;
SARC	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	15.03	0.7	3.78e-36	Chronic sinus infection;
SARC	cis	rs8067545	0.586	rs2526463	chr17:20078297	G/A	cg13482628	chr17:19912719	NA	-0.55	-7.18	-0.43	9.03e-12	Schizophrenia;
SARC	cis	rs8079658	1.000	rs72831444	chr17:63815666	A/G	cg03442606	chr17:63822778	CCDC46	-0.39	-4.86	-0.3	2.13e-6	Post bronchodilator FEV1;
SARC	cis	rs17401966	0.838	rs2105212	chr1:10281012	T/C	cg15208524	chr1:10270712	KIF1B	0.46	5.34	0.33	2.16e-7	Hepatocellular carcinoma;
SARC	cis	rs3858526	0.920	rs11039698	chr11:5950907	C/T	cg02574844	chr11:5959923	NA	-0.43	-5.24	-0.32	3.68e-7	DNA methylation (variation);
SARC	cis	rs7772486	0.654	rs4896829	chr6:145953675	T/A	cg23711669	chr6:146136114	FBXO30	0.8	12.51	0.63	8.52e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.76	7.62	0.45	6.36e-13	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs9381040	0.610	rs2268196	chr6:41021950	C/G	cg03644281	chr6:41068752	NFYA;LOC221442	0.41	4.94	0.31	1.51e-6	Alzheimer's disease (late onset);
SARC	cis	rs9467603	1.000	rs6939997	chr6:25821224	C/T	cg21479132	chr6:26055353	NA	0.77	4.86	0.3	2.19e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg00800038	chr16:89945340	TCF25	-0.6	-4.92	-0.31	1.61e-6	Skin colour saturation;
SARC	cis	rs748404	0.587	rs690276	chr15:43704558	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.4	4.85	0.3	2.29e-6	Lung cancer;
SARC	cis	rs67311347	1.000	rs6599102	chr3:40468406	G/A	cg01475735	chr3:40494733	NA	-0.42	-4.93	-0.31	1.55e-6	Renal cell carcinoma;
SARC	cis	rs9291683	0.655	rs3822242	chr4:10094904	T/C	cg00071950	chr4:10020882	SLC2A9	-0.34	-5.22	-0.32	3.97e-7	Bone mineral density;
SARC	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg17971929	chr21:40555470	PSMG1	-0.86	-11.47	-0.6	1.98e-24	Cognitive function;
SARC	cis	rs9291683	0.546	rs7442336	chr4:10045783	G/A	cg00071950	chr4:10020882	SLC2A9	0.33	4.98	0.31	1.26e-6	Bone mineral density;
SARC	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg04944784	chr2:26401820	FAM59B	-0.48	-5.72	-0.35	3.28e-8	Gut microbiome composition (summer);
SARC	cis	rs708547	0.830	rs1713983	chr4:57883084	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.72	9.02	0.51	6.93e-17	Response to bleomycin (chromatid breaks);
SARC	trans	rs2727020	0.729	rs10839283	chr11:49490943	T/C	cg03929089	chr4:120376271	NA	0.77	9.63	0.53	1.1e-18	Coronary artery disease;
SARC	cis	rs4642101	0.618	rs7612317	chr3:12820558	C/T	cg05775895	chr3:12838266	CAND2	0.84	15.68	0.72	2.67e-38	QRS complex (12-leadsum);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg23088989	chr10:38301786	ZNF33A	0.48	6.68	0.4	1.71e-10	Thyroid stimulating hormone;
SARC	cis	rs9807989	0.507	rs2293224	chr2:103035779	T/C	cg03938978	chr2:103052716	IL18RAP	0.32	5.12	0.32	6.49e-7	Asthma;
SARC	cis	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg15556689	chr8:8085844	FLJ10661	0.47	5.69	0.35	3.7e-8	Mood instability;
SARC	cis	rs9640161	0.711	rs55881542	chr7:150025734	G/A	cg10018233	chr7:150070692	REPIN1	0.72	9.38	0.52	5.95e-18	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs6446731	0.593	rs7674472	chr4:3273538	C/G	cg06533319	chr4:3265114	C4orf44	-0.33	-5.3	-0.33	2.74e-7	Mean platelet volume;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg19502122	chr13:45775900	KCTD4;GTF2F2	-0.54	-6.74	-0.4	1.2e-10	Alcohol dependence;
SARC	cis	rs57506017	0.585	rs1468803	chr7:12275675	A/C	cg23422036	chr7:12250390	TMEM106B	0.47	6.08	0.37	4.96e-9	Neuroticism;
SARC	cis	rs2070488	0.775	rs6794397	chr3:38559307	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	11.88	0.61	9.42e-26	Electrocardiographic conduction measures;
SARC	cis	rs10464366	0.544	rs12701697	chr7:39182165	C/T	cg18850127	chr7:39170497	POU6F2	0.39	5.08	0.32	7.68e-7	IgG glycosylation;
SARC	cis	rs6867032	0.527	rs13153217	chr5:2012788	G/T	cg16754747	chr5:1339235	CLPTM1L	0.33	4.78	0.3	3.14e-6	Gut microbiome composition (winter);
SARC	trans	rs11098499	0.863	rs12498539	chr4:120468370	C/T	cg25214090	chr10:38739885	LOC399744	0.57	7.25	0.43	6.27e-12	Corneal astigmatism;
SARC	cis	rs1865760	0.566	rs7772312	chr6:26049616	G/C	cg16482183	chr6:26056742	HIST1H1C	0.49	6.29	0.38	1.6e-9	Height;
SARC	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-4.91	-0.31	1.71e-6	Total body bone mineral density;
SARC	cis	rs9790314	0.663	rs4557202	chr3:160820524	G/C	cg03342759	chr3:160939853	NMD3	-0.59	-7.47	-0.44	1.65e-12	Morning vs. evening chronotype;
SARC	cis	rs1538970	1.000	rs11211101	chr1:45849311	C/G	cg05343316	chr1:45956843	TESK2	0.68	8.18	0.47	1.84e-14	Platelet count;
SARC	cis	rs36051895	0.622	rs10974952	chr9:5079828	A/T	cg02405213	chr9:5042618	JAK2	-0.46	-5.15	-0.32	5.58e-7	Pediatric autoimmune diseases;
SARC	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg11062466	chr8:58055876	NA	0.67	5.84	0.36	1.78e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7582180	0.629	rs11678148	chr2:100966950	A/T	cg14675211	chr2:100938903	LONRF2	0.51	7.51	0.44	1.23e-12	Intelligence (multi-trait analysis);
SARC	cis	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg22496380	chr5:211416	CCDC127	-0.88	-9.32	-0.52	9.29e-18	Breast cancer;
SARC	cis	rs698833	0.852	rs698823	chr2:44720947	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.6	7.66	0.45	5e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs10883723	0.810	rs2296586	chr10:104245575	C/T	cg22532475	chr10:104410764	TRIM8	-0.26	-5.27	-0.33	3.04e-7	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.39	5.6	0.34	5.94e-8	Total body bone mineral density;
SARC	cis	rs2304069	0.817	rs216132	chr5:149431259	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.71	-7.78	-0.45	2.35e-13	HIV-1 control;
SARC	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg20102877	chr2:27665638	KRTCAP3	-0.37	-5.08	-0.32	7.84e-7	Total body bone mineral density;
SARC	cis	rs7769051	0.522	rs7759524	chr6:133109574	A/G	cg22852734	chr6:133119734	C6orf192	1.18	7.85	0.46	1.49e-13	Type 2 diabetes nephropathy;
SARC	cis	rs1018836	0.699	rs13271657	chr8:91474599	C/G	cg16814680	chr8:91681699	NA	-0.74	-11.19	-0.59	1.57e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs9868809	0.772	rs73078349	chr3:48688114	G/A	cg00383909	chr3:49044727	WDR6	0.69	5.15	0.32	5.54e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg08677398	chr8:58056175	NA	0.48	4.78	0.3	3.07e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs10504073	0.584	rs4873300	chr8:49902201	C/G	cg00325661	chr8:49890786	NA	0.52	6.9	0.41	4.88e-11	Blood metabolite ratios;
SARC	cis	rs1448094	0.556	rs4897831	chr12:86168248	C/T	cg00310523	chr12:86230176	RASSF9	0.32	5.06	0.31	8.7e-7	Major depressive disorder;
SARC	cis	rs9640161	0.830	rs13307276	chr7:150061525	T/C	cg17279839	chr7:150038598	RARRES2	0.34	5.08	0.32	7.91e-7	Blood protein levels;Circulating chemerin levels;
SARC	trans	rs1814175	0.715	rs11040586	chr11:49858432	T/A	cg15704280	chr7:45808275	SEPT13	-0.96	-18.1	-0.76	2.52e-46	Height;
SARC	cis	rs4481887	0.741	rs6587462	chr1:248539094	C/T	cg00666640	chr1:248458726	OR2T12	-0.34	-5.94	-0.36	1.02e-8	Common traits (Other);
SARC	cis	rs1707322	1.000	rs11211204	chr1:46317864	A/G	cg03146154	chr1:46216737	IPP	0.47	5.65	0.35	4.76e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs807669	0.807	rs698422	chr22:19205826	A/T	cg02655711	chr22:19163373	SLC25A1	0.41	5.78	0.35	2.43e-8	Metabolite levels;
SARC	cis	rs6546550	0.901	rs1979214	chr2:70137498	G/C	cg02498382	chr2:70120550	SNRNP27	-0.31	-5.04	-0.31	9.3e-7	Prevalent atrial fibrillation;
SARC	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg00684032	chr4:1343700	KIAA1530	0.34	5.2	0.32	4.4e-7	Obesity-related traits;
SARC	cis	rs6866344	0.697	rs11742808	chr5:178131658	G/A	cg03877680	chr5:178157825	ZNF354A	1.03	12.86	0.64	5.82e-29	Neutrophil percentage of white cells;
SARC	cis	rs4803468	1.000	rs10422956	chr19:41901261	C/T	cg14132834	chr19:41945861	ATP5SL	-0.56	-7.41	-0.44	2.28e-12	Height;
SARC	cis	rs1448094	0.549	rs7297996	chr12:86235899	C/T	cg02569458	chr12:86230093	RASSF9	0.39	5.48	0.34	1.11e-7	Major depressive disorder;
SARC	cis	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg18252515	chr7:66147081	NA	-1.3	-11.12	-0.59	2.58e-23	Diabetic kidney disease;
SARC	cis	rs2916247	0.954	rs16914736	chr8:93082043	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.64	-6.87	-0.41	5.71e-11	Intelligence (multi-trait analysis);
SARC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg04234412	chr22:24373322	LOC391322	-0.64	-8.58	-0.49	1.32e-15	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6687430	0.562	rs12139169	chr1:10635328	C/T	cg17425144	chr1:10567563	PEX14	0.33	4.87	0.3	2.06e-6	Hand grip strength;
SARC	cis	rs2952156	0.920	rs732083	chr17:37834367	G/A	cg07936489	chr17:37558343	FBXL20	-0.41	-5.29	-0.33	2.82e-7	Asthma;
SARC	cis	rs16854884	0.586	rs7634145	chr3:143754150	G/A	cg06585982	chr3:143692056	C3orf58	0.7	9.83	0.54	2.77e-19	Economic and political preferences (feminism/equality);
SARC	trans	rs4332037	0.539	rs11764780	chr7:2020904	G/C	cg11693508	chr17:37793320	STARD3	0.64	6.42	0.39	7.64e-10	Bipolar disorder;
SARC	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg25214090	chr10:38739885	LOC399744	0.54	7.2	0.43	8.07e-12	Corneal astigmatism;
SARC	cis	rs2075371	0.897	rs1643033	chr7:134004662	T/C	cg00033643	chr7:134001901	SLC35B4	0.52	6.46	0.39	6.08e-10	Mean platelet volume;
SARC	cis	rs9303401	0.659	rs36109237	chr17:56653834	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	11.65	0.61	5.15e-25	Cognitive test performance;
SARC	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	11.03	0.59	4.93e-23	Alzheimer's disease;
SARC	cis	rs4642101	0.793	rs12714880	chr3:12832101	G/A	cg12400702	chr3:12838781	CAND2	-0.26	-5.23	-0.32	3.7e-7	QRS complex (12-leadsum);
SARC	cis	rs1707322	0.656	rs3014210	chr1:46066608	A/G	cg03146154	chr1:46216737	IPP	-0.5	-5.79	-0.35	2.23e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6665290	0.901	rs61834004	chr1:227202782	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.08	-23.75	-0.84	3.76e-64	Myeloid white cell count;
SARC	cis	rs10463554	0.963	rs187427	chr5:102512803	C/T	cg23492399	chr5:102201601	PAM	-0.51	-5.55	-0.34	7.76e-8	Parkinson's disease;
SARC	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg00152838	chr16:24741724	TNRC6A	-0.59	-6.19	-0.38	2.75e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7020830	0.898	rs12000309	chr9:37230844	G/A	cg14294708	chr9:37120828	ZCCHC7	1.11	20.34	0.8	1.43e-53	Schizophrenia;
SARC	cis	rs36051895	0.632	rs62541945	chr9:5161571	T/C	cg02405213	chr9:5042618	JAK2	-0.45	-5.02	-0.31	1.01e-6	Pediatric autoimmune diseases;
SARC	cis	rs848	0.500	rs2158177	chr5:131984058	C/T	cg11797159	chr5:131991491	NA	-0.4	-5.19	-0.32	4.68e-7	Alopecia areata;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg06618935	chr21:46677482	NA	-0.38	-5.03	-0.31	9.7e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs11168351	0.591	rs4258439	chr12:48468652	A/G	cg21466736	chr12:48725269	NA	0.31	5.37	0.33	1.95e-7	Bipolar disorder and schizophrenia;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg21331461	chr12:21927773	KCNJ8	-0.5	-6.43	-0.39	7.23e-10	Chemerin levels;
SARC	cis	rs60871478	1.000	rs12531530	chr7:827366	T/C	cg05535760	chr7:792225	HEATR2	0.84	8.24	0.47	1.26e-14	Cerebrospinal P-tau181p levels;
SARC	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs3762637	1.000	rs78381804	chr3:122222262	A/T	cg24169773	chr3:122142474	KPNA1	-0.58	-5.96	-0.36	9.17e-9	LDL cholesterol levels;
SARC	cis	rs10463554	0.892	rs32842	chr5:102478002	A/G	cg23492399	chr5:102201601	PAM	-0.52	-5.67	-0.35	4.14e-8	Parkinson's disease;
SARC	trans	rs9388451	0.772	rs1268064	chr6:126042578	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.52	6.72	0.4	1.42e-10	Brugada syndrome;
SARC	cis	rs651907	0.557	rs36002990	chr3:101437862	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	6.39	0.39	8.85e-10	Colorectal cancer;
SARC	cis	rs41271473	0.526	rs10916343	chr1:228727961	C/T	cg10167378	chr1:228756711	NA	0.6	5.3	0.33	2.69e-7	Chronic lymphocytic leukemia;
SARC	cis	rs11190604	1.000	rs11190601	chr10:102296730	A/G	cg07080220	chr10:102295463	HIF1AN	0.8	9.44	0.53	3.91e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs6999452	0.967	rs2957454	chr8:106368346	A/C	cg12032713	chr8:106369363	ZFPM2	-0.3	-4.87	-0.3	2.06e-6	Gut microbiome composition (summer);
SARC	trans	rs8073060	0.586	rs225280	chr17:33976296	C/T	cg19694781	chr19:47549865	TMEM160	-0.68	-6.86	-0.41	6.05e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg18404041	chr3:52824283	ITIH1	-0.44	-6.7	-0.4	1.58e-10	Bipolar disorder;
SARC	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg11062466	chr8:58055876	NA	0.53	5.16	0.32	5.35e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9916302	0.904	rs8076494	chr17:37516722	A/G	cg07936489	chr17:37558343	FBXL20	0.67	8.13	0.47	2.59e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs6088813	0.961	rs6060373	chr20:33914208	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	-0.43	-5.2	-0.32	4.27e-7	Height;
SARC	cis	rs12950390	0.853	rs11079790	chr17:45853626	G/A	cg24803719	chr17:45855879	NA	-0.48	-7.82	-0.46	1.84e-13	IgG glycosylation;
SARC	cis	rs67311347	1.000	rs4973878	chr3:40407565	C/T	cg24209194	chr3:40518798	ZNF619	0.59	7.46	0.44	1.69e-12	Renal cell carcinoma;
SARC	cis	rs7772486	0.754	rs6937661	chr6:146113299	T/C	cg05347473	chr6:146136440	FBXO30	-0.55	-7.84	-0.46	1.6e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg11965913	chr1:205819406	PM20D1	0.59	7.74	0.45	3.05e-13	Menarche (age at onset);
SARC	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg18252515	chr7:66147081	NA	-1.33	-11.96	-0.62	5.03e-26	Diabetic kidney disease;
SARC	cis	rs10895987	1.000	rs9971407	chr11:64898226	C/T	cg21152694	chr11:64885413	ZNHIT2	-0.44	-4.79	-0.3	2.97e-6	Blood protein levels;
SARC	cis	rs910316	1.000	rs12589876	chr14:75544189	G/A	cg06637938	chr14:75390232	RPS6KL1	0.56	7.89	0.46	1.2e-13	Height;
SARC	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg18252515	chr7:66147081	NA	-1.29	-11.32	-0.6	5.72e-24	Diabetic kidney disease;
SARC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.5	6.42	0.39	7.41e-10	Lymphocyte counts;
SARC	cis	rs9910055	0.571	rs10208	chr17:42300278	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.46	5.95	0.36	9.54e-9	Total body bone mineral density;
SARC	cis	rs9326248	0.581	rs10892076	chr11:116988936	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.69	8.87	0.5	1.95e-16	Blood protein levels;
SARC	cis	rs472402	0.623	rs7727273	chr5:6635933	A/C	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.39	-4.86	-0.3	2.18e-6	Response to amphetamines;
SARC	cis	rs9788682	0.747	rs11637630	chr15:78899719	G/A	cg06917634	chr15:78832804	PSMA4	0.45	5.03	0.31	9.84e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs933688	1.000	rs985434	chr5:90744509	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.0	12.52	0.63	7.66e-28	Smoking behavior;
SARC	cis	rs11122272	0.614	rs78172021	chr1:231525160	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs4430311	0.723	rs1809247	chr1:243882064	C/T	cg21452805	chr1:244014465	NA	-0.42	-5.42	-0.33	1.52e-7	Post-traumatic stress disorder (asjusted for relatedness);
SARC	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg00933542	chr6:150070202	PCMT1	0.33	5.7	0.35	3.61e-8	Lung cancer;
SARC	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	11.56	0.6	9.64e-25	Alzheimer's disease;
SARC	trans	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg10343233	chr15:40987673	RAD51	-0.51	-6.44	-0.39	6.71e-10	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4268898	0.662	rs56006260	chr2:24409903	A/G	cg06627628	chr2:24431161	ITSN2	-0.8	-9.58	-0.53	1.49e-18	Asthma;
SARC	cis	rs2011503	0.941	rs72999063	chr19:19380596	G/T	cg03709012	chr19:19516395	GATAD2A	0.61	5.39	0.33	1.68e-7	Bipolar disorder;
SARC	cis	rs4595586	0.545	rs7136002	chr12:39369168	G/A	cg26384229	chr12:38710491	ALG10B	0.51	6.25	0.38	1.9e-9	Morning vs. evening chronotype;
SARC	cis	rs7927771	0.524	rs4539273	chr11:47694699	C/T	cg05585544	chr11:47624801	NA	-0.32	-4.84	-0.3	2.32e-6	Subjective well-being;
SARC	cis	rs1008375	0.966	rs4235392	chr4:17696422	A/G	cg27347728	chr4:17578864	LAP3	0.44	5.67	0.35	4.13e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs921968	0.540	rs6746040	chr2:219588890	G/T	cg02176678	chr2:219576539	TTLL4	-0.33	-5.02	-0.31	1.02e-6	Mean corpuscular hemoglobin concentration;
SARC	trans	rs7927370	1.000	rs55647117	chr11:55340896	A/C	cg07162727	chr16:4848039	ROGDI	0.85	6.42	0.39	7.45e-10	Systemic lupus erythematosus;
SARC	cis	rs2997447	0.761	rs2783622	chr1:26458990	A/T	cg19633962	chr1:26362018	EXTL1	-0.6	-5.53	-0.34	8.53e-8	QRS complex (12-leadsum);
SARC	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg17971929	chr21:40555470	PSMG1	-0.56	-7.11	-0.42	1.37e-11	Menarche (age at onset);
SARC	cis	rs1949733	0.598	rs869602	chr4:8535371	G/T	cg11789530	chr4:8429930	ACOX3	-0.56	-6.18	-0.38	2.77e-9	Response to antineoplastic agents;
SARC	cis	rs11718455	0.960	rs34179760	chr3:44002303	A/G	cg21419209	chr3:44054225	NA	-0.42	-5.05	-0.31	8.76e-7	Coronary artery disease;
SARC	cis	rs963731	0.649	rs10439459	chr2:39236983	G/T	cg04010122	chr2:39346883	SOS1	-0.92	-5.46	-0.34	1.24e-7	Corticobasal degeneration;
SARC	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.28	5.22	0.32	3.95e-7	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6997458	0.742	rs3758076	chr8:86375535	G/C	cg21346043	chr8:86351067	CA3	-0.35	-4.8	-0.3	2.78e-6	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs7551222	0.663	rs1563828	chr1:204516577	A/G	cg20240347	chr1:204465584	NA	-0.33	-5.85	-0.36	1.68e-8	Schizophrenia;
SARC	cis	rs2834188	1.000	rs1018741	chr21:34686345	G/A	cg14352951	chr21:34696688	IFNAR1	0.45	5.49	0.34	1.05e-7	Narcolepsy;
SARC	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg15506890	chr2:3487001	NA	-0.48	-6.4	-0.39	8.25e-10	Neurofibrillary tangles;
SARC	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg06221963	chr1:154839813	KCNN3	-0.5	-8.07	-0.47	3.68e-14	Prostate cancer;
SARC	cis	rs644799	0.965	rs502521	chr11:95533557	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	14.99	0.7	5.07e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9399137	0.507	rs11759077	chr6:135381351	A/G	cg22676075	chr6:135203613	NA	0.4	5.01	0.31	1.09e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs9916302	0.904	rs7216086	chr17:37709422	G/A	cg20243544	chr17:37824526	PNMT	0.56	6.71	0.4	1.46e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs743757	0.878	rs1467913	chr3:50525017	G/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.52	5.03	0.31	9.79e-7	Diastolic blood pressure;
SARC	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg22496380	chr5:211416	CCDC127	-0.85	-8.75	-0.5	4.45e-16	Breast cancer;
SARC	trans	rs6934651	0.529	rs9444314	chr6:85953339	G/T	cg04848555	chr14:53975804	NA	0.67	6.48	0.39	5.45e-10	Breast cancer;
SARC	cis	rs5753618	0.561	rs1858821	chr22:31676454	T/C	cg07713946	chr22:31675144	LIMK2	-0.38	-5.32	-0.33	2.44e-7	Colorectal cancer;
SARC	cis	rs2730245	0.569	rs1188955	chr7:158690866	A/G	cg11945929	chr7:158750384	NA	0.33	4.98	0.31	1.24e-6	Height;
SARC	cis	rs9457247	1.000	rs398278	chr6:167388169	A/G	cg23791538	chr6:167370224	RNASET2	-0.61	-8.48	-0.49	2.65e-15	Crohn's disease;
SARC	cis	rs4742903	0.935	rs7872170	chr9:106957103	G/A	cg14250997	chr9:106856677	SMC2	0.44	5.52	0.34	9.08e-8	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs2075371	0.829	rs1993058	chr7:133930361	G/A	cg20476274	chr7:133979776	SLC35B4	0.53	6.78	0.41	9.88e-11	Mean platelet volume;
SARC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg23034840	chr1:205782522	SLC41A1	0.78	11.54	0.6	1.19e-24	Monocyte percentage of white cells;
SARC	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg16325326	chr1:53192061	ZYG11B	-0.95	-17.89	-0.76	1.25e-45	Monocyte count;
SARC	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg11062466	chr8:58055876	NA	0.61	5.75	0.35	2.74e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6582630	0.512	rs11181007	chr12:38266700	C/T	cg14851346	chr12:38532713	NA	-0.45	-5.29	-0.33	2.86e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg25427524	chr10:38739819	LOC399744	0.57	9.08	0.51	4.6e-17	Extrinsic epigenetic age acceleration;
SARC	cis	rs617791	0.508	rs10896074	chr11:65776304	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.62	7.64	0.45	5.75e-13	Breast cancer;
SARC	cis	rs11578119	0.898	rs11577004	chr1:170440622	C/T	cg09767346	chr1:170501363	GORAB	0.45	5.25	0.33	3.42e-7	Male-pattern baldness;
SARC	cis	rs67311347	0.956	rs4974029	chr3:40521318	C/G	cg01475735	chr3:40494733	NA	-0.47	-5.43	-0.34	1.4e-7	Renal cell carcinoma;
SARC	cis	rs79976124	0.879	rs12213669	chr6:66627704	G/A	cg07460842	chr6:66804631	NA	0.66	7.06	0.42	1.9e-11	Type 2 diabetes;
SARC	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg21171335	chr12:122356390	WDR66	-0.41	-6.68	-0.4	1.77e-10	Mean corpuscular volume;
SARC	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg00684032	chr4:1343700	KIAA1530	0.37	5.32	0.33	2.49e-7	Obesity-related traits;
SARC	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg16479474	chr6:28041457	NA	0.37	5.44	0.34	1.37e-7	Depression;
SARC	cis	rs12079745	0.793	rs12082748	chr1:169116247	T/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.84	-5.38	-0.33	1.79e-7	QT interval;
SARC	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.95	9.52	0.53	2.38e-18	Platelet count;
SARC	cis	rs9747201	0.963	rs4789729	chr17:80146089	G/A	cg09264619	chr17:80180166	NA	-0.51	-5.96	-0.36	9.16e-9	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg06212747	chr3:49208901	KLHDC8B	0.67	8.89	0.5	1.72e-16	Parkinson's disease;
SARC	cis	rs3126085	0.825	rs11204933	chr1:152172185	C/T	cg03465714	chr1:152285911	FLG	-0.47	-5.56	-0.34	7.45e-8	Atopic dermatitis;
SARC	cis	rs2834188	1.000	rs2409488	chr21:34688914	A/C	cg14352951	chr21:34696688	IFNAR1	0.45	5.41	0.33	1.54e-7	Narcolepsy;
SARC	cis	rs13314892	0.764	rs1549745	chr3:69851305	T/C	cg17445875	chr3:69859618	MITF	-0.49	-5.09	-0.32	7.54e-7	QRS complex (12-leadsum);
SARC	cis	rs796364	0.950	rs56155997	chr2:200768491	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.73	-6.1	-0.37	4.36e-9	Schizophrenia;
SARC	cis	rs17345786	0.511	rs1138818	chr3:101399583	C/G	cg12386194	chr3:101231763	SENP7	0.5	5.99	0.37	7.81e-9	Colonoscopy-negative controls vs population controls;
SARC	cis	rs11098499	0.722	rs7673476	chr4:120248683	C/T	cg09307838	chr4:120376055	NA	0.73	9.74	0.54	4.97e-19	Corneal astigmatism;
SARC	cis	rs2075371	1.000	rs1868783	chr7:133975087	A/G	cg11752832	chr7:134001865	SLC35B4	0.57	7.45	0.44	1.81e-12	Mean platelet volume;
SARC	cis	rs1707322	1.000	rs11211200	chr1:46288352	A/G	cg03146154	chr1:46216737	IPP	0.46	5.41	0.33	1.57e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	10.04	0.55	6.12e-20	Platelet count;
SARC	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg07308232	chr7:1071921	C7orf50	-0.53	-6.39	-0.39	8.89e-10	Longevity;Endometriosis;
SARC	cis	rs4764124	0.652	rs6488712	chr12:14939332	G/A	cg19759883	chr12:14956454	WBP11;C12orf60	0.64	8.54	0.49	1.73e-15	Pubertal anthropometrics;
SARC	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg24549020	chr5:56110836	MAP3K1	0.81	8.4	0.48	4.37e-15	Initial pursuit acceleration;
SARC	cis	rs514406	0.505	rs835609	chr1:53170494	T/C	cg24675658	chr1:53192096	ZYG11B	-0.66	-9.73	-0.54	5.31e-19	Monocyte count;
SARC	cis	rs7481584	0.624	rs449164	chr11:3053454	C/T	cg05729581	chr11:3078854	CARS	0.58	7.64	0.45	5.63e-13	Calcium levels;
SARC	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg16049864	chr8:95962084	TP53INP1	-0.44	-7.15	-0.42	1.14e-11	Type 2 diabetes;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg06111627	chr3:127309564	TPRA1	-0.54	-6.87	-0.41	5.69e-11	Height;
SARC	cis	rs1448094	0.512	rs2405632	chr12:86252456	A/G	cg02569458	chr12:86230093	RASSF9	0.38	5.26	0.33	3.31e-7	Major depressive disorder;
SARC	cis	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg11608241	chr8:8085544	FLJ10661	-0.39	-4.77	-0.3	3.26e-6	Joint mobility (Beighton score);
SARC	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.79	7.86	0.46	1.43e-13	Age-related macular degeneration (geographic atrophy);
SARC	trans	rs11098499	0.863	rs3775845	chr4:120432447	T/C	cg25214090	chr10:38739885	LOC399744	0.58	7.35	0.43	3.33e-12	Corneal astigmatism;
SARC	cis	rs2050392	0.590	rs303433	chr10:30714963	A/T	cg25182066	chr10:30743637	MAP3K8	0.43	5.8	0.36	2.17e-8	Inflammatory bowel disease;
SARC	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg23262073	chr20:60523788	NA	-0.39	-5.67	-0.35	4.2e-8	Body mass index;
SARC	cis	rs12249377	0.519	rs66650915	chr10:92592468	T/C	cg14313238	chr10:92632228	RPP30	0.43	5.1	0.32	7.02e-7	White matter microstructure (global fractional anisotropy);
SARC	cis	rs1538970	0.962	rs2185549	chr1:45814103	C/T	cg16078521	chr1:45672383	ZSWIM5	-0.46	-4.92	-0.31	1.66e-6	Platelet count;
SARC	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.05	13.16	0.65	6.14e-30	Smoking behavior;
SARC	cis	rs9796	0.870	rs2412574	chr15:41259707	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.41	-5.74	-0.35	2.88e-8	Menopause (age at onset);
SARC	cis	rs1865760	0.865	rs1436306	chr6:25948421	A/G	cg18357526	chr6:26021779	HIST1H4A	0.4	4.91	0.31	1.74e-6	Height;
SARC	cis	rs4737010	0.501	rs12548116	chr8:41645074	A/G	cg08923054	chr8:41654455	ANK1	0.68	8.17	0.47	1.94e-14	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
SARC	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg18404041	chr3:52824283	ITIH1	-0.36	-5.37	-0.33	1.94e-7	Electroencephalogram traits;
SARC	cis	rs1008375	0.966	rs2302393	chr4:17654341	G/A	cg02297831	chr4:17616191	MED28	0.49	6.33	0.38	1.24e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg19418458	chr7:158789849	NA	-0.46	-6.48	-0.39	5.33e-10	Facial morphology (factor 20);
SARC	cis	rs7740797	0.791	rs9384245	chr6:155160128	T/C	cg02865717	chr6:155053990	RBM16	0.33	4.8	0.3	2.83e-6	Colorectal or endometrial cancer;
SARC	cis	rs12079745	0.590	rs3766088	chr1:169268692	A/T	cg09363564	chr1:169337483	NME7;BLZF1	0.99	5.3	0.33	2.63e-7	QT interval;
SARC	cis	rs2991971	0.967	rs6661321	chr1:45954599	C/G	cg24296786	chr1:45957014	TESK2	0.64	9.27	0.52	1.28e-17	High light scatter reticulocyte count;
SARC	cis	rs4481887	0.741	rs6681758	chr1:248540413	T/A	cg13385794	chr1:248469461	NA	0.35	5.62	0.35	5.4e-8	Common traits (Other);
SARC	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg17971929	chr21:40555470	PSMG1	0.6	7.66	0.45	4.94e-13	Menarche (age at onset);
SARC	cis	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg14019146	chr3:50243930	SLC38A3	0.31	4.83	0.3	2.44e-6	Body mass index;
SARC	cis	rs651907	0.535	rs34161138	chr3:101510388	T/C	cg12386194	chr3:101231763	SENP7	0.48	5.54	0.34	7.97e-8	Colorectal cancer;
SARC	cis	rs7674212	0.512	rs2720462	chr4:104056210	T/G	cg16532752	chr4:104119610	CENPE	-0.46	-5.66	-0.35	4.41e-8	Type 2 diabetes;
SARC	cis	rs365132	0.875	rs353494	chr5:176431759	C/G	cg16309518	chr5:176445507	NA	-0.49	-6.3	-0.38	1.46e-9	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs12311304	1.000	rs12311304	chr12:15389637	T/C	cg08258403	chr12:15378311	NA	0.46	7.1	0.42	1.47e-11	Behavioural disinhibition (generation interaction);
SARC	cis	rs2070488	0.965	rs4679053	chr3:38523495	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	13.63	0.67	1.66e-31	Electrocardiographic conduction measures;
SARC	cis	rs4561483	0.801	rs33660	chr16:11961858	A/G	cg08843971	chr16:11963173	GSPT1	-0.44	-5.47	-0.34	1.17e-7	Testicular germ cell tumor;
SARC	cis	rs637571	0.522	rs542332	chr11:65744421	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.43	-5.36	-0.33	2e-7	Eosinophil percentage of white cells;
SARC	cis	rs1538970	0.774	rs67683090	chr1:45977803	T/G	cg05343316	chr1:45956843	TESK2	0.81	8.78	0.5	3.47e-16	Platelet count;
SARC	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg08859206	chr1:53392774	SCP2	0.43	6.22	0.38	2.31e-9	Monocyte count;
SARC	cis	rs742614	0.533	rs2626547	chr20:32404921	G/A	cg06304546	chr20:32448765	NA	-0.55	-6.91	-0.41	4.46e-11	Stearic acid (18:0) levels;
SARC	cis	rs2576037	1.000	rs2576037	chr18:44585420	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.55	7.11	0.42	1.43e-11	Personality dimensions;
SARC	cis	rs74181299	0.653	rs2723091	chr2:65302017	C/T	cg20592124	chr2:65290738	CEP68	0.37	5.07	0.32	8.13e-7	Pulse pressure;
SARC	cis	rs4718428	0.662	rs34577323	chr7:66310041	G/C	cg18252515	chr7:66147081	NA	-0.58	-6.32	-0.38	1.29e-9	Corneal structure;
SARC	cis	rs8031584	0.918	rs35396566	chr15:31263057	T/C	cg08109568	chr15:31115862	NA	-0.45	-5.13	-0.32	6.01e-7	Huntington's disease progression;
SARC	cis	rs9611519	0.894	rs8136923	chr22:41470522	G/A	cg03806693	chr22:41940476	POLR3H	-0.59	-7.34	-0.43	3.44e-12	Neuroticism;
SARC	cis	rs8028182	0.636	rs4886712	chr15:75812888	C/T	cg20655648	chr15:75932815	IMP3	0.64	7.41	0.44	2.38e-12	Sudden cardiac arrest;
SARC	cis	rs698761	0.505	rs7609180	chr2:44538484	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.62	6.79	0.41	9.23e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg22465281	chr5:65017296	NLN;SGTB	-0.77	-7.03	-0.42	2.27e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg06636001	chr8:8085503	FLJ10661	0.65	8.91	0.5	1.5e-16	Mood instability;
SARC	cis	rs1983891	0.774	rs6935446	chr6:41514372	A/G	cg15051332	chr6:41514432	FOXP4	0.54	5.76	0.35	2.59e-8	Prostate cancer;
SARC	cis	rs453301	0.598	rs2921383	chr8:8892221	C/T	cg15556689	chr8:8085844	FLJ10661	0.4	5.12	0.32	6.45e-7	Joint mobility (Beighton score);
SARC	cis	rs3540	0.597	rs4932346	chr15:91048991	T/C	cg22089800	chr15:90895588	ZNF774	-0.6	-7.58	-0.44	8.16e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs7044106	0.791	rs4836830	chr9:123483668	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.72	9.02	0.51	7.1e-17	Hip circumference adjusted for BMI;
SARC	cis	rs11098499	0.866	rs3756156	chr4:120524841	G/A	cg09307838	chr4:120376055	NA	0.83	11.31	0.6	6.28e-24	Corneal astigmatism;
SARC	cis	rs733592	0.507	rs3825403	chr12:48457159	G/A	cg24011408	chr12:48396354	COL2A1	-0.51	-7.1	-0.42	1.49e-11	Plateletcrit;
SARC	cis	rs1008375	0.931	rs10008337	chr4:17593849	G/C	cg16339924	chr4:17578868	LAP3	0.68	8.85	0.5	2.27e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9902453	0.967	rs61014003	chr17:28485233	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	6.66	0.4	1.91e-10	Coffee consumption (cups per day);
SARC	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg06221963	chr1:154839813	KCNN3	0.49	7.76	0.45	2.64e-13	Prostate cancer;
SARC	cis	rs6840360	0.615	rs3828546	chr4:152679816	A/G	cg22705602	chr4:152727874	NA	-0.49	-8.47	-0.49	2.73e-15	Intelligence (multi-trait analysis);
SARC	cis	rs7560272	0.538	rs13014700	chr2:73920121	C/G	cg20560298	chr2:73613845	ALMS1	0.47	6.29	0.38	1.59e-9	Schizophrenia;
SARC	cis	rs2228479	0.850	rs2238532	chr16:89863672	T/C	cg00800038	chr16:89945340	TCF25	-0.83	-5.76	-0.35	2.65e-8	Skin colour saturation;
SARC	cis	rs2777491	0.957	rs7163788	chr15:41704789	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.82	-12.42	-0.63	1.63e-27	Ulcerative colitis;
SARC	cis	rs6964587	0.839	rs2049314	chr7:91464134	C/T	cg17063962	chr7:91808500	NA	0.83	11.85	0.61	1.19e-25	Breast cancer;
SARC	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg18876405	chr7:65276391	NA	0.47	5.73	0.35	3.09e-8	Aortic root size;
SARC	cis	rs9303401	0.659	rs3809724	chr17:57061238	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.08	10.98	0.58	6.99e-23	Cognitive test performance;
SARC	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg02841227	chr6:26021843	HIST1H4A	0.68	8.21	0.47	1.54e-14	Intelligence (multi-trait analysis);
SARC	cis	rs9300255	0.602	rs2695476	chr12:123694206	T/C	cg00376283	chr12:123451042	ABCB9	0.58	5.7	0.35	3.65e-8	Neutrophil percentage of white cells;
SARC	cis	rs7529073	0.815	rs1431982	chr1:214149061	T/G	cg24083324	chr1:214162604	PROX1	-0.43	-6.39	-0.39	8.74e-10	Schizophrenia;
SARC	trans	rs7937682	0.961	rs17113227	chr11:111620491	A/G	cg18187862	chr3:45730750	SACM1L	0.58	7.32	0.43	3.89e-12	Primary sclerosing cholangitis;
SARC	cis	rs208520	0.633	rs7738469	chr6:66807446	T/C	cg07460842	chr6:66804631	NA	-1.08	-15.01	-0.7	4.51e-36	Exhaled nitric oxide output;
SARC	cis	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg12591125	chr7:1885375	MAD1L1	0.47	4.99	0.31	1.18e-6	Bipolar disorder;
SARC	cis	rs5753618	0.561	rs2283881	chr22:31638932	G/A	cg02404636	chr22:31891804	SFI1	-0.48	-5.14	-0.32	5.93e-7	Colorectal cancer;
SARC	cis	rs13191362	0.507	rs2849518	chr6:163134248	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.48	-5.17	-0.32	5.01e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2977993	1	rs2977993	chr9:131608786	G/A	cg00228799	chr9:131580591	ENDOG	0.57	6.98	0.42	3e-11	Schizophrenia;
SARC	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg03806693	chr22:41940476	POLR3H	0.87	11.46	0.6	2.15e-24	Vitiligo;
SARC	cis	rs7044106	0.762	rs10491783	chr9:123450155	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	8.99	0.51	9.01e-17	Hip circumference adjusted for BMI;
SARC	cis	rs7740797	0.967	rs2351845	chr6:155140291	T/C	cg02865717	chr6:155053990	RBM16	-0.35	-4.79	-0.3	2.99e-6	Colorectal or endometrial cancer;
SARC	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	5.7	0.35	3.58e-8	Bipolar disorder;
SARC	cis	rs36051895	0.659	rs12348771	chr9:5083634	T/C	cg02405213	chr9:5042618	JAK2	-0.46	-5.31	-0.33	2.51e-7	Pediatric autoimmune diseases;
SARC	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg04944784	chr2:26401820	FAM59B	0.6	7.95	0.46	8.14e-14	Gut microbiome composition (summer);
SARC	cis	rs16976116	0.901	rs1050931	chr15:55497691	G/A	cg11288833	chr15:55489084	RSL24D1	0.63	6.13	0.37	3.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg12311346	chr5:56204834	C5orf35	-0.57	-5.87	-0.36	1.52e-8	Initial pursuit acceleration;
SARC	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg06384055	chr11:17099234	RPS13	-0.49	-6.28	-0.38	1.68e-9	Thyroid cancer;
SARC	cis	rs6582630	0.533	rs4103689	chr12:38702980	A/C	cg26384229	chr12:38710491	ALG10B	0.6	8.02	0.47	5.03e-14	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6545883	0.524	rs2694619	chr2:61536901	C/T	cg10580144	chr2:61372316	C2orf74	-0.37	-4.91	-0.31	1.71e-6	Tuberculosis;
SARC	cis	rs709400	0.628	rs7146506	chr14:103924477	A/G	cg12935359	chr14:103987150	CKB	-0.4	-5.83	-0.36	1.88e-8	Body mass index;
SARC	cis	rs2268241	0.938	rs2300373	chr21:34788739	A/T	cg14850771	chr21:34775459	IFNGR2	0.99	8.76	0.5	4.18e-16	Obesity-related traits;
SARC	cis	rs478304	0.654	rs10896034	chr11:65460783	T/A	cg27068330	chr11:65405492	SIPA1	-0.41	-4.85	-0.3	2.28e-6	Acne (severe);
SARC	cis	rs77372450	0.636	rs28621556	chr5:156997323	C/G	cg23851860	chr5:157002805	ADAM19	0.51	4.85	0.3	2.24e-6	Bipolar disorder (body mass index interaction);
SARC	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg25036284	chr2:26402008	FAM59B	-0.45	-5.61	-0.34	5.83e-8	Gut microbiome composition (summer);
SARC	cis	rs9359856	0.564	rs72913975	chr6:90387116	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.61	-4.79	-0.3	2.93e-6	Bipolar disorder;
SARC	cis	rs7296418	0.961	rs1727307	chr12:123575742	A/G	cg00376283	chr12:123451042	ABCB9	0.6	7.48	0.44	1.55e-12	Platelet count;
SARC	cis	rs6582630	0.615	rs11182380	chr12:38511735	G/T	cg13010199	chr12:38710504	ALG10B	-0.5	-6.19	-0.38	2.63e-9	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs3796352	1.000	rs13058817	chr3:53024139	C/T	cg15956490	chr3:53032818	SFMBT1	0.87	5.73	0.35	3.14e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs950169	0.922	rs6603022	chr15:84830170	T/C	cg24253500	chr15:84953950	NA	-0.37	-5.09	-0.32	7.32e-7	Schizophrenia;
SARC	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.66	-9.58	-0.53	1.52e-18	Birth weight;
SARC	cis	rs2439831	1.000	rs689754	chr15:43775895	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	7.54	0.44	1.05e-12	Lung cancer in ever smokers;
SARC	cis	rs11585357	0.895	rs72633812	chr1:17623140	T/C	cg08277548	chr1:17600880	PADI3	-0.47	-5.44	-0.34	1.38e-7	Hair shape;
SARC	cis	rs554111	0.637	rs529162	chr1:21063311	T/A	cg08890418	chr1:21044141	KIF17	0.42	5.76	0.35	2.64e-8	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg16325326	chr1:53192061	ZYG11B	0.8	12.65	0.64	2.97e-28	Monocyte count;
SARC	cis	rs9303401	0.646	rs7213269	chr17:57237796	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.57	6.82	0.41	7.71e-11	Cognitive test performance;
SARC	cis	rs9400467	0.506	rs12197149	chr6:111656067	G/A	cg15721981	chr6:111408429	SLC16A10	0.65	5.65	0.35	4.61e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs10078	0.515	rs6872510	chr5:481610	T/C	cg07599136	chr5:415885	AHRR	0.67	5.72	0.35	3.32e-8	Fat distribution (HIV);
SARC	cis	rs637571	0.565	rs570387	chr11:65637076	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.41	-5.13	-0.32	5.98e-7	Eosinophil percentage of white cells;
SARC	cis	rs4268898	0.610	rs72791170	chr2:24449776	C/T	cg06627628	chr2:24431161	ITSN2	-0.81	-9.67	-0.54	8.19e-19	Asthma;
SARC	cis	rs7843479	0.601	rs9969551	chr8:21860007	T/C	cg17168535	chr8:21777572	XPO7	0.84	12.74	0.64	1.43e-28	Mean corpuscular volume;
SARC	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg22903471	chr2:27725779	GCKR	-0.46	-6.78	-0.41	1.01e-10	Total body bone mineral density;
SARC	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.39	0.44	2.66e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2075371	0.501	rs1643043	chr7:134013902	C/T	cg00033643	chr7:134001901	SLC35B4	0.47	5.77	0.35	2.46e-8	Mean platelet volume;
SARC	cis	rs2921073	0.509	rs2976931	chr8:8257317	C/A	cg06636001	chr8:8085503	FLJ10661	0.63	7.55	0.44	9.69e-13	Parkinson's disease;
SARC	cis	rs6003958	1	rs6003958	chr22:24264089	T/G	cg15242686	chr22:24348715	GSTTP1	-0.48	-5.44	-0.34	1.36e-7	S-phenylmercapturic acid levels in smokers;
SARC	cis	rs6938	0.563	rs12917376	chr15:75116167	C/T	cg17294928	chr15:75287854	SCAMP5	0.58	7.64	0.45	5.76e-13	Breast cancer;
SARC	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg11843238	chr5:131593191	PDLIM4	0.39	4.82	0.3	2.57e-6	Breast cancer;
SARC	cis	rs2013441	1.000	rs2703787	chr17:20158665	A/G	cg13482628	chr17:19912719	NA	-0.47	-6.2	-0.38	2.57e-9	Obesity-related traits;
SARC	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg22903471	chr2:27725779	GCKR	-0.5	-7.53	-0.44	1.11e-12	Total body bone mineral density;
SARC	cis	rs644799	0.710	rs523153	chr11:95570961	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.93	15.6	0.71	4.9e-38	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg05861140	chr6:150128134	PCMT1	-0.37	-4.78	-0.3	3.08e-6	Lung cancer;
SARC	cis	rs3733585	0.699	rs62294331	chr4:9959889	A/G	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.55	-0.34	7.65e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs11608355	1.000	rs7132057	chr12:109880279	A/C	cg05360138	chr12:110035743	NA	0.44	4.96	0.31	1.36e-6	Neuroticism;
SARC	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg10207240	chr12:122356781	WDR66	0.29	4.91	0.31	1.68e-6	Mean corpuscular volume;
SARC	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg24829409	chr8:58192753	C8orf71	-0.49	-4.85	-0.3	2.21e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs889312	0.500	rs832577	chr5:56163787	G/A	cg14703610	chr5:56206110	C5orf35	0.54	6.82	0.41	7.93e-11	Breast cancer;Breast cancer (early onset);
SARC	cis	rs2204008	0.805	rs11179579	chr12:38213957	A/C	cg26384229	chr12:38710491	ALG10B	0.89	13.09	0.65	1.03e-29	Bladder cancer;
SARC	cis	rs1943345	0.556	rs588956	chr11:82926047	T/C	cg07047830	chr11:82868014	PCF11	0.46	5.78	0.35	2.44e-8	Obesity-related traits;
SARC	cis	rs4253772	0.701	rs9627280	chr22:46643964	T/C	cg24881330	chr22:46731750	TRMU	0.54	5.99	0.37	8.05e-9	LDL cholesterol;Cholesterol, total;
SARC	cis	rs8141529	0.732	rs6005872	chr22:29172898	T/G	cg02153584	chr22:29168773	CCDC117	0.83	12.78	0.64	1.11e-28	Lymphocyte counts;
SARC	cis	rs2370759	1.000	rs79487858	chr10:32616405	T/C	cg18270830	chr10:32634957	EPC1	0.69	6.26	0.38	1.85e-9	Sexual dysfunction (female);
SARC	cis	rs11098499	0.954	rs7656252	chr4:120404268	T/C	cg09307838	chr4:120376055	NA	0.93	12.78	0.64	1.08e-28	Corneal astigmatism;
SARC	cis	rs7264396	0.635	rs6060709	chr20:34536022	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-7.5	-0.44	1.37e-12	Total cholesterol levels;
SARC	cis	rs2288073	0.965	rs10192600	chr2:24396680	A/G	cg26838691	chr2:24397539	C2orf84	-0.56	-6.94	-0.41	3.81e-11	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs9815354	0.904	rs73073368	chr3:41843391	A/G	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs858239	0.600	rs7790157	chr7:23126998	G/A	cg23682824	chr7:23144976	KLHL7	0.71	9.6	0.53	1.34e-18	Cerebrospinal fluid biomarker levels;
SARC	trans	rs1961637	0.603	rs1550423	chr2:223885812	C/T	cg13662093	chr20:33865505	NA	-0.49	-6.64	-0.4	2.15e-10	Oropharynx cancer;
SARC	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg12463550	chr7:65579703	CRCP	-0.49	-5.42	-0.33	1.47e-7	Aortic root size;
SARC	cis	rs4642101	0.512	rs12629892	chr3:12818920	A/G	cg24848339	chr3:12840334	CAND2	0.39	6.3	0.38	1.48e-9	QRS complex (12-leadsum);
SARC	cis	rs73198271	0.562	rs964773	chr8:8651314	T/C	cg06636001	chr8:8085503	FLJ10661	-0.49	-4.78	-0.3	3.09e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs12681288	0.676	rs7011999	chr8:1008446	A/G	cg15309053	chr8:964076	NA	0.47	7.75	0.45	2.79e-13	Schizophrenia;
SARC	cis	rs8031584	0.958	rs1043742	chr15:31232581	A/C	cg14298792	chr15:30685198	CHRFAM7A	-0.44	-4.82	-0.3	2.6e-6	Huntington's disease progression;
SARC	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg11764359	chr7:65958608	NA	-0.67	-7.95	-0.46	7.86e-14	Aortic root size;
SARC	trans	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg00938859	chr5:1591904	SDHAP3	0.79	7.66	0.45	5.1e-13	Breast cancer;
SARC	trans	rs9329221	0.683	rs658385	chr8:9892177	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.46	-0.39	5.97e-10	Neuroticism;
SARC	cis	rs7020830	0.928	rs11544336	chr9:37089150	A/G	cg14294708	chr9:37120828	ZCCHC7	1.14	21.62	0.82	1.27e-57	Schizophrenia;
SARC	cis	rs10791323	0.581	rs2723608	chr11:133710149	A/G	cg14349672	chr11:133703707	NA	-0.37	-5.42	-0.33	1.5e-7	Childhood ear infection;
SARC	cis	rs10911232	0.520	rs10797831	chr1:183036816	A/G	cg13390022	chr1:182993471	LAMC1	0.33	5.03	0.31	9.72e-7	Hypertriglyceridemia;
SARC	cis	rs72717009	0.825	rs7552317	chr1:161479438	C/T	cg23840854	chr1:161414152	NA	-0.55	-5.16	-0.32	5.26e-7	Rheumatoid arthritis;
SARC	cis	rs7084402	1.000	rs1427201	chr10:60269755	G/T	cg07615347	chr10:60278583	BICC1	-0.58	-8.47	-0.49	2.84e-15	Refractive error;
SARC	cis	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg25427524	chr10:38739819	LOC399744	-0.6	-9.24	-0.52	1.56e-17	Extrinsic epigenetic age acceleration;
SARC	cis	rs3087591	1.000	rs2040791	chr17:29627297	G/C	cg24425628	chr17:29625626	OMG;NF1	-0.53	-6.66	-0.4	1.92e-10	Hip circumference;
SARC	cis	rs796364	1.000	rs11895190	chr2:200838613	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.74	-6.89	-0.41	5.1e-11	Schizophrenia;
SARC	cis	rs3617	0.591	rs11918800	chr3:52868145	G/A	cg04865290	chr3:52927548	TMEM110	0.35	5.07	0.32	8.25e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	trans	rs3780486	0.846	rs10116966	chr9:33122370	T/A	cg04842962	chr6:43655489	MRPS18A	1.09	20.81	0.81	4.59e-55	IgG glycosylation;
SARC	cis	rs6570726	0.935	rs377130	chr6:145836632	C/T	cg23711669	chr6:146136114	FBXO30	0.78	11.86	0.61	1.04e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs950169	0.650	rs12902052	chr15:85125838	A/T	cg03959625	chr15:84868606	LOC388152	0.38	5.1	0.32	6.93e-7	Schizophrenia;
SARC	cis	rs6496667	1.000	rs1971898	chr15:90890836	C/G	cg22089800	chr15:90895588	ZNF774	0.5	4.81	0.3	2.76e-6	Rheumatoid arthritis;
SARC	cis	rs508618	0.731	rs11805033	chr1:231546452	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.56	6.63	0.4	2.33e-10	Red blood cell count;
SARC	cis	rs57024841	0.562	rs2071006	chr9:139839904	G/T	cg00693599	chr9:139836323	FBXW5	-0.32	-5.36	-0.33	1.96e-7	Beta-trace protein levels;
SARC	cis	rs3771570	1.000	rs62186411	chr2:242236667	A/C	cg21155796	chr2:242212141	HDLBP	0.63	5.48	0.34	1.1e-7	Prostate cancer;
SARC	cis	rs2153535	0.580	rs1414349	chr6:8472290	A/G	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	cis	rs13256369	0.760	rs7839473	chr8:8575836	C/T	cg18904891	chr8:8559673	CLDN23	0.49	5.58	0.34	6.5e-8	Obesity-related traits;
SARC	cis	rs854765	0.647	rs854767	chr17:18018263	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.51	-6.98	-0.42	2.99e-11	Total body bone mineral density;
SARC	cis	rs30380	0.587	rs469674	chr5:96130015	G/C	cg16492584	chr5:96139282	ERAP1	-0.48	-5.47	-0.34	1.17e-7	Cerebrospinal fluid biomarker levels;
SARC	cis	rs36051895	0.632	rs7030853	chr9:5179002	C/T	cg02405213	chr9:5042618	JAK2	-0.42	-4.93	-0.31	1.6e-6	Pediatric autoimmune diseases;
SARC	cis	rs7191439	0.858	rs4238685	chr16:88775220	T/C	cg27087555	chr16:88793112	FAM38A	-1.05	-7.23	-0.43	6.75e-12	Plateletcrit;
SARC	cis	rs936229	0.861	rs3935077	chr15:75120211	C/G	cg10253484	chr15:75165896	SCAMP2	-0.47	-4.98	-0.31	1.23e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs7824557	0.564	rs1435275	chr8:11235735	T/C	cg21775007	chr8:11205619	TDH	-0.65	-8.62	-0.49	1.05e-15	Retinal vascular caliber;
SARC	cis	rs17376456	0.825	rs12716453	chr5:93271697	T/C	cg21475434	chr5:93447410	FAM172A	0.86	7.72	0.45	3.37e-13	Diabetic retinopathy;
SARC	cis	rs7959452	0.530	rs12811632	chr12:69755003	G/A	cg20891283	chr12:69753455	YEATS4	0.54	7.3	0.43	4.49e-12	Blood protein levels;
SARC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.59	7.77	0.45	2.5e-13	Lymphocyte counts;
SARC	cis	rs787274	0.681	rs787284	chr9:115538040	A/G	cg13803584	chr9:115635662	SNX30	-0.79	-6.14	-0.37	3.47e-9	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs9815354	0.951	rs9831404	chr3:41871825	T/G	cg03022575	chr3:42003672	ULK4	0.57	5.32	0.33	2.38e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.37	-4.73	-0.3	3.92e-6	Lymphocyte counts;
SARC	cis	rs7264396	0.635	rs6058382	chr20:34553948	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	5.3	0.33	2.71e-7	Total cholesterol levels;
SARC	cis	rs8523	0.901	rs68148747	chr6:10967020	A/T	cg13562911	chr6:11044106	ELOVL2	0.44	5.86	0.36	1.56e-8	Red blood cell fatty acid levels;
SARC	cis	rs7089973	0.624	rs11196930	chr10:116583596	C/T	cg08188268	chr10:116634841	FAM160B1	0.28	4.76	0.3	3.41e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs362296	0.698	rs362279	chr4:3260072	G/A	cg06533319	chr4:3265114	C4orf44	0.34	5.2	0.32	4.45e-7	Parental longevity (mother's age at death);
SARC	cis	rs72781680	0.898	rs72780123	chr2:23996009	G/A	cg06627628	chr2:24431161	ITSN2	-0.67	-6.35	-0.38	1.14e-9	Lymphocyte counts;
SARC	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg12463550	chr7:65579703	CRCP	-0.48	-5.68	-0.35	4.02e-8	Aortic root size;
SARC	cis	rs35213789	0.843	rs12698812	chr7:69362580	A/C	cg10619644	chr7:69149951	AUTS2	0.47	5.69	0.35	3.87e-8	Childhood ear infection;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg10571824	chr7:1963144	MAD1L1	0.45	6.33	0.38	1.23e-9	Schizophrenia;
SARC	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg05368731	chr17:41323189	NBR1	0.79	9.36	0.52	7.2e-18	Menopause (age at onset);
SARC	cis	rs9788682	0.747	rs8042374	chr15:78908032	A/G	cg24631222	chr15:78858424	CHRNA5	0.71	9.65	0.53	9.2e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	ch.13.1783356F	chr13:111136316	COL4A2	-0.73	-5.65	-0.35	4.66e-8	Obesity-related traits;
SARC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg03452623	chr4:187889614	NA	-0.76	-11.83	-0.61	1.32e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs208520	0.955	rs208532	chr6:66961280	T/A	cg07460842	chr6:66804631	NA	-0.86	-9.56	-0.53	1.79e-18	Exhaled nitric oxide output;
SARC	cis	rs651907	0.640	rs771578	chr3:101613434	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.43	-4.75	-0.3	3.53e-6	Colorectal cancer;
SARC	cis	rs12142240	0.698	rs17361805	chr1:46813967	C/T	cg14993813	chr1:46806288	NSUN4	-0.49	-5.09	-0.32	7.44e-7	Menopause (age at onset);
SARC	trans	rs1814175	0.702	rs4881644	chr11:49786367	C/T	cg03929089	chr4:120376271	NA	-0.88	-14.29	-0.68	1.12e-33	Height;
SARC	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg11644478	chr21:40555479	PSMG1	-0.89	-11.46	-0.6	2.09e-24	Cognitive function;
SARC	cis	rs3126085	0.735	rs4845752	chr1:152226576	C/A	cg03465714	chr1:152285911	FLG	-0.44	-5.34	-0.33	2.26e-7	Atopic dermatitis;
SARC	trans	rs2727020	0.637	rs1164673	chr11:49328356	C/G	cg06756931	chr17:78820893	RPTOR	-0.51	-6.45	-0.39	6.28e-10	Coronary artery disease;
SARC	cis	rs3892630	0.817	rs35408716	chr19:33187961	A/C	cg22980127	chr19:33182716	NUDT19	1.06	9.77	0.54	4.14e-19	Red blood cell traits;
SARC	cis	rs6570726	0.935	rs415590	chr6:145851244	T/C	cg23711669	chr6:146136114	FBXO30	0.78	12.08	0.62	2.13e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6598955	0.612	rs12738188	chr1:26548029	G/C	cg04990556	chr1:26633338	UBXN11	-0.61	-8.56	-0.49	1.5e-15	Obesity-related traits;
SARC	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg12016809	chr21:47604291	C21orf56	-0.46	-5.57	-0.34	7.17e-8	Testicular germ cell tumor;
SARC	cis	rs1348850	0.914	rs4341974	chr2:178324879	A/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.63	7.91	0.46	1.02e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7927771	0.965	rs35985502	chr11:47847428	G/A	cg05585544	chr11:47624801	NA	-0.36	-4.82	-0.3	2.59e-6	Subjective well-being;
SARC	cis	rs950169	0.922	rs62028133	chr15:84919375	A/C	cg17507749	chr15:85114479	UBE2QP1	0.8	9.7	0.54	6.72e-19	Schizophrenia;
SARC	cis	rs8084125	0.832	rs7238522	chr18:74948730	A/C	cg07390210	chr18:74961196	GALR1	-0.54	-6.04	-0.37	5.9e-9	Obesity-related traits;
SARC	trans	rs208520	0.874	rs208515	chr6:66945749	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.9	-10.42	-0.56	4.04e-21	Exhaled nitric oxide output;
SARC	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg03452623	chr4:187889614	NA	0.78	12.3	0.63	4.06e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1865760	0.516	rs9358903	chr6:26061949	A/C	cg10373733	chr6:25993375	NA	0.39	4.82	0.3	2.55e-6	Height;
SARC	cis	rs473651	0.935	rs35080527	chr2:239351387	T/C	cg18131467	chr2:239335373	ASB1	0.95	15.67	0.72	2.71e-38	Multiple system atrophy;
SARC	cis	rs8014204	0.566	rs7145575	chr14:75145528	T/A	cg06637938	chr14:75390232	RPS6KL1	0.63	9.12	0.51	3.63e-17	Caffeine consumption;
SARC	cis	rs4595586	0.545	rs4438082	chr12:39363870	C/T	cg13010199	chr12:38710504	ALG10B	0.4	4.75	0.3	3.57e-6	Morning vs. evening chronotype;
SARC	cis	rs1348850	0.567	rs7605493	chr2:178534983	C/G	cg22681709	chr2:178499509	PDE11A	-0.36	-5.15	-0.32	5.51e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7824557	0.628	rs3174048	chr8:11184937	G/A	cg21775007	chr8:11205619	TDH	0.65	8.33	0.48	7.13e-15	Retinal vascular caliber;
SARC	cis	rs2645694	0.626	rs2703129	chr4:77818548	T/C	cg06046430	chr4:77819534	ANKRD56	0.55	7.75	0.45	2.81e-13	Emphysema distribution in smoking;
SARC	cis	rs6570726	0.764	rs1912023	chr6:145824278	C/A	cg23711669	chr6:146136114	FBXO30	0.87	14.58	0.69	1.18e-34	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg09021430	chr5:549028	NA	-0.45	-5.83	-0.36	1.86e-8	Obesity-related traits;
SARC	cis	rs834603	0.575	rs2462638	chr7:47471286	A/G	cg23694490	chr7:47445681	TNS3	-0.32	-5.89	-0.36	1.36e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs367615	0.537	rs1965670	chr5:108649798	A/T	cg17395555	chr5:108820864	NA	-0.34	-4.98	-0.31	1.26e-6	Colorectal cancer (SNP x SNP interaction);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg03749393	chr13:31191824	USPL1	-0.78	-6.43	-0.39	7.29e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6121246	0.567	rs6120815	chr20:30184866	T/C	cg13852791	chr20:30311386	BCL2L1	0.68	5.91	0.36	1.2e-8	Mean corpuscular hemoglobin;
SARC	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg11644478	chr21:40555479	PSMG1	-0.58	-6.93	-0.41	4e-11	Menarche (age at onset);
SARC	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg12310025	chr6:25882481	NA	0.5	6.65	0.4	2.09e-10	Blood metabolite levels;
SARC	cis	rs11676348	0.901	rs7562334	chr2:219003360	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.47	-6.23	-0.38	2.15e-9	Ulcerative colitis;
SARC	cis	rs2228479	0.850	rs17233448	chr16:89816424	G/T	cg06558623	chr16:89946397	TCF25	0.88	6.21	0.38	2.39e-9	Skin colour saturation;
SARC	cis	rs986417	1.000	rs1254255	chr14:60831342	G/A	cg27398547	chr14:60952738	C14orf39	-1.0	-8.65	-0.49	8.38e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs35213789	0.590	rs1029812	chr7:69037335	T/C	cg10619644	chr7:69149951	AUTS2	-0.36	-5.1	-0.32	7.1e-7	Childhood ear infection;
SARC	cis	rs3087591	1.000	rs2051506	chr17:29699860	T/A	cg24425628	chr17:29625626	OMG;NF1	-0.53	-6.46	-0.39	6.15e-10	Hip circumference;
SARC	trans	rs61931739	0.500	rs11053197	chr12:34441949	C/T	cg26384229	chr12:38710491	ALG10B	0.92	13.84	0.67	3.3e-32	Morning vs. evening chronotype;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg26364903	chr2:67624840	ETAA1	0.55	6.83	0.41	7.14e-11	Breast cancer;
SARC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg11494091	chr17:61959527	GH2	0.54	7.99	0.46	6.26e-14	Prudent dietary pattern;
SARC	cis	rs7667	0.919	rs12026907	chr1:19738518	C/T	cg15311933	chr1:19638897	PQLC2;AKR7A2	-0.48	-5.64	-0.35	4.84e-8	Crohn's disease and psoriasis;
SARC	trans	rs1814175	0.817	rs80244685	chr11:49763292	C/A	cg03929089	chr4:120376271	NA	-0.83	-12.15	-0.62	1.26e-26	Height;
SARC	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg09699651	chr6:150184138	LRP11	-0.39	-4.77	-0.3	3.24e-6	Lung cancer;
SARC	cis	rs1707322	0.721	rs28641748	chr1:46212836	A/G	cg03146154	chr1:46216737	IPP	0.53	6.37	0.39	1.01e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs3768617	0.528	rs3736888	chr1:183084607	A/G	cg13390022	chr1:182993471	LAMC1	0.32	4.83	0.3	2.52e-6	Fuchs's corneal dystrophy;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg25395653	chr11:69455731	CCND1	-0.5	-6.37	-0.39	9.73e-10	Schizophrenia;
SARC	cis	rs6466055	0.867	rs10241415	chr7:104948076	A/G	cg04380332	chr7:105027541	SRPK2	0.4	4.72	0.3	4.14e-6	Schizophrenia;
SARC	cis	rs453301	0.571	rs2929456	chr8:9083416	G/A	cg11608241	chr8:8085544	FLJ10661	-0.4	-4.9	-0.31	1.83e-6	Joint mobility (Beighton score);
SARC	cis	rs3796352	1.000	rs71301809	chr3:53090312	C/T	cg15956490	chr3:53032818	SFMBT1	0.89	6.02	0.37	6.61e-9	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs9815354	0.953	rs4615050	chr3:41942498	T/A	cg03022575	chr3:42003672	ULK4	-0.55	-5.22	-0.32	4.05e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs7582180	0.614	rs6737217	chr2:101006267	T/G	cg14675211	chr2:100938903	LONRF2	0.52	7.71	0.45	3.74e-13	Intelligence (multi-trait analysis);
SARC	cis	rs1568889	1.000	rs12800354	chr11:28047723	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	9.61	0.53	1.23e-18	Bipolar disorder;
SARC	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg11644478	chr21:40555479	PSMG1	1.07	15.43	0.71	1.82e-37	Cognitive function;
SARC	cis	rs11190604	1.000	rs11190597	chr10:102293676	A/T	cg07080220	chr10:102295463	HIF1AN	0.8	9.6	0.53	1.36e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg05025164	chr4:1340916	KIAA1530	0.88	11.4	0.6	3.16e-24	Longevity;
SARC	cis	rs6545883	0.965	rs6718887	chr2:61727215	G/A	cg15711740	chr2:61764176	XPO1	-0.42	-5.15	-0.32	5.47e-7	Tuberculosis;
SARC	cis	rs9467773	1.000	rs1078679	chr6:26568741	C/T	cg12292205	chr6:26970375	C6orf41	0.45	5.43	0.33	1.45e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg05368731	chr17:41323189	NBR1	0.79	9.45	0.53	3.82e-18	Menopause (age at onset);
SARC	cis	rs7568458	0.684	rs6731700	chr2:85760991	C/G	cg02493740	chr2:85810744	VAMP5	-0.42	-5.24	-0.32	3.58e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs10752881	0.967	rs6695746	chr1:182991355	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.71	0.57	5.09e-22	Colorectal cancer;
SARC	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg06558623	chr16:89946397	TCF25	0.71	5.97	0.36	8.69e-9	Skin colour saturation;
SARC	cis	rs2777491	0.915	rs9302109	chr15:41612180	G/T	cg01768344	chr15:41576519	LOC729082	0.44	4.9	0.31	1.76e-6	Ulcerative colitis;
SARC	cis	rs10752881	0.905	rs10797830	chr1:183036274	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.08	0.55	4.44e-20	Colorectal cancer;
SARC	cis	rs9381040	0.610	rs717883	chr6:41045270	T/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.46	-5.27	-0.33	3.05e-7	Alzheimer's disease (late onset);
SARC	cis	rs10489202	0.632	rs202265	chr1:167990231	G/C	cg24449463	chr1:168025552	DCAF6	-0.66	-8.97	-0.51	9.71e-17	Schizophrenia;
SARC	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg02487422	chr3:49467188	NICN1	0.5	6.83	0.41	7.5e-11	Resting heart rate;
SARC	cis	rs4423214	0.798	rs12224205	chr11:71180992	A/G	cg24826892	chr11:71159390	DHCR7	-0.42	-4.81	-0.3	2.75e-6	Vitamin D levels;
SARC	cis	rs2731664	0.792	rs335420	chr5:176898619	C/T	cg23176889	chr5:176863531	GRK6	0.59	8.79	0.5	3.36e-16	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2816062	0.775	rs2745315	chr1:18897118	G/A	cg10574377	chr1:18908098	NA	0.35	5.02	0.31	1.02e-6	Urate levels in lean individuals;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg08298679	chr19:1095376	POLR2E	0.51	6.86	0.41	6.07e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg26663063	chr12:49239477	DDX23	0.51	6.32	0.38	1.32e-9	Schizophrenia;
SARC	cis	rs11756659	0.653	rs412968	chr6:25954193	C/T	cg00631329	chr6:26305371	NA	-0.48	-5.05	-0.31	8.75e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;Red cell distribution width;
SARC	cis	rs9435341	0.965	rs12401598	chr1:107580533	C/A	cg09367891	chr1:107599246	PRMT6	0.74	9.31	0.52	1.02e-17	Facial morphology (factor 21, depth of nasal alae);
SARC	cis	rs986417	0.688	rs6573321	chr14:61101710	A/G	cg27398547	chr14:60952738	C14orf39	0.74	7.01	0.42	2.56e-11	Gut microbiota (bacterial taxa);
SARC	cis	rs11711311	0.747	rs2895415	chr3:113345565	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	7.23	0.43	6.78e-12	IgG glycosylation;
SARC	cis	rs734999	0.588	rs876938	chr1:2523212	G/C	cg00980319	chr1:2560884	MMEL1	-0.35	-4.93	-0.31	1.55e-6	Ulcerative colitis;
SARC	cis	rs1153858	1.000	rs7171577	chr15:45627979	G/A	cg14582100	chr15:45693742	SPATA5L1	0.36	4.99	0.31	1.19e-6	Homoarginine levels;
SARC	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg11366901	chr6:160182831	ACAT2	0.91	9.4	0.52	5.5e-18	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs58653258	1.000	rs67527053	chr1:234997033	C/T	cg14037484	chr1:235490207	ARID4B	-0.66	-5.21	-0.32	4.12e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs7089973	0.525	rs11196945	chr10:116600424	G/A	cg08188268	chr10:116634841	FAM160B1	0.29	4.97	0.31	1.3e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs1559088	0.895	rs7259582	chr19:33593979	A/G	cg17764715	chr19:33622953	WDR88	0.49	6.72	0.4	1.4e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs1580019	0.961	rs1868777	chr7:32494076	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.57	6.56	0.39	3.48e-10	Cognitive ability;
SARC	cis	rs12421382	0.659	rs1837396	chr11:109389257	G/A	cg16359550	chr11:109292809	C11orf87	0.34	5.14	0.32	5.73e-7	Schizophrenia;
SARC	cis	rs34375054	0.660	rs58624919	chr12:125596458	G/A	cg25124228	chr12:125621409	AACS	-0.52	-5.54	-0.34	8.06e-8	Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs2991971	0.967	rs2356551	chr1:46009318	C/T	cg24296786	chr1:45957014	TESK2	0.64	9.03	0.51	6.46e-17	High light scatter reticulocyte count;
SARC	cis	rs9916302	0.861	rs11078896	chr17:37415544	C/T	cg07936489	chr17:37558343	FBXL20	-0.68	-9.09	-0.51	4.41e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg00409905	chr10:38381863	ZNF37A	0.53	7.45	0.44	1.86e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs4803468	0.967	rs13345590	chr19:41886455	T/G	cg14132834	chr19:41945861	ATP5SL	-0.54	-7.28	-0.43	5.22e-12	Height;
SARC	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg01448562	chr3:133502909	NA	-0.58	-9.0	-0.51	8.39e-17	Iron status biomarkers;
SARC	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg14983838	chr19:29218262	NA	0.78	10.63	0.57	8.86e-22	Methadone dose in opioid dependence;
SARC	cis	rs7264396	0.513	rs2425092	chr20:34306815	T/C	cg01084648	chr20:34329383	RBM39	0.56	4.93	0.31	1.57e-6	Total cholesterol levels;
SARC	cis	rs826838	0.874	rs11183816	chr12:38834656	T/G	cg26384229	chr12:38710491	ALG10B	0.93	15.06	0.7	3.05e-36	Heart rate;
SARC	cis	rs651907	0.557	rs2288272	chr3:101378476	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	6.21	0.38	2.47e-9	Colorectal cancer;
SARC	cis	rs6700896	0.931	rs12042779	chr1:66133950	T/C	cg04111102	chr1:66153794	NA	0.37	5.71	0.35	3.5e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs2153535	0.580	rs2327058	chr6:8447018	C/T	cg21535247	chr6:8435926	SLC35B3	0.55	6.87	0.41	5.72e-11	Motion sickness;
SARC	cis	rs2834188	1.000	rs2834190	chr21:34693011	A/T	cg14352951	chr21:34696688	IFNAR1	-0.46	-5.51	-0.34	9.69e-8	Narcolepsy;
SARC	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg03709012	chr19:19516395	GATAD2A	0.95	14.76	0.7	2.9e-35	Tonsillectomy;
SARC	cis	rs1355223	0.525	rs12280958	chr11:34872799	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.5	-6.36	-0.38	1.06e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs9457247	1.000	rs406095	chr6:167409087	C/T	cg23791538	chr6:167370224	RNASET2	-0.6	-8.22	-0.47	1.39e-14	Crohn's disease;
SARC	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.68	6.53	0.39	4.09e-10	Platelet count;
SARC	cis	rs9611519	0.828	rs28814423	chr22:41452301	G/A	cg03806693	chr22:41940476	POLR3H	-0.6	-7.6	-0.45	7.24e-13	Neuroticism;
SARC	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg13939156	chr17:80058883	NA	-0.39	-6.08	-0.37	4.91e-9	Life satisfaction;
SARC	cis	rs933688	1.000	rs6862125	chr5:90724598	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.04	13.18	0.65	5.19e-30	Smoking behavior;
SARC	cis	rs7264396	0.563	rs2425086	chr20:34302873	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	5.7	0.35	3.66e-8	Total cholesterol levels;
SARC	cis	rs12950390	0.893	rs4239165	chr17:45847272	A/T	cg03474202	chr17:45855739	NA	-0.46	-7.29	-0.43	4.86e-12	IgG glycosylation;
SARC	cis	rs7474896	0.559	rs1212108	chr10:38094322	A/C	cg25427524	chr10:38739819	LOC399744	-0.5	-6.08	-0.37	4.93e-9	Obesity (extreme);
SARC	cis	rs7560272	0.501	rs12713798	chr2:73986421	C/T	cg20560298	chr2:73613845	ALMS1	0.43	5.7	0.35	3.61e-8	Schizophrenia;
SARC	trans	rs1994135	0.715	rs11052742	chr12:33692290	A/C	cg26384229	chr12:38710491	ALG10B	0.68	8.21	0.47	1.54e-14	Resting heart rate;
SARC	cis	rs6867032	0.917	rs10474733	chr5:2004160	A/G	cg26168224	chr5:2018326	NA	-0.78	-10.74	-0.58	3.96e-22	Gut microbiome composition (winter);
SARC	cis	rs470119	1.000	rs470119	chr22:50966914	C/T	cg12969734	chr22:50962224	SCO2	-0.53	-7.08	-0.42	1.67e-11	Mean corpuscular hemoglobin;
SARC	cis	rs35110281	0.594	rs230641	chr21:44915441	T/C	cg01579765	chr21:45077557	HSF2BP	0.28	4.74	0.3	3.69e-6	Mean corpuscular volume;
SARC	cis	rs9894429	0.572	rs112417725	chr17:79578219	A/G	cg10661904	chr17:79619235	PDE6G	0.44	6.27	0.38	1.72e-9	Eye color traits;
SARC	cis	rs929354	0.742	rs7784442	chr7:156934475	G/C	cg05182265	chr7:156933206	UBE3C	-0.34	-5.19	-0.32	4.49e-7	Body mass index;
SARC	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg10876282	chr6:28092338	ZSCAN16	-0.47	-4.79	-0.3	3e-6	Depression;
SARC	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg22920501	chr2:26401640	FAM59B	-0.55	-7.24	-0.43	6.63e-12	Gut microbiome composition (summer);
SARC	cis	rs636523	0.561	rs10889363	chr1:63194009	C/T	cg06896770	chr1:63153194	DOCK7	0.69	7.12	0.42	1.33e-11	Lipid traits;
SARC	cis	rs2011503	1.000	rs8111093	chr19:19505548	C/T	cg03709012	chr19:19516395	GATAD2A	0.65	5.63	0.35	5.07e-8	Bipolar disorder;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25562306	chr2:189157510	GULP1	-0.53	-6.33	-0.38	1.23e-9	Fibrinogen levels;
SARC	cis	rs3768617	0.510	rs10797843	chr1:183081995	A/G	cg13390022	chr1:182993471	LAMC1	0.32	4.88	0.3	1.95e-6	Fuchs's corneal dystrophy;
SARC	cis	rs6952809	0.532	rs6953297	chr7:2440874	C/G	cg05083358	chr7:2394359	EIF3B	-0.54	-5.0	-0.31	1.11e-6	Multiple sclerosis;
SARC	cis	rs4689388	0.816	rs13147655	chr4:6293474	A/G	cg00701064	chr4:6280414	WFS1	0.54	8.58	0.49	1.38e-15	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.04	0.37	6.11e-9	Prudent dietary pattern;
SARC	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg11987759	chr7:65425863	GUSB	0.5	6.5	0.39	4.88e-10	Aortic root size;
SARC	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.48	5.99	0.37	8.05e-9	Lymphocyte counts;
SARC	cis	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg13072238	chr3:49761600	GMPPB	0.42	5.54	0.34	8.33e-8	Intelligence (multi-trait analysis);
SARC	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.78	0.45	2.38e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7326068	0.576	rs9552273	chr13:21333750	A/C	cg16922012	chr13:21400325	XPO4	-0.44	-6.09	-0.37	4.5e-9	Schizophrenia, bipolar disorder and depression (combined);
SARC	cis	rs10504073	0.584	rs10957337	chr8:49959027	G/T	cg00325661	chr8:49890786	NA	0.53	6.89	0.41	5.3e-11	Blood metabolite ratios;
SARC	cis	rs34172651	0.917	rs11074654	chr16:24813743	A/G	cg00152838	chr16:24741724	TNRC6A	-0.4	-4.9	-0.31	1.76e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7766436	0.727	rs6908574	chr6:22610165	T/C	cg13666174	chr6:22585274	NA	-0.49	-6.7	-0.4	1.51e-10	Coronary artery disease;
SARC	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg09263875	chr16:632152	PIGQ	0.53	8.13	0.47	2.51e-14	Height;
SARC	cis	rs1348850	0.645	rs11887886	chr2:178425730	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.56	5.88	0.36	1.42e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs16854884	0.770	rs4450810	chr3:143809091	C/A	cg06585982	chr3:143692056	C3orf58	0.6	7.9	0.46	1.09e-13	Economic and political preferences (feminism/equality);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg18338181	chr19:13044658	FARSA	0.53	6.61	0.4	2.59e-10	Breast cancer;
SARC	cis	rs7296418	0.663	rs11057284	chr12:123830692	G/C	cg00376283	chr12:123451042	ABCB9	0.57	6.99	0.42	2.88e-11	Platelet count;
SARC	cis	rs6998277	0.830	rs12543008	chr8:103603747	C/T	cg10187029	chr8:103597600	NA	0.89	12.58	0.64	4.69e-28	Migraine;
SARC	cis	rs62408225	0.722	rs1319433	chr6:90921988	G/A	cg06866423	chr6:90926672	BACH2	0.32	5.13	0.32	6.01e-7	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs1008375	0.931	rs10939734	chr4:17570709	C/T	cg27347728	chr4:17578864	LAP3	0.45	5.48	0.34	1.1e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg25072359	chr17:41440525	NA	0.55	6.82	0.41	7.97e-11	Menopause (age at onset);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg11491770	chr20:60961646	RPS21	0.76	6.28	0.38	1.64e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg25894440	chr7:65020034	NA	-0.74	-5.64	-0.35	4.95e-8	Diabetic kidney disease;
SARC	cis	rs8114671	0.562	rs4911161	chr20:33402231	C/T	cg24642439	chr20:33292090	TP53INP2	0.53	6.79	0.41	9.38e-11	Height;
SARC	cis	rs113835537	0.529	rs4930183	chr11:66255732	C/T	cg24851651	chr11:66362959	CCS	0.38	4.79	0.3	2.98e-6	Airway imaging phenotypes;
SARC	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg00933542	chr6:150070202	PCMT1	0.33	5.63	0.35	5.13e-8	Lung cancer;
SARC	cis	rs6061231	1.000	rs11908473	chr20:60957770	C/G	cg22601191	chr20:60968625	CABLES2	0.36	4.86	0.3	2.16e-6	Colorectal cancer;
SARC	cis	rs9325144	0.555	rs7960411	chr12:38703019	A/G	cg26384229	chr12:38710491	ALG10B	-0.62	-8.2	-0.47	1.57e-14	Morning vs. evening chronotype;
SARC	cis	rs561341	1.000	rs510264	chr17:30323414	A/G	cg00745463	chr17:30367425	LRRC37B	-0.71	-5.58	-0.34	6.7e-8	Hip circumference adjusted for BMI;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg02377685	chr7:150865060	GBX1	0.44	6.32	0.38	1.28e-9	Breast cancer;
SARC	cis	rs3820928	0.933	rs1429267	chr2:227767593	G/C	cg05526886	chr2:227700861	RHBDD1	-0.49	-5.87	-0.36	1.49e-8	Pulmonary function;
SARC	cis	rs4280164	0.551	rs3181251	chr14:24805824	C/T	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.53	-5.37	-0.33	1.91e-7	Parent of origin effect on language impairment (paternal);
SARC	cis	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg07777115	chr5:623756	CEP72	-0.56	-5.03	-0.31	9.96e-7	Lung disease severity in cystic fibrosis;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg00731404	chr13:28024444	MTIF3	0.47	6.31	0.38	1.39e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs11734570	0.581	rs75356782	chr4:38600053	T/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.61	6.63	0.4	2.3e-10	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg06634786	chr22:41940651	POLR3H	0.55	6.33	0.38	1.24e-9	Vitiligo;
SARC	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg13175981	chr1:150552382	MCL1	-0.54	-6.9	-0.41	4.97e-11	Tonsillectomy;
SARC	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg21870776	chr12:49731125	C1QL4	0.5	6.26	0.38	1.86e-9	Migraine with aura;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg01406988	chr2:66662810	MEIS1	-0.52	-7.13	-0.42	1.22e-11	Thyroid stimulating hormone;
SARC	cis	rs6088590	1.000	rs2236270	chr20:33523155	G/T	cg06115741	chr20:33292138	TP53INP2	0.54	6.54	0.39	3.81e-10	Coronary artery disease;
SARC	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg11764359	chr7:65958608	NA	0.59	7.07	0.42	1.78e-11	Calcium levels;
SARC	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg22618164	chr12:122356400	WDR66	-0.42	-6.81	-0.41	8.03e-11	Mean corpuscular volume;
SARC	cis	rs9911578	0.835	rs1476596	chr17:56485358	C/T	cg05425664	chr17:57184151	TRIM37	-0.66	-7.97	-0.46	6.89e-14	Intelligence (multi-trait analysis);
SARC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg09033563	chr22:24373618	LOC391322	-0.49	-5.9	-0.36	1.28e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	trans	rs9858542	1.000	rs13085791	chr3:49721798	C/A	cg21659725	chr3:3221576	CRBN	-0.55	-6.32	-0.38	1.3e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs709400	0.859	rs942863	chr14:104021268	C/T	cg26031613	chr14:104095156	KLC1	1.02	18.01	0.76	5.08e-46	Body mass index;
SARC	cis	rs2916247	1.000	rs6995893	chr8:93034861	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.58	-6.03	-0.37	6.49e-9	Intelligence (multi-trait analysis);
SARC	cis	rs870825	0.549	rs10015956	chr4:185614705	T/C	cg04058563	chr4:185651563	MLF1IP	0.82	11.05	0.59	4.24e-23	Blood protein levels;
SARC	cis	rs9896052	0.608	rs61264861	chr17:73459278	T/C	cg04121983	chr17:73511085	CASKIN2	0.44	5.1	0.32	7.14e-7	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg01485165	chr20:49411421	BCAS4	0.79	6.59	0.4	2.94e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg03709012	chr19:19516395	GATAD2A	1.01	17.59	0.76	1.21e-44	Tonsillectomy;
SARC	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg11062466	chr8:58055876	NA	0.58	5.61	0.35	5.65e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs11651000	0.857	rs56172120	chr17:45824904	G/A	cg03474202	chr17:45855739	NA	-0.45	-6.34	-0.38	1.19e-9	IgG glycosylation;
SARC	cis	rs7621025	0.617	rs12637102	chr3:136211960	A/G	cg15507776	chr3:136538369	TMEM22	0.58	6.57	0.4	3.3e-10	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
SARC	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg20887711	chr4:1340912	KIAA1530	-0.61	-7.27	-0.43	5.29e-12	Obesity-related traits;
SARC	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9902453	1.000	rs6505152	chr17:28331466	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.52	-6.82	-0.41	7.67e-11	Coffee consumption (cups per day);
SARC	cis	rs6840360	0.615	rs9884167	chr4:152470799	A/G	cg22705602	chr4:152727874	NA	-0.4	-6.25	-0.38	1.92e-9	Intelligence (multi-trait analysis);
SARC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg09177884	chr7:1199841	ZFAND2A	0.46	5.26	0.33	3.21e-7	Longevity;Endometriosis;
SARC	cis	rs11155671	0.530	rs9383914	chr6:150207234	T/G	cg00933542	chr6:150070202	PCMT1	0.29	4.91	0.31	1.73e-6	Testicular germ cell tumor;
SARC	cis	rs2599510	0.840	rs466146	chr2:32539236	A/C	cg02381751	chr2:32503542	YIPF4	0.51	6.61	0.4	2.59e-10	Interleukin-18 levels;
SARC	cis	rs908922	0.651	rs1337341	chr1:152508259	A/C	cg09873164	chr1:152488093	CRCT1	0.65	8.49	0.49	2.49e-15	Hair morphology;
SARC	cis	rs10463316	0.894	rs3846711	chr5:150740749	A/G	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.39	-0.33	1.71e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.61	7.4	0.44	2.43e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs60733400	0.817	rs4648657	chr1:2560735	A/G	cg20673091	chr1:2541236	MMEL1	-0.33	-5.03	-0.31	9.66e-7	Multiple sclerosis;
SARC	cis	rs7005380	0.556	rs62528692	chr8:120945207	T/A	cg21744203	chr8:120868354	DSCC1	0.45	4.72	0.3	4e-6	Interstitial lung disease;
SARC	cis	rs2327429	0.821	rs1967917	chr6:134198175	C/T	cg25632230	chr6:134101081	NA	-0.46	-5.62	-0.35	5.52e-8	Coronary artery disease;
SARC	trans	rs9354308	0.866	rs2802054	chr6:66544766	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.57	6.66	0.4	1.92e-10	Metabolite levels;
SARC	cis	rs4742903	0.967	rs2417485	chr9:106867106	A/C	cg14250997	chr9:106856677	SMC2	0.53	7.01	0.42	2.51e-11	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs4642101	0.597	rs9839769	chr3:12821405	C/T	cg24848339	chr3:12840334	CAND2	0.36	5.85	0.36	1.64e-8	QRS complex (12-leadsum);
SARC	cis	rs1395	0.961	rs4665963	chr2:27528692	T/C	cg21747090	chr2:27597821	SNX17	-0.45	-5.35	-0.33	2.15e-7	Blood metabolite levels;
SARC	cis	rs7786808	0.586	rs7794256	chr7:158206214	T/G	cg01191920	chr7:158217561	PTPRN2	0.36	6.12	0.37	3.97e-9	Obesity-related traits;
SARC	cis	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg06440646	chr4:146403418	SMAD1	0.48	5.94	0.36	1.02e-8	Height;
SARC	cis	rs6762477	0.748	rs11711407	chr3:50225029	A/G	cg24110177	chr3:50126178	RBM5	0.5	6.56	0.39	3.47e-10	Menarche (age at onset);
SARC	cis	rs7027203	0.797	rs7870672	chr9:96606693	A/C	cg14598338	chr9:96623480	NA	-0.54	-7.64	-0.45	5.77e-13	DNA methylation (variation);
SARC	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg08859206	chr1:53392774	SCP2	0.38	5.38	0.33	1.85e-7	Monocyte count;
SARC	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg02574844	chr11:5959923	NA	-0.39	-5.52	-0.34	8.8e-8	DNA methylation (variation);
SARC	cis	rs477895	1.000	rs7939107	chr11:64034773	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	6.64	0.4	2.24e-10	Mean platelet volume;
SARC	cis	rs4951018	0.821	rs7529037	chr1:205637501	C/G	cg11965913	chr1:205819406	PM20D1	-0.41	-5.36	-0.33	1.99e-7	Prostate-specific antigen levels;
SARC	cis	rs4423214	0.515	rs4944042	chr11:71118788	C/A	cg05163923	chr11:71159392	DHCR7	0.45	6.08	0.37	4.83e-9	Vitamin D levels;
SARC	cis	rs4974559	0.739	rs10012819	chr4:1324758	G/C	cg02980000	chr4:1222292	CTBP1	0.65	4.98	0.31	1.23e-6	Systolic blood pressure;
SARC	cis	rs2832191	0.791	rs7282843	chr21:30475226	A/G	cg08807101	chr21:30365312	RNF160	0.83	11.57	0.6	9.22e-25	Dental caries;
SARC	trans	rs61931739	0.500	rs7489270	chr12:34432062	C/T	cg26384229	chr12:38710491	ALG10B	0.92	13.84	0.67	3.3e-32	Morning vs. evening chronotype;
SARC	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg09839136	chr7:766187	HEATR2;PRKAR1B	0.59	5.1	0.32	7e-7	Cerebrospinal P-tau181p levels;
SARC	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg18252515	chr7:66147081	NA	-1.33	-11.84	-0.61	1.22e-25	Diabetic kidney disease;
SARC	cis	rs6867032	0.527	rs4246752	chr5:1975575	T/A	cg26168224	chr5:2018326	NA	-0.57	-6.54	-0.39	3.78e-10	Gut microbiome composition (winter);
SARC	cis	rs3126085	1.000	rs3126085	chr1:152300817	G/A	cg26876637	chr1:152193138	HRNR	-0.44	-4.75	-0.3	3.5e-6	Atopic dermatitis;
SARC	trans	rs6716963	0.585	rs11687224	chr2:194568323	A/G	cg16774013	chr18:77160150	NFATC1	0.54	6.54	0.39	3.81e-10	Schizophrenia;
SARC	cis	rs6964587	1.000	rs2961020	chr7:91573308	G/A	cg17063962	chr7:91808500	NA	-0.95	-14.91	-0.7	9.58e-36	Breast cancer;
SARC	cis	rs7326068	0.647	rs2818978	chr13:21319537	C/G	cg16922012	chr13:21400325	XPO4	-0.42	-5.68	-0.35	4.05e-8	Schizophrenia, bipolar disorder and depression (combined);
SARC	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg17971929	chr21:40555470	PSMG1	0.99	13.99	0.68	1.05e-32	Cognitive function;
SARC	cis	rs2204008	0.604	rs11172718	chr12:38069819	T/C	cg13010199	chr12:38710504	ALG10B	0.73	9.75	0.54	4.82e-19	Bladder cancer;
SARC	cis	rs2228479	0.681	rs62052184	chr16:89967217	T/C	cg06558623	chr16:89946397	TCF25	0.77	6.37	0.39	1e-9	Skin colour saturation;
SARC	cis	rs6831352	0.505	rs11722561	chr4:100088737	T/A	cg12011299	chr4:100065546	ADH4	0.31	5.69	0.35	3.8e-8	Alcohol dependence;
SARC	cis	rs644799	1.000	rs566204	chr11:95580926	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.67	9.09	0.51	4.54e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs208520	0.909	rs62414639	chr6:67023706	G/A	cg07460842	chr6:66804631	NA	0.84	8.59	0.49	1.29e-15	Exhaled nitric oxide output;
SARC	cis	rs1050631	0.564	rs1785925	chr18:33727186	C/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.59	7.16	0.42	1.06e-11	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs6542838	0.611	rs7588441	chr2:99518858	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-5.76	-0.35	2.66e-8	Fear of minor pain;
SARC	cis	rs765787	0.530	rs12906537	chr15:45520061	T/C	cg26924012	chr15:45694286	SPATA5L1	0.42	5.0	0.31	1.12e-6	Uric acid levels;
SARC	cis	rs1395	0.744	rs3739092	chr2:27462076	C/T	cg21747090	chr2:27597821	SNX17	-0.49	-5.85	-0.36	1.68e-8	Blood metabolite levels;
SARC	cis	rs709400	0.663	rs62007718	chr14:103940436	G/A	cg12935359	chr14:103987150	CKB	-0.39	-5.65	-0.35	4.62e-8	Body mass index;
SARC	cis	rs12079745	0.793	rs10800430	chr1:169276782	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.83	-5.04	-0.31	9.33e-7	QT interval;
SARC	cis	rs6570726	0.791	rs425999	chr6:145819370	C/A	cg05347473	chr6:146136440	FBXO30	0.53	7.35	0.43	3.43e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs13161895	0.877	rs75654641	chr5:179486021	C/T	cg02702477	chr5:179499311	RNF130	0.7	6.4	0.39	8.27e-10	LDL cholesterol;
SARC	cis	rs911555	0.546	rs28798508	chr14:104068970	T/C	cg24130564	chr14:104152367	KLC1	-0.7	-9.72	-0.54	5.67e-19	Intelligence (multi-trait analysis);
SARC	cis	rs2227564	0.729	rs2675676	chr10:75648287	A/C	cg16540259	chr10:75572220	NDST2	0.34	4.84	0.3	2.31e-6	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs7103648	0.669	rs7131262	chr11:47836302	T/A	cg20307385	chr11:47447363	PSMC3	0.76	10.35	0.56	6.86e-21	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs854765	0.583	rs8078105	chr17:17853782	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	9.85	0.54	2.34e-19	Total body bone mineral density;
SARC	cis	rs11874712	0.931	rs8095031	chr18:43666861	T/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.46	5.5	0.34	1.02e-7	Migraine - clinic-based;
SARC	cis	rs9911578	1.000	rs9898916	chr17:57048660	C/T	cg20303301	chr17:57937339	TUBD1	-0.34	-4.81	-0.3	2.73e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7474896	0.526	rs1208716	chr10:38089273	T/A	cg25427524	chr10:38739819	LOC399744	-0.51	-6.12	-0.37	4.02e-9	Obesity (extreme);
SARC	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg20887711	chr4:1340912	KIAA1530	0.54	6.4	0.39	8.49e-10	Obesity-related traits;
SARC	cis	rs17376456	0.825	rs17314762	chr5:93231200	C/T	cg21475434	chr5:93447410	FAM172A	0.83	7.26	0.43	5.75e-12	Diabetic retinopathy;
SARC	cis	rs4555082	1.000	rs7146683	chr14:105759385	A/G	cg13114125	chr14:105738426	BRF1	-0.73	-10.54	-0.57	1.78e-21	Mean platelet volume;Platelet distribution width;
SARC	cis	rs7412746	0.503	rs72704639	chr1:150798335	A/C	cg13175981	chr1:150552382	MCL1	-0.51	-6.23	-0.38	2.18e-9	Melanoma;
SARC	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg26335602	chr6:28129616	ZNF389	-0.48	-5.62	-0.35	5.57e-8	Depression;
SARC	trans	rs61931739	0.534	rs11053005	chr12:34091626	A/C	cg26384229	chr12:38710491	ALG10B	0.87	12.44	0.63	1.37e-27	Morning vs. evening chronotype;
SARC	cis	rs72781680	0.846	rs72780198	chr2:24014883	T/A	cg06627628	chr2:24431161	ITSN2	-0.66	-6.26	-0.38	1.83e-9	Lymphocyte counts;
SARC	cis	rs8072100	0.790	rs7222225	chr17:45693497	A/G	cg08085267	chr17:45401833	C17orf57	0.42	4.99	0.31	1.17e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg24642844	chr7:1081250	C7orf50	-0.57	-6.05	-0.37	5.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs6831352	0.918	rs34936974	chr4:100052384	A/G	cg13256891	chr4:100009986	ADH5	0.57	7.24	0.43	6.44e-12	Alcohol dependence;
SARC	cis	rs262150	0.630	rs2730274	chr7:158796062	C/A	cg09640425	chr7:158790006	NA	-0.41	-5.7	-0.35	3.69e-8	Facial morphology (factor 20);
SARC	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg24642844	chr7:1081250	C7orf50	-0.39	-5.42	-0.33	1.48e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs10435719	0.902	rs6601633	chr8:11805173	C/T	cg12395012	chr8:11607386	GATA4	0.3	4.89	0.31	1.85e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
SARC	cis	rs7937682	0.889	rs1784787	chr11:111486125	T/A	cg09085632	chr11:111637200	PPP2R1B	-0.89	-14.18	-0.68	2.61e-33	Primary sclerosing cholangitis;
SARC	cis	rs8141529	0.509	rs6005927	chr22:29255884	A/G	cg02153584	chr22:29168773	CCDC117	0.7	9.32	0.52	9.51e-18	Lymphocyte counts;
SARC	trans	rs12310956	0.532	rs1906134	chr12:33957135	A/C	cg26384229	chr12:38710491	ALG10B	0.85	12.4	0.63	1.85e-27	Morning vs. evening chronotype;
SARC	trans	rs4295623	0.553	rs11250163	chr8:11596437	G/T	cg08975724	chr8:8085496	FLJ10661	0.54	6.68	0.4	1.7e-10	Morning vs. evening chronotype;
SARC	cis	rs7551222	0.614	rs4951386	chr1:204454547	A/G	cg20240347	chr1:204465584	NA	-0.29	-4.93	-0.31	1.55e-6	Schizophrenia;
SARC	cis	rs11264799	0.603	rs10489674	chr1:157566019	G/A	cg18268488	chr1:157545234	FCRL4	0.31	5.34	0.33	2.19e-7	IgA nephropathy;
SARC	cis	rs17376456	0.825	rs10079708	chr5:93261796	G/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	5.84	0.36	1.75e-8	Diabetic retinopathy;
SARC	cis	rs34779708	0.931	rs72789687	chr10:35372489	G/A	cg03585969	chr10:35415529	CREM	0.39	4.86	0.3	2.17e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs17270561	0.609	rs4145217	chr6:25743997	T/C	cg16482183	chr6:26056742	HIST1H1C	0.43	5.08	0.32	7.76e-7	Iron status biomarkers;
SARC	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.43	0.39	7.27e-10	Height;
SARC	cis	rs7712401	0.791	rs1531340	chr5:122108017	G/A	cg19412675	chr5:122181750	SNX24	0.35	4.76	0.3	3.47e-6	Mean platelet volume;
SARC	cis	rs4588572	0.644	rs891150	chr5:77761794	G/A	cg18281939	chr5:77783895	LHFPL2	0.35	4.94	0.31	1.47e-6	Triglycerides;
SARC	cis	rs73206853	0.841	rs56251637	chr12:110833869	T/G	cg10860002	chr12:110842031	ANAPC7	0.63	5.03	0.31	9.95e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg18825119	chr6:163149453	PACRG;PARK2	0.39	4.83	0.3	2.51e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs8044995	0.563	rs73613962	chr16:68361974	T/G	cg09835421	chr16:68378352	PRMT7	-0.64	-5.87	-0.36	1.52e-8	Schizophrenia;
SARC	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg08219700	chr8:58056026	NA	0.48	5.01	0.31	1.08e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs920590	0.500	rs7819535	chr8:19689058	A/G	cg03894339	chr8:19674705	INTS10	0.78	7.08	0.42	1.7e-11	Acute lymphoblastic leukemia (childhood);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg09724427	chr17:47866462	MYST2	0.51	6.32	0.38	1.35e-9	Breast cancer;
SARC	cis	rs2486288	0.656	rs12908818	chr15:45571668	A/G	cg15395560	chr15:45543142	SLC28A2	0.3	5.75	0.35	2.75e-8	Glomerular filtration rate;
SARC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg03435677	chr6:158093883	ZDHHC14	0.48	6.29	0.38	1.55e-9	HDL cholesterol;
SARC	cis	rs2733201	1.000	rs1160066	chr15:44410937	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.77	-5.83	-0.36	1.82e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	cis	rs10754283	0.967	rs4658302	chr1:90103336	A/G	cg21401794	chr1:90099060	LRRC8C	0.6	8.27	0.48	1.04e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg24549020	chr5:56110836	MAP3K1	0.8	8.36	0.48	5.75e-15	Initial pursuit acceleration;
SARC	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg03575189	chr17:44344142	NA	0.55	5.33	0.33	2.27e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs16854884	0.657	rs35309714	chr3:143735011	T/A	cg06585982	chr3:143692056	C3orf58	0.67	9.14	0.51	3.13e-17	Economic and political preferences (feminism/equality);
SARC	cis	rs12421382	0.659	rs35093943	chr11:109379872	C/A	cg27471124	chr11:109292789	C11orf87	0.36	5.04	0.31	9.21e-7	Schizophrenia;
SARC	cis	rs12142240	0.659	rs1984491	chr1:46858607	T/G	cg10495392	chr1:46806563	NSUN4	0.65	6.88	0.41	5.6e-11	Menopause (age at onset);
SARC	cis	rs2200578	0.786	rs62154639	chr2:99646954	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.53	4.76	0.3	3.35e-6	IgG glycosylation;
SARC	cis	rs858239	0.511	rs10256996	chr7:23145295	G/T	cg23682824	chr7:23144976	KLHL7	-0.6	-7.82	-0.46	1.79e-13	Cerebrospinal fluid biomarker levels;
SARC	cis	rs2115630	0.967	rs8027779	chr15:85255385	T/C	cg12501888	chr15:85177176	SCAND2	-0.46	-5.57	-0.34	7.03e-8	P wave terminal force;
SARC	cis	rs503341	0.756	rs612010	chr11:63591005	G/A	cg04362095	chr11:63592001	C11orf84	-0.56	-7.62	-0.45	6.53e-13	Pulse pressure;
SARC	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg11987759	chr7:65425863	GUSB	-0.47	-6.27	-0.38	1.7e-9	Aortic root size;
SARC	cis	rs9467773	0.620	rs2451741	chr6:26629404	A/G	cg11502198	chr6:26597334	ABT1	0.64	8.75	0.5	4.35e-16	Intelligence (multi-trait analysis);
SARC	cis	rs832540	0.931	rs832535	chr5:56213334	C/T	cg14703610	chr5:56206110	C5orf35	0.53	6.7	0.4	1.58e-10	Coronary artery disease;
SARC	cis	rs16976116	0.502	rs7165565	chr15:55452689	T/C	cg17854078	chr15:55489399	RSL24D1	-0.66	-5.82	-0.36	1.97e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs13314892	0.764	rs62251027	chr3:69862454	C/G	cg17445875	chr3:69859618	MITF	-0.49	-5.1	-0.32	6.98e-7	QRS complex (12-leadsum);
SARC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg24846343	chr22:24311635	DDTL	-0.52	-7.04	-0.42	2.09e-11	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7647973	0.710	rs9869120	chr3:49624065	T/C	cg03060546	chr3:49711283	APEH	0.72	6.71	0.4	1.44e-10	Menarche (age at onset);
SARC	cis	rs8031584	0.697	rs8036176	chr15:31175269	A/G	cg19680485	chr15:31195859	MTMR15	-0.55	-6.56	-0.4	3.37e-10	Huntington's disease progression;
SARC	cis	rs7659604	0.502	rs28522256	chr4:122709266	C/T	cg19671926	chr4:122722719	EXOSC9	0.67	8.79	0.5	3.44e-16	Type 2 diabetes;
SARC	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg26335602	chr6:28129616	ZNF389	0.51	5.62	0.35	5.41e-8	Depression;
SARC	cis	rs7662987	0.517	rs2602882	chr4:100040765	C/T	cg13256891	chr4:100009986	ADH5	0.68	8.6	0.49	1.22e-15	Smoking initiation;
SARC	cis	rs1153858	1.000	rs4775907	chr15:45638647	G/A	cg26924012	chr15:45694286	SPATA5L1	0.75	10.34	0.56	7.46e-21	Homoarginine levels;
SARC	cis	rs4727027	0.870	rs1534196	chr7:148790591	G/A	cg23583168	chr7:148888333	NA	-0.74	-10.79	-0.58	2.91e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs7412746	0.658	rs897815	chr1:150879101	C/T	cg13175981	chr1:150552382	MCL1	0.46	5.5	0.34	1.01e-7	Melanoma;
SARC	cis	rs7084402	0.935	rs12263522	chr10:60343527	C/A	cg07615347	chr10:60278583	BICC1	0.6	8.7	0.5	6.13e-16	Refractive error;
SARC	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg18876405	chr7:65276391	NA	-0.74	-9.42	-0.53	4.63e-18	Aortic root size;
SARC	cis	rs72781680	0.898	rs72796154	chr2:23933839	G/A	cg06627628	chr2:24431161	ITSN2	-0.63	-5.59	-0.34	6.42e-8	Lymphocyte counts;
SARC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg14159672	chr1:205819179	PM20D1	0.58	7.9	0.46	1.08e-13	Menarche (age at onset);
SARC	cis	rs2479724	0.935	rs7753507	chr6:41784094	C/T	cg17623882	chr6:41773611	USP49	0.44	5.5	0.34	9.89e-8	Menarche (age at onset);
SARC	cis	rs11676348	0.846	rs11677534	chr2:219007060	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.51	-6.76	-0.4	1.1e-10	Ulcerative colitis;
SARC	cis	rs4803468	1.000	rs4803463	chr19:41911040	C/G	cg09537434	chr19:41945824	ATP5SL	-0.96	-16.37	-0.73	1.31e-40	Height;
SARC	cis	rs10513432	0.826	rs78414640	chr3:152556972	T/C	cg04845053	chr3:152552877	P2RY1	0.81	4.73	0.3	3.96e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs698833	0.548	rs1067350	chr2:44669946	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	5.87	0.36	1.48e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs6728642	0.519	rs6718420	chr2:97572470	C/T	cg26665480	chr2:98280029	ACTR1B	-0.65	-5.56	-0.34	7.29e-8	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg02725872	chr8:58115012	NA	-0.27	-4.87	-0.3	2.09e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs10754283	0.967	rs6428562	chr1:90102665	G/A	cg21401794	chr1:90099060	LRRC8C	0.6	8.43	0.48	3.54e-15	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg20203395	chr5:56204925	C5orf35	0.52	4.82	0.3	2.6e-6	Initial pursuit acceleration;
SARC	cis	rs4253772	0.614	rs11090859	chr22:46687460	T/G	cg24881330	chr22:46731750	TRMU	0.72	7.54	0.44	1.05e-12	LDL cholesterol;Cholesterol, total;
SARC	cis	rs17384381	1.000	rs12140935	chr1:85855716	G/A	cg16011679	chr1:85725395	C1orf52	0.61	5.81	0.36	2.07e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9355610	0.927	rs2757041	chr6:167370532	C/G	cg23791538	chr6:167370224	RNASET2	0.72	10.17	0.55	2.48e-20	Graves' disease;
SARC	cis	rs9486719	0.857	rs2983897	chr6:97033780	C/T	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.8	-0.5	3.06e-16	Migraine;Coronary artery disease;
SARC	cis	rs7666738	0.830	rs35213297	chr4:98984049	T/C	cg05340658	chr4:99064831	C4orf37	0.64	8.6	0.49	1.18e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7246657	0.943	rs8106839	chr19:37958475	C/G	cg23950597	chr19:37808831	NA	-0.56	-5.72	-0.35	3.34e-8	Coronary artery calcification;
SARC	cis	rs10782582	0.586	rs1796813	chr1:76400403	G/A	cg03433033	chr1:76189801	ACADM	-0.4	-5.09	-0.32	7.55e-7	Daytime sleep phenotypes;
SARC	cis	rs72627123	0.867	rs61522544	chr14:74481953	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.76	5.99	0.37	7.73e-9	Morning vs. evening chronotype;
SARC	cis	rs9660992	0.762	rs1172130	chr1:205244953	G/A	cg21545522	chr1:205238299	TMCC2	0.47	6.57	0.4	3.24e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs2933343	0.859	rs789245	chr3:128583580	C/A	cg24203234	chr3:128598194	ACAD9	0.52	5.71	0.35	3.43e-8	IgG glycosylation;
SARC	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg02711726	chr17:80685570	FN3KRP	0.53	6.61	0.4	2.54e-10	Glycated hemoglobin levels;
SARC	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg19223190	chr17:80058835	NA	-0.38	-5.26	-0.33	3.18e-7	Life satisfaction;
SARC	cis	rs7953249	0.594	rs11065384	chr12:121423285	T/C	cg25281562	chr12:121454272	C12orf43	-0.52	-6.37	-0.39	9.76e-10	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs2635047	0.783	rs9952447	chr18:44784700	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.55	7.07	0.42	1.76e-11	Educational attainment;
SARC	cis	rs2762353	0.562	rs1165206	chr6:25867566	G/A	cg18357526	chr6:26021779	HIST1H4A	0.39	5.08	0.32	7.84e-7	Blood metabolite levels;
SARC	cis	rs6088580	0.634	rs1205336	chr20:32926336	G/A	cg24642439	chr20:33292090	TP53INP2	-0.65	-8.52	-0.49	1.99e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs9650657	0.812	rs10107289	chr8:10634248	T/C	cg21775007	chr8:11205619	TDH	-0.38	-4.74	-0.3	3.76e-6	Neuroticism;
SARC	cis	rs12079745	0.793	rs3766064	chr1:169157919	A/G	cg09363564	chr1:169337483	NME7;BLZF1	0.71	4.78	0.3	3.14e-6	QT interval;
SARC	cis	rs3857067	0.772	rs4438731	chr4:95091384	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.34	-4.99	-0.31	1.2e-6	QT interval;
SARC	cis	rs9467773	0.967	rs6924865	chr6:26521353	A/G	cg12292205	chr6:26970375	C6orf41	0.44	5.46	0.34	1.24e-7	Intelligence (multi-trait analysis);
SARC	cis	rs11997175	0.569	rs36034014	chr8:33814219	G/A	ch.8.33884649F	chr8:33765107	NA	-0.45	-5.69	-0.35	3.78e-8	Body mass index;
SARC	cis	rs854765	0.547	rs2955385	chr17:17939247	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.42	5.27	0.33	3.12e-7	Total body bone mineral density;
SARC	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg19901468	chr14:105411992	AHNAK2	-0.71	-10.45	-0.56	3.23e-21	Rheumatoid arthritis;
SARC	cis	rs6831352	0.879	rs4699717	chr4:100066137	C/T	cg12011299	chr4:100065546	ADH4	-0.32	-5.09	-0.32	7.33e-7	Alcohol dependence;
SARC	trans	rs9650657	0.537	rs4841457	chr8:10773511	T/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.26	-0.43	5.8e-12	Neuroticism;
SARC	cis	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg18252515	chr7:66147081	NA	-1.3	-11.12	-0.59	2.58e-23	Diabetic kidney disease;
SARC	cis	rs7959452	0.868	rs10878967	chr12:69740869	T/C	cg20891283	chr12:69753455	YEATS4	0.46	6.16	0.37	3.18e-9	Blood protein levels;
SARC	cis	rs9905704	0.647	rs7221274	chr17:57008128	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.39	-4.78	-0.3	3.11e-6	Testicular germ cell tumor;
SARC	cis	rs9354308	0.868	rs9363465	chr6:66557802	A/C	cg07460842	chr6:66804631	NA	-0.45	-5.1	-0.32	6.89e-7	Metabolite levels;
SARC	cis	rs1055129	0.560	rs3682	chr17:73942150	A/G	cg06969265	chr17:73775802	H3F3B	0.44	5.3	0.33	2.63e-7	White matter hyperintensity burden;
SARC	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg26681399	chr22:41777847	TEF	0.43	4.98	0.31	1.22e-6	Vitiligo;
SARC	cis	rs9420	0.961	rs7936998	chr11:57639017	G/A	cg19752551	chr11:57585705	CTNND1	-0.5	-6.71	-0.4	1.48e-10	Schizophrenia;
SARC	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.71	6.88	0.41	5.63e-11	Platelet count;
SARC	cis	rs6665290	0.904	rs9727512	chr1:227185375	G/T	cg14016676	chr1:227182615	CDC42BPA	0.36	5.12	0.32	6.28e-7	Myeloid white cell count;
SARC	cis	rs35213789	0.562	rs2533457	chr7:69055951	G/A	cg10619644	chr7:69149951	AUTS2	-0.34	-4.79	-0.3	3.01e-6	Childhood ear infection;
SARC	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg00684032	chr4:1343700	KIAA1530	0.45	6.56	0.4	3.35e-10	Obesity-related traits;
SARC	cis	rs910316	0.935	rs2268620	chr14:75640403	G/A	cg11812906	chr14:75593930	NEK9	-0.85	-12.28	-0.63	4.48e-27	Height;
SARC	trans	rs208520	0.690	rs207091	chr6:66799847	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-14.36	-0.69	6.28e-34	Exhaled nitric oxide output;
SARC	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg03264133	chr6:25882463	NA	-0.48	-6.22	-0.38	2.32e-9	Intelligence (multi-trait analysis);
SARC	cis	rs6772849	0.930	rs7639400	chr3:128323356	T/C	cg01163369	chr3:128370232	RPN1	-0.34	-4.85	-0.3	2.26e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg26681399	chr22:41777847	TEF	-0.49	-5.29	-0.33	2.87e-7	Vitiligo;
SARC	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg20120463	chr17:44301886	NA	0.32	5.03	0.31	9.89e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs1018836	0.923	rs9643308	chr8:91625399	A/C	cg16814680	chr8:91681699	NA	-0.85	-13.99	-0.68	1.06e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg00149659	chr3:10157352	C3orf10	0.8	7.55	0.44	9.91e-13	Alzheimer's disease;
SARC	cis	rs9462027	0.675	rs13206387	chr6:34696792	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.91	-0.36	1.19e-8	Systemic lupus erythematosus;
SARC	cis	rs883565	0.569	rs6599273	chr3:38998552	T/G	cg26331595	chr3:39149181	GORASP1;TTC21A	0.44	5.12	0.32	6.25e-7	Handedness;
SARC	cis	rs67311347	0.911	rs9849224	chr3:40392562	T/C	cg24209194	chr3:40518798	ZNF619	0.58	7.21	0.43	7.61e-12	Renal cell carcinoma;
SARC	cis	rs722599	0.748	rs731952	chr14:75366447	A/G	cg06637938	chr14:75390232	RPS6KL1	0.38	4.79	0.3	2.94e-6	IgG glycosylation;
SARC	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.44	7.17	0.43	9.77e-12	Schizophrenia;
SARC	cis	rs8067545	0.611	rs16960697	chr17:20027718	A/G	cg13482628	chr17:19912719	NA	0.52	6.86	0.41	6.28e-11	Schizophrenia;
SARC	cis	rs1707322	0.685	rs11211177	chr1:46226349	A/G	cg06784218	chr1:46089804	CCDC17	0.4	7.12	0.42	1.33e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs1814175	0.817	rs1319547	chr11:49916705	C/T	cg03929089	chr4:120376271	NA	-0.89	-14.41	-0.69	4.28e-34	Height;
SARC	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg24503407	chr1:205819492	PM20D1	0.45	5.17	0.32	5.15e-7	Parkinson's disease;
SARC	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg08859206	chr1:53392774	SCP2	0.39	5.61	0.34	5.81e-8	Monocyte count;
SARC	cis	rs7592578	0.639	rs61709084	chr2:191287685	A/C	cg10560079	chr2:191398806	TMEM194B	-0.71	-8.19	-0.47	1.73e-14	Diastolic blood pressure;
SARC	cis	rs933688	0.532	rs973332	chr5:90555129	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.44	-4.86	-0.3	2.13e-6	Smoking behavior;
SARC	cis	rs7223966	1.000	rs113134232	chr17:61715461	G/A	cg00588841	chr17:61851480	DDX42;CCDC47	-0.67	-7.01	-0.42	2.53e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs8067545	0.611	rs10491107	chr17:20188174	C/T	cg13482628	chr17:19912719	NA	0.54	7.0	0.42	2.68e-11	Schizophrenia;
SARC	cis	rs9914988	0.943	rs4794836	chr17:27082710	C/G	cg20469991	chr17:27169893	C17orf63	0.51	5.51	0.34	9.43e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs58688157	0.883	rs7936397	chr11:577534	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.52	-6.26	-0.38	1.86e-9	Systemic lupus erythematosus;
SARC	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg19223190	chr17:80058835	NA	0.45	6.21	0.38	2.39e-9	Life satisfaction;
SARC	cis	rs2221894	0.506	rs17525359	chr8:28829417	C/A	cg07962641	chr8:28805897	HMBOX1	-0.77	-7.72	-0.45	3.36e-13	Obesity-related traits;
SARC	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.67	9.15	0.51	2.98e-17	Menarche (age at onset);
SARC	cis	rs12586317	0.525	rs10144430	chr14:35433682	T/A	cg26967526	chr14:35346199	BAZ1A	-0.63	-7.32	-0.43	3.98e-12	Psoriasis;
SARC	cis	rs787274	1.000	rs787297	chr9:115542133	G/T	cg13803584	chr9:115635662	SNX30	-0.79	-6.2	-0.38	2.51e-9	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs7833790	0.553	rs9693128	chr8:82706128	A/G	cg06027949	chr8:82754900	SNX16	-0.53	-6.82	-0.41	7.89e-11	Diastolic blood pressure;
SARC	cis	rs7089973	0.934	rs68085797	chr10:116632130	A/T	cg08188268	chr10:116634841	FAM160B1	0.34	4.93	0.31	1.56e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs5753618	0.583	rs5753628	chr22:31860322	A/G	cg13145458	chr22:31556086	RNF185	-0.46	-4.85	-0.3	2.26e-6	Colorectal cancer;
SARC	cis	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg05623727	chr3:50126028	RBM5	-0.36	-5.64	-0.35	4.84e-8	Intelligence (multi-trait analysis);
SARC	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg11764359	chr7:65958608	NA	0.65	7.65	0.45	5.15e-13	Aortic root size;
SARC	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg12463550	chr7:65579703	CRCP	0.48	5.38	0.33	1.83e-7	Aortic root size;
SARC	cis	rs7264396	0.563	rs2425109	chr20:34316218	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	5.79	0.35	2.31e-8	Total cholesterol levels;
SARC	cis	rs865483	0.929	rs853215	chr17:35861133	A/G	cg06561646	chr17:35873369	DUSP14	-0.48	-6.46	-0.39	6.12e-10	Monocyte count;
SARC	cis	rs995000	0.899	rs1305521	chr1:62949034	A/G	cg06896770	chr1:63153194	DOCK7	-0.89	-13.31	-0.66	2.01e-30	Triglyceride levels;
SARC	cis	rs7772486	0.686	rs4896833	chr6:145965673	T/G	cg05347473	chr6:146136440	FBXO30	0.51	7.11	0.42	1.41e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1318878	0.565	rs10082839	chr12:15447714	G/A	cg08258403	chr12:15378311	NA	0.5	6.94	0.41	3.96e-11	Intelligence (multi-trait analysis);
SARC	cis	rs2898290	0.540	rs12677146	chr8:11450737	C/G	cg00262122	chr8:11665843	FDFT1	-0.39	-4.94	-0.31	1.53e-6	Systolic blood pressure;
SARC	cis	rs4906332	1.000	rs12892062	chr14:103883512	A/G	cg26031613	chr14:104095156	KLC1	-0.5	-5.84	-0.36	1.72e-8	Coronary artery disease;
SARC	cis	rs806795	0.605	rs6935954	chr6:26255451	A/G	cg00631329	chr6:26305371	NA	-0.54	-6.42	-0.39	7.61e-10	Mosquito bite size;
SARC	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg14926445	chr8:58193284	C8orf71	-0.41	-4.89	-0.31	1.86e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs9303401	0.614	rs28687626	chr17:57191904	G/A	cg25039879	chr17:56429692	SUPT4H1	0.62	5.57	0.34	6.84e-8	Cognitive test performance;
SARC	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg24675658	chr1:53192096	ZYG11B	-0.67	-10.01	-0.55	7.44e-20	Monocyte count;
SARC	trans	rs7819412	0.595	rs10503416	chr8:10987553	C/T	cg15556689	chr8:8085844	FLJ10661	0.5	6.6	0.4	2.79e-10	Triglycerides;
SARC	cis	rs763121	0.853	rs4821811	chr22:39075145	C/T	cg21395723	chr22:39101663	GTPBP1	0.53	5.83	0.36	1.79e-8	Menopause (age at onset);
SARC	trans	rs9354352	0.967	rs9354351	chr6:66696271	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.59	7.7	0.45	3.76e-13	Initial pursuit acceleration in psychotic disorders;
SARC	cis	rs12709013	0.561	rs1657174	chr16:58789043	T/C	cg04273148	chr16:57808038	KIFC3	0.32	4.72	0.3	4.08e-6	Blood metabolite ratios;
SARC	cis	rs2404618	0.534	rs2214861	chr8:1490604	A/G	cg13402656	chr8:1511478	DLGAP2	-0.63	-9.56	-0.53	1.81e-18	Lung cancer;
SARC	cis	rs9398803	0.698	rs853979	chr6:127057941	A/T	cg19875578	chr6:126661172	C6orf173	-0.6	-8.29	-0.48	8.89e-15	Male-pattern baldness;
SARC	cis	rs9640161	0.742	rs11983355	chr7:150016697	A/C	cg21361702	chr7:150065534	REPIN1	0.47	4.89	0.31	1.87e-6	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs367615	0.731	rs58241713	chr5:108853664	G/A	cg17395555	chr5:108820864	NA	0.42	5.98	0.36	8.3e-9	Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs1030877	0.515	rs3828300	chr2:105901107	G/A	cg02079111	chr2:105885981	TGFBRAP1	-0.49	-5.46	-0.34	1.24e-7	Obesity-related traits;
SARC	cis	rs6840360	1.000	rs6846114	chr4:152604558	A/G	cg22705602	chr4:152727874	NA	0.34	5.56	0.34	7.53e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7561149	0.534	rs12477346	chr2:179737610	A/G	cg17765952	chr2:179737173	CCDC141	0.48	6.63	0.4	2.38e-10	QT interval;
SARC	cis	rs240764	0.764	rs11155472	chr6:100921549	A/T	cg21058520	chr6:100914733	NA	0.34	5.27	0.33	3.15e-7	Neuroticism;
SARC	cis	rs7626444	0.625	rs843529	chr3:196480595	A/G	cg12930392	chr3:196481615	PAK2	-0.25	-4.93	-0.31	1.54e-6	Monocyte count;
SARC	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	trans	rs61931739	0.534	rs10844728	chr12:34020109	G/C	cg13010199	chr12:38710504	ALG10B	0.75	10.14	0.55	3.05e-20	Morning vs. evening chronotype;
SARC	trans	rs1411916	0.841	rs62568070	chr9:80974743	G/A	cg22801675	chr5:175971121	NA	-0.8	-6.23	-0.38	2.15e-9	Visceral fat;
SARC	cis	rs3808502	0.549	rs11991139	chr8:11428395	C/T	cg21775007	chr8:11205619	TDH	-0.46	-5.94	-0.36	1.02e-8	Neuroticism;
SARC	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg23982607	chr1:1823379	GNB1	-0.65	-11.33	-0.6	5.63e-24	Body mass index;
SARC	cis	rs9457247	0.967	rs385460	chr6:167403888	A/T	cg07741184	chr6:167504864	NA	0.29	5.55	0.34	7.59e-8	Crohn's disease;
SARC	cis	rs208520	0.954	rs72884027	chr6:66995044	T/G	cg07460842	chr6:66804631	NA	0.9	10.25	0.56	1.39e-20	Exhaled nitric oxide output;
SARC	cis	rs2075371	0.966	rs1619682	chr7:133996703	T/G	cg20476274	chr7:133979776	SLC35B4	0.63	8.51	0.49	2.17e-15	Mean platelet volume;
SARC	cis	rs67311347	0.577	rs2887951	chr3:40282104	C/G	cg24209194	chr3:40518798	ZNF619	0.45	5.33	0.33	2.33e-7	Renal cell carcinoma;
SARC	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg04944784	chr2:26401820	FAM59B	-0.57	-7.59	-0.45	7.48e-13	Gut microbiome composition (summer);
SARC	cis	rs1348850	0.567	rs4893838	chr2:178531436	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.4	4.79	0.3	3e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs6500602	0.727	rs3761681	chr16:4566857	C/T	cg08645402	chr16:4508243	NA	0.46	5.88	0.36	1.4e-8	Schizophrenia;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg18555811	chr3:193852889	HES1	0.48	6.53	0.39	4.07e-10	Thyroid stimulating hormone;
SARC	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg04756594	chr16:24857601	SLC5A11	0.41	5.22	0.32	4.02e-7	Intelligence (multi-trait analysis);
SARC	cis	rs796364	0.951	rs36086821	chr2:201067436	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.52	5.21	0.32	4.18e-7	Schizophrenia;
SARC	cis	rs1062177	1.000	rs2915877	chr5:151150601	C/G	cg00977110	chr5:151150581	G3BP1	0.62	6.23	0.38	2.19e-9	Preschool internalizing problems;
SARC	cis	rs6060717	0.536	rs6060669	chr20:34480557	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-5.88	-0.36	1.44e-8	Hip circumference adjusted for BMI;
SARC	cis	rs1707322	0.685	rs28617418	chr1:46189526	T/A	cg03146154	chr1:46216737	IPP	0.53	6.37	0.39	1.01e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4325129	0.773	rs7556355	chr1:159453252	C/T	cg26826434	chr1:160058314	KCNJ9	-0.53	-4.81	-0.3	2.66e-6	Obesity-related traits;
SARC	cis	rs1044826	0.913	rs9849039	chr3:139147106	A/G	cg15131784	chr3:139108705	COPB2	0.45	5.28	0.33	2.95e-7	Obesity-related traits;
SARC	cis	rs3809566	0.637	rs8026047	chr15:63323347	C/G	cg07525445	chr15:63335302	TPM1	-0.41	-4.76	-0.3	3.34e-6	Platelet count;
SARC	cis	rs11098499	0.909	rs28581362	chr4:120283548	T/A	cg09307838	chr4:120376055	NA	0.83	11.82	0.61	1.46e-25	Corneal astigmatism;
SARC	cis	rs933688	1.000	rs10058025	chr5:90689052	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.02	12.78	0.64	1.09e-28	Smoking behavior;
SARC	cis	rs7412746	0.611	rs11204748	chr1:150927369	G/T	cg13175981	chr1:150552382	MCL1	-0.54	-6.58	-0.4	3.12e-10	Melanoma;
SARC	cis	rs4481887	0.741	rs6587467	chr1:248550976	T/G	cg00666640	chr1:248458726	OR2T12	0.32	5.81	0.36	2.08e-8	Common traits (Other);
SARC	cis	rs969413	0.624	rs9914093	chr17:79260653	C/G	cg25342872	chr17:79175132	AZI1	-0.38	-5.31	-0.33	2.5e-7	Frontotemporal dementia;
SARC	cis	rs910316	0.967	rs12890371	chr14:75593839	T/C	cg23033748	chr14:75592666	NEK9	0.37	5.3	0.33	2.73e-7	Height;
SARC	cis	rs9457247	0.967	rs447042	chr6:167405435	C/T	cg23791538	chr6:167370224	RNASET2	-0.63	-8.74	-0.5	4.69e-16	Crohn's disease;
SARC	cis	rs10751667	1.000	rs7927156	chr11:970607	A/G	cg10932868	chr11:921992	NA	0.33	4.94	0.31	1.47e-6	Alzheimer's disease (late onset);
SARC	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg05890377	chr2:74357713	NA	0.6	7.22	0.43	7.09e-12	Gestational age at birth (maternal effect);
SARC	cis	rs66887589	0.870	rs10518336	chr4:120522934	G/A	cg09307838	chr4:120376055	NA	0.54	7.21	0.43	7.6e-12	Diastolic blood pressure;
SARC	cis	rs2985684	0.894	rs4900932	chr14:50022928	A/G	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.44	4.92	0.31	1.6e-6	Carotid intima media thickness;
SARC	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg13880726	chr7:1868755	MAD1L1	0.51	6.14	0.37	3.51e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs2204008	0.846	rs2030416	chr12:38465118	A/G	cg26384229	chr12:38710491	ALG10B	-0.8	-11.54	-0.6	1.15e-24	Bladder cancer;
SARC	cis	rs4481887	1.000	rs6659039	chr1:248465689	C/T	cg13385794	chr1:248469461	NA	0.36	5.57	0.34	6.92e-8	Common traits (Other);
SARC	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg22834771	chr12:69754056	YEATS4	-0.48	-6.34	-0.38	1.15e-9	Cerebrospinal fluid biomarker levels;
SARC	cis	rs2070433	0.539	rs2839314	chr21:47961067	A/G	cg12379764	chr21:47803548	PCNT	0.53	5.82	0.36	1.94e-8	Lymphocyte counts;
SARC	cis	rs9341808	0.718	rs6910201	chr6:80904938	G/C	cg08355045	chr6:80787529	NA	0.33	5.33	0.33	2.26e-7	Sitting height ratio;
SARC	cis	rs2594989	1.000	rs2606761	chr3:11344427	G/A	cg00170343	chr3:11313890	ATG7	0.54	5.22	0.32	4.05e-7	Circulating chemerin levels;
SARC	cis	rs4430311	0.723	rs2291409	chr1:243732197	A/G	cg21452805	chr1:244014465	NA	0.39	4.77	0.3	3.24e-6	Post-traumatic stress disorder (asjusted for relatedness);
SARC	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	9.56	0.53	1.74e-18	Platelet count;
SARC	cis	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg25894440	chr7:65020034	NA	-0.78	-6.04	-0.37	6.1e-9	Diabetic kidney disease;
SARC	cis	rs2153535	0.580	rs9393019	chr6:8462091	G/A	cg23788917	chr6:8435910	SLC35B3	0.64	8.55	0.49	1.6e-15	Motion sickness;
SARC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.61	-8.05	-0.47	4.29e-14	Lymphocyte counts;
SARC	cis	rs17345786	0.667	rs7622940	chr3:101133155	T/C	cg12386194	chr3:101231763	SENP7	0.67	8.09	0.47	3.21e-14	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg24110177	chr3:50126178	RBM5	-0.63	-8.28	-0.48	9.81e-15	Intelligence (multi-trait analysis);
SARC	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg22433210	chr17:43662623	NA	1.02	12.43	0.63	1.48e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg08493051	chr2:3487164	NA	-0.39	-4.86	-0.3	2.18e-6	Neurofibrillary tangles;
SARC	cis	rs7927771	0.770	rs11039203	chr11:47384597	A/G	cg20307385	chr11:47447363	PSMC3	-0.57	-7.01	-0.42	2.62e-11	Subjective well-being;
SARC	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg06108461	chr20:60628389	TAF4	-0.92	-12.7	-0.64	1.92e-28	Body mass index;
SARC	cis	rs8044868	0.586	rs6499564	chr16:72189655	G/A	cg16558253	chr16:72132732	DHX38	-0.43	-6.35	-0.38	1.13e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
SARC	cis	rs17666538	0.591	rs7818950	chr8:643831	C/T	cg00450029	chr8:599525	NA	0.65	5.61	0.35	5.67e-8	IgG glycosylation;
SARC	cis	rs818427	0.748	rs468735	chr5:112260972	T/C	cg07820702	chr5:112228657	REEP5	-0.44	-4.87	-0.3	2.1e-6	Total body bone mineral density;
SARC	cis	rs748404	0.578	rs507178	chr15:43610135	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	5.7	0.35	3.65e-8	Lung cancer;
SARC	cis	rs9326248	0.861	rs1871757	chr11:117030581	A/T	cg01368799	chr11:117014884	PAFAH1B2	0.61	6.1	0.37	4.34e-9	Blood protein levels;
SARC	cis	rs9354308	0.933	rs2802062	chr6:66561973	C/G	cg07460842	chr6:66804631	NA	0.48	5.45	0.34	1.3e-7	Metabolite levels;
SARC	cis	rs7264396	0.790	rs6579255	chr20:34219496	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-7.79	-0.45	2.14e-13	Total cholesterol levels;
SARC	cis	rs17253792	0.732	rs8017891	chr14:56172967	A/G	cg01858014	chr14:56050164	KTN1	0.7	6.06	0.37	5.3e-9	Putamen volume;
SARC	cis	rs10489525	0.599	rs910622	chr1:115600424	A/G	cg01522456	chr1:115632236	TSPAN2	-0.47	-5.7	-0.35	3.62e-8	Autism;
SARC	cis	rs1881797	0.932	rs10925071	chr1:247686521	C/T	cg05639522	chr1:247681581	NA	-0.43	-4.84	-0.3	2.4e-6	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs861020	0.630	rs628300	chr1:209998298	C/T	cg05527609	chr1:210001259	C1orf107	0.82	10.43	0.56	3.9e-21	Orofacial clefts;
SARC	cis	rs4689388	0.853	rs4293850	chr4:6292020	A/C	cg25554036	chr4:6271136	WFS1	0.39	6.24	0.38	2.06e-9	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs644799	1.000	rs534497	chr11:95562868	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	14.89	0.7	1.07e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs12950390	0.853	rs4793647	chr17:45854090	G/C	cg24803719	chr17:45855879	NA	-0.46	-7.55	-0.44	9.68e-13	IgG glycosylation;
SARC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg11494091	chr17:61959527	GH2	0.53	7.95	0.46	7.84e-14	Prudent dietary pattern;
SARC	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg13206674	chr6:150067644	NUP43	0.48	6.12	0.37	3.85e-9	Lung cancer;
SARC	cis	rs2952156	1.000	rs1565923	chr17:37858678	A/G	cg20243544	chr17:37824526	PNMT	0.46	5.42	0.33	1.49e-7	Asthma;
SARC	cis	rs10078	0.510	rs2278248	chr5:469570	G/T	cg24955955	chr5:415729	AHRR	0.61	5.84	0.36	1.74e-8	Fat distribution (HIV);
SARC	cis	rs1707322	0.663	rs3935296	chr1:46180470	T/C	cg03146154	chr1:46216737	IPP	-0.53	-6.35	-0.38	1.12e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2832077	0.943	rs4816336	chr21:30193519	C/T	cg24692254	chr21:30365293	RNF160	-0.52	-4.78	-0.3	3.09e-6	Cognitive test performance;
SARC	cis	rs11122272	0.735	rs910822	chr1:231498721	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.11	-0.55	3.67e-20	Hemoglobin concentration;
SARC	cis	rs13082711	0.911	rs2003886	chr3:27527732	G/T	cg02860705	chr3:27208620	NA	0.45	5.69	0.35	3.84e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg22025132	chr6:143771787	ADAT2;PEX3	0.5	6.43	0.39	6.98e-10	Lung adenocarcinoma;
SARC	cis	rs11770686	0.658	rs4731597	chr7:75309363	C/G	cg17787366	chr7:75369077	HIP1	0.4	4.98	0.31	1.25e-6	Essential tremor;
SARC	cis	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg00409905	chr10:38381863	ZNF37A	-0.52	-7.32	-0.43	3.91e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs9916302	0.861	rs644173	chr17:37430519	T/C	cg00129232	chr17:37814104	STARD3	-0.59	-7.39	-0.44	2.58e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs965469	0.895	rs6037595	chr20:3401128	T/G	cg25506879	chr20:3388711	C20orf194	-0.54	-5.84	-0.36	1.74e-8	IFN-related cytopenia;
SARC	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg22433210	chr17:43662623	NA	1.08	12.71	0.64	1.84e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg06873352	chr17:61820015	STRADA	0.52	6.76	0.4	1.1e-10	Prudent dietary pattern;
SARC	cis	rs3762637	1.000	rs72960431	chr3:122228661	T/C	cg24169773	chr3:122142474	KPNA1	-0.58	-6.03	-0.37	6.25e-9	LDL cholesterol levels;
SARC	cis	rs651907	0.557	rs1056579	chr3:101397877	T/G	cg12386194	chr3:101231763	SENP7	0.51	6.13	0.37	3.72e-9	Colorectal cancer;
SARC	cis	rs7666738	0.830	rs13138920	chr4:99020786	A/G	cg05340658	chr4:99064831	C4orf37	0.66	9.04	0.51	6.35e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-10.68	-0.57	6.36e-22	Chronic sinus infection;
SARC	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg06634786	chr22:41940651	POLR3H	-0.57	-6.77	-0.41	1.05e-10	Vitiligo;
SARC	cis	rs1448094	0.511	rs10506918	chr12:86227913	A/G	cg02569458	chr12:86230093	RASSF9	-0.37	-5.23	-0.32	3.8e-7	Major depressive disorder;
SARC	cis	rs3820928	0.874	rs13385711	chr2:227830414	G/T	cg05526886	chr2:227700861	RHBDD1	-0.56	-6.78	-0.41	9.69e-11	Pulmonary function;
SARC	cis	rs8114671	0.836	rs2038504	chr20:33648187	T/C	cg08999081	chr20:33150536	PIGU	-0.34	-4.86	-0.3	2.15e-6	Height;
SARC	cis	rs709400	0.633	rs3783395	chr14:103895020	T/C	cg26031613	chr14:104095156	KLC1	0.8	11.23	0.59	1.12e-23	Body mass index;
SARC	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg16325326	chr1:53192061	ZYG11B	0.92	16.96	0.74	1.48e-42	Monocyte count;
SARC	cis	rs7980687	0.662	rs585522	chr12:123550813	A/G	cg05973401	chr12:123451056	ABCB9	0.51	5.68	0.35	4.02e-8	Height;Educational attainment;Head circumference (infant);
SARC	cis	rs4268898	0.662	rs72793208	chr2:24510284	C/T	cg06627628	chr2:24431161	ITSN2	-0.81	-9.94	-0.55	1.26e-19	Asthma;
SARC	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg12463550	chr7:65579703	CRCP	0.67	5.06	0.31	8.43e-7	Diabetic kidney disease;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg10970614	chr2:149510684	EPC2	0.51	7.51	0.44	1.22e-12	Thyroid stimulating hormone;
SARC	trans	rs61931739	0.500	rs6488215	chr12:34434803	A/T	cg26384229	chr12:38710491	ALG10B	0.84	12.74	0.64	1.41e-28	Morning vs. evening chronotype;
SARC	cis	rs611744	0.967	rs597992	chr8:109193808	A/T	cg21045802	chr8:109455806	TTC35	0.44	5.3	0.33	2.63e-7	Dupuytren's disease;
SARC	cis	rs651907	0.557	rs34624546	chr3:101374226	T/G	cg12386194	chr3:101231763	SENP7	0.52	6.2	0.38	2.56e-9	Colorectal cancer;
SARC	cis	rs920590	0.918	rs11777075	chr8:19655666	G/A	cg01411142	chr8:19674711	INTS10	0.4	4.85	0.3	2.25e-6	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs72634258	0.945	rs7539255	chr1:8133352	T/C	cg00042356	chr1:8021962	PARK7	0.93	8.31	0.48	7.76e-15	Inflammatory bowel disease;
SARC	cis	rs1395	0.744	rs57881048	chr2:27474165	T/C	cg21747090	chr2:27597821	SNX17	-0.46	-5.62	-0.35	5.42e-8	Blood metabolite levels;
SARC	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg21171335	chr12:122356390	WDR66	0.48	7.58	0.44	8.32e-13	Mean corpuscular volume;
SARC	cis	rs17376456	1.000	rs61132622	chr5:93539684	G/A	cg21475434	chr5:93447410	FAM172A	0.93	8.14	0.47	2.44e-14	Diabetic retinopathy;
SARC	cis	rs9611519	0.929	rs11090039	chr22:41496800	G/A	cg17376030	chr22:41985996	PMM1	0.45	5.02	0.31	1.05e-6	Neuroticism;
SARC	cis	rs853679	0.550	rs1225598	chr6:28160799	T/G	cg17221315	chr6:27791827	HIST1H4J	0.48	5.28	0.33	2.97e-7	Depression;
SARC	cis	rs76419734	0.510	rs4699198	chr4:106645771	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.79	9.74	0.54	5.03e-19	Post bronchodilator FEV1;
SARC	cis	rs9815354	0.812	rs73069240	chr3:41950973	A/T	cg03022575	chr3:42003672	ULK4	0.7	5.7	0.35	3.66e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs870825	0.549	rs7699919	chr4:185648610	A/C	cg04058563	chr4:185651563	MLF1IP	0.8	11.35	0.6	4.56e-24	Blood protein levels;
SARC	cis	rs3126085	0.935	rs4845751	chr1:152208997	T/C	cg03465714	chr1:152285911	FLG	-0.44	-5.3	-0.33	2.67e-7	Atopic dermatitis;
SARC	cis	rs78545713	0.881	rs74608402	chr6:26240474	C/T	cg00631329	chr6:26305371	NA	-0.76	-5.07	-0.32	8.03e-7	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs11098499	0.739	rs7441137	chr4:120133221	G/T	cg09307838	chr4:120376055	NA	-0.78	-10.49	-0.57	2.38e-21	Corneal astigmatism;
SARC	cis	rs2916247	0.954	rs10109190	chr8:93171673	C/T	cg10183463	chr8:93005414	RUNX1T1	0.46	4.94	0.31	1.51e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7681440	0.904	rs7671549	chr4:90771147	T/A	cg06632027	chr4:90757378	SNCA	0.4	5.68	0.35	3.9e-8	Dementia with Lewy bodies;
SARC	cis	rs6582630	0.519	rs8189461	chr12:38374870	G/T	cg13010199	chr12:38710504	ALG10B	0.78	10.77	0.58	3.24e-22	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs2727020	0.576	rs12293522	chr11:49558425	T/A	cg03929089	chr4:120376271	NA	-0.81	-12.36	-0.63	2.56e-27	Coronary artery disease;
SARC	cis	rs6545883	0.929	rs2600663	chr2:61540687	A/G	cg15711740	chr2:61764176	XPO1	0.41	4.96	0.31	1.38e-6	Tuberculosis;
SARC	cis	rs7566780	0.714	rs4610058	chr2:16723577	A/T	cg09580478	chr2:16689509	NA	-0.51	-5.49	-0.34	1.05e-7	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg08948823	chr16:67881367	CENPT;NUTF2	0.54	7.15	0.42	1.1e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	trans	rs61931739	0.534	rs10844819	chr12:34261389	G/T	cg26384229	chr12:38710491	ALG10B	0.82	11.54	0.6	1.12e-24	Morning vs. evening chronotype;
SARC	cis	rs6138458	1.000	rs227616	chr20:24908811	T/C	cg26195577	chr20:24973756	C20orf3	0.87	9.5	0.53	2.73e-18	Blood protein levels;
SARC	cis	rs6570726	0.934	rs430003	chr6:145819506	C/T	cg23711669	chr6:146136114	FBXO30	0.78	11.91	0.62	7.29e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg12257692	chr3:49977190	RBM6	0.27	4.78	0.3	3.07e-6	Body mass index;
SARC	cis	rs7666738	1.000	rs35066600	chr4:98991066	C/A	cg05340658	chr4:99064831	C4orf37	0.57	7.09	0.42	1.58e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg14456004	chr13:21872349	NA	0.47	5.6	0.34	6.1e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs3733585	0.699	rs7683283	chr4:9969974	T/C	cg11266682	chr4:10021025	SLC2A9	-0.38	-6.41	-0.39	7.9e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	trans	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg20587970	chr11:113659929	NA	-1.29	-13.65	-0.67	1.47e-31	Hip circumference adjusted for BMI;
SARC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	20.71	0.8	9.91e-55	Prudent dietary pattern;
SARC	cis	rs897984	0.683	rs72799316	chr16:30827205	A/G	cg00531865	chr16:30841666	NA	-0.51	-6.1	-0.37	4.4e-9	Dementia with Lewy bodies;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg06898199	chr7:128502890	ATP6V1F	0.74	6.24	0.38	2.05e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg22535103	chr8:58192502	C8orf71	-0.68	-8.08	-0.47	3.56e-14	Developmental language disorder (linguistic errors);
SARC	cis	rs7474896	0.515	rs675628	chr10:38305331	C/G	cg00409905	chr10:38381863	ZNF37A	0.45	4.9	0.31	1.79e-6	Obesity (extreme);
SARC	cis	rs7772486	0.790	rs2249147	chr6:146184999	T/C	cg05347473	chr6:146136440	FBXO30	0.51	7.31	0.43	4.27e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2834188	0.557	rs1058867	chr21:34669381	A/G	cg14352951	chr21:34696688	IFNAR1	-0.4	-5.09	-0.32	7.41e-7	Narcolepsy;
SARC	cis	rs7917772	0.629	rs1475646	chr10:104522564	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-6.38	-0.39	9.19e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs79146658	0.736	rs4894060	chr2:179751817	T/A	cg17765952	chr2:179737173	CCDC141	-0.62	-5.08	-0.32	7.7300000000000005e-07	Diastolic blood pressure;
SARC	cis	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg20965017	chr5:231967	SDHA	-0.54	-5.35	-0.33	2.09e-7	Breast cancer;
SARC	cis	rs4481887	0.927	rs10888343	chr1:248446642	A/G	cg13385794	chr1:248469461	NA	0.35	5.27	0.33	3.1e-7	Common traits (Other);
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg02870950	chr10:46168231	ANUBL1	0.51	6.44	0.39	6.71e-10	Gallstone disease;
SARC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg14159672	chr1:205819179	PM20D1	0.94	17.54	0.75	1.82e-44	Menarche (age at onset);
SARC	cis	rs13191362	0.935	rs73008456	chr6:163013697	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.57	5.47	0.34	1.16e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs2303759	0.626	rs12982246	chr19:49801169	A/G	cg24324837	chr19:49891574	CCDC155	0.39	4.72	0.3	4.14e-6	Multiple sclerosis;
SARC	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg19729930	chr2:74357872	NA	0.73	10.65	0.57	7.48e-22	Gestational age at birth (maternal effect);
SARC	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.45	-5.68	-0.35	4.01e-8	Personality dimensions;
SARC	cis	rs10892173	0.678	rs4537790	chr11:117661356	A/G	cg21640587	chr11:117668038	DSCAML1	0.4	5.56	0.34	7.4e-8	Myopia;
SARC	cis	rs7766436	0.885	rs4712698	chr6:22592807	C/T	cg13666174	chr6:22585274	NA	-0.61	-7.98	-0.46	6.78e-14	Coronary artery disease;
SARC	cis	rs17376456	0.569	rs7702348	chr5:93065683	A/G	cg21475434	chr5:93447410	FAM172A	-0.56	-5.51	-0.34	9.55e-8	Diabetic retinopathy;
SARC	cis	rs17270561	0.609	rs2000350	chr6:25763154	T/C	cg17691542	chr6:26056736	HIST1H1C	0.57	7.0	0.42	2.78e-11	Iron status biomarkers;
SARC	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg23758822	chr17:41437982	NA	0.88	11.66	0.61	4.86e-25	Menopause (age at onset);
SARC	cis	rs6540556	0.723	rs12090931	chr1:209889601	A/G	cg05527609	chr1:210001259	C1orf107	-0.56	-5.02	-0.31	1.01e-6	Red blood cell count;
SARC	cis	rs2834188	1.000	rs2409488	chr21:34688914	A/C	cg04842828	chr21:34696676	IFNAR1	0.41	4.83	0.3	2.43e-6	Narcolepsy;
SARC	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg08280861	chr8:58055591	NA	0.65	5.56	0.34	7.33e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs8180040	0.739	rs4683320	chr3:47152992	C/T	cg02527881	chr3:46936655	PTH1R	-0.31	-4.9	-0.31	1.8e-6	Colorectal cancer;
SARC	cis	rs826838	1.000	rs12366971	chr12:38737687	T/G	cg26384229	chr12:38710491	ALG10B	0.97	15.75	0.72	1.54e-38	Heart rate;
SARC	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg22535103	chr8:58192502	C8orf71	-0.57	-5.67	-0.35	4.3e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs453301	0.571	rs330054	chr8:9088291	G/A	cg06636001	chr8:8085503	FLJ10661	-0.68	-9.25	-0.52	1.5e-17	Joint mobility (Beighton score);
SARC	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg20573242	chr4:122745356	CCNA2	0.64	8.11	0.47	2.93e-14	Type 2 diabetes;
SARC	trans	rs61931739	0.500	rs34287388	chr12:34444626	C/A	cg26384229	chr12:38710491	ALG10B	0.92	13.84	0.67	3.3e-32	Morning vs. evening chronotype;
SARC	cis	rs9303401	0.527	rs2116450	chr17:56745561	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	11.45	0.6	2.21e-24	Cognitive test performance;
SARC	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg11987759	chr7:65425863	GUSB	-0.47	-6.25	-0.38	1.91e-9	Aortic root size;
SARC	cis	rs6714710	0.627	rs11680883	chr2:98472610	T/C	cg26665480	chr2:98280029	ACTR1B	0.57	7.73	0.45	3.19e-13	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs10206020	0.885	rs13411553	chr2:1574018	A/G	cg12573674	chr2:1569213	NA	-0.44	-5.22	-0.32	3.95e-7	IgG glycosylation;
SARC	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.97e-8	Aortic root size;
SARC	cis	rs11585357	0.947	rs2977303	chr1:17611548	A/T	cg08277548	chr1:17600880	PADI3	-0.43	-5.19	-0.32	4.58e-7	Hair shape;
SARC	cis	rs7659604	0.791	rs57316471	chr4:122663939	A/G	cg20573242	chr4:122745356	CCNA2	0.48	6.14	0.37	3.45e-9	Type 2 diabetes;
SARC	cis	rs17376456	0.877	rs9314101	chr5:93461593	A/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.79	0.35	2.3e-8	Diabetic retinopathy;
SARC	cis	rs4851254	0.961	rs11680586	chr2:100746207	G/T	cg17356467	chr2:100759845	AFF3	0.31	5.29	0.33	2.79e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg27266027	chr21:40555129	PSMG1	-0.5	-5.42	-0.33	1.5e-7	Cognitive function;
SARC	cis	rs754466	0.606	rs10824581	chr10:79599501	A/G	cg17075019	chr10:79541650	NA	-0.83	-12.71	-0.64	1.76e-28	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs524281	0.773	rs11227448	chr11:66048491	G/A	cg14036092	chr11:66035641	RAB1B	-0.58	-5.75	-0.35	2.74e-8	Electroencephalogram traits;
SARC	cis	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg12064134	chr16:90016061	DEF8	-0.58	-5.01	-0.31	1.08e-6	Skin colour saturation;
SARC	cis	rs6964587	0.692	rs2158138	chr7:91700879	A/G	cg17063962	chr7:91808500	NA	0.82	12.17	0.62	1.08e-26	Breast cancer;
SARC	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg06420487	chr17:61919686	SMARCD2	0.48	5.47	0.34	1.16e-7	Height;
SARC	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg22968622	chr17:43663579	NA	-1.13	-15.28	-0.71	5.37e-37	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9611519	1.000	rs5758268	chr22:41622419	A/T	cg17376030	chr22:41985996	PMM1	0.48	5.82	0.36	1.95e-8	Neuroticism;
SARC	cis	rs7086627	0.515	rs10887895	chr10:82210011	A/G	cg01528321	chr10:82214614	TSPAN14	0.57	8.41	0.48	4.07e-15	Post bronchodilator FEV1;
SARC	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg01341218	chr17:43662625	NA	-0.84	-9.47	-0.53	3.19e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs28374715	0.662	rs28587487	chr15:41495460	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.0	-13.62	-0.67	1.85e-31	Ulcerative colitis;
SARC	cis	rs11608355	1.000	rs2075439	chr12:109859374	A/G	cg19025524	chr12:109796872	NA	-0.4	-5.1	-0.32	6.98e-7	Neuroticism;
SARC	cis	rs1044826	1.000	rs114427693	chr3:139121721	G/A	cg15131784	chr3:139108705	COPB2	0.45	5.28	0.33	2.95e-7	Obesity-related traits;
SARC	cis	rs2742234	0.955	rs2503841	chr10:43675721	C/T	cg11200635	chr10:43573195	RET	-0.4	-4.75	-0.3	3.61e-6	Hirschsprung disease;
SARC	cis	rs7552404	0.628	rs5745442	chr1:76342858	T/G	cg03433033	chr1:76189801	ACADM	0.46	5.47	0.34	1.15e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs3008870	0.755	rs2208577	chr1:67513574	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.39	4.75	0.3	3.48e-6	Lymphocyte percentage of white cells;
SARC	cis	rs10140922	0.966	rs4982265	chr14:35828393	T/A	cg26967526	chr14:35346199	BAZ1A	-0.39	-4.73	-0.3	3.92e-6	Hip circumference adjusted for BMI;
SARC	cis	rs9896052	0.580	rs7406977	chr17:73460417	T/G	cg25649188	chr17:73499917	CASKIN2	0.35	4.98	0.31	1.25e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg03735888	chr19:58951602	ZNF132	0.42	5.48	0.34	1.1e-7	Uric acid clearance;
SARC	cis	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg13072238	chr3:49761600	GMPPB	0.44	5.64	0.35	4.82e-8	Intelligence (multi-trait analysis);
SARC	trans	rs34421088	0.560	rs2467520	chr8:11398953	T/C	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.58	-0.4	3.1e-10	Neuroticism;
SARC	cis	rs62344088	0.590	rs62345236	chr5:283519	G/A	cg22857025	chr5:266934	NA	-1.04	-7.75	-0.45	2.87e-13	Asthma (childhood onset);
SARC	cis	rs5753618	0.539	rs1034588	chr22:31616301	A/G	cg13145458	chr22:31556086	RNF185	0.47	4.99	0.31	1.17e-6	Colorectal cancer;
SARC	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.2	0.38	2.57e-9	Height;
SARC	cis	rs595982	0.559	rs17272680	chr19:49364511	A/G	cg15549821	chr19:49342101	PLEKHA4	0.64	7.66	0.45	4.89e-13	Red cell distribution width;
SARC	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg14517863	chr17:44321492	NA	0.38	5.6	0.34	5.96e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg22903657	chr4:1355424	KIAA1530	-0.36	-4.89	-0.31	1.84e-6	Obesity-related traits;
SARC	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.5	-6.31	-0.38	1.39e-9	Lymphocyte counts;
SARC	cis	rs6120849	0.708	rs6087659	chr20:33606383	C/A	cg06115741	chr20:33292138	TP53INP2	0.56	5.25	0.33	3.49e-7	Protein C levels;
SARC	cis	rs981844	0.816	rs56109239	chr4:154726500	A/G	cg14289246	chr4:154710475	SFRP2	0.58	6.32	0.38	1.31e-9	Response to statins (LDL cholesterol change);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg19502122	chr13:45775900	KCTD4;GTF2F2	0.48	6.78	0.41	9.55e-11	Thyroid stimulating hormone;
SARC	trans	rs877282	0.898	rs11253346	chr10:765313	A/G	cg22713356	chr15:30763199	NA	1.04	10.06	0.55	5.37e-20	Uric acid levels;
SARC	cis	rs9513627	1.000	rs7327068	chr13:100126965	A/G	cg25919922	chr13:100150906	NA	-0.66	-5.0	-0.31	1.14e-6	Obesity-related traits;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg19812938	chr17:80888632	TBCD	-0.5	-6.41	-0.39	7.9e-10	Height;
SARC	cis	rs2658782	0.901	rs11604909	chr11:93218355	C/G	cg15737290	chr11:93063684	CCDC67	0.58	6.09	0.37	4.66e-9	Pulmonary function decline;
SARC	cis	rs3820928	0.935	rs10203363	chr2:227896976	C/T	cg11843606	chr2:227700838	RHBDD1	-0.55	-6.84	-0.41	6.88e-11	Pulmonary function;
SARC	cis	rs9393692	0.905	rs6908328	chr6:26292855	C/A	cg05868516	chr6:26286170	HIST1H4H	0.58	7.62	0.45	6.39e-13	Educational attainment;
SARC	cis	rs9430161	0.611	rs72644043	chr1:11033051	T/A	cg27631724	chr1:11040367	C1orf127	0.33	4.71	0.3	4.2e-6	Ewing sarcoma;
SARC	cis	rs73086581	1.000	rs73086505	chr20:3921571	A/G	cg02187196	chr20:3869020	PANK2	0.66	6.36	0.38	1.03e-9	Response to antidepressants in depression;
SARC	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg22920501	chr2:26401640	FAM59B	0.61	7.93	0.46	8.99e-14	Gut microbiome composition (summer);
SARC	cis	rs7089973	0.604	rs11196932	chr10:116584386	C/T	cg03647239	chr10:116582469	FAM160B1	0.49	6.31	0.38	1.42e-9	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs4481887	0.830	rs28581861	chr1:248506028	T/G	cg01631408	chr1:248437212	OR2T33	-0.45	-6.05	-0.37	5.83e-9	Common traits (Other);
SARC	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg05368731	chr17:41323189	NBR1	0.81	9.93	0.55	1.36e-19	Menopause (age at onset);
SARC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.71	9.51	0.53	2.53e-18	Lymphocyte counts;
SARC	cis	rs911263	0.603	rs1956532	chr14:68783274	A/G	cg18825221	chr14:68749962	RAD51L1	0.4	7.18	0.43	9.09e-12	Primary biliary cholangitis;
SARC	trans	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg20587970	chr11:113659929	NA	-1.35	-13.48	-0.66	5.32e-31	Hip circumference adjusted for BMI;
SARC	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9398803	0.584	rs3850234	chr6:127001534	T/G	cg19875578	chr6:126661172	C6orf173	0.64	8.86	0.5	2.09e-16	Male-pattern baldness;
SARC	cis	rs1881797	1.000	rs1881794	chr1:247682920	G/C	cg18198730	chr1:247681584	NA	-0.52	-5.92	-0.36	1.15e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs7555523	0.830	rs12691500	chr1:165687761	A/G	cg24409356	chr1:165738333	TMCO1	0.68	5.51	0.34	9.7e-8	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	cis	rs6964587	0.743	rs33993294	chr7:91998655	A/C	cg17063962	chr7:91808500	NA	0.91	12.93	0.65	3.42e-29	Breast cancer;
SARC	cis	rs8044995	0.563	rs61602448	chr16:68377520	C/T	cg09835421	chr16:68378352	PRMT7	-0.67	-6.33	-0.38	1.23e-9	Schizophrenia;
SARC	cis	rs9398803	0.687	rs12208811	chr6:126926898	T/G	cg19875578	chr6:126661172	C6orf173	0.63	8.7	0.5	5.9e-16	Male-pattern baldness;
SARC	cis	rs113835537	0.597	rs3825065	chr11:66311011	A/G	cg24851651	chr11:66362959	CCS	0.39	4.91	0.31	1.7e-6	Airway imaging phenotypes;
SARC	cis	rs35995292	0.963	rs10239557	chr7:38950137	C/T	cg19327137	chr7:38886074	VPS41	0.36	5.14	0.32	5.77e-7	Subjective well-being (multi-trait analysis);
SARC	cis	rs1448094	0.533	rs2169572	chr12:86170370	G/T	cg02569458	chr12:86230093	RASSF9	-0.37	-5.03	-0.31	9.78e-7	Major depressive disorder;
SARC	cis	rs694739	1.000	rs1783521	chr11:64106291	T/C	cg26898376	chr11:64110657	CCDC88B	0.35	4.9	0.31	1.82e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg03264133	chr6:25882463	NA	-0.55	-7.21	-0.43	7.59e-12	Intelligence (multi-trait analysis);
SARC	cis	rs7712401	0.601	rs246322	chr5:122307269	C/T	cg19412675	chr5:122181750	SNX24	-0.4	-5.14	-0.32	5.79e-7	Mean platelet volume;
SARC	cis	rs1949733	0.701	rs2631735	chr4:8476118	A/G	cg13073564	chr4:8508604	NA	-0.37	-5.4	-0.33	1.66e-7	Response to antineoplastic agents;
SARC	cis	rs6991838	0.798	rs6994889	chr8:66474782	T/C	cg13398993	chr8:66546079	ARMC1	0.47	6.25	0.38	1.91e-9	Intelligence (multi-trait analysis);
SARC	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg04277193	chr17:41438351	NA	0.46	5.0	0.31	1.1e-6	Menopause (age at onset);
SARC	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg23758822	chr17:41437982	NA	0.89	11.37	0.6	3.91e-24	Menopause (age at onset);
SARC	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg27347728	chr4:17578864	LAP3	0.46	5.85	0.36	1.68e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7843479	0.965	rs4636204	chr8:21823206	T/G	cg17168535	chr8:21777572	XPO7	0.62	7.87	0.46	1.37e-13	Mean corpuscular volume;
SARC	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.59e-6	Depression;
SARC	cis	rs265548	0.510	rs28415068	chr19:17910582	T/A	cg16744531	chr19:17905626	B3GNT3	0.36	4.73	0.3	3.91e-6	Tumor biomarkers;
SARC	cis	rs11722228	1.000	rs6825187	chr4:9915325	T/C	cg11266682	chr4:10021025	SLC2A9	-0.32	-5.3	-0.33	2.64e-7	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs6696846	0.716	rs6593921	chr1:205062861	A/G	cg07972983	chr1:205091412	RBBP5	0.56	6.87	0.41	5.79e-11	Red blood cell count;
SARC	trans	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg17712092	chr4:129076599	LARP1B	0.72	9.7	0.54	6.65e-19	Eosinophil percentage of white cells;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg15604507	chr11:19263433	E2F8	-0.5	-6.46	-0.39	6.03e-10	Height;
SARC	cis	rs8141529	0.664	rs5762861	chr22:29250505	T/G	cg02153584	chr22:29168773	CCDC117	0.66	8.51	0.49	2.1e-15	Lymphocyte counts;
SARC	cis	rs9790314	0.846	rs6441371	chr3:161008727	C/A	cg04691961	chr3:161091175	C3orf57	-0.75	-10.77	-0.58	3.23e-22	Morning vs. evening chronotype;
SARC	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg19774624	chr17:42201019	HDAC5	-0.83	-13.05	-0.65	1.42e-29	Total body bone mineral density;
SARC	cis	rs2742234	0.518	rs1254967	chr10:43690391	G/A	cg15436174	chr10:43711423	RASGEF1A	0.4	4.74	0.3	3.67e-6	Hirschsprung disease;
SARC	cis	rs11690935	0.851	rs6433319	chr2:172830953	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.77	-10.71	-0.57	4.89e-22	Schizophrenia;
SARC	cis	rs7666738	0.791	rs28858828	chr4:98950442	C/G	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg19346786	chr7:2764209	NA	-0.4	-5.97	-0.36	8.84e-9	Height;
SARC	cis	rs7772486	0.790	rs9390365	chr6:146235626	A/G	cg23711669	chr6:146136114	FBXO30	-0.81	-12.86	-0.64	5.82e-29	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs763121	0.853	rs5757162	chr22:38993370	C/T	cg06022373	chr22:39101656	GTPBP1	0.87	10.88	0.58	1.46e-22	Menopause (age at onset);
SARC	cis	rs8114671	0.527	rs2295352	chr20:33320055	C/G	cg08999081	chr20:33150536	PIGU	-0.32	-4.73	-0.3	3.9e-6	Height;
SARC	cis	rs9398803	0.723	rs853983	chr6:127046153	G/A	cg20229609	chr6:126660872	C6orf173	-0.34	-4.85	-0.3	2.29e-6	Male-pattern baldness;
SARC	cis	rs9894429	0.752	rs6565610	chr17:79592652	A/G	cg18240062	chr17:79603768	NPLOC4	0.88	13.71	0.67	9.24e-32	Eye color traits;
SARC	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg03060546	chr3:49711283	APEH	0.43	5.33	0.33	2.31e-7	Parkinson's disease;
SARC	cis	rs5758659	0.652	rs133323	chr22:42405922	T/C	cg04733989	chr22:42467013	NAGA	0.5	6.7	0.4	1.52e-10	Cognitive function;
SARC	cis	rs11792861	0.816	rs744980	chr9:111690388	C/T	cg13535736	chr9:111863775	C9orf5	-0.38	-4.78	-0.3	3.12e-6	Menarche (age at onset);
SARC	cis	rs1371867	0.846	rs1616833	chr8:101271821	C/T	cg11906718	chr8:101322791	RNF19A	-0.68	-9.07	-0.51	5.09e-17	Atrioventricular conduction;
SARC	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	10.98	0.58	6.89e-23	Platelet count;
SARC	cis	rs921968	0.565	rs13408427	chr2:219628389	C/T	cg02176678	chr2:219576539	TTLL4	-0.33	-4.96	-0.31	1.37e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs9831754	0.906	rs4680929	chr3:78387591	T/A	cg06138941	chr3:78371609	NA	-0.59	-6.91	-0.41	4.53e-11	Calcium levels;
SARC	cis	rs2836633	0.929	rs62217519	chr21:40034390	G/A	cg12884169	chr21:40033163	ERG	0.48	8.76	0.5	3.97e-16	Coronary artery disease;
SARC	cis	rs6582630	0.598	rs11182207	chr12:38477514	T/C	cg13010199	chr12:38710504	ALG10B	-0.46	-5.63	-0.35	5.15e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs4690686	0.500	rs7683662	chr4:177272004	A/T	cg17059388	chr4:177262070	NA	0.39	5.01	0.31	1.06e-6	Essential tremor;
SARC	cis	rs5769765	0.954	rs5770709	chr22:50245196	G/T	cg03033257	chr22:50311977	ALG12;CRELD2	-0.55	-5.59	-0.34	6.42e-8	Schizophrenia;
SARC	trans	rs1814175	0.559	rs1818892	chr11:49863084	C/A	cg03929089	chr4:120376271	NA	-0.83	-12.24	-0.63	6.14e-27	Height;
SARC	cis	rs10911251	0.528	rs10911265	chr1:183115071	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.67	9.56	0.53	1.72e-18	Colorectal cancer;
SARC	cis	rs2070488	0.689	rs6809352	chr3:38544349	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.74	-10.65	-0.57	7.79e-22	Electrocardiographic conduction measures;
SARC	cis	rs9300255	0.568	rs3018098	chr12:123654812	T/C	cg00376283	chr12:123451042	ABCB9	0.58	6.82	0.41	7.75e-11	Neutrophil percentage of white cells;
SARC	cis	rs4595586	0.525	rs35089392	chr12:39414547	T/G	cg26384229	chr12:38710491	ALG10B	0.55	6.09	0.37	4.74e-9	Morning vs. evening chronotype;
SARC	cis	rs1050631	0.592	rs1789508	chr18:33736845	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.55	6.41	0.39	8.08e-10	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg24503407	chr1:205819492	PM20D1	0.8	12.35	0.63	2.7e-27	Menarche (age at onset);
SARC	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg00409905	chr10:38381863	ZNF37A	-0.49	-6.62	-0.4	2.42e-10	Extrinsic epigenetic age acceleration;
SARC	cis	rs9303401	0.614	rs34058624	chr17:57118121	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.97	9.9	0.54	1.68e-19	Cognitive test performance;
SARC	cis	rs6582630	0.555	rs11503799	chr12:38294578	G/A	cg26384229	chr12:38710491	ALG10B	-0.62	-7.76	-0.45	2.61e-13	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7103648	0.695	rs12223593	chr11:47789082	T/G	cg10504702	chr11:47789108	FNBP4	0.77	10.07	0.55	4.85e-20	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs1056053	0.514	rs3127332	chr6:166573438	G/A	cg11088901	chr6:166572345	T	-0.42	-5.5	-0.34	9.98e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs672059	1.000	rs510642	chr1:183162776	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.51	6.94	0.41	3.79e-11	Hypertriglyceridemia;
SARC	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg17376030	chr22:41985996	PMM1	-0.64	-8.03	-0.47	4.72e-14	Vitiligo;
SARC	cis	rs2120243	0.539	rs9990136	chr3:157075834	C/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.4	5.08	0.32	7.77e-7	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs28386778	0.700	rs12452767	chr17:62010503	G/A	cg11494091	chr17:61959527	GH2	-0.45	-6.47	-0.39	5.7e-10	Prudent dietary pattern;
SARC	cis	rs7208859	0.673	rs2269915	chr17:29233344	C/T	cg13385521	chr17:29058706	SUZ12P	0.85	7.23	0.43	7.08e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9341808	0.529	rs2322765	chr6:81064596	A/G	cg08355045	chr6:80787529	NA	0.32	4.93	0.31	1.56e-6	Sitting height ratio;
SARC	cis	rs7336332	0.662	rs9581862	chr13:28039993	T/G	cg01674679	chr13:27998804	GTF3A	-0.6	-5.9	-0.36	1.27e-8	Weight;
SARC	cis	rs7000551	0.606	rs3802199	chr8:22267385	A/G	cg12081754	chr8:22256438	SLC39A14	0.87	12.5	0.63	8.56e-28	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs6582630	0.555	rs35284307	chr12:38509999	T/G	cg13010199	chr12:38710504	ALG10B	0.76	10.49	0.57	2.39e-21	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9916302	0.861	rs11658219	chr17:37709782	G/A	cg20243544	chr17:37824526	PNMT	0.56	6.71	0.4	1.45e-10	Glomerular filtration rate (creatinine);
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg11939780	chr7:104654463	MLL5;LOC100216545	-0.52	-6.96	-0.41	3.34e-11	Neuroticism;
SARC	cis	rs79149102	0.579	rs7163390	chr15:75280426	T/C	cg17294928	chr15:75287854	SCAMP5	-0.99	-8.95	-0.51	1.16e-16	Lung cancer;
SARC	cis	rs4481887	0.927	rs4350233	chr1:248489994	G/A	cg13385794	chr1:248469461	NA	0.33	4.96	0.31	1.35e-6	Common traits (Other);
SARC	cis	rs9868809	0.505	rs13063223	chr3:48750340	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.57	-5.28	-0.33	2.94e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21627760	chr19:57862638	ZNF304	-0.51	-6.31	-0.38	1.37e-9	Smoking initiation;
SARC	cis	rs4722166	0.630	rs10950916	chr7:22799667	C/T	cg26061582	chr7:22766209	IL6	0.61	6.74	0.4	1.2e-10	Lung cancer;
SARC	cis	rs72627123	0.867	rs57685514	chr14:74487592	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.74	5.84	0.36	1.78e-8	Morning vs. evening chronotype;
SARC	trans	rs1994135	0.654	rs1384591	chr12:33734170	T/C	cg26384229	chr12:38710491	ALG10B	0.71	8.74	0.5	4.71e-16	Resting heart rate;
SARC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg09373136	chr17:61933544	TCAM1	-0.45	-6.2	-0.38	2.48e-9	Prudent dietary pattern;
SARC	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg05863683	chr7:1912471	MAD1L1	0.36	5.43	0.33	1.45e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs921968	0.565	rs6704575	chr2:219589594	C/T	cg02176678	chr2:219576539	TTLL4	0.36	5.54	0.34	8.23e-8	Mean corpuscular hemoglobin concentration;
SARC	cis	rs13256369	0.851	rs13258283	chr8:8563630	T/C	cg18904891	chr8:8559673	CLDN23	0.49	5.49	0.34	1.02e-7	Obesity-related traits;
SARC	cis	rs7481584	0.624	rs413368	chr11:3047646	C/G	cg20651018	chr11:3035856	CARS	0.41	6.08	0.37	4.91e-9	Calcium levels;
SARC	cis	rs10504229	0.593	rs2317990	chr8:58024168	G/T	cg08280861	chr8:58055591	NA	0.61	5.41	0.33	1.59e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs17401966	0.894	rs12722830	chr1:10395134	A/G	cg15208524	chr1:10270712	KIF1B	0.51	6.01	0.37	7.13e-9	Hepatocellular carcinoma;
SARC	cis	rs3126085	0.877	rs4456097	chr1:152229741	G/A	cg26876637	chr1:152193138	HRNR	0.45	5.14	0.32	5.9e-7	Atopic dermatitis;
SARC	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	5.56	0.34	7.37e-8	Height;
SARC	cis	rs3741151	1.000	rs74749711	chr11:73052839	A/T	cg17517138	chr11:73019481	ARHGEF17	0.82	6.75	0.4	1.14e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs3820928	0.874	rs6728239	chr2:227856552	A/G	cg11843606	chr2:227700838	RHBDD1	-0.49	-5.96	-0.36	9.38e-9	Pulmonary function;
SARC	cis	rs2273669	0.667	rs116189763	chr6:109302894	T/C	cg05315195	chr6:109294784	ARMC2	-0.57	-5.24	-0.32	3.62e-7	Prostate cancer;
SARC	cis	rs17021463	0.966	rs10856908	chr4:95222755	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.5	-7.37	-0.43	2.93e-12	Testicular germ cell tumor;
SARC	cis	rs6542838	0.671	rs6752025	chr2:99505699	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.51	-6.62	-0.4	2.46e-10	Fear of minor pain;
SARC	trans	rs12310956	0.532	rs11052935	chr12:33970946	C/T	cg13010199	chr12:38710504	ALG10B	0.65	8.66	0.49	7.86e-16	Morning vs. evening chronotype;
SARC	cis	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg24110177	chr3:50126178	RBM5	0.65	8.8	0.5	3.23e-16	Body mass index;
SARC	cis	rs9300255	0.602	rs2695479	chr12:123689386	T/C	cg00376283	chr12:123451042	ABCB9	0.58	5.7	0.35	3.65e-8	Neutrophil percentage of white cells;
SARC	cis	rs4642101	0.793	rs13086170	chr3:12832604	G/C	cg05775895	chr3:12838266	CAND2	0.75	11.88	0.61	9.49e-26	QRS complex (12-leadsum);
SARC	cis	rs12311304	0.965	rs12322836	chr12:15368093	G/C	cg08258403	chr12:15378311	NA	0.5	7.49	0.44	1.41e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs412050	0.744	rs735244	chr22:22292099	C/T	cg17089214	chr22:22089827	YPEL1	0.6	5.53	0.34	8.4e-8	Attention deficit hyperactivity disorder;
SARC	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg18252515	chr7:66147081	NA	-0.48	-5.24	-0.32	3.55e-7	Aortic root size;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg04769705	chr14:69262517	C14orf181	-0.52	-6.64	-0.4	2.14e-10	Schizophrenia;
SARC	cis	rs12956009	0.558	rs12960592	chr18:44857203	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.57	7.35	0.43	3.24e-12	Educational attainment (years of education);
SARC	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg05793240	chr7:2802953	GNA12	-0.36	-5.21	-0.32	4.19e-7	Height;
SARC	cis	rs2200578	1.000	rs7566277	chr2:99916242	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.53	4.85	0.3	2.28e-6	IgG glycosylation;
SARC	cis	rs1538970	1.000	rs4520450	chr1:45834773	A/G	cg05343316	chr1:45956843	TESK2	0.67	7.72	0.45	3.51e-13	Platelet count;
SARC	cis	rs17125944	0.615	rs1998779	chr14:53295950	T/A	cg00686598	chr14:53173677	PSMC6	-0.77	-5.89	-0.36	1.35e-8	Alzheimer's disease (late onset);
SARC	cis	rs10463316	0.894	rs7707964	chr5:150765475	C/T	cg03212797	chr5:150827313	SLC36A1	-0.46	-5.46	-0.34	1.23e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs807669	0.548	rs723414	chr22:19185736	G/A	cg02655711	chr22:19163373	SLC25A1	0.47	6.98	0.42	3.01e-11	Metabolite levels;
SARC	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.78	-11.7	-0.61	3.43e-25	Personality dimensions;
SARC	trans	rs61931739	0.500	rs7309931	chr12:34483471	A/C	cg13010199	chr12:38710504	ALG10B	0.77	10.92	0.58	1.08e-22	Morning vs. evening chronotype;
SARC	cis	rs79349575	0.721	rs3744608	chr17:46993233	C/G	cg16584676	chr17:46985605	UBE2Z	0.53	6.38	0.39	9.28e-10	Type 2 diabetes;
SARC	cis	rs7412746	0.658	rs3843843	chr1:150918084	C/T	cg13175981	chr1:150552382	MCL1	-0.49	-5.89	-0.36	1.37e-8	Melanoma;
SARC	cis	rs7681440	0.904	rs1372521	chr4:90765223	G/A	cg06632027	chr4:90757378	SNCA	0.39	5.66	0.35	4.49e-8	Dementia with Lewy bodies;
SARC	cis	rs1008375	1.000	rs10939743	chr4:17662731	G/A	cg02297831	chr4:17616191	MED28	0.41	5.05	0.31	8.72e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2075371	0.897	rs1646702	chr7:134000177	C/G	cg11752832	chr7:134001865	SLC35B4	0.56	7.1	0.42	1.47e-11	Mean platelet volume;
SARC	cis	rs67311347	1.000	rs12638199	chr3:40475285	A/G	cg01475735	chr3:40494733	NA	-0.41	-4.81	-0.3	2.69e-6	Renal cell carcinoma;
SARC	cis	rs3106136	0.843	rs901615	chr4:95228687	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.38	-5.74	-0.35	2.94e-8	Capecitabine sensitivity;
SARC	cis	rs240110	0.539	rs6934256	chr6:101338728	G/A	cg09795085	chr6:101329169	ASCC3	0.57	7.9	0.46	1.07e-13	Neuroticism;
SARC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg11494091	chr17:61959527	GH2	0.53	7.86	0.46	1.4e-13	Prudent dietary pattern;
SARC	cis	rs8031584	0.958	rs1043742	chr15:31232581	A/C	cg08109568	chr15:31115862	NA	-0.46	-5.66	-0.35	4.4e-8	Huntington's disease progression;
SARC	cis	rs2153535	0.580	rs7741403	chr6:8530578	C/T	cg21535247	chr6:8435926	SLC35B3	-0.49	-6.19	-0.38	2.74e-9	Motion sickness;
SARC	cis	rs854765	0.583	rs9635697	chr17:17870394	T/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.43	5.44	0.34	1.33e-7	Total body bone mineral density;
SARC	cis	rs765787	0.530	rs2413775	chr15:45544288	T/A	cg24006582	chr15:45444508	DUOX1	-0.5	-6.62	-0.4	2.4e-10	Uric acid levels;
SARC	cis	rs2273669	0.667	rs78714994	chr6:109350351	G/C	cg05315195	chr6:109294784	ARMC2	-0.63	-5.7	-0.35	3.6e-8	Prostate cancer;
SARC	cis	rs288326	0.561	rs75848966	chr2:183878093	A/C	cg09997497	chr2:183902928	NCKAP1	0.74	5.1	0.32	6.97e-7	Blood protein levels;
SARC	cis	rs3771570	1.000	rs62193207	chr2:242318501	G/C	cg21155796	chr2:242212141	HDLBP	0.68	6.08	0.37	4.93e-9	Prostate cancer;
SARC	cis	rs8067545	0.750	rs34290687	chr17:19991211	G/A	cg13482628	chr17:19912719	NA	0.52	6.93	0.41	4.18e-11	Schizophrenia;
SARC	cis	rs2073499	0.872	rs78671882	chr3:50411188	C/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.55	5.05	0.31	8.77e-7	Schizophrenia;
SARC	cis	rs4689388	0.856	rs4308430	chr4:6294095	A/G	cg25554036	chr4:6271136	WFS1	0.39	6.36	0.38	1.08e-9	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs2439831	0.850	rs28858500	chr15:44156942	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	8.13	0.47	2.58e-14	Lung cancer in ever smokers;
SARC	cis	rs6912958	0.678	rs9450744	chr6:88280529	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-6.8	-0.41	8.58e-11	Monocyte percentage of white cells;
SARC	cis	rs17376456	0.825	rs12188163	chr5:93250608	A/G	cg21475434	chr5:93447410	FAM172A	-0.85	-7.57	-0.44	8.53e-13	Diabetic retinopathy;
SARC	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.93	-0.51	1.28e-16	Alzheimer's disease;
SARC	cis	rs929354	0.772	rs2023977	chr7:156996022	C/G	cg05182265	chr7:156933206	UBE3C	-0.33	-5.02	-0.31	1.03e-6	Body mass index;
SARC	cis	rs13082711	1.000	rs35944308	chr3:27536356	G/A	cg02860705	chr3:27208620	NA	0.49	6.16	0.37	3.2e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs3617	0.625	rs7612624	chr3:52893426	T/C	cg04865290	chr3:52927548	TMEM110	0.35	5.01	0.31	1.06e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg15448220	chr1:150897856	SETDB1	0.47	6.25	0.38	1.94e-9	Tonsillectomy;
SARC	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg22875332	chr1:76189707	ACADM	0.48	6.71	0.4	1.5e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg18876405	chr7:65276391	NA	-0.44	-4.87	-0.3	2.02e-6	Aortic root size;
SARC	cis	rs314370	0.521	rs314308	chr7:100420878	C/T	cg10426581	chr7:100472382	SRRT	0.42	5.27	0.33	3.18e-7	Resting heart rate;
SARC	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs11098499	0.863	rs3775848	chr4:120447724	C/T	cg09307838	chr4:120376055	NA	0.91	12.31	0.63	3.63e-27	Corneal astigmatism;
SARC	cis	rs6540556	0.723	rs11119331	chr1:209889712	G/A	cg05527609	chr1:210001259	C1orf107	-0.56	-5.05	-0.31	8.93e-7	Red blood cell count;
SARC	cis	rs8067354	0.831	rs2333617	chr17:57896220	T/A	cg02344993	chr17:57696989	CLTC	-0.44	-5.13	-0.32	5.97e-7	Hemoglobin concentration;
SARC	cis	rs4237845	0.611	rs10877036	chr12:58321650	A/G	cg02175503	chr12:58329896	NA	-0.64	-9.28	-0.52	1.23e-17	Intelligence (multi-trait analysis);
SARC	cis	rs4792901	0.694	rs9907819	chr17:41602865	T/C	cg22562494	chr17:41607896	ETV4	-0.32	-4.87	-0.3	2.1e-6	Dupuytren's disease;
SARC	cis	rs7792596	0.861	rs7788014	chr7:94012278	C/T	cg20814616	chr7:94014465	NA	0.48	6.28	0.38	1.61e-9	Intelligence;
SARC	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg23758822	chr17:41437982	NA	0.89	11.28	0.59	7.77e-24	Menopause (age at onset);
SARC	cis	rs12579753	1.000	rs34031374	chr12:82235615	G/C	cg07988820	chr12:82153109	PPFIA2	-0.52	-6.07	-0.37	5.24e-9	Resting heart rate;
SARC	cis	rs2439831	0.867	rs2255440	chr15:43830467	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.95	9.06	0.51	5.3e-17	Lung cancer in ever smokers;
SARC	cis	rs854765	0.583	rs11656840	chr17:17837354	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.43	5.58	0.34	6.58e-8	Total body bone mineral density;
SARC	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg08219700	chr8:58056026	NA	0.48	4.9	0.31	1.81e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg13939156	chr17:80058883	NA	-0.38	-5.89	-0.36	1.35e-8	Life satisfaction;
SARC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg25703541	chr22:24373054	LOC391322	-0.8	-10.45	-0.56	3.23e-21	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs4819052	0.679	rs2236450	chr21:46702553	T/C	cg06618935	chr21:46677482	NA	-0.36	-4.91	-0.31	1.69e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg24829409	chr8:58192753	C8orf71	-0.63	-5.96	-0.36	9.37e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs897080	0.515	rs1067402	chr2:44676226	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.48	-5.0	-0.31	1.15e-6	Height;
SARC	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg11764359	chr7:65958608	NA	0.65	7.59	0.45	7.45e-13	Aortic root size;
SARC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.61	7.98	0.46	6.53e-14	Lymphocyte counts;
SARC	cis	rs2599510	0.783	rs13399071	chr2:32793783	C/T	cg02381751	chr2:32503542	YIPF4	0.42	4.91	0.31	1.68e-6	Interleukin-18 levels;
SARC	cis	rs2228479	0.557	rs62056097	chr16:89933420	A/G	cg04013166	chr16:89971882	TCF25	0.55	4.86	0.3	2.16e-6	Skin colour saturation;
SARC	cis	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg20965017	chr5:231967	SDHA	-0.54	-5.17	-0.32	5.11e-7	Breast cancer;
SARC	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg08280861	chr8:58055591	NA	0.6	5.28	0.33	2.92e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9486719	1.000	rs2472895	chr6:96870387	A/T	cg06623918	chr6:96969491	KIAA0776	0.73	7.93	0.46	9.06e-14	Migraine;Coronary artery disease;
SARC	cis	rs2832191	0.716	rs2297252	chr21:30377104	G/A	cg08807101	chr21:30365312	RNF160	0.9	14.21	0.68	1.99e-33	Dental caries;
SARC	cis	rs17376456	0.825	rs12188163	chr5:93250608	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.64	-5.77	-0.35	2.56e-8	Diabetic retinopathy;
SARC	cis	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg15556689	chr8:8085844	FLJ10661	-0.4	-4.91	-0.31	1.75e-6	Neuroticism;
SARC	cis	rs72781680	0.898	rs56315094	chr2:23941952	T/C	cg08917208	chr2:24149416	ATAD2B	0.75	7.07	0.42	1.78e-11	Lymphocyte counts;
SARC	cis	rs921968	0.541	rs6710383	chr2:219359685	T/G	cg02176678	chr2:219576539	TTLL4	0.46	7.12	0.42	1.33e-11	Mean corpuscular hemoglobin concentration;
SARC	cis	rs7592578	0.771	rs10432434	chr2:191387079	T/G	cg27211696	chr2:191398769	TMEM194B	-0.54	-5.63	-0.35	5.24e-8	Diastolic blood pressure;
SARC	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg04944784	chr2:26401820	FAM59B	0.6	7.95	0.46	8.14e-14	Gut microbiome composition (summer);
SARC	cis	rs11122272	0.735	rs2808603	chr1:231537738	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.09	-0.55	4.24e-20	Hemoglobin concentration;
SARC	trans	rs1814175	0.791	rs9787917	chr11:49937281	C/T	cg03929089	chr4:120376271	NA	-0.88	-13.88	-0.67	2.51e-32	Height;
SARC	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg18252515	chr7:66147081	NA	-1.31	-11.67	-0.61	4.38e-25	Diabetic kidney disease;
SARC	cis	rs2832077	0.506	rs2832093	chr21:30164855	C/T	cg08807101	chr21:30365312	RNF160	-0.5	-5.43	-0.33	1.43e-7	Cognitive test performance;
SARC	cis	rs2777491	0.574	rs28700583	chr15:41714072	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.17	-18.82	-0.78	1.15e-48	Ulcerative colitis;
SARC	cis	rs787274	1.000	rs787292	chr9:115508529	A/G	cg13803584	chr9:115635662	SNX30	0.82	5.39	0.33	1.71e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs1559088	1.000	rs1974783	chr19:33551507	C/G	cg17764715	chr19:33622953	WDR88	0.48	6.26	0.38	1.79e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs2273669	0.667	rs2356575	chr6:109367255	T/C	cg05315195	chr6:109294784	ARMC2	-0.63	-5.73	-0.35	3.16e-8	Prostate cancer;
SARC	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg20887711	chr4:1340912	KIAA1530	0.43	5.22	0.32	3.96e-7	Longevity;
SARC	cis	rs62064224	0.560	rs12162135	chr17:30805795	A/C	cg18200150	chr17:30822561	MYO1D	0.5	8.16	0.47	2.05e-14	Schizophrenia;
SARC	cis	rs6448317	0.556	rs6814108	chr4:24904781	C/T	cg21108841	chr4:24914750	CCDC149	0.49	4.79	0.3	3.04e-6	Heschl's gyrus morphology;
SARC	trans	rs8073060	0.544	rs225258	chr17:33956883	C/T	cg19694781	chr19:47549865	TMEM160	-0.68	-7.11	-0.42	1.44e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs7644634	0.688	rs13065142	chr3:105456983	T/C	cg23051926	chr3:105466016	CBLB	0.43	5.34	0.33	2.18e-7	Itch intensity from mosquito bite;
SARC	cis	rs9309473	0.583	rs6713196	chr2:73576405	T/C	cg20560298	chr2:73613845	ALMS1	-0.57	-7.1	-0.42	1.47e-11	Metabolite levels;
SARC	cis	rs13256369	1.000	rs4841017	chr8:8577093	A/G	cg18904891	chr8:8559673	CLDN23	0.49	5.84	0.36	1.75e-8	Obesity-related traits;
SARC	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg05185784	chr16:90016020	DEF8	-0.45	-4.76	-0.3	3.32e-6	Skin colour saturation;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg16539640	chr15:22945028	CYFIP1	-0.49	-6.37	-0.39	9.78e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg08219700	chr8:58056026	NA	0.51	5.25	0.33	3.36e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2075371	0.547	rs12666682	chr7:134021784	C/A	cg00033643	chr7:134001901	SLC35B4	0.44	5.38	0.33	1.77e-7	Mean platelet volume;
SARC	cis	rs6964587	0.967	rs1978061	chr7:91779242	G/A	cg17063962	chr7:91808500	NA	0.98	17.35	0.75	7.27e-44	Breast cancer;
SARC	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg12756686	chr19:29218302	NA	0.7	9.06	0.51	5.28e-17	Methadone dose in opioid dependence;
SARC	cis	rs2832077	1.000	rs2832077	chr21:30141021	G/A	cg24692254	chr21:30365293	RNF160	-0.54	-5.05	-0.31	8.79e-7	Cognitive test performance;
SARC	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.11	23.97	0.84	7.87e-65	Chronic sinus infection;
SARC	cis	rs36051895	0.664	rs10117459	chr9:5094034	G/A	cg02405213	chr9:5042618	JAK2	-0.46	-5.56	-0.34	7.46e-8	Pediatric autoimmune diseases;
SARC	cis	rs4481887	0.927	rs10158431	chr1:248481253	A/G	cg13385794	chr1:248469461	NA	0.36	5.47	0.34	1.18e-7	Common traits (Other);
SARC	cis	rs3796352	1.000	rs17052727	chr3:53070914	T/C	cg07884673	chr3:53033167	SFMBT1	0.69	4.97	0.31	1.27e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs6912958	0.559	rs395358	chr6:88057924	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.75	11.6	0.6	7.56e-25	Monocyte percentage of white cells;
SARC	cis	rs12950390	0.814	rs4794099	chr17:45838358	T/C	cg03474202	chr17:45855739	NA	-0.46	-7.26	-0.43	5.71e-12	IgG glycosylation;
SARC	cis	rs10463554	0.889	rs34822	chr5:102437711	T/C	cg23492399	chr5:102201601	PAM	-0.46	-5.14	-0.32	5.78e-7	Parkinson's disease;
SARC	cis	rs7412746	0.622	rs11552229	chr1:150783985	T/C	cg13175981	chr1:150552382	MCL1	-0.51	-6.17	-0.37	2.98e-9	Melanoma;
SARC	cis	rs9790314	0.521	rs1450523	chr3:161077270	G/A	cg17135325	chr3:160939158	NMD3	0.52	6.53	0.39	4.14e-10	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg08280861	chr8:58055591	NA	0.51	4.78	0.3	3.18e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs10849605	1.000	rs10849605	chr12:1064438	C/T	cg02055889	chr12:1059459	RAD52	-0.4	-5.6	-0.34	6e-8	Lung cancer;
SARC	cis	rs7582720	1.000	rs4510208	chr2:203734866	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.28	0.43	5.16e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs12142240	0.698	rs9661240	chr1:46827050	G/A	cg10495392	chr1:46806563	NSUN4	0.65	6.8	0.41	8.89e-11	Menopause (age at onset);
SARC	cis	rs72653721	0.838	rs949557	chr6:11025983	C/T	cg13562911	chr6:11044106	ELOVL2	0.49	5.63	0.35	5.03e-8	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	trans	rs10771431	0.597	rs10843142	chr12:9357502	A/G	cg27600084	chr12:12264075	NA	0.55	7.26	0.43	5.74e-12	Breast size;
SARC	cis	rs2908197	0.806	rs12534035	chr7:75980946	G/C	cg22830091	chr7:75961684	YWHAG	-0.31	-4.78	-0.3	3.11e-6	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs2239547	0.522	rs9311485	chr3:52987645	T/G	cg18404041	chr3:52824283	ITIH1	0.38	4.72	0.3	4.02e-6	Schizophrenia;
SARC	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg20965017	chr5:231967	SDHA	-0.55	-5.26	-0.33	3.23e-7	Breast cancer;
SARC	cis	rs1707322	1.000	rs1622208	chr1:46498375	A/G	cg06784218	chr1:46089804	CCDC17	-0.37	-6.47	-0.39	5.57e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9858542	0.953	rs1987628	chr3:49399259	G/A	cg07274523	chr3:49395745	GPX1	0.53	6.25	0.38	1.94e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs9815354	0.767	rs12185934	chr3:41836558	A/C	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs13191362	0.935	rs13215748	chr6:163010710	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.56	5.35	0.33	2.07e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg09455208	chr3:40491958	NA	-0.39	-5.69	-0.35	3.85e-8	Renal cell carcinoma;
SARC	cis	rs1580019	0.961	rs6949851	chr7:32493807	T/G	cg06627557	chr7:32535165	LSM5;AVL9	0.73	9.57	0.53	1.6e-18	Cognitive ability;
SARC	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	9.03	0.51	6.68e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs656319	0.580	rs13272793	chr8:10002027	C/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.15	-0.42	1.09e-11	Myopia (pathological);
SARC	cis	rs9420	0.961	rs7117205	chr11:57641883	A/G	cg23127183	chr11:57508653	C11orf31	-0.6	-6.69	-0.4	1.67e-10	Schizophrenia;
SARC	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.54	0.44	1.06e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7824557	0.614	rs5029571	chr8:11213389	C/T	cg21775007	chr8:11205619	TDH	0.71	9.49	0.53	2.8e-18	Retinal vascular caliber;
SARC	cis	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg06558623	chr16:89946397	TCF25	0.92	6.42	0.39	7.75e-10	Skin colour saturation;
SARC	cis	rs2985684	1.000	rs2985697	chr14:50092902	A/G	cg04989706	chr14:50066350	PPIL5	-0.57	-6.1	-0.37	4.38e-9	Carotid intima media thickness;
SARC	cis	rs6815814	0.898	rs5743592	chr4:38803063	A/G	cg02016764	chr4:38805732	TLR1	-0.4	-4.8	-0.3	2.84e-6	Breast cancer;
SARC	cis	rs5758511	0.680	rs34107327	chr22:42648353	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.46	6.9	0.41	4.87e-11	Birth weight;
SARC	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg08742575	chr21:47604166	C21orf56	0.47	5.89	0.36	1.34e-8	Testicular germ cell tumor;
SARC	cis	rs9916302	0.904	rs1619021	chr17:37739274	G/A	cg20243544	chr17:37824526	PNMT	0.53	6.03	0.37	6.39e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs3858526	0.959	rs4559671	chr11:5923419	C/T	cg13902645	chr11:5959945	NA	-0.42	-4.95	-0.31	1.45e-6	DNA methylation (variation);
SARC	cis	rs66573146	0.831	rs6832482	chr4:7023433	A/T	cg15105060	chr4:7024189	TBC1D14	-0.67	-4.85	-0.3	2.25e-6	Granulocyte percentage of myeloid white cells;
SARC	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg24633833	chr3:10029261	TMEM111	0.52	5.25	0.33	3.43e-7	Alzheimer's disease;
SARC	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.71	8.06	0.47	3.91e-14	Multiple sclerosis;
SARC	cis	rs9398803	0.687	rs1340953	chr6:126951748	A/G	cg19875578	chr6:126661172	C6orf173	0.61	8.32	0.48	7.54e-15	Male-pattern baldness;
SARC	cis	rs10911251	0.546	rs2147578	chr1:183107699	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.68	9.86	0.54	2.24e-19	Colorectal cancer;
SARC	cis	rs910316	0.663	rs175034	chr14:75463687	T/G	cg06637938	chr14:75390232	RPS6KL1	-0.46	-6.04	-0.37	6.04e-9	Height;
SARC	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg11764359	chr7:65958608	NA	0.88	12.58	0.64	4.89e-28	Aortic root size;
SARC	cis	rs9303401	0.659	rs12150264	chr17:56939927	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	11.27	0.59	8.61e-24	Cognitive test performance;
SARC	cis	rs7216064	1.000	rs58551145	chr17:65837235	A/G	cg12091567	chr17:66097778	LOC651250	-0.72	-7.09	-0.42	1.57e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs9314323	0.692	rs6557914	chr8:26208744	G/C	cg11498726	chr8:26250323	BNIP3L	-0.57	-7.36	-0.43	3.16e-12	Red cell distribution width;
SARC	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg12667521	chr19:29218732	NA	0.39	5.26	0.33	3.27e-7	Methadone dose in opioid dependence;
SARC	cis	rs9513627	0.915	rs73556179	chr13:100122009	G/A	cg25919922	chr13:100150906	NA	-0.69	-5.22	-0.32	3.92e-7	Obesity-related traits;
SARC	cis	rs992157	0.835	rs6707559	chr2:219142773	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.69	10.03	0.55	6.45e-20	Colorectal cancer;
SARC	cis	rs9341808	0.754	rs1015158	chr6:80945745	C/T	cg08355045	chr6:80787529	NA	0.33	5.31	0.33	2.59e-7	Sitting height ratio;
SARC	cis	rs9660992	0.547	rs748012	chr1:205216573	C/T	cg21643547	chr1:205240462	TMCC2	-0.57	-7.52	-0.44	1.19e-12	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg22903471	chr2:27725779	GCKR	-0.54	-8.21	-0.47	1.52e-14	Total body bone mineral density;
SARC	cis	rs6582630	0.577	rs12312748	chr12:38343326	T/C	cg26384229	chr12:38710491	ALG10B	-0.58	-7.16	-0.42	1.08e-11	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs1814175	0.645	rs10839456	chr11:49964093	C/T	cg15704280	chr7:45808275	SEPT13	-0.89	-14.17	-0.68	2.73e-33	Height;
SARC	cis	rs6500602	0.727	rs11076836	chr16:4569331	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.32	5.3	0.33	2.69e-7	Schizophrenia;
SARC	cis	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg25427524	chr10:38739819	LOC399744	-0.62	-9.94	-0.55	1.25e-19	Extrinsic epigenetic age acceleration;
SARC	cis	rs7264396	0.733	rs2425105	chr20:34312834	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	6.0	0.37	7.38e-9	Total cholesterol levels;
SARC	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg27266027	chr21:40555129	PSMG1	0.5	5.06	0.31	8.62e-7	Cognitive function;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg05303249	chr11:66036138	RAB1B	-0.53	-6.69	-0.4	1.65e-10	Schizophrenia;
SARC	cis	rs11574514	1.000	rs16957590	chr16:67934725	C/T	cg01866162	chr16:67596514	CTCF	-0.84	-5.86	-0.36	1.55e-8	Crohn's disease;
SARC	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg26850624	chr5:429559	AHRR	-0.31	-4.77	-0.3	3.21e-6	Cystic fibrosis severity;
SARC	cis	rs870142	0.506	rs28824487	chr4:4656287	T/C	cg20817824	chr4:4389918	D4S234E	0.36	5.22	0.32	3.9e-7	Congenital heart disease;
SARC	cis	rs8005677	1.000	rs8016061	chr14:23375809	A/G	cg01529538	chr14:23388837	RBM23	0.46	5.77	0.35	2.53e-8	Cognitive ability (multi-trait analysis);
SARC	cis	rs10504229	0.679	rs10504217	chr8:58037522	A/G	cg20607798	chr8:58055168	NA	0.56	5.26	0.33	3.25e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9398803	0.723	rs853969	chr6:127061318	C/T	cg19875578	chr6:126661172	C6orf173	0.59	8.14	0.47	2.33e-14	Male-pattern baldness;
SARC	cis	rs3796352	1.000	rs60942590	chr3:53016421	G/A	cg27565382	chr3:53032988	SFMBT1	0.88	6.16	0.37	3.18e-9	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs9303280	0.901	rs2305479	chr17:38062217	C/T	cg00129232	chr17:37814104	STARD3	-0.36	-4.79	-0.3	3.01e-6	Self-reported allergy;
SARC	cis	rs4144743	0.941	rs7211563	chr17:45324061	T/C	cg18085866	chr17:45331354	ITGB3	-0.71	-7.35	-0.43	3.36e-12	Body mass index;
SARC	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	11.97	0.62	4.86e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9815354	0.812	rs73071358	chr3:41830487	G/A	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs34172651	0.876	rs11074653	chr16:24795959	C/T	cg00339695	chr16:24857497	SLC5A11	0.31	4.94	0.31	1.47e-6	Intelligence (multi-trait analysis);
SARC	cis	rs6908034	0.607	rs73376681	chr6:19808175	A/G	cg02682789	chr6:19804855	NA	0.72	5.71	0.35	3.37e-8	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs1348850	0.914	rs4893950	chr2:178304885	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.71	9.16	0.51	2.7e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs36051895	0.659	rs7045491	chr9:5045658	G/A	cg02405213	chr9:5042618	JAK2	-0.52	-6.06	-0.37	5.47e-9	Pediatric autoimmune diseases;
SARC	cis	rs7005380	0.581	rs9987142	chr8:120937021	G/C	cg21744203	chr8:120868354	DSCC1	0.45	5.29	0.33	2.75e-7	Interstitial lung disease;
SARC	cis	rs3857536	0.740	rs7756519	chr6:66892275	A/G	cg07460842	chr6:66804631	NA	-0.6	-7.16	-0.42	1.04e-11	Blood trace element (Cu levels);
SARC	cis	rs5769765	0.955	rs8135816	chr22:50291976	G/C	cg03033257	chr22:50311977	ALG12;CRELD2	0.52	5.33	0.33	2.28e-7	Schizophrenia;
SARC	cis	rs459571	0.920	rs455073	chr9:136909141	G/C	cg13789015	chr9:136890014	NCRNA00094	0.62	8.46	0.48	2.97e-15	Platelet distribution width;
SARC	cis	rs11585357	0.843	rs72633805	chr1:17617471	A/T	cg08277548	chr1:17600880	PADI3	-0.49	-5.48	-0.34	1.11e-7	Hair shape;
SARC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg05863683	chr7:1912471	MAD1L1	0.34	5.05	0.31	8.82e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg22535103	chr8:58192502	C8orf71	-0.73	-7.11	-0.42	1.4e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg10435706	chr6:150039699	LATS1	0.36	4.8	0.3	2.88e-6	Lung cancer;
SARC	cis	rs7216064	1.000	rs60432293	chr17:65860407	T/C	cg12091567	chr17:66097778	LOC651250	-0.7	-7.64	-0.45	5.5e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs2070488	0.775	rs4371464	chr3:38548021	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.74	-11.09	-0.59	3.08e-23	Electrocardiographic conduction measures;
SARC	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg01181863	chr3:195395398	SDHAP2	-0.57	-6.4	-0.39	8.24e-10	Pancreatic cancer;
SARC	cis	rs72781680	0.821	rs111571980	chr2:24201695	C/G	cg08917208	chr2:24149416	ATAD2B	0.58	6.09	0.37	4.69e-9	Lymphocyte counts;
SARC	cis	rs11574514	1.000	rs9929423	chr16:67733113	T/C	cg01866162	chr16:67596514	CTCF	0.82	5.13	0.32	6e-7	Crohn's disease;
SARC	cis	rs10464366	0.544	rs4540324	chr7:39185299	G/C	cg18850127	chr7:39170497	POU6F2	0.39	5.08	0.32	7.68e-7	IgG glycosylation;
SARC	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.63e-10	Life satisfaction;
SARC	cis	rs7044106	0.762	rs10760112	chr9:123467570	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	5.46	0.34	1.2e-7	Hip circumference adjusted for BMI;
SARC	cis	rs10782582	0.593	rs4646960	chr1:76211103	C/A	cg10523679	chr1:76189770	ACADM	-0.44	-5.36	-0.33	1.98e-7	Daytime sleep phenotypes;
SARC	cis	rs2046867	0.908	rs62251654	chr3:72816488	C/T	cg25664220	chr3:72788482	NA	-0.29	-4.81	-0.3	2.66e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
SARC	cis	rs2153535	0.580	rs2327062	chr6:8453858	G/A	cg07606381	chr6:8435919	SLC35B3	0.77	10.87	0.58	1.52e-22	Motion sickness;
SARC	cis	rs668210	0.793	rs1192184	chr11:65773382	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.5	-4.71	-0.3	4.18e-6	Cerebrospinal fluid biomarker levels;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg13763308	chr10:75910788	AP3M1;ADK	0.5	6.33	0.38	1.24e-9	Breast cancer;
SARC	cis	rs5769765	0.954	rs1569954	chr22:50244071	C/T	cg03033257	chr22:50311977	ALG12;CRELD2	-0.55	-5.51	-0.34	9.37e-8	Schizophrenia;
SARC	cis	rs1008375	0.863	rs4590022	chr4:17614434	T/C	cg16339924	chr4:17578868	LAP3	0.62	8.04	0.47	4.65e-14	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg06808227	chr14:105710500	BRF1	-0.54	-7.22	-0.43	7.33e-12	Mean platelet volume;Platelet distribution width;
SARC	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg13939156	chr17:80058883	NA	-0.41	-6.35	-0.38	1.11e-9	Life satisfaction;
SARC	cis	rs4332037	0.950	rs11771828	chr7:1941003	T/C	cg23422044	chr7:1970798	MAD1L1	-0.46	-4.86	-0.3	2.19e-6	Bipolar disorder;
SARC	trans	rs1814175	0.645	rs28436748	chr11:50046422	G/A	cg03929089	chr4:120376271	NA	-0.83	-11.84	-0.61	1.24e-25	Height;
SARC	cis	rs2032447	0.613	rs6456708	chr6:26032847	G/C	cg16482183	chr6:26056742	HIST1H1C	0.44	5.63	0.35	5.07e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7940866	0.838	rs1991898	chr11:130801786	C/G	cg12179176	chr11:130786555	SNX19	-0.65	-9.49	-0.53	2.89e-18	Schizophrenia;
SARC	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.63e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs4646312	0.555	rs5748482	chr22:19922374	C/T	cg07194846	chr22:19930177	COMT;TXNRD2	0.51	6.62	0.4	2.41e-10	Schizophrenia;
SARC	cis	rs4911259	0.552	rs62208880	chr20:31463284	T/C	cg13636640	chr20:31349939	DNMT3B	-0.66	-9.01	-0.51	7.8e-17	Inflammatory bowel disease;
SARC	cis	rs1538970	0.962	rs2298018	chr1:45813441	T/C	cg05343316	chr1:45956843	TESK2	0.66	7.96	0.46	7.3e-14	Platelet count;
SARC	cis	rs1318878	0.667	rs56361757	chr12:15517492	C/G	cg08258403	chr12:15378311	NA	0.48	6.63	0.4	2.36e-10	Intelligence (multi-trait analysis);
SARC	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg23985595	chr17:80112537	CCDC57	-0.31	-4.77	-0.3	3.25e-6	Life satisfaction;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg09186482	chr17:8082780	NA	0.46	6.25	0.38	1.88e-9	Thyroid stimulating hormone;
SARC	cis	rs5753037	0.702	rs131301	chr22:30185889	A/T	cg01021169	chr22:30184971	ASCC2	-0.44	-6.03	-0.37	6.43e-9	Type 1 diabetes;
SARC	cis	rs9660992	0.639	rs1151786	chr1:205227760	G/C	cg21545522	chr1:205238299	TMCC2	0.49	6.78	0.41	9.87e-11	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs57083693	0.518	rs1009090	chr12:101703251	C/T	cg22051763	chr12:101673672	UTP20	-0.45	-5.38	-0.33	1.77e-7	Alcohol dependence (age at onset);
SARC	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg09699651	chr6:150184138	LRP11	0.43	5.29	0.33	2.88e-7	Lung cancer;
SARC	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg26335602	chr6:28129616	ZNF389	0.53	5.96	0.36	9.42e-9	Depression;
SARC	cis	rs72717009	0.825	rs9427397	chr1:161476204	C/T	cg23840854	chr1:161414152	NA	-0.54	-5.07	-0.32	8.2e-7	Rheumatoid arthritis;
SARC	cis	rs6991838	0.584	rs4737221	chr8:66481310	G/A	cg13398993	chr8:66546079	ARMC1	-0.62	-8.2	-0.47	1.66e-14	Intelligence (multi-trait analysis);
SARC	cis	rs11025559	0.796	rs10833317	chr11:20412277	A/T	cg19653624	chr11:20408972	PRMT3	-0.59	-6.55	-0.39	3.65e-10	Pursuit maintenance gain;
SARC	cis	rs36715	1.000	rs36697	chr5:127549613	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.61	6.82	0.41	7.84e-11	Breast cancer;
SARC	cis	rs7589728	0.563	rs2292868	chr2:88475047	A/G	cg04511125	chr2:88470314	THNSL2	-0.77	-7.36	-0.43	3.07e-12	Plasma clusterin levels;
SARC	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg11987759	chr7:65425863	GUSB	0.47	5.8	0.36	2.11e-8	Aortic root size;
SARC	cis	rs7833790	0.685	rs13255262	chr8:82728024	T/G	cg17211192	chr8:82754475	SNX16	-0.51	-6.32	-0.38	1.29e-9	Diastolic blood pressure;
SARC	cis	rs7836436	0.686	rs61519992	chr8:120954517	A/C	cg21659575	chr8:120844832	TAF2	0.7	5.15	0.32	5.42e-7	HIV-1 viral setpoint;
SARC	cis	rs9467773	0.596	rs2451751	chr6:26646714	T/C	cg12292205	chr6:26970375	C6orf41	0.4	4.88	0.3	1.95e-6	Intelligence (multi-trait analysis);
SARC	cis	rs801193	0.591	rs9986881	chr7:66173040	A/G	cg25405998	chr7:65216604	CCT6P1	0.58	6.63	0.4	2.31e-10	Aortic root size;
SARC	cis	rs826838	0.616	rs2387921	chr12:38624767	T/C	cg26384229	chr12:38710491	ALG10B	-0.59	-7.54	-0.44	1.04e-12	Heart rate;
SARC	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.69	8.07	0.47	3.68e-14	Gut microbiome composition (summer);
SARC	cis	rs2070997	0.527	rs3847192	chr9:133724916	T/G	cg03924115	chr9:133768966	QRFP	0.5	5.54	0.34	8.34e-8	Response to amphetamines;
SARC	cis	rs910316	0.763	rs175044	chr14:75472109	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.46	-5.91	-0.36	1.22e-8	Height;
SARC	cis	rs8114671	0.662	rs6058146	chr20:33540529	A/G	cg24642439	chr20:33292090	TP53INP2	0.42	5.0	0.31	1.12e-6	Height;
SARC	cis	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg25894440	chr7:65020034	NA	-0.74	-5.55	-0.34	7.85e-8	Diabetic kidney disease;
SARC	cis	rs8031584	0.918	rs34693097	chr15:31253984	A/G	cg19680485	chr15:31195859	MTMR15	-0.5	-5.73	-0.35	3.1e-8	Huntington's disease progression;
SARC	cis	rs1451375	0.527	rs6950777	chr7:50597056	G/A	cg18232548	chr7:50535776	DDC	0.48	5.29	0.33	2.85e-7	Malaria;
SARC	cis	rs57506017	0.585	rs1020006	chr7:12255664	G/A	cg23422036	chr7:12250390	TMEM106B	0.5	6.68	0.4	1.72e-10	Neuroticism;
SARC	trans	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg21659725	chr3:3221576	CRBN	-0.79	-11.96	-0.62	5.19e-26	Intelligence (multi-trait analysis);
SARC	trans	rs1814175	0.538	rs1684260	chr11:49224231	G/A	cg03929089	chr4:120376271	NA	0.73	10.23	0.56	1.61e-20	Height;
SARC	cis	rs6121246	0.559	rs12479491	chr20:30265450	T/C	cg13852791	chr20:30311386	BCL2L1	0.88	10.96	0.58	8.1e-23	Mean corpuscular hemoglobin;
SARC	cis	rs3857536	0.706	rs7755994	chr6:66891747	T/C	cg07460842	chr6:66804631	NA	-0.6	-7.16	-0.42	1.04e-11	Blood trace element (Cu levels);
SARC	cis	rs8014204	0.550	rs2302832	chr14:75137664	T/C	cg06637938	chr14:75390232	RPS6KL1	0.62	9.02	0.51	7.03e-17	Caffeine consumption;
SARC	cis	rs7103648	0.669	rs10437655	chr11:47391948	G/A	cg10504702	chr11:47789108	FNBP4	0.55	6.98	0.42	3.09e-11	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs4243830	0.850	rs10779790	chr1:6608435	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.88	-8.48	-0.49	2.61e-15	Body mass index;
SARC	cis	rs1662342	0.800	rs60336569	chr18:3279687	T/C	cg00760847	chr18:3262519	MYL12B	-0.6	-4.88	-0.3	1.99e-6	QRS duration;
SARC	cis	rs1538970	0.962	rs2487442	chr1:45857176	C/G	cg05343316	chr1:45956843	TESK2	-0.68	-8.36	-0.48	5.87e-15	Platelet count;
SARC	cis	rs4253772	0.550	rs9615949	chr22:46722531	C/T	cg24881330	chr22:46731750	TRMU	0.64	4.77	0.3	3.21e-6	LDL cholesterol;Cholesterol, total;
SARC	cis	rs881375	0.678	rs3761846	chr9:123689597	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	6.22	0.38	2.25e-9	Rheumatoid arthritis;
SARC	trans	rs7944735	0.507	rs10742827	chr11:48102350	C/T	cg15704280	chr7:45808275	SEPT13	0.6	6.83	0.41	7.38e-11	Intraocular pressure;
SARC	cis	rs4555082	0.874	rs28822720	chr14:105746282	T/C	cg13114125	chr14:105738426	BRF1	-0.72	-10.58	-0.57	1.31e-21	Mean platelet volume;Platelet distribution width;
SARC	cis	rs57920188	0.535	rs4295856	chr1:4094842	C/T	cg20703997	chr1:4087676	NA	0.5	5.35	0.33	2.07e-7	Interleukin-17 levels;
SARC	cis	rs787274	0.850	rs7862183	chr9:115529696	C/T	cg13803584	chr9:115635662	SNX30	-0.79	-6.14	-0.37	3.47e-9	Age-related hearing impairment (SNP x SNP interaction);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg19425870	chr11:3876808	STIM1	0.47	6.26	0.38	1.83e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs910316	1.000	rs175425	chr14:75626131	T/C	cg08847533	chr14:75593920	NEK9	-0.86	-12.84	-0.64	7.01e-29	Height;
SARC	cis	rs12893668	0.667	rs71417869	chr14:104077434	A/G	cg24130564	chr14:104152367	KLC1	-0.44	-4.89	-0.31	1.84e-6	Reticulocyte count;
SARC	cis	rs4141404	0.818	rs5997897	chr22:31570436	G/A	cg13145458	chr22:31556086	RNF185	0.41	5.18	0.32	4.81e-7	Paclitaxel-induced neuropathy;
SARC	cis	rs7246865	0.510	rs2305756	chr19:17169936	C/T	cg16202187	chr19:17186497	HAUS8;MYO9B	0.39	4.77	0.3	3.21e-6	Reticulocyte fraction of red cells;
SARC	cis	rs477692	0.596	rs12247555	chr10:131370520	T/C	cg05714579	chr10:131428358	MGMT	-0.55	-7.18	-0.43	9.13e-12	Response to temozolomide;
SARC	cis	rs892961	0.932	rs67719929	chr17:75412605	G/A	cg05865280	chr17:75406074	SEPT9	0.57	8.47	0.48	2.87e-15	Airflow obstruction;
SARC	cis	rs9916302	0.904	rs2303316	chr17:37704217	A/G	cg00129232	chr17:37814104	STARD3	-0.65	-7.99	-0.46	6.37e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs3091242	0.933	rs932372	chr1:25755014	G/A	cg02931644	chr1:25747376	RHCE	0.42	6.92	0.41	4.45e-11	Erythrocyte sedimentation rate;
SARC	cis	rs9894429	0.752	rs7502883	chr17:79588557	T/C	cg18240062	chr17:79603768	NPLOC4	0.88	13.62	0.67	1.84e-31	Eye color traits;
SARC	cis	rs1949733	0.959	rs2688242	chr4:8429943	T/G	cg11789530	chr4:8429930	ACOX3	0.9	12.04	0.62	2.79e-26	Response to antineoplastic agents;
SARC	cis	rs9747201	0.832	rs4072580	chr17:80160337	A/C	cg09264619	chr17:80180166	NA	-0.52	-6.06	-0.37	5.5e-9	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs8177179	0.505	rs1405023	chr3:133481128	T/C	cg08048268	chr3:133502702	NA	0.37	4.79	0.3	3.01e-6	Iron status biomarkers (transferrin levels);
SARC	cis	rs6570726	0.764	rs76635693	chr6:145834070	T/C	cg23711669	chr6:146136114	FBXO30	0.87	14.58	0.69	1.18e-34	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg12463550	chr7:65579703	CRCP	0.68	5.09	0.32	7.53e-7	Gout;
SARC	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg16414030	chr3:133502952	NA	-0.38	-4.97	-0.31	1.32e-6	Iron status biomarkers;
SARC	cis	rs1538970	0.962	rs3219489	chr1:45797505	C/G	cg16078521	chr1:45672383	ZSWIM5	0.48	4.73	0.3	3.94e-6	Platelet count;
SARC	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg18404041	chr3:52824283	ITIH1	-0.5	-7.54	-0.44	1.05e-12	Bipolar disorder;
SARC	cis	rs17270561	0.636	rs6923839	chr6:25745853	G/A	cg17691542	chr6:26056736	HIST1H1C	0.61	7.36	0.43	3.06e-12	Iron status biomarkers;
SARC	cis	rs11785400	0.793	rs7007891	chr8:143749228	C/T	cg10596483	chr8:143751796	JRK	-0.55	-6.99	-0.42	2.9e-11	Schizophrenia;
SARC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.64	0.53	9.96e-19	Prudent dietary pattern;
SARC	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg13628971	chr7:2884303	GNA12	0.68	8.34	0.48	6.42e-15	Height;
SARC	cis	rs7089973	0.668	rs10885622	chr10:116643844	C/T	cg03647239	chr10:116582469	FAM160B1	0.41	5.0	0.31	1.11e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg13939156	chr17:80058883	NA	0.4	6.37	0.39	9.98e-10	Life satisfaction;
SARC	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg22974920	chr21:40686053	BRWD1	-0.44	-4.83	-0.3	2.42e-6	Cognitive function;
SARC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg06074448	chr4:187884817	NA	-0.38	-5.25	-0.33	3.46e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12908161	1.000	rs56864281	chr15:85357649	C/A	cg17507749	chr15:85114479	UBE2QP1	0.56	6.48	0.39	5.28e-10	Schizophrenia;
SARC	cis	rs931127	0.502	rs1466462	chr11:65419364	C/G	cg27068330	chr11:65405492	SIPA1	0.47	5.66	0.35	4.42e-8	Systemic lupus erythematosus;
SARC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg11905131	chr22:24372483	LOC391322	-0.46	-5.05	-0.31	8.85e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9303401	1.000	rs9303401	chr17:56847945	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.7	8.27	0.48	1.01e-14	Cognitive test performance;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg07755343	chr16:1712697	CRAMP1L	0.48	6.46	0.39	5.99e-10	Schizophrenia;
SARC	cis	rs6582630	0.519	rs11520262	chr12:38333051	A/G	cg26384229	chr12:38710491	ALG10B	0.87	12.6	0.64	4.2e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs17270561	0.636	rs9393671	chr6:25789189	G/C	cg16482183	chr6:26056742	HIST1H1C	-0.48	-6.15	-0.37	3.3e-9	Iron status biomarkers;
SARC	cis	rs9322817	0.593	rs9404579	chr6:105229807	T/C	cg02098413	chr6:105308735	HACE1	-0.4	-6.21	-0.38	2.39e-9	Thyroid stimulating hormone;
SARC	cis	rs7264396	0.690	rs2425170	chr20:34442672	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.52	5.1	0.32	7.09e-7	Total cholesterol levels;
SARC	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg13206674	chr6:150067644	NUP43	0.39	5.18	0.32	4.91e-7	Lung cancer;
SARC	trans	rs61931739	0.500	rs6488213	chr12:34393319	C/T	cg26384229	chr12:38710491	ALG10B	0.84	12.77	0.64	1.2e-28	Morning vs. evening chronotype;
SARC	cis	rs17376456	0.569	rs11135394	chr5:93187135	C/T	cg25358565	chr5:93447407	FAM172A	-0.77	-8.76	-0.5	4.13e-16	Diabetic retinopathy;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg07989678	chr2:172543677	DYNC1I2	0.55	7.73	0.45	3.16e-13	Thyroid stimulating hormone;
SARC	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg16132339	chr22:24313637	DDTL;DDT	-0.41	-4.87	-0.3	2.07e-6	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs4148883	0.629	rs10009145	chr4:100047929	G/A	cg12011299	chr4:100065546	ADH4	0.38	7.18	0.43	9.17e-12	Alcohol dependence;
SARC	cis	rs892961	1.000	rs2164449	chr17:75401190	G/A	cg05865280	chr17:75406074	SEPT9	0.51	7.3	0.43	4.46e-12	Airflow obstruction;
SARC	cis	rs2043112	1.000	rs2043112	chr5:38955796	A/G	cg04869206	chr5:39074266	RICTOR	-0.54	-6.94	-0.41	3.78e-11	Obesity-related traits;
SARC	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg24209194	chr3:40518798	ZNF619	0.63	7.58	0.44	8.27e-13	Renal cell carcinoma;
SARC	trans	rs9329221	0.741	rs9650622	chr8:9804292	G/T	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.55	-0.39	3.58e-10	Neuroticism;
SARC	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6686643	0.868	rs9333471	chr1:165619712	A/G	cg19407955	chr1:165599744	MGST3	-0.51	-5.87	-0.36	1.47e-8	Total ventricular volume;
SARC	cis	rs12367572	0.930	rs11615964	chr12:45261564	C/T	cg04608330	chr12:45269318	NELL2	-0.42	-5.18	-0.32	4.75e-7	Gut microbiome composition (summer);
SARC	cis	rs1322639	0.614	rs9364361	chr6:169580499	C/T	cg03254818	chr6:169586852	NA	0.7	7.31	0.43	4.26e-12	Pulse pressure;
SARC	trans	rs57994514	0.524	rs3793365	chr8:71078015	C/G	cg04828133	chr7:155259845	NA	0.96	6.73	0.4	1.27e-10	Intelligence (multi-trait analysis);
SARC	cis	rs36051895	0.632	rs10115962	chr9:5140841	T/C	cg02405213	chr9:5042618	JAK2	-0.45	-5.48	-0.34	1.12e-7	Pediatric autoimmune diseases;
SARC	cis	rs3020736	0.500	rs6002618	chr22:42507859	G/C	cg15557168	chr22:42548783	NA	0.36	4.92	0.31	1.62e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-6.36	-0.38	1.07e-9	Personality dimensions;
SARC	trans	rs6600671	1.000	rs10903161	chr1:121178741	A/T	cg00646200	chr1:148855367	NA	0.5	6.97	0.42	3.26e-11	Hip geometry;
SARC	cis	rs6831352	0.918	rs13112176	chr4:100055825	G/A	cg13256891	chr4:100009986	ADH5	-0.64	-8.0	-0.46	5.7e-14	Alcohol dependence;
SARC	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg11301795	chr4:187892539	NA	-0.72	-10.68	-0.57	6.21e-22	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9398803	0.650	rs1101559	chr6:127047683	C/T	cg19875578	chr6:126661172	C6orf173	-0.61	-8.22	-0.47	1.46e-14	Male-pattern baldness;
SARC	cis	rs12541335	0.579	rs59283125	chr8:22212311	G/A	cg02463440	chr8:22132932	PIWIL2	0.47	6.48	0.39	5.52e-10	Hypertriglyceridemia;
SARC	cis	rs1008375	1.000	rs10805359	chr4:17684886	A/G	cg27347728	chr4:17578864	LAP3	0.45	5.52	0.34	8.87e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7264396	0.676	rs6060727	chr20:34556000	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-6.92	-0.41	4.41e-11	Total cholesterol levels;
SARC	cis	rs7103648	0.966	rs1534576	chr11:47419663	A/C	cg10504702	chr11:47789108	FNBP4	-0.59	-7.67	-0.45	4.52e-13	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs2013441	0.896	rs1812934	chr17:20030960	A/T	cg13482628	chr17:19912719	NA	-0.42	-5.4	-0.33	1.65e-7	Obesity-related traits;
SARC	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg23758822	chr17:41437982	NA	0.85	10.5	0.57	2.32e-21	Menopause (age at onset);
SARC	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	-0.93	-10.62	-0.57	9.98e-22	Platelet count;
SARC	cis	rs1003719	0.788	rs1543748	chr21:38446581	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.67	9.98	0.55	9.59e-20	Eye color traits;
SARC	cis	rs911555	0.511	rs8007489	chr14:104054572	A/G	cg26031613	chr14:104095156	KLC1	-0.58	-7.71	-0.45	3.66e-13	Intelligence (multi-trait analysis);
SARC	cis	rs2180341	0.824	rs9321076	chr6:127655614	G/A	cg17762328	chr6:126965162	NA	-0.45	-5.11	-0.32	6.78e-7	Breast cancer;
SARC	cis	rs13191362	0.507	rs6936804	chr6:163069424	A/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.43	-4.74	-0.3	3.75e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	trans	rs9325144	0.600	rs10785621	chr12:38744912	C/T	cg23762105	chr12:34175262	ALG10	-0.55	-7.15	-0.42	1.1e-11	Morning vs. evening chronotype;
SARC	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg11965913	chr1:205819406	PM20D1	0.63	6.88	0.41	5.59e-11	Prostate-specific antigen levels;
SARC	cis	rs7412746	0.524	rs58304714	chr1:150831561	T/A	cg15448220	chr1:150897856	SETDB1	0.51	6.52	0.39	4.3e-10	Melanoma;
SARC	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg18876405	chr7:65276391	NA	-0.44	-4.95	-0.31	1.41e-6	Aortic root size;
SARC	cis	rs9462027	0.628	rs3734264	chr6:34831866	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-6.01	-0.37	7.18e-9	Systemic lupus erythematosus;
SARC	cis	rs796364	0.806	rs203767	chr2:200902411	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.69	-5.65	-0.35	4.63e-8	Schizophrenia;
SARC	cis	rs708547	0.575	rs6847086	chr4:57791864	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.52	-6.31	-0.38	1.39e-9	Response to bleomycin (chromatid breaks);
SARC	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	12.74	0.64	1.44e-28	Platelet count;
SARC	cis	rs2153904	0.590	rs823106	chr1:205656453	G/C	cg23034840	chr1:205782522	SLC41A1	0.63	5.39	0.33	1.75e-7	Prostate-specific antigen levels;
SARC	cis	rs4555082	0.915	rs28594491	chr14:105758018	G/A	cg06808227	chr14:105710500	BRF1	-0.49	-6.07	-0.37	5.16e-9	Mean platelet volume;Platelet distribution width;
SARC	cis	rs1964356	0.967	rs2953802	chr8:8851881	G/A	cg06636001	chr8:8085503	FLJ10661	0.48	5.78	0.35	2.44e-8	Mean corpuscular volume;
SARC	cis	rs533581	0.873	rs579740	chr16:88973937	A/G	cg05579598	chr16:88989069	CBFA2T3	-0.39	-5.93	-0.36	1.1e-8	Social autistic-like traits;
SARC	cis	rs2282802	0.685	rs7715538	chr5:139665181	T/C	cg26211634	chr5:139558579	C5orf32	0.37	4.81	0.3	2.75e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	10.98	0.58	6.89e-23	Platelet count;
SARC	cis	rs4253772	0.530	rs28362161	chr22:46807439	C/T	cg18190219	chr22:46762943	CELSR1	-0.65	-5.39	-0.33	1.72e-7	LDL cholesterol;Cholesterol, total;
SARC	cis	rs7659604	1.000	rs35249024	chr4:122664538	C/A	cg19748678	chr4:122722346	EXOSC9	0.42	5.2	0.32	4.29e-7	Type 2 diabetes;
SARC	cis	rs4423214	1.000	rs909217	chr11:71146577	G/A	cg24826892	chr11:71159390	DHCR7	0.44	5.33	0.33	2.34e-7	Vitamin D levels;
SARC	cis	rs12142240	0.698	rs68112720	chr1:46813888	T/C	cg00530320	chr1:46809349	NSUN4	0.57	6.92	0.41	4.4e-11	Menopause (age at onset);
SARC	cis	rs888194	0.544	rs2196612	chr12:109849535	A/G	cg19025524	chr12:109796872	NA	-0.34	-4.78	-0.3	3.04e-6	Neuroticism;
SARC	cis	rs2439831	1.000	rs2444032	chr15:43755346	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	8.4	0.48	4.44e-15	Lung cancer in ever smokers;
SARC	cis	rs7552404	0.696	rs1417405	chr1:76457797	T/C	cg10523679	chr1:76189770	ACADM	0.48	5.4	0.33	1.66e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs793571	0.566	rs610877	chr15:59103328	C/A	cg05156742	chr15:59063176	FAM63B	0.75	10.36	0.56	6.3e-21	Schizophrenia;
SARC	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2073300	0.609	rs12625164	chr20:23354269	T/C	cg12062639	chr20:23401060	NAPB	1.01	6.9	0.41	4.88e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs6120849	0.754	rs6120813	chr20:33642112	T/C	cg24642439	chr20:33292090	TP53INP2	0.57	5.48	0.34	1.1e-7	Protein C levels;
SARC	cis	rs2651899	0.902	rs2742673	chr1:3080019	A/C	cg22674798	chr1:3096360	PRDM16	-0.25	-5.25	-0.33	3.37e-7	Migraine;
SARC	cis	rs2645694	0.533	rs2645674	chr4:77818202	T/C	cg03477792	chr4:77819574	ANKRD56	0.5	7.37	0.43	2.94e-12	Emphysema distribution in smoking;
SARC	cis	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg11625631	chr7:19453933	NA	0.37	4.88	0.3	1.97e-6	Thyroid stimulating hormone;
SARC	cis	rs9341808	0.667	rs6938280	chr6:80897782	G/A	cg08355045	chr6:80787529	NA	0.37	5.87	0.36	1.48e-8	Sitting height ratio;
SARC	cis	rs2033711	0.654	rs734380	chr19:58898963	A/C	cg03735888	chr19:58951602	ZNF132	0.4	5.04	0.31	9.16e-7	Uric acid clearance;
SARC	cis	rs262150	0.501	rs1062610	chr7:158821175	C/T	cg09640425	chr7:158790006	NA	-0.38	-5.43	-0.33	1.44e-7	Facial morphology (factor 20);
SARC	cis	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg18876405	chr7:65276391	NA	-0.68	-8.19	-0.47	1.72e-14	Aortic root size;
SARC	cis	rs7927771	1.000	rs1317149	chr11:47486885	C/T	cg05585544	chr11:47624801	NA	-0.36	-4.81	-0.3	2.71e-6	Subjective well-being;
SARC	cis	rs79149102	0.737	rs12593975	chr15:75189591	G/A	cg09165964	chr15:75287851	SCAMP5	-1.12	-7.33	-0.43	3.83e-12	Lung cancer;
SARC	cis	rs7264396	0.790	rs6060542	chr20:34249061	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-8.24	-0.47	1.25e-14	Total cholesterol levels;
SARC	cis	rs2034088	0.965	rs4968070	chr17:446162	A/G	cg13332499	chr17:408570	NA	0.33	5.06	0.31	8.45e-7	Hip circumference adjusted for BMI;
SARC	cis	rs7772486	0.790	rs7753696	chr6:146279098	G/T	cg05347473	chr6:146136440	FBXO30	-0.47	-6.32	-0.38	1.32e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs56011263	0.687	rs4690187	chr4:703813	C/T	cg14024328	chr4:719362	PCGF3	-0.42	-5.63	-0.35	5.06e-8	White blood cell count;
SARC	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg11987759	chr7:65425863	GUSB	0.59	7.68	0.45	4.47e-13	Aortic root size;
SARC	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg02711726	chr17:80685570	FN3KRP	-0.53	-6.51	-0.39	4.49e-10	Glycated hemoglobin levels;
SARC	cis	rs9811216	1.000	rs9811216	chr3:169487501	T/C	cg14222479	chr3:169487675	ARPM1	0.44	5.23	0.32	3.83e-7	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg18876405	chr7:65276391	NA	-0.45	-4.94	-0.31	1.46e-6	Aortic root size;
SARC	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg03452623	chr4:187889614	NA	-0.59	-7.53	-0.44	1.08e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1568889	1.000	rs12791341	chr11:28335452	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.72	9.49	0.53	2.79e-18	Bipolar disorder;
SARC	trans	rs12310956	0.515	rs1830086	chr12:33958874	C/T	cg13010199	chr12:38710504	ALG10B	0.73	9.9	0.54	1.69e-19	Morning vs. evening chronotype;
SARC	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg16405210	chr4:1374714	KIAA1530	-0.59	-7.12	-0.42	1.37e-11	Longevity;
SARC	cis	rs832540	0.931	rs832536	chr5:56212595	C/T	cg14703610	chr5:56206110	C5orf35	0.54	6.83	0.41	7.24e-11	Coronary artery disease;
SARC	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg11494091	chr17:61959527	GH2	0.36	5.14	0.32	5.83e-7	Height;
SARC	cis	rs7044106	0.762	rs1158553	chr9:123400974	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	5.01	0.31	1.09e-6	Hip circumference adjusted for BMI;
SARC	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg04772025	chr11:68637568	NA	0.51	6.16	0.37	3.11e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg25072359	chr17:41440525	NA	0.5	6.17	0.37	2.96e-9	Menopause (age at onset);
SARC	cis	rs4308124	0.708	rs6749633	chr2:111988016	A/G	cg04571233	chr2:111982156	NA	0.51	5.85	0.36	1.7e-8	Vitiligo;
SARC	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	11.01	0.58	5.84e-23	Platelet count;
SARC	cis	rs77633900	0.614	rs2468116	chr15:76870998	G/A	cg21673338	chr15:77095150	SCAPER	-0.61	-5.08	-0.32	7.58e-7	Non-glioblastoma glioma;Glioma;
SARC	cis	rs9911578	0.874	rs302865	chr17:56756977	A/G	cg05425664	chr17:57184151	TRIM37	-0.64	-7.91	-0.46	1.01e-13	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.39	0.44	2.61e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1109861	0.647	rs693950	chr10:11212852	C/A	cg17290701	chr10:11059714	CUGBP2	0.38	4.82	0.3	2.54e-6	Urinary albumin-to-creatinine ratio;
SARC	cis	rs6831352	0.819	rs2851274	chr4:100025866	G/C	cg12011299	chr4:100065546	ADH4	0.26	4.75	0.3	3.49e-6	Alcohol dependence;
SARC	cis	rs10870270	1.000	rs11146324	chr10:133767445	A/C	cg26149184	chr10:133730230	NA	0.48	5.33	0.33	2.28e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs2011503	1.000	rs77616520	chr19:19652776	G/A	cg15839431	chr19:19639596	YJEFN3	-0.48	-4.77	-0.3	3.32e-6	Bipolar disorder;
SARC	cis	rs6964587	0.839	rs10808086	chr7:91447515	T/C	cg17063962	chr7:91808500	NA	0.81	11.43	0.6	2.67e-24	Breast cancer;
SARC	cis	rs3784262	0.607	rs4646576	chr15:58338998	A/T	cg12031962	chr15:58353849	ALDH1A2	-0.38	-5.56	-0.34	7.38e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs16854884	1.000	rs16854884	chr3:143778708	A/C	cg06585982	chr3:143692056	C3orf58	0.55	6.64	0.4	2.25e-10	Economic and political preferences (feminism/equality);
SARC	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg24675658	chr1:53192096	ZYG11B	-0.65	-9.46	-0.53	3.52e-18	Monocyte count;
SARC	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.68	6.53	0.39	4.09e-10	Platelet count;
SARC	cis	rs6866344	0.570	rs4266420	chr5:178137161	C/G	cg10224037	chr5:178157518	ZNF354A	0.97	13.4	0.66	9.88e-31	Neutrophil percentage of white cells;
SARC	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg18252515	chr7:66147081	NA	0.47	5.06	0.31	8.32e-7	Aortic root size;
SARC	cis	rs9291683	0.530	rs998675	chr4:9948829	A/G	cg11266682	chr4:10021025	SLC2A9	0.41	7.24	0.43	6.56e-12	Bone mineral density;
SARC	cis	rs853679	0.760	rs9357067	chr6:28210293	C/G	cg26450541	chr6:28235208	ZNF187	0.59	5.21	0.32	4.25e-7	Depression;
SARC	cis	rs55823223	0.503	rs9906971	chr17:73848477	A/G	cg06969265	chr17:73775802	H3F3B	0.48	5.36	0.33	1.97e-7	Psoriasis;
SARC	cis	rs17666538	0.591	rs1669716	chr8:593707	C/T	cg00450029	chr8:599525	NA	0.54	4.89	0.31	1.86e-6	IgG glycosylation;
SARC	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg03060546	chr3:49711283	APEH	0.48	6.39	0.39	8.85e-10	Menarche (age at onset);
SARC	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg11764359	chr7:65958608	NA	-0.72	-8.41	-0.48	4.1e-15	Aortic root size;
SARC	cis	rs1124376	1.000	rs4417886	chr3:20108511	C/T	cg05072819	chr3:20081367	KAT2B	0.55	5.37	0.33	1.88e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg13647721	chr17:30228624	UTP6	0.59	4.74	0.3	3.78e-6	Hip circumference adjusted for BMI;
SARC	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.85	12.13	0.62	1.43e-26	Chronic sinus infection;
SARC	cis	rs7617480	0.648	rs4858800	chr3:48755820	A/G	cg06212747	chr3:49208901	KLHDC8B	0.49	4.86	0.3	2.21e-6	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs7727544	0.618	rs2631367	chr5:131705458	C/G	cg24060327	chr5:131705240	SLC22A5	0.43	5.26	0.33	3.2e-7	Blood metabolite levels;
SARC	cis	rs614226	0.935	rs588132	chr12:121024066	A/G	cg01236616	chr12:121019343	POP5	1.25	18.7	0.77	2.74e-48	Type 1 diabetes nephropathy;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg13623384	chr6:160176839	WTAP	-0.5	-6.36	-0.38	1.06e-9	Alcohol dependence;
SARC	cis	rs66887589	0.934	rs2389873	chr4:120554714	A/G	cg09307838	chr4:120376055	NA	-0.54	-7.45	-0.44	1.82e-12	Diastolic blood pressure;
SARC	cis	rs6831352	0.879	rs2602879	chr4:100040652	G/A	cg12011299	chr4:100065546	ADH4	0.33	5.49	0.34	1.03e-7	Alcohol dependence;
SARC	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg22618164	chr12:122356400	WDR66	0.51	8.25	0.48	1.17e-14	Mean corpuscular volume;
SARC	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg12310025	chr6:25882481	NA	-0.5	-6.33	-0.38	1.22e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg22168489	chr12:122356033	WDR66	0.66	10.27	0.56	1.15e-20	Mean corpuscular volume;
SARC	trans	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg20587970	chr11:113659929	NA	-1.26	-12.74	-0.64	1.48e-28	Hip circumference adjusted for BMI;
SARC	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg10373733	chr6:25993375	NA	0.39	4.73	0.3	3.84e-6	Height;
SARC	cis	rs9291683	0.632	rs12508991	chr4:10041104	C/T	cg00071950	chr4:10020882	SLC2A9	0.4	6.4	0.39	8.53e-10	Bone mineral density;
SARC	cis	rs9816226	0.591	rs80080062	chr3:185812169	C/G	cg00760338	chr3:185826511	ETV5	-0.82	-8.06	-0.47	3.85e-14	Obesity;Body mass index;
SARC	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg26335602	chr6:28129616	ZNF389	0.52	5.69	0.35	3.74e-8	Depression;
SARC	cis	rs2976388	0.692	rs1435453	chr8:143780775	C/T	cg06565975	chr8:143823917	SLURP1	0.3	5.15	0.32	5.58e-7	Urinary tract infection frequency;
SARC	cis	rs6121246	0.529	rs750144	chr20:30179027	C/T	cg21427119	chr20:30132790	HM13	0.5	5.61	0.34	5.83e-8	Mean corpuscular hemoglobin;
SARC	cis	rs9457247	1.000	rs2757047	chr6:167374489	C/T	cg07741184	chr6:167504864	NA	-0.3	-5.61	-0.35	5.69e-8	Crohn's disease;
SARC	cis	rs9309711	0.666	rs6723101	chr2:3484443	T/C	cg08493051	chr2:3487164	NA	-0.4	-5.06	-0.31	8.4e-7	Neurofibrillary tangles;
SARC	cis	rs155076	1.000	rs261427	chr13:21860998	G/A	cg14456004	chr13:21872349	NA	-0.99	-12.55	-0.64	6.18e-28	White matter hyperintensity burden;
SARC	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg13175981	chr1:150552382	MCL1	-0.54	-6.82	-0.41	7.54e-11	Tonsillectomy;
SARC	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg07234876	chr8:600039	NA	-0.77	-5.72	-0.35	3.32e-8	IgG glycosylation;
SARC	cis	rs12754538	0.777	rs6675857	chr1:8652154	A/G	cg13785123	chr1:8931135	ENO1	-0.47	-5.2	-0.32	4.42e-7	Subjective well-being;
SARC	cis	rs4780401	0.901	rs34774904	chr16:11817107	G/A	cg01061890	chr16:11836724	TXNDC11	-0.52	-6.78	-0.41	9.59e-11	Rheumatoid arthritis;
SARC	cis	rs10876993	0.672	rs2640611	chr12:58037757	T/A	cg18357645	chr12:58087776	OS9	0.44	5.81	0.36	2.01e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs2273669	0.504	rs78662936	chr6:109449690	G/T	cg05315195	chr6:109294784	ARMC2	-0.6	-5.02	-0.31	1.01e-6	Prostate cancer;
SARC	cis	rs6701037	1.000	rs11580331	chr1:175123288	T/C	cg00321850	chr1:175162397	KIAA0040	-0.34	-5.11	-0.32	6.73e-7	Alcohol dependence;
SARC	cis	rs9392918	0.935	rs9406052	chr6:7700988	T/C	cg23089261	chr6:7723385	NA	0.41	5.41	0.33	1.56e-7	Height;
SARC	cis	rs2624839	0.704	rs2526384	chr3:50181136	C/T	cg24110177	chr3:50126178	RBM5	-0.55	-6.8	-0.41	8.53e-11	Intelligence (multi-trait analysis);
SARC	cis	rs6500602	0.702	rs2058812	chr16:4524443	C/G	cg08645402	chr16:4508243	NA	0.45	5.96	0.36	9.08e-9	Schizophrenia;
SARC	cis	rs763121	0.889	rs9610971	chr22:38910810	C/T	cg21395723	chr22:39101663	GTPBP1	0.62	6.95	0.41	3.73e-11	Menopause (age at onset);
SARC	cis	rs11098499	1.000	rs11098500	chr4:120219239	T/A	cg09307838	chr4:120376055	NA	0.85	11.65	0.61	5.04e-25	Corneal astigmatism;
SARC	cis	rs11969893	0.737	rs1854483	chr6:101378117	G/A	cg12253828	chr6:101329408	ASCC3	0.97	6.62	0.4	2.48e-10	Economic and political preferences (immigration/crime);
SARC	cis	rs3749237	0.595	rs4855877	chr3:49448527	T/C	cg03060546	chr3:49711283	APEH	0.75	10.66	0.57	7.15e-22	Resting heart rate;
SARC	cis	rs7412746	0.611	rs10788794	chr1:150728676	T/C	cg10589385	chr1:150898437	SETDB1	0.4	5.29	0.33	2.88e-7	Melanoma;
SARC	cis	rs10876993	0.928	rs1689595	chr12:58056763	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.47	-5.93	-0.36	1.08e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs4443100	0.958	rs11090217	chr22:23378505	G/A	cg14186256	chr22:23484241	RTDR1	0.46	4.77	0.3	3.26e-6	Serum parathyroid hormone levels;
SARC	cis	rs7772486	0.597	rs6570732	chr6:146245151	G/A	cg05347473	chr6:146136440	FBXO30	-0.73	-9.9	-0.54	1.66e-19	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12042938	0.600	rs823161	chr1:231775017	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.55	7.58	0.44	8.06e-13	Neuranatomic and neurocognitive phenotypes;
SARC	cis	rs17125944	0.505	rs75661138	chr14:53259262	G/A	cg00686598	chr14:53173677	PSMC6	1.3	8.95	0.51	1.12e-16	Alzheimer's disease (late onset);
SARC	cis	rs1003719	0.591	rs2835618	chr21:38503126	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-8.08	-0.47	3.42e-14	Eye color traits;
SARC	cis	rs11190604	0.697	rs4559619	chr10:102199884	C/T	cg07080220	chr10:102295463	HIF1AN	-0.7	-8.73	-0.5	4.83e-16	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs4481887	1.000	rs6681423	chr1:248482834	C/A	cg00666640	chr1:248458726	OR2T12	0.39	6.37	0.39	9.89e-10	Common traits (Other);
SARC	cis	rs10492096	1.000	rs10492096	chr12:6580582	A/G	cg13857086	chr12:6580257	VAMP1	0.76	7.57	0.44	8.56e-13	Hip geometry;
SARC	cis	rs36051895	0.559	rs7850228	chr9:5210671	C/G	cg02405213	chr9:5042618	JAK2	0.43	5.07	0.32	8.06e-7	Pediatric autoimmune diseases;
SARC	cis	rs780094	0.528	rs1728918	chr2:27635463	C/T	cg11618577	chr2:27665543	KRTCAP3	0.32	4.84	0.3	2.37e-6	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs2204008	0.807	rs12816136	chr12:38456037	A/G	cg13010199	chr12:38710504	ALG10B	-0.69	-9.44	-0.53	4.09e-18	Bladder cancer;
SARC	cis	rs5022636	0.507	rs4579761	chr1:151335909	T/G	cg13175981	chr1:150552382	MCL1	0.54	5.61	0.35	5.57e-8	Gut microbiota (functional units);
SARC	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg22800045	chr5:56110881	MAP3K1	0.74	7.83	0.46	1.74e-13	Initial pursuit acceleration;
SARC	cis	rs504918	0.584	rs9847323	chr3:123985684	C/T	cg05766129	chr3:123988013	KALRN	0.32	5.33	0.33	2.34e-7	Schizophrenia;
SARC	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg07414643	chr4:187882934	NA	0.48	6.7	0.4	1.58e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11792861	0.855	rs72607165	chr9:111814498	C/T	cg13535736	chr9:111863775	C9orf5	-0.4	-4.84	-0.3	2.34e-6	Menarche (age at onset);
SARC	cis	rs2153535	0.580	rs1328862	chr6:8526681	A/T	cg23788917	chr6:8435910	SLC35B3	0.63	8.57	0.49	1.43e-15	Motion sickness;
SARC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg15305172	chr6:116892775	RWDD1	-0.56	-6.26	-0.38	1.85e-9	Plasma amyloid beta peptide concentrations (ABx-40);
SARC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg21280719	chr6:42927975	GNMT	-0.45	-7.67	-0.45	4.54e-13	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs11785400	0.793	rs9297970	chr8:143723386	C/T	cg10596483	chr8:143751796	JRK	0.57	7.47	0.44	1.65e-12	Schizophrenia;
SARC	cis	rs992157	0.798	rs7557709	chr2:219167529	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.61	8.52	0.49	1.96e-15	Colorectal cancer;
SARC	cis	rs6912958	1.000	rs13214153	chr6:88153983	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.46	-0.34	1.2e-7	Monocyte percentage of white cells;
SARC	trans	rs61931739	0.517	rs7958755	chr12:34294699	T/C	cg13010199	chr12:38710504	ALG10B	0.75	10.04	0.55	6.11e-20	Morning vs. evening chronotype;
SARC	cis	rs4925386	1.000	rs2151512	chr20:60913495	T/C	cg24112000	chr20:60950667	NA	0.35	5.86	0.36	1.61e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs3733585	0.673	rs10000983	chr4:9951606	T/C	cg00071950	chr4:10020882	SLC2A9	-0.34	-5.31	-0.33	2.55e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7914558	0.933	rs10786729	chr10:104719378	A/G	cg04362960	chr10:104952993	NT5C2	0.4	4.84	0.3	2.42e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs1865760	0.566	rs4529296	chr6:26083135	C/G	cg10373733	chr6:25993375	NA	0.45	5.43	0.34	1.4e-7	Height;
SARC	cis	rs7726839	0.561	rs72703044	chr5:579737	G/A	cg07777115	chr5:623756	CEP72	-0.61	-5.53	-0.34	8.61e-8	Obesity-related traits;
SARC	cis	rs4481887	0.790	rs10888364	chr1:248488387	T/G	cg01631408	chr1:248437212	OR2T33	-0.39	-4.89	-0.31	1.84e-6	Common traits (Other);
SARC	cis	rs73001065	0.901	rs73002956	chr19:19578743	A/G	cg03709012	chr19:19516395	GATAD2A	0.95	5.59	0.34	6.43e-8	LDL cholesterol;
SARC	cis	rs59918340	0.616	rs3739222	chr8:142205904	C/G	cg18755752	chr8:142205143	DENND3	-0.35	-5.0	-0.31	1.11e-6	Immature fraction of reticulocytes;
SARC	cis	rs12824058	0.831	rs12297939	chr12:130811923	G/C	cg24838063	chr12:130822603	PIWIL1	0.63	8.93	0.5	1.34e-16	Menopause (age at onset);
SARC	cis	rs909341	0.537	rs4809334	chr20:62384972	G/A	cg14758556	chr20:62440591	NA	0.49	4.92	0.31	1.65e-6	Atopic dermatitis;
SARC	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg08219700	chr8:58056026	NA	0.59	6.06	0.37	5.52e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9291683	0.620	rs4383618	chr4:10125151	T/C	cg00071950	chr4:10020882	SLC2A9	-0.33	-5.14	-0.32	5.79e-7	Bone mineral density;
SARC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg12419862	chr22:24373484	LOC391322	-1.0	-17.1	-0.75	4.87e-43	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg05368731	chr17:41323189	NBR1	0.8	9.77	0.54	3.97e-19	Menopause (age at onset);
SARC	cis	rs858239	0.600	rs6461691	chr7:23139345	G/A	cg23682824	chr7:23144976	KLHL7	0.67	8.8	0.5	3.09e-16	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9905704	0.801	rs2013182	chr17:56637770	G/A	cg12560992	chr17:57184187	TRIM37	-0.43	-4.98	-0.31	1.23e-6	Testicular germ cell tumor;
SARC	cis	rs11711311	0.911	rs9817327	chr3:113478500	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	8.71	0.5	5.64e-16	IgG glycosylation;
SARC	cis	rs6690583	0.697	rs4907126	chr1:85523453	C/T	cg22153463	chr1:85462885	MCOLN2	0.59	6.42	0.39	7.44e-10	Serum sulfate level;
SARC	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg16982087	chr7:924964	C7orf20	0.48	6.6	0.4	2.79e-10	Schizophrenia;
SARC	cis	rs17539620	0.624	rs62432743	chr6:154836214	T/G	cg17771515	chr6:154831774	CNKSR3	0.53	5.07	0.32	8.2e-7	Lipoprotein (a) levels;
SARC	cis	rs752092	0.894	rs8036083	chr15:101767822	T/G	cg19997662	chr15:101784653	CHSY1	-0.48	-6.37	-0.38	1.03e-9	Corneal structure;
SARC	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg18252515	chr7:66147081	NA	-0.47	-5.03	-0.31	9.63e-7	Aortic root size;
SARC	cis	rs4319547	0.695	rs10846746	chr12:122868696	C/T	cg23029597	chr12:123009494	RSRC2	0.43	5.29	0.33	2.85e-7	Body mass index;
SARC	cis	rs9790314	0.586	rs34727114	chr3:161138929	A/C	cg04691961	chr3:161091175	C3orf57	-0.48	-6.07	-0.37	5.03e-9	Morning vs. evening chronotype;
SARC	trans	rs9395865	0.520	rs6903708	chr6:53332940	A/G	cg06589161	chr5:180618230	NA	-0.51	-6.43	-0.39	7.03e-10	Electroencephalographic traits in alcoholism;
SARC	cis	rs7953249	0.564	rs1183910	chr12:121420807	G/A	cg15155738	chr12:121454335	C12orf43	0.48	5.89	0.36	1.34e-8	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs637571	0.546	rs10791827	chr11:65596546	C/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.48	-6.22	-0.38	2.29e-9	Eosinophil percentage of white cells;
SARC	cis	rs4927850	0.794	rs13070153	chr3:195741185	A/T	cg00031303	chr3:195681400	NA	0.7	7.74	0.45	2.93e-13	Pancreatic cancer;
SARC	cis	rs113835537	0.559	rs57045447	chr11:66339683	A/G	cg24851651	chr11:66362959	CCS	0.41	5.28	0.33	2.93e-7	Airway imaging phenotypes;
SARC	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg07701084	chr6:150067640	NUP43	0.37	4.89	0.31	1.86e-6	Lung cancer;
SARC	cis	rs7607369	0.536	rs4646535	chr2:219664663	C/T	cg02176678	chr2:219576539	TTLL4	-0.4	-6.11	-0.37	4.06e-9	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs4553849	1.000	rs4553849	chr2:1855567	G/T	cg17187595	chr2:1878990	MYT1L	0.53	4.91	0.31	1.73e-6	Gut microbiota (functional units);
SARC	cis	rs7044106	0.615	rs10818470	chr9:123359204	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	5.3	0.33	2.69e-7	Hip circumference adjusted for BMI;
SARC	cis	rs1065656	0.619	rs2492883	chr16:1902105	C/T	cg01637482	chr16:1880436	FAHD1	-0.34	-4.88	-0.3	1.96e-6	Insulin-like growth factors;
SARC	cis	rs208520	0.821	rs9363572	chr6:67012231	C/T	cg07460842	chr6:66804631	NA	0.84	8.59	0.49	1.29e-15	Exhaled nitric oxide output;
SARC	cis	rs834603	0.575	rs1704970	chr7:47466512	C/T	cg23694490	chr7:47445681	TNS3	-0.33	-6.04	-0.37	6.18e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	trans	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.73	10.46	0.57	2.95e-21	Intelligence (multi-trait analysis);
SARC	cis	rs11697848	1.000	rs55992502	chr20:48560544	C/T	cg17849948	chr20:48532315	SPATA2	0.87	5.2	0.32	4.3e-7	Systemic lupus erythematosus;
SARC	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg08219700	chr8:58056026	NA	0.78	7.03	0.42	2.21e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg18252515	chr7:66147081	NA	0.48	5.18	0.32	4.86e-7	Aortic root size;
SARC	cis	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg11266682	chr4:10021025	SLC2A9	0.41	7.29	0.43	4.75e-12	Bone mineral density;
SARC	trans	rs1814175	0.715	rs7479622	chr11:49673340	T/G	cg03929089	chr4:120376271	NA	-0.85	-13.26	-0.66	2.92e-30	Height;
SARC	cis	rs6570726	0.935	rs414222	chr6:145850482	C/T	cg23711669	chr6:146136114	FBXO30	0.78	12.08	0.62	2.13e-26	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg26484090	chr6:99960583	USP45	0.51	7.6	0.45	7.37e-13	Thyroid stimulating hormone;
SARC	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg01316550	chr5:56110833	MAP3K1	0.54	4.92	0.31	1.62e-6	Initial pursuit acceleration;
SARC	cis	rs2073300	0.609	rs12625164	chr20:23354269	T/C	cg16736954	chr20:23401023	NAPB	0.79	4.89	0.31	1.86e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.43	0.56	3.79e-21	Prudent dietary pattern;
SARC	cis	rs8014204	0.806	rs11159105	chr14:75298052	C/T	cg17347104	chr14:75034677	LTBP2	-0.45	-5.72	-0.35	3.29e-8	Caffeine consumption;
SARC	cis	rs4727027	0.933	rs6955564	chr7:148866173	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.4	4.92	0.31	1.64e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs1008375	0.966	rs3775927	chr4:17599894	G/T	cg16339924	chr4:17578868	LAP3	0.66	8.43	0.48	3.68e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs76419734	1.000	rs17036308	chr4:106749593	T/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	5.33	0.33	2.37e-7	Post bronchodilator FEV1;
SARC	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg13939156	chr17:80058883	NA	-0.42	-6.48	-0.39	5.51e-10	Life satisfaction;
SARC	cis	rs1559088	0.749	rs10405757	chr19:33616526	C/A	cg27124370	chr19:33622961	WDR88	0.46	5.93	0.36	1.09e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs1044826	0.642	rs295482	chr3:139229264	A/T	cg15131784	chr3:139108705	COPB2	-0.4	-5.06	-0.31	8.66e-7	Obesity-related traits;
SARC	cis	rs2295359	0.892	rs72676067	chr1:67658803	G/A	cg12940439	chr1:67600707	NA	0.45	6.43	0.39	6.96e-10	Psoriasis;
SARC	cis	rs4566357	0.615	rs10198406	chr2:227913539	A/G	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.86	-0.36	1.53e-8	Coronary artery disease;
SARC	cis	rs7481584	0.624	rs377765	chr11:3046298	C/T	cg25174290	chr11:3078921	CARS	-0.59	-8.18	-0.47	1.8e-14	Calcium levels;
SARC	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	12.27	0.63	4.95e-27	Platelet count;
SARC	cis	rs7246657	0.943	rs3803895	chr19:37898669	A/G	cg14683738	chr19:37701593	ZNF585B	0.49	4.76	0.3	3.42e-6	Coronary artery calcification;
SARC	cis	rs7949030	1.000	rs10897289	chr11:62400016	T/C	cg11742103	chr11:62369870	EML3;MTA2	0.38	5.48	0.34	1.09e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs6696846	0.765	rs2836	chr1:205111761	G/T	cg21643547	chr1:205240462	TMCC2	0.56	7.8	0.45	2.09e-13	Red blood cell count;
SARC	cis	rs9393692	0.645	rs4145910	chr6:26313305	T/C	cg00631329	chr6:26305371	NA	-0.61	-7.88	-0.46	1.25e-13	Educational attainment;
SARC	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg19223190	chr17:80058835	NA	-0.43	-6.02	-0.37	6.57e-9	Life satisfaction;
SARC	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg24531977	chr5:56204891	C5orf35	-0.52	-5.22	-0.32	4.03e-7	Initial pursuit acceleration;
SARC	trans	rs1865760	0.929	rs9461224	chr6:25936402	G/T	cg14106298	chr2:70475633	TIA1	-0.55	-6.58	-0.4	3e-10	Height;
SARC	cis	rs4481887	1.000	rs6697863	chr1:248495588	G/A	cg13385794	chr1:248469461	NA	0.36	5.35	0.33	2.06e-7	Common traits (Other);
SARC	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg24846343	chr22:24311635	DDTL	0.5	7.26	0.43	5.85e-12	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs11112613	0.713	rs55646142	chr12:105949557	G/A	cg03607813	chr12:105948248	NA	0.56	7.54	0.44	1.06e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	5.98	0.36	8.24e-9	Bipolar disorder;
SARC	cis	rs1348850	0.526	rs2293475	chr2:178407897	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.61	-5.5	-0.34	1.01e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1941023	0.503	rs7944025	chr11:60142538	C/A	cg08716584	chr11:60157161	MS4A7	-0.4	-6.36	-0.38	1.05e-9	Congenital heart disease (maternal effect);
SARC	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg17221315	chr6:27791827	HIST1H4J	0.46	4.83	0.3	2.53e-6	Depression;
SARC	cis	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg13072238	chr3:49761600	GMPPB	0.43	5.65	0.35	4.57e-8	Intelligence (multi-trait analysis);
SARC	cis	rs425277	1.000	rs809912	chr1:2078385	C/T	cg24578937	chr1:2090814	PRKCZ	0.31	5.85	0.36	1.63e-8	Height;
SARC	cis	rs2387326	0.761	rs2071496	chr10:129901501	G/C	cg16087940	chr10:129947807	NA	-0.47	-6.16	-0.37	3.14e-9	Select biomarker traits;
SARC	cis	rs11122272	0.735	rs2739515	chr1:231514681	G/A	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg17100158	chr2:180307728	ZNF385B	0.44	6.77	0.41	1.02e-10	Thyroid stimulating hormone;
SARC	cis	rs9814567	0.806	rs9824185	chr3:134324024	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.5	-6.55	-0.39	3.6e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg26681399	chr22:41777847	TEF	-0.46	-4.99	-0.31	1.17e-6	Vitiligo;
SARC	trans	rs12310956	0.532	rs2087270	chr12:33850109	C/T	cg26384229	chr12:38710491	ALG10B	0.59	7.55	0.44	1e-12	Morning vs. evening chronotype;
SARC	cis	rs1349547	0.510	rs3824144	chr8:39495325	G/A	cg12140000	chr8:38554703	NA	0.31	4.74	0.3	3.71e-6	HIV-1 susceptibility;
SARC	cis	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg13147721	chr7:65941812	NA	-0.52	-4.76	-0.3	3.38e-6	Diabetic kidney disease;
SARC	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	11.63	0.61	5.84e-25	Alzheimer's disease;
SARC	trans	rs61931739	0.500	rs11053249	chr12:34518834	A/T	cg26384229	chr12:38710491	ALG10B	0.88	13.24	0.66	3.41e-30	Morning vs. evening chronotype;
SARC	cis	rs7560272	0.538	rs4852977	chr2:73938295	C/T	cg20560298	chr2:73613845	ALMS1	0.44	5.92	0.36	1.14e-8	Schizophrenia;
SARC	cis	rs9640161	0.702	rs11765692	chr7:150026567	C/T	cg17279839	chr7:150038598	RARRES2	0.48	6.88	0.41	5.4e-11	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg20607798	chr8:58055168	NA	0.58	5.57	0.34	6.9e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1865760	0.929	rs2876693	chr6:25954434	C/G	cg17691542	chr6:26056736	HIST1H1C	0.59	7.45	0.44	1.76e-12	Height;
SARC	cis	rs4891159	0.790	rs17059325	chr18:74119567	A/C	cg24786174	chr18:74118243	ZNF516	-0.62	-8.47	-0.49	2.78e-15	Longevity;
SARC	cis	rs7005380	0.581	rs9987139	chr8:120936859	G/A	cg21744203	chr8:120868354	DSCC1	0.45	5.29	0.33	2.75e-7	Interstitial lung disease;
SARC	cis	rs11098499	0.604	rs17051352	chr4:120581427	G/A	cg09307838	chr4:120376055	NA	0.82	10.77	0.58	3.22e-22	Corneal astigmatism;
SARC	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg12310025	chr6:25882481	NA	-0.5	-6.4	-0.39	8.62e-10	Intelligence (multi-trait analysis);
SARC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg11494091	chr17:61959527	GH2	0.53	7.94	0.46	8.67e-14	Prudent dietary pattern;
SARC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg24846343	chr22:24311635	DDTL	0.52	7.13	0.42	1.24e-11	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs55883249	0.957	rs62119393	chr2:9718247	C/T	cg23886495	chr2:9695866	ADAM17	0.69	6.98	0.42	3.12e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs6570726	0.935	rs447247	chr6:145812678	G/T	cg05347473	chr6:146136440	FBXO30	0.49	6.48	0.39	5.27e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs13392177	0.647	rs10932761	chr2:219064391	T/A	cg00012203	chr2:219082015	ARPC2	-0.7	-9.43	-0.53	4.46e-18	Pyoderma gangrenosum in inflammatory bowel disease;
SARC	cis	rs3733585	0.806	rs11723382	chr4:9954660	T/C	cg11266682	chr4:10021025	SLC2A9	-0.39	-7.0	-0.42	2.66e-11	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg16606324	chr3:10149918	C3orf24	0.48	4.75	0.3	3.56e-6	Alzheimer's disease;
SARC	cis	rs798766	0.514	rs798750	chr4:1717171	G/A	cg00010108	chr4:1615271	NA	-0.34	-4.78	-0.3	3.09e-6	Bladder cancer;Urinary bladder cancer;
SARC	cis	rs921968	0.565	rs7599365	chr2:219620566	G/A	cg02176678	chr2:219576539	TTLL4	-0.32	-4.88	-0.3	1.93e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs6121246	0.909	rs6058450	chr20:30343911	G/A	cg13852791	chr20:30311386	BCL2L1	0.85	9.18	0.52	2.48e-17	Mean corpuscular hemoglobin;
SARC	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg12311346	chr5:56204834	C5orf35	-0.56	-5.78	-0.35	2.39e-8	Initial pursuit acceleration;
SARC	cis	rs6991838	0.584	rs16932250	chr8:66511014	T/G	cg13398993	chr8:66546079	ARMC1	-0.62	-8.37	-0.48	5.33e-15	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg18252515	chr7:66147081	NA	0.51	5.5	0.34	1.01e-7	Aortic root size;
SARC	trans	rs28425639	0.850	rs72819146	chr2:100553285	T/C	cg08602190	chr10:128076260	ADAM12	-0.67	-6.27	-0.38	1.76e-9	Response to paliperidone in schizophrenia (negative Marder score);
SARC	cis	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg24110177	chr3:50126178	RBM5	0.4	5.06	0.31	8.7e-7	Intelligence (multi-trait analysis);
SARC	cis	rs75920871	0.528	rs11216241	chr11:116899249	A/C	cg01368799	chr11:117014884	PAFAH1B2	-0.46	-4.75	-0.3	3.57e-6	Subjective well-being;
SARC	cis	rs9368481	0.761	rs4358615	chr6:26998567	A/G	cg12292205	chr6:26970375	C6orf41	0.48	5.44	0.34	1.35e-7	Autism spectrum disorder or schizophrenia;
SARC	cis	rs796364	0.950	rs188146	chr2:200750444	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.64	0.4	2.24e-10	Schizophrenia;
SARC	cis	rs7772486	0.686	rs857875	chr6:145980033	T/G	cg05220968	chr6:146057943	EPM2A	0.28	4.88	0.3	1.93e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs995000	0.931	rs2131925	chr1:63025942	G/T	cg06896770	chr1:63153194	DOCK7	-0.9	-13.26	-0.66	2.87e-30	Triglyceride levels;
SARC	cis	rs9420	0.884	rs589914	chr11:57661032	A/G	cg23127183	chr11:57508653	C11orf31	0.61	6.66	0.4	1.98e-10	Schizophrenia;
SARC	cis	rs9611519	0.964	rs4820428	chr22:41537589	C/T	cg03806693	chr22:41940476	POLR3H	0.53	6.06	0.37	5.55e-9	Neuroticism;
SARC	cis	rs10504229	0.679	rs16921683	chr8:58053270	T/C	cg22535103	chr8:58192502	C8orf71	-0.59	-5.94	-0.36	1.03e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7635838	0.822	rs9861633	chr3:11473437	C/G	cg00170343	chr3:11313890	ATG7	0.63	8.5	0.49	2.34e-15	HDL cholesterol;
SARC	cis	rs9388451	0.839	rs3757217	chr6:126069636	G/C	cg06289844	chr6:126071538	HEY2	0.39	6.31	0.38	1.4e-9	Brugada syndrome;
SARC	cis	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg23332699	chr15:44069569	ELL3	0.55	5.51	0.34	9.3e-8	Lung cancer in ever smokers;
SARC	cis	rs10779751	0.690	rs743577	chr1:11119135	G/A	cg04508216	chr1:11107452	MASP2	0.35	4.93	0.31	1.56e-6	Body mass index;
SARC	cis	rs11098499	0.818	rs12498599	chr4:120468503	C/T	cg24375607	chr4:120327624	NA	0.42	4.92	0.31	1.64e-6	Corneal astigmatism;
SARC	cis	rs12079745	1.000	rs12083249	chr1:169111592	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.89	-5.45	-0.34	1.26e-7	QT interval;
SARC	cis	rs7772486	0.790	rs80050589	chr6:146230454	T/C	cg23711669	chr6:146136114	FBXO30	-0.81	-13.07	-0.65	1.23e-29	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1044826	1.000	rs9868544	chr3:139163154	C/T	cg15131784	chr3:139108705	COPB2	0.46	5.15	0.32	5.6e-7	Obesity-related traits;
SARC	cis	rs8013055	0.706	rs8003957	chr14:105971702	A/G	cg19700328	chr14:106028568	NA	-0.59	-8.17	-0.47	1.93e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
SARC	cis	rs72781680	1.000	rs72781675	chr2:24232092	G/A	cg06627628	chr2:24431161	ITSN2	-0.73	-6.9	-0.41	4.77e-11	Lymphocyte counts;
SARC	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg20607798	chr8:58055168	NA	0.61	5.41	0.33	1.57e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs8077889	0.869	rs11713	chr17:41845824	A/G	cg26893861	chr17:41843967	DUSP3	-0.67	-7.83	-0.46	1.68e-13	Triglycerides;
SARC	cis	rs644799	1.000	rs12291986	chr11:95523030	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.94	15.6	0.71	4.77e-38	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2236918	1.000	rs1635511	chr1:242026172	C/T	cg17736920	chr1:242011382	EXO1	0.77	10.73	0.58	4.32e-22	Menopause (age at onset);
SARC	cis	rs2120243	0.533	rs34263112	chr3:157056048	A/G	cg24825693	chr3:157122686	VEPH1	-0.41	-5.81	-0.36	2.06e-8	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs11997175	1.000	rs11997175	chr8:33770070	A/G	ch.8.33884649F	chr8:33765107	NA	-0.58	-8.07	-0.47	3.61e-14	Body mass index;
SARC	cis	rs769267	0.501	rs2965187	chr19:19522970	T/A	cg03709012	chr19:19516395	GATAD2A	0.82	8.75	0.5	4.36e-16	Tonsillectomy;
SARC	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg21724239	chr8:58056113	NA	0.63	6.01	0.37	6.97e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	12.03	0.62	3.06e-26	Chronic sinus infection;
SARC	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg09165964	chr15:75287851	SCAMP5	0.48	6.46	0.39	6.03e-10	Breast cancer;
SARC	trans	rs12486865	0.500	rs113381478	chr3:99924479	C/T	cg21934772	chr13:110198949	NA	0.51	6.89	0.41	5.2e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs7639513	0.767	rs2348201	chr3:12711696	A/G	cg23032965	chr3:12705835	RAF1	0.85	12.11	0.62	1.66e-26	Itch intensity from mosquito bite;
SARC	cis	rs7605378	0.528	rs281780	chr2:200756331	G/C	cg23649088	chr2:200775458	C2orf69	0.78	10.93	0.58	1.01e-22	Osteoporosis;
SARC	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.44	0.44	1.92e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4243830	0.850	rs7552196	chr1:6590502	G/A	cg04093404	chr1:6614507	TAS1R1;NOL9	0.58	5.04	0.31	9.45e-7	Body mass index;
SARC	cis	rs17253792	0.822	rs9972180	chr14:56073732	G/T	cg01858014	chr14:56050164	KTN1	-0.69	-5.36	-0.33	2.02e-7	Putamen volume;
SARC	cis	rs3820928	0.874	rs12614648	chr2:227785535	G/A	cg11843606	chr2:227700838	RHBDD1	-0.57	-7.27	-0.43	5.52e-12	Pulmonary function;
SARC	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg23758822	chr17:41437982	NA	0.91	11.54	0.6	1.16e-24	Menopause (age at onset);
SARC	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg22496380	chr5:211416	CCDC127	-0.88	-9.59	-0.53	1.47e-18	Breast cancer;
SARC	trans	rs1814175	0.935	rs10839329	chr11:49694206	G/A	cg03929089	chr4:120376271	NA	-0.87	-13.82	-0.67	3.82e-32	Height;
SARC	cis	rs735539	0.555	rs2818987	chr13:21304911	C/T	cg16922012	chr13:21400325	XPO4	-0.36	-4.95	-0.31	1.43e-6	Dental caries;
SARC	cis	rs10448080	0.879	rs240946	chr8:28568905	A/G	cg08296263	chr8:28938433	KIF13B	-0.32	-4.74	-0.3	3.69e-6	Height;
SARC	cis	rs2635047	0.519	rs2668771	chr18:44775897	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.4	4.76	0.3	3.33e-6	Educational attainment;
SARC	trans	rs17685	0.712	rs59659102	chr7:75710114	G/A	cg19862616	chr7:65841803	NCRNA00174	0.61	7.41	0.44	2.28e-12	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg03351412	chr1:154909251	PMVK	0.61	7.77	0.45	2.56e-13	Prostate cancer;
SARC	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.87	11.71	0.61	3.24e-25	Multiple sclerosis;
SARC	cis	rs3008870	1.000	rs3008888	chr1:67368965	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.9	10.88	0.58	1.43e-22	Lymphocyte percentage of white cells;
SARC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.79	8.04	0.47	4.48e-14	Platelet count;
SARC	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg24642844	chr7:1081250	C7orf50	-0.56	-5.89	-0.36	1.36e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs4689388	0.926	rs5018647	chr4:6292799	A/C	cg25554036	chr4:6271136	WFS1	0.4	6.5	0.39	4.93e-10	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs3126085	0.825	rs11204938	chr1:152193990	A/G	cg09127314	chr1:152161683	NA	0.41	4.81	0.3	2.72e-6	Atopic dermatitis;
SARC	cis	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg08564027	chr20:61660810	NA	0.75	11.63	0.61	5.9e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs7772486	0.754	rs2064185	chr6:146066814	G/A	cg23711669	chr6:146136114	FBXO30	-0.92	-16.52	-0.73	4.25e-41	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.99	12.06	0.62	2.46e-26	Platelet count;
SARC	cis	rs112790992	1	rs112790992	chr14:105758217	A/C	cg06808227	chr14:105710500	BRF1	-0.52	-6.88	-0.41	5.52e-11	Platelet count;
SARC	cis	rs2730245	0.528	rs1188954	chr7:158691417	G/A	cg24397884	chr7:158709396	WDR60	0.72	9.11	0.51	3.88e-17	Height;
SARC	cis	rs17253792	0.732	rs10146604	chr14:56045770	C/G	cg01858014	chr14:56050164	KTN1	-0.69	-5.25	-0.33	3.42e-7	Putamen volume;
SARC	cis	rs72781680	1.000	rs72796326	chr2:24137047	G/A	cg06627628	chr2:24431161	ITSN2	-0.68	-6.44	-0.39	6.58e-10	Lymphocyte counts;
SARC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg03452623	chr4:187889614	NA	-0.78	-11.72	-0.61	2.97e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs35849525	1.000	rs35849525	chr3:50067350	T/C	cg14019146	chr3:50243930	SLC38A3	-0.36	-5.13	-0.32	5.96e-7	Intelligence (multi-trait analysis);
SARC	cis	rs57994353	0.600	rs10870172	chr9:139319469	G/A	cg14169450	chr9:139327907	INPP5E	0.45	5.59	0.34	6.43e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs7587476	0.784	rs17424051	chr2:215688992	G/C	cg04004882	chr2:215674386	BARD1	0.56	6.4	0.39	8.5e-10	Neuroblastoma;
SARC	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg16606324	chr3:10149918	C3orf24	0.48	5.04	0.31	9.53e-7	Alzheimer's disease;
SARC	cis	rs6430585	0.528	rs586964	chr2:136652491	G/A	cg07169764	chr2:136633963	MCM6	1.04	13.27	0.66	2.57e-30	Corneal structure;
SARC	cis	rs8141529	0.764	rs5762824	chr22:29222930	C/T	cg02153584	chr22:29168773	CCDC117	0.8	11.69	0.61	3.83e-25	Lymphocyte counts;
SARC	cis	rs826838	0.967	rs2892410	chr12:38990282	A/G	cg13010199	chr12:38710504	ALG10B	-0.78	-10.94	-0.58	9.37e-23	Heart rate;
SARC	cis	rs1949733	0.598	rs16842480	chr4:8535621	G/T	cg11789530	chr4:8429930	ACOX3	-0.55	-6.15	-0.37	3.4e-9	Response to antineoplastic agents;
SARC	cis	rs703842	1.000	rs10877015	chr12:58167788	A/G	cg00677455	chr12:58241039	CTDSP2	0.51	6.59	0.4	2.86e-10	Multiple sclerosis;
SARC	trans	rs7824557	0.592	rs2572371	chr8:11223793	G/T	cg06636001	chr8:8085503	FLJ10661	0.58	7.8	0.46	2.11e-13	Retinal vascular caliber;
SARC	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg20607798	chr8:58055168	NA	0.71	5.79	0.35	2.29e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7829975	0.560	rs56094035	chr8:8551622	G/A	cg06636001	chr8:8085503	FLJ10661	-0.46	-5.58	-0.34	6.62e-8	Mood instability;
SARC	cis	rs7824557	0.628	rs17797894	chr8:11212081	A/G	cg21775007	chr8:11205619	TDH	0.7	9.04	0.51	6.28e-17	Retinal vascular caliber;
SARC	cis	rs1832871	0.672	rs1342211	chr6:158759496	G/T	cg07165851	chr6:158734300	TULP4	0.57	6.64	0.4	2.22e-10	Height;
SARC	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg05861140	chr6:150128134	PCMT1	-0.37	-4.84	-0.3	2.32e-6	Lung cancer;
SARC	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg03806693	chr22:41940476	POLR3H	0.89	11.95	0.62	5.29e-26	Vitiligo;
SARC	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg04944784	chr2:26401820	FAM59B	-0.48	-5.99	-0.37	7.95e-9	Gut microbiome composition (summer);
SARC	cis	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg24110177	chr3:50126178	RBM5	0.39	5.04	0.31	9.18e-7	Intelligence (multi-trait analysis);
SARC	cis	rs17376456	0.877	rs35747258	chr5:93310129	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.46	0.34	1.24e-7	Diabetic retinopathy;
SARC	trans	rs9329221	0.698	rs12547997	chr8:10260837	A/G	cg06636001	chr8:8085503	FLJ10661	0.55	6.79	0.41	9e-11	Neuroticism;
SARC	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg12463550	chr7:65579703	CRCP	0.7	5.29	0.33	2.87e-7	Diabetic kidney disease;
SARC	cis	rs11997175	0.583	rs12680755	chr8:33815282	G/A	ch.8.33884649F	chr8:33765107	NA	0.46	5.91	0.36	1.2e-8	Body mass index;
SARC	cis	rs2576037	0.796	rs2576039	chr18:44582148	C/T	cg19077165	chr18:44547161	KATNAL2	0.45	6.22	0.38	2.25e-9	Personality dimensions;
SARC	cis	rs7312933	0.669	rs7974476	chr12:42542484	C/A	cg19980929	chr12:42632907	YAF2	0.43	5.81	0.36	1.99e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs35213789	1.000	rs1008379	chr7:69306139	C/G	cg10619644	chr7:69149951	AUTS2	0.46	5.79	0.35	2.25e-8	Childhood ear infection;
SARC	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	6.7	0.4	1.53e-10	Platelet count;
SARC	cis	rs8084125	0.832	rs62105180	chr18:74951197	C/G	cg05528293	chr18:74961138	GALR1	0.51	5.79	0.35	2.23e-8	Obesity-related traits;
SARC	cis	rs67311347	1.000	rs9829800	chr3:40443927	T/C	cg09455208	chr3:40491958	NA	0.43	6.79	0.41	9.45e-11	Renal cell carcinoma;
SARC	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg15847926	chr7:2749597	AMZ1	-0.3	-4.93	-0.31	1.59e-6	Height;
SARC	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg02951883	chr7:2050386	MAD1L1	-0.48	-6.11	-0.37	4.1e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs6121246	0.909	rs6060633	chr20:30263317	G/T	cg13852791	chr20:30311386	BCL2L1	0.86	9.16	0.51	2.76e-17	Mean corpuscular hemoglobin;
SARC	cis	rs10504073	0.669	rs341809	chr8:50042557	C/T	cg00325661	chr8:49890786	NA	0.55	7.32	0.43	4.02e-12	Blood metabolite ratios;
SARC	cis	rs7429990	0.930	rs13075457	chr3:48054553	A/G	cg11946769	chr3:48343235	NME6	-0.46	-5.25	-0.33	3.49e-7	Educational attainment (years of education);
SARC	cis	rs858239	0.676	rs274032	chr7:23374559	C/G	cg23682824	chr7:23144976	KLHL7	0.54	6.6	0.4	2.69e-10	Cerebrospinal fluid biomarker levels;
SARC	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg11062466	chr8:58055876	NA	0.56	5.69	0.35	3.79e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs17030434	0.953	rs74845915	chr4:154696778	G/T	cg14289246	chr4:154710475	SFRP2	-0.8	-7.93	-0.46	8.89e-14	Electrocardiographic conduction measures;
SARC	cis	rs7522061	0.546	rs10908586	chr1:157643457	A/G	cg18268488	chr1:157545234	FCRL4	0.26	4.83	0.3	2.45e-6	Blood protein levels;
SARC	cis	rs30380	0.632	rs27434	chr5:96129512	A/G	cg16492584	chr5:96139282	ERAP1	-0.48	-5.52	-0.34	8.89e-8	Cerebrospinal fluid biomarker levels;
SARC	cis	rs12142240	0.698	rs41293273	chr1:46806393	T/C	cg10495392	chr1:46806563	NSUN4	0.64	6.84	0.41	6.77e-11	Menopause (age at onset);
SARC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg03647317	chr4:187891568	NA	-0.35	-4.95	-0.31	1.39e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs8141529	0.702	rs132536	chr22:29302906	A/G	cg15103426	chr22:29168792	CCDC117	-0.68	-8.93	-0.5	1.31e-16	Lymphocyte counts;
SARC	cis	rs11585357	0.501	rs4262593	chr1:17594263	T/C	cg08277548	chr1:17600880	PADI3	-0.49	-5.23	-0.32	3.79e-7	Hair shape;
SARC	cis	rs7520050	0.807	rs6671802	chr1:46124663	A/G	cg24296786	chr1:45957014	TESK2	-0.44	-5.69	-0.35	3.74e-8	Red blood cell count;Reticulocyte count;
SARC	cis	rs4846217	1.000	rs4846217	chr1:10451799	C/T	cg19092837	chr1:10271724	KIF1B	0.42	5.72	0.35	3.32e-8	Platelet count;
SARC	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg11843238	chr5:131593191	PDLIM4	0.41	5.08	0.32	7.81e-7	Acylcarnitine levels;
SARC	cis	rs736408	1.000	rs736408	chr3:52835354	C/T	cg18404041	chr3:52824283	ITIH1	-0.45	-6.45	-0.39	6.23e-10	Bipolar disorder;
SARC	cis	rs2153535	0.580	rs9406169	chr6:8509470	A/T	cg07606381	chr6:8435919	SLC35B3	0.76	11.11	0.59	2.7e-23	Motion sickness;
SARC	cis	rs644799	0.710	rs666398	chr11:95551136	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.6	7.87	0.46	1.36e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7931462	0.655	rs6483208	chr11:92705844	A/C	cg09757709	chr11:93464721	SNORA32;SNORD6;SNORA25	-0.66	-5.15	-0.32	5.49e-7	DNA methylation (parent-of-origin);
SARC	cis	rs10242455	0.571	rs41258334	chr7:99271808	T/C	cg03695448	chr7:99016977	BUD31;PTCD1	0.91	4.88	0.3	2e-6	Blood metabolite levels;
SARC	cis	rs9457247	0.602	rs6456152	chr6:167472062	A/G	cg07741184	chr6:167504864	NA	0.38	7.32	0.43	3.92e-12	Crohn's disease;
SARC	trans	rs7922314	0.571	rs57110080	chr10:64736699	G/A	cg25304107	chr2:177017331	HOXD4	-0.78	-6.29	-0.38	1.52e-9	Cutaneous psoriasis;
SARC	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg13939156	chr17:80058883	NA	-0.44	-6.84	-0.41	6.73e-11	Life satisfaction;
SARC	cis	rs2463822	1.000	rs2463821	chr11:62111662	T/C	cg06239285	chr11:62104954	ASRGL1	0.85	8.27	0.48	1.05e-14	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs6450176	1.000	rs67430852	chr5:53290586	T/A	ch.5.1024479R	chr5:53302184	ARL15	-0.63	-7.07	-0.42	1.75e-11	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs1003719	0.788	rs4817843	chr21:38447040	C/A	cg10648535	chr21:38446584	PIGP;TTC3	0.67	9.98	0.55	9.49e-20	Eye color traits;
SARC	cis	rs5750830	0.594	rs6001568	chr22:39775786	G/A	cg24399712	chr22:39784796	NA	-0.42	-5.58	-0.34	6.73e-8	Intelligence (multi-trait analysis);
SARC	cis	rs35213789	0.687	rs2533425	chr7:69053248	A/G	cg10619644	chr7:69149951	AUTS2	-0.41	-5.35	-0.33	2.08e-7	Childhood ear infection;
SARC	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg20607798	chr8:58055168	NA	0.57	5.33	0.33	2.27e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9660992	0.710	rs1668864	chr1:205248799	T/C	cg07972983	chr1:205091412	RBBP5	0.55	6.57	0.4	3.2e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs2832191	0.671	rs68101501	chr21:30513229	G/T	cg24692254	chr21:30365293	RNF160	-0.68	-8.19	-0.47	1.73e-14	Dental caries;
SARC	cis	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg07777115	chr5:623756	CEP72	-0.61	-5.53	-0.34	8.61e-8	Obesity-related traits;
SARC	cis	rs9399137	0.507	rs12664898	chr6:135288663	T/C	cg24558204	chr6:135376177	HBS1L	0.62	7.98	0.46	6.83e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs1707322	0.721	rs28817701	chr1:46186050	C/T	cg03146154	chr1:46216737	IPP	0.53	6.35	0.38	1.12e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4851266	1.000	rs2871344	chr2:100839430	A/G	cg22139774	chr2:100720529	AFF3	-0.28	-4.75	-0.3	3.49e-6	Educational attainment;
SARC	cis	rs1691799	0.899	rs1168322	chr12:66743769	C/T	cg16791601	chr12:66731901	HELB	-0.71	-10.73	-0.57	4.42e-22	White blood cell count (basophil);
SARC	cis	rs3762637	1.000	rs28434553	chr3:122229515	C/A	cg24169773	chr3:122142474	KPNA1	-0.56	-5.67	-0.35	4.18e-8	LDL cholesterol levels;
SARC	cis	rs1865760	0.516	rs9393684	chr6:26075531	G/C	cg10373733	chr6:25993375	NA	0.41	5.0	0.31	1.15e-6	Height;
SARC	cis	rs9547692	0.938	rs17217404	chr13:37466215	C/T	cg01493522	chr13:37497338	NA	-0.44	-4.74	-0.3	3.76e-6	Coronary artery disease;
SARC	cis	rs614226	0.748	rs78714658	chr12:121009944	G/A	cg01236616	chr12:121019343	POP5	-1.24	-16.84	-0.74	3.79e-42	Type 1 diabetes nephropathy;
SARC	cis	rs6815814	0.950	rs5743563	chr4:38806019	A/G	cg02016764	chr4:38805732	TLR1	-0.42	-4.89	-0.31	1.87e-6	Breast cancer;
SARC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg11494091	chr17:61959527	GH2	0.54	8.0	0.46	5.95e-14	Prudent dietary pattern;
SARC	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg03433033	chr1:76189801	ACADM	-0.43	-5.35	-0.33	2.08e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7592578	0.766	rs35818159	chr2:191409616	C/G	cg27211696	chr2:191398769	TMEM194B	-0.54	-5.6	-0.34	6.07e-8	Diastolic blood pressure;
SARC	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg19729930	chr2:74357872	NA	0.73	10.65	0.57	7.48e-22	Gestational age at birth (maternal effect);
SARC	cis	rs9325144	0.647	rs11169258	chr12:39113040	C/T	cg26384229	chr12:38710491	ALG10B	-0.58	-7.31	-0.43	4.12e-12	Morning vs. evening chronotype;
SARC	cis	rs7940866	0.903	rs10750457	chr11:130850277	T/C	cg12179176	chr11:130786555	SNX19	0.64	8.49	0.49	2.39e-15	Schizophrenia;
SARC	cis	rs986417	1.000	rs1956557	chr14:60972569	G/A	cg27398547	chr14:60952738	C14orf39	0.99	9.02	0.51	6.89e-17	Gut microbiota (bacterial taxa);
SARC	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg03351412	chr1:154909251	PMVK	0.65	8.45	0.48	3.23e-15	Prostate cancer;
SARC	cis	rs9858542	1.000	rs11130213	chr3:49712297	C/T	cg07274523	chr3:49395745	GPX1	0.48	5.43	0.34	1.38e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs12579753	0.917	rs7132465	chr12:82205840	C/T	cg07988820	chr12:82153109	PPFIA2	-0.52	-6.11	-0.37	4.18e-9	Resting heart rate;
SARC	cis	rs11209002	0.614	rs12140736	chr1:67586671	T/C	cg02640540	chr1:67518911	SLC35D1	0.52	6.03	0.37	6.3e-9	Crohn's disease;
SARC	cis	rs10513788	0.665	rs1565182	chr3:181991158	A/G	cg05977900	chr3:182512126	ATP11B	0.48	5.01	0.31	1.08e-6	Cognitive function;
SARC	trans	rs208520	0.661	rs1776361	chr6:66822270	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.04	-14.05	-0.68	6.6e-33	Exhaled nitric oxide output;
SARC	cis	rs7772486	0.790	rs2253764	chr6:146199881	T/A	cg23711669	chr6:146136114	FBXO30	0.8	13.13	0.65	7.67e-30	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7481584	0.624	rs397919	chr11:3063094	A/C	cg05729581	chr11:3078854	CARS	0.52	6.82	0.41	7.73e-11	Calcium levels;
SARC	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg05313129	chr8:58192883	C8orf71	-0.56	-6.16	-0.37	3.15e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2836633	0.929	rs764482	chr21:40033661	C/G	cg12884169	chr21:40033163	ERG	0.47	8.06	0.47	3.87e-14	Coronary artery disease;
SARC	cis	rs6912958	0.630	rs9450726	chr6:88236728	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.29	-4.99	-0.31	1.18e-6	Monocyte percentage of white cells;
SARC	cis	rs3796352	1.000	rs13092352	chr3:52969697	C/T	cg12962167	chr3:53033115	SFMBT1	0.75	4.9	0.31	1.8e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg08392591	chr16:89556376	ANKRD11	0.54	7.69	0.45	4.15e-13	Multiple myeloma (IgH translocation);
SARC	cis	rs6912958	0.712	rs6908386	chr6:88354746	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.54	-0.34	8.09e-8	Monocyte percentage of white cells;
SARC	cis	rs8027181	0.839	rs7176235	chr15:72999104	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	0.4	5.27	0.33	3.06e-7	Triglyceride levels;
SARC	cis	rs2624839	0.630	rs2624841	chr3:50198415	C/T	cg19755318	chr3:50243323	SLC38A3	-0.31	-5.39	-0.33	1.73e-7	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg11764359	chr7:65958608	NA	0.54	6.42	0.39	7.66e-10	Aortic root size;
SARC	cis	rs3749237	0.595	rs7621003	chr3:49411404	T/C	cg06212747	chr3:49208901	KLHDC8B	0.51	6.24	0.38	1.99e-9	Resting heart rate;
SARC	trans	rs9329221	0.638	rs12543645	chr8:10246325	C/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-6.91	-0.41	4.72e-11	Neuroticism;
SARC	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg13628971	chr7:2884303	GNA12	0.58	6.78	0.41	9.69e-11	Height;
SARC	cis	rs1144333	0.655	rs17097681	chr1:76376926	C/T	cg03433033	chr1:76189801	ACADM	0.56	4.75	0.3	3.61e-6	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.34	-4.93	-0.31	1.54e-6	Total body bone mineral density;
SARC	cis	rs1008375	1.000	rs6854733	chr4:17640526	C/T	cg27347728	chr4:17578864	LAP3	0.47	5.91	0.36	1.22e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7681440	0.904	rs28734152	chr4:90767359	C/T	cg02192967	chr4:90758406	SNCA	0.36	5.13	0.32	6.11e-7	Dementia with Lewy bodies;
SARC	cis	rs10791097	0.694	rs2155751	chr11:130755240	G/A	cg12179176	chr11:130786555	SNX19	0.75	11.27	0.59	8.38e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs7043114	0.525	rs10761153	chr9:95130769	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.49	-0.34	1.03e-7	Height;
SARC	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg13298116	chr11:62369859	EML3;MTA2	-0.43	-6.0	-0.37	7.52e-9	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs2916247	1.000	rs6991006	chr8:93064270	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.58	-5.95	-0.36	1e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7843479	0.931	rs1031883	chr8:21788936	G/A	cg17168535	chr8:21777572	XPO7	0.62	7.78	0.45	2.34e-13	Mean corpuscular volume;
SARC	cis	rs4481887	0.893	rs10736379	chr1:248455876	A/T	cg01631408	chr1:248437212	OR2T33	-0.41	-5.21	-0.32	4.07e-7	Common traits (Other);
SARC	cis	rs6991838	0.702	rs34496943	chr8:66589213	G/A	cg13398993	chr8:66546079	ARMC1	0.39	4.86	0.3	2.17e-6	Intelligence (multi-trait analysis);
SARC	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg16325326	chr1:53192061	ZYG11B	0.79	12.59	0.64	4.54e-28	Monocyte count;
SARC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg26338869	chr17:61819248	STRADA	0.78	9.96	0.55	1.06e-19	Prudent dietary pattern;
SARC	cis	rs950169	0.922	rs17531523	chr15:85132449	C/G	cg17507749	chr15:85114479	UBE2QP1	0.8	9.6	0.53	1.37e-18	Schizophrenia;
SARC	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs734999	0.545	rs10797436	chr1:2538349	G/A	cg20673091	chr1:2541236	MMEL1	0.34	5.13	0.32	6.15e-7	Ulcerative colitis;
SARC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg26338869	chr17:61819248	STRADA	0.8	10.85	0.58	1.86e-22	Prudent dietary pattern;
SARC	cis	rs453301	0.657	rs36056437	chr8:8792865	T/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.28	-0.38	1.65e-9	Joint mobility (Beighton score);
SARC	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.78	11.17	0.59	1.72e-23	Total body bone mineral density;
SARC	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg13939156	chr17:80058883	NA	-0.42	-6.48	-0.39	5.51e-10	Life satisfaction;
SARC	cis	rs2204008	0.774	rs11180977	chr12:38263094	G/T	cg26384229	chr12:38710491	ALG10B	0.91	13.64	0.67	1.61e-31	Bladder cancer;
SARC	cis	rs11190604	1.000	rs12219158	chr10:102302923	T/C	cg07080220	chr10:102295463	HIF1AN	0.83	9.78	0.54	3.84e-19	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs7336332	0.598	rs12018313	chr13:28012266	C/A	cg01674679	chr13:27998804	GTF3A	-0.54	-4.97	-0.31	1.3e-6	Weight;
SARC	cis	rs73001065	0.818	rs16996185	chr19:19720788	G/T	cg03709012	chr19:19516395	GATAD2A	-0.81	-5.82	-0.36	1.95e-8	LDL cholesterol;
SARC	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg18404041	chr3:52824283	ITIH1	-0.44	-6.34	-0.38	1.19e-9	Bipolar disorder;
SARC	cis	rs2204008	0.837	rs4432085	chr12:38181146	C/T	cg26384229	chr12:38710491	ALG10B	0.88	12.94	0.65	3.26e-29	Bladder cancer;
SARC	cis	rs1008375	1.000	rs10939756	chr4:17693867	C/T	cg16339924	chr4:17578868	LAP3	0.56	7.03	0.42	2.24e-11	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs8067354	0.645	rs16943838	chr17:57839604	C/T	cg02344993	chr17:57696989	CLTC	0.63	6.09	0.37	4.59e-9	Hemoglobin concentration;
SARC	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg18252515	chr7:66147081	NA	-0.47	-5.09	-0.32	7.32e-7	Aortic root size;
SARC	trans	rs3734266	0.702	rs9469836	chr6:34614779	A/C	cg08157914	chr7:2646478	IQCE	-0.49	-6.45	-0.39	6.52e-10	Systemic lupus erythematosus;
SARC	cis	rs7236492	0.688	rs7241538	chr18:77191247	C/T	cg15644404	chr18:77186268	NFATC1	-0.66	-6.62	-0.4	2.44e-10	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs4319547	0.698	rs10773178	chr12:122944752	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.52	-6.11	-0.37	4.14e-9	Body mass index;
SARC	cis	rs2952156	0.920	rs9675194	chr17:37833805	A/G	cg00129232	chr17:37814104	STARD3	-0.72	-9.99	-0.55	8.51e-20	Asthma;
SARC	cis	rs748404	0.578	rs576557	chr15:43597737	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.44	5.47	0.34	1.15e-7	Lung cancer;
SARC	cis	rs9399135	0.933	rs7755680	chr6:135294259	A/G	cg24558204	chr6:135376177	HBS1L	0.45	6.07	0.37	5.05e-9	Red blood cell count;
SARC	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.74	8.75	0.5	4.46e-16	Height;
SARC	cis	rs10463554	0.927	rs257311	chr5:102419098	C/G	cg23492399	chr5:102201601	PAM	-0.52	-5.75	-0.35	2.78e-8	Parkinson's disease;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg19147570	chr2:63815760	C2orf86;MDH1	0.51	6.31	0.38	1.42e-9	Breast cancer;
SARC	cis	rs11225247	0.772	rs11601671	chr11:102250065	C/T	cg11690896	chr11:102217788	BIRC2	0.77	5.37	0.33	1.93e-7	Vein graft stenosis in coronary artery bypass grafting;
SARC	cis	rs1008375	1.000	rs10939747	chr4:17691166	C/A	cg16339924	chr4:17578868	LAP3	0.59	7.46	0.44	1.68e-12	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg09172817	chr18:9915098	VAPA	-0.6	-6.86	-0.41	6.27e-11	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs4148883	0.645	rs1154404	chr4:100009004	A/T	cg13256891	chr4:100009986	ADH5	0.61	8.2	0.47	1.64e-14	Alcohol dependence;
SARC	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg21782813	chr7:2030301	MAD1L1	0.39	6.21	0.38	2.38e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg05872129	chr22:39784769	NA	0.42	5.98	0.36	8.28e-9	Intelligence (multi-trait analysis);
SARC	cis	rs78487399	0.808	rs13417883	chr2:43700154	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-5.08	-0.32	7.76e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs7044106	0.762	rs10760107	chr9:123383630	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	4.89	0.31	1.85e-6	Hip circumference adjusted for BMI;
SARC	cis	rs8031584	1.000	rs35811129	chr15:31241346	G/A	cg08109568	chr15:31115862	NA	-0.45	-5.07	-0.31	8.28e-7	Huntington's disease progression;
SARC	cis	rs9309473	1.000	rs10189574	chr2:73698518	C/A	cg20560298	chr2:73613845	ALMS1	-0.51	-6.12	-0.37	3.98e-9	Metabolite levels;
SARC	cis	rs3126085	0.935	rs3126091	chr1:152307338	T/C	cg26876637	chr1:152193138	HRNR	-0.48	-5.53	-0.34	8.74e-8	Atopic dermatitis;
SARC	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.41	4.91	0.31	1.73e-6	Tonsillectomy;
SARC	cis	rs12451471	0.500	rs8077056	chr17:78076006	C/T	cg24585782	chr17:78113791	EIF4A3	-0.5	-5.58	-0.34	6.81e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
SARC	cis	rs875971	0.545	rs2707851	chr7:66089165	C/T	cg11764359	chr7:65958608	NA	-0.62	-6.13	-0.37	3.78e-9	Aortic root size;
SARC	cis	rs644799	0.710	rs519511	chr11:95538270	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	13.53	0.66	3.66e-31	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9640161	0.830	rs76741564	chr7:150059529	A/T	cg17279839	chr7:150038598	RARRES2	0.34	5.02	0.31	1.03e-6	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg00149659	chr3:10157352	C3orf10	0.7	6.89	0.41	5.14e-11	Alzheimer's disease;
SARC	cis	rs453301	0.686	rs7017868	chr8:8873293	G/A	cg11608241	chr8:8085544	FLJ10661	-0.45	-5.64	-0.35	4.89e-8	Joint mobility (Beighton score);
SARC	cis	rs910316	1.000	rs10138183	chr14:75615227	T/C	cg06637938	chr14:75390232	RPS6KL1	0.46	6.34	0.38	1.16e-9	Height;
SARC	cis	rs1008375	0.800	rs28754811	chr4:17612312	C/T	cg02297831	chr4:17616191	MED28	0.5	6.4	0.39	8.47e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs826838	1.000	rs10875717	chr12:38911174	T/C	cg13010199	chr12:38710504	ALG10B	0.77	10.73	0.58	4.26e-22	Heart rate;
SARC	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg18252515	chr7:66147081	NA	0.44	4.75	0.3	3.5e-6	Aortic root size;
SARC	cis	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg00409905	chr10:38381863	ZNF37A	0.52	7.2	0.43	8.45e-12	Extrinsic epigenetic age acceleration;
SARC	trans	rs238295	0.696	rs6053451	chr20:5493904	C/T	cg01409985	chr3:133524160	SRPRB	-0.46	-6.25	-0.38	1.98e-9	Occipital cortical area (total cortical area interaction);
SARC	cis	rs2760061	0.583	rs708124	chr1:228220771	A/T	cg01200585	chr1:228362443	C1orf69	0.45	5.92	0.36	1.12e-8	Diastolic blood pressure;
SARC	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg05313129	chr8:58192883	C8orf71	-0.62	-6.23	-0.38	2.14e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6988636	0.818	rs62521808	chr8:124169568	C/T	cg23067535	chr8:124195133	FAM83A	-0.69	-4.96	-0.31	1.36e-6	Urinary uromodulin levels;
SARC	cis	rs1883415	0.534	rs2817205	chr6:24477134	G/A	cg20631270	chr6:24437470	GPLD1	0.38	5.31	0.33	2.51e-7	Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs875971	0.545	rs10261710	chr7:65714189	T/A	cg11764359	chr7:65958608	NA	0.63	6.13	0.37	3.82e-9	Aortic root size;
SARC	cis	rs1153858	0.621	rs2687512	chr15:45581495	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.41	-5.34	-0.33	2.26e-7	Homoarginine levels;
SARC	cis	rs6912958	0.712	rs4587138	chr6:88356915	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-6.42	-0.39	7.39e-10	Monocyte percentage of white cells;
SARC	cis	rs7762018	0.607	rs61740334	chr6:170047902	T/A	cg19338460	chr6:170058176	WDR27	-0.79	-5.32	-0.33	2.46e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg11709150	chr1:2440438	PANK4	-0.6	-6.34	-0.38	1.18e-9	Lung cancer in ever smokers;
SARC	cis	rs8180040	0.654	rs11714373	chr3:47214817	G/A	cg27129171	chr3:47204927	SETD2	-0.69	-9.43	-0.53	4.2e-18	Colorectal cancer;
SARC	cis	rs876084	0.505	rs4871044	chr8:121158773	C/T	cg06265175	chr8:121136014	COL14A1	0.57	7.41	0.44	2.34e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs6570726	0.837	rs419991	chr6:145864212	C/T	cg05347473	chr6:146136440	FBXO30	0.49	6.58	0.4	3.04e-10	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs6894249	1.000	rs6894249	chr5:131797547	A/G	cg26476595	chr16:2284284	E4F1	-0.5	-6.68	-0.4	1.75e-10	Asthma;
SARC	trans	rs35833281	1.000	rs34694541	chr6:55051052	T/G	cg19977494	chr7:128431264	CCDC136	-0.71	-6.57	-0.4	3.25e-10	Morning vs. evening chronotype;
SARC	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.49	-6.14	-0.37	3.52e-9	Lymphocyte counts;
SARC	cis	rs9902453	0.765	rs2467334	chr17:28135508	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.19	-0.43	8.72e-12	Coffee consumption (cups per day);
SARC	cis	rs651907	0.712	rs796410	chr3:101610189	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.42	4.92	0.31	1.61e-6	Colorectal cancer;
SARC	cis	rs17739167	0.550	rs6493013	chr15:42224824	T/C	cg20935245	chr15:42234343	EHD4	0.45	5.99	0.37	7.99e-9	Monocyte count;
SARC	cis	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg15145296	chr3:125709740	NA	-0.48	-4.73	-0.3	3.92e-6	Blood pressure (smoking interaction);
SARC	cis	rs950169	0.887	rs220333	chr15:85091133	C/T	cg17507749	chr15:85114479	UBE2QP1	0.77	9.31	0.52	1.02e-17	Schizophrenia;
SARC	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg13902645	chr11:5959945	NA	-0.4	-5.35	-0.33	2.07e-7	DNA methylation (variation);
SARC	cis	rs957448	1.000	rs72674843	chr8:95533000	T/C	cg26464482	chr8:95565502	KIAA1429	0.43	4.83	0.3	2.45e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs1153858	0.945	rs16943246	chr15:45720597	G/A	cg21132104	chr15:45694354	SPATA5L1	0.72	9.14	0.51	3.25e-17	Homoarginine levels;
SARC	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg11890956	chr21:40555474	PSMG1	1.16	19.07	0.78	1.72e-49	Cognitive function;
SARC	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg12311346	chr5:56204834	C5orf35	-0.57	-5.9	-0.36	1.25e-8	Initial pursuit acceleration;
SARC	cis	rs7264396	0.563	rs78084033	chr20:34219990	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	5.11	0.32	6.63e-7	Total cholesterol levels;
SARC	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg22875332	chr1:76189707	ACADM	0.5	7.17	0.42	1.01e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9473924	0.542	rs36093098	chr6:50833931	G/A	cg14470998	chr6:50812995	TFAP2B	0.72	6.47	0.39	5.64e-10	Body mass index;
SARC	cis	rs1348850	0.526	rs10803912	chr2:178407176	A/C	cg23306229	chr2:178417860	TTC30B	-0.78	-7.67	-0.45	4.6e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1559088	0.803	rs10405770	chr19:33616549	C/T	cg27124370	chr19:33622961	WDR88	0.46	5.93	0.36	1.09e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg20891283	chr12:69753455	YEATS4	0.68	9.76	0.54	4.39e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs2268241	0.938	rs28653198	chr21:34782395	A/C	cg14850771	chr21:34775459	IFNGR2	0.97	9.33	0.52	8.64e-18	Obesity-related traits;
SARC	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg04267008	chr7:1944627	MAD1L1	-0.52	-5.92	-0.36	1.12e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg11644478	chr21:40555479	PSMG1	-0.88	-11.6	-0.6	7.56e-25	Cognitive function;
SARC	cis	rs2074585	0.708	rs2589939	chr15:90930875	C/T	cg22089800	chr15:90895588	ZNF774	0.76	9.77	0.54	3.94e-19	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
SARC	trans	rs641862	1	rs641862	chr13:110790232	C/T	cg22301984	chr13:113242683	TUBGCP3	-0.89	-6.61	-0.4	2.55e-10	Obesity-related traits;
SARC	cis	rs7481584	0.669	rs12421922	chr11:3035070	A/G	cg08508325	chr11:3079039	CARS	0.22	5.13	0.32	6.03e-7	Calcium levels;
SARC	cis	rs2387326	0.818	rs2782862	chr10:129919825	A/G	cg16087940	chr10:129947807	NA	-0.43	-5.23	-0.32	3.78e-7	Select biomarker traits;
SARC	cis	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg12463550	chr7:65579703	CRCP	0.69	5.24	0.32	3.57e-7	Diabetic kidney disease;
SARC	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.59e-6	Depression;
SARC	cis	rs7429990	0.932	rs60446735	chr3:47971448	A/G	cg11946769	chr3:48343235	NME6	0.44	5.03	0.31	9.79e-7	Educational attainment (years of education);
SARC	cis	rs763121	0.853	rs3827357	chr22:39079413	A/G	cg21395723	chr22:39101663	GTPBP1	0.52	5.79	0.35	2.3e-8	Menopause (age at onset);
SARC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg09373136	chr17:61933544	TCAM1	-0.43	-5.94	-0.36	1.04e-8	Prudent dietary pattern;
SARC	cis	rs9486719	1.000	rs12205655	chr6:96891733	T/A	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.01	-0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs4841097	0.806	rs6992247	chr8:8948469	G/T	cg06636001	chr8:8085503	FLJ10661	0.44	5.53	0.34	8.39e-8	Platelet distribution width;
SARC	cis	rs861020	0.606	rs4844903	chr1:210006267	C/T	cg23166289	chr1:210001082	C1orf107	0.39	4.74	0.3	3.66e-6	Orofacial clefts;
SARC	cis	rs6450176	1.000	rs60492935	chr5:53306240	G/T	ch.5.1024479R	chr5:53302184	ARL15	-0.68	-7.87	-0.46	1.29e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs9640161	0.830	rs3757424	chr7:150067679	C/A	cg21361702	chr7:150065534	REPIN1	0.55	6.84	0.41	6.84e-11	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs713477	0.967	rs4901565	chr14:55912508	T/G	cg13175173	chr14:55914753	NA	-0.31	-4.8	-0.3	2.79e-6	Pediatric bone mineral content (femoral neck);
SARC	cis	rs651907	0.557	rs2303474	chr3:101371899	G/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.46	5.5	0.34	1e-7	Colorectal cancer;
SARC	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.41	-5.19	-0.32	4.51e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	11.35	0.6	4.83e-24	Platelet count;
SARC	cis	rs9916302	0.665	rs4795369	chr17:37609120	G/A	cg07936489	chr17:37558343	FBXL20	-0.66	-8.63	-0.49	9.62e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs11122272	0.735	rs2486737	chr1:231520523	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs67311347	0.955	rs4973999	chr3:40460383	G/A	cg24209194	chr3:40518798	ZNF619	0.63	8.25	0.48	1.18e-14	Renal cell carcinoma;
SARC	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.95	10.32	0.56	8.04e-21	Platelet count;
SARC	cis	rs2370759	1.000	rs16933243	chr10:32615135	T/C	cg05361325	chr10:32636312	EPC1	-0.76	-6.78	-0.41	9.81e-11	Sexual dysfunction (female);
SARC	cis	rs12579753	0.869	rs12366920	chr12:82223015	G/A	cg07988820	chr12:82153109	PPFIA2	-0.53	-6.1	-0.37	4.27e-9	Resting heart rate;
SARC	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg13699009	chr12:122356056	WDR66	0.53	8.07	0.47	3.83e-14	Mean corpuscular volume;
SARC	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg05527609	chr1:210001259	C1orf107	0.49	6.27	0.38	1.76e-9	Monobrow;
SARC	cis	rs13096357	0.520	rs17080319	chr3:48732480	T/C	cg07636037	chr3:49044803	WDR6	-0.69	-6.61	-0.4	2.58e-10	Cognitive ability (multi-trait analysis);
SARC	cis	rs41271473	0.526	rs942852	chr1:228730748	A/G	cg10167378	chr1:228756711	NA	0.61	5.41	0.33	1.6e-7	Chronic lymphocytic leukemia;
SARC	cis	rs10504229	0.593	rs7000752	chr8:58026980	C/G	cg08280861	chr8:58055591	NA	0.58	5.34	0.33	2.18e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs526231	0.543	rs158395	chr5:102411389	T/C	cg23492399	chr5:102201601	PAM	-0.51	-5.52	-0.34	8.81e-8	Primary biliary cholangitis;
SARC	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg19748678	chr4:122722346	EXOSC9	0.76	9.43	0.53	4.18e-18	Type 2 diabetes;
SARC	cis	rs6570726	0.905	rs419575	chr6:145840174	A/G	cg23711669	chr6:146136114	FBXO30	0.78	11.86	0.61	1.04e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs57994353	0.793	rs12552167	chr9:139322927	C/T	cg14169450	chr9:139327907	INPP5E	0.44	5.63	0.35	5.26e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs3126085	0.597	rs12047544	chr1:152169922	C/T	cg26876637	chr1:152193138	HRNR	0.48	5.52	0.34	8.97e-8	Atopic dermatitis;
SARC	cis	rs2735413	0.918	rs12598024	chr16:78079114	G/A	cg04733911	chr16:78082701	NA	-0.31	-5.61	-0.34	5.78e-8	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg17221315	chr6:27791827	HIST1H4J	0.45	4.98	0.31	1.24e-6	Cardiac Troponin-T levels;
SARC	cis	rs1865760	0.963	rs3846838	chr6:25911775	T/C	cg16482183	chr6:26056742	HIST1H1C	0.5	6.22	0.38	2.27e-9	Height;
SARC	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg24829409	chr8:58192753	C8orf71	0.57	5.07	0.32	8.09e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs3808502	0.503	rs2061830	chr8:11397457	C/G	cg08975724	chr8:8085496	FLJ10661	0.57	7.53	0.44	1.09e-12	Neuroticism;
SARC	cis	rs637571	0.522	rs528736	chr11:65705108	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.78	10.9	0.58	1.29e-22	Eosinophil percentage of white cells;
SARC	cis	rs4253772	0.745	rs78023664	chr22:46647844	G/A	cg18190219	chr22:46762943	CELSR1	-0.62	-4.81	-0.3	2.75e-6	LDL cholesterol;Cholesterol, total;
SARC	cis	rs1348850	0.632	rs13008833	chr2:178514439	G/C	cg23306229	chr2:178417860	TTC30B	0.48	5.45	0.34	1.28e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs74181299	0.964	rs2540949	chr2:65284231	A/T	cg20592124	chr2:65290738	CEP68	0.48	7.12	0.42	1.3e-11	Pulse pressure;
SARC	cis	rs10512697	0.803	rs1867710	chr5:3576229	C/T	cg19473799	chr5:3511975	NA	-0.59	-4.74	-0.3	3.66e-6	Immune response to smallpox vaccine (IL-6);
SARC	cis	rs7598759	0.679	rs6740843	chr2:232332139	A/C	cg19187155	chr2:232395269	NMUR1	0.6	8.5	0.49	2.32e-15	Noise-induced hearing loss;
SARC	cis	rs7412746	0.646	rs1972060	chr1:150937594	T/C	cg10589385	chr1:150898437	SETDB1	0.38	5.05	0.31	8.9e-7	Melanoma;
SARC	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg03351412	chr1:154909251	PMVK	0.41	4.97	0.31	1.31e-6	Prostate cancer;
SARC	cis	rs514024	0.729	rs3824523	chr9:130426944	T/G	cg13643465	chr9:130375613	STXBP1	0.49	6.2	0.38	2.54e-9	Eating disorders (purging via substances);
SARC	cis	rs10492096	0.947	rs10849483	chr12:6635374	G/A	cg13857086	chr12:6580257	VAMP1	0.66	6.66	0.4	1.99e-10	Hip geometry;
SARC	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg13395646	chr4:1353034	KIAA1530	-0.55	-6.64	-0.4	2.24e-10	Obesity-related traits;
SARC	cis	rs6809651	0.524	rs10937240	chr3:185802823	C/T	cg00760338	chr3:185826511	ETV5	-0.86	-10.99	-0.58	6.77e-23	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
SARC	cis	rs854765	0.547	rs2955378	chr17:17930253	G/A	cg04398451	chr17:18023971	MYO15A	-0.46	-6.52	-0.39	4.31e-10	Total body bone mineral density;
SARC	cis	rs668210	0.793	rs586921	chr11:65747701	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.63	-6.18	-0.38	2.77e-9	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9503598	0.783	rs9503599	chr6:3451048	T/C	cg00476032	chr6:3446245	SLC22A23	0.35	5.53	0.34	8.6e-8	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
SARC	cis	rs611744	0.819	rs424012	chr8:109154652	A/G	cg21045802	chr8:109455806	TTC35	0.44	5.11	0.32	6.66e-7	Dupuytren's disease;
SARC	cis	rs910316	0.935	rs175422	chr14:75627319	T/A	cg08847533	chr14:75593920	NEK9	-0.86	-12.84	-0.64	7.01e-29	Height;
SARC	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.34	-5.04	-0.31	9.51e-7	Total body bone mineral density;
SARC	cis	rs4423214	0.592	rs10898223	chr11:71219264	G/A	cg05163923	chr11:71159392	DHCR7	-0.54	-5.26	-0.33	3.21e-7	Vitamin D levels;
SARC	cis	rs4660306	0.744	rs11211115	chr1:45926438	A/T	cg24296786	chr1:45957014	TESK2	-0.54	-5.32	-0.33	2.48e-7	Homocysteine levels;
SARC	cis	rs244731	0.959	rs6872021	chr5:176610012	G/A	cg17509989	chr5:176798049	RGS14	-0.68	-8.48	-0.49	2.68e-15	Urate levels in lean individuals;
SARC	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg26681399	chr22:41777847	TEF	0.47	5.33	0.33	2.33e-7	Vitiligo;
SARC	cis	rs7551222	0.691	rs11240760	chr1:204547268	A/G	cg20240347	chr1:204465584	NA	-0.32	-5.76	-0.35	2.68e-8	Schizophrenia;
SARC	cis	rs8016982	0.674	rs8004096	chr14:81701082	T/G	cg01989461	chr14:81687754	GTF2A1	0.73	10.55	0.57	1.56e-21	Schizophrenia;
SARC	cis	rs950027	0.595	rs2486288	chr15:45712339	T/C	cg26924012	chr15:45694286	SPATA5L1	0.52	6.44	0.39	6.66e-10	Response to fenofibrate (adiponectin levels);
SARC	cis	rs7208859	0.573	rs7223803	chr17:29077193	A/G	cg13385521	chr17:29058706	SUZ12P	0.88	7.75	0.45	2.9e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9818758	0.607	rs9990153	chr3:49291883	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.68	-5.86	-0.36	1.55e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.95	-13.96	-0.67	1.32e-32	Gut microbiome composition (summer);
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25091829	chr6:116601170	DSE;TSPYL1	-0.54	-6.41	-0.39	7.83e-10	Fibrinogen levels;
SARC	cis	rs427394	0.802	rs274698	chr5:6730957	T/G	cg10857441	chr5:6722123	POLS	-0.34	-5.1	-0.32	7.2e-7	Menopause (age at onset);
SARC	cis	rs7647973	0.961	rs62259943	chr3:49425167	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.57	-5.57	-0.34	7.17e-8	Menarche (age at onset);
SARC	cis	rs67460515	0.596	rs4856700	chr3:160922951	A/C	cg17135325	chr3:160939158	NMD3	0.68	8.66	0.49	8.01e-16	Parkinson's disease;
SARC	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg23262073	chr20:60523788	NA	-0.38	-5.26	-0.33	3.31e-7	Body mass index;
SARC	cis	rs795484	0.633	rs904661	chr12:118581860	C/T	cg16572268	chr12:118583242	PEBP1	0.41	5.35	0.33	2.12e-7	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
SARC	cis	rs3768617	0.510	rs2296294	chr1:183095596	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.82e-21	Fuchs's corneal dystrophy;
SARC	cis	rs986417	1.000	rs11845369	chr14:60944959	A/G	cg27398547	chr14:60952738	C14orf39	1.02	9.71	0.54	6e-19	Gut microbiota (bacterial taxa);
SARC	trans	rs3779273	1.000	rs3779273	chr7:77828940	G/A	cg05596911	chr5:118502651	DMXL1	0.52	6.57	0.4	3.32e-10	Body mass index;
SARC	cis	rs13161895	0.941	rs6876648	chr5:179441842	T/C	cg02702477	chr5:179499311	RNF130	-0.65	-6.46	-0.39	6.01e-10	LDL cholesterol;
SARC	cis	rs7216064	1.000	rs8081517	chr17:65845697	A/T	cg12091567	chr17:66097778	LOC651250	-0.72	-7.9	-0.46	1.09e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs7766436	0.687	rs10485012	chr6:22607026	A/C	cg13666174	chr6:22585274	NA	-0.51	-6.88	-0.41	5.62e-11	Coronary artery disease;
SARC	cis	rs9911578	1.000	rs7216680	chr17:56988243	G/C	cg12560992	chr17:57184187	TRIM37	0.85	11.57	0.6	9.08e-25	Intelligence (multi-trait analysis);
SARC	cis	rs7666738	0.830	rs6825211	chr4:98807698	A/T	cg05340658	chr4:99064831	C4orf37	0.65	8.54	0.49	1.74e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg09359103	chr1:154839909	KCNN3	-0.45	-7.67	-0.45	4.61e-13	Prostate cancer;
SARC	cis	rs1008375	0.932	rs7697329	chr4:17657853	C/A	cg16339924	chr4:17578868	LAP3	0.66	8.65	0.49	8.66e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-9.14	-0.51	3.19e-17	Alzheimer's disease;
SARC	cis	rs6815814	0.950	rs5743580	chr4:38804405	C/T	cg02016764	chr4:38805732	TLR1	-0.42	-4.89	-0.31	1.89e-6	Breast cancer;
SARC	trans	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg21659725	chr3:3221576	CRBN	-0.79	-11.96	-0.62	5.19e-26	Intelligence (multi-trait analysis);
SARC	cis	rs654950	0.934	rs665223	chr1:42000654	A/T	cg06885757	chr1:42089581	HIVEP3	-0.37	-5.19	-0.32	4.58e-7	Airway imaging phenotypes;
SARC	trans	rs656319	0.625	rs4526366	chr8:9890179	C/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-7.88	-0.46	1.22e-13	Myopia (pathological);
SARC	cis	rs7412746	0.611	rs11204726	chr1:150743492	T/C	cg10589385	chr1:150898437	SETDB1	0.4	5.31	0.33	2.53e-7	Melanoma;
SARC	cis	rs1865760	1.000	rs2071301	chr6:25914263	G/T	cg17691542	chr6:26056736	HIST1H1C	0.59	7.19	0.43	8.55e-12	Height;
SARC	cis	rs523522	0.926	rs10774555	chr12:120971978	G/A	cg12219531	chr12:120966889	COQ5	0.84	11.3	0.59	6.87e-24	High light scatter reticulocyte count;
SARC	cis	rs4588572	0.644	rs10942856	chr5:77746199	A/G	cg18281939	chr5:77783895	LHFPL2	-0.34	-4.76	-0.3	3.4e-6	Triglycerides;
SARC	cis	rs4803468	0.935	rs12602	chr19:41889748	T/C	cg14132834	chr19:41945861	ATP5SL	-0.56	-7.45	-0.44	1.81e-12	Height;
SARC	cis	rs7264396	0.563	rs2425130	chr20:34335059	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-6.71	-0.4	1.47e-10	Total cholesterol levels;
SARC	cis	rs7568458	0.846	rs6547621	chr2:85774676	G/A	cg17127132	chr2:85788382	GGCX	0.48	6.53	0.39	3.98e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs2481665	1.000	rs2481665	chr1:62594677	T/C	cg18591186	chr1:62594603	INADL	-0.63	-9.05	-0.51	5.67e-17	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs9467160	1.000	rs9461012	chr6:24441844	A/G	cg16211469	chr6:24423932	MRS2	-0.41	-5.22	-0.32	3.93e-7	Liver enzyme levels;
SARC	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg11764359	chr7:65958608	NA	-0.75	-9.33	-0.52	8.74e-18	Aortic root size;
SARC	cis	rs1008375	0.966	rs2159582	chr4:17695655	T/C	cg27347728	chr4:17578864	LAP3	0.45	5.8	0.35	2.2e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg08260549	chr8:21777063	XPO7	0.54	7.3	0.43	4.56e-12	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs11605924	0.901	rs11038672	chr11:45846498	C/G	ch.11.939596F	chr11:45881766	CRY2	-0.47	-5.55	-0.34	7.76e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs2239547	0.657	rs7620706	chr3:52891756	A/T	cg18404041	chr3:52824283	ITIH1	-0.42	-5.15	-0.32	5.55e-7	Schizophrenia;
SARC	cis	rs9303401	0.659	rs62083525	chr17:56658088	A/G	cg25039879	chr17:56429692	SUPT4H1	0.67	6.21	0.38	2.4e-9	Cognitive test performance;
SARC	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.39	-4.93	-0.31	1.58e-6	Lymphocyte counts;
SARC	cis	rs761746	0.960	rs738656	chr22:31935347	G/A	cg27454842	chr22:32027588	PISD	0.36	4.98	0.31	1.25e-6	Intelligence;
SARC	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg24531977	chr5:56204891	C5orf35	-0.52	-5.24	-0.32	3.63e-7	Initial pursuit acceleration;
SARC	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg16325326	chr1:53192061	ZYG11B	-0.71	-9.59	-0.53	1.43e-18	Monocyte count;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg07066918	chr10:129910468	MKI67	0.45	6.41	0.39	8.09e-10	Thyroid stimulating hormone;
SARC	cis	rs6121246	0.567	rs7361893	chr20:30200751	C/T	cg13852791	chr20:30311386	BCL2L1	0.66	5.82	0.36	1.89e-8	Mean corpuscular hemoglobin;
SARC	cis	rs10851411	0.559	rs62019322	chr15:42897374	T/C	cg21293051	chr15:42870591	STARD9	0.49	4.88	0.3	1.94e-6	Glucose homeostasis traits;
SARC	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.65	7.58	0.44	8e-13	Gut microbiome composition (summer);
SARC	cis	rs1050631	0.564	rs559289	chr18:33752890	A/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.58	7.11	0.42	1.38e-11	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs365132	0.846	rs353470	chr5:176444861	C/T	cg16309518	chr5:176445507	NA	-0.48	-6.14	-0.37	3.47e-9	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs908922	0.676	rs526099	chr1:152497811	T/C	cg09873164	chr1:152488093	CRCT1	0.63	8.06	0.47	4.07e-14	Hair morphology;
SARC	cis	rs965469	0.901	rs6037586	chr20:3368114	G/A	cg25506879	chr20:3388711	C20orf194	-0.47	-4.76	-0.3	3.43e-6	IFN-related cytopenia;
SARC	trans	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-6.81	-0.41	8.45e-11	Intelligence (multi-trait analysis);
SARC	cis	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg00071950	chr4:10020882	SLC2A9	0.39	6.34	0.38	1.21e-9	Bone mineral density;
SARC	cis	rs36051895	0.659	rs62541539	chr9:5038180	C/T	cg02405213	chr9:5042618	JAK2	-0.53	-5.98	-0.36	8.31e-9	Pediatric autoimmune diseases;
SARC	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg03806693	chr22:41940476	POLR3H	-0.97	-13.31	-0.66	1.97e-30	Vitiligo;
SARC	cis	rs13202913	0.733	rs13215869	chr6:151803659	G/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.64	5.43	0.34	1.39e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg18252515	chr7:66147081	NA	1.13	9.86	0.54	2.16e-19	Diabetic kidney disease;
SARC	cis	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg00745463	chr17:30367425	LRRC37B	-0.63	-5.02	-0.31	1.05e-6	Hip circumference adjusted for BMI;
SARC	trans	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.74	-10.81	-0.58	2.44e-22	Intelligence (multi-trait analysis);
SARC	cis	rs12950390	0.853	rs17700008	chr17:45863591	A/C	cg24803719	chr17:45855879	NA	0.46	7.19	0.43	8.7e-12	IgG glycosylation;
SARC	cis	rs9314323	0.767	rs13271042	chr8:26190212	T/G	cg11498726	chr8:26250323	BNIP3L	-0.65	-8.12	-0.47	2.71e-14	Red cell distribution width;
SARC	cis	rs4713118	0.513	rs149989	chr6:27998184	T/A	cg26450541	chr6:28235208	ZNF187	0.46	4.82	0.3	2.55e-6	Parkinson's disease;
SARC	cis	rs2191566	0.959	rs7256345	chr19:44510905	T/G	cg20607764	chr19:44506953	ZNF230	-0.44	-5.0	-0.31	1.11e-6	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs748404	0.697	rs572959	chr15:43550502	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	5.63	0.35	5.04e-8	Lung cancer;
SARC	cis	rs7607369	0.536	rs6436090	chr2:219669002	A/G	cg02176678	chr2:219576539	TTLL4	-0.4	-6.16	-0.37	3.12e-9	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs1371867	0.846	rs1660328	chr8:101303450	A/G	cg11906718	chr8:101322791	RNF19A	0.65	8.53	0.49	1.93e-15	Atrioventricular conduction;
SARC	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.23e-9	Life satisfaction;
SARC	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg22535103	chr8:58192502	C8orf71	-0.59	-6.21	-0.38	2.35e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-9.59	-0.53	1.43e-18	Chronic sinus infection;
SARC	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg11766577	chr21:47581405	C21orf56	-0.46	-5.53	-0.34	8.58e-8	Testicular germ cell tumor;
SARC	cis	rs9987353	0.519	rs2929465	chr8:9064002	C/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-5.76	-0.35	2.59e-8	Recombination measurement;
SARC	trans	rs561341	0.740	rs11080174	chr17:30208521	C/A	cg20587970	chr11:113659929	NA	0.69	6.85	0.41	6.35e-11	Hip circumference adjusted for BMI;
SARC	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg25072359	chr17:41440525	NA	0.52	6.14	0.37	3.43e-9	Menopause (age at onset);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg11368578	chr7:150754936	CDK5	-0.63	-7.12	-0.42	1.37e-11	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs11190604	1.000	rs3750629	chr10:102275727	A/G	cg07080220	chr10:102295463	HIF1AN	0.8	10.38	0.56	5.46e-21	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg13866156	chr1:1669148	SLC35E2	-0.62	-9.29	-0.52	1.15e-17	Body mass index;
SARC	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg00933542	chr6:150070202	PCMT1	0.31	5.31	0.33	2.6e-7	Lung cancer;
SARC	cis	rs11874712	1.000	rs28504655	chr18:43665348	G/A	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.46	5.5	0.34	1.02e-7	Migraine - clinic-based;
SARC	cis	rs3092073	0.624	rs3848719	chr20:44596545	G/A	cg00981651	chr20:44574847	PCIF1	0.31	5.02	0.31	1.02e-6	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.502	rs2465121	chr7:65621004	A/G	cg11764359	chr7:65958608	NA	-0.66	-6.46	-0.39	5.96e-10	Aortic root size;
SARC	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg05368731	chr17:41323189	NBR1	0.77	9.18	0.52	2.34e-17	Menopause (age at onset);
SARC	cis	rs8180040	0.764	rs11130115	chr3:47181661	C/A	cg27129171	chr3:47204927	SETD2	0.67	9.52	0.53	2.38e-18	Colorectal cancer;
SARC	cis	rs4646312	0.555	rs9606189	chr22:19924612	G/C	cg07194846	chr22:19930177	COMT;TXNRD2	0.5	6.46	0.39	5.94e-10	Schizophrenia;
SARC	cis	rs668210	0.793	rs590531	chr11:65773939	C/A	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.5	-4.71	-0.3	4.18e-6	Cerebrospinal fluid biomarker levels;
SARC	trans	rs12310956	0.515	rs11052934	chr12:33970381	T/C	cg13010199	chr12:38710504	ALG10B	0.65	8.81	0.5	2.83e-16	Morning vs. evening chronotype;
SARC	cis	rs72945132	0.882	rs61260732	chr11:70162145	G/A	cg05964544	chr11:70165517	PPFIA1	-0.61	-5.87	-0.36	1.5e-8	Coronary artery disease;
SARC	cis	rs965469	1.000	rs1040726	chr20:3264267	C/T	cg25506879	chr20:3388711	C20orf194	-0.5	-5.08	-0.32	7.59e-7	IFN-related cytopenia;
SARC	cis	rs9462027	0.628	rs2764207	chr6:34712998	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.4	-5.7	-0.35	3.67e-8	Systemic lupus erythematosus;
SARC	cis	rs763121	0.853	rs5757203	chr22:39044152	G/C	cg21395723	chr22:39101663	GTPBP1	0.58	6.67	0.4	1.85e-10	Menopause (age at onset);
SARC	cis	rs7762018	0.607	rs75999653	chr6:170066927	A/G	cg13015042	chr6:170102002	WDR27;C6orf120	0.73	4.99	0.31	1.2e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs2735413	0.914	rs12448754	chr16:78066747	T/C	cg04733911	chr16:78082701	NA	-0.28	-4.96	-0.31	1.34e-6	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs9487051	0.872	rs9386791	chr6:109608497	C/T	cg01475377	chr6:109611718	NA	-0.42	-5.94	-0.36	1.04e-8	Reticulocyte fraction of red cells;
SARC	cis	rs13161115	0.806	rs11242644	chr5:107012127	C/A	cg15160843	chr5:107008084	EFNA5	0.53	4.73	0.3	3.91e-6	Number of children ever born;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg19763699	chr10:17756784	STAM	0.57	7.77	0.45	2.52e-13	Thyroid stimulating hormone;
SARC	cis	rs10823500	0.748	rs2394668	chr10:71943951	G/A	cg04118878	chr10:71993077	PPA1	0.53	5.72	0.35	3.27e-8	Blood protein levels;
SARC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.28	0.8	2.29e-53	Prudent dietary pattern;
SARC	cis	rs55883249	1.000	rs62119422	chr2:9726599	A/G	cg23886495	chr2:9695866	ADAM17	0.69	6.98	0.42	3.12e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg08219700	chr8:58056026	NA	0.62	6.52	0.39	4.28e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.03	12.03	0.62	3.06e-26	Alzheimer's disease;
SARC	cis	rs4820294	1.000	rs732856	chr22:38060691	C/G	cg21798802	chr22:38057573	PDXP	-0.36	-5.44	-0.34	1.33e-7	Fat distribution (HIV);
SARC	cis	rs2066819	1.000	rs2629447	chr12:56700809	G/A	cg26734620	chr12:56694298	CS	-0.86	-6.37	-0.39	1.01e-9	Psoriasis vulgaris;
SARC	cis	rs7103648	0.966	rs10769263	chr11:47417183	A/C	cg10504702	chr11:47789108	FNBP4	0.59	7.61	0.45	6.83e-13	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs3008870	1.000	rs11208976	chr1:67434411	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.9	-11.09	-0.59	3.24e-23	Lymphocyte percentage of white cells;
SARC	cis	rs6540556	0.723	rs1000283	chr1:209894661	A/G	cg05527609	chr1:210001259	C1orf107	0.59	5.67	0.35	4.1e-8	Red blood cell count;
SARC	cis	rs9911578	1.000	rs8076121	chr17:57041699	G/A	cg05425664	chr17:57184151	TRIM37	-0.65	-8.04	-0.47	4.55e-14	Intelligence (multi-trait analysis);
SARC	cis	rs3857536	0.813	rs9363554	chr6:66930183	A/G	cg07460842	chr6:66804631	NA	-0.51	-5.77	-0.35	2.47e-8	Blood trace element (Cu levels);
SARC	cis	rs2380220	0.516	rs7748108	chr6:96008082	T/C	cg15832292	chr6:96025679	MANEA	0.63	7.42	0.44	2.15e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs10791097	0.967	rs6590512	chr11:130717916	A/G	cg12179176	chr11:130786555	SNX19	-0.58	-8.18	-0.47	1.79e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs6484504	0.576	rs11031323	chr11:31245413	T/G	cg02090638	chr11:31391270	DNAJC24;DCDC1	-0.4	-5.01	-0.31	1.1e-6	Red blood cell count;
SARC	cis	rs9818758	0.607	rs71324929	chr3:49044713	C/T	cg03060546	chr3:49711283	APEH	-0.6	-4.93	-0.31	1.55e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs6456156	0.819	rs7765739	chr6:167518472	C/T	cg23791538	chr6:167370224	RNASET2	-0.38	-4.79	-0.3	2.92e-6	Primary biliary cholangitis;
SARC	cis	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg05623727	chr3:50126028	RBM5	0.34	5.08	0.32	7.68e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	11.03	0.59	4.93e-23	Alzheimer's disease;
SARC	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg22903471	chr2:27725779	GCKR	-0.48	-7.15	-0.42	1.12e-11	Total body bone mineral density;
SARC	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg06634786	chr22:41940651	POLR3H	-0.58	-6.95	-0.41	3.64e-11	Vitiligo;
SARC	cis	rs7223966	1.000	rs9903903	chr17:61762044	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.45	5.03	0.31	9.75e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9917256	0.748	rs12987123	chr2:169120541	A/T	cg07857142	chr2:169103971	STK39	0.63	5.21	0.32	4.16e-7	Parkinson's disease;
SARC	cis	rs6840360	0.533	rs13139327	chr4:152728590	A/C	cg22705602	chr4:152727874	NA	-0.5	-9.0	-0.51	8.24e-17	Intelligence (multi-trait analysis);
SARC	cis	rs73001065	0.636	rs73002960	chr19:19582992	C/T	cg03709012	chr19:19516395	GATAD2A	1.09	7.49	0.44	1.44e-12	LDL cholesterol;
SARC	cis	rs3796352	1.000	rs33999310	chr3:52883332	G/A	cg27565382	chr3:53032988	SFMBT1	0.87	5.72	0.35	3.25e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg10876282	chr6:28092338	ZSCAN16	0.47	4.8	0.3	2.85e-6	Parkinson's disease;
SARC	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg27266027	chr21:40555129	PSMG1	-0.5	-5.45	-0.34	1.27e-7	Cognitive function;
SARC	cis	rs1144333	0.655	rs76416835	chr1:76341511	G/T	cg03433033	chr1:76189801	ACADM	0.59	4.74	0.3	3.76e-6	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs4711336	0.809	rs749338	chr6:33653448	A/G	cg15676125	chr6:33679581	C6orf125	-0.62	-7.19	-0.43	8.78e-12	Height;
SARC	cis	rs3781913	0.845	rs2037030	chr11:72370200	C/T	cg03713592	chr11:72463424	ARAP1	-0.47	-5.64	-0.35	5.02e-8	Rheumatoid arthritis;
SARC	cis	rs651907	0.535	rs13084113	chr3:101534039	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.49	5.71	0.35	3.51e-8	Colorectal cancer;
SARC	cis	rs55823223	0.503	rs9906971	chr17:73848477	A/G	cg14829360	chr17:73884958	NA	-0.59	-8.0	-0.46	5.7e-14	Psoriasis;
SARC	cis	rs453301	0.686	rs10217044	chr8:8894752	A/G	cg11995313	chr8:8860691	ERI1	0.45	5.85	0.36	1.69e-8	Joint mobility (Beighton score);
SARC	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg08662619	chr6:150070041	PCMT1	0.33	4.75	0.3	3.53e-6	Lung cancer;
SARC	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg00149659	chr3:10157352	C3orf10	1.08	9.95	0.55	1.11e-19	Alzheimer's disease;
SARC	cis	rs739401	0.572	rs12276060	chr11:3015572	A/T	cg20651018	chr11:3035856	CARS	-0.47	-7.26	-0.43	5.9e-12	Longevity;
SARC	cis	rs911555	0.692	rs60235428	chr14:103904350	T/C	cg12935359	chr14:103987150	CKB	0.4	5.45	0.34	1.26e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9815354	0.812	rs4577439	chr3:41952540	T/A	cg03022575	chr3:42003672	ULK4	0.7	5.7	0.35	3.66e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs1957429	0.808	rs1570296	chr14:65332294	T/A	cg23373153	chr14:65346875	NA	0.91	9.52	0.53	2.26e-18	Pediatric areal bone mineral density (radius);
SARC	cis	rs4273100	1.000	rs12602286	chr17:19236954	G/T	cg25447019	chr17:19030144	GRAPL	0.37	4.89	0.31	1.86e-6	Schizophrenia;
SARC	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg09323728	chr8:95962352	TP53INP1	-0.29	-4.95	-0.31	1.41e-6	Type 2 diabetes;
SARC	cis	rs2295359	1.000	rs12043240	chr1:67624304	C/T	cg12940439	chr1:67600707	NA	0.44	6.62	0.4	2.46e-10	Psoriasis;
SARC	cis	rs72627123	0.656	rs17096949	chr14:74602360	A/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.76	5.81	0.36	2.05e-8	Morning vs. evening chronotype;
SARC	cis	rs11098499	0.754	rs878376	chr4:120237702	G/A	cg09307838	chr4:120376055	NA	0.79	10.56	0.57	1.5e-21	Corneal astigmatism;
SARC	cis	rs10992471	0.580	rs10992304	chr9:95085365	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.49	-0.34	1.06e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs9341808	0.754	rs3805925	chr6:80883833	T/C	cg08355045	chr6:80787529	NA	0.34	5.54	0.34	8.01e-8	Sitting height ratio;
SARC	cis	rs9515201	0.627	rs9521730	chr13:111031180	C/T	cg06243866	chr13:111019493	COL4A2	-0.55	-7.86	-0.46	1.4e-13	White matter hyperintensity burden;
SARC	cis	rs875971	0.965	rs697968	chr7:65535033	G/A	cg11764359	chr7:65958608	NA	-0.85	-11.95	-0.62	5.53e-26	Aortic root size;
SARC	cis	rs7027203	0.828	rs4344139	chr9:96600298	T/C	cg13679303	chr9:96623674	NA	-0.35	-5.0	-0.31	1.14e-6	DNA methylation (variation);
SARC	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg18357526	chr6:26021779	HIST1H4A	0.65	8.11	0.47	2.96e-14	Intelligence (multi-trait analysis);
SARC	cis	rs9843304	0.546	rs13071608	chr3:149219590	C/A	cg08667024	chr3:149219783	TM4SF4	0.48	7.27	0.43	5.52e-12	Gallstone disease;
SARC	cis	rs9916302	0.718	rs10445306	chr17:37591422	A/G	cg20243544	chr17:37824526	PNMT	0.55	6.56	0.39	3.39e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs7582180	0.590	rs11123828	chr2:100960918	T/G	cg14675211	chr2:100938903	LONRF2	0.51	7.64	0.45	5.61e-13	Intelligence (multi-trait analysis);
SARC	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg11878867	chr6:150167359	LRP11	-0.34	-4.72	-0.3	4.01e-6	Lung cancer;
SARC	cis	rs778371	0.697	rs2344613	chr2:233603065	C/G	cg13252401	chr2:233793311	NGEF	-0.3	-4.77	-0.3	3.18e-6	Schizophrenia;
SARC	cis	rs34172651	0.537	rs8049014	chr16:24698903	A/G	cg06028605	chr16:24865363	SLC5A11	0.33	5.02	0.31	1.04e-6	Intelligence (multi-trait analysis);
SARC	cis	rs17023223	0.537	rs61808892	chr1:119599207	C/T	cg05756136	chr1:119680316	WARS2	-0.43	-5.03	-0.31	9.81e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs6058796	1.000	rs6087972	chr20:31268102	A/G	cg13636640	chr20:31349939	DNMT3B	0.59	5.18	0.32	4.9e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs73198271	0.737	rs506960	chr8:8630269	A/C	cg06636001	chr8:8085503	FLJ10661	-0.49	-5.75	-0.35	2.79e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg08280861	chr8:58055591	NA	0.61	5.94	0.36	1.01e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6087990	0.735	rs4911261	chr20:31391360	A/G	cg13636640	chr20:31349939	DNMT3B	0.78	12.04	0.62	2.86e-26	Ulcerative colitis;
SARC	cis	rs17102884	0.506	rs11845397	chr14:75404587	G/A	cg08847533	chr14:75593920	NEK9	-0.44	-5.45	-0.34	1.29e-7	Neuroticism;
SARC	cis	rs9790314	0.521	rs1450522	chr3:161077630	A/G	cg03342759	chr3:160939853	NMD3	-0.65	-8.08	-0.47	3.43e-14	Morning vs. evening chronotype;
SARC	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	7.25	0.43	6.27e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs986417	1.000	rs1116853	chr14:60917476	A/G	cg27398547	chr14:60952738	C14orf39	0.97	8.86	0.5	2.15e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs11190604	1.000	rs79831012	chr10:102237059	T/C	cg07080220	chr10:102295463	HIF1AN	0.76	9.07	0.51	5.2e-17	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs2730245	0.593	rs842699	chr7:158663404	T/A	cg17136484	chr7:158649327	WDR60	0.49	5.59	0.34	6.4e-8	Height;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg25464034	chr11:450264	PTDSS2	-0.82	-6.81	-0.41	8.22e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9303280	0.806	rs62067034	chr17:38063738	C/T	cg00129232	chr17:37814104	STARD3	-0.37	-4.84	-0.3	2.37e-6	Self-reported allergy;
SARC	cis	rs12497850	1.000	rs6788650	chr3:48749543	T/C	cg03060546	chr3:49711283	APEH	0.42	5.32	0.33	2.48e-7	Parkinson's disease;
SARC	cis	rs72945132	0.882	rs11235953	chr11:70184937	C/T	cg05964544	chr11:70165517	PPFIA1	-0.57	-5.54	-0.34	8.15e-8	Coronary artery disease;
SARC	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg07332563	chr6:291687	DUSP22	-0.48	-6.52	-0.39	4.39e-10	Menopause (age at onset);
SARC	cis	rs12477438	1.000	rs11897712	chr2:99735697	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.89	-10.26	-0.56	1.32e-20	Chronic sinus infection;
SARC	trans	rs7618501	0.966	rs2246832	chr3:49881134	A/T	cg21659725	chr3:3221576	CRBN	0.8	11.79	0.61	1.75e-25	Intelligence (multi-trait analysis);
SARC	cis	rs1920116	0.661	rs13062210	chr3:169549773	A/T	cg14222479	chr3:169487675	ARPM1	0.47	5.21	0.32	4.08e-7	Glioma (high-grade);
SARC	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg00933542	chr6:150070202	PCMT1	0.32	5.45	0.34	1.29e-7	Lung cancer;
SARC	cis	rs1707322	0.721	rs61784796	chr1:46163256	A/G	cg03146154	chr1:46216737	IPP	0.53	6.35	0.38	1.12e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs72781680	0.898	rs12623079	chr2:24103749	G/A	cg08917208	chr2:24149416	ATAD2B	0.78	7.68	0.45	4.49e-13	Lymphocyte counts;
SARC	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.42	-0.44	2.15e-12	Gut microbiome composition (summer);
SARC	cis	rs10782582	0.593	rs2147039	chr1:76143166	C/T	cg03433033	chr1:76189801	ACADM	-0.42	-5.38	-0.33	1.79e-7	Daytime sleep phenotypes;
SARC	trans	rs61931739	0.517	rs56308002	chr12:34016021	C/G	cg13010199	chr12:38710504	ALG10B	0.75	10.14	0.55	3.05e-20	Morning vs. evening chronotype;
SARC	cis	rs6570726	0.846	rs371186	chr6:145886971	T/C	cg05347473	chr6:146136440	FBXO30	0.52	7.14	0.42	1.15e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12995849	0.905	rs12712218	chr2:106451751	G/T	cg16077055	chr2:106428750	NCK2	0.26	4.76	0.3	3.41e-6	Addiction;
SARC	cis	rs1348850	0.958	rs1545364	chr2:178462882	G/T	cg23306229	chr2:178417860	TTC30B	0.56	6.53	0.39	4.02e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs12079745	0.793	rs34847919	chr1:169105882	G/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.69	-4.87	-0.3	2.08e-6	QT interval;
SARC	cis	rs9660992	0.573	rs1172161	chr1:205206495	C/T	cg21545522	chr1:205238299	TMCC2	0.39	5.34	0.33	2.25e-7	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs12541335	0.579	rs59283125	chr8:22212311	G/A	cg07298985	chr8:22133076	PIWIL2	0.37	4.85	0.3	2.3e-6	Hypertriglyceridemia;
SARC	cis	rs10911232	0.542	rs12128323	chr1:183050087	G/A	cg13390022	chr1:182993471	LAMC1	0.33	5.04	0.31	9.29e-7	Hypertriglyceridemia;
SARC	cis	rs2120019	0.567	rs12385940	chr15:75168162	C/T	cg09165964	chr15:75287851	SCAMP5	-0.96	-10.75	-0.58	3.69e-22	Blood trace element (Zn levels);
SARC	cis	rs155076	1.000	rs261427	chr13:21860998	G/A	cg25811766	chr13:21894605	NA	-0.51	-5.5	-0.34	9.84e-8	White matter hyperintensity burden;
SARC	cis	rs7681440	0.874	rs1442154	chr4:90775761	C/G	cg06632027	chr4:90757378	SNCA	0.4	5.68	0.35	3.91e-8	Dementia with Lewy bodies;
SARC	cis	rs4430311	0.536	rs10927055	chr1:243815781	A/G	cg21452805	chr1:244014465	NA	-0.41	-5.09	-0.32	7.27e-7	Post-traumatic stress disorder (asjusted for relatedness);
SARC	cis	rs7106204	0.764	rs28833840	chr11:24206736	G/A	ch.11.24196551F	chr11:24239977	NA	0.74	5.45	0.34	1.31e-7	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs9902453	0.967	rs8067576	chr17:28444254	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	6.53	0.39	4.18e-10	Coffee consumption (cups per day);
SARC	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg03433033	chr1:76189801	ACADM	0.57	8.02	0.47	5.09e-14	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs1355223	0.583	rs2941044	chr11:34867444	A/C	cg18508148	chr11:34937573	PDHX;APIP	0.54	7.11	0.42	1.43e-11	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.65	-6.44	-0.39	6.6e-10	Platelet count;
SARC	cis	rs7712401	0.623	rs922140	chr5:122088890	A/G	cg19412675	chr5:122181750	SNX24	0.4	5.42	0.33	1.51e-7	Mean platelet volume;
SARC	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg27266027	chr21:40555129	PSMG1	-0.53	-5.92	-0.36	1.17e-8	Cognitive function;
SARC	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg17691542	chr6:26056736	HIST1H1C	0.43	4.86	0.3	2.16e-6	Intelligence (multi-trait analysis);
SARC	cis	rs8014204	0.836	rs7154256	chr14:75252587	A/G	cg06637938	chr14:75390232	RPS6KL1	0.67	9.37	0.52	6.47e-18	Caffeine consumption;
SARC	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-9.68	-0.54	7.76e-19	Chronic sinus infection;
SARC	cis	rs7793919	0.726	rs10232008	chr7:4783206	T/G	cg09789173	chr7:4769017	FOXK1	0.42	5.65	0.35	4.67e-8	Mosquito bite size;
SARC	cis	rs262150	0.851	rs2527224	chr7:158769198	G/A	cg19418458	chr7:158789849	NA	-0.46	-6.18	-0.38	2.78e-9	Facial morphology (factor 20);
SARC	cis	rs13401104	0.796	rs72620809	chr2:237116050	T/C	cg19324714	chr2:237145437	ASB18	0.56	5.44	0.34	1.36e-7	Educational attainment;
SARC	cis	rs6545883	0.524	rs2694618	chr2:61536984	A/G	cg10580144	chr2:61372316	C2orf74	0.42	5.82	0.36	1.89e-8	Tuberculosis;
SARC	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg13271783	chr10:134563150	INPP5A	0.38	5.06	0.31	8.33e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs9916302	0.800	rs11869259	chr17:37518141	C/A	cg20243544	chr17:37824526	PNMT	-0.53	-6.37	-0.39	9.76e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs3126085	0.935	rs12738889	chr1:152257688	G/A	cg26876637	chr1:152193138	HRNR	-0.45	-5.21	-0.32	4.07e-7	Atopic dermatitis;
SARC	cis	rs8067354	0.645	rs72840522	chr17:57829992	G/A	cg02344993	chr17:57696989	CLTC	0.65	6.69	0.4	1.61e-10	Hemoglobin concentration;
SARC	cis	rs709400	0.567	rs28496120	chr14:103897899	C/T	cg12935359	chr14:103987150	CKB	-0.4	-5.89	-0.36	1.34e-8	Body mass index;
SARC	cis	rs9911578	1.000	rs4793952	chr17:56608465	C/T	cg05425664	chr17:57184151	TRIM37	0.66	8.12	0.47	2.65e-14	Intelligence (multi-trait analysis);
SARC	cis	rs753778	0.667	rs10103731	chr8:142206068	C/T	cg16341495	chr8:142228727	SLC45A4	-0.41	-5.62	-0.35	5.38e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg26338869	chr17:61819248	STRADA	0.81	10.84	0.58	1.98e-22	Prudent dietary pattern;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg07168392	chr1:86861658	ODF2L	0.52	6.24	0.38	2.04e-9	Breast cancer;
SARC	cis	rs1200821	0.529	rs2475206	chr10:37802532	A/G	cg25427524	chr10:38739819	LOC399744	0.45	6.71	0.4	1.48e-10	Hemostatic factors and hematological phenotypes;
SARC	cis	rs76419734	1.000	rs11734571	chr4:106703557	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.8	5.36	0.33	2.02e-7	Post bronchodilator FEV1;
SARC	cis	rs6670533	0.571	rs11801548	chr1:24861448	A/G	cg07475527	chr1:24864545	NA	-1.0	-5.65	-0.35	4.76e-8	Fasting blood insulin (BMI interaction);
SARC	cis	rs11098499	0.863	rs10013305	chr4:120450424	G/A	cg09307838	chr4:120376055	NA	0.91	12.31	0.63	3.63e-27	Corneal astigmatism;
SARC	cis	rs796364	0.806	rs11694236	chr2:200916230	T/C	cg23649088	chr2:200775458	C2orf69	-0.6	-5.29	-0.33	2.77e-7	Schizophrenia;
SARC	cis	rs1865760	0.929	rs1436307	chr6:25939723	C/T	cg17691542	chr6:26056736	HIST1H1C	0.61	7.76	0.45	2.73e-13	Height;
SARC	cis	rs3771570	1.000	rs73018141	chr2:242221570	G/A	cg21155796	chr2:242212141	HDLBP	0.73	6.36	0.38	1.05e-9	Prostate cancer;
SARC	cis	rs365132	1.000	rs2292255	chr5:176334195	C/T	cg16309518	chr5:176445507	NA	-0.45	-5.97	-0.36	8.6e-9	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs2228479	0.867	rs17784386	chr16:89947457	A/G	cg00800038	chr16:89945340	TCF25	-0.72	-5.75	-0.35	2.8e-8	Skin colour saturation;
SARC	cis	rs1609391	0.543	rs1347209	chr3:136626697	G/T	cg15507776	chr3:136538369	TMEM22	0.83	11.51	0.6	1.49e-24	Neuroticism;
SARC	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg21724239	chr8:58056113	NA	0.63	5.99	0.37	7.96e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs7829975	0.511	rs2948286	chr8:8130160	A/G	cg16141378	chr3:129829833	LOC729375	-0.61	-7.48	-0.44	1.53e-12	Mood instability;
SARC	cis	rs79976124	0.800	rs12194767	chr6:66639599	A/G	cg07460842	chr6:66804631	NA	0.61	6.92	0.41	4.21e-11	Type 2 diabetes;
SARC	cis	rs71327718	1	rs71327718	chr3:125592857	C/G	cg05084668	chr3:125655381	ALG1L	-0.86	-8.1	-0.47	2.98e-14	Metabolite levels (HVA/5-HIAA ratio);
SARC	cis	rs7772486	0.754	rs6921073	chr6:146144377	G/A	cg05347473	chr6:146136440	FBXO30	0.51	7.22	0.43	7.1e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs13034020	0.790	rs72809405	chr2:61173382	G/A	cg18625361	chr2:61244694	PEX13;PUS10	0.63	4.89	0.31	1.85e-6	Hodgkin's lymphoma;
SARC	trans	rs1814175	0.676	rs1721999	chr11:49917372	A/G	cg15704280	chr7:45808275	SEPT13	-0.88	-14.0	-0.68	1.02e-32	Height;
SARC	cis	rs898097	0.607	rs2199111	chr17:80823203	A/G	cg02711726	chr17:80685570	FN3KRP	0.36	4.94	0.31	1.49e-6	Breast cancer;
SARC	cis	rs11690462	0.794	rs2384364	chr2:26541427	C/G	cg26119090	chr2:26468346	HADHA;HADHB	0.44	5.61	0.34	5.7e-8	Coronary artery disease;
SARC	cis	rs155076	0.711	rs4770131	chr13:21897468	A/G	cg14456004	chr13:21872349	NA	1.12	15.4	0.71	2.21e-37	White matter hyperintensity burden;
SARC	cis	rs9733	0.744	rs12568757	chr1:150729793	C/T	cg13175981	chr1:150552382	MCL1	0.6	8.04	0.47	4.42e-14	Tonsillectomy;
SARC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg11494091	chr17:61959527	GH2	0.55	8.24	0.48	1.24e-14	Prudent dietary pattern;
SARC	cis	rs17750015	0.733	rs7506986	chr18:54404558	C/T	cg18434998	chr18:54306185	TXNL1	-0.41	-4.89	-0.31	1.89e-6	Depression and alcohol dependence;
SARC	cis	rs7208487	0.684	rs12449852	chr17:37632088	A/G	cg00129232	chr17:37814104	STARD3	-0.57	-5.72	-0.35	3.18e-8	Primary biliary cholangitis;Glomerular filtration rate in non diabetics (creatinine);
SARC	cis	rs7772486	0.720	rs6570713	chr6:146075085	G/A	cg05347473	chr6:146136440	FBXO30	-0.56	-7.76	-0.45	2.73e-13	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs2727020	0.658	rs4980442	chr11:49445016	G/T	cg03929089	chr4:120376271	NA	-0.79	-11.63	-0.61	6.04e-25	Coronary artery disease;
SARC	trans	rs208520	1.000	rs72880045	chr6:66965232	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.82	8.98	0.51	9.32e-17	Exhaled nitric oxide output;
SARC	cis	rs6594499	0.872	rs10059658	chr5:110452815	T/C	cg04022379	chr5:110408740	TSLP	0.46	5.89	0.36	1.35e-8	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs7582180	0.614	rs1030901	chr2:101007314	G/A	cg14675211	chr2:100938903	LONRF2	0.53	8.03	0.47	4.93e-14	Intelligence (multi-trait analysis);
SARC	cis	rs6598955	0.543	rs3795689	chr1:26560366	C/G	cg04990556	chr1:26633338	UBXN11	0.74	7.98	0.46	6.74e-14	Obesity-related traits;
SARC	cis	rs11264799	0.520	rs849820	chr1:157541565	G/C	cg18268488	chr1:157545234	FCRL4	0.3	5.38	0.33	1.78e-7	IgA nephropathy;
SARC	cis	rs11225247	0.892	rs12277747	chr11:102281614	C/T	cg11690896	chr11:102217788	BIRC2	-0.71	-5.39	-0.33	1.74e-7	Vein graft stenosis in coronary artery bypass grafting;
SARC	cis	rs8031584	0.918	rs34095794	chr15:31269691	C/T	cg14829155	chr15:31115871	NA	-0.44	-5.59	-0.34	6.21e-8	Huntington's disease progression;
SARC	cis	rs7208859	0.623	rs7208088	chr17:29143667	C/T	cg13385521	chr17:29058706	SUZ12P	0.9	7.58	0.44	7.91e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs67311347	1.000	rs7648952	chr3:40457038	C/T	cg09455208	chr3:40491958	NA	-0.41	-6.57	-0.4	3.32e-10	Renal cell carcinoma;
SARC	cis	rs4555082	0.957	rs3825762	chr14:105752404	T/C	cg10792982	chr14:105748885	BRF1	0.5	7.78	0.45	2.36e-13	Mean platelet volume;Platelet distribution width;
SARC	cis	rs36207871	1	rs36207871	chr12:56684496	TAGGAA/T	cg26734620	chr12:56694298	CS	-0.86	-6.37	-0.39	1.01e-9	Inflammatory skin disease;
SARC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg19318889	chr4:1322082	MAEA	0.44	5.4	0.33	1.62e-7	Longevity;
SARC	cis	rs9309473	0.519	rs2421667	chr2:73832459	T/C	cg20560298	chr2:73613845	ALMS1	0.52	7.0	0.42	2.66e-11	Metabolite levels;
SARC	cis	rs2228479	0.850	rs17226966	chr16:89825338	A/G	cg00800038	chr16:89945340	TCF25	-0.74	-5.14	-0.32	5.79e-7	Skin colour saturation;
SARC	cis	rs3814231	0.531	rs12771689	chr10:115467068	A/G	cg24846397	chr10:115438155	CASP7	-0.35	-4.92	-0.31	1.61e-6	Vitiligo;
SARC	cis	rs6831352	0.918	rs2851253	chr4:100043505	G/T	cg13256891	chr4:100009986	ADH5	-0.66	-8.3	-0.48	8.19e-15	Alcohol dependence;
SARC	cis	rs12136530	0.593	rs4911988	chr1:19724480	C/T	cg18923740	chr1:19971790	NBL1	0.3	4.99	0.31	1.18e-6	Lead levels in blood;
SARC	cis	rs7123876	0.553	rs10898868	chr11:72431679	A/G	cg03713592	chr11:72463424	ARAP1	0.52	6.08	0.37	4.97e-9	Body mass index;
SARC	cis	rs4891159	0.513	rs2554831	chr18:74113513	C/G	cg24786174	chr18:74118243	ZNF516	0.76	12.54	0.63	6.53e-28	Longevity;
SARC	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg05368731	chr17:41323189	NBR1	0.79	9.83	0.54	2.62e-19	Menopause (age at onset);
SARC	cis	rs950776	0.616	rs12901300	chr15:78892952	G/A	cg06917634	chr15:78832804	PSMA4	0.78	11.58	0.6	8.37e-25	Sudden cardiac arrest;
SARC	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg03647317	chr4:187891568	NA	-0.37	-5.1	-0.32	7.18e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7267979	0.966	rs6050611	chr20:25414419	A/G	cg03522245	chr20:25566470	NINL	0.34	4.87	0.3	2.08e-6	Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs6539288	0.901	rs1444580	chr12:107314558	G/A	cg07730007	chr12:107377277	MTERFD3	0.38	4.83	0.3	2.45e-6	Total body bone mineral density;
SARC	cis	rs6565180	0.507	rs4471699	chr16:30320307	G/T	cg17640201	chr16:30407289	ZNF48	-0.67	-9.24	-0.52	1.56e-17	Tonsillectomy;
SARC	cis	rs7953249	0.542	rs2244608	chr12:121416988	A/G	cg02403541	chr12:121454288	C12orf43	0.79	10.74	0.58	3.91e-22	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs1152591	1.000	rs1152591	chr14:64680848	A/G	cg23250157	chr14:64679961	SYNE2	0.53	7.88	0.46	1.25e-13	Atrial fibrillation;
SARC	cis	rs2976388	0.609	rs2717602	chr8:143805683	G/A	cg06565975	chr8:143823917	SLURP1	0.29	4.86	0.3	2.13e-6	Urinary tract infection frequency;
SARC	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg10523679	chr1:76189770	ACADM	0.54	7.38	0.44	2.73e-12	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6964587	0.967	rs28615927	chr7:91600648	C/A	cg17063962	chr7:91808500	NA	0.93	15.52	0.71	8.63e-38	Breast cancer;
SARC	trans	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	7.03	0.42	2.21e-11	Intelligence (multi-trait analysis);
SARC	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg13393036	chr8:95962371	TP53INP1	-0.36	-6.15	-0.37	3.29e-9	Type 2 diabetes;
SARC	cis	rs3020736	0.500	rs2413672	chr22:42513261	C/T	cg15557168	chr22:42548783	NA	0.36	4.92	0.31	1.62e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs240764	0.746	rs239197	chr6:101133600	T/C	cg09795085	chr6:101329169	ASCC3	0.44	5.75	0.35	2.77e-8	Neuroticism;
SARC	cis	rs3796352	1.000	rs34313969	chr3:52995166	A/G	cg15956490	chr3:53032818	SFMBT1	0.79	5.18	0.32	4.85e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs7766436	0.885	rs5010014	chr6:22587299	A/G	cg13666174	chr6:22585274	NA	-0.61	-7.82	-0.46	1.85e-13	Coronary artery disease;
SARC	trans	rs890100	0.706	rs10193613	chr2:56695597	A/C	cg26233084	chr5:15510258	FBXL7	-0.31	-6.32	-0.38	1.3e-9	Gut microbiome composition (summer);
SARC	cis	rs4130590	0.934	rs7041940	chr9:130109746	T/C	cg13736810	chr9:130213283	LRSAM1;RPL12	0.48	5.93	0.36	1.08e-8	Bipolar disorder;
SARC	cis	rs73635312	0.850	rs77097907	chr10:8946470	C/A	cg24467326	chr10:9646929	NA	0.6	5.03	0.31	9.81e-7	Basal cell carcinoma;
SARC	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg06634786	chr22:41940651	POLR3H	0.52	6.08	0.37	4.88e-9	Vitiligo;
SARC	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg18252515	chr7:66147081	NA	-1.35	-11.94	-0.62	5.84e-26	Diabetic kidney disease;
SARC	cis	rs17376456	0.877	rs9314095	chr5:93425495	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.89	0.36	1.36e-8	Diabetic retinopathy;
SARC	cis	rs3820928	0.874	rs4234066	chr2:227882180	G/A	cg11843606	chr2:227700838	RHBDD1	-0.57	-7.32	-0.43	3.95e-12	Pulmonary function;
SARC	cis	rs829883	0.646	rs4762494	chr12:98933834	T/G	cg25150519	chr12:98850993	NA	-0.59	-7.3	-0.43	4.42e-12	Colorectal adenoma (advanced);
SARC	cis	rs883565	0.792	rs784491	chr3:39174462	T/C	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.52	-5.88	-0.36	1.45e-8	Handedness;
SARC	cis	rs1008375	0.900	rs13101742	chr4:17701297	G/A	cg27347728	chr4:17578864	LAP3	-0.48	-5.89	-0.36	1.36e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs8017423	0.967	rs6575117	chr14:90715412	G/A	cg20276874	chr14:90721474	PSMC1	-0.37	-5.09	-0.32	7.21e-7	Mortality in heart failure;
SARC	cis	rs2795502	0.882	rs2744087	chr10:43340270	A/C	cg20628663	chr10:43360327	NA	-0.47	-6.32	-0.38	1.33e-9	Blood protein levels;
SARC	cis	rs72945132	0.882	rs12294540	chr11:70118973	A/T	cg00319359	chr11:70116639	PPFIA1	0.68	6.37	0.39	1.01e-9	Coronary artery disease;
SARC	cis	rs12421382	1.000	rs12421382	chr11:109378071	C/T	cg11473876	chr11:109292803	C11orf87	0.37	4.87	0.3	2.02e-6	Schizophrenia;
SARC	cis	rs7568458	0.777	rs12473819	chr2:85773061	A/G	cg02493740	chr2:85810744	VAMP5	-0.37	-5.48	-0.34	1.1e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs7223966	1.000	rs2854223	chr17:61939014	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.52	-5.75	-0.35	2.82e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs3741151	0.881	rs10898917	chr11:73065979	G/A	cg17517138	chr11:73019481	ARHGEF17	0.78	6.57	0.4	3.28e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs4243830	1.000	rs58415361	chr1:6592377	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	1.04	8.63	0.49	9.5e-16	Body mass index;
SARC	cis	rs9300255	0.596	rs7304782	chr12:123719444	A/G	cg05973401	chr12:123451056	ABCB9	-0.5	-5.56	-0.34	7.48e-8	Neutrophil percentage of white cells;
SARC	cis	rs11122272	0.735	rs2749716	chr1:231486908	T/C	cg06096015	chr1:231504339	EGLN1	0.38	5.63	0.35	5.19e-8	Hemoglobin concentration;
SARC	cis	rs9393692	0.676	rs806977	chr6:26189615	A/G	cg13736514	chr6:26305472	NA	-0.65	-8.46	-0.48	3.03e-15	Educational attainment;
SARC	cis	rs4555082	1.000	rs7149013	chr14:105759840	T/C	cg06808227	chr14:105710500	BRF1	-0.52	-6.74	-0.4	1.25e-10	Mean platelet volume;Platelet distribution width;
SARC	trans	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.39	-0.39	8.91e-10	Neuroticism;
SARC	cis	rs9948	1.000	rs72811623	chr2:97496473	C/T	cg01990225	chr2:97406019	LMAN2L	-0.9	-6.26	-0.38	1.81e-9	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg05861140	chr6:150128134	PCMT1	-0.41	-5.34	-0.33	2.25e-7	Lung cancer;
SARC	cis	rs6665290	0.669	rs3768421	chr1:227177193	G/A	cg14016676	chr1:227182615	CDC42BPA	0.37	5.24	0.32	3.54e-7	Myeloid white cell count;
SARC	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg20965017	chr5:231967	SDHA	-0.56	-5.3	-0.33	2.71e-7	Breast cancer;
SARC	cis	rs10927875	0.562	rs10803401	chr1:16147377	G/A	cg21385522	chr1:16154831	NA	-0.92	-13.12	-0.65	8.01e-30	Dilated cardiomyopathy;
SARC	cis	rs6088813	1.000	rs6579234	chr20:33983485	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.43	-5.24	-0.32	3.67e-7	Height;
SARC	cis	rs1153858	1.000	rs1719247	chr15:45620985	C/T	cg21132104	chr15:45694354	SPATA5L1	0.72	9.7	0.54	6.78e-19	Homoarginine levels;
SARC	cis	rs79839061	0.732	rs35177456	chr4:828994	C/T	cg07828340	chr4:882639	GAK	0.75	4.74	0.3	3.78e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2652834	1.000	rs2729788	chr15:63400378	G/C	cg05507819	chr15:63340323	TPM1	0.52	5.17	0.32	4.99e-7	HDL cholesterol;
SARC	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	10.56	0.57	1.49e-21	Alzheimer's disease;
SARC	cis	rs9341808	0.727	rs9352809	chr6:80999316	C/T	cg08355045	chr6:80787529	NA	0.36	5.7	0.35	3.63e-8	Sitting height ratio;
SARC	cis	rs4268898	0.552	rs6754391	chr2:24369019	C/T	cg26838691	chr2:24397539	C2orf84	-0.42	-5.55	-0.34	7.62e-8	Asthma;
SARC	cis	rs2820315	0.505	rs10800792	chr1:201811144	G/A	cg11586189	chr1:201857591	SHISA4	0.41	6.82	0.41	7.59e-11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
SARC	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg04277193	chr17:41438351	NA	0.44	4.78	0.3	3.04e-6	Menopause (age at onset);
SARC	cis	rs593982	0.920	rs1151500	chr11:65481166	T/C	cg08755490	chr11:65554678	OVOL1	0.92	8.74	0.5	4.6e-16	Atopic dermatitis;
SARC	cis	rs2814982	0.605	rs73405697	chr6:34470396	T/C	cg17674042	chr6:34482479	PACSIN1	-0.53	-4.86	-0.3	2.15e-6	Cholesterol, total;Total cholesterol levels;
SARC	cis	rs1448094	0.512	rs6539924	chr12:86236935	T/C	cg02569458	chr12:86230093	RASSF9	0.4	5.63	0.35	5.08e-8	Major depressive disorder;
SARC	cis	rs6582630	0.502	rs4379906	chr12:38295673	G/A	cg26384229	chr12:38710491	ALG10B	0.84	12.1	0.62	1.74e-26	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg05890377	chr2:74357713	NA	0.58	7.08	0.42	1.72e-11	Gestational age at birth (maternal effect);
SARC	trans	rs61931739	0.635	rs7138254	chr12:33914422	G/T	cg26384229	chr12:38710491	ALG10B	0.55	7.14	0.42	1.21e-11	Morning vs. evening chronotype;
SARC	cis	rs1348850	0.560	rs13019660	chr2:178498214	C/T	cg23306229	chr2:178417860	TTC30B	0.61	6.31	0.38	1.38e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs739401	0.611	rs401707	chr11:3050965	T/C	cg05729581	chr11:3078854	CARS	-0.46	-5.95	-0.36	9.68e-9	Longevity;
SARC	cis	rs6088580	0.524	rs7269596	chr20:33229063	T/C	cg08999081	chr20:33150536	PIGU	-0.33	-4.94	-0.31	1.48e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs708547	0.874	rs1630798	chr4:57883558	T/C	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.47	-5.17	-0.32	5.08e-7	Response to bleomycin (chromatid breaks);
SARC	cis	rs3923518	1.000	rs13079538	chr3:38906903	T/C	cg15678707	chr3:39149194	GORASP1;TTC21A	0.49	5.3	0.33	2.67e-7	Migraine;
SARC	cis	rs796364	0.806	rs79156935	chr2:200913822	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.68	-5.72	-0.35	3.32e-8	Schizophrenia;
SARC	cis	rs73198271	0.531	rs3827812	chr8:8654898	C/T	cg01851573	chr8:8652454	MFHAS1	0.42	4.99	0.31	1.2e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg22535103	chr8:58192502	C8orf71	-0.59	-6.21	-0.38	2.35e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10484885	0.690	rs292236	chr6:90528422	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.54	-5.0	-0.31	1.1e-6	QRS interval (sulfonylurea treatment interaction);
SARC	cis	rs2070488	0.662	rs7373930	chr3:38454931	A/G	cg27533700	chr3:38537683	EXOG	-0.4	-5.16	-0.32	5.21e-7	Electrocardiographic conduction measures;
SARC	cis	rs11770686	0.666	rs2525476	chr7:75307467	C/G	cg17787366	chr7:75369077	HIP1	0.38	4.76	0.3	3.43e-6	Essential tremor;
SARC	cis	rs4853036	1.000	rs13020991	chr2:70068642	A/G	cg02498382	chr2:70120550	SNRNP27	-0.41	-5.5	-0.34	9.72e-8	Colorectal or endometrial cancer;
SARC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg02951883	chr7:2050386	MAD1L1	-0.51	-6.52	-0.39	4.4e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs17376456	0.569	rs7736892	chr5:93205597	G/A	cg21475434	chr5:93447410	FAM172A	-0.64	-6.37	-0.39	9.72e-10	Diabetic retinopathy;
SARC	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg24209194	chr3:40518798	ZNF619	0.61	7.49	0.44	1.41e-12	Renal cell carcinoma;
SARC	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.41	-5.55	-0.34	7.6e-8	Personality dimensions;
SARC	cis	rs10463554	0.963	rs257294	chr5:102467267	A/G	cg23492399	chr5:102201601	PAM	-0.5	-5.54	-0.34	8.31e-8	Parkinson's disease;
SARC	cis	rs9393777	0.588	rs6941920	chr6:26492149	C/T	cg12826209	chr6:26865740	GUSBL1	0.8	7.81	0.46	1.9e-13	Intelligence (multi-trait analysis);
SARC	cis	rs12594515	1.000	rs56412446	chr15:45996424	A/G	cg14863074	chr15:45997064	NA	0.34	5.18	0.32	4.79e-7	Waist circumference;Weight;
SARC	cis	rs4919087	0.620	rs793515	chr10:98988469	A/C	cg25902810	chr10:99078978	FRAT1	-0.55	-5.75	-0.35	2.78e-8	Monocyte count;
SARC	cis	rs9911578	1.000	rs2055779	chr17:57030561	A/G	cg05425664	chr17:57184151	TRIM37	-0.66	-8.25	-0.48	1.17e-14	Intelligence (multi-trait analysis);
SARC	cis	rs9611565	0.921	rs5758297	chr22:41720697	A/G	cg17376030	chr22:41985996	PMM1	0.52	6.6	0.4	2.7e-10	Vitiligo;
SARC	cis	rs10791323	0.628	rs10750543	chr11:133718467	G/A	cg03690763	chr11:133734501	NA	-0.29	-4.78	-0.3	3.15e-6	Childhood ear infection;
SARC	cis	rs796364	1.000	rs281774	chr2:200814572	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.78	7.06	0.42	1.85e-11	Schizophrenia;
SARC	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.69	7.28	0.43	5.17e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs11785400	0.793	rs4403386	chr8:143736770	C/G	cg24634471	chr8:143751801	JRK	0.59	7.62	0.45	6.34e-13	Schizophrenia;
SARC	cis	rs3096299	0.679	rs3096322	chr16:89441123	A/G	cg02187348	chr16:89574699	SPG7	-0.38	-4.99	-0.31	1.18e-6	Multiple myeloma (IgH translocation);
SARC	cis	rs2415984	0.520	rs60342772	chr14:46935394	C/A	cg14871534	chr14:47121158	RPL10L	0.38	5.18	0.32	4.85e-7	Number of children ever born;
SARC	cis	rs12142240	0.660	rs72885163	chr1:46807117	C/A	cg00530320	chr1:46809349	NSUN4	0.55	6.71	0.4	1.47e-10	Menopause (age at onset);
SARC	cis	rs11874712	1.000	rs2298787	chr18:43669980	T/C	cg25174615	chr18:43684699	ATP5A1;HAUS1	0.4	4.75	0.3	3.52e-6	Migraine - clinic-based;
SARC	cis	rs6867032	0.874	rs4975786	chr5:2004724	T/C	cg26168224	chr5:2018326	NA	-0.74	-10.04	-0.55	6.26e-20	Gut microbiome composition (winter);
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg27525876	chr16:89294245	ZNF778	0.47	6.27	0.38	1.74e-9	Neuroticism;
SARC	cis	rs7412746	0.658	rs4970988	chr1:150950062	A/G	cg15448220	chr1:150897856	SETDB1	-0.52	-6.78	-0.41	1.01e-10	Melanoma;
SARC	cis	rs4727027	0.840	rs12670633	chr7:148796707	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	5.84	0.36	1.72e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs10752881	0.967	rs10911186	chr1:182972542	A/G	cg13390022	chr1:182993471	LAMC1	0.33	5.02	0.31	1.01e-6	Colorectal cancer;
SARC	cis	rs13191362	1.000	rs34918316	chr6:163005386	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.57	5.38	0.33	1.85e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2439831	0.717	rs2447198	chr15:43895118	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.76	7.39	0.44	2.68e-12	Lung cancer in ever smokers;
SARC	cis	rs67311347	0.577	rs1317217	chr3:40271697	T/G	cg24209194	chr3:40518798	ZNF619	0.46	5.38	0.33	1.78e-7	Renal cell carcinoma;
SARC	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg03709012	chr19:19516395	GATAD2A	1.03	18.4	0.77	2.65e-47	Tonsillectomy;
SARC	cis	rs796364	0.715	rs11688872	chr2:201052418	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.77	-6.66	-0.4	1.94e-10	Schizophrenia;
SARC	cis	rs6060717	0.536	rs6058364	chr20:34507890	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	4.95	0.31	1.42e-6	Hip circumference adjusted for BMI;
SARC	cis	rs7615952	0.512	rs11929125	chr3:125359443	G/A	cg21696256	chr3:125484277	NA	-0.35	-5.05	-0.31	8.97e-7	Blood pressure (smoking interaction);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg02122052	chr13:46550203	ZC3H13	0.49	6.7	0.4	1.58e-10	Thyroid stimulating hormone;
SARC	cis	rs7647973	0.925	rs9881860	chr3:49352522	A/T	cg06212747	chr3:49208901	KLHDC8B	0.54	5.62	0.35	5.56e-8	Menarche (age at onset);
SARC	cis	rs208520	0.661	rs207090	chr6:66783963	T/A	cg07460842	chr6:66804631	NA	-1.08	-15.02	-0.7	4.17e-36	Exhaled nitric oxide output;
SARC	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg00684032	chr4:1343700	KIAA1530	0.37	5.34	0.33	2.24e-7	Obesity-related traits;
SARC	cis	rs7726839	0.578	rs10080150	chr5:593160	C/T	cg23206463	chr5:561769	NA	0.41	5.89	0.36	1.31e-8	Obesity-related traits;
SARC	cis	rs6121246	0.821	rs6119718	chr20:30331074	A/G	cg13852791	chr20:30311386	BCL2L1	0.85	9.18	0.52	2.48e-17	Mean corpuscular hemoglobin;
SARC	cis	rs2276314	0.857	rs6507158	chr18:33636066	A/C	cg19628046	chr18:33552617	C18orf21	0.55	6.21	0.38	2.38e-9	Endometriosis;Drug-induced torsades de pointes;
SARC	trans	rs17685	0.753	rs13240967	chr7:75658197	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.61	-7.8	-0.46	2.04e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg00684032	chr4:1343700	KIAA1530	0.33	4.91	0.31	1.73e-6	Obesity-related traits;
SARC	cis	rs12142240	0.698	rs66516678	chr1:46810112	G/T	cg14993813	chr1:46806288	NSUN4	-0.52	-5.45	-0.34	1.28e-7	Menopause (age at onset);
SARC	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg16325326	chr1:53192061	ZYG11B	0.95	17.72	0.76	4.59e-45	Monocyte count;
SARC	cis	rs9796	0.558	rs7166205	chr15:41514733	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.55	-7.92	-0.46	9.44e-14	Menopause (age at onset);
SARC	cis	rs2075371	0.829	rs9641970	chr7:134004887	C/A	cg00033643	chr7:134001901	SLC35B4	0.46	5.53	0.34	8.61e-8	Mean platelet volume;
SARC	cis	rs910316	0.935	rs175076	chr14:75505486	A/G	cg11812906	chr14:75593930	NEK9	-0.87	-12.79	-0.64	1.02e-28	Height;
SARC	cis	rs35110281	0.632	rs9306160	chr21:45107562	T/C	cg21573476	chr21:45109991	RRP1B	-0.6	-8.51	-0.49	2.16e-15	Mean corpuscular volume;
SARC	cis	rs6540556	0.678	rs12094117	chr1:209888435	G/T	cg05527609	chr1:210001259	C1orf107	-0.56	-5.02	-0.31	1.01e-6	Red blood cell count;
SARC	trans	rs7615952	0.512	rs4234285	chr3:125404477	G/A	cg07211511	chr3:129823064	LOC729375	-0.57	-6.24	-0.38	2.04e-9	Blood pressure (smoking interaction);
SARC	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg06221963	chr1:154839813	KCNN3	-0.47	-7.3	-0.43	4.59e-12	Prostate cancer;
SARC	cis	rs10463554	0.963	rs26261	chr5:102545693	A/G	cg23492399	chr5:102201601	PAM	-0.45	-4.95	-0.31	1.44e-6	Parkinson's disease;
SARC	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg12923728	chr3:195709715	SDHAP1	-0.68	-8.28	-0.48	9.55e-15	Pancreatic cancer;
SARC	cis	rs7481584	0.624	rs440130	chr11:3051476	A/G	cg20651018	chr11:3035856	CARS	0.41	6.12	0.37	4.01e-9	Calcium levels;
SARC	cis	rs13082711	0.516	rs1492339	chr3:27371526	A/C	cg02860705	chr3:27208620	NA	-0.49	-6.66	-0.4	1.97e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg12463550	chr7:65579703	CRCP	0.55	5.86	0.36	1.54e-8	Aortic root size;
SARC	cis	rs131777	0.547	rs131753	chr22:51022862	A/G	cg16386697	chr22:51017162	CPT1B;CHKB-CPT1B	0.3	4.72	0.3	4.12e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg02951883	chr7:2050386	MAD1L1	-0.48	-6.14	-0.37	3.5e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs7904368	0.754	rs12246217	chr10:16853349	G/C	cg14835575	chr10:16859367	RSU1	0.73	7.29	0.43	4.83e-12	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs7927771	0.832	rs7105851	chr11:47383275	T/C	cg20307385	chr11:47447363	PSMC3	0.57	7.01	0.42	2.51e-11	Subjective well-being;
SARC	trans	rs17685	0.753	rs6465000	chr7:75787417	G/A	cg19862616	chr7:65841803	NCRNA00174	0.63	7.95	0.46	8.05e-14	Coffee consumption;Coffee consumption (cups per day);
SARC	trans	rs8081395	0.741	rs180520	chr17:58015149	T/C	cg15604357	chr1:160386408	VANGL2	0.37	6.24	0.38	2.08e-9	White blood cell count;
SARC	cis	rs7647973	0.626	rs62262672	chr3:49655927	T/A	cg07636037	chr3:49044803	WDR6	-0.6	-5.73	-0.35	3.16e-8	Menarche (age at onset);
SARC	cis	rs7927592	0.956	rs11228277	chr11:68308324	G/A	cg01657329	chr11:68192670	LRP5	-0.37	-4.73	-0.3	3.87e-6	Total body bone mineral density;
SARC	trans	rs9325144	0.600	rs10748442	chr12:38732939	A/T	cg23762105	chr12:34175262	ALG10	-0.55	-7.17	-0.43	9.69e-12	Morning vs. evening chronotype;
SARC	cis	rs9581857	0.556	rs9581863	chr13:28040171	A/G	cg01674679	chr13:27998804	GTF3A	-0.6	-5.9	-0.36	1.27e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg23982607	chr1:1823379	GNB1	-0.64	-10.77	-0.58	3.17e-22	Body mass index;
SARC	cis	rs17270561	0.609	rs4711103	chr6:25742224	C/T	cg16482183	chr6:26056742	HIST1H1C	0.43	5.08	0.32	7.76e-7	Iron status biomarkers;
SARC	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg22484793	chr3:52261325	TLR9	0.29	4.73	0.3	3.83e-6	Bipolar disorder;
SARC	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg14983838	chr19:29218262	NA	0.77	10.48	0.57	2.56e-21	Methadone dose in opioid dependence;
SARC	cis	rs910316	1.000	rs10149880	chr14:75633008	A/G	cg08847533	chr14:75593920	NEK9	-0.91	-14.13	-0.68	3.66e-33	Height;
SARC	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg08219700	chr8:58056026	NA	0.47	4.86	0.3	2.14e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs1451375	0.617	rs2329366	chr7:50544966	G/A	cg14593290	chr7:50529359	DDC	-0.47	-5.16	-0.32	5.23e-7	Malaria;
SARC	trans	rs1814175	0.817	rs2866863	chr11:49953242	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-18.54	-0.77	9.52e-48	Height;
SARC	cis	rs2230307	0.536	rs2893426	chr1:100528200	G/T	cg24955406	chr1:100503596	HIAT1	0.72	6.97	0.42	3.14e-11	Carotid intima media thickness;
SARC	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg05861140	chr6:150128134	PCMT1	-0.41	-5.28	-0.33	3.03e-7	Lung cancer;
SARC	cis	rs4975616	0.869	rs421284	chr5:1325590	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.53	-7.15	-0.42	1.08e-11	Lung cancer;
SARC	cis	rs4727027	0.870	rs13237714	chr7:148884083	A/G	cg23583168	chr7:148888333	NA	-0.74	-10.83	-0.58	2.17e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	trans	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.74	10.81	0.58	2.44e-22	Intelligence (multi-trait analysis);
SARC	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg10295955	chr4:187884368	NA	-1.07	-20.18	-0.8	4.55e-53	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs826838	0.586	rs10880753	chr12:38628147	C/A	cg14851346	chr12:38532713	NA	-0.43	-5.2	-0.32	4.3e-7	Heart rate;
SARC	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg23982607	chr1:1823379	GNB1	-0.66	-11.35	-0.6	4.59e-24	Body mass index;
SARC	cis	rs9660992	0.674	rs56198325	chr1:205265450	G/A	cg21643547	chr1:205240462	TMCC2	-0.59	-7.38	-0.44	2.71e-12	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs7647973	1.000	rs6446268	chr3:49445695	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.6	-6.31	-0.38	1.36e-9	Menarche (age at onset);
SARC	cis	rs7818345	0.845	rs11782540	chr8:19268251	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.39	4.94	0.31	1.47e-6	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs3126085	0.935	rs1353436	chr1:152172658	G/A	cg03465714	chr1:152285911	FLG	-0.47	-5.56	-0.34	7.25e-8	Atopic dermatitis;
SARC	cis	rs7937682	0.575	rs10789851	chr11:111750955	G/C	cg09085632	chr11:111637200	PPP2R1B	0.77	10.29	0.56	1.05e-20	Primary sclerosing cholangitis;
SARC	cis	rs9462027	0.606	rs2395606	chr6:34778486	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.86	-0.36	1.54e-8	Systemic lupus erythematosus;
SARC	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg15049968	chr18:44337910	ST8SIA5	-0.37	-6.14	-0.37	3.54e-9	Personality dimensions;
SARC	cis	rs6835098	0.924	rs13138282	chr4:174120906	C/T	cg08422745	chr4:174089978	GALNT7	0.75	9.57	0.53	1.66e-18	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg18876405	chr7:65276391	NA	-0.44	-4.83	-0.3	2.43e-6	Aortic root size;
SARC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg21747090	chr2:27597821	SNX17	-0.55	-7.68	-0.45	4.44e-13	Total body bone mineral density;
SARC	trans	rs208520	0.690	rs3899423	chr6:66835285	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-13.99	-0.68	1.11e-32	Exhaled nitric oxide output;
SARC	cis	rs35213789	0.887	rs588004	chr7:69172377	A/G	cg10619644	chr7:69149951	AUTS2	-0.44	-5.97	-0.36	8.71e-9	Childhood ear infection;
SARC	cis	rs4319547	0.661	rs10846830	chr12:122897220	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.53	-5.94	-0.36	1.01e-8	Body mass index;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg00026230	chr16:30064606	ALDOA	0.62	6.38	0.39	9.26e-10	Lung cancer in ever smokers;
SARC	cis	rs1497406	0.744	rs4661718	chr1:16505908	C/T	cg20430773	chr1:16534157	ARHGEF19	0.51	7.7	0.45	3.86e-13	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7582720	1.000	rs72932776	chr2:203688300	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.71	7.13	0.42	1.29e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	trans	rs3780486	0.541	rs10738909	chr9:33148834	T/C	cg20290983	chr6:43655470	MRPS18A	0.91	13.15	0.65	6.3e-30	IgG glycosylation;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg13823205	chr2:153032683	STAM2	-0.52	-6.55	-0.39	3.57e-10	Schizophrenia;
SARC	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.68	9.05	0.51	5.73e-17	Menarche (age at onset);
SARC	cis	rs7714584	1.000	rs11747065	chr5:150295486	C/T	cg22134413	chr5:150180641	NA	0.8	6.59	0.4	2.97e-10	Crohn's disease;
SARC	cis	rs13161895	1.000	rs4129403	chr5:179476610	A/G	cg02702477	chr5:179499311	RNF130	0.71	6.72	0.4	1.35e-10	LDL cholesterol;
SARC	cis	rs2295359	0.643	rs1569923	chr1:67665210	A/G	cg11235152	chr1:67600687	NA	0.35	5.06	0.31	8.55e-7	Psoriasis;
SARC	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg20007245	chr22:24372913	LOC391322	-0.72	-9.05	-0.51	5.88e-17	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9660992	0.674	rs72745219	chr1:205262271	G/A	cg00857998	chr1:205179979	DSTYK	0.43	4.99	0.31	1.2e-6	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs17376456	0.877	rs10062711	chr5:93348659	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.86	0.36	1.59e-8	Diabetic retinopathy;
SARC	cis	rs7552404	0.731	rs11588578	chr1:76400539	T/G	cg22875332	chr1:76189707	ACADM	0.39	4.72	0.3	4.04e-6	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs561341	1.000	rs8070262	chr17:30262467	A/G	cg13647721	chr17:30228624	UTP6	0.57	4.96	0.31	1.36e-6	Hip circumference adjusted for BMI;
SARC	cis	rs1949733	0.543	rs62287446	chr4:8535988	G/A	cg13073564	chr4:8508604	NA	0.4	6.52	0.39	4.39e-10	Response to antineoplastic agents;
SARC	cis	rs2153535	0.580	rs7743686	chr6:8526111	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	10.59	0.57	1.15e-21	Motion sickness;
SARC	cis	rs1707322	0.752	rs11211146	chr1:46109794	T/C	cg06784218	chr1:46089804	CCDC17	0.36	6.15	0.37	3.35e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2425143	1.000	rs11696369	chr20:34378629	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-6.31	-0.38	1.36e-9	Blood protein levels;
SARC	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg26335602	chr6:28129616	ZNF389	0.53	5.92	0.36	1.12e-8	Depression;
SARC	cis	rs7647973	0.626	rs1996663	chr3:49878264	C/G	cg13072238	chr3:49761600	GMPPB	0.58	5.78	0.35	2.33e-8	Menarche (age at onset);
SARC	cis	rs17826219	0.500	rs61685770	chr17:29085713	G/A	cg13385521	chr17:29058706	SUZ12P	0.9	7.81	0.46	1.96e-13	Body mass index;
SARC	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg05313129	chr8:58192883	C8orf71	-0.57	-6.36	-0.38	1.07e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2952156	0.920	rs2952152	chr17:37832735	T/C	cg20243544	chr17:37824526	PNMT	0.53	7.03	0.42	2.33e-11	Asthma;
SARC	cis	rs7666738	0.830	rs35235971	chr4:98999833	G/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1050631	0.960	rs1789512	chr18:33694542	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	-0.42	-5.33	-0.33	2.3e-7	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs72945132	0.882	rs67529561	chr11:70162055	G/T	cg00319359	chr11:70116639	PPFIA1	0.67	6.08	0.37	4.85e-9	Coronary artery disease;
SARC	cis	rs7512552	0.809	rs9436112	chr1:150406449	A/C	cg15654264	chr1:150340011	RPRD2	0.39	5.03	0.31	9.63e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	trans	rs61931739	0.534	rs10844791	chr12:34211659	C/T	cg13010199	chr12:38710504	ALG10B	0.73	9.94	0.55	1.19e-19	Morning vs. evening chronotype;
SARC	cis	rs72781680	1.000	rs72781679	chr2:24237712	G/A	cg08917208	chr2:24149416	ATAD2B	0.92	9.04	0.51	6.34e-17	Lymphocyte counts;
SARC	cis	rs7666738	0.830	rs35939134	chr4:98980311	A/G	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10493773	0.510	rs11161645	chr1:86092872	T/C	cg17807903	chr1:86174739	ZNHIT6	0.48	6.86	0.41	6.31e-11	Urate levels in overweight individuals;
SARC	cis	rs7474896	0.515	rs594594	chr10:38307723	A/G	cg25427524	chr10:38739819	LOC399744	0.48	5.81	0.36	2.06e-8	Obesity (extreme);
SARC	cis	rs551517	0.541	rs496475	chr9:113638236	G/T	cg13900023	chr9:113799879	LPAR1	-0.4	-5.25	-0.33	3.35e-7	Post bronchodilator FEV1 in COPD;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
SARC	cis	rs10892173	0.566	rs10892174	chr11:117672565	A/C	cg21014159	chr11:117668035	DSCAML1	0.43	5.81	0.36	2.01e-8	Myopia;
SARC	cis	rs4803468	0.967	rs11083619	chr19:41913267	A/C	cg08477640	chr19:41863820	B9D2	0.46	5.85	0.36	1.64e-8	Height;
SARC	cis	rs7438	0.528	rs11725757	chr4:170516219	C/G	cg07701716	chr4:170533879	NEK1	0.39	4.77	0.3	3.19e-6	Schizophrenia;
SARC	cis	rs1448094	0.933	rs11836175	chr12:86311644	A/T	cg02569458	chr12:86230093	RASSF9	0.39	5.61	0.34	5.7e-8	Major depressive disorder;
SARC	cis	rs5167	0.536	rs1882752	chr19:45461342	G/C	cg13119609	chr19:45449297	APOC2	0.4	5.7	0.35	3.67e-8	Blood protein levels;
SARC	cis	rs4742903	0.527	rs10820607	chr9:106888750	A/C	cg14250997	chr9:106856677	SMC2	0.5	6.29	0.38	1.59e-9	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs854765	0.583	rs6502622	chr17:17834691	A/G	cg04398451	chr17:18023971	MYO15A	-0.38	-5.38	-0.33	1.84e-7	Total body bone mineral density;
SARC	cis	rs7647973	0.710	rs7629322	chr3:49621994	C/T	cg07636037	chr3:49044803	WDR6	0.83	7.61	0.45	6.61e-13	Menarche (age at onset);
SARC	cis	rs4974559	0.739	rs28411197	chr4:1279781	C/T	cg02980000	chr4:1222292	CTBP1	0.72	5.54	0.34	8.1e-8	Systolic blood pressure;
SARC	cis	rs6540556	0.724	rs6679631	chr1:209935491	C/A	cg23920097	chr1:209922102	NA	-0.62	-7.2	-0.43	8.36e-12	Red blood cell count;
SARC	cis	rs9399137	0.507	rs13209780	chr6:135344795	G/C	cg22676075	chr6:135203613	NA	0.39	4.97	0.31	1.29e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs929354	0.772	rs2366214	chr7:156992461	A/G	cg05182265	chr7:156933206	UBE3C	-0.33	-5.02	-0.31	1.03e-6	Body mass index;
SARC	trans	rs1814175	0.817	rs7927373	chr11:49957640	A/C	cg15704280	chr7:45808275	SEPT13	-0.97	-18.54	-0.77	9.52e-48	Height;
SARC	cis	rs6426558	0.537	rs10495253	chr1:227471820	A/T	cg10327440	chr1:227177885	CDC42BPA	0.43	5.09	0.32	7.44e-7	Neutrophil percentage of white cells;
SARC	cis	rs8114671	0.562	rs2424999	chr20:33386430	G/A	cg07148914	chr20:33460835	GGT7	0.4	5.08	0.32	7.65e-7	Height;
SARC	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg13206674	chr6:150067644	NUP43	0.45	5.86	0.36	1.53e-8	Lung cancer;
SARC	cis	rs9868809	0.505	rs56735597	chr3:48765168	A/G	cg00383909	chr3:49044727	WDR6	0.65	5.57	0.34	6.91e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs2832191	0.636	rs8131283	chr21:30516796	A/G	cg08807101	chr21:30365312	RNF160	-0.7	-8.54	-0.49	1.74e-15	Dental caries;
SARC	cis	rs933688	0.583	rs10036206	chr5:90609178	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.65	5.77	0.35	2.5e-8	Smoking behavior;
SARC	cis	rs7681440	0.904	rs6816305	chr4:90772902	C/G	cg06632027	chr4:90757378	SNCA	0.4	5.68	0.35	3.9e-8	Dementia with Lewy bodies;
SARC	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg13770153	chr20:60521292	NA	0.75	10.95	0.58	8.61e-23	Obesity-related traits;
SARC	cis	rs6138458	0.626	rs6132789	chr20:25012809	C/T	cg26195577	chr20:24973756	C20orf3	-0.69	-8.39	-0.48	4.8e-15	Blood protein levels;
SARC	cis	rs8114671	0.562	rs6088642	chr20:33483186	G/T	cg07148914	chr20:33460835	GGT7	0.43	5.36	0.33	1.96e-7	Height;
SARC	trans	rs1853207	1.000	rs78831378	chr10:96713686	C/G	cg02737782	chr1:8014393	NA	-0.89	-6.4	-0.39	8.69e-10	Blood metabolite levels;
SARC	cis	rs761746	0.920	rs5998011	chr22:31889566	T/C	cg15823100	chr22:32027580	PISD	0.34	4.91	0.31	1.69e-6	Intelligence;
SARC	cis	rs3772130	0.583	rs11710169	chr3:121426655	A/G	cg20356878	chr3:121714668	ILDR1	0.39	6.23	0.38	2.19e-9	Cognitive performance;
SARC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg23131131	chr22:24373011	LOC391322	0.48	5.18	0.32	4.69e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs79839061	0.610	rs2306252	chr4:892116	T/C	cg07828340	chr4:882639	GAK	0.57	4.86	0.3	2.11e-6	Intelligence (multi-trait analysis);
SARC	cis	rs477692	0.789	rs568166	chr10:131400088	G/A	cg14263093	chr10:131365266	MGMT	0.35	4.88	0.3	1.94e-6	Response to temozolomide;
SARC	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	5.75	0.35	2.77e-8	Personality dimensions;
SARC	cis	rs9303401	0.615	rs7502342	chr17:56922629	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.07	12.11	0.62	1.62e-26	Cognitive test performance;
SARC	cis	rs881375	0.967	rs1930781	chr9:123687834	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.43	5.15	0.32	5.67e-7	Rheumatoid arthritis;
SARC	cis	rs6446731	0.517	rs2858086	chr4:3270611	A/G	cg06533319	chr4:3265114	C4orf44	0.31	4.91	0.31	1.71e-6	Mean platelet volume;
SARC	cis	rs4742903	0.509	rs10991155	chr9:106954420	G/C	cg14250997	chr9:106856677	SMC2	0.4	4.99	0.31	1.16e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs9814567	1.000	rs9871305	chr3:134213538	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.08	-0.42	1.7e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs477692	1.000	rs479478	chr10:131428959	G/A	cg05714579	chr10:131428358	MGMT	0.58	7.51	0.44	1.23e-12	Response to temozolomide;
SARC	cis	rs3733585	0.699	rs6815001	chr4:9958662	G/C	cg11266682	chr4:10021025	SLC2A9	-0.35	-6.03	-0.37	6.35e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg24642844	chr7:1081250	C7orf50	-0.39	-5.35	-0.33	2.14e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs228769	0.792	rs454192	chr17:42171206	T/C	cg19774624	chr17:42201019	HDAC5	0.57	6.0	0.37	7.4e-9	Bone mineral density (hip);Bone mineral density (spine);
SARC	cis	rs9921222	0.500	rs8046256	chr16:393948	C/T	cg12437481	chr16:420112	MRPL28	-0.48	-6.49	-0.39	5.14e-10	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg11987759	chr7:65425863	GUSB	-0.49	-5.95	-0.36	1e-8	Aortic root size;
SARC	cis	rs7223966	1.000	rs113134232	chr17:61715461	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.5	-4.96	-0.31	1.37e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs8114671	0.967	rs3746427	chr20:33730464	A/G	cg08999081	chr20:33150536	PIGU	0.34	4.76	0.3	3.43e-6	Height;
SARC	cis	rs41271473	0.500	rs4606285	chr1:228887544	G/T	cg16512390	chr1:228756714	NA	0.39	5.1	0.32	7.06e-7	Chronic lymphocytic leukemia;
SARC	cis	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg25833597	chr17:30823145	MYO1D	0.48	4.9	0.31	1.84e-6	Hip circumference adjusted for BMI;
SARC	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg07701084	chr6:150067640	NUP43	0.38	5.05	0.31	9.09e-7	Lung cancer;
SARC	cis	rs7043114	0.525	rs7045409	chr9:95201540	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.43	-5.18	-0.32	4.81e-7	Height;
SARC	cis	rs11734570	0.581	rs73811716	chr4:38590773	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.63	6.82	0.41	7.94e-11	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs6933660	0.646	rs9383899	chr6:151781022	G/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.66	8.86	0.5	2.06e-16	Menarche (age at onset);
SARC	cis	rs55871839	0.708	rs13263261	chr8:59814688	T/G	cg07426533	chr8:59803705	TOX	-0.44	-5.88	-0.36	1.43e-8	Pneumonia;
SARC	cis	rs7178909	0.872	rs3931863	chr15:90433913	T/G	cg19708238	chr15:90437601	AP3S2	0.58	7.6	0.45	6.98e-13	Common traits (Other);
SARC	cis	rs7408868	1.000	rs7245814	chr19:15274503	A/G	cg14696996	chr19:15285081	NOTCH3	1.09	8.72	0.5	5.22e-16	Pulse pressure;
SARC	cis	rs2286885	1.000	rs10987296	chr9:129245316	C/T	cg14319473	chr9:129242481	FAM125B	0.39	4.86	0.3	2.12e-6	Intraocular pressure;
SARC	cis	rs9916302	0.904	rs10852933	chr17:37698194	G/T	cg20243544	chr17:37824526	PNMT	0.53	6.17	0.37	2.93e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs787274	1.000	rs885387	chr9:115596390	G/A	cg13803584	chr9:115635662	SNX30	-0.83	-5.03	-0.31	9.96e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs9790314	0.613	rs4679666	chr3:160629025	C/G	cg04691961	chr3:161091175	C3orf57	0.53	7.26	0.43	5.83e-12	Morning vs. evening chronotype;
SARC	cis	rs3768617	0.510	rs4652776	chr1:183091920	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.68	10.11	0.55	3.67e-20	Fuchs's corneal dystrophy;
SARC	cis	rs7772486	0.806	rs7740785	chr6:146171299	C/A	cg05347473	chr6:146136440	FBXO30	0.51	7.15	0.42	1.13e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2562456	0.516	rs56072098	chr19:21651960	G/T	cg00455402	chr19:21769736	NA	0.37	4.82	0.3	2.58e-6	Pain;
SARC	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg24675658	chr1:53192096	ZYG11B	0.7	10.2	0.56	2.02e-20	Monocyte count;
SARC	cis	rs2180341	0.961	rs9375501	chr6:127652539	C/T	cg27446573	chr6:127587934	RNF146	1.04	14.77	0.7	2.87e-35	Breast cancer;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25858983	chr17:42295711	UBTF	0.51	6.62	0.4	2.44e-10	Smoking initiation;
SARC	cis	rs2425143	0.908	rs6060605	chr20:34378132	T/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.74	5.37	0.33	1.93e-7	Blood protein levels;
SARC	cis	rs35306767	0.671	rs11253473	chr10:906826	A/G	cg26597838	chr10:835615	NA	0.83	8.4	0.48	4.32e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs5753618	0.561	rs4141404	chr22:31675185	A/C	cg00478049	chr22:31556069	RNF185	0.44	4.81	0.3	2.71e-6	Colorectal cancer;
SARC	cis	rs79349575	0.729	rs62075824	chr17:46986679	A/G	cg16584676	chr17:46985605	UBE2Z	0.54	6.59	0.4	2.95e-10	Type 2 diabetes;
SARC	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg11494091	chr17:61959527	GH2	0.38	5.41	0.33	1.53e-7	Height;
SARC	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg11890956	chr21:40555474	PSMG1	-0.71	-9.33	-0.52	8.34e-18	Menarche (age at onset);
SARC	cis	rs4648845	0.777	rs2477686	chr1:2392648	C/G	cg07700843	chr1:2391317	NA	-0.3	-5.74	-0.35	2.94e-8	Schizophrenia;
SARC	cis	rs3771570	1.000	rs17386555	chr2:242371825	G/A	cg21155796	chr2:242212141	HDLBP	0.71	6.43	0.39	7.01e-10	Prostate cancer;
SARC	cis	rs3126085	1.000	rs72696989	chr1:152248674	A/C	cg26876637	chr1:152193138	HRNR	-0.5	-5.14	-0.32	5.95e-7	Atopic dermatitis;
SARC	cis	rs79839061	0.610	rs11733713	chr4:869169	A/G	cg07828340	chr4:882639	GAK	0.77	5.84	0.36	1.75e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg08975724	chr8:8085496	FLJ10661	0.51	6.43	0.39	7.23e-10	Mood instability;
SARC	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg18404041	chr3:52824283	ITIH1	-0.38	-5.61	-0.35	5.58e-8	Bipolar disorder;
SARC	cis	rs9517320	0.515	rs9556972	chr13:99209815	C/T	cg07423050	chr13:99094983	FARP1	-0.41	-5.29	-0.33	2.78e-7	Longevity;
SARC	cis	rs2197308	0.606	rs12314897	chr12:38392293	C/T	cg14851346	chr12:38532713	NA	-0.48	-5.83	-0.36	1.79e-8	Morning vs. evening chronotype;
SARC	cis	rs10791323	0.633	rs2171006	chr11:133728323	T/C	cg13461336	chr11:133711254	SPATA19	-0.28	-5.02	-0.31	1.02e-6	Childhood ear infection;
SARC	cis	rs611744	0.967	rs594405	chr8:109193607	A/G	cg21045802	chr8:109455806	TTC35	0.44	5.3	0.33	2.63e-7	Dupuytren's disease;
SARC	cis	rs2197308	0.565	rs4123923	chr12:37857684	T/C	cg26384229	chr12:38710491	ALG10B	0.92	13.54	0.66	3.28e-31	Morning vs. evening chronotype;
SARC	cis	rs483180	0.512	rs677277	chr1:120202298	C/T	cg19096424	chr1:120255104	PHGDH	-0.49	-5.64	-0.35	5e-8	Macular telangiectasia type 2;
SARC	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg22920501	chr2:26401640	FAM59B	-0.52	-6.76	-0.4	1.1e-10	Gut microbiome composition (summer);
SARC	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg05863683	chr7:1912471	MAD1L1	0.37	5.47	0.34	1.15e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg26354017	chr1:205819088	PM20D1	-0.47	-5.1	-0.32	6.94e-7	White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs9581943	0.967	rs9581929	chr13:28464203	C/T	cg17352152	chr13:28491409	NA	0.4	5.28	0.33	2.9e-7	Pancreatic cancer;
SARC	cis	rs10791323	0.569	rs5019134	chr11:133713082	G/C	cg14349672	chr11:133703707	NA	-0.37	-5.42	-0.33	1.5e-7	Childhood ear infection;
SARC	cis	rs1215050	1.000	rs1215050	chr4:98849826	A/G	cg05340658	chr4:99064831	C4orf37	-0.4	-5.11	-0.32	6.69e-7	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs11583043	0.575	rs56403901	chr1:101586047	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.45	5.14	0.32	5.81e-7	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs9796	0.558	rs7166905	chr15:41514876	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.55	-7.92	-0.46	9.44e-14	Menopause (age at onset);
SARC	cis	rs17376456	0.866	rs13356088	chr5:93423479	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.3	0.33	2.73e-7	Diabetic retinopathy;
SARC	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.5	-6.25	-0.38	1.94e-9	Intelligence (multi-trait analysis);
SARC	cis	rs78366141	0.649	rs73842243	chr4:89738899	T/C	cg01026744	chr4:89619053	NAP1L5;HERC3	0.76	4.79	0.3	2.95e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
SARC	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg24642844	chr7:1081250	C7orf50	-0.52	-5.83	-0.36	1.85e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs10782582	0.593	rs6673786	chr1:76149637	C/T	cg03433033	chr1:76189801	ACADM	-0.41	-5.12	-0.32	6.52e-7	Daytime sleep phenotypes;
SARC	cis	rs4588572	0.643	rs7700390	chr5:77789532	T/C	cg11547950	chr5:77652471	NA	-0.42	-5.15	-0.32	5.62e-7	Triglycerides;
SARC	cis	rs926392	0.896	rs1569538	chr20:37685216	A/G	cg16355469	chr20:37678765	NA	-0.59	-7.66	-0.45	5.07e-13	Dialysis-related mortality;
SARC	cis	rs1707322	0.721	rs10157795	chr1:46228192	G/A	cg03146154	chr1:46216737	IPP	0.48	5.71	0.35	3.45e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs3126085	1.000	rs72698906	chr1:152307184	G/A	cg03465714	chr1:152285911	FLG	0.45	4.88	0.3	1.94e-6	Atopic dermatitis;
SARC	cis	rs6539267	0.847	rs17217845	chr12:106697802	C/T	cg00173435	chr12:106696525	TCP11L2	-0.62	-6.41	-0.39	8.09e-10	Tourette syndrome;
SARC	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg06028605	chr16:24865363	SLC5A11	0.36	5.28	0.33	2.92e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1008375	0.931	rs6449309	chr4:17573208	C/T	cg02297831	chr4:17616191	MED28	0.44	5.4	0.33	1.67e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6088590	0.687	rs8115656	chr20:33282780	G/C	cg08999081	chr20:33150536	PIGU	0.41	6.18	0.38	2.76e-9	Coronary artery disease;
SARC	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg22105103	chr4:187893119	NA	0.52	6.66	0.4	1.96e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9788682	0.747	rs2568497	chr15:78721397	G/T	cg24631222	chr15:78858424	CHRNA5	-0.74	-8.7	-0.5	6.17e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs6484504	0.576	rs208088	chr11:31192686	T/C	cg02090638	chr11:31391270	DNAJC24;DCDC1	-0.37	-4.78	-0.3	3.17e-6	Red blood cell count;
SARC	cis	rs11785400	0.731	rs4736363	chr8:143742112	C/A	cg10596483	chr8:143751796	JRK	0.58	7.47	0.44	1.61e-12	Schizophrenia;
SARC	cis	rs7927592	0.956	rs2155730	chr11:68329474	T/C	cg01657329	chr11:68192670	LRP5	-0.4	-4.9	-0.31	1.78e-6	Total body bone mineral density;
SARC	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg08219700	chr8:58056026	NA	0.5	5.18	0.32	4.79e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg21782813	chr7:2030301	MAD1L1	0.48	7.76	0.45	2.58e-13	Bipolar disorder and schizophrenia;
SARC	cis	rs12922317	0.556	rs11648938	chr16:12094149	C/T	cg09319797	chr16:12061715	TNFRSF17	0.31	4.74	0.3	3.78e-6	Schizophrenia;
SARC	cis	rs4253772	0.591	rs7291444	chr22:46656246	T/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.64	7.13	0.42	1.27e-11	LDL cholesterol;Cholesterol, total;
SARC	cis	rs2645694	0.626	rs2703118	chr4:77823672	A/G	cg18351406	chr4:77819688	ANKRD56	0.44	6.25	0.38	1.9e-9	Emphysema distribution in smoking;
SARC	cis	rs412050	0.547	rs61757982	chr22:22113740	A/G	cg17089214	chr22:22089827	YPEL1	0.78	6.78	0.41	9.96e-11	Attention deficit hyperactivity disorder;
SARC	cis	rs9398803	0.651	rs4895813	chr6:126975786	G/T	cg20229609	chr6:126660872	C6orf173	0.37	5.38	0.33	1.8e-7	Male-pattern baldness;
SARC	cis	rs72781680	0.898	rs72780123	chr2:23996009	G/A	cg08917208	chr2:24149416	ATAD2B	0.77	7.29	0.43	4.79e-12	Lymphocyte counts;
SARC	cis	rs7762018	1.000	rs6459657	chr6:170136454	A/G	cg15038512	chr6:170123185	PHF10	0.52	4.78	0.3	3.04e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs2013441	1.000	rs11871827	chr17:20215905	C/G	cg13482628	chr17:19912719	NA	-0.46	-5.96	-0.36	9.28e-9	Obesity-related traits;
SARC	cis	rs7959452	0.535	rs7308481	chr12:69659299	A/G	cg22834771	chr12:69754056	YEATS4	-0.41	-5.41	-0.33	1.55e-7	Blood protein levels;
SARC	cis	rs4595586	0.756	rs7137139	chr12:39364013	C/T	cg26384229	chr12:38710491	ALG10B	0.48	6.09	0.37	4.67e-9	Morning vs. evening chronotype;
SARC	cis	rs9843304	0.528	rs12488126	chr3:149192676	G/A	cg08667024	chr3:149219783	TM4SF4	0.43	6.59	0.4	2.94e-10	Gallstone disease;
SARC	cis	rs7220711	0.902	rs4793019	chr17:41781160	A/C	cg26893861	chr17:41843967	DUSP3	-0.43	-5.53	-0.34	8.5e-8	Bone mineral density (spine);Bone mineral density (hip);
SARC	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.42	5.1	0.32	6.99e-7	Electroencephalogram traits;
SARC	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7208859	0.623	rs9915566	chr17:29132158	G/A	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs1153858	1.000	rs56669689	chr15:45637729	A/C	cg03999130	chr15:45571217	NA	0.4	5.21	0.32	4.21e-7	Homoarginine levels;
SARC	cis	rs116095464	0.850	rs6896163	chr5:303686	A/G	cg22496380	chr5:211416	CCDC127	-0.85	-6.41	-0.39	8.04e-10	Breast cancer;
SARC	cis	rs8067545	0.641	rs119672	chr17:19818601	A/G	cg04132472	chr17:19861366	AKAP10	0.37	5.0	0.31	1.15e-6	Schizophrenia;
SARC	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg12564285	chr5:131593104	PDLIM4	0.44	5.9	0.36	1.29e-8	Breast cancer;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg05124242	chr4:47845589	NA	0.48	6.42	0.39	7.75e-10	Thyroid stimulating hormone;
SARC	cis	rs2387326	0.761	rs3191122	chr10:129900858	C/T	cg16087940	chr10:129947807	NA	-0.47	-6.3	-0.38	1.48e-9	Select biomarker traits;
SARC	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg00908189	chr16:619842	PIGQ	0.85	12.24	0.63	6.5e-27	Height;
SARC	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg25072359	chr17:41440525	NA	0.51	6.13	0.37	3.66e-9	Menopause (age at onset);
SARC	cis	rs2425143	1.000	rs2378409	chr20:34392464	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.66	5.24	0.32	3.54e-7	Blood protein levels;
SARC	cis	rs1538970	0.924	rs10890327	chr1:45891458	C/T	cg05343316	chr1:45956843	TESK2	0.77	8.82	0.5	2.75e-16	Platelet count;
SARC	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg17971929	chr21:40555470	PSMG1	-0.59	-7.41	-0.44	2.25e-12	Menarche (age at onset);
SARC	cis	rs13401104	0.796	rs12468256	chr2:237111995	T/C	cg19324714	chr2:237145437	ASB18	0.58	6.05	0.37	5.77e-9	Educational attainment;
SARC	cis	rs926938	0.618	rs360675	chr1:115490918	T/C	cg12756093	chr1:115239321	AMPD1	0.37	4.77	0.3	3.25e-6	Autism;
SARC	cis	rs2011503	1.000	rs7252453	chr19:19654117	G/C	cg03709012	chr19:19516395	GATAD2A	0.62	5.95	0.36	9.57e-9	Bipolar disorder;
SARC	cis	rs9796	0.621	rs12324159	chr15:41462468	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.56	-7.84	-0.46	1.59e-13	Menopause (age at onset);
SARC	cis	rs9487051	0.872	rs9487043	chr6:109610474	C/T	cg01475377	chr6:109611718	NA	-0.4	-5.72	-0.35	3.32e-8	Reticulocyte fraction of red cells;
SARC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.74	0.54	4.92e-19	Prudent dietary pattern;
SARC	cis	rs7666738	0.680	rs34267968	chr4:99002574	A/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.8	7.88	0.46	1.25e-13	Age-related macular degeneration (geographic atrophy);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg21548032	chr12:104850767	CHST11	-0.85	-7.1	-0.42	1.49e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs12586317	0.620	rs17091786	chr14:35565856	A/T	cg16230307	chr14:35515116	FAM177A1	1.0	11.65	0.61	5.12e-25	Psoriasis;
SARC	cis	rs208520	0.690	rs207107	chr6:66794385	T/C	cg07460842	chr6:66804631	NA	-1.08	-15.02	-0.7	4.17e-36	Exhaled nitric oxide output;
SARC	cis	rs3008870	0.958	rs12131222	chr1:67438535	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.89	-11.03	-0.59	4.76e-23	Lymphocyte percentage of white cells;
SARC	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg03433033	chr1:76189801	ACADM	0.55	7.8	0.46	2.04e-13	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs35110281	0.748	rs2838324	chr21:44999820	T/C	cg01579765	chr21:45077557	HSF2BP	-0.35	-5.98	-0.36	8.25e-9	Mean corpuscular volume;
SARC	cis	rs1707322	1.000	rs4454479	chr1:46423555	G/A	cg03146154	chr1:46216737	IPP	0.46	5.5	0.34	9.8e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2228479	0.541	rs9922515	chr16:89954138	G/C	cg12064134	chr16:90016061	DEF8	-0.45	-4.83	-0.3	2.52e-6	Skin colour saturation;
SARC	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.35	4.81	0.3	2.73e-6	Personality dimensions;
SARC	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg22857025	chr5:266934	NA	-1.07	-11.71	-0.61	3.33e-25	Breast cancer;
SARC	cis	rs10754283	0.967	rs7552896	chr1:90103194	A/G	cg21401794	chr1:90099060	LRRC8C	0.6	8.38	0.48	4.89e-15	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs853679	0.585	rs201001	chr6:27808899	T/C	cg17221315	chr6:27791827	HIST1H4J	0.56	5.15	0.32	5.56e-7	Depression;
SARC	cis	rs8078723	1.000	rs56922390	chr17:38157021	C/G	cg17467752	chr17:38218738	THRA	0.46	5.89	0.36	1.31e-8	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg22968622	chr17:43663579	NA	1.23	16.88	0.74	2.8e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs3820928	0.874	rs10210963	chr2:227821845	A/G	cg05526886	chr2:227700861	RHBDD1	-0.54	-6.56	-0.39	3.41e-10	Pulmonary function;
SARC	cis	rs17102884	0.506	rs11845397	chr14:75404587	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.41	-5.45	-0.34	1.25e-7	Neuroticism;
SARC	cis	rs3087591	0.919	rs7406870	chr17:29590617	G/A	cg24425628	chr17:29625626	OMG;NF1	0.57	6.86	0.41	6.06e-11	Hip circumference;
SARC	cis	rs1003719	0.788	rs3787783	chr21:38462959	T/A	cg10648535	chr21:38446584	PIGP;TTC3	0.63	9.05	0.51	5.67e-17	Eye color traits;
SARC	cis	rs6815814	0.799	rs11466640	chr4:38778903	A/G	cg06935464	chr4:38784597	TLR10	-0.63	-5.96	-0.36	9.13e-9	Breast cancer;
SARC	cis	rs7223966	1.000	rs16947005	chr17:61702989	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.51	5.52	0.34	8.97e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9894429	0.789	rs9747336	chr17:79584189	C/T	cg18240062	chr17:79603768	NPLOC4	0.87	13.54	0.66	3.33e-31	Eye color traits;
SARC	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg24829409	chr8:58192753	C8orf71	-0.53	-5.82	-0.36	1.93e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg18758796	chr5:131593413	PDLIM4	0.38	4.93	0.31	1.55e-6	Acylcarnitine levels;
SARC	cis	rs950027	0.967	rs2643718	chr15:45794662	T/C	cg26924012	chr15:45694286	SPATA5L1	0.51	5.74	0.35	2.9e-8	Response to fenofibrate (adiponectin levels);
SARC	cis	rs40363	0.723	rs2379831	chr16:3538927	T/C	cg22508957	chr16:3507546	NAT15	-0.58	-5.01	-0.31	1.06e-6	Tuberculosis;
SARC	cis	rs7829975	0.840	rs555617	chr8:8592845	C/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.28	-0.48	9.44e-15	Mood instability;
SARC	cis	rs7980687	0.657	rs10744151	chr12:123723735	G/C	cg00376283	chr12:123451042	ABCB9	0.56	6.58	0.4	3.1e-10	Height;Educational attainment;Head circumference (infant);
SARC	cis	rs897080	0.552	rs1067374	chr2:44650250	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.54	-6.42	-0.39	7.45e-10	Height;
SARC	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.73	10.4	0.56	4.58e-21	Menarche (age at onset);
SARC	cis	rs2721811	0.738	rs1544366	chr7:24758248	A/G	cg17569154	chr7:24781545	DFNA5	0.44	6.29	0.38	1.58e-9	Depressive symptoms (multi-trait analysis);
SARC	cis	rs796364	0.806	rs34582889	chr2:201010527	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.66	-6.39	-0.39	8.99e-10	Schizophrenia;
SARC	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg17221315	chr6:27791827	HIST1H4J	0.43	4.85	0.3	2.29e-6	Parkinson's disease;
SARC	cis	rs3812049	0.532	rs251390	chr5:127538346	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	7.71	0.45	3.66e-13	Lymphocyte counts;Red cell distribution width;
SARC	cis	rs1348850	0.958	rs4243390	chr2:178468008	G/A	cg23306229	chr2:178417860	TTC30B	0.53	6.1	0.37	4.35e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2228479	1.000	rs11642267	chr16:89957635	T/C	cg06558623	chr16:89946397	TCF25	0.89	6.28	0.38	1.67e-9	Skin colour saturation;
SARC	cis	rs713477	1.000	rs12887846	chr14:55911139	T/C	cg13175173	chr14:55914753	NA	-0.3	-4.74	-0.3	3.66e-6	Pediatric bone mineral content (femoral neck);
SARC	cis	rs4969178	0.896	rs11077361	chr17:76397128	A/G	cg20026190	chr17:76395443	PGS1	0.4	5.37	0.33	1.94e-7	HDL cholesterol levels;
SARC	cis	rs7772486	0.790	rs6926657	chr6:146255794	G/A	cg23711669	chr6:146136114	FBXO30	-0.8	-12.46	-0.63	1.2100000000000001e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9467711	0.651	rs35402046	chr6:26099472	G/A	cg21479132	chr6:26055353	NA	0.92	7.01	0.42	2.55e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg03354898	chr7:1950403	MAD1L1	-0.39	-5.23	-0.32	3.73e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs9916302	0.706	rs801418	chr17:37457982	G/C	cg07936489	chr17:37558343	FBXL20	0.75	8.92	0.5	1.37e-16	Glomerular filtration rate (creatinine);
SARC	trans	rs12310956	0.532	rs1852226	chr12:33962940	G/A	cg13010199	chr12:38710504	ALG10B	0.65	8.61	0.49	1.11e-15	Morning vs. evening chronotype;
SARC	cis	rs9325144	0.513	rs12313652	chr12:38665412	G/A	cg13010199	chr12:38710504	ALG10B	-0.56	-6.97	-0.42	3.3e-11	Morning vs. evening chronotype;
SARC	cis	rs16866061	0.926	rs1523919	chr2:225403615	G/A	cg12698349	chr2:225449008	CUL3	0.69	9.54	0.53	2.03e-18	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.63e-10	Life satisfaction;
SARC	trans	rs17685	0.753	rs1574107	chr7:75685047	A/C	cg19862616	chr7:65841803	NCRNA00174	0.62	7.7	0.45	3.85e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	trans	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.61	-7.53	-0.44	1.11e-12	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs826838	0.806	rs826873	chr12:39121305	G/A	cg13010199	chr12:38710504	ALG10B	-0.7	-9.83	-0.54	2.63e-19	Heart rate;
SARC	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.41	-6.84	-0.41	6.94e-11	Total body bone mineral density;
SARC	cis	rs11690935	0.595	rs788170	chr2:172919958	T/C	cg13550731	chr2:172543902	DYNC1I2	0.67	9.49	0.53	2.84e-18	Schizophrenia;
SARC	cis	rs11249608	0.548	rs6859936	chr5:178451214	T/C	cg21905437	chr5:178450457	ZNF879	0.58	7.92	0.46	9.53e-14	Pubertal anthropometrics;
SARC	cis	rs921968	0.643	rs833083	chr2:219336959	A/T	cg02176678	chr2:219576539	TTLL4	-0.41	-6.22	-0.38	2.33e-9	Mean corpuscular hemoglobin concentration;
SARC	trans	rs11098499	0.909	rs9759478	chr4:120367998	G/A	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	cis	rs7551222	0.752	rs10793767	chr1:204549564	A/C	cg20240347	chr1:204465584	NA	-0.33	-5.78	-0.35	2.42e-8	Schizophrenia;
SARC	cis	rs505401	0.667	rs78148525	chr19:6088005	T/G	cg18109231	chr19:6110877	RFX2	0.68	4.77	0.3	3.18e-6	Mean platelet volume;
SARC	cis	rs11697848	1.000	rs78700554	chr20:48522124	T/G	cg17849948	chr20:48532315	SPATA2	0.86	5.17	0.32	4.97e-7	Systemic lupus erythematosus;
SARC	cis	rs9894429	1.000	rs4074916	chr17:79579248	G/A	cg18240062	chr17:79603768	NPLOC4	-0.71	-9.81	-0.54	3.03e-19	Eye color traits;
SARC	cis	rs4481887	0.927	rs12744455	chr1:248479960	A/G	cg01631408	chr1:248437212	OR2T33	-0.38	-4.81	-0.3	2.73e-6	Common traits (Other);
SARC	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs10782582	0.593	rs6664254	chr1:76235084	G/T	cg03433033	chr1:76189801	ACADM	-0.43	-5.39	-0.33	1.74e-7	Daytime sleep phenotypes;
SARC	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg13877915	chr19:58951672	ZNF132	0.66	9.97	0.55	9.64e-20	Uric acid clearance;
SARC	cis	rs4268898	0.679	rs2543666	chr2:24446042	C/T	cg06627628	chr2:24431161	ITSN2	0.67	8.21	0.47	1.51e-14	Asthma;
SARC	cis	rs7465272	0.957	rs11994668	chr8:143687392	G/T	cg24634471	chr8:143751801	JRK	0.58	6.27	0.38	1.71e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs6701037	0.566	rs729675	chr1:175136946	T/C	cg00321850	chr1:175162397	KIAA0040	0.38	5.92	0.36	1.13e-8	Alcohol dependence;
SARC	cis	rs73086581	1.000	rs73086510	chr20:3922131	T/C	cg02187196	chr20:3869020	PANK2	0.66	6.36	0.38	1.03e-9	Response to antidepressants in depression;
SARC	cis	rs7044106	1.000	rs7044106	chr9:123494062	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.59	6.59	0.4	2.89e-10	Hip circumference adjusted for BMI;
SARC	cis	rs12586317	0.547	rs28589276	chr14:35478865	A/G	cg16230307	chr14:35515116	FAM177A1	1.02	11.85	0.61	1.18e-25	Psoriasis;
SARC	cis	rs79149102	0.579	rs74023936	chr15:75362084	C/T	cg09165964	chr15:75287851	SCAMP5	-0.9	-8.18	-0.47	1.84e-14	Lung cancer;
SARC	cis	rs4901847	0.967	rs6573188	chr14:58549613	C/G	cg15908186	chr14:58618357	C14orf37	0.44	5.07	0.32	8.09e-7	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs6752107	0.791	rs3792106	chr2:234190740	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.41	5.13	0.32	5.99e-7	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs1395	0.710	rs11674947	chr2:27471996	A/G	cg21747090	chr2:27597821	SNX17	-0.46	-5.62	-0.35	5.55e-8	Blood metabolite levels;
SARC	cis	rs41307935	0.822	rs71636786	chr1:27177925	T/A	cg14665203	chr1:27337923	FAM46B	0.63	4.75	0.3	3.62e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs8114671	0.562	rs2223881	chr20:33506463	A/C	cg24642439	chr20:33292090	TP53INP2	0.47	5.61	0.35	5.66e-8	Height;
SARC	cis	rs4356932	1.000	rs4422436	chr4:76977784	A/G	cg24176760	chr4:76958061	ART3;CXCL11	-0.29	-4.8	-0.3	2.79e-6	Blood protein levels;
SARC	cis	rs2429369	0.528	rs2526376	chr17:56427142	A/C	cg12560992	chr17:57184187	TRIM37	0.58	6.86	0.41	6.23e-11	Cognitive function;
SARC	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg03806693	chr22:41940476	POLR3H	-1.01	-13.99	-0.68	1.08e-32	Vitiligo;
SARC	cis	rs41271473	1.000	rs4993975	chr1:228878669	A/C	cg16512390	chr1:228756714	NA	0.49	4.92	0.31	1.66e-6	Chronic lymphocytic leukemia;
SARC	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg07701084	chr6:150067640	NUP43	0.39	5.27	0.33	3.15e-7	Lung cancer;
SARC	cis	rs8077889	0.750	rs72836564	chr17:41935064	G/A	cg26893861	chr17:41843967	DUSP3	0.75	7.18	0.43	9.48e-12	Triglycerides;
SARC	cis	rs11098499	0.954	rs67265404	chr4:120359270	C/T	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.62	-6.04	-0.37	6.16e-9	Lung function (FEV1/FVC);
SARC	cis	rs4566357	0.787	rs6748048	chr2:227822440	T/C	cg11843606	chr2:227700838	RHBDD1	-0.49	-5.95	-0.36	9.93e-9	Coronary artery disease;
SARC	cis	rs11585357	0.895	rs72633803	chr1:17616758	G/A	cg08277548	chr1:17600880	PADI3	-0.49	-5.48	-0.34	1.11e-7	Hair shape;
SARC	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.5	5.96	0.36	9.48e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs838147	0.507	rs692854	chr19:49209464	C/A	cg07051648	chr19:49177693	NTN5;SEC1	-0.41	-5.3	-0.33	2.64e-7	Dietary macronutrient intake;
SARC	cis	rs4780401	0.782	rs933573	chr16:11793395	A/G	cg01061890	chr16:11836724	TXNDC11	0.47	6.4	0.39	8.42e-10	Rheumatoid arthritis;
SARC	cis	rs2576037	0.899	rs2576035	chr18:44587654	C/T	cg19077165	chr18:44547161	KATNAL2	0.49	6.75	0.4	1.18e-10	Personality dimensions;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg13389213	chr19:58838502	ZSCAN22	0.55	7.15	0.42	1.09e-11	Lung adenocarcinoma;
SARC	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg20891283	chr12:69753455	YEATS4	0.54	7.43	0.44	2.09e-12	Blood protein levels;
SARC	cis	rs208520	0.526	rs9354366	chr6:66788559	C/T	cg07460842	chr6:66804631	NA	-1.12	-22.84	-0.83	2.24e-61	Exhaled nitric oxide output;
SARC	cis	rs7917772	0.636	rs1475644	chr10:104491164	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.59	6.98	0.42	3.1e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	trans	rs1814175	0.645	rs7928714	chr11:49887622	G/A	cg03929089	chr4:120376271	NA	-0.83	-12.22	-0.62	7.28e-27	Height;
SARC	cis	rs694739	0.628	rs538147	chr11:64129722	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.66	7.52	0.44	1.15e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs763121	0.853	rs4821798	chr22:39021165	T/C	cg21395723	chr22:39101663	GTPBP1	0.59	7.12	0.42	1.3e-11	Menopause (age at onset);
SARC	cis	rs7184046	0.797	rs13737	chr15:75932129	G/T	cg20655648	chr15:75932815	IMP3	0.67	8.09	0.47	3.37e-14	Height;
SARC	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.39	5.38	0.33	1.85e-7	Personality dimensions;
SARC	cis	rs6426558	0.537	rs4500279	chr1:227484482	G/A	cg10327440	chr1:227177885	CDC42BPA	0.46	5.46	0.34	1.2e-7	Neutrophil percentage of white cells;
SARC	cis	rs920590	0.704	rs7008703	chr8:19656648	C/T	cg03894339	chr8:19674705	INTS10	0.42	5.31	0.33	2.58e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-10.5	-0.57	2.35e-21	Chronic sinus infection;
SARC	cis	rs2273669	0.588	rs12205061	chr6:109338161	T/C	cg05315195	chr6:109294784	ARMC2	-0.63	-5.7	-0.35	3.6e-8	Prostate cancer;
SARC	cis	rs995000	0.931	rs638714	chr1:62906489	G/T	cg06896770	chr1:63153194	DOCK7	0.85	12.1	0.62	1.82e-26	Triglyceride levels;
SARC	cis	rs27434	0.583	rs151909	chr5:96156888	T/C	cg16492584	chr5:96139282	ERAP1	-0.57	-7.1	-0.42	1.49e-11	Ankylosing spondylitis;
SARC	cis	rs9640161	0.789	rs28432021	chr7:150046235	G/C	cg17279839	chr7:150038598	RARRES2	0.42	6.1	0.37	4.4e-9	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg11266682	chr4:10021025	SLC2A9	0.42	7.53	0.44	1.09e-12	Bone mineral density;
SARC	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg13206674	chr6:150067644	NUP43	0.42	5.47	0.34	1.17e-7	Lung cancer;
SARC	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg11987759	chr7:65425863	GUSB	0.58	7.61	0.45	6.82e-13	Aortic root size;
SARC	cis	rs17345786	0.798	rs9817043	chr3:101281852	A/G	cg12386194	chr3:101231763	SENP7	0.59	7.16	0.42	1.06e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg22496380	chr5:211416	CCDC127	0.75	7.77	0.45	2.51e-13	Breast cancer;
SARC	cis	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg07777115	chr5:623756	CEP72	-0.6	-5.74	-0.35	3e-8	Obesity-related traits;
SARC	cis	rs4595586	0.655	rs7953715	chr12:39325539	T/C	cg26384229	chr12:38710491	ALG10B	0.41	5.15	0.32	5.61e-7	Morning vs. evening chronotype;
SARC	cis	rs41271473	1.000	rs11583565	chr1:228880135	C/T	cg10167378	chr1:228756711	NA	0.48	4.9	0.31	1.76e-6	Chronic lymphocytic leukemia;
SARC	cis	rs7084402	0.967	rs1303970	chr10:60298477	G/T	cg07615347	chr10:60278583	BICC1	0.6	8.66	0.49	7.72e-16	Refractive error;
SARC	cis	rs9325144	0.723	rs11169482	chr12:39164327	A/T	cg26384229	chr12:38710491	ALG10B	0.6	7.36	0.43	3.08e-12	Morning vs. evening chronotype;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg25270632	chr7:43751042	C7orf44	-0.48	-6.31	-0.38	1.39e-9	Electrocardiographic conduction measures;
SARC	cis	rs6964587	0.773	rs12740	chr7:92029302	A/G	cg17063962	chr7:91808500	NA	0.87	12.15	0.62	1.2e-26	Breast cancer;
SARC	cis	rs523522	0.847	rs11065132	chr12:120908459	C/T	cg27279351	chr12:120934652	DYNLL1	0.7	8.44	0.48	3.44e-15	High light scatter reticulocyte count;
SARC	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs9300255	0.507	rs1615350	chr12:123650335	C/T	cg05973401	chr12:123451056	ABCB9	0.57	6.69	0.4	1.66e-10	Neutrophil percentage of white cells;
SARC	trans	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg06437703	chr8:37914619	EIF4EBP1	-0.61	-7.62	-0.45	6.32e-13	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs360798	0.512	rs2058566	chr2:63179076	C/T	cg17519650	chr2:63277830	OTX1	0.4	5.0	0.31	1.14e-6	Coronary artery disease;
SARC	cis	rs14978	1.000	rs12699336	chr7:12283250	T/A	cg23422036	chr7:12250390	TMEM106B	0.44	5.32	0.33	2.49e-7	Response to amphetamines;
SARC	cis	rs6690583	0.573	rs7547317	chr1:85456961	T/G	cg22153463	chr1:85462885	MCOLN2	0.75	6.45	0.39	6.42e-10	Serum sulfate level;
SARC	cis	rs11122272	0.668	rs2790874	chr1:231537988	A/G	cg06096015	chr1:231504339	EGLN1	0.39	5.73	0.35	3.13e-8	Hemoglobin concentration;
SARC	cis	rs11601602	0.576	rs12576396	chr11:28555952	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.64	7.63	0.45	6.15e-13	Obesity-related traits;
SARC	cis	rs17376456	0.877	rs2290937	chr5:93356515	A/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.65	5.91	0.36	1.18e-8	Diabetic retinopathy;
SARC	cis	rs4128725	1.000	rs10908716	chr1:159376343	A/G	cg25076881	chr1:159409836	OR10J1	0.4	4.78	0.3	3.16e-6	Select biomarker traits;
SARC	cis	rs959260	1.000	rs4788889	chr17:73389126	A/G	cg14668889	chr17:73230827	NUP85	-0.43	-4.74	-0.3	3.7e-6	Systemic lupus erythematosus;
SARC	cis	rs2075371	0.796	rs10954440	chr7:134005657	C/T	cg00033643	chr7:134001901	SLC35B4	0.47	5.66	0.35	4.48e-8	Mean platelet volume;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg16642003	chr16:30456845	SEPHS2	0.48	6.56	0.39	3.41e-10	Thyroid stimulating hormone;
SARC	trans	rs11098499	0.863	rs10030660	chr4:120436704	G/A	cg25214090	chr10:38739885	LOC399744	0.57	7.35	0.43	3.31e-12	Corneal astigmatism;
SARC	cis	rs1957429	0.808	rs7144718	chr14:65333831	G/A	cg23373153	chr14:65346875	NA	0.96	10.11	0.55	3.79e-20	Pediatric areal bone mineral density (radius);
SARC	cis	rs9309473	0.607	rs2421488	chr2:73590625	C/T	cg20560298	chr2:73613845	ALMS1	-0.57	-7.09	-0.42	1.57e-11	Metabolite levels;
SARC	cis	rs9457247	1.000	rs376551	chr6:167384923	G/A	cg23791538	chr6:167370224	RNASET2	-0.63	-8.74	-0.5	4.74e-16	Crohn's disease;
SARC	cis	rs710865	0.723	rs710870	chr1:19549759	G/A	cg13387374	chr1:19411106	UBR4	0.5	6.39	0.39	8.97e-10	Brain structure;
SARC	cis	rs11626933	0.885	rs28517514	chr14:90788709	G/A	cg14092571	chr14:90743983	NA	-0.58	-8.74	-0.5	4.83e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs17539620	0.624	rs12665520	chr6:154835273	C/T	cg20019720	chr6:154832845	CNKSR3	0.41	4.74	0.3	3.71e-6	Lipoprotein (a) levels;
SARC	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs861020	0.606	rs695140	chr1:210005061	G/A	cg23166289	chr1:210001082	C1orf107	0.39	4.74	0.3	3.66e-6	Orofacial clefts;
SARC	cis	rs10483282	1.000	rs6573383	chr14:24254337	C/T	cg02879798	chr14:24800305	ADCY4	-0.33	-5.07	-0.32	7.96e-7	Alcohol dependence;
SARC	cis	rs5167	0.566	rs60876330	chr19:45488133	C/T	cg09555818	chr19:45449301	APOC2	0.39	5.17	0.32	5.11e-7	Blood protein levels;
SARC	cis	rs1957429	0.808	rs11158564	chr14:65335082	G/A	cg23373153	chr14:65346875	NA	0.96	10.11	0.55	3.79e-20	Pediatric areal bone mineral density (radius);
SARC	cis	rs2916247	0.954	rs2996056	chr8:93180247	A/C	cg10183463	chr8:93005414	RUNX1T1	0.49	5.18	0.32	4.85e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg11203670	chr7:100026453	MEPCE;ZCWPW1	0.49	4.83	0.3	2.48e-6	Platelet count;
SARC	cis	rs67460515	0.563	rs4494975	chr3:160866768	C/T	cg03342759	chr3:160939853	NMD3	-0.62	-7.63	-0.45	6.11e-13	Parkinson's disease;
SARC	cis	rs13401104	0.796	rs72620803	chr2:237110460	T/C	cg19324714	chr2:237145437	ASB18	0.57	5.6	0.34	5.92e-8	Educational attainment;
SARC	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg22549504	chr19:17448937	GTPBP3	0.48	4.92	0.31	1.6e-6	Systemic lupus erythematosus;
SARC	cis	rs1707322	1.000	rs4660889	chr1:46297331	C/T	cg03146154	chr1:46216737	IPP	0.47	5.65	0.35	4.76e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg21747090	chr2:27597821	SNX17	0.56	7.84	0.46	1.56e-13	Total body bone mineral density;
SARC	cis	rs2153535	0.601	rs2143353	chr6:8530111	T/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.31	0.48	8.11e-15	Motion sickness;
SARC	cis	rs2991971	0.810	rs12119202	chr1:45925931	A/T	cg05343316	chr1:45956843	TESK2	0.41	5.02	0.31	1.01e-6	High light scatter reticulocyte count;
SARC	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	6.7	0.4	1.53e-10	Platelet count;
SARC	cis	rs861020	0.630	rs686582	chr1:210008673	A/C	cg05527609	chr1:210001259	C1orf107	0.76	9.77	0.54	4.08e-19	Orofacial clefts;
SARC	cis	rs1008375	0.618	rs6842764	chr4:17568420	C/T	cg27347728	chr4:17578864	LAP3	-0.52	-6.06	-0.37	5.48e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs12709013	0.636	rs257627	chr16:58792860	G/A	cg04273148	chr16:57808038	KIFC3	0.32	4.72	0.3	4.08e-6	Blood metabolite ratios;
SARC	cis	rs796364	1.000	rs4410273	chr2:200818258	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.77	7.01	0.42	2.61e-11	Schizophrenia;
SARC	cis	rs2486288	0.656	rs11632419	chr15:45557456	C/A	cg15395560	chr15:45543142	SLC28A2	0.29	5.68	0.35	3.91e-8	Glomerular filtration rate;
SARC	cis	rs12541335	0.615	rs4872464	chr8:22153381	G/A	cg26039829	chr8:22132926	PIWIL2	0.46	6.46	0.39	5.93e-10	Hypertriglyceridemia;
SARC	cis	rs4595586	0.545	rs12831116	chr12:39401456	C/T	cg26384229	chr12:38710491	ALG10B	0.53	6.18	0.38	2.8e-9	Morning vs. evening chronotype;
SARC	cis	rs7312933	0.558	rs1796394	chr12:42826359	G/A	cg19980929	chr12:42632907	YAF2	-0.44	-6.5	-0.39	4.74e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs58688157	0.883	rs34793529	chr11:575800	T/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.51	-6.2	-0.38	2.53e-9	Systemic lupus erythematosus;
SARC	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg16479474	chr6:28041457	NA	0.37	5.25	0.33	3.45e-7	Parkinson's disease;
SARC	cis	rs2710642	0.888	rs13418889	chr2:63079775	T/C	cg17519650	chr2:63277830	OTX1	0.37	4.75	0.3	3.6e-6	LDL cholesterol levels;LDL cholesterol;
SARC	cis	rs2354432	0.556	rs11239965	chr1:146753907	C/A	cg25205988	chr1:146714368	CHD1L	-1.0	-7.56	-0.44	9.4e-13	Mitochondrial DNA levels;
SARC	cis	rs10463554	0.963	rs26816	chr5:102540522	C/T	cg23492399	chr5:102201601	PAM	-0.45	-4.99	-0.31	1.18e-6	Parkinson's disease;
SARC	cis	rs12291225	0.645	rs3763950	chr11:14278049	T/A	cg19336497	chr11:14380999	RRAS2	-0.41	-6.88	-0.41	5.48e-11	Sense of smell;
SARC	cis	rs79149102	0.579	rs73436579	chr15:75294514	C/T	cg17294928	chr15:75287854	SCAMP5	-0.99	-8.87	-0.5	1.91e-16	Lung cancer;
SARC	cis	rs2732480	0.557	rs923397	chr12:48720392	G/A	cg21466736	chr12:48725269	NA	-0.31	-4.83	-0.3	2.45e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg14893161	chr1:205819251	PM20D1	0.93	15.81	0.72	9.92e-39	Menarche (age at onset);
SARC	cis	rs7647973	1.000	rs62261249	chr3:49594060	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.58	-5.71	-0.35	3.47e-8	Menarche (age at onset);
SARC	cis	rs2439831	0.867	rs3809481	chr15:43662829	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.0	9.76	0.54	4.32e-19	Lung cancer in ever smokers;
SARC	cis	rs2033732	0.706	rs6473527	chr8:85070610	C/T	cg05716166	chr8:85095498	RALYL	0.47	5.64	0.35	4.83e-8	Body mass index;
SARC	cis	rs6060960	0.537	rs6089119	chr20:30514161	T/G	cg13852791	chr20:30311386	BCL2L1	0.64	5.81	0.36	2.04e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
SARC	cis	rs9916302	0.800	rs9892675	chr17:37549200	C/T	cg00129232	chr17:37814104	STARD3	0.54	6.06	0.37	5.49e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	13.66	0.67	1.39e-31	Chronic sinus infection;
SARC	cis	rs981844	0.775	rs17371274	chr4:154738713	A/G	cg14289246	chr4:154710475	SFRP2	0.57	6.1	0.37	4.47e-9	Response to statins (LDL cholesterol change);
SARC	trans	rs656319	0.607	rs35437983	chr8:10005053	C/T	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.15	-0.47	2.24e-14	Myopia (pathological);
SARC	cis	rs9296092	0.517	rs7743064	chr6:33470529	C/T	cg13560919	chr6:33536144	NA	-0.44	-5.07	-0.32	8.23e-7	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg25072359	chr17:41440525	NA	0.52	6.17	0.37	3.07e-9	Menopause (age at onset);
SARC	trans	rs36093844	0.706	rs116940726	chr11:85584052	A/C	cg15359163	chr5:122429178	PRDM6	-0.53	-6.33	-0.38	1.28e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs1707322	1.000	rs2458400	chr1:46530798	C/T	cg06784218	chr1:46089804	CCDC17	-0.37	-6.42	-0.39	7.43e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs965469	0.895	rs6051839	chr20:3391191	C/T	cg25506879	chr20:3388711	C20orf194	0.46	4.94	0.31	1.48e-6	IFN-related cytopenia;
SARC	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg02788857	chr8:22132959	PIWIL2	0.35	4.95	0.31	1.43e-6	Hypertriglyceridemia;
SARC	cis	rs2327429	0.858	rs13218281	chr6:134193714	T/G	cg25632230	chr6:134101081	NA	-0.46	-5.5	-0.34	9.97e-8	Coronary artery disease;
SARC	cis	rs4243830	0.737	rs11581831	chr1:6609958	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.87	-8.42	-0.48	3.98e-15	Body mass index;
SARC	cis	rs7945705	0.875	rs2568065	chr11:8889648	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.47	-6.85	-0.41	6.48e-11	Hemoglobin concentration;
SARC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.45	0.56	3.24e-21	Prudent dietary pattern;
SARC	cis	rs9325144	0.723	rs10161183	chr12:39182087	T/C	cg26384229	chr12:38710491	ALG10B	-0.61	-7.5	-0.44	1.31e-12	Morning vs. evening chronotype;
SARC	cis	rs651907	0.557	rs11720745	chr3:101441690	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	6.39	0.39	8.85e-10	Colorectal cancer;
SARC	cis	rs897984	0.683	rs8050330	chr16:30824970	C/T	cg02466173	chr16:30829666	NA	-0.54	-7.61	-0.45	6.82e-13	Dementia with Lewy bodies;
SARC	cis	rs66887589	0.748	rs28439855	chr4:120262256	G/A	cg09307838	chr4:120376055	NA	0.53	7.15	0.42	1.09e-11	Diastolic blood pressure;
SARC	cis	rs7931462	0.655	rs6483208	chr11:92705844	A/C	cg06762969	chr11:93474102	C11orf54;TAF1D	0.72	5.55	0.34	7.68e-8	DNA methylation (parent-of-origin);
SARC	cis	rs9926296	0.715	rs467035	chr16:89740285	C/G	cg04287289	chr16:89883240	FANCA	0.47	5.73	0.35	3.03e-8	Vitiligo;
SARC	cis	rs11098499	0.863	rs11947234	chr4:120474859	A/G	cg09307838	chr4:120376055	NA	0.91	12.25	0.63	5.66e-27	Corneal astigmatism;
SARC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg11494091	chr17:61959527	GH2	0.53	7.94	0.46	8.65e-14	Prudent dietary pattern;
SARC	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg18252515	chr7:66147081	NA	0.52	5.57	0.34	6.9e-8	Aortic root size;
SARC	cis	rs11621710	0.798	rs10132769	chr14:35576458	A/C	cg16230307	chr14:35515116	FAM177A1	0.5	6.07	0.37	5.2e-9	Granulocyte percentage of myeloid white cells;
SARC	cis	rs11785693	0.862	rs11774126	chr8:4979583	A/C	cg26367366	chr8:4980734	NA	0.69	6.19	0.38	2.75e-9	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs7264396	0.690	rs2425165	chr20:34438059	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-7.07	-0.42	1.76e-11	Total cholesterol levels;
SARC	cis	rs2933343	0.700	rs789239	chr3:128633808	T/C	cg24203234	chr3:128598194	ACAD9	0.63	8.01	0.46	5.49e-14	IgG glycosylation;
SARC	cis	rs208520	1.000	rs12216109	chr6:66987488	C/G	cg07460842	chr6:66804631	NA	0.9	10.32	0.56	8.16e-21	Exhaled nitric oxide output;
SARC	cis	rs897080	0.552	rs1067318	chr2:44634509	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.7	0.4	1.59e-10	Height;
SARC	cis	rs4642101	0.597	rs12638595	chr3:12819281	T/C	cg05775895	chr3:12838266	CAND2	0.81	15.09	0.7	2.45e-36	QRS complex (12-leadsum);
SARC	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg03060546	chr3:49711283	APEH	0.42	5.31	0.33	2.5e-7	Parkinson's disease;
SARC	cis	rs6570726	0.846	rs6919684	chr6:145883801	A/G	cg23711669	chr6:146136114	FBXO30	0.8	13.05	0.65	1.36e-29	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs875971	1.000	rs1144895	chr7:65541307	C/G	cg12463550	chr7:65579703	CRCP	-0.48	-5.67	-0.35	4.28e-8	Aortic root size;
SARC	cis	rs7615952	0.546	rs2922171	chr3:125343193	C/T	cg05084668	chr3:125655381	ALG1L	-0.53	-5.01	-0.31	1.1e-6	Blood pressure (smoking interaction);
SARC	cis	rs12711979	0.509	rs10178286	chr2:3823821	A/G	cg17052675	chr2:3827356	NA	0.49	7.02	0.42	2.43e-11	Itch intensity from mosquito bite adjusted by bite size;
SARC	cis	rs7412746	0.587	rs3849279	chr1:150944707	T/C	cg13175981	chr1:150552382	MCL1	-0.53	-6.41	-0.39	7.98e-10	Melanoma;
SARC	cis	rs3008870	0.755	rs1570838	chr1:67403315	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.59	7.54	0.44	1.07e-12	Lymphocyte percentage of white cells;
SARC	cis	rs6582630	0.519	rs11519914	chr12:38287014	A/G	cg26384229	chr12:38710491	ALG10B	0.86	12.4	0.63	1.85e-27	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs11098499	0.954	rs7681544	chr4:120411255	T/C	cg24375607	chr4:120327624	NA	0.41	4.86	0.3	2.12e-6	Corneal astigmatism;
SARC	cis	rs898097	0.691	rs7222773	chr17:80907283	A/G	cg02711726	chr17:80685570	FN3KRP	-0.37	-4.96	-0.31	1.34e-6	Breast cancer;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg09114546	chr16:70099078	PDXDC2	0.49	6.24	0.38	2.08e-9	Lung adenocarcinoma;
SARC	cis	rs2204008	0.623	rs4882302	chr12:38415608	T/A	cg14851346	chr12:38532713	NA	-0.47	-5.66	-0.35	4.49e-8	Bladder cancer;
SARC	cis	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg06636001	chr8:8085503	FLJ10661	0.54	7.28	0.43	5.19e-12	Joint mobility (Beighton score);
SARC	cis	rs644799	0.509	rs580181	chr11:95643040	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	9.92	0.54	1.43e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs765787	0.530	rs2554455	chr15:45521304	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.41	-5.08	-0.32	7.58e-7	Uric acid levels;
SARC	cis	rs9296092	0.538	rs62407567	chr6:33537213	A/G	cg13560919	chr6:33536144	NA	-0.46	-5.04	-0.31	9.55e-7	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs1949733	1.000	rs2140337	chr4:8502112	A/G	cg11789530	chr4:8429930	ACOX3	0.83	11.23	0.59	1.15e-23	Response to antineoplastic agents;
SARC	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg12463550	chr7:65579703	CRCP	-0.48	-5.71	-0.35	3.43e-8	Aortic root size;
SARC	cis	rs3008870	0.755	rs1024230	chr1:67512920	A/C	cg02640540	chr1:67518911	SLC35D1	0.61	7.69	0.45	4.01e-13	Lymphocyte percentage of white cells;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg06312003	chr17:26662584	IFT20;TNFAIP1	0.62	6.52	0.39	4.24e-10	Lung cancer in ever smokers;
SARC	cis	rs2011503	0.943	rs756997	chr19:19467085	G/C	cg03709012	chr19:19516395	GATAD2A	-0.67	-5.81	-0.36	2.04e-8	Bipolar disorder;
SARC	cis	rs9840812	0.861	rs1153871	chr3:135954599	T/C	cg15507776	chr3:136538369	TMEM22	0.49	5.31	0.33	2.5e-7	Fibrinogen levels;
SARC	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg26335602	chr6:28129616	ZNF389	0.47	5.41	0.33	1.55e-7	Cardiac Troponin-T levels;
SARC	cis	rs9916302	0.706	rs903507	chr17:37726423	A/G	cg20243544	chr17:37824526	PNMT	0.54	5.52	0.34	9.13e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs6060717	0.536	rs6058356	chr20:34491530	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-6.05	-0.37	5.71e-9	Hip circumference adjusted for BMI;
SARC	cis	rs28829049	0.535	rs12565185	chr1:19498309	G/A	cg13387374	chr1:19411106	UBR4	0.45	5.29	0.33	2.88e-7	QRS duration in Tripanosoma cruzi seropositivity;
SARC	cis	rs10875746	0.859	rs4760622	chr12:48591960	C/A	cg27446233	chr12:48516484	PFKM	-0.39	-4.72	-0.3	4.06e-6	Longevity (90 years and older);
SARC	cis	rs854765	0.583	rs7214536	chr17:17852446	G/A	cg05444541	chr17:17804740	TOM1L2	-0.29	-4.82	-0.3	2.56e-6	Total body bone mineral density;
SARC	cis	rs6700896	0.898	rs1938495	chr1:66106469	A/G	cg04111102	chr1:66153794	NA	0.35	5.52	0.34	9.17e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs986417	1.000	rs1955699	chr14:61045989	A/G	cg27398547	chr14:60952738	C14orf39	0.96	8.35	0.48	6.27e-15	Gut microbiota (bacterial taxa);
SARC	cis	rs35213789	0.821	rs674865	chr7:69166762	G/A	cg10619644	chr7:69149951	AUTS2	-0.44	-5.89	-0.36	1.35e-8	Childhood ear infection;
SARC	cis	rs113835537	0.529	rs2305533	chr11:66298623	A/C	cg24851651	chr11:66362959	CCS	0.38	4.78	0.3	3.11e-6	Airway imaging phenotypes;
SARC	trans	rs1814175	0.765	rs1722003	chr11:49895896	G/A	cg15704280	chr7:45808275	SEPT13	-0.97	-18.17	-0.77	1.53e-46	Height;
SARC	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg21747090	chr2:27597821	SNX17	-0.56	-7.82	-0.46	1.77e-13	Total body bone mineral density;
SARC	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.42	-0.44	2.12e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg00149659	chr3:10157352	C3orf10	0.68	6.38	0.39	9.46e-10	Alzheimer's disease;
SARC	cis	rs4481887	1.000	rs4916125	chr1:248466583	A/T	cg00666640	chr1:248458726	OR2T12	0.37	6.3	0.38	1.43e-9	Common traits (Other);
SARC	cis	rs4642101	0.793	rs3889513	chr3:12844070	G/A	cg05775895	chr3:12838266	CAND2	0.74	12.05	0.62	2.69e-26	QRS complex (12-leadsum);
SARC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	20.48	0.8	5.33e-54	Prudent dietary pattern;
SARC	cis	rs2439831	0.867	rs2264876	chr15:43757419	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	8.4	0.48	4.54e-15	Lung cancer in ever smokers;
SARC	cis	rs2200578	0.786	rs62158261	chr2:99563210	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	0.63	5.79	0.35	2.28e-8	IgG glycosylation;
SARC	cis	rs600231	0.623	rs587080	chr11:65253800	A/C	cg17120908	chr11:65337727	SSSCA1	-0.42	-5.47	-0.34	1.14e-7	Bone mineral density;
SARC	cis	rs2439831	1.000	rs2253708	chr15:43797273	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.12	11.16	0.59	1.93e-23	Lung cancer in ever smokers;
SARC	cis	rs7296418	0.961	rs4148862	chr12:123568619	A/C	cg05973401	chr12:123451056	ABCB9	0.53	6.17	0.37	3.02e-9	Platelet count;
SARC	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg18876405	chr7:65276391	NA	-0.46	-5.51	-0.34	9.4e-8	Aortic root size;
SARC	cis	rs7561149	1.000	rs7561149	chr2:179689856	T/C	cg17765952	chr2:179737173	CCDC141	-0.39	-5.15	-0.32	5.62e-7	QT interval;
SARC	cis	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.57	8.97	0.51	9.82e-17	Eosinophil percentage of white cells;
SARC	cis	rs17376456	0.877	rs10055741	chr5:93297187	C/T	cg21475434	chr5:93447410	FAM172A	0.84	7.56	0.44	9.44e-13	Diabetic retinopathy;
SARC	cis	rs2832191	0.692	rs8134627	chr21:30349069	C/T	cg24692254	chr21:30365293	RNF160	-1.03	-18.71	-0.77	2.65e-48	Dental caries;
SARC	cis	rs2191566	0.960	rs367209	chr19:44506249	A/G	cg20607764	chr19:44506953	ZNF230	0.53	6.26	0.38	1.86e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9420	0.922	rs35808061	chr11:57547000	T/C	cg23127183	chr11:57508653	C11orf31	-0.6	-6.86	-0.41	6.03e-11	Schizophrenia;
SARC	cis	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg05623727	chr3:50126028	RBM5	0.36	5.41	0.33	1.54e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7870753	0.838	rs10820666	chr9:99234997	G/T	cg25260653	chr9:99212216	HABP4	0.51	4.77	0.3	3.21e-6	Height;
SARC	cis	rs2120019	0.938	rs2304903	chr15:75315778	A/G	cg00629941	chr15:75287862	SCAMP5	-0.7	-8.35	-0.48	5.97e-15	Blood trace element (Zn levels);
SARC	cis	rs8028182	0.636	rs4322627	chr15:75810659	C/T	cg20655648	chr15:75932815	IMP3	0.64	7.42	0.44	2.22e-12	Sudden cardiac arrest;
SARC	cis	rs698813	0.763	rs1067335	chr2:44625958	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.7	0.4	1.59e-10	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs883565	0.654	rs7642737	chr3:39032469	T/C	cg26331595	chr3:39149181	GORASP1;TTC21A	0.41	4.78	0.3	3.07e-6	Handedness;
SARC	cis	rs7582180	0.764	rs10180423	chr2:100919012	C/G	cg14675211	chr2:100938903	LONRF2	0.5	7.38	0.44	2.77e-12	Intelligence (multi-trait analysis);
SARC	cis	rs36051895	0.659	rs1322224	chr9:5267889	C/A	cg02405213	chr9:5042618	JAK2	-0.42	-4.92	-0.31	1.64e-6	Pediatric autoimmune diseases;
SARC	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg00990874	chr7:1149470	C7orf50	-0.54	-5.88	-0.36	1.43e-8	Bronchopulmonary dysplasia;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg18159740	chr13:30881703	KATNAL1	0.5	6.53	0.39	4.14e-10	Chemerin levels;
SARC	cis	rs11608355	0.545	rs7315846	chr12:109908617	T/C	cg05360138	chr12:110035743	NA	0.93	9.71	0.54	6.21e-19	Neuroticism;
SARC	cis	rs3733585	0.699	rs2018643	chr4:9947121	C/T	cg11266682	chr4:10021025	SLC2A9	0.38	6.52	0.39	4.36e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7223966	1.000	rs8078862	chr17:61854068	C/T	cg00588841	chr17:61851480	DDX42;CCDC47	-0.67	-7.46	-0.44	1.69e-12	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs72781680	1.000	rs72788278	chr2:24095285	A/C	cg08917208	chr2:24149416	ATAD2B	0.76	7.49	0.44	1.42e-12	Lymphocyte counts;
SARC	cis	rs910316	1.000	rs10142626	chr14:75555636	A/T	cg23033748	chr14:75592666	NEK9	0.37	5.27	0.33	3.12e-7	Height;
SARC	cis	rs55794721	0.509	rs12027135	chr1:25775733	A/T	cg27572855	chr1:25598939	RHD	0.53	8.72	0.5	5.18e-16	Plateletcrit;Mean corpuscular volume;
SARC	cis	rs10875746	0.669	rs61941006	chr12:48631133	G/A	cg26205652	chr12:48591994	NA	0.46	5.03	0.31	9.83e-7	Longevity (90 years and older);
SARC	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-7.83	-0.46	1.71e-13	Alzheimer's disease;
SARC	cis	rs3008870	1.000	rs6673462	chr1:67461857	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.89	-11.03	-0.59	4.76e-23	Lymphocyte percentage of white cells;
SARC	cis	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg24965984	chr10:113943723	GPAM	0.42	5.26	0.33	3.23e-7	Breast cancer;
SARC	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg18404041	chr3:52824283	ITIH1	-0.38	-5.59	-0.34	6.45e-8	Bipolar disorder;
SARC	cis	rs6570726	0.905	rs388728	chr6:145816419	T/C	cg05220968	chr6:146057943	EPM2A	-0.29	-4.83	-0.3	2.44e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2075371	0.644	rs1643041	chr7:134012211	C/T	cg20476274	chr7:133979776	SLC35B4	0.55	7.13	0.42	1.28e-11	Mean platelet volume;
SARC	cis	rs2952156	0.959	rs2934952	chr17:37832366	G/A	cg20243544	chr17:37824526	PNMT	0.47	5.84	0.36	1.71e-8	Asthma;
SARC	cis	rs6912958	0.712	rs6930600	chr6:88349787	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-6.46	-0.39	6.16e-10	Monocyte percentage of white cells;
SARC	cis	rs999943	0.774	rs10947421	chr6:33611278	G/T	cg14003231	chr6:33640908	ITPR3	0.54	8.79	0.5	3.29e-16	Obesity (extreme);
SARC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg13126279	chr21:47581558	C21orf56	0.43	5.1	0.32	7.11e-7	Testicular germ cell tumor;
SARC	cis	rs9581943	0.967	rs7999100	chr13:28477401	C/A	cg16302790	chr13:28498334	PDX1	0.54	8.16	0.47	2.13e-14	Pancreatic cancer;
SARC	cis	rs2115630	0.653	rs61394864	chr15:85170174	T/C	cg17507749	chr15:85114479	UBE2QP1	-0.49	-5.88	-0.36	1.39e-8	P wave terminal force;
SARC	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg01740367	chr2:27294264	LOC100128731	0.59	7.34	0.43	3.61e-12	Breast cancer;
SARC	cis	rs9303401	0.614	rs2333409	chr17:57139134	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	10.33	0.56	7.57e-21	Cognitive test performance;
SARC	cis	rs7772486	0.754	rs9386132	chr6:146140751	T/C	cg23711669	chr6:146136114	FBXO30	0.91	16.04	0.72	1.67e-39	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg15966229	chr18:44337664	ST8SIA5	0.37	4.88	0.3	1.98e-6	Personality dimensions;
SARC	cis	rs1784581	0.802	rs9365355	chr6:162414604	A/G	cg17173639	chr6:162384350	PARK2	0.64	8.7	0.5	6.24e-16	Itch intensity from mosquito bite;
SARC	cis	rs7666738	0.606	rs6852813	chr4:99084671	G/A	cg05340658	chr4:99064831	C4orf37	0.47	5.95	0.36	9.8e-9	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6840360	0.530	rs6839802	chr4:152485834	G/A	cg22705602	chr4:152727874	NA	-0.41	-6.47	-0.39	5.71e-10	Intelligence (multi-trait analysis);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg10521094	chr7:107262441	BCAP29	0.48	6.39	0.39	9.03e-10	Thyroid stimulating hormone;
SARC	cis	rs2204008	0.665	rs11495668	chr12:38221018	C/T	cg26384229	chr12:38710491	ALG10B	0.88	12.86	0.64	5.78e-29	Bladder cancer;
SARC	cis	rs7635838	0.859	rs6768611	chr3:11434465	G/A	cg00170343	chr3:11313890	ATG7	0.53	7.01	0.42	2.53e-11	HDL cholesterol;
SARC	cis	rs2635047	0.713	rs9952628	chr18:44754651	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.51	6.79	0.41	9.08e-11	Educational attainment;
SARC	cis	rs1267303	0.682	rs1886117	chr1:46964909	T/A	cg25110126	chr1:46999211	NA	-0.45	-5.42	-0.33	1.48e-7	Monobrow;
SARC	cis	rs4774830	0.744	rs2414455	chr15:56290399	C/A	cg24530489	chr15:56299380	NA	-0.8	-4.72	-0.3	4.12e-6	Delta-5 desaturase activity;
SARC	cis	rs4727027	0.933	rs12154382	chr7:148862284	C/T	cg23583168	chr7:148888333	NA	-0.73	-11.03	-0.59	4.91e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs34311866	0.808	rs4583705	chr4:973036	C/T	cg07828340	chr4:882639	GAK	0.7	5.5	0.34	9.79e-8	Parkinson's disease;
SARC	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg05313129	chr8:58192883	C8orf71	-0.62	-6.34	-0.38	1.18e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10979	0.965	rs9376758	chr6:143886878	G/A	cg25407410	chr6:143891975	LOC285740	-0.6	-7.85	-0.46	1.55e-13	Hypospadias;
SARC	cis	rs16866061	1.000	rs72974267	chr2:225454209	T/C	cg12698349	chr2:225449008	CUL3	0.73	10.64	0.57	8.55e-22	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	cis	rs282587	0.569	rs282601	chr13:113392619	A/G	cg02820901	chr13:113351484	ATP11A	-0.53	-5.08	-0.32	7.67e-7	Glycated hemoglobin levels;
SARC	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg06634786	chr22:41940651	POLR3H	-0.56	-6.65	-0.4	2.03e-10	Vitiligo;
SARC	cis	rs4481887	0.927	rs10157089	chr1:248488157	A/G	cg00666640	chr1:248458726	OR2T12	0.37	6.02	0.37	6.83e-9	Common traits (Other);
SARC	cis	rs13401104	0.796	rs1530956	chr2:237111086	T/C	cg19324714	chr2:237145437	ASB18	0.58	6.02	0.37	6.73e-9	Educational attainment;
SARC	cis	rs6496044	0.547	rs8039929	chr15:86080962	C/T	cg10818794	chr15:86012489	AKAP13	-0.39	-4.86	-0.3	2.18e-6	Interstitial lung disease;
SARC	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg11843238	chr5:131593191	PDLIM4	0.41	5.55	0.34	7.64e-8	Acylcarnitine levels;
SARC	cis	rs1348850	0.914	rs10194648	chr2:178337031	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.66	8.35	0.48	6.17e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs72653721	0.838	rs72653724	chr6:11028293	C/T	cg13562911	chr6:11044106	ELOVL2	0.59	6.75	0.4	1.16e-10	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	cis	rs3796352	1.000	rs36090694	chr3:53010742	T/C	cg15956490	chr3:53032818	SFMBT1	0.85	5.55	0.34	7.7e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs1961637	0.603	rs1550423	chr2:223885812	C/T	cg22239167	chr2:224822509	MRPL44	0.39	5.07	0.32	7.98e-7	Oropharynx cancer;
SARC	cis	rs6088590	0.687	rs8115656	chr20:33282780	G/C	cg24642439	chr20:33292090	TP53INP2	0.71	9.54	0.53	2.04e-18	Coronary artery disease;
SARC	cis	rs6714710	0.603	rs11691494	chr2:98419726	T/A	cg26665480	chr2:98280029	ACTR1B	0.51	6.84	0.41	6.93e-11	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs2797160	0.651	rs1268093	chr6:126029235	C/T	cg05901451	chr6:126070800	HEY2	0.46	5.68	0.35	3.96e-8	Endometrial cancer;
SARC	trans	rs34421088	0.560	rs2245357	chr8:11399484	A/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.23	-0.38	2.11e-9	Neuroticism;
SARC	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg05025164	chr4:1340916	KIAA1530	0.85	10.6	0.57	1.1e-21	Longevity;
SARC	cis	rs9486715	0.838	rs7770889	chr6:96858453	C/T	cg18709589	chr6:96969512	KIAA0776	-0.55	-6.78	-0.41	9.57e-11	Headache;
SARC	cis	rs9388451	1.000	rs9388451	chr6:126090377	A/G	cg06289844	chr6:126071538	HEY2	0.34	5.52	0.34	9.03e-8	Brugada syndrome;
SARC	cis	rs7712401	0.715	rs13164161	chr5:122346897	G/A	cg19412675	chr5:122181750	SNX24	-0.41	-5.26	-0.33	3.18e-7	Mean platelet volume;
SARC	cis	rs734999	0.572	rs2985857	chr1:2532624	C/T	cg18854424	chr1:2615690	NA	-0.31	-4.97	-0.31	1.29e-6	Ulcerative colitis;
SARC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg17178900	chr1:205818956	PM20D1	0.39	5.08	0.32	7.89e-7	Menarche (age at onset);
SARC	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg25427524	chr10:38739819	LOC399744	-0.63	-10.05	-0.55	5.66e-20	Extrinsic epigenetic age acceleration;
SARC	cis	rs2288912	0.872	rs9304646	chr19:45450408	T/C	cg20090143	chr19:45452003	APOC2	0.31	4.93	0.31	1.55e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg04267008	chr7:1944627	MAD1L1	-0.52	-5.76	-0.35	2.62e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs894734	0.567	rs7138907	chr12:54324576	C/T	cg17410650	chr12:54324560	NA	-0.33	-5.04	-0.31	9.24e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
SARC	cis	rs1008375	0.932	rs4698627	chr4:17605959	T/C	cg02297831	chr4:17616191	MED28	0.51	6.45	0.39	6.53e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs9650657	0.836	rs2898252	chr8:10604164	T/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.88	-0.41	5.32e-11	Neuroticism;
SARC	cis	rs6120849	0.707	rs6120799	chr20:33614955	T/C	cg06115741	chr20:33292138	TP53INP2	0.54	5.16	0.32	5.3e-7	Protein C levels;
SARC	cis	rs2933343	0.553	rs789212	chr3:128686912	A/C	cg24203234	chr3:128598194	ACAD9	0.49	5.86	0.36	1.61e-8	IgG glycosylation;
SARC	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	11.91	0.62	7.3e-26	Alzheimer's disease;
SARC	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg13939156	chr17:80058883	NA	-0.43	-6.7	-0.4	1.55e-10	Life satisfaction;
SARC	cis	rs11098499	0.863	rs9997631	chr4:120469995	C/G	cg24375607	chr4:120327624	NA	0.4	4.82	0.3	2.64e-6	Corneal astigmatism;
SARC	cis	rs3858526	0.883	rs10769326	chr11:5934358	C/T	cg13902645	chr11:5959945	NA	-0.45	-5.01	-0.31	1.08e-6	DNA methylation (variation);
SARC	cis	rs7520050	0.778	rs2088102	chr1:46032974	T/C	cg06784218	chr1:46089804	CCDC17	-0.26	-4.74	-0.3	3.76e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs2228479	0.850	rs62056066	chr16:89906563	G/A	cg12064134	chr16:90016061	DEF8	-0.56	-4.83	-0.3	2.47e-6	Skin colour saturation;
SARC	cis	rs9660992	0.674	rs17345837	chr1:205263122	C/T	cg19090574	chr1:205240910	TMCC2	-0.39	-4.78	-0.3	3.04e-6	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg11987759	chr7:65425863	GUSB	0.57	7.75	0.45	2.91e-13	Aortic root size;
SARC	cis	rs1153858	0.895	rs12593402	chr15:45617392	G/A	cg21132104	chr15:45694354	SPATA5L1	0.81	11.31	0.6	6.21e-24	Homoarginine levels;
SARC	cis	rs524281	0.692	rs2254388	chr11:65837599	C/T	cg14036092	chr11:66035641	RAB1B	0.59	7.03	0.42	2.29e-11	Electroencephalogram traits;
SARC	cis	rs908922	0.676	rs1538082	chr1:152517304	A/G	cg09873164	chr1:152488093	CRCT1	0.65	8.67	0.49	7.67e-16	Hair morphology;
SARC	cis	rs10771431	0.738	rs11049697	chr12:9385339	T/C	cg08997352	chr12:9597637	DDX12	-0.63	-8.53	-0.49	1.87e-15	Breast size;
SARC	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg08219700	chr8:58056026	NA	0.73	6.39	0.39	9.16e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs10861342	0.892	rs12227605	chr12:105501100	G/A	cg23923672	chr12:105501055	KIAA1033	0.86	6.45	0.39	6.52e-10	IgG glycosylation;
SARC	cis	rs9420	0.961	rs499188	chr11:57434122	C/A	cg23127183	chr11:57508653	C11orf31	-0.51	-6.0	-0.37	7.68e-9	Schizophrenia;
SARC	cis	rs12079745	1.000	rs1320966	chr1:169115138	G/C	cg09363564	chr1:169337483	NME7;BLZF1	-0.7	-4.89	-0.31	1.88e-6	QT interval;
SARC	cis	rs61409971	0.961	rs67868394	chr14:93015848	T/C	cg04718702	chr14:93020195	RIN3	-0.37	-4.88	-0.3	1.96e-6	Lymphocyte percentage of white cells;
SARC	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg11764359	chr7:65958608	NA	0.88	12.55	0.63	6.26e-28	Aortic root size;
SARC	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg02574844	chr11:5959923	NA	0.44	6.05	0.37	5.71e-9	DNA methylation (variation);
SARC	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	9.68	0.54	7.66e-19	Platelet count;
SARC	cis	rs7666738	0.578	rs1989109	chr4:98881246	T/A	cg05340658	chr4:99064831	C4orf37	0.65	8.72	0.5	5.23e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg25036284	chr2:26402008	FAM59B	-0.43	-5.45	-0.34	1.27e-7	Gut microbiome composition (summer);
SARC	cis	rs2180341	0.576	rs2057224	chr6:127624414	C/G	cg27446573	chr6:127587934	RNF146	0.68	9.01	0.51	7.72e-17	Breast cancer;
SARC	cis	rs3743266	0.507	rs10162677	chr15:60748568	C/T	cg22293140	chr15:60689852	ANXA2	-0.55	-5.09	-0.32	7.5e-7	Menarche (age at onset);
SARC	cis	rs5753618	0.539	rs737888	chr22:31611549	A/G	cg13145458	chr22:31556086	RNF185	0.47	4.91	0.31	1.74e-6	Colorectal cancer;
SARC	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg17971929	chr21:40555470	PSMG1	-0.59	-7.44	-0.44	1.96e-12	Menarche (age at onset);
SARC	cis	rs422249	0.512	rs174562	chr11:61585144	A/G	cg19610905	chr11:61596333	FADS2	-0.42	-4.96	-0.31	1.36e-6	Trans fatty acid levels;
SARC	cis	rs9325144	0.560	rs1825802	chr12:38650341	C/T	cg26384229	chr12:38710491	ALG10B	-0.66	-8.86	-0.5	2.06e-16	Morning vs. evening chronotype;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg24040382	chr1:224622855	WDR26	-0.76	-6.5	-0.39	4.85e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs13256369	1.000	rs7843488	chr8:8576217	C/T	cg17143192	chr8:8559678	CLDN23	0.51	5.47	0.34	1.16e-7	Obesity-related traits;
SARC	cis	rs79149102	0.579	rs74023936	chr15:75362084	C/T	cg00629941	chr15:75287862	SCAMP5	-0.61	-4.92	-0.31	1.62e-6	Lung cancer;
SARC	cis	rs8031584	0.578	rs1088473	chr15:31139298	A/G	cg08109568	chr15:31115862	NA	0.52	6.71	0.4	1.46e-10	Huntington's disease progression;
SARC	cis	rs11098499	0.754	rs12506487	chr4:120271361	T/G	cg24375607	chr4:120327624	NA	0.37	4.73	0.3	3.87e-6	Corneal astigmatism;
SARC	cis	rs918629	1.000	rs3777167	chr5:95286017	A/G	cg16656078	chr5:95278638	ELL2	-0.52	-6.47	-0.39	5.77e-10	IgG glycosylation;
SARC	cis	rs8077889	0.917	rs58080788	chr17:41902909	A/G	cg26893861	chr17:41843967	DUSP3	0.83	10.1	0.55	3.97e-20	Triglycerides;
SARC	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg19774624	chr17:42201019	HDAC5	-0.79	-11.49	-0.6	1.65e-24	Total body bone mineral density;
SARC	cis	rs10782582	0.609	rs5745325	chr1:76269460	G/A	cg03433033	chr1:76189801	ACADM	-0.37	-4.73	-0.3	3.89e-6	Daytime sleep phenotypes;
SARC	cis	rs634534	0.562	rs642293	chr11:65730217	G/A	cg26695010	chr11:65641043	EFEMP2	-0.55	-7.19	-0.43	8.49e-12	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs3771570	1.000	rs62186400	chr2:242226700	A/G	cg21155796	chr2:242212141	HDLBP	0.65	5.84	0.36	1.77e-8	Prostate cancer;
SARC	trans	rs56279505	0.629	rs62307295	chr4:100260545	C/A	cg18024358	chr1:3420815	MEGF6	-0.84	-6.43	-0.39	7.04e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs12780845	0.505	rs973307	chr10:17246333	C/T	cg11116878	chr10:17243438	TRDMT1	0.4	4.95	0.31	1.42e-6	Homocysteine levels;
SARC	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg08859206	chr1:53392774	SCP2	0.36	5.22	0.32	4.05e-7	Monocyte count;
SARC	cis	rs12711979	0.509	rs10192699	chr2:3824297	A/G	cg17052675	chr2:3827356	NA	-0.53	-7.74	-0.45	2.97e-13	Itch intensity from mosquito bite adjusted by bite size;
SARC	cis	rs13191362	1.000	rs13201023	chr6:162981381	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.56	5.41	0.33	1.55e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs8177253	0.507	rs4241357	chr3:133475563	A/C	cg01448562	chr3:133502909	NA	0.38	5.65	0.35	4.74e-8	Iron status biomarkers;
SARC	cis	rs1878931	0.615	rs4786412	chr16:3440390	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	1.01	18.26	0.77	7.75e-47	Body mass index (adult);
SARC	trans	rs9325144	0.647	rs3759139	chr12:39087609	G/A	cg23762105	chr12:34175262	ALG10	0.5	6.26	0.38	1.79e-9	Morning vs. evening chronotype;
SARC	cis	rs28795989	0.795	rs2385910	chr4:7903151	G/C	cg18538662	chr4:7941764	AFAP1	-0.41	-5.29	-0.33	2.83e-7	Intraocular pressure;
SARC	cis	rs72627123	0.867	rs73301479	chr14:74467757	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.79	5.97	0.36	8.61e-9	Morning vs. evening chronotype;
SARC	cis	rs1580019	0.520	rs6945238	chr7:32646096	C/T	cg07520158	chr7:32535189	LSM5;AVL9	-0.6	-6.92	-0.41	4.26e-11	Cognitive ability;
SARC	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg20933005	chr20:20033039	CRNKL1;C20orf26	-0.47	-6.27	-0.38	1.7e-9	Thyroid cancer;
SARC	cis	rs6545883	0.965	rs6545872	chr2:61724568	G/A	cg15711740	chr2:61764176	XPO1	-0.43	-5.27	-0.33	3.14e-7	Tuberculosis;
SARC	cis	rs36051895	0.664	rs10974960	chr9:5095842	G/A	cg02405213	chr9:5042618	JAK2	-0.49	-5.99	-0.37	7.99e-9	Pediatric autoimmune diseases;
SARC	cis	rs7615952	0.611	rs35321002	chr3:125612065	G/C	cg05084668	chr3:125655381	ALG1L	-0.78	-7.64	-0.45	5.74e-13	Blood pressure (smoking interaction);
SARC	cis	rs3126085	0.825	rs12045492	chr1:152253866	A/T	cg03465714	chr1:152285911	FLG	-0.46	-5.55	-0.34	7.91e-8	Atopic dermatitis;
SARC	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg12379764	chr21:47803548	PCNT	-0.5	-5.11	-0.32	6.73e-7	Testicular germ cell tumor;
SARC	cis	rs8067354	0.645	rs9910518	chr17:57812067	T/C	cg02344993	chr17:57696989	CLTC	0.65	6.69	0.4	1.61e-10	Hemoglobin concentration;
SARC	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg03735888	chr19:58951602	ZNF132	0.39	5.17	0.32	5.01e-7	Uric acid clearance;
SARC	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg15242686	chr22:24348715	GSTTP1	0.42	5.22	0.32	3.88e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs11785400	0.793	rs2280879	chr8:143722228	T/C	cg24634471	chr8:143751801	JRK	0.6	7.85	0.46	1.51e-13	Schizophrenia;
SARC	cis	rs12477438	0.834	rs1563107	chr2:99701276	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.65	8.21	0.47	1.48e-14	Chronic sinus infection;
SARC	cis	rs6570726	1.000	rs450076	chr6:145847655	G/T	cg05347473	chr6:146136440	FBXO30	0.49	6.52	0.39	4.27e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs870825	0.616	rs7678900	chr4:185635249	A/G	cg04058563	chr4:185651563	MLF1IP	0.82	11.04	0.59	4.68e-23	Blood protein levels;
SARC	cis	rs950027	0.620	rs2486274	chr15:45666228	G/T	cg21132104	chr15:45694354	SPATA5L1	0.56	7.12	0.42	1.29e-11	Response to fenofibrate (adiponectin levels);
SARC	cis	rs708547	0.874	rs1315006	chr4:57858193	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.68	7.85	0.46	1.49e-13	Response to bleomycin (chromatid breaks);
SARC	cis	rs7954584	0.505	rs11043278	chr12:122412145	C/T	cg10207240	chr12:122356781	WDR66	0.3	4.82	0.3	2.63e-6	Mean corpuscular volume;
SARC	cis	rs4780401	0.609	rs8047190	chr16:11807097	T/C	cg01061890	chr16:11836724	TXNDC11	-0.61	-8.7	-0.5	6.01e-16	Rheumatoid arthritis;
SARC	cis	rs7769051	0.803	rs59740783	chr6:133231711	G/A	cg07930552	chr6:133119739	C6orf192	0.79	6.46	0.39	5.99e-10	Type 2 diabetes nephropathy;
SARC	cis	rs12497850	0.931	rs6442130	chr3:48778027	A/G	cg06212747	chr3:49208901	KLHDC8B	0.6	7.75	0.45	2.75e-13	Parkinson's disease;
SARC	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg02725872	chr8:58115012	NA	-0.32	-4.89	-0.31	1.89e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg26335602	chr6:28129616	ZNF389	0.52	5.42	0.33	1.46e-7	Parkinson's disease;
SARC	cis	rs7808935	0.914	rs10807843	chr7:27992390	T/C	cg05786569	chr7:27702416	HIBADH	0.57	5.83	0.36	1.83e-8	Prostate cancer;
SARC	cis	rs2916247	1.000	rs35604666	chr8:93037953	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.59	-6.03	-0.37	6.24e-9	Intelligence (multi-trait analysis);
SARC	cis	rs10752881	1.000	rs4593781	chr1:182984983	C/T	cg13390022	chr1:182993471	LAMC1	0.34	5.23	0.32	3.74e-7	Colorectal cancer;
SARC	cis	rs2712184	0.756	rs2024487	chr2:217663271	C/T	cg05032264	chr2:217675019	NA	0.45	5.81	0.36	2e-8	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
SARC	cis	rs3126085	1.000	rs6661167	chr1:152312870	A/G	cg03465714	chr1:152285911	FLG	0.47	4.92	0.31	1.67e-6	Atopic dermatitis;
SARC	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg12436631	chr1:155007014	DCST1;DCST2	-0.37	-6.47	-0.39	5.68e-10	Schizophrenia;
SARC	cis	rs10791097	0.720	rs6590515	chr11:130733365	A/G	cg09137382	chr11:130731461	NA	-0.33	-5.2	-0.32	4.35e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg09699651	chr6:150184138	LRP11	0.41	5.11	0.32	6.6e-7	Lung cancer;
SARC	cis	rs9303401	0.625	rs10515159	chr17:56802693	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	11.87	0.61	9.72e-26	Cognitive test performance;
SARC	cis	rs16976116	0.901	rs3179664	chr15:55496853	G/A	cg11288833	chr15:55489084	RSL24D1	0.62	6.02	0.37	6.78e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg20618750	chr5:149380010	HMGXB3;TIGD6	0.53	6.8	0.41	8.91e-11	Breast cancer;
SARC	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs17376456	0.825	rs6865441	chr5:93284746	G/A	cg21475434	chr5:93447410	FAM172A	0.85	7.47	0.44	1.61e-12	Diabetic retinopathy;
SARC	cis	rs1707322	0.717	rs1547925	chr1:46085356	C/T	cg03146154	chr1:46216737	IPP	-0.51	-6.1	-0.37	4.42e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg03828693	chr10:63661686	ARID5B	-0.53	-5.03	-0.31	9.84e-7	Cutaneous psoriasis;
SARC	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg22875332	chr1:76189707	ACADM	-0.46	-6.45	-0.39	6.27e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs4276643	0.842	rs939715	chr8:27810626	C/T	cg26001764	chr8:28560637	EXTL3	-0.29	-4.85	-0.3	2.25e-6	Low vWF levels;
SARC	cis	rs34172651	0.917	rs2059134	chr16:24816492	C/T	cg00152838	chr16:24741724	TNRC6A	0.48	5.79	0.35	2.28e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9916302	0.706	rs12950186	chr17:37393395	A/C	cg00129232	chr17:37814104	STARD3	-0.57	-6.05	-0.37	5.67e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg25072359	chr17:41440525	NA	0.51	6.08	0.37	4.92e-9	Menopause (age at onset);
SARC	cis	rs4660306	0.961	rs3748643	chr1:45965703	G/T	cg24296786	chr1:45957014	TESK2	0.56	6.54	0.39	3.8e-10	Homocysteine levels;
SARC	cis	rs17270561	0.609	rs1165155	chr6:25795577	A/T	cg16482183	chr6:26056742	HIST1H1C	0.48	6.15	0.37	3.3e-9	Iron status biomarkers;
SARC	cis	rs4722166	0.630	rs7781534	chr7:22778592	A/C	cg26061582	chr7:22766209	IL6	0.57	6.19	0.38	2.73e-9	Lung cancer;
SARC	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg11764359	chr7:65958608	NA	0.66	7.61	0.45	6.89e-13	Aortic root size;
SARC	cis	rs6860806	0.531	rs274556	chr5:131722075	A/G	cg12564285	chr5:131593104	PDLIM4	-0.46	-6.23	-0.38	2.13e-9	Breast cancer;
SARC	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	5.45	0.34	1.26e-7	Bipolar disorder;
SARC	cis	rs757978	1.000	rs80085676	chr2:242347907	G/A	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.83	-7.11	-0.42	1.38e-11	Chronic lymphocytic leukemia;
SARC	cis	rs9868809	0.505	rs56735597	chr3:48765168	A/G	cg03060546	chr3:49711283	APEH	-0.58	-5.01	-0.31	1.1e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	trans	rs1814175	0.645	rs7928714	chr11:49887622	G/A	cg15704280	chr7:45808275	SEPT13	-0.88	-13.91	-0.67	1.97e-32	Height;
SARC	trans	rs1814175	0.586	rs2866862	chr11:49954588	T/C	cg03929089	chr4:120376271	NA	-0.82	-11.86	-0.61	1.06e-25	Height;
SARC	cis	rs9341808	0.690	rs3805926	chr6:80879280	C/G	cg08355045	chr6:80787529	NA	0.34	5.53	0.34	8.66e-8	Sitting height ratio;
SARC	cis	rs9398803	0.687	rs1340952	chr6:126951510	C/T	cg19875578	chr6:126661172	C6orf173	0.61	8.32	0.48	7.54e-15	Male-pattern baldness;
SARC	cis	rs7662987	0.517	rs2602878	chr4:100039953	T/G	cg13256891	chr4:100009986	ADH5	0.68	8.61	0.49	1.13e-15	Smoking initiation;
SARC	cis	rs1318878	0.840	rs7135743	chr12:15545143	C/T	cg08258403	chr12:15378311	NA	-0.47	-6.47	-0.39	5.66e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7524258	0.868	rs6693725	chr1:7307810	G/T	cg07173049	chr1:7289937	CAMTA1	0.36	7.2	0.43	8e-12	Tourette's syndrome or obsessive-compulsive disorder;
SARC	cis	rs9457247	0.602	rs10484530	chr6:167461562	C/T	cg23791538	chr6:167370224	RNASET2	-0.53	-6.99	-0.42	2.88e-11	Crohn's disease;
SARC	cis	rs13161895	1.000	rs12656814	chr5:179471556	G/A	cg02702477	chr5:179499311	RNF130	0.65	6.2	0.38	2.6e-9	LDL cholesterol;
SARC	cis	rs1865760	1.000	rs6905887	chr6:25912103	T/C	cg16482183	chr6:26056742	HIST1H1C	0.5	6.18	0.38	2.86e-9	Height;
SARC	cis	rs10791323	0.569	rs10750552	chr11:133740141	A/C	cg15485101	chr11:133734466	NA	-0.3	-4.8	-0.3	2.79e-6	Childhood ear infection;
SARC	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	9.06	0.51	5.47e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs78487399	0.808	rs7575024	chr2:43666991	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.69	-5.82	-0.36	1.91e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	trans	rs7615952	0.688	rs12638240	chr3:125541238	G/A	cg07211511	chr3:129823064	LOC729375	-0.74	-8.57	-0.49	1.41e-15	Blood pressure (smoking interaction);
SARC	cis	rs6908034	0.660	rs6918235	chr6:19788427	A/T	cg02682789	chr6:19804855	NA	0.68	4.94	0.31	1.47e-6	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	trans	rs6894249	1.000	rs6894249	chr5:131797547	A/G	cg10261819	chr16:22448417	RRN3P3;LOC641298	0.5	6.24	0.38	2.08e-9	Asthma;
SARC	cis	rs1448094	0.549	rs10863085	chr12:86236328	G/A	cg00310523	chr12:86230176	RASSF9	0.33	5.27	0.33	3.04e-7	Major depressive disorder;
SARC	cis	rs8114671	0.562	rs4911163	chr20:33470694	C/T	cg07148914	chr20:33460835	GGT7	0.42	5.19	0.32	4.5e-7	Height;
SARC	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg00933542	chr6:150070202	PCMT1	0.31	5.36	0.33	2.04e-7	Lung cancer;
SARC	cis	rs34779708	0.931	rs4934719	chr10:35376769	T/C	cg03585969	chr10:35415529	CREM	0.39	4.86	0.3	2.17e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs921968	0.643	rs526134	chr2:219402371	G/A	cg02176678	chr2:219576539	TTLL4	0.35	5.5	0.34	1e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs514406	0.505	rs269292	chr1:53187911	T/C	cg16325326	chr1:53192061	ZYG11B	0.91	16.41	0.73	9.61e-41	Monocyte count;
SARC	cis	rs72781680	1.000	rs72781665	chr2:24223086	G/A	cg06627628	chr2:24431161	ITSN2	-0.68	-6.64	-0.4	2.19e-10	Lymphocyte counts;
SARC	cis	rs3845702	0.668	rs6759271	chr2:180844303	T/C	cg01881094	chr2:180872142	CWC22	-1.12	-9.3	-0.52	1.07e-17	Schizophrenia;
SARC	cis	rs9581943	0.967	rs7995917	chr13:28472724	T/C	cg25299895	chr13:28498091	PDX1	0.37	4.98	0.31	1.24e-6	Pancreatic cancer;
SARC	cis	rs523522	0.962	rs9040	chr12:120900274	C/T	cg27279351	chr12:120934652	DYNLL1	0.71	8.42	0.48	3.83e-15	High light scatter reticulocyte count;
SARC	cis	rs4242434	0.889	rs11783129	chr8:22453426	G/A	cg03733263	chr8:22462867	KIAA1967	0.9	13.38	0.66	1.1e-30	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs9640161	0.830	rs1051760	chr7:150070630	A/G	cg17279839	chr7:150038598	RARRES2	0.37	6.07	0.37	5.27e-9	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg13880726	chr7:1868755	MAD1L1	0.41	4.86	0.3	2.19e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs7216064	1.000	rs7208663	chr17:65885171	T/C	cg12091567	chr17:66097778	LOC651250	-0.7	-7.64	-0.45	5.5e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs7607369	0.596	rs10165754	chr2:219287370	A/G	cg02176678	chr2:219576539	TTLL4	-0.52	-7.42	-0.44	2.14e-12	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs9309473	0.950	rs6546859	chr2:73842055	C/A	cg20560298	chr2:73613845	ALMS1	-0.44	-5.2	-0.32	4.34e-7	Metabolite levels;
SARC	cis	rs11105298	0.891	rs3741898	chr12:89933763	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.55	-5.55	-0.34	7.56e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs2153535	0.541	rs6905934	chr6:8440043	C/A	cg07606381	chr6:8435919	SLC35B3	0.78	11.09	0.59	3.11e-23	Motion sickness;
SARC	cis	rs6952809	0.532	rs6956223	chr7:2431331	T/C	cg23289794	chr7:2394357	EIF3B	-0.75	-7.28	-0.43	5.03e-12	Multiple sclerosis;
SARC	cis	rs912057	1.000	rs912056	chr6:6736197	A/T	cg06612196	chr6:6737390	NA	0.61	8.93	0.5	1.3e-16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs10504229	0.679	rs12679920	chr8:58051710	G/T	cg11062466	chr8:58055876	NA	0.5	4.93	0.31	1.58e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs2153535	0.542	rs1120393	chr6:8486890	G/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.09	0.59	3.06e-23	Motion sickness;
SARC	cis	rs7662987	0.517	rs2602880	chr4:100040653	C/T	cg12011299	chr4:100065546	ADH4	0.33	5.49	0.34	1.03e-7	Smoking initiation;
SARC	cis	rs546131	0.515	rs7128804	chr11:34857948	C/G	cg06937548	chr11:34938143	PDHX;APIP	-0.47	-5.22	-0.32	4.03e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs5167	0.506	rs35193317	chr19:45470344	C/T	cg13119609	chr19:45449297	APOC2	-0.51	-8.68	-0.49	7.16e-16	Blood protein levels;
SARC	cis	rs1215050	0.791	rs684210	chr4:98678740	G/C	cg05340658	chr4:99064831	C4orf37	0.44	5.78	0.35	2.38e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs7474896	0.583	rs10740950	chr10:38003496	C/T	cg00409905	chr10:38381863	ZNF37A	-0.44	-4.84	-0.3	2.31e-6	Obesity (extreme);
SARC	cis	rs11122272	0.735	rs2491416	chr1:231547335	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.69	10.1	0.55	4.09e-20	Hemoglobin concentration;
SARC	cis	rs2645694	0.626	rs2703124	chr4:77820626	G/T	cg10057126	chr4:77819792	ANKRD56	0.44	6.58	0.4	3.1e-10	Emphysema distribution in smoking;
SARC	cis	rs1322639	0.614	rs9455889	chr6:169566087	A/T	cg03254818	chr6:169586852	NA	0.7	7.23	0.43	6.85e-12	Pulse pressure;
SARC	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg09699651	chr6:150184138	LRP11	0.39	4.83	0.3	2.5e-6	Lung cancer;
SARC	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg04277193	chr17:41438351	NA	0.44	4.78	0.3	3.04e-6	Menopause (age at onset);
SARC	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg10150615	chr22:24372951	LOC391322	-0.45	-5.0	-0.31	1.15e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg11247378	chr22:39784982	NA	-0.3	-4.83	-0.3	2.45e-6	Intelligence (multi-trait analysis);
SARC	cis	rs1018836	0.923	rs6986689	chr8:91626709	A/C	cg16814680	chr8:91681699	NA	-0.86	-14.05	-0.68	6.71e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs12545109	0.800	rs2118260	chr8:57393481	T/C	cg19413350	chr8:57351067	NA	-0.43	-4.78	-0.3	3.07e-6	Obesity-related traits;
SARC	cis	rs7624766	0.695	rs1839019	chr3:160578472	A/G	cg22637730	chr3:160473554	PPM1L	0.4	4.92	0.31	1.61e-6	Response to methotrexate in rheumatoid arthritis;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg05823146	chr10:99496860	ZFYVE27	0.55	6.83	0.41	7.36e-11	Breast cancer;
SARC	cis	rs883565	0.792	rs784492	chr3:39175576	A/C	cg26331595	chr3:39149181	GORASP1;TTC21A	0.48	5.51	0.34	9.57e-8	Handedness;
SARC	cis	rs2425143	1.000	rs2425141	chr20:34350123	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-6.35	-0.38	1.1e-9	Blood protein levels;
SARC	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg11890956	chr21:40555474	PSMG1	-1.03	-15.71	-0.72	1.99e-38	Cognitive function;
SARC	cis	rs3087591	1.000	rs984125	chr17:29547254	A/G	cg24425628	chr17:29625626	OMG;NF1	0.5	6.06	0.37	5.31e-9	Hip circumference;
SARC	cis	rs8031584	0.560	rs1056118	chr15:31203786	G/A	cg08109568	chr15:31115862	NA	0.43	5.71	0.35	3.47e-8	Huntington's disease progression;
SARC	cis	rs3126085	0.935	rs4534386	chr1:152251714	A/G	cg26876637	chr1:152193138	HRNR	0.46	5.29	0.33	2.86e-7	Atopic dermatitis;
SARC	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg17971929	chr21:40555470	PSMG1	-0.57	-7.21	-0.43	7.55e-12	Menarche (age at onset);
SARC	cis	rs818427	0.858	rs461866	chr5:112231450	G/A	cg07820702	chr5:112228657	REEP5	-0.48	-5.44	-0.34	1.34e-7	Total body bone mineral density;
SARC	cis	rs7772486	0.754	rs13214277	chr6:146136125	G/T	cg23711669	chr6:146136114	FBXO30	0.91	16.04	0.72	1.67e-39	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1707322	1.000	rs11211200	chr1:46288352	A/G	cg06784218	chr1:46089804	CCDC17	0.35	5.92	0.36	1.16e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg08677398	chr8:58056175	NA	0.43	5.09	0.32	7.42e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg01840575	chr2:38977957	SFRS7	-0.58	-6.6	-0.4	2.75e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs9902453	0.904	rs8078638	chr17:28290358	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	6.89	0.41	5.16e-11	Coffee consumption (cups per day);
SARC	cis	rs7537052	0.646	rs114480320	chr1:36650692	T/A	cg24686825	chr1:36642396	MAP7D1	-0.65	-8.52	-0.49	2e-15	Schizophrenia;
SARC	cis	rs644799	0.525	rs3016206	chr11:95536724	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.63	8.29	0.48	8.76e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs11032090	1	rs11032090	chr11:4417129	A/G	cg09983885	chr11:4415245	TRIM21	0.42	5.17	0.32	4.93e-7	Lung cancer;
SARC	trans	rs11098499	0.865	rs11722183	chr4:120280597	A/C	cg25214090	chr10:38739885	LOC399744	0.53	6.9	0.41	4.84e-11	Corneal astigmatism;
SARC	cis	rs2997447	0.846	rs61775427	chr1:26408768	G/A	cg19633962	chr1:26362018	EXTL1	-0.68	-5.78	-0.35	2.34e-8	QRS complex (12-leadsum);
SARC	trans	rs12121840	0.688	rs285438	chr1:165518186	C/T	cg13809270	chr4:830645	NA	0.55	6.43	0.39	7.31e-10	Interleukin-1-receptor antagonist levels;
SARC	trans	rs7824557	0.527	rs4634600	chr8:11239017	T/A	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.36	-0.38	1.08e-9	Retinal vascular caliber;
SARC	cis	rs67460515	0.563	rs11713441	chr3:160906855	T/C	cg03342759	chr3:160939853	NMD3	-0.64	-7.95	-0.46	7.77e-14	Parkinson's disease;
SARC	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg03650068	chr1:25596491	NA	0.34	5.21	0.32	4.24e-7	Erythrocyte sedimentation rate;
SARC	cis	rs751728	0.965	rs9394168	chr6:33759701	T/A	cg25922239	chr6:33757077	LEMD2	0.77	10.25	0.56	1.35e-20	Crohn's disease;
SARC	cis	rs12893668	0.572	rs4906350	chr14:104111794	C/T	cg26031613	chr14:104095156	KLC1	-0.54	-5.96	-0.36	9.14e-9	Reticulocyte count;
SARC	cis	rs3106136	0.681	rs1609423	chr4:95301949	G/A	cg11021082	chr4:95130006	SMARCAD1	0.33	4.91	0.31	1.73e-6	Capecitabine sensitivity;
SARC	cis	rs2304069	0.545	rs7728248	chr5:149394965	A/G	cg12661370	chr5:149340060	SLC26A2	0.55	6.38	0.39	9.62e-10	HIV-1 control;
SARC	cis	rs244731	0.959	rs9313752	chr5:176645435	G/T	cg16006841	chr5:176797999	RGS14	-0.57	-6.91	-0.41	4.66e-11	Urate levels in lean individuals;
SARC	cis	rs959260	0.614	rs9914731	chr17:73408824	T/G	cg14668889	chr17:73230827	NUP85	-0.52	-5.18	-0.32	4.89e-7	Systemic lupus erythematosus;
SARC	cis	rs908922	0.651	rs4240886	chr1:152530396	A/T	cg09873164	chr1:152488093	CRCT1	-0.6	-7.61	-0.45	6.8e-13	Hair morphology;
SARC	cis	rs28437878	1	rs28437878	chr15:78807872	C/T	cg06917634	chr15:78832804	PSMA4	-0.6	-6.64	-0.4	2.25e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs6665290	0.901	rs7535826	chr1:227213968	A/C	cg10327440	chr1:227177885	CDC42BPA	1.03	22.11	0.82	3.89e-59	Myeloid white cell count;
SARC	cis	rs3820928	1.000	rs6723774	chr2:227770592	C/T	cg11843606	chr2:227700838	RHBDD1	0.56	7.42	0.44	2.24e-12	Pulmonary function;
SARC	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg01181863	chr3:195395398	SDHAP2	-0.64	-7.48	-0.44	1.52e-12	Pancreatic cancer;
SARC	cis	rs6542838	0.704	rs56125264	chr2:99516699	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-5.88	-0.36	1.38e-8	Fear of minor pain;
SARC	cis	rs858239	0.601	rs4599714	chr7:23168801	C/T	cg23682824	chr7:23144976	KLHL7	0.73	9.84	0.54	2.45e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg26338869	chr17:61819248	STRADA	0.8	10.72	0.57	4.8e-22	Prudent dietary pattern;
SARC	cis	rs8038465	0.662	rs7497012	chr15:73968719	G/A	cg15420318	chr15:73925796	NPTN	0.48	5.55	0.34	7.56e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7829975	0.567	rs6601273	chr8:8796519	T/G	cg08975724	chr8:8085496	FLJ10661	-0.39	-4.76	-0.3	3.35e-6	Mood instability;
SARC	cis	rs7614311	0.681	rs3774708	chr3:63881549	A/C	cg22134162	chr3:63841271	THOC7	-0.43	-4.8	-0.3	2.79e-6	Lung function (FVC);Lung function (FEV1);
SARC	cis	rs796364	0.951	rs12996313	chr2:200997916	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.58	-5.34	-0.33	2.21e-7	Schizophrenia;
SARC	cis	rs11697848	1.000	rs34499196	chr20:48536152	G/A	cg17849948	chr20:48532315	SPATA2	0.87	5.2	0.32	4.3e-7	Systemic lupus erythematosus;
SARC	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg05025164	chr4:1340916	KIAA1530	0.69	8.61	0.49	1.13e-15	Longevity;
SARC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg11301795	chr4:187892539	NA	-0.74	-11.19	-0.59	1.49e-23	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4727027	0.866	rs3735311	chr7:148877737	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	5.85	0.36	1.66e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs1843834	0.611	rs1058360	chr2:225449242	A/T	cg22509189	chr2:225307070	NA	-0.61	-7.4	-0.44	2.47e-12	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs2221894	0.506	rs78029870	chr8:28963659	A/G	cg07962641	chr8:28805897	HMBOX1	-0.76	-7.72	-0.45	3.41e-13	Obesity-related traits;
SARC	cis	rs3733585	0.638	rs7377625	chr4:9953099	T/C	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.55	-0.34	7.78e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs2594989	0.943	rs9836824	chr3:11463517	G/A	cg00170343	chr3:11313890	ATG7	0.6	5.6	0.34	6.04e-8	Circulating chemerin levels;
SARC	cis	rs11758351	0.866	rs55815656	chr6:26207303	G/A	cg01420254	chr6:26195488	NA	0.53	4.82	0.3	2.63e-6	Gout;Renal underexcretion gout;
SARC	cis	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg24110177	chr3:50126178	RBM5	0.39	5.04	0.31	9.18e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg03433033	chr1:76189801	ACADM	-0.42	-5.32	-0.33	2.45e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs11105298	0.891	rs10777184	chr12:89919568	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-5.43	-0.34	1.39e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	trans	rs1814175	0.588	rs1721994	chr11:49914050	G/A	cg15704280	chr7:45808275	SEPT13	-0.88	-14.0	-0.68	1.02e-32	Height;
SARC	cis	rs4356932	1.000	rs1554013	chr4:76933484	T/C	cg24176760	chr4:76958061	ART3;CXCL11	-0.28	-4.73	-0.3	3.86e-6	Blood protein levels;
SARC	cis	rs12369635	0.810	rs11060119	chr12:129560574	A/G	cg01909103	chr12:129572610	TMEM132D	-0.52	-5.32	-0.33	2.38e-7	Schizophrenia (inflammation and infection response interaction);
SARC	cis	rs3733585	0.699	rs7663079	chr4:9966771	T/C	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.65	-0.35	4.69e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs4555082	1.000	rs7146683	chr14:105759385	A/G	cg06808227	chr14:105710500	BRF1	-0.53	-6.94	-0.41	3.86e-11	Mean platelet volume;Platelet distribution width;
SARC	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg22903657	chr4:1355424	KIAA1530	-0.36	-4.9	-0.31	1.82e-6	Obesity-related traits;
SARC	cis	rs72781680	0.611	rs2303287	chr2:24302246	A/G	cg08917208	chr2:24149416	ATAD2B	-0.65	-6.7	-0.4	1.56e-10	Lymphocyte counts;
SARC	cis	rs13166103	0.571	rs62366402	chr5:57766031	G/A	cg10487770	chr5:57879443	RAB3C	0.53	5.58	0.34	6.73e-8	Type 2 diabetes (age of onset);
SARC	cis	rs3781913	0.874	rs12797368	chr11:72369385	C/T	cg03713592	chr11:72463424	ARAP1	-0.47	-5.71	-0.35	3.42e-8	Rheumatoid arthritis;
SARC	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.62	7.84	0.46	1.61e-13	Chronic sinus infection;
SARC	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.62	0.45	6.48e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg04518342	chr5:131593106	PDLIM4	0.37	5.27	0.33	3.16e-7	Breast cancer;
SARC	cis	rs28386778	0.703	rs2286565	chr17:62010232	G/T	cg09373136	chr17:61933544	TCAM1	0.41	5.58	0.34	6.76e-8	Prudent dietary pattern;
SARC	cis	rs950880	0.677	rs17027087	chr2:103015918	C/T	cg03938978	chr2:103052716	IL18RAP	-0.33	-4.73	-0.3	3.83e-6	Serum protein levels (sST2);
SARC	cis	rs1318878	0.565	rs28832932	chr12:15452087	A/T	cg08258403	chr12:15378311	NA	0.48	6.84	0.41	6.91e-11	Intelligence (multi-trait analysis);
SARC	cis	rs9815354	0.812	rs73069356	chr3:41752845	G/A	cg03022575	chr3:42003672	ULK4	0.62	4.82	0.3	2.56e-6	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6964587	0.967	rs410	chr7:91557425	C/G	cg17063962	chr7:91808500	NA	-0.92	-14.33	-0.68	8.1e-34	Breast cancer;
SARC	cis	rs4588572	0.570	rs2362832	chr5:77795843	A/G	cg11547950	chr5:77652471	NA	-0.4	-5.03	-0.31	9.8e-7	Triglycerides;
SARC	cis	rs6088590	0.561	rs6059918	chr20:33150503	C/T	cg08999081	chr20:33150536	PIGU	0.44	6.78	0.41	9.94e-11	Coronary artery disease;
SARC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.32	6.53e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1023500	0.505	rs134874	chr22:42661144	A/G	cg04733989	chr22:42467013	NAGA	0.53	6.73	0.4	1.29e-10	Schizophrenia;
SARC	cis	rs2075371	0.933	rs2544182	chr7:133949793	C/T	cg20476274	chr7:133979776	SLC35B4	0.61	8.33	0.48	6.83e-15	Mean platelet volume;
SARC	cis	rs9902453	0.740	rs2617884	chr17:28120430	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.15	-0.42	1.09e-11	Coffee consumption (cups per day);
SARC	trans	rs8020941	0.585	rs75424745	chr14:97498188	T/C	cg05136476	chr3:53190709	NA	-0.63	-6.39	-0.39	8.99e-10	Diabetic kidney disease;
SARC	cis	rs782590	0.837	rs809732	chr2:55914621	T/C	cg18811423	chr2:55921094	PNPT1	0.78	11.89	0.61	8.85e-26	Metabolic syndrome;
SARC	cis	rs3204955	0.721	rs35672929	chr1:116270234	A/C	cg20810993	chr1:116250018	CASQ2	-0.49	-5.39	-0.33	1.7e-7	Itch intensity from mosquito bite adjusted by bite size;
SARC	cis	rs8067545	0.616	rs203470	chr17:19858626	C/T	cg13482628	chr17:19912719	NA	0.5	6.23	0.38	2.21e-9	Schizophrenia;
SARC	cis	rs6942407	0.546	rs7810647	chr7:86805961	C/A	cg02420886	chr7:86849541	C7orf23	0.71	6.11	0.37	4.04e-9	Food allergy;
SARC	cis	rs6831352	0.959	rs6848050	chr4:100053733	T/C	cg13256891	chr4:100009986	ADH5	0.65	8.65	0.49	8.37e-16	Alcohol dependence;
SARC	cis	rs4481887	1.000	rs4244180	chr1:248471033	A/G	cg00666640	chr1:248458726	OR2T12	0.37	6.18	0.38	2.86e-9	Common traits (Other);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg20999565	chr14:68265668	ZFYVE26	0.52	6.32	0.38	1.33e-9	Breast cancer;
SARC	cis	rs7312774	0.618	rs61061573	chr12:107372758	T/C	cg16260113	chr12:107380972	MTERFD3	1.16	8.91	0.5	1.49e-16	Severe influenza A (H1N1) infection;
SARC	cis	rs7582720	1.000	rs72936353	chr2:204070956	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	7.88	0.46	1.21e-13	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs757978	1.000	rs73116396	chr2:242368693	A/G	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.82	-7.01	-0.42	2.58e-11	Chronic lymphocytic leukemia;
SARC	cis	rs12971120	0.685	rs34780792	chr18:72173278	G/A	cg25817165	chr18:72167213	CNDP2	-0.53	-7.38	-0.44	2.79e-12	Refractive error;
SARC	cis	rs787274	1.000	rs4304397	chr9:115598154	C/T	cg13803584	chr9:115635662	SNX30	0.77	4.74	0.3	3.74e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg07414643	chr4:187882934	NA	0.51	7.57	0.44	8.44e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10078	0.571	rs890977	chr5:476910	T/C	cg07599136	chr5:415885	AHRR	0.65	5.63	0.35	5.04e-8	Fat distribution (HIV);
SARC	cis	rs2011503	1.000	rs77427798	chr19:19652982	T/C	cg03709012	chr19:19516395	GATAD2A	0.6	5.29	0.33	2.8e-7	Bipolar disorder;
SARC	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg11987759	chr7:65425863	GUSB	-0.47	-6.26	-0.38	1.88e-9	Aortic root size;
SARC	cis	rs28374715	0.662	rs28493087	chr15:41486504	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.0	-13.58	-0.66	2.57e-31	Ulcerative colitis;
SARC	cis	rs4646312	0.555	rs737865	chr22:19930121	A/G	cg07194846	chr22:19930177	COMT;TXNRD2	0.52	6.8	0.41	8.56e-11	Schizophrenia;
SARC	trans	rs4295623	0.585	rs34421088	chr8:11589042	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.13	-0.42	1.25e-11	Morning vs. evening chronotype;
SARC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg26338869	chr17:61819248	STRADA	0.8	10.72	0.57	4.8e-22	Prudent dietary pattern;
SARC	cis	rs1448094	0.967	rs7313443	chr12:86332940	G/A	cg02569458	chr12:86230093	RASSF9	0.4	5.84	0.36	1.75e-8	Major depressive disorder;
SARC	cis	rs10904908	1.000	rs7903402	chr10:17259772	C/T	cg01003015	chr10:17271136	VIM	-0.42	-5.07	-0.32	8.15e-7	Total cholesterol levels;Cholesterol, total;
SARC	cis	rs9467711	0.591	rs3734528	chr6:26022244	A/G	cg21479132	chr6:26055353	NA	0.97	7.03	0.42	2.29e-11	Autism spectrum disorder or schizophrenia;
SARC	trans	rs7980799	0.649	rs1994135	chr12:33682405	T/C	cg26384229	chr12:38710491	ALG10B	0.54	6.44	0.39	6.59e-10	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs763121	0.853	rs5750669	chr22:39080638	T/A	cg06022373	chr22:39101656	GTPBP1	0.85	10.52	0.57	2.01e-21	Menopause (age at onset);
SARC	cis	rs3099143	0.901	rs28551558	chr15:77234637	C/T	cg21673338	chr15:77095150	SCAPER	-0.68	-5.37	-0.33	1.91e-7	Recalcitrant atopic dermatitis;
SARC	cis	rs7666738	0.830	rs7682991	chr4:98982595	C/A	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs8067354	0.645	rs2645489	chr17:57883371	T/G	cg13753209	chr17:57696993	CLTC	0.67	7.39	0.44	2.6e-12	Hemoglobin concentration;
SARC	cis	rs10861342	1.000	rs1076	chr12:105562788	C/T	cg23923672	chr12:105501055	KIAA1033	-0.67	-5.29	-0.33	2.86e-7	IgG glycosylation;
SARC	cis	rs916888	0.610	rs142167	chr17:44795234	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.53	-6.12	-0.37	3.88e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs1448094	1.000	rs7305284	chr12:86343786	C/T	cg02569458	chr12:86230093	RASSF9	0.39	5.71	0.35	3.36e-8	Major depressive disorder;
SARC	trans	rs61931739	0.534	rs11053005	chr12:34091626	A/C	cg13010199	chr12:38710504	ALG10B	0.77	10.37	0.56	5.83e-21	Morning vs. evening chronotype;
SARC	cis	rs72717009	0.825	rs7515174	chr1:161476949	C/G	cg23840854	chr1:161414152	NA	-0.54	-5.07	-0.32	8.2e-7	Rheumatoid arthritis;
SARC	cis	rs2204008	0.623	rs1315348	chr12:38163044	G/A	cg14851346	chr12:38532713	NA	-0.44	-5.26	-0.33	3.29e-7	Bladder cancer;
SARC	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg13395646	chr4:1353034	KIAA1530	-0.55	-6.58	-0.4	3.03e-10	Obesity-related traits;
SARC	cis	rs10752881	0.933	rs2027086	chr1:183057933	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.35	0.56	6.48e-21	Colorectal cancer;
SARC	cis	rs28374715	0.532	rs316606	chr15:41772202	A/C	cg18705301	chr15:41695430	NDUFAF1	-1.15	-17.69	-0.76	5.77e-45	Ulcerative colitis;
SARC	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.21	-0.52	1.94e-17	Developmental language disorder (linguistic errors);
SARC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.34	-5.1	-0.32	6.9e-7	Total body bone mineral density;
SARC	cis	rs9487051	0.872	rs1320612	chr6:109611990	C/A	cg01475377	chr6:109611718	NA	-0.41	-5.9	-0.36	1.25e-8	Reticulocyte fraction of red cells;
SARC	cis	rs3126085	0.877	rs12116736	chr1:152167062	C/T	cg09127314	chr1:152161683	NA	0.42	4.79	0.3	3.03e-6	Atopic dermatitis;
SARC	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg18252515	chr7:66147081	NA	-0.45	-4.98	-0.31	1.23e-6	Aortic root size;
SARC	cis	rs9325144	0.560	rs10785586	chr12:38676197	G/A	cg13010199	chr12:38710504	ALG10B	-0.58	-7.21	-0.43	7.87e-12	Morning vs. evening chronotype;
SARC	cis	rs7760949	0.852	rs9349847	chr6:13927711	T/C	cg27413430	chr6:13925136	RNF182	0.42	4.88	0.3	1.93e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs1707322	0.721	rs11211163	chr1:46153548	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.17	0.37	2.95e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4803455	0.586	rs4803457	chr19:41861359	T/C	cg08477640	chr19:41863820	B9D2	0.65	8.73	0.5	4.87e-16	Migraine;Coronary artery disease;
SARC	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg05890377	chr2:74357713	NA	0.58	7.29	0.43	4.83e-12	Gestational age at birth (maternal effect);
SARC	cis	rs6088580	0.524	rs6088565	chr20:33254986	A/C	cg08999081	chr20:33150536	PIGU	-0.35	-5.15	-0.32	5.45e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/TA	cg12826209	chr6:26865740	GUSBL1	0.63	5.63	0.35	5.06e-8	Intelligence (multi-trait analysis);
SARC	trans	rs208520	0.690	rs866452	chr6:66849936	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-13.07	-0.65	1.24e-29	Exhaled nitric oxide output;
SARC	cis	rs3820928	1.000	rs10193404	chr2:227777757	A/G	cg05526886	chr2:227700861	RHBDD1	-0.52	-6.23	-0.38	2.19e-9	Pulmonary function;
SARC	cis	rs11792861	0.781	rs72607158	chr9:111763010	T/C	cg13535736	chr9:111863775	C9orf5	-0.38	-4.71	-0.3	4.2e-6	Menarche (age at onset);
SARC	cis	rs838147	0.844	rs11083948	chr19:49248120	A/G	cg13540341	chr19:49222985	MAMSTR	0.28	4.73	0.3	3.83e-6	Dietary macronutrient intake;
SARC	cis	rs1865760	0.566	rs2858993	chr6:26087856	T/A	cg10373733	chr6:25993375	NA	0.46	5.56	0.34	7.36e-8	Height;
SARC	cis	rs8141529	0.956	rs469989	chr22:29303595	G/C	cg15103426	chr22:29168792	CCDC117	-0.63	-7.69	-0.45	4.05e-13	Lymphocyte counts;
SARC	cis	rs7582180	0.764	rs11691684	chr2:100921776	T/A	cg14675211	chr2:100938903	LONRF2	0.54	7.96	0.46	7.71e-14	Intelligence (multi-trait analysis);
SARC	cis	rs11792861	0.530	rs1772047	chr9:111679012	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.65	-8.25	-0.48	1.14e-14	Menarche (age at onset);
SARC	cis	rs9916302	0.706	rs4795385	chr17:37733148	A/G	cg20243544	chr17:37824526	PNMT	-0.55	-5.64	-0.35	4.83e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-6.16	-0.37	3.21e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1055129	0.682	rs7217432	chr17:73834604	A/G	cg06969265	chr17:73775802	H3F3B	0.44	5.1	0.32	7.03e-7	White matter hyperintensity burden;
SARC	cis	rs1707322	1.000	rs10890370	chr1:46389217	C/T	cg03146154	chr1:46216737	IPP	0.44	5.07	0.32	7.93e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9487051	1.000	rs1341271	chr6:109617542	A/T	cg01475377	chr6:109611718	NA	-0.4	-5.54	-0.34	8.03e-8	Reticulocyte fraction of red cells;
SARC	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg22834771	chr12:69754056	YEATS4	-0.45	-5.86	-0.36	1.54e-8	Blood protein levels;
SARC	cis	rs10191773	0.535	rs56048537	chr2:113078467	G/T	cg07905836	chr2:113190072	RGPD8;RGPD5	0.91	8.79	0.5	3.26e-16	Yeast infection;
SARC	cis	rs477692	0.673	rs487120	chr10:131367552	C/T	cg14263093	chr10:131365266	MGMT	0.35	4.84	0.3	2.37e-6	Response to temozolomide;
SARC	cis	rs74417235	0.684	rs7723312	chr5:154053249	A/G	cg17344516	chr5:154026930	NA	-0.55	-5.6	-0.34	6.12e-8	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
SARC	cis	rs10754283	0.967	rs4658130	chr1:90113447	G/C	cg21401794	chr1:90099060	LRRC8C	0.59	8.09	0.47	3.24e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs9611519	0.894	rs9611488	chr22:41462592	G/T	cg03806693	chr22:41940476	POLR3H	-0.59	-7.37	-0.43	2.88e-12	Neuroticism;
SARC	cis	rs2204008	0.775	rs2387809	chr12:38363338	T/A	cg26384229	chr12:38710491	ALG10B	0.87	12.69	0.64	2.17e-28	Bladder cancer;
SARC	cis	rs3857536	0.776	rs4710316	chr6:66935097	T/A	cg07460842	chr6:66804631	NA	-0.51	-5.83	-0.36	1.86e-8	Blood trace element (Cu levels);
SARC	cis	rs9467773	0.967	rs6932865	chr6:26540166	C/A	cg11502198	chr6:26597334	ABT1	0.46	5.61	0.34	5.83e-8	Intelligence (multi-trait analysis);
SARC	cis	rs36051895	0.672	rs12353218	chr9:5162828	T/C	cg02405213	chr9:5042618	JAK2	-0.46	-5.47	-0.34	1.14e-7	Pediatric autoimmune diseases;
SARC	cis	rs17854409	0.803	rs3210314	chr20:61472117	C/A	cg05147244	chr20:61493195	TCFL5	0.94	6.03	0.37	6.42e-9	Obesity-related traits;
SARC	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg24399712	chr22:39784796	NA	-0.46	-6.27	-0.38	1.69e-9	Intelligence (multi-trait analysis);
SARC	cis	rs1707322	1.000	rs785498	chr1:46592414	C/T	cg06784218	chr1:46089804	CCDC17	-0.36	-6.2	-0.38	2.58e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs735396	0.627	rs2264778	chr12:121450354	C/A	cg02403541	chr12:121454288	C12orf43	0.89	14.49	0.69	2.27e-34	N-glycan levels;
SARC	cis	rs7617773	0.780	rs34946886	chr3:48338487	A/G	cg11946769	chr3:48343235	NME6	0.76	9.72	0.54	5.94e-19	Coronary artery disease;
SARC	cis	rs7208859	0.623	rs73271869	chr17:29152221	G/A	cg13385521	chr17:29058706	SUZ12P	0.85	7.66	0.45	4.88e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg27665769	chr4:2757761	TNIP2	0.52	7.15	0.42	1.13e-11	Chemerin levels;
SARC	trans	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg00938859	chr5:1591904	SDHAP3	0.74	6.91	0.41	4.61e-11	Breast cancer;
SARC	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg11644478	chr21:40555479	PSMG1	1.02	12.45	0.63	1.28e-27	Cognitive function;
SARC	cis	rs9660992	0.573	rs1172139	chr1:205213962	G/A	cg00857998	chr1:205179979	DSTYK	0.52	6.54	0.39	3.78e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs1843834	0.539	rs6713629	chr2:225410973	A/T	cg12698349	chr2:225449008	CUL3	0.63	8.14	0.47	2.34e-14	IgE levels in asthmatics (D.p. specific);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg00423826	chr8:143534636	NA	-0.83	-7.16	-0.42	1.02e-11	Autism spectrum disorder or schizophrenia;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg05602567	chr22:32871203	FBXO7	-0.51	-6.29	-0.38	1.53e-9	Height;
SARC	cis	rs6991838	0.584	rs35790435	chr8:66502523	G/A	cg13398993	chr8:66546079	ARMC1	-0.62	-8.43	-0.48	3.51e-15	Intelligence (multi-trait analysis);
SARC	cis	rs7246657	0.943	rs7259968	chr19:37811854	T/C	cg14683738	chr19:37701593	ZNF585B	0.5	4.93	0.31	1.6e-6	Coronary artery calcification;
SARC	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg04166393	chr7:2884313	GNA12	0.42	5.03	0.31	9.74e-7	Height;
SARC	cis	rs78487399	0.808	rs13405158	chr2:43705286	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.52	4.72	0.3	4.13e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs8005677	1.000	rs4982712	chr14:23403728	A/G	cg01529538	chr14:23388837	RBM23	0.42	5.06	0.31	8.61e-7	Cognitive ability (multi-trait analysis);
SARC	cis	rs798554	0.610	rs1182209	chr7:2808595	C/T	cg13628971	chr7:2884303	GNA12	0.44	5.4	0.33	1.66e-7	Height;
SARC	cis	rs2760061	0.583	rs3094911	chr1:228210179	A/G	cg02753203	chr1:228287806	NA	0.79	11.68	0.61	3.96e-25	Diastolic blood pressure;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg07316263	chr16:67193999	TRADD;FBXL8	0.62	6.36	0.38	1.09e-9	Lung cancer in ever smokers;
SARC	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.48	-5.78	-0.35	2.43e-8	Calcium levels;
SARC	cis	rs6087990	0.731	rs2424897	chr20:31338098	A/T	cg13636640	chr20:31349939	DNMT3B	0.78	12.42	0.63	1.59e-27	Ulcerative colitis;
SARC	trans	rs7395662	0.548	rs4882000	chr11:48546496	A/G	cg15704280	chr7:45808275	SEPT13	-0.49	-6.69	-0.4	1.6e-10	HDL cholesterol;
SARC	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg07636037	chr3:49044803	WDR6	0.91	15.46	0.71	1.35e-37	Menarche (age at onset);
SARC	cis	rs941408	0.928	rs2741991	chr19:2802092	T/C	cg00079169	chr19:2811669	THOP1	0.43	4.84	0.3	2.32e-6	Total cholesterol levels;
SARC	cis	rs7408868	1.000	rs10418305	chr19:15278808	C/G	cg14696996	chr19:15285081	NOTCH3	1.01	8.87	0.5	1.93e-16	Pulse pressure;
SARC	cis	rs3796352	1.000	rs13069006	chr3:52973305	G/C	cg15956490	chr3:53032818	SFMBT1	0.89	5.76	0.35	2.62e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg22590775	chr19:49891494	CCDC155	0.52	6.16	0.37	3.18e-9	Multiple sclerosis;
SARC	cis	rs1569175	0.677	rs281773	chr2:200813584	T/C	cg23649088	chr2:200775458	C2orf69	-0.81	-4.95	-0.31	1.42e-6	Response to treatment for acute lymphoblastic leukemia;
SARC	cis	rs17376456	0.569	rs6556834	chr5:93123067	C/T	cg25358565	chr5:93447407	FAM172A	-0.93	-10.51	-0.57	2.14e-21	Diabetic retinopathy;
SARC	cis	rs7089973	0.624	rs17586888	chr10:116598121	T/C	cg08188268	chr10:116634841	FAM160B1	0.28	4.86	0.3	2.13e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs7833790	1.000	rs7833790	chr8:82731157	T/C	cg27398817	chr8:82754497	SNX16	-0.5	-5.61	-0.34	5.79e-8	Diastolic blood pressure;
SARC	cis	rs9462027	0.675	rs34657938	chr6:34801631	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-6.14	-0.37	3.58e-9	Systemic lupus erythematosus;
SARC	cis	rs459482	1.000	rs464783	chr21:42796480	A/G	cg14166395	chr21:42792516	MX1	-0.64	-8.29	-0.48	9.21e-15	IgG glycosylation;
SARC	cis	rs10088262	0.629	rs1367829	chr8:124797135	A/G	cg20713898	chr8:124780851	FAM91A1	-0.64	-7.16	-0.42	1.07e-11	Pancreatic cancer;
SARC	cis	rs9457247	0.663	rs9295384	chr6:167448113	T/A	cg07741184	chr6:167504864	NA	0.36	7.2	0.43	8.2e-12	Crohn's disease;
SARC	cis	rs7937682	0.632	rs1045282	chr11:111754574	A/C	cg22437258	chr11:111473054	SIK2	-0.47	-5.47	-0.34	1.17e-7	Primary sclerosing cholangitis;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg05910138	chr5:74632922	HMGCR	0.49	6.29	0.38	1.52e-9	Lung adenocarcinoma;
SARC	trans	rs12310956	0.532	rs10844707	chr12:33936089	T/C	cg13010199	chr12:38710504	ALG10B	0.72	9.62	0.53	1.12e-18	Morning vs. evening chronotype;
SARC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg14159672	chr1:205819179	PM20D1	0.85	13.88	0.67	2.48e-32	Menarche (age at onset);
SARC	cis	rs13202913	0.652	rs9383578	chr6:151838192	C/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.53	5.02	0.31	1.04e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs16854884	0.584	rs59768870	chr3:143738366	G/A	cg06585982	chr3:143692056	C3orf58	0.67	9.12	0.51	3.73e-17	Economic and political preferences (feminism/equality);
SARC	trans	rs208520	0.526	rs2881644	chr6:66803535	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.1	21.74	0.82	5.34e-58	Exhaled nitric oxide output;
SARC	cis	rs911263	0.603	rs12885750	chr14:68770031	T/G	cg18825221	chr14:68749962	RAD51L1	0.43	7.65	0.45	5.43e-13	Primary biliary cholangitis;
SARC	cis	rs7582180	0.627	rs2099611	chr2:101021090	A/G	cg14675211	chr2:100938903	LONRF2	0.52	7.48	0.44	1.48e-12	Intelligence (multi-trait analysis);
SARC	cis	rs1728785	1.000	rs8058314	chr16:68584151	G/A	cg02972257	chr16:68554789	NA	-0.43	-5.01	-0.31	1.08e-6	Ulcerative colitis;
SARC	cis	rs3733585	0.673	rs6836706	chr4:9964251	T/A	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.55	-0.34	7.65e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs4761669	0.876	rs10777624	chr12:95199015	T/C	cg21533806	chr12:95267307	NA	0.44	5.57	0.34	7.17e-8	Common carotid intima-media thickness in HIV infection;
SARC	cis	rs6714710	0.580	rs13032265	chr2:98409565	T/C	cg26665480	chr2:98280029	ACTR1B	0.5	6.62	0.4	2.42e-10	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs748404	0.660	rs2467742	chr15:43750237	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	5.54	0.34	8.19e-8	Lung cancer;
SARC	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg13939156	chr17:80058883	NA	0.4	6.25	0.38	1.92e-9	Life satisfaction;
SARC	cis	rs7927771	1.000	rs7927771	chr11:47781306	A/G	cg20307385	chr11:47447363	PSMC3	-0.47	-5.59	-0.34	6.3e-8	Subjective well-being;
SARC	cis	rs3796352	1.000	rs10510761	chr3:52965255	A/G	cg07884673	chr3:53033167	SFMBT1	-0.73	-5.03	-0.31	9.71e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs804280	0.638	rs36038176	chr8:11609995	C/T	cg26752888	chr8:11627280	NEIL2	0.51	5.35	0.33	2.05e-7	Myopia (pathological);
SARC	cis	rs7659604	1.000	rs6814995	chr4:122664963	A/T	cg19671926	chr4:122722719	EXOSC9	0.53	6.49	0.39	5.01e-10	Type 2 diabetes;
SARC	cis	rs698833	0.926	rs1067353	chr2:44666626	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.68	8.7	0.5	6.13e-16	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs4563143	0.514	rs55727361	chr19:29300415	A/T	cg14983838	chr19:29218262	NA	0.66	7.61	0.45	6.72e-13	Methadone dose in opioid dependence;
SARC	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg03709012	chr19:19516395	GATAD2A	1.0	17.34	0.75	7.93e-44	Tonsillectomy;
SARC	cis	rs4642101	0.590	rs6799544	chr3:12812979	T/C	cg24848339	chr3:12840334	CAND2	0.35	5.3	0.33	2.71e-7	QRS complex (12-leadsum);
SARC	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.76	7.91	0.46	1.03e-13	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs35110281	0.714	rs2282526	chr21:45080552	A/T	cg21573476	chr21:45109991	RRP1B	-0.58	-8.39	-0.48	4.59e-15	Mean corpuscular volume;
SARC	cis	rs11792861	0.926	rs72607169	chr9:111832471	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.67	7.64	0.45	5.51e-13	Menarche (age at onset);
SARC	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg23172400	chr8:95962367	TP53INP1	-0.3	-5.26	-0.33	3.24e-7	Type 2 diabetes;
SARC	cis	rs7617773	0.815	rs7624450	chr3:48350375	A/G	cg11946769	chr3:48343235	NME6	0.76	9.7	0.54	6.55e-19	Coronary artery disease;
SARC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg21782813	chr7:2030301	MAD1L1	0.44	6.94	0.41	3.88e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs2730245	0.851	rs2657333	chr7:158728743	G/A	cg24397884	chr7:158709396	WDR60	-1.03	-15.54	-0.71	7.54e-38	Height;
SARC	cis	rs11098499	0.909	rs28793658	chr4:120307214	A/C	cg09160332	chr4:120329925	NA	-0.34	-4.81	-0.3	2.75e-6	Corneal astigmatism;
SARC	cis	rs733592	0.524	rs10875726	chr12:48425992	A/G	cg24011408	chr12:48396354	COL2A1	-0.51	-7.08	-0.42	1.73e-11	Plateletcrit;
SARC	cis	rs7914558	0.966	rs3902934	chr10:104746649	A/G	cg04362960	chr10:104952993	NT5C2	0.41	5.06	0.31	8.32e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	trans	rs208515	0.525	rs4145045	chr6:66678949	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.9	10.58	0.57	1.26e-21	Exhaled nitric oxide levels;
SARC	cis	rs7178909	0.835	rs12437459	chr15:90420773	A/C	cg19708238	chr15:90437601	AP3S2	0.6	7.92	0.46	9.41e-14	Common traits (Other);
SARC	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg16680214	chr1:154839983	KCNN3	-0.38	-5.93	-0.36	1.1e-8	Prostate cancer;
SARC	cis	rs7843479	0.544	rs4872110	chr8:21784989	A/G	cg17168535	chr8:21777572	XPO7	0.86	12.7	0.64	1.95e-28	Mean corpuscular volume;
SARC	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg23758822	chr17:41437982	NA	0.9	11.27	0.59	8.66e-24	Menopause (age at onset);
SARC	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg01475735	chr3:40494733	NA	0.48	5.65	0.35	4.77e-8	Renal cell carcinoma;
SARC	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg23758822	chr17:41437982	NA	0.87	10.66	0.57	7.3e-22	Menopause (age at onset);
SARC	cis	rs3218477	1.000	rs3218382	chr7:152373416	G/A	cg06618968	chr7:152373420	XRCC2	-0.76	-4.97	-0.31	1.32e-6	Mean platelet volume;
SARC	cis	rs7633857	0.512	rs733948	chr3:160652784	C/G	cg03342759	chr3:160939853	NMD3	-0.5	-6.0	-0.37	7.41e-9	Educational attainment (years of education);
SARC	cis	rs17376456	0.825	rs10056879	chr5:93282218	C/A	cg21475434	chr5:93447410	FAM172A	0.82	6.78	0.41	9.59e-11	Diabetic retinopathy;
SARC	cis	rs12200560	0.505	rs2387378	chr6:97077504	C/A	cg06623918	chr6:96969491	KIAA0776	0.46	5.29	0.33	2.82e-7	Coronary heart disease;
SARC	cis	rs1843834	0.539	rs6713629	chr2:225410973	A/T	cg22455342	chr2:225449267	CUL3	0.64	7.96	0.46	7.31e-14	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg22920501	chr2:26401640	FAM59B	-0.56	-7.63	-0.45	6e-13	Gut microbiome composition (summer);
SARC	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	10.58	0.57	1.27e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs2425143	1.000	rs1970357	chr20:34339200	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.7	6.18	0.38	2.86e-9	Blood protein levels;
SARC	trans	rs1814175	0.587	rs847628	chr11:49927064	A/T	cg03929089	chr4:120376271	NA	-0.81	-11.69	-0.61	3.89e-25	Height;
SARC	cis	rs9788721	0.836	rs17484524	chr15:78772676	A/G	cg18825076	chr15:78729989	IREB2	-0.53	-6.4	-0.39	8.63e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs2230307	0.536	rs11166407	chr1:100637708	C/T	cg24955406	chr1:100503596	HIAT1	0.66	6.45	0.39	6.35e-10	Carotid intima media thickness;
SARC	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg11764359	chr7:65958608	NA	-0.62	-7.32	-0.43	3.88e-12	Aortic root size;
SARC	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg27266027	chr21:40555129	PSMG1	0.46	4.9	0.31	1.83e-6	Cognitive function;
SARC	cis	rs2841277	0.676	rs4264326	chr14:105411700	A/G	cg21017887	chr14:105400489	NA	0.5	6.97	0.42	3.2e-11	Rheumatoid arthritis;
SARC	cis	rs713587	0.624	rs1550110	chr2:25124563	T/C	cg04586622	chr2:25135609	ADCY3	0.32	5.49	0.34	1.04e-7	Body mass index in non-asthmatics;
SARC	cis	rs4911259	0.552	rs11697394	chr20:31460076	G/A	cg13636640	chr20:31349939	DNMT3B	-0.7	-9.67	-0.54	8.4e-19	Inflammatory bowel disease;
SARC	cis	rs7949030	0.688	rs2849031	chr11:62365665	G/A	cg13298116	chr11:62369859	EML3;MTA2	-0.45	-7.13	-0.42	1.26e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs6540556	0.769	rs9430017	chr1:209925058	C/T	cg05527609	chr1:210001259	C1orf107	-0.64	-5.97	-0.36	8.95e-9	Red blood cell count;
SARC	cis	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg25427524	chr10:38739819	LOC399744	-0.52	-8.23	-0.47	1.32e-14	Extrinsic epigenetic age acceleration;
SARC	cis	rs7084921	0.579	rs2862947	chr10:101863817	C/G	cg11888571	chr10:102027403	CWF19L1	-0.42	-4.73	-0.3	3.82e-6	Bone mineral density;
SARC	cis	rs757110	0.866	rs5213	chr11:17408404	C/T	cg15432903	chr11:17409602	KCNJ11	0.57	9.25	0.52	1.44e-17	Type 2 diabetes;
SARC	cis	rs7561149	1.000	rs12464151	chr2:179690909	C/T	cg17765952	chr2:179737173	CCDC141	-0.38	-5.03	-0.31	1e-6	QT interval;
SARC	cis	rs881375	0.678	rs1930782	chr9:123687905	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	6.6	0.4	2.8e-10	Rheumatoid arthritis;
SARC	cis	rs9398803	0.624	rs1455738	chr6:126636820	A/G	cg19875578	chr6:126661172	C6orf173	0.45	6.16	0.37	3.21e-9	Male-pattern baldness;
SARC	cis	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg25894440	chr7:65020034	NA	-0.74	-5.64	-0.35	4.95e-8	Diabetic kidney disease;
SARC	cis	rs6087990	0.735	rs2424914	chr20:31374520	A/G	cg13636640	chr20:31349939	DNMT3B	0.8	12.43	0.63	1.48e-27	Ulcerative colitis;
SARC	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	10.75	0.58	3.81e-22	Alzheimer's disease;
SARC	cis	rs2658782	0.789	rs1456238	chr11:93117370	G/C	cg15737290	chr11:93063684	CCDC67	0.69	7.22	0.43	7.32e-12	Pulmonary function decline;
SARC	cis	rs2731664	0.792	rs335434	chr5:176867276	A/G	cg23176889	chr5:176863531	GRK6	-0.56	-8.0	-0.46	5.67e-14	Intelligence (multi-trait analysis);
SARC	cis	rs10905065	0.930	rs7096742	chr10:5735648	C/T	cg09072322	chr10:5726702	C10orf18	-0.41	-5.09	-0.32	7.23e-7	Menopause (age at onset);
SARC	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg24549020	chr5:56110836	MAP3K1	-0.79	-8.24	-0.48	1.25e-14	Initial pursuit acceleration;
SARC	cis	rs1153858	1.000	rs12591058	chr15:45640172	T/C	cg26924012	chr15:45694286	SPATA5L1	0.75	10.34	0.56	7.26e-21	Homoarginine levels;
SARC	trans	rs61931739	0.517	rs1586409	chr12:34046614	C/A	cg13010199	chr12:38710504	ALG10B	0.67	9.0	0.51	7.94e-17	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg21724239	chr8:58056113	NA	0.6	6.37	0.38	1.03e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs11690935	0.550	rs11676438	chr2:172826668	G/A	cg13550731	chr2:172543902	DYNC1I2	0.54	7.11	0.42	1.45e-11	Schizophrenia;
SARC	cis	rs13191362	0.938	rs35395472	chr6:163008493	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.56	5.35	0.33	2.07e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs11098499	0.909	rs28793658	chr4:120307214	A/C	cg09307838	chr4:120376055	NA	0.91	12.95	0.65	2.99e-29	Corneal astigmatism;
SARC	cis	rs947211	0.898	rs1772153	chr1:205745782	C/T	cg14893161	chr1:205819251	PM20D1	-0.48	-5.45	-0.34	1.3e-7	Parkinson's disease;
SARC	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg26335602	chr6:28129616	ZNF389	0.52	5.88	0.36	1.44e-8	Depression;
SARC	cis	rs10905065	0.569	rs4750553	chr10:5728174	C/T	cg09072322	chr10:5726702	C10orf18	-0.46	-5.62	-0.35	5.41e-8	Menopause (age at onset);
SARC	cis	rs2120019	1.000	rs12901243	chr15:75374233	C/T	cg12414181	chr15:75287860	SCAMP5	-0.42	-4.89	-0.31	1.87e-6	Blood trace element (Zn levels);
SARC	cis	rs2439831	0.850	rs12441984	chr15:44126285	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	7.59	0.45	7.57e-13	Lung cancer in ever smokers;
SARC	cis	rs208520	0.690	rs1304672	chr6:66847973	A/G	cg07460842	chr6:66804631	NA	0.96	11.65	0.61	4.97e-25	Exhaled nitric oxide output;
SARC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.03	0.37	6.27e-9	Prudent dietary pattern;
SARC	cis	rs4727027	0.704	rs4727031	chr7:148908305	T/C	cg23583168	chr7:148888333	NA	-0.78	-11.28	-0.59	7.75e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs67311347	0.911	rs6776044	chr3:40377503	T/G	cg24209194	chr3:40518798	ZNF619	0.58	7.29	0.43	4.74e-12	Renal cell carcinoma;
SARC	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg24642844	chr7:1081250	C7orf50	-0.57	-6.05	-0.37	5.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	trans	rs2456568	0.803	rs10831142	chr11:93640781	A/G	cg27370028	chr20:62693943	TCEA2	0.42	6.29	0.38	1.55e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
SARC	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg03433033	chr1:76189801	ACADM	-0.52	-6.5	-0.39	4.83e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs8141529	0.732	rs2239815	chr22:29192670	C/T	cg15103426	chr22:29168792	CCDC117	-0.71	-9.56	-0.53	1.78e-18	Lymphocyte counts;
SARC	cis	rs2180341	0.960	rs7753913	chr6:127671296	A/G	cg24812749	chr6:127587940	RNF146	1.01	13.21	0.65	4.13e-30	Breast cancer;
SARC	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg03264133	chr6:25882463	NA	0.38	5.03	0.31	9.81e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6714710	0.603	rs12104810	chr2:98443658	C/T	cg26665480	chr2:98280029	ACTR1B	0.5	6.7	0.4	1.55e-10	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg13395646	chr4:1353034	KIAA1530	-0.56	-6.69	-0.4	1.66e-10	Obesity-related traits;
SARC	cis	rs1609391	0.543	rs7651085	chr3:136625339	C/G	cg15507776	chr3:136538369	TMEM22	0.83	11.54	0.6	1.17e-24	Neuroticism;
SARC	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg11742103	chr11:62369870	EML3;MTA2	0.36	4.75	0.3	3.6e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs60733400	0.782	rs4648564	chr1:2562169	C/T	cg18854424	chr1:2615690	NA	-0.33	-5.24	-0.32	3.66e-7	Multiple sclerosis;
SARC	cis	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg11266682	chr4:10021025	SLC2A9	0.41	7.29	0.43	4.75e-12	Bone mineral density;
SARC	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg23172400	chr8:95962367	TP53INP1	-0.31	-5.42	-0.33	1.49e-7	Type 2 diabetes;
SARC	cis	rs9296092	0.500	rs9469503	chr6:33527234	G/T	cg13560919	chr6:33536144	NA	-0.52	-6.41	-0.39	8.07e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	trans	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg11693508	chr17:37793320	STARD3	0.73	6.94	0.41	3.88e-11	Bipolar disorder;
SARC	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.54	6.97	0.42	3.19e-11	Personality dimensions;
SARC	cis	rs11155671	0.530	rs1334510	chr6:150201179	A/G	cg05036130	chr6:150231994	NA	0.32	5.36	0.33	1.96e-7	Testicular germ cell tumor;
SARC	trans	rs1814175	0.534	rs1983448	chr11:49933856	C/A	cg15704280	chr7:45808275	SEPT13	-0.9	-13.82	-0.67	3.88e-32	Height;
SARC	cis	rs611744	0.870	rs381742	chr8:109142079	G/T	cg21045802	chr8:109455806	TTC35	0.41	4.86	0.3	2.21e-6	Dupuytren's disease;
SARC	cis	rs1865760	1.000	rs6938233	chr6:25914077	C/T	cg17691542	chr6:26056736	HIST1H1C	0.57	7.02	0.42	2.47e-11	Height;
SARC	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg26818010	chr10:134567672	INPP5A	-0.65	-6.92	-0.41	4.21e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg03709012	chr19:19516395	GATAD2A	-0.98	-16.29	-0.73	2.51e-40	Tonsillectomy;
SARC	cis	rs921968	0.541	rs576901	chr2:219424364	A/G	cg02176678	chr2:219576539	TTLL4	0.45	6.75	0.4	1.18e-10	Mean corpuscular hemoglobin concentration;
SARC	cis	rs4819052	0.635	rs2838808	chr21:46621106	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.42	4.93	0.31	1.54e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs870825	0.616	rs6843185	chr4:185649878	A/C	cg04058563	chr4:185651563	MLF1IP	0.79	11.18	0.59	1.67e-23	Blood protein levels;
SARC	cis	rs6539267	0.741	rs7314289	chr12:106686260	A/C	cg00173435	chr12:106696525	TCP11L2	0.82	9.74	0.54	5.05e-19	Tourette syndrome;
SARC	trans	rs61931739	0.517	rs7139189	chr12:34319757	T/C	cg26384229	chr12:38710491	ALG10B	0.73	10.21	0.56	1.81e-20	Morning vs. evening chronotype;
SARC	trans	rs1814175	0.712	rs9665784	chr11:50030617	C/T	cg03929089	chr4:120376271	NA	-0.87	-13.86	-0.67	2.91e-32	Height;
SARC	cis	rs4555082	0.874	rs113291192	chr14:105738181	C/T	cg06808227	chr14:105710500	BRF1	-0.53	-6.74	-0.4	1.27e-10	Mean platelet volume;Platelet distribution width;
SARC	cis	rs7843479	0.506	rs7818430	chr8:21798429	C/T	cg17168535	chr8:21777572	XPO7	0.87	13.95	0.67	1.46e-32	Mean corpuscular volume;
SARC	cis	rs1077216	0.522	rs3729704	chr3:46900051	A/G	cg02527881	chr3:46936655	PTH1R	-0.49	-5.03	-0.31	9.74e-7	Microalbuminuria;
SARC	cis	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg07777115	chr5:623756	CEP72	-0.64	-5.75	-0.35	2.75e-8	Obesity-related traits;
SARC	cis	rs9905704	0.647	rs11652713	chr17:57079742	C/T	cg12560992	chr17:57184187	TRIM37	0.43	5.24	0.32	3.64e-7	Testicular germ cell tumor;
SARC	cis	rs7027203	0.688	rs4075733	chr9:96624645	C/T	cg14598338	chr9:96623480	NA	-0.56	-8.19	-0.47	1.7e-14	DNA methylation (variation);
SARC	cis	rs7659604	0.537	rs6815973	chr4:122663430	A/T	cg19671926	chr4:122722719	EXOSC9	0.48	5.45	0.34	1.26e-7	Type 2 diabetes;
SARC	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg21782813	chr7:2030301	MAD1L1	0.33	5.15	0.32	5.49e-7	Schizophrenia;
SARC	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg03806693	chr22:41940476	POLR3H	0.83	11.81	0.61	1.51e-25	Vitiligo;
SARC	cis	rs67478160	0.619	rs2368560	chr14:104273311	C/T	cg26031613	chr14:104095156	KLC1	-0.42	-4.91	-0.31	1.68e-6	Schizophrenia;
SARC	cis	rs6582630	0.555	rs1906260	chr12:38601013	T/G	cg26384229	chr12:38710491	ALG10B	0.9	13.74	0.67	7.52e-32	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1483890	0.723	rs12629229	chr3:69411222	A/G	cg22125112	chr3:69402811	FRMD4B	0.29	4.9	0.31	1.81e-6	Resting heart rate;
SARC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg26338869	chr17:61819248	STRADA	0.81	10.95	0.58	8.96e-23	Prudent dietary pattern;
SARC	cis	rs3858526	0.883	rs4758183	chr11:5925178	C/G	cg02574844	chr11:5959923	NA	-0.39	-4.91	-0.31	1.74e-6	DNA methylation (variation);
SARC	cis	rs3733585	0.673	rs6814664	chr4:9956228	C/T	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.39	-0.33	1.73e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg17747265	chr1:1875780	NA	-0.33	-4.8	-0.3	2.81e-6	Body mass index;
SARC	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg12463550	chr7:65579703	CRCP	0.69	5.23	0.32	3.73e-7	Diabetic kidney disease;
SARC	cis	rs2797685	1.000	rs2640908	chr1:7889941	C/T	cg00864860	chr1:7907996	UTS2	-0.37	-5.23	-0.32	3.74e-7	Crohn's disease;
SARC	cis	rs11758351	1.000	rs76329209	chr6:26196430	A/G	cg01420254	chr6:26195488	NA	0.55	4.8	0.3	2.79e-6	Gout;Renal underexcretion gout;
SARC	cis	rs7828089	1.000	rs7837964	chr8:22264417	G/C	cg12081754	chr8:22256438	SLC39A14	0.44	5.71	0.35	3.4e-8	Verbal declarative memory;
SARC	cis	rs9303401	0.659	rs17222621	chr17:56695923	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	12.09	0.62	2e-26	Cognitive test performance;
SARC	cis	rs2273669	0.667	rs12215614	chr6:109313629	T/C	cg05315195	chr6:109294784	ARMC2	-0.59	-5.45	-0.34	1.28e-7	Prostate cancer;
SARC	cis	rs17384381	1.000	rs12128907	chr1:85891385	A/G	cg16011679	chr1:85725395	C1orf52	0.61	5.66	0.35	4.32e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7615952	0.932	rs11922218	chr3:125631289	C/T	cg05084668	chr3:125655381	ALG1L	-0.68	-6.71	-0.4	1.45e-10	Blood pressure (smoking interaction);
SARC	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg16405210	chr4:1374714	KIAA1530	-0.45	-5.51	-0.34	9.41e-8	Longevity;
SARC	cis	rs2652822	0.933	rs7170846	chr15:63449543	A/C	cg02713581	chr15:63449717	RPS27L	0.71	9.78	0.54	3.74e-19	Metabolic traits;
SARC	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg03354898	chr7:1950403	MAD1L1	-0.36	-4.86	-0.3	2.12e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs6942407	0.696	rs6465103	chr7:86862068	A/G	cg02420886	chr7:86849541	C7orf23	0.64	5.75	0.35	2.79e-8	Food allergy;
SARC	cis	rs76419734	0.614	rs72669979	chr4:106523289	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.68	6.04	0.37	6.02e-9	Post bronchodilator FEV1;
SARC	cis	rs963731	0.649	rs2278914	chr2:39218552	G/A	cg04010122	chr2:39346883	SOS1	-1.07	-6.23	-0.38	2.13e-9	Corticobasal degeneration;
SARC	cis	rs3087591	0.919	rs2953004	chr17:29502723	C/T	cg24425628	chr17:29625626	OMG;NF1	0.53	6.49	0.39	5.23e-10	Hip circumference;
SARC	cis	rs883565	0.568	rs4381879	chr3:39028460	G/C	cg01426195	chr3:39028469	NA	-0.39	-5.74	-0.35	3e-8	Handedness;
SARC	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg03060546	chr3:49711283	APEH	-0.74	-10.96	-0.58	8.28e-23	Resting heart rate;
SARC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.7	9.59	0.53	1.43e-18	Lymphocyte counts;
SARC	cis	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.75	-0.45	2.91e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs6570726	0.764	rs9403731	chr6:145907937	G/A	cg23711669	chr6:146136114	FBXO30	0.83	13.55	0.66	3.08e-31	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6831352	0.918	rs1042365	chr4:100045500	G/T	cg12011299	chr4:100065546	ADH4	-0.33	-5.53	-0.34	8.38e-8	Alcohol dependence;
SARC	cis	rs17270561	0.609	rs1165208	chr6:25803904	G/A	cg17691542	chr6:26056736	HIST1H1C	0.45	5.52	0.34	8.96e-8	Iron status biomarkers;
SARC	cis	rs1395	0.744	rs9653564	chr2:27472618	G/A	cg21747090	chr2:27597821	SNX17	-0.45	-5.57	-0.34	6.9e-8	Blood metabolite levels;
SARC	trans	rs656319	0.674	rs1484639	chr8:9983224	T/G	cg06636001	chr8:8085503	FLJ10661	0.53	7.35	0.43	3.29e-12	Myopia (pathological);
SARC	cis	rs7524258	0.900	rs1476047	chr1:7312172	C/T	cg07173049	chr1:7289937	CAMTA1	0.35	6.82	0.41	7.75e-11	Tourette's syndrome or obsessive-compulsive disorder;
SARC	cis	rs7937682	1.000	rs11608122	chr11:111535105	C/T	cg09085632	chr11:111637200	PPP2R1B	0.98	16.05	0.72	1.52e-39	Primary sclerosing cholangitis;
SARC	cis	rs12142240	0.698	rs17357711	chr1:46829013	A/G	cg00530320	chr1:46809349	NSUN4	0.58	7.07	0.42	1.78e-11	Menopause (age at onset);
SARC	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg16680214	chr1:154839983	KCNN3	-0.38	-6.06	-0.37	5.53e-9	Prostate cancer;
SARC	cis	rs2070488	0.804	rs7372452	chr3:38444298	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	11.59	0.6	7.73e-25	Electrocardiographic conduction measures;
SARC	cis	rs826838	1.000	rs11168217	chr12:38884278	T/C	cg13010199	chr12:38710504	ALG10B	0.77	10.7	0.57	5.42e-22	Heart rate;
SARC	cis	rs950776	0.518	rs11630349	chr15:78824608	C/T	cg22563815	chr15:78856949	CHRNA5	0.41	6.82	0.41	7.56e-11	Sudden cardiac arrest;
SARC	cis	rs9290065	0.538	rs9840600	chr3:160769101	G/A	cg04691961	chr3:161091175	C3orf57	-0.51	-6.45	-0.39	6.4e-10	Kawasaki disease;
SARC	cis	rs5758659	0.714	rs5758589	chr22:42518382	A/G	cg04692870	chr22:42525206	CYP2D6	-0.35	-4.74	-0.3	3.78e-6	Cognitive function;
SARC	cis	rs6831352	0.918	rs7670638	chr4:100059807	G/C	cg13256891	chr4:100009986	ADH5	-0.65	-8.0	-0.46	5.94e-14	Alcohol dependence;
SARC	cis	rs4319547	0.619	rs7973869	chr12:122874284	G/C	cg05707623	chr12:122985044	ZCCHC8	-0.56	-6.42	-0.39	7.61e-10	Body mass index;
SARC	cis	rs734999	0.588	rs4648653	chr1:2535895	C/T	cg20673091	chr1:2541236	MMEL1	0.35	5.32	0.33	2.38e-7	Ulcerative colitis;
SARC	cis	rs113835537	0.529	rs11227512	chr11:66281291	T/C	cg24851651	chr11:66362959	CCS	0.37	4.76	0.3	3.36e-6	Airway imaging phenotypes;
SARC	cis	rs9303401	0.659	rs17222523	chr17:56620501	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	11.81	0.61	1.61e-25	Cognitive test performance;
SARC	cis	rs2997447	0.802	rs61775415	chr1:26391849	A/C	cg19633962	chr1:26362018	EXTL1	-0.68	-5.35	-0.33	2.11e-7	QRS complex (12-leadsum);
SARC	cis	rs2354432	0.607	rs3766524	chr1:146729093	A/G	cg25205988	chr1:146714368	CHD1L	-1.02	-7.73	-0.45	3.15e-13	Mitochondrial DNA levels;
SARC	cis	rs6753739	0.784	rs7578383	chr2:219930851	T/G	cg24212621	chr2:219920517	IHH	0.35	4.91	0.31	1.75e-6	Height;
SARC	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg19748678	chr4:122722346	EXOSC9	0.78	9.75	0.54	4.8e-19	Type 2 diabetes;
SARC	cis	rs709400	0.520	rs28583452	chr14:103938664	C/A	cg26031613	chr14:104095156	KLC1	0.82	11.93	0.62	6.36e-26	Body mass index;
SARC	cis	rs7296418	0.961	rs1790094	chr12:123586688	T/C	cg00376283	chr12:123451042	ABCB9	0.69	9.03	0.51	6.83e-17	Platelet count;
SARC	cis	rs9818758	0.607	rs11706052	chr3:49064110	A/G	cg01304814	chr3:48885189	PRKAR2A	0.65	5.25	0.33	3.46e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg05107953	chr2:65283308	CEP68	0.48	6.53	0.39	4.13e-10	Chemerin levels;
SARC	cis	rs910316	0.712	rs175037	chr14:75465038	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.41	-5.51	-0.34	9.67e-8	Height;
SARC	cis	rs2280630	0.898	rs1828678	chr3:39195517	C/G	cg26331595	chr3:39149181	GORASP1;TTC21A	0.44	4.96	0.31	1.36e-6	Verbal declarative memory;
SARC	cis	rs2204008	0.713	rs12366709	chr12:38210179	G/A	cg26384229	chr12:38710491	ALG10B	0.88	12.94	0.65	3.26e-29	Bladder cancer;
SARC	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg13395646	chr4:1353034	KIAA1530	-0.53	-6.33	-0.38	1.23e-9	Obesity-related traits;
SARC	cis	rs7336332	0.598	rs10220056	chr13:28003781	T/G	cg01674679	chr13:27998804	GTF3A	-0.57	-5.31	-0.33	2.51e-7	Weight;
SARC	cis	rs6570726	0.791	rs1280276	chr6:145892350	A/C	cg23711669	chr6:146136114	FBXO30	0.86	13.96	0.67	1.4e-32	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9902453	0.904	rs11654983	chr17:28370042	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.16	-0.42	1.02e-11	Coffee consumption (cups per day);
SARC	trans	rs11098499	0.954	rs17006190	chr4:120418838	C/G	cg25214090	chr10:38739885	LOC399744	0.58	7.47	0.44	1.63e-12	Corneal astigmatism;
SARC	cis	rs17376456	0.877	rs17083460	chr5:93462354	A/G	cg21475434	chr5:93447410	FAM172A	0.88	8.11	0.47	2.81e-14	Diabetic retinopathy;
SARC	cis	rs9815354	0.812	rs4547673	chr3:41952303	A/C	cg03022575	chr3:42003672	ULK4	0.7	5.7	0.35	3.66e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.53	6.04	0.37	6e-9	Renal function-related traits (BUN);
SARC	cis	rs2380220	0.678	rs4308568	chr6:96009525	A/C	cg23517279	chr6:96025343	MANEA	-0.53	-6.0	-0.37	7.42e-9	Behavioural disinhibition (generation interaction);
SARC	cis	rs1865760	0.532	rs2006736	chr6:26086017	C/T	cg18357526	chr6:26021779	HIST1H4A	0.41	4.98	0.31	1.23e-6	Height;
SARC	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg09323728	chr8:95962352	TP53INP1	-0.32	-5.47	-0.34	1.18e-7	Type 2 diabetes;
SARC	cis	rs5995756	0.761	rs6001637	chr22:40001083	A/G	cg10455938	chr22:40058150	CACNA1I	-0.48	-6.25	-0.38	1.98e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.84	8.24	0.47	1.27e-14	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs2529049	0.537	rs2721789	chr7:24673252	A/G	cg17569154	chr7:24781545	DFNA5	0.5	7.1	0.42	1.47e-11	Urate levels in obese individuals;
SARC	trans	rs9329221	0.537	rs1351876	chr8:9984777	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.85	-0.46	1.46e-13	Neuroticism;
SARC	cis	rs763121	0.819	rs5757160	chr22:38989646	T/C	cg06022373	chr22:39101656	GTPBP1	0.9	12.24	0.63	6.39e-27	Menopause (age at onset);
SARC	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg00149659	chr3:10157352	C3orf10	0.81	7.87	0.46	1.36e-13	Alzheimer's disease;
SARC	cis	rs734999	0.566	rs4648658	chr1:2560882	G/A	cg18854424	chr1:2615690	NA	-0.32	-5.04	-0.31	9.48e-7	Ulcerative colitis;
SARC	cis	rs1355223	0.506	rs11032894	chr11:34865544	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.25	-0.38	1.89e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs6938	0.618	rs11072514	chr15:75221865	T/A	cg09165964	chr15:75287851	SCAMP5	0.58	7.76	0.45	2.61e-13	Breast cancer;
SARC	cis	rs17376456	0.809	rs10476602	chr5:93445255	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	6.14	0.37	3.45e-9	Diabetic retinopathy;
SARC	cis	rs4595586	0.525	rs11612680	chr12:39344443	A/G	cg26384229	chr12:38710491	ALG10B	0.52	6.09	0.37	4.58e-9	Morning vs. evening chronotype;
SARC	cis	rs992157	0.661	rs10171839	chr2:219051314	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.62	8.25	0.48	1.2e-14	Colorectal cancer;
SARC	cis	rs898097	0.690	rs12452304	chr17:80811659	G/A	cg05255149	chr17:80675120	FN3KRP	-0.4	-4.81	-0.3	2.75e-6	Breast cancer;
SARC	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg04277193	chr17:41438351	NA	0.46	4.94	0.31	1.48e-6	Menopause (age at onset);
SARC	cis	rs10046574	0.519	rs10250947	chr7:135211017	T/G	cg27474649	chr7:135195673	CNOT4	0.81	7.76	0.45	2.65e-13	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	trans	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg25998680	chr6:43044239	PTK7	0.48	6.71	0.4	1.48e-10	Immature fraction of reticulocytes;
SARC	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg12064134	chr16:90016061	DEF8	-0.49	-5.16	-0.32	5.36e-7	Skin colour saturation;
SARC	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg10435706	chr6:150039699	LATS1	0.37	4.88	0.3	2.01e-6	Lung cancer;
SARC	cis	rs2976388	0.609	rs2164308	chr8:143785659	A/G	cg06565975	chr8:143823917	SLURP1	-0.31	-5.41	-0.33	1.56e-7	Urinary tract infection frequency;
SARC	cis	rs7197653	0.748	rs61460037	chr16:68336125	A/C	cg09835421	chr16:68378352	PRMT7	-0.67	-5.77	-0.35	2.47e-8	Magnesium levels;
SARC	cis	rs6912958	0.515	rs381782	chr6:88040649	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.76	11.28	0.59	7.57e-24	Monocyte percentage of white cells;
SARC	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg25894440	chr7:65020034	NA	-0.71	-5.4	-0.33	1.62e-7	Diabetic kidney disease;
SARC	cis	rs6582630	0.533	rs11181379	chr12:38332381	C/T	cg13010199	chr12:38710504	ALG10B	0.51	6.23	0.38	2.15e-9	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg03647317	chr4:187891568	NA	-0.37	-5.1	-0.32	7e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg25894440	chr7:65020034	NA	0.73	5.51	0.34	9.25e-8	Diabetic kidney disease;
SARC	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg16606324	chr3:10149918	C3orf24	0.49	4.82	0.3	2.56e-6	Alzheimer's disease;
SARC	cis	rs7312933	0.558	rs11181463	chr12:42763636	C/T	cg19980929	chr12:42632907	YAF2	0.45	6.16	0.37	3.24e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	trans	rs1853207	1.000	rs74963911	chr10:96706316	C/T	cg02737782	chr1:8014393	NA	-0.99	-6.74	-0.4	1.21e-10	Blood metabolite levels;
SARC	cis	rs16854884	0.586	rs4613453	chr3:143735600	C/G	cg06585982	chr3:143692056	C3orf58	0.71	10.07	0.55	4.88e-20	Economic and political preferences (feminism/equality);
SARC	cis	rs7824557	0.614	rs2736286	chr8:11227104	A/G	cg21775007	chr8:11205619	TDH	-0.71	-9.59	-0.53	1.47e-18	Retinal vascular caliber;
SARC	cis	rs7208859	0.623	rs8075341	chr17:29136565	A/G	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9300255	0.602	rs1727315	chr12:123638930	A/G	cg05973401	chr12:123451056	ABCB9	-0.52	-5.78	-0.35	2.41e-8	Neutrophil percentage of white cells;
SARC	cis	rs3781913	0.845	rs12804316	chr11:72370557	C/T	cg03713592	chr11:72463424	ARAP1	-0.47	-5.71	-0.35	3.42e-8	Rheumatoid arthritis;
SARC	cis	rs1538970	0.781	rs11211139	chr1:46015751	G/T	cg05343316	chr1:45956843	TESK2	0.83	9.04	0.51	6.34e-17	Platelet count;
SARC	trans	rs1814175	0.645	rs1851845	chr11:49982396	C/T	cg15704280	chr7:45808275	SEPT13	-0.89	-14.17	-0.68	2.8e-33	Height;
SARC	trans	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg17830980	chr10:43048298	ZNF37B	-0.52	-6.99	-0.42	2.86e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs7474896	0.559	rs1212108	chr10:38094322	A/C	cg00409905	chr10:38381863	ZNF37A	-0.45	-4.85	-0.3	2.28e-6	Obesity (extreme);
SARC	cis	rs6121246	0.567	rs6060399	chr20:30220823	C/T	cg13852791	chr20:30311386	BCL2L1	0.65	5.66	0.35	4.48e-8	Mean corpuscular hemoglobin;
SARC	cis	rs1538970	0.924	rs12046816	chr1:45891543	G/T	cg05343316	chr1:45956843	TESK2	0.76	8.69	0.49	6.36e-16	Platelet count;
SARC	cis	rs9815354	1.000	rs6599176	chr3:41788492	G/T	cg03022575	chr3:42003672	ULK4	-0.59	-5.65	-0.35	4.55e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6446731	0.593	rs2530601	chr4:3272378	C/G	cg06533319	chr4:3265114	C4orf44	-0.32	-5.22	-0.32	3.99e-7	Mean platelet volume;
SARC	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg18876405	chr7:65276391	NA	0.48	5.61	0.35	5.61e-8	Aortic root size;
SARC	cis	rs2425143	1.000	rs2425149	chr20:34359587	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	5.19	0.32	4.57e-7	Blood protein levels;
SARC	cis	rs11190604	1.000	rs10883497	chr10:102228519	A/G	cg07080220	chr10:102295463	HIF1AN	0.77	9.29	0.52	1.17e-17	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs6089584	1.000	rs6089581	chr20:60562394	G/A	cg13770153	chr20:60521292	NA	-0.55	-7.78	-0.45	2.37e-13	Body mass index;
SARC	cis	rs3820928	0.874	rs4675133	chr2:227843010	A/G	cg11843606	chr2:227700838	RHBDD1	0.5	6.22	0.38	2.29e-9	Pulmonary function;
SARC	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg18404041	chr3:52824283	ITIH1	-0.42	-6.29	-0.38	1.53e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7826238	0.601	rs2979206	chr8:8345581	G/C	cg08975724	chr8:8085496	FLJ10661	0.53	7.15	0.42	1.1e-11	Systolic blood pressure;
SARC	cis	rs6598955	0.756	rs10902723	chr1:26568542	T/C	cg04990556	chr1:26633338	UBXN11	-0.6	-8.32	-0.48	7.57e-15	Obesity-related traits;
SARC	cis	rs734999	0.566	rs10797435	chr1:2534801	G/C	cg18854424	chr1:2615690	NA	0.31	4.97	0.31	1.31e-6	Ulcerative colitis;
SARC	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg20891558	chr2:74357851	NA	0.59	7.56	0.44	8.97e-13	Gestational age at birth (maternal effect);
SARC	cis	rs12950390	0.853	rs28589850	chr17:45855713	A/G	cg24803719	chr17:45855879	NA	-0.48	-7.83	-0.46	1.72e-13	IgG glycosylation;
SARC	cis	rs2228479	0.850	rs62056102	chr16:89941438	T/C	cg00800038	chr16:89945340	TCF25	-0.75	-5.25	-0.32	3.5e-7	Skin colour saturation;
SARC	cis	rs55871839	0.684	rs9298002	chr8:59815118	T/C	cg07426533	chr8:59803705	TOX	-0.43	-5.69	-0.35	3.82e-8	Pneumonia;
SARC	cis	rs1153858	0.945	rs7182300	chr15:45634928	G/A	cg26924012	chr15:45694286	SPATA5L1	0.76	10.58	0.57	1.3e-21	Homoarginine levels;
SARC	cis	rs9399135	0.935	rs4445070	chr6:135309212	C/T	cg24558204	chr6:135376177	HBS1L	0.45	6.05	0.37	5.82e-9	Red blood cell count;
SARC	cis	rs17270561	0.666	rs17320090	chr6:25720215	C/G	cg16482183	chr6:26056742	HIST1H1C	0.43	5.11	0.32	6.67e-7	Iron status biomarkers;
SARC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.79	10.17	0.55	2.43e-20	Prudent dietary pattern;
SARC	cis	rs1008375	0.898	rs10008445	chr4:17593978	G/T	cg27347728	chr4:17578864	LAP3	0.47	5.76	0.35	2.71e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7084402	0.967	rs7079648	chr10:60273155	C/A	cg07615347	chr10:60278583	BICC1	-0.58	-8.4	-0.48	4.55e-15	Refractive error;
SARC	cis	rs7726839	0.555	rs4541696	chr5:581053	A/G	cg16447950	chr5:562315	NA	-0.5	-7.55	-0.44	9.72e-13	Obesity-related traits;
SARC	cis	rs908922	0.676	rs2181172	chr1:152491794	A/G	cg09873164	chr1:152488093	CRCT1	0.62	7.96	0.46	7.55e-14	Hair morphology;
SARC	cis	rs1983170	0.668	rs11164944	chr1:92021152	A/G	cg25838465	chr1:92012736	NA	0.5	4.85	0.3	2.23e-6	Eosinophil percentage of white cells;
SARC	cis	rs992157	0.835	rs6729058	chr2:219148369	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.69	-10.04	-0.55	6.05e-20	Colorectal cancer;
SARC	cis	rs7647973	1.000	rs12583	chr3:49571462	G/T	cg06212747	chr3:49208901	KLHDC8B	-0.57	-6.02	-0.37	6.71e-9	Menarche (age at onset);
SARC	cis	rs12545109	0.571	rs7002482	chr8:57295200	C/T	cg19413350	chr8:57351067	NA	-0.4	-5.04	-0.31	9.15e-7	Obesity-related traits;
SARC	cis	rs6732160	0.845	rs6546809	chr2:73389681	A/C	cg01422370	chr2:73384389	NA	0.32	5.38	0.33	1.78e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9297145	0.565	rs4729516	chr7:98745679	G/A	cg05967295	chr7:98741636	SMURF1	-0.56	-6.24	-0.38	2.09e-9	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
SARC	trans	rs61931739	0.500	rs34061369	chr12:34519283	C/T	cg26384229	chr12:38710491	ALG10B	0.91	13.78	0.67	5.4e-32	Morning vs. evening chronotype;
SARC	cis	rs607987	0.871	rs673740	chr11:30271845	C/T	cg06241208	chr11:30344200	C11orf46	-0.41	-4.96	-0.31	1.34e-6	Body mass index;
SARC	cis	rs7084402	0.967	rs10763552	chr10:60273977	C/T	cg07615347	chr10:60278583	BICC1	-0.58	-8.42	-0.48	3.92e-15	Refractive error;
SARC	cis	rs7762018	0.621	rs3823465	chr6:170068180	A/G	cg15038512	chr6:170123185	PHF10	0.55	5.6	0.34	6.04e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs950776	0.616	rs56276142	chr15:78889795	T/C	cg17108064	chr15:78857060	CHRNA5	0.3	5.35	0.33	2.05e-7	Sudden cardiac arrest;
SARC	cis	rs1008375	0.932	rs4698650	chr4:17692878	G/C	cg16339924	chr4:17578868	LAP3	0.56	7.03	0.42	2.24e-11	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs11252926	0.528	rs11252090	chr10:436547	C/T	cg08603382	chr10:743973	NA	-0.42	-5.44	-0.34	1.33e-7	Psychosis in Alzheimer's disease;
SARC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.79	10.29	0.56	1.05e-20	Prudent dietary pattern;
SARC	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg24642844	chr7:1081250	C7orf50	-0.53	-5.64	-0.35	4.92e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs1538970	0.924	rs11211111	chr1:45908782	C/T	cg05343316	chr1:45956843	TESK2	0.78	9.01	0.51	7.82e-17	Platelet count;
SARC	cis	rs2916247	1.000	rs35749070	chr8:93053007	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.58	-5.95	-0.36	9.54e-9	Intelligence (multi-trait analysis);
SARC	cis	rs2180341	1.000	rs2144743	chr6:127633810	A/T	cg17762328	chr6:126965162	NA	-0.46	-5.24	-0.32	3.55e-7	Breast cancer;
SARC	cis	rs10897473	0.529	rs10751006	chr11:63852194	C/T	cg04317338	chr11:64019027	PLCB3	0.41	4.81	0.3	2.69e-6	Immature fraction of reticulocytes;
SARC	cis	rs9902453	0.765	rs2264303	chr17:28055348	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.19	-0.43	8.94e-12	Coffee consumption (cups per day);
SARC	cis	rs883565	0.682	rs7623850	chr3:39053311	C/T	cg01426195	chr3:39028469	NA	-0.36	-5.26	-0.33	3.29e-7	Handedness;
SARC	cis	rs2153535	1.000	rs11243251	chr6:8368207	G/A	cg21535247	chr6:8435926	SLC35B3	-0.4	-4.73	-0.3	3.84e-6	Motion sickness;
SARC	cis	rs11792861	0.962	rs3750454	chr9:111801325	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.68	-7.72	-0.45	3.31e-13	Menarche (age at onset);
SARC	trans	rs61931739	0.890	rs1197560	chr12:34121447	G/C	cg13010199	chr12:38710504	ALG10B	0.56	7.61	0.45	6.66e-13	Morning vs. evening chronotype;
SARC	cis	rs2120243	0.504	rs1824058	chr3:157124780	C/A	cg01018701	chr3:157155998	VEPH1;PTX3	0.38	4.91	0.31	1.73e-6	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs7247513	0.639	rs12984441	chr19:12760287	A/C	cg23899408	chr19:12877188	HOOK2	0.42	5.2	0.32	4.37e-7	Bipolar disorder;
SARC	cis	rs910316	1.000	rs11845639	chr14:75570293	C/T	cg11812906	chr14:75593930	NEK9	0.87	13.28	0.66	2.41e-30	Height;
SARC	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg23758822	chr17:41437982	NA	-0.85	-11.08	-0.59	3.39e-23	Menopause (age at onset);
SARC	cis	rs6582630	0.599	rs1851114	chr12:38424671	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-6.82	-0.41	7.72e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9814567	1.000	rs1814337	chr3:134200682	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.03	-0.42	2.25e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs11098499	0.863	rs12508173	chr4:120318526	T/C	cg09307838	chr4:120376055	NA	0.89	12.27	0.63	4.85e-27	Corneal astigmatism;
SARC	cis	rs4423214	0.879	rs4945008	chr11:71221248	A/G	cg05163923	chr11:71159392	DHCR7	0.65	8.73	0.5	4.85e-16	Vitamin D levels;
SARC	cis	rs1843834	0.898	rs12623277	chr2:225548072	T/G	cg22455342	chr2:225449267	CUL3	0.48	6.29	0.38	1.54e-9	IgE levels in asthmatics (D.p. specific);
SARC	trans	rs1814175	0.511	rs61905634	chr11:49819736	G/A	cg03929089	chr4:120376271	NA	-0.9	-14.58	-0.69	1.14e-34	Height;
SARC	cis	rs9436747	0.667	rs7413823	chr1:66023716	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	-0.47	-5.11	-0.32	6.76e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs7666738	0.830	rs7696568	chr4:99005333	A/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg15320075	chr8:145703422	NA	-0.67	-9.26	-0.52	1.38e-17	Age at first birth;
SARC	cis	rs7044106	0.791	rs7036766	chr9:123479621	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	6.13	0.37	3.79e-9	Hip circumference adjusted for BMI;
SARC	cis	rs763121	0.853	rs35565791	chr22:39063011	C/A	cg06022373	chr22:39101656	GTPBP1	0.89	11.26	0.59	8.85e-24	Menopause (age at onset);
SARC	cis	rs9921222	0.656	rs12719801	chr16:381141	C/T	cg26913058	chr16:419975	MRPL28	-0.37	-6.73	-0.4	1.27e-10	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs9398803	0.605	rs112166936	chr6:126733140	A/C	cg20229609	chr6:126660872	C6orf173	0.41	5.94	0.36	1.04e-8	Male-pattern baldness;
SARC	cis	rs80130819	0.515	rs7315258	chr12:48572670	T/C	cg24011408	chr12:48396354	COL2A1	0.48	5.36	0.33	2e-7	Prostate cancer;
SARC	cis	rs7582180	0.739	rs11123824	chr2:100924029	G/A	cg14675211	chr2:100938903	LONRF2	0.51	7.37	0.44	2.87e-12	Intelligence (multi-trait analysis);
SARC	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg03806693	chr22:41940476	POLR3H	-0.98	-13.54	-0.66	3.3e-31	Vitiligo;
SARC	cis	rs67311347	0.955	rs2123999	chr3:40378738	C/T	cg09455208	chr3:40491958	NA	0.35	5.59	0.34	6.25e-8	Renal cell carcinoma;
SARC	cis	rs6690583	0.623	rs12042160	chr1:85504516	A/G	cg22488158	chr1:85528044	WDR63	0.66	5.3	0.33	2.62e-7	Serum sulfate level;
SARC	cis	rs2991971	0.933	rs12568144	chr1:45965307	G/A	cg24296786	chr1:45957014	TESK2	0.64	9.27	0.52	1.28e-17	High light scatter reticulocyte count;
SARC	cis	rs2857078	0.720	rs9906669	chr17:42305706	A/G	cg13607699	chr17:42295918	UBTF	0.86	13.55	0.66	3.21e-31	Red cell distribution width;Reticulocyte count;
SARC	cis	rs6582630	0.560	rs4882325	chr12:38510037	C/T	cg14851346	chr12:38532713	NA	-0.44	-5.41	-0.33	1.54e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs3784262	1.000	rs10851630	chr15:58242148	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.37	-5.49	-0.34	1.03e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs6964587	1.000	rs28927678	chr7:91715662	C/T	cg17063962	chr7:91808500	NA	0.96	15.52	0.71	9.09e-38	Breast cancer;
SARC	cis	rs9914988	0.943	rs9908881	chr17:27100924	T/A	cg20469991	chr17:27169893	C17orf63	-0.5	-5.21	-0.32	4.1e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs12681366	0.663	rs2919666	chr8:95465287	T/C	cg26464482	chr8:95565502	KIAA1429	0.42	5.25	0.33	3.39e-7	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs66573146	0.831	rs56320732	chr4:6974319	G/A	cg15105060	chr4:7024189	TBC1D14	-0.69	-4.92	-0.31	1.63e-6	Granulocyte percentage of myeloid white cells;
SARC	cis	rs929354	0.772	rs6459741	chr7:157014553	G/T	cg05182265	chr7:156933206	UBE3C	-0.31	-4.79	-0.3	2.93e-6	Body mass index;
SARC	cis	rs9914988	0.725	rs66531973	chr17:27125993	G/T	cg20469991	chr17:27169893	C17orf63	-0.49	-5.1	-0.32	6.99e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs807669	0.742	rs1206544	chr22:19215039	C/T	cg02655711	chr22:19163373	SLC25A1	0.41	5.76	0.35	2.67e-8	Metabolite levels;
SARC	cis	rs3820928	1.000	rs978909	chr2:227771389	A/C	cg11843606	chr2:227700838	RHBDD1	-0.55	-7.21	-0.43	7.99e-12	Pulmonary function;
SARC	cis	rs12190007	0.846	rs6905725	chr6:169730253	G/C	cg16388071	chr6:169726476	NA	-0.36	-5.02	-0.31	1.03e-6	Obesity-related traits;
SARC	cis	rs5753618	0.583	rs7285619	chr22:31842554	C/T	cg13145458	chr22:31556086	RNF185	-0.47	-5.12	-0.32	6.46e-7	Colorectal cancer;
SARC	cis	rs4642101	0.793	rs6763619	chr3:12822147	T/G	cg24848339	chr3:12840334	CAND2	0.33	4.93	0.31	1.59e-6	QRS complex (12-leadsum);
SARC	cis	rs7223966	1.000	rs16947042	chr17:61766457	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.73	0.4	1.32e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs477692	0.935	rs557158	chr10:131420534	C/T	cg05714579	chr10:131428358	MGMT	0.57	7.35	0.43	3.31e-12	Response to temozolomide;
SARC	cis	rs80130819	0.688	rs10783233	chr12:48590899	C/G	cg05342945	chr12:48394962	COL2A1	-0.53	-5.55	-0.34	7.89e-8	Prostate cancer;
SARC	cis	rs8067545	0.532	rs4925074	chr17:19962554	C/T	cg13482628	chr17:19912719	NA	0.43	4.88	0.3	1.99e-6	Schizophrenia;
SARC	cis	rs34779708	0.897	rs12764820	chr10:35386321	G/A	cg03585969	chr10:35415529	CREM	0.41	4.98	0.31	1.21e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg03081930	chr13:111288583	CARKD	-0.61	-4.74	-0.3	3.66e-6	Obesity-related traits;
SARC	cis	rs3812049	0.506	rs36694	chr5:127548955	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.65	7.13	0.42	1.22e-11	Lymphocyte counts;Red cell distribution width;
SARC	cis	rs4972806	0.849	rs2071581	chr2:177026148	G/T	cg14324370	chr2:177042789	NA	0.55	7.44	0.44	1.95e-12	IgG glycosylation;
SARC	cis	rs10982256	0.905	rs10982255	chr9:117255744	C/T	cg15903421	chr9:117267460	DFNB31	-0.36	-4.83	-0.3	2.51e-6	Bipolar disorder;
SARC	cis	rs698833	0.548	rs8410	chr2:44546016	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.65	7.55	0.44	1.01e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg25894440	chr7:65020034	NA	0.52	4.85	0.3	2.22e-6	Aortic root size;
SARC	cis	rs1008375	0.966	rs2191504	chr4:17675592	C/G	cg16339924	chr4:17578868	LAP3	0.64	8.39	0.48	4.6e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9486719	0.857	rs2971609	chr6:97039665	A/G	cg18709589	chr6:96969512	KIAA0776	-0.5	-5.53	-0.34	8.42e-8	Migraine;Coronary artery disease;
SARC	cis	rs7662987	0.517	rs2602858	chr4:100030461	T/C	cg13256891	chr4:100009986	ADH5	0.68	8.56	0.49	1.59e-15	Smoking initiation;
SARC	cis	rs372883	0.648	rs2832296	chr21:30741454	C/T	cg24692254	chr21:30365293	RNF160	-0.59	-7.61	-0.45	6.82e-13	Pancreatic cancer;
SARC	cis	rs2562456	0.834	rs2173727	chr19:21673957	C/T	cg00806126	chr19:22604979	ZNF98	0.49	4.98	0.31	1.23e-6	Pain;
SARC	cis	rs4713118	0.669	rs200997	chr6:27811815	G/A	cg17221315	chr6:27791827	HIST1H4J	0.47	5.38	0.33	1.81e-7	Parkinson's disease;
SARC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.03	12.46	0.63	1.18e-27	Platelet count;
SARC	cis	rs2304069	0.507	rs13167061	chr5:149388624	T/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.44	4.94	0.31	1.48e-6	HIV-1 control;
SARC	cis	rs2204008	0.774	rs7959048	chr12:37948276	T/A	cg26384229	chr12:38710491	ALG10B	0.89	13.3	0.66	2.05e-30	Bladder cancer;
SARC	cis	rs61332075	0.540	rs55986470	chr2:239363773	A/G	cg21699342	chr2:239360505	ASB1	-0.55	-5.25	-0.33	3.43e-7	Lung function (FEV1/FVC);
SARC	trans	rs7937682	0.883	rs12804962	chr11:111442683	A/T	cg18187862	chr3:45730750	SACM1L	-0.55	-6.64	-0.4	2.16e-10	Primary sclerosing cholangitis;
SARC	cis	rs5753618	0.583	rs5749268	chr22:31809152	G/A	cg02404636	chr22:31891804	SFI1	0.49	5.17	0.32	4.93e-7	Colorectal cancer;
SARC	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg08859206	chr1:53392774	SCP2	0.43	6.21	0.38	2.39e-9	Monocyte count;
SARC	cis	rs709400	0.663	rs9671911	chr14:103967343	T/C	cg26031613	chr14:104095156	KLC1	0.83	12.01	0.62	3.41e-26	Body mass index;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg27597069	chr6:37321822	RNF8	-0.59	-6.64	-0.4	2.15e-10	Brain volume in infants (cerebrospinal fluid);
SARC	trans	rs9951602	0.512	rs4799247	chr18:76653449	G/A	cg02800362	chr5:177631904	HNRNPAB	0.7	8.91	0.5	1.49e-16	Obesity-related traits;
SARC	cis	rs2997447	0.688	rs3008431	chr1:26371281	A/G	cg19633962	chr1:26362018	EXTL1	-0.79	-7.89	-0.46	1.19e-13	QRS complex (12-leadsum);
SARC	trans	rs3780486	0.846	rs73484568	chr9:33132492	G/A	cg04842962	chr6:43655489	MRPS18A	1.1	20.63	0.8	1.68e-54	IgG glycosylation;
SARC	cis	rs10493773	0.566	rs11161659	chr1:86183967	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.61	-9.96	-0.55	1.1e-19	Urate levels in overweight individuals;
SARC	cis	rs10463554	0.927	rs34799	chr5:102426202	A/G	cg23492399	chr5:102201601	PAM	-0.54	-5.91	-0.36	1.23e-8	Parkinson's disease;
SARC	cis	rs57920188	0.535	rs10915659	chr1:4092949	G/A	cg20703997	chr1:4087676	NA	0.5	5.35	0.33	2.07e-7	Interleukin-17 levels;
SARC	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg21724239	chr8:58056113	NA	0.57	6.07	0.37	5.07e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs12130219	0.500	rs1552991	chr1:152165878	C/T	cg09127314	chr1:152161683	NA	0.39	5.08	0.32	7.91e-7	Inflammatory skin disease;
SARC	cis	rs4144743	0.941	rs10438782	chr17:45323892	G/A	cg18085866	chr17:45331354	ITGB3	-0.71	-7.35	-0.43	3.36e-12	Body mass index;
SARC	cis	rs4689388	0.926	rs10937720	chr4:6295451	A/G	cg14416269	chr4:6271139	WFS1	0.32	4.92	0.31	1.61e-6	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10416265	0.528	rs7249097	chr19:33589144	T/C	cg17764715	chr19:33622953	WDR88	0.57	7.97	0.46	7.22e-14	Bone properties (heel);
SARC	cis	rs644799	0.965	rs566877	chr11:95528045	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.7	9.55	0.53	1.87e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs3857536	0.544	rs208453	chr6:66906841	A/T	cg07460842	chr6:66804631	NA	-0.74	-8.52	-0.49	1.99e-15	Blood trace element (Cu levels);
SARC	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg23758822	chr17:41437982	NA	0.86	10.56	0.57	1.52e-21	Menopause (age at onset);
SARC	cis	rs908922	0.676	rs4845782	chr1:152492225	A/G	cg09873164	chr1:152488093	CRCT1	0.61	7.91	0.46	1.01e-13	Hair morphology;
SARC	cis	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg25427524	chr10:38739819	LOC399744	-0.59	-9.67	-0.54	8.35e-19	Extrinsic epigenetic age acceleration;
SARC	cis	rs3768617	0.510	rs10458355	chr1:183063993	C/T	cg13390022	chr1:182993471	LAMC1	0.33	4.94	0.31	1.49e-6	Fuchs's corneal dystrophy;
SARC	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg11764359	chr7:65958608	NA	0.49	5.6	0.34	5.93e-8	Aortic root size;
SARC	cis	rs2250402	0.510	rs2291619	chr15:40329033	C/T	cg10636054	chr15:40330586	SRP14	-0.88	-6.67	-0.4	1.86e-10	Corneal curvature;
SARC	cis	rs733592	0.507	rs7304428	chr12:48494275	T/G	cg24011408	chr12:48396354	COL2A1	-0.51	-7.13	-0.42	1.25e-11	Plateletcrit;
SARC	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2594989	0.943	rs7622627	chr3:11357419	T/C	cg00170343	chr3:11313890	ATG7	0.54	5.22	0.32	4.05e-7	Circulating chemerin levels;
SARC	cis	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg15145296	chr3:125709740	NA	-0.51	-5.01	-0.31	1.09e-6	Blood pressure (smoking interaction);
SARC	cis	rs2486288	0.656	rs8024620	chr15:45574329	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.53	-6.65	-0.4	2.03e-10	Glomerular filtration rate;
SARC	cis	rs10791097	0.694	rs1893017	chr11:130756253	C/T	cg09137382	chr11:130731461	NA	0.31	4.73	0.3	3.97e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg24250549	chr1:154909240	PMVK	0.78	11.2	0.59	1.41e-23	Prostate cancer;
SARC	cis	rs17270561	0.609	rs9356985	chr6:25728098	C/T	cg16482183	chr6:26056742	HIST1H1C	0.43	5.25	0.33	3.49e-7	Iron status biomarkers;
SARC	cis	rs6450176	1.000	rs6450175	chr5:53297824	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.66	-7.64	-0.45	5.69e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs2204008	0.506	rs11495470	chr12:38026904	C/T	cg26384229	chr12:38710491	ALG10B	0.87	12.44	0.63	1.39e-27	Bladder cancer;
SARC	cis	rs9911578	1.000	rs11079365	chr17:56945430	T/C	cg05425664	chr17:57184151	TRIM37	-0.65	-8.0	-0.46	5.84e-14	Intelligence (multi-trait analysis);
SARC	cis	rs1153858	0.621	rs2687512	chr15:45581495	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.72	-9.0	-0.51	8.42e-17	Homoarginine levels;
SARC	cis	rs6088813	0.961	rs2425062	chr20:33923566	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.46	5.58	0.34	6.5e-8	Height;
SARC	cis	rs7592578	0.766	rs62181052	chr2:191387858	A/G	cg27211696	chr2:191398769	TMEM194B	-0.51	-5.08	-0.32	7.61e-7	Diastolic blood pressure;
SARC	cis	rs4803468	0.967	rs13345590	chr19:41886455	T/G	cg09537434	chr19:41945824	ATP5SL	-0.94	-16.62	-0.74	1.95e-41	Height;
SARC	cis	rs34233420	1	rs34233420	chr17:38004929	GATTT/G	cg20243544	chr17:37824526	PNMT	0.42	5.51	0.34	9.32e-8	Lymphocyte counts;
SARC	cis	rs694739	0.628	rs508168	chr11:64135435	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.66	7.6	0.45	7e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs950776	0.593	rs621849	chr15:78872861	G/A	cg22563815	chr15:78856949	CHRNA5	-0.38	-6.44	-0.39	6.68e-10	Sudden cardiac arrest;
SARC	cis	rs4595586	0.546	rs11609849	chr12:39258090	C/G	cg26384229	chr12:38710491	ALG10B	0.7	8.61	0.49	1.14e-15	Morning vs. evening chronotype;
SARC	cis	rs2075371	0.673	rs35290398	chr7:134011773	C/T	cg00033643	chr7:134001901	SLC35B4	0.46	5.43	0.34	1.39e-7	Mean platelet volume;
SARC	cis	rs2576037	0.526	rs6507714	chr18:44519574	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-6.91	-0.41	4.68e-11	Personality dimensions;
SARC	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg02725872	chr8:58115012	NA	-0.37	-6.37	-0.39	9.78e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1559088	0.948	rs3760893	chr19:33597930	C/A	cg27124370	chr19:33622961	WDR88	0.44	5.86	0.36	1.6e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg03433033	chr1:76189801	ACADM	-0.53	-7.56	-0.44	9.29e-13	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	12.15	0.62	1.24e-26	Platelet count;
SARC	cis	rs67460515	0.892	rs4856757	chr3:160999418	A/T	cg17135325	chr3:160939158	NMD3	0.63	7.94	0.46	8.49e-14	Parkinson's disease;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg26581448	chr2:216234370	FN1	0.5	7.02	0.42	2.39e-11	Thyroid stimulating hormone;
SARC	cis	rs1832871	0.711	rs9459826	chr6:158680396	C/G	cg07165851	chr6:158734300	TULP4	-0.54	-6.34	-0.38	1.16e-9	Height;
SARC	cis	rs3767633	0.925	rs2134696	chr1:161781200	A/T	cg09175582	chr1:161736000	ATF6	-0.57	-4.94	-0.31	1.51e-6	IgG glycosylation;
SARC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg21747090	chr2:27597821	SNX17	-0.53	-7.27	-0.43	5.46e-12	Total body bone mineral density;
SARC	cis	rs703842	1.000	rs4646536	chr12:58157988	A/G	cg00677455	chr12:58241039	CTDSP2	0.48	6.39	0.39	8.87e-10	Multiple sclerosis;
SARC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	20.35	0.8	1.32e-53	Prudent dietary pattern;
SARC	cis	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg03213289	chr20:61660250	NA	0.47	6.41	0.39	7.78e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs17270561	0.609	rs4711100	chr6:25741954	G/A	cg17691542	chr6:26056736	HIST1H1C	0.61	7.36	0.43	3.06e-12	Iron status biomarkers;
SARC	cis	rs2273669	0.667	rs12206423	chr6:109353216	C/T	cg05315195	chr6:109294784	ARMC2	-0.63	-5.7	-0.35	3.6e-8	Prostate cancer;
SARC	trans	rs1994135	0.669	rs11052746	chr12:33697473	A/C	cg13010199	chr12:38710504	ALG10B	-0.57	-6.83	-0.41	7.38e-11	Resting heart rate;
SARC	cis	rs79349575	0.783	rs17635252	chr17:47006950	T/C	cg07967210	chr17:47022446	SNF8	0.37	4.74	0.3	3.66e-6	Type 2 diabetes;
SARC	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg11987759	chr7:65425863	GUSB	-0.38	-4.85	-0.3	2.28e-6	Calcium levels;
SARC	cis	rs2836974	0.583	rs2735307	chr21:40713358	C/T	cg11644478	chr21:40555479	PSMG1	0.64	8.24	0.47	1.26e-14	Cognitive function;
SARC	cis	rs9443189	0.570	rs6903124	chr6:76290079	A/C	cg01950844	chr6:76311363	SENP6	0.87	7.89	0.46	1.19e-13	Prostate cancer;
SARC	cis	rs7829975	0.623	rs7010753	chr8:8373956	A/G	cg06636001	chr8:8085503	FLJ10661	0.61	7.83	0.46	1.67e-13	Mood instability;
SARC	trans	rs79976124	0.879	rs78012385	chr6:66618091	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.69	7.5	0.44	1.36e-12	Type 2 diabetes;
SARC	cis	rs2635047	0.565	rs2571004	chr18:44710302	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	5.94	0.36	1.05e-8	Educational attainment;
SARC	cis	rs1023500	0.552	rs133368	chr22:42463689	T/C	cg04733989	chr22:42467013	NAGA	0.74	10.59	0.57	1.21e-21	Schizophrenia;
SARC	cis	rs796364	1.000	rs796364	chr2:200716119	C/A	cg23649088	chr2:200775458	C2orf69	0.6	5.3	0.33	2.66e-7	Schizophrenia;
SARC	cis	rs2153535	0.563	rs4428546	chr6:8490376	A/G	cg21535247	chr6:8435926	SLC35B3	0.56	6.96	0.41	3.41e-11	Motion sickness;
SARC	cis	rs3768617	0.510	rs10797839	chr1:183077797	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.28	0.56	1.08e-20	Fuchs's corneal dystrophy;
SARC	cis	rs10489202	0.632	rs413168	chr1:168005789	C/G	cg17859187	chr1:168147929	TIPRL	0.39	4.78	0.3	3.15e-6	Schizophrenia;
SARC	cis	rs17826219	0.500	rs9891256	chr17:29072692	C/T	cg13385521	chr17:29058706	SUZ12P	0.88	7.94	0.46	8.37e-14	Body mass index;
SARC	cis	rs637571	0.522	rs493899	chr11:65747952	A/C	cg26695010	chr11:65641043	EFEMP2	-0.55	-7.22	-0.43	7.28e-12	Eosinophil percentage of white cells;
SARC	cis	rs910316	1.000	rs7142235	chr14:75559963	T/C	cg06637938	chr14:75390232	RPS6KL1	0.54	7.72	0.45	3.41e-13	Height;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg21344215	chr2:27851972	GPN1;CCDC121	0.48	6.36	0.38	1.05e-9	Tetralogy of Fallot;
SARC	cis	rs244731	0.959	rs9313752	chr5:176645435	G/T	cg06060754	chr5:176797920	RGS14	-0.44	-5.19	-0.32	4.54e-7	Urate levels in lean individuals;
SARC	cis	rs2985684	1.000	rs1952012	chr14:50098896	T/A	cg04989706	chr14:50066350	PPIL5	-0.53	-5.58	-0.34	6.5e-8	Carotid intima media thickness;
SARC	cis	rs3857536	0.505	rs208459	chr6:66911055	C/T	cg07460842	chr6:66804631	NA	-0.74	-8.57	-0.49	1.41e-15	Blood trace element (Cu levels);
SARC	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg14829360	chr17:73884958	NA	-0.6	-7.49	-0.44	1.4e-12	Psoriasis;
SARC	cis	rs892961	0.899	rs8071024	chr17:75414067	T/C	cg05865280	chr17:75406074	SEPT9	0.56	8.32	0.48	7.56e-15	Airflow obstruction;
SARC	cis	rs5753618	0.504	rs5753661	chr22:31899797	C/A	cg07713946	chr22:31675144	LIMK2	0.37	5.23	0.32	3.85e-7	Colorectal cancer;
SARC	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg02574844	chr11:5959923	NA	-0.41	-5.79	-0.35	2.21e-8	DNA methylation (variation);
SARC	trans	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg21659725	chr3:3221576	CRBN	0.81	12.46	0.63	1.2e-27	Intelligence (multi-trait analysis);
SARC	cis	rs2204008	0.774	rs7304438	chr12:38361146	T/G	cg26384229	chr12:38710491	ALG10B	0.87	12.69	0.64	2.17e-28	Bladder cancer;
SARC	cis	rs7246657	0.943	rs12709813	chr19:37844983	G/A	cg14683738	chr19:37701593	ZNF585B	0.51	4.99	0.31	1.16e-6	Coronary artery calcification;
SARC	cis	rs7481584	0.517	rs80872	chr11:3049984	G/T	cg08508325	chr11:3079039	CARS	0.23	5.15	0.32	5.5e-7	Calcium levels;
SARC	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg26818010	chr10:134567672	INPP5A	-0.65	-7.07	-0.42	1.83e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs17376456	0.877	rs67066109	chr5:93494101	G/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.09	0.32	7.3e-7	Diabetic retinopathy;
SARC	cis	rs7927592	0.913	rs3758643	chr11:68367193	C/T	cg01657329	chr11:68192670	LRP5	-0.43	-5.12	-0.32	6.29e-7	Total body bone mineral density;
SARC	cis	rs3796352	1.000	rs4478072	chr3:53106125	G/T	cg27565382	chr3:53032988	SFMBT1	0.66	4.78	0.3	3.16e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.49	5.6	0.34	5.9e-8	Renal function-related traits (BUN);
SARC	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg11644478	chr21:40555479	PSMG1	0.99	13.22	0.65	3.72e-30	Cognitive function;
SARC	trans	rs11098499	0.954	rs7436506	chr4:120393769	T/C	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	cis	rs7223966	1.000	rs8064261	chr17:61705212	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.52	-5.59	-0.34	6.42e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs61931739	0.517	rs1197562	chr12:34122037	G/A	cg26384229	chr12:38710491	ALG10B	0.78	11.11	0.59	2.72e-23	Morning vs. evening chronotype;
SARC	cis	rs9399135	0.933	rs9389262	chr6:135376409	G/T	cg22676075	chr6:135203613	NA	0.35	4.82	0.3	2.54e-6	Red blood cell count;
SARC	cis	rs995000	0.931	rs4329540	chr1:63027024	C/T	cg06896770	chr1:63153194	DOCK7	-0.9	-13.26	-0.66	2.87e-30	Triglyceride levels;
SARC	cis	rs6121246	0.567	rs6060260	chr20:30192907	C/T	cg21427119	chr20:30132790	HM13	-0.48	-5.29	-0.33	2.84e-7	Mean corpuscular hemoglobin;
SARC	cis	rs6582630	0.502	rs7312212	chr12:38274760	T/G	cg13010199	chr12:38710504	ALG10B	0.78	10.48	0.57	2.62e-21	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6570726	0.599	rs9403725	chr6:145897622	A/T	cg05347473	chr6:146136440	FBXO30	-0.68	-8.72	-0.5	5.25e-16	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg06618935	chr21:46677482	NA	-0.42	-5.65	-0.35	4.7e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9487051	0.872	rs9487042	chr6:109610443	T/G	cg01475377	chr6:109611718	NA	-0.41	-5.92	-0.36	1.13e-8	Reticulocyte fraction of red cells;
SARC	cis	rs7412746	0.658	rs59988025	chr1:150940358	C/T	cg15448220	chr1:150897856	SETDB1	0.52	6.67	0.4	1.85e-10	Melanoma;
SARC	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg08219700	chr8:58056026	NA	0.52	5.66	0.35	4.52e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10782582	0.545	rs12138018	chr1:76186794	T/C	cg10523679	chr1:76189770	ACADM	-0.43	-5.38	-0.33	1.77e-7	Daytime sleep phenotypes;
SARC	cis	rs7447593	0.518	rs4074995	chr5:176797343	C/T	cg06060754	chr5:176797920	RGS14	0.64	8.77	0.5	3.79e-16	Urinary electrolytes (magnesium/calcium ratio);
SARC	cis	rs7264396	0.563	rs2425138	chr20:34345710	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.66	0.35	4.43e-8	Total cholesterol levels;
SARC	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg16606324	chr3:10149918	C3orf24	0.48	4.81	0.3	2.69e-6	Alzheimer's disease;
SARC	cis	rs2180341	0.814	rs9401959	chr6:127736464	T/C	cg27446573	chr6:127587934	RNF146	0.79	10.27	0.56	1.21e-20	Breast cancer;
SARC	cis	rs3093024	1.000	rs3093024	chr6:167532793	C/T	cg07741184	chr6:167504864	NA	0.31	6.21	0.38	2.35e-9	Rheumatoid arthritis;
SARC	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg07701084	chr6:150067640	NUP43	0.41	5.39	0.33	1.75e-7	Lung cancer;
SARC	cis	rs9457247	1.000	rs422562	chr6:167406318	A/G	cg07741184	chr6:167504864	NA	0.31	5.77	0.35	2.56e-8	Crohn's disease;
SARC	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg11366901	chr6:160182831	ACAT2	1.04	10.91	0.58	1.22e-22	Age-related macular degeneration (geographic atrophy);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg00721207	chr19:40337107	FBL	0.5	6.38	0.39	9.44e-10	Chemerin levels;
SARC	cis	rs453301	0.631	rs11780774	chr8:8799111	C/A	cg15556689	chr8:8085844	FLJ10661	-0.47	-5.65	-0.35	4.71e-8	Joint mobility (Beighton score);
SARC	cis	rs9457247	1.000	rs2757042	chr6:167371234	A/T	cg07741184	chr6:167504864	NA	-0.31	-5.84	-0.36	1.76e-8	Crohn's disease;
SARC	cis	rs9987353	0.519	rs11779181	chr8:9063027	A/G	cg15556689	chr8:8085844	FLJ10661	0.4	4.82	0.3	2.64e-6	Recombination measurement;
SARC	cis	rs950776	0.616	rs56276142	chr15:78889795	T/C	cg06917634	chr15:78832804	PSMA4	0.78	11.49	0.6	1.65e-24	Sudden cardiac arrest;
SARC	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg04277193	chr17:41438351	NA	0.44	4.86	0.3	2.18e-6	Menopause (age at onset);
SARC	cis	rs6087990	0.735	rs1855350	chr20:31387525	C/T	cg13636640	chr20:31349939	DNMT3B	0.78	12.04	0.62	2.77e-26	Ulcerative colitis;
SARC	cis	rs9843304	0.529	rs34895718	chr3:149205217	A/G	cg08667024	chr3:149219783	TM4SF4	-0.39	-5.72	-0.35	3.26e-8	Gallstone disease;
SARC	cis	rs7828089	0.935	rs2293144	chr8:22262418	A/G	cg12081754	chr8:22256438	SLC39A14	0.46	6.09	0.37	4.64e-9	Verbal declarative memory;
SARC	cis	rs7666738	0.830	rs9995370	chr4:98732145	T/G	cg05340658	chr4:99064831	C4orf37	0.65	8.54	0.49	1.74e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg25894440	chr7:65020034	NA	-0.74	-5.63	-0.35	5.28e-8	Diabetic kidney disease;
SARC	cis	rs155076	1.000	rs658244	chr13:21850976	T/C	cg25811766	chr13:21894605	NA	-0.52	-5.6	-0.34	5.89e-8	White matter hyperintensity burden;
SARC	cis	rs3770770	0.903	rs17020125	chr2:37241050	G/A	cg14987922	chr2:37194071	STRN	-0.51	-4.97	-0.31	1.31e-6	QRS duration;
SARC	cis	rs9868809	0.772	rs2286651	chr3:48694147	G/A	cg00383909	chr3:49044727	WDR6	0.57	4.98	0.31	1.26e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs2916247	0.954	rs7003305	chr8:93101992	T/C	cg10183463	chr8:93005414	RUNX1T1	0.65	6.56	0.39	3.53e-10	Intelligence (multi-trait analysis);
SARC	trans	rs66573146	0.831	rs6832482	chr4:7023433	A/T	cg07817883	chr1:32538562	TMEM39B	1.2	7.85	0.46	1.53e-13	Granulocyte percentage of myeloid white cells;
SARC	cis	rs9899728	0.665	rs2307008	chr17:73042682	G/A	cg27626185	chr17:73056755	KCTD2	-0.61	-5.11	-0.32	6.69e-7	Alzheimer's disease or small vessel stroke;
SARC	cis	rs7644634	0.624	rs9870097	chr3:105417893	T/C	cg23051926	chr3:105466016	CBLB	0.44	5.53	0.34	8.51e-8	Itch intensity from mosquito bite;
SARC	cis	rs6598955	0.670	rs12733645	chr1:26540356	G/T	cg04990556	chr1:26633338	UBXN11	-0.6	-8.41	-0.48	4.25e-15	Obesity-related traits;
SARC	cis	rs7119	0.717	rs10519167	chr15:77723027	G/T	cg17802220	chr15:77601643	NA	-0.44	-5.71	-0.35	3.41e-8	Type 2 diabetes;
SARC	cis	rs754466	0.580	rs10762763	chr10:79560803	C/G	cg17075019	chr10:79541650	NA	-0.8	-12.25	-0.63	5.82e-27	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs963731	0.649	rs3765058	chr2:39189636	A/G	cg04010122	chr2:39346883	SOS1	0.85	5.46	0.34	1.21e-7	Corticobasal degeneration;
SARC	cis	rs4742903	1.000	rs7854630	chr9:106875277	A/C	cg14250997	chr9:106856677	SMC2	-0.53	-7.15	-0.42	1.14e-11	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg07308232	chr7:1071921	C7orf50	-0.59	-7.34	-0.43	3.64e-12	Longevity;Endometriosis;
SARC	cis	rs2153535	0.580	rs763376	chr6:8492776	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	8.17	0.47	2.01e-14	Motion sickness;
SARC	cis	rs8002861	0.935	rs4101376	chr13:44469835	C/T	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.36	-5.0	-0.31	1.12e-6	Leprosy;
SARC	cis	rs7927771	0.524	rs10838774	chr11:47856114	A/G	cg20307385	chr11:47447363	PSMC3	0.5	6.79	0.41	9.47e-11	Subjective well-being;
SARC	cis	rs77106637	0.585	rs12292949	chr11:72457531	C/T	cg03713592	chr11:72463424	ARAP1	0.86	9.57	0.53	1.68e-18	Type 2 diabetes;
SARC	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg26335602	chr6:28129616	ZNF389	0.47	5.23	0.32	3.78e-7	Parkinson's disease;
SARC	cis	rs3756766	0.500	rs7715815	chr5:137660982	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.51	6.23	0.38	2.22e-9	Schizophrenia;
SARC	cis	rs12908161	0.853	rs11633788	chr15:85305142	T/A	cg17507749	chr15:85114479	UBE2QP1	0.47	5.54	0.34	8.27e-8	Schizophrenia;
SARC	cis	rs3858526	0.883	rs10769326	chr11:5934358	C/T	cg02574844	chr11:5959923	NA	-0.43	-5.05	-0.31	8.99e-7	DNA methylation (variation);
SARC	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg18876405	chr7:65276391	NA	-0.71	-9.03	-0.51	6.53e-17	Aortic root size;
SARC	cis	rs4642101	0.639	rs9870433	chr3:12853566	T/C	cg24848339	chr3:12840334	CAND2	0.34	4.99	0.31	1.17e-6	QRS complex (12-leadsum);
SARC	cis	rs16854884	0.770	rs1445417	chr3:143808972	A/T	cg06585982	chr3:143692056	C3orf58	0.6	7.9	0.46	1.09e-13	Economic and political preferences (feminism/equality);
SARC	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg16405210	chr4:1374714	KIAA1530	-0.48	-5.6	-0.34	5.88e-8	Obesity-related traits;
SARC	cis	rs2153535	0.580	rs6913100	chr6:8456855	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	10.3	0.56	9.5e-21	Motion sickness;
SARC	cis	rs4595586	0.545	rs12820138	chr12:39357049	A/G	cg13010199	chr12:38710504	ALG10B	0.4	4.75	0.3	3.57e-6	Morning vs. evening chronotype;
SARC	cis	rs6540556	0.723	rs1000282	chr1:209894785	T/C	cg05527609	chr1:210001259	C1orf107	-0.61	-5.69	-0.35	3.83e-8	Red blood cell count;
SARC	cis	rs7264396	0.563	rs6060567	chr20:34288250	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.6	5.56	0.34	7.46e-8	Total cholesterol levels;
SARC	cis	rs7666738	0.830	rs2098934	chr4:98992403	A/G	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9902453	0.791	rs62068629	chr17:28187596	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	7.39	0.44	2.64e-12	Coffee consumption (cups per day);
SARC	cis	rs870825	0.860	rs72703521	chr4:185603080	T/C	cg04058563	chr4:185651563	MLF1IP	0.76	9.26	0.52	1.4e-17	Blood protein levels;
SARC	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg19223190	chr17:80058835	NA	-0.43	-6.02	-0.37	6.57e-9	Life satisfaction;
SARC	cis	rs1153858	0.943	rs67045941	chr15:45677011	A/G	cg26924012	chr15:45694286	SPATA5L1	0.79	11.28	0.59	7.91e-24	Homoarginine levels;
SARC	cis	rs9322817	0.617	rs9404574	chr6:105162372	T/C	cg02098413	chr6:105308735	HACE1	-0.39	-6.11	-0.37	4.05e-9	Thyroid stimulating hormone;
SARC	cis	rs17539620	0.519	rs871071	chr6:154837667	T/C	cg20019720	chr6:154832845	CNKSR3	0.44	5.29	0.33	2.79e-7	Lipoprotein (a) levels;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg22240533	chr12:25348648	CASC1;LYRM5	-0.5	-7.05	-0.42	2.06e-11	Thyroid stimulating hormone;
SARC	cis	rs9473924	0.542	rs2817378	chr6:50789197	G/A	cg14470998	chr6:50812995	TFAP2B	0.68	5.94	0.36	1.01e-8	Body mass index;
SARC	cis	rs929354	0.772	rs6459739	chr7:156998863	A/T	cg05182265	chr7:156933206	UBE3C	-0.33	-5.02	-0.31	1.03e-6	Body mass index;
SARC	cis	rs72653721	0.667	rs57729033	chr6:11058436	A/T	cg13562911	chr6:11044106	ELOVL2	0.54	6.09	0.37	4.62e-9	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	cis	rs986417	0.892	rs55695351	chr14:60796565	G/T	cg27398547	chr14:60952738	C14orf39	-1.06	-8.79	-0.5	3.34e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs9325144	0.555	rs7955128	chr12:38684121	A/T	cg26384229	chr12:38710491	ALG10B	0.62	8.43	0.48	3.55e-15	Morning vs. evening chronotype;
SARC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg26338869	chr17:61819248	STRADA	0.8	10.69	0.57	5.7e-22	Prudent dietary pattern;
SARC	cis	rs9914988	0.832	rs4795462	chr17:27130991	C/T	cg20469991	chr17:27169893	C17orf63	-0.5	-5.25	-0.33	3.36e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg18357526	chr6:26021779	HIST1H4A	0.67	8.88	0.5	1.89e-16	Intelligence (multi-trait analysis);
SARC	cis	rs1318878	0.519	rs11056436	chr12:15500036	C/T	cg08258403	chr12:15378311	NA	0.49	6.81	0.41	8.27e-11	Intelligence (multi-trait analysis);
SARC	trans	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg17830980	chr10:43048298	ZNF37B	-0.48	-6.27	-0.38	1.74e-9	Extrinsic epigenetic age acceleration;
SARC	cis	rs546131	0.642	rs11603640	chr11:34832907	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-4.83	-0.3	2.52e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs2115630	1.000	rs58581703	chr15:85276935	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.47	-5.61	-0.35	5.67e-8	P wave terminal force;
SARC	trans	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg21127318	chr5:130971048	RAPGEF6	-0.66	-6.42	-0.39	7.65e-10	Cutaneous psoriasis;
SARC	cis	rs826415	0.931	rs1630312	chr1:118165691	C/G	cg09992184	chr1:118151821	FAM46C	0.7	4.97	0.31	1.31e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9916302	0.904	rs6503519	chr17:37706578	A/G	cg20243544	chr17:37824526	PNMT	0.52	6.12	0.37	3.86e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs2180341	0.782	rs4897214	chr6:127723625	G/T	cg27446573	chr6:127587934	RNF146	0.79	10.81	0.58	2.49e-22	Breast cancer;
SARC	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg24675658	chr1:53192096	ZYG11B	-0.56	-7.7	-0.45	3.93e-13	Monocyte count;
SARC	cis	rs7560272	0.538	rs12233115	chr2:73931891	G/A	cg20560298	chr2:73613845	ALMS1	0.46	6.02	0.37	6.77e-9	Schizophrenia;
SARC	cis	rs9818758	0.607	rs9847839	chr3:49289003	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.69	-6.0	-0.37	7.4e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs76419734	1.000	rs11727348	chr4:106679848	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.76	5.11	0.32	6.56e-7	Post bronchodilator FEV1;
SARC	cis	rs2439831	0.867	rs2251844	chr15:43836478	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	7.88	0.46	1.29e-13	Lung cancer in ever smokers;
SARC	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg27286337	chr10:134555280	INPP5A	0.7	9.03	0.51	6.57e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg03060546	chr3:49711283	APEH	0.6	7.47	0.44	1.57e-12	Resting heart rate;
SARC	cis	rs72781680	1.000	rs12623496	chr2:24181583	C/T	cg06627628	chr2:24431161	ITSN2	-0.7	-6.69	-0.4	1.64e-10	Lymphocyte counts;
SARC	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg06221963	chr1:154839813	KCNN3	-0.51	-8.12	-0.47	2.74e-14	Prostate cancer;
SARC	cis	rs11719291	0.831	rs11715177	chr3:48763894	G/A	cg07636037	chr3:49044803	WDR6	-0.73	-6.7	-0.4	1.57e-10	Cognitive function;
SARC	cis	rs911555	0.723	rs7144010	chr14:103869869	G/A	cg12935359	chr14:103987150	CKB	0.4	5.44	0.34	1.37e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7772486	0.686	rs9399564	chr6:146078907	C/T	cg23711669	chr6:146136114	FBXO30	-0.8	-13.09	-0.65	1.04e-29	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	-0.77	-9.82	-0.54	2.94e-19	Prudent dietary pattern;
SARC	cis	rs2832191	0.720	rs4643617	chr21:30485278	T/C	cg24692254	chr21:30365293	RNF160	-0.95	-14.51	-0.69	2.05e-34	Dental caries;
SARC	cis	rs7412746	0.611	rs1889741	chr1:150869045	T/C	cg13175981	chr1:150552382	MCL1	-0.51	-6.28	-0.38	1.64e-9	Melanoma;
SARC	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg20891283	chr12:69753455	YEATS4	0.68	9.8	0.54	3.26e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs1957429	0.614	rs17883073	chr14:65404059	G/A	cg23373153	chr14:65346875	NA	-1.03	-6.44	-0.39	6.81e-10	Pediatric areal bone mineral density (radius);
SARC	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.74	-7.74	-0.45	3.01e-13	Platelet count;
SARC	cis	rs7130144	0.541	rs73572221	chr11:130459948	A/G	cg26307797	chr11:130446613	NA	-0.7	-5.81	-0.36	2.02e-8	Urate levels in lean individuals;
SARC	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg22496380	chr5:211416	CCDC127	-0.87	-8.86	-0.5	2.06e-16	Breast cancer;
SARC	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	14.89	0.7	1.14e-35	Chronic sinus infection;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg13434638	chr15:68723690	ITGA11	-0.5	-6.38	-0.39	9.46e-10	Height;
SARC	cis	rs62229266	0.626	rs2835268	chr21:37449136	C/G	cg12218747	chr21:37451666	NA	-0.36	-5.18	-0.32	4.75e-7	Mitral valve prolapse;
SARC	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg12310025	chr6:25882481	NA	-0.46	-6.07	-0.37	5.08e-9	Intelligence (multi-trait analysis);
SARC	cis	rs3008870	1.000	rs2985822	chr1:67404910	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.9	11.08	0.59	3.48e-23	Lymphocyte percentage of white cells;
SARC	cis	rs6714710	0.603	rs34503448	chr2:98587288	A/G	cg26665480	chr2:98280029	ACTR1B	0.54	7.09	0.42	1.61e-11	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs2070488	0.804	rs13059256	chr3:38504315	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	12.41	0.63	1.82e-27	Electrocardiographic conduction measures;
SARC	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg03709012	chr19:19516395	GATAD2A	-1.02	-17.93	-0.76	9.26e-46	Tonsillectomy;
SARC	cis	rs981844	1.000	rs2606337	chr4:154656845	C/T	cg14289246	chr4:154710475	SFRP2	0.58	6.64	0.4	2.14e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs9302635	0.513	rs13334151	chr16:72189727	A/C	cg16558253	chr16:72132732	DHX38	-0.53	-6.35	-0.38	1.09e-9	Blood protein levels;
SARC	cis	rs6834538	0.965	rs2101391	chr4:113531599	A/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.44	5.22	0.32	3.94e-7	Free thyroxine concentration;
SARC	cis	rs7568458	0.870	rs2366639	chr2:85809955	A/G	cg02493740	chr2:85810744	VAMP5	-0.36	-5.24	-0.32	3.62e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs9309473	0.607	rs7586361	chr2:73601606	G/A	cg20560298	chr2:73613845	ALMS1	-0.55	-7.04	-0.42	2.11e-11	Metabolite levels;
SARC	cis	rs7044106	0.791	rs10739572	chr9:123489815	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.72	9.36	0.52	7e-18	Hip circumference adjusted for BMI;
SARC	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg09699651	chr6:150184138	LRP11	0.39	4.87	0.3	2.04e-6	Lung cancer;
SARC	cis	rs7264396	0.635	rs2064724	chr20:34522520	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.52	5.27	0.33	3.18e-7	Total cholesterol levels;
SARC	cis	rs15676	0.786	rs7875300	chr9:131573261	G/A	cg00228799	chr9:131580591	ENDOG	-0.61	-7.61	-0.45	6.97e-13	Blood metabolite levels;
SARC	cis	rs4423214	0.798	rs1894100	chr11:71130343	G/T	cg05163923	chr11:71159392	DHCR7	-0.53	-6.09	-0.37	4.73e-9	Vitamin D levels;
SARC	cis	rs3784262	0.669	rs12915821	chr15:58315685	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.32	-4.82	-0.3	2.58e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs6504663	0.558	rs11871603	chr17:48559037	T/G	cg03611598	chr17:48586076	MYCBPAP	0.51	5.78	0.35	2.39e-8	Visceral fat;
SARC	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg25894440	chr7:65020034	NA	-0.73	-5.48	-0.34	1.09e-7	Diabetic kidney disease;
SARC	cis	rs9916302	0.851	rs11868029	chr17:37650304	A/G	cg00129232	chr17:37814104	STARD3	-0.64	-7.9	-0.46	1.09e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs10463316	0.928	rs4958451	chr5:150740007	T/C	cg03212797	chr5:150827313	SLC36A1	-0.47	-5.71	-0.35	3.4e-8	Metabolite levels (Pyroglutamine);
SARC	cis	rs910316	0.663	rs175034	chr14:75463687	T/G	cg11812906	chr14:75593930	NEK9	-0.76	-10.02	-0.55	7.1e-20	Height;
SARC	trans	rs1814175	0.616	rs1794139	chr11:49910855	C/T	cg03929089	chr4:120376271	NA	-0.82	-11.73	-0.61	2.77e-25	Height;
SARC	cis	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg09021430	chr5:549028	NA	-0.43	-5.6	-0.34	5.99e-8	Obesity-related traits;
SARC	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg22857025	chr5:266934	NA	-1.08	-11.86	-0.61	1.06e-25	Breast cancer;
SARC	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg13395646	chr4:1353034	KIAA1530	-0.42	-4.99	-0.31	1.19e-6	Obesity-related traits;
SARC	cis	rs1799949	0.587	rs1824890	chr17:41421904	T/C	cg25072359	chr17:41440525	NA	0.51	5.24	0.32	3.65e-7	Menopause (age at onset);
SARC	cis	rs425277	0.628	rs3128340	chr1:2047496	C/G	cg21442419	chr1:2182373	SKI	0.46	5.98	0.36	8.38e-9	Height;
SARC	cis	rs77106637	0.860	rs7129793	chr11:72455885	C/T	cg03713592	chr11:72463424	ARAP1	1.09	10.09	0.55	4.16e-20	Type 2 diabetes;
SARC	cis	rs55962025	0.842	rs362267	chr4:3243218	C/T	cg06533319	chr4:3265114	C4orf44	0.34	5.05	0.31	9.07e-7	Parental longevity (mother's age at death);
SARC	cis	rs61409971	0.961	rs10131571	chr14:93015743	C/T	cg04718702	chr14:93020195	RIN3	-0.37	-4.88	-0.3	1.96e-6	Lymphocyte percentage of white cells;
SARC	cis	rs870825	0.616	rs6852082	chr4:185645783	T/C	cg04058563	chr4:185651563	MLF1IP	0.8	11.35	0.6	4.56e-24	Blood protein levels;
SARC	cis	rs3092073	0.624	rs11696196	chr20:44574533	C/T	cg27529037	chr20:44575021	PCIF1	0.39	6.18	0.38	2.89e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7246657	1.000	rs1529957	chr19:37739801	A/G	cg23950597	chr19:37808831	NA	-0.51	-4.87	-0.3	2.05e-6	Coronary artery calcification;
SARC	cis	rs1322639	0.614	rs6925201	chr6:169563357	C/T	cg03254818	chr6:169586852	NA	-0.6	-5.5	-0.34	9.81e-8	Pulse pressure;
SARC	cis	rs9790314	0.586	rs1839491	chr3:161126429	C/A	cg03342759	chr3:160939853	NMD3	-0.58	-7.01	-0.42	2.6e-11	Morning vs. evening chronotype;
SARC	cis	rs637571	0.522	rs503524	chr11:65751764	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.56	8.77	0.5	3.7e-16	Eosinophil percentage of white cells;
SARC	cis	rs9910055	0.529	rs228764	chr17:42185469	A/G	cg19774624	chr17:42201019	HDAC5	0.55	6.75	0.4	1.16e-10	Total body bone mineral density;
SARC	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg20102877	chr2:27665638	KRTCAP3	-0.39	-5.41	-0.33	1.54e-7	Total body bone mineral density;
SARC	cis	rs1008375	0.966	rs4698619	chr4:17580955	G/A	cg02297831	chr4:17616191	MED28	0.49	6.22	0.38	2.31e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs8067545	0.750	rs3862152	chr17:19959693	C/T	cg13482628	chr17:19912719	NA	0.57	7.6	0.45	7.22e-13	Schizophrenia;
SARC	cis	rs3796352	1.000	rs13072395	chr3:52980573	T/C	cg27565382	chr3:53032988	SFMBT1	0.98	6.46	0.39	6.08e-10	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg04267008	chr7:1944627	MAD1L1	0.48	5.42	0.33	1.48e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs637571	0.522	rs491973	chr11:65727301	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.4	5.06	0.31	8.61e-7	Eosinophil percentage of white cells;
SARC	cis	rs9303401	0.614	rs56284918	chr17:57178838	A/G	cg25039879	chr17:56429692	SUPT4H1	0.58	5.22	0.32	3.88e-7	Cognitive test performance;
SARC	cis	rs1865760	1.000	rs9393675	chr6:25930116	G/A	cg16482183	chr6:26056742	HIST1H1C	0.52	6.35	0.38	1.14e-9	Height;
SARC	cis	rs7223966	1.000	rs8081612	chr17:61724695	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.59	-6.91	-0.41	4.72e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7589342	0.929	rs12053259	chr2:106428720	G/A	cg16077055	chr2:106428750	NCK2	0.4	7.36	0.43	3.1e-12	Addiction;
SARC	cis	rs11581859	0.613	rs67882326	chr1:99189338	T/C	cg20286094	chr1:99190917	SNX7	-0.41	-4.88	-0.3	1.97e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs11719291	0.833	rs11715835	chr3:48770732	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.68	-5.56	-0.34	7.47e-8	Cognitive function;
SARC	cis	rs4689388	0.890	rs4688991	chr4:6302220	C/G	cg25554036	chr4:6271136	WFS1	0.37	6.04	0.37	6.13e-9	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs9322817	0.691	rs4946648	chr6:105329422	G/T	cg02098413	chr6:105308735	HACE1	0.38	5.92	0.36	1.17e-8	Thyroid stimulating hormone;
SARC	cis	rs2231884	0.697	rs11227332	chr11:65623739	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.6	6.29	0.38	1.54e-9	Inflammatory bowel disease;
SARC	cis	rs7945718	0.934	rs7114040	chr11:12781659	C/T	ch.11.340609R	chr11:12831013	TEAD1	0.37	4.73	0.3	3.9e-6	Educational attainment (years of education);
SARC	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg03060546	chr3:49711283	APEH	0.42	5.32	0.33	2.47e-7	Parkinson's disease;
SARC	cis	rs62158211	1.000	rs62158211	chr2:114106139	G/T	cg17784749	chr2:114082611	LOC440839	0.65	7.0	0.42	2.7e-11	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
SARC	cis	rs6772849	0.768	rs9820741	chr3:128416080	G/A	cg01163369	chr3:128370232	RPN1	-0.34	-4.74	-0.3	3.69e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs9303280	0.901	rs869402	chr17:38068043	C/T	cg19468946	chr17:37922297	IKZF3	-0.29	-4.81	-0.3	2.68e-6	Self-reported allergy;
SARC	cis	rs10875746	0.951	rs10875747	chr12:48525861	A/G	cg26205652	chr12:48591994	NA	0.55	6.11	0.37	4.11e-9	Longevity (90 years and older);
SARC	cis	rs7940866	0.804	rs6590540	chr11:130805444	T/C	cg12179176	chr11:130786555	SNX19	0.67	9.79	0.54	3.54e-19	Schizophrenia;
SARC	cis	rs7937682	0.602	rs11214036	chr11:111773169	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.79	-10.71	-0.57	4.93e-22	Primary sclerosing cholangitis;
SARC	cis	rs739401	0.869	rs395188	chr11:3072631	A/G	cg08508325	chr11:3079039	CARS	0.23	5.27	0.33	3.06e-7	Longevity;
SARC	cis	rs72945132	0.882	rs55915603	chr11:70210067	G/T	cg05964544	chr11:70165517	PPFIA1	-0.57	-5.36	-0.33	2.04e-7	Coronary artery disease;
SARC	cis	rs986417	0.748	rs11158289	chr14:61032390	C/T	cg27398547	chr14:60952738	C14orf39	0.75	7.67	0.45	4.77e-13	Gut microbiota (bacterial taxa);
SARC	cis	rs10924970	0.524	rs2803851	chr1:235500649	C/T	cg26050004	chr1:235667680	B3GALNT2	0.51	6.3	0.38	1.49e-9	Asthma;
SARC	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs508618	0.638	rs479200	chr1:231543780	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-6.43	-0.39	6.97e-10	Red blood cell count;
SARC	cis	rs7223966	1.000	rs11657306	chr17:61704822	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.44	4.93	0.31	1.53e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg13393036	chr8:95962371	TP53INP1	-0.36	-6.13	-0.37	3.75e-9	Type 2 diabetes;
SARC	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.53	-5.18	-0.32	4.87e-7	Ankle injury;
SARC	cis	rs3820928	0.874	rs13413235	chr2:227893863	C/T	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.67	-0.35	4.12e-8	Pulmonary function;
SARC	trans	rs61931739	0.782	rs3903201	chr12:34248275	G/A	cg13010199	chr12:38710504	ALG10B	0.58	7.42	0.44	2.12e-12	Morning vs. evening chronotype;
SARC	cis	rs501120	1.000	rs694425	chr10:44761804	C/G	cg09554077	chr10:44749378	NA	0.37	4.81	0.3	2.71e-6	Coronary artery disease;Coronary heart disease;
SARC	cis	rs765787	0.530	rs11636440	chr15:45535982	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.67e-7	Uric acid levels;
SARC	cis	rs829883	0.902	rs829884	chr12:98879500	C/G	cg25150519	chr12:98850993	NA	0.7	9.48	0.53	3.07e-18	Colorectal adenoma (advanced);
SARC	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg17143192	chr8:8559678	CLDN23	-0.54	-6.17	-0.37	2.95e-9	Obesity-related traits;
SARC	cis	rs7808935	0.628	rs72598551	chr7:27939885	C/T	cg05786569	chr7:27702416	HIBADH	0.77	8.19	0.47	1.68e-14	Prostate cancer;
SARC	cis	rs7811528	0.527	rs7787450	chr7:2707709	A/G	cg11411865	chr7:2701802	TTYH3	0.62	6.13	0.37	3.81e-9	Schizophrenia;
SARC	cis	rs921968	0.541	rs3755042	chr2:219317248	T/C	cg02176678	chr2:219576539	TTLL4	-0.5	-7.57	-0.44	8.87e-13	Mean corpuscular hemoglobin concentration;
SARC	cis	rs17376456	0.877	rs28539612	chr5:93499099	C/T	cg25358565	chr5:93447407	FAM172A	1.36	14.0	0.68	1.04e-32	Diabetic retinopathy;
SARC	cis	rs8114671	0.562	rs6088655	chr20:33527838	A/G	cg07148914	chr20:33460835	GGT7	0.41	5.0	0.31	1.13e-6	Height;
SARC	cis	rs9399137	0.507	rs4520025	chr6:135278619	G/T	cg22676075	chr6:135203613	NA	0.4	5.13	0.32	6.19e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs2988277	0.737	rs1723015	chr1:167432894	T/C	cg09179987	chr1:167433047	CD247	0.37	5.73	0.35	3.11e-8	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg22535103	chr8:58192502	C8orf71	-0.59	-6.21	-0.38	2.35e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs72781680	1.000	rs72781653	chr2:24215633	T/C	cg06627628	chr2:24431161	ITSN2	-0.68	-6.64	-0.4	2.19e-10	Lymphocyte counts;
SARC	cis	rs34172651	0.917	rs1465422	chr16:24772486	C/T	cg00152838	chr16:24741724	TNRC6A	-0.43	-5.4	-0.33	1.65e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9400467	0.506	rs12200610	chr6:111663567	C/G	cg15721981	chr6:111408429	SLC16A10	0.64	5.51	0.34	9.48e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs2153535	0.580	rs1414350	chr6:8472331	C/T	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs17401966	0.931	rs11121545	chr1:10411211	A/G	cg15208524	chr1:10270712	KIF1B	0.52	6.16	0.37	3.23e-9	Hepatocellular carcinoma;
SARC	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg16680214	chr1:154839983	KCNN3	-0.36	-5.64	-0.35	4.97e-8	Prostate cancer;
SARC	cis	rs8180040	0.620	rs11917361	chr3:47070497	G/T	cg27129171	chr3:47204927	SETD2	-0.66	-9.03	-0.51	6.71e-17	Colorectal cancer;
SARC	cis	rs6952809	0.532	rs10227362	chr7:2456799	A/G	cg23289794	chr7:2394357	EIF3B	-0.63	-6.16	-0.37	3.12e-9	Multiple sclerosis;
SARC	cis	rs11764590	0.671	rs17734969	chr7:2110517	T/C	cg21782813	chr7:2030301	MAD1L1	-0.38	-5.09	-0.32	7.51e-7	Neuroticism;
SARC	cis	rs9457247	0.663	rs10946205	chr6:167451311	A/G	cg07741184	chr6:167504864	NA	0.35	6.89	0.41	5.17e-11	Crohn's disease;
SARC	trans	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.07	-0.42	1.8e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs787274	1.000	rs10739370	chr9:115556941	A/G	cg13803584	chr9:115635662	SNX30	-0.83	-5.06	-0.31	8.34e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.96	-14.13	-0.68	3.74e-33	Gut microbiome composition (summer);
SARC	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg24633833	chr3:10029261	TMEM111	0.52	5.25	0.33	3.43e-7	Alzheimer's disease;
SARC	cis	rs2130392	1.000	rs873686	chr4:185638876	A/G	cg04058563	chr4:185651563	MLF1IP	-0.39	-5.5	-0.34	9.75e-8	Kawasaki disease;
SARC	cis	rs911555	0.755	rs2756135	chr14:103962579	G/A	cg12935359	chr14:103987150	CKB	0.38	5.28	0.33	2.99e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9910055	0.529	rs228746	chr17:42173752	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	-0.48	-5.62	-0.35	5.53e-8	Total body bone mineral density;
SARC	cis	rs7647973	0.710	rs2029591	chr3:49646981	C/T	cg07636037	chr3:49044803	WDR6	-0.74	-6.79	-0.41	9e-11	Menarche (age at onset);
SARC	cis	rs7772486	0.790	rs4314514	chr6:146260010	A/G	cg05347473	chr6:146136440	FBXO30	-0.48	-6.53	-0.39	4.01e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1728785	1.000	rs1645928	chr16:68590610	G/T	cg02972257	chr16:68554789	NA	-0.52	-5.88	-0.36	1.39e-8	Ulcerative colitis;
SARC	cis	rs9462027	0.606	rs9394248	chr6:34739875	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.4	-5.72	-0.35	3.24e-8	Systemic lupus erythematosus;
SARC	trans	rs1814175	0.817	rs10769648	chr11:50013992	T/C	cg15704280	chr7:45808275	SEPT13	-0.97	-18.31	-0.77	5.28e-47	Height;
SARC	cis	rs6545883	0.965	rs11887205	chr2:61774473	T/G	cg15711740	chr2:61764176	XPO1	-0.45	-5.46	-0.34	1.22e-7	Tuberculosis;
SARC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg14159672	chr1:205819179	PM20D1	-0.85	-12.67	-0.64	2.44e-28	Menarche (age at onset);
SARC	cis	rs4423214	0.840	rs1629220	chr11:71174553	C/T	cg05163923	chr11:71159392	DHCR7	-0.61	-7.39	-0.44	2.64e-12	Vitamin D levels;
SARC	cis	rs11112613	0.713	rs12296355	chr12:105953321	C/A	cg03607813	chr12:105948248	NA	0.54	7.59	0.45	7.65e-13	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg08045932	chr20:61659980	NA	0.5	6.88	0.41	5.6e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg20573242	chr4:122745356	CCNA2	0.65	8.25	0.48	1.16e-14	Type 2 diabetes;
SARC	cis	rs3820928	0.845	rs10165767	chr2:227781863	G/A	cg11843606	chr2:227700838	RHBDD1	-0.59	-7.47	-0.44	1.64e-12	Pulmonary function;
SARC	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.5	-5.89	-0.36	1.35e-8	Blood metabolite levels;
SARC	cis	rs1669338	0.510	rs3804788	chr3:3169466	C/A	cg16797762	chr3:3221439	CRBN	-0.93	-9.19	-0.52	2.2e-17	White matter integrity;
SARC	trans	rs4332037	0.539	rs11764590	chr7:2032803	C/T	cg11693508	chr17:37793320	STARD3	0.67	6.41	0.39	7.83e-10	Bipolar disorder;
SARC	cis	rs2153535	0.580	rs2327062	chr6:8453858	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	8.34	0.48	6.39e-15	Motion sickness;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg07496861	chr2:208489667	FAM119A	0.52	6.31	0.38	1.38e-9	Fibrinogen levels;
SARC	cis	rs9399137	0.507	rs6918512	chr6:135284839	T/G	cg24558204	chr6:135376177	HBS1L	0.62	7.98	0.46	6.83e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs73206853	0.697	rs56084592	chr12:110577910	T/A	cg10860002	chr12:110842031	ANAPC7	0.63	5.09	0.32	7.41e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs11630290	0.592	rs11071767	chr15:64154635	A/G	cg12036633	chr15:63758958	NA	-0.47	-5.02	-0.31	1.03e-6	Iris characteristics;
SARC	cis	rs2952156	0.959	rs2941504	chr17:37830900	A/G	cg00129232	chr17:37814104	STARD3	-0.67	-9.1	-0.51	4.06e-17	Asthma;
SARC	cis	rs6089584	0.507	rs6061989	chr20:60627893	C/T	cg13770153	chr20:60521292	NA	-0.38	-5.41	-0.33	1.53e-7	Body mass index;
SARC	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg08280861	chr8:58055591	NA	0.59	5.8	0.36	2.12e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7412746	0.586	rs2864882	chr1:150883037	C/T	cg15448220	chr1:150897856	SETDB1	0.52	6.87	0.41	5.67e-11	Melanoma;
SARC	cis	rs2439831	0.850	rs11856795	chr15:44160582	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	7.77	0.45	2.55e-13	Lung cancer in ever smokers;
SARC	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.66	6.4	0.39	8.23e-10	Platelet count;
SARC	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg25952890	chr19:58913133	NA	0.36	5.12	0.32	6.45e-7	Uric acid clearance;
SARC	cis	rs9581857	0.547	rs78273785	chr13:28052884	T/C	cg01674679	chr13:27998804	GTF3A	-0.66	-5.0	-0.31	1.11e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	cis	rs921968	0.541	rs664514	chr2:219329819	A/G	cg02176678	chr2:219576539	TTLL4	0.47	7.22	0.43	7.15e-12	Mean corpuscular hemoglobin concentration;
SARC	cis	rs1707322	0.963	rs12145287	chr1:46325002	C/G	cg06784218	chr1:46089804	CCDC17	0.35	6.16	0.37	3.2e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7089973	0.872	rs35628210	chr10:116630031	G/A	cg08188268	chr10:116634841	FAM160B1	0.35	5.64	0.35	4.96e-8	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs10752881	1.000	rs10752885	chr1:182982878	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.64	0.57	8.23e-22	Colorectal cancer;
SARC	cis	rs3770770	0.903	rs62133108	chr2:37253455	C/T	cg14987922	chr2:37194071	STRN	-0.48	-4.77	-0.3	3.31e-6	QRS duration;
SARC	cis	rs427394	0.772	rs274689	chr5:6736215	G/C	cg10857441	chr5:6722123	POLS	-0.34	-5.1	-0.32	7.2e-7	Menopause (age at onset);
SARC	cis	rs7178572	0.633	rs11857860	chr15:77839761	T/C	cg22256960	chr15:77711686	NA	-0.43	-4.81	-0.3	2.65e-6	Type 2 diabetes;
SARC	cis	rs1008375	0.898	rs7678654	chr4:17575376	T/G	cg02297831	chr4:17616191	MED28	0.47	5.92	0.36	1.16e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6493487	0.512	rs12916334	chr15:51159835	C/G	cg02338191	chr15:51200825	AP4E1	0.49	4.75	0.3	3.63e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs910316	0.763	rs175435	chr14:75612025	A/G	cg08847533	chr14:75593920	NEK9	0.81	11.92	0.62	6.84e-26	Height;
SARC	cis	rs8051517	1.000	rs1106583	chr16:68417796	C/T	cg01866162	chr16:67596514	CTCF	0.9	5.32	0.33	2.45e-7	Blood protein levels;
SARC	cis	rs7662987	0.517	rs2602865	chr4:100034841	T/C	cg13256891	chr4:100009986	ADH5	0.68	8.58	0.49	1.31e-15	Smoking initiation;
SARC	cis	rs6087990	0.806	rs875041	chr20:31383530	C/T	cg13636640	chr20:31349939	DNMT3B	0.81	13.22	0.65	3.69e-30	Ulcerative colitis;
SARC	cis	rs2361710	0.668	rs2304855	chr17:78118266	T/A	cg23534315	chr17:78082725	GAA	0.33	4.94	0.31	1.51e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
SARC	cis	rs13256369	1.000	rs1109619	chr8:8571616	G/T	cg18904891	chr8:8559673	CLDN23	0.49	5.76	0.35	2.71e-8	Obesity-related traits;
SARC	cis	rs858239	0.539	rs6971673	chr7:23159523	C/G	cg23682824	chr7:23144976	KLHL7	0.73	9.83	0.54	2.71e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs1023500	0.573	rs133380	chr22:42468910	C/T	cg15557168	chr22:42548783	NA	-0.34	-4.71	-0.3	4.18e-6	Schizophrenia;
SARC	cis	rs96067	0.805	rs12033825	chr1:36600311	C/T	cg24686825	chr1:36642396	MAP7D1	-0.54	-6.26	-0.38	1.83e-9	Corneal structure;
SARC	cis	rs9814567	1.000	rs1880377	chr3:134270468	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	7.03	0.42	2.31e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs4481887	0.927	rs4390208	chr1:248472211	C/T	cg00666640	chr1:248458726	OR2T12	0.32	5.47	0.34	1.14e-7	Common traits (Other);
SARC	cis	rs2228479	0.850	rs117675822	chr16:89919081	C/A	cg06558623	chr16:89946397	TCF25	0.93	6.61	0.4	2.59e-10	Skin colour saturation;
SARC	cis	rs67311347	1.000	rs9841335	chr3:40475858	G/A	cg09455208	chr3:40491958	NA	0.42	6.69	0.4	1.63e-10	Renal cell carcinoma;
SARC	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg17971929	chr21:40555470	PSMG1	0.98	13.64	0.67	1.59e-31	Cognitive function;
SARC	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg08677398	chr8:58056175	NA	0.44	5.25	0.33	3.38e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs4742903	0.935	rs10820602	chr9:106861282	C/T	cg21169611	chr9:106856078	SMC2	0.39	4.83	0.3	2.52e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs1707322	1.000	rs6675222	chr1:46326576	G/T	cg03146154	chr1:46216737	IPP	0.47	5.67	0.35	4.31e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6504663	0.558	rs7627	chr17:48552154	G/C	cg03168497	chr17:48586147	MYCBPAP	0.49	5.16	0.32	5.24e-7	Visceral fat;
SARC	cis	rs8031584	0.958	rs11629793	chr15:31238423	G/A	cg14829155	chr15:31115871	NA	-0.42	-5.28	-0.33	2.99e-7	Huntington's disease progression;
SARC	cis	rs1865760	0.555	rs2051541	chr6:25945211	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.52	-6.01	-0.37	6.93e-9	Height;
SARC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg11494091	chr17:61959527	GH2	0.53	8.0	0.46	5.72e-14	Prudent dietary pattern;
SARC	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg24549020	chr5:56110836	MAP3K1	0.81	8.4	0.48	4.37e-15	Initial pursuit acceleration;
SARC	cis	rs992157	0.560	rs12987130	chr2:219104990	T/C	cg00012203	chr2:219082015	ARPC2	-0.74	-10.88	-0.58	1.47e-22	Colorectal cancer;
SARC	cis	rs12190007	0.846	rs9505962	chr6:169726667	A/G	cg16388071	chr6:169726476	NA	0.37	5.29	0.33	2.85e-7	Obesity-related traits;
SARC	cis	rs7223966	1.000	rs8068603	chr17:61755211	T/A	cg26338869	chr17:61819248	STRADA	0.44	5.14	0.32	5.82e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1865760	0.622	rs9295685	chr6:26071725	G/C	cg16482183	chr6:26056742	HIST1H1C	0.47	5.97	0.36	8.71e-9	Height;
SARC	cis	rs7953249	0.502	rs1169294	chr12:121426594	G/A	cg02403541	chr12:121454288	C12orf43	0.78	10.79	0.58	2.76e-22	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs2153535	0.541	rs6932434	chr6:8467679	G/A	cg21535247	chr6:8435926	SLC35B3	0.54	6.79	0.41	9.19e-11	Motion sickness;
SARC	cis	rs9303401	0.573	rs35104446	chr17:57180234	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.97	10.17	0.55	2.42e-20	Cognitive test performance;
SARC	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg12463550	chr7:65579703	CRCP	-0.44	-4.84	-0.3	2.32e-6	Aortic root size;
SARC	cis	rs1448094	0.512	rs12313775	chr12:86241197	G/A	cg02569458	chr12:86230093	RASSF9	0.39	5.45	0.34	1.26e-7	Major depressive disorder;
SARC	cis	rs1008375	0.863	rs7680984	chr4:17600884	A/G	cg16339924	chr4:17578868	LAP3	0.64	8.33	0.48	6.98e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs262150	0.579	rs73167299	chr7:158784367	C/T	cg19418458	chr7:158789849	NA	0.45	4.91	0.31	1.71e-6	Facial morphology (factor 20);
SARC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.7	9.1	0.51	4.07e-17	Prudent dietary pattern;
SARC	trans	rs2018683	0.677	rs12540529	chr7:28969384	A/G	cg19402173	chr7:128379420	CALU	-0.52	-6.81	-0.41	8.32e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.97e-8	Aortic root size;
SARC	cis	rs11098499	0.954	rs6848389	chr4:120402622	A/G	cg09307838	chr4:120376055	NA	0.94	13.07	0.65	1.21e-29	Corneal astigmatism;
SARC	cis	rs10504229	0.679	rs78941440	chr8:58052095	A/G	cg22535103	chr8:58192502	C8orf71	-0.56	-5.58	-0.34	6.75e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7829975	0.684	rs546603	chr8:8595838	T/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-5.77	-0.35	2.55e-8	Mood instability;
SARC	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg13393036	chr8:95962371	TP53INP1	-0.39	-6.55	-0.39	3.61e-10	Type 2 diabetes;
SARC	trans	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg11598976	chr3:16926680	PLCL2	-0.67	-6.38	-0.39	9.3e-10	Cutaneous psoriasis;
SARC	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg18252515	chr7:66147081	NA	0.58	6.21	0.38	2.41e-9	Aortic root size;
SARC	cis	rs35213789	0.762	rs2533428	chr7:69142457	G/C	cg10619644	chr7:69149951	AUTS2	-0.36	-4.95	-0.31	1.44e-6	Childhood ear infection;
SARC	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg13699009	chr12:122356056	WDR66	0.62	10.0	0.55	8.26e-20	Mean corpuscular volume;
SARC	cis	rs11764590	0.694	rs55860148	chr7:2105594	G/A	cg21782813	chr7:2030301	MAD1L1	-0.39	-5.34	-0.33	2.17e-7	Neuroticism;
SARC	cis	rs600231	0.665	rs1784858	chr11:65222952	T/C	cg17120908	chr11:65337727	SSSCA1	-0.42	-5.42	-0.33	1.49e-7	Bone mineral density;
SARC	cis	rs5753618	0.509	rs5997913	chr22:31593959	C/A	cg00478049	chr22:31556069	RNF185	0.44	4.74	0.3	3.65e-6	Colorectal cancer;
SARC	cis	rs2841277	0.676	rs4264326	chr14:105411700	A/G	cg19901468	chr14:105411992	AHNAK2	-0.73	-10.65	-0.57	7.94e-22	Rheumatoid arthritis;
SARC	cis	rs1790761	0.692	rs638140	chr11:67333858	G/C	cg00290607	chr11:67383545	NA	0.39	5.24	0.32	3.56e-7	Mean corpuscular volume;
SARC	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg20887711	chr4:1340912	KIAA1530	0.77	9.36	0.52	6.85e-18	Longevity;
SARC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.45	-5.84	-0.36	1.75e-8	Longevity;Endometriosis;
SARC	cis	rs72945132	0.638	rs11236127	chr11:70241536	G/C	cg05964544	chr11:70165517	PPFIA1	-0.64	-6.6	-0.4	2.82e-10	Coronary artery disease;
SARC	trans	rs1973993	0.662	rs2057427	chr1:96888897	C/G	cg10631902	chr5:14652156	NA	-0.41	-6.48	-0.39	5.42e-10	Weight;
SARC	cis	rs2273669	0.667	rs11153139	chr6:109279381	C/T	cg05315195	chr6:109294784	ARMC2	-0.59	-5.05	-0.31	8.71e-7	Prostate cancer;
SARC	cis	rs3126085	0.935	rs3120659	chr1:152293202	A/G	cg26876637	chr1:152193138	HRNR	-0.48	-5.32	-0.33	2.49e-7	Atopic dermatitis;
SARC	cis	rs6484504	0.576	rs2150213	chr11:31244634	A/G	cg26647111	chr11:31128758	NA	-0.4	-5.21	-0.32	4.21e-7	Red blood cell count;
SARC	cis	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg25427524	chr10:38739819	LOC399744	-0.6	-9.67	-0.54	8.06e-19	Extrinsic epigenetic age acceleration;
SARC	cis	rs4805272	0.626	rs12610050	chr19:29331324	A/T	cg12756686	chr19:29218302	NA	0.53	6.32	0.38	1.3e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs11608355	0.538	rs7305165	chr12:109804222	G/A	cg19025524	chr12:109796872	NA	-0.42	-6.23	-0.38	2.19e-9	Neuroticism;
SARC	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg00339695	chr16:24857497	SLC5A11	0.39	5.27	0.33	3.09e-7	Intelligence (multi-trait analysis);
SARC	cis	rs798554	0.704	rs2527684	chr7:2825922	G/T	cg04166393	chr7:2884313	GNA12	0.41	4.97	0.31	1.28e-6	Height;
SARC	cis	rs981844	0.712	rs1037654	chr4:154750300	C/G	cg14289246	chr4:154710475	SFRP2	-0.45	-5.36	-0.33	1.96e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs765787	0.530	rs2433228	chr15:45515371	A/C	cg26924012	chr15:45694286	SPATA5L1	-0.43	-5.39	-0.33	1.73e-7	Uric acid levels;
SARC	cis	rs9486715	0.867	rs2499775	chr6:97007340	C/T	cg18709589	chr6:96969512	KIAA0776	-0.61	-7.67	-0.45	4.59e-13	Headache;
SARC	cis	rs12956009	0.518	rs1347343	chr18:44818996	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	7.74	0.45	2.93e-13	Educational attainment (years of education);
SARC	cis	rs1949733	0.958	rs3103069	chr4:8509451	T/G	cg13073564	chr4:8508604	NA	0.47	7.74	0.45	2.93e-13	Response to antineoplastic agents;
SARC	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg11843238	chr5:131593191	PDLIM4	-0.42	-5.14	-0.32	5.92e-7	Blood metabolite levels;
SARC	cis	rs6964587	0.934	rs6465344	chr7:91640273	G/A	cg17063962	chr7:91808500	NA	0.96	16.55	0.74	3.24e-41	Breast cancer;
SARC	cis	rs4787491	0.729	rs12446378	chr16:30043110	T/G	cg06326092	chr16:30034487	C16orf92	0.27	4.72	0.3	4.15e-6	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs6942407	0.546	rs3747807	chr7:86800351	A/G	cg02420886	chr7:86849541	C7orf23	0.61	5.51	0.34	9.41e-8	Food allergy;
SARC	cis	rs9297145	1.000	rs10953280	chr7:98763405	A/G	cg05967295	chr7:98741636	SMURF1	-0.86	-10.4	-0.56	4.72e-21	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
SARC	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg11644478	chr21:40555479	PSMG1	1.05	14.79	0.7	2.43e-35	Cognitive function;
SARC	cis	rs2213920	0.679	rs10759780	chr9:118196088	A/C	cg13918206	chr9:118159781	DEC1	0.81	6.46	0.39	5.89e-10	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	23.05	0.83	5.02e-62	Chronic sinus infection;
SARC	trans	rs61931739	0.635	rs1601627	chr12:33962420	G/A	cg13010199	chr12:38710504	ALG10B	0.5	6.42	0.39	7.45e-10	Morning vs. evening chronotype;
SARC	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg08859206	chr1:53392774	SCP2	-0.38	-5.42	-0.33	1.47e-7	Monocyte count;
SARC	cis	rs612683	0.599	rs2809823	chr1:101003762	C/A	cg06223162	chr1:101003688	GPR88	0.31	5.85	0.36	1.66e-8	Breast cancer;
SARC	cis	rs9660992	0.512	rs12142402	chr1:205128215	A/T	cg07972983	chr1:205091412	RBBP5	0.56	7.29	0.43	4.85e-12	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs559928	0.606	rs61083753	chr11:63892665	C/T	cg05555928	chr11:63887634	MACROD1	-0.51	-5.24	-0.32	3.55e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs3540	0.597	rs7498113	chr15:91051192	C/G	cg22089800	chr15:90895588	ZNF774	-0.61	-7.83	-0.46	1.74e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs6450176	0.951	rs5013866	chr5:53300947	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.67	-7.73	-0.45	3.15e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs483180	0.532	rs561931	chr1:120254506	A/G	cg19096424	chr1:120255104	PHGDH	0.61	7.38	0.44	2.76e-12	Macular telangiectasia type 2;
SARC	cis	rs2273669	0.915	rs7753554	chr6:109292133	G/C	cg05315195	chr6:109294784	ARMC2	-0.48	-4.78	-0.3	3.15e-6	Prostate cancer;
SARC	cis	rs11098499	1.000	rs6849889	chr4:120186348	A/C	cg09307838	chr4:120376055	NA	0.8	10.31	0.56	9e-21	Corneal astigmatism;
SARC	trans	rs208520	0.661	rs7747492	chr6:66857788	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.03	-13.96	-0.67	1.41e-32	Exhaled nitric oxide output;
SARC	cis	rs559928	0.557	rs7122408	chr11:63898826	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	5.26	0.33	3.29e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs2327429	0.789	rs12202017	chr6:134173151	A/G	cg25632230	chr6:134101081	NA	-0.48	-5.9	-0.36	1.29e-8	Coronary artery disease;
SARC	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg18225595	chr11:63971243	STIP1	-0.47	-6.88	-0.41	5.59e-11	Platelet count;
SARC	cis	rs910316	0.737	rs108621	chr14:75480637	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.46	-6.02	-0.37	6.78e-9	Height;
SARC	cis	rs559928	0.597	rs2186572	chr11:63895887	A/G	cg05555928	chr11:63887634	MACROD1	-0.51	-4.85	-0.3	2.26e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs4919694	1.000	rs58317752	chr10:104799267	T/A	cg04362960	chr10:104952993	NT5C2	0.65	5.56	0.34	7.45e-8	Arsenic metabolism;
SARC	cis	rs2635047	0.615	rs9304343	chr18:44720664	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	5.65	0.35	4.57e-8	Educational attainment;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg03241244	chr12:122017052	KDM2B	0.5	6.66	0.4	1.89e-10	Chemerin levels;
SARC	cis	rs9796	0.870	rs11855248	chr15:41276158	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.42	-5.77	-0.35	2.45e-8	Menopause (age at onset);
SARC	cis	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg07777115	chr5:623756	CEP72	-0.55	-4.98	-0.31	1.25e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs9843304	0.526	rs9850213	chr3:149202590	C/T	cg08667024	chr3:149219783	TM4SF4	0.45	6.87	0.41	5.69e-11	Gallstone disease;
SARC	cis	rs9393692	1.000	rs3999544	chr6:26285867	C/T	cg00631329	chr6:26305371	NA	-0.65	-9.03	-0.51	6.57e-17	Educational attainment;
SARC	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg20887711	chr4:1340912	KIAA1530	0.79	9.69	0.54	7.1e-19	Longevity;
SARC	cis	rs3741798	1.000	rs61922049	chr12:12497395	C/T	cg08615371	chr12:12503544	MANSC1	0.68	5.43	0.34	1.43e-7	Cerebrospinal fluid biomarker levels;
SARC	cis	rs6964587	1.000	rs6968870	chr7:91661111	G/C	cg17063962	chr7:91808500	NA	0.93	15.78	0.72	1.18e-38	Breast cancer;
SARC	cis	rs8114671	0.628	rs6060130	chr20:33549319	C/T	cg07148914	chr20:33460835	GGT7	0.43	5.26	0.33	3.31e-7	Height;
SARC	cis	rs3857067	0.740	rs6532470	chr4:95108211	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.07	-0.32	8.15e-7	QT interval;
SARC	cis	rs7584330	0.826	rs72620824	chr2:238381083	G/A	cg14458575	chr2:238380390	NA	0.56	6.08	0.37	4.98e-9	Prostate cancer;
SARC	cis	rs8014204	0.541	rs35591392	chr14:75157713	G/T	cg17347104	chr14:75034677	LTBP2	-0.48	-6.48	-0.39	5.35e-10	Caffeine consumption;
SARC	cis	rs9399135	0.935	rs11759999	chr6:135370495	G/T	cg24558204	chr6:135376177	HBS1L	0.46	6.23	0.38	2.19e-9	Red blood cell count;
SARC	cis	rs2342371	0.715	rs9846106	chr3:196126539	G/A	cg15048948	chr3:196158458	UBXN7	0.63	7.62	0.45	6.4e-13	Fat distribution (HIV);
SARC	cis	rs734999	0.588	rs2764848	chr1:2530694	G/A	cg18854424	chr1:2615690	NA	-0.32	-5.03	-0.31	9.77e-7	Ulcerative colitis;
SARC	cis	rs10875746	0.903	rs11168420	chr12:48515896	C/T	cg26205652	chr12:48591994	NA	0.55	6.18	0.38	2.89e-9	Longevity (90 years and older);
SARC	cis	rs9329221	0.935	rs3750310	chr8:10283426	G/A	cg21775007	chr8:11205619	TDH	-0.45	-5.49	-0.34	1.05e-7	Neuroticism;
SARC	cis	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg21573476	chr21:45109991	RRP1B	-0.56	-8.21	-0.47	1.55e-14	Mean corpuscular volume;
SARC	cis	rs6867032	0.527	rs1017924	chr5:1976187	C/T	cg26168224	chr5:2018326	NA	0.55	6.44	0.39	6.9e-10	Gut microbiome composition (winter);
SARC	cis	rs4268898	0.662	rs2891380	chr2:24525830	G/A	cg06627628	chr2:24431161	ITSN2	-0.82	-10.05	-0.55	5.58e-20	Asthma;
SARC	cis	rs12497850	0.966	rs6792510	chr3:48723302	G/C	cg07636037	chr3:49044803	WDR6	0.93	14.34	0.68	7.41e-34	Parkinson's disease;
SARC	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg27266027	chr21:40555129	PSMG1	0.51	5.66	0.35	4.48e-8	Cognitive function;
SARC	cis	rs2153535	0.580	rs7775909	chr6:8477778	A/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.24	0.48	1.23e-14	Motion sickness;
SARC	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg24531977	chr5:56204891	C5orf35	-0.53	-5.31	-0.33	2.5e-7	Initial pursuit acceleration;
SARC	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg11987759	chr7:65425863	GUSB	-0.47	-6.27	-0.38	1.7e-9	Aortic root size;
SARC	cis	rs2204008	0.640	rs2320744	chr12:38162389	A/G	cg13010199	chr12:38710504	ALG10B	0.78	10.64	0.57	8.61e-22	Bladder cancer;
SARC	cis	rs854765	0.616	rs8076747	chr17:17853595	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.68	9.95	0.55	1.13e-19	Total body bone mineral density;
SARC	cis	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.44	-0.44	1.95e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs4664308	0.870	rs1870104	chr2:161032285	A/G	cg03641300	chr2:160917029	PLA2R1	-0.63	-8.39	-0.48	4.77e-15	Idiopathic membranous nephropathy;
SARC	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg07701084	chr6:150067640	NUP43	0.41	5.39	0.33	1.68e-7	Lung cancer;
SARC	cis	rs79149102	0.649	rs1531162	chr15:75111984	C/T	cg09165964	chr15:75287851	SCAMP5	-0.92	-6.03	-0.37	6.52e-9	Lung cancer;
SARC	cis	rs11098499	0.789	rs9991166	chr4:120237851	G/A	cg09307838	chr4:120376055	NA	0.81	11.15	0.59	2.11e-23	Corneal astigmatism;
SARC	cis	rs6570726	0.935	rs12663211	chr6:145818427	G/A	cg05347473	chr6:146136440	FBXO30	0.49	6.48	0.39	5.27e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9790314	1.000	rs336577	chr3:161066294	C/T	cg04691961	chr3:161091175	C3orf57	-0.81	-11.91	-0.62	7.32e-26	Morning vs. evening chronotype;
SARC	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg06108461	chr20:60628389	TAF4	0.87	10.74	0.58	4.11e-22	Body mass index;
SARC	cis	rs9894429	0.646	rs9902264	chr17:79613828	G/A	cg18240062	chr17:79603768	NPLOC4	0.59	7.31	0.43	4.15e-12	Eye color traits;
SARC	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg15595755	chr5:1867978	NA	0.48	6.57	0.4	3.31e-10	Cardiovascular disease risk factors;
SARC	cis	rs7772486	0.659	rs9376957	chr6:146011064	C/T	cg05347473	chr6:146136440	FBXO30	-0.52	-7.21	-0.43	7.84e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4427176	0.652	rs62493910	chr8:9456863	C/T	cg21625330	chr8:9911636	MSRA	-0.63	-4.77	-0.3	3.25e-6	Mosquito bite size;
SARC	cis	rs698833	0.886	rs8886	chr2:44547909	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.69	-9.33	-0.52	8.56e-18	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs12347191	0.500	rs1465965	chr9:100620326	C/T	cg13688889	chr9:100608707	NA	-0.48	-5.07	-0.32	8.16e-7	Orofacial clefts;
SARC	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg23172400	chr8:95962367	TP53INP1	-0.31	-5.38	-0.33	1.83e-7	Type 2 diabetes;
SARC	cis	rs13256369	1.000	rs9329165	chr8:8576642	C/T	cg18904891	chr8:8559673	CLDN23	-0.5	-5.93	-0.36	1.09e-8	Obesity-related traits;
SARC	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.77	-11.13	-0.59	2.3e-23	Age at first birth;
SARC	cis	rs782590	1.000	rs782590	chr2:55843413	C/T	cg18811423	chr2:55921094	PNPT1	0.68	10.52	0.57	1.96e-21	Metabolic syndrome;
SARC	trans	rs61931739	0.612	rs1906136	chr12:33905293	C/T	cg13010199	chr12:38710504	ALG10B	0.52	6.57	0.4	3.31e-10	Morning vs. evening chronotype;
SARC	cis	rs9322193	0.504	rs7771014	chr6:150205446	T/A	cg09699651	chr6:150184138	LRP11	0.53	6.64	0.4	2.14e-10	Lung cancer;
SARC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg11905131	chr22:24372483	LOC391322	-0.48	-5.59	-0.34	6.41e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs854765	0.583	rs11078406	chr17:17840823	G/T	cg04398451	chr17:18023971	MYO15A	-0.42	-6.01	-0.37	7.26e-9	Total body bone mineral density;
SARC	cis	rs9388451	0.839	rs9401845	chr6:126104118	A/G	cg06289844	chr6:126071538	HEY2	0.34	5.49	0.34	1.05e-7	Brugada syndrome;
SARC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.51	-5.67	-0.35	4.27e-8	Longevity;Endometriosis;
SARC	cis	rs11785400	0.793	rs4430071	chr8:143737680	T/C	cg10596483	chr8:143751796	JRK	0.55	7.01	0.42	2.59e-11	Schizophrenia;
SARC	cis	rs796364	0.625	rs1369843	chr2:201088171	A/G	cg23649088	chr2:200775458	C2orf69	0.74	8.15	0.47	2.22e-14	Schizophrenia;
SARC	cis	rs6842047	0.611	rs12186257	chr4:187183498	G/C	cg02012338	chr4:187126139	CYP4V2	0.59	5.13	0.32	6.05e-7	Blood protein levels;
SARC	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg20891558	chr2:74357851	NA	0.67	9.08	0.51	4.83e-17	Gestational age at birth (maternal effect);
SARC	cis	rs2681735	0.512	rs2238199	chr14:72799003	A/C	cg17922283	chr14:72799938	RGS6	-0.3	-4.8	-0.3	2.85e-6	Antibody status in Tripanosoma cruzi seropositivity;
SARC	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg01448562	chr3:133502909	NA	-0.5	-7.67	-0.45	4.75e-13	Iron status biomarkers;
SARC	cis	rs7937682	0.924	rs4630327	chr11:111539327	C/T	cg22437258	chr11:111473054	SIK2	-0.75	-10.65	-0.57	7.62e-22	Primary sclerosing cholangitis;
SARC	cis	rs7264396	0.515	rs2425134	chr20:34339439	G/A	cg01084648	chr20:34329383	RBM39	0.58	5.0	0.31	1.14e-6	Total cholesterol levels;
SARC	cis	rs9362426	0.887	rs1209113	chr6:88079456	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.41	5.01	0.31	1.1e-6	Depressive episodes in bipolar disorder;
SARC	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg07701084	chr6:150067640	NUP43	0.39	5.14	0.32	5.83e-7	Lung cancer;
SARC	cis	rs6963495	0.769	rs11556986	chr7:105177041	A/T	cg19920283	chr7:105172520	RINT1	0.68	6.0	0.37	7.55e-9	Bipolar disorder (body mass index interaction);
SARC	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg25427524	chr10:38739819	LOC399744	-0.63	-10.02	-0.55	6.79e-20	Extrinsic epigenetic age acceleration;
SARC	cis	rs7635838	0.819	rs904474	chr3:11524648	C/G	cg00170343	chr3:11313890	ATG7	0.62	8.75	0.5	4.31e-16	HDL cholesterol;
SARC	cis	rs9916302	0.706	rs590051	chr17:37446571	T/C	cg00129232	chr17:37814104	STARD3	0.54	5.76	0.35	2.7e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs9868809	0.772	rs28452701	chr3:48708575	C/T	cg07636037	chr3:49044803	WDR6	-0.75	-6.41	-0.39	8.07e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg11987759	chr7:65425863	GUSB	0.48	5.88	0.36	1.42e-8	Aortic root size;
SARC	cis	rs7833986	0.501	rs72653978	chr8:57018393	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.73	7.47	0.44	1.56e-12	Height;
SARC	cis	rs6685188	0.920	rs6593964	chr1:205662337	G/T	cg11965913	chr1:205819406	PM20D1	0.47	5.14	0.32	5.95e-7	White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs1153858	0.621	rs2413769	chr15:45561868	A/C	cg14582100	chr15:45693742	SPATA5L1	0.4	5.34	0.33	2.21e-7	Homoarginine levels;
SARC	cis	rs11203032	0.831	rs7074977	chr10:90948409	C/T	cg16672925	chr10:90967113	CH25H	0.51	5.49	0.34	1.03e-7	Heart failure;
SARC	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg20607798	chr8:58055168	NA	0.66	5.6	0.34	6.09e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg10435706	chr6:150039699	LATS1	0.36	4.78	0.3	3.14e-6	Lung cancer;
SARC	cis	rs35306767	0.903	rs1341741	chr10:888073	A/G	cg26597838	chr10:835615	NA	0.78	8.53	0.49	1.89e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg04277193	chr17:41438351	NA	0.45	4.9	0.31	1.83e-6	Menopause (age at onset);
SARC	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.33	-4.91	-0.31	1.73e-6	Longevity;Endometriosis;
SARC	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg21782813	chr7:2030301	MAD1L1	0.39	6.15	0.37	3.39e-9	Schizophrenia;
SARC	cis	rs12142240	0.698	rs72677599	chr1:46834251	G/A	cg10495392	chr1:46806563	NSUN4	0.64	6.83	0.41	7.39e-11	Menopause (age at onset);
SARC	cis	rs6594499	0.872	rs7723819	chr5:110427347	A/G	cg04022379	chr5:110408740	TSLP	-0.48	-5.79	-0.35	2.22e-8	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs2200578	1.000	rs72961173	chr2:99886868	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.55	5.22	0.32	4.01e-7	IgG glycosylation;
SARC	cis	rs796364	0.755	rs6739563	chr2:201134216	A/C	cg23649088	chr2:200775458	C2orf69	0.63	5.16	0.32	5.36e-7	Schizophrenia;
SARC	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg08280861	chr8:58055591	NA	0.59	5.22	0.32	4.02e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs965469	1.000	rs6051737	chr20:3296992	G/A	cg25506879	chr20:3388711	C20orf194	-0.49	-4.96	-0.31	1.33e-6	IFN-related cytopenia;
SARC	cis	rs7429990	1.000	rs1684942	chr3:47900703	C/T	cg11946769	chr3:48343235	NME6	0.45	5.16	0.32	5.26e-7	Educational attainment (years of education);
SARC	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.67	-0.4	1.87e-10	Total body bone mineral density;
SARC	trans	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.21	-0.43	7.82e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs3087591	0.960	rs2953000	chr17:29509791	C/T	cg24425628	chr17:29625626	OMG;NF1	0.48	5.84	0.36	1.7e-8	Hip circumference;
SARC	cis	rs11722228	1.000	rs11722228	chr4:9915741	C/T	cg25986240	chr4:9926439	SLC2A9	-0.3	-4.99	-0.31	1.2e-6	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.9	-0.41	4.83e-11	Neuroticism;
SARC	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg27266027	chr21:40555129	PSMG1	0.46	4.89	0.31	1.85e-6	Cognitive function;
SARC	cis	rs1941023	0.584	rs4938941	chr11:60173360	C/T	cg08716584	chr11:60157161	MS4A7	0.41	6.7	0.4	1.59e-10	Congenital heart disease (maternal effect);
SARC	cis	rs72781680	0.611	rs72781699	chr2:24277709	G/A	cg08917208	chr2:24149416	ATAD2B	0.65	6.48	0.39	5.55e-10	Lymphocyte counts;
SARC	cis	rs7615952	0.512	rs4234285	chr3:125404477	G/A	cg21696256	chr3:125484277	NA	-0.35	-4.99	-0.31	1.17e-6	Blood pressure (smoking interaction);
SARC	cis	rs6089584	0.606	rs2144674	chr20:60576579	G/A	cg13770153	chr20:60521292	NA	-0.43	-6.2	-0.38	2.55e-9	Body mass index;
SARC	cis	rs6089584	0.566	rs6061972	chr20:60610245	C/T	cg06108461	chr20:60628389	TAF4	-0.69	-9.16	-0.51	2.74e-17	Body mass index;
SARC	cis	rs763121	0.853	rs2072798	chr22:39148483	G/A	cg06022373	chr22:39101656	GTPBP1	0.87	11.14	0.59	2.16e-23	Menopause (age at onset);
SARC	cis	rs137699	1.000	rs760742	chr22:39755190	G/T	cg24399712	chr22:39784796	NA	-0.33	-4.81	-0.3	2.67e-6	IgG glycosylation;
SARC	cis	rs2576037	0.796	rs2576034	chr18:44588548	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.35	-4.94	-0.31	1.47e-6	Personality dimensions;
SARC	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg11644478	chr21:40555479	PSMG1	1.02	14.16	0.68	2.93e-33	Cognitive function;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg27498304	chr1:28415137	EYA3	-0.53	-7.03	-0.42	2.2e-11	Neuroticism;
SARC	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg03517284	chr6:25882590	NA	-0.5	-6.46	-0.39	5.93e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7246657	0.943	rs8109038	chr19:38015709	A/G	cg18154014	chr19:37997991	ZNF793	-0.43	-4.9	-0.31	1.77e-6	Coronary artery calcification;
SARC	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg04518342	chr5:131593106	PDLIM4	0.4	5.47	0.34	1.16e-7	Acylcarnitine levels;
SARC	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg00933542	chr6:150070202	PCMT1	0.33	5.68	0.35	4.05e-8	Lung cancer;
SARC	cis	rs3768617	0.811	rs10911205	chr1:183009277	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	8.21	0.47	1.53e-14	Fuchs's corneal dystrophy;
SARC	cis	rs7644634	0.661	rs3772515	chr3:105486255	T/C	cg23051926	chr3:105466016	CBLB	0.46	5.75	0.35	2.83e-8	Itch intensity from mosquito bite;
SARC	cis	rs16854884	0.657	rs1867609	chr3:143752916	A/G	cg06585982	chr3:143692056	C3orf58	0.67	9.14	0.51	3.13e-17	Economic and political preferences (feminism/equality);
SARC	cis	rs3126085	0.935	rs1496051	chr1:152164923	G/A	cg26876637	chr1:152193138	HRNR	0.48	5.51	0.34	9.32e-8	Atopic dermatitis;
SARC	cis	rs11758351	1.000	rs16891405	chr6:26204506	A/G	cg23601095	chr6:26197514	HIST1H3D	0.61	5.31	0.33	2.55e-7	Gout;Renal underexcretion gout;
SARC	trans	rs36093844	0.800	rs76464398	chr11:85583898	C/T	cg15359163	chr5:122429178	PRDM6	-0.53	-6.33	-0.38	1.28e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs7712401	0.562	rs401729	chr5:122264285	G/T	cg19412675	chr5:122181750	SNX24	0.41	5.24	0.32	3.56e-7	Mean platelet volume;
SARC	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg00800038	chr16:89945340	TCF25	-0.79	-5.45	-0.34	1.26e-7	Skin colour saturation;
SARC	cis	rs2806561	0.704	rs636940	chr1:23522967	A/T	cg12483005	chr1:23474871	LUZP1	0.47	6.13	0.37	3.82e-9	Height;
SARC	cis	rs9325144	0.560	rs2013804	chr12:38631079	C/T	cg13010199	chr12:38710504	ALG10B	-0.57	-7.37	-0.43	2.95e-12	Morning vs. evening chronotype;
SARC	cis	rs9611565	0.506	rs1883825	chr22:41703408	A/G	cg03806693	chr22:41940476	POLR3H	-0.71	-9.38	-0.52	6.19e-18	Vitiligo;
SARC	cis	rs1355223	0.872	rs913204	chr11:34706224	C/G	cg11058730	chr11:34937778	PDHX;APIP	0.43	5.07	0.32	8.09e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs79976124	0.876	rs17511913	chr6:66644361	C/T	cg07460842	chr6:66804631	NA	0.59	6.43	0.39	7.17e-10	Type 2 diabetes;
SARC	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg20818283	chr2:191399100	TMEM194B	-0.46	-5.77	-0.35	2.53e-8	Pulse pressure;
SARC	cis	rs7666738	0.753	rs2865957	chr4:99040725	G/A	cg05340658	chr4:99064831	C4orf37	0.64	8.6	0.49	1.18e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg07777115	chr5:623756	CEP72	-0.56	-5.03	-0.31	9.96e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs12142240	0.698	rs12385697	chr1:46818898	T/C	cg10495392	chr1:46806563	NSUN4	0.65	6.83	0.41	7.25e-11	Menopause (age at onset);
SARC	cis	rs6815814	0.731	rs10776482	chr4:38774785	A/G	cg06935464	chr4:38784597	TLR10	0.5	5.19	0.32	4.66e-7	Breast cancer;
SARC	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg14784868	chr12:69753453	YEATS4	0.51	6.77	0.41	1.01e-10	Blood protein levels;
SARC	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg27266027	chr21:40555129	PSMG1	0.5	5.46	0.34	1.21e-7	Cognitive function;
SARC	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg25072359	chr17:41440525	NA	0.52	6.19	0.38	2.63e-9	Menopause (age at onset);
SARC	cis	rs6912958	0.712	rs4498321	chr6:88339251	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.54	-0.34	8.34e-8	Monocyte percentage of white cells;
SARC	trans	rs1973993	0.561	rs7554152	chr1:96987865	G/C	cg10631902	chr5:14652156	NA	-0.44	-6.28	-0.38	1.67e-9	Weight;
SARC	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg05036130	chr6:150231994	NA	0.29	5.08	0.32	7.92e-7	Testicular germ cell tumor;
SARC	cis	rs12477438	0.765	rs2278895	chr2:99613484	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-8.16	-0.47	2.11e-14	Chronic sinus infection;
SARC	cis	rs13256369	0.951	rs13259955	chr8:8565885	C/G	cg18904891	chr8:8559673	CLDN23	0.49	5.45	0.34	1.27e-7	Obesity-related traits;
SARC	cis	rs55871839	0.708	rs1448541	chr8:59812938	G/A	cg07426533	chr8:59803705	TOX	-0.43	-5.77	-0.35	2.51e-8	Pneumonia;
SARC	cis	rs9948	0.521	rs62156207	chr2:97359236	C/A	cg01990225	chr2:97406019	LMAN2L	-0.89	-6.98	-0.42	3.06e-11	Erectile dysfunction and prostate cancer treatment;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg24588891	chr3:9848638	ARPC4	-0.52	-7.2	-0.43	8.47e-12	Chemerin levels;
SARC	cis	rs9486719	0.843	rs2499797	chr6:96848669	C/T	cg06623918	chr6:96969491	KIAA0776	0.74	7.51	0.44	1.27e-12	Migraine;Coronary artery disease;
SARC	cis	rs6901004	0.933	rs12208141	chr6:111572138	A/G	cg15721981	chr6:111408429	SLC16A10	-0.45	-5.53	-0.34	8.49e-8	Blood metabolite levels;
SARC	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.45	-5.59	-0.34	6.28e-8	Systemic lupus erythematosus;
SARC	cis	rs13082711	0.871	rs73046194	chr3:27454558	C/T	cg02860705	chr3:27208620	NA	0.45	5.87	0.36	1.51e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs4660306	0.677	rs6429566	chr1:45941852	T/C	cg24296786	chr1:45957014	TESK2	0.57	5.81	0.36	2.01e-8	Homocysteine levels;
SARC	cis	rs6540556	0.769	rs909710	chr1:209930694	A/G	cg05527609	chr1:210001259	C1orf107	0.67	6.41	0.39	8.11e-10	Red blood cell count;
SARC	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg18252515	chr7:66147081	NA	-0.66	-6.99	-0.42	2.82e-11	Aortic root size;
SARC	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	8.75	0.5	4.29e-16	Alzheimer's disease;
SARC	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-6.06	-0.37	5.5e-9	Personality dimensions;
SARC	cis	rs5753037	0.543	rs140128	chr22:30150140	T/C	cg01021169	chr22:30184971	ASCC2	-0.51	-6.84	-0.41	7.08e-11	Type 1 diabetes;
SARC	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg12696929	chr3:195401817	SDHAP2	0.4	5.3	0.33	2.67e-7	Pancreatic cancer;
SARC	cis	rs6582630	0.621	rs10880656	chr12:38571220	A/C	cg26384229	chr12:38710491	ALG10B	-0.6	-7.67	-0.45	4.63e-13	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2120019	1.000	rs12903201	chr15:75370776	A/C	cg12414181	chr15:75287860	SCAMP5	-0.42	-4.89	-0.31	1.87e-6	Blood trace element (Zn levels);
SARC	cis	rs9457247	0.765	rs9459836	chr6:167419105	G/A	cg23791538	chr6:167370224	RNASET2	-0.53	-6.93	-0.41	4.17e-11	Crohn's disease;
SARC	trans	rs61931739	0.534	rs11052979	chr12:34035774	G/T	cg13010199	chr12:38710504	ALG10B	0.76	10.32	0.56	8.23e-21	Morning vs. evening chronotype;
SARC	cis	rs4319547	0.615	rs2341439	chr12:122848096	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.54	-6.32	-0.38	1.29e-9	Body mass index;
SARC	cis	rs634534	0.561	rs613924	chr11:65769295	C/T	cg26695010	chr11:65641043	EFEMP2	-0.51	-6.56	-0.39	3.49e-10	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs7818345	0.967	rs17479099	chr8:19277144	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.43	5.92	0.36	1.12e-8	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg07061783	chr6:25882402	NA	0.39	4.79	0.3	3.01e-6	Blood metabolite levels;
SARC	cis	rs10089	1.000	rs59484271	chr5:127503781	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	8.22	0.47	1.44e-14	Ileal carcinoids;
SARC	cis	rs9733	0.680	rs3738484	chr1:150552330	G/T	cg13175981	chr1:150552382	MCL1	0.7	9.46	0.53	3.4e-18	Tonsillectomy;
SARC	cis	rs748404	0.697	rs530683	chr15:43568999	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.54	-6.37	-0.39	9.95e-10	Lung cancer;
SARC	trans	rs12310956	0.510	rs10844693	chr12:33865197	A/G	cg13010199	chr12:38710504	ALG10B	-0.6	-7.91	-0.46	1.02e-13	Morning vs. evening chronotype;
SARC	cis	rs858239	0.539	rs6965833	chr7:23192366	T/C	cg23682824	chr7:23144976	KLHL7	0.73	9.52	0.53	2.31e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs6448317	0.556	rs61793775	chr4:24902343	C/T	cg21108841	chr4:24914750	CCDC149	-0.55	-4.74	-0.3	3.75e-6	Heschl's gyrus morphology;
SARC	trans	rs11098499	0.865	rs2389809	chr4:120377399	T/C	cg25214090	chr10:38739885	LOC399744	0.54	7.11	0.42	1.38e-11	Corneal astigmatism;
SARC	cis	rs818427	0.681	rs469702	chr5:112293523	G/T	cg07820702	chr5:112228657	REEP5	-0.43	-4.97	-0.31	1.31e-6	Total body bone mineral density;
SARC	cis	rs12893668	0.703	rs34896432	chr14:104027995	C/T	cg26031613	chr14:104095156	KLC1	-0.48	-5.07	-0.32	7.96e-7	Reticulocyte count;
SARC	cis	rs11719291	0.915	rs1048940	chr3:48725707	C/T	cg00383909	chr3:49044727	WDR6	0.76	5.75	0.35	2.81e-8	Cognitive function;
SARC	cis	rs6539288	0.933	rs10778513	chr12:107302183	A/G	cg07730007	chr12:107377277	MTERFD3	0.38	4.8	0.3	2.88e-6	Total body bone mineral density;
SARC	cis	rs7659604	1.000	rs7689714	chr4:122665943	T/A	cg19748678	chr4:122722346	EXOSC9	0.41	5.04	0.31	9.17e-7	Type 2 diabetes;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg09799789	chr1:245836746	KIF26B	0.43	6.38	0.39	9.62e-10	Tetralogy of Fallot;
SARC	cis	rs7326068	0.610	rs2477165	chr13:21445435	A/G	cg16922012	chr13:21400325	XPO4	-0.44	-6.17	-0.37	2.92e-9	Schizophrenia, bipolar disorder and depression (combined);
SARC	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	14.77	0.7	2.69e-35	Chronic sinus infection;
SARC	cis	rs4911259	0.552	rs2014837	chr20:31461082	C/T	cg13636640	chr20:31349939	DNMT3B	0.66	8.99	0.51	8.53e-17	Inflammatory bowel disease;
SARC	cis	rs832540	0.629	rs10055224	chr5:56081201	C/T	cg24531977	chr5:56204891	C5orf35	0.39	4.79	0.3	3.01e-6	Coronary artery disease;
SARC	cis	rs7772486	0.632	rs9386128	chr6:146049053	G/A	cg05347473	chr6:146136440	FBXO30	-0.5	-6.94	-0.41	3.76e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg19723775	chr5:179050963	HNRNPH1	-0.43	-5.64	-0.35	4.99e-8	Lung cancer;
SARC	cis	rs10791323	0.572	rs10750551	chr11:133737462	G/A	cg15485101	chr11:133734466	NA	0.33	5.11	0.32	6.65e-7	Childhood ear infection;
SARC	cis	rs7785360	0.800	rs6975814	chr7:69732592	G/A	cg10619644	chr7:69149951	AUTS2	0.42	4.9	0.31	1.77e-6	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
SARC	cis	rs12188164	0.561	rs2251843	chr5:457955	C/T	cg16584290	chr5:462447	EXOC3	-0.43	-6.69	-0.4	1.6e-10	Cystic fibrosis severity;
SARC	cis	rs2439831	1.000	rs527921	chr15:43770416	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	-1.02	-10.02	-0.55	7.15e-20	Lung cancer in ever smokers;
SARC	cis	rs1707322	0.721	rs12049027	chr1:46118184	A/T	cg06784218	chr1:46089804	CCDC17	0.36	6.25	0.38	1.93e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs9325144	0.581	rs2730929	chr12:38942739	T/C	cg23762105	chr12:34175262	ALG10	0.54	7.04	0.42	2.19e-11	Morning vs. evening chronotype;
SARC	cis	rs17253792	0.822	rs28409547	chr14:56047826	C/T	cg01858014	chr14:56050164	KTN1	-0.7	-5.39	-0.33	1.7e-7	Putamen volume;
SARC	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg06212747	chr3:49208901	KLHDC8B	0.76	11.07	0.59	3.64e-23	Menarche (age at onset);
SARC	cis	rs7818345	0.967	rs12678336	chr8:19280552	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.4	5.31	0.33	2.55e-7	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs10870270	0.956	rs11146425	chr10:133734261	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.8	-10.31	-0.56	8.65e-21	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs9916302	0.904	rs7221875	chr17:37543328	G/A	cg20243544	chr17:37824526	PNMT	-0.57	-7.01	-0.42	2.57e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg07701084	chr6:150067640	NUP43	0.41	5.39	0.33	1.68e-7	Lung cancer;
SARC	cis	rs30380	0.587	rs30185	chr5:96125465	G/A	cg16492584	chr5:96139282	ERAP1	-0.48	-5.48	-0.34	1.12e-7	Cerebrospinal fluid biomarker levels;
SARC	cis	rs4595586	0.545	rs969469	chr12:39366775	A/C	cg26384229	chr12:38710491	ALG10B	0.5	6.22	0.38	2.31e-9	Morning vs. evening chronotype;
SARC	cis	rs9325144	0.510	rs7952795	chr12:38720686	C/T	cg04568710	chr12:38710424	ALG10B	0.4	4.98	0.31	1.24e-6	Morning vs. evening chronotype;
SARC	cis	rs1797081	0.561	rs2603795	chr10:16860256	A/G	cg14835575	chr10:16859367	RSU1	0.47	5.54	0.34	8.09e-8	Platelet distribution width;
SARC	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg10792982	chr14:105748885	BRF1	0.53	7.73	0.45	3.1400000000000003e-13	Mean platelet volume;Platelet distribution width;
SARC	cis	rs2380220	0.810	rs877096	chr6:95937046	A/G	cg23517279	chr6:96025343	MANEA	-0.54	-5.39	-0.33	1.76e-7	Behavioural disinhibition (generation interaction);
SARC	cis	rs941408	0.515	rs4624312	chr19:2774460	T/C	cg06609049	chr19:2785107	THOP1	1.01	15.26	0.71	6.25e-37	Total cholesterol levels;
SARC	cis	rs1059312	0.808	rs2306683	chr12:129299675	C/G	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.48	6.94	0.41	3.76e-11	Systemic lupus erythematosus;
SARC	trans	rs3476	0.578	rs9477726	chr6:18360261	G/A	cg10594510	chr5:1089753	SLC12A7	0.5	6.46	0.39	6.18e-10	Cancer;
SARC	cis	rs9486719	1.000	rs9373978	chr6:97056255	T/C	cg06623918	chr6:96969491	KIAA0776	-0.74	-7.81	-0.46	1.96e-13	Migraine;Coronary artery disease;
SARC	cis	rs9790314	0.645	rs6778254	chr3:160892792	T/C	cg04691961	chr3:161091175	C3orf57	-0.61	-8.17	-0.47	1.9e-14	Morning vs. evening chronotype;
SARC	cis	rs7927592	0.956	rs2510384	chr11:68391837	C/A	cg01657329	chr11:68192670	LRP5	-0.42	-4.95	-0.31	1.45e-6	Total body bone mineral density;
SARC	cis	rs79149102	0.579	rs7181942	chr15:75300623	G/C	cg17294928	chr15:75287854	SCAMP5	-1.01	-9.17	-0.52	2.56e-17	Lung cancer;
SARC	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.49	7.46	0.44	1.66e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs3923518	1.000	rs4371451	chr3:38906037	A/C	cg15678707	chr3:39149194	GORASP1;TTC21A	0.48	5.12	0.32	6.5e-7	Migraine;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg01434618	chr1:185126331	C1orf25;C1orf26	-0.47	-6.49	-0.39	5.08e-10	Chemerin levels;
SARC	cis	rs7681440	0.904	rs1822217	chr4:90765052	C/T	cg02192967	chr4:90758406	SNCA	0.36	5.13	0.32	6.11e-7	Dementia with Lewy bodies;
SARC	cis	rs644799	1.000	rs617999	chr11:95589935	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	14.39	0.69	5.05e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9302635	0.513	rs8050238	chr16:72154187	C/T	cg16558253	chr16:72132732	DHX38	-0.55	-7.15	-0.42	1.09e-11	Blood protein levels;
SARC	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg11644478	chr21:40555479	PSMG1	-0.56	-6.95	-0.41	3.64e-11	Menarche (age at onset);
SARC	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg22920501	chr2:26401640	FAM59B	0.61	7.93	0.46	8.99e-14	Gut microbiome composition (summer);
SARC	cis	rs9818758	0.607	rs11552724	chr3:49156473	C/G	cg06212747	chr3:49208901	KLHDC8B	-0.68	-5.69	-0.35	3.71e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs10779751	0.690	rs2791659	chr1:11126569	C/A	cg08854313	chr1:11322531	MTOR	0.82	11.26	0.59	8.86e-24	Body mass index;
SARC	cis	rs67460515	0.926	rs66508859	chr3:160946351	C/T	cg03342759	chr3:160939853	NMD3	-0.71	-9.12	-0.51	3.55e-17	Parkinson's disease;
SARC	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	7.7	0.45	3.9e-13	Age-related macular degeneration (geographic atrophy);
SARC	trans	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	7.03	0.42	2.21e-11	Intelligence (multi-trait analysis);
SARC	cis	rs7247513	0.897	rs12979146	chr19:12717904	C/T	cg01871581	chr19:12707946	ZNF490	-0.88	-13.59	-0.67	2.24e-31	Bipolar disorder;
SARC	cis	rs6815814	0.950	rs56357984	chr4:38806462	G/A	cg06935464	chr4:38784597	TLR10	0.55	5.27	0.33	3.12e-7	Breast cancer;
SARC	cis	rs6693567	0.565	rs471738	chr1:150276429	G/A	cg09579323	chr1:150459698	TARS2	-0.41	-5.3	-0.33	2.62e-7	Migraine;
SARC	cis	rs11785400	0.793	rs9774627	chr8:143731267	G/A	cg24634471	chr8:143751801	JRK	0.6	7.74	0.45	2.98e-13	Schizophrenia;
SARC	cis	rs8114671	0.839	rs2104084	chr20:33649217	G/C	cg08999081	chr20:33150536	PIGU	-0.34	-4.86	-0.3	2.15e-6	Height;
SARC	cis	rs3812049	0.784	rs3749748	chr5:127350549	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.86	-9.63	-0.53	1.09e-18	Lymphocyte counts;Red cell distribution width;
SARC	cis	rs7647973	0.710	rs7629322	chr3:49621994	C/T	cg13072238	chr3:49761600	GMPPB	-0.66	-5.83	-0.36	1.81e-8	Menarche (age at onset);
SARC	cis	rs4077515	0.527	rs10870146	chr9:139308054	G/A	cg14169450	chr9:139327907	INPP5E	0.44	5.9	0.36	1.28e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg11644478	chr21:40555479	PSMG1	-0.89	-11.52	-0.6	1.37e-24	Cognitive function;
SARC	cis	rs6738485	0.531	rs72819612	chr2:106846316	T/C	cg23109721	chr2:106886537	NA	-0.52	-5.19	-0.32	4.51e-7	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
SARC	cis	rs9290065	0.519	rs1562465	chr3:160701442	G/A	cg03342759	chr3:160939853	NMD3	-0.49	-5.94	-0.36	1.01e-8	Kawasaki disease;
SARC	cis	rs2980439	0.557	rs2976876	chr8:8318850	T/C	cg15556689	chr8:8085844	FLJ10661	0.47	5.78	0.35	2.43e-8	Neuroticism;
SARC	cis	rs6429082	0.783	rs291365	chr1:235688043	A/G	cg26050004	chr1:235667680	B3GALNT2	0.64	8.36	0.48	5.87e-15	Adiposity;
SARC	cis	rs1348850	0.632	rs12616288	chr2:178503813	G/T	cg23306229	chr2:178417860	TTC30B	0.52	5.89	0.36	1.32e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs4974559	0.739	rs28444605	chr4:1290281	C/A	cg02980000	chr4:1222292	CTBP1	0.73	5.6	0.34	5.97e-8	Systolic blood pressure;
SARC	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg13206674	chr6:150067644	NUP43	0.44	5.74	0.35	2.86e-8	Lung cancer;
SARC	cis	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg07636037	chr3:49044803	WDR6	0.65	8.6	0.49	1.19e-15	Resting heart rate;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg22025132	chr6:143771787	ADAT2;PEX3	0.55	7.08	0.42	1.72e-11	Breast cancer;
SARC	cis	rs78456975	1.000	rs28742145	chr2:1562671	T/C	cg26248373	chr2:1572462	NA	-0.6	-5.91	-0.36	1.2e-8	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg14868726	chr18:2571660	METTL4;NDC80	-0.45	-5.11	-0.32	6.6e-7	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.11	-0.37	4.23e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs34421088	0.560	rs2618434	chr8:11398865	A/G	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.57	-0.4	3.29e-10	Neuroticism;
SARC	cis	rs4481887	0.927	rs4307598	chr1:248474544	T/C	cg13385794	chr1:248469461	NA	0.34	5.32	0.33	2.46e-7	Common traits (Other);
SARC	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg02297831	chr4:17616191	MED28	0.51	6.61	0.4	2.65e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2933343	0.951	rs796862	chr3:128593040	G/A	cg24203234	chr3:128598194	ACAD9	0.53	5.93	0.36	1.11e-8	IgG glycosylation;
SARC	cis	rs9398803	0.713	rs3861457	chr6:126902245	T/C	cg20229609	chr6:126660872	C6orf173	0.35	5.07	0.31	8.26e-7	Male-pattern baldness;
SARC	cis	rs10927875	0.632	rs2862162	chr1:16142960	A/C	cg07117364	chr1:16154769	NA	0.42	4.98	0.31	1.26e-6	Dilated cardiomyopathy;
SARC	cis	rs4308124	0.708	rs6716091	chr2:111991133	C/T	cg04571233	chr2:111982156	NA	-0.49	-5.65	-0.35	4.67e-8	Vitiligo;
SARC	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg09699651	chr6:150184138	LRP11	0.39	4.75	0.3	3.59e-6	Lung cancer;
SARC	cis	rs4969178	0.965	rs4969179	chr17:76391454	A/C	cg20026190	chr17:76395443	PGS1	0.4	5.36	0.33	2.04e-7	HDL cholesterol levels;
SARC	cis	rs459571	0.920	rs455073	chr9:136909141	G/C	cg01294253	chr9:136912663	BRD3	0.45	5.82	0.36	1.97e-8	Platelet distribution width;
SARC	cis	rs926392	1.000	rs926392	chr20:37690464	A/G	cg16355469	chr20:37678765	NA	0.51	6.63	0.4	2.37e-10	Dialysis-related mortality;
SARC	cis	rs739401	0.611	rs7394974	chr11:3038868	C/T	cg08508325	chr11:3079039	CARS	-0.33	-8.09	-0.47	3.32e-14	Longevity;
SARC	cis	rs6582630	0.634	rs10748443	chr12:38734062	G/T	cg26384229	chr12:38710491	ALG10B	0.58	7.56	0.44	9.05e-13	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg24642844	chr7:1081250	C7orf50	-0.59	-6.21	-0.38	2.41e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs2841277	0.676	rs4264326	chr14:105411700	A/G	cg15352829	chr14:105391018	PLD4	-0.32	-6.04	-0.37	6.07e-9	Rheumatoid arthritis;
SARC	cis	rs938554	0.558	rs4697701	chr4:9946095	C/T	cg25986240	chr4:9926439	SLC2A9	0.3	4.9	0.31	1.82e-6	Blood metabolite levels;
SARC	cis	rs9309473	1.000	rs7584575	chr2:73666402	C/T	cg20560298	chr2:73613845	ALMS1	-0.47	-5.63	-0.35	5.2100000000000003e-08	Metabolite levels;
SARC	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg26681399	chr22:41777847	TEF	0.47	5.14	0.32	5.91e-7	Vitiligo;
SARC	cis	rs7560272	0.538	rs2421575	chr2:73919522	G/A	cg20560298	chr2:73613845	ALMS1	0.47	6.34	0.38	1.16e-9	Schizophrenia;
SARC	cis	rs748404	0.578	rs573615	chr15:43614281	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	6.87	0.41	5.71e-11	Lung cancer;
SARC	cis	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg21775007	chr8:11205619	TDH	0.42	5.38	0.33	1.81e-7	Retinal vascular caliber;
SARC	cis	rs950776	0.518	rs12902493	chr15:78819275	C/G	cg06917634	chr15:78832804	PSMA4	0.85	12.53	0.63	6.93e-28	Sudden cardiac arrest;
SARC	cis	rs854765	0.583	rs4257260	chr17:17857003	A/G	cg05444541	chr17:17804740	TOM1L2	-0.29	-4.82	-0.3	2.56e-6	Total body bone mineral density;
SARC	cis	rs763121	0.853	rs9622833	chr22:39000397	G/A	cg06022373	chr22:39101656	GTPBP1	0.86	10.58	0.57	1.25e-21	Menopause (age at onset);
SARC	cis	rs7000551	0.751	rs2461481	chr8:22382780	A/G	cg12081754	chr8:22256438	SLC39A14	-0.57	-7.87	-0.46	1.37e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs6570726	0.935	rs398060	chr6:145841515	C/T	cg23711669	chr6:146136114	FBXO30	-0.8	-12.27	-0.63	5.01e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6866344	0.570	rs1132338	chr5:178139442	T/G	cg03877680	chr5:178157825	ZNF354A	1.02	14.52	0.69	1.88e-34	Neutrophil percentage of white cells;
SARC	cis	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg24110177	chr3:50126178	RBM5	0.4	5.07	0.32	8e-7	Intelligence (multi-trait analysis);
SARC	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg05665937	chr4:1216051	CTBP1	0.35	5.0	0.31	1.12e-6	Obesity-related traits;
SARC	cis	rs3758785	0.665	rs7933565	chr11:94111808	G/A	cg13023536	chr11:94226537	MRE11A;ANKRD49	-0.42	-5.36	-0.33	2.03e-7	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
SARC	cis	rs763121	0.853	rs5757253	chr22:39104320	C/T	cg06022373	chr22:39101656	GTPBP1	0.9	12.64	0.64	3.13e-28	Menopause (age at onset);
SARC	cis	rs12042938	0.905	rs823160	chr1:231776636	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.56	7.89	0.46	1.17e-13	Neuranatomic and neurocognitive phenotypes;
SARC	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg15395560	chr15:45543142	SLC28A2	-0.27	-5.16	-0.32	5.27e-7	Homoarginine levels;
SARC	cis	rs6840360	0.571	rs12650655	chr4:152556075	G/A	cg22705602	chr4:152727874	NA	-0.41	-6.44	-0.39	6.64e-10	Intelligence (multi-trait analysis);
SARC	cis	rs668210	0.793	rs502363	chr11:65775592	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.51	5.21	0.32	4.21e-7	Cerebrospinal fluid biomarker levels;
SARC	cis	rs854765	0.547	rs8075189	chr17:17901946	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.64	9.44	0.53	4.01e-18	Total body bone mineral density;
SARC	cis	rs10875746	0.903	rs11168414	chr12:48512331	C/T	cg26205652	chr12:48591994	NA	0.55	6.07	0.37	5.02e-9	Longevity (90 years and older);
SARC	cis	rs1008375	1.000	rs10939748	chr4:17691230	T/C	cg27347728	chr4:17578864	LAP3	0.46	5.71	0.35	3.38e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg00933542	chr6:150070202	PCMT1	0.3	5.14	0.32	5.77e-7	Lung cancer;
SARC	cis	rs6570726	0.526	rs9376928	chr6:145724403	T/G	cg05347473	chr6:146136440	FBXO30	-0.44	-5.47	-0.34	1.13e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7552404	0.924	rs1303169	chr1:76195041	T/C	cg22875332	chr1:76189707	ACADM	0.4	5.86	0.36	1.59e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	trans	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg25328477	chr19:33571995	GPATCH1	-0.51	-6.44	-0.39	6.74e-10	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg05368731	chr17:41323189	NBR1	-0.7	-8.86	-0.5	2.09e-16	Menopause (age at onset);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg09747578	chr1:46769076	LRRC41;UQCRH	-0.65	-7.32	-0.43	3.95e-12	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs2576037	0.526	rs6507714	chr18:44519574	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.57	7.8	0.45	2.11e-13	Personality dimensions;
SARC	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg18357526	chr6:26021779	HIST1H4A	0.84	11.27	0.59	8.31e-24	Intelligence (multi-trait analysis);
SARC	cis	rs10504073	0.647	rs1511359	chr8:50006448	T/A	cg00325661	chr8:49890786	NA	0.54	7.31	0.43	4.28e-12	Blood metabolite ratios;
SARC	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	11.02	0.59	5.28e-23	Alzheimer's disease;
SARC	cis	rs709400	1.000	rs3783404	chr14:104118498	A/G	cg26031613	chr14:104095156	KLC1	0.99	18.8	0.78	1.38e-48	Body mass index;
SARC	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg10435706	chr6:150039699	LATS1	0.37	4.87	0.3	2.04e-6	Lung cancer;
SARC	cis	rs2075371	0.829	rs11770764	chr7:134003308	T/C	cg00033643	chr7:134001901	SLC35B4	0.46	5.53	0.34	8.61e-8	Mean platelet volume;
SARC	cis	rs76419734	0.510	rs2553463	chr4:106730663	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	-0.74	-7.56	-0.44	9.26e-13	Post bronchodilator FEV1;
SARC	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg13012494	chr21:47604986	C21orf56	-0.44	-5.07	-0.32	8.18e-7	Testicular germ cell tumor;
SARC	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.12	23.94	0.84	9.77e-65	Chronic sinus infection;
SARC	cis	rs6674970	0.748	rs56299877	chr1:151115645	C/T	cg11822372	chr1:151115635	SEMA6C	-0.66	-7.32	-0.43	3.98e-12	Childhood ear infection;
SARC	cis	rs10782582	0.593	rs74090712	chr1:76189098	A/G	cg10523679	chr1:76189770	ACADM	-0.43	-5.34	-0.33	2.25e-7	Daytime sleep phenotypes;
SARC	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg24829409	chr8:58192753	C8orf71	-0.5	-5.71	-0.35	3.37e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9462027	0.606	rs205260	chr6:34563958	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-6.02	-0.37	6.65e-9	Systemic lupus erythematosus;
SARC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg11905131	chr22:24372483	LOC391322	-0.45	-4.93	-0.31	1.59e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg22484793	chr3:52261325	TLR9	0.29	4.77	0.3	3.31e-6	Bipolar disorder;
SARC	cis	rs644799	0.672	rs61902245	chr11:95517737	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.59	7.96	0.46	7.39e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg18357526	chr6:26021779	HIST1H4A	-0.44	-5.52	-0.34	8.98e-8	Blood metabolite levels;
SARC	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg00684032	chr4:1343700	KIAA1530	0.49	7.31	0.43	4.24e-12	Obesity-related traits;
SARC	cis	rs16976116	0.901	rs1061824	chr15:55495963	T/C	cg17854078	chr15:55489399	RSL24D1	0.66	6.53	0.39	4.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs17270561	0.609	rs4711098	chr6:25734339	C/T	cg17691542	chr6:26056736	HIST1H1C	0.58	7.09	0.42	1.6e-11	Iron status biomarkers;
SARC	cis	rs12479064	0.694	rs11896520	chr2:99995517	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.64	-7.67	-0.45	4.74e-13	Chronic sinus infection;
SARC	cis	rs9858542	0.953	rs35261698	chr3:49537839	C/G	cg07274523	chr3:49395745	GPX1	0.53	6.13	0.37	3.82e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs2204008	0.837	rs11183232	chr12:37941053	A/G	cg26384229	chr12:38710491	ALG10B	0.87	12.47	0.63	1.15e-27	Bladder cancer;
SARC	cis	rs11992162	0.573	rs13275808	chr8:11782815	T/C	cg02127589	chr8:12458309	NA	-0.32	-4.77	-0.3	3.26e-6	Monocyte count;
SARC	cis	rs6121246	0.559	rs6119652	chr20:30259445	C/G	cg13852791	chr20:30311386	BCL2L1	0.89	10.96	0.58	7.99e-23	Mean corpuscular hemoglobin;
SARC	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg26839252	chr6:160211577	TCP1;MRPL18	0.63	6.84	0.41	6.82e-11	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs6728642	1.000	rs59178801	chr2:97604455	C/T	cg26665480	chr2:98280029	ACTR1B	-0.54	-4.95	-0.31	1.41e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs9796	0.870	rs4244584	chr15:41259523	A/G	cg18705301	chr15:41695430	NDUFAF1	0.42	5.71	0.35	3.47e-8	Menopause (age at onset);
SARC	cis	rs17021463	0.872	rs10856909	chr4:95268748	C/G	cg11021082	chr4:95130006	SMARCAD1	0.35	4.89	0.31	1.87e-6	Testicular germ cell tumor;
SARC	cis	rs826838	0.804	rs6580755	chr12:39159190	C/T	cg26384229	chr12:38710491	ALG10B	0.9	13.43	0.66	7.49e-31	Heart rate;
SARC	cis	rs17209837	1.000	rs2072383	chr7:87081349	A/G	cg00919237	chr7:87102261	ABCB4	-0.47	-4.96	-0.31	1.38e-6	Gallbladder cancer;
SARC	cis	rs4689388	0.890	rs4501291	chr4:6298582	C/T	cg25554036	chr4:6271136	WFS1	0.39	6.39	0.39	8.85e-10	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg01341218	chr17:43662625	NA	0.69	8.24	0.48	1.22e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7644634	0.531	rs9840891	chr3:105407561	T/C	cg23051926	chr3:105466016	CBLB	0.47	5.38	0.33	1.84e-7	Itch intensity from mosquito bite;
SARC	cis	rs11168351	0.517	rs10875754	chr12:48557922	G/C	cg21466736	chr12:48725269	NA	-0.31	-5.5	-0.34	9.83e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs7954584	0.505	rs11043278	chr12:122412145	C/T	cg22168489	chr12:122356033	WDR66	0.66	9.99	0.55	8.57e-20	Mean corpuscular volume;
SARC	cis	rs2236918	0.710	rs2526702	chr1:242017983	G/A	cg17736920	chr1:242011382	EXO1	0.66	9.04	0.51	6.24e-17	Menopause (age at onset);
SARC	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg12564285	chr5:131593104	PDLIM4	0.46	6.32	0.38	1.34e-9	Breast cancer;
SARC	cis	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg03020000	chr10:63662887	ARID5B	-0.57	-5.31	-0.33	2.57e-7	Cutaneous psoriasis;
SARC	cis	rs6500395	0.962	rs1039341	chr16:48574869	C/T	cg04672837	chr16:48644449	N4BP1	0.42	5.45	0.34	1.31e-7	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs13082711	0.522	rs543882	chr3:27331854	T/C	cg02860705	chr3:27208620	NA	0.47	6.26	0.38	1.86e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg10351095	chr21:47802916	PCNT	0.48	5.26	0.33	3.22e-7	Testicular germ cell tumor;
SARC	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.48	5.68	0.35	4.1e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg11987759	chr7:65425863	GUSB	-0.49	-5.8	-0.36	2.17e-8	Aortic root size;
SARC	cis	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg08975724	chr8:8085496	FLJ10661	0.47	5.86	0.36	1.56e-8	Mood instability;
SARC	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg13393036	chr8:95962371	TP53INP1	-0.36	-6.21	-0.38	2.45e-9	Type 2 diabetes;
SARC	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg11987759	chr7:65425863	GUSB	0.48	5.91	0.36	1.22e-8	Aortic root size;
SARC	cis	rs6120849	0.901	rs11696967	chr20:33743609	A/C	cg24642439	chr20:33292090	TP53INP2	0.49	4.93	0.31	1.56e-6	Protein C levels;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg24084422	chr4:128703088	HSPA4L	0.51	6.79	0.41	9.33e-11	Lung adenocarcinoma;
SARC	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg06028808	chr11:68637592	NA	0.47	6.02	0.37	6.88e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg25072359	chr17:41440525	NA	0.54	6.36	0.38	1.05e-9	Menopause (age at onset);
SARC	cis	rs35110281	0.837	rs7279968	chr21:45077398	C/G	cg21573476	chr21:45109991	RRP1B	-0.5	-7.3	-0.43	4.42e-12	Mean corpuscular volume;
SARC	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg13206674	chr6:150067644	NUP43	0.46	6.1	0.37	4.29e-9	Lung cancer;
SARC	cis	rs796364	1.000	rs281763	chr2:200794870	C/T	cg23649088	chr2:200775458	C2orf69	0.64	6.06	0.37	5.52e-9	Schizophrenia;
SARC	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg22508957	chr16:3507546	NAT15	0.39	5.81	0.36	2e-8	Tuberculosis;
SARC	cis	rs2153535	0.601	rs9328487	chr6:8529378	G/C	cg21535247	chr6:8435926	SLC35B3	0.51	6.48	0.39	5.5e-10	Motion sickness;
SARC	cis	rs6062302	0.522	rs13043255	chr20:62218916	C/G	cg09650180	chr20:62225654	GMEB2	-0.46	-5.61	-0.34	5.75e-8	Glioblastoma;
SARC	cis	rs6690583	0.623	rs2083284	chr1:85440023	C/T	cg22153463	chr1:85462885	MCOLN2	0.71	6.76	0.4	1.11e-10	Serum sulfate level;
SARC	cis	rs8141529	0.529	rs16987024	chr22:29208975	A/G	cg15103426	chr22:29168792	CCDC117	0.61	5.94	0.36	1.03e-8	Lymphocyte counts;
SARC	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg24399712	chr22:39784796	NA	0.42	5.68	0.35	3.91e-8	IgG glycosylation;
SARC	cis	rs6840360	0.550	rs62327267	chr4:152518753	G/T	cg22705602	chr4:152727874	NA	-0.41	-6.47	-0.39	5.71e-10	Intelligence (multi-trait analysis);
SARC	cis	rs734999	0.588	rs2843401	chr1:2528133	T/C	cg18854424	chr1:2615690	NA	-0.32	-5.03	-0.31	9.77e-7	Ulcerative colitis;
SARC	cis	rs11122272	0.735	rs2749723	chr1:231493302	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-9.84	-0.54	2.5e-19	Hemoglobin concentration;
SARC	cis	rs9486715	0.838	rs7770889	chr6:96858453	C/T	cg06623918	chr6:96969491	KIAA0776	-0.83	-11.61	-0.61	7e-25	Headache;
SARC	cis	rs7712401	0.765	rs10079941	chr5:122381363	G/A	cg19412675	chr5:122181750	SNX24	0.43	5.6	0.34	6.08e-8	Mean platelet volume;
SARC	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg12463550	chr7:65579703	CRCP	-0.49	-5.75	-0.35	2.75e-8	Aortic root size;
SARC	cis	rs13166103	0.723	rs13174477	chr5:57748792	C/A	cg10487770	chr5:57879443	RAB3C	0.52	5.5	0.34	9.92e-8	Type 2 diabetes (age of onset);
SARC	cis	rs9290065	0.622	rs11705811	chr3:160643787	C/T	cg04691961	chr3:161091175	C3orf57	-0.48	-6.3	-0.38	1.49e-9	Kawasaki disease;
SARC	cis	rs1670533	1.000	rs2045065	chr4:1052488	A/G	cg27284194	chr4:1044797	NA	0.46	4.79	0.3	3.01e-6	Recombination rate (females);
SARC	cis	rs262150	0.659	rs2730275	chr7:158793397	A/G	cg09640425	chr7:158790006	NA	-0.38	-5.14	-0.32	5.76e-7	Facial morphology (factor 20);
SARC	cis	rs11155671	0.530	rs9371215	chr6:150194298	C/T	cg05036130	chr6:150231994	NA	0.31	5.13	0.32	6.02e-7	Testicular germ cell tumor;
SARC	cis	rs7312933	0.510	rs61942483	chr12:42499538	T/A	cg17420585	chr12:42539391	GXYLT1	-0.45	-7.12	-0.42	1.3e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs172166	0.637	rs1225592	chr6:28150242	G/A	cg26335602	chr6:28129616	ZNF389	0.42	5.13	0.32	5.98e-7	Cardiac Troponin-T levels;
SARC	cis	rs9399137	0.507	rs11154791	chr6:135379148	A/G	cg22676075	chr6:135203613	NA	0.41	5.1	0.32	7.1e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg18357526	chr6:26021779	HIST1H4A	0.54	6.26	0.38	1.84e-9	Blood metabolite levels;
SARC	cis	rs3008870	0.701	rs2815367	chr1:67500762	G/A	cg02640540	chr1:67518911	SLC35D1	0.46	5.25	0.33	3.48e-7	Lymphocyte percentage of white cells;
SARC	cis	rs16854884	0.770	rs7653331	chr3:143810909	G/A	cg06585982	chr3:143692056	C3orf58	0.61	8.08	0.47	3.59e-14	Economic and political preferences (feminism/equality);
SARC	cis	rs6807306	1.000	rs6807003	chr3:167349441	C/T	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.49	4.78	0.3	3.15e-6	Mean platelet volume;
SARC	cis	rs7587476	0.682	rs13009646	chr2:215691259	T/A	cg11970703	chr2:215861251	ABCA12	-0.31	-4.75	-0.3	3.63e-6	Neuroblastoma;
SARC	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg22834771	chr12:69754056	YEATS4	-0.48	-6.29	-0.38	1.55e-9	Cerebrospinal fluid biomarker levels;
SARC	cis	rs864537	0.646	rs1723016	chr1:167433056	T/C	cg09179987	chr1:167433047	CD247	0.43	6.92	0.41	4.33e-11	Celiac disease or Rheumatoid arthritis;Celiac disease;
SARC	cis	rs2721811	0.509	rs2529038	chr7:24620682	A/T	cg17569154	chr7:24781545	DFNA5	-0.38	-4.94	-0.31	1.47e-6	Depressive symptoms (multi-trait analysis);
SARC	cis	rs7659604	0.540	rs10004284	chr4:122699222	A/T	cg19748678	chr4:122722346	EXOSC9	-0.43	-5.44	-0.34	1.32e-7	Type 2 diabetes;
SARC	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg16405210	chr4:1374714	KIAA1530	-0.58	-7.29	-0.43	4.69e-12	Longevity;
SARC	cis	rs9911578	1.000	rs4372750	chr17:57013803	A/C	cg05425664	chr17:57184151	TRIM37	0.65	7.96	0.46	7.42e-14	Intelligence (multi-trait analysis);
SARC	cis	rs6570726	0.935	rs399169	chr6:145836353	C/A	cg23711669	chr6:146136114	FBXO30	0.78	11.86	0.61	1.04e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3087591	1.000	rs12600974	chr17:29589360	A/G	cg24425628	chr17:29625626	OMG;NF1	0.52	6.48	0.39	5.45e-10	Hip circumference;
SARC	cis	rs10078	0.528	rs2434697	chr5:466811	T/C	cg24955955	chr5:415729	AHRR	0.73	6.66	0.4	1.93e-10	Fat distribution (HIV);
SARC	trans	rs11098499	0.913	rs11098496	chr4:120167466	C/G	cg25214090	chr10:38739885	LOC399744	0.52	6.89	0.41	5.07e-11	Corneal astigmatism;
SARC	cis	rs4689388	0.926	rs5018648	chr4:6292818	C/G	cg14416269	chr4:6271139	WFS1	-0.32	-4.94	-0.31	1.47e-6	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs73086581	1.000	rs17287822	chr20:3978536	C/T	cg02187196	chr20:3869020	PANK2	0.54	5.18	0.32	4.71e-7	Response to antidepressants in depression;
SARC	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg11301795	chr4:187892539	NA	-0.71	-10.14	-0.55	3.07e-20	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg03575189	chr17:44344142	NA	0.6	5.71	0.35	3.43e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg21280719	chr6:42927975	GNMT	-0.46	-7.86	-0.46	1.41e-13	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs1348850	0.537	rs3770010	chr2:178537796	T/C	cg22681709	chr2:178499509	PDE11A	-0.37	-5.22	-0.32	3.98e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs11122272	0.735	rs2437149	chr1:231490105	C/T	cg06096015	chr1:231504339	EGLN1	0.36	5.37	0.33	1.92e-7	Hemoglobin concentration;
SARC	cis	rs2153535	0.580	rs1034273	chr6:8468145	A/G	cg21535247	chr6:8435926	SLC35B3	0.54	6.79	0.41	9.19e-11	Motion sickness;
SARC	cis	rs1448094	0.512	rs12309296	chr12:86241566	T/C	cg02569458	chr12:86230093	RASSF9	0.39	5.45	0.34	1.26e-7	Major depressive disorder;
SARC	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg06028808	chr11:68637592	NA	0.43	5.59	0.34	6.45e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg11987759	chr7:65425863	GUSB	-0.48	-6.06	-0.37	5.3300000000000004e-09	Aortic root size;
SARC	trans	rs1814175	0.645	rs1721996	chr11:49915527	G/A	cg15704280	chr7:45808275	SEPT13	-0.88	-14.0	-0.68	1.02e-32	Height;
SARC	cis	rs4889855	0.530	rs7220588	chr17:78598231	G/A	cg17956530	chr17:78667699	RPTOR	-0.47	-5.4	-0.33	1.65e-7	Fractional excretion of uric acid;
SARC	cis	rs2732480	0.523	rs34286639	chr12:48629044	C/T	cg24011408	chr12:48396354	COL2A1	0.47	5.43	0.34	1.43e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	trans	rs656319	0.559	rs17689037	chr8:9974858	C/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.03	-0.42	2.23e-11	Myopia (pathological);
SARC	cis	rs11608355	0.515	rs2241204	chr12:109972037	G/A	cg05360138	chr12:110035743	NA	0.9	9.4	0.52	5.19e-18	Neuroticism;
SARC	cis	rs72945132	0.882	rs7122057	chr11:70201430	T/C	cg00319359	chr11:70116639	PPFIA1	0.67	6.29	0.38	1.54e-9	Coronary artery disease;
SARC	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg05793240	chr7:2802953	GNA12	-0.35	-5.06	-0.31	8.36e-7	Height;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22717114	chr5:110074384	SLC25A46	-0.52	-6.75	-0.4	1.19e-10	Smoking initiation;
SARC	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg12311346	chr5:56204834	C5orf35	-0.57	-5.86	-0.36	1.56e-8	Initial pursuit acceleration;
SARC	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.72	-7.24	-0.43	6.52e-12	Platelet count;
SARC	cis	rs11098499	0.863	rs11098532	chr4:120490726	C/A	cg24375607	chr4:120327624	NA	0.42	4.92	0.31	1.64e-6	Corneal astigmatism;
SARC	cis	rs9381040	0.610	rs9367094	chr6:41017860	T/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.41	-4.8	-0.3	2.9e-6	Alzheimer's disease (late onset);
SARC	trans	rs8073060	0.586	rs225288	chr17:33929291	G/A	cg19694781	chr19:47549865	TMEM160	-0.64	-6.39	-0.39	8.79e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs9303401	0.614	rs34920953	chr17:56589406	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	11.68	0.61	4.19e-25	Cognitive test performance;
SARC	cis	rs9398803	0.931	rs1361262	chr6:126701967	T/C	cg20229609	chr6:126660872	C6orf173	0.4	5.85	0.36	1.64e-8	Male-pattern baldness;
SARC	cis	rs2425143	1.000	rs1118233	chr20:34228349	T/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	5.02	0.31	1.01e-6	Blood protein levels;
SARC	cis	rs7937682	0.847	rs11213948	chr11:111464401	G/A	cg22437258	chr11:111473054	SIK2	0.76	9.87	0.54	2.07e-19	Primary sclerosing cholangitis;
SARC	cis	rs950027	0.620	rs2453533	chr15:45641225	C/A	cg26924012	chr15:45694286	SPATA5L1	0.53	6.74	0.4	1.2e-10	Response to fenofibrate (adiponectin levels);
SARC	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg24503407	chr1:205819492	PM20D1	0.55	6.06	0.37	5.47e-9	Prostate-specific antigen levels;
SARC	cis	rs763121	0.925	rs4821815	chr22:39105707	G/A	cg21395723	chr22:39101663	GTPBP1	0.52	6.17	0.37	2.98e-9	Menopause (age at onset);
SARC	cis	rs9807989	0.839	rs6749114	chr2:102967587	A/C	cg09003973	chr2:102972529	NA	0.41	5.67	0.35	4.18e-8	Asthma;
SARC	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg16405210	chr4:1374714	KIAA1530	-0.42	-5.13	-0.32	6.07e-7	Obesity-related traits;
SARC	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg17971929	chr21:40555470	PSMG1	-0.98	-13.99	-0.68	1.12e-32	Cognitive function;
SARC	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg11644478	chr21:40555479	PSMG1	-0.9	-11.49	-0.6	1.65e-24	Cognitive function;
SARC	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg24633833	chr3:10029261	TMEM111	0.52	5.25	0.33	3.43e-7	Alzheimer's disease;
SARC	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg22618164	chr12:122356400	WDR66	0.43	6.66	0.4	1.98e-10	Mean corpuscular volume;
SARC	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg25072359	chr17:41440525	NA	0.51	6.0	0.37	7.33e-9	Menopause (age at onset);
SARC	cis	rs7659604	0.537	rs6815973	chr4:122663430	A/T	cg19748678	chr4:122722346	EXOSC9	-0.49	-5.73	-0.35	3.08e-8	Type 2 diabetes;
SARC	cis	rs1256061	0.543	rs6573553	chr14:64754361	G/T	cg23250157	chr14:64679961	SYNE2	0.44	6.12	0.37	3.82e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	trans	rs877282	0.853	rs11253332	chr10:755262	G/C	cg22713356	chr15:30763199	NA	0.99	9.88	0.54	1.92e-19	Uric acid levels;
SARC	trans	rs278567	0.788	rs278568	chr8:94169379	A/G	cg23357130	chr11:3181928	OSBPL5	-0.48	-6.66	-0.4	2e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs9457247	0.508	rs9457268	chr6:167503639	A/T	cg23791538	chr6:167370224	RNASET2	-0.4	-4.97	-0.31	1.32e-6	Crohn's disease;
SARC	cis	rs262150	0.659	rs2657340	chr7:158796968	C/T	cg19418458	chr7:158789849	NA	0.46	6.54	0.39	3.8e-10	Facial morphology (factor 20);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg07617175	chr5:99871683	FAM174A	0.54	6.92	0.41	4.23e-11	Breast cancer;
SARC	cis	rs1568889	1.000	rs78140392	chr11:28203231	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.72	9.32	0.52	8.99e-18	Bipolar disorder;
SARC	cis	rs6500602	0.727	rs10451135	chr16:4580214	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.33	5.42	0.33	1.45e-7	Schizophrenia;
SARC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg06873352	chr17:61820015	STRADA	0.53	6.82	0.41	7.72e-11	Prudent dietary pattern;
SARC	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg23262073	chr20:60523788	NA	-0.46	-6.78	-0.41	1e-10	Body mass index;
SARC	cis	rs6429082	0.683	rs868815	chr1:235584543	C/G	cg26050004	chr1:235667680	B3GALNT2	-0.62	-7.46	-0.44	1.71e-12	Adiposity;
SARC	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg22903471	chr2:27725779	GCKR	0.47	7.14	0.42	1.16e-11	Total body bone mineral density;
SARC	cis	rs72781680	0.898	rs718139	chr2:23975911	G/A	cg06627628	chr2:24431161	ITSN2	-0.73	-6.64	-0.4	2.16e-10	Lymphocyte counts;
SARC	cis	rs6435862	0.636	rs717548	chr2:215676905	G/A	cg04530015	chr2:215796436	ABCA12	0.46	8.38	0.48	4.91e-15	Neuroblastoma (high-risk);
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg15113064	chr3:124774855	HEG1	0.47	6.24	0.38	2.03e-9	Tetralogy of Fallot;
SARC	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.01	11.2	0.59	1.42e-23	Platelet count;
SARC	cis	rs73242632	0.881	rs10034395	chr4:57863131	G/A	cg20415529	chr4:57845134	POLR2B;C4orf14	1.07	6.6	0.4	2.74e-10	Congenital heart disease (maternal effect);
SARC	cis	rs67460515	0.500	rs9812507	chr3:160723393	G/A	cg03342759	chr3:160939853	NMD3	-0.49	-5.88	-0.36	1.42e-8	Parkinson's disease;
SARC	trans	rs9354308	0.899	rs2802055	chr6:66545756	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.57	6.66	0.4	1.92e-10	Metabolite levels;
SARC	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg26874164	chr19:58962979	ZNF324B	0.51	6.6	0.4	2.81e-10	Uric acid clearance;
SARC	trans	rs61931739	0.817	rs1705771	chr12:34174950	C/G	cg26384229	chr12:38710491	ALG10B	0.61	8.31	0.48	7.93e-15	Morning vs. evening chronotype;
SARC	cis	rs888194	0.690	rs11067231	chr12:109993603	C/A	cg13986417	chr12:110012484	MVK;MMAB	-0.32	-4.84	-0.3	2.4e-6	Neuroticism;
SARC	cis	rs7264396	0.570	rs1970576	chr20:34336720	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.56	5.76	0.35	2.68e-8	Total cholesterol levels;
SARC	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg26818010	chr10:134567672	INPP5A	-0.62	-6.71	-0.4	1.49e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.41	4.98	0.31	1.22e-6	Electroencephalogram traits;
SARC	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg13114125	chr14:105738426	BRF1	-0.74	-11.08	-0.59	3.52e-23	Mean platelet volume;Platelet distribution width;
SARC	cis	rs2718058	0.613	rs2718037	chr7:37777846	G/C	cg15028436	chr7:37888078	TXNDC3	0.37	5.17	0.32	5.01e-7	Alzheimer's disease (late onset);
SARC	cis	rs3806933	0.500	rs10491423	chr5:110453977	C/A	cg04022379	chr5:110408740	TSLP	0.7	9.03	0.51	6.51e-17	Eosinophilic esophagitis;
SARC	cis	rs7662987	0.540	rs2851278	chr4:100021253	G/C	cg13256891	chr4:100009986	ADH5	0.66	8.13	0.47	2.55e-14	Smoking initiation;
SARC	cis	rs717267	0.933	rs7039703	chr9:16404310	C/T	cg14093630	chr9:15423618	SNAPC3	-0.4	-5.16	-0.32	5.38e-7	Gestational age at birth (maternal effect);
SARC	cis	rs2070997	0.667	rs10901291	chr9:133717881	C/T	cg11464064	chr9:133710261	ABL1	0.62	5.99	0.37	7.99e-9	Response to amphetamines;
SARC	cis	rs826838	0.904	rs10876086	chr12:39188208	C/A	cg26384229	chr12:38710491	ALG10B	0.87	12.47	0.63	1.11e-27	Heart rate;
SARC	cis	rs797680	0.648	rs11164938	chr1:93939870	A/G	cg06221222	chr1:94147831	BCAR3	-0.34	-4.78	-0.3	3.08e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
SARC	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.97e-8	Aortic root size;
SARC	cis	rs6840360	1.000	rs10007015	chr4:152603528	C/G	cg22705602	chr4:152727874	NA	-0.39	-6.63	-0.4	2.36e-10	Intelligence (multi-trait analysis);
SARC	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg22968622	chr17:43663579	NA	0.8	9.85	0.54	2.35e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs3796352	1.000	rs11710707	chr3:52975916	A/G	cg27565382	chr3:53032988	SFMBT1	0.95	6.34	0.38	1.17e-9	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs4906332	1.000	rs3783398	chr14:103949378	C/T	cg15820818	chr14:102984158	NA	-0.37	-4.8	-0.3	2.89e-6	Coronary artery disease;
SARC	cis	rs8064299	0.597	rs2053748	chr17:72775911	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	-0.77	-9.94	-0.55	1.25e-19	Monocyte count;
SARC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.58	0.57	1.3e-21	Prudent dietary pattern;
SARC	cis	rs8016982	0.617	rs2241621	chr14:81737076	G/T	cg01989461	chr14:81687754	GTF2A1	-0.64	-9.4	-0.52	5.39e-18	Schizophrenia;
SARC	cis	rs765787	0.530	rs28733848	chr15:45516047	C/T	cg24006582	chr15:45444508	DUOX1	-0.49	-6.47	-0.39	5.7e-10	Uric acid levels;
SARC	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg04267008	chr7:1944627	MAD1L1	-0.61	-7.11	-0.42	1.42e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs730775	0.505	rs325004	chr6:44270365	C/G	cg21130236	chr6:44246755	TMEM151B	-0.25	-4.97	-0.31	1.29e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs4423214	0.610	rs3763856	chr11:71125345	G/A	cg05163923	chr11:71159392	DHCR7	0.47	6.49	0.39	5.03e-10	Vitamin D levels;
SARC	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg16606324	chr3:10149918	C3orf24	0.49	5.04	0.31	9.35e-7	Alzheimer's disease;
SARC	cis	rs7429990	0.965	rs35199727	chr3:47946708	T/C	cg11946769	chr3:48343235	NME6	0.47	5.08	0.32	7.76e-7	Educational attainment (years of education);
SARC	cis	rs3857536	0.740	rs9342532	chr6:66886297	T/C	cg07460842	chr6:66804631	NA	-0.61	-7.22	-0.43	7.11e-12	Blood trace element (Cu levels);
SARC	cis	rs12579753	0.719	rs11115060	chr12:82269624	C/T	cg07988820	chr12:82153109	PPFIA2	-0.44	-5.36	-0.33	2.04e-7	Resting heart rate;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg27002758	chr8:87354745	WWP1	-0.54	-6.8	-0.41	8.51e-11	Schizophrenia;
SARC	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg05793240	chr7:2802953	GNA12	-0.36	-5.15	-0.32	5.67e-7	Height;
SARC	cis	rs67460515	0.563	rs9883566	chr3:160770323	C/T	cg17135325	chr3:160939158	NMD3	-0.56	-6.44	-0.39	6.75e-10	Parkinson's disease;
SARC	cis	rs11581859	0.613	rs11166084	chr1:99192462	G/A	cg20286094	chr1:99190917	SNX7	-0.42	-4.93	-0.31	1.55e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs9646954	0.542	rs4149512	chr2:101022886	C/T	cg14675211	chr2:100938903	LONRF2	0.52	7.8	0.46	2.01e-13	Intelligence (multi-trait analysis);
SARC	cis	rs1865760	1.000	rs6910138	chr6:25904352	C/G	cg17691542	chr6:26056736	HIST1H1C	0.57	7.05	0.42	1.98e-11	Height;
SARC	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg01475735	chr3:40494733	NA	-0.46	-5.22	-0.32	3.98e-7	Renal cell carcinoma;
SARC	cis	rs6120849	0.754	rs3746446	chr20:33574765	T/C	cg24642439	chr20:33292090	TP53INP2	0.57	5.49	0.34	1.07e-7	Protein C levels;
SARC	cis	rs7953249	0.656	rs2178463	chr12:121389721	A/G	cg02403541	chr12:121454288	C12orf43	-0.72	-9.69	-0.54	7.25e-19	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs79149102	0.579	rs7342591	chr15:75306863	C/T	cg17294928	chr15:75287854	SCAMP5	0.92	8.76	0.5	4.18e-16	Lung cancer;
SARC	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg24250549	chr1:154909240	PMVK	0.83	11.95	0.62	5.56e-26	Prostate cancer;
SARC	cis	rs7408868	0.908	rs62113793	chr19:15277336	G/A	cg14696996	chr19:15285081	NOTCH3	1.01	8.51	0.49	2.08e-15	Pulse pressure;
SARC	cis	rs611744	0.836	rs684412	chr8:109210905	T/A	cg21045802	chr8:109455806	TTC35	0.45	5.32	0.33	2.41e-7	Dupuytren's disease;
SARC	cis	rs2832191	0.755	rs55671430	chr21:30492421	G/C	cg24692254	chr21:30365293	RNF160	-0.88	-12.46	-0.63	1.2e-27	Dental caries;
SARC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.03	0.37	6.27e-9	Prudent dietary pattern;
SARC	cis	rs12421382	0.659	rs2028337	chr11:109380887	G/C	cg16359550	chr11:109292809	C11orf87	0.33	4.97	0.31	1.31e-6	Schizophrenia;
SARC	cis	rs6840360	0.904	rs73862064	chr4:152503100	T/A	cg22705602	chr4:152727874	NA	-0.29	-4.8	-0.3	2.84e-6	Intelligence (multi-trait analysis);
SARC	trans	rs8073060	0.586	rs9649	chr17:34050934	C/T	cg19694781	chr19:47549865	TMEM160	0.72	6.95	0.41	3.67e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs79839061	0.656	rs28662837	chr4:879776	G/A	cg07828340	chr4:882639	GAK	0.78	6.45	0.39	6.41e-10	Intelligence (multi-trait analysis);
SARC	cis	rs8072100	0.875	rs7208530	chr17:45544107	C/T	cg08085267	chr17:45401833	C17orf57	-0.45	-5.47	-0.34	1.15e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs950027	0.620	rs2461700	chr15:45640627	T/C	cg26924012	chr15:45694286	SPATA5L1	0.53	6.74	0.4	1.2e-10	Response to fenofibrate (adiponectin levels);
SARC	cis	rs8017423	0.935	rs12880102	chr14:90793526	G/T	cg20276874	chr14:90721474	PSMC1	0.38	5.01	0.31	1.07e-6	Mortality in heart failure;
SARC	cis	rs7772486	0.743	rs9376955	chr6:145949404	T/A	cg05347473	chr6:146136440	FBXO30	0.5	6.82	0.41	7.69e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs875971	1.000	rs1167612	chr7:65567976	C/A	cg12463550	chr7:65579703	CRCP	-0.48	-5.58	-0.34	6.74e-8	Aortic root size;
SARC	cis	rs4808199	0.649	rs17216693	chr19:19666574	T/C	cg03709012	chr19:19516395	GATAD2A	0.97	8.69	0.49	6.49e-16	Nonalcoholic fatty liver disease;
SARC	cis	rs3796352	1.000	rs3796352	chr3:52913279	C/T	cg07884673	chr3:53033167	SFMBT1	0.89	5.86	0.36	1.55e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs7089973	0.624	rs10885613	chr10:116589400	G/A	cg08188268	chr10:116634841	FAM160B1	0.28	4.77	0.3	3.18e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs4481887	0.927	rs7524700	chr1:248472816	A/G	cg01631408	chr1:248437212	OR2T33	-0.38	-4.92	-0.31	1.67e-6	Common traits (Other);
SARC	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg16049864	chr8:95962084	TP53INP1	-0.46	-7.52	-0.44	1.18e-12	Type 2 diabetes;
SARC	cis	rs2153535	0.563	rs3117071	chr6:8537908	C/T	cg21535247	chr6:8435926	SLC35B3	0.55	6.82	0.41	7.78e-11	Motion sickness;
SARC	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg12311346	chr5:56204834	C5orf35	-0.56	-5.64	-0.35	4.81e-8	Initial pursuit acceleration;
SARC	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg01324507	chr7:1177794	C7orf50	0.48	4.72	0.3	4.14e-6	Bronchopulmonary dysplasia;
SARC	cis	rs7223966	1.000	rs11079508	chr17:61750066	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.56	-5.99	-0.37	7.8e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs208520	1.000	rs12200490	chr6:66976084	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	9.19	0.52	2.31e-17	Exhaled nitric oxide output;
SARC	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg03060546	chr3:49711283	APEH	0.48	6.27	0.38	1.69e-9	Menarche (age at onset);
SARC	trans	rs9354308	0.933	rs2802062	chr6:66561973	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.57	6.71	0.4	1.42e-10	Metabolite levels;
SARC	cis	rs4319547	1.000	rs4319547	chr12:123079035	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.66	-7.9	-0.46	1.1e-13	Body mass index;
SARC	cis	rs2228479	0.702	rs2074963	chr16:89877269	T/C	cg06558623	chr16:89946397	TCF25	0.92	6.23	0.38	2.17e-9	Skin colour saturation;
SARC	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg00990874	chr7:1149470	C7orf50	-0.54	-5.8	-0.36	2.11e-8	Bronchopulmonary dysplasia;
SARC	cis	rs7216064	0.684	rs62084675	chr17:66027025	A/G	cg12091567	chr17:66097778	LOC651250	0.94	12.11	0.62	1.69e-26	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs7937682	0.883	rs568506	chr11:111466429	C/T	cg22437258	chr11:111473054	SIK2	0.76	9.87	0.54	2.07e-19	Primary sclerosing cholangitis;
SARC	cis	rs9987353	0.544	rs2929470	chr8:9062490	A/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-5.92	-0.36	1.17e-8	Recombination measurement;
SARC	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg24209194	chr3:40518798	ZNF619	0.64	8.06	0.47	4.02e-14	Renal cell carcinoma;
SARC	cis	rs6782228	0.606	rs7650156	chr3:128361555	T/A	cg08795948	chr3:128337044	NA	0.37	5.03	0.31	9.79e-7	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
SARC	cis	rs7772486	0.754	rs4896832	chr6:145964151	G/A	cg05347473	chr6:146136440	FBXO30	0.54	7.43	0.44	2.02e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1561198	0.523	rs2118177	chr2:85890293	A/G	cg17127132	chr2:85788382	GGCX	0.4	4.88	0.3	2e-6	Coronary artery disease;
SARC	trans	rs629535	0.590	rs62513426	chr8:70136843	T/G	cg21567404	chr3:27674614	NA	-0.94	-10.24	-0.56	1.44e-20	Dupuytren's disease;
SARC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg22564285	chr15:28393860	HERC2	0.49	6.25	0.38	1.91e-9	HDL cholesterol;
SARC	cis	rs7633857	0.595	rs7640874	chr3:160672617	T/A	cg04691961	chr3:161091175	C3orf57	-0.5	-6.34	-0.38	1.19e-9	Educational attainment (years of education);
SARC	cis	rs11722228	1.000	rs6823877	chr4:9921931	T/C	cg11266682	chr4:10021025	SLC2A9	-0.32	-5.38	-0.33	1.85e-7	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs9815354	1.000	rs1716657	chr3:41918456	C/T	cg03022575	chr3:42003672	ULK4	-0.54	-5.12	-0.32	6.5e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg17971929	chr21:40555470	PSMG1	0.99	14.22	0.68	1.86e-33	Cognitive function;
SARC	trans	rs8073060	0.614	rs225279	chr17:33974214	A/G	cg19694781	chr19:47549865	TMEM160	-0.68	-6.86	-0.41	6.05e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg10591111	chr5:226296	SDHA	-0.55	-4.97	-0.31	1.31e-6	Breast cancer;
SARC	trans	rs2727020	0.731	rs10450572	chr11:49281073	T/C	cg15704280	chr7:45808275	SEPT13	0.82	13.26	0.66	2.74e-30	Coronary artery disease;
SARC	cis	rs2624839	0.704	rs14321	chr3:50226151	T/C	cg24110177	chr3:50126178	RBM5	0.57	7.2	0.43	8.13e-12	Intelligence (multi-trait analysis);
SARC	cis	rs9611519	0.603	rs8142276	chr22:41471447	T/C	cg17376030	chr22:41985996	PMM1	0.39	4.84	0.3	2.36e-6	Neuroticism;
SARC	cis	rs10088262	0.540	rs6988602	chr8:124788502	C/T	cg02993010	chr8:124780839	FAM91A1	0.76	8.06	0.47	3.88e-14	Pancreatic cancer;
SARC	cis	rs67460515	0.596	rs35127376	chr3:160927289	T/C	cg04691961	chr3:161091175	C3orf57	-0.42	-5.06	-0.31	8.36e-7	Parkinson's disease;
SARC	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg06634786	chr22:41940651	POLR3H	-0.51	-6.14	-0.37	3.45e-9	Vitiligo;
SARC	cis	rs9388451	0.839	rs4897157	chr6:126102981	A/T	cg06289844	chr6:126071538	HEY2	0.35	5.55	0.34	7.74e-8	Brugada syndrome;
SARC	cis	rs11630290	0.592	rs1039818	chr15:64155296	A/G	cg12036633	chr15:63758958	NA	0.47	4.99	0.31	1.17e-6	Iris characteristics;
SARC	trans	rs17685	0.753	rs2108274	chr7:75781636	C/A	cg19862616	chr7:65841803	NCRNA00174	0.64	8.01	0.46	5.51e-14	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs6540556	0.521	rs9430015	chr1:209911734	G/A	cg23920097	chr1:209922102	NA	-0.51	-5.72	-0.35	3.17e-8	Red blood cell count;
SARC	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg18357526	chr6:26021779	HIST1H4A	0.46	5.89	0.36	1.34e-8	Blood metabolite levels;
SARC	cis	rs67311347	1.000	rs9834052	chr3:40399060	G/A	cg09455208	chr3:40491958	NA	0.4	6.18	0.38	2.84e-9	Renal cell carcinoma;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg05224827	chr14:50999389	MAP4K5;ATL1	0.49	6.48	0.39	5.47e-10	Chemerin levels;
SARC	cis	rs372883	0.597	rs2018956	chr21:30736622	C/A	cg24692254	chr21:30365293	RNF160	0.53	6.52	0.39	4.33e-10	Pancreatic cancer;
SARC	cis	rs12971120	1.000	rs2278161	chr18:72176083	T/C	cg26446133	chr18:72167187	CNDP2	-0.47	-6.94	-0.41	3.86e-11	Refractive error;
SARC	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg22496380	chr5:211416	CCDC127	0.9	9.38	0.52	5.94e-18	Breast cancer;
SARC	cis	rs6061231	0.837	rs6121558	chr20:60961365	A/G	cg24112000	chr20:60950667	NA	-0.34	-4.91	-0.31	1.71e-6	Colorectal cancer;
SARC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.63	-0.4	2.28e-10	Total body bone mineral density;
SARC	cis	rs2228479	0.702	rs12599561	chr16:89894358	C/G	cg12064134	chr16:90016061	DEF8	-0.55	-4.78	-0.3	3.16e-6	Skin colour saturation;
SARC	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg00339695	chr16:24857497	SLC5A11	-0.43	-5.69	-0.35	3.79e-8	Intelligence (multi-trait analysis);
SARC	cis	rs10463316	0.894	rs13361316	chr5:150765593	T/C	cg03212797	chr5:150827313	SLC36A1	-0.46	-5.39	-0.33	1.7e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs561341	1.000	rs8064843	chr17:30245744	A/G	cg13647721	chr17:30228624	UTP6	0.63	5.5	0.34	9.81e-8	Hip circumference adjusted for BMI;
SARC	cis	rs2486288	0.587	rs12899942	chr15:45547280	T/C	cg15395560	chr15:45543142	SLC28A2	0.29	5.59	0.34	6.44e-8	Glomerular filtration rate;
SARC	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg19500275	chr17:80737654	TBCD	0.43	5.1	0.32	7.15e-7	Glycated hemoglobin levels;
SARC	cis	rs1707322	0.721	rs28442079	chr1:46172001	A/G	cg03146154	chr1:46216737	IPP	0.53	6.35	0.38	1.12e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs796364	0.806	rs74938253	chr2:201008386	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.53	-4.87	-0.3	2.08e-6	Schizophrenia;
SARC	cis	rs2204008	0.805	rs2874289	chr12:38258420	G/A	cg13010199	chr12:38710504	ALG10B	0.81	11.27	0.59	8.63e-24	Bladder cancer;
SARC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.72	7.45	0.44	1.79e-12	Platelet count;
SARC	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg12311346	chr5:56204834	C5orf35	-0.58	-6.01	-0.37	7.24e-9	Initial pursuit acceleration;
SARC	trans	rs9951602	0.512	rs4799248	chr18:76653459	G/A	cg02800362	chr5:177631904	HNRNPAB	0.71	9.05	0.51	5.86e-17	Obesity-related traits;
SARC	cis	rs9302635	0.513	rs3902135	chr16:72175820	C/T	cg01557791	chr16:72042693	DHODH	-0.57	-5.85	-0.36	1.69e-8	Blood protein levels;
SARC	cis	rs2576037	0.901	rs2060416	chr18:44576240	G/C	cg19077165	chr18:44547161	KATNAL2	0.46	6.47	0.39	5.72e-10	Personality dimensions;
SARC	cis	rs2635047	0.542	rs2668768	chr18:44783447	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	4.96	0.31	1.34e-6	Educational attainment;
SARC	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg16479474	chr6:28041457	NA	-0.38	-5.48	-0.34	1.12e-7	Parkinson's disease;
SARC	cis	rs2777491	1.000	rs7167729	chr15:41721042	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.82	-12.26	-0.63	5.57e-27	Ulcerative colitis;
SARC	cis	rs4595586	1.000	rs4595586	chr12:39225991	A/T	cg26384229	chr12:38710491	ALG10B	-0.41	-4.96	-0.31	1.33e-6	Morning vs. evening chronotype;
SARC	cis	rs2710642	0.611	rs2204656	chr2:62883868	C/T	cg16915676	chr2:62734870	TMEM17	-0.37	-4.73	-0.3	3.85e-6	LDL cholesterol levels;LDL cholesterol;
SARC	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg26681399	chr22:41777847	TEF	0.47	5.13	0.32	6.11e-7	Vitiligo;
SARC	cis	rs7615952	1.000	rs7615952	chr3:125649403	A/C	cg05084668	chr3:125655381	ALG1L	0.66	6.9	0.41	4.85e-11	Blood pressure (smoking interaction);
SARC	cis	rs8017423	0.647	rs10132599	chr14:90815342	C/T	cg20276874	chr14:90721474	PSMC1	0.37	4.95	0.31	1.43e-6	Mortality in heart failure;
SARC	cis	rs72945132	0.825	rs72947052	chr11:70188575	A/G	cg05964544	chr11:70165517	PPFIA1	-0.63	-5.88	-0.36	1.4e-8	Coronary artery disease;
SARC	cis	rs910316	1.000	rs910316	chr14:75626042	A/C	cg23033748	chr14:75592666	NEK9	0.36	4.81	0.3	2.7e-6	Height;
SARC	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	9.96	0.55	1.08e-19	Platelet count;
SARC	cis	rs7647973	1.000	rs13096474	chr3:49443081	C/T	cg07636037	chr3:49044803	WDR6	-0.71	-7.83	-0.46	1.72e-13	Menarche (age at onset);
SARC	cis	rs936229	0.861	rs12441505	chr15:75107311	A/C	cg14664628	chr15:75095509	CSK	-1.04	-14.9	-0.7	1.04e-35	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs910316	1.000	rs10146482	chr14:75574087	C/T	cg23033748	chr14:75592666	NEK9	0.36	5.11	0.32	6.6e-7	Height;
SARC	cis	rs7481584	0.624	rs2106229	chr11:3041195	G/A	cg08508325	chr11:3079039	CARS	0.24	5.39	0.33	1.74e-7	Calcium levels;
SARC	cis	rs986417	0.711	rs2224409	chr14:60957216	C/T	cg27398547	chr14:60952738	C14orf39	0.99	9.02	0.51	6.89e-17	Gut microbiota (bacterial taxa);
SARC	trans	rs629535	0.862	rs638412	chr8:70047690	C/T	cg21567404	chr3:27674614	NA	1.04	13.82	0.67	3.98e-32	Dupuytren's disease;
SARC	cis	rs1348850	0.632	rs12467363	chr2:178502512	C/T	cg22681709	chr2:178499509	PDE11A	-0.41	-5.52	-0.34	9.11e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9815354	1.000	rs17061431	chr3:41792655	T/C	cg03022575	chr3:42003672	ULK4	0.59	5.69	0.35	3.85e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9322817	0.902	rs9391238	chr6:105197874	A/G	cg02098413	chr6:105308735	HACE1	-0.33	-4.78	-0.3	3.16e-6	Thyroid stimulating hormone;
SARC	cis	rs9815354	1.000	rs9869207	chr3:41878661	C/G	cg03022575	chr3:42003672	ULK4	0.56	5.29	0.33	2.81e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs55823223	0.646	rs55868394	chr17:73851113	C/A	cg14829360	chr17:73884958	NA	-0.65	-6.33	-0.38	1.27e-9	Psoriasis;
SARC	cis	rs11792861	0.890	rs2900481	chr9:111831825	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.66	7.54	0.44	1.05e-12	Menarche (age at onset);
SARC	cis	rs13256369	0.851	rs11249890	chr8:8565245	G/T	cg17143192	chr8:8559678	CLDN23	0.52	5.83	0.36	1.82e-8	Obesity-related traits;
SARC	cis	rs10782582	0.522	rs12125933	chr1:76130920	C/T	cg03433033	chr1:76189801	ACADM	-0.41	-5.14	-0.32	5.69e-7	Daytime sleep phenotypes;
SARC	cis	rs7084402	1.000	rs12259315	chr10:60266152	T/C	cg07615347	chr10:60278583	BICC1	-0.6	-8.4	-0.48	4.32e-15	Refractive error;
SARC	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg24642844	chr7:1081250	C7orf50	-0.57	-6.05	-0.37	5.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs6570726	0.935	rs12663211	chr6:145818427	G/A	cg23711669	chr6:146136114	FBXO30	0.78	11.91	0.62	7.29e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs13256369	0.851	rs13267036	chr8:8566685	G/A	cg18904891	chr8:8559673	CLDN23	0.49	5.53	0.34	8.47e-8	Obesity-related traits;
SARC	cis	rs10791323	0.569	rs2257004	chr11:133712473	C/T	cg14349672	chr11:133703707	NA	-0.38	-5.42	-0.33	1.47e-7	Childhood ear infection;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg15874270	chr4:123161078	KIAA1109	0.48	6.45	0.39	6.55e-10	Thyroid stimulating hormone;
SARC	cis	rs2276314	1.000	rs2298715	chr18:33552425	T/C	cg19628046	chr18:33552617	C18orf21	0.57	5.87	0.36	1.49e-8	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg03806693	chr22:41940476	POLR3H	-0.87	-11.95	-0.62	5.34e-26	Vitiligo;
SARC	cis	rs1483890	0.851	rs6762186	chr3:69402923	T/G	cg22125112	chr3:69402811	FRMD4B	0.29	4.92	0.31	1.65e-6	Resting heart rate;
SARC	cis	rs1190552	0.739	rs1998421	chr14:102979644	C/T	cg10241871	chr14:102965420	TECPR2	-0.41	-4.75	-0.3	3.5e-6	Blood protein levels;
SARC	cis	rs4481887	0.893	rs10888349	chr1:248448625	T/C	cg13385794	chr1:248469461	NA	0.34	5.05	0.31	8.77e-7	Common traits (Other);
SARC	cis	rs6714710	0.603	rs17489454	chr2:98407350	C/T	cg26665480	chr2:98280029	ACTR1B	0.5	6.7	0.4	1.56e-10	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs240764	0.658	rs705584	chr6:101261553	C/T	cg09795085	chr6:101329169	ASCC3	0.48	6.35	0.38	1.12e-9	Neuroticism;
SARC	cis	rs7000551	0.751	rs2469770	chr8:22379856	G/A	cg12081754	chr8:22256438	SLC39A14	0.57	8.06	0.47	4.07e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs9902453	0.967	rs4325622	chr17:28526475	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	6.66	0.4	1.92e-10	Coffee consumption (cups per day);
SARC	cis	rs17384381	0.834	rs12130380	chr1:85901309	T/C	cg16011679	chr1:85725395	C1orf52	0.56	5.52	0.34	9.13e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs453301	0.658	rs3855900	chr8:8901921	A/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.98	-0.42	2.98e-11	Joint mobility (Beighton score);
SARC	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg06212747	chr3:49208901	KLHDC8B	0.65	8.62	0.49	1.06e-15	Parkinson's disease;
SARC	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg12463550	chr7:65579703	CRCP	0.48	5.23	0.32	3.76e-7	Aortic root size;
SARC	cis	rs601339	1.000	rs645491	chr12:123181661	T/C	cg18578876	chr12:123200353	GPR109B	0.43	4.87	0.3	2.07e-6	Adiponectin levels;
SARC	cis	rs13191362	1.000	rs35103567	chr6:163183400	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.76	6.5	0.39	4.95e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs739401	0.572	rs410820	chr11:3080102	G/A	cg25174290	chr11:3078921	CARS	0.6	8.68	0.49	6.93e-16	Longevity;
SARC	cis	rs7659604	0.521	rs13114801	chr4:122670855	C/A	cg19671926	chr4:122722719	EXOSC9	0.55	6.89	0.41	5.15e-11	Type 2 diabetes;
SARC	cis	rs6500602	0.727	rs7193136	chr16:4580034	C/T	cg08645402	chr16:4508243	NA	0.38	5.0	0.31	1.15e-6	Schizophrenia;
SARC	cis	rs9486715	0.867	rs9373829	chr6:96897201	A/C	cg18709589	chr6:96969512	KIAA0776	-0.52	-6.37	-0.39	9.75e-10	Headache;
SARC	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg09323728	chr8:95962352	TP53INP1	-0.29	-4.91	-0.31	1.73e-6	Type 2 diabetes;
SARC	cis	rs7020830	0.858	rs67036212	chr9:37133538	A/G	cg14294708	chr9:37120828	ZCCHC7	1.13	19.06	0.78	1.98e-49	Schizophrenia;
SARC	cis	rs698833	0.501	rs35347977	chr2:44506921	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.44	5.39	0.33	1.71e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs9818758	0.505	rs67286839	chr3:49265744	C/T	cg03060546	chr3:49711283	APEH	-0.55	-4.74	-0.3	3.75e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs60871478	1.000	rs62432251	chr7:801855	T/G	cg05535760	chr7:792225	HEATR2	0.77	7.97	0.46	7.2e-14	Cerebrospinal P-tau181p levels;
SARC	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg00149659	chr3:10157352	C3orf10	0.68	6.38	0.39	9.46e-10	Alzheimer's disease;
SARC	cis	rs910316	0.591	rs7157158	chr14:75457238	A/G	cg06637938	chr14:75390232	RPS6KL1	0.47	6.23	0.38	2.21e-9	Height;
SARC	cis	rs9815354	1.000	rs1016669	chr3:41894440	T/C	cg03022575	chr3:42003672	ULK4	0.56	5.29	0.33	2.81e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs1832871	0.711	rs9459918	chr6:158703604	A/C	cg07165851	chr6:158734300	TULP4	0.51	6.18	0.38	2.85e-9	Height;
SARC	cis	rs6867032	1.000	rs4975794	chr5:2015330	A/G	cg26168224	chr5:2018326	NA	-0.96	-16.25	-0.73	3.36e-40	Gut microbiome composition (winter);
SARC	cis	rs12421382	0.592	rs2029297	chr11:109465968	A/G	cg16359550	chr11:109292809	C11orf87	0.35	5.21	0.32	4.1e-7	Schizophrenia;
SARC	cis	rs17401966	1.000	rs12141416	chr1:10327867	A/G	cg15208524	chr1:10270712	KIF1B	0.5	6.03	0.37	6.29e-9	Hepatocellular carcinoma;
SARC	cis	rs1949733	0.877	rs940133	chr4:8473614	T/C	cg13073564	chr4:8508604	NA	-0.38	-5.6	-0.34	5.95e-8	Response to antineoplastic agents;
SARC	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg05896524	chr21:47604654	C21orf56	-0.5	-6.12	-0.37	4e-9	Testicular germ cell tumor;
SARC	cis	rs763121	0.853	rs138712	chr22:39141600	C/T	cg06022373	chr22:39101656	GTPBP1	0.81	10.64	0.57	8.26e-22	Menopause (age at onset);
SARC	cis	rs1008375	1.000	rs2159583	chr4:17658838	T/C	cg16339924	chr4:17578868	LAP3	0.66	8.83	0.5	2.61e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg09373136	chr17:61933544	TCAM1	-0.45	-6.12	-0.37	3.9e-9	Prudent dietary pattern;
SARC	cis	rs66573146	0.831	rs56031152	chr4:6973832	C/A	cg15105060	chr4:7024189	TBC1D14	-0.69	-4.92	-0.31	1.63e-6	Granulocyte percentage of myeloid white cells;
SARC	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg23262073	chr20:60523788	NA	-0.41	-5.65	-0.35	4.61e-8	Body mass index;
SARC	cis	rs7937682	0.889	rs1784786	chr11:111486043	A/G	cg22437258	chr11:111473054	SIK2	-0.69	-8.89	-0.5	1.74e-16	Primary sclerosing cholangitis;
SARC	cis	rs11190604	1.000	rs2495750	chr10:102327708	A/G	cg07080220	chr10:102295463	HIF1AN	0.78	8.86	0.5	2.04e-16	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs7146395	1	rs7146395	chr14:75228647	A/C	cg06637938	chr14:75390232	RPS6KL1	0.41	5.03	0.31	9.95e-7	Platelet count;
SARC	cis	rs7824557	0.591	rs2293859	chr8:11216761	T/G	cg21775007	chr8:11205619	TDH	0.73	9.63	0.53	1.08e-18	Retinal vascular caliber;
SARC	cis	rs637571	0.522	rs679581	chr11:65746653	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.58	8.9	0.5	1.65e-16	Eosinophil percentage of white cells;
SARC	cis	rs3087591	0.683	rs2854303	chr17:29716342	C/G	cg24425628	chr17:29625626	OMG;NF1	0.41	5.13	0.32	6.23e-7	Hip circumference;
SARC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg19318889	chr4:1322082	MAEA	0.44	5.43	0.34	1.4e-7	Longevity;
SARC	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg13126279	chr21:47581558	C21orf56	-0.47	-5.73	-0.35	3.11e-8	Testicular germ cell tumor;
SARC	cis	rs2370759	1.000	rs78959390	chr10:32616346	C/T	cg18270830	chr10:32634957	EPC1	0.69	6.26	0.38	1.85e-9	Sexual dysfunction (female);
SARC	cis	rs7726839	1.000	rs7726839	chr5:618586	A/G	cg09021430	chr5:549028	NA	-0.42	-6.54	-0.39	3.93e-10	Obesity-related traits;
SARC	cis	rs2075371	0.501	rs1613152	chr7:134019837	A/G	cg00033643	chr7:134001901	SLC35B4	0.47	5.82	0.36	1.94e-8	Mean platelet volume;
SARC	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg12756686	chr19:29218302	NA	0.57	6.49	0.39	5e-10	Methadone dose in opioid dependence;
SARC	cis	rs17125944	0.505	rs17125762	chr14:53289288	A/G	cg00686598	chr14:53173677	PSMC6	1.17	8.05	0.47	4.2e-14	Alzheimer's disease (late onset);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg08090396	chr3:52805200	NEK4	-0.51	-6.88	-0.41	5.51e-11	Chemerin levels;
SARC	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg13206674	chr6:150067644	NUP43	0.42	5.41	0.33	1.6e-7	Lung cancer;
SARC	cis	rs6496667	0.557	rs2526002	chr15:90965655	C/T	cg22089800	chr15:90895588	ZNF774	0.45	5.13	0.32	6.19e-7	Rheumatoid arthritis;
SARC	cis	rs72945132	1.000	rs72945129	chr11:70110808	C/T	cg00319359	chr11:70116639	PPFIA1	0.69	6.22	0.38	2.33e-9	Coronary artery disease;
SARC	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-8.54	-0.49	1.8e-15	Alzheimer's disease;
SARC	cis	rs2816062	0.813	rs2745321	chr1:18889198	G/C	cg10574377	chr1:18908098	NA	0.36	5.08	0.32	7.78e-7	Urate levels in lean individuals;
SARC	cis	rs3768617	0.510	rs10797835	chr1:183072908	T/C	cg13390022	chr1:182993471	LAMC1	0.32	4.83	0.3	2.48e-6	Fuchs's corneal dystrophy;
SARC	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg11878867	chr6:150167359	LRP11	-0.35	-4.89	-0.31	1.85e-6	Lung cancer;
SARC	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg12463550	chr7:65579703	CRCP	-0.71	-5.42	-0.33	1.47e-7	Diabetic kidney disease;
SARC	cis	rs9527	0.615	rs9733635	chr10:104711940	G/A	cg04362960	chr10:104952993	NT5C2	0.41	4.79	0.3	2.97e-6	Arsenic metabolism;
SARC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	6.02	0.37	6.63e-9	Prudent dietary pattern;
SARC	cis	rs149026780	1	rs149026780	chr2:97881612	A/C	cg26665480	chr2:98280029	ACTR1B	-0.64	-4.99	-0.31	1.2e-6	Monocyte chemoattractant protein-3 levels;
SARC	cis	rs7481584	1.000	rs12786344	chr11:3021392	G/A	cg25174290	chr11:3078921	CARS	-0.51	-6.59	-0.4	2.98e-10	Calcium levels;
SARC	cis	rs9486715	0.867	rs9373833	chr6:96904998	A/G	cg18709589	chr6:96969512	KIAA0776	-0.61	-7.62	-0.45	6.2800000000000005e-13	Headache;
SARC	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg05279229	chr7:1896384	MAD1L1	-0.35	-4.77	-0.3	3.23e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs921968	0.643	rs2178019	chr2:219316303	G/A	cg02176678	chr2:219576539	TTLL4	0.37	5.49	0.34	1.06e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs74181299	0.750	rs1420185	chr2:65315903	A/G	cg20592124	chr2:65290738	CEP68	0.44	6.12	0.37	3.84e-9	Pulse pressure;
SARC	cis	rs36051895	0.659	rs57204002	chr9:5062610	T/C	cg02405213	chr9:5042618	JAK2	-0.47	-5.33	-0.33	2.28e-7	Pediatric autoimmune diseases;
SARC	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg13939156	chr17:80058883	NA	-0.42	-6.48	-0.39	5.51e-10	Life satisfaction;
SARC	cis	rs2370759	1.000	rs2370759	chr10:32634972	G/A	cg18270830	chr10:32634957	EPC1	0.68	6.04	0.37	5.98e-9	Sexual dysfunction (female);
SARC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg20607798	chr8:58055168	NA	0.7	6.18	0.38	2.91e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4481887	0.893	rs6587450	chr1:248480496	T/A	cg00666640	chr1:248458726	OR2T12	0.33	5.54	0.34	7.95e-8	Common traits (Other);
SARC	cis	rs910316	0.967	rs175505	chr14:75529619	C/T	cg11812906	chr14:75593930	NEK9	-0.85	-12.57	-0.64	5.18e-28	Height;
SARC	cis	rs2933343	0.700	rs789238	chr3:128636715	A/G	cg24203234	chr3:128598194	ACAD9	0.63	7.99	0.46	6.15e-14	IgG glycosylation;
SARC	cis	rs644799	0.526	rs542509	chr11:95641602	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	5.91	0.36	1.18e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs1256061	0.603	rs1256039	chr14:64738979	G/C	cg23250157	chr14:64679961	SYNE2	0.48	6.62	0.4	2.49e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs75229567	0.618	rs11495622	chr12:70161286	G/A	cg10114359	chr12:70132523	RAB3IP	1.11	7.39	0.44	2.63e-12	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
SARC	cis	rs2576037	0.796	rs2571018	chr18:44585344	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.69	-10.09	-0.55	4.37e-20	Personality dimensions;
SARC	cis	rs6450176	1.000	rs12654393	chr5:53302620	A/C	ch.5.1024479R	chr5:53302184	ARL15	0.69	8.13	0.47	2.53e-14	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs6484504	0.532	rs12788257	chr11:31255045	T/C	cg02090638	chr11:31391270	DNAJC24;DCDC1	-0.42	-5.29	-0.33	2.83e-7	Red blood cell count;
SARC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.33	-5.17	-0.32	4.93e-7	Longevity;Endometriosis;
SARC	cis	rs9790314	1.000	rs9872514	chr3:161042833	T/C	cg03342759	chr3:160939853	NMD3	-0.59	-7.6	-0.45	7.41e-13	Morning vs. evening chronotype;
SARC	trans	rs61931739	0.500	rs7965421	chr12:34523624	G/T	cg13010199	chr12:38710504	ALG10B	0.83	11.73	0.61	2.89e-25	Morning vs. evening chronotype;
SARC	cis	rs826838	1.000	rs1684416	chr12:39130301	G/A	cg13010199	chr12:38710504	ALG10B	-0.63	-8.88	-0.5	1.87e-16	Heart rate;
SARC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.63	-0.4	2.28e-10	Total body bone mineral density;
SARC	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs10992471	0.528	rs10117627	chr9:95203953	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.42	-4.73	-0.3	3.91e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs6831352	0.918	rs7670060	chr4:100059568	G/T	cg13256891	chr4:100009986	ADH5	-0.64	-8.0	-0.46	5.7e-14	Alcohol dependence;
SARC	cis	rs208520	0.874	rs208512	chr6:66943869	C/G	cg07460842	chr6:66804631	NA	-0.89	-10.43	-0.56	3.83e-21	Exhaled nitric oxide output;
SARC	cis	rs3741151	1.000	rs76570090	chr11:73066321	A/T	cg17517138	chr11:73019481	ARHGEF17	0.97	6.83	0.41	7.16e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs10821556	1	rs10821556	chr9:136942136	C/A	cg13495838	chr9:136934004	BRD3	0.48	5.59	0.34	6.31e-8	Mean platelet volume;
SARC	cis	rs921968	0.565	rs4674330	chr2:219595710	T/C	cg02176678	chr2:219576539	TTLL4	-0.34	-5.14	-0.32	5.75e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs981844	0.961	rs62325108	chr4:154679767	G/A	cg14289246	chr4:154710475	SFRP2	0.59	6.77	0.41	1.06e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs10927875	0.518	rs732286	chr1:16344360	A/G	cg21385522	chr1:16154831	NA	0.54	6.47	0.39	5.8e-10	Dilated cardiomyopathy;
SARC	cis	rs9916302	0.861	rs11078896	chr17:37415544	C/T	cg15445000	chr17:37608096	MED1	0.42	5.14	0.32	5.76e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-4.93	-0.31	1.54e-6	Total body bone mineral density;
SARC	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.44	6.95	0.41	3.61e-11	Schizophrenia;
SARC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.11	-19.61	-0.79	3.22e-51	Prudent dietary pattern;
SARC	cis	rs832540	0.512	rs33320	chr5:56206529	C/T	cg12311346	chr5:56204834	C5orf35	-0.41	-5.0	-0.31	1.15e-6	Coronary artery disease;
SARC	cis	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg21144161	chr5:423903	AHRR	0.31	4.84	0.3	2.39e-6	Cystic fibrosis severity;
SARC	cis	rs8523	0.586	rs1225753	chr6:10956689	A/G	cg13562911	chr6:11044106	ELOVL2	0.39	5.15	0.32	5.56e-7	Red blood cell fatty acid levels;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11088380	chr13:25497236	CENPJ	0.53	6.51	0.39	4.49e-10	Fibrinogen levels;
SARC	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-9.6	-0.53	1.3e-18	Chronic sinus infection;
SARC	cis	rs910316	1.000	rs13099	chr14:75599155	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.49	-6.79	-0.41	9e-11	Height;
SARC	cis	rs910316	0.934	rs8016330	chr14:75657507	G/T	cg11812906	chr14:75593930	NEK9	-0.81	-11.76	-0.61	2.25e-25	Height;
SARC	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg09323728	chr8:95962352	TP53INP1	-0.3	-5.0	-0.31	1.13e-6	Type 2 diabetes;
SARC	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg17971929	chr21:40555470	PSMG1	-0.97	-13.3	-0.66	2.16e-30	Cognitive function;
SARC	cis	rs9858542	0.537	rs9864406	chr3:49352619	A/G	cg00383909	chr3:49044727	WDR6	0.47	4.84	0.3	2.37e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs3862260	0.509	rs1045827	chr1:120162442	C/T	cg16322792	chr1:120165303	ZNF697	-0.29	-6.13	-0.37	3.73e-9	Systemic lupus erythematosus;
SARC	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg11987759	chr7:65425863	GUSB	0.51	6.56	0.39	3.42e-10	Aortic root size;
SARC	cis	rs2288073	0.930	rs7604097	chr2:24401805	G/C	cg26838691	chr2:24397539	C2orf84	-0.55	-6.84	-0.41	6.96e-11	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs9896052	0.591	rs11077790	chr17:73464718	G/A	cg14668889	chr17:73230827	NUP85	-0.39	-4.95	-0.31	1.4e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs742320	0.756	rs3765263	chr16:840378	A/G	cg03433313	chr16:819064	MIR662	-0.42	-5.56	-0.34	7.24e-8	Mean corpuscular volume;
SARC	cis	rs459571	0.959	rs465535	chr9:136910905	C/T	cg01294253	chr9:136912663	BRD3	0.39	5.13	0.32	6.07e-7	Platelet distribution width;
SARC	cis	rs4243830	0.737	rs925745	chr1:6615690	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.88	-8.39	-0.48	4.86e-15	Body mass index;
SARC	cis	rs897984	0.683	rs12926237	chr16:30837596	C/T	cg02466173	chr16:30829666	NA	0.51	7.39	0.44	2.66e-12	Dementia with Lewy bodies;
SARC	cis	rs1865760	0.663	rs9467656	chr6:25993559	G/A	cg18357526	chr6:26021779	HIST1H4A	0.38	4.83	0.3	2.43e-6	Height;
SARC	trans	rs8002861	0.870	rs9567293	chr13:44447243	A/G	cg17145862	chr1:211918768	LPGAT1	0.51	6.79	0.41	8.99e-11	Leprosy;
SARC	cis	rs6120849	0.754	rs13433216	chr20:33616301	T/C	cg24642439	chr20:33292090	TP53INP2	0.57	5.48	0.34	1.1e-7	Protein C levels;
SARC	cis	rs9399135	0.935	rs11760000	chr6:135370496	G/A	cg24558204	chr6:135376177	HBS1L	0.46	6.23	0.38	2.19e-9	Red blood cell count;
SARC	cis	rs2013441	0.932	rs3850785	chr17:20185248	A/G	cg13482628	chr17:19912719	NA	-0.48	-6.3	-0.38	1.49e-9	Obesity-related traits;
SARC	cis	rs796364	1.000	rs281760	chr2:200787804	A/G	cg23649088	chr2:200775458	C2orf69	0.64	6.06	0.37	5.35e-9	Schizophrenia;
SARC	cis	rs2273669	0.667	rs12198182	chr6:109318704	T/G	cg05315195	chr6:109294784	ARMC2	-0.59	-5.45	-0.34	1.28e-7	Prostate cancer;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg10784777	chr12:56552019	MYL6	0.57	6.91	0.41	4.53e-11	Blood pressure;
SARC	cis	rs6540556	0.608	rs2205985	chr1:209912100	A/G	cg05527609	chr1:210001259	C1orf107	-0.54	-5.79	-0.35	2.21e-8	Red blood cell count;
SARC	cis	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg25894440	chr7:65020034	NA	-0.78	-6.06	-0.37	5.44e-9	Diabetic kidney disease;
SARC	cis	rs6582630	0.502	rs2387603	chr12:38353389	A/C	cg13010199	chr12:38710504	ALG10B	0.78	10.79	0.58	2.78e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg05313129	chr8:58192883	C8orf71	-0.62	-6.34	-0.38	1.18e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg13800542	chr6:137113325	MAP3K5	0.54	7.34	0.43	3.56e-12	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.47	7.39	0.44	2.66e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs7662987	0.517	rs2602872	chr4:100038996	A/G	cg13256891	chr4:100009986	ADH5	0.69	8.85	0.5	2.28e-16	Smoking initiation;
SARC	cis	rs6570726	0.935	rs452552	chr6:145820781	G/A	cg05347473	chr6:146136440	FBXO30	0.49	6.48	0.39	5.27e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9911578	1.000	rs2567905	chr17:56782297	T/C	cg05425664	chr17:57184151	TRIM37	-0.66	-8.16	-0.47	2.04e-14	Intelligence (multi-trait analysis);
SARC	cis	rs1018836	0.828	rs756568	chr8:91557038	G/C	cg16814680	chr8:91681699	NA	-0.74	-11.35	-0.6	4.85e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs9486715	0.867	rs3860243	chr6:96905303	T/G	cg06623918	chr6:96969491	KIAA0776	0.84	11.84	0.61	1.24e-25	Headache;
SARC	cis	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg25427524	chr10:38739819	LOC399744	-0.52	-8.22	-0.47	1.45e-14	Extrinsic epigenetic age acceleration;
SARC	trans	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg00938859	chr5:1591904	SDHAP3	0.79	7.66	0.45	5.1e-13	Breast cancer;
SARC	cis	rs7412746	0.658	rs6677420	chr1:150946490	G/A	cg13175981	chr1:150552382	MCL1	-0.49	-5.79	-0.35	2.3e-8	Melanoma;
SARC	cis	rs9905704	0.647	rs12944274	chr17:57041293	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.39	4.8	0.3	2.89e-6	Testicular germ cell tumor;
SARC	cis	rs8141529	0.673	rs132548	chr22:29317559	C/G	cg02153584	chr22:29168773	CCDC117	-0.78	-11.2	-0.59	1.37e-23	Lymphocyte counts;
SARC	cis	rs2180341	0.782	rs6912750	chr6:127723081	A/T	cg24812749	chr6:127587940	RNF146	0.76	10.11	0.55	3.65e-20	Breast cancer;
SARC	cis	rs2645694	0.626	rs904050	chr4:77826089	T/G	cg10057126	chr4:77819792	ANKRD56	0.42	6.2	0.38	2.5e-9	Emphysema distribution in smoking;
SARC	cis	rs763121	0.925	rs17032	chr22:39130843	C/G	cg06022373	chr22:39101656	GTPBP1	0.82	11.27	0.59	8.62e-24	Menopause (age at onset);
SARC	cis	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg12463550	chr7:65579703	CRCP	0.68	5.24	0.32	3.61e-7	Diabetic kidney disease;
SARC	cis	rs7843479	1.000	rs11775444	chr8:21813018	A/G	cg17168535	chr8:21777572	XPO7	0.61	7.75	0.45	2.87e-13	Mean corpuscular volume;
SARC	cis	rs7635838	0.684	rs2606762	chr3:11343889	G/C	cg00170343	chr3:11313890	ATG7	0.64	8.83	0.5	2.64e-16	HDL cholesterol;
SARC	cis	rs2455799	0.574	rs2455801	chr3:15701857	C/T	cg16303742	chr3:15540471	COLQ	-0.33	-4.73	-0.3	3.96e-6	Mean platelet volume;
SARC	trans	rs9650657	0.515	rs6601560	chr8:10950866	T/C	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.09	-0.42	1.56e-11	Neuroticism;
SARC	cis	rs10193935	0.901	rs222488	chr2:42648570	T/G	cg27598129	chr2:42591480	NA	-0.37	-5.12	-0.32	6.51e-7	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4808199	0.847	rs34647936	chr19:19548239	T/G	cg03709012	chr19:19516395	GATAD2A	1.17	13.18	0.65	5.03e-30	Nonalcoholic fatty liver disease;
SARC	cis	rs2276314	0.857	rs59649576	chr18:33616075	G/T	cg19628046	chr18:33552617	C18orf21	0.6	6.19	0.38	2.69e-9	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs7829975	0.514	rs2979139	chr8:8268313	A/G	cg15556689	chr8:8085844	FLJ10661	0.51	6.06	0.37	5.38e-9	Mood instability;
SARC	cis	rs4742903	0.545	rs2089459	chr9:106953527	C/T	cg14250997	chr9:106856677	SMC2	0.39	4.84	0.3	2.39e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs11025559	0.773	rs16906274	chr11:20470142	T/C	cg04101203	chr11:20408940	PRMT3	-0.53	-5.74	-0.35	3e-8	Pursuit maintenance gain;
SARC	cis	rs6999452	1.000	rs2941657	chr8:106372180	A/G	cg12032713	chr8:106369363	ZFPM2	-0.31	-5.08	-0.32	7.66e-7	Gut microbiome composition (summer);
SARC	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.78	-0.5	3.56e-16	Alzheimer's disease;
SARC	cis	rs7568458	0.709	rs2028898	chr2:85777270	G/A	cg23752985	chr2:85803571	VAMP8	0.45	5.75	0.35	2.78e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs4713118	0.869	rs9283880	chr6:27715243	A/C	cg17221315	chr6:27791827	HIST1H4J	0.49	5.33	0.33	2.26e-7	Parkinson's disease;
SARC	cis	rs11574514	0.590	rs118108102	chr16:67844471	G/A	cg01866162	chr16:67596514	CTCF	1.12	6.46	0.39	5.91e-10	Crohn's disease;
SARC	cis	rs9896052	0.559	rs7220850	chr17:73436994	T/C	cg25649188	chr17:73499917	CASKIN2	0.49	5.51	0.34	9.54e-8	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg05368731	chr17:41323189	NBR1	0.75	8.88	0.5	1.86e-16	Menopause (age at onset);
SARC	cis	rs7551222	0.752	rs4252718	chr1:204512195	A/T	cg20240347	chr1:204465584	NA	0.35	6.15	0.37	3.36e-9	Schizophrenia;
SARC	cis	rs2380220	0.938	rs6923253	chr6:95970141	C/G	cg07718321	chr6:96025334	MANEA	0.49	5.01	0.31	1.05e-6	Behavioural disinhibition (generation interaction);
SARC	cis	rs2279817	1.000	rs35148872	chr1:18020184	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.48	-4.78	-0.3	3.11e-6	Neuroticism;
SARC	cis	rs11711311	1.000	rs9288982	chr3:113470149	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	8.6	0.49	1.21e-15	IgG glycosylation;
SARC	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg24642844	chr7:1081250	C7orf50	-0.57	-6.05	-0.37	5.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs2230307	0.656	rs1395332	chr1:100503993	A/C	cg24955406	chr1:100503596	HIAT1	0.68	6.71	0.4	1.45e-10	Carotid intima media thickness;
SARC	cis	rs2204008	0.522	rs117743143	chr12:38030824	C/T	cg26384229	chr12:38710491	ALG10B	0.78	11.3	0.59	6.81e-24	Bladder cancer;
SARC	cis	rs7336332	0.547	rs9581859	chr13:28035147	A/T	cg01674679	chr13:27998804	GTF3A	-0.61	-4.76	-0.3	3.4e-6	Weight;
SARC	cis	rs6121246	0.567	rs6120815	chr20:30184866	T/C	cg21427119	chr20:30132790	HM13	-0.48	-5.29	-0.33	2.84e-7	Mean corpuscular hemoglobin;
SARC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.54	6.15	0.37	3.35e-9	Prudent dietary pattern;
SARC	cis	rs7520050	0.966	rs4073846	chr1:46462881	C/T	cg06784218	chr1:46089804	CCDC17	0.27	4.87	0.3	2.03e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs950027	0.620	rs35861938	chr15:45637343	T/C	cg21132104	chr15:45694354	SPATA5L1	0.55	7.1	0.42	1.49e-11	Response to fenofibrate (adiponectin levels);
SARC	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	14.03	0.68	8.15e-33	Chronic sinus infection;
SARC	cis	rs9303401	0.614	rs8081058	chr17:57160513	G/C	cg25039879	chr17:56429692	SUPT4H1	0.58	5.22	0.32	3.88e-7	Cognitive test performance;
SARC	cis	rs55823223	0.503	rs9906971	chr17:73848477	A/G	cg10935138	chr17:73851978	WBP2	0.47	5.31	0.33	2.53e-7	Psoriasis;
SARC	cis	rs9291683	0.530	rs882223	chr4:9981625	A/C	cg11266682	chr4:10021025	SLC2A9	0.39	7.04	0.42	2.15e-11	Bone mineral density;
SARC	cis	rs6700896	0.931	rs12044840	chr1:66115213	C/G	cg04111102	chr1:66153794	NA	0.35	5.55	0.34	7.6e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs2289583	0.500	rs67168917	chr15:75391494	G/T	cg09165964	chr15:75287851	SCAMP5	-0.49	-6.59	-0.4	2.95e-10	Systemic lupus erythematosus;
SARC	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg24675658	chr1:53192096	ZYG11B	-0.54	-7.5	-0.44	1.34e-12	Monocyte count;
SARC	cis	rs7659604	0.728	rs3924987	chr4:122689784	G/T	cg19671926	chr4:122722719	EXOSC9	-0.5	-5.72	-0.35	3.27e-8	Type 2 diabetes;
SARC	cis	rs7712401	0.755	rs3756362	chr5:122108890	C/G	cg19412675	chr5:122181750	SNX24	0.36	4.73	0.3	3.91e-6	Mean platelet volume;
SARC	cis	rs9906944	0.707	rs729003	chr17:47117775	C/T	cg16584676	chr17:46985605	UBE2Z	-0.44	-5.3	-0.33	2.67e-7	Intelligence (multi-trait analysis);Body fat percentage;
SARC	cis	rs6540556	0.517	rs1474654	chr1:209884387	A/G	cg05527609	chr1:210001259	C1orf107	-0.54	-4.75	-0.3	3.61e-6	Red blood cell count;
SARC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	10.64	0.57	8.43e-22	Platelet count;
SARC	cis	rs6570726	1.000	rs455109	chr6:145872665	C/T	cg05220968	chr6:146057943	EPM2A	-0.29	-4.91	-0.31	1.72e-6	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs1853207	1.000	rs61604699	chr10:96696903	G/A	cg02737782	chr1:8014393	NA	-0.92	-6.55	-0.39	3.72e-10	Blood metabolite levels;
SARC	cis	rs12911832	0.727	rs2604454	chr15:59098732	C/A	cg05156742	chr15:59063176	FAM63B	0.72	10.15	0.55	2.73e-20	Schizophrenia;
SARC	cis	rs67311347	0.911	rs6775936	chr3:40377399	T/G	cg09455208	chr3:40491958	NA	0.39	6.16	0.37	3.22e-9	Renal cell carcinoma;
SARC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg26668828	chr6:292823	DUSP22	-0.61	-7.91	-0.46	1e-13	Menopause (age at onset);
SARC	cis	rs1707322	1.000	rs7547189	chr1:46319514	C/A	cg03146154	chr1:46216737	IPP	0.47	5.67	0.35	4.31e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs17376456	1.000	rs66978370	chr5:93553633	G/A	cg21475434	chr5:93447410	FAM172A	0.95	8.25	0.48	1.16e-14	Diabetic retinopathy;
SARC	cis	rs2273669	0.915	rs6908714	chr6:109294336	T/C	cg05315195	chr6:109294784	ARMC2	-0.48	-4.78	-0.3	3.15e-6	Prostate cancer;
SARC	cis	rs11997175	0.646	rs4733177	chr8:33691754	A/G	ch.8.33884649F	chr8:33765107	NA	0.63	8.6	0.49	1.21e-15	Body mass index;
SARC	cis	rs2985684	0.948	rs7143010	chr14:50081803	T/C	cg04989706	chr14:50066350	PPIL5	-0.66	-6.89	-0.41	5.19e-11	Carotid intima media thickness;
SARC	cis	rs1008375	1.000	rs4698634	chr4:17630192	A/C	cg27347728	chr4:17578864	LAP3	-0.47	-5.72	-0.35	3.26e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7568458	0.875	rs2044474	chr2:85758790	G/A	cg02493740	chr2:85810744	VAMP5	-0.35	-5.16	-0.32	5.3e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg13939156	chr17:80058883	NA	-0.4	-6.26	-0.38	1.79e-9	Life satisfaction;
SARC	cis	rs9467711	0.538	rs7766531	chr6:25886577	T/C	cg08501292	chr6:25962987	TRIM38	0.68	4.72	0.3	4.05e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9486719	0.857	rs4839833	chr6:96882069	T/C	cg06623918	chr6:96969491	KIAA0776	0.72	8.47	0.48	2.88e-15	Migraine;Coronary artery disease;
SARC	cis	rs11608355	0.618	rs2075435	chr12:109796832	C/T	cg19025524	chr12:109796872	NA	-0.48	-6.69	-0.4	1.67e-10	Neuroticism;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg15040075	chr2:232379222	C2orf52	-0.48	-6.42	-0.39	7.56e-10	Schizophrenia;
SARC	trans	rs17685	0.712	rs6976236	chr7:75741087	G/T	cg19862616	chr7:65841803	NCRNA00174	0.61	7.48	0.44	1.47e-12	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs7605378	1.000	rs10194076	chr2:200677663	T/C	cg23649088	chr2:200775458	C2orf69	0.5	5.82	0.36	1.91e-8	Osteoporosis;
SARC	cis	rs6964587	0.933	rs28671255	chr7:91770705	A/G	cg17063962	chr7:91808500	NA	0.97	16.98	0.74	1.23e-42	Breast cancer;
SARC	cis	rs12545912	0.909	rs12675893	chr8:9479460	G/A	cg21625330	chr8:9911636	MSRA	0.5	4.8	0.3	2.79e-6	Multiple myeloma (hyperdiploidy);
SARC	cis	rs7027203	1.000	rs7856374	chr9:96529791	G/A	cg14598338	chr9:96623480	NA	0.51	6.9	0.41	4.96e-11	DNA methylation (variation);
SARC	cis	rs16854884	0.657	rs62268458	chr3:143736219	T/C	cg06585982	chr3:143692056	C3orf58	0.63	8.44	0.48	3.36e-15	Economic and political preferences (feminism/equality);
SARC	cis	rs546131	0.928	rs552627	chr11:34826680	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.46	5.59	0.34	6.37e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs6570726	0.791	rs9376953	chr6:145912226	G/T	cg05347473	chr6:146136440	FBXO30	0.54	7.32	0.43	4.05e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4466137	0.794	rs6869296	chr5:83007333	C/G	cg16102102	chr5:83017553	HAPLN1	0.72	9.65	0.53	9.7e-19	Prostate cancer;
SARC	cis	rs10826995	0.808	rs211387	chr10:32293334	C/G	cg17893399	chr10:32345482	KIF5B	0.42	4.76	0.3	3.39e-6	Pulse pressure;
SARC	cis	rs240764	0.697	rs239195	chr6:101132368	T/C	cg09795085	chr6:101329169	ASCC3	0.37	4.76	0.3	3.35e-6	Neuroticism;
SARC	cis	rs2204008	0.775	rs3900361	chr12:38238936	A/G	cg26384229	chr12:38710491	ALG10B	-0.87	-12.92	-0.65	3.73e-29	Bladder cancer;
SARC	cis	rs7017697	0.507	rs10113140	chr8:19684745	A/C	cg03894339	chr8:19674705	INTS10	-0.53	-5.77	-0.35	2.53e-8	Breast cancer;
SARC	cis	rs2239547	0.603	rs71301807	chr3:53085475	C/G	cg11645453	chr3:52864694	ITIH4	0.32	4.94	0.31	1.49e-6	Schizophrenia;
SARC	cis	rs7223966	1.000	rs11079508	chr17:61750066	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	6.35	0.38	1.1e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2832077	0.689	rs2832055	chr21:30132382	C/G	cg24692254	chr21:30365293	RNF160	0.57	5.86	0.36	1.6e-8	Cognitive test performance;
SARC	cis	rs6088580	0.634	rs6059867	chr20:33078103	C/T	cg24642439	chr20:33292090	TP53INP2	0.66	8.68	0.49	7.08e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs754466	0.561	rs11002344	chr10:79709725	A/T	cg17075019	chr10:79541650	NA	-0.62	-5.51	-0.34	9.55e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-10.33	-0.56	7.79e-21	Chronic sinus infection;
SARC	cis	rs9303401	0.659	rs34351230	chr17:56782555	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	12.31	0.63	3.57e-27	Cognitive test performance;
SARC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg17178900	chr1:205818956	PM20D1	0.75	11.95	0.62	5.42e-26	Menarche (age at onset);
SARC	cis	rs17826219	0.706	rs61643715	chr17:29057762	A/G	cg13385521	chr17:29058706	SUZ12P	0.89	8.0	0.46	5.9e-14	Body mass index;
SARC	cis	rs911555	0.546	rs28798508	chr14:104068970	T/C	cg26031613	chr14:104095156	KLC1	0.62	8.19	0.47	1.73e-14	Intelligence (multi-trait analysis);
SARC	cis	rs8014204	0.836	rs888413	chr14:75267396	C/T	cg06637938	chr14:75390232	RPS6KL1	0.68	9.79	0.54	3.45e-19	Caffeine consumption;
SARC	cis	rs2204008	0.597	rs4002591	chr12:38133841	A/G	cg13010199	chr12:38710504	ALG10B	0.78	10.63	0.57	8.95e-22	Bladder cancer;
SARC	cis	rs11098499	0.954	rs6846442	chr4:120326323	G/A	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg22903657	chr4:1355424	KIAA1530	-0.37	-5.12	-0.32	6.38e-7	Obesity-related traits;
SARC	cis	rs644799	1.000	rs472231	chr11:95532166	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	14.15	0.68	3.08e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg22920501	chr2:26401640	FAM59B	-0.6	-8.06	-0.47	3.88e-14	Gut microbiome composition (summer);
SARC	cis	rs10463554	0.963	rs62362546	chr5:102351319	C/T	cg23492399	chr5:102201601	PAM	-0.47	-5.32	-0.33	2.43e-7	Parkinson's disease;
SARC	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg15242686	chr22:24348715	GSTTP1	0.45	5.76	0.35	2.59e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1008375	1.000	rs7688682	chr4:17693794	A/G	cg02297831	chr4:17616191	MED28	-0.41	-5.09	-0.32	7.41e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9581943	0.967	rs9554197	chr13:28476978	C/T	cg17352152	chr13:28491409	NA	0.37	5.05	0.31	8.79e-7	Pancreatic cancer;
SARC	cis	rs796364	0.760	rs2881594	chr2:201026183	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-5.08	-0.32	7.66e-7	Schizophrenia;
SARC	cis	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg05623727	chr3:50126028	RBM5	0.33	4.99	0.31	1.2e-6	Intelligence (multi-trait analysis);
SARC	cis	rs3008870	0.959	rs2815359	chr1:67494374	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.9	11.27	0.59	8.24e-24	Lymphocyte percentage of white cells;
SARC	trans	rs7937682	0.921	rs12806479	chr11:111443192	G/C	cg18187862	chr3:45730750	SACM1L	-0.53	-6.37	-0.39	9.98e-10	Primary sclerosing cholangitis;
SARC	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg23758822	chr17:41437982	NA	0.89	11.47	0.6	1.88e-24	Menopause (age at onset);
SARC	cis	rs950776	0.667	rs57728226	chr15:78929350	G/C	cg22563815	chr15:78856949	CHRNA5	0.33	5.13	0.32	6.19e-7	Sudden cardiac arrest;
SARC	trans	rs61931739	0.534	rs10844800	chr12:34230734	A/G	cg13010199	chr12:38710504	ALG10B	0.74	9.99	0.55	8.5e-20	Morning vs. evening chronotype;
SARC	cis	rs7666738	0.830	rs880472	chr4:98922595	C/A	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2806561	0.704	rs2746560	chr1:23526279	G/A	cg12483005	chr1:23474871	LUZP1	0.47	6.09	0.37	4.65e-9	Height;
SARC	cis	rs6570726	0.935	rs385185	chr6:145814992	A/G	cg05220968	chr6:146057943	EPM2A	-0.29	-4.83	-0.3	2.44e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2130392	0.961	rs2696035	chr4:185612953	A/G	cg04058563	chr4:185651563	MLF1IP	0.34	4.91	0.31	1.72e-6	Kawasaki disease;
SARC	cis	rs9398803	0.723	rs853975	chr6:127070234	C/T	cg20229609	chr6:126660872	C6orf173	-0.35	-5.08	-0.32	7.61e-7	Male-pattern baldness;
SARC	cis	rs2404602	0.716	rs17362383	chr15:76650702	A/G	cg22467129	chr15:76604101	ETFA	-0.36	-4.78	-0.3	3.1e-6	Blood metabolite levels;
SARC	cis	rs3741151	0.686	rs7123985	chr11:73260463	A/C	cg17517138	chr11:73019481	ARHGEF17	0.72	6.16	0.37	3.11e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs7084402	0.902	rs1346300	chr10:60287635	G/C	cg07615347	chr10:60278583	BICC1	0.61	8.99	0.51	8.84e-17	Refractive error;
SARC	cis	rs2985684	0.894	rs2281837	chr14:50065359	C/G	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.46	5.03	0.31	9.59e-7	Carotid intima media thickness;
SARC	trans	rs17685	0.753	rs8200	chr7:75696606	C/G	cg19862616	chr7:65841803	NCRNA00174	-0.64	-7.98	-0.46	6.57e-14	Coffee consumption;Coffee consumption (cups per day);
SARC	trans	rs208520	0.754	rs851593	chr6:66875783	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.12	14.87	0.7	1.33e-35	Exhaled nitric oxide output;
SARC	cis	rs16976116	0.901	rs28449712	chr15:55500681	A/C	cg17854078	chr15:55489399	RSL24D1	0.66	6.53	0.39	4.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2832191	0.679	rs2705659	chr21:30363908	G/C	cg08807101	chr21:30365312	RNF160	0.9	14.4	0.69	4.56e-34	Dental caries;
SARC	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg12311346	chr5:56204834	C5orf35	-0.56	-5.78	-0.35	2.39e-8	Initial pursuit acceleration;
SARC	cis	rs35110281	0.633	rs762400	chr21:45113629	C/G	cg01579765	chr21:45077557	HSF2BP	0.37	6.2	0.38	2.54e-9	Mean corpuscular volume;
SARC	cis	rs1878931	0.507	rs34370895	chr16:3396319	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.58	-5.94	-0.36	1.02e-8	Body mass index (adult);
SARC	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg24531977	chr5:56204891	C5orf35	0.6	6.02	0.37	6.61e-9	Initial pursuit acceleration;
SARC	cis	rs1580019	0.885	rs4580942	chr7:32496435	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.73	9.81	0.54	3.02e-19	Cognitive ability;
SARC	cis	rs933688	0.583	rs6882172	chr5:90576958	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.5	-5.13	-0.32	6e-7	Smoking behavior;
SARC	cis	rs7647973	0.626	rs4855882	chr3:49715354	G/T	cg06212747	chr3:49208901	KLHDC8B	0.57	5.34	0.33	2.24e-7	Menarche (age at onset);
SARC	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg11890956	chr21:40555474	PSMG1	-0.69	-9.06	-0.51	5.56e-17	Menarche (age at onset);
SARC	cis	rs116095464	1.000	rs7736	chr5:314935	T/C	cg20965017	chr5:231967	SDHA	-0.7	-5.48	-0.34	1.08e-7	Breast cancer;
SARC	cis	rs721399	1.000	rs4244446	chr8:18262518	C/T	cg18736775	chr8:18248649	NAT2	0.4	5.09	0.32	7.26e-7	Blood metabolite levels;
SARC	cis	rs80130819	0.591	rs10875783	chr12:48649736	G/A	cg24011408	chr12:48396354	COL2A1	0.52	5.87	0.36	1.46e-8	Prostate cancer;
SARC	cis	rs1949733	0.701	rs940136	chr4:8448992	G/A	cg11789530	chr4:8429930	ACOX3	0.81	10.61	0.57	1.07e-21	Response to antineoplastic agents;
SARC	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg14893161	chr1:205819251	PM20D1	0.47	5.32	0.33	2.45e-7	Parkinson's disease;
SARC	cis	rs9916302	0.861	rs4795376	chr17:37669043	T/C	cg20243544	chr17:37824526	PNMT	0.56	6.72	0.4	1.37e-10	Glomerular filtration rate (creatinine);
SARC	trans	rs208520	0.661	rs207111	chr6:66792513	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.06	-14.41	-0.69	4.36e-34	Exhaled nitric oxide output;
SARC	cis	rs1348850	0.540	rs10172355	chr2:178443225	A/G	cg23306229	chr2:178417860	TTC30B	0.74	7.86	0.46	1.42e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	trans	rs9354308	0.868	rs9345695	chr6:66554270	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.56	-6.63	-0.4	2.36e-10	Metabolite levels;
SARC	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg03264133	chr6:25882463	NA	-0.5	-6.77	-0.41	1.04e-10	Intelligence (multi-trait analysis);
SARC	cis	rs11122272	0.766	rs2790872	chr1:231540543	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-9.74	-0.54	5.14e-19	Hemoglobin concentration;
SARC	cis	rs10463554	0.927	rs154369	chr5:102406844	C/T	cg23492399	chr5:102201601	PAM	-0.51	-5.67	-0.35	4.23e-8	Parkinson's disease;
SARC	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg24675658	chr1:53192096	ZYG11B	0.74	11.15	0.59	2.11e-23	Monocyte count;
SARC	cis	rs7605378	0.528	rs812760	chr2:200724372	C/T	cg17644776	chr2:200775616	C2orf69	0.53	6.54	0.39	3.81e-10	Osteoporosis;
SARC	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg21226059	chr5:178986404	RUFY1	0.35	4.91	0.31	1.72e-6	Lung cancer;
SARC	cis	rs10504229	0.593	rs80174614	chr8:58024631	G/A	cg11062466	chr8:58055876	NA	0.58	5.5	0.34	1e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9402673	0.517	rs978036	chr6:135342903	C/T	cg24558204	chr6:135376177	HBS1L	0.45	6.07	0.37	5.25e-9	Reticulocyte count;High light scatter reticulocyte count;
SARC	cis	rs367943	1.000	rs348925	chr5:112817533	T/A	cg12552261	chr5:112820674	MCC	-0.45	-5.21	-0.32	4.24e-7	Type 2 diabetes;
SARC	cis	rs9815354	0.812	rs57809229	chr3:41840162	G/A	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs12600053	0.658	rs4783076	chr16:84848220	T/C	cg09249803	chr16:84846936	NA	0.37	5.3	0.33	2.65e-7	Asthma (childhood onset);
SARC	cis	rs6988636	1.000	rs28694222	chr8:124195017	C/T	cg23067535	chr8:124195133	FAM83A	-0.66	-5.49	-0.34	1.03e-7	Urinary uromodulin levels;
SARC	cis	rs6088580	0.634	rs6059887	chr20:33101102	C/G	cg08999081	chr20:33150536	PIGU	0.45	6.91	0.41	4.59e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs12709013	0.613	rs1646288	chr16:58789480	A/T	cg04273148	chr16:57808038	KIFC3	0.32	4.72	0.3	4.08e-6	Blood metabolite ratios;
SARC	cis	rs950169	0.887	rs71395453	chr15:85113490	G/C	cg17507749	chr15:85114479	UBE2QP1	0.79	9.45	0.53	3.89e-18	Schizophrenia;
SARC	cis	rs16854884	0.837	rs6767236	chr3:143758399	A/C	cg06585982	chr3:143692056	C3orf58	0.61	7.88	0.46	1.24e-13	Economic and political preferences (feminism/equality);
SARC	cis	rs11264799	0.539	rs2777968	chr1:157549325	T/G	cg18268488	chr1:157545234	FCRL4	0.32	5.79	0.35	2.21e-8	IgA nephropathy;
SARC	cis	rs56235845	0.694	rs11949401	chr5:176765989	A/G	cg16006841	chr5:176797999	RGS14	0.51	6.99	0.42	2.95e-11	Hemoglobin concentration;Hematocrit;
SARC	cis	rs11098499	0.954	rs6820115	chr4:120398182	T/C	cg09307838	chr4:120376055	NA	0.83	11.85	0.61	1.16e-25	Corneal astigmatism;
SARC	cis	rs4253772	0.591	rs12167567	chr22:46659942	G/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.64	7.11	0.42	1.41e-11	LDL cholesterol;Cholesterol, total;
SARC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg11062466	chr8:58055876	NA	0.68	5.98	0.36	8.51e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg11764359	chr7:65958608	NA	0.78	10.75	0.58	3.85e-22	Aortic root size;
SARC	cis	rs992157	0.835	rs2292551	chr2:219143229	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.7	-10.25	-0.56	1.35e-20	Colorectal cancer;
SARC	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg17507749	chr15:85114479	UBE2QP1	0.55	6.56	0.39	3.39e-10	P wave terminal force;
SARC	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg20607798	chr8:58055168	NA	0.56	5.43	0.34	1.4e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg07777115	chr5:623756	CEP72	-0.6	-5.27	-0.33	3.08e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs6504663	0.586	rs60117965	chr17:48569755	G/A	cg03168497	chr17:48586147	MYCBPAP	0.47	5.08	0.32	7.6e-7	Visceral fat;
SARC	cis	rs16986825	0.570	rs5762879	chr22:29286180	C/T	cg02153584	chr22:29168773	CCDC117	0.65	7.64	0.45	5.45e-13	Pancreatic cancer;
SARC	cis	rs858239	0.539	rs2103281	chr7:23194231	A/G	cg23682824	chr7:23144976	KLHL7	0.67	8.68	0.49	6.94e-16	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9303401	0.614	rs17175663	chr17:57108437	G/C	cg25039879	chr17:56429692	SUPT4H1	0.61	5.44	0.34	1.35e-7	Cognitive test performance;
SARC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg26338869	chr17:61819248	STRADA	0.8	10.8	0.58	2.52e-22	Prudent dietary pattern;
SARC	cis	rs6963495	0.818	rs73190133	chr7:105147821	G/C	cg13798780	chr7:105162888	PUS7	0.61	5.75	0.35	2.79e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs3829251	0.786	rs7103591	chr11:71237619	T/C	cg05163923	chr11:71159392	DHCR7	-0.5	-5.01	-0.31	1.06e-6	Vitamin D levels;
SARC	cis	rs721399	0.539	rs10103148	chr8:18267429	A/C	cg18736775	chr8:18248649	NAT2	-0.57	-5.67	-0.35	4.25e-8	Blood metabolite levels;
SARC	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg24675658	chr1:53192096	ZYG11B	-0.64	-9.15	-0.51	2.96e-17	Monocyte count;
SARC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg17178900	chr1:205818956	PM20D1	0.64	9.07	0.51	5.19e-17	Menarche (age at onset);
SARC	cis	rs2832191	0.692	rs2776240	chr21:30310639	C/T	cg08807101	chr21:30365312	RNF160	0.87	13.6	0.67	2.19e-31	Dental caries;
SARC	cis	rs372883	0.530	rs2832305	chr21:30752964	G/A	cg24692254	chr21:30365293	RNF160	0.55	6.84	0.41	6.97e-11	Pancreatic cancer;
SARC	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg03060546	chr3:49711283	APEH	-0.76	-11.29	-0.59	7.24e-24	Resting heart rate;
SARC	cis	rs35306767	0.903	rs11813210	chr10:919796	G/A	cg26597838	chr10:835615	NA	0.84	8.41	0.48	4.07e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs9814567	0.964	rs9820425	chr3:134223018	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.08	-0.42	1.7e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs7216064	1.000	rs7212293	chr17:65847325	A/G	cg12091567	chr17:66097778	LOC651250	-0.72	-7.88	-0.46	1.27e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs13191362	0.938	rs13213746	chr6:163167777	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.36	4.74	0.3	3.79e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg13385521	chr17:29058706	SUZ12P	0.65	5.97	0.36	8.62e-9	Body mass index;
SARC	cis	rs3796352	0.892	rs58515094	chr3:52995575	C/T	cg27565382	chr3:53032988	SFMBT1	0.83	5.57	0.34	7.16e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs644799	0.710	rs564480	chr11:95561741	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	13.25	0.66	3.13e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg07402261	chr13:111340250	CARS2	-0.86	-7.08	-0.42	1.68e-11	Obesity-related traits;
SARC	cis	rs11098499	0.566	rs17051356	chr4:120585308	C/T	cg09307838	chr4:120376055	NA	0.78	10.45	0.56	3.26e-21	Corneal astigmatism;
SARC	cis	rs17102884	0.506	rs887746	chr14:75403817	C/T	cg08847533	chr14:75593920	NEK9	-0.42	-5.25	-0.33	3.47e-7	Neuroticism;
SARC	trans	rs2950163	0.538	rs6707580	chr2:6146103	C/G	cg25116709	chr5:122426797	PRDM6	-0.42	-6.41	-0.39	7.79e-10	Response to metformin (IC50);
SARC	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg13699009	chr12:122356056	WDR66	0.69	11.51	0.6	1.42e-24	Mean corpuscular volume;
SARC	cis	rs4588572	0.643	rs1529499	chr5:77721431	T/C	cg11547950	chr5:77652471	NA	-0.42	-5.09	-0.32	7.32e-7	Triglycerides;
SARC	trans	rs9858213	1	rs9858213	chr3:49731861	G/T	cg21659725	chr3:3221576	CRBN	-0.57	-6.34	-0.38	1.17e-9	Educational attainment;
SARC	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg11987759	chr7:65425863	GUSB	-0.61	-8.41	-0.48	4.01e-15	Aortic root size;
SARC	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg23262073	chr20:60523788	NA	-0.39	-5.63	-0.35	5.17e-8	Body mass index;
SARC	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg17971929	chr21:40555470	PSMG1	-0.85	-10.56	-0.57	1.44e-21	Cognitive function;
SARC	cis	rs911263	0.961	rs2104047	chr14:68754417	T/C	cg18825221	chr14:68749962	RAD51L1	0.51	9.04	0.51	6.19e-17	Primary biliary cholangitis;
SARC	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg05234568	chr11:5960015	NA	-0.43	-5.61	-0.34	5.77e-8	DNA methylation (variation);
SARC	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg22920501	chr2:26401640	FAM59B	-0.55	-7.43	-0.44	2e-12	Gut microbiome composition (summer);
SARC	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg11987759	chr7:65425863	GUSB	-0.48	-5.87	-0.36	1.51e-8	Aortic root size;
SARC	cis	rs8067545	0.641	rs397969	chr17:19804247	T/C	cg04132472	chr17:19861366	AKAP10	0.4	5.36	0.33	1.96e-7	Schizophrenia;
SARC	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg19223190	chr17:80058835	NA	-0.42	-5.73	-0.35	3.09e-8	Life satisfaction;
SARC	cis	rs4481887	0.927	rs10888340	chr1:248440381	C/T	cg13385794	chr1:248469461	NA	0.34	5.04	0.31	9.53e-7	Common traits (Other);
SARC	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg10207240	chr12:122356781	WDR66	0.29	5.01	0.31	1.09e-6	Mean corpuscular volume;
SARC	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg11366901	chr6:160182831	ACAT2	0.64	6.65	0.4	2.1e-10	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg00800038	chr16:89945340	TCF25	-0.74	-5.1	-0.32	7.08e-7	Skin colour saturation;
SARC	cis	rs6964587	1.000	rs10280927	chr7:91582205	G/A	cg17063962	chr7:91808500	NA	-0.94	-15.25	-0.71	6.82e-37	Breast cancer;
SARC	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.43	0.44	2.1e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg11764359	chr7:65958608	NA	0.74	8.58	0.49	1.39e-15	Aortic root size;
SARC	cis	rs10465746	0.725	rs1359331	chr1:84360301	C/A	cg10977910	chr1:84465055	TTLL7	0.44	5.42	0.33	1.49e-7	Obesity-related traits;
SARC	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg11062466	chr8:58055876	NA	0.61	5.75	0.35	2.74e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg10435706	chr6:150039699	LATS1	0.37	4.87	0.3	2.04e-6	Lung cancer;
SARC	cis	rs796364	0.806	rs55985986	chr2:201120987	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.8	-6.59	-0.4	2.87e-10	Schizophrenia;
SARC	cis	rs9815354	0.953	rs7631914	chr3:41813557	T/C	cg03022575	chr3:42003672	ULK4	0.59	5.73	0.35	3.14e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs709400	0.663	rs62007684	chr14:103894223	T/C	cg26031613	chr14:104095156	KLC1	0.82	11.55	0.6	1.09e-24	Body mass index;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg14690181	chr5:115387984	NA	-0.77	-6.25	-0.38	1.93e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2797685	1.000	rs707466	chr1:7861600	C/A	cg00864860	chr1:7907996	UTS2	-0.36	-5.04	-0.31	9.5e-7	Crohn's disease;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg04153289	chr16:72698852	NA	0.52	6.28	0.38	1.65e-9	Blood pressure;
SARC	cis	rs7614311	0.636	rs73117045	chr3:63910613	A/G	cg22134162	chr3:63841271	THOC7	-0.46	-5.01	-0.31	1.1e-6	Lung function (FVC);Lung function (FEV1);
SARC	cis	rs2075371	0.796	rs1646645	chr7:134012232	G/T	cg00033643	chr7:134001901	SLC35B4	-0.5	-6.29	-0.38	1.57e-9	Mean platelet volume;
SARC	cis	rs995000	0.899	rs1748201	chr1:63045506	A/C	cg06896770	chr1:63153194	DOCK7	-0.89	-13.19	-0.65	4.67e-30	Triglyceride levels;
SARC	cis	rs9420	0.961	rs7116341	chr11:57481155	G/A	cg19752551	chr11:57585705	CTNND1	-0.49	-6.71	-0.4	1.46e-10	Schizophrenia;
SARC	cis	rs11098699	0.784	rs7674700	chr4:124239023	C/T	cg09941581	chr4:124220074	SPATA5	-0.37	-4.84	-0.3	2.37e-6	Mosquito bite size;
SARC	cis	rs6539288	0.899	rs7298423	chr12:107301980	A/G	cg07730007	chr12:107377277	MTERFD3	0.38	4.79	0.3	2.94e-6	Total body bone mineral density;
SARC	cis	rs4737010	0.511	rs7006871	chr8:41670952	A/G	cg17182837	chr8:41585554	ANK1	-0.5	-5.49	-0.34	1.05e-7	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
SARC	cis	rs710216	0.917	rs2297977	chr1:43415288	G/T	cg22176566	chr1:43424700	SLC2A1	0.53	5.39	0.33	1.69e-7	Red cell distribution width;
SARC	cis	rs8114671	0.869	rs2145559	chr20:33651725	G/A	cg08999081	chr20:33150536	PIGU	-0.36	-5.1	-0.32	6.91e-7	Height;
SARC	cis	rs9682041	0.696	rs13101192	chr3:170080752	C/G	cg11886554	chr3:170076028	SKIL	0.8	7.34	0.43	3.62e-12	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs8072100	0.701	rs2013383	chr17:45791123	T/G	cg08085267	chr17:45401833	C17orf57	-0.47	-5.47	-0.34	1.18e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg09373136	chr17:61933544	TCAM1	-0.45	-6.19	-0.38	2.75e-9	Prudent dietary pattern;
SARC	cis	rs9916302	0.645	rs1053651	chr17:37822311	A/C	cg00129232	chr17:37814104	STARD3	-0.76	-10.84	-0.58	1.95e-22	Glomerular filtration rate (creatinine);
SARC	trans	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg06437703	chr8:37914619	EIF4EBP1	-0.69	-9.43	-0.53	4.41e-18	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.47	5.8	0.36	2.13e-8	Gut microbiome composition (summer);
SARC	cis	rs908922	0.651	rs11205035	chr1:152532832	A/G	cg09873164	chr1:152488093	CRCT1	0.59	7.72	0.45	3.34e-13	Hair morphology;
SARC	cis	rs1008375	0.900	rs1003413	chr4:17582442	C/T	cg27347728	chr4:17578864	LAP3	-0.52	-6.34	-0.38	1.16e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2197308	0.643	rs1842597	chr12:37862142	C/G	cg13010199	chr12:38710504	ALG10B	-0.75	-10.28	-0.56	1.11e-20	Morning vs. evening chronotype;
SARC	cis	rs2415984	0.562	rs1389604	chr14:46972218	C/A	cg14871534	chr14:47121158	RPL10L	0.41	5.33	0.33	2.31e-7	Number of children ever born;
SARC	cis	rs8016982	1.000	rs12147118	chr14:81652975	A/C	cg01989461	chr14:81687754	GTF2A1	-0.56	-6.76	-0.41	1.07e-10	Schizophrenia;
SARC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg06873352	chr17:61820015	STRADA	0.53	6.93	0.41	4.07e-11	Prudent dietary pattern;
SARC	cis	rs9911578	0.900	rs4793593	chr17:56892699	C/G	cg05425664	chr17:57184151	TRIM37	0.66	8.09	0.47	3.24e-14	Intelligence (multi-trait analysis);
SARC	cis	rs35110281	0.774	rs2838323	chr21:44999086	G/A	cg21573476	chr21:45109991	RRP1B	-0.47	-6.89	-0.41	5.28e-11	Mean corpuscular volume;
SARC	cis	rs35110281	0.720	rs162375	chr21:44927015	C/T	cg21573476	chr21:45109991	RRP1B	0.53	7.84	0.46	1.63e-13	Mean corpuscular volume;
SARC	cis	rs9646303	0.774	rs9936994	chr16:87502815	A/G	cg06045579	chr16:87425660	FBXO31;MAP1LC3B	-0.5	-4.82	-0.3	2.56e-6	Major depressive disorder;
SARC	cis	rs9868809	0.505	rs13434258	chr3:48738491	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.57	-5.28	-0.33	2.94e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs6088590	1.000	rs6120748	chr20:33458284	T/G	cg06115741	chr20:33292138	TP53INP2	0.58	6.99	0.42	2.88e-11	Coronary artery disease;
SARC	cis	rs155076	1.000	rs564685	chr13:21846879	A/G	cg06138931	chr13:21896616	NA	-0.39	-5.08	-0.32	7.88e-7	White matter hyperintensity burden;
SARC	cis	rs7103648	0.669	rs7927445	chr11:47780754	G/T	cg20307385	chr11:47447363	PSMC3	0.76	10.21	0.56	1.77e-20	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs9325144	0.534	rs4882350	chr12:38686979	A/G	cg13010199	chr12:38710504	ALG10B	0.55	7.21	0.43	7.83e-12	Morning vs. evening chronotype;
SARC	cis	rs9341808	0.754	rs3812126	chr6:80952701	A/G	cg08355045	chr6:80787529	NA	-0.33	-5.4	-0.33	1.68e-7	Sitting height ratio;
SARC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.08	0.37	4.77e-9	Prudent dietary pattern;
SARC	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg27266027	chr21:40555129	PSMG1	0.47	4.71	0.3	4.18e-6	Cognitive function;
SARC	cis	rs921968	0.643	rs545779	chr2:219336108	A/G	cg02176678	chr2:219576539	TTLL4	0.36	5.58	0.34	6.83e-8	Mean corpuscular hemoglobin concentration;
SARC	cis	rs1448094	0.512	rs7953318	chr12:86245929	G/A	cg02569458	chr12:86230093	RASSF9	0.38	5.39	0.33	1.71e-7	Major depressive disorder;
SARC	cis	rs4319547	1.000	rs7307735	chr12:123087442	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.59	-7.03	-0.42	2.28e-11	Body mass index;
SARC	cis	rs17376456	0.877	rs56373208	chr5:93491276	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.02	0.31	1.01e-6	Diabetic retinopathy;
SARC	trans	rs1865760	0.929	rs9461224	chr6:25936402	G/T	cg20188282	chr9:135906200	GTF3C5	-0.55	-6.62	-0.4	2.51e-10	Height;
SARC	cis	rs3741404	0.574	rs638227	chr11:63871549	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	9.05	0.51	5.95e-17	Platelet count;
SARC	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg18850127	chr7:39170497	POU6F2	0.42	5.63	0.35	5.07e-8	IgG glycosylation;
SARC	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg26818010	chr10:134567672	INPP5A	-0.64	-7.11	-0.42	1.45e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs2070677	0.935	rs2864985	chr10:135348757	C/G	cg20169779	chr10:135381914	SYCE1	0.46	5.89	0.36	1.31e-8	Gout;
SARC	cis	rs4727027	0.901	rs1534198	chr7:148772323	T/C	cg23583168	chr7:148888333	NA	-0.74	-10.65	-0.57	7.49e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs7953249	0.656	rs6489786	chr12:121397875	A/G	cg02403541	chr12:121454288	C12orf43	-0.73	-9.74	-0.54	4.87e-19	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs2479724	0.846	rs2251084	chr6:41838119	T/C	cg17623882	chr6:41773611	USP49	-0.46	-5.56	-0.34	7.45e-8	Menarche (age at onset);
SARC	cis	rs910316	0.737	rs175080	chr14:75513828	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.52	-7.07	-0.42	1.82e-11	Height;
SARC	cis	rs7727544	0.735	rs273914	chr5:131660431	A/T	cg24060327	chr5:131705240	SLC22A5	-0.69	-8.98	-0.51	9.58e-17	Blood metabolite levels;
SARC	cis	rs2191566	0.576	rs405763	chr19:44493547	A/G	cg20607764	chr19:44506953	ZNF230	0.42	4.8	0.3	2.86e-6	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9291683	0.679	rs3756225	chr4:10094133	G/C	cg11266682	chr4:10021025	SLC2A9	-0.44	-7.98	-0.46	6.81e-14	Bone mineral density;
SARC	cis	rs13065560	0.562	rs6786732	chr3:38920203	C/T	cg26331595	chr3:39149181	GORASP1;TTC21A	0.4	4.84	0.3	2.37e-6	Interleukin-18 levels;
SARC	cis	rs10463316	0.894	rs4099169	chr5:150766526	C/T	cg03212797	chr5:150827313	SLC36A1	-0.47	-5.53	-0.34	8.76e-8	Metabolite levels (Pyroglutamine);
SARC	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg02725872	chr8:58115012	NA	-0.35	-6.03	-0.37	6.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1395	0.710	rs1992291	chr2:27504312	A/G	cg22903471	chr2:27725779	GCKR	-0.4	-5.09	-0.32	7.27e-7	Blood metabolite levels;
SARC	cis	rs7824557	0.527	rs2572369	chr8:11238597	C/T	cg21775007	chr8:11205619	TDH	-0.56	-7.33	-0.43	3.87e-12	Retinal vascular caliber;
SARC	cis	rs9457247	0.602	rs17615336	chr6:167506734	A/G	cg23791538	chr6:167370224	RNASET2	-0.51	-6.43	-0.39	7.16e-10	Crohn's disease;
SARC	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg17971929	chr21:40555470	PSMG1	0.99	13.44	0.66	7.41e-31	Cognitive function;
SARC	cis	rs4853036	1.000	rs1454499	chr2:70062939	T/C	cg02498382	chr2:70120550	SNRNP27	-0.45	-6.9	-0.41	4.97e-11	Colorectal or endometrial cancer;
SARC	cis	rs9309473	0.898	rs28879089	chr2:73812886	G/A	cg20560298	chr2:73613845	ALMS1	-0.48	-5.83	-0.36	1.81e-8	Metabolite levels;
SARC	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg14159672	chr1:205819179	PM20D1	0.44	5.12	0.32	6.37e-7	Parkinson's disease;
SARC	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg05313129	chr8:58192883	C8orf71	-0.62	-6.34	-0.38	1.18e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs554111	0.560	rs592060	chr1:21050958	A/G	cg08890418	chr1:21044141	KIF17	-0.54	-6.14	-0.37	3.5e-9	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs240764	0.817	rs12214151	chr6:101159516	G/T	cg09795085	chr6:101329169	ASCC3	-0.48	-6.25	-0.38	1.97e-9	Neuroticism;
SARC	cis	rs1348850	0.750	rs55792594	chr2:178496468	C/T	cg22681709	chr2:178499509	PDE11A	-0.37	-4.9	-0.31	1.81e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs13095912	0.962	rs11916386	chr3:185308069	G/T	cg11274856	chr3:185301563	NA	0.35	4.84	0.3	2.33e-6	Systolic blood pressure;
SARC	cis	rs11122272	0.735	rs2250719	chr1:231486208	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs2230307	0.536	rs631977	chr1:100544564	C/G	cg24955406	chr1:100503596	HIAT1	0.68	6.62	0.4	2.41e-10	Carotid intima media thickness;
SARC	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg07636037	chr3:49044803	WDR6	0.98	17.1	0.75	4.92e-43	Parkinson's disease;
SARC	cis	rs7429990	0.932	rs2166772	chr3:48047874	C/T	cg11946769	chr3:48343235	NME6	-0.45	-5.27	-0.33	3.07e-7	Educational attainment (years of education);
SARC	cis	rs12979813	1.000	rs12979813	chr19:11342703	C/T	cg00586551	chr19:11347513	LOC55908;DOCK6	-0.43	-5.29	-0.33	2.87e-7	HDL cholesterol;
SARC	cis	rs96067	0.711	rs795047	chr1:36637708	C/T	cg24686825	chr1:36642396	MAP7D1	0.56	6.88	0.41	5.33e-11	Corneal structure;
SARC	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg11890956	chr21:40555474	PSMG1	1.14	15.46	0.71	1.36e-37	Cognitive function;
SARC	trans	rs9392653	0.847	rs9405255	chr6:5066039	A/T	cg03813033	chr19:50380022	AKT1S1;TBC1D17	-0.56	-6.54	-0.39	3.87e-10	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs698833	1.000	rs1067352	chr2:44669724	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.62	7.36	0.43	3.13e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	10.52	0.57	2.03e-21	Alzheimer's disease;
SARC	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg06212747	chr3:49208901	KLHDC8B	0.65	8.63	0.49	9.91e-16	Parkinson's disease;
SARC	cis	rs60871478	0.679	rs4076965	chr7:793272	A/G	cg05535760	chr7:792225	HEATR2	0.84	7.79	0.45	2.26e-13	Cerebrospinal P-tau181p levels;
SARC	cis	rs11190604	1.000	rs1106565	chr10:102211613	T/C	cg07080220	chr10:102295463	HIF1AN	0.78	9.58	0.53	1.56e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs2486288	0.656	rs7171312	chr15:45570225	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.54	-6.88	-0.41	5.51e-11	Glomerular filtration rate;
SARC	cis	rs17376456	0.877	rs12153788	chr5:93405437	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.68	0.35	3.93e-8	Diabetic retinopathy;
SARC	cis	rs7617773	0.963	rs6800730	chr3:48174210	C/T	cg11946769	chr3:48343235	NME6	0.5	5.96	0.36	9.04e-9	Coronary artery disease;
SARC	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg02018176	chr4:1364513	KIAA1530	0.33	4.82	0.3	2.56e-6	Longevity;
SARC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg19318889	chr4:1322082	MAEA	0.42	5.15	0.32	5.64e-7	Longevity;
SARC	cis	rs2180341	0.960	rs7753913	chr6:127671296	A/G	cg27446573	chr6:127587934	RNF146	1.05	14.53	0.69	1.75e-34	Breast cancer;
SARC	cis	rs2916247	1.000	rs6987284	chr8:93018479	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.59	-6.26	-0.38	1.81e-9	Intelligence (multi-trait analysis);
SARC	cis	rs17270561	0.609	rs7746609	chr6:25727996	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.51	-6.46	-0.39	5.98e-10	Iron status biomarkers;
SARC	cis	rs9303401	0.555	rs8071831	chr17:57292950	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.68	8.66	0.49	7.78e-16	Cognitive test performance;
SARC	cis	rs4642101	0.662	rs3901664	chr3:12824660	T/C	cg05775895	chr3:12838266	CAND2	0.84	15.7	0.72	2.23e-38	QRS complex (12-leadsum);
SARC	cis	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg12064134	chr16:90016061	DEF8	-0.59	-5.05	-0.31	8.75e-7	Skin colour saturation;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg23712980	chr20:30795555	POFUT1;PLAGL2	0.56	6.93	0.41	4.09e-11	Breast cancer;
SARC	cis	rs7246657	0.943	rs7246993	chr19:37890154	C/T	cg23950597	chr19:37808831	NA	-0.62	-6.05	-0.37	5.66e-9	Coronary artery calcification;
SARC	cis	rs4742903	0.875	rs1605449	chr9:106976397	T/C	cg14250997	chr9:106856677	SMC2	0.4	5.02	0.31	1.02e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs11764590	0.694	rs6977161	chr7:2099361	T/C	cg21782813	chr7:2030301	MAD1L1	-0.32	-4.9	-0.31	1.76e-6	Neuroticism;
SARC	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg11987759	chr7:65425863	GUSB	0.49	6.06	0.37	5.48e-9	Aortic root size;
SARC	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg13175981	chr1:150552382	MCL1	-0.54	-6.9	-0.41	4.97e-11	Tonsillectomy;
SARC	cis	rs9309473	0.554	rs4330127	chr2:73581320	A/T	cg20560298	chr2:73613845	ALMS1	-0.58	-7.37	-0.43	3e-12	Metabolite levels;
SARC	cis	rs8016982	0.674	rs61980899	chr14:81676844	T/C	cg01989461	chr14:81687754	GTF2A1	0.76	11.56	0.6	1.01e-24	Schizophrenia;
SARC	cis	rs7998202	0.775	rs282580	chr13:113357540	T/C	cg02820901	chr13:113351484	ATP11A	0.55	5.01	0.31	1.07e-6	Glycated hemoglobin levels;
SARC	trans	rs2727020	0.553	rs3862350	chr11:49595912	A/C	cg03929089	chr4:120376271	NA	-0.76	-11.35	-0.6	4.6e-24	Coronary artery disease;
SARC	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg16479474	chr6:28041457	NA	0.37	5.37	0.33	1.94e-7	Parkinson's disease;
SARC	cis	rs6088813	1.000	rs6141548	chr20:33971085	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.43	-5.24	-0.32	3.67e-7	Height;
SARC	cis	rs13082711	0.689	rs34946790	chr3:27345170	G/A	cg02860705	chr3:27208620	NA	0.74	8.51	0.49	2.1e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	trans	rs1973993	0.689	rs17375929	chr1:96962246	A/T	cg10631902	chr5:14652156	NA	-0.43	-7.01	-0.42	2.57e-11	Weight;
SARC	cis	rs9858542	0.543	rs2230929	chr3:49343175	G/A	cg00383909	chr3:49044727	WDR6	0.54	5.5	0.34	1.02e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	8.86	0.5	2.11e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs34779708	0.966	rs12784482	chr10:35446865	A/G	cg03585969	chr10:35415529	CREM	0.39	4.79	0.3	2.91e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs12477438	1.000	rs12466388	chr2:99916538	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-10.11	-0.55	3.61e-20	Chronic sinus infection;
SARC	cis	rs11997175	0.550	rs10105616	chr8:33786830	G/A	ch.8.33884649F	chr8:33765107	NA	0.43	5.66	0.35	4.39e-8	Body mass index;
SARC	cis	rs9911578	1.000	rs12453459	chr17:56624291	C/T	cg12560992	chr17:57184187	TRIM37	-0.81	-10.83	-0.58	2.14e-22	Intelligence (multi-trait analysis);
SARC	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg08859206	chr1:53392774	SCP2	0.36	5.22	0.32	3.96e-7	Monocyte count;
SARC	cis	rs7772486	0.754	rs12199362	chr6:146118225	A/G	cg05347473	chr6:146136440	FBXO30	0.57	7.97	0.46	6.94e-14	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2012796	0.743	rs61986598	chr14:81856865	G/A	cg02996355	chr14:81879375	NA	0.51	5.71	0.35	3.51e-8	Night sleep phenotypes;
SARC	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg19748678	chr4:122722346	EXOSC9	0.78	9.75	0.54	4.8e-19	Type 2 diabetes;
SARC	cis	rs3768617	0.510	rs10911254	chr1:183088627	A/G	cg13390022	chr1:182993471	LAMC1	0.32	4.83	0.3	2.44e-6	Fuchs's corneal dystrophy;
SARC	cis	rs2073499	1.000	rs3806708	chr3:50306249	T/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.6	5.51	0.34	9.67e-8	Schizophrenia;
SARC	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg07308232	chr7:1071921	C7orf50	-0.51	-6.3	-0.38	1.51e-9	Longevity;Endometriosis;
SARC	cis	rs7474896	0.507	rs2474555	chr10:38465220	G/C	cg00409905	chr10:38381863	ZNF37A	-0.54	-5.29	-0.33	2.87e-7	Obesity (extreme);
SARC	cis	rs10876993	0.890	rs1678539	chr12:58060359	A/G	cg18357645	chr12:58087776	OS9	0.44	5.73	0.35	3.02e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs10861342	1.000	rs10861360	chr12:105570041	A/G	cg23923672	chr12:105501055	KIAA1033	-0.68	-5.64	-0.35	4.99e-8	IgG glycosylation;
SARC	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs17401966	1.000	rs12130220	chr1:10359944	T/G	cg15208524	chr1:10270712	KIF1B	0.6	6.8	0.41	8.5e-11	Hepatocellular carcinoma;
SARC	cis	rs1707322	0.716	rs6699444	chr1:46135120	G/C	cg06784218	chr1:46089804	CCDC17	0.36	6.25	0.38	1.97e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs74181299	0.684	rs1420184	chr2:65315880	G/C	cg20592124	chr2:65290738	CEP68	-0.36	-4.91	-0.31	1.74e-6	Pulse pressure;
SARC	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg03806693	chr22:41940476	POLR3H	-0.94	-13.03	-0.65	1.64e-29	Vitiligo;
SARC	cis	rs778371	0.748	rs2675953	chr2:233749565	G/C	cg16596103	chr2:233749413	NGEF	0.37	5.35	0.33	2.13e-7	Schizophrenia;
SARC	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg22800045	chr5:56110881	MAP3K1	0.46	5.23	0.32	3.74e-7	Coronary artery disease;
SARC	cis	rs9467773	0.596	rs2451750	chr6:26646579	A/T	cg11502198	chr6:26597334	ABT1	0.63	8.46	0.48	2.95e-15	Intelligence (multi-trait analysis);
SARC	cis	rs644799	0.965	rs545342	chr11:95545369	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	15.35	0.71	3.21e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs7824557	0.603	rs2736278	chr8:11219781	C/T	cg06636001	chr8:8085503	FLJ10661	0.64	8.2	0.47	1.59e-14	Retinal vascular caliber;
SARC	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg22920501	chr2:26401640	FAM59B	-0.56	-7.34	-0.43	3.55e-12	Gut microbiome composition (summer);
SARC	cis	rs1153858	0.943	rs12439575	chr15:45684816	T/G	cg21132104	chr15:45694354	SPATA5L1	0.77	10.75	0.58	3.66e-22	Homoarginine levels;
SARC	cis	rs72945132	0.882	rs67283107	chr11:70221204	C/T	cg05964544	chr11:70165517	PPFIA1	-0.57	-5.65	-0.35	4.7e-8	Coronary artery disease;
SARC	cis	rs34779708	0.931	rs11010082	chr10:35351155	A/G	cg03585969	chr10:35415529	CREM	0.38	4.87	0.3	2.1e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg18876405	chr7:65276391	NA	0.49	6.04	0.37	6e-9	Aortic root size;
SARC	cis	rs2180341	0.843	rs4895821	chr6:127572761	T/A	cg27446573	chr6:127587934	RNF146	1.0	13.77	0.67	5.8e-32	Breast cancer;
SARC	cis	rs546131	0.928	rs547504	chr11:34847225	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.45	5.61	0.35	5.62e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs4775413	1.000	rs11853920	chr15:61839660	A/C	cg09972561	chr15:62353371	VPS13C	0.35	4.79	0.3	2.97e-6	Schizophrenia;
SARC	cis	rs9291683	0.588	rs3733586	chr4:9997534	C/T	cg11266682	chr4:10021025	SLC2A9	0.42	7.49	0.44	1.46e-12	Bone mineral density;
SARC	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg03806693	chr22:41940476	POLR3H	0.83	11.73	0.61	2.8e-25	Vitiligo;
SARC	cis	rs698833	0.509	rs1946932	chr2:44543125	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.67	7.76	0.45	2.7e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs78487399	0.731	rs13408697	chr2:43706244	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-4.81	-0.3	2.67e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.74	8.99	0.51	8.92e-17	Height;
SARC	cis	rs1707322	1.000	rs4660318	chr1:46334876	A/G	cg03146154	chr1:46216737	IPP	0.47	5.67	0.35	4.31e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs3008870	0.727	rs11208971	chr1:67383901	G/A	cg02640540	chr1:67518911	SLC35D1	0.44	5.05	0.31	9.1e-7	Lymphocyte percentage of white cells;
SARC	cis	rs13401104	0.754	rs11687335	chr2:237117233	A/C	cg19324714	chr2:237145437	ASB18	0.58	5.83	0.36	1.87e-8	Educational attainment;
SARC	cis	rs965469	1.000	rs6037562	chr20:3326141	A/C	cg25506879	chr20:3388711	C20orf194	-0.52	-5.34	-0.33	2.2e-7	IFN-related cytopenia;
SARC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg09373136	chr17:61933544	TCAM1	-0.45	-6.17	-0.37	2.98e-9	Prudent dietary pattern;
SARC	cis	rs9388451	0.874	rs13209968	chr6:126089285	G/C	cg05901451	chr6:126070800	HEY2	-0.67	-9.34	-0.52	7.98e-18	Brugada syndrome;
SARC	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg06420487	chr17:61919686	SMARCD2	0.5	5.78	0.35	2.38e-8	Height;
SARC	cis	rs11098499	0.754	rs2036856	chr4:120249288	G/A	cg09307838	chr4:120376055	NA	0.82	11.14	0.59	2.19e-23	Corneal astigmatism;
SARC	cis	rs7927771	0.965	rs12364432	chr11:47902883	G/A	cg20307385	chr11:47447363	PSMC3	-0.47	-5.55	-0.34	7.92e-8	Subjective well-being;
SARC	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.65	-6.7	-0.4	1.58e-10	Platelet count;
SARC	cis	rs1322639	0.614	rs6908401	chr6:169564716	A/C	cg04662567	chr6:169592167	NA	0.48	4.91	0.31	1.71e-6	Pulse pressure;
SARC	cis	rs9486715	0.964	rs6921480	chr6:97066329	C/G	cg18709589	chr6:96969512	KIAA0776	-0.59	-7.34	-0.43	3.61e-12	Headache;
SARC	cis	rs6120849	0.901	rs6088733	chr20:33744904	A/G	cg24642439	chr20:33292090	TP53INP2	0.49	4.82	0.3	2.56e-6	Protein C levels;
SARC	cis	rs10870270	0.956	rs7915388	chr10:133734972	G/A	cg26149184	chr10:133730230	NA	0.47	5.39	0.33	1.68e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs2455826	0.500	rs2455852	chr3:15688688	C/T	cg16303742	chr3:15540471	COLQ	-0.41	-6.01	-0.37	7.04e-9	Inflammatory skin disease;
SARC	trans	rs1814175	0.616	rs1851848	chr11:49992254	G/C	cg03929089	chr4:120376271	NA	-0.82	-11.86	-0.61	1.06e-25	Height;
SARC	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	0.4	4.82	0.3	2.59e-6	Tonsillectomy;
SARC	cis	rs6912958	0.500	rs9342104	chr6:87798512	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.59	-7.48	-0.44	1.47e-12	Monocyte percentage of white cells;
SARC	cis	rs3761847	0.651	rs1323472	chr9:123826335	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.41	5.2	0.32	4.43e-7	Rheumatoid arthritis;
SARC	cis	rs7412746	0.658	rs4970986	chr1:150907955	A/G	cg15448220	chr1:150897856	SETDB1	0.51	6.65	0.4	2.02e-10	Melanoma;
SARC	cis	rs9300255	0.539	rs1969355	chr12:123742061	G/A	cg00376283	chr12:123451042	ABCB9	0.51	5.84	0.36	1.77e-8	Neutrophil percentage of white cells;
SARC	cis	rs79149102	0.579	rs12593476	chr15:75282092	A/C	cg17294928	chr15:75287854	SCAMP5	-1.07	-9.16	-0.51	2.75e-17	Lung cancer;
SARC	cis	rs4742903	0.935	rs10991165	chr9:106973498	A/G	cg14250997	chr9:106856677	SMC2	-0.46	-5.66	-0.35	4.35e-8	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-6.38	-0.39	9.39e-10	Personality dimensions;
SARC	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg03400443	chr2:74347616	NA	-0.45	-4.72	-0.3	4.1e-6	Gestational age at birth (maternal effect);
SARC	cis	rs9291683	0.618	rs13137343	chr4:10043028	C/A	cg00071950	chr4:10020882	SLC2A9	0.39	6.29	0.38	1.52e-9	Bone mineral density;
SARC	cis	rs8141529	0.719	rs2097461	chr22:29191879	T/C	cg15103426	chr22:29168792	CCDC117	0.69	9.09	0.51	4.51e-17	Lymphocyte counts;
SARC	cis	rs3020736	0.500	rs6002597	chr22:42488160	C/A	cg04733989	chr22:42467013	NAGA	-0.76	-10.61	-0.57	1.04e-21	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7264396	0.790	rs3746410	chr20:34190870	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.46	4.78	0.3	3.17e-6	Total cholesterol levels;
SARC	cis	rs9815354	1.000	rs9867627	chr3:41795841	G/T	cg03022575	chr3:42003672	ULK4	-0.63	-5.59	-0.34	6.37e-8	Pulse pressure;Diastolic blood pressure;
SARC	trans	rs11039798	0.511	rs7948129	chr11:48167828	G/A	cg15704280	chr7:45808275	SEPT13	-0.64	-6.47	-0.39	5.8e-10	Axial length;
SARC	cis	rs9911578	1.000	rs12947785	chr17:57045160	A/C	cg12560992	chr17:57184187	TRIM37	0.85	11.74	0.61	2.67e-25	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.679	rs16921677	chr8:58052431	T/C	cg11062466	chr8:58055876	NA	0.5	4.9	0.31	1.77e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs7617480	0.648	rs9859473	chr3:48837182	A/G	cg07636037	chr3:49044803	WDR6	0.83	8.99	0.51	8.87e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs9436747	0.667	rs6657632	chr1:66038666	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.48	5.16	0.32	5.29e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs4481887	0.927	rs4916087	chr1:248493833	T/C	cg13385794	chr1:248469461	NA	0.33	4.98	0.31	1.21e-6	Common traits (Other);
SARC	cis	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg25894440	chr7:65020034	NA	-0.62	-4.88	-0.3	2e-6	Diabetic kidney disease;
SARC	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg05863683	chr7:1912471	MAD1L1	0.35	5.21	0.32	4.25e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs7551222	0.716	rs10494852	chr1:204457786	A/G	cg07972458	chr1:204535000	NA	-0.36	-4.84	-0.3	2.31e-6	Schizophrenia;
SARC	trans	rs877282	0.898	rs12357995	chr10:765739	T/C	cg22713356	chr15:30763199	NA	1.04	10.06	0.55	5.37e-20	Uric acid levels;
SARC	trans	rs629535	0.814	rs62513371	chr8:70077779	T/A	cg21567404	chr3:27674614	NA	-1.06	-13.84	-0.67	3.53e-32	Dupuytren's disease;
SARC	cis	rs4141404	0.828	rs2413043	chr22:31648576	G/T	cg02404636	chr22:31891804	SFI1	-0.46	-4.89	-0.3	1.92e-6	Paclitaxel-induced neuropathy;
SARC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg27588902	chr6:42928151	GNMT	-0.36	-5.63	-0.35	5.17e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs138857	0.515	rs9616373	chr22:50308597	G/A	cg03033257	chr22:50311977	ALG12;CRELD2	0.66	5.01	0.31	1.06e-6	Mean platelet volume;
SARC	cis	rs2075371	0.863	rs2075370	chr7:133967812	A/G	cg11752832	chr7:134001865	SLC35B4	0.52	6.66	0.4	1.99e-10	Mean platelet volume;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg16256492	chr1:154989843	ZBTB7B	0.54	6.78	0.41	9.93e-11	Breast cancer;
SARC	cis	rs644799	1.000	rs644799	chr11:95564259	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.67	8.96	0.51	1.1e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg11764359	chr7:65958608	NA	0.88	12.58	0.64	4.89e-28	Aortic root size;
SARC	cis	rs3820928	0.904	rs59135978	chr2:227857763	T/C	cg05526886	chr2:227700861	RHBDD1	-0.49	-5.84	-0.36	1.71e-8	Pulmonary function;
SARC	cis	rs7937682	1.000	rs11213973	chr11:111538903	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.96	-15.81	-0.72	9.32e-39	Primary sclerosing cholangitis;
SARC	cis	rs111326718	1	rs111326718	chr10:104771211	A/AAAAAT	cg04362960	chr10:104952993	NT5C2	0.45	5.6	0.34	5.97e-8	Reticulocyte count;
SARC	cis	rs9747201	0.962	rs11656153	chr17:80072950	G/A	cg09264619	chr17:80180166	NA	0.51	5.74	0.35	2.91e-8	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs722599	0.748	rs929579	chr14:75330697	C/T	cg08847533	chr14:75593920	NEK9	-0.42	-4.84	-0.3	2.38e-6	IgG glycosylation;
SARC	cis	rs8084125	0.832	rs62105174	chr18:74948324	G/A	cg05528293	chr18:74961138	GALR1	0.51	5.74	0.35	2.95e-8	Obesity-related traits;
SARC	cis	rs4481887	0.893	rs6587450	chr1:248480496	T/A	cg13385794	chr1:248469461	NA	0.33	5.08	0.32	7.75e-7	Common traits (Other);
SARC	cis	rs8067545	0.641	rs203455	chr17:19821185	A/G	cg04132472	chr17:19861366	AKAP10	0.38	5.08	0.32	7.88e-7	Schizophrenia;
SARC	cis	rs3540	0.554	rs34650360	chr15:91059017	T/C	cg22089800	chr15:90895588	ZNF774	-0.6	-7.47	-0.44	1.57e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs3770770	0.903	rs62133104	chr2:37242041	G/A	cg14987922	chr2:37194071	STRN	-0.51	-4.95	-0.31	1.4e-6	QRS duration;
SARC	cis	rs8012	0.537	rs741702	chr19:13024250	A/C	cg11738485	chr19:12877000	HOOK2	0.47	5.3	0.33	2.64e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
SARC	cis	rs9457247	0.765	rs2237276	chr6:167442115	C/T	cg23791538	chr6:167370224	RNASET2	-0.52	-7.0	-0.42	2.73e-11	Crohn's disease;
SARC	cis	rs7582180	0.629	rs4850926	chr2:100954117	C/T	cg14675211	chr2:100938903	LONRF2	0.51	7.63	0.45	5.86e-13	Intelligence (multi-trait analysis);
SARC	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg19077165	chr18:44547161	KATNAL2	-0.5	-6.95	-0.41	3.54e-11	Personality dimensions;
SARC	cis	rs7084402	0.967	rs1658451	chr10:60311527	A/T	cg07615347	chr10:60278583	BICC1	0.59	8.39	0.48	4.85e-15	Refractive error;
SARC	cis	rs10489202	0.686	rs11590282	chr1:167848231	C/T	cg24449463	chr1:168025552	DCAF6	-0.66	-5.76	-0.35	2.65e-8	Schizophrenia;
SARC	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg08219700	chr8:58056026	NA	0.57	6.07	0.37	5.05e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6708331	0.715	rs11899723	chr2:70196019	G/A	cg05298696	chr2:70188691	ASPRV1	-0.38	-4.79	-0.3	2.93e-6	Obesity-related traits;
SARC	cis	rs8067545	0.641	rs175922	chr17:19825579	T/C	cg13482628	chr17:19912719	NA	0.54	6.86	0.41	5.97e-11	Schizophrenia;
SARC	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg05368731	chr17:41323189	NBR1	0.8	9.77	0.54	3.97e-19	Menopause (age at onset);
SARC	cis	rs1865760	0.865	rs9467645	chr6:25955176	G/C	cg18357526	chr6:26021779	HIST1H4A	0.4	4.87	0.3	2.02e-6	Height;
SARC	cis	rs6568686	0.786	rs4458728	chr6:111840562	A/C	cg15721981	chr6:111408429	SLC16A10	0.62	5.12	0.32	6.48e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs7617773	0.743	rs4632568	chr3:48367819	C/T	cg11946769	chr3:48343235	NME6	0.77	9.81	0.54	2.97e-19	Coronary artery disease;
SARC	cis	rs7027203	0.595	rs2398876	chr9:96536853	T/C	cg14598338	chr9:96623480	NA	0.34	4.75	0.3	3.57e-6	DNA methylation (variation);
SARC	cis	rs9831754	0.704	rs7647185	chr3:78468807	T/C	cg06138941	chr3:78371609	NA	-0.54	-6.48	-0.39	5.3e-10	Calcium levels;
SARC	cis	rs908922	0.628	rs488393	chr1:152489548	C/T	cg09873164	chr1:152488093	CRCT1	0.65	8.48	0.49	2.69e-15	Hair morphology;
SARC	cis	rs7264396	0.790	rs6058288	chr20:34228680	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.68	7.57	0.44	8.54e-13	Total cholesterol levels;
SARC	cis	rs8078723	0.966	rs57968500	chr17:38145828	A/G	cg17467752	chr17:38218738	THRA	0.47	6.04	0.37	6.19e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs2439831	0.681	rs1549525	chr15:43627855	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.09	12.69	0.64	2.16e-28	Lung cancer in ever smokers;
SARC	cis	rs72945132	0.882	rs17425511	chr11:70183737	C/G	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.59	-0.34	6.44e-8	Coronary artery disease;
SARC	cis	rs4906332	1.000	rs17617832	chr14:103943140	T/C	cg26031613	chr14:104095156	KLC1	-0.49	-5.74	-0.35	2.94e-8	Coronary artery disease;
SARC	cis	rs6570726	0.935	rs585292	chr6:145862228	T/C	cg23711669	chr6:146136114	FBXO30	0.78	12.0	0.62	3.86e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9430161	0.579	rs11121667	chr1:11038476	C/T	cg02454025	chr1:11042201	C1orf127	0.84	12.47	0.63	1.1e-27	Ewing sarcoma;
SARC	trans	rs1814175	0.588	rs10466497	chr11:49864381	A/T	cg15704280	chr7:45808275	SEPT13	-0.87	-13.81	-0.67	4.37e-32	Height;
SARC	cis	rs1707322	0.821	rs10749857	chr1:46248143	C/T	cg03146154	chr1:46216737	IPP	0.5	6.13	0.37	3.79e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg11657440	chr19:46296263	DMWD	0.8	10.61	0.57	1.04e-21	Coronary artery disease;
SARC	cis	rs244731	0.959	rs10037110	chr5:176658066	A/T	cg17509989	chr5:176798049	RGS14	-0.68	-8.47	-0.49	2.85e-15	Urate levels in lean individuals;
SARC	cis	rs9916302	0.706	rs12937013	chr17:37665571	G/A	cg20243544	chr17:37824526	PNMT	0.53	5.45	0.34	1.28e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs10752881	1.000	rs4454510	chr1:182982303	A/G	cg13390022	chr1:182993471	LAMC1	-0.32	-4.99	-0.31	1.19e-6	Colorectal cancer;
SARC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg21747090	chr2:27597821	SNX17	-0.55	-7.68	-0.45	4.41e-13	Total body bone mineral density;
SARC	cis	rs79149102	0.579	rs6495135	chr15:75295030	T/C	cg17294928	chr15:75287854	SCAMP5	-0.99	-8.87	-0.5	1.91e-16	Lung cancer;
SARC	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg11764359	chr7:65958608	NA	-0.86	-12.41	-0.63	1.78e-27	Aortic root size;
SARC	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg13628971	chr7:2884303	GNA12	0.65	7.35	0.43	3.26e-12	Height;
SARC	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg07701084	chr6:150067640	NUP43	0.37	4.9	0.31	1.82e-6	Lung cancer;
SARC	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg22968622	chr17:43663579	NA	-1.19	-15.98	-0.72	2.63e-39	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7084402	0.967	rs1649026	chr10:60281400	A/G	cg07615347	chr10:60278583	BICC1	-0.6	-8.82	-0.5	2.71e-16	Refractive error;
SARC	cis	rs3820928	0.874	rs4675128	chr2:227814757	T/C	cg05526886	chr2:227700861	RHBDD1	-0.53	-6.52	-0.39	4.25e-10	Pulmonary function;
SARC	cis	rs12048904	0.964	rs12027668	chr1:101330984	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.4	4.92	0.31	1.67e-6	Multiple sclerosis;
SARC	cis	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg24110177	chr3:50126178	RBM5	0.38	4.86	0.3	2.11e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7927771	0.965	rs4752881	chr11:47898535	A/G	cg20307385	chr11:47447363	PSMC3	-0.47	-5.52	-0.34	8.87e-8	Subjective well-being;
SARC	cis	rs965469	0.779	rs6133039	chr20:3385006	C/T	cg25506879	chr20:3388711	C20orf194	-0.46	-4.96	-0.31	1.34e-6	IFN-related cytopenia;
SARC	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.36	5.54	0.34	8.06e-8	Schizophrenia;
SARC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg24846343	chr22:24311635	DDTL	0.51	7.43	0.44	2.05e-12	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7666738	0.830	rs10017557	chr4:98983969	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs748404	0.586	rs2584700	chr15:43685332	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.4	4.79	0.3	2.99e-6	Lung cancer;
SARC	cis	rs2396442	1.000	rs2256819	chr6:45418402	A/G	cg19569551	chr6:45346086	SUPT3H;RUNX2	0.45	4.8	0.3	2.79e-6	Left ventricle wall thickness;
SARC	cis	rs533123	0.818	rs204051	chr1:29166578	A/G	cg08366446	chr1:29138936	OPRD1	0.86	6.64	0.4	2.21e-10	Schizophrenia;
SARC	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	10.48	0.57	2.62e-21	Alzheimer's disease;
SARC	cis	rs6570726	0.764	rs9322028	chr6:145895797	G/T	cg23711669	chr6:146136114	FBXO30	0.84	13.98	0.68	1.14e-32	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6831352	0.918	rs2602891	chr4:100043284	C/T	cg13256891	chr4:100009986	ADH5	0.66	8.34	0.48	6.55e-15	Alcohol dependence;
SARC	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	12.45	0.63	1.33e-27	Platelet count;
SARC	cis	rs7178572	0.849	rs12901503	chr15:77819056	A/G	cg22256960	chr15:77711686	NA	-0.51	-5.71	-0.35	3.36e-8	Type 2 diabetes;
SARC	cis	rs2273669	0.915	rs7738483	chr6:109341834	C/T	cg05315195	chr6:109294784	ARMC2	-0.51	-5.11	-0.32	6.7e-7	Prostate cancer;
SARC	cis	rs77633900	0.614	rs280024	chr15:77034518	A/C	cg21673338	chr15:77095150	SCAPER	-0.6	-5.05	-0.31	8.84e-7	Non-glioblastoma glioma;Glioma;
SARC	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg02725872	chr8:58115012	NA	-0.36	-6.44	-0.39	6.94e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7927592	0.513	rs531163	chr11:68194496	A/G	cg01657329	chr11:68192670	LRP5	-0.38	-5.04	-0.31	9.25e-7	Total body bone mineral density;
SARC	cis	rs3892630	0.588	rs2112917	chr19:33317543	C/T	cg22980127	chr19:33182716	NUDT19	1.01	10.8	0.58	2.56e-22	Red blood cell traits;
SARC	cis	rs1395	0.778	rs6749393	chr2:27451000	C/T	cg21747090	chr2:27597821	SNX17	-0.49	-5.88	-0.36	1.4e-8	Blood metabolite levels;
SARC	cis	rs7666738	1.000	rs13124102	chr4:98990696	G/A	cg05340658	chr4:99064831	C4orf37	0.57	7.09	0.42	1.58e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs929354	0.772	rs1182444	chr7:157024510	A/G	cg05182265	chr7:156933206	UBE3C	0.32	4.82	0.3	2.59e-6	Body mass index;
SARC	cis	rs752010	0.655	rs10890145	chr1:42086290	A/G	cg06885757	chr1:42089581	HIVEP3	0.43	6.68	0.4	1.7e-10	Lupus nephritis in systemic lupus erythematosus;
SARC	trans	rs1973993	0.689	rs17131755	chr1:96886167	G/A	cg10631902	chr5:14652156	NA	-0.41	-6.48	-0.39	5.42e-10	Weight;
SARC	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.46	5.14	0.32	5.84e-7	Renal function-related traits (BUN);
SARC	cis	rs9916302	0.904	rs4794813	chr17:37670994	A/T	cg15445000	chr17:37608096	MED1	0.42	5.04	0.31	9.31e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs6815814	0.950	rs11722889	chr4:38810975	C/T	cg02016764	chr4:38805732	TLR1	-0.41	-4.86	-0.3	2.18e-6	Breast cancer;
SARC	cis	rs3796352	1.000	rs11720191	chr3:53013839	T/C	cg27565382	chr3:53032988	SFMBT1	0.83	5.68	0.35	4e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs4601821	0.823	rs4938013	chr11:113264470	A/C	cg14159747	chr11:113255604	NA	0.4	5.31	0.33	2.54e-7	Alcoholic chronic pancreatitis;
SARC	cis	rs7959452	0.535	rs7308481	chr12:69659299	A/G	cg20891283	chr12:69753455	YEATS4	0.42	5.6	0.34	6.1e-8	Blood protein levels;
SARC	cis	rs10489202	0.608	rs7533646	chr1:168077593	A/C	cg24449463	chr1:168025552	DCAF6	-0.57	-7.26	-0.43	5.7e-12	Schizophrenia;
SARC	cis	rs4319547	0.915	rs7316734	chr12:123117425	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.55	-6.45	-0.39	6.24e-10	Body mass index;
SARC	trans	rs61931739	0.534	rs11052991	chr12:34059018	G/T	cg13010199	chr12:38710504	ALG10B	-0.62	-8.42	-0.48	3.79e-15	Morning vs. evening chronotype;
SARC	trans	rs1814175	0.645	rs4598671	chr11:50003191	C/A	cg15704280	chr7:45808275	SEPT13	-0.9	-14.33	-0.68	7.84e-34	Height;
SARC	cis	rs282587	0.569	rs7987238	chr13:113409944	G/A	cg02820901	chr13:113351484	ATP11A	-0.49	-4.75	-0.3	3.51e-6	Glycated hemoglobin levels;
SARC	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg22535103	chr8:58192502	C8orf71	-0.7	-8.34	-0.48	6.61e-15	Developmental language disorder (linguistic errors);
SARC	cis	rs2562456	0.917	rs2681392	chr19:21695987	T/G	cg00806126	chr19:22604979	ZNF98	0.47	4.85	0.3	2.27e-6	Pain;
SARC	cis	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg20965017	chr5:231967	SDHA	-0.55	-5.28	-0.33	2.98e-7	Breast cancer;
SARC	cis	rs34779708	0.931	rs67261877	chr10:35386340	T/A	cg03585969	chr10:35415529	CREM	0.41	4.98	0.31	1.21e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs9341808	0.935	rs4706113	chr6:80839315	C/T	cg08355045	chr6:80787529	NA	0.36	5.91	0.36	1.2e-8	Sitting height ratio;
SARC	cis	rs9355610	0.609	rs9366076	chr6:167373708	C/T	cg23791538	chr6:167370224	RNASET2	0.54	6.19	0.38	2.65e-9	Graves' disease;
SARC	trans	rs61931739	0.500	rs7303318	chr12:34467789	T/C	cg13010199	chr12:38710504	ALG10B	0.75	10.59	0.57	1.21e-21	Morning vs. evening chronotype;
SARC	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.44	5.41	0.33	1.54e-7	Tonsillectomy;
SARC	cis	rs10875746	0.903	rs10875735	chr12:48463806	T/C	cg26205652	chr12:48591994	NA	0.56	6.05	0.37	5.72e-9	Longevity (90 years and older);
SARC	cis	rs911555	0.519	rs8014069	chr14:104004311	A/C	cg26031613	chr14:104095156	KLC1	0.42	4.82	0.3	2.56e-6	Intelligence (multi-trait analysis);
SARC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	18.94	0.78	4.67e-49	Prudent dietary pattern;
SARC	cis	rs2295359	1.000	rs963427	chr1:67609347	A/G	cg03340356	chr1:67600835	NA	0.34	5.03	0.31	9.76e-7	Psoriasis;
SARC	cis	rs76419734	0.510	rs3943980	chr4:106676766	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	-0.7	-7.02	-0.42	2.43e-11	Post bronchodilator FEV1;
SARC	trans	rs2727020	0.704	rs2988340	chr11:49176057	C/T	cg03929089	chr4:120376271	NA	-0.59	-7.86	-0.46	1.41e-13	Coronary artery disease;
SARC	cis	rs6840360	0.806	rs13149588	chr4:152717757	C/T	cg22705602	chr4:152727874	NA	0.37	6.55	0.39	3.66e-10	Intelligence (multi-trait analysis);
SARC	cis	rs36051895	0.632	rs7040922	chr9:5174829	A/G	cg02405213	chr9:5042618	JAK2	0.43	5.17	0.32	5.12e-7	Pediatric autoimmune diseases;
SARC	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg22920501	chr2:26401640	FAM59B	-0.55	-7.06	-0.42	1.89e-11	Gut microbiome composition (summer);
SARC	cis	rs763121	0.853	rs7289855	chr22:39042221	G/T	cg21395723	chr22:39101663	GTPBP1	0.62	7.01	0.42	2.49e-11	Menopause (age at onset);
SARC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.63	-6.51	-0.39	4.53e-10	Platelet count;
SARC	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg11987759	chr7:65425863	GUSB	0.48	5.87	0.36	1.48e-8	Aortic root size;
SARC	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg02725872	chr8:58115012	NA	-0.34	-5.37	-0.33	1.91e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs986417	1.000	rs1254302	chr14:60885343	A/C	cg27398547	chr14:60952738	C14orf39	-0.99	-9.0	-0.51	8.36e-17	Gut microbiota (bacterial taxa);
SARC	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg25036284	chr2:26402008	FAM59B	0.46	5.59	0.34	6.48e-8	Gut microbiome composition (summer);
SARC	cis	rs2380220	0.872	rs67846436	chr6:95951521	G/T	cg23517279	chr6:96025343	MANEA	-0.54	-5.39	-0.33	1.76e-7	Behavioural disinhibition (generation interaction);
SARC	cis	rs240764	0.578	rs9322216	chr6:101251720	A/C	cg09795085	chr6:101329169	ASCC3	-0.44	-5.55	-0.34	7.79e-8	Neuroticism;
SARC	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg11211951	chr8:145729740	GPT	-0.6	-9.2	-0.52	2.07e-17	Age at first birth;
SARC	cis	rs1448094	0.967	rs10779222	chr12:86330775	G/A	cg02569458	chr12:86230093	RASSF9	0.4	5.81	0.36	2.07e-8	Major depressive disorder;
SARC	cis	rs67478160	0.572	rs8016014	chr14:104293798	G/C	cg26031613	chr14:104095156	KLC1	-0.42	-4.97	-0.31	1.32e-6	Schizophrenia;
SARC	cis	rs765787	0.530	rs11636018	chr15:45539137	T/C	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.81e-6	Uric acid levels;
SARC	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg03517284	chr6:25882590	NA	0.48	6.38	0.39	9.22e-10	Blood metabolite levels;
SARC	cis	rs6570726	0.935	rs365658	chr6:145844588	C/T	cg23711669	chr6:146136114	FBXO30	0.77	11.79	0.61	1.79e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg10591111	chr5:226296	SDHA	-0.56	-5.08	-0.32	7.89e-7	Breast cancer;
SARC	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg03576123	chr11:487126	PTDSS2	-0.54	-5.51	-0.34	9.66e-8	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs7819412	0.715	rs2409727	chr8:11043236	C/T	cg03403963	chr8:11986501	LOC392196;FAM66D	-0.36	-5.15	-0.32	5.53e-7	Triglycerides;
SARC	cis	rs12190007	0.547	rs3006217	chr6:169862878	A/G	cg15038512	chr6:170123185	PHF10	-0.48	-6.58	-0.4	3.03e-10	Obesity-related traits;
SARC	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg12463550	chr7:65579703	CRCP	0.67	5.06	0.31	8.43e-7	Diabetic kidney disease;
SARC	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg05025164	chr4:1340916	KIAA1530	0.43	4.88	0.3	1.93e-6	Obesity-related traits;
SARC	cis	rs7582720	1.000	rs72926772	chr2:203804289	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg13647721	chr17:30228624	UTP6	-0.69	-5.81	-0.36	2.05e-8	Hip circumference adjusted for BMI;
SARC	cis	rs7412746	0.658	rs11204723	chr1:150731618	T/C	cg10589385	chr1:150898437	SETDB1	0.39	5.06	0.31	8.49e-7	Melanoma;
SARC	cis	rs6088590	0.561	rs764597	chr20:33161225	C/T	cg08999081	chr20:33150536	PIGU	0.43	6.53	0.39	4.09e-10	Coronary artery disease;
SARC	cis	rs8058578	0.775	rs8046391	chr16:30836648	G/C	cg02466173	chr16:30829666	NA	-0.45	-5.99	-0.37	7.82e-9	Multiple myeloma;
SARC	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg08677398	chr8:58056175	NA	0.42	5.07	0.32	8.07e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs13191362	1.000	rs34697913	chr6:163000187	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.49	0.34	1.04e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs62432291	0.681	rs425906	chr6:159657575	C/T	cg14500486	chr6:159655392	FNDC1	-0.64	-6.37	-0.39	9.75e-10	Joint mobility (Beighton score);
SARC	cis	rs753778	0.628	rs11579	chr8:142205132	G/A	cg18755752	chr8:142205143	DENND3	-0.55	-8.05	-0.47	4.33e-14	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs4243830	0.737	rs925745	chr1:6615690	A/G	cg04093404	chr1:6614507	TAS1R1;NOL9	0.61	5.13	0.32	5.98e-7	Body mass index;
SARC	cis	rs7398996	1	rs7398996	chr12:53659448	C/T	cg26875137	chr12:53738046	NA	0.41	5.45	0.34	1.26e-7	Total body bone mineral density (age 45-60);
SARC	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg11890956	chr21:40555474	PSMG1	1.18	20.27	0.8	2.38e-53	Cognitive function;
SARC	cis	rs933688	1.000	rs1895448	chr5:90743854	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	13.18	0.65	5.03e-30	Smoking behavior;
SARC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg26354017	chr1:205819088	PM20D1	0.85	13.08	0.65	1.1e-29	Menarche (age at onset);
SARC	cis	rs3733585	0.699	rs7677710	chr4:9969517	T/G	cg11266682	chr4:10021025	SLC2A9	-0.37	-6.48	-0.39	5.28e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs634534	0.622	rs531612	chr11:65705432	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.41	5.02	0.31	1.02e-6	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs2153535	0.601	rs2143353	chr6:8530111	T/G	cg21535247	chr6:8435926	SLC35B3	0.52	6.53	0.39	4.11e-10	Motion sickness;
SARC	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg10560079	chr2:191398806	TMEM194B	-0.64	-9.2	-0.52	2.16e-17	Pulse pressure;
SARC	cis	rs6089584	0.566	rs6061401	chr20:60607482	G/A	cg23262073	chr20:60523788	NA	-0.33	-5.0	-0.31	1.12e-6	Body mass index;
SARC	trans	rs8073060	0.544	rs225283	chr17:33934912	A/G	cg19694781	chr19:47549865	TMEM160	-0.64	-6.37	-0.39	9.89e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs56104184	0.578	rs7254608	chr19:49395774	G/T	cg03707168	chr19:49379127	PPP1R15A	0.44	5.68	0.35	4.05e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg22484793	chr3:52261325	TLR9	0.3	4.86	0.3	2.14e-6	Bipolar disorder;
SARC	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg13770153	chr20:60521292	NA	0.55	7.1	0.42	1.53e-11	Body mass index;
SARC	cis	rs9381040	0.655	rs2268194	chr6:41024447	T/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.41	-4.85	-0.3	2.31e-6	Alzheimer's disease (late onset);
SARC	cis	rs6580649	0.941	rs17122611	chr12:48458149	C/T	cg24011408	chr12:48396354	COL2A1	-0.48	-5.31	-0.33	2.56e-7	Lung cancer;
SARC	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg24642844	chr7:1081250	C7orf50	-0.59	-6.23	-0.38	2.16e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg17971929	chr21:40555470	PSMG1	0.99	13.95	0.67	1.46e-32	Cognitive function;
SARC	cis	rs7647973	0.560	rs77473999	chr3:49777660	T/C	cg07636037	chr3:49044803	WDR6	-0.59	-5.63	-0.35	5.09e-8	Menarche (age at onset);
SARC	cis	rs2153535	0.580	rs9505448	chr6:8459804	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	6.55	0.39	3.66e-10	Motion sickness;
SARC	cis	rs6456156	0.586	rs12525855	chr6:167480013	T/G	cg23791538	chr6:167370224	RNASET2	-0.54	-7.12	-0.42	1.33e-11	Primary biliary cholangitis;
SARC	cis	rs765787	0.530	rs28524974	chr15:45543528	C/T	cg24006582	chr15:45444508	DUOX1	-0.56	-7.49	-0.44	1.4e-12	Uric acid levels;
SARC	cis	rs10089	0.953	rs3805615	chr5:127519049	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	9.18	0.52	2.36e-17	Ileal carcinoids;
SARC	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg17971929	chr21:40555470	PSMG1	-1.02	-14.3	-0.68	9.98e-34	Cognitive function;
SARC	cis	rs72945132	0.556	rs57172967	chr11:70160060	G/A	cg00319359	chr11:70116639	PPFIA1	0.67	6.08	0.37	4.85e-9	Coronary artery disease;
SARC	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg07636037	chr3:49044803	WDR6	0.99	17.31	0.75	1.02e-43	Parkinson's disease;
SARC	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg04267008	chr7:1944627	MAD1L1	-0.54	-6.22	-0.38	2.33e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs2635047	0.811	rs12958943	chr18:44786818	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.51	6.55	0.39	3.58e-10	Educational attainment;
SARC	cis	rs3733585	0.631	rs4697924	chr4:10124239	A/G	cg00071950	chr4:10020882	SLC2A9	-0.39	-5.81	-0.36	2.01e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	trans	rs61931739	0.635	rs1405024	chr12:33937939	A/T	cg26384229	chr12:38710491	ALG10B	-0.57	-7.46	-0.44	1.72e-12	Morning vs. evening chronotype;
SARC	cis	rs2273669	0.915	rs6907937	chr6:109293898	T/G	cg05315195	chr6:109294784	ARMC2	-0.49	-4.82	-0.3	2.57e-6	Prostate cancer;
SARC	cis	rs6963495	0.556	rs711427	chr7:105161755	T/G	cg19920283	chr7:105172520	RINT1	0.54	5.5	0.34	9.85e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg14517863	chr17:44321492	NA	-0.32	-4.76	-0.3	3.46e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	11.03	0.59	4.93e-23	Alzheimer's disease;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg14036097	chr4:190862158	FRG1	-0.5	-6.66	-0.4	1.91e-10	Blood pressure;
SARC	cis	rs9325144	0.671	rs7306605	chr12:38730471	C/T	cg04568710	chr12:38710424	ALG10B	0.39	4.93	0.31	1.58e-6	Morning vs. evening chronotype;
SARC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg04234412	chr22:24373322	LOC391322	-0.54	-6.38	-0.39	9.26e-10	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-8.57	-0.49	1.45e-15	Alzheimer's disease;
SARC	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg01475735	chr3:40494733	NA	0.48	5.56	0.34	7.37e-8	Renal cell carcinoma;
SARC	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg19077165	chr18:44547161	KATNAL2	-0.53	-7.25	-0.43	6.03e-12	Personality dimensions;
SARC	cis	rs2963155	0.518	rs852978	chr5:142690596	T/C	cg17617527	chr5:142782415	NR3C1	0.87	6.64	0.4	2.24e-10	Breast cancer;
SARC	cis	rs2153535	0.580	rs1577468	chr6:8444266	C/A	cg21535247	chr6:8435926	SLC35B3	0.56	7.01	0.42	2.6e-11	Motion sickness;
SARC	cis	rs9323205	0.798	rs2999391	chr14:51655109	A/G	cg23942311	chr14:51606299	NA	0.29	4.72	0.3	4.06e-6	Cancer;
SARC	cis	rs2033711	0.870	rs4801583	chr19:58918405	A/G	cg13877915	chr19:58951672	ZNF132	0.66	9.91	0.54	1.51e-19	Uric acid clearance;
SARC	cis	rs7914558	1.000	rs11191541	chr10:104824199	A/G	cg04362960	chr10:104952993	NT5C2	0.42	5.12	0.32	6.3e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs6752107	1.000	rs34123137	chr2:234167881	T/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.48	6.22	0.38	2.22e-9	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs2204008	0.743	rs2132212	chr12:38039405	G/A	cg13010199	chr12:38710504	ALG10B	0.67	8.9	0.5	1.59e-16	Bladder cancer;
SARC	cis	rs11711311	0.747	rs7638449	chr3:113343646	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	6.27	0.38	1.7e-9	IgG glycosylation;
SARC	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.95	9.65	0.53	9.29e-19	Platelet count;
SARC	cis	rs17376456	0.877	rs35075119	chr5:93385457	T/C	cg21475434	chr5:93447410	FAM172A	0.87	7.91	0.46	1.06e-13	Diabetic retinopathy;
SARC	cis	rs8102137	0.637	rs7250406	chr19:30325379	G/A	cg27475126	chr19:30303651	CCNE1	-0.34	-4.77	-0.3	3.25e-6	Bladder cancer;
SARC	cis	rs9457247	1.000	rs385113	chr6:167403971	A/G	cg23791538	chr6:167370224	RNASET2	-0.63	-8.73	-0.5	4.84e-16	Crohn's disease;
SARC	cis	rs72781680	0.898	rs72788218	chr2:24090435	C/T	cg06627628	chr2:24431161	ITSN2	-0.65	-6.43	-0.39	7.08e-10	Lymphocyte counts;
SARC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.42	0.53	4.72e-18	Prudent dietary pattern;
SARC	cis	rs7264396	0.676	rs6060727	chr20:34556000	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	5.3	0.33	2.71e-7	Total cholesterol levels;
SARC	cis	rs1707322	1.000	rs4606257	chr1:46307268	G/A	cg03146154	chr1:46216737	IPP	0.51	6.17	0.37	2.94e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs9616064	0.506	rs2542038	chr22:47059282	C/T	cg05621596	chr22:47072043	GRAMD4	-0.5	-7.26	-0.43	5.69e-12	Urate levels in obese individuals;
SARC	cis	rs8180040	0.726	rs4234465	chr3:47026885	C/G	cg27129171	chr3:47204927	SETD2	0.56	7.58	0.44	8.32e-13	Colorectal cancer;
SARC	cis	rs9325144	0.505	rs7955162	chr12:38711658	G/A	cg13010199	chr12:38710504	ALG10B	0.71	9.93	0.55	1.31e-19	Morning vs. evening chronotype;
SARC	cis	rs1957429	0.901	rs3813422	chr14:65347404	G/A	cg23373153	chr14:65346875	NA	1.07	11.5	0.6	1.53e-24	Pediatric areal bone mineral density (radius);
SARC	cis	rs17376456	0.877	rs12109629	chr5:93359702	A/G	cg25358565	chr5:93447407	FAM172A	1.3	14.78	0.7	2.47e-35	Diabetic retinopathy;
SARC	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg24675658	chr1:53192096	ZYG11B	0.78	11.25	0.59	9.66e-24	Monocyte count;
SARC	cis	rs6840360	1.000	rs1864300	chr4:152663326	T/C	cg22705602	chr4:152727874	NA	-0.37	-6.51	-0.39	4.54e-10	Intelligence (multi-trait analysis);
SARC	cis	rs1008375	1.000	rs1121090	chr4:17676437	C/G	cg02297831	chr4:17616191	MED28	0.43	5.47	0.34	1.16e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6582630	0.555	rs2197308	chr12:38281261	A/G	cg04568710	chr12:38710424	ALG10B	-0.4	-4.77	-0.3	3.21e-6	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2933343	0.729	rs813732	chr3:128619357	C/T	cg25356066	chr3:128598488	ACAD9	0.73	9.49	0.53	2.84e-18	IgG glycosylation;
SARC	cis	rs7208859	0.673	rs12103588	chr17:29197460	C/T	cg13385521	chr17:29058706	SUZ12P	0.86	7.34	0.43	3.54e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs2070433	0.500	rs9306156	chr21:47960493	T/C	cg12379764	chr21:47803548	PCNT	0.52	5.87	0.36	1.46e-8	Lymphocyte counts;
SARC	cis	rs3780378	0.967	rs7043371	chr9:5040203	T/A	cg02405213	chr9:5042618	JAK2	-0.44	-5.39	-0.33	1.75e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
SARC	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg05863683	chr7:1912471	MAD1L1	0.33	4.8	0.3	2.82e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2204008	0.623	rs1315348	chr12:38163044	G/A	cg26384229	chr12:38710491	ALG10B	-0.67	-8.62	-0.49	1.05e-15	Bladder cancer;
SARC	cis	rs3796352	1.000	rs34933390	chr3:53006265	T/G	cg15956490	chr3:53032818	SFMBT1	0.71	4.88	0.3	1.97e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg25072359	chr17:41440525	NA	0.48	5.62	0.35	5.43e-8	Menopause (age at onset);
SARC	cis	rs6568686	0.786	rs2146459	chr6:111815963	T/C	cg15721981	chr6:111408429	SLC16A10	-0.6	-4.84	-0.3	2.32e-6	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs7252981	0.632	rs8113682	chr19:19743730	T/G	cg03709012	chr19:19516395	GATAD2A	-0.59	-6.38	-0.39	9.55e-10	Perceived unattractiveness to mosquitoes;
SARC	cis	rs12367572	0.965	rs10880696	chr12:45234989	A/G	cg04608330	chr12:45269318	NELL2	0.51	6.41	0.39	8.1e-10	Gut microbiome composition (summer);
SARC	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg24209194	chr3:40518798	ZNF619	0.66	7.86	0.46	1.42e-13	Renal cell carcinoma;
SARC	cis	rs7937682	0.883	rs659529	chr11:111436896	T/A	cg09085632	chr11:111637200	PPP2R1B	-0.88	-13.26	-0.66	2.81e-30	Primary sclerosing cholangitis;
SARC	cis	rs4566648	0.536	rs12508182	chr4:84130153	A/G	cg21707633	chr4:83703977	SCD5	-0.36	-4.99	-0.31	1.16e-6	Monocyte count;
SARC	cis	rs9814567	0.752	rs4955547	chr3:134334975	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.52	-6.62	-0.4	2.39e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs7635838	0.892	rs9870881	chr3:11447082	A/G	cg00170343	chr3:11313890	ATG7	0.61	8.23	0.47	1.33e-14	HDL cholesterol;
SARC	cis	rs858239	0.539	rs6461694	chr7:23187779	G/A	cg23682824	chr7:23144976	KLHL7	0.65	8.12	0.47	2.63e-14	Cerebrospinal fluid biomarker levels;
SARC	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg26338869	chr17:61819248	STRADA	-0.71	-9.18	-0.52	2.48e-17	Prudent dietary pattern;
SARC	cis	rs2273669	0.915	rs12191613	chr6:109289203	G/A	cg05315195	chr6:109294784	ARMC2	-0.48	-4.76	-0.3	3.42e-6	Prostate cancer;
SARC	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.51	-5.86	-0.36	1.57e-8	Systemic lupus erythematosus;
SARC	cis	rs77669868	0.929	rs3782002	chr11:114070563	A/T	cg01914181	chr11:114070210	ZBTB16	0.45	5.57	0.34	7.16e-8	Monocyte percentage of white cells;
SARC	cis	rs2439831	0.850	rs28578398	chr15:44075046	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	8.62	0.49	1.07e-15	Lung cancer in ever smokers;
SARC	cis	rs4742903	0.527	rs10991114	chr9:106885616	A/G	cg14250997	chr9:106856677	SMC2	0.5	6.29	0.38	1.6e-9	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs950027	0.967	rs2643718	chr15:45794662	T/C	cg21132104	chr15:45694354	SPATA5L1	0.54	6.16	0.37	3.15e-9	Response to fenofibrate (adiponectin levels);
SARC	cis	rs17270561	0.609	rs9356985	chr6:25728098	C/T	cg17691542	chr6:26056736	HIST1H1C	0.58	7.09	0.42	1.59e-11	Iron status biomarkers;
SARC	cis	rs3733585	0.673	rs4560411	chr4:9953361	A/G	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.94	-0.36	1.06e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.46	-5.77	-0.35	2.46e-8	Lymphocyte counts;
SARC	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg21747090	chr2:27597821	SNX17	-0.54	-7.52	-0.44	1.16e-12	Total body bone mineral density;
SARC	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg09455208	chr3:40491958	NA	-0.37	-5.53	-0.34	8.71e-8	Renal cell carcinoma;
SARC	cis	rs826838	0.904	rs7973992	chr12:39168233	T/C	cg13010199	chr12:38710504	ALG10B	0.74	9.81	0.54	3e-19	Heart rate;
SARC	cis	rs607987	0.871	rs11031024	chr11:30292176	G/T	cg06241208	chr11:30344200	C11orf46	0.42	5.03	0.31	9.7e-7	Body mass index;
SARC	cis	rs6964587	1.000	rs11982213	chr7:91722966	A/G	cg17063962	chr7:91808500	NA	0.96	16.19	0.73	5.15e-40	Breast cancer;
SARC	cis	rs57994353	0.632	rs68142670	chr9:139324573	T/C	cg14169450	chr9:139327907	INPP5E	0.44	5.63	0.35	5.26e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs9303401	0.659	rs62081315	chr17:56781468	T/C	cg25039879	chr17:56429692	SUPT4H1	0.68	6.4	0.39	8.57e-10	Cognitive test performance;
SARC	cis	rs950027	0.620	rs2486274	chr15:45666228	G/T	cg26924012	chr15:45694286	SPATA5L1	0.52	6.68	0.4	1.76e-10	Response to fenofibrate (adiponectin levels);
SARC	cis	rs9660992	0.762	rs1668871	chr1:205237137	T/C	cg21545522	chr1:205238299	TMCC2	0.45	6.35	0.38	1.11e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg11062466	chr8:58055876	NA	0.67	6.06	0.37	5.41e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg12463550	chr7:65579703	CRCP	-0.49	-5.24	-0.32	3.63e-7	Aortic root size;
SARC	cis	rs7833790	0.724	rs10958045	chr8:82722994	T/C	cg27398817	chr8:82754497	SNX16	-0.44	-5.58	-0.34	6.51e-8	Diastolic blood pressure;
SARC	cis	rs1348850	0.567	rs3770012	chr2:178538023	A/G	cg22681709	chr2:178499509	PDE11A	0.37	5.09	0.32	7.53e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs3820928	0.874	rs9288618	chr2:227872617	A/G	cg11843606	chr2:227700838	RHBDD1	-0.55	-7.03	-0.42	2.26e-11	Pulmonary function;
SARC	cis	rs2832077	1.000	rs12329875	chr21:30137796	C/T	cg03476357	chr21:30257390	N6AMT1	-0.59	-5.64	-0.35	4.9e-8	Cognitive test performance;
SARC	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg02931644	chr1:25747376	RHCE	-0.44	-7.22	-0.43	7.18e-12	Plateletcrit;Mean corpuscular volume;
SARC	cis	rs1386809	1.000	rs1857764	chr12:55417725	A/C	cg20056324	chr12:55413610	NEUROD4	0.42	4.86	0.3	2.18e-6	IgG glycosylation;
SARC	cis	rs12545109	0.959	rs12546307	chr8:57314790	T/A	cg19413350	chr8:57351067	NA	-0.41	-4.78	-0.3	3.14e-6	Obesity-related traits;
SARC	trans	rs5760092	0.755	rs11090298	chr22:24262061	G/A	cg06437703	chr8:37914619	EIF4EBP1	0.68	7.72	0.45	3.31e-13	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs7171869	1	rs7171869	chr15:78900909	A/G	cg06917634	chr15:78832804	PSMA4	0.46	5.1	0.32	7.09e-7	Post bronchodilator FEV1;
SARC	cis	rs7412746	0.611	rs16827671	chr1:150738759	T/C	cg10589385	chr1:150898437	SETDB1	0.4	5.31	0.33	2.53e-7	Melanoma;
SARC	cis	rs17401966	0.800	rs2039778	chr1:10354601	A/G	cg15208524	chr1:10270712	KIF1B	0.47	5.59	0.34	6.44e-8	Hepatocellular carcinoma;
SARC	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg26335602	chr6:28129616	ZNF389	0.52	5.84	0.36	1.75e-8	Depression;
SARC	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg16325326	chr1:53192061	ZYG11B	-0.91	-16.08	-0.73	1.21e-39	Monocyte count;
SARC	cis	rs908922	0.702	rs569232	chr1:152526643	A/G	cg09873164	chr1:152488093	CRCT1	0.63	8.13	0.47	2.49e-14	Hair morphology;
SARC	cis	rs933688	0.502	rs4916858	chr5:90601290	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.55	-6.4	-0.39	8.26e-10	Smoking behavior;
SARC	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg26681399	chr22:41777847	TEF	-0.46	-5.05	-0.31	8.79e-7	Vitiligo;
SARC	cis	rs1059312	0.966	rs12368452	chr12:129277164	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.47	-5.86	-0.36	1.57e-8	Systemic lupus erythematosus;
SARC	cis	rs7681440	0.804	rs1442140	chr4:90816023	A/G	cg02192967	chr4:90758406	SNCA	0.36	4.98	0.31	1.25e-6	Dementia with Lewy bodies;
SARC	cis	rs4713118	0.513	rs149958	chr6:28013617	A/C	cg17221315	chr6:27791827	HIST1H4J	0.45	4.84	0.3	2.4e-6	Parkinson's disease;
SARC	cis	rs79349575	0.783	rs55771415	chr17:46999937	C/T	cg16584676	chr17:46985605	UBE2Z	0.53	6.39	0.39	8.93e-10	Type 2 diabetes;
SARC	cis	rs7766436	0.621	rs2294822	chr6:22596815	C/T	cg13666174	chr6:22585274	NA	0.47	6.49	0.39	5.22e-10	Coronary artery disease;
SARC	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg11890956	chr21:40555474	PSMG1	0.78	10.78	0.58	3.03e-22	Cognitive function;
SARC	cis	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg07636037	chr3:49044803	WDR6	0.64	6.51	0.39	4.58e-10	Menarche (age at onset);
SARC	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.6	7.3	0.43	4.42e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs748404	0.676	rs4401024	chr15:43650335	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	5.83	0.36	1.79e-8	Lung cancer;
SARC	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg18252515	chr7:66147081	NA	0.58	6.26	0.38	1.79e-9	Aortic root size;
SARC	cis	rs7481584	0.646	rs434114	chr11:3050210	A/G	cg08508325	chr11:3079039	CARS	0.23	5.15	0.32	5.5e-7	Calcium levels;
SARC	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg11366901	chr6:160182831	ACAT2	1.01	10.55	0.57	1.64e-21	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg00933542	chr6:150070202	PCMT1	0.3	4.89	0.31	1.89e-6	Lung cancer;
SARC	cis	rs9926296	0.715	rs467035	chr16:89740285	C/G	cg27121462	chr16:89883253	FANCA	0.42	5.16	0.32	5.37e-7	Vitiligo;
SARC	cis	rs449789	0.681	rs12529478	chr6:159704722	T/C	cg14500486	chr6:159655392	FNDC1	-0.44	-5.02	-0.31	1.01e-6	Pulse pressure;
SARC	cis	rs2481665	0.510	rs2481676	chr1:62627675	C/T	cg18591186	chr1:62594603	INADL	-0.61	-9.09	-0.51	4.29e-17	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs7659604	0.540	rs4833775	chr4:122716826	T/C	cg19748678	chr4:122722346	EXOSC9	-0.41	-4.95	-0.31	1.45e-6	Type 2 diabetes;
SARC	cis	rs7086627	0.515	rs10887900	chr10:82210265	A/G	cg01528321	chr10:82214614	TSPAN14	0.63	8.56	0.49	1.52e-15	Post bronchodilator FEV1;
SARC	cis	rs7681440	0.904	rs58864428	chr4:90766986	T/C	cg06632027	chr4:90757378	SNCA	0.39	5.66	0.35	4.49e-8	Dementia with Lewy bodies;
SARC	cis	rs2421770	0.504	rs4756213	chr11:35363566	T/C	cg13971030	chr11:35366721	SLC1A2	-0.34	-5.25	-0.33	3.39e-7	Staphylococcus aureus nasal carriage (persistent);
SARC	cis	rs11638352	1.000	rs2555385	chr15:44419459	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.77	-5.84	-0.36	1.78e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	cis	rs698813	0.572	rs13424464	chr2:44482263	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	6.09	0.37	4.53e-9	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs6964587	1.000	rs10488512	chr7:91753579	C/T	cg17063962	chr7:91808500	NA	0.94	15.69	0.72	2.43e-38	Breast cancer;
SARC	cis	rs17253792	0.822	rs28513551	chr14:56094993	G/A	cg01858014	chr14:56050164	KTN1	-0.68	-5.37	-0.33	1.86e-7	Putamen volume;
SARC	cis	rs995000	0.931	rs638305	chr1:62906537	G/T	cg06896770	chr1:63153194	DOCK7	0.89	13.58	0.66	2.52e-31	Triglyceride levels;
SARC	cis	rs765787	0.530	rs11639403	chr15:45538350	A/G	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.51e-10	Uric acid levels;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg21656520	chr2:210867290	RPE	0.49	6.56	0.39	3.44e-10	Chemerin levels;
SARC	cis	rs7940866	0.903	rs10791109	chr11:130850377	A/C	cg12179176	chr11:130786555	SNX19	0.65	8.8	0.5	3.18e-16	Schizophrenia;
SARC	cis	rs9916302	0.706	rs4287601	chr17:37513852	T/C	cg07936489	chr17:37558343	FBXL20	0.76	9.22	0.52	1.85e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs3857536	0.605	rs36040831	chr6:66876588	G/A	cg07460842	chr6:66804631	NA	-0.73	-9.68	-0.54	7.77e-19	Blood trace element (Cu levels);
SARC	cis	rs4481887	0.893	rs10888355	chr1:248457180	G/A	cg01631408	chr1:248437212	OR2T33	-0.43	-5.55	-0.34	7.73e-8	Common traits (Other);
SARC	cis	rs6484504	0.576	rs176373	chr11:31136026	G/T	cg02090638	chr11:31391270	DNAJC24;DCDC1	-0.38	-4.78	-0.3	3.09e-6	Red blood cell count;
SARC	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg05368731	chr17:41323189	NBR1	0.79	9.57	0.53	1.59e-18	Menopause (age at onset);
SARC	cis	rs9790314	0.663	rs61105146	chr3:160651949	T/A	cg04691961	chr3:161091175	C3orf57	0.6	8.41	0.48	4.19e-15	Morning vs. evening chronotype;
SARC	trans	rs12310956	0.527	rs10772117	chr12:33900096	C/T	cg13010199	chr12:38710504	ALG10B	0.62	8.29	0.48	9.11e-15	Morning vs. evening chronotype;
SARC	cis	rs910316	0.664	rs2098252	chr14:75492732	T/C	cg08847533	chr14:75593920	NEK9	0.82	11.75	0.61	2.39e-25	Height;
SARC	cis	rs897080	0.515	rs1067319	chr2:44633458	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.7	0.4	1.59e-10	Height;
SARC	cis	rs11098499	0.863	rs13149407	chr4:120437825	A/G	cg24375607	chr4:120327624	NA	0.42	4.9	0.31	1.76e-6	Corneal astigmatism;
SARC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg02725872	chr8:58115012	NA	-0.37	-6.47	-0.39	5.76e-10	Developmental language disorder (linguistic errors);
SARC	trans	rs7395662	0.504	rs2019666	chr11:48437729	C/T	cg15704280	chr7:45808275	SEPT13	-0.48	-6.55	-0.39	3.63e-10	HDL cholesterol;
SARC	cis	rs11122272	0.735	rs910824	chr1:231498773	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.17	-0.55	2.42e-20	Hemoglobin concentration;
SARC	cis	rs7220711	0.967	rs1828720	chr17:41797692	A/C	cg26893861	chr17:41843967	DUSP3	0.39	4.88	0.3	2e-6	Bone mineral density (spine);Bone mineral density (hip);
SARC	cis	rs10028773	0.666	rs12498657	chr4:120262866	G/C	cg09307838	chr4:120376055	NA	0.75	10.42	0.56	4.03e-21	Educational attainment;
SARC	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg03033257	chr22:50311977	ALG12;CRELD2	0.61	5.8	0.36	2.1e-8	Schizophrenia;
SARC	cis	rs17539620	0.534	rs7768635	chr6:154827861	C/T	cg20019720	chr6:154832845	CNKSR3	0.39	4.82	0.3	2.63e-6	Lipoprotein (a) levels;
SARC	cis	rs4642101	0.512	rs9813960	chr3:12818205	A/G	cg24848339	chr3:12840334	CAND2	0.4	6.47	0.39	5.76e-10	QRS complex (12-leadsum);
SARC	cis	rs11098499	0.874	rs6822498	chr4:120120183	T/C	cg09307838	chr4:120376055	NA	0.82	11.06	0.59	3.96e-23	Corneal astigmatism;
SARC	cis	rs763121	0.819	rs5757237	chr22:39073835	G/C	cg14440974	chr22:39074834	NA	-0.33	-4.77	-0.3	3.24e-6	Menopause (age at onset);
SARC	cis	rs7520050	0.778	rs3014216	chr1:46035760	A/T	cg06784218	chr1:46089804	CCDC17	0.28	5.04	0.31	9.2e-7	Red blood cell count;Reticulocyte count;
SARC	trans	rs3780486	0.846	rs12554995	chr9:33132044	A/G	cg20290983	chr6:43655470	MRPS18A	1.15	22.78	0.83	3.27e-61	IgG glycosylation;
SARC	cis	rs1580019	0.563	rs4723169	chr7:32567577	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.56	7.35	0.43	3.34e-12	Cognitive ability;
SARC	cis	rs10207060	0.778	rs6543581	chr2:240702308	C/T	cg20333904	chr2:240724165	NA	0.28	5.02	0.31	1.02e-6	Obesity-related traits;
SARC	cis	rs7220711	0.934	rs4793017	chr17:41780980	A/G	cg26893861	chr17:41843967	DUSP3	0.38	4.79	0.3	3.02e-6	Bone mineral density (spine);Bone mineral density (hip);
SARC	cis	rs7819412	0.645	rs10156356	chr8:11046209	T/C	cg12395012	chr8:11607386	GATA4	0.31	5.34	0.33	2.24e-7	Triglycerides;
SARC	cis	rs832540	0.898	rs331498	chr5:56249842	C/G	cg14703610	chr5:56206110	C5orf35	-0.44	-5.59	-0.34	6.49e-8	Coronary artery disease;
SARC	cis	rs80130819	0.688	rs7313023	chr12:48584179	T/C	cg05342945	chr12:48394962	COL2A1	-0.51	-5.37	-0.33	1.92e-7	Prostate cancer;
SARC	cis	rs1348850	0.632	rs13009207	chr2:178501632	A/G	cg22681709	chr2:178499509	PDE11A	-0.41	-5.4	-0.33	1.63e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs8180040	0.701	rs34103310	chr3:47073266	C/T	cg02527881	chr3:46936655	PTH1R	-0.32	-5.01	-0.31	1.06e-6	Colorectal cancer;
SARC	cis	rs1904096	0.506	rs7439869	chr4:95173779	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.48	-7.02	-0.42	2.4e-11	Type 2 diabetes;
SARC	cis	rs9916302	0.904	rs4795359	chr17:37573146	C/T	cg15445000	chr17:37608096	MED1	0.43	5.1	0.32	6.92e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg18252515	chr7:66147081	NA	0.52	5.57	0.34	6.9e-8	Aortic root size;
SARC	cis	rs7769051	1.000	rs9493438	chr6:133098349	T/C	cg07930552	chr6:133119739	C6orf192	0.94	8.55	0.49	1.69e-15	Type 2 diabetes nephropathy;
SARC	cis	rs9875589	0.957	rs60060718	chr3:13950333	G/A	cg19554555	chr3:13937349	NA	0.52	6.61	0.4	2.64e-10	Ovarian reserve;
SARC	cis	rs1048238	0.846	rs945420	chr1:16345208	G/A	cg21385522	chr1:16154831	NA	0.51	6.13	0.37	3.63e-9	Systolic blood pressure;
SARC	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg13175981	chr1:150552382	MCL1	-0.54	-6.9	-0.41	4.97e-11	Tonsillectomy;
SARC	cis	rs2213920	0.522	rs4978640	chr9:118241462	G/T	cg13918206	chr9:118159781	DEC1	0.45	4.86	0.3	2.13e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg11764359	chr7:65958608	NA	-0.86	-12.1	-0.62	1.74e-26	Aortic root size;
SARC	cis	rs6089584	0.924	rs6142906	chr20:60552554	G/C	cg13770153	chr20:60521292	NA	-0.52	-7.16	-0.42	1.02e-11	Body mass index;
SARC	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg04248312	chr19:17393744	ANKLE1	0.61	7.99	0.46	6.35e-14	Systemic lupus erythematosus;
SARC	cis	rs7264396	0.790	rs6060526	chr20:34225302	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.59	-5.89	-0.36	1.34e-8	Total cholesterol levels;
SARC	cis	rs12709013	0.636	rs1646280	chr16:58784324	G/A	cg04273148	chr16:57808038	KIFC3	0.32	4.72	0.3	4.08e-6	Blood metabolite ratios;
SARC	cis	rs4803468	1.000	rs10417311	chr19:41902038	G/A	cg09537434	chr19:41945824	ATP5SL	-0.94	-16.3	-0.73	2.27e-40	Height;
SARC	cis	rs1538970	0.961	rs7553318	chr1:45843086	A/G	cg05343316	chr1:45956843	TESK2	0.67	7.88	0.46	1.22e-13	Platelet count;
SARC	cis	rs2153535	0.601	rs2327091	chr6:8540369	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	6.49	0.39	5.1e-10	Motion sickness;
SARC	cis	rs6088580	0.524	rs6088575	chr20:33273403	C/T	cg07148914	chr20:33460835	GGT7	0.41	4.88	0.3	1.98e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs1468333	0.567	rs10045383	chr5:137689212	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.65	7.76	0.45	2.59e-13	Resting heart rate;
SARC	cis	rs62064224	0.791	rs2344977	chr17:30720573	C/G	cg18200150	chr17:30822561	MYO1D	0.4	6.29	0.38	1.56e-9	Schizophrenia;
SARC	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg18252515	chr7:66147081	NA	-0.54	-6.03	-0.37	6.23e-9	Aortic root size;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg11313997	chr5:177027589	B4GALT7	0.49	6.31	0.38	1.39e-9	Breast cancer;
SARC	trans	rs7819412	0.775	rs4545055	chr8:10935366	T/C	cg08975724	chr8:8085496	FLJ10661	-0.59	-7.79	-0.45	2.22e-13	Triglycerides;
SARC	trans	rs61931739	0.500	rs7313094	chr12:34457508	T/C	cg13010199	chr12:38710504	ALG10B	0.75	10.6	0.57	1.14e-21	Morning vs. evening chronotype;
SARC	cis	rs7712401	0.580	rs4288111	chr5:122388182	A/G	cg19412675	chr5:122181750	SNX24	-0.45	-6.13	-0.37	3.7e-9	Mean platelet volume;
SARC	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.98	11.15	0.59	2.09e-23	Platelet count;
SARC	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg08677398	chr8:58056175	NA	0.43	5.05	0.31	8.96e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg19963313	chr8:59571604	NSMAF	0.56	7.09	0.42	1.61e-11	Breast cancer;
SARC	cis	rs9393777	0.623	rs9358944	chr6:26469875	A/C	cg12826209	chr6:26865740	GUSBL1	0.83	7.61	0.45	6.76e-13	Intelligence (multi-trait analysis);
SARC	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg06028808	chr11:68637592	NA	0.45	5.8	0.36	2.14e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9818758	0.607	rs13068038	chr3:49294250	C/A	cg00383909	chr3:49044727	WDR6	0.72	6.26	0.38	1.86e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs8114671	0.562	rs6058120	chr20:33402829	A/G	cg24642439	chr20:33292090	TP53INP2	0.53	6.77	0.41	1.03e-10	Height;
SARC	cis	rs6546550	0.935	rs10202159	chr2:70062454	G/T	cg02498382	chr2:70120550	SNRNP27	-0.42	-7.11	-0.42	1.44e-11	Prevalent atrial fibrillation;
SARC	cis	rs7560272	0.538	rs11126414	chr2:73932044	G/A	cg20560298	chr2:73613845	ALMS1	0.46	6.0	0.37	7.37e-9	Schizophrenia;
SARC	cis	rs834603	0.687	rs4724578	chr7:47482829	A/C	cg23694490	chr7:47445681	TNS3	0.34	6.08	0.37	4.83e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs172166	0.637	rs1233708	chr6:28173219	C/T	cg17221315	chr6:27791827	HIST1H4J	0.43	5.21	0.32	4.11e-7	Cardiac Troponin-T levels;
SARC	cis	rs7107174	1.000	rs2512546	chr11:77957276	T/C	cg02023728	chr11:77925099	USP35	0.37	4.78	0.3	3.17e-6	Testicular germ cell tumor;
SARC	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg11987759	chr7:65425863	GUSB	0.47	6.19	0.38	2.63e-9	Aortic root size;
SARC	cis	rs763121	0.706	rs3827356	chr22:39064806	G/T	cg06022373	chr22:39101656	GTPBP1	-0.78	-10.11	-0.55	3.73e-20	Menopause (age at onset);
SARC	trans	rs3857536	0.605	rs36040831	chr6:66876588	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.73	-9.69	-0.54	7.29e-19	Blood trace element (Cu levels);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg18014247	chr2:220083722	ABCB6	0.57	7.14	0.42	1.17e-11	Breast cancer;
SARC	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.12	-19.13	-0.78	1.16e-49	Prudent dietary pattern;
SARC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg26338869	chr17:61819248	STRADA	0.79	10.62	0.57	9.65e-22	Prudent dietary pattern;
SARC	cis	rs7927771	1.000	rs12361031	chr11:47783076	G/A	cg05585544	chr11:47624801	NA	-0.36	-4.82	-0.3	2.59e-6	Subjective well-being;
SARC	cis	rs72653721	0.793	rs4713102	chr6:10968671	A/G	cg13562911	chr6:11044106	ELOVL2	0.6	6.4	0.39	8.33e-10	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	trans	rs7824557	0.527	rs2572448	chr8:11239352	G/A	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.39	-0.39	8.91e-10	Retinal vascular caliber;
SARC	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg26119090	chr2:26468346	HADHA;HADHB	0.95	13.96	0.67	1.32e-32	Gut microbiome composition (summer);
SARC	cis	rs6456156	0.792	rs10946215	chr6:167516181	A/G	cg23791538	chr6:167370224	RNASET2	0.41	5.01	0.31	1.09e-6	Primary biliary cholangitis;
SARC	cis	rs9462027	0.628	rs6921363	chr6:34770820	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.91	-0.36	1.23e-8	Systemic lupus erythematosus;
SARC	cis	rs7681440	0.904	rs28777703	chr4:90769924	A/G	cg06632027	chr4:90757378	SNCA	-0.37	-5.23	-0.32	3.86e-7	Dementia with Lewy bodies;
SARC	cis	rs73086581	1.000	rs73086508	chr20:3921715	C/T	cg02187196	chr20:3869020	PANK2	0.66	6.36	0.38	1.03e-9	Response to antidepressants in depression;
SARC	cis	rs7216064	1.000	rs62085992	chr17:65923083	T/A	cg12091567	chr17:66097778	LOC651250	-0.71	-7.25	-0.43	6.16e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs826838	0.559	rs1843891	chr12:38617018	T/C	cg13010199	chr12:38710504	ALG10B	0.52	6.58	0.4	3.09e-10	Heart rate;
SARC	cis	rs950776	0.722	rs471889	chr15:78870235	T/C	cg06917634	chr15:78832804	PSMA4	-0.76	-10.29	-0.56	1.02e-20	Sudden cardiac arrest;
SARC	cis	rs2075371	0.863	rs12707139	chr7:133954153	A/G	cg11752832	chr7:134001865	SLC35B4	0.48	5.85	0.36	1.66e-8	Mean platelet volume;
SARC	cis	rs698833	0.501	rs12473699	chr2:44507673	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	5.62	0.35	5.49e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs2486288	0.656	rs8040185	chr15:45552081	G/A	cg15395560	chr15:45543142	SLC28A2	0.29	5.63	0.35	5.17e-8	Glomerular filtration rate;
SARC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg26338869	chr17:61819248	STRADA	0.79	10.63	0.57	8.77e-22	Prudent dietary pattern;
SARC	cis	rs4660306	0.677	rs781061	chr1:45932887	T/C	cg24296786	chr1:45957014	TESK2	-0.51	-4.84	-0.3	2.37e-6	Homocysteine levels;
SARC	cis	rs963731	0.649	rs10201980	chr2:39204820	C/T	cg04010122	chr2:39346883	SOS1	0.93	6.03	0.37	6.48e-9	Corticobasal degeneration;
SARC	cis	rs16866061	0.515	rs114968850	chr2:225352461	C/G	cg12698349	chr2:225449008	CUL3	0.82	14.31	0.68	9.19e-34	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg00933542	chr6:150070202	PCMT1	0.31	5.29	0.33	2.83e-7	Lung cancer;
SARC	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg00933542	chr6:150070202	PCMT1	0.3	5.14	0.32	5.92e-7	Lung cancer;
SARC	cis	rs7091068	0.518	rs9633674	chr10:95455431	C/T	cg20715218	chr10:95462985	C10orf4	0.56	6.82	0.41	7.78e-11	Urinary tract infection frequency;
SARC	cis	rs912057	0.601	rs1294413	chr6:6739924	C/A	cg06612196	chr6:6737390	NA	0.76	12.84	0.64	6.93e-29	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	trans	rs17685	0.753	rs2302438	chr7:75677065	C/A	cg19862616	chr7:65841803	NCRNA00174	0.6	7.58	0.44	8.16e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg25072359	chr17:41440525	NA	0.48	5.2	0.32	4.31e-7	Menopause (age at onset);
SARC	cis	rs796364	0.789	rs1653297	chr2:201075483	C/T	cg23649088	chr2:200775458	C2orf69	0.66	7.87	0.46	1.36e-13	Schizophrenia;
SARC	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg06028808	chr11:68637592	NA	0.45	5.8	0.36	2.15e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg12311346	chr5:56204834	C5orf35	-0.5	-4.86	-0.3	2.17e-6	Initial pursuit acceleration;
SARC	cis	rs1215050	0.791	rs165247	chr4:98692399	A/G	cg05340658	chr4:99064831	C4orf37	0.44	5.85	0.36	1.62e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg12463550	chr7:65579703	CRCP	0.65	5.0	0.31	1.11e-6	Diabetic kidney disease;
SARC	cis	rs4481887	0.927	rs6689193	chr1:248482900	T/A	cg01631408	chr1:248437212	OR2T33	-0.37	-4.73	-0.3	3.98e-6	Common traits (Other);
SARC	cis	rs7412746	0.658	rs7526489	chr1:150726238	C/T	cg13175981	chr1:150552382	MCL1	-0.46	-5.44	-0.34	1.35e-7	Melanoma;
SARC	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg17376030	chr22:41985996	PMM1	0.62	7.41	0.44	2.28e-12	Vitiligo;
SARC	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	10.28	0.56	1.08e-20	Platelet count;
SARC	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	12.49	0.63	9.23e-28	Personality dimensions;
SARC	cis	rs6714710	0.603	rs6746768	chr2:98466647	C/T	cg26665480	chr2:98280029	ACTR1B	0.51	6.96	0.42	3.35e-11	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs7666738	0.535	rs6850010	chr4:98971601	A/T	cg05340658	chr4:99064831	C4orf37	0.67	9.01	0.51	7.44e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1729951	0.575	rs361244	chr3:136697506	C/T	cg15507776	chr3:136538369	TMEM22	0.49	5.39	0.33	1.69e-7	Neuroticism;
SARC	cis	rs2153535	0.580	rs9392220	chr6:8457946	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	10.66	0.57	7.43e-22	Motion sickness;
SARC	cis	rs9790314	0.696	rs9290069	chr3:160890946	A/G	cg04691961	chr3:161091175	C3orf57	-0.6	-8.0	-0.46	5.73e-14	Morning vs. evening chronotype;
SARC	cis	rs708547	0.914	rs58228066	chr4:57735787	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.57	-5.95	-0.36	9.62e-9	Response to bleomycin (chromatid breaks);
SARC	cis	rs7681440	0.630	rs356195	chr4:90683168	T/C	cg06632027	chr4:90757378	SNCA	0.43	5.3	0.33	2.74e-7	Dementia with Lewy bodies;
SARC	cis	rs6831352	0.918	rs2851251	chr4:100044111	A/G	cg12011299	chr4:100065546	ADH4	0.34	5.61	0.35	5.65e-8	Alcohol dependence;
SARC	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg15595755	chr5:1867978	NA	0.49	6.69	0.4	1.61e-10	Cardiovascular disease risk factors;
SARC	trans	rs11098499	0.954	rs66506550	chr4:120371445	T/A	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6952808	0.929	rs2280550	chr7:1976556	G/A	cg05863683	chr7:1912471	MAD1L1	0.34	4.94	0.31	1.47e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs11676348	1.000	rs11676348	chr2:219010146	C/T	cg00012203	chr2:219082015	ARPC2	-0.43	-5.7	-0.35	3.61e-8	Ulcerative colitis;
SARC	cis	rs933688	1.000	rs1964292	chr5:90743608	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	13.03	0.65	1.61e-29	Smoking behavior;
SARC	cis	rs1008375	0.932	rs4698629	chr4:17608884	C/G	cg02297831	chr4:17616191	MED28	0.53	6.58	0.4	3.1e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6807306	1.000	rs9864328	chr3:167398997	C/T	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.5	5.0	0.31	1.11e-6	Mean platelet volume;
SARC	cis	rs9715521	0.803	rs62301187	chr4:59840420	T/C	cg11281224	chr4:60001000	NA	-0.42	-5.23	-0.32	3.75e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs965469	1.000	rs2236087	chr20:3255905	C/T	cg25506879	chr20:3388711	C20orf194	-0.53	-5.34	-0.33	2.26e-7	IFN-related cytopenia;
SARC	cis	rs9815354	0.761	rs12186109	chr3:41836920	T/C	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg13012494	chr21:47604986	C21orf56	0.45	5.34	0.33	2.24e-7	Testicular germ cell tumor;
SARC	trans	rs3780486	0.846	rs10738905	chr9:33123627	A/G	cg20290983	chr6:43655470	MRPS18A	1.14	23.53	0.84	1.73e-63	IgG glycosylation;
SARC	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg10523679	chr1:76189770	ACADM	0.52	6.89	0.41	5.02e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7568458	0.709	rs1446669	chr2:85762209	T/C	cg02493740	chr2:85810744	VAMP5	-0.41	-5.45	-0.34	1.3e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs2295359	1.000	rs9729046	chr1:67607082	C/G	cg03340356	chr1:67600835	NA	0.33	4.91	0.31	1.74e-6	Psoriasis;
SARC	cis	rs6456156	0.565	rs12525345	chr6:167478875	T/C	cg07741184	chr6:167504864	NA	0.36	7.09	0.42	1.62e-11	Primary biliary cholangitis;
SARC	cis	rs1865760	0.566	rs9467663	chr6:26021456	C/G	cg10373733	chr6:25993375	NA	0.41	5.0	0.31	1.15e-6	Height;
SARC	cis	rs36051895	0.623	rs12349113	chr9:5254224	T/A	cg02405213	chr9:5042618	JAK2	-0.41	-4.83	-0.3	2.51e-6	Pediatric autoimmune diseases;
SARC	cis	rs62344088	0.590	rs73016639	chr5:172465	C/T	cg20965017	chr5:231967	SDHA	-0.86	-5.72	-0.35	3.24e-8	Asthma (childhood onset);
SARC	cis	rs7762018	0.891	rs12529402	chr6:170147675	A/T	cg13891659	chr6:170190454	C6orf122;C6orf208	0.55	4.88	0.3	2e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs9325144	0.647	rs12424190	chr12:39111206	A/T	cg13010199	chr12:38710504	ALG10B	-0.53	-6.47	-0.39	5.8e-10	Morning vs. evening chronotype;
SARC	cis	rs1949733	0.701	rs4696828	chr4:8455604	G/A	cg11789530	chr4:8429930	ACOX3	-0.83	-10.75	-0.58	3.89e-22	Response to antineoplastic agents;
SARC	cis	rs8017423	0.935	rs11159960	chr14:90740012	C/T	cg20276874	chr14:90721474	PSMC1	0.36	4.87	0.3	2.04e-6	Mortality in heart failure;
SARC	cis	rs4253772	0.550	rs6007818	chr22:46703776	C/T	cg24881330	chr22:46731750	TRMU	0.68	5.71	0.35	3.35e-8	LDL cholesterol;Cholesterol, total;
SARC	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	10.17	0.55	2.47e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs2204008	0.837	rs11612397	chr12:38357455	T/C	cg13010199	chr12:38710504	ALG10B	0.78	10.77	0.58	3.24e-22	Bladder cancer;
SARC	cis	rs12681366	0.537	rs9297939	chr8:95480189	A/C	cg13257157	chr8:95487014	RAD54B	0.4	4.82	0.3	2.64e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs2204008	0.702	rs8175764	chr12:38363690	T/C	cg13010199	chr12:38710504	ALG10B	0.78	10.77	0.58	3.24e-22	Bladder cancer;
SARC	cis	rs6860806	0.507	rs273901	chr5:131694360	G/T	cg04518342	chr5:131593106	PDLIM4	0.44	5.57	0.34	7.06e-8	Breast cancer;
SARC	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg17971929	chr21:40555470	PSMG1	0.95	11.62	0.61	6.15e-25	Cognitive function;
SARC	cis	rs13191362	0.935	rs13215748	chr6:163010710	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.5	0.34	1.01e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs710216	0.843	rs710214	chr1:43439282	C/T	cg07803811	chr1:43423981	SLC2A1	0.48	4.73	0.3	3.93e-6	Red cell distribution width;
SARC	cis	rs637571	0.522	rs649000	chr11:65742933	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.87	12.9	0.65	4.47e-29	Eosinophil percentage of white cells;
SARC	cis	rs2153535	0.525	rs1335644	chr6:8488041	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.45	0.6	2.26e-24	Motion sickness;
SARC	cis	rs9309711	0.736	rs9309717	chr2:3495078	C/T	cg10845886	chr2:3471009	TTC15	0.52	6.28	0.38	1.67e-9	Neurofibrillary tangles;
SARC	cis	rs7937682	1.000	rs11213973	chr11:111538903	A/T	cg22437258	chr11:111473054	SIK2	0.76	10.4	0.56	4.64e-21	Primary sclerosing cholangitis;
SARC	cis	rs950027	0.620	rs1153855	chr15:45660758	C/G	cg21132104	chr15:45694354	SPATA5L1	0.55	7.07	0.42	1.84e-11	Response to fenofibrate (adiponectin levels);
SARC	cis	rs4819052	0.679	rs8132135	chr21:46694782	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.52	6.36	0.38	1.08e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs12586317	0.586	rs2295103	chr14:35515920	C/G	cg26967526	chr14:35346199	BAZ1A	-0.59	-6.14	-0.37	3.57e-9	Psoriasis;
SARC	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	13.96	0.67	1.39e-32	Chronic sinus infection;
SARC	cis	rs526231	0.511	rs7731395	chr5:102361761	G/T	cg23492399	chr5:102201601	PAM	-0.46	-4.99	-0.31	1.19e-6	Primary biliary cholangitis;
SARC	cis	rs4481887	0.927	rs4244187	chr1:248493511	T/C	cg00666640	chr1:248458726	OR2T12	0.35	5.85	0.36	1.67e-8	Common traits (Other);
SARC	cis	rs5769765	0.954	rs5770707	chr22:50244533	G/A	cg03033257	chr22:50311977	ALG12;CRELD2	-0.56	-5.62	-0.35	5.46e-8	Schizophrenia;
SARC	cis	rs735396	0.770	rs1169314	chr12:121443116	A/G	cg04422896	chr12:121454269	C12orf43	0.4	4.93	0.31	1.54e-6	N-glycan levels;
SARC	cis	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg18252515	chr7:66147081	NA	-1.32	-11.44	-0.6	2.39e-24	Diabetic kidney disease;
SARC	cis	rs7666738	0.830	rs1426666	chr4:99030887	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg17376030	chr22:41985996	PMM1	-0.71	-8.94	-0.51	1.26e-16	Vitiligo;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg15385386	chr5:133968421	SAR1B	0.48	6.24	0.38	2.05e-9	Chemerin levels;
SARC	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg11502198	chr6:26597334	ABT1	0.65	8.92	0.5	1.44e-16	Intelligence (multi-trait analysis);
SARC	trans	rs3780486	0.801	rs10971424	chr9:33138775	T/C	cg04842962	chr6:43655489	MRPS18A	1.1	20.43	0.8	7.36e-54	IgG glycosylation;
SARC	cis	rs2075371	0.547	rs12666682	chr7:134021784	C/A	cg11752832	chr7:134001865	SLC35B4	0.49	6.1	0.37	4.45e-9	Mean platelet volume;
SARC	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.65	0.35	4.66e-8	Bipolar disorder;
SARC	cis	rs6570726	0.935	rs414222	chr6:145850482	C/T	cg05220968	chr6:146057943	EPM2A	-0.29	-5.04	-0.31	9.48e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg22535103	chr8:58192502	C8orf71	-0.81	-9.21	-0.52	1.91e-17	Developmental language disorder (linguistic errors);
SARC	cis	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg15145296	chr3:125709740	NA	-0.49	-4.74	-0.3	3.66e-6	Blood pressure (smoking interaction);
SARC	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg00149659	chr3:10157352	C3orf10	0.74	7.14	0.42	1.21e-11	Alzheimer's disease;
SARC	cis	rs1059312	0.808	rs4760533	chr12:129297651	A/G	cg09035930	chr12:129282057	SLC15A4	-0.55	-7.72	-0.45	3.41e-13	Systemic lupus erythematosus;
SARC	cis	rs1881797	1.000	rs67977965	chr1:247687835	G/A	cg18198730	chr1:247681584	NA	0.48	5.29	0.33	2.85e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs734999	0.545	rs6684865	chr1:2546229	A/G	cg20673091	chr1:2541236	MMEL1	-0.37	-5.6	-0.34	5.87e-8	Ulcerative colitis;
SARC	trans	rs34421088	0.560	rs2248325	chr8:11396874	A/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.98	-0.51	9.29e-17	Neuroticism;
SARC	cis	rs453301	0.631	rs7843789	chr8:8800561	G/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-6.94	-0.41	3.87e-11	Joint mobility (Beighton score);
SARC	cis	rs12824058	0.831	rs7299065	chr12:130809661	A/T	cg26677194	chr12:130822605	PIWIL1	0.54	7.4	0.44	2.4e-12	Menopause (age at onset);
SARC	cis	rs4555082	0.794	rs2735829	chr14:105708472	C/T	cg06808227	chr14:105710500	BRF1	-0.51	-6.54	-0.39	3.94e-10	Mean platelet volume;Platelet distribution width;
SARC	cis	rs7043114	0.525	rs10283572	chr9:95133074	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.49	-0.34	1.03e-7	Height;
SARC	cis	rs1185460	0.546	rs2508948	chr11:118951642	A/T	cg23280166	chr11:118938394	VPS11	-0.49	-5.71	-0.35	3.44e-8	Coronary artery disease;
SARC	cis	rs7582720	1.000	rs72934707	chr2:203707878	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	7.55	0.44	1e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs6545883	0.929	rs2264100	chr2:61670829	G/A	cg15711740	chr2:61764176	XPO1	-0.43	-5.19	-0.32	4.68e-7	Tuberculosis;
SARC	cis	rs10782582	0.532	rs12132503	chr1:76137762	C/G	cg10523679	chr1:76189770	ACADM	-0.43	-5.22	-0.32	4e-7	Daytime sleep phenotypes;
SARC	cis	rs10911232	0.507	rs35782443	chr1:183051502	A/C	cg13390022	chr1:182993471	LAMC1	0.33	5.06	0.31	8.41e-7	Hypertriglyceridemia;
SARC	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg08109568	chr15:31115862	NA	0.46	5.98	0.36	8.2e-9	Huntington's disease progression;
SARC	cis	rs698833	0.962	rs1065785	chr2:44660699	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.67	8.74	0.5	4.73e-16	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs4742903	0.967	rs10512325	chr9:106861191	C/T	cg21169611	chr9:106856078	SMC2	0.39	4.83	0.3	2.52e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs2153535	0.580	rs1577468	chr6:8444266	C/A	cg07606381	chr6:8435919	SLC35B3	0.78	11.09	0.59	3.11e-23	Motion sickness;
SARC	cis	rs9858542	0.953	rs7648841	chr3:49416825	G/A	cg03060546	chr3:49711283	APEH	-0.58	-7.24	-0.43	6.34e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg17221315	chr6:27791827	HIST1H4J	0.47	5.32	0.33	2.46e-7	Depression;
SARC	cis	rs734999	0.549	rs2764840	chr1:2529437	C/T	cg00980319	chr1:2560884	MMEL1	0.34	4.91	0.31	1.7e-6	Ulcerative colitis;
SARC	cis	rs2204008	0.580	rs36118148	chr12:38411812	G/A	cg26384229	chr12:38710491	ALG10B	-0.57	-7.06	-0.42	1.88e-11	Bladder cancer;
SARC	cis	rs10752881	1.000	rs10752887	chr1:182990834	T/C	cg13390022	chr1:182993471	LAMC1	0.34	5.23	0.32	3.79e-7	Colorectal cancer;
SARC	cis	rs17826219	0.706	rs8075107	chr17:29106649	C/A	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Body mass index;
SARC	cis	rs1559088	0.948	rs10408093	chr19:33597816	T/C	cg27124370	chr19:33622961	WDR88	0.44	5.86	0.36	1.6e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs11690935	0.959	rs7604918	chr2:172588094	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.99	-15.92	-0.72	4.25e-39	Schizophrenia;
SARC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.44	-5.79	-0.35	2.25e-8	Longevity;Endometriosis;
SARC	trans	rs1973993	0.689	rs17115225	chr1:96884330	C/T	cg10631902	chr5:14652156	NA	-0.42	-6.55	-0.39	3.59e-10	Weight;
SARC	cis	rs60871478	0.636	rs12532761	chr7:905229	C/T	cg05535760	chr7:792225	HEATR2	-0.73	-6.71	-0.4	1.48e-10	Cerebrospinal P-tau181p levels;
SARC	cis	rs6450176	0.625	rs56193151	chr5:53287790	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.84	-9.96	-0.55	1.09e-19	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs1707322	0.721	rs10430123	chr1:46221440	T/C	cg06784218	chr1:46089804	CCDC17	0.36	6.22	0.38	2.26e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4803468	1.000	rs3816037	chr19:41918009	C/T	cg08477640	chr19:41863820	B9D2	0.41	5.2	0.32	4.46e-7	Height;
SARC	cis	rs73001065	0.636	rs11668104	chr19:19426181	G/A	cg03709012	chr19:19516395	GATAD2A	1.09	7.25	0.43	6.03e-12	LDL cholesterol;
SARC	cis	rs7412746	0.658	rs8444	chr1:150938571	G/A	cg10589385	chr1:150898437	SETDB1	0.4	5.2	0.32	4.36e-7	Melanoma;
SARC	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg20891558	chr2:74357851	NA	0.69	9.73	0.54	5.54e-19	Gestational age at birth (maternal effect);
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg11351687	chr6:170863423	PSMB1;TBP	0.6	6.24	0.38	2e-9	Lung cancer in ever smokers;
SARC	cis	rs651907	0.557	rs7651404	chr3:101393294	C/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	6.43	0.39	6.98e-10	Colorectal cancer;
SARC	cis	rs8005677	1.000	rs8006396	chr14:23380850	A/G	cg01529538	chr14:23388837	RBM23	0.46	5.72	0.35	3.25e-8	Cognitive ability (multi-trait analysis);
SARC	cis	rs611744	0.647	rs1584373	chr8:109263399	C/A	cg21045802	chr8:109455806	TTC35	0.57	7.21	0.43	7.54e-12	Dupuytren's disease;
SARC	cis	rs3204270	1.000	rs3204270	chr17:79682051	C/T	cg26965718	chr17:79658957	HGS	-0.69	-5.06	-0.31	8.58e-7	Dental caries;
SARC	cis	rs2652822	0.525	rs1910094	chr15:63485527	G/C	cg02713581	chr15:63449717	RPS27L	0.54	6.55	0.39	3.71e-10	Metabolic traits;
SARC	cis	rs60752752	0.852	rs11580467	chr1:153377503	A/G	cg26882115	chr1:153603048	S100A1;S100A13	0.55	4.74	0.3	3.64e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs2439831	0.850	rs28513374	chr15:44125495	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	8.16	0.47	2.16e-14	Lung cancer in ever smokers;
SARC	cis	rs7772486	0.790	rs9497425	chr6:146234197	G/A	cg05347473	chr6:146136440	FBXO30	-0.46	-6.31	-0.38	1.43e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1348850	0.567	rs7605609	chr2:178534942	C/G	cg22681709	chr2:178499509	PDE11A	-0.37	-5.26	-0.33	3.2e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	trans	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg00938859	chr5:1591904	SDHAP3	0.79	7.66	0.45	5.1e-13	Breast cancer;
SARC	trans	rs61931739	0.500	rs7308338	chr12:34553181	A/G	cg26384229	chr12:38710491	ALG10B	0.84	12.54	0.63	6.36e-28	Morning vs. evening chronotype;
SARC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg26354017	chr1:205819088	PM20D1	-0.84	-13.37	-0.66	1.21e-30	Menarche (age at onset);
SARC	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg14664628	chr15:75095509	CSK	-0.51	-6.47	-0.39	5.75e-10	Breast cancer;
SARC	cis	rs6582630	0.559	rs12318620	chr12:38522340	T/C	cg26384229	chr12:38710491	ALG10B	-0.59	-7.58	-0.44	8.36e-13	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9831754	1.000	rs9831754	chr3:78353591	A/C	cg06138941	chr3:78371609	NA	-0.56	-6.66	-0.4	1.95e-10	Calcium levels;
SARC	cis	rs11997175	0.624	rs17778980	chr8:33700926	T/C	ch.8.33884649F	chr8:33765107	NA	0.63	8.6	0.49	1.21e-15	Body mass index;
SARC	cis	rs6867032	1.000	rs4413568	chr5:2016894	A/G	cg26168224	chr5:2018326	NA	0.92	15.7	0.72	2.16e-38	Gut microbiome composition (winter);
SARC	cis	rs7951870	0.645	rs2070852	chr11:46744925	C/G	cg03339077	chr11:47165057	C11orf49	-0.37	-4.97	-0.31	1.29e-6	Schizophrenia;
SARC	cis	rs5753618	0.561	rs2413049	chr22:31686144	A/G	cg02404636	chr22:31891804	SFI1	-0.48	-5.15	-0.32	5.56e-7	Colorectal cancer;
SARC	cis	rs9467711	0.651	rs35778245	chr6:25944803	G/A	cg21479132	chr6:26055353	NA	0.84	5.2	0.32	4.46e-7	Autism spectrum disorder or schizophrenia;
SARC	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg08067268	chr2:26466485	HADHB;HADHA	0.51	6.22	0.38	2.31e-9	Mean corpuscular hemoglobin;
SARC	cis	rs1008375	1.000	rs9991307	chr4:17662408	A/G	cg02297831	chr4:17616191	MED28	0.41	5.21	0.32	4.15e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs780096	1.000	rs780096	chr2:27741072	C/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-5.27	-0.33	3.15e-7	Total body bone mineral density;
SARC	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg05368731	chr17:41323189	NBR1	0.82	9.88	0.54	1.83e-19	Menopause (age at onset);
SARC	trans	rs7980799	0.682	rs61927702	chr12:33631695	A/G	cg26384229	chr12:38710491	ALG10B	-0.62	-7.61	-0.45	6.76e-13	Heart rate;Heart rate variability traits (RMSSD);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg11248049	chr14:53619600	DDHD1	0.56	6.93	0.41	4.01e-11	Breast cancer;
SARC	cis	rs9894429	0.646	rs7406522	chr17:79615396	G/T	cg10661904	chr17:79619235	PDE6G	-0.45	-6.37	-0.39	9.91e-10	Eye color traits;
SARC	cis	rs9828933	0.766	rs704361	chr3:63883671	T/G	cg16258503	chr3:63850278	ATXN7;THOC7	0.77	6.52	0.39	4.38e-10	Type 2 diabetes;
SARC	cis	rs763121	0.853	rs4821809	chr22:39065743	G/C	cg06022373	chr22:39101656	GTPBP1	0.85	10.56	0.57	1.45e-21	Menopause (age at onset);
SARC	cis	rs6831352	0.918	rs17218073	chr4:100055739	G/A	cg13256891	chr4:100009986	ADH5	-0.64	-8.0	-0.46	5.7e-14	Alcohol dependence;
SARC	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg12463550	chr7:65579703	CRCP	-0.49	-5.5	-0.34	9.88e-8	Aortic root size;
SARC	trans	rs1814175	0.645	rs28839231	chr11:50044292	G/T	cg15704280	chr7:45808275	SEPT13	-0.89	-14.15	-0.68	3.23e-33	Height;
SARC	cis	rs1552244	0.882	rs9812006	chr3:10022658	T/C	cg00149659	chr3:10157352	C3orf10	0.71	6.66	0.4	1.95e-10	Alzheimer's disease;
SARC	trans	rs61931739	0.500	rs7296061	chr12:34435009	A/G	cg26384229	chr12:38710491	ALG10B	-0.87	-12.73	-0.64	1.61e-28	Morning vs. evening chronotype;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg02994863	chr1:64059297	PGM1	-0.58	-6.55	-0.39	3.62e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs72781680	1.000	rs72796329	chr2:24141912	G/A	cg08917208	chr2:24149416	ATAD2B	0.77	7.18	0.43	9.09e-12	Lymphocyte counts;
SARC	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg18225595	chr11:63971243	STIP1	0.44	5.36	0.33	1.97e-7	Mean platelet volume;
SARC	cis	rs826838	0.900	rs11169301	chr12:39128497	C/A	cg26384229	chr12:38710491	ALG10B	0.87	12.4	0.63	1.9e-27	Heart rate;
SARC	cis	rs875971	0.545	rs10950029	chr7:65634321	A/C	cg25894440	chr7:65020034	NA	0.51	4.81	0.3	2.77e-6	Aortic root size;
SARC	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg05861140	chr6:150128134	PCMT1	-0.42	-5.22	-0.32	3.92e-7	Lung cancer;
SARC	cis	rs981844	0.683	rs1105495	chr4:154756867	T/C	cg14289246	chr4:154710475	SFRP2	-0.47	-5.62	-0.35	5.39e-8	Response to statins (LDL cholesterol change);
SARC	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg27266027	chr21:40555129	PSMG1	0.51	5.11	0.32	6.57e-7	Cognitive function;
SARC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg16145915	chr7:1198662	ZFAND2A	0.33	4.84	0.3	2.32e-6	Longevity;Endometriosis;
SARC	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs12709013	0.591	rs30841	chr16:58743723	C/T	cg04273148	chr16:57808038	KIFC3	0.39	5.38	0.33	1.85e-7	Blood metabolite ratios;
SARC	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg01316550	chr5:56110833	MAP3K1	0.54	4.92	0.31	1.62e-6	Initial pursuit acceleration;
SARC	cis	rs6456156	0.586	rs7762156	chr6:167485831	A/T	cg07741184	chr6:167504864	NA	0.36	6.99	0.42	2.83e-11	Primary biliary cholangitis;
SARC	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg11890956	chr21:40555474	PSMG1	1.18	20.18	0.8	4.68e-53	Cognitive function;
SARC	cis	rs17666538	0.792	rs58523286	chr8:675683	C/T	cg23958373	chr8:599963	NA	-0.9	-5.67	-0.35	4.14e-8	IgG glycosylation;
SARC	cis	rs7582720	1.000	rs72934512	chr2:203926271	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.72	0.45	3.5e-13	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs739401	0.572	rs739399	chr11:3016452	A/G	cg20651018	chr11:3035856	CARS	-0.48	-7.6	-0.45	7.21e-13	Longevity;
SARC	cis	rs77633900	0.614	rs2629025	chr15:76943363	G/C	cg21673338	chr15:77095150	SCAPER	-0.76	-6.36	-0.38	1.07e-9	Non-glioblastoma glioma;Glioma;
SARC	cis	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg16185493	chr20:3451615	ATRN	0.4	5.44	0.34	1.37e-7	Immature fraction of reticulocytes;
SARC	cis	rs4481887	0.927	rs28524655	chr1:248474331	C/T	cg01631408	chr1:248437212	OR2T33	-0.39	-5.06	-0.31	8.56e-7	Common traits (Other);
SARC	cis	rs9807989	0.839	rs10182710	chr2:102981306	A/G	cg09003973	chr2:102972529	NA	0.42	5.73	0.35	3.03e-8	Asthma;
SARC	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg06636001	chr8:8085503	FLJ10661	0.77	10.83	0.58	2.05e-22	Systolic blood pressure;
SARC	cis	rs12893668	0.667	rs8017628	chr14:104047428	C/T	cg26031613	chr14:104095156	KLC1	-0.59	-6.63	-0.4	2.31e-10	Reticulocyte count;
SARC	cis	rs10227331	0.846	rs10237006	chr7:157298250	A/G	cg04156418	chr7:157293606	NA	0.43	7.11	0.42	1.41e-11	Inattentive symptoms;
SARC	trans	rs61931739	0.612	rs1906137	chr12:33939676	T/A	cg13010199	chr12:38710504	ALG10B	0.51	6.44	0.39	6.63e-10	Morning vs. evening chronotype;
SARC	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg06618935	chr21:46677482	NA	-0.39	-5.2	-0.32	4.34e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2273669	0.667	rs1407241	chr6:109328432	G/A	cg05315195	chr6:109294784	ARMC2	-0.61	-5.57	-0.34	6.99e-8	Prostate cancer;
SARC	cis	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg03060546	chr3:49711283	APEH	0.59	7.42	0.44	2.22e-12	Resting heart rate;
SARC	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg11366901	chr6:160182831	ACAT2	-1.01	-10.53	-0.57	1.81e-21	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs4319547	0.695	rs11836188	chr12:122865507	T/C	cg23029597	chr12:123009494	RSRC2	0.41	5.09	0.32	7.41e-7	Body mass index;
SARC	cis	rs477692	0.673	rs511361	chr10:131365052	C/T	cg14263093	chr10:131365266	MGMT	0.36	5.13	0.32	5.98e-7	Response to temozolomide;
SARC	cis	rs910316	1.000	rs4903281	chr14:75554361	G/C	cg23033748	chr14:75592666	NEK9	0.35	4.88	0.3	1.96e-6	Height;
SARC	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.97e-8	Aortic root size;
SARC	cis	rs7589728	1.000	rs6722069	chr2:88533151	C/T	cg04511125	chr2:88470314	THNSL2	0.57	5.32	0.33	2.41e-7	Plasma clusterin levels;
SARC	cis	rs854765	0.647	rs8066764	chr17:17974668	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.62	8.42	0.48	3.76e-15	Total body bone mineral density;
SARC	cis	rs67311347	0.869	rs9832311	chr3:40381322	A/T	cg09455208	chr3:40491958	NA	0.4	6.05	0.37	5.62e-9	Renal cell carcinoma;
SARC	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg04317338	chr11:64019027	PLCB3	0.55	6.4	0.39	8.42e-10	Platelet count;
SARC	cis	rs72781680	0.611	rs72797810	chr2:24336469	G/A	cg08917208	chr2:24149416	ATAD2B	0.58	6.18	0.38	2.88e-9	Lymphocyte counts;
SARC	trans	rs3808502	0.525	rs13280813	chr8:11425105	G/T	cg06636001	chr8:8085503	FLJ10661	-0.63	-9.05	-0.51	5.84e-17	Neuroticism;
SARC	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	8.67	0.49	7.58e-16	Alzheimer's disease;
SARC	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg22535103	chr8:58192502	C8orf71	-0.74	-8.66	-0.49	8.13e-16	Developmental language disorder (linguistic errors);
SARC	cis	rs59918340	0.764	rs4961338	chr8:142230192	C/T	cg16341495	chr8:142228727	SLC45A4	0.35	5.02	0.31	1.05e-6	Immature fraction of reticulocytes;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg11172967	chr5:122847744	CSNK1G3	0.51	6.64	0.4	2.18e-10	Gallstone disease;
SARC	cis	rs5769765	1.000	rs4824106	chr22:50267822	T/C	cg03033257	chr22:50311977	ALG12;CRELD2	-0.54	-5.64	-0.35	4.81e-8	Schizophrenia;
SARC	trans	rs2420915	0.630	rs2243609	chr10:122874348	A/C	cg20938157	chr5:156693294	CYFIP2	-0.51	-6.28	-0.38	1.6e-9	Fibrinogen levels;
SARC	cis	rs6088580	0.634	rs6059779	chr20:32950325	C/T	cg08999081	chr20:33150536	PIGU	-0.45	-6.77	-0.41	1.02e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs7220711	0.902	rs4793020	chr17:41785377	G/A	cg26893861	chr17:41843967	DUSP3	0.39	4.93	0.31	1.6e-6	Bone mineral density (spine);Bone mineral density (hip);
SARC	cis	rs4268898	0.760	rs4665675	chr2:24468132	C/T	cg26838691	chr2:24397539	C2orf84	-0.42	-5.83	-0.36	1.81e-8	Asthma;
SARC	cis	rs2075371	1.000	rs2241334	chr7:133979225	C/G	cg20476274	chr7:133979776	SLC35B4	0.6	8.09	0.47	3.23e-14	Mean platelet volume;
SARC	cis	rs9462027	0.651	rs13220394	chr6:34810172	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-6.05	-0.37	5.63e-9	Systemic lupus erythematosus;
SARC	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg24549020	chr5:56110836	MAP3K1	0.81	8.46	0.48	3.01e-15	Initial pursuit acceleration;
SARC	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg00149659	chr3:10157352	C3orf10	0.69	6.38	0.39	9.6e-10	Alzheimer's disease;
SARC	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg17376030	chr22:41985996	PMM1	0.64	7.52	0.44	1.19e-12	Vitiligo;
SARC	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg23758822	chr17:41437982	NA	0.86	10.56	0.57	1.52e-21	Menopause (age at onset);
SARC	cis	rs7264396	0.635	rs2425166	chr20:34439391	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-7.07	-0.42	1.76e-11	Total cholesterol levels;
SARC	cis	rs2985684	0.894	rs2883436	chr14:50013822	T/C	cg04989706	chr14:50066350	PPIL5	-0.48	-5.1	-0.32	7.08e-7	Carotid intima media thickness;
SARC	cis	rs898097	0.578	rs2380173	chr17:80909157	G/T	cg15664640	chr17:80829946	TBCD	-0.34	-5.39	-0.33	1.73e-7	Breast cancer;
SARC	cis	rs16854884	0.770	rs951865	chr3:143812677	G/A	cg06585982	chr3:143692056	C3orf58	0.61	8.14	0.47	2.41e-14	Economic and political preferences (feminism/equality);
SARC	cis	rs11122272	0.668	rs1122131	chr1:231476501	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.55	-0.53	1.94e-18	Hemoglobin concentration;
SARC	cis	rs908922	0.676	rs1337338	chr1:152511885	G/A	cg09873164	chr1:152488093	CRCT1	0.65	8.72	0.5	5.41e-16	Hair morphology;
SARC	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg02018176	chr4:1364513	KIAA1530	0.36	5.25	0.33	3.37e-7	Longevity;
SARC	cis	rs240764	0.853	rs2001102	chr6:100978351	C/T	cg09795085	chr6:101329169	ASCC3	-0.46	-6.04	-0.37	5.97e-9	Neuroticism;
SARC	cis	rs1790761	0.692	rs10896179	chr11:67316928	C/A	cg24690094	chr11:67383802	NA	0.36	5.44	0.34	1.32e-7	Mean corpuscular volume;
SARC	cis	rs7953249	0.542	rs2244608	chr12:121416988	A/G	cg25281562	chr12:121454272	C12orf43	0.54	6.45	0.39	6.49e-10	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	trans	rs61931739	0.500	rs35391785	chr12:34444478	C/T	cg13010199	chr12:38710504	ALG10B	0.81	11.29	0.59	7.09e-24	Morning vs. evening chronotype;
SARC	cis	rs9790314	0.967	rs336541	chr3:161056698	A/C	cg04691961	chr3:161091175	C3orf57	-0.79	-11.97	-0.62	4.71e-26	Morning vs. evening chronotype;
SARC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.65	-6.44	-0.39	6.6e-10	Platelet count;
SARC	cis	rs554111	0.656	rs12567861	chr1:21395133	C/T	cg04902671	chr1:21058625	SH2D5	0.44	5.4	0.33	1.67e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs918629	0.724	rs3734131	chr5:95278679	G/A	cg16656078	chr5:95278638	ELL2	-0.69	-8.14	-0.47	2.38e-14	IgG glycosylation;
SARC	cis	rs1008375	1.000	rs10939750	chr4:17692422	C/G	cg27347728	chr4:17578864	LAP3	0.46	5.65	0.35	4.76e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg10438487	chr15:99640813	NA	0.75	6.28	0.38	1.62e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9875589	0.509	rs1844108	chr3:14024328	A/G	cg19554555	chr3:13937349	NA	-0.4	-5.22	-0.32	4.03e-7	Ovarian reserve;
SARC	cis	rs5770917	0.522	rs5770916	chr22:51016098	C/T	cg25309564	chr22:51001381	C22orf41	-0.56	-4.91	-0.31	1.69e-6	Narcolepsy;
SARC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg21747090	chr2:27597821	SNX17	-0.55	-7.82	-0.46	1.81e-13	Total body bone mineral density;
SARC	cis	rs60752752	0.852	rs3006480	chr1:153355785	C/T	cg26882115	chr1:153603048	S100A1;S100A13	-0.66	-5.02	-0.31	1.03e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs11690935	0.589	rs62182403	chr2:172747182	G/A	cg13550731	chr2:172543902	DYNC1I2	0.52	6.71	0.4	1.46e-10	Schizophrenia;
SARC	cis	rs881375	0.933	rs7021206	chr9:123684157	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.47	-5.59	-0.34	6.34e-8	Rheumatoid arthritis;
SARC	cis	rs6500602	0.679	rs736685	chr16:4508606	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.36	6.09	0.37	4.73e-9	Schizophrenia;
SARC	cis	rs2836633	0.929	rs8130434	chr21:40036243	C/T	cg12884169	chr21:40033163	ERG	-0.5	-9.13	-0.51	3.31e-17	Coronary artery disease;
SARC	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg23758822	chr17:41437982	NA	0.85	11.08	0.59	3.39e-23	Menopause (age at onset);
SARC	cis	rs10979	1.000	rs1416208	chr6:143889241	T/A	cg25407410	chr6:143891975	LOC285740	-0.64	-8.64	-0.49	9.21e-16	Hypospadias;
SARC	cis	rs561341	0.739	rs7213369	chr17:30211878	G/A	cg13647721	chr17:30228624	UTP6	-0.71	-6.98	-0.42	3.02e-11	Hip circumference adjusted for BMI;
SARC	trans	rs1973993	0.691	rs553785	chr1:96895325	G/A	cg10631902	chr5:14652156	NA	0.51	8.81	0.5	2.85e-16	Weight;
SARC	trans	rs13098911	0.540	rs71327015	chr3:46102173	G/C	cg03842258	chr15:67135396	NA	0.78	6.27	0.38	1.74e-9	Celiac disease;
SARC	cis	rs77372450	0.551	rs10866685	chr5:157104711	G/A	cg05585991	chr5:157099197	C5orf52	0.55	5.42	0.33	1.46e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs9486719	0.948	rs12203657	chr6:96883285	G/A	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.01	-0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs975210	0.656	rs16954106	chr15:70357918	C/T	cg01666796	chr15:70364327	TLE3	-0.58	-5.24	-0.32	3.51e-7	Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
SARC	cis	rs9916302	0.904	rs755500	chr17:37409865	C/T	cg15445000	chr17:37608096	MED1	0.44	5.39	0.33	1.75e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg21442419	chr1:2182373	SKI	0.38	4.83	0.3	2.42e-6	Height;
SARC	cis	rs568617	0.953	rs583887	chr11:65644027	T/C	cg00576331	chr11:65640516	EFEMP2	0.46	5.41	0.33	1.53e-7	Crohn's disease;
SARC	cis	rs654950	0.901	rs1885654	chr1:42007188	C/A	cg06885757	chr1:42089581	HIVEP3	-0.45	-6.55	-0.39	3.54e-10	Airway imaging phenotypes;
SARC	cis	rs270601	0.837	rs367805	chr5:131701279	T/C	cg24060327	chr5:131705240	SLC22A5	-0.65	-7.94	-0.46	8.44e-14	Acylcarnitine levels;
SARC	cis	rs11731606	0.508	rs57403425	chr4:95312411	G/T	cg20625393	chr4:95128694	SMARCAD1	0.57	5.39	0.33	1.75e-7	Mean platelet volume;
SARC	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg13175981	chr1:150552382	MCL1	-0.54	-6.84	-0.41	6.75e-11	Tonsillectomy;
SARC	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg18876405	chr7:65276391	NA	0.7	8.84	0.5	2.4e-16	Aortic root size;
SARC	cis	rs9303401	0.614	rs34941454	chr17:57102742	T/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.98	10.0	0.55	7.88e-20	Cognitive test performance;
SARC	trans	rs7819412	0.540	rs2409725	chr8:11041661	T/C	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.39	-0.39	8.98e-10	Triglycerides;
SARC	cis	rs2153535	0.580	rs9392224	chr6:8472614	G/A	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	cis	rs7727544	0.684	rs272889	chr5:131665378	A/G	cg24060327	chr5:131705240	SLC22A5	-0.7	-9.05	-0.51	6e-17	Blood metabolite levels;
SARC	cis	rs1448094	0.967	rs10047659	chr12:86338278	C/A	cg02569458	chr12:86230093	RASSF9	0.4	5.84	0.36	1.75e-8	Major depressive disorder;
SARC	cis	rs7005380	0.538	rs6469875	chr8:120926633	C/G	cg21744203	chr8:120868354	DSCC1	-0.46	-5.32	-0.33	2.45e-7	Interstitial lung disease;
SARC	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2404602	0.536	rs12915248	chr15:76765615	A/T	cg22467129	chr15:76604101	ETFA	-0.37	-4.91	-0.31	1.72e-6	Blood metabolite levels;
SARC	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.3	-4.72	-0.3	4.08e-6	Menopause (age at onset);
SARC	cis	rs1707322	0.928	rs10732844	chr1:46372688	T/C	cg06784218	chr1:46089804	CCDC17	0.34	5.94	0.36	1.03e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs1549733	0.559	rs4674193	chr2:218444361	C/T	cg19642148	chr3:47844666	DHX30	0.69	6.34	0.38	1.17e-9	Optic disc area;
SARC	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg04277193	chr17:41438351	NA	0.45	4.93	0.31	1.59e-6	Menopause (age at onset);
SARC	cis	rs2230307	0.572	rs621212	chr1:100559281	T/C	cg24955406	chr1:100503596	HIAT1	0.68	6.62	0.4	2.41e-10	Carotid intima media thickness;
SARC	cis	rs2645694	0.626	rs2703136	chr4:77828957	T/A	cg18351406	chr4:77819688	ANKRD56	0.4	5.6	0.34	6.14e-8	Emphysema distribution in smoking;
SARC	cis	rs1008375	0.932	rs4698629	chr4:17608884	C/G	cg27347728	chr4:17578864	LAP3	0.41	4.81	0.3	2.77e-6	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg15049968	chr18:44337910	ST8SIA5	-0.36	-5.79	-0.35	2.27e-8	Personality dimensions;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg21519867	chr5:159846116	SLU7	0.48	6.31	0.38	1.4e-9	Chemerin levels;
SARC	cis	rs3733585	0.699	rs4473653	chr4:9971058	A/G	cg11266682	chr4:10021025	SLC2A9	-0.39	-6.59	-0.4	2.93e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs9314323	0.592	rs6981737	chr8:26271100	T/G	cg11498726	chr8:26250323	BNIP3L	-0.49	-6.42	-0.39	7.39e-10	Red cell distribution width;
SARC	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg08219700	chr8:58056026	NA	0.62	6.52	0.39	4.28e-10	Developmental language disorder (linguistic errors);
SARC	trans	rs3808502	0.549	rs11991139	chr8:11428395	C/T	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.51	-0.39	4.57e-10	Neuroticism;
SARC	cis	rs1008375	0.932	rs6845288	chr4:17665498	A/T	cg27347728	chr4:17578864	LAP3	-0.48	-5.76	-0.35	2.65e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs113507773	1	rs113507773	chr6:26255739	G/A	cg13736514	chr6:26305472	NA	-0.6	-4.98	-0.31	1.23e-6	Iron status biomarkers (transferrin saturation);Iron status biomarkers (iron levels);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg04749066	chr2:192746843	NA	-0.51	-6.32	-0.38	1.33e-9	Height;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg20697188	chr5:82360356	TMEM167A;SCARNA18	0.46	6.28	0.38	1.68e-9	Thyroid stimulating hormone;
SARC	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg16606324	chr3:10149918	C3orf24	0.5	5.01	0.31	1.08e-6	Alzheimer's disease;
SARC	cis	rs898097	0.625	rs7406464	chr17:80891460	A/G	cg10494973	chr17:80897199	TBCD	0.42	5.79	0.35	2.22e-8	Breast cancer;
SARC	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg15049968	chr18:44337910	ST8SIA5	-0.36	-5.78	-0.35	2.44e-8	Personality dimensions;
SARC	cis	rs13392177	0.647	rs6718220	chr2:219066518	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.57	-7.35	-0.43	3.29e-12	Pyoderma gangrenosum in inflammatory bowel disease;
SARC	cis	rs3768617	0.565	rs3768626	chr1:183078462	A/G	cg13390022	chr1:182993471	LAMC1	0.32	4.88	0.3	1.95e-6	Fuchs's corneal dystrophy;
SARC	cis	rs2839186	0.585	rs2839154	chr21:47637760	C/T	cg08742575	chr21:47604166	C21orf56	-0.37	-4.75	-0.3	3.6e-6	Testicular germ cell tumor;
SARC	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-6.96	-0.41	3.46e-11	Gut microbiome composition (summer);
SARC	cis	rs7249142	0.597	rs7250650	chr19:19285989	A/T	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.23	4.85	0.3	2.23e-6	IgG glycosylation;
SARC	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg09455208	chr3:40491958	NA	0.38	5.58	0.34	6.74e-8	Renal cell carcinoma;
SARC	cis	rs27434	0.583	rs149544	chr5:96157854	C/G	cg16492584	chr5:96139282	ERAP1	-0.57	-7.11	-0.42	1.4e-11	Ankylosing spondylitis;
SARC	cis	rs9911578	0.835	rs58647683	chr17:56483194	T/C	cg12560992	chr17:57184187	TRIM37	-0.77	-9.93	-0.55	1.31e-19	Intelligence (multi-trait analysis);
SARC	cis	rs651907	0.535	rs17412601	chr3:101499275	T/C	cg12386194	chr3:101231763	SENP7	0.49	5.81	0.36	2.06e-8	Colorectal cancer;
SARC	cis	rs9486719	1.000	rs34209750	chr6:96882215	G/T	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.01	-0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs8103278	0.507	rs16939	chr19:46276056	C/A	cg14061069	chr19:46274453	DMPK	0.66	11.27	0.59	8.64e-24	Coronary artery disease;
SARC	cis	rs782590	0.967	rs62165172	chr2:55736237	A/G	cg18811423	chr2:55921094	PNPT1	0.73	11.57	0.6	8.91e-25	Metabolic syndrome;
SARC	cis	rs4919087	0.590	rs2861877	chr10:99053316	C/A	cg25902810	chr10:99078978	FRAT1	-0.55	-6.09	-0.37	4.53e-9	Monocyte count;
SARC	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg05896524	chr21:47604654	C21orf56	0.41	4.91	0.31	1.75e-6	Testicular germ cell tumor;
SARC	cis	rs4595586	0.545	rs7970850	chr12:39397878	T/C	cg26384229	chr12:38710491	ALG10B	0.5	6.12	0.37	3.98e-9	Morning vs. evening chronotype;
SARC	cis	rs2439831	0.850	rs12442129	chr15:44055856	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	7.55	0.44	1.01e-12	Lung cancer in ever smokers;
SARC	cis	rs1267303	0.642	rs114746843	chr1:46999239	C/A	cg25110126	chr1:46999211	NA	0.92	9.94	0.55	1.22e-19	Monobrow;
SARC	cis	rs17376456	0.825	rs36042718	chr5:93180997	C/T	cg25358565	chr5:93447407	FAM172A	1.22	12.41	0.63	1.8e-27	Diabetic retinopathy;
SARC	cis	rs7633770	0.735	rs4683271	chr3:46684823	A/G	cg11219411	chr3:46661640	NA	-0.41	-6.64	-0.4	2.15e-10	Coronary artery disease;
SARC	cis	rs282587	0.569	rs7986147	chr13:113398784	A/C	cg02820901	chr13:113351484	ATP11A	-0.5	-4.92	-0.31	1.65e-6	Glycated hemoglobin levels;
SARC	cis	rs992157	0.585	rs62182795	chr2:219100202	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.59	-7.89	-0.46	1.14e-13	Colorectal cancer;
SARC	cis	rs651907	0.535	rs17347156	chr3:101504674	G/A	cg12386194	chr3:101231763	SENP7	0.52	6.02	0.37	6.6e-9	Colorectal cancer;
SARC	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg21724239	chr8:58056113	NA	0.61	5.93	0.36	1.1e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg08219700	chr8:58056026	NA	0.7	6.57	0.4	3.23e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6429082	0.755	rs291384	chr1:235644300	C/T	cg26050004	chr1:235667680	B3GALNT2	0.66	8.09	0.47	3.2e-14	Adiposity;
SARC	cis	rs7296418	0.816	rs1790096	chr12:123710364	C/T	cg05973401	chr12:123451056	ABCB9	0.56	6.55	0.39	3.63e-10	Platelet count;
SARC	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg07636037	chr3:49044803	WDR6	0.96	16.51	0.73	4.4e-41	Parkinson's disease;
SARC	cis	rs10193935	0.892	rs6744964	chr2:42441088	A/G	cg27598129	chr2:42591480	NA	-0.38	-5.44	-0.34	1.37e-7	Colonoscopy-negative controls vs population controls;
SARC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.54	6.12	0.37	3.9e-9	Prudent dietary pattern;
SARC	cis	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg09021430	chr5:549028	NA	-0.48	-6.35	-0.38	1.12e-9	Obesity-related traits;
SARC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.52	6.78	0.41	9.88e-11	Lymphocyte counts;
SARC	cis	rs10463316	0.894	rs7719630	chr5:150760961	C/T	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.28	-0.33	2.89e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs7833790	0.724	rs72603871	chr8:82754460	C/G	cg06027949	chr8:82754900	SNX16	0.49	6.12	0.37	4.01e-9	Diastolic blood pressure;
SARC	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg11987759	chr7:65425863	GUSB	0.49	5.95	0.36	9.67e-9	Aortic root size;
SARC	cis	rs8017423	0.967	rs1005788	chr14:90692747	C/T	cg20276874	chr14:90721474	PSMC1	-0.34	-4.75	-0.3	3.63e-6	Mortality in heart failure;
SARC	cis	rs8077889	0.917	rs28694735	chr17:41912144	A/G	cg26893861	chr17:41843967	DUSP3	0.86	10.77	0.58	3.2e-22	Triglycerides;
SARC	cis	rs1559088	0.842	rs12977993	chr19:33580453	T/A	cg17764715	chr19:33622953	WDR88	0.49	6.57	0.4	3.18e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs9457247	0.935	rs2757050	chr6:167377165	G/T	cg23791538	chr6:167370224	RNASET2	0.63	8.74	0.5	4.81e-16	Crohn's disease;
SARC	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.44	-5.61	-0.35	5.63e-8	Personality dimensions;
SARC	cis	rs1008375	0.966	rs6832414	chr4:17696866	C/G	cg16339924	chr4:17578868	LAP3	0.52	6.67	0.4	1.8e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7667	0.881	rs12036866	chr1:19751333	T/C	cg15311933	chr1:19638897	PQLC2;AKR7A2	-0.43	-5.14	-0.32	5.82e-7	Crohn's disease and psoriasis;
SARC	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg08219700	chr8:58056026	NA	0.73	6.39	0.39	9.16e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs8031584	0.679	rs34017474	chr15:31230611	T/C	cg08109568	chr15:31115862	NA	-0.41	-5.23	-0.32	3.81e-7	Huntington's disease progression;
SARC	cis	rs9296092	0.517	rs62405895	chr6:33471969	G/T	cg13560919	chr6:33536144	NA	-0.46	-5.21	-0.32	4.24e-7	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg18252515	chr7:66147081	NA	0.55	5.82	0.36	1.89e-8	Aortic root size;
SARC	trans	rs7937682	0.924	rs489783	chr11:111520522	A/G	cg18187862	chr3:45730750	SACM1L	0.55	6.96	0.41	3.46e-11	Primary sclerosing cholangitis;
SARC	cis	rs4690686	0.500	rs11725547	chr4:177268444	T/C	cg17059388	chr4:177262070	NA	0.37	4.9	0.31	1.76e-6	Essential tremor;
SARC	cis	rs2304069	0.545	rs13168011	chr5:149392377	C/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.44	4.94	0.31	1.48e-6	HIV-1 control;
SARC	cis	rs17345786	0.953	rs78645744	chr3:101327789	T/A	cg12386194	chr3:101231763	SENP7	0.72	8.64	0.49	9.18e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs11155671	0.530	rs9383912	chr6:150206615	T/C	cg05036130	chr6:150231994	NA	0.29	5.05	0.31	8.9e-7	Testicular germ cell tumor;
SARC	cis	rs13256369	0.950	rs12548792	chr8:8568031	T/C	cg17143192	chr8:8559678	CLDN23	0.52	6.0	0.37	7.31e-9	Obesity-related traits;
SARC	cis	rs3540	0.512	rs7176518	chr15:91079637	C/T	cg22089800	chr15:90895588	ZNF774	-0.59	-7.39	-0.44	2.6e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs17270561	0.609	rs1892246	chr6:25764408	C/T	cg16482183	chr6:26056742	HIST1H1C	0.49	6.12	0.37	3.93e-9	Iron status biomarkers;
SARC	cis	rs7223966	1.000	rs9903903	chr17:61762044	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.73	0.4	1.32e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9815354	0.812	rs59873855	chr3:41929538	T/C	cg03022575	chr3:42003672	ULK4	0.61	5.26	0.33	3.3e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9611519	0.894	rs9623320	chr22:41478482	G/A	cg17376030	chr22:41985996	PMM1	0.5	6.01	0.37	7.2e-9	Neuroticism;
SARC	cis	rs35213789	0.887	rs622767	chr7:69189405	T/G	cg10619644	chr7:69149951	AUTS2	-0.44	-5.89	-0.36	1.34e-8	Childhood ear infection;
SARC	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg17221315	chr6:27791827	HIST1H4J	0.44	4.76	0.3	3.4e-6	Cardiac Troponin-T levels;
SARC	cis	rs561341	0.700	rs8079471	chr17:30218317	A/G	cg13647721	chr17:30228624	UTP6	0.78	9.09	0.51	4.29e-17	Hip circumference adjusted for BMI;
SARC	cis	rs861020	0.959	rs658860	chr1:209990549	C/T	cg05527609	chr1:210001259	C1orf107	0.95	10.98	0.58	7.05e-23	Orofacial clefts;
SARC	cis	rs13191362	0.507	rs2849520	chr6:163132038	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.5	-5.52	-0.34	8.95e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs7824557	1.000	rs7824557	chr8:11104111	C/T	cg21775007	chr8:11205619	TDH	-0.44	-5.27	-0.33	3.17e-7	Retinal vascular caliber;
SARC	cis	rs892961	0.806	rs35489990	chr17:75412312	T/C	cg05865280	chr17:75406074	SEPT9	0.57	8.47	0.48	2.87e-15	Airflow obstruction;
SARC	cis	rs72653721	0.838	rs3798717	chr6:11026471	G/A	cg13562911	chr6:11044106	ELOVL2	0.5	5.7	0.35	3.54e-8	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg18656860	chr13:50018171	SETDB2;CAB39L	0.58	6.39	0.39	9.09e-10	Lung cancer in ever smokers;
SARC	cis	rs228437	0.802	rs228447	chr6:134902903	C/T	cg24504307	chr6:134963096	NA	0.44	4.92	0.31	1.67e-6	Melanoma;
SARC	cis	rs405956	1.000	rs923404	chr6:105617761	A/G	cg08749305	chr6:106441987	NA	-0.48	-4.76	-0.3	3.38e-6	QT interval;
SARC	cis	rs5753618	0.561	rs9606830	chr22:31717799	T/G	cg00478049	chr22:31556069	RNF185	-0.45	-4.82	-0.3	2.61e-6	Colorectal cancer;
SARC	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg13939156	chr17:80058883	NA	-0.37	-5.76	-0.35	2.6e-8	Life satisfaction;
SARC	cis	rs13161895	1.000	rs394616	chr5:179418134	T/G	cg02702477	chr5:179499311	RNF130	0.63	5.92	0.36	1.15e-8	LDL cholesterol;
SARC	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg00933542	chr6:150070202	PCMT1	0.31	5.24	0.32	3.56e-7	Lung cancer;
SARC	cis	rs9815354	0.812	rs17214945	chr3:41808660	A/C	cg03022575	chr3:42003672	ULK4	0.73	6.3	0.38	1.43e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2073499	1.000	rs76846888	chr3:50406058	C/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.54	5.04	0.31	9.41e-7	Schizophrenia;
SARC	cis	rs1729951	0.575	rs10935214	chr3:136693485	G/A	cg15507776	chr3:136538369	TMEM22	0.5	5.6	0.34	6.04e-8	Neuroticism;
SARC	cis	rs4780401	0.609	rs4781143	chr16:11809721	T/G	cg01061890	chr16:11836724	TXNDC11	-0.61	-8.7	-0.5	6.01e-16	Rheumatoid arthritis;
SARC	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg11764359	chr7:65958608	NA	-0.75	-8.8	-0.5	3.11e-16	Aortic root size;
SARC	cis	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg12463550	chr7:65579703	CRCP	0.69	5.24	0.32	3.57e-7	Diabetic kidney disease;
SARC	cis	rs1003719	0.646	rs2032063	chr21:38576657	A/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-8.88	-0.5	1.88e-16	Eye color traits;
SARC	cis	rs10875746	0.951	rs2228500	chr12:48526712	A/G	cg27446233	chr12:48516484	PFKM	0.43	4.92	0.31	1.66e-6	Longevity (90 years and older);
SARC	cis	rs793571	0.669	rs28864995	chr15:58945671	T/G	cg05156742	chr15:59063176	FAM63B	0.65	8.11	0.47	2.95e-14	Schizophrenia;
SARC	cis	rs4642101	0.824	rs9852222	chr3:12848491	G/T	cg24848339	chr3:12840334	CAND2	0.31	4.74	0.3	3.68e-6	QRS complex (12-leadsum);
SARC	cis	rs7937682	0.961	rs11828343	chr11:111491322	A/G	cg22437258	chr11:111473054	SIK2	-0.68	-8.8	-0.5	3.12e-16	Primary sclerosing cholangitis;
SARC	cis	rs931812	1.000	rs4734495	chr8:101917817	C/A	cg07585502	chr8:101912084	NA	-0.43	-4.87	-0.3	2.08e-6	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs1051424	0.651	rs1292063	chr17:57907768	T/A	cg02344993	chr17:57696989	CLTC	-0.66	-6.83	-0.41	7.52e-11	Obesity-related traits;
SARC	cis	rs748404	0.660	rs518288	chr15:43763999	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	5.58	0.34	6.68e-8	Lung cancer;
SARC	cis	rs4253772	0.637	rs36125344	chr22:46655779	G/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.63	4.94	0.31	1.47e-6	LDL cholesterol;Cholesterol, total;
SARC	cis	rs7769051	0.522	rs34688576	chr6:133118214	C/T	cg22852734	chr6:133119734	C6orf192	1.25	7.92	0.46	9.87e-14	Type 2 diabetes nephropathy;
SARC	cis	rs9457247	1.000	rs448060	chr6:167382622	A/G	cg07741184	chr6:167504864	NA	0.3	5.61	0.35	5.69e-8	Crohn's disease;
SARC	cis	rs4888262	0.545	rs7184754	chr16:74667864	C/T	cg02853019	chr16:75273486	BCAR1	0.35	4.84	0.3	2.34e-6	Testicular germ cell tumor;
SARC	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg18956956	chr14:31028000	G2E3	-0.56	-7.24	-0.43	6.36e-12	Parental extreme longevity (95 years and older);
SARC	cis	rs12079745	0.793	rs12092506	chr1:169405517	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.8	-5.51	-0.34	9.54e-8	QT interval;
SARC	cis	rs35306767	0.903	rs11253458	chr10:882843	T/C	cg26597838	chr10:835615	NA	0.82	8.42	0.48	3.87e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs734999	1.000	rs2016366	chr1:2513678	A/T	cg18854424	chr1:2615690	NA	0.3	4.87	0.3	2.1e-6	Ulcerative colitis;
SARC	cis	rs7843479	0.509	rs3758156	chr8:21770796	A/G	cg17168535	chr8:21777572	XPO7	0.8	10.77	0.58	3.36e-22	Mean corpuscular volume;
SARC	cis	rs3768617	0.510	rs3765521	chr1:183077615	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.67	9.85	0.54	2.33e-19	Fuchs's corneal dystrophy;
SARC	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg05896524	chr21:47604654	C21orf56	0.42	5.04	0.31	9.35e-7	Testicular germ cell tumor;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg11525834	chr7:73153318	ABHD11	0.48	6.47	0.39	5.87e-10	Neuroticism;
SARC	cis	rs7374004	0.628	rs7374289	chr3:38633071	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.5	5.84	0.36	1.75e-8	PR interval;
SARC	cis	rs34779708	0.931	rs4934702	chr10:35323074	T/C	cg03585969	chr10:35415529	CREM	0.38	4.74	0.3	3.7e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs7945705	0.747	rs2568020	chr11:8994715	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-7.03	-0.42	2.25e-11	Hemoglobin concentration;
SARC	cis	rs10911232	0.507	rs6672306	chr1:183058898	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.68	10.4	0.56	4.66e-21	Hypertriglyceridemia;
SARC	cis	rs1670533	0.872	rs935969	chr4:1062588	A/G	cg27284194	chr4:1044797	NA	0.47	4.87	0.3	2.07e-6	Recombination rate (females);
SARC	cis	rs10463554	0.853	rs2241565	chr5:102301937	A/T	cg23492399	chr5:102201601	PAM	-0.46	-5.5	-0.34	1.01e-7	Parkinson's disease;
SARC	trans	rs61931739	0.500	rs11053290	chr12:34582392	C/T	cg26384229	chr12:38710491	ALG10B	-0.85	-12.8	-0.64	9.59e-29	Morning vs. evening chronotype;
SARC	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-8.76	-0.5	4.15e-16	Alzheimer's disease;
SARC	cis	rs6484504	0.600	rs942272	chr11:31364368	C/T	cg26647111	chr11:31128758	NA	0.39	4.98	0.31	1.23e-6	Red blood cell count;
SARC	cis	rs9457247	0.534	rs9356551	chr6:167400345	T/C	cg23791538	chr6:167370224	RNASET2	0.66	9.38	0.52	5.93e-18	Crohn's disease;
SARC	cis	rs4713118	0.539	rs200951	chr6:27835930	A/G	cg20933634	chr6:27740509	NA	0.39	4.86	0.3	2.11e-6	Parkinson's disease;
SARC	cis	rs1153858	0.945	rs16943246	chr15:45720597	G/A	cg26924012	chr15:45694286	SPATA5L1	0.71	9.1	0.51	4.05e-17	Homoarginine levels;
SARC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.35	-4.9	-0.31	1.81e-6	Lymphocyte counts;
SARC	cis	rs7586879	0.658	rs7563204	chr2:25125075	T/G	cg04586622	chr2:25135609	ADCY3	0.32	5.49	0.34	1.07e-7	Body mass index;
SARC	cis	rs751728	0.664	rs4711347	chr6:33735292	G/A	cg25922239	chr6:33757077	LEMD2	0.58	7.46	0.44	1.65e-12	Crohn's disease;
SARC	cis	rs6484504	0.532	rs2761589	chr11:31311429	C/G	cg26647111	chr11:31128758	NA	0.39	4.96	0.31	1.37e-6	Red blood cell count;
SARC	cis	rs2075671	0.903	rs11520986	chr7:100276994	A/G	cg16850897	chr7:100343110	ZAN	-0.62	-6.54	-0.39	3.83e-10	Other erythrocyte phenotypes;
SARC	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg19680485	chr15:31195859	MTMR15	0.52	6.0	0.37	7.5e-9	Huntington's disease progression;
SARC	cis	rs9290065	0.519	rs6770180	chr3:160703786	C/T	cg17135325	chr3:160939158	NMD3	0.4	4.73	0.3	3.91e-6	Kawasaki disease;
SARC	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg11764359	chr7:65958608	NA	-0.78	-9.67	-0.54	8.24e-19	Aortic root size;
SARC	cis	rs1865760	0.820	rs9348697	chr6:25890834	C/T	cg16482183	chr6:26056742	HIST1H1C	0.48	6.09	0.37	4.53e-9	Height;
SARC	cis	rs6456156	0.586	rs6456149	chr6:167463902	T/C	cg07741184	chr6:167504864	NA	0.35	6.83	0.41	7.46e-11	Primary biliary cholangitis;
SARC	cis	rs11874712	1.000	rs28504655	chr18:43665348	G/A	cg25174615	chr18:43684699	ATP5A1;HAUS1	0.4	4.75	0.3	3.52e-6	Migraine - clinic-based;
SARC	trans	rs9929218	0.817	rs3114405	chr16:68722377	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.7	-9.05	-0.51	5.91e-17	Colorectal cancer;
SARC	cis	rs7555523	0.943	rs4537525	chr1:165711089	T/G	cg19769164	chr1:165738335	TMCO1	0.59	4.91	0.31	1.7e-6	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	cis	rs2204008	0.818	rs1589389	chr12:38416041	G/A	cg26384229	chr12:38710491	ALG10B	-0.8	-11.5	-0.6	1.59e-24	Bladder cancer;
SARC	cis	rs72781680	0.560	rs111310684	chr2:24265682	C/G	cg06627628	chr2:24431161	ITSN2	-0.61	-6.04	-0.37	6.18e-9	Lymphocyte counts;
SARC	cis	rs8017423	0.967	rs11159957	chr14:90715972	A/G	cg20276874	chr14:90721474	PSMC1	0.37	5.23	0.32	3.82e-7	Mortality in heart failure;
SARC	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg14024328	chr4:719362	PCGF3	-0.37	-4.9	-0.31	1.83e-6	White blood cell count;
SARC	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg12463550	chr7:65579703	CRCP	-0.48	-5.21	-0.32	4.14e-7	Aortic root size;
SARC	cis	rs73086581	1.000	rs17287486	chr20:3946267	T/C	cg02187196	chr20:3869020	PANK2	0.67	6.4	0.39	8.3e-10	Response to antidepressants in depression;
SARC	cis	rs4128725	1.000	rs11265185	chr1:159373861	T/G	cg25076881	chr1:159409836	OR10J1	0.4	4.78	0.3	3.16e-6	Select biomarker traits;
SARC	cis	rs9815354	0.812	rs17280952	chr3:41810834	T/C	cg03022575	chr3:42003672	ULK4	0.72	5.99	0.37	7.83e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs8070128	0.601	rs8080602	chr17:17954728	G/C	cg05444541	chr17:17804740	TOM1L2	0.3	4.89	0.31	1.85e-6	Total body bone mineral density;
SARC	cis	rs6864727	0.963	rs10479177	chr5:137388440	A/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.55	6.16	0.37	3.08e-9	Atrial fibrillation;
SARC	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	7.36	0.43	3.21e-12	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs9911578	0.967	rs4932693	chr17:57110327	T/C	cg05425664	chr17:57184151	TRIM37	0.64	8.01	0.46	5.41e-14	Intelligence (multi-trait analysis);
SARC	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.56	5.04	0.31	9.54e-7	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs3126085	0.735	rs4845744	chr1:152185095	T/A	cg03465714	chr1:152285911	FLG	-0.46	-5.5	-0.34	1e-7	Atopic dermatitis;
SARC	cis	rs7937682	0.632	rs4441050	chr11:111772506	C/T	cg09085632	chr11:111637200	PPP2R1B	0.8	10.64	0.57	8.05e-22	Primary sclerosing cholangitis;
SARC	cis	rs1008375	0.966	rs4698636	chr4:17632834	T/C	cg02297831	chr4:17616191	MED28	0.5	6.36	0.38	1.04e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.99	11.07	0.59	3.57e-23	Platelet count;
SARC	cis	rs912057	0.632	rs1294432	chr6:6745027	C/T	cg06612196	chr6:6737390	NA	0.63	9.53	0.53	2.18e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs910316	0.819	rs175461	chr14:75581816	G/A	cg08847533	chr14:75593920	NEK9	-0.84	-12.53	-0.63	6.96e-28	Height;
SARC	cis	rs10421328	0.784	rs8107058	chr19:19759651	T/C	cg03709012	chr19:19516395	GATAD2A	0.54	5.75	0.35	2.81e-8	Parental longevity (combined parental age at death);
SARC	cis	rs2153535	0.580	rs2327061	chr6:8447231	G/C	cg23788917	chr6:8435910	SLC35B3	0.65	8.75	0.5	4.47e-16	Motion sickness;
SARC	trans	rs3780486	0.718	rs7859454	chr9:33119583	T/A	cg20290983	chr6:43655470	MRPS18A	0.93	11.33	0.6	5.59e-24	IgG glycosylation;
SARC	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg19963728	chr2:44588792	PREPL;C2orf34	-0.51	-6.34	-0.38	1.17e-9	Thyroid cancer;
SARC	cis	rs2652834	0.851	rs4238370	chr15:63347363	T/G	cg05507819	chr15:63340323	TPM1	0.59	5.92	0.36	1.14e-8	HDL cholesterol;
SARC	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg24531977	chr5:56204891	C5orf35	0.52	5.29	0.33	2.84e-7	Initial pursuit acceleration;
SARC	cis	rs1468333	0.667	rs4835677	chr5:137700251	A/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.72	8.23	0.47	1.29e-14	Resting heart rate;
SARC	cis	rs73242632	1.000	rs12510703	chr4:57748298	A/G	cg20415529	chr4:57845134	POLR2B;C4orf14	0.8	5.53	0.34	8.73e-8	Congenital heart disease (maternal effect);
SARC	cis	rs7635838	0.718	rs2594979	chr3:11381910	T/G	cg00170343	chr3:11313890	ATG7	0.62	8.57	0.49	1.45e-15	HDL cholesterol;
SARC	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.47	-5.89	-0.36	1.31e-8	Tonsillectomy;
SARC	cis	rs7833790	0.636	rs12544174	chr8:82731477	G/A	cg27398817	chr8:82754497	SNX16	-0.43	-5.42	-0.33	1.46e-7	Diastolic blood pressure;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg00832928	chr3:150329458	SELT	-0.47	-6.31	-0.38	1.37e-9	Electrocardiographic conduction measures;
SARC	cis	rs7113850	0.541	rs114370606	chr11:24232247	C/T	ch.11.24196551F	chr11:24239977	NA	0.71	5.31	0.33	2.55e-7	Bone fracture in osteoporosis;
SARC	trans	rs6076960	0.684	rs3909086	chr20:6251639	A/G	cg17788362	chr6:86352627	SYNCRIP	0.47	6.28	0.38	1.63e-9	Smooth-surface caries;
SARC	cis	rs4141404	0.851	rs9606833	chr22:31750013	T/C	cg00478049	chr22:31556069	RNF185	-0.52	-5.21	-0.32	4.2e-7	Paclitaxel-induced neuropathy;
SARC	cis	rs9858542	0.953	rs11713474	chr3:49611457	A/G	cg07274523	chr3:49395745	GPX1	0.5	5.91	0.36	1.19e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	trans	rs6792151	0.738	rs7626674	chr3:171501314	C/G	cg16086185	chr12:133324413	ANKLE2	-0.66	-6.66	-0.4	1.96e-10	Red cell distribution width;
SARC	cis	rs7113850	0.541	rs7933381	chr11:24237534	T/C	ch.11.24196551F	chr11:24239977	NA	0.74	5.62	0.35	5.48e-8	Bone fracture in osteoporosis;
SARC	cis	rs9807989	0.839	rs7603730	chr2:102974371	A/C	cg09003973	chr2:102972529	NA	0.42	5.8	0.36	2.16e-8	Asthma;
SARC	cis	rs3857536	0.813	rs9354405	chr6:66948575	G/T	cg07460842	chr6:66804631	NA	-0.46	-5.29	-0.33	2.83e-7	Blood trace element (Cu levels);
SARC	cis	rs1008375	1.000	rs11737138	chr4:17657986	G/A	cg16339924	chr4:17578868	LAP3	0.66	8.83	0.5	2.57e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10513788	0.665	rs1565180	chr3:181993165	T/C	cg05977900	chr3:182512126	ATP11B	0.47	4.97	0.31	1.3e-6	Cognitive function;
SARC	cis	rs6840360	1.000	rs12502055	chr4:152596668	G/A	cg22705602	chr4:152727874	NA	-0.38	-6.51	-0.39	4.49e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg21016266	chr12:122356598	WDR66	0.3	4.78	0.3	3.07e-6	Mean corpuscular volume;
SARC	cis	rs17030434	0.822	rs28367474	chr4:154718642	A/G	cg14289246	chr4:154710475	SFRP2	-0.56	-6.25	-0.38	1.92e-9	Electrocardiographic conduction measures;
SARC	cis	rs2200578	0.732	rs56143125	chr2:99565143	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.54	4.81	0.3	2.73e-6	IgG glycosylation;
SARC	cis	rs546131	0.642	rs836950	chr11:34852020	C/G	cg06937548	chr11:34938143	PDHX;APIP	-0.43	-4.81	-0.3	2.7e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.88	11.11	0.59	2.75e-23	Multiple sclerosis;
SARC	cis	rs9399137	0.507	rs11759077	chr6:135381351	A/G	cg24558204	chr6:135376177	HBS1L	0.64	8.17	0.47	1.9e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.76	9.86	0.54	2.16e-19	Prudent dietary pattern;
SARC	cis	rs6570726	0.935	rs421268	chr6:145845558	A/T	cg05220968	chr6:146057943	EPM2A	-0.29	-5.04	-0.31	9.48e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7672847	0.500	rs4692722	chr4:170332331	A/T	cg00846720	chr4:170533756	NEK1	-0.62	-4.79	-0.3	2.97e-6	Subjective well-being;
SARC	cis	rs1008375	0.544	rs7685265	chr4:17568510	C/T	cg27347728	chr4:17578864	LAP3	0.48	5.53	0.34	8.49e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs5769765	1.000	rs5770728	chr22:50259984	G/A	cg03033257	chr22:50311977	ALG12;CRELD2	-0.54	-5.64	-0.35	4.81e-8	Schizophrenia;
SARC	cis	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg05623727	chr3:50126028	RBM5	-0.35	-5.34	-0.33	2.22e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1449587	0.749	rs9535094	chr13:49424148	A/G	cg25335349	chr13:50018531	SETDB2;CAB39L	-0.4	-5.02	-0.31	1.05e-6	Verbal memory performance (immediate recall level);
SARC	cis	rs796364	1.000	rs10178177	chr2:200829993	G/A	cg23649088	chr2:200775458	C2orf69	0.61	5.87	0.36	1.48e-8	Schizophrenia;
SARC	cis	rs3741151	0.773	rs73542967	chr11:73123512	C/T	cg17517138	chr11:73019481	ARHGEF17	0.91	6.77	0.41	1.04e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.43	-6.45	-0.39	6.52e-10	Total body bone mineral density;
SARC	cis	rs2814982	0.605	rs80254589	chr6:34478514	C/T	cg17674042	chr6:34482479	PACSIN1	-0.58	-5.05	-0.31	9.01e-7	Cholesterol, total;Total cholesterol levels;
SARC	cis	rs9911578	1.000	rs1267545	chr17:56646909	A/G	cg12560992	chr17:57184187	TRIM37	0.82	11.23	0.59	1.13e-23	Intelligence (multi-trait analysis);
SARC	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg09517075	chr8:22133004	PIWIL2	0.35	4.74	0.3	3.75e-6	Hypertriglyceridemia;
SARC	cis	rs1559088	0.948	rs6510346	chr19:33598526	T/A	cg17764715	chr19:33622953	WDR88	0.49	6.72	0.4	1.4e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs2228479	0.717	rs17226274	chr16:89850170	C/T	cg00800038	chr16:89945340	TCF25	-0.72	-5.58	-0.34	6.51e-8	Skin colour saturation;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg24905370	chr5:74063138	NSA2;GFM2	-0.51	-6.87	-0.41	5.8e-11	Electrocardiographic conduction measures;
SARC	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg19077165	chr18:44547161	KATNAL2	0.53	7.35	0.43	3.3e-12	Personality dimensions;
SARC	cis	rs11608355	0.597	rs7300290	chr12:109832545	T/G	cg05360138	chr12:110035743	NA	0.38	4.72	0.3	4.13e-6	Neuroticism;
SARC	cis	rs3008870	0.583	rs17497947	chr1:67457199	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.83	-8.83	-0.5	2.64e-16	Lymphocyte percentage of white cells;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg09581413	chr5:56508803	GPBP1	0.46	6.36	0.38	1.04e-9	Thyroid stimulating hormone;
SARC	cis	rs4481887	0.927	rs10788779	chr1:248481661	C/G	cg00666640	chr1:248458726	OR2T12	0.35	5.8	0.36	2.16e-8	Common traits (Other);
SARC	cis	rs16976116	0.901	rs28499113	chr15:55503621	T/C	cg17854078	chr15:55489399	RSL24D1	0.66	6.45	0.39	6.3e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9916302	0.904	rs7223331	chr17:37482930	A/G	cg15445000	chr17:37608096	MED1	-0.44	-5.39	-0.33	1.71e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs1451375	0.583	rs3807556	chr7:50610536	G/A	cg18232548	chr7:50535776	DDC	0.48	4.81	0.3	2.67e-6	Malaria;
SARC	cis	rs1448094	0.845	rs17354637	chr12:86347752	A/G	cg02569458	chr12:86230093	RASSF9	0.44	6.31	0.38	1.4e-9	Major depressive disorder;
SARC	cis	rs1371867	1.000	rs1371867	chr8:101330209	A/C	cg11906718	chr8:101322791	RNF19A	0.58	7.41	0.44	2.28e-12	Atrioventricular conduction;
SARC	cis	rs2153535	0.580	rs1414351	chr6:8476634	T/C	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	cis	rs7666738	0.830	rs1456208	chr4:98678563	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.52	0.49	1.94e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1153858	1.000	rs59889118	chr15:45618730	G/A	cg03999130	chr15:45571217	NA	0.4	5.05	0.31	8.98e-7	Homoarginine levels;
SARC	cis	rs9462027	0.628	rs7742652	chr6:34667075	G/A	cg07306190	chr6:34760872	UHRF1BP1	0.43	6.14	0.37	3.47e-9	Systemic lupus erythematosus;
SARC	cis	rs9640161	0.750	rs3735169	chr7:150034378	A/G	cg10018233	chr7:150070692	REPIN1	0.67	8.6	0.49	1.16e-15	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs5167	0.750	rs3786505	chr19:45490570	A/G	cg09555818	chr19:45449301	APOC2	0.41	5.89	0.36	1.36e-8	Blood protein levels;
SARC	cis	rs9325144	0.560	rs10785573	chr12:38654166	G/A	cg26384229	chr12:38710491	ALG10B	-0.63	-8.12	-0.47	2.64e-14	Morning vs. evening chronotype;
SARC	trans	rs61931739	0.534	rs1352207	chr12:34036862	C/T	cg13010199	chr12:38710504	ALG10B	-0.67	-8.93	-0.5	1.35e-16	Morning vs. evening chronotype;
SARC	cis	rs155076	1.000	rs598754	chr13:21845010	C/A	cg25811766	chr13:21894605	NA	-0.51	-5.5	-0.34	9.92e-8	White matter hyperintensity burden;
SARC	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.23e-9	Life satisfaction;
SARC	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg24642844	chr7:1081250	C7orf50	-0.6	-6.11	-0.37	4.06e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs1008375	0.931	rs7435102	chr4:17571480	C/G	cg27347728	chr4:17578864	LAP3	0.45	5.48	0.34	1.1e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9646954	0.542	rs4149505	chr2:101033697	G/A	cg14675211	chr2:100938903	LONRF2	0.55	8.17	0.47	1.93e-14	Intelligence (multi-trait analysis);
SARC	cis	rs10448080	0.879	rs240946	chr8:28568905	A/G	cg01805427	chr8:29124444	NA	0.35	5.04	0.31	9.42e-7	Height;
SARC	cis	rs4268898	0.760	rs11676939	chr2:24479057	C/T	cg26838691	chr2:24397539	C2orf84	0.39	5.32	0.33	2.44e-7	Asthma;
SARC	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg16606324	chr3:10149918	C3orf24	0.5	5.01	0.31	1.08e-6	Alzheimer's disease;
SARC	cis	rs1018836	0.923	rs4734266	chr8:91628147	C/T	cg16814680	chr8:91681699	NA	-0.85	-13.87	-0.67	2.65e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg19077165	chr18:44547161	KATNAL2	-0.48	-6.33	-0.38	1.28e-9	Personality dimensions;
SARC	cis	rs116095464	1.000	rs56700778	chr5:313186	A/T	cg22496380	chr5:211416	CCDC127	-0.89	-5.75	-0.35	2.74e-8	Breast cancer;
SARC	cis	rs26232	0.521	rs40508	chr5:102443938	A/T	cg23492399	chr5:102201601	PAM	-0.51	-5.54	-0.34	8.26e-8	Rheumatoid arthritis;
SARC	cis	rs3092073	0.624	rs11696196	chr20:44574533	C/T	cg00981651	chr20:44574847	PCIF1	0.3	4.85	0.3	2.24e-6	Intelligence (multi-trait analysis);
SARC	cis	rs28795989	0.795	rs6848540	chr4:7904779	T/A	cg18538662	chr4:7941764	AFAP1	-0.42	-5.42	-0.33	1.5e-7	Intraocular pressure;
SARC	cis	rs17270561	0.779	rs1165200	chr6:25875212	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.68	-7.86	-0.46	1.46e-13	Iron status biomarkers;
SARC	cis	rs2204008	0.563	rs2320512	chr12:38266913	G/A	cg14851346	chr12:38532713	NA	-0.44	-5.17	-0.32	5.01e-7	Bladder cancer;
SARC	cis	rs6502050	0.723	rs8077209	chr17:80163221	A/G	cg13939156	chr17:80058883	NA	-0.44	-6.91	-0.41	4.66e-11	Life satisfaction;
SARC	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg09699651	chr6:150184138	LRP11	0.49	5.98	0.36	8.48e-9	Lung cancer;
SARC	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg16325326	chr1:53192061	ZYG11B	-0.82	-12.99	-0.65	2.19e-29	Monocyte count;
SARC	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg04944784	chr2:26401820	FAM59B	-0.47	-5.83	-0.36	1.84e-8	Gut microbiome composition (summer);
SARC	cis	rs7769051	1.000	rs73554431	chr6:133129922	T/G	cg22852734	chr6:133119734	C6orf192	1.08	11.12	0.59	2.51e-23	Type 2 diabetes nephropathy;
SARC	cis	rs3820928	0.605	rs6718767	chr2:227800776	A/G	cg11843606	chr2:227700838	RHBDD1	-0.57	-7.57	-0.44	8.47e-13	Pulmonary function;
SARC	cis	rs7395581	0.877	rs10838690	chr11:47335075	A/G	cg25783544	chr11:47291846	MADD	0.49	5.55	0.34	7.7e-8	HDL cholesterol;
SARC	cis	rs9381040	1.000	rs2093396	chr6:41155000	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.47	-5.45	-0.34	1.29e-7	Alzheimer's disease (late onset);
SARC	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg18876405	chr7:65276391	NA	0.68	8.26	0.48	1.09e-14	Aortic root size;
SARC	cis	rs2153535	0.580	rs2327058	chr6:8447018	C/T	cg07606381	chr6:8435919	SLC35B3	0.77	11.03	0.59	5.01e-23	Motion sickness;
SARC	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg06634786	chr22:41940651	POLR3H	-0.59	-7.01	-0.42	2.59e-11	Vitiligo;
SARC	cis	rs6573604	0.605	rs4902383	chr14:65764573	G/C	cg15999311	chr14:65749247	NA	0.37	4.74	0.3	3.78e-6	N-glycan levels;
SARC	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg20120463	chr17:44301886	NA	-0.36	-5.61	-0.35	5.65e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs899997	1.000	rs11632672	chr15:79044330	A/G	cg04896959	chr15:78267971	NA	0.45	5.27	0.33	3.18e-7	Coronary artery disease or large artery stroke;
SARC	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg16606324	chr3:10149918	C3orf24	0.48	4.75	0.3	3.54e-6	Alzheimer's disease;
SARC	cis	rs7833790	0.724	rs6473309	chr8:82707880	A/G	cg27398817	chr8:82754497	SNX16	-0.43	-5.48	-0.34	1.13e-7	Diastolic blood pressure;
SARC	cis	rs8005150	0.737	rs10220371	chr14:88501852	C/T	cg05349646	chr14:88934340	PTPN21	0.54	5.25	0.32	3.5e-7	Hepatitis B;
SARC	cis	rs7666738	0.791	rs6851549	chr4:99029827	G/A	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	8.88	0.5	1.83e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2486288	0.656	rs1706768	chr15:45569443	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.55	-6.88	-0.41	5.44e-11	Glomerular filtration rate;
SARC	cis	rs6840360	1.000	rs6535810	chr4:152592953	C/T	cg22705602	chr4:152727874	NA	-0.38	-6.65	-0.4	2.09e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7274811	0.681	rs158676	chr20:31974395	G/A	cg21523528	chr20:32077966	CBFA2T2	-0.41	-4.82	-0.3	2.58e-6	Height;
SARC	trans	rs1814175	0.645	rs28627251	chr11:50048125	G/T	cg03929089	chr4:120376271	NA	-0.83	-11.84	-0.61	1.24e-25	Height;
SARC	cis	rs2180341	0.960	rs7751865	chr6:127683040	G/A	cg27446573	chr6:127587934	RNF146	1.06	14.55	0.69	1.52e-34	Breast cancer;
SARC	cis	rs10463316	0.779	rs1810084	chr5:150777048	A/G	cg03212797	chr5:150827313	SLC36A1	-0.42	-5.07	-0.32	7.95e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs7223966	1.000	rs7223966	chr17:61893398	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.52	-5.51	-0.34	9.69e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs34779708	0.966	rs11010095	chr10:35395948	A/G	cg03585969	chr10:35415529	CREM	0.4	5.06	0.31	8.47e-7	Inflammatory bowel disease;Crohn's disease;
SARC	trans	rs804280	0.542	rs34117651	chr8:11791617	G/C	cg06636001	chr8:8085503	FLJ10661	0.5	6.28	0.38	1.63e-9	Myopia (pathological);
SARC	cis	rs7520050	0.966	rs785503	chr1:46595868	T/C	cg24296786	chr1:45957014	TESK2	0.38	4.82	0.3	2.56e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs17023223	0.537	rs2361272	chr1:119603417	T/C	cg05756136	chr1:119680316	WARS2	-0.43	-5.13	-0.32	6.03e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs4660261	0.526	rs2485997	chr1:44345841	G/C	cg12908607	chr1:44402522	ARTN	-0.29	-5.03	-0.31	9.7e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1707322	0.963	rs11211202	chr1:46292382	C/T	cg03146154	chr1:46216737	IPP	0.47	5.65	0.35	4.76e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1059312	1.000	rs3825180	chr12:129279242	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.42	5.02	0.31	1.04e-6	Systemic lupus erythematosus;
SARC	cis	rs11792861	0.566	rs1003346	chr9:111815340	C/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.41	5.06	0.31	8.32e-7	Menarche (age at onset);
SARC	cis	rs9682041	0.696	rs6798399	chr3:170086482	G/A	cg11886554	chr3:170076028	SKIL	0.83	7.75	0.45	2.91e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs2073499	0.935	rs28365992	chr3:50340996	T/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.55	5.17	0.32	4.93e-7	Schizophrenia;
SARC	cis	rs9296092	0.500	rs35150558	chr6:33519612	T/A	cg13560919	chr6:33536144	NA	-0.5	-6.31	-0.38	1.38e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs9790314	0.543	rs1349352	chr3:161118486	C/T	cg17135325	chr3:160939158	NMD3	0.53	6.55	0.39	3.73e-10	Morning vs. evening chronotype;
SARC	cis	rs400736	0.930	rs408320	chr1:8085328	T/C	cg25007680	chr1:8021821	PARK7	0.5	6.5	0.39	4.9e-10	Response to antidepressants and depression;
SARC	cis	rs2290159	0.800	rs60953453	chr3:12654921	C/A	cg23032965	chr3:12705835	RAF1	0.73	7.89	0.46	1.18e-13	Cholesterol, total;
SARC	cis	rs2342371	0.701	rs4916498	chr3:196202961	G/C	cg15048948	chr3:196158458	UBXN7	-0.52	-6.52	-0.39	4.24e-10	Fat distribution (HIV);
SARC	cis	rs7561273	0.586	rs6545264	chr2:24310105	A/G	cg08917208	chr2:24149416	ATAD2B	0.48	5.24	0.32	3.6e-7	Quantitative traits;
SARC	cis	rs72945132	0.882	rs3133179	chr11:70187574	T/G	cg05964544	chr11:70165517	PPFIA1	-0.58	-5.65	-0.35	4.56e-8	Coronary artery disease;
SARC	cis	rs12142240	0.698	rs7515598	chr1:46818479	C/T	cg10495392	chr1:46806563	NSUN4	0.65	6.83	0.41	7.25e-11	Menopause (age at onset);
SARC	cis	rs9296092	0.538	rs5000098	chr6:33519231	T/G	cg13560919	chr6:33536144	NA	-0.51	-6.24	-0.38	2.08e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs4243830	0.510	rs7518459	chr1:6596678	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.9	-9.26	-0.52	1.41e-17	Body mass index;
SARC	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg24549020	chr5:56110836	MAP3K1	-0.78	-8.23	-0.47	1.34e-14	Initial pursuit acceleration;
SARC	cis	rs753778	1.000	rs4961257	chr8:142232704	A/G	cg18755752	chr8:142205143	DENND3	0.46	5.81	0.36	1.99e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs546131	0.642	rs12278295	chr11:34846254	G/A	cg06937548	chr11:34938143	PDHX;APIP	-0.42	-4.71	-0.3	4.19e-6	Lung disease severity in cystic fibrosis;
SARC	trans	rs11098499	0.820	rs6534140	chr4:120455311	C/T	cg25214090	chr10:38739885	LOC399744	0.57	7.35	0.43	3.31e-12	Corneal astigmatism;
SARC	cis	rs2153535	0.580	rs9378554	chr6:8488468	C/T	cg21535247	chr6:8435926	SLC35B3	0.55	6.9	0.41	4.76e-11	Motion sickness;
SARC	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-8.39	-0.48	4.81e-15	Chronic sinus infection;
SARC	cis	rs13166103	0.657	rs10513145	chr5:57707254	C/T	cg10487770	chr5:57879443	RAB3C	-0.52	-5.63	-0.35	5.12e-8	Type 2 diabetes (age of onset);
SARC	trans	rs3942852	0.726	rs1503171	chr11:48175152	T/C	cg15704280	chr7:45808275	SEPT13	-0.61	-7.11	-0.42	1.42e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs13191362	0.507	rs1079020	chr6:163066596	C/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.44	-4.76	-0.3	3.45e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg03213289	chr20:61660250	NA	0.46	6.43	0.39	7.22e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg24642844	chr7:1081250	C7orf50	-0.54	-6.04	-0.37	5.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs7635838	0.620	rs1666988	chr3:11284950	A/G	cg00170343	chr3:11313890	ATG7	0.65	8.06	0.47	3.93e-14	HDL cholesterol;
SARC	trans	rs3780486	1.000	rs12342831	chr9:33124872	A/G	cg04842962	chr6:43655489	MRPS18A	0.94	12.58	0.64	4.92e-28	IgG glycosylation;
SARC	cis	rs765787	0.530	rs1648289	chr15:45516494	A/G	cg24006582	chr15:45444508	DUOX1	-0.56	-7.42	-0.44	2.14e-12	Uric acid levels;
SARC	cis	rs67460515	0.500	rs9860537	chr3:160660500	G/T	cg17135325	chr3:160939158	NMD3	-0.48	-5.42	-0.33	1.52e-7	Parkinson's disease;
SARC	cis	rs820218	0.743	rs4789223	chr17:73641899	G/A	cg01592526	chr17:73663357	RECQL5;SAP30BP	-0.58	-7.59	-0.45	7.87e-13	Rotator cuff tears;
SARC	cis	rs1707322	1.000	rs946524	chr1:46487560	A/G	cg06784218	chr1:46089804	CCDC17	-0.34	-6.0	-0.37	7.61e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7666738	0.830	rs10034330	chr4:99064849	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.7	0.5	6.15e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs854765	0.663	rs16960744	chr17:17755259	A/G	cg04398451	chr17:18023971	MYO15A	0.42	6.11	0.37	4.15e-9	Total body bone mineral density;
SARC	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg13880726	chr7:1868755	MAD1L1	0.43	4.97	0.31	1.3e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs10849893	0.576	rs10849886	chr12:121886921	G/T	cg01154721	chr12:121881891	KDM2B	-0.39	-5.64	-0.35	4.94e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs9818758	0.607	rs55873331	chr3:49597055	C/T	cg03060546	chr3:49711283	APEH	-0.63	-5.25	-0.33	3.43e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs41278232	0.557	rs817348	chr20:62609670	A/G	cg07620230	chr20:62328084	TNFRSF6B	0.34	4.78	0.3	3.09e-6	Tonsillectomy;
SARC	cis	rs13161895	1.000	rs4235504	chr5:179453680	T/C	cg02702477	chr5:179499311	RNF130	0.66	6.41	0.39	7.78e-10	LDL cholesterol;
SARC	cis	rs2242116	0.796	rs4683296	chr3:46973820	G/C	cg02527881	chr3:46936655	PTH1R	0.37	5.73	0.35	3.15e-8	Birth weight;
SARC	cis	rs7592578	0.882	rs58568707	chr2:191468987	G/A	cg27211696	chr2:191398769	TMEM194B	-0.52	-5.45	-0.34	1.29e-7	Diastolic blood pressure;
SARC	cis	rs16976116	0.619	rs7168057	chr15:55465483	G/A	cg17854078	chr15:55489399	RSL24D1	-0.61	-5.26	-0.33	3.3e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg20607798	chr8:58055168	NA	0.58	5.57	0.34	6.9e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg06931446	chr19:7459819	ARHGEF18	0.75	6.48	0.39	5.3e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg02711726	chr17:80685570	FN3KRP	-0.52	-6.34	-0.38	1.16e-9	Glycated hemoglobin levels;
SARC	cis	rs6733011	0.604	rs12712035	chr2:99461298	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.4	-5.03	-0.31	9.75e-7	Bipolar disorder;
SARC	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg05234568	chr11:5960015	NA	0.5	6.88	0.41	5.4e-11	DNA methylation (variation);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg09560911	chr6:47276890	TNFRSF21	0.53	7.04	0.42	2.11e-11	Breast cancer;
SARC	trans	rs11039798	0.512	rs1588069	chr11:48694871	A/G	cg15704280	chr7:45808275	SEPT13	0.64	6.41	0.39	8.11e-10	Axial length;
SARC	trans	rs804280	0.509	rs10109241	chr8:11784985	A/T	cg06636001	chr8:8085503	FLJ10661	0.52	6.66	0.4	1.98e-10	Myopia (pathological);
SARC	cis	rs2228479	0.850	rs62054609	chr16:89816569	C/A	cg26513180	chr16:89883248	FANCA	0.72	4.79	0.3	2.99e-6	Skin colour saturation;
SARC	cis	rs72653721	0.838	rs3778166	chr6:11033164	A/G	cg13562911	chr6:11044106	ELOVL2	-0.6	-6.78	-0.41	9.98e-11	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	cis	rs6667605	0.527	rs6673993	chr1:2552071	T/C	cg00980319	chr1:2560884	MMEL1	-0.33	-4.73	-0.3	3.89e-6	Inflammatory bowel disease;Ulcerative colitis;
SARC	trans	rs208520	0.874	rs208470	chr6:66916402	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-10.9	-0.58	1.25e-22	Exhaled nitric oxide output;
SARC	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg11062466	chr8:58055876	NA	0.54	5.56	0.34	7.55e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs3768716	0.500	rs777329	chr2:215742595	A/G	cg04530015	chr2:215796436	ABCA12	0.37	5.96	0.36	9.24e-9	Neuroblastoma;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg05953927	chr3:112930782	BOC	0.5	6.33	0.38	1.24e-9	Lung adenocarcinoma;
SARC	cis	rs986417	1.000	rs713336	chr14:60974958	T/G	cg27398547	chr14:60952738	C14orf39	1.03	9.89	0.54	1.74e-19	Gut microbiota (bacterial taxa);
SARC	cis	rs3087591	0.887	rs1013946	chr17:29530350	A/C	cg24425628	chr17:29625626	OMG;NF1	0.49	6.1	0.37	4.48e-9	Hip circumference;
SARC	cis	rs11098499	0.820	rs2389885	chr4:120533931	C/T	cg09307838	chr4:120376055	NA	0.82	10.67	0.57	6.78e-22	Corneal astigmatism;
SARC	cis	rs9840812	0.725	rs3821445	chr3:136002809	T/C	cg15507776	chr3:136538369	TMEM22	-0.53	-5.1	-0.32	7.19e-7	Fibrinogen levels;
SARC	cis	rs36051895	0.659	rs57299248	chr9:5062932	C/G	cg02405213	chr9:5042618	JAK2	-0.51	-6.03	-0.37	6.37e-9	Pediatric autoimmune diseases;
SARC	cis	rs9462027	0.583	rs2814949	chr6:34656722	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.97	-0.36	8.62e-9	Systemic lupus erythematosus;
SARC	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg08677398	chr8:58056175	NA	0.44	5.24	0.32	3.59e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9462027	0.628	rs9469859	chr6:34722902	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.84	-0.36	1.71e-8	Systemic lupus erythematosus;
SARC	cis	rs8180040	0.966	rs9683177	chr3:47490493	G/A	cg27129171	chr3:47204927	SETD2	0.67	9.32	0.52	9.19e-18	Colorectal cancer;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg13876481	chr6:147124881	C6orf103;LOC729176	0.5	6.28	0.38	1.65e-9	Breast cancer;
SARC	cis	rs881375	0.967	rs758959	chr9:123676699	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	4.77	0.3	3.2e-6	Rheumatoid arthritis;
SARC	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg26874164	chr19:58962979	ZNF324B	0.48	5.98	0.36	8.55e-9	Uric acid clearance;
SARC	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg19223190	chr17:80058835	NA	0.45	6.29	0.38	1.57e-9	Life satisfaction;
SARC	cis	rs7560272	0.723	rs4852927	chr2:73641557	C/T	cg20560298	chr2:73613845	ALMS1	0.52	7.14	0.42	1.19e-11	Schizophrenia;
SARC	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg18357526	chr6:26021779	HIST1H4A	-0.5	-5.73	-0.35	3.06e-8	Blood metabolite levels;
SARC	cis	rs838147	0.844	rs8105137	chr19:49249888	G/A	cg13540341	chr19:49222985	MAMSTR	0.28	4.84	0.3	2.32e-6	Dietary macronutrient intake;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg00714078	chr2:135809744	RAB3GAP1	-0.71	-6.23	-0.38	2.13e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6060717	0.536	rs6060664	chr20:34478884	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	5.16	0.32	5.29e-7	Hip circumference adjusted for BMI;
SARC	trans	rs13106975	0.558	rs4694860	chr4:47620435	C/T	cg16146322	chr2:131513144	FAM123C	-0.46	-6.28	-0.38	1.6e-9	Sphingolipid levels;
SARC	cis	rs7429990	0.932	rs7620736	chr3:48109969	C/T	cg11946769	chr3:48343235	NME6	-0.46	-5.34	-0.33	2.16e-7	Educational attainment (years of education);
SARC	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg11644478	chr21:40555479	PSMG1	-0.86	-11.28	-0.59	7.99e-24	Cognitive function;
SARC	cis	rs7824557	0.564	rs2572386	chr8:11236975	A/G	cg21775007	chr8:11205619	TDH	-0.65	-8.56	-0.49	1.59e-15	Retinal vascular caliber;
SARC	cis	rs10484885	0.824	rs28372875	chr6:90529343	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.6	-5.16	-0.32	5.29e-7	QRS interval (sulfonylurea treatment interaction);
SARC	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.55	-6.58	-0.4	3.11e-10	Renal function-related traits (BUN);
SARC	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg05313129	chr8:58192883	C8orf71	-0.51	-4.77	-0.3	3.19e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs73206853	0.609	rs7966169	chr12:111045898	T/C	cg10860002	chr12:110842031	ANAPC7	0.59	5.09	0.32	7.42e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs7621025	0.500	rs16844241	chr3:136635171	A/G	cg15507776	chr3:136538369	TMEM22	-0.97	-10.86	-0.58	1.69e-22	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
SARC	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.4	5.03	0.31	9.63e-7	Total body bone mineral density;
SARC	cis	rs7777754	0.512	rs3757472	chr7:50537983	A/C	cg18232548	chr7:50535776	DDC	-0.5	-5.72	-0.35	3.26e-8	Response to zileuton treatment in asthma (FEV1 change interaction);
SARC	cis	rs13191362	0.872	rs13194619	chr6:163203657	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.64	5.64	0.35	4.86e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg15242686	chr22:24348715	GSTTP1	0.46	5.54	0.34	8.08e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9473924	0.505	rs6908879	chr6:50869856	C/T	cg14470998	chr6:50812995	TFAP2B	0.77	7.24	0.43	6.59e-12	Body mass index;
SARC	cis	rs2075371	1.000	rs2598286	chr7:133976029	G/A	cg20476274	chr7:133979776	SLC35B4	0.6	8.19	0.47	1.7e-14	Mean platelet volume;
SARC	cis	rs7412746	0.658	rs12068264	chr1:150727329	C/T	cg10589385	chr1:150898437	SETDB1	0.38	5.03	0.31	9.83e-7	Melanoma;
SARC	cis	rs6484504	0.532	rs7121949	chr11:31288160	G/T	cg02090638	chr11:31391270	DNAJC24;DCDC1	-0.37	-4.74	-0.3	3.71e-6	Red blood cell count;
SARC	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg12042659	chr19:58951599	ZNF132	0.42	5.56	0.34	7.42e-8	Uric acid clearance;
SARC	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg18370025	chr7:2749541	AMZ1	0.3	4.86	0.3	2.13e-6	Height;
SARC	cis	rs611744	0.625	rs11991891	chr8:109294858	G/A	cg21045802	chr8:109455806	TTC35	0.67	8.68	0.49	6.84e-16	Dupuytren's disease;
SARC	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg22800045	chr5:56110881	MAP3K1	0.74	7.8	0.46	2.03e-13	Initial pursuit acceleration;
SARC	cis	rs73206853	0.764	rs3026425	chr12:110688168	A/G	cg10860002	chr12:110842031	ANAPC7	0.63	5.25	0.33	3.4e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs9815354	1.000	rs1717014	chr3:41917395	C/T	cg03022575	chr3:42003672	ULK4	0.54	5.12	0.32	6.5e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2304069	1.000	rs216126	chr5:149428424	G/C	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.55	5.76	0.35	2.69e-8	HIV-1 control;
SARC	cis	rs7223966	1.000	rs16947014	chr17:61719032	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.57	-6.11	-0.37	4.12e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs72634258	0.554	rs10462018	chr1:7879627	C/T	cg26816564	chr1:7831052	VAMP3	0.55	5.05	0.31	9.11e-7	Inflammatory bowel disease;
SARC	cis	rs2213920	0.516	rs35976675	chr9:118173444	T/C	cg13918206	chr9:118159781	DEC1	-0.78	-6.16	-0.37	3.11e-9	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	trans	rs3780486	1.000	rs10813951	chr9:33128021	C/T	cg20290983	chr6:43655470	MRPS18A	-0.99	-14.16	-0.68	2.97e-33	IgG glycosylation;
SARC	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg02725872	chr8:58115012	NA	-0.34	-5.37	-0.33	1.91e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6565180	0.926	rs8046445	chr16:30386262	A/G	cg17640201	chr16:30407289	ZNF48	-1.0	-17.7	-0.76	5.38e-45	Tonsillectomy;
SARC	cis	rs765787	0.530	rs4775822	chr15:45527127	A/G	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.51e-10	Uric acid levels;
SARC	cis	rs55823223	0.646	rs74410877	chr17:73832384	C/T	cg23806715	chr17:73775811	H3F3B	1.07	9.39	0.52	5.69e-18	Psoriasis;
SARC	cis	rs4742903	0.967	rs7023085	chr9:106904265	C/T	cg14250997	chr9:106856677	SMC2	0.47	6.11	0.37	4.06e-9	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs7833986	0.534	rs17813240	chr8:56925791	C/T	cg26371346	chr8:56986568	SNORD54;RPS20	0.7	6.93	0.41	3.97e-11	Height;
SARC	cis	rs7666738	0.680	rs11097613	chr4:99079991	G/T	cg05340658	chr4:99064831	C4orf37	0.54	6.86	0.41	6.03e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7044106	0.762	rs1158554	chr9:123400898	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	5.51	0.34	9.37e-8	Hip circumference adjusted for BMI;
SARC	cis	rs9916302	0.904	rs12952384	chr17:37669536	T/C	cg07936489	chr17:37558343	FBXL20	-0.69	-8.9	-0.5	1.63e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs7103648	0.897	rs3758675	chr11:47400602	G/A	cg10504702	chr11:47789108	FNBP4	0.52	6.27	0.38	1.77e-9	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs116095464	0.558	rs7714335	chr5:263513	T/C	cg22857025	chr5:266934	NA	-1.04	-11.24	-0.59	1.07e-23	Breast cancer;
SARC	cis	rs34779708	0.931	rs35388511	chr10:35296616	A/G	cg03585969	chr10:35415529	CREM	0.38	4.78	0.3	3.14e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs4423214	0.592	rs7114252	chr11:71237606	G/A	cg05163923	chr11:71159392	DHCR7	-0.51	-5.07	-0.32	7.99e-7	Vitamin D levels;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg23537193	chr12:39300744	CPNE8	-0.52	-6.84	-0.41	6.89e-11	Chemerin levels;
SARC	cis	rs950776	0.518	rs1504545	chr15:78818471	C/G	cg17108064	chr15:78857060	CHRNA5	-0.29	-4.96	-0.31	1.36e-6	Sudden cardiac arrest;
SARC	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg17376030	chr22:41985996	PMM1	-0.64	-8.25	-0.48	1.19e-14	Vitiligo;
SARC	cis	rs694739	0.536	rs11231740	chr11:64046641	C/T	cg02228329	chr11:64053129	BAD;GPR137	-0.5	-6.28	-0.38	1.64e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs78487399	0.808	rs6752448	chr2:43682596	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-4.95	-0.31	1.45e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg01475735	chr3:40494733	NA	-0.49	-5.43	-0.34	1.39e-7	Renal cell carcinoma;
SARC	cis	rs526821	0.553	rs510095	chr11:55289154	T/C	cg04317927	chr11:55418816	OR4S2	0.39	5.69	0.35	3.85e-8	Pediatric bone mineral density (spine);
SARC	trans	rs10435719	0.647	rs10092605	chr8:11787395	T/G	cg06636001	chr8:8085503	FLJ10661	0.51	6.62	0.4	2.43e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
SARC	cis	rs7740797	0.818	rs9397744	chr6:155073206	T/G	cg02865717	chr6:155053990	RBM16	-0.33	-4.76	-0.3	3.37e-6	Colorectal or endometrial cancer;
SARC	cis	rs7904368	0.754	rs7091240	chr10:16855683	G/A	cg23933602	chr10:16859644	RSU1	0.59	5.94	0.36	1.02e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg16479474	chr6:28041457	NA	0.37	5.44	0.34	1.37e-7	Depression;
SARC	cis	rs9291683	0.530	rs73227883	chr4:9979279	T/C	cg00071950	chr4:10020882	SLC2A9	0.41	6.64	0.4	2.24e-10	Bone mineral density;
SARC	cis	rs3126085	0.935	rs11583524	chr1:152161657	T/C	cg03465714	chr1:152285911	FLG	0.48	5.46	0.34	1.24e-7	Atopic dermatitis;
SARC	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg25036284	chr2:26402008	FAM59B	0.47	5.55	0.34	7.65e-8	Gut microbiome composition (summer);
SARC	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg03060546	chr3:49711283	APEH	0.44	5.41	0.33	1.52e-7	Parkinson's disease;
SARC	cis	rs3126085	0.935	rs4845734	chr1:152167473	T/C	cg26876637	chr1:152193138	HRNR	0.48	5.47	0.34	1.14e-7	Atopic dermatitis;
SARC	cis	rs77372450	0.551	rs10515752	chr5:157072377	G/A	cg05585991	chr5:157099197	C5orf52	0.52	5.11	0.32	6.68e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg10876282	chr6:28092338	ZSCAN16	0.49	4.82	0.3	2.57e-6	Parkinson's disease;
SARC	cis	rs9815354	1.000	rs28755797	chr3:41774446	C/T	cg03022575	chr3:42003672	ULK4	0.65	5.52	0.34	8.91e-8	Pulse pressure;Diastolic blood pressure;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg14797887	chr15:56757312	MNS1	0.5	6.48	0.39	5.4e-10	Schizophrenia;
SARC	cis	rs1707322	1.000	rs11211239	chr1:46451947	A/G	cg03146154	chr1:46216737	IPP	0.45	5.41	0.33	1.57e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	12.21	0.62	7.99e-27	Platelet count;
SARC	cis	rs36051895	0.632	rs10115335	chr9:5140963	A/T	cg02405213	chr9:5042618	JAK2	-0.45	-5.48	-0.34	1.12e-7	Pediatric autoimmune diseases;
SARC	cis	rs854765	0.547	rs6502633	chr17:17941037	G/C	cg05444541	chr17:17804740	TOM1L2	-0.3	-4.87	-0.3	2.1e-6	Total body bone mineral density;
SARC	cis	rs9527	0.590	rs12246739	chr10:104787019	A/C	cg04362960	chr10:104952993	NT5C2	-0.43	-5.12	-0.32	6.48e-7	Arsenic metabolism;
SARC	cis	rs7666738	0.830	rs13130923	chr4:99046281	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs453301	0.686	rs6601281	chr8:8911004	A/G	cg11995313	chr8:8860691	ERI1	0.49	6.24	0.38	2.02e-9	Joint mobility (Beighton score);
SARC	cis	rs829883	0.664	rs865509	chr12:98854444	T/A	cg25150519	chr12:98850993	NA	0.84	13.52	0.66	4.05e-31	Colorectal adenoma (advanced);
SARC	cis	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg12463550	chr7:65579703	CRCP	0.71	5.34	0.33	2.19e-7	Diabetic kidney disease;
SARC	cis	rs1267303	0.642	rs1267301	chr1:46992853	C/G	cg25110126	chr1:46999211	NA	-0.93	-9.64	-0.53	9.77e-19	Monobrow;
SARC	cis	rs9814567	0.964	rs9847788	chr3:134186496	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.53	-6.56	-0.39	3.5e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg19077165	chr18:44547161	KATNAL2	-0.49	-6.66	-0.4	1.93e-10	Personality dimensions;
SARC	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg08677398	chr8:58056175	NA	0.44	5.25	0.33	3.38e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs523522	0.885	rs524735	chr12:121022099	T/C	cg12219531	chr12:120966889	COQ5	0.82	11.03	0.59	4.87e-23	High light scatter reticulocyte count;
SARC	cis	rs6701037	0.748	rs11583687	chr1:175132049	A/C	cg00321850	chr1:175162397	KIAA0040	0.34	4.99	0.31	1.17e-6	Alcohol dependence;
SARC	cis	rs78487399	0.710	rs6743071	chr2:43586287	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.65	-5.02	-0.31	1.03e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs820218	0.926	rs820201	chr17:73634687	G/A	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.65	8.72	0.5	5.43e-16	Rotator cuff tears;
SARC	cis	rs7824557	0.806	rs6601574	chr8:11094885	G/A	cg21775007	chr8:11205619	TDH	-0.46	-5.47	-0.34	1.15e-7	Retinal vascular caliber;
SARC	cis	rs9398803	0.799	rs1538170	chr6:126752874	C/T	cg19875578	chr6:126661172	C6orf173	0.58	7.72	0.45	3.51e-13	Male-pattern baldness;
SARC	cis	rs10512697	0.803	rs11739180	chr5:3580077	C/A	cg19473799	chr5:3511975	NA	-0.62	-4.72	-0.3	4.03e-6	Immune response to smallpox vaccine (IL-6);
SARC	cis	rs9660992	0.710	rs1668872	chr1:205236069	G/A	cg07972983	chr1:205091412	RBBP5	0.56	6.71	0.4	1.48e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs910316	0.967	rs11159116	chr14:75550584	G/T	cg08847533	chr14:75593920	NEK9	0.93	15.83	0.72	8.49e-39	Height;
SARC	cis	rs3845702	0.736	rs259811	chr2:180787801	C/T	cg01881094	chr2:180872142	CWC22	-1.14	-8.79	-0.5	3.39e-16	Schizophrenia;
SARC	trans	rs61931739	0.571	rs4001689	chr12:34243271	C/T	cg13010199	chr12:38710504	ALG10B	0.72	9.88	0.54	1.85e-19	Morning vs. evening chronotype;
SARC	cis	rs17376456	0.877	rs34595581	chr5:93369422	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.86	0.36	1.59e-8	Diabetic retinopathy;
SARC	trans	rs9329221	0.648	rs4512422	chr8:10258889	C/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.87	-0.41	5.87e-11	Neuroticism;
SARC	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg11644478	chr21:40555479	PSMG1	1.04	14.56	0.69	1.39e-34	Cognitive function;
SARC	cis	rs10911232	0.524	rs10911229	chr1:183050368	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.35	0.56	6.82e-21	Hypertriglyceridemia;
SARC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.62	-0.4	2.4e-10	Total body bone mineral density;
SARC	cis	rs897080	0.515	rs698815	chr2:44706974	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	6.08	0.37	4.93e-9	Height;
SARC	cis	rs748404	0.697	rs493177	chr15:43543258	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	6.92	0.41	4.23e-11	Lung cancer;
SARC	cis	rs473651	0.935	rs35080527	chr2:239351387	T/C	cg21699342	chr2:239360505	ASB1	0.48	7.1	0.42	1.52e-11	Multiple system atrophy;
SARC	cis	rs929354	0.685	rs1808217	chr7:157002741	T/C	cg05182265	chr7:156933206	UBE3C	-0.31	-4.84	-0.3	2.41e-6	Body mass index;
SARC	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg11890956	chr21:40555474	PSMG1	1.18	19.56	0.79	4.77e-51	Cognitive function;
SARC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.72	9.84	0.54	2.49e-19	Lymphocyte counts;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg25465019	chr1:87794181	LMO4	0.56	7.17	0.43	9.78e-12	Breast cancer;
SARC	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg22004693	chr7:99632812	ZKSCAN1	0.53	5.2	0.32	4.35e-7	Lung function (FEV1/FVC);
SARC	cis	rs6570726	0.935	rs384519	chr6:145846017	C/A	cg05347473	chr6:146136440	FBXO30	0.49	6.55	0.39	3.56e-10	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs12310956	0.532	rs10844720	chr12:33987859	G/T	cg13010199	chr12:38710504	ALG10B	0.65	8.68	0.49	7.12e-16	Morning vs. evening chronotype;
SARC	cis	rs1355223	0.902	rs704744	chr11:34736561	A/G	cg18508148	chr11:34937573	PDHX;APIP	-0.38	-4.83	-0.3	2.46e-6	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs2845885	0.793	rs57779243	chr11:63882363	G/T	cg24431193	chr11:63883947	FLRT1;MACROD1	0.75	6.95	0.41	3.73e-11	Body mass index;
SARC	cis	rs9906944	0.933	rs35051752	chr17:47089908	G/A	cg16584676	chr17:46985605	UBE2Z	-0.43	-5.21	-0.32	4.23e-7	Intelligence (multi-trait analysis);Body fat percentage;
SARC	cis	rs7246657	0.943	rs7253091	chr19:37967214	C/T	cg23950597	chr19:37808831	NA	-0.57	-5.69	-0.35	3.83e-8	Coronary artery calcification;
SARC	cis	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg20965017	chr5:231967	SDHA	-0.55	-5.26	-0.33	3.23e-7	Breast cancer;
SARC	cis	rs10489202	1.000	rs2272911	chr1:167936302	C/T	cg24449463	chr1:168025552	DCAF6	-0.65	-7.05	-0.42	2.04e-11	Schizophrenia;
SARC	cis	rs7208859	0.573	rs7214313	chr17:29138596	T/C	cg13385521	chr17:29058706	SUZ12P	0.89	7.77	0.45	2.44e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9309711	0.736	rs13412581	chr2:3497187	G/A	cg10845886	chr2:3471009	TTC15	-0.51	-5.32	-0.33	2.46e-7	Neurofibrillary tangles;
SARC	cis	rs7666738	0.723	rs35327100	chr4:98977788	C/A	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2304069	0.955	rs4288106	chr5:149394872	A/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.65	6.41	0.39	7.82e-10	HIV-1 control;
SARC	cis	rs9840812	0.728	rs12630999	chr3:136300927	G/A	cg15507776	chr3:136538369	TMEM22	0.51	5.74	0.35	2.96e-8	Fibrinogen levels;
SARC	cis	rs11190604	1.000	rs2489046	chr10:102346282	A/C	cg07080220	chr10:102295463	HIF1AN	0.79	10.14	0.55	3.02e-20	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs7727544	0.735	rs272860	chr5:131684175	C/G	cg24060327	chr5:131705240	SLC22A5	-0.66	-8.28	-0.48	9.56e-15	Blood metabolite levels;
SARC	cis	rs617791	0.508	rs747526	chr11:65776071	C/A	cg09462587	chr11:65769444	EIF1AD;BANF1	0.41	4.79	0.3	2.95e-6	Breast cancer;
SARC	cis	rs1691799	0.899	rs1168307	chr12:66739539	A/G	cg16791601	chr12:66731901	HELB	-0.71	-10.61	-0.57	1.05e-21	White blood cell count (basophil);
SARC	cis	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg05623727	chr3:50126028	RBM5	0.33	5.0	0.31	1.14e-6	Intelligence (multi-trait analysis);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg15133313	chr6:53213956	ELOVL5	0.56	7.04	0.42	2.18e-11	Height;
SARC	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg00800038	chr16:89945340	TCF25	-0.72	-5.35	-0.33	2.12e-7	Skin colour saturation;
SARC	cis	rs7769051	1.000	rs58832890	chr6:133127139	C/T	cg07930552	chr6:133119739	C6orf192	0.89	8.0	0.46	5.97e-14	Type 2 diabetes nephropathy;
SARC	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs6580649	0.941	rs1793931	chr12:48396505	G/T	cg24011408	chr12:48396354	COL2A1	0.65	7.26	0.43	5.61e-12	Lung cancer;
SARC	trans	rs2420915	0.630	rs2243609	chr10:122874348	A/C	cg21948465	chr5:131705150	SLC22A5	-0.54	-6.7	-0.4	1.57e-10	Fibrinogen levels;
SARC	cis	rs7772486	0.720	rs702320	chr6:146006654	G/A	cg05347473	chr6:146136440	FBXO30	-0.55	-7.76	-0.45	2.64e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs751728	1.000	rs2296747	chr6:33744882	C/G	cg25922239	chr6:33757077	LEMD2	0.78	10.18	0.55	2.33e-20	Crohn's disease;
SARC	cis	rs881375	0.967	rs1930780	chr9:123686219	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.42	5.09	0.32	7.3e-7	Rheumatoid arthritis;
SARC	cis	rs9420	0.961	rs7121169	chr11:57452543	G/A	cg23127183	chr11:57508653	C11orf31	-0.56	-6.36	-0.38	1.08e-9	Schizophrenia;
SARC	cis	rs854765	0.547	rs2955380	chr17:17944349	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-9.75	-0.54	4.63e-19	Total body bone mineral density;
SARC	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-10.73	-0.58	4.38e-22	Chronic sinus infection;
SARC	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	5.19	0.32	4.62e-7	Personality dimensions;
SARC	cis	rs1559088	0.600	rs7246566	chr19:33589618	A/T	cg27124370	chr19:33622961	WDR88	0.5	6.67	0.4	1.82e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs2735413	0.881	rs12921945	chr16:78080133	G/T	cg04733911	chr16:78082701	NA	-0.3	-5.45	-0.34	1.29e-7	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs7568458	0.846	rs1078004	chr2:85769711	C/G	cg02493740	chr2:85810744	VAMP5	-0.36	-5.3	-0.33	2.66e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.45	5.57	0.34	6.93e-8	Tonsillectomy;
SARC	cis	rs16933812	0.510	rs10114416	chr9:36990635	T/C	cg14294708	chr9:37120828	ZCCHC7	-0.43	-4.81	-0.3	2.7e-6	Obesity-related traits;
SARC	cis	rs8014204	0.720	rs34752362	chr14:75232306	G/A	cg17347104	chr14:75034677	LTBP2	-0.41	-5.05	-0.31	9.01e-7	Caffeine consumption;
SARC	cis	rs478304	0.651	rs11227299	chr11:65549570	C/G	cg27068330	chr11:65405492	SIPA1	-0.4	-4.75	-0.3	3.49e-6	Acne (severe);
SARC	cis	rs74181299	0.784	rs2723082	chr2:65289623	C/T	cg20592124	chr2:65290738	CEP68	0.47	6.84	0.41	6.8e-11	Pulse pressure;
SARC	cis	rs11792861	0.816	rs113624314	chr9:111689953	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.74	8.95	0.51	1.16e-16	Menarche (age at onset);
SARC	cis	rs35213789	0.959	rs12698814	chr7:69368003	G/A	cg10619644	chr7:69149951	AUTS2	0.47	5.65	0.35	4.61e-8	Childhood ear infection;
SARC	cis	rs5753618	0.583	rs5749279	chr22:31854209	A/G	cg02404636	chr22:31891804	SFI1	0.57	7.04	0.42	2.09e-11	Colorectal cancer;
SARC	cis	rs7568458	0.905	rs59877521	chr2:85759494	C/T	cg02493740	chr2:85810744	VAMP5	-0.35	-5.11	-0.32	6.73e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs34375054	0.641	rs34624329	chr12:125608028	T/G	cg25124228	chr12:125621409	AACS	-0.56	-7.03	-0.42	2.3e-11	Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs9733	0.526	rs6587542	chr1:150907701	G/T	cg13175981	chr1:150552382	MCL1	-0.52	-6.37	-0.39	1.01e-9	Tonsillectomy;
SARC	cis	rs12973672	1.000	rs1052033	chr19:35770471	C/T	cg12095397	chr19:35769544	USF2	0.38	4.79	0.3	2.9e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9815354	0.953	rs13088394	chr3:41951715	G/A	cg03022575	chr3:42003672	ULK4	-0.55	-5.22	-0.32	4.05e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs34779708	0.966	rs4934537	chr10:35441512	C/T	cg03585969	chr10:35415529	CREM	0.39	4.79	0.3	2.91e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs6740322	0.895	rs9309098	chr2:43554972	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.58	6.91	0.41	4.69e-11	Coronary artery disease;
SARC	cis	rs3768617	0.510	rs7542640	chr1:183063738	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.65	0.57	7.77e-22	Fuchs's corneal dystrophy;
SARC	trans	rs925098	0.597	rs2658751	chr4:17941563	T/A	cg08521178	chr6:170491202	NA	0.42	6.58	0.4	3.03e-10	Birth weight;Height;
SARC	cis	rs9914988	0.943	rs9893782	chr17:27108132	C/T	cg20469991	chr17:27169893	C17orf63	-0.5	-5.21	-0.32	4.1e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs7520050	0.933	rs12045165	chr1:46256022	C/A	cg06784218	chr1:46089804	CCDC17	-0.27	-4.89	-0.3	1.92e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg25072359	chr17:41440525	NA	0.48	5.63	0.35	5.24e-8	Menopause (age at onset);
SARC	cis	rs9467773	0.620	rs2494716	chr6:26662736	T/C	cg11502198	chr6:26597334	ABT1	0.63	8.48	0.49	2.58e-15	Intelligence (multi-trait analysis);
SARC	trans	rs7815944	0.661	rs11780606	chr8:129355112	G/A	cg25487405	chr22:46473039	NA	0.64	6.37	0.39	9.82e-10	Atopic dermatitis;
SARC	cis	rs4911259	0.593	rs6058924	chr20:31464467	G/A	cg13636640	chr20:31349939	DNMT3B	-0.69	-9.6	-0.53	1.34e-18	Inflammatory bowel disease;
SARC	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9733	0.650	rs11204684	chr1:150608894	A/G	cg18016565	chr1:150552671	MCL1	-0.38	-5.19	-0.32	4.51e-7	Tonsillectomy;
SARC	cis	rs55823223	0.646	rs74410877	chr17:73832384	C/T	cg06969265	chr17:73775802	H3F3B	1.07	9.58	0.53	1.51e-18	Psoriasis;
SARC	cis	rs9443189	0.526	rs775060	chr6:76373567	G/A	cg01950844	chr6:76311363	SENP6	-0.86	-8.12	-0.47	2.7e-14	Prostate cancer;
SARC	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.27	-4.87	-0.3	2.02e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs929354	0.713	rs1034785	chr7:157002383	T/C	cg05182265	chr7:156933206	UBE3C	-0.31	-4.73	-0.3	3.91e-6	Body mass index;
SARC	cis	rs2624839	0.679	rs2624835	chr3:50209049	G/A	cg14019146	chr3:50243930	SLC38A3	-0.43	-6.82	-0.41	7.83e-11	Intelligence (multi-trait analysis);
SARC	cis	rs1971762	0.527	rs6580958	chr12:54073483	A/G	cg06632207	chr12:54070931	ATP5G2	0.53	6.91	0.41	4.52e-11	Height;
SARC	cis	rs2243480	1.000	rs1618893	chr7:66096119	C/T	cg18252515	chr7:66147081	NA	-1.0	-8.65	-0.49	8.55e-16	Diabetic kidney disease;
SARC	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg16680214	chr1:154839983	KCNN3	-0.36	-5.87	-0.36	1.46e-8	Prostate cancer;
SARC	cis	rs2180341	0.814	rs7768435	chr6:127737038	A/C	cg27446573	chr6:127587934	RNF146	0.79	10.27	0.56	1.21e-20	Breast cancer;
SARC	cis	rs898097	0.841	rs4986136	chr17:80865119	A/G	cg20578329	chr17:80767326	TBCD	0.55	7.36	0.43	3.08e-12	Breast cancer;
SARC	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg20102877	chr2:27665638	KRTCAP3	-0.37	-5.35	-0.33	2.08e-7	Total body bone mineral density;
SARC	cis	rs73242632	1.000	rs2271806	chr4:57887150	C/T	cg20415529	chr4:57845134	POLR2B;C4orf14	1.07	6.6	0.4	2.74e-10	Congenital heart disease (maternal effect);
SARC	cis	rs796364	1.000	rs769949	chr2:200729558	A/G	cg23649088	chr2:200775458	C2orf69	0.59	5.34	0.33	2.23e-7	Schizophrenia;
SARC	cis	rs3859192	0.599	rs12451897	chr17:38179275	G/T	cg17467752	chr17:38218738	THRA	-0.38	-4.85	-0.3	2.23e-6	White blood cell count;
SARC	cis	rs7772486	0.754	rs2328707	chr6:146053498	G/A	cg23711669	chr6:146136114	FBXO30	-0.93	-16.43	-0.73	8.61e-41	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs546131	0.890	rs485845	chr11:34830389	G/T	cg06937548	chr11:34938143	PDHX;APIP	-0.51	-6.78	-0.41	1e-10	Lung disease severity in cystic fibrosis;
SARC	cis	rs858239	0.601	rs1558313	chr7:23156079	G/A	cg23682824	chr7:23144976	KLHL7	0.73	9.83	0.54	2.71e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs5167	0.566	rs7253458	chr19:45482570	C/T	cg09555818	chr19:45449301	APOC2	0.39	5.17	0.32	5.11e-7	Blood protein levels;
SARC	cis	rs12142240	0.698	rs56063031	chr1:46825433	C/T	cg14993813	chr1:46806288	NSUN4	-0.51	-5.34	-0.33	2.19e-7	Menopause (age at onset);
SARC	cis	rs933688	1.000	rs6862125	chr5:90724598	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.05	12.98	0.65	2.37e-29	Smoking behavior;
SARC	cis	rs11785400	1.000	rs6988393	chr8:143740596	A/G	cg24634471	chr8:143751801	JRK	0.68	9.17	0.52	2.5e-17	Schizophrenia;
SARC	cis	rs10089	1.000	rs4835941	chr5:127430905	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.85	10.44	0.56	3.42e-21	Ileal carcinoids;
SARC	cis	rs2304069	0.507	rs4705407	chr5:149404983	G/T	cg12661370	chr5:149340060	SLC26A2	0.59	7.21	0.43	7.73e-12	HIV-1 control;
SARC	cis	rs4595586	0.545	rs1562728	chr12:39405740	C/T	cg26384229	chr12:38710491	ALG10B	0.5	6.12	0.37	3.98e-9	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg08219700	chr8:58056026	NA	0.48	4.93	0.31	1.57e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg20887711	chr4:1340912	KIAA1530	0.4	4.74	0.3	3.76e-6	Longevity;
SARC	cis	rs13191362	1.000	rs34138336	chr6:163144929	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.72	6.11	0.37	4.25e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg16132339	chr22:24313637	DDTL;DDT	-0.44	-5.64	-0.35	4.86e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6570726	0.599	rs9376951	chr6:145898911	C/T	cg05347473	chr6:146136440	FBXO30	0.71	9.92	0.55	1.38e-19	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs61931739	0.534	rs2389276	chr12:34097891	T/C	cg26384229	chr12:38710491	ALG10B	0.74	10.14	0.55	2.95e-20	Morning vs. evening chronotype;
SARC	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg03060546	chr3:49711283	APEH	0.48	6.31	0.38	1.37e-9	Menarche (age at onset);
SARC	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg12310025	chr6:25882481	NA	-0.55	-7.08	-0.42	1.68e-11	Intelligence (multi-trait analysis);
SARC	cis	rs735396	0.770	rs1169314	chr12:121443116	A/G	cg02403541	chr12:121454288	C12orf43	0.84	12.5	0.63	8.82e-28	N-glycan levels;
SARC	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg03433033	chr1:76189801	ACADM	0.47	5.93	0.36	1.1e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.5	-6.22	-0.38	2.25e-9	Bipolar disorder;
SARC	cis	rs9788721	0.836	rs17483548	chr15:78730313	G/A	cg06917634	chr15:78832804	PSMA4	-0.58	-6.16	-0.37	3.21e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs3754214	0.769	rs509345	chr1:150276022	A/G	cg09579323	chr1:150459698	TARS2	-0.41	-5.02	-0.31	1.01e-6	Cerebrospinal fluid biomarker levels;
SARC	cis	rs8523	0.933	rs1225717	chr6:10978240	C/T	cg13562911	chr6:11044106	ELOVL2	-0.47	-6.2	-0.38	2.6e-9	Red blood cell fatty acid levels;
SARC	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg15448220	chr1:150897856	SETDB1	0.48	6.13	0.37	3.81e-9	Melanoma;
SARC	cis	rs9790314	0.905	rs6441370	chr3:160993754	C/T	cg03342759	chr3:160939853	NMD3	-0.63	-8.01	-0.46	5.57e-14	Morning vs. evening chronotype;
SARC	cis	rs4481887	1.000	rs4593862	chr1:248480176	G/T	cg01631408	chr1:248437212	OR2T33	-0.42	-5.22	-0.32	4e-7	Common traits (Other);
SARC	cis	rs898097	0.625	rs7406464	chr17:80891460	A/G	cg02711726	chr17:80685570	FN3KRP	0.4	5.75	0.35	2.8e-8	Breast cancer;
SARC	cis	rs7089973	0.624	rs10885614	chr10:116609098	C/T	cg08188268	chr10:116634841	FAM160B1	0.28	4.79	0.3	3.02e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs4742903	0.527	rs7852515	chr9:106916916	G/A	cg14250997	chr9:106856677	SMC2	0.4	4.78	0.3	3.05e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	5.34	0.33	2.17e-7	Tonsillectomy;
SARC	cis	rs9325144	0.555	rs4882279	chr12:38688918	C/A	cg26384229	chr12:38710491	ALG10B	0.59	7.85	0.46	1.51e-13	Morning vs. evening chronotype;
SARC	cis	rs2236918	0.932	rs1635517	chr1:242012033	A/G	cg17736920	chr1:242011382	EXO1	-0.79	-11.13	-0.59	2.32e-23	Menopause (age at onset);
SARC	cis	rs8114671	0.836	rs6060165	chr20:33619480	A/C	cg24642439	chr20:33292090	TP53INP2	-0.51	-5.96	-0.36	9.08e-9	Height;
SARC	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg03433033	chr1:76189801	ACADM	0.53	7.72	0.45	3.49e-13	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9875589	0.509	rs7648345	chr3:14039901	G/A	cg19554555	chr3:13937349	NA	-0.4	-5.22	-0.32	4.03e-7	Ovarian reserve;
SARC	cis	rs9905704	0.624	rs4932691	chr17:57094617	T/C	cg12560992	chr17:57184187	TRIM37	-0.43	-5.08	-0.32	7.6e-7	Testicular germ cell tumor;
SARC	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	8.97	0.51	1.03e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2180341	0.960	rs9401952	chr6:127677027	A/C	cg24812749	chr6:127587940	RNF146	1.0	13.05	0.65	1.42e-29	Breast cancer;
SARC	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg16405210	chr4:1374714	KIAA1530	-0.48	-5.72	-0.35	3.29e-8	Obesity-related traits;
SARC	cis	rs8114671	0.562	rs6088640	chr20:33472509	C/T	cg07148914	chr20:33460835	GGT7	0.42	5.06	0.31	8.36e-7	Height;
SARC	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg04772025	chr11:68637568	NA	0.5	6.27	0.38	1.76e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs763121	0.853	rs9306329	chr22:39072454	C/T	cg21395723	chr22:39101663	GTPBP1	0.54	6.04	0.37	6.17e-9	Menopause (age at onset);
SARC	cis	rs8013055	0.846	rs8013827	chr14:105970176	C/T	cg19700328	chr14:106028568	NA	0.58	8.24	0.48	1.22e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
SARC	trans	rs804280	0.509	rs9886639	chr8:11784529	G/T	cg06636001	chr8:8085503	FLJ10661	0.52	6.66	0.4	1.97e-10	Myopia (pathological);
SARC	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg04267008	chr7:1944627	MAD1L1	-0.48	-5.17	-0.32	5.08e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs6500395	1.000	rs28577888	chr16:48673281	T/G	cg04672837	chr16:48644449	N4BP1	0.47	6.24	0.38	2.05e-9	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg05368731	chr17:41323189	NBR1	0.79	9.6	0.53	1.33e-18	Menopause (age at onset);
SARC	cis	rs17539620	0.519	rs12665532	chr6:154835182	C/G	cg20019720	chr6:154832845	CNKSR3	0.44	5.32	0.33	2.45e-7	Lipoprotein (a) levels;
SARC	cis	rs7296418	0.580	rs78455769	chr12:123856443	G/A	cg00376283	chr12:123451042	ABCB9	0.59	7.26	0.43	5.8e-12	Platelet count;
SARC	cis	rs6669919	0.553	rs11587632	chr1:211668437	T/C	cg10512769	chr1:211675356	NA	-0.36	-5.81	-0.36	2.03e-8	Intelligence (multi-trait analysis);
SARC	cis	rs1153858	1.000	rs59889118	chr15:45618730	G/A	cg26924012	chr15:45694286	SPATA5L1	0.76	10.27	0.56	1.15e-20	Homoarginine levels;
SARC	cis	rs1008375	0.932	rs13109475	chr4:17677565	C/G	cg02297831	chr4:17616191	MED28	-0.43	-5.29	-0.33	2.78e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs656319	0.586	rs35013996	chr8:9947145	A/G	cg21775007	chr8:11205619	TDH	-0.54	-6.38	-0.39	9.47e-10	Myopia (pathological);
SARC	cis	rs7607369	0.559	rs4674343	chr2:219660346	C/T	cg02176678	chr2:219576539	TTLL4	0.4	6.24	0.38	2.01e-9	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg27266027	chr21:40555129	PSMG1	-0.42	-4.97	-0.31	1.31e-6	Menarche (age at onset);
SARC	cis	rs9911578	1.000	rs2009948	chr17:56611920	A/C	cg12560992	chr17:57184187	TRIM37	-0.8	-10.77	-0.58	3.19e-22	Intelligence (multi-trait analysis);
SARC	cis	rs607987	0.836	rs11031027	chr11:30297374	T/C	cg06241208	chr11:30344200	C11orf46	0.42	5.03	0.31	9.7e-7	Body mass index;
SARC	cis	rs9467711	0.591	rs16891315	chr6:26111756	T/C	cg21479132	chr6:26055353	NA	0.93	7.0	0.42	2.7e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs367615	0.552	rs2963024	chr5:108730773	C/T	cg17395555	chr5:108820864	NA	-0.35	-5.0	-0.31	1.12e-6	Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	11.57	0.6	9.38e-25	Platelet count;
SARC	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.4	-5.01	-0.31	1.06e-6	Menarche (age at onset);
SARC	cis	rs11122272	0.735	rs2024878	chr1:231528415	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.63	8.88	0.5	1.87e-16	Hemoglobin concentration;
SARC	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg18252515	chr7:66147081	NA	1.35	12.11	0.62	1.7e-26	Diabetic kidney disease;
SARC	cis	rs11581859	0.613	rs72726139	chr1:99198542	G/A	cg20286094	chr1:99190917	SNX7	-0.42	-4.93	-0.31	1.55e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	trans	rs3857536	0.740	rs4710574	chr6:66890631	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.6	-7.14	-0.42	1.19e-11	Blood trace element (Cu levels);
SARC	cis	rs7084402	0.529	rs7912116	chr10:60335389	G/C	cg07615347	chr10:60278583	BICC1	0.4	5.35	0.33	2.12e-7	Refractive error;
SARC	cis	rs13166103	0.571	rs62366396	chr5:57758511	G/T	cg10487770	chr5:57879443	RAB3C	0.52	5.35	0.33	2.12e-7	Type 2 diabetes (age of onset);
SARC	cis	rs10504073	0.565	rs974780	chr8:49930976	G/A	cg00325661	chr8:49890786	NA	0.52	6.9	0.41	4.88e-11	Blood metabolite ratios;
SARC	cis	rs9303401	0.625	rs66508449	chr17:56691034	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	11.81	0.61	1.61e-25	Cognitive test performance;
SARC	cis	rs986417	1.000	rs2144114	chr14:61064210	T/C	cg27398547	chr14:60952738	C14orf39	0.87	7.44	0.44	1.96e-12	Gut microbiota (bacterial taxa);
SARC	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg11764359	chr7:65958608	NA	0.39	4.73	0.3	3.98e-6	Aortic root size;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg20731999	chr2:25190741	DNAJC27	0.47	6.62	0.4	2.47e-10	Thyroid stimulating hormone;
SARC	cis	rs17292804	0.506	rs71417868	chr14:104046592	A/T	cg26031613	chr14:104095156	KLC1	-0.59	-6.66	-0.4	1.93e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs8141529	0.956	rs469989	chr22:29303595	G/C	cg02153584	chr22:29168773	CCDC117	-0.76	-10.44	-0.56	3.53e-21	Lymphocyte counts;
SARC	cis	rs6700896	0.897	rs2375805	chr1:66156567	C/T	cg04111102	chr1:66153794	NA	0.36	5.54	0.34	8.17e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs1580019	0.587	rs7806113	chr7:32553084	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.61	8.07	0.47	3.62e-14	Cognitive ability;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg03862999	chr6:71874711	NA	-0.49	-6.25	-0.38	1.92e-9	Height;
SARC	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.23e-9	Life satisfaction;
SARC	cis	rs12701220	0.744	rs35588238	chr7:1012006	G/A	cg02733842	chr7:1102375	C7orf50	-0.38	-5.02	-0.31	1.04e-6	Bronchopulmonary dysplasia;
SARC	cis	rs2486288	0.656	rs12915314	chr15:45551491	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.45	-5.57	-0.34	7.07e-8	Glomerular filtration rate;
SARC	cis	rs7772486	0.790	rs9791313	chr6:146266172	T/C	cg23711669	chr6:146136114	FBXO30	-0.76	-11.77	-0.61	2.12e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9393692	1.000	rs2393593	chr6:26285683	T/C	cg13736514	chr6:26305472	NA	-0.67	-8.86	-0.5	2.05e-16	Educational attainment;
SARC	cis	rs4481887	0.962	rs6663952	chr1:248465682	A/G	cg13385794	chr1:248469461	NA	0.36	5.57	0.34	6.92e-8	Common traits (Other);
SARC	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.42	-5.23	-0.32	3.74e-7	Tonsillectomy;
SARC	cis	rs3087591	0.708	rs7502834	chr17:29689430	G/A	cg24425628	chr17:29625626	OMG;NF1	0.43	5.45	0.34	1.28e-7	Hip circumference;
SARC	cis	rs9814567	1.000	rs4974483	chr3:134219001	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-7.09	-0.42	1.56e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs2228479	0.717	rs1800358	chr16:89809319	T/C	cg00800038	chr16:89945340	TCF25	-0.66	-5.1	-0.32	7.1e-7	Skin colour saturation;
SARC	cis	rs34779708	0.931	rs35126129	chr10:35452141	G/A	cg03585969	chr10:35415529	CREM	0.38	4.74	0.3	3.76e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg07701084	chr6:150067640	NUP43	0.43	5.51	0.34	9.24e-8	Lung cancer;
SARC	trans	rs3780486	0.846	rs10813954	chr9:33137596	A/C	cg04842962	chr6:43655489	MRPS18A	1.09	19.8	0.79	7.63e-52	IgG glycosylation;
SARC	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.49	-5.42	-0.33	1.48e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg03351412	chr1:154909251	PMVK	0.62	7.87	0.46	1.37e-13	Prostate cancer;
SARC	cis	rs7659604	1.000	rs28640980	chr4:122664284	T/C	cg19748678	chr4:122722346	EXOSC9	0.44	5.46	0.34	1.2e-7	Type 2 diabetes;
SARC	cis	rs763121	0.853	rs5757187	chr22:39021522	A/G	cg14440974	chr22:39074834	NA	0.33	4.85	0.3	2.31e-6	Menopause (age at onset);
SARC	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg27121462	chr16:89883253	FANCA	0.67	10.72	0.57	4.78e-22	Vitiligo;
SARC	cis	rs9916302	0.861	rs11658219	chr17:37709782	G/A	cg07936489	chr17:37558343	FBXL20	-0.66	-8.43	-0.48	3.57e-15	Glomerular filtration rate (creatinine);
SARC	trans	rs1945213	0.694	rs7129022	chr11:55876132	A/G	cg15704280	chr7:45808275	SEPT13	0.67	6.94	0.41	3.74e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9796	0.558	rs11855102	chr15:41513257	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.55	-7.85	-0.46	1.51e-13	Menopause (age at onset);
SARC	cis	rs11170631	0.507	rs12307701	chr12:54090724	A/C	cg06632207	chr12:54070931	ATP5G2	0.44	5.63	0.35	5.22e-8	Height;
SARC	cis	rs6582630	0.622	rs11182004	chr12:38441254	G/A	cg26384229	chr12:38710491	ALG10B	-0.55	-6.86	-0.41	6.16e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9814567	1.000	rs6793487	chr3:134299426	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.56	6.93	0.41	4.14e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs2439831	0.850	rs3825783	chr15:44102309	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	8.35	0.48	6.09e-15	Lung cancer in ever smokers;
SARC	cis	rs7949030	1.000	rs7949030	chr11:62394881	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.46	6.65	0.4	2.08e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs911263	0.961	rs7148882	chr14:68740924	A/G	cg18825221	chr14:68749962	RAD51L1	-0.49	-8.55	-0.49	1.61e-15	Primary biliary cholangitis;
SARC	cis	rs7223966	1.000	rs9912904	chr17:61763534	A/C	cg00588841	chr17:61851480	DDX42;CCDC47	-0.62	-6.79	-0.41	9.03e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg15242686	chr22:24348715	GSTTP1	0.43	5.29	0.33	2.83e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs10463554	0.963	rs32840	chr5:102479150	A/C	cg23492399	chr5:102201601	PAM	-0.46	-5.16	-0.32	5.33e-7	Parkinson's disease;
SARC	trans	rs11098499	0.954	rs11935596	chr4:120412457	G/C	cg25214090	chr10:38739885	LOC399744	0.58	7.47	0.44	1.63e-12	Corneal astigmatism;
SARC	cis	rs9303401	0.659	rs62083436	chr17:57031742	G/A	cg25039879	chr17:56429692	SUPT4H1	0.62	5.77	0.35	2.46e-8	Cognitive test performance;
SARC	cis	rs317689	0.513	rs317678	chr12:69692166	C/G	cg22834771	chr12:69754056	YEATS4	-0.5	-6.47	-0.39	5.8e-10	Response to diuretic therapy;
SARC	cis	rs2908197	0.843	rs2961041	chr7:75945944	C/T	cg24580635	chr7:76178542	LOC100133091	-0.42	-4.79	-0.3	2.93e-6	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs780096	0.814	rs780093	chr2:27742603	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.32	-5.15	-0.32	5.47e-7	Total body bone mineral density;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24991001	chr8:94929228	PDP1	-0.54	-6.51	-0.39	4.67e-10	Fibrinogen levels;
SARC	cis	rs709400	1.000	rs3915733	chr14:104147353	G/A	cg12935359	chr14:103987150	CKB	-0.35	-5.18	-0.32	4.82e-7	Body mass index;
SARC	cis	rs72827839	0.516	rs72833461	chr17:45938105	T/G	cg23391107	chr17:45924227	SP6	0.41	4.73	0.3	3.97e-6	Ease of getting up in the morning;
SARC	cis	rs9811216	1.000	rs9831661	chr3:169528523	A/C	cg14222479	chr3:169487675	ARPM1	-0.42	-5.21	-0.32	4.26e-7	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg26681399	chr22:41777847	TEF	-0.45	-4.93	-0.31	1.59e-6	Vitiligo;
SARC	cis	rs5167	0.504	rs4803779	chr19:45456497	T/C	cg20090143	chr19:45452003	APOC2	0.31	4.99	0.31	1.18e-6	Blood protein levels;
SARC	trans	rs7844647	0.556	rs2719292	chr8:34169112	C/A	cg26394233	chr7:157444480	PTPRN2	0.43	6.41	0.39	7.99e-10	Body mass index;
SARC	cis	rs9457247	0.534	rs9366078	chr6:167399512	A/G	cg23791538	chr6:167370224	RNASET2	0.66	9.38	0.52	5.93e-18	Crohn's disease;
SARC	cis	rs13191362	1.000	rs68144677	chr6:163149024	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.72	6.11	0.37	4.25e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs4132509	0.739	rs10927033	chr1:243695539	C/A	cg21452805	chr1:244014465	NA	0.6	5.61	0.34	5.8e-8	RR interval (heart rate);
SARC	cis	rs7412746	0.658	rs6660845	chr1:150841066	G/A	cg15448220	chr1:150897856	SETDB1	0.5	6.51	0.39	4.62e-10	Melanoma;
SARC	cis	rs854765	0.583	rs9913724	chr17:17819101	A/G	cg05444541	chr17:17804740	TOM1L2	-0.3	-4.98	-0.31	1.21e-6	Total body bone mineral density;
SARC	cis	rs8053891	0.855	rs8053861	chr16:71997675	C/G	cg16558253	chr16:72132732	DHX38	-0.41	-5.32	-0.33	2.44e-7	Coronary artery disease;
SARC	cis	rs9611519	0.602	rs8138520	chr22:41412928	A/G	cg06634786	chr22:41940651	POLR3H	-0.38	-4.9	-0.31	1.8e-6	Neuroticism;
SARC	cis	rs55962025	0.883	rs362336	chr4:3213832	G/A	cg06533319	chr4:3265114	C4orf44	0.33	5.08	0.32	7.84e-7	Parental longevity (mother's age at death);
SARC	cis	rs1109501	0.770	rs34877483	chr4:71418769	T/C	cg22786090	chr4:71381880	NA	-0.37	-4.81	-0.3	2.68e-6	Alcoholism (heaviness of drinking);
SARC	cis	rs7937682	0.632	rs11823089	chr11:111673539	A/G	cg22437258	chr11:111473054	SIK2	-0.49	-5.71	-0.35	3.44e-8	Primary sclerosing cholangitis;
SARC	cis	rs2985684	0.841	rs2281836	chr14:50065717	G/C	cg04989706	chr14:50066350	PPIL5	-0.57	-6.32	-0.38	1.34e-9	Carotid intima media thickness;
SARC	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg16049864	chr8:95962084	TP53INP1	-0.47	-7.53	-0.44	1.08e-12	Type 2 diabetes;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg04410073	chr11:86511545	PRSS23	0.49	6.24	0.38	2.07e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	trans	rs61931739	0.534	rs11053075	chr12:34207009	A/G	cg13010199	chr12:38710504	ALG10B	-0.74	-9.97	-0.55	9.68e-20	Morning vs. evening chronotype;
SARC	cis	rs2153535	0.580	rs2327050	chr6:8440630	A/G	cg07606381	chr6:8435919	SLC35B3	0.78	11.09	0.59	3.11e-23	Motion sickness;
SARC	cis	rs473651	0.935	rs541128	chr2:239336449	A/G	cg00800569	chr2:239229395	TRAF3IP1	0.44	5.26	0.33	3.23e-7	Multiple system atrophy;
SARC	cis	rs10791097	0.694	rs10894275	chr11:130756251	C/T	cg12179176	chr11:130786555	SNX19	0.76	11.43	0.6	2.59e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs593982	0.920	rs618456	chr11:65475620	C/T	cg08755490	chr11:65554678	OVOL1	0.86	8.49	0.49	2.38e-15	Atopic dermatitis;
SARC	cis	rs6493487	0.582	rs116871859	chr15:51445569	G/A	cg02338191	chr15:51200825	AP4E1	0.52	4.84	0.3	2.35e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs3741404	0.583	rs640999	chr11:63869425	C/A	cg18225595	chr11:63971243	STIP1	0.4	5.67	0.35	4.24e-8	Platelet count;
SARC	trans	rs3734266	0.591	rs9469812	chr6:34567531	C/T	cg08157914	chr7:2646478	IQCE	0.55	6.35	0.38	1.1e-9	Systemic lupus erythematosus;
SARC	cis	rs34779708	0.931	rs2505631	chr10:35368385	A/T	cg03585969	chr10:35415529	CREM	-0.38	-4.92	-0.31	1.67e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg11764359	chr7:65958608	NA	0.86	12.33	0.63	3.29e-27	Aortic root size;
SARC	cis	rs9733	0.593	rs10888384	chr1:150574256	C/T	cg18016565	chr1:150552671	MCL1	-0.39	-5.33	-0.33	2.31e-7	Tonsillectomy;
SARC	cis	rs72772090	0.634	rs17401901	chr5:96091925	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.62	-5.16	-0.32	5.27e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2230307	0.536	rs580611	chr1:100622925	G/A	cg24955406	chr1:100503596	HIAT1	-0.68	-6.8	-0.41	8.78e-11	Carotid intima media thickness;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg09882061	chr5:175874675	FAF2	0.62	6.31	0.38	1.37e-9	Lung cancer in ever smokers;
SARC	cis	rs17401966	1.000	rs11121552	chr1:10435324	C/A	cg15208524	chr1:10270712	KIF1B	0.57	6.09	0.37	4.53e-9	Hepatocellular carcinoma;
SARC	cis	rs11792861	0.816	rs2304779	chr9:111670513	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.74	-9.01	-0.51	7.4e-17	Menarche (age at onset);
SARC	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg04277193	chr17:41438351	NA	0.45	4.85	0.3	2.21e-6	Menopause (age at onset);
SARC	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg01276201	chr10:134613136	NA	0.32	5.49	0.34	1.07e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs1153858	1.000	rs1890565	chr15:45663299	T/C	cg21132104	chr15:45694354	SPATA5L1	0.78	11.07	0.59	3.71e-23	Homoarginine levels;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg16697775	chr6:43543259	POLH;XPO5	-0.59	-6.69	-0.4	1.68e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs6570726	0.935	rs366621	chr6:145861275	A/G	cg05347473	chr6:146136440	FBXO30	0.48	6.43	0.39	7.04e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs60871478	1.000	rs62432253	chr7:802928	A/G	cg05535760	chr7:792225	HEATR2	0.84	8.3	0.48	8.65e-15	Cerebrospinal P-tau181p levels;
SARC	cis	rs2439831	0.681	rs999047	chr15:43688916	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	10.74	0.58	4.05e-22	Lung cancer in ever smokers;
SARC	cis	rs2486288	0.656	rs11637364	chr15:45579238	C/T	cg15395560	chr15:45543142	SLC28A2	0.28	5.11	0.32	6.74e-7	Glomerular filtration rate;
SARC	cis	rs3126085	0.935	rs6681457	chr1:152297117	C/T	cg03465714	chr1:152285911	FLG	0.49	5.46	0.34	1.19e-7	Atopic dermatitis;
SARC	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg02725872	chr8:58115012	NA	-0.34	-5.37	-0.33	1.91e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7312774	0.618	rs726943	chr12:107331647	A/G	cg16260113	chr12:107380972	MTERFD3	0.99	7.83	0.46	1.74e-13	Severe influenza A (H1N1) infection;
SARC	cis	rs9840812	0.610	rs34967300	chr3:136268818	A/G	cg15507776	chr3:136538369	TMEM22	-0.58	-6.03	-0.37	6.47e-9	Fibrinogen levels;
SARC	cis	rs28493229	0.522	rs2233152	chr19:41281016	C/T	cg07297178	chr19:42193084	CEACAM7	0.4	4.93	0.31	1.57e-6	Kawasaki disease;
SARC	cis	rs1865760	0.602	rs9467662	chr6:26021327	G/A	cg16482183	chr6:26056742	HIST1H1C	0.5	6.26	0.38	1.86e-9	Height;
SARC	cis	rs10089	1.000	rs10060181	chr5:127475573	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.82	10.0	0.55	8.01e-20	Ileal carcinoids;
SARC	cis	rs11786130	1.000	rs11786130	chr8:129004975	G/A	cg17583432	chr8:129005567	PVT1	-0.39	-6.78	-0.41	9.57e-11	Eosinophil counts;Sum eosinophil basophil counts;
SARC	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg03452623	chr4:187889614	NA	-0.79	-12.13	-0.62	1.44e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9399137	0.507	rs6923512	chr6:135335268	A/G	cg22676075	chr6:135203613	NA	-0.4	-4.93	-0.31	1.58e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs734999	0.588	rs10910098	chr1:2533250	C/A	cg20673091	chr1:2541236	MMEL1	0.33	5.19	0.32	4.53e-7	Ulcerative colitis;
SARC	cis	rs3796352	1.000	rs9874517	chr3:53128371	A/G	cg15956490	chr3:53032818	SFMBT1	0.7	4.86	0.3	2.18e-6	Immune reponse to smallpox (secreted IL-2);
SARC	trans	rs360488	0.639	rs13022704	chr2:14266475	T/C	cg13543375	chr1:22470218	WNT4	0.56	6.27	0.38	1.76e-9	Emphysema imaging phenotypes;
SARC	cis	rs548181	0.611	rs1293672	chr11:125461034	A/G	cg03464685	chr11:125439445	EI24	1.09	9.77	0.54	3.94e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs9796	0.835	rs11856848	chr15:41370961	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.43	-5.88	-0.36	1.4e-8	Menopause (age at onset);
SARC	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg12311346	chr5:56204834	C5orf35	0.69	6.55	0.39	3.74e-10	Initial pursuit acceleration;
SARC	cis	rs2439831	0.850	rs7163245	chr15:43671294	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.07	11.5	0.6	1.57e-24	Lung cancer in ever smokers;
SARC	trans	rs1814175	0.647	rs61306292	chr11:49856040	G/C	cg03929089	chr4:120376271	NA	-0.89	-14.2	-0.68	2.1e-33	Height;
SARC	cis	rs11874712	0.931	rs8095608	chr18:43678911	A/G	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.46	5.48	0.34	1.08e-7	Migraine - clinic-based;
SARC	cis	rs6964587	1.000	rs34548928	chr7:91668365	G/A	cg17063962	chr7:91808500	NA	0.94	15.52	0.71	8.99e-38	Breast cancer;
SARC	cis	rs981844	0.712	rs4632640	chr4:154742389	G/C	cg14289246	chr4:154710475	SFRP2	-0.44	-5.07	-0.32	8.03e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs9303401	0.614	rs34550282	chr17:57092788	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.97	9.88	0.54	1.94e-19	Cognitive test performance;
SARC	trans	rs61931739	0.534	rs4931783	chr12:34115322	G/A	cg13010199	chr12:38710504	ALG10B	0.76	10.28	0.56	1.08e-20	Morning vs. evening chronotype;
SARC	cis	rs2075371	1.000	rs2598297	chr7:133993001	T/G	cg00033643	chr7:134001901	SLC35B4	0.43	5.21	0.32	4.18e-7	Mean platelet volume;
SARC	cis	rs926392	0.589	rs6093115	chr20:37693817	T/C	cg16355469	chr20:37678765	NA	0.72	9.42	0.53	4.61e-18	Dialysis-related mortality;
SARC	cis	rs1580019	0.568	rs2122633	chr7:32523870	G/T	cg14728415	chr7:32535168	LSM5;AVL9	0.48	6.0	0.37	7.35e-9	Cognitive ability;
SARC	cis	rs7647973	0.626	rs35129566	chr3:49866584	T/G	cg13072238	chr3:49761600	GMPPB	0.59	5.9	0.36	1.25e-8	Menarche (age at onset);
SARC	cis	rs1728785	1.000	rs1099296	chr16:68588653	G/A	cg02972257	chr16:68554789	NA	-0.45	-5.32	-0.33	2.48e-7	Ulcerative colitis;
SARC	cis	rs11723261	0.582	rs4634177	chr4:136837	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.39	5.22	0.32	3.87e-7	Immune response to smallpox vaccine (IL-6);
SARC	cis	rs1008375	0.618	rs13129002	chr4:17567513	A/G	cg16339924	chr4:17578868	LAP3	0.61	7.18	0.43	9.52e-12	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10870270	0.956	rs10870281	chr10:133762642	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.5	-5.73	-0.35	3.08e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg24549020	chr5:56110836	MAP3K1	-0.56	-4.88	-0.3	1.98e-6	Initial pursuit acceleration;
SARC	cis	rs1144333	0.655	rs3920847	chr1:76435939	C/T	cg03433033	chr1:76189801	ACADM	0.61	4.9	0.31	1.77e-6	Attention function in attention deficit hyperactive disorder;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg22992591	chr20:32891100	AHCY	0.53	6.53	0.39	4.12e-10	Breast cancer;
SARC	cis	rs1707322	1.000	rs12077974	chr1:46384141	G/A	cg06784218	chr1:46089804	CCDC17	0.35	5.69	0.35	3.88e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2075371	0.933	rs2544182	chr7:133949793	C/T	cg11752832	chr7:134001865	SLC35B4	0.53	6.74	0.4	1.23e-10	Mean platelet volume;
SARC	cis	rs7647973	1.000	rs892974	chr3:49398514	C/A	cg07636037	chr3:49044803	WDR6	0.72	7.36	0.43	3.15e-12	Menarche (age at onset);
SARC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.63	-7.69	-0.45	4.04e-13	Longevity;Endometriosis;
SARC	cis	rs72781680	1.000	rs74704838	chr2:24158270	C/A	cg08917208	chr2:24149416	ATAD2B	0.77	7.19	0.43	8.94e-12	Lymphocyte counts;
SARC	cis	rs9381040	0.610	rs2294694	chr6:41046177	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.47	-5.34	-0.33	2.22e-7	Alzheimer's disease (late onset);
SARC	cis	rs7582720	0.561	rs114407963	chr2:204154677	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	7.68	0.45	4.37e-13	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs1865760	0.786	rs1436308	chr6:25939567	T/G	cg10373733	chr6:25993375	NA	0.41	4.85	0.3	2.27e-6	Height;
SARC	cis	rs79149102	0.649	rs9788672	chr15:74876353	T/C	cg09165964	chr15:75287851	SCAMP5	-0.66	-5.14	-0.32	5.74e-7	Lung cancer;
SARC	cis	rs6088813	1.000	rs1570004	chr20:33958253	A/T	cg23207816	chr20:34252616	CPNE1;RBM12	-0.42	-5.11	-0.32	6.72e-7	Height;
SARC	cis	rs9303280	0.806	rs36038753	chr17:38035370	G/T	cg17467752	chr17:38218738	THRA	-0.37	-4.76	-0.3	3.34e-6	Self-reported allergy;
SARC	cis	rs6088813	0.890	rs6088817	chr20:33984976	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	-0.45	-5.39	-0.33	1.71e-7	Height;
SARC	cis	rs4242434	0.854	rs3064	chr8:22451688	C/G	cg03733263	chr8:22462867	KIAA1967	-0.88	-13.32	-0.66	1.73e-30	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg27170947	chr2:26402098	FAM59B	0.4	5.19	0.32	4.64e-7	Gut microbiome composition (summer);
SARC	cis	rs1003719	0.708	rs2000417	chr21:38502868	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-9.12	-0.51	3.5e-17	Eye color traits;
SARC	cis	rs10875746	0.855	rs11168369	chr12:48431168	G/A	cg26205652	chr12:48591994	NA	0.52	5.54	0.34	8.28e-8	Longevity (90 years and older);
SARC	cis	rs6003958	1	rs6003958	chr22:24264089	T/G	cg24846343	chr22:24311635	DDTL	-0.41	-4.98	-0.31	1.21e-6	S-phenylmercapturic acid levels in smokers;
SARC	cis	rs12311304	1.000	rs1479406	chr12:15387543	C/T	cg08258403	chr12:15378311	NA	0.45	6.95	0.41	3.6e-11	Behavioural disinhibition (generation interaction);
SARC	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg16680214	chr1:154839983	KCNN3	-0.37	-5.82	-0.36	1.96e-8	Prostate cancer;
SARC	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg11494091	chr17:61959527	GH2	0.36	5.11	0.32	6.66e-7	Height;
SARC	trans	rs11098499	0.954	rs59866101	chr4:120296591	T/G	cg25214090	chr10:38739885	LOC399744	0.55	7.14	0.42	1.15e-11	Corneal astigmatism;
SARC	cis	rs3768617	0.510	rs20558	chr1:183094547	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.82e-21	Fuchs's corneal dystrophy;
SARC	cis	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg14343924	chr8:8086146	FLJ10661	0.44	5.53	0.34	8.51e-8	Mood instability;
SARC	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg20102877	chr2:27665638	KRTCAP3	-0.37	-5.05	-0.31	8.9e-7	Total body bone mineral density;
SARC	cis	rs3813567	0.759	rs12148319	chr15:78956192	A/G	cg04896959	chr15:78267971	NA	-0.51	-5.19	-0.32	4.6e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
SARC	cis	rs9815354	0.904	rs9852991	chr3:41875455	C/A	cg03022575	chr3:42003672	ULK4	0.62	5.43	0.34	1.39e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg16479474	chr6:28041457	NA	-0.36	-5.33	-0.33	2.36e-7	Depression;
SARC	cis	rs10463316	0.784	rs906678	chr5:150779040	T/C	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.34	-0.33	2.21e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs17253792	0.822	rs17746106	chr14:56069168	C/T	cg01858014	chr14:56050164	KTN1	-0.79	-6.94	-0.41	3.91e-11	Putamen volume;
SARC	cis	rs4853036	1.000	rs35084691	chr2:70094137	C/T	cg02498382	chr2:70120550	SNRNP27	-0.42	-5.44	-0.34	1.34e-7	Colorectal or endometrial cancer;
SARC	cis	rs12142240	0.698	rs17357621	chr1:46807697	C/T	cg00530320	chr1:46809349	NSUN4	0.58	7.07	0.42	1.74e-11	Menopause (age at onset);
SARC	cis	rs832540	0.519	rs6450411	chr5:56265771	A/G	cg14703610	chr5:56206110	C5orf35	0.44	5.19	0.32	4.54e-7	Coronary artery disease;
SARC	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.15	0.37	3.32e-9	Electroencephalogram traits;
SARC	trans	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg21659725	chr3:3221576	CRBN	0.56	7.19	0.43	8.92e-12	Intelligence (multi-trait analysis);
SARC	cis	rs9462027	1.000	rs9462027	chr6:34797241	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.56	-0.34	7.34e-8	Systemic lupus erythematosus;
SARC	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg03433033	chr1:76189801	ACADM	0.57	8.02	0.47	5.09e-14	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2916247	1.000	rs10092162	chr8:93062830	A/C	cg10183463	chr8:93005414	RUNX1T1	-0.59	-6.08	-0.37	4.75e-9	Intelligence (multi-trait analysis);
SARC	cis	rs12545109	1.000	rs1975284	chr8:57314663	A/G	cg19413350	chr8:57351067	NA	-0.45	-5.08	-0.32	7.61e-7	Obesity-related traits;
SARC	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg11987759	chr7:65425863	GUSB	0.49	6.49	0.39	5.04e-10	Aortic root size;
SARC	cis	rs2075371	0.966	rs1646646	chr7:133996905	G/T	cg00033643	chr7:134001901	SLC35B4	0.42	5.15	0.32	5.55e-7	Mean platelet volume;
SARC	cis	rs644799	1.000	rs488246	chr11:95560473	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	14.89	0.7	1.07e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9309473	0.950	rs11689588	chr2:73773691	A/G	cg20560298	chr2:73613845	ALMS1	-0.54	-6.2	-0.38	2.59e-9	Metabolite levels;
SARC	cis	rs9815354	1.000	rs1613759	chr3:41906183	G/A	cg03022575	chr3:42003672	ULK4	0.56	5.29	0.33	2.81e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2777491	0.574	rs11858812	chr15:41731550	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.17	-19.21	-0.78	6.11e-50	Ulcerative colitis;
SARC	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg24549020	chr5:56110836	MAP3K1	0.58	5.1	0.32	6.95e-7	Initial pursuit acceleration;
SARC	cis	rs4689388	0.926	rs4689391	chr4:6280449	G/A	cg25554036	chr4:6271136	WFS1	0.42	6.87	0.41	5.71e-11	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs950169	0.545	rs4354897	chr15:84644971	T/C	cg17507749	chr15:85114479	UBE2QP1	0.69	7.28	0.43	5e-12	Schizophrenia;
SARC	cis	rs708547	0.871	rs2687238	chr4:57880474	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.7	8.33	0.48	6.91e-15	Response to bleomycin (chromatid breaks);
SARC	cis	rs72634258	0.945	rs28624	chr1:8084355	G/T	cg00042356	chr1:8021962	PARK7	-0.55	-5.19	-0.32	4.61e-7	Inflammatory bowel disease;
SARC	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg08219700	chr8:58056026	NA	0.61	6.36	0.38	1.05e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg23248424	chr5:179741104	GFPT2	-0.46	-5.76	-0.35	2.67e-8	Height;
SARC	cis	rs6121246	0.909	rs6060923	chr20:30336655	A/C	cg13852791	chr20:30311386	BCL2L1	0.85	9.18	0.52	2.48e-17	Mean corpuscular hemoglobin;
SARC	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs113835537	0.597	rs11227523	chr11:66305938	C/T	cg24851651	chr11:66362959	CCS	0.39	4.91	0.31	1.7e-6	Airway imaging phenotypes;
SARC	trans	rs9329221	0.527	rs10903328	chr8:10332167	G/C	cg06636001	chr8:8085503	FLJ10661	0.62	8.91	0.5	1.52e-16	Neuroticism;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg11111859	chr10:97686634	C10orf131	0.47	6.65	0.4	2.03e-10	Thyroid stimulating hormone;
SARC	cis	rs950776	0.518	rs2869544	chr15:78839400	G/A	cg17108064	chr15:78857060	CHRNA5	-0.28	-4.8	-0.3	2.84e-6	Sudden cardiac arrest;
SARC	cis	rs6580649	0.941	rs58046797	chr12:48487619	T/C	cg24011408	chr12:48396354	COL2A1	-0.47	-5.34	-0.33	2.22e-7	Lung cancer;
SARC	cis	rs9640161	0.789	rs28432021	chr7:150046235	G/C	cg10018233	chr7:150070692	REPIN1	0.62	8.41	0.48	4.21e-15	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs1034435	0.609	rs6007863	chr22:48883054	T/C	cg05992904	chr22:48892994	FAM19A5	-0.41	-5.15	-0.32	5.45e-7	Late-onset Alzheimer's disease;
SARC	cis	rs9840812	0.655	rs696516	chr3:136067778	G/T	cg15507776	chr3:136538369	TMEM22	0.5	5.45	0.34	1.28e-7	Fibrinogen levels;
SARC	cis	rs9915657	0.870	rs12600458	chr17:70130545	C/T	cg06234051	chr17:70120541	SOX9	-0.33	-4.96	-0.31	1.34e-6	Thyroid hormone levels;
SARC	cis	rs832540	0.512	rs33320	chr5:56206529	C/T	cg14703610	chr5:56206110	C5orf35	0.45	5.13	0.32	6.03e-7	Coronary artery disease;
SARC	cis	rs2230307	0.536	rs7530361	chr1:100462860	T/C	cg24955406	chr1:100503596	HIAT1	0.67	6.56	0.4	3.38e-10	Carotid intima media thickness;
SARC	cis	rs1707322	0.964	rs10437063	chr1:46273666	G/A	cg06784218	chr1:46089804	CCDC17	0.33	5.76	0.35	2.66e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2718058	0.630	rs2718051	chr7:37824790	G/A	cg24998770	chr7:37888106	TXNDC3	0.36	5.2	0.32	4.41e-7	Alzheimer's disease (late onset);
SARC	cis	rs11711311	1.000	rs62268169	chr3:113493860	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	8.64	0.49	9.08e-16	IgG glycosylation;
SARC	cis	rs9828933	0.752	rs13433909	chr3:63948609	C/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.92	-8.41	-0.48	4.05e-15	Type 2 diabetes;
SARC	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg00933542	chr6:150070202	PCMT1	0.33	5.49	0.34	1.06e-7	Lung cancer;
SARC	cis	rs7772486	0.875	rs1331645	chr6:146398407	C/G	cg05347473	chr6:146136440	FBXO30	0.5	6.85	0.41	6.59e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7659604	1.000	rs6823488	chr4:122664819	A/G	cg20573242	chr4:122745356	CCNA2	0.43	5.7	0.35	3.59e-8	Type 2 diabetes;
SARC	cis	rs9677476	0.863	rs2006780	chr2:232066704	T/G	cg23338755	chr2:231921595	PSMD1	0.43	5.19	0.32	4.68e-7	Food antigen IgG levels;
SARC	cis	rs2952156	0.959	rs1565922	chr17:37831035	A/G	cg20243544	chr17:37824526	PNMT	0.47	5.88	0.36	1.43e-8	Asthma;
SARC	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg16479474	chr6:28041457	NA	0.37	5.29	0.33	2.84e-7	Depression;
SARC	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1355223	0.525	rs55796371	chr11:34872769	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.5	-6.36	-0.38	1.06e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs6570726	0.935	rs377130	chr6:145836632	C/T	cg05347473	chr6:146136440	FBXO30	0.48	6.42	0.39	7.51e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1957429	0.522	rs76721513	chr14:65403891	C/G	cg23373153	chr14:65346875	NA	-1.03	-6.42	-0.39	7.58e-10	Pediatric areal bone mineral density (radius);
SARC	cis	rs751728	0.965	rs2013381	chr6:33763837	C/T	cg15252951	chr6:33757062	LEMD2	0.57	6.81	0.41	8.32e-11	Crohn's disease;
SARC	cis	rs12311304	0.901	rs9788111	chr12:15417254	T/C	cg08258403	chr12:15378311	NA	0.42	6.54	0.39	3.9e-10	Behavioural disinhibition (generation interaction);
SARC	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.51	-5.94	-0.36	1.01e-8	Height;
SARC	cis	rs1707322	1.000	rs6675222	chr1:46326576	G/T	cg06784218	chr1:46089804	CCDC17	0.33	5.78	0.35	2.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg24642844	chr7:1081250	C7orf50	-0.59	-6.06	-0.37	5.31e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.59	-7.07	-0.42	1.81e-11	Gut microbiome composition (summer);
SARC	trans	rs3780486	0.846	rs3780490	chr9:33129839	A/G	cg04842962	chr6:43655489	MRPS18A	1.1	20.63	0.8	1.68e-54	IgG glycosylation;
SARC	cis	rs2153535	0.580	rs9505458	chr6:8479215	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.49	0.6	1.71e-24	Motion sickness;
SARC	cis	rs8016982	0.651	rs1885601	chr14:81641210	C/T	cg01989461	chr14:81687754	GTF2A1	0.77	11.75	0.61	2.42e-25	Schizophrenia;
SARC	cis	rs8067545	0.586	rs57837691	chr17:20203073	T/C	cg13482628	chr17:19912719	NA	-0.57	-7.44	-0.44	1.95e-12	Schizophrenia;
SARC	cis	rs2599510	0.811	rs176410	chr2:32643437	C/G	cg02381751	chr2:32503542	YIPF4	-0.47	-5.95	-0.36	1e-8	Interleukin-18 levels;
SARC	cis	rs1468333	1.000	rs13356202	chr5:137564588	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.81	10.8	0.58	2.62e-22	Resting heart rate;
SARC	cis	rs5758659	0.714	rs6002626	chr22:42517989	C/G	cg04733989	chr22:42467013	NAGA	-0.49	-5.83	-0.36	1.85e-8	Cognitive function;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg25684981	chr13:111567603	ANKRD10	-0.87	-6.5	-0.39	4.7e-10	Obesity-related traits;
SARC	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg17376030	chr22:41985996	PMM1	-0.64	-8.25	-0.48	1.19e-14	Vitiligo;
SARC	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg16405210	chr4:1374714	KIAA1530	-0.47	-5.64	-0.35	4.97e-8	Obesity-related traits;
SARC	cis	rs7264396	0.635	rs6058346	chr20:34481043	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-7.0	-0.42	2.68e-11	Total cholesterol levels;
SARC	cis	rs981844	0.712	rs1350189	chr4:154744951	A/T	cg14289246	chr4:154710475	SFRP2	-0.45	-5.27	-0.33	3.05e-7	Response to statins (LDL cholesterol change);
SARC	trans	rs3945119	0.838	rs1335732	chr1:91154009	C/A	cg01730148	chr2:3698421	NA	0.34	6.45	0.39	6.49e-10	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg18876405	chr7:65276391	NA	0.48	5.68	0.35	4.06e-8	Aortic root size;
SARC	cis	rs1580019	0.885	rs3801331	chr7:32497039	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.78	-10.63	-0.57	9.06e-22	Cognitive ability;
SARC	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs12681366	0.636	rs2515155	chr8:95388697	T/C	cg26464482	chr8:95565502	KIAA1429	-0.44	-5.42	-0.33	1.49e-7	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs7681440	0.801	rs1372513	chr4:90790237	G/A	cg02192967	chr4:90758406	SNCA	0.35	4.95	0.31	1.4e-6	Dementia with Lewy bodies;
SARC	cis	rs6772849	1.000	rs9839508	chr3:128310794	A/T	cg08795948	chr3:128337044	NA	-0.36	-4.82	-0.3	2.54e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs9473924	0.542	rs56240592	chr6:50815514	T/A	cg14470998	chr6:50812995	TFAP2B	0.7	6.19	0.38	2.66e-9	Body mass index;
SARC	cis	rs875971	0.789	rs28815324	chr7:65565776	A/T	cg11764359	chr7:65958608	NA	-0.63	-6.14	-0.37	3.47e-9	Aortic root size;
SARC	cis	rs4144743	1.000	rs67615769	chr17:45325478	A/G	cg18085866	chr17:45331354	ITGB3	-0.72	-7.34	-0.43	3.63e-12	Body mass index;
SARC	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	8.86	0.5	2.13e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs854765	0.583	rs7213225	chr17:17869111	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	9.72	0.54	5.87e-19	Total body bone mineral density;
SARC	cis	rs899997	1.000	rs11634628	chr15:79005579	G/A	cg04896959	chr15:78267971	NA	0.52	6.36	0.38	1.06e-9	Coronary artery disease or large artery stroke;
SARC	cis	rs3126085	0.935	rs6676012	chr1:152213203	G/A	cg26876637	chr1:152193138	HRNR	0.44	4.91	0.31	1.75e-6	Atopic dermatitis;
SARC	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.78	-0.5	3.56e-16	Alzheimer's disease;
SARC	cis	rs3106136	0.681	rs62321981	chr4:95310408	A/G	cg11021082	chr4:95130006	SMARCAD1	0.32	4.86	0.3	2.19e-6	Capecitabine sensitivity;
SARC	cis	rs1008375	0.932	rs964012	chr4:17619184	A/G	cg27347728	chr4:17578864	LAP3	0.49	6.09	0.37	4.55e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs17376456	0.825	rs17372057	chr5:93071916	C/A	cg25358565	chr5:93447407	FAM172A	1.16	12.04	0.62	2.74e-26	Diabetic retinopathy;
SARC	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg08280861	chr8:58055591	NA	0.6	5.28	0.33	2.92e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg23758822	chr17:41437982	NA	0.89	11.37	0.6	3.91e-24	Menopause (age at onset);
SARC	cis	rs6912958	0.781	rs9444512	chr6:88223397	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-5.84	-0.36	1.78e-8	Monocyte percentage of white cells;
SARC	trans	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg17830980	chr10:43048298	ZNF37B	-0.51	-6.71	-0.4	1.5e-10	Extrinsic epigenetic age acceleration;
SARC	cis	rs35213789	0.762	rs2851507	chr7:69115202	A/G	cg10619644	chr7:69149951	AUTS2	-0.35	-4.81	-0.3	2.75e-6	Childhood ear infection;
SARC	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg11878867	chr6:150167359	LRP11	-0.34	-4.72	-0.3	4.01e-6	Lung cancer;
SARC	cis	rs748404	0.697	rs504417	chr15:43554226	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	5.63	0.35	5.04e-8	Lung cancer;
SARC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.54	6.15	0.37	3.33e-9	Prudent dietary pattern;
SARC	cis	rs7043114	0.525	rs10761161	chr9:95262342	C/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.84	-0.36	1.77e-8	Height;
SARC	cis	rs4481887	0.861	rs6669290	chr1:248476804	G/A	cg13385794	chr1:248469461	NA	0.35	5.45	0.34	1.29e-7	Common traits (Other);
SARC	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg22496380	chr5:211416	CCDC127	-0.86	-8.85	-0.5	2.23e-16	Breast cancer;
SARC	trans	rs7937682	0.924	rs501089	chr11:111502479	G/T	cg18187862	chr3:45730750	SACM1L	-0.57	-6.82	-0.41	7.92e-11	Primary sclerosing cholangitis;
SARC	cis	rs7246657	0.943	rs10407084	chr19:37907792	T/C	cg23950597	chr19:37808831	NA	-0.63	-6.03	-0.37	6.33e-9	Coronary artery calcification;
SARC	cis	rs920590	0.796	rs10788700	chr8:19635098	T/C	cg17834443	chr8:19674713	INTS10	0.48	5.73	0.35	3.13e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs2760061	0.603	rs697762	chr1:228192410	G/A	cg01200585	chr1:228362443	C1orf69	0.44	5.74	0.35	3e-8	Diastolic blood pressure;
SARC	cis	rs2414059	0.518	rs56398519	chr15:50773432	A/G	cg05456662	chr15:50716270	USP8	-0.4	-4.85	-0.3	2.26e-6	QT interval;
SARC	trans	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg20587970	chr11:113659929	NA	-0.96	-8.42	-0.48	3.85e-15	Hip circumference adjusted for BMI;
SARC	cis	rs3768617	0.677	rs12739316	chr1:183052080	G/A	cg13390022	chr1:182993471	LAMC1	0.33	4.91	0.31	1.73e-6	Fuchs's corneal dystrophy;
SARC	cis	rs2242116	0.796	rs7645278	chr3:46974100	A/C	cg27129171	chr3:47204927	SETD2	0.62	8.0	0.46	5.94e-14	Birth weight;
SARC	cis	rs12367572	0.965	rs1506676	chr12:45237401	T/C	cg04608330	chr12:45269318	NELL2	-0.46	-5.68	-0.35	4.02e-8	Gut microbiome composition (summer);
SARC	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.8	7.99	0.46	6.06e-14	Mean platelet volume;
SARC	cis	rs7937682	0.855	rs527078	chr11:111479713	T/C	cg22437258	chr11:111473054	SIK2	0.74	10.37	0.56	5.85e-21	Primary sclerosing cholangitis;
SARC	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs35306767	0.953	rs11253520	chr10:975961	C/G	cg25019033	chr10:957182	NA	0.44	5.89	0.36	1.36e-8	Eosinophil percentage of granulocytes;
SARC	cis	rs3099143	1.000	rs3110379	chr15:77095175	A/G	cg21673338	chr15:77095150	SCAPER	-0.6	-4.97	-0.31	1.32e-6	Recalcitrant atopic dermatitis;
SARC	cis	rs9487051	0.700	rs7773815	chr6:109602343	A/C	cg01475377	chr6:109611718	NA	-0.34	-4.98	-0.31	1.24e-6	Reticulocyte fraction of red cells;
SARC	cis	rs2273669	0.748	rs114830980	chr6:109297857	A/T	cg01304950	chr6:109416612	SESN1;C6orf182	0.56	4.93	0.31	1.58e-6	Prostate cancer;
SARC	cis	rs9486715	0.867	rs926277	chr6:96868837	T/A	cg18709589	chr6:96969512	KIAA0776	0.58	7.27	0.43	5.5e-12	Headache;
SARC	cis	rs881375	0.967	rs10435843	chr9:123668033	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	4.87	0.3	2.03e-6	Rheumatoid arthritis;
SARC	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg02725872	chr8:58115012	NA	-0.27	-4.87	-0.3	2.09e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs16976116	0.851	rs11855907	chr15:55494634	A/C	cg11288833	chr15:55489084	RSL24D1	0.63	6.13	0.37	3.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs17345786	0.954	rs17508319	chr3:101318903	G/A	cg12386194	chr3:101231763	SENP7	0.72	8.64	0.49	9.18e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg16339924	chr4:17578868	LAP3	0.68	9.17	0.52	2.49e-17	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2425143	1.000	rs78421482	chr20:34376486	A/G	cg01084648	chr20:34329383	RBM39	0.63	4.73	0.3	3.86e-6	Blood protein levels;
SARC	cis	rs6060717	0.536	rs11699899	chr20:34525646	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	4.95	0.31	1.4e-6	Hip circumference adjusted for BMI;
SARC	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	7.88	0.46	1.26e-13	Mean platelet volume;
SARC	cis	rs34779708	0.931	rs4934535	chr10:35432721	G/T	cg03585969	chr10:35415529	CREM	0.39	4.78	0.3	3.13e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs950776	0.518	rs12594391	chr15:78816240	A/G	cg22563815	chr15:78856949	CHRNA5	0.42	7.02	0.42	2.38e-11	Sudden cardiac arrest;
SARC	cis	rs2303745	0.544	rs6512180	chr19:17399153	C/T	cg10664184	chr19:17420304	DDA1	0.48	4.89	0.3	1.91e-6	Systemic lupus erythematosus;
SARC	cis	rs9920506	0.536	rs11636605	chr15:78928878	A/G	cg04896959	chr15:78267971	NA	0.42	5.01	0.31	1.09e-6	Post bronchodilator FEV1;
SARC	cis	rs6580649	0.941	rs11613485	chr12:48462455	T/C	cg24011408	chr12:48396354	COL2A1	-0.48	-5.38	-0.33	1.78e-7	Lung cancer;
SARC	cis	rs55871839	0.684	rs10095333	chr8:59815629	G/A	cg07426533	chr8:59803705	TOX	-0.41	-5.42	-0.33	1.48e-7	Pneumonia;
SARC	cis	rs11785400	0.793	rs4581034	chr8:143736968	G/A	cg10596483	chr8:143751796	JRK	0.56	7.2	0.43	8.42e-12	Schizophrenia;
SARC	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg17376030	chr22:41985996	PMM1	0.75	9.44	0.53	4.14e-18	Vitiligo;
SARC	cis	rs2425143	1.000	rs73905926	chr20:34251982	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-5.75	-0.35	2.78e-8	Blood protein levels;
SARC	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg09455208	chr3:40491958	NA	0.38	5.51	0.34	9.28e-8	Renal cell carcinoma;
SARC	cis	rs995000	0.965	rs11207982	chr1:63007182	C/T	cg06896770	chr1:63153194	DOCK7	0.99	15.42	0.71	1.97e-37	Triglyceride levels;
SARC	cis	rs30380	0.632	rs26491	chr5:96134113	A/G	cg16492584	chr5:96139282	ERAP1	-0.47	-5.35	-0.33	2.07e-7	Cerebrospinal fluid biomarker levels;
SARC	cis	rs941408	0.515	rs759067	chr19:2775668	C/T	cg00079169	chr19:2811669	THOP1	0.43	4.78	0.3	3.17e-6	Total cholesterol levels;
SARC	cis	rs41271473	1.000	rs11578216	chr1:228880098	A/T	cg10167378	chr1:228756711	NA	-0.51	-5.27	-0.33	3.1e-7	Chronic lymphocytic leukemia;
SARC	cis	rs10089	1.000	rs4836369	chr5:127486462	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.81	10.17	0.55	2.39e-20	Ileal carcinoids;
SARC	cis	rs7647973	0.667	rs6446286	chr3:49681704	A/G	cg03060546	chr3:49711283	APEH	0.69	7.41	0.44	2.36e-12	Menarche (age at onset);
SARC	trans	rs2243123	0.602	rs2133310	chr3:159716352	A/G	cg23862792	chr14:59656716	DAAM1	0.5	6.37	0.39	9.95e-10	Multiple sclerosis;
SARC	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg21132104	chr15:45694354	SPATA5L1	0.77	10.98	0.58	6.87e-23	Homoarginine levels;
SARC	cis	rs6835098	0.962	rs10027704	chr4:174083107	T/C	cg08422745	chr4:174089978	GALNT7	-0.75	-10.19	-0.56	2.1e-20	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg22974920	chr21:40686053	BRWD1	-0.46	-5.15	-0.32	5.6e-7	Cognitive function;
SARC	cis	rs2011503	1.000	rs76095338	chr19:19633908	G/A	cg03709012	chr19:19516395	GATAD2A	0.6	5.29	0.33	2.8e-7	Bipolar disorder;
SARC	cis	rs12155623	0.619	rs11775403	chr8:49877323	A/T	cg22283653	chr8:49824208	NA	0.35	4.97	0.31	1.32e-6	Sudden cardiac arrest;
SARC	cis	rs10078	0.571	rs890973	chr5:471494	T/C	cg07599136	chr5:415885	AHRR	0.67	5.93	0.36	1.08e-8	Fat distribution (HIV);
SARC	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg17376030	chr22:41985996	PMM1	-0.65	-8.04	-0.47	4.56e-14	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg24642844	chr7:1081250	C7orf50	-0.4	-5.43	-0.34	1.39e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	trans	rs4834272	0.580	rs9884682	chr4:113302639	A/G	cg04861380	chr7:150497663	TMEM176B;TMEM176A	0.47	6.82	0.41	7.72e-11	Body mass index;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg05560165	chr5:133450315	TCF7	0.55	7.25	0.43	5.97e-12	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs3733346	0.553	rs2290403	chr4:942006	G/A	cg08222618	chr4:941054	TMEM175	0.51	7.83	0.46	1.75e-13	Sjögren's syndrome;
SARC	cis	rs7208859	0.725	rs6505215	chr17:29189903	C/A	cg13385521	chr17:29058706	SUZ12P	0.76	6.76	0.4	1.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs644799	1.000	rs1784135	chr11:95531748	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	9.23	0.52	1.67e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9790314	0.846	rs13083229	chr3:161008125	G/A	cg04691961	chr3:161091175	C3orf57	-0.65	-8.8	-0.5	3.1e-16	Morning vs. evening chronotype;
SARC	cis	rs17270561	0.609	rs9358872	chr6:25727517	G/A	cg17691542	chr6:26056736	HIST1H1C	0.58	7.09	0.42	1.59e-11	Iron status biomarkers;
SARC	cis	rs7223966	1.000	rs12325866	chr17:61755974	G/A	cg26338869	chr17:61819248	STRADA	0.44	4.82	0.3	2.56e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg11843238	chr5:131593191	PDLIM4	0.39	4.92	0.31	1.6e-6	Breast cancer;
SARC	cis	rs881375	0.967	rs1930778	chr9:123641369	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.44	5.23	0.32	3.84e-7	Rheumatoid arthritis;
SARC	trans	rs10519937	1.000	rs10519937	chr5:126721853	C/T	cg26526953	chr19:1921199	SCAMP4	0.63	6.39	0.39	9.11e-10	IgG glycosylation;
SARC	cis	rs137699	1.000	rs2413588	chr22:39755175	A/G	cg24399712	chr22:39784796	NA	-0.33	-4.81	-0.3	2.67e-6	IgG glycosylation;
SARC	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs1814175	0.645	rs28445479	chr11:50047999	A/G	cg03929089	chr4:120376271	NA	-0.81	-11.64	-0.61	5.33e-25	Height;
SARC	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.32	-4.89	-0.31	1.86e-6	Total body bone mineral density;
SARC	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.6	-6.31	-0.38	1.42e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs1865760	0.566	rs10807006	chr6:26048752	C/A	cg10373733	chr6:25993375	NA	0.41	5.01	0.31	1.1e-6	Height;
SARC	trans	rs1814175	0.781	rs11040681	chr11:49981654	G/T	cg03929089	chr4:120376271	NA	-0.89	-14.59	-0.69	1.1e-34	Height;
SARC	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg03060546	chr3:49711283	APEH	0.42	5.23	0.32	3.68e-7	Parkinson's disease;
SARC	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg27266027	chr21:40555129	PSMG1	0.52	5.68	0.35	3.9e-8	Cognitive function;
SARC	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	cis	rs721399	0.752	rs35246381	chr8:18272535	C/T	cg18736775	chr8:18248649	NAT2	0.42	5.24	0.32	3.62e-7	Blood metabolite levels;
SARC	cis	rs3126085	0.935	rs10888473	chr1:152220235	G/A	cg26876637	chr1:152193138	HRNR	0.46	5.37	0.33	1.89e-7	Atopic dermatitis;
SARC	cis	rs17666538	0.636	rs10107345	chr8:603700	G/T	cg23958373	chr8:599963	NA	0.69	5.98	0.36	8.42e-9	IgG glycosylation;
SARC	cis	rs9790314	0.645	rs9879687	chr3:160874938	A/G	cg04691961	chr3:161091175	C3orf57	-0.52	-6.8	-0.41	8.85e-11	Morning vs. evening chronotype;
SARC	cis	rs965469	0.779	rs6051770	chr20:3327014	A/G	cg25506879	chr20:3388711	C20orf194	-0.46	-4.99	-0.31	1.17e-6	IFN-related cytopenia;
SARC	cis	rs28374715	0.578	rs10518717	chr15:41623368	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.16	-18.1	-0.76	2.52e-46	Ulcerative colitis;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21240523	chr9:130965902	CIZ1;DNM1	0.58	7.67	0.45	4.67e-13	Smoking initiation;
SARC	cis	rs6542838	0.641	rs13005124	chr2:99527680	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.41	-5.14	-0.32	5.95e-7	Fear of minor pain;
SARC	cis	rs4423214	1.000	rs2282621	chr11:71183474	C/T	cg05163923	chr11:71159392	DHCR7	0.68	9.42	0.53	4.51e-18	Vitamin D levels;
SARC	cis	rs7647973	0.593	rs4855885	chr3:49690199	G/A	cg07636037	chr3:49044803	WDR6	0.61	5.8	0.36	2.14e-8	Menarche (age at onset);
SARC	trans	rs11098499	0.863	rs6835635	chr4:120458867	A/G	cg25214090	chr10:38739885	LOC399744	0.58	7.35	0.43	3.34e-12	Corneal astigmatism;
SARC	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg11890956	chr21:40555474	PSMG1	-0.73	-9.73	-0.54	5.3e-19	Menarche (age at onset);
SARC	cis	rs7772486	0.875	rs9399573	chr6:146403255	A/T	cg23711669	chr6:146136114	FBXO30	0.72	10.98	0.58	7.19e-23	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg07701084	chr6:150067640	NUP43	0.4	5.2	0.32	4.31e-7	Lung cancer;
SARC	cis	rs7772486	0.727	rs6941429	chr6:145952283	G/A	cg23711669	chr6:146136114	FBXO30	0.88	15.08	0.7	2.57e-36	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4128725	1.000	rs10908717	chr1:159376352	C/A	cg25076881	chr1:159409836	OR10J1	0.4	4.78	0.3	3.16e-6	Select biomarker traits;
SARC	cis	rs11155671	0.530	rs7768665	chr6:150208024	G/A	cg00933542	chr6:150070202	PCMT1	0.29	4.91	0.31	1.73e-6	Testicular germ cell tumor;
SARC	cis	rs17270561	0.553	rs9379784	chr6:25725506	A/G	cg16482183	chr6:26056742	HIST1H1C	0.42	5.06	0.31	8.38e-7	Iron status biomarkers;
SARC	cis	rs7772486	0.686	rs10872579	chr6:145966012	C/G	cg23711669	chr6:146136114	FBXO30	0.76	12.09	0.62	1.98e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7621025	0.586	rs34553037	chr3:136379413	T/C	cg15507776	chr3:136538369	TMEM22	-0.47	-4.94	-0.31	1.48e-6	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
SARC	cis	rs981844	1.000	rs62325085	chr4:154663283	A/G	cg14289246	chr4:154710475	SFRP2	0.59	6.74	0.4	1.25e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg22857025	chr5:266934	NA	-1.04	-11.52	-0.6	1.33e-24	Breast cancer;
SARC	cis	rs79149102	0.522	rs7170734	chr15:74989406	C/T	cg09165964	chr15:75287851	SCAMP5	-0.58	-4.73	-0.3	3.88e-6	Lung cancer;
SARC	cis	rs4891159	0.790	rs1787448	chr18:74113179	T/C	cg24786174	chr18:74118243	ZNF516	0.67	9.76	0.54	4.5e-19	Longevity;
SARC	cis	rs2204008	0.606	rs1581358	chr12:38391582	G/T	cg13010199	chr12:38710504	ALG10B	0.85	11.22	0.59	1.23e-23	Bladder cancer;
SARC	cis	rs7084402	0.565	rs4948522	chr10:60334575	T/C	cg07615347	chr10:60278583	BICC1	0.4	5.38	0.33	1.84e-7	Refractive error;
SARC	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg08280861	chr8:58055591	NA	0.57	5.47	0.34	1.14e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1153858	1.000	rs16942000	chr15:45633003	C/T	cg03999130	chr15:45571217	NA	0.42	5.46	0.34	1.23e-7	Homoarginine levels;
SARC	cis	rs870825	0.616	rs4256263	chr4:185622959	C/A	cg04058563	chr4:185651563	MLF1IP	0.82	11.42	0.6	2.8e-24	Blood protein levels;
SARC	trans	rs1814175	0.645	rs1818895	chr11:50031523	G/T	cg03929089	chr4:120376271	NA	-0.83	-12.1	-0.62	1.73e-26	Height;
SARC	cis	rs2279817	1.000	rs10788681	chr1:18019524	C/A	cg21791023	chr1:18019539	ARHGEF10L	0.45	4.95	0.31	1.42e-6	Neuroticism;
SARC	cis	rs6089584	0.606	rs2296082	chr20:60573983	A/G	cg06108461	chr20:60628389	TAF4	-0.7	-8.99	-0.51	8.54e-17	Body mass index;
SARC	cis	rs7208859	0.573	rs73267873	chr17:29068457	C/T	cg13385521	chr17:29058706	SUZ12P	0.84	7.72	0.45	3.43e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs8114671	0.527	rs2295352	chr20:33320055	C/G	cg07148914	chr20:33460835	GGT7	-0.42	-5.2	-0.32	4.34e-7	Height;
SARC	cis	rs3733585	0.673	rs9993410	chr4:9951264	C/T	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.5	-0.34	9.79e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs6500395	0.926	rs1039342	chr16:48577498	G/A	cg04672837	chr16:48644449	N4BP1	0.45	5.89	0.36	1.35e-8	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs7424096	0.555	rs75219072	chr2:37225706	C/T	cg14987922	chr2:37194071	STRN	0.58	6.67	0.4	1.8e-10	High light scatter reticulocyte percentage of red cells;
SARC	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg11644478	chr21:40555479	PSMG1	1.03	14.26	0.68	1.35e-33	Cognitive function;
SARC	cis	rs722599	0.715	rs2080086	chr14:75338408	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.38	-4.76	-0.3	3.42e-6	IgG glycosylation;
SARC	cis	rs12545912	0.820	rs7834823	chr8:9437352	C/A	cg21625330	chr8:9911636	MSRA	-0.51	-4.72	-0.3	4.15e-6	Multiple myeloma (hyperdiploidy);
SARC	cis	rs74417235	0.684	rs12655636	chr5:154057618	T/C	cg08754654	chr5:154026448	NA	0.48	4.8	0.3	2.86e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg16774013	chr18:77160150	NFATC1	-0.64	-6.61	-0.4	2.56e-10	Lung cancer in ever smokers;
SARC	cis	rs1267303	0.675	rs1745370	chr1:46982863	C/G	cg25110126	chr1:46999211	NA	-0.74	-8.18	-0.47	1.8e-14	Monobrow;
SARC	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg14517863	chr17:44321492	NA	-0.32	-4.76	-0.3	3.46e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs72781680	0.948	rs72790326	chr2:24126153	C/T	cg08917208	chr2:24149416	ATAD2B	0.8	7.78	0.45	2.37e-13	Lymphocyte counts;
SARC	cis	rs11997175	0.646	rs7005018	chr8:33700210	A/G	ch.8.33884649F	chr8:33765107	NA	0.63	8.6	0.49	1.21e-15	Body mass index;
SARC	cis	rs986417	1.000	rs1254318	chr14:60902549	T/C	cg27398547	chr14:60952738	C14orf39	-1.01	-9.11	-0.51	3.86e-17	Gut microbiota (bacterial taxa);
SARC	cis	rs1348850	0.668	rs13010396	chr2:178492934	T/C	cg23306229	chr2:178417860	TTC30B	0.68	7.29	0.43	4.78e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1008375	0.863	rs10003291	chr4:17600728	A/C	cg02297831	chr4:17616191	MED28	0.49	6.02	0.37	6.66e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4595586	0.679	rs35743713	chr12:39318539	C/G	cg26384229	chr12:38710491	ALG10B	0.49	6.09	0.37	4.5e-9	Morning vs. evening chronotype;
SARC	cis	rs6565180	0.962	rs6565182	chr16:30374381	C/T	cg17640201	chr16:30407289	ZNF48	-0.94	-13.68	-0.67	1.12e-31	Tonsillectomy;
SARC	cis	rs721399	0.553	rs10109286	chr8:18243603	A/G	cg18736775	chr8:18248649	NAT2	-0.65	-7.28	-0.43	5.04e-12	Blood metabolite levels;
SARC	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg24829409	chr8:58192753	C8orf71	-0.62	-5.91	-0.36	1.2e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs8067354	0.645	rs2645487	chr17:57886125	T/G	cg13753209	chr17:57696993	CLTC	0.66	7.23	0.43	6.94e-12	Hemoglobin concentration;
SARC	cis	rs853679	0.766	rs9368561	chr6:28168343	C/T	cg19592336	chr6:28129416	ZNF389	0.63	4.81	0.3	2.65e-6	Depression;
SARC	cis	rs137603	0.562	rs470080	chr22:39712368	C/T	cg01093212	chr22:39715156	SNORD43;RPL3	-0.46	-5.35	-0.33	2.13e-7	Primary biliary cholangitis;
SARC	cis	rs7635838	0.785	rs7427412	chr3:11535020	G/A	cg00170343	chr3:11313890	ATG7	0.6	8.31	0.48	7.9e-15	HDL cholesterol;
SARC	cis	rs6060960	0.502	rs6057968	chr20:30082779	A/T	cg13852791	chr20:30311386	BCL2L1	0.6	5.15	0.32	5.58e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
SARC	cis	rs11785400	0.793	rs2978973	chr8:143747271	C/G	cg24634471	chr8:143751801	JRK	0.6	7.53	0.44	1.11e-12	Schizophrenia;
SARC	trans	rs7824557	0.564	rs2572404	chr8:11199584	A/G	cg06636001	chr8:8085503	FLJ10661	0.62	8.06	0.47	3.91e-14	Retinal vascular caliber;
SARC	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	8.54	0.49	1.71e-15	Alzheimer's disease;
SARC	cis	rs4268898	0.717	rs3731626	chr2:24427864	G/A	cg26838691	chr2:24397539	C2orf84	-0.44	-5.29	-0.33	2.82e-7	Asthma;
SARC	cis	rs477895	1.000	rs2286614	chr11:64068310	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.66	5.3	0.33	2.67e-7	Mean platelet volume;
SARC	cis	rs6909279	0.678	rs11753987	chr6:151851428	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	-0.49	-6.5	-0.39	4.88e-10	Bone mineral density;
SARC	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs8036358	1.000	rs8036358	chr15:86551743	C/G	cg02810291	chr15:85973746	AKAP13	0.54	4.9	0.31	1.8e-6	Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs208520	0.690	rs4710311	chr6:66823223	C/T	cg07460842	chr6:66804631	NA	-1.04	-14.68	-0.69	5.72e-35	Exhaled nitric oxide output;
SARC	cis	rs3767633	0.858	rs4300199	chr1:161852057	A/G	cg09175582	chr1:161736000	ATF6	0.65	5.5	0.34	9.86e-8	IgG glycosylation;
SARC	cis	rs12079745	0.793	rs77538715	chr1:169290007	T/C	cg09363564	chr1:169337483	NME7;BLZF1	-0.87	-5.22	-0.32	3.93e-7	QT interval;
SARC	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg18135555	chr8:22132992	PIWIL2	-0.36	-5.37	-0.33	1.89e-7	Hypertriglyceridemia;
SARC	cis	rs4819052	0.679	rs2255761	chr21:46683622	A/G	cg06618935	chr21:46677482	NA	-0.37	-5.02	-0.31	1.04e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs854765	0.647	rs854767	chr17:18018263	A/C	cg04398451	chr17:18023971	MYO15A	0.61	9.57	0.53	1.67e-18	Total body bone mineral density;
SARC	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg11764359	chr7:65958608	NA	0.76	9.06	0.51	5.44e-17	Aortic root size;
SARC	cis	rs10876993	0.890	rs1082502	chr12:58035706	C/T	cg18357645	chr12:58087776	OS9	0.43	5.58	0.34	6.76e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs9400467	0.506	rs74510204	chr6:111803797	G/A	cg15721981	chr6:111408429	SLC16A10	0.65	5.71	0.35	3.5e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs8102137	1.000	rs56400371	chr19:30299634	A/C	cg27475126	chr19:30303651	CCNE1	-0.42	-5.91	-0.36	1.23e-8	Bladder cancer;
SARC	cis	rs2242663	0.529	rs1785640	chr11:66223158	C/T	cg25197388	chr11:66278006	BBS1	0.35	5.06	0.31	8.51e-7	Bipolar disorder;
SARC	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg12696929	chr3:195401817	SDHAP2	0.4	5.29	0.33	2.87e-7	Pancreatic cancer;
SARC	cis	rs2239547	0.522	rs2710345	chr3:52976075	T/C	cg07507251	chr3:52567010	NT5DC2	-0.38	-5.0	-0.31	1.13e-6	Schizophrenia;
SARC	cis	rs7904368	0.806	rs1130684	chr10:16859335	C/G	cg23933602	chr10:16859644	RSU1	0.54	5.61	0.34	5.78e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg17971929	chr21:40555470	PSMG1	-0.58	-7.32	-0.43	3.99e-12	Menarche (age at onset);
SARC	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg18230493	chr5:56204884	C5orf35	-0.58	-5.27	-0.33	3.04e-7	Initial pursuit acceleration;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg22420249	chr8:108298379	ANGPT1	0.48	6.85	0.41	6.37e-11	Thyroid stimulating hormone;
SARC	cis	rs6912958	0.781	rs6916732	chr6:88259225	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.38	-0.33	1.84e-7	Monocyte percentage of white cells;
SARC	cis	rs9902453	0.765	rs3102560	chr17:28029938	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	6.98	0.42	3e-11	Coffee consumption (cups per day);
SARC	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg22484793	chr3:52261325	TLR9	0.29	4.77	0.3	3.31e-6	Bipolar disorder;
SARC	cis	rs7607369	0.719	rs7567622	chr2:219624549	A/T	cg02176678	chr2:219576539	TTLL4	-0.32	-4.89	-0.3	1.92e-6	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs13166103	0.628	rs3914030	chr5:57690476	T/A	cg10487770	chr5:57879443	RAB3C	0.52	5.36	0.33	2e-7	Type 2 diabetes (age of onset);
SARC	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg18876405	chr7:65276391	NA	-0.44	-4.91	-0.31	1.75e-6	Aortic root size;
SARC	cis	rs10489525	0.599	rs11102879	chr1:115603504	C/T	cg01522456	chr1:115632236	TSPAN2	0.46	5.46	0.34	1.24e-7	Autism;
SARC	cis	rs9896933	0.832	rs75552659	chr17:80804630	G/A	cg15369054	chr17:80825471	TBCD	0.44	4.79	0.3	2.96e-6	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
SARC	cis	rs6964587	1.000	rs9969198	chr7:91567492	G/T	cg17063962	chr7:91808500	NA	-0.92	-14.47	-0.69	2.82e-34	Breast cancer;
SARC	cis	rs910316	1.000	rs3742780	chr14:75505008	G/C	cg06637938	chr14:75390232	RPS6KL1	0.56	7.81	0.46	2e-13	Height;
SARC	cis	rs9462027	0.606	rs2814981	chr6:34581055	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.96	-0.36	9.21e-9	Systemic lupus erythematosus;
SARC	cis	rs1005277	0.505	rs200931	chr10:38128434	A/C	cg25427524	chr10:38739819	LOC399744	-0.54	-8.54	-0.49	1.81e-15	Extrinsic epigenetic age acceleration;
SARC	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg15242686	chr22:24348715	GSTTP1	-0.46	-5.46	-0.34	1.25e-7	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs16976116	0.901	rs1061874	chr15:55496287	A/T	cg11288833	chr15:55489084	RSL24D1	0.63	6.13	0.37	3.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1056053	0.539	rs3099270	chr6:166571525	T/C	cg11088901	chr6:166572345	T	-0.41	-5.43	-0.33	1.44e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg26335602	chr6:28129616	ZNF389	0.52	5.65	0.35	4.72e-8	Depression;
SARC	cis	rs8072100	0.790	rs11656856	chr17:45714671	C/T	cg08085267	chr17:45401833	C17orf57	0.42	4.96	0.31	1.34e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg17554472	chr22:41940697	POLR3H	-0.46	-5.15	-0.32	5.48e-7	Vitiligo;
SARC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	20.23	0.8	3.17e-53	Prudent dietary pattern;
SARC	cis	rs9788682	0.747	rs6495308	chr15:78907656	A/G	cg24631222	chr15:78858424	CHRNA5	0.71	9.64	0.53	1.04e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs875971	0.545	rs221986	chr7:65570310	T/C	cg11764359	chr7:65958608	NA	-0.63	-6.14	-0.37	3.47e-9	Aortic root size;
SARC	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg12000995	chr2:27665139	KRTCAP3	-0.31	-4.86	-0.3	2.17e-6	Total body bone mineral density;
SARC	cis	rs9486719	0.522	rs4839683	chr6:96851933	A/G	cg18709589	chr6:96969512	KIAA0776	0.45	4.91	0.31	1.71e-6	Migraine;Coronary artery disease;
SARC	cis	rs9790314	0.723	rs12631850	chr3:160883062	C/T	cg03342759	chr3:160939853	NMD3	0.56	7.1	0.42	1.53e-11	Morning vs. evening chronotype;
SARC	cis	rs7635838	0.859	rs6779840	chr3:11425423	A/G	cg00170343	chr3:11313890	ATG7	0.61	8.24	0.47	1.29e-14	HDL cholesterol;
SARC	cis	rs9916302	0.851	rs11868029	chr17:37650304	A/G	cg20243544	chr17:37824526	PNMT	0.58	6.92	0.41	4.44e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs2439831	0.850	rs3759790	chr15:44121030	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	8.07	0.47	3.66e-14	Lung cancer in ever smokers;
SARC	cis	rs12130219	0.500	rs1552991	chr1:152165878	C/T	cg26320663	chr1:152161521	NA	0.44	5.42	0.33	1.5e-7	Inflammatory skin disease;
SARC	trans	rs3780486	0.846	rs10813954	chr9:33137596	A/C	cg20290983	chr6:43655470	MRPS18A	1.14	21.94	0.82	1.32e-58	IgG glycosylation;
SARC	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg02018176	chr4:1364513	KIAA1530	0.61	9.38	0.52	6.02e-18	Longevity;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg16908782	chr14:55494158	SOCS4;WDHD1	0.51	6.78	0.41	9.95e-11	Lung adenocarcinoma;
SARC	cis	rs910316	1.000	rs7156105	chr14:75541954	C/A	cg06637938	chr14:75390232	RPS6KL1	0.55	7.99	0.46	6.15e-14	Height;
SARC	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-9.15	-0.51	2.85e-17	Alzheimer's disease;
SARC	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg12463550	chr7:65579703	CRCP	-0.48	-5.71	-0.35	3.43e-8	Aortic root size;
SARC	cis	rs7223966	1.000	rs2665826	chr17:61944924	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.47	-4.87	-0.3	2.04e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1691799	0.867	rs1168338	chr12:66759369	T/C	cg16791601	chr12:66731901	HELB	-0.71	-10.71	-0.57	4.87e-22	White blood cell count (basophil);
SARC	cis	rs11758351	1.000	rs2143347	chr6:26198494	C/T	cg23601095	chr6:26197514	HIST1H3D	0.63	5.49	0.34	1.07e-7	Gout;Renal underexcretion gout;
SARC	cis	rs7824557	0.628	rs6988922	chr8:11194911	A/G	cg21775007	chr8:11205619	TDH	0.65	8.34	0.48	6.54e-15	Retinal vascular caliber;
SARC	cis	rs9462027	0.628	rs2764197	chr6:34705055	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.88	-0.36	1.39e-8	Systemic lupus erythematosus;
SARC	cis	rs3087591	0.920	rs7225014	chr17:29572973	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.51	-6.27	-0.38	1.71e-9	Hip circumference;
SARC	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6728642	0.908	rs10203833	chr2:98017363	G/A	cg26665480	chr2:98280029	ACTR1B	-0.63	-5.88	-0.36	1.43e-8	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs897984	0.568	rs8063565	chr16:30883965	G/C	cg00531865	chr16:30841666	NA	0.5	5.2	0.32	4.35e-7	Dementia with Lewy bodies;
SARC	cis	rs3806933	0.522	rs13186912	chr5:110456704	A/T	cg04022379	chr5:110408740	TSLP	-0.69	-8.89	-0.5	1.75e-16	Eosinophilic esophagitis;
SARC	cis	rs6570726	0.905	rs430248	chr6:145874104	A/G	cg23711669	chr6:146136114	FBXO30	0.78	11.97	0.62	4.89e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12908161	1.000	rs12905057	chr15:85210765	A/G	cg17507749	chr15:85114479	UBE2QP1	0.58	6.51	0.39	4.54e-10	Schizophrenia;
SARC	cis	rs10876993	0.928	rs774890	chr12:58068388	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.47	-5.94	-0.36	1.01e-8	Celiac disease or Rheumatoid arthritis;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg26193372	chr2:85154136	NA	0.49	6.27	0.38	1.75e-9	Lung adenocarcinoma;
SARC	cis	rs1832871	0.672	rs9457337	chr6:158726292	C/T	cg07165851	chr6:158734300	TULP4	0.57	6.51	0.39	4.65e-10	Height;
SARC	cis	rs7818345	0.967	rs13255677	chr8:19288985	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.43	5.79	0.35	2.25e-8	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg07777115	chr5:623756	CEP72	-0.62	-5.58	-0.34	6.66e-8	Obesity-related traits;
SARC	cis	rs2236918	1.000	rs1635509	chr1:242028027	C/T	cg17736920	chr1:242011382	EXO1	0.77	10.9	0.58	1.29e-22	Menopause (age at onset);
SARC	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg05861140	chr6:150128134	PCMT1	-0.4	-5.23	-0.32	3.79e-7	Lung cancer;
SARC	cis	rs4689388	0.926	rs4688987	chr4:6287329	C/T	cg14416269	chr4:6271139	WFS1	0.36	5.51	0.34	9.28e-8	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg18225595	chr11:63971243	STIP1	-0.42	-5.15	-0.32	5.58e-7	Mean platelet volume;
SARC	trans	rs7819412	0.539	rs11250131	chr8:11251175	C/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.7	-0.45	3.89e-13	Triglycerides;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg18075720	chr19:45349207	PVRL2	-0.52	-6.53	-0.39	3.97e-10	Breast cancer;
SARC	cis	rs9840812	0.817	rs61789561	chr3:135917627	G/A	cg15507776	chr3:136538369	TMEM22	-0.55	-5.35	-0.33	2.1e-7	Fibrinogen levels;
SARC	trans	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg00938859	chr5:1591904	SDHAP3	0.77	7.45	0.44	1.79e-12	Breast cancer;
SARC	cis	rs17376456	1.000	rs13181660	chr5:93533658	A/G	cg21475434	chr5:93447410	FAM172A	0.94	8.37	0.48	5.33e-15	Diabetic retinopathy;
SARC	cis	rs6570726	0.846	rs6899900	chr6:145883873	T/G	cg05347473	chr6:146136440	FBXO30	0.51	7.2	0.43	8.38e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg06697600	chr4:7070879	GRPEL1	-0.38	-4.85	-0.3	2.21e-6	Monocyte percentage of white cells;
SARC	cis	rs9747201	1.000	rs58472289	chr17:80111895	G/T	cg09264619	chr17:80180166	NA	0.51	6.02	0.37	6.73e-9	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs7614311	0.731	rs3733121	chr3:63850660	C/G	cg22134162	chr3:63841271	THOC7	-0.47	-5.12	-0.32	6.41e-7	Lung function (FVC);Lung function (FEV1);
SARC	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg20607798	chr8:58055168	NA	0.56	5.27	0.33	3.12e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs912057	1.000	rs912057	chr6:6736931	C/T	cg06612196	chr6:6737390	NA	-0.59	-8.69	-0.49	6.48e-16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg01448562	chr3:133502909	NA	-0.44	-6.53	-0.39	4.13e-10	Iron status biomarkers;
SARC	cis	rs7647973	0.626	rs1996664	chr3:49878395	A/G	cg07636037	chr3:49044803	WDR6	-0.63	-6.45	-0.39	6.52e-10	Menarche (age at onset);
SARC	cis	rs9309473	0.950	rs6740766	chr2:73780913	A/G	cg20560298	chr2:73613845	ALMS1	-0.48	-5.92	-0.36	1.14e-8	Metabolite levels;
SARC	cis	rs875971	0.793	rs460678	chr7:65527200	C/G	cg12463550	chr7:65579703	CRCP	0.42	4.89	0.31	1.84e-6	Aortic root size;
SARC	cis	rs4280164	0.945	rs4374085	chr14:24771080	T/C	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.58	-5.44	-0.34	1.32e-7	Parent of origin effect on language impairment (paternal);
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg02656525	chr5:110427854	WDR36	0.72	7.47	0.44	1.64e-12	Lung cancer in ever smokers;
SARC	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg08280861	chr8:58055591	NA	0.59	5.71	0.35	3.51e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2180341	0.960	rs9398840	chr6:127669744	G/A	cg27446573	chr6:127587934	RNF146	1.05	14.53	0.69	1.75e-34	Breast cancer;
SARC	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg08280861	chr8:58055591	NA	0.7	5.87	0.36	1.49e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7829975	0.511	rs1543238	chr8:8134809	A/G	cg15556689	chr8:8085844	FLJ10661	0.55	7.0	0.42	2.77e-11	Mood instability;
SARC	cis	rs787274	0.619	rs58643876	chr9:115627285	C/A	cg13803584	chr9:115635662	SNX30	-0.78	-6.41	-0.39	8.17e-10	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs9462027	0.651	rs2395599	chr6:34641415	G/C	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-6.05	-0.37	5.68e-9	Systemic lupus erythematosus;
SARC	cis	rs6840360	0.571	rs4696270	chr4:152498289	G/A	cg22705602	chr4:152727874	NA	-0.41	-6.47	-0.39	5.71e-10	Intelligence (multi-trait analysis);
SARC	cis	rs1185460	0.967	rs4454730	chr11:118937444	G/A	cg23280166	chr11:118938394	VPS11	0.81	12.29	0.63	4.3e-27	Coronary artery disease;
SARC	cis	rs4711336	1.000	rs4711337	chr6:33659987	T/C	cg15676125	chr6:33679581	C6orf125	0.57	7.01	0.42	2.49e-11	Height;
SARC	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg21747090	chr2:27597821	SNX17	-0.5	-6.99	-0.42	2.8e-11	Total body bone mineral density;
SARC	cis	rs96067	0.772	rs6700737	chr1:36598214	A/G	cg24686825	chr1:36642396	MAP7D1	-0.54	-6.19	-0.38	2.63e-9	Corneal structure;
SARC	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg11764359	chr7:65958608	NA	0.79	10.07	0.55	4.93e-20	Aortic root size;
SARC	cis	rs654950	0.934	rs638859	chr1:42001444	A/G	cg06885757	chr1:42089581	HIVEP3	0.36	5.01	0.31	1.08e-6	Airway imaging phenotypes;
SARC	cis	rs473651	0.935	rs474478	chr2:239335473	C/T	cg21699342	chr2:239360505	ASB1	0.47	6.81	0.41	8.41e-11	Multiple system atrophy;
SARC	cis	rs854765	0.547	rs12150369	chr17:17911014	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.64	9.45	0.53	3.79e-18	Total body bone mineral density;
SARC	cis	rs6570726	0.689	rs411785	chr6:145888398	G/A	cg23711669	chr6:146136114	FBXO30	0.87	14.21	0.68	2.03e-33	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10078	0.898	rs2241598	chr5:438564	C/T	cg08916839	chr5:415575	AHRR	-0.5	-5.61	-0.35	5.58e-8	Fat distribution (HIV);
SARC	cis	rs8031584	0.541	rs2955777	chr15:31219788	A/C	cg08109568	chr15:31115862	NA	0.45	5.96	0.36	9.12e-9	Huntington's disease progression;
SARC	cis	rs7552404	0.731	rs12090849	chr1:76400261	A/G	cg03433033	chr1:76189801	ACADM	0.44	5.3	0.33	2.64e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	trans	rs330048	0.561	rs330088	chr8:9149746	T/C	cg06636001	chr8:8085503	FLJ10661	0.64	8.76	0.5	4.02e-16	Systemic lupus erythematosus;
SARC	trans	rs11098499	0.954	rs10014845	chr4:120301077	T/G	cg25214090	chr10:38739885	LOC399744	0.55	7.14	0.42	1.15e-11	Corneal astigmatism;
SARC	cis	rs1062177	1.000	rs62377945	chr5:151208004	C/G	cg00977110	chr5:151150581	G3BP1	0.56	5.51	0.34	9.71e-8	Preschool internalizing problems;
SARC	cis	rs6670533	0.571	rs6669881	chr1:24862749	A/G	cg07475527	chr1:24864545	NA	-1.0	-5.65	-0.35	4.76e-8	Fasting blood insulin (BMI interaction);
SARC	cis	rs7654585	0.645	rs1123943	chr4:25924426	A/G	cg10409131	chr4:25915609	C4orf52	-0.47	-6.0	-0.37	7.67e-9	Obesity-related traits;
SARC	cis	rs1355223	0.583	rs2915238	chr11:34884405	C/A	cg18508148	chr11:34937573	PDHX;APIP	0.53	6.77	0.41	1.02e-10	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs7568458	0.684	rs60012532	chr2:85752474	A/C	cg02493740	chr2:85810744	VAMP5	-0.41	-5.42	-0.33	1.45e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs2730245	1.000	rs6965685	chr7:158726462	C/T	cg00815399	chr7:158750607	NA	0.35	5.08	0.32	7.84e-7	Height;
SARC	cis	rs6912958	0.559	rs373646	chr6:88056896	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.36	6.4	0.39	8.52e-10	Monocyte percentage of white cells;
SARC	cis	rs2380220	1.000	rs9632496	chr6:95976450	C/G	cg23517279	chr6:96025343	MANEA	0.54	5.51	0.34	9.41e-8	Behavioural disinhibition (generation interaction);
SARC	cis	rs9303401	0.580	rs12946396	chr17:57164195	T/A	cg25039879	chr17:56429692	SUPT4H1	0.62	5.66	0.35	4.43e-8	Cognitive test performance;
SARC	trans	rs9354308	0.868	rs9345692	chr6:66544714	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.56	-6.64	-0.4	2.19e-10	Metabolite levels;
SARC	cis	rs3784262	0.669	rs2197092	chr15:58247781	C/T	cg12031962	chr15:58353849	ALDH1A2	0.32	4.75	0.3	3.49e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	trans	rs2018683	1.000	rs4719963	chr7:29011064	A/G	cg19402173	chr7:128379420	CALU	0.62	8.4	0.48	4.53e-15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs2991971	0.810	rs12738318	chr1:45929589	A/G	cg24296786	chr1:45957014	TESK2	-0.57	-7.72	-0.45	3.35e-13	High light scatter reticulocyte count;
SARC	cis	rs9818758	0.607	rs9990153	chr3:49291883	C/T	cg07636037	chr3:49044803	WDR6	-0.75	-6.63	-0.4	2.37e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg13206674	chr6:150067644	NUP43	0.45	5.75	0.35	2.73e-8	Lung cancer;
SARC	cis	rs11581859	0.613	rs11811184	chr1:99212311	T/C	cg20286094	chr1:99190917	SNX7	-0.43	-5.21	-0.32	4.23e-7	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs1559088	1.000	rs7245404	chr19:33550589	C/T	cg27124370	chr19:33622961	WDR88	0.42	5.25	0.33	3.44e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg08790301	chr8:30318172	RBPMS	0.55	7.67	0.45	4.68e-13	Thyroid stimulating hormone;
SARC	cis	rs3857536	0.740	rs7766407	chr6:66885658	C/A	cg07460842	chr6:66804631	NA	-0.61	-7.22	-0.43	7.11e-12	Blood trace element (Cu levels);
SARC	cis	rs9303280	0.773	rs12949100	chr17:38057189	G/A	cg00129232	chr17:37814104	STARD3	-0.38	-4.87	-0.3	2.06e-6	Self-reported allergy;
SARC	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg13939156	chr17:80058883	NA	-0.4	-6.27	-0.38	1.77e-9	Life satisfaction;
SARC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.59	0.53	1.39e-18	Prudent dietary pattern;
SARC	cis	rs2425143	0.915	rs74355238	chr20:34441541	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	4.98	0.31	1.22e-6	Blood protein levels;
SARC	cis	rs9818758	0.556	rs9814987	chr3:49207849	T/C	cg01304814	chr3:48885189	PRKAR2A	0.59	4.99	0.31	1.19e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs62344088	1.000	rs6898413	chr5:173927	A/C	cg22496380	chr5:211416	CCDC127	-0.84	-5.65	-0.35	4.58e-8	Asthma (childhood onset);
SARC	cis	rs3126085	0.935	rs12730241	chr1:152274016	G/A	cg26876637	chr1:152193138	HRNR	-0.49	-5.29	-0.33	2.86e-7	Atopic dermatitis;
SARC	cis	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg25427524	chr10:38739819	LOC399744	0.58	9.41	0.52	4.81e-18	Extrinsic epigenetic age acceleration;
SARC	cis	rs2120243	0.539	rs2168430	chr3:157120408	T/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.39	4.96	0.31	1.37e-6	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs57994353	0.897	rs11999609	chr9:139363539	C/T	cg13611204	chr9:139324423	INPP5E	-0.28	-4.88	-0.3	1.93e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs5995756	0.600	rs5757748	chr22:40010636	T/A	cg10455938	chr22:40058150	CACNA1I	0.43	5.08	0.32	7.9e-7	Autism spectrum disorder or schizophrenia;
SARC	cis	rs3820928	0.874	rs4675132	chr2:227841792	A/C	cg11843606	chr2:227700838	RHBDD1	-0.58	-7.36	-0.43	3.22e-12	Pulmonary function;
SARC	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg19077165	chr18:44547161	KATNAL2	-0.53	-7.16	-0.42	1.05e-11	Personality dimensions;
SARC	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.75	-10.71	-0.57	4.89e-22	Homoarginine levels;
SARC	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg21348586	chr8:141461100	TRAPPC9	0.5	6.92	0.41	4.38e-11	Schizophrenia;
SARC	cis	rs7246657	0.943	rs2045908	chr19:37979768	C/G	cg23950597	chr19:37808831	NA	-0.55	-5.38	-0.33	1.82e-7	Coronary artery calcification;
SARC	cis	rs763121	0.819	rs5757126	chr22:38923675	T/C	cg06022373	chr22:39101656	GTPBP1	0.88	10.97	0.58	7.78e-23	Menopause (age at onset);
SARC	cis	rs10463554	0.963	rs11242483	chr5:102323766	C/T	cg23492399	chr5:102201601	PAM	-0.51	-6.46	-0.39	6.14e-10	Parkinson's disease;
SARC	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg11764359	chr7:65958608	NA	-0.75	-8.8	-0.5	3.11e-16	Aortic root size;
SARC	cis	rs2204008	0.807	rs12816136	chr12:38456037	A/G	cg26384229	chr12:38710491	ALG10B	-0.8	-11.54	-0.6	1.15e-24	Bladder cancer;
SARC	cis	rs2075371	0.501	rs1421469	chr7:134028260	C/G	cg00033643	chr7:134001901	SLC35B4	0.45	5.66	0.35	4.44e-8	Mean platelet volume;
SARC	cis	rs2153535	0.623	rs2327055	chr6:8443145	A/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.39	0.48	4.78e-15	Motion sickness;
SARC	cis	rs2681735	0.600	rs2283391	chr14:72802433	T/C	cg17922283	chr14:72799938	RGS6	0.32	5.16	0.32	5.25e-7	Antibody status in Tripanosoma cruzi seropositivity;
SARC	cis	rs6991838	0.612	rs7842162	chr8:66556292	T/G	cg13398993	chr8:66546079	ARMC1	0.59	7.61	0.45	6.62e-13	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg18876405	chr7:65276391	NA	-0.47	-5.27	-0.33	3.15e-7	Aortic root size;
SARC	cis	rs7644634	0.700	rs4321559	chr3:105480602	C/T	cg23051926	chr3:105466016	CBLB	0.46	5.78	0.35	2.39e-8	Itch intensity from mosquito bite;
SARC	cis	rs2658782	0.789	rs3020057	chr11:93118515	C/T	cg15737290	chr11:93063684	CCDC67	0.69	7.32	0.43	3.92e-12	Pulmonary function decline;
SARC	cis	rs3106136	0.609	rs11097406	chr4:95146042	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.33	-4.78	-0.3	3.13e-6	Capecitabine sensitivity;
SARC	cis	rs7681440	0.904	rs17192189	chr4:90774928	A/C	cg06632027	chr4:90757378	SNCA	-0.39	-5.44	-0.34	1.36e-7	Dementia with Lewy bodies;
SARC	cis	rs6424115	0.557	rs35904775	chr1:24180623	T/C	cg15997130	chr1:24165203	NA	-0.41	-5.51	-0.34	9.49e-8	Immature fraction of reticulocytes;
SARC	cis	rs7681440	0.874	rs1372523	chr4:90775923	G/A	cg02192967	chr4:90758406	SNCA	0.37	5.26	0.33	3.25e-7	Dementia with Lewy bodies;
SARC	cis	rs73206853	0.688	rs55805203	chr12:110819142	G/T	cg10860002	chr12:110842031	ANAPC7	0.61	4.76	0.3	3.39e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs7662987	0.517	rs1311618	chr4:100012612	A/G	cg13256891	chr4:100009986	ADH5	0.66	8.33	0.48	7.17e-15	Smoking initiation;
SARC	cis	rs1865760	0.516	rs9379819	chr6:26049819	A/C	cg16482183	chr6:26056742	HIST1H1C	0.47	6.11	0.37	4.23e-9	Height;
SARC	cis	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg14343924	chr8:8086146	FLJ10661	0.42	5.18	0.32	4.84e-7	Mood instability;
SARC	cis	rs2976388	0.647	rs2572898	chr8:143782274	G/C	cg06565975	chr8:143823917	SLURP1	0.29	5.04	0.31	9.48e-7	Urinary tract infection frequency;
SARC	cis	rs7296418	0.619	rs7139321	chr12:123719528	T/G	cg05973401	chr12:123451056	ABCB9	0.5	5.91	0.36	1.23e-8	Platelet count;
SARC	cis	rs7312933	0.618	rs6582394	chr12:42686189	A/G	cg19980929	chr12:42632907	YAF2	0.47	6.84	0.41	7.09e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs9929218	0.817	rs3114400	chr16:68719430	C/T	cg02972257	chr16:68554789	NA	0.41	4.81	0.3	2.73e-6	Colorectal cancer;
SARC	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg05025164	chr4:1340916	KIAA1530	0.43	4.96	0.31	1.36e-6	Obesity-related traits;
SARC	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg22535103	chr8:58192502	C8orf71	-0.59	-6.21	-0.38	2.35e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	11.64	0.61	5.7e-25	Alzheimer's disease;
SARC	trans	rs7824557	0.767	rs1897950	chr8:11169551	C/A	cg06636001	chr8:8085503	FLJ10661	0.57	6.98	0.42	3.06e-11	Retinal vascular caliber;
SARC	cis	rs7552404	0.731	rs11161857	chr1:76370228	G/C	cg22875332	chr1:76189707	ACADM	0.4	4.74	0.3	3.75e-6	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs1008375	0.931	rs6837181	chr4:17701253	A/C	cg27347728	chr4:17578864	LAP3	0.46	5.77	0.35	2.45e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs13166103	0.657	rs10805507	chr5:57697770	G/A	cg10487770	chr5:57879443	RAB3C	0.52	5.54	0.34	8.05e-8	Type 2 diabetes (age of onset);
SARC	cis	rs6570726	0.935	rs425731	chr6:145834151	A/G	cg05347473	chr6:146136440	FBXO30	0.48	6.42	0.39	7.51e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7296418	0.961	rs11608811	chr12:123529056	A/G	cg05973401	chr12:123451056	ABCB9	0.59	7.15	0.42	1.11e-11	Platelet count;
SARC	trans	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg27297753	chr3:10052900	LOC401052	-0.68	-6.51	-0.39	4.48e-10	Cutaneous psoriasis;
SARC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg09373136	chr17:61933544	TCAM1	-0.44	-6.04	-0.37	5.99e-9	Prudent dietary pattern;
SARC	cis	rs2832191	0.716	rs1543652	chr21:30448000	G/C	cg24692254	chr21:30365293	RNF160	1.04	17.91	0.76	1.08e-45	Dental caries;
SARC	cis	rs1008375	1.000	rs10939740	chr4:17617490	T/C	cg27347728	chr4:17578864	LAP3	0.48	6.05	0.37	5.73e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg11987759	chr7:65425863	GUSB	-0.51	-6.1	-0.37	4.39e-9	Aortic root size;
SARC	cis	rs2153535	0.580	rs9406159	chr6:8464859	C/G	cg21535247	chr6:8435926	SLC35B3	0.54	6.79	0.41	9.19e-11	Motion sickness;
SARC	cis	rs7264396	0.563	rs2425111	chr20:34319765	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-7.01	-0.42	2.5e-11	Total cholesterol levels;
SARC	cis	rs920590	0.641	rs2035889	chr8:19634087	T/A	cg17834443	chr8:19674713	INTS10	0.45	5.04	0.31	9.34e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs524281	0.861	rs7937281	chr11:65950074	T/C	cg14036092	chr11:66035641	RAB1B	-0.5	-5.5	-0.34	9.95e-8	Electroencephalogram traits;
SARC	cis	rs7666738	0.830	rs1365458	chr4:98950961	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.67e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7412746	0.658	rs11204739	chr1:150865760	A/G	cg13175981	chr1:150552382	MCL1	-0.48	-5.86	-0.36	1.57e-8	Melanoma;
SARC	trans	rs9325144	0.555	rs7960411	chr12:38703019	A/G	cg23762105	chr12:34175262	ALG10	0.49	6.28	0.38	1.68e-9	Morning vs. evening chronotype;
SARC	cis	rs2295359	1.000	rs963427	chr1:67609347	A/G	cg08029281	chr1:67600428	NA	0.36	5.13	0.32	6.14e-7	Psoriasis;
SARC	cis	rs360798	0.512	rs10221574	chr2:62838666	G/T	cg16915676	chr2:62734870	TMEM17	0.37	4.72	0.3	4.01e-6	Coronary artery disease;
SARC	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg21724239	chr8:58056113	NA	0.43	4.77	0.3	3.23e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs748404	0.578	rs478028	chr15:43610772	C/T	cg08831455	chr15:43942014	CATSPER2	-0.4	-4.74	-0.3	3.79e-6	Lung cancer;
SARC	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg26119090	chr2:26468346	HADHA;HADHB	0.7	7.97	0.46	7.22e-14	Gut microbiome composition (summer);
SARC	cis	rs911555	0.673	rs7144271	chr14:103890674	A/G	cg12935359	chr14:103987150	CKB	-0.38	-5.24	-0.32	3.57e-7	Intelligence (multi-trait analysis);
SARC	cis	rs820218	0.886	rs820146	chr17:73614969	G/A	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.58	7.39	0.44	2.54e-12	Rotator cuff tears;
SARC	cis	rs11097912	0.632	rs17333899	chr4:107220483	C/T	cg09646026	chr4:107269030	AIMP1	-0.46	-4.93	-0.31	1.55e-6	Airflow obstruction;
SARC	cis	rs9916302	0.561	rs12453198	chr17:37741879	T/C	cg20243544	chr17:37824526	PNMT	0.53	5.47	0.34	1.17e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg13770153	chr20:60521292	NA	-0.45	-6.31	-0.38	1.39e-9	Body mass index;
SARC	cis	rs1707322	0.662	rs11211160	chr1:46146229	T/A	cg06784218	chr1:46089804	CCDC17	0.35	6.02	0.37	6.66e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg05234568	chr11:5960015	NA	-0.43	-5.82	-0.36	1.97e-8	DNA methylation (variation);
SARC	cis	rs12142240	0.698	rs56284503	chr1:46847127	C/G	cg14993813	chr1:46806288	NSUN4	-0.52	-5.56	-0.34	7.46e-8	Menopause (age at onset);
SARC	cis	rs748404	0.697	rs1095389	chr15:43566671	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.53	6.28	0.38	1.63e-9	Lung cancer;
SARC	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg21782813	chr7:2030301	MAD1L1	0.45	7.11	0.42	1.42e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.53	0.53	2.2e-18	Prudent dietary pattern;
SARC	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg09455208	chr3:40491958	NA	-0.36	-5.4	-0.33	1.64e-7	Renal cell carcinoma;
SARC	cis	rs11574514	1.000	rs11861657	chr16:67824395	A/G	cg01866162	chr16:67596514	CTCF	0.81	5.35	0.33	2.08e-7	Crohn's disease;
SARC	cis	rs7524258	0.900	rs2412151	chr1:7303216	G/C	cg07173049	chr1:7289937	CAMTA1	0.35	6.77	0.41	1.03e-10	Tourette's syndrome or obsessive-compulsive disorder;
SARC	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.06	17.7	0.76	5.38e-45	Height;
SARC	cis	rs5753618	0.583	rs5753615	chr22:31828027	T/C	cg07713946	chr22:31675144	LIMK2	0.36	4.98	0.31	1.23e-6	Colorectal cancer;
SARC	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg03709012	chr19:19516395	GATAD2A	-1.02	-17.9	-0.76	1.17e-45	Tonsillectomy;
SARC	cis	rs8031584	1.000	rs12906054	chr15:31292023	A/C	cg19680485	chr15:31195859	MTMR15	-0.55	-5.72	-0.35	3.25e-8	Huntington's disease progression;
SARC	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg19748678	chr4:122722346	EXOSC9	0.76	9.43	0.53	4.18e-18	Type 2 diabetes;
SARC	cis	rs12367572	0.965	rs10748405	chr12:45321341	C/G	cg04608330	chr12:45269318	NELL2	-0.45	-5.58	-0.34	6.6e-8	Gut microbiome composition (summer);
SARC	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg24642844	chr7:1081250	C7orf50	-0.59	-6.06	-0.37	5.31e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg05623727	chr3:50126028	RBM5	0.34	5.19	0.32	4.52e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9796	0.621	rs691702	chr15:41474399	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.55	-7.93	-0.46	8.92e-14	Menopause (age at onset);
SARC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg07157834	chr1:205819609	PM20D1	0.87	15.88	0.72	5.61e-39	Menarche (age at onset);
SARC	cis	rs60871478	0.945	rs4719279	chr7:813618	T/C	cg19087971	chr7:751233	PRKAR1B	-0.43	-4.94	-0.31	1.52e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs11630290	0.649	rs1036910	chr15:64157015	T/C	cg12036633	chr15:63758958	NA	0.48	4.96	0.31	1.34e-6	Iris characteristics;
SARC	cis	rs6732160	0.691	rs10197935	chr2:73412362	A/T	cg01422370	chr2:73384389	NA	0.3	5.23	0.32	3.7e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2153535	0.580	rs1335643	chr6:8488021	T/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.09	0.47	3.25e-14	Motion sickness;
SARC	cis	rs7296418	0.961	rs949143	chr12:123595163	G/A	cg05973401	chr12:123451056	ABCB9	0.59	7.25	0.43	6.18e-12	Platelet count;
SARC	cis	rs8180040	0.726	rs6785790	chr3:47146932	C/T	cg27129171	chr3:47204927	SETD2	0.66	9.29	0.52	1.15e-17	Colorectal cancer;
SARC	cis	rs7683537	0.725	rs28837443	chr4:185641497	G/A	cg04058563	chr4:185651563	MLF1IP	0.81	11.48	0.6	1.8e-24	Systemic lupus erythematosus;
SARC	cis	rs6910061	1.000	rs6938870	chr6:11095317	A/G	cg27233058	chr6:11094804	LOC221710	0.57	5.5	0.34	1.02e-7	Diabetic kidney disease;
SARC	cis	rs2439831	0.850	rs28684672	chr15:44107662	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	7.66	0.45	4.94e-13	Lung cancer in ever smokers;
SARC	cis	rs10463316	0.817	rs906679	chr5:150779302	T/A	cg03212797	chr5:150827313	SLC36A1	-0.5	-5.83	-0.36	1.88e-8	Metabolite levels (Pyroglutamine);
SARC	cis	rs8014204	0.816	rs10144023	chr14:75291531	T/C	cg06637938	chr14:75390232	RPS6KL1	0.54	7.51	0.44	1.24e-12	Caffeine consumption;
SARC	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg13607699	chr17:42295918	UBTF	0.58	7.02	0.42	2.44e-11	Total body bone mineral density;
SARC	cis	rs7044106	0.791	rs12554440	chr9:123485333	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.41	0.52	4.85e-18	Hip circumference adjusted for BMI;
SARC	cis	rs899997	0.862	rs57260218	chr15:78973772	C/T	cg04896959	chr15:78267971	NA	-0.45	-5.53	-0.34	8.75e-8	Coronary artery disease or large artery stroke;
SARC	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg04277193	chr17:41438351	NA	0.45	4.74	0.3	3.7e-6	Menopause (age at onset);
SARC	cis	rs9818758	0.607	rs61729488	chr3:49067904	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.68	-5.76	-0.35	2.62e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs876084	0.505	rs10216978	chr8:121105620	C/A	cg06265175	chr8:121136014	COL14A1	0.57	7.44	0.44	1.89e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs921968	0.541	rs3770216	chr2:219443717	A/G	cg02176678	chr2:219576539	TTLL4	-0.48	-7.35	-0.43	3.42e-12	Mean corpuscular hemoglobin concentration;
SARC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.97	10.89	0.58	1.39e-22	Platelet count;
SARC	cis	rs4750440	0.706	rs12358733	chr10:14016290	A/G	cg27542038	chr10:14027202	FRMD4A	0.37	5.34	0.33	2.2e-7	Adiponectin levels;
SARC	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg16606324	chr3:10149918	C3orf24	0.49	4.86	0.3	2.13e-6	Alzheimer's disease;
SARC	cis	rs2120243	0.591	rs9871290	chr3:157099591	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.41	5.16	0.32	5.19e-7	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg10295955	chr4:187884368	NA	-1.12	-20.39	-0.8	9.96e-54	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs611744	0.573	rs1457210	chr8:109261562	A/G	cg21045802	chr8:109455806	TTC35	-0.46	-5.37	-0.33	1.94e-7	Dupuytren's disease;
SARC	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg11890956	chr21:40555474	PSMG1	-0.73	-9.64	-0.53	1.02e-18	Menarche (age at onset);
SARC	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg18876405	chr7:65276391	NA	0.49	6.04	0.37	6e-9	Aortic root size;
SARC	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg22800045	chr5:56110881	MAP3K1	0.72	7.66	0.45	4.94e-13	Initial pursuit acceleration;
SARC	cis	rs2594989	0.790	rs2454491	chr3:11514290	A/G	cg00170343	chr3:11313890	ATG7	0.51	5.71	0.35	3.44e-8	Circulating chemerin levels;
SARC	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1215050	0.765	rs6852699	chr4:98767505	T/C	cg05340658	chr4:99064831	C4orf37	0.44	5.85	0.36	1.62e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs2486288	0.656	rs11639420	chr15:45559268	A/C	cg26924012	chr15:45694286	SPATA5L1	-0.46	-5.66	-0.35	4.39e-8	Glomerular filtration rate;
SARC	cis	rs9733	0.621	rs6669122	chr1:150591732	A/G	cg17724175	chr1:150552817	MCL1	-0.4	-5.19	-0.32	4.54e-7	Tonsillectomy;
SARC	cis	rs1865760	1.000	rs7757666	chr6:25902626	T/C	cg16482183	chr6:26056742	HIST1H1C	0.49	6.13	0.37	3.78e-9	Height;
SARC	cis	rs4803468	0.967	rs67047091	chr19:41938684	C/T	cg09537434	chr19:41945824	ATP5SL	0.97	16.95	0.74	1.56e-42	Height;
SARC	cis	rs7818688	0.697	rs11781757	chr8:95987891	A/T	cg13393036	chr8:95962371	TP53INP1	0.42	5.1	0.32	7.18e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg22920501	chr2:26401640	FAM59B	-0.57	-7.43	-0.44	2.09e-12	Gut microbiome composition (summer);
SARC	cis	rs7568458	0.660	rs55692129	chr2:85792404	A/T	cg23752985	chr2:85803571	VAMP8	0.44	5.43	0.34	1.39e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs2066819	1.000	rs2695788	chr12:56697110	G/A	cg26316697	chr12:56727976	PAN2	-0.9	-6.4	-0.39	8.55e-10	Psoriasis vulgaris;
SARC	cis	rs240764	0.658	rs60658003	chr6:101201191	C/A	cg09795085	chr6:101329169	ASCC3	-0.48	-6.32	-0.38	1.29e-9	Neuroticism;
SARC	cis	rs4819052	0.679	rs4819053	chr21:46711357	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.6	-7.45	-0.44	1.78e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs748404	0.604	rs2278857	chr15:43632549	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	6.8	0.41	8.88e-11	Lung cancer;
SARC	cis	rs7923609	0.936	rs10822160	chr10:65112796	T/G	cg01631684	chr10:65280961	REEP3	-0.37	-4.89	-0.3	1.91e-6	Educational attainment;Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs6912958	0.525	rs242262	chr6:88018057	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.37	6.41	0.39	8.21e-10	Monocyte percentage of white cells;
SARC	cis	rs1008375	0.900	rs13101742	chr4:17701297	G/A	cg02297831	chr4:17616191	MED28	-0.39	-4.76	-0.3	3.33e-6	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs17270561	0.609	rs4712959	chr6:25727057	C/T	cg17691542	chr6:26056736	HIST1H1C	0.58	7.09	0.42	1.59e-11	Iron status biomarkers;
SARC	cis	rs17331151	0.573	rs3755801	chr3:52865798	G/A	cg04865290	chr3:52927548	TMEM110	-0.6	-5.93	-0.36	1.07e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs3204270	0.759	rs62075725	chr17:79611510	A/G	cg26965718	chr17:79658957	HGS	-0.59	-4.77	-0.3	3.29e-6	Dental caries;
SARC	cis	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg19223190	chr17:80058835	NA	-0.36	-4.94	-0.31	1.48e-6	Life satisfaction;
SARC	cis	rs1215050	0.740	rs10025482	chr4:99053277	T/C	cg05340658	chr4:99064831	C4orf37	0.49	6.69	0.4	1.67e-10	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs713477	0.967	rs1572613	chr14:55909897	C/T	cg13175173	chr14:55914753	NA	-0.3	-4.75	-0.3	3.63e-6	Pediatric bone mineral content (femoral neck);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg04991071	chr3:71615924	FOXP1	-0.5	-6.63	-0.4	2.25e-10	Chemerin levels;
SARC	cis	rs1949733	1.000	rs1880023	chr4:8480831	C/T	cg13073564	chr4:8508604	NA	0.47	7.76	0.45	2.67e-13	Response to antineoplastic agents;
SARC	cis	rs9457247	0.967	rs433191	chr6:167409662	T/A	cg23791538	chr6:167370224	RNASET2	-0.6	-8.25	-0.48	1.15e-14	Crohn's disease;
SARC	cis	rs7582720	1.000	rs72936838	chr2:203772984	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.31	0.43	4.24e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg18876405	chr7:65276391	NA	-0.71	-9.12	-0.51	3.6e-17	Aortic root size;
SARC	cis	rs2439831	1.000	rs2467743	chr15:43750346	T/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	8.4	0.48	4.54e-15	Lung cancer in ever smokers;
SARC	cis	rs3099143	0.908	rs6495222	chr15:77180015	A/C	cg21673338	chr15:77095150	SCAPER	0.6	5.09	0.32	7.43e-7	Recalcitrant atopic dermatitis;
SARC	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg06634786	chr22:41940651	POLR3H	0.49	6.09	0.37	4.68e-9	Vitiligo;
SARC	cis	rs995000	0.899	rs7518497	chr1:63177696	G/T	cg06896770	chr1:63153194	DOCK7	-0.92	-13.99	-0.68	1.07e-32	Triglyceride levels;
SARC	cis	rs6121246	0.567	rs6120890	chr20:30207659	T/G	cg13852791	chr20:30311386	BCL2L1	0.64	5.62	0.35	5.35e-8	Mean corpuscular hemoglobin;
SARC	cis	rs11764590	0.694	rs10241537	chr7:2083358	A/G	cg23043544	chr7:2124092	MAD1L1	-0.36	-4.95	-0.31	1.4e-6	Neuroticism;
SARC	cis	rs1843834	0.611	rs1058360	chr2:225449242	A/T	cg12698349	chr2:225449008	CUL3	0.69	9.13	0.51	3.31e-17	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg17971929	chr21:40555470	PSMG1	0.96	11.73	0.61	2.76e-25	Cognitive function;
SARC	cis	rs7523050	0.730	rs35100394	chr1:109433989	C/G	cg08274380	chr1:109419600	GPSM2	1.1	8.68	0.49	6.9e-16	Fat distribution (HIV);
SARC	cis	rs7937682	0.961	rs4935790	chr11:111633014	T/C	cg22437258	chr11:111473054	SIK2	-0.68	-8.75	-0.5	4.49e-16	Primary sclerosing cholangitis;
SARC	cis	rs10883723	0.810	rs2296582	chr10:104244139	G/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.55	7.25	0.43	5.98e-12	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs4319547	0.656	rs6488951	chr12:122873928	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.57	-6.41	-0.39	7.89e-10	Body mass index;
SARC	trans	rs7824557	0.527	rs2736298	chr8:11235136	C/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.7	-0.5	6e-16	Retinal vascular caliber;
SARC	cis	rs995000	0.931	rs1168013	chr1:62996838	C/G	cg06896770	chr1:63153194	DOCK7	0.9	13.49	0.66	5.08e-31	Triglyceride levels;
SARC	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg01475735	chr3:40494733	NA	-0.48	-5.31	-0.33	2.5e-7	Renal cell carcinoma;
SARC	cis	rs526231	0.578	rs1898672	chr5:102293853	A/T	cg23492399	chr5:102201601	PAM	0.43	5.19	0.32	4.61e-7	Primary biliary cholangitis;
SARC	cis	rs11605924	0.935	rs6485645	chr11:45862353	A/G	ch.11.939596F	chr11:45881766	CRY2	-0.47	-5.56	-0.34	7.41e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs950027	0.620	rs1145089	chr15:45652054	G/C	cg26924012	chr15:45694286	SPATA5L1	0.53	6.78	0.41	9.61e-11	Response to fenofibrate (adiponectin levels);
SARC	cis	rs17381785	0.773	rs13119988	chr4:14921247	A/G	cg12377275	chr4:15005593	CPEB2	0.48	5.2	0.32	4.45e-7	Urate levels in overweight individuals;
SARC	cis	rs4332037	0.950	rs56403963	chr7:1946130	C/G	cg23422044	chr7:1970798	MAD1L1	-0.46	-4.86	-0.3	2.19e-6	Bipolar disorder;
SARC	cis	rs2066819	1.000	rs808919	chr12:56647911	C/G	cg26734620	chr12:56694298	CS	-0.75	-5.66	-0.35	4.52e-8	Psoriasis vulgaris;
SARC	cis	rs9787249	1.000	rs9787249	chr1:40212878	G/A	cg24920358	chr1:40204285	PPIE	0.43	5.25	0.33	3.45e-7	Blood protein levels;
SARC	trans	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.73	10.55	0.57	1.63e-21	Intelligence (multi-trait analysis);
SARC	cis	rs11971779	0.680	rs7799598	chr7:139051833	C/T	cg23387468	chr7:139079360	LUC7L2	0.33	4.71	0.3	4.2e-6	Diisocyanate-induced asthma;
SARC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg02353165	chr6:42928485	GNMT	-0.61	-8.51	-0.49	2.12e-15	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs2204008	0.777	rs8189597	chr12:38307739	G/C	cg26384229	chr12:38710491	ALG10B	-0.88	-13.33	-0.66	1.61e-30	Bladder cancer;
SARC	cis	rs12586317	0.547	rs77262907	chr14:35495734	C/G	cg26967526	chr14:35346199	BAZ1A	-0.57	-5.71	-0.35	3.4e-8	Psoriasis;
SARC	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg17376030	chr22:41985996	PMM1	0.78	10.05	0.55	5.66e-20	Vitiligo;
SARC	cis	rs9660992	0.710	rs1668864	chr1:205248799	T/C	cg21643547	chr1:205240462	TMCC2	-0.63	-8.04	-0.47	4.47e-14	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs910316	0.967	rs119076	chr14:75572419	G/T	cg08847533	chr14:75593920	NEK9	-0.86	-13.76	-0.67	6.39e-32	Height;
SARC	cis	rs2439831	0.867	rs6493085	chr15:43654182	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.76	7.92	0.46	9.46e-14	Lung cancer in ever smokers;
SARC	cis	rs4144743	1.000	rs2015049	chr17:45332231	G/A	cg18085866	chr17:45331354	ITGB3	-0.72	-7.29	-0.43	4.8e-12	Body mass index;
SARC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg20887711	chr4:1340912	KIAA1530	0.81	10.32	0.56	8.52e-21	Longevity;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg05295558	chr17:40761584	FAM134C;TUBG1	0.51	6.37	0.39	9.74e-10	Breast cancer;
SARC	cis	rs9902453	0.967	rs12450441	chr17:28495021	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	6.77	0.41	1.05e-10	Coffee consumption (cups per day);
SARC	cis	rs6582630	0.555	rs35186318	chr12:38295822	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-7.76	-0.45	2.61e-13	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs80130819	0.748	rs2732478	chr12:48699537	G/A	cg05342945	chr12:48394962	COL2A1	-0.51	-5.45	-0.34	1.28e-7	Prostate cancer;
SARC	cis	rs778371	0.676	rs13024330	chr2:233715487	A/G	cg16596103	chr2:233749413	NGEF	-0.32	-5.01	-0.31	1.08e-6	Schizophrenia;
SARC	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg13206674	chr6:150067644	NUP43	0.42	5.53	0.34	8.65e-8	Lung cancer;
SARC	cis	rs2439831	0.850	rs28476182	chr15:44139643	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.76	7.53	0.44	1.14e-12	Lung cancer in ever smokers;
SARC	cis	rs644799	1.000	rs3748256	chr11:95521953	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	15.23	0.71	8.29e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg22903657	chr4:1355424	KIAA1530	-0.35	-4.82	-0.3	2.55e-6	Obesity-related traits;
SARC	cis	rs2204008	0.805	rs11179579	chr12:38213957	A/C	cg13010199	chr12:38710504	ALG10B	0.78	10.64	0.57	8.11e-22	Bladder cancer;
SARC	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg22834771	chr12:69754056	YEATS4	-0.48	-6.29	-0.38	1.55e-9	Cerebrospinal fluid biomarker levels;
SARC	cis	rs711830	1.000	rs1051929	chr2:177036754	T/C	cg13092806	chr2:177043255	NA	0.64	6.56	0.39	3.47e-10	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
SARC	cis	rs11077998	0.967	rs4789790	chr17:80510789	G/A	cg10255544	chr17:80519551	FOXK2	0.45	6.79	0.41	9.46e-11	Reticulocyte fraction of red cells;
SARC	cis	rs4689388	0.890	rs4688989	chr4:6290594	T/C	cg14416269	chr4:6271139	WFS1	0.34	5.19	0.32	4.54e-7	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs908922	0.676	rs4845784	chr1:152494583	G/C	cg09873164	chr1:152488093	CRCT1	0.66	8.45	0.48	3.1e-15	Hair morphology;
SARC	cis	rs9486715	1.000	rs11153085	chr6:97066355	A/T	cg06623918	chr6:96969491	KIAA0776	-0.81	-11.12	-0.59	2.56e-23	Headache;
SARC	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg13175981	chr1:150552382	MCL1	-0.54	-6.9	-0.41	4.97e-11	Tonsillectomy;
SARC	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg24250549	chr1:154909240	PMVK	-0.81	-11.7	-0.61	3.48e-25	Prostate cancer;
SARC	cis	rs6933660	0.744	rs35143743	chr6:151768532	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.59	7.26	0.43	5.76e-12	Menarche (age at onset);
SARC	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg16482183	chr6:26056742	HIST1H1C	0.41	5.16	0.32	5.23e-7	Height;
SARC	cis	rs34172651	0.917	rs11074654	chr16:24813743	A/G	cg04756594	chr16:24857601	SLC5A11	0.35	5.78	0.35	2.35e-8	Intelligence (multi-trait analysis);
SARC	cis	rs6500637	0.591	rs2075466	chr16:4872970	G/C	cg06965925	chr16:4818988	NA	0.3	4.93	0.31	1.6e-6	Cancer;
SARC	cis	rs11122272	0.766	rs1435166	chr1:231502310	T/C	cg06096015	chr1:231504339	EGLN1	0.36	5.45	0.34	1.25e-7	Hemoglobin concentration;
SARC	cis	rs1865760	0.865	rs6929805	chr6:25950834	T/A	cg16482183	chr6:26056742	HIST1H1C	0.51	6.46	0.39	5.94e-10	Height;
SARC	cis	rs7223966	1.000	rs9893348	chr17:61676534	G/T	cg00588841	chr17:61851480	DDX42;CCDC47	-0.57	-5.43	-0.34	1.4e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs11792861	0.926	rs11787878	chr9:111866749	C/T	cg13535736	chr9:111863775	C9orf5	-0.4	-4.89	-0.31	1.87e-6	Menarche (age at onset);
SARC	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg03806693	chr22:41940476	POLR3H	0.93	12.74	0.64	1.45e-28	Vitiligo;
SARC	cis	rs8078723	0.966	rs7021	chr17:38153875	T/A	cg17467752	chr17:38218738	THRA	0.47	6.02	0.37	6.67e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg26335602	chr6:28129616	ZNF389	0.53	5.88	0.36	1.43e-8	Depression;
SARC	cis	rs1044826	1.000	rs9289578	chr3:139200514	G/A	cg15131784	chr3:139108705	COPB2	0.46	5.16	0.32	5.24e-7	Obesity-related traits;
SARC	cis	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg09021430	chr5:549028	NA	-0.45	-5.72	-0.35	3.18e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs317689	0.613	rs315112	chr12:69785926	T/A	cg20891283	chr12:69753455	YEATS4	0.51	6.32	0.38	1.32e-9	Response to diuretic therapy;
SARC	trans	rs7980799	0.682	rs7311794	chr12:33635630	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-7.44	-0.44	1.98e-12	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs4481887	0.927	rs4453081	chr1:248475691	C/G	cg13385794	chr1:248469461	NA	0.36	5.59	0.34	6.18e-8	Common traits (Other);
SARC	trans	rs453301	0.571	rs330048	chr8:9087278	A/C	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.56	-0.39	3.35e-10	Joint mobility (Beighton score);
SARC	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	5.62	0.35	5.51e-8	Bipolar disorder;
SARC	cis	rs6908034	0.660	rs12525506	chr6:19794234	G/T	cg02682789	chr6:19804855	NA	0.73	5.73	0.35	3.07e-8	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs7824557	0.603	rs2736278	chr8:11219781	C/T	cg12395012	chr8:11607386	GATA4	-0.3	-4.87	-0.3	2.09e-6	Retinal vascular caliber;
SARC	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg12288994	chr5:1860383	NA	0.41	6.66	0.4	1.98e-10	Cardiovascular disease risk factors;
SARC	cis	rs72949976	0.707	rs10932473	chr2:214039057	C/T	cg08319019	chr2:214017104	IKZF2	-0.44	-5.4	-0.33	1.63e-7	Lung cancer;Squamous cell lung carcinoma;
SARC	cis	rs2576037	0.796	rs2247221	chr18:44580082	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.67	-9.79	-0.54	3.52e-19	Personality dimensions;
SARC	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg04518342	chr5:131593106	PDLIM4	0.39	5.42	0.33	1.46e-7	Acylcarnitine levels;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg09058860	chr1:173837788	SNORD74;ZBTB37;GAS5	0.46	6.3	0.38	1.49e-9	Lung adenocarcinoma;
SARC	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg00908189	chr16:619842	PIGQ	0.87	12.55	0.64	5.88e-28	Height;
SARC	cis	rs13161895	1.000	rs35592104	chr5:179447661	A/T	cg06664874	chr5:179499304	RNF130	0.52	5.1	0.32	7.19e-7	LDL cholesterol;
SARC	cis	rs2834188	1.000	rs13050445	chr21:34703597	C/T	cg14352951	chr21:34696688	IFNAR1	-0.46	-5.44	-0.34	1.35e-7	Narcolepsy;
SARC	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg07308232	chr7:1071921	C7orf50	-0.54	-6.9	-0.41	5.01e-11	Longevity;Endometriosis;
SARC	cis	rs1018836	0.739	rs4734247	chr8:91569144	A/G	cg16814680	chr8:91681699	NA	-0.76	-11.48	-0.6	1.84e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs733592	0.524	rs10875726	chr12:48425992	A/G	cg21466736	chr12:48725269	NA	0.31	5.5	0.34	1.01e-7	Plateletcrit;
SARC	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg01316550	chr5:56110833	MAP3K1	0.53	4.79	0.3	2.98e-6	Initial pursuit acceleration;
SARC	cis	rs12044355	0.927	rs11585959	chr1:231833718	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-8.12	-0.47	2.76e-14	Alzheimer's disease;
SARC	cis	rs72772090	0.634	rs17402639	chr5:96107005	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-5.17	-0.32	4.99e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs796364	1.000	rs10178177	chr2:200829993	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.79	7.58	0.44	8.24e-13	Schizophrenia;
SARC	cis	rs1008375	1.000	rs3733579	chr4:17694943	A/G	cg16339924	chr4:17578868	LAP3	0.55	6.82	0.41	7.6e-11	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4148883	0.898	rs4699726	chr4:100099513	T/C	cg12011299	chr4:100065546	ADH4	0.31	5.69	0.35	3.8e-8	Alcohol dependence;
SARC	trans	rs278567	0.655	rs412719	chr8:94163708	A/G	cg23357130	chr11:3181928	OSBPL5	-0.45	-6.23	-0.38	2.15e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg09021430	chr5:549028	NA	-0.44	-5.71	-0.35	3.51e-8	Obesity-related traits;
SARC	cis	rs11583043	1.000	rs6682873	chr1:101470906	C/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.49	5.88	0.36	1.42e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs67460515	0.563	rs7618924	chr3:160855599	A/G	cg03342759	chr3:160939853	NMD3	-0.65	-7.91	-0.46	1.02e-13	Parkinson's disease;
SARC	cis	rs4765905	0.549	rs2239025	chr12:2312282	A/G	cg10668781	chr12:2307325	CACNA1C	-0.3	-4.75	-0.3	3.56e-6	Schizophrenia;
SARC	cis	rs7178572	0.524	rs12904088	chr15:77399397	C/G	cg22256960	chr15:77711686	NA	-0.49	-5.18	-0.32	4.78e-7	Type 2 diabetes;
SARC	cis	rs711245	0.545	rs848617	chr2:36811298	G/C	cg09467607	chr2:36825704	FEZ2	0.53	7.07	0.42	1.79e-11	Height;
SARC	cis	rs6088813	1.000	rs6088816	chr20:33982435	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	-0.44	-5.29	-0.33	2.78e-7	Height;
SARC	cis	rs55823223	0.564	rs936391	chr17:73847799	A/G	cg08125733	chr17:73851984	WBP2	-0.58	-6.98	-0.42	3.01e-11	Psoriasis;
SARC	cis	rs4957048	0.577	rs56294732	chr5:568144	T/C	cg09021430	chr5:549028	NA	-0.46	-6.21	-0.38	2.36e-9	Ulcerative colitis;
SARC	cis	rs644799	0.562	rs1313288	chr11:95520695	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	6.24	0.38	2.03e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs8072100	0.846	rs6503796	chr17:45765249	T/C	cg08085267	chr17:45401833	C17orf57	-0.4	-4.72	-0.3	4.15e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs1023500	0.573	rs133381	chr22:42470608	C/G	cg04733989	chr22:42467013	NAGA	0.77	10.67	0.57	6.65e-22	Schizophrenia;
SARC	cis	rs7246657	0.943	rs6508732	chr19:38000468	C/T	cg23950597	chr19:37808831	NA	-0.54	-5.36	-0.33	2.01e-7	Coronary artery calcification;
SARC	cis	rs72949976	0.966	rs6752061	chr2:214027818	C/T	cg08319019	chr2:214017104	IKZF2	-0.53	-7.3	-0.43	4.44e-12	Lung cancer;Squamous cell lung carcinoma;
SARC	cis	rs6504663	0.596	rs7208018	chr17:48557863	C/T	cg03168497	chr17:48586147	MYCBPAP	-0.48	-5.22	-0.32	3.93e-7	Visceral fat;
SARC	cis	rs2073499	1.000	rs57319506	chr3:50285677	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.5	4.77	0.3	3.28e-6	Schizophrenia;
SARC	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg27266027	chr21:40555129	PSMG1	0.48	5.17	0.32	5.05e-7	Cognitive function;
SARC	cis	rs4713675	0.565	rs942640	chr6:33686442	G/T	cg15676125	chr6:33679581	C6orf125	0.51	6.22	0.38	2.27e-9	Plateletcrit;
SARC	cis	rs4595586	0.545	rs12809206	chr12:39388748	A/C	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg11987759	chr7:65425863	GUSB	0.46	6.08	0.37	4.94e-9	Aortic root size;
SARC	cis	rs6665290	0.904	rs9727512	chr1:227185375	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.09	-25.11	-0.85	3.14e-68	Myeloid white cell count;
SARC	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg08109568	chr15:31115862	NA	-0.52	-6.71	-0.4	1.46e-10	Huntington's disease progression;
SARC	cis	rs3892630	1.000	rs3892630	chr19:33181484	A/G	cg22980127	chr19:33182716	NUDT19	-1.0	-9.29	-0.52	1.14e-17	Red blood cell traits;
SARC	cis	rs1018836	0.923	rs7812970	chr8:91541229	G/A	cg16814680	chr8:91681699	NA	-0.76	-12.06	-0.62	2.47e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs8523	0.901	rs4532436	chr6:10983971	C/G	cg13562911	chr6:11044106	ELOVL2	0.37	4.88	0.3	1.93e-6	Red blood cell fatty acid levels;
SARC	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.41	4.85	0.3	2.23e-6	Tonsillectomy;
SARC	cis	rs7264396	0.635	rs6060692	chr20:34517925	A/T	cg23207816	chr20:34252616	CPNE1;RBM12	-0.53	-5.35	-0.33	2.06e-7	Total cholesterol levels;
SARC	cis	rs2250402	0.510	rs6492926	chr15:40325829	T/G	cg09159619	chr15:40331526	SRP14	0.71	4.85	0.3	2.25e-6	Corneal curvature;
SARC	cis	rs854765	0.551	rs12600546	chr17:17867614	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	9.69	0.54	6.98e-19	Total body bone mineral density;
SARC	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	9.58	0.53	1.49e-18	Platelet count;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg05306006	chr2:210867127	RPE	0.52	6.46	0.39	5.96e-10	Breast cancer;
SARC	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg13395646	chr4:1353034	KIAA1530	0.43	5.1	0.32	7.01e-7	Obesity-related traits;
SARC	cis	rs3820928	0.874	rs12105952	chr2:227864521	G/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-6.62	-0.4	2.43e-10	Pulmonary function;
SARC	trans	rs2727020	0.786	rs10839263	chr11:49354462	A/G	cg03929089	chr4:120376271	NA	-0.71	-9.01	-0.51	7.72e-17	Coronary artery disease;
SARC	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg22857025	chr5:266934	NA	-1.06	-11.66	-0.61	4.71e-25	Breast cancer;
SARC	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg04267008	chr7:1944627	MAD1L1	-0.61	-7.0	-0.42	2.69e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs1957429	0.520	rs2181127	chr14:65336455	C/T	cg23373153	chr14:65346875	NA	-0.84	-5.81	-0.36	2.04e-8	Pediatric areal bone mineral density (radius);
SARC	cis	rs7020830	0.894	rs12337316	chr9:37148105	G/A	cg14294708	chr9:37120828	ZCCHC7	1.1	19.43	0.79	1.22e-50	Schizophrenia;
SARC	cis	rs2228479	0.557	rs62054639	chr16:89821489	C/T	cg26513180	chr16:89883248	FANCA	0.72	4.79	0.3	2.99e-6	Skin colour saturation;
SARC	cis	rs6456156	0.586	rs12198816	chr6:167483546	G/A	cg07741184	chr6:167504864	NA	0.37	6.98	0.42	2.99e-11	Primary biliary cholangitis;
SARC	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.78	7.31	0.43	4.17e-12	Platelet count;
SARC	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg22168489	chr12:122356033	WDR66	-0.55	-8.12	-0.47	2.73e-14	Mean corpuscular volume;
SARC	cis	rs5769765	1.000	rs738711	chr22:50282603	A/G	cg03033257	chr22:50311977	ALG12;CRELD2	-0.54	-5.64	-0.35	4.81e-8	Schizophrenia;
SARC	cis	rs1044826	1.000	rs3772877	chr3:139187626	C/G	cg15131784	chr3:139108705	COPB2	0.45	5.17	0.32	5.05e-7	Obesity-related traits;
SARC	cis	rs1801251	1.000	rs12478564	chr2:233598340	C/T	cg25237894	chr2:233734115	C2orf82	0.38	4.96	0.31	1.36e-6	Coronary artery disease;
SARC	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg27266027	chr21:40555129	PSMG1	0.5	5.32	0.33	2.48e-7	Cognitive function;
SARC	cis	rs4072980	0.545	rs10890285	chr1:38453576	A/C	cg12658694	chr1:38397304	INPP5B	-0.76	-8.38	-0.48	4.88e-15	Coronary artery disease;
SARC	cis	rs2075371	0.501	rs1646654	chr7:134027547	G/C	cg00033643	chr7:134001901	SLC35B4	0.47	5.75	0.35	2.83e-8	Mean platelet volume;
SARC	cis	rs35213789	0.762	rs565505	chr7:69161391	T/G	cg10619644	chr7:69149951	AUTS2	-0.36	-4.95	-0.31	1.44e-6	Childhood ear infection;
SARC	cis	rs2916247	0.954	rs4623479	chr8:93038708	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.57	-5.99	-0.37	8.03e-9	Intelligence (multi-trait analysis);
SARC	cis	rs698813	0.774	rs786625	chr2:44604156	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.64	7.63	0.45	6e-13	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	trans	rs800082	0.698	rs800074	chr3:144347638	A/G	cg24215973	chr2:240111563	HDAC4	-0.52	-6.33	-0.38	1.26e-9	Smoking behavior;
SARC	cis	rs617791	0.508	rs10791837	chr11:65774596	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.41	-4.73	-0.3	3.89e-6	Breast cancer;
SARC	trans	rs12310956	0.532	rs11052954	chr12:33993512	C/G	cg13010199	chr12:38710504	ALG10B	0.66	8.84	0.5	2.45e-16	Morning vs. evening chronotype;
SARC	cis	rs34779708	0.931	rs34876468	chr10:35424450	G/A	cg03585969	chr10:35415529	CREM	0.38	4.71	0.3	4.16e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg10295955	chr4:187884368	NA	-1.07	-20.91	-0.81	2.28e-55	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg16479474	chr6:28041457	NA	0.37	5.37	0.33	1.94e-7	Depression;
SARC	cis	rs1348850	0.632	rs12467363	chr2:178502512	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.49	5.66	0.35	4.54e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs5167	0.506	rs7257916	chr19:45482884	T/C	cg10169327	chr19:45448959	APOC2	-0.32	-5.17	-0.32	4.92e-7	Blood protein levels;
SARC	cis	rs1580019	0.961	rs4357201	chr7:32496333	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.73	9.78	0.54	3.93e-19	Cognitive ability;
SARC	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg05368731	chr17:41323189	NBR1	0.78	9.52	0.53	2.33e-18	Menopause (age at onset);
SARC	cis	rs7296418	0.961	rs12425850	chr12:123501972	T/C	cg16085171	chr12:123569118	PITPNM2	-0.38	-4.85	-0.3	2.29e-6	Platelet count;
SARC	cis	rs8133932	0.677	rs6518257	chr21:47210107	T/C	cg11214348	chr21:47283868	PCBP3	0.47	5.95	0.36	9.93e-9	Schizophrenia;
SARC	cis	rs959260	0.588	rs2385263	chr17:73321117	T/C	cg14668889	chr17:73230827	NUP85	-0.56	-7.15	-0.42	1.1e-11	Systemic lupus erythematosus;
SARC	cis	rs2072499	0.932	rs2736613	chr1:156196016	T/C	cg25208724	chr1:156163844	SLC25A44	0.76	9.26	0.52	1.42e-17	Testicular germ cell tumor;
SARC	cis	rs17666538	1.000	rs59631161	chr8:587808	G/T	cg07234876	chr8:600039	NA	-0.86	-6.74	-0.4	1.24e-10	IgG glycosylation;
SARC	cis	rs698833	0.886	rs4953087	chr2:44561627	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.73	9.27	0.52	1.27e-17	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs17666538	1.000	rs73177066	chr8:585750	C/T	cg26554054	chr8:600488	NA	-0.62	-4.96	-0.31	1.35e-6	IgG glycosylation;
SARC	cis	rs950776	0.714	rs3743073	chr15:78909539	G/T	cg06917634	chr15:78832804	PSMA4	-0.71	-9.48	-0.53	2.97e-18	Sudden cardiac arrest;
SARC	cis	rs2153535	0.580	rs6920779	chr6:8437624	C/T	cg07606381	chr6:8435919	SLC35B3	0.79	11.03	0.59	4.73e-23	Motion sickness;
SARC	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg11247378	chr22:39784982	NA	-0.31	-5.01	-0.31	1.09e-6	Intelligence (multi-trait analysis);
SARC	cis	rs870825	0.616	rs28660669	chr4:185623312	C/T	cg04058563	chr4:185651563	MLF1IP	0.82	11.42	0.6	2.8e-24	Blood protein levels;
SARC	cis	rs34779708	0.931	rs1926556	chr10:35344907	T/C	cg03585969	chr10:35415529	CREM	0.38	4.85	0.3	2.27e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs7553864	0.966	rs4529687	chr1:87614083	T/C	cg18153957	chr1:87613403	LOC339524	-0.47	-5.55	-0.34	7.8e-8	Smoking behavior;
SARC	cis	rs6570726	0.791	rs9403730	chr6:145907233	C/T	cg23711669	chr6:146136114	FBXO30	0.85	14.24	0.68	1.55e-33	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg11764359	chr7:65958608	NA	0.62	4.91	0.31	1.74e-6	Diabetic kidney disease;
SARC	cis	rs3857067	0.806	rs17374832	chr4:95114394	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.05	-0.31	8.98e-7	QT interval;
SARC	cis	rs710865	1.000	rs710866	chr1:19568722	G/C	cg13387374	chr1:19411106	UBR4	0.45	5.82	0.36	1.96e-8	Brain structure;
SARC	cis	rs2276314	0.857	rs56230698	chr18:33628885	A/G	cg19628046	chr18:33552617	C18orf21	0.57	6.0	0.37	7.61e-9	Endometriosis;Drug-induced torsades de pointes;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg24568646	chr21:30446238	CCT8	-0.6	-6.89	-0.41	5.13e-11	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs7296418	0.619	rs7139321	chr12:123719528	T/G	cg00376283	chr12:123451042	ABCB9	0.57	7.0	0.42	2.75e-11	Platelet count;
SARC	cis	rs7552404	0.731	rs11161857	chr1:76370228	G/C	cg10523679	chr1:76189770	ACADM	0.47	5.31	0.33	2.55e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs72627123	0.867	rs74635757	chr14:74489225	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.76	5.99	0.37	7.73e-9	Morning vs. evening chronotype;
SARC	cis	rs6540556	0.723	rs12060420	chr1:209906819	T/G	cg23920097	chr1:209922102	NA	-0.48	-4.88	-0.3	1.99e-6	Red blood cell count;
SARC	cis	rs992157	0.798	rs7587220	chr2:219160864	C/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.64	-8.95	-0.51	1.11e-16	Colorectal cancer;
SARC	cis	rs7932354	0.502	rs7118546	chr11:47087128	C/G	cg03339077	chr11:47165057	C11orf49	-0.4	-5.31	-0.33	2.57e-7	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs3741151	1.000	rs3741151	chr11:73020846	G/T	cg17517138	chr11:73019481	ARHGEF17	1.07	8.13	0.47	2.52e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs78487399	0.710	rs77620935	chr2:43673765	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.58	-4.78	-0.3	3.11e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs10088262	0.629	rs6990565	chr8:124785645	C/A	cg20713898	chr8:124780851	FAM91A1	-0.65	-7.2	-0.43	8.03e-12	Pancreatic cancer;
SARC	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg04166393	chr7:2884313	GNA12	0.57	6.74	0.4	1.26e-10	Height;
SARC	trans	rs1814175	0.527	rs7128827	chr11:49665644	C/T	cg03929089	chr4:120376271	NA	0.77	9.3	0.52	1.09e-17	Height;
SARC	cis	rs911263	0.961	rs1885013	chr14:68754695	G/A	cg18825221	chr14:68749962	RAD51L1	0.51	9.04	0.51	6.19e-17	Primary biliary cholangitis;
SARC	cis	rs981844	1.000	rs2251994	chr4:154654097	C/T	cg14289246	chr4:154710475	SFRP2	0.51	5.9	0.36	1.29e-8	Response to statins (LDL cholesterol change);
SARC	cis	rs787274	1.000	rs787280	chr9:115539085	C/T	cg13803584	chr9:115635662	SNX30	-0.79	-6.14	-0.37	3.47e-9	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs950169	1.000	rs12902672	chr15:84716986	G/A	cg17507749	chr15:85114479	UBE2QP1	0.76	9.16	0.51	2.76e-17	Schizophrenia;
SARC	cis	rs761746	0.960	rs5753733	chr22:32027922	A/G	cg15823100	chr22:32027580	PISD	-0.32	-4.79	-0.3	2.94e-6	Intelligence;
SARC	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg00933542	chr6:150070202	PCMT1	0.31	5.29	0.33	2.83e-7	Lung cancer;
SARC	cis	rs244731	0.920	rs244707	chr5:176555636	A/T	cg06060754	chr5:176797920	RGS14	0.44	4.98	0.31	1.21e-6	Urate levels in lean individuals;
SARC	cis	rs3126085	0.825	rs868303	chr1:152178563	C/A	cg03465714	chr1:152285911	FLG	-0.46	-5.51	-0.34	9.24e-8	Atopic dermatitis;
SARC	cis	rs3808502	0.526	rs1042701	chr8:11422045	G/A	cg21775007	chr8:11205619	TDH	-0.46	-5.85	-0.36	1.65e-8	Neuroticism;
SARC	cis	rs6860806	0.507	rs2631372	chr5:131703578	C/G	cg24060327	chr5:131705240	SLC22A5	-0.7	-7.52	-0.44	1.18e-12	Breast cancer;
SARC	cis	rs7582720	1.000	rs72936852	chr2:203775475	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.26	0.43	5.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs3784262	1.000	rs4646640	chr15:58247563	C/G	cg12031962	chr15:58353849	ALDH1A2	0.41	6.04	0.37	5.94e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs2276314	0.857	rs62101402	chr18:33629435	A/G	cg19628046	chr18:33552617	C18orf21	0.57	5.98	0.36	8.5e-9	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs7607369	0.637	rs17462630	chr2:219286541	C/G	cg02176678	chr2:219576539	TTLL4	-0.51	-7.59	-0.45	7.73e-13	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs1153858	1.000	rs4271549	chr15:45652730	G/A	cg21132104	chr15:45694354	SPATA5L1	0.77	10.99	0.58	6.68e-23	Homoarginine levels;
SARC	cis	rs72792276	1.000	rs17839658	chr5:127423013	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	6.52	0.39	4.25e-10	Red cell distribution width;
SARC	cis	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg00262122	chr8:11665843	FDFT1	-0.39	-4.73	-0.3	3.93e-6	Retinal vascular caliber;
SARC	cis	rs72634258	0.554	rs12741937	chr1:7897622	A/T	cg05338066	chr1:7812865	CAMTA1	0.62	5.0	0.31	1.13e-6	Inflammatory bowel disease;
SARC	cis	rs459571	0.920	rs417142	chr9:136891370	G/T	cg13789015	chr9:136890014	NCRNA00094	0.63	8.71	0.5	5.6e-16	Platelet distribution width;
SARC	trans	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg21659725	chr3:3221576	CRBN	-0.55	-7.2	-0.43	7.99e-12	Intelligence (multi-trait analysis);
SARC	cis	rs7674212	0.510	rs2720468	chr4:104085153	A/G	cg16532752	chr4:104119610	CENPE	-0.49	-5.87	-0.36	1.52e-8	Type 2 diabetes;
SARC	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg19680485	chr15:31195859	MTMR15	-0.62	-7.03	-0.42	2.22e-11	Huntington's disease progression;
SARC	cis	rs3008870	0.701	rs2815358	chr1:67493778	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.62	8.03	0.47	4.73e-14	Lymphocyte percentage of white cells;
SARC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.46	0.57	3.12e-21	Prudent dietary pattern;
SARC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg27588902	chr6:42928151	GNMT	-0.32	-4.83	-0.3	2.5e-6	Alzheimer's disease in APOE e4+ carriers;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg24054508	chr1:38273761	C1orf122;YRDC	0.5	6.57	0.4	3.28e-10	Tetralogy of Fallot;
SARC	cis	rs908922	0.676	rs4845788	chr1:152519496	T/C	cg09873164	chr1:152488093	CRCT1	0.61	7.99	0.46	6.32e-14	Hair morphology;
SARC	cis	rs80282103	0.867	rs80254477	chr10:1077387	T/G	cg08668510	chr10:1095578	IDI1	0.76	5.19	0.32	4.61e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg12564285	chr5:131593104	PDLIM4	0.35	5.16	0.32	5.37e-7	Breast cancer;
SARC	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg07701084	chr6:150067640	NUP43	0.41	5.29	0.33	2.81e-7	Lung cancer;
SARC	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg27266027	chr21:40555129	PSMG1	-0.41	-4.72	-0.3	3.99e-6	Menarche (age at onset);
SARC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg03188948	chr7:1209495	NA	0.47	6.04	0.37	6.15e-9	Longevity;Endometriosis;
SARC	cis	rs3126085	0.825	rs12045492	chr1:152253866	A/T	cg26876637	chr1:152193138	HRNR	0.44	5.05	0.31	9.01e-7	Atopic dermatitis;
SARC	cis	rs10489202	0.632	rs413168	chr1:168005789	C/G	cg24449463	chr1:168025552	DCAF6	-0.67	-9.08	-0.51	4.62e-17	Schizophrenia;
SARC	cis	rs4713118	0.786	rs200503	chr6:27785882	A/G	cg17221315	chr6:27791827	HIST1H4J	0.55	5.96	0.36	9.09e-9	Parkinson's disease;
SARC	cis	rs7662987	0.517	rs2602876	chr4:100039535	A/T	cg12011299	chr4:100065546	ADH4	0.32	5.37	0.33	1.95e-7	Smoking initiation;
SARC	cis	rs6772849	0.930	rs68090762	chr3:128343907	C/T	cg01163369	chr3:128370232	RPN1	-0.34	-5.0	-0.31	1.12e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg23758822	chr17:41437982	NA	0.88	10.75	0.58	3.73e-22	Menopause (age at onset);
SARC	cis	rs9359856	0.564	rs3818133	chr6:90374456	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.61	-4.79	-0.3	2.93e-6	Bipolar disorder;
SARC	cis	rs7192750	0.583	rs8046916	chr16:72047751	C/G	cg14768367	chr16:72042858	DHODH	-0.79	-6.16	-0.37	3.18e-9	LDL cholesterol levels;Total cholesterol levels;
SARC	trans	rs6964833	1.000	rs6964833	chr7:74101909	T/C	cg07504079	chr7:72649617	NCF1B	-0.61	-6.59	-0.4	2.83e-10	Menarche (age at onset);
SARC	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg22920501	chr2:26401640	FAM59B	0.56	6.98	0.42	3.03e-11	Gut microbiome composition (summer);
SARC	trans	rs9650657	0.812	rs4240669	chr8:10629987	C/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.43	-0.39	7.17e-10	Neuroticism;
SARC	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.72	-7.56	-0.44	9.01e-13	Platelet count;
SARC	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg16486109	chr11:613632	IRF7	0.45	6.05	0.37	5.59e-9	Systemic lupus erythematosus;
SARC	cis	rs13314892	0.734	rs74491124	chr3:69854510	C/G	cg17445875	chr3:69859618	MITF	-0.58	-5.7	-0.35	3.56e-8	QRS complex (12-leadsum);
SARC	cis	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg13147721	chr7:65941812	NA	-0.52	-4.76	-0.3	3.38e-6	Diabetic kidney disease;
SARC	cis	rs6963495	0.674	rs75880756	chr7:105163821	G/C	cg19920283	chr7:105172520	RINT1	0.65	5.48	0.34	1.09e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg22535103	chr8:58192502	C8orf71	-0.73	-6.78	-0.41	9.94e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs9790314	0.669	rs7630768	chr3:160864879	T/A	cg04691961	chr3:161091175	C3orf57	-0.54	-7.19	-0.43	8.51e-12	Morning vs. evening chronotype;
SARC	cis	rs4423214	0.610	rs12789253	chr11:71125765	G/A	cg05163923	chr11:71159392	DHCR7	0.47	6.56	0.39	3.39e-10	Vitamin D levels;
SARC	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg21226059	chr5:178986404	RUFY1	0.35	4.94	0.31	1.52e-6	Lung cancer;
SARC	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg18876405	chr7:65276391	NA	-0.46	-5.15	-0.32	5.63e-7	Aortic root size;
SARC	cis	rs6121246	0.567	rs6088796	chr20:30213229	C/T	cg21427119	chr20:30132790	HM13	-0.46	-5.05	-0.31	8.92e-7	Mean corpuscular hemoglobin;
SARC	cis	rs4276643	0.732	rs2685411	chr8:27811098	A/G	cg25028855	chr8:28560486	EXTL3	0.28	4.75	0.3	3.5e-6	Low vWF levels;
SARC	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg11764359	chr7:65958608	NA	0.83	11.09	0.59	3.09e-23	Aortic root size;
SARC	cis	rs11785400	1.000	rs4266629	chr8:143736635	A/G	cg24634471	chr8:143751801	JRK	0.68	9.12	0.51	3.57e-17	Schizophrenia;
SARC	cis	rs2797160	0.651	rs1269176	chr6:126029682	A/T	cg05901451	chr6:126070800	HEY2	-0.41	-4.86	-0.3	2.2e-6	Endometrial cancer;
SARC	cis	rs2120019	1.000	rs35577967	chr15:75354621	G/A	cg17294928	chr15:75287854	SCAMP5	-0.96	-13.74	-0.67	7.34e-32	Blood trace element (Zn levels);
SARC	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg18252515	chr7:66147081	NA	-1.29	-11.04	-0.59	4.48e-23	Diabetic kidney disease;
SARC	trans	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg21659725	chr3:3221576	CRBN	0.55	7.24	0.43	6.34e-12	Intelligence (multi-trait analysis);
SARC	cis	rs17270561	0.609	rs12192077	chr6:25732794	G/A	cg17691542	chr6:26056736	HIST1H1C	0.58	7.09	0.42	1.59e-11	Iron status biomarkers;
SARC	cis	rs2916247	0.954	rs7845969	chr8:93022087	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.58	-6.04	-0.37	5.91e-9	Intelligence (multi-trait analysis);
SARC	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg00149659	chr3:10157352	C3orf10	0.72	6.64	0.4	2.14e-10	Alzheimer's disease;
SARC	cis	rs7847628	0.587	rs3793638	chr9:123582697	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	9.37	0.52	6.61e-18	Birth weight;
SARC	cis	rs2997447	0.706	rs12062488	chr1:26466253	G/A	cg19633962	chr1:26362018	EXTL1	-0.58	-5.22	-0.32	4.04e-7	QRS complex (12-leadsum);
SARC	cis	rs9486719	0.947	rs12208556	chr6:96903486	C/T	cg18709589	chr6:96969512	KIAA0776	-0.49	-5.07	-0.31	8.27e-7	Migraine;Coronary artery disease;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg17034360	chr1:68629032	GPR177	-0.52	-6.32	-0.38	1.31e-9	Height;
SARC	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.31	-4.79	-0.3	2.97e-6	Total body bone mineral density;
SARC	cis	rs13191362	1.000	rs13201023	chr6:162981381	C/G	cg21926612	chr6:163149169	PACRG;PARK2	0.57	5.52	0.34	8.87e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg23262073	chr20:60523788	NA	-0.39	-5.63	-0.35	5.17e-8	Body mass index;
SARC	cis	rs2916247	0.908	rs7002049	chr8:93114414	T/C	cg10183463	chr8:93005414	RUNX1T1	0.59	5.89	0.36	1.33e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg19077165	chr18:44547161	KATNAL2	-0.47	-6.38	-0.39	9.39e-10	Personality dimensions;
SARC	cis	rs67311347	0.544	rs12635762	chr3:40332759	C/T	cg24209194	chr3:40518798	ZNF619	-0.5	-6.72	-0.4	1.36e-10	Renal cell carcinoma;
SARC	cis	rs2048656	0.524	rs12543959	chr8:9539000	G/A	cg21625330	chr8:9911636	MSRA	0.45	4.74	0.3	3.64e-6	Schizophrenia;
SARC	cis	rs6831352	0.918	rs28987097	chr4:100049579	C/T	cg13256891	chr4:100009986	ADH5	-0.65	-8.11	-0.47	2.83e-14	Alcohol dependence;
SARC	cis	rs4595586	0.545	rs7486598	chr12:39371159	C/T	cg13010199	chr12:38710504	ALG10B	0.4	4.75	0.3	3.57e-6	Morning vs. evening chronotype;
SARC	cis	rs4853036	0.951	rs10165061	chr2:70146363	C/T	cg02498382	chr2:70120550	SNRNP27	-0.38	-5.19	-0.32	4.55e-7	Colorectal or endometrial cancer;
SARC	cis	rs10911232	0.507	rs6660111	chr1:183014289	G/A	cg13390022	chr1:182993471	LAMC1	0.35	5.23	0.32	3.81e-7	Hypertriglyceridemia;
SARC	cis	rs8067545	0.611	rs7219615	chr17:20132558	T/A	cg13482628	chr17:19912719	NA	-0.54	-7.03	-0.42	2.23e-11	Schizophrenia;
SARC	cis	rs73206853	0.563	rs56386451	chr12:111174516	A/G	cg10860002	chr12:110842031	ANAPC7	0.6	4.99	0.31	1.2e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs2014572	0.967	rs7248000	chr19:57762139	C/T	cg24459738	chr19:57751996	ZNF805	-0.42	-4.91	-0.31	1.7e-6	Hyperactive-impulsive symptoms;
SARC	cis	rs12464559	0.522	rs1916301	chr2:152640498	G/A	cg01189475	chr2:152685088	ARL5A	0.63	5.12	0.32	6.51e-7	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs2153535	0.580	rs2143354	chr6:8517907	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	8.21	0.47	1.56e-14	Motion sickness;
SARC	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg06212747	chr3:49208901	KLHDC8B	0.65	8.56	0.49	1.57e-15	Parkinson's disease;
SARC	cis	rs72945132	0.882	rs61260732	chr11:70162145	G/A	cg00319359	chr11:70116639	PPFIA1	0.67	6.08	0.37	4.85e-9	Coronary artery disease;
SARC	cis	rs8016982	0.630	rs61980900	chr14:81686436	T/C	cg01989461	chr14:81687754	GTF2A1	0.74	11.38	0.6	3.77e-24	Schizophrenia;
SARC	cis	rs7927592	0.871	rs12941	chr11:68382193	C/T	cg01657329	chr11:68192670	LRP5	-0.44	-5.23	-0.32	3.81e-7	Total body bone mineral density;
SARC	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.59e-6	Depression;
SARC	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg18876405	chr7:65276391	NA	0.44	4.89	0.31	1.89e-6	Aortic root size;
SARC	cis	rs2124969	0.562	rs4665164	chr2:161070078	T/G	cg03641300	chr2:160917029	PLA2R1	-0.4	-5.47	-0.34	1.16e-7	Waist circumference adjusted for body mass index;
SARC	cis	rs2342371	0.539	rs35959625	chr3:196131941	C/T	cg15048948	chr3:196158458	UBXN7	0.47	5.75	0.35	2.82e-8	Fat distribution (HIV);
SARC	cis	rs524281	0.861	rs10896080	chr11:65876796	G/A	cg14036092	chr11:66035641	RAB1B	-0.51	-5.34	-0.33	2.16e-7	Electroencephalogram traits;
SARC	cis	rs4595586	0.545	rs12809435	chr12:39404341	C/T	cg13010199	chr12:38710504	ALG10B	-0.42	-4.95	-0.31	1.41e-6	Morning vs. evening chronotype;
SARC	cis	rs9393692	0.905	rs4412192	chr6:26290377	A/G	cg00631329	chr6:26305371	NA	0.61	8.74	0.5	4.63e-16	Educational attainment;
SARC	cis	rs400736	0.930	rs225100	chr1:8066914	C/T	cg25007680	chr1:8021821	PARK7	-0.51	-6.64	-0.4	2.18e-10	Response to antidepressants and depression;
SARC	cis	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg22496380	chr5:211416	CCDC127	-0.89	-9.32	-0.52	9.49e-18	Breast cancer;
SARC	cis	rs9790314	0.502	rs7647118	chr3:161016165	T/C	cg03342759	chr3:160939853	NMD3	-0.67	-8.62	-0.49	1.04e-15	Morning vs. evening chronotype;
SARC	cis	rs7927771	0.839	rs3817334	chr11:47650993	C/T	cg05585544	chr11:47624801	NA	-0.35	-4.87	-0.3	2.04e-6	Subjective well-being;
SARC	cis	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg12463550	chr7:65579703	CRCP	0.66	5.05	0.31	9.09e-7	Diabetic kidney disease;
SARC	cis	rs7662987	0.517	rs2851286	chr4:100014976	A/G	cg13256891	chr4:100009986	ADH5	-0.67	-8.2	-0.47	1.63e-14	Smoking initiation;
SARC	cis	rs739401	0.611	rs2239899	chr11:3024624	A/G	cg20651018	chr11:3035856	CARS	0.45	6.88	0.41	5.4e-11	Longevity;
SARC	cis	rs7412746	0.611	rs2864873	chr1:150814174	A/G	cg10589385	chr1:150898437	SETDB1	0.41	5.47	0.34	1.15e-7	Melanoma;
SARC	cis	rs9398803	0.865	rs2184967	chr6:126773487	C/T	cg20229609	chr6:126660872	C6orf173	0.4	5.81	0.36	2.09e-8	Male-pattern baldness;
SARC	cis	rs7264396	0.790	rs6121020	chr20:34252006	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	5.91	0.36	1.21e-8	Total cholesterol levels;
SARC	cis	rs7178909	0.797	rs1910586	chr15:90440489	T/G	cg19708238	chr15:90437601	AP3S2	0.64	8.66	0.49	8.21e-16	Common traits (Other);
SARC	cis	rs7223966	1.000	rs72848797	chr17:61934664	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	5.2	0.32	4.28e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2011503	0.941	rs4808944	chr19:19426613	A/C	cg03709012	chr19:19516395	GATAD2A	0.64	5.7	0.35	3.69e-8	Bipolar disorder;
SARC	cis	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg11764359	chr7:65958608	NA	0.62	4.91	0.31	1.74e-6	Diabetic kidney disease;
SARC	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg19346786	chr7:2764209	NA	-0.38	-5.64	-0.35	4.89e-8	Height;
SARC	trans	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg07211511	chr3:129823064	LOC729375	-0.62	-6.6	-0.4	2.72e-10	Blood pressure (smoking interaction);
SARC	cis	rs6570726	1.000	rs386678	chr6:145869010	A/G	cg23711669	chr6:146136114	FBXO30	0.75	11.23	0.59	1.16e-23	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	7.03	0.42	2.21e-11	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg18252515	chr7:66147081	NA	0.45	4.8	0.3	2.84e-6	Aortic root size;
SARC	trans	rs2898290	0.622	rs978802	chr8:11343278	A/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.33	-0.43	3.71e-12	Systolic blood pressure;
SARC	cis	rs7481584	0.624	rs369461	chr11:3061992	A/G	cg05729581	chr11:3078854	CARS	0.53	7.05	0.42	2.01e-11	Calcium levels;
SARC	cis	rs17401966	0.838	rs1013952	chr1:10319247	G/A	cg15208524	chr1:10270712	KIF1B	0.46	5.37	0.33	1.91e-7	Hepatocellular carcinoma;
SARC	cis	rs3617	0.625	rs2245647	chr3:52862753	A/G	cg18404041	chr3:52824283	ITIH1	-0.36	-5.3	-0.33	2.73e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs10464366	0.746	rs11760807	chr7:39142377	G/A	cg18850127	chr7:39170497	POU6F2	0.44	5.4	0.33	1.64e-7	IgG glycosylation;
SARC	cis	rs1707322	0.686	rs1084086	chr1:46041100	A/C	cg03146154	chr1:46216737	IPP	-0.5	-5.89	-0.36	1.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs12310956	0.510	rs1825903	chr12:33870437	G/C	cg13010199	chr12:38710504	ALG10B	0.56	7.32	0.43	3.98e-12	Morning vs. evening chronotype;
SARC	cis	rs78487399	0.808	rs7587268	chr2:43673892	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-5.17	-0.32	4.96e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg04546413	chr19:29218101	NA	0.55	6.49	0.39	5.04e-10	Methadone dose in opioid dependence;
SARC	cis	rs920590	0.510	rs4922101	chr8:19648895	A/G	cg03894339	chr8:19674705	INTS10	0.7	7.47	0.44	1.56e-12	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg08219700	chr8:58056026	NA	0.62	6.56	0.4	3.37e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9300255	0.830	rs28413626	chr12:123861452	G/A	cg00376283	chr12:123451042	ABCB9	-0.53	-5.77	-0.35	2.49e-8	Neutrophil percentage of white cells;
SARC	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg13175981	chr1:150552382	MCL1	-0.54	-6.9	-0.41	4.97e-11	Tonsillectomy;
SARC	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg21724239	chr8:58056113	NA	0.75	6.81	0.41	7.99e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs7000551	0.751	rs2469775	chr8:22373238	T/C	cg12081754	chr8:22256438	SLC39A14	0.56	7.98	0.46	6.56e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg03060546	chr3:49711283	APEH	0.42	5.36	0.33	1.95e-7	Parkinson's disease;
SARC	cis	rs3815700	1.000	rs7247420	chr19:33096786	G/A	cg24916020	chr19:33096688	ANKRD27	0.53	5.29	0.33	2.87e-7	Eosinophilic esophagitis;
SARC	trans	rs4332037	0.950	rs7807014	chr7:1939021	T/C	cg11693508	chr17:37793320	STARD3	0.72	6.54	0.39	3.95e-10	Bipolar disorder;
SARC	cis	rs9400467	0.506	rs1061388	chr6:111620294	A/C	cg15721981	chr6:111408429	SLC16A10	0.69	5.85	0.36	1.67e-8	Blood metabolite levels;Amino acid levels;
SARC	trans	rs11098499	0.954	rs12508504	chr4:120410607	A/C	cg25214090	chr10:38739885	LOC399744	0.56	7.44	0.44	1.97e-12	Corneal astigmatism;
SARC	cis	rs10875746	0.903	rs11168403	chr12:48484958	T/C	cg26205652	chr12:48591994	NA	0.56	6.1	0.37	4.37e-9	Longevity (90 years and older);
SARC	cis	rs2276314	0.762	rs3826600	chr18:33609053	A/G	cg05985134	chr18:33552581	C18orf21	0.68	7.17	0.43	9.87e-12	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs35110281	0.627	rs11701746	chr21:44975137	C/T	cg21573476	chr21:45109991	RRP1B	-0.38	-5.5	-0.34	9.94e-8	Mean corpuscular volume;
SARC	cis	rs6912958	0.559	rs376633	chr6:88042785	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	11.04	0.59	4.52e-23	Monocyte percentage of white cells;
SARC	cis	rs858239	0.601	rs12539331	chr7:23151330	A/G	cg23682824	chr7:23144976	KLHL7	0.66	8.56	0.49	1.55e-15	Cerebrospinal fluid biomarker levels;
SARC	cis	rs2732480	0.577	rs2732481	chr12:48736985	T/G	cg24011408	chr12:48396354	COL2A1	0.43	5.11	0.32	6.81e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs17125944	0.615	rs12587286	chr14:53304751	C/T	cg00686598	chr14:53173677	PSMC6	0.88	6.07	0.37	5.11e-9	Alzheimer's disease (late onset);
SARC	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg03647317	chr4:187891568	NA	-0.35	-5.13	-0.32	6.24e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs17666538	1.000	rs57896286	chr8:571479	T/C	cg07234876	chr8:600039	NA	-0.94	-6.65	-0.4	2.09e-10	IgG glycosylation;
SARC	cis	rs3091242	0.933	rs61775167	chr1:25780893	A/G	cg02931644	chr1:25747376	RHCE	-0.43	-7.29	-0.43	4.85e-12	Erythrocyte sedimentation rate;
SARC	cis	rs67311347	0.955	rs73078170	chr3:40483947	C/T	cg09455208	chr3:40491958	NA	0.39	5.46	0.34	1.2e-7	Renal cell carcinoma;
SARC	cis	rs2204008	0.749	rs4579984	chr12:38166266	A/G	cg13010199	chr12:38710504	ALG10B	0.74	9.75	0.54	4.75e-19	Bladder cancer;
SARC	cis	rs748404	0.697	rs531910	chr15:43560607	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.52	6.14	0.37	3.6e-9	Lung cancer;
SARC	cis	rs568617	0.953	rs583887	chr11:65644027	T/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.47	-5.45	-0.34	1.31e-7	Crohn's disease;
SARC	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg27266027	chr21:40555129	PSMG1	-0.5	-5.35	-0.33	2.07e-7	Cognitive function;
SARC	cis	rs611744	0.967	rs641820	chr8:109190717	T/C	cg21045802	chr8:109455806	TTC35	0.44	5.3	0.33	2.64e-7	Dupuytren's disease;
SARC	cis	rs1046896	0.553	rs8073413	chr17:80836005	G/A	cg02711726	chr17:80685570	FN3KRP	-0.56	-6.93	-0.41	4.18e-11	Glycated hemoglobin levels;
SARC	cis	rs1050631	1.000	rs11873168	chr18:33707581	T/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.47	5.49	0.34	1.05e-7	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs59918340	0.728	rs4961340	chr8:142232002	G/A	cg16341495	chr8:142228727	SLC45A4	-0.36	-5.11	-0.32	6.78e-7	Immature fraction of reticulocytes;
SARC	trans	rs459571	0.959	rs2520100	chr9:136918137	A/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.63	-7.3	-0.43	4.5e-12	Platelet distribution width;
SARC	cis	rs908922	0.676	rs4112786	chr1:152532872	T/A	cg09873164	chr1:152488093	CRCT1	0.6	7.73	0.45	3.1400000000000003e-13	Hair morphology;
SARC	trans	rs75246769	1.000	rs12670287	chr7:145456202	G/T	cg00210271	chr12:54088934	NA	-0.48	-6.29	-0.38	1.55e-9	Facial morphology (factor 10, width of nasal floor);
SARC	cis	rs10870270	0.917	rs11146417	chr10:133791034	C/G	cg17892150	chr10:133769511	PPP2R2D	-0.78	-8.82	-0.5	2.79e-16	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs3213545	0.700	rs10849829	chr12:121470256	A/G	cg02403541	chr12:121454288	C12orf43	-0.7	-9.72	-0.54	5.69e-19	Subjective well-being;Cardiovascular disease risk factors;
SARC	trans	rs6815916	1.000	rs6841868	chr4:182553178	T/C	cg13864546	chr1:2310327	MORN1	0.66	6.24	0.38	2.04e-9	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg03060546	chr3:49711283	APEH	0.45	5.65	0.35	4.75e-8	Parkinson's disease;
SARC	cis	rs12545109	0.800	rs2670054	chr8:57421616	C/T	cg09654669	chr8:57350985	NA	-0.39	-4.98	-0.31	1.26e-6	Obesity-related traits;
SARC	cis	rs4595586	0.525	rs11609150	chr12:39408622	A/C	cg26384229	chr12:38710491	ALG10B	0.49	5.74	0.35	2.97e-8	Morning vs. evening chronotype;
SARC	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg13866156	chr1:1669148	SLC35E2	-0.63	-9.58	-0.53	1.52e-18	Body mass index;
SARC	cis	rs2070488	0.965	rs13093640	chr3:38487176	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	14.68	0.69	5.62e-35	Electrocardiographic conduction measures;
SARC	cis	rs4763879	0.778	rs9332411	chr12:9834345	C/T	cg27502298	chr12:9555721	NA	0.47	5.38	0.33	1.81e-7	Type 1 diabetes;
SARC	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg10295955	chr4:187884368	NA	-1.06	-20.71	-0.8	9.99e-55	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1401999	1.000	rs1401999	chr3:183678342	C/G	cg01324343	chr3:183735012	ABCC5	0.67	13.43	0.66	7.75e-31	Anterior chamber depth;
SARC	cis	rs12367572	1.000	rs12822444	chr12:45276677	G/A	cg04608330	chr12:45269318	NELL2	-0.48	-5.94	-0.36	1.03e-8	Gut microbiome composition (summer);
SARC	cis	rs7769051	0.522	rs6930703	chr6:133111266	C/T	cg07930552	chr6:133119739	C6orf192	0.88	5.24	0.32	3.66e-7	Type 2 diabetes nephropathy;
SARC	cis	rs6998277	1.000	rs34217554	chr8:103646352	T/C	cg10187029	chr8:103597600	NA	0.66	6.64	0.4	2.17e-10	Migraine;
SARC	cis	rs10861342	1.000	rs11112368	chr12:105494218	T/C	cg23923672	chr12:105501055	KIAA1033	0.83	6.18	0.38	2.86e-9	IgG glycosylation;
SARC	cis	rs7264396	0.635	rs6058382	chr20:34553948	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-6.92	-0.41	4.41e-11	Total cholesterol levels;
SARC	trans	rs7824557	0.614	rs2736277	chr8:11218893	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.62	-0.4	2.45e-10	Retinal vascular caliber;
SARC	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg01088093	chr15:75748402	SIN3A	0.52	6.8	0.41	8.52e-11	Chemerin levels;
SARC	cis	rs4253772	0.575	rs9615979	chr22:46789021	G/T	cg24881330	chr22:46731750	TRMU	0.72	4.84	0.3	2.41e-6	LDL cholesterol;Cholesterol, total;
SARC	cis	rs698833	0.886	rs786613	chr2:44590066	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.71	-9.49	-0.53	2.93e-18	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs4642101	0.765	rs6791647	chr3:12826425	C/T	cg24848339	chr3:12840334	CAND2	-0.34	-5.29	-0.33	2.85e-7	QRS complex (12-leadsum);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg21235025	chr13:72249355	DACH1	-0.43	-6.55	-0.39	3.71e-10	Chemerin levels;
SARC	cis	rs3768617	0.811	rs4350171	chr1:182982148	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.64	8.81	0.5	3.02e-16	Fuchs's corneal dystrophy;
SARC	cis	rs9322193	1.000	rs58189451	chr6:149921388	G/A	cg00933542	chr6:150070202	PCMT1	0.31	5.27	0.33	3.16e-7	Lung cancer;
SARC	cis	rs796364	0.664	rs3106089	chr2:200884615	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.77	6.8	0.41	8.96e-11	Schizophrenia;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg14131431	chr9:110093467	RAD23B	0.57	7.76	0.45	2.59e-13	Thyroid stimulating hormone;
SARC	cis	rs2204008	0.744	rs8189486	chr12:38244968	C/T	cg26384229	chr12:38710491	ALG10B	0.91	13.64	0.67	1.61e-31	Bladder cancer;
SARC	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg27286337	chr10:134555280	INPP5A	0.66	8.42	0.48	3.86e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs2730245	0.528	rs1188954	chr7:158691417	G/A	cg17136484	chr7:158649327	WDR60	0.43	4.99	0.31	1.17e-6	Height;
SARC	cis	rs4141404	0.828	rs2413043	chr22:31648576	G/T	cg07713946	chr22:31675144	LIMK2	-0.37	-5.11	-0.32	6.77e-7	Paclitaxel-induced neuropathy;
SARC	cis	rs11676348	0.714	rs4674254	chr2:218986077	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.5	-6.42	-0.39	7.61e-10	Ulcerative colitis;
SARC	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg03161606	chr19:29218774	NA	0.47	6.75	0.4	1.16e-10	Methadone dose in opioid dependence;
SARC	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg26335602	chr6:28129616	ZNF389	0.46	5.29	0.33	2.8e-7	Cardiac Troponin-T levels;
SARC	cis	rs13202913	0.837	rs9397052	chr6:151779228	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.57	4.95	0.31	1.41e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs6759839	0.506	rs1430038	chr2:16611452	C/A	cg09580478	chr2:16689509	NA	0.42	4.74	0.3	3.7e-6	Mean platelet volume;
SARC	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg11764359	chr7:65958608	NA	0.88	12.58	0.64	4.89e-28	Aortic root size;
SARC	cis	rs1538970	0.962	rs4660849	chr1:45819872	A/G	cg16078521	chr1:45672383	ZSWIM5	-0.46	-5.04	-0.31	9.45e-7	Platelet count;
SARC	cis	rs899997	1.000	rs11629824	chr15:79005524	T/G	cg04896959	chr15:78267971	NA	0.52	6.36	0.38	1.06e-9	Coronary artery disease or large artery stroke;
SARC	cis	rs861020	0.630	rs656566	chr1:210006603	C/T	cg05527609	chr1:210001259	C1orf107	0.78	10.12	0.55	3.37e-20	Orofacial clefts;
SARC	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg08219700	chr8:58056026	NA	0.6	5.82	0.36	1.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg22800045	chr5:56110881	MAP3K1	0.75	8.02	0.47	5.06e-14	Initial pursuit acceleration;
SARC	cis	rs11971779	0.616	rs1862878	chr7:139019914	C/G	cg23387468	chr7:139079360	LUC7L2	0.33	4.8	0.3	2.84e-6	Diisocyanate-induced asthma;
SARC	cis	rs10875746	0.903	rs3782911	chr12:48483492	T/G	cg26205652	chr12:48591994	NA	0.56	6.1	0.37	4.37e-9	Longevity (90 years and older);
SARC	trans	rs12310956	0.532	rs35366144	chr12:33992000	C/G	cg26384229	chr12:38710491	ALG10B	0.85	12.1	0.62	1.86e-26	Morning vs. evening chronotype;
SARC	cis	rs611744	0.967	rs686630	chr8:109233239	G/C	cg21045802	chr8:109455806	TTC35	0.46	5.43	0.34	1.38e-7	Dupuytren's disease;
SARC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.54	6.92	0.41	4.38e-11	Lymphocyte counts;
SARC	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg13607699	chr17:42295918	UBTF	0.59	7.17	0.43	9.66e-12	Total body bone mineral density;
SARC	cis	rs870825	0.929	rs72689278	chr4:185593718	C/T	cg04058563	chr4:185651563	MLF1IP	0.81	9.73	0.54	5.47e-19	Blood protein levels;
SARC	cis	rs240764	0.507	rs9404033	chr6:101211541	A/T	cg09795085	chr6:101329169	ASCC3	0.41	5.02	0.31	1.04e-6	Neuroticism;
SARC	cis	rs10876993	1.000	rs10876993	chr12:58062667	C/T	cg18357645	chr12:58087776	OS9	0.5	6.64	0.4	2.13e-10	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs6450176	0.909	rs3776712	chr5:53304179	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.68	-7.9	-0.46	1.08e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs1878931	0.559	rs2106863	chr16:3391330	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.72	9.34	0.52	7.85e-18	Body mass index (adult);
SARC	cis	rs950169	0.686	rs12906474	chr15:85109237	A/G	cg24253500	chr15:84953950	NA	0.35	4.96	0.31	1.35e-6	Schizophrenia;
SARC	trans	rs1814175	0.591	rs11040589	chr11:49862449	A/G	cg03929089	chr4:120376271	NA	-0.83	-12.24	-0.63	6.14e-27	Height;
SARC	cis	rs9921192	1.000	rs2892165	chr16:4324293	A/T	cg00021532	chr16:4324280	TFAP4	0.8	12.15	0.62	1.21e-26	Prostate-specific antigen levels;
SARC	cis	rs924607	1.000	rs1697978	chr5:642829	A/G	cg09021430	chr5:549028	NA	-0.32	-6.03	-0.37	6.48e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs2635047	0.967	rs2668786	chr18:44708472	A/G	cg19077165	chr18:44547161	KATNAL2	-0.38	-5.13	-0.32	6.15e-7	Educational attainment;
SARC	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg15049968	chr18:44337910	ST8SIA5	-0.33	-5.3	-0.33	2.65e-7	Personality dimensions;
SARC	cis	rs2463822	1.000	rs2246920	chr11:62104937	T/G	cg06239285	chr11:62104954	ASRGL1	0.9	9.55	0.53	1.91e-18	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs12101261	0.556	rs2300516	chr14:81446908	A/G	cg06600135	chr14:81408086	NA	0.37	4.72	0.3	4.15e-6	Graves' disease;
SARC	cis	rs10782582	0.593	rs11164042	chr1:76178440	G/A	cg10523679	chr1:76189770	ACADM	-0.42	-5.17	-0.32	5.05e-7	Daytime sleep phenotypes;
SARC	cis	rs7617480	0.648	rs6766238	chr3:48801929	G/A	cg07636037	chr3:49044803	WDR6	0.85	9.2	0.52	2.11e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs1707322	0.717	rs3014249	chr1:46079493	A/G	cg06784218	chr1:46089804	CCDC17	-0.38	-6.68	-0.4	1.79e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs861020	0.630	rs685248	chr1:210008367	C/G	cg05527609	chr1:210001259	C1orf107	0.78	10.05	0.55	5.79e-20	Orofacial clefts;
SARC	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg24531977	chr5:56204891	C5orf35	-0.5	-5.09	-0.32	7.48e-7	Initial pursuit acceleration;
SARC	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg18904891	chr8:8559673	CLDN23	-0.5	-5.73	-0.35	3.04e-8	Obesity-related traits;
SARC	cis	rs3733585	0.699	rs10001964	chr4:9959275	C/T	cg00071950	chr4:10020882	SLC2A9	-0.38	-5.91	-0.36	1.2e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs910316	1.000	rs2098297	chr14:75619118	G/T	cg11812906	chr14:75593930	NEK9	-0.87	-13.95	-0.67	1.46e-32	Height;
SARC	cis	rs3733585	0.683	rs6449140	chr4:9936437	G/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.32	-0.43	4.09e-12	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs11997175	0.583	rs7824990	chr8:33779934	A/G	ch.8.33884649F	chr8:33765107	NA	0.48	6.44	0.39	6.58e-10	Body mass index;
SARC	cis	rs67311347	0.911	rs9849224	chr3:40392562	T/C	cg09455208	chr3:40491958	NA	0.4	6.1	0.37	4.45e-9	Renal cell carcinoma;
SARC	cis	rs4481887	0.927	rs4578248	chr1:248434069	G/A	cg00666640	chr1:248458726	OR2T12	0.34	5.53	0.34	8.52e-8	Common traits (Other);
SARC	trans	rs66573146	0.656	rs41410847	chr4:6957332	C/T	cg07817883	chr1:32538562	TMEM39B	0.97	7.53	0.44	1.08e-12	Granulocyte percentage of myeloid white cells;
SARC	cis	rs4144743	1.000	rs67080286	chr17:45322248	T/G	cg18085866	chr17:45331354	ITGB3	-0.73	-7.4	-0.44	2.42e-12	Body mass index;
SARC	cis	rs11191193	0.686	rs11191160	chr10:103719913	C/T	cg15320455	chr10:103880129	LDB1	0.55	5.84	0.36	1.72e-8	Educational attainment;
SARC	cis	rs10870270	1.000	rs10870292	chr10:133770782	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.84	-10.21	-0.56	1.77e-20	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	15.0	0.7	4.66e-36	Chronic sinus infection;
SARC	cis	rs4803468	0.934	rs2317131	chr19:41885151	C/T	cg09537434	chr19:41945824	ATP5SL	-0.93	-16.06	-0.72	1.36e-39	Height;
SARC	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg08859206	chr1:53392774	SCP2	-0.36	-4.87	-0.3	2.04e-6	Monocyte count;
SARC	cis	rs9916302	0.904	rs10221223	chr17:37489100	T/G	cg15445000	chr17:37608096	MED1	-0.46	-5.69	-0.35	3.78e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs7829975	1.000	rs7829975	chr8:8548117	T/A	cg15556689	chr8:8085844	FLJ10661	-0.46	-5.53	-0.34	8.73e-8	Mood instability;
SARC	cis	rs918629	0.530	rs2829	chr5:95258447	T/C	cg16656078	chr5:95278638	ELL2	-0.59	-7.05	-0.42	1.96e-11	IgG glycosylation;
SARC	cis	rs826838	0.967	rs2069211	chr12:39128892	C/T	cg26384229	chr12:38710491	ALG10B	-0.76	-11.59	-0.6	7.97e-25	Heart rate;
SARC	trans	rs561341	0.941	rs7215147	chr17:30266711	G/A	cg20587970	chr11:113659929	NA	-0.99	-9.99	-0.55	8.58e-20	Hip circumference adjusted for BMI;
SARC	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg01475735	chr3:40494733	NA	-0.45	-5.13	-0.32	6.22e-7	Renal cell carcinoma;
SARC	cis	rs208520	0.526	rs4710310	chr6:66802808	T/C	cg07460842	chr6:66804631	NA	-1.11	-21.75	-0.82	5.04e-58	Exhaled nitric oxide output;
SARC	cis	rs7635838	0.539	rs430353	chr3:11254071	G/A	cg00170343	chr3:11313890	ATG7	0.66	8.58	0.49	1.38e-15	HDL cholesterol;
SARC	cis	rs2832077	0.943	rs2832097	chr21:30173340	A/T	cg03476357	chr21:30257390	N6AMT1	0.57	5.46	0.34	1.23e-7	Cognitive test performance;
SARC	cis	rs10779751	0.575	rs2791655	chr1:11128654	A/G	cg08854313	chr1:11322531	MTOR	-0.81	-11.23	-0.59	1.12e-23	Body mass index;
SARC	cis	rs7681440	0.560	rs67876224	chr4:90808918	T/C	cg06632027	chr4:90757378	SNCA	-0.46	-5.51	-0.34	9.39e-8	Dementia with Lewy bodies;
SARC	cis	rs9549367	0.713	rs9549691	chr13:113861606	A/C	cg18105134	chr13:113819100	PROZ	-0.48	-6.79	-0.41	9.23e-11	Platelet distribution width;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22485059	chr12:12764594	CREBL2	-0.61	-7.54	-0.44	1.01e-12	Fibrinogen levels;
SARC	cis	rs9902453	0.765	rs2250320	chr17:28128657	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.19	-0.43	8.87e-12	Coffee consumption (cups per day);
SARC	cis	rs9911578	1.000	rs9807057	chr17:56889952	A/C	cg12560992	chr17:57184187	TRIM37	0.87	12.15	0.62	1.19e-26	Intelligence (multi-trait analysis);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg22307732	chr7:2559417	LFNG	0.51	6.35	0.38	1.12e-9	Height;
SARC	cis	rs2898681	0.519	rs76606067	chr4:53728221	G/T	cg00338735	chr4:53728038	RASL11B	0.48	5.35	0.33	2.11e-7	Optic nerve measurement (cup area);
SARC	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	6.83	0.41	7.18e-11	Platelet count;
SARC	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg05861140	chr6:150128134	PCMT1	-0.42	-5.44	-0.34	1.32e-7	Lung cancer;
SARC	trans	rs3942852	0.774	rs924715	chr11:48181060	G/A	cg03929089	chr4:120376271	NA	-0.6	-6.75	-0.4	1.13e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs6840360	0.615	rs10001603	chr4:152647577	T/A	cg22705602	chr4:152727874	NA	-0.49	-8.42	-0.48	3.85e-15	Intelligence (multi-trait analysis);
SARC	cis	rs2013441	0.932	rs2526488	chr17:20098617	T/A	cg13482628	chr17:19912719	NA	-0.48	-6.13	-0.37	3.65e-9	Obesity-related traits;
SARC	trans	rs11098499	1.000	rs6849889	chr4:120186348	A/C	cg25214090	chr10:38739885	LOC399744	0.55	7.06	0.42	1.85e-11	Corneal astigmatism;
SARC	cis	rs12142240	0.692	rs7529674	chr1:46818508	T/C	cg00530320	chr1:46809349	NSUN4	0.57	6.92	0.41	4.4e-11	Menopause (age at onset);
SARC	cis	rs3771570	1.000	rs17386695	chr2:242379751	A/G	cg21155796	chr2:242212141	HDLBP	-0.7	-6.41	-0.39	7.9e-10	Prostate cancer;
SARC	cis	rs4242434	0.757	rs7005025	chr8:22519815	G/T	cg03733263	chr8:22462867	KIAA1967	0.81	12.43	0.63	1.46e-27	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg05508447	chr12:133264322	PXMP2;POLE	0.51	6.27	0.38	1.72e-9	Myopia (pathological);
SARC	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg23149560	chr2:74406255	MOBKL1B	0.47	4.77	0.3	3.3e-6	Gestational age at birth (maternal effect);
SARC	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg00933542	chr6:150070202	PCMT1	0.32	5.29	0.33	2.76e-7	Lung cancer;
SARC	cis	rs6901004	0.803	rs1150083	chr6:111510767	C/T	cg15721981	chr6:111408429	SLC16A10	-0.44	-5.44	-0.34	1.38e-7	Blood metabolite levels;
SARC	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg17376030	chr22:41985996	PMM1	-0.8	-10.12	-0.55	3.37e-20	Vitiligo;
SARC	cis	rs16854884	0.586	rs6440212	chr3:143748526	T/C	cg06585982	chr3:143692056	C3orf58	0.7	9.83	0.54	2.77e-19	Economic and political preferences (feminism/equality);
SARC	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.98	-16.11	-0.73	9.49e-40	Chronic sinus infection;
SARC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	20.2	0.8	4.16e-53	Prudent dietary pattern;
SARC	cis	rs10791097	0.694	rs61910787	chr11:130744473	G/A	cg12179176	chr11:130786555	SNX19	0.73	10.9	0.58	1.26e-22	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs2239547	0.522	rs2581801	chr3:52972907	G/T	cg07507251	chr3:52567010	NT5DC2	-0.36	-4.72	-0.3	4.07e-6	Schizophrenia;
SARC	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg02725872	chr8:58115012	NA	-0.37	-6.49	-0.39	5.13e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg03806693	chr22:41940476	POLR3H	-1.01	-13.85	-0.67	3.24e-32	Vitiligo;
SARC	cis	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg00745463	chr17:30367425	LRRC37B	-0.63	-5.09	-0.32	7.39e-7	Hip circumference adjusted for BMI;
SARC	cis	rs9467773	0.873	rs9295698	chr6:26566099	T/A	cg12292205	chr6:26970375	C6orf41	0.45	5.41	0.33	1.6e-7	Intelligence (multi-trait analysis);
SARC	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg12000995	chr2:27665139	KRTCAP3	-0.32	-4.88	-0.3	1.94e-6	Menopause (age at onset);
SARC	cis	rs965469	1.000	rs6051838	chr20:3389012	A/C	cg25506879	chr20:3388711	C20orf194	-0.57	-5.94	-0.36	1.01e-8	IFN-related cytopenia;
SARC	cis	rs3820928	1.000	rs10193404	chr2:227777757	A/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-6.78	-0.41	9.82e-11	Pulmonary function;
SARC	cis	rs3767633	0.925	rs1394070	chr1:161814020	T/G	cg09175582	chr1:161736000	ATF6	0.68	5.95	0.36	9.52e-9	IgG glycosylation;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg14479014	chr6:49460031	CENPQ	0.53	7.37	0.43	3.01e-12	Thyroid stimulating hormone;
SARC	cis	rs7113850	0.541	rs79932281	chr11:24231839	T/G	ch.11.24196551F	chr11:24239977	NA	0.73	5.37	0.33	1.91e-7	Bone fracture in osteoporosis;
SARC	cis	rs9682041	0.867	rs6444925	chr3:170123358	G/T	cg11886554	chr3:170076028	SKIL	1.15	8.41	0.48	4.08e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg22875332	chr1:76189707	ACADM	0.5	7.17	0.42	1.01e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg20607798	chr8:58055168	NA	0.56	5.27	0.33	3.12e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs459571	0.715	rs401826	chr9:136890591	C/T	cg01294253	chr9:136912663	BRD3	0.43	5.51	0.34	9.65e-8	Platelet distribution width;
SARC	cis	rs10493773	0.618	rs17394091	chr1:86075098	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.46	-6.25	-0.38	1.93e-9	Urate levels in overweight individuals;
SARC	cis	rs2290402	0.536	rs60492656	chr4:875008	C/T	cg00846425	chr4:957561	DGKQ	-0.43	-4.82	-0.3	2.64e-6	Type 2 diabetes;
SARC	cis	rs9902453	0.935	rs4310926	chr17:28433275	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	7.04	0.42	2.12e-11	Coffee consumption (cups per day);
SARC	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg12463550	chr7:65579703	CRCP	-0.7	-5.31	-0.33	2.51e-7	Diabetic kidney disease;
SARC	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-9.68	-0.54	7.76e-19	Chronic sinus infection;
SARC	cis	rs17253792	0.822	rs75897560	chr14:56090965	C/T	cg01858014	chr14:56050164	KTN1	-0.67	-5.11	-0.32	6.86e-7	Putamen volume;
SARC	cis	rs7566780	0.656	rs2340761	chr2:16664193	G/A	cg09580478	chr2:16689509	NA	0.46	6.27	0.38	1.72e-9	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	11.03	0.59	4.93e-23	Alzheimer's disease;
SARC	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg03264133	chr6:25882463	NA	-0.5	-6.38	-0.39	9.61e-10	Intelligence (multi-trait analysis);
SARC	cis	rs6665290	0.582	rs72764213	chr1:227207391	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.05	-22.72	-0.83	4.89e-61	Myeloid white cell count;
SARC	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs9650657	0.571	rs4240673	chr8:10787612	T/C	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.81	-0.46	1.99e-13	Neuroticism;
SARC	cis	rs881375	0.933	rs10818485	chr9:123667816	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	4.87	0.3	2.03e-6	Rheumatoid arthritis;
SARC	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg02725872	chr8:58115012	NA	-0.34	-5.37	-0.33	1.91e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9457247	0.624	rs9457260	chr6:167466665	C/T	cg23791538	chr6:167370224	RNASET2	-0.54	-7.02	-0.42	2.35e-11	Crohn's disease;
SARC	cis	rs7727544	0.684	rs272874	chr5:131675046	A/G	cg24060327	chr5:131705240	SLC22A5	0.56	6.01	0.37	7.16e-9	Blood metabolite levels;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg03056153	chr12:122125142	NA	0.77	6.42	0.39	7.55e-10	Autism spectrum disorder or schizophrenia;
SARC	trans	rs55704346	0.515	rs10939041	chr4:25188794	C/T	cg21101356	chr14:34420266	EGLN3	0.48	6.26	0.38	1.82e-9	Tonsillectomy;
SARC	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.51	-6.51	-0.39	4.51e-10	Lymphocyte counts;
SARC	cis	rs66887589	0.967	rs59516282	chr4:120502016	G/A	cg09307838	chr4:120376055	NA	-0.53	-7.26	-0.43	5.69e-12	Diastolic blood pressure;
SARC	trans	rs9388451	0.903	rs7758115	chr6:126061502	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.59	-7.64	-0.45	5.56e-13	Brugada syndrome;
SARC	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg24642844	chr7:1081250	C7orf50	-0.57	-6.05	-0.37	5.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg02366844	chr16:31044544	STX4	0.49	6.26	0.38	1.88e-9	Height;
SARC	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg18876405	chr7:65276391	NA	-0.44	-5.07	-0.32	8.18e-7	Aortic root size;
SARC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg11905131	chr22:24372483	LOC391322	0.51	5.6	0.34	5.87e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg14820908	chr5:178986412	RUFY1	0.37	5.27	0.33	3.09e-7	Lung cancer;
SARC	cis	rs2425143	0.643	rs6058324	chr20:34388789	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-6.37	-0.39	9.75e-10	Blood protein levels;
SARC	cis	rs17376456	0.825	rs10075217	chr5:93176774	C/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	5.37	0.33	1.88e-7	Diabetic retinopathy;
SARC	trans	rs73242632	1.000	rs2271807	chr4:57898729	A/G	cg05789714	chr11:74178462	KCNE3	-0.81	-6.34	-0.38	1.17e-9	Congenital heart disease (maternal effect);
SARC	cis	rs2777491	0.915	rs8032838	chr15:41605632	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.74	-10.89	-0.58	1.32e-22	Ulcerative colitis;
SARC	cis	rs240764	0.658	rs4463266	chr6:101223997	C/T	cg09795085	chr6:101329169	ASCC3	-0.44	-5.64	-0.35	4.85e-8	Neuroticism;
SARC	cis	rs7208859	0.673	rs9891179	chr17:29208160	G/T	cg13385521	chr17:29058706	SUZ12P	0.86	7.34	0.43	3.54e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9473924	0.542	rs67538952	chr6:50894400	T/C	cg14470998	chr6:50812995	TFAP2B	0.77	7.17	0.43	9.95e-12	Body mass index;
SARC	cis	rs34172651	0.571	rs9922156	chr16:24704329	C/A	cg06028605	chr16:24865363	SLC5A11	-0.32	-4.9	-0.31	1.79e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7914558	1.000	rs7914558	chr10:104775908	G/A	cg04362960	chr10:104952993	NT5C2	0.45	5.6	0.34	5.89e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs7264396	0.563	rs6060567	chr20:34288250	G/C	cg01084648	chr20:34329383	RBM39	0.55	4.83	0.3	2.45e-6	Total cholesterol levels;
SARC	cis	rs12142240	0.698	rs10158236	chr1:46820896	G/T	cg14993813	chr1:46806288	NSUN4	-0.51	-5.34	-0.33	2.19e-7	Menopause (age at onset);
SARC	cis	rs8141529	0.732	rs5762815	chr22:29205076	A/G	cg15103426	chr22:29168792	CCDC117	0.67	8.75	0.5	4.37e-16	Lymphocyte counts;
SARC	cis	rs2559856	1.000	rs10778139	chr12:102083202	C/T	cg12924262	chr12:102091054	CHPT1	-0.59	-7.98	-0.46	6.58e-14	Blood protein levels;
SARC	cis	rs9840812	0.577	rs503973	chr3:136059537	C/G	cg15507776	chr3:136538369	TMEM22	-0.51	-5.29	-0.33	2.79e-7	Fibrinogen levels;
SARC	cis	rs2120019	0.938	rs8028632	chr15:75321262	T/C	cg17294928	chr15:75287854	SCAMP5	-1.01	-15.27	-0.71	6.03e-37	Blood trace element (Zn levels);
SARC	cis	rs3204955	0.758	rs4240549	chr1:116259428	C/A	cg20810993	chr1:116250018	CASQ2	-0.48	-4.75	-0.3	3.54e-6	Itch intensity from mosquito bite adjusted by bite size;
SARC	cis	rs6912958	0.559	rs395358	chr6:88057924	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.27	4.71	0.3	4.18e-6	Monocyte percentage of white cells;
SARC	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg22683308	chr4:1340831	KIAA1530	0.42	5.2	0.32	4.29e-7	Longevity;
SARC	cis	rs7582720	1.000	rs72934519	chr2:203939640	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	7.78	0.45	2.39e-13	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs1008375	0.932	rs1008894	chr4:17704667	C/T	cg02297831	chr4:17616191	MED28	-0.41	-5.12	-0.32	6.52e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.76	-0.5	4.22e-16	Alzheimer's disease;
SARC	cis	rs9355610	0.727	rs2247315	chr6:167370211	A/C	cg23791538	chr6:167370224	RNASET2	0.74	10.61	0.57	1.02e-21	Graves' disease;
SARC	cis	rs208520	1.000	rs72880045	chr6:66965232	A/C	cg07460842	chr6:66804631	NA	0.86	9.56	0.53	1.79e-18	Exhaled nitric oxide output;
SARC	cis	rs6831352	0.879	rs56295995	chr4:100060899	C/T	cg13256891	chr4:100009986	ADH5	-0.65	-8.0	-0.46	5.94e-14	Alcohol dependence;
SARC	cis	rs9682041	1.000	rs4955588	chr3:170072864	C/A	cg11886554	chr3:170076028	SKIL	0.78	6.61	0.4	2.55e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	trans	rs1814175	0.645	rs847639	chr11:49919603	C/T	cg15704280	chr7:45808275	SEPT13	-0.88	-14.0	-0.68	1.02e-32	Height;
SARC	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg00149659	chr3:10157352	C3orf10	1.08	9.44	0.53	4.15e-18	Alzheimer's disease;
SARC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg09033563	chr22:24373618	LOC391322	-0.61	-8.02	-0.47	5.08e-14	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs11235843	0.636	rs1464908	chr11:73402679	A/C	cg18195628	chr11:73498948	MRPL48	-0.56	-5.68	-0.35	4e-8	Hand grip strength;
SARC	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg21724239	chr8:58056113	NA	0.63	6.38	0.39	9.53e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg04277193	chr17:41438351	NA	-0.48	-5.23	-0.32	3.7e-7	Menopause (age at onset);
SARC	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg02951883	chr7:2050386	MAD1L1	-0.43	-5.54	-0.34	8.08e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs950776	0.518	rs12907169	chr15:78825498	G/C	cg17108064	chr15:78857060	CHRNA5	0.29	4.93	0.31	1.56e-6	Sudden cardiac arrest;
SARC	cis	rs7216064	1.000	rs11869819	chr17:65868669	A/C	cg12091567	chr17:66097778	LOC651250	-0.64	-6.45	-0.39	6.56e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg06634786	chr22:41940651	POLR3H	0.51	6.23	0.38	2.17e-9	Vitiligo;
SARC	cis	rs9393777	0.588	rs6926677	chr6:26478825	G/C	cg12826209	chr6:26865740	GUSBL1	0.8	7.81	0.46	1.91e-13	Intelligence (multi-trait analysis);
SARC	cis	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg13072238	chr3:49761600	GMPPB	-0.44	-5.64	-0.35	4.82e-8	Intelligence (multi-trait analysis);
SARC	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg06108461	chr20:60628389	TAF4	-0.99	-13.45	-0.66	6.49e-31	Body mass index;
SARC	cis	rs1707322	0.721	rs10890336	chr1:46111056	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.25	0.38	1.93e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4076764	0.958	rs12022261	chr1:163398422	A/G	cg06092702	chr1:163392909	NA	-0.29	-4.74	-0.3	3.68e-6	Motion sickness;
SARC	cis	rs9633740	0.578	rs11185982	chr10:82305627	C/T	cg01528321	chr10:82214614	TSPAN14	0.71	7.02	0.42	2.4e-11	Post bronchodilator FEV1;
SARC	cis	rs73206853	0.620	rs112599609	chr12:111147643	C/T	cg10860002	chr12:110842031	ANAPC7	0.63	5.18	0.32	4.7e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	trans	rs2727020	0.615	rs10128582	chr11:49447424	C/T	cg03929089	chr4:120376271	NA	-0.77	-11.05	-0.59	4.33e-23	Coronary artery disease;
SARC	cis	rs1594829	0.553	rs11135933	chr8:26162364	A/G	cg11498726	chr8:26250323	BNIP3L	-0.4	-5.27	-0.33	3.09e-7	Height;
SARC	cis	rs3741151	0.572	rs12290623	chr11:73121872	C/G	cg17517138	chr11:73019481	ARHGEF17	0.69	5.84	0.36	1.78e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs7429990	0.901	rs6442091	chr3:48043058	T/C	cg11946769	chr3:48343235	NME6	-0.47	-5.34	-0.33	2.2e-7	Educational attainment (years of education);
SARC	cis	rs10752881	1.000	rs6701400	chr1:182977197	C/T	cg13390022	chr1:182993471	LAMC1	0.33	5.06	0.31	8.36e-7	Colorectal cancer;
SARC	cis	rs7727544	0.735	rs274566	chr5:131715011	A/G	cg24060327	chr5:131705240	SLC22A5	0.68	8.88	0.5	1.78e-16	Blood metabolite levels;
SARC	cis	rs4144743	1.000	rs55827077	chr17:45331083	G/C	cg18085866	chr17:45331354	ITGB3	-0.73	-7.38	-0.44	2.79e-12	Body mass index;
SARC	cis	rs11785400	0.731	rs9720504	chr8:143725502	T/C	cg24634471	chr8:143751801	JRK	0.6	7.74	0.45	2.98e-13	Schizophrenia;
SARC	cis	rs12368653	0.525	rs1564374	chr12:58010163	C/T	cg00677455	chr12:58241039	CTDSP2	-0.39	-5.26	-0.33	3.23e-7	Multiple sclerosis;
SARC	trans	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-10.55	-0.57	1.63e-21	Intelligence (multi-trait analysis);
SARC	cis	rs8078723	0.546	rs8067817	chr17:38163936	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.29	-5.2	-0.32	4.41e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs35306767	0.903	rs34270014	chr10:904666	T/C	cg26597838	chr10:835615	NA	0.82	8.37	0.48	5.47e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs9807841	0.592	rs1053007	chr19:10754400	A/G	cg17710535	chr19:10819994	QTRT1	0.4	4.81	0.3	2.73e-6	Inflammatory skin disease;
SARC	cis	rs889312	0.924	rs1910020	chr5:56026500	T/C	cg14703610	chr5:56206110	C5orf35	0.42	5.01	0.31	1.07e-6	Breast cancer;Breast cancer (early onset);
SARC	cis	rs9303280	0.934	rs56380902	chr17:38066372	T/C	cg20243544	chr17:37824526	PNMT	0.46	6.17	0.37	3.05e-9	Self-reported allergy;
SARC	cis	rs644799	1.000	rs481630	chr11:95582447	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.89	14.3	0.68	1e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs910187	0.605	rs8124918	chr20:45811860	A/G	cg27589058	chr20:45804311	EYA2	-0.29	-4.73	-0.3	3.89e-6	Migraine;
SARC	trans	rs1814175	0.541	rs12287397	chr11:49819799	G/A	cg03929089	chr4:120376271	NA	-0.91	-14.83	-0.7	1.69e-35	Height;
SARC	cis	rs13191362	0.938	rs59067610	chr6:163030440	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.55	5.32	0.33	2.48e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs3733589	1.000	rs3796831	chr4:10015952	C/G	cg16430538	chr4:10459836	ZNF518B	0.64	4.89	0.3	1.92e-6	Renal overload gout;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg24382680	chr15:80351977	ZFAND6	0.51	6.37	0.39	9.73e-10	Breast cancer;
SARC	cis	rs912057	0.695	rs1294419	chr6:6742549	C/G	cg06612196	chr6:6737390	NA	0.63	9.21	0.52	1.93e-17	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	trans	rs9329221	0.662	rs12541491	chr8:10250048	C/T	cg06636001	chr8:8085503	FLJ10661	0.59	7.14	0.42	1.21e-11	Neuroticism;
SARC	trans	rs208515	0.525	rs10944871	chr6:66690306	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	11.92	0.62	6.64e-26	Exhaled nitric oxide levels;
SARC	cis	rs2439831	0.717	rs690170	chr15:43810422	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.98	7.86	0.46	1.45e-13	Lung cancer in ever smokers;
SARC	trans	rs9329221	0.905	rs28507213	chr8:10250849	C/T	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.63	-0.4	2.26e-10	Neuroticism;
SARC	cis	rs17095355	1.000	rs17126886	chr10:111695257	G/C	cg00817464	chr10:111662876	XPNPEP1	-0.41	-4.74	-0.3	3.74e-6	Biliary atresia;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg11641080	chr2:27893449	SLC4A1AP	0.51	7.05	0.42	2e-11	Thyroid stimulating hormone;
SARC	cis	rs79149102	0.579	rs7174129	chr15:75305040	A/G	cg09165964	chr15:75287851	SCAMP5	-0.96	-8.95	-0.51	1.14e-16	Lung cancer;
SARC	cis	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg00745463	chr17:30367425	LRRC37B	-0.67	-5.13	-0.32	6.02e-7	Hip circumference adjusted for BMI;
SARC	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs34891900	0.507	rs738133	chr22:18205557	C/T	cg19898043	chr22:18121309	BCL2L13	0.65	7.32	0.43	3.96e-12	Sum neutrophil eosinophil counts;
SARC	cis	rs2576037	0.796	rs2576038	chr18:44582200	C/G	cg19077165	chr18:44547161	KATNAL2	0.45	6.2	0.38	2.49e-9	Personality dimensions;
SARC	cis	rs9818758	0.607	rs113186424	chr3:49272726	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.71	-6.16	-0.37	3.14e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs17125944	0.615	rs17125798	chr14:53319905	G/A	cg00686598	chr14:53173677	PSMC6	0.71	4.78	0.3	3.17e-6	Alzheimer's disease (late onset);
SARC	cis	rs9894429	0.621	rs9747119	chr17:79607017	A/G	cg10661904	chr17:79619235	PDE6G	-0.45	-6.39	-0.39	8.96e-10	Eye color traits;
SARC	cis	rs9790314	0.502	rs34972965	chr3:160984296	G/A	cg04691961	chr3:161091175	C3orf57	-0.47	-5.82	-0.36	1.89e-8	Morning vs. evening chronotype;
SARC	cis	rs13034020	0.522	rs72809436	chr2:61251145	C/T	cg18625361	chr2:61244694	PEX13;PUS10	0.71	6.13	0.37	3.79e-9	Hodgkin's lymphoma;
SARC	cis	rs8028182	0.636	rs7163451	chr15:75861076	G/T	cg20655648	chr15:75932815	IMP3	0.62	7.18	0.43	9.2e-12	Sudden cardiac arrest;
SARC	trans	rs1814175	0.645	rs1851869	chr11:49960552	T/C	cg15704280	chr7:45808275	SEPT13	-0.89	-14.17	-0.68	2.8e-33	Height;
SARC	cis	rs6912958	0.559	rs446851	chr6:88043640	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.35	6.08	0.37	4.98e-9	Monocyte percentage of white cells;
SARC	cis	rs2204008	0.837	rs11495722	chr12:38337245	G/A	cg13010199	chr12:38710504	ALG10B	0.81	11.05	0.59	4.32e-23	Bladder cancer;
SARC	cis	rs11083475	0.714	rs1471432	chr19:39260282	G/A	cg17759274	chr19:39260954	NA	0.37	5.64	0.35	4.93e-8	Heart rate;
SARC	cis	rs2204008	0.605	rs4608149	chr12:38132057	G/C	cg26384229	chr12:38710491	ALG10B	0.88	12.94	0.65	3.26e-29	Bladder cancer;
SARC	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg11987759	chr7:65425863	GUSB	-0.48	-6.54	-0.39	3.9e-10	Aortic root size;
SARC	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs548181	0.736	rs497344	chr11:125470524	T/C	cg03464685	chr11:125439445	EI24	1.03	9.37	0.52	6.72e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs6693567	0.565	rs12739706	chr1:150261653	C/G	cg09579323	chr1:150459698	TARS2	-0.4	-4.96	-0.31	1.34e-6	Migraine;
SARC	cis	rs1707322	0.964	rs1707339	chr1:46513179	A/G	cg06784218	chr1:46089804	CCDC17	-0.38	-6.82	-0.41	7.8e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2836633	0.895	rs991816	chr21:40042150	C/A	cg12884169	chr21:40033163	ERG	0.48	8.78	0.5	3.63e-16	Coronary artery disease;
SARC	cis	rs9585327	0.566	rs9517974	chr13:100728700	G/A	cg17575446	chr13:100037464	UBAC2	0.35	4.73	0.3	3.81e-6	Myopia;
SARC	trans	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg01470323	chr11:66139715	SLC29A2	0.46	6.48	0.39	5.3e-10	Immature fraction of reticulocytes;
SARC	cis	rs2075671	0.903	rs11983334	chr7:100302434	C/T	cg16850897	chr7:100343110	ZAN	-0.63	-6.76	-0.4	1.12e-10	Other erythrocyte phenotypes;
SARC	cis	rs6933660	0.536	rs3800274	chr6:151759192	T/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.5	5.58	0.34	6.62e-8	Menarche (age at onset);
SARC	cis	rs2227564	0.645	rs2633309	chr10:75654086	G/A	cg16540259	chr10:75572220	NDST2	0.34	4.9	0.31	1.83e-6	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs807669	0.835	rs698423	chr22:19197896	T/C	cg02655711	chr22:19163373	SLC25A1	0.54	7.33	0.43	3.83e-12	Metabolite levels;
SARC	cis	rs6493487	0.512	rs7162325	chr15:51121400	A/T	cg02338191	chr15:51200825	AP4E1	0.48	4.77	0.3	3.3e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs2832077	0.527	rs1048546	chr21:30244877	G/T	cg03476357	chr21:30257390	N6AMT1	-0.61	-6.75	-0.4	1.17e-10	Cognitive test performance;
SARC	cis	rs6910061	1.000	rs6913027	chr6:11107276	G/A	cg27233058	chr6:11094804	LOC221710	0.56	5.32	0.33	2.43e-7	Diabetic kidney disease;
SARC	cis	rs2228479	0.702	rs62052710	chr16:89854893	C/T	cg12064134	chr16:90016061	DEF8	-0.59	-5.06	-0.31	8.56e-7	Skin colour saturation;
SARC	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg11987759	chr7:65425863	GUSB	-0.48	-5.88	-0.36	1.44e-8	Aortic root size;
SARC	cis	rs9911578	1.000	rs9902994	chr17:56948722	T/A	cg05425664	chr17:57184151	TRIM37	-0.65	-8.0	-0.46	5.84e-14	Intelligence (multi-trait analysis);
SARC	cis	rs9911578	1.000	rs2567911	chr17:56734977	A/G	cg05425664	chr17:57184151	TRIM37	-0.68	-8.49	-0.49	2.48e-15	Intelligence (multi-trait analysis);
SARC	cis	rs11864453	0.826	rs2072142	chr16:72132713	C/T	cg01557791	chr16:72042693	DHODH	-0.65	-9.09	-0.51	4.3e-17	Fibrinogen levels;
SARC	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg13298116	chr11:62369859	EML3;MTA2	0.48	7.48	0.44	1.52e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	trans	rs7819412	0.775	rs11773990	chr8:10935082	T/C	cg06636001	chr8:8085503	FLJ10661	-0.7	-9.87	-0.54	1.97e-19	Triglycerides;
SARC	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg13175981	chr1:150552382	MCL1	0.52	6.41	0.39	7.93e-10	Tonsillectomy;
SARC	cis	rs6580649	0.657	rs57863747	chr12:48470425	G/T	cg24011408	chr12:48396354	COL2A1	-0.48	-5.36	-0.33	2.04e-7	Lung cancer;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg26544725	chr10:22266348	DNAJC1	0.57	8.07	0.47	3.84e-14	Thyroid stimulating hormone;
SARC	cis	rs6062509	0.965	rs4809330	chr20:62349586	A/G	cg27236539	chr20:62289627	RTEL1	0.49	5.44	0.34	1.32e-7	Prostate cancer;
SARC	cis	rs10904908	1.000	rs7920112	chr10:17259863	T/C	cg01003015	chr10:17271136	VIM	-0.42	-5.07	-0.32	8.18e-7	Total cholesterol levels;Cholesterol, total;
SARC	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg03452623	chr4:187889614	NA	0.79	12.77	0.64	1.14e-28	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg21028463	chr17:74733682	MIR636;SFRS2;MFSD11	-0.58	-6.49	-0.39	5.05e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs2204008	0.592	rs2320501	chr12:38145285	T/G	cg26384229	chr12:38710491	ALG10B	0.87	12.42	0.63	1.68e-27	Bladder cancer;
SARC	cis	rs16866061	1.000	rs3768886	chr2:225450161	G/C	cg12698349	chr2:225449008	CUL3	0.72	10.42	0.56	4.13e-21	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	cis	rs4253772	0.637	rs56017104	chr22:46651982	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.63	4.94	0.31	1.47e-6	LDL cholesterol;Cholesterol, total;
SARC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg03188948	chr7:1209495	NA	0.48	6.54	0.39	3.81e-10	Longevity;Endometriosis;
SARC	cis	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg07636037	chr3:49044803	WDR6	0.62	8.07	0.47	3.76e-14	Resting heart rate;
SARC	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	7.34	0.43	3.43e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1008375	0.966	rs4698621	chr4:17587565	C/T	cg02297831	chr4:17616191	MED28	0.49	6.22	0.38	2.31e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7944584	0.511	rs10838725	chr11:47557871	T/C	cg10504702	chr11:47789108	FNBP4	0.7	9.16	0.51	2.79e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs910316	0.967	rs10142770	chr14:75525449	G/A	cg06637938	chr14:75390232	RPS6KL1	0.58	8.43	0.48	3.59e-15	Height;
SARC	cis	rs9660992	0.573	rs7531256	chr1:205191202	T/G	cg21643547	chr1:205240462	TMCC2	-0.6	-7.74	-0.45	2.95e-13	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs13082711	0.595	rs17681498	chr3:27331258	T/C	cg02860705	chr3:27208620	NA	0.66	7.98	0.46	6.45e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg14773178	chr5:1868261	NA	0.35	5.55	0.34	7.91e-8	Cardiovascular disease risk factors;
SARC	cis	rs4481887	1.000	rs10888356	chr1:248465044	C/T	cg01631408	chr1:248437212	OR2T33	0.41	5.22	0.32	3.92e-7	Common traits (Other);
SARC	cis	rs4253772	0.591	rs6008362	chr22:46652737	G/A	cg24881330	chr22:46731750	TRMU	0.62	6.86	0.41	6.14e-11	LDL cholesterol;Cholesterol, total;
SARC	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg18357526	chr6:26021779	HIST1H4A	0.44	5.43	0.33	1.44e-7	Blood metabolite levels;
SARC	cis	rs11098499	0.697	rs6832410	chr4:120296800	A/G	cg09160332	chr4:120329925	NA	-0.33	-4.77	-0.3	3.27e-6	Corneal astigmatism;
SARC	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg07701084	chr6:150067640	NUP43	0.41	5.43	0.34	1.38e-7	Lung cancer;
SARC	cis	rs1048238	0.506	rs698890	chr1:16267371	C/G	cg21385522	chr1:16154831	NA	-0.47	-5.79	-0.35	2.23e-8	Systolic blood pressure;
SARC	cis	rs2120243	0.874	rs2316706	chr3:157160061	A/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.71	9.96	0.55	1.08e-19	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs7824557	0.545	rs2572450	chr8:11229638	C/T	cg21775007	chr8:11205619	TDH	-0.64	-8.51	-0.49	2.19e-15	Retinal vascular caliber;
SARC	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg08280861	chr8:58055591	NA	0.65	5.53	0.34	8.55e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs17376456	0.569	rs6881815	chr5:93105666	A/G	cg21475434	chr5:93447410	FAM172A	0.59	5.78	0.35	2.33e-8	Diabetic retinopathy;
SARC	cis	rs7027203	0.828	rs4344139	chr9:96600298	T/C	cg14598338	chr9:96623480	NA	-0.54	-7.64	-0.45	5.77e-13	DNA methylation (variation);
SARC	cis	rs733592	0.560	rs2158515	chr12:48507668	T/C	cg24011408	chr12:48396354	COL2A1	-0.49	-6.87	-0.41	5.74e-11	Plateletcrit;
SARC	cis	rs17270561	0.609	rs3922699	chr6:25734969	A/G	cg16482183	chr6:26056742	HIST1H1C	0.43	5.22	0.32	3.92e-7	Iron status biomarkers;
SARC	cis	rs7666738	0.830	rs13118945	chr4:98968586	T/G	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs796364	0.760	rs55906940	chr2:201049386	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.75	-6.43	-0.39	6.99e-10	Schizophrenia;
SARC	cis	rs9790314	0.846	rs12495310	chr3:160970956	T/A	cg03342759	chr3:160939853	NMD3	-0.73	-9.94	-0.55	1.26e-19	Morning vs. evening chronotype;
SARC	cis	rs6952808	0.707	rs13244345	chr7:1973004	A/G	cg05863683	chr7:1912471	MAD1L1	0.35	5.22	0.32	3.89e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs4906332	1.000	rs8004780	chr14:103853360	A/C	cg15820818	chr14:102984158	NA	0.38	4.85	0.3	2.22e-6	Coronary artery disease;
SARC	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs644799	1.000	rs593665	chr11:95574302	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.89	13.95	0.67	1.5e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs61931739	0.534	rs1844526	chr12:34102780	G/A	cg13010199	chr12:38710504	ALG10B	0.77	10.37	0.56	5.83e-21	Morning vs. evening chronotype;
SARC	cis	rs2204008	0.539	rs1283295	chr12:38146014	A/C	cg14851346	chr12:38532713	NA	-0.43	-5.14	-0.32	5.87e-7	Bladder cancer;
SARC	cis	rs3796352	1.000	rs75217232	chr3:53132373	A/C	cg15956490	chr3:53032818	SFMBT1	0.77	5.29	0.33	2.88e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs668210	0.947	rs559161	chr11:65761637	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.57	6.28	0.38	1.61e-9	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9814567	1.000	rs1880376	chr3:134270347	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	7.08	0.42	1.73e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs17376456	0.757	rs10476591	chr5:93333723	G/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.53	0.34	8.39e-8	Diabetic retinopathy;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg22373676	chr13:30374285	UBL3	-0.56	-6.84	-0.41	7e-11	Alcohol dependence;
SARC	cis	rs3741404	0.609	rs669913	chr11:63869879	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	9.03	0.51	6.46e-17	Platelet count;
SARC	trans	rs9951602	0.512	rs9946123	chr18:76654557	A/G	cg02800362	chr5:177631904	HNRNPAB	0.7	8.92	0.5	1.38e-16	Obesity-related traits;
SARC	cis	rs2463822	1.000	rs118049526	chr11:62107508	C/T	cg06239285	chr11:62104954	ASRGL1	-0.85	-8.1	-0.47	3.09e-14	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs35110281	0.837	rs2838342	chr21:45077865	G/A	cg21573476	chr21:45109991	RRP1B	-0.54	-7.9	-0.46	1.12e-13	Mean corpuscular volume;
SARC	cis	rs2463822	1.000	rs11231050	chr11:62131660	C/G	cg06239285	chr11:62104954	ASRGL1	-0.78	-7.58	-0.44	8.08e-13	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs7084402	0.967	rs1658481	chr10:60289339	A/G	cg07615347	chr10:60278583	BICC1	0.6	8.85	0.5	2.28e-16	Refractive error;
SARC	cis	rs7020830	0.898	rs13289199	chr9:37278064	A/T	cg14294708	chr9:37120828	ZCCHC7	1.08	18.95	0.78	4.42e-49	Schizophrenia;
SARC	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg16606324	chr3:10149918	C3orf24	0.48	5.04	0.31	9.53e-7	Alzheimer's disease;
SARC	cis	rs79149102	0.579	rs3812946	chr15:75288610	G/C	cg09165964	chr15:75287851	SCAMP5	-1.08	-8.89	-0.5	1.66e-16	Lung cancer;
SARC	cis	rs71277158	0.688	rs7615039	chr3:169806170	G/A	cg04067573	chr3:169899625	PHC3	0.55	4.92	0.31	1.66e-6	Prostate cancer;
SARC	cis	rs2425143	1.000	rs17093027	chr20:34319118	A/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.67	5.47	0.34	1.15e-7	Blood protein levels;
SARC	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg11987759	chr7:65425863	GUSB	0.48	5.7	0.35	3.52e-8	Aortic root size;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg20390150	chr22:43547555	TSPO	0.69	7.0	0.42	2.76e-11	Lung cancer in ever smokers;
SARC	cis	rs478304	0.754	rs2004649	chr11:65380916	G/A	cg27068330	chr11:65405492	SIPA1	-0.39	-4.75	-0.3	3.54e-6	Acne (severe);
SARC	cis	rs34172651	0.617	rs9922436	chr16:24704490	C/G	cg06028605	chr16:24865363	SLC5A11	0.33	4.91	0.31	1.7e-6	Intelligence (multi-trait analysis);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg13474011	chr10:49515374	NA	0.55	6.94	0.41	3.76e-11	Breast cancer;
SARC	cis	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg08975724	chr8:8085496	FLJ10661	0.5	6.45	0.39	6.25e-10	Mood instability;
SARC	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg24060327	chr5:131705240	SLC22A5	-0.43	-5.11	-0.32	6.58e-7	Blood metabolite levels;
SARC	cis	rs6840360	1.000	rs1896883	chr4:152595373	C/T	cg22705602	chr4:152727874	NA	0.35	6.0	0.37	7.44e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7937682	1.000	rs11608149	chr11:111535102	G/A	cg22437258	chr11:111473054	SIK2	-0.72	-9.42	-0.53	4.57e-18	Primary sclerosing cholangitis;
SARC	trans	rs11098499	0.955	rs56386062	chr4:120155135	T/C	cg25214090	chr10:38739885	LOC399744	0.53	6.86	0.41	6.12e-11	Corneal astigmatism;
SARC	cis	rs8180040	0.966	rs11716763	chr3:47518266	C/T	cg27129171	chr3:47204927	SETD2	-0.68	-9.53	-0.53	2.24e-18	Colorectal cancer;
SARC	cis	rs34779708	0.966	rs35814343	chr10:35427714	G/T	cg03585969	chr10:35415529	CREM	0.38	4.71	0.3	4.16e-6	Inflammatory bowel disease;Crohn's disease;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg02263426	chr18:14378524	NA	-0.47	-6.26	-0.38	1.88e-9	Electrocardiographic conduction measures;
SARC	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg01475735	chr3:40494733	NA	-0.46	-5.15	-0.32	5.56e-7	Renal cell carcinoma;
SARC	cis	rs2721811	0.701	rs2721810	chr7:24748565	T/C	cg17569154	chr7:24781545	DFNA5	0.46	6.35	0.38	1.11e-9	Depressive symptoms (multi-trait analysis);
SARC	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg03188948	chr7:1209495	NA	0.59	4.99	0.31	1.19e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs400736	0.655	rs55634431	chr1:8149549	G/A	cg25007680	chr1:8021821	PARK7	-0.45	-5.63	-0.35	5.25e-8	Response to antidepressants and depression;
SARC	cis	rs6570726	0.791	rs414600	chr6:145879606	G/A	cg05347473	chr6:146136440	FBXO30	0.54	7.57	0.44	8.62e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs67311347	1.000	rs28491638	chr3:40496263	T/C	cg24209194	chr3:40518798	ZNF619	0.66	8.04	0.47	4.42e-14	Renal cell carcinoma;
SARC	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg19223190	chr17:80058835	NA	-0.42	-5.8	-0.36	2.18e-8	Life satisfaction;
SARC	cis	rs6121246	0.909	rs6089070	chr20:30377773	A/G	cg13852791	chr20:30311386	BCL2L1	-0.86	-8.62	-0.49	1.06e-15	Mean corpuscular hemoglobin;
SARC	cis	rs865483	0.895	rs878520	chr17:35762107	C/G	cg06561646	chr17:35873369	DUSP14	0.48	6.12	0.37	4e-9	Monocyte count;
SARC	cis	rs6450176	0.625	rs3776725	chr5:53290138	C/A	ch.5.1024479R	chr5:53302184	ARL15	-0.85	-9.95	-0.55	1.14e-19	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	trans	rs9325144	0.534	rs1843866	chr12:38703160	G/T	cg23762105	chr12:34175262	ALG10	-0.54	-7.21	-0.43	7.61e-12	Morning vs. evening chronotype;
SARC	cis	rs4242434	0.927	rs7843828	chr8:22463623	C/T	cg03733263	chr8:22462867	KIAA1967	1.05	17.68	0.76	6.4e-45	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg12196367	chr3:183892577	AP2M1	-0.51	-6.32	-0.38	1.34e-9	Fibrinogen levels;
SARC	trans	rs3808502	0.526	rs7823101	chr8:11422492	C/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.37	-0.39	9.81e-10	Neuroticism;
SARC	cis	rs1843834	0.539	rs12694643	chr2:225446603	A/G	cg12698349	chr2:225449008	CUL3	0.71	9.39	0.52	5.79e-18	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs7208859	0.623	rs9912283	chr17:29110373	A/G	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs476633	0.691	rs6492997	chr15:41541171	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.56	-7.8	-0.46	2.03e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs12594515	1.000	rs6493176	chr15:45990026	A/G	cg14863074	chr15:45997064	NA	0.34	5.24	0.32	3.57e-7	Waist circumference;Weight;
SARC	cis	rs10979	0.679	rs9321918	chr6:143883460	T/C	cg25407410	chr6:143891975	LOC285740	-0.59	-7.11	-0.42	1.44e-11	Hypospadias;
SARC	cis	rs854765	0.552	rs11078407	chr17:17841083	T/C	cg04398451	chr17:18023971	MYO15A	-0.43	-6.14	-0.37	3.52e-9	Total body bone mineral density;
SARC	cis	rs7959663	1	rs7959663	chr12:109884367	G/C	cg05360138	chr12:110035743	NA	0.78	8.27	0.48	1.02e-14	Bipolar disorder lithium response (categorical) or schizophrenia;
SARC	cis	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg13647721	chr17:30228624	UTP6	-0.69	-5.83	-0.36	1.84e-8	Hip circumference adjusted for BMI;
SARC	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg08280861	chr8:58055591	NA	0.6	5.83	0.36	1.8e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2153535	0.580	rs5001322	chr6:8451608	A/G	cg07606381	chr6:8435919	SLC35B3	0.78	11.11	0.59	2.68e-23	Motion sickness;
SARC	cis	rs2997447	0.761	rs79778025	chr1:26449337	A/G	cg19633962	chr1:26362018	EXTL1	-0.57	-5.13	-0.32	6.22e-7	QRS complex (12-leadsum);
SARC	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg03806693	chr22:41940476	POLR3H	0.86	11.91	0.62	7.51e-26	Vitiligo;
SARC	cis	rs35110281	0.807	rs2838325	chr21:45014284	A/T	cg01579765	chr21:45077557	HSF2BP	0.3	5.06	0.31	8.52e-7	Mean corpuscular volume;
SARC	cis	rs1044826	1.000	rs747346	chr3:139231914	A/C	cg15131784	chr3:139108705	COPB2	0.45	5.11	0.32	6.62e-7	Obesity-related traits;
SARC	cis	rs55823223	0.564	rs936396	chr17:73846829	C/G	cg06969265	chr17:73775802	H3F3B	0.49	5.41	0.33	1.59e-7	Psoriasis;
SARC	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg13393036	chr8:95962371	TP53INP1	-0.36	-6.09	-0.37	4.7e-9	Type 2 diabetes;
SARC	cis	rs965469	0.696	rs6037570	chr20:3334292	C/A	cg25506879	chr20:3388711	C20orf194	-0.47	-5.24	-0.32	3.66e-7	IFN-related cytopenia;
SARC	cis	rs4148883	0.651	rs10020052	chr4:100086331	C/G	cg12011299	chr4:100065546	ADH4	0.36	6.77	0.41	1.03e-10	Alcohol dependence;
SARC	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.43	-0.44	2.03e-12	Extrinsic epigenetic age acceleration;
SARC	trans	rs36093844	0.752	rs7121363	chr11:85575110	C/T	cg15359163	chr5:122429178	PRDM6	-0.52	-6.76	-0.4	1.11e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs4722166	0.695	rs7793125	chr7:22809160	A/G	cg26061582	chr7:22766209	IL6	0.47	5.5	0.34	1.02e-7	Lung cancer;
SARC	cis	rs986417	0.901	rs1955688	chr14:60989237	G/A	cg27398547	chr14:60952738	C14orf39	0.96	8.88	0.5	1.87e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs921968	0.541	rs599973	chr2:219387273	C/G	cg02176678	chr2:219576539	TTLL4	0.47	7.19	0.43	8.58e-12	Mean corpuscular hemoglobin concentration;
SARC	cis	rs2562456	0.682	rs11085464	chr19:21751778	C/G	cg00806126	chr19:22604979	ZNF98	-0.48	-4.96	-0.31	1.38e-6	Pain;
SARC	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg11764359	chr7:65958608	NA	-0.8	-10.27	-0.56	1.22e-20	Aortic root size;
SARC	cis	rs9914544	0.545	rs9898426	chr17:18794071	A/G	cg25390199	chr17:18761479	PRPSAP2	0.46	6.05	0.37	5.66e-9	Educational attainment (years of education);
SARC	cis	rs9788721	0.592	rs28564957	chr15:78906107	C/A	cg06917634	chr15:78832804	PSMA4	-0.8	-11.66	-0.61	4.88e-25	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs2011503	1.000	rs6511031	chr19:19471506	T/C	cg03709012	chr19:19516395	GATAD2A	-0.65	-5.87	-0.36	1.52e-8	Bipolar disorder;
SARC	cis	rs6701037	0.566	rs4344281	chr1:175135376	C/T	cg08873628	chr1:175162347	KIAA0040	0.35	4.82	0.3	2.59e-6	Alcohol dependence;
SARC	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg20965017	chr5:231967	SDHA	-0.58	-5.73	-0.35	3.14e-8	Breast cancer;
SARC	cis	rs9398803	0.932	rs9401876	chr6:126669479	C/A	cg20229609	chr6:126660872	C6orf173	0.4	5.85	0.36	1.62e-8	Male-pattern baldness;
SARC	cis	rs7412746	0.611	rs2280627	chr1:150935872	A/G	cg15448220	chr1:150897856	SETDB1	0.52	6.79	0.41	9.19e-11	Melanoma;
SARC	cis	rs7412746	0.611	rs4970931	chr1:150910727	G/A	cg13175981	chr1:150552382	MCL1	-0.52	-6.43	-0.39	7.28e-10	Melanoma;
SARC	trans	rs10519937	0.935	rs17839693	chr5:126735871	T/C	cg26526953	chr19:1921199	SCAMP4	0.6	6.36	0.38	1.05e-9	IgG glycosylation;
SARC	cis	rs71277158	0.688	rs16854836	chr3:169804730	T/C	cg04067573	chr3:169899625	PHC3	0.54	4.86	0.3	2.15e-6	Prostate cancer;
SARC	cis	rs2070997	0.651	rs34149255	chr9:133669533	T/C	cg11464064	chr9:133710261	ABL1	0.59	5.67	0.35	4.12e-8	Response to amphetamines;
SARC	cis	rs17376456	0.877	rs10476598	chr5:93367281	C/T	cg21475434	chr5:93447410	FAM172A	-0.89	-7.72	-0.45	3.36e-13	Diabetic retinopathy;
SARC	cis	rs6088590	0.523	rs6059913	chr20:33143288	G/A	cg08999081	chr20:33150536	PIGU	0.45	6.82	0.41	7.73e-11	Coronary artery disease;
SARC	cis	rs6912958	0.781	rs6940150	chr6:88287114	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.43	-0.34	1.42e-7	Monocyte percentage of white cells;
SARC	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.48	-5.48	-0.34	1.12e-7	Huntington's disease progression;
SARC	cis	rs7824557	0.564	rs2736301	chr8:11236413	C/T	cg21775007	chr8:11205619	TDH	-0.65	-8.62	-0.49	1.01e-15	Retinal vascular caliber;
SARC	cis	rs9747201	1.000	rs56283054	chr17:80135326	C/T	cg17462356	chr17:80056334	FASN	0.47	5.42	0.33	1.47e-7	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs4944092	0.793	rs94111	chr11:75915139	A/G	cg04588336	chr11:75916460	WNT11	-0.49	-6.69	-0.4	1.65e-10	PR interval;
SARC	cis	rs6942407	0.546	rs765968	chr7:86794724	G/A	cg02420886	chr7:86849541	C7orf23	0.72	6.32	0.38	1.3e-9	Food allergy;
SARC	cis	rs11785400	0.762	rs2280880	chr8:143721929	C/A	cg24634471	chr8:143751801	JRK	0.6	7.85	0.46	1.51e-13	Schizophrenia;
SARC	cis	rs9612	1.000	rs12669	chr19:44235535	G/A	cg07522664	chr19:44259120	C19orf61	0.48	5.57	0.34	6.89e-8	Exhaled nitric oxide output;
SARC	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.62	7.47	0.44	1.61e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9807989	0.507	rs7581119	chr2:103049865	G/A	cg03938978	chr2:103052716	IL18RAP	0.32	5.18	0.32	4.71e-7	Asthma;
SARC	cis	rs12477438	0.765	rs10181422	chr2:99558970	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-7.83	-0.46	1.69e-13	Chronic sinus infection;
SARC	cis	rs1163251	0.837	rs611365	chr1:120242571	C/T	cg19096424	chr1:120255104	PHGDH	0.59	6.95	0.41	3.61e-11	Blood metabolite levels;
SARC	trans	rs1814175	0.527	rs10769595	chr11:49638212	A/G	cg03929089	chr4:120376271	NA	-0.71	-8.23	-0.47	1.37e-14	Height;
SARC	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg20573242	chr4:122745356	CCNA2	0.65	8.25	0.48	1.16e-14	Type 2 diabetes;
SARC	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg25894440	chr7:65020034	NA	-0.71	-5.4	-0.33	1.62e-7	Diabetic kidney disease;
SARC	cis	rs5167	0.601	rs892131	chr19:45496996	C/T	cg10169327	chr19:45448959	APOC2	0.33	5.0	0.31	1.15e-6	Blood protein levels;
SARC	cis	rs2120019	1.000	rs2415253	chr15:75375699	A/G	cg12414181	chr15:75287860	SCAMP5	-0.42	-4.94	-0.31	1.5e-6	Blood trace element (Zn levels);
SARC	cis	rs9303401	0.646	rs7217845	chr17:57236900	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.57	6.82	0.41	7.71e-11	Cognitive test performance;
SARC	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	9.03	0.51	6.74e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs7937682	0.889	rs564086	chr11:111501079	C/G	cg18187862	chr3:45730750	SACM1L	0.55	6.96	0.41	3.46e-11	Primary sclerosing cholangitis;
SARC	cis	rs9457247	1.000	rs439237	chr6:167391392	A/G	cg23791538	chr6:167370224	RNASET2	-0.62	-8.66	-0.49	8.17e-16	Crohn's disease;
SARC	cis	rs918629	0.798	rs6556894	chr5:95289542	G/A	cg16656078	chr5:95278638	ELL2	-0.64	-7.74	-0.45	3.03e-13	IgG glycosylation;
SARC	cis	rs1371867	0.846	rs1660327	chr8:101292206	A/C	cg11906718	chr8:101322791	RNF19A	0.69	8.92	0.5	1.36e-16	Atrioventricular conduction;
SARC	cis	rs473651	0.904	rs508274	chr2:239337723	G/A	cg18131467	chr2:239335373	ASB1	0.95	15.69	0.72	2.43e-38	Multiple system atrophy;
SARC	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg19774624	chr17:42201019	HDAC5	0.86	13.35	0.66	1.45e-30	Total body bone mineral density;
SARC	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg24060327	chr5:131705240	SLC22A5	-0.5	-6.11	-0.37	4.13e-9	Blood metabolite levels;
SARC	cis	rs9815354	1.000	rs9834098	chr3:41833493	A/G	cg03022575	chr3:42003672	ULK4	0.56	5.37	0.33	1.94e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9394841	0.667	rs9357366	chr6:41786976	T/G	cg08135965	chr6:41755394	TOMM6	0.6	6.24	0.38	2.04e-9	Mean corpuscular hemoglobin;Red cell distribution width;
SARC	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg03806693	chr22:41940476	POLR3H	-0.94	-13.03	-0.65	1.62e-29	Vitiligo;
SARC	cis	rs2120019	1.000	rs8036197	chr15:75370232	T/C	cg09165964	chr15:75287851	SCAMP5	-0.87	-13.08	-0.65	1.1e-29	Blood trace element (Zn levels);
SARC	cis	rs16976116	0.951	rs11857087	chr15:55487181	T/A	cg17854078	chr15:55489399	RSL24D1	0.62	6.0	0.37	7.39e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs12079745	0.793	rs10919079	chr1:169133805	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.77	-5.1	-0.32	6.87e-7	QT interval;
SARC	cis	rs6570726	0.935	rs374000	chr6:145855290	C/T	cg23711669	chr6:146136114	FBXO30	0.78	12.03	0.62	3.08e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6089584	0.527	rs927589	chr20:60606363	A/G	cg23262073	chr20:60523788	NA	-0.34	-5.14	-0.32	5.88e-7	Body mass index;
SARC	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg00933542	chr6:150070202	PCMT1	0.3	5.08	0.32	7.89e-7	Lung cancer;
SARC	cis	rs4276643	0.732	rs2685411	chr8:27811098	A/G	cg26001764	chr8:28560637	EXTL3	0.3	4.81	0.3	2.66e-6	Low vWF levels;
SARC	cis	rs2439831	1.000	rs2467743	chr15:43750346	T/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.05	10.98	0.58	7.25e-23	Lung cancer in ever smokers;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg07263984	chr5:115177777	ATG12;AP3S1	0.54	6.77	0.41	1.04e-10	Breast cancer;
SARC	cis	rs10795130	1.000	rs10904188	chr10:4150191	G/A	cg24830971	chr10:3180960	PITRM1	-0.48	-4.92	-0.31	1.65e-6	Sex hormone-binding globulin levels;
SARC	cis	rs7520050	0.966	rs785471	chr1:46518677	T/C	cg06784218	chr1:46089804	CCDC17	-0.26	-4.72	-0.3	4.03e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs6062302	0.522	rs2872810	chr20:62241931	C/T	cg16989086	chr20:62203971	PRIC285	-0.46	-4.73	-0.3	3.84e-6	Glioblastoma;
SARC	cis	rs10979	0.546	rs9496686	chr6:143908735	G/C	cg25407410	chr6:143891975	LOC285740	-0.49	-5.78	-0.35	2.38e-8	Hypospadias;
SARC	cis	rs898097	0.625	rs2125479	chr17:80890262	A/G	cg15664640	chr17:80829946	TBCD	-0.34	-5.21	-0.32	4.19e-7	Breast cancer;
SARC	trans	rs61931739	0.534	rs2220547	chr12:34106255	G/A	cg13010199	chr12:38710504	ALG10B	0.77	10.36	0.56	6.18e-21	Morning vs. evening chronotype;
SARC	trans	rs9951602	0.512	rs73494176	chr18:76644895	T/C	cg02800362	chr5:177631904	HNRNPAB	0.68	8.45	0.48	3.09e-15	Obesity-related traits;
SARC	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg11247378	chr22:39784982	NA	-0.32	-5.18	-0.32	4.77e-7	Intelligence (multi-trait analysis);
SARC	cis	rs17600642	0.724	rs72814547	chr10:72458069	C/T	cg19779893	chr10:72451501	ADAMTS14	-0.39	-6.02	-0.37	6.61e-9	Bipolar disorder;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg24529941	chr4:146100818	OTUD4	0.57	7.59	0.45	7.64e-13	Chemerin levels;
SARC	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.47	5.63	0.35	5.16e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs3096299	0.933	rs2965824	chr16:89455306	A/G	cg08392591	chr16:89556376	ANKRD11	0.38	4.92	0.31	1.66e-6	Multiple myeloma (IgH translocation);
SARC	cis	rs7772486	0.790	rs2254288	chr6:146204470	G/A	cg05347473	chr6:146136440	FBXO30	0.47	6.52	0.39	4.38e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs8017423	0.647	rs11623736	chr14:90746471	G/T	cg20276874	chr14:90721474	PSMC1	0.37	4.93	0.31	1.58e-6	Mortality in heart failure;
SARC	cis	rs13314892	0.770	rs56099248	chr3:69857773	C/T	cg17445875	chr3:69859618	MITF	-0.59	-5.76	-0.35	2.64e-8	QRS complex (12-leadsum);
SARC	cis	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg07777115	chr5:623756	CEP72	-0.56	-4.81	-0.3	2.68e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs4595586	0.545	rs12826080	chr12:39387772	A/G	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg25894440	chr7:65020034	NA	-0.77	-5.85	-0.36	1.67e-8	Diabetic kidney disease;
SARC	cis	rs881375	1.000	rs881375	chr9:123652898	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.43	5.22	0.32	4.01e-7	Rheumatoid arthritis;
SARC	cis	rs11690935	0.959	rs12692973	chr2:172642057	A/G	cg13550731	chr2:172543902	DYNC1I2	0.99	15.28	0.71	5.46e-37	Schizophrenia;
SARC	cis	rs67311347	1.000	rs9848083	chr3:40466979	A/G	cg24209194	chr3:40518798	ZNF619	-0.61	-8.04	-0.47	4.52e-14	Renal cell carcinoma;
SARC	cis	rs3857067	0.806	rs9996975	chr4:95101338	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.08	-0.32	7.8e-7	QT interval;
SARC	cis	rs6669543	1.000	rs12025136	chr1:161980502	A/G	cg10810183	chr1:161993987	OLFML2B	-0.45	-4.97	-0.31	1.31e-6	QT interval;
SARC	cis	rs617791	0.508	rs1047464	chr11:65769456	A/T	cg26695010	chr11:65641043	EFEMP2	0.56	6.89	0.41	5.22e-11	Breast cancer;
SARC	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg08975724	chr8:8085496	FLJ10661	0.51	6.46	0.39	6.19e-10	Mood instability;
SARC	trans	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg17830980	chr10:43048298	ZNF37B	-0.53	-7.3	-0.43	4.42e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs9325144	0.647	rs11169222	chr12:39105210	C/T	cg13010199	chr12:38710504	ALG10B	-0.52	-6.47	-0.39	5.68e-10	Morning vs. evening chronotype;
SARC	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	11.08	0.59	3.32e-23	Alzheimer's disease;
SARC	cis	rs505401	0.505	rs80001830	chr19:6070471	G/T	cg18109231	chr19:6110877	RFX2	0.75	5.23	0.32	3.77e-7	Mean platelet volume;
SARC	cis	rs7662987	0.517	rs3018047	chr4:100014510	C/T	cg13256891	chr4:100009986	ADH5	-0.66	-8.28	-0.48	9.84e-15	Smoking initiation;
SARC	cis	rs6456042	0.893	rs3099283	chr6:166554170	A/C	cg11088901	chr6:166572345	T	-0.34	-4.94	-0.31	1.52e-6	Asthma;
SARC	cis	rs763121	1.000	rs86796	chr22:38881454	A/C	cg06022373	chr22:39101656	GTPBP1	-0.75	-9.78	-0.54	3.85e-19	Menopause (age at onset);
SARC	cis	rs11190604	1.000	rs2495754	chr10:102324812	C/T	cg07080220	chr10:102295463	HIF1AN	0.8	8.88	0.5	1.77e-16	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg22618164	chr12:122356400	WDR66	0.51	8.25	0.48	1.17e-14	Mean corpuscular volume;
SARC	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg24675658	chr1:53192096	ZYG11B	-0.56	-7.82	-0.46	1.87e-13	Monocyte count;
SARC	cis	rs7566780	0.575	rs4832645	chr2:16694736	C/G	cg09580478	chr2:16689509	NA	0.51	6.37	0.39	9.84e-10	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs2153535	0.580	rs962590	chr6:8450899	A/G	cg23788917	chr6:8435910	SLC35B3	0.64	8.54	0.49	1.8e-15	Motion sickness;
SARC	cis	rs9513593	1.000	rs35912802	chr13:99886236	A/C	cg21788972	chr13:99853209	UBAC2	0.51	4.9	0.31	1.78e-6	Psoriasis;
SARC	cis	rs11608355	0.538	rs11611957	chr12:109801803	A/G	cg19025524	chr12:109796872	NA	-0.42	-6.17	-0.37	2.99e-9	Neuroticism;
SARC	cis	rs7592578	0.664	rs10931461	chr2:191405280	T/A	cg10560079	chr2:191398806	TMEM194B	0.82	9.23	0.52	1.73e-17	Diastolic blood pressure;
SARC	cis	rs1707322	0.928	rs7527244	chr1:46368772	A/G	cg06784218	chr1:46089804	CCDC17	0.34	6.03	0.37	6.51e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs5753037	0.653	rs131285	chr22:30157940	T/C	cg01021169	chr22:30184971	ASCC2	-0.44	-6.03	-0.37	6.28e-9	Type 1 diabetes;
SARC	cis	rs17270561	0.636	rs9393656	chr6:25722059	A/C	cg16482183	chr6:26056742	HIST1H1C	0.43	5.13	0.32	6.15e-7	Iron status biomarkers;
SARC	cis	rs4423214	1.000	rs4944955	chr11:71167677	C/T	cg24826892	chr11:71159390	DHCR7	0.48	6.12	0.37	3.92e-9	Vitamin D levels;
SARC	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.38	4.76	0.3	3.34e-6	Lymphocyte counts;
SARC	cis	rs7914558	0.966	rs1591915	chr10:104646849	C/T	cg04362960	chr10:104952993	NT5C2	0.41	4.95	0.31	1.42e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	trans	rs1814175	0.817	rs7924619	chr11:49620632	G/A	cg03929089	chr4:120376271	NA	-0.9	-14.65	-0.69	6.79e-35	Height;
SARC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg08219700	chr8:58056026	NA	0.62	6.56	0.4	3.37e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg05861140	chr6:150128134	PCMT1	0.39	5.16	0.32	5.4e-7	Lung cancer;
SARC	cis	rs7762018	0.607	rs78941587	chr6:170061157	G/C	cg13015042	chr6:170102002	WDR27;C6orf120	0.7	4.9	0.31	1.83e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs6570726	1.000	rs450076	chr6:145847655	G/T	cg23711669	chr6:146136114	FBXO30	0.75	11.27	0.59	8.17e-24	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7666738	0.830	rs4699601	chr4:99034429	G/A	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2404602	0.647	rs12904149	chr15:77043652	A/C	cg15268244	chr15:77196840	NA	0.44	5.13	0.32	6.08e-7	Blood metabolite levels;
SARC	cis	rs2180341	0.961	rs7775493	chr6:127615000	C/A	cg27446573	chr6:127587934	RNF146	1.02	14.46	0.69	2.89e-34	Breast cancer;
SARC	cis	rs3892630	0.612	rs10413282	chr19:33182751	A/G	cg22980127	chr19:33182716	NUDT19	1.14	12.38	0.63	2.13e-27	Red blood cell traits;
SARC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg11301795	chr4:187892539	NA	-0.7	-9.75	-0.54	4.67e-19	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7769051	0.522	rs11965927	chr6:133101353	T/C	cg07930552	chr6:133119739	C6orf192	0.93	5.78	0.35	2.38e-8	Type 2 diabetes nephropathy;
SARC	cis	rs611744	0.870	rs613179	chr8:109166006	G/A	cg21045802	chr8:109455806	TTC35	0.51	6.27	0.38	1.69e-9	Dupuytren's disease;
SARC	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg02733842	chr7:1102375	C7orf50	-0.43	-5.29	-0.33	2.78e-7	Bronchopulmonary dysplasia;
SARC	cis	rs67478160	0.634	rs2368558	chr14:104230518	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.35	-4.98	-0.31	1.21e-6	Schizophrenia;
SARC	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.43	-6.56	-0.39	3.5e-10	Total body bone mineral density;
SARC	cis	rs10276381	1.000	rs10263857	chr7:28187284	C/G	cg23620719	chr7:28220237	JAZF1	0.71	5.89	0.36	1.31e-8	Crohn's disease;
SARC	cis	rs9303401	0.573	rs67378767	chr17:57194237	G/T	cg12560992	chr17:57184187	TRIM37	0.58	5.19	0.32	4.58e-7	Cognitive test performance;
SARC	cis	rs950776	0.593	rs6495306	chr15:78865893	C/T	cg17108064	chr15:78857060	CHRNA5	-0.3	-5.18	-0.32	4.71e-7	Sudden cardiac arrest;
SARC	cis	rs7659604	0.643	rs6839054	chr4:122663628	C/T	cg06713675	chr4:122721982	EXOSC9	-0.38	-4.98	-0.31	1.26e-6	Type 2 diabetes;
SARC	cis	rs796364	1.000	rs281785	chr2:200749566	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.77	6.82	0.41	7.98e-11	Schizophrenia;
SARC	cis	rs79149102	0.579	rs12591175	chr15:75356073	C/T	cg17294928	chr15:75287854	SCAMP5	-1.1	-9.2	-0.52	2.09e-17	Lung cancer;
SARC	trans	rs9929218	0.954	rs9929479	chr16:68821271	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.52	-6.43	-0.39	6.99e-10	Colorectal cancer;
SARC	cis	rs1003719	0.762	rs3787780	chr21:38462614	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.7	0.5	5.92e-16	Eye color traits;
SARC	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg24503407	chr1:205819492	PM20D1	0.43	4.98	0.31	1.26e-6	Parkinson's disease;
SARC	cis	rs2073300	0.609	rs77908916	chr20:23405626	C/G	cg16736954	chr20:23401023	NAPB	0.77	4.76	0.3	3.39e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs1949733	0.523	rs16842563	chr4:8545146	C/T	cg11789530	chr4:8429930	ACOX3	-0.66	-7.37	-0.43	2.95e-12	Response to antineoplastic agents;
SARC	cis	rs9399137	0.507	rs4896128	chr6:135349756	A/G	cg22676075	chr6:135203613	NA	-0.38	-4.81	-0.3	2.69e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	trans	rs9427116	0.502	rs12125166	chr1:154582129	A/G	cg23145622	chr1:206859650	MAPKAPK2	-0.52	-6.6	-0.4	2.82e-10	Blood protein levels;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg09528265	chr5:146258195	PPP2R2B	-0.5	-6.28	-0.38	1.67e-9	Schizophrenia;
SARC	cis	rs4713118	0.615	rs57252182	chr6:27720249	C/A	cg17221315	chr6:27791827	HIST1H4J	0.4	4.94	0.31	1.49e-6	Parkinson's disease;
SARC	trans	rs11098499	0.954	rs11098525	chr4:120390152	G/A	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-5.94	-0.36	1.04e-8	Personality dimensions;
SARC	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg11890956	chr21:40555474	PSMG1	-1.04	-15.54	-0.71	7.66e-38	Cognitive function;
SARC	cis	rs17376456	0.569	rs1349711	chr5:93179032	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.54	-5.75	-0.35	2.72e-8	Diabetic retinopathy;
SARC	cis	rs6570726	0.935	rs391524	chr6:145823844	A/G	cg23711669	chr6:146136114	FBXO30	0.78	11.86	0.61	1.04e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	16.15	0.73	6.91e-40	Chronic sinus infection;
SARC	cis	rs2952156	0.959	rs2517956	chr17:37843859	G/A	cg00129232	chr17:37814104	STARD3	-0.69	-8.99	-0.51	8.97e-17	Asthma;
SARC	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg00933542	chr6:150070202	PCMT1	0.31	5.35	0.33	2.07e-7	Lung cancer;
SARC	cis	rs2475553	0.520	rs62437129	chr6:158655757	T/G	cg07165851	chr6:158734300	TULP4	0.6	6.73	0.4	1.34e-10	Lipoprotein (a) - cholesterol levels;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg00366352	chr12:96184415	NTN4	0.5	6.43	0.39	7.3e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg25427524	chr10:38739819	LOC399744	-0.6	-9.59	-0.53	1.38e-18	Extrinsic epigenetic age acceleration;
SARC	cis	rs1348850	0.958	rs11689550	chr2:178456298	A/G	cg23306229	chr2:178417860	TTC30B	0.58	6.64	0.4	2.19e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs911555	0.723	rs6575991	chr14:103908433	C/T	cg12935359	chr14:103987150	CKB	0.4	5.45	0.34	1.26e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6089584	0.566	rs6061963	chr20:60607480	C/G	cg06108461	chr20:60628389	TAF4	-0.7	-9.27	-0.52	1.27e-17	Body mass index;
SARC	trans	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.07	-0.42	1.8e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs76419734	1.000	rs7676975	chr4:106763811	A/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.73	5.35	0.33	2.06e-7	Post bronchodilator FEV1;
SARC	cis	rs10227331	0.934	rs2302447	chr7:157295985	A/T	cg04156418	chr7:157293606	NA	0.48	8.29	0.48	9.31e-15	Inattentive symptoms;
SARC	cis	rs4242434	0.927	rs35952885	chr8:22491622	T/G	cg03733263	chr8:22462867	KIAA1967	1.04	16.42	0.73	8.82e-41	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs12142240	0.667	rs41293287	chr1:46808852	C/T	cg10495392	chr1:46806563	NSUN4	0.64	6.76	0.4	1.09e-10	Menopause (age at onset);
SARC	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg24642844	chr7:1081250	C7orf50	-0.59	-6.06	-0.37	5.31e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs2834188	1.000	rs4408796	chr21:34698741	C/G	cg14352951	chr21:34696688	IFNAR1	-0.45	-5.46	-0.34	1.22e-7	Narcolepsy;
SARC	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg16606324	chr3:10149918	C3orf24	0.52	5.27	0.33	3.08e-7	Alzheimer's disease;
SARC	cis	rs4481887	0.741	rs6587471	chr1:248560741	C/T	cg13385794	chr1:248469461	NA	0.31	5.11	0.32	6.71e-7	Common traits (Other);
SARC	cis	rs62344088	0.590	rs62345236	chr5:283519	G/A	cg20965017	chr5:231967	SDHA	-0.76	-5.56	-0.34	7.29e-8	Asthma (childhood onset);
SARC	cis	rs7666738	0.753	rs11097594	chr4:98944486	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg06808227	chr14:105710500	BRF1	0.59	8.02	0.47	5.16e-14	Mean platelet volume;Platelet distribution width;
SARC	cis	rs2635047	0.967	rs12960444	chr18:44607314	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	7.97	0.46	6.96e-14	Educational attainment;
SARC	cis	rs76419734	1.000	rs72673811	chr4:106707297	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.81	5.48	0.34	1.08e-7	Post bronchodilator FEV1;
SARC	cis	rs2221894	0.506	rs36118625	chr8:28762798	A/G	cg07962641	chr8:28805897	HMBOX1	-0.75	-7.34	-0.43	3.61e-12	Obesity-related traits;
SARC	cis	rs6121246	0.567	rs6058203	chr20:30198979	C/T	cg13852791	chr20:30311386	BCL2L1	0.68	5.91	0.36	1.2e-8	Mean corpuscular hemoglobin;
SARC	cis	rs1420338	0.837	rs17753041	chr7:34176925	G/A	cg01275685	chr7:34179230	BMPER	-0.44	-5.47	-0.34	1.15e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
SARC	trans	rs6600671	0.932	rs6600663	chr1:121222437	A/T	cg00646200	chr1:148855367	NA	0.53	7.33	0.43	3.66e-12	Hip geometry;
SARC	cis	rs804280	0.564	rs4639	chr8:11644751	A/G	cg26752888	chr8:11627280	NEIL2	-0.41	-4.83	-0.3	2.5e-6	Myopia (pathological);
SARC	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.43	6.4	0.39	8.27e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs61935443	0.501	rs10777622	chr12:95195183	C/G	cg21533806	chr12:95267307	NA	0.4	5.08	0.32	7.84e-7	Schizophrenia;
SARC	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg11764359	chr7:65958608	NA	0.69	8.18	0.47	1.88e-14	Aortic root size;
SARC	cis	rs9911578	0.967	rs302843	chr17:56727986	C/T	cg05425664	chr17:57184151	TRIM37	-0.68	-8.49	-0.49	2.48e-15	Intelligence (multi-trait analysis);
SARC	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg13395646	chr4:1353034	KIAA1530	-0.56	-6.6	-0.4	2.77e-10	Obesity-related traits;
SARC	cis	rs614226	1.000	rs12310837	chr12:120880572	C/T	cg01236616	chr12:121019343	POP5	1.14	16.32	0.73	1.87e-40	Type 1 diabetes nephropathy;
SARC	cis	rs2011503	1.000	rs45631651	chr19:19638743	A/G	cg03709012	chr19:19516395	GATAD2A	0.6	5.29	0.33	2.8e-7	Bipolar disorder;
SARC	cis	rs858239	0.699	rs858260	chr7:23212934	G/T	cg23682824	chr7:23144976	KLHL7	0.67	8.53	0.49	1.88e-15	Cerebrospinal fluid biomarker levels;
SARC	cis	rs12594515	1.000	rs6493170	chr15:45987019	G/A	cg14863074	chr15:45997064	NA	0.34	5.18	0.32	4.76e-7	Waist circumference;Weight;
SARC	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg09699651	chr6:150184138	LRP11	0.43	5.28	0.33	2.96e-7	Lung cancer;
SARC	cis	rs9905704	0.918	rs12947196	chr17:56902444	G/A	cg12560992	chr17:57184187	TRIM37	0.41	4.83	0.3	2.46e-6	Testicular germ cell tumor;
SARC	cis	rs9916302	0.904	rs4794807	chr17:37531718	T/A	cg07936489	chr17:37558343	FBXL20	0.67	8.95	0.51	1.11e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs3820928	0.874	rs67513858	chr2:227804819	A/C	cg05526886	chr2:227700861	RHBDD1	-0.54	-6.65	-0.4	2.04e-10	Pulmonary function;
SARC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg08219700	chr8:58056026	NA	0.62	6.56	0.4	3.37e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs4555082	1.000	rs7146012	chr14:105757566	G/A	cg13114125	chr14:105738426	BRF1	-0.81	-11.85	-0.61	1.14e-25	Mean platelet volume;Platelet distribution width;
SARC	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg12311346	chr5:56204834	C5orf35	-0.56	-5.78	-0.35	2.39e-8	Initial pursuit acceleration;
SARC	cis	rs9916302	0.706	rs4795385	chr17:37733148	A/G	cg07936489	chr17:37558343	FBXL20	0.74	8.39	0.48	4.57e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs7626444	0.625	rs1357287	chr3:196484967	A/G	cg12930392	chr3:196481615	PAK2	0.25	4.78	0.3	3.12e-6	Monocyte count;
SARC	cis	rs9393777	0.588	rs4518487	chr6:26467531	A/G	cg12826209	chr6:26865740	GUSBL1	0.82	8.26	0.48	1.1e-14	Intelligence (multi-trait analysis);
SARC	cis	rs9303401	0.659	rs11079357	chr17:56902778	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.07	12.11	0.62	1.62e-26	Cognitive test performance;
SARC	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg18404041	chr3:52824283	ITIH1	-0.44	-6.62	-0.4	2.5e-10	Bipolar disorder;
SARC	cis	rs6964587	0.626	rs1011372	chr7:91509867	T/C	cg17063962	chr7:91808500	NA	-0.79	-11.69	-0.61	3.68e-25	Breast cancer;
SARC	cis	rs16937	0.662	rs10900472	chr1:205181526	A/G	cg21643547	chr1:205240462	TMCC2	-0.39	-4.73	-0.3	3.9e-6	Schizophrenia;
SARC	cis	rs7659604	0.521	rs4833235	chr4:122695136	C/A	cg19671926	chr4:122722719	EXOSC9	0.65	8.32	0.48	7.5e-15	Type 2 diabetes;
SARC	cis	rs208515	0.525	rs10755508	chr6:66675790	T/C	cg07460842	chr6:66804631	NA	0.86	9.87	0.54	2.02e-19	Exhaled nitric oxide levels;
SARC	cis	rs950027	0.620	rs1426932	chr15:45687256	T/C	cg15395560	chr15:45543142	SLC28A2	-0.28	-5.37	-0.33	1.89e-7	Response to fenofibrate (adiponectin levels);
SARC	cis	rs7219021	0.674	rs11656939	chr17:46964406	G/C	cg16584676	chr17:46985605	UBE2Z	-0.5	-5.78	-0.35	2.36e-8	Schizophrenia or bipolar disorder;
SARC	cis	rs644799	0.525	rs3016206	chr11:95536724	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.95	15.89	0.72	5.01e-39	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs950169	0.887	rs12903946	chr15:84954430	T/C	cg17507749	chr15:85114479	UBE2QP1	0.77	9.42	0.53	4.67e-18	Schizophrenia;
SARC	cis	rs11122272	0.735	rs2437147	chr1:231516756	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg20120463	chr17:44301886	NA	-0.36	-5.58	-0.34	6.74e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs58235267	0.544	rs12478556	chr2:63341711	T/A	cg17519650	chr2:63277830	OTX1	0.45	5.61	0.35	5.62e-8	Prostate-specific antigen levels (conditioned on lead SNPs);
SARC	cis	rs10992471	0.603	rs987553	chr9:95298694	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.6	-0.34	6.12e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg12310025	chr6:25882481	NA	-0.52	-6.74	-0.4	1.21e-10	Blood metabolite levels;
SARC	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg22800045	chr5:56110881	MAP3K1	0.66	6.92	0.41	4.25e-11	Initial pursuit acceleration;
SARC	cis	rs4073582	1.000	rs801732	chr11:65935502	T/A	cg14036092	chr11:66035641	RAB1B	0.52	6.32	0.38	1.31e-9	Gout;
SARC	cis	rs9443189	0.763	rs2647411	chr6:76433692	C/T	cg01950844	chr6:76311363	SENP6	-0.68	-6.23	-0.38	2.13e-9	Prostate cancer;
SARC	cis	rs8014204	0.901	rs2080087	chr14:75365062	C/T	cg17347104	chr14:75034677	LTBP2	-0.39	-4.71	-0.3	4.18e-6	Caffeine consumption;
SARC	cis	rs7520050	0.966	rs11211208	chr1:46334256	A/C	cg24296786	chr1:45957014	TESK2	0.38	4.72	0.3	4.06e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs3784262	0.669	rs4646635	chr15:58252277	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.34	-5.02	-0.31	1.02e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.46	5.89	0.36	1.36e-8	Personality dimensions;
SARC	cis	rs16976116	0.851	rs28699327	chr15:55500335	A/G	cg17854078	chr15:55489399	RSL24D1	0.66	6.53	0.39	4.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs17079247	1.000	rs9575763	chr13:85659922	G/A	ch.13.84760847R	chr13:85862846	NA	-0.56	-4.8	-0.3	2.85e-6	Bipolar disorder (mania);
SARC	cis	rs2213920	0.749	rs6478172	chr9:118251281	C/T	cg13918206	chr9:118159781	DEC1	0.84	6.55	0.39	3.71e-10	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs3771570	1.000	rs55645375	chr2:242269024	A/G	cg21155796	chr2:242212141	HDLBP	0.67	5.75	0.35	2.82e-8	Prostate cancer;
SARC	cis	rs72781680	0.898	rs12623333	chr2:24111823	T/G	cg08917208	chr2:24149416	ATAD2B	0.78	7.68	0.45	4.49e-13	Lymphocyte counts;
SARC	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.34	-5.1	-0.32	7e-7	Total body bone mineral density;
SARC	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg11890956	chr21:40555474	PSMG1	-0.72	-9.52	-0.53	2.32e-18	Menarche (age at onset);
SARC	cis	rs7772486	0.875	rs9399573	chr6:146403255	A/T	cg05347473	chr6:146136440	FBXO30	0.47	6.53	0.39	4.05e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs751728	1.000	rs3793079	chr6:33767788	T/A	cg25922239	chr6:33757077	LEMD2	0.78	10.3	0.56	9.26e-21	Crohn's disease;
SARC	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg06420487	chr17:61919686	SMARCD2	0.43	4.78	0.3	3.11e-6	Height;
SARC	cis	rs7772486	0.790	rs6926657	chr6:146255794	G/A	cg05347473	chr6:146136440	FBXO30	-0.48	-6.52	-0.39	4.23e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4555082	0.957	rs2816628	chr14:105736134	T/G	cg06808227	chr14:105710500	BRF1	-0.56	-7.7	-0.45	3.96e-13	Mean platelet volume;Platelet distribution width;
SARC	cis	rs67311347	1.000	rs9332450	chr3:40458041	C/T	cg01475735	chr3:40494733	NA	0.43	4.97	0.31	1.32e-6	Renal cell carcinoma;
SARC	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.54	6.97	0.42	3.25e-11	Personality dimensions;
SARC	cis	rs10078	0.571	rs2721014	chr5:463539	G/A	cg07599136	chr5:415885	AHRR	0.67	5.93	0.36	1.08e-8	Fat distribution (HIV);
SARC	cis	rs72766638	0.895	rs11795079	chr9:136930134	T/C	cg13789015	chr9:136890014	NCRNA00094	0.59	6.51	0.39	4.49e-10	Mosquito bite size;
SARC	cis	rs10781543	0.776	rs11145760	chr9:139382594	G/A	cg14169450	chr9:139327907	INPP5E	0.44	6.34	0.38	1.18e-9	Monocyte percentage of white cells;
SARC	cis	rs9905704	0.647	rs8077332	chr17:57105223	A/G	cg12560992	chr17:57184187	TRIM37	0.44	5.32	0.33	2.43e-7	Testicular germ cell tumor;
SARC	cis	rs113835537	0.660	rs7116940	chr11:66303895	T/C	cg24851651	chr11:66362959	CCS	0.39	4.93	0.31	1.55e-6	Airway imaging phenotypes;
SARC	cis	rs986417	0.818	rs10133871	chr14:61063771	A/C	cg27398547	chr14:60952738	C14orf39	0.75	7.05	0.42	2.06e-11	Gut microbiota (bacterial taxa);
SARC	cis	rs4901847	0.967	rs8015039	chr14:58547391	A/C	cg15908186	chr14:58618357	C14orf37	-0.49	-5.9	-0.36	1.27e-8	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	12.63	0.64	3.43e-28	Platelet count;
SARC	cis	rs6496667	0.533	rs2074584	chr15:91009381	C/T	cg22089800	chr15:90895588	ZNF774	0.44	5.17	0.32	4.94e-7	Rheumatoid arthritis;
SARC	trans	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.55	-7.09	-0.42	1.57e-11	Intelligence (multi-trait analysis);
SARC	cis	rs1949733	0.701	rs2631754	chr4:8449233	A/G	cg11789530	chr4:8429930	ACOX3	0.81	10.55	0.57	1.58e-21	Response to antineoplastic agents;
SARC	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg02951883	chr7:2050386	MAD1L1	-0.37	-4.74	-0.3	3.77e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs7617773	0.674	rs13069029	chr3:48355024	A/G	cg11946769	chr3:48343235	NME6	0.76	9.7	0.54	6.55e-19	Coronary artery disease;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg03958229	chr6:117804230	DCBLD1	-0.45	-6.34	-0.38	1.16e-9	Neuroticism;
SARC	cis	rs55823223	0.618	rs11867339	chr17:73862093	A/G	cg23806715	chr17:73775811	H3F3B	0.61	6.24	0.38	2.02e-9	Psoriasis;
SARC	cis	rs611744	0.781	rs656406	chr8:109173843	G/A	cg21045802	chr8:109455806	TTC35	0.5	6.14	0.37	3.45e-9	Dupuytren's disease;
SARC	cis	rs7429990	0.965	rs7627645	chr3:48093133	A/T	cg11946769	chr3:48343235	NME6	-0.45	-5.22	-0.32	3.87e-7	Educational attainment (years of education);
SARC	cis	rs12477438	0.539	rs720228	chr2:99704547	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	13.54	0.66	3.27e-31	Chronic sinus infection;
SARC	cis	rs10911251	0.528	rs10911263	chr1:183115018	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.67	9.66	0.53	8.88e-19	Colorectal cancer;
SARC	cis	rs854765	0.547	rs7212167	chr17:17913504	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.66	9.63	0.53	1.1e-18	Total body bone mineral density;
SARC	cis	rs7620457	1.000	rs7620457	chr3:183747266	A/G	cg01324343	chr3:183735012	ABCC5	-0.51	-6.67	-0.4	1.82e-10	Body mass index;
SARC	cis	rs1448094	0.511	rs61930035	chr12:86153695	G/A	cg02569458	chr12:86230093	RASSF9	0.36	4.78	0.3	3.06e-6	Major depressive disorder;
SARC	cis	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg08975724	chr8:8085496	FLJ10661	-0.56	-7.12	-0.42	1.32e-11	Joint mobility (Beighton score);
SARC	cis	rs6582630	0.555	rs11503799	chr12:38294578	G/A	cg14851346	chr12:38532713	NA	-0.46	-5.39	-0.33	1.69e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs911555	0.755	rs8016676	chr14:103904842	C/A	cg12935359	chr14:103987150	CKB	0.4	5.45	0.34	1.26e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6540556	0.769	rs6540552	chr1:209927710	C/T	cg23920097	chr1:209922102	NA	0.57	6.66	0.4	2e-10	Red blood cell count;
SARC	cis	rs7772486	0.623	rs735535	chr6:146036829	C/T	cg23711669	chr6:146136114	FBXO30	-0.8	-12.71	-0.64	1.82e-28	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs11039798	0.588	rs7483361	chr11:48593786	G/A	cg15704280	chr7:45808275	SEPT13	0.63	6.71	0.4	1.46e-10	Axial length;
SARC	cis	rs7216064	1.000	rs6504555	chr17:65940727	A/G	cg12091567	chr17:66097778	LOC651250	0.75	8.29	0.48	9.02e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs7020830	0.898	rs308492	chr9:37298020	C/T	cg14294708	chr9:37120828	ZCCHC7	1.14	20.87	0.81	3.01e-55	Schizophrenia;
SARC	cis	rs7264396	0.563	rs7268195	chr20:34339854	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	5.32	0.33	2.49e-7	Total cholesterol levels;
SARC	cis	rs3733589	1.000	rs35271694	chr4:10017838	G/A	cg16430538	chr4:10459836	ZNF518B	0.64	4.89	0.3	1.92e-6	Renal overload gout;
SARC	cis	rs8044868	0.887	rs12449073	chr16:72171004	A/T	cg16558253	chr16:72132732	DHX38	-0.35	-4.96	-0.31	1.33e-6	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
SARC	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.63e-10	Life satisfaction;
SARC	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7615952	0.534	rs1503072	chr3:125754691	C/T	cg05084668	chr3:125655381	ALG1L	-0.49	-5.15	-0.32	5.64e-7	Blood pressure (smoking interaction);
SARC	trans	rs10085978	0.565	rs7463437	chr8:143236759	C/T	cg12891252	chr10:43902500	HNRNPF	0.53	6.57	0.4	3.22e-10	Mosquito bite size;
SARC	cis	rs6450176	0.909	rs3776720	chr5:53296158	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.66	-7.53	-0.44	1.12e-12	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs1448094	0.520	rs12304244	chr12:86272823	C/T	cg02569458	chr12:86230093	RASSF9	0.42	5.7	0.35	3.53e-8	Major depressive disorder;
SARC	cis	rs262150	0.837	rs2657404	chr7:158783155	C/T	cg19418458	chr7:158789849	NA	-0.48	-6.5	-0.39	4.83e-10	Facial morphology (factor 20);
SARC	cis	rs9486715	0.867	rs2475025	chr6:96988696	A/T	cg06623918	chr6:96969491	KIAA0776	-0.94	-14.15	-0.68	3.13e-33	Headache;
SARC	cis	rs12458462	0.892	rs2242175	chr18:77464406	G/A	cg11879182	chr18:77439856	CTDP1	0.87	12.78	0.64	1.11e-28	Monocyte count;
SARC	cis	rs739401	0.595	rs6578304	chr11:2998279	A/G	cg20651018	chr11:3035856	CARS	0.46	7.21	0.43	7.98e-12	Longevity;
SARC	cis	rs78545713	0.502	rs3823157	chr6:26272039	A/G	cg00631329	chr6:26305371	NA	-0.67	-7.08	-0.42	1.72e-11	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs2204008	0.618	rs8186932	chr12:38338386	G/A	cg26384229	chr12:38710491	ALG10B	-0.57	-6.96	-0.42	3.33e-11	Bladder cancer;
SARC	cis	rs9503598	1.000	rs9503598	chr6:3446263	A/G	cg00476032	chr6:3446245	SLC22A23	-0.38	-5.91	-0.36	1.24e-8	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
SARC	cis	rs7223966	0.961	rs17631783	chr17:61687600	A/G	cg00588841	chr17:61851480	DDX42;CCDC47	0.54	5.4	0.33	1.65e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6456156	0.819	rs9457273	chr6:167520749	A/T	cg23791538	chr6:167370224	RNASET2	0.4	4.94	0.31	1.5e-6	Primary biliary cholangitis;
SARC	cis	rs67460515	0.563	rs11922957	chr3:160828865	A/C	cg03342759	chr3:160939853	NMD3	-0.63	-7.65	-0.45	5.18e-13	Parkinson's disease;
SARC	cis	rs3758785	0.537	rs480572	chr11:94070139	A/T	cg13023536	chr11:94226537	MRE11A;ANKRD49	-0.44	-5.51	-0.34	9.4e-8	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
SARC	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg13206674	chr6:150067644	NUP43	0.45	5.78	0.35	2.32e-8	Lung cancer;
SARC	cis	rs11190604	1.000	rs4919466	chr10:102241213	T/C	cg07080220	chr10:102295463	HIF1AN	0.7	8.13	0.47	2.6e-14	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs8180040	0.800	rs7632501	chr3:47268306	T/C	cg27129171	chr3:47204927	SETD2	-0.73	-9.54	-0.53	1.96e-18	Colorectal cancer;
SARC	cis	rs6981523	0.553	rs11989369	chr8:11055385	A/G	cg21775007	chr8:11205619	TDH	0.43	5.51	0.34	9.38e-8	Neuroticism;
SARC	cis	rs9911578	0.900	rs8067264	chr17:57182793	G/C	cg20303301	chr17:57937339	TUBD1	-0.34	-4.87	-0.3	2.04e-6	Intelligence (multi-trait analysis);
SARC	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg07308232	chr7:1071921	C7orf50	0.54	6.85	0.41	6.56e-11	Longevity;Endometriosis;
SARC	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg23262073	chr20:60523788	NA	-0.39	-5.71	-0.35	3.43e-8	Body mass index;
SARC	cis	rs4319547	0.656	rs10773075	chr12:122814236	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.6	-7.03	-0.42	2.26e-11	Body mass index;
SARC	cis	rs1270639	0.778	rs1796271	chr7:157438129	T/G	cg13357408	chr7:157437802	PTPRN2	0.48	5.18	0.32	4.72e-7	Colorectal cancer;
SARC	cis	rs6582630	0.572	rs7315897	chr12:38449081	C/T	cg13010199	chr12:38710504	ALG10B	-0.46	-5.69	-0.35	3.84e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg10295955	chr4:187884368	NA	-1.09	-21.06	-0.81	7.62e-56	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2562456	0.874	rs9304986	chr19:21682062	G/A	cg00806126	chr19:22604979	ZNF98	0.47	4.85	0.3	2.27e-6	Pain;
SARC	cis	rs9486719	0.843	rs2103539	chr6:96844342	T/A	cg06623918	chr6:96969491	KIAA0776	0.75	7.39	0.44	2.65e-12	Migraine;Coronary artery disease;
SARC	cis	rs11731606	0.508	rs17021533	chr4:95280587	C/T	cg00507259	chr4:95128692	SMARCAD1	0.56	5.41	0.33	1.59e-7	Mean platelet volume;
SARC	cis	rs1949733	0.656	rs2631762	chr4:8423122	A/T	cg13073564	chr4:8508604	NA	-0.42	-6.7	-0.4	1.58e-10	Response to antineoplastic agents;
SARC	cis	rs7937682	0.847	rs500163	chr11:111462649	T/G	cg22437258	chr11:111473054	SIK2	0.76	9.87	0.54	2.07e-19	Primary sclerosing cholangitis;
SARC	cis	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg03060546	chr3:49711283	APEH	-0.66	-7.87	-0.46	1.33e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs113835537	0.529	rs3741360	chr11:66300348	A/G	cg24851651	chr11:66362959	CCS	0.37	4.76	0.3	3.4e-6	Airway imaging phenotypes;
SARC	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg23758822	chr17:41437982	NA	0.91	11.49	0.6	1.7e-24	Menopause (age at onset);
SARC	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	12.24	0.63	6.48e-27	Chronic sinus infection;
SARC	cis	rs763121	0.853	rs3747172	chr22:39067524	A/G	cg14440974	chr22:39074834	NA	-0.33	-4.8	-0.3	2.84e-6	Menopause (age at onset);
SARC	cis	rs240764	0.853	rs12206182	chr6:101033379	A/C	cg09795085	chr6:101329169	ASCC3	-0.45	-5.95	-0.36	9.78e-9	Neuroticism;
SARC	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.34	-5.1	-0.32	7.09e-7	Total body bone mineral density;
SARC	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-9.31	-0.52	9.88e-18	Alzheimer's disease;
SARC	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg23172400	chr8:95962367	TP53INP1	-0.34	-5.91	-0.36	1.18e-8	Type 2 diabetes;
SARC	cis	rs2658782	0.547	rs3020054	chr11:93055556	C/T	cg15737290	chr11:93063684	CCDC67	0.99	14.32	0.68	8.45e-34	Pulmonary function decline;
SARC	cis	rs908922	0.676	rs3753451	chr1:152485227	T/G	cg09873164	chr1:152488093	CRCT1	0.64	8.46	0.48	2.91e-15	Hair morphology;
SARC	cis	rs6991838	0.701	rs7829434	chr8:66629144	T/C	cg13398993	chr8:66546079	ARMC1	0.44	5.67	0.35	4.14e-8	Intelligence (multi-trait analysis);
SARC	cis	rs1008375	1.000	rs4698200	chr4:17657051	G/A	cg16339924	chr4:17578868	LAP3	0.68	9.1	0.51	4.27e-17	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09319202	chr1:111506715	C1orf103	-0.53	-6.76	-0.4	1.11e-10	Smoking initiation;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14951488	chr10:95256188	CEP55	-0.56	-6.69	-0.4	1.68e-10	Fibrinogen levels;
SARC	cis	rs8114671	0.628	rs6060130	chr20:33549319	C/T	cg24642439	chr20:33292090	TP53INP2	0.44	5.21	0.32	4.25e-7	Height;
SARC	cis	rs2204008	0.837	rs12370891	chr12:37984531	A/G	cg26384229	chr12:38710491	ALG10B	0.89	13.14	0.65	7.28e-30	Bladder cancer;
SARC	trans	rs1973993	0.934	rs588660	chr1:96886604	G/A	cg10631902	chr5:14652156	NA	0.44	7.53	0.44	1.09e-12	Weight;
SARC	cis	rs4803468	1.000	rs284657	chr19:41929915	G/C	cg08477640	chr19:41863820	B9D2	0.41	5.15	0.32	5.59e-7	Height;
SARC	cis	rs10654220	1	rs10654220	chr12:123703422	A/AGTT	cg00376283	chr12:123451042	ABCB9	0.58	5.7	0.35	3.65e-8	Platelet count;
SARC	cis	rs12681288	0.676	rs2701913	chr8:999982	A/T	cg15309053	chr8:964076	NA	0.44	7.0	0.42	2.63e-11	Schizophrenia;
SARC	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg24642844	chr7:1081250	C7orf50	-0.57	-6.05	-0.37	5.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg02463440	chr8:22132932	PIWIL2	0.47	6.7	0.4	1.55e-10	Hypertriglyceridemia;
SARC	cis	rs1008375	0.932	rs11938710	chr4:17670664	G/C	cg16339924	chr4:17578868	LAP3	-0.62	-7.94	-0.46	8.53e-14	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7785360	0.800	rs12698887	chr7:69739690	A/G	cg10619644	chr7:69149951	AUTS2	-0.42	-4.88	-0.3	1.99e-6	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
SARC	cis	rs7917772	0.636	rs10786708	chr10:104526245	C/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.46	5.3	0.33	2.71e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs1355223	0.902	rs836462	chr11:34743263	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.34	-0.33	2.21e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg18252515	chr7:66147081	NA	-1.34	-11.74	-0.61	2.62e-25	Diabetic kidney disease;
SARC	cis	rs7666738	0.791	rs7678564	chr4:99057341	A/G	cg05340658	chr4:99064831	C4orf37	0.64	8.6	0.49	1.22e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4742903	0.870	rs10991171	chr9:106976150	G/T	cg14250997	chr9:106856677	SMC2	0.4	5.02	0.31	1.02e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs7197653	0.748	rs58542611	chr16:68350219	C/T	cg05110241	chr16:68378359	PRMT7	-0.64	-5.66	-0.35	4.44e-8	Magnesium levels;
SARC	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	8.8	0.5	3.1e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6831352	0.703	rs3133152	chr4:100031721	C/G	cg12011299	chr4:100065546	ADH4	0.28	4.8	0.3	2.86e-6	Alcohol dependence;
SARC	cis	rs4742903	0.967	rs10125661	chr9:106868443	A/G	cg14250997	chr9:106856677	SMC2	0.53	7.04	0.42	2.11e-11	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs7681440	0.583	rs2619366	chr4:90763260	A/G	cg06632027	chr4:90757378	SNCA	-0.45	-5.67	-0.35	4.27e-8	Dementia with Lewy bodies;
SARC	cis	rs9517313	0.770	rs9517301	chr13:99095088	A/G	cg07423050	chr13:99094983	FARP1	-0.48	-7.42	-0.44	2.21e-12	Neuroticism;
SARC	trans	rs877282	0.583	rs12356155	chr10:823940	C/T	cg22713356	chr15:30763199	NA	0.88	8.54	0.49	1.76e-15	Uric acid levels;
SARC	cis	rs3087591	0.708	rs2189525	chr17:29668808	C/T	cg24425628	chr17:29625626	OMG;NF1	-0.41	-5.2	-0.32	4.28e-7	Hip circumference;
SARC	cis	rs10979	0.931	rs9403509	chr6:143888691	G/A	cg25407410	chr6:143891975	LOC285740	-0.64	-8.68	-0.49	6.88e-16	Hypospadias;
SARC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg07157834	chr1:205819609	PM20D1	0.71	11.28	0.59	7.58e-24	Menarche (age at onset);
SARC	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.98	-15.84	-0.72	7.78e-39	Chronic sinus infection;
SARC	trans	rs11039798	0.502	rs961863	chr11:48417021	T/C	cg15704280	chr7:45808275	SEPT13	-0.63	-6.39	-0.39	8.74e-10	Axial length;
SARC	cis	rs1008375	0.966	rs3733581	chr4:17695206	C/G	cg02297831	chr4:17616191	MED28	-0.4	-4.87	-0.3	2.02e-6	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9400467	0.506	rs12214933	chr6:111558006	A/G	cg15721981	chr6:111408429	SLC16A10	0.72	5.94	0.36	1.03e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs6834538	1.000	rs6823117	chr4:113447354	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.46	5.56	0.34	7.33e-8	Free thyroxine concentration;
SARC	cis	rs2116941	1.000	rs7250265	chr19:10339818	G/C	cg01850179	chr19:10340795	S1PR2	-0.65	-8.06	-0.47	4.1e-14	Pulse pressure;
SARC	cis	rs8044995	0.563	rs1110572	chr16:68396119	A/G	cg09835421	chr16:68378352	PRMT7	-0.56	-5.3	-0.33	2.64e-7	Schizophrenia;
SARC	cis	rs1707322	0.752	rs11211147	chr1:46110094	A/G	cg03146154	chr1:46216737	IPP	0.51	6.03	0.37	6.22e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7833790	0.724	rs10958045	chr8:82722994	T/C	cg17211192	chr8:82754475	SNX16	-0.5	-6.35	-0.38	1.12e-9	Diastolic blood pressure;
SARC	trans	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg20587970	chr11:113659929	NA	-1.31	-13.7	-0.67	9.62e-32	Hip circumference adjusted for BMI;
SARC	cis	rs74417235	0.610	rs13178134	chr5:154063032	A/T	cg17344516	chr5:154026930	NA	-0.48	-4.86	-0.3	2.17e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
SARC	cis	rs80130819	0.688	rs1552551	chr12:48643101	C/A	cg05342945	chr12:48394962	COL2A1	-0.53	-5.64	-0.35	4.93e-8	Prostate cancer;
SARC	trans	rs208520	1.000	rs208537	chr6:66963544	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.82	-8.94	-0.51	1.2e-16	Exhaled nitric oxide output;
SARC	cis	rs7712401	0.540	rs416763	chr5:122317241	G/A	cg19412675	chr5:122181750	SNX24	-0.43	-5.5	-0.34	9.81e-8	Mean platelet volume;
SARC	cis	rs7582720	1.000	rs72932590	chr2:203884308	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	7.23	0.43	6.7e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg03395511	chr6:291903	DUSP22	-0.54	-6.92	-0.41	4.35e-11	Menopause (age at onset);
SARC	trans	rs9888736	0.501	rs16959883	chr15:47911263	C/T	cg01357263	chr12:122459509	BCL7A	-0.51	-6.54	-0.39	3.75e-10	Body mass index;
SARC	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg07930192	chr7:1003750	NA	0.42	5.66	0.35	4.46e-8	Longevity;Endometriosis;
SARC	cis	rs12545109	0.800	rs1440746	chr8:57415912	G/A	cg21220214	chr8:57350948	NA	-0.4	-4.79	-0.3	3.01e-6	Obesity-related traits;
SARC	cis	rs9467711	0.591	rs35335639	chr6:26038681	C/G	cg21479132	chr6:26055353	NA	0.99	7.28	0.43	5.04e-12	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-8.93	-0.5	1.31e-16	Alzheimer's disease;
SARC	cis	rs9807841	0.592	rs10419865	chr19:10772685	C/G	cg17710535	chr19:10819994	QTRT1	0.39	4.74	0.3	3.67e-6	Inflammatory skin disease;
SARC	cis	rs35160687	0.901	rs12478653	chr2:86535394	A/C	cg10973622	chr2:86423274	IMMT	-0.38	-4.92	-0.31	1.66e-6	Night sleep phenotypes;
SARC	cis	rs1218582	0.741	rs705094	chr1:154917314	G/A	cg16680214	chr1:154839983	KCNN3	-0.35	-5.4	-0.33	1.64e-7	Prostate cancer;
SARC	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg02788857	chr8:22132959	PIWIL2	0.35	4.95	0.31	1.43e-6	Hypertriglyceridemia;
SARC	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg26681399	chr22:41777847	TEF	0.43	4.89	0.3	1.92e-6	Vitiligo;
SARC	cis	rs2816062	0.813	rs6698315	chr1:18895806	A/G	cg18795169	chr1:18902165	NA	-0.78	-12.69	-0.64	2.13e-28	Urate levels in lean individuals;
SARC	cis	rs2120243	0.508	rs1456106	chr3:157123456	T/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.39	5.07	0.32	8e-7	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs2836974	0.545	rs8128901	chr21:40710419	G/A	cg11644478	chr21:40555479	PSMG1	0.66	8.32	0.48	7.19e-15	Cognitive function;
SARC	cis	rs6496667	0.532	rs2601207	chr15:90963542	C/G	cg22089800	chr15:90895588	ZNF774	-0.44	-5.06	-0.31	8.53e-7	Rheumatoid arthritis;
SARC	cis	rs79976124	0.797	rs74995761	chr6:66640216	G/A	cg07460842	chr6:66804631	NA	0.62	6.74	0.4	1.2e-10	Type 2 diabetes;
SARC	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-5.55	-0.34	7.71e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg12463550	chr7:65579703	CRCP	0.66	4.9	0.31	1.78e-6	Diabetic kidney disease;
SARC	cis	rs79149102	0.579	rs6495137	chr15:75295541	G/A	cg17294928	chr15:75287854	SCAMP5	-0.99	-8.87	-0.5	1.91e-16	Lung cancer;
SARC	cis	rs11770686	0.747	rs2525456	chr7:75312201	C/T	cg17787366	chr7:75369077	HIP1	0.42	5.23	0.32	3.74e-7	Essential tremor;
SARC	cis	rs2043112	0.691	rs10057314	chr5:39081164	T/G	cg04869206	chr5:39074266	RICTOR	0.51	6.42	0.39	7.54e-10	Obesity-related traits;
SARC	cis	rs2153535	0.580	rs9406172	chr6:8515464	T/A	cg23788917	chr6:8435910	SLC35B3	0.63	8.28	0.48	9.37e-15	Motion sickness;
SARC	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg09699651	chr6:150184138	LRP11	0.39	4.87	0.3	2.04e-6	Lung cancer;
SARC	cis	rs796364	0.865	rs769948	chr2:200728475	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.8	7.11	0.42	1.4e-11	Schizophrenia;
SARC	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg09699651	chr6:150184138	LRP11	0.41	5.11	0.32	6.6e-7	Lung cancer;
SARC	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg02725872	chr8:58115012	NA	-0.28	-4.98	-0.31	1.25e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs7528684	0.546	rs11264794	chr1:157647789	A/C	cg18268488	chr1:157545234	FCRL4	-0.28	-5.15	-0.32	5.49e-7	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;
SARC	cis	rs72781680	0.898	rs6545127	chr2:24060670	C/T	cg08917208	chr2:24149416	ATAD2B	0.78	7.54	0.44	1.03e-12	Lymphocyte counts;
SARC	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.59	-6.99	-0.42	2.86e-11	Gut microbiome composition (summer);
SARC	cis	rs3820928	0.874	rs10933163	chr2:227815286	A/G	cg05526886	chr2:227700861	RHBDD1	-0.54	-6.64	-0.4	2.19e-10	Pulmonary function;
SARC	cis	rs7587476	0.601	rs1129804	chr2:215674323	C/G	cg04004882	chr2:215674386	BARD1	-0.6	-6.97	-0.42	3.22e-11	Neuroblastoma;
SARC	cis	rs2013441	0.804	rs1811453	chr17:20232193	A/C	cg13482628	chr17:19912719	NA	-0.46	-6.03	-0.37	6.41e-9	Obesity-related traits;
SARC	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg01316550	chr5:56110833	MAP3K1	0.54	4.92	0.31	1.62e-6	Initial pursuit acceleration;
SARC	cis	rs4423214	1.000	rs2276361	chr11:71169648	A/G	cg05163923	chr11:71159392	DHCR7	0.68	9.54	0.53	2.07e-18	Vitamin D levels;
SARC	cis	rs5758659	0.652	rs133336	chr22:42416303	C/T	cg04733989	chr22:42467013	NAGA	0.52	6.94	0.41	3.81e-11	Cognitive function;
SARC	cis	rs7113850	0.541	rs7944769	chr11:24224823	G/C	ch.11.24196551F	chr11:24239977	NA	0.71	5.85	0.36	1.67e-8	Bone fracture in osteoporosis;
SARC	cis	rs7481584	0.624	rs449164	chr11:3053454	C/T	cg08508325	chr11:3079039	CARS	0.23	5.18	0.32	4.85e-7	Calcium levels;
SARC	cis	rs1348850	0.958	rs1405713	chr2:178461560	G/C	cg23306229	chr2:178417860	TTC30B	0.55	6.34	0.38	1.15e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9443189	0.570	rs7765254	chr6:76398143	T/C	cg01950844	chr6:76311363	SENP6	0.79	6.6	0.4	2.75e-10	Prostate cancer;
SARC	cis	rs35955747	0.869	rs131219	chr22:31760250	T/C	cg13145458	chr22:31556086	RNF185	-0.39	-4.92	-0.31	1.63e-6	Neutrophil count;Sum basophil neutrophil counts;
SARC	cis	rs3008870	0.755	rs2755251	chr1:67496425	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.58	7.38	0.44	2.82e-12	Lymphocyte percentage of white cells;
SARC	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg04277193	chr17:41438351	NA	0.45	4.8	0.3	2.85e-6	Menopause (age at onset);
SARC	cis	rs7681440	0.904	rs7698219	chr4:90771351	C/A	cg06632027	chr4:90757378	SNCA	0.4	5.68	0.35	3.9e-8	Dementia with Lewy bodies;
SARC	cis	rs9399135	0.967	rs6925424	chr6:135313948	T/A	cg24558204	chr6:135376177	HBS1L	0.45	6.11	0.37	4.1e-9	Red blood cell count;
SARC	cis	rs35955747	0.869	rs7286648	chr22:31539614	A/T	cg13145458	chr22:31556086	RNF185	-0.39	-4.76	-0.3	3.46e-6	Neutrophil count;Sum basophil neutrophil counts;
SARC	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.97e-8	Aortic root size;
SARC	cis	rs539096	0.501	rs713191	chr1:44314553	A/G	cg12908607	chr1:44402522	ARTN	-0.33	-5.83	-0.36	1.88e-8	Intelligence (multi-trait analysis);
SARC	cis	rs6696846	0.749	rs11578293	chr1:205070178	T/C	cg21643547	chr1:205240462	TMCC2	-0.54	-6.9	-0.41	5.01e-11	Red blood cell count;
SARC	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg18252515	chr7:66147081	NA	-1.34	-11.86	-0.61	1.09e-25	Diabetic kidney disease;
SARC	cis	rs787274	0.718	rs4979171	chr9:115627262	T/C	cg13803584	chr9:115635662	SNX30	-0.96	-6.0	-0.37	7.61e-9	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs4664308	0.618	rs62175487	chr2:160892521	C/T	cg03641300	chr2:160917029	PLA2R1	-0.39	-5.06	-0.31	8.7e-7	Idiopathic membranous nephropathy;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg00639286	chr5:151138064	ATOX1	0.62	6.24	0.38	2.05e-9	Lung cancer in ever smokers;
SARC	cis	rs4689388	0.856	rs1046314	chr4:6303955	A/G	cg14416269	chr4:6271139	WFS1	-0.31	-4.77	-0.3	3.27e-6	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs4689388	0.890	rs4689398	chr4:6302199	C/T	cg00701064	chr4:6280414	WFS1	0.55	9.14	0.51	3.13e-17	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg15966229	chr18:44337664	ST8SIA5	-0.37	-4.8	-0.3	2.9e-6	Personality dimensions;
SARC	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg16325326	chr1:53192061	ZYG11B	0.82	13.19	0.65	4.74e-30	Monocyte count;
SARC	cis	rs9916302	0.904	rs4794807	chr17:37531718	T/A	cg15445000	chr17:37608096	MED1	-0.4	-4.85	-0.3	2.21e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs4711350	0.765	rs6921772	chr6:33749686	A/G	cg07979401	chr6:33739406	LEMD2	-0.39	-4.88	-0.3	1.99e-6	Schizophrenia;
SARC	cis	rs614226	1.000	rs7174	chr12:121017171	A/G	cg01236616	chr12:121019343	POP5	1.25	18.78	0.78	1.57e-48	Type 1 diabetes nephropathy;
SARC	trans	rs10209086	0.736	rs1584436	chr2:138298878	A/G	cg15990800	chr14:55738852	FBXO34	-0.52	-6.98	-0.42	3.05e-11	Multiple system atrophy;
SARC	cis	rs2439831	1.000	rs2601014	chr15:43756013	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	7.08	0.42	1.72e-11	Lung cancer in ever smokers;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg01223422	chr19:42463610	RABAC1	0.49	6.4	0.39	8.66e-10	Lung adenocarcinoma;
SARC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.64	7.89	0.46	1.15e-13	Prudent dietary pattern;
SARC	cis	rs7762018	0.607	rs3800544	chr6:170058374	C/T	cg13891659	chr6:170190454	C6orf122;C6orf208	0.7	5.02	0.31	1.01e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs3768617	0.510	rs2296288	chr1:183072590	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.19	0.56	2.07e-20	Fuchs's corneal dystrophy;
SARC	cis	rs6088580	0.524	rs6142210	chr20:33223012	C/T	cg08999081	chr20:33150536	PIGU	-0.33	-4.94	-0.31	1.47e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs12586317	0.547	rs2273154	chr14:35433187	C/T	cg16230307	chr14:35515116	FAM177A1	1.06	11.55	0.6	1.06e-24	Psoriasis;
SARC	cis	rs2276314	0.857	rs7237599	chr18:33639396	T/C	cg05985134	chr18:33552581	C18orf21	0.7	7.58	0.44	8.22e-13	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs7223966	1.000	rs7211213	chr17:61769456	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	6.86	0.41	6.1e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg03517284	chr6:25882590	NA	-0.46	-5.87	-0.36	1.53e-8	Intelligence (multi-trait analysis);
SARC	cis	rs6543140	0.572	rs17027173	chr2:103057043	G/A	cg09003973	chr2:102972529	NA	0.55	6.36	0.38	1.06e-9	Blood protein levels;
SARC	cis	rs7264396	0.563	rs6058296	chr20:34269225	G/T	cg01084648	chr20:34329383	RBM39	0.63	5.24	0.32	3.65e-7	Total cholesterol levels;
SARC	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg11644478	chr21:40555479	PSMG1	-0.89	-11.18	-0.59	1.69e-23	Cognitive function;
SARC	cis	rs2652822	0.686	rs4774476	chr15:63407390	A/G	cg02713581	chr15:63449717	RPS27L	-0.56	-6.97	-0.42	3.27e-11	Metabolic traits;
SARC	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg12463550	chr7:65579703	CRCP	0.71	5.37	0.33	1.9e-7	Diabetic kidney disease;
SARC	cis	rs1707322	1.000	rs1768801	chr1:46549137	C/G	cg03146154	chr1:46216737	IPP	-0.48	-5.66	-0.35	4.54e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs72945132	0.825	rs7950280	chr11:70213455	G/T	cg05964544	chr11:70165517	PPFIA1	-0.57	-5.72	-0.35	3.18e-8	Coronary artery disease;
SARC	cis	rs11785400	1.000	rs10099892	chr8:143734608	C/T	cg24634471	chr8:143751801	JRK	0.68	9.06	0.51	5.49e-17	Schizophrenia;
SARC	cis	rs703842	1.000	rs10877019	chr12:58172929	A/G	cg00677455	chr12:58241039	CTDSP2	-0.51	-6.41	-0.39	8.03e-10	Multiple sclerosis;
SARC	cis	rs778371	0.649	rs13021823	chr2:233686862	A/G	cg16596103	chr2:233749413	NGEF	0.32	4.84	0.3	2.38e-6	Schizophrenia;
SARC	cis	rs7772486	0.790	rs1062067	chr6:146207563	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.67	0.4	1.79e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7833790	0.660	rs10091077	chr8:82705464	A/G	cg17211192	chr8:82754475	SNX16	-0.47	-5.57	-0.34	6.86e-8	Diastolic blood pressure;
SARC	cis	rs9393692	0.905	rs7747133	chr6:26293470	C/T	cg13736514	chr6:26305472	NA	-0.64	-9.08	-0.51	4.91e-17	Educational attainment;
SARC	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg00149659	chr3:10157352	C3orf10	0.69	6.9	0.41	4.76e-11	Alzheimer's disease;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg22379574	chr13:45915321	TPT1;LOC100190939	0.57	7.18	0.43	9.51e-12	Breast cancer;
SARC	cis	rs11997175	0.626	rs12155927	chr8:33789851	A/G	ch.8.33884649F	chr8:33765107	NA	0.42	5.45	0.34	1.25e-7	Body mass index;
SARC	cis	rs7223966	1.000	rs9901507	chr17:61765524	G/A	cg26338869	chr17:61819248	STRADA	0.44	5.14	0.32	5.82e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1983170	1.000	rs12563578	chr1:91993702	T/C	cg25838465	chr1:92012736	NA	0.53	5.72	0.35	3.21e-8	Eosinophil percentage of white cells;
SARC	cis	rs228437	1.000	rs228436	chr6:134896913	A/T	cg24504307	chr6:134963096	NA	0.48	5.57	0.34	7.12e-8	Melanoma;
SARC	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg03433033	chr1:76189801	ACADM	-0.5	-7.03	-0.42	2.27e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	trans	rs7937682	0.855	rs527078	chr11:111479713	T/C	cg18187862	chr3:45730750	SACM1L	0.54	6.78	0.41	9.9e-11	Primary sclerosing cholangitis;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg15727783	chr10:105727545	SLK	-0.58	-6.52	-0.39	4.2e-10	Brain volume in infants (cerebrospinal fluid);
SARC	trans	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg23814129	chr1:36930061	MRPS15	-0.68	-6.37	-0.39	9.95e-10	Cutaneous psoriasis;
SARC	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg22857025	chr5:266934	NA	-1.06	-11.8	-0.61	1.74e-25	Breast cancer;
SARC	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg11890956	chr21:40555474	PSMG1	1.14	16.46	0.73	6.79e-41	Cognitive function;
SARC	trans	rs7615952	0.932	rs13321217	chr3:125631771	G/A	cg07211511	chr3:129823064	LOC729375	-0.92	-10.59	-0.57	1.19e-21	Blood pressure (smoking interaction);
SARC	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg05896524	chr21:47604654	C21orf56	0.41	4.84	0.3	2.4e-6	Testicular germ cell tumor;
SARC	cis	rs9788721	0.836	rs17483686	chr15:78733390	A/T	cg18825076	chr15:78729989	IREB2	-0.52	-6.45	-0.39	6.47e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs372883	0.638	rs117213	chr21:30720536	G/A	cg24692254	chr21:30365293	RNF160	-0.62	-7.81	-0.46	1.97e-13	Pancreatic cancer;
SARC	cis	rs15676	0.783	rs10988121	chr9:131564926	A/T	cg00228799	chr9:131580591	ENDOG	-0.56	-7.09	-0.42	1.59e-11	Blood metabolite levels;
SARC	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg22903657	chr4:1355424	KIAA1530	-0.36	-4.91	-0.31	1.69e-6	Obesity-related traits;
SARC	cis	rs1144333	0.655	rs76735776	chr1:76455211	A/G	cg03433033	chr1:76189801	ACADM	0.57	4.74	0.3	3.65e-6	Attention function in attention deficit hyperactive disorder;
SARC	trans	rs10771431	0.597	rs10771413	chr12:9354413	C/T	cg27600084	chr12:12264075	NA	0.52	6.87	0.41	5.96e-11	Breast size;
SARC	cis	rs9911578	0.757	rs4793954	chr17:56629527	G/T	cg05425664	chr17:57184151	TRIM37	0.64	7.13	0.42	1.23e-11	Intelligence (multi-trait analysis);
SARC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	20.42	0.8	8.2e-54	Prudent dietary pattern;
SARC	trans	rs17685	0.753	rs1104879	chr7:75685568	C/T	cg19862616	chr7:65841803	NCRNA00174	0.59	7.32	0.43	4.05e-12	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs55728055	0.661	rs7293143	chr22:32013365	A/G	cg01338084	chr22:32026380	PISD	-0.98	-5.82	-0.36	1.9e-8	Age-related hearing impairment;
SARC	cis	rs918629	0.716	rs3777178	chr5:95273915	G/C	cg16656078	chr5:95278638	ELL2	-0.62	-7.48	-0.44	1.52e-12	IgG glycosylation;
SARC	cis	rs9457247	1.000	rs429083	chr6:167383972	T/C	cg23791538	chr6:167370224	RNASET2	-0.63	-8.73	-0.5	4.98e-16	Crohn's disease;
SARC	cis	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg05623727	chr3:50126028	RBM5	-0.33	-4.98	-0.31	1.26e-6	Intelligence (multi-trait analysis);
SARC	cis	rs6901004	0.712	rs367734	chr6:111512378	C/G	cg15721981	chr6:111408429	SLC16A10	-0.44	-5.35	-0.33	2.08e-7	Blood metabolite levels;
SARC	cis	rs6570726	0.791	rs408443	chr6:145874643	T/C	cg05347473	chr6:146136440	FBXO30	0.54	7.43	0.44	2.05e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs79349575	0.783	rs4793996	chr17:47019597	T/C	cg16584676	chr17:46985605	UBE2Z	0.55	6.66	0.4	1.91e-10	Type 2 diabetes;
SARC	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg22535103	chr8:58192502	C8orf71	0.74	7.93	0.46	9.23e-14	Developmental language disorder (linguistic errors);
SARC	cis	rs412050	0.547	rs79111189	chr22:22164597	T/G	cg17089214	chr22:22089827	YPEL1	0.8	6.96	0.41	3.45e-11	Attention deficit hyperactivity disorder;
SARC	cis	rs2070488	0.965	rs1065800	chr3:38566480	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.84	-13.42	-0.66	8.55e-31	Electrocardiographic conduction measures;
SARC	cis	rs2498796	0.727	rs7155192	chr14:105211426	G/A	cg07523784	chr14:105186699	NA	-0.37	-5.26	-0.33	3.25e-7	Endometrial cancer;Endometrial endometrioid carcinoma;
SARC	cis	rs554111	0.634	rs4654875	chr1:21165176	A/G	cg04902671	chr1:21058625	SH2D5	0.44	5.35	0.33	2.12e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg02574844	chr11:5959923	NA	-0.37	-4.99	-0.31	1.17e-6	DNA methylation (variation);
SARC	trans	rs11165623	0.564	rs6593611	chr1:97001996	T/C	cg10631902	chr5:14652156	NA	-0.42	-6.36	-0.38	1.04e-9	Hip circumference;Waist circumference;
SARC	cis	rs7660520	0.524	rs4862101	chr4:183733177	T/C	cg04181038	chr4:183730758	NA	0.57	5.93	0.36	1.1e-8	Pediatric autoimmune diseases;
SARC	cis	rs155076	1.000	rs261406	chr13:21855854	G/A	cg25811766	chr13:21894605	NA	-0.52	-5.53	-0.34	8.74e-8	White matter hyperintensity burden;
SARC	cis	rs1270639	0.778	rs2906933	chr7:157450749	T/A	cg13357408	chr7:157437802	PTPRN2	0.49	4.98	0.31	1.25e-6	Colorectal cancer;
SARC	cis	rs2658782	0.724	rs1869914	chr11:93112492	C/G	cg15737290	chr11:93063684	CCDC67	0.66	7.17	0.43	9.65e-12	Pulmonary function decline;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg27092995	chr16:88826522	FAM38A	-0.73	-6.26	-0.38	1.79e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.59	0.34	6.22e-8	Bipolar disorder;
SARC	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg04166393	chr7:2884313	GNA12	0.5	5.52	0.34	9.05e-8	Height;
SARC	cis	rs2070488	1.000	rs3792527	chr3:38493212	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	14.64	0.69	7.76e-35	Electrocardiographic conduction measures;
SARC	cis	rs8067545	0.750	rs4925072	chr17:19956899	C/T	cg13482628	chr17:19912719	NA	-0.54	-7.36	-0.43	3.04e-12	Schizophrenia;
SARC	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg04166393	chr7:2884313	GNA12	0.49	5.71	0.35	3.36e-8	Height;
SARC	cis	rs526231	0.543	rs8488	chr5:102538752	T/C	cg23492399	chr5:102201601	PAM	-0.52	-5.55	-0.34	7.57e-8	Primary biliary cholangitis;
SARC	cis	rs1448094	0.512	rs10779216	chr12:86240315	A/G	cg02569458	chr12:86230093	RASSF9	-0.38	-5.34	-0.33	2.15e-7	Major depressive disorder;
SARC	cis	rs9303401	0.614	rs35245220	chr17:56510305	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.99	9.99	0.55	8.42e-20	Cognitive test performance;
SARC	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg09808176	chr11:108092413	ATM;NPAT	0.53	6.71	0.4	1.46e-10	Brain structure;
SARC	cis	rs9660992	0.710	rs1172138	chr1:205246019	G/A	cg21545522	chr1:205238299	TMCC2	0.48	6.58	0.4	3.16e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg06634786	chr22:41940651	POLR3H	-0.46	-5.82	-0.36	1.96e-8	Vitiligo;
SARC	cis	rs11583043	0.708	rs36023027	chr1:101575205	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.45	4.81	0.3	2.69e-6	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs78487399	0.731	rs6747229	chr2:43712610	T/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.68	-5.42	-0.33	1.5e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs6582630	0.502	rs11181230	chr12:38300085	A/G	cg26384229	chr12:38710491	ALG10B	0.87	12.74	0.64	1.45e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs10504073	0.647	rs4873317	chr8:50021111	C/T	cg00325661	chr8:49890786	NA	0.54	7.39	0.44	2.67e-12	Blood metabolite ratios;
SARC	cis	rs941408	0.515	rs56000942	chr19:2774104	G/C	cg06609049	chr19:2785107	THOP1	0.97	13.11	0.65	8.52e-30	Total cholesterol levels;
SARC	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.45	-5.55	-0.34	7.7e-8	Gut microbiome composition (summer);
SARC	cis	rs3796352	1.000	rs13092352	chr3:52969697	C/T	cg15956490	chr3:53032818	SFMBT1	0.79	5.18	0.32	4.85e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs36051895	0.659	rs59668095	chr9:5043688	C/G	cg02405213	chr9:5042618	JAK2	-0.52	-5.79	-0.35	2.21e-8	Pediatric autoimmune diseases;
SARC	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg14664628	chr15:75095509	CSK	-0.52	-6.48	-0.39	5.56e-10	Breast cancer;
SARC	cis	rs708547	0.874	rs1718837	chr4:57871203	A/G	cg14719990	chr4:57843890	C4orf14;POLR2B	0.42	4.79	0.3	2.96e-6	Response to bleomycin (chromatid breaks);
SARC	cis	rs6918586	0.658	rs198813	chr6:26128226	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.44	-5.53	-0.34	8.47e-8	Schizophrenia;
SARC	cis	rs6840360	0.593	rs11723227	chr4:152689717	G/A	cg22705602	chr4:152727874	NA	-0.5	-8.81	-0.5	2.85e-16	Intelligence (multi-trait analysis);
SARC	cis	rs4808199	0.947	rs1465695	chr19:19588546	A/C	cg03709012	chr19:19516395	GATAD2A	1.19	13.19	0.65	4.85e-30	Nonalcoholic fatty liver disease;
SARC	cis	rs739401	0.611	rs3782069	chr11:3033275	G/A	cg05729581	chr11:3078854	CARS	-0.46	-5.78	-0.35	2.43e-8	Longevity;
SARC	cis	rs1348850	0.793	rs6736390	chr2:178480314	T/C	cg23306229	chr2:178417860	TTC30B	0.49	5.24	0.32	3.6e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs16976116	0.806	rs28466870	chr15:55495113	C/T	cg17854078	chr15:55489399	RSL24D1	0.66	6.53	0.39	4.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7474896	0.609	rs1830612	chr10:37999883	A/G	cg25427524	chr10:38739819	LOC399744	-0.46	-5.42	-0.33	1.47e-7	Obesity (extreme);
SARC	cis	rs1008375	1.000	rs6811887	chr4:17640858	C/T	cg16339924	chr4:17578868	LAP3	0.67	8.91	0.5	1.47e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg26338869	chr17:61819248	STRADA	0.78	10.36	0.56	6.12e-21	Prudent dietary pattern;
SARC	cis	rs4808199	0.649	rs12983940	chr19:19516431	G/A	cg03709012	chr19:19516395	GATAD2A	1.17	12.99	0.65	2.14e-29	Nonalcoholic fatty liver disease;
SARC	cis	rs10911363	0.592	rs12117885	chr1:183494214	C/T	cg09173681	chr1:183549694	NCF2	-0.32	-5.35	-0.33	2.11e-7	Systemic lupus erythematosus;
SARC	trans	rs9329221	0.935	rs3750311	chr8:10283602	C/A	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.55	-0.49	1.66e-15	Neuroticism;
SARC	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.6	-6.31	-0.38	1.42e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs2576037	0.521	rs4986227	chr18:44595031	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.55	6.96	0.41	3.44e-11	Personality dimensions;
SARC	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg05332525	chr7:65337924	VKORC1L1	-0.43	-4.86	-0.3	2.19e-6	Aortic root size;
SARC	cis	rs10463554	0.892	rs66759661	chr5:102261598	A/T	cg23492399	chr5:102201601	PAM	-0.47	-5.62	-0.35	5.52e-8	Parkinson's disease;
SARC	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg13902645	chr11:5959945	NA	-0.47	-6.24	-0.38	2e-9	DNA methylation (variation);
SARC	cis	rs4803468	0.935	rs12602	chr19:41889748	T/C	cg08477640	chr19:41863820	B9D2	0.45	5.82	0.36	1.98e-8	Height;
SARC	cis	rs763121	0.853	rs5750677	chr22:39147715	C/T	cg06022373	chr22:39101656	GTPBP1	0.87	11.14	0.59	2.16e-23	Menopause (age at onset);
SARC	cis	rs10782582	0.586	rs5745383	chr1:76288590	G/C	cg03433033	chr1:76189801	ACADM	-0.39	-4.98	-0.31	1.24e-6	Daytime sleep phenotypes;
SARC	cis	rs2180341	1.000	rs6569479	chr6:127606588	A/G	cg27446573	chr6:127587934	RNF146	0.99	13.56	0.66	2.82e-31	Breast cancer;
SARC	cis	rs4481887	0.830	rs10888341	chr1:248441995	T/C	cg00666640	chr1:248458726	OR2T12	0.34	5.58	0.34	6.72e-8	Common traits (Other);
SARC	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg11843238	chr5:131593191	PDLIM4	0.41	5.57	0.34	6.94e-8	Acylcarnitine levels;
SARC	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg11987759	chr7:65425863	GUSB	-0.48	-6.54	-0.39	3.9e-10	Aortic root size;
SARC	cis	rs1865760	0.516	rs9358903	chr6:26061949	A/C	cg16482183	chr6:26056742	HIST1H1C	0.47	6.06	0.37	5.51e-9	Height;
SARC	cis	rs7582180	0.629	rs11686880	chr2:100956229	C/T	cg14675211	chr2:100938903	LONRF2	0.48	7.13	0.42	1.23e-11	Intelligence (multi-trait analysis);
SARC	cis	rs1348850	0.793	rs6736390	chr2:178480314	T/C	cg22681709	chr2:178499509	PDE11A	-0.42	-5.52	-0.34	8.94e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7560272	0.723	rs7609249	chr2:73813820	G/A	cg20560298	chr2:73613845	ALMS1	-0.52	-7.13	-0.42	1.25e-11	Schizophrenia;
SARC	cis	rs3760047	0.609	rs2541639	chr16:205035	C/T	cg08400316	chr16:204221	HBZ	0.46	4.91	0.31	1.73e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg11764359	chr7:65958608	NA	-0.74	-9.0	-0.51	8.38e-17	Aortic root size;
SARC	cis	rs9916302	0.904	rs2168785	chr17:37407135	C/T	cg15445000	chr17:37608096	MED1	0.45	5.47	0.34	1.15e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs11578119	0.933	rs12124515	chr1:170452501	C/T	cg09767346	chr1:170501363	GORAB	0.44	5.15	0.32	5.49e-7	Male-pattern baldness;
SARC	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg18876405	chr7:65276391	NA	0.49	6.04	0.37	6e-9	Aortic root size;
SARC	cis	rs67460515	0.563	rs16831886	chr3:160799830	A/C	cg04691961	chr3:161091175	C3orf57	-0.43	-4.89	-0.31	1.87e-6	Parkinson's disease;
SARC	cis	rs589448	0.535	rs12423794	chr12:69713018	G/A	cg14784868	chr12:69753453	YEATS4	0.5	6.52	0.39	4.31e-10	Cerebrospinal fluid biomarker levels;
SARC	cis	rs3768617	0.811	rs12043805	chr1:183008150	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	8.21	0.47	1.53e-14	Fuchs's corneal dystrophy;
SARC	cis	rs7481584	0.624	rs1077335	chr11:3030524	A/G	cg25174290	chr11:3078921	CARS	-0.58	-8.01	-0.46	5.33e-14	Calcium levels;
SARC	cis	rs12893668	0.703	rs35498576	chr14:104025893	T/C	cg24130564	chr14:104152367	KLC1	-0.44	-4.75	-0.3	3.49e-6	Reticulocyte count;
SARC	cis	rs9902453	1.000	rs4074170	chr17:28381141	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.52	-6.87	-0.41	5.67e-11	Coffee consumption (cups per day);
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg07177569	chr2:187454747	ITGAV	0.49	6.34	0.38	1.18e-9	Schizophrenia;
SARC	cis	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg24110177	chr3:50126178	RBM5	-0.56	-7.34	-0.43	3.62e-12	Intelligence (multi-trait analysis);
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg11159519	chr1:210857380	KCNH1	0.41	6.31	0.38	1.36e-9	Blood pressure;
SARC	cis	rs79149102	0.579	rs6495137	chr15:75295541	G/A	cg00629941	chr15:75287862	SCAMP5	-0.64	-5.11	-0.32	6.76e-7	Lung cancer;
SARC	cis	rs1865760	0.566	rs9295688	chr6:26084217	G/A	cg10373733	chr6:25993375	NA	0.45	5.43	0.34	1.4e-7	Height;
SARC	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	5.77	0.35	2.53e-8	Bipolar disorder;
SARC	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg03264133	chr6:25882463	NA	-0.61	-8.11	-0.47	2.91e-14	Intelligence (multi-trait analysis);
SARC	cis	rs13161895	1.000	rs3797763	chr5:179439516	C/T	cg02702477	chr5:179499311	RNF130	-0.65	-6.46	-0.39	5.92e-10	LDL cholesterol;
SARC	cis	rs7647973	0.925	rs4384984	chr3:49289878	T/G	cg07636037	chr3:49044803	WDR6	0.78	9.19	0.52	2.24e-17	Menarche (age at onset);
SARC	cis	rs4727027	0.933	rs34578816	chr7:148847606	G/A	cg23583168	chr7:148888333	NA	-0.74	-11.43	-0.6	2.63e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs10483282	1.000	rs10483282	chr14:24253696	T/G	cg02879798	chr14:24800305	ADCY4	-0.31	-4.76	-0.3	3.34e-6	Alcohol dependence;
SARC	cis	rs611744	0.647	rs1457211	chr8:109261318	C/T	cg21045802	chr8:109455806	TTC35	-0.63	-8.18	-0.47	1.87e-14	Dupuytren's disease;
SARC	cis	rs7666738	0.830	rs732299	chr4:98995389	C/T	cg05340658	chr4:99064831	C4orf37	0.64	8.6	0.49	1.18e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs12474201	0.775	rs7584870	chr2:46973400	A/T	cg06386533	chr2:46925753	SOCS5	0.78	12.05	0.62	2.63e-26	Height;
SARC	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg13175981	chr1:150552382	MCL1	-0.54	-6.82	-0.41	7.54e-11	Tonsillectomy;
SARC	cis	rs11697848	1.000	rs78873470	chr20:48556099	C/A	cg17849948	chr20:48532315	SPATA2	0.87	5.2	0.32	4.3e-7	Systemic lupus erythematosus;
SARC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.0	12.26	0.63	5.27e-27	Platelet count;
SARC	cis	rs36051895	0.632	rs11791281	chr9:5172540	G/A	cg02405213	chr9:5042618	JAK2	-0.44	-5.31	-0.33	2.53e-7	Pediatric autoimmune diseases;
SARC	cis	rs10789491	1.000	rs4660956	chr1:47158486	A/G	cg15501359	chr1:47185051	KIAA0494	0.71	7.04	0.42	2.09e-11	Response to hepatitis C treatment;
SARC	cis	rs2624839	0.704	rs13067082	chr3:50221715	A/G	cg24110177	chr3:50126178	RBM5	0.56	7.04	0.42	2.11e-11	Intelligence (multi-trait analysis);
SARC	cis	rs10979	1.000	rs9484767	chr6:143887912	C/A	cg25407410	chr6:143891975	LOC285740	-0.62	-8.39	-0.48	4.84e-15	Hypospadias;
SARC	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg25072359	chr17:41440525	NA	0.53	6.65	0.4	2.05e-10	Menopause (age at onset);
SARC	cis	rs78456975	1.000	rs4073861	chr2:1563611	G/A	cg01028140	chr2:1542097	TPO	-0.48	-4.94	-0.31	1.53e-6	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs9868809	0.656	rs73078362	chr3:48703917	G/C	cg07636037	chr3:49044803	WDR6	-0.91	-6.74	-0.4	1.25e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs11098499	0.909	rs28884220	chr4:120307211	A/G	cg09160332	chr4:120329925	NA	-0.34	-4.81	-0.3	2.75e-6	Corneal astigmatism;
SARC	cis	rs1707322	0.890	rs2297883	chr1:46511487	G/C	cg03146154	chr1:46216737	IPP	-0.47	-5.65	-0.35	4.59e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs793571	0.774	rs10851640	chr15:59137870	T/C	cg05156742	chr15:59063176	FAM63B	-0.51	-5.23	-0.32	3.83e-7	Schizophrenia;
SARC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.54	6.15	0.37	3.35e-9	Prudent dietary pattern;
SARC	cis	rs4820539	0.934	rs3788351	chr22:23469181	T/C	cg14186256	chr22:23484241	RTDR1	0.88	13.77	0.67	5.65e-32	Bone mineral density;
SARC	cis	rs17253792	0.822	rs10142497	chr14:56047948	C/T	cg01858014	chr14:56050164	KTN1	0.72	5.45	0.34	1.27e-7	Putamen volume;
SARC	cis	rs7772486	0.686	rs9390348	chr6:146044748	C/T	cg23711669	chr6:146136114	FBXO30	-0.8	-12.65	-0.64	2.79e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7726839	0.561	rs4957049	chr5:579080	C/A	cg09021430	chr5:549028	NA	-0.48	-6.35	-0.38	1.12e-9	Obesity-related traits;
SARC	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.42	-6.42	-0.39	7.71e-10	Total body bone mineral density;
SARC	cis	rs999943	0.846	rs9366826	chr6:33619184	C/G	cg14003231	chr6:33640908	ITPR3	0.52	9.19	0.52	2.27e-17	Obesity (extreme);
SARC	cis	rs1348850	0.567	rs2222711	chr2:178534110	G/T	cg22681709	chr2:178499509	PDE11A	-0.36	-5.08	-0.32	7.89e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7264396	0.513	rs2425092	chr20:34306815	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	5.69	0.35	3.71e-8	Total cholesterol levels;
SARC	trans	rs6076960	0.684	rs6054059	chr20:6262472	G/T	cg21095983	chr6:86352623	SYNCRIP	0.45	6.59	0.4	2.95e-10	Smooth-surface caries;
SARC	trans	rs2929451	0.566	rs17658270	chr8:9153619	C/G	cg15556689	chr8:8085844	FLJ10661	0.51	6.48	0.39	5.36e-10	Nose size;
SARC	cis	rs8014204	0.762	rs2359237	chr14:75245002	G/A	cg06637938	chr14:75390232	RPS6KL1	0.57	8.04	0.47	4.41e-14	Caffeine consumption;
SARC	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.76	9.64	0.53	9.91e-19	Height;
SARC	cis	rs425277	1.000	rs12401379	chr1:2058580	G/C	cg21442419	chr1:2182373	SKI	-0.48	-5.87	-0.36	1.5e-8	Height;
SARC	cis	rs9902453	0.765	rs2729436	chr17:28120670	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.19	-0.43	8.87e-12	Coffee consumption (cups per day);
SARC	cis	rs6690583	0.623	rs12030730	chr1:85454109	C/G	cg22153463	chr1:85462885	MCOLN2	0.69	6.65	0.4	2.09e-10	Serum sulfate level;
SARC	cis	rs2916247	0.954	rs6988521	chr8:93167504	A/G	cg10183463	chr8:93005414	RUNX1T1	0.46	4.94	0.31	1.47e-6	Intelligence (multi-trait analysis);
SARC	cis	rs6546550	0.933	rs57278310	chr2:70093647	T/C	cg02498382	chr2:70120550	SNRNP27	-0.36	-6.03	-0.37	6.25e-9	Prevalent atrial fibrillation;
SARC	cis	rs600231	0.542	rs11227198	chr11:65237974	G/A	cg17120908	chr11:65337727	SSSCA1	-0.45	-4.99	-0.31	1.17e-6	Bone mineral density;
SARC	cis	rs12995491	0.731	rs12992162	chr2:88508773	G/C	cg04511125	chr2:88470314	THNSL2	-0.38	-5.62	-0.35	5.49e-8	Response to metformin (IC50);
SARC	cis	rs7666738	0.830	rs60994860	chr4:99046753	G/A	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg07701084	chr6:150067640	NUP43	0.41	5.31	0.33	2.58e-7	Lung cancer;
SARC	cis	rs2997447	0.761	rs17184891	chr1:26447557	A/T	cg19633962	chr1:26362018	EXTL1	-0.56	-5.06	-0.31	8.55e-7	QRS complex (12-leadsum);
SARC	cis	rs1153858	1.000	rs28679834	chr15:45616206	C/T	cg21132104	chr15:45694354	SPATA5L1	0.81	11.23	0.59	1.09e-23	Homoarginine levels;
SARC	cis	rs7766436	0.885	rs7742025	chr6:22575798	A/T	cg13666174	chr6:22585274	NA	-0.56	-6.76	-0.4	1.11e-10	Coronary artery disease;
SARC	cis	rs3126085	0.935	rs12401851	chr1:152259022	T/C	cg03465714	chr1:152285911	FLG	0.48	5.67	0.35	4.16e-8	Atopic dermatitis;
SARC	cis	rs8070128	0.637	rs4925133	chr17:17884801	A/G	cg23370820	chr17:17987590	NA	-0.26	-4.86	-0.3	2.16e-6	Total body bone mineral density;
SARC	cis	rs3126085	0.935	rs7533529	chr1:152176871	T/C	cg03465714	chr1:152285911	FLG	-0.47	-5.59	-0.34	6.31e-8	Atopic dermatitis;
SARC	cis	rs6088813	1.000	rs4911496	chr20:33972053	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.48	5.63	0.35	5.17e-8	Height;
SARC	cis	rs7726839	0.578	rs112516582	chr5:584319	G/A	cg16447950	chr5:562315	NA	-0.51	-7.3	-0.43	4.47e-12	Obesity-related traits;
SARC	cis	rs9911578	0.935	rs7216698	chr17:57007495	G/A	cg05425664	chr17:57184151	TRIM37	-0.57	-6.89	-0.41	5.26e-11	Intelligence (multi-trait analysis);
SARC	cis	rs6582630	0.563	rs923281	chr12:38590241	G/A	cg26384229	chr12:38710491	ALG10B	-0.61	-7.7	-0.45	3.75e-13	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs3087591	0.960	rs2905869	chr17:29519016	C/A	cg24425628	chr17:29625626	OMG;NF1	0.47	5.79	0.35	2.26e-8	Hip circumference;
SARC	cis	rs16976116	0.901	rs1061873	chr15:55496756	T/C	cg11288833	chr15:55489084	RSL24D1	0.63	6.13	0.37	3.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs208520	0.690	rs2126120	chr6:66742754	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	13.79	0.67	5.04e-32	Exhaled nitric oxide output;
SARC	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg24060327	chr5:131705240	SLC22A5	0.71	8.52	0.49	1.96e-15	Breast cancer;
SARC	cis	rs10992471	0.580	rs1535756	chr9:95202032	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.26	-0.33	3.34e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs35110281	0.693	rs2251253	chr21:45092257	T/A	cg21573476	chr21:45109991	RRP1B	-0.59	-8.58	-0.49	1.31e-15	Mean corpuscular volume;
SARC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.79	10.36	0.56	6.36e-21	Prudent dietary pattern;
SARC	cis	rs7666738	0.830	rs10031292	chr4:99056877	A/G	cg05340658	chr4:99064831	C4orf37	0.65	8.73	0.5	5.02e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg11987759	chr7:65425863	GUSB	0.57	7.46	0.44	1.68e-12	Aortic root size;
SARC	cis	rs10791323	0.575	rs4489760	chr11:133732265	A/T	cg15485101	chr11:133734466	NA	0.3	5.02	0.31	1.03e-6	Childhood ear infection;
SARC	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg21724239	chr8:58056113	NA	0.58	6.24	0.38	2.03e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7659604	0.728	rs6852923	chr4:122688324	G/A	cg19671926	chr4:122722719	EXOSC9	-0.48	-5.57	-0.34	6.96e-8	Type 2 diabetes;
SARC	cis	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg12463550	chr7:65579703	CRCP	0.69	5.23	0.32	3.73e-7	Diabetic kidney disease;
SARC	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg09699651	chr6:150184138	LRP11	0.51	6.56	0.39	3.51e-10	Testicular germ cell tumor;
SARC	cis	rs67311347	0.544	rs7644643	chr3:40350209	C/T	cg24209194	chr3:40518798	ZNF619	-0.46	-6.19	-0.38	2.65e-9	Renal cell carcinoma;
SARC	cis	rs5753618	0.561	rs2283879	chr22:31638448	G/A	cg00478049	chr22:31556069	RNF185	0.45	4.93	0.31	1.56e-6	Colorectal cancer;
SARC	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg03433033	chr1:76189801	ACADM	0.55	7.71	0.45	3.52e-13	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7937682	0.883	rs1784776	chr11:111472392	C/T	cg22437258	chr11:111473054	SIK2	0.75	10.37	0.56	5.96e-21	Primary sclerosing cholangitis;
SARC	cis	rs950169	0.723	rs17589320	chr15:84919996	C/A	cg17507749	chr15:85114479	UBE2QP1	0.8	9.7	0.54	6.72e-19	Schizophrenia;
SARC	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg23958373	chr8:599963	NA	0.74	6.18	0.38	2.91e-9	IgG glycosylation;
SARC	cis	rs722599	0.715	rs12147629	chr14:75307588	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.42	-5.31	-0.33	2.51e-7	IgG glycosylation;
SARC	cis	rs950169	0.887	rs62029593	chr15:84955180	A/G	cg24253500	chr15:84953950	NA	0.36	5.21	0.32	4.19e-7	Schizophrenia;
SARC	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg20965017	chr5:231967	SDHA	-0.55	-5.26	-0.33	3.23e-7	Breast cancer;
SARC	cis	rs876084	0.505	rs11985197	chr8:121107553	G/A	cg06265175	chr8:121136014	COL14A1	0.58	7.56	0.44	9.46e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg05623727	chr3:50126028	RBM5	-0.34	-5.19	-0.32	4.56e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7553864	0.667	rs7512650	chr1:87609076	T/C	cg17420885	chr1:87600446	LOC339524	-0.35	-4.81	-0.3	2.66e-6	Smoking behavior;
SARC	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg13939156	chr17:80058883	NA	-0.44	-6.84	-0.41	6.73e-11	Life satisfaction;
SARC	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg16479474	chr6:28041457	NA	0.37	5.39	0.33	1.73e-7	Depression;
SARC	cis	rs2290159	0.800	rs73812836	chr3:12655149	T/G	cg23032965	chr3:12705835	RAF1	0.73	7.89	0.46	1.18e-13	Cholesterol, total;
SARC	cis	rs2011503	0.882	rs10407933	chr19:19364319	A/G	cg03709012	chr19:19516395	GATAD2A	0.59	5.38	0.33	1.83e-7	Bipolar disorder;
SARC	cis	rs123509	0.687	rs17238972	chr3:42819975	C/G	cg12982090	chr3:42733453	KBTBD5	-0.53	-5.95	-0.36	9.96e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7674212	0.540	rs2711897	chr4:104023567	C/T	cg16532752	chr4:104119610	CENPE	-0.47	-5.75	-0.35	2.82e-8	Type 2 diabetes;
SARC	cis	rs1355223	0.902	rs1773910	chr11:34741253	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.34	-0.33	2.21e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs9486719	1.000	rs12193732	chr6:96942609	G/A	cg06623918	chr6:96969491	KIAA0776	-0.74	-8.09	-0.47	3.37e-14	Migraine;Coronary artery disease;
SARC	cis	rs921968	0.612	rs832810	chr2:219322430	T/C	cg02176678	chr2:219576539	TTLL4	0.37	5.49	0.34	1.03e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs3857536	0.813	rs9354404	chr6:66948408	C/T	cg07460842	chr6:66804631	NA	-0.45	-5.19	-0.32	4.5e-7	Blood trace element (Cu levels);
SARC	cis	rs11097912	0.632	rs72876594	chr4:107207527	C/T	cg09646026	chr4:107269030	AIMP1	-0.43	-4.79	-0.3	2.96e-6	Airflow obstruction;
SARC	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.39	5.34	0.33	2.2e-7	Personality dimensions;
SARC	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg24531977	chr5:56204891	C5orf35	-0.57	-5.98	-0.36	8.41e-9	Initial pursuit acceleration;
SARC	cis	rs73198271	0.740	rs10105920	chr8:8648737	A/G	cg06636001	chr8:8085503	FLJ10661	0.45	4.96	0.31	1.33e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg06634786	chr22:41940651	POLR3H	0.54	6.62	0.4	2.4e-10	Vitiligo;
SARC	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg13206674	chr6:150067644	NUP43	0.42	5.04	0.31	9.48e-7	Lung cancer;
SARC	cis	rs2228479	0.850	rs62054638	chr16:89821131	G/C	cg00800038	chr16:89945340	TCF25	-0.74	-5.14	-0.32	5.75e-7	Skin colour saturation;
SARC	cis	rs2644899	0.793	rs2644916	chr19:41309211	A/G	cg24958765	chr19:41283667	RAB4B	-0.54	-6.15	-0.37	3.43e-9	Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs7223966	1.000	rs11657081	chr17:61792339	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.48	-5.15	-0.32	5.54e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg22496380	chr5:211416	CCDC127	-0.87	-9.01	-0.51	7.42e-17	Breast cancer;
SARC	cis	rs11122272	0.735	rs2250734	chr1:231485958	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-9.87	-0.54	1.98e-19	Hemoglobin concentration;
SARC	cis	rs501120	1.000	rs503859	chr10:44753560	G/C	cg09554077	chr10:44749378	NA	0.48	6.67	0.4	1.85e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg26338869	chr17:61819248	STRADA	0.79	10.65	0.57	7.85e-22	Prudent dietary pattern;
SARC	cis	rs17125944	0.505	rs2295827	chr14:53174981	C/T	cg00686598	chr14:53173677	PSMC6	1.36	9.17	0.52	2.51e-17	Alzheimer's disease (late onset);
SARC	cis	rs888194	1.000	rs888194	chr12:109986918	C/G	cg13986417	chr12:110012484	MVK;MMAB	-0.34	-5.12	-0.32	6.32e-7	Neuroticism;
SARC	cis	rs2072499	0.838	rs2758619	chr1:156162559	A/G	cg24450063	chr1:156163899	SLC25A44	1.18	21.59	0.82	1.66e-57	Testicular germ cell tumor;
SARC	cis	rs12311304	0.901	rs12579002	chr12:15409959	A/G	cg08258403	chr12:15378311	NA	0.43	6.76	0.4	1.11e-10	Behavioural disinhibition (generation interaction);
SARC	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg14983838	chr19:29218262	NA	0.78	10.41	0.56	4.39e-21	Methadone dose in opioid dependence;
SARC	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg03433033	chr1:76189801	ACADM	0.54	7.23	0.43	7e-12	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg05872129	chr22:39784769	NA	-0.41	-5.43	-0.34	1.4e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.95	-13.94	-0.67	1.6e-32	Gut microbiome composition (summer);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg04530666	chr10:3759553	NA	0.48	6.72	0.4	1.37e-10	Thyroid stimulating hormone;
SARC	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg00684032	chr4:1343700	KIAA1530	0.38	5.52	0.34	9.14e-8	Obesity-related traits;
SARC	cis	rs981844	0.714	rs6853529	chr4:154706267	C/T	cg14289246	chr4:154710475	SFRP2	0.63	6.98	0.42	2.99e-11	Response to statins (LDL cholesterol change);
SARC	cis	rs9398803	0.865	rs9388494	chr6:126776094	G/T	cg19875578	chr6:126661172	C6orf173	0.63	8.6	0.49	1.17e-15	Male-pattern baldness;
SARC	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg11987759	chr7:65425863	GUSB	0.49	6.39	0.39	8.71e-10	Aortic root size;
SARC	trans	rs1814175	0.616	rs10839388	chr11:49842603	C/T	cg15704280	chr7:45808275	SEPT13	-0.88	-13.98	-0.68	1.2e-32	Height;
SARC	cis	rs6963495	0.818	rs55691539	chr7:105165774	T/C	cg13798780	chr7:105162888	PUS7	0.6	5.56	0.34	7.22e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1003719	0.591	rs9636914	chr21:38589732	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.58	8.07	0.47	3.62e-14	Eye color traits;
SARC	cis	rs3126085	0.877	rs12133847	chr1:152170101	T/G	cg09127314	chr1:152161683	NA	0.43	4.87	0.3	2.05e-6	Atopic dermatitis;
SARC	cis	rs765787	0.530	rs28897155	chr15:45533974	T/C	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.51e-10	Uric acid levels;
SARC	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg17328964	chr8:145687451	CYHR1	0.47	6.32	0.38	1.35e-9	Age at first birth;
SARC	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg17971929	chr21:40555470	PSMG1	0.91	11.94	0.62	6.02e-26	Cognitive function;
SARC	cis	rs5758511	0.680	rs5758686	chr22:42655377	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.46	6.79	0.41	9.09e-11	Birth weight;
SARC	cis	rs9326248	0.581	rs6589590	chr11:116936081	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.66	8.32	0.48	7.31e-15	Blood protein levels;
SARC	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.49	5.59	0.34	6.49e-8	Renal function-related traits (BUN);
SARC	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg07701084	chr6:150067640	NUP43	0.45	5.67	0.35	4.26e-8	Lung cancer;
SARC	trans	rs1814175	0.935	rs1827017	chr11:49632592	C/G	cg03929089	chr4:120376271	NA	-0.85	-13.28	-0.66	2.49e-30	Height;
SARC	cis	rs7792596	1.000	rs4729126	chr7:94007064	C/T	cg20814616	chr7:94014465	NA	0.45	5.6	0.34	6.07e-8	Intelligence;
SARC	cis	rs2282802	0.685	rs2053055	chr5:139646776	C/T	cg26211634	chr5:139558579	C5orf32	0.41	5.28	0.33	2.98e-7	Intelligence (multi-trait analysis);
SARC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg06074448	chr4:187884817	NA	-0.38	-5.07	-0.32	8.06e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg11764359	chr7:65958608	NA	0.79	9.82	0.54	2.94e-19	Aortic root size;
SARC	cis	rs7824557	0.614	rs2060456	chr8:11213363	C/T	cg21775007	chr8:11205619	TDH	0.71	9.49	0.53	2.8e-18	Retinal vascular caliber;
SARC	trans	rs1814175	0.791	rs10219223	chr11:49791468	A/T	cg15704280	chr7:45808275	SEPT13	-0.97	-18.15	-0.77	1.71e-46	Height;
SARC	cis	rs34172651	0.917	rs35283675	chr16:24820393	A/G	cg00152838	chr16:24741724	TNRC6A	-0.48	-5.81	-0.36	2.03e-8	Intelligence (multi-trait analysis);
SARC	cis	rs77372450	0.636	rs10066998	chr5:157008510	G/A	cg23851860	chr5:157002805	ADAM19	0.51	4.91	0.31	1.72e-6	Bipolar disorder (body mass index interaction);
SARC	cis	rs3812049	0.784	rs6889311	chr5:127431285	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.89	9.68	0.54	7.83e-19	Lymphocyte counts;Red cell distribution width;
SARC	cis	rs7639513	0.545	rs55977822	chr3:12704438	C/A	cg23032965	chr3:12705835	RAF1	0.71	8.25	0.48	1.19e-14	Itch intensity from mosquito bite;
SARC	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs995000	0.931	rs1168086	chr1:63112389	A/G	cg06896770	chr1:63153194	DOCK7	-0.89	-13.41	-0.66	9.23e-31	Triglyceride levels;
SARC	cis	rs9436747	0.803	rs1751485	chr1:66020219	C/A	cg14976592	chr1:65886160	LEPROT;LEPR	-0.44	-5.06	-0.31	8.51e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs9790314	0.715	rs980976	chr3:160771668	T/G	cg03342759	chr3:160939853	NMD3	-0.42	-5.04	-0.31	9.13e-7	Morning vs. evening chronotype;
SARC	cis	rs3733585	0.648	rs67820465	chr4:9975873	A/G	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.88	-0.36	1.38e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs2153535	0.580	rs7453115	chr6:8447261	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.42	0.6	2.9e-24	Motion sickness;
SARC	cis	rs7712401	0.580	rs35902490	chr5:122323398	G/T	cg19412675	chr5:122181750	SNX24	-0.43	-5.43	-0.34	1.41e-7	Mean platelet volume;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg23064501	chr12:42680748	NA	-0.57	-7.44	-0.44	1.93e-12	Height;
SARC	cis	rs9814567	1.000	rs9829092	chr3:134229866	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-7.0	-0.42	2.75e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs6439153	0.933	rs7648877	chr3:128709980	T/C	cg25356066	chr3:128598488	ACAD9	0.46	5.42	0.33	1.46e-7	Pneumococcal bacteremia;
SARC	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg20607798	chr8:58055168	NA	0.49	4.75	0.3	3.49e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs13191362	0.938	rs35760705	chr6:163020637	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.55	5.29	0.33	2.77e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs35213789	0.562	rs2533426	chr7:69043872	G/A	cg10619644	chr7:69149951	AUTS2	-0.35	-4.93	-0.31	1.57e-6	Childhood ear infection;
SARC	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg06212747	chr3:49208901	KLHDC8B	0.64	8.51	0.49	2.17e-15	Parkinson's disease;
SARC	cis	rs2303759	0.666	rs66967196	chr19:49808894	G/A	cg22590775	chr19:49891494	CCDC155	0.46	5.17	0.32	5.14e-7	Multiple sclerosis;
SARC	cis	rs6502050	0.736	rs11658040	chr17:80059891	C/T	cg13939156	chr17:80058883	NA	0.42	6.73	0.4	1.28e-10	Life satisfaction;
SARC	cis	rs12681366	0.659	rs2450558	chr8:95410507	T/C	cg26464482	chr8:95565502	KIAA1429	-0.43	-5.27	-0.33	3.18e-7	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs12681288	0.550	rs4410933	chr8:959581	A/G	cg15309053	chr8:964076	NA	0.48	8.07	0.47	3.63e-14	Schizophrenia;
SARC	cis	rs11644362	0.966	rs12933348	chr16:12991081	C/T	cg06890432	chr16:12997467	SHISA9	-0.55	-7.26	-0.43	5.59e-12	Positive affect;Subjective well-being;
SARC	cis	rs854765	0.583	rs9908832	chr17:17871068	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.69	9.9	0.54	1.66e-19	Total body bone mineral density;
SARC	trans	rs1814175	0.817	rs28544182	chr11:50049577	G/T	cg03929089	chr4:120376271	NA	-0.87	-13.68	-0.67	1.14e-31	Height;
SARC	trans	rs2727020	0.724	rs4109837	chr11:49372051	A/T	cg15704280	chr7:45808275	SEPT13	-0.76	-10.02	-0.55	6.87e-20	Coronary artery disease;
SARC	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg06634786	chr22:41940651	POLR3H	0.49	6.09	0.37	4.68e-9	Vitiligo;
SARC	cis	rs2960422	0.546	rs6782178	chr3:12334555	C/T	cg04748988	chr3:12329223	PPARG	-0.37	-4.87	-0.3	2.05e-6	Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
SARC	cis	rs6714710	0.603	rs11690687	chr2:98461821	C/T	cg26665480	chr2:98280029	ACTR1B	0.51	6.93	0.41	4.1e-11	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs172166	0.637	rs1225595	chr6:28151340	A/T	cg26335602	chr6:28129616	ZNF389	0.42	5.07	0.32	8.06e-7	Cardiac Troponin-T levels;
SARC	trans	rs61931739	0.517	rs9668303	chr12:34366701	C/T	cg26384229	chr12:38710491	ALG10B	0.9	13.25	0.66	3.08e-30	Morning vs. evening chronotype;
SARC	cis	rs2439831	0.717	rs7165471	chr15:43644788	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.05	11.01	0.58	5.67e-23	Lung cancer in ever smokers;
SARC	cis	rs1865760	0.865	rs9393678	chr6:25945819	C/T	cg18357526	chr6:26021779	HIST1H4A	0.38	4.72	0.3	3.99e-6	Height;
SARC	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg10351095	chr21:47802916	PCNT	0.41	4.9	0.31	1.77e-6	Testicular germ cell tumor;
SARC	cis	rs7103648	1.000	rs11039225	chr11:47430599	G/A	cg10504702	chr11:47789108	FNBP4	0.58	7.58	0.44	8.01e-13	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg24101359	chr6:42928495	GNMT	0.43	5.92	0.36	1.14e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs3126085	0.935	rs12144058	chr1:152170216	C/T	cg09127314	chr1:152161683	NA	0.42	4.79	0.3	3.03e-6	Atopic dermatitis;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg23862389	chr6:143771429	ADAT2;PEX3	-0.49	-6.73	-0.4	1.3100000000000001e-10	Neuroticism;
SARC	cis	rs2832077	0.689	rs2832055	chr21:30132382	C/G	cg08807101	chr21:30365312	RNF160	0.51	5.22	0.32	3.99e-7	Cognitive test performance;
SARC	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.02	0.37	6.61e-9	Height;
SARC	cis	rs73198271	0.920	rs11781542	chr8:8617181	G/T	cg01851573	chr8:8652454	MFHAS1	0.43	5.64	0.35	4.93e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg18404041	chr3:52824283	ITIH1	-0.39	-5.8	-0.35	2.2e-8	Bipolar disorder;
SARC	cis	rs76917914	0.561	rs73492791	chr9:100833925	T/C	cg03040243	chr9:100819229	NANS	0.55	6.21	0.38	2.4e-9	Immature fraction of reticulocytes;
SARC	cis	rs910316	0.967	rs175479	chr14:75561871	A/C	cg08847533	chr14:75593920	NEK9	-0.87	-13.93	-0.67	1.67e-32	Height;
SARC	cis	rs7084402	0.967	rs1427196	chr10:60278573	C/T	cg07615347	chr10:60278583	BICC1	-0.6	-8.82	-0.5	2.78e-16	Refractive error;
SARC	cis	rs262150	1.000	rs262150	chr7:158777934	G/A	cg09640425	chr7:158790006	NA	-0.37	-4.84	-0.3	2.32e-6	Facial morphology (factor 20);
SARC	cis	rs8067545	0.641	rs2108978	chr17:19861458	C/T	cg04132472	chr17:19861366	AKAP10	0.38	4.99	0.31	1.19e-6	Schizophrenia;
SARC	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg02018176	chr4:1364513	KIAA1530	0.33	4.96	0.31	1.39e-6	Longevity;
SARC	cis	rs4243830	0.850	rs2274553	chr1:6586553	C/T	cg04093404	chr1:6614507	TAS1R1;NOL9	0.57	5.07	0.32	8.23e-7	Body mass index;
SARC	cis	rs62064224	0.593	rs916663	chr17:30835833	A/C	cg12855166	chr17:30846586	MYO1D	-0.38	-4.71	-0.3	4.17e-6	Schizophrenia;
SARC	cis	rs11098499	0.954	rs4345162	chr4:120312959	G/A	cg09307838	chr4:120376055	NA	0.91	12.88	0.65	4.9e-29	Corneal astigmatism;
SARC	cis	rs6964587	1.000	rs2282971	chr7:91584356	A/G	cg17063962	chr7:91808500	NA	0.87	12.75	0.64	1.37e-28	Breast cancer;
SARC	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg21724239	chr8:58056113	NA	0.6	6.37	0.38	1.03e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg18252515	chr7:66147081	NA	-1.34	-11.86	-0.61	1.09e-25	Diabetic kidney disease;
SARC	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg12463550	chr7:65579703	CRCP	-0.7	-5.31	-0.33	2.51e-7	Diabetic kidney disease;
SARC	cis	rs6539267	0.741	rs35816179	chr12:106693710	T/C	cg00173435	chr12:106696525	TCP11L2	0.83	9.82	0.54	2.84e-19	Tourette syndrome;
SARC	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg21226059	chr5:178986404	RUFY1	0.36	4.95	0.31	1.4e-6	Lung cancer;
SARC	cis	rs6430585	0.591	rs1374330	chr2:136420908	A/C	cg07169764	chr2:136633963	MCM6	0.84	10.14	0.55	3.05e-20	Corneal structure;
SARC	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg19671926	chr4:122722719	EXOSC9	-0.55	-6.03	-0.37	6.38e-9	Type 2 diabetes;
SARC	cis	rs4919087	0.748	rs701814	chr10:98975719	C/T	cg25902810	chr10:99078978	FRAT1	-0.51	-5.76	-0.35	2.64e-8	Monocyte count;
SARC	cis	rs986417	0.892	rs12101132	chr14:60789588	A/G	cg27398547	chr14:60952738	C14orf39	-1.06	-8.8	-0.5	3.23e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs2204008	0.543	rs2387018	chr12:38065638	C/T	cg26384229	chr12:38710491	ALG10B	0.89	13.3	0.66	2.05e-30	Bladder cancer;
SARC	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg02018176	chr4:1364513	KIAA1530	-0.35	-4.99	-0.31	1.19e-6	Obesity-related traits;
SARC	cis	rs3784262	0.869	rs4646628	chr15:58255282	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.38	-5.68	-0.35	3.91e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs6842047	0.611	rs12186257	chr4:187183498	G/C	cg23442198	chr4:187126114	CYP4V2	0.54	4.81	0.3	2.7e-6	Blood protein levels;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg08806468	chr10:31593433	NA	0.56	7.67	0.45	4.67e-13	Thyroid stimulating hormone;
SARC	cis	rs6089584	1.000	rs3787424	chr20:60559219	G/A	cg06108461	chr20:60628389	TAF4	-0.93	-12.23	-0.63	6.6e-27	Body mass index;
SARC	cis	rs9894429	0.738	rs8077038	chr17:79577127	T/G	cg18240062	chr17:79603768	NPLOC4	-0.87	-13.54	-0.66	3.34e-31	Eye color traits;
SARC	cis	rs73086581	1.000	rs73088416	chr20:3995276	A/G	cg02187196	chr20:3869020	PANK2	0.64	6.2	0.38	2.52e-9	Response to antidepressants in depression;
SARC	cis	rs6840360	0.571	rs11736116	chr4:152531816	A/G	cg22705602	chr4:152727874	NA	-0.42	-6.6	-0.4	2.71e-10	Intelligence (multi-trait analysis);
SARC	cis	rs9815354	0.951	rs17060961	chr3:41763711	A/G	cg03022575	chr3:42003672	ULK4	0.57	5.34	0.33	2.2e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs71007656	1	rs71007656	chr10:37970845	CGGCTG/C	cg00409905	chr10:38381863	ZNF37A	-0.52	-7.08	-0.42	1.72e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs854765	0.647	rs7406744	chr17:17981938	C/G	cg04398451	chr17:18023971	MYO15A	-0.54	-7.84	-0.46	1.62e-13	Total body bone mineral density;
SARC	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg04518342	chr5:131593106	PDLIM4	-0.43	-5.5	-0.34	1.02e-7	Breast cancer;
SARC	cis	rs8102137	1.000	rs62104473	chr19:30289779	C/T	cg27475126	chr19:30303651	CCNE1	-0.38	-5.24	-0.32	3.51e-7	Bladder cancer;
SARC	cis	rs6912958	0.559	rs107690	chr6:88069352	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.8	-13.1	-0.65	9.83e-30	Monocyte percentage of white cells;
SARC	trans	rs9532669	0.963	rs9532662	chr13:41500351	A/C	cg11469325	chr10:75012359	MRPS16	0.49	6.4	0.39	8.6e-10	Cervical cancer;
SARC	cis	rs1953600	0.870	rs2789695	chr10:81946840	C/T	cg00277334	chr10:82204260	NA	0.36	5.29	0.33	2.85e-7	Sarcoidosis;
SARC	cis	rs9814567	1.000	rs1357762	chr3:134264859	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.1	-0.42	1.49e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs734999	0.545	rs12752515	chr1:2564465	T/C	cg20673091	chr1:2541236	MMEL1	-0.33	-5.11	-0.32	6.56e-7	Ulcerative colitis;
SARC	cis	rs27434	0.583	rs40091	chr5:96154919	A/G	cg16492584	chr5:96139282	ERAP1	-0.56	-6.97	-0.42	3.17e-11	Ankylosing spondylitis;
SARC	cis	rs10875746	0.623	rs10875793	chr12:48697430	T/A	cg26205652	chr12:48591994	NA	0.46	4.92	0.31	1.61e-6	Longevity (90 years and older);
SARC	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg21782813	chr7:2030301	MAD1L1	0.32	4.92	0.31	1.65e-6	Schizophrenia;
SARC	cis	rs11997175	0.603	rs11778978	chr8:33804743	G/T	ch.8.33884649F	chr8:33765107	NA	0.44	5.61	0.34	5.7e-8	Body mass index;
SARC	cis	rs3733585	0.699	rs62294332	chr4:9959989	T/C	cg11266682	chr4:10021025	SLC2A9	-0.35	-6.03	-0.37	6.35e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg26335602	chr6:28129616	ZNF389	0.51	5.58	0.34	6.82e-8	Parkinson's disease;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg08004131	chr11:93212017	C11orf75	0.45	6.35	0.38	1.09e-9	Thyroid stimulating hormone;
SARC	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg09455208	chr3:40491958	NA	0.36	5.35	0.33	2.15e-7	Renal cell carcinoma;
SARC	trans	rs61931739	0.500	rs11053177	chr12:34412829	G/A	cg26384229	chr12:38710491	ALG10B	0.84	12.74	0.64	1.41e-28	Morning vs. evening chronotype;
SARC	cis	rs2425143	1.000	rs6060591	chr20:34351476	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-6.35	-0.38	1.14e-9	Blood protein levels;
SARC	cis	rs79149102	0.579	rs3812943	chr15:75312715	C/G	cg17294928	chr15:75287854	SCAMP5	-1.11	-9.1	-0.51	4.14e-17	Lung cancer;
SARC	cis	rs651907	0.557	rs11917569	chr3:101355063	G/C	cg12386194	chr3:101231763	SENP7	0.5	5.95	0.36	9.98e-9	Colorectal cancer;
SARC	cis	rs2290159	0.898	rs2290160	chr3:12633083	A/G	cg23032965	chr3:12705835	RAF1	0.71	7.69	0.45	4.24e-13	Cholesterol, total;
SARC	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg27170947	chr2:26402098	FAM59B	0.39	4.98	0.31	1.22e-6	Gut microbiome composition (summer);
SARC	cis	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg21775007	chr8:11205619	TDH	-0.47	-5.82	-0.36	1.95e-8	Triglycerides;
SARC	cis	rs7729447	0.776	rs4867472	chr5:32693566	C/T	cg16267343	chr5:32710456	NPR3	0.65	8.59	0.49	1.24e-15	Blood pressure;
SARC	cis	rs13082711	0.522	rs864241	chr3:27332674	T/C	cg02860705	chr3:27208620	NA	0.47	6.25	0.38	1.94e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs10982256	0.935	rs1555700	chr9:117256375	T/C	cg15903421	chr9:117267460	DFNB31	-0.37	-4.87	-0.3	2.07e-6	Bipolar disorder;
SARC	cis	rs17376456	0.877	rs2290937	chr5:93356515	A/T	cg21475434	chr5:93447410	FAM172A	0.85	7.52	0.44	1.15e-12	Diabetic retinopathy;
SARC	cis	rs1983891	0.955	rs4714480	chr6:41520891	T/C	cg15051332	chr6:41514432	FOXP4	0.57	6.19	0.38	2.64e-9	Prostate cancer;
SARC	cis	rs4742903	0.509	rs1507506	chr9:106956123	A/G	cg14250997	chr9:106856677	SMC2	0.39	4.87	0.3	2.03e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs2304069	0.545	rs6866616	chr5:149415401	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.61	7.08	0.42	1.71e-11	HIV-1 control;
SARC	cis	rs7216064	0.954	rs4790973	chr17:65951133	C/T	cg12091567	chr17:66097778	LOC651250	-0.72	-7.46	-0.44	1.65e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg03433033	chr1:76189801	ACADM	0.55	7.82	0.46	1.86e-13	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs854765	0.547	rs9912096	chr17:17896673	A/C	cg04398451	chr17:18023971	MYO15A	-0.45	-6.47	-0.39	5.65e-10	Total body bone mineral density;
SARC	cis	rs4718428	0.705	rs28648401	chr7:66367132	T/C	cg12165864	chr7:66369176	NA	-0.46	-5.16	-0.32	5.41e-7	Corneal structure;
SARC	cis	rs11122272	0.766	rs2808608	chr1:231543175	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-9.71	-0.54	6.4e-19	Hemoglobin concentration;
SARC	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg25072359	chr17:41440525	NA	0.48	5.63	0.35	5.24e-8	Menopause (age at onset);
SARC	cis	rs79387448	0.745	rs17027413	chr2:103153667	A/G	cg09003973	chr2:102972529	NA	-0.64	-6.15	-0.37	3.3e-9	Gut microbiota (bacterial taxa);
SARC	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg22535103	chr8:58192502	C8orf71	-0.66	-5.66	-0.35	4.4e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs372883	0.600	rs1153276	chr21:30661694	T/C	cg08807101	chr21:30365312	RNF160	-0.58	-7.3	-0.43	4.51e-12	Pancreatic cancer;
SARC	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg24549020	chr5:56110836	MAP3K1	0.44	5.07	0.32	8.11e-7	Coronary artery disease;
SARC	cis	rs10489202	1.000	rs4656564	chr1:167928992	T/C	cg24449463	chr1:168025552	DCAF6	-0.65	-7.05	-0.42	2.04e-11	Schizophrenia;
SARC	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg11987759	chr7:65425863	GUSB	0.56	7.55	0.44	9.53e-13	Aortic root size;
SARC	cis	rs9393777	0.513	rs13190754	chr6:26587406	G/A	cg12826209	chr6:26865740	GUSBL1	0.67	6.21	0.38	2.45e-9	Intelligence (multi-trait analysis);
SARC	cis	rs1008375	0.966	rs4698619	chr4:17580955	G/A	cg27347728	chr4:17578864	LAP3	0.49	6.06	0.37	5.46e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs1865760	0.929	rs9461224	chr6:25936402	G/T	cg08536977	chr17:73780663	UNK	-0.53	-6.51	-0.39	4.53e-10	Height;
SARC	cis	rs10197940	0.662	rs1047957	chr2:152333773	C/T	cg19508488	chr2:152266495	RIF1	0.47	5.2	0.32	4.35e-7	Lung cancer;
SARC	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg04267008	chr7:1944627	MAD1L1	-0.49	-5.63	-0.35	5.08e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs2439831	0.867	rs496584	chr15:43831923	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	9.45	0.53	3.84e-18	Lung cancer in ever smokers;
SARC	cis	rs9322817	0.691	rs2499667	chr6:105319125	G/A	cg02098413	chr6:105308735	HACE1	0.38	5.92	0.36	1.17e-8	Thyroid stimulating hormone;
SARC	cis	rs6688363	0.943	rs1016732	chr1:160086968	A/G	cg22802111	chr1:160068614	IGSF8	0.54	5.09	0.32	7.53e-7	Response to antipsychotic treatment;
SARC	cis	rs10140922	0.931	rs4982261	chr14:35822159	C/T	cg26967526	chr14:35346199	BAZ1A	-0.4	-5.04	-0.31	9.47e-7	Hip circumference adjusted for BMI;
SARC	cis	rs35110281	0.591	rs86138	chr21:44932398	G/A	cg21573476	chr21:45109991	RRP1B	-0.48	-7.07	-0.42	1.79e-11	Mean corpuscular volume;
SARC	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg11987759	chr7:65425863	GUSB	0.47	5.9	0.36	1.27e-8	Aortic root size;
SARC	cis	rs78487399	0.710	rs17334919	chr2:43707385	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.6	4.87	0.3	2.1e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs6582630	0.502	rs11181214	chr12:38298313	C/A	cg13010199	chr12:38710504	ALG10B	0.77	10.59	0.57	1.16e-21	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs9929218	0.551	rs2274239	chr16:68725783	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.85	14.6	0.69	1.02e-34	Colorectal cancer;
SARC	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg22903471	chr2:27725779	GCKR	-0.54	-8.16	-0.47	2.06e-14	Total body bone mineral density;
SARC	cis	rs10911251	0.546	rs2027085	chr1:183108611	G/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.68	-9.8	-0.54	3.37e-19	Colorectal cancer;
SARC	cis	rs11945232	1.000	rs4314250	chr4:88340969	A/G	cg23841344	chr4:88312519	HSD17B11	0.58	7.34	0.43	3.47e-12	Intelligence (multi-trait analysis);
SARC	cis	rs317689	0.613	rs315112	chr12:69785926	T/A	cg14784868	chr12:69753453	YEATS4	0.5	6.1	0.37	4.35e-9	Response to diuretic therapy;
SARC	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg03575189	chr17:44344142	NA	0.57	5.67	0.35	4.21e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg18404041	chr3:52824283	ITIH1	-0.44	-6.59	-0.4	2.82e-10	Bipolar disorder;
SARC	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg05793240	chr7:2802953	GNA12	-0.37	-5.04	-0.31	9.41e-7	Height;
SARC	cis	rs6429082	0.713	rs867363	chr1:235579727	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.58	-7.52	-0.44	1.16e-12	Adiposity;
SARC	cis	rs7589342	0.745	rs933793	chr2:106511846	C/T	cg14210321	chr2:106509881	NCK2	0.46	5.36	0.33	1.96e-7	Addiction;
SARC	cis	rs7412746	0.611	rs10888398	chr1:150886782	A/G	cg13175981	chr1:150552382	MCL1	0.53	6.49	0.39	4.99e-10	Melanoma;
SARC	cis	rs2635047	0.512	rs9962436	chr18:44599109	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.4	-4.91	-0.31	1.72e-6	Educational attainment;
SARC	cis	rs244731	1.000	rs244730	chr5:176539212	A/G	cg17509989	chr5:176798049	RGS14	-0.66	-8.56	-0.49	1.56e-15	Urate levels in lean individuals;
SARC	cis	rs916888	0.610	rs199536	chr17:44820425	T/C	cg01570182	chr17:44337453	NA	-0.67	-8.16	-0.47	2.07e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs911555	0.755	rs9671414	chr14:103967299	C/T	cg24130564	chr14:104152367	KLC1	0.53	6.33	0.38	1.26e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7264396	0.635	rs6119672	chr20:34479767	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	5.42	0.33	1.49e-7	Total cholesterol levels;
SARC	cis	rs4642101	0.618	rs11128614	chr3:12819212	A/G	cg24848339	chr3:12840334	CAND2	0.36	5.86	0.36	1.59e-8	QRS complex (12-leadsum);
SARC	cis	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg09021430	chr5:549028	NA	-0.4	-5.29	-0.33	2.88e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs9859260	0.744	rs419059	chr3:195782184	C/T	cg03462622	chr3:195777018	TFRC	-0.47	-5.41	-0.33	1.53e-7	Mean corpuscular volume;
SARC	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg26818010	chr10:134567672	INPP5A	-0.66	-7.06	-0.42	1.89e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg16325326	chr1:53192061	ZYG11B	0.77	12.09	0.62	1.96e-26	Monocyte count;
SARC	cis	rs554111	0.656	rs4654900	chr1:21422021	G/C	cg04902671	chr1:21058625	SH2D5	0.42	5.11	0.32	6.74e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg17376030	chr22:41985996	PMM1	-0.64	-7.78	-0.45	2.35e-13	Vitiligo;
SARC	cis	rs2239547	0.603	rs17304995	chr3:53070755	A/G	cg05564831	chr3:52568323	NT5DC2	0.35	4.92	0.31	1.65e-6	Schizophrenia;
SARC	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg21724239	chr8:58056113	NA	0.6	6.37	0.38	1.03e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs501120	1.000	rs518594	chr10:44757107	T/C	cg09554077	chr10:44749378	NA	0.48	6.49	0.39	5.12e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs2576037	0.526	rs6507714	chr18:44519574	A/G	cg19077165	chr18:44547161	KATNAL2	-0.45	-6.21	-0.38	2.38e-9	Personality dimensions;
SARC	cis	rs2239547	0.603	rs12489490	chr3:53064022	C/A	cg18404041	chr3:52824283	ITIH1	-0.39	-4.72	-0.3	4.12e-6	Schizophrenia;
SARC	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg08677398	chr8:58056175	NA	0.44	5.24	0.32	3.59e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg16414030	chr3:133502952	NA	-0.38	-4.97	-0.31	1.32e-6	Iron status biomarkers;
SARC	cis	rs2559856	1.000	rs2559857	chr12:102089399	A/C	cg12924262	chr12:102091054	CHPT1	0.57	7.86	0.46	1.44e-13	Blood protein levels;
SARC	cis	rs1371867	0.875	rs1660319	chr8:101337530	A/G	cg11906718	chr8:101322791	RNF19A	0.68	8.66	0.49	7.89e-16	Atrioventricular conduction;
SARC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg09033563	chr22:24373618	LOC391322	-0.51	-6.44	-0.39	6.62e-10	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7264396	0.563	rs2425117	chr20:34323776	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.83	0.36	1.88e-8	Total cholesterol levels;
SARC	cis	rs6867032	0.527	rs13190594	chr5:2012474	T/C	cg26168224	chr5:2018326	NA	0.69	10.03	0.55	6.74e-20	Gut microbiome composition (winter);
SARC	cis	rs6121246	0.567	rs6060247	chr20:30190720	C/G	cg13852791	chr20:30311386	BCL2L1	0.65	5.64	0.35	4.92e-8	Mean corpuscular hemoglobin;
SARC	cis	rs4642101	0.561	rs9831765	chr3:12805934	A/T	cg05775895	chr3:12838266	CAND2	0.54	7.66	0.45	5.03e-13	QRS complex (12-leadsum);
SARC	cis	rs1983170	0.808	rs10874788	chr1:92017941	C/T	cg25838465	chr1:92012736	NA	0.45	5.49	0.34	1.04e-7	Eosinophil percentage of white cells;
SARC	cis	rs912057	0.671	rs1294427	chr6:6744546	T/G	cg06612196	chr6:6737390	NA	0.63	9.53	0.53	2.1e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs6815814	0.950	rs55903115	chr4:38786474	C/A	cg09316306	chr4:38807337	TLR1	0.48	4.96	0.31	1.35e-6	Breast cancer;
SARC	cis	rs2204008	0.782	rs11514339	chr12:38236670	G/A	cg26384229	chr12:38710491	ALG10B	0.91	13.43	0.66	7.61e-31	Bladder cancer;
SARC	cis	rs11225247	0.772	rs10219215	chr11:102238237	C/T	cg11690896	chr11:102217788	BIRC2	0.75	6.07	0.37	5.01e-9	Vein graft stenosis in coronary artery bypass grafting;
SARC	cis	rs17376456	0.809	rs12152763	chr5:93405509	T/A	cg21475434	chr5:93447410	FAM172A	0.85	7.5	0.44	1.34e-12	Diabetic retinopathy;
SARC	cis	rs6087990	0.899	rs1883729	chr20:31363193	G/A	cg13636640	chr20:31349939	DNMT3B	0.8	12.66	0.64	2.7e-28	Ulcerative colitis;
SARC	cis	rs2204008	0.774	rs9669565	chr12:38294428	C/A	cg13010199	chr12:38710504	ALG10B	0.79	11.02	0.59	5.26e-23	Bladder cancer;
SARC	cis	rs644799	1.000	rs580255	chr11:95577929	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.66	8.88	0.5	1.8e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs12348691	0.503	rs1348386	chr9:100612807	A/G	cg13688889	chr9:100608707	NA	-0.47	-5.08	-0.32	7.65e-7	Alopecia areata;
SARC	cis	rs1008375	0.931	rs6449310	chr4:17575530	T/C	cg02297831	chr4:17616191	MED28	0.47	5.92	0.36	1.13e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7666738	0.830	rs35752787	chr4:98935202	G/A	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs17376456	0.569	rs6879620	chr5:93119893	G/A	cg25358565	chr5:93447407	FAM172A	-0.93	-10.47	-0.57	2.74e-21	Diabetic retinopathy;
SARC	cis	rs7197653	0.586	rs55856208	chr16:68324210	A/T	cg09835421	chr16:68378352	PRMT7	-0.62	-5.23	-0.32	3.85e-7	Magnesium levels;
SARC	cis	rs17376456	0.569	rs7721668	chr5:93290995	G/A	cg25358565	chr5:93447407	FAM172A	-0.81	-9.64	-0.53	1.02e-18	Diabetic retinopathy;
SARC	cis	rs12908161	0.959	rs34342559	chr15:85331271	A/G	cg17507749	chr15:85114479	UBE2QP1	0.53	6.04	0.37	6.03e-9	Schizophrenia;
SARC	cis	rs2120019	0.567	rs72625793	chr15:75207083	A/G	cg12414181	chr15:75287860	SCAMP5	-0.51	-4.84	-0.3	2.37e-6	Blood trace element (Zn levels);
SARC	cis	rs1448094	0.817	rs10863121	chr12:86343834	A/C	cg02569458	chr12:86230093	RASSF9	-0.42	-5.87	-0.36	1.48e-8	Major depressive disorder;
SARC	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg19223190	chr17:80058835	NA	0.44	6.19	0.38	2.67e-9	Life satisfaction;
SARC	cis	rs910316	0.737	rs424120	chr14:75482828	G/T	cg08847533	chr14:75593920	NEK9	-0.8	-11.35	-0.6	4.72e-24	Height;
SARC	cis	rs72945132	0.882	rs10466703	chr11:70218548	C/T	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.89	-0.36	1.31e-8	Coronary artery disease;
SARC	cis	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg06212747	chr3:49208901	KLHDC8B	0.51	6.48	0.39	5.37e-10	Resting heart rate;
SARC	cis	rs9747201	0.889	rs4789784	chr17:80179213	G/A	cg17462356	chr17:80056334	FASN	-0.48	-5.21	-0.32	4.19e-7	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs4253772	0.591	rs8143066	chr22:46656607	C/T	cg24881330	chr22:46731750	TRMU	0.62	6.68	0.4	1.73e-10	LDL cholesterol;Cholesterol, total;
SARC	cis	rs6430585	0.528	rs10496738	chr2:136751488	C/T	cg07169764	chr2:136633963	MCM6	1.01	12.7	0.64	2.01e-28	Corneal structure;
SARC	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg24399712	chr22:39784796	NA	-0.38	-4.91	-0.31	1.7e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg07636037	chr3:49044803	WDR6	0.98	17.1	0.75	4.92e-43	Parkinson's disease;
SARC	cis	rs9815354	1.000	rs56776628	chr3:41866856	A/G	cg03022575	chr3:42003672	ULK4	0.57	5.32	0.33	2.38e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2120019	0.938	rs8030089	chr15:75290377	C/T	cg09165964	chr15:75287851	SCAMP5	-0.98	-14.89	-0.7	1.13e-35	Blood trace element (Zn levels);
SARC	cis	rs67460515	0.630	rs7638370	chr3:160921793	G/T	cg03342759	chr3:160939853	NMD3	-0.66	-8.19	-0.47	1.78e-14	Parkinson's disease;
SARC	trans	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.83	11.6	0.61	7.41e-25	Intelligence (multi-trait analysis);
SARC	trans	rs637571	0.522	rs491973	chr11:65727301	A/G	cg17712092	chr4:129076599	LARP1B	0.69	9.37	0.52	6.47e-18	Eosinophil percentage of white cells;
SARC	cis	rs546131	0.928	rs552171	chr11:34830709	G/T	cg06937548	chr11:34938143	PDHX;APIP	0.51	6.68	0.4	1.72e-10	Lung disease severity in cystic fibrosis;
SARC	cis	rs11676348	0.838	rs17844697	chr2:218999255	G/A	cg00012203	chr2:219082015	ARPC2	-0.41	-5.26	-0.33	3.34e-7	Ulcerative colitis;
SARC	cis	rs12824058	0.831	rs12297939	chr12:130811923	G/C	cg26677194	chr12:130822605	PIWIL1	0.54	7.41	0.44	2.25e-12	Menopause (age at onset);
SARC	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg04267008	chr7:1944627	MAD1L1	-0.61	-7.1	-0.42	1.53e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg06634786	chr22:41940651	POLR3H	0.56	6.63	0.4	2.27e-10	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg12016809	chr21:47604291	C21orf56	-0.47	-5.64	-0.35	4.8e-8	Testicular germ cell tumor;
SARC	cis	rs7043114	0.507	rs6479420	chr9:95116406	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.75	-0.35	2.84e-8	Height;
SARC	cis	rs6582630	0.531	rs3850000	chr12:38483752	T/C	cg26384229	chr12:38710491	ALG10B	0.84	12.0	0.62	3.64e-26	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg24829409	chr8:58192753	C8orf71	-0.56	-4.75	-0.3	3.61e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg22857025	chr5:266934	NA	-1.09	-11.97	-0.62	4.86e-26	Breast cancer;
SARC	cis	rs10892173	0.818	rs7947524	chr11:117671091	C/T	cg21640587	chr11:117668038	DSCAML1	0.44	6.07	0.37	5.21e-9	Myopia;
SARC	cis	rs7223966	0.729	rs9902761	chr17:62010627	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-4.72	-0.3	4.04e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-5.96	-0.36	9.37e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.06	0.8	1.11e-52	Prudent dietary pattern;
SARC	cis	rs950776	0.518	rs11632604	chr15:78821914	T/C	cg17108064	chr15:78857060	CHRNA5	0.29	4.93	0.31	1.56e-6	Sudden cardiac arrest;
SARC	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.42	-4.84	-0.3	2.37e-6	Prudent dietary pattern;
SARC	cis	rs1152591	0.562	rs1262242	chr14:64653869	C/T	cg23250157	chr14:64679961	SYNE2	0.39	5.36	0.33	2e-7	Atrial fibrillation;
SARC	cis	rs9910055	0.530	rs2269908	chr17:42294198	G/C	cg13607699	chr17:42295918	UBTF	0.85	13.59	0.67	2.25e-31	Total body bone mineral density;
SARC	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg02951883	chr7:2050386	MAD1L1	-0.5	-6.5	-0.39	4.92e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs9914988	0.943	rs9907178	chr17:27124307	G/C	cg20469991	chr17:27169893	C17orf63	-0.5	-5.21	-0.32	4.1e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12601757	chr1:76540465	ST6GALNAC3	-0.45	-6.5	-0.39	4.77e-10	Smoking initiation;
SARC	cis	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg09021430	chr5:549028	NA	-0.43	-5.68	-0.35	3.92e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs12893668	0.572	rs11846404	chr14:104156108	C/G	cg26031613	chr14:104095156	KLC1	-0.51	-5.61	-0.35	5.66e-8	Reticulocyte count;
SARC	cis	rs6772849	0.805	rs13325747	chr3:128336023	G/A	cg08795948	chr3:128337044	NA	0.55	7.8	0.45	2.08e-13	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs9733	0.818	rs12403609	chr1:150676485	T/C	cg13175981	chr1:150552382	MCL1	0.64	8.92	0.5	1.42e-16	Tonsillectomy;
SARC	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg24209194	chr3:40518798	ZNF619	0.65	7.94	0.46	8.27e-14	Renal cell carcinoma;
SARC	cis	rs6570726	0.935	rs452552	chr6:145820781	G/A	cg23711669	chr6:146136114	FBXO30	0.78	11.91	0.62	7.29e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs876084	0.505	rs4407921	chr8:121156585	C/T	cg06265175	chr8:121136014	COL14A1	0.57	7.37	0.43	2.9e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs9790314	1.000	rs336593	chr3:161076431	T/C	cg04691961	chr3:161091175	C3orf57	-0.81	-12.41	-0.63	1.74e-27	Morning vs. evening chronotype;
SARC	cis	rs2075371	0.501	rs1421469	chr7:134028260	C/G	cg20476274	chr7:133979776	SLC35B4	0.41	5.18	0.32	4.76e-7	Mean platelet volume;
SARC	cis	rs9389248	0.737	rs56358308	chr6:135306980	A/T	cg22676075	chr6:135203613	NA	0.37	4.76	0.3	3.33e-6	High light scatter reticulocyte percentage of red cells;
SARC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg24503407	chr1:205819492	PM20D1	0.53	6.93	0.41	4.05e-11	Menarche (age at onset);
SARC	cis	rs10504229	0.511	rs16921553	chr8:57979314	T/C	cg24829409	chr8:58192753	C8orf71	-0.5	-4.77	-0.3	3.21e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs2832191	0.720	rs2832194	chr21:30494250	T/C	cg08807101	chr21:30365312	RNF160	-0.82	-11.26	-0.59	9.12e-24	Dental caries;
SARC	cis	rs66887589	0.934	rs7681980	chr4:120533223	G/A	cg09307838	chr4:120376055	NA	-0.51	-6.98	-0.42	2.99e-11	Diastolic blood pressure;
SARC	cis	rs7666738	0.830	rs13139078	chr4:99020774	C/T	cg05340658	chr4:99064831	C4orf37	0.66	9.04	0.51	6.35e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs5753618	0.539	rs2228619	chr22:31663842	C/G	cg00478049	chr22:31556069	RNF185	0.44	4.84	0.3	2.37e-6	Colorectal cancer;
SARC	cis	rs12303914	0.802	rs7135494	chr12:10470093	C/T	cg16417563	chr12:10365564	GABARAPL1	-0.4	-4.84	-0.3	2.35e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg22535103	chr8:58192502	C8orf71	-0.81	-9.18	-0.52	2.33e-17	Developmental language disorder (linguistic errors);
SARC	cis	rs1538970	0.962	rs7532762	chr1:45864695	C/A	cg05343316	chr1:45956843	TESK2	0.68	8.32	0.48	7.61e-15	Platelet count;
SARC	cis	rs17345786	0.798	rs9817043	chr3:101281852	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.48	5.74	0.35	2.89e-8	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10791323	0.604	rs2853116	chr11:133707063	A/G	cg14349672	chr11:133703707	NA	-0.38	-5.51	-0.34	9.43e-8	Childhood ear infection;
SARC	cis	rs7927592	0.956	rs7104877	chr11:68377602	G/T	cg01657329	chr11:68192670	LRP5	0.39	4.84	0.3	2.39e-6	Total body bone mineral density;
SARC	cis	rs12545912	0.909	rs12674762	chr8:9484126	C/T	cg21625330	chr8:9911636	MSRA	0.52	4.88	0.3	1.95e-6	Multiple myeloma (hyperdiploidy);
SARC	cis	rs829883	0.902	rs1620317	chr12:98890566	T/C	cg25150519	chr12:98850993	NA	0.7	9.54	0.53	1.99e-18	Colorectal adenoma (advanced);
SARC	cis	rs2153535	0.580	rs5001130	chr6:8442298	G/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.06	0.59	3.93e-23	Motion sickness;
SARC	cis	rs9818758	0.607	rs34343820	chr3:49309534	C/G	cg07636037	chr3:49044803	WDR6	-0.75	-6.54	-0.39	3.94e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs995000	0.965	rs1690761	chr1:62955862	C/T	cg06896770	chr1:63153194	DOCK7	-0.89	-13.16	-0.65	6.14e-30	Triglyceride levels;
SARC	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg16405210	chr4:1374714	KIAA1530	-0.48	-5.72	-0.35	3.29e-8	Obesity-related traits;
SARC	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg03161606	chr19:29218774	NA	0.48	6.97	0.42	3.3e-11	Methadone dose in opioid dependence;
SARC	trans	rs61931739	0.500	rs11053140	chr12:34316122	T/C	cg26384229	chr12:38710491	ALG10B	0.84	12.0	0.62	3.8e-26	Morning vs. evening chronotype;
SARC	cis	rs12421382	0.659	rs2165137	chr11:109381995	G/T	cg16359550	chr11:109292809	C11orf87	0.36	5.14	0.32	5.75e-7	Schizophrenia;
SARC	cis	rs8141529	0.719	rs5762825	chr22:29223642	A/G	cg15103426	chr22:29168792	CCDC117	0.67	8.66	0.49	8.19e-16	Lymphocyte counts;
SARC	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.46	-5.72	-0.35	3.33e-8	Gut microbiome composition (summer);
SARC	cis	rs870825	0.616	rs2003994	chr4:185636568	G/T	cg04058563	chr4:185651563	MLF1IP	0.84	11.36	0.6	4.49e-24	Blood protein levels;
SARC	cis	rs2549003	1.000	rs2549004	chr5:131827825	C/G	cg21138405	chr5:131827807	IRF1	-0.29	-5.76	-0.35	2.69e-8	Asthma (sex interaction);
SARC	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs13082711	0.522	rs820617	chr3:27335510	T/C	cg02860705	chr3:27208620	NA	0.47	6.26	0.38	1.86e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg22683308	chr4:1340831	KIAA1530	0.44	5.25	0.33	3.46e-7	Longevity;
SARC	cis	rs27434	0.607	rs34753	chr5:96150911	C/T	cg16492584	chr5:96139282	ERAP1	-0.56	-7.19	-0.43	8.54e-12	Ankylosing spondylitis;
SARC	cis	rs926938	0.527	rs58658580	chr1:115539726	A/G	cg12756093	chr1:115239321	AMPD1	0.39	4.83	0.3	2.46e-6	Autism;
SARC	cis	rs644799	0.542	rs10831418	chr11:95468828	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.73	9.67	0.54	8.36e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7659604	0.605	rs67772833	chr4:122723106	G/A	cg06713675	chr4:122721982	EXOSC9	-0.4	-5.27	-0.33	3.07e-7	Type 2 diabetes;
SARC	cis	rs2289583	0.544	rs12050759	chr15:75265191	G/A	cg10253484	chr15:75165896	SCAMP2	0.5	5.39	0.33	1.71e-7	Systemic lupus erythematosus;
SARC	cis	rs79149102	0.579	rs7168638	chr15:75280826	T/C	cg00629941	chr15:75287862	SCAMP5	-0.7	-5.36	-0.33	1.96e-7	Lung cancer;
SARC	cis	rs807669	0.802	rs762528	chr22:19166680	A/G	cg02655711	chr22:19163373	SLC25A1	0.57	8.0	0.46	5.92e-14	Metabolite levels;
SARC	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.54	0.44	1.06e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs17376456	0.877	rs13153245	chr5:93374891	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.76	0.35	2.64e-8	Diabetic retinopathy;
SARC	cis	rs10979	0.597	rs9321927	chr6:143913295	A/G	cg25407410	chr6:143891975	LOC285740	0.49	5.63	0.35	5.23e-8	Hypospadias;
SARC	cis	rs2011503	1.000	rs8101219	chr19:19643715	G/A	cg03709012	chr19:19516395	GATAD2A	0.6	5.29	0.33	2.8e-7	Bipolar disorder;
SARC	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg04166393	chr7:2884313	GNA12	0.6	7.31	0.43	4.3e-12	Height;
SARC	cis	rs3812831	0.654	rs6560933	chr13:114937294	A/G	cg08824895	chr13:115047677	UPF3A	-0.42	-5.29	-0.33	2.83e-7	Schizophrenia;
SARC	cis	rs3008870	1.000	rs2815361	chr1:67494591	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.9	11.27	0.59	8.39e-24	Lymphocyte percentage of white cells;
SARC	trans	rs9951602	0.512	rs8084836	chr18:76647841	A/G	cg02800362	chr5:177631904	HNRNPAB	0.71	8.82	0.5	2.73e-16	Obesity-related traits;
SARC	cis	rs9911578	0.967	rs1588322	chr17:56990099	T/C	cg12560992	chr17:57184187	TRIM37	0.85	11.57	0.6	9.08e-25	Intelligence (multi-trait analysis);
SARC	cis	rs6450176	0.564	rs381024	chr5:53326234	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.54	-6.19	-0.38	2.63e-9	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs2180341	0.920	rs9398836	chr6:127576497	T/G	cg24812749	chr6:127587940	RNF146	0.95	12.4	0.63	1.86e-27	Breast cancer;
SARC	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg05368731	chr17:41323189	NBR1	0.78	9.3	0.52	1.06e-17	Menopause (age at onset);
SARC	cis	rs7513165	0.935	rs4951316	chr1:204161490	C/T	cg23788856	chr1:204159729	KISS1	0.35	5.28	0.33	2.92e-7	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
SARC	cis	rs9787249	0.957	rs12086750	chr1:40210468	G/C	cg24920358	chr1:40204285	PPIE	0.44	5.25	0.33	3.38e-7	Blood protein levels;
SARC	cis	rs4481887	0.676	rs6691314	chr1:248548020	G/A	cg13385794	chr1:248469461	NA	0.31	5.06	0.31	8.45e-7	Common traits (Other);
SARC	cis	rs78132593	0.757	rs41305070	chr1:150666860	A/G	cg13175981	chr1:150552382	MCL1	0.48	4.85	0.3	2.23e-6	High light scatter reticulocyte count;
SARC	cis	rs9814567	1.000	rs6769885	chr3:134286913	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.04	-0.42	2.19e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs57506017	0.585	rs6460897	chr7:12252741	T/G	cg23422036	chr7:12250390	TMEM106B	0.49	6.49	0.39	5.19e-10	Neuroticism;
SARC	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg18876405	chr7:65276391	NA	0.43	4.74	0.3	3.78e-6	Aortic root size;
SARC	cis	rs11608355	0.552	rs2304549	chr12:109794875	A/G	cg19025524	chr12:109796872	NA	-0.48	-6.85	-0.41	6.57e-11	Neuroticism;
SARC	trans	rs11098499	0.863	rs1383532	chr4:120434404	A/T	cg25214090	chr10:38739885	LOC399744	-0.56	-7.14	-0.42	1.21e-11	Corneal astigmatism;
SARC	cis	rs17270561	0.609	rs7772382	chr6:25708116	C/T	cg16482183	chr6:26056742	HIST1H1C	0.44	5.28	0.33	2.9e-7	Iron status biomarkers;
SARC	cis	rs668210	0.793	rs1151514	chr11:65758854	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	0.71	7.71	0.45	3.67e-13	Cerebrospinal fluid biomarker levels;
SARC	cis	rs6582630	0.537	rs10785436	chr12:38461040	G/C	cg26384229	chr12:38710491	ALG10B	0.84	12.17	0.62	1.04e-26	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs722599	0.639	rs2193596	chr14:75234101	A/C	cg08847533	chr14:75593920	NEK9	0.48	5.31	0.33	2.59e-7	IgG glycosylation;
SARC	cis	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg05623727	chr3:50126028	RBM5	-0.33	-4.99	-0.31	1.21e-6	Intelligence (multi-trait analysis);
SARC	cis	rs861020	0.630	rs9308411	chr1:210005713	C/T	cg23166289	chr1:210001082	C1orf107	0.39	4.76	0.3	3.47e-6	Orofacial clefts;
SARC	cis	rs9894429	1.000	rs9674872	chr17:79581931	T/A	cg18240062	chr17:79603768	NPLOC4	0.71	9.81	0.54	3.03e-19	Eye color traits;
SARC	trans	rs61931739	0.500	rs10772160	chr12:34456848	G/A	cg26384229	chr12:38710491	ALG10B	0.84	12.51	0.63	8.09e-28	Morning vs. evening chronotype;
SARC	cis	rs1008375	0.966	rs6832387	chr4:17697546	G/T	cg27347728	chr4:17578864	LAP3	0.44	5.67	0.35	4.13e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7772486	0.875	rs7767660	chr6:146436550	T/C	cg05347473	chr6:146136440	FBXO30	0.49	6.7	0.4	1.59e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs8180040	0.726	rs11130112	chr3:47024495	G/T	cg27129171	chr3:47204927	SETD2	0.63	8.39	0.48	4.74e-15	Colorectal cancer;
SARC	cis	rs2439831	0.850	rs16977798	chr15:44151948	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.95	8.28	0.48	9.52e-15	Lung cancer in ever smokers;
SARC	cis	rs6700896	0.931	rs10443261	chr1:66129121	T/C	cg04111102	chr1:66153794	NA	0.36	5.66	0.35	4.49e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs1559088	0.901	rs7249983	chr19:33598851	C/A	cg03563238	chr19:33554763	RHPN2	-0.26	-4.77	-0.3	3.27e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs7762018	1.000	rs6912959	chr6:170126224	G/A	cg15038512	chr6:170123185	PHF10	0.53	5.12	0.32	6.25e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs9297145	0.724	rs6954584	chr7:98766930	G/A	cg05967295	chr7:98741636	SMURF1	0.77	7.95	0.46	8.16e-14	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
SARC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.8	10.32	0.56	8.57e-21	Prudent dietary pattern;
SARC	cis	rs11785400	1.000	rs6997771	chr8:143747752	T/G	cg10596483	chr8:143751796	JRK	0.65	8.68	0.49	6.74e-16	Schizophrenia;
SARC	cis	rs3888647	0.561	rs4758617	chr11:2995185	T/A	cg05729581	chr11:3078854	CARS	-0.54	-7.18	-0.43	9.03e-12	Type 2 diabetes;
SARC	cis	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg25427524	chr10:38739819	LOC399744	-0.53	-8.32	-0.48	7.24e-15	Extrinsic epigenetic age acceleration;
SARC	cis	rs2380220	0.938	rs6923253	chr6:95970141	C/G	cg04719120	chr6:96025338	MANEA	0.64	6.64	0.4	2.24e-10	Behavioural disinhibition (generation interaction);
SARC	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg13206674	chr6:150067644	NUP43	0.42	5.53	0.34	8.42e-8	Lung cancer;
SARC	cis	rs7635838	0.819	rs12714866	chr3:11539058	C/T	cg00170343	chr3:11313890	ATG7	0.61	8.35	0.48	6.05e-15	HDL cholesterol;
SARC	cis	rs4727027	0.840	rs12670633	chr7:148796707	G/A	cg23583168	chr7:148888333	NA	-0.74	-10.4	-0.56	4.66e-21	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs9527	0.615	rs7080462	chr10:104736699	T/C	cg04362960	chr10:104952993	NT5C2	0.42	4.99	0.31	1.2e-6	Arsenic metabolism;
SARC	cis	rs7940866	0.646	rs10894293	chr11:130824213	C/T	cg12179176	chr11:130786555	SNX19	-0.57	-7.94	-0.46	8.37e-14	Schizophrenia;
SARC	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg11764359	chr7:65958608	NA	-0.81	-10.88	-0.58	1.48e-22	Aortic root size;
SARC	cis	rs2952156	0.876	rs2313171	chr17:37833842	T/C	cg20243544	chr17:37824526	PNMT	0.56	7.44	0.44	1.94e-12	Asthma;
SARC	cis	rs6882046	0.513	rs454214	chr5:88003403	A/G	cg22951263	chr5:87985283	NA	0.37	4.94	0.31	1.48e-6	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
SARC	cis	rs12545109	0.800	rs1440746	chr8:57415912	G/A	cg19413350	chr8:57351067	NA	-0.43	-5.41	-0.33	1.53e-7	Obesity-related traits;
SARC	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg05313129	chr8:58192883	C8orf71	-0.58	-6.36	-0.38	1.03e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.78	-0.5	3.56e-16	Alzheimer's disease;
SARC	cis	rs7312933	0.558	rs1669886	chr12:42838240	A/G	cg19980929	chr12:42632907	YAF2	-0.44	-6.5	-0.39	4.74e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.85	12.08	0.62	2.05e-26	Chronic sinus infection;
SARC	cis	rs1691799	0.899	rs1177555	chr12:66727568	A/G	cg16791601	chr12:66731901	HELB	-0.72	-11.02	-0.59	5.4e-23	White blood cell count (basophil);
SARC	cis	rs3820928	0.874	rs13430941	chr2:227904447	G/A	cg05526886	chr2:227700861	RHBDD1	-0.51	-5.87	-0.36	1.48e-8	Pulmonary function;
SARC	cis	rs9790314	0.586	rs11713185	chr3:161111357	C/G	cg03342759	chr3:160939853	NMD3	-0.57	-7.02	-0.42	2.38e-11	Morning vs. evening chronotype;
SARC	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg09699651	chr6:150184138	LRP11	0.43	5.28	0.33	2.96e-7	Lung cancer;
SARC	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg17376030	chr22:41985996	PMM1	0.68	8.18	0.47	1.87e-14	Vitiligo;
SARC	cis	rs2832077	0.527	rs2250141	chr21:30241984	A/T	cg03476357	chr21:30257390	N6AMT1	0.67	7.47	0.44	1.62e-12	Cognitive test performance;
SARC	cis	rs7918232	0.941	rs7907988	chr10:27444344	T/G	cg14442939	chr10:27389572	ANKRD26	0.68	5.9	0.36	1.28e-8	Breast cancer;
SARC	trans	rs9650657	0.530	rs6982381	chr8:10952500	A/T	cg08975724	chr8:8085496	FLJ10661	-0.48	-6.29	-0.38	1.55e-9	Neuroticism;
SARC	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	8.82	0.5	2.77e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6495122	0.501	rs6495151	chr15:75385990	A/G	cg17294928	chr15:75287854	SCAMP5	-0.49	-6.41	-0.39	8.01e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	cis	rs4566357	0.615	rs2272202	chr2:227914625	C/T	cg11843606	chr2:227700838	RHBDD1	0.43	5.67	0.35	4.27e-8	Coronary artery disease;
SARC	cis	rs4268898	0.865	rs13021828	chr2:24439276	G/C	cg26838691	chr2:24397539	C2orf84	-0.42	-5.35	-0.33	2.09e-7	Asthma;
SARC	cis	rs2795502	1.000	rs2744090	chr10:43339614	G/C	cg20628663	chr10:43360327	NA	-0.47	-6.32	-0.38	1.33e-9	Blood protein levels;
SARC	cis	rs508618	0.666	rs480902	chr1:231531627	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.57	6.71	0.4	1.48e-10	Red blood cell count;
SARC	cis	rs17376456	0.877	rs10476596	chr5:93367074	C/T	cg25358565	chr5:93447407	FAM172A	-1.28	-14.14	-0.68	3.31e-33	Diabetic retinopathy;
SARC	cis	rs17125944	0.686	rs11157933	chr14:53349798	G/A	cg00686598	chr14:53173677	PSMC6	-0.63	-4.76	-0.3	3.33e-6	Alzheimer's disease (late onset);
SARC	cis	rs1691799	0.899	rs1185244	chr12:66725160	C/T	cg16791601	chr12:66731901	HELB	-0.74	-11.26	-0.59	9.08e-24	White blood cell count (basophil);
SARC	cis	rs7659604	0.537	rs6815973	chr4:122663430	A/T	cg06713675	chr4:122721982	EXOSC9	0.39	5.08	0.32	7.71e-7	Type 2 diabetes;
SARC	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg12756686	chr19:29218302	NA	0.68	8.99	0.51	8.47e-17	Methadone dose in opioid dependence;
SARC	cis	rs7819412	0.936	rs7814499	chr8:11040647	A/G	cg21775007	chr8:11205619	TDH	-0.43	-5.25	-0.33	3.38e-7	Triglycerides;
SARC	cis	rs11792861	0.816	rs11791845	chr9:111683898	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.76	9.23	0.52	1.69e-17	Menarche (age at onset);
SARC	cis	rs6493487	0.512	rs12913094	chr15:51219284	T/C	cg02338191	chr15:51200825	AP4E1	0.54	4.97	0.31	1.28e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs2073499	1.000	rs4141060	chr3:50300117	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.7	7.12	0.42	1.34e-11	Schizophrenia;
SARC	cis	rs6701037	0.566	rs1883102	chr1:175136793	T/A	cg08873628	chr1:175162347	KIAA0040	0.34	4.82	0.3	2.64e-6	Alcohol dependence;
SARC	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg11987759	chr7:65425863	GUSB	0.48	6.34	0.38	1.2e-9	Aortic root size;
SARC	cis	rs950027	0.549	rs2899375	chr15:45598335	G/A	cg15395560	chr15:45543142	SLC28A2	0.31	5.75	0.35	2.73e-8	Response to fenofibrate (adiponectin levels);
SARC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg05552183	chr6:42928497	GNMT	0.53	7.24	0.43	6.65e-12	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs10191773	0.589	rs11691239	chr2:112950600	A/C	cg07905836	chr2:113190072	RGPD8;RGPD5	-0.95	-8.08	-0.47	3.55e-14	Yeast infection;
SARC	cis	rs7027203	0.964	rs7853688	chr9:96523254	C/A	cg14598338	chr9:96623480	NA	0.51	6.85	0.41	6.52e-11	DNA methylation (variation);
SARC	cis	rs7560272	0.695	rs780393	chr2:73701669	T/A	cg20560298	chr2:73613845	ALMS1	0.55	7.44	0.44	1.88e-12	Schizophrenia;
SARC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.63	7.98	0.46	6.52e-14	Lymphocyte counts;
SARC	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg23758822	chr17:41437982	NA	0.84	10.48	0.57	2.62e-21	Menopause (age at onset);
SARC	cis	rs12701220	0.817	rs7798459	chr7:1087965	C/T	cg02733842	chr7:1102375	C7orf50	-0.5	-6.46	-0.39	5.93e-10	Bronchopulmonary dysplasia;
SARC	cis	rs6580649	0.783	rs7969749	chr12:48550755	C/T	cg24011408	chr12:48396354	COL2A1	0.46	5.18	0.32	4.85e-7	Lung cancer;
SARC	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9300255	0.602	rs1616181	chr12:123619856	T/A	cg00376283	chr12:123451042	ABCB9	0.56	6.52	0.39	4.36e-10	Neutrophil percentage of white cells;
SARC	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	10.7	0.57	5.58e-22	Platelet count;
SARC	cis	rs6964587	1.000	rs4727267	chr7:91570290	G/C	cg17063962	chr7:91808500	NA	-0.92	-14.58	-0.69	1.19e-34	Breast cancer;
SARC	cis	rs910316	1.000	rs2098297	chr14:75619118	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.51	-7.26	-0.43	5.69e-12	Height;
SARC	cis	rs10504229	0.871	rs56048296	chr8:58163781	C/T	cg24829409	chr8:58192753	C8orf71	-0.56	-6.29	-0.38	1.53e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6496667	0.509	rs2253419	chr15:90945875	A/G	cg22089800	chr15:90895588	ZNF774	0.42	4.84	0.3	2.34e-6	Rheumatoid arthritis;
SARC	cis	rs79149102	0.579	rs78434425	chr15:75304754	C/T	cg17294928	chr15:75287854	SCAMP5	-1.12	-8.92	-0.5	1.39e-16	Lung cancer;
SARC	cis	rs9400467	0.537	rs55831749	chr6:111430282	T/C	cg15721981	chr6:111408429	SLC16A10	0.68	5.86	0.36	1.56e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs1568889	1.000	rs61889046	chr11:28297024	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	9.97	0.55	9.64e-20	Bipolar disorder;
SARC	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg18252515	chr7:66147081	NA	-0.53	-5.69	-0.35	3.86e-8	Aortic root size;
SARC	cis	rs2963155	0.518	rs55817235	chr5:142765733	C/T	cg17617527	chr5:142782415	NR3C1	0.73	5.34	0.33	2.16e-7	Breast cancer;
SARC	trans	rs17685	0.753	rs10251863	chr7:75790192	T/C	cg19862616	chr7:65841803	NCRNA00174	0.64	8.01	0.46	5.5e-14	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg16680214	chr1:154839983	KCNN3	-0.37	-6.0	-0.37	7.62e-9	Prostate cancer;
SARC	cis	rs240110	0.570	rs966741	chr6:101218375	A/G	cg09795085	chr6:101329169	ASCC3	-0.44	-5.64	-0.35	4.87e-8	Neuroticism;
SARC	cis	rs7592578	0.508	rs55919641	chr2:191265414	G/A	cg25963032	chr2:191064776	C2orf88	-0.46	-5.36	-0.33	1.96e-7	Diastolic blood pressure;
SARC	cis	rs7772486	0.590	rs1890170	chr6:146071839	G/C	cg23711669	chr6:146136114	FBXO30	-0.84	-12.47	-0.63	1.15e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7178572	1.000	rs12904938	chr15:77721225	A/G	cg22256960	chr15:77711686	NA	-0.56	-6.59	-0.4	2.95e-10	Type 2 diabetes;
SARC	trans	rs7573615	0.500	rs62138397	chr2:53271211	A/G	cg12257439	chr2:97360893	FER1L5	-0.72	-6.51	-0.39	4.64e-10	Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.53	-6.25	-0.38	1.98e-9	Renal function-related traits (BUN);
SARC	cis	rs10865397	0.506	rs6546810	chr2:73389716	A/G	cg01422370	chr2:73384389	NA	0.35	5.53	0.34	8.57e-8	Intelligence (multi-trait analysis);
SARC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.33	-5.0	-0.31	1.11e-6	Total body bone mineral density;
SARC	cis	rs8044995	0.563	rs57434514	chr16:68402649	G/A	cg09835421	chr16:68378352	PRMT7	-0.68	-6.38	-0.39	9.37e-10	Schizophrenia;
SARC	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.82	-11.5	-0.6	1.59e-24	Chronic sinus infection;
SARC	cis	rs634534	0.561	rs655744	chr11:65776585	G/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.41	-5.18	-0.32	4.73e-7	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg03354898	chr7:1950403	MAD1L1	-0.4	-5.45	-0.34	1.29e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs41278232	0.557	rs817348	chr20:62609670	A/G	cg24354818	chr20:62328094	TNFRSF6B	0.35	4.93	0.31	1.54e-6	Tonsillectomy;
SARC	cis	rs7223966	1.000	rs9912201	chr17:61763208	A/G	cg00588841	chr17:61851480	DDX42;CCDC47	-0.65	-6.99	-0.42	2.9100000000000002e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg11062466	chr8:58055876	NA	0.54	5.56	0.34	7.55e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs12545109	0.800	rs990301	chr8:57406021	G/C	cg19413350	chr8:57351067	NA	-0.44	-5.44	-0.34	1.32e-7	Obesity-related traits;
SARC	cis	rs72781680	1.000	rs12616250	chr2:24211550	T/C	cg06627628	chr2:24431161	ITSN2	-0.7	-6.78	-0.41	9.65e-11	Lymphocyte counts;
SARC	cis	rs6088580	0.505	rs6141503	chr20:33274469	G/A	cg08999081	chr20:33150536	PIGU	-0.36	-5.26	-0.33	3.19e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs9303401	0.614	rs28687626	chr17:57191904	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.99	10.29	0.56	1.04e-20	Cognitive test performance;
SARC	cis	rs240764	0.782	rs239222	chr6:101112817	T/A	cg09795085	chr6:101329169	ASCC3	0.46	5.96	0.36	9.03e-9	Neuroticism;
SARC	cis	rs751728	0.687	rs943471	chr6:33738314	C/T	cg25922239	chr6:33757077	LEMD2	0.61	7.93	0.46	9.01e-14	Crohn's disease;
SARC	cis	rs3092073	0.624	rs3848719	chr20:44596545	G/A	cg10662479	chr20:44420225	WFDC3;DNTTIP1	0.44	5.48	0.34	1.08e-7	Intelligence (multi-trait analysis);
SARC	cis	rs12586317	0.653	rs4981287	chr14:35828198	G/A	cg16230307	chr14:35515116	FAM177A1	0.67	7.17	0.43	9.63e-12	Psoriasis;
SARC	cis	rs651907	0.535	rs34263427	chr3:101507805	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	5.86	0.36	1.61e-8	Colorectal cancer;
SARC	cis	rs11676348	0.846	rs4674257	chr2:218988774	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.5	-6.42	-0.39	7.61e-10	Ulcerative colitis;
SARC	cis	rs7945705	0.905	rs7947631	chr11:8844909	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.39	-5.06	-0.31	8.31e-7	Hemoglobin concentration;
SARC	cis	rs9457247	0.534	rs1130033	chr6:167385623	C/T	cg23791538	chr6:167370224	RNASET2	-0.62	-8.69	-0.49	6.51e-16	Crohn's disease;
SARC	cis	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg05623727	chr3:50126028	RBM5	0.33	5.0	0.31	1.14e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2153535	0.580	rs6914276	chr6:8450435	A/T	cg23788917	chr6:8435910	SLC35B3	-0.66	-8.74	-0.5	4.7e-16	Motion sickness;
SARC	cis	rs2880765	0.835	rs7178991	chr15:86050944	G/C	cg10818794	chr15:86012489	AKAP13	-0.39	-4.88	-0.3	1.98e-6	Coronary artery disease;
SARC	cis	rs79839061	0.610	rs17781499	chr4:889384	C/A	cg07828340	chr4:882639	GAK	0.78	6.12	0.37	4.04e-9	Intelligence (multi-trait analysis);
SARC	cis	rs72781680	1.000	rs72781649	chr2:24210864	A/G	cg06627628	chr2:24431161	ITSN2	-0.7	-6.78	-0.41	9.65e-11	Lymphocyte counts;
SARC	cis	rs6060717	0.536	rs8125393	chr20:34496162	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-5.64	-0.35	5.01e-8	Hip circumference adjusted for BMI;
SARC	cis	rs208515	0.525	rs12193560	chr6:66690457	A/T	cg07460842	chr6:66804631	NA	0.96	11.01	0.59	5.47e-23	Exhaled nitric oxide levels;
SARC	cis	rs9715521	0.900	rs72634623	chr4:59827419	T/C	cg11281224	chr4:60001000	NA	-0.38	-4.83	-0.3	2.47e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs3824867	0.920	rs7108143	chr11:47453722	T/G	cg20307385	chr11:47447363	PSMC3	-0.47	-5.17	-0.32	4.98e-7	Mean corpuscular hemoglobin;
SARC	cis	rs9296092	0.500	rs9469504	chr6:33527243	G/A	cg13560919	chr6:33536144	NA	-0.52	-6.41	-0.39	8.07e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs11718455	0.883	rs4682926	chr3:44006170	C/T	cg21419209	chr3:44054225	NA	-0.41	-4.97	-0.31	1.31e-6	Coronary artery disease;
SARC	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg11764359	chr7:65958608	NA	0.78	10.14	0.55	3.05e-20	Aortic root size;
SARC	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg06212747	chr3:49208901	KLHDC8B	0.78	11.45	0.6	2.24e-24	Menarche (age at onset);
SARC	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	8.32	0.48	7.26e-15	Mean platelet volume;
SARC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg22903471	chr2:27725779	GCKR	-0.49	-7.42	-0.44	2.21e-12	Total body bone mineral density;
SARC	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg24829409	chr8:58192753	C8orf71	-0.54	-5.85	-0.36	1.62e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.52	6.17	0.37	2.97e-9	Gut microbiome composition (summer);
SARC	trans	rs1865760	0.929	rs9461224	chr6:25936402	G/T	cg23749163	chr14:77563968	KIAA1737	-0.53	-6.28	-0.38	1.61e-9	Height;
SARC	cis	rs477692	1.000	rs577227	chr10:131404528	C/T	cg05714579	chr10:131428358	MGMT	0.59	7.78	0.45	2.39e-13	Response to temozolomide;
SARC	cis	rs9285223	1.000	rs4770290	chr13:23126907	C/G	cg08083251	chr13:23309930	NA	-0.48	-5.06	-0.31	8.5e-7	Idiopathic osteonecrosis of the femoral head;
SARC	cis	rs4443100	0.670	rs8139280	chr22:23405957	G/A	cg14186256	chr22:23484241	RTDR1	0.59	5.95	0.36	9.77e-9	Serum parathyroid hormone levels;
SARC	trans	rs2736345	0.788	rs9693589	chr8:11348961	G/A	cg06636001	chr8:8085503	FLJ10661	0.56	6.27	0.38	1.76e-9	Sjögren's syndrome;Systemic lupus erythematosus;
SARC	cis	rs834603	0.575	rs1612394	chr7:47467609	G/A	cg23694490	chr7:47445681	TNS3	-0.32	-5.89	-0.36	1.36e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs79349575	0.811	rs12601072	chr17:46997998	T/C	cg16584676	chr17:46985605	UBE2Z	0.53	6.38	0.39	9.28e-10	Type 2 diabetes;
SARC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.03	0.37	6.28e-9	Prudent dietary pattern;
SARC	cis	rs67311347	1.000	rs7617989	chr3:40512463	A/G	cg24209194	chr3:40518798	ZNF619	-0.66	-8.52	-0.49	1.98e-15	Renal cell carcinoma;
SARC	cis	rs6071524	0.784	rs2016946	chr20:37456205	T/C	cg24229276	chr20:36931287	BPI	-0.33	-5.12	-0.32	6.42e-7	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7106204	0.541	rs78630920	chr11:24291192	C/A	ch.11.24196551F	chr11:24239977	NA	0.66	4.88	0.3	2e-6	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs9527	0.590	rs12785223	chr10:104844011	C/T	cg04362960	chr10:104952993	NT5C2	-0.43	-5.06	-0.31	8.35e-7	Arsenic metabolism;
SARC	cis	rs11122272	0.735	rs2808601	chr1:231536571	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-9.72	-0.54	5.66e-19	Hemoglobin concentration;
SARC	trans	rs7647973	0.593	rs1799844	chr3:49847642	G/A	cg21659725	chr3:3221576	CRBN	0.68	6.39	0.39	9e-10	Menarche (age at onset);
SARC	cis	rs12348691	0.503	rs7023267	chr9:100603935	G/A	cg13688889	chr9:100608707	NA	-0.44	-4.8	-0.3	2.86e-6	Alopecia areata;
SARC	cis	rs1801251	1.000	rs6724117	chr2:233593660	T/G	cg25237894	chr2:233734115	C2orf82	0.38	4.93	0.31	1.59e-6	Coronary artery disease;
SARC	cis	rs2439831	1.000	rs2584725	chr15:43793135	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	8.42	0.48	3.97e-15	Lung cancer in ever smokers;
SARC	cis	rs67460515	0.500	rs1345156	chr3:160649272	G/T	cg03342759	chr3:160939853	NMD3	0.47	5.27	0.33	3.14e-7	Parkinson's disease;
SARC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg07308232	chr7:1071921	C7orf50	-0.5	-5.9	-0.36	1.24e-8	Longevity;Endometriosis;
SARC	cis	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg18252515	chr7:66147081	NA	-1.34	-11.93	-0.62	6.47e-26	Diabetic kidney disease;
SARC	cis	rs2425143	1.000	rs55761608	chr20:34344226	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.67	5.49	0.34	1.04e-7	Blood protein levels;
SARC	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg19077165	chr18:44547161	KATNAL2	-0.56	-7.94	-0.46	8.66e-14	Personality dimensions;
SARC	cis	rs4689592	0.503	rs11945642	chr4:7051065	G/C	cg26116260	chr4:7069785	GRPEL1	-0.91	-10.32	-0.56	8.13e-21	Monocyte percentage of white cells;
SARC	cis	rs11122272	0.701	rs2883799	chr1:231531166	C/G	cg06096015	chr1:231504339	EGLN1	0.38	5.7	0.35	3.54e-8	Hemoglobin concentration;
SARC	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg11987759	chr7:65425863	GUSB	-0.61	-8.01	-0.46	5.48e-14	Aortic root size;
SARC	cis	rs344364	0.511	rs62040569	chr16:1948137	C/T	cg26617929	chr16:1858877	NA	-0.71	-6.06	-0.37	5.5e-9	Glomerular filtration rate in chronic kidney disease;
SARC	cis	rs4742903	0.967	rs2122577	chr9:106866703	C/T	cg14250997	chr9:106856677	SMC2	0.52	6.74	0.4	1.23e-10	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs4253772	0.637	rs7284687	chr22:46690321	T/C	cg24881330	chr22:46731750	TRMU	0.61	5.02	0.31	1.02e-6	LDL cholesterol;Cholesterol, total;
SARC	trans	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg21659725	chr3:3221576	CRBN	0.53	6.87	0.41	5.76e-11	Intelligence (multi-trait analysis);
SARC	cis	rs9300255	0.602	rs1790131	chr12:123701010	G/T	cg05973401	chr12:123451056	ABCB9	0.52	5.89	0.36	1.34e-8	Neutrophil percentage of white cells;
SARC	cis	rs6582630	0.593	rs12816835	chr12:38533304	C/T	cg13010199	chr12:38710504	ALG10B	-0.52	-6.48	-0.39	5.28e-10	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg03264133	chr6:25882463	NA	0.55	7.23	0.43	6.97e-12	Blood metabolite levels;
SARC	cis	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg00409905	chr10:38381863	ZNF37A	-0.5	-6.77	-0.41	1.02e-10	Extrinsic epigenetic age acceleration;
SARC	cis	rs826838	0.967	rs11169169	chr12:39093153	A/C	cg26384229	chr12:38710491	ALG10B	0.89	13.53	0.66	3.69e-31	Heart rate;
SARC	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg09455208	chr3:40491958	NA	0.4	5.81	0.36	2.01e-8	Renal cell carcinoma;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg22819135	chr5:41920822	C5orf51	0.54	7.6	0.45	7.42e-13	Thyroid stimulating hormone;
SARC	cis	rs35306767	0.903	rs11253495	chr10:937064	C/T	cg26597838	chr10:835615	NA	0.76	7.91	0.46	1.05e-13	Eosinophil percentage of granulocytes;
SARC	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg13175981	chr1:150552382	MCL1	-0.54	-6.82	-0.41	7.54e-11	Tonsillectomy;
SARC	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg15847926	chr7:2749597	AMZ1	-0.3	-4.95	-0.31	1.4e-6	Height;
SARC	cis	rs796364	0.951	rs7586284	chr2:201068002	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.53	5.25	0.33	3.49e-7	Schizophrenia;
SARC	cis	rs2228479	0.702	rs17233441	chr16:89817998	C/G	cg00800038	chr16:89945340	TCF25	-0.74	-5.14	-0.32	5.75e-7	Skin colour saturation;
SARC	cis	rs9682041	0.597	rs13076319	chr3:170104630	T/G	cg11886554	chr3:170076028	SKIL	0.62	6.11	0.37	4.21e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs1153858	0.621	rs1706824	chr15:45579948	C/T	cg14582100	chr15:45693742	SPATA5L1	0.41	5.48	0.34	1.13e-7	Homoarginine levels;
SARC	cis	rs4253772	0.591	rs6007795	chr22:46686792	C/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.72	7.51	0.44	1.28e-12	LDL cholesterol;Cholesterol, total;
SARC	cis	rs7818688	0.674	rs74632106	chr8:95978032	A/G	cg13393036	chr8:95962371	TP53INP1	0.4	4.85	0.3	2.27e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs6121246	0.865	rs77130187	chr20:30269060	G/A	cg13852791	chr20:30311386	BCL2L1	0.87	8.46	0.48	2.91e-15	Mean corpuscular hemoglobin;
SARC	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg08564027	chr20:61660810	NA	0.76	11.8	0.61	1.69e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.63	-7.73	-0.45	3.24e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9325144	0.647	rs12229104	chr12:39110811	T/A	cg13010199	chr12:38710504	ALG10B	-0.53	-6.54	-0.39	3.87e-10	Morning vs. evening chronotype;
SARC	cis	rs35110281	0.720	rs162392	chr21:44941406	A/G	cg01579765	chr21:45077557	HSF2BP	-0.35	-5.94	-0.36	1.04e-8	Mean corpuscular volume;
SARC	cis	rs865483	0.895	rs2522972	chr17:35839021	C/T	cg06561646	chr17:35873369	DUSP14	-0.5	-6.66	-0.4	1.98e-10	Monocyte count;
SARC	cis	rs2760061	0.626	rs1636192	chr1:228124688	A/G	cg02753203	chr1:228287806	NA	-0.56	-7.63	-0.45	5.85e-13	Diastolic blood pressure;
SARC	cis	rs7647973	0.593	rs55997059	chr3:49858661	A/T	cg07636037	chr3:49044803	WDR6	-0.64	-6.45	-0.39	6.28e-10	Menarche (age at onset);
SARC	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg11062466	chr8:58055876	NA	0.53	5.39	0.33	1.74e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2439831	1.000	rs550239	chr15:43720197	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.09	11.37	0.6	4.12e-24	Lung cancer in ever smokers;
SARC	cis	rs9815354	1.000	rs1628874	chr3:41955714	G/A	cg03022575	chr3:42003672	ULK4	-0.55	-5.26	-0.33	3.22e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2204008	0.547	rs12318267	chr12:38250905	T/G	cg13010199	chr12:38710504	ALG10B	-0.53	-6.63	-0.4	2.35e-10	Bladder cancer;
SARC	cis	rs10876993	0.890	rs812304	chr12:58074853	A/C	cg18357645	chr12:58087776	OS9	0.46	6.05	0.37	5.81e-9	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs2153535	0.601	rs1737581	chr6:8539138	A/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.06	0.47	4.07e-14	Motion sickness;
SARC	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg13628971	chr7:2884303	GNA12	0.49	5.52	0.34	8.85e-8	Height;
SARC	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	cis	rs6831352	0.918	rs29001232	chr4:100046654	G/C	cg12011299	chr4:100065546	ADH4	-0.34	-5.64	-0.35	4.82e-8	Alcohol dependence;
SARC	cis	rs7044106	0.791	rs10985008	chr9:123492960	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	9.92	0.54	1.43e-19	Hip circumference adjusted for BMI;
SARC	cis	rs7599312	0.534	rs10207878	chr2:213409337	A/G	cg16329650	chr2:213403929	ERBB4	0.7	10.54	0.57	1.76e-21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs858239	0.600	rs7789237	chr7:23124713	T/G	cg23682824	chr7:23144976	KLHL7	0.71	9.57	0.53	1.59e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs950776	0.518	rs12916999	chr15:78826912	C/T	cg22563815	chr15:78856949	CHRNA5	0.41	6.82	0.41	7.56e-11	Sudden cardiac arrest;
SARC	cis	rs7712401	0.601	rs30027	chr5:122283390	T/C	cg19412675	chr5:122181750	SNX24	0.38	4.76	0.3	3.46e-6	Mean platelet volume;
SARC	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg17328964	chr8:145687451	CYHR1	-0.41	-5.6	-0.34	6.07e-8	Age at first birth;
SARC	cis	rs9715521	0.900	rs62299249	chr4:59824174	G/A	cg11281224	chr4:60001000	NA	-0.37	-4.74	-0.3	3.74e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	trans	rs36093844	0.698	rs79435802	chr11:85585206	T/C	cg27065003	chr5:122429449	PRDM6	-0.55	-6.45	-0.39	6.26e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs883565	0.611	rs4676588	chr3:38940741	C/T	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.5	-5.79	-0.35	2.23e-8	Handedness;
SARC	cis	rs35160687	0.862	rs12476706	chr2:86528370	C/T	cg10973622	chr2:86423274	IMMT	0.4	5.14	0.32	5.69e-7	Night sleep phenotypes;
SARC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.58	7.56	0.44	9.28e-13	Lymphocyte counts;
SARC	cis	rs1267303	0.675	rs1267312	chr1:46986748	C/G	cg25110126	chr1:46999211	NA	-0.69	-7.8	-0.45	2.1e-13	Monobrow;
SARC	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg24209194	chr3:40518798	ZNF619	-0.67	-8.78	-0.5	3.65e-16	Renal cell carcinoma;
SARC	cis	rs1163251	0.837	rs517533	chr1:120229170	T/G	cg19096424	chr1:120255104	PHGDH	0.52	6.18	0.38	2.8e-9	Blood metabolite levels;
SARC	cis	rs7712401	0.601	rs62377424	chr5:122332322	G/A	cg19412675	chr5:122181750	SNX24	-0.43	-5.43	-0.34	1.41e-7	Mean platelet volume;
SARC	cis	rs7589342	0.831	rs6714861	chr2:106518893	C/T	cg14210321	chr2:106509881	NCK2	0.47	5.41	0.33	1.56e-7	Addiction;
SARC	cis	rs7552404	0.889	rs1250874	chr1:76190978	A/G	cg22875332	chr1:76189707	ACADM	0.41	5.91	0.36	1.2e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg11890956	chr21:40555474	PSMG1	1.16	16.5	0.73	4.88e-41	Cognitive function;
SARC	cis	rs9916302	0.904	rs1077715	chr17:37683548	A/T	cg20243544	chr17:37824526	PNMT	0.57	6.76	0.41	1.07e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs9916302	0.706	rs8182252	chr17:37727950	T/C	cg00129232	chr17:37814104	STARD3	0.57	6.34	0.38	1.2e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs2066819	0.901	rs1274490	chr12:56649601	A/G	cg26316697	chr12:56727976	PAN2	-0.86	-6.11	-0.37	4.07e-9	Psoriasis vulgaris;
SARC	cis	rs4792901	0.759	rs60442473	chr17:41579287	A/G	cg22562494	chr17:41607896	ETV4	-0.31	-4.73	-0.3	3.84e-6	Dupuytren's disease;
SARC	trans	rs1910358	0.554	rs10057796	chr5:23759746	C/T	cg24775454	chr2:220083696	ABCB6	0.54	6.26	0.38	1.8e-9	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs950776	0.593	rs601079	chr15:78869579	T/A	cg24631222	chr15:78858424	CHRNA5	0.37	4.87	0.3	2.04e-6	Sudden cardiac arrest;
SARC	cis	rs10791097	0.765	rs4622274	chr11:130729486	C/T	cg09137382	chr11:130731461	NA	0.32	4.95	0.31	1.4e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg11764359	chr7:65958608	NA	0.86	12.32	0.63	3.32e-27	Aortic root size;
SARC	cis	rs7824557	0.564	rs2043508	chr8:11227406	G/A	cg21775007	chr8:11205619	TDH	-0.6	-7.78	-0.45	2.36e-13	Retinal vascular caliber;
SARC	cis	rs6911965	0.577	rs2817245	chr6:24547606	A/G	cg20631270	chr6:24437470	GPLD1	-0.49	-4.91	-0.31	1.72e-6	Hematological and biochemical traits;
SARC	cis	rs9815354	1.000	rs1716999	chr3:41930041	C/G	cg03022575	chr3:42003672	ULK4	-0.56	-5.38	-0.33	1.81e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs10504229	0.679	rs7840100	chr8:58036662	T/G	cg21724239	chr8:58056113	NA	0.59	6.18	0.38	2.81e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg17221315	chr6:27791827	HIST1H4J	0.51	5.28	0.33	2.97e-7	Parkinson's disease;
SARC	cis	rs9309711	0.623	rs7569694	chr2:3483390	T/G	cg15541040	chr2:3486749	NA	-0.43	-5.76	-0.35	2.6e-8	Neurofibrillary tangles;
SARC	cis	rs55665837	0.524	rs61884009	chr11:14426462	C/T	cg19336497	chr11:14380999	RRAS2	-0.35	-5.7	-0.35	3.6e-8	Vitamin D levels;
SARC	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg22105103	chr4:187893119	NA	0.46	6.2	0.38	2.53e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg06074448	chr4:187884817	NA	-0.4	-5.25	-0.33	3.39e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7666738	0.830	rs4345191	chr4:98945408	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs3768617	0.510	rs20557	chr1:183093875	T/C	cg13390022	chr1:182993471	LAMC1	0.31	4.79	0.3	3.01e-6	Fuchs's corneal dystrophy;
SARC	cis	rs5167	0.750	rs3786505	chr19:45490570	A/G	cg10169327	chr19:45448959	APOC2	0.31	4.92	0.31	1.61e-6	Blood protein levels;
SARC	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg06618935	chr21:46677482	NA	-0.41	-5.37	-0.33	1.92e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9436747	0.867	rs6588147	chr1:65935494	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	-0.46	-4.95	-0.31	1.44e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs72634258	0.554	rs7556518	chr1:7847846	G/A	cg26816564	chr1:7831052	VAMP3	0.54	4.87	0.3	2.06e-6	Inflammatory bowel disease;
SARC	cis	rs2404602	0.692	rs2117369	chr15:76748861	A/T	cg22467129	chr15:76604101	ETFA	-0.37	-4.92	-0.31	1.63e-6	Blood metabolite levels;
SARC	cis	rs1448094	0.874	rs10779219	chr12:86322643	T/G	cg02569458	chr12:86230093	RASSF9	0.4	5.8	0.36	2.17e-8	Major depressive disorder;
SARC	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7587476	0.689	rs10498025	chr2:215749256	A/G	cg04004882	chr2:215674386	BARD1	0.53	6.09	0.37	4.54e-9	Neuroblastoma;
SARC	cis	rs9291683	0.530	rs4235346	chr4:9945296	C/T	cg11266682	chr4:10021025	SLC2A9	-0.38	-6.63	-0.4	2.33e-10	Bone mineral density;
SARC	cis	rs9902453	1.000	rs57411618	chr17:28273052	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	6.86	0.41	6.29e-11	Coffee consumption (cups per day);
SARC	cis	rs6582630	0.555	rs7301250	chr12:38596244	G/T	cg26384229	chr12:38710491	ALG10B	0.84	12.42	0.63	1.6e-27	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg24250549	chr1:154909240	PMVK	0.77	10.71	0.57	5.09e-22	Prostate cancer;
SARC	cis	rs12908161	1.000	rs12908549	chr15:85322351	C/G	cg17507749	chr15:85114479	UBE2QP1	0.55	6.27	0.38	1.69e-9	Schizophrenia;
SARC	cis	rs920590	0.684	rs7461774	chr8:19666645	G/A	cg03894339	chr8:19674705	INTS10	0.64	7.55	0.44	9.77e-13	Acute lymphoblastic leukemia (childhood);
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg17478615	chr1:185285364	IVNS1ABP	-0.53	-6.47	-0.39	5.56e-10	Fibrinogen levels;
SARC	cis	rs10463554	0.963	rs3776859	chr5:102352034	A/C	cg23492399	chr5:102201601	PAM	-0.45	-5.14	-0.32	5.85e-7	Parkinson's disease;
SARC	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg15506890	chr2:3487001	NA	-0.47	-6.0	-0.37	7.31e-9	Neurofibrillary tangles;
SARC	cis	rs861020	0.630	rs655713	chr1:210006438	C/T	cg05527609	chr1:210001259	C1orf107	0.78	10.12	0.55	3.37e-20	Orofacial clefts;
SARC	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg23758822	chr17:41437982	NA	0.88	11.26	0.59	8.79e-24	Menopause (age at onset);
SARC	cis	rs2273669	0.748	rs114830980	chr6:109297857	A/T	cg05315195	chr6:109294784	ARMC2	-0.51	-5.05	-0.31	8.96e-7	Prostate cancer;
SARC	cis	rs1355223	0.902	rs12802120	chr11:34747650	G/A	cg18508148	chr11:34937573	PDHX;APIP	-0.4	-5.1	-0.32	7.11e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs4595586	0.545	rs9669705	chr12:39374459	C/T	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	cis	rs7551222	0.749	rs10900600	chr1:204559707	G/T	cg20240347	chr1:204465584	NA	-0.27	-4.87	-0.3	2.08e-6	Schizophrenia;
SARC	cis	rs2549003	1.000	rs2549002	chr5:131829578	C/A	cg21138405	chr5:131827807	IRF1	-0.3	-6.02	-0.37	6.6e-9	Asthma (sex interaction);
SARC	cis	rs453301	0.597	rs7001187	chr8:8792782	G/A	cg15556689	chr8:8085844	FLJ10661	-0.4	-4.92	-0.31	1.66e-6	Joint mobility (Beighton score);
SARC	cis	rs2073300	0.609	rs8183135	chr20:23384284	C/T	cg12062639	chr20:23401060	NAPB	1.02	6.94	0.41	3.78e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs7953249	0.542	rs1169284	chr12:121419926	T/C	cg15155738	chr12:121454335	C12orf43	0.46	5.74	0.35	2.87e-8	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs858239	0.571	rs6953020	chr7:23172132	T/C	cg23682824	chr7:23144976	KLHL7	0.71	9.28	0.52	1.21e-17	Cerebrospinal fluid biomarker levels;
SARC	cis	rs1144333	1.000	rs75399471	chr1:76339092	A/T	cg03433033	chr1:76189801	ACADM	0.61	4.94	0.31	1.46e-6	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs7843479	0.965	rs13278159	chr8:21799737	C/A	cg17168535	chr8:21777572	XPO7	0.63	8.06	0.47	3.85e-14	Mean corpuscular volume;
SARC	cis	rs7216064	0.953	rs4791046	chr17:65851973	G/A	cg12091567	chr17:66097778	LOC651250	-0.71	-7.78	-0.45	2.29e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs2153535	0.504	rs9328472	chr6:8470848	G/A	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs1707322	1.000	rs6661500	chr1:46465662	T/C	cg06784218	chr1:46089804	CCDC17	0.35	6.04	0.37	6.05e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2425143	1.000	rs57963833	chr20:34344225	T/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.67	5.49	0.34	1.04e-7	Blood protein levels;
SARC	cis	rs2836950	1.000	rs2836950	chr21:40604429	C/G	cg11644478	chr21:40555479	PSMG1	-0.45	-5.06	-0.31	8.32e-7	Menarche (age at onset);
SARC	cis	rs2529049	0.565	rs2521763	chr7:24770653	T/A	cg17569154	chr7:24781545	DFNA5	0.45	6.22	0.38	2.23e-9	Urate levels in obese individuals;
SARC	cis	rs2760061	0.583	rs708110	chr1:228190805	T/A	cg02753203	chr1:228287806	NA	0.81	11.43	0.6	2.62e-24	Diastolic blood pressure;
SARC	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg13628971	chr7:2884303	GNA12	0.69	8.4	0.48	4.35e-15	Height;
SARC	cis	rs1609391	0.561	rs9289523	chr3:136635589	C/G	cg15507776	chr3:136538369	TMEM22	0.84	11.51	0.6	1.39e-24	Neuroticism;
SARC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.54	6.14	0.37	3.48e-9	Prudent dietary pattern;
SARC	cis	rs7674212	0.507	rs223361	chr4:103769304	T/C	cg16532752	chr4:104119610	CENPE	-0.43	-4.9	-0.31	1.77e-6	Type 2 diabetes;
SARC	cis	rs12200560	0.505	rs211175	chr6:97073320	C/T	cg06623918	chr6:96969491	KIAA0776	0.45	5.03	0.31	9.91e-7	Coronary heart disease;
SARC	cis	rs7592578	0.771	rs12053190	chr2:191383348	A/G	cg25963032	chr2:191064776	C2orf88	-0.47	-5.22	-0.32	3.97e-7	Diastolic blood pressure;
SARC	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg18252515	chr7:66147081	NA	-1.29	-11.31	-0.6	6.31e-24	Diabetic kidney disease;
SARC	cis	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg13072238	chr3:49761600	GMPPB	-0.42	-5.43	-0.34	1.4e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7223966	1.000	rs8075422	chr17:61804686	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-6.08	-0.37	5.01e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6840360	0.593	rs10022023	chr4:152560731	A/G	cg22705602	chr4:152727874	NA	-0.41	-6.44	-0.39	6.64e-10	Intelligence (multi-trait analysis);
SARC	cis	rs920590	0.721	rs920587	chr8:19663339	C/A	cg17834443	chr8:19674713	INTS10	0.6	7.37	0.43	2.88e-12	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg16680214	chr1:154839983	KCNN3	-0.36	-5.68	-0.35	3.92e-8	Prostate cancer;
SARC	cis	rs6456156	0.742	rs2022000	chr6:167529611	A/G	cg07741184	chr6:167504864	NA	-0.29	-5.41	-0.33	1.53e-7	Primary biliary cholangitis;
SARC	cis	rs2153535	0.580	rs7743995	chr6:8496212	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	8.26	0.48	1.09e-14	Motion sickness;
SARC	cis	rs8038465	0.874	rs2291013	chr15:74000506	T/G	cg15420318	chr15:73925796	NPTN	0.42	4.81	0.3	2.72e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2439831	0.702	rs495175	chr15:43798684	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	8.13	0.47	2.52e-14	Lung cancer in ever smokers;
SARC	cis	rs908922	0.676	rs7545336	chr1:152527863	A/G	cg09873164	chr1:152488093	CRCT1	0.61	7.89	0.46	1.18e-13	Hair morphology;
SARC	cis	rs6496667	1.000	rs6496667	chr15:90893668	C/A	cg22089800	chr15:90895588	ZNF774	0.5	4.73	0.3	3.95e-6	Rheumatoid arthritis;
SARC	cis	rs2730245	0.636	rs710421	chr7:158668575	T/C	cg17136484	chr7:158649327	WDR60	0.44	5.14	0.32	5.95e-7	Height;
SARC	cis	rs5167	0.677	rs2238682	chr19:45458593	C/T	cg09555818	chr19:45449301	APOC2	0.38	5.01	0.31	1.09e-6	Blood protein levels;
SARC	cis	rs4737010	0.501	rs2032736	chr8:41639266	C/A	cg08923054	chr8:41654455	ANK1	-0.61	-6.92	-0.41	4.33e-11	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
SARC	trans	rs36093844	0.800	rs17744711	chr11:85600724	T/C	cg15359163	chr5:122429178	PRDM6	-0.53	-6.44	-0.39	6.62e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	8.82	0.5	2.72e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg11987759	chr7:65425863	GUSB	0.47	5.81	0.36	2.05e-8	Aortic root size;
SARC	cis	rs1371867	0.817	rs1788179	chr8:101333345	A/G	cg11906718	chr8:101322791	RNF19A	0.71	9.13	0.51	3.37e-17	Atrioventricular conduction;
SARC	trans	rs17266958	0.901	rs77464146	chr9:83356509	C/T	cg03038418	chr19:3096512	GNA11	0.65	6.37	0.39	1e-9	Preschool internalizing problems;
SARC	cis	rs34172651	0.874	rs200534	chr16:24752641	G/A	cg04756594	chr16:24857601	SLC5A11	-0.38	-6.05	-0.37	5.72e-9	Intelligence (multi-trait analysis);
SARC	cis	rs8084125	0.832	rs62105179	chr18:74950858	A/G	cg05528293	chr18:74961138	GALR1	0.51	5.79	0.35	2.23e-8	Obesity-related traits;
SARC	cis	rs7681440	0.835	rs6532198	chr4:90798870	C/T	cg02192967	chr4:90758406	SNCA	0.35	4.88	0.3	1.95e-6	Dementia with Lewy bodies;
SARC	cis	rs995000	0.899	rs1168031	chr1:62967987	C/T	cg06896770	chr1:63153194	DOCK7	-0.89	-12.99	-0.65	2.12e-29	Triglyceride levels;
SARC	cis	rs7927592	0.913	rs6591346	chr11:68384618	T/A	cg01657329	chr11:68192670	LRP5	-0.39	-4.95	-0.31	1.42e-6	Total body bone mineral density;
SARC	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.81	-12.37	-0.63	2.3e-27	Personality dimensions;
SARC	cis	rs1153858	0.621	rs2687512	chr15:45581495	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.77	-9.76	-0.54	4.37e-19	Homoarginine levels;
SARC	cis	rs2153535	0.580	rs1319169	chr6:8464456	G/A	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg12501888	chr15:85177176	SCAND2	0.54	6.5	0.39	4.82e-10	P wave terminal force;
SARC	cis	rs3733585	0.699	rs6449172	chr4:9966036	A/T	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.46	-0.34	1.2e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg18876405	chr7:65276391	NA	0.49	6.04	0.37	6e-9	Aortic root size;
SARC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.71	7.03	0.42	2.32e-11	Platelet count;
SARC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg26338869	chr17:61819248	STRADA	0.79	10.66	0.57	7.32e-22	Prudent dietary pattern;
SARC	cis	rs453301	0.574	rs10081437	chr8:8948979	T/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.05	-0.42	2.01e-11	Joint mobility (Beighton score);
SARC	cis	rs7953249	0.564	rs11065385	chr12:121423386	A/G	cg15155738	chr12:121454335	C12orf43	-0.47	-5.72	-0.35	3.33e-8	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs11734570	0.581	rs55958238	chr4:38604331	A/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.67	7.33	0.43	3.73e-12	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.41	-6.52	-0.39	4.33e-10	Longevity;Endometriosis;
SARC	cis	rs7772486	0.720	rs991507	chr6:146023609	G/A	cg23711669	chr6:146136114	FBXO30	-0.9	-15.58	-0.71	5.57e-38	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs28386778	0.700	rs12452767	chr17:62010503	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.66	-8.05	-0.47	4.2e-14	Prudent dietary pattern;
SARC	cis	rs6964587	0.839	rs10236107	chr7:91485461	G/A	cg17063962	chr7:91808500	NA	-0.9	-13.15	-0.65	6.73e-30	Breast cancer;
SARC	cis	rs11098499	0.863	rs7664986	chr4:120429952	A/C	cg09307838	chr4:120376055	NA	0.9	11.88	0.61	9.34e-26	Corneal astigmatism;
SARC	cis	rs427394	0.664	rs274697	chr5:6731477	A/C	cg10857441	chr5:6722123	POLS	-0.31	-4.75	-0.3	3.52e-6	Menopause (age at onset);
SARC	cis	rs11098499	0.954	rs10006877	chr4:120242793	C/T	cg09307838	chr4:120376055	NA	0.9	12.43	0.63	1.54e-27	Corneal astigmatism;
SARC	cis	rs17270561	0.609	rs9358884	chr6:25756592	A/G	cg16482183	chr6:26056742	HIST1H1C	0.42	5.03	0.31	9.6e-7	Iron status biomarkers;
SARC	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg01475735	chr3:40494733	NA	-0.45	-4.97	-0.31	1.32e-6	Renal cell carcinoma;
SARC	cis	rs2279817	1.000	rs10888048	chr1:18019742	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.46	4.95	0.31	1.4e-6	Neuroticism;
SARC	cis	rs9788682	0.747	rs2568490	chr15:78738370	T/C	cg06917634	chr15:78832804	PSMA4	0.52	5.44	0.34	1.35e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	trans	rs61931739	0.500	rs11053199	chr12:34450534	C/T	cg13010199	chr12:38710504	ALG10B	-0.74	-10.39	-0.56	4.99e-21	Morning vs. evening chronotype;
SARC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg09373136	chr17:61933544	TCAM1	-0.45	-6.21	-0.38	2.4e-9	Prudent dietary pattern;
SARC	cis	rs2153535	0.580	rs4404802	chr6:8442052	A/G	cg07606381	chr6:8435919	SLC35B3	0.78	11.09	0.59	3.11e-23	Motion sickness;
SARC	cis	rs17270561	0.609	rs9358886	chr6:25758253	T/A	cg16482183	chr6:26056742	HIST1H1C	0.41	4.87	0.3	2.06e-6	Iron status biomarkers;
SARC	cis	rs6732160	0.510	rs57825971	chr2:73384796	C/G	cg01422370	chr2:73384389	NA	0.37	6.13	0.37	3.66e-9	Intelligence (multi-trait analysis);
SARC	cis	rs9899728	0.539	rs35928207	chr17:73033629	T/G	cg27626185	chr17:73056755	KCTD2	-0.98	-7.15	-0.42	1.1e-11	Alzheimer's disease or small vessel stroke;
SARC	cis	rs7223966	0.921	rs7225092	chr17:61864005	G/T	cg00588841	chr17:61851480	DDX42;CCDC47	-0.66	-7.15	-0.42	1.14e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs4319547	0.656	rs10846664	chr12:122823777	C/T	cg23029597	chr12:123009494	RSRC2	0.42	5.36	0.33	2e-7	Body mass index;
SARC	cis	rs787274	0.543	rs10759590	chr9:115610567	G/C	cg13803584	chr9:115635662	SNX30	-0.89	-5.45	-0.34	1.25e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs7818345	0.967	rs6992893	chr8:19287504	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.43	5.82	0.36	1.93e-8	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg04772025	chr11:68637568	NA	-0.43	-5.37	-0.33	1.95e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs34330	0.562	rs17212236	chr12:12855483	G/C	cg09462578	chr12:12878428	APOLD1	-0.6	-5.78	-0.35	2.43e-8	Systemic lupus erythematosus;
SARC	cis	rs1044826	0.879	rs13071857	chr3:139152153	T/C	cg15131784	chr3:139108705	COPB2	0.4	4.93	0.31	1.55e-6	Obesity-related traits;
SARC	cis	rs2594989	0.943	rs11128550	chr3:11466828	C/T	cg00170343	chr3:11313890	ATG7	-0.55	-5.3	-0.33	2.73e-7	Circulating chemerin levels;
SARC	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg22920501	chr2:26401640	FAM59B	0.61	8.19	0.47	1.71e-14	Gut microbiome composition (summer);
SARC	cis	rs9467773	1.000	rs9295695	chr6:26528250	C/T	cg12292205	chr6:26970375	C6orf41	-0.44	-5.31	-0.33	2.56e-7	Intelligence (multi-trait analysis);
SARC	cis	rs4774830	0.744	rs62046381	chr15:56300281	T/G	cg24530489	chr15:56299380	NA	-0.84	-4.97	-0.31	1.28e-6	Delta-5 desaturase activity;
SARC	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg03351412	chr1:154909251	PMVK	0.64	8.12	0.47	2.73e-14	Prostate cancer;
SARC	trans	rs1945213	0.694	rs12222077	chr11:55848116	T/A	cg15704280	chr7:45808275	SEPT13	0.66	6.87	0.41	5.94e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9818758	0.607	rs11710247	chr3:49249800	G/T	cg00383909	chr3:49044727	WDR6	0.66	5.85	0.36	1.66e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg18288666	chr13:111364929	ING1	0.75	5.36	0.33	1.99e-7	Obesity-related traits;
SARC	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg14456004	chr13:21872349	NA	0.49	5.72	0.35	3.23e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs7666738	0.830	rs7667796	chr4:99071415	G/T	cg05340658	chr4:99064831	C4orf37	-0.66	-9.01	-0.51	7.58e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7826238	0.601	rs2976907	chr8:8345168	C/T	cg06636001	chr8:8085503	FLJ10661	0.62	8.66	0.49	8.04e-16	Systolic blood pressure;
SARC	cis	rs4988958	0.565	rs1420100	chr2:103037002	C/A	cg03938978	chr2:103052716	IL18RAP	0.32	5.12	0.32	6.49e-7	Asthma (childhood onset);
SARC	cis	rs7639513	0.590	rs3729931	chr3:12626516	A/G	cg23032965	chr3:12705835	RAF1	-0.74	-10.39	-0.56	4.99e-21	Itch intensity from mosquito bite;
SARC	cis	rs9868809	0.505	rs35064573	chr3:48740280	C/A	cg07636037	chr3:49044803	WDR6	-0.69	-6.61	-0.4	2.58e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9443189	0.950	rs6938349	chr6:76484280	A/T	cg01950844	chr6:76311363	SENP6	0.77	6.56	0.39	3.53e-10	Prostate cancer;
SARC	cis	rs12545109	1.000	rs2217957	chr8:57313360	T/C	cg19413350	chr8:57351067	NA	-0.43	-5.26	-0.33	3.22e-7	Obesity-related traits;
SARC	cis	rs10779751	0.734	rs2748878	chr1:11129434	T/C	cg08854313	chr1:11322531	MTOR	0.83	11.49	0.6	1.66e-24	Body mass index;
SARC	cis	rs6860806	0.507	rs270615	chr5:131641573	G/C	cg24060327	chr5:131705240	SLC22A5	-0.72	-8.53	-0.49	1.93e-15	Breast cancer;
SARC	cis	rs7762018	0.556	rs75659875	chr6:170054800	A/C	cg14662283	chr6:170068385	WDR27	-0.64	-4.79	-0.3	2.94e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs13191362	0.938	rs59067610	chr6:163030440	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.57	5.48	0.34	1.09e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4742903	0.904	rs7048676	chr9:106998349	G/A	cg14250997	chr9:106856677	SMC2	0.38	4.87	0.3	2.08e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs7553864	0.614	rs4559475	chr1:87614236	T/C	cg18153957	chr1:87613403	LOC339524	-0.44	-5.04	-0.31	9.34e-7	Smoking behavior;
SARC	cis	rs11122272	0.614	rs78172021	chr1:231525160	A/T	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs4742903	0.935	rs4743692	chr9:106931890	A/G	cg14250997	chr9:106856677	SMC2	0.44	5.5	0.34	1.01e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs2290405	0.527	rs4690329	chr4:931385	T/A	cg04824913	chr4:887549	GAK	0.57	6.73	0.4	1.28e-10	Systemic sclerosis;
SARC	cis	rs2439831	1.000	rs690316	chr15:43737880	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	8.11	0.47	2.95e-14	Lung cancer in ever smokers;
SARC	cis	rs12545912	0.909	rs4840431	chr8:9470848	A/C	cg21625330	chr8:9911636	MSRA	-0.51	-4.94	-0.31	1.51e-6	Multiple myeloma (hyperdiploidy);
SARC	cis	rs7937682	0.924	rs10891288	chr11:111552053	G/T	cg22437258	chr11:111473054	SIK2	-0.71	-9.86	-0.54	2.11e-19	Primary sclerosing cholangitis;
SARC	cis	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg13647721	chr17:30228624	UTP6	-0.7	-5.88	-0.36	1.4e-8	Hip circumference adjusted for BMI;
SARC	cis	rs9549260	0.569	rs117615233	chr13:41309223	G/A	cg21288729	chr13:41239152	FOXO1	0.54	4.82	0.3	2.63e-6	Red blood cell count;
SARC	cis	rs637571	0.522	rs649000	chr11:65742933	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.57	8.7	0.5	5.94e-16	Eosinophil percentage of white cells;
SARC	cis	rs9309473	1.000	rs6546838	chr2:73679280	A/G	cg20560298	chr2:73613845	ALMS1	-0.51	-6.12	-0.37	3.98e-9	Metabolite levels;
SARC	cis	rs6866344	0.697	rs62392823	chr5:178126968	T/C	cg10224037	chr5:178157518	ZNF354A	0.99	11.97	0.62	4.81e-26	Neutrophil percentage of white cells;
SARC	cis	rs57920188	0.535	rs10915658	chr1:4092921	T/C	cg20703997	chr1:4087676	NA	0.49	5.25	0.33	3.39e-7	Interleukin-17 levels;
SARC	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg13944838	chr5:179740914	GFPT2	-0.59	-7.59	-0.45	7.63e-13	Height;
SARC	cis	rs910316	0.789	rs175457	chr14:75584507	C/T	cg11812906	chr14:75593930	NEK9	-0.77	-10.74	-0.58	4.13e-22	Height;
SARC	cis	rs9420	1.000	rs9420	chr11:57510294	A/G	cg19752551	chr11:57585705	CTNND1	0.4	5.42	0.33	1.47e-7	Schizophrenia;
SARC	cis	rs4742903	0.509	rs10820615	chr9:106919996	C/T	cg14250997	chr9:106856677	SMC2	0.4	4.78	0.3	3.1e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs11711311	1.000	rs9811746	chr3:113515060	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	8.58	0.49	1.31e-15	IgG glycosylation;
SARC	cis	rs9916302	0.706	rs9893735	chr17:37469858	A/C	cg15445000	chr17:37608096	MED1	-0.45	-4.92	-0.31	1.62e-6	Glomerular filtration rate (creatinine);
SARC	trans	rs3942852	0.524	rs7118665	chr11:48078427	C/A	cg15704280	chr7:45808275	SEPT13	0.69	8.9	0.5	1.65e-16	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg02725872	chr8:58115012	NA	-0.32	-4.84	-0.3	2.35e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs7772486	0.686	rs1292334	chr6:145968288	A/G	cg23711669	chr6:146136114	FBXO30	0.86	13.81	0.67	4.36e-32	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12368653	0.591	rs1038914	chr12:58011066	G/A	cg00677455	chr12:58241039	CTDSP2	0.4	5.31	0.33	2.55e-7	Multiple sclerosis;
SARC	cis	rs7666738	0.830	rs7663438	chr4:99014582	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.79	0.5	3.4e-16	Colonoscopy-negative controls vs population controls;
SARC	trans	rs2018683	0.711	rs917213	chr7:28968204	A/G	cg19402173	chr7:128379420	CALU	-0.59	-7.61	-0.45	6.87e-13	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs1050631	0.960	rs4799848	chr18:33686292	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.42	5.15	0.32	5.58e-7	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs4481887	0.893	rs28579823	chr1:248506881	C/T	cg00666640	chr1:248458726	OR2T12	0.34	5.81	0.36	2.07e-8	Common traits (Other);
SARC	cis	rs763014	0.931	rs7199839	chr16:636126	T/C	cg09263875	chr16:632152	PIGQ	0.5	7.59	0.45	7.5e-13	Height;
SARC	cis	rs16921914	0.565	rs286650	chr11:31230207	T/C	cg26647111	chr11:31128758	NA	-0.4	-5.19	-0.32	4.52e-7	Bone mineral density (spine);
SARC	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg16325326	chr1:53192061	ZYG11B	-0.82	-13.46	-0.66	6.13e-31	Monocyte count;
SARC	trans	rs9929218	1.000	rs12446575	chr16:68791644	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.62	-7.8	-0.46	2.06e-13	Colorectal cancer;
SARC	cis	rs6570726	0.935	rs395948	chr6:145820185	G/A	cg23711669	chr6:146136114	FBXO30	0.78	11.91	0.62	7.29e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs208515	0.556	rs12206707	chr6:66697182	A/G	cg07460842	chr6:66804631	NA	0.96	10.95	0.58	8.64e-23	Exhaled nitric oxide levels;
SARC	cis	rs3733585	0.638	rs6449155	chr4:9956547	T/G	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.95	-0.36	9.9e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs6500602	0.727	rs7193136	chr16:4580034	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.32	5.49	0.34	1.03e-7	Schizophrenia;
SARC	cis	rs459571	0.635	rs379471	chr9:136890649	G/A	cg01294253	chr9:136912663	BRD3	0.42	5.52	0.34	9.07e-8	Platelet distribution width;
SARC	cis	rs7020830	0.931	rs9775431	chr9:37130433	G/A	cg14294708	chr9:37120828	ZCCHC7	1.11	19.98	0.79	2.01e-52	Schizophrenia;
SARC	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg12463550	chr7:65579703	CRCP	-0.47	-5.62	-0.35	5.54e-8	Aortic root size;
SARC	trans	rs61931739	0.817	rs10772144	chr12:34242463	A/C	cg26384229	chr12:38710491	ALG10B	0.62	8.06	0.47	3.98e-14	Morning vs. evening chronotype;
SARC	cis	rs17376456	0.825	rs17374166	chr5:93238655	T/C	cg25358565	chr5:93447407	FAM172A	1.29	14.31	0.68	9.44e-34	Diabetic retinopathy;
SARC	cis	rs4589502	0.800	rs2035150	chr15:67201794	A/C	cg12317470	chr15:67143691	NA	-0.5	-4.83	-0.3	2.46e-6	Lung cancer (smoking interaction);
SARC	trans	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	7.03	0.42	2.21e-11	Intelligence (multi-trait analysis);
SARC	cis	rs9858542	0.953	rs7633271	chr3:49555963	T/C	cg07274523	chr3:49395745	GPX1	0.53	6.3	0.38	1.44e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs9443189	0.570	rs659807	chr6:76293435	C/A	cg01950844	chr6:76311363	SENP6	0.85	7.74	0.45	3.02e-13	Prostate cancer;
SARC	cis	rs1865721	0.804	rs62089468	chr18:73158850	C/T	cg26385618	chr18:73139727	C18orf62	-0.37	-5.1	-0.32	7.06e-7	Intelligence;
SARC	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg11890956	chr21:40555474	PSMG1	1.17	19.54	0.79	5.25e-51	Cognitive function;
SARC	cis	rs60733400	0.782	rs4648564	chr1:2562169	C/T	cg20673091	chr1:2541236	MMEL1	-0.33	-5.05	-0.31	8.78e-7	Multiple sclerosis;
SARC	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	8.71	0.5	5.56e-16	Alzheimer's disease;
SARC	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	12.83	0.64	7.44e-29	Platelet count;
SARC	trans	rs61931739	0.500	rs7489270	chr12:34432062	C/T	cg13010199	chr12:38710504	ALG10B	0.81	11.39	0.6	3.58e-24	Morning vs. evening chronotype;
SARC	cis	rs950027	0.596	rs2467865	chr15:45638307	T/C	cg26924012	chr15:45694286	SPATA5L1	0.53	6.74	0.4	1.2e-10	Response to fenofibrate (adiponectin levels);
SARC	cis	rs10911251	0.508	rs944970	chr1:183112566	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	9.86	0.54	2.11e-19	Colorectal cancer;
SARC	cis	rs11687170	0.882	rs73131631	chr2:237061290	C/T	cg19324714	chr2:237145437	ASB18	0.47	4.73	0.3	3.82e-6	Educational attainment;Educational attainment (years of education);
SARC	cis	rs17376456	0.778	rs10440717	chr5:93424852	C/A	cg21475434	chr5:93447410	FAM172A	0.88	8.11	0.47	2.81e-14	Diabetic retinopathy;
SARC	cis	rs1055129	0.537	rs1135640	chr17:73949540	C/G	cg14829360	chr17:73884958	NA	0.55	8.27	0.48	1e-14	White matter hyperintensity burden;
SARC	cis	rs4848143	0.864	rs921089	chr2:121808766	C/G	cg01730274	chr2:122407247	CLASP1	0.38	4.9	0.31	1.76e-6	Capecitabine sensitivity;
SARC	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg26513180	chr16:89883248	FANCA	0.71	4.79	0.3	2.98e-6	Skin colour saturation;
SARC	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg22857025	chr5:266934	NA	-1.08	-11.86	-0.61	1.06e-25	Breast cancer;
SARC	cis	rs9473924	0.542	rs2894780	chr6:50924527	T/G	cg14470998	chr6:50812995	TFAP2B	0.71	6.27	0.38	1.73e-9	Body mass index;
SARC	cis	rs6446731	0.517	rs2858087	chr4:3268892	A/T	cg06533319	chr4:3265114	C4orf44	0.31	4.99	0.31	1.18e-6	Mean platelet volume;
SARC	trans	rs11098499	0.909	rs1809406	chr4:120377122	G/A	cg25214090	chr10:38739885	LOC399744	0.54	7.11	0.42	1.38e-11	Corneal astigmatism;
SARC	cis	rs7712401	0.601	rs30039	chr5:122277179	A/C	cg19412675	chr5:122181750	SNX24	-0.42	-5.45	-0.34	1.29e-7	Mean platelet volume;
SARC	cis	rs6693567	0.545	rs6664703	chr1:150459087	G/C	cg09579323	chr1:150459698	TARS2	0.44	5.56	0.34	7.54e-8	Migraine;
SARC	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg11987759	chr7:65425863	GUSB	-0.6	-7.95	-0.46	7.8500000000000006e-14	Aortic root size;
SARC	cis	rs1784581	0.706	rs9346895	chr6:162431168	T/C	cg17173639	chr6:162384350	PARK2	0.65	8.81	0.5	2.91e-16	Itch intensity from mosquito bite;
SARC	cis	rs10791323	0.569	rs10736608	chr11:133740048	C/T	cg15485101	chr11:133734466	NA	0.33	5.28	0.33	2.92e-7	Childhood ear infection;
SARC	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg24675658	chr1:53192096	ZYG11B	-0.56	-7.7	-0.45	3.93e-13	Monocyte count;
SARC	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg21724239	chr8:58056113	NA	0.55	5.8	0.36	2.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2486288	0.586	rs12909883	chr15:45572054	G/C	cg21132104	chr15:45694354	SPATA5L1	-0.55	-6.86	-0.41	5.98e-11	Glomerular filtration rate;
SARC	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.89	12.64	0.64	3.1e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg24531977	chr5:56204891	C5orf35	-0.54	-5.45	-0.34	1.26e-7	Initial pursuit acceleration;
SARC	cis	rs3768617	0.510	rs2296288	chr1:183072590	T/C	cg13390022	chr1:182993471	LAMC1	0.32	4.84	0.3	2.39e-6	Fuchs's corneal dystrophy;
SARC	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2836974	0.604	rs2854727	chr21:40713787	A/G	cg11890956	chr21:40555474	PSMG1	0.73	9.97	0.55	1.03e-19	Cognitive function;
SARC	cis	rs681343	1.000	rs516246	chr19:49206172	C/T	cg21064579	chr19:49206444	FUT2	0.36	5.1	0.32	6.92e-7	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
SARC	cis	rs2342371	0.848	rs9864836	chr3:196200737	C/T	cg15048948	chr3:196158458	UBXN7	0.51	6.35	0.38	1.1e-9	Fat distribution (HIV);
SARC	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg24549020	chr5:56110836	MAP3K1	-0.48	-5.25	-0.33	3.41e-7	Initial pursuit acceleration;
SARC	cis	rs7904368	0.754	rs7076955	chr10:16852781	G/A	cg14835575	chr10:16859367	RSU1	0.69	6.79	0.41	9.24e-11	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs7666738	0.830	rs1405767	chr4:98965295	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9473924	0.542	rs6901576	chr6:50926064	G/T	cg14470998	chr6:50812995	TFAP2B	-0.71	-6.32	-0.38	1.28e-9	Body mass index;
SARC	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.5e-10	Life satisfaction;
SARC	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg18357526	chr6:26021779	HIST1H4A	0.88	11.44	0.6	2.33e-24	Intelligence (multi-trait analysis);
SARC	cis	rs8072100	0.713	rs11651643	chr17:45483229	A/G	cg08085267	chr17:45401833	C17orf57	-0.44	-5.18	-0.32	4.76e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg05015635	chr9:89563603	GAS1	-0.49	-6.61	-0.4	2.65e-10	Thyroid stimulating hormone;
SARC	trans	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg17830980	chr10:43048298	ZNF37B	-0.54	-7.28	-0.43	5.16e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs17153755	0.931	rs12677897	chr8:11612963	G/A	cg12395012	chr8:11607386	GATA4	-0.31	-4.85	-0.3	2.28e-6	Testicular germ cell tumor;
SARC	cis	rs11098499	0.657	rs7664458	chr4:120371967	A/G	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs9420	0.961	rs80304923	chr11:57522823	C/G	cg23127183	chr11:57508653	C11orf31	-0.58	-6.74	-0.4	1.23e-10	Schizophrenia;
SARC	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg18135555	chr8:22132992	PIWIL2	0.41	6.15	0.37	3.33e-9	Hypertriglyceridemia;
SARC	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg10435706	chr6:150039699	LATS1	0.36	4.8	0.3	2.88e-6	Lung cancer;
SARC	cis	rs17376456	1.000	rs12188453	chr5:93560807	G/T	cg21475434	chr5:93447410	FAM172A	-0.91	-8.17	-0.47	1.94e-14	Diabetic retinopathy;
SARC	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg19223190	chr17:80058835	NA	0.44	6.19	0.38	2.67e-9	Life satisfaction;
SARC	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg05313129	chr8:58192883	C8orf71	-0.48	-5.68	-0.35	4.05e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs8014204	0.736	rs2111705	chr14:75261641	G/A	cg06637938	chr14:75390232	RPS6KL1	0.56	7.86	0.46	1.41e-13	Caffeine consumption;
SARC	cis	rs4742903	0.509	rs10820619	chr9:106964344	G/C	cg14250997	chr9:106856677	SMC2	0.39	4.8	0.3	2.77e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs6570726	0.967	rs418662	chr6:145848832	A/C	cg05220968	chr6:146057943	EPM2A	-0.28	-4.82	-0.3	2.54e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg17221315	chr6:27791827	HIST1H4J	-0.48	-5.32	-0.33	2.45e-7	Depression;
SARC	cis	rs9486719	1.000	rs3798295	chr6:97052164	C/T	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.42	-0.48	3.9e-15	Migraine;Coronary artery disease;
SARC	cis	rs644799	0.930	rs631099	chr11:95563482	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	14.89	0.7	1.07e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg11764359	chr7:65958608	NA	0.59	6.91	0.41	4.63e-11	Aortic root size;
SARC	cis	rs6912958	0.781	rs1051148	chr6:88221892	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-5.79	-0.35	2.32e-8	Monocyte percentage of white cells;
SARC	cis	rs2011503	0.714	rs7250233	chr19:19630948	C/T	cg03709012	chr19:19516395	GATAD2A	0.6	5.29	0.33	2.8e-7	Bipolar disorder;
SARC	cis	rs1003719	0.788	rs7275582	chr21:38451130	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.68	9.69	0.54	7.27e-19	Eye color traits;
SARC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08219700	chr8:58056026	NA	0.66	8.57	0.49	1.43e-15	Developmental language disorder (linguistic errors);
SARC	cis	rs12681288	0.862	rs34510005	chr8:1018943	T/C	cg15309053	chr8:964076	NA	0.43	7.42	0.44	2.22e-12	Schizophrenia;
SARC	cis	rs7762018	0.607	rs3800544	chr6:170058374	C/T	cg14662283	chr6:170068385	WDR27	-0.64	-4.86	-0.3	2.17e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs7512552	0.966	rs1122967	chr1:150258838	C/G	cg09579323	chr1:150459698	TARS2	-0.41	-4.95	-0.31	1.41e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs9479482	1.000	rs9479405	chr6:150338065	G/A	cg03788504	chr6:150331562	NA	-0.32	-5.2	-0.32	4.37e-7	Alopecia areata;
SARC	cis	rs3796352	0.892	rs11718388	chr3:53076415	G/A	cg07884673	chr3:53033167	SFMBT1	0.77	5.33	0.33	2.35e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2013441	1.000	rs2080673	chr17:20062395	C/A	cg13482628	chr17:19912719	NA	0.48	6.15	0.37	3.36e-9	Obesity-related traits;
SARC	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg25894440	chr7:65020034	NA	-0.72	-5.51	-0.34	9.49e-8	Diabetic kidney disease;
SARC	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg06618935	chr21:46677482	NA	-0.42	-5.52	-0.34	9.02e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1538970	1.000	rs9326141	chr1:45828943	A/G	cg05343316	chr1:45956843	TESK2	-0.71	-8.28	-0.48	9.43e-15	Platelet count;
SARC	cis	rs4563143	0.514	rs73029081	chr19:29295583	C/G	cg14983838	chr19:29218262	NA	0.68	7.88	0.46	1.26e-13	Methadone dose in opioid dependence;
SARC	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg14298792	chr15:30685198	CHRFAM7A	-0.48	-5.48	-0.34	1.12e-7	Huntington's disease progression;
SARC	cis	rs1185460	0.967	rs1784461	chr11:118937985	G/A	cg01677386	chr11:118938358	VPS11	-0.39	-4.85	-0.3	2.23e-6	Coronary artery disease;
SARC	cis	rs7647973	0.961	rs4955417	chr3:49298205	T/C	cg06212747	chr3:49208901	KLHDC8B	0.61	6.66	0.4	1.99e-10	Menarche (age at onset);
SARC	cis	rs1707322	1.000	rs7547284	chr1:46319565	C/G	cg06784218	chr1:46089804	CCDC17	0.33	5.78	0.35	2.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs288326	0.561	rs77460513	chr2:183819625	C/T	cg09997497	chr2:183902928	NCKAP1	0.74	5.12	0.32	6.43e-7	Blood protein levels;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg05056288	chr2:30673635	LCLAT1	0.47	6.68	0.4	1.69e-10	Thyroid stimulating hormone;
SARC	cis	rs7208859	0.673	rs11656462	chr17:29160700	G/A	cg13385521	chr17:29058706	SUZ12P	0.85	7.22	0.43	7.1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs1832871	0.672	rs9456286	chr6:158734315	A/G	cg07165851	chr6:158734300	TULP4	0.58	6.77	0.41	1.05e-10	Height;
SARC	cis	rs7959452	0.535	rs7135092	chr12:69658330	T/C	cg20891283	chr12:69753455	YEATS4	0.42	5.6	0.34	6.1e-8	Blood protein levels;
SARC	cis	rs710216	0.623	rs841858	chr1:43399167	G/T	cg03128534	chr1:43423976	SLC2A1	0.63	5.98	0.36	8.42e-9	Red cell distribution width;
SARC	cis	rs9581943	0.967	rs9581929	chr13:28464203	C/T	cg25299895	chr13:28498091	PDX1	0.38	5.13	0.32	6.03e-7	Pancreatic cancer;
SARC	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.61e-6	Depression;
SARC	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg12310025	chr6:25882481	NA	-0.47	-6.06	-0.37	5.46e-9	Blood metabolite levels;
SARC	cis	rs8141529	0.956	rs132539	chr22:29304253	C/T	cg15103426	chr22:29168792	CCDC117	0.61	7.42	0.44	2.18e-12	Lymphocyte counts;
SARC	cis	rs2380220	0.810	rs66524640	chr6:95956566	T/C	cg23517279	chr6:96025343	MANEA	-0.54	-5.39	-0.33	1.76e-7	Behavioural disinhibition (generation interaction);
SARC	cis	rs12681288	0.676	rs1562925	chr8:1010894	A/G	cg15309053	chr8:964076	NA	0.41	6.5	0.39	4.79e-10	Schizophrenia;
SARC	cis	rs3956705	0.798	rs6462427	chr7:32907344	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.46	5.64	0.35	4.83e-8	Red cell distribution width;
SARC	cis	rs7927771	0.524	rs7118747	chr11:47889545	C/T	cg10504702	chr11:47789108	FNBP4	-0.43	-5.53	-0.34	8.41e-8	Subjective well-being;
SARC	cis	rs7872515	1.000	rs7852067	chr9:94815594	A/G	cg01248375	chr9:94877805	SPTLC1	0.65	4.98	0.31	1.23e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs17401966	0.964	rs17400510	chr1:10290421	T/C	cg15208524	chr1:10270712	KIF1B	0.6	6.91	0.41	4.59e-11	Hepatocellular carcinoma;
SARC	cis	rs4141404	0.828	rs2413043	chr22:31648576	G/T	cg13145458	chr22:31556086	RNF185	0.48	5.18	0.32	4.83e-7	Paclitaxel-induced neuropathy;
SARC	trans	rs8073060	0.586	rs225278	chr17:33974170	C/T	cg19694781	chr19:47549865	TMEM160	-0.67	-6.82	-0.41	7.85e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs787274	0.543	rs1041086	chr9:115627744	C/G	cg13803584	chr9:115635662	SNX30	-0.91	-7.23	-0.43	6.97e-12	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-4.93	-0.31	1.59e-6	Total body bone mineral density;
SARC	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg01570182	chr17:44337453	NA	-0.85	-9.89	-0.54	1.72e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs72945132	0.882	rs12289915	chr11:70131956	G/C	cg00319359	chr11:70116639	PPFIA1	0.68	6.37	0.39	1.01e-9	Coronary artery disease;
SARC	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg01238044	chr22:24384105	GSTT1	-0.6	-6.9	-0.41	4.81e-11	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1580019	0.922	rs1376289	chr7:32486980	C/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.76	-10.35	-0.56	6.47e-21	Cognitive ability;
SARC	cis	rs17376456	0.569	rs11135397	chr5:93214975	G/T	cg25358565	chr5:93447407	FAM172A	0.93	10.63	0.57	9.01e-22	Diabetic retinopathy;
SARC	cis	rs9436747	0.641	rs7413467	chr1:66047893	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.48	4.94	0.31	1.48e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs62344088	0.590	rs2115276	chr5:169829	C/G	cg22496380	chr5:211416	CCDC127	-0.84	-5.65	-0.35	4.69e-8	Asthma (childhood onset);
SARC	cis	rs523522	0.962	rs3893104	chr12:120903936	G/A	cg12219531	chr12:120966889	COQ5	0.8	10.41	0.56	4.49e-21	High light scatter reticulocyte count;
SARC	cis	rs7647973	0.566	rs57630346	chr3:49086215	T/C	cg07636037	chr3:49044803	WDR6	0.85	9.34	0.52	7.97e-18	Menarche (age at onset);
SARC	cis	rs56176327	0.583	rs7613603	chr3:49812866	C/T	cg13072238	chr3:49761600	GMPPB	0.6	6.16	0.37	3.16e-9	Intelligence (multi-trait analysis);
SARC	cis	rs12681366	0.537	rs3019284	chr8:95473076	A/C	cg13257157	chr8:95487014	RAD54B	0.4	4.81	0.3	2.67e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs7659604	0.702	rs6815790	chr4:122695385	A/C	cg20573242	chr4:122745356	CCNA2	0.55	7.0	0.42	2.74e-11	Type 2 diabetes;
SARC	trans	rs561341	1.000	rs535151	chr17:30317405	C/T	cg20587970	chr11:113659929	NA	-1.01	-10.12	-0.55	3.53e-20	Hip circumference adjusted for BMI;
SARC	cis	rs17023223	0.537	rs10923741	chr1:119604473	A/T	cg05756136	chr1:119680316	WARS2	-0.43	-5.03	-0.31	9.81e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs2832191	0.633	rs2832166	chr21:30462395	G/C	cg24692254	chr21:30365293	RNF160	1.02	18.09	0.76	2.83e-46	Dental caries;
SARC	cis	rs57506017	0.585	rs5011431	chr7:12268551	G/A	cg23422036	chr7:12250390	TMEM106B	0.45	5.87	0.36	1.46e-8	Neuroticism;
SARC	cis	rs11098499	0.708	rs1546506	chr4:120241240	T/C	cg09307838	chr4:120376055	NA	0.81	11.15	0.59	2.11e-23	Corneal astigmatism;
SARC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg11494091	chr17:61959527	GH2	0.52	7.92	0.46	9.41e-14	Prudent dietary pattern;
SARC	cis	rs3771570	0.901	rs3821285	chr2:242421314	A/G	cg21155796	chr2:242212141	HDLBP	-0.51	-5.43	-0.34	1.41e-7	Prostate cancer;
SARC	cis	rs6546550	0.869	rs6720498	chr2:70124805	T/C	cg02498382	chr2:70120550	SNRNP27	-0.33	-5.35	-0.33	2.07e-7	Prevalent atrial fibrillation;
SARC	cis	rs1401999	0.674	rs562	chr3:183637845	T/C	cg01324343	chr3:183735012	ABCC5	0.59	10.72	0.57	4.79e-22	Anterior chamber depth;
SARC	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg22920501	chr2:26401640	FAM59B	0.61	7.93	0.46	8.99e-14	Gut microbiome composition (summer);
SARC	cis	rs7089973	0.872	rs3180654	chr10:116615045	T/C	cg08188268	chr10:116634841	FAM160B1	0.36	5.8	0.36	2.13e-8	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs3540	0.512	rs8033818	chr15:91075535	C/T	cg22089800	chr15:90895588	ZNF774	-0.61	-7.62	-0.45	6.34e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs3764563	1.000	rs1022413	chr19:15741984	G/A	cg20725493	chr19:15740067	CYP4F8	-0.77	-5.96	-0.36	9.12e-9	Inflammatory biomarkers;
SARC	cis	rs78456975	1.000	rs55761535	chr2:1561450	A/G	cg01028140	chr2:1542097	TPO	-0.5	-4.97	-0.31	1.3e-6	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.39	4.72	0.3	4.01e-6	Tonsillectomy;
SARC	cis	rs6942407	0.649	rs6975202	chr7:86860382	C/A	cg02420886	chr7:86849541	C7orf23	0.61	5.39	0.33	1.72e-7	Food allergy;
SARC	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg03709012	chr19:19516395	GATAD2A	1.01	16.05	0.72	1.54e-39	Tonsillectomy;
SARC	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	13.86	0.67	2.88e-32	Chronic sinus infection;
SARC	cis	rs787274	1.000	rs9409123	chr9:115507165	G/A	cg13803584	chr9:115635662	SNX30	0.8	5.39	0.33	1.69e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs7043114	0.544	rs12335553	chr9:95297871	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.51	-6.28	-0.38	1.65e-9	Height;
SARC	trans	rs6716963	0.585	rs11687224	chr2:194568323	A/G	cg24883574	chr7:127225343	GCC1	0.53	6.34	0.38	1.19e-9	Schizophrenia;
SARC	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg04944784	chr2:26401820	FAM59B	-0.48	-6.0	-0.37	7.54e-9	Gut microbiome composition (summer);
SARC	cis	rs2153535	0.580	rs4451187	chr6:8473910	C/T	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	cis	rs2952156	0.920	rs2517954	chr17:37843550	T/C	cg00129232	chr17:37814104	STARD3	-0.69	-8.99	-0.51	8.97e-17	Asthma;
SARC	cis	rs75920871	0.545	rs7939934	chr11:116861268	A/T	cg01368799	chr11:117014884	PAFAH1B2	-0.48	-4.95	-0.31	1.46e-6	Subjective well-being;
SARC	trans	rs5417	0.662	rs8067500	chr17:7172631	A/G	cg15655154	chr3:113604241	GRAMD1C	0.59	8.02	0.47	5.28e-14	Diastolic blood pressure;
SARC	cis	rs55823223	0.564	rs936396	chr17:73846829	C/G	cg08125733	chr17:73851984	WBP2	0.56	6.42	0.39	7.69e-10	Psoriasis;
SARC	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.97	-15.37	-0.71	2.73e-37	Chronic sinus infection;
SARC	cis	rs6088580	0.524	rs7269596	chr20:33229063	T/C	cg24642439	chr20:33292090	TP53INP2	-0.53	-6.55	-0.39	3.57e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs10892173	0.765	rs7125693	chr11:117670651	C/T	cg07621104	chr11:117668040	DSCAML1	0.36	4.73	0.3	3.96e-6	Myopia;
SARC	cis	rs6831352	0.918	rs34876213	chr4:100062216	G/A	cg13256891	chr4:100009986	ADH5	-0.66	-8.16	-0.47	2.08e-14	Alcohol dependence;
SARC	cis	rs11098499	0.532	rs12512646	chr4:120585733	G/A	cg09307838	chr4:120376055	NA	0.78	11.03	0.59	4.91e-23	Corneal astigmatism;
SARC	cis	rs3008870	0.755	rs1535365	chr1:67497613	T/C	cg02640540	chr1:67518911	SLC35D1	0.46	5.25	0.33	3.48e-7	Lymphocyte percentage of white cells;
SARC	cis	rs2916247	1.000	rs2976502	chr8:92980734	A/G	cg10183463	chr8:93005414	RUNX1T1	0.6	5.83	0.36	1.81e-8	Intelligence (multi-trait analysis);
SARC	cis	rs6089584	0.566	rs7274240	chr20:60622004	C/T	cg13770153	chr20:60521292	NA	-0.35	-5.12	-0.32	6.47e-7	Body mass index;
SARC	cis	rs4911259	0.507	rs8118663	chr20:31398876	A/G	cg13636640	chr20:31349939	DNMT3B	0.65	7.49	0.44	1.44e-12	Inflammatory bowel disease;
SARC	cis	rs7524258	0.868	rs2412152	chr1:7303213	C/T	cg07173049	chr1:7289937	CAMTA1	0.39	7.57	0.44	8.55e-13	Tourette's syndrome or obsessive-compulsive disorder;
SARC	cis	rs2522056	1.000	rs2522063	chr5:131805591	G/T	cg24060327	chr5:131705240	SLC22A5	0.48	4.76	0.3	3.47e-6	Lymphocyte counts;Fibrinogen;
SARC	cis	rs7904368	0.806	rs45495501	chr10:16861476	G/A	cg14835575	chr10:16859367	RSU1	0.8	8.11	0.47	2.93e-14	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs4975616	0.714	rs37007	chr5:1352372	G/C	cg07493874	chr5:1342172	CLPTM1L	-0.39	-5.18	-0.32	4.9e-7	Lung cancer;
SARC	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg03647317	chr4:187891568	NA	-0.38	-5.27	-0.33	3.09e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2425143	1.000	rs7273815	chr20:34232415	G/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	5.02	0.31	1.01e-6	Blood protein levels;
SARC	cis	rs6545883	0.826	rs2694617	chr2:61537214	G/A	cg15711740	chr2:61764176	XPO1	0.39	4.75	0.3	3.61e-6	Tuberculosis;
SARC	cis	rs10927875	0.864	rs1976402	chr1:16143779	G/A	cg21385522	chr1:16154831	NA	-0.93	-10.97	-0.58	7.57e-23	Dilated cardiomyopathy;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg18466498	chr7:27498473	NA	-0.8	-7.05	-0.42	2.01e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg22535103	chr8:58192502	C8orf71	-0.58	-6.24	-0.38	2.05e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs17376456	1.000	rs34854140	chr5:93538169	G/A	cg21475434	chr5:93447410	FAM172A	0.94	8.22	0.47	1.4e-14	Diabetic retinopathy;
SARC	cis	rs13314892	0.728	rs74280296	chr3:69889006	T/A	cg17445875	chr3:69859618	MITF	-0.48	-4.88	-0.3	1.97e-6	QRS complex (12-leadsum);
SARC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg18404041	chr3:52824283	ITIH1	-0.38	-5.86	-0.36	1.58e-8	Bipolar disorder;
SARC	cis	rs7937682	0.960	rs480293	chr11:111469132	A/C	cg22437258	chr11:111473054	SIK2	0.76	9.87	0.54	2.07e-19	Primary sclerosing cholangitis;
SARC	cis	rs908922	0.676	rs12132469	chr1:152491856	G/T	cg09873164	chr1:152488093	CRCT1	0.62	7.96	0.46	7.55e-14	Hair morphology;
SARC	cis	rs11105298	0.891	rs10858871	chr12:89871613	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.49	-5.0	-0.31	1.11e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs9790314	0.747	rs9990242	chr3:160838461	T/C	cg04691961	chr3:161091175	C3orf57	-0.68	-9.55	-0.53	1.9e-18	Morning vs. evening chronotype;
SARC	cis	rs9494142	0.592	rs1547247	chr6:135390836	C/T	cg22676075	chr6:135203613	NA	0.49	5.7	0.35	3.63e-8	Lymphocyte counts;Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs7412746	0.611	rs6660084	chr1:150748803	T/C	cg10589385	chr1:150898437	SETDB1	0.4	5.31	0.33	2.53e-7	Melanoma;
SARC	cis	rs9473924	0.505	rs7756058	chr6:50904438	G/A	cg14470998	chr6:50812995	TFAP2B	0.76	7.13	0.42	1.27e-11	Body mass index;
SARC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg22105103	chr4:187893119	NA	0.45	5.94	0.36	1.05e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2073499	0.935	rs2236939	chr3:50243510	G/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.57	5.19	0.32	4.65e-7	Schizophrenia;
SARC	cis	rs3741151	0.686	rs12285885	chr11:73294478	A/G	cg17517138	chr11:73019481	ARHGEF17	0.66	5.41	0.33	1.55e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg17347471	chr5:52405518	MOCS2	0.56	7.07	0.42	1.79e-11	Breast cancer;
SARC	cis	rs709400	0.663	rs11628969	chr14:103940911	G/A	cg26031613	chr14:104095156	KLC1	0.82	11.97	0.62	4.77e-26	Body mass index;
SARC	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-9.68	-0.54	7.76e-19	Chronic sinus infection;
SARC	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg06028605	chr16:24865363	SLC5A11	0.36	5.52	0.34	9.05e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9914988	0.943	rs2043031	chr17:27085564	A/G	cg20469991	chr17:27169893	C17orf63	-0.51	-5.37	-0.33	1.89e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg02297831	chr4:17616191	MED28	0.51	6.63	0.4	2.36e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg00933542	chr6:150070202	PCMT1	0.33	5.72	0.35	3.28e-8	Lung cancer;
SARC	cis	rs11105298	0.891	rs1008764	chr12:89887649	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-5.42	-0.33	1.49e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs637571	0.726	rs669371	chr11:65674153	G/T	cg26695010	chr11:65641043	EFEMP2	0.61	7.12	0.42	1.36e-11	Eosinophil percentage of white cells;
SARC	cis	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg10591111	chr5:226296	SDHA	-0.52	-4.79	-0.3	2.93e-6	Breast cancer;
SARC	cis	rs637571	0.522	rs503524	chr11:65751764	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.41	5.15	0.32	5.49e-7	Eosinophil percentage of white cells;
SARC	cis	rs4443100	0.958	rs9620213	chr22:23395411	A/C	cg14186256	chr22:23484241	RTDR1	0.5	5.06	0.31	8.41e-7	Serum parathyroid hormone levels;
SARC	cis	rs7786808	0.778	rs34212455	chr7:158224490	C/T	cg09998033	chr7:158218633	PTPRN2	-0.39	-6.36	-0.38	1.08e-9	Obesity-related traits;
SARC	cis	rs7740797	0.818	rs7752180	chr6:155093458	G/T	cg02865717	chr6:155053990	RBM16	-0.33	-4.8	-0.3	2.84e-6	Colorectal or endometrial cancer;
SARC	cis	rs4276643	0.842	rs939715	chr8:27810626	C/T	cg25028855	chr8:28560486	EXTL3	-0.27	-4.72	-0.3	3.98e-6	Low vWF levels;
SARC	cis	rs7647973	1.000	rs10155014	chr3:49432321	C/T	cg06212747	chr3:49208901	KLHDC8B	0.58	6.05	0.37	5.65e-9	Menarche (age at onset);
SARC	cis	rs453301	0.571	rs2929456	chr8:9083416	G/A	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.76	-0.41	1.09e-10	Joint mobility (Beighton score);
SARC	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg15595755	chr5:1867978	NA	0.48	6.63	0.4	2.36e-10	Cardiovascular disease risk factors;
SARC	cis	rs17209837	1.000	rs6465116	chr7:87113001	G/A	cg00919237	chr7:87102261	ABCB4	-0.47	-4.84	-0.3	2.41e-6	Gallbladder cancer;
SARC	cis	rs1729951	0.575	rs1682357	chr3:136692009	G/A	cg15507776	chr3:136538369	TMEM22	0.5	5.6	0.34	6.04e-8	Neuroticism;
SARC	cis	rs12893668	0.663	rs12889731	chr14:104087482	C/T	cg26031613	chr14:104095156	KLC1	-0.54	-5.87	-0.36	1.52e-8	Reticulocyte count;
SARC	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg25072359	chr17:41440525	NA	0.53	6.32	0.38	1.33e-9	Menopause (age at onset);
SARC	cis	rs9389248	0.690	rs2072826	chr6:135253558	G/C	cg22676075	chr6:135203613	NA	-0.43	-5.58	-0.34	6.52e-8	High light scatter reticulocyte percentage of red cells;
SARC	cis	rs9660992	0.573	rs12126439	chr1:205200720	C/T	cg21643547	chr1:205240462	TMCC2	-0.6	-7.83	-0.46	1.76e-13	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg21144161	chr5:423903	AHRR	0.31	4.87	0.3	2.05e-6	Cystic fibrosis severity;
SARC	cis	rs41271473	0.526	rs72765760	chr1:228743222	G/A	cg10167378	chr1:228756711	NA	0.65	6.34	0.38	1.15e-9	Chronic lymphocytic leukemia;
SARC	trans	rs12310956	0.532	rs11052930	chr12:33964824	A/G	cg26384229	chr12:38710491	ALG10B	0.84	12.09	0.62	1.93e-26	Morning vs. evening chronotype;
SARC	cis	rs60843830	0.662	rs6721594	chr2:305203	C/T	cg12623918	chr2:306882	NA	-0.31	-5.54	-0.34	8.08e-8	Spherical equivalent (joint analysis main effects and education interaction);
SARC	cis	rs17401966	0.838	rs4846206	chr1:10310258	G/C	cg15208524	chr1:10270712	KIF1B	0.44	5.22	0.32	4.01e-7	Hepatocellular carcinoma;
SARC	cis	rs6570726	0.935	rs385185	chr6:145814992	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.48	0.39	5.27e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7336332	0.598	rs9581852	chr13:28013748	A/G	cg01674679	chr13:27998804	GTF3A	-0.54	-4.97	-0.31	1.3e-6	Weight;
SARC	cis	rs2227564	0.729	rs2688616	chr10:75650652	G/C	cg16540259	chr10:75572220	NDST2	0.35	4.97	0.31	1.29e-6	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs12477438	0.834	rs1563106	chr2:99701381	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-14.85	-0.7	1.49e-35	Chronic sinus infection;
SARC	cis	rs7043114	0.525	rs10820964	chr9:95041636	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-5.47	-0.34	1.16e-7	Height;
SARC	cis	rs7833790	0.660	rs67666182	chr8:82772037	A/G	cg17211192	chr8:82754475	SNX16	0.48	5.99	0.37	7.79e-9	Diastolic blood pressure;
SARC	cis	rs2228479	0.850	rs62052711	chr16:89855100	C/A	cg06558623	chr16:89946397	TCF25	0.93	6.44	0.39	6.63e-10	Skin colour saturation;
SARC	cis	rs607987	0.836	rs4531442	chr11:30278829	A/G	cg06241208	chr11:30344200	C11orf46	0.42	5.06	0.31	8.31e-7	Body mass index;
SARC	cis	rs7512552	0.839	rs698919	chr1:150387000	A/G	cg15654264	chr1:150340011	RPRD2	0.38	4.91	0.31	1.73e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs7582720	1.000	rs72934514	chr2:203933339	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	7.29	0.43	4.84e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs8072100	0.782	rs62074054	chr17:45771816	T/C	cg08085267	chr17:45401833	C17orf57	-0.43	-5.08	-0.32	7.61e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs1865760	0.588	rs9467658	chr6:26010881	T/G	cg18357526	chr6:26021779	HIST1H4A	0.4	5.08	0.32	7.75e-7	Height;
SARC	cis	rs425277	1.000	rs12401379	chr1:2058580	G/C	cg24578937	chr1:2090814	PRKCZ	0.32	6.03	0.37	6.43e-9	Height;
SARC	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg26850624	chr5:429559	AHRR	-0.33	-5.23	-0.32	3.7e-7	Cystic fibrosis severity;
SARC	cis	rs6448317	0.954	rs35276311	chr4:24923493	C/T	cg21108841	chr4:24914750	CCDC149	-0.53	-5.79	-0.35	2.29e-8	Heschl's gyrus morphology;
SARC	cis	rs3733585	0.699	rs4339211	chr4:9947658	C/T	cg00071950	chr4:10020882	SLC2A9	-0.39	-6.06	-0.37	5.32e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs950776	0.518	rs4887062	chr15:78837801	G/A	cg17108064	chr15:78857060	CHRNA5	-0.29	-4.87	-0.3	2.1e-6	Sudden cardiac arrest;
SARC	cis	rs3956705	0.762	rs13311608	chr7:32999601	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.58	-7.42	-0.44	2.15e-12	Red cell distribution width;
SARC	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg00684032	chr4:1343700	KIAA1530	0.34	5.07	0.32	7.99e-7	Obesity-related traits;
SARC	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg11494091	chr17:61959527	GH2	0.36	5.14	0.32	5.83e-7	Height;
SARC	cis	rs10227331	1.000	rs10227331	chr7:157294938	A/T	cg04156418	chr7:157293606	NA	0.45	7.72	0.45	3.42e-13	Inattentive symptoms;
SARC	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg23982607	chr1:1823379	GNB1	-0.67	-11.45	-0.6	2.24e-24	Body mass index;
SARC	cis	rs7647973	1.000	rs10865956	chr3:49581559	C/A	cg07636037	chr3:49044803	WDR6	0.75	8.37	0.48	5.43e-15	Menarche (age at onset);
SARC	cis	rs9747201	1.000	rs12943668	chr17:80109930	C/T	cg17462356	chr17:80056334	FASN	0.46	5.28	0.33	2.96e-7	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs17826219	0.706	rs9905827	chr17:29192168	C/A	cg13385521	chr17:29058706	SUZ12P	0.86	7.34	0.43	3.54e-12	Body mass index;
SARC	cis	rs7582720	1.000	rs4675310	chr2:203880834	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	-0.69	-6.22	-0.38	2.27e-9	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg14784868	chr12:69753453	YEATS4	0.64	8.93	0.5	1.3e-16	Cerebrospinal fluid biomarker levels;
SARC	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg24209194	chr3:40518798	ZNF619	0.59	7.2	0.43	8.24e-12	Renal cell carcinoma;
SARC	cis	rs240764	0.717	rs13208757	chr6:101175014	C/T	cg09795085	chr6:101329169	ASCC3	-0.46	-5.7	-0.35	3.61e-8	Neuroticism;
SARC	cis	rs35306767	0.903	rs11253488	chr10:922482	G/C	cg26597838	chr10:835615	NA	0.77	7.91	0.46	1.04e-13	Eosinophil percentage of granulocytes;
SARC	cis	rs7681440	0.583	rs2619339	chr4:90777468	G/C	cg06632027	chr4:90757378	SNCA	-0.47	-5.81	-0.36	2.03e-8	Dementia with Lewy bodies;
SARC	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg02018176	chr4:1364513	KIAA1530	0.44	6.61	0.4	2.57e-10	Longevity;
SARC	cis	rs1008375	1.000	rs28497813	chr4:17685503	A/G	cg16339924	chr4:17578868	LAP3	0.62	8.1	0.47	3.05e-14	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.93	10.56	0.57	1.51e-21	Platelet count;
SARC	cis	rs7100689	0.577	rs9285726	chr10:82035150	A/T	cg01528321	chr10:82214614	TSPAN14	0.67	8.51	0.49	2.12e-15	Post bronchodilator FEV1;
SARC	cis	rs701145	0.556	rs355762	chr3:154012614	G/A	cg16511985	chr3:153974050	SGEF	0.41	4.88	0.3	1.98e-6	Coronary artery disease;
SARC	cis	rs3106136	0.843	rs6532479	chr4:95259235	C/A	cg11021082	chr4:95130006	SMARCAD1	0.35	5.38	0.33	1.83e-7	Capecitabine sensitivity;
SARC	cis	rs1957429	0.901	rs1957427	chr14:65354085	A/G	cg23373153	chr14:65346875	NA	1.0	10.21	0.56	1.76e-20	Pediatric areal bone mineral density (radius);
SARC	cis	rs8180040	0.726	rs2385867	chr3:47059323	C/T	cg27129171	chr3:47204927	SETD2	0.65	9.06	0.51	5.56e-17	Colorectal cancer;
SARC	cis	rs16976116	0.901	rs1061875	chr15:55496278	C/T	cg17854078	chr15:55489399	RSL24D1	0.66	6.53	0.39	4.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2415984	0.562	rs34368760	chr14:46928532	T/A	cg14871534	chr14:47121158	RPL10L	0.38	5.28	0.33	2.89e-7	Number of children ever born;
SARC	cis	rs210143	1	rs210143	chr6:33546930	T/C	cg24505687	chr6:33548425	BAK1	0.36	4.86	0.3	2.13e-6	Neutrophil percentage of granulocytes;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);Chronic lymphocytic leukemia;
SARC	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg15556689	chr8:8085844	FLJ10661	0.55	7.15	0.42	1.08e-11	Systolic blood pressure;
SARC	cis	rs1348850	0.914	rs10194648	chr2:178337031	G/A	cg23306229	chr2:178417860	TTC30B	0.57	6.79	0.41	9.33e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.36	0.8	1.22e-53	Prudent dietary pattern;
SARC	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg04944784	chr2:26401820	FAM59B	-0.5	-6.14	-0.37	3.58e-9	Gut microbiome composition (summer);
SARC	cis	rs854765	0.654	rs9911281	chr17:17762457	G/C	cg04398451	chr17:18023971	MYO15A	0.45	6.53	0.39	4.06e-10	Total body bone mineral density;
SARC	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs2153535	0.580	rs1932280	chr6:8473654	G/A	cg21535247	chr6:8435926	SLC35B3	0.54	6.88	0.41	5.44e-11	Motion sickness;
SARC	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg22535103	chr8:58192502	C8orf71	-0.59	-6.24	-0.38	2.02e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.3	-4.81	-0.3	2.73e-6	Total body bone mineral density;
SARC	cis	rs9814567	0.727	rs4437193	chr3:134352344	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.49	-6.33	-0.38	1.22e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs9916302	0.645	rs1053651	chr17:37822311	A/C	cg20243544	chr17:37824526	PNMT	0.6	7.77	0.45	2.45e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs10823500	0.674	rs7089860	chr10:71992848	C/G	cg04118878	chr10:71993077	PPA1	0.53	5.51	0.34	9.59e-8	Blood protein levels;
SARC	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg11211951	chr8:145729740	GPT	0.48	6.96	0.41	3.49e-11	Age at first birth;
SARC	cis	rs6679356	0.906	rs72678531	chr1:67798445	T/C	cg09018107	chr1:67798929	IL12RB2	0.39	4.96	0.31	1.37e-6	Primary biliary cholangitis;
SARC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg14159672	chr1:205819179	PM20D1	0.86	14.62	0.69	8.7e-35	Menarche (age at onset);
SARC	trans	rs561341	0.609	rs7214626	chr17:30190989	G/A	cg20587970	chr11:113659929	NA	0.68	6.54	0.39	3.95e-10	Hip circumference adjusted for BMI;
SARC	cis	rs6121246	0.567	rs6060260	chr20:30192907	C/T	cg13852791	chr20:30311386	BCL2L1	0.68	5.91	0.36	1.2e-8	Mean corpuscular hemoglobin;
SARC	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg03433033	chr1:76189801	ACADM	-0.43	-5.64	-0.35	4.81e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2016266	0.819	rs1976938	chr12:53661925	C/T	cg26875137	chr12:53738046	NA	0.42	5.57	0.34	7.08e-8	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs3741151	0.881	rs79623427	chr11:73094896	C/T	cg17517138	chr11:73019481	ARHGEF17	0.92	6.65	0.4	2.01e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs6088580	0.634	rs6088508	chr20:33060081	A/G	cg08999081	chr20:33150536	PIGU	0.42	6.18	0.38	2.81e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs6540556	0.906	rs6540554	chr1:209932297	A/T	cg23920097	chr1:209922102	NA	0.6	6.86	0.41	6.16e-11	Red blood cell count;
SARC	cis	rs9682041	0.561	rs1477211	chr3:170140792	A/G	cg11886554	chr3:170076028	SKIL	0.84	7.77	0.45	2.48e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs1472147	0.955	rs3736611	chr7:128509243	C/G	cg00260937	chr7:128520193	KCP	0.41	4.73	0.3	3.83e-6	Calcium levels;
SARC	cis	rs11792861	0.855	rs72607165	chr9:111814498	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.68	7.68	0.45	4.3e-13	Menarche (age at onset);
SARC	cis	rs2832191	0.791	rs2832197	chr21:30497790	T/C	cg08807101	chr21:30365312	RNF160	-0.79	-10.93	-0.58	1.04e-22	Dental caries;
SARC	cis	rs2425143	1.000	rs8116836	chr20:34453362	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.58	-0.4	3.01e-10	Blood protein levels;
SARC	cis	rs698833	0.926	rs698827	chr2:44730496	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.63	-8.21	-0.47	1.54e-14	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs7937682	0.632	rs57414412	chr11:111769431	G/A	cg22437258	chr11:111473054	SIK2	-0.48	-5.51	-0.34	9.29e-8	Primary sclerosing cholangitis;
SARC	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg16680214	chr1:154839983	KCNN3	-0.34	-5.32	-0.33	2.44e-7	Prostate cancer;
SARC	cis	rs7824557	0.707	rs3808518	chr8:11143272	A/C	cg21775007	chr8:11205619	TDH	-0.53	-6.31	-0.38	1.37e-9	Retinal vascular caliber;
SARC	cis	rs9473924	0.542	rs2744504	chr6:50798668	G/C	cg14470998	chr6:50812995	TFAP2B	0.7	6.22	0.38	2.26e-9	Body mass index;
SARC	cis	rs6963495	0.818	rs6956249	chr7:105149743	A/T	cg13798780	chr7:105162888	PUS7	0.61	5.75	0.35	2.79e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg04546413	chr19:29218101	NA	0.64	8.59	0.49	1.29e-15	Methadone dose in opioid dependence;
SARC	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg08219700	chr8:58056026	NA	0.6	5.71	0.35	3.49e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg10902432	chr16:19565565	C16orf62	0.5	6.68	0.4	1.72e-10	Thyroid stimulating hormone;
SARC	cis	rs35955747	0.669	rs878718	chr22:31552702	C/T	cg02404636	chr22:31891804	SFI1	0.38	4.74	0.3	3.71e-6	Neutrophil count;Sum basophil neutrophil counts;
SARC	cis	rs3857536	0.869	rs7771991	chr6:66876021	C/G	cg07460842	chr6:66804631	NA	-0.51	-5.96	-0.36	9.32e-9	Blood trace element (Cu levels);
SARC	cis	rs9398803	0.723	rs853973	chr6:127068347	A/G	cg19875578	chr6:126661172	C6orf173	-0.6	-8.29	-0.48	8.89e-15	Male-pattern baldness;
SARC	cis	rs6570726	0.875	rs373313	chr6:145857791	T/C	cg23711669	chr6:146136114	FBXO30	0.78	12.0	0.62	3.86e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs921968	0.565	rs3770219	chr2:219619766	T/C	cg02176678	chr2:219576539	TTLL4	-0.32	-4.88	-0.3	1.93e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs7712401	0.601	rs396941	chr5:122318265	G/T	cg19412675	chr5:122181750	SNX24	-0.43	-5.47	-0.34	1.15e-7	Mean platelet volume;
SARC	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg12463550	chr7:65579703	CRCP	-0.5	-5.59	-0.34	6.32e-8	Aortic root size;
SARC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg11494091	chr17:61959527	GH2	0.53	7.86	0.46	1.4e-13	Prudent dietary pattern;
SARC	cis	rs9436747	0.667	rs4370791	chr1:66052228	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.49	5.16	0.32	5.33e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs3796352	0.892	rs35076015	chr3:53026366	C/T	cg27565382	chr3:53032988	SFMBT1	1.04	7.27	0.43	5.28e-12	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2933343	1.000	rs1683782	chr3:128640277	A/G	cg24203234	chr3:128598194	ACAD9	0.55	6.11	0.37	4.25e-9	IgG glycosylation;
SARC	trans	rs61931739	0.534	rs2087128	chr12:34000173	T/C	cg26384229	chr12:38710491	ALG10B	0.75	10.9	0.58	1.27e-22	Morning vs. evening chronotype;
SARC	cis	rs9916302	0.706	rs4795375	chr17:37662932	T/C	cg00129232	chr17:37814104	STARD3	-0.58	-6.16	-0.37	3.21e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs798554	0.616	rs1636251	chr7:2884720	T/C	cg04166393	chr7:2884313	GNA12	0.47	5.72	0.35	3.28e-8	Height;
SARC	cis	rs11235843	0.929	rs4944032	chr11:73413121	A/G	cg18195628	chr11:73498948	MRPL48	-0.64	-5.02	-0.31	1.05e-6	Hand grip strength;
SARC	cis	rs9660992	0.649	rs72745216	chr1:205261016	G/A	cg19090574	chr1:205240910	TMCC2	-0.4	-4.75	-0.3	3.49e-6	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg05025164	chr4:1340916	KIAA1530	-0.68	-8.1	-0.47	3.08e-14	Obesity-related traits;
SARC	cis	rs16854884	0.683	rs2053211	chr3:143774592	C/T	cg06585982	chr3:143692056	C3orf58	-0.49	-6.69	-0.4	1.66e-10	Economic and political preferences (feminism/equality);
SARC	cis	rs7824557	0.628	rs3779891	chr8:11183505	G/A	cg21775007	chr8:11205619	TDH	0.65	8.33	0.48	7.13e-15	Retinal vascular caliber;
SARC	cis	rs9309473	1.000	rs3813227	chr2:73651967	A/G	cg20560298	chr2:73613845	ALMS1	0.44	5.25	0.33	3.39e-7	Metabolite levels;
SARC	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg16434002	chr17:42200994	HDAC5	-0.41	-5.0	-0.31	1.14e-6	Total body bone mineral density;
SARC	cis	rs2235642	0.928	rs9932984	chr16:1605051	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.33	4.75	0.3	3.62e-6	Coronary artery disease;
SARC	cis	rs4588572	0.537	rs7719228	chr5:77730576	G/A	cg18281939	chr5:77783895	LHFPL2	0.34	4.71	0.3	4.17e-6	Triglycerides;
SARC	cis	rs55871839	0.559	rs4737527	chr8:59823491	A/G	cg07426533	chr8:59803705	TOX	0.49	5.55	0.34	7.72e-8	Pneumonia;
SARC	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg06618935	chr21:46677482	NA	-0.39	-5.14	-0.32	5.72e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs1994135	0.549	rs2218650	chr12:33734783	A/G	cg26384229	chr12:38710491	ALG10B	0.66	8.16	0.47	2.14e-14	Resting heart rate;
SARC	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg21782813	chr7:2030301	MAD1L1	-0.36	-5.73	-0.35	3.1e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg06873352	chr17:61820015	STRADA	0.54	6.96	0.41	3.45e-11	Prudent dietary pattern;
SARC	cis	rs240764	0.817	rs11155596	chr6:101152631	C/T	cg09795085	chr6:101329169	ASCC3	-0.45	-5.92	-0.36	1.17e-8	Neuroticism;
SARC	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg14500267	chr11:67383377	NA	0.34	4.92	0.31	1.61e-6	Mean corpuscular volume;
SARC	cis	rs4906332	1.000	rs12885762	chr14:103882200	C/A	cg26031613	chr14:104095156	KLC1	-0.5	-5.84	-0.36	1.72e-8	Coronary artery disease;
SARC	cis	rs57506017	0.585	rs13237715	chr7:12269575	G/C	cg23422036	chr7:12250390	TMEM106B	0.45	5.87	0.36	1.49e-8	Neuroticism;
SARC	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg05313129	chr8:58192883	C8orf71	-0.62	-6.37	-0.39	9.92e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs3796352	1.000	rs71299622	chr3:52917038	G/A	cg15956490	chr3:53032818	SFMBT1	0.89	6.09	0.37	4.52e-9	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs7680126	0.585	rs34768406	chr4:10118350	C/A	cg11266682	chr4:10021025	SLC2A9	-0.41	-4.91	-0.31	1.72e-6	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
SARC	cis	rs10911251	0.546	rs3768625	chr1:183078712	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.32	0.56	8.07e-21	Colorectal cancer;
SARC	cis	rs6580649	0.941	rs3742074	chr12:48457385	C/T	cg05342945	chr12:48394962	COL2A1	0.57	6.15	0.37	3.42e-9	Lung cancer;
SARC	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg22535103	chr8:58192502	C8orf71	-0.7	-7.06	-0.42	1.93e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs7089973	0.641	rs7079234	chr10:116741810	A/G	cg08188268	chr10:116634841	FAM160B1	0.4	5.37	0.33	1.88e-7	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs861020	0.527	rs614662	chr1:209962419	C/T	cg06929287	chr1:210001192	C1orf107	0.43	5.26	0.33	3.22e-7	Orofacial clefts;
SARC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg15744359	chr8:67940823	LRRC67	-0.54	-6.37	-0.39	9.85e-10	Hepatitis;
SARC	cis	rs7520050	0.807	rs12025621	chr1:46228391	G/A	cg24296786	chr1:45957014	TESK2	0.43	5.53	0.34	8.76e-8	Red blood cell count;Reticulocyte count;
SARC	cis	rs10504073	0.584	rs62507178	chr8:49938572	A/C	cg00325661	chr8:49890786	NA	0.53	6.98	0.42	3.08e-11	Blood metabolite ratios;
SARC	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg18252515	chr7:66147081	NA	-1.25	-10.99	-0.58	6.44e-23	Diabetic kidney disease;
SARC	cis	rs6831352	0.760	rs2602859	chr4:100030583	G/A	cg13256891	chr4:100009986	ADH5	0.68	8.56	0.49	1.59e-15	Alcohol dependence;
SARC	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg27541892	chr1:1571801	CDK11B	0.43	5.96	0.36	9.31e-9	Body mass index;
SARC	cis	rs9807989	0.839	rs10204137	chr2:102968212	A/G	cg09003973	chr2:102972529	NA	0.41	5.56	0.34	7.26e-8	Asthma;
SARC	cis	rs9902453	0.845	rs10853135	chr17:28188675	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	7.3	0.43	4.65e-12	Coffee consumption (cups per day);
SARC	cis	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg07777115	chr5:623756	CEP72	-0.56	-4.83	-0.3	2.49e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg05863683	chr7:1912471	MAD1L1	0.35	5.26	0.33	3.28e-7	Bipolar disorder and schizophrenia;
SARC	trans	rs7824557	0.724	rs2251473	chr8:11177126	C/A	cg15556689	chr8:8085844	FLJ10661	0.53	6.6	0.4	2.75e-10	Retinal vascular caliber;
SARC	cis	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg12064134	chr16:90016061	DEF8	-0.59	-5.05	-0.31	8.75e-7	Skin colour saturation;
SARC	cis	rs2075371	0.501	rs1646654	chr7:134027547	G/C	cg11752832	chr7:134001865	SLC35B4	0.46	5.65	0.35	4.59e-8	Mean platelet volume;
SARC	cis	rs6087990	0.871	rs2424905	chr20:31352927	T/C	cg13636640	chr20:31349939	DNMT3B	0.79	12.15	0.62	1.21e-26	Ulcerative colitis;
SARC	cis	rs9329221	0.527	rs34308302	chr8:10332022	C/T	cg21775007	chr8:11205619	TDH	-0.38	-4.98	-0.31	1.23e-6	Neuroticism;
SARC	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg15049968	chr18:44337910	ST8SIA5	-0.35	-5.38	-0.33	1.81e-7	Personality dimensions;
SARC	cis	rs7833790	0.660	rs1451995	chr8:82746123	G/C	cg06027949	chr8:82754900	SNX16	0.48	6.1	0.37	4.28e-9	Diastolic blood pressure;
SARC	cis	rs240764	0.658	rs10223467	chr6:101207589	A/G	cg09795085	chr6:101329169	ASCC3	-0.44	-5.7	-0.35	3.63e-8	Neuroticism;
SARC	cis	rs17270561	0.636	rs2070642	chr6:25831212	G/A	cg16482183	chr6:26056742	HIST1H1C	0.51	6.69	0.4	1.66e-10	Iron status biomarkers;
SARC	cis	rs6815814	0.861	rs12233670	chr4:38787216	C/T	cg06935464	chr4:38784597	TLR10	0.5	5.72	0.35	3.18e-8	Breast cancer;
SARC	cis	rs2295359	0.643	rs1569922	chr1:67664963	C/T	cg12940439	chr1:67600707	NA	0.34	5.18	0.32	4.84e-7	Psoriasis;
SARC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg26338869	chr17:61819248	STRADA	0.79	10.07	0.55	4.93e-20	Prudent dietary pattern;
SARC	cis	rs4481887	0.745	rs4540687	chr1:248476099	C/G	cg13385794	chr1:248469461	NA	0.34	5.32	0.33	2.46e-7	Common traits (Other);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg20930040	chr1:42685845	FOXJ3	0.48	6.57	0.4	3.24e-10	Thyroid stimulating hormone;
SARC	cis	rs2070488	0.965	rs2366119	chr3:38484453	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	14.68	0.69	5.62e-35	Electrocardiographic conduction measures;
SARC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.0	-16.75	-0.74	7.42e-42	Prudent dietary pattern;
SARC	cis	rs17376456	0.877	rs56373208	chr5:93491276	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.61	5.12	0.32	6.49e-7	Diabetic retinopathy;
SARC	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs3845702	0.736	rs2678936	chr2:180872179	G/C	cg01881094	chr2:180872142	CWC22	1.04	8.14	0.47	2.43e-14	Schizophrenia;
SARC	cis	rs7539542	0.556	rs3820152	chr1:202878492	A/T	cg08940984	chr1:202857613	RABIF	-0.36	-4.97	-0.31	1.31e-6	Mean platelet volume;
SARC	cis	rs782590	0.694	rs2627775	chr2:55877113	C/T	cg18811423	chr2:55921094	PNPT1	0.67	9.66	0.53	8.52e-19	Metabolic syndrome;
SARC	cis	rs2933343	0.700	rs2249514	chr3:128643812	C/T	cg24203234	chr3:128598194	ACAD9	0.64	8.2	0.47	1.61e-14	IgG glycosylation;
SARC	cis	rs4919044	0.808	rs10748590	chr10:94812426	A/T	cg05127821	chr10:94822908	CYP26C1	0.92	7.11	0.42	1.38e-11	Coronary artery disease;
SARC	cis	rs2153535	0.580	rs2152348	chr6:8474301	C/A	cg07606381	chr6:8435919	SLC35B3	0.77	11.16	0.59	1.85e-23	Motion sickness;
SARC	cis	rs2153535	0.560	rs2210798	chr6:8481522	C/T	cg07606381	chr6:8435919	SLC35B3	0.78	11.13	0.59	2.44e-23	Motion sickness;
SARC	cis	rs9290065	0.519	rs9857743	chr3:160677732	G/A	cg04691961	chr3:161091175	C3orf57	-0.5	-6.44	-0.39	6.69e-10	Kawasaki disease;
SARC	cis	rs1550582	1.000	rs62523710	chr8:135538773	T/C	cg17885191	chr8:135476712	NA	0.58	6.04	0.37	6.09e-9	Educational attainment;
SARC	cis	rs12922317	0.538	rs442234	chr16:12072161	A/G	cg02368508	chr16:12060182	TNFRSF17	0.42	7.13	0.42	1.24e-11	Schizophrenia;
SARC	cis	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg02487422	chr3:49467188	NICN1	0.52	6.94	0.41	3.82e-11	Resting heart rate;
SARC	cis	rs28374715	0.787	rs11856169	chr15:41547938	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.97	-13.48	-0.66	5.31e-31	Ulcerative colitis;
SARC	cis	rs7223966	1.000	rs6504167	chr17:61693194	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.57	-6.12	-0.37	3.91e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs629535	0.773	rs686683	chr8:70070364	G/A	cg21567404	chr3:27674614	NA	1.04	13.3	0.66	2.13e-30	Dupuytren's disease;
SARC	cis	rs7589728	0.620	rs76687350	chr2:88473832	G/A	cg04511125	chr2:88470314	THNSL2	0.78	7.28	0.43	4.97e-12	Plasma clusterin levels;
SARC	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.43	0.44	2.1e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs61931739	0.500	rs11053177	chr12:34412829	G/A	cg13010199	chr12:38710504	ALG10B	0.75	10.66	0.57	7.34e-22	Morning vs. evening chronotype;
SARC	cis	rs6665290	0.669	rs3738725	chr1:227174210	T/C	cg14016676	chr1:227182615	CDC42BPA	0.35	4.99	0.31	1.18e-6	Myeloid white cell count;
SARC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg11494091	chr17:61959527	GH2	0.54	8.07	0.47	3.81e-14	Prudent dietary pattern;
SARC	cis	rs4481887	1.000	rs11204626	chr1:248458974	T/A	cg13385794	chr1:248469461	NA	0.32	4.83	0.3	2.44e-6	Common traits (Other);
SARC	trans	rs5751901	0.614	rs4820599	chr22:24990213	A/G	cg04670666	chr10:124896129	HMX3	-0.42	-6.24	-0.38	2.1e-9	Protein quantitative trait loci;
SARC	cis	rs950169	0.800	rs34302901	chr15:85110943	C/G	cg17507749	chr15:85114479	UBE2QP1	0.79	9.55	0.53	1.89e-18	Schizophrenia;
SARC	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	8.71	0.5	5.56e-16	Alzheimer's disease;
SARC	cis	rs8067545	0.586	rs2526459	chr17:20090042	G/T	cg13482628	chr17:19912719	NA	-0.55	-7.18	-0.43	9.11e-12	Schizophrenia;
SARC	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg17158414	chr2:27665306	KRTCAP3	-0.41	-6.88	-0.41	5.52e-11	Total body bone mineral density;
SARC	cis	rs3741151	0.656	rs73550316	chr11:73299799	G/A	cg17517138	chr11:73019481	ARHGEF17	0.92	6.64	0.4	2.15e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs559928	0.597	rs11600667	chr11:63976183	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.67	4.98	0.31	1.23e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs734999	0.505	rs10797439	chr1:2540364	G/A	cg18854424	chr1:2615690	NA	0.33	5.16	0.32	5.25e-7	Ulcerative colitis;
SARC	cis	rs1568889	1.000	rs61889026	chr11:28274803	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	9.43	0.53	4.22e-18	Bipolar disorder;
SARC	cis	rs10979	1.000	rs9399447	chr6:143896163	T/A	cg25407410	chr6:143891975	LOC285740	-0.64	-8.78	-0.5	3.67e-16	Hypospadias;
SARC	cis	rs826838	1.000	rs7953227	chr12:38946193	G/A	cg26384229	chr12:38710491	ALG10B	0.92	14.42	0.69	3.9e-34	Heart rate;
SARC	trans	rs877282	0.853	rs7083589	chr10:754494	G/A	cg22713356	chr15:30763199	NA	0.99	9.88	0.54	1.92e-19	Uric acid levels;
SARC	cis	rs3812831	0.695	rs3118895	chr13:114931742	G/A	cg06611532	chr13:114900021	NA	0.35	5.83	0.36	1.79e-8	Schizophrenia;
SARC	cis	rs709400	0.663	rs11624367	chr14:103892818	T/A	cg26031613	chr14:104095156	KLC1	0.81	11.42	0.6	2.88e-24	Body mass index;
SARC	cis	rs1801251	0.711	rs2592117	chr2:233735693	C/T	cg25237894	chr2:233734115	C2orf82	-0.34	-4.82	-0.3	2.57e-6	Coronary artery disease;
SARC	cis	rs79976124	0.879	rs10944856	chr6:66636960	G/C	cg07460842	chr6:66804631	NA	0.62	6.67	0.4	1.89e-10	Type 2 diabetes;
SARC	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg18357526	chr6:26021779	HIST1H4A	0.79	11.0	0.58	6.32e-23	Intelligence (multi-trait analysis);
SARC	cis	rs709400	0.628	rs2010281	chr14:103862322	G/A	cg26031613	chr14:104095156	KLC1	0.81	11.84	0.61	1.26e-25	Body mass index;
SARC	cis	rs4332037	0.624	rs11764337	chr7:1892309	A/G	cg12591125	chr7:1885375	MAD1L1	-0.46	-4.88	-0.3	2.01e-6	Bipolar disorder;
SARC	cis	rs12142240	0.698	rs41293285	chr1:46808426	C/T	cg00530320	chr1:46809349	NSUN4	0.58	7.07	0.42	1.74e-11	Menopause (age at onset);
SARC	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg11062466	chr8:58055876	NA	0.56	5.69	0.35	3.79e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg09455208	chr3:40491958	NA	-0.37	-5.56	-0.34	7.43e-8	Renal cell carcinoma;
SARC	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg13206674	chr6:150067644	NUP43	0.42	5.46	0.34	1.2e-7	Lung cancer;
SARC	cis	rs12594515	1.000	rs8033148	chr15:45997929	G/A	cg14863074	chr15:45997064	NA	0.34	5.2	0.32	4.34e-7	Waist circumference;Weight;
SARC	cis	rs7017697	0.642	rs3927029	chr8:19681933	G/A	cg01411142	chr8:19674711	INTS10	-0.48	-5.32	-0.33	2.44e-7	Breast cancer;
SARC	cis	rs721399	0.583	rs4646267	chr8:18247913	A/G	cg18736775	chr8:18248649	NAT2	-0.63	-6.65	-0.4	2.01e-10	Blood metabolite levels;
SARC	cis	rs2531992	0.800	rs2601782	chr16:4021051	T/C	cg02839220	chr16:4400790	Magmas	0.5	4.81	0.3	2.74e-6	Waist circumference;
SARC	cis	rs6840360	0.967	rs10049728	chr4:152672121	C/G	cg22705602	chr4:152727874	NA	-0.36	-6.32	-0.38	1.34e-9	Intelligence (multi-trait analysis);
SARC	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg04277193	chr17:41438351	NA	0.44	4.73	0.3	3.83e-6	Menopause (age at onset);
SARC	cis	rs10771431	0.967	rs7137443	chr12:9372029	C/T	cg08997352	chr12:9597637	DDX12	-0.55	-7.81	-0.46	1.92e-13	Breast size;
SARC	cis	rs67614146	1	rs67614146	chr6:87821827	AC/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.39	-6.62	-0.4	2.42e-10	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs6439153	0.933	rs11711812	chr3:128708554	G/A	cg25356066	chr3:128598488	ACAD9	0.46	5.42	0.33	1.46e-7	Pneumococcal bacteremia;
SARC	cis	rs9790314	0.663	rs9860360	chr3:160747963	G/A	cg04691961	chr3:161091175	C3orf57	-0.59	-8.13	-0.47	2.59e-14	Morning vs. evening chronotype;
SARC	cis	rs72781680	1.000	rs72781631	chr2:24195064	G/A	cg06627628	chr2:24431161	ITSN2	-0.71	-6.82	-0.41	7.86e-11	Lymphocyte counts;
SARC	cis	rs6912958	0.781	rs2325064	chr6:88224467	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.52	-7.03	-0.42	2.22e-11	Monocyte percentage of white cells;
SARC	cis	rs57221529	0.664	rs72704802	chr5:554211	C/T	cg07777115	chr5:623756	CEP72	-0.55	-4.76	-0.3	3.42e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg09839136	chr7:766187	HEATR2;PRKAR1B	0.56	4.8	0.3	2.89e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs4969178	0.896	rs12602206	chr17:76397133	A/G	cg20026190	chr17:76395443	PGS1	0.4	5.37	0.33	1.94e-7	HDL cholesterol levels;
SARC	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg15049968	chr18:44337910	ST8SIA5	-0.33	-5.2	-0.32	4.42e-7	Personality dimensions;
SARC	cis	rs6426558	0.537	rs2492630	chr1:227286931	A/G	cg10327440	chr1:227177885	CDC42BPA	0.42	4.97	0.31	1.31e-6	Neutrophil percentage of white cells;
SARC	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg11764359	chr7:65958608	NA	0.77	8.74	0.5	4.53e-16	Aortic root size;
SARC	cis	rs6977660	0.598	rs72591445	chr7:19773035	G/A	cg05791153	chr7:19748676	TWISTNB	0.9	7.53	0.44	1.1e-12	Thyroid stimulating hormone;
SARC	cis	rs908922	0.676	rs533917	chr1:152518294	A/G	cg09873164	chr1:152488093	CRCT1	0.6	7.73	0.45	3.3e-13	Hair morphology;
SARC	cis	rs2997447	0.761	rs17257107	chr1:26448447	A/G	cg19633962	chr1:26362018	EXTL1	-0.56	-5.06	-0.31	8.55e-7	QRS complex (12-leadsum);
SARC	cis	rs2012796	0.785	rs61986597	chr14:81853107	T/C	cg02996355	chr14:81879375	NA	0.53	5.81	0.36	2e-8	Night sleep phenotypes;
SARC	trans	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg17830980	chr10:43048298	ZNF37B	-0.53	-7.24	-0.43	6.47e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs17376456	0.877	rs10060462	chr5:93455073	C/T	cg25358565	chr5:93447407	FAM172A	1.32	14.75	0.69	3.21e-35	Diabetic retinopathy;
SARC	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg25072359	chr17:41440525	NA	0.52	6.33	0.38	1.26e-9	Menopause (age at onset);
SARC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg24846343	chr22:24311635	DDTL	0.48	6.73	0.4	1.28e-10	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs992157	0.560	rs4674274	chr2:219089131	A/T	cg00012203	chr2:219082015	ARPC2	-0.73	-10.74	-0.58	3.92e-22	Colorectal cancer;
SARC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.44	-5.61	-0.35	5.61e-8	Longevity;Endometriosis;
SARC	trans	rs1814175	0.817	rs12295885	chr11:50036762	T/G	cg15704280	chr7:45808275	SEPT13	-0.98	-18.99	-0.78	3.23e-49	Height;
SARC	cis	rs8016982	0.657	rs11625861	chr14:81735001	C/T	cg01989461	chr14:81687754	GTF2A1	-0.68	-9.75	-0.54	4.63e-19	Schizophrenia;
SARC	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg04944784	chr2:26401820	FAM59B	0.59	7.88	0.46	1.25e-13	Gut microbiome composition (summer);
SARC	cis	rs12142240	0.731	rs12385693	chr1:46818921	A/C	cg14993813	chr1:46806288	NSUN4	-0.54	-5.76	-0.35	2.58e-8	Menopause (age at onset);
SARC	cis	rs2071303	0.836	rs198835	chr6:26113994	T/G	cg18357526	chr6:26021779	HIST1H4A	-0.45	-5.82	-0.36	1.97e-8	Intelligence (multi-trait analysis);
SARC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg09373136	chr17:61933544	TCAM1	-0.45	-6.09	-0.37	4.56e-9	Prudent dietary pattern;
SARC	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg18404041	chr3:52824283	ITIH1	-0.44	-6.59	-0.4	2.82e-10	Bipolar disorder;
SARC	trans	rs3780486	0.718	rs3818593	chr9:33120706	A/G	cg20290983	chr6:43655470	MRPS18A	0.93	11.49	0.6	1.63e-24	IgG glycosylation;
SARC	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.82	12.64	0.64	3.01e-28	Personality dimensions;
SARC	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg11890956	chr21:40555474	PSMG1	1.16	19.35	0.79	2.15e-50	Cognitive function;
SARC	cis	rs7412746	0.611	rs10888391	chr1:150729983	G/A	cg13175981	chr1:150552382	MCL1	-0.52	-6.38	-0.39	9.28e-10	Melanoma;
SARC	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg11890956	chr21:40555474	PSMG1	-0.7	-9.31	-0.52	1.02e-17	Menarche (age at onset);
SARC	cis	rs4803468	0.763	rs17318596	chr19:41937095	A/G	cg14132834	chr19:41945861	ATP5SL	-0.52	-6.84	-0.41	7.02e-11	Height;
SARC	cis	rs17270561	0.636	rs6456697	chr6:25741434	A/G	cg17691542	chr6:26056736	HIST1H1C	0.61	7.36	0.43	3.06e-12	Iron status biomarkers;
SARC	cis	rs2658782	0.547	rs3020052	chr11:93055184	C/G	cg15737290	chr11:93063684	CCDC67	0.95	13.25	0.66	3.13e-30	Pulmonary function decline;
SARC	cis	rs7647973	0.593	rs58339610	chr3:49845006	T/A	cg13072238	chr3:49761600	GMPPB	0.59	5.9	0.36	1.25e-8	Menarche (age at onset);
SARC	cis	rs9462027	0.628	rs9357181	chr6:34673833	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.43	6.14	0.37	3.47e-9	Systemic lupus erythematosus;
SARC	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg18876405	chr7:65276391	NA	0.46	5.25	0.33	3.41e-7	Aortic root size;
SARC	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg22875332	chr1:76189707	ACADM	-0.47	-6.49	-0.39	5.17e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg11987759	chr7:65425863	GUSB	-0.48	-6.2	-0.38	2.59e-9	Aortic root size;
SARC	cis	rs77956314	0.515	rs9804817	chr12:117440220	G/A	cg16111737	chr12:117408163	FBXW8	0.5	6.49	0.39	5.2e-10	Subcortical brain region volumes;Hippocampal volume;
SARC	cis	rs28829049	0.597	rs72651403	chr1:19519887	G/C	cg13387374	chr1:19411106	UBR4	0.43	5.09	0.32	7.27e-7	QRS duration in Tripanosoma cruzi seropositivity;
SARC	cis	rs6840360	0.571	rs4696273	chr4:152528477	G/A	cg22705602	chr4:152727874	NA	-0.43	-6.69	-0.4	1.65e-10	Intelligence (multi-trait analysis);
SARC	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg06634786	chr22:41940651	POLR3H	0.54	6.41	0.39	8.14e-10	Vitiligo;
SARC	cis	rs1559088	0.948	rs12608825	chr19:33581219	C/T	cg27124370	chr19:33622961	WDR88	-0.41	-5.2	-0.32	4.43e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs17376456	1.000	rs61132622	chr5:93539684	G/A	cg25358565	chr5:93447407	FAM172A	1.34	14.17	0.68	2.79e-33	Diabetic retinopathy;
SARC	cis	rs35146811	0.844	rs34031156	chr7:99677917	T/A	cg10426581	chr7:100472382	SRRT	0.4	4.71	0.3	4.18e-6	Coronary artery disease;
SARC	cis	rs7635838	0.892	rs12163566	chr3:11483096	T/A	cg00170343	chr3:11313890	ATG7	0.64	8.69	0.49	6.54e-16	HDL cholesterol;
SARC	cis	rs6952808	0.929	rs2280550	chr7:1976556	G/A	cg04267008	chr7:1944627	MAD1L1	-0.65	-7.38	-0.44	2.77e-12	Bipolar disorder and schizophrenia;
SARC	cis	rs9513627	0.604	rs11069366	chr13:100116569	G/T	cg25919922	chr13:100150906	NA	0.63	6.51	0.39	4.6e-10	Obesity-related traits;
SARC	cis	rs10463554	0.824	rs34818	chr5:102436111	T/A	cg23492399	chr5:102201601	PAM	-0.51	-5.6	-0.34	5.97e-8	Parkinson's disease;
SARC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.45	-7.18	-0.43	9.53e-12	Longevity;Endometriosis;
SARC	cis	rs2742234	0.541	rs2742235	chr10:43616325	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.43	-5.22	-0.32	4.04e-7	Hirschsprung disease;
SARC	cis	rs798554	0.660	rs2644275	chr7:2854010	G/A	cg13628971	chr7:2884303	GNA12	0.46	5.66	0.35	4.39e-8	Height;
SARC	cis	rs2658782	0.951	rs117384439	chr11:93111478	T/G	cg15737290	chr11:93063684	CCDC67	-0.73	-7.26	-0.43	5.64e-12	Pulmonary function decline;
SARC	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.62	7.54	0.44	1.04e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg23355546	chr19:38129121	ZFP30	0.5	6.92	0.41	4.38e-11	Chemerin levels;
SARC	cis	rs9462027	0.585	rs2814974	chr6:34572028	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-6.18	-0.38	2.84e-9	Systemic lupus erythematosus;
SARC	cis	rs9660992	0.674	rs1151785	chr1:205232299	C/T	cg21545522	chr1:205238299	TMCC2	0.49	6.8	0.41	8.94e-11	Mean corpuscular volume;Mean platelet volume;
SARC	trans	rs208515	0.525	rs12191500	chr6:66668681	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	11.5	0.6	1.56e-24	Exhaled nitric oxide levels;
SARC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg04234412	chr22:24373322	LOC391322	-0.64	-8.39	-0.48	4.66e-15	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs910316	1.000	rs12879542	chr14:75507525	C/T	cg11812906	chr14:75593930	NEK9	0.9	13.68	0.67	1.14e-31	Height;
SARC	cis	rs2760061	0.545	rs1636196	chr1:228204030	A/G	cg02753203	chr1:228287806	NA	0.8	11.11	0.59	2.83e-23	Diastolic blood pressure;
SARC	cis	rs1707322	1.000	rs1588663	chr1:46548825	G/A	cg06784218	chr1:46089804	CCDC17	-0.36	-6.21	-0.38	2.44e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs921968	0.565	rs1554622	chr2:219606218	T/G	cg02176678	chr2:219576539	TTLL4	-0.33	-5.03	-0.31	9.93e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs34779708	0.931	rs4934697	chr10:35287192	C/T	cg03585969	chr10:35415529	CREM	0.42	5.1	0.32	7.02e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs12311304	0.932	rs12301533	chr12:15384217	T/C	cg08258403	chr12:15378311	NA	0.48	7.24	0.43	6.45e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs965469	1.000	rs6051716	chr20:3267736	C/T	cg25506879	chr20:3388711	C20orf194	-0.5	-5.11	-0.32	6.73e-7	IFN-related cytopenia;
SARC	cis	rs1865760	0.508	rs9379820	chr6:26049924	T/C	cg10373733	chr6:25993375	NA	0.41	5.07	0.32	7.96e-7	Height;
SARC	cis	rs4925386	0.840	rs6143036	chr20:60921721	C/A	cg24112000	chr20:60950667	NA	-0.36	-5.37	-0.33	1.93e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
SARC	trans	rs61931739	0.517	rs11052980	chr12:34036036	T/C	cg26384229	chr12:38710491	ALG10B	0.75	10.79	0.58	2.83e-22	Morning vs. evening chronotype;
SARC	cis	rs9398803	0.687	rs1340953	chr6:126951748	A/G	cg20229609	chr6:126660872	C6orf173	0.37	5.28	0.33	2.99e-7	Male-pattern baldness;
SARC	cis	rs12824058	0.831	rs12320318	chr12:130812335	T/C	cg26677194	chr12:130822605	PIWIL1	0.54	7.41	0.44	2.25e-12	Menopause (age at onset);
SARC	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg23958373	chr8:599963	NA	0.87	6.67	0.4	1.89e-10	IgG glycosylation;
SARC	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-9.52	-0.53	2.34e-18	Chronic sinus infection;
SARC	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.52	6.58	0.4	3.06e-10	Personality dimensions;
SARC	cis	rs13256369	0.901	rs4841015	chr8:8567140	C/G	cg17143192	chr8:8559678	CLDN23	0.54	6.42	0.39	7.45e-10	Obesity-related traits;
SARC	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg00149659	chr3:10157352	C3orf10	0.69	6.44	0.39	6.6e-10	Alzheimer's disease;
SARC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg12648201	chr2:27665141	KRTCAP3	-0.33	-5.0	-0.31	1.11e-6	Total body bone mineral density;
SARC	cis	rs9733	0.526	rs6587542	chr1:150907701	G/T	cg15448220	chr1:150897856	SETDB1	0.52	6.99	0.42	2.86e-11	Tonsillectomy;
SARC	cis	rs694739	1.000	rs499425	chr11:64105929	A/G	cg02228329	chr11:64053129	BAD;GPR137	-0.66	-8.47	-0.49	2.79e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg05725452	chr22:21996709	SDF2L1	-0.5	-6.54	-0.39	3.94e-10	Electrocardiographic conduction measures;
SARC	cis	rs6912958	0.781	rs2284908	chr6:88194500	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.3	-5.04	-0.31	9.29e-7	Monocyte percentage of white cells;
SARC	cis	rs453301	0.658	rs6983877	chr8:8904639	T/C	cg11608241	chr8:8085544	FLJ10661	-0.43	-5.39	-0.33	1.74e-7	Joint mobility (Beighton score);
SARC	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg17221315	chr6:27791827	HIST1H4J	0.45	4.74	0.3	3.76e-6	Depression;
SARC	cis	rs7561149	0.646	rs6433735	chr2:179690233	C/T	cg17765952	chr2:179737173	CCDC141	-0.44	-6.18	-0.38	2.83e-9	QT interval;
SARC	cis	rs834603	0.575	rs1534137	chr7:47482719	T/C	cg23694490	chr7:47445681	TNS3	-0.32	-5.82	-0.36	1.94e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg14019146	chr3:50243930	SLC38A3	-0.31	-4.85	-0.3	2.21e-6	Body mass index;
SARC	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg12463550	chr7:65579703	CRCP	0.7	5.26	0.33	3.34e-7	Diabetic kidney disease;
SARC	cis	rs3857536	0.740	rs9354391	chr6:66890183	C/T	cg07460842	chr6:66804631	NA	0.6	7.33	0.43	3.78e-12	Blood trace element (Cu levels);
SARC	cis	rs17826219	0.706	rs8071236	chr17:29100002	T/C	cg13385521	chr17:29058706	SUZ12P	0.84	7.05	0.42	2e-11	Body mass index;
SARC	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg13395646	chr4:1353034	KIAA1530	0.42	4.98	0.31	1.23e-6	Obesity-related traits;
SARC	cis	rs6500602	0.727	rs4786515	chr16:4578133	T/A	cg08645402	chr16:4508243	NA	0.42	5.37	0.33	1.86e-7	Schizophrenia;
SARC	cis	rs2235642	0.787	rs2235646	chr16:1601287	A/G	cg26528668	chr16:1614120	IFT140	0.36	4.77	0.3	3.23e-6	Coronary artery disease;
SARC	cis	rs6570726	0.875	rs416243	chr6:145868081	A/T	cg23711669	chr6:146136114	FBXO30	0.78	12.0	0.62	3.86e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6696239	0.513	rs1021554	chr1:227743951	C/T	cg26340147	chr1:227730820	NA	0.33	4.77	0.3	3.23e-6	Height;
SARC	cis	rs2505675	0.887	rs2505676	chr6:2355375	C/G	cg16550324	chr6:2245327	GMDS	-0.38	-4.74	-0.3	3.8e-6	Tuberculosis;
SARC	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs2797685	1.000	rs1689904	chr1:7890801	C/T	cg00864860	chr1:7907996	UTS2	-0.37	-5.23	-0.32	3.74e-7	Crohn's disease;
SARC	cis	rs17376456	0.877	rs10050465	chr5:93349963	C/A	cg25358565	chr5:93447407	FAM172A	1.3	14.47	0.69	2.77e-34	Diabetic retinopathy;
SARC	cis	rs7587476	1.000	rs7587476	chr2:215653887	T/C	cg04530015	chr2:215796436	ABCA12	0.39	6.29	0.38	1.56e-9	Neuroblastoma;
SARC	cis	rs7264396	0.733	rs6060515	chr20:34211779	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-7.35	-0.43	3.4e-12	Total cholesterol levels;
SARC	cis	rs3796352	1.000	rs13078971	chr3:53103645	G/C	cg15956490	chr3:53032818	SFMBT1	0.91	6.02	0.37	6.9e-9	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg09839136	chr7:766187	HEATR2;PRKAR1B	0.56	4.79	0.3	3.02e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs11190604	1.000	rs2489036	chr10:102319581	A/G	cg07080220	chr10:102295463	HIF1AN	0.82	8.66	0.49	8.16e-16	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs2882877	0.648	rs13032311	chr2:190397020	T/C	cg21926118	chr2:190387206	NA	-0.41	-5.1	-0.32	6.88e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-9.15	-0.51	2.85e-17	Alzheimer's disease;
SARC	cis	rs6089584	0.566	rs6061963	chr20:60607480	C/G	cg13770153	chr20:60521292	NA	-0.39	-5.71	-0.35	3.46e-8	Body mass index;
SARC	cis	rs6570726	1.000	rs455109	chr6:145872665	C/T	cg05347473	chr6:146136440	FBXO30	0.48	6.49	0.39	5.13e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg05313129	chr8:58192883	C8orf71	-0.57	-6.56	-0.39	3.42e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.41	-5.11	-0.32	6.64e-7	Lymphocyte counts;
SARC	cis	rs9309711	0.689	rs4535075	chr2:3481716	T/C	cg08493051	chr2:3487164	NA	-0.4	-5.06	-0.31	8.4e-7	Neurofibrillary tangles;
SARC	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg04287289	chr16:89883240	FANCA	0.8	13.63	0.67	1.64e-31	Vitiligo;
SARC	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg02951883	chr7:2050386	MAD1L1	-0.42	-5.38	-0.33	1.78e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs7429990	0.965	rs319689	chr3:47928167	C/T	cg11946769	chr3:48343235	NME6	0.48	5.48	0.34	1.09e-7	Educational attainment (years of education);
SARC	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg07701084	chr6:150067640	NUP43	0.41	5.46	0.34	1.23e-7	Lung cancer;
SARC	cis	rs13314892	0.728	rs62252233	chr3:69890439	A/G	cg17445875	chr3:69859618	MITF	-0.48	-4.95	-0.31	1.45e-6	QRS complex (12-leadsum);
SARC	cis	rs6908034	0.556	rs7750703	chr6:19804814	C/G	cg02682789	chr6:19804855	NA	0.86	7.59	0.45	7.44e-13	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs950169	0.922	rs17531523	chr15:85132449	C/G	cg24253500	chr15:84953950	NA	0.37	5.33	0.33	2.36e-7	Schizophrenia;
SARC	cis	rs6582630	0.519	rs12372510	chr12:38293074	T/C	cg13010199	chr12:38710504	ALG10B	0.79	11.03	0.59	4.82e-23	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg13397359	chr6:42928475	GNMT	0.6	8.22	0.47	1.47e-14	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs72653721	0.689	rs17697071	chr6:11052580	C/T	cg13562911	chr6:11044106	ELOVL2	0.59	6.63	0.4	2.35e-10	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	cis	rs738322	0.574	rs28653361	chr22:38570700	C/A	cg25457927	chr22:38595422	NA	-0.25	-4.78	-0.3	3.11e-6	Cutaneous nevi;
SARC	cis	rs6546550	1.000	rs6546550	chr2:70038232	C/G	cg02498382	chr2:70120550	SNRNP27	-0.37	-5.95	-0.36	9.54e-9	Prevalent atrial fibrillation;
SARC	cis	rs7223966	1.000	rs8080211	chr17:61729882	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.53	-5.39	-0.33	1.76e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6089584	0.528	rs881994	chr20:60623931	G/A	cg06108461	chr20:60628389	TAF4	-0.72	-9.38	-0.52	5.95e-18	Body mass index;
SARC	cis	rs7084402	0.967	rs1658435	chr10:60327527	A/G	cg07615347	chr10:60278583	BICC1	0.58	8.66	0.49	8.07e-16	Refractive error;
SARC	cis	rs2576037	0.901	rs2060416	chr18:44576240	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.68	-10.0	-0.55	7.89e-20	Personality dimensions;
SARC	cis	rs17345786	1.000	rs17345528	chr3:101294830	A/C	cg12386194	chr3:101231763	SENP7	-0.67	-7.8	-0.46	2.02e-13	Colonoscopy-negative controls vs population controls;
SARC	cis	rs16854884	0.584	rs2164554	chr3:143755528	A/G	cg06585982	chr3:143692056	C3orf58	0.63	8.44	0.48	3.36e-15	Economic and political preferences (feminism/equality);
SARC	cis	rs10492096	0.947	rs12371184	chr12:6632925	A/G	cg13857086	chr12:6580257	VAMP1	0.65	6.9	0.41	4.96e-11	Hip geometry;
SARC	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs60871478	1.000	rs62432223	chr7:787959	A/G	cg19087971	chr7:751233	PRKAR1B	-0.45	-4.98	-0.31	1.22e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.45	0.53	3.64e-18	Prudent dietary pattern;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg00444581	chr8:141856401	PTK2	-0.51	-6.36	-0.38	1.04e-9	Alcohol dependence;
SARC	cis	rs561341	0.739	rs4795663	chr17:30214542	T/C	cg13647721	chr17:30228624	UTP6	-0.74	-8.84	-0.5	2.4e-16	Hip circumference adjusted for BMI;
SARC	cis	rs7829975	0.577	rs940032	chr8:8546343	C/T	cg06636001	chr8:8085503	FLJ10661	-0.47	-5.5	-0.34	9.99e-8	Mood instability;
SARC	cis	rs2486288	0.656	rs2413774	chr15:45549423	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.51	-6.44	-0.39	6.68e-10	Glomerular filtration rate;
SARC	cis	rs8044995	0.563	rs2279540	chr16:68395061	T/C	cg05110241	chr16:68378359	PRMT7	-0.67	-6.57	-0.4	3.28e-10	Schizophrenia;
SARC	cis	rs7224737	0.956	rs8081327	chr17:40274200	G/A	cg20291162	chr17:40259547	DHX58	-0.33	-4.87	-0.3	2.08e-6	Fibrinogen levels;
SARC	cis	rs600231	0.598	rs2508712	chr11:65232261	C/G	cg17120908	chr11:65337727	SSSCA1	-0.41	-5.27	-0.33	3.07e-7	Bone mineral density;
SARC	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg22974920	chr21:40686053	BRWD1	0.44	4.82	0.3	2.6e-6	Cognitive function;
SARC	cis	rs72781680	0.898	rs116113042	chr2:23960194	G/T	cg06627628	chr2:24431161	ITSN2	-0.63	-5.96	-0.36	9.46e-9	Lymphocyte counts;
SARC	cis	rs9381040	0.599	rs2057001	chr6:41022947	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.42	-4.87	-0.3	2.08e-6	Alzheimer's disease (late onset);
SARC	cis	rs3845702	0.736	rs12465592	chr2:180862654	C/G	cg01881094	chr2:180872142	CWC22	1.04	8.14	0.47	2.43e-14	Schizophrenia;
SARC	cis	rs1355223	0.506	rs7131229	chr11:34869328	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.48	6.06	0.37	5.43e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs858239	0.730	rs858290	chr7:23248036	A/G	cg23682824	chr7:23144976	KLHL7	0.64	8.09	0.47	3.33e-14	Cerebrospinal fluid biomarker levels;
SARC	cis	rs10463554	0.963	rs26524	chr5:102456304	A/G	cg23492399	chr5:102201601	PAM	-0.47	-5.26	-0.33	3.23e-7	Parkinson's disease;
SARC	cis	rs73001065	0.792	rs17216525	chr19:19662220	C/T	cg03709012	chr19:19516395	GATAD2A	0.89	5.27	0.33	3.06e-7	LDL cholesterol;
SARC	cis	rs796364	0.760	rs2202922	chr2:200882610	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.71	6.04	0.37	6.12e-9	Schizophrenia;
SARC	cis	rs7208859	0.673	rs8077116	chr17:29140162	A/G	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs6714710	0.603	rs35505530	chr2:98506910	T/C	cg26665480	chr2:98280029	ACTR1B	0.51	6.94	0.41	3.94e-11	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs9457247	1.000	rs415842	chr6:167406681	G/A	cg23791538	chr6:167370224	RNASET2	-0.62	-8.59	-0.49	1.27e-15	Crohn's disease;
SARC	cis	rs56104184	0.779	rs2131093	chr19:49350693	A/T	cg15549821	chr19:49342101	PLEKHA4	-0.93	-9.22	-0.52	1.82e-17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs7582720	1.000	rs72932566	chr2:203855342	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg24531977	chr5:56204891	C5orf35	-0.54	-5.45	-0.34	1.26e-7	Initial pursuit acceleration;
SARC	cis	rs6121246	0.567	rs6087701	chr20:30217708	A/C	cg13852791	chr20:30311386	BCL2L1	0.64	5.64	0.35	4.79e-8	Mean corpuscular hemoglobin;
SARC	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg11890956	chr21:40555474	PSMG1	1.02	15.13	0.7	1.79e-36	Cognitive function;
SARC	trans	rs2816316	0.583	rs2760529	chr1:192537062	C/T	cg02079908	chr2:42411760	EML4	0.51	6.31	0.38	1.37e-9	Celiac disease;
SARC	cis	rs9916302	0.706	rs8069074	chr17:37685401	C/T	cg07936489	chr17:37558343	FBXL20	0.75	8.72	0.5	5.45e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs8028182	0.636	rs11638974	chr15:75799306	G/A	cg20655648	chr15:75932815	IMP3	0.6	6.92	0.41	4.31e-11	Sudden cardiac arrest;
SARC	cis	rs11608355	1.000	rs11608355	chr12:109879292	T/C	cg05360138	chr12:110035743	NA	0.44	4.96	0.31	1.36e-6	Neuroticism;
SARC	cis	rs228437	1.000	rs450801	chr6:134905309	T/C	cg24504307	chr6:134963096	NA	0.48	5.42	0.33	1.52e-7	Melanoma;
SARC	cis	rs2933343	0.729	rs1680786	chr3:128644840	T/C	cg25356066	chr3:128598488	ACAD9	0.7	9.29	0.52	1.17e-17	IgG glycosylation;
SARC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	10.24	0.56	1.52e-20	Platelet count;
SARC	cis	rs3733585	0.699	rs7657340	chr4:9966772	A/T	cg11266682	chr4:10021025	SLC2A9	-0.37	-6.48	-0.39	5.28e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg00149659	chr3:10157352	C3orf10	0.78	7.3	0.43	4.52e-12	Alzheimer's disease;
SARC	cis	rs3796352	1.000	rs11713859	chr3:53042080	C/A	cg12962167	chr3:53033115	SFMBT1	0.82	5.4	0.33	1.61e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2236918	1.000	rs2236918	chr1:242017826	C/G	cg17736920	chr1:242011382	EXO1	-0.79	-11.23	-0.59	1.13e-23	Menopause (age at onset);
SARC	cis	rs7246657	0.943	rs10422967	chr19:37850137	T/C	cg23950597	chr19:37808831	NA	-0.6	-5.85	-0.36	1.67e-8	Coronary artery calcification;
SARC	cis	rs2481665	0.777	rs17379217	chr1:62545085	C/T	cg18591186	chr1:62594603	INADL	-0.55	-7.44	-0.44	1.92e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs1005277	0.522	rs289648	chr10:37971837	T/C	cg25427524	chr10:38739819	LOC399744	-0.53	-8.14	-0.47	2.38e-14	Extrinsic epigenetic age acceleration;
SARC	cis	rs1371867	0.875	rs1788187	chr8:101336099	A/G	cg11906718	chr8:101322791	RNF19A	0.66	8.65	0.49	8.33e-16	Atrioventricular conduction;
SARC	cis	rs7223966	1.000	rs11657306	chr17:61704822	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-6.37	-0.38	1.01e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7712401	0.601	rs30069	chr5:122293026	A/G	cg19412675	chr5:122181750	SNX24	0.4	5.13	0.32	5.98e-7	Mean platelet volume;
SARC	cis	rs2280630	0.529	rs4342048	chr3:39012943	A/G	cg01426195	chr3:39028469	NA	-0.34	-4.85	-0.3	2.27e-6	Verbal declarative memory;
SARC	cis	rs4713118	0.513	rs149972	chr6:27983227	C/T	cg17221315	chr6:27791827	HIST1H4J	0.43	4.85	0.3	2.29e-6	Parkinson's disease;
SARC	cis	rs4308124	0.708	rs2137168	chr2:111986509	C/T	cg04571233	chr2:111982156	NA	-0.52	-6.02	-0.37	6.73e-9	Vitiligo;
SARC	cis	rs3099143	0.803	rs28618274	chr15:77220243	C/T	cg21673338	chr15:77095150	SCAPER	-0.66	-5.13	-0.32	6.23e-7	Recalcitrant atopic dermatitis;
SARC	cis	rs7644634	0.688	rs12493181	chr3:105475655	T/C	cg23051926	chr3:105466016	CBLB	0.46	5.71	0.35	3.39e-8	Itch intensity from mosquito bite;
SARC	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg08859206	chr1:53392774	SCP2	-0.39	-5.59	-0.34	6.49e-8	Monocyte count;
SARC	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg16325326	chr1:53192061	ZYG11B	0.93	17.33	0.75	8.45e-44	Monocyte count;
SARC	cis	rs6963495	0.818	rs73192124	chr7:105171528	C/T	cg13798780	chr7:105162888	PUS7	0.61	5.59	0.34	6.32e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs950169	0.840	rs62029595	chr15:84955301	C/T	cg17507749	chr15:85114479	UBE2QP1	0.77	9.38	0.52	5.99e-18	Schizophrenia;
SARC	cis	rs921968	0.643	rs579610	chr2:219327582	C/A	cg02176678	chr2:219576539	TTLL4	0.36	5.51	0.34	9.42e-8	Mean corpuscular hemoglobin concentration;
SARC	cis	rs1153858	0.621	rs12913645	chr15:45555066	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.75	-10.0	-0.55	8.2e-20	Homoarginine levels;
SARC	cis	rs2834188	0.961	rs8130807	chr21:34690013	A/G	cg04842828	chr21:34696676	IFNAR1	0.4	4.74	0.3	3.78e-6	Narcolepsy;
SARC	cis	rs2354432	0.556	rs12568866	chr1:146718430	A/C	cg25205988	chr1:146714368	CHD1L	-1.04	-7.58	-0.44	8.14e-13	Mitochondrial DNA levels;
SARC	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	11.97	0.62	4.71e-26	Chronic sinus infection;
SARC	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg24675658	chr1:53192096	ZYG11B	-0.66	-9.9	-0.54	1.63e-19	Monocyte count;
SARC	cis	rs208520	0.690	rs1738970	chr6:66809491	T/G	cg07460842	chr6:66804631	NA	-1.07	-14.89	-0.7	1.11e-35	Exhaled nitric oxide output;
SARC	trans	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg21659725	chr3:3221576	CRBN	-0.81	-12.44	-0.63	1.37e-27	Intelligence (multi-trait analysis);
SARC	cis	rs17666538	0.901	rs73177064	chr8:585293	C/G	cg13264159	chr8:625131	ERICH1	0.7	4.72	0.3	4.13e-6	IgG glycosylation;
SARC	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg25036284	chr2:26402008	FAM59B	0.48	5.96	0.36	9.03e-9	Gut microbiome composition (summer);
SARC	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg22800045	chr5:56110881	MAP3K1	0.47	5.28	0.33	2.97e-7	Coronary artery disease;
SARC	cis	rs9300255	0.537	rs1618679	chr12:123650714	A/G	cg05973401	chr12:123451056	ABCB9	0.54	6.17	0.37	3e-9	Neutrophil percentage of white cells;
SARC	cis	rs2387326	1.000	rs34558168	chr10:129932106	T/C	cg16087940	chr10:129947807	NA	-0.49	-6.29	-0.38	1.59e-9	Select biomarker traits;
SARC	cis	rs5753618	0.561	rs4820963	chr22:31698166	C/T	cg00478049	chr22:31556069	RNF185	0.44	4.78	0.3	3.05e-6	Colorectal cancer;
SARC	cis	rs3733585	0.648	rs67820465	chr4:9975873	A/G	cg00071950	chr4:10020882	SLC2A9	-0.34	-5.18	-0.32	4.76e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs6456156	0.692	rs9457270	chr6:167512928	A/G	cg23791538	chr6:167370224	RNASET2	-0.46	-5.72	-0.35	3.17e-8	Primary biliary cholangitis;
SARC	cis	rs2921036	0.545	rs4840975	chr8:8363258	C/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.32	-0.38	1.32e-9	Neuroticism;
SARC	cis	rs2652822	0.967	rs4775633	chr15:63437746	G/A	cg02713581	chr15:63449717	RPS27L	0.72	9.74	0.54	4.89e-19	Metabolic traits;
SARC	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg03033257	chr22:50311977	ALG12;CRELD2	0.62	5.86	0.36	1.61e-8	Schizophrenia;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg21652344	chr17:17740365	SREBF1	0.48	6.64	0.4	2.12e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs3126085	0.935	rs1496050	chr1:152163549	T/C	cg26876637	chr1:152193138	HRNR	0.48	5.51	0.34	9.32e-8	Atopic dermatitis;
SARC	cis	rs3106136	0.967	rs61514245	chr4:95165053	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.39	-6.05	-0.37	5.83e-9	Capecitabine sensitivity;
SARC	cis	rs73206853	0.841	rs73206894	chr12:110876328	C/T	cg10860002	chr12:110842031	ANAPC7	0.63	4.98	0.31	1.22e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs2153535	0.580	rs7761937	chr6:8459434	A/T	cg21535247	chr6:8435926	SLC35B3	0.55	6.93	0.41	4.04e-11	Motion sickness;
SARC	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg04772025	chr11:68637568	NA	0.51	6.32	0.38	1.34e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs78545713	0.892	rs79262959	chr6:26259578	A/T	cg13736514	chr6:26305472	NA	-0.64	-5.38	-0.33	1.83e-7	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.81	-11.42	-0.6	2.71e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg24531977	chr5:56204891	C5orf35	0.66	6.36	0.38	1.07e-9	Initial pursuit acceleration;
SARC	cis	rs8031584	0.918	rs11639169	chr15:31255438	C/T	cg14829155	chr15:31115871	NA	-0.45	-5.42	-0.33	1.49e-7	Huntington's disease progression;
SARC	cis	rs4820539	1.000	rs885965	chr22:23461425	A/G	cg14186256	chr22:23484241	RTDR1	0.85	13.39	0.66	1.04e-30	Bone mineral density;
SARC	cis	rs12554020	0.892	rs76488437	chr9:96367796	A/C	cg21184699	chr9:96277131	FAM120A	-0.5	-4.73	-0.3	3.97e-6	Schizophrenia;
SARC	cis	rs3733346	0.529	rs6842493	chr4:914638	T/C	cg08222618	chr4:941054	TMEM175	0.53	8.02	0.46	5.29e-14	Sjögren's syndrome;
SARC	cis	rs9790314	0.747	rs9990115	chr3:160838412	C/G	cg03342759	chr3:160939853	NMD3	-0.46	-5.67	-0.35	4.11e-8	Morning vs. evening chronotype;
SARC	cis	rs11785400	1.000	rs4736342	chr8:143735190	A/G	cg24634471	chr8:143751801	JRK	0.68	8.9	0.5	1.57e-16	Schizophrenia;
SARC	cis	rs9457247	0.663	rs2282860	chr6:167440244	T/C	cg07741184	chr6:167504864	NA	0.35	6.99	0.42	2.9e-11	Crohn's disease;
SARC	cis	rs2120019	0.938	rs8028632	chr15:75321262	T/C	cg00629941	chr15:75287862	SCAMP5	-0.7	-8.35	-0.48	6.18e-15	Blood trace element (Zn levels);
SARC	cis	rs6546550	0.867	rs726920	chr2:70152027	G/C	cg02498382	chr2:70120550	SNRNP27	-0.33	-5.36	-0.33	1.99e-7	Prevalent atrial fibrillation;
SARC	cis	rs67311347	0.568	rs57287242	chr3:40335538	T/C	cg24209194	chr3:40518798	ZNF619	0.49	6.6	0.4	2.72e-10	Renal cell carcinoma;
SARC	cis	rs7635838	0.927	rs13082150	chr3:11437813	T/C	cg00170343	chr3:11313890	ATG7	0.61	8.14	0.47	2.45e-14	HDL cholesterol;
SARC	cis	rs818427	0.820	rs712666	chr5:112227939	T/C	cg07820702	chr5:112228657	REEP5	-0.47	-5.3	-0.33	2.7e-7	Total body bone mineral density;
SARC	cis	rs6456156	0.805	rs6909252	chr6:167527097	C/T	cg07741184	chr6:167504864	NA	-0.28	-5.35	-0.33	2.07e-7	Primary biliary cholangitis;
SARC	cis	rs17376456	0.877	rs55832164	chr5:93436579	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.89	0.36	1.36e-8	Diabetic retinopathy;
SARC	cis	rs12044355	0.929	rs6693517	chr1:231852444	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.52	7.04	0.42	2.1e-11	Alzheimer's disease;
SARC	cis	rs17666538	0.792	rs115204727	chr8:676639	G/A	cg23958373	chr8:599963	NA	-0.9	-5.67	-0.35	4.14e-8	IgG glycosylation;
SARC	cis	rs4319547	0.656	rs7397299	chr12:122821649	G/T	cg05707623	chr12:122985044	ZCCHC8	-0.56	-6.46	-0.39	5.96e-10	Body mass index;
SARC	cis	rs10751667	0.961	rs10902263	chr11:992691	A/C	cg10932868	chr11:921992	NA	-0.34	-5.13	-0.32	6.18e-7	Alzheimer's disease (late onset);
SARC	cis	rs2304069	1.000	rs2304069	chr5:149406733	G/T	cg12661370	chr5:149340060	SLC26A2	0.62	6.3	0.38	1.46e-9	HIV-1 control;
SARC	cis	rs4481887	1.000	rs10788775	chr1:248471945	C/G	cg13385794	chr1:248469461	NA	0.36	5.43	0.34	1.41e-7	Common traits (Other);
SARC	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg25072359	chr17:41440525	NA	0.52	6.63	0.4	2.26e-10	Menopause (age at onset);
SARC	cis	rs698833	0.509	rs10198291	chr2:44539009	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.65	7.33	0.43	3.67e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg18252515	chr7:66147081	NA	-1.34	-11.82	-0.61	1.45e-25	Diabetic kidney disease;
SARC	cis	rs17376456	0.877	rs12716460	chr5:93416733	A/G	cg25358565	chr5:93447407	FAM172A	1.32	14.8	0.7	2.14e-35	Diabetic retinopathy;
SARC	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg19223190	chr17:80058835	NA	-0.45	-6.2	-0.38	2.52e-9	Life satisfaction;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25674838	chr17:41856568	C17orf105;DUSP3	0.54	6.63	0.4	2.34e-10	Fibrinogen levels;
SARC	cis	rs9457247	1.000	rs422780	chr6:167406209	A/G	cg07741184	chr6:167504864	NA	0.29	5.61	0.34	5.85e-8	Crohn's disease;
SARC	cis	rs11809207	0.523	rs2783626	chr1:26501044	C/T	cg00300879	chr1:26503847	CNKSR1	-0.32	-4.97	-0.31	1.3e-6	Height;
SARC	cis	rs965469	0.779	rs6515791	chr20:3310443	C/G	cg25506879	chr20:3388711	C20orf194	-0.45	-4.96	-0.31	1.37e-6	IFN-related cytopenia;
SARC	cis	rs9660992	0.686	rs1668870	chr1:205239031	C/G	cg21643547	chr1:205240462	TMCC2	-0.64	-8.25	-0.48	1.16e-14	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs2594989	0.943	rs346070	chr3:11303874	T/C	cg00170343	chr3:11313890	ATG7	0.64	5.97	0.36	8.61e-9	Circulating chemerin levels;
SARC	cis	rs738322	0.555	rs5750548	chr22:38547016	C/A	cg25457927	chr22:38595422	NA	-0.26	-4.88	-0.3	1.94e-6	Cutaneous nevi;
SARC	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg11366901	chr6:160182831	ACAT2	0.98	9.94	0.55	1.26e-19	Age-related macular degeneration (geographic atrophy);
SARC	trans	rs6076960	0.684	rs3852947	chr20:6255341	A/G	cg21095983	chr6:86352623	SYNCRIP	0.47	6.78	0.41	9.55e-11	Smooth-surface caries;
SARC	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg11764359	chr7:65958608	NA	0.78	10.75	0.58	3.63e-22	Aortic root size;
SARC	cis	rs2439831	0.681	rs11858152	chr15:43634196	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	8.92	0.5	1.39e-16	Lung cancer in ever smokers;
SARC	cis	rs9487051	0.872	rs9372211	chr6:109609648	C/T	cg01475377	chr6:109611718	NA	-0.42	-5.94	-0.36	1.01e-8	Reticulocyte fraction of red cells;
SARC	cis	rs7923609	0.746	rs7070761	chr10:65317056	A/T	cg01631684	chr10:65280961	REEP3	0.35	4.72	0.3	4.06e-6	Educational attainment;Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs9818758	0.607	rs9855123	chr3:49229457	C/T	cg01304814	chr3:48885189	PRKAR2A	0.6	4.92	0.31	1.63e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs2762353	0.526	rs6912391	chr6:25710763	C/G	cg17691542	chr6:26056736	HIST1H1C	-0.44	-5.42	-0.33	1.46e-7	Blood metabolite levels;
SARC	cis	rs35306767	0.903	rs10508208	chr10:910983	C/T	cg26597838	chr10:835615	NA	0.72	7.59	0.45	7.59e-13	Eosinophil percentage of granulocytes;
SARC	cis	rs3087591	0.521	rs1013948	chr17:29530709	C/T	cg24425628	chr17:29625626	OMG;NF1	0.51	5.14	0.32	5.73e-7	Hip circumference;
SARC	cis	rs699371	0.507	rs10149538	chr14:74925397	A/G	cg16374328	chr14:74960395	NPC2;ISCA2	0.5	6.36	0.38	1.03e-9	Height;
SARC	cis	rs6665290	0.935	rs11588904	chr1:227196211	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.09	-25.43	-0.86	3.74e-69	Myeloid white cell count;
SARC	cis	rs1163251	0.902	rs511059	chr1:120217081	G/T	cg19096424	chr1:120255104	PHGDH	0.51	5.95	0.36	9.93e-9	Blood metabolite levels;
SARC	trans	rs9929218	0.953	rs3118227	chr16:68734855	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.64	-8.23	-0.47	1.37e-14	Colorectal cancer;
SARC	cis	rs9467773	1.000	rs9393732	chr6:26530898	G/A	cg12292205	chr6:26970375	C6orf41	0.45	5.43	0.34	1.41e-7	Intelligence (multi-trait analysis);
SARC	cis	rs644799	0.648	rs1255176	chr11:95471465	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.57	7.26	0.43	5.71e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg11494091	chr17:61959527	GH2	0.54	8.18	0.47	1.86e-14	Prudent dietary pattern;
SARC	cis	rs1348850	0.874	rs12996447	chr2:178283592	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.63	7.8	0.46	2.07e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs11785400	0.793	rs750530	chr8:143744931	G/A	cg10596483	chr8:143751796	JRK	0.55	7.01	0.42	2.59e-11	Schizophrenia;
SARC	cis	rs9902453	0.904	rs4528633	chr17:28356136	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.54	-7.09	-0.42	1.57e-11	Coffee consumption (cups per day);
SARC	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg23758822	chr17:41437982	NA	0.89	11.27	0.59	8.17e-24	Menopause (age at onset);
SARC	cis	rs4242434	0.819	rs1871902	chr8:22470710	G/A	cg03733263	chr8:22462867	KIAA1967	0.92	15.05	0.7	3.13e-36	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs8077889	1.000	rs2342310	chr17:41866199	T/C	cg26893861	chr17:41843967	DUSP3	0.9	10.81	0.58	2.48e-22	Triglycerides;
SARC	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.46	5.77	0.35	2.54e-8	Gut microbiome composition (summer);
SARC	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg14784868	chr12:69753453	YEATS4	0.5	6.68	0.4	1.77e-10	Blood protein levels;
SARC	cis	rs965469	1.000	rs6051703	chr20:3252347	A/T	cg25506879	chr20:3388711	C20orf194	-0.5	-5.08	-0.32	7.59e-7	IFN-related cytopenia;
SARC	cis	rs921968	0.565	rs7586384	chr2:219582897	T/C	cg02176678	chr2:219576539	TTLL4	-0.33	-4.98	-0.31	1.21e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs34779708	0.966	rs34776628	chr10:35426324	G/A	cg03585969	chr10:35415529	CREM	0.38	4.85	0.3	2.25e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs8079658	0.720	rs4791115	chr17:63859894	C/G	cg03442606	chr17:63822778	CCDC46	0.35	4.75	0.3	3.53e-6	Post bronchodilator FEV1;
SARC	cis	rs1371867	0.875	rs1612773	chr8:101337818	G/C	cg11906718	chr8:101322791	RNF19A	0.68	8.66	0.49	7.89e-16	Atrioventricular conduction;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg12908952	chr1:167190631	POU2F1	0.49	6.31	0.38	1.38e-9	Lung adenocarcinoma;
SARC	cis	rs2153535	0.580	rs2143354	chr6:8517907	G/A	cg07606381	chr6:8435919	SLC35B3	0.77	10.9	0.58	1.28e-22	Motion sickness;
SARC	cis	rs1707322	0.963	rs10789478	chr1:46350506	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.44	0.39	6.65e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	9.01	0.51	7.53e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs76419734	1.000	rs11723639	chr4:106741163	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	5.2	0.32	4.29e-7	Post bronchodilator FEV1;
SARC	cis	rs9611519	0.929	rs2064560	chr22:41530040	A/G	cg03806693	chr22:41940476	POLR3H	-0.55	-6.23	-0.38	2.13e-9	Neuroticism;
SARC	cis	rs7223966	1.000	rs55674647	chr17:61794195	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	6.94	0.41	3.91e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1048238	0.548	rs848217	chr1:16272250	A/G	cg21385522	chr1:16154831	NA	-0.56	-7.01	-0.42	2.51e-11	Systolic blood pressure;
SARC	cis	rs651907	0.535	rs11919389	chr3:101424458	T/C	cg12386194	chr3:101231763	SENP7	0.48	5.71	0.35	3.46e-8	Colorectal cancer;
SARC	cis	rs12477438	0.765	rs2309454	chr2:99595418	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.95	-15.47	-0.71	1.34e-37	Chronic sinus infection;
SARC	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.79	11.84	0.61	1.25e-25	Personality dimensions;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg07404466	chr20:56064128	HMGB1L1	-0.64	-6.55	-0.39	3.65e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1580019	0.961	rs3801328	chr7:32496930	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.73	9.78	0.54	3.93e-19	Cognitive ability;
SARC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.36	0.8	1.22e-53	Prudent dietary pattern;
SARC	cis	rs7572733	0.555	rs35563720	chr2:198923075	A/G	cg00792783	chr2:198669748	PLCL1	0.44	5.0	0.31	1.12e-6	Dermatomyositis;
SARC	cis	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg03213289	chr20:61660250	NA	0.46	6.37	0.39	9.75e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg02018176	chr4:1364513	KIAA1530	-0.35	-4.95	-0.31	1.43e-6	Obesity-related traits;
SARC	cis	rs9815354	1.000	rs1717000	chr3:41930219	A/C	cg03022575	chr3:42003672	ULK4	-0.56	-5.38	-0.33	1.81e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs910316	0.726	rs61979167	chr14:75663610	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.47	-6.25	-0.38	1.97e-9	Height;
SARC	cis	rs6714710	0.603	rs11679828	chr2:98517626	G/A	cg26665480	chr2:98280029	ACTR1B	0.49	6.72	0.4	1.38e-10	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs920590	0.684	rs3899017	chr8:19669198	A/T	cg17834443	chr8:19674713	INTS10	0.63	7.4	0.44	2.41e-12	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg12463550	chr7:65579703	CRCP	-0.47	-5.03	-0.31	9.64e-7	Aortic root size;
SARC	cis	rs1801251	0.778	rs778338	chr2:233740227	A/G	cg25237894	chr2:233734115	C2orf82	-0.33	-4.72	-0.3	4.12e-6	Coronary artery disease;
SARC	cis	rs17030434	0.834	rs6843172	chr4:154760600	T/C	cg14289246	chr4:154710475	SFRP2	-0.63	-7.21	-0.43	7.72e-12	Electrocardiographic conduction measures;
SARC	cis	rs910316	0.874	rs61980828	chr14:75630378	G/A	cg11812906	chr14:75593930	NEK9	-0.87	-12.71	-0.64	1.87e-28	Height;
SARC	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	-0.88	-9.09	-0.51	4.3e-17	Platelet count;
SARC	cis	rs3737883	1.000	rs11579055	chr1:203031315	G/T	cg03900565	chr1:203031815	PPFIA4	0.35	5.49	0.34	1.02e-7	Early onset atrial fibrillation;
SARC	trans	rs6486986	0.646	rs6416210	chr12:19800619	A/G	cg12087108	chr2:45838413	SRBD1	0.64	6.25	0.38	1.9e-9	Cognitive performance;
SARC	cis	rs1003719	0.715	rs9981715	chr21:38499610	C/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-9.12	-0.51	3.7e-17	Eye color traits;
SARC	cis	rs1008375	0.898	rs61047804	chr4:17593965	G/A	cg27347728	chr4:17578864	LAP3	0.47	5.76	0.35	2.71e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs12477438	0.501	rs11123770	chr2:99825102	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.8	11.24	0.59	1.09e-23	Chronic sinus infection;
SARC	cis	rs10771431	0.810	rs10771418	chr12:9358995	A/G	cg08997352	chr12:9597637	DDX12	-0.63	-8.93	-0.51	1.26e-16	Breast size;
SARC	cis	rs3126085	0.935	rs1466757	chr1:152212469	G/A	cg26876637	chr1:152193138	HRNR	0.48	5.6	0.34	6.08e-8	Atopic dermatitis;
SARC	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg04277193	chr17:41438351	NA	0.46	4.94	0.31	1.48e-6	Menopause (age at onset);
SARC	cis	rs1008375	0.931	rs2109519	chr4:17695453	A/G	cg16339924	chr4:17578868	LAP3	0.53	6.77	0.41	1.04e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2180341	0.538	rs4577822	chr6:127712911	T/G	cg27446573	chr6:127587934	RNF146	0.51	6.35	0.38	1.09e-9	Breast cancer;
SARC	cis	rs6582630	0.519	rs2387812	chr12:38381480	A/G	cg26384229	chr12:38710491	ALG10B	0.87	12.85	0.64	6.2e-29	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs3099143	0.901	rs78020233	chr15:77107050	T/G	cg21673338	chr15:77095150	SCAPER	-0.75	-5.76	-0.35	2.64e-8	Recalcitrant atopic dermatitis;
SARC	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg12463550	chr7:65579703	CRCP	-0.48	-5.51	-0.34	9.61e-8	Aortic root size;
SARC	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg00149659	chr3:10157352	C3orf10	0.69	6.44	0.39	6.6e-10	Alzheimer's disease;
SARC	cis	rs7824557	0.547	rs2736287	chr8:11228006	G/A	cg21775007	chr8:11205619	TDH	-0.71	-9.7	-0.54	6.54e-19	Retinal vascular caliber;
SARC	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg11764359	chr7:65958608	NA	-0.63	-7.67	-0.45	4.55e-13	Aortic root size;
SARC	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg26335602	chr6:28129616	ZNF389	0.53	5.88	0.36	1.43e-8	Parkinson's disease;
SARC	cis	rs6670533	0.571	rs1055703	chr1:24863478	A/C	cg07475527	chr1:24864545	NA	-1.0	-5.65	-0.35	4.76e-8	Fasting blood insulin (BMI interaction);
SARC	cis	rs6693567	0.565	rs2264417	chr1:150368501	C/T	cg09579323	chr1:150459698	TARS2	0.46	5.8	0.36	2.11e-8	Migraine;
SARC	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.72	-9.1	-0.51	4.11e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9487051	0.604	rs9320282	chr6:109619377	A/G	cg01475377	chr6:109611718	NA	-0.39	-5.53	-0.34	8.41e-8	Reticulocyte fraction of red cells;
SARC	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg03264133	chr6:25882463	NA	-0.52	-6.53	-0.39	4.01e-10	Intelligence (multi-trait analysis);
SARC	cis	rs8180040	0.966	rs11705957	chr3:47443262	T/G	cg27129171	chr3:47204927	SETD2	-0.68	-9.5	-0.53	2.68e-18	Colorectal cancer;
SARC	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg13628971	chr7:2884303	GNA12	0.49	5.71	0.35	3.46e-8	Height;
SARC	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	-0.68	-9.06	-0.51	5.54e-17	Menarche (age at onset);
SARC	cis	rs763121	0.853	rs7289577	chr22:39042214	C/G	cg21395723	chr22:39101663	GTPBP1	0.58	6.67	0.4	1.85e-10	Menopause (age at onset);
SARC	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg03735888	chr19:58951602	ZNF132	0.65	8.05	0.47	4.37e-14	Mean platelet volume;
SARC	cis	rs7712401	0.601	rs30072	chr5:122292220	C/A	cg19412675	chr5:122181750	SNX24	0.4	5.13	0.32	5.98e-7	Mean platelet volume;
SARC	cis	rs4481887	0.927	rs4551626	chr1:248489128	G/T	cg13385794	chr1:248469461	NA	0.33	4.96	0.31	1.35e-6	Common traits (Other);
SARC	cis	rs4727443	0.899	rs886453	chr7:99588225	G/A	cg22004693	chr7:99632812	ZKSCAN1	0.61	7.96	0.46	7.48e-14	Interstitial lung disease;
SARC	cis	rs79057730	0.528	rs6965219	chr7:821807	C/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.66	4.91	0.31	1.68e-6	Initial pursuit acceleration;
SARC	cis	rs6831352	0.918	rs2851248	chr4:100045974	A/G	cg13256891	chr4:100009986	ADH5	0.66	8.31	0.48	7.88e-15	Alcohol dependence;
SARC	cis	rs765787	0.530	rs11858988	chr15:45522114	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.41	-4.9	-0.31	1.82e-6	Uric acid levels;
SARC	cis	rs13191362	1.000	rs13207671	chr6:162979056	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.56	5.44	0.34	1.36e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs6582630	0.555	rs1969362	chr12:38514843	C/T	cg13010199	chr12:38710504	ALG10B	0.79	10.86	0.58	1.69e-22	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs6600671	0.934	rs11249429	chr1:121291080	C/T	cg00646200	chr1:148855367	NA	-0.53	-7.23	-0.43	6.76e-12	Hip geometry;
SARC	cis	rs7666738	1.000	rs2865983	chr4:99033352	C/T	cg05340658	chr4:99064831	C4orf37	0.57	7.16	0.42	1.02e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs67460515	0.596	rs35589595	chr3:160930984	G/A	cg04691961	chr3:161091175	C3orf57	-0.4	-4.75	-0.3	3.56e-6	Parkinson's disease;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg17404397	chr10:12174728	SEC61A2	0.52	7.67	0.45	4.75e-13	Thyroid stimulating hormone;
SARC	cis	rs11785693	0.862	rs62491189	chr8:4991309	T/C	cg26367366	chr8:4980734	NA	0.71	6.26	0.38	1.81e-9	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs17125944	0.505	rs74620173	chr14:53194068	G/T	cg00686598	chr14:53173677	PSMC6	1.36	9.42	0.53	4.76e-18	Alzheimer's disease (late onset);
SARC	cis	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg03060546	chr3:49711283	APEH	0.6	7.49	0.44	1.41e-12	Resting heart rate;
SARC	cis	rs7659604	0.502	rs13128434	chr4:122672461	A/C	cg19671926	chr4:122722719	EXOSC9	0.56	6.86	0.41	6.16e-11	Type 2 diabetes;
SARC	cis	rs854765	0.618	rs8068820	chr17:17834119	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	9.75	0.54	4.62e-19	Total body bone mineral density;
SARC	cis	rs7647973	0.593	rs7620848	chr3:49828021	G/C	cg13072238	chr3:49761600	GMPPB	0.6	6.16	0.37	3.16e-9	Menarche (age at onset);
SARC	cis	rs7909074	0.865	rs10900123	chr10:45376574	C/T	cg04218760	chr10:45406644	TMEM72	-0.25	-4.85	-0.3	2.22e-6	Mean corpuscular volume;
SARC	cis	rs2463822	0.669	rs72919480	chr11:62043133	G/A	cg06239285	chr11:62104954	ASRGL1	-0.9	-8.28	-0.48	9.53e-15	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg09033563	chr22:24373618	LOC391322	0.52	5.56	0.34	7.19e-8	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs1009170	0.541	rs10145684	chr14:92639862	T/C	ch.14.1475328F	chr14:92585817	NDUFB1	0.38	4.8	0.3	2.84e-6	Dialysis-related mortality;
SARC	cis	rs4481887	0.893	rs1339991	chr1:248509363	C/T	cg00666640	chr1:248458726	OR2T12	0.33	5.67	0.35	4.17e-8	Common traits (Other);
SARC	cis	rs77686669	1	rs77686669	chr7:99744572	T/C	cg22004693	chr7:99632812	ZKSCAN1	0.61	7.3	0.43	4.4e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
SARC	cis	rs6582630	0.519	rs7305545	chr12:38349223	G/A	cg26384229	chr12:38710491	ALG10B	0.87	12.69	0.64	2.17e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2251381	0.722	rs2251278	chr21:30529234	A/G	cg24692254	chr21:30365293	RNF160	0.87	12.41	0.63	1.72e-27	Selective IgA deficiency;
SARC	cis	rs7044106	0.791	rs4617229	chr9:123480696	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	6.39	0.39	8.98e-10	Hip circumference adjusted for BMI;
SARC	trans	rs11098499	0.821	rs3775852	chr4:120454556	A/G	cg25214090	chr10:38739885	LOC399744	0.57	7.35	0.43	3.31e-12	Corneal astigmatism;
SARC	cis	rs4481887	0.927	rs4586010	chr1:248437568	G/A	cg01631408	chr1:248437212	OR2T33	-0.46	-5.8	-0.36	2.18e-8	Common traits (Other);
SARC	cis	rs1707322	0.717	rs1135850	chr1:46093692	G/A	cg06784218	chr1:46089804	CCDC17	0.37	6.56	0.4	3.37e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1707322	0.752	rs28568986	chr1:46207743	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.37	0.38	1.03e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs933688	1.000	rs889213	chr5:90682151	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.06	13.47	0.66	5.91e-31	Smoking behavior;
SARC	cis	rs208520	0.661	rs150263	chr6:66777620	T/C	cg07460842	chr6:66804631	NA	-1.08	-14.95	-0.7	7e-36	Exhaled nitric oxide output;
SARC	cis	rs12079745	0.793	rs11809180	chr1:169100095	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.69	-4.94	-0.31	1.5e-6	QT interval;
SARC	cis	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg08564027	chr20:61660810	NA	0.78	11.75	0.61	2.44e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs6546550	0.900	rs897122	chr2:70140271	C/T	cg02498382	chr2:70120550	SNRNP27	-0.32	-5.13	-0.32	6.02e-7	Prevalent atrial fibrillation;
SARC	cis	rs9905704	0.918	rs36071323	chr17:56916804	C/T	cg12560992	chr17:57184187	TRIM37	0.4	4.76	0.3	3.45e-6	Testicular germ cell tumor;
SARC	cis	rs9916302	0.861	rs644173	chr17:37430519	T/C	cg20243544	chr17:37824526	PNMT	0.57	6.91	0.41	4.52e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs7084402	0.967	rs1658470	chr10:60292383	A/G	cg07615347	chr10:60278583	BICC1	0.61	8.99	0.51	8.99e-17	Refractive error;
SARC	cis	rs2908197	0.737	rs10230188	chr7:75980872	A/G	cg07849177	chr7:76178544	LOC100133091	-0.43	-4.89	-0.31	1.86e-6	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs2658782	0.666	rs2925361	chr11:93098823	G/A	cg15737290	chr11:93063684	CCDC67	0.72	7.61	0.45	6.74e-13	Pulmonary function decline;
SARC	cis	rs9296092	0.538	rs56205713	chr6:33517510	A/G	cg13560919	chr6:33536144	NA	-0.51	-6.2	-0.38	2.48e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs911555	0.504	rs8006526	chr14:104075015	T/C	cg24130564	chr14:104152367	KLC1	-0.7	-9.92	-0.54	1.47e-19	Intelligence (multi-trait analysis);
SARC	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg13939156	chr17:80058883	NA	-0.44	-6.8	-0.41	8.86e-11	Life satisfaction;
SARC	cis	rs9916302	0.784	rs4795382	chr17:37700860	A/G	cg20243544	chr17:37824526	PNMT	0.53	6.17	0.37	2.93e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs6815814	0.950	rs5743556	chr4:38806851	A/G	cg02016764	chr4:38805732	TLR1	-0.42	-4.89	-0.31	1.89e-6	Breast cancer;
SARC	cis	rs2645694	0.603	rs2703123	chr4:77821154	C/T	cg10057126	chr4:77819792	ANKRD56	0.44	6.58	0.4	3.1e-10	Emphysema distribution in smoking;
SARC	cis	rs546131	0.515	rs731727	chr11:34857834	A/G	cg06937548	chr11:34938143	PDHX;APIP	-0.44	-4.95	-0.31	1.41e-6	Lung disease severity in cystic fibrosis;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg21451253	chr1:5950833	NPHP4	-0.72	-6.38	-0.39	9.31e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9300255	0.568	rs3018098	chr12:123654812	T/C	cg05973401	chr12:123451056	ABCB9	0.53	5.95	0.36	9.6e-9	Neutrophil percentage of white cells;
SARC	cis	rs7408868	1.000	rs7254269	chr19:15277429	A/T	cg14696996	chr19:15285081	NOTCH3	-1.03	-8.87	-0.5	1.91e-16	Pulse pressure;
SARC	cis	rs796364	1.000	rs1704186	chr2:200769539	A/C	cg23649088	chr2:200775458	C2orf69	0.62	5.93	0.36	1.08e-8	Schizophrenia;
SARC	trans	rs9325144	0.555	rs2387843	chr12:38711203	T/C	cg23762105	chr12:34175262	ALG10	-0.53	-7.14	-0.42	1.2e-11	Morning vs. evening chronotype;
SARC	cis	rs7546668	0.640	rs12139377	chr1:15809428	C/T	cg18192808	chr1:15853278	DNAJC16	0.44	5.06	0.31	8.63e-7	Glomerular filtration rate (creatinine);
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20014778	chr1:229761614	URB2;TAF5L	-0.52	-6.34	-0.38	1.18e-9	Fibrinogen levels;
SARC	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg27121462	chr16:89883253	FANCA	-0.41	-5.54	-0.34	8.03e-8	Vitiligo;
SARC	cis	rs9354308	0.834	rs12212376	chr6:66598879	T/C	cg07460842	chr6:66804631	NA	0.49	5.55	0.34	7.93e-8	Metabolite levels;
SARC	trans	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg08975724	chr8:8085496	FLJ10661	0.48	6.23	0.38	2.11e-9	Retinal vascular caliber;
SARC	cis	rs17376456	0.877	rs10060160	chr5:93387879	G/A	cg25358565	chr5:93447407	FAM172A	1.3	14.36	0.69	6.16e-34	Diabetic retinopathy;
SARC	cis	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-6.07	-0.37	5.07e-9	Mood instability;
SARC	cis	rs9914988	0.943	rs4794839	chr17:27131393	G/A	cg20469991	chr17:27169893	C17orf63	-0.5	-5.25	-0.33	3.36e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs950776	0.593	rs481134	chr15:78877563	C/T	cg06917634	chr15:78832804	PSMA4	0.84	12.73	0.64	1.58e-28	Sudden cardiac arrest;
SARC	cis	rs2204008	0.837	rs55962152	chr12:38234281	G/A	cg13010199	chr12:38710504	ALG10B	0.81	11.19	0.59	1.48e-23	Bladder cancer;
SARC	cis	rs9814567	0.896	rs4435682	chr3:134344182	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.49	6.27	0.38	1.73e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs826838	0.935	rs1719855	chr12:39127242	C/T	cg26384229	chr12:38710491	ALG10B	-0.76	-11.59	-0.6	7.97e-25	Heart rate;
SARC	cis	rs11098699	0.718	rs13116874	chr4:124212211	T/C	cg09941581	chr4:124220074	SPATA5	0.39	4.87	0.3	2.07e-6	Mosquito bite size;
SARC	cis	rs8031584	0.918	rs35784593	chr15:31254588	G/A	cg19680485	chr15:31195859	MTMR15	-0.5	-5.73	-0.35	3.1e-8	Huntington's disease progression;
SARC	cis	rs870825	0.616	rs7660939	chr4:185640792	T/C	cg04058563	chr4:185651563	MLF1IP	0.81	11.48	0.6	1.8e-24	Blood protein levels;
SARC	cis	rs1957429	0.520	rs17102258	chr14:65332369	G/A	cg23373153	chr14:65346875	NA	-0.71	-5.79	-0.35	2.28e-8	Pediatric areal bone mineral density (radius);
SARC	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg22535103	chr8:58192502	C8orf71	-0.59	-6.21	-0.38	2.35e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9322817	0.691	rs9404586	chr6:105332814	A/G	cg02098413	chr6:105308735	HACE1	0.39	6.06	0.37	5.5e-9	Thyroid stimulating hormone;
SARC	cis	rs77741769	1.000	rs77741769	chr12:121363835	C/T	cg02403541	chr12:121454288	C12orf43	0.57	6.88	0.41	5.34e-11	Mean corpuscular volume;
SARC	cis	rs875971	0.545	rs67688847	chr7:65626051	G/A	cg25894440	chr7:65020034	NA	0.51	4.74	0.3	3.69e-6	Aortic root size;
SARC	cis	rs7551222	0.752	rs12032733	chr1:204481209	G/A	cg20240347	chr1:204465584	NA	-0.34	-5.87	-0.36	1.49e-8	Schizophrenia;
SARC	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg27266027	chr21:40555129	PSMG1	-0.47	-5.2	-0.32	4.38e-7	Cognitive function;
SARC	cis	rs17270561	0.609	rs9358878	chr6:25740273	C/T	cg16482183	chr6:26056742	HIST1H1C	0.43	5.21	0.32	4.07e-7	Iron status biomarkers;
SARC	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg11890956	chr21:40555474	PSMG1	1.17	19.68	0.79	1.83e-51	Cognitive function;
SARC	cis	rs3733585	0.699	rs4621431	chr4:9947590	C/T	cg11266682	chr4:10021025	SLC2A9	-0.37	-6.39	-0.39	8.89e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg09263875	chr16:632152	PIGQ	0.54	8.08	0.47	3.59e-14	Height;
SARC	cis	rs6088580	0.634	rs6059860	chr20:33063830	A/C	cg08999081	chr20:33150536	PIGU	0.44	6.73	0.4	1.3100000000000001e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs10513788	0.906	rs72622591	chr3:182032448	C/T	cg05977900	chr3:182512126	ATP11B	0.46	4.75	0.3	3.56e-6	Cognitive function;
SARC	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg27266027	chr21:40555129	PSMG1	0.47	5.08	0.32	7.88e-7	Cognitive function;
SARC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.42	0.53	4.71e-18	Prudent dietary pattern;
SARC	cis	rs7402982	0.625	rs4966009	chr15:99203496	C/T	cg03437748	chr15:99193247	IGF1R	0.62	7.51	0.44	1.27e-12	Birth weight;
SARC	cis	rs10189230	0.967	rs13026380	chr2:222352715	G/A	cg14652038	chr2:222343519	EPHA4	0.43	5.64	0.35	4.79e-8	Urate levels in lean individuals;
SARC	cis	rs514406	0.505	rs431427	chr1:53179094	C/A	cg16325326	chr1:53192061	ZYG11B	0.94	17.9	0.76	1.15e-45	Monocyte count;
SARC	cis	rs17376456	0.877	rs34673483	chr5:93315079	C/A	cg21475434	chr5:93447410	FAM172A	0.85	7.72	0.45	3.4e-13	Diabetic retinopathy;
SARC	cis	rs7246657	0.943	rs2081096	chr19:37964700	G/A	cg23950597	chr19:37808831	NA	-0.56	-5.62	-0.35	5.53e-8	Coronary artery calcification;
SARC	cis	rs11608355	1.000	rs11608355	chr12:109879292	T/C	cg19025524	chr12:109796872	NA	-0.4	-5.13	-0.32	6.17e-7	Neuroticism;
SARC	cis	rs1568889	1.000	rs12796293	chr11:28177723	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.75	-9.73	-0.54	5.25e-19	Bipolar disorder;
SARC	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg11890956	chr21:40555474	PSMG1	-1.06	-15.71	-0.72	2.01e-38	Cognitive function;
SARC	cis	rs9329221	0.905	rs28712068	chr8:10251145	G/C	cg21775007	chr8:11205619	TDH	-0.41	-4.96	-0.31	1.38e-6	Neuroticism;
SARC	cis	rs2832191	0.692	rs2254872	chr21:30414724	C/T	cg24692254	chr21:30365293	RNF160	1.01	17.39	0.75	5.37e-44	Dental caries;
SARC	cis	rs1008375	1.000	rs1121089	chr4:17676476	C/A	cg16339924	chr4:17578868	LAP3	0.63	8.25	0.48	1.2e-14	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs17376456	0.877	rs10514380	chr5:93409370	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.76	0.35	2.64e-8	Diabetic retinopathy;
SARC	cis	rs9486715	1.000	rs9386670	chr6:97060688	C/A	cg18709589	chr6:96969512	KIAA0776	-0.61	-7.18	-0.43	9.13e-12	Headache;
SARC	cis	rs910316	1.000	rs4903279	chr14:75546583	C/T	cg23033748	chr14:75592666	NEK9	0.37	5.19	0.32	4.6e-7	Height;
SARC	cis	rs1318878	0.840	rs7136113	chr12:15545446	A/G	cg08258403	chr12:15378311	NA	0.46	6.22	0.38	2.27e-9	Intelligence (multi-trait analysis);
SARC	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg06028808	chr11:68637592	NA	0.45	5.67	0.35	4.3e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7523050	0.643	rs35526993	chr1:109405107	A/T	cg08274380	chr1:109419600	GPSM2	0.99	7.56	0.44	9.38e-13	Fat distribution (HIV);
SARC	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.47	-5.85	-0.36	1.65e-8	Tonsillectomy;
SARC	cis	rs9398803	0.651	rs4339479	chr6:126936953	G/A	cg19875578	chr6:126661172	C6orf173	0.61	8.32	0.48	7.54e-15	Male-pattern baldness;
SARC	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg00933542	chr6:150070202	PCMT1	0.31	5.42	0.33	1.47e-7	Lung cancer;
SARC	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg24675658	chr1:53192096	ZYG11B	0.74	11.28	0.59	7.93e-24	Monocyte count;
SARC	cis	rs7818688	0.697	rs60003497	chr8:95983423	A/T	cg13393036	chr8:95962371	TP53INP1	0.4	4.85	0.3	2.27e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs12421382	0.659	rs1866530	chr11:109380899	T/A	cg16359550	chr11:109292809	C11orf87	0.33	4.97	0.31	1.31e-6	Schizophrenia;
SARC	cis	rs7824557	0.628	rs34237267	chr8:11197301	G/C	cg21775007	chr8:11205619	TDH	0.66	8.52	0.49	2e-15	Retinal vascular caliber;
SARC	cis	rs66573146	1.000	rs6812771	chr4:6964048	G/A	cg00086871	chr4:6988644	TBC1D14	0.91	5.07	0.32	8.14e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs2153535	0.580	rs1410766	chr6:8525360	T/C	cg21535247	chr6:8435926	SLC35B3	0.55	6.96	0.41	3.42e-11	Motion sickness;
SARC	cis	rs72781680	0.716	rs7564732	chr2:24034178	C/T	cg08917208	chr2:24149416	ATAD2B	0.56	6.01	0.37	7.27e-9	Lymphocyte counts;
SARC	cis	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg00800038	chr16:89945340	TCF25	-0.67	-4.82	-0.3	2.63e-6	Skin colour saturation;
SARC	trans	rs61931739	0.782	rs7969373	chr12:34249655	T/G	cg13010199	chr12:38710504	ALG10B	0.58	7.44	0.44	1.93e-12	Morning vs. evening chronotype;
SARC	trans	rs9951602	0.512	rs12458828	chr18:76648522	C/T	cg02800362	chr5:177631904	HNRNPAB	-0.75	-9.31	-0.52	9.76e-18	Obesity-related traits;
SARC	cis	rs453301	0.686	rs28665409	chr8:8869277	G/A	cg11608241	chr8:8085544	FLJ10661	-0.43	-5.29	-0.33	2.8e-7	Joint mobility (Beighton score);
SARC	cis	rs738322	1.000	rs4382	chr22:38570842	T/C	cg25457927	chr22:38595422	NA	-0.29	-5.95	-0.36	9.77e-9	Cutaneous nevi;
SARC	cis	rs208520	0.690	rs12213581	chr6:66735818	T/C	cg07460842	chr6:66804631	NA	1.04	13.88	0.67	2.45e-32	Exhaled nitric oxide output;
SARC	cis	rs1355223	1.000	rs1396883	chr11:34757447	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.49	-6.15	-0.37	3.26e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs1153858	1.000	rs4534782	chr15:45652933	G/A	cg03999130	chr15:45571217	NA	0.39	4.97	0.31	1.27e-6	Homoarginine levels;
SARC	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg20102877	chr2:27665638	KRTCAP3	-0.37	-5.22	-0.32	4.05e-7	Total body bone mineral density;
SARC	cis	rs9916302	0.904	rs620686	chr17:37453617	A/G	cg15445000	chr17:37608096	MED1	-0.44	-5.31	-0.33	2.6e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg24675658	chr1:53192096	ZYG11B	0.67	9.85	0.54	2.29e-19	Monocyte count;
SARC	cis	rs1878931	0.624	rs27235	chr16:3439138	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.68	-7.65	-0.45	5.28e-13	Body mass index (adult);
SARC	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg12373951	chr3:133503437	NA	0.37	5.3	0.33	2.65e-7	Iron status biomarkers;
SARC	cis	rs981844	0.890	rs55850399	chr4:154684906	C/T	cg14289246	chr4:154710475	SFRP2	0.63	7.05	0.42	2.04e-11	Response to statins (LDL cholesterol change);
SARC	trans	rs7615952	0.800	rs11915699	chr3:125632684	A/G	cg07211511	chr3:129823064	LOC729375	-0.94	-10.81	-0.58	2.45e-22	Blood pressure (smoking interaction);
SARC	cis	rs1318878	0.840	rs983800	chr12:15544399	T/C	cg08258403	chr12:15378311	NA	0.47	6.22	0.38	2.23e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7552404	0.883	rs11161493	chr1:76206254	T/A	cg03433033	chr1:76189801	ACADM	0.51	7.44	0.44	1.95e-12	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs4975616	0.869	rs465498	chr5:1325803	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.53	-7.26	-0.43	5.82e-12	Lung cancer;
SARC	cis	rs76419734	1.000	rs74497593	chr4:106616214	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.8	4.9	0.31	1.8e-6	Post bronchodilator FEV1;
SARC	cis	rs8141529	0.711	rs5752797	chr22:29179998	C/T	cg15103426	chr22:29168792	CCDC117	0.62	6.95	0.41	3.69e-11	Lymphocyte counts;
SARC	cis	rs6940638	0.688	rs9461335	chr6:27138529	C/A	cg12826209	chr6:26865740	GUSBL1	0.56	6.1	0.37	4.29e-9	Intelligence (multi-trait analysis);
SARC	cis	rs1483890	0.723	rs1843046	chr3:69410614	C/A	cg22125112	chr3:69402811	FRMD4B	0.3	5.06	0.31	8.32e-7	Resting heart rate;
SARC	cis	rs4763879	0.778	rs1044771	chr12:9851929	C/A	cg27502298	chr12:9555721	NA	0.44	4.84	0.3	2.33e-6	Type 1 diabetes;
SARC	cis	rs7223966	1.000	rs8078462	chr17:61857937	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.53	-5.52	-0.34	9.09e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs13191362	1.000	rs13218900	chr6:163081638	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.69	6.04	0.37	5.94e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs9291683	0.546	rs13120348	chr4:10053155	C/G	cg00071950	chr4:10020882	SLC2A9	-0.34	-5.19	-0.32	4.51e-7	Bone mineral density;
SARC	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg24838063	chr12:130822603	PIWIL1	0.66	9.48	0.53	3.09e-18	Menopause (age at onset);
SARC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.35	-5.1	-0.32	7.01e-7	Longevity;Endometriosis;
SARC	cis	rs6728642	0.572	rs1320147	chr2:97600626	A/C	cg26665480	chr2:98280029	ACTR1B	0.68	7.53	0.44	1.11e-12	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs11785400	0.793	rs4430070	chr8:143729184	G/C	cg24634471	chr8:143751801	JRK	0.6	7.74	0.45	2.98e-13	Schizophrenia;
SARC	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg11366901	chr6:160182831	ACAT2	0.64	6.65	0.4	2.1e-10	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs12824058	0.831	rs55726136	chr12:130810312	G/A	cg26677194	chr12:130822605	PIWIL1	0.54	7.4	0.44	2.4e-12	Menopause (age at onset);
SARC	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg00149659	chr3:10157352	C3orf10	0.74	7.17	0.43	9.81e-12	Alzheimer's disease;
SARC	cis	rs7937682	0.883	rs549143	chr11:111463779	C/T	cg22437258	chr11:111473054	SIK2	0.76	9.87	0.54	2.07e-19	Primary sclerosing cholangitis;
SARC	cis	rs12709013	0.636	rs1624301	chr16:58787395	T/C	cg04273148	chr16:57808038	KIFC3	0.32	4.72	0.3	4.08e-6	Blood metabolite ratios;
SARC	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg23172400	chr8:95962367	TP53INP1	-0.34	-5.82	-0.36	1.91e-8	Type 2 diabetes;
SARC	cis	rs2075371	0.897	rs1646733	chr7:134002228	C/A	cg20476274	chr7:133979776	SLC35B4	0.57	7.44	0.44	1.95e-12	Mean platelet volume;
SARC	cis	rs1957429	0.614	rs72625640	chr14:65333231	G/A	cg23373153	chr14:65346875	NA	-0.84	-5.81	-0.36	2.04e-8	Pediatric areal bone mineral density (radius);
SARC	cis	rs11792861	0.926	rs7856626	chr9:111775502	C/G	cg13535736	chr9:111863775	C9orf5	-0.38	-4.72	-0.3	4.16e-6	Menarche (age at onset);
SARC	cis	rs501120	0.657	rs494207	chr10:44741256	G/A	cg09554077	chr10:44749378	NA	0.38	4.74	0.3	3.78e-6	Coronary artery disease;Coronary heart disease;
SARC	cis	rs7568458	1.000	rs7568458	chr2:85788175	T/A	cg17127132	chr2:85788382	GGCX	0.48	6.33	0.38	1.25e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs367615	0.552	rs2416210	chr5:108741137	C/T	cg17395555	chr5:108820864	NA	-0.34	-4.91	-0.31	1.72e-6	Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs10078	0.559	rs2037077	chr5:447226	A/G	cg24955955	chr5:415729	AHRR	0.69	6.26	0.38	1.84e-9	Fat distribution (HIV);
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg07383130	chr1:16161673	FLJ37453	-0.62	-6.31	-0.38	1.41e-9	Lung cancer in ever smokers;
SARC	cis	rs10791323	0.572	rs10791334	chr11:133735810	A/C	cg15485101	chr11:133734466	NA	0.33	5.16	0.32	5.39e-7	Childhood ear infection;
SARC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg07167872	chr1:205819463	PM20D1	0.61	9.28	0.52	1.25e-17	Menarche (age at onset);
SARC	cis	rs9393692	0.905	rs7747133	chr6:26293470	C/T	cg00631329	chr6:26305371	NA	-0.63	-9.22	-0.52	1.85e-17	Educational attainment;
SARC	cis	rs858239	0.570	rs6968242	chr7:23167411	T/G	cg23682824	chr7:23144976	KLHL7	0.74	10.1	0.55	3.93e-20	Cerebrospinal fluid biomarker levels;
SARC	cis	rs7666738	0.830	rs28887893	chr4:98963006	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10088262	0.527	rs3911939	chr8:124793744	T/G	cg02993010	chr8:124780839	FAM91A1	-0.81	-8.98	-0.51	9.34e-17	Pancreatic cancer;
SARC	cis	rs9814567	1.000	rs7374158	chr3:134270156	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-7.16	-0.42	1.06e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs9650657	0.501	rs3021500	chr8:11023997	G/C	cg21775007	chr8:11205619	TDH	-0.5	-6.19	-0.38	2.75e-9	Neuroticism;
SARC	cis	rs986417	0.901	rs1955690	chr14:61000492	A/G	cg27398547	chr14:60952738	C14orf39	-1.05	-9.48	-0.53	3.14e-18	Gut microbiota (bacterial taxa);
SARC	cis	rs10752881	0.967	rs12404594	chr1:182988027	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.35	0.56	6.8e-21	Colorectal cancer;
SARC	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg16414030	chr3:133502952	NA	-0.37	-4.91	-0.31	1.69e-6	Iron status biomarkers;
SARC	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg01475735	chr3:40494733	NA	-0.46	-5.06	-0.31	8.33e-7	Renal cell carcinoma;
SARC	cis	rs6738485	0.531	rs72819612	chr2:106846316	T/C	cg16099169	chr2:106886729	NA	-0.65	-6.85	-0.41	6.39e-11	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
SARC	trans	rs75804782	0.641	rs3769124	chr2:239349362	G/A	cg01134436	chr17:81009848	B3GNTL1	0.86	6.23	0.38	2.11e-9	Morning vs. evening chronotype;Chronotype;
SARC	cis	rs11098499	0.657	rs9996569	chr4:120299004	G/C	cg09160332	chr4:120329925	NA	-0.33	-4.77	-0.3	3.27e-6	Corneal astigmatism;
SARC	cis	rs6598955	0.724	rs12726972	chr1:26639634	A/G	cg04990556	chr1:26633338	UBXN11	0.58	7.78	0.45	2.35e-13	Obesity-related traits;
SARC	cis	rs4919087	1.000	rs10786333	chr10:99090390	A/G	cg25902810	chr10:99078978	FRAT1	-0.46	-5.75	-0.35	2.72e-8	Monocyte count;
SARC	cis	rs1348850	0.645	rs10164417	chr2:178444130	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.52	5.56	0.34	7.28e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs6735179	1.000	rs1124200	chr2:1778558	A/G	cg08534653	chr2:1747700	PXDN	0.41	5.01	0.31	1.06e-6	Response to antipsychotic treatment;
SARC	cis	rs6570726	0.791	rs2096201	chr6:145934273	C/T	cg23711669	chr6:146136114	FBXO30	0.9	15.27	0.71	5.88e-37	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12311304	1.000	rs12310061	chr12:15390019	A/T	cg08258403	chr12:15378311	NA	0.46	7.2	0.43	8.48e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs2710642	0.821	rs56373728	chr2:63095792	G/A	cg17519650	chr2:63277830	OTX1	0.42	5.38	0.33	1.84e-7	LDL cholesterol levels;LDL cholesterol;
SARC	cis	rs5769765	0.955	rs8135963	chr22:50301476	T/C	cg03033257	chr22:50311977	ALG12;CRELD2	0.51	5.25	0.33	3.4e-7	Schizophrenia;
SARC	trans	rs1814175	0.615	rs4545557	chr11:50027329	A/C	cg03929089	chr4:120376271	NA	-0.82	-11.88	-0.61	9.03e-26	Height;
SARC	trans	rs10771431	0.817	rs17202253	chr12:9361850	A/G	cg27600084	chr12:12264075	NA	0.58	7.86	0.46	1.39e-13	Breast size;
SARC	cis	rs533123	0.701	rs204054	chr1:29160462	T/C	cg08366446	chr1:29138936	OPRD1	0.92	7.65	0.45	5.3e-13	Schizophrenia;
SARC	cis	rs7223966	0.961	rs17631783	chr17:61687600	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.59	-6.11	-0.37	4.23e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7927771	0.832	rs11607981	chr11:47401060	T/G	cg20307385	chr11:47447363	PSMC3	-0.56	-7.0	-0.42	2.78e-11	Subjective well-being;
SARC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.8	10.38	0.56	5.49e-21	Prudent dietary pattern;
SARC	cis	rs7760949	0.889	rs9396264	chr6:13930342	T/A	cg27413430	chr6:13925136	RNF182	0.44	5.22	0.32	3.91e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg06618935	chr21:46677482	NA	-0.4	-4.97	-0.31	1.31e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs651907	0.557	rs12629658	chr3:101356535	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	6.29	0.38	1.57e-9	Colorectal cancer;
SARC	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg14784868	chr12:69753453	YEATS4	0.63	8.77	0.5	3.92e-16	Cerebrospinal fluid biomarker levels;
SARC	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg13939156	chr17:80058883	NA	-0.42	-6.48	-0.39	5.51e-10	Life satisfaction;
SARC	trans	rs1814175	0.669	rs11040455	chr11:49669829	G/C	cg15704280	chr7:45808275	SEPT13	-0.79	-12.33	-0.63	3.13e-27	Height;
SARC	cis	rs10887741	0.966	rs7085195	chr10:89429897	T/C	cg24243914	chr10:89418206	PAPSS2	0.29	4.72	0.3	4.01e-6	Exercise (leisure time);
SARC	cis	rs2011503	1.000	rs61744761	chr19:19656615	C/T	cg03709012	chr19:19516395	GATAD2A	0.59	5.12	0.32	6.49e-7	Bipolar disorder;
SARC	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.53	4.97	0.31	1.27e-6	Lung function (FEV1/FVC);
SARC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.55	0.57	1.61e-21	Prudent dietary pattern;
SARC	cis	rs34172651	0.797	rs12920941	chr16:24830866	T/A	cg06028605	chr16:24865363	SLC5A11	0.27	4.86	0.3	2.2e-6	Intelligence (multi-trait analysis);
SARC	cis	rs1008375	0.932	rs6841784	chr4:17626418	G/A	cg27347728	chr4:17578864	LAP3	0.49	6.18	0.38	2.89e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1008375	0.932	rs964012	chr4:17619184	A/G	cg02297831	chr4:17616191	MED28	0.47	6.04	0.37	5.97e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs11997175	0.510	rs34465523	chr8:33796849	C/T	ch.8.33884649F	chr8:33765107	NA	0.47	6.04	0.37	6.2e-9	Body mass index;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg14102832	chr19:12943497	RTBDN	0.53	6.73	0.4	1.33e-10	Breast cancer;
SARC	cis	rs6087771	0.662	rs6058298	chr20:30247916	C/T	cg13852791	chr20:30311386	BCL2L1	0.8	9.59	0.53	1.39e-18	Subcortical brain region volumes;Putamen volume;
SARC	cis	rs11785693	0.909	rs62489558	chr8:4968620	G/A	cg26367366	chr8:4980734	NA	0.72	6.28	0.38	1.62e-9	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs262150	1.000	rs262149	chr7:158778256	A/G	cg19418458	chr7:158789849	NA	0.45	6.01	0.37	7.28e-9	Facial morphology (factor 20);
SARC	cis	rs8180040	0.764	rs4082155	chr3:47125385	G/A	cg02527881	chr3:46936655	PTH1R	-0.32	-5.03	-0.31	1e-6	Colorectal cancer;
SARC	cis	rs7647973	0.626	rs62262722	chr3:49769419	G/C	cg13072238	chr3:49761600	GMPPB	0.73	6.78	0.41	9.57e-11	Menarche (age at onset);
SARC	cis	rs10489202	1.000	rs7538581	chr1:167979347	A/G	cg24449463	chr1:168025552	DCAF6	-0.64	-7.01	-0.42	2.5e-11	Schizophrenia;
SARC	cis	rs11190604	1.000	rs7090431	chr10:102261753	A/G	cg14256752	chr10:102295592	HIF1AN	0.43	4.87	0.3	2.02e-6	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs9309473	0.514	rs62149630	chr2:73581755	C/G	cg20560298	chr2:73613845	ALMS1	-0.55	-5.45	-0.34	1.25e-7	Metabolite levels;
SARC	cis	rs9916302	0.904	rs11655531	chr17:37697959	T/C	cg07936489	chr17:37558343	FBXL20	-0.69	-8.95	-0.51	1.15e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs2130392	1.000	rs4862406	chr4:185629339	G/A	cg04058563	chr4:185651563	MLF1IP	-0.34	-4.92	-0.31	1.63e-6	Kawasaki disease;
SARC	cis	rs738321	0.762	rs5995543	chr22:38579026	G/A	cg25457927	chr22:38595422	NA	-0.26	-4.71	-0.3	4.16e-6	Breast cancer;
SARC	cis	rs6088580	0.634	rs6088471	chr20:32932643	C/A	cg08999081	chr20:33150536	PIGU	-0.43	-6.51	-0.39	4.47e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg11494091	chr17:61959527	GH2	0.53	7.95	0.46	7.84e-14	Prudent dietary pattern;
SARC	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg23758822	chr17:41437982	NA	0.91	11.49	0.6	1.7e-24	Menopause (age at onset);
SARC	cis	rs2075671	0.903	rs11979818	chr7:100293639	A/G	cg20848291	chr7:100343083	ZAN	0.62	6.8	0.41	8.69e-11	Other erythrocyte phenotypes;
SARC	cis	rs400736	0.655	rs11121086	chr1:8151224	C/T	cg25007680	chr1:8021821	PARK7	-0.42	-5.29	-0.33	2.76e-7	Response to antidepressants and depression;
SARC	cis	rs1957429	0.901	rs7143661	chr14:65378981	G/A	cg23373153	chr14:65346875	NA	1.02	10.39	0.56	4.87e-21	Pediatric areal bone mineral density (radius);
SARC	cis	rs8141529	0.748	rs132529	chr22:29296652	A/G	cg15103426	chr22:29168792	CCDC117	-0.66	-8.39	-0.48	4.86e-15	Lymphocyte counts;
SARC	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg20607798	chr8:58055168	NA	0.58	5.57	0.34	6.9e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs8053891	0.756	rs9930930	chr16:72001971	A/G	cg16558253	chr16:72132732	DHX38	-0.38	-4.86	-0.3	2.12e-6	Coronary artery disease;
SARC	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg03060546	chr3:49711283	APEH	0.41	5.14	0.32	5.86e-7	Parkinson's disease;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg26878734	chr2:176793622	KIAA1715	0.46	6.37	0.39	1e-9	Tetralogy of Fallot;
SARC	cis	rs6570726	1.000	rs405622	chr6:145871897	G/T	cg05347473	chr6:146136440	FBXO30	0.48	6.49	0.39	5.13e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2153535	0.580	rs1855769	chr6:8473095	A/G	cg21535247	chr6:8435926	SLC35B3	0.53	6.6	0.4	2.69e-10	Motion sickness;
SARC	cis	rs992157	0.965	rs62182826	chr2:219148723	C/A	cg20019365	chr2:219134978	PNKD;AAMP	0.73	11.12	0.59	2.5e-23	Colorectal cancer;
SARC	cis	rs1144333	0.655	rs4949685	chr1:76463270	A/T	cg03433033	chr1:76189801	ACADM	0.63	5.15	0.32	5.47e-7	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs936229	0.861	rs3935077	chr15:75120211	C/G	cg14664628	chr15:75095509	CSK	-1.1	-15.51	-0.71	9.83e-38	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs761746	0.847	rs4820976	chr22:31876466	G/A	cg15823100	chr22:32027580	PISD	0.33	4.76	0.3	3.36e-6	Intelligence;
SARC	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg23205692	chr1:25664452	TMEM50A	0.42	5.24	0.32	3.51e-7	Erythrocyte sedimentation rate;
SARC	cis	rs9517313	0.551	rs2274051	chr13:99091634	A/G	cg07423050	chr13:99094983	FARP1	0.48	7.12	0.42	1.29e-11	Neuroticism;
SARC	trans	rs9329221	0.683	rs688491	chr8:9884823	C/G	cg06636001	chr8:8085503	FLJ10661	-0.68	-9.68	-0.54	7.69e-19	Neuroticism;
SARC	cis	rs568617	0.767	rs2231884	chr11:65656564	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.6	6.33	0.38	1.24e-9	Crohn's disease;
SARC	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg14773178	chr5:1868261	NA	0.33	5.23	0.32	3.72e-7	Cardiovascular disease risk factors;
SARC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg18404041	chr3:52824283	ITIH1	-0.36	-5.3	-0.33	2.64e-7	Bipolar disorder;
SARC	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg09359103	chr1:154839909	KCNN3	0.33	5.27	0.33	3.13e-7	Schizophrenia;
SARC	cis	rs7772486	0.790	rs2265469	chr6:146219049	T/C	cg05347473	chr6:146136440	FBXO30	0.49	6.62	0.4	2.39e-10	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg20493901	chr14:77564376	KIAA1737	0.5	6.46	0.39	6.06e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs2204008	0.688	rs12824232	chr12:38175901	G/A	cg26384229	chr12:38710491	ALG10B	0.88	12.94	0.65	3.26e-29	Bladder cancer;
SARC	cis	rs12545109	0.807	rs13263281	chr8:57346582	C/A	cg19413350	chr8:57351067	NA	-0.45	-5.41	-0.33	1.58e-7	Obesity-related traits;
SARC	cis	rs9916302	0.904	rs2024073	chr17:37471330	T/G	cg00129232	chr17:37814104	STARD3	0.59	7.27	0.43	5.32e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs11758351	1.000	rs41266807	chr6:26199822	A/G	cg01420254	chr6:26195488	NA	0.55	4.78	0.3	3.08e-6	Gout;Renal underexcretion gout;
SARC	cis	rs9393692	0.645	rs766407	chr6:26319534	T/C	cg00631329	chr6:26305371	NA	-0.61	-7.88	-0.46	1.25e-13	Educational attainment;
SARC	cis	rs7208859	0.673	rs12103759	chr17:29235687	G/A	cg13385521	chr17:29058706	SUZ12P	0.86	7.14	0.42	1.2e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs73206853	0.764	rs7299230	chr12:110618512	A/T	cg10860002	chr12:110842031	ANAPC7	0.64	5.27	0.33	3.06e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs1580019	0.563	rs13244332	chr7:32537679	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.61	8.05	0.47	4.23e-14	Cognitive ability;
SARC	cis	rs3749237	1.000	rs1317140	chr3:49878652	G/A	cg03060546	chr3:49711283	APEH	0.56	6.54	0.39	3.79e-10	Resting heart rate;
SARC	cis	rs708547	0.599	rs2948348	chr4:57848772	G/A	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.44	-5.58	-0.34	6.78e-8	Response to bleomycin (chromatid breaks);
SARC	cis	rs11098499	0.954	rs10006877	chr4:120242793	C/T	cg09160332	chr4:120329925	NA	-0.35	-4.96	-0.31	1.38e-6	Corneal astigmatism;
SARC	cis	rs780096	0.778	rs780094	chr2:27741237	C/T	cg22903471	chr2:27725779	GCKR	0.32	4.82	0.3	2.64e-6	Total body bone mineral density;
SARC	cis	rs67311347	0.544	rs9864601	chr3:40345318	C/T	cg09455208	chr3:40491958	NA	0.28	4.74	0.3	3.73e-6	Renal cell carcinoma;
SARC	cis	rs4595586	0.525	rs12825567	chr12:39386621	C/T	cg26384229	chr12:38710491	ALG10B	0.53	6.47	0.39	5.57e-10	Morning vs. evening chronotype;
SARC	cis	rs10936602	0.520	rs12486767	chr3:169550759	A/G	cg27020690	chr3:169482358	NA	-0.41	-5.18	-0.32	4.77e-7	Renal cell carcinoma;
SARC	cis	rs8044995	0.563	rs56899435	chr16:68395675	G/A	cg05110241	chr16:68378359	PRMT7	-0.63	-5.91	-0.36	1.19e-8	Schizophrenia;
SARC	cis	rs4253772	0.591	rs12167567	chr22:46659942	G/C	cg24881330	chr22:46731750	TRMU	0.62	6.88	0.41	5.39e-11	LDL cholesterol;Cholesterol, total;
SARC	cis	rs1153858	1.000	rs11070456	chr15:45686835	G/A	cg15395560	chr15:45543142	SLC28A2	-0.27	-4.91	-0.31	1.74e-6	Homoarginine levels;
SARC	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.42	-5.2	-0.32	4.29e-7	Tonsillectomy;
SARC	cis	rs4481887	0.741	rs6587462	chr1:248539094	C/T	cg13385794	chr1:248469461	NA	-0.33	-5.37	-0.33	1.87e-7	Common traits (Other);
SARC	cis	rs858239	0.601	rs7805206	chr7:23160210	C/T	cg23682824	chr7:23144976	KLHL7	0.59	7.53	0.44	1.12e-12	Cerebrospinal fluid biomarker levels;
SARC	cis	rs611744	0.967	rs637626	chr8:109235785	G/T	cg21045802	chr8:109455806	TTC35	0.46	5.43	0.34	1.38e-7	Dupuytren's disease;
SARC	cis	rs17376456	0.877	rs17315943	chr5:93442830	T/C	cg21475434	chr5:93447410	FAM172A	0.86	7.77	0.45	2.57e-13	Diabetic retinopathy;
SARC	cis	rs7552404	0.924	rs7550974	chr1:76204185	A/G	cg22875332	chr1:76189707	ACADM	0.46	6.61	0.4	2.66e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg11987759	chr7:65425863	GUSB	0.51	6.48	0.39	5.42e-10	Aortic root size;
SARC	cis	rs950776	0.752	rs62010328	chr15:78894971	C/T	cg06917634	chr15:78832804	PSMA4	0.8	10.87	0.58	1.55e-22	Sudden cardiac arrest;
SARC	trans	rs12554020	0.892	rs75775593	chr9:96330893	G/A	cg26442883	chr16:49686662	ZNF423	0.58	6.38	0.39	9.6e-10	Schizophrenia;
SARC	cis	rs7617480	0.585	rs7373072	chr3:48960017	T/A	cg06212747	chr3:49208901	KLHDC8B	0.51	5.1	0.32	7e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs7106204	0.590	rs7114724	chr11:24239976	A/G	ch.11.24196551F	chr11:24239977	NA	0.59	6.0	0.37	7.45e-9	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs10771431	0.782	rs10771415	chr12:9358223	C/T	cg08997352	chr12:9597637	DDX12	-0.63	-8.94	-0.51	1.18e-16	Breast size;
SARC	cis	rs240764	0.604	rs4840153	chr6:101213723	C/T	cg09795085	chr6:101329169	ASCC3	-0.44	-5.52	-0.34	9.19e-8	Neuroticism;
SARC	cis	rs17401966	0.798	rs12408435	chr1:10323342	T/A	cg15208524	chr1:10270712	KIF1B	0.52	5.7	0.35	3.65e-8	Hepatocellular carcinoma;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg17315833	chr5:179499106	RNF130	0.62	6.32	0.38	1.29e-9	Lung cancer in ever smokers;
SARC	cis	rs4555082	0.834	rs2735819	chr14:105713449	C/T	cg13114125	chr14:105738426	BRF1	-0.82	-12.11	-0.62	1.66e-26	Mean platelet volume;Platelet distribution width;
SARC	cis	rs9398803	0.865	rs9375439	chr6:126758540	C/G	cg19875578	chr6:126661172	C6orf173	0.63	8.6	0.49	1.17e-15	Male-pattern baldness;
SARC	cis	rs6083	0.512	rs17269397	chr15:58857378	A/G	cg05156742	chr15:59063176	FAM63B	-0.66	-8.76	-0.5	3.97e-16	Schizophrenia;
SARC	cis	rs1950500	0.509	rs12879087	chr14:24826900	A/T	cg22990158	chr14:24802150	ADCY4	-0.34	-5.76	-0.35	2.58e-8	Height;
SARC	cis	rs4689388	0.926	rs11725494	chr4:6293855	C/T	cg14416269	chr4:6271139	WFS1	0.35	5.49	0.34	1.07e-7	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs6964587	0.655	rs6465351	chr7:91773213	T/C	cg17063962	chr7:91808500	NA	0.79	12.09	0.62	1.89e-26	Breast cancer;
SARC	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg15448220	chr1:150897856	SETDB1	0.47	6.25	0.38	1.94e-9	Tonsillectomy;
SARC	cis	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg05084668	chr3:125655381	ALG1L	-0.47	-4.83	-0.3	2.49e-6	Blood pressure (smoking interaction);
SARC	cis	rs15676	0.947	rs2997913	chr9:131589033	C/T	cg00228799	chr9:131580591	ENDOG	0.61	7.62	0.45	6.27e-13	Blood metabolite levels;
SARC	cis	rs7927592	0.913	rs10896338	chr11:68299360	G/A	cg01657329	chr11:68192670	LRP5	-0.4	-4.94	-0.31	1.51e-6	Total body bone mineral density;
SARC	cis	rs172166	0.637	rs1225595	chr6:28151340	A/T	cg16479474	chr6:28041457	NA	0.33	5.33	0.33	2.3e-7	Cardiac Troponin-T levels;
SARC	cis	rs72634258	0.945	rs12735338	chr1:8078569	T/C	cg00042356	chr1:8021962	PARK7	0.82	7.5	0.44	1.3e-12	Inflammatory bowel disease;
SARC	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg16606324	chr3:10149918	C3orf24	0.48	5.04	0.31	9.53e-7	Alzheimer's disease;
SARC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg08157638	chr1:116194194	VANGL1	-0.48	-6.39	-0.39	8.93e-10	Gut microbiota (bacterial taxa);
SARC	cis	rs3087591	0.960	rs2905880	chr17:29546175	A/G	cg24425628	chr17:29625626	OMG;NF1	0.54	6.7	0.4	1.58e-10	Hip circumference;
SARC	cis	rs17539620	0.624	rs62432751	chr6:154841027	A/G	cg17771515	chr6:154831774	CNKSR3	0.53	4.96	0.31	1.39e-6	Lipoprotein (a) levels;
SARC	cis	rs7937682	0.681	rs7107378	chr11:111401840	C/A	cg09085632	chr11:111637200	PPP2R1B	0.49	6.25	0.38	1.98e-9	Primary sclerosing cholangitis;
SARC	cis	rs17209837	1.000	rs45590633	chr7:87090480	C/T	cg00919237	chr7:87102261	ABCB4	-0.5	-5.12	-0.32	6.43e-7	Gallbladder cancer;
SARC	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg24531977	chr5:56204891	C5orf35	-0.56	-5.09	-0.32	7.36e-7	Type 2 diabetes;
SARC	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg26874164	chr19:58962979	ZNF324B	0.51	6.6	0.4	2.76e-10	Uric acid clearance;
SARC	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg12463550	chr7:65579703	CRCP	0.51	5.74	0.35	2.94e-8	Aortic root size;
SARC	cis	rs752010	0.875	rs11210502	chr1:42093712	A/C	cg06885757	chr1:42089581	HIVEP3	0.45	7.23	0.43	6.79e-12	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs858239	0.539	rs4504540	chr7:23186198	C/G	cg23682824	chr7:23144976	KLHL7	0.72	9.31	0.52	9.94e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.58	5.57	0.34	6.96e-8	Lung function (FEV1/FVC);
SARC	cis	rs4481887	0.927	rs4472779	chr1:248474603	G/A	cg00666640	chr1:248458726	OR2T12	0.34	5.7	0.35	3.65e-8	Common traits (Other);
SARC	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	13.05	0.65	1.41e-29	Chronic sinus infection;
SARC	cis	rs6866344	0.598	rs11742176	chr5:178147931	C/T	cg10224037	chr5:178157518	ZNF354A	0.97	12.66	0.64	2.68e-28	Neutrophil percentage of white cells;
SARC	cis	rs74181299	0.890	rs2540950	chr2:65279223	C/T	cg20592124	chr2:65290738	CEP68	0.45	6.51	0.39	4.49e-10	Pulse pressure;
SARC	cis	rs9486719	0.802	rs2983896	chr6:97029871	G/A	cg18709589	chr6:96969512	KIAA0776	-0.49	-5.35	-0.33	2.06e-7	Migraine;Coronary artery disease;
SARC	trans	rs9929218	0.507	rs62057805	chr16:68742390	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.81	13.3	0.66	2.16e-30	Colorectal cancer;
SARC	cis	rs9304742	0.611	rs10415443	chr19:53464864	C/G	cg24044776	chr19:53454761	ZNF816A	-0.36	-4.99	-0.31	1.18e-6	Psoriasis;
SARC	cis	rs9790314	1.000	rs189270	chr3:161063504	T/C	cg04691961	chr3:161091175	C3orf57	-0.8	-11.83	-0.61	1.36e-25	Morning vs. evening chronotype;
SARC	cis	rs929354	0.772	rs3802123	chr7:156970641	G/A	cg05182265	chr7:156933206	UBE3C	-0.34	-5.15	-0.32	5.44e-7	Body mass index;
SARC	cis	rs9916302	0.904	rs9944411	chr17:37483599	T/C	cg07936489	chr17:37558343	FBXL20	0.68	9.2	0.52	2.14e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs561341	1.000	rs555629	chr17:30294136	T/C	cg00745463	chr17:30367425	LRRC37B	-0.68	-5.23	-0.32	3.82e-7	Hip circumference adjusted for BMI;
SARC	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.44	-5.43	-0.33	1.45e-7	Lymphocyte counts;
SARC	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg26818010	chr10:134567672	INPP5A	-0.65	-7.1	-0.42	1.51e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg00684032	chr4:1343700	KIAA1530	0.48	7.2	0.43	8.48e-12	Obesity-related traits;
SARC	cis	rs1167827	0.805	rs809439	chr7:75161318	T/A	cg19252891	chr7:75132457	SPDYE5	0.4	4.93	0.31	1.55e-6	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs698833	0.852	rs698774	chr2:44584314	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.7	9.16	0.51	2.73e-17	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs6570726	0.935	rs419847	chr6:145827278	A/G	cg05220968	chr6:146057943	EPM2A	-0.29	-4.83	-0.3	2.44e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2688419	0.565	rs2688414	chr3:23078904	T/C	cg00327796	chr3:23032191	NA	-0.4	-5.78	-0.35	2.4e-8	Type 2 diabetes;
SARC	cis	rs11190604	1.000	rs2495760	chr10:102318771	T/C	cg07080220	chr10:102295463	HIF1AN	0.83	8.43	0.48	3.56e-15	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg23758822	chr17:41437982	NA	0.88	10.75	0.58	3.73e-22	Menopause (age at onset);
SARC	cis	rs6840360	0.571	rs62327272	chr4:152545090	A/C	cg22705602	chr4:152727874	NA	-0.42	-6.62	-0.4	2.46e-10	Intelligence (multi-trait analysis);
SARC	cis	rs9399135	0.967	rs59329760	chr6:135342437	G/A	cg24558204	chr6:135376177	HBS1L	0.44	5.91	0.36	1.22e-8	Red blood cell count;
SARC	cis	rs1865760	0.566	rs9467663	chr6:26021456	C/G	cg16482183	chr6:26056742	HIST1H1C	0.49	6.23	0.38	2.11e-9	Height;
SARC	trans	rs1814175	0.817	rs1794164	chr11:49899610	T/C	cg15704280	chr7:45808275	SEPT13	-0.97	-18.23	-0.77	9.87e-47	Height;
SARC	cis	rs10911251	0.546	rs3768625	chr1:183078712	G/T	cg13390022	chr1:182993471	LAMC1	0.32	4.85	0.3	2.26e-6	Colorectal cancer;
SARC	cis	rs7659604	1.000	rs10016433	chr4:122664771	A/G	cg20573242	chr4:122745356	CCNA2	0.44	5.82	0.36	1.99e-8	Type 2 diabetes;
SARC	cis	rs616402	0.564	rs7419116	chr1:10578606	G/A	cg17425144	chr1:10567563	PEX14	0.47	7.6	0.45	7.4e-13	Breast size;
SARC	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg22800045	chr5:56110881	MAP3K1	0.75	7.9	0.46	1.12e-13	Initial pursuit acceleration;
SARC	cis	rs1538970	0.924	rs12097497	chr1:45880669	C/T	cg05343316	chr1:45956843	TESK2	0.73	8.6	0.49	1.16e-15	Platelet count;
SARC	cis	rs703842	0.642	rs73123375	chr12:58063664	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.75	8.73	0.5	5.13e-16	Multiple sclerosis;
SARC	cis	rs3768617	0.510	rs12078729	chr1:183060072	T/A	cg13390022	chr1:182993471	LAMC1	0.33	4.94	0.31	1.5e-6	Fuchs's corneal dystrophy;
SARC	cis	rs7833790	0.660	rs1451995	chr8:82746123	G/C	cg27398817	chr8:82754497	SNX16	0.43	5.42	0.33	1.46e-7	Diastolic blood pressure;
SARC	cis	rs1050631	1.000	rs1789504	chr18:33696772	A/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.42	5.06	0.31	8.67e-7	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs2204008	0.683	rs11519834	chr12:38053575	T/A	cg26384229	chr12:38710491	ALG10B	0.89	13.14	0.65	6.99e-30	Bladder cancer;
SARC	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg11890956	chr21:40555474	PSMG1	1.18	16.58	0.74	2.61e-41	Cognitive function;
SARC	cis	rs4803468	1.000	rs2288871	chr19:41917868	C/T	cg14132834	chr19:41945861	ATP5SL	-0.56	-7.37	-0.43	2.9e-12	Height;
SARC	cis	rs763121	0.853	rs138713	chr22:39142615	T/C	cg06022373	chr22:39101656	GTPBP1	0.89	11.98	0.62	4.47e-26	Menopause (age at onset);
SARC	trans	rs629535	0.814	rs652483	chr8:70055083	G/A	cg21567404	chr3:27674614	NA	1.05	13.54	0.66	3.47e-31	Dupuytren's disease;
SARC	trans	rs561341	0.769	rs559228	chr17:30294527	T/C	cg20587970	chr11:113659929	NA	-1.35	-13.48	-0.66	5.32e-31	Hip circumference adjusted for BMI;
SARC	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg05313129	chr8:58192883	C8orf71	-0.49	-4.74	-0.3	3.69e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs9858542	0.953	rs7622302	chr3:49547561	T/C	cg07274523	chr3:49395745	GPX1	0.54	6.28	0.38	1.62e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs12681288	0.823	rs2701906	chr8:1003316	T/C	cg15309053	chr8:964076	NA	0.4	6.81	0.41	8.33e-11	Schizophrenia;
SARC	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg19223190	chr17:80058835	NA	0.44	6.04	0.37	6.11e-9	Life satisfaction;
SARC	cis	rs10743315	0.599	rs11044451	chr12:19365798	C/T	cg02471346	chr12:19282374	PLEKHA5	-0.54	-5.54	-0.34	8.01e-8	Gut microbiota (bacterial taxa);
SARC	cis	rs12311304	0.965	rs7980227	chr12:15367715	T/A	cg08258403	chr12:15378311	NA	0.47	7.42	0.44	2.24e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs6545883	0.783	rs6545888	chr2:61845215	T/G	cg15711740	chr2:61764176	XPO1	-0.45	-5.72	-0.35	3.29e-8	Tuberculosis;
SARC	cis	rs10504073	0.584	rs4873306	chr8:49950369	T/C	cg00325661	chr8:49890786	NA	0.51	6.78	0.41	9.76e-11	Blood metabolite ratios;
SARC	trans	rs208520	0.955	rs28684412	chr6:66979430	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.83	9.35	0.52	7.46e-18	Exhaled nitric oxide output;
SARC	cis	rs459571	0.959	rs465724	chr9:136910097	C/T	cg01294253	chr9:136912663	BRD3	0.37	4.73	0.3	3.85e-6	Platelet distribution width;
SARC	cis	rs1153858	1.000	rs11852800	chr15:45639131	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.75	-10.36	-0.56	6.12e-21	Homoarginine levels;
SARC	cis	rs631288	0.793	rs10900331	chr1:146733128	C/G	cg25205988	chr1:146714368	CHD1L	1.06	7.29	0.43	4.68e-12	PR interval in Tripanosoma cruzi seropositivity;
SARC	trans	rs17685	0.753	rs13240404	chr7:75675719	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.62	-7.88	-0.46	1.22e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs12956009	0.583	rs4452038	chr18:44856529	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.56	7.08	0.42	1.7e-11	Educational attainment (years of education);
SARC	cis	rs7481584	0.624	rs2106229	chr11:3041195	G/A	cg05729581	chr11:3078854	CARS	0.57	7.26	0.43	5.7e-12	Calcium levels;
SARC	cis	rs2760061	0.583	rs1636195	chr1:228211589	T/C	cg01200585	chr1:228362443	C1orf69	0.49	6.03	0.37	6.55e-9	Diastolic blood pressure;
SARC	cis	rs3820928	0.874	rs2228557	chr2:227872182	G/A	cg11843606	chr2:227700838	RHBDD1	-0.51	-6.39	-0.39	8.82e-10	Pulmonary function;
SARC	cis	rs9790314	1.000	rs163328	chr3:161073599	A/G	cg03342759	chr3:160939853	NMD3	-0.59	-7.53	-0.44	1.13e-12	Morning vs. evening chronotype;
SARC	cis	rs9457247	0.967	rs424185	chr6:167410907	C/T	cg07741184	chr6:167504864	NA	0.3	5.6	0.34	5.91e-8	Crohn's disease;
SARC	cis	rs875971	0.545	rs73376401	chr7:65639828	G/A	cg11764359	chr7:65958608	NA	0.66	6.47	0.39	5.8e-10	Aortic root size;
SARC	trans	rs7395662	0.517	rs10454483	chr11:48754997	A/G	cg15704280	chr7:45808275	SEPT13	-0.53	-7.19	-0.43	8.73e-12	HDL cholesterol;
SARC	cis	rs12188164	0.965	rs77101200	chr5:443059	G/T	cg26850624	chr5:429559	AHRR	-0.33	-5.12	-0.32	6.27e-7	Cystic fibrosis severity;
SARC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg26770870	chr10:71561502	COL13A1	0.54	6.86	0.41	6.32e-11	Myopia (pathological);
SARC	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg00149659	chr3:10157352	C3orf10	0.78	7.3	0.43	4.52e-12	Alzheimer's disease;
SARC	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg27347728	chr4:17578864	LAP3	0.49	6.1	0.37	4.34e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9527	0.545	rs10218853	chr10:104796787	A/C	cg04362960	chr10:104952993	NT5C2	0.43	5.22	0.32	3.94e-7	Arsenic metabolism;
SARC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg07332563	chr6:291687	DUSP22	-0.58	-7.85	-0.46	1.47e-13	Menopause (age at onset);
SARC	cis	rs986417	1.000	rs10142455	chr14:60980963	G/A	cg27398547	chr14:60952738	C14orf39	1.0	9.03	0.51	6.84e-17	Gut microbiota (bacterial taxa);
SARC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg06873352	chr17:61820015	STRADA	0.51	6.53	0.39	4.01e-10	Prudent dietary pattern;
SARC	cis	rs739401	0.611	rs450817	chr11:3056712	A/G	cg20651018	chr11:3035856	CARS	-0.45	-7.01	-0.42	2.5e-11	Longevity;
SARC	cis	rs11122272	0.667	rs2244992	chr1:231537220	T/C	cg06096015	chr1:231504339	EGLN1	0.38	5.7	0.35	3.54e-8	Hemoglobin concentration;
SARC	cis	rs965604	0.965	rs4299116	chr15:78766194	T/A	cg24631222	chr15:78858424	CHRNA5	-0.45	-5.85	-0.36	1.68e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs933688	1.000	rs332544	chr5:90778848	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.96	12.52	0.63	7.57e-28	Smoking behavior;
SARC	cis	rs9473924	0.542	rs9473923	chr6:50833565	A/T	cg14470998	chr6:50812995	TFAP2B	0.75	6.83	0.41	7.45e-11	Body mass index;
SARC	trans	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg21659725	chr3:3221576	CRBN	0.8	12.22	0.62	7.09e-27	Intelligence (multi-trait analysis);
SARC	cis	rs114858855	1.000	rs9386817	chr6:109895430	T/C	cg26835506	chr6:109038353	NA	-0.61	-4.98	-0.31	1.26e-6	Plasma trimethylamine N-oxide levels;
SARC	cis	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg11608241	chr8:8085544	FLJ10661	-0.4	-4.89	-0.3	1.91e-6	Joint mobility (Beighton score);
SARC	cis	rs1355223	0.902	rs836462	chr11:34743263	G/A	cg18508148	chr11:34937573	PDHX;APIP	-0.38	-4.83	-0.3	2.46e-6	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs1559088	0.847	rs10416218	chr19:33599127	T/C	cg27124370	chr19:33622961	WDR88	0.44	5.87	0.36	1.49e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs6546550	0.901	rs4144081	chr2:70155482	G/A	cg02498382	chr2:70120550	SNRNP27	-0.33	-5.4	-0.33	1.66e-7	Prevalent atrial fibrillation;
SARC	trans	rs9951602	0.512	rs6506868	chr18:76642559	C/G	cg02800362	chr5:177631904	HNRNPAB	0.68	8.61	0.49	1.13e-15	Obesity-related traits;
SARC	cis	rs2732480	0.557	rs2732454	chr12:48719677	T/C	cg24011408	chr12:48396354	COL2A1	0.4	4.74	0.3	3.68e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs1008375	0.966	rs12503540	chr4:17698781	C/G	cg16339924	chr4:17578868	LAP3	-0.5	-6.42	-0.39	7.67e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs11719291	0.667	rs9877542	chr3:48748545	C/T	cg03060546	chr3:49711283	APEH	-0.51	-4.84	-0.3	2.39e-6	Cognitive function;
SARC	cis	rs6429082	0.608	rs4659838	chr1:235565315	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.61	-7.09	-0.42	1.62e-11	Adiposity;
SARC	cis	rs17250963	0.842	rs1697126	chr5:14746296	T/C	cg12465520	chr5:14733886	ANKH	0.53	4.86	0.3	2.16e-6	Homeostasis model assessment of insulin resistance (dietary factor interaction);
SARC	trans	rs61931739	0.500	rs11053235	chr12:34507899	G/A	cg26384229	chr12:38710491	ALG10B	0.91	13.63	0.67	1.63e-31	Morning vs. evening chronotype;
SARC	cis	rs15676	0.783	rs7860949	chr9:131586883	C/T	cg00228799	chr9:131580591	ENDOG	-0.62	-7.77	-0.45	2.5e-13	Blood metabolite levels;
SARC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg06873352	chr17:61820015	STRADA	0.52	6.76	0.4	1.1e-10	Prudent dietary pattern;
SARC	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg16325326	chr1:53192061	ZYG11B	-0.71	-9.62	-0.53	1.16e-18	Monocyte count;
SARC	cis	rs6981523	0.532	rs1987190	chr8:11053514	T/A	cg21775007	chr8:11205619	TDH	-0.44	-5.5	-0.34	1e-7	Neuroticism;
SARC	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg22974920	chr21:40686053	BRWD1	0.45	4.89	0.31	1.88e-6	Cognitive function;
SARC	cis	rs2908197	0.699	rs2860469	chr7:75960506	A/C	cg07849177	chr7:76178544	LOC100133091	-0.43	-4.93	-0.31	1.57e-6	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg13206674	chr6:150067644	NUP43	0.43	5.61	0.34	5.83e-8	Lung cancer;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg24776498	chr12:12421246	LRP6	0.5	6.82	0.41	7.89e-11	Thyroid stimulating hormone;
SARC	cis	rs9309473	1.000	rs13428235	chr2:73633430	G/A	cg20560298	chr2:73613845	ALMS1	-0.52	-6.26	-0.38	1.84e-9	Metabolite levels;
SARC	cis	rs57920188	0.535	rs77116992	chr1:4095498	T/A	cg20703997	chr1:4087676	NA	0.5	5.34	0.33	2.21e-7	Interleukin-17 levels;
SARC	cis	rs7833986	0.534	rs2458083	chr8:56898785	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.68	6.48	0.39	5.31e-10	Height;
SARC	cis	rs17270561	0.636	rs1165157	chr6:25792250	A/G	cg16482183	chr6:26056742	HIST1H1C	0.48	6.15	0.37	3.3e-9	Iron status biomarkers;
SARC	cis	rs4805272	0.512	rs4805279	chr19:29336966	A/G	cg14983838	chr19:29218262	NA	0.54	5.8	0.36	2.17e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs2933343	0.630	rs75824035	chr3:128652985	T/C	cg25356066	chr3:128598488	ACAD9	0.74	9.57	0.53	1.65e-18	IgG glycosylation;
SARC	cis	rs2115630	0.967	rs11073702	chr15:85310071	G/A	cg17507749	chr15:85114479	UBE2QP1	-0.46	-5.39	-0.33	1.73e-7	P wave terminal force;
SARC	cis	rs523522	0.962	rs2393590	chr12:120913900	G/A	cg12219531	chr12:120966889	COQ5	0.82	10.81	0.58	2.42e-22	High light scatter reticulocyte count;
SARC	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg08677398	chr8:58056175	NA	0.44	5.25	0.33	3.38e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7647973	0.580	rs12637576	chr3:49237334	C/T	cg03060546	chr3:49711283	APEH	0.49	6.32	0.38	1.35e-9	Menarche (age at onset);
SARC	cis	rs2180341	0.538	rs3756993	chr6:127651551	A/C	cg27446573	chr6:127587934	RNF146	0.68	8.85	0.5	2.29e-16	Breast cancer;
SARC	cis	rs10992471	0.603	rs11794346	chr9:95247288	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.37	-0.33	1.91e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs137699	1.000	rs2049986	chr22:39756854	C/G	cg24399712	chr22:39784796	NA	0.34	5.06	0.31	8.46e-7	IgG glycosylation;
SARC	cis	rs1832871	0.644	rs56180963	chr6:158773990	G/A	cg07165851	chr6:158734300	TULP4	0.53	6.34	0.38	1.16e-9	Height;
SARC	cis	rs4319547	0.585	rs7953007	chr12:122816977	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.6	-7.03	-0.42	2.27e-11	Body mass index;
SARC	cis	rs11785400	0.793	rs3735993	chr8:143741170	G/A	cg10596483	chr8:143751796	JRK	0.55	7.1	0.42	1.52e-11	Schizophrenia;
SARC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-4.93	-0.31	1.59e-6	Total body bone mineral density;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg07310525	chr12:121789816	ANAPC5	0.51	6.53	0.39	3.97e-10	Lung adenocarcinoma;
SARC	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg10523679	chr1:76189770	ACADM	-0.44	-5.25	-0.32	3.5e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	trans	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg21659725	chr3:3221576	CRBN	-0.52	-6.85	-0.41	6.58e-11	Intelligence (multi-trait analysis);
SARC	cis	rs28829049	0.539	rs34441374	chr1:19392689	G/C	cg13387374	chr1:19411106	UBR4	0.46	5.74	0.35	2.96e-8	QRS duration in Tripanosoma cruzi seropositivity;
SARC	trans	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-10.55	-0.57	1.63e-21	Intelligence (multi-trait analysis);
SARC	cis	rs12142240	0.698	rs72890727	chr1:46860237	G/A	cg10495392	chr1:46806563	NSUN4	0.65	6.88	0.41	5.6e-11	Menopause (age at onset);
SARC	cis	rs7726839	0.540	rs11738281	chr5:662547	T/C	cg14541582	chr5:601475	NA	-0.41	-5.06	-0.31	8.6e-7	Obesity-related traits;
SARC	cis	rs7772486	0.754	rs9390356	chr6:146118983	A/T	cg23711669	chr6:146136114	FBXO30	-0.92	-15.92	-0.72	4.12e-39	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1953600	1.000	rs1953600	chr10:81911725	A/G	cg00277334	chr10:82204260	NA	0.34	4.94	0.31	1.46e-6	Sarcoidosis;
SARC	cis	rs6772849	1.000	rs2734037	chr3:128308884	C/T	cg08795948	chr3:128337044	NA	0.37	4.88	0.3	1.96e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg26338869	chr17:61819248	STRADA	0.8	10.68	0.57	6.2e-22	Prudent dietary pattern;
SARC	cis	rs820218	0.728	rs820149	chr17:73615933	T/C	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.5	6.21	0.38	2.37e-9	Rotator cuff tears;
SARC	cis	rs10911232	0.507	rs4652767	chr1:183002483	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.32	0.56	8.28e-21	Hypertriglyceridemia;
SARC	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg08859206	chr1:53392774	SCP2	0.36	5.22	0.32	3.97e-7	Monocyte count;
SARC	cis	rs72781680	1.000	rs12617839	chr2:24166277	A/T	cg06627628	chr2:24431161	ITSN2	-0.68	-6.44	-0.39	6.6e-10	Lymphocyte counts;
SARC	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg12463550	chr7:65579703	CRCP	-0.46	-5.03	-0.31	9.79e-7	Aortic root size;
SARC	cis	rs3126085	0.778	rs9887901	chr1:152248552	A/C	cg03465714	chr1:152285911	FLG	-0.45	-5.45	-0.34	1.25e-7	Atopic dermatitis;
SARC	cis	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg15556689	chr8:8085844	FLJ10661	-0.41	-4.82	-0.3	2.63e-6	Mood instability;
SARC	cis	rs2522056	1.000	rs2106854	chr5:131769174	C/T	cg24060327	chr5:131705240	SLC22A5	0.61	6.52	0.39	4.26e-10	Lymphocyte counts;Fibrinogen;
SARC	cis	rs12824058	0.831	rs7299065	chr12:130809661	A/T	cg24838063	chr12:130822603	PIWIL1	0.63	8.94	0.51	1.25e-16	Menopause (age at onset);
SARC	cis	rs874628	0.703	rs72999449	chr19:18237050	A/T	cg00493341	chr19:18228948	MAST3	0.49	5.33	0.33	2.27e-7	Multiple sclerosis;
SARC	cis	rs734999	0.545	rs3890745	chr1:2553624	C/T	cg00980319	chr1:2560884	MMEL1	0.35	4.96	0.31	1.39e-6	Ulcerative colitis;
SARC	cis	rs4808199	0.948	rs2301668	chr19:19452249	G/A	cg03709012	chr19:19516395	GATAD2A	1.13	11.33	0.6	5.5e-24	Nonalcoholic fatty liver disease;
SARC	cis	rs2153535	0.869	rs11962457	chr6:8375855	A/T	cg07606381	chr6:8435919	SLC35B3	-0.49	-5.96	-0.36	9.1e-9	Motion sickness;
SARC	cis	rs4727027	0.727	rs3801980	chr7:148878620	T/A	cg23583168	chr7:148888333	NA	-0.73	-9.73	-0.54	5.35e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	trans	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg00938859	chr5:1591904	SDHAP3	0.79	7.66	0.45	5.1e-13	Breast cancer;
SARC	cis	rs6138458	0.887	rs227622	chr20:24910597	T/C	cg26195577	chr20:24973756	C20orf3	0.88	9.75	0.54	4.69e-19	Blood protein levels;
SARC	cis	rs4713118	0.662	rs149947	chr6:27972433	A/T	cg16479474	chr6:28041457	NA	0.34	4.8	0.3	2.89e-6	Parkinson's disease;
SARC	cis	rs763121	0.853	rs6519124	chr22:39045099	T/C	cg21395723	chr22:39101663	GTPBP1	0.58	6.91	0.41	4.55e-11	Menopause (age at onset);
SARC	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg19077165	chr18:44547161	KATNAL2	-0.53	-7.46	-0.44	1.7e-12	Personality dimensions;
SARC	cis	rs9911578	1.000	rs8067571	chr17:56868856	C/T	cg05425664	chr17:57184151	TRIM37	-0.65	-8.03	-0.47	4.77e-14	Intelligence (multi-trait analysis);
SARC	cis	rs3008870	0.917	rs12044492	chr1:67461667	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.89	-11.03	-0.59	4.76e-23	Lymphocyte percentage of white cells;
SARC	cis	rs13082711	0.911	rs34098124	chr3:27451242	G/T	cg02860705	chr3:27208620	NA	0.44	5.64	0.35	4.87e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg13206674	chr6:150067644	NUP43	-0.46	-5.99	-0.37	8.05e-9	Lung cancer;
SARC	cis	rs1348850	0.914	rs3902850	chr2:178315899	G/A	cg23306229	chr2:178417860	TTC30B	0.55	6.41	0.39	7.79e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg16479474	chr6:28041457	NA	0.37	5.49	0.34	1.04e-7	Depression;
SARC	cis	rs5769765	0.865	rs9616369	chr22:50304591	A/C	cg03033257	chr22:50311977	ALG12;CRELD2	0.5	5.07	0.32	8.07e-7	Schizophrenia;
SARC	cis	rs1003719	0.788	rs1155785	chr21:38447939	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.67	9.98	0.55	9.34e-20	Eye color traits;
SARC	cis	rs4728302	0.583	rs1424583	chr7:133159583	T/G	cg10665199	chr7:133106180	EXOC4	0.41	5.22	0.32	4.05e-7	Intelligence;Intelligence (multi-trait analysis);
SARC	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg05863683	chr7:1912471	MAD1L1	0.36	5.52	0.34	8.85e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg12463550	chr7:65579703	CRCP	-0.46	-5.52	-0.34	9.21e-8	Aortic root size;
SARC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg01238044	chr22:24384105	GSTT1	0.61	6.77	0.41	1.01e-10	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs554111	0.660	rs12042978	chr1:21170811	T/C	cg04902671	chr1:21058625	SH2D5	0.43	5.2	0.32	4.35e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs4319547	0.794	rs61954972	chr12:123074167	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.66	-7.98	-0.46	6.73e-14	Body mass index;
SARC	cis	rs3796352	1.000	rs11713859	chr3:53042080	C/A	cg07884673	chr3:53033167	SFMBT1	0.9	5.87	0.36	1.49e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg18252515	chr7:66147081	NA	0.45	4.8	0.3	2.84e-6	Aortic root size;
SARC	cis	rs72781680	0.611	rs7596820	chr2:24335036	G/C	cg06627628	chr2:24431161	ITSN2	-0.5	-5.28	-0.33	2.98e-7	Lymphocyte counts;
SARC	cis	rs72627509	0.523	rs12650282	chr4:57733604	A/G	cg26694713	chr4:57773883	REST	-0.44	-5.22	-0.32	3.87e-7	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg06636001	chr8:8085503	FLJ10661	0.75	10.4	0.56	4.73e-21	Mood instability;
SARC	trans	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg21659725	chr3:3221576	CRBN	0.8	12.22	0.62	7.09e-27	Intelligence (multi-trait analysis);
SARC	cis	rs910316	0.737	rs175043	chr14:75471803	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.45	-5.75	-0.35	2.84e-8	Height;
SARC	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg22974920	chr21:40686053	BRWD1	0.45	4.81	0.3	2.69e-6	Cognitive function;
SARC	cis	rs7772486	0.790	rs11760	chr6:146205973	G/T	cg05347473	chr6:146136440	FBXO30	0.49	6.67	0.4	1.79e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1008375	0.900	rs4698622	chr4:17589557	C/T	cg16339924	chr4:17578868	LAP3	0.7	9.05	0.51	5.88e-17	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs11098499	0.618	rs6858383	chr4:120296772	T/C	cg25214090	chr10:38739885	LOC399744	0.55	7.14	0.42	1.15e-11	Corneal astigmatism;
SARC	cis	rs10791323	0.593	rs11223599	chr11:133717902	A/T	cg15485101	chr11:133734466	NA	-0.33	-4.95	-0.31	1.45e-6	Childhood ear infection;
SARC	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.47	-5.93	-0.36	1.07e-8	Lymphocyte counts;
SARC	cis	rs554111	0.656	rs10916891	chr1:21199974	A/C	cg04902671	chr1:21058625	SH2D5	0.42	5.02	0.31	1.03e-6	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs12754538	0.715	rs4440881	chr1:8689006	T/C	cg13785123	chr1:8931135	ENO1	-0.48	-5.41	-0.33	1.53e-7	Subjective well-being;
SARC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.42	-6.54	-0.39	3.78e-10	Total body bone mineral density;
SARC	cis	rs9911578	0.967	rs6416932	chr17:57148991	G/A	cg05425664	chr17:57184151	TRIM37	-0.64	-8.08	-0.47	3.5e-14	Intelligence (multi-trait analysis);
SARC	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg15448220	chr1:150897856	SETDB1	0.47	6.25	0.38	1.94e-9	Tonsillectomy;
SARC	trans	rs8073060	0.586	rs7208672	chr17:33989759	G/A	cg19694781	chr19:47549865	TMEM160	-0.72	-7.14	-0.42	1.16e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs72634258	0.796	rs6703955	chr1:8165975	C/G	cg00042356	chr1:8021962	PARK7	-0.6	-5.5	-0.34	9.99e-8	Inflammatory bowel disease;
SARC	cis	rs1707322	0.721	rs6697821	chr1:46216722	A/G	cg03146154	chr1:46216737	IPP	0.53	6.37	0.39	1.01e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs11864453	0.713	rs8051882	chr16:72142072	A/G	cg01557791	chr16:72042693	DHODH	0.57	7.63	0.45	5.81e-13	Fibrinogen levels;
SARC	cis	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg15145296	chr3:125709740	NA	-0.48	-4.73	-0.3	3.86e-6	Blood pressure (smoking interaction);
SARC	cis	rs3796352	1.000	rs34340609	chr3:53077276	A/G	cg15956490	chr3:53032818	SFMBT1	0.64	5.06	0.31	8.44e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs9747201	0.962	rs6502062	chr17:80086177	T/G	cg17462356	chr17:80056334	FASN	0.43	4.74	0.3	3.71e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs7666738	0.830	rs13121558	chr4:99002848	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.81	0.5	2.95e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9787249	0.957	rs7518431	chr1:40214944	C/T	cg24920358	chr1:40204285	PPIE	-0.47	-5.71	-0.35	3.36e-8	Blood protein levels;
SARC	cis	rs10504229	0.679	rs1442125	chr8:58036258	A/C	cg08219700	chr8:58056026	NA	-0.57	-5.68	-0.35	3.99e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg18252515	chr7:66147081	NA	0.51	5.5	0.34	1.01e-7	Aortic root size;
SARC	cis	rs981844	0.712	rs897610	chr4:154755439	C/A	cg14289246	chr4:154710475	SFRP2	-0.47	-5.49	-0.34	1.04e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs2991971	0.934	rs11211129	chr1:45983080	C/T	cg24296786	chr1:45957014	TESK2	0.64	9.17	0.51	2.62e-17	High light scatter reticulocyte count;
SARC	cis	rs765787	0.530	rs4775819	chr15:45525966	C/T	cg24006582	chr15:45444508	DUOX1	-0.5	-6.65	-0.4	2.07e-10	Uric acid levels;
SARC	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg07308232	chr7:1071921	C7orf50	-0.46	-5.52	-0.34	9.01e-8	Longevity;Endometriosis;
SARC	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg11890956	chr21:40555474	PSMG1	-1.04	-15.69	-0.72	2.38e-38	Cognitive function;
SARC	cis	rs9487051	0.837	rs9480920	chr6:109605322	C/A	cg01475377	chr6:109611718	NA	-0.42	-5.99	-0.37	8.01e-9	Reticulocyte fraction of red cells;
SARC	cis	rs703842	1.000	rs10877014	chr12:58167661	A/G	cg00677455	chr12:58241039	CTDSP2	0.51	6.81	0.41	8.29e-11	Multiple sclerosis;
SARC	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs17376456	0.877	rs12716456	chr5:93397557	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	6.12	0.37	3.99e-9	Diabetic retinopathy;
SARC	cis	rs2594989	1.000	rs2594994	chr3:11339960	T/A	cg00170343	chr3:11313890	ATG7	0.54	5.22	0.32	4.05e-7	Circulating chemerin levels;
SARC	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg20607798	chr8:58055168	NA	0.56	5.27	0.33	3.12e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1153858	1.000	rs12909158	chr15:45621174	A/G	cg26924012	chr15:45694286	SPATA5L1	0.76	10.62	0.57	9.91e-22	Homoarginine levels;
SARC	cis	rs78545713	1.000	rs114970164	chr6:26241993	G/C	cg13736514	chr6:26305472	NA	-0.59	-4.8	-0.3	2.9e-6	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs7828089	0.504	rs12676477	chr8:22266425	T/C	cg12081754	chr8:22256438	SLC39A14	0.63	8.54	0.49	1.73e-15	Verbal declarative memory;
SARC	cis	rs7931462	0.655	rs6483208	chr11:92705844	A/C	cg11879480	chr11:92930739	SLC36A4	0.66	5.18	0.32	4.86e-7	DNA methylation (parent-of-origin);
SARC	cis	rs73198271	0.531	rs56100346	chr8:8652844	C/T	cg01851573	chr8:8652454	MFHAS1	0.39	4.81	0.3	2.69e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs10870270	0.956	rs11146325	chr10:133767529	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.48	-5.38	-0.33	1.8e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs6500602	0.927	rs7200817	chr16:4480598	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.3	4.85	0.3	2.25e-6	Schizophrenia;
SARC	cis	rs654950	0.806	rs2759251	chr1:42041749	C/G	cg06885757	chr1:42089581	HIVEP3	-0.41	-6.05	-0.37	5.84e-9	Airway imaging phenotypes;
SARC	cis	rs4711350	0.954	rs1536501	chr6:33727885	C/T	cg18005901	chr6:33739558	LEMD2	0.45	4.77	0.3	3.26e-6	Schizophrenia;
SARC	cis	rs7197653	0.748	rs8060690	chr16:68340085	G/T	cg05110241	chr16:68378359	PRMT7	-0.69	-6.21	-0.38	2.4e-9	Magnesium levels;
SARC	cis	rs7552404	0.691	rs1770890	chr1:76401117	A/G	cg10523679	chr1:76189770	ACADM	-0.44	-5.13	-0.32	6.17e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs4780401	0.933	rs8058003	chr16:11815178	C/T	cg01061890	chr16:11836724	TXNDC11	-0.52	-6.79	-0.41	9.48e-11	Rheumatoid arthritis;
SARC	trans	rs9388451	0.807	rs1269175	chr6:126040435	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.52	6.69	0.4	1.68e-10	Brugada syndrome;
SARC	cis	rs711830	0.576	rs72916141	chr2:177069364	G/T	cg13092806	chr2:177043255	NA	-0.59	-5.28	-0.33	3e-7	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
SARC	cis	rs6840360	0.571	rs7692700	chr4:152552797	C/T	cg22705602	chr4:152727874	NA	-0.44	-6.86	-0.41	6.03e-11	Intelligence (multi-trait analysis);
SARC	cis	rs2832191	0.967	rs3787660	chr21:30520907	C/T	cg08807101	chr21:30365312	RNF160	0.71	9.63	0.53	1.1e-18	Dental caries;
SARC	cis	rs11122272	0.705	rs2491411	chr1:231533448	C/G	cg06096015	chr1:231504339	EGLN1	0.38	5.64	0.35	4.92e-8	Hemoglobin concentration;
SARC	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg17376030	chr22:41985996	PMM1	0.7	8.38	0.48	5.11e-15	Vitiligo;
SARC	cis	rs11785693	0.862	rs11774099	chr8:4988218	C/T	cg26367366	chr8:4980734	NA	0.66	6.04	0.37	5.96e-9	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs11690935	0.885	rs10202823	chr2:172780132	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.94	-13.72	-0.67	8.32e-32	Schizophrenia;
SARC	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg06636001	chr8:8085503	FLJ10661	0.64	8.97	0.51	1.02e-16	Mood instability;
SARC	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg18252515	chr7:66147081	NA	-1.33	-11.84	-0.61	1.22e-25	Diabetic kidney disease;
SARC	cis	rs9487051	0.714	rs7774390	chr6:109602461	C/G	cg01475377	chr6:109611718	NA	0.34	4.89	0.3	1.9e-6	Reticulocyte fraction of red cells;
SARC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.35	-5.44	-0.34	1.35e-7	Longevity;Endometriosis;
SARC	cis	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg12463550	chr7:65579703	CRCP	0.69	5.29	0.33	2.86e-7	Diabetic kidney disease;
SARC	cis	rs9660992	0.736	rs1180734	chr1:205255438	A/G	cg21545522	chr1:205238299	TMCC2	0.4	5.65	0.35	4.62e-8	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs2153535	0.563	rs4428546	chr6:8490376	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.12	0.59	2.5e-23	Motion sickness;
SARC	cis	rs9300255	0.510	rs1790133	chr12:123698518	T/G	cg00376283	chr12:123451042	ABCB9	0.56	6.57	0.4	3.18e-10	Neutrophil percentage of white cells;
SARC	cis	rs861020	0.771	rs629150	chr1:209998467	C/T	cg23166289	chr1:210001082	C1orf107	0.49	5.12	0.32	6.32e-7	Orofacial clefts;
SARC	cis	rs7592578	0.882	rs58568707	chr2:191468987	G/A	cg10560079	chr2:191398806	TMEM194B	-0.81	-9.29	-0.52	1.13e-17	Diastolic blood pressure;
SARC	cis	rs752010	0.871	rs2038976	chr1:42094498	A/G	cg06885757	chr1:42089581	HIVEP3	0.45	7.29	0.43	4.78e-12	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.77	9.09	0.51	4.41e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs3106136	0.967	rs3113862	chr4:95143122	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.39	-6.06	-0.37	5.56e-9	Capecitabine sensitivity;
SARC	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg03351412	chr1:154909251	PMVK	0.65	8.34	0.48	6.47e-15	Prostate cancer;
SARC	trans	rs7824557	0.737	rs2293855	chr8:11177410	G/A	cg06636001	chr8:8085503	FLJ10661	0.59	7.29	0.43	4.86e-12	Retinal vascular caliber;
SARC	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	8.64	0.49	9.31e-16	Mean platelet volume;
SARC	cis	rs10461617	0.512	rs7715746	chr5:56048837	C/T	cg22800045	chr5:56110881	MAP3K1	0.68	7.83	0.46	1.68e-13	Type 2 diabetes;
SARC	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg25894440	chr7:65020034	NA	-0.71	-5.4	-0.33	1.62e-7	Diabetic kidney disease;
SARC	cis	rs8014131	0.689	rs1955433	chr14:85981729	A/G	cg10406690	chr14:85995726	FLRT2	0.39	5.03	0.31	9.61e-7	Menarche (age at onset);
SARC	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.51	6.61	0.4	2.57e-10	Personality dimensions;
SARC	cis	rs72949976	0.646	rs11681232	chr2:214033002	G/A	cg08319019	chr2:214017104	IKZF2	0.45	6.02	0.37	6.78e-9	Lung cancer;Squamous cell lung carcinoma;
SARC	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg15049968	chr18:44337910	ST8SIA5	0.33	5.32	0.33	2.42e-7	Personality dimensions;
SARC	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg22496380	chr5:211416	CCDC127	-0.86	-8.8	-0.5	3.04e-16	Breast cancer;
SARC	cis	rs1401999	0.714	rs1000002	chr3:183635768	A/G	cg01324343	chr3:183735012	ABCC5	-0.59	-10.64	-0.57	8.17e-22	Anterior chamber depth;
SARC	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.42	-0.44	2.12e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs7769051	0.522	rs6934155	chr6:133124021	C/T	cg07930552	chr6:133119739	C6orf192	0.98	5.85	0.36	1.62e-8	Type 2 diabetes nephropathy;
SARC	cis	rs240110	0.588	rs9390675	chr6:101204973	A/G	cg09795085	chr6:101329169	ASCC3	0.4	4.97	0.31	1.31e-6	Neuroticism;
SARC	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4077515	0.839	rs4307445	chr9:139279776	C/G	cg14169450	chr9:139327907	INPP5E	0.36	4.77	0.3	3.19e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs1062177	0.756	rs2964591	chr5:151117397	A/G	cg00977110	chr5:151150581	G3BP1	-0.48	-4.82	-0.3	2.6e-6	Preschool internalizing problems;
SARC	cis	rs17401966	0.838	rs4846209	chr1:10322054	G/A	cg15208524	chr1:10270712	KIF1B	0.46	5.45	0.34	1.25e-7	Hepatocellular carcinoma;
SARC	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg02725872	chr8:58115012	NA	-0.32	-4.84	-0.3	2.35e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs763121	0.853	rs6001214	chr22:39149155	C/T	cg21395723	chr22:39101663	GTPBP1	0.55	6.26	0.38	1.81e-9	Menopause (age at onset);
SARC	cis	rs2425143	1.000	rs6060524	chr20:34221155	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-5.83	-0.36	1.88e-8	Blood protein levels;
SARC	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg13175981	chr1:150552382	MCL1	-0.54	-6.82	-0.41	7.54e-11	Tonsillectomy;
SARC	cis	rs2153535	0.580	rs9406164	chr6:8470048	C/T	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	cis	rs4481887	0.893	rs10888355	chr1:248457180	G/A	cg13385794	chr1:248469461	NA	0.34	5.15	0.32	5.62e-7	Common traits (Other);
SARC	cis	rs4911259	0.552	rs11700082	chr20:31460244	A/G	cg13636640	chr20:31349939	DNMT3B	-0.7	-9.67	-0.54	8.4e-19	Inflammatory bowel disease;
SARC	cis	rs12142240	0.621	rs66828173	chr1:46818166	G/A	cg10495392	chr1:46806563	NSUN4	0.65	6.83	0.41	7.25e-11	Menopause (age at onset);
SARC	cis	rs1801251	1.000	rs2675974	chr2:233727071	A/G	cg25237894	chr2:233734115	C2orf82	0.37	5.02	0.31	1.03e-6	Coronary artery disease;
SARC	cis	rs2952156	0.883	rs2517960	chr17:37846521	T/C	cg00129232	chr17:37814104	STARD3	-0.72	-10.03	-0.55	6.39e-20	Asthma;
SARC	cis	rs9640161	0.742	rs2108851	chr7:150019634	T/C	cg21361702	chr7:150065534	REPIN1	0.47	4.94	0.31	1.49e-6	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs9787249	0.957	rs1046988	chr1:40219065	A/G	cg24920358	chr1:40204285	PPIE	-0.43	-5.27	-0.33	3.15e-7	Blood protein levels;
SARC	cis	rs7617773	0.817	rs9818937	chr3:48325281	G/A	cg11946769	chr3:48343235	NME6	0.69	9.27	0.52	1.29e-17	Coronary artery disease;
SARC	cis	rs12142240	0.698	rs966907	chr1:46817125	C/G	cg10495392	chr1:46806563	NSUN4	0.65	6.83	0.41	7.25e-11	Menopause (age at onset);
SARC	cis	rs288326	0.561	rs79096460	chr2:183798677	A/G	cg09997497	chr2:183902928	NCKAP1	0.75	5.16	0.32	5.32e-7	Blood protein levels;
SARC	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg06634786	chr22:41940651	POLR3H	-0.55	-6.55	-0.39	3.65e-10	Vitiligo;
SARC	cis	rs9807989	0.507	rs2041739	chr2:102994333	A/G	cg03938978	chr2:103052716	IL18RAP	-0.31	-5.05	-0.31	9.07e-7	Asthma;
SARC	cis	rs910316	0.810	rs77939209	chr14:75670070	A/G	cg08847533	chr14:75593920	NEK9	-0.83	-12.55	-0.64	5.88e-28	Height;
SARC	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.62	5.4	0.33	1.68e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs9650657	0.648	rs7833945	chr8:10700266	T/G	cg21775007	chr8:11205619	TDH	-0.39	-4.91	-0.31	1.7e-6	Neuroticism;
SARC	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg16405210	chr4:1374714	KIAA1530	-0.44	-5.45	-0.34	1.28e-7	Longevity;
SARC	cis	rs709400	0.663	rs11628969	chr14:103940911	G/A	cg12935359	chr14:103987150	CKB	-0.39	-5.74	-0.35	2.92e-8	Body mass index;
SARC	cis	rs599083	0.530	rs546803	chr11:68186392	C/T	cg01657329	chr11:68192670	LRP5	0.47	6.29	0.38	1.58e-9	Bone mineral density (spine);
SARC	cis	rs4810685	0.816	rs1413146	chr20:46407290	C/T	cg08288986	chr20:46415360	SULF2	0.41	4.79	0.3	2.95e-6	Attention deficit hyperactivity disorder (time to onset);
SARC	cis	rs9914988	0.943	rs11656256	chr17:27153553	G/A	cg20469991	chr17:27169893	C17orf63	-0.52	-5.39	-0.33	1.74e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg24209194	chr3:40518798	ZNF619	-0.6	-7.59	-0.45	7.47e-13	Renal cell carcinoma;
SARC	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg03806693	chr22:41940476	POLR3H	0.89	11.95	0.62	5.29e-26	Vitiligo;
SARC	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.47	-5.82	-0.36	1.93e-8	Tonsillectomy;
SARC	cis	rs9486719	1.000	rs11153064	chr6:97021959	A/G	cg06623918	chr6:96969491	KIAA0776	-0.79	-8.83	-0.5	2.51e-16	Migraine;Coronary artery disease;
SARC	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg17294928	chr15:75287854	SCAMP5	0.46	5.86	0.36	1.54e-8	Breast cancer;
SARC	cis	rs10425738	0.830	rs3852872	chr19:41416143	C/T	cg17435250	chr19:41386441	CYP2A7	-0.4	-4.72	-0.3	4.06e-6	nicotine metabolite ratio in current smokers;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
SARC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.72	0.81	9.31e-55	Prudent dietary pattern;
SARC	cis	rs4720575	0.931	rs10242850	chr7:47099868	A/C	cg00036614	chr7:47093842	NA	-0.48	-6.58	-0.4	3.1e-10	Angiotensin-converting enzyme inhibitor intolerance;
SARC	cis	rs7178572	0.568	rs11632941	chr15:77533888	A/G	cg22256960	chr15:77711686	NA	-0.51	-5.58	-0.34	6.56e-8	Type 2 diabetes;
SARC	cis	rs72945132	0.882	rs72949076	chr11:70217695	T/C	cg00319359	chr11:70116639	PPFIA1	0.69	6.39	0.39	9.15e-10	Coronary artery disease;
SARC	cis	rs6456156	0.904	rs2023305	chr6:167524898	A/G	cg07741184	chr6:167504864	NA	0.26	4.87	0.3	2.02e-6	Primary biliary cholangitis;
SARC	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	trans	rs7752643	0.622	rs2022267	chr6:84264202	A/T	cg14512089	chr1:160771850	LY9	0.32	6.67	0.4	1.81e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs13191362	0.507	rs2155506	chr6:163035342	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.43	-4.81	-0.3	2.66e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs753778	0.667	rs10092439	chr8:142210881	C/T	cg16341495	chr8:142228727	SLC45A4	-0.42	-5.97	-0.36	8.69e-9	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs240764	0.658	rs1039030	chr6:101198707	G/A	cg09795085	chr6:101329169	ASCC3	-0.49	-6.42	-0.39	7.76e-10	Neuroticism;
SARC	cis	rs67311347	1.000	rs2276868	chr3:40498845	C/T	cg01475735	chr3:40494733	NA	0.46	5.34	0.33	2.19e-7	Renal cell carcinoma;
SARC	cis	rs62064224	0.765	rs62065463	chr17:30732405	G/T	cg25809561	chr17:30822961	MYO1D	0.39	5.85	0.36	1.64e-8	Schizophrenia;
SARC	cis	rs9397240	0.789	rs12191935	chr6:155555457	A/G	cg07943832	chr6:155568918	TIAM2	-0.51	-4.74	-0.3	3.67e-6	Life satisfaction;
SARC	cis	rs11693319	1.000	rs11693319	chr2:179738269	C/T	cg17765952	chr2:179737173	CCDC141	0.61	6.8	0.41	8.84e-11	Blood pressure measurement (cold pressor test);
SARC	cis	rs7044106	0.762	rs10818471	chr9:123394045	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	8.56	0.49	1.55e-15	Hip circumference adjusted for BMI;
SARC	cis	rs5753618	0.583	rs5753628	chr22:31860322	A/G	cg02404636	chr22:31891804	SFI1	0.52	5.63	0.35	5.22e-8	Colorectal cancer;
SARC	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg17691542	chr6:26056736	HIST1H1C	0.41	4.76	0.3	3.4e-6	Intelligence (multi-trait analysis);
SARC	cis	rs1023500	0.596	rs133350	chr22:42429049	A/G	cg04733989	chr22:42467013	NAGA	0.72	9.58	0.53	1.5e-18	Schizophrenia;
SARC	cis	rs7465272	1.000	rs13258638	chr8:143683582	C/T	cg24634471	chr8:143751801	JRK	0.59	6.41	0.39	7.81e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs12594515	1.000	rs8039974	chr15:45986665	A/G	cg14863074	chr15:45997064	NA	0.34	5.18	0.32	4.84e-7	Waist circumference;Weight;
SARC	cis	rs79349575	0.783	rs318090	chr17:46991752	G/A	cg16584676	chr17:46985605	UBE2Z	0.53	6.38	0.39	9.28e-10	Type 2 diabetes;
SARC	cis	rs6570726	0.967	rs373704	chr6:145860618	C/A	cg05220968	chr6:146057943	EPM2A	-0.29	-4.97	-0.31	1.32e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9875589	0.509	rs1844107	chr3:14065319	C/G	cg19554555	chr3:13937349	NA	-0.4	-5.14	-0.32	5.95e-7	Ovarian reserve;
SARC	cis	rs6570726	0.791	rs9373464	chr6:145907167	T/C	cg23711669	chr6:146136114	FBXO30	0.83	13.68	0.67	1.19e-31	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs5167	0.566	rs934427	chr19:45478816	T/G	cg09555818	chr19:45449301	APOC2	0.38	5.12	0.32	6.51e-7	Blood protein levels;
SARC	cis	rs9517320	0.515	rs4772099	chr13:99196121	A/C	cg07423050	chr13:99094983	FARP1	-0.42	-5.5	-0.34	9.8e-8	Longevity;
SARC	cis	rs7552404	0.731	rs5745491	chr1:76350159	T/G	cg22875332	chr1:76189707	ACADM	-0.41	-5.32	-0.33	2.47e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7264396	0.563	rs2425100	chr20:34310115	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	5.69	0.35	3.71e-8	Total cholesterol levels;
SARC	cis	rs9300255	0.596	rs11057202	chr12:123720775	G/T	cg05973401	chr12:123451056	ABCB9	0.52	5.89	0.36	1.37e-8	Neutrophil percentage of white cells;
SARC	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg06634786	chr22:41940651	POLR3H	-0.65	-7.61	-0.45	6.74e-13	Vitiligo;
SARC	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg16414030	chr3:133502952	NA	-0.4	-5.43	-0.34	1.4e-7	Iron status biomarkers;
SARC	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg00409905	chr10:38381863	ZNF37A	-0.55	-7.41	-0.44	2.29e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs11098499	0.863	rs1552095	chr4:120460306	A/G	cg09307838	chr4:120376055	NA	0.93	12.78	0.64	1.11e-28	Corneal astigmatism;
SARC	cis	rs9467773	1.000	rs9467779	chr6:26536687	A/T	cg11502198	chr6:26597334	ABT1	-0.47	-5.72	-0.35	3.29e-8	Intelligence (multi-trait analysis);
SARC	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg06221963	chr1:154839813	KCNN3	-0.53	-8.58	-0.49	1.35e-15	Prostate cancer;
SARC	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg08975724	chr8:8085496	FLJ10661	-0.46	-5.91	-0.36	1.2e-8	Mood instability;
SARC	cis	rs7979473	1	rs7979473	chr12:121420260	A/G	cg02403541	chr12:121454288	C12orf43	-0.56	-7.15	-0.42	1.14e-11	C-reactive protein;
SARC	cis	rs12887734	0.524	rs722637	chr14:104261723	G/T	cg26031613	chr14:104095156	KLC1	0.44	5.18	0.32	4.85e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	cis	rs35955747	0.869	rs34873968	chr22:31581773	C/T	cg02404636	chr22:31891804	SFI1	-0.4	-4.76	-0.3	3.41e-6	Neutrophil count;Sum basophil neutrophil counts;
SARC	cis	rs6542838	0.641	rs10192266	chr2:99521837	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.53	-6.91	-0.41	4.47e-11	Fear of minor pain;
SARC	cis	rs7084402	0.902	rs1658417	chr10:60333039	T/C	cg07615347	chr10:60278583	BICC1	0.58	8.47	0.49	2.76e-15	Refractive error;
SARC	cis	rs2075371	0.966	rs2544225	chr7:133995838	A/C	cg11752832	chr7:134001865	SLC35B4	0.57	7.28	0.43	5.03e-12	Mean platelet volume;
SARC	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg22903657	chr4:1355424	KIAA1530	-0.41	-5.53	-0.34	8.43e-8	Obesity-related traits;
SARC	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg11890956	chr21:40555474	PSMG1	1.03	15.44	0.71	1.62e-37	Cognitive function;
SARC	cis	rs2712184	1.000	rs2712184	chr2:217682779	G/T	cg05032264	chr2:217675019	NA	-0.64	-8.35	-0.48	6.04e-15	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
SARC	trans	rs1814175	0.765	rs1794141	chr11:49914135	G/C	cg15704280	chr7:45808275	SEPT13	-0.98	-18.3	-0.77	5.62e-47	Height;
SARC	cis	rs854765	0.583	rs11656840	chr17:17837354	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	9.75	0.54	4.62e-19	Total body bone mineral density;
SARC	cis	rs7264396	0.623	rs2425127	chr20:34332037	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-6.71	-0.4	1.47e-10	Total cholesterol levels;
SARC	cis	rs2153535	0.562	rs9379211	chr6:8463927	C/T	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs9325144	0.555	rs7955128	chr12:38684121	A/T	cg13010199	chr12:38710504	ALG10B	0.56	7.41	0.44	2.25e-12	Morning vs. evening chronotype;
SARC	cis	rs4589502	0.841	rs56401320	chr15:67140517	C/G	cg12317470	chr15:67143691	NA	0.73	5.31	0.33	2.61e-7	Lung cancer (smoking interaction);
SARC	cis	rs7818345	1.000	rs7823194	chr8:19292528	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.4	5.39	0.33	1.71e-7	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs921968	0.528	rs13022583	chr2:219589175	T/C	cg02176678	chr2:219576539	TTLL4	-0.33	-5.07	-0.32	8.2e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs4689388	0.926	rs10937718	chr4:6295217	T/C	cg00701064	chr4:6280414	WFS1	0.54	8.58	0.49	1.38e-15	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg22862634	chr11:62369728	EML3;MTA2	0.53	8.09	0.47	3.27e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg12463550	chr7:65579703	CRCP	-0.49	-5.32	-0.33	2.44e-7	Aortic root size;
SARC	cis	rs123509	0.687	rs73077214	chr3:42838020	G/A	cg12982090	chr3:42733453	KBTBD5	-0.53	-5.95	-0.36	9.96e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs3796352	1.000	rs11710707	chr3:52975916	A/G	cg15956490	chr3:53032818	SFMBT1	0.89	5.76	0.35	2.62e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs7662987	0.517	rs2602881	chr4:100040695	A/G	cg13256891	chr4:100009986	ADH5	0.68	8.61	0.49	1.13e-15	Smoking initiation;
SARC	cis	rs854765	0.552	rs6502624	chr17:17847936	G/A	cg05444541	chr17:17804740	TOM1L2	-0.29	-4.84	-0.3	2.35e-6	Total body bone mineral density;
SARC	cis	rs9462027	0.628	rs2814970	chr6:34713500	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.4	-5.7	-0.35	3.69e-8	Systemic lupus erythematosus;
SARC	cis	rs116095464	1.000	rs56095714	chr5:311256	C/T	cg22496380	chr5:211416	CCDC127	-0.93	-6.16	-0.37	3.21e-9	Breast cancer;
SARC	cis	rs6570726	1.000	rs450076	chr6:145847655	G/T	cg05220968	chr6:146057943	EPM2A	-0.29	-4.88	-0.3	2.01e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.72	7.75	0.45	2.83e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7412746	0.611	rs2228099	chr1:150808889	C/G	cg10589385	chr1:150898437	SETDB1	0.39	5.4	0.33	1.63e-7	Melanoma;
SARC	cis	rs597539	0.521	rs7943745	chr11:68605828	A/G	cg17547346	chr11:68671486	IGHMBP2;MRPL21	0.39	4.79	0.3	2.99e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs11711311	1.000	rs10212375	chr3:113471336	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	8.23	0.47	1.32e-14	IgG glycosylation;
SARC	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg17376030	chr22:41985996	PMM1	0.62	7.97	0.46	6.93e-14	Vitiligo;
SARC	cis	rs10197940	0.710	rs4500942	chr2:152334580	A/G	cg19508488	chr2:152266495	RIF1	0.57	6.5	0.39	4.87e-10	Lung cancer;
SARC	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	11.31	0.6	6.28e-24	Alzheimer's disease;
SARC	cis	rs6912958	0.559	rs107690	chr6:88069352	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.29	-5.08	-0.32	7.59e-7	Monocyte percentage of white cells;
SARC	cis	rs10131894	0.611	rs175002	chr14:75436466	C/G	cg11812906	chr14:75593930	NEK9	0.6	7.48	0.44	1.51e-12	Coronary artery disease;
SARC	cis	rs10782582	0.546	rs79652169	chr1:76233882	G/A	cg10523679	chr1:76189770	ACADM	-0.43	-5.14	-0.32	5.7e-7	Daytime sleep phenotypes;
SARC	cis	rs7312933	0.670	rs2406568	chr12:42552297	G/C	cg19980929	chr12:42632907	YAF2	0.44	6.08	0.37	4.81e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs12311304	0.901	rs7132337	chr12:15416115	A/G	cg08258403	chr12:15378311	NA	0.43	6.68	0.4	1.76e-10	Behavioural disinhibition (generation interaction);
SARC	cis	rs7520050	0.807	rs72688483	chr1:46149209	A/G	cg06784218	chr1:46089804	CCDC17	0.27	4.9	0.31	1.8e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs4664308	1.000	rs4665147	chr2:160917062	A/G	cg03641300	chr2:160917029	PLA2R1	-0.68	-9.29	-0.52	1.11e-17	Idiopathic membranous nephropathy;
SARC	cis	rs1371867	0.846	rs1660348	chr8:101315248	A/G	cg11906718	chr8:101322791	RNF19A	0.65	8.55	0.49	1.63e-15	Atrioventricular conduction;
SARC	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg17971929	chr21:40555470	PSMG1	-0.58	-7.36	-0.43	3.15e-12	Menarche (age at onset);
SARC	cis	rs6871536	1.000	rs2240032	chr5:131977127	C/T	cg11797159	chr5:131991491	NA	0.39	4.85	0.3	2.22e-6	Asthma (childhood onset);
SARC	cis	rs9392918	0.600	rs4960342	chr6:7697612	G/A	cg23089261	chr6:7723385	NA	0.51	6.35	0.38	1.11e-9	Height;
SARC	cis	rs3796352	1.000	rs11713859	chr3:53042080	C/A	cg15956490	chr3:53032818	SFMBT1	0.87	5.73	0.35	3.14e-8	Immune reponse to smallpox (secreted IL-2);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg08402439	chr4:180980552	NA	-0.61	-7.45	-0.44	1.86e-12	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.34	-5.06	-0.31	8.5e-7	Total body bone mineral density;
SARC	cis	rs10927875	0.619	rs7546589	chr1:16129530	A/G	cg21385522	chr1:16154831	NA	-0.6	-7.92	-0.46	9.7e-14	Dilated cardiomyopathy;
SARC	cis	rs9381040	0.655	rs6939989	chr6:41020205	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.39	-4.74	-0.3	3.71e-6	Alzheimer's disease (late onset);
SARC	cis	rs7647973	0.710	rs2029591	chr3:49646981	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.72	-6.53	-0.39	4.17e-10	Menarche (age at onset);
SARC	cis	rs10089	1.000	rs77086350	chr5:127494431	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	9.05	0.51	5.62e-17	Ileal carcinoids;
SARC	cis	rs9399135	0.967	rs9389258	chr6:135361140	T/C	cg22676075	chr6:135203613	NA	0.35	4.81	0.3	2.7e-6	Red blood cell count;
SARC	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg05861140	chr6:150128134	PCMT1	-0.44	-5.41	-0.33	1.57e-7	Lung cancer;
SARC	cis	rs11997175	0.715	rs7012923	chr8:33630937	A/C	ch.8.33884649F	chr8:33765107	NA	0.56	7.29	0.43	4.7e-12	Body mass index;
SARC	cis	rs1949733	0.675	rs2688235	chr4:8450546	T/C	cg11789530	chr4:8429930	ACOX3	0.81	10.55	0.57	1.58e-21	Response to antineoplastic agents;
SARC	cis	rs11122272	0.735	rs2572249	chr1:231514829	G/A	cg06096015	chr1:231504339	EGLN1	0.38	5.72	0.35	3.28e-8	Hemoglobin concentration;
SARC	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6831352	0.879	rs29001212	chr4:100051877	T/C	cg13256891	chr4:100009986	ADH5	-0.65	-8.09	-0.47	3.18e-14	Alcohol dependence;
SARC	cis	rs7520050	0.743	rs61789988	chr1:46085242	G/C	cg24296786	chr1:45957014	TESK2	0.42	5.39	0.33	1.75e-7	Red blood cell count;Reticulocyte count;
SARC	cis	rs6088580	0.634	rs6059829	chr20:33017074	G/A	cg24642439	chr20:33292090	TP53INP2	0.67	8.56	0.49	1.53e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs10927875	0.501	rs61782229	chr1:16220118	G/A	cg21385522	chr1:16154831	NA	-0.85	-9.47	-0.53	3.23e-18	Dilated cardiomyopathy;
SARC	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	11.07	0.59	3.59e-23	Alzheimer's disease;
SARC	cis	rs9290065	0.519	rs6808386	chr3:160673263	A/T	cg04691961	chr3:161091175	C3orf57	-0.5	-6.34	-0.38	1.18e-9	Kawasaki disease;
SARC	cis	rs3857067	0.806	rs72665627	chr4:95111824	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.05	-0.31	8.98e-7	QT interval;
SARC	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg25894440	chr7:65020034	NA	-0.75	-5.64	-0.35	5e-8	Diabetic kidney disease;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg03591676	chr8:96281769	C8orf37	0.77	6.29	0.38	1.59e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1200821	0.535	rs1208783	chr10:37767467	A/G	cg00409905	chr10:38381863	ZNF37A	-0.46	-6.23	-0.38	2.18e-9	Hemostatic factors and hematological phenotypes;
SARC	cis	rs501120	0.925	rs1746049	chr10:44776310	C/T	cg09554077	chr10:44749378	NA	0.52	7.07	0.42	1.75e-11	Coronary artery disease;Coronary heart disease;
SARC	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg22875332	chr1:76189707	ACADM	0.47	6.44	0.39	6.83e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9325144	0.647	rs10875953	chr12:39050536	G/C	cg26384229	chr12:38710491	ALG10B	-0.62	-8.1	-0.47	3.07e-14	Morning vs. evening chronotype;
SARC	cis	rs710216	0.957	rs841570	chr1:43435571	C/G	cg22176566	chr1:43424700	SLC2A1	0.51	5.06	0.31	8.51e-7	Red cell distribution width;
SARC	cis	rs3126085	0.867	rs12748016	chr1:152197235	T/C	cg03465714	chr1:152285911	FLG	0.49	5.8	0.36	2.13e-8	Atopic dermatitis;
SARC	cis	rs11969893	0.649	rs12527901	chr6:101280435	G/A	cg12253828	chr6:101329408	ASCC3	0.94	7.22	0.43	7.23e-12	Economic and political preferences (immigration/crime);
SARC	cis	rs62380364	0.613	rs254781	chr5:88000636	C/T	cg22951263	chr5:87985283	NA	-0.36	-4.8	-0.3	2.88e-6	Intelligence (multi-trait analysis);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg21304211	chr1:112281877	C1orf183	0.48	6.28	0.38	1.68e-9	Chemerin levels;
SARC	cis	rs2425143	1.000	rs11696947	chr20:34312658	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.09	-0.37	4.6e-9	Blood protein levels;
SARC	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg00933542	chr6:150070202	PCMT1	0.31	5.13	0.32	6.04e-7	Testicular germ cell tumor;
SARC	cis	rs3768617	0.782	rs12146099	chr1:182968079	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.65	8.9	0.5	1.59e-16	Fuchs's corneal dystrophy;
SARC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg07308232	chr7:1071921	C7orf50	-0.51	-6.29	-0.38	1.53e-9	Longevity;Endometriosis;
SARC	cis	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg00071950	chr4:10020882	SLC2A9	0.4	6.4	0.39	8.68e-10	Bone mineral density;
SARC	cis	rs17376456	0.825	rs10064368	chr5:93266396	C/A	cg25358565	chr5:93447407	FAM172A	1.29	14.23	0.68	1.68e-33	Diabetic retinopathy;
SARC	cis	rs950169	0.920	rs2135551	chr15:84707851	A/G	cg17507749	chr15:85114479	UBE2QP1	0.76	9.16	0.51	2.76e-17	Schizophrenia;
SARC	cis	rs1059312	0.771	rs11059922	chr12:129290418	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.45	-5.55	-0.34	7.8e-8	Systemic lupus erythematosus;
SARC	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg08859206	chr1:53392774	SCP2	-0.35	-5.07	-0.32	8.05e-7	Monocyte count;
SARC	cis	rs10448080	0.879	rs240946	chr8:28568905	A/G	cg08943089	chr8:28351457	FZD3	0.36	5.09	0.32	7.38e-7	Height;
SARC	trans	rs34421088	0.560	rs2248699	chr8:11393764	A/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-9.29	-0.52	1.15e-17	Neuroticism;
SARC	cis	rs2467099	0.732	rs2168855	chr17:73943350	C/T	cg06969265	chr17:73775802	H3F3B	0.64	6.73	0.4	1.34e-10	Systolic blood pressure;
SARC	cis	rs765787	0.530	rs2413784	chr15:45530516	A/C	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.51e-10	Uric acid levels;
SARC	cis	rs9840812	0.645	rs9883916	chr3:136208788	C/T	cg15507776	chr3:136538369	TMEM22	0.56	5.93	0.36	1.07e-8	Fibrinogen levels;
SARC	cis	rs4975616	0.714	rs27069	chr5:1347128	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.44	-5.89	-0.36	1.32e-8	Lung cancer;
SARC	cis	rs992157	0.798	rs12053514	chr2:219167965	C/T	cg00012203	chr2:219082015	ARPC2	-0.64	-9.15	-0.51	2.99e-17	Colorectal cancer;
SARC	cis	rs1609391	0.543	rs9859810	chr3:136629986	A/G	cg15507776	chr3:136538369	TMEM22	0.85	11.74	0.61	2.59e-25	Neuroticism;
SARC	cis	rs2153535	0.580	rs6597322	chr6:8449952	T/G	cg07606381	chr6:8435919	SLC35B3	0.77	11.03	0.59	5.01e-23	Motion sickness;
SARC	cis	rs10992471	0.575	rs1152759	chr9:95129359	T/C	cg13798575	chr9:95087839	CENPP;NOL8	0.4	4.94	0.31	1.48e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs35110281	0.667	rs9941787	chr21:45116042	A/G	cg04455712	chr21:45112962	RRP1B	0.36	5.2	0.32	4.39e-7	Mean corpuscular volume;
SARC	cis	rs7635838	0.819	rs6776159	chr3:11519324	A/G	cg00170343	chr3:11313890	ATG7	0.62	8.77	0.5	3.86e-16	HDL cholesterol;
SARC	trans	rs6894249	1.000	rs6894249	chr5:131797547	A/G	cg12956598	chr19:10662582	ATG4D;MIR1238	-0.48	-6.76	-0.4	1.08e-10	Asthma;
SARC	cis	rs9467773	0.967	rs9461267	chr6:26525455	T/G	cg11502198	chr6:26597334	ABT1	0.47	5.93	0.36	1.1e-8	Intelligence (multi-trait analysis);
SARC	trans	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg00938859	chr5:1591904	SDHAP3	0.69	6.42	0.39	7.38e-10	Breast cancer;
SARC	cis	rs921968	0.541	rs12617603	chr2:219369288	A/G	cg02176678	chr2:219576539	TTLL4	-0.49	-7.5	-0.44	1.37e-12	Mean corpuscular hemoglobin concentration;
SARC	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg17971929	chr21:40555470	PSMG1	-0.86	-11.3	-0.6	6.67e-24	Cognitive function;
SARC	cis	rs1348850	0.958	rs11684320	chr2:178456346	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.63	7.7	0.45	3.95e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg05332525	chr7:65337924	VKORC1L1	-0.43	-4.81	-0.3	2.73e-6	Calcium levels;
SARC	cis	rs151349	0.555	rs151343	chr20:57583298	C/G	cg23907860	chr20:57583709	CTSZ	0.38	5.9	0.36	1.3e-8	Platelet distribution width;
SARC	cis	rs8044868	0.530	rs2287999	chr16:72059149	A/G	cg01557791	chr16:72042693	DHODH	-0.38	-4.8	-0.3	2.82e-6	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
SARC	cis	rs12702595	0.552	rs10263069	chr7:7269366	C/T	cg04827551	chr7:7268805	C1GALT1	0.41	4.93	0.31	1.54e-6	Serum dimethylarginine levels (asymmetric/symetric ratio);Symmetrical dimethylarginine levels;
SARC	cis	rs8114671	0.967	rs1415773	chr20:33765585	G/A	cg24642439	chr20:33292090	TP53INP2	0.51	5.88	0.36	1.4e-8	Height;
SARC	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg22920501	chr2:26401640	FAM59B	-0.53	-6.57	-0.4	3.17e-10	Gut microbiome composition (summer);
SARC	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg19077165	chr18:44547161	KATNAL2	-0.5	-6.58	-0.4	3.1e-10	Personality dimensions;
SARC	cis	rs6424115	1.000	rs2256179	chr1:24132305	A/G	cg15997130	chr1:24165203	NA	-0.49	-6.73	-0.4	1.27e-10	Immature fraction of reticulocytes;
SARC	cis	rs2235544	0.542	rs585269	chr1:54469976	C/T	cg10336722	chr1:54665764	CYB5RL;MRPL37	-0.38	-4.72	-0.3	4.04e-6	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
SARC	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg18876405	chr7:65276391	NA	0.48	5.81	0.36	2.07e-8	Aortic root size;
SARC	cis	rs13256369	0.789	rs13282500	chr8:8568489	A/T	cg18904891	chr8:8559673	CLDN23	0.46	5.59	0.34	6.19e-8	Obesity-related traits;
SARC	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg09455208	chr3:40491958	NA	-0.36	-5.52	-0.34	8.85e-8	Renal cell carcinoma;
SARC	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg16414030	chr3:133502952	NA	-0.4	-5.44	-0.34	1.32e-7	Iron status biomarkers;
SARC	cis	rs763121	0.889	rs9607557	chr22:39040279	G/A	cg21395723	chr22:39101663	GTPBP1	0.54	6.27	0.38	1.7e-9	Menopause (age at onset);
SARC	cis	rs6964587	1.000	rs3753107	chr7:91629151	C/T	cg17063962	chr7:91808500	NA	-0.99	-17.34	-0.75	8.44e-44	Breast cancer;
SARC	cis	rs826838	0.935	rs1486357	chr12:39073675	A/G	cg26384229	chr12:38710491	ALG10B	0.91	14.19	0.68	2.43e-33	Heart rate;
SARC	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg17294928	chr15:75287854	SCAMP5	0.49	6.23	0.38	2.15e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	cis	rs12824058	0.831	rs55726136	chr12:130810312	G/A	cg23887609	chr12:130822674	PIWIL1	0.37	5.15	0.32	5.48e-7	Menopause (age at onset);
SARC	cis	rs17376456	0.825	rs36042718	chr5:93180997	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.7	6.24	0.38	2.02e-9	Diabetic retinopathy;
SARC	cis	rs644799	0.965	rs10831426	chr11:95505888	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	15.47	0.71	1.31e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs3008870	0.755	rs6657065	chr1:67384639	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.61	7.85	0.46	1.53e-13	Lymphocyte percentage of white cells;
SARC	cis	rs4969178	0.931	rs6501208	chr17:76395038	A/T	cg20026190	chr17:76395443	PGS1	0.39	5.3	0.33	2.71e-7	HDL cholesterol levels;
SARC	cis	rs9513627	0.573	rs7325697	chr13:100117793	A/G	cg25919922	chr13:100150906	NA	0.7	7.06	0.42	1.87e-11	Obesity-related traits;
SARC	cis	rs9682041	0.660	rs13089074	chr3:170113481	G/A	cg11886554	chr3:170076028	SKIL	0.84	7.76	0.45	2.72e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg25427524	chr10:38739819	LOC399744	-0.53	-8.46	-0.48	2.95e-15	Extrinsic epigenetic age acceleration;
SARC	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg14983838	chr19:29218262	NA	0.78	10.59	0.57	1.2e-21	Methadone dose in opioid dependence;
SARC	cis	rs9323205	0.723	rs12587352	chr14:51739441	T/C	cg23942311	chr14:51606299	NA	-0.36	-4.89	-0.3	1.92e-6	Cancer;
SARC	cis	rs920590	0.796	rs7820520	chr8:19634864	A/G	cg17834443	chr8:19674713	INTS10	-0.44	-5.23	-0.32	3.82e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9303280	0.901	rs1008723	chr17:38066267	G/T	cg20243544	chr17:37824526	PNMT	0.43	5.91	0.36	1.18e-8	Self-reported allergy;
SARC	trans	rs9527419	0.882	rs681846	chr13:56219314	A/G	cg24135946	chr13:45010973	TSC22D1	-0.56	-6.33	-0.38	1.27e-9	Response to platinum-based chemotherapy (cisplatin);
SARC	cis	rs7113850	0.541	rs56732861	chr11:24234333	C/G	ch.11.24196551F	chr11:24239977	NA	0.72	5.35	0.33	2.07e-7	Bone fracture in osteoporosis;
SARC	cis	rs9905704	0.846	rs304262	chr17:56814456	A/G	cg12560992	chr17:57184187	TRIM37	0.45	5.26	0.33	3.21e-7	Testicular germ cell tumor;
SARC	cis	rs78545713	1.000	rs11753610	chr6:26251601	C/T	cg13736514	chr6:26305472	NA	0.55	4.92	0.31	1.65e-6	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs4242434	0.819	rs6558173	chr8:22492103	A/C	cg03733263	chr8:22462867	KIAA1967	-1.01	-16.92	-0.74	1.93e-42	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs9467773	0.620	rs2101581	chr6:26622769	G/T	cg11502198	chr6:26597334	ABT1	0.63	8.55	0.49	1.65e-15	Intelligence (multi-trait analysis);
SARC	cis	rs1008375	0.932	rs13134570	chr4:17692863	C/T	cg27347728	chr4:17578864	LAP3	-0.49	-5.91	-0.36	1.2e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs3771570	0.901	rs3771587	chr2:242409701	A/G	cg21155796	chr2:242212141	HDLBP	0.64	5.99	0.37	7.87e-9	Prostate cancer;
SARC	cis	rs708547	0.647	rs1718831	chr4:57886946	T/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.56	6.81	0.41	8.03e-11	Response to bleomycin (chromatid breaks);
SARC	trans	rs7824557	0.872	rs2572417	chr8:11111462	A/T	cg06636001	chr8:8085503	FLJ10661	-0.6	-7.96	-0.46	7.66e-14	Retinal vascular caliber;
SARC	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg18252515	chr7:66147081	NA	1.29	11.12	0.59	2.48e-23	Diabetic kidney disease;
SARC	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg02524346	chr8:600233	NA	0.68	5.52	0.34	8.88e-8	IgG glycosylation;
SARC	cis	rs9398803	0.661	rs9375449	chr6:126963807	T/C	cg19875578	chr6:126661172	C6orf173	0.63	8.7	0.5	5.9e-16	Male-pattern baldness;
SARC	cis	rs875971	0.545	rs6979636	chr7:65741625	A/G	cg11764359	chr7:65958608	NA	0.63	6.26	0.38	1.88e-9	Aortic root size;
SARC	trans	rs61931739	0.890	rs1849160	chr12:34140191	A/G	cg13010199	chr12:38710504	ALG10B	0.58	7.67	0.45	4.76e-13	Morning vs. evening chronotype;
SARC	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg04267008	chr7:1944627	MAD1L1	0.51	5.81	0.36	2.06e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs1023500	0.573	rs133378	chr22:42467695	G/C	cg04733989	chr22:42467013	NAGA	0.76	10.61	0.57	1e-21	Schizophrenia;
SARC	cis	rs11874712	1.000	rs1800640	chr18:43671400	A/G	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.45	5.36	0.33	2e-7	Migraine - clinic-based;
SARC	cis	rs9398803	0.678	rs1155938	chr6:126866472	C/A	cg19875578	chr6:126661172	C6orf173	0.64	8.83	0.5	2.58e-16	Male-pattern baldness;
SARC	cis	rs2295359	1.000	rs11465753	chr1:67631423	T/C	cg11235152	chr1:67600687	NA	0.47	7.0	0.42	2.72e-11	Psoriasis;
SARC	cis	rs644799	0.544	rs1527450	chr11:95467777	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.71	9.38	0.52	6.13e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs6430585	0.528	rs309159	chr2:136684940	C/T	cg07169764	chr2:136633963	MCM6	0.99	12.69	0.64	2.2e-28	Corneal structure;
SARC	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg01324507	chr7:1177794	C7orf50	0.48	4.75	0.3	3.5e-6	Bronchopulmonary dysplasia;
SARC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg04234412	chr22:24373322	LOC391322	0.55	6.56	0.39	3.51e-10	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs8054556	0.760	rs12598856	chr16:30029548	C/T	cg06015834	chr16:30021696	DOC2A	-0.35	-4.72	-0.3	4e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs4481887	1.000	rs4916124	chr1:248466495	T/C	cg13385794	chr1:248469461	NA	0.36	5.57	0.34	7.1e-8	Common traits (Other);
SARC	cis	rs9916302	0.861	rs644173	chr17:37430519	T/C	cg15445000	chr17:37608096	MED1	0.42	5.07	0.32	7.96e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs9296092	0.538	rs9461875	chr6:33516644	C/T	cg13560919	chr6:33536144	NA	-0.5	-5.91	-0.36	1.22e-8	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs4243830	1.000	rs12027598	chr1:6600804	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	1.03	8.42	0.48	3.86e-15	Body mass index;
SARC	cis	rs72781680	0.678	rs56145919	chr2:24088489	A/G	cg08917208	chr2:24149416	ATAD2B	0.59	6.28	0.38	1.63e-9	Lymphocyte counts;
SARC	trans	rs11098499	0.863	rs1480939	chr4:120456927	T/C	cg25214090	chr10:38739885	LOC399744	0.57	7.35	0.43	3.31e-12	Corneal astigmatism;
SARC	cis	rs72781680	0.898	rs56216411	chr2:23934533	G/A	cg06627628	chr2:24431161	ITSN2	-0.63	-5.59	-0.34	6.42e-8	Lymphocyte counts;
SARC	cis	rs921968	0.541	rs3845835	chr2:219342284	T/C	cg02176678	chr2:219576539	TTLL4	-0.5	-7.57	-0.44	8.83e-13	Mean corpuscular hemoglobin concentration;
SARC	trans	rs61931739	0.890	rs1705750	chr12:34142648	C/T	cg13010199	chr12:38710504	ALG10B	0.58	7.56	0.44	9.02e-13	Morning vs. evening chronotype;
SARC	cis	rs16937	0.574	rs10900455	chr1:205123534	T/C	cg00857998	chr1:205179979	DSTYK	0.4	4.79	0.3	2.97e-6	Schizophrenia;
SARC	cis	rs4128725	0.706	rs77731748	chr1:159482209	A/G	cg25076881	chr1:159409836	OR10J1	0.56	6.14	0.37	3.44e-9	Select biomarker traits;
SARC	cis	rs1475911	0.507	rs11702347	chr21:43526454	C/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.7	8.28	0.48	9.57e-15	IgG glycosylation;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg12048536	chr14:76044591	FLVCR2	0.52	6.94	0.41	3.94e-11	Thyroid stimulating hormone;
SARC	cis	rs17001868	0.568	rs9611311	chr22:40733951	T/C	cg07138101	chr22:40742427	ADSL	0.54	5.94	0.36	1.01e-8	Mammographic density (dense area);
SARC	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg22920501	chr2:26401640	FAM59B	-0.55	-7.26	-0.43	5.77e-12	Gut microbiome composition (summer);
SARC	cis	rs1467026	0.584	rs9865381	chr3:12801685	C/T	cg05775895	chr3:12838266	CAND2	0.61	8.63	0.49	9.88e-16	P wave duration;
SARC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.58	0.53	1.52e-18	Prudent dietary pattern;
SARC	cis	rs6456156	0.586	rs12203510	chr6:167473006	C/T	cg23791538	chr6:167370224	RNASET2	-0.47	-6.17	-0.37	3.08e-9	Primary biliary cholangitis;
SARC	cis	rs6840360	0.571	rs1473305	chr4:152511721	T/G	cg22705602	chr4:152727874	NA	-0.43	-6.66	-0.4	1.91e-10	Intelligence (multi-trait analysis);
SARC	cis	rs72634258	0.945	rs12753070	chr1:8114319	C/G	cg00042356	chr1:8021962	PARK7	0.91	8.35	0.48	6.28e-15	Inflammatory bowel disease;
SARC	cis	rs17079247	1.000	rs9575764	chr13:85664467	C/T	ch.13.84760847R	chr13:85862846	NA	0.56	5.06	0.31	8.45e-7	Bipolar disorder (mania);
SARC	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg04277193	chr17:41438351	NA	0.46	4.93	0.31	1.56e-6	Menopause (age at onset);
SARC	cis	rs2304069	0.779	rs245081	chr5:149356075	G/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.46	4.73	0.3	3.93e-6	HIV-1 control;
SARC	cis	rs986417	0.901	rs11158292	chr14:61043183	G/T	cg27398547	chr14:60952738	C14orf39	0.89	8.5	0.49	2.3e-15	Gut microbiota (bacterial taxa);
SARC	cis	rs3099143	1.000	rs10431768	chr15:77162158	A/G	cg21673338	chr15:77095150	SCAPER	0.73	6.15	0.37	3.32e-9	Recalcitrant atopic dermatitis;
SARC	cis	rs6988636	1.000	rs62521841	chr8:124194625	G/A	cg23067535	chr8:124195133	FAM83A	-0.75	-5.85	-0.36	1.68e-8	Urinary uromodulin levels;
SARC	cis	rs7717697	0.797	rs13161552	chr5:82737804	T/A	cg19814134	chr5:82768288	VCAN	0.42	5.01	0.31	1.06e-6	Vertical cup-disc ratio;
SARC	cis	rs2153535	0.563	rs1737586	chr6:8535897	C/T	cg21535247	chr6:8435926	SLC35B3	0.55	6.81	0.41	8.27e-11	Motion sickness;
SARC	cis	rs7949030	0.590	rs12225213	chr11:62350248	T/A	cg13298116	chr11:62369859	EML3;MTA2	0.48	7.3	0.43	4.57e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs9790314	0.934	rs455386	chr3:161102495	A/T	cg03342759	chr3:160939853	NMD3	-0.55	-6.77	-0.41	1.01e-10	Morning vs. evening chronotype;
SARC	trans	rs7615952	0.800	rs2062773	chr3:125639648	T/C	cg07211511	chr3:129823064	LOC729375	-0.95	-11.08	-0.59	3.52e-23	Blood pressure (smoking interaction);
SARC	cis	rs950776	0.616	rs56276142	chr15:78889795	T/C	cg22563815	chr15:78856949	CHRNA5	0.37	6.32	0.38	1.33e-9	Sudden cardiac arrest;
SARC	cis	rs11690935	0.688	rs7600835	chr2:172521827	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.68	-9.22	-0.52	1.89e-17	Schizophrenia;
SARC	cis	rs8141529	0.719	rs9625619	chr22:29272328	T/A	cg15103426	chr22:29168792	CCDC117	0.65	8.57	0.49	1.44e-15	Lymphocyte counts;
SARC	cis	rs16854884	0.657	rs6440210	chr3:143705763	A/G	cg06585982	chr3:143692056	C3orf58	0.68	9.21	0.52	1.9e-17	Economic and political preferences (feminism/equality);
SARC	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg12288994	chr5:1860383	NA	0.33	5.49	0.34	1.05e-7	Cardiovascular disease risk factors;
SARC	cis	rs78487399	0.808	rs111812200	chr2:43674278	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-5.01	-0.31	1.08e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs8031584	1.000	rs35239376	chr15:31290538	A/C	cg19680485	chr15:31195859	MTMR15	-0.55	-5.74	-0.35	2.88e-8	Huntington's disease progression;
SARC	cis	rs4713118	0.513	rs149942	chr6:28001610	T/C	cg26335602	chr6:28129616	ZNF389	0.45	5.29	0.33	2.85e-7	Parkinson's disease;
SARC	cis	rs4974559	0.947	rs10018627	chr4:1356358	G/A	cg09010372	chr4:1323433	MAEA	-0.47	-4.72	-0.3	3.99e-6	Systolic blood pressure;
SARC	cis	rs477692	0.612	rs58103386	chr10:131319958	C/A	cg05714579	chr10:131428358	MGMT	0.58	7.57	0.44	8.58e-13	Response to temozolomide;
SARC	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.56	-7.2	-0.43	8.01e-12	Mean platelet volume;
SARC	cis	rs7089973	0.604	rs7904188	chr10:116610271	G/C	cg08188268	chr10:116634841	FAM160B1	0.28	4.79	0.3	3.02e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs8180040	0.726	rs7610636	chr3:47064436	A/C	cg02527881	chr3:46936655	PTH1R	0.31	4.77	0.3	3.31e-6	Colorectal cancer;
SARC	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg19223190	chr17:80058835	NA	0.44	6.19	0.38	2.67e-9	Life satisfaction;
SARC	cis	rs113835537	0.935	rs15969	chr11:66394387	C/T	cg24851651	chr11:66362959	CCS	0.49	5.23	0.32	3.8e-7	Airway imaging phenotypes;
SARC	cis	rs9790314	0.586	rs1839491	chr3:161126429	C/A	cg17135325	chr3:160939158	NMD3	0.53	6.48	0.39	5.49e-10	Morning vs. evening chronotype;
SARC	cis	rs11190604	1.000	rs1417823	chr10:102227886	C/T	cg07080220	chr10:102295463	HIF1AN	-0.73	-9.25	-0.52	1.49e-17	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs8114671	0.647	rs6060267	chr20:33734012	A/G	cg24642439	chr20:33292090	TP53INP2	0.48	5.81	0.36	2.06e-8	Height;
SARC	cis	rs9420	0.961	rs11229148	chr11:57621460	A/T	cg19752551	chr11:57585705	CTNND1	-0.49	-6.75	-0.4	1.15e-10	Schizophrenia;
SARC	trans	rs17266958	0.901	rs78755462	chr9:83356510	A/G	cg03038418	chr19:3096512	GNA11	0.65	6.37	0.39	1e-9	Preschool internalizing problems;
SARC	trans	rs10435719	0.764	rs10103485	chr8:11787563	C/T	cg06636001	chr8:8085503	FLJ10661	0.51	6.52	0.39	4.3e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
SARC	cis	rs155076	0.702	rs482731	chr13:21846075	G/A	cg14456004	chr13:21872349	NA	-1.0	-12.77	-0.64	1.13e-28	White matter hyperintensity burden;
SARC	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg22903657	chr4:1355424	KIAA1530	-0.43	-5.83	-0.36	1.8e-8	Obesity-related traits;
SARC	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg12310025	chr6:25882481	NA	-0.57	-7.32	-0.43	4.1e-12	Intelligence (multi-trait analysis);
SARC	cis	rs35079168	0.735	rs1887309	chr9:137308242	A/G	cg00753924	chr9:137298813	RXRA	0.38	4.83	0.3	2.5e-6	Intelligence;
SARC	cis	rs7312933	0.531	rs1796380	chr12:42791543	T/G	cg19980929	chr12:42632907	YAF2	-0.46	-6.89	-0.41	5.21e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs7932354	0.528	rs4752962	chr11:47141670	C/G	cg03339077	chr11:47165057	C11orf49	0.41	5.6	0.34	6.14e-8	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg00409905	chr10:38381863	ZNF37A	-0.52	-7.25	-0.43	6.2e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs72781680	0.898	rs112985192	chr2:24102797	G/A	cg06627628	chr2:24431161	ITSN2	-0.68	-6.66	-0.4	1.97e-10	Lymphocyte counts;
SARC	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg26119090	chr2:26468346	HADHA;HADHB	0.95	13.96	0.67	1.32e-32	Gut microbiome composition (summer);
SARC	cis	rs11792861	0.781	rs28361152	chr9:111727529	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.75	9.03	0.51	6.87e-17	Menarche (age at onset);
SARC	cis	rs6835098	0.962	rs4419455	chr4:174083622	C/T	cg08422745	chr4:174089978	GALNT7	0.75	9.25	0.52	1.5e-17	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.41	-4.79	-0.3	2.91e-6	Renal function-related traits (BUN);
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg16603964	chr6:111803680	REV3L	-0.49	-6.68	-0.4	1.73e-10	Schizophrenia;
SARC	cis	rs7714584	1.000	rs2004711	chr5:150225068	C/T	cg22134413	chr5:150180641	NA	0.78	6.52	0.39	4.32e-10	Crohn's disease;
SARC	cis	rs10791097	0.653	rs11222362	chr11:130731425	T/C	cg09137382	chr11:130731461	NA	0.37	5.65	0.35	4.6e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs739401	0.611	rs3782069	chr11:3033275	G/A	cg08508325	chr11:3079039	CARS	-0.34	-8.2	-0.47	1.62e-14	Longevity;
SARC	cis	rs193541	0.530	rs6595405	chr5:122084745	C/T	cg19412675	chr5:122181750	SNX24	0.48	6.42	0.39	7.41e-10	Glucose homeostasis traits;
SARC	trans	rs1814175	0.646	rs61904497	chr11:49883449	A/T	cg03929089	chr4:120376271	NA	-0.83	-12.24	-0.63	6.14e-27	Height;
SARC	cis	rs933688	0.938	rs7708782	chr5:90718517	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.08	13.76	0.67	6.36e-32	Smoking behavior;
SARC	cis	rs9388451	0.868	rs1268083	chr6:126049040	T/C	cg06289844	chr6:126071538	HEY2	-0.34	-5.47	-0.34	1.18e-7	Brugada syndrome;
SARC	cis	rs9640161	0.789	rs3735174	chr7:150020489	T/C	cg21361702	chr7:150065534	REPIN1	0.48	5.11	0.32	6.76e-7	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs3540	1.000	rs7173724	chr15:91036855	A/G	cg22089800	chr15:90895588	ZNF774	0.51	5.96	0.36	9.43e-9	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs6964587	1.000	rs7797834	chr7:91743150	C/T	cg17063962	chr7:91808500	NA	-0.95	-16.27	-0.73	2.84e-40	Breast cancer;
SARC	cis	rs60871478	0.588	rs6952577	chr7:872100	C/T	cg05535760	chr7:792225	HEATR2	0.66	6.61	0.4	2.6e-10	Cerebrospinal P-tau181p levels;
SARC	cis	rs7772486	0.701	rs2244308	chr6:146213706	C/T	cg05347473	chr6:146136440	FBXO30	0.47	6.43	0.39	7.28e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7681440	0.874	rs1442151	chr4:90775491	T/A	cg02192967	chr4:90758406	SNCA	0.37	5.26	0.33	3.25e-7	Dementia with Lewy bodies;
SARC	cis	rs7589728	0.563	rs78168096	chr2:88473575	G/A	cg04511125	chr2:88470314	THNSL2	0.78	7.28	0.43	4.97e-12	Plasma clusterin levels;
SARC	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg11644478	chr21:40555479	PSMG1	-0.89	-11.4	-0.6	3.15e-24	Cognitive function;
SARC	cis	rs698833	0.532	rs698810	chr2:44703171	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	5.56	0.34	7.47e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs7833986	1.000	rs34952804	chr8:57097399	T/C	cg26371346	chr8:56986568	SNORD54;RPS20	0.6	5.33	0.33	2.36e-7	Height;
SARC	cis	rs7712401	0.623	rs426877	chr5:122314635	A/G	cg19412675	chr5:122181750	SNX24	-0.43	-5.5	-0.34	9.81e-8	Mean platelet volume;
SARC	cis	rs16912285	0.786	rs112633506	chr11:24250766	G/A	ch.11.24196551F	chr11:24239977	NA	0.64	4.78	0.3	3.11e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs950027	0.620	rs1145093	chr15:45649813	C/A	cg15395560	chr15:45543142	SLC28A2	-0.27	-5.21	-0.32	4.22e-7	Response to fenofibrate (adiponectin levels);
SARC	cis	rs744373	0.507	rs77260225	chr2:127865104	C/T	cg12632573	chr2:127783243	NA	0.73	6.61	0.4	2.63e-10	Alzheimer's disease;Alzheimer's disease (late onset);
SARC	cis	rs9859260	0.710	rs419068	chr3:195782176	C/T	cg03462622	chr3:195777018	TFRC	-0.47	-5.41	-0.33	1.53e-7	Mean corpuscular volume;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg10038259	chr5:177631514	HNRNPAB	-0.52	-6.86	-0.41	6.07e-11	Electrocardiographic conduction measures;
SARC	cis	rs9303401	0.614	rs62084387	chr17:57148027	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.04	10.07	0.55	4.78e-20	Cognitive test performance;
SARC	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg11644478	chr21:40555479	PSMG1	0.56	7.01	0.42	2.57e-11	Menarche (age at onset);
SARC	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-6.85	-0.41	6.65e-11	Personality dimensions;
SARC	cis	rs8114671	0.562	rs6088622	chr20:33419977	C/A	cg24642439	chr20:33292090	TP53INP2	0.55	6.72	0.4	1.37e-10	Height;
SARC	cis	rs736408	0.583	rs2710323	chr3:52815905	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.34	4.93	0.31	1.54e-6	Bipolar disorder;
SARC	cis	rs6089584	0.830	rs6089309	chr20:60585687	T/C	cg06108461	chr20:60628389	TAF4	-0.91	-11.87	-0.61	1.03e-25	Body mass index;
SARC	cis	rs10504229	0.679	rs1442125	chr8:58036258	A/C	cg11062466	chr8:58055876	NA	-0.5	-4.84	-0.3	2.4e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs2011503	1.000	rs34667451	chr19:19617017	C/T	cg03709012	chr19:19516395	GATAD2A	0.61	5.36	0.33	1.95e-7	Bipolar disorder;
SARC	cis	rs12971120	0.838	rs747176	chr18:72154931	G/A	cg26446133	chr18:72167187	CNDP2	-0.53	-8.44	-0.48	3.49e-15	Refractive error;
SARC	trans	rs61931739	0.534	rs10844801	chr12:34230940	A/T	cg26384229	chr12:38710491	ALG10B	0.8	11.11	0.59	2.8e-23	Morning vs. evening chronotype;
SARC	trans	rs1635	0.655	rs16893975	chr6:28302278	C/T	cg08080395	chr15:65488966	CILP	-0.69	-6.57	-0.4	3.18e-10	Schizophrenia;
SARC	cis	rs861020	0.630	rs599649	chr1:210003402	T/C	cg23166289	chr1:210001082	C1orf107	0.4	4.8	0.3	2.84e-6	Orofacial clefts;
SARC	cis	rs1865760	1.000	rs3799371	chr6:25912816	A/G	cg10373733	chr6:25993375	NA	-0.48	-5.87	-0.36	1.5e-8	Height;
SARC	cis	rs17666538	1.000	rs73177066	chr8:585750	C/T	cg23958373	chr8:599963	NA	-0.99	-7.45	-0.44	1.79e-12	IgG glycosylation;
SARC	trans	rs2727020	0.523	rs7948958	chr11:49506749	G/A	cg03929089	chr4:120376271	NA	0.72	8.03	0.47	4.92e-14	Coronary artery disease;
SARC	cis	rs858239	0.508	rs7805085	chr7:23190243	C/T	cg23682824	chr7:23144976	KLHL7	0.65	8.09	0.47	3.33e-14	Cerebrospinal fluid biomarker levels;
SARC	cis	rs7681440	0.874	rs10028246	chr4:90766704	G/A	cg06632027	chr4:90757378	SNCA	0.39	5.66	0.35	4.49e-8	Dementia with Lewy bodies;
SARC	cis	rs9916302	0.861	rs11078912	chr17:37671490	A/G	cg15445000	chr17:37608096	MED1	0.42	4.79	0.3	2.96e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs1034435	0.547	rs5768686	chr22:48899214	G/A	cg05992904	chr22:48892994	FAM19A5	-0.42	-5.69	-0.35	3.73e-8	Late-onset Alzheimer's disease;
SARC	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg12311346	chr5:56204834	C5orf35	0.66	6.73	0.4	1.27e-10	Initial pursuit acceleration;
SARC	cis	rs2562456	0.833	rs2562507	chr19:21726337	C/T	cg00806126	chr19:22604979	ZNF98	0.47	4.84	0.3	2.31e-6	Pain;
SARC	cis	rs6912958	0.525	rs59322	chr6:88020521	C/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.37	6.26	0.38	1.83e-9	Monocyte percentage of white cells;
SARC	cis	rs4242434	0.927	rs2291231	chr8:22463912	C/T	cg03733263	chr8:22462867	KIAA1967	1.02	17.13	0.75	3.91e-43	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs858239	0.600	rs2014768	chr7:23122440	C/A	cg23682824	chr7:23144976	KLHL7	0.71	9.6	0.53	1.34e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs941408	1.000	rs1640271	chr19:2799979	C/T	cg00079169	chr19:2811669	THOP1	0.49	5.5	0.34	1.01e-7	Total cholesterol levels;
SARC	cis	rs7617773	0.817	rs4131362	chr3:48329036	A/C	cg11946769	chr3:48343235	NME6	0.73	9.69	0.54	6.93e-19	Coronary artery disease;
SARC	cis	rs453301	0.686	rs6987107	chr8:8893581	A/G	cg11608241	chr8:8085544	FLJ10661	-0.44	-5.6	-0.34	6e-8	Joint mobility (Beighton score);
SARC	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg09699651	chr6:150184138	LRP11	0.39	4.86	0.3	2.13e-6	Lung cancer;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg14824382	chr8:144680115	EEF1D;TIGD5	-0.52	-6.37	-0.39	1.01e-9	Schizophrenia;
SARC	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg17971929	chr21:40555470	PSMG1	-0.91	-12.46	-0.63	1.24e-27	Cognitive function;
SARC	cis	rs7208859	0.573	rs73277960	chr17:29177441	T/C	cg13385521	chr17:29058706	SUZ12P	0.86	7.34	0.43	3.54e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs6088590	0.748	rs6142206	chr20:33212055	G/A	cg24642439	chr20:33292090	TP53INP2	0.67	7.95	0.46	8.04e-14	Coronary artery disease;
SARC	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg02951883	chr7:2050386	MAD1L1	-0.44	-5.65	-0.35	4.7e-8	Schizophrenia;
SARC	cis	rs710216	0.917	rs3754223	chr1:43419091	A/T	cg03128534	chr1:43423976	SLC2A1	0.62	6.52	0.39	4.38e-10	Red cell distribution width;
SARC	cis	rs3733585	0.806	rs7375599	chr4:9954918	C/T	cg00071950	chr4:10020882	SLC2A9	0.41	6.55	0.39	3.6e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs6424115	0.793	rs2502998	chr1:24198327	T/A	cg15997130	chr1:24165203	NA	0.41	5.51	0.34	9.33e-8	Immature fraction of reticulocytes;
SARC	cis	rs12134245	0.747	rs17501512	chr1:92012481	C/G	cg02896835	chr1:92012615	NA	0.53	7.11	0.42	1.41e-11	Breast cancer;
SARC	cis	rs9457247	0.765	rs10455982	chr6:167448728	C/T	cg07741184	chr6:167504864	NA	0.38	7.5	0.44	1.32e-12	Crohn's disease;
SARC	cis	rs7113850	0.541	rs7116120	chr11:24235050	A/G	ch.11.24196551F	chr11:24239977	NA	0.68	5.21	0.32	4.06e-7	Bone fracture in osteoporosis;
SARC	cis	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg14541582	chr5:601475	NA	-0.4	-4.8	-0.3	2.85e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs7236492	0.748	rs76617579	chr18:77200655	C/T	cg15644404	chr18:77186268	NFATC1	-0.64	-6.04	-0.37	5.9e-9	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs453301	0.686	rs13252797	chr8:8861430	A/G	cg11608241	chr8:8085544	FLJ10661	0.42	5.23	0.32	3.78e-7	Joint mobility (Beighton score);
SARC	cis	rs6582630	0.638	rs61931383	chr12:38513845	G/A	cg26384229	chr12:38710491	ALG10B	-0.56	-7.11	-0.42	1.4e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs4481887	0.927	rs10888340	chr1:248440381	C/T	cg00666640	chr1:248458726	OR2T12	0.33	5.34	0.33	2.2e-7	Common traits (Other);
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg21155998	chr19:48825036	NA	0.63	6.62	0.4	2.51e-10	Lung cancer in ever smokers;
SARC	cis	rs17030434	0.775	rs4696493	chr4:154680007	T/C	cg14289246	chr4:154710475	SFRP2	0.63	6.8	0.41	8.76e-11	Electrocardiographic conduction measures;
SARC	cis	rs6088580	0.524	rs6088570	chr20:33268295	T/C	cg08999081	chr20:33150536	PIGU	-0.34	-5.02	-0.31	1.01e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs2531992	0.800	rs1045476	chr16:4015313	A/G	cg07628416	chr16:4033297	ADCY9	-0.32	-5.05	-0.31	8.87e-7	Waist circumference;
SARC	cis	rs7833986	0.534	rs2976022	chr8:57007843	T/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.73	7.47	0.44	1.56e-12	Height;
SARC	cis	rs240764	0.817	rs239242	chr6:101092776	C/T	cg09795085	chr6:101329169	ASCC3	0.46	6.01	0.37	7.2e-9	Neuroticism;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg09824706	chr7:6487775	DAGLB	-0.55	-7.31	-0.43	4.13e-12	Neuroticism;
SARC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.67	0.54	8.17e-19	Prudent dietary pattern;
SARC	cis	rs6582630	0.598	rs10880645	chr12:38556172	G/A	cg14851346	chr12:38532713	NA	-0.44	-5.3	-0.33	2.63e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs151234	0.741	rs11644791	chr16:28601186	G/C	cg01378222	chr16:28622494	SULT1A1	-0.49	-5.77	-0.35	2.47e-8	Platelet distribution width;
SARC	cis	rs2425143	1.000	rs7273668	chr20:34442731	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-5.46	-0.34	1.21e-7	Blood protein levels;
SARC	cis	rs1894116	0.786	rs11225166	chr11:102090467	C/G	cg00496961	chr11:102638706	NA	-0.52	-4.76	-0.3	3.35e-6	Polycystic ovary syndrome;
SARC	cis	rs8141529	0.748	rs132528	chr22:29295898	C/T	cg15103426	chr22:29168792	CCDC117	-0.67	-8.68	-0.49	6.98e-16	Lymphocyte counts;
SARC	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg13012494	chr21:47604986	C21orf56	-0.56	-6.69	-0.4	1.62e-10	Testicular germ cell tumor;
SARC	cis	rs432925	0.572	rs2685120	chr16:342080	C/G	cg06233593	chr16:337645	AXIN1	0.37	5.06	0.31	8.44e-7	Morning vs. evening chronotype;
SARC	cis	rs12421382	0.690	rs2716049	chr11:109609889	A/C	cg27471124	chr11:109292789	C11orf87	0.48	6.64	0.4	2.2e-10	Schizophrenia;
SARC	cis	rs6723226	0.961	rs13010404	chr2:32848854	T/G	cg02381751	chr2:32503542	YIPF4	-0.65	-8.17	-0.47	2.02e-14	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.636	rs114725691	chr8:58054292	C/T	cg20607798	chr8:58055168	NA	0.62	5.72	0.35	3.29e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg27588902	chr6:42928151	GNMT	-0.37	-5.7	-0.35	3.62e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs7084402	0.967	rs6481404	chr10:60286071	C/G	cg07615347	chr10:60278583	BICC1	-0.55	-8.01	-0.46	5.54e-14	Refractive error;
SARC	cis	rs2033732	0.706	rs1370414	chr8:85076043	G/A	cg05716166	chr8:85095498	RALYL	0.49	5.65	0.35	4.59e-8	Body mass index;
SARC	cis	rs10911232	0.507	rs61081633	chr1:182995608	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.57	0.57	1.37e-21	Hypertriglyceridemia;
SARC	cis	rs17209837	1.000	rs17149641	chr7:87086090	T/C	cg00919237	chr7:87102261	ABCB4	-0.5	-5.47	-0.34	1.14e-7	Gallbladder cancer;
SARC	cis	rs11122272	0.735	rs2437149	chr1:231490105	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-9.83	-0.54	2.61e-19	Hemoglobin concentration;
SARC	cis	rs1057239	0.510	rs3766694	chr1:175143207	T/C	cg08873628	chr1:175162347	KIAA0040	-0.36	-4.96	-0.31	1.33e-6	Diastolic blood pressure;
SARC	cis	rs8141529	0.529	rs36112964	chr22:29178130	T/C	cg15103426	chr22:29168792	CCDC117	0.61	5.94	0.36	1.03e-8	Lymphocyte counts;
SARC	cis	rs2997447	0.655	rs2275947	chr1:26383875	A/G	cg19633962	chr1:26362018	EXTL1	-0.73	-7.5	-0.44	1.31e-12	QRS complex (12-leadsum);
SARC	cis	rs1044826	0.692	rs295484	chr3:139231782	A/G	cg15131784	chr3:139108705	COPB2	-0.41	-5.21	-0.32	4.22e-7	Obesity-related traits;
SARC	cis	rs7870753	0.838	rs16910870	chr9:99247103	A/G	cg25260653	chr9:99212216	HABP4	0.52	4.78	0.3	3.16e-6	Height;
SARC	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg17691542	chr6:26056736	HIST1H1C	0.48	5.98	0.36	8.53e-9	Height;
SARC	cis	rs995000	0.931	rs1748195	chr1:63049593	C/G	cg06896770	chr1:63153194	DOCK7	-0.88	-13.19	-0.65	4.82e-30	Triglyceride levels;
SARC	cis	rs34172651	0.876	rs1862451	chr16:24803620	A/G	cg00339695	chr16:24857497	SLC5A11	0.31	4.92	0.31	1.64e-6	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg20007245	chr22:24372913	LOC391322	-0.75	-10.1	-0.55	3.84e-20	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg22920501	chr2:26401640	FAM59B	-0.57	-7.45	-0.44	1.82e-12	Gut microbiome composition (summer);
SARC	cis	rs78487399	0.808	rs998768	chr2:43711523	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.58	-5.06	-0.31	8.5e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs72781680	0.821	rs72796361	chr2:24160689	A/T	cg08917208	chr2:24149416	ATAD2B	0.58	5.89	0.36	1.34e-8	Lymphocyte counts;
SARC	cis	rs9858542	0.537	rs2304442	chr3:49322027	A/T	cg07274523	chr3:49395745	GPX1	-0.48	-5.0	-0.31	1.14e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs11578119	0.898	rs6427253	chr1:170433401	C/T	cg09767346	chr1:170501363	GORAB	0.45	5.25	0.33	3.42e-7	Male-pattern baldness;
SARC	cis	rs7727544	0.547	rs56083751	chr5:131664638	T/A	cg24060327	chr5:131705240	SLC22A5	-0.43	-5.17	-0.32	5.15e-7	Blood metabolite levels;
SARC	cis	rs12545912	0.908	rs10097438	chr8:9461692	G/C	cg21625330	chr8:9911636	MSRA	-0.53	-5.06	-0.31	8.69e-7	Multiple myeloma (hyperdiploidy);
SARC	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7904368	0.806	rs7899853	chr10:16857603	A/T	cg23933602	chr10:16859644	RSU1	0.61	6.17	0.37	2.98e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs2273669	0.915	rs6908714	chr6:109294336	T/C	cg01304950	chr6:109416612	SESN1;C6orf182	0.54	4.74	0.3	3.75e-6	Prostate cancer;
SARC	cis	rs9486715	1.000	rs11153085	chr6:97066355	A/T	cg18709589	chr6:96969512	KIAA0776	-0.59	-7.34	-0.43	3.61e-12	Headache;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg18710692	chr13:20437712	ZMYM5	-0.5	-6.39	-0.39	8.89e-10	Chemerin levels;
SARC	cis	rs1008375	0.931	rs7435102	chr4:17571480	C/G	cg02297831	chr4:17616191	MED28	0.46	5.72	0.35	3.33e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg24675658	chr1:53192096	ZYG11B	0.65	9.21	0.52	1.91e-17	Monocyte count;
SARC	trans	rs9650657	0.836	rs3905581	chr8:10603705	G/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.78	-0.41	9.53e-11	Neuroticism;
SARC	cis	rs6546550	0.901	rs10167142	chr2:70062360	T/C	cg02498382	chr2:70120550	SNRNP27	-0.42	-7.16	-0.42	1.07e-11	Prevalent atrial fibrillation;
SARC	cis	rs2279817	0.818	rs11582250	chr1:17994234	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.5	-4.94	-0.31	1.5e-6	Neuroticism;
SARC	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg04944784	chr2:26401820	FAM59B	0.6	7.95	0.46	8.14e-14	Gut microbiome composition (summer);
SARC	cis	rs11608355	0.508	rs11066411	chr12:109804194	A/G	cg05360138	chr12:110035743	NA	0.56	6.25	0.38	1.91e-9	Neuroticism;
SARC	cis	rs7429990	0.930	rs71323371	chr3:47945817	A/T	cg11946769	chr3:48343235	NME6	0.45	5.11	0.32	6.55e-7	Educational attainment (years of education);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg02600875	chr7:8008949	GLCCI1	0.5	6.38	0.39	9.63e-10	Height;
SARC	cis	rs244731	0.959	rs4976677	chr5:176629546	G/A	cg06060754	chr5:176797920	RGS14	-0.43	-5.0	-0.31	1.14e-6	Urate levels in lean individuals;
SARC	cis	rs62064224	0.658	rs62065460	chr17:30715007	A/G	cg18200150	chr17:30822561	MYO1D	0.42	6.81	0.41	8.26e-11	Schizophrenia;
SARC	cis	rs9921222	1.000	rs9921222	chr16:375782	A/G	cg26913058	chr16:419975	MRPL28	0.34	6.26	0.38	1.79e-9	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs72781680	0.898	rs6712175	chr2:24023431	T/G	cg06627628	chr2:24431161	ITSN2	-0.66	-6.27	-0.38	1.69e-9	Lymphocyte counts;
SARC	cis	rs6860806	0.531	rs270612	chr5:131637338	G/A	cg11843238	chr5:131593191	PDLIM4	0.39	4.8	0.3	2.88e-6	Breast cancer;
SARC	trans	rs1493916	1.000	rs4799729	chr18:31393521	C/T	cg27147174	chr7:100797783	AP1S1	0.57	7.39	0.44	2.64e-12	Life satisfaction;
SARC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg14893161	chr1:205819251	PM20D1	0.75	11.61	0.61	6.8e-25	Menarche (age at onset);
SARC	cis	rs2832191	0.716	rs1888439	chr21:30454457	A/G	cg08807101	chr21:30365312	RNF160	0.89	13.34	0.66	1.51e-30	Dental caries;
SARC	cis	rs36051895	0.695	rs11794778	chr9:5023794	G/T	cg02405213	chr9:5042618	JAK2	-0.52	-5.73	-0.35	3.15e-8	Pediatric autoimmune diseases;
SARC	cis	rs9487051	0.933	rs5005289	chr6:109617673	C/G	cg01475377	chr6:109611718	NA	-0.4	-5.66	-0.35	4.54e-8	Reticulocyte fraction of red cells;
SARC	cis	rs3820928	0.874	rs6740108	chr2:227889559	G/T	cg11843606	chr2:227700838	RHBDD1	0.55	6.85	0.41	6.38e-11	Pulmonary function;
SARC	cis	rs9393692	0.627	rs2179517	chr6:26198845	G/C	cg05868516	chr6:26286170	HIST1H4H	0.63	8.19	0.47	1.73e-14	Educational attainment;
SARC	cis	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg24110177	chr3:50126178	RBM5	0.39	4.96	0.31	1.37e-6	Intelligence (multi-trait analysis);
SARC	cis	rs3766606	0.505	rs72633047	chr1:7935440	G/A	cg00042356	chr1:8021962	PARK7	0.64	5.41	0.33	1.57e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg07546262	chr12:54753490	NA	-0.65	-6.51	-0.39	4.46e-10	Lung cancer in ever smokers;
SARC	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2180341	0.920	rs7756880	chr6:127683999	A/T	cg27446573	chr6:127587934	RNF146	1.06	14.76	0.7	2.94e-35	Breast cancer;
SARC	cis	rs9646954	0.791	rs4851300	chr2:100958804	C/A	cg14675211	chr2:100938903	LONRF2	0.54	6.88	0.41	5.35e-11	Intelligence (multi-trait analysis);
SARC	cis	rs1150668	0.796	rs213236	chr6:28324397	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.46	-5.58	-0.34	6.67e-8	Pubertal anthropometrics;
SARC	cis	rs11838776	0.586	rs750598	chr13:111028978	C/T	cg06243866	chr13:111019493	COL4A2	-0.52	-7.41	-0.44	2.37e-12	Coronary artery disease;
SARC	cis	rs11098499	0.863	rs6833334	chr4:120504227	C/T	cg24375607	chr4:120327624	NA	0.42	4.92	0.31	1.64e-6	Corneal astigmatism;
SARC	cis	rs2380220	0.606	rs7747776	chr6:96005852	C/T	cg23517279	chr6:96025343	MANEA	0.55	6.3	0.38	1.48e-9	Behavioural disinhibition (generation interaction);
SARC	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg00933542	chr6:150070202	PCMT1	0.3	5.14	0.32	5.77e-7	Lung cancer;
SARC	cis	rs7666738	0.830	rs13149404	chr4:99070236	A/G	cg05340658	chr4:99064831	C4orf37	0.65	8.71	0.5	5.79e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7027203	0.576	rs4415381	chr9:96554603	A/G	cg14598338	chr9:96623480	NA	0.34	4.76	0.3	3.42e-6	DNA methylation (variation);
SARC	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.42	-5.16	-0.32	5.4e-7	Tonsillectomy;
SARC	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg13628971	chr7:2884303	GNA12	-0.56	-6.61	-0.4	2.56e-10	Height;
SARC	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg24250549	chr1:154909240	PMVK	0.82	11.83	0.61	1.3e-25	Prostate cancer;
SARC	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg06221963	chr1:154839813	KCNN3	-0.52	-8.26	-0.48	1.11e-14	Prostate cancer;
SARC	cis	rs877282	0.583	rs12358255	chr10:828626	C/T	cg15764593	chr10:829463	NA	-0.47	-5.25	-0.33	3.45e-7	Uric acid levels;
SARC	cis	rs950169	0.580	rs36126054	chr15:85177723	T/G	cg17507749	chr15:85114479	UBE2QP1	0.58	6.77	0.41	1.03e-10	Schizophrenia;
SARC	cis	rs7927771	1.000	rs11039412	chr11:47841581	G/A	cg05585544	chr11:47624801	NA	-0.36	-4.82	-0.3	2.59e-6	Subjective well-being;
SARC	cis	rs11608355	0.545	rs56144717	chr12:109902304	T/C	cg05360138	chr12:110035743	NA	0.92	9.65	0.53	9.69e-19	Neuroticism;
SARC	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg09699651	chr6:150184138	LRP11	0.39	4.87	0.3	2.04e-6	Lung cancer;
SARC	cis	rs2011503	1.000	rs77254326	chr19:19626781	T/G	cg15839431	chr19:19639596	YJEFN3	-0.48	-4.77	-0.3	3.32e-6	Bipolar disorder;
SARC	cis	rs6088590	0.687	rs6088582	chr20:33286798	G/A	cg24642439	chr20:33292090	TP53INP2	0.76	10.26	0.56	1.25e-20	Coronary artery disease;
SARC	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg22484793	chr3:52261325	TLR9	-0.29	-4.76	-0.3	3.38e-6	Bipolar disorder;
SARC	cis	rs9486715	0.867	rs9486444	chr6:96963619	A/G	cg06623918	chr6:96969491	KIAA0776	0.88	12.63	0.64	3.28e-28	Headache;
SARC	cis	rs4481887	0.927	rs4244181	chr1:248471118	A/G	cg01631408	chr1:248437212	OR2T33	-0.41	-5.16	-0.32	5.18e-7	Common traits (Other);
SARC	cis	rs1559088	0.948	rs7257858	chr19:33591231	T/C	cg27124370	chr19:33622961	WDR88	0.44	5.86	0.36	1.6e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs453301	0.658	rs9329175	chr8:8866661	C/T	cg15556689	chr8:8085844	FLJ10661	-0.42	-5.16	-0.32	5.26e-7	Joint mobility (Beighton score);
SARC	cis	rs10484885	0.588	rs9344947	chr6:90304789	A/G	cg13799429	chr6:90582589	CASP8AP2	0.54	4.73	0.3	3.83e-6	QRS interval (sulfonylurea treatment interaction);
SARC	cis	rs7786877	0.500	rs2272572	chr7:100285888	C/T	cg03098644	chr7:100410630	EPHB4	0.45	4.88	0.3	1.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9467773	1.000	rs767471	chr6:26557854	C/T	cg12292205	chr6:26970375	C6orf41	0.46	5.51	0.34	9.65e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7666738	0.830	rs11097598	chr4:98946057	T/C	cg05340658	chr4:99064831	C4orf37	0.68	9.39	0.52	5.81e-18	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10752881	1.000	rs10737237	chr1:182989269	A/G	cg13390022	chr1:182993471	LAMC1	0.34	5.23	0.32	3.82e-7	Colorectal cancer;
SARC	cis	rs992157	0.710	rs6719789	chr2:219057810	G/T	cg00012203	chr2:219082015	ARPC2	-0.8	-13.2	-0.65	4.63e-30	Colorectal cancer;
SARC	cis	rs7932354	0.528	rs11039112	chr11:47174296	C/T	cg03339077	chr11:47165057	C11orf49	0.44	5.96	0.36	9.21e-9	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg04772025	chr11:68637568	NA	0.52	6.7	0.4	1.59e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs2204008	0.743	rs11182052	chr12:38450421	T/C	cg13010199	chr12:38710504	ALG10B	0.75	10.19	0.56	2.16e-20	Bladder cancer;
SARC	cis	rs6964587	1.000	rs60147309	chr7:91736098	C/G	cg17063962	chr7:91808500	NA	0.93	15.65	0.72	3.24e-38	Breast cancer;
SARC	cis	rs6752107	0.782	rs12692254	chr2:234161211	A/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.48	6.68	0.4	1.75e-10	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg22920501	chr2:26401640	FAM59B	-0.55	-7.06	-0.42	1.93e-11	Gut microbiome composition (summer);
SARC	cis	rs3087591	0.614	rs3785955	chr17:29647802	C/T	cg24425628	chr17:29625626	OMG;NF1	0.42	5.36	0.33	1.98e-7	Hip circumference;
SARC	cis	rs1943345	0.642	rs642669	chr11:82892454	A/T	cg07047830	chr11:82868014	PCF11	0.64	8.35	0.48	6.09e-15	Obesity-related traits;
SARC	cis	rs2645694	0.626	rs2703122	chr4:77821418	A/C	cg03477792	chr4:77819574	ANKRD56	0.5	7.5	0.44	1.35e-12	Emphysema distribution in smoking;
SARC	cis	rs1865760	0.827	rs9295680	chr6:25944103	T/C	cg16482183	chr6:26056742	HIST1H1C	0.51	6.53	0.39	3.99e-10	Height;
SARC	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg11494091	chr17:61959527	GH2	0.35	4.76	0.3	3.42e-6	Height;
SARC	cis	rs9393692	0.676	rs1543681	chr6:26187783	G/T	cg00631329	chr6:26305371	NA	-0.62	-8.25	-0.48	1.2e-14	Educational attainment;
SARC	cis	rs11190604	1.000	rs2295773	chr10:102265815	A/G	cg07080220	chr10:102295463	HIF1AN	0.78	9.5	0.53	2.76e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs9300255	0.510	rs1790086	chr12:123672518	A/G	cg05973401	chr12:123451056	ABCB9	0.52	5.86	0.36	1.6e-8	Neutrophil percentage of white cells;
SARC	cis	rs6088590	1.000	rs2295353	chr20:33356511	C/T	cg24642439	chr20:33292090	TP53INP2	0.88	12.29	0.63	4.16e-27	Coronary artery disease;
SARC	cis	rs8180040	0.800	rs2088135	chr3:47280018	T/C	cg27129171	chr3:47204927	SETD2	-0.73	-9.54	-0.53	1.96e-18	Colorectal cancer;
SARC	cis	rs13314892	0.692	rs62252228	chr3:69886816	G/A	cg17445875	chr3:69859618	MITF	-0.5	-5.24	-0.32	3.6e-7	QRS complex (12-leadsum);
SARC	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg19729930	chr2:74357872	NA	0.74	10.67	0.57	6.6e-22	Gestational age at birth (maternal effect);
SARC	cis	rs920590	0.560	rs10090638	chr8:19673750	T/G	cg03894339	chr8:19674705	INTS10	-0.43	-5.03	-0.31	9.76e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs11997175	0.597	rs4472473	chr8:33610255	A/G	ch.8.33884649F	chr8:33765107	NA	0.51	6.56	0.39	3.52e-10	Body mass index;
SARC	cis	rs35110281	0.626	rs162389	chr21:44936227	T/C	cg21573476	chr21:45109991	RRP1B	-0.45	-6.67	-0.4	1.79e-10	Mean corpuscular volume;
SARC	cis	rs28669119	0.778	rs159950	chr5:88116319	C/T	cg18498987	chr5:88179539	MEF2C	0.52	5.28	0.33	2.93e-7	Schizophrenia;
SARC	cis	rs9790314	0.521	rs13084746	chr3:161086038	G/A	cg03342759	chr3:160939853	NMD3	-0.57	-7.11	-0.42	1.45e-11	Morning vs. evening chronotype;
SARC	cis	rs2276314	1.000	rs2298716	chr18:33552598	C/T	cg05985134	chr18:33552581	C18orf21	0.74	7.88	0.46	1.22e-13	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs2594989	0.887	rs2442799	chr3:11488640	A/G	cg00170343	chr3:11313890	ATG7	0.53	4.88	0.3	2e-6	Circulating chemerin levels;
SARC	cis	rs7103648	0.553	rs12803857	chr11:47890172	G/A	cg10504702	chr11:47789108	FNBP4	0.71	8.4	0.48	4.54e-15	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg08045932	chr20:61659980	NA	0.5	6.84	0.41	7.06e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg22800045	chr5:56110881	MAP3K1	0.47	5.3	0.33	2.72e-7	Coronary artery disease;
SARC	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg22484793	chr3:52261325	TLR9	0.29	4.75	0.3	3.63e-6	Bipolar disorder;
SARC	cis	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg07636037	chr3:49044803	WDR6	0.46	5.29	0.33	2.78e-7	Resting heart rate;
SARC	cis	rs7208859	0.725	rs9897673	chr17:29243366	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	7.01	0.42	2.48e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs1153858	1.000	rs1980288	chr15:45620612	T/C	cg21132104	chr15:45694354	SPATA5L1	0.79	10.98	0.58	7.12e-23	Homoarginine levels;
SARC	cis	rs9790314	0.663	rs6804650	chr3:160648953	A/G	cg04691961	chr3:161091175	C3orf57	-0.58	-7.99	-0.46	6.23e-14	Morning vs. evening chronotype;
SARC	cis	rs10140922	0.966	rs28589517	chr14:35820643	G/A	cg26967526	chr14:35346199	BAZ1A	-0.39	-4.81	-0.3	2.74e-6	Hip circumference adjusted for BMI;
SARC	cis	rs9325144	0.555	rs7977200	chr12:38713745	C/T	cg04568710	chr12:38710424	ALG10B	0.39	4.93	0.31	1.58e-6	Morning vs. evening chronotype;
SARC	cis	rs2963155	0.518	rs862489	chr5:142634355	T/C	cg17617527	chr5:142782415	NR3C1	0.81	5.67	0.35	4.31e-8	Breast cancer;
SARC	trans	rs925098	0.556	rs2724473	chr4:17977352	T/C	cg08521178	chr6:170491202	NA	0.42	6.5	0.39	4.77e-10	Birth weight;Height;
SARC	cis	rs735396	0.770	rs2257764	chr12:121446446	T/A	cg02403541	chr12:121454288	C12orf43	-0.84	-12.51	-0.63	8.09e-28	N-glycan levels;
SARC	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	8.51	0.49	2.07e-15	Alzheimer's disease;
SARC	cis	rs7726839	0.540	rs74553517	chr5:665671	C/T	cg07777115	chr5:623756	CEP72	-0.57	-4.86	-0.3	2.2e-6	Obesity-related traits;
SARC	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg12463550	chr7:65579703	CRCP	-0.71	-5.37	-0.33	1.9e-7	Diabetic kidney disease;
SARC	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg18252515	chr7:66147081	NA	0.47	4.98	0.31	1.22e-6	Aortic root size;
SARC	cis	rs9814567	1.000	rs9869981	chr3:134248801	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.1	-0.42	1.49e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs4423214	1.000	rs12422045	chr11:71154820	C/T	cg24826892	chr11:71159390	DHCR7	0.48	5.81	0.36	1.99e-8	Vitamin D levels;
SARC	cis	rs11785400	0.793	rs4336593	chr8:143739647	A/C	cg24634471	chr8:143751801	JRK	-0.59	-7.4	-0.44	2.53e-12	Schizophrenia;
SARC	cis	rs9840812	0.953	rs4678322	chr3:135812523	G/T	cg15507776	chr3:136538369	TMEM22	-0.47	-4.91	-0.31	1.72e-6	Fibrinogen levels;
SARC	cis	rs4319547	1.000	rs10998	chr12:122989412	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.65	-7.6	-0.45	7.06e-13	Body mass index;
SARC	cis	rs12594515	1.000	rs12592190	chr15:45994028	G/A	cg14863074	chr15:45997064	NA	0.34	5.18	0.32	4.84e-7	Waist circumference;Weight;
SARC	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg24675658	chr1:53192096	ZYG11B	-0.65	-9.47	-0.53	3.2e-18	Monocyte count;
SARC	cis	rs35849525	0.776	rs7615318	chr3:49987475	C/T	cg14019146	chr3:50243930	SLC38A3	-0.37	-5.34	-0.33	2.2e-7	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg02725872	chr8:58115012	NA	-0.37	-6.55	-0.39	3.71e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2985684	0.802	rs8015368	chr14:50020510	G/A	cg04989706	chr14:50066350	PPIL5	-0.51	-5.72	-0.35	3.29e-8	Carotid intima media thickness;
SARC	cis	rs637571	0.522	rs556643	chr11:65733289	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.59	9.62	0.53	1.16e-18	Eosinophil percentage of white cells;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg23858565	chr16:67595703	CTCF	0.49	6.51	0.39	4.6e-10	Lung adenocarcinoma;
SARC	cis	rs6701037	0.512	rs4650716	chr1:175128711	C/A	cg00321850	chr1:175162397	KIAA0040	0.37	5.82	0.36	1.94e-8	Alcohol dependence;
SARC	cis	rs11608355	0.521	rs6606703	chr12:109813665	C/T	cg19025524	chr12:109796872	NA	-0.42	-6.22	-0.38	2.29e-9	Neuroticism;
SARC	cis	rs2011503	1.000	rs111406321	chr19:19637437	G/A	cg03709012	chr19:19516395	GATAD2A	0.6	5.29	0.33	2.8e-7	Bipolar disorder;
SARC	cis	rs12142240	0.698	rs12385696	chr1:46818836	A/G	cg14993813	chr1:46806288	NSUN4	-0.51	-5.39	-0.33	1.75e-7	Menopause (age at onset);
SARC	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.7	6.55	0.39	3.61e-10	Platelet count;
SARC	cis	rs10779751	0.610	rs2486921	chr1:11124943	G/A	cg08854313	chr1:11322531	MTOR	0.82	11.26	0.59	8.86e-24	Body mass index;
SARC	cis	rs41278232	0.557	rs817349	chr20:62609766	C/T	cg07620230	chr20:62328084	TNFRSF6B	0.34	4.81	0.3	2.73e-6	Tonsillectomy;
SARC	cis	rs7523050	0.730	rs34182354	chr1:109416340	C/T	cg08274380	chr1:109419600	GPSM2	1.07	8.17	0.47	1.92e-14	Fat distribution (HIV);
SARC	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.41	-6.25	-0.38	1.93e-9	Total body bone mineral density;
SARC	cis	rs2228479	0.850	rs62056069	chr16:89912000	C/T	cg12064134	chr16:90016061	DEF8	-0.56	-4.83	-0.3	2.47e-6	Skin colour saturation;
SARC	cis	rs12701220	0.894	rs2141274	chr7:1034717	G/A	cg26769984	chr7:1090371	C7orf50	0.47	4.85	0.3	2.21e-6	Bronchopulmonary dysplasia;
SARC	cis	rs9788721	0.967	rs72740955	chr15:78849779	C/T	cg18825076	chr15:78729989	IREB2	-0.49	-5.89	-0.36	1.32e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg12920882	chr2:69664317	NFU1	0.51	6.51	0.39	4.6e-10	Lung adenocarcinoma;
SARC	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg23758822	chr17:41437982	NA	0.85	10.41	0.56	4.4e-21	Menopause (age at onset);
SARC	cis	rs67460515	0.892	rs35100811	chr3:161084046	A/C	cg17135325	chr3:160939158	NMD3	0.6	7.5	0.44	1.34e-12	Parkinson's disease;
SARC	cis	rs7000551	0.556	rs35359294	chr8:22249755	G/A	cg12081754	chr8:22256438	SLC39A14	0.87	11.86	0.61	1.04e-25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg05623727	chr3:50126028	RBM5	-0.33	-5.04	-0.31	9.3e-7	Intelligence (multi-trait analysis);
SARC	cis	rs3768617	0.510	rs10797846	chr1:183087485	A/T	cg13390022	chr1:182993471	LAMC1	0.32	4.83	0.3	2.44e-6	Fuchs's corneal dystrophy;
SARC	cis	rs7044106	0.762	rs1547267	chr9:123408736	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	8.61	0.49	1.09e-15	Hip circumference adjusted for BMI;
SARC	cis	rs10927875	0.596	rs1806990	chr1:16129377	G/A	cg21385522	chr1:16154831	NA	-0.92	-13.17	-0.65	5.55e-30	Dilated cardiomyopathy;
SARC	cis	rs4911259	0.552	rs6058926	chr20:31465450	T/C	cg13636640	chr20:31349939	DNMT3B	-0.69	-9.6	-0.53	1.34e-18	Inflammatory bowel disease;
SARC	cis	rs9393777	0.528	rs35982103	chr6:27243134	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.36	-4.72	-0.3	4.03e-6	Intelligence (multi-trait analysis);
SARC	cis	rs4808199	0.948	rs2023883	chr19:19405480	G/A	cg03709012	chr19:19516395	GATAD2A	1.1	10.47	0.57	2.8e-21	Nonalcoholic fatty liver disease;
SARC	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	7.79	0.45	2.15e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs17376456	0.877	rs12716456	chr5:93397557	A/G	cg25358565	chr5:93447407	FAM172A	1.3	14.78	0.7	2.47e-35	Diabetic retinopathy;
SARC	trans	rs2727020	0.521	rs2088526	chr11:49531968	G/A	cg03929089	chr4:120376271	NA	0.7	7.95	0.46	7.79e-14	Coronary artery disease;
SARC	cis	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg06636001	chr8:8085503	FLJ10661	0.65	8.73	0.5	4.92e-16	Mood instability;
SARC	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg07636037	chr3:49044803	WDR6	0.99	17.31	0.75	1.02e-43	Parkinson's disease;
SARC	cis	rs2075671	0.903	rs4727459	chr7:100276821	T/C	cg16850897	chr7:100343110	ZAN	-0.62	-6.51	-0.39	4.63e-10	Other erythrocyte phenotypes;
SARC	cis	rs950776	0.518	rs12906846	chr15:78825295	G/A	cg22563815	chr15:78856949	CHRNA5	0.41	6.82	0.41	7.56e-11	Sudden cardiac arrest;
SARC	cis	rs73086581	0.568	rs6084541	chr20:3962731	G/A	cg02187196	chr20:3869020	PANK2	-0.44	-5.19	-0.32	4.66e-7	Response to antidepressants in depression;
SARC	cis	rs929596	0.785	rs11695484	chr2:234654449	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.35	-4.93	-0.31	1.55e-6	Total bilirubin levels in HIV-1 infection;
SARC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg21747090	chr2:27597821	SNX17	-0.55	-7.75	-0.45	2.9e-13	Total body bone mineral density;
SARC	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	5.51	0.34	9.65e-8	Personality dimensions;
SARC	cis	rs113835537	0.529	rs2279864	chr11:66247844	G/A	cg24851651	chr11:66362959	CCS	0.38	4.79	0.3	2.98e-6	Airway imaging phenotypes;
SARC	cis	rs7236492	0.572	rs7237333	chr18:77178511	G/A	cg15644404	chr18:77186268	NFATC1	-0.64	-5.06	-0.31	8.55e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs713477	0.967	rs6573029	chr14:55913550	A/C	cg13175173	chr14:55914753	NA	-0.31	-4.74	-0.3	3.7e-6	Pediatric bone mineral content (femoral neck);
SARC	cis	rs9902453	0.904	rs9900112	chr17:28282910	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	6.85	0.41	6.43e-11	Coffee consumption (cups per day);
SARC	cis	rs36051895	0.558	rs7038687	chr9:5134065	C/T	cg02405213	chr9:5042618	JAK2	0.46	5.51	0.34	9.65e-8	Pediatric autoimmune diseases;
SARC	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg24642844	chr7:1081250	C7orf50	-0.49	-5.25	-0.33	3.42e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs8141529	0.551	rs34578331	chr22:29347215	G/T	cg02153584	chr22:29168773	CCDC117	0.66	6.77	0.41	1.05e-10	Lymphocyte counts;
SARC	cis	rs2197308	0.765	rs117216293	chr12:37882982	T/C	cg26384229	chr12:38710491	ALG10B	-0.79	-11.38	-0.6	3.64e-24	Morning vs. evening chronotype;
SARC	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg04277193	chr17:41438351	NA	0.44	4.73	0.3	3.83e-6	Menopause (age at onset);
SARC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg14893161	chr1:205819251	PM20D1	0.63	8.37	0.48	5.34e-15	Menarche (age at onset);
SARC	cis	rs7103648	0.643	rs12365079	chr11:47696596	A/T	cg20307385	chr11:47447363	PSMC3	0.76	10.51	0.57	2.16e-21	Diastolic blood pressure;Systolic blood pressure;
SARC	trans	rs61931739	0.591	rs1608907	chr12:33945435	A/G	cg13010199	chr12:38710504	ALG10B	0.5	6.27	0.38	1.72e-9	Morning vs. evening chronotype;
SARC	cis	rs10174077	0.874	rs6750342	chr2:152485754	A/G	cg19508488	chr2:152266495	RIF1	0.49	5.64	0.35	4.84e-8	Squamous cell lung carcinoma;
SARC	cis	rs8114671	0.836	rs2104083	chr20:33649133	G/A	cg08999081	chr20:33150536	PIGU	-0.34	-4.86	-0.3	2.15e-6	Height;
SARC	cis	rs6450176	1.000	rs60652351	chr5:53306140	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.68	-7.87	-0.46	1.29e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	10.47	0.57	2.77e-21	Platelet count;
SARC	cis	rs939574	0.929	rs10190834	chr2:220070301	T/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.53	-4.87	-0.3	2.03e-6	Platelet distribution width;
SARC	cis	rs763121	0.853	rs6519119	chr22:38989007	C/G	cg21395723	chr22:39101663	GTPBP1	0.56	6.33	0.38	1.26e-9	Menopause (age at onset);
SARC	cis	rs523522	0.962	rs4767905	chr12:120930835	C/T	cg27279351	chr12:120934652	DYNLL1	0.72	8.91	0.5	1.5e-16	High light scatter reticulocyte count;
SARC	cis	rs1062177	0.774	rs2964574	chr5:151155711	G/A	cg00977110	chr5:151150581	G3BP1	0.64	6.55	0.39	3.66e-10	Preschool internalizing problems;
SARC	trans	rs877282	0.898	rs11253349	chr10:765897	C/G	cg22713356	chr15:30763199	NA	1.04	10.06	0.55	5.37e-20	Uric acid levels;
SARC	cis	rs7223966	1.000	rs8066719	chr17:61825764	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.53	-5.54	-0.34	8.29e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7843479	0.601	rs12056476	chr8:21854188	T/A	cg17168535	chr8:21777572	XPO7	0.84	12.75	0.64	1.39e-28	Mean corpuscular volume;
SARC	cis	rs838147	0.505	rs1688264	chr19:49209560	T/G	cg07051648	chr19:49177693	NTN5;SEC1	-0.4	-5.19	-0.32	4.68e-7	Dietary macronutrient intake;
SARC	cis	rs2760061	0.545	rs1745423	chr1:228224153	G/T	cg02753203	chr1:228287806	NA	-0.61	-8.24	-0.47	1.26e-14	Diastolic blood pressure;
SARC	cis	rs5769765	0.657	rs8136116	chr22:50256886	T/A	cg03033257	chr22:50311977	ALG12;CRELD2	-0.54	-4.72	-0.3	4.08e-6	Schizophrenia;
SARC	cis	rs9397240	0.841	rs950995	chr6:155621052	T/C	cg07943832	chr6:155568918	TIAM2	-0.57	-5.54	-0.34	8.11e-8	Life satisfaction;
SARC	cis	rs36051895	0.632	rs7038813	chr9:5177685	A/G	cg02405213	chr9:5042618	JAK2	-0.44	-5.28	-0.33	2.98e-7	Pediatric autoimmune diseases;
SARC	cis	rs67311347	1.000	rs28536038	chr3:40496382	A/C	cg24209194	chr3:40518798	ZNF619	0.66	8.04	0.47	4.42e-14	Renal cell carcinoma;
SARC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg11203670	chr7:100026453	MEPCE;ZCWPW1	0.52	4.88	0.3	1.95e-6	Platelet count;
SARC	cis	rs1059312	1.000	rs7135987	chr12:129280117	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.48	-5.86	-0.36	1.56e-8	Systemic lupus erythematosus;
SARC	cis	rs6087990	0.899	rs1333469	chr20:31361249	C/T	cg13636640	chr20:31349939	DNMT3B	0.8	12.66	0.64	2.7e-28	Ulcerative colitis;
SARC	cis	rs739401	0.527	rs423236	chr11:3065916	C/T	cg20651018	chr11:3035856	CARS	-0.45	-7.12	-0.42	1.31e-11	Longevity;
SARC	cis	rs11809207	0.501	rs3762460	chr1:26495550	A/G	cg00300879	chr1:26503847	CNKSR1	0.33	4.95	0.31	1.43e-6	Height;
SARC	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg10207240	chr12:122356781	WDR66	0.3	5.03	0.31	9.7e-7	Mean corpuscular volume;
SARC	cis	rs72781680	1.000	rs72796359	chr2:24160545	T/C	cg06627628	chr2:24431161	ITSN2	-0.75	-6.81	-0.41	7.99e-11	Lymphocyte counts;
SARC	cis	rs6964587	0.967	rs10429103	chr7:91598443	T/A	cg17063962	chr7:91808500	NA	0.93	15.52	0.71	8.63e-38	Breast cancer;
SARC	cis	rs9381040	0.655	rs2268190	chr6:41030226	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.42	-4.9	-0.31	1.76e-6	Alzheimer's disease (late onset);
SARC	cis	rs73206853	0.764	rs56205958	chr12:111027361	G/C	cg10860002	chr12:110842031	ANAPC7	0.59	5.09	0.32	7.42e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs12709013	0.636	rs1369934	chr16:58788028	C/T	cg04273148	chr16:57808038	KIFC3	0.32	4.72	0.3	4.08e-6	Blood metabolite ratios;
SARC	cis	rs2228479	1.000	rs4257207	chr16:89947861	T/A	cg06558623	chr16:89946397	TCF25	0.89	6.28	0.38	1.67e-9	Skin colour saturation;
SARC	cis	rs4295623	0.585	rs34421088	chr8:11589042	A/G	cg00262122	chr8:11665843	FDFT1	-0.43	-5.19	-0.32	4.49e-7	Morning vs. evening chronotype;
SARC	cis	rs6866344	0.697	rs11742808	chr5:178131658	G/A	cg10224037	chr5:178157518	ZNF354A	1.01	12.71	0.64	1.83e-28	Neutrophil percentage of white cells;
SARC	trans	rs11098499	0.955	rs35916640	chr4:120155852	T/C	cg25214090	chr10:38739885	LOC399744	0.54	6.95	0.41	3.66e-11	Corneal astigmatism;
SARC	cis	rs7819412	0.838	rs3021494	chr8:10983534	A/G	cg21775007	chr8:11205619	TDH	-0.46	-5.54	-0.34	8.08e-8	Triglycerides;
SARC	cis	rs7223966	1.000	rs8081541	chr17:61812483	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.53	-5.55	-0.34	7.66e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg26162836	chr1:160232429	DCAF8	-0.62	-7.1	-0.42	1.53e-11	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs875971	0.793	rs460678	chr7:65527200	C/G	cg11764359	chr7:65958608	NA	0.79	10.76	0.58	3.44e-22	Aortic root size;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg17596921	chr2:101179170	PDCL3	-0.54	-6.88	-0.41	5.51e-11	Schizophrenia;
SARC	cis	rs4969178	0.965	rs12450528	chr17:76395753	G/A	cg20026190	chr17:76395443	PGS1	0.4	5.37	0.33	1.94e-7	HDL cholesterol levels;
SARC	cis	rs66573146	0.808	rs73202120	chr4:7005588	A/G	cg15105060	chr4:7024189	TBC1D14	-0.63	-4.82	-0.3	2.63e-6	Granulocyte percentage of myeloid white cells;
SARC	trans	rs36093844	0.898	rs11512932	chr11:85591130	T/G	cg27065003	chr5:122429449	PRDM6	-0.49	-6.24	-0.38	2.06e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg08219700	chr8:58056026	NA	0.61	6.36	0.38	1.05e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6582630	0.615	rs3914894	chr12:38480280	C/T	cg13010199	chr12:38710504	ALG10B	-0.46	-5.68	-0.35	4e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2050392	0.760	rs10826797	chr10:30690376	A/C	cg25182066	chr10:30743637	MAP3K8	0.42	5.79	0.35	2.25e-8	Inflammatory bowel disease;
SARC	cis	rs9479482	0.648	rs912558	chr6:150385730	G/T	cg03788504	chr6:150331562	NA	0.3	4.8	0.3	2.9e-6	Alopecia areata;
SARC	cis	rs11190604	0.945	rs2495735	chr10:102338609	G/A	cg07080220	chr10:102295463	HIF1AN	0.78	10.08	0.55	4.56e-20	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg06212747	chr3:49208901	KLHDC8B	0.57	5.7	0.35	3.6e-8	Menarche (age at onset);
SARC	cis	rs7044106	0.762	rs966397	chr9:123453312	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	8.99	0.51	9.01e-17	Hip circumference adjusted for BMI;
SARC	cis	rs6450176	0.564	rs390420	chr5:53326731	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.55	-6.23	-0.38	2.11e-9	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs9355610	0.609	rs3756838	chr6:167371251	G/A	cg23791538	chr6:167370224	RNASET2	0.54	6.15	0.37	3.29e-9	Graves' disease;
SARC	cis	rs2463822	0.925	rs6863	chr11:62160725	G/T	cg06239285	chr11:62104954	ASRGL1	-0.8	-7.71	-0.45	3.54e-13	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.78	-0.5	3.56e-16	Alzheimer's disease;
SARC	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg20120463	chr17:44301886	NA	-0.3	-4.77	-0.3	3.29e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg08280861	chr8:58055591	NA	0.57	5.1	0.32	6.94e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg17971929	chr21:40555470	PSMG1	-0.59	-7.32	-0.43	3.96e-12	Menarche (age at onset);
SARC	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg08280861	chr8:58055591	NA	0.61	5.81	0.36	2.02e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg17330251	chr7:94953956	PON1	-0.38	-5.16	-0.32	5.35e-7	Paraoxonase activity;
SARC	cis	rs6815814	0.950	rs55903115	chr4:38786474	C/A	cg02016764	chr4:38805732	TLR1	-0.42	-4.98	-0.31	1.23e-6	Breast cancer;
SARC	cis	rs2120019	1.000	rs12903201	chr15:75370776	A/C	cg17294928	chr15:75287854	SCAMP5	-0.9	-13.28	-0.66	2.39e-30	Blood trace element (Zn levels);
SARC	cis	rs9905704	0.647	rs11650809	chr17:56972741	A/G	cg12560992	chr17:57184187	TRIM37	0.4	4.79	0.3	2.97e-6	Testicular germ cell tumor;
SARC	trans	rs1814175	0.645	rs1608632	chr11:49967148	C/T	cg15704280	chr7:45808275	SEPT13	-0.88	-14.06	-0.68	6.36e-33	Height;
SARC	cis	rs6088580	0.634	rs7271970	chr20:32987666	A/G	cg24642439	chr20:33292090	TP53INP2	-0.66	-8.63	-0.49	9.96e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg02931644	chr1:25747376	RHCE	0.43	6.98	0.42	3.11e-11	Erythrocyte sedimentation rate;
SARC	cis	rs9462027	0.628	rs2395598	chr6:34640686	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-6.02	-0.37	6.85e-9	Systemic lupus erythematosus;
SARC	cis	rs9393692	0.905	rs7769028	chr6:26267568	C/T	cg05868516	chr6:26286170	HIST1H4H	0.58	7.68	0.45	4.46e-13	Educational attainment;
SARC	cis	rs4555082	0.750	rs2816650	chr14:105708343	C/T	cg13114125	chr14:105738426	BRF1	-0.8	-11.82	-0.61	1.47e-25	Mean platelet volume;Platelet distribution width;
SARC	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg24829409	chr8:58192753	C8orf71	-0.62	-5.91	-0.36	1.2e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs61931739	0.534	rs11053014	chr12:34103519	G/A	cg13010199	chr12:38710504	ALG10B	0.77	10.37	0.56	5.83e-21	Morning vs. evening chronotype;
SARC	cis	rs7084402	0.967	rs1593677	chr10:60291642	A/T	cg07615347	chr10:60278583	BICC1	0.61	8.99	0.51	8.84e-17	Refractive error;
SARC	trans	rs459571	0.876	rs2520095	chr9:136919568	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.63	-7.3	-0.43	4.5e-12	Platelet distribution width;
SARC	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg11987759	chr7:65425863	GUSB	0.57	7.56	0.44	9.44e-13	Aortic root size;
SARC	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg18876405	chr7:65276391	NA	-0.74	-9.42	-0.53	4.63e-18	Aortic root size;
SARC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg11905131	chr22:24372483	LOC391322	0.46	5.32	0.33	2.44e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6991838	0.584	rs10089708	chr8:66555162	T/C	cg13398993	chr8:66546079	ARMC1	0.61	7.85	0.46	1.55e-13	Intelligence (multi-trait analysis);
SARC	cis	rs67311347	0.956	rs13066971	chr3:40462510	A/T	cg01475735	chr3:40494733	NA	0.42	4.91	0.31	1.71e-6	Renal cell carcinoma;
SARC	cis	rs3120667	0.790	rs726863	chr1:152400361	A/G	cg26876637	chr1:152193138	HRNR	0.49	4.92	0.31	1.63e-6	Eating disorders;
SARC	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	7.63	0.45	5.85e-13	Alzheimer's disease;
SARC	cis	rs12893668	0.572	rs4900591	chr14:104154878	G/A	cg26031613	chr14:104095156	KLC1	-0.52	-5.76	-0.35	2.59e-8	Reticulocyte count;
SARC	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg00149659	chr3:10157352	C3orf10	0.71	6.68	0.4	1.77e-10	Alzheimer's disease;
SARC	cis	rs10870270	1.000	rs10870270	chr10:133754334	G/A	cg26149184	chr10:133730230	NA	0.45	5.06	0.31	8.52e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs6964587	1.000	rs10225885	chr7:91671007	A/G	cg17063962	chr7:91808500	NA	0.94	15.69	0.72	2.46e-38	Breast cancer;
SARC	cis	rs782590	0.902	rs2586947	chr2:55854009	C/G	cg18811423	chr2:55921094	PNPT1	0.69	10.53	0.57	1.81e-21	Metabolic syndrome;
SARC	cis	rs6545883	0.894	rs1186703	chr2:61672965	A/C	cg15711740	chr2:61764176	XPO1	-0.42	-5.05	-0.31	9.09e-7	Tuberculosis;
SARC	cis	rs7568458	0.663	rs699664	chr2:85780536	A/G	cg23752985	chr2:85803571	VAMP8	-0.36	-4.76	-0.3	3.38e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs35306767	0.903	rs10904577	chr10:922077	A/G	cg26597838	chr10:835615	NA	0.83	8.39	0.48	4.83e-15	Eosinophil percentage of granulocytes;
SARC	trans	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg00938859	chr5:1591904	SDHAP3	0.79	7.66	0.45	5.1e-13	Breast cancer;
SARC	cis	rs4891159	0.790	rs7234653	chr18:74111988	C/T	cg24786174	chr18:74118243	ZNF516	-0.67	-9.78	-0.54	3.87e-19	Longevity;
SARC	cis	rs6450176	0.951	rs255757	chr5:53309371	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.65	-7.26	-0.43	5.57e-12	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs6991838	0.557	rs7012578	chr8:66504827	A/C	cg13398993	chr8:66546079	ARMC1	-0.62	-8.36	-0.48	5.86e-15	Intelligence (multi-trait analysis);
SARC	cis	rs116095464	1.000	rs56700778	chr5:313186	A/T	cg22857025	chr5:266934	NA	-1.07	-6.96	-0.41	3.53e-11	Breast cancer;
SARC	cis	rs11098499	0.863	rs12498539	chr4:120468370	C/T	cg24375607	chr4:120327624	NA	0.42	4.92	0.31	1.64e-6	Corneal astigmatism;
SARC	cis	rs7615952	0.673	rs35955861	chr3:125626201	T/C	cg05084668	chr3:125655381	ALG1L	-0.89	-8.26	-0.48	1.09e-14	Blood pressure (smoking interaction);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg20757019	chr2:95873242	NA	0.5	6.92	0.41	4.34e-11	Thyroid stimulating hormone;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg09735598	chr1:183603895	ARPC5;RGL1	-0.47	-6.36	-0.38	1.03e-9	Thyroid stimulating hormone;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg22561380	chr8:42829775	HOOK3	0.51	6.35	0.38	1.12e-9	Schizophrenia;
SARC	cis	rs9868809	0.505	rs9811027	chr3:48725014	G/C	cg03060546	chr3:49711283	APEH	-0.52	-4.9	-0.31	1.79e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.67	-8.35	-0.48	5.95e-15	Prudent dietary pattern;
SARC	cis	rs9814567	1.000	rs1138273	chr3:134261437	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.08	-0.42	1.73e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs1976403	0.659	rs10799701	chr1:21820990	A/G	cg00786952	chr1:21763130	NA	0.36	6.06	0.37	5.36e-9	Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs7937682	0.889	rs541198	chr11:111475340	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.88	-13.98	-0.68	1.14e-32	Primary sclerosing cholangitis;
SARC	cis	rs7582180	0.764	rs11683121	chr2:100920705	C/T	cg14675211	chr2:100938903	LONRF2	0.53	7.89	0.46	1.14e-13	Intelligence (multi-trait analysis);
SARC	cis	rs2273669	0.915	rs6929070	chr6:109294322	G/T	cg01304950	chr6:109416612	SESN1;C6orf182	0.54	4.81	0.3	2.77e-6	Prostate cancer;
SARC	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.63	-7.53	-0.44	1.1e-12	Gut microbiome composition (summer);
SARC	cis	rs17253792	0.822	rs17253723	chr14:56154015	A/G	cg01858014	chr14:56050164	KTN1	-0.63	-4.8	-0.3	2.9e-6	Putamen volume;
SARC	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg03709012	chr19:19516395	GATAD2A	0.97	15.48	0.71	1.19e-37	Tonsillectomy;
SARC	cis	rs801193	0.591	rs9986881	chr7:66173040	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.46	5.19	0.32	4.53e-7	Aortic root size;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg16364152	chr20:5591818	RP5-1022P6.2	0.51	6.77	0.41	1.03e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs344364	0.511	rs1742472	chr16:1953040	A/G	cg26617929	chr16:1858877	NA	-0.65	-5.21	-0.32	4.24e-7	Glomerular filtration rate in chronic kidney disease;
SARC	cis	rs8523	0.804	rs6900220	chr6:11065138	T/C	cg13562911	chr6:11044106	ELOVL2	0.44	6.04	0.37	6e-9	Red blood cell fatty acid levels;
SARC	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-8.84	-0.5	2.38e-16	Alzheimer's disease;
SARC	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	8.5	0.49	2.28e-15	Mean platelet volume;
SARC	cis	rs6991838	0.673	rs7462352	chr8:66496613	G/A	cg13398993	chr8:66546079	ARMC1	0.47	6.2	0.38	2.61e-9	Intelligence (multi-trait analysis);
SARC	cis	rs76419734	1.000	rs11731714	chr4:106675946	A/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.76	5.11	0.32	6.56e-7	Post bronchodilator FEV1;
SARC	cis	rs2120019	0.938	rs3850093	chr15:75318482	A/G	cg17294928	chr15:75287854	SCAMP5	1.0	13.25	0.66	3.03e-30	Blood trace element (Zn levels);
SARC	cis	rs17021463	0.872	rs11097417	chr4:95268071	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.37	-5.34	-0.33	2.2e-7	Testicular germ cell tumor;
SARC	cis	rs9902453	1.000	rs9891871	chr17:28370191	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.53	-6.96	-0.41	3.47e-11	Coffee consumption (cups per day);
SARC	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg11764359	chr7:65958608	NA	0.88	12.58	0.64	4.89e-28	Aortic root size;
SARC	cis	rs9660992	0.539	rs113699533	chr1:205122895	G/A	cg07972983	chr1:205091412	RBBP5	0.56	7.34	0.43	3.54e-12	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs1003719	0.788	rs2251161	chr21:38467857	C/G	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.89	0.5	1.73e-16	Eye color traits;
SARC	cis	rs6964587	0.597	rs975707	chr7:91874527	C/G	cg17063962	chr7:91808500	NA	0.79	11.42	0.6	2.79e-24	Breast cancer;
SARC	cis	rs539096	0.501	rs713191	chr1:44314553	A/G	cg13606994	chr1:44402422	ARTN	-0.29	-4.77	-0.3	3.3e-6	Intelligence (multi-trait analysis);
SARC	cis	rs4711350	0.734	rs9380379	chr6:33766131	A/G	cg18005901	chr6:33739558	LEMD2	-0.39	-4.72	-0.3	4.12e-6	Schizophrenia;
SARC	cis	rs1707322	0.927	rs11211194	chr1:46282084	C/T	cg03146154	chr1:46216737	IPP	0.47	5.62	0.35	5.38e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs644799	0.544	rs1150360	chr11:95512060	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.72	9.76	0.54	4.28e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs751728	0.687	rs943479	chr6:33752013	A/G	cg25922239	chr6:33757077	LEMD2	0.58	7.64	0.45	5.71e-13	Crohn's disease;
SARC	cis	rs9790314	0.690	rs9860738	chr3:160843290	G/A	cg03342759	chr3:160939853	NMD3	-0.57	-7.22	-0.43	7.36e-12	Morning vs. evening chronotype;
SARC	cis	rs7552404	0.731	rs11588578	chr1:76400539	T/G	cg03433033	chr1:76189801	ACADM	0.47	5.65	0.35	4.66e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7223966	1.000	rs6504170	chr17:61709168	C/T	cg00588841	chr17:61851480	DDX42;CCDC47	-0.6	-6.65	-0.4	2.03e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2251381	0.778	rs722013	chr21:30549245	G/T	cg24692254	chr21:30365293	RNF160	0.84	12.34	0.63	2.96e-27	Selective IgA deficiency;
SARC	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	13.88	0.67	2.44e-32	Chronic sinus infection;
SARC	cis	rs524281	0.773	rs7925123	chr11:65993213	G/C	cg14036092	chr11:66035641	RAB1B	-0.59	-6.22	-0.38	2.26e-9	Electroencephalogram traits;
SARC	cis	rs9916302	0.904	rs10221223	chr17:37489100	T/G	cg20243544	chr17:37824526	PNMT	-0.56	-6.92	-0.41	4.39e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs41271473	1.000	rs41271473	chr1:228880296	G/A	cg10167378	chr1:228756711	NA	0.48	4.92	0.31	1.63e-6	Chronic lymphocytic leukemia;
SARC	cis	rs73206853	0.841	rs17187412	chr12:110766767	C/T	cg10860002	chr12:110842031	ANAPC7	-0.58	-4.74	-0.3	3.7e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs9650315	0.706	rs36112366	chr8:57138676	T/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.65	4.94	0.31	1.46e-6	Height;
SARC	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg03433033	chr1:76189801	ACADM	0.53	7.72	0.45	3.49e-13	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2011503	0.825	rs4808932	chr19:19358819	C/T	cg03709012	chr19:19516395	GATAD2A	0.6	5.5	0.34	1.02e-7	Bipolar disorder;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg16364833	chr2:70121066	SNRNP27	0.5	6.71	0.4	1.43e-10	Chemerin levels;
SARC	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg26119090	chr2:26468346	HADHA;HADHB	0.95	13.96	0.67	1.32e-32	Gut microbiome composition (summer);
SARC	cis	rs10779751	0.649	rs1318348	chr1:11130418	A/G	cg08854313	chr1:11322531	MTOR	0.83	11.4	0.6	3.16e-24	Body mass index;
SARC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs8031584	0.918	rs1425292	chr15:31285422	G/A	cg08109568	chr15:31115862	NA	-0.46	-5.49	-0.34	1.06e-7	Huntington's disease progression;
SARC	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	27.41	0.87	7.3e-75	Chronic sinus infection;
SARC	cis	rs734999	0.588	rs3001837	chr1:2532506	G/A	cg00980319	chr1:2560884	MMEL1	0.35	4.95	0.31	1.44e-6	Ulcerative colitis;
SARC	cis	rs11608355	0.545	rs12819142	chr12:109896316	G/T	cg05360138	chr12:110035743	NA	0.92	9.15	0.51	2.93e-17	Neuroticism;
SARC	cis	rs12709013	0.597	rs1646286	chr16:58786555	C/T	cg04273148	chr16:57808038	KIFC3	0.32	4.72	0.3	4.08e-6	Blood metabolite ratios;
SARC	cis	rs2933343	1.000	rs2929859	chr3:128608341	T/G	cg25356066	chr3:128598488	ACAD9	0.6	6.91	0.41	4.64e-11	IgG glycosylation;
SARC	cis	rs9527	0.535	rs4917999	chr10:104963051	C/G	cg04362960	chr10:104952993	NT5C2	-0.45	-5.45	-0.34	1.28e-7	Arsenic metabolism;
SARC	cis	rs3087591	0.960	rs2905794	chr17:29470002	G/A	cg24425628	chr17:29625626	OMG;NF1	0.57	7.21	0.43	7.97e-12	Hip circumference;
SARC	cis	rs17376456	0.569	rs10057664	chr5:93182274	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.49	-4.97	-0.31	1.32e-6	Diabetic retinopathy;
SARC	cis	rs2228479	0.541	rs62052173	chr16:89950739	T/C	cg06558623	chr16:89946397	TCF25	0.78	6.85	0.41	6.69e-11	Skin colour saturation;
SARC	cis	rs10979	0.928	rs9496676	chr6:143895610	A/G	cg25407410	chr6:143891975	LOC285740	-0.62	-8.35	-0.48	6.1e-15	Hypospadias;
SARC	cis	rs651907	0.535	rs17412601	chr3:101499275	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	6.25	0.38	1.89e-9	Colorectal cancer;
SARC	cis	rs2576037	0.763	rs2060418	chr18:44576535	A/C	cg15049968	chr18:44337910	ST8SIA5	0.31	5.0	0.31	1.12e-6	Personality dimensions;
SARC	cis	rs3008870	0.755	rs2065002	chr1:67487119	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.57	-7.15	-0.42	1.12e-11	Lymphocyte percentage of white cells;
SARC	cis	rs8114671	0.539	rs2064453	chr20:33460810	T/C	cg07148914	chr20:33460835	GGT7	0.47	5.74	0.35	2.95e-8	Height;
SARC	cis	rs35110281	0.720	rs162372	chr21:44928863	C/T	cg01579765	chr21:45077557	HSF2BP	0.36	6.15	0.37	3.37e-9	Mean corpuscular volume;
SARC	cis	rs9393692	0.676	rs806977	chr6:26189615	A/G	cg05868516	chr6:26286170	HIST1H4H	0.57	6.99	0.42	2.87e-11	Educational attainment;
SARC	cis	rs11697848	1.000	rs2268324	chr20:48529761	C/T	cg17849948	chr20:48532315	SPATA2	-0.87	-5.2	-0.32	4.3e-7	Systemic lupus erythematosus;
SARC	trans	rs3780486	0.629	rs10971439	chr9:33180813	C/T	cg04842962	chr6:43655489	MRPS18A	-0.78	-8.35	-0.48	5.92e-15	IgG glycosylation;
SARC	cis	rs17376456	0.825	rs35496867	chr5:93220400	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.5	0.34	9.89e-8	Diabetic retinopathy;
SARC	cis	rs7959452	0.535	rs4761228	chr12:69682327	G/A	cg22834771	chr12:69754056	YEATS4	-0.4	-5.39	-0.33	1.76e-7	Blood protein levels;
SARC	cis	rs818427	0.927	rs153546	chr5:112238039	A/C	cg07820702	chr5:112228657	REEP5	-0.53	-5.83	-0.36	1.81e-8	Total body bone mineral density;
SARC	cis	rs7829975	0.846	rs11779061	chr8:8549432	G/A	cg15556689	chr8:8085844	FLJ10661	-0.47	-5.71	-0.35	3.34e-8	Mood instability;
SARC	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg17971929	chr21:40555470	PSMG1	-0.59	-7.42	-0.44	2.15e-12	Menarche (age at onset);
SARC	cis	rs4906332	1.000	rs12896612	chr14:103877868	A/G	cg26031613	chr14:104095156	KLC1	-0.54	-6.3	-0.38	1.5e-9	Coronary artery disease;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg17401635	chr5:176944162	DDX41	0.62	6.43	0.39	7.17e-10	Lung cancer in ever smokers;
SARC	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg06697600	chr4:7070879	GRPEL1	-0.38	-4.93	-0.31	1.54e-6	Monocyte percentage of white cells;
SARC	cis	rs6570726	0.791	rs952406	chr6:145925616	C/A	cg23711669	chr6:146136114	FBXO30	0.79	12.38	0.63	2.23e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg03452623	chr4:187889614	NA	0.47	6.08	0.37	4.98e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg03806693	chr22:41940476	POLR3H	0.92	12.37	0.63	2.4e-27	Vitiligo;
SARC	cis	rs1348850	0.567	rs1527401	chr2:178522104	C/T	cg22681709	chr2:178499509	PDE11A	-0.38	-5.22	-0.32	3.98e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg18402987	chr7:1209562	NA	0.46	6.13	0.37	3.8e-9	Longevity;Endometriosis;
SARC	trans	rs8073060	0.586	rs2428464	chr17:34021994	C/G	cg19694781	chr19:47549865	TMEM160	-0.71	-6.94	-0.41	3.88e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs3784262	1.000	rs4646619	chr15:58258342	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.4	-5.92	-0.36	1.13e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-5.46	-0.34	1.24e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs7374004	0.870	rs7373819	chr3:38619312	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.43	-5.38	-0.33	1.78e-7	PR interval;
SARC	cis	rs7617773	0.743	rs11716371	chr3:48362750	C/T	cg11946769	chr3:48343235	NME6	0.77	9.81	0.54	2.97e-19	Coronary artery disease;
SARC	cis	rs1355223	0.506	rs1509659	chr11:34865133	A/G	cg18508148	chr11:34937573	PDHX;APIP	-0.37	-4.74	-0.3	3.74e-6	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs9902453	0.817	rs62068620	chr17:28167674	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	7.23	0.43	6.79e-12	Coffee consumption (cups per day);
SARC	cis	rs2147959	0.882	rs4653551	chr1:228627913	A/G	cg16894439	chr1:228634806	NA	0.45	4.79	0.3	2.92e-6	Adult asthma;
SARC	cis	rs2816062	0.786	rs742486	chr1:18900829	G/A	cg10574377	chr1:18908098	NA	0.35	4.91	0.31	1.71e-6	Urate levels in lean individuals;
SARC	cis	rs838147	0.844	rs8111288	chr19:49247900	G/A	cg13540341	chr19:49222985	MAMSTR	0.28	4.73	0.3	3.83e-6	Dietary macronutrient intake;
SARC	cis	rs7714584	1.000	rs11748158	chr5:150226345	C/T	cg22134413	chr5:150180641	NA	0.78	6.56	0.39	3.42e-10	Crohn's disease;
SARC	cis	rs1008375	0.931	rs3796814	chr4:17602033	G/C	cg27347728	chr4:17578864	LAP3	0.45	5.48	0.34	1.09e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2011503	0.883	rs17216041	chr19:19366643	C/T	cg03709012	chr19:19516395	GATAD2A	0.63	5.76	0.35	2.59e-8	Bipolar disorder;
SARC	cis	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg05623727	chr3:50126028	RBM5	-0.34	-4.93	-0.31	1.57e-6	Body mass index;
SARC	cis	rs6834538	0.597	rs1486865	chr4:113465651	A/G	cg05193411	chr4:113558554	LARP7;C4orf21	0.4	4.93	0.31	1.53e-6	Free thyroxine concentration;
SARC	cis	rs13256369	1.000	rs7820159	chr8:8576215	T/C	cg17143192	chr8:8559678	CLDN23	0.51	5.47	0.34	1.16e-7	Obesity-related traits;
SARC	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	11.99	0.62	4.13e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg02018176	chr4:1364513	KIAA1530	0.35	4.86	0.3	2.19e-6	Obesity-related traits;
SARC	trans	rs2727020	0.554	rs7111711	chr11:49557880	G/A	cg15704280	chr7:45808275	SEPT13	-0.7	-8.11	-0.47	2.85e-14	Coronary artery disease;
SARC	cis	rs67311347	1.000	rs34762643	chr3:40475433	C/T	cg09455208	chr3:40491958	NA	0.42	6.7	0.4	1.58e-10	Renal cell carcinoma;
SARC	cis	rs7599312	1.000	rs7599312	chr2:213413231	C/T	cg16329650	chr2:213403929	ERBB4	0.43	4.75	0.3	3.54e-6	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs7551222	0.752	rs10900593	chr1:204470096	G/T	cg20240347	chr1:204465584	NA	-0.33	-5.94	-0.36	1.01e-8	Schizophrenia;
SARC	cis	rs453301	0.686	rs6748	chr8:8890802	C/T	cg11608241	chr8:8085544	FLJ10661	-0.43	-5.43	-0.34	1.42e-7	Joint mobility (Beighton score);
SARC	trans	rs36093844	0.752	rs113529766	chr11:85583401	G/A	cg27065003	chr5:122429449	PRDM6	-0.55	-6.46	-0.39	5.9e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs9788721	0.836	rs2009746	chr15:78754102	A/G	cg06917634	chr15:78832804	PSMA4	-0.48	-5.22	-0.32	4.04e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs35213789	0.768	rs10085775	chr7:69222084	C/T	cg10619644	chr7:69149951	AUTS2	-0.42	-5.66	-0.35	4.45e-8	Childhood ear infection;
SARC	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg13282195	chr8:144660772	NAPRT1	-0.53	-5.08	-0.32	7.62e-7	Attention deficit hyperactivity disorder;
SARC	cis	rs9303401	0.659	rs17822735	chr17:56620167	C/T	cg25039879	chr17:56429692	SUPT4H1	0.67	6.25	0.38	1.94e-9	Cognitive test performance;
SARC	cis	rs2425143	0.915	rs2378408	chr20:34367732	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	0.74	6.35	0.38	1.1e-9	Blood protein levels;
SARC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.79	10.36	0.56	6.36e-21	Prudent dietary pattern;
SARC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg07157834	chr1:205819609	PM20D1	0.72	11.42	0.6	2.81e-24	Menarche (age at onset);
SARC	cis	rs7123876	0.717	rs58249351	chr11:72463462	G/A	cg03713592	chr11:72463424	ARAP1	0.84	9.45	0.53	3.78e-18	Body mass index;
SARC	cis	rs2380220	0.576	rs4368819	chr6:96031109	T/G	cg23517279	chr6:96025343	MANEA	0.56	6.26	0.38	1.84e-9	Behavioural disinhibition (generation interaction);
SARC	cis	rs2797685	1.000	rs707467	chr1:7861684	A/C	cg00864860	chr1:7907996	UTS2	-0.36	-5.04	-0.31	9.5e-7	Crohn's disease;
SARC	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg12419862	chr22:24373484	LOC391322	-0.75	-9.47	-0.53	3.3e-18	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs10489202	0.583	rs203782	chr1:167882386	A/G	cg24449463	chr1:168025552	DCAF6	0.65	8.59	0.49	1.25e-15	Schizophrenia;
SARC	cis	rs4689388	0.856	rs3200	chr4:6304878	C/T	cg14416269	chr4:6271139	WFS1	0.31	4.8	0.3	2.84e-6	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs9914988	0.887	rs9895625	chr17:27108516	A/G	cg20469991	chr17:27169893	C17orf63	-0.5	-5.21	-0.32	4.1e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg18305652	chr10:134549665	INPP5A	-0.35	-5.17	-0.32	5.09e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs11122272	0.735	rs2295420	chr1:231485640	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.02	-0.55	6.86e-20	Hemoglobin concentration;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg00682103	chr8:141554380	EIF2C2	-0.45	-6.35	-0.38	1.12e-9	Chemerin levels;
SARC	cis	rs9398803	0.678	rs4895811	chr6:126899853	T/A	cg20229609	chr6:126660872	C6orf173	0.35	5.02	0.31	1.03e-6	Male-pattern baldness;
SARC	cis	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg11608241	chr8:8085544	FLJ10661	0.4	4.79	0.3	2.99e-6	Systolic blood pressure;
SARC	cis	rs2204008	0.774	rs7959048	chr12:37948276	T/A	cg13010199	chr12:38710504	ALG10B	0.78	10.85	0.58	1.76e-22	Bladder cancer;
SARC	cis	rs9790314	1.000	rs1993891	chr3:161047467	A/G	cg04691961	chr3:161091175	C3orf57	-0.79	-11.9	-0.61	7.81e-26	Morning vs. evening chronotype;
SARC	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg00933542	chr6:150070202	PCMT1	0.31	5.42	0.33	1.47e-7	Lung cancer;
SARC	cis	rs9815354	0.597	rs59432762	chr3:41812294	G/C	cg03022575	chr3:42003672	ULK4	0.72	5.99	0.37	7.83e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9309473	0.687	rs12465867	chr2:73612102	C/T	cg20560298	chr2:73613845	ALMS1	-0.54	-7.02	-0.42	2.46e-11	Metabolite levels;
SARC	cis	rs6738485	0.531	rs72819612	chr2:106846316	T/C	cg15412446	chr2:106886593	NA	-0.57	-5.81	-0.36	2.06e-8	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
SARC	cis	rs17345786	0.817	rs11720560	chr3:101328484	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.49	5.46	0.34	1.21e-7	Colonoscopy-negative controls vs population controls;
SARC	cis	rs36051895	0.564	rs7874624	chr9:5179865	A/G	cg02405213	chr9:5042618	JAK2	-0.45	-5.28	-0.33	3.03e-7	Pediatric autoimmune diseases;
SARC	cis	rs4711336	0.638	rs4713664	chr6:33674198	A/G	cg13560919	chr6:33536144	NA	0.37	4.78	0.3	3.06e-6	Height;
SARC	cis	rs963731	0.649	rs7571052	chr2:39189831	C/T	cg04010122	chr2:39346883	SOS1	0.89	5.42	0.33	1.49e-7	Corticobasal degeneration;
SARC	cis	rs208520	0.690	rs12202913	chr6:66734198	C/T	cg07460842	chr6:66804631	NA	1.04	13.88	0.67	2.45e-32	Exhaled nitric oxide output;
SARC	cis	rs2635047	0.507	rs2668767	chr18:44785302	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.4	5.04	0.31	9.45e-7	Educational attainment;
SARC	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg19223190	chr17:80058835	NA	0.48	6.63	0.4	2.29e-10	Life satisfaction;
SARC	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg16680214	chr1:154839983	KCNN3	0.36	5.68	0.35	4.06e-8	Prostate cancer;
SARC	cis	rs546131	0.928	rs499183	chr11:34836678	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.48	6.3	0.38	1.45e-9	Lung disease severity in cystic fibrosis;
SARC	cis	rs7223966	1.000	rs8075521	chr17:61804954	C/T	cg00588841	chr17:61851480	DDX42;CCDC47	-0.68	-7.6	-0.45	7.42e-13	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9302635	0.640	rs9933009	chr16:72190650	G/A	cg01557791	chr16:72042693	DHODH	-0.48	-5.28	-0.33	2.97e-7	Blood protein levels;
SARC	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg11764359	chr7:65958608	NA	-0.83	-11.09	-0.59	3.13e-23	Aortic root size;
SARC	cis	rs73206853	0.764	rs61117387	chr12:110867725	C/A	cg10860002	chr12:110842031	ANAPC7	0.61	4.87	0.3	2.04e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg24690094	chr11:67383802	NA	-0.48	-7.21	-0.43	7.86e-12	Mean corpuscular volume;
SARC	cis	rs9875589	0.509	rs4685058	chr3:14030384	T/C	cg19554555	chr3:13937349	NA	-0.4	-5.22	-0.32	4.03e-7	Ovarian reserve;
SARC	cis	rs1008375	0.900	rs7658447	chr4:17579415	T/C	cg27347728	chr4:17578864	LAP3	0.51	6.2	0.38	2.59e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1865760	1.000	rs9358895	chr6:25924655	C/T	cg10373733	chr6:25993375	NA	0.42	5.0	0.31	1.11e-6	Height;
SARC	cis	rs9457247	1.000	rs393558	chr6:167397750	A/C	cg23791538	chr6:167370224	RNASET2	-0.63	-8.73	-0.5	4.84e-16	Crohn's disease;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg06735200	chr2:176867187	KIAA1715	-0.52	-6.58	-0.4	3.1e-10	Schizophrenia;
SARC	cis	rs79976124	0.760	rs74295030	chr6:66654441	T/C	cg07460842	chr6:66804631	NA	0.63	6.82	0.41	7.8e-11	Type 2 diabetes;
SARC	cis	rs751728	0.865	rs751726	chr6:33764386	G/A	cg25922239	chr6:33757077	LEMD2	0.77	10.26	0.56	1.25e-20	Crohn's disease;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg27012203	chr1:11865920	CLCN6;MTHFR	0.48	6.57	0.4	3.18e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg04317338	chr11:64019027	PLCB3	0.83	9.04	0.51	6.17e-17	Mean platelet volume;
SARC	cis	rs8067354	0.872	rs2645488	chr17:57889405	T/G	cg13753209	chr17:57696993	CLTC	0.52	6.48	0.39	5.28e-10	Hemoglobin concentration;
SARC	cis	rs13191362	0.872	rs35443919	chr6:163055804	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.62	5.27	0.33	3.07e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg21017887	chr14:105400489	NA	0.52	7.49	0.44	1.38e-12	Rheumatoid arthritis;
SARC	cis	rs6500395	1.000	rs9928051	chr16:48557316	T/A	cg04672837	chr16:48644449	N4BP1	0.4	5.27	0.33	3.06e-7	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs7027203	0.828	rs10122041	chr9:96615517	A/G	cg13679303	chr9:96623674	NA	-0.34	-4.95	-0.31	1.44e-6	DNA methylation (variation);
SARC	cis	rs9393692	0.557	rs989133	chr6:26336300	T/C	cg13736514	chr6:26305472	NA	-0.44	-5.11	-0.32	6.57e-7	Educational attainment;
SARC	cis	rs9297145	0.585	rs10953281	chr7:98772131	C/T	cg05967295	chr7:98741636	SMURF1	-0.51	-6.04	-0.37	6.13e-9	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
SARC	cis	rs10089	1.000	rs3805607	chr5:127477418	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.8	10.06	0.55	5.18e-20	Ileal carcinoids;
SARC	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.63	7.52	0.44	1.18e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7945705	0.837	rs10769966	chr11:8847041	C/A	cg14711859	chr11:8959438	ASCL3	-0.33	-5.32	-0.33	2.43e-7	Hemoglobin concentration;
SARC	cis	rs7089973	0.604	rs2420069	chr10:116605103	A/G	cg03647239	chr10:116582469	FAM160B1	0.5	6.49	0.39	5.19e-10	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs8014204	0.836	rs12588415	chr14:75278211	G/A	cg06637938	chr14:75390232	RPS6KL1	0.69	9.88	0.54	1.84e-19	Caffeine consumption;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg12694510	chr17:26646013	TMEM97	0.63	6.3	0.38	1.51e-9	Lung cancer in ever smokers;
SARC	cis	rs9790314	0.589	rs13097130	chr3:160669279	G/A	cg04691961	chr3:161091175	C3orf57	0.62	8.58	0.49	1.33e-15	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.511	rs16921553	chr8:57979314	T/C	cg22535103	chr8:58192502	C8orf71	-0.54	-5.39	-0.33	1.76e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs62344088	0.590	rs73016637	chr5:172462	G/A	cg20965017	chr5:231967	SDHA	-0.87	-5.69	-0.35	3.79e-8	Asthma (childhood onset);
SARC	cis	rs4595586	0.545	rs2197940	chr12:39401937	C/T	cg26384229	chr12:38710491	ALG10B	0.5	6.12	0.37	3.98e-9	Morning vs. evening chronotype;
SARC	cis	rs191220855	1	rs191220855	chr2:200778130	A/G	cg23649088	chr2:200775458	C2orf69	-0.69	-6.84	-0.41	6.91e-11	Chickenpox;
SARC	cis	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg13072238	chr3:49761600	GMPPB	-0.44	-5.64	-0.35	4.82e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2486288	0.656	rs11632752	chr15:45551140	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.51	-6.44	-0.39	6.68e-10	Glomerular filtration rate;
SARC	cis	rs3857536	0.704	rs4710570	chr6:66890244	A/G	cg07460842	chr6:66804631	NA	-0.6	-7.16	-0.42	1.04e-11	Blood trace element (Cu levels);
SARC	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg04546413	chr19:29218101	NA	0.64	8.69	0.49	6.5e-16	Methadone dose in opioid dependence;
SARC	cis	rs17021463	0.673	rs12646467	chr4:95288819	G/A	cg11021082	chr4:95130006	SMARCAD1	0.35	4.97	0.31	1.31e-6	Testicular germ cell tumor;
SARC	cis	rs2645694	0.626	rs2645709	chr4:77824474	G/A	cg18351406	chr4:77819688	ANKRD56	0.41	5.88	0.36	1.43e-8	Emphysema distribution in smoking;
SARC	cis	rs72627123	0.749	rs58199545	chr14:74452495	G/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	5.52	0.34	8.92e-8	Morning vs. evening chronotype;
SARC	cis	rs9818758	0.607	rs56306491	chr3:49314960	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.7	-5.93	-0.36	1.11e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg02841227	chr6:26021843	HIST1H4A	0.55	6.76	0.4	1.1e-10	Intelligence (multi-trait analysis);
SARC	cis	rs6141769	0.542	rs6057625	chr20:31304994	G/A	cg17884169	chr20:31446444	EFCAB8	-0.44	-4.78	-0.3	3.09e-6	Subjective well-being;
SARC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg07167872	chr1:205819463	PM20D1	0.75	11.56	0.6	9.92e-25	Menarche (age at onset);
SARC	cis	rs9341808	0.667	rs742833	chr6:80921446	C/T	cg08355045	chr6:80787529	NA	0.36	5.73	0.35	3.1e-8	Sitting height ratio;
SARC	trans	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg00938859	chr5:1591904	SDHAP3	0.79	7.61	0.45	6.69e-13	Breast cancer;
SARC	cis	rs9309473	0.606	rs77962988	chr2:73886090	T/C	cg07208825	chr2:73871855	ALMS1P	0.37	4.89	0.31	1.88e-6	Metabolite levels;
SARC	cis	rs9815354	1.000	rs1716676	chr3:41903208	T/C	cg03022575	chr3:42003672	ULK4	0.56	5.29	0.33	2.81e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9402673	0.558	rs9688342	chr6:135323026	A/T	cg24558204	chr6:135376177	HBS1L	0.45	6.11	0.37	4.1e-9	Reticulocyte count;High light scatter reticulocyte count;
SARC	cis	rs78487399	0.710	rs7590220	chr2:43702151	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-5.13	-0.32	6.24e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs2486288	0.554	rs1719235	chr15:45576108	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.55	-6.69	-0.4	1.66e-10	Glomerular filtration rate;
SARC	cis	rs992157	0.687	rs35271699	chr2:219117482	G/A	cg00012203	chr2:219082015	ARPC2	0.85	13.58	0.66	2.52e-31	Colorectal cancer;
SARC	cis	rs1008375	1.000	rs11947857	chr4:17691047	T/C	cg02297831	chr4:17616191	MED28	-0.47	-5.75	-0.35	2.86e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs372883	0.530	rs2832302	chr21:30749793	G/T	cg08807101	chr21:30365312	RNF160	-0.53	-6.68	-0.4	1.72e-10	Pancreatic cancer;
SARC	cis	rs7647973	0.554	rs13096480	chr3:49658084	A/G	cg13072238	chr3:49761600	GMPPB	-0.61	-6.14	-0.37	3.48e-9	Menarche (age at onset);
SARC	cis	rs637571	0.584	rs7107912	chr11:65603252	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.49	-6.46	-0.39	6.1e-10	Eosinophil percentage of white cells;
SARC	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.57	-7.44	-0.44	1.9e-12	Mean platelet volume;
SARC	cis	rs4268898	0.717	rs2543662	chr2:24443271	G/T	cg26838691	chr2:24397539	C2orf84	0.43	4.95	0.31	1.4e-6	Asthma;
SARC	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg21782813	chr7:2030301	MAD1L1	0.32	4.95	0.31	1.45e-6	Schizophrenia;
SARC	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg11062466	chr8:58055876	NA	0.61	5.75	0.35	2.74e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs17401966	0.838	rs12120191	chr1:10345772	A/G	cg15208524	chr1:10270712	KIF1B	0.45	5.19	0.32	4.51e-7	Hepatocellular carcinoma;
SARC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.11	0.37	4.1e-9	Prudent dietary pattern;
SARC	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg12756686	chr19:29218302	NA	0.6	6.86	0.41	6.11e-11	Methadone dose in opioid dependence;
SARC	cis	rs4930561	0.765	rs4930564	chr11:67983281	C/T	cg16338278	chr11:67432957	ALDH3B2	-0.35	-5.6	-0.34	6.03e-8	Breast cancer in childhood cancer survivors;IgG glycosylation;
SARC	trans	rs7819412	0.775	rs2898257	chr8:10935368	A/C	cg06636001	chr8:8085503	FLJ10661	-0.7	-9.87	-0.54	2.04e-19	Triglycerides;
SARC	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg06138931	chr13:21896616	NA	0.36	5.27	0.33	3.14e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs614226	1.000	rs580016	chr12:120933977	T/C	cg01236616	chr12:121019343	POP5	-1.13	-13.3	-0.66	2.09e-30	Type 1 diabetes nephropathy;
SARC	cis	rs11874712	1.000	rs8088881	chr18:43664970	T/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.46	5.5	0.34	1.02e-7	Migraine - clinic-based;
SARC	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.43	-5.38	-0.33	1.82e-7	Lymphocyte counts;
SARC	cis	rs2011503	1.000	rs4808968	chr19:19644402	C/T	cg15839431	chr19:19639596	YJEFN3	-0.48	-4.77	-0.3	3.32e-6	Bipolar disorder;
SARC	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg11366901	chr6:160182831	ACAT2	0.87	9.04	0.51	6.08e-17	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs6582630	0.519	rs1607882	chr12:38361657	G/A	cg13010199	chr12:38710504	ALG10B	0.76	10.16	0.55	2.6e-20	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs62158211	0.955	rs7556815	chr2:114085785	G/A	cg17784749	chr2:114082611	LOC440839	0.74	7.64	0.45	5.74e-13	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
SARC	cis	rs7523050	0.908	rs17621536	chr1:109396908	A/G	cg08274380	chr1:109419600	GPSM2	0.67	5.84	0.36	1.77e-8	Fat distribution (HIV);
SARC	cis	rs4253772	0.550	rs6008615	chr22:46707928	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.6	4.88	0.3	2e-6	LDL cholesterol;Cholesterol, total;
SARC	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg05368731	chr17:41323189	NBR1	0.79	9.57	0.53	1.62e-18	Menopause (age at onset);
SARC	cis	rs73086581	1.000	rs6052220	chr20:3970594	C/T	cg02187196	chr20:3869020	PANK2	0.6	5.79	0.35	2.26e-8	Response to antidepressants in depression;
SARC	cis	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg00409905	chr10:38381863	ZNF37A	-0.53	-7.54	-0.44	1.02e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg00933542	chr6:150070202	PCMT1	0.31	5.42	0.33	1.47e-7	Lung cancer;
SARC	cis	rs317689	0.581	rs160829	chr12:69769538	G/C	cg20891283	chr12:69753455	YEATS4	0.49	6.06	0.37	5.45e-9	Response to diuretic therapy;
SARC	cis	rs208520	0.690	rs207077	chr6:66769855	A/C	cg07460842	chr6:66804631	NA	-1.07	-14.01	-0.68	9.03e-33	Exhaled nitric oxide output;
SARC	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg05368731	chr17:41323189	NBR1	0.79	9.6	0.53	1.34e-18	Menopause (age at onset);
SARC	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg12412775	chr1:25698385	RHCE	-0.29	-4.73	-0.3	3.91e-6	Erythrocyte sedimentation rate;
SARC	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg22974920	chr21:40686053	BRWD1	0.45	4.88	0.3	1.98e-6	Cognitive function;
SARC	cis	rs9290065	0.519	rs1530636	chr3:160697442	A/G	cg04691961	chr3:161091175	C3orf57	0.51	6.5	0.39	4.95e-10	Kawasaki disease;
SARC	cis	rs9303401	0.659	rs17222523	chr17:56620501	A/G	cg25039879	chr17:56429692	SUPT4H1	0.67	6.25	0.38	1.94e-9	Cognitive test performance;
SARC	cis	rs4919694	0.611	rs2271750	chr10:105174869	A/G	cg04362960	chr10:104952993	NT5C2	-0.62	-5.17	-0.32	5.02e-7	Arsenic metabolism;
SARC	cis	rs9303401	0.659	rs2072316	chr17:56604813	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	11.86	0.61	1.07e-25	Cognitive test performance;
SARC	cis	rs11785693	0.909	rs62489556	chr8:4968149	G/A	cg26367366	chr8:4980734	NA	0.72	6.23	0.38	2.19e-9	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs4803468	1.000	rs3213861	chr19:41919944	A/C	cg09537434	chr19:41945824	ATP5SL	-0.98	-17.48	-0.75	2.73e-44	Height;
SARC	cis	rs13191362	0.872	rs56404230	chr6:163252863	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.62	6.01	0.37	7.19e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs9309473	0.519	rs1815027	chr2:73831840	T/C	cg20560298	chr2:73613845	ALMS1	0.48	6.39	0.39	9.03e-10	Metabolite levels;
SARC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.21	0.8	3.69e-53	Prudent dietary pattern;
SARC	cis	rs6933660	0.800	rs3800273	chr6:151759035	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.74	10.84	0.58	2.02e-22	Menarche (age at onset);
SARC	cis	rs9388451	0.626	rs7748729	chr6:126077381	C/T	cg06289844	chr6:126071538	HEY2	0.35	5.55	0.34	7.9e-8	Brugada syndrome;
SARC	cis	rs796364	1.000	rs281794	chr2:200846666	C/T	cg23649088	chr2:200775458	C2orf69	0.61	5.81	0.36	2.09e-8	Schizophrenia;
SARC	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg17376030	chr22:41985996	PMM1	0.63	7.62	0.45	6.2e-13	Vitiligo;
SARC	cis	rs1008375	1.000	rs4698199	chr4:17656738	G/C	cg16339924	chr4:17578868	LAP3	0.66	8.83	0.5	2.57e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs11574514	1.000	rs75843134	chr16:67767553	C/T	cg01866162	chr16:67596514	CTCF	1.13	6.68	0.4	1.7e-10	Crohn's disease;
SARC	cis	rs17270561	0.609	rs1892245	chr6:25764833	G/T	cg17691542	chr6:26056736	HIST1H1C	0.57	7.0	0.42	2.78e-11	Iron status biomarkers;
SARC	cis	rs13191362	1.000	rs13195226	chr6:163006421	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.56	5.41	0.33	1.53e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05186522	chr4:177241619	SPCS3	-0.5	-6.42	-0.39	7.5e-10	Smoking initiation;
SARC	cis	rs1008375	1.000	rs6818639	chr4:17633049	A/G	cg16339924	chr4:17578868	LAP3	0.66	8.83	0.5	2.57e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.4	-4.97	-0.31	1.32e-6	Lymphocyte counts;
SARC	cis	rs11098699	0.821	rs11939262	chr4:124207018	A/G	cg09941581	chr4:124220074	SPATA5	0.39	4.73	0.3	3.98e-6	Mosquito bite size;
SARC	trans	rs1865760	0.929	rs9461224	chr6:25936402	G/T	cg00292047	chr11:33279899	HIPK3	-0.52	-6.24	-0.38	2.03e-9	Height;
SARC	trans	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg00938859	chr5:1591904	SDHAP3	0.69	6.36	0.38	1.03e-9	Breast cancer;
SARC	cis	rs11214589	0.774	rs7107223	chr11:113255574	A/T	cg14159747	chr11:113255604	NA	0.38	5.5	0.34	1.01e-7	Neuroticism;
SARC	cis	rs7662987	0.517	rs2602881	chr4:100040695	A/G	cg12011299	chr4:100065546	ADH4	0.33	5.47	0.34	1.13e-7	Smoking initiation;
SARC	cis	rs7617773	0.817	rs13072018	chr3:48320332	G/A	cg11946769	chr3:48343235	NME6	0.71	9.1	0.51	4.05e-17	Coronary artery disease;
SARC	cis	rs116095464	0.558	rs55833259	chr5:286728	G/A	cg22857025	chr5:266934	NA	-1.1	-10.35	-0.56	6.84e-21	Breast cancer;
SARC	cis	rs738322	0.718	rs2899297	chr22:38594668	A/G	cg25457927	chr22:38595422	NA	-0.38	-8.45	-0.48	3.13e-15	Cutaneous nevi;
SARC	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg24250549	chr1:154909240	PMVK	-0.62	-8.41	-0.48	4.01e-15	Prostate cancer;
SARC	cis	rs6450176	0.909	rs11742688	chr5:53291081	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.64	-7.22	-0.43	7.11e-12	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs898097	0.841	rs11656358	chr17:80853956	G/A	cg15369054	chr17:80825471	TBCD	0.54	7.75	0.45	2.85e-13	Breast cancer;
SARC	cis	rs2011503	1.000	rs80200208	chr19:19554725	C/T	cg03709012	chr19:19516395	GATAD2A	0.64	5.69	0.35	3.77e-8	Bipolar disorder;
SARC	cis	rs10992471	0.603	rs10761160	chr9:95208701	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.26	-0.33	3.34e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs17428076	0.831	rs55957712	chr2:172587956	C/T	cg13550731	chr2:172543902	DYNC1I2	0.44	4.81	0.3	2.77e-6	Myopia;
SARC	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg00450029	chr8:599525	NA	0.8	6.03	0.37	6.4e-9	IgG glycosylation;
SARC	cis	rs6988636	1.000	rs28600861	chr8:124189063	C/T	cg23067535	chr8:124195133	FAM83A	-0.69	-5.46	-0.34	1.24e-7	Urinary uromodulin levels;
SARC	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg13628971	chr7:2884303	GNA12	0.63	7.39	0.44	2.69e-12	Height;
SARC	cis	rs12142240	0.698	rs61519400	chr1:46855298	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-5.56	-0.34	7.46e-8	Menopause (age at onset);
SARC	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg04277193	chr17:41438351	NA	0.45	4.87	0.3	2.03e-6	Menopause (age at onset);
SARC	cis	rs6963495	0.818	rs73192145	chr7:105203628	A/C	cg19920283	chr7:105172520	RINT1	0.67	5.72	0.35	3.33e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs4803468	0.967	rs1077856	chr19:41885221	T/C	cg14132834	chr19:41945861	ATP5SL	-0.56	-7.61	-0.45	6.64e-13	Height;
SARC	cis	rs1728785	0.901	rs2862781	chr16:68639234	A/T	cg02972257	chr16:68554789	NA	-0.43	-5.03	-0.31	9.85e-7	Ulcerative colitis;
SARC	cis	rs1957429	0.901	rs8009996	chr14:65351582	A/G	cg23373153	chr14:65346875	NA	1.13	12.09	0.62	1.95e-26	Pediatric areal bone mineral density (radius);
SARC	cis	rs1018836	0.923	rs4735260	chr8:91617157	C/G	cg16814680	chr8:91681699	NA	0.86	14.29	0.68	1.06e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.76	-9.68	-0.54	7.56e-19	Prudent dietary pattern;
SARC	cis	rs2594989	0.895	rs439738	chr3:11322577	G/C	cg00170343	chr3:11313890	ATG7	0.56	5.41	0.33	1.59e-7	Circulating chemerin levels;
SARC	cis	rs2439831	0.681	rs484846	chr15:43600803	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.77	8.45	0.48	3.19e-15	Lung cancer in ever smokers;
SARC	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg09455208	chr3:40491958	NA	0.4	6.0	0.37	7.55e-9	Renal cell carcinoma;
SARC	cis	rs6964587	1.000	rs11772102	chr7:91558326	A/T	cg17063962	chr7:91808500	NA	-0.92	-14.47	-0.69	2.82e-34	Breast cancer;
SARC	cis	rs10089	0.953	rs10223203	chr5:127527646	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.77	-9.37	-0.52	6.39e-18	Ileal carcinoids;
SARC	cis	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg07777115	chr5:623756	CEP72	-0.61	-5.55	-0.34	7.75e-8	Obesity-related traits;
SARC	cis	rs7223966	1.000	rs2854223	chr17:61939014	A/G	cg00588841	chr17:61851480	DDX42;CCDC47	-0.57	-6.38	-0.39	9.3e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs34172651	0.917	rs7202252	chr16:24741686	T/C	cg04756594	chr16:24857601	SLC5A11	-0.39	-6.18	-0.38	2.89e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7681440	0.606	rs1372516	chr4:90755730	G/A	cg06632027	chr4:90757378	SNCA	-0.43	-5.36	-0.33	2e-7	Dementia with Lewy bodies;
SARC	cis	rs9467711	0.538	rs36012762	chr6:25980523	A/C	cg21479132	chr6:26055353	NA	0.93	6.17	0.37	2.93e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9790314	1.000	rs336589	chr3:161080358	C/T	cg03342759	chr3:160939853	NMD3	-0.58	-7.45	-0.44	1.83e-12	Morning vs. evening chronotype;
SARC	cis	rs17376456	0.778	rs10440717	chr5:93424852	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.79	0.35	2.3e-8	Diabetic retinopathy;
SARC	cis	rs12681366	0.537	rs2919667	chr8:95465202	C/G	cg13257157	chr8:95487014	RAD54B	0.4	4.81	0.3	2.67e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs10463554	0.963	rs32850	chr5:102470029	G/C	cg23492399	chr5:102201601	PAM	-0.47	-5.16	-0.32	5.18e-7	Parkinson's disease;
SARC	cis	rs4148883	0.545	rs17595102	chr4:99986316	C/G	cg13256891	chr4:100009986	ADH5	0.61	8.1	0.47	3.17e-14	Alcohol dependence;
SARC	cis	rs782590	0.967	rs1084522	chr2:55843294	A/G	cg18811423	chr2:55921094	PNPT1	0.68	10.45	0.56	3.28e-21	Metabolic syndrome;
SARC	trans	rs9354308	0.781	rs9363455	chr6:66547322	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.53	-6.32	-0.38	1.32e-9	Metabolite levels;
SARC	cis	rs2645694	0.626	rs2703116	chr4:77824289	C/T	cg03477792	chr4:77819574	ANKRD56	-0.5	-7.6	-0.45	7.05e-13	Emphysema distribution in smoking;
SARC	cis	rs875971	0.571	rs160641	chr7:65577346	G/A	cg11764359	chr7:65958608	NA	-0.64	-6.31	-0.38	1.38e-9	Aortic root size;
SARC	cis	rs2644899	0.859	rs2604893	chr19:41293543	A/G	cg24958765	chr19:41283667	RAB4B	-0.57	-6.25	-0.38	1.95e-9	Post bronchodilator FEV1/FVC ratio;
SARC	trans	rs11039798	0.528	rs10839208	chr11:49030456	C/T	cg15704280	chr7:45808275	SEPT13	0.66	7.05	0.42	1.96e-11	Axial length;
SARC	cis	rs288326	0.561	rs78745965	chr2:183848475	T/C	cg09997497	chr2:183902928	NCKAP1	0.74	5.1	0.32	6.97e-7	Blood protein levels;
SARC	cis	rs10789491	1.000	rs7516616	chr1:47186274	A/G	cg15501359	chr1:47185051	KIAA0494	-0.72	-7.29	-0.43	4.94e-12	Response to hepatitis C treatment;
SARC	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.85	12.26	0.63	5.49e-27	Chronic sinus infection;
SARC	cis	rs240764	0.507	rs2101814	chr6:101202822	T/A	cg09795085	chr6:101329169	ASCC3	0.4	4.96	0.31	1.35e-6	Neuroticism;
SARC	cis	rs10911363	0.550	rs10911353	chr1:183489203	G/A	cg09173681	chr1:183549694	NCF2	0.33	5.27	0.33	3.12e-7	Systemic lupus erythematosus;
SARC	cis	rs12134245	0.776	rs12137878	chr1:91973210	G/T	cg25838465	chr1:92012736	NA	-0.67	-9.61	-0.53	1.25e-18	Breast cancer;
SARC	cis	rs637571	0.522	rs550435	chr11:65732651	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.82	11.98	0.62	4.22e-26	Eosinophil percentage of white cells;
SARC	cis	rs2011503	1.000	rs2916072	chr19:19525712	G/A	cg03709012	chr19:19516395	GATAD2A	0.68	5.89	0.36	1.33e-8	Bipolar disorder;
SARC	cis	rs2303759	0.709	rs7256363	chr19:49827804	C/T	cg24324837	chr19:49891574	CCDC155	0.4	4.78	0.3	3.05e-6	Multiple sclerosis;
SARC	cis	rs2153535	0.580	rs2225766	chr6:8481833	G/A	cg23788917	chr6:8435910	SLC35B3	0.64	8.59	0.49	1.25e-15	Motion sickness;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg22881914	chr14:52536147	NID2	-0.73	-6.58	-0.4	3.03e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs35110281	0.641	rs4818858	chr21:45083097	C/T	cg01579765	chr21:45077557	HSF2BP	0.35	5.44	0.34	1.34e-7	Mean corpuscular volume;
SARC	trans	rs561341	1.000	rs55959993	chr17:30254771	C/G	cg20587970	chr11:113659929	NA	-1.35	-13.06	-0.65	1.27e-29	Hip circumference adjusted for BMI;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg17840343	chr10:93683703	BTAF1	0.57	7.79	0.45	2.23e-13	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs6952808	0.635	rs6952727	chr7:1947958	A/G	cg03354898	chr7:1950403	MAD1L1	-0.38	-5.12	-0.32	6.48e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs10078	0.515	rs2672739	chr5:443447	A/C	cg24955955	chr5:415729	AHRR	0.68	6.21	0.38	2.36e-9	Fat distribution (HIV);
SARC	cis	rs12291225	0.679	rs11605531	chr11:14291594	A/G	cg19336497	chr11:14380999	RRAS2	-0.41	-6.81	-0.41	8.46e-11	Sense of smell;
SARC	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg03351412	chr1:154909251	PMVK	0.63	8.12	0.47	2.72e-14	Prostate cancer;
SARC	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg11764359	chr7:65958608	NA	-0.67	-7.97	-0.46	7.24e-14	Aortic root size;
SARC	cis	rs826838	0.904	rs11612004	chr12:39204282	G/A	cg13010199	chr12:38710504	ALG10B	0.74	9.69	0.54	7.24e-19	Heart rate;
SARC	cis	rs11098499	0.954	rs13107475	chr4:120393011	A/T	cg09160332	chr4:120329925	NA	-0.33	-4.74	-0.3	3.75e-6	Corneal astigmatism;
SARC	cis	rs9467773	0.620	rs2451744	chr6:26633463	G/T	cg12292205	chr6:26970375	C6orf41	0.41	5.12	0.32	6.46e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1707322	0.638	rs9429095	chr1:46603348	A/C	cg06784218	chr1:46089804	CCDC17	-0.28	-4.75	-0.3	3.54e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs12701220	0.503	rs12531999	chr7:1181601	T/A	cg02733842	chr7:1102375	C7orf50	-0.41	-5.03	-0.31	1e-6	Bronchopulmonary dysplasia;
SARC	cis	rs7149337	0.933	rs28705789	chr14:51713508	C/T	cg23942311	chr14:51606299	NA	0.33	5.77	0.35	2.56e-8	Cancer;
SARC	cis	rs4808199	0.895	rs4808196	chr19:19476520	G/A	cg03709012	chr19:19516395	GATAD2A	1.2	12.99	0.65	2.23e-29	Nonalcoholic fatty liver disease;
SARC	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-5.96	-0.36	9.27e-9	Personality dimensions;
SARC	cis	rs6733011	0.531	rs13004923	chr2:99497561	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.43	-5.51	-0.34	9.32e-8	Bipolar disorder;
SARC	cis	rs2806561	0.765	rs1738470	chr1:23511911	G/A	cg12483005	chr1:23474871	LUZP1	0.43	5.66	0.35	4.44e-8	Height;
SARC	cis	rs9733	0.744	rs11204737	chr1:150847647	C/T	cg15448220	chr1:150897856	SETDB1	-0.39	-5.17	-0.32	4.95e-7	Tonsillectomy;
SARC	cis	rs67311347	1.000	rs7625736	chr3:40441345	C/G	cg24209194	chr3:40518798	ZNF619	-0.62	-8.01	-0.46	5.59e-14	Renal cell carcinoma;
SARC	cis	rs11264799	0.520	rs849814	chr1:157542216	G/A	cg18268488	chr1:157545234	FCRL4	0.3	5.34	0.33	2.18e-7	IgA nephropathy;
SARC	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg19346786	chr7:2764209	NA	-0.38	-5.63	-0.35	5.29e-8	Height;
SARC	cis	rs3733585	0.673	rs6449156	chr4:9956712	G/C	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.95	-0.36	9.9e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	trans	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg00938859	chr5:1591904	SDHAP3	0.81	7.82	0.46	1.86e-13	Breast cancer;
SARC	cis	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg24110177	chr3:50126178	RBM5	-0.55	-7.3	-0.43	4.64e-12	Intelligence (multi-trait analysis);
SARC	cis	rs10870270	0.784	rs10430614	chr10:133748640	C/T	cg08754478	chr10:133766260	PPP2R2D	0.42	5.07	0.32	7.99e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs2153535	0.580	rs2327064	chr6:8454052	C/T	cg23788917	chr6:8435910	SLC35B3	0.62	8.05	0.47	4.26e-14	Motion sickness;
SARC	cis	rs9527	0.590	rs12775302	chr10:104911356	A/G	cg04362960	chr10:104952993	NT5C2	0.44	5.2	0.32	4.39e-7	Arsenic metabolism;
SARC	cis	rs41271473	0.500	rs10916366	chr1:228894575	T/C	cg00850481	chr1:228891306	NA	-0.33	-5.23	-0.32	3.73e-7	Chronic lymphocytic leukemia;
SARC	cis	rs561341	0.883	rs72821942	chr17:30234460	C/T	cg25833597	chr17:30823145	MYO1D	-0.55	-5.06	-0.31	8.48e-7	Hip circumference adjusted for BMI;
SARC	cis	rs7412746	0.611	rs6660084	chr1:150748803	T/C	cg13175981	chr1:150552382	MCL1	-0.54	-6.57	-0.4	3.32e-10	Melanoma;
SARC	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg12310025	chr6:25882481	NA	-0.47	-5.98	-0.37	8.13e-9	Intelligence (multi-trait analysis);
SARC	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg23991368	chr14:102414729	NA	-0.51	-6.56	-0.39	3.39e-10	Parental extreme longevity (95 years and older);
SARC	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg17554472	chr22:41940697	POLR3H	-0.48	-5.22	-0.32	4.02e-7	Vitiligo;
SARC	cis	rs4727027	0.782	rs10245343	chr7:148796333	T/C	cg23583168	chr7:148888333	NA	-0.73	-9.31	-0.52	9.6e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg21782813	chr7:2030301	MAD1L1	0.42	6.21	0.38	2.37e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs9549260	0.604	rs9549273	chr13:41302147	C/G	cg21288729	chr13:41239152	FOXO1	-0.58	-5.42	-0.33	1.5e-7	Red blood cell count;
SARC	cis	rs6582630	0.502	rs7311700	chr12:38463232	T/A	cg26384229	chr12:38710491	ALG10B	0.87	12.52	0.63	7.68e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs875971	1.000	rs1144895	chr7:65541307	C/G	cg11987759	chr7:65425863	GUSB	0.43	5.69	0.35	3.81e-8	Aortic root size;
SARC	cis	rs2282802	0.685	rs7737543	chr5:139646026	A/G	cg26211634	chr5:139558579	C5orf32	0.39	5.12	0.32	6.32e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6942407	0.546	rs2108271	chr7:86805372	G/A	cg02420886	chr7:86849541	C7orf23	0.71	6.11	0.37	4.04e-9	Food allergy;
SARC	cis	rs17270561	0.609	rs4712957	chr6:25719814	C/T	cg16482183	chr6:26056742	HIST1H1C	0.43	5.11	0.32	6.67e-7	Iron status biomarkers;
SARC	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg21782813	chr7:2030301	MAD1L1	0.36	5.58	0.34	6.55e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs6496667	0.557	rs2589951	chr15:90958392	T/C	cg22089800	chr15:90895588	ZNF774	0.43	4.97	0.31	1.32e-6	Rheumatoid arthritis;
SARC	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg19774624	chr17:42201019	HDAC5	-0.8	-11.43	-0.6	2.52e-24	Total body bone mineral density;
SARC	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg04277193	chr17:41438351	NA	0.45	4.86	0.3	2.15e-6	Menopause (age at onset);
SARC	cis	rs6696846	0.740	rs11240369	chr1:205115099	G/A	cg07972983	chr1:205091412	RBBP5	0.57	7.38	0.44	2.72e-12	Red blood cell count;
SARC	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg25072359	chr17:41440525	NA	0.52	6.11	0.37	4.12e-9	Menopause (age at onset);
SARC	cis	rs12477438	0.715	rs7586608	chr2:99558017	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-7.85	-0.46	1.53e-13	Chronic sinus infection;
SARC	cis	rs17376456	0.877	rs9314100	chr5:93447394	T/C	cg21475434	chr5:93447410	FAM172A	0.86	7.71	0.45	3.65e-13	Diabetic retinopathy;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg17658084	chr8:75262759	GDAP1	-0.51	-6.41	-0.39	7.92e-10	Height;
SARC	cis	rs4742903	0.527	rs10991112	chr9:106878906	C/T	cg14250997	chr9:106856677	SMC2	0.49	6.27	0.38	1.72e-9	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs13082711	0.520	rs2643825	chr3:27562613	A/G	cg02860705	chr3:27208620	NA	0.39	5.17	0.32	4.98e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs1904096	0.506	rs3113863	chr4:95147827	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.47	-7.07	-0.42	1.74e-11	Type 2 diabetes;
SARC	cis	rs2153535	0.580	rs7767756	chr6:8453428	A/C	cg21535247	chr6:8435926	SLC35B3	0.55	6.84	0.41	6.72e-11	Motion sickness;
SARC	cis	rs7927771	1.000	rs7927771	chr11:47781306	A/G	cg05585544	chr11:47624801	NA	-0.36	-4.82	-0.3	2.59e-6	Subjective well-being;
SARC	cis	rs244731	0.959	rs6556307	chr5:176641434	C/T	cg06060754	chr5:176797920	RGS14	0.45	5.25	0.33	3.44e-7	Urate levels in lean individuals;
SARC	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg12463550	chr7:65579703	CRCP	-0.49	-5.28	-0.33	2.93e-7	Aortic root size;
SARC	trans	rs3780486	1.000	rs3780480	chr9:33163486	G/T	cg20290983	chr6:43655470	MRPS18A	1.01	14.3	0.68	9.93e-34	IgG glycosylation;
SARC	cis	rs9796	0.870	rs28479904	chr15:41268305	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.42	-5.76	-0.35	2.69e-8	Menopause (age at onset);
SARC	trans	rs7824557	0.806	rs7007394	chr8:11094566	G/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.27	-0.38	1.72e-9	Retinal vascular caliber;
SARC	cis	rs11608355	0.545	rs11066782	chr12:109910552	C/T	cg05360138	chr12:110035743	NA	0.93	9.71	0.54	6.21e-19	Neuroticism;
SARC	cis	rs1048238	0.935	rs761760	chr1:16342419	A/G	cg21385522	chr1:16154831	NA	0.55	6.64	0.4	2.24e-10	Systolic blood pressure;
SARC	cis	rs12142240	0.698	rs1984490	chr1:46858734	C/T	cg10495392	chr1:46806563	NSUN4	-0.64	-6.76	-0.41	1.09e-10	Menopause (age at onset);
SARC	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg22903657	chr4:1355424	KIAA1530	-0.36	-4.85	-0.3	2.24e-6	Obesity-related traits;
SARC	cis	rs7760949	0.852	rs9475801	chr6:13933115	G/A	cg27413430	chr6:13925136	RNF182	0.43	5.11	0.32	6.79e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs526231	0.575	rs26822	chr5:102518795	A/G	cg23492399	chr5:102201601	PAM	-0.51	-5.41	-0.33	1.58e-7	Primary biliary cholangitis;
SARC	cis	rs561341	0.883	rs2074102	chr17:30228884	G/A	cg13647721	chr17:30228624	UTP6	0.65	5.37	0.33	1.89e-7	Hip circumference adjusted for BMI;
SARC	cis	rs611744	0.647	rs628206	chr8:109247873	A/G	cg21045802	chr8:109455806	TTC35	0.6	7.65	0.45	5.26e-13	Dupuytren's disease;
SARC	cis	rs1318878	0.565	rs11056414	chr12:15429864	T/G	cg08258403	chr12:15378311	NA	0.49	6.84	0.41	7.09e-11	Intelligence (multi-trait analysis);
SARC	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg16414030	chr3:133502952	NA	-0.4	-5.39	-0.33	1.75e-7	Iron status biomarkers;
SARC	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.48	5.68	0.35	4.1e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	trans	rs10746997	0.630	rs7854396	chr9:78848554	G/C	cg22374213	chr18:67136976	DOK6	0.39	6.46	0.39	6.17e-10	Response to fenofibrate (adiponectin levels);
SARC	cis	rs2832191	0.791	rs2832198	chr21:30498240	C/T	cg24692254	chr21:30365293	RNF160	0.83	11.54	0.6	1.18e-24	Dental caries;
SARC	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg24642844	chr7:1081250	C7orf50	-0.6	-6.11	-0.37	4.06e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs67311347	1.000	rs7642906	chr3:40492633	G/A	cg09455208	chr3:40491958	NA	-0.41	-6.54	-0.39	3.89e-10	Renal cell carcinoma;
SARC	cis	rs748404	0.646	rs2253268	chr15:43800968	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.42	4.88	0.3	2.01e-6	Lung cancer;
SARC	cis	rs11098499	0.955	rs7684942	chr4:120162201	C/T	cg24375607	chr4:120327624	NA	0.39	4.72	0.3	4.14e-6	Corneal astigmatism;
SARC	cis	rs6456156	0.875	rs55802221	chr6:167517320	G/A	cg23791538	chr6:167370224	RNASET2	0.38	4.75	0.3	3.62e-6	Primary biliary cholangitis;
SARC	cis	rs9843304	0.568	rs11720325	chr3:149216311	A/T	cg08667024	chr3:149219783	TM4SF4	-0.36	-5.1	-0.32	7.12e-7	Gallstone disease;
SARC	cis	rs7927771	0.864	rs55927797	chr11:47446292	A/T	cg20307385	chr11:47447363	PSMC3	-0.59	-7.41	-0.44	2.35e-12	Subjective well-being;
SARC	cis	rs240764	0.817	rs240113	chr6:101058886	G/A	cg09795085	chr6:101329169	ASCC3	0.44	5.7	0.35	3.59e-8	Neuroticism;
SARC	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg11062466	chr8:58055876	NA	0.54	5.56	0.34	7.55e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg04518342	chr5:131593106	PDLIM4	-0.4	-5.06	-0.31	8.52e-7	Breast cancer;
SARC	cis	rs2985684	1.000	rs2985684	chr14:50101682	C/G	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.47	4.86	0.3	2.21e-6	Carotid intima media thickness;
SARC	cis	rs7223966	1.000	rs9895920	chr17:61852719	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.46	-4.99	-0.31	1.17e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2070488	1.000	rs13079757	chr3:38491444	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	14.64	0.69	7.76e-35	Electrocardiographic conduction measures;
SARC	cis	rs2304069	0.954	rs216127	chr5:149428890	A/G	cg12661370	chr5:149340060	SLC26A2	0.57	5.66	0.35	4.37e-8	HIV-1 control;
SARC	cis	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg00071950	chr4:10020882	SLC2A9	0.41	6.61	0.4	2.57e-10	Bone mineral density;
SARC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-4.83	-0.3	2.45e-6	Total body bone mineral density;
SARC	cis	rs77956314	0.901	rs118117321	chr12:117414790	C/G	cg02017074	chr12:117425053	FBXW8	-0.59	-4.81	-0.3	2.74e-6	Subcortical brain region volumes;Hippocampal volume;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg17394996	chr5:76326080	AGGF1	-0.46	-6.26	-0.38	1.79e-9	Chemerin levels;
SARC	cis	rs1976403	0.659	rs10799701	chr1:21820990	A/G	cg07708622	chr1:21763251	NA	0.34	5.45	0.34	1.26e-7	Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs1008375	0.931	rs6449310	chr4:17575530	T/C	cg16339924	chr4:17578868	LAP3	0.68	8.93	0.51	1.28e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10766496	1.000	rs10766496	chr11:18738718	C/T	cg10955973	chr11:19366714	NA	-0.44	-4.87	-0.3	2.09e-6	Diabetic kidney disease;
SARC	cis	rs3784262	0.631	rs4646584	chr15:58305402	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.35	-5.21	-0.32	4.09e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs3126085	0.935	rs12760382	chr1:152260287	G/T	cg03465714	chr1:152285911	FLG	0.47	5.61	0.34	5.79e-8	Atopic dermatitis;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg23259381	chr4:185570876	CASP3;CCDC111	0.49	6.23	0.38	2.16e-9	Chemerin levels;
SARC	trans	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg06636001	chr8:8085503	FLJ10661	-0.61	-8.05	-0.47	4.2e-14	Neuroticism;
SARC	cis	rs7647973	0.925	rs4955423	chr3:49220448	G/A	cg06212747	chr3:49208901	KLHDC8B	0.61	6.48	0.39	5.53e-10	Menarche (age at onset);
SARC	cis	rs17270561	0.609	rs1165155	chr6:25795577	A/T	cg17691542	chr6:26056736	HIST1H1C	0.45	5.49	0.34	1.05e-7	Iron status biomarkers;
SARC	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg18252515	chr7:66147081	NA	0.47	5.11	0.32	6.8e-7	Aortic root size;
SARC	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg18252515	chr7:66147081	NA	1.35	12.11	0.62	1.7e-26	Diabetic kidney disease;
SARC	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.71	9.69	0.54	7.03e-19	Menarche (age at onset);
SARC	cis	rs4563143	0.514	rs73029076	chr19:29292032	G/T	cg03161606	chr19:29218774	NA	0.42	5.28	0.33	2.9e-7	Methadone dose in opioid dependence;
SARC	cis	rs35146811	0.844	rs59261051	chr7:99650429	C/T	cg22004693	chr7:99632812	ZKSCAN1	-0.45	-4.91	-0.31	1.74e-6	Coronary artery disease;
SARC	cis	rs644799	1.000	rs617999	chr11:95589935	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.9	13.36	0.66	1.35e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs8031584	0.958	rs3512	chr15:31235005	G/C	cg14829155	chr15:31115871	NA	-0.42	-5.23	-0.32	3.72e-7	Huntington's disease progression;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09226159	chr3:97483488	ARL6	-0.53	-6.89	-0.41	5.2e-11	Smoking initiation;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg24829313	chr11:63684597	RCOR2	0.49	6.47	0.39	5.62e-10	Chemerin levels;
SARC	cis	rs9815354	1.000	rs12639255	chr3:41861738	T/C	cg03022575	chr3:42003672	ULK4	0.57	5.32	0.33	2.38e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9818758	0.607	rs34580506	chr3:49113713	C/A	cg07636037	chr3:49044803	WDR6	-0.78	-6.78	-0.41	9.86e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs523522	0.962	rs10849759	chr12:120994488	T/A	cg27279351	chr12:120934652	DYNLL1	0.71	8.82	0.5	2.71e-16	High light scatter reticulocyte count;
SARC	trans	rs1957429	0.614	rs72625640	chr14:65333231	G/A	cg10286983	chr6:24494717	ALDH5A1	-0.71	-6.29	-0.38	1.52e-9	Pediatric areal bone mineral density (radius);
SARC	cis	rs9304742	0.962	rs1808106	chr19:53452944	T/G	cg24044776	chr19:53454761	ZNF816A	-0.38	-5.26	-0.33	3.31e-7	Psoriasis;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg12769354	chr4:140004069	ELF2	0.51	6.38	0.39	9.62e-10	Breast cancer;
SARC	cis	rs6728642	0.572	rs60621865	chr2:97598001	T/C	cg26665480	chr2:98280029	ACTR1B	-0.72	-7.49	-0.44	1.45e-12	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs9486719	1.000	rs2472887	chr6:96865437	A/G	cg06623918	chr6:96969491	KIAA0776	0.73	8.01	0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs763121	0.853	rs1013338	chr22:38974154	C/A	cg21395723	chr22:39101663	GTPBP1	0.58	6.92	0.41	4.3e-11	Menopause (age at onset);
SARC	cis	rs7945705	0.714	rs2653570	chr11:8987823	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-7.02	-0.42	2.35e-11	Hemoglobin concentration;
SARC	cis	rs7315438	0.600	rs1874893	chr12:115886473	A/G	cg00387115	chr12:115889598	NA	0.35	4.75	0.3	3.53e-6	Colorectal cancer;
SARC	cis	rs12922317	0.538	rs446289	chr16:12070486	T/G	cg02368508	chr16:12060182	TNFRSF17	-0.41	-6.73	-0.4	1.33e-10	Schizophrenia;
SARC	cis	rs2120019	1.000	rs12910644	chr15:75358388	A/G	cg17294928	chr15:75287854	SCAMP5	-0.96	-13.78	-0.67	5.52e-32	Blood trace element (Zn levels);
SARC	cis	rs3770770	0.953	rs17020136	chr2:37248015	T/C	cg14987922	chr2:37194071	STRN	-0.51	-5.0	-0.31	1.13e-6	QRS duration;
SARC	cis	rs7264396	0.513	rs3787169	chr20:34419884	G/A	cg01084648	chr20:34329383	RBM39	0.63	5.01	0.31	1.09e-6	Total cholesterol levels;
SARC	cis	rs4713118	0.597	rs172166	chr6:28020820	C/G	cg17221315	chr6:27791827	HIST1H4J	0.52	5.27	0.33	3.1e-7	Parkinson's disease;
SARC	cis	rs2153535	0.580	rs9406165	chr6:8488837	C/T	cg21535247	chr6:8435926	SLC35B3	0.56	6.95	0.41	3.56e-11	Motion sickness;
SARC	cis	rs66573146	1.000	rs67067921	chr4:6984341	A/T	cg00086871	chr4:6988644	TBC1D14	0.99	5.28	0.33	2.99e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg15145296	chr3:125709740	NA	-0.45	-4.78	-0.3	3.12e-6	Blood pressure (smoking interaction);
SARC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg20102877	chr2:27665638	KRTCAP3	-0.37	-5.25	-0.33	3.44e-7	Total body bone mineral density;
SARC	cis	rs7043114	0.525	rs10992374	chr9:95336327	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.5	-6.11	-0.37	4.13e-9	Height;
SARC	cis	rs9858542	0.953	rs9821311	chr3:49543656	C/T	cg07274523	chr3:49395745	GPX1	0.53	6.13	0.37	3.82e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs2120243	0.625	rs4482625	chr3:157096009	G/A	cg24825693	chr3:157122686	VEPH1	-0.42	-5.73	-0.35	3.15e-8	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs2204008	0.619	rs8189576	chr12:38307275	G/A	cg26384229	chr12:38710491	ALG10B	-0.6	-7.47	-0.44	1.6e-12	Bladder cancer;
SARC	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.37	-4.8	-0.3	2.78e-6	Bronchopulmonary dysplasia;
SARC	cis	rs17376456	0.597	rs11135401	chr5:93365716	G/A	cg25358565	chr5:93447407	FAM172A	-0.83	-9.72	-0.54	5.8e-19	Diabetic retinopathy;
SARC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg19318889	chr4:1322082	MAEA	0.42	5.15	0.32	5.59e-7	Longevity;
SARC	cis	rs9916302	0.706	rs8069074	chr17:37685401	C/T	cg00129232	chr17:37814104	STARD3	0.57	6.03	0.37	6.21e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg03806693	chr22:41940476	POLR3H	0.83	11.73	0.61	2.8e-25	Vitiligo;
SARC	cis	rs11098499	0.542	rs7677836	chr4:120310638	T/A	cg09307838	chr4:120376055	NA	0.91	12.88	0.65	4.9e-29	Corneal astigmatism;
SARC	cis	rs2481665	0.772	rs12730782	chr1:62537265	A/G	cg18591186	chr1:62594603	INADL	-0.55	-7.38	-0.44	2.76e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	trans	rs1945213	0.694	rs7122627	chr11:55862565	A/G	cg15704280	chr7:45808275	SEPT13	0.66	6.87	0.41	5.7e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg25703541	chr22:24373054	LOC391322	0.79	10.11	0.55	3.75e-20	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9462027	0.628	rs2814957	chr6:34702689	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.91	-0.36	1.19e-8	Systemic lupus erythematosus;
SARC	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg07636037	chr3:49044803	WDR6	0.74	10.83	0.58	2.07e-22	Menarche (age at onset);
SARC	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	10.12	0.55	3.42e-20	Platelet count;
SARC	cis	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.8	-0.46	2.01e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs6988636	1.000	rs57902736	chr8:124189893	G/A	cg23067535	chr8:124195133	FAM83A	-0.67	-5.3	-0.33	2.71e-7	Urinary uromodulin levels;
SARC	cis	rs2276314	0.857	rs28530656	chr18:33588700	C/T	cg19628046	chr18:33552617	C18orf21	-0.58	-6.34	-0.38	1.16e-9	Endometriosis;Drug-induced torsades de pointes;
SARC	trans	rs877282	0.898	rs10904547	chr10:766283	C/T	cg22713356	chr15:30763199	NA	1.04	10.06	0.55	5.37e-20	Uric acid levels;
SARC	cis	rs66573146	1.000	rs73088528	chr4:6967747	G/C	cg00086871	chr4:6988644	TBC1D14	0.91	5.07	0.32	8.14e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs1971762	0.545	rs7297461	chr12:54047178	A/T	cg06632207	chr12:54070931	ATP5G2	0.6	8.15	0.47	2.25e-14	Height;
SARC	cis	rs11098499	0.575	rs9996586	chr4:120326942	A/G	cg09307838	chr4:120376055	NA	0.54	7.39	0.44	2.63e-12	Corneal astigmatism;
SARC	cis	rs2228479	0.702	rs3819574	chr16:89826630	G/A	cg26513180	chr16:89883248	FANCA	0.72	4.79	0.3	2.94e-6	Skin colour saturation;
SARC	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg22968622	chr17:43663579	NA	-1.13	-15.28	-0.71	5.37e-37	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs995000	0.899	rs1305520	chr1:62926057	A/T	cg06896770	chr1:63153194	DOCK7	-0.91	-13.95	-0.67	1.45e-32	Triglyceride levels;
SARC	cis	rs6500395	0.775	rs7191225	chr16:48662675	C/G	cg04672837	chr16:48644449	N4BP1	0.43	5.85	0.36	1.63e-8	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs1003719	0.751	rs55740803	chr21:38542761	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.38	-0.52	5.99e-18	Eye color traits;
SARC	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg03647317	chr4:187891568	NA	-0.41	-6.13	-0.37	3.67e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs79149102	0.579	rs74025863	chr15:75284161	T/C	cg17294928	chr15:75287854	SCAMP5	-0.99	-8.81	-0.5	2.87e-16	Lung cancer;
SARC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg02353165	chr6:42928485	GNMT	-0.63	-8.79	-0.5	3.45e-16	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs2832077	0.943	rs2832106	chr21:30191767	A/G	cg24692254	chr21:30365293	RNF160	-0.53	-4.88	-0.3	2.01e-6	Cognitive test performance;
SARC	cis	rs6696846	0.515	rs11240364	chr1:205105917	C/G	cg00857998	chr1:205179979	DSTYK	0.4	4.8	0.3	2.89e-6	Red blood cell count;
SARC	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg01570182	chr17:44337453	NA	0.86	9.7	0.54	6.74e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs12477438	0.765	rs7571390	chr2:99626593	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-15.64	-0.72	3.44e-38	Chronic sinus infection;
SARC	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg21132104	chr15:45694354	SPATA5L1	0.77	10.98	0.58	6.87e-23	Homoarginine levels;
SARC	cis	rs78487399	0.808	rs77852659	chr2:43761652	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-5.11	-0.32	6.6e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs7829975	0.511	rs1401390	chr8:8136410	C/T	cg08975724	chr8:8085496	FLJ10661	0.66	8.81	0.5	2.93e-16	Mood instability;
SARC	trans	rs10506458	0.915	rs2013042	chr12:63394211	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.74	-6.26	-0.38	1.81e-9	Hemostatic factors and hematological phenotypes;
SARC	cis	rs1008375	0.933	rs7689101	chr4:17694034	G/A	cg27347728	chr4:17578864	LAP3	0.46	5.73	0.35	3.07e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs3796352	1.000	rs3806692	chr3:53080987	C/G	cg15956490	chr3:53032818	SFMBT1	0.73	5.34	0.33	2.18e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs11644362	0.966	rs4781348	chr16:12986742	A/C	cg06890432	chr16:12997467	SHISA9	-0.47	-6.23	-0.38	2.2e-9	Positive affect;Subjective well-being;
SARC	trans	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg00938859	chr5:1591904	SDHAP3	0.8	7.55	0.44	9.66e-13	Breast cancer;
SARC	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg11890956	chr21:40555474	PSMG1	1.16	19.38	0.79	1.73e-50	Cognitive function;
SARC	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg11764359	chr7:65958608	NA	-0.8	-9.66	-0.53	8.63e-19	Aortic root size;
SARC	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg13206674	chr6:150067644	NUP43	0.41	5.37	0.33	1.95e-7	Lung cancer;
SARC	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg16132339	chr22:24313637	DDTL;DDT	0.44	5.76	0.35	2.64e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg08677398	chr8:58056175	NA	0.44	5.25	0.33	3.38e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs4144743	1.000	rs11871407	chr17:45331358	C/G	cg18085866	chr17:45331354	ITGB3	-0.72	-7.26	-0.43	5.77e-12	Body mass index;
SARC	cis	rs9457247	0.905	rs444210	chr6:167390242	A/G	cg07741184	chr6:167504864	NA	0.28	5.32	0.33	2.48e-7	Crohn's disease;
SARC	cis	rs60843830	0.633	rs1078763	chr2:113763	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	-0.58	-8.29	-0.48	9.2e-15	Spherical equivalent (joint analysis main effects and education interaction);
SARC	trans	rs9850225	0.801	rs521796	chr3:80674387	A/C	cg19992450	chr8:141613380	EIF2C2	0.49	6.34	0.38	1.19e-9	Erectile dysfunction in type 1 diabetes;
SARC	cis	rs995000	0.783	rs6686331	chr1:63182135	C/T	cg06896770	chr1:63153194	DOCK7	-0.84	-12.3	-0.63	3.95e-27	Triglyceride levels;
SARC	cis	rs3820928	0.904	rs2894623	chr2:227766112	T/C	cg05526886	chr2:227700861	RHBDD1	-0.51	-6.08	-0.37	4.88e-9	Pulmonary function;
SARC	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg08048268	chr3:133502702	NA	-0.43	-5.73	-0.35	3.03e-8	Iron status biomarkers;
SARC	cis	rs8064299	0.597	rs6501737	chr17:72780830	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.8	-10.88	-0.58	1.49e-22	Monocyte count;
SARC	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg26335602	chr6:28129616	ZNF389	0.53	5.92	0.36	1.12e-8	Depression;
SARC	cis	rs2976388	0.573	rs1529865	chr8:143789171	C/T	cg06565975	chr8:143823917	SLURP1	0.32	5.53	0.34	8.39e-8	Urinary tract infection frequency;
SARC	cis	rs1865760	0.622	rs10946807	chr6:26079638	T/C	cg10373733	chr6:25993375	NA	0.52	5.93	0.36	1.1e-8	Height;
SARC	cis	rs11098499	0.866	rs72676074	chr4:120359841	A/C	cg09307838	chr4:120376055	NA	0.91	12.98	0.65	2.42e-29	Corneal astigmatism;
SARC	cis	rs7524258	0.868	rs916393	chr1:7272250	T/C	cg07173049	chr1:7289937	CAMTA1	0.36	6.89	0.41	5.1e-11	Tourette's syndrome or obsessive-compulsive disorder;
SARC	cis	rs6772849	0.930	rs4857912	chr3:128329224	G/A	cg08795948	chr3:128337044	NA	0.55	7.78	0.45	2.36e-13	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs8014204	0.870	rs3742790	chr14:75308758	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.71	-10.51	-0.57	2.2e-21	Caffeine consumption;
SARC	cis	rs11690935	0.851	rs10930502	chr2:172890588	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.7	-9.31	-0.52	1.02e-17	Schizophrenia;
SARC	cis	rs3733585	0.673	rs7376505	chr4:9952744	C/A	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.94	-0.36	1.06e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs6840258	1.000	rs56201818	chr4:87952633	T/C	cg11209507	chr4:87813803	C4orf36	0.43	4.72	0.3	4.12e-6	Mean corpuscular volume;Basophil percentage of granulocytes;
SARC	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg24675658	chr1:53192096	ZYG11B	-0.56	-7.89	-0.46	1.16e-13	Monocyte count;
SARC	cis	rs2235642	0.826	rs8053605	chr16:1594158	G/A	cg09025071	chr16:1593152	IFT140;TMEM204	0.33	4.82	0.3	2.62e-6	Coronary artery disease;
SARC	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg18252515	chr7:66147081	NA	-0.57	-6.2	-0.38	2.51e-9	Aortic root size;
SARC	cis	rs6570726	0.791	rs385729	chr6:145855465	T/C	cg23711669	chr6:146136114	FBXO30	0.87	14.71	0.69	4.26e-35	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11581859	0.613	rs1482139	chr1:99206542	G/A	cg20286094	chr1:99190917	SNX7	-0.42	-4.89	-0.31	1.86e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	trans	rs61931739	0.534	rs1384860	chr12:34045388	T/C	cg26384229	chr12:38710491	ALG10B	0.75	10.62	0.57	9.96e-22	Morning vs. evening chronotype;
SARC	cis	rs6456156	0.586	rs1407315	chr6:167468659	A/G	cg07741184	chr6:167504864	NA	0.36	7.09	0.42	1.62e-11	Primary biliary cholangitis;
SARC	cis	rs763014	0.898	rs2017567	chr16:637212	T/C	cg09263875	chr16:632152	PIGQ	0.51	7.61	0.45	6.8e-13	Height;
SARC	cis	rs6088580	0.634	rs6142164	chr20:33006597	C/T	cg24642439	chr20:33292090	TP53INP2	-0.66	-8.63	-0.49	9.96e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs2425143	1.000	rs79035779	chr20:34343004	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-6.15	-0.37	3.37e-9	Blood protein levels;
SARC	cis	rs10089	0.552	rs11955148	chr5:127557814	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.58	6.05	0.37	5.74e-9	Ileal carcinoids;
SARC	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg08677398	chr8:58056175	NA	0.43	5.13	0.32	6.07e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs13202913	0.733	rs13215869	chr6:151803659	G/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.76	6.45	0.39	6.54e-10	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs2481665	0.775	rs2476201	chr1:62619960	C/T	cg18591186	chr1:62594603	INADL	0.57	7.98	0.46	6.45e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2204008	0.777	rs2049130	chr12:38444837	G/A	cg13010199	chr12:38710504	ALG10B	0.72	9.15	0.51	3.01e-17	Bladder cancer;
SARC	cis	rs908922	0.651	rs7529157	chr1:152531365	C/A	cg09873164	chr1:152488093	CRCT1	0.61	7.84	0.46	1.6e-13	Hair morphology;
SARC	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	5.42	0.33	1.47e-7	Bipolar disorder;
SARC	cis	rs9815354	1.000	rs3890604	chr3:41760625	C/T	cg03022575	chr3:42003672	ULK4	0.55	5.23	0.32	3.75e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs1408799	0.720	rs13284453	chr9:12724280	C/T	cg05274944	chr9:12693694	TYRP1	0.35	5.2	0.32	4.28e-7	Eye color;Blue vs. green eyes;
SARC	cis	rs9911578	0.935	rs2567912	chr17:56731270	T/C	cg05425664	chr17:57184151	TRIM37	-0.66	-8.32	-0.48	7.43e-15	Intelligence (multi-trait analysis);
SARC	cis	rs4975241	1.000	rs4975241	chr4:129526996	C/G	cg26838532	chr4:128983634	LARP1B	0.69	4.72	0.3	4.15e-6	Type 2 diabetes;
SARC	cis	rs4671400	0.571	rs68020555	chr2:61485782	G/A	cg10580144	chr2:61372316	C2orf74	-0.4	-5.19	-0.32	4.68e-7	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs950169	1.000	rs950169	chr15:84706461	C/T	cg17507749	chr15:85114479	UBE2QP1	0.76	9.27	0.52	1.28e-17	Schizophrenia;
SARC	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg00933542	chr6:150070202	PCMT1	0.32	5.31	0.33	2.55e-7	Lung cancer;
SARC	cis	rs1008375	0.932	rs6845288	chr4:17665498	A/T	cg02297831	chr4:17616191	MED28	-0.43	-5.28	-0.33	2.93e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	8.05	0.47	4.34e-14	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg09373136	chr17:61933544	TCAM1	-0.45	-6.12	-0.37	3.9e-9	Prudent dietary pattern;
SARC	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg16606324	chr3:10149918	C3orf24	0.51	4.95	0.31	1.39e-6	Alzheimer's disease;
SARC	cis	rs10791323	0.628	rs2853117	chr11:133705266	T/G	cg14349672	chr11:133703707	NA	-0.39	-5.79	-0.35	2.32e-8	Childhood ear infection;
SARC	cis	rs1707322	0.721	rs12049027	chr1:46118184	A/T	cg03146154	chr1:46216737	IPP	0.52	6.32	0.38	1.33e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6582630	0.524	rs10785494	chr12:38532431	C/G	cg26384229	chr12:38710491	ALG10B	-0.57	-7.22	-0.43	7.37e-12	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg16606324	chr3:10149918	C3orf24	0.48	5.04	0.31	9.53e-7	Alzheimer's disease;
SARC	cis	rs4295623	0.553	rs34962960	chr8:11594597	G/A	cg00262122	chr8:11665843	FDFT1	-0.46	-5.48	-0.34	1.08e-7	Morning vs. evening chronotype;
SARC	cis	rs3733585	0.699	rs6815001	chr4:9958662	G/C	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.55	-0.34	7.65e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs8014204	0.566	rs11629369	chr14:75162021	G/A	cg06637938	chr14:75390232	RPS6KL1	0.59	8.64	0.49	9.29e-16	Caffeine consumption;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg18151519	chr1:193053877	TROVE2	0.48	6.89	0.41	5.23e-11	Thyroid stimulating hormone;
SARC	cis	rs6728642	0.519	rs4260285	chr2:97570081	A/G	cg26665480	chr2:98280029	ACTR1B	-0.61	-5.57	-0.34	6.89e-8	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs6665290	0.904	rs1186	chr1:227177731	A/T	cg14016676	chr1:227182615	CDC42BPA	0.34	5.03	0.31	1e-6	Myeloid white cell count;
SARC	cis	rs10779751	0.734	rs1211575	chr1:11118390	G/A	cg08854313	chr1:11322531	MTOR	0.85	11.66	0.61	4.79e-25	Body mass index;
SARC	cis	rs4820294	1.000	rs7291867	chr22:38062112	C/G	cg21798802	chr22:38057573	PDXP	0.39	5.85	0.36	1.62e-8	Fat distribution (HIV);
SARC	cis	rs2070488	1.000	rs2268757	chr3:38505853	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	14.23	0.68	1.7e-33	Electrocardiographic conduction measures;
SARC	cis	rs9467711	0.591	rs9467635	chr6:25909166	A/C	cg21479132	chr6:26055353	NA	0.74	4.72	0.3	4.08e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs4423214	1.000	rs12419279	chr11:71139061	T/A	cg05163923	chr11:71159392	DHCR7	0.66	8.69	0.49	6.41e-16	Vitamin D levels;
SARC	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg12667521	chr19:29218732	NA	0.4	5.4	0.33	1.61e-7	Methadone dose in opioid dependence;
SARC	cis	rs4148883	0.603	rs6833176	chr4:100131163	G/C	cg12011299	chr4:100065546	ADH4	-0.35	-6.25	-0.38	1.96e-9	Alcohol dependence;
SARC	cis	rs7772486	0.658	rs6570706	chr6:145962922	T/C	cg05347473	chr6:146136440	FBXO30	0.51	7.13	0.42	1.25e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs9457247	1.000	rs376551	chr6:167384923	G/A	cg07741184	chr6:167504864	NA	0.3	5.62	0.35	5.54e-8	Crohn's disease;
SARC	cis	rs3824867	0.920	rs4752836	chr11:47465095	T/C	cg20307385	chr11:47447363	PSMC3	0.48	5.24	0.32	3.68e-7	Mean corpuscular hemoglobin;
SARC	cis	rs6582630	0.594	rs7308707	chr12:38450428	G/C	cg26384229	chr12:38710491	ALG10B	-0.55	-6.82	-0.41	7.76e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs172166	0.769	rs149965	chr6:28018689	T/A	cg17221315	chr6:27791827	HIST1H4J	0.46	4.94	0.31	1.49e-6	Cardiac Troponin-T levels;
SARC	cis	rs10791111	1	rs10791111	chr11:130856099	T/G	cg12179176	chr11:130786555	SNX19	0.64	8.54	0.49	1.74e-15	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1448094	0.872	rs7313373	chr12:86398370	C/G	cg02569458	chr12:86230093	RASSF9	0.38	5.7	0.35	3.56e-8	Major depressive disorder;
SARC	cis	rs10992471	0.512	rs331379	chr9:95261104	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.42	-5.21	-0.32	4.12e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs453301	0.652	rs2043129	chr8:8825504	C/G	cg06636001	chr8:8085503	FLJ10661	0.62	7.8	0.46	2.03e-13	Joint mobility (Beighton score);
SARC	cis	rs9905704	0.846	rs302877	chr17:56764018	G/A	cg12560992	chr17:57184187	TRIM37	0.45	5.23	0.32	3.77e-7	Testicular germ cell tumor;
SARC	cis	rs9457247	0.967	rs428805	chr6:167403132	C/A	cg07741184	chr6:167504864	NA	0.29	5.55	0.34	7.59e-8	Crohn's disease;
SARC	cis	rs1707322	0.682	rs12037459	chr1:46094959	T/G	cg03146154	chr1:46216737	IPP	0.51	5.99	0.37	7.72e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg09165964	chr15:75287851	SCAMP5	0.52	7.0	0.42	2.78e-11	Breast cancer;
SARC	cis	rs4555082	1.000	rs7146012	chr14:105757566	G/A	cg06808227	chr14:105710500	BRF1	-0.46	-5.7	-0.35	3.55e-8	Mean platelet volume;Platelet distribution width;
SARC	cis	rs72781680	0.678	rs2551341	chr2:24014778	G/T	cg06627628	chr2:24431161	ITSN2	-0.54	-5.49	-0.34	1.04e-7	Lymphocyte counts;
SARC	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg16606324	chr3:10149918	C3orf24	0.5	5.01	0.31	1.08e-6	Alzheimer's disease;
SARC	cis	rs13401104	0.796	rs72617202	chr2:237108405	T/C	cg19324714	chr2:237145437	ASB18	0.58	5.74	0.35	2.94e-8	Educational attainment;
SARC	cis	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg15145296	chr3:125709740	NA	-0.45	-4.78	-0.3	3.06e-6	Blood pressure (smoking interaction);
SARC	cis	rs1728785	0.901	rs3087783	chr16:68599668	C/T	cg02972257	chr16:68554789	NA	-0.48	-5.63	-0.35	5.29e-8	Ulcerative colitis;
SARC	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg01316550	chr5:56110833	MAP3K1	0.53	4.81	0.3	2.74e-6	Initial pursuit acceleration;
SARC	cis	rs3762637	1.000	rs28497203	chr3:122231819	T/C	cg24169773	chr3:122142474	KPNA1	-0.56	-5.61	-0.34	5.77e-8	LDL cholesterol levels;
SARC	cis	rs73635312	0.778	rs113677559	chr10:8962007	T/C	cg24467326	chr10:9646929	NA	0.61	5.08	0.32	7.78e-7	Basal cell carcinoma;
SARC	cis	rs13191362	1.000	rs34066731	chr6:163011047	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.56	5.35	0.33	2.07e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg09858160	chr5:162943755	MAT2B	0.49	6.92	0.41	4.23e-11	Thyroid stimulating hormone;
SARC	cis	rs9325144	0.555	rs1843867	chr12:38703855	A/G	cg13010199	chr12:38710504	ALG10B	-0.54	-7.02	-0.42	2.42e-11	Morning vs. evening chronotype;
SARC	cis	rs7980687	0.662	rs585522	chr12:123550813	A/G	cg00376283	chr12:123451042	ABCB9	0.54	6.27	0.38	1.71e-9	Height;Educational attainment;Head circumference (infant);
SARC	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg10591111	chr5:226296	SDHA	-0.52	-4.79	-0.3	2.93e-6	Breast cancer;
SARC	cis	rs7587476	0.784	rs62202001	chr2:215690359	C/G	cg11970703	chr2:215861251	ABCA12	-0.31	-4.75	-0.3	3.63e-6	Neuroblastoma;
SARC	cis	rs9290065	0.538	rs9840600	chr3:160769101	G/A	cg03342759	chr3:160939853	NMD3	-0.57	-6.99	-0.42	2.82e-11	Kawasaki disease;
SARC	cis	rs7086627	0.515	rs11202963	chr10:82210392	A/G	cg00277334	chr10:82204260	NA	-0.57	-9.45	-0.53	3.67e-18	Post bronchodilator FEV1;
SARC	cis	rs2153535	0.580	rs1577467	chr6:8444241	G/A	cg07606381	chr6:8435919	SLC35B3	0.78	11.09	0.59	3.11e-23	Motion sickness;
SARC	cis	rs12579753	0.917	rs7138651	chr12:82253615	A/G	cg07988820	chr12:82153109	PPFIA2	0.48	5.85	0.36	1.69e-8	Resting heart rate;
SARC	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg17971929	chr21:40555470	PSMG1	0.98	13.57	0.66	2.58e-31	Cognitive function;
SARC	trans	rs1814175	0.817	rs10839358	chr11:49770972	G/A	cg15704280	chr7:45808275	SEPT13	-0.97	-18.04	-0.76	3.96e-46	Height;
SARC	cis	rs36051895	0.659	rs10815150	chr9:5067301	C/A	cg02405213	chr9:5042618	JAK2	-0.47	-5.42	-0.33	1.48e-7	Pediatric autoimmune diseases;
SARC	cis	rs2153535	0.601	rs1928183	chr6:8530018	A/G	cg21535247	chr6:8435926	SLC35B3	0.54	6.84	0.41	6.76e-11	Motion sickness;
SARC	cis	rs6582630	0.638	rs12425531	chr12:38550387	A/G	cg13010199	chr12:38710504	ALG10B	-0.52	-6.44	-0.39	6.84e-10	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs12545109	0.800	rs1553969	chr8:57420187	A/G	cg09654669	chr8:57350985	NA	-0.39	-4.98	-0.31	1.26e-6	Obesity-related traits;
SARC	cis	rs703842	0.642	rs73123375	chr12:58063664	C/T	cg00677455	chr12:58241039	CTDSP2	0.55	6.06	0.37	5.53e-9	Multiple sclerosis;
SARC	cis	rs4803468	1.000	rs17318666	chr19:41940342	T/G	cg09537434	chr19:41945824	ATP5SL	0.97	16.95	0.74	1.56e-42	Height;
SARC	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg00275962	chr6:43484808	POLR1C;YIPF3	0.49	6.84	0.41	6.72e-11	Cancer;
SARC	cis	rs273218	0.951	rs428213	chr5:53382790	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.67	-7.55	-0.44	9.84e-13	Migraine;
SARC	cis	rs7726839	0.555	rs4541696	chr5:581053	A/G	cg09021430	chr5:549028	NA	-0.53	-11.03	-0.59	5.03e-23	Obesity-related traits;
SARC	cis	rs2425143	1.000	rs12479473	chr20:34398628	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.66	5.23	0.32	3.86e-7	Blood protein levels;
SARC	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg06618935	chr21:46677482	NA	-0.4	-5.41	-0.33	1.54e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs854765	0.547	rs2955385	chr17:17939247	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	9.58	0.53	1.58e-18	Total body bone mineral density;
SARC	cis	rs4930103	0.534	rs2063550	chr11:1979223	G/C	cg23202291	chr11:1979235	NA	0.42	5.38	0.33	1.8e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg04205664	chr7:139209511	CLEC2L	0.53	7.36	0.43	3.09e-12	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs3820928	0.874	rs12105952	chr2:227864521	G/A	cg05526886	chr2:227700861	RHBDD1	-0.5	-6.01	-0.37	7.28e-9	Pulmonary function;
SARC	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg04234412	chr22:24373322	LOC391322	-0.52	-6.31	-0.38	1.4e-9	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg07648498	chr16:89883185	FANCA	0.45	5.73	0.35	3.08e-8	Vitiligo;
SARC	cis	rs965469	1.000	rs6037551	chr20:3306690	T/C	cg25506879	chr20:3388711	C20orf194	-0.5	-5.08	-0.32	7.89e-7	IFN-related cytopenia;
SARC	cis	rs1538970	1.000	rs7417107	chr1:45831915	G/C	cg05343316	chr1:45956843	TESK2	0.65	7.6	0.45	7.13e-13	Platelet count;
SARC	cis	rs1707322	0.963	rs4660900	chr1:46419605	T/C	cg06784218	chr1:46089804	CCDC17	0.34	5.98	0.36	8.31e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6087990	0.806	rs2424918	chr20:31382770	C/T	cg13636640	chr20:31349939	DNMT3B	0.83	13.46	0.66	6.33e-31	Ulcerative colitis;
SARC	cis	rs897080	0.515	rs786616	chr2:44592975	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.62	7.4	0.44	2.48e-12	Height;
SARC	cis	rs9325144	0.510	rs6582599	chr12:38715965	T/G	cg13010199	chr12:38710504	ALG10B	0.56	7.32	0.43	3.97e-12	Morning vs. evening chronotype;
SARC	cis	rs9660992	0.700	rs7547565	chr1:205259402	G/A	cg07972983	chr1:205091412	RBBP5	-0.52	-6.36	-0.38	1.08e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs752010	1.000	rs4999015	chr1:42093547	G/A	cg06885757	chr1:42089581	HIVEP3	0.34	5.48	0.34	1.11e-7	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs7712401	0.601	rs30060	chr5:122296700	T/C	cg19412675	chr5:122181750	SNX24	0.4	5.13	0.32	5.98e-7	Mean platelet volume;
SARC	cis	rs9611198	0.765	rs5757721	chr22:39947574	A/G	cg10455938	chr22:40058150	CACNA1I	0.39	4.83	0.3	2.48e-6	Schizophrenia;
SARC	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg25405998	chr7:65216604	CCT6P1	0.51	6.15	0.37	3.29e-9	Calcium levels;
SARC	cis	rs7828089	0.561	rs13266541	chr8:22266135	G/A	cg12081754	chr8:22256438	SLC39A14	0.65	8.85	0.5	2.24e-16	Verbal declarative memory;
SARC	cis	rs7582180	0.663	rs2053263	chr2:100971407	A/G	cg14675211	chr2:100938903	LONRF2	0.54	7.97	0.46	7.06e-14	Intelligence (multi-trait analysis);
SARC	cis	rs10162002	0.872	rs3764067	chr13:24042897	T/C	cg00158254	chr13:24040743	NA	0.51	4.89	0.31	1.86e-6	Hypothyroidism;
SARC	cis	rs11792861	0.926	rs11788904	chr9:111865052	T/C	cg13535736	chr9:111863775	C9orf5	-0.4	-4.89	-0.31	1.87e-6	Menarche (age at onset);
SARC	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.72	8.41	0.48	4.24e-15	Height;
SARC	cis	rs2204008	0.623	rs1607878	chr12:38376000	A/G	cg26384229	chr12:38710491	ALG10B	0.85	12.17	0.62	1.02e-26	Bladder cancer;
SARC	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg00800038	chr16:89945340	TCF25	-0.72	-5.75	-0.35	2.8e-8	Skin colour saturation;
SARC	cis	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg03060546	chr3:49711283	APEH	0.75	11.17	0.59	1.7e-23	Resting heart rate;
SARC	cis	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg07274523	chr3:49395745	GPX1	0.49	5.58	0.34	6.49e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs3784262	0.934	rs7164408	chr15:58259336	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.41	-6.05	-0.37	5.79e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg18876405	chr7:65276391	NA	-0.45	-5.04	-0.31	9.18e-7	Aortic root size;
SARC	cis	rs16976116	0.855	rs28522816	chr15:55495114	C/G	cg11288833	chr15:55489084	RSL24D1	0.63	6.13	0.37	3.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6831352	0.879	rs2602888	chr4:100041706	C/T	cg12011299	chr4:100065546	ADH4	0.33	5.57	0.34	7.13e-8	Alcohol dependence;
SARC	cis	rs11105298	0.786	rs10858897	chr12:89922032	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.53	-5.33	-0.33	2.3e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs7586879	0.639	rs7580081	chr2:25097072	G/C	cg04586622	chr2:25135609	ADCY3	0.31	5.38	0.33	1.79e-7	Body mass index;
SARC	cis	rs6866344	0.601	rs4419608	chr5:178097049	C/T	cg10224037	chr5:178157518	ZNF354A	0.8	8.42	0.48	3.91e-15	Neutrophil percentage of white cells;
SARC	trans	rs61931739	0.500	rs11053193	chr12:34438838	G/T	cg13010199	chr12:38710504	ALG10B	0.81	11.39	0.6	3.58e-24	Morning vs. evening chronotype;
SARC	cis	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg01579765	chr21:45077557	HSF2BP	-0.38	-6.46	-0.39	5.93e-10	Mean corpuscular volume;
SARC	cis	rs10791323	0.519	rs329663	chr11:133754543	A/G	cg15485101	chr11:133734466	NA	0.32	5.09	0.32	7.38e-7	Childhood ear infection;
SARC	cis	rs992157	0.835	rs7559416	chr2:219150211	A/G	cg00012203	chr2:219082015	ARPC2	-0.65	-9.51	-0.53	2.5e-18	Colorectal cancer;
SARC	cis	rs3857536	0.904	rs4710577	chr6:66898073	A/G	cg07460842	chr6:66804631	NA	-0.44	-5.27	-0.33	3.08e-7	Blood trace element (Cu levels);
SARC	cis	rs924043	0.636	rs80251809	chr6:170382335	G/A	cg17770813	chr6:170484120	NA	0.49	5.1	0.32	6.97e-7	Type 1 diabetes;
SARC	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg19223190	chr17:80058835	NA	0.44	6.04	0.37	6.02e-9	Life satisfaction;
SARC	cis	rs6831352	0.840	rs17817868	chr4:100060623	C/T	cg13256891	chr4:100009986	ADH5	-0.65	-8.0	-0.46	5.94e-14	Alcohol dependence;
SARC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg10862848	chr6:42927986	GNMT	-0.45	-7.44	-0.44	1.97e-12	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs7191700	0.644	rs918738	chr16:11439679	C/G	cg00044050	chr16:11439710	C16orf75	-0.41	-5.05	-0.31	8.99e-7	Multiple sclerosis;
SARC	cis	rs6582630	0.555	rs10880602	chr12:38505660	T/C	cg13010199	chr12:38710504	ALG10B	0.73	10.17	0.55	2.35e-20	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs637571	0.584	rs594689	chr11:65635559	G/A	cg17712092	chr4:129076599	LARP1B	-0.55	-7.24	-0.43	6.51e-12	Eosinophil percentage of white cells;
SARC	cis	rs1008375	1.000	rs10939742	chr4:17659936	G/T	cg27347728	chr4:17578864	LAP3	0.47	5.89	0.36	1.36e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9394841	0.692	rs34073739	chr6:41829970	A/G	cg08135965	chr6:41755394	TOMM6	0.64	6.79	0.41	9.18e-11	Mean corpuscular hemoglobin;Red cell distribution width;
SARC	cis	rs7044106	0.791	rs3904196	chr9:123480369	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	6.09	0.37	4.64e-9	Hip circumference adjusted for BMI;
SARC	cis	rs614226	0.935	rs3887875	chr12:120895749	A/G	cg01236616	chr12:121019343	POP5	-1.15	-16.1	-0.73	1.02e-39	Type 1 diabetes nephropathy;
SARC	cis	rs7666738	0.546	rs7679681	chr4:98882221	A/G	cg05340658	chr4:99064831	C4orf37	0.57	7.03	0.42	2.28e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2153535	0.580	rs2327051	chr6:8441150	A/G	cg21535247	chr6:8435926	SLC35B3	-0.56	-6.82	-0.41	7.98e-11	Motion sickness;
SARC	cis	rs4072980	0.545	rs7528185	chr1:38452059	C/T	cg18451016	chr1:38461880	NA	-0.34	-4.73	-0.3	3.88e-6	Coronary artery disease;
SARC	cis	rs10875746	0.855	rs73102067	chr12:48494426	A/C	cg26205652	chr12:48591994	NA	0.56	6.1	0.37	4.43e-9	Longevity (90 years and older);
SARC	cis	rs17401966	0.931	rs61778401	chr1:10426474	G/A	cg15208524	chr1:10270712	KIF1B	0.5	5.99	0.37	7.88e-9	Hepatocellular carcinoma;
SARC	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg23221052	chr5:179740743	GFPT2	-0.55	-6.79	-0.41	9.06e-11	Height;
SARC	cis	rs10206020	0.885	rs13411553	chr2:1574018	A/G	cg26248373	chr2:1572462	NA	-0.6	-8.5	-0.49	2.24e-15	IgG glycosylation;
SARC	cis	rs78487399	0.808	rs6746632	chr2:43712163	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-5.37	-0.33	1.91e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.04	13.22	0.65	3.9e-30	Smoking behavior;
SARC	cis	rs9393692	0.905	rs9366649	chr6:26329103	A/T	cg13736514	chr6:26305472	NA	0.64	8.96	0.51	1.09e-16	Educational attainment;
SARC	cis	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg02487422	chr3:49467188	NICN1	0.5	6.66	0.4	1.9e-10	Resting heart rate;
SARC	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg11644478	chr21:40555479	PSMG1	-0.6	-7.5	-0.44	1.37e-12	Menarche (age at onset);
SARC	cis	rs17376456	0.877	rs10063045	chr5:93457584	A/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	4.94	0.31	1.52e-6	Diabetic retinopathy;
SARC	cis	rs7044106	0.708	rs2416760	chr9:123374639	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	9.1	0.51	4.25e-17	Hip circumference adjusted for BMI;
SARC	trans	rs61931739	0.857	rs1828514	chr12:34139600	A/G	cg13010199	chr12:38710504	ALG10B	0.54	7.22	0.43	7.38e-12	Morning vs. evening chronotype;
SARC	trans	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg20587970	chr11:113659929	NA	-1.35	-13.48	-0.66	5.32e-31	Hip circumference adjusted for BMI;
SARC	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg11062466	chr8:58055876	NA	-0.56	-5.23	-0.32	3.83e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs1814175	0.533	rs4528310	chr11:49983106	C/A	cg15704280	chr7:45808275	SEPT13	-0.89	-14.17	-0.68	2.8e-33	Height;
SARC	cis	rs6910061	1.000	rs9468436	chr6:11112626	C/G	cg27233058	chr6:11094804	LOC221710	0.56	5.42	0.33	1.46e-7	Diabetic kidney disease;
SARC	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.39	-6.48	-0.39	5.4e-10	Total body bone mineral density;
SARC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg22903471	chr2:27725779	GCKR	0.53	8.23	0.47	1.33e-14	Total body bone mineral density;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg09924173	chr13:32526671	EEF1DP3	-0.5	-6.31	-0.38	1.36e-9	Height;
SARC	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.46	5.09	0.32	7.3e-7	Renal function-related traits (BUN);
SARC	cis	rs28374715	0.681	rs7168307	chr15:41620534	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.96	-15.67	-0.72	2.84e-38	Ulcerative colitis;
SARC	cis	rs4595586	0.545	rs2197941	chr12:39402223	G/A	cg26384229	chr12:38710491	ALG10B	0.5	6.12	0.37	3.98e-9	Morning vs. evening chronotype;
SARC	trans	rs9388451	0.807	rs1268065	chr6:126042783	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.52	6.71	0.4	1.45e-10	Brugada syndrome;
SARC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg11494091	chr17:61959527	GH2	0.53	7.82	0.46	1.83e-13	Prudent dietary pattern;
SARC	cis	rs2952156	0.883	rs907088	chr17:37833567	G/C	cg07936489	chr17:37558343	FBXL20	-0.4	-5.28	-0.33	2.89e-7	Asthma;
SARC	trans	rs2727020	0.658	rs10839269	chr11:49385596	A/G	cg03929089	chr4:120376271	NA	-0.8	-11.95	-0.62	5.47e-26	Coronary artery disease;
SARC	cis	rs72781680	1.000	rs72796389	chr2:24171761	A/G	cg08917208	chr2:24149416	ATAD2B	0.79	7.54	0.44	1.05e-12	Lymphocyte counts;
SARC	cis	rs10489202	1.000	rs17557135	chr1:167985888	A/G	cg24449463	chr1:168025552	DCAF6	-0.64	-7.01	-0.42	2.5e-11	Schizophrenia;
SARC	cis	rs1107366	0.618	rs1447657	chr3:125929471	A/G	cg01346077	chr3:125931526	NA	0.39	5.47	0.34	1.15e-7	Metabolite levels;
SARC	cis	rs3796352	1.000	rs34933390	chr3:53006265	T/G	cg27565382	chr3:53032988	SFMBT1	0.76	5.34	0.33	2.25e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg03517284	chr6:25882590	NA	-0.43	-5.63	-0.35	5.2100000000000003e-08	Intelligence (multi-trait analysis);
SARC	cis	rs2200578	1.000	rs72961173	chr2:99886868	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	0.66	6.48	0.39	5.35e-10	IgG glycosylation;
SARC	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg13607699	chr17:42295918	UBTF	0.55	6.45	0.39	6.31e-10	Total body bone mineral density;
SARC	cis	rs9868809	0.505	rs11706203	chr3:48746239	T/A	cg03060546	chr3:49711283	APEH	-0.51	-4.74	-0.3	3.73e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs79149102	0.579	rs6495142	chr15:75320166	C/T	cg09165964	chr15:75287851	SCAMP5	-1.02	-9.12	-0.51	3.52e-17	Lung cancer;
SARC	cis	rs770189	0.955	rs6870660	chr5:88086124	A/C	cg18498987	chr5:88179539	MEF2C	-0.38	-4.72	-0.3	4.01e-6	Tonometry;
SARC	cis	rs7216064	0.628	rs62084702	chr17:66043157	C/T	cg12091567	chr17:66097778	LOC651250	0.93	12.18	0.62	9.86e-27	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs12701220	0.817	rs1058729	chr7:1087283	C/T	cg02733842	chr7:1102375	C7orf50	-0.47	-5.89	-0.36	1.37e-8	Bronchopulmonary dysplasia;
SARC	cis	rs1371867	0.875	rs1788178	chr8:101332518	A/C	cg11906718	chr8:101322791	RNF19A	0.71	9.13	0.51	3.37e-17	Atrioventricular conduction;
SARC	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg17376030	chr22:41985996	PMM1	0.64	7.84	0.46	1.64e-13	Vitiligo;
SARC	cis	rs636523	0.561	rs12403212	chr1:63199377	T/C	cg06896770	chr1:63153194	DOCK7	0.73	7.55	0.44	1.01e-12	Lipid traits;
SARC	cis	rs17270561	0.636	rs1575535	chr6:25809909	C/T	cg17691542	chr6:26056736	HIST1H1C	0.5	6.04	0.37	6.11e-9	Iron status biomarkers;
SARC	cis	rs17376456	0.825	rs10476590	chr5:93244884	A/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	5.75	0.35	2.81e-8	Diabetic retinopathy;
SARC	cis	rs13095912	0.962	rs6785918	chr3:185330631	A/G	cg11274856	chr3:185301563	NA	0.36	4.98	0.31	1.22e-6	Systolic blood pressure;
SARC	cis	rs12079745	0.793	rs12058325	chr1:169264037	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.92	-5.68	-0.35	3.93e-8	QT interval;
SARC	cis	rs6991838	0.765	rs6472219	chr8:66556722	A/T	cg13398993	chr8:66546079	ARMC1	0.45	5.82	0.36	1.93e-8	Intelligence (multi-trait analysis);
SARC	cis	rs10979	0.679	rs9403510	chr6:143892174	C/T	cg25407410	chr6:143891975	LOC285740	-0.6	-7.43	-0.44	2.01e-12	Hypospadias;
SARC	cis	rs7224737	0.750	rs2230326	chr17:40280291	G/A	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-0.57	-5.02	-0.31	1.02e-6	Fibrinogen levels;
SARC	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg05793240	chr7:2802953	GNA12	-0.34	-4.8	-0.3	2.9e-6	Height;
SARC	cis	rs12824058	0.831	rs12322456	chr12:130813594	A/G	cg23887609	chr12:130822674	PIWIL1	0.38	5.22	0.32	4e-7	Menopause (age at onset);
SARC	cis	rs4919087	0.590	rs1253397	chr10:99045556	C/T	cg25902810	chr10:99078978	FRAT1	-0.56	-6.14	-0.37	3.43e-9	Monocyte count;
SARC	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg11987759	chr7:65425863	GUSB	-0.64	-8.37	-0.48	5.34e-15	Aortic root size;
SARC	cis	rs992157	0.835	rs2292555	chr2:219146882	G/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.69	-10.08	-0.55	4.62e-20	Colorectal cancer;
SARC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.44	0.56	3.48e-21	Prudent dietary pattern;
SARC	cis	rs79976124	0.879	rs12214948	chr6:66633603	G/A	cg07460842	chr6:66804631	NA	0.64	6.92	0.41	4.37e-11	Type 2 diabetes;
SARC	cis	rs199814749	1	rs199814749	chr1:71591184	C/CT	cg14963735	chr1:71513566	PTGER3	0.77	5.91	0.36	1.2e-8	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip);
SARC	cis	rs12971120	0.838	rs2241510	chr18:72180739	G/A	cg26446133	chr18:72167187	CNDP2	-0.48	-6.46	-0.39	5.98e-10	Refractive error;
SARC	cis	rs910316	0.763	rs175047	chr14:75479039	C/G	cg08847533	chr14:75593920	NEK9	-0.85	-12.68	-0.64	2.26e-28	Height;
SARC	cis	rs7089973	0.604	rs2420066	chr10:116583897	A/G	cg03647239	chr10:116582469	FAM160B1	0.49	6.31	0.38	1.42e-9	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-8.16	-0.47	2.11e-14	Chronic sinus infection;
SARC	cis	rs2153535	0.541	rs6938688	chr6:8521629	G/T	cg07606381	chr6:8435919	SLC35B3	0.76	11.08	0.59	3.38e-23	Motion sickness;
SARC	cis	rs72781680	0.528	rs56258075	chr2:24104256	C/G	cg08917208	chr2:24149416	ATAD2B	0.78	7.68	0.45	4.49e-13	Lymphocyte counts;
SARC	cis	rs6570726	0.791	rs10457788	chr6:145921136	T/A	cg05347473	chr6:146136440	FBXO30	0.54	7.4	0.44	2.43e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2760061	0.583	rs1745413	chr1:228212456	A/G	cg02753203	chr1:228287806	NA	0.79	11.09	0.59	3.23e-23	Diastolic blood pressure;
SARC	cis	rs2732480	0.500	rs12829841	chr12:48628739	A/G	cg24011408	chr12:48396354	COL2A1	0.47	5.43	0.34	1.43e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs2153535	0.580	rs2184582	chr6:8447793	G/A	cg07606381	chr6:8435919	SLC35B3	0.77	11.03	0.59	5.01e-23	Motion sickness;
SARC	cis	rs1401999	1.000	rs9858774	chr3:183652736	G/A	cg01324343	chr3:183735012	ABCC5	0.67	13.72	0.67	8.33e-32	Anterior chamber depth;
SARC	cis	rs6060717	0.536	rs17431878	chr20:34502107	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-5.78	-0.35	2.33e-8	Hip circumference adjusted for BMI;
SARC	cis	rs240764	0.736	rs9968897	chr6:100945858	G/A	cg09795085	chr6:101329169	ASCC3	-0.38	-4.86	-0.3	2.16e-6	Neuroticism;
SARC	cis	rs17331151	0.573	rs11626	chr3:52873984	C/T	cg04865290	chr3:52927548	TMEM110	-0.61	-5.73	-0.35	3.15e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2916247	0.954	rs1484559	chr8:93111532	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.53	-5.75	-0.35	2.74e-8	Intelligence (multi-trait analysis);
SARC	cis	rs6088590	0.687	rs13044899	chr20:33287078	G/A	cg24642439	chr20:33292090	TP53INP2	0.75	10.03	0.55	6.47e-20	Coronary artery disease;
SARC	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg05313129	chr8:58192883	C8orf71	-0.65	-6.45	-0.39	6.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg26338869	chr17:61819248	STRADA	0.81	10.86	0.58	1.68e-22	Prudent dietary pattern;
SARC	cis	rs10892173	0.765	rs1892902	chr11:117669794	T/G	cg07621104	chr11:117668040	DSCAML1	0.36	4.76	0.3	3.4e-6	Myopia;
SARC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.4	4.96	0.31	1.39e-6	Electroencephalogram traits;
SARC	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg16405210	chr4:1374714	KIAA1530	-0.47	-5.54	-0.34	8.28e-8	Obesity-related traits;
SARC	cis	rs9400467	0.506	rs12209969	chr6:111668167	G/A	cg15721981	chr6:111408429	SLC16A10	0.64	5.51	0.34	9.48e-8	Blood metabolite levels;Amino acid levels;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg00858417	chr14:100705568	YY1	0.55	7.79	0.45	2.18e-13	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs651907	0.557	rs3094295	chr3:101401995	T/C	cg12386194	chr3:101231763	SENP7	0.5	6.04	0.37	5.9e-9	Colorectal cancer;
SARC	cis	rs17122278	1.000	rs2277293	chr11:118422868	C/T	cg06090739	chr11:118230722	UBE4A	0.59	4.72	0.3	4.01e-6	Total cholesterol levels;
SARC	trans	rs17685	0.712	rs1859794	chr7:75821544	G/A	cg19862616	chr7:65841803	NCRNA00174	0.61	7.57	0.44	8.42e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-5.73	-0.35	3.13e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	trans	rs7937682	0.961	rs11828343	chr11:111491322	A/G	cg18187862	chr3:45730750	SACM1L	-0.54	-6.6	-0.4	2.8e-10	Primary sclerosing cholangitis;
SARC	cis	rs7644634	0.531	rs9873552	chr3:105382315	C/A	cg23051926	chr3:105466016	CBLB	0.47	5.4	0.33	1.62e-7	Itch intensity from mosquito bite;
SARC	cis	rs3812163	0.500	rs1575291	chr6:7715587	C/T	cg23089261	chr6:7723385	NA	-0.64	-8.39	-0.48	4.73e-15	Height;
SARC	cis	rs7208859	0.673	rs9889968	chr17:29220128	C/A	cg13385521	chr17:29058706	SUZ12P	0.85	7.23	0.43	7.08e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs6570726	0.599	rs4398765	chr6:145935006	C/A	cg05347473	chr6:146136440	FBXO30	0.71	9.82	0.54	2.81e-19	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs61931739	0.534	rs4539411	chr12:34014807	T/C	cg26384229	chr12:38710491	ALG10B	0.74	10.56	0.57	1.51e-21	Morning vs. evening chronotype;
SARC	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg27286337	chr10:134555280	INPP5A	0.71	8.16	0.47	2.03e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs1707322	1.000	rs10890382	chr1:46469674	A/G	cg03146154	chr1:46216737	IPP	0.5	5.98	0.36	8.33e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs5769765	0.955	rs7511159	chr22:50307896	A/G	cg03033257	chr22:50311977	ALG12;CRELD2	0.49	5.02	0.31	1.05e-6	Schizophrenia;
SARC	cis	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg11266682	chr4:10021025	SLC2A9	0.41	7.34	0.43	3.52e-12	Bone mineral density;
SARC	cis	rs2242194	0.816	rs11264296	chr1:154994750	T/C	cg24250549	chr1:154909240	PMVK	0.53	6.58	0.4	3.06e-10	Schizophrenia;
SARC	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg11764359	chr7:65958608	NA	0.79	10.91	0.58	1.16e-22	Aortic root size;
SARC	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.52	-6.48	-0.39	5.36e-10	Resting heart rate;
SARC	cis	rs7223966	0.921	rs2727300	chr17:61965398	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	6.28	0.38	1.64e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs10256972	0.669	rs10229964	chr7:1051776	A/G	cg00431813	chr7:1051703	C7orf50	-0.34	-5.08	-0.32	7.78e-7	Longevity;Endometriosis;
SARC	cis	rs911555	0.723	rs11160751	chr14:103925740	T/C	cg24130564	chr14:104152367	KLC1	-0.5	-5.96	-0.36	9.47e-9	Intelligence (multi-trait analysis);
SARC	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg23758822	chr17:41437982	NA	0.86	10.52	0.57	1.97e-21	Menopause (age at onset);
SARC	cis	rs8031584	0.958	rs34294266	chr15:31246840	A/G	cg14829155	chr15:31115871	NA	-0.43	-5.3	-0.33	2.71e-7	Huntington's disease progression;
SARC	cis	rs2084898	0.550	rs550164	chr11:120002727	C/T	cg07435449	chr11:120005650	TRIM29	0.3	4.73	0.3	3.97e-6	Stroke (pediatric);
SARC	cis	rs13082711	0.554	rs73055724	chr3:27380397	T/G	cg02860705	chr3:27208620	NA	0.65	8.04	0.47	4.42e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs17376456	0.741	rs10036829	chr5:93309897	G/C	cg21475434	chr5:93447410	FAM172A	0.84	7.56	0.44	9.44e-13	Diabetic retinopathy;
SARC	cis	rs9768139	0.903	rs28503558	chr7:158119568	C/T	cg25566285	chr7:158114605	PTPRN2	-0.31	-5.4	-0.33	1.63e-7	Calcium levels;
SARC	cis	rs7647973	0.961	rs4955443	chr3:49286618	T/G	cg07636037	chr3:49044803	WDR6	0.78	9.24	0.52	1.65e-17	Menarche (age at onset);
SARC	cis	rs1018836	0.599	rs9643295	chr8:91492283	T/G	cg16814680	chr8:91681699	NA	-0.67	-9.6	-0.53	1.35e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs1318878	0.565	rs73057216	chr12:15474108	C/T	cg08258403	chr12:15378311	NA	0.5	6.86	0.41	6.24e-11	Intelligence (multi-trait analysis);
SARC	cis	rs79149102	0.579	rs7173218	chr15:75315328	A/G	cg09165964	chr15:75287851	SCAMP5	-1.01	-9.85	-0.54	2.37e-19	Lung cancer;
SARC	cis	rs7937682	0.883	rs12366001	chr11:111433916	A/G	cg22437258	chr11:111473054	SIK2	-0.76	-9.94	-0.55	1.24e-19	Primary sclerosing cholangitis;
SARC	cis	rs11122272	0.701	rs7414807	chr1:231476874	G/A	cg06096015	chr1:231504339	EGLN1	0.38	5.84	0.36	1.71e-8	Hemoglobin concentration;
SARC	cis	rs12545109	0.800	rs2610052	chr8:57411316	C/A	cg19413350	chr8:57351067	NA	-0.45	-5.55	-0.34	7.71e-8	Obesity-related traits;
SARC	cis	rs7274811	0.652	rs291672	chr20:31951168	G/A	cg21523528	chr20:32077966	CBFA2T2	-0.42	-4.95	-0.31	1.44e-6	Height;
SARC	cis	rs9858542	0.953	rs35169793	chr3:49423274	A/G	cg07274523	chr3:49395745	GPX1	0.53	6.26	0.38	1.8e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs11792861	0.781	rs2297581	chr9:111755008	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.74	8.67	0.49	7.68e-16	Menarche (age at onset);
SARC	cis	rs7633857	0.536	rs1447609	chr3:160696311	A/G	cg04691961	chr3:161091175	C3orf57	-0.49	-6.38	-0.39	9.65e-10	Educational attainment (years of education);
SARC	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg06108461	chr20:60628389	TAF4	-0.92	-12.69	-0.64	2.14e-28	Body mass index;
SARC	cis	rs9303401	0.615	rs35288118	chr17:56600748	A/C	cg25039879	chr17:56429692	SUPT4H1	0.68	6.23	0.38	2.12e-9	Cognitive test performance;
SARC	cis	rs13401104	0.796	rs11894118	chr2:237119192	C/A	cg19324714	chr2:237145437	ASB18	0.57	5.66	0.35	4.32e-8	Educational attainment;
SARC	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg16339924	chr4:17578868	LAP3	0.66	8.76	0.5	4e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs7465272	1.000	rs13259747	chr8:143683567	A/C	cg16922340	chr20:33873526	FAM83C;EIF6	0.47	6.25	0.38	1.98e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs6933660	0.536	rs3800274	chr6:151759192	T/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.55	6.34	0.38	1.15e-9	Menarche (age at onset);
SARC	cis	rs12477438	1.000	rs11897712	chr2:99735697	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-7.93	-0.46	9.21e-14	Chronic sinus infection;
SARC	cis	rs7584330	0.826	rs72620825	chr2:238381243	G/A	cg11271282	chr2:238384023	NA	0.48	4.75	0.3	3.62e-6	Prostate cancer;
SARC	cis	rs2204008	0.502	rs2387275	chr12:38142836	G/A	cg26384229	chr12:38710491	ALG10B	0.9	13.03	0.65	1.64e-29	Bladder cancer;
SARC	cis	rs2718058	0.630	rs2722363	chr7:37835603	A/G	cg15028436	chr7:37888078	TXNDC3	0.39	4.97	0.31	1.31e-6	Alzheimer's disease (late onset);
SARC	cis	rs6429082	0.715	rs9793740	chr1:235595590	T/C	cg26050004	chr1:235667680	B3GALNT2	-0.6	-7.42	-0.44	2.23e-12	Adiposity;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg14968603	chr10:102046143	BLOC1S2	-0.57	-6.32	-0.38	1.34e-9	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs739401	0.611	rs391188	chr11:3047634	G/A	cg05729581	chr11:3078854	CARS	-0.5	-6.69	-0.4	1.67e-10	Longevity;
SARC	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg14343924	chr8:8086146	FLJ10661	0.42	5.11	0.32	6.61e-7	Mood instability;
SARC	cis	rs7412746	0.611	rs4970984	chr1:150887377	T/C	cg13175981	chr1:150552382	MCL1	-0.52	-6.4	-0.39	8.43e-10	Melanoma;
SARC	cis	rs754466	0.580	rs2579177	chr10:79529245	C/T	cg17075019	chr10:79541650	NA	-0.81	-12.17	-0.62	1.09e-26	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2204008	0.837	rs34381557	chr12:38181983	T/C	cg13010199	chr12:38710504	ALG10B	0.78	10.64	0.57	8.61e-22	Bladder cancer;
SARC	trans	rs1814175	0.817	rs10769648	chr11:50013992	T/C	cg03929089	chr4:120376271	NA	-0.87	-13.86	-0.67	2.91e-32	Height;
SARC	cis	rs4865169	0.691	rs1056364	chr4:57889677	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.42	-4.94	-0.31	1.52e-6	Breast cancer;
SARC	cis	rs7582720	0.832	rs114139737	chr2:203721733	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.76	7.4	0.44	2.38e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs11098499	0.780	rs7692994	chr4:120427489	C/A	cg09307838	chr4:120376055	NA	0.82	11.09	0.59	3.26e-23	Corneal astigmatism;
SARC	cis	rs1008375	1.000	rs6818639	chr4:17633049	A/G	cg02297831	chr4:17616191	MED28	0.49	6.31	0.38	1.39e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs8177253	0.530	rs8177177	chr3:133463195	A/G	cg01448562	chr3:133502909	NA	-0.45	-6.92	-0.41	4.4e-11	Iron status biomarkers;
SARC	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.39	0.44	2.61e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	8.51	0.49	2.13e-15	Mean platelet volume;
SARC	trans	rs7927370	1.000	rs61894885	chr11:55031130	C/T	cg07162727	chr16:4848039	ROGDI	0.8	6.25	0.38	1.98e-9	Systemic lupus erythematosus;
SARC	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1949733	1.000	rs6837429	chr4:8502374	A/G	cg13073564	chr4:8508604	NA	-0.48	-7.9	-0.46	1.1e-13	Response to antineoplastic agents;
SARC	cis	rs4853036	1.000	rs13025205	chr2:70044159	C/G	cg02498382	chr2:70120550	SNRNP27	-0.42	-5.59	-0.34	6.2e-8	Colorectal or endometrial cancer;
SARC	cis	rs4423214	0.610	rs12793607	chr11:71129316	C/T	cg05163923	chr11:71159392	DHCR7	-0.44	-6.15	-0.37	3.31e-9	Vitamin D levels;
SARC	cis	rs7614311	0.689	rs73120898	chr3:63828780	G/A	cg22134162	chr3:63841271	THOC7	-0.47	-5.06	-0.31	8.33e-7	Lung function (FVC);Lung function (FEV1);
SARC	cis	rs79349575	0.783	rs4294857	chr17:46983391	G/A	cg16584676	chr17:46985605	UBE2Z	0.54	6.59	0.4	2.95e-10	Type 2 diabetes;
SARC	cis	rs3741151	1.000	rs75109191	chr11:73023532	T/C	cg17517138	chr11:73019481	ARHGEF17	1.01	7.58	0.44	8.21e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs7246865	0.510	rs2305752	chr19:17186127	A/C	cg16202187	chr19:17186497	HAUS8;MYO9B	0.42	4.98	0.31	1.24e-6	Reticulocyte fraction of red cells;
SARC	cis	rs2396545	0.680	rs35467761	chr11:571568	A/G	cg02461776	chr11:598696	PHRF1	0.48	4.97	0.31	1.28e-6	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg18876405	chr7:65276391	NA	-0.46	-5.51	-0.34	9.31e-8	Aortic root size;
SARC	cis	rs7089973	0.604	rs7897937	chr10:116591318	A/G	cg03647239	chr10:116582469	FAM160B1	0.49	6.3	0.38	1.48e-9	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs6570726	0.967	rs374728	chr6:145854598	T/A	cg23711669	chr6:146136114	FBXO30	0.78	12.0	0.62	3.86e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9660992	0.710	rs1768587	chr1:205236432	C/T	cg21643547	chr1:205240462	TMCC2	-0.64	-8.25	-0.48	1.2e-14	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs2153535	0.580	rs1577470	chr6:8462426	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	8.3	0.48	8.25e-15	Motion sickness;
SARC	trans	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.55	7.09	0.42	1.62e-11	Intelligence (multi-trait analysis);
SARC	cis	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg13147721	chr7:65941812	NA	-0.52	-4.79	-0.3	3.03e-6	Diabetic kidney disease;
SARC	trans	rs1814175	0.781	rs2866734	chr11:49886338	A/G	cg03929089	chr4:120376271	NA	-0.89	-14.53	-0.69	1.73e-34	Height;
SARC	cis	rs17270561	0.609	rs7746502	chr6:25718762	T/A	cg16482183	chr6:26056742	HIST1H1C	-0.4	-4.99	-0.31	1.17e-6	Iron status biomarkers;
SARC	cis	rs1832871	0.683	rs11752399	chr6:158711188	G/A	cg07165851	chr6:158734300	TULP4	0.54	6.51	0.39	4.65e-10	Height;
SARC	cis	rs7760949	0.889	rs9475795	chr6:13931270	A/C	cg27413430	chr6:13925136	RNF182	0.42	5.02	0.31	1.03e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs174601	0.861	rs174550	chr11:61571478	T/C	cg19610905	chr11:61596333	FADS2	-0.4	-4.79	-0.3	3.03e-6	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
SARC	cis	rs829883	1.000	rs249837	chr12:98876535	A/G	cg25150519	chr12:98850993	NA	0.7	9.48	0.53	3.07e-18	Colorectal adenoma (advanced);
SARC	cis	rs559928	0.606	rs17773078	chr11:63906224	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	5.26	0.33	3.29e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs7474896	0.515	rs662928	chr10:38316216	G/T	cg25427524	chr10:38739819	LOC399744	0.45	5.61	0.34	5.81e-8	Obesity (extreme);
SARC	cis	rs7666738	0.570	rs10032272	chr4:99095601	T/C	cg05340658	chr4:99064831	C4orf37	0.49	6.28	0.38	1.65e-9	Colonoscopy-negative controls vs population controls;
SARC	cis	rs17023223	0.537	rs12081585	chr1:119615956	A/C	cg05756136	chr1:119680316	WARS2	-0.42	-4.76	-0.3	3.39e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs12908161	0.920	rs12904605	chr15:85201419	T/C	cg17507749	chr15:85114479	UBE2QP1	0.6	6.85	0.41	6.46e-11	Schizophrenia;
SARC	cis	rs62244186	0.535	rs59726036	chr3:44850074	G/T	cg15687855	chr3:44754131	ZNF502	-0.34	-5.01	-0.31	1.08e-6	Depressive symptoms;
SARC	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg07930192	chr7:1003750	NA	0.41	5.68	0.35	4e-8	Longevity;Endometriosis;
SARC	cis	rs897080	0.552	rs1067388	chr2:44642482	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.58	6.71	0.4	1.45e-10	Height;
SARC	cis	rs2645694	0.626	rs2645705	chr4:77830434	G/A	cg06046430	chr4:77819534	ANKRD56	0.48	6.83	0.41	7.24e-11	Emphysema distribution in smoking;
SARC	cis	rs9486715	0.867	rs7451950	chr6:96879974	T/C	cg18709589	chr6:96969512	KIAA0776	0.58	7.27	0.43	5.5e-12	Headache;
SARC	cis	rs1355223	1.000	rs11601923	chr11:34764354	C/G	cg18508148	chr11:34937573	PDHX;APIP	-0.43	-5.58	-0.34	6.74e-8	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs10489202	0.632	rs275143	chr1:168056724	A/G	cg24449463	chr1:168025552	DCAF6	-0.66	-8.71	-0.5	5.63e-16	Schizophrenia;
SARC	cis	rs36051895	0.664	rs12340866	chr9:5094185	G/A	cg02405213	chr9:5042618	JAK2	-0.47	-5.61	-0.35	5.6e-8	Pediatric autoimmune diseases;
SARC	cis	rs12142240	0.738	rs10489769	chr1:46806703	A/G	cg14993813	chr1:46806288	NSUN4	-0.53	-5.62	-0.35	5.53e-8	Menopause (age at onset);
SARC	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg17376030	chr22:41985996	PMM1	0.77	8.95	0.51	1.11e-16	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs611744	0.967	rs584716	chr8:109178634	A/T	cg21045802	chr8:109455806	TTC35	0.44	5.3	0.33	2.64e-7	Dupuytren's disease;
SARC	cis	rs13191362	1.000	rs34591938	chr6:163087003	C/G	cg21926612	chr6:163149169	PACRG;PARK2	0.75	6.52	0.39	4.24e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg00684032	chr4:1343700	KIAA1530	0.35	4.96	0.31	1.34e-6	Obesity-related traits;
SARC	cis	rs7223966	1.000	rs78172786	chr17:61847114	A/C	cg00588841	chr17:61851480	DDX42;CCDC47	-0.67	-7.17	-0.42	1.01e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg05332525	chr7:65337924	VKORC1L1	0.46	5.13	0.32	5.95e-7	Aortic root size;
SARC	cis	rs7666738	0.800	rs10028921	chr4:98962630	G/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10489202	0.865	rs744168	chr1:168094079	G/T	cg17859187	chr1:168147929	TIPRL	0.51	5.3	0.33	2.66e-7	Schizophrenia;
SARC	cis	rs9326248	0.817	rs1242127	chr11:117076564	A/G	cg01368799	chr11:117014884	PAFAH1B2	-0.48	-5.35	-0.33	2.06e-7	Blood protein levels;
SARC	cis	rs910316	0.935	rs175422	chr14:75627319	T/A	cg11812906	chr14:75593930	NEK9	-0.82	-11.68	-0.61	4.09e-25	Height;
SARC	cis	rs2120243	0.508	rs1965246	chr3:157111586	G/A	cg01018701	chr3:157155998	VEPH1;PTX3	0.39	4.96	0.31	1.38e-6	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs240764	0.612	rs4840132	chr6:100914602	C/T	cg09795085	chr6:101329169	ASCC3	-0.38	-4.76	-0.3	3.41e-6	Neuroticism;
SARC	cis	rs7020830	0.867	rs13301916	chr9:37361455	A/C	cg14294708	chr9:37120828	ZCCHC7	1.09	20.2	0.8	3.97e-53	Schizophrenia;
SARC	cis	rs709400	0.628	rs2273700	chr14:103923414	A/G	cg26031613	chr14:104095156	KLC1	0.83	12.16	0.62	1.15e-26	Body mass index;
SARC	cis	rs4660306	0.677	rs10493120	chr1:45903488	C/T	cg24296786	chr1:45957014	TESK2	-0.5	-4.85	-0.3	2.3e-6	Homocysteine levels;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg02836479	chr16:21964489	UQCRC2	-0.5	-6.61	-0.4	2.6200000000000003e-10	Electrocardiographic conduction measures;
SARC	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-6.47	-0.39	5.81e-10	Bipolar disorder;
SARC	cis	rs12477438	0.765	rs6542846	chr2:99563654	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-7.9	-0.46	1.13e-13	Chronic sinus infection;
SARC	cis	rs10875746	0.810	rs10875732	chr12:48442105	A/C	cg26205652	chr12:48591994	NA	0.54	5.77	0.35	2.49e-8	Longevity (90 years and older);
SARC	cis	rs9790314	0.690	rs6799130	chr3:160847801	C/G	cg04691961	chr3:161091175	C3orf57	-0.55	-7.33	-0.43	3.76e-12	Morning vs. evening chronotype;
SARC	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg24642844	chr7:1081250	C7orf50	-0.6	-6.11	-0.37	4.06e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs4727027	0.754	rs11764892	chr7:148858916	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	6.01	0.37	7.21e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs2228479	1.000	rs2228479	chr16:89985940	G/A	cg06558623	chr16:89946397	TCF25	0.88	5.83	0.36	1.84e-8	Skin colour saturation;
SARC	cis	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg09021430	chr5:549028	NA	-0.43	-5.58	-0.34	6.79e-8	Obesity-related traits;
SARC	cis	rs34779708	0.966	rs4934540	chr10:35474699	T/C	cg03585969	chr10:35415529	CREM	0.41	5.12	0.32	6.39e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs13077101	1.000	rs13077101	chr3:120425331	T/C	cg24332942	chr3:120408071	RABL3	0.41	4.97	0.31	1.29e-6	Obesity-related traits;
SARC	cis	rs7582720	0.731	rs1971819	chr2:203705787	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	-0.47	-5.22	-0.32	3.93e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs7937682	0.883	rs1789358	chr11:111474116	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.87	-13.62	-0.67	1.79e-31	Primary sclerosing cholangitis;
SARC	cis	rs2153535	0.580	rs1119690	chr6:8460660	G/A	cg21535247	chr6:8435926	SLC35B3	0.53	6.61	0.4	2.59e-10	Motion sickness;
SARC	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg20891558	chr2:74357851	NA	0.72	9.73	0.54	5.28e-19	Gestational age at birth (maternal effect);
SARC	cis	rs6964587	0.869	rs2023784	chr7:91524677	A/G	cg17063962	chr7:91808500	NA	-0.91	-14.0	-0.68	9.98e-33	Breast cancer;
SARC	cis	rs7223966	0.961	rs35844156	chr17:61837568	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.46	4.8	0.3	2.87e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs6716963	0.585	rs11687224	chr2:194568323	A/G	cg03406422	chr11:77850844	ALG8	0.54	6.41	0.39	8.06e-10	Schizophrenia;
SARC	cis	rs7296418	0.599	rs2277343	chr12:123794450	A/T	cg05973401	chr12:123451056	ABCB9	0.46	5.36	0.33	1.99e-7	Platelet count;
SARC	cis	rs73206853	0.534	rs73205062	chr12:110511136	G/C	cg08946844	chr12:110511112	NA	0.63	5.02	0.31	1.03e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs12711979	0.509	rs13021385	chr2:3826387	T/C	cg17052675	chr2:3827356	NA	-0.55	-8.26	-0.48	1.1e-14	Itch intensity from mosquito bite adjusted by bite size;
SARC	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg00933542	chr6:150070202	PCMT1	0.34	5.52	0.34	9.04e-8	Lung cancer;
SARC	cis	rs6450176	0.638	rs16881969	chr5:53300748	A/G	ch.5.1024479R	chr5:53302184	ARL15	1.01	11.65	0.61	4.95e-25	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs986417	1.000	rs1072328	chr14:60876439	C/G	cg27398547	chr14:60952738	C14orf39	-0.99	-8.88	-0.5	1.89e-16	Gut microbiota (bacterial taxa);
SARC	trans	rs629535	0.814	rs62513373	chr8:70080753	C/T	cg21567404	chr3:27674614	NA	-1.06	-13.76	-0.67	6.44e-32	Dupuytren's disease;
SARC	cis	rs4718428	0.705	rs4718424	chr7:66376095	G/A	cg12165864	chr7:66369176	NA	-0.47	-5.27	-0.33	3.1e-7	Corneal structure;
SARC	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg22535103	chr8:58192502	C8orf71	-0.59	-6.21	-0.38	2.35e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs9388451	0.626	rs3734637	chr6:126081319	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.61	-7.96	-0.46	7.66e-14	Brugada syndrome;
SARC	cis	rs17270561	0.636	rs9358880	chr6:25743161	C/T	cg17691542	chr6:26056736	HIST1H1C	0.61	7.36	0.43	3.06e-12	Iron status biomarkers;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg09167119	chr1:218519576	TGFB2	-0.5	-6.53	-0.39	4.05e-10	Breast cancer;
SARC	cis	rs7043114	0.525	rs710162	chr9:95059790	A/T	cg13798575	chr9:95087839	CENPP;NOL8	0.45	5.41	0.33	1.54e-7	Height;
SARC	cis	rs72781680	0.848	rs2339926	chr2:24045734	C/G	cg08917208	chr2:24149416	ATAD2B	0.78	7.41	0.44	2.26e-12	Lymphocyte counts;
SARC	cis	rs7633857	0.537	rs9813700	chr3:160683279	G/T	cg04691961	chr3:161091175	C3orf57	-0.5	-6.28	-0.38	1.68e-9	Educational attainment (years of education);
SARC	cis	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg06212747	chr3:49208901	KLHDC8B	0.57	5.67	0.35	4.22e-8	Menarche (age at onset);
SARC	cis	rs3126085	0.935	rs11589587	chr1:152184129	T/C	cg26876637	chr1:152193138	HRNR	-0.48	-5.06	-0.31	8.36e-7	Atopic dermatitis;
SARC	cis	rs34330	0.562	rs11055023	chr12:12853197	A/G	cg04607235	chr12:12878440	APOLD1	-0.57	-5.54	-0.34	8.19e-8	Systemic lupus erythematosus;
SARC	cis	rs524281	0.773	rs2155030	chr11:66030687	A/G	cg14036092	chr11:66035641	RAB1B	-0.59	-6.01	-0.37	7.02e-9	Electroencephalogram traits;
SARC	cis	rs13256369	0.851	rs13256611	chr8:8564341	G/A	cg17143192	chr8:8559678	CLDN23	0.52	5.83	0.36	1.82e-8	Obesity-related traits;
SARC	cis	rs6570726	0.935	rs414646	chr6:145831685	T/C	cg05220968	chr6:146057943	EPM2A	-0.29	-4.99	-0.31	1.19e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs78487399	0.710	rs7607777	chr2:43629931	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-5.03	-0.31	9.83e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	trans	rs1975991	0.711	rs6793597	chr3:187965285	A/G	cg16786178	chr14:75764329	NA	0.34	6.3	0.38	1.48e-9	White matter integrity (bipolar disorder risk interaction);
SARC	cis	rs1881797	1.000	rs68059491	chr1:247683070	C/T	cg11166453	chr1:247681781	NA	0.45	4.9	0.31	1.83e-6	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs754466	0.510	rs10824579	chr10:79590685	C/T	cg17075019	chr10:79541650	NA	-0.66	-9.97	-0.55	9.83e-20	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6840360	0.869	rs55668815	chr4:152473828	C/G	cg22705602	chr4:152727874	NA	-0.37	-6.11	-0.37	4.1e-9	Intelligence (multi-trait analysis);
SARC	cis	rs12477438	0.765	rs28648058	chr2:99696417	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.69	-9.17	-0.51	2.66e-17	Chronic sinus infection;
SARC	cis	rs2075371	0.863	rs9641966	chr7:133961205	G/A	cg20476274	chr7:133979776	SLC35B4	0.57	7.41	0.44	2.28e-12	Mean platelet volume;
SARC	cis	rs11097912	0.632	rs7673949	chr4:107194036	G/A	cg09646026	chr4:107269030	AIMP1	-0.45	-4.94	-0.31	1.47e-6	Airflow obstruction;
SARC	cis	rs3768617	0.811	rs12066082	chr1:183054863	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	8.25	0.48	1.14e-14	Fuchs's corneal dystrophy;
SARC	cis	rs3820928	0.874	rs10188770	chr2:227877037	G/A	cg05526886	chr2:227700861	RHBDD1	-0.5	-5.99	-0.37	8.01e-9	Pulmonary function;
SARC	cis	rs526231	0.578	rs35100629	chr5:102246085	C/G	cg23492399	chr5:102201601	PAM	-0.45	-5.37	-0.33	1.91e-7	Primary biliary cholangitis;
SARC	trans	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg00938859	chr5:1591904	SDHAP3	0.79	7.42	0.44	2.12e-12	Breast cancer;
SARC	cis	rs9457247	0.534	rs2757053	chr6:167380338	A/C	cg23791538	chr6:167370224	RNASET2	0.67	9.53	0.53	2.18e-18	Crohn's disease;
SARC	cis	rs1448094	0.512	rs4362214	chr12:86245145	C/T	cg02569458	chr12:86230093	RASSF9	0.38	5.39	0.33	1.71e-7	Major depressive disorder;
SARC	trans	rs11098499	0.954	rs10017543	chr4:120321420	G/A	cg25214090	chr10:38739885	LOC399744	0.57	7.46	0.44	1.7e-12	Corneal astigmatism;
SARC	cis	rs9902453	0.845	rs7501472	chr17:28010628	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	7.26	0.43	5.81e-12	Coffee consumption (cups per day);
SARC	cis	rs7186908	0.711	rs9923344	chr16:72190653	T/C	cg01557791	chr16:72042693	DHODH	-0.54	-5.7	-0.35	3.68e-8	Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg24110177	chr3:50126178	RBM5	-0.54	-7.17	-0.43	1e-11	Intelligence (multi-trait analysis);
SARC	cis	rs11098499	0.754	rs938056	chr4:120237453	C/T	cg09307838	chr4:120376055	NA	0.8	10.76	0.58	3.61e-22	Corneal astigmatism;
SARC	cis	rs6424115	1.000	rs35385477	chr1:24155924	G/A	cg15997130	chr1:24165203	NA	0.49	6.78	0.41	1e-10	Immature fraction of reticulocytes;
SARC	cis	rs317689	0.718	rs160827	chr12:69770147	G/A	cg14784868	chr12:69753453	YEATS4	0.46	5.12	0.32	6.4e-7	Response to diuretic therapy;
SARC	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg05665937	chr4:1216051	CTBP1	0.38	5.61	0.34	5.75e-8	Obesity-related traits;
SARC	cis	rs2075371	0.611	rs34573600	chr7:134018937	C/T	cg20476274	chr7:133979776	SLC35B4	0.38	4.72	0.3	4.03e-6	Mean platelet volume;
SARC	cis	rs514024	0.520	rs836333	chr9:130486384	C/T	cg13643465	chr9:130375613	STXBP1	0.39	4.91	0.31	1.7e-6	Eating disorders (purging via substances);
SARC	cis	rs2295359	0.892	rs12401432	chr1:67656931	C/G	cg12940439	chr1:67600707	NA	0.45	6.51	0.39	4.65e-10	Psoriasis;
SARC	cis	rs6496667	0.509	rs6496677	chr15:90990358	A/G	cg22089800	chr15:90895588	ZNF774	0.43	4.89	0.31	1.87e-6	Rheumatoid arthritis;
SARC	cis	rs2304069	0.507	rs13167061	chr5:149388624	T/G	cg12661370	chr5:149340060	SLC26A2	0.56	6.54	0.39	3.93e-10	HIV-1 control;
SARC	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg13395646	chr4:1353034	KIAA1530	-0.4	-4.74	-0.3	3.77e-6	Obesity-related traits;
SARC	cis	rs6500395	0.962	rs9941275	chr16:48573428	A/G	cg04672837	chr16:48644449	N4BP1	0.45	5.83	0.36	1.85e-8	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs17376456	0.825	rs66564678	chr5:93165894	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.72	6.33	0.38	1.25e-9	Diabetic retinopathy;
SARC	cis	rs4308124	0.708	rs10179596	chr2:111970380	G/A	cg04571233	chr2:111982156	NA	-0.51	-5.9	-0.36	1.27e-8	Vitiligo;
SARC	cis	rs17376456	0.877	rs10072592	chr5:93405989	C/G	cg25358565	chr5:93447407	FAM172A	1.3	14.36	0.69	6.16e-34	Diabetic retinopathy;
SARC	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg10018233	chr7:150070692	REPIN1	0.66	7.93	0.46	9.21e-14	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg08219700	chr8:58056026	NA	-0.65	-6.05	-0.37	5.86e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9814567	0.806	rs1880375	chr3:134322163	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.51	-6.63	-0.4	2.36e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg22618164	chr12:122356400	WDR66	0.43	6.88	0.41	5.45e-11	Mean corpuscular volume;
SARC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg20007245	chr22:24372913	LOC391322	-0.63	-7.49	-0.44	1.45e-12	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg06636001	chr8:8085503	FLJ10661	0.64	8.22	0.47	1.44e-14	Mood instability;
SARC	cis	rs876084	0.505	rs12541796	chr8:121112830	G/A	cg06265175	chr8:121136014	COL14A1	0.58	7.56	0.44	9.46e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg25894440	chr7:65020034	NA	-0.72	-5.46	-0.34	1.2e-7	Diabetic kidney disease;
SARC	trans	rs2018683	0.621	rs10261556	chr7:28976636	G/T	cg19402173	chr7:128379420	CALU	-0.62	-8.07	-0.47	3.67e-14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg11482376	chr11:124709245	NA	0.54	6.87	0.41	5.74e-11	Breast cancer;
SARC	cis	rs9479482	0.967	rs34006533	chr6:150350574	C/A	cg03788504	chr6:150331562	NA	-0.33	-5.49	-0.34	1.06e-7	Alopecia areata;
SARC	cis	rs2115630	0.875	rs8039472	chr15:85361644	A/G	cg09876464	chr15:85330779	ZNF592	0.34	4.74	0.3	3.75e-6	P wave terminal force;
SARC	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg19346786	chr7:2764209	NA	-0.35	-5.35	-0.33	2.11e-7	Height;
SARC	cis	rs7647973	0.925	rs11130183	chr3:49228946	A/G	cg06212747	chr3:49208901	KLHDC8B	0.61	6.48	0.39	5.53e-10	Menarche (age at onset);
SARC	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg11905131	chr22:24372483	LOC391322	-0.5	-5.62	-0.35	5.42e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg07308232	chr7:1071921	C7orf50	-0.64	-7.88	-0.46	1.24e-13	Longevity;Endometriosis;
SARC	cis	rs13095912	1.000	rs36066570	chr3:185314454	C/A	cg11274856	chr3:185301563	NA	0.35	4.81	0.3	2.71e-6	Systolic blood pressure;
SARC	cis	rs7246657	0.943	rs7255407	chr19:37933936	G/A	cg23950597	chr19:37808831	NA	-0.57	-5.67	-0.35	4.24e-8	Coronary artery calcification;
SARC	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg19223190	chr17:80058835	NA	0.48	6.68	0.4	1.69e-10	Life satisfaction;
SARC	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg03188948	chr7:1209495	NA	0.54	4.77	0.3	3.26e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	trans	rs12967884	0.892	rs907283	chr18:76563295	A/T	cg10946435	chr1:154843044	KCNN3	0.57	6.31	0.38	1.38e-9	Subcutaneous adipose tissue;
SARC	cis	rs9400467	0.506	rs17539875	chr6:111674350	C/T	cg15721981	chr6:111408429	SLC16A10	0.64	5.51	0.34	9.48e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs155076	1.000	rs261427	chr13:21860998	G/A	cg11317459	chr13:21872234	NA	-0.96	-11.99	-0.62	4.01e-26	White matter hyperintensity burden;
SARC	cis	rs6120849	0.754	rs6087667	chr20:33651887	A/G	cg06115741	chr20:33292138	TP53INP2	0.56	5.28	0.33	3.02e-7	Protein C levels;
SARC	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg21016266	chr12:122356598	WDR66	0.31	4.79	0.3	2.92e-6	Mean corpuscular volume;
SARC	cis	rs1865760	1.000	rs3830057	chr6:25918510	G/T	cg17691542	chr6:26056736	HIST1H1C	0.57	6.96	0.41	3.43e-11	Height;
SARC	cis	rs7824557	0.568	rs35747588	chr8:11206627	C/G	cg21775007	chr8:11205619	TDH	0.67	8.67	0.49	7.42e-16	Retinal vascular caliber;
SARC	cis	rs870825	0.929	rs72689254	chr4:185589941	C/T	cg04058563	chr4:185651563	MLF1IP	0.81	9.0	0.51	8.08e-17	Blood protein levels;
SARC	cis	rs13256369	0.760	rs7839473	chr8:8575836	C/T	cg17143192	chr8:8559678	CLDN23	0.5	5.7	0.35	3.64e-8	Obesity-related traits;
SARC	cis	rs6570726	0.935	rs366308	chr6:145814532	T/A	cg05220968	chr6:146057943	EPM2A	-0.29	-4.83	-0.3	2.44e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7582720	1.000	rs116382857	chr2:203751932	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	6.82	0.41	7.86e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs6570726	0.533	rs1832374	chr6:145717752	A/G	cg23711669	chr6:146136114	FBXO30	0.52	6.97	0.42	3.18e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs56077333	1	rs56077333	chr15:78899003	C/A	cg06917634	chr15:78832804	PSMA4	-0.56	-6.01	-0.37	7.11e-9	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs11581859	0.613	rs35836386	chr1:99197780	T/C	cg20286094	chr1:99190917	SNX7	-0.42	-4.99	-0.31	1.2e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs7927771	1.000	rs34128973	chr11:47851376	C/T	cg20307385	chr11:47447363	PSMC3	-0.47	-5.59	-0.34	6.3e-8	Subjective well-being;
SARC	cis	rs56176327	0.600	rs7628207	chr3:49754970	T/C	cg07636037	chr3:49044803	WDR6	0.59	6.09	0.37	4.71e-9	Intelligence (multi-trait analysis);
SARC	cis	rs10174077	0.874	rs4664490	chr2:152471923	C/G	cg19508488	chr2:152266495	RIF1	-0.49	-5.7	-0.35	3.69e-8	Squamous cell lung carcinoma;
SARC	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg20965017	chr5:231967	SDHA	-0.56	-5.3	-0.33	2.72e-7	Breast cancer;
SARC	cis	rs8114671	0.562	rs6088647	chr20:33505997	T/C	cg07148914	chr20:33460835	GGT7	0.44	5.39	0.33	1.69e-7	Height;
SARC	cis	rs427394	0.593	rs880993	chr5:6732120	C/G	cg10857441	chr5:6722123	POLS	-0.33	-4.85	-0.3	2.29e-6	Menopause (age at onset);
SARC	cis	rs2180341	1.000	rs9398837	chr6:127635217	G/A	cg27446573	chr6:127587934	RNF146	1.03	14.58	0.69	1.15e-34	Breast cancer;
SARC	cis	rs9733	0.503	rs7556451	chr1:150913142	A/G	cg10589385	chr1:150898437	SETDB1	0.4	5.31	0.33	2.54e-7	Tonsillectomy;
SARC	cis	rs7818688	0.697	rs76815619	chr8:95981330	G/A	cg13393036	chr8:95962371	TP53INP1	0.4	4.85	0.3	2.27e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs858239	0.698	rs4265084	chr7:23407240	G/C	cg23682824	chr7:23144976	KLHL7	0.52	6.35	0.38	1.14e-9	Cerebrospinal fluid biomarker levels;
SARC	trans	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg21659725	chr3:3221576	CRBN	0.52	6.71	0.4	1.46e-10	Intelligence (multi-trait analysis);
SARC	cis	rs6546324	0.625	rs4671817	chr2:67866437	T/G	cg18237512	chr2:67827392	NA	-0.56	-6.71	-0.4	1.49e-10	Endometriosis;
SARC	cis	rs6831352	0.725	rs2602846	chr4:100025151	T/A	cg13256891	chr4:100009986	ADH5	0.66	8.13	0.47	2.55e-14	Alcohol dependence;
SARC	cis	rs796364	0.806	rs74771155	chr2:200913743	C/T	cg23649088	chr2:200775458	C2orf69	-0.6	-5.31	-0.33	2.51e-7	Schizophrenia;
SARC	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg02574844	chr11:5959923	NA	-0.35	-4.88	-0.3	1.95e-6	DNA methylation (variation);
SARC	cis	rs858239	0.600	rs4409314	chr7:23127952	T/C	cg23682824	chr7:23144976	KLHL7	0.69	9.1	0.51	4.15e-17	Cerebrospinal fluid biomarker levels;
SARC	cis	rs8060686	0.545	rs12597573	chr16:68167521	A/C	cg27539214	chr16:67997921	SLC12A4	0.55	5.11	0.32	6.57e-7	HDL cholesterol;Metabolic syndrome;
SARC	cis	rs668210	0.793	rs506873	chr11:65767215	A/C	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.69	-7.64	-0.45	5.73e-13	Cerebrospinal fluid biomarker levels;
SARC	cis	rs7144547	0.950	rs8004137	chr14:81884857	A/G	cg23690444	chr14:81902736	NA	0.6	7.39	0.44	2.54e-12	Prudent dietary pattern;
SARC	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg18252515	chr7:66147081	NA	0.58	6.26	0.38	1.79e-9	Aortic root size;
SARC	cis	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg15145296	chr3:125709740	NA	-0.45	-4.78	-0.3	3.12e-6	Blood pressure (smoking interaction);
SARC	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg02733842	chr7:1102375	C7orf50	-0.62	-7.19	-0.43	8.55e-12	Bronchopulmonary dysplasia;
SARC	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg11878867	chr6:150167359	LRP11	-0.34	-4.75	-0.3	3.56e-6	Lung cancer;
SARC	cis	rs2404618	0.624	rs4457358	chr8:1477213	C/A	cg13402656	chr8:1511478	DLGAP2	-0.6	-8.71	-0.5	5.82e-16	Lung cancer;
SARC	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg20607798	chr8:58055168	NA	0.56	5.33	0.33	2.31e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs644799	0.526	rs542509	chr11:95641602	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.69	8.99	0.51	8.69e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs1008375	0.872	rs6831115	chr4:17640463	A/G	cg16339924	chr4:17578868	LAP3	0.67	8.91	0.5	1.47e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7681440	0.606	rs2619354	chr4:90748284	C/T	cg06632027	chr4:90757378	SNCA	-0.42	-5.25	-0.33	3.41e-7	Dementia with Lewy bodies;
SARC	cis	rs12479064	0.724	rs112900993	chr2:99948805	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.46	-5.27	-0.33	3.07e-7	Chronic sinus infection;
SARC	cis	rs3784262	0.669	rs4646623	chr15:58257123	T/G	cg12031962	chr15:58353849	ALDH1A2	-0.35	-5.12	-0.32	6.4e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs12586317	0.545	rs58342373	chr14:35395269	T/C	cg16230307	chr14:35515116	FAM177A1	0.75	7.98	0.46	6.59e-14	Psoriasis;
SARC	cis	rs288326	0.561	rs74953433	chr2:183872665	T/C	cg09997497	chr2:183902928	NCKAP1	0.74	5.1	0.32	6.97e-7	Blood protein levels;
SARC	cis	rs3126085	0.935	rs4326625	chr1:152223996	C/T	cg09127314	chr1:152161683	NA	0.43	5.1	0.32	7.08e-7	Atopic dermatitis;
SARC	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.39	-4.88	-0.3	1.95e-6	Lymphocyte counts;
SARC	cis	rs13161895	1.000	rs17079966	chr5:179443190	G/T	cg04265672	chr5:179402240	RNF130	-0.51	-5.11	-0.32	6.74e-7	LDL cholesterol;
SARC	cis	rs7216064	0.773	rs74541577	chr17:65853651	C/T	cg12091567	chr17:66097778	LOC651250	-0.64	-6.45	-0.39	6.56e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs910316	0.763	rs175042	chr14:75470833	A/T	cg06637938	chr14:75390232	RPS6KL1	-0.46	-6.04	-0.37	5.96e-9	Height;
SARC	cis	rs10046574	0.561	rs13438700	chr7:135207626	C/A	cg27474649	chr7:135195673	CNOT4	0.81	7.74	0.45	3e-13	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs7208859	0.623	rs11657990	chr17:29124200	C/T	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs7644634	0.649	rs13084260	chr3:105381695	G/C	cg23051926	chr3:105466016	CBLB	0.47	5.93	0.36	1.08e-8	Itch intensity from mosquito bite;
SARC	cis	rs79349575	0.749	rs1057902	chr17:47005588	C/T	cg16584676	chr17:46985605	UBE2Z	0.52	6.28	0.38	1.61e-9	Type 2 diabetes;
SARC	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg03264133	chr6:25882463	NA	-0.55	-7.23	-0.43	6.81e-12	Intelligence (multi-trait analysis);
SARC	cis	rs2153535	0.580	rs2327067	chr6:8518482	C/G	cg21535247	chr6:8435926	SLC35B3	0.58	7.25	0.43	6.2e-12	Motion sickness;
SARC	trans	rs3780486	0.846	rs10758192	chr9:33131651	G/A	cg20290983	chr6:43655470	MRPS18A	1.13	22.15	0.82	2.9e-59	IgG glycosylation;
SARC	cis	rs6977660	1.000	rs1468288	chr7:19810580	C/G	cg05791153	chr7:19748676	TWISTNB	0.57	5.24	0.32	3.62e-7	Thyroid stimulating hormone;
SARC	cis	rs9916302	0.904	rs679995	chr17:37441679	A/T	cg20243544	chr17:37824526	PNMT	-0.59	-7.23	-0.43	7.01e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs6448317	1.000	rs13105803	chr4:24940002	A/G	cg21108841	chr4:24914750	CCDC149	-0.53	-5.52	-0.34	9.23e-8	Heschl's gyrus morphology;
SARC	trans	rs7647973	0.667	rs6446286	chr3:49681704	A/G	cg21659725	chr3:3221576	CRBN	-0.64	-6.3	-0.38	1.43e-9	Menarche (age at onset);
SARC	cis	rs7617773	0.817	rs9837228	chr3:48324466	A/T	cg11946769	chr3:48343235	NME6	-0.68	-9.02	-0.51	7.01e-17	Coronary artery disease;
SARC	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg03575189	chr17:44344142	NA	0.59	5.52	0.34	8.99e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7520050	0.807	rs5021934	chr1:46109304	A/G	cg24296786	chr1:45957014	TESK2	0.44	5.53	0.34	8.63e-8	Red blood cell count;Reticulocyte count;
SARC	cis	rs7223966	0.883	rs2727317	chr17:61961302	C/T	cg26338869	chr17:61819248	STRADA	0.5	5.64	0.35	5.01e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7246657	0.943	rs3745765	chr19:37854235	G/T	cg14683738	chr19:37701593	ZNF585B	0.51	4.99	0.31	1.16e-6	Coronary artery calcification;
SARC	cis	rs1580019	0.921	rs1580023	chr7:32497881	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.73	9.78	0.54	3.93e-19	Cognitive ability;
SARC	cis	rs9393692	0.875	rs12526215	chr6:26262916	T/C	cg00631329	chr6:26305371	NA	-0.61	-8.82	-0.5	2.77e-16	Educational attainment;
SARC	cis	rs1023500	0.505	rs134886	chr22:42673856	C/T	cg04733989	chr22:42467013	NAGA	-0.54	-7.04	-0.42	2.14e-11	Schizophrenia;
SARC	cis	rs7587476	0.906	rs17487792	chr2:215643500	A/G	cg11970703	chr2:215861251	ABCA12	0.37	5.16	0.32	5.21e-7	Neuroblastoma;
SARC	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg11987759	chr7:65425863	GUSB	0.5	6.22	0.38	2.3e-9	Aortic root size;
SARC	cis	rs898097	0.756	rs11655103	chr17:80813467	T/C	cg15369054	chr17:80825471	TBCD	0.54	7.71	0.45	3.65e-13	Breast cancer;
SARC	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg22920501	chr2:26401640	FAM59B	-0.54	-7.11	-0.42	1.41e-11	Gut microbiome composition (summer);
SARC	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg10589385	chr1:150898437	SETDB1	0.4	5.25	0.33	3.37e-7	Melanoma;
SARC	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.95	14.28	0.68	1.21e-33	Chronic sinus infection;
SARC	cis	rs6991838	0.584	rs7012856	chr8:66534975	C/T	cg13398993	chr8:66546079	ARMC1	0.62	8.19	0.47	1.72e-14	Intelligence (multi-trait analysis);
SARC	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg12310025	chr6:25882481	NA	-0.45	-5.82	-0.36	1.91e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.4	5.06	0.31	8.51e-7	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg11987759	chr7:65425863	GUSB	0.57	7.54	0.44	1.03e-12	Aortic root size;
SARC	cis	rs881375	0.933	rs1548784	chr9:123685280	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.44	5.22	0.32	3.9e-7	Rheumatoid arthritis;
SARC	cis	rs10782582	0.593	rs79552201	chr1:76215497	A/T	cg03433033	chr1:76189801	ACADM	-0.42	-5.41	-0.33	1.52e-7	Daytime sleep phenotypes;
SARC	cis	rs7659604	0.689	rs4283687	chr4:122663460	A/G	cg19671926	chr4:122722719	EXOSC9	-0.44	-5.06	-0.31	8.68e-7	Type 2 diabetes;
SARC	cis	rs698833	0.562	rs10182045	chr2:44704236	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	7.14	0.42	1.2e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs1003719	0.688	rs2000416	chr21:38540089	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-9.22	-0.52	1.79e-17	Eye color traits;
SARC	cis	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg05623727	chr3:50126028	RBM5	0.32	5.04	0.31	9.51e-7	Intelligence (multi-trait analysis);
SARC	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg16479474	chr6:28041457	NA	0.37	5.44	0.34	1.37e-7	Depression;
SARC	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg18252515	chr7:66147081	NA	0.58	6.23	0.38	2.16e-9	Aortic root size;
SARC	cis	rs875971	0.825	rs59466412	chr7:65565358	A/G	cg11987759	chr7:65425863	GUSB	0.51	6.32	0.38	1.3e-9	Aortic root size;
SARC	trans	rs11098499	0.863	rs7657849	chr4:120455494	T/C	cg25214090	chr10:38739885	LOC399744	0.57	7.35	0.43	3.31e-12	Corneal astigmatism;
SARC	cis	rs1971762	0.712	rs7302232	chr12:53965423	A/T	cg06632207	chr12:54070931	ATP5G2	0.56	7.57	0.44	8.63e-13	Height;
SARC	cis	rs986417	1.000	rs1474999	chr14:60905920	T/C	cg27398547	chr14:60952738	C14orf39	-1.03	-9.75	-0.54	4.8e-19	Gut microbiota (bacterial taxa);
SARC	cis	rs14978	0.628	rs7791726	chr7:12283329	G/C	cg23422036	chr7:12250390	TMEM106B	0.48	6.35	0.38	1.12e-9	Response to amphetamines;
SARC	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.86	8.86	0.5	2.13e-16	Platelet count;
SARC	cis	rs71636778	0.722	rs35650645	chr1:27169484	T/C	cg04852280	chr1:26496234	ZNF593	0.58	5.33	0.33	2.36e-7	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs75804782	0.641	rs2340870	chr2:239356026	C/T	cg21699342	chr2:239360505	ASB1	-0.58	-4.86	-0.3	2.2e-6	Morning vs. evening chronotype;Chronotype;
SARC	cis	rs10493773	0.609	rs3753789	chr1:86174814	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.62	-10.01	-0.55	7.27e-20	Urate levels in overweight individuals;
SARC	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg25072359	chr17:41440525	NA	-0.5	-5.94	-0.36	1.02e-8	Menopause (age at onset);
SARC	cis	rs747650	0.892	rs1976142	chr11:47225694	T/C	cg03339077	chr11:47165057	C11orf49	-0.45	-6.35	-0.38	1.14e-9	Acne (severe);
SARC	cis	rs16933812	0.510	rs4880048	chr9:36989054	A/G	cg14294708	chr9:37120828	ZCCHC7	0.41	4.75	0.3	3.52e-6	Obesity-related traits;
SARC	cis	rs739401	0.611	rs401707	chr11:3050965	T/C	cg25174290	chr11:3078921	CARS	0.58	8.26	0.48	1.07e-14	Longevity;
SARC	cis	rs9372253	1.000	rs2235989	chr6:110714584	A/T	cg19196401	chr6:110721138	DDO	-0.42	-5.62	-0.35	5.44e-8	Platelet distribution width;
SARC	cis	rs916888	0.610	rs199452	chr17:44801340	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.52	6.19	0.38	2.71e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs4595586	0.525	rs17464772	chr12:39247777	G/A	cg26384229	chr12:38710491	ALG10B	0.69	8.5	0.49	2.23e-15	Morning vs. evening chronotype;
SARC	cis	rs13166103	0.584	rs833355	chr5:57718041	T/C	cg10487770	chr5:57879443	RAB3C	0.49	5.17	0.32	5.1e-7	Type 2 diabetes (age of onset);
SARC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg14893161	chr1:205819251	PM20D1	0.94	16.52	0.73	4.32e-41	Menarche (age at onset);
SARC	cis	rs6700896	0.931	rs4655764	chr1:66126159	C/T	cg04111102	chr1:66153794	NA	0.35	5.35	0.33	2.11e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs13314892	0.764	rs62251033	chr3:69865352	G/A	cg17445875	chr3:69859618	MITF	-0.48	-5.08	-0.32	7.89e-7	QRS complex (12-leadsum);
SARC	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg08280861	chr8:58055591	NA	0.7	6.12	0.37	3.95e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9818758	0.607	rs34326553	chr3:49134429	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.66	-5.51	-0.34	9.32e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg13939156	chr17:80058883	NA	-0.42	-6.48	-0.39	5.51e-10	Life satisfaction;
SARC	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6831352	0.693	rs2602875	chr4:100039495	C/G	cg12011299	chr4:100065546	ADH4	0.28	4.8	0.3	2.86e-6	Alcohol dependence;
SARC	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg18876405	chr7:65276391	NA	0.46	5.11	0.32	6.58e-7	Aortic root size;
SARC	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg15320075	chr8:145703422	NA	-0.52	-6.76	-0.4	1.11e-10	Age at first birth;
SARC	cis	rs13004237	1	rs13004237	chr2:172833139	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.79	-10.94	-0.58	9.34e-23	Schizophrenia;
SARC	cis	rs9868809	0.881	rs7620853	chr3:48666503	G/A	cg00383909	chr3:49044727	WDR6	0.54	4.72	0.3	3.99e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs7429990	0.932	rs6766641	chr3:48145224	G/A	cg11946769	chr3:48343235	NME6	-0.49	-5.49	-0.34	1.04e-7	Educational attainment (years of education);
SARC	cis	rs7766436	0.848	rs13207207	chr6:22579066	G/A	cg13666174	chr6:22585274	NA	-0.59	-7.66	-0.45	5.07e-13	Coronary artery disease;
SARC	cis	rs2072499	0.932	rs3001790	chr1:156165290	T/G	cg24450063	chr1:156163899	SLC25A44	1.18	21.2	0.81	2.66e-56	Testicular germ cell tumor;
SARC	cis	rs295140	0.507	rs4673814	chr2:201108133	G/A	cg23649088	chr2:200775458	C2orf69	-0.5	-7.19	-0.43	8.78e-12	QT interval;
SARC	cis	rs1355223	0.966	rs11602318	chr11:34766983	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.49	6.28	0.38	1.68e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs477692	1.000	rs503660	chr10:131418999	A/G	cg05714579	chr10:131428358	MGMT	0.56	7.27	0.43	5.25e-12	Response to temozolomide;
SARC	cis	rs2908197	0.737	rs2109857	chr7:75963169	T/C	cg22830091	chr7:75961684	YWHAG	-0.35	-5.22	-0.32	3.98e-7	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs7174348	1	rs7174348	chr15:78792439	G/A	cg06917634	chr15:78832804	PSMA4	-0.53	-5.45	-0.34	1.26e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
SARC	cis	rs9916302	0.861	rs33933929	chr17:37426441	A/C	cg07936489	chr17:37558343	FBXL20	-0.69	-9.22	-0.52	1.82e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs113835537	0.597	rs7116921	chr11:66303854	T/C	cg24851651	chr11:66362959	CCS	0.39	4.92	0.31	1.61e-6	Airway imaging phenotypes;
SARC	trans	rs9951602	0.512	rs9946115	chr18:76654531	A/C	cg02800362	chr5:177631904	HNRNPAB	0.7	8.92	0.5	1.4e-16	Obesity-related traits;
SARC	cis	rs4803468	0.901	rs3745292	chr19:41888506	A/G	cg09537434	chr19:41945824	ATP5SL	-0.94	-16.46	-0.73	6.75e-41	Height;
SARC	cis	rs757110	0.745	rs2074311	chr11:17421860	A/G	cg15432903	chr11:17409602	KCNJ11	0.5	8.11	0.47	2.87e-14	Type 2 diabetes;
SARC	cis	rs7219021	0.705	rs11869991	chr17:47027763	C/T	cg16584676	chr17:46985605	UBE2Z	-0.51	-5.91	-0.36	1.2e-8	Schizophrenia or bipolar disorder;
SARC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg11494091	chr17:61959527	GH2	0.53	7.85	0.46	1.49e-13	Prudent dietary pattern;
SARC	cis	rs798554	0.591	rs1182156	chr7:2901084	G/T	cg03185022	chr7:2884158	GNA12	0.41	4.74	0.3	3.7e-6	Height;
SARC	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg08280861	chr8:58055591	NA	0.67	5.29	0.33	2.82e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs4853036	1.000	rs11903034	chr2:70060278	T/G	cg02498382	chr2:70120550	SNRNP27	-0.42	-5.62	-0.35	5.57e-8	Colorectal or endometrial cancer;
SARC	cis	rs6060717	0.536	rs3787173	chr20:34472105	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-5.85	-0.36	1.62e-8	Hip circumference adjusted for BMI;
SARC	cis	rs17826219	0.706	rs9893922	chr17:29068425	T/C	cg13385521	chr17:29058706	SUZ12P	0.88	7.94	0.46	8.37e-14	Body mass index;
SARC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg11494091	chr17:61959527	GH2	0.54	7.89	0.46	1.16e-13	Prudent dietary pattern;
SARC	cis	rs7659604	0.540	rs7699289	chr4:122671553	G/A	cg19671926	chr4:122722719	EXOSC9	0.56	6.87	0.41	5.72e-11	Type 2 diabetes;
SARC	cis	rs6669543	0.883	rs6676438	chr1:161983089	A/G	cg11795308	chr1:161133984	USP21	-0.4	-4.8	-0.3	2.84e-6	QT interval;
SARC	trans	rs7859245	1.000	rs7873626	chr9:138490710	C/T	cg01352810	chr12:133707387	ZNF10	0.55	6.75	0.4	1.16e-10	Response to paliperidone in schizophrenia (negative Marder score);
SARC	cis	rs9814567	1.000	rs3846055	chr3:134203973	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-7.06	-0.42	1.85e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg03188526	chr2:55556201	CCDC88A	-0.43	-5.27	-0.33	3.12e-7	Alcohol dependence;
SARC	cis	rs889312	0.500	rs33328	chr5:56143419	T/C	cg14703610	chr5:56206110	C5orf35	0.53	6.7	0.4	1.59e-10	Breast cancer;Breast cancer (early onset);
SARC	cis	rs8014204	0.575	rs1045430	chr14:75130235	T/G	cg06637938	chr14:75390232	RPS6KL1	0.6	8.82	0.5	2.71e-16	Caffeine consumption;
SARC	cis	rs4792901	0.802	rs55989313	chr17:41606248	T/C	cg22562494	chr17:41607896	ETV4	-0.32	-4.88	-0.3	2e-6	Dupuytren's disease;
SARC	cis	rs72781680	0.898	rs12623333	chr2:24111823	T/G	cg06627628	chr2:24431161	ITSN2	-0.67	-6.59	-0.4	2.95e-10	Lymphocyte counts;
SARC	cis	rs7246657	0.943	rs7257672	chr19:37823859	G/C	cg23950597	chr19:37808831	NA	-0.54	-5.46	-0.34	1.24e-7	Coronary artery calcification;
SARC	cis	rs7833790	0.654	rs7835342	chr8:82698092	A/G	cg17211192	chr8:82754475	SNX16	-0.49	-5.87	-0.36	1.49e-8	Diastolic blood pressure;
SARC	cis	rs858239	0.670	rs6967526	chr7:23159241	C/A	cg23682824	chr7:23144976	KLHL7	0.66	8.54	0.49	1.75e-15	Cerebrospinal fluid biomarker levels;
SARC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg27588902	chr6:42928151	GNMT	0.36	5.49	0.34	1.05e-7	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg22800045	chr5:56110881	MAP3K1	0.74	7.83	0.46	1.74e-13	Initial pursuit acceleration;
SARC	cis	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg14343924	chr8:8086146	FLJ10661	0.43	5.42	0.33	1.45e-7	Mood instability;
SARC	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg08048268	chr3:133502702	NA	-0.43	-5.73	-0.35	3.03e-8	Iron status biomarkers;
SARC	cis	rs7020830	0.858	rs7856690	chr9:37127545	A/T	cg14294708	chr9:37120828	ZCCHC7	1.1	18.91	0.78	5.78e-49	Schizophrenia;
SARC	cis	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg05234568	chr11:5960015	NA	-0.41	-4.79	-0.3	2.93e-6	DNA methylation (variation);
SARC	cis	rs2635047	0.811	rs9965170	chr18:44788274	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	6.29	0.38	1.54e-9	Educational attainment;
SARC	cis	rs2303759	0.709	rs3760667	chr19:49814832	C/T	cg22307029	chr19:49891270	CCDC155	0.6	6.77	0.41	1.02e-10	Multiple sclerosis;
SARC	cis	rs12079745	0.793	rs3765227	chr1:169437153	C/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.96	-5.52	-0.34	9.09e-8	QT interval;
SARC	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg24549020	chr5:56110836	MAP3K1	0.47	5.21	0.32	4.06e-7	Initial pursuit acceleration;
SARC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg02018176	chr4:1364513	KIAA1530	0.65	9.99	0.55	8.58e-20	Longevity;
SARC	cis	rs9916302	0.706	rs594794	chr17:37453485	T/C	cg00129232	chr17:37814104	STARD3	0.54	5.76	0.35	2.7e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs9916302	0.904	rs35285898	chr17:37555872	A/C	cg00129232	chr17:37814104	STARD3	0.62	7.61	0.45	6.89e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs1707322	0.681	rs12048866	chr1:46117492	T/G	cg06784218	chr1:46089804	CCDC17	0.36	6.25	0.38	1.97e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg07234876	chr8:600039	NA	0.77	5.83	0.36	1.8e-8	IgG glycosylation;
SARC	cis	rs3824867	0.879	rs10769267	chr11:47460098	C/T	cg20307385	chr11:47447363	PSMC3	0.48	5.21	0.32	4.25e-7	Mean corpuscular hemoglobin;
SARC	cis	rs9325144	0.555	rs6582607	chr12:38717678	T/C	cg04568710	chr12:38710424	ALG10B	-0.39	-4.75	-0.3	3.56e-6	Morning vs. evening chronotype;
SARC	cis	rs4268898	0.862	rs11125549	chr2:24576240	C/T	cg06627628	chr2:24431161	ITSN2	0.6	8.55	0.49	1.6e-15	Asthma;
SARC	cis	rs11764590	0.694	rs4721321	chr7:2068470	A/G	cg23043544	chr7:2124092	MAD1L1	-0.35	-4.83	-0.3	2.53e-6	Neuroticism;
SARC	cis	rs9640161	0.750	rs11538922	chr7:150035183	C/T	cg21361702	chr7:150065534	REPIN1	0.5	4.86	0.3	2.14e-6	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs7264396	0.733	rs6058305	chr20:34310757	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	6.0	0.37	7.38e-9	Total cholesterol levels;
SARC	cis	rs9303280	0.776	rs11078926	chr17:38062976	G/A	cg20243544	chr17:37824526	PNMT	0.44	5.77	0.35	2.56e-8	Self-reported allergy;
SARC	cis	rs2304069	0.954	rs6579767	chr5:149406271	C/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.71	7.24	0.43	6.47e-12	HIV-1 control;
SARC	cis	rs9581943	0.933	rs61652270	chr13:28461726	C/T	cg16302790	chr13:28498334	PDX1	0.56	8.37	0.48	5.41e-15	Pancreatic cancer;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20808462	chr4:2243252	HAUS3	-0.5	-6.25	-0.38	1.91e-9	Smoking initiation;
SARC	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg11987759	chr7:65425863	GUSB	0.49	5.98	0.36	8.43e-9	Aortic root size;
SARC	cis	rs15676	0.679	rs6478853	chr9:131588813	C/G	cg00228799	chr9:131580591	ENDOG	-0.61	-7.68	-0.45	4.42e-13	Blood metabolite levels;
SARC	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg22800045	chr5:56110881	MAP3K1	0.74	7.83	0.46	1.74e-13	Initial pursuit acceleration;
SARC	cis	rs1881797	1.000	rs12063141	chr1:247688343	G/A	cg18198730	chr1:247681584	NA	0.51	5.51	0.34	9.45e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg10876282	chr6:28092338	ZSCAN16	0.47	4.84	0.3	2.34e-6	Parkinson's disease;
SARC	cis	rs13256369	0.901	rs4841015	chr8:8567140	C/G	cg18904891	chr8:8559673	CLDN23	0.51	6.06	0.37	5.35e-9	Obesity-related traits;
SARC	cis	rs9467773	0.620	rs2504599	chr6:26641060	C/T	cg12292205	chr6:26970375	C6orf41	0.4	4.92	0.31	1.64e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg11366901	chr6:160182831	ACAT2	1.02	9.89	0.54	1.79e-19	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs752010	0.619	rs10789406	chr1:42105182	G/T	cg06885757	chr1:42089581	HIVEP3	-0.33	-5.22	-0.32	4.02e-7	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg08219700	chr8:58056026	NA	0.62	6.52	0.39	4.28e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6121246	0.909	rs6060821	chr20:30294034	C/T	cg13852791	chr20:30311386	BCL2L1	0.83	8.92	0.5	1.43e-16	Mean corpuscular hemoglobin;
SARC	cis	rs7589342	0.831	rs34554853	chr2:106448931	G/A	cg16077055	chr2:106428750	NCK2	0.41	7.49	0.44	1.43e-12	Addiction;
SARC	trans	rs2727020	0.595	rs10769583	chr11:49483193	G/A	cg03929089	chr4:120376271	NA	-0.8	-12.04	-0.62	2.73e-26	Coronary artery disease;
SARC	cis	rs139156536	1	rs139156536	chr17:38164432	TTTTA/T	cg17467752	chr17:38218738	THRA	0.43	5.73	0.35	3.03e-8	Lymphocyte percentage of white cells;
SARC	cis	rs2239547	0.522	rs2336669	chr3:52994138	C/T	cg18404041	chr3:52824283	ITIH1	0.38	4.82	0.3	2.58e-6	Schizophrenia;
SARC	trans	rs9650657	0.737	rs4504595	chr8:10655505	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.41	-0.39	7.99e-10	Neuroticism;
SARC	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg22857025	chr5:266934	NA	-1.04	-11.74	-0.61	2.61e-25	Breast cancer;
SARC	cis	rs11690935	0.959	rs12185567	chr2:172560729	A/C	cg13550731	chr2:172543902	DYNC1I2	0.98	15.22	0.71	8.63e-37	Schizophrenia;
SARC	cis	rs1799949	1.000	rs4793236	chr17:41436440	T/C	cg23758822	chr17:41437982	NA	0.87	11.19	0.59	1.55e-23	Menopause (age at onset);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg17380693	chr7:23382571	IGF2BP3	0.43	6.81	0.41	8.05e-11	Thyroid stimulating hormone;
SARC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg09033563	chr22:24373618	LOC391322	-0.53	-6.67	-0.4	1.83e-10	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1448094	0.512	rs10863086	chr12:86244225	G/A	cg02569458	chr12:86230093	RASSF9	0.39	5.44	0.34	1.34e-7	Major depressive disorder;
SARC	cis	rs933688	1.000	rs2367526	chr5:90740525	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.0	12.52	0.63	7.66e-28	Smoking behavior;
SARC	cis	rs501120	1.000	rs504799	chr10:44753456	C/T	cg09554077	chr10:44749378	NA	0.48	6.67	0.4	1.85e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs9341808	0.718	rs11962614	chr6:80823306	A/T	cg08355045	chr6:80787529	NA	0.34	5.5	0.34	1.02e-7	Sitting height ratio;
SARC	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg15352829	chr14:105391018	PLD4	-0.33	-6.34	-0.38	1.19e-9	Rheumatoid arthritis;
SARC	cis	rs67478160	0.643	rs3742369	chr14:104251276	T/C	cg26031613	chr14:104095156	KLC1	-0.4	-4.83	-0.3	2.43e-6	Schizophrenia;
SARC	cis	rs9486719	0.947	rs11757102	chr6:96885073	G/A	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.01	-0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs7826238	0.720	rs12546760	chr8:8374836	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.66	-0.4	1.98e-10	Systolic blood pressure;
SARC	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg26513180	chr16:89883248	FANCA	0.75	4.84	0.3	2.35e-6	Skin colour saturation;
SARC	cis	rs1023500	0.573	rs2269524	chr22:42475703	T/G	cg15557168	chr22:42548783	NA	0.35	4.81	0.3	2.67e-6	Schizophrenia;
SARC	cis	rs473651	1.000	rs473651	chr2:239335401	A/C	cg21699342	chr2:239360505	ASB1	0.47	6.81	0.41	8.41e-11	Multiple system atrophy;
SARC	cis	rs9467773	0.935	rs9461270	chr6:26544110	A/G	cg11502198	chr6:26597334	ABT1	0.46	5.61	0.34	5.83e-8	Intelligence (multi-trait analysis);
SARC	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg16325326	chr1:53192061	ZYG11B	-0.79	-12.07	-0.62	2.16e-26	Monocyte count;
SARC	cis	rs2529049	0.606	rs2257061	chr7:24740177	T/C	cg17569154	chr7:24781545	DFNA5	0.49	6.97	0.42	3.3e-11	Urate levels in obese individuals;
SARC	cis	rs365132	1.000	rs601923	chr5:176417386	C/G	cg16309518	chr5:176445507	NA	-0.47	-6.11	-0.37	4.2e-9	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	trans	rs17685	0.523	rs10246583	chr7:75746667	C/A	cg19862616	chr7:65841803	NCRNA00174	0.61	7.48	0.44	1.47e-12	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs11605924	1.000	rs11605924	chr11:45873091	A/C	ch.11.939596F	chr11:45881766	CRY2	-0.48	-5.71	-0.35	3.43e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs7681440	0.874	rs10028246	chr4:90766704	G/A	cg02192967	chr4:90758406	SNCA	0.36	5.13	0.32	6.11e-7	Dementia with Lewy bodies;
SARC	cis	rs6570726	0.643	rs9403735	chr6:145936591	C/T	cg23711669	chr6:146136114	FBXO30	0.88	14.88	0.7	1.19e-35	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg18876405	chr7:65276391	NA	-0.45	-5.58	-0.34	6.61e-8	Aortic root size;
SARC	cis	rs7647973	0.580	rs12637576	chr3:49237334	C/T	cg07636037	chr3:49044803	WDR6	0.92	15.22	0.71	8.52e-37	Menarche (age at onset);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg08365438	chr10:21683093	NA	-0.51	-6.26	-0.38	1.88e-9	Height;
SARC	cis	rs6963495	0.818	rs6977748	chr7:105167462	T/G	cg13798780	chr7:105162888	PUS7	0.63	5.85	0.36	1.7e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs10513788	0.665	rs4859116	chr3:181993063	C/T	cg05977900	chr3:182512126	ATP11B	0.47	4.97	0.31	1.3e-6	Cognitive function;
SARC	cis	rs6964587	0.934	rs35968894	chr7:91762145	A/G	cg17063962	chr7:91808500	NA	0.92	13.7	0.67	9.56e-32	Breast cancer;
SARC	cis	rs6540556	0.682	rs2282741	chr1:209900609	G/C	cg23920097	chr1:209922102	NA	-0.5	-5.67	-0.35	4.16e-8	Red blood cell count;
SARC	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg13126279	chr21:47581558	C21orf56	-0.43	-5.27	-0.33	3.06e-7	Testicular germ cell tumor;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg06747745	chr11:120894801	TBCEL	-0.77	-6.47	-0.39	5.72e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg25894440	chr7:65020034	NA	-0.79	-5.99	-0.37	8.04e-9	Diabetic kidney disease;
SARC	cis	rs138249	0.966	rs138238	chr22:50563140	T/C	cg24864161	chr22:50528282	MOV10L1	0.31	5.03	0.31	9.71e-7	Gestational age at birth in labor-initiated deliveries (child effect);
SARC	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg25427524	chr10:38739819	LOC399744	-0.56	-8.73	-0.5	5.08e-16	Extrinsic epigenetic age acceleration;
SARC	cis	rs4642101	0.597	rs9865624	chr3:12822786	T/A	cg05775895	chr3:12838266	CAND2	0.75	11.88	0.61	9.18e-26	QRS complex (12-leadsum);
SARC	cis	rs959260	0.557	rs12946365	chr17:73317644	C/T	cg07104495	chr17:73266070	MIF4GD	-0.33	-4.99	-0.31	1.2e-6	Systemic lupus erythematosus;
SARC	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg06108461	chr20:60628389	TAF4	-0.92	-12.69	-0.64	2.14e-28	Body mass index;
SARC	cis	rs1371867	0.875	rs28595052	chr8:101327553	G/A	cg11906718	chr8:101322791	RNF19A	0.71	9.12	0.51	3.68e-17	Atrioventricular conduction;
SARC	cis	rs9911578	1.000	rs12947785	chr17:57045160	A/C	cg05425664	chr17:57184151	TRIM37	-0.65	-8.04	-0.47	4.55e-14	Intelligence (multi-trait analysis);
SARC	cis	rs6456156	0.811	rs975822	chr6:167516458	C/T	cg07741184	chr6:167504864	NA	-0.31	-5.54	-0.34	8.05e-8	Primary biliary cholangitis;
SARC	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg26335602	chr6:28129616	ZNF389	0.51	5.56	0.34	7.41e-8	Parkinson's disease;
SARC	cis	rs7223966	0.621	rs9906747	chr17:61639694	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.48	5.22	0.32	3.95e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs55823223	0.702	rs3785437	chr17:73906222	G/T	cg23806715	chr17:73775811	H3F3B	1.03	8.79	0.5	3.38e-16	Psoriasis;
SARC	cis	rs889312	0.961	rs6450401	chr5:56033234	G/C	cg14703610	chr5:56206110	C5orf35	0.41	4.79	0.3	3.02e-6	Breast cancer;Breast cancer (early onset);
SARC	cis	rs10046574	0.519	rs10265128	chr7:135211446	A/G	cg27474649	chr7:135195673	CNOT4	0.81	7.74	0.45	3e-13	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs6120849	0.901	rs6088735	chr20:33745676	C/T	cg24642439	chr20:33292090	TP53INP2	0.49	4.83	0.3	2.44e-6	Protein C levels;
SARC	cis	rs870825	1.000	rs870821	chr4:185587377	T/C	cg04058563	chr4:185651563	MLF1IP	0.74	8.9	0.5	1.58e-16	Blood protein levels;
SARC	cis	rs11792861	0.926	rs72607171	chr9:111837776	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.67	7.73	0.45	3.27e-13	Menarche (age at onset);
SARC	trans	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg20587970	chr11:113659929	NA	-1.34	-13.79	-0.67	4.87e-32	Hip circumference adjusted for BMI;
SARC	cis	rs72627123	0.867	rs58894370	chr14:74485382	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.74	5.84	0.36	1.78e-8	Morning vs. evening chronotype;
SARC	cis	rs11574514	0.661	rs117024179	chr16:67795150	A/G	cg01866162	chr16:67596514	CTCF	1.13	6.68	0.4	1.7e-10	Crohn's disease;
SARC	cis	rs4141404	0.561	rs5994376	chr22:31563555	A/C	cg02404636	chr22:31891804	SFI1	-0.45	-5.56	-0.34	7.27e-8	Paclitaxel-induced neuropathy;
SARC	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.63e-10	Life satisfaction;
SARC	cis	rs963731	0.649	rs2278913	chr2:39199880	A/G	cg04010122	chr2:39346883	SOS1	-0.86	-5.59	-0.34	6.24e-8	Corticobasal degeneration;
SARC	cis	rs2075371	0.829	rs35897242	chr7:134004041	G/A	cg11752832	chr7:134001865	SLC35B4	0.57	7.12	0.42	1.3e-11	Mean platelet volume;
SARC	cis	rs10782582	0.545	rs111927462	chr1:76195422	A/G	cg03433033	chr1:76189801	ACADM	-0.41	-5.17	-0.32	5.01e-7	Daytime sleep phenotypes;
SARC	cis	rs7712401	0.562	rs383638	chr5:122324678	A/C	cg19412675	chr5:122181750	SNX24	-0.43	-5.43	-0.34	1.41e-7	Mean platelet volume;
SARC	cis	rs17376456	0.569	rs10067754	chr5:93093110	T/A	cg21475434	chr5:93447410	FAM172A	0.61	5.95	0.36	9.98e-9	Diabetic retinopathy;
SARC	cis	rs1348850	0.567	rs4893838	chr2:178531436	T/C	cg22681709	chr2:178499509	PDE11A	-0.36	-5.18	-0.32	4.87e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg26681399	chr22:41777847	TEF	0.43	4.92	0.31	1.67e-6	Vitiligo;
SARC	cis	rs7819412	0.775	rs4545055	chr8:10935366	T/C	cg21775007	chr8:11205619	TDH	-0.47	-5.94	-0.36	1.03e-8	Triglycerides;
SARC	cis	rs7615952	0.673	rs9821905	chr3:125620850	A/G	cg05084668	chr3:125655381	ALG1L	0.86	7.69	0.45	4.03e-13	Blood pressure (smoking interaction);
SARC	cis	rs7223966	0.921	rs6504186	chr17:61863932	G/A	cg00588841	chr17:61851480	DDX42;CCDC47	-0.66	-7.33	-0.43	3.71e-12	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6121246	0.529	rs6120862	chr20:30199459	T/C	cg21427119	chr20:30132790	HM13	-0.48	-5.23	-0.32	3.71e-7	Mean corpuscular hemoglobin;
SARC	cis	rs35306767	0.903	rs12260800	chr10:927933	T/C	cg26597838	chr10:835615	NA	0.82	8.5	0.49	2.22e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs9807989	0.839	rs1362348	chr2:102984624	C/G	cg09003973	chr2:102972529	NA	0.43	5.58	0.34	6.78e-8	Asthma;
SARC	cis	rs66573146	1.000	rs56074877	chr4:6990374	C/T	cg15105060	chr4:7024189	TBC1D14	-0.66	-4.75	-0.3	3.49e-6	Granulocyte percentage of myeloid white cells;
SARC	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs34779708	0.931	rs4351760	chr10:35280254	A/G	cg03585969	chr10:35415529	CREM	0.42	5.14	0.32	5.83e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs2204008	0.560	rs1315354	chr12:38165716	A/G	cg14851346	chr12:38532713	NA	-0.43	-5.07	-0.32	8.25e-7	Bladder cancer;
SARC	cis	rs1800469	1.000	rs1549933	chr19:41871142	A/G	cg14132834	chr19:41945861	ATP5SL	-0.42	-5.06	-0.31	8.67e-7	Colorectal cancer;
SARC	cis	rs11711311	0.955	rs7650764	chr3:113414439	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	7.74	0.45	3.04e-13	IgG glycosylation;
SARC	cis	rs748404	0.697	rs498227	chr15:43573052	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	6.66	0.4	1.91e-10	Lung cancer;
SARC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg08280861	chr8:58055591	NA	0.61	5.94	0.36	1.01e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9911578	0.935	rs9911753	chr17:56983174	G/A	cg12560992	chr17:57184187	TRIM37	0.69	8.68	0.49	7.01e-16	Intelligence (multi-trait analysis);
SARC	cis	rs2439831	0.850	rs10163054	chr15:44047638	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	8.57	0.49	1.44e-15	Lung cancer in ever smokers;
SARC	cis	rs8523	0.804	rs3798720	chr6:11040002	C/T	cg13562911	chr6:11044106	ELOVL2	0.48	6.42	0.39	7.46e-10	Red blood cell fatty acid levels;
SARC	cis	rs35306767	0.855	rs11253465	chr10:897208	A/C	cg26597838	chr10:835615	NA	0.82	8.48	0.49	2.61e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs7647973	0.588	rs9883000	chr3:49667691	A/G	cg03060546	chr3:49711283	APEH	0.64	6.96	0.42	3.36e-11	Menarche (age at onset);
SARC	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs734999	0.505	rs10797438	chr1:2540262	C/T	cg20673091	chr1:2541236	MMEL1	0.33	5.08	0.32	7.7e-7	Ulcerative colitis;
SARC	cis	rs12579753	1.000	rs66646148	chr12:82248520	T/G	cg07988820	chr12:82153109	PPFIA2	-0.55	-6.48	-0.39	5.55e-10	Resting heart rate;
SARC	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg09839136	chr7:766187	HEATR2;PRKAR1B	0.56	4.8	0.3	2.89e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg22857025	chr5:266934	NA	-1.05	-11.87	-0.61	9.76e-26	Breast cancer;
SARC	cis	rs2075371	0.931	rs1646697	chr7:133999930	G/A	cg11752832	chr7:134001865	SLC35B4	0.56	7.1	0.42	1.47e-11	Mean platelet volume;
SARC	cis	rs10876993	0.928	rs2640637	chr12:58077586	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.43	-5.36	-0.33	1.96e-7	Celiac disease or Rheumatoid arthritis;
SARC	trans	rs2840044	0.554	rs225267	chr17:33964228	T/C	cg19694781	chr19:47549865	TMEM160	-0.68	-6.84	-0.41	7.09e-11	Response to radiotherapy in cancer (late toxicity);
SARC	cis	rs3540	0.533	rs12708585	chr15:91052285	C/T	cg22089800	chr15:90895588	ZNF774	-0.61	-7.87	-0.46	1.3e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs10085978	0.604	rs11167127	chr8:143225736	C/T	cg24634471	chr8:143751801	JRK	0.42	4.89	0.31	1.86e-6	Mosquito bite size;
SARC	cis	rs7208859	0.623	rs9897728	chr17:29108804	A/G	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs67478160	0.643	rs12880821	chr14:104276049	C/T	cg26031613	chr14:104095156	KLC1	-0.4	-4.78	-0.3	3.04e-6	Schizophrenia;
SARC	cis	rs765787	0.530	rs12904265	chr15:45526713	C/T	cg24006582	chr15:45444508	DUOX1	0.46	5.76	0.35	2.63e-8	Uric acid levels;
SARC	cis	rs9790314	1.000	rs1382428	chr3:161032386	A/C	cg03342759	chr3:160939853	NMD3	-0.59	-7.41	-0.44	2.26e-12	Morning vs. evening chronotype;
SARC	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg26335602	chr6:28129616	ZNF389	0.52	5.88	0.36	1.44e-8	Parkinson's disease;
SARC	cis	rs4925386	0.921	rs11204472	chr20:60920887	G/A	cg22307297	chr20:60903441	LAMA5	-0.31	-4.74	-0.3	3.77e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs9303401	0.573	rs34097494	chr17:57171917	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.97	10.15	0.55	2.73e-20	Cognitive test performance;
SARC	cis	rs2732480	0.577	rs2732466	chr12:48732459	A/G	cg24011408	chr12:48396354	COL2A1	0.43	5.06	0.31	8.35e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs9660992	0.710	rs1180721	chr1:205232696	T/C	cg21643547	chr1:205240462	TMCC2	-0.66	-8.82	-0.5	2.65e-16	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs6088580	0.634	rs6088512	chr20:33095891	G/A	cg24642439	chr20:33292090	TP53INP2	0.66	8.68	0.49	6.79e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs10791323	0.720	rs2851117	chr11:133705905	A/G	cg13461336	chr11:133711254	SPATA19	0.28	4.95	0.31	1.39e-6	Childhood ear infection;
SARC	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg11987759	chr7:65425863	GUSB	-0.47	-6.27	-0.38	1.7e-9	Aortic root size;
SARC	cis	rs12155623	0.592	rs12682003	chr8:49865454	G/T	cg01449144	chr8:49782592	NA	0.31	5.14	0.32	5.73e-7	Sudden cardiac arrest;
SARC	trans	rs61931739	0.817	rs10772143	chr12:34230651	T/G	cg13010199	chr12:38710504	ALG10B	0.57	7.33	0.43	3.68e-12	Morning vs. evening chronotype;
SARC	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg04518342	chr5:131593106	PDLIM4	0.42	5.76	0.35	2.64e-8	Acylcarnitine levels;
SARC	cis	rs6570726	0.791	rs9497357	chr6:145912888	G/A	cg05347473	chr6:146136440	FBXO30	0.54	7.45	0.44	1.85e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9814567	0.896	rs7642266	chr3:134346025	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.5	-6.4	-0.39	8.24e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs1048238	0.506	rs7547314	chr1:16186722	G/A	cg21385522	chr1:16154831	NA	0.48	5.97	0.36	8.76e-9	Systolic blood pressure;
SARC	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	11.6	0.61	7.26e-25	Alzheimer's disease;
SARC	cis	rs12022452	0.591	rs61781641	chr1:40983084	G/T	cg25568243	chr1:40974465	DEM1	0.52	4.8	0.3	2.79e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs9303280	0.806	rs2872507	chr17:38040763	C/T	cg20243544	chr17:37824526	PNMT	0.43	5.66	0.35	4.53e-8	Self-reported allergy;
SARC	cis	rs67311347	0.577	rs11712626	chr3:40259927	G/A	cg24209194	chr3:40518798	ZNF619	0.46	5.51	0.34	9.62e-8	Renal cell carcinoma;
SARC	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg10295955	chr4:187884368	NA	-1.07	-20.91	-0.81	2.28e-55	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg26874164	chr19:58962979	ZNF324B	0.46	6.04	0.37	6.12e-9	Uric acid clearance;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg23273911	chr17:72869156	FDXR	0.79	6.56	0.39	3.43e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1707322	0.964	rs7546237	chr1:46285610	A/C	cg06784218	chr1:46089804	CCDC17	0.33	5.76	0.35	2.66e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4481887	0.962	rs4244177	chr1:248468279	C/T	cg01631408	chr1:248437212	OR2T33	-0.42	-5.3	-0.33	2.68e-7	Common traits (Other);
SARC	cis	rs6088580	0.524	rs4911437	chr20:33266149	G/T	cg08999081	chr20:33150536	PIGU	-0.35	-5.15	-0.32	5.45e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg06221963	chr1:154839813	KCNN3	-0.41	-6.01	-0.37	7.22e-9	Prostate cancer;
SARC	trans	rs459571	0.959	rs465724	chr9:136910097	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.61	-6.86	-0.41	6.07e-11	Platelet distribution width;
SARC	cis	rs7582720	1.000	rs6725887	chr2:203745885	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	-0.75	-7.29	-0.43	4.72e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	trans	rs877282	1.000	rs11253367	chr10:773389	G/A	cg22713356	chr15:30763199	NA	1.02	10.28	0.56	1.08e-20	Uric acid levels;
SARC	cis	rs244293	0.730	rs11079142	chr17:53021955	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.41	-4.98	-0.31	1.22e-6	Menarche (age at onset);
SARC	cis	rs116095464	0.558	rs56298907	chr5:283280	C/A	cg22857025	chr5:266934	NA	-1.1	-10.35	-0.56	6.84e-21	Breast cancer;
SARC	cis	rs7927771	0.965	rs11039416	chr11:47846711	G/A	cg20307385	chr11:47447363	PSMC3	-0.47	-5.59	-0.34	6.3e-8	Subjective well-being;
SARC	cis	rs2658782	0.547	rs4753453	chr11:93041174	T/G	cg15737290	chr11:93063684	CCDC67	0.95	12.84	0.64	6.66e-29	Pulmonary function decline;
SARC	cis	rs9916302	0.904	rs8068427	chr17:37511517	G/A	cg07936489	chr17:37558343	FBXL20	0.68	9.2	0.52	2.14e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg04234412	chr22:24373322	LOC391322	-0.66	-9.02	-0.51	7.32e-17	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs4718428	1.000	rs12534637	chr7:66327654	G/C	cg18252515	chr7:66147081	NA	-0.48	-5.17	-0.32	5.03e-7	Corneal structure;
SARC	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg15049968	chr18:44337910	ST8SIA5	-0.36	-5.49	-0.34	1.03e-7	Personality dimensions;
SARC	cis	rs17173637	1.000	rs73165540	chr7:150538879	G/A	cg26935020	chr7:151217007	RHEB	-0.74	-4.8	-0.3	2.82e-6	HDL cholesterol;HDL cholesterol levels;
SARC	cis	rs950169	0.881	rs150965	chr15:85080527	T/G	cg17507749	chr15:85114479	UBE2QP1	0.78	9.16	0.51	2.68e-17	Schizophrenia;
SARC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.3	-4.74	-0.3	3.71e-6	Total body bone mineral density;
SARC	cis	rs10916814	0.632	rs10916819	chr1:20901000	A/G	cg24502330	chr1:20914028	CDA	-0.29	-5.0	-0.31	1.1e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs9300255	0.568	rs1790090	chr12:123633424	G/A	cg00376283	chr12:123451042	ABCB9	0.57	6.67	0.4	1.81e-10	Neutrophil percentage of white cells;
SARC	cis	rs8114671	0.562	rs2273683	chr20:33509523	C/T	cg24642439	chr20:33292090	TP53INP2	0.48	5.76	0.35	2.6e-8	Height;
SARC	cis	rs710216	0.957	rs12041787	chr1:43432275	G/C	cg03128534	chr1:43423976	SLC2A1	0.65	6.61	0.4	2.59e-10	Red cell distribution width;
SARC	cis	rs6121246	0.567	rs6060261	chr20:30192948	C/G	cg21427119	chr20:30132790	HM13	-0.48	-5.29	-0.33	2.84e-7	Mean corpuscular hemoglobin;
SARC	cis	rs589448	0.538	rs622656	chr12:69753595	C/T	cg14784868	chr12:69753453	YEATS4	0.51	6.17	0.37	2.98e-9	Cerebrospinal fluid biomarker levels;
SARC	cis	rs12579753	0.917	rs71466033	chr12:82242187	C/T	cg07988820	chr12:82153109	PPFIA2	-0.52	-6.07	-0.37	5.24e-9	Resting heart rate;
SARC	cis	rs8014204	0.935	rs10141438	chr14:75354600	A/G	cg17347104	chr14:75034677	LTBP2	0.4	4.93	0.31	1.55e-6	Caffeine consumption;
SARC	cis	rs883565	0.502	rs9839582	chr3:38943120	G/A	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.44	-5.29	-0.33	2.87e-7	Handedness;
SARC	cis	rs57221529	0.709	rs72707023	chr5:667620	G/A	cg09021430	chr5:549028	NA	-0.44	-5.15	-0.32	5.5e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs10463554	0.927	rs257317	chr5:102422585	T/C	cg23492399	chr5:102201601	PAM	-0.43	-4.84	-0.3	2.33e-6	Parkinson's disease;
SARC	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg18876405	chr7:65276391	NA	-0.47	-5.29	-0.33	2.84e-7	Aortic root size;
SARC	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	8.67	0.49	7.35e-16	Mean platelet volume;
SARC	cis	rs7762018	0.891	rs7740218	chr6:170141552	G/A	cg13891659	chr6:170190454	C6orf122;C6orf208	0.55	4.88	0.3	2e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg14983838	chr19:29218262	NA	0.77	10.47	0.57	2.77e-21	Methadone dose in opioid dependence;
SARC	cis	rs4865169	0.811	rs6841086	chr4:57903268	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.44	5.32	0.33	2.42e-7	Breast cancer;
SARC	cis	rs7829975	0.782	rs6990746	chr8:8547811	A/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-5.88	-0.36	1.42e-8	Mood instability;
SARC	cis	rs13161895	1.000	rs4235504	chr5:179453680	T/C	cg04265672	chr5:179402240	RNF130	-0.49	-4.72	-0.3	4.02e-6	LDL cholesterol;
SARC	cis	rs28530618	0.603	rs11167173	chr20:31241612	A/T	cg13636640	chr20:31349939	DNMT3B	-0.43	-4.96	-0.31	1.33e-6	Birth weight;
SARC	cis	rs4065321	0.609	rs8075668	chr17:38137623	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.31	5.68	0.35	3.98e-8	White blood cell count (basophil);White blood cell count;
SARC	cis	rs12142240	0.698	rs56130131	chr1:46861306	A/C	cg00530320	chr1:46809349	NSUN4	0.58	7.12	0.42	1.34e-11	Menopause (age at onset);
SARC	cis	rs1707322	0.752	rs28438704	chr1:46170544	G/A	cg03146154	chr1:46216737	IPP	0.53	6.35	0.38	1.12e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1348850	0.526	rs7588049	chr2:178390778	C/T	cg23306229	chr2:178417860	TTC30B	-0.8	-6.8	-0.41	8.65e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs611744	0.647	rs12675265	chr8:109268805	C/T	cg21045802	chr8:109455806	TTC35	0.57	7.1	0.42	1.45e-11	Dupuytren's disease;
SARC	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.73	-7.16	-0.42	1.02e-11	Platelet count;
SARC	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg10591111	chr5:226296	SDHA	-0.55	-4.97	-0.31	1.31e-6	Breast cancer;
SARC	cis	rs787274	1.000	rs2796035	chr9:115515597	C/T	cg13803584	chr9:115635662	SNX30	-0.83	-4.9	-0.31	1.79e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	trans	rs61931739	0.534	rs11053021	chr12:34111157	C/T	cg26384229	chr12:38710491	ALG10B	0.87	12.43	0.63	1.5e-27	Morning vs. evening chronotype;
SARC	cis	rs7412746	0.611	rs4970985	chr1:150887442	C/T	cg10589385	chr1:150898437	SETDB1	-0.38	-5.11	-0.32	6.69e-7	Melanoma;
SARC	cis	rs7647973	1.000	rs13322887	chr3:49555583	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.57	-6.06	-0.37	5.34e-9	Menarche (age at onset);
SARC	cis	rs7666738	0.830	rs10516426	chr4:99035827	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2180341	1.000	rs3798853	chr6:127636823	C/T	cg17762328	chr6:126965162	NA	0.44	4.98	0.31	1.21e-6	Breast cancer;
SARC	cis	rs8014204	0.748	rs12889277	chr14:75229376	A/T	cg17347104	chr14:75034677	LTBP2	-0.42	-5.11	-0.32	6.57e-7	Caffeine consumption;
SARC	trans	rs9929218	0.508	rs6499194	chr16:68744100	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.81	13.3	0.66	2.16e-30	Colorectal cancer;
SARC	cis	rs72781680	1.000	rs12614452	chr2:24194608	C/T	cg06627628	chr2:24431161	ITSN2	-0.7	-6.71	-0.4	1.49e-10	Lymphocyte counts;
SARC	cis	rs4481887	1.000	rs4409693	chr1:248479061	C/T	cg00666640	chr1:248458726	OR2T12	0.39	6.51	0.39	4.66e-10	Common traits (Other);
SARC	cis	rs796364	0.951	rs7565005	chr2:201013277	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.54	-5.32	-0.33	2.4e-7	Schizophrenia;
SARC	cis	rs7917772	0.636	rs2482499	chr10:104516246	G/A	ch.10.2196322F	chr10:104248062	ACTR1A	0.49	5.91	0.36	1.18e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg26354017	chr1:205819088	PM20D1	0.92	15.93	0.72	3.83e-39	Menarche (age at onset);
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg23119039	chr13:111164546	COL4A2	0.77	5.79	0.35	2.27e-8	Obesity-related traits;
SARC	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-8.85	-0.5	2.28e-16	Alzheimer's disease;
SARC	cis	rs7681440	0.904	rs28415623	chr4:90767110	C/T	cg02192967	chr4:90758406	SNCA	0.36	5.13	0.32	6.11e-7	Dementia with Lewy bodies;
SARC	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg05368731	chr17:41323189	NBR1	0.8	9.72	0.54	5.95e-19	Menopause (age at onset);
SARC	cis	rs765787	0.530	rs11636367	chr15:45535862	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.67e-7	Uric acid levels;
SARC	cis	rs6964587	1.000	rs7797369	chr7:91570615	C/A	cg17063962	chr7:91808500	NA	-0.92	-14.58	-0.69	1.19e-34	Breast cancer;
SARC	cis	rs2730245	0.505	rs1188956	chr7:158690576	G/A	cg14689365	chr7:158441557	NCAPG2	0.43	5.16	0.32	5.4e-7	Height;
SARC	cis	rs7223966	1.000	rs9899491	chr17:61934384	G/C	cg26338869	chr17:61819248	STRADA	0.52	5.47	0.34	1.13e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs11690462	0.528	rs6710942	chr2:26636390	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.42	5.02	0.31	1.04e-6	Coronary artery disease;
SARC	cis	rs10911232	0.507	rs4266836	chr1:183029070	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.68	9.96	0.55	1.08e-19	Hypertriglyceridemia;
SARC	cis	rs611744	0.647	rs2597658	chr8:109256014	C/T	cg21045802	chr8:109455806	TTC35	0.61	7.7	0.45	3.89e-13	Dupuytren's disease;
SARC	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg12923728	chr3:195709715	SDHAP1	-0.68	-8.28	-0.48	9.55e-15	Pancreatic cancer;
SARC	cis	rs2439831	0.681	rs956391	chr15:43617493	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.77	-8.15	-0.47	2.16e-14	Lung cancer in ever smokers;
SARC	cis	rs920590	1.000	rs6995371	chr8:19650268	A/G	cg17834443	chr8:19674713	INTS10	0.48	6.08	0.37	4.84e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg16405210	chr4:1374714	KIAA1530	-0.48	-5.61	-0.35	5.59e-8	Obesity-related traits;
SARC	cis	rs80130819	0.688	rs6580660	chr12:48588112	T/C	cg05342945	chr12:48394962	COL2A1	-0.55	-5.73	-0.35	3.13e-8	Prostate cancer;
SARC	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg12756686	chr19:29218302	NA	0.71	9.44	0.53	4.05e-18	Methadone dose in opioid dependence;
SARC	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg17279839	chr7:150038598	RARRES2	0.48	6.65	0.4	2.06e-10	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs2645694	0.626	rs12502590	chr4:77823642	G/A	cg18351406	chr4:77819688	ANKRD56	0.44	6.25	0.38	1.9e-9	Emphysema distribution in smoking;
SARC	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg08219700	chr8:58056026	NA	0.49	5.01	0.31	1.05e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs7772486	0.790	rs6917135	chr6:146152426	T/C	cg05347473	chr6:146136440	FBXO30	0.5	7.02	0.42	2.44e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs933688	1.000	rs60513756	chr5:90727692	A/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.05	12.87	0.64	5.49e-29	Smoking behavior;
SARC	cis	rs228769	0.653	rs2523162	chr17:42179281	A/G	cg19774624	chr17:42201019	HDAC5	0.56	5.99	0.37	7.91e-9	Bone mineral density (hip);Bone mineral density (spine);
SARC	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg21724239	chr8:58056113	NA	0.58	6.14	0.37	3.49e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg00502533	chr1:113498761	SLC16A1	0.52	6.43	0.39	7.2e-10	Breast cancer;
SARC	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg08280861	chr8:58055591	NA	0.61	5.96	0.36	9.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs425277	0.917	rs12410859	chr1:2038732	C/T	cg21442419	chr1:2182373	SKI	-0.41	-4.89	-0.31	1.86e-6	Height;
SARC	cis	rs765787	0.530	rs3759893	chr15:45542950	G/T	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.81e-6	Uric acid levels;
SARC	cis	rs9818758	0.545	rs9853352	chr3:49813258	C/T	cg01304814	chr3:48885189	PRKAR2A	-0.65	-5.55	-0.34	7.69e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs6908034	0.607	rs78402429	chr6:19811690	C/A	cg02682789	chr6:19804855	NA	0.69	5.56	0.34	7.3900000000000007e-08	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs9392918	0.600	rs932660	chr6:7695798	G/T	cg23089261	chr6:7723385	NA	0.51	6.37	0.38	1.03e-9	Height;
SARC	cis	rs4664304	0.511	rs2303547	chr2:160691829	C/T	cg18514922	chr2:160761262	LY75	-0.32	-4.73	-0.3	3.85e-6	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs13401104	0.796	rs57900956	chr2:237119214	C/A	cg19324714	chr2:237145437	ASB18	0.57	5.66	0.35	4.32e-8	Educational attainment;
SARC	cis	rs2658782	0.951	rs2608215	chr11:93148817	G/A	cg15737290	chr11:93063684	CCDC67	0.71	7.54	0.44	1.03e-12	Pulmonary function decline;
SARC	cis	rs526821	0.595	rs565859	chr11:55297367	T/C	cg04317927	chr11:55418816	OR4S2	0.38	5.55	0.34	7.91e-8	Pediatric bone mineral density (spine);
SARC	cis	rs13082711	0.558	rs640912	chr3:27364092	C/A	cg02860705	chr3:27208620	NA	0.44	5.96	0.36	9.41e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs1865760	0.623	rs12216125	chr6:25997458	C/T	cg17691542	chr6:26056736	HIST1H1C	0.57	6.85	0.41	6.39e-11	Height;
SARC	cis	rs453301	0.631	rs7843789	chr8:8800561	G/C	cg15556689	chr8:8085844	FLJ10661	-0.45	-5.47	-0.34	1.14e-7	Joint mobility (Beighton score);
SARC	cis	rs2764208	0.576	rs6457791	chr6:34759954	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.85	-0.36	1.64e-8	Systemic lupus erythematosus;
SARC	trans	rs656319	0.564	rs11776035	chr8:10071527	A/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.32	-0.38	1.3e-9	Myopia (pathological);
SARC	cis	rs4742903	0.904	rs12380062	chr9:106941903	A/G	cg14250997	chr9:106856677	SMC2	0.44	5.49	0.34	1.02e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs72781680	0.821	rs72796401	chr2:24180078	T/A	cg08917208	chr2:24149416	ATAD2B	0.58	6.01	0.37	7.09e-9	Lymphocyte counts;
SARC	cis	rs11711311	1.000	rs9288984	chr3:113525956	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	8.12	0.47	2.72e-14	IgG glycosylation;
SARC	cis	rs1448094	0.549	rs57614821	chr12:86235361	A/C	cg02569458	chr12:86230093	RASSF9	0.39	5.41	0.33	1.57e-7	Major depressive disorder;
SARC	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg17971929	chr21:40555470	PSMG1	-0.6	-7.48	-0.44	1.54e-12	Menarche (age at onset);
SARC	cis	rs1395	0.922	rs11898114	chr2:27515527	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.33	-4.89	-0.31	1.86e-6	Blood metabolite levels;
SARC	trans	rs11039798	0.660	rs28435129	chr11:48629795	A/T	cg15704280	chr7:45808275	SEPT13	0.59	6.23	0.38	2.12e-9	Axial length;
SARC	cis	rs10911251	0.509	rs4652780	chr1:183105923	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.04	0.55	6e-20	Colorectal cancer;
SARC	cis	rs8017423	0.967	rs11628881	chr14:90713833	C/T	cg20276874	chr14:90721474	PSMC1	-0.38	-5.19	-0.32	4.47e-7	Mortality in heart failure;
SARC	cis	rs67460515	0.892	rs10513564	chr3:161059762	A/G	cg03342759	chr3:160939853	NMD3	-0.65	-8.45	-0.48	3.16e-15	Parkinson's disease;
SARC	cis	rs12044355	0.927	rs11577035	chr1:231835941	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.6	8.02	0.47	5.16e-14	Alzheimer's disease;
SARC	cis	rs12044355	0.858	rs3738401	chr1:231830295	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.61	8.15	0.47	2.27e-14	Alzheimer's disease;
SARC	cis	rs453301	0.686	rs28665409	chr8:8869277	G/A	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.42	-0.39	7.57e-10	Joint mobility (Beighton score);
SARC	trans	rs61931739	0.534	rs7313137	chr12:34010231	T/G	cg13010199	chr12:38710504	ALG10B	0.75	10.07	0.55	4.77e-20	Morning vs. evening chronotype;
SARC	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg15105011	chr4:940614	TMEM175	0.36	4.95	0.31	1.43e-6	Sjögren's syndrome;
SARC	cis	rs2624839	0.602	rs2526390	chr3:50192760	C/T	cg24110177	chr3:50126178	RBM5	-0.56	-6.93	-0.41	4.11e-11	Intelligence (multi-trait analysis);
SARC	cis	rs763121	0.853	rs1056610	chr22:39080078	C/T	cg06022373	chr22:39101656	GTPBP1	-0.89	-12.32	-0.63	3.43e-27	Menopause (age at onset);
SARC	cis	rs2760061	0.583	rs708124	chr1:228220771	A/T	cg02753203	chr1:228287806	NA	0.8	12.05	0.62	2.64e-26	Diastolic blood pressure;
SARC	cis	rs9682041	0.627	rs4955722	chr3:170102959	G/T	cg11886554	chr3:170076028	SKIL	0.84	7.76	0.45	2.72e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	trans	rs11098499	0.542	rs7677836	chr4:120310638	T/A	cg25214090	chr10:38739885	LOC399744	0.55	7.14	0.42	1.15e-11	Corneal astigmatism;
SARC	cis	rs1152591	0.811	rs1255984	chr14:64654431	C/T	cg23250157	chr14:64679961	SYNE2	-0.47	-6.9	-0.41	4.98e-11	Atrial fibrillation;
SARC	cis	rs7236492	0.748	rs11663658	chr18:77197555	T/C	cg15644404	chr18:77186268	NFATC1	-0.66	-6.65	-0.4	2.12e-10	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs8067354	0.645	rs2132715	chr17:57858374	A/T	cg13753209	chr17:57696993	CLTC	0.62	6.25	0.38	1.98e-9	Hemoglobin concentration;
SARC	cis	rs4660306	0.961	rs2991966	chr1:45999503	G/A	cg24296786	chr1:45957014	TESK2	0.58	6.75	0.4	1.15e-10	Homocysteine levels;
SARC	cis	rs2836974	0.897	rs2776308	chr21:40715175	A/G	cg17971929	chr21:40555470	PSMG1	0.9	11.94	0.62	5.97e-26	Cognitive function;
SARC	cis	rs55986470	0.703	rs11887099	chr2:239447550	T/C	cg21699342	chr2:239360505	ASB1	-0.45	-4.74	-0.3	3.72e-6	Chronotype;
SARC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.35	-5.25	-0.33	3.38e-7	Longevity;Endometriosis;
SARC	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg13939156	chr17:80058883	NA	-0.38	-5.85	-0.36	1.62e-8	Life satisfaction;
SARC	cis	rs4803468	0.967	rs892044	chr19:41903671	A/G	cg14132834	chr19:41945861	ATP5SL	-0.56	-7.51	-0.44	1.24e-12	Height;
SARC	cis	rs6459804	0.967	rs10233396	chr7:157512290	C/T	cg05731713	chr7:157510257	PTPRN2	0.31	6.05	0.37	5.65e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs66887589	0.660	rs4833613	chr4:120150156	A/C	cg09307838	chr4:120376055	NA	-0.59	-7.84	-0.46	1.64e-13	Diastolic blood pressure;
SARC	cis	rs17376456	0.542	rs17083380	chr5:93170476	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.5	-5.51	-0.34	9.46e-8	Diabetic retinopathy;
SARC	cis	rs9790314	0.905	rs7611367	chr3:161003182	A/G	cg03342759	chr3:160939853	NMD3	0.52	5.94	0.36	1.01e-8	Morning vs. evening chronotype;
SARC	cis	rs2933343	1.000	rs1680790	chr3:128625853	G/T	cg25356066	chr3:128598488	ACAD9	0.6	6.79	0.41	9.22e-11	IgG glycosylation;
SARC	cis	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg08045932	chr20:61659980	NA	0.5	6.84	0.41	7.06e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs1865721	0.771	rs72975985	chr18:73127648	C/T	cg26385618	chr18:73139727	C18orf62	-0.41	-5.61	-0.34	5.86e-8	Intelligence;
SARC	cis	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg22857025	chr5:266934	NA	-1.05	-11.66	-0.61	4.62e-25	Breast cancer;
SARC	cis	rs4253772	0.550	rs6008601	chr22:46705326	C/G	cg24881330	chr22:46731750	TRMU	0.68	5.73	0.35	3.04e-8	LDL cholesterol;Cholesterol, total;
SARC	cis	rs7312933	0.645	rs12049942	chr12:42587052	G/A	cg19980929	chr12:42632907	YAF2	0.44	5.98	0.36	8.49e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg11062466	chr8:58055876	NA	0.61	5.75	0.35	2.74e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg12000995	chr2:27665139	KRTCAP3	-0.3	-4.75	-0.3	3.51e-6	Total body bone mineral density;
SARC	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg18404041	chr3:52824283	ITIH1	-0.45	-6.66	-0.4	1.91e-10	Bipolar disorder;
SARC	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.5	0.39	4.96e-10	Bipolar disorder;
SARC	cis	rs9916302	0.665	rs4795369	chr17:37609120	G/A	cg15445000	chr17:37608096	MED1	0.49	6.0	0.37	7.59e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs12477438	1.000	rs995617	chr2:99857904	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.69	7.42	0.44	2.19e-12	Chronic sinus infection;
SARC	cis	rs11122272	0.735	rs2808600	chr1:231534723	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.28	-0.56	1.11e-20	Hemoglobin concentration;
SARC	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg18876405	chr7:65276391	NA	-0.46	-5.06	-0.31	8.57e-7	Aortic root size;
SARC	cis	rs7084402	0.967	rs7897298	chr10:60274606	T/C	cg07615347	chr10:60278583	BICC1	-0.57	-8.4	-0.48	4.36e-15	Refractive error;
SARC	cis	rs7769051	0.522	rs7738256	chr6:133113066	C/G	cg07930552	chr6:133119739	C6orf192	1.03	6.42	0.39	7.51e-10	Type 2 diabetes nephropathy;
SARC	cis	rs9323205	0.954	rs4258524	chr14:51638739	A/T	cg23942311	chr14:51606299	NA	-0.31	-4.87	-0.3	2.1e-6	Cancer;
SARC	cis	rs239198	0.602	rs17672397	chr6:101288160	C/T	cg09795085	chr6:101329169	ASCC3	0.46	5.78	0.35	2.32e-8	Menarche (age at onset);
SARC	cis	rs6840360	0.571	rs62329101	chr4:152512239	G/T	cg22705602	chr4:152727874	NA	-0.43	-6.66	-0.4	1.91e-10	Intelligence (multi-trait analysis);
SARC	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg15448220	chr1:150897856	SETDB1	0.47	6.25	0.38	1.94e-9	Tonsillectomy;
SARC	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.8	7.88	0.46	1.25e-13	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs1348850	0.958	rs4243390	chr2:178468008	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.59	7.02	0.42	2.47e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg00149659	chr3:10157352	C3orf10	0.69	6.9	0.41	4.76e-11	Alzheimer's disease;
SARC	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg11766577	chr21:47581405	C21orf56	0.51	6.1	0.37	4.27e-9	Testicular germ cell tumor;
SARC	cis	rs72781680	0.611	rs72783605	chr2:24287864	A/G	cg08917208	chr2:24149416	ATAD2B	0.61	6.31	0.38	1.42e-9	Lymphocyte counts;
SARC	cis	rs4975616	0.869	rs452932	chr5:1330253	T/C	cg26373071	chr5:1325741	CLPTM1L	0.3	4.94	0.31	1.48e-6	Lung cancer;
SARC	cis	rs561341	0.739	rs4795663	chr17:30214542	T/C	cg12000587	chr17:30186630	C17orf79	0.32	4.86	0.3	2.19e-6	Hip circumference adjusted for BMI;
SARC	cis	rs11608355	1.000	rs11611370	chr12:109870291	A/G	cg19025524	chr12:109796872	NA	0.39	5.07	0.32	8.15e-7	Neuroticism;
SARC	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg20102877	chr2:27665638	KRTCAP3	-0.37	-5.08	-0.32	7.84e-7	Total body bone mineral density;
SARC	cis	rs74181299	0.620	rs6546123	chr2:65303582	T/C	cg20592124	chr2:65290738	CEP68	-0.38	-5.42	-0.33	1.45e-7	Pulse pressure;
SARC	cis	rs12311304	0.965	rs7302643	chr12:15394463	T/C	cg08258403	chr12:15378311	NA	0.46	7.2	0.43	8.47e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs6456156	0.586	rs9457261	chr6:167467679	A/G	cg23791538	chr6:167370224	RNASET2	-0.52	-6.81	-0.41	8.22e-11	Primary biliary cholangitis;
SARC	cis	rs1707322	1.000	rs10789485	chr1:46407308	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.35	0.38	1.09e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs11249608	0.548	rs35568336	chr5:178451854	A/G	cg21905437	chr5:178450457	ZNF879	0.58	7.86	0.46	1.45e-13	Pubertal anthropometrics;
SARC	cis	rs2370759	1.000	rs79442609	chr10:32608749	C/T	cg18270830	chr10:32634957	EPC1	0.7	6.39	0.39	9.17e-10	Sexual dysfunction (female);
SARC	cis	rs7216064	1.000	rs11079707	chr17:65835617	A/G	cg12091567	chr17:66097778	LOC651250	0.57	5.88	0.36	1.4e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs3106136	0.933	rs35718240	chr4:95164030	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.35	-5.41	-0.33	1.59e-7	Capecitabine sensitivity;
SARC	cis	rs1707322	0.964	rs796773	chr1:46564475	C/T	cg06784218	chr1:46089804	CCDC17	-0.35	-6.16	-0.37	3.23e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs17270561	0.609	rs9379786	chr6:25730255	T/C	cg16482183	chr6:26056742	HIST1H1C	0.43	5.25	0.33	3.49e-7	Iron status biomarkers;
SARC	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg11764359	chr7:65958608	NA	-0.85	-12.1	-0.62	1.77e-26	Aortic root size;
SARC	cis	rs7589342	0.801	rs13411829	chr2:106466101	G/C	cg16077055	chr2:106428750	NCK2	0.41	7.4	0.44	2.43e-12	Addiction;
SARC	cis	rs9910055	0.529	rs228764	chr17:42185469	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.45	-5.32	-0.33	2.4e-7	Total body bone mineral density;
SARC	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg00149659	chr3:10157352	C3orf10	0.69	6.9	0.41	4.76e-11	Alzheimer's disease;
SARC	cis	rs11155671	0.530	rs9371215	chr6:150194298	C/T	cg00933542	chr6:150070202	PCMT1	0.31	4.98	0.31	1.24e-6	Testicular germ cell tumor;
SARC	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg03433033	chr1:76189801	ACADM	0.53	7.75	0.45	2.86e-13	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs4925386	0.959	rs4925385	chr20:60920624	A/G	cg22307297	chr20:60903441	LAMA5	-0.31	-4.72	-0.3	4.14e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs67478160	0.619	rs55824307	chr14:104271207	C/T	cg26031613	chr14:104095156	KLC1	-0.4	-4.79	-0.3	3e-6	Schizophrenia;
SARC	cis	rs62244186	0.545	rs7640654	chr3:44763037	A/C	cg15687855	chr3:44754131	ZNF502	-0.32	-4.76	-0.3	3.46e-6	Depressive symptoms;
SARC	cis	rs17030434	1.000	rs12651051	chr4:154722114	A/G	cg14289246	chr4:154710475	SFRP2	-0.78	-7.29	-0.43	4.92e-12	Electrocardiographic conduction measures;
SARC	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg03806693	chr22:41940476	POLR3H	0.86	11.91	0.62	7.51e-26	Vitiligo;
SARC	cis	rs7635838	0.654	rs346083	chr3:11280017	T/C	cg00170343	chr3:11313890	ATG7	0.61	7.52	0.44	1.18e-12	HDL cholesterol;
SARC	cis	rs4128725	1.000	rs4656230	chr1:159363923	G/T	cg25076881	chr1:159409836	OR10J1	0.4	4.78	0.3	3.16e-6	Select biomarker traits;
SARC	cis	rs3857536	0.730	rs7766281	chr6:66988573	T/G	cg07460842	chr6:66804631	NA	-0.44	-4.96	-0.31	1.34e-6	Blood trace element (Cu levels);
SARC	cis	rs9494142	0.592	rs1547247	chr6:135390836	C/T	cg24558204	chr6:135376177	HBS1L	0.53	5.96	0.36	9.43e-9	Lymphocyte counts;Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg26681399	chr22:41777847	TEF	-0.5	-5.53	-0.34	8.77e-8	Vitiligo;
SARC	cis	rs7264396	0.635	rs6121073	chr20:34457513	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.51	5.15	0.32	5.65e-7	Total cholesterol levels;
SARC	cis	rs7586879	0.616	rs6545813	chr2:25131287	C/T	cg04586622	chr2:25135609	ADCY3	0.31	5.2	0.32	4.26e-7	Body mass index;
SARC	cis	rs2832191	0.791	rs2832199	chr21:30498501	G/A	cg24692254	chr21:30365293	RNF160	-0.87	-12.51	-0.63	8.52e-28	Dental caries;
SARC	trans	rs747334	0.846	rs7897603	chr10:92708759	C/G	cg00540891	chr10:43572244	RET	-0.48	-6.44	-0.39	6.92e-10	Fibroblast growth factor basic levels;
SARC	cis	rs72781680	0.898	rs72780121	chr2:23995918	T/C	cg08917208	chr2:24149416	ATAD2B	0.77	7.29	0.43	4.79e-12	Lymphocyte counts;
SARC	trans	rs61931739	0.890	rs1705748	chr12:34133171	A/G	cg26384229	chr12:38710491	ALG10B	0.58	7.85	0.46	1.47e-13	Morning vs. evening chronotype;
SARC	cis	rs9303401	1.000	rs6503877	chr17:56841948	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.7	8.3	0.48	8.28e-15	Cognitive test performance;
SARC	cis	rs1152591	0.624	rs1266927	chr14:64651663	C/A	cg23250157	chr14:64679961	SYNE2	0.43	5.96	0.36	9.48e-9	Atrial fibrillation;
SARC	cis	rs1448094	0.512	rs4540904	chr12:86235472	A/G	cg00310523	chr12:86230176	RASSF9	0.31	4.91	0.31	1.7e-6	Major depressive disorder;
SARC	cis	rs7481584	0.581	rs420127	chr11:3077990	C/T	cg20651018	chr11:3035856	CARS	0.4	5.91	0.36	1.18e-8	Calcium levels;
SARC	cis	rs9303280	0.806	rs11078928	chr17:38064469	T/C	cg20243544	chr17:37824526	PNMT	0.44	5.77	0.35	2.56e-8	Self-reported allergy;
SARC	cis	rs2073300	0.609	rs6132606	chr20:23367453	G/A	cg16736954	chr20:23401023	NAPB	0.79	4.99	0.31	1.16e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs3784262	0.692	rs4646590	chr15:58303137	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.35	-5.24	-0.32	3.64e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs137603	0.562	rs137644	chr22:39728139	A/G	cg01093212	chr22:39715156	SNORD43;RPL3	-0.58	-6.87	-0.41	5.64e-11	Primary biliary cholangitis;
SARC	cis	rs3796352	1.000	rs35163227	chr3:53127876	A/G	cg27565382	chr3:53032988	SFMBT1	0.99	6.73	0.4	1.27e-10	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs3106136	0.967	rs13135934	chr4:95207688	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.39	-6.06	-0.37	5.53e-9	Capecitabine sensitivity;
SARC	cis	rs920590	0.549	rs11204077	chr8:19653739	C/G	cg17834443	chr8:19674713	INTS10	0.4	5.1	0.32	6.91e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9443189	0.527	rs775059	chr6:76370130	G/T	cg01950844	chr6:76311363	SENP6	0.86	8.19	0.47	1.68e-14	Prostate cancer;
SARC	cis	rs240764	0.680	rs12209777	chr6:101156639	G/A	cg09795085	chr6:101329169	ASCC3	-0.46	-5.83	-0.36	1.86e-8	Neuroticism;
SARC	cis	rs7264396	0.673	rs2425163	chr20:34432670	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.51	4.96	0.31	1.36e-6	Total cholesterol levels;
SARC	cis	rs12478296	0.792	rs57482298	chr2:243011148	C/A	cg06360820	chr2:242988706	NA	-0.61	-4.92	-0.31	1.64e-6	Obesity-related traits;
SARC	cis	rs7647973	0.626	rs1996663	chr3:49878264	C/G	cg07636037	chr3:49044803	WDR6	-0.64	-6.45	-0.39	6.33e-10	Menarche (age at onset);
SARC	cis	rs5167	0.743	rs8111069	chr19:45483438	A/C	cg13119609	chr19:45449297	APOC2	0.39	5.97	0.36	8.91e-9	Blood protein levels;
SARC	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg22903471	chr2:27725779	GCKR	-0.54	-8.25	-0.48	1.21e-14	Total body bone mineral density;
SARC	cis	rs2467099	0.679	rs2608882	chr17:73934130	G/A	cg06969265	chr17:73775802	H3F3B	0.64	6.7	0.4	1.59e-10	Systolic blood pressure;
SARC	cis	rs9393692	0.967	rs6456712	chr6:26302573	A/C	cg05868516	chr6:26286170	HIST1H4H	0.53	6.61	0.4	2.6200000000000003e-10	Educational attainment;
SARC	cis	rs2075371	0.501	rs1613152	chr7:134019837	A/G	cg20476274	chr7:133979776	SLC35B4	0.4	5.09	0.32	7.3e-7	Mean platelet volume;
SARC	cis	rs10504229	0.871	rs56048296	chr8:58163781	C/T	cg05313129	chr8:58192883	C8orf71	-0.5	-6.02	-0.37	6.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4919087	0.926	rs953097	chr10:98981914	T/C	cg25902810	chr10:99078978	FRAT1	0.45	5.52	0.34	8.9e-8	Monocyte count;
SARC	cis	rs2832191	0.791	rs4817270	chr21:30480368	G/A	cg24692254	chr21:30365293	RNF160	-0.92	-13.86	-0.67	2.95e-32	Dental caries;
SARC	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg25036284	chr2:26402008	FAM59B	0.46	5.7	0.35	3.59e-8	Gut microbiome composition (summer);
SARC	cis	rs1371867	0.817	rs1660315	chr8:101332956	G/A	cg11906718	chr8:101322791	RNF19A	0.71	9.13	0.51	3.37e-17	Atrioventricular conduction;
SARC	cis	rs9788721	0.836	rs17483548	chr15:78730313	G/A	cg18825076	chr15:78729989	IREB2	-0.55	-6.59	-0.4	2.99e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs2599510	0.811	rs2754520	chr2:32810293	G/A	cg02381751	chr2:32503542	YIPF4	0.46	5.57	0.34	6.98e-8	Interleukin-18 levels;
SARC	cis	rs9296092	0.538	rs9461879	chr6:33516907	C/T	cg13560919	chr6:33536144	NA	-0.5	-5.91	-0.36	1.22e-8	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs9297145	1.000	rs9297145	chr7:98759117	A/C	cg05967295	chr7:98741636	SMURF1	0.8	9.35	0.52	7.75e-18	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
SARC	cis	rs17600642	0.672	rs72814544	chr10:72454923	G/A	cg18679544	chr10:72432482	ADAMTS14	0.46	4.72	0.3	4.08e-6	Bipolar disorder;
SARC	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg16414030	chr3:133502952	NA	-0.4	-5.52	-0.34	8.81e-8	Iron status biomarkers;
SARC	cis	rs35955747	0.902	rs131209	chr22:31732461	A/G	cg13145458	chr22:31556086	RNF185	-0.41	-5.2	-0.32	4.42e-7	Neutrophil count;Sum basophil neutrophil counts;
SARC	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg11764359	chr7:65958608	NA	0.78	10.22	0.56	1.74e-20	Aortic root size;
SARC	cis	rs9393692	0.557	rs9379846	chr6:26314238	G/C	cg13736514	chr6:26305472	NA	-0.4	-4.96	-0.31	1.35e-6	Educational attainment;
SARC	trans	rs7980799	0.653	rs11052722	chr12:33626530	G/A	cg26384229	chr12:38710491	ALG10B	-0.54	-6.53	-0.39	4.03e-10	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs6910061	1.000	rs36067344	chr6:11094764	C/T	cg27233058	chr6:11094804	LOC221710	0.57	5.5	0.34	1.02e-7	Diabetic kidney disease;
SARC	cis	rs10490913	0.806	rs766478	chr10:120164906	T/C	cg23160142	chr10:120154512	NA	0.38	5.82	0.36	1.95e-8	Cancer;
SARC	cis	rs8141529	0.509	rs5762863	chr22:29253335	A/C	cg15103426	chr22:29168792	CCDC117	0.63	7.85	0.46	1.55e-13	Lymphocyte counts;
SARC	cis	rs7326068	0.595	rs9552284	chr13:21378344	A/G	cg16922012	chr13:21400325	XPO4	-0.43	-5.76	-0.35	2.65e-8	Schizophrenia, bipolar disorder and depression (combined);
SARC	cis	rs637571	0.512	rs660118	chr11:65735174	G/C	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.4	-4.87	-0.3	2.09e-6	Eosinophil percentage of white cells;
SARC	cis	rs9921222	1.000	rs10794639	chr16:377367	A/G	cg00101154	chr16:420108	MRPL28	-0.46	-7.55	-0.44	9.68e-13	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs2180341	0.711	rs4371861	chr6:127568447	G/T	cg27446573	chr6:127587934	RNF146	0.66	9.04	0.51	6.33e-17	Breast cancer;
SARC	cis	rs703842	1.000	rs1599932	chr12:58177943	G/A	cg00677455	chr12:58241039	CTDSP2	0.5	6.53	0.39	4.05e-10	Multiple sclerosis;
SARC	cis	rs3087591	0.659	rs7218930	chr17:29640204	A/G	cg24425628	chr17:29625626	OMG;NF1	0.42	5.38	0.33	1.8e-7	Hip circumference;
SARC	cis	rs35110281	0.627	rs1836855	chr21:44965414	C/G	cg21573476	chr21:45109991	RRP1B	-0.4	-5.66	-0.35	4.52e-8	Mean corpuscular volume;
SARC	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg20573242	chr4:122745356	CCNA2	0.64	8.11	0.47	2.93e-14	Type 2 diabetes;
SARC	cis	rs7617773	0.963	rs12493256	chr3:48176747	C/T	cg11946769	chr3:48343235	NME6	-0.48	-5.78	-0.35	2.41e-8	Coronary artery disease;
SARC	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg18252515	chr7:66147081	NA	1.35	12.11	0.62	1.7e-26	Diabetic kidney disease;
SARC	cis	rs889312	0.500	rs252906	chr5:56119190	G/T	cg14703610	chr5:56206110	C5orf35	0.49	6.1	0.37	4.32e-9	Breast cancer;Breast cancer (early onset);
SARC	cis	rs3126085	0.935	rs4845421	chr1:152173259	G/T	cg09127314	chr1:152161683	NA	0.42	4.79	0.3	3.03e-6	Atopic dermatitis;
SARC	cis	rs11871801	0.517	rs60929812	chr17:40759448	G/A	cg20126647	chr17:40714003	COASY	0.5	5.57	0.34	7.04e-8	Crohn's disease;
SARC	cis	rs11651000	0.625	rs11079786	chr17:45805916	A/G	cg03474202	chr17:45855739	NA	0.37	5.71	0.35	3.41e-8	IgG glycosylation;
SARC	cis	rs898097	0.578	rs6502021	chr17:80907728	T/C	cg02711726	chr17:80685570	FN3KRP	-0.41	-5.68	-0.35	4.1e-8	Breast cancer;
SARC	cis	rs12681288	0.676	rs34282191	chr8:991290	G/A	cg15309053	chr8:964076	NA	0.46	7.34	0.43	3.64e-12	Schizophrenia;
SARC	cis	rs2235642	0.893	rs2076445	chr16:1592266	A/T	cg26528668	chr16:1614120	IFT140	0.37	4.88	0.3	1.94e-6	Coronary artery disease;
SARC	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg10589385	chr1:150898437	SETDB1	0.42	5.61	0.34	5.7e-8	Melanoma;
SARC	cis	rs910316	0.737	rs175424	chr14:75626257	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.48	-6.23	-0.38	2.21e-9	Height;
SARC	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg13902645	chr11:5959945	NA	-0.44	-5.53	-0.34	8.52e-8	DNA methylation (variation);
SARC	cis	rs11098499	0.874	rs6826823	chr4:120112098	G/C	cg09307838	chr4:120376055	NA	0.82	11.06	0.59	3.96e-23	Corneal astigmatism;
SARC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg14893161	chr1:205819251	PM20D1	0.92	15.04	0.7	3.58e-36	Menarche (age at onset);
SARC	cis	rs2115630	0.936	rs8033459	chr15:85253258	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.48	-5.77	-0.35	2.49e-8	P wave terminal force;
SARC	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg13206674	chr6:150067644	NUP43	0.46	6.1	0.37	4.29e-9	Lung cancer;
SARC	cis	rs11785400	1.000	rs4557682	chr8:143738182	T/C	cg10596483	chr8:143751796	JRK	0.64	8.65	0.49	8.4e-16	Schizophrenia;
SARC	cis	rs4975616	0.869	rs401681	chr5:1322087	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.54	-7.59	-0.45	7.76e-13	Lung cancer;
SARC	trans	rs2727020	0.635	rs7124266	chr11:49280857	T/G	cg03929089	chr4:120376271	NA	0.76	9.94	0.55	1.23e-19	Coronary artery disease;
SARC	cis	rs7223966	1.000	rs11658175	chr17:61923838	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.48	-4.97	-0.31	1.33e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1023500	0.505	rs134885	chr22:42673811	C/G	cg15557168	chr22:42548783	NA	-0.39	-5.58	-0.34	6.52e-8	Schizophrenia;
SARC	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg26681399	chr22:41777847	TEF	-0.43	-4.81	-0.3	2.68e-6	Vitiligo;
SARC	trans	rs61931739	0.517	rs2101396	chr12:34048927	T/A	cg26384229	chr12:38710491	ALG10B	0.76	10.94	0.58	9.15e-23	Morning vs. evening chronotype;
SARC	cis	rs2243480	0.666	rs1880311	chr7:65276752	G/C	cg25894440	chr7:65020034	NA	0.75	5.39	0.33	1.69e-7	Diabetic kidney disease;
SARC	cis	rs2280018	0.526	rs1510148	chr16:15167379	T/A	cg07549590	chr16:15018862	NA	-0.53	-6.75	-0.4	1.14e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs734999	0.588	rs4648652	chr1:2535758	A/G	cg18854424	chr1:2615690	NA	0.32	5.12	0.32	6.39e-7	Ulcerative colitis;
SARC	cis	rs17213078	0.510	rs17032713	chr2:106886839	T/C	cg15412446	chr2:106886593	NA	-0.6	-8.13	-0.47	2.62e-14	Facial morphology (factor 23);
SARC	cis	rs2153535	0.580	rs1335643	chr6:8488021	T/G	cg21535247	chr6:8435926	SLC35B3	0.55	6.9	0.41	4.76e-11	Motion sickness;
SARC	cis	rs3126085	0.877	rs7543541	chr1:152230878	T/C	cg26876637	chr1:152193138	HRNR	0.45	5.14	0.32	5.9e-7	Atopic dermatitis;
SARC	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg11987759	chr7:65425863	GUSB	-0.47	-6.28	-0.38	1.63e-9	Aortic root size;
SARC	cis	rs2439831	0.850	rs28413704	chr15:44148427	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	7.64	0.45	5.56e-13	Lung cancer in ever smokers;
SARC	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg24531977	chr5:56204891	C5orf35	-0.57	-5.98	-0.36	8.41e-9	Initial pursuit acceleration;
SARC	cis	rs9814567	0.806	rs9839705	chr3:134323819	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.5	-6.55	-0.39	3.6e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs6582630	0.554	rs7299735	chr12:38450890	A/C	cg26384229	chr12:38710491	ALG10B	-0.56	-7.02	-0.42	2.39e-11	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg18805032	chr6:3853096	NA	0.56	7.58	0.44	8.09e-13	Thyroid stimulating hormone;
SARC	cis	rs3106136	0.967	rs7435106	chr4:95169772	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.39	-6.05	-0.37	5.83e-9	Capecitabine sensitivity;
SARC	cis	rs72781680	0.821	rs72796378	chr2:24167385	G/A	cg08917208	chr2:24149416	ATAD2B	0.58	6.01	0.37	7.09e-9	Lymphocyte counts;
SARC	cis	rs6840360	0.550	rs6816471	chr4:152494869	A/G	cg22705602	chr4:152727874	NA	-0.43	-6.66	-0.4	1.91e-10	Intelligence (multi-trait analysis);
SARC	cis	rs244293	0.730	rs12165058	chr17:53022049	T/C	cg19360675	chr17:53046073	COX11;STXBP4	-0.41	-4.99	-0.31	1.2e-6	Menarche (age at onset);
SARC	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg24060327	chr5:131705240	SLC22A5	-0.72	-8.77	-0.5	3.92e-16	Breast cancer;
SARC	cis	rs17270561	0.609	rs4711097	chr6:25732314	C/T	cg16482183	chr6:26056742	HIST1H1C	0.43	5.25	0.33	3.49e-7	Iron status biomarkers;
SARC	cis	rs6089584	0.927	rs6089593	chr20:60572312	G/A	cg23262073	chr20:60523788	NA	-0.45	-6.6	-0.4	2.76e-10	Body mass index;
SARC	cis	rs7312774	0.748	rs4964191	chr12:107306497	G/A	cg16260113	chr12:107380972	MTERFD3	0.71	6.16	0.37	3.2e-9	Severe influenza A (H1N1) infection;
SARC	cis	rs1448094	0.512	rs7302741	chr12:86237127	C/T	cg02569458	chr12:86230093	RASSF9	0.39	5.48	0.34	1.11e-7	Major depressive disorder;
SARC	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg08280861	chr8:58055591	NA	0.6	5.79	0.35	2.28e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg13175981	chr1:150552382	MCL1	-0.53	-6.81	-0.41	8.15e-11	Tonsillectomy;
SARC	cis	rs2404602	0.716	rs12907805	chr15:76690606	C/T	cg22467129	chr15:76604101	ETFA	-0.36	-4.76	-0.3	3.35e-6	Blood metabolite levels;
SARC	cis	rs9325144	0.647	rs1386018	chr12:39104360	C/T	cg26384229	chr12:38710491	ALG10B	-0.6	-7.74	-0.45	2.98e-13	Morning vs. evening chronotype;
SARC	cis	rs933688	1.000	rs2059207	chr5:90731931	C/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.01	13.44	0.66	7.14e-31	Smoking behavior;
SARC	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg17376030	chr22:41985996	PMM1	-0.68	-8.73	-0.5	5.08e-16	Vitiligo;
SARC	cis	rs7223966	1.000	rs11657081	chr17:61792339	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-6.05	-0.37	5.68e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs4742903	0.509	rs4451366	chr9:106959666	G/A	cg14250997	chr9:106856677	SMC2	0.39	4.87	0.3	2.03e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs4780401	0.609	rs4781142	chr16:11808806	T/C	cg01061890	chr16:11836724	TXNDC11	-0.61	-8.7	-0.5	6.01e-16	Rheumatoid arthritis;
SARC	cis	rs7566780	0.632	rs7575477	chr2:16678122	C/T	cg09580478	chr2:16689509	NA	0.45	6.06	0.37	5.34e-9	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs4891159	0.756	rs55763305	chr18:74161249	G/C	cg24786174	chr18:74118243	ZNF516	-0.63	-8.94	-0.51	1.23e-16	Longevity;
SARC	cis	rs4423214	0.959	rs12794668	chr11:71168715	C/T	cg05163923	chr11:71159392	DHCR7	0.66	9.13	0.51	3.43e-17	Vitamin D levels;
SARC	cis	rs10992471	0.603	rs4744141	chr9:95352140	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.44	-0.34	1.37e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs877282	0.583	rs12356155	chr10:823940	C/T	cg15764593	chr10:829463	NA	-0.43	-4.81	-0.3	2.75e-6	Uric acid levels;
SARC	cis	rs765787	0.530	rs2899381	chr15:45529630	C/T	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.81e-6	Uric acid levels;
SARC	cis	rs12464559	0.522	rs6715027	chr2:152626657	T/C	cg01189475	chr2:152685088	ARL5A	0.63	5.08	0.32	7.71e-7	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg25894440	chr7:65020034	NA	0.52	4.8	0.3	2.79e-6	Aortic root size;
SARC	cis	rs17376456	0.877	rs13169675	chr5:93331284	A/G	cg21475434	chr5:93447410	FAM172A	0.85	7.51	0.44	1.28e-12	Diabetic retinopathy;
SARC	cis	rs1707322	1.000	rs11211235	chr1:46440375	G/A	cg06784218	chr1:46089804	CCDC17	0.34	5.95	0.36	9.76e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6565180	0.962	rs11642676	chr16:30371655	C/G	cg17640201	chr16:30407289	ZNF48	-0.93	-13.34	-0.66	1.48e-30	Tonsillectomy;
SARC	cis	rs9326248	0.569	rs10892082	chr11:117039325	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.59	5.02	0.31	1.01e-6	Blood protein levels;
SARC	cis	rs2180341	1.000	rs2144742	chr6:127595786	C/A	cg17762328	chr6:126965162	NA	-0.46	-5.28	-0.33	3.01e-7	Breast cancer;
SARC	cis	rs6120849	0.754	rs7268266	chr20:33581889	T/C	cg24642439	chr20:33292090	TP53INP2	0.58	5.58	0.34	6.55e-8	Protein C levels;
SARC	trans	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg08164334	chr1:19229453	ALDH4A1	-0.68	-6.45	-0.39	6.29e-10	Cutaneous psoriasis;
SARC	cis	rs12421382	0.614	rs12418763	chr11:109390360	C/T	cg16359550	chr11:109292809	C11orf87	0.34	5.19	0.32	4.5e-7	Schizophrenia;
SARC	trans	rs7395662	0.526	rs4882001	chr11:48546675	A/G	cg15704280	chr7:45808275	SEPT13	-0.47	-6.42	-0.39	7.45e-10	HDL cholesterol;
SARC	cis	rs372883	0.648	rs368322	chr21:30717151	C/T	cg08807101	chr21:30365312	RNF160	-0.57	-7.05	-0.42	2.05e-11	Pancreatic cancer;
SARC	cis	rs6582630	0.638	rs4882309	chr12:38448595	A/G	cg14851346	chr12:38532713	NA	-0.48	-5.94	-0.36	1.04e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7223966	1.000	rs17549954	chr17:61707032	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	6.65	0.4	2.11e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs12432203	1.000	rs4566067	chr14:51729487	A/G	cg00964063	chr14:51134117	SAV1	0.6	5.33	0.33	2.31e-7	Cancer;
SARC	trans	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg15704280	chr7:45808275	SEPT13	0.81	10.39	0.56	4.97e-21	Height;
SARC	cis	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg12257692	chr3:49977190	RBM6	-0.28	-5.01	-0.31	1.06e-6	Body mass index;
SARC	cis	rs6121246	0.909	rs6060812	chr20:30292803	C/T	cg13852791	chr20:30311386	BCL2L1	0.86	9.16	0.51	2.76e-17	Mean corpuscular hemoglobin;
SARC	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg13393036	chr8:95962371	TP53INP1	0.34	5.51	0.34	9.66e-8	Type 2 diabetes;
SARC	cis	rs9788721	0.836	rs72738732	chr15:78752188	C/G	cg06917634	chr15:78832804	PSMA4	-0.5	-5.26	-0.33	3.22e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs7647973	0.710	rs2029591	chr3:49646981	C/T	cg13072238	chr3:49761600	GMPPB	0.58	5.12	0.32	6.45e-7	Menarche (age at onset);
SARC	cis	rs2153535	0.580	rs1577470	chr6:8462426	G/A	cg21535247	chr6:8435926	SLC35B3	0.54	6.75	0.4	1.14e-10	Motion sickness;
SARC	cis	rs9611565	0.921	rs4822021	chr22:41726053	G/A	cg03806693	chr22:41940476	POLR3H	-0.77	-10.53	-0.57	1.8e-21	Vitiligo;
SARC	cis	rs34172651	0.797	rs12920941	chr16:24830866	T/A	cg00152838	chr16:24741724	TNRC6A	-0.42	-5.13	-0.32	6.16e-7	Intelligence (multi-trait analysis);
SARC	cis	rs367943	0.966	rs451425	chr5:112808637	A/G	cg12552261	chr5:112820674	MCC	-0.45	-5.19	-0.32	4.65e-7	Type 2 diabetes;
SARC	cis	rs7827545	0.620	rs6578009	chr8:135522989	T/C	cg17885191	chr8:135476712	NA	-0.44	-5.08	-0.32	7.59e-7	Hypertension (SNP x SNP interaction);
SARC	cis	rs240764	0.764	rs2213594	chr6:100931400	G/A	cg21058520	chr6:100914733	NA	0.31	4.81	0.3	2.76e-6	Neuroticism;
SARC	cis	rs36051895	0.623	rs62541541	chr9:5040817	G/C	cg02405213	chr9:5042618	JAK2	-0.53	-5.88	-0.36	1.39e-8	Pediatric autoimmune diseases;
SARC	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg00684032	chr4:1343700	KIAA1530	0.36	5.23	0.32	3.77e-7	Obesity-related traits;
SARC	cis	rs698813	0.774	rs1085492	chr2:44609371	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.64	7.63	0.45	6.06e-13	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs17023223	0.553	rs56234947	chr1:119707744	G/A	cg05756136	chr1:119680316	WARS2	-0.47	-5.31	-0.33	2.61e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs10876993	0.890	rs1689597	chr12:58051886	G/A	cg18357645	chr12:58087776	OS9	0.47	6.11	0.37	4.09e-9	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg03806693	chr22:41940476	POLR3H	-0.89	-11.72	-0.61	3.12e-25	Vitiligo;
SARC	cis	rs1152591	0.505	rs1152593	chr14:64675895	C/T	cg23250157	chr14:64679961	SYNE2	0.43	5.87	0.36	1.47e-8	Atrial fibrillation;
SARC	cis	rs2710642	0.962	rs6545972	chr2:63084682	G/A	cg17519650	chr2:63277830	OTX1	0.37	4.71	0.3	4.17e-6	LDL cholesterol levels;LDL cholesterol;
SARC	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg22800045	chr5:56110881	MAP3K1	0.74	7.83	0.46	1.74e-13	Initial pursuit acceleration;
SARC	cis	rs539096	0.540	rs3011219	chr1:44306120	A/G	cg12908607	chr1:44402522	ARTN	-0.32	-5.72	-0.35	3.29e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9325144	0.600	rs10785621	chr12:38744912	C/T	cg26384229	chr12:38710491	ALG10B	0.61	8.03	0.47	4.84e-14	Morning vs. evening chronotype;
SARC	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6121246	0.529	rs7261354	chr20:30202414	T/C	cg21427119	chr20:30132790	HM13	-0.44	-4.89	-0.3	1.9e-6	Mean corpuscular hemoglobin;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg18487508	chr19:39926862	RPS16	0.51	6.45	0.39	6.38e-10	Height;
SARC	cis	rs765787	0.530	rs2554454	chr15:45521536	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.43	-5.28	-0.33	2.91e-7	Uric acid levels;
SARC	cis	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg05623727	chr3:50126028	RBM5	-0.33	-4.98	-0.31	1.22e-6	Intelligence (multi-trait analysis);
SARC	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg25072359	chr17:41440525	NA	0.48	5.59	0.34	6.37e-8	Menopause (age at onset);
SARC	cis	rs7772486	0.623	rs9485021	chr6:146068797	A/G	cg05347473	chr6:146136440	FBXO30	-0.52	-7.26	-0.43	5.88e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs950027	0.596	rs2467853	chr15:45698793	T/G	cg15395560	chr15:45543142	SLC28A2	-0.28	-5.38	-0.33	1.81e-7	Response to fenofibrate (adiponectin levels);
SARC	cis	rs9303401	0.614	rs2007993	chr17:56590643	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.06	11.67	0.61	4.53e-25	Cognitive test performance;
SARC	cis	rs9309473	0.519	rs2421586	chr2:73899719	C/T	cg20560298	chr2:73613845	ALMS1	0.49	6.68	0.4	1.71e-10	Metabolite levels;
SARC	cis	rs1448094	0.935	rs11117120	chr12:86336447	G/A	cg02569458	chr12:86230093	RASSF9	0.4	5.83	0.36	1.85e-8	Major depressive disorder;
SARC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg06873352	chr17:61820015	STRADA	0.53	6.93	0.41	4.07e-11	Prudent dietary pattern;
SARC	trans	rs7395662	0.553	rs4882155	chr11:48705801	T/C	cg00717180	chr2:96193071	NA	-0.38	-6.36	-0.38	1.04e-9	HDL cholesterol;
SARC	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg09517075	chr8:22133004	PIWIL2	0.37	5.19	0.32	4.5e-7	Hypertriglyceridemia;
SARC	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg11764359	chr7:65958608	NA	-0.75	-9.13	-0.51	3.43e-17	Aortic root size;
SARC	cis	rs7829975	0.572	rs28730413	chr8:8795447	A/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.22	-0.43	7.09e-12	Mood instability;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg22907761	chr6:3409679	SLC22A23	0.51	7.2	0.43	8.18e-12	Thyroid stimulating hormone;
SARC	cis	rs1153858	1.000	rs7167900	chr15:45639471	A/G	cg26924012	chr15:45694286	SPATA5L1	0.75	10.34	0.56	7.46e-21	Homoarginine levels;
SARC	cis	rs11997175	0.583	rs66622174	chr8:33812542	T/G	ch.8.33884649F	chr8:33765107	NA	0.48	6.12	0.37	3.98e-9	Body mass index;
SARC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg06873352	chr17:61820015	STRADA	0.5	6.49	0.39	5.11e-10	Prudent dietary pattern;
SARC	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	5.97	0.36	8.98e-9	Bipolar disorder;
SARC	cis	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg06636001	chr8:8085503	FLJ10661	-0.7	-9.42	-0.53	4.63e-18	Joint mobility (Beighton score);
SARC	cis	rs2439831	0.867	rs2245176	chr15:43750762	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	8.4	0.48	4.54e-15	Lung cancer in ever smokers;
SARC	cis	rs1371867	0.846	rs1660330	chr8:101305015	T/A	cg11906718	chr8:101322791	RNF19A	0.7	8.98	0.51	9.31e-17	Atrioventricular conduction;
SARC	cis	rs2730245	0.527	rs2527202	chr7:158738849	T/C	cg24397884	chr7:158709396	WDR60	-1.17	-10.83	-0.58	2.1e-22	Height;
SARC	cis	rs3749237	0.557	rs7631908	chr3:49425707	T/G	cg03060546	chr3:49711283	APEH	0.75	10.72	0.57	4.68e-22	Resting heart rate;
SARC	cis	rs11597390	0.867	rs11596837	chr10:101850079	C/A	cg11888571	chr10:102027403	CWF19L1	-0.4	-4.79	-0.3	2.9e-6	Liver enzyme levels;
SARC	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.32	-4.93	-0.31	1.57e-6	Total body bone mineral density;
SARC	cis	rs9399135	0.967	rs12527707	chr6:135324511	G/A	cg24558204	chr6:135376177	HBS1L	0.45	6.11	0.37	4.1e-9	Red blood cell count;
SARC	cis	rs2180341	0.694	rs2875972	chr6:127585522	T/C	cg27446573	chr6:127587934	RNF146	0.94	13.38	0.66	1.16e-30	Breast cancer;
SARC	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg18876405	chr7:65276391	NA	0.72	9.42	0.53	4.61e-18	Aortic root size;
SARC	cis	rs910316	0.967	rs7146523	chr14:75659880	T/C	cg23033748	chr14:75592666	NEK9	-0.34	-4.75	-0.3	3.63e-6	Height;
SARC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg15383120	chr6:291909	DUSP22	-0.62	-8.11	-0.47	2.94e-14	Menopause (age at onset);
SARC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg06074448	chr4:187884817	NA	-0.43	-5.91	-0.36	1.22e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7582180	0.715	rs11123823	chr2:100916315	A/G	cg14675211	chr2:100938903	LONRF2	0.5	6.78	0.41	9.63e-11	Intelligence (multi-trait analysis);
SARC	cis	rs7769051	0.522	rs6911773	chr6:133128848	T/C	cg07930552	chr6:133119739	C6orf192	0.98	5.79	0.35	2.31e-8	Type 2 diabetes nephropathy;
SARC	cis	rs2342371	0.545	rs7646273	chr3:196210894	T/C	cg15048948	chr3:196158458	UBXN7	-0.42	-5.46	-0.34	1.22e-7	Fat distribution (HIV);
SARC	cis	rs57502260	0.704	rs72936599	chr11:68320405	G/A	cg01657329	chr11:68192670	LRP5	-0.52	-5.06	-0.31	8.49e-7	Total body bone mineral density (age 45-60);
SARC	cis	rs9951602	0.920	rs28639710	chr18:76679847	G/A	cg00806245	chr18:76673096	NA	-0.43	-5.17	-0.32	5.08e-7	Obesity-related traits;
SARC	cis	rs2834188	0.924	rs6517160	chr21:34683512	A/G	cg04842828	chr21:34696676	IFNAR1	0.42	5.07	0.32	8.05e-7	Narcolepsy;
SARC	cis	rs5762813	0.524	rs5762835	chr22:29230754	A/G	cg15103426	chr22:29168792	CCDC117	0.62	6.5	0.39	4.81e-10	Hematocrit;Hemoglobin concentration;
SARC	cis	rs7395581	0.918	rs10838693	chr11:47350553	G/C	cg25783544	chr11:47291846	MADD	0.48	5.35	0.33	2.06e-7	HDL cholesterol;
SARC	cis	rs6964587	0.934	rs7793861	chr7:91742728	C/G	cg17063962	chr7:91808500	NA	0.95	15.87	0.72	5.88e-39	Breast cancer;
SARC	cis	rs2933343	1.000	rs1680790	chr3:128625853	G/T	cg24203234	chr3:128598194	ACAD9	0.56	6.27	0.38	1.75e-9	IgG glycosylation;
SARC	cis	rs12701220	0.503	rs12531999	chr7:1181601	T/A	cg01324507	chr7:1177794	C7orf50	0.49	4.71	0.3	4.18e-6	Bronchopulmonary dysplasia;
SARC	cis	rs9314323	0.729	rs7007256	chr8:26203081	G/A	cg11498726	chr8:26250323	BNIP3L	-0.57	-7.15	-0.42	1.09e-11	Red cell distribution width;
SARC	cis	rs6831352	0.734	rs2602856	chr4:100029145	C/A	cg13256891	chr4:100009986	ADH5	0.62	8.7	0.5	6.16e-16	Alcohol dependence;
SARC	cis	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg00745463	chr17:30367425	LRRC37B	-0.68	-5.23	-0.32	3.82e-7	Hip circumference adjusted for BMI;
SARC	cis	rs9931543	0.638	rs12448100	chr16:56292043	C/A	cg02433656	chr16:56322654	GNAO1	0.37	5.15	0.32	5.65e-7	Subjective well-being;
SARC	cis	rs3862030	0.810	rs5870	chr10:104239100	A/G	ch.10.2196322F	chr10:104248062	ACTR1A	-0.46	-6.36	-0.38	1.07e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
SARC	cis	rs12134245	0.874	rs35115044	chr1:92021650	A/G	cg02896835	chr1:92012615	NA	-0.45	-6.14	-0.37	3.55e-9	Breast cancer;
SARC	cis	rs7829975	0.540	rs2976909	chr8:8346690	C/T	cg06636001	chr8:8085503	FLJ10661	-0.59	-8.09	-0.47	3.35e-14	Mood instability;
SARC	cis	rs10463554	0.857	rs158397	chr5:102412201	C/T	cg23492399	chr5:102201601	PAM	-0.52	-5.7	-0.35	3.63e-8	Parkinson's disease;
SARC	cis	rs712039	0.652	rs829163	chr17:35766026	G/C	cg16670864	chr17:35848621	DUSP14	0.5	5.49	0.34	1.02e-7	Tuberculosis;
SARC	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg22496380	chr5:211416	CCDC127	0.85	8.82	0.5	2.81e-16	Breast cancer;
SARC	cis	rs7219021	0.705	rs11079842	chr17:47002762	G/A	cg16584676	chr17:46985605	UBE2Z	-0.48	-5.64	-0.35	4.81e-8	Schizophrenia or bipolar disorder;
SARC	cis	rs644799	0.544	rs498553	chr11:95534441	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	9.55	0.53	1.93e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs5753618	0.583	rs5753632	chr22:31863097	C/T	cg02404636	chr22:31891804	SFI1	0.62	7.61	0.45	6.64e-13	Colorectal cancer;
SARC	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg03517284	chr6:25882590	NA	-0.43	-5.78	-0.35	2.41e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2658782	0.724	rs2248655	chr11:93254612	T/C	cg15737290	chr11:93063684	CCDC67	0.72	7.96	0.46	7.5e-14	Pulmonary function decline;
SARC	cis	rs208520	0.690	rs1563929	chr6:66702108	G/A	cg07460842	chr6:66804631	NA	1.11	14.61	0.69	9.67e-35	Exhaled nitric oxide output;
SARC	trans	rs12753816	0.749	rs6688139	chr1:169190655	C/T	cg11914256	chr19:14359744	NA	-0.5	-6.39	-0.39	9.16e-10	Coronary artery disease;
SARC	cis	rs9457247	0.582	rs9459855	chr6:167466150	G/T	cg23791538	chr6:167370224	RNASET2	-0.53	-6.99	-0.42	2.88e-11	Crohn's disease;
SARC	cis	rs4664308	1.000	rs925410	chr2:160912652	C/T	cg03641300	chr2:160917029	PLA2R1	0.67	9.11	0.51	3.78e-17	Idiopathic membranous nephropathy;
SARC	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg19077165	chr18:44547161	KATNAL2	-0.53	-7.28	-0.43	4.97e-12	Personality dimensions;
SARC	cis	rs8014204	0.901	rs4899536	chr14:75316614	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.75	-10.91	-0.58	1.14e-22	Caffeine consumption;
SARC	cis	rs3857536	0.813	rs6455084	chr6:66935658	A/T	cg07460842	chr6:66804631	NA	-0.51	-5.83	-0.36	1.86e-8	Blood trace element (Cu levels);
SARC	cis	rs1728785	0.818	rs12926059	chr16:68569459	T/C	cg02972257	chr16:68554789	NA	-0.44	-5.15	-0.32	5.43e-7	Ulcerative colitis;
SARC	trans	rs3942852	0.774	rs10838814	chr11:48187178	G/A	cg03929089	chr4:120376271	NA	-0.6	-6.75	-0.4	1.13e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg27572855	chr1:25598939	RHD	0.52	9.01	0.51	7.56e-17	Erythrocyte sedimentation rate;
SARC	cis	rs995000	0.965	rs4587594	chr1:63133930	G/A	cg06896770	chr1:63153194	DOCK7	0.97	15.32	0.71	3.94e-37	Triglyceride levels;
SARC	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.77	9.74	0.54	5.03e-19	Prudent dietary pattern;
SARC	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.71	5.26	0.33	3.31e-7	Initial pursuit acceleration;
SARC	cis	rs2342371	0.816	rs11707744	chr3:196213855	C/G	cg15048948	chr3:196158458	UBXN7	-0.53	-6.62	-0.4	2.52e-10	Fat distribution (HIV);
SARC	cis	rs11992162	0.560	rs13256329	chr8:11782214	G/A	cg02127589	chr8:12458309	NA	-0.32	-4.78	-0.3	3.13e-6	Monocyte count;
SARC	cis	rs644799	0.710	rs522536	chr11:95528714	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	13.53	0.66	3.66e-31	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs72772090	0.710	rs11750399	chr5:96077940	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.57	-4.88	-0.3	1.95e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2635047	0.967	rs2571001	chr18:44665083	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.54	7.07	0.42	1.75e-11	Educational attainment;
SARC	cis	rs4742903	0.527	rs10991150	chr9:106951497	C/A	cg14250997	chr9:106856677	SMC2	0.39	4.85	0.3	2.3e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg11366901	chr6:160182831	ACAT2	0.96	9.97	0.55	9.69e-20	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg16606324	chr3:10149918	C3orf24	0.51	4.95	0.31	1.39e-6	Alzheimer's disease;
SARC	cis	rs9486719	0.857	rs9285393	chr6:97020917	C/A	cg18709589	chr6:96969512	KIAA0776	-0.44	-4.74	-0.3	3.65e-6	Migraine;Coronary artery disease;
SARC	trans	rs7395662	0.591	rs4882233	chr11:48739653	A/G	cg15704280	chr7:45808275	SEPT13	-0.53	-7.19	-0.43	8.73e-12	HDL cholesterol;
SARC	cis	rs1371867	0.817	rs1660314	chr8:101332953	C/T	cg11906718	chr8:101322791	RNF19A	0.71	9.13	0.51	3.37e-17	Atrioventricular conduction;
SARC	cis	rs12681288	0.723	rs12545453	chr8:970582	C/T	cg15309053	chr8:964076	NA	0.43	7.36	0.43	3.05e-12	Schizophrenia;
SARC	cis	rs7044106	0.791	rs747819	chr9:123488441	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.7	0.54	6.57e-19	Hip circumference adjusted for BMI;
SARC	cis	rs4660261	0.526	rs3011228	chr1:44325995	A/G	cg12908607	chr1:44402522	ARTN	-0.33	-5.83	-0.36	1.88e-8	Intelligence (multi-trait analysis);
SARC	cis	rs10883723	0.810	rs2296586	chr10:104245575	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.63	8.16	0.47	2.12e-14	Allergic disease (asthma, hay fever or eczema);
SARC	trans	rs3780486	0.581	rs1137642	chr9:33118904	A/G	cg20290983	chr6:43655470	MRPS18A	0.93	13.96	0.67	1.34e-32	IgG glycosylation;
SARC	cis	rs10979	0.964	rs35205240	chr6:143898676	T/C	cg25407410	chr6:143891975	LOC285740	-0.63	-8.38	-0.48	5.13e-15	Hypospadias;
SARC	cis	rs3818285	0.655	rs623980	chr10:111646147	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.52	-8.07	-0.47	3.68e-14	Superior crus of antihelix expression;
SARC	cis	rs1008375	1.000	rs56308330	chr4:17643050	G/A	cg27347728	chr4:17578864	LAP3	0.48	5.96	0.36	9.13e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9660992	0.573	rs12125276	chr1:205199440	C/T	cg21643547	chr1:205240462	TMCC2	-0.6	-7.83	-0.46	1.76e-13	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg09263875	chr16:632152	PIGQ	0.54	8.26	0.48	1.1e-14	Height;
SARC	cis	rs9399135	0.967	rs2183709	chr6:135377091	C/T	cg22676075	chr6:135203613	NA	0.35	4.76	0.3	3.45e-6	Red blood cell count;
SARC	cis	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg08975724	chr8:8085496	FLJ10661	0.51	6.46	0.39	6.03e-10	Mood instability;
SARC	cis	rs2380220	0.606	rs9488080	chr6:96006973	A/G	cg23517279	chr6:96025343	MANEA	0.54	6.11	0.37	4.23e-9	Behavioural disinhibition (generation interaction);
SARC	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg01448562	chr3:133502909	NA	0.5	7.63	0.45	6.01e-13	Iron status biomarkers;
SARC	cis	rs763121	0.853	rs8142098	chr22:39058757	T/G	cg06022373	chr22:39101656	GTPBP1	0.91	11.32	0.6	5.9e-24	Menopause (age at onset);
SARC	cis	rs826838	0.967	rs1719854	chr12:39127707	G/A	cg26384229	chr12:38710491	ALG10B	-0.76	-11.59	-0.6	7.97e-25	Heart rate;
SARC	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg25894440	chr7:65020034	NA	-0.75	-5.64	-0.35	5e-8	Diabetic kidney disease;
SARC	cis	rs2439831	0.681	rs3742971	chr15:43622916	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-1.02	-11.99	-0.62	3.97e-26	Lung cancer in ever smokers;
SARC	cis	rs17376456	0.877	rs10044139	chr5:93407803	T/C	cg25358565	chr5:93447407	FAM172A	1.3	14.56	0.69	1.43e-34	Diabetic retinopathy;
SARC	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg00800038	chr16:89945340	TCF25	-0.7	-5.25	-0.33	3.44e-7	Skin colour saturation;
SARC	cis	rs9916302	0.904	rs8077104	chr17:37530510	A/G	cg00129232	chr17:37814104	STARD3	0.6	7.43	0.44	2.06e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs11077998	0.967	rs4789788	chr17:80510285	C/T	cg10255544	chr17:80519551	FOXK2	-0.42	-6.28	-0.38	1.64e-9	Reticulocyte fraction of red cells;
SARC	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	20.88	0.81	2.79e-55	Chronic sinus infection;
SARC	cis	rs9322193	0.607	rs10457852	chr6:150201720	C/T	cg11878867	chr6:150167359	LRP11	-0.41	-4.89	-0.3	1.91e-6	Lung cancer;
SARC	cis	rs10492096	0.947	rs10774435	chr12:6616120	G/T	cg13857086	chr12:6580257	VAMP1	0.67	6.73	0.4	1.28e-10	Hip geometry;
SARC	trans	rs9951602	0.512	rs4799246	chr18:76653417	A/G	cg02800362	chr5:177631904	HNRNPAB	0.7	8.91	0.5	1.49e-16	Obesity-related traits;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg04712436	chr5:90675933	LOC100129716;ARRDC3	0.5	6.56	0.39	3.39e-10	Chemerin levels;
SARC	cis	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg12476490	chr10:64576179	EGR2	-0.62	-5.85	-0.36	1.66e-8	Cutaneous psoriasis;
SARC	cis	rs208520	0.690	rs1233103	chr6:66855943	T/G	cg07460842	chr6:66804631	NA	-1.06	-14.89	-0.7	1.12e-35	Exhaled nitric oxide output;
SARC	cis	rs11098499	1.000	rs12506395	chr4:120185094	C/T	cg09307838	chr4:120376055	NA	0.85	11.7	0.61	3.45e-25	Corneal astigmatism;
SARC	cis	rs2387326	1.000	rs2387326	chr10:129933456	C/T	cg16087940	chr10:129947807	NA	-0.45	-5.9	-0.36	1.28e-8	Select biomarker traits;
SARC	cis	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg07274523	chr3:49395745	GPX1	-0.5	-5.55	-0.34	7.64e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg06873352	chr17:61820015	STRADA	0.46	5.9	0.36	1.3e-8	Prudent dietary pattern;
SARC	cis	rs8067545	0.611	rs11653630	chr17:20189046	C/T	cg13482628	chr17:19912719	NA	-0.56	-7.51	-0.44	1.27e-12	Schizophrenia;
SARC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg26338869	chr17:61819248	STRADA	-0.83	-10.97	-0.58	7.56e-23	Prudent dietary pattern;
SARC	cis	rs523522	0.962	rs651627	chr12:121009198	C/T	cg27279351	chr12:120934652	DYNLL1	0.71	8.94	0.51	1.22e-16	High light scatter reticulocyte count;
SARC	trans	rs61931739	0.817	rs11053071	chr12:34201400	A/G	cg26384229	chr12:38710491	ALG10B	0.6	8.09	0.47	3.27e-14	Morning vs. evening chronotype;
SARC	trans	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg06636001	chr8:8085503	FLJ10661	0.59	7.72	0.45	3.45e-13	Triglycerides;
SARC	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg11062466	chr8:58055876	NA	0.54	5.56	0.34	7.55e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7595412	1.000	rs10180112	chr2:198982858	C/G	cg00208931	chr2:198669586	PLCL1	0.7	5.36	0.33	1.96e-7	Hip bone size;
SARC	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg11987759	chr7:65425863	GUSB	0.58	7.64	0.45	5.63e-13	Aortic root size;
SARC	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg22433210	chr17:43662623	NA	-0.94	-11.19	-0.59	1.56e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs11651000	0.761	rs11079788	chr17:45820723	C/T	cg03474202	chr17:45855739	NA	-0.37	-5.31	-0.33	2.56e-7	IgG glycosylation;
SARC	cis	rs3617	0.625	rs56019197	chr3:52874753	T/C	cg18404041	chr3:52824283	ITIH1	0.36	5.32	0.33	2.37e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs8067545	0.750	rs4267380	chr17:19971564	A/G	cg13482628	chr17:19912719	NA	0.54	7.14	0.42	1.17e-11	Schizophrenia;
SARC	trans	rs61931739	0.570	rs7315655	chr12:33912869	G/A	cg26384229	chr12:38710491	ALG10B	0.55	7.13	0.42	1.25e-11	Morning vs. evening chronotype;
SARC	trans	rs61931739	0.635	rs10772122	chr12:33964674	A/C	cg26384229	chr12:38710491	ALG10B	0.58	7.63	0.45	5.98e-13	Morning vs. evening chronotype;
SARC	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg01570182	chr17:44337453	NA	0.77	8.95	0.51	1.16e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7824557	0.836	rs2736378	chr8:11119760	G/A	cg21775007	chr8:11205619	TDH	-0.47	-5.56	-0.34	7.32e-8	Retinal vascular caliber;
SARC	cis	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg18252515	chr7:66147081	NA	-1.22	-10.67	-0.57	6.88e-22	Diabetic kidney disease;
SARC	cis	rs7666738	0.830	rs62318470	chr4:98925846	A/C	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg10207240	chr12:122356781	WDR66	0.3	4.98	0.31	1.23e-6	Mean corpuscular volume;
SARC	cis	rs7681440	0.606	rs2737005	chr4:90750590	A/G	cg06632027	chr4:90757378	SNCA	-0.42	-5.25	-0.33	3.35e-7	Dementia with Lewy bodies;
SARC	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg01341218	chr17:43662625	NA	0.97	11.18	0.59	1.66e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	trans	rs453301	0.624	rs330049	chr8:9087299	C/T	cg08975724	chr8:8085496	FLJ10661	0.53	6.92	0.41	4.28e-11	Joint mobility (Beighton score);
SARC	cis	rs9611565	0.918	rs2281333	chr22:41749630	T/C	cg06634786	chr22:41940651	POLR3H	-0.42	-5.21	-0.32	4.23e-7	Vitiligo;
SARC	cis	rs8017423	0.967	rs7146640	chr14:90720114	C/T	cg20276874	chr14:90721474	PSMC1	0.35	4.95	0.31	1.44e-6	Mortality in heart failure;
SARC	cis	rs9309473	0.898	rs11126403	chr2:73796923	A/G	cg07208825	chr2:73871855	ALMS1P	0.33	4.84	0.3	2.38e-6	Metabolite levels;
SARC	cis	rs4906332	1.000	rs34347076	chr14:103955069	G/A	cg26031613	chr14:104095156	KLC1	-0.49	-5.76	-0.35	2.64e-8	Coronary artery disease;
SARC	cis	rs67311347	1.000	rs11716675	chr3:40485280	G/T	cg09455208	chr3:40491958	NA	0.42	6.69	0.4	1.63e-10	Renal cell carcinoma;
SARC	cis	rs798554	0.549	rs1623138	chr7:2899410	A/G	cg13628971	chr7:2884303	GNA12	0.5	5.94	0.36	1.03e-8	Height;
SARC	cis	rs11764590	0.666	rs3996325	chr7:2053747	T/C	cg21782813	chr7:2030301	MAD1L1	-0.34	-4.99	-0.31	1.18e-6	Neuroticism;
SARC	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg08280861	chr8:58055591	NA	0.61	5.89	0.36	1.34e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6430585	0.702	rs2015532	chr2:136555525	G/T	cg07169764	chr2:136633963	MCM6	-0.96	-13.53	-0.66	3.71e-31	Corneal structure;
SARC	cis	rs2380220	0.606	rs9488080	chr6:96006973	A/G	cg04719120	chr6:96025338	MANEA	0.6	6.78	0.41	1.01e-10	Behavioural disinhibition (generation interaction);
SARC	cis	rs240764	0.507	rs7759463	chr6:101183819	C/T	cg09795085	chr6:101329169	ASCC3	0.4	4.81	0.3	2.67e-6	Neuroticism;
SARC	cis	rs875971	0.545	rs316316	chr7:65614257	C/T	cg11764359	chr7:65958608	NA	-0.65	-6.42	-0.39	7.5e-10	Aortic root size;
SARC	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg23758822	chr17:41437982	NA	0.83	10.16	0.55	2.52e-20	Menopause (age at onset);
SARC	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs950776	0.518	rs1979907	chr15:78842239	T/C	cg22563815	chr15:78856949	CHRNA5	-0.4	-6.65	-0.4	2.08e-10	Sudden cardiac arrest;
SARC	cis	rs7772486	0.686	rs7744014	chr6:146123818	G/A	cg23711669	chr6:146136114	FBXO30	0.79	12.69	0.64	2.16e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12956009	0.583	rs7240132	chr18:44858634	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.53	-7.06	-0.42	1.88e-11	Educational attainment (years of education);
SARC	cis	rs13095912	1.000	rs2034343	chr3:185337854	A/T	cg11274856	chr3:185301563	NA	0.36	5.03	0.31	9.8e-7	Systolic blood pressure;
SARC	cis	rs3126085	0.935	rs4421596	chr1:152181673	G/A	cg09127314	chr1:152161683	NA	0.41	4.76	0.3	3.39e-6	Atopic dermatitis;
SARC	cis	rs7828089	1.000	rs7838127	chr8:22264561	G/A	cg12081754	chr8:22256438	SLC39A14	0.44	5.71	0.35	3.4e-8	Verbal declarative memory;
SARC	cis	rs2933343	0.553	rs35076317	chr3:128715535	T/C	cg24203234	chr3:128598194	ACAD9	0.45	5.23	0.32	3.86e-7	IgG glycosylation;
SARC	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg15049968	chr18:44337910	ST8SIA5	0.33	5.2	0.32	4.27e-7	Personality dimensions;
SARC	cis	rs2120019	0.938	rs8033925	chr15:75311959	A/G	cg09165964	chr15:75287851	SCAMP5	-0.95	-14.5	-0.69	2.24e-34	Blood trace element (Zn levels);
SARC	cis	rs66887589	0.934	rs12648182	chr4:120503891	T/A	cg09307838	chr4:120376055	NA	-0.53	-7.27	-0.43	5.41e-12	Diastolic blood pressure;
SARC	cis	rs9354308	0.903	rs9360158	chr6:66558164	C/T	cg07460842	chr6:66804631	NA	-0.45	-5.19	-0.32	4.6e-7	Metabolite levels;
SARC	cis	rs870825	0.616	rs4519834	chr4:185633865	A/G	cg04058563	chr4:185651563	MLF1IP	-0.84	-11.27	-0.59	8.45e-24	Blood protein levels;
SARC	cis	rs6910061	1.000	rs5027679	chr6:11118871	A/G	cg27233058	chr6:11094804	LOC221710	-0.52	-4.95	-0.31	1.44e-6	Diabetic kidney disease;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg07867325	chr3:73159953	NA	-0.5	-6.63	-0.4	2.26e-10	Height;
SARC	cis	rs787274	0.850	rs10733598	chr9:115615329	G/A	cg13803584	chr9:115635662	SNX30	-0.83	-5.27	-0.33	3.12e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs412050	0.948	rs34239349	chr22:22325624	G/A	cg17089214	chr22:22089827	YPEL1	0.61	5.51	0.34	9.62e-8	Attention deficit hyperactivity disorder;
SARC	cis	rs2120019	0.505	rs77456790	chr15:75330095	G/T	cg09165964	chr15:75287851	SCAMP5	-1.1	-8.84	-0.5	2.34e-16	Blood trace element (Zn levels);
SARC	cis	rs208520	0.955	rs12204033	chr6:67001525	T/C	cg07460842	chr6:66804631	NA	0.86	9.79	0.54	3.48e-19	Exhaled nitric oxide output;
SARC	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg05368731	chr17:41323189	NBR1	0.78	9.52	0.53	2.33e-18	Menopause (age at onset);
SARC	cis	rs2404618	0.624	rs4338133	chr8:1477507	T/C	cg13402656	chr8:1511478	DLGAP2	-0.59	-8.68	-0.49	6.82e-16	Lung cancer;
SARC	cis	rs611744	0.934	rs1989388	chr8:109220269	A/T	cg21045802	chr8:109455806	TTC35	0.46	5.6	0.34	6.03e-8	Dupuytren's disease;
SARC	cis	rs11676348	0.818	rs7423433	chr2:218985084	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.5	-6.42	-0.39	7.61e-10	Ulcerative colitis;
SARC	cis	rs6500602	0.702	rs11076835	chr16:4549618	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.33	5.69	0.35	3.83e-8	Schizophrenia;
SARC	cis	rs1008375	1.000	rs10939738	chr4:17604295	G/C	cg27347728	chr4:17578864	LAP3	0.45	5.52	0.34	9.09e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs425277	0.917	rs12410859	chr1:2038732	C/T	cg24578937	chr1:2090814	PRKCZ	0.32	5.96	0.36	9.16e-9	Height;
SARC	cis	rs1355223	0.525	rs12280958	chr11:34872799	G/A	cg11622362	chr11:34938112	PDHX;APIP	0.45	5.88	0.36	1.42e-8	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs55823223	0.646	rs55868394	chr17:73851113	C/A	cg08125733	chr17:73851984	WBP2	0.62	5.3	0.33	2.71e-7	Psoriasis;
SARC	cis	rs721399	0.924	rs1115784	chr8:18255410	C/T	cg18736775	chr8:18248649	NAT2	0.4	5.23	0.32	3.81e-7	Blood metabolite levels;
SARC	cis	rs3733585	0.638	rs13145554	chr4:9979589	C/T	cg00071950	chr4:10020882	SLC2A9	0.38	5.77	0.35	2.45e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs78487399	0.808	rs76993899	chr2:43671157	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.58	-4.78	-0.3	3.11e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs4243830	1.000	rs10158949	chr1:6583701	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.01	-7.87	-0.46	1.29e-13	Body mass index;
SARC	cis	rs16912285	0.688	rs12279442	chr11:24317174	C/G	ch.11.24196551F	chr11:24239977	NA	0.53	5.05	0.31	8.73e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs72634258	0.554	rs17374781	chr1:7919363	A/G	cg00042356	chr1:8021962	PARK7	-0.55	-4.77	-0.3	3.2e-6	Inflammatory bowel disease;
SARC	cis	rs7829975	0.560	rs6994131	chr8:8550958	G/A	cg06636001	chr8:8085503	FLJ10661	-0.44	-5.47	-0.34	1.13e-7	Mood instability;
SARC	cis	rs7666738	0.830	rs1426668	chr4:98945585	T/A	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4148883	0.898	rs4699726	chr4:100099513	T/C	cg13256891	chr4:100009986	ADH5	0.48	6.25	0.38	1.99e-9	Alcohol dependence;
SARC	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg12311346	chr5:56204834	C5orf35	0.57	5.89	0.36	1.36e-8	Initial pursuit acceleration;
SARC	cis	rs9467773	0.596	rs2494693	chr6:26619226	T/C	cg12292205	chr6:26970375	C6orf41	0.4	5.04	0.31	9.34e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg13206674	chr6:150067644	NUP43	0.41	5.36	0.33	1.98e-7	Lung cancer;
SARC	cis	rs11098499	0.618	rs28491261	chr4:120294900	C/A	cg09160332	chr4:120329925	NA	-0.34	-4.79	-0.3	2.91e-6	Corneal astigmatism;
SARC	cis	rs6540556	0.723	rs3765240	chr1:209918151	G/A	cg05527609	chr1:210001259	C1orf107	-0.57	-5.89	-0.36	1.32e-8	Red blood cell count;
SARC	cis	rs2072499	0.750	rs7534339	chr1:156156219	A/G	cg25208724	chr1:156163844	SLC25A44	0.88	9.91	0.54	1.58e-19	Testicular germ cell tumor;
SARC	cis	rs9527	0.545	rs11191602	chr10:104954219	C/T	cg04362960	chr10:104952993	NT5C2	0.43	5.06	0.31	8.57e-7	Arsenic metabolism;
SARC	cis	rs2439831	1.000	rs2584726	chr15:43715382	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.81	8.27	0.48	1.02e-14	Lung cancer in ever smokers;
SARC	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg09455208	chr3:40491958	NA	0.43	6.53	0.39	3.97e-10	Renal cell carcinoma;
SARC	cis	rs3020736	0.500	rs6002604	chr22:42493081	A/T	cg04733989	chr22:42467013	NAGA	-0.76	-10.7	-0.57	5.23e-22	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7914558	1.000	rs7077291	chr10:104945751	C/T	cg04362960	chr10:104952993	NT5C2	0.4	4.73	0.3	3.95e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg21724239	chr8:58056113	NA	0.56	5.34	0.33	2.17e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7940866	0.838	rs10736592	chr11:130800572	C/T	cg12179176	chr11:130786555	SNX19	0.67	9.5	0.53	2.74e-18	Schizophrenia;
SARC	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg03517284	chr6:25882590	NA	-0.45	-5.87	-0.36	1.45e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9815354	0.812	rs73083333	chr3:41927505	G/A	cg03022575	chr3:42003672	ULK4	0.69	5.65	0.35	4.69e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg05368731	chr17:41323189	NBR1	0.76	8.93	0.51	1.3e-16	Menopause (age at onset);
SARC	cis	rs11599315	1.000	rs11599315	chr10:1343017	C/T	cg09624528	chr10:1369823	ADARB2	0.48	7.14	0.42	1.16e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs11264799	0.603	rs12134075	chr1:157586516	C/T	cg18268488	chr1:157545234	FCRL4	0.31	5.38	0.33	1.82e-7	IgA nephropathy;
SARC	cis	rs11722228	1.000	rs4697695	chr4:9915850	C/T	cg11266682	chr4:10021025	SLC2A9	0.36	6.04	0.37	6.02e-9	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs9303401	0.573	rs67378767	chr17:57194237	G/T	cg25039879	chr17:56429692	SUPT4H1	0.58	5.23	0.32	3.71e-7	Cognitive test performance;
SARC	trans	rs1814175	0.615	rs12417290	chr11:49876951	G/A	cg03929089	chr4:120376271	NA	-0.83	-12.24	-0.63	6.14e-27	Height;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg13303229	chr5:154136254	LARP1	-0.65	-7.54	-0.44	1.04e-12	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs8017423	0.967	rs8009493	chr14:90690083	G/C	cg20276874	chr14:90721474	PSMC1	-0.34	-4.75	-0.3	3.56e-6	Mortality in heart failure;
SARC	cis	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg15556689	chr8:8085844	FLJ10661	0.52	6.09	0.37	4.72e-9	Mood instability;
SARC	cis	rs1983170	0.736	rs13447495	chr1:91974965	A/G	cg25838465	chr1:92012736	NA	0.57	5.64	0.35	4.93e-8	Eosinophil percentage of white cells;
SARC	trans	rs1945213	0.694	rs12422168	chr11:55866840	A/G	cg15704280	chr7:45808275	SEPT13	0.65	6.77	0.41	1.02e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg13849007	chr1:1677539	SLC35E2	-0.37	-4.77	-0.3	3.3e-6	Body mass index;
SARC	cis	rs7568458	0.811	rs10175792	chr2:85761654	A/G	cg17127132	chr2:85788382	GGCX	0.46	6.2	0.38	2.51e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	trans	rs12660691	0.685	rs9398917	chr6:130014226	G/A	cg19261306	chr1:59234911	NA	-0.75	-6.53	-0.39	3.98e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
SARC	cis	rs59112743	0.588	rs2769562	chr6:15671877	G/A	cg06375068	chr6:15849678	NA	0.56	5.11	0.32	6.57e-7	Multiple keratinocyte cancers;
SARC	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg12463550	chr7:65579703	CRCP	-0.52	-5.56	-0.34	7.34e-8	Aortic root size;
SARC	cis	rs7246657	0.525	rs10410594	chr19:37477758	C/T	cg14683738	chr19:37701593	ZNF585B	0.55	4.86	0.3	2.13e-6	Coronary artery calcification;
SARC	cis	rs2425143	1.000	rs6058325	chr20:34388806	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-6.37	-0.39	9.75e-10	Blood protein levels;
SARC	cis	rs6500395	1.000	rs9933976	chr16:48590145	A/G	cg04672837	chr16:48644449	N4BP1	0.48	6.51	0.39	4.57e-10	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs7264396	0.563	rs78084033	chr20:34219990	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-5.98	-0.36	8.32e-9	Total cholesterol levels;
SARC	cis	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg05623727	chr3:50126028	RBM5	0.33	5.0	0.31	1.14e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9457247	0.935	rs1794697	chr6:167395410	C/T	cg23791538	chr6:167370224	RNASET2	-0.63	-8.73	-0.5	4.9e-16	Crohn's disease;
SARC	cis	rs10979	0.965	rs9403508	chr6:143887857	G/A	cg25407410	chr6:143891975	LOC285740	-0.64	-8.63	-0.49	9.65e-16	Hypospadias;
SARC	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.67	-8.61	-0.49	1.09e-15	Intelligence (multi-trait analysis);
SARC	cis	rs7605378	0.528	rs281791	chr2:200850402	A/G	cg23649088	chr2:200775458	C2orf69	-0.82	-11.92	-0.62	6.64e-26	Osteoporosis;
SARC	cis	rs7647973	0.593	rs4855885	chr3:49690199	G/A	cg03060546	chr3:49711283	APEH	0.64	6.36	0.38	1.06e-9	Menarche (age at onset);
SARC	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg01341218	chr17:43662625	NA	-0.92	-10.32	-0.56	8.56e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs74181299	0.571	rs12990465	chr2:65281401	C/T	cg20592124	chr2:65290738	CEP68	0.38	4.94	0.31	1.49e-6	Pulse pressure;
SARC	cis	rs208520	0.739	rs1935894	chr6:66891434	A/G	cg07460842	chr6:66804631	NA	-1.04	-13.4	-0.66	9.54e-31	Exhaled nitric oxide output;
SARC	cis	rs7615952	0.673	rs35001498	chr3:125628644	A/G	cg05084668	chr3:125655381	ALG1L	-0.89	-8.26	-0.48	1.09e-14	Blood pressure (smoking interaction);
SARC	cis	rs6991838	0.584	rs6997959	chr8:66540482	T/C	cg13398993	chr8:66546079	ARMC1	0.62	8.19	0.47	1.72e-14	Intelligence (multi-trait analysis);
SARC	cis	rs9916302	0.904	rs11078915	chr17:37715426	T/C	cg00129232	chr17:37814104	STARD3	-0.65	-7.95	-0.46	8.03e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs854765	0.547	rs7224047	chr17:17932931	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.66	9.52	0.53	2.25e-18	Total body bone mineral density;
SARC	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg17221315	chr6:27791827	HIST1H4J	0.46	4.83	0.3	2.53e-6	Depression;
SARC	cis	rs7666738	0.716	rs9994641	chr4:99101605	C/T	cg05340658	chr4:99064831	C4orf37	0.54	6.97	0.42	3.2e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs67311347	0.955	rs73078170	chr3:40483947	C/T	cg24209194	chr3:40518798	ZNF619	0.67	7.86	0.46	1.4e-13	Renal cell carcinoma;
SARC	cis	rs1044826	0.642	rs9833307	chr3:139181370	G/A	cg15131784	chr3:139108705	COPB2	0.4	5.1	0.32	7.05e-7	Obesity-related traits;
SARC	cis	rs2273669	0.915	rs4992382	chr6:109292826	T/A	cg05315195	chr6:109294784	ARMC2	-0.49	-4.88	-0.3	1.99e-6	Prostate cancer;
SARC	cis	rs2721195	0.626	rs59464125	chr8:145857786	G/A	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.73	-10.14	-0.55	3.09e-20	Age at first birth;
SARC	cis	rs10861342	1.000	rs11112398	chr12:105572967	A/G	cg23923672	chr12:105501055	KIAA1033	0.65	5.01	0.31	1.09e-6	IgG glycosylation;
SARC	cis	rs9393813	1.000	rs6913166	chr6:27355460	C/T	cg11502198	chr6:26597334	ABT1	0.39	4.73	0.3	3.96e-6	Bipolar disorder;
SARC	cis	rs1008375	1.000	rs10440301	chr4:17663199	G/A	cg02297831	chr4:17616191	MED28	0.46	5.66	0.35	4.33e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs1994135	0.617	rs10844644	chr12:33735871	A/G	cg13010199	chr12:38710504	ALG10B	0.59	7.03	0.42	2.33e-11	Resting heart rate;
SARC	cis	rs8072100	0.817	rs12449647	chr17:45548958	C/A	cg08085267	chr17:45401833	C17orf57	-0.49	-6.04	-0.37	6.17e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs17270561	0.666	rs1937129	chr6:25789132	A/G	cg17691542	chr6:26056736	HIST1H1C	0.51	6.24	0.38	2.07e-9	Iron status biomarkers;
SARC	cis	rs7927771	0.864	rs10838724	chr11:47527052	G/T	cg05585544	chr11:47624801	NA	-0.38	-5.19	-0.32	4.62e-7	Subjective well-being;
SARC	cis	rs2153535	0.601	rs4140585	chr6:8503298	T/A	cg23788917	chr6:8435910	SLC35B3	0.64	8.23	0.47	1.32e-14	Motion sickness;
SARC	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg00684032	chr4:1343700	KIAA1530	0.37	5.37	0.33	1.9e-7	Obesity-related traits;
SARC	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg04267008	chr7:1944627	MAD1L1	-0.59	-6.75	-0.4	1.19e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs35213789	0.762	rs2851498	chr7:69108635	C/T	cg10619644	chr7:69149951	AUTS2	-0.34	-4.72	-0.3	4.15e-6	Childhood ear infection;
SARC	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg07343612	chr16:622815	PIGQ	-0.63	-8.75	-0.5	4.47e-16	Height;
SARC	cis	rs4780401	0.609	rs35902600	chr16:11800848	C/T	cg01061890	chr16:11836724	TXNDC11	-0.61	-8.63	-0.49	9.63e-16	Rheumatoid arthritis;
SARC	cis	rs6728642	0.519	rs62152906	chr2:97572270	T/C	cg26665480	chr2:98280029	ACTR1B	-0.65	-5.53	-0.34	8.41e-8	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs9660992	0.573	rs12140703	chr1:205182865	G/C	cg07972983	chr1:205091412	RBBP5	0.56	6.91	0.41	4.7e-11	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg12463550	chr7:65579703	CRCP	0.7	5.25	0.32	3.5e-7	Diabetic kidney disease;
SARC	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg06634786	chr22:41940651	POLR3H	-0.63	-7.6	-0.45	6.98e-13	Vitiligo;
SARC	cis	rs920590	0.643	rs13280085	chr8:19669959	G/T	cg03894339	chr8:19674705	INTS10	-0.42	-5.08	-0.32	7.88e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs8031584	0.958	rs7168641	chr15:31235452	G/A	cg14298792	chr15:30685198	CHRFAM7A	-0.45	-4.93	-0.31	1.57e-6	Huntington's disease progression;
SARC	cis	rs7772486	0.905	rs9373486	chr6:146446024	C/G	cg23711669	chr6:146136114	FBXO30	-0.72	-10.61	-0.57	1.07e-21	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs77372450	0.636	rs7718217	chr5:156998684	C/T	cg23851860	chr5:157002805	ADAM19	0.51	4.85	0.3	2.24e-6	Bipolar disorder (body mass index interaction);
SARC	cis	rs2228479	0.850	rs62052711	chr16:89855100	C/A	cg12064134	chr16:90016061	DEF8	-0.59	-5.06	-0.31	8.56e-7	Skin colour saturation;
SARC	cis	rs7246760	0.867	rs61011126	chr19:9814421	A/C	cg16876255	chr19:9731953	ZNF561	0.79	4.88	0.3	1.96e-6	Pursuit maintenance gain;
SARC	cis	rs2832191	0.720	rs2832194	chr21:30494250	T/C	cg24692254	chr21:30365293	RNF160	-0.88	-12.46	-0.63	1.2e-27	Dental caries;
SARC	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg22875332	chr1:76189707	ACADM	0.5	6.9	0.41	4.87e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6071524	0.818	rs909865	chr20:37455269	C/T	cg24229276	chr20:36931287	BPI	-0.31	-4.87	-0.3	2.1e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs12950390	0.853	rs28589850	chr17:45855713	A/G	cg03474202	chr17:45855739	NA	-0.44	-7.06	-0.42	1.88e-11	IgG glycosylation;
SARC	cis	rs11792861	0.926	rs75472294	chr9:111804239	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.68	7.72	0.45	3.51e-13	Menarche (age at onset);
SARC	cis	rs11122272	0.735	rs2749704	chr1:231526243	A/G	cg06096015	chr1:231504339	EGLN1	0.4	6.0	0.37	7.58e-9	Hemoglobin concentration;
SARC	cis	rs796364	1.000	rs281774	chr2:200814572	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.79	7.31	0.43	4.32e-12	Schizophrenia;
SARC	cis	rs9916302	0.571	rs28799952	chr17:37533056	C/T	cg00129232	chr17:37814104	STARD3	0.54	5.78	0.35	2.34e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs9303401	0.659	rs17822908	chr17:56801778	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	11.87	0.61	9.72e-26	Cognitive test performance;
SARC	cis	rs8058578	0.945	rs8058961	chr16:30809063	G/A	cg02466173	chr16:30829666	NA	-0.45	-5.95	-0.36	9.8e-9	Multiple myeloma;
SARC	cis	rs9818758	0.607	rs11552724	chr3:49156473	C/G	cg00383909	chr3:49044727	WDR6	0.76	6.56	0.39	3.52e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs28655083	0.828	rs7404322	chr16:77130003	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	0.44	6.36	0.38	1.06e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7552404	0.731	rs931507	chr1:76401577	G/A	cg03433033	chr1:76189801	ACADM	-0.45	-5.6	-0.34	6.03e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs72781680	1.000	rs17762102	chr2:24085606	A/G	cg08917208	chr2:24149416	ATAD2B	0.76	7.5	0.44	1.3e-12	Lymphocyte counts;
SARC	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg08219700	chr8:58056026	NA	0.71	6.73	0.4	1.33e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs12477438	0.520	rs11695751	chr2:99708247	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	15.42	0.71	1.95e-37	Chronic sinus infection;
SARC	cis	rs757647	0.503	rs4835672	chr5:137568867	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.49	5.16	0.32	5.38e-7	Menarche (age at onset);
SARC	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg09699651	chr6:150184138	LRP11	0.42	5.14	0.32	5.9e-7	Lung cancer;
SARC	cis	rs3126085	0.935	rs11204976	chr1:152273777	C/T	cg03465714	chr1:152285911	FLG	0.51	5.76	0.35	2.6e-8	Atopic dermatitis;
SARC	cis	rs7715806	0.500	rs34355	chr5:74959970	G/A	cg06933384	chr5:74808293	COL4A3BP;POLK	-0.51	-4.96	-0.31	1.33e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6089584	0.893	rs6089305	chr20:60571817	T/C	cg23262073	chr20:60523788	NA	-0.45	-6.65	-0.4	2.06e-10	Body mass index;
SARC	cis	rs7666738	0.830	rs10010698	chr4:98981594	C/T	cg05340658	chr4:99064831	C4orf37	0.64	8.6	0.49	1.18e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.59	5.49	0.34	1.07e-7	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs9398803	0.835	rs4897182	chr6:126755642	A/C	cg20229609	chr6:126660872	C6orf173	0.39	5.65	0.35	4.68e-8	Male-pattern baldness;
SARC	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg04944784	chr2:26401820	FAM59B	0.6	7.95	0.46	8.14e-14	Gut microbiome composition (summer);
SARC	cis	rs7523050	0.643	rs12741359	chr1:109400489	T/C	cg08274380	chr1:109419600	GPSM2	1.07	8.3	0.48	8.22e-15	Fat distribution (HIV);
SARC	cis	rs16954776	1	rs16954776	chr13:98700617	C/T	cg01837275	chr13:97874533	MBNL2	-0.81	-5.16	-0.32	5.38e-7	Smooth-surface caries;
SARC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	10.24	0.56	1.52e-20	Platelet count;
SARC	cis	rs1008375	0.966	rs10006317	chr4:17702525	A/G	cg16339924	chr4:17578868	LAP3	0.55	7.02	0.42	2.36e-11	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs12545109	0.837	rs6474063	chr8:57355545	C/T	cg19413350	chr8:57351067	NA	-0.42	-4.77	-0.3	3.25e-6	Obesity-related traits;
SARC	cis	rs35110281	0.805	rs4818855	chr21:45038951	C/T	cg21573476	chr21:45109991	RRP1B	-0.52	-7.72	-0.45	3.33e-13	Mean corpuscular volume;
SARC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg21747090	chr2:27597821	SNX17	-0.55	-7.68	-0.45	4.44e-13	Total body bone mineral density;
SARC	cis	rs9843304	0.837	rs9289789	chr3:149207968	T/C	cg08667024	chr3:149219783	TM4SF4	0.37	5.97	0.36	8.89e-9	Gallstone disease;
SARC	cis	rs1678542	0.651	rs2888334	chr12:57976647	C/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.53	-6.03	-0.37	6.37e-9	Rheumatoid arthritis;
SARC	cis	rs9487051	0.872	rs7772602	chr6:109608661	C/G	cg01475377	chr6:109611718	NA	0.42	6.05	0.37	5.82e-9	Reticulocyte fraction of red cells;
SARC	cis	rs8141529	0.748	rs132529	chr22:29296652	A/G	cg02153584	chr22:29168773	CCDC117	-0.78	-11.24	-0.59	1.06e-23	Lymphocyte counts;
SARC	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg02733842	chr7:1102375	C7orf50	-0.5	-5.97	-0.36	8.96e-9	Bronchopulmonary dysplasia;
SARC	cis	rs6582630	0.555	rs11182422	chr12:38522833	A/G	cg13010199	chr12:38710504	ALG10B	0.75	10.44	0.56	3.64e-21	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	5.42	0.33	1.46e-7	Bipolar disorder;
SARC	cis	rs41278232	0.557	rs1093456	chr20:62604361	G/A	cg24354818	chr20:62328094	TNFRSF6B	0.35	4.83	0.3	2.43e-6	Tonsillectomy;
SARC	cis	rs7681440	0.606	rs2737000	chr4:90754022	G/T	cg06632027	chr4:90757378	SNCA	-0.41	-5.17	-0.32	5.14e-7	Dementia with Lewy bodies;
SARC	cis	rs10463554	0.963	rs17154959	chr5:102356291	G/A	cg23492399	chr5:102201601	PAM	-0.47	-5.33	-0.33	2.27e-7	Parkinson's disease;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09252805	chr1:22778600	ZBTB40	0.53	6.44	0.39	6.68e-10	Smoking initiation;
SARC	cis	rs4481887	0.962	rs10788770	chr1:248457474	T/G	cg00666640	chr1:248458726	OR2T12	0.35	5.73	0.35	3.14e-8	Common traits (Other);
SARC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg08219700	chr8:58056026	NA	0.62	6.56	0.4	3.37e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs28669119	0.778	rs622803	chr5:88069593	G/T	cg18498987	chr5:88179539	MEF2C	-0.5	-5.13	-0.32	6.13e-7	Schizophrenia;
SARC	cis	rs11509153	0.687	rs6947327	chr7:12257169	C/G	cg23422036	chr7:12250390	TMEM106B	0.47	6.03	0.37	6.26e-9	Residual cognition;
SARC	cis	rs7512552	0.839	rs1694385	chr1:150377960	G/A	cg15654264	chr1:150340011	RPRD2	0.38	4.8	0.3	2.86e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs523522	0.962	rs651627	chr12:121009198	C/T	cg12219531	chr12:120966889	COQ5	0.83	11.41	0.6	2.93e-24	High light scatter reticulocyte count;
SARC	cis	rs4319547	0.956	rs7316149	chr12:123063912	G/A	cg23029597	chr12:123009494	RSRC2	-0.4	-5.0	-0.31	1.12e-6	Body mass index;
SARC	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg16606324	chr3:10149918	C3orf24	0.48	4.75	0.3	3.56e-6	Alzheimer's disease;
SARC	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.46	-5.77	-0.35	2.54e-8	Gut microbiome composition (summer);
SARC	cis	rs17030434	0.871	rs6847648	chr4:154729700	G/A	cg14289246	chr4:154710475	SFRP2	-0.6	-6.85	-0.41	6.65e-11	Electrocardiographic conduction measures;
SARC	cis	rs870825	0.616	rs7683615	chr4:185618373	C/T	cg04058563	chr4:185651563	MLF1IP	0.82	11.42	0.6	2.8e-24	Blood protein levels;
SARC	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg13849007	chr1:1677539	SLC35E2	-0.37	-4.76	-0.3	3.39e-6	Body mass index;
SARC	cis	rs1267303	0.710	rs1535739	chr1:46957719	A/C	cg22795216	chr1:47078649	MOBKL2C	0.43	4.72	0.3	3.99e-6	Monobrow;
SARC	cis	rs9420	0.961	rs682503	chr11:57640994	C/G	cg23127183	chr11:57508653	C11orf31	0.57	6.46	0.39	5.9e-10	Schizophrenia;
SARC	cis	rs7772486	0.754	rs9386134	chr6:146145508	G/A	cg05347473	chr6:146136440	FBXO30	0.56	7.73	0.45	3.26e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs637571	0.780	rs677029	chr11:65683531	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.39	4.82	0.3	2.64e-6	Eosinophil percentage of white cells;
SARC	cis	rs742614	0.533	rs13041078	chr20:32435497	G/T	cg06304546	chr20:32448765	NA	-0.56	-7.16	-0.42	1.07e-11	Stearic acid (18:0) levels;
SARC	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg07167872	chr1:205819463	PM20D1	0.48	5.3	0.33	2.67e-7	Prostate-specific antigen levels;
SARC	cis	rs820218	0.847	rs11470	chr17:73616864	C/A	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.59	7.4	0.44	2.41e-12	Rotator cuff tears;
SARC	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg27266027	chr21:40555129	PSMG1	0.51	5.47	0.34	1.16e-7	Cognitive function;
SARC	cis	rs4727443	0.866	rs13238380	chr7:99629061	C/T	cg22004693	chr7:99632812	ZKSCAN1	0.59	7.25	0.43	6.21e-12	Interstitial lung disease;
SARC	cis	rs4713118	0.662	rs149969	chr6:27977737	A/G	cg26335602	chr6:28129616	ZNF389	0.47	5.09	0.32	7.42e-7	Parkinson's disease;
SARC	cis	rs2976388	0.692	rs2585175	chr8:143781289	G/C	cg06565975	chr8:143823917	SLURP1	0.32	5.55	0.34	7.72e-8	Urinary tract infection frequency;
SARC	cis	rs67311347	1.000	rs7612015	chr3:40399974	A/C	cg09455208	chr3:40491958	NA	0.4	6.18	0.38	2.84e-9	Renal cell carcinoma;
SARC	cis	rs6908034	0.556	rs79028848	chr6:19783153	G/A	cg02682789	chr6:19804855	NA	0.66	4.78	0.3	3.15e-6	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs13191362	1.000	rs13192894	chr6:163052444	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.61	5.28	0.33	2.91e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg01832569	chr1:171711313	VAMP4	0.49	6.38	0.39	9.49e-10	Chemerin levels;
SARC	cis	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg02487422	chr3:49467188	NICN1	0.5	6.83	0.41	7.5e-11	Resting heart rate;
SARC	cis	rs9807989	0.801	rs4851566	chr2:102972799	G/C	cg09003973	chr2:102972529	NA	0.41	5.6	0.34	6.11e-8	Asthma;
SARC	cis	rs1707322	1.000	rs785468	chr1:46521517	G/A	cg06784218	chr1:46089804	CCDC17	-0.37	-6.57	-0.4	3.18e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs561341	1.000	rs473356	chr17:30321762	G/C	cg20587970	chr11:113659929	NA	-1.34	-13.79	-0.67	4.87e-32	Hip circumference adjusted for BMI;
SARC	cis	rs6866344	0.570	rs11740283	chr5:178136440	T/C	cg10224037	chr5:178157518	ZNF354A	1.01	14.12	0.68	4.15e-33	Neutrophil percentage of white cells;
SARC	cis	rs6723226	0.765	rs12612824	chr2:32579759	C/T	cg02381751	chr2:32503542	YIPF4	-0.83	-11.26	-0.59	9.03e-24	Intelligence (multi-trait analysis);
SARC	cis	rs15676	0.783	rs7044955	chr9:131567152	C/T	cg00228799	chr9:131580591	ENDOG	-0.56	-7.13	-0.42	1.23e-11	Blood metabolite levels;
SARC	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg04756594	chr16:24857601	SLC5A11	0.46	6.32	0.38	1.34e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs7659604	0.540	rs11734075	chr4:122695685	C/T	cg19748678	chr4:122722346	EXOSC9	-0.42	-5.23	-0.32	3.82e-7	Type 2 diabetes;
SARC	cis	rs11690935	0.550	rs62183801	chr2:172867475	G/A	cg13550731	chr2:172543902	DYNC1I2	0.52	6.63	0.4	2.27e-10	Schizophrenia;
SARC	cis	rs12142240	0.698	rs7548675	chr1:46809321	C/G	cg00530320	chr1:46809349	NSUN4	0.58	7.07	0.42	1.74e-11	Menopause (age at onset);
SARC	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg18876405	chr7:65276391	NA	-0.46	-5.07	-0.32	7.94e-7	Aortic root size;
SARC	cis	rs1046896	0.594	rs67813226	chr17:80851134	G/A	cg19500275	chr17:80737654	TBCD	0.45	5.28	0.33	2.98e-7	Glycated hemoglobin levels;
SARC	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg27266027	chr21:40555129	PSMG1	0.51	5.56	0.34	7.49e-8	Cognitive function;
SARC	cis	rs7216064	0.953	rs62086043	chr17:65968003	A/G	cg12091567	chr17:66097778	LOC651250	-0.62	-6.5	-0.39	4.94e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg06634786	chr22:41940651	POLR3H	-0.43	-4.92	-0.31	1.62e-6	Vitiligo;
SARC	trans	rs11098499	0.697	rs10016448	chr4:120298845	A/G	cg25214090	chr10:38739885	LOC399744	0.55	7.14	0.42	1.15e-11	Corneal astigmatism;
SARC	cis	rs4820539	1.000	rs6003518	chr22:23471533	C/T	cg14186256	chr22:23484241	RTDR1	0.91	14.75	0.69	3.12e-35	Bone mineral density;
SARC	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg25072359	chr17:41440525	NA	0.49	5.7	0.35	3.67e-8	Menopause (age at onset);
SARC	cis	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg25894440	chr7:65020034	NA	-0.78	-6.04	-0.37	6.1e-9	Diabetic kidney disease;
SARC	cis	rs11191205	1.000	rs11191205	chr10:103831598	G/A	cg15320455	chr10:103880129	LDB1	0.94	8.64	0.49	9.25e-16	Intelligence (multi-trait analysis);
SARC	cis	rs926392	1.000	rs926391	chr20:37690485	A/G	cg16355469	chr20:37678765	NA	0.51	6.57	0.4	3.17e-10	Dialysis-related mortality;
SARC	cis	rs3820928	1.000	rs59904960	chr2:227761269	T/C	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.07	-0.42	1.74e-11	Pulmonary function;
SARC	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs61931739	0.517	rs4104182	chr12:34081343	G/A	cg13010199	chr12:38710504	ALG10B	0.74	10.01	0.55	7.69e-20	Morning vs. evening chronotype;
SARC	cis	rs11098499	0.955	rs4145951	chr4:120155817	A/G	cg09307838	chr4:120376055	NA	0.86	11.6	0.61	7.28e-25	Corneal astigmatism;
SARC	cis	rs9398803	0.865	rs4418209	chr6:126819699	T/G	cg20229609	chr6:126660872	C6orf173	0.4	5.79	0.35	2.23e-8	Male-pattern baldness;
SARC	cis	rs11583043	1.000	rs7541397	chr1:101322866	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.48	-5.62	-0.35	5.54e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg26335602	chr6:28129616	ZNF389	0.52	5.94	0.36	1.04e-8	Depression;
SARC	cis	rs7220711	0.934	rs8068071	chr17:41782779	C/T	cg26893861	chr17:41843967	DUSP3	-0.38	-4.84	-0.3	2.37e-6	Bone mineral density (spine);Bone mineral density (hip);
SARC	cis	rs12446492	0.549	rs11643772	chr16:20402499	G/T	cg07222434	chr16:20395031	PDILT	-0.31	-4.99	-0.31	1.17e-6	Urinary uromodulin levels;
SARC	cis	rs3824867	0.920	rs9919526	chr11:47451623	C/T	cg20307385	chr11:47447363	PSMC3	-0.47	-5.14	-0.32	5.71e-7	Mean corpuscular hemoglobin;
SARC	cis	rs8077889	1.000	rs113919636	chr17:41877740	A/C	cg26893861	chr17:41843967	DUSP3	0.87	10.3	0.56	9.65e-21	Triglycerides;
SARC	cis	rs6831352	0.918	rs17218602	chr4:100061073	A/G	cg12011299	chr4:100065546	ADH4	-0.34	-5.67	-0.35	4.2e-8	Alcohol dependence;
SARC	cis	rs6831352	0.744	rs2602847	chr4:100025963	T/C	cg13256891	chr4:100009986	ADH5	0.66	8.13	0.47	2.55e-14	Alcohol dependence;
SARC	cis	rs72781680	0.611	rs72797818	chr2:24351107	G/A	cg06627628	chr2:24431161	ITSN2	-0.5	-5.0	-0.31	1.14e-6	Lymphocyte counts;
SARC	cis	rs9398803	0.723	rs4460221	chr6:127031221	G/A	cg19875578	chr6:126661172	C6orf173	-0.62	-8.55	-0.49	1.62e-15	Male-pattern baldness;
SARC	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg23758822	chr17:41437982	NA	0.86	10.56	0.57	1.52e-21	Menopause (age at onset);
SARC	cis	rs1044826	0.642	rs295479	chr3:139223865	C/T	cg15131784	chr3:139108705	COPB2	0.4	5.06	0.31	8.66e-7	Obesity-related traits;
SARC	cis	rs17780086	0.529	rs7406406	chr17:30220153	T/G	cg13647721	chr17:30228624	UTP6	0.74	9.04	0.51	6.03e-17	Height;
SARC	cis	rs12190007	0.573	rs3006218	chr6:169868769	G/A	cg15038512	chr6:170123185	PHF10	-0.48	-6.51	-0.39	4.67e-10	Obesity-related traits;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg05175599	chr18:12432947	NA	0.5	6.87	0.41	5.79e-11	Schizophrenia;
SARC	cis	rs11718455	1.000	rs28731098	chr3:44019816	A/C	cg21419209	chr3:44054225	NA	-0.41	-5.04	-0.31	9.47e-7	Coronary artery disease;
SARC	cis	rs6087990	1.000	rs1007124	chr20:31345752	G/C	cg13636640	chr20:31349939	DNMT3B	0.8	12.74	0.64	1.5e-28	Ulcerative colitis;
SARC	cis	rs2439831	0.867	rs2447211	chr15:43936351	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.93	8.34	0.48	6.57e-15	Lung cancer in ever smokers;
SARC	cis	rs74181299	0.684	rs17040050	chr2:65327042	G/A	cg20592124	chr2:65290738	CEP68	-0.35	-4.78	-0.3	3.12e-6	Pulse pressure;
SARC	cis	rs4132509	1.000	rs6675851	chr1:243787494	G/A	cg21452805	chr1:244014465	NA	0.5	5.4	0.33	1.66e-7	RR interval (heart rate);
SARC	cis	rs7829975	0.514	rs2920991	chr8:8259117	T/A	cg06636001	chr8:8085503	FLJ10661	0.64	7.96	0.46	7.54e-14	Mood instability;
SARC	cis	rs957448	1.000	rs1023767	chr8:95530969	C/T	cg26464482	chr8:95565502	KIAA1429	0.43	4.82	0.3	2.63e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs9807989	0.524	rs7594402	chr2:103021267	A/T	cg03938978	chr2:103052716	IL18RAP	0.31	4.91	0.31	1.72e-6	Asthma;
SARC	cis	rs4803468	1.000	rs284663	chr19:41932612	C/T	cg08477640	chr19:41863820	B9D2	0.44	5.5	0.34	1.02e-7	Height;
SARC	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg24549020	chr5:56110836	MAP3K1	0.69	7.02	0.42	2.34e-11	Initial pursuit acceleration;
SARC	cis	rs1185460	1.000	rs1799993	chr11:118958127	A/C	cg23280166	chr11:118938394	VPS11	-0.71	-9.91	-0.54	1.5700000000000001e-19	Coronary artery disease;
SARC	cis	rs3092073	0.624	rs11696196	chr20:44574533	C/T	cg17986701	chr20:44574422	PCIF1	0.35	4.94	0.31	1.49e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2075371	1.000	rs2598297	chr7:133993001	T/G	cg20476274	chr7:133979776	SLC35B4	0.62	8.42	0.48	3.78e-15	Mean platelet volume;
SARC	cis	rs17401966	0.540	rs1467653	chr1:10413123	A/G	cg15208524	chr1:10270712	KIF1B	-0.37	-4.76	-0.3	3.38e-6	Hepatocellular carcinoma;
SARC	cis	rs7786808	0.705	rs1377373	chr7:158215549	A/C	cg09998033	chr7:158218633	PTPRN2	0.34	5.35	0.33	2.12e-7	Obesity-related traits;
SARC	cis	rs921968	0.643	rs612874	chr2:219492924	T/C	cg02176678	chr2:219576539	TTLL4	0.35	5.05	0.31	8.84e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs11583043	0.957	rs6577223	chr1:101499750	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.49	5.8	0.36	2.12e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs1580019	0.520	rs13228793	chr7:32711465	C/T	cg14728415	chr7:32535168	LSM5;AVL9	0.44	4.85	0.3	2.21e-6	Cognitive ability;
SARC	trans	rs9329221	0.683	rs814359	chr8:9883132	T/G	cg21775007	chr8:11205619	TDH	-0.5	-6.52	-0.39	4.44e-10	Neuroticism;
SARC	cis	rs523522	0.923	rs2235217	chr12:120884328	C/T	cg12219531	chr12:120966889	COQ5	0.81	10.48	0.57	2.58e-21	High light scatter reticulocyte count;
SARC	trans	rs7927370	1.000	rs11819980	chr11:55304399	C/T	cg07162727	chr16:4848039	ROGDI	0.77	6.25	0.38	1.97e-9	Systemic lupus erythematosus;
SARC	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.62	7.29	0.43	4.71e-12	Gut microbiome composition (summer);
SARC	cis	rs7582720	1.000	rs72934740	chr2:203741362	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.28	0.43	5.16e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs79839061	0.610	rs62297087	chr4:913289	T/A	cg07828340	chr4:882639	GAK	0.83	6.23	0.38	2.18e-9	Intelligence (multi-trait analysis);
SARC	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg15448220	chr1:150897856	SETDB1	0.47	6.25	0.38	1.94e-9	Tonsillectomy;
SARC	cis	rs1008375	1.000	rs11722037	chr4:17683811	G/A	cg16339924	chr4:17578868	LAP3	0.62	8.13	0.47	2.6e-14	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2777491	0.915	rs7165675	chr15:41614704	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.74	-10.89	-0.58	1.32e-22	Ulcerative colitis;
SARC	cis	rs16870629	1.000	rs16870629	chr5:1015063	C/T	cg00278107	chr5:1061253	SLC12A7	-0.67	-8.96	-0.51	1.04e-16	QT interval;
SARC	cis	rs10791097	0.582	rs2282578	chr11:130735691	A/T	cg12179176	chr11:130786555	SNX19	0.73	10.74	0.58	4.05e-22	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs9388451	0.626	rs7748729	chr6:126077381	C/T	cg05901451	chr6:126070800	HEY2	-0.49	-6.22	-0.38	2.24e-9	Brugada syndrome;
SARC	cis	rs4906332	0.966	rs35799018	chr14:103893475	G/A	cg26031613	chr14:104095156	KLC1	-0.5	-5.84	-0.36	1.72e-8	Coronary artery disease;
SARC	cis	rs11098499	0.615	rs59867181	chr4:120556467	C/T	cg09307838	chr4:120376055	NA	-0.7	-9.69	-0.54	7.36e-19	Corneal astigmatism;
SARC	cis	rs62064224	0.546	rs1018866	chr17:30829664	A/C	cg12855166	chr17:30846586	MYO1D	0.37	4.73	0.3	3.88e-6	Schizophrenia;
SARC	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg10374962	chr7:1011985	COX19	-0.44	-4.95	-0.31	1.44e-6	Bronchopulmonary dysplasia;
SARC	cis	rs959260	0.623	rs2164244	chr17:73325244	C/T	cg07104495	chr17:73266070	MIF4GD	-0.33	-4.99	-0.31	1.2e-6	Systemic lupus erythematosus;
SARC	cis	rs6912958	0.781	rs6454632	chr6:88231824	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-7.19	-0.43	9.01e-12	Monocyte percentage of white cells;
SARC	cis	rs9905704	0.647	rs11079367	chr17:57009024	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.39	-4.78	-0.3	3.11e-6	Testicular germ cell tumor;
SARC	cis	rs986417	1.000	rs10143118	chr14:61066043	G/A	cg27398547	chr14:60952738	C14orf39	0.88	7.72	0.45	3.39e-13	Gut microbiota (bacterial taxa);
SARC	cis	rs3741404	0.609	rs687581	chr11:63871533	G/T	cg04317338	chr11:64019027	PLCB3	-0.5	-5.69	-0.35	3.82e-8	Platelet count;
SARC	cis	rs2273669	0.915	rs7738483	chr6:109341834	C/T	cg01304950	chr6:109416612	SESN1;C6orf182	0.57	5.09	0.32	7.51e-7	Prostate cancer;
SARC	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.67	8.6	0.49	1.15e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg04277193	chr17:41438351	NA	0.44	4.78	0.3	3.04e-6	Menopause (age at onset);
SARC	cis	rs7762018	0.607	rs80267898	chr6:170040306	G/A	cg19338460	chr6:170058176	WDR27	-0.78	-5.16	-0.32	5.37e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs3820928	0.874	rs13393902	chr2:227880554	A/G	cg05526886	chr2:227700861	RHBDD1	-0.52	-6.37	-0.39	1e-9	Pulmonary function;
SARC	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg22920501	chr2:26401640	FAM59B	0.56	7.63	0.45	6e-13	Gut microbiome composition (summer);
SARC	cis	rs1950500	0.509	rs12888965	chr14:24834291	C/T	cg22990158	chr14:24802150	ADCY4	-0.33	-5.51	-0.34	9.51e-8	Height;
SARC	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg02951883	chr7:2050386	MAD1L1	-0.41	-5.06	-0.31	8.53e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs2016266	0.929	rs1318648	chr12:53670545	C/A	cg26875137	chr12:53738046	NA	0.35	4.9	0.31	1.77e-6	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs3857536	0.611	rs7748258	chr6:66932840	A/G	cg07460842	chr6:66804631	NA	-0.51	-5.86	-0.36	1.54e-8	Blood trace element (Cu levels);
SARC	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg21132104	chr15:45694354	SPATA5L1	0.77	10.98	0.58	6.87e-23	Homoarginine levels;
SARC	cis	rs7923609	0.749	rs12247907	chr10:65317045	G/C	cg01631684	chr10:65280961	REEP3	0.35	4.72	0.3	4.06e-6	Educational attainment;Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs12155623	0.619	rs17641604	chr8:49842784	C/T	cg06076277	chr8:49783056	NA	0.3	5.06	0.31	8.54e-7	Sudden cardiac arrest;
SARC	cis	rs4713118	0.868	rs742047	chr6:27739380	A/G	cg17221315	chr6:27791827	HIST1H4J	0.56	5.75	0.35	2.84e-8	Parkinson's disease;
SARC	cis	rs11025559	0.796	rs11603462	chr11:20412180	C/A	cg04101203	chr11:20408940	PRMT3	-0.55	-6.01	-0.37	7.28e-9	Pursuit maintenance gain;
SARC	cis	rs11097912	0.632	rs78856396	chr4:107277293	A/G	cg09646026	chr4:107269030	AIMP1	-0.44	-4.82	-0.3	2.59e-6	Airflow obstruction;
SARC	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg18252515	chr7:66147081	NA	-0.58	-6.21	-0.38	2.41e-9	Aortic root size;
SARC	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg10523679	chr1:76189770	ACADM	0.51	6.71	0.4	1.42e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg05313129	chr8:58192883	C8orf71	-0.62	-6.34	-0.38	1.18e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6674176	0.597	rs3762422	chr1:44400532	T/A	cg13606994	chr1:44402422	ARTN	-0.32	-5.31	-0.33	2.52e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs2845885	1.000	rs2845885	chr11:63869062	A/G	cg24431193	chr11:63883947	FLRT1;MACROD1	0.71	5.18	0.32	4.9e-7	Body mass index;
SARC	cis	rs72781680	1.000	rs6731001	chr2:24192952	A/G	cg08917208	chr2:24149416	ATAD2B	0.79	7.55	0.44	9.78e-13	Lymphocyte counts;
SARC	cis	rs12780845	0.505	rs10795460	chr10:17244253	A/G	cg11116878	chr10:17243438	TRDMT1	0.37	4.78	0.3	3.06e-6	Homocysteine levels;
SARC	cis	rs11122272	0.735	rs2572263	chr1:231509408	C/T	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs2120243	0.508	rs4435581	chr3:157096217	G/A	cg24825693	chr3:157122686	VEPH1	-0.46	-6.19	-0.38	2.74e-9	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs9398803	0.678	rs9388500	chr6:126876580	C/G	cg19875578	chr6:126661172	C6orf173	0.63	8.62	0.49	1e-15	Male-pattern baldness;
SARC	cis	rs7666738	0.791	rs13120773	chr4:98972589	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4689388	0.926	rs4688986	chr4:6285797	C/A	cg14416269	chr4:6271139	WFS1	0.37	5.78	0.35	2.42e-8	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs477895	0.938	rs28395875	chr11:64024048	G/C	cg04317338	chr11:64019027	PLCB3	0.71	6.38	0.39	9.24e-10	Mean platelet volume;
SARC	cis	rs12950390	0.853	rs66471233	chr17:45867086	C/T	cg24803719	chr17:45855879	NA	-0.46	-7.52	-0.44	1.18e-12	IgG glycosylation;
SARC	cis	rs854765	0.693	rs4924823	chr17:17764502	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.66	-9.79	-0.54	3.47e-19	Total body bone mineral density;
SARC	cis	rs7595412	0.935	rs4850823	chr2:199019445	A/T	cg00208931	chr2:198669586	PLCL1	-0.73	-5.85	-0.36	1.63e-8	Hip bone size;
SARC	cis	rs2635047	1.000	rs2684841	chr18:44724262	C/T	cg19077165	chr18:44547161	KATNAL2	-0.37	-4.98	-0.31	1.23e-6	Educational attainment;
SARC	cis	rs6901004	0.803	rs405948	chr6:111540372	C/T	cg15721981	chr6:111408429	SLC16A10	-0.44	-5.18	-0.32	4.81e-7	Blood metabolite levels;
SARC	cis	rs4595586	0.546	rs10876163	chr12:39244915	G/A	cg26384229	chr12:38710491	ALG10B	0.69	8.56	0.49	1.58e-15	Morning vs. evening chronotype;
SARC	cis	rs2952156	0.920	rs11078919	chr17:37835755	T/C	cg07936489	chr17:37558343	FBXL20	-0.41	-5.29	-0.33	2.84e-7	Asthma;
SARC	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg17971929	chr21:40555470	PSMG1	0.98	13.68	0.67	1.14e-31	Cognitive function;
SARC	cis	rs9902453	0.791	rs3115086	chr17:28025949	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	7.02	0.42	2.45e-11	Coffee consumption (cups per day);
SARC	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg05872129	chr22:39784769	NA	-0.42	-5.88	-0.36	1.38e-8	Intelligence (multi-trait analysis);
SARC	trans	rs10519937	0.935	rs17165090	chr5:126740316	G/A	cg26526953	chr19:1921199	SCAMP4	0.6	6.26	0.38	1.79e-9	IgG glycosylation;
SARC	cis	rs9790314	0.572	rs13073571	chr3:160665720	G/A	cg04691961	chr3:161091175	C3orf57	0.61	8.47	0.49	2.72e-15	Morning vs. evening chronotype;
SARC	cis	rs1801251	1.000	rs6746294	chr2:233583050	C/G	cg25237894	chr2:233734115	C2orf82	-0.42	-5.41	-0.33	1.56e-7	Coronary artery disease;
SARC	cis	rs116979167	0.514	rs1706915	chr7:105196437	A/G	cg19920283	chr7:105172520	RINT1	0.55	5.64	0.35	4.99e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg06212747	chr3:49208901	KLHDC8B	0.51	6.48	0.39	5.37e-10	Resting heart rate;
SARC	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.8	-11.67	-0.61	4.36e-25	Menarche (age at onset);
SARC	cis	rs9902453	0.933	rs1128156	chr17:28513176	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	6.66	0.4	1.97e-10	Coffee consumption (cups per day);
SARC	cis	rs36051895	0.603	rs1590804	chr9:5177573	T/C	cg02405213	chr9:5042618	JAK2	-0.45	-5.42	-0.33	1.48e-7	Pediatric autoimmune diseases;
SARC	cis	rs453301	0.686	rs11787026	chr8:8902371	A/T	cg11608241	chr8:8085544	FLJ10661	0.42	5.26	0.33	3.33e-7	Joint mobility (Beighton score);
SARC	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.64	4.74	0.3	3.75e-6	Initial pursuit acceleration;
SARC	cis	rs7197653	0.748	rs2279538	chr16:68397106	C/G	cg05110241	chr16:68378359	PRMT7	-0.67	-6.57	-0.4	3.28e-10	Magnesium levels;
SARC	cis	rs889312	1.000	rs889312	chr5:56031884	C/A	cg14703610	chr5:56206110	C5orf35	0.41	4.75	0.3	3.61e-6	Breast cancer;Breast cancer (early onset);
SARC	cis	rs11122272	0.701	rs7414807	chr1:231476874	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.55	-0.53	1.94e-18	Hemoglobin concentration;
SARC	cis	rs9398803	0.589	rs853965	chr6:127036174	C/T	cg19875578	chr6:126661172	C6orf173	-0.64	-8.92	-0.5	1.4e-16	Male-pattern baldness;
SARC	cis	rs3820928	0.874	rs13423714	chr2:227896652	C/G	cg05526886	chr2:227700861	RHBDD1	0.46	5.45	0.34	1.26e-7	Pulmonary function;
SARC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.54	6.14	0.37	3.48e-9	Prudent dietary pattern;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg26628795	chr2:111435723	BUB1	0.48	6.29	0.38	1.58e-9	Chemerin levels;
SARC	cis	rs453301	0.624	rs4841083	chr8:8870428	A/G	cg06636001	chr8:8085503	FLJ10661	0.44	5.65	0.35	4.78e-8	Joint mobility (Beighton score);
SARC	trans	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.52	6.84	0.41	6.75e-11	Brugada syndrome;
SARC	cis	rs11583043	0.575	rs7528842	chr1:101583663	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.45	-5.2	-0.32	4.35e-7	Ulcerative colitis;Inflammatory bowel disease;
SARC	trans	rs61931739	0.517	rs11052980	chr12:34036036	T/C	cg13010199	chr12:38710504	ALG10B	0.67	9.22	0.52	1.77e-17	Morning vs. evening chronotype;
SARC	cis	rs2153535	0.580	rs6912193	chr6:8456306	T/G	cg07606381	chr6:8435919	SLC35B3	0.75	10.66	0.57	7.43e-22	Motion sickness;
SARC	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.47	5.9	0.36	1.29e-8	Tonsillectomy;
SARC	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg26335602	chr6:28129616	ZNF389	0.53	5.81	0.36	2.05e-8	Depression;
SARC	cis	rs7843479	0.965	rs11135763	chr8:21813962	A/G	cg17168535	chr8:21777572	XPO7	0.61	7.92	0.46	9.5e-14	Mean corpuscular volume;
SARC	cis	rs11249608	0.789	rs7700958	chr5:178436617	G/A	cg21905437	chr5:178450457	ZNF879	0.49	6.39	0.39	9e-10	Pubertal anthropometrics;
SARC	cis	rs7044106	0.718	rs1981021	chr9:123388393	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	8.99	0.51	8.91e-17	Hip circumference adjusted for BMI;
SARC	cis	rs425277	1.000	rs262665	chr1:2083173	A/G	cg21442419	chr1:2182373	SKI	-0.52	-6.64	-0.4	2.22e-10	Height;
SARC	cis	rs1055129	0.560	rs2666003	chr17:73942976	G/A	cg14829360	chr17:73884958	NA	-0.57	-8.65	-0.49	8.53e-16	White matter hyperintensity burden;
SARC	cis	rs6912958	0.559	rs242287	chr6:88071825	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.34	5.68	0.35	4.1e-8	Monocyte percentage of white cells;
SARC	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg27266027	chr21:40555129	PSMG1	-0.5	-5.39	-0.33	1.73e-7	Cognitive function;
SARC	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.57	7.51	0.44	1.24e-12	Menarche (age at onset);
SARC	cis	rs10088262	0.629	rs7827665	chr8:124804190	G/A	cg20713898	chr8:124780851	FAM91A1	-0.64	-7.16	-0.42	1.07e-11	Pancreatic cancer;
SARC	cis	rs7959452	0.868	rs12812860	chr12:69746671	T/C	cg14784868	chr12:69753453	YEATS4	0.4	5.19	0.32	4.63e-7	Blood protein levels;
SARC	cis	rs1371867	0.775	rs3020183	chr8:101233297	A/T	cg11906718	chr8:101322791	RNF19A	-0.68	-8.69	-0.49	6.65e-16	Atrioventricular conduction;
SARC	cis	rs881375	0.678	rs2416804	chr9:123676396	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.42	-5.14	-0.32	5.9e-7	Rheumatoid arthritis;
SARC	cis	rs2439831	0.867	rs16957627	chr15:43642657	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.76	7.92	0.46	9.46e-14	Lung cancer in ever smokers;
SARC	cis	rs9916302	0.851	rs9909064	chr17:37500434	G/T	cg00129232	chr17:37814104	STARD3	0.6	7.36	0.43	3.15e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs10782582	0.593	rs17848068	chr1:76190216	G/A	cg10523679	chr1:76189770	ACADM	-0.43	-5.42	-0.33	1.49e-7	Daytime sleep phenotypes;
SARC	cis	rs11838776	0.586	rs750598	chr13:111028978	C/T	cg05272587	chr13:111038400	COL4A2	-0.38	-5.86	-0.36	1.54e-8	Coronary artery disease;
SARC	cis	rs3733585	0.673	rs4580649	chr4:9948461	G/A	cg11266682	chr4:10021025	SLC2A9	-0.37	-6.31	-0.38	1.4e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg00149659	chr3:10157352	C3orf10	0.74	7.17	0.43	9.81e-12	Alzheimer's disease;
SARC	cis	rs6570726	0.935	rs453609	chr6:145812332	T/C	cg23711669	chr6:146136114	FBXO30	0.78	11.91	0.62	7.29e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10979	1.000	rs9386034	chr6:143890572	T/G	cg25407410	chr6:143891975	LOC285740	-0.65	-8.8	-0.5	3.16e-16	Hypospadias;
SARC	cis	rs986417	1.000	rs986417	chr14:60858761	C/T	cg27398547	chr14:60952738	C14orf39	-0.86	-7.8	-0.45	2.09e-13	Gut microbiota (bacterial taxa);
SARC	cis	rs8114671	0.869	rs1544047	chr20:33670753	T/C	cg24642439	chr20:33292090	TP53INP2	-0.5	-5.85	-0.36	1.66e-8	Height;
SARC	cis	rs2204008	0.506	rs11495470	chr12:38026904	C/T	cg13010199	chr12:38710504	ALG10B	0.74	9.7	0.54	6.52e-19	Bladder cancer;
SARC	cis	rs6840360	0.571	rs7678080	chr4:152557350	A/G	cg22705602	chr4:152727874	NA	-0.41	-6.44	-0.39	6.64e-10	Intelligence (multi-trait analysis);
SARC	cis	rs698813	0.642	rs1837702	chr2:44492444	T/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	6.04	0.37	6.11e-9	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs10927875	0.632	rs4661667	chr1:16162731	C/T	cg07117364	chr1:16154769	NA	-0.44	-5.35	-0.33	2.08e-7	Dilated cardiomyopathy;
SARC	cis	rs921968	0.643	rs1516086	chr2:219431535	C/T	cg02176678	chr2:219576539	TTLL4	0.4	6.0	0.37	7.47e-9	Mean corpuscular hemoglobin concentration;
SARC	cis	rs2599510	0.783	rs2568464	chr2:32848658	C/T	cg02381751	chr2:32503542	YIPF4	-0.41	-5.03	-0.31	9.71e-7	Interleukin-18 levels;
SARC	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.22	0.38	2.3e-9	Electroencephalogram traits;
SARC	cis	rs7000551	0.681	rs2461488	chr8:22371858	G/A	cg12081754	chr8:22256438	SLC39A14	0.55	7.81	0.46	1.96e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg22800045	chr5:56110881	MAP3K1	0.64	5.87	0.36	1.49e-8	Type 2 diabetes;
SARC	cis	rs9420	0.961	rs11602109	chr11:57435296	G/A	cg19752551	chr11:57585705	CTNND1	-0.5	-6.77	-0.41	1.02e-10	Schizophrenia;
SARC	cis	rs7666738	1.000	rs1426673	chr4:98924024	G/A	cg05340658	chr4:99064831	C4orf37	0.55	6.93	0.41	4.1e-11	Colonoscopy-negative controls vs population controls;
SARC	trans	rs641862	1	rs641862	chr13:110790232	C/T	cg22945824	chr13:114115194	DCUN1D2	-0.97	-7.61	-0.45	6.66e-13	Obesity-related traits;
SARC	cis	rs2645424	0.550	rs12338	chr8:11710888	G/C	cg21281001	chr8:11725306	CTSB	0.49	6.12	0.37	3.92e-9	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
SARC	cis	rs1057510	0.858	rs11064260	chr12:6685269	T/A	cg19104830	chr12:7342086	PEX5	0.5	5.06	0.31	8.35e-7	Myopia (pathological);
SARC	trans	rs9329221	0.683	rs525726	chr8:9887797	G/C	cg06636001	chr8:8085503	FLJ10661	-0.7	-10.01	-0.55	7.43e-20	Neuroticism;
SARC	cis	rs6840360	0.571	rs875668	chr4:152525661	C/T	cg22705602	chr4:152727874	NA	-0.43	-6.73	-0.4	1.28e-10	Intelligence (multi-trait analysis);
SARC	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.77	7.62	0.45	6.49e-13	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs847851	0.569	rs3800439	chr6:34961406	T/C	cg13137465	chr6:34857473	ANKS1A	0.6	4.83	0.3	2.48e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs668210	0.793	rs590531	chr11:65773939	C/A	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.66	-6.46	-0.39	5.96e-10	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg00933542	chr6:150070202	PCMT1	0.34	5.95	0.36	9.85e-9	Lung cancer;
SARC	cis	rs7000551	0.532	rs55726237	chr8:22252985	C/T	cg12081754	chr8:22256438	SLC39A14	0.83	11.66	0.61	4.65e-25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs7618915	0.773	rs10510760	chr3:52650348	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	5.5	0.34	1.01e-7	Bipolar disorder;
SARC	cis	rs10504229	0.679	rs72649107	chr8:58030453	C/A	cg20607798	chr8:58055168	NA	0.55	5.1	0.32	7.12e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs17376456	0.825	rs10075217	chr5:93176774	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.68	5.79	0.35	2.3e-8	Diabetic retinopathy;
SARC	cis	rs7833790	1.000	rs1463259	chr8:82737745	A/G	cg17211192	chr8:82754475	SNX16	-0.58	-6.61	-0.4	2.6e-10	Diastolic blood pressure;
SARC	trans	rs17221829	0.733	rs11018668	chr11:89356178	C/T	cg25015290	chr10:14996185	DCLRE1C	-0.49	-6.59	-0.4	2.85e-10	Anxiety in major depressive disorder;
SARC	cis	rs6500602	0.727	rs11076837	chr16:4569440	C/T	cg08645402	chr16:4508243	NA	0.42	5.59	0.34	6.18e-8	Schizophrenia;
SARC	cis	rs1348850	0.558	rs4337505	chr2:178529714	A/T	cg22681709	chr2:178499509	PDE11A	-0.36	-5.03	-0.31	9.82e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg18099408	chr3:52552593	STAB1	-0.4	-5.27	-0.33	3.06e-7	Electroencephalogram traits;
SARC	cis	rs16986825	0.546	rs9625612	chr22:29258140	T/A	cg02153584	chr22:29168773	CCDC117	0.68	7.28	0.43	4.95e-12	Pancreatic cancer;
SARC	cis	rs9397240	0.789	rs12193765	chr6:155563584	C/T	cg07943832	chr6:155568918	TIAM2	-0.57	-5.27	-0.33	3.09e-7	Life satisfaction;
SARC	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.34	-4.89	-0.31	1.86e-6	Longevity;Endometriosis;
SARC	cis	rs965469	1.000	rs6051705	chr20:3253143	G/A	cg25506879	chr20:3388711	C20orf194	-0.5	-5.08	-0.32	7.59e-7	IFN-related cytopenia;
SARC	cis	rs2839186	0.605	rs2839174	chr21:47676934	T/C	cg03841560	chr21:47649172	MCM3APAS;LSS	0.36	4.78	0.3	3.18e-6	Testicular germ cell tumor;
SARC	cis	rs7005380	0.531	rs7018038	chr8:120934904	T/C	cg21744203	chr8:120868354	DSCC1	0.45	5.29	0.33	2.75e-7	Interstitial lung disease;
SARC	cis	rs4805272	0.512	rs4805278	chr19:29336664	C/T	cg04546413	chr19:29218101	NA	0.46	5.17	0.32	5.12e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.39	4.75	0.3	3.55e-6	Tonsillectomy;
SARC	cis	rs751728	1.000	rs4713684	chr6:33766488	T/C	cg25922239	chr6:33757077	LEMD2	0.78	10.26	0.56	1.25e-20	Crohn's disease;
SARC	cis	rs12142240	0.698	rs1475389	chr1:46816429	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-5.46	-0.34	1.22e-7	Menopause (age at onset);
SARC	cis	rs870825	0.860	rs72703518	chr4:185602109	T/C	cg04058563	chr4:185651563	MLF1IP	0.8	9.84	0.54	2.51e-19	Blood protein levels;
SARC	cis	rs5753618	0.561	rs4141404	chr22:31675185	A/C	cg07713946	chr22:31675144	LIMK2	-0.38	-5.32	-0.33	2.44e-7	Colorectal cancer;
SARC	cis	rs1691799	0.806	rs1168319	chr12:66744857	T/A	cg16791601	chr12:66731901	HELB	-0.71	-10.66	-0.57	7.05e-22	White blood cell count (basophil);
SARC	trans	rs3942852	0.568	rs10769312	chr11:48094769	C/T	cg15704280	chr7:45808275	SEPT13	0.67	8.76	0.5	4.06e-16	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs2251381	0.750	rs8129616	chr21:30520085	C/T	cg08807101	chr21:30365312	RNF160	-0.75	-9.6	-0.53	1.36e-18	Selective IgA deficiency;
SARC	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-7.01	-0.42	2.61e-11	Gut microbiome composition (summer);
SARC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.46	0.8	5.92e-54	Prudent dietary pattern;
SARC	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg07157834	chr1:205819609	PM20D1	0.43	5.03	0.31	9.75e-7	Prostate-specific antigen levels;
SARC	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg02725872	chr8:58115012	NA	-0.34	-5.38	-0.33	1.78e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2832191	0.755	rs2832192	chr21:30491173	G/T	cg24692254	chr21:30365293	RNF160	-0.85	-11.91	-0.62	7.22e-26	Dental caries;
SARC	cis	rs6088580	0.634	rs6088478	chr20:32971719	T/C	cg08999081	chr20:33150536	PIGU	-0.42	-6.39	-0.39	9.12e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs7712401	0.562	rs30062	chr5:122296376	C/G	cg19412675	chr5:122181750	SNX24	0.4	5.13	0.32	5.98e-7	Mean platelet volume;
SARC	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg11987759	chr7:65425863	GUSB	0.37	4.77	0.3	3.18e-6	Calcium levels;
SARC	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg06221963	chr1:154839813	KCNN3	-0.53	-8.45	-0.48	3.08e-15	Prostate cancer;
SARC	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg19223190	chr17:80058835	NA	0.45	6.27	0.38	1.72e-9	Life satisfaction;
SARC	cis	rs11785400	1.000	rs4736368	chr8:143748528	G/C	cg10596483	chr8:143751796	JRK	0.65	8.68	0.49	6.74e-16	Schizophrenia;
SARC	cis	rs1729951	0.545	rs1097288	chr3:136693721	C/T	cg15507776	chr3:136538369	TMEM22	0.5	5.6	0.34	6.04e-8	Neuroticism;
SARC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.67	6.4	0.39	8.37e-10	Platelet count;
SARC	cis	rs412050	0.793	rs74576380	chr22:22283280	A/G	cg17089214	chr22:22089827	YPEL1	0.57	5.3	0.33	2.65e-7	Attention deficit hyperactivity disorder;
SARC	cis	rs72781680	1.000	rs12616985	chr2:24165511	A/C	cg06627628	chr2:24431161	ITSN2	-0.69	-6.48	-0.39	5.36e-10	Lymphocyte counts;
SARC	cis	rs1008375	1.000	rs10939750	chr4:17692422	C/G	cg02297831	chr4:17616191	MED28	0.39	4.81	0.3	2.67e-6	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs875971	0.545	rs1796222	chr7:66057154	T/C	cg11764359	chr7:65958608	NA	-0.6	-5.83	-0.36	1.83e-8	Aortic root size;
SARC	cis	rs709400	0.663	rs17679475	chr14:103916958	A/G	cg12935359	chr14:103987150	CKB	-0.37	-5.47	-0.34	1.17e-7	Body mass index;
SARC	cis	rs9325144	0.555	rs2387855	chr12:38687964	T/G	cg10518543	chr12:38710700	ALG10B	0.38	4.88	0.3	2.01e-6	Morning vs. evening chronotype;
SARC	cis	rs4803468	1.000	rs6508977	chr19:41909346	A/G	cg14132834	chr19:41945861	ATP5SL	-0.57	-7.53	-0.44	1.14e-12	Height;
SARC	cis	rs12348691	0.503	rs4743138	chr9:100614296	C/T	cg13688889	chr9:100608707	NA	0.5	5.31	0.33	2.58e-7	Alopecia areata;
SARC	cis	rs4713118	0.784	rs9468219	chr6:27731755	C/A	cg17221315	chr6:27791827	HIST1H4J	0.51	5.56	0.34	7.36e-8	Parkinson's disease;
SARC	cis	rs765787	0.530	rs4544188	chr15:45535393	C/A	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.51e-10	Uric acid levels;
SARC	cis	rs6704644	0.656	rs11694654	chr2:234332343	G/A	cg27060346	chr2:234359958	DGKD	-0.68	-5.03	-0.31	9.97e-7	Bilirubin levels;
SARC	cis	rs2421770	0.561	rs11033081	chr11:35363885	C/G	cg13971030	chr11:35366721	SLC1A2	-0.37	-4.97	-0.31	1.28e-6	Staphylococcus aureus nasal carriage (persistent);
SARC	cis	rs11969893	0.850	rs9390713	chr6:101424262	G/A	cg12253828	chr6:101329408	ASCC3	1.03	6.07	0.37	5.28e-9	Economic and political preferences (immigration/crime);
SARC	cis	rs9916302	0.706	rs667239	chr17:37442241	A/G	cg07936489	chr17:37558343	FBXL20	0.72	8.65	0.49	8.47e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs2242116	0.796	rs7623898	chr3:46974172	C/T	cg02527881	chr3:46936655	PTH1R	0.37	5.73	0.35	3.15e-8	Birth weight;
SARC	cis	rs1865760	0.566	rs9295686	chr6:26081983	G/C	cg18357526	chr6:26021779	HIST1H4A	0.41	4.98	0.31	1.23e-6	Height;
SARC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.53	0.53	2.2e-18	Prudent dietary pattern;
SARC	cis	rs7551222	0.752	rs4252725	chr1:204513256	A/G	cg20240347	chr1:204465584	NA	-0.36	-6.24	-0.38	2.04e-9	Schizophrenia;
SARC	cis	rs651907	0.557	rs7612283	chr3:101434919	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	6.37	0.39	9.84e-10	Colorectal cancer;
SARC	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg00933542	chr6:150070202	PCMT1	0.31	5.29	0.33	2.83e-7	Lung cancer;
SARC	cis	rs883565	0.569	rs1274968	chr3:39170090	A/G	cg26331595	chr3:39149181	GORASP1;TTC21A	0.46	5.37	0.33	1.9e-7	Handedness;
SARC	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg10435706	chr6:150039699	LATS1	0.37	4.87	0.3	2.04e-6	Lung cancer;
SARC	cis	rs2153535	0.526	rs9406179	chr6:8538224	G/A	cg07606381	chr6:8435919	SLC35B3	0.77	10.96	0.58	7.97e-23	Motion sickness;
SARC	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	8.28	0.48	9.57e-15	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs796364	0.906	rs1658810	chr2:200816382	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.78	7.11	0.42	1.45e-11	Schizophrenia;
SARC	cis	rs1707322	1.000	rs9429186	chr1:46539687	C/T	cg03146154	chr1:46216737	IPP	-0.48	-5.64	-0.35	4.92e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg08859206	chr1:53392774	SCP2	0.38	5.45	0.34	1.29e-7	Monocyte count;
SARC	cis	rs6582630	0.638	rs35864536	chr12:38472255	T/A	cg26384229	chr12:38710491	ALG10B	-0.56	-7.06	-0.42	1.89e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg08219700	chr8:58056026	NA	0.46	4.81	0.3	2.75e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs10089	0.953	rs17164427	chr5:127361736	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.87	-11.12	-0.59	2.45e-23	Ileal carcinoids;
SARC	cis	rs668210	0.793	rs677350	chr11:65761967	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	0.71	7.71	0.45	3.67e-13	Cerebrospinal fluid biomarker levels;
SARC	cis	rs11155671	0.530	rs4870080	chr6:150202644	T/C	cg00933542	chr6:150070202	PCMT1	0.29	4.75	0.3	3.58e-6	Testicular germ cell tumor;
SARC	cis	rs9916302	0.904	rs2338797	chr17:37548241	G/A	cg00129232	chr17:37814104	STARD3	0.62	7.59	0.45	7.72e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs7223966	1.000	rs11079508	chr17:61750066	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.51	-5.36	-0.33	2e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7246657	0.943	rs2112923	chr19:37940327	C/T	cg23950597	chr19:37808831	NA	-0.57	-5.67	-0.35	4.24e-8	Coronary artery calcification;
SARC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg11494091	chr17:61959527	GH2	0.55	7.99	0.46	6.3e-14	Prudent dietary pattern;
SARC	cis	rs1580019	0.961	rs1610143	chr7:32498331	C/T	cg14728415	chr7:32535168	LSM5;AVL9	0.43	5.04	0.31	9.3e-7	Cognitive ability;
SARC	cis	rs1920116	0.778	rs11717389	chr3:169566247	T/C	cg14222479	chr3:169487675	ARPM1	0.45	5.26	0.33	3.18e-7	Glioma (high-grade);
SARC	trans	rs804280	0.560	rs10503426	chr8:11589383	A/C	cg06636001	chr8:8085503	FLJ10661	0.53	6.58	0.4	3.1e-10	Myopia (pathological);
SARC	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg22496380	chr5:211416	CCDC127	-0.88	-9.35	-0.52	7.72e-18	Breast cancer;
SARC	cis	rs6840360	0.571	rs1822347	chr4:152525319	A/G	cg22705602	chr4:152727874	NA	-0.41	-6.45	-0.39	6.45e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7851660	0.548	rs1156850	chr9:100573164	G/A	cg13688889	chr9:100608707	NA	-0.45	-5.23	-0.32	3.85e-7	Strep throat;
SARC	cis	rs7589342	0.509	rs10168944	chr2:106386067	T/C	cg16077055	chr2:106428750	NCK2	0.3	6.1	0.37	4.48e-9	Addiction;
SARC	cis	rs3126085	0.778	rs9887901	chr1:152248552	A/C	cg26876637	chr1:152193138	HRNR	0.45	5.21	0.32	4.07e-7	Atopic dermatitis;
SARC	cis	rs1008375	1.000	rs10027755	chr4:17615954	G/C	cg16339924	chr4:17578868	LAP3	0.66	8.61	0.49	1.13e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4243830	1.000	rs41278016	chr1:6584045	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	1.04	7.97	0.46	7.01e-14	Body mass index;
SARC	cis	rs16866061	1.000	rs17480230	chr2:225399864	G/A	cg12698349	chr2:225449008	CUL3	0.72	10.49	0.57	2.52e-21	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	cis	rs55883249	1.000	rs62119391	chr2:9712272	A/G	cg23886495	chr2:9695866	ADAM17	0.7	6.95	0.41	3.59e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs147499554	1	rs147499554	chr15:78900650	C/T	cg18825076	chr15:78729989	IREB2	-0.43	-5.11	-0.32	6.81e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg03354898	chr7:1950403	MAD1L1	-0.38	-5.15	-0.32	5.59e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs7666738	0.546	rs2098935	chr4:98914376	A/G	cg05340658	chr4:99064831	C4orf37	0.59	7.24	0.43	6.6e-12	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg21574574	chr3:132400646	NPHP3	0.44	6.29	0.38	1.52e-9	Thyroid stimulating hormone;
SARC	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg05368731	chr17:41323189	NBR1	0.79	9.75	0.54	4.8e-19	Menopause (age at onset);
SARC	cis	rs3820928	0.874	rs10174073	chr2:227794944	A/G	cg11843606	chr2:227700838	RHBDD1	-0.57	-7.22	-0.43	7.36e-12	Pulmonary function;
SARC	cis	rs1559088	0.600	rs7259117	chr19:33550113	G/T	cg17764715	chr19:33622953	WDR88	0.59	7.93	0.46	9.28e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg24846343	chr22:24311635	DDTL	0.57	8.13	0.47	2.6e-14	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7178572	0.568	rs1446312	chr15:77412189	G/C	cg22256960	chr15:77711686	NA	-0.51	-5.43	-0.33	1.44e-7	Type 2 diabetes;
SARC	cis	rs7937682	0.575	rs34558891	chr11:111737912	C/T	cg09085632	chr11:111637200	PPP2R1B	0.78	10.33	0.56	7.51e-21	Primary sclerosing cholangitis;
SARC	cis	rs1957429	0.522	rs57319601	chr14:65415743	C/T	cg23373153	chr14:65346875	NA	-0.72	-4.91	-0.31	1.7e-6	Pediatric areal bone mineral density (radius);
SARC	cis	rs6693567	0.545	rs1694386	chr1:150377965	C/G	cg09579323	chr1:150459698	TARS2	0.46	5.84	0.36	1.74e-8	Migraine;
SARC	cis	rs6912958	0.559	rs1201409	chr6:88055264	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.36	6.25	0.38	1.93e-9	Monocyte percentage of white cells;
SARC	cis	rs2777491	0.874	rs28716108	chr15:41655523	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.87	-12.95	-0.65	2.89e-29	Ulcerative colitis;
SARC	cis	rs6084875	0.733	rs6052854	chr20:4742399	A/G	cg05143360	chr20:4741328	NA	0.4	4.86	0.3	2.2e-6	Systemic lupus erythematosus;
SARC	cis	rs4243830	0.850	rs12029123	chr1:6607142	C/T	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.59	-4.85	-0.3	2.24e-6	Body mass index;
SARC	cis	rs2304069	0.909	rs30831	chr5:149359053	C/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	-0.66	-6.43	-0.39	7.26e-10	HIV-1 control;
SARC	cis	rs4660306	0.677	rs781059	chr1:45934562	A/G	cg24296786	chr1:45957014	TESK2	0.53	5.39	0.33	1.73e-7	Homocysteine levels;
SARC	cis	rs950169	0.922	rs4842940	chr15:84831225	C/T	cg24253500	chr15:84953950	NA	-0.35	-4.97	-0.31	1.27e-6	Schizophrenia;
SARC	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.45	-5.57	-0.34	6.97e-8	Lymphocyte counts;
SARC	cis	rs2115630	0.905	rs1975277	chr15:85329558	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.45	-5.38	-0.33	1.82e-7	P wave terminal force;
SARC	cis	rs7264396	0.563	rs6058296	chr20:34269225	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-6.53	-0.39	3.96e-10	Total cholesterol levels;
SARC	cis	rs17401966	1.000	rs7520651	chr1:10329872	G/A	cg15208524	chr1:10270712	KIF1B	0.59	6.8	0.41	8.47e-11	Hepatocellular carcinoma;
SARC	cis	rs921968	0.643	rs4674324	chr2:219523433	T/G	cg02176678	chr2:219576539	TTLL4	0.36	5.39	0.33	1.76e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs2153535	0.601	rs1928183	chr6:8530018	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	8.57	0.49	1.43e-15	Motion sickness;
SARC	cis	rs12579753	0.692	rs9943807	chr12:82279404	T/A	cg07988820	chr12:82153109	PPFIA2	-0.47	-5.65	-0.35	4.74e-8	Resting heart rate;
SARC	cis	rs71277158	0.688	rs77248289	chr3:169905625	C/T	cg04067573	chr3:169899625	PHC3	0.57	4.81	0.3	2.73e-6	Prostate cancer;
SARC	cis	rs2814982	0.605	rs114672114	chr6:34480065	A/G	cg17674042	chr6:34482479	PACSIN1	-0.58	-5.0	-0.31	1.1e-6	Cholesterol, total;Total cholesterol levels;
SARC	cis	rs12638540	0.543	rs12487678	chr3:32603358	A/C	cg11605617	chr3:32612461	DYNC1LI1	0.71	6.1	0.37	4.4e-9	Mortality in heart failure;
SARC	cis	rs6570726	0.935	rs368848	chr6:145855281	A/T	cg23711669	chr6:146136114	FBXO30	0.78	12.03	0.62	3.08e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9815354	1.000	rs73077367	chr3:41851959	G/A	cg03022575	chr3:42003672	ULK4	0.55	5.3	0.33	2.73e-7	Pulse pressure;Diastolic blood pressure;
SARC	trans	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg20587970	chr11:113659929	NA	0.97	8.67	0.49	7.47e-16	Hip circumference adjusted for BMI;
SARC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg13397359	chr6:42928475	GNMT	0.6	8.12	0.47	2.67e-14	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg26338869	chr17:61819248	STRADA	0.8	10.83	0.58	2.04e-22	Prudent dietary pattern;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg03871526	chr3:142447949	TRPC1	-0.52	-6.56	-0.39	3.5e-10	Alcohol dependence;
SARC	cis	rs9911578	0.757	rs8081906	chr17:56631907	A/T	cg12560992	chr17:57184187	TRIM37	-0.75	-9.01	-0.51	7.48e-17	Intelligence (multi-trait analysis);
SARC	cis	rs2235544	0.565	rs664848	chr1:54468321	C/T	cg10336722	chr1:54665764	CYB5RL;MRPL37	-0.38	-4.74	-0.3	3.66e-6	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
SARC	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg03060546	chr3:49711283	APEH	-0.45	-5.38	-0.33	1.82e-7	Parkinson's disease;
SARC	trans	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg21659725	chr3:3221576	CRBN	-0.54	-7.22	-0.43	7.48e-12	Intelligence (multi-trait analysis);
SARC	cis	rs16976116	0.901	rs28433503	chr15:55499857	T/C	cg17854078	chr15:55489399	RSL24D1	0.66	6.53	0.39	4.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7824557	0.628	rs6601580	chr8:11193736	T/G	cg21775007	chr8:11205619	TDH	0.65	8.35	0.48	6.2e-15	Retinal vascular caliber;
SARC	cis	rs2204008	0.748	rs7312204	chr12:38334909	T/C	cg26384229	chr12:38710491	ALG10B	0.86	12.08	0.62	2.05e-26	Bladder cancer;
SARC	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg11366901	chr6:160182831	ACAT2	0.99	10.71	0.57	5.04e-22	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs854765	0.583	rs67253360	chr17:17828973	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	9.75	0.54	4.62e-19	Total body bone mineral density;
SARC	cis	rs3857536	0.813	rs7766786	chr6:66932889	C/A	cg07460842	chr6:66804631	NA	-0.51	-5.75	-0.35	2.79e-8	Blood trace element (Cu levels);
SARC	trans	rs8073060	0.586	rs225265	chr17:33961972	C/T	cg19694781	chr19:47549865	TMEM160	-0.68	-6.84	-0.41	7.09e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs11690935	1.000	rs3795999	chr2:172544483	A/G	cg13550731	chr2:172543902	DYNC1I2	0.99	15.05	0.7	3.14e-36	Schizophrenia;
SARC	cis	rs10484885	0.824	rs112817281	chr6:90555658	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.61	-5.23	-0.32	3.71e-7	QRS interval (sulfonylurea treatment interaction);
SARC	cis	rs6448317	0.556	rs4697496	chr4:24907809	C/T	cg21108841	chr4:24914750	CCDC149	0.49	4.79	0.3	3.04e-6	Heschl's gyrus morphology;
SARC	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg25894440	chr7:65020034	NA	-0.73	-5.48	-0.34	1.09e-7	Diabetic kidney disease;
SARC	cis	rs2011503	1.000	rs4808206	chr19:19645645	C/A	cg03709012	chr19:19516395	GATAD2A	0.6	5.29	0.33	2.8e-7	Bipolar disorder;
SARC	cis	rs798554	0.567	rs1182190	chr7:2869391	A/G	cg13628971	chr7:2884303	GNA12	0.41	4.97	0.31	1.27e-6	Height;
SARC	cis	rs7412746	0.658	rs72704682	chr1:150897677	A/T	cg13175981	chr1:150552382	MCL1	-0.48	-5.86	-0.36	1.57e-8	Melanoma;
SARC	cis	rs3820928	0.874	rs10183633	chr2:227887828	A/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-6.49	-0.39	5.11e-10	Pulmonary function;
SARC	cis	rs2865126	0.818	rs35033671	chr18:10759840	C/A	cg21165219	chr18:10698044	FAM38B	0.5	4.98	0.31	1.24e-6	Metabolite levels (5-HIAA/ MHPG Ratio);
SARC	cis	rs12586317	0.534	rs2273157	chr14:35438836	A/G	cg16230307	chr14:35515116	FAM177A1	0.77	9.65	0.53	9.51e-19	Psoriasis;
SARC	cis	rs929354	0.772	rs10229630	chr7:157004790	C/T	cg05182265	chr7:156933206	UBE3C	-0.33	-5.1	-0.32	7.08e-7	Body mass index;
SARC	cis	rs10463316	0.894	rs7710277	chr5:150767405	T/C	cg03212797	chr5:150827313	SLC36A1	-0.44	-5.26	-0.33	3.34e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs11758351	1.000	rs80259160	chr6:26190199	C/T	cg23601095	chr6:26197514	HIST1H3D	0.64	5.51	0.34	9.33e-8	Gout;Renal underexcretion gout;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg05414835	chr15:59225898	SLTM	-0.8	-6.75	-0.4	1.19e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1448094	0.512	rs61930864	chr12:86246740	G/A	cg02569458	chr12:86230093	RASSF9	0.38	5.42	0.33	1.52e-7	Major depressive disorder;
SARC	cis	rs796364	0.756	rs2949006	chr2:200715388	T/G	cg23649088	chr2:200775458	C2orf69	0.57	5.03	0.31	9.8e-7	Schizophrenia;
SARC	trans	rs1994135	0.617	rs10844642	chr12:33730368	A/C	cg13010199	chr12:38710504	ALG10B	0.61	6.99	0.42	2.86e-11	Resting heart rate;
SARC	cis	rs832540	0.898	rs252890	chr5:56226410	T/C	cg14703610	chr5:56206110	C5orf35	0.52	6.56	0.4	3.37e-10	Coronary artery disease;
SARC	cis	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg26695010	chr11:65641043	EFEMP2	-0.54	-6.99	-0.42	2.88e-11	Eosinophil percentage of white cells;
SARC	cis	rs2976388	0.609	rs2572907	chr8:143801938	G/A	cg06565975	chr8:143823917	SLURP1	0.29	4.99	0.31	1.2e-6	Urinary tract infection frequency;
SARC	cis	rs17376456	0.741	rs7718842	chr5:93480568	G/A	cg25358565	chr5:93447407	FAM172A	1.36	13.76	0.67	6.25e-32	Diabetic retinopathy;
SARC	cis	rs9309473	0.607	rs7560272	chr2:73561485	A/T	cg20560298	chr2:73613845	ALMS1	-0.6	-7.26	-0.43	5.88e-12	Metabolite levels;
SARC	cis	rs981844	0.712	rs11099914	chr4:154743519	C/T	cg14289246	chr4:154710475	SFRP2	-0.48	-5.72	-0.35	3.23e-8	Response to statins (LDL cholesterol change);
SARC	cis	rs4430311	0.723	rs10927075	chr1:243956120	A/T	cg21452805	chr1:244014465	NA	-0.45	-5.82	-0.36	1.92e-8	Post-traumatic stress disorder (asjusted for relatedness);
SARC	cis	rs12762955	0.561	rs6560863	chr10:1013535	C/A	cg18964960	chr10:1102726	WDR37	-0.57	-6.46	-0.39	6.17e-10	Response to angiotensin II receptor blocker therapy;
SARC	cis	rs950169	0.840	rs12905223	chr15:85114268	T/C	cg03959625	chr15:84868606	LOC388152	0.35	4.83	0.3	2.5e-6	Schizophrenia;
SARC	cis	rs9733	0.650	rs2048558	chr1:150571730	A/G	cg13175981	chr1:150552382	MCL1	0.69	9.52	0.53	2.36e-18	Tonsillectomy;
SARC	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.41	-6.18	-0.38	2.86e-9	Menopause (age at onset);
SARC	cis	rs6580649	0.941	rs4760615	chr12:48428150	A/G	cg05342945	chr12:48394962	COL2A1	-0.58	-6.02	-0.37	6.64e-9	Lung cancer;
SARC	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg06634786	chr22:41940651	POLR3H	0.52	6.08	0.37	4.88e-9	Vitiligo;
SARC	cis	rs208520	0.909	rs9354410	chr6:67018584	C/T	cg07460842	chr6:66804631	NA	0.84	8.58	0.49	1.32e-15	Exhaled nitric oxide output;
SARC	cis	rs1348850	0.567	rs4144276	chr2:178523420	T/C	cg22681709	chr2:178499509	PDE11A	-0.36	-5.09	-0.32	7.4e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1580019	0.844	rs1376290	chr7:32486922	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.8	11.31	0.6	6.22e-24	Cognitive ability;
SARC	cis	rs9527	0.590	rs7067663	chr10:104883650	A/G	cg04362960	chr10:104952993	NT5C2	0.43	4.94	0.31	1.47e-6	Arsenic metabolism;
SARC	cis	rs7914558	0.966	rs10786719	chr10:104637992	C/T	cg04362960	chr10:104952993	NT5C2	-0.41	-4.92	-0.31	1.61e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.42	5.14	0.32	5.79e-7	Tonsillectomy;
SARC	cis	rs16976116	0.901	rs1061824	chr15:55495963	T/C	cg11288833	chr15:55489084	RSL24D1	0.63	6.13	0.37	3.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs72945132	0.825	rs7950280	chr11:70213455	G/T	cg00319359	chr11:70116639	PPFIA1	0.67	6.43	0.39	7.22e-10	Coronary artery disease;
SARC	cis	rs7264396	0.635	rs6060703	chr20:34529906	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-7.5	-0.44	1.37e-12	Total cholesterol levels;
SARC	cis	rs9467773	1.000	rs1535277	chr6:26567802	G/T	cg12292205	chr6:26970375	C6orf41	0.45	5.43	0.33	1.45e-7	Intelligence (multi-trait analysis);
SARC	cis	rs34779708	0.966	rs57081218	chr10:35434608	A/G	cg03585969	chr10:35415529	CREM	0.39	4.94	0.31	1.5e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs11997175	0.583	rs17781020	chr8:33850858	C/G	ch.8.33884649F	chr8:33765107	NA	0.43	5.07	0.32	7.99e-7	Body mass index;
SARC	cis	rs1691799	0.867	rs1168347	chr12:66757303	T/C	cg16791601	chr12:66731901	HELB	-0.73	-10.93	-0.58	1.02e-22	White blood cell count (basophil);
SARC	cis	rs7223966	0.960	rs8082651	chr17:61675292	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.51	-5.22	-0.32	3.97e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs796364	0.806	rs6435041	chr2:200867144	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.77	6.78	0.41	9.78e-11	Schizophrenia;
SARC	cis	rs2760061	0.603	rs697762	chr1:228192410	G/A	cg02753203	chr1:228287806	NA	0.79	11.67	0.61	4.33e-25	Diastolic blood pressure;
SARC	cis	rs7216064	0.954	rs8079291	chr17:65887622	A/G	cg12091567	chr17:66097778	LOC651250	-0.64	-6.45	-0.39	6.56e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs7635838	0.892	rs7372723	chr3:11466511	G/A	cg00170343	chr3:11313890	ATG7	0.62	8.4	0.48	4.42e-15	HDL cholesterol;
SARC	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg01316550	chr5:56110833	MAP3K1	0.54	4.92	0.31	1.62e-6	Initial pursuit acceleration;
SARC	cis	rs2985684	1.000	rs56098064	chr14:50105849	T/C	cg04989706	chr14:50066350	PPIL5	-0.52	-5.51	-0.34	9.63e-8	Carotid intima media thickness;
SARC	cis	rs3126085	0.935	rs3126094	chr1:152308243	T/C	cg03465714	chr1:152285911	FLG	0.45	5.44	0.34	1.34e-7	Atopic dermatitis;
SARC	cis	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg25894440	chr7:65020034	NA	-0.78	-6.04	-0.37	6.1e-9	Diabetic kidney disease;
SARC	cis	rs10463554	0.927	rs158396	chr5:102411719	G/A	cg23492399	chr5:102201601	PAM	-0.45	-5.01	-0.31	1.1e-6	Parkinson's disease;
SARC	cis	rs7208859	0.573	rs73267865	chr17:29064204	C/G	cg13385521	chr17:29058706	SUZ12P	0.84	7.31	0.43	4.29e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs7819412	0.775	rs2898257	chr8:10935368	A/C	cg21775007	chr8:11205619	TDH	-0.47	-5.94	-0.36	1.03e-8	Triglycerides;
SARC	cis	rs742614	0.533	rs2747536	chr20:32404128	C/G	cg06304546	chr20:32448765	NA	-0.6	-7.81	-0.46	1.98e-13	Stearic acid (18:0) levels;
SARC	cis	rs12682352	0.602	rs13260419	chr8:8675176	A/G	cg06636001	chr8:8085503	FLJ10661	0.53	6.82	0.41	7.53e-11	Neuroticism;
SARC	cis	rs7762018	0.660	rs41265385	chr6:170068086	C/T	cg13891659	chr6:170190454	C6orf122;C6orf208	0.62	5.02	0.31	1e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg14926445	chr8:58193284	C8orf71	-0.43	-4.8	-0.3	2.84e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs6933660	0.646	rs9383899	chr6:151781022	G/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.72	9.63	0.53	1.06e-18	Menarche (age at onset);
SARC	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg17971929	chr21:40555470	PSMG1	-0.55	-6.89	-0.41	5.08e-11	Menarche (age at onset);
SARC	cis	rs2204008	0.616	rs1607852	chr12:38398125	G/A	cg26384229	chr12:38710491	ALG10B	0.89	12.43	0.63	1.47e-27	Bladder cancer;
SARC	cis	rs3741404	0.620	rs2236648	chr11:63964657	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	9.69	0.54	7.15e-19	Platelet count;
SARC	cis	rs8014204	0.503	rs11621186	chr14:75120628	C/T	cg17347104	chr14:75034677	LTBP2	-0.48	-6.21	-0.38	2.41e-9	Caffeine consumption;
SARC	cis	rs4803468	1.000	rs2569754	chr19:41936734	A/G	cg08477640	chr19:41863820	B9D2	0.42	5.3	0.33	2.64e-7	Height;
SARC	cis	rs9302635	0.513	rs3812987	chr16:72158920	C/A	cg16558253	chr16:72132732	DHX38	-0.55	-7.17	-0.43	1e-11	Blood protein levels;
SARC	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg21747090	chr2:27597821	SNX17	-0.55	-7.61	-0.45	6.95e-13	Total body bone mineral density;
SARC	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg23758822	chr17:41437982	NA	0.91	11.49	0.6	1.7e-24	Menopause (age at onset);
SARC	cis	rs56176327	0.532	rs9849038	chr3:49771990	A/G	cg07636037	chr3:49044803	WDR6	0.59	6.09	0.37	4.62e-9	Intelligence (multi-trait analysis);
SARC	cis	rs921968	0.643	rs590771	chr2:219369851	C/T	cg02176678	chr2:219576539	TTLL4	0.36	5.53	0.34	8.72e-8	Mean corpuscular hemoglobin concentration;
SARC	cis	rs6088590	0.813	rs1884668	chr20:33285514	A/G	cg08999081	chr20:33150536	PIGU	0.43	6.43	0.39	6.98e-10	Coronary artery disease;
SARC	cis	rs6835098	1.000	rs4561909	chr4:174086937	A/T	cg08422745	chr4:174089978	GALNT7	-0.74	-9.42	-0.53	4.67e-18	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs1009170	0.522	rs28866188	chr14:92637578	T/C	ch.14.1475328F	chr14:92585817	NDUFB1	0.38	4.95	0.31	1.45e-6	Dialysis-related mortality;
SARC	cis	rs10463316	0.894	rs4099171	chr5:150766623	C/T	cg03212797	chr5:150827313	SLC36A1	-0.44	-5.26	-0.33	3.34e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs3213545	0.659	rs2259690	chr12:121457914	T/G	cg02403541	chr12:121454288	C12orf43	0.75	10.63	0.57	8.65e-22	Subjective well-being;Cardiovascular disease risk factors;
SARC	cis	rs6429082	0.967	rs704710	chr1:235621026	A/G	cg26050004	chr1:235667680	B3GALNT2	0.42	5.53	0.34	8.58e-8	Adiposity;
SARC	cis	rs6940638	0.688	rs7764984	chr6:27034181	A/G	cg12826209	chr6:26865740	GUSBL1	0.46	4.85	0.3	2.21e-6	Intelligence (multi-trait analysis);
SARC	cis	rs546131	0.642	rs1594425	chr11:34833322	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-4.72	-0.3	4.06e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs7624766	1.000	rs7624766	chr3:160429869	A/G	cg22637730	chr3:160473554	PPM1L	0.37	4.76	0.3	3.36e-6	Response to methotrexate in rheumatoid arthritis;
SARC	cis	rs2916247	1.000	rs6992515	chr8:93042269	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.59	-6.03	-0.37	6.24e-9	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg08280861	chr8:58055591	NA	0.58	4.81	0.3	2.77e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs2303759	0.918	rs10405465	chr19:49869298	C/T	cg24324837	chr19:49891574	CCDC155	0.39	4.79	0.3	3.03e-6	Multiple sclerosis;
SARC	cis	rs2845885	0.793	rs35927325	chr11:63882495	C/T	cg24431193	chr11:63883947	FLRT1;MACROD1	0.67	4.88	0.3	1.98e-6	Body mass index;
SARC	cis	rs1185460	0.967	rs1784460	chr11:118938371	A/T	cg23280166	chr11:118938394	VPS11	-0.8	-12.11	-0.62	1.7e-26	Coronary artery disease;
SARC	cis	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg03060546	chr3:49711283	APEH	-0.67	-8.3	-0.48	8.2e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg04108811	chr1:246670728	SMYD3	-0.5	-6.38	-0.39	9.47e-10	Schizophrenia;
SARC	cis	rs62244186	0.627	rs12386385	chr3:44457540	A/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.46	5.69	0.35	3.72e-8	Depressive symptoms;
SARC	cis	rs11645898	0.872	rs72791121	chr16:72225294	C/T	cg14768367	chr16:72042858	DHODH	-0.61	-5.56	-0.34	7.27e-8	Blood protein levels;
SARC	cis	rs7681440	0.606	rs2736999	chr4:90754111	C/T	cg06632027	chr4:90757378	SNCA	0.45	5.49	0.34	1.07e-7	Dementia with Lewy bodies;
SARC	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg09323728	chr8:95962352	TP53INP1	-0.29	-4.91	-0.31	1.73e-6	Type 2 diabetes;
SARC	cis	rs611744	0.839	rs638238	chr8:109169152	A/G	cg21045802	chr8:109455806	TTC35	0.48	6.1	0.37	4.32e-9	Dupuytren's disease;
SARC	cis	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg18252515	chr7:66147081	NA	-1.42	-13.08	-0.65	1.15e-29	Diabetic kidney disease;
SARC	cis	rs9513627	1.000	rs73556170	chr13:100121612	T/A	cg25919922	chr13:100150906	NA	-0.7	-5.26	-0.33	3.21e-7	Obesity-related traits;
SARC	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg16405210	chr4:1374714	KIAA1530	0.54	6.57	0.4	3.34e-10	Obesity-related traits;
SARC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.04	0.37	6e-9	Prudent dietary pattern;
SARC	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg05861140	chr6:150128134	PCMT1	-0.44	-5.35	-0.33	2.09e-7	Lung cancer;
SARC	cis	rs2204008	0.775	rs8186812	chr12:38305055	C/T	cg26384229	chr12:38710491	ALG10B	0.88	12.91	0.65	3.91e-29	Bladder cancer;
SARC	cis	rs7851660	0.506	rs1912996	chr9:100598261	G/T	cg13688889	chr9:100608707	NA	-0.45	-4.87	-0.3	2.03e-6	Strep throat;
SARC	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg12288994	chr5:1860383	NA	0.32	4.97	0.31	1.3e-6	Cardiovascular disease risk factors;
SARC	cis	rs526231	0.547	rs34780	chr5:102453557	G/A	cg23492399	chr5:102201601	PAM	-0.51	-5.55	-0.34	7.77e-8	Primary biliary cholangitis;
SARC	cis	rs11785400	0.928	rs750529	chr8:143744877	G/C	cg24634471	chr8:143751801	JRK	0.68	9.25	0.52	1.46e-17	Schizophrenia;
SARC	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg05861140	chr6:150128134	PCMT1	-0.41	-5.36	-0.33	1.95e-7	Lung cancer;
SARC	cis	rs12950390	0.893	rs4794110	chr17:45847230	A/G	cg24803719	chr17:45855879	NA	-0.44	-7.3	-0.43	4.65e-12	IgG glycosylation;
SARC	cis	rs3796352	1.000	rs60942590	chr3:53016421	G/A	cg12962167	chr3:53033115	SFMBT1	0.75	5.06	0.31	8.45e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	11.37	0.6	3.9e-24	Platelet count;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg09754991	chr13:107220236	ARGLU1	-0.87	-7.31	-0.43	4.31e-12	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2576037	0.796	rs2571030	chr18:44573854	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.68	-9.87	-0.54	2.04e-19	Personality dimensions;
SARC	cis	rs9462027	0.628	rs2038839	chr6:34777791	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.87	-0.36	1.52e-8	Systemic lupus erythematosus;
SARC	cis	rs11690935	0.632	rs1607254	chr2:172626552	A/G	cg13550731	chr2:172543902	DYNC1I2	0.66	9.36	0.52	6.8e-18	Schizophrenia;
SARC	cis	rs7223966	1.000	rs8076717	chr17:61850301	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.51	5.31	0.33	2.55e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs4792901	0.722	rs35714338	chr17:41614213	T/C	cg22562494	chr17:41607896	ETV4	-0.32	-5.02	-0.31	1.04e-6	Dupuytren's disease;
SARC	cis	rs6558174	0.965	rs6558172	chr8:22492052	C/T	cg03733263	chr8:22462867	KIAA1967	0.54	6.4	0.39	8.26e-10	Breast cancer;
SARC	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg11644478	chr21:40555479	PSMG1	1.02	14.16	0.68	2.93e-33	Cognitive function;
SARC	cis	rs9393777	0.588	rs6456728	chr6:26477779	G/A	cg12826209	chr6:26865740	GUSBL1	0.75	7.34	0.43	3.45e-12	Intelligence (multi-trait analysis);
SARC	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg01475735	chr3:40494733	NA	-0.47	-5.16	-0.32	5.31e-7	Renal cell carcinoma;
SARC	cis	rs709400	0.633	rs8013101	chr14:103951772	G/C	cg12935359	chr14:103987150	CKB	-0.39	-5.79	-0.35	2.22e-8	Body mass index;
SARC	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg11987759	chr7:65425863	GUSB	0.57	7.52	0.44	1.18e-12	Aortic root size;
SARC	cis	rs1215050	0.740	rs804051	chr4:98935935	A/T	cg05340658	chr4:99064831	C4orf37	-0.47	-6.3	-0.38	1.45e-9	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs765787	0.530	rs28414644	chr15:45536721	G/C	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.81e-6	Uric acid levels;
SARC	cis	rs7829975	0.811	rs7011229	chr8:8543324	T/C	cg15556689	chr8:8085844	FLJ10661	-0.46	-5.59	-0.34	6.28e-8	Mood instability;
SARC	cis	rs10028773	0.600	rs4001390	chr4:120265783	G/C	cg09307838	chr4:120376055	NA	0.75	10.42	0.56	4.08e-21	Educational attainment;
SARC	cis	rs8044868	0.530	rs12446480	chr16:72056757	A/G	cg01557791	chr16:72042693	DHODH	-0.38	-4.79	-0.3	2.95e-6	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
SARC	cis	rs4423214	1.000	rs28364617	chr11:71159764	T/G	cg05163923	chr11:71159392	DHCR7	0.66	8.68	0.49	6.93e-16	Vitamin D levels;
SARC	cis	rs1865760	0.625	rs9393681	chr6:26008260	A/G	cg16482183	chr6:26056742	HIST1H1C	0.49	6.56	0.39	3.51e-10	Height;
SARC	cis	rs79149102	0.579	rs74023935	chr15:75359184	T/C	cg17294928	chr15:75287854	SCAMP5	-1.1	-9.2	-0.52	2.09e-17	Lung cancer;
SARC	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs41271473	0.898	rs12028277	chr1:228829657	A/G	cg16512390	chr1:228756714	NA	0.5	4.72	0.3	4.06e-6	Chronic lymphocytic leukemia;
SARC	cis	rs11214589	0.774	rs7116782	chr11:113250938	A/G	cg14159747	chr11:113255604	NA	0.35	5.0	0.31	1.1e-6	Neuroticism;
SARC	cis	rs12079745	0.793	rs75134881	chr1:169186127	T/C	cg09363564	chr1:169337483	NME7;BLZF1	-0.88	-5.6	-0.34	5.96e-8	QT interval;
SARC	cis	rs317689	0.918	rs610192	chr12:69739941	T/C	cg20891283	chr12:69753455	YEATS4	0.47	5.13	0.32	6.01e-7	Response to diuretic therapy;
SARC	cis	rs17021463	0.676	rs11097421	chr4:95302915	T/C	cg11021082	chr4:95130006	SMARCAD1	0.35	4.73	0.3	3.83e-6	Testicular germ cell tumor;
SARC	cis	rs12709013	0.601	rs2432621	chr16:58783580	A/G	cg04273148	chr16:57808038	KIFC3	0.32	4.76	0.3	3.34e-6	Blood metabolite ratios;
SARC	cis	rs2481665	0.904	rs2481677	chr1:62632571	G/A	cg18591186	chr1:62594603	INADL	-0.58	-8.05	-0.47	4.17e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2361718	0.527	rs11150847	chr17:78153130	G/A	cg06718696	chr17:78121285	EIF4A3	0.49	6.05	0.37	5.59e-9	Yeast infection;
SARC	cis	rs6582630	0.576	rs4403871	chr12:38292193	G/A	cg14851346	chr12:38532713	NA	-0.43	-5.05	-0.31	8.75e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs881375	0.933	rs2239657	chr9:123671520	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.44	-5.27	-0.33	3.04e-7	Rheumatoid arthritis;
SARC	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg23758822	chr17:41437982	NA	0.87	10.68	0.57	6.2e-22	Menopause (age at onset);
SARC	cis	rs9815354	0.761	rs73079307	chr3:41862273	A/C	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg16325326	chr1:53192061	ZYG11B	0.93	17.39	0.75	5.69e-44	Monocyte count;
SARC	cis	rs1790761	0.667	rs11227837	chr11:67336424	A/T	cg24690094	chr11:67383802	NA	0.37	5.45	0.34	1.25e-7	Mean corpuscular volume;
SARC	cis	rs11098499	0.954	rs3733523	chr4:120423719	C/T	cg24375607	chr4:120327624	NA	0.41	4.86	0.3	2.12e-6	Corneal astigmatism;
SARC	cis	rs1538970	0.816	rs34673142	chr1:45985561	G/A	cg05343316	chr1:45956843	TESK2	0.82	9.01	0.51	7.85e-17	Platelet count;
SARC	cis	rs965604	1.000	rs1504549	chr15:78766629	C/T	cg24631222	chr15:78858424	CHRNA5	-0.46	-5.94	-0.36	1.02e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg04277193	chr17:41438351	NA	0.44	4.76	0.3	3.35e-6	Menopause (age at onset);
SARC	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg13264159	chr8:625131	ERICH1	-0.68	-4.78	-0.3	3.13e-6	IgG glycosylation;
SARC	cis	rs1401999	1.000	rs2313217	chr3:183635997	A/G	cg01324343	chr3:183735012	ABCC5	0.68	13.92	0.67	1.84e-32	Anterior chamber depth;
SARC	cis	rs75920871	0.588	rs721783	chr11:116907449	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.5	-5.06	-0.31	8.49e-7	Subjective well-being;
SARC	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg11764359	chr7:65958608	NA	0.51	5.67	0.35	4.3e-8	Aortic root size;
SARC	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg12311346	chr5:56204834	C5orf35	0.66	6.46	0.39	6.16e-10	Initial pursuit acceleration;
SARC	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg24829409	chr8:58192753	C8orf71	-0.54	-4.75	-0.3	3.58e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs524281	0.861	rs2177054	chr11:65944612	C/A	cg14036092	chr11:66035641	RAB1B	-0.49	-5.16	-0.32	5.24e-7	Electroencephalogram traits;
SARC	cis	rs3617	0.625	rs6769789	chr3:52874446	C/T	cg18404041	chr3:52824283	ITIH1	0.36	5.32	0.33	2.39e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.14	0.8	6.21e-53	Prudent dietary pattern;
SARC	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg18404041	chr3:52824283	ITIH1	-0.44	-6.58	-0.4	3.05e-10	Bipolar disorder;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg00826921	chr3:143692146	C3orf58	-0.56	-6.29	-0.38	1.53e-9	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs7633770	0.786	rs1607737	chr3:46681846	G/C	cg11219411	chr3:46661640	NA	0.43	7.07	0.42	1.8e-11	Coronary artery disease;
SARC	cis	rs10791097	0.609	rs3751039	chr11:130773076	A/G	cg12179176	chr11:130786555	SNX19	-0.82	-13.4	-0.66	9.83e-31	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs2933343	0.700	rs883602	chr3:128653952	A/G	cg25356066	chr3:128598488	ACAD9	0.7	9.18	0.52	2.35e-17	IgG glycosylation;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg02813563	chr13:75905813	TBC1D4	0.44	6.35	0.38	1.1e-9	Thyroid stimulating hormone;
SARC	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.75	10.78	0.58	3.04e-22	Personality dimensions;
SARC	cis	rs651907	0.557	rs2303474	chr3:101371899	G/T	cg12386194	chr3:101231763	SENP7	0.52	6.08	0.37	4.89e-9	Colorectal cancer;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg22373676	chr13:30374285	UBL3	0.48	6.41	0.39	7.81e-10	Thyroid stimulating hormone;
SARC	cis	rs644799	0.965	rs2950522	chr11:95524719	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	14.35	0.68	7.11e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs66887589	0.967	rs56173225	chr4:120509972	G/A	cg09307838	chr4:120376055	NA	-0.52	-7.02	-0.42	2.4e-11	Diastolic blood pressure;
SARC	cis	rs2236918	0.710	rs1776130	chr1:242023362	A/G	cg17736920	chr1:242011382	EXO1	0.66	8.99	0.51	8.66e-17	Menopause (age at onset);
SARC	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg22535103	chr8:58192502	C8orf71	-0.73	-7.31	-0.43	4.37e-12	Developmental language disorder (linguistic errors);
SARC	trans	rs5417	0.662	rs12601936	chr17:7172609	A/G	cg15655154	chr3:113604241	GRAMD1C	-0.52	-7.36	-0.43	3.15e-12	Diastolic blood pressure;
SARC	cis	rs9611519	0.929	rs9611466	chr22:41426299	A/T	cg03806693	chr22:41940476	POLR3H	-0.61	-7.56	-0.44	8.99e-13	Neuroticism;
SARC	cis	rs6685188	0.925	rs12752037	chr1:205661614	A/C	cg14893161	chr1:205819251	PM20D1	-0.56	-6.6	-0.4	2.67e-10	White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs818427	0.896	rs712665	chr5:112227799	C/T	cg07820702	chr5:112228657	REEP5	0.47	5.35	0.33	2.05e-7	Total body bone mineral density;
SARC	cis	rs854765	0.663	rs4925120	chr17:17754633	C/T	cg16928487	chr17:17741425	SREBF1	0.24	5.13	0.32	6.23e-7	Total body bone mineral density;
SARC	cis	rs7296418	0.699	rs1109559	chr12:123757861	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-5.07	-0.32	8.06e-7	Platelet count;
SARC	cis	rs9462027	0.628	rs9469887	chr6:34758940	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.85	-0.36	1.64e-8	Systemic lupus erythematosus;
SARC	cis	rs8180040	0.967	rs807935	chr3:47321669	A/G	cg27129171	chr3:47204927	SETD2	0.67	9.24	0.52	1.54e-17	Colorectal cancer;
SARC	cis	rs12134245	0.776	rs12122066	chr1:92005140	C/T	cg02896835	chr1:92012615	NA	-0.53	-7.2	-0.43	8.24e-12	Breast cancer;
SARC	cis	rs9467773	0.565	rs4343916	chr6:26522675	A/T	cg11502198	chr6:26597334	ABT1	0.58	7.49	0.44	1.39e-12	Intelligence (multi-trait analysis);
SARC	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg19077165	chr18:44547161	KATNAL2	-0.52	-6.77	-0.41	1.05e-10	Personality dimensions;
SARC	cis	rs1003719	0.715	rs2252893	chr21:38507572	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-9.13	-0.51	3.35e-17	Eye color traits;
SARC	cis	rs9815354	0.716	rs76313799	chr3:41931751	A/C	cg03022575	chr3:42003672	ULK4	0.7	5.7	0.35	3.66e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs12780845	0.540	rs10490959	chr10:17230836	A/T	cg11116878	chr10:17243438	TRDMT1	0.38	4.74	0.3	3.65e-6	Homocysteine levels;
SARC	cis	rs2898681	0.874	rs59649036	chr4:53741175	T/C	cg00338735	chr4:53728038	RASL11B	0.4	4.96	0.31	1.38e-6	Optic nerve measurement (cup area);
SARC	cis	rs918629	0.530	rs17085249	chr5:95236415	C/T	cg16656078	chr5:95278638	ELL2	-0.58	-6.92	-0.41	4.28e-11	IgG glycosylation;
SARC	cis	rs12926788	0.689	rs34365165	chr16:24856208	G/A	cg00152838	chr16:24741724	TNRC6A	-0.55	-5.58	-0.34	6.59e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs9457247	0.602	rs2157388	chr6:167481912	G/A	cg23791538	chr6:167370224	RNASET2	-0.55	-7.13	-0.42	1.26e-11	Crohn's disease;
SARC	cis	rs1799949	1.000	rs4793236	chr17:41436440	T/C	cg05368731	chr17:41323189	NBR1	0.77	9.48	0.53	3.15e-18	Menopause (age at onset);
SARC	trans	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg21659725	chr3:3221576	CRBN	0.54	6.96	0.41	3.41e-11	Intelligence (multi-trait analysis);
SARC	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg18404041	chr3:52824283	ITIH1	-0.43	-6.44	-0.39	6.8e-10	Bipolar disorder;
SARC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg23131131	chr22:24373011	LOC391322	-0.46	-4.99	-0.31	1.19e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs10861342	1.000	rs1444608	chr12:105559157	A/G	cg23923672	chr12:105501055	KIAA1033	0.7	5.24	0.32	3.61e-7	IgG glycosylation;
SARC	cis	rs2594989	1.000	rs2594967	chr3:11349748	T/G	cg00170343	chr3:11313890	ATG7	0.57	5.59	0.34	6.27e-8	Circulating chemerin levels;
SARC	cis	rs4974559	0.739	rs3817604	chr4:1291337	C/T	cg02980000	chr4:1222292	CTBP1	0.73	5.64	0.35	5.03e-8	Systolic blood pressure;
SARC	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.68	7.44	0.44	1.97e-12	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs883565	0.569	rs7614000	chr3:39152575	C/G	cg26331595	chr3:39149181	GORASP1;TTC21A	0.44	5.11	0.32	6.63e-7	Handedness;
SARC	cis	rs3771570	0.901	rs4675963	chr2:242324763	G/A	cg21155796	chr2:242212141	HDLBP	0.53	5.11	0.32	6.73e-7	Prostate cancer;
SARC	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg15105969	chr2:36825350	FEZ2	0.49	5.6	0.34	5.9e-8	Height;
SARC	cis	rs7937682	0.961	rs7119563	chr11:111543916	T/A	cg22437258	chr11:111473054	SIK2	-0.68	-8.89	-0.5	1.74e-16	Primary sclerosing cholangitis;
SARC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.39	-5.67	-0.35	4.17e-8	Longevity;Endometriosis;
SARC	cis	rs9843304	0.546	rs13075906	chr3:149225582	C/A	cg08667024	chr3:149219783	TM4SF4	0.45	6.78	0.41	9.62e-11	Gallstone disease;
SARC	trans	rs208520	1.000	rs12190316	chr6:66973365	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.76	8.48	0.49	2.58e-15	Exhaled nitric oxide output;
SARC	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg22968622	chr17:43663579	NA	1.17	15.54	0.71	7.33e-38	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7208859	0.524	rs59923796	chr17:29064919	G/A	cg13385521	chr17:29058706	SUZ12P	0.84	7.31	0.43	4.29e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg20965017	chr5:231967	SDHA	-0.55	-5.26	-0.33	3.23e-7	Breast cancer;
SARC	cis	rs1355223	0.902	rs860712	chr11:34743494	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.34	-0.33	2.21e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs10992471	0.651	rs2296669	chr9:95373790	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.43	4.89	0.31	1.84e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs11190604	1.000	rs9420797	chr10:102331147	C/T	cg07080220	chr10:102295463	HIF1AN	0.82	10.6	0.57	1.15e-21	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs17030434	1.000	rs79094565	chr4:154718997	T/C	cg14289246	chr4:154710475	SFRP2	-0.76	-7.12	-0.42	1.31e-11	Electrocardiographic conduction measures;
SARC	cis	rs599083	0.530	rs686921	chr11:68170833	G/T	cg01657329	chr11:68192670	LRP5	0.46	6.27	0.38	1.71e-9	Bone mineral density (spine);
SARC	trans	rs61931739	0.534	rs1912773	chr12:34097401	T/C	cg13010199	chr12:38710504	ALG10B	0.77	10.37	0.56	5.83e-21	Morning vs. evening chronotype;
SARC	cis	rs16854884	0.586	rs7639366	chr3:143752034	T/G	cg06585982	chr3:143692056	C3orf58	0.7	9.83	0.54	2.77e-19	Economic and political preferences (feminism/equality);
SARC	trans	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.52	6.58	0.4	3.1e-10	Intelligence (multi-trait analysis);
SARC	cis	rs748404	0.631	rs7166812	chr15:43644760	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.41	4.93	0.31	1.55e-6	Lung cancer;
SARC	cis	rs7773004	0.601	rs13210340	chr6:26326314	G/A	cg13736514	chr6:26305472	NA	-0.39	-4.73	-0.3	3.88e-6	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
SARC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg03452623	chr4:187889614	NA	0.82	12.52	0.63	7.74e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12579753	0.879	rs7958566	chr12:82131478	A/T	cg07988820	chr12:82153109	PPFIA2	-0.6	-7.07	-0.42	1.8e-11	Resting heart rate;
SARC	cis	rs6450176	1.000	rs12521454	chr5:53297304	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.66	-7.64	-0.45	5.69e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs3126085	0.935	rs11204934	chr1:152176848	C/A	cg09127314	chr1:152161683	NA	-0.43	-4.77	-0.3	3.19e-6	Atopic dermatitis;
SARC	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg09165964	chr15:75287851	SCAMP5	0.53	7.03	0.42	2.31e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg11987759	chr7:65425863	GUSB	-0.49	-6.02	-0.37	6.86e-9	Aortic root size;
SARC	cis	rs3857536	0.845	rs9360187	chr6:66899317	G/A	cg07460842	chr6:66804631	NA	-0.44	-5.26	-0.33	3.22e-7	Blood trace element (Cu levels);
SARC	cis	rs1538970	0.781	rs12049503	chr1:46021556	G/T	cg05343316	chr1:45956843	TESK2	0.82	9.09	0.51	4.49e-17	Platelet count;
SARC	cis	rs7584330	0.868	rs58057291	chr2:238395479	T/A	cg14458575	chr2:238380390	NA	0.45	5.32	0.33	2.47e-7	Prostate cancer;
SARC	cis	rs34172651	0.687	rs8044992	chr16:24811207	T/C	cg00152838	chr16:24741724	TNRC6A	-0.49	-5.92	-0.36	1.14e-8	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg22535103	chr8:58192502	C8orf71	-0.8	-8.3	-0.48	8.23e-15	Developmental language disorder (linguistic errors);
SARC	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg25894440	chr7:65020034	NA	-0.76	-5.66	-0.35	4.52e-8	Diabetic kidney disease;
SARC	cis	rs208520	1.000	rs12192261	chr6:66985268	A/G	cg07460842	chr6:66804631	NA	0.9	10.32	0.56	8.16e-21	Exhaled nitric oxide output;
SARC	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg13206674	chr6:150067644	NUP43	0.4	5.24	0.32	3.57e-7	Lung cancer;
SARC	cis	rs12497850	1.000	rs4858831	chr3:48735558	C/T	cg03060546	chr3:49711283	APEH	0.42	5.34	0.33	2.16e-7	Parkinson's disease;
SARC	cis	rs1044826	0.692	rs184155	chr3:139229772	G/A	cg15131784	chr3:139108705	COPB2	-0.4	-5.06	-0.31	8.66e-7	Obesity-related traits;
SARC	cis	rs782590	0.967	rs17798852	chr2:55805172	A/C	cg18811423	chr2:55921094	PNPT1	0.68	10.49	0.57	2.47e-21	Metabolic syndrome;
SARC	cis	rs10492096	0.783	rs11064220	chr12:6592574	C/T	cg13857086	chr12:6580257	VAMP1	0.7	6.99	0.42	2.84e-11	Hip geometry;
SARC	cis	rs735539	0.521	rs2251031	chr13:21414326	G/T	cg16922012	chr13:21400325	XPO4	-0.41	-5.62	-0.35	5.35e-8	Dental caries;
SARC	cis	rs6963495	0.818	rs56268110	chr7:105166712	T/C	cg13798780	chr7:105162888	PUS7	0.6	5.55	0.34	7.64e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs11583043	0.575	rs12759611	chr1:101587145	T/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.45	5.14	0.32	5.81e-7	Ulcerative colitis;Inflammatory bowel disease;
SARC	trans	rs11722228	0.508	rs2241472	chr4:10085902	C/G	cg26043149	chr18:55253948	FECH	0.67	7.61	0.45	6.61e-13	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs17125944	0.505	rs2295826	chr14:53174923	C/T	cg00686598	chr14:53173677	PSMC6	-1.13	-8.65	-0.49	8.54e-16	Alzheimer's disease (late onset);
SARC	cis	rs3008870	0.755	rs1925410	chr1:67365230	C/T	cg02640540	chr1:67518911	SLC35D1	-0.45	-5.21	-0.32	4.1e-7	Lymphocyte percentage of white cells;
SARC	cis	rs3923518	0.956	rs11919589	chr3:38935192	A/G	cg26331595	chr3:39149181	GORASP1;TTC21A	0.45	4.75	0.3	3.58e-6	Migraine;
SARC	cis	rs7044106	0.791	rs4837792	chr9:123483559	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.72	9.52	0.53	2.27e-18	Hip circumference adjusted for BMI;
SARC	cis	rs7647973	0.626	rs4855833	chr3:49657441	A/G	cg03060546	chr3:49711283	APEH	0.67	7.1	0.42	1.48e-11	Menarche (age at onset);
SARC	cis	rs4566357	0.615	rs4675140	chr2:227908665	C/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.6	-0.34	5.99e-8	Coronary artery disease;
SARC	cis	rs2011503	1.000	rs1557723	chr19:19443033	A/G	cg03709012	chr19:19516395	GATAD2A	-0.61	-5.67	-0.35	4.12e-8	Bipolar disorder;
SARC	cis	rs10791323	0.604	rs2250025	chr11:133710914	G/A	cg15485101	chr11:133734466	NA	0.33	5.08	0.32	7.91e-7	Childhood ear infection;
SARC	cis	rs1008375	1.000	rs28480159	chr4:17685707	A/C	cg27347728	chr4:17578864	LAP3	0.45	5.54	0.34	8.14e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2997447	0.802	rs61776621	chr1:26459058	C/G	cg19633962	chr1:26362018	EXTL1	-0.57	-4.93	-0.31	1.54e-6	QRS complex (12-leadsum);
SARC	cis	rs2204008	0.869	rs34438288	chr12:38211582	G/T	cg26384229	chr12:38710491	ALG10B	0.88	12.94	0.65	3.26e-29	Bladder cancer;
SARC	trans	rs17685	0.753	rs2286830	chr7:75693963	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.61	-7.78	-0.45	2.3e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs17270561	0.583	rs7749149	chr6:25781139	G/A	cg17691542	chr6:26056736	HIST1H1C	0.55	6.8	0.41	8.72e-11	Iron status biomarkers;
SARC	cis	rs79149102	0.579	rs3816261	chr15:75336173	T/A	cg09165964	chr15:75287851	SCAMP5	-1.04	-8.64	-0.49	9.32e-16	Lung cancer;
SARC	cis	rs2153535	0.580	rs1577466	chr6:8444192	T/C	cg23788917	chr6:8435910	SLC35B3	0.65	8.39	0.48	4.61e-15	Motion sickness;
SARC	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg18252515	chr7:66147081	NA	-1.34	-11.85	-0.61	1.15e-25	Diabetic kidney disease;
SARC	cis	rs927821	0.618	rs1572531	chr10:104193733	T/C	cg15941413	chr10:103420568	FBXW4	-0.5	-4.95	-0.31	1.44e-6	Social autistic-like traits;
SARC	cis	rs74181299	0.684	rs1228	chr2:65311555	C/T	cg20592124	chr2:65290738	CEP68	-0.36	-4.88	-0.3	1.96e-6	Pulse pressure;
SARC	cis	rs4742903	0.935	rs10820616	chr9:106945991	G/A	cg14250997	chr9:106856677	SMC2	0.43	5.37	0.33	1.88e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg06697600	chr4:7070879	GRPEL1	-0.38	-4.91	-0.31	1.72e-6	Monocyte percentage of white cells;
SARC	cis	rs1983170	0.668	rs17131491	chr1:92017649	A/C	cg25838465	chr1:92012736	NA	0.51	5.16	0.32	5.4e-7	Eosinophil percentage of white cells;
SARC	cis	rs854765	0.583	rs11656840	chr17:17837354	C/T	cg05444541	chr17:17804740	TOM1L2	-0.3	-5.06	-0.31	8.38e-7	Total body bone mineral density;
SARC	cis	rs7412746	0.611	rs4319334	chr1:150766822	G/A	cg15448220	chr1:150897856	SETDB1	0.5	6.42	0.39	7.65e-10	Melanoma;
SARC	cis	rs3857067	0.772	rs4692999	chr4:95107644	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.07	-0.32	8.15e-7	QT interval;
SARC	cis	rs829883	0.724	rs11109508	chr12:98905985	T/C	cg25150519	chr12:98850993	NA	-0.68	-8.61	-0.49	1.09e-15	Colorectal adenoma (advanced);
SARC	trans	rs9388451	0.839	rs4897155	chr6:126095144	C/A	cg05039488	chr6:79577232	IRAK1BP1	-0.57	-7.44	-0.44	1.89e-12	Brugada syndrome;
SARC	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg23758822	chr17:41437982	NA	0.87	10.68	0.57	6.2e-22	Menopause (age at onset);
SARC	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg03709012	chr19:19516395	GATAD2A	1.0	17.34	0.75	7.93e-44	Tonsillectomy;
SARC	cis	rs9324022	0.929	rs72698718	chr14:101178555	G/A	cg18089426	chr14:101175970	NA	0.57	5.43	0.34	1.43e-7	Plateletcrit;
SARC	trans	rs4076764	0.958	rs6688181	chr1:163384193	C/T	cg06646285	chr11:14521639	COPB1	0.52	6.76	0.4	1.08e-10	Motion sickness;
SARC	cis	rs6142102	0.812	rs6059574	chr20:32523172	C/G	cg24642439	chr20:33292090	TP53INP2	-0.48	-5.21	-0.32	4.15e-7	Skin pigmentation;
SARC	cis	rs1609391	0.561	rs9817967	chr3:136629490	G/A	cg15507776	chr3:136538369	TMEM22	0.84	11.5	0.6	1.56e-24	Neuroticism;
SARC	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg03517284	chr6:25882590	NA	-0.45	-5.81	-0.36	2.02e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg11644478	chr21:40555479	PSMG1	1.03	14.35	0.69	6.72e-34	Cognitive function;
SARC	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg11987759	chr7:65425863	GUSB	-0.46	-6.29	-0.38	1.53e-9	Aortic root size;
SARC	cis	rs7219021	0.739	rs3760451	chr17:46969177	G/A	cg16584676	chr17:46985605	UBE2Z	-0.49	-5.69	-0.35	3.72e-8	Schizophrenia or bipolar disorder;
SARC	cis	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg12463550	chr7:65579703	CRCP	0.68	5.09	0.32	7.53e-7	Gout;
SARC	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg18252515	chr7:66147081	NA	-1.28	-11.07	-0.59	3.61e-23	Diabetic kidney disease;
SARC	cis	rs96067	0.805	rs3767705	chr1:36602044	A/T	cg24686825	chr1:36642396	MAP7D1	-0.51	-5.75	-0.35	2.85e-8	Corneal structure;
SARC	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg04277193	chr17:41438351	NA	0.44	4.78	0.3	3.04e-6	Menopause (age at onset);
SARC	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg07701084	chr6:150067640	NUP43	0.41	5.29	0.33	2.81e-7	Lung cancer;
SARC	cis	rs9325144	0.505	rs10785560	chr12:38636622	C/T	cg13010199	chr12:38710504	ALG10B	0.71	9.63	0.53	1.05e-18	Morning vs. evening chronotype;
SARC	cis	rs4727027	0.865	rs62505077	chr7:148849656	T/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	5.69	0.35	3.74e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg27266027	chr21:40555129	PSMG1	0.51	5.56	0.34	7.49e-8	Cognitive function;
SARC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg08163220	chr3:31574309	STT3B	0.51	6.33	0.38	1.24e-9	Myopia (pathological);
SARC	cis	rs763121	0.886	rs1013339	chr22:38974680	C/T	cg06022373	chr22:39101656	GTPBP1	0.82	10.84	0.58	1.92e-22	Menopause (age at onset);
SARC	cis	rs7818345	0.967	rs12543061	chr8:19286181	G/T	cg11303988	chr8:19266685	CSGALNACT1	-0.44	-5.95	-0.36	9.67e-9	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs11249608	0.548	rs10516150	chr5:178459169	G/C	cg01312482	chr5:178451176	ZNF879	-0.38	-4.98	-0.31	1.25e-6	Pubertal anthropometrics;
SARC	cis	rs3213545	0.700	rs2260399	chr12:121469653	C/T	cg02403541	chr12:121454288	C12orf43	0.74	10.45	0.56	3.23e-21	Subjective well-being;Cardiovascular disease risk factors;
SARC	cis	rs4481887	0.927	rs4472779	chr1:248474603	G/A	cg13385794	chr1:248469461	NA	0.35	5.45	0.34	1.29e-7	Common traits (Other);
SARC	cis	rs4481887	0.927	rs4537599	chr1:248508741	G/A	cg13385794	chr1:248469461	NA	0.37	5.56	0.34	7.47e-8	Common traits (Other);
SARC	cis	rs9381040	0.655	rs2268194	chr6:41024447	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-4.92	-0.31	1.64e-6	Alzheimer's disease (late onset);
SARC	cis	rs6964587	0.610	rs6950682	chr7:91464218	G/T	cg17063962	chr7:91808500	NA	0.69	9.83	0.54	2.67e-19	Breast cancer;
SARC	cis	rs6546324	0.625	rs6717863	chr2:67844799	C/A	cg18237512	chr2:67827392	NA	-0.53	-6.33	-0.38	1.22e-9	Endometriosis;
SARC	cis	rs7635838	0.892	rs754015	chr3:11493945	T/C	cg00170343	chr3:11313890	ATG7	0.61	8.15	0.47	2.29e-14	HDL cholesterol;
SARC	cis	rs7555523	0.887	rs10918274	chr1:165714416	T/C	cg24409356	chr1:165738333	TMCO1	0.8	6.67	0.4	1.88e-10	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	cis	rs8058578	1.000	rs6565197	chr16:30706477	T/C	cg00531865	chr16:30841666	NA	-0.51	-5.79	-0.35	2.24e-8	Multiple myeloma;
SARC	cis	rs939574	0.586	rs3731892	chr2:220136351	G/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.5	-5.1	-0.32	6.91e-7	Platelet distribution width;
SARC	cis	rs11190604	0.767	rs10786590	chr10:102164604	T/C	cg07080220	chr10:102295463	HIF1AN	0.69	7.57	0.44	8.81e-13	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg03575189	chr17:44344142	NA	-0.53	-5.13	-0.32	6.11e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs2033732	0.706	rs10958208	chr8:85070836	A/C	cg05716166	chr8:85095498	RALYL	0.48	5.65	0.35	4.56e-8	Body mass index;
SARC	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg07701084	chr6:150067640	NUP43	0.42	5.43	0.33	1.44e-7	Lung cancer;
SARC	cis	rs7552404	0.961	rs1767458	chr1:76219155	A/G	cg03433033	chr1:76189801	ACADM	0.48	6.89	0.41	5.18e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9303401	0.659	rs66514313	chr17:56714057	C/T	cg25039879	chr17:56429692	SUPT4H1	0.69	6.55	0.39	3.71e-10	Cognitive test performance;
SARC	cis	rs6088580	0.561	rs3761147	chr20:32996689	G/T	cg08999081	chr20:33150536	PIGU	-0.44	-6.65	-0.4	2.07e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs400736	0.930	rs370812	chr1:8075894	C/T	cg25007680	chr1:8021821	PARK7	0.5	6.54	0.39	3.84e-10	Response to antidepressants and depression;
SARC	cis	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg03060546	chr3:49711283	APEH	-0.58	-7.3	-0.43	4.62e-12	Resting heart rate;
SARC	cis	rs4555082	0.874	rs11622166	chr14:105759763	C/A	cg13114125	chr14:105738426	BRF1	-0.78	-10.8	-0.58	2.7e-22	Mean platelet volume;Platelet distribution width;
SARC	cis	rs7250872	0.647	rs12976128	chr19:1817113	A/C	cg05970437	chr19:1864622	KLF16	0.44	4.8	0.3	2.79e-6	Bipolar disorder;
SARC	cis	rs10791097	0.703	rs11222360	chr11:130730871	C/T	cg12179176	chr11:130786555	SNX19	0.65	9.06	0.51	5.39e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs752010	0.619	rs10736421	chr1:42106230	G/A	cg06885757	chr1:42089581	HIVEP3	0.47	6.65	0.4	2.1e-10	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs864537	0.646	rs1723018	chr1:167433420	A/G	cg09179987	chr1:167433047	CD247	0.43	6.94	0.41	3.79e-11	Celiac disease or Rheumatoid arthritis;Celiac disease;
SARC	cis	rs57994353	0.897	rs55824202	chr9:139357273	A/T	cg14169450	chr9:139327907	INPP5E	0.41	5.25	0.33	3.46e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs73086581	0.947	rs56123574	chr20:3878081	C/G	cg02187196	chr20:3869020	PANK2	0.65	5.79	0.35	2.3e-8	Response to antidepressants in depression;
SARC	cis	rs12142240	0.659	rs72677591	chr1:46818219	T/G	cg00530320	chr1:46809349	NSUN4	0.57	6.92	0.41	4.4e-11	Menopause (age at onset);
SARC	cis	rs36051895	0.632	rs966871	chr9:5121070	A/T	cg02405213	chr9:5042618	JAK2	-0.47	-5.75	-0.35	2.75e-8	Pediatric autoimmune diseases;
SARC	cis	rs41433250	1	rs41433250	chr13:31495835	A/G	cg19813030	chr13:30996374	NA	-0.7	-5.14	-0.32	5.85e-7	Influenza A (H1N1) infection;Mild influenza (H1N1) infection;
SARC	cis	rs7474896	0.515	rs624359	chr10:38299132	T/C	cg25427524	chr10:38739819	LOC399744	0.45	5.61	0.34	5.81e-8	Obesity (extreme);
SARC	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg22862634	chr11:62369728	EML3;MTA2	0.53	8.15	0.47	2.22e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs4689388	0.926	rs3889821	chr4:6282596	C/T	cg14416269	chr4:6271139	WFS1	0.35	5.44	0.34	1.31e-7	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs8084125	0.832	rs2156646	chr18:74946660	C/T	cg26065057	chr18:74961000	GALR1	0.46	4.91	0.31	1.72e-6	Obesity-related traits;
SARC	cis	rs7914558	0.966	rs4532960	chr10:104667406	C/T	cg04362960	chr10:104952993	NT5C2	0.41	4.91	0.31	1.73e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs11581859	0.613	rs993217	chr1:99205992	G/A	cg20286094	chr1:99190917	SNX7	-0.42	-4.89	-0.31	1.86e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs7818688	0.697	rs3802191	chr8:95987584	C/T	cg13393036	chr8:95962371	TP53INP1	-0.41	-5.11	-0.32	6.74e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs3812049	0.737	rs1993878	chr5:127476971	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.87	9.41	0.52	4.95e-18	Lymphocyte counts;Red cell distribution width;
SARC	cis	rs2115630	1.000	rs10220733	chr15:85280864	G/A	cg12501888	chr15:85177176	SCAND2	-0.47	-5.63	-0.35	5.2e-8	P wave terminal force;
SARC	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg19318889	chr4:1322082	MAEA	0.38	4.8	0.3	2.84e-6	Obesity-related traits;
SARC	cis	rs67460515	0.892	rs7647374	chr3:160975576	T/A	cg17135325	chr3:160939158	NMD3	0.63	7.94	0.46	8.51e-14	Parkinson's disease;
SARC	cis	rs10463316	0.894	rs7727926	chr5:150767216	G/A	cg03212797	chr5:150827313	SLC36A1	-0.44	-5.26	-0.33	3.34e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs854765	0.654	rs9911281	chr17:17762457	G/C	cg16928487	chr17:17741425	SREBF1	0.23	4.87	0.3	2.1e-6	Total body bone mineral density;
SARC	cis	rs10463554	0.927	rs7717343	chr5:102361983	T/C	cg23492399	chr5:102201601	PAM	-0.46	-5.09	-0.32	7.29e-7	Parkinson's disease;
SARC	cis	rs3768617	0.510	rs2296292	chr1:183086757	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.1	0.55	4.11e-20	Fuchs's corneal dystrophy;
SARC	cis	rs2153535	0.541	rs945304	chr6:8442892	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	7.37	0.43	2.94e-12	Motion sickness;
SARC	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg05872129	chr22:39784769	NA	-0.43	-6.1	-0.37	4.28e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs9309473	1.000	rs13432605	chr2:73810981	C/G	cg20560298	chr2:73613845	ALMS1	-0.48	-5.89	-0.36	1.32e-8	Metabolite levels;
SARC	cis	rs1124769	1.000	rs1124769	chr15:51352249	A/G	cg21246271	chr15:51200259	AP4E1	-0.55	-5.11	-0.32	6.73e-7	Cognitive performance;
SARC	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg11890956	chr21:40555474	PSMG1	1.17	19.44	0.79	1.14e-50	Cognitive function;
SARC	cis	rs12479064	0.724	rs3792150	chr2:100041849	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.46	-5.27	-0.33	3.1e-7	Chronic sinus infection;
SARC	cis	rs10870270	1.000	rs10430617	chr10:133748889	T/C	cg17892150	chr10:133769511	PPP2R2D	-0.83	-10.76	-0.58	3.57e-22	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs2549003	1.000	rs2070726	chr5:131821738	C/A	cg21138405	chr5:131827807	IRF1	0.27	5.32	0.33	2.4e-7	Asthma (sex interaction);
SARC	cis	rs6693567	0.516	rs7554686	chr1:150265619	A/T	cg09579323	chr1:150459698	TARS2	-0.41	-5.3	-0.33	2.69e-7	Migraine;
SARC	cis	rs4268898	0.662	rs2303297	chr2:24432937	C/T	cg26838691	chr2:24397539	C2orf84	-0.54	-6.2	-0.38	2.54e-9	Asthma;
SARC	cis	rs7772486	0.790	rs9376971	chr6:146259505	C/T	cg05347473	chr6:146136440	FBXO30	-0.48	-6.53	-0.39	4.01e-10	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg23932593	chr6:133135524	RPS12;SNORD101	0.47	6.25	0.38	1.93e-9	Chemerin levels;
SARC	cis	rs1707322	0.650	rs4553239	chr1:46150486	C/A	cg06784218	chr1:46089804	CCDC17	0.36	6.18	0.38	2.76e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs3126085	0.935	rs12746239	chr1:152246726	G/A	cg03465714	chr1:152285911	FLG	0.48	5.67	0.35	4.16e-8	Atopic dermatitis;
SARC	cis	rs66887589	0.616	rs6822808	chr4:120217365	C/A	cg09307838	chr4:120376055	NA	0.63	8.32	0.48	7.66e-15	Diastolic blood pressure;
SARC	cis	rs7528419	0.895	rs1277930	chr1:109822143	G/A	cg00908766	chr1:109817496	CELSR2	0.54	6.83	0.41	7.21e-11	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
SARC	cis	rs6121246	0.909	rs1075698	chr20:30387992	G/C	cg13852791	chr20:30311386	BCL2L1	0.86	9.09	0.51	4.55e-17	Mean corpuscular hemoglobin;
SARC	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.44	-5.38	-0.33	1.8e-7	Lymphocyte counts;
SARC	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg13939156	chr17:80058883	NA	-0.43	-6.68	-0.4	1.72e-10	Life satisfaction;
SARC	trans	rs1814175	0.616	rs1722001	chr11:49894427	A/G	cg15704280	chr7:45808275	SEPT13	-0.87	-13.84	-0.67	3.4e-32	Height;
SARC	cis	rs11687170	0.882	rs34967014	chr2:237062376	G/A	cg19324714	chr2:237145437	ASB18	0.47	4.73	0.3	3.82e-6	Educational attainment;Educational attainment (years of education);
SARC	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.07	-22.29	-0.83	1.1e-59	Chronic sinus infection;
SARC	cis	rs3099143	1.000	rs3099143	chr15:77104856	A/C	cg21673338	chr15:77095150	SCAPER	-0.77	-6.25	-0.38	1.92e-9	Recalcitrant atopic dermatitis;
SARC	cis	rs9640161	0.742	rs2108851	chr7:150019634	T/C	cg17279839	chr7:150038598	RARRES2	0.47	6.62	0.4	2.44e-10	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs4906332	1.000	rs3783397	chr14:103947289	A/G	cg26031613	chr14:104095156	KLC1	-0.47	-5.57	-0.34	6.92e-8	Coronary artery disease;
SARC	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg05861140	chr6:150128134	PCMT1	-0.42	-5.44	-0.34	1.32e-7	Lung cancer;
SARC	cis	rs7666738	0.830	rs1967977	chr4:98966141	A/G	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9886651	0.776	rs4733560	chr8:128779001	G/A	cg24514600	chr8:128805414	PVT1	-0.38	-4.86	-0.3	2.16e-6	Epithelial ovarian cancer;Serous invasive ovarian cancer;
SARC	cis	rs807669	0.903	rs1780637	chr22:19178250	A/G	cg02655711	chr22:19163373	SLC25A1	0.55	7.49	0.44	1.44e-12	Metabolite levels;
SARC	cis	rs4792901	0.759	rs2271957	chr17:41598940	A/G	cg22562494	chr17:41607896	ETV4	-0.31	-4.96	-0.31	1.35e-6	Dupuytren's disease;
SARC	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	5.69	0.35	3.71e-8	Bipolar disorder;
SARC	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg04944784	chr2:26401820	FAM59B	-0.47	-5.75	-0.35	2.81e-8	Gut microbiome composition (summer);
SARC	cis	rs4481887	1.000	rs10788781	chr1:248494262	C/T	cg13385794	chr1:248469461	NA	0.36	5.35	0.33	2.06e-7	Common traits (Other);
SARC	cis	rs2439831	1.000	rs2467740	chr15:43746792	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	8.47	0.49	2.78e-15	Lung cancer in ever smokers;
SARC	cis	rs7223966	1.000	rs1877316	chr17:61766880	C/A	cg00588841	chr17:61851480	DDX42;CCDC47	-0.65	-7.23	-0.43	7.04e-12	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2997447	0.846	rs61775430	chr1:26411109	G/A	cg19633962	chr1:26362018	EXTL1	-0.67	-5.78	-0.35	2.42e-8	QRS complex (12-leadsum);
SARC	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-5.72	-0.35	3.18e-8	Lung cancer;
SARC	cis	rs6690583	0.623	rs61770879	chr1:85504938	A/C	cg22153463	chr1:85462885	MCOLN2	0.74	6.05	0.37	5.67e-9	Serum sulfate level;
SARC	cis	rs372883	0.600	rs407712	chr21:30722531	G/A	cg24692254	chr21:30365293	RNF160	-0.65	-8.42	-0.48	3.79e-15	Pancreatic cancer;
SARC	cis	rs1448094	0.556	rs2061686	chr12:86170951	C/T	cg02569458	chr12:86230093	RASSF9	-0.36	-4.91	-0.31	1.75e-6	Major depressive disorder;
SARC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg18404041	chr3:52824283	ITIH1	-0.38	-5.61	-0.34	5.73e-8	Cognitive function;
SARC	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.59	-7.15	-0.42	1.13e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2204008	0.840	rs3892363	chr12:38479487	G/A	cg26384229	chr12:38710491	ALG10B	0.84	12.0	0.62	3.64e-26	Bladder cancer;
SARC	cis	rs698833	0.892	rs786418	chr2:44688413	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.68	8.7	0.5	6e-16	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs1044826	0.642	rs295473	chr3:139215585	T/C	cg15131784	chr3:139108705	COPB2	0.4	5.06	0.31	8.66e-7	Obesity-related traits;
SARC	cis	rs6028335	0.674	rs66486072	chr20:37647882	G/A	cg16355469	chr20:37678765	NA	0.52	4.81	0.3	2.75e-6	Alcohol and nicotine co-dependence;
SARC	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg18364779	chr6:26104403	HIST1H4C	0.42	5.09	0.32	7.3e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2730245	1.000	rs2657365	chr7:158722753	A/T	cg24397884	chr7:158709396	WDR60	-1.05	-15.16	-0.7	1.4e-36	Height;
SARC	cis	rs853679	0.760	rs11962305	chr6:28199937	G/C	cg26450541	chr6:28235208	ZNF187	0.57	5.06	0.31	8.43e-7	Depression;
SARC	cis	rs9300255	0.602	rs1727296	chr12:123647725	G/C	cg05973401	chr12:123451056	ABCB9	0.53	6.13	0.37	3.64e-9	Neutrophil percentage of white cells;
SARC	cis	rs5753618	0.583	rs7287267	chr22:31748415	C/T	cg07713946	chr22:31675144	LIMK2	0.36	5.19	0.32	4.67e-7	Colorectal cancer;
SARC	cis	rs2576037	0.796	rs2571033	chr18:44578552	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.49	6.48	0.39	5.32e-10	Personality dimensions;
SARC	cis	rs12586317	0.545	rs58342373	chr14:35395269	T/C	cg26967526	chr14:35346199	BAZ1A	-0.54	-5.55	-0.34	7.78e-8	Psoriasis;
SARC	cis	rs34891900	0.507	rs9605364	chr22:18127437	G/A	cg19898043	chr22:18121309	BCL2L13	0.65	7.14	0.42	1.18e-11	Sum neutrophil eosinophil counts;
SARC	cis	rs3857536	0.813	rs4710580	chr6:66935200	C/T	cg07460842	chr6:66804631	NA	-0.51	-5.83	-0.36	1.86e-8	Blood trace element (Cu levels);
SARC	cis	rs4516970	0.826	rs59246098	chr6:160149462	C/CA	cg25736982	chr6:160182554	ACAT2	0.62	6.25	0.38	1.89e-9	Iron status biomarkers;
SARC	trans	rs61931739	0.500	rs11053278	chr12:34555955	T/C	cg26384229	chr12:38710491	ALG10B	0.85	12.64	0.64	3.01e-28	Morning vs. evening chronotype;
SARC	cis	rs2916247	0.954	rs1552314	chr8:93104805	C/T	cg10183463	chr8:93005414	RUNX1T1	0.49	5.35	0.33	2.12e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2997447	0.761	rs12088601	chr1:26445504	G/A	cg19633962	chr1:26362018	EXTL1	-0.57	-5.21	-0.32	4.19e-7	QRS complex (12-leadsum);
SARC	cis	rs1707322	0.963	rs4553121	chr1:46375253	G/A	cg06784218	chr1:46089804	CCDC17	0.34	5.94	0.36	1.03e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7914558	0.869	rs10883842	chr10:104941589	C/T	cg04362960	chr10:104952993	NT5C2	0.4	4.8	0.3	2.83e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs11638352	1.000	rs2615292	chr15:44414376	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.77	-5.84	-0.36	1.78e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	trans	rs7859245	1.000	rs7859245	chr9:138490597	A/G	cg01352810	chr12:133707387	ZNF10	0.55	6.67	0.4	1.8e-10	Response to paliperidone in schizophrenia (negative Marder score);
SARC	cis	rs858239	0.601	rs929508	chr7:23166709	C/A	cg23682824	chr7:23144976	KLHL7	0.74	10.09	0.55	4.18e-20	Cerebrospinal fluid biomarker levels;
SARC	cis	rs2303745	0.589	rs1465576	chr19:17398487	G/A	cg22549504	chr19:17448937	GTPBP3	0.49	5.01	0.31	1.06e-6	Systemic lupus erythematosus;
SARC	cis	rs16944613	0.541	rs7183319	chr15:91095032	A/T	cg26821196	chr15:91095069	CRTC3	0.54	5.62	0.35	5.36e-8	Colorectal cancer;
SARC	cis	rs6732160	0.564	rs60796597	chr2:73382914	C/T	cg01422370	chr2:73384389	NA	0.37	5.65	0.35	4.61e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9910055	0.530	rs2269905	chr17:42294462	A/G	cg13607699	chr17:42295918	UBTF	0.85	13.59	0.67	2.25e-31	Total body bone mineral density;
SARC	cis	rs2204008	0.570	rs12318341	chr12:38251087	T/C	cg13010199	chr12:38710504	ALG10B	-0.52	-6.44	-0.39	6.73e-10	Bladder cancer;
SARC	cis	rs9430161	0.579	rs7542354	chr1:11040385	G/A	cg27631724	chr1:11040367	C1orf127	0.39	5.88	0.36	1.44e-8	Ewing sarcoma;
SARC	cis	rs8084125	0.832	rs884472	chr18:74946087	A/G	cg07390210	chr18:74961196	GALR1	0.55	6.05	0.37	5.65e-9	Obesity-related traits;
SARC	cis	rs1580019	0.844	rs1376290	chr7:32486922	C/T	cg07520158	chr7:32535189	LSM5;AVL9	0.42	4.99	0.31	1.16e-6	Cognitive ability;
SARC	cis	rs72781680	0.898	rs17762609	chr2:24114729	G/T	cg06627628	chr2:24431161	ITSN2	-0.67	-6.55	-0.39	3.59e-10	Lymphocyte counts;
SARC	cis	rs10908458	0.808	rs11264322	chr1:155087933	G/A	cg22049894	chr1:155113146	DPM3	0.41	5.15	0.32	5.44e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs8078723	0.966	rs2227322	chr17:38171668	C/G	cg17467752	chr17:38218738	THRA	0.47	5.94	0.36	1.01e-8	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs6860806	0.507	rs2631371	chr5:131703691	G/A	cg12564285	chr5:131593104	PDLIM4	-0.46	-6.29	-0.38	1.58e-9	Breast cancer;
SARC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg09373136	chr17:61933544	TCAM1	-0.45	-6.21	-0.38	2.43e-9	Prudent dietary pattern;
SARC	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg25894440	chr7:65020034	NA	-0.71	-5.37	-0.33	1.88e-7	Diabetic kidney disease;
SARC	cis	rs2742234	0.541	rs10899779	chr10:43723976	C/T	cg15436174	chr10:43711423	RASGEF1A	0.42	4.99	0.31	1.18e-6	Hirschsprung disease;
SARC	cis	rs9297145	0.565	rs6952161	chr7:98733337	A/G	cg05967295	chr7:98741636	SMURF1	0.51	5.78	0.35	2.42e-8	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
SARC	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg06618935	chr21:46677482	NA	0.38	5.16	0.32	5.24e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs524281	0.861	rs4013917	chr11:65926185	A/G	cg14036092	chr11:66035641	RAB1B	-0.51	-5.48	-0.34	1.11e-7	Electroencephalogram traits;
SARC	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg18305652	chr10:134549665	INPP5A	0.36	5.1	0.32	7.09e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs7726839	0.540	rs7558	chr5:660491	C/T	cg07777115	chr5:623756	CEP72	-0.57	-5.11	-0.32	6.69e-7	Obesity-related traits;
SARC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.7	6.7	0.4	1.54e-10	Platelet count;
SARC	cis	rs9902453	0.838	rs9646437	chr17:28209065	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	7.05	0.42	2.07e-11	Coffee consumption (cups per day);
SARC	cis	rs7017697	1.000	rs7017697	chr8:19685909	G/T	cg03894339	chr8:19674705	INTS10	-0.42	-5.15	-0.32	5.45e-7	Breast cancer;
SARC	cis	rs7223966	0.621	rs72845875	chr17:61639269	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.47	-4.73	-0.3	3.98e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6570726	0.791	rs405206	chr6:145836873	C/A	cg05347473	chr6:146136440	FBXO30	0.53	7.29	0.43	4.79e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2354432	0.556	rs4424557	chr1:146871119	A/G	cg25205988	chr1:146714368	CHD1L	0.96	7.2	0.43	8.01e-12	Mitochondrial DNA levels;
SARC	cis	rs10504073	0.525	rs10081464	chr8:50058707	A/G	cg00325661	chr8:49890786	NA	0.36	4.77	0.3	3.23e-6	Blood metabolite ratios;
SARC	cis	rs13191362	0.810	rs28360533	chr6:162996742	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.49	0.34	1.04e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg03517284	chr6:25882590	NA	0.47	6.27	0.38	1.78e-9	Blood metabolite levels;
SARC	cis	rs9902453	0.933	rs8080343	chr17:28456758	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	6.67	0.4	1.84e-10	Coffee consumption (cups per day);
SARC	cis	rs2304206	0.614	rs12104272	chr19:50148052	A/G	cg09250473	chr19:50168907	IRF3;BCL2L12	-0.53	-6.6	-0.4	2.78e-10	Vitiligo;
SARC	cis	rs763121	0.776	rs5757177	chr22:39007174	A/C	cg21395723	chr22:39101663	GTPBP1	0.57	6.48	0.39	5.5e-10	Menopause (age at onset);
SARC	cis	rs7264396	0.635	rs7263302	chr20:34545858	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-7.1	-0.42	1.54e-11	Total cholesterol levels;
SARC	cis	rs4713118	0.513	rs149972	chr6:27983227	C/T	cg26335602	chr6:28129616	ZNF389	0.44	5.23	0.32	3.72e-7	Parkinson's disease;
SARC	cis	rs1707322	0.721	rs4609469	chr1:46117185	C/T	cg03146154	chr1:46216737	IPP	0.52	6.32	0.38	1.33e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs11734570	0.581	rs79354477	chr4:38597448	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.61	6.63	0.4	2.3e-10	Inflammatory bowel disease;Crohn's disease;
SARC	trans	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg07211511	chr3:129823064	LOC729375	-0.61	-6.46	-0.39	6.08e-10	Blood pressure (smoking interaction);
SARC	cis	rs910316	0.737	rs175077	chr14:75506875	G/A	cg08847533	chr14:75593920	NEK9	-0.81	-11.62	-0.61	6.43e-25	Height;
SARC	cis	rs262150	1.000	rs262154	chr7:158773936	G/A	cg09640425	chr7:158790006	NA	-0.38	-4.83	-0.3	2.44e-6	Facial morphology (factor 20);
SARC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg09373136	chr17:61933544	TCAM1	-0.43	-5.96	-0.36	9.34e-9	Prudent dietary pattern;
SARC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg09436375	chr6:42928200	GNMT	-0.37	-5.79	-0.35	2.26e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg11062466	chr8:58055876	NA	0.56	5.14	0.32	5.84e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg04518342	chr5:131593106	PDLIM4	0.37	5.21	0.32	4.06e-7	Breast cancer;
SARC	trans	rs61931739	0.500	rs3924704	chr12:34557833	C/T	cg13010199	chr12:38710504	ALG10B	0.81	11.47	0.6	1.87e-24	Morning vs. evening chronotype;
SARC	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg05861140	chr6:150128134	PCMT1	-0.41	-5.38	-0.33	1.78e-7	Lung cancer;
SARC	cis	rs9916302	0.904	rs7501488	chr17:37576417	T/G	cg00129232	chr17:37814104	STARD3	-0.62	-7.61	-0.45	6.89e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs3857536	0.813	rs9360190	chr6:66942302	T/C	cg07460842	chr6:66804631	NA	-0.51	-5.83	-0.36	1.86e-8	Blood trace element (Cu levels);
SARC	cis	rs651907	0.535	rs35810977	chr3:101531380	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.49	5.71	0.35	3.45e-8	Colorectal cancer;
SARC	cis	rs4727027	0.651	rs12704068	chr7:148856153	T/C	cg23583168	chr7:148888333	NA	-0.74	-10.14	-0.55	2.89e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.0	11.07	0.59	3.66e-23	Alzheimer's disease;
SARC	cis	rs2066819	1.000	rs2695782	chr12:56722830	C/T	cg26316697	chr12:56727976	PAN2	-0.87	-5.45	-0.34	1.31e-7	Psoriasis vulgaris;
SARC	cis	rs3820928	0.709	rs10178202	chr2:227914561	C/T	cg05526886	chr2:227700861	RHBDD1	-0.43	-4.73	-0.3	3.81e-6	Pulmonary function;
SARC	cis	rs11574514	1.000	rs79631436	chr16:67728369	T/A	cg01866162	chr16:67596514	CTCF	1.1	6.57	0.4	3.33e-10	Crohn's disease;
SARC	cis	rs694739	0.628	rs538147	chr11:64129722	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.52	5.61	0.35	5.66e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs9818758	0.607	rs56306491	chr3:49314960	G/A	cg00383909	chr3:49044727	WDR6	0.77	6.67	0.4	1.88e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg21724239	chr8:58056113	NA	0.66	5.88	0.36	1.41e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1322639	0.614	rs6903921	chr6:169563957	C/T	cg04662567	chr6:169592167	NA	-0.57	-5.64	-0.35	4.88e-8	Pulse pressure;
SARC	cis	rs2180341	0.722	rs9388555	chr6:127576363	G/A	cg24812749	chr6:127587940	RNF146	0.89	11.94	0.62	5.74e-26	Breast cancer;
SARC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.77	10.0	0.55	8.01e-20	Prudent dietary pattern;
SARC	cis	rs9486719	1.000	rs12208449	chr6:96903253	A/G	cg06623918	chr6:96969491	KIAA0776	0.76	8.28	0.48	9.34e-15	Migraine;Coronary artery disease;
SARC	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	cis	rs6674176	0.561	rs12127226	chr1:44395309	C/T	cg12908607	chr1:44402522	ARTN	-0.41	-7.12	-0.42	1.34e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs9549260	0.712	rs1334241	chr13:41223110	C/T	cg21288729	chr13:41239152	FOXO1	0.61	6.09	0.37	4.59e-9	Red blood cell count;
SARC	trans	rs877282	0.898	rs11253338	chr10:759559	C/T	cg22713356	chr15:30763199	NA	0.76	7.69	0.45	4.14e-13	Uric acid levels;
SARC	cis	rs3733585	0.699	rs7699609	chr4:9961059	A/G	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.56	-0.34	7.47e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs440932	0.565	rs19334	chr8:9009906	C/T	cg06636001	chr8:8085503	FLJ10661	0.43	5.12	0.32	6.43e-7	High light scatter reticulocyte percentage of red cells;
SARC	cis	rs6582630	0.599	rs11181807	chr12:38403763	G/A	cg14851346	chr12:38532713	NA	-0.48	-5.83	-0.36	1.82e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9443189	0.570	rs775075	chr6:76380035	A/C	cg01950844	chr6:76311363	SENP6	-0.86	-8.19	-0.47	1.68e-14	Prostate cancer;
SARC	trans	rs1814175	0.527	rs7128827	chr11:49665644	C/T	cg15704280	chr7:45808275	SEPT13	0.76	9.4	0.52	5.19e-18	Height;
SARC	cis	rs757110	0.803	rs7928810	chr11:17372443	G/T	cg15432903	chr11:17409602	KCNJ11	0.53	8.86	0.5	2.03e-16	Type 2 diabetes;
SARC	cis	rs9660992	0.762	rs1172129	chr1:205244972	T/A	cg21643547	chr1:205240462	TMCC2	-0.57	-7.29	-0.43	4.73e-12	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs57221529	0.709	rs72707023	chr5:667620	G/A	cg14541582	chr5:601475	NA	-0.45	-5.14	-0.32	5.74e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs7617773	0.780	rs11130164	chr3:48369034	G/A	cg11946769	chr3:48343235	NME6	0.77	9.81	0.54	2.97e-19	Coronary artery disease;
SARC	trans	rs61931739	0.853	rs7137146	chr12:34102394	G/A	cg13010199	chr12:38710504	ALG10B	-0.51	-6.71	-0.4	1.49e-10	Morning vs. evening chronotype;
SARC	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg02788857	chr8:22132959	PIWIL2	0.34	4.87	0.3	2.02e-6	Hypertriglyceridemia;
SARC	cis	rs10992471	0.580	rs4743875	chr9:95423674	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.43	-4.71	-0.3	4.19e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	10.98	0.58	6.89e-23	Platelet count;
SARC	cis	rs1395	0.710	rs58965570	chr2:27481460	C/T	cg21747090	chr2:27597821	SNX17	-0.49	-5.91	-0.36	1.2e-8	Blood metabolite levels;
SARC	cis	rs6963495	0.818	rs73190161	chr7:105156871	C/T	cg13798780	chr7:105162888	PUS7	0.6	5.45	0.34	1.31e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs208520	1.000	rs72882079	chr6:66973878	T/C	cg07460842	chr6:66804631	NA	0.88	9.81	0.54	3.15e-19	Exhaled nitric oxide output;
SARC	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	0.73	7.72	0.45	3.47e-13	Platelet count;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg02910194	chr3:173438075	NLGN1	0.53	7.94	0.46	8.33e-14	Thyroid stimulating hormone;
SARC	cis	rs12681366	0.683	rs2515161	chr8:95370918	T/C	cg26464482	chr8:95565502	KIAA1429	-0.46	-5.7	-0.35	3.57e-8	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs1348850	0.958	rs4528793	chr2:178464271	C/T	cg23306229	chr2:178417860	TTC30B	0.56	6.47	0.39	5.64e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs992157	0.735	rs13388024	chr2:219097773	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.67	9.4	0.52	5.47e-18	Colorectal cancer;
SARC	cis	rs1707322	0.752	rs12024590	chr1:46127496	A/C	cg03146154	chr1:46216737	IPP	0.52	6.25	0.38	1.92e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs12142240	0.698	rs112068407	chr1:46822291	T/C	cg00530320	chr1:46809349	NSUN4	0.57	6.79	0.41	9.05e-11	Menopause (age at onset);
SARC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg24053721	chr4:142053970	RNF150	0.44	6.26	0.38	1.83e-9	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2073300	0.609	rs6137929	chr20:23376357	G/A	cg16736954	chr20:23401023	NAPB	0.79	4.99	0.31	1.16e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs6582630	0.638	rs7963994	chr12:38555535	G/A	cg14851346	chr12:38532713	NA	-0.44	-5.29	-0.33	2.83e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6545883	0.783	rs12713442	chr2:61848078	G/A	cg15711740	chr2:61764176	XPO1	-0.42	-5.29	-0.33	2.88e-7	Tuberculosis;
SARC	cis	rs2120243	0.510	rs10936087	chr3:157106628	T/G	cg24825693	chr3:157122686	VEPH1	-0.46	-6.42	-0.39	7.47e-10	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs6543140	0.601	rs7558013	chr2:102992806	G/T	cg09003973	chr2:102972529	NA	0.56	6.75	0.4	1.17e-10	Blood protein levels;
SARC	cis	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg25894440	chr7:65020034	NA	-0.78	-6.04	-0.37	6.1e-9	Diabetic kidney disease;
SARC	cis	rs2228479	1.000	rs2228479	chr16:89985940	G/A	cg00800038	chr16:89945340	TCF25	-0.72	-4.72	-0.3	4.08e-6	Skin colour saturation;
SARC	cis	rs7633770	0.786	rs4234464	chr3:46679675	C/T	cg11219411	chr3:46661640	NA	-0.4	-6.48	-0.39	5.5e-10	Coronary artery disease;
SARC	cis	rs11792861	0.926	rs7046725	chr9:111882729	T/G	cg13535736	chr9:111863775	C9orf5	-0.39	-4.86	-0.3	2.13e-6	Menarche (age at onset);
SARC	cis	rs7772486	0.806	rs2265477	chr6:146212338	T/C	cg23711669	chr6:146136114	FBXO30	0.76	11.78	0.61	1.95e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9815354	0.761	rs73083329	chr3:41927151	C/T	cg03022575	chr3:42003672	ULK4	0.69	5.65	0.35	4.69e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs10782582	0.609	rs112205173	chr1:76310100	C/T	cg03433033	chr1:76189801	ACADM	-0.38	-4.79	-0.3	3.03e-6	Daytime sleep phenotypes;
SARC	cis	rs2153535	0.580	rs7341201	chr6:8470270	T/C	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg05368731	chr17:41323189	NBR1	0.77	9.18	0.52	2.34e-17	Menopause (age at onset);
SARC	cis	rs9517320	0.534	rs61971163	chr13:99188883	G/A	cg07423050	chr13:99094983	FARP1	-0.44	-5.72	-0.35	3.23e-8	Longevity;
SARC	cis	rs7818345	1.000	rs11991105	chr8:19290655	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.42	5.6	0.34	6.01e-8	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs8084125	0.832	rs62105175	chr18:74948498	T/C	cg26065057	chr18:74961000	GALR1	0.47	4.91	0.31	1.75e-6	Obesity-related traits;
SARC	cis	rs858239	0.676	rs3807459	chr7:23389751	T/C	cg23682824	chr7:23144976	KLHL7	0.5	6.23	0.38	2.16e-9	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9457247	0.624	rs17524252	chr6:167466978	T/G	cg07741184	chr6:167504864	NA	0.38	7.32	0.43	3.92e-12	Crohn's disease;
SARC	cis	rs7223966	1.000	rs16947005	chr17:61702989	C/T	cg26338869	chr17:61819248	STRADA	-0.43	-4.84	-0.3	2.4e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs453301	0.658	rs12114954	chr8:8904862	T/G	cg11608241	chr8:8085544	FLJ10661	-0.43	-5.39	-0.33	1.74e-7	Joint mobility (Beighton score);
SARC	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs35110281	0.641	rs4819283	chr21:45083011	T/A	cg21573476	chr21:45109991	RRP1B	-0.59	-8.55	-0.49	1.6e-15	Mean corpuscular volume;
SARC	cis	rs965469	1.000	rs2236117	chr20:3302021	T/C	cg25506879	chr20:3388711	C20orf194	-0.49	-4.96	-0.31	1.33e-6	IFN-related cytopenia;
SARC	cis	rs3820928	1.000	rs59904960	chr2:227761269	T/C	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.97	-0.36	8.88e-9	Pulmonary function;
SARC	trans	rs6695352	0.802	rs12026786	chr1:214969949	C/T	cg20107201	chr22:41788401	TEF	0.46	6.42	0.39	7.62e-10	Migraine without aura;
SARC	trans	rs8177876	0.822	rs1563077	chr16:81107556	T/A	cg14909325	chr11:1674770	HCCA2	0.67	6.57	0.4	3.23e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
SARC	cis	rs13161895	1.000	rs248320	chr5:179432096	G/A	cg06664874	chr5:179499304	RNF130	0.49	4.77	0.3	3.32e-6	LDL cholesterol;
SARC	cis	rs10911232	0.507	rs6664995	chr1:183017345	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.37	0.56	5.93e-21	Hypertriglyceridemia;
SARC	cis	rs9399135	0.967	rs4896125	chr6:135342569	C/T	cg24558204	chr6:135376177	HBS1L	0.45	6.07	0.37	5.25e-9	Red blood cell count;
SARC	cis	rs7312774	0.618	rs7968263	chr12:107330844	C/A	cg16260113	chr12:107380972	MTERFD3	0.98	7.83	0.46	1.73e-13	Severe influenza A (H1N1) infection;
SARC	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.48	-6.04	-0.37	6.07e-9	Lymphocyte counts;
SARC	cis	rs262150	0.567	rs2040897	chr7:158803848	C/T	cg09640425	chr7:158790006	NA	-0.43	-6.11	-0.37	4.11e-9	Facial morphology (factor 20);
SARC	cis	rs751728	0.687	rs4711355	chr6:33759906	G/T	cg25922239	chr6:33757077	LEMD2	0.57	7.53	0.44	1.1e-12	Crohn's disease;
SARC	cis	rs4737010	0.570	rs10112594	chr8:41645565	C/T	cg08923054	chr8:41654455	ANK1	0.71	8.59	0.49	1.28e-15	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg02544571	chr7:139187165	NA	-0.47	-6.42	-0.39	7.5e-10	Electrocardiographic conduction measures;
SARC	cis	rs7084402	0.967	rs7100474	chr10:60273121	T/C	cg07615347	chr10:60278583	BICC1	-0.58	-8.4	-0.48	4.55e-15	Refractive error;
SARC	cis	rs77633900	0.502	rs116917406	chr15:76922940	T/C	cg21673338	chr15:77095150	SCAPER	-0.73	-5.58	-0.34	6.72e-8	Non-glioblastoma glioma;Glioma;
SARC	cis	rs34779708	0.931	rs4934711	chr10:35360310	G/A	cg03585969	chr10:35415529	CREM	0.39	5.04	0.31	9.4e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs17376456	0.877	rs9314092	chr5:93326362	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.56	4.94	0.31	1.48e-6	Diabetic retinopathy;
SARC	cis	rs921968	0.613	rs2303565	chr2:219545309	T/C	cg02176678	chr2:219576539	TTLL4	-0.35	-5.06	-0.31	8.59e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs7326068	0.610	rs4769128	chr13:21322682	A/G	cg16922012	chr13:21400325	XPO4	0.42	5.43	0.33	1.44e-7	Schizophrenia, bipolar disorder and depression (combined);
SARC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg04234412	chr22:24373322	LOC391322	-0.5	-5.91	-0.36	1.18e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs8141529	0.778	rs5762795	chr22:29182500	C/A	cg02153584	chr22:29168773	CCDC117	0.81	12.57	0.64	5.36e-28	Lymphocyte counts;
SARC	cis	rs2204008	0.744	rs2222344	chr12:38406832	T/G	cg13010199	chr12:38710504	ALG10B	0.75	10.24	0.56	1.51e-20	Bladder cancer;
SARC	cis	rs17264034	0.500	rs1508800	chr5:9556461	A/C	cg18616062	chr5:9546347	SEMA5A	0.42	5.04	0.31	9.53e-7	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;
SARC	cis	rs6545883	0.929	rs3732171	chr2:61749690	C/T	cg15711740	chr2:61764176	XPO1	-0.41	-5.18	-0.32	4.82e-7	Tuberculosis;
SARC	cis	rs9303401	0.646	rs9303403	chr17:57219300	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.58	-7.03	-0.42	2.29e-11	Cognitive test performance;
SARC	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-1.01	-11.75	-0.61	2.52e-25	Alzheimer's disease;
SARC	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg22920501	chr2:26401640	FAM59B	0.61	8.19	0.47	1.71e-14	Gut microbiome composition (summer);
SARC	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.71	7.07	0.42	1.79e-11	Platelet count;
SARC	cis	rs9486719	1.000	rs11153023	chr6:96968525	C/T	cg18709589	chr6:96969512	KIAA0776	-0.49	-5.01	-0.31	1.06e-6	Migraine;Coronary artery disease;
SARC	cis	rs9814567	1.000	rs4974484	chr3:134219019	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.08	-0.42	1.7e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg19729930	chr2:74357872	NA	0.75	10.97	0.58	7.81e-23	Gestational age at birth (maternal effect);
SARC	cis	rs8141529	0.764	rs5752809	chr22:29225500	G/A	cg15103426	chr22:29168792	CCDC117	0.67	8.75	0.5	4.51e-16	Lymphocyte counts;
SARC	cis	rs2439831	0.850	rs7169322	chr15:44131014	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	8.16	0.47	2.04e-14	Lung cancer in ever smokers;
SARC	cis	rs9818758	0.505	rs67286839	chr3:49265744	C/T	cg00383909	chr3:49044727	WDR6	0.71	6.15	0.37	3.37e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.48	5.59	0.34	6.28e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs734999	0.545	rs10752748	chr1:2544640	G/A	cg18854424	chr1:2615690	NA	0.32	5.14	0.32	5.93e-7	Ulcerative colitis;
SARC	cis	rs73198271	0.740	rs10092720	chr8:8649117	A/C	cg06636001	chr8:8085503	FLJ10661	-0.49	-5.41	-0.33	1.6e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs992157	0.735	rs13392177	chr2:219112956	C/T	cg00012203	chr2:219082015	ARPC2	-0.86	-14.21	-0.68	2.04e-33	Colorectal cancer;
SARC	cis	rs4141404	0.582	rs5753630	chr22:31861950	A/G	cg02404636	chr22:31891804	SFI1	0.44	5.53	0.34	8.43e-8	Paclitaxel-induced neuropathy;
SARC	cis	rs13161895	1.000	rs17079966	chr5:179443190	G/T	cg06664874	chr5:179499304	RNF130	0.51	5.15	0.32	5.65e-7	LDL cholesterol;
SARC	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.74	8.73	0.5	5.14e-16	Height;
SARC	cis	rs593982	0.843	rs552312	chr11:65477349	C/T	cg08755490	chr11:65554678	OVOL1	0.86	8.03	0.47	4.91e-14	Atopic dermatitis;
SARC	cis	rs2749592	0.505	rs7915670	chr10:37870212	T/C	cg25427524	chr10:38739819	LOC399744	0.44	6.33	0.38	1.27e-9	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs6450176	0.564	rs255759	chr5:53328549	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.55	-6.23	-0.38	2.11e-9	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs6546550	0.901	rs3732266	chr2:70057448	T/G	cg02498382	chr2:70120550	SNRNP27	-0.42	-7.09	-0.42	1.58e-11	Prevalent atrial fibrillation;
SARC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg02353165	chr6:42928485	GNMT	0.65	8.9	0.5	1.57e-16	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs3791556	0.504	rs1001285	chr2:240107814	A/G	cg03281426	chr2:240109471	HDAC4	0.47	6.94	0.41	3.94e-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs7412746	0.611	rs4509581	chr1:150774465	A/G	cg10589385	chr1:150898437	SETDB1	0.41	5.4	0.33	1.61e-7	Melanoma;
SARC	cis	rs3862260	0.509	rs10754416	chr1:120163531	A/G	cg16322792	chr1:120165303	ZNF697	0.29	6.07	0.37	5.27e-9	Systemic lupus erythematosus;
SARC	cis	rs9341808	0.718	rs9448898	chr6:80845341	T/A	cg08355045	chr6:80787529	NA	0.35	5.5	0.34	9.83e-8	Sitting height ratio;
SARC	cis	rs734999	0.545	rs12730932	chr1:2559589	T/G	cg18854424	chr1:2615690	NA	-0.31	-4.91	-0.31	1.73e-6	Ulcerative colitis;
SARC	cis	rs4713118	0.662	rs469228	chr6:27970704	A/G	cg16479474	chr6:28041457	NA	0.35	5.03	0.31	9.78e-7	Parkinson's disease;
SARC	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg27121462	chr16:89883253	FANCA	0.69	10.75	0.58	3.87e-22	Vitiligo;
SARC	cis	rs2806561	0.765	rs2806556	chr1:23502850	G/A	cg12483005	chr1:23474871	LUZP1	0.43	5.56	0.34	7.45e-8	Height;
SARC	cis	rs3733585	0.673	rs6449156	chr4:9956712	G/C	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.39	-0.33	1.73e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg05623727	chr3:50126028	RBM5	-0.33	-5.0	-0.31	1.14e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9486719	1.000	rs2092096	chr6:96870919	A/G	cg18709589	chr6:96969512	KIAA0776	0.49	4.92	0.31	1.65e-6	Migraine;Coronary artery disease;
SARC	trans	rs61931739	0.500	rs11052994	chr12:34065843	C/T	cg26384229	chr12:38710491	ALG10B	0.87	12.36	0.63	2.53e-27	Morning vs. evening chronotype;
SARC	cis	rs9420	0.961	rs17455520	chr11:57540458	C/A	cg23127183	chr11:57508653	C11orf31	-0.6	-6.86	-0.41	6.03e-11	Schizophrenia;
SARC	cis	rs6570726	0.846	rs371186	chr6:145886971	T/C	cg23711669	chr6:146136114	FBXO30	0.8	12.67	0.64	2.5e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2228479	0.850	rs62056068	chr16:89909737	C/T	cg00800038	chr16:89945340	TCF25	-0.82	-5.8	-0.35	2.19e-8	Skin colour saturation;
SARC	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg24633833	chr3:10029261	TMEM111	0.52	5.25	0.33	3.43e-7	Alzheimer's disease;
SARC	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg05332525	chr7:65337924	VKORC1L1	0.43	4.84	0.3	2.38e-6	Aortic root size;
SARC	cis	rs9388451	0.626	rs1739384	chr6:126099246	C/A	cg05901451	chr6:126070800	HEY2	-0.51	-6.37	-0.39	9.89e-10	Brugada syndrome;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg03246824	chr11:118966313	H2AFX	0.52	6.87	0.41	5.8e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs9309473	0.583	rs6718864	chr2:73574591	A/G	cg20560298	chr2:73613845	ALMS1	-0.54	-6.85	-0.41	6.51e-11	Metabolite levels;
SARC	cis	rs7617773	0.780	rs35411187	chr3:48360017	C/G	cg11946769	chr3:48343235	NME6	0.76	9.67	0.54	8.16e-19	Coronary artery disease;
SARC	cis	rs2777491	0.574	rs316611	chr15:41751678	A/G	cg18705301	chr15:41695430	NDUFAF1	1.13	16.98	0.74	1.24e-42	Ulcerative colitis;
SARC	cis	rs55962025	0.883	rs2298967	chr4:3185747	T/C	cg06533319	chr4:3265114	C4orf44	0.32	4.83	0.3	2.46e-6	Parental longevity (mother's age at death);
SARC	cis	rs11168187	0.891	rs4505143	chr12:48124148	G/A	cg12761788	chr12:48120090	P11	0.41	5.23	0.32	3.83e-7	Vertical cup-disc ratio;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg09782245	chr16:30845959	NA	0.51	6.94	0.41	3.95e-11	Schizophrenia;
SARC	cis	rs7474896	0.515	rs2749582	chr10:38275284	A/G	cg00409905	chr10:38381863	ZNF37A	0.42	4.72	0.3	4.14e-6	Obesity (extreme);
SARC	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg03060546	chr3:49711283	APEH	0.43	5.33	0.33	2.27e-7	Parkinson's disease;
SARC	cis	rs4555082	0.874	rs56263609	chr14:105756944	C/T	cg06808227	chr14:105710500	BRF1	-0.52	-6.54	-0.39	3.78e-10	Mean platelet volume;Platelet distribution width;
SARC	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg17971929	chr21:40555470	PSMG1	0.98	13.64	0.67	1.59e-31	Cognitive function;
SARC	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.6	-6.31	-0.38	1.42e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs4689388	0.889	rs10026334	chr4:6294607	G/A	cg00701064	chr4:6280414	WFS1	0.54	8.58	0.49	1.38e-15	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs7666738	0.830	rs2903152	chr4:99067992	A/G	cg05340658	chr4:99064831	C4orf37	0.65	8.71	0.5	5.54e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs820218	0.886	rs2165634	chr17:73663297	T/G	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.7	9.64	0.53	9.89e-19	Rotator cuff tears;
SARC	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.39	5.29	0.33	2.79e-7	Personality dimensions;
SARC	cis	rs60871478	0.898	rs35928069	chr7:823067	G/C	cg05535760	chr7:792225	HEATR2	0.77	7.75	0.45	2.75e-13	Cerebrospinal P-tau181p levels;
SARC	cis	rs6866344	0.697	rs11743893	chr5:178125194	C/T	cg03877680	chr5:178157825	ZNF354A	1.02	12.7	0.64	1.9e-28	Neutrophil percentage of white cells;
SARC	cis	rs9611519	0.929	rs4821991	chr22:41440683	T/C	cg03806693	chr22:41940476	POLR3H	-0.6	-7.69	-0.45	4.15e-13	Neuroticism;
SARC	cis	rs672059	0.513	rs572977	chr1:183164991	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	5.19	0.32	4.54e-7	Hypertriglyceridemia;
SARC	cis	rs7520050	0.966	rs785520	chr1:46568836	T/C	cg24296786	chr1:45957014	TESK2	0.38	4.82	0.3	2.56e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg22455342	chr2:225449267	CUL3	0.62	7.82	0.46	1.83e-13	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs2645694	0.626	rs2703115	chr4:77824442	C/T	cg18351406	chr4:77819688	ANKRD56	0.42	6.02	0.37	6.82e-9	Emphysema distribution in smoking;
SARC	cis	rs6910061	0.750	rs13214645	chr6:11147323	A/G	cg27233058	chr6:11094804	LOC221710	0.55	4.88	0.3	1.93e-6	Diabetic kidney disease;
SARC	cis	rs1707322	0.752	rs4607935	chr1:46117161	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.25	0.38	1.97e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs16976116	0.855	rs28649719	chr15:55500211	C/T	cg11288833	chr15:55489084	RSL24D1	0.63	6.13	0.37	3.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9322193	0.567	rs7742692	chr6:150213499	A/G	cg09699651	chr6:150184138	LRP11	0.52	6.65	0.4	2.07e-10	Lung cancer;
SARC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.57	-6.61	-0.4	2.59e-10	Longevity;Endometriosis;
SARC	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg07636037	chr3:49044803	WDR6	-0.95	-14.49	-0.69	2.45e-34	Parkinson's disease;
SARC	cis	rs67478160	0.584	rs12433009	chr14:104196405	C/G	cg26031613	chr14:104095156	KLC1	-0.41	-5.21	-0.32	4.21e-7	Schizophrenia;
SARC	cis	rs6088813	1.000	rs56306402	chr20:33937704	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	-0.46	-5.51	-0.34	9.28e-8	Height;
SARC	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg11366901	chr6:160182831	ACAT2	-0.65	-6.72	-0.4	1.37e-10	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs1153858	1.000	rs4775895	chr15:45617957	T/A	cg26924012	chr15:45694286	SPATA5L1	0.76	10.36	0.56	6.37e-21	Homoarginine levels;
SARC	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg04277193	chr17:41438351	NA	0.44	4.76	0.3	3.35e-6	Menopause (age at onset);
SARC	cis	rs9303401	0.659	rs34556735	chr17:56694447	A/C	cg25039879	chr17:56429692	SUPT4H1	0.71	6.64	0.4	2.25e-10	Cognitive test performance;
SARC	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg11644478	chr21:40555479	PSMG1	1.03	14.32	0.68	8.7e-34	Cognitive function;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	ch.13.1744822R	chr13:109806861	MYO16	-0.75	-5.38	-0.33	1.78e-7	Obesity-related traits;
SARC	cis	rs4846217	1.000	rs12125492	chr1:10421878	A/G	cg19092837	chr1:10271724	KIF1B	0.41	5.2	0.32	4.43e-7	Platelet count;
SARC	cis	rs7247513	0.964	rs8100964	chr19:12720631	C/T	cg01871581	chr19:12707946	ZNF490	-0.87	-12.47	-0.63	1.13e-27	Bipolar disorder;
SARC	cis	rs9916302	0.904	rs11869109	chr17:37518205	G/T	cg07936489	chr17:37558343	FBXL20	0.69	9.14	0.51	3.18e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs12249377	0.519	rs11597471	chr10:92598767	C/G	cg14313238	chr10:92632228	RPP30	0.44	4.85	0.3	2.23e-6	White matter microstructure (global fractional anisotropy);
SARC	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs2073499	0.872	rs58051625	chr3:50278717	G/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.5	4.75	0.3	3.56e-6	Schizophrenia;
SARC	cis	rs6121246	0.567	rs6060247	chr20:30190720	C/G	cg21427119	chr20:30132790	HM13	-0.49	-5.33	-0.33	2.36e-7	Mean corpuscular hemoglobin;
SARC	cis	rs9660992	0.573	rs1172139	chr1:205213962	G/A	cg21643547	chr1:205240462	TMCC2	-0.56	-7.3	-0.43	4.44e-12	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg11301795	chr4:187892539	NA	-0.69	-10.22	-0.56	1.69e-20	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7824557	0.602	rs1435273	chr8:11209499	T/C	cg21775007	chr8:11205619	TDH	0.69	8.97	0.51	1.03e-16	Retinal vascular caliber;
SARC	cis	rs9640161	0.830	rs11768108	chr7:150064150	C/T	cg21361702	chr7:150065534	REPIN1	0.6	6.84	0.41	6.83e-11	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs807669	0.548	rs762522	chr22:19180575	C/T	cg02655711	chr22:19163373	SLC25A1	0.48	6.94	0.41	3.88e-11	Metabolite levels;
SARC	trans	rs6600671	0.934	rs67718113	chr1:121238910	C/T	cg00646200	chr1:148855367	NA	-0.5	-6.79	-0.41	9.37e-11	Hip geometry;
SARC	cis	rs17854409	0.881	rs1046784	chr20:61472808	G/C	cg05147244	chr20:61493195	TCFL5	0.92	5.95	0.36	9.87e-9	Obesity-related traits;
SARC	cis	rs644799	1.000	rs693597	chr11:95589629	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.67	8.87	0.5	1.93e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7264396	0.635	rs6058366	chr20:34512172	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-7.47	-0.44	1.56e-12	Total cholesterol levels;
SARC	cis	rs7666738	0.822	rs9992360	chr4:98937123	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9660180	0.967	rs12040325	chr1:1702436	G/A	cg13849007	chr1:1677539	SLC35E2	-0.37	-4.76	-0.3	3.39e-6	Body mass index;
SARC	cis	rs2200578	1.000	rs116648076	chr2:99882347	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.62	5.9	0.36	1.29e-8	IgG glycosylation;
SARC	cis	rs10464366	0.746	rs34792397	chr7:39146331	G/A	cg15212455	chr7:39170539	POU6F2	0.4	4.88	0.3	1.97e-6	IgG glycosylation;
SARC	cis	rs3126085	0.877	rs1969019	chr1:152211502	A/C	cg03465714	chr1:152285911	FLG	-0.44	-5.3	-0.33	2.67e-7	Atopic dermatitis;
SARC	cis	rs748404	0.660	rs694725	chr15:43756210	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.49	5.51	0.34	9.32e-8	Lung cancer;
SARC	cis	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg11995313	chr8:8860691	ERI1	-0.39	-5.03	-0.31	9.86e-7	Mood instability;
SARC	cis	rs9788682	0.792	rs35031105	chr15:78772806	C/T	cg24631222	chr15:78858424	CHRNA5	0.74	8.95	0.51	1.17e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs17376456	0.825	rs28412976	chr5:93248377	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.67	0.35	4.28e-8	Diabetic retinopathy;
SARC	cis	rs7714584	1.000	rs34156253	chr5:150226230	A/G	cg22134413	chr5:150180641	NA	0.78	6.56	0.39	3.42e-10	Crohn's disease;
SARC	cis	rs11190604	1.000	rs2298075	chr10:102247408	C/A	cg07080220	chr10:102295463	HIF1AN	0.76	8.99	0.51	8.6e-17	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs17376456	0.877	rs7728736	chr5:93404277	C/T	cg21475434	chr5:93447410	FAM172A	0.87	7.91	0.46	1.06e-13	Diabetic retinopathy;
SARC	cis	rs8067545	0.750	rs4005937	chr17:19959828	A/C	cg13482628	chr17:19912719	NA	0.54	7.25	0.43	5.95e-12	Schizophrenia;
SARC	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg25894440	chr7:65020034	NA	0.73	5.51	0.34	9.25e-8	Diabetic kidney disease;
SARC	cis	rs2070488	0.965	rs7433277	chr3:38529818	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	13.36	0.66	1.33e-30	Electrocardiographic conduction measures;
SARC	cis	rs1348850	0.526	rs7588049	chr2:178390778	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.65	-5.52	-0.34	8.88e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2013441	1.000	rs2526472	chr17:20137888	G/A	cg13482628	chr17:19912719	NA	-0.47	-6.2	-0.38	2.57e-9	Obesity-related traits;
SARC	cis	rs10189230	0.967	rs12613015	chr2:222356119	G/A	cg14652038	chr2:222343519	EPHA4	0.46	6.06	0.37	5.42e-9	Urate levels in lean individuals;
SARC	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	11.89	0.61	8.48e-26	Chronic sinus infection;
SARC	trans	rs66573146	0.572	rs67922134	chr4:6955772	G/A	cg07817883	chr1:32538562	TMEM39B	1.07	8.35	0.48	6.04e-15	Granulocyte percentage of myeloid white cells;
SARC	cis	rs796364	0.806	rs1605900	chr2:200870197	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.78	6.8	0.41	8.82e-11	Schizophrenia;
SARC	cis	rs4713118	0.629	rs149899	chr6:28019979	C/T	cg26335602	chr6:28129616	ZNF389	0.5	5.28	0.33	2.95e-7	Parkinson's disease;
SARC	cis	rs4919694	1.000	rs10509760	chr10:104634107	A/G	cg04362960	chr10:104952993	NT5C2	0.66	5.68	0.35	3.93e-8	Arsenic metabolism;
SARC	cis	rs7644634	0.559	rs17202348	chr3:105454483	A/G	cg23051926	chr3:105466016	CBLB	0.47	5.25	0.33	3.47e-7	Itch intensity from mosquito bite;
SARC	cis	rs73242632	1.000	rs28474684	chr4:57875469	A/G	cg20415529	chr4:57845134	POLR2B;C4orf14	1.07	6.6	0.4	2.74e-10	Congenital heart disease (maternal effect);
SARC	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg02725872	chr8:58115012	NA	-0.36	-6.12	-0.37	3.91e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg13939156	chr17:80058883	NA	0.4	6.09	0.37	4.56e-9	Life satisfaction;
SARC	cis	rs6580649	0.882	rs59766465	chr12:48470169	G/A	cg05342945	chr12:48394962	COL2A1	0.55	5.91	0.36	1.22e-8	Lung cancer;
SARC	cis	rs13256369	1.000	rs873063	chr8:8572447	A/G	cg17143192	chr8:8559678	CLDN23	0.54	6.14	0.37	3.46e-9	Obesity-related traits;
SARC	cis	rs17345786	0.520	rs12638134	chr3:101334609	G/T	cg12386194	chr3:101231763	SENP7	0.57	6.85	0.41	6.35e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg12463550	chr7:65579703	CRCP	0.67	5.15	0.32	5.59e-7	Diabetic kidney disease;
SARC	cis	rs911555	0.755	rs8010247	chr14:103933556	A/G	cg12935359	chr14:103987150	CKB	0.38	5.28	0.33	2.99e-7	Intelligence (multi-trait analysis);
SARC	cis	rs889312	0.500	rs1867731	chr5:56132115	C/G	cg14703610	chr5:56206110	C5orf35	0.5	6.17	0.37	2.96e-9	Breast cancer;Breast cancer (early onset);
SARC	cis	rs453301	0.522	rs2929455	chr8:9083433	A/T	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.73	-0.5	4.84e-16	Joint mobility (Beighton score);
SARC	cis	rs34779708	0.966	rs12775799	chr10:35488264	C/T	cg03585969	chr10:35415529	CREM	0.4	4.93	0.31	1.55e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs1044826	0.642	rs6787649	chr3:139193321	C/T	cg15131784	chr3:139108705	COPB2	0.39	4.96	0.31	1.36e-6	Obesity-related traits;
SARC	cis	rs7772486	0.754	rs4566902	chr6:146244128	A/G	cg05347473	chr6:146136440	FBXO30	-0.48	-6.52	-0.39	4.23e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6582630	0.537	rs7310749	chr12:38400472	C/T	cg26384229	chr12:38710491	ALG10B	0.85	12.2	0.62	8.77e-27	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6686643	1.000	rs959617	chr1:165616881	C/G	cg19407955	chr1:165599744	MGST3	-0.58	-6.07	-0.37	5.18e-9	Total ventricular volume;
SARC	cis	rs240764	0.817	rs11155606	chr6:101163915	T/C	cg09795085	chr6:101329169	ASCC3	-0.47	-6.14	-0.37	3.56e-9	Neuroticism;
SARC	cis	rs116095464	0.558	rs62346508	chr5:203668	T/C	cg22496380	chr5:211416	CCDC127	-0.92	-8.21	-0.47	1.56e-14	Breast cancer;
SARC	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg26681399	chr22:41777847	TEF	-0.5	-5.53	-0.34	8.77e-8	Vitiligo;
SARC	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg13206674	chr6:150067644	NUP43	0.42	5.45	0.34	1.26e-7	Lung cancer;
SARC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.64	0.57	8.23e-22	Prudent dietary pattern;
SARC	cis	rs7223966	0.921	rs2006123	chr17:61958669	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	7.13	0.42	1.25e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9302635	0.513	rs35460163	chr16:72177060	C/T	cg01557791	chr16:72042693	DHODH	-0.55	-5.63	-0.35	5.15e-8	Blood protein levels;
SARC	cis	rs6582630	0.555	rs7133706	chr12:38475465	G/A	cg26384229	chr12:38710491	ALG10B	-0.8	-11.6	-0.61	7.15e-25	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs8141529	0.748	rs5762874	chr22:29269658	C/G	cg15103426	chr22:29168792	CCDC117	0.66	8.77	0.5	3.84e-16	Lymphocyte counts;
SARC	cis	rs7644634	0.535	rs9872897	chr3:105473827	T/A	cg23051926	chr3:105466016	CBLB	0.49	5.54	0.34	7.98e-8	Itch intensity from mosquito bite;
SARC	cis	rs6088580	0.524	rs11167241	chr20:33250835	C/T	cg24642439	chr20:33292090	TP53INP2	-0.54	-6.65	-0.4	2.07e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.03	0.37	6.27e-9	Prudent dietary pattern;
SARC	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg08859206	chr1:53392774	SCP2	-0.42	-6.08	-0.37	4.85e-9	Monocyte count;
SARC	cis	rs7647973	0.710	rs6446285	chr3:49626306	G/A	cg06212747	chr3:49208901	KLHDC8B	0.77	6.38	0.39	9.66e-10	Menarche (age at onset);
SARC	cis	rs7666738	0.546	rs28444809	chr4:98916934	C/T	cg05340658	chr4:99064831	C4orf37	0.6	7.3	0.43	4.55e-12	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7336332	0.598	rs76249173	chr13:28010445	A/G	cg01674679	chr13:27998804	GTF3A	-0.55	-5.13	-0.32	5.96e-7	Weight;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg04896381	chr17:45772467	TBKBP1	-0.66	-6.73	-0.4	1.29e-10	Lung cancer in ever smokers;
SARC	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg16479474	chr6:28041457	NA	0.37	5.37	0.33	1.94e-7	Depression;
SARC	cis	rs2197308	0.606	rs2218397	chr12:38278307	C/T	cg13010199	chr12:38710504	ALG10B	-0.55	-6.7	-0.4	1.56e-10	Morning vs. evening chronotype;
SARC	cis	rs67311347	0.956	rs4974029	chr3:40521318	C/G	cg24209194	chr3:40518798	ZNF619	0.63	8.04	0.47	4.48e-14	Renal cell carcinoma;
SARC	cis	rs34779708	0.966	rs12769484	chr10:35465746	G/A	cg03585969	chr10:35415529	CREM	0.38	4.77	0.3	3.19e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs67366981	0.720	rs4447349	chr14:77685381	G/A	cg06779847	chr14:77687015	TMEM63C	-0.45	-4.87	-0.3	2.09e-6	Obsessive-compulsive symptoms;
SARC	cis	rs12477438	0.539	rs12999417	chr2:99865548	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.79	-11.51	-0.6	1.45e-24	Chronic sinus infection;
SARC	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg06713675	chr4:122721982	EXOSC9	-0.51	-7.05	-0.42	2.06e-11	Type 2 diabetes;
SARC	trans	rs34645974	0.580	rs7556649	chr1:221452090	C/T	cg15765380	chr3:150477722	SIAH2	0.56	6.23	0.38	2.1e-9	Interferon gamma-induced protein 10 levels;
SARC	cis	rs644799	0.601	rs7902	chr11:95565288	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.47	5.89	0.36	1.31e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-7.83	-0.46	1.71e-13	Alzheimer's disease;
SARC	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.44	5.44	0.34	1.37e-7	Tonsillectomy;
SARC	cis	rs4803468	1.000	rs284652	chr19:41928652	C/T	cg09537434	chr19:41945824	ATP5SL	-0.98	-17.28	-0.75	1.27e-43	Height;
SARC	cis	rs13191362	0.935	rs35942036	chr6:163163297	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.43	5.3	0.33	2.71e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	trans	rs1994135	0.647	rs1351681	chr12:33698724	G/A	cg26384229	chr12:38710491	ALG10B	0.82	10.21	0.56	1.78e-20	Resting heart rate;
SARC	cis	rs7818688	0.697	rs74633621	chr8:95981037	A/G	cg13393036	chr8:95962371	TP53INP1	0.4	4.85	0.3	2.27e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs1348850	0.747	rs1047884	chr2:178488281	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.58	6.55	0.39	3.63e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg03517284	chr6:25882590	NA	-0.35	-4.93	-0.31	1.57e-6	Blood metabolite levels;
SARC	cis	rs1467026	0.523	rs9865548	chr3:12801785	C/T	cg05775895	chr3:12838266	CAND2	0.61	8.63	0.49	9.88e-16	P wave duration;
SARC	cis	rs986417	0.901	rs10134736	chr14:60998540	A/T	cg27398547	chr14:60952738	C14orf39	0.92	8.62	0.49	1.04e-15	Gut microbiota (bacterial taxa);
SARC	cis	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg00800038	chr16:89945340	TCF25	-0.74	-5.14	-0.32	5.79e-7	Skin colour saturation;
SARC	cis	rs7223966	1.000	rs8075061	chr17:61804723	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-5.86	-0.36	1.6e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs61931739	0.517	rs2636074	chr12:34064056	C/T	cg13010199	chr12:38710504	ALG10B	0.66	8.79	0.5	3.28e-16	Morning vs. evening chronotype;
SARC	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg12463550	chr7:65579703	CRCP	0.69	5.23	0.32	3.77e-7	Diabetic kidney disease;
SARC	cis	rs17376456	0.825	rs13155452	chr5:93164449	C/T	cg25358565	chr5:93447407	FAM172A	-1.24	-12.9	-0.65	4.48e-29	Diabetic retinopathy;
SARC	trans	rs2727020	0.553	rs4103567	chr11:49255389	C/T	cg15704280	chr7:45808275	SEPT13	-0.64	-9.31	-0.52	9.84e-18	Coronary artery disease;
SARC	cis	rs7223966	1.000	rs9895920	chr17:61852719	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-5.98	-0.36	8.43e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9747201	1.000	rs9747668	chr17:80161081	A/G	cg09264619	chr17:80180166	NA	-0.52	-6.06	-0.37	5.5e-9	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg00684032	chr4:1343700	KIAA1530	0.37	5.32	0.33	2.43e-7	Obesity-related traits;
SARC	trans	rs8073060	0.586	rs6505487	chr17:33996850	A/G	cg19694781	chr19:47549865	TMEM160	-0.7	-6.97	-0.42	3.31e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs7264396	0.836	rs41293080	chr20:34187697	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.54	-5.82	-0.36	1.93e-8	Total cholesterol levels;
SARC	cis	rs6570726	0.935	rs380433	chr6:145859601	A/T	cg05220968	chr6:146057943	EPM2A	-0.3	-5.08	-0.32	7.76e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7635838	0.855	rs9816564	chr3:11475297	T/C	cg00170343	chr3:11313890	ATG7	0.62	8.23	0.47	1.33e-14	HDL cholesterol;
SARC	cis	rs2033711	0.870	rs4801583	chr19:58918405	A/G	cg25952890	chr19:58913133	NA	0.36	5.16	0.32	5.34e-7	Uric acid clearance;
SARC	trans	rs9325144	0.600	rs34138871	chr12:38735261	A/G	cg23762105	chr12:34175262	ALG10	-0.55	-7.16	-0.42	1.04e-11	Morning vs. evening chronotype;
SARC	cis	rs2228479	0.557	rs62056064	chr16:89903843	G/A	cg00800038	chr16:89945340	TCF25	-0.82	-5.77	-0.35	2.46e-8	Skin colour saturation;
SARC	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg03709012	chr19:19516395	GATAD2A	-0.93	-15.05	-0.7	3.29e-36	Tonsillectomy;
SARC	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg06634786	chr22:41940651	POLR3H	0.49	6.09	0.37	4.68e-9	Vitiligo;
SARC	cis	rs1468333	0.667	rs113322698	chr5:137769576	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.68	8.1	0.47	3e-14	Resting heart rate;
SARC	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg21724239	chr8:58056113	NA	0.61	5.93	0.36	1.1e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs936229	0.749	rs4886633	chr15:75178207	G/A	cg14664628	chr15:75095509	CSK	-0.85	-10.27	-0.56	1.22e-20	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs3858526	0.959	rs4758219	chr11:5951846	G/C	cg02574844	chr11:5959923	NA	-0.43	-5.32	-0.33	2.47e-7	DNA methylation (variation);
SARC	cis	rs910316	0.763	rs175490	chr14:75545685	A/G	cg08847533	chr14:75593920	NEK9	0.84	12.54	0.63	6.67e-28	Height;
SARC	cis	rs9902453	1.000	rs4239227	chr17:28389103	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.53	-6.96	-0.41	3.52e-11	Coffee consumption (cups per day);
SARC	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.54	8.13	0.47	2.5e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs6942407	0.542	rs1981535	chr7:86747375	A/G	cg02420886	chr7:86849541	C7orf23	0.59	5.41	0.33	1.55e-7	Food allergy;
SARC	cis	rs2115536	0.730	rs4573897	chr15:80187225	G/A	cg00225070	chr15:80189496	MTHFS	0.52	6.78	0.41	1e-10	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
SARC	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg16479474	chr6:28041457	NA	0.37	5.39	0.33	1.73e-7	Depression;
SARC	cis	rs9747201	1.000	rs3922470	chr17:80110159	C/T	cg17462356	chr17:80056334	FASN	0.46	5.28	0.33	2.96e-7	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs6495122	0.501	rs12148488	chr15:75382542	G/T	cg09165964	chr15:75287851	SCAMP5	-0.51	-6.92	-0.41	4.41e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	cis	rs593982	0.920	rs72939198	chr11:65438079	G/A	cg08755490	chr11:65554678	OVOL1	-0.86	-8.14	-0.47	2.39e-14	Atopic dermatitis;
SARC	cis	rs459482	0.501	rs148214	chr21:42814218	A/G	cg14166395	chr21:42792516	MX1	-0.45	-5.5	-0.34	1.01e-7	IgG glycosylation;
SARC	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg00933542	chr6:150070202	PCMT1	0.33	5.63	0.35	5.13e-8	Lung cancer;
SARC	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg26335602	chr6:28129616	ZNF389	0.52	5.69	0.35	3.74e-8	Depression;
SARC	cis	rs7249142	0.512	rs12981160	chr19:19298099	T/A	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.23	4.78	0.3	3.15e-6	IgG glycosylation;
SARC	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-6.25	-0.38	1.89e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4930561	0.765	rs4930229	chr11:67944080	G/A	cg16338278	chr11:67432957	ALDH3B2	0.34	5.42	0.33	1.49e-7	Breast cancer in childhood cancer survivors;IgG glycosylation;
SARC	cis	rs356220	0.656	rs356170	chr4:90632276	C/G	cg06632027	chr4:90757378	SNCA	0.41	5.42	0.33	1.49e-7	Parkinson's disease;
SARC	cis	rs5753618	0.561	rs4141404	chr22:31675185	A/C	cg13145458	chr22:31556086	RNF185	0.47	5.01	0.31	1.06e-6	Colorectal cancer;
SARC	cis	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg07777115	chr5:623756	CEP72	-0.64	-5.77	-0.35	2.52e-8	Obesity-related traits;
SARC	cis	rs9462027	0.583	rs912716	chr6:34715761	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.4	-5.7	-0.35	3.69e-8	Systemic lupus erythematosus;
SARC	cis	rs34375054	0.738	rs3751181	chr12:125626535	A/G	cg25124228	chr12:125621409	AACS	-0.54	-7.1	-0.42	1.49e-11	Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs6912958	0.559	rs499373	chr6:88042062	A/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.37	6.39	0.39	8.91e-10	Monocyte percentage of white cells;
SARC	cis	rs875971	0.545	rs4718364	chr7:66001340	C/A	cg11764359	chr7:65958608	NA	0.64	6.4	0.39	8.5e-10	Aortic root size;
SARC	cis	rs5758659	0.652	rs133322	chr22:42405659	A/G	cg04733989	chr22:42467013	NAGA	0.54	7.19	0.43	9e-12	Cognitive function;
SARC	cis	rs2841233	0.692	rs2028416	chr14:105348552	C/T	cg16576083	chr14:105354267	KIAA0284	0.54	8.67	0.49	7.45e-16	IgG glycosylation;
SARC	cis	rs6088580	0.634	rs6059880	chr20:33088669	G/A	cg08999081	chr20:33150536	PIGU	0.43	6.64	0.4	2.18e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg22920501	chr2:26401640	FAM59B	0.61	8.19	0.47	1.71e-14	Gut microbiome composition (summer);
SARC	cis	rs3768617	0.510	rs1413388	chr1:183096694	T/C	cg13390022	chr1:182993471	LAMC1	0.31	4.79	0.3	3.01e-6	Fuchs's corneal dystrophy;
SARC	cis	rs73086581	0.947	rs73084523	chr20:3875626	T/C	cg02187196	chr20:3869020	PANK2	0.65	5.92	0.36	1.15e-8	Response to antidepressants in depression;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg12632573	chr2:127783243	NA	-0.57	-7.2	-0.43	8.46e-12	Gallstone disease;
SARC	trans	rs61931739	0.929	rs10844740	chr12:34067930	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-7.5	-0.44	1.37e-12	Morning vs. evening chronotype;
SARC	cis	rs9400467	0.506	rs12215396	chr6:111572395	T/C	cg15721981	chr6:111408429	SLC16A10	0.67	5.75	0.35	2.85e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg04546413	chr19:29218101	NA	0.63	8.55	0.49	1.7e-15	Methadone dose in opioid dependence;
SARC	cis	rs3617	0.625	rs2336558	chr3:52886240	C/T	cg04865290	chr3:52927548	TMEM110	0.34	4.87	0.3	2.04e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs5758659	0.714	rs133373	chr22:42465788	G/A	cg15128208	chr22:42549153	NA	-0.36	-5.18	-0.32	4.83e-7	Cognitive function;
SARC	cis	rs601339	1.000	rs1798219	chr12:123180061	A/C	cg18578876	chr12:123200353	GPR109B	0.43	4.84	0.3	2.35e-6	Adiponectin levels;
SARC	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg00684032	chr4:1343700	KIAA1530	0.34	4.72	0.3	4.06e-6	Obesity-related traits;
SARC	cis	rs559928	0.606	rs17773078	chr11:63906224	G/A	cg05555928	chr11:63887634	MACROD1	-0.51	-4.85	-0.3	2.26e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs2011503	1.000	rs2965194	chr19:19460702	C/T	cg03709012	chr19:19516395	GATAD2A	-0.67	-5.81	-0.36	2.04e-8	Bipolar disorder;
SARC	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg25072359	chr17:41440525	NA	0.51	6.08	0.37	4.92e-9	Menopause (age at onset);
SARC	cis	rs459571	0.792	rs55923934	chr9:136888233	C/G	cg13789015	chr9:136890014	NCRNA00094	0.62	8.75	0.5	4.37e-16	Platelet distribution width;
SARC	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg11890956	chr21:40555474	PSMG1	1.15	18.86	0.78	8.26e-49	Cognitive function;
SARC	cis	rs9815354	1.000	rs6802340	chr3:41894034	T/C	cg03022575	chr3:42003672	ULK4	0.56	5.29	0.33	2.81e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs11711311	1.000	rs9851731	chr3:113502651	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.63	-7.81	-0.46	1.9e-13	IgG glycosylation;
SARC	cis	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg08045932	chr20:61659980	NA	0.5	6.84	0.41	7.06e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs7937682	0.774	rs59921976	chr11:111473088	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.87	-13.62	-0.67	1.79e-31	Primary sclerosing cholangitis;
SARC	cis	rs2013441	1.000	rs4924808	chr17:20026548	C/T	cg13482628	chr17:19912719	NA	-0.45	-5.83	-0.36	1.87e-8	Obesity-related traits;
SARC	cis	rs2841233	0.791	rs2028415	chr14:105349220	T/G	cg16576083	chr14:105354267	KIAA0284	0.65	9.64	0.53	1.04e-18	IgG glycosylation;
SARC	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg18404041	chr3:52824283	ITIH1	-0.38	-5.59	-0.34	6.45e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9831754	0.906	rs2102601	chr3:78410536	G/A	cg06138941	chr3:78371609	NA	-0.59	-6.86	-0.41	6.06e-11	Calcium levels;
SARC	cis	rs1371867	0.817	rs7846076	chr8:101327629	A/G	cg11906718	chr8:101322791	RNF19A	0.67	8.67	0.49	7.44e-16	Atrioventricular conduction;
SARC	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.47	-5.93	-0.36	1.07e-8	Lymphocyte counts;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg08811588	chr7:100473311	SRRT	-0.64	-7.4	-0.44	2.42e-12	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg23758822	chr17:41437982	NA	0.89	11.27	0.59	8.17e-24	Menopause (age at onset);
SARC	cis	rs7727544	0.735	rs272860	chr5:131684175	C/G	cg07395648	chr5:131743802	NA	-0.42	-4.94	-0.31	1.51e-6	Blood metabolite levels;
SARC	cis	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg07777115	chr5:623756	CEP72	-0.56	-4.9	-0.31	1.77e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg16434002	chr17:42200994	HDAC5	0.47	5.91	0.36	1.18e-8	Total body bone mineral density;
SARC	cis	rs6598955	0.724	rs12132137	chr1:26631243	C/T	cg04990556	chr1:26633338	UBXN11	-0.61	-8.35	-0.48	5.93e-15	Obesity-related traits;
SARC	cis	rs11673344	0.566	rs256735	chr19:37866043	A/G	cg14683738	chr19:37701593	ZNF585B	0.45	5.48	0.34	1.11e-7	Obesity-related traits;
SARC	cis	rs7829975	0.514	rs2920991	chr8:8259117	T/A	cg15556689	chr8:8085844	FLJ10661	0.52	6.13	0.37	3.66e-9	Mood instability;
SARC	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg11644478	chr21:40555479	PSMG1	-0.58	-7.02	-0.42	2.4e-11	Menarche (age at onset);
SARC	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg11987759	chr7:65425863	GUSB	-0.5	-6.46	-0.39	6.15e-10	Aortic root size;
SARC	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg13206674	chr6:150067644	NUP43	0.47	5.67	0.35	4.14e-8	Lung cancer;
SARC	cis	rs344364	0.511	rs2906912	chr16:1953151	G/A	cg26617929	chr16:1858877	NA	-0.66	-5.51	-0.34	9.69e-8	Glomerular filtration rate in chronic kidney disease;
SARC	cis	rs7617773	0.780	rs7653336	chr3:48369464	T/A	cg11946769	chr3:48343235	NME6	0.77	9.81	0.54	2.97e-19	Coronary artery disease;
SARC	cis	rs4819052	0.645	rs2838817	chr21:46631698	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.54	5.96	0.36	9.08e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6582630	0.599	rs7967598	chr12:38540760	C/T	cg14851346	chr12:38532713	NA	-0.44	-5.37	-0.33	1.94e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2624839	0.704	rs12632110	chr3:50224225	A/G	cg14019146	chr3:50243930	SLC38A3	0.37	6.0	0.37	7.5e-9	Intelligence (multi-trait analysis);
SARC	cis	rs644799	0.965	rs3789960	chr11:95509037	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.88	13.79	0.67	5.12e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs137603	0.966	rs137585	chr22:39683444	G/A	cg01093212	chr22:39715156	SNORD43;RPL3	-0.39	-4.72	-0.3	4.04e-6	Primary biliary cholangitis;
SARC	cis	rs131777	0.575	rs963980	chr22:51022117	C/A	cg16386697	chr22:51017162	CPT1B;CHKB-CPT1B	0.31	4.82	0.3	2.65e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs10992471	1.000	rs10992471	chr9:95559505	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.48	5.82	0.36	1.97e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs17376456	0.877	rs10076052	chr5:93317762	C/T	cg25358565	chr5:93447407	FAM172A	1.29	14.58	0.69	1.2e-34	Diabetic retinopathy;
SARC	cis	rs11098499	0.863	rs2291185	chr4:120434833	C/A	cg09307838	chr4:120376055	NA	0.91	12.31	0.63	3.63e-27	Corneal astigmatism;
SARC	cis	rs2033732	0.706	rs10103882	chr8:85073033	C/T	cg05716166	chr8:85095498	RALYL	0.47	5.5	0.34	1.01e-7	Body mass index;
SARC	cis	rs10489202	1.000	rs10489202	chr1:167903079	A/C	cg24449463	chr1:168025552	DCAF6	0.63	7.04	0.42	2.16e-11	Schizophrenia;
SARC	cis	rs3126085	0.877	rs4415568	chr1:152181207	G/A	cg09127314	chr1:152161683	NA	0.41	4.76	0.3	3.39e-6	Atopic dermatitis;
SARC	cis	rs7568458	0.660	rs6547623	chr2:85801964	T/A	cg23752985	chr2:85803571	VAMP8	0.41	5.44	0.34	1.36e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs1153858	1.000	rs67461176	chr15:45676819	C/T	cg03999130	chr15:45571217	NA	0.39	4.98	0.31	1.25e-6	Homoarginine levels;
SARC	cis	rs7772486	0.790	rs9403755	chr6:146231470	C/A	cg05347473	chr6:146136440	FBXO30	-0.48	-6.53	-0.39	4.02e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2075371	0.796	rs1646644	chr7:134011817	A/T	cg20476274	chr7:133979776	SLC35B4	0.51	6.47	0.39	5.6e-10	Mean platelet volume;
SARC	cis	rs1355223	0.583	rs2915177	chr11:34880266	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.79	11.33	0.6	5.42e-24	Systemic lupus erythematosus and Systemic sclerosis;
SARC	trans	rs56279505	0.581	rs62307318	chr4:100267023	G/A	cg18024358	chr1:3420815	MEGF6	-0.83	-6.4	-0.39	8.29e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg25894440	chr7:65020034	NA	-0.7	-5.43	-0.34	1.43e-7	Diabetic kidney disease;
SARC	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	10.84	0.58	2.01e-22	Alzheimer's disease;
SARC	cis	rs7659604	1.000	rs73844281	chr4:122664688	A/G	cg19671926	chr4:122722719	EXOSC9	-0.5	-6.13	-0.37	3.77e-9	Type 2 diabetes;
SARC	cis	rs7644634	0.661	rs3772526	chr3:105441707	A/G	cg23051926	chr3:105466016	CBLB	0.44	5.52	0.34	9.1e-8	Itch intensity from mosquito bite;
SARC	cis	rs9790314	0.846	rs4290817	chr3:160967354	G/A	cg04691961	chr3:161091175	C3orf57	-0.64	-8.7	-0.5	5.91e-16	Morning vs. evening chronotype;
SARC	cis	rs2273669	0.667	rs7766248	chr6:109347262	C/T	cg05315195	chr6:109294784	ARMC2	-0.63	-5.7	-0.35	3.6e-8	Prostate cancer;
SARC	cis	rs262150	0.788	rs2657408	chr7:158782275	A/G	cg04111992	chr7:158790115	NA	-0.36	-4.97	-0.31	1.28e-6	Facial morphology (factor 20);
SARC	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg12292205	chr6:26970375	C6orf41	-0.57	-6.4	-0.39	8.58e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg06420487	chr17:61919686	SMARCD2	0.43	4.77	0.3	3.22e-6	Height;
SARC	cis	rs9916302	0.904	rs11078910	chr17:37671269	G/T	cg15445000	chr17:37608096	MED1	0.4	4.74	0.3	3.78e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs4148883	0.689	rs1800760	chr4:100065626	A/T	cg13256891	chr4:100009986	ADH5	0.6	8.01	0.46	5.3e-14	Alcohol dependence;
SARC	trans	rs7395662	0.525	rs4882060	chr11:48441874	G/C	cg15704280	chr7:45808275	SEPT13	-0.48	-6.59	-0.4	2.89e-10	HDL cholesterol;
SARC	cis	rs1832871	0.672	rs9457343	chr6:158740567	A/G	cg07165851	chr6:158734300	TULP4	0.58	6.77	0.41	1.05e-10	Height;
SARC	cis	rs6120849	0.754	rs6120804	chr20:33623701	C/A	cg06115741	chr20:33292138	TP53INP2	0.54	5.16	0.32	5.3e-7	Protein C levels;
SARC	trans	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.51	6.5	0.39	4.86e-10	Intelligence (multi-trait analysis);
SARC	cis	rs62229266	0.626	rs7280896	chr21:37460906	G/A	cg12218747	chr21:37451666	NA	-0.38	-5.35	-0.33	2.14e-7	Mitral valve prolapse;
SARC	cis	rs17401966	0.867	rs6696056	chr1:10305992	C/A	cg15208524	chr1:10270712	KIF1B	0.45	5.27	0.33	3.06e-7	Hepatocellular carcinoma;
SARC	cis	rs7607369	0.719	rs690882	chr2:219640620	T/C	cg02176678	chr2:219576539	TTLL4	-0.32	-4.79	-0.3	2.98e-6	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs644799	0.930	rs587123	chr11:95560539	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.9	14.07	0.68	5.98e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs4689388	0.889	rs10026334	chr4:6294607	G/A	cg25554036	chr4:6271136	WFS1	0.39	6.42	0.39	7.48e-10	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	trans	rs61931739	0.534	rs4001713	chr12:34154195	A/C	cg26384229	chr12:38710491	ALG10B	-0.82	-11.18	-0.59	1.69e-23	Morning vs. evening chronotype;
SARC	cis	rs9303401	0.580	rs34076823	chr17:57114497	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.97	9.84	0.54	2.48e-19	Cognitive test performance;
SARC	cis	rs514406	0.505	rs374849	chr1:53185631	G/A	cg16325326	chr1:53192061	ZYG11B	0.91	16.41	0.73	9.61e-41	Monocyte count;
SARC	cis	rs5417	0.662	rs8067500	chr17:7172631	A/G	cg14660024	chr17:7154518	C17orf81;DULLARD	-0.39	-5.24	-0.32	3.6e-7	Diastolic blood pressure;
SARC	cis	rs1376877	0.519	rs4675332	chr2:204190907	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.43	5.12	0.32	6.5e-7	Subclinical atherosclerosis traits (other);
SARC	cis	rs11676348	0.808	rs1008563	chr2:219026888	G/A	cg00012203	chr2:219082015	ARPC2	-0.44	-5.78	-0.35	2.44e-8	Ulcerative colitis;
SARC	cis	rs950027	0.549	rs9920634	chr15:45596546	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.48	-5.6	-0.34	5.98e-8	Response to fenofibrate (adiponectin levels);
SARC	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg24633833	chr3:10029261	TMEM111	0.52	5.25	0.33	3.43e-7	Alzheimer's disease;
SARC	cis	rs6834538	0.965	rs1580476	chr4:113493365	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.45	5.4	0.33	1.62e-7	Free thyroxine concentration;
SARC	cis	rs2204008	0.837	rs2892296	chr12:37969785	C/T	cg26384229	chr12:38710491	ALG10B	-0.78	-11.38	-0.6	3.88e-24	Bladder cancer;
SARC	cis	rs6088590	0.523	rs6088536	chr20:33189106	T/C	cg24642439	chr20:33292090	TP53INP2	0.66	8.51	0.49	2.17e-15	Coronary artery disease;
SARC	cis	rs2228479	0.718	rs62054253	chr16:89896932	T/C	cg12064134	chr16:90016061	DEF8	-0.56	-4.9	-0.31	1.77e-6	Skin colour saturation;
SARC	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg22535103	chr8:58192502	C8orf71	-0.6	-6.33	-0.38	1.24e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7979473	1	rs7979473	chr12:121420260	A/G	cg25281562	chr12:121454272	C12orf43	-0.41	-4.99	-0.31	1.17e-6	C-reactive protein;
SARC	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg05861140	chr6:150128134	PCMT1	-0.41	-5.41	-0.33	1.55e-7	Lung cancer;
SARC	cis	rs761746	0.921	rs7291918	chr22:32008039	A/G	cg15823100	chr22:32027580	PISD	-0.34	-5.06	-0.31	8.63e-7	Intelligence;
SARC	cis	rs4900538	0.855	rs762105	chr14:102830175	A/G	cg18135206	chr14:102964638	TECPR2	-0.59	-7.71	-0.45	3.65e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.52	-5.79	-0.35	2.28e-8	Prudent dietary pattern;
SARC	cis	rs112374894	1.000	rs112374894	chr14:89008546	T/C	cg01020840	chr14:89016979	PTPN21	0.84	4.95	0.31	1.43e-6	Prudent dietary pattern;
SARC	cis	rs67311347	1.000	rs9332450	chr3:40458041	C/T	cg09455208	chr3:40491958	NA	-0.42	-6.64	-0.4	2.22e-10	Renal cell carcinoma;
SARC	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg02725872	chr8:58115012	NA	-0.36	-6.09	-0.37	4.62e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1865760	0.551	rs9461230	chr6:26019240	G/C	cg17691542	chr6:26056736	HIST1H1C	0.51	6.36	0.38	1.03e-9	Height;
SARC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg04013093	chr6:42928303	GNMT	0.33	4.82	0.3	2.56e-6	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs6679356	0.901	rs10489626	chr1:67793171	C/G	cg09018107	chr1:67798929	IL12RB2	0.42	5.19	0.32	4.51e-7	Primary biliary cholangitis;
SARC	cis	rs9462027	0.506	rs6934662	chr6:34759884	G/C	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.85	-0.36	1.64e-8	Systemic lupus erythematosus;
SARC	cis	rs73206853	0.620	rs111354540	chr12:111150302	A/G	cg10860002	chr12:110842031	ANAPC7	0.63	5.18	0.32	4.7e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs854765	0.583	rs9908832	chr17:17871068	C/T	cg04398451	chr17:18023971	MYO15A	-0.45	-6.24	-0.38	2.1e-9	Total body bone mineral density;
SARC	cis	rs12142240	0.698	rs68083747	chr1:46807416	T/G	cg00530320	chr1:46809349	NSUN4	0.55	6.71	0.4	1.47e-10	Menopause (age at onset);
SARC	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg04518342	chr5:131593106	PDLIM4	0.44	5.69	0.35	3.86e-8	Breast cancer;
SARC	cis	rs10504229	0.679	rs1596142	chr8:58032406	G/A	cg08280861	chr8:58055591	NA	0.54	4.97	0.31	1.28e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs9916302	0.800	rs8069451	chr17:37504933	C/T	cg00129232	chr17:37814104	STARD3	-0.59	-7.2	-0.43	8.33e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs208520	0.661	rs7740835	chr6:66865548	G/A	cg07460842	chr6:66804631	NA	-1.06	-14.96	-0.7	6.65e-36	Exhaled nitric oxide output;
SARC	cis	rs11786130	1.000	rs4733812	chr8:128999640	C/T	cg01765152	chr8:129005526	PVT1	-0.47	-7.75	-0.45	2.87e-13	Eosinophil counts;Sum eosinophil basophil counts;
SARC	cis	rs3771570	1.000	rs62193204	chr2:242315443	A/G	cg21155796	chr2:242212141	HDLBP	0.68	6.08	0.37	4.93e-9	Prostate cancer;
SARC	cis	rs7223966	1.000	rs9908044	chr17:61747032	A/C	cg00588841	chr17:61851480	DDX42;CCDC47	-0.59	-6.86	-0.41	6.03e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs11098499	0.908	rs11098527	chr4:120399906	A/G	cg25214090	chr10:38739885	LOC399744	0.56	7.2	0.43	8.41e-12	Corneal astigmatism;
SARC	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg25894440	chr7:65020034	NA	-0.72	-5.46	-0.34	1.23e-7	Diabetic kidney disease;
SARC	cis	rs1018836	0.608	rs7821069	chr8:91465548	C/G	cg16814680	chr8:91681699	NA	-0.6	-8.5	-0.49	2.23e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs6991952	0.702	rs3936201	chr8:25705256	C/T	cg21775463	chr8:25538546	NA	0.27	4.75	0.3	3.54e-6	Inguinal hernia;
SARC	cis	rs10979	0.597	rs9496684	chr6:143908687	C/A	cg25407410	chr6:143891975	LOC285740	-0.5	-5.82	-0.36	1.94e-8	Hypospadias;
SARC	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg05036130	chr6:150231994	NA	0.31	5.32	0.33	2.43e-7	Testicular germ cell tumor;
SARC	cis	rs7359276	1	rs7359276	chr15:78892661	C/T	cg06917634	chr15:78832804	PSMA4	0.46	5.26	0.33	3.28e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs16866061	1.000	rs72972378	chr2:225372562	A/G	cg12698349	chr2:225449008	CUL3	0.7	10.11	0.55	3.76e-20	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	cis	rs6087990	0.735	rs6058891	chr20:31386347	T/C	cg13636640	chr20:31349939	DNMT3B	0.78	12.0	0.62	3.77e-26	Ulcerative colitis;
SARC	cis	rs2952156	0.920	rs732084	chr17:37834357	A/C	cg00129232	chr17:37814104	STARD3	-0.7	-10.11	-0.55	3.81e-20	Asthma;
SARC	cis	rs514406	0.505	rs6703127	chr1:53180565	C/T	cg08859206	chr1:53392774	SCP2	-0.36	-5.16	-0.32	5.33e-7	Monocyte count;
SARC	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	9.07	0.51	5.15e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7513165	0.736	rs4889	chr1:204159787	G/C	cg23788856	chr1:204159729	KISS1	-0.34	-5.16	-0.32	5.27e-7	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
SARC	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg26818010	chr10:134567672	INPP5A	-0.47	-5.59	-0.34	6.21e-8	Migraine;
SARC	cis	rs910316	0.967	rs10246	chr14:75544470	T/A	cg06637938	chr14:75390232	RPS6KL1	0.56	7.89	0.46	1.2e-13	Height;
SARC	cis	rs7644634	0.559	rs2305036	chr3:105438957	T/G	cg23051926	chr3:105466016	CBLB	0.47	5.27	0.33	3.18e-7	Itch intensity from mosquito bite;
SARC	cis	rs10504229	0.593	rs74760806	chr8:58024785	C/T	cg20607798	chr8:58055168	NA	0.62	5.51	0.34	9.38e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.54	6.15	0.37	3.35e-9	Prudent dietary pattern;
SARC	cis	rs798554	0.610	rs2248390	chr7:2855594	T/C	cg04166393	chr7:2884313	GNA12	0.44	5.47	0.34	1.14e-7	Height;
SARC	cis	rs9309473	0.606	rs1589576	chr2:73738804	A/G	cg20560298	chr2:73613845	ALMS1	-0.52	-5.51	-0.34	9.7e-8	Metabolite levels;
SARC	cis	rs7512552	0.839	rs1097070	chr1:150332955	A/T	cg15654264	chr1:150340011	RPRD2	0.38	4.83	0.3	2.49e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg12807013	chr5:41922931	NA	0.46	6.26	0.38	1.81e-9	Thyroid stimulating hormone;
SARC	cis	rs7980687	0.628	rs1609520	chr12:123735937	A/G	cg05973401	chr12:123451056	ABCB9	-0.55	-6.27	-0.38	1.76e-9	Height;Educational attainment;Head circumference (infant);
SARC	cis	rs17270561	0.636	rs9348696	chr6:25781938	A/G	cg17691542	chr6:26056736	HIST1H1C	0.55	6.74	0.4	1.26e-10	Iron status biomarkers;
SARC	cis	rs17666538	0.901	rs73177064	chr8:585293	C/G	cg00450029	chr8:599525	NA	-0.78	-5.81	-0.36	2.05e-8	IgG glycosylation;
SARC	trans	rs11039798	0.591	rs74992349	chr11:49019252	G/A	cg15704280	chr7:45808275	SEPT13	0.7	6.96	0.41	3.42e-11	Axial length;
SARC	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg24399712	chr22:39784796	NA	-0.44	-6.19	-0.38	2.71e-9	Intelligence (multi-trait analysis);
SARC	cis	rs11098499	0.779	rs7356491	chr4:120381974	C/T	cg09307838	chr4:120376055	NA	0.92	13.13	0.65	7.35e-30	Corneal astigmatism;
SARC	trans	rs9329221	0.772	rs7824675	chr8:10243418	G/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.56	-0.44	8.95e-13	Neuroticism;
SARC	cis	rs2361710	0.704	rs12937349	chr17:78120320	G/C	cg20811857	chr17:78079795	GAA	-0.32	-5.23	-0.32	3.8e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
SARC	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg22875332	chr1:76189707	ACADM	-0.65	-10.35	-0.56	6.68e-21	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2075371	1.000	rs2598285	chr7:133971153	A/T	cg20476274	chr7:133979776	SLC35B4	0.61	8.45	0.48	3.12e-15	Mean platelet volume;
SARC	cis	rs7178572	0.568	rs12911371	chr15:77689050	C/T	cg22256960	chr15:77711686	NA	-0.51	-5.59	-0.34	6.36e-8	Type 2 diabetes;
SARC	cis	rs11997175	0.631	rs7826866	chr8:33665090	A/T	ch.8.33884649F	chr8:33765107	NA	0.46	6.04	0.37	6.19e-9	Body mass index;
SARC	cis	rs9398803	0.965	rs6907898	chr6:126666416	C/T	cg20229609	chr6:126660872	C6orf173	0.4	5.85	0.36	1.62e-8	Male-pattern baldness;
SARC	cis	rs7208859	0.623	rs9911173	chr17:29154750	C/T	cg13385521	chr17:29058706	SUZ12P	0.85	7.66	0.45	4.88e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs6500602	0.627	rs934929	chr16:4587789	A/G	cg09269891	chr16:3843415	CREBBP	0.4	4.79	0.3	2.96e-6	Schizophrenia;
SARC	cis	rs11581859	0.613	rs6665235	chr1:99200741	G/A	cg20286094	chr1:99190917	SNX7	-0.42	-4.93	-0.31	1.55e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs10744422	1.000	rs7959441	chr12:123363825	C/T	cg25930673	chr12:123319894	HIP1R	-0.65	-4.72	-0.3	4.08e-6	Schizophrenia;
SARC	cis	rs11608355	0.545	rs9943724	chr12:109902903	G/A	cg05360138	chr12:110035743	NA	0.92	9.65	0.53	9.69e-19	Neuroticism;
SARC	cis	rs365132	0.715	rs181330	chr5:176404962	A/G	cg16309518	chr5:176445507	NA	-0.48	-6.24	-0.38	2.06e-9	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs2251381	0.741	rs2735966	chr21:30538174	G/A	cg24692254	chr21:30365293	RNF160	0.88	13.26	0.66	2.81e-30	Selective IgA deficiency;
SARC	cis	rs11249608	0.548	rs6880315	chr5:178452502	G/A	cg21905437	chr5:178450457	ZNF879	0.58	8.07	0.47	3.63e-14	Pubertal anthropometrics;
SARC	cis	rs7937890	0.967	rs963212	chr11:14324732	A/G	cg02886208	chr11:14281011	SPON1	0.38	5.28	0.33	3.02e-7	Mitochondrial DNA levels;
SARC	trans	rs9650657	0.682	rs6989160	chr8:10705360	A/C	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.0	-0.42	2.65e-11	Neuroticism;
SARC	cis	rs6669919	0.553	rs12568639	chr1:211675300	G/A	cg10512769	chr1:211675356	NA	-0.35	-5.47	-0.34	1.17e-7	Intelligence (multi-trait analysis);
SARC	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.94	13.76	0.67	6.22e-32	Gut microbiome composition (summer);
SARC	cis	rs1387259	0.931	rs1107654	chr12:48681097	T/G	cg24011408	chr12:48396354	COL2A1	0.46	5.44	0.34	1.32e-7	Obstructive sleep apnea trait (apnea hypopnea index);
SARC	cis	rs7617773	0.817	rs6801801	chr3:48326433	T/C	cg11946769	chr3:48343235	NME6	0.72	9.53	0.53	2.21e-18	Coronary artery disease;
SARC	cis	rs2204008	0.715	rs11525003	chr12:38332359	G/A	cg26384229	chr12:38710491	ALG10B	0.87	12.6	0.64	4.2e-28	Bladder cancer;
SARC	cis	rs763121	0.853	rs9610993	chr22:39042818	C/A	cg21395723	chr22:39101663	GTPBP1	0.58	6.67	0.4	1.85e-10	Menopause (age at onset);
SARC	trans	rs6076960	0.684	rs6054055	chr20:6257517	C/G	cg21095983	chr6:86352623	SYNCRIP	0.47	6.69	0.4	1.67e-10	Smooth-surface caries;
SARC	cis	rs1059312	0.808	rs900982	chr12:129304369	G/A	cg09035930	chr12:129282057	SLC15A4	0.56	7.93	0.46	8.99e-14	Systemic lupus erythematosus;
SARC	cis	rs710216	0.879	rs710218	chr1:43427218	A/T	cg03128534	chr1:43423976	SLC2A1	0.63	7.13	0.42	1.27e-11	Red cell distribution width;
SARC	cis	rs6546550	0.867	rs4401231	chr2:70063563	G/C	cg02498382	chr2:70120550	SNRNP27	-0.41	-6.85	-0.41	6.51e-11	Prevalent atrial fibrillation;
SARC	cis	rs2115536	1.000	rs7163338	chr15:80198408	C/G	cg00225070	chr15:80189496	MTHFS	0.67	8.95	0.51	1.17e-16	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
SARC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.63	-6.7	-0.4	1.51e-10	Platelet count;
SARC	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg12463550	chr7:65579703	CRCP	0.5	5.9	0.36	1.27e-8	Aortic root size;
SARC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg22535103	chr8:58192502	C8orf71	-0.68	-6.45	-0.39	6.25e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs11098499	0.954	rs28572238	chr4:120316686	T/G	cg09307838	chr4:120376055	NA	0.91	12.88	0.65	4.9e-29	Corneal astigmatism;
SARC	trans	rs61931739	0.534	rs7302688	chr12:34235064	A/G	cg13010199	chr12:38710504	ALG10B	0.74	9.99	0.55	8.5e-20	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg21724239	chr8:58056113	NA	0.6	6.37	0.38	1.03e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg11247378	chr22:39784982	NA	-0.33	-5.4	-0.33	1.65e-7	Intelligence (multi-trait analysis);
SARC	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg23205692	chr1:25664452	TMEM50A	0.42	5.13	0.32	6.2e-7	Erythrocyte sedimentation rate;
SARC	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg11764359	chr7:65958608	NA	0.69	8.14	0.47	2.37e-14	Aortic root size;
SARC	trans	rs561341	1.000	rs693116	chr17:30246124	C/T	cg20587970	chr11:113659929	NA	-1.35	-13.06	-0.65	1.27e-29	Hip circumference adjusted for BMI;
SARC	cis	rs9325144	0.555	rs1813392	chr12:38692203	C/T	cg04568710	chr12:38710424	ALG10B	-0.47	-6.14	-0.37	3.6e-9	Morning vs. evening chronotype;
SARC	trans	rs17685	0.712	rs1637049	chr7:75729975	C/G	cg19862616	chr7:65841803	NCRNA00174	0.63	7.83	0.46	1.68e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs7312933	0.584	rs6582395	chr12:42700141	T/C	cg19980929	chr12:42632907	YAF2	0.48	6.82	0.41	7.63e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs7560272	0.501	rs12992607	chr2:73959960	G/T	cg20560298	chr2:73613845	ALMS1	0.45	5.96	0.36	9.16e-9	Schizophrenia;
SARC	cis	rs16854884	0.657	rs6778627	chr3:143720869	G/T	cg06585982	chr3:143692056	C3orf58	0.69	9.49	0.53	2.88e-18	Economic and political preferences (feminism/equality);
SARC	cis	rs2235642	0.893	rs2143285	chr16:1593171	A/G	cg26528668	chr16:1614120	IFT140	0.37	4.85	0.3	2.29e-6	Coronary artery disease;
SARC	trans	rs8073060	0.544	rs1080352	chr17:34002362	A/G	cg19694781	chr19:47549865	TMEM160	-0.7	-6.92	-0.41	4.32e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg03709012	chr19:19516395	GATAD2A	0.95	15.26	0.71	6.57e-37	Tonsillectomy;
SARC	cis	rs35995292	0.534	rs2008199	chr7:38939678	T/C	cg19327137	chr7:38886074	VPS41	0.52	7.81	0.46	2e-13	Subjective well-being (multi-trait analysis);
SARC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.35	5.13	0.32	5.97e-7	Bipolar disorder;
SARC	cis	rs208520	1.000	rs72882100	chr6:66981495	G/C	cg07460842	chr6:66804631	NA	0.9	10.32	0.56	8.16e-21	Exhaled nitric oxide output;
SARC	cis	rs9303401	0.614	rs34550282	chr17:57092788	G/A	cg25039879	chr17:56429692	SUPT4H1	0.55	4.9	0.31	1.77e-6	Cognitive test performance;
SARC	cis	rs7584330	0.657	rs7599658	chr2:238352898	A/C	cg11271282	chr2:238384023	NA	-0.46	-5.12	-0.32	6.42e-7	Prostate cancer;
SARC	cis	rs2730245	0.527	rs842707	chr7:158656012	C/T	cg24397884	chr7:158709396	WDR60	1.12	9.89	0.54	1.76e-19	Height;
SARC	cis	rs2635047	0.747	rs9956387	chr18:44773382	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	5.81	0.36	2.08e-8	Educational attainment;
SARC	cis	rs12142240	0.621	rs13374968	chr1:46843908	T/G	cg14993813	chr1:46806288	NSUN4	-0.52	-5.56	-0.34	7.46e-8	Menopause (age at onset);
SARC	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg16606324	chr3:10149918	C3orf24	0.52	4.97	0.31	1.32e-6	Alzheimer's disease;
SARC	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-5.61	-0.35	5.58e-8	Bipolar disorder;
SARC	cis	rs11997175	0.625	rs4733171	chr8:33615617	C/G	ch.8.33884649F	chr8:33765107	NA	-0.58	-7.3	-0.43	4.62e-12	Body mass index;
SARC	cis	rs6088590	0.931	rs6088617	chr20:33408036	G/A	cg06115741	chr20:33292138	TP53INP2	0.54	6.51	0.39	4.68e-10	Coronary artery disease;
SARC	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.41	-6.37	-0.39	9.93e-10	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs2153535	0.601	rs9502715	chr6:8455709	C/T	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.04e-14	Motion sickness;
SARC	trans	rs3780486	0.801	rs3780495	chr9:33125942	A/C	cg20290983	chr6:43655470	MRPS18A	1.15	22.54	0.83	1.85e-60	IgG glycosylation;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg06792154	chr17:29157990	ATAD5	0.53	6.52	0.39	4.36e-10	Breast cancer;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21755457	chr12:54020320	ATF7	-0.52	-6.34	-0.38	1.19e-9	Fibrinogen levels;
SARC	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg24209194	chr3:40518798	ZNF619	0.66	7.98	0.46	6.78e-14	Renal cell carcinoma;
SARC	cis	rs6840360	0.571	rs28454076	chr4:152520083	G/T	cg22705602	chr4:152727874	NA	-0.41	-6.47	-0.39	5.71e-10	Intelligence (multi-trait analysis);
SARC	cis	rs10463316	0.608	rs13360453	chr5:150769143	T/C	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.32	-0.33	2.4e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs9868809	0.505	rs11708786	chr3:48752654	C/T	cg07636037	chr3:49044803	WDR6	-0.67	-6.37	-0.39	1e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs9393692	0.905	rs7746807	chr6:26293338	C/A	cg05868516	chr6:26286170	HIST1H4H	0.58	7.62	0.45	6.39e-13	Educational attainment;
SARC	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg15448220	chr1:150897856	SETDB1	0.47	6.25	0.38	1.94e-9	Tonsillectomy;
SARC	cis	rs240764	0.658	rs11155673	chr6:101243283	A/T	cg09795085	chr6:101329169	ASCC3	-0.44	-5.68	-0.35	3.94e-8	Neuroticism;
SARC	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg07308232	chr7:1071921	C7orf50	-0.53	-6.09	-0.37	4.68e-9	Longevity;Endometriosis;
SARC	cis	rs6582630	0.555	rs11182148	chr12:38464883	A/C	cg26384229	chr12:38710491	ALG10B	0.83	12.01	0.62	3.43e-26	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs10754283	0.967	rs2390763	chr1:90105688	A/G	cg21401794	chr1:90099060	LRRC8C	0.59	8.1	0.47	2.99e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	trans	rs36093844	0.800	rs17817355	chr11:85599945	C/A	cg15359163	chr5:122429178	PRDM6	-0.52	-6.29	-0.38	1.53e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs5753037	0.838	rs1076135	chr22:30238317	A/T	cg01021169	chr22:30184971	ASCC2	-0.39	-5.08	-0.32	7.88e-7	Type 1 diabetes;
SARC	cis	rs611744	0.967	rs569701	chr8:109239207	G/A	cg21045802	chr8:109455806	TTC35	0.46	5.43	0.34	1.38e-7	Dupuytren's disease;
SARC	cis	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg15556689	chr8:8085844	FLJ10661	0.45	5.6	0.34	6.08e-8	Mood instability;
SARC	cis	rs9807989	0.507	rs10439410	chr2:102990788	A/C	cg03938978	chr2:103052716	IL18RAP	-0.31	-5.02	-0.31	1.04e-6	Asthma;
SARC	cis	rs6998277	0.830	rs7017839	chr8:103610769	G/C	cg10187029	chr8:103597600	NA	0.86	12.25	0.63	5.76e-27	Migraine;
SARC	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg13628971	chr7:2884303	GNA12	0.59	6.78	0.41	1.01e-10	Height;
SARC	cis	rs10870270	1.000	rs11146338	chr10:133770291	C/G	cg17892150	chr10:133769511	PPP2R2D	-0.84	-10.4	-0.56	4.62e-21	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs2985684	0.894	rs7152110	chr14:50018218	T/C	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.48	5.25	0.33	3.36e-7	Carotid intima media thickness;
SARC	cis	rs2486288	0.656	rs11637838	chr15:45550657	A/G	cg15395560	chr15:45543142	SLC28A2	0.29	5.6	0.34	5.91e-8	Glomerular filtration rate;
SARC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg16405210	chr4:1374714	KIAA1530	-0.84	-10.35	-0.56	6.91e-21	Longevity;
SARC	cis	rs6138458	0.717	rs2179732	chr20:25000446	A/T	cg26195577	chr20:24973756	C20orf3	0.74	8.78	0.5	3.6e-16	Blood protein levels;
SARC	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg14784868	chr12:69753453	YEATS4	-0.68	-9.59	-0.53	1.39e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs763121	0.814	rs5757212	chr22:39053757	G/C	cg21395723	chr22:39101663	GTPBP1	0.58	6.91	0.41	4.55e-11	Menopause (age at onset);
SARC	cis	rs60871478	1.000	rs62432251	chr7:801855	T/G	cg19087971	chr7:751233	PRKAR1B	-0.42	-4.86	-0.3	2.16e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs8044995	0.563	rs56331745	chr16:68368770	G/T	cg05110241	chr16:68378359	PRMT7	-0.66	-6.23	-0.38	2.12e-9	Schizophrenia;
SARC	cis	rs13082711	0.595	rs7615321	chr3:27368010	A/G	cg02860705	chr3:27208620	NA	0.64	7.94	0.46	8.8e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs2153535	0.580	rs4960421	chr6:8459292	C/T	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.04e-14	Motion sickness;
SARC	cis	rs72781680	0.611	rs72797824	chr2:24356456	T/G	cg08917208	chr2:24149416	ATAD2B	0.59	6.02	0.37	6.72e-9	Lymphocyte counts;
SARC	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg12463550	chr7:65579703	CRCP	-0.7	-5.31	-0.33	2.51e-7	Diabetic kidney disease;
SARC	cis	rs875971	0.545	rs73378304	chr7:65640747	G/A	cg11764359	chr7:65958608	NA	0.67	6.88	0.41	5.4e-11	Aortic root size;
SARC	cis	rs10504229	0.593	rs7000752	chr8:58026980	C/G	cg20607798	chr8:58055168	NA	0.55	5.1	0.32	6.9e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7766436	0.614	rs12660580	chr6:22564428	C/G	cg13666174	chr6:22585274	NA	-0.56	-5.86	-0.36	1.59e-8	Coronary artery disease;
SARC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.41	-6.52	-0.39	4.33e-10	Longevity;Endometriosis;
SARC	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg22168489	chr12:122356033	WDR66	0.68	10.54	0.57	1.76e-21	Mean platelet volume;
SARC	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-9.22	-0.52	1.78e-17	Alzheimer's disease;
SARC	cis	rs7772486	0.790	rs2253307	chr6:146196181	T/G	cg23711669	chr6:146136114	FBXO30	0.84	13.76	0.67	6.41e-32	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.89	12.64	0.64	3.1e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg23262073	chr20:60523788	NA	0.44	6.11	0.37	4.21e-9	Body mass index;
SARC	cis	rs11718455	0.920	rs13084408	chr3:44008967	G/A	cg08738300	chr3:44038990	NA	0.53	5.89	0.36	1.37e-8	Coronary artery disease;
SARC	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg17971929	chr21:40555470	PSMG1	-0.86	-11.32	-0.6	5.86e-24	Cognitive function;
SARC	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg05861140	chr6:150128134	PCMT1	-0.41	-5.36	-0.33	1.95e-7	Lung cancer;
SARC	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg22535103	chr8:58192502	C8orf71	-0.72	-6.74	-0.4	1.25e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2933343	0.649	rs728839	chr3:128589359	A/G	cg24203234	chr3:128598194	ACAD9	0.62	7.99	0.46	6.04e-14	IgG glycosylation;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg02797930	chr3:153839287	SGEF	0.48	6.37	0.39	1e-9	Chemerin levels;
SARC	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg09359103	chr1:154839909	KCNN3	-0.45	-7.67	-0.45	4.61e-13	Prostate cancer;
SARC	cis	rs4481887	0.927	rs6678798	chr1:248476617	C/T	cg00666640	chr1:248458726	OR2T12	0.34	5.7	0.35	3.65e-8	Common traits (Other);
SARC	cis	rs11690935	0.655	rs17614941	chr2:172541378	A/G	cg13550731	chr2:172543902	DYNC1I2	0.59	8.63	0.49	9.95e-16	Schizophrenia;
SARC	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg08067268	chr2:26466485	HADHB;HADHA	0.46	5.77	0.35	2.54e-8	Gut microbiome composition (summer);
SARC	cis	rs2463822	0.748	rs2513053	chr11:62109473	T/A	cg06239285	chr11:62104954	ASRGL1	0.88	9.32	0.52	9.26e-18	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs35995292	0.926	rs10259755	chr7:38897012	A/C	cg19327137	chr7:38886074	VPS41	0.37	5.17	0.32	5.14e-7	Subjective well-being (multi-trait analysis);
SARC	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg17294928	chr15:75287854	SCAMP5	0.54	6.97	0.42	3.15e-11	Breast cancer;
SARC	cis	rs9303401	1.000	rs7218362	chr17:56888299	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.68	8.1	0.47	3.07e-14	Cognitive test performance;
SARC	cis	rs4853036	0.951	rs6718298	chr2:70145450	A/C	cg02498382	chr2:70120550	SNRNP27	-0.36	-4.91	-0.31	1.73e-6	Colorectal or endometrial cancer;
SARC	cis	rs9788682	0.894	rs4461039	chr15:78817447	A/T	cg24631222	chr15:78858424	CHRNA5	-0.74	-10.19	-0.56	2.07e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg09359103	chr1:154839909	KCNN3	-0.46	-7.63	-0.45	5.84e-13	Prostate cancer;
SARC	cis	rs644799	1.000	rs474442	chr11:95583995	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.68	9.35	0.52	7.7e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs875971	0.965	rs697968	chr7:65535033	G/A	cg18876405	chr7:65276391	NA	-0.47	-5.68	-0.35	3.99e-8	Aortic root size;
SARC	trans	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg26450188	chr19:46850188	PPP5C	-0.53	-6.46	-0.39	6e-10	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg03806693	chr22:41940476	POLR3H	0.85	11.81	0.61	1.61e-25	Vitiligo;
SARC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg11494091	chr17:61959527	GH2	0.53	7.98	0.46	6.66e-14	Prudent dietary pattern;
SARC	cis	rs67311347	0.955	rs9821036	chr3:40379007	A/G	cg09455208	chr3:40491958	NA	0.39	6.08	0.37	4.85e-9	Renal cell carcinoma;
SARC	cis	rs709400	0.633	rs1951391	chr14:103898313	T/C	cg26031613	chr14:104095156	KLC1	0.79	11.3	0.6	6.59e-24	Body mass index;
SARC	cis	rs6696846	0.765	rs11577406	chr1:205065733	G/T	cg07972983	chr1:205091412	RBBP5	0.58	7.51	0.44	1.24e-12	Red blood cell count;
SARC	cis	rs910316	1.000	rs8017642	chr14:75590822	G/A	cg06637938	chr14:75390232	RPS6KL1	0.51	7.14	0.42	1.19e-11	Height;
SARC	cis	rs17376456	0.569	rs6895356	chr5:93060781	A/G	cg25358565	chr5:93447407	FAM172A	0.89	9.7	0.54	6.45e-19	Diabetic retinopathy;
SARC	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg25894440	chr7:65020034	NA	0.79	5.95	0.36	9.65e-9	Diabetic kidney disease;
SARC	cis	rs137603	0.644	rs137621	chr22:39710244	G/A	cg01093212	chr22:39715156	SNORD43;RPL3	-0.53	-6.12	-0.37	3.96e-9	Primary biliary cholangitis;
SARC	cis	rs1865760	0.533	rs1408270	chr6:25873184	A/G	cg16482183	chr6:26056742	HIST1H1C	0.58	7.37	0.43	3.03e-12	Height;
SARC	cis	rs7520050	0.933	rs4504835	chr1:46455571	G/A	cg24296786	chr1:45957014	TESK2	0.38	4.87	0.3	2.02e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	10.35	0.56	6.64e-21	Platelet count;
SARC	cis	rs7584330	0.554	rs76408976	chr2:238384784	C/T	cg08992911	chr2:238395768	MLPH	0.72	5.66	0.35	4.39e-8	Prostate cancer;
SARC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg02353165	chr6:42928485	GNMT	0.59	8.08	0.47	3.45e-14	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs2016266	0.855	rs4759086	chr12:53666713	A/G	cg26875137	chr12:53738046	NA	0.42	5.47	0.34	1.18e-7	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs9309473	0.950	rs13427832	chr2:73844818	G/A	cg20560298	chr2:73613845	ALMS1	-0.44	-5.3	-0.33	2.66e-7	Metabolite levels;
SARC	cis	rs9394841	0.667	rs3747750	chr6:41760372	C/G	cg08135965	chr6:41755394	TOMM6	0.62	6.55	0.39	3.7e-10	Mean corpuscular hemoglobin;Red cell distribution width;
SARC	cis	rs7044106	0.762	rs4837789	chr9:123426256	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	4.89	0.31	1.86e-6	Hip circumference adjusted for BMI;
SARC	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg05863683	chr7:1912471	MAD1L1	0.37	5.53	0.34	8.5e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs6871536	0.951	rs12652920	chr5:131885240	G/C	cg11797159	chr5:131991491	NA	0.36	4.74	0.3	3.65e-6	Asthma (childhood onset);
SARC	cis	rs524281	0.773	rs2282568	chr11:66052832	C/G	cg14036092	chr11:66035641	RAB1B	-0.55	-5.45	-0.34	1.26e-7	Electroencephalogram traits;
SARC	cis	rs826838	0.616	rs4418873	chr12:38625473	C/A	cg13010199	chr12:38710504	ALG10B	0.52	6.58	0.4	3.09e-10	Heart rate;
SARC	cis	rs1018836	0.608	rs1033348	chr8:91464169	C/G	cg16814680	chr8:91681699	NA	-0.65	-9.19	-0.52	2.2e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs9611565	0.592	rs9611612	chr22:41961189	T/C	cg17376030	chr22:41985996	PMM1	0.69	8.41	0.48	4.11e-15	Vitiligo;
SARC	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg17971929	chr21:40555470	PSMG1	0.96	11.67	0.61	4.44e-25	Cognitive function;
SARC	cis	rs1707322	0.752	rs11211169	chr1:46166709	A/G	cg03146154	chr1:46216737	IPP	0.52	6.28	0.38	1.6e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2396545	0.680	rs35467761	chr11:571568	A/G	cg03576123	chr11:487126	PTDSS2	-0.55	-5.65	-0.35	4.58e-8	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs9814567	1.000	rs11928499	chr3:134232350	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.56	7.02	0.42	2.39e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs6558174	0.965	rs4872524	chr8:22489537	A/G	cg03733263	chr8:22462867	KIAA1967	0.55	6.49	0.39	5.06e-10	Breast cancer;
SARC	cis	rs9326248	0.539	rs10892058	chr11:116876621	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.61	7.61	0.45	6.58e-13	Blood protein levels;
SARC	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg22920501	chr2:26401640	FAM59B	-0.55	-7.16	-0.42	1.03e-11	Gut microbiome composition (summer);
SARC	cis	rs13082711	0.911	rs11716531	chr3:27457208	G/A	cg02860705	chr3:27208620	NA	0.46	5.8	0.36	2.12e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs3857536	0.776	rs9363560	chr6:66949686	T/G	cg07460842	chr6:66804631	NA	-0.45	-5.19	-0.32	4.5e-7	Blood trace element (Cu levels);
SARC	cis	rs11168187	0.843	rs3764020	chr12:48120132	C/T	cg12761788	chr12:48120090	P11	0.36	4.75	0.3	3.5e-6	Vertical cup-disc ratio;
SARC	cis	rs3812831	0.630	rs9562129	chr13:114917152	A/G	cg08824895	chr13:115047677	UPF3A	0.52	6.94	0.41	3.92e-11	Schizophrenia;
SARC	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg06808227	chr14:105710500	BRF1	0.51	6.44	0.39	6.62e-10	Mean platelet volume;Platelet distribution width;
SARC	cis	rs7084402	1.000	rs6481401	chr10:60268880	A/C	cg07615347	chr10:60278583	BICC1	-0.58	-8.47	-0.49	2.82e-15	Refractive error;
SARC	cis	rs6120849	0.901	rs6058193	chr20:33734464	A/G	cg24642439	chr20:33292090	TP53INP2	0.56	5.76	0.35	2.6e-8	Protein C levels;
SARC	cis	rs854765	0.583	rs4925125	chr17:17794444	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.68	-10.2	-0.56	1.91e-20	Total body bone mineral density;
SARC	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg16434002	chr17:42200994	HDAC5	-0.43	-5.21	-0.32	4.15e-7	Total body bone mineral density;
SARC	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs3020736	0.500	rs6002616	chr22:42504679	A/G	cg04733989	chr22:42467013	NAGA	-0.77	-10.79	-0.58	2.84e-22	Autism spectrum disorder or schizophrenia;
SARC	trans	rs12310956	0.510	rs6488178	chr12:33885251	C/G	cg13010199	chr12:38710504	ALG10B	0.56	7.21	0.43	7.81e-12	Morning vs. evening chronotype;
SARC	cis	rs17376456	0.569	rs6895356	chr5:93060781	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.57	6.02	0.37	6.72e-9	Diabetic retinopathy;
SARC	trans	rs6600671	1.000	rs10903159	chr1:121181997	G/T	cg00646200	chr1:148855367	NA	0.53	7.3	0.43	4.52e-12	Hip geometry;
SARC	cis	rs6088590	1.000	rs910870	chr20:33292893	T/C	cg06115741	chr20:33292138	TP53INP2	0.49	5.97	0.36	8.95e-9	Coronary artery disease;
SARC	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg21724239	chr8:58056113	NA	0.6	6.37	0.38	1.03e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg12463550	chr7:65579703	CRCP	-0.71	-5.42	-0.33	1.47e-7	Diabetic kidney disease;
SARC	cis	rs2230307	0.536	rs6577152	chr1:100434610	A/G	cg24955406	chr1:100503596	HIAT1	0.7	7.04	0.42	2.14e-11	Carotid intima media thickness;
SARC	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs981844	1.000	rs72731674	chr4:154667447	C/A	cg14289246	chr4:154710475	SFRP2	0.57	6.43	0.39	7.08e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs7208859	0.623	rs55638872	chr17:29149552	G/C	cg13385521	chr17:29058706	SUZ12P	0.9	7.36	0.43	3.12e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs644799	0.965	rs687529	chr11:95545587	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.7	9.55	0.53	1.87e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs1348850	0.574	rs12988366	chr2:178417945	A/C	cg23306229	chr2:178417860	TTC30B	-0.79	-7.83	-0.46	1.75e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs72781680	1.000	rs17711825	chr2:24124578	A/G	cg08917208	chr2:24149416	ATAD2B	0.77	7.68	0.45	4.43e-13	Lymphocyte counts;
SARC	cis	rs6977660	0.714	rs10486365	chr7:19801364	A/G	cg05791153	chr7:19748676	TWISTNB	0.7	6.4	0.39	8.29e-10	Thyroid stimulating hormone;
SARC	trans	rs1814175	0.645	rs1818895	chr11:50031523	G/T	cg15704280	chr7:45808275	SEPT13	-0.89	-14.14	-0.68	3.32e-33	Height;
SARC	cis	rs2120019	1.000	rs7167285	chr15:75368769	A/G	cg12414181	chr15:75287860	SCAMP5	-0.42	-4.89	-0.31	1.87e-6	Blood trace element (Zn levels);
SARC	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	11.73	0.61	2.91e-25	Alzheimer's disease;
SARC	trans	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg00938859	chr5:1591904	SDHAP3	0.74	6.91	0.41	4.61e-11	Breast cancer;
SARC	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg11987759	chr7:65425863	GUSB	-0.58	-7.99	-0.46	6.34e-14	Aortic root size;
SARC	cis	rs1345301	1.000	rs11686567	chr2:102876609	A/G	cg12451869	chr2:102867685	NA	0.38	5.39	0.33	1.75e-7	Waist circumference;
SARC	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg16479474	chr6:28041457	NA	0.36	5.84	0.36	1.7e-8	Depression;
SARC	cis	rs2204008	0.837	rs7315255	chr12:37949279	G/A	cg13010199	chr12:38710504	ALG10B	0.79	10.95	0.58	8.57e-23	Bladder cancer;
SARC	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg16405210	chr4:1374714	KIAA1530	-0.51	-6.28	-0.38	1.6e-9	Longevity;
SARC	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg22920501	chr2:26401640	FAM59B	0.61	8.13	0.47	2.54e-14	Gut microbiome composition (summer);
SARC	cis	rs2486288	0.656	rs7165039	chr15:45570413	C/G	cg15395560	chr15:45543142	SLC28A2	0.32	6.17	0.37	2.98e-9	Glomerular filtration rate;
SARC	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.4	-6.04	-0.37	5.89e-9	Total body bone mineral density;
SARC	cis	rs1371867	0.513	rs1542812	chr8:101207064	G/A	cg11906718	chr8:101322791	RNF19A	-0.65	-8.54	-0.49	1.73e-15	Atrioventricular conduction;
SARC	cis	rs6484504	0.532	rs12222329	chr11:31274340	T/C	cg26647111	chr11:31128758	NA	-0.39	-5.05	-0.31	9.01e-7	Red blood cell count;
SARC	cis	rs7223966	1.000	rs7223966	chr17:61893398	G/A	cg00588841	chr17:61851480	DDX42;CCDC47	-0.63	-6.83	-0.41	7.43e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg27090007	chr13:28519388	ATP5EP2	0.52	6.56	0.39	3.42e-10	Breast cancer;
SARC	cis	rs2635047	0.638	rs2635054	chr18:44653028	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.49	-6.33	-0.38	1.26e-9	Educational attainment;
SARC	cis	rs4561483	0.801	rs33619	chr16:12008941	T/G	cg08843971	chr16:11963173	GSPT1	-0.41	-5.01	-0.31	1.08e-6	Testicular germ cell tumor;
SARC	cis	rs2295359	1.000	rs11209006	chr1:67619259	T/G	cg08029281	chr1:67600428	NA	0.36	5.01	0.31	1.1e-6	Psoriasis;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg02089135	chr10:105614699	SH3PXD2A	0.49	6.44	0.39	6.73e-10	Lung adenocarcinoma;
SARC	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg14773178	chr5:1868261	NA	0.33	5.26	0.33	3.31e-7	Cardiovascular disease risk factors;
SARC	cis	rs1018836	0.632	rs1028255	chr8:91485578	A/T	cg16814680	chr8:91681699	NA	-0.68	-10.24	-0.56	1.43e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs4927850	1.000	rs6799572	chr3:195740408	C/T	cg12923728	chr3:195709715	SDHAP1	-0.69	-8.49	-0.49	2.41e-15	Pancreatic cancer;
SARC	cis	rs2712184	0.873	rs1548945	chr2:217665788	T/C	cg05032264	chr2:217675019	NA	-0.57	-7.73	-0.45	3.26e-13	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20640305	chr18:19180778	ESCO1	-0.48	-6.42	-0.39	7.45e-10	Smoking initiation;
SARC	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg02725872	chr8:58115012	NA	-0.36	-6.12	-0.37	3.91e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs36715	0.953	rs185177	chr5:127547810	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	7.19	0.43	8.57e-12	Breast cancer;
SARC	cis	rs2033711	0.811	rs9304814	chr19:58951811	C/A	cg26874164	chr19:58962979	ZNF324B	0.51	6.51	0.39	4.57e-10	Uric acid clearance;
SARC	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.95	13.96	0.67	1.32e-32	Gut microbiome composition (summer);
SARC	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg03709012	chr19:19516395	GATAD2A	0.91	14.47	0.69	2.75e-34	Tonsillectomy;
SARC	cis	rs9790314	0.690	rs7651087	chr3:160821929	T/C	cg03342759	chr3:160939853	NMD3	-0.59	-7.47	-0.44	1.65e-12	Morning vs. evening chronotype;
SARC	cis	rs7917772	0.636	rs4919674	chr10:104522226	T/C	ch.10.2196322F	chr10:104248062	ACTR1A	-0.46	-5.4	-0.33	1.61e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs9660992	0.710	rs1180721	chr1:205232696	T/C	cg21545522	chr1:205238299	TMCC2	0.45	6.24	0.38	1.99e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs473651	0.904	rs551859	chr2:239371836	T/C	cg21699342	chr2:239360505	ASB1	0.44	6.43	0.39	7.1e-10	Multiple system atrophy;
SARC	cis	rs6580649	0.943	rs9651993	chr12:48404692	G/A	cg05342945	chr12:48394962	COL2A1	-0.58	-6.13	-0.37	3.71e-9	Lung cancer;
SARC	cis	rs9616064	0.531	rs9616086	chr22:47050744	G/A	cg05621596	chr22:47072043	GRAMD4	-0.61	-8.46	-0.48	2.97e-15	Urate levels in obese individuals;
SARC	cis	rs797680	0.658	rs11164904	chr1:93780742	G/A	cg01538778	chr1:93646459	TMED5;CCDC18	0.4	4.84	0.3	2.38e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
SARC	cis	rs2857078	0.720	rs9906669	chr17:42305706	A/G	cg19774624	chr17:42201019	HDAC5	-0.44	-5.84	-0.36	1.73e-8	Red cell distribution width;Reticulocyte count;
SARC	cis	rs9948	0.881	rs3731941	chr2:97476219	A/G	cg01990225	chr2:97406019	LMAN2L	-0.9	-6.28	-0.38	1.6e-9	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs7940866	0.834	rs10791108	chr11:130849354	T/A	cg12179176	chr11:130786555	SNX19	0.65	8.7	0.5	6.14e-16	Schizophrenia;
SARC	cis	rs7223966	1.000	rs9903903	chr17:61762044	A/G	cg00588841	chr17:61851480	DDX42;CCDC47	-0.59	-6.86	-0.41	6.03e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9916302	0.706	rs8069074	chr17:37685401	C/T	cg20243544	chr17:37824526	PNMT	-0.53	-5.51	-0.34	9.58e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs7599312	0.534	rs2128321	chr2:213405276	G/T	cg20637307	chr2:213403960	ERBB4	0.81	12.7	0.64	1.99e-28	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg03709012	chr19:19516395	GATAD2A	0.99	16.83	0.74	3.94e-42	Tonsillectomy;
SARC	trans	rs4679904	0.694	rs6777739	chr3:160377140	C/T	cg15555402	chr12:19593456	AEBP2	0.5	6.53	0.39	4.07e-10	Primary biliary cholangitis;
SARC	cis	rs4642101	0.765	rs9872103	chr3:12827452	G/T	cg12400702	chr3:12838781	CAND2	-0.26	-5.14	-0.32	5.75e-7	QRS complex (12-leadsum);
SARC	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.71	-7.18	-0.43	9.41e-12	Platelet count;
SARC	cis	rs7429990	0.965	rs7427418	chr3:48022707	T/C	cg11946769	chr3:48343235	NME6	-0.46	-5.39	-0.33	1.75e-7	Educational attainment (years of education);
SARC	cis	rs6912958	0.781	rs2284908	chr6:88194500	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.52	-6.8	-0.41	8.92e-11	Monocyte percentage of white cells;
SARC	cis	rs858239	0.537	rs6955115	chr7:23227144	A/G	cg23682824	chr7:23144976	KLHL7	0.66	8.44	0.48	3.4e-15	Cerebrospinal fluid biomarker levels;
SARC	cis	rs151234	0.612	rs11641853	chr16:28589719	A/G	cg01378222	chr16:28622494	SULT1A1	-0.5	-5.78	-0.35	2.36e-8	Platelet distribution width;
SARC	cis	rs67311347	0.824	rs73073561	chr3:40357298	G/T	cg09455208	chr3:40491958	NA	0.4	6.2	0.38	2.54e-9	Renal cell carcinoma;
SARC	cis	rs2933343	0.533	rs11915889	chr3:128700866	A/C	cg24203234	chr3:128598194	ACAD9	0.48	5.65	0.35	4.76e-8	IgG glycosylation;
SARC	cis	rs11098499	0.874	rs6851169	chr4:120117510	T/C	cg09307838	chr4:120376055	NA	0.82	11.06	0.59	3.96e-23	Corneal astigmatism;
SARC	cis	rs9303401	0.659	rs7210432	chr17:56668170	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	11.65	0.61	5.15e-25	Cognitive test performance;
SARC	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg00825309	chr19:58991885	ZNF446	-0.55	-7.65	-0.45	5.22e-13	Uric acid clearance;
SARC	cis	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg05623727	chr3:50126028	RBM5	0.36	5.16	0.32	5.39e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7412746	0.658	rs10888397	chr1:150886752	A/G	cg10589385	chr1:150898437	SETDB1	-0.41	-5.59	-0.34	6.27e-8	Melanoma;
SARC	cis	rs4141404	0.923	rs2413046	chr22:31665909	C/A	cg07713946	chr22:31675144	LIMK2	-0.37	-5.15	-0.32	5.57e-7	Paclitaxel-induced neuropathy;
SARC	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg22920501	chr2:26401640	FAM59B	0.58	7.58	0.44	8.39e-13	Gut microbiome composition (summer);
SARC	cis	rs2624839	0.704	rs2624838	chr3:50205642	C/G	cg24110177	chr3:50126178	RBM5	-0.43	-5.34	-0.33	2.16e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg07701084	chr6:150067640	NUP43	0.43	5.63	0.35	5.26e-8	Lung cancer;
SARC	cis	rs6963495	0.818	rs73190163	chr7:105157294	G/T	cg19920283	chr7:105172520	RINT1	0.65	5.48	0.34	1.09e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg03575189	chr17:44344142	NA	0.61	5.72	0.35	3.33e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg13607699	chr17:42295918	UBTF	0.56	6.63	0.4	2.29e-10	Total body bone mineral density;
SARC	cis	rs7666738	0.830	rs1115616	chr4:99006603	A/C	cg05340658	chr4:99064831	C4orf37	0.64	8.73	0.5	5.16e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs3126085	1.000	rs11590365	chr1:152165489	C/A	cg03465714	chr1:152285911	FLG	0.45	4.86	0.3	2.2e-6	Atopic dermatitis;
SARC	cis	rs10927875	0.691	rs1048261	chr1:16340951	A/T	cg21385522	chr1:16154831	NA	0.72	9.17	0.51	2.62e-17	Dilated cardiomyopathy;
SARC	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg17221315	chr6:27791827	HIST1H4J	0.49	5.0	0.31	1.15e-6	Parkinson's disease;
SARC	cis	rs9660992	0.710	rs1172138	chr1:205246019	G/A	cg07972983	chr1:205091412	RBBP5	0.55	6.56	0.39	3.53e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs7772486	0.686	rs1337841	chr6:146059487	A/G	cg23711669	chr6:146136114	FBXO30	-0.82	-13.27	-0.66	2.57e-30	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg10295955	chr4:187884368	NA	1.05	19.18	0.78	7.58e-50	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs918629	0.567	rs6885567	chr5:95258754	T/G	cg16656078	chr5:95278638	ELL2	-0.53	-6.65	-0.4	2.05e-10	IgG glycosylation;
SARC	cis	rs9603616	0.719	rs4943688	chr13:40236390	A/G	cg06101725	chr13:40230077	COG6	0.41	4.76	0.3	3.38e-6	Rheumatoid arthritis;
SARC	cis	rs9660180	0.620	rs34298494	chr1:1663402	A/C	cg13866156	chr1:1669148	SLC35E2	0.65	8.44	0.48	3.41e-15	Body mass index;
SARC	cis	rs2997447	0.761	rs2783670	chr1:26455182	A/G	cg19633962	chr1:26362018	EXTL1	-0.58	-5.23	-0.32	3.74e-7	QRS complex (12-leadsum);
SARC	cis	rs11098699	0.821	rs7684799	chr4:124207659	C/T	cg09941581	chr4:124220074	SPATA5	0.39	4.73	0.3	3.98e-6	Mosquito bite size;
SARC	cis	rs3087591	1.000	rs2905884	chr17:29512476	A/G	cg24425628	chr17:29625626	OMG;NF1	0.48	5.9	0.36	1.28e-8	Hip circumference;
SARC	trans	rs1814175	0.817	rs1615305	chr11:49895222	T/A	cg03929089	chr4:120376271	NA	-0.9	-14.56	-0.69	1.39e-34	Height;
SARC	cis	rs11758351	1.000	rs78012445	chr6:26195080	G/C	cg01420254	chr6:26195488	NA	0.56	4.82	0.3	2.61e-6	Gout;Renal underexcretion gout;
SARC	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	8.51	0.49	2.13e-15	Mean platelet volume;
SARC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg11494091	chr17:61959527	GH2	-0.48	-7.43	-0.44	2.08e-12	Prudent dietary pattern;
SARC	cis	rs11098499	0.909	rs73842633	chr4:120375464	G/A	cg09307838	chr4:120376055	NA	0.92	12.49	0.63	9.37e-28	Corneal astigmatism;
SARC	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg24549020	chr5:56110836	MAP3K1	0.8	8.36	0.48	5.61e-15	Initial pursuit acceleration;
SARC	cis	rs7847628	0.765	rs10985024	chr9:123516812	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	6.2	0.38	2.56e-9	Birth weight;
SARC	cis	rs918629	0.530	rs3777193	chr5:95246760	G/A	cg16656078	chr5:95278638	ELL2	-0.52	-6.55	-0.39	3.74e-10	IgG glycosylation;
SARC	cis	rs433852	0.904	rs8102492	chr19:49140809	A/C	cg06530960	chr19:49140787	SEC1;DBP	0.63	7.15	0.42	1.11e-11	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg11890956	chr21:40555474	PSMG1	1.18	16.97	0.74	1.32e-42	Cognitive function;
SARC	cis	rs4280164	0.551	rs12436194	chr14:24804859	C/T	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.53	-5.37	-0.33	1.91e-7	Parent of origin effect on language impairment (paternal);
SARC	cis	rs2439831	0.850	rs3097773	chr15:43893072	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.65	-6.88	-0.41	5.45e-11	Lung cancer in ever smokers;
SARC	cis	rs11711311	0.955	rs11715350	chr3:113418376	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.69	8.52	0.49	2.02e-15	IgG glycosylation;
SARC	cis	rs7770848	1	rs7770848	chr6:44769237	A/C	cg17348667	chr6:45346345	SUPT3H;RUNX2	0.54	4.82	0.3	2.63e-6	Asthma (childhood onset);
SARC	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg16325326	chr1:53192061	ZYG11B	0.93	17.39	0.75	5.69e-44	Monocyte count;
SARC	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg07636037	chr3:49044803	WDR6	0.99	17.87	0.76	1.44e-45	Parkinson's disease;
SARC	cis	rs66887589	0.777	rs10015883	chr4:120268146	A/G	cg09307838	chr4:120376055	NA	0.53	7.1	0.42	1.46e-11	Diastolic blood pressure;
SARC	cis	rs11608355	0.545	rs12819658	chr12:109907670	A/T	cg05360138	chr12:110035743	NA	0.93	9.71	0.54	6.21e-19	Neuroticism;
SARC	cis	rs7772486	0.686	rs9497396	chr6:146014963	C/A	cg05347473	chr6:146136440	FBXO30	-0.52	-7.21	-0.43	7.84e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs8067545	0.611	rs2703781	chr17:20144714	A/G	cg13482628	chr17:19912719	NA	-0.53	-6.9	-0.41	4.96e-11	Schizophrenia;
SARC	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg21724239	chr8:58056113	NA	0.66	6.19	0.38	2.74e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs3768617	0.903	rs10911251	chr1:183081194	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	8.27	0.48	1.04e-14	Fuchs's corneal dystrophy;
SARC	cis	rs734999	0.505	rs4073286	chr1:2539901	A/C	cg20673091	chr1:2541236	MMEL1	0.33	5.11	0.32	6.65e-7	Ulcerative colitis;
SARC	cis	rs2952156	0.684	rs11658786	chr17:37815899	G/A	cg00129232	chr17:37814104	STARD3	-0.8	-11.7	-0.61	3.63e-25	Asthma;
SARC	cis	rs2115630	0.645	rs2292463	chr15:85175750	A/G	cg12501888	chr15:85177176	SCAND2	-0.49	-5.91	-0.36	1.23e-8	P wave terminal force;
SARC	trans	rs10862219	0.929	rs10862220	chr12:81430599	T/G	cg03835158	chr8:52773607	PCMTD1	-0.48	-6.55	-0.39	3.71e-10	Neuroticism;
SARC	cis	rs3087591	0.639	rs2854333	chr17:29713300	T/C	cg24425628	chr17:29625626	OMG;NF1	0.43	5.44	0.34	1.37e-7	Hip circumference;
SARC	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg00339695	chr16:24857497	SLC5A11	-0.42	-5.86	-0.36	1.56e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs17345786	0.861	rs79181492	chr3:101216021	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.45	-4.8	-0.3	2.86e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs616402	0.564	rs602601	chr1:10567058	C/T	cg17425144	chr1:10567563	PEX14	0.45	7.39	0.44	2.61e-12	Breast size;
SARC	cis	rs7772486	0.776	rs4316025	chr6:146238032	C/T	cg23711669	chr6:146136114	FBXO30	-0.76	-11.59	-0.6	8.26e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs921968	0.519	rs72966020	chr2:219642620	C/G	cg02176678	chr2:219576539	TTLL4	-0.5	-7.92	-0.46	9.85e-14	Mean corpuscular hemoglobin concentration;
SARC	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.44	-5.54	-0.34	8.21e-8	Blood metabolite levels;
SARC	cis	rs73206853	0.688	rs7314248	chr12:110559173	G/A	cg10860002	chr12:110842031	ANAPC7	0.68	5.44	0.34	1.35e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg00152838	chr16:24741724	TNRC6A	-0.61	-6.18	-0.38	2.87e-9	Intelligence (multi-trait analysis);
SARC	cis	rs748404	0.578	rs507178	chr15:43610135	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	6.87	0.41	5.71e-11	Lung cancer;
SARC	cis	rs644799	0.930	rs3802764	chr11:95514599	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	15.14	0.7	1.65e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9398803	0.865	rs1490388	chr6:126835655	C/T	cg20229609	chr6:126660872	C6orf173	0.4	5.79	0.35	2.23e-8	Male-pattern baldness;
SARC	cis	rs7667	0.853	rs7529705	chr1:19720092	C/T	cg15311933	chr1:19638897	PQLC2;AKR7A2	-0.41	-5.01	-0.31	1.05e-6	Crohn's disease and psoriasis;
SARC	cis	rs7264396	0.887	rs6120954	chr20:34059536	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-4.73	-0.3	3.93e-6	Total cholesterol levels;
SARC	cis	rs796364	0.806	rs79053279	chr2:201057443	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.63	-5.09	-0.32	7.35e-7	Schizophrenia;
SARC	cis	rs9467711	0.538	rs35942482	chr6:26444938	T/A	cg12826209	chr6:26865740	GUSBL1	0.8	4.91	0.31	1.73e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9910055	0.529	rs425038	chr17:42182028	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	-0.47	-5.52	-0.34	9e-8	Total body bone mineral density;
SARC	cis	rs17401966	0.838	rs4846212	chr1:10370312	T/C	cg15208524	chr1:10270712	KIF1B	0.49	5.76	0.35	2.68e-8	Hepatocellular carcinoma;
SARC	cis	rs761746	0.804	rs5749304	chr22:31967775	A/G	cg15823100	chr22:32027580	PISD	0.33	4.93	0.31	1.57e-6	Intelligence;
SARC	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg23758822	chr17:41437982	NA	-0.86	-11.08	-0.59	3.47e-23	Menopause (age at onset);
SARC	trans	rs208520	0.690	rs1233103	chr6:66855943	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-13.87	-0.67	2.61e-32	Exhaled nitric oxide output;
SARC	cis	rs9790314	0.704	rs4618258	chr3:160869129	G/C	cg03342759	chr3:160939853	NMD3	-0.59	-7.4	-0.44	2.45e-12	Morning vs. evening chronotype;
SARC	cis	rs9916302	0.904	rs35335692	chr17:37710006	A/G	cg07936489	chr17:37558343	FBXL20	-0.69	-8.89	-0.5	1.7e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs4900538	0.963	rs1998422	chr14:102980993	G/C	cg18135206	chr14:102964638	TECPR2	0.7	9.36	0.52	7.16e-18	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs7539409	0.651	rs6696140	chr1:84317468	C/T	cg10977910	chr1:84465055	TTLL7	-0.62	-5.94	-0.36	1.05e-8	Alzheimer's disease;
SARC	trans	rs11098499	0.780	rs12504773	chr4:120562149	G/C	cg25214090	chr10:38739885	LOC399744	0.52	6.71	0.4	1.49e-10	Corneal astigmatism;
SARC	cis	rs7772486	0.790	rs9497435	chr6:146265340	C/A	cg05347473	chr6:146136440	FBXO30	-0.46	-6.31	-0.38	1.4e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg15242686	chr22:24348715	GSTTP1	-0.44	-5.22	-0.32	3.92e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs412050	0.895	rs6000236	chr22:22296459	A/G	cg17089214	chr22:22089827	YPEL1	0.55	5.17	0.32	5.1e-7	Attention deficit hyperactivity disorder;
SARC	cis	rs3857536	0.874	rs10806524	chr6:66900486	T/C	cg07460842	chr6:66804631	NA	-0.46	-5.45	-0.34	1.26e-7	Blood trace element (Cu levels);
SARC	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg05457628	chr5:178986728	RUFY1	0.36	4.93	0.31	1.58e-6	Lung cancer;
SARC	cis	rs9894429	0.646	rs12603868	chr17:79618834	G/C	cg18240062	chr17:79603768	NPLOC4	0.56	6.62	0.4	2.49e-10	Eye color traits;
SARC	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg00933542	chr6:150070202	PCMT1	0.31	5.36	0.33	2.04e-7	Lung cancer;
SARC	cis	rs554111	0.613	rs1567128	chr1:21404653	G/A	cg08890418	chr1:21044141	KIF17	-0.36	-5.11	-0.32	6.71e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs73001065	0.792	rs16996148	chr19:19658472	G/T	cg03709012	chr19:19516395	GATAD2A	0.95	7.18	0.43	9.53e-12	LDL cholesterol;
SARC	cis	rs74181299	0.964	rs1009358	chr2:65276452	C/T	cg20592124	chr2:65290738	CEP68	-0.44	-6.59	-0.4	2.88e-10	Pulse pressure;
SARC	cis	rs2236918	0.932	rs2526697	chr1:242040129	A/G	cg17736920	chr1:242011382	EXO1	-0.72	-10.24	-0.56	1.48e-20	Menopause (age at onset);
SARC	cis	rs539096	0.540	rs37452	chr1:44297573	A/C	cg12908607	chr1:44402522	ARTN	-0.31	-5.55	-0.34	7.69e-8	Intelligence (multi-trait analysis);
SARC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg11235426	chr6:292522	DUSP22	-0.6	-7.67	-0.45	4.59e-13	Menopause (age at onset);
SARC	cis	rs796364	0.625	rs1369843	chr2:201088171	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.56	5.5	0.34	9.78e-8	Schizophrenia;
SARC	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg08219700	chr8:58056026	NA	0.6	5.73	0.35	3.15e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs114858855	0.661	rs9487193	chr6:110030579	A/G	cg26835506	chr6:109038353	NA	-0.59	-4.83	-0.3	2.48e-6	Plasma trimethylamine N-oxide levels;
SARC	cis	rs798554	0.679	rs2644300	chr7:2883071	G/A	cg04166393	chr7:2884313	GNA12	0.68	8.27	0.48	1.04e-14	Height;
SARC	cis	rs7084402	0.935	rs1593675	chr10:60291694	G/A	cg07615347	chr10:60278583	BICC1	0.61	8.99	0.51	8.84e-17	Refractive error;
SARC	cis	rs10504073	0.584	rs11778863	chr8:49954893	C/T	cg00325661	chr8:49890786	NA	0.52	6.78	0.41	9.87e-11	Blood metabolite ratios;
SARC	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg11764359	chr7:65958608	NA	0.86	12.33	0.63	3.29e-27	Aortic root size;
SARC	cis	rs4689388	0.793	rs4689393	chr4:6287241	T/C	cg25554036	chr4:6271136	WFS1	0.42	6.76	0.4	1.11e-10	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs11583043	0.575	rs658861	chr1:101584241	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.45	-5.21	-0.32	4.11e-7	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs11509153	0.687	rs1020005	chr7:12255668	C/A	cg23422036	chr7:12250390	TMEM106B	0.49	6.33	0.38	1.24e-9	Residual cognition;
SARC	cis	rs6977660	0.714	rs12386623	chr7:19791875	A/G	cg07541023	chr7:19748670	TWISTNB	-0.75	-7.06	-0.42	1.92e-11	Thyroid stimulating hormone;
SARC	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg13206674	chr6:150067644	NUP43	-0.41	-5.19	-0.32	4.53e-7	Lung cancer;
SARC	cis	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg18252515	chr7:66147081	NA	-1.36	-12.06	-0.62	2.47e-26	Diabetic kidney disease;
SARC	trans	rs61931739	0.500	rs11053189	chr12:34433455	G/A	cg26384229	chr12:38710491	ALG10B	0.92	13.84	0.67	3.3e-32	Morning vs. evening chronotype;
SARC	cis	rs1008375	0.898	rs7678654	chr4:17575376	T/G	cg16339924	chr4:17578868	LAP3	0.68	8.86	0.5	2.04e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs72634258	0.519	rs744001	chr1:7934557	G/A	cg00042356	chr1:8021962	PARK7	0.65	5.58	0.34	6.51e-8	Inflammatory bowel disease;
SARC	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg15448220	chr1:150897856	SETDB1	0.48	6.38	0.39	9.29e-10	Tonsillectomy;
SARC	cis	rs3126085	1.000	rs3120662	chr1:152302865	G/T	cg26876637	chr1:152193138	HRNR	-0.44	-4.76	-0.3	3.46e-6	Atopic dermatitis;
SARC	cis	rs9457247	1.000	rs10946199	chr6:167404492	G/A	cg23791538	chr6:167370224	RNASET2	-0.63	-8.74	-0.5	4.69e-16	Crohn's disease;
SARC	cis	rs2425143	1.000	rs6058303	chr20:34290281	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-5.96	-0.36	9.09e-9	Blood protein levels;
SARC	cis	rs2070488	0.804	rs4678605	chr3:38444489	T/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.81	12.46	0.63	1.22e-27	Electrocardiographic conduction measures;
SARC	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg03452623	chr4:187889614	NA	-0.82	-12.89	-0.65	4.57e-29	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7937682	0.883	rs517982	chr11:111462687	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.93	-14.14	-0.68	3.55e-33	Primary sclerosing cholangitis;
SARC	cis	rs9916302	0.904	rs11654018	chr17:37703740	C/T	cg20243544	chr17:37824526	PNMT	-0.54	-6.17	-0.37	3e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs7582180	0.591	rs2241810	chr2:101011877	T/C	cg14675211	chr2:100938903	LONRF2	0.52	7.73	0.45	3.24e-13	Intelligence (multi-trait analysis);
SARC	trans	rs2727020	0.590	rs7949936	chr11:49378902	G/A	cg03929089	chr4:120376271	NA	-0.73	-7.89	-0.46	1.17e-13	Coronary artery disease;
SARC	cis	rs2806561	0.704	rs2868573	chr1:23508253	C/G	cg12483005	chr1:23474871	LUZP1	0.43	5.72	0.35	3.23e-8	Height;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05367846	chr22:18507520	MICAL3	0.46	6.25	0.38	1.9e-9	Smoking initiation;
SARC	cis	rs2370759	0.891	rs76164690	chr10:32590362	T/G	cg01819863	chr10:32635814	EPC1	0.97	7.53	0.44	1.12e-12	Sexual dysfunction (female);
SARC	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg22168489	chr12:122356033	WDR66	0.64	9.79	0.54	3.44e-19	Mean corpuscular volume;
SARC	cis	rs9653442	0.866	rs12712065	chr2:100761105	C/G	cg22139774	chr2:100720529	AFF3	-0.27	-4.81	-0.3	2.66e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
SARC	cis	rs1395	0.744	rs1975384	chr2:27542041	C/T	cg21747090	chr2:27597821	SNX17	-0.56	-6.46	-0.39	6.08e-10	Blood metabolite levels;
SARC	cis	rs7566780	0.931	rs7573656	chr2:16735432	A/G	cg09580478	chr2:16689509	NA	0.36	4.83	0.3	2.45e-6	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs9790314	1.000	rs336583	chr3:161081981	A/T	cg03342759	chr3:160939853	NMD3	0.6	7.42	0.44	2.2e-12	Morning vs. evening chronotype;
SARC	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg07701084	chr6:150067640	NUP43	0.41	4.97	0.31	1.33e-6	Lung cancer;
SARC	cis	rs889312	0.521	rs12651942	chr5:56088484	C/T	cg14703610	chr5:56206110	C5orf35	0.48	5.73	0.35	3.09e-8	Breast cancer;Breast cancer (early onset);
SARC	cis	rs4906332	1.000	rs55731474	chr14:103878481	G/A	cg26031613	chr14:104095156	KLC1	-0.5	-5.78	-0.35	2.36e-8	Coronary artery disease;
SARC	cis	rs7296418	0.738	rs1568428	chr12:123738876	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.37	4.99	0.31	1.21e-6	Platelet count;
SARC	cis	rs4792901	0.592	rs57462570	chr17:41607979	T/C	cg22562494	chr17:41607896	ETV4	-0.33	-4.98	-0.31	1.24e-6	Dupuytren's disease;
SARC	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg02733842	chr7:1102375	C7orf50	-0.39	-4.9	-0.31	1.76e-6	Bronchopulmonary dysplasia;
SARC	cis	rs9911578	1.000	rs1494977	chr17:56863064	C/T	cg12560992	chr17:57184187	TRIM37	0.88	11.95	0.62	5.44e-26	Intelligence (multi-trait analysis);
SARC	cis	rs950027	0.549	rs11636114	chr15:45601412	C/G	cg26924012	chr15:45694286	SPATA5L1	0.44	5.19	0.32	4.67e-7	Response to fenofibrate (adiponectin levels);
SARC	cis	rs920590	0.573	rs6986456	chr8:19680562	A/G	cg03894339	chr8:19674705	INTS10	0.52	6.13	0.37	3.78e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs11718455	0.960	rs3843372	chr3:43997666	C/T	cg21419209	chr3:44054225	NA	-0.43	-5.3	-0.33	2.71e-7	Coronary artery disease;
SARC	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	11.69	0.61	3.89e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs3784262	0.669	rs3204690	chr15:58246768	A/C	cg12031962	chr15:58353849	ALDH1A2	-0.32	-4.73	-0.3	3.94e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg05863683	chr7:1912471	MAD1L1	0.37	5.73	0.35	3.11e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg15448220	chr1:150897856	SETDB1	0.47	6.25	0.38	1.94e-9	Tonsillectomy;
SARC	cis	rs1003719	0.762	rs11088381	chr21:38478429	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.95	0.51	1.17e-16	Eye color traits;
SARC	cis	rs7772486	0.754	rs1055212	chr6:146058315	A/T	cg23711669	chr6:146136114	FBXO30	-0.93	-16.44	-0.73	7.78e-41	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4664308	0.875	rs60908067	chr2:161004983	T/G	cg03641300	chr2:160917029	PLA2R1	-0.65	-8.58	-0.49	1.36e-15	Idiopathic membranous nephropathy;
SARC	cis	rs3733585	0.648	rs7376155	chr4:9952588	C/T	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.94	-0.36	1.06e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	trans	rs11098499	0.954	rs7681544	chr4:120411255	T/C	cg25214090	chr10:38739885	LOC399744	0.58	7.47	0.44	1.63e-12	Corneal astigmatism;
SARC	cis	rs6977660	0.714	rs10260866	chr7:19793151	T/C	cg07541023	chr7:19748670	TWISTNB	0.75	7.0	0.42	2.65e-11	Thyroid stimulating hormone;
SARC	cis	rs3858526	0.959	rs11039699	chr11:5951091	G/A	cg02574844	chr11:5959923	NA	-0.43	-5.32	-0.33	2.47e-7	DNA methylation (variation);
SARC	cis	rs6545883	0.929	rs9679557	chr2:61709349	C/A	cg15711740	chr2:61764176	XPO1	-0.44	-5.26	-0.33	3.29e-7	Tuberculosis;
SARC	cis	rs735539	0.521	rs1570672	chr13:21408818	C/T	cg16922012	chr13:21400325	XPO4	-0.45	-6.16	-0.37	3.11e-9	Dental caries;
SARC	cis	rs7666738	0.830	rs34412187	chr4:99010454	A/G	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6701037	1.000	rs1057305	chr1:175126223	T/A	cg00321850	chr1:175162397	KIAA0040	-0.35	-5.2	-0.32	4.33e-7	Alcohol dependence;
SARC	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.38	-4.83	-0.3	2.5e-6	Lymphocyte counts;
SARC	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg20887711	chr4:1340912	KIAA1530	-0.62	-7.28	-0.43	5.1e-12	Obesity-related traits;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg08664849	chr16:2546474	TBC1D24	0.47	6.25	0.38	1.95e-9	Schizophrenia;
SARC	cis	rs11676348	0.846	rs7607437	chr2:219008392	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.48	-6.18	-0.38	2.81e-9	Ulcerative colitis;
SARC	cis	rs67311347	0.876	rs13068097	chr3:40504424	T/A	cg24209194	chr3:40518798	ZNF619	-0.66	-8.44	-0.48	3.29e-15	Renal cell carcinoma;
SARC	cis	rs7520050	1.000	rs785511	chr1:46534498	T/C	cg06784218	chr1:46089804	CCDC17	-0.26	-4.83	-0.3	2.42e-6	Red blood cell count;Reticulocyte count;
SARC	trans	rs17685	0.753	rs7788763	chr7:75651665	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.63	-7.92	-0.46	9.6e-14	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs4555082	1.000	rs4334224	chr14:105759198	C/T	cg06808227	chr14:105710500	BRF1	-0.45	-5.59	-0.34	6.45e-8	Mean platelet volume;Platelet distribution width;
SARC	cis	rs6676180	0.514	rs868675	chr1:119773596	A/G	cg05756136	chr1:119680316	WARS2	-0.38	-5.16	-0.32	5.19e-7	Monobrow;
SARC	cis	rs1976403	0.633	rs1780324	chr1:21821757	A/G	cg17800788	chr1:21766015	NBPF3	0.3	4.96	0.31	1.39e-6	Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg19901468	chr14:105411992	AHNAK2	-0.76	-10.72	-0.57	4.54e-22	Rheumatoid arthritis;
SARC	cis	rs7586879	0.639	rs6545776	chr2:25099357	A/C	cg04586622	chr2:25135609	ADCY3	0.33	5.58	0.34	6.65e-8	Body mass index;
SARC	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg19223190	chr17:80058835	NA	0.43	6.07	0.37	5.09e-9	Life satisfaction;
SARC	cis	rs10416265	0.528	rs3786932	chr19:33620488	T/A	cg17764715	chr19:33622953	WDR88	0.47	4.88	0.3	2e-6	Bone properties (heel);
SARC	cis	rs17376456	0.877	rs7702521	chr5:93484579	G/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.19	0.32	4.66e-7	Diabetic retinopathy;
SARC	cis	rs2075371	0.611	rs34573600	chr7:134018937	C/T	cg00033643	chr7:134001901	SLC35B4	0.43	5.27	0.33	3.17e-7	Mean platelet volume;
SARC	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg22455342	chr2:225449267	CUL3	-0.68	-8.89	-0.5	1.66e-16	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs6582630	0.576	rs2387836	chr12:38560070	A/G	cg26384229	chr12:38710491	ALG10B	0.65	8.25	0.48	1.17e-14	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg22920501	chr2:26401640	FAM59B	0.6	7.73	0.45	3.17e-13	Gut microbiome composition (summer);
SARC	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg07636037	chr3:49044803	WDR6	0.99	17.47	0.75	3.09e-44	Parkinson's disease;
SARC	cis	rs7552404	0.731	rs5745445	chr1:76344332	G/A	cg22875332	chr1:76189707	ACADM	0.44	5.47	0.34	1.13e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs16854884	0.837	rs4362712	chr3:143801076	G/A	cg06585982	chr3:143692056	C3orf58	0.6	7.81	0.46	1.99e-13	Economic and political preferences (feminism/equality);
SARC	cis	rs9902453	0.836	rs62070337	chr17:28466257	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	6.53	0.39	4.03e-10	Coffee consumption (cups per day);
SARC	cis	rs11785400	0.793	rs6996760	chr8:143722386	G/A	cg24634471	chr8:143751801	JRK	0.6	7.85	0.46	1.51e-13	Schizophrenia;
SARC	cis	rs6696846	0.765	rs2836	chr1:205111761	G/T	cg07972983	chr1:205091412	RBBP5	-0.56	-7.44	-0.44	1.97e-12	Red blood cell count;
SARC	cis	rs17209837	0.915	rs7805184	chr7:87118601	G/A	cg00919237	chr7:87102261	ABCB4	-0.45	-4.74	-0.3	3.73e-6	Gallbladder cancer;
SARC	cis	rs72627123	0.867	rs73301500	chr14:74473413	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.79	5.88	0.36	1.38e-8	Morning vs. evening chronotype;
SARC	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg08067268	chr2:26466485	HADHB;HADHA	0.46	5.77	0.35	2.54e-8	Gut microbiome composition (summer);
SARC	trans	rs11088226	0.598	rs79634586	chr21:33959363	A/G	cg09050820	chr6:167586206	TCP10L2	0.66	7.25	0.43	6.2e-12	Gastritis;
SARC	cis	rs57506017	0.585	rs2356065	chr7:12276885	T/C	cg23422036	chr7:12250390	TMEM106B	0.46	5.97	0.36	8.71e-9	Neuroticism;
SARC	cis	rs72945132	0.678	rs12786421	chr11:70235314	G/C	cg00319359	chr11:70116639	PPFIA1	0.56	5.19	0.32	4.56e-7	Coronary artery disease;
SARC	cis	rs67311347	0.544	rs9814779	chr3:40340431	T/C	cg09455208	chr3:40491958	NA	0.3	5.08	0.32	7.74e-7	Renal cell carcinoma;
SARC	cis	rs826838	1.000	rs826838	chr12:39106731	C/T	cg13010199	chr12:38710504	ALG10B	-0.67	-9.55	-0.53	1.89e-18	Heart rate;
SARC	cis	rs447735	0.587	rs7188458	chr16:89726484	A/G	cg03605463	chr16:89740564	NA	0.4	5.48	0.34	1.08e-7	Hemoglobin concentration;
SARC	cis	rs17376456	0.877	rs9314100	chr5:93447394	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.54	0.34	8.18e-8	Diabetic retinopathy;
SARC	cis	rs72781680	0.611	rs72781695	chr2:24266744	T/C	cg06627628	chr2:24431161	ITSN2	-0.61	-6.04	-0.37	6.18e-9	Lymphocyte counts;
SARC	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.6	5.08	0.32	7.91e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs763121	0.853	rs138705	chr22:39133803	C/T	cg06022373	chr22:39101656	GTPBP1	0.89	11.55	0.6	1.07e-24	Menopause (age at onset);
SARC	cis	rs748404	0.690	rs1079309	chr15:43783164	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.48	5.22	0.32	3.92e-7	Lung cancer;
SARC	cis	rs6910061	0.913	rs35199324	chr6:11112863	C/T	cg27233058	chr6:11094804	LOC221710	0.58	5.66	0.35	4.42e-8	Diabetic kidney disease;
SARC	cis	rs1670533	1.000	rs6822863	chr4:1055606	G/A	cg27284194	chr4:1044797	NA	0.47	4.96	0.31	1.37e-6	Recombination rate (females);
SARC	cis	rs3760982	0.585	rs67704568	chr19:44294019	T/C	cg11993925	chr19:44307056	LYPD5	0.3	4.75	0.3	3.49e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
SARC	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.47	-5.82	-0.36	1.93e-8	Tonsillectomy;
SARC	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg13395646	chr4:1353034	KIAA1530	-0.41	-4.91	-0.31	1.75e-6	Obesity-related traits;
SARC	cis	rs4148883	0.689	rs1869458	chr4:100024728	C/G	cg12011299	chr4:100065546	ADH4	0.36	6.7	0.4	1.59e-10	Alcohol dependence;
SARC	cis	rs11122272	0.735	rs2486740	chr1:231517552	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs7923452	0.507	rs103441	chr10:30778184	C/T	cg25182066	chr10:30743637	MAP3K8	0.38	4.77	0.3	3.2e-6	Itch intensity from mosquito bite;
SARC	cis	rs3740540	0.507	rs897292	chr10:126290035	A/G	cg04949429	chr10:126290192	LHPP	0.42	5.98	0.36	8.42e-9	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
SARC	cis	rs244731	0.959	rs7721671	chr5:176630984	A/G	cg16006841	chr5:176797999	RGS14	-0.57	-6.89	-0.41	5.01e-11	Urate levels in lean individuals;
SARC	cis	rs765787	0.530	rs11854690	chr15:45516016	C/T	cg24006582	chr15:45444508	DUOX1	-0.49	-6.47	-0.39	5.7e-10	Uric acid levels;
SARC	cis	rs36093924	0.646	rs4822069	chr22:42351481	T/C	cg04733989	chr22:42467013	NAGA	-0.4	-5.0	-0.31	1.12e-6	Intelligence;
SARC	trans	rs9329221	0.905	rs17709397	chr8:10249861	G/A	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.64	-0.4	2.17e-10	Neuroticism;
SARC	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg06212747	chr3:49208901	KLHDC8B	0.62	8.26	0.48	1.08e-14	Parkinson's disease;
SARC	cis	rs807669	1.000	rs807670	chr22:19154608	A/C	cg02655711	chr22:19163373	SLC25A1	0.43	6.12	0.37	3.84e-9	Metabolite levels;
SARC	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	11.9	0.61	7.73e-26	Platelet count;
SARC	cis	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg25427524	chr10:38739819	LOC399744	-0.53	-8.29	-0.48	8.97e-15	Extrinsic epigenetic age acceleration;
SARC	cis	rs796364	1.000	rs1509835	chr2:200814809	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.76	6.86	0.41	6.2e-11	Schizophrenia;
SARC	cis	rs9457247	0.508	rs9459874	chr6:167504127	A/G	cg07741184	chr6:167504864	NA	-0.33	-6.38	-0.39	9.65e-10	Crohn's disease;
SARC	cis	rs4646312	0.555	rs9605031	chr22:19921378	C/T	cg07194846	chr22:19930177	COMT;TXNRD2	0.51	6.62	0.4	2.41e-10	Schizophrenia;
SARC	cis	rs7647973	0.710	rs1532204	chr3:49609477	C/G	cg13072238	chr3:49761600	GMPPB	-0.61	-5.33	-0.33	2.34e-7	Menarche (age at onset);
SARC	cis	rs9916302	0.706	rs9893735	chr17:37469858	A/C	cg07936489	chr17:37558343	FBXL20	0.75	8.92	0.5	1.37e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs782590	0.643	rs5012561	chr2:55742032	G/C	cg18811423	chr2:55921094	PNPT1	-0.56	-6.78	-0.41	9.99e-11	Metabolic syndrome;
SARC	cis	rs2228479	0.557	rs12933317	chr16:89828220	A/G	cg06558623	chr16:89946397	TCF25	0.77	5.6	0.34	6.06e-8	Skin colour saturation;
SARC	cis	rs11252926	0.537	rs4881274	chr10:459940	G/A	cg08603382	chr10:743973	NA	0.4	5.15	0.32	5.66e-7	Psychosis in Alzheimer's disease;
SARC	cis	rs3784262	0.904	rs4646616	chr15:58261349	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.37	-5.38	-0.33	1.81e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs10992471	0.598	rs331380	chr9:95256519	C/T	cg13798575	chr9:95087839	CENPP;NOL8	0.41	4.98	0.31	1.26e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs829880	0.789	rs1096146	chr12:98850966	A/G	cg25150519	chr12:98850993	NA	0.71	10.32	0.56	8.47e-21	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.37	-4.73	-0.3	3.92e-6	Lymphocyte counts;
SARC	cis	rs4969178	0.931	rs6501208	chr17:76395038	A/T	cg02836325	chr17:76403955	PGS1	0.32	4.99	0.31	1.17e-6	HDL cholesterol levels;
SARC	cis	rs6952809	0.532	rs6952152	chr7:2440912	G/A	cg05083358	chr7:2394359	EIF3B	-0.57	-5.28	-0.33	2.95e-7	Multiple sclerosis;
SARC	cis	rs992157	0.697	rs13384682	chr2:219069137	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.65	9.12	0.51	3.63e-17	Colorectal cancer;
SARC	cis	rs72945132	0.769	rs3781644	chr11:70190375	G/A	cg00319359	chr11:70116639	PPFIA1	0.68	6.34	0.38	1.15e-9	Coronary artery disease;
SARC	cis	rs17376456	0.877	rs10073039	chr5:93467709	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.71	0.35	3.39e-8	Diabetic retinopathy;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg23121350	chr17:38219361	THRA	0.5	6.57	0.4	3.21e-10	Lung adenocarcinoma;
SARC	cis	rs2439831	1.000	rs28628574	chr15:43802038	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.04	8.58	0.49	1.31e-15	Lung cancer in ever smokers;
SARC	cis	rs7927771	0.524	rs4752798	chr11:47886364	T/C	cg20307385	chr11:47447363	PSMC3	-0.48	-6.54	-0.39	3.96e-10	Subjective well-being;
SARC	trans	rs11165623	0.792	rs2104236	chr1:96908690	C/T	cg10631902	chr5:14652156	NA	-0.47	-7.72	-0.45	3.33e-13	Hip circumference;Waist circumference;
SARC	cis	rs7927771	0.832	rs11601603	chr11:47401171	A/C	cg20307385	chr11:47447363	PSMC3	-0.56	-7.0	-0.42	2.78e-11	Subjective well-being;
SARC	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.68	-7.47	-0.44	1.6e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9916302	0.752	rs6503513	chr17:37561613	A/G	cg00129232	chr17:37814104	STARD3	0.54	6.06	0.37	5.32e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs60871478	0.636	rs12534606	chr7:895928	A/G	cg05535760	chr7:792225	HEATR2	-0.73	-6.9	-0.41	4.97e-11	Cerebrospinal P-tau181p levels;
SARC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.12	0.37	3.96e-9	Prudent dietary pattern;
SARC	cis	rs72781680	0.756	rs2551337	chr2:24006886	C/T	cg06627628	chr2:24431161	ITSN2	-0.55	-5.59	-0.34	6.23e-8	Lymphocyte counts;
SARC	cis	rs7178909	0.835	rs2174292	chr15:90415581	A/C	cg19708238	chr15:90437601	AP3S2	0.6	7.93	0.46	9.08e-14	Common traits (Other);
SARC	cis	rs9467773	1.000	rs9461271	chr6:26554968	G/A	cg11502198	chr6:26597334	ABT1	0.5	6.09	0.37	4.53e-9	Intelligence (multi-trait analysis);
SARC	cis	rs4268898	0.722	rs7564420	chr2:24414002	C/T	cg06627628	chr2:24431161	ITSN2	-0.52	-6.96	-0.41	3.52e-11	Asthma;
SARC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg09373136	chr17:61933544	TCAM1	-0.45	-6.12	-0.37	3.97e-9	Prudent dietary pattern;
SARC	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg04166393	chr7:2884313	GNA12	0.61	7.24	0.43	6.64e-12	Height;
SARC	cis	rs4332037	0.901	rs7791299	chr7:1935598	T/C	cg23422044	chr7:1970798	MAD1L1	-0.42	-4.91	-0.31	1.7e-6	Bipolar disorder;
SARC	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg08280861	chr8:58055591	NA	0.68	5.89	0.36	1.31e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg26681399	chr22:41777847	TEF	0.48	5.27	0.33	3.16e-7	Vitiligo;
SARC	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg23939001	chr4:940644	TMEM175	0.5	7.63	0.45	5.8e-13	Sjögren's syndrome;
SARC	cis	rs10512697	0.803	rs77728185	chr5:3577798	T/A	cg19473799	chr5:3511975	NA	-0.68	-4.86	-0.3	2.11e-6	Immune response to smallpox vaccine (IL-6);
SARC	cis	rs1843834	0.539	rs2068244	chr2:225440011	A/G	cg22455342	chr2:225449267	CUL3	-0.69	-8.3	-0.48	8.42e-15	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs2204008	0.811	rs11520277	chr12:38359611	G/A	cg26384229	chr12:38710491	ALG10B	0.87	12.85	0.64	6.2e-29	Bladder cancer;
SARC	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg22903471	chr2:27725779	GCKR	-0.43	-6.43	-0.39	7.35e-10	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs807669	0.903	rs807668	chr22:19162686	A/G	cg02655711	chr22:19163373	SLC25A1	0.57	8.0	0.46	5.92e-14	Metabolite levels;
SARC	cis	rs698833	0.710	rs1441048	chr2:44511929	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.63	7.77	0.45	2.45e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs9894429	0.646	rs8079963	chr17:79603285	C/T	cg10661904	chr17:79619235	PDE6G	-0.45	-6.31	-0.38	1.4e-9	Eye color traits;
SARC	cis	rs72781680	1.000	rs72796337	chr2:24142957	G/A	cg08917208	chr2:24149416	ATAD2B	0.77	7.18	0.43	9.09e-12	Lymphocyte counts;
SARC	cis	rs6088580	0.524	rs6088570	chr20:33268295	T/C	cg24642439	chr20:33292090	TP53INP2	-0.55	-6.72	-0.4	1.36e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs2073300	0.609	rs3827086	chr20:23357331	C/T	cg12062639	chr20:23401060	NAPB	0.95	6.46	0.39	6.01e-10	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg11987759	chr7:65425863	GUSB	-0.49	-5.8	-0.36	2.17e-8	Aortic root size;
SARC	trans	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg17830980	chr10:43048298	ZNF37B	-0.53	-6.78	-0.41	9.92e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs11711311	0.824	rs9833810	chr3:113363762	C/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	8.01	0.46	5.44e-14	IgG glycosylation;
SARC	cis	rs11209002	0.614	rs7552205	chr1:67551741	C/A	cg02640540	chr1:67518911	SLC35D1	0.59	6.87	0.41	5.66e-11	Crohn's disease;
SARC	cis	rs2421770	0.532	rs7106813	chr11:35372432	C/T	cg13971030	chr11:35366721	SLC1A2	-0.36	-4.88	-0.3	1.97e-6	Staphylococcus aureus nasal carriage (persistent);
SARC	cis	rs2180341	1.000	rs9321073	chr6:127609691	C/T	cg24812749	chr6:127587940	RNF146	0.95	12.49	0.63	9.25e-28	Breast cancer;
SARC	cis	rs5753037	0.702	rs81800	chr22:30200362	C/G	cg01021169	chr22:30184971	ASCC2	0.45	6.2	0.38	2.48e-9	Type 1 diabetes;
SARC	cis	rs12545109	0.800	rs1440746	chr8:57415912	G/A	cg09654669	chr8:57350985	NA	-0.39	-4.96	-0.31	1.35e-6	Obesity-related traits;
SARC	cis	rs2562456	0.958	rs2562508	chr19:21726281	G/A	cg00806126	chr19:22604979	ZNF98	0.46	4.74	0.3	3.67e-6	Pain;
SARC	cis	rs8113308	0.752	rs113374423	chr19:52490952	G/A	cg25782003	chr19:52490127	ZNF350	0.83	5.86	0.36	1.57e-8	Survival in endocrine treated breast cancer (estrogen-receptor positive);
SARC	cis	rs17401966	0.838	rs34636442	chr1:10427459	T/G	cg15208524	chr1:10270712	KIF1B	0.47	5.57	0.34	6.85e-8	Hepatocellular carcinoma;
SARC	cis	rs4481887	0.893	rs4423045	chr1:248479495	T/C	cg01631408	chr1:248437212	OR2T33	-0.38	-4.73	-0.3	3.94e-6	Common traits (Other);
SARC	cis	rs7959452	0.535	rs11177577	chr12:69671791	C/T	cg14784868	chr12:69753453	YEATS4	0.41	5.37	0.33	1.91e-7	Blood protein levels;
SARC	cis	rs72781680	1.000	rs6710426	chr2:24159288	A/G	cg08917208	chr2:24149416	ATAD2B	0.77	7.19	0.43	8.94e-12	Lymphocyte counts;
SARC	cis	rs2645694	0.626	rs2703115	chr4:77824442	C/T	cg06046430	chr4:77819534	ANKRD56	0.55	8.03	0.47	4.68e-14	Emphysema distribution in smoking;
SARC	cis	rs9807989	0.507	rs1592459	chr2:103031569	A/G	cg03938978	chr2:103052716	IL18RAP	0.31	4.96	0.31	1.34e-6	Asthma;
SARC	cis	rs826838	1.000	rs11169031	chr12:39056738	T/C	cg13010199	chr12:38710504	ALG10B	0.76	10.6	0.57	1.09e-21	Heart rate;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg10398288	chr1:205561315	MFSD4	0.52	6.77	0.41	1.03e-10	Lung adenocarcinoma;
SARC	cis	rs9341808	0.519	rs607130	chr6:80999233	T/C	cg08355045	chr6:80787529	NA	-0.33	-5.04	-0.31	9.52e-7	Sitting height ratio;
SARC	cis	rs17401966	0.624	rs6696978	chr1:10209557	C/T	cg15208524	chr1:10270712	KIF1B	-0.49	-5.45	-0.34	1.26e-7	Hepatocellular carcinoma;
SARC	cis	rs7914558	0.966	rs4917997	chr10:104945213	A/G	cg04362960	chr10:104952993	NT5C2	0.4	4.72	0.3	3.99e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs5769765	0.862	rs138856	chr22:50199378	G/T	cg03033257	chr22:50311977	ALG12;CRELD2	0.51	4.89	0.31	1.84e-6	Schizophrenia;
SARC	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg11987759	chr7:65425863	GUSB	-0.48	-6.54	-0.39	3.9e-10	Aortic root size;
SARC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg16405210	chr4:1374714	KIAA1530	-0.85	-11.18	-0.59	1.67e-23	Longevity;
SARC	cis	rs7666738	0.830	rs6532701	chr4:98745134	C/T	cg05340658	chr4:99064831	C4orf37	0.64	8.48	0.49	2.57e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2204008	0.571	rs7970136	chr12:38531951	G/C	cg13010199	chr12:38710504	ALG10B	-0.51	-6.34	-0.38	1.19e-9	Bladder cancer;
SARC	cis	rs1707322	0.721	rs12091503	chr1:46107868	T/C	cg06784218	chr1:46089804	CCDC17	0.36	6.2	0.38	2.59e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2290416	0.892	rs58774517	chr8:144656764	C/T	cg08017634	chr8:144659831	NAPRT1	0.67	4.79	0.3	2.95e-6	Attention deficit hyperactivity disorder;
SARC	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-6.25	-0.38	1.99e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg11494091	chr17:61959527	GH2	0.53	7.94	0.46	8.67e-14	Prudent dietary pattern;
SARC	cis	rs72781680	0.898	rs12619592	chr2:23971415	C/A	cg08917208	chr2:24149416	ATAD2B	0.75	7.2	0.43	8.08e-12	Lymphocyte counts;
SARC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.45	0.53	3.79e-18	Prudent dietary pattern;
SARC	cis	rs155076	1.000	rs658244	chr13:21850976	T/C	cg11317459	chr13:21872234	NA	-0.96	-11.79	-0.61	1.75e-25	White matter hyperintensity burden;
SARC	cis	rs920590	0.876	rs3907478	chr8:19657753	G/T	cg03894339	chr8:19674705	INTS10	0.56	7.1	0.42	1.51e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9462027	0.675	rs7755926	chr6:34722574	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.84	-0.36	1.71e-8	Systemic lupus erythematosus;
SARC	cis	rs651907	0.514	rs10936744	chr3:101433440	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	6.39	0.39	8.85e-10	Colorectal cancer;
SARC	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg01448562	chr3:133502909	NA	-0.57	-8.74	-0.5	4.68e-16	Iron status biomarkers;
SARC	cis	rs2486288	0.656	rs12915314	chr15:45551491	C/G	cg21132104	chr15:45694354	SPATA5L1	-0.51	-6.44	-0.39	6.68e-10	Glomerular filtration rate;
SARC	cis	rs2832191	0.791	rs2251517	chr21:30531951	T/G	cg24692254	chr21:30365293	RNF160	0.99	16.2	0.73	4.87e-40	Dental caries;
SARC	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg26450541	chr6:28235208	ZNF187	0.46	4.9	0.31	1.79e-6	Parkinson's disease;
SARC	cis	rs3213545	0.676	rs1179998	chr12:121483653	G/A	cg15155738	chr12:121454335	C12orf43	0.45	5.48	0.34	1.11e-7	Subjective well-being;Cardiovascular disease risk factors;
SARC	cis	rs8523	0.808	rs3734398	chr6:10982973	A/G	cg13562911	chr6:11044106	ELOVL2	0.42	5.54	0.34	8.32e-8	Red blood cell fatty acid levels;
SARC	cis	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg07636037	chr3:49044803	WDR6	0.65	6.64	0.4	2.24e-10	Menarche (age at onset);
SARC	cis	rs1707322	0.963	rs6690652	chr1:46376692	G/T	cg06784218	chr1:46089804	CCDC17	0.34	5.94	0.36	1.03e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1144333	0.655	rs3765682	chr1:76333172	T/C	cg03433033	chr1:76189801	ACADM	0.61	4.94	0.31	1.46e-6	Attention function in attention deficit hyperactive disorder;
SARC	trans	rs61931739	0.534	rs35056575	chr12:34142914	A/T	cg13010199	chr12:38710504	ALG10B	0.74	10.04	0.55	6.04e-20	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg02725872	chr8:58115012	NA	-0.32	-4.73	-0.3	3.91e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs995000	0.931	rs7539035	chr1:63106767	G/T	cg06896770	chr1:63153194	DOCK7	0.89	13.51	0.66	4.1e-31	Triglyceride levels;
SARC	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg11644478	chr21:40555479	PSMG1	-0.89	-11.32	-0.6	5.64e-24	Cognitive function;
SARC	cis	rs1050631	0.564	rs1785904	chr18:33713132	T/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.59	7.17	0.43	9.66e-12	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs6570726	0.764	rs9386125	chr6:145911677	C/T	cg23711669	chr6:146136114	FBXO30	0.84	14.12	0.68	3.87e-33	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg20349824	chr13:52249333	WDFY2	0.46	6.35	0.38	1.12e-9	Thyroid stimulating hormone;
SARC	cis	rs3106136	0.934	rs34396188	chr4:95191292	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.35	-5.41	-0.33	1.59e-7	Capecitabine sensitivity;
SARC	cis	rs9527	0.545	rs7894588	chr10:104756030	A/T	cg04362960	chr10:104952993	NT5C2	0.42	4.73	0.3	3.93e-6	Arsenic metabolism;
SARC	cis	rs17253792	0.731	rs3736876	chr14:56120178	T/C	cg01858014	chr14:56050164	KTN1	-0.67	-5.22	-0.32	4.03e-7	Putamen volume;
SARC	trans	rs7824557	0.707	rs3808519	chr8:11142970	C/G	cg06636001	chr8:8085503	FLJ10661	0.59	7.13	0.42	1.28e-11	Retinal vascular caliber;
SARC	cis	rs6910061	1.000	rs9468412	chr6:11095876	C/T	cg27233058	chr6:11094804	LOC221710	0.58	5.56	0.34	7.5e-8	Diabetic kidney disease;
SARC	cis	rs7953249	0.618	rs7954331	chr12:121398657	G/T	cg25281562	chr12:121454272	C12orf43	-0.45	-5.38	-0.33	1.84e-7	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg27170947	chr2:26402098	FAM59B	0.37	4.8	0.3	2.79e-6	Gut microbiome composition (summer);
SARC	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.23e-9	Life satisfaction;
SARC	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg11965913	chr1:205819406	PM20D1	0.44	4.94	0.31	1.47e-6	Parkinson's disease;
SARC	cis	rs6912958	0.702	rs2300909	chr6:88212100	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-6.75	-0.4	1.14e-10	Monocyte percentage of white cells;
SARC	cis	rs477692	0.699	rs578932	chr10:131370724	C/A	cg14263093	chr10:131365266	MGMT	0.35	4.88	0.3	1.95e-6	Response to temozolomide;
SARC	cis	rs9309473	0.950	rs11126412	chr2:73887634	A/T	cg20560298	chr2:73613845	ALMS1	-0.46	-5.68	-0.35	4e-8	Metabolite levels;
SARC	trans	rs66573146	0.656	rs56094305	chr4:6956086	C/T	cg07817883	chr1:32538562	TMEM39B	1.07	8.35	0.48	6.04e-15	Granulocyte percentage of myeloid white cells;
SARC	cis	rs916888	0.779	rs199498	chr17:44865603	A/G	cg01570182	chr17:44337453	NA	0.61	7.05	0.42	2e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg09323728	chr8:95962352	TP53INP1	-0.33	-5.63	-0.35	5.27e-8	Type 2 diabetes;
SARC	cis	rs9303401	0.538	rs35454383	chr17:56475599	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.01	9.91	0.54	1.51e-19	Cognitive test performance;
SARC	cis	rs751728	0.689	rs3763257	chr6:33773696	T/A	cg15252951	chr6:33757062	LEMD2	0.45	4.83	0.3	2.42e-6	Crohn's disease;
SARC	cis	rs8141529	0.529	rs5762814	chr22:29203964	G/A	cg02153584	chr22:29168773	CCDC117	0.64	6.53	0.39	4.16e-10	Lymphocyte counts;
SARC	cis	rs752010	0.714	rs6658500	chr1:42088344	A/G	cg06885757	chr1:42089581	HIVEP3	-0.43	-6.53	-0.39	4.01e-10	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg18876405	chr7:65276391	NA	0.49	6.04	0.37	6e-9	Aortic root size;
SARC	cis	rs2952156	1.000	rs1810132	chr17:37866005	C/T	cg20243544	chr17:37824526	PNMT	0.44	5.19	0.32	4.5e-7	Asthma;
SARC	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg22535103	chr8:58192502	C8orf71	-0.56	-5.49	-0.34	1.02e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6430585	0.583	rs59213715	chr2:136646582	A/C	cg07169764	chr2:136633963	MCM6	1.05	13.68	0.67	1.12e-31	Corneal structure;
SARC	cis	rs6062302	0.522	rs13038448	chr20:62218453	C/T	cg09650180	chr20:62225654	GMEB2	-0.48	-5.74	-0.35	2.93e-8	Glioblastoma;
SARC	cis	rs7223966	0.961	rs112709843	chr17:61836936	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.45	4.87	0.3	2.09e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.71	6.81	0.41	8.11e-11	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg11764359	chr7:65958608	NA	0.76	8.71	0.5	5.53e-16	Aortic root size;
SARC	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg05863683	chr7:1912471	MAD1L1	0.32	4.72	0.3	4.11e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs4919694	1.000	rs12266291	chr10:104806884	G/A	cg04362960	chr10:104952993	NT5C2	0.65	5.56	0.34	7.45e-8	Arsenic metabolism;
SARC	cis	rs7824557	0.614	rs2060459	chr8:11212599	C/T	cg21775007	chr8:11205619	TDH	0.72	9.4	0.52	5.47e-18	Retinal vascular caliber;
SARC	cis	rs6088580	0.634	rs6059897	chr20:33113224	A/G	cg24642439	chr20:33292090	TP53INP2	0.66	8.64	0.49	9.27e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs9354308	0.868	rs9453438	chr6:66540534	C/T	cg07460842	chr6:66804631	NA	-0.42	-4.85	-0.3	2.27e-6	Metabolite levels;
SARC	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.83	8.49	0.49	2.52e-15	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg17221315	chr6:27791827	HIST1H4J	0.47	4.81	0.3	2.76e-6	Depression;
SARC	cis	rs3762637	1.000	rs12638866	chr3:122194382	T/C	cg24169773	chr3:122142474	KPNA1	-0.57	-5.85	-0.36	1.67e-8	LDL cholesterol levels;
SARC	cis	rs2228479	0.850	rs17227057	chr16:89816333	C/T	cg00800038	chr16:89945340	TCF25	-0.74	-5.14	-0.32	5.75e-7	Skin colour saturation;
SARC	cis	rs7762018	1.000	rs6923339	chr6:170128033	T/A	cg15038512	chr6:170123185	PHF10	0.53	5.12	0.32	6.25e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs4727027	0.754	rs11764892	chr7:148858916	G/A	cg23583168	chr7:148888333	NA	-0.73	-9.58	-0.53	1.57e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg25719378	chr4:1235292	CTBP1	-0.42	-6.51	-0.39	4.57e-10	Chemerin levels;
SARC	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg05368731	chr17:41323189	NBR1	0.8	9.59	0.53	1.43e-18	Menopause (age at onset);
SARC	cis	rs2016266	0.820	rs11170496	chr12:53666195	G/A	cg26875137	chr12:53738046	NA	0.38	5.11	0.32	6.65e-7	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs9457247	0.935	rs9348211	chr6:167375173	G/C	cg07741184	chr6:167504864	NA	-0.3	-5.74	-0.35	2.93e-8	Crohn's disease;
SARC	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg12463550	chr7:65579703	CRCP	-0.49	-5.46	-0.34	1.19e-7	Aortic root size;
SARC	cis	rs2228479	0.850	rs57267516	chr16:89903552	G/A	cg06558623	chr16:89946397	TCF25	0.95	6.91	0.41	4.7e-11	Skin colour saturation;
SARC	cis	rs9325144	0.555	rs1825806	chr12:38692547	G/A	cg10518543	chr12:38710700	ALG10B	0.39	4.94	0.31	1.5e-6	Morning vs. evening chronotype;
SARC	trans	rs2727020	0.704	rs4144700	chr11:49370834	C/A	cg03929089	chr4:120376271	NA	-0.76	-11.22	-0.59	1.25e-23	Coronary artery disease;
SARC	cis	rs9815354	0.812	rs12186050	chr3:41836879	G/C	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs34172651	0.876	rs2112785	chr16:24781176	C/T	cg06028605	chr16:24865363	SLC5A11	0.27	4.85	0.3	2.22e-6	Intelligence (multi-trait analysis);
SARC	cis	rs16976116	0.619	rs11071172	chr15:55467185	A/C	cg17854078	chr15:55489399	RSL24D1	-0.6	-5.19	-0.32	4.57e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs3741151	1.000	rs7949364	chr11:73041077	A/G	cg17517138	chr11:73019481	ARHGEF17	0.81	7.3	0.43	4.64e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs1707322	0.682	rs28508523	chr1:46189625	G/A	cg03146154	chr1:46216737	IPP	0.5	6.06	0.37	5.56e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs365132	0.846	rs184784	chr5:176440229	G/T	cg16309518	chr5:176445507	NA	-0.49	-6.35	-0.38	1.14e-9	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs1864400	0.645	rs2249005	chr10:43627280	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.41	-4.88	-0.3	1.96e-6	Hirschsprung disease;
SARC	cis	rs763121	0.853	rs3788545	chr22:39065172	A/G	cg14440974	chr22:39074834	NA	-0.34	-4.96	-0.31	1.35e-6	Menopause (age at onset);
SARC	cis	rs2806561	0.765	rs643492	chr1:23501354	C/T	cg12483005	chr1:23474871	LUZP1	-0.42	-5.53	-0.34	8.38e-8	Height;
SARC	cis	rs73206853	0.841	rs73206847	chr12:110672353	G/A	cg10860002	chr12:110842031	ANAPC7	0.65	5.13	0.32	5.97e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs1545257	0.537	rs2702089	chr2:24643291	A/G	cg06627628	chr2:24431161	ITSN2	0.55	6.85	0.41	6.47e-11	Sjögren's syndrome;
SARC	cis	rs2153535	0.580	rs9328483	chr6:8521295	A/G	cg21535247	chr6:8435926	SLC35B3	0.54	6.92	0.41	4.29e-11	Motion sickness;
SARC	cis	rs7772486	0.686	rs7739735	chr6:146123536	G/A	cg05347473	chr6:146136440	FBXO30	0.51	7.16	0.42	1.03e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2933343	0.729	rs789224	chr3:128598231	A/C	cg25356066	chr3:128598488	ACAD9	0.71	9.53	0.53	2.1e-18	IgG glycosylation;
SARC	cis	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg24110177	chr3:50126178	RBM5	0.64	8.48	0.49	2.65e-15	Body mass index;
SARC	cis	rs9296092	0.560	rs3846853	chr6:33528194	C/G	cg13560919	chr6:33536144	NA	-0.52	-6.41	-0.39	8.07e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg07167872	chr1:205819463	PM20D1	0.75	11.75	0.61	2.35e-25	Menarche (age at onset);
SARC	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg13849007	chr1:1677539	SLC35E2	-0.37	-4.9	-0.31	1.81e-6	Body mass index;
SARC	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg20965017	chr5:231967	SDHA	-0.58	-5.57	-0.34	7.03e-8	Breast cancer;
SARC	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg23205692	chr1:25664452	TMEM50A	0.39	4.78	0.3	3.11e-6	Erythrocyte sedimentation rate;
SARC	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg05861140	chr6:150128134	PCMT1	-0.37	-4.84	-0.3	2.37e-6	Lung cancer;
SARC	cis	rs910316	0.967	rs175502	chr14:75533679	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.58	-8.34	-0.48	6.36e-15	Height;
SARC	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg23758822	chr17:41437982	NA	-0.85	-10.58	-0.57	1.3e-21	Menopause (age at onset);
SARC	cis	rs2479724	0.840	rs10498752	chr6:41768510	T/C	cg17623882	chr6:41773611	USP49	0.43	5.33	0.33	2.33e-7	Menarche (age at onset);
SARC	cis	rs4722166	0.508	rs1474347	chr7:22768124	A/C	cg26061582	chr7:22766209	IL6	-0.52	-5.63	-0.35	5.08e-8	Lung cancer;
SARC	cis	rs2243480	1.000	rs958550	chr7:65635679	C/T	cg12463550	chr7:65579703	CRCP	-0.72	-5.56	-0.34	7.33e-8	Diabetic kidney disease;
SARC	cis	rs4742903	0.527	rs10991156	chr9:106954609	C/T	cg14250997	chr9:106856677	SMC2	-0.42	-5.25	-0.33	3.4e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs116095464	1.000	rs10475185	chr5:306981	C/T	cg22857025	chr5:266934	NA	-1.06	-6.98	-0.42	3.02e-11	Breast cancer;
SARC	cis	rs6693567	0.545	rs1260391	chr1:150373077	T/C	cg09579323	chr1:150459698	TARS2	0.46	5.84	0.36	1.74e-8	Migraine;
SARC	cis	rs6918586	0.636	rs198816	chr6:26127184	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.44	-5.53	-0.34	8.42e-8	Schizophrenia;
SARC	cis	rs75920871	0.588	rs10892054	chr11:116868221	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.48	-4.95	-0.31	1.39e-6	Subjective well-being;
SARC	cis	rs4944092	0.960	rs10400322	chr11:75910913	C/T	cg04588336	chr11:75916460	WNT11	0.43	5.71	0.35	3.34e-8	PR interval;
SARC	cis	rs3733585	0.534	rs7375642	chr4:9955236	A/G	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.39	-0.33	1.73e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs56235845	0.694	rs6876677	chr5:176755342	T/C	cg06060754	chr5:176797920	RGS14	0.46	6.07	0.37	5.02e-9	Hemoglobin concentration;Hematocrit;
SARC	cis	rs2073300	0.609	rs2295238	chr20:23387946	C/G	cg12062639	chr20:23401060	NAPB	0.96	6.67	0.4	1.88e-10	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs13040088	0.935	rs62200158	chr20:61557906	C/T	cg23096297	chr20:61557774	DIDO1	0.96	10.47	0.57	2.83e-21	Menopause (age at onset);
SARC	trans	rs7927370	1.000	rs9666744	chr11:55276602	C/T	cg07162727	chr16:4848039	ROGDI	-0.76	-6.27	-0.38	1.73e-9	Systemic lupus erythematosus;
SARC	cis	rs1005277	0.638	rs1005278	chr10:38218748	G/A	cg00409905	chr10:38381863	ZNF37A	0.43	5.7	0.35	3.7e-8	Extrinsic epigenetic age acceleration;
SARC	cis	rs10911232	0.507	rs4129857	chr1:183004547	C/T	cg13390022	chr1:182993471	LAMC1	0.35	5.34	0.33	2.24e-7	Hypertriglyceridemia;
SARC	cis	rs11711311	1.000	rs3773682	chr3:113520576	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	8.41	0.48	4.12e-15	IgG glycosylation;
SARC	cis	rs721399	0.568	rs7816847	chr8:18275189	A/C	cg18736775	chr8:18248649	NAT2	-0.53	-5.68	-0.35	3.9e-8	Blood metabolite levels;
SARC	cis	rs7312933	0.558	rs11181466	chr12:42765181	A/T	cg19980929	chr12:42632907	YAF2	0.49	6.99	0.42	2.9e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs6121246	0.559	rs6060621	chr20:30261562	G/C	cg13852791	chr20:30311386	BCL2L1	0.89	10.96	0.58	7.99e-23	Mean corpuscular hemoglobin;
SARC	trans	rs9354352	0.935	rs9345749	chr6:66699892	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.58	-8.06	-0.47	3.91e-14	Initial pursuit acceleration in psychotic disorders;
SARC	cis	rs9616064	0.557	rs5767318	chr22:47048792	A/G	cg05621596	chr22:47072043	GRAMD4	-0.61	-8.1	-0.47	3e-14	Urate levels in obese individuals;
SARC	cis	rs7667	1.000	rs10753559	chr1:19698026	C/T	cg15311933	chr1:19638897	PQLC2;AKR7A2	0.49	5.55	0.34	7.87e-8	Crohn's disease and psoriasis;
SARC	cis	rs986417	0.901	rs11627533	chr14:61037801	C/T	cg27398547	chr14:60952738	C14orf39	0.87	8.04	0.47	4.42e-14	Gut microbiota (bacterial taxa);
SARC	cis	rs7224737	1.000	rs11079034	chr17:40288890	G/A	cg20291162	chr17:40259547	DHX58	-0.32	-4.78	-0.3	3.06e-6	Fibrinogen levels;
SARC	cis	rs2760061	0.599	rs644794	chr1:228148670	T/C	cg02753203	chr1:228287806	NA	-0.54	-7.53	-0.44	1.12e-12	Diastolic blood pressure;
SARC	cis	rs6942407	0.744	rs6968640	chr7:86862783	T/G	cg02420886	chr7:86849541	C7orf23	0.57	5.17	0.32	5.03e-7	Food allergy;
SARC	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg11764359	chr7:65958608	NA	0.6	7.18	0.43	9.26e-12	Aortic root size;
SARC	cis	rs7429990	0.965	rs6772396	chr3:47959770	A/G	cg11946769	chr3:48343235	NME6	0.45	5.16	0.32	5.26e-7	Educational attainment (years of education);
SARC	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-7.93	-0.46	8.87e-14	Chronic sinus infection;
SARC	cis	rs2204008	0.643	rs1315347	chr12:38162494	C/T	cg26384229	chr12:38710491	ALG10B	-0.68	-8.74	-0.5	4.76e-16	Bladder cancer;
SARC	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg05368731	chr17:41323189	NBR1	0.76	9.01	0.51	7.77e-17	Menopause (age at onset);
SARC	cis	rs526231	0.578	rs6867392	chr5:102281887	C/G	cg23492399	chr5:102201601	PAM	-0.45	-5.31	-0.33	2.51e-7	Primary biliary cholangitis;
SARC	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg07414643	chr4:187882934	NA	0.5	7.5	0.44	1.34e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs965604	1.000	rs11637656	chr15:78751961	C/T	cg24631222	chr15:78858424	CHRNA5	-0.47	-6.01	-0.37	7.02e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg22618164	chr12:122356400	WDR66	0.51	8.26	0.48	1.12e-14	Mean corpuscular volume;
SARC	cis	rs7624766	0.555	rs7618832	chr3:160488395	A/C	cg22637730	chr3:160473554	PPM1L	0.38	4.9	0.31	1.82e-6	Response to methotrexate in rheumatoid arthritis;
SARC	cis	rs9467773	1.000	rs9467791	chr6:26562486	A/G	cg11502198	chr6:26597334	ABT1	-0.48	-5.87	-0.36	1.47e-8	Intelligence (multi-trait analysis);
SARC	trans	rs656319	0.605	rs13252276	chr8:9904713	C/T	cg06636001	chr8:8085503	FLJ10661	-0.67	-8.53	-0.49	1.83e-15	Myopia (pathological);
SARC	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg18230493	chr5:56204884	C5orf35	0.54	4.78	0.3	3.16e-6	Initial pursuit acceleration;
SARC	cis	rs2425143	1.000	rs6058304	chr20:34299851	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.1	-0.37	4.39e-9	Blood protein levels;
SARC	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg02788857	chr8:22132959	PIWIL2	0.37	5.33	0.33	2.37e-7	Hypertriglyceridemia;
SARC	cis	rs1318878	0.501	rs7956696	chr12:15422505	A/T	cg08258403	chr12:15378311	NA	0.42	6.22	0.38	2.24e-9	Intelligence (multi-trait analysis);
SARC	cis	rs1670533	1.000	rs6821725	chr4:1060360	C/G	cg27284194	chr4:1044797	NA	0.45	4.76	0.3	3.42e-6	Recombination rate (females);
SARC	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.78	-0.5	3.56e-16	Alzheimer's disease;
SARC	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg03806693	chr22:41940476	POLR3H	0.88	12.31	0.63	3.69e-27	Vitiligo;
SARC	cis	rs3815700	1.000	rs7260624	chr19:33096562	A/G	cg02997394	chr19:33096574	ANKRD27	0.79	8.55	0.49	1.67e-15	Eosinophilic esophagitis;
SARC	cis	rs826838	0.586	rs1843903	chr12:38627524	C/T	cg13010199	chr12:38710504	ALG10B	0.65	8.41	0.48	4.14e-15	Heart rate;
SARC	cis	rs9341808	0.628	rs2490245	chr6:80892427	A/G	cg08355045	chr6:80787529	NA	0.37	5.89	0.36	1.35e-8	Sitting height ratio;
SARC	cis	rs826838	0.616	rs11182893	chr12:38627715	C/G	cg26384229	chr12:38710491	ALG10B	-0.6	-7.64	-0.45	5.47e-13	Heart rate;
SARC	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs72781680	1.000	rs72781632	chr2:24198342	A/C	cg06627628	chr2:24431161	ITSN2	-0.75	-6.98	-0.42	3.08e-11	Lymphocyte counts;
SARC	cis	rs67478160	0.608	rs4906368	chr14:104242397	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.35	-4.83	-0.3	2.46e-6	Schizophrenia;
SARC	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.31	-4.86	-0.3	2.17e-6	Total body bone mineral density;
SARC	cis	rs7312933	0.703	rs10459290	chr12:42613290	T/G	cg19980929	chr12:42632907	YAF2	0.45	5.99	0.37	7.7e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs9397240	0.789	rs9397237	chr6:155591551	A/G	cg07943832	chr6:155568918	TIAM2	-0.61	-5.86	-0.36	1.56e-8	Life satisfaction;
SARC	cis	rs9397240	0.689	rs1048587	chr6:155578684	G/A	cg07943832	chr6:155568918	TIAM2	-0.58	-5.5	-0.34	1.01e-7	Life satisfaction;
SARC	cis	rs4742903	0.935	rs7875929	chr9:106931408	A/G	cg14250997	chr9:106856677	SMC2	0.44	5.47	0.34	1.17e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs12681288	0.792	rs12678495	chr8:1000858	C/G	cg15309053	chr8:964076	NA	0.41	6.97	0.42	3.3e-11	Schizophrenia;
SARC	cis	rs11122272	0.701	rs1009227	chr1:231480507	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-10.4	-0.56	4.78e-21	Hemoglobin concentration;
SARC	trans	rs61931739	0.556	rs7954221	chr12:33825077	C/T	cg13010199	chr12:38710504	ALG10B	0.51	6.58	0.4	3e-10	Morning vs. evening chronotype;
SARC	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg04277193	chr17:41438351	NA	0.45	4.9	0.31	1.83e-6	Menopause (age at onset);
SARC	cis	rs7818345	1.000	rs7818345	chr8:19306618	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.38	5.12	0.32	6.39e-7	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg25894440	chr7:65020034	NA	-0.73	-5.54	-0.34	8.11e-8	Diabetic kidney disease;
SARC	cis	rs7178572	1.000	rs6495240	chr15:77766556	T/C	cg22256960	chr15:77711686	NA	-0.56	-6.65	-0.4	2.09e-10	Type 2 diabetes;
SARC	cis	rs73086581	1.000	rs17286349	chr20:3914302	G/A	cg02187196	chr20:3869020	PANK2	0.65	6.31	0.38	1.4e-9	Response to antidepressants in depression;
SARC	cis	rs2295359	0.892	rs2064689	chr1:67653010	G/A	cg11235152	chr1:67600687	NA	0.5	7.04	0.42	2.11e-11	Psoriasis;
SARC	cis	rs2228479	0.619	rs77847775	chr16:89896243	C/T	cg12064134	chr16:90016061	DEF8	-0.56	-4.9	-0.31	1.77e-6	Skin colour saturation;
SARC	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg02725872	chr8:58115012	NA	-0.37	-6.54	-0.39	3.94e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.43	0.56	3.8e-21	Prudent dietary pattern;
SARC	cis	rs453301	0.686	rs7017868	chr8:8873293	G/A	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.48	-0.39	5.34e-10	Joint mobility (Beighton score);
SARC	cis	rs116095464	0.558	rs10059907	chr5:205360	G/C	cg22496380	chr5:211416	CCDC127	-0.9	-8.06	-0.47	3.98e-14	Breast cancer;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg16124402	chr11:126139086	FOXRED1;SRPR	0.49	6.28	0.38	1.62e-9	Lung adenocarcinoma;
SARC	cis	rs8070624	0.543	rs11078409	chr17:17876296	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	10.75	0.58	3.66e-22	Total body bone mineral density;
SARC	cis	rs888194	0.738	rs7311187	chr12:109937907	C/T	cg13986417	chr12:110012484	MVK;MMAB	-0.31	-4.77	-0.3	3.19e-6	Neuroticism;
SARC	cis	rs6570726	0.791	rs1935612	chr6:145906090	T/A	cg05347473	chr6:146136440	FBXO30	0.52	7.33	0.43	3.74e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs16854884	0.632	rs4563409	chr3:143682122	T/G	cg06585982	chr3:143692056	C3orf58	0.64	8.29	0.48	8.96e-15	Economic and political preferences (feminism/equality);
SARC	cis	rs4664308	0.840	rs17218566	chr2:161054748	C/T	cg03641300	chr2:160917029	PLA2R1	-0.63	-8.28	-0.48	9.61e-15	Idiopathic membranous nephropathy;
SARC	cis	rs7219021	0.705	rs28635466	chr17:46983820	G/A	cg16584676	chr17:46985605	UBE2Z	-0.48	-5.72	-0.35	3.22e-8	Schizophrenia or bipolar disorder;
SARC	cis	rs9914988	0.943	rs11658884	chr17:27132742	A/G	cg20469991	chr17:27169893	C17orf63	0.52	5.44	0.34	1.35e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs9818758	0.607	rs34566463	chr3:49245077	T/C	cg03060546	chr3:49711283	APEH	-0.54	-4.73	-0.3	3.87e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs1832871	0.672	rs111782080	chr6:158765385	G/A	cg07165851	chr6:158734300	TULP4	0.58	6.78	0.41	9.7e-11	Height;
SARC	cis	rs7178572	1.000	rs1565756	chr15:77741640	G/A	cg22256960	chr15:77711686	NA	-0.57	-6.69	-0.4	1.68e-10	Type 2 diabetes;
SARC	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg22535103	chr8:58192502	C8orf71	-0.66	-5.66	-0.35	4.4e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7659604	1.000	rs7660078	chr4:122665577	G/T	cg19748678	chr4:122722346	EXOSC9	0.41	5.04	0.31	9.17e-7	Type 2 diabetes;
SARC	cis	rs8067545	0.641	rs2108978	chr17:19861458	C/T	cg13482628	chr17:19912719	NA	0.54	6.64	0.4	2.12e-10	Schizophrenia;
SARC	cis	rs10504073	0.647	rs10808745	chr8:49989037	G/A	cg00325661	chr8:49890786	NA	0.54	7.22	0.43	7.43e-12	Blood metabolite ratios;
SARC	cis	rs62244186	0.606	rs6798590	chr3:44556861	T/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.42	5.14	0.32	5.84e-7	Depressive symptoms;
SARC	cis	rs4664308	1.000	rs17341301	chr2:160902420	G/A	cg03641300	chr2:160917029	PLA2R1	-0.62	-8.18	-0.47	1.8e-14	Idiopathic membranous nephropathy;
SARC	cis	rs929354	0.772	rs6459738	chr7:156998532	T/G	cg05182265	chr7:156933206	UBE3C	-0.33	-5.02	-0.31	1.03e-6	Body mass index;
SARC	cis	rs6912958	0.874	rs9294381	chr6:88152681	A/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.38	-0.33	1.79e-7	Monocyte percentage of white cells;
SARC	cis	rs6484504	0.600	rs12796587	chr11:31266443	T/C	cg02090638	chr11:31391270	DNAJC24;DCDC1	-0.43	-5.45	-0.34	1.26e-7	Red blood cell count;
SARC	cis	rs6424115	0.931	rs2473377	chr1:24148260	T/C	cg15997130	chr1:24165203	NA	0.45	6.04	0.37	5.93e-9	Immature fraction of reticulocytes;
SARC	cis	rs72949976	0.864	rs10176806	chr2:214022596	T/G	cg08319019	chr2:214017104	IKZF2	-0.53	-7.21	-0.43	7.64e-12	Lung cancer;Squamous cell lung carcinoma;
SARC	cis	rs2075371	0.796	rs12672752	chr7:134007382	C/T	cg11752832	chr7:134001865	SLC35B4	0.56	6.99	0.42	2.82e-11	Mean platelet volume;
SARC	cis	rs11731606	0.567	rs17377951	chr4:95321099	C/T	cg20625393	chr4:95128694	SMARCAD1	0.55	5.15	0.32	5.54e-7	Mean platelet volume;
SARC	cis	rs735539	0.521	rs9552289	chr13:21427839	C/T	cg16922012	chr13:21400325	XPO4	-0.42	-5.55	-0.34	7.62e-8	Dental caries;
SARC	cis	rs9682041	0.561	rs7616830	chr3:170146445	A/G	cg11886554	chr3:170076028	SKIL	0.83	7.67	0.45	4.71e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg19077165	chr18:44547161	KATNAL2	-0.5	-6.78	-0.41	9.9e-11	Personality dimensions;
SARC	cis	rs13161895	0.938	rs594202	chr5:179417335	C/T	cg04265672	chr5:179402240	RNF130	-0.53	-5.13	-0.32	6.03e-7	LDL cholesterol;
SARC	cis	rs7551222	0.681	rs4252686	chr1:204496895	A/G	cg20240347	chr1:204465584	NA	-0.34	-5.92	-0.36	1.14e-8	Schizophrenia;
SARC	cis	rs2288073	0.930	rs7604097	chr2:24401805	G/C	cg06627628	chr2:24431161	ITSN2	-0.63	-7.59	-0.45	7.68e-13	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.3	-4.77	-0.3	3.24e-6	Total body bone mineral density;
SARC	cis	rs7582180	0.629	rs34745556	chr2:100942506	A/G	cg14675211	chr2:100938903	LONRF2	0.51	7.68	0.45	4.44e-13	Intelligence (multi-trait analysis);
SARC	cis	rs9326248	0.581	rs4938331	chr11:116930682	C/A	cg01368799	chr11:117014884	PAFAH1B2	0.65	8.3	0.48	8.38e-15	Blood protein levels;
SARC	cis	rs2073300	0.609	rs2295238	chr20:23387946	C/G	cg16736954	chr20:23401023	NAPB	0.78	4.98	0.31	1.26e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs9677476	0.863	rs4637098	chr2:232075528	C/T	cg23338755	chr2:231921595	PSMD1	0.45	5.4	0.33	1.67e-7	Food antigen IgG levels;
SARC	cis	rs9303401	0.612	rs2526370	chr17:56487636	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.48	5.87	0.36	1.48e-8	Cognitive test performance;
SARC	cis	rs9296092	0.538	rs34222093	chr6:33519584	G/C	cg13560919	chr6:33536144	NA	-0.5	-6.31	-0.38	1.38e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-8.89	-0.5	1.75e-16	Alzheimer's disease;
SARC	cis	rs2073300	0.609	rs3736755	chr20:23377642	C/T	cg12062639	chr20:23401060	NAPB	0.88	6.41	0.39	8.02e-10	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs992157	0.835	rs10932769	chr2:219147245	T/G	cg00012203	chr2:219082015	ARPC2	-0.64	-9.13	-0.51	3.49e-17	Colorectal cancer;
SARC	trans	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg21659725	chr3:3221576	CRBN	0.83	11.62	0.61	6.15e-25	Intelligence (multi-trait analysis);
SARC	cis	rs9790314	0.645	rs10936224	chr3:160902531	G/A	cg03342759	chr3:160939853	NMD3	-0.63	-7.97	-0.46	6.98e-14	Morning vs. evening chronotype;
SARC	cis	rs6964587	0.692	rs4729025	chr7:91847504	C/T	cg17063962	chr7:91808500	NA	0.84	13.09	0.65	1.05e-29	Breast cancer;
SARC	cis	rs10276381	0.786	rs740261	chr7:28241276	A/G	cg23620719	chr7:28220237	JAZF1	0.71	5.55	0.34	7.92e-8	Crohn's disease;
SARC	trans	rs503734	0.643	rs2317749	chr3:101121980	C/T	cg06692023	chr10:12238229	CDC123;NUDT5	-0.49	-6.32	-0.38	1.3e-9	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs1215050	0.558	rs35714120	chr4:98465844	A/G	cg05340658	chr4:99064831	C4orf37	-0.45	-5.28	-0.33	2.97e-7	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg06221963	chr1:154839813	KCNN3	-0.52	-8.26	-0.48	1.11e-14	Prostate cancer;
SARC	trans	rs17685	0.775	rs11761172	chr7:75761547	C/T	cg19862616	chr7:65841803	NCRNA00174	0.62	7.72	0.45	3.44e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs9640161	0.789	rs2373751	chr7:150021599	G/C	cg10018233	chr7:150070692	REPIN1	0.7	8.62	0.49	1.06e-15	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs9733	0.650	rs2048558	chr1:150571730	A/G	cg17724175	chr1:150552817	MCL1	-0.39	-5.02	-0.31	1.01e-6	Tonsillectomy;
SARC	cis	rs16976116	0.901	rs3759861	chr15:55473192	C/T	cg17854078	chr15:55489399	RSL24D1	0.62	6.27	0.38	1.71e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7779181	0.556	rs12538119	chr7:32344644	T/C	cg16719466	chr7:32338569	NA	-0.68	-5.65	-0.35	4.7e-8	Body mass index;
SARC	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg20102877	chr2:27665638	KRTCAP3	-0.34	-4.75	-0.3	3.62e-6	Menopause (age at onset);
SARC	cis	rs2408955	0.522	rs2051851	chr12:48485940	G/C	cg24011408	chr12:48396354	COL2A1	-0.41	-5.03	-0.31	9.68e-7	Glycated hemoglobin levels;
SARC	cis	rs986417	0.901	rs7159628	chr14:61010688	A/C	cg27398547	chr14:60952738	C14orf39	0.96	8.75	0.5	4.38e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs3935695	0.796	rs10185293	chr2:239918946	A/G	cg13907363	chr2:239229182	TRAF3IP1	0.46	4.83	0.3	2.47e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg21171335	chr12:122356390	WDR66	0.44	6.99	0.42	2.86e-11	Mean platelet volume;
SARC	cis	rs11208659	1.000	rs1011527	chr1:65988093	G/A	cg15721051	chr1:65537288	NA	0.67	4.8	0.3	2.79e-6	Obesity (early onset extreme);
SARC	cis	rs4711350	0.765	rs943473	chr6:33743651	G/C	cg18005901	chr6:33739558	LEMD2	-0.41	-4.79	-0.3	3.03e-6	Schizophrenia;
SARC	cis	rs644799	1.000	rs644799	chr11:95564259	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	14.72	0.69	4.15e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg16339185	chr3:20227809	SGOL1	-0.83	-7.44	-0.44	1.98e-12	Autism spectrum disorder or schizophrenia;
SARC	cis	rs644799	0.930	rs587123	chr11:95560539	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.68	9.22	0.52	1.82e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2816062	0.786	rs2816055	chr1:18898248	A/G	cg18795169	chr1:18902165	NA	-0.77	-12.23	-0.63	6.97e-27	Urate levels in lean individuals;
SARC	cis	rs12421382	0.614	rs12799395	chr11:109390862	G/T	cg16359550	chr11:109292809	C11orf87	0.33	5.02	0.31	1.04e-6	Schizophrenia;
SARC	cis	rs17079247	1.000	rs1591608	chr13:85745395	C/A	ch.13.84760847R	chr13:85862846	NA	-0.56	-4.73	-0.3	3.93e-6	Bipolar disorder (mania);
SARC	cis	rs72781680	0.898	rs17763224	chr2:24213776	T/C	cg06627628	chr2:24431161	ITSN2	-0.7	-6.78	-0.41	9.98e-11	Lymphocyte counts;
SARC	cis	rs1545257	0.505	rs7583687	chr2:24634003	C/G	cg06627628	chr2:24431161	ITSN2	-0.56	-7.21	-0.43	7.95e-12	Sjögren's syndrome;
SARC	cis	rs55823223	0.564	rs9894009	chr17:73850414	C/T	cg08125733	chr17:73851984	WBP2	0.58	6.82	0.41	7.73e-11	Psoriasis;
SARC	cis	rs7539409	0.915	rs1977119	chr1:84275509	A/G	cg10977910	chr1:84465055	TTLL7	0.56	4.87	0.3	2.06e-6	Alzheimer's disease;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg14509437	chr2:37543814	PRKD3	0.44	6.43	0.39	7.09e-10	Thyroid stimulating hormone;
SARC	cis	rs7074356	0.915	rs17617970	chr10:82206892	A/G	cg00277334	chr10:82204260	NA	-0.63	-5.15	-0.32	5.56e-7	Borderline personality disorder;
SARC	cis	rs7713065	0.531	rs2522051	chr5:131797578	C/T	cg04518342	chr5:131593106	PDLIM4	0.36	5.07	0.32	7.95e-7	Lung function (FEV1/FVC);
SARC	cis	rs7520050	0.966	rs785485	chr1:46574424	C/T	cg06784218	chr1:46089804	CCDC17	-0.26	-4.82	-0.3	2.56e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs55823223	0.564	rs58363746	chr17:73850819	C/T	cg06969265	chr17:73775802	H3F3B	0.49	5.33	0.33	2.37e-7	Psoriasis;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg13426544	chr11:65729012	SART1	-0.46	-6.25	-0.38	1.92e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs8114671	0.836	rs4911461	chr20:33629993	A/C	cg24642439	chr20:33292090	TP53INP2	-0.51	-5.99	-0.37	8.05e-9	Height;
SARC	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg01316550	chr5:56110833	MAP3K1	0.53	4.9	0.31	1.8e-6	Initial pursuit acceleration;
SARC	cis	rs6570726	0.935	rs1883406	chr6:145823205	A/G	cg05220968	chr6:146057943	EPM2A	-0.29	-4.99	-0.31	1.19e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11690935	0.959	rs4667694	chr2:172605399	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.99	-15.62	-0.72	4e-38	Schizophrenia;
SARC	cis	rs4988958	0.565	rs885088	chr2:103039044	A/G	cg03938978	chr2:103052716	IL18RAP	0.31	4.95	0.31	1.44e-6	Asthma (childhood onset);
SARC	cis	rs3126085	0.935	rs4845431	chr1:152227977	A/G	cg26876637	chr1:152193138	HRNR	0.47	5.4	0.33	1.66e-7	Atopic dermatitis;
SARC	cis	rs4727027	0.680	rs6464941	chr7:148826352	A/G	cg15662616	chr7:148823355	ZNF425;ZNF398	0.43	4.81	0.3	2.68e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs7552404	0.924	rs1611823	chr1:76221706	T/G	cg03433033	chr1:76189801	ACADM	0.48	6.89	0.41	5.18e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg02462569	chr6:150064036	NUP43	-0.4	-5.01	-0.31	1.06e-6	Lung cancer;
SARC	cis	rs10416265	0.528	rs7249097	chr19:33589144	T/C	cg27124370	chr19:33622961	WDR88	0.5	6.67	0.4	1.82e-10	Bone properties (heel);
SARC	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg11764359	chr7:65958608	NA	0.65	7.6	0.45	7.08e-13	Aortic root size;
SARC	cis	rs4588572	0.644	rs6870646	chr5:77741082	G/A	cg18281939	chr5:77783895	LHFPL2	0.34	4.75	0.3	3.62e-6	Triglycerides;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg13459077	chr9:37261078	ZCCHC7	0.45	6.42	0.39	7.48e-10	Thyroid stimulating hormone;
SARC	cis	rs9399137	0.507	rs4594969	chr6:135285586	A/T	cg24558204	chr6:135376177	HBS1L	0.61	7.95	0.46	8e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs7829975	0.517	rs12542733	chr8:8824858	G/T	cg15556689	chr8:8085844	FLJ10661	-0.42	-5.46	-0.34	1.21e-7	Mood instability;
SARC	cis	rs7582180	0.700	rs11685401	chr2:100976685	A/G	cg14675211	chr2:100938903	LONRF2	0.48	7.18	0.43	9.31e-12	Intelligence (multi-trait analysis);
SARC	cis	rs2594989	0.887	rs2442797	chr3:11555935	C/T	cg00170343	chr3:11313890	ATG7	0.56	5.34	0.33	2.2e-7	Circulating chemerin levels;
SARC	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg25036284	chr2:26402008	FAM59B	0.46	5.7	0.35	3.59e-8	Gut microbiome composition (summer);
SARC	cis	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.38	-0.44	2.7e-12	Mood instability;
SARC	cis	rs13401104	0.716	rs10929176	chr2:237129131	G/A	cg19324714	chr2:237145437	ASB18	0.62	6.21	0.38	2.44e-9	Educational attainment;
SARC	cis	rs34779708	0.966	rs1213392	chr10:35430285	C/T	cg03585969	chr10:35415529	CREM	0.39	4.99	0.31	1.2e-6	Inflammatory bowel disease;Crohn's disease;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg26783297	chr6:24406649	MRS2	0.57	7.71	0.45	3.72e-13	Thyroid stimulating hormone;
SARC	cis	rs9457247	0.663	rs9459845	chr6:167440501	C/G	cg23791538	chr6:167370224	RNASET2	-0.53	-7.06	-0.42	1.89e-11	Crohn's disease;
SARC	cis	rs6429082	0.689	rs10925965	chr1:235708443	C/A	cg26050004	chr1:235667680	B3GALNT2	-0.56	-6.2	-0.38	2.53e-9	Adiposity;
SARC	cis	rs644799	0.965	rs573758	chr11:95539591	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	14.15	0.68	3.08e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.77	7.83	0.46	1.69e-13	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs73198271	0.603	rs777705	chr8:8586868	C/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-4.94	-0.31	1.46e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs6121246	0.559	rs6119650	chr20:30258480	C/A	cg13852791	chr20:30311386	BCL2L1	0.88	10.57	0.57	1.34e-21	Mean corpuscular hemoglobin;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg03243700	chr9:137000940	WDR5	0.52	6.5	0.39	4.89e-10	Breast cancer;
SARC	cis	rs11651000	0.894	rs11650354	chr17:45822092	A/G	cg24803719	chr17:45855879	NA	0.38	4.91	0.31	1.68e-6	IgG glycosylation;
SARC	cis	rs8180040	0.577	rs12493425	chr3:47176946	T/G	cg27129171	chr3:47204927	SETD2	0.69	9.51	0.53	2.45e-18	Colorectal cancer;
SARC	cis	rs3741404	0.512	rs4980504	chr11:63873083	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.63	-7.73	-0.45	3.25e-13	Platelet count;
SARC	cis	rs62432291	0.681	rs438853	chr6:159630352	A/C	cg14500486	chr6:159655392	FNDC1	-0.6	-6.18	-0.38	2.8e-9	Joint mobility (Beighton score);
SARC	cis	rs6137287	0.643	rs6047259	chr20:21098319	A/G	cg22058250	chr20:21685842	PAX1	0.39	4.84	0.3	2.34e-6	Height;
SARC	cis	rs60871478	0.947	rs62432866	chr7:809281	T/G	cg19087971	chr7:751233	PRKAR1B	-0.42	-4.8	-0.3	2.79e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs7412746	0.658	rs10305711	chr1:150802996	T/C	cg10589385	chr1:150898437	SETDB1	0.4	5.38	0.33	1.8e-7	Melanoma;
SARC	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs3018712	0.532	rs28551086	chr11:68400739	G/A	cg01657329	chr11:68192670	LRP5	-0.61	-5.18	-0.32	4.71e-7	Total body bone mineral density;
SARC	cis	rs2073300	0.609	rs2277765	chr20:23425163	C/T	cg16736954	chr20:23401023	NAPB	0.77	4.81	0.3	2.76e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.7	-8.8	-0.5	3.21e-16	Prudent dietary pattern;
SARC	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.73	6.33	0.38	1.27e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs1971762	0.504	rs1843318	chr12:53958077	C/T	cg06632207	chr12:54070931	ATP5G2	0.56	7.78	0.45	2.37e-13	Height;
SARC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.59	-7.44	-0.44	1.9e-12	Prudent dietary pattern;
SARC	cis	rs6674176	0.561	rs7161	chr1:44438974	A/G	cg12908607	chr1:44402522	ARTN	0.39	6.85	0.41	6.56e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.41	4.95	0.31	1.41e-6	Electroencephalogram traits;
SARC	cis	rs3126085	0.877	rs7535536	chr1:152193544	A/G	cg03465714	chr1:152285911	FLG	-0.48	-5.85	-0.36	1.63e-8	Atopic dermatitis;
SARC	cis	rs7829975	0.871	rs7829826	chr8:8578120	T/A	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.45	-0.48	3.17e-15	Mood instability;
SARC	cis	rs7208487	0.684	rs12449852	chr17:37632088	A/G	cg20243544	chr17:37824526	PNMT	0.56	5.63	0.35	5.27e-8	Primary biliary cholangitis;Glomerular filtration rate in non diabetics (creatinine);
SARC	cis	rs10779751	0.770	rs2015818	chr1:11170743	G/A	cg04508216	chr1:11107452	MASP2	0.33	4.82	0.3	2.62e-6	Body mass index;
SARC	cis	rs3126085	0.935	rs1496051	chr1:152164923	G/A	cg09127314	chr1:152161683	NA	0.42	4.79	0.3	3.03e-6	Atopic dermatitis;
SARC	cis	rs6089584	0.546	rs6061980	chr20:60618877	G/A	cg06108461	chr20:60628389	TAF4	-0.66	-8.67	-0.49	7.54e-16	Body mass index;
SARC	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg04944784	chr2:26401820	FAM59B	-0.47	-6.11	-0.37	4.23e-9	Gut microbiome composition (summer);
SARC	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4273100	0.688	rs12938803	chr17:19204432	A/C	cg18906043	chr17:18967111	NA	-0.43	-4.77	-0.3	3.25e-6	Schizophrenia;
SARC	cis	rs9399135	0.967	rs11755229	chr6:135369913	A/G	cg22676075	chr6:135203613	NA	0.34	4.75	0.3	3.59e-6	Red blood cell count;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg02547794	chr2:61108331	REL	-0.77	-6.46	-0.39	6.2e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs78456975	1.000	rs72776298	chr2:1570163	C/G	cg26248373	chr2:1572462	NA	-0.64	-6.46	-0.39	6.1e-10	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs875971	0.545	rs67775320	chr7:65658779	T/C	cg25894440	chr7:65020034	NA	0.51	4.76	0.3	3.33e-6	Aortic root size;
SARC	cis	rs300703	0.748	rs4484059	chr2:286812	G/A	cg21211680	chr2:198530	NA	0.58	5.46	0.34	1.24e-7	Blood protein levels;
SARC	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg21782813	chr7:2030301	MAD1L1	0.44	6.95	0.41	3.69e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs1044826	0.642	rs6799312	chr3:139211932	C/T	cg15131784	chr3:139108705	COPB2	0.39	4.95	0.31	1.43e-6	Obesity-related traits;
SARC	cis	rs72945132	0.882	rs947812	chr11:70209169	C/T	cg05964544	chr11:70165517	PPFIA1	-0.57	-5.36	-0.33	2.04e-7	Coronary artery disease;
SARC	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg05890377	chr2:74357713	NA	-0.59	-7.36	-0.43	3.22e-12	Gestational age at birth (maternal effect);
SARC	cis	rs908922	0.676	rs549044	chr1:152514332	C/T	cg09873164	chr1:152488093	CRCT1	0.64	8.55	0.49	1.62e-15	Hair morphology;
SARC	cis	rs8141529	0.764	rs5762854	chr22:29246278	T/C	cg02153584	chr22:29168773	CCDC117	0.79	11.77	0.61	2.14e-25	Lymphocyte counts;
SARC	trans	rs1941687	0.505	rs9956918	chr18:31315878	C/G	cg27147174	chr7:100797783	AP1S1	0.5	6.44	0.39	6.6e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
SARC	cis	rs6582630	0.576	rs2387837	chr12:38403164	G/T	cg13010199	chr12:38710504	ALG10B	-0.48	-5.81	-0.36	2.05e-8	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs11088226	0.681	rs2833911	chr21:33949629	C/T	cg09050820	chr6:167586206	TCP10L2	-0.59	-6.5	-0.39	4.84e-10	Gastritis;
SARC	cis	rs1707322	0.721	rs6429574	chr1:46134054	A/G	cg06784218	chr1:46089804	CCDC17	0.36	6.2	0.38	2.6e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg17277821	chr12:123942602	SNRNP35	-0.64	-7.26	-0.43	5.65e-12	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs2486288	0.656	rs7171312	chr15:45570225	C/G	cg21132104	chr15:45694354	SPATA5L1	-0.54	-6.81	-0.41	8.2e-11	Glomerular filtration rate;
SARC	cis	rs3768617	0.510	rs10752903	chr1:183100863	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.66e-21	Fuchs's corneal dystrophy;
SARC	cis	rs7833790	0.660	rs10091077	chr8:82705464	A/G	cg06027949	chr8:82754900	SNX16	-0.48	-5.7	-0.35	3.61e-8	Diastolic blood pressure;
SARC	cis	rs1448094	0.512	rs4488288	chr12:86245450	A/C	cg02569458	chr12:86230093	RASSF9	0.38	5.39	0.33	1.71e-7	Major depressive disorder;
SARC	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg15049968	chr18:44337910	ST8SIA5	-0.32	-5.05	-0.31	9.03e-7	Personality dimensions;
SARC	trans	rs11098499	0.954	rs13107475	chr4:120393011	A/T	cg25214090	chr10:38739885	LOC399744	0.54	7.11	0.42	1.38e-11	Corneal astigmatism;
SARC	cis	rs1153858	1.000	rs4774579	chr15:45651803	G/A	cg14582100	chr15:45693742	SPATA5L1	0.35	4.82	0.3	2.64e-6	Homoarginine levels;
SARC	cis	rs11792861	0.926	rs59904140	chr9:111910051	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.68	7.73	0.45	3.1400000000000003e-13	Menarche (age at onset);
SARC	cis	rs36051895	0.632	rs12001334	chr9:5152604	C/A	cg02405213	chr9:5042618	JAK2	-0.47	-5.62	-0.35	5.56e-8	Pediatric autoimmune diseases;
SARC	cis	rs7829975	0.744	rs2409092	chr8:8682192	A/T	cg08975724	chr8:8085496	FLJ10661	0.48	6.11	0.37	4.15e-9	Mood instability;
SARC	cis	rs208520	0.661	rs207111	chr6:66792513	C/T	cg07460842	chr6:66804631	NA	-1.08	-15.02	-0.7	4.17e-36	Exhaled nitric oxide output;
SARC	cis	rs11758351	0.734	rs56220351	chr6:26206884	A/G	cg23601095	chr6:26197514	HIST1H3D	0.53	4.74	0.3	3.72e-6	Gout;Renal underexcretion gout;
SARC	cis	rs67460515	0.531	rs1585483	chr3:160843111	G/A	cg03342759	chr3:160939853	NMD3	-0.62	-7.41	-0.44	2.32e-12	Parkinson's disease;
SARC	cis	rs9400467	0.537	rs12213673	chr6:111544839	C/T	cg15721981	chr6:111408429	SLC16A10	0.7	5.85	0.36	1.7e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs2486288	0.656	rs8039153	chr15:45579813	T/C	cg15395560	chr15:45543142	SLC28A2	0.27	4.89	0.3	1.91e-6	Glomerular filtration rate;
SARC	cis	rs10911232	0.507	rs4652763	chr1:182994084	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.67	0.57	6.63e-22	Hypertriglyceridemia;
SARC	cis	rs2832191	0.903	rs11700687	chr21:30486767	A/G	cg24692254	chr21:30365293	RNF160	-0.77	-10.73	-0.58	4.22e-22	Dental caries;
SARC	cis	rs6815814	0.950	rs5743595	chr4:38802644	A/G	cg02016764	chr4:38805732	TLR1	-0.42	-4.93	-0.31	1.56e-6	Breast cancer;
SARC	cis	rs56104184	0.725	rs4347731	chr19:49385154	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.67	-6.5	-0.39	4.84e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs11770686	0.967	rs6964826	chr7:75328424	A/G	cg17787366	chr7:75369077	HIP1	0.43	5.32	0.33	2.48e-7	Essential tremor;
SARC	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg16049864	chr8:95962084	TP53INP1	-0.46	-7.52	-0.44	1.18e-12	Type 2 diabetes;
SARC	cis	rs4808199	0.948	rs7250368	chr19:19452763	G/A	cg03709012	chr19:19516395	GATAD2A	1.06	11.05	0.59	4.25e-23	Nonalcoholic fatty liver disease;
SARC	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-6.26	-0.38	1.84e-9	Personality dimensions;
SARC	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg18876405	chr7:65276391	NA	0.49	6.06	0.37	5.53e-9	Aortic root size;
SARC	cis	rs7223966	1.000	rs2665826	chr17:61944924	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-5.2	-0.32	4.39e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs55962025	0.846	rs16843804	chr4:3104390	C/T	cg06533319	chr4:3265114	C4orf44	0.35	5.27	0.33	3.18e-7	Parental longevity (mother's age at death);
SARC	cis	rs11585357	0.895	rs72646797	chr1:17613838	C/G	cg08277548	chr1:17600880	PADI3	-0.5	-5.56	-0.34	7.52e-8	Hair shape;
SARC	cis	rs7551222	0.789	rs2290855	chr1:204515863	C/T	cg20240347	chr1:204465584	NA	-0.33	-5.86	-0.36	1.55e-8	Schizophrenia;
SARC	cis	rs9818758	0.607	rs10049462	chr3:49309684	C/T	cg01304814	chr3:48885189	PRKAR2A	0.65	5.29	0.33	2.75e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs897080	0.831	rs56205860	chr2:44770731	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.43	4.79	0.3	2.94e-6	Height;
SARC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg26354017	chr1:205819088	PM20D1	0.91	15.33	0.71	3.68e-37	Menarche (age at onset);
SARC	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg08742575	chr21:47604166	C21orf56	0.4	5.07	0.32	7.92e-7	Testicular germ cell tumor;
SARC	cis	rs7465272	1.000	rs7465272	chr8:143691838	A/T	cg10596483	chr8:143751796	JRK	0.57	6.24	0.38	2.08e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg06636001	chr8:8085503	FLJ10661	0.72	10.14	0.55	3.07e-20	Mood instability;
SARC	cis	rs9399135	0.967	rs1854865	chr6:135360300	C/G	cg24558204	chr6:135376177	HBS1L	0.45	6.06	0.37	5.29e-9	Red blood cell count;
SARC	cis	rs9916302	0.706	rs4795358	chr17:37573065	A/C	cg00129232	chr17:37814104	STARD3	-0.55	-5.83	-0.36	1.82e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs2276314	0.857	rs59649576	chr18:33616075	G/T	cg05985134	chr18:33552581	C18orf21	0.69	7.21	0.43	7.93e-12	Endometriosis;Drug-induced torsades de pointes;
SARC	trans	rs9329221	0.650	rs657913	chr8:9882575	G/T	cg21775007	chr8:11205619	TDH	-0.49	-6.37	-0.39	1.03e-9	Neuroticism;
SARC	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg22496380	chr5:211416	CCDC127	-0.88	-9.35	-0.52	7.72e-18	Breast cancer;
SARC	cis	rs1538970	0.884	rs1771551	chr1:45883643	C/G	cg05343316	chr1:45956843	TESK2	0.71	8.28	0.48	9.69e-15	Platelet count;
SARC	cis	rs362272	0.505	rs13104157	chr4:3366950	T/C	cg08741688	chr4:3415352	RGS12	-0.53	-6.7	-0.4	1.53e-10	Serum sulfate level;
SARC	cis	rs7666738	0.830	rs58367603	chr4:99015350	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6088580	0.634	rs6059851	chr20:33047945	G/A	cg24642439	chr20:33292090	TP53INP2	0.65	8.48	0.49	2.54e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs11785400	0.762	rs1137522	chr8:143739020	A/C	cg10596483	chr8:143751796	JRK	0.55	7.01	0.42	2.59e-11	Schizophrenia;
SARC	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg06634786	chr22:41940651	POLR3H	0.51	5.94	0.36	1.04e-8	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg09373136	chr17:61933544	TCAM1	0.38	5.31	0.33	2.51e-7	Prudent dietary pattern;
SARC	cis	rs595982	0.546	rs9941490	chr19:49396737	G/A	cg03707168	chr19:49379127	PPP1R15A	0.45	5.82	0.36	1.96e-8	Red cell distribution width;
SARC	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg09263875	chr16:632152	PIGQ	0.52	7.99	0.46	6.26e-14	Height;
SARC	cis	rs6964415	0.614	rs12670623	chr7:46225617	C/T	cg00683984	chr7:45615337	ADCY1	-0.52	-4.84	-0.3	2.35e-6	Sudden cardiac arrest;
SARC	cis	rs7084402	0.967	rs10826199	chr10:60274213	T/C	cg07615347	chr10:60278583	BICC1	-0.58	-8.45	-0.48	3.16e-15	Refractive error;
SARC	cis	rs4900538	0.927	rs2403058	chr14:102964654	A/G	cg18135206	chr14:102964638	TECPR2	0.68	9.17	0.52	2.5e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs7818688	0.697	rs61591488	chr8:95984955	C/T	cg13393036	chr8:95962371	TP53INP1	0.4	4.85	0.3	2.23e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs854765	0.583	rs12603148	chr17:17865257	C/T	cg05444541	chr17:17804740	TOM1L2	-0.3	-4.86	-0.3	2.14e-6	Total body bone mineral density;
SARC	cis	rs3733585	0.699	rs60045583	chr4:9971950	G/A	cg11266682	chr4:10021025	SLC2A9	-0.36	-6.2	-0.38	2.48e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs1568889	1.000	rs61236373	chr11:28212720	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	10.04	0.55	6.23e-20	Bipolar disorder;
SARC	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg02733842	chr7:1102375	C7orf50	-0.43	-5.29	-0.33	2.78e-7	Bronchopulmonary dysplasia;
SARC	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg08219700	chr8:58056026	NA	0.47	4.87	0.3	2.04e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg10792982	chr14:105748885	BRF1	0.49	7.51	0.44	1.27e-12	Mean platelet volume;Platelet distribution width;
SARC	cis	rs6087990	0.899	rs6087999	chr20:31363774	A/G	cg13636640	chr20:31349939	DNMT3B	0.79	12.58	0.64	4.89e-28	Ulcerative colitis;
SARC	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg20965017	chr5:231967	SDHA	-0.55	-5.26	-0.33	3.23e-7	Breast cancer;
SARC	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg21747090	chr2:27597821	SNX17	-0.54	-7.52	-0.44	1.16e-12	Menopause (age at onset);
SARC	cis	rs6582630	0.502	rs11610978	chr12:38356957	C/G	cg13010199	chr12:38710504	ALG10B	0.76	10.35	0.56	6.79e-21	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg18357526	chr6:26021779	HIST1H4A	-0.52	-5.94	-0.36	1.04e-8	Blood metabolite levels;
SARC	cis	rs896854	0.548	rs574183	chr8:95973816	A/G	cg16049864	chr8:95962084	TP53INP1	0.43	6.25	0.38	1.95e-9	Type 2 diabetes;
SARC	cis	rs709400	1.000	rs3783404	chr14:104118498	A/G	cg12935359	chr14:103987150	CKB	-0.31	-4.73	-0.3	3.84e-6	Body mass index;
SARC	cis	rs9916302	0.904	rs6503503	chr17:37514373	G/A	cg15445000	chr17:37608096	MED1	-0.46	-5.69	-0.35	3.78e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg16405210	chr4:1374714	KIAA1530	0.52	6.21	0.38	2.38e-9	Obesity-related traits;
SARC	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg04166393	chr7:2884313	GNA12	0.54	6.43	0.39	6.99e-10	Height;
SARC	cis	rs763121	0.853	rs2294296	chr22:39053049	T/C	cg21395723	chr22:39101663	GTPBP1	0.58	6.57	0.4	3.32e-10	Menopause (age at onset);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg04873026	chr21:30365177	RNF160	0.5	6.66	0.4	1.97e-10	Chemerin levels;
SARC	cis	rs55962025	0.883	rs3755883	chr4:3223250	A/G	cg06533319	chr4:3265114	C4orf44	0.31	4.87	0.3	2.08e-6	Parental longevity (mother's age at death);
SARC	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg21724239	chr8:58056113	NA	0.75	6.81	0.41	7.99e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs9902453	0.753	rs7226121	chr17:28208125	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	7.28	0.43	5.22e-12	Coffee consumption (cups per day);
SARC	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg06634786	chr22:41940651	POLR3H	0.57	6.72	0.4	1.41e-10	Vitiligo;
SARC	cis	rs4595586	0.545	rs12812762	chr12:39371141	T/C	cg26384229	chr12:38710491	ALG10B	0.51	6.25	0.38	1.9e-9	Morning vs. evening chronotype;
SARC	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-15.51	-0.71	9.76e-38	Chronic sinus infection;
SARC	cis	rs4803468	1.000	rs4674	chr19:41930396	A/G	cg14132834	chr19:41945861	ATP5SL	-0.57	-7.49	-0.44	1.39e-12	Height;
SARC	cis	rs3741798	0.614	rs61922044	chr12:12490914	G/A	cg08615371	chr12:12503544	MANSC1	0.81	6.31	0.38	1.42e-9	Cerebrospinal fluid biomarker levels;
SARC	cis	rs713477	0.935	rs4901564	chr14:55912409	G/T	cg13175173	chr14:55914753	NA	-0.31	-4.8	-0.3	2.79e-6	Pediatric bone mineral content (femoral neck);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg14526939	chr1:179851391	TOR1AIP1	-0.48	-6.34	-0.38	1.19e-9	Chemerin levels;
SARC	cis	rs1008375	0.933	rs7689101	chr4:17694034	G/A	cg02297831	chr4:17616191	MED28	0.39	4.8	0.3	2.78e-6	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2115630	1.000	rs55646601	chr15:85323568	G/T	cg12501888	chr15:85177176	SCAND2	-0.47	-5.61	-0.35	5.62e-8	P wave terminal force;
SARC	trans	rs61931739	0.736	rs7314457	chr12:34454301	G/A	cg26384229	chr12:38710491	ALG10B	0.81	11.48	0.6	1.75e-24	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg22535103	chr8:58192502	C8orf71	-0.59	-6.21	-0.38	2.35e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2227564	0.597	rs2633305	chr10:75652123	A/G	cg16540259	chr10:75572220	NDST2	0.35	4.96	0.31	1.38e-6	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs7772486	0.790	rs6926076	chr6:146232804	C/T	cg23711669	chr6:146136114	FBXO30	-0.79	-12.49	-0.63	9.48e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs239198	0.577	rs34716527	chr6:101284416	T/C	cg09795085	chr6:101329169	ASCC3	0.47	5.96	0.36	9.05e-9	Menarche (age at onset);
SARC	trans	rs61931739	0.817	rs304313	chr12:34216898	C/T	cg13010199	chr12:38710504	ALG10B	0.54	7.14	0.42	1.21e-11	Morning vs. evening chronotype;
SARC	cis	rs240764	0.687	rs1336245	chr6:101197640	A/T	cg09795085	chr6:101329169	ASCC3	-0.49	-6.42	-0.39	7.72e-10	Neuroticism;
SARC	cis	rs73001065	0.536	rs10408596	chr19:19512657	A/T	cg03709012	chr19:19516395	GATAD2A	1.1	8.27	0.48	1.06e-14	LDL cholesterol;
SARC	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg11764359	chr7:65958608	NA	-0.74	-8.55	-0.49	1.64e-15	Aortic root size;
SARC	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs854765	0.547	rs2955353	chr17:17948979	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.68	-9.8	-0.54	3.4e-19	Total body bone mineral density;
SARC	cis	rs9916302	0.904	rs11078897	chr17:37415870	C/T	cg15445000	chr17:37608096	MED1	0.41	5.06	0.31	8.45e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs1580019	0.961	rs11765387	chr7:32494790	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.73	9.78	0.54	3.93e-19	Cognitive ability;
SARC	cis	rs1865760	0.964	rs1324084	chr6:25915134	C/T	cg17691542	chr6:26056736	HIST1H1C	0.56	6.83	0.41	7.18e-11	Height;
SARC	cis	rs2153535	1.000	rs2153535	chr6:8369679	C/G	cg23788917	chr6:8435910	SLC35B3	-0.43	-5.33	-0.33	2.29e-7	Motion sickness;
SARC	cis	rs12134245	0.776	rs625525	chr1:91997593	C/T	cg25838465	chr1:92012736	NA	-0.68	-9.96	-0.55	1.07e-19	Breast cancer;
SARC	cis	rs7551222	0.752	rs35270244	chr1:204548416	A/C	cg20240347	chr1:204465584	NA	-0.33	-5.78	-0.35	2.36e-8	Schizophrenia;
SARC	cis	rs826838	1.000	rs851934	chr12:39104453	G/T	cg26384229	chr12:38710491	ALG10B	-0.78	-12.11	-0.62	1.68e-26	Heart rate;
SARC	cis	rs9916302	0.861	rs2338801	chr17:37490780	G/T	cg20243544	chr17:37824526	PNMT	-0.56	-6.67	-0.4	1.81e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs787274	1.000	rs787274	chr9:115550363	A/C	cg13803584	chr9:115635662	SNX30	-0.75	-5.49	-0.34	1.04e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs6831352	0.918	rs29001211	chr4:100051941	C/T	cg12011299	chr4:100065546	ADH4	-0.34	-5.67	-0.35	4.13e-8	Alcohol dependence;
SARC	cis	rs10992471	0.603	rs12336884	chr9:95234183	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.25	-0.33	3.37e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs738321	0.711	rs5995541	chr22:38553411	C/T	cg25457927	chr22:38595422	NA	-0.25	-4.72	-0.3	4.13e-6	Breast cancer;
SARC	cis	rs6733011	0.628	rs4263159	chr2:99456151	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.41	-5.03	-0.31	9.93e-7	Bipolar disorder;
SARC	cis	rs2228479	0.850	rs1800344	chr16:89816367	T/G	cg26513180	chr16:89883248	FANCA	0.72	4.79	0.3	2.99e-6	Skin colour saturation;
SARC	cis	rs17376456	0.877	rs12153788	chr5:93405437	A/G	cg21475434	chr5:93447410	FAM172A	0.85	7.56	0.44	9.4e-13	Diabetic retinopathy;
SARC	cis	rs7772486	0.790	rs2265917	chr6:146212285	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.62	0.4	2.39e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3824867	0.920	rs10742805	chr11:47454701	A/G	cg20307385	chr11:47447363	PSMC3	0.5	5.46	0.34	1.19e-7	Mean corpuscular hemoglobin;
SARC	cis	rs16854884	1.000	rs13068298	chr3:143772247	T/C	cg06585982	chr3:143692056	C3orf58	0.54	6.73	0.4	1.27e-10	Economic and political preferences (feminism/equality);
SARC	cis	rs17270561	0.609	rs4711100	chr6:25741954	G/A	cg16482183	chr6:26056742	HIST1H1C	0.43	5.08	0.32	7.76e-7	Iron status biomarkers;
SARC	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg05313129	chr8:58192883	C8orf71	-0.62	-6.34	-0.38	1.18e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs17376456	0.825	rs13161885	chr5:93071242	A/C	cg21475434	chr5:93447410	FAM172A	0.71	6.04	0.37	6.13e-9	Diabetic retinopathy;
SARC	trans	rs629535	0.773	rs569064	chr8:70065967	A/G	cg21567404	chr3:27674614	NA	1.05	13.61	0.67	2.02e-31	Dupuytren's disease;
SARC	cis	rs13191362	0.935	rs35537826	chr6:163145867	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.6	5.3	0.33	2.69e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs748404	0.660	rs493377	chr15:43773467	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.48	5.22	0.32	3.92e-7	Lung cancer;
SARC	trans	rs11722228	0.549	rs73212830	chr4:10078759	A/T	cg26043149	chr18:55253948	FECH	0.68	7.6	0.45	7.08e-13	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs11997175	0.625	rs17698353	chr8:33592241	A/G	ch.8.33884649F	chr8:33765107	NA	0.48	6.05	0.37	5.66e-9	Body mass index;
SARC	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg24209194	chr3:40518798	ZNF619	0.66	8.04	0.47	4.45e-14	Renal cell carcinoma;
SARC	cis	rs36051895	0.623	rs76960049	chr9:5064548	G/A	cg02405213	chr9:5042618	JAK2	-0.47	-5.55	-0.34	7.69e-8	Pediatric autoimmune diseases;
SARC	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg18876405	chr7:65276391	NA	-0.44	-4.93	-0.31	1.56e-6	Aortic root size;
SARC	cis	rs459571	0.959	rs461462	chr9:136911272	C/T	cg13789015	chr9:136890014	NCRNA00094	0.6	8.38	0.48	5.17e-15	Platelet distribution width;
SARC	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg15049968	chr18:44337910	ST8SIA5	-0.34	-5.24	-0.32	3.58e-7	Personality dimensions;
SARC	cis	rs425277	0.958	rs7546523	chr1:2043792	G/A	cg24578937	chr1:2090814	PRKCZ	0.32	5.9	0.36	1.25e-8	Height;
SARC	cis	rs67460515	0.563	rs4521287	chr3:160812752	C/T	cg03342759	chr3:160939853	NMD3	-0.65	-7.79	-0.45	2.27e-13	Parkinson's disease;
SARC	cis	rs8014204	0.836	rs888413	chr14:75267396	C/T	cg17347104	chr14:75034677	LTBP2	-0.47	-5.9	-0.36	1.3e-8	Caffeine consumption;
SARC	cis	rs2273669	0.915	rs2145766	chr6:109296261	G/C	cg05315195	chr6:109294784	ARMC2	-0.48	-4.75	-0.3	3.61e-6	Prostate cancer;
SARC	cis	rs12971120	0.891	rs2278158	chr18:72178300	G/T	cg26446133	chr18:72167187	CNDP2	-0.47	-6.32	-0.38	1.32e-9	Refractive error;
SARC	cis	rs7130144	0.541	rs60284315	chr11:130467096	A/C	cg26307797	chr11:130446613	NA	-0.68	-4.92	-0.31	1.65e-6	Urate levels in lean individuals;
SARC	trans	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg20587970	chr11:113659929	NA	-1.36	-14.08	-0.68	5.46e-33	Hip circumference adjusted for BMI;
SARC	cis	rs4803468	1.000	rs10409485	chr19:41920765	C/T	cg14132834	chr19:41945861	ATP5SL	0.52	6.94	0.41	3.83e-11	Height;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg05843257	chr22:24951377	SNRPD3;C22orf13	-0.49	-6.26	-0.38	1.82e-9	Height;
SARC	cis	rs11885103	0.754	rs11127478	chr2:592455	T/C	cg21195176	chr2:593345	NA	0.3	4.78	0.3	3.12e-6	Heschl's gyrus morphology;
SARC	cis	rs1059312	0.808	rs10847693	chr12:129292006	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.49	7.17	0.43	9.93e-12	Systemic lupus erythematosus;
SARC	cis	rs7659604	1.000	rs73844281	chr4:122664688	A/G	cg19748678	chr4:122722346	EXOSC9	0.42	5.17	0.32	5.01e-7	Type 2 diabetes;
SARC	cis	rs6696846	0.936	rs1042831	chr1:205043250	G/C	cg21643547	chr1:205240462	TMCC2	-0.53	-7.18	-0.43	9.51e-12	Red blood cell count;
SARC	cis	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg24110177	chr3:50126178	RBM5	-0.62	-8.13	-0.47	2.61e-14	Body mass index;
SARC	cis	rs1003719	0.680	rs2835621	chr21:38510616	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-9.13	-0.51	3.35e-17	Eye color traits;
SARC	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg00933542	chr6:150070202	PCMT1	0.31	5.36	0.33	2.04e-7	Lung cancer;
SARC	cis	rs7149337	0.805	rs4350491	chr14:51675798	A/G	cg23942311	chr14:51606299	NA	0.34	6.09	0.37	4.55e-9	Cancer;
SARC	cis	rs4737010	0.501	rs7000282	chr8:41647493	A/C	cg08923054	chr8:41654455	ANK1	0.7	8.27	0.48	1.05e-14	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
SARC	cis	rs2645694	0.626	rs2645708	chr4:77822682	G/A	cg03477792	chr4:77819574	ANKRD56	0.5	7.55	0.44	9.53e-13	Emphysema distribution in smoking;
SARC	cis	rs999943	0.846	rs1570760	chr6:33622933	C/T	cg14003231	chr6:33640908	ITPR3	0.54	9.17	0.52	2.55e-17	Obesity (extreme);
SARC	cis	rs2153535	0.580	rs6927589	chr6:8456632	A/G	cg21535247	chr6:8435926	SLC35B3	-0.56	-7.09	-0.42	1.6e-11	Motion sickness;
SARC	cis	rs933688	0.532	rs11740007	chr5:90545498	C/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.43	-4.86	-0.3	2.13e-6	Smoking behavior;
SARC	cis	rs524281	0.861	rs2889313	chr11:65966066	G/C	cg14036092	chr11:66035641	RAB1B	-0.47	-4.88	-0.3	1.96e-6	Electroencephalogram traits;
SARC	cis	rs7412746	0.634	rs4451553	chr1:150937329	C/T	cg10589385	chr1:150898437	SETDB1	0.43	5.59	0.34	6.24e-8	Melanoma;
SARC	cis	rs9487051	0.676	rs4406271	chr6:109598213	G/A	cg01475377	chr6:109611718	NA	-0.35	-5.08	-0.32	7.8e-7	Reticulocyte fraction of red cells;
SARC	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg13393036	chr8:95962371	TP53INP1	-0.4	-6.73	-0.4	1.33e-10	Type 2 diabetes;
SARC	cis	rs6963495	0.818	rs73190184	chr7:105163736	C/T	cg13798780	chr7:105162888	PUS7	0.6	5.45	0.34	1.31e-7	Bipolar disorder (body mass index interaction);
SARC	trans	rs453301	0.624	rs330049	chr8:9087299	C/T	cg06636001	chr8:8085503	FLJ10661	0.71	9.96	0.55	1.07e-19	Joint mobility (Beighton score);
SARC	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg07343612	chr16:622815	PIGQ	-0.6	-8.37	-0.48	5.3e-15	Height;
SARC	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs2635047	1.000	rs2277717	chr18:44702718	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.53	7.06	0.42	1.94e-11	Educational attainment;
SARC	cis	rs796364	1.000	rs4263095	chr2:200830137	A/C	cg23649088	chr2:200775458	C2orf69	-0.61	-5.95	-0.36	9.72e-9	Schizophrenia;
SARC	cis	rs1185460	0.967	rs3825061	chr11:118944675	C/T	cg23280166	chr11:118938394	VPS11	0.77	10.86	0.58	1.68e-22	Coronary artery disease;
SARC	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg01570182	chr17:44337453	NA	0.84	9.48	0.53	3.08e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9457247	0.529	rs6907666	chr6:167523395	A/G	cg07741184	chr6:167504864	NA	-0.34	-6.32	-0.38	1.33e-9	Crohn's disease;
SARC	cis	rs2153535	0.580	rs1115079	chr6:8449615	G/C	cg23788917	chr6:8435910	SLC35B3	0.63	8.4	0.48	4.42e-15	Motion sickness;
SARC	cis	rs11098499	0.644	rs10050092	chr4:120532085	T/C	cg09307838	chr4:120376055	NA	0.76	10.27	0.56	1.2e-20	Corneal astigmatism;
SARC	cis	rs2742234	0.554	rs1270015	chr10:43698240	G/T	cg15436174	chr10:43711423	RASGEF1A	0.41	4.81	0.3	2.7e-6	Hirschsprung disease;
SARC	cis	rs28374715	0.578	rs7165914	chr15:41632451	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.17	-19.16	-0.78	8.85e-50	Ulcerative colitis;
SARC	cis	rs2180341	0.618	rs11961994	chr6:127649350	A/G	cg27446573	chr6:127587934	RNF146	-0.64	-8.15	-0.47	2.2e-14	Breast cancer;
SARC	trans	rs12310956	0.532	rs7955514	chr12:33978737	G/A	cg13010199	chr12:38710504	ALG10B	0.75	10.16	0.55	2.58e-20	Morning vs. evening chronotype;
SARC	cis	rs6831352	0.918	rs13133633	chr4:100058697	C/G	cg12011299	chr4:100065546	ADH4	-0.34	-5.74	-0.35	2.95e-8	Alcohol dependence;
SARC	cis	rs13256369	1.000	rs9329166	chr8:8576655	C/T	cg18904891	chr8:8559673	CLDN23	0.46	5.42	0.33	1.47e-7	Obesity-related traits;
SARC	cis	rs965469	0.843	rs6051698	chr20:3248983	T/C	cg25506879	chr20:3388711	C20orf194	-0.48	-5.11	-0.32	6.63e-7	IFN-related cytopenia;
SARC	cis	rs1570884	0.516	rs2146144	chr13:50170245	C/T	cg08779649	chr13:50194554	NA	0.37	6.4	0.39	8.38e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs1008375	0.931	rs6449328	chr4:17700474	C/T	cg02297831	chr4:17616191	MED28	0.38	4.75	0.3	3.52e-6	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs889312	0.500	rs185219	chr5:56136492	A/G	cg14703610	chr5:56206110	C5orf35	0.53	6.71	0.4	1.46e-10	Breast cancer;Breast cancer (early onset);
SARC	trans	rs9329221	0.623	rs7825778	chr8:10261010	C/T	cg00262122	chr8:11665843	FDFT1	-0.52	-6.41	-0.39	8.13e-10	Neuroticism;
SARC	cis	rs1707322	0.721	rs7520123	chr1:46235219	C/G	cg03146154	chr1:46216737	IPP	0.48	5.76	0.35	2.7e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs10848704	0.637	rs11062351	chr12:2881763	C/T	cg19995117	chr12:2880862	NA	0.28	4.95	0.31	1.41e-6	Quantitative traits;
SARC	cis	rs1865721	0.771	rs4622605	chr18:73139008	T/C	cg26385618	chr18:73139727	C18orf62	-0.4	-5.64	-0.35	4.85e-8	Intelligence;
SARC	cis	rs2916247	0.954	rs10808644	chr8:93127873	C/T	cg10183463	chr8:93005414	RUNX1T1	0.52	5.74	0.35	2.89e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9612	0.950	rs7256472	chr19:44246970	C/T	cg08581076	chr19:44259116	C19orf61	0.73	9.09	0.51	4.42e-17	Exhaled nitric oxide output;
SARC	cis	rs514406	0.505	rs269293	chr1:53187767	A/C	cg16325326	chr1:53192061	ZYG11B	0.91	16.41	0.73	9.61e-41	Monocyte count;
SARC	cis	rs912330	0.529	rs4772100	chr13:99196573	G/T	cg07423050	chr13:99094983	FARP1	-0.32	-5.12	-0.32	6.47e-7	Alzheimer's disease;
SARC	cis	rs747650	0.892	rs2029298	chr11:47234718	C/T	cg03339077	chr11:47165057	C11orf49	-0.45	-6.2	-0.38	2.55e-9	Acne (severe);
SARC	cis	rs4481887	0.927	rs4345830	chr1:248474845	G/C	cg00666640	chr1:248458726	OR2T12	0.34	5.7	0.35	3.65e-8	Common traits (Other);
SARC	cis	rs1953600	0.870	rs12770550	chr10:81953451	G/T	cg00277334	chr10:82204260	NA	0.37	5.36	0.33	1.96e-7	Sarcoidosis;
SARC	cis	rs9788721	0.836	rs2568494	chr15:78740964	G/A	cg06917634	chr15:78832804	PSMA4	-0.48	-5.28	-0.33	2.91e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs6701037	1.000	rs7514749	chr1:175122123	A/G	cg00321850	chr1:175162397	KIAA0040	-0.34	-5.11	-0.32	6.73e-7	Alcohol dependence;
SARC	cis	rs7589342	0.517	rs6726571	chr2:106390251	T/C	cg16077055	chr2:106428750	NCK2	0.28	5.45	0.34	1.25e-7	Addiction;
SARC	cis	rs2635047	0.783	rs9948677	chr18:44790343	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.53	6.76	0.4	1.12e-10	Educational attainment;
SARC	cis	rs11792861	0.926	rs72607166	chr9:111821530	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.66	7.62	0.45	6.29e-13	Menarche (age at onset);
SARC	cis	rs963731	0.579	rs6739807	chr2:39287668	G/A	cg04010122	chr2:39346883	SOS1	-0.62	-4.89	-0.31	1.88e-6	Corticobasal degeneration;
SARC	cis	rs11786130	1.000	rs10956403	chr8:129007207	A/G	cg17583432	chr8:129005567	PVT1	-0.39	-6.73	-0.4	1.33e-10	Eosinophil counts;Sum eosinophil basophil counts;
SARC	cis	rs12044355	0.827	rs11586191	chr1:231831781	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.56	7.57	0.44	8.53e-13	Alzheimer's disease;
SARC	cis	rs2014572	0.967	rs10418480	chr19:57755055	C/T	cg24459738	chr19:57751996	ZNF805	-0.45	-5.43	-0.34	1.41e-7	Hyperactive-impulsive symptoms;
SARC	cis	rs910316	0.934	rs4903278	chr14:75535019	C/A	cg23033748	chr14:75592666	NEK9	0.35	4.91	0.31	1.74e-6	Height;
SARC	cis	rs2013441	0.613	rs888424	chr17:19985427	C/T	cg13482628	chr17:19912719	NA	0.38	4.85	0.3	2.29e-6	Obesity-related traits;
SARC	cis	rs7666738	0.830	rs11940273	chr4:98979965	T/A	cg05340658	chr4:99064831	C4orf37	0.64	8.73	0.5	5.14e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg25894440	chr7:65020034	NA	-0.77	-5.85	-0.36	1.67e-8	Diabetic kidney disease;
SARC	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg04277193	chr17:41438351	NA	0.45	4.93	0.31	1.59e-6	Menopause (age at onset);
SARC	cis	rs7223966	1.000	rs16947014	chr17:61719032	C/T	cg00588841	chr17:61851480	DDX42;CCDC47	-0.63	-6.81	-0.41	8.12e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs12579753	0.810	rs1922565	chr12:82135348	T/C	cg07988820	chr12:82153109	PPFIA2	-0.57	-6.65	-0.4	2.07e-10	Resting heart rate;
SARC	cis	rs7566780	0.516	rs7567636	chr2:16664016	A/C	cg09580478	chr2:16689509	NA	0.55	6.92	0.41	4.42e-11	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs6121246	0.520	rs6060425	chr20:30224355	C/T	cg13852791	chr20:30311386	BCL2L1	0.77	8.02	0.46	5.27e-14	Mean corpuscular hemoglobin;
SARC	cis	rs9486715	0.838	rs9400034	chr6:96954566	C/T	cg18709589	chr6:96969512	KIAA0776	0.59	7.33	0.43	3.65e-12	Headache;
SARC	cis	rs282587	0.569	rs385990	chr13:113396575	A/G	cg02820901	chr13:113351484	ATP11A	-0.51	-4.86	-0.3	2.13e-6	Glycated hemoglobin levels;
SARC	cis	rs6545883	1.000	rs6742276	chr2:61768745	G/A	cg15711740	chr2:61764176	XPO1	-0.43	-5.27	-0.33	3.06e-7	Tuberculosis;
SARC	cis	rs17125944	0.505	rs75296244	chr14:53233218	G/A	cg00686598	chr14:53173677	PSMC6	1.32	9.08	0.51	4.59e-17	Alzheimer's disease (late onset);
SARC	cis	rs735396	0.770	rs2264782	chr12:121432603	C/T	cg02403541	chr12:121454288	C12orf43	0.71	9.18	0.52	2.44e-17	N-glycan levels;
SARC	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg16479474	chr6:28041457	NA	0.38	5.51	0.34	9.48e-8	Depression;
SARC	cis	rs7818688	0.697	rs112076731	chr8:95978121	C/G	cg13393036	chr8:95962371	TP53INP1	0.4	4.85	0.3	2.27e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg11764359	chr7:65958608	NA	-0.84	-11.39	-0.6	3.57e-24	Aortic root size;
SARC	cis	rs3768617	0.510	rs12091137	chr1:183075732	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.28	0.56	1.07e-20	Fuchs's corneal dystrophy;
SARC	cis	rs6964587	1.000	rs6967256	chr7:91643219	G/A	cg17063962	chr7:91808500	NA	0.96	16.55	0.74	3.4e-41	Breast cancer;
SARC	cis	rs208520	0.690	rs12192710	chr6:66718137	C/T	cg07460842	chr6:66804631	NA	1.06	14.4	0.69	4.75e-34	Exhaled nitric oxide output;
SARC	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg11987759	chr7:65425863	GUSB	-0.48	-6.04	-0.37	5.99e-9	Aortic root size;
SARC	cis	rs2075371	0.897	rs1643102	chr7:133999983	T/A	cg20476274	chr7:133979776	SLC35B4	0.63	8.51	0.49	2.17e-15	Mean platelet volume;
SARC	cis	rs9858542	0.953	rs7622302	chr3:49547561	T/C	cg03060546	chr3:49711283	APEH	-0.59	-7.2	-0.43	8.12e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs12586317	0.534	rs2273157	chr14:35438836	A/G	cg02047889	chr14:35452176	SRP54	0.44	4.77	0.3	3.26e-6	Psoriasis;
SARC	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg25072359	chr17:41440525	NA	0.53	6.28	0.38	1.61e-9	Menopause (age at onset);
SARC	cis	rs7945705	0.870	rs4910156	chr11:8941197	T/G	cg21881798	chr11:8931708	C11orf17;ST5	0.42	5.67	0.35	4.24e-8	Hemoglobin concentration;
SARC	cis	rs9443189	0.570	rs7770824	chr6:76408189	G/A	cg01950844	chr6:76311363	SENP6	0.86	8.18	0.47	1.82e-14	Prostate cancer;
SARC	cis	rs17783634	0.509	rs11775489	chr8:11036843	T/C	cg12395012	chr8:11607386	GATA4	0.31	5.32	0.33	2.44e-7	Subjective well-being;
SARC	cis	rs9902453	0.817	rs2617881	chr17:28063275	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.52	-6.95	-0.41	3.56e-11	Coffee consumption (cups per day);
SARC	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg12463550	chr7:65579703	CRCP	-0.5	-5.48	-0.34	1.09e-7	Aortic root size;
SARC	cis	rs12477438	1.000	rs57846982	chr2:99921574	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-6.67	-0.4	1.79e-10	Chronic sinus infection;
SARC	cis	rs9831754	0.654	rs9837024	chr3:78451637	C/T	cg06138941	chr3:78371609	NA	0.56	6.79	0.41	9.44e-11	Calcium levels;
SARC	cis	rs5753037	0.653	rs140123	chr22:30143206	A/G	cg01021169	chr22:30184971	ASCC2	0.42	5.7	0.35	3.58e-8	Type 1 diabetes;
SARC	cis	rs2576037	0.899	rs2060417	chr18:44576486	C/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.35	-4.76	-0.3	3.44e-6	Personality dimensions;
SARC	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg13175981	chr1:150552382	MCL1	-0.54	-6.82	-0.41	7.54e-11	Tonsillectomy;
SARC	cis	rs12142240	0.583	rs5013330	chr1:46815154	G/A	cg00530320	chr1:46809349	NSUN4	0.57	6.92	0.41	4.4e-11	Menopause (age at onset);
SARC	cis	rs7520050	0.807	rs3013594	chr1:46138000	T/C	cg24296786	chr1:45957014	TESK2	-0.43	-5.54	-0.34	8.14e-8	Red blood cell count;Reticulocyte count;
SARC	cis	rs763121	0.853	rs5757232	chr22:39071677	C/T	cg06022373	chr22:39101656	GTPBP1	0.85	10.65	0.57	7.52e-22	Menopause (age at onset);
SARC	cis	rs4926611	0.730	rs6662142	chr1:54059368	T/C	cg08927728	chr1:54059983	GLIS1	0.3	4.94	0.31	1.52e-6	Hand grip strength;
SARC	cis	rs4774830	0.744	rs12438427	chr15:56295062	A/T	cg24530489	chr15:56299380	NA	0.8	5.21	0.32	4.19e-7	Delta-5 desaturase activity;
SARC	cis	rs7647973	0.696	rs3087866	chr3:49054692	A/G	cg07636037	chr3:49044803	WDR6	0.85	8.96	0.51	1.1e-16	Menarche (age at onset);
SARC	cis	rs9381040	0.655	rs9381032	chr6:41044986	A/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.49	-5.62	-0.35	5.4e-8	Alzheimer's disease (late onset);
SARC	cis	rs748404	0.560	rs570933	chr15:43824030	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.44	4.73	0.3	3.84e-6	Lung cancer;
SARC	cis	rs4819052	1.000	rs2297284	chr21:46705345	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.81	9.29	0.52	1.1e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg08048268	chr3:133502702	NA	0.48	6.36	0.38	1.06e-9	Iron status biomarkers;
SARC	cis	rs4689388	0.581	rs1801212	chr4:6302519	C/T	cg00701064	chr4:6280414	WFS1	0.44	5.6	0.34	5.87e-8	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg16479474	chr6:28041457	NA	0.34	5.27	0.33	3.18e-7	Cardiac Troponin-T levels;
SARC	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg13395646	chr4:1353034	KIAA1530	0.43	5.07	0.31	8.29e-7	Obesity-related traits;
SARC	cis	rs7582720	1.000	rs78907692	chr2:203932176	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	7.78	0.45	2.39e-13	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg05552183	chr6:42928497	GNMT	0.52	7.3	0.43	4.64e-12	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.6	5.67	0.35	4.16e-8	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs2228479	0.850	rs11639925	chr16:89908250	C/T	cg06558623	chr16:89946397	TCF25	0.9	6.38	0.39	9.63e-10	Skin colour saturation;
SARC	cis	rs2997447	0.761	rs61776582	chr1:26437262	A/C	cg19633962	chr1:26362018	EXTL1	-0.57	-5.05	-0.31	8.95e-7	QRS complex (12-leadsum);
SARC	cis	rs17270561	0.609	rs1408271	chr6:25859621	T/A	cg17691542	chr6:26056736	HIST1H1C	0.59	7.67	0.45	4.55e-13	Iron status biomarkers;
SARC	cis	rs2635047	1.000	rs2635047	chr18:44736336	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.52	6.8	0.41	8.64e-11	Educational attainment;
SARC	cis	rs3617	0.591	rs2276823	chr3:52869263	C/A	cg04865290	chr3:52927548	TMEM110	0.36	5.17	0.32	5.15e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg11890956	chr21:40555474	PSMG1	1.16	18.3	0.77	5.68e-47	Cognitive function;
SARC	cis	rs9486715	0.867	rs9384628	chr6:96960232	T/C	cg06623918	chr6:96969491	KIAA0776	0.89	12.91	0.65	3.96e-29	Headache;
SARC	cis	rs9902453	0.838	rs3110495	chr17:27978455	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.56	-7.26	-0.43	5.64e-12	Coffee consumption (cups per day);
SARC	trans	rs11098499	0.863	rs1010740	chr4:120463409	C/T	cg25214090	chr10:38739885	LOC399744	-0.56	-7.18	-0.43	9.39e-12	Corneal astigmatism;
SARC	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.37	-4.73	-0.3	3.92e-6	Lymphocyte counts;
SARC	cis	rs3796352	1.000	rs11706035	chr3:53011868	A/T	cg27565382	chr3:53032988	SFMBT1	0.76	5.34	0.33	2.25e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg10295955	chr4:187884368	NA	-1.07	-20.18	-0.8	4.55e-53	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg18225595	chr11:63971243	STIP1	0.44	5.36	0.33	1.97e-7	Mean platelet volume;
SARC	cis	rs7918232	0.830	rs7087033	chr10:27392522	A/G	cg14240646	chr10:27532245	ACBD5	-0.55	-4.97	-0.31	1.32e-6	Breast cancer;
SARC	cis	rs7586879	0.593	rs11689546	chr2:25130451	A/G	cg04586622	chr2:25135609	ADCY3	0.31	5.29	0.33	2.8e-7	Body mass index;
SARC	cis	rs1728785	1.000	rs1728765	chr16:68589433	G/A	cg02972257	chr16:68554789	NA	-0.45	-5.32	-0.33	2.48e-7	Ulcerative colitis;
SARC	cis	rs838147	0.505	rs1688264	chr19:49209560	T/G	cg21064579	chr19:49206444	FUT2	0.34	4.83	0.3	2.44e-6	Dietary macronutrient intake;
SARC	cis	rs7552404	0.883	rs11161493	chr1:76206254	T/A	cg22875332	chr1:76189707	ACADM	0.46	6.61	0.4	2.66e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9309473	0.950	rs10178678	chr2:73762236	A/G	cg20560298	chr2:73613845	ALMS1	-0.54	-6.5	-0.39	4.86e-10	Metabolite levels;
SARC	cis	rs7647973	0.769	rs7434187	chr3:49032967	C/T	cg07636037	chr3:49044803	WDR6	0.92	9.74	0.54	5.07e-19	Menarche (age at onset);
SARC	cis	rs9612	1.000	rs346527	chr19:44259361	A/G	cg08581076	chr19:44259116	C19orf61	0.65	7.93	0.46	9.08e-14	Exhaled nitric oxide output;
SARC	cis	rs12048904	0.505	rs4517368	chr1:101255052	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.62	-7.1	-0.42	1.54e-11	Multiple sclerosis;
SARC	cis	rs1050631	0.527	rs592261	chr18:33752244	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.59	7.07	0.42	1.8e-11	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs1784581	0.569	rs9364629	chr6:162416831	T/G	cg17173639	chr6:162384350	PARK2	0.51	6.5	0.39	4.82e-10	Itch intensity from mosquito bite;
SARC	cis	rs7296418	0.961	rs4275659	chr12:123447928	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.44	6.08	0.37	4.81e-9	Platelet count;
SARC	cis	rs7644634	0.688	rs11915926	chr3:105482422	T/C	cg23051926	chr3:105466016	CBLB	0.46	5.71	0.35	3.39e-8	Itch intensity from mosquito bite;
SARC	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg24642844	chr7:1081250	C7orf50	-0.5	-5.82	-0.36	1.97e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs9354352	0.791	rs4710306	chr6:66700271	A/G	cg07460842	chr6:66804631	NA	-0.59	-7.55	-0.44	9.65e-13	Initial pursuit acceleration in psychotic disorders;
SARC	trans	rs2727020	0.724	rs4109837	chr11:49372051	A/T	cg03929089	chr4:120376271	NA	-0.72	-9.0	-0.51	8.06e-17	Coronary artery disease;
SARC	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg06212747	chr3:49208901	KLHDC8B	0.68	9.04	0.51	6.29e-17	Parkinson's disease;
SARC	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg03264133	chr6:25882463	NA	-0.43	-5.77	-0.35	2.46e-8	Intelligence (multi-trait analysis);
SARC	trans	rs61931739	0.890	rs1687020	chr12:34137924	G/C	cg13010199	chr12:38710504	ALG10B	0.59	7.77	0.45	2.5e-13	Morning vs. evening chronotype;
SARC	cis	rs9916302	0.706	rs590051	chr17:37446571	T/C	cg15445000	chr17:37608096	MED1	-0.45	-4.92	-0.31	1.62e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs765787	0.530	rs4775831	chr15:45534722	A/C	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.81e-6	Uric acid levels;
SARC	cis	rs11758351	0.866	rs75091077	chr6:26207546	A/C	cg01420254	chr6:26195488	NA	0.54	4.89	0.31	1.89e-6	Gout;Renal underexcretion gout;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24847154	chr1:151118794	SEMA6C	-0.52	-6.24	-0.38	2.07e-9	Fibrinogen levels;
SARC	cis	rs3091242	0.933	rs9438905	chr1:25764177	A/G	cg27572855	chr1:25598939	RHD	0.54	9.3	0.52	1.06e-17	Erythrocyte sedimentation rate;
SARC	cis	rs2013441	0.786	rs4003797	chr17:20288900	T/C	cg13482628	chr17:19912719	NA	-0.47	-6.07	-0.37	5.17e-9	Obesity-related traits;
SARC	cis	rs644799	1.000	rs505220	chr11:95563228	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.9	14.03	0.68	7.82e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs826838	0.967	rs11183577	chr12:38781887	A/G	cg13010199	chr12:38710504	ALG10B	0.8	11.45	0.6	2.31e-24	Heart rate;
SARC	cis	rs7714584	1.000	rs12659118	chr5:150324622	T/C	cg22134413	chr5:150180641	NA	0.83	6.83	0.41	7.27e-11	Crohn's disease;
SARC	cis	rs2066819	1.000	rs2066808	chr12:56737973	A/G	cg26734620	chr12:56694298	CS	0.86	6.37	0.39	1.01e-9	Psoriasis vulgaris;
SARC	cis	rs3820928	0.874	rs1054413	chr2:227867719	A/G	cg05526886	chr2:227700861	RHBDD1	0.49	5.9	0.36	1.29e-8	Pulmonary function;
SARC	cis	rs2948294	0.588	rs12544596	chr8:8116346	A/T	cg06636001	chr8:8085503	FLJ10661	0.61	7.28	0.43	5.24e-12	Red cell distribution width;
SARC	cis	rs7011049	1.000	rs79169015	chr8:53843908	C/T	cg26025543	chr8:53854495	NA	0.6	5.43	0.34	1.42e-7	Systolic blood pressure;
SARC	cis	rs10782582	0.609	rs5745394	chr1:76311731	G/A	cg10523679	chr1:76189770	ACADM	-0.43	-5.27	-0.33	3.06e-7	Daytime sleep phenotypes;
SARC	trans	rs2396442	1.000	rs2256819	chr6:45418402	A/G	cg11956111	chr2:74710460	TTC31;CCDC142	-0.55	-6.51	-0.39	4.46e-10	Left ventricle wall thickness;
SARC	cis	rs4722166	0.630	rs6969258	chr7:22782528	C/T	cg26061582	chr7:22766209	IL6	0.55	6.06	0.37	5.44e-9	Lung cancer;
SARC	trans	rs11098499	0.863	rs10034450	chr4:120455649	A/G	cg25214090	chr10:38739885	LOC399744	0.57	7.35	0.43	3.31e-12	Corneal astigmatism;
SARC	cis	rs9291683	0.546	rs13146686	chr4:10034933	A/G	cg11266682	chr4:10021025	SLC2A9	0.36	6.28	0.38	1.62e-9	Bone mineral density;
SARC	cis	rs7712401	0.601	rs246275	chr5:122231413	C/T	cg19412675	chr5:122181750	SNX24	0.41	5.16	0.32	5.19e-7	Mean platelet volume;
SARC	cis	rs6582630	0.502	rs1915395	chr12:38420726	A/G	cg26384229	chr12:38710491	ALG10B	0.87	12.57	0.64	5.36e-28	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg16282910	chr9:112296723	NA	-0.52	-6.57	-0.4	3.26e-10	Height;
SARC	cis	rs6918586	0.658	rs198844	chr6:26108282	C/G	cg18357526	chr6:26021779	HIST1H4A	-0.46	-5.86	-0.36	1.54e-8	Schizophrenia;
SARC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg10862848	chr6:42927986	GNMT	-0.45	-7.44	-0.44	1.94e-12	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg27286337	chr10:134555280	INPP5A	-0.64	-7.49	-0.44	1.43e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.82	12.26	0.63	5.4e-27	Personality dimensions;
SARC	cis	rs1545257	0.537	rs11125583	chr2:24646278	C/A	cg06627628	chr2:24431161	ITSN2	-0.55	-7.07	-0.42	1.82e-11	Sjögren's syndrome;
SARC	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg09359103	chr1:154839909	KCNN3	-0.48	-8.08	-0.47	3.42e-14	Prostate cancer;
SARC	cis	rs2011503	1.000	rs2916075	chr19:19530590	G/C	cg15839431	chr19:19639596	YJEFN3	-0.49	-4.85	-0.3	2.28e-6	Bipolar disorder;
SARC	cis	rs765787	0.530	rs4775832	chr15:45534828	A/G	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.51e-10	Uric acid levels;
SARC	cis	rs9325144	0.647	rs7980932	chr12:38921583	G/T	cg13010199	chr12:38710504	ALG10B	-0.48	-6.07	-0.37	5.21e-9	Morning vs. evening chronotype;
SARC	cis	rs10782582	0.593	rs114421765	chr1:76141802	C/T	cg03433033	chr1:76189801	ACADM	-0.38	-4.78	-0.3	3.11e-6	Daytime sleep phenotypes;
SARC	cis	rs7208859	0.623	rs56378576	chr17:29010120	C/T	cg13385521	chr17:29058706	SUZ12P	0.81	6.15	0.37	3.27e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs11785693	0.862	rs6994150	chr8:4996630	T/G	cg26367366	chr8:4980734	NA	0.76	6.78	0.41	9.62e-11	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg25072359	chr17:41440525	NA	-0.5	-6.17	-0.37	2.96e-9	Menopause (age at onset);
SARC	cis	rs75920871	0.660	rs12271161	chr11:116979911	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.45	-4.8	-0.3	2.85e-6	Subjective well-being;
SARC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg26354017	chr1:205819088	PM20D1	0.92	16.06	0.72	1.38e-39	Menarche (age at onset);
SARC	cis	rs13191362	1.000	rs34443622	chr6:163208214	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.4	5.16	0.32	5.17e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs9916302	0.904	rs1966916	chr17:37425238	T/G	cg15445000	chr17:37608096	MED1	0.42	5.16	0.32	5.18e-7	Glomerular filtration rate (creatinine);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg07721005	chr5:87564621	TMEM161B	0.47	6.26	0.38	1.79e-9	Chemerin levels;
SARC	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg01276201	chr10:134613136	NA	0.3	5.14	0.32	5.73e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs561341	1.000	rs550923	chr17:30327013	G/C	cg00745463	chr17:30367425	LRRC37B	-0.69	-5.53	-0.34	8.77e-8	Hip circumference adjusted for BMI;
SARC	cis	rs9467773	0.620	rs2494696	chr6:26620894	A/G	cg12292205	chr6:26970375	C6orf41	0.4	5.04	0.31	9.34e-7	Intelligence (multi-trait analysis);
SARC	cis	rs11025559	0.773	rs10833334	chr11:20498640	T/C	cg04101203	chr11:20408940	PRMT3	-0.47	-5.01	-0.31	1.08e-6	Pursuit maintenance gain;
SARC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg01238044	chr22:24384105	GSTT1	0.81	11.31	0.6	6.34e-24	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2963155	0.518	rs56150733	chr5:142765099	T/C	cg17617527	chr5:142782415	NR3C1	0.73	5.34	0.33	2.16e-7	Breast cancer;
SARC	cis	rs2273669	0.915	rs6908104	chr6:109293973	T/C	cg01304950	chr6:109416612	SESN1;C6orf182	0.54	4.81	0.3	2.77e-6	Prostate cancer;
SARC	cis	rs11718455	0.960	rs4682713	chr3:44013191	G/C	cg08738300	chr3:44038990	NA	0.53	5.8	0.36	2.16e-8	Coronary artery disease;
SARC	cis	rs6604026	0.656	rs2774954	chr1:93363525	G/A	cg17283838	chr1:93427260	FAM69A	-0.42	-4.75	-0.3	3.59e-6	Multiple sclerosis;
SARC	cis	rs2439831	0.867	rs12323999	chr15:43683115	T/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.07	11.55	0.6	1.04e-24	Lung cancer in ever smokers;
SARC	cis	rs9916302	0.706	rs667193	chr17:37448835	T/C	cg20243544	chr17:37824526	PNMT	-0.56	-6.02	-0.37	6.66e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs76419734	1.000	rs17036177	chr4:106672511	T/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.76	4.95	0.31	1.4e-6	Post bronchodilator FEV1;
SARC	cis	rs9815354	0.812	rs10510731	chr3:41853310	C/T	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs995000	0.931	rs998403	chr1:62928549	G/A	cg06896770	chr1:63153194	DOCK7	0.99	15.58	0.71	5.53e-38	Triglyceride levels;
SARC	cis	rs9916302	0.706	rs801427	chr17:37436711	A/G	cg07936489	chr17:37558343	FBXL20	-0.74	-8.91	-0.5	1.47e-16	Glomerular filtration rate (creatinine);
SARC	trans	rs61931739	0.513	rs10772116	chr12:33897795	G/C	cg13010199	chr12:38710504	ALG10B	0.63	8.45	0.48	3.15e-15	Morning vs. evening chronotype;
SARC	cis	rs11608355	0.618	rs60819157	chr12:109795766	G/A	cg05360138	chr12:110035743	NA	0.44	5.23	0.32	3.75e-7	Neuroticism;
SARC	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg02297831	chr4:17616191	MED28	0.51	6.63	0.4	2.36e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6674176	0.628	rs2240447	chr1:44415415	C/T	cg12908607	chr1:44402522	ARTN	-0.4	-6.78	-0.41	1.01e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg05313129	chr8:58192883	C8orf71	-0.56	-6.23	-0.38	2.15e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	5.42	0.33	1.46e-7	Bipolar disorder;
SARC	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg06634786	chr22:41940651	POLR3H	-0.59	-7.04	-0.42	2.17e-11	Vitiligo;
SARC	cis	rs10782582	0.609	rs79835994	chr1:76287508	G/T	cg10523679	chr1:76189770	ACADM	-0.41	-5.02	-0.31	1.02e-6	Daytime sleep phenotypes;
SARC	cis	rs2073300	0.609	rs6137915	chr20:23358509	A/G	cg12062639	chr20:23401060	NAPB	-0.85	-5.89	-0.36	1.31e-8	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs9467773	0.620	rs2504540	chr6:26641626	A/G	cg12292205	chr6:26970375	C6orf41	0.4	4.9	0.31	1.77e-6	Intelligence (multi-trait analysis);
SARC	cis	rs427394	0.664	rs274701	chr5:6728707	C/A	cg10857441	chr5:6722123	POLS	-0.31	-4.75	-0.3	3.52e-6	Menopause (age at onset);
SARC	cis	rs709400	0.663	rs1028613	chr14:103888324	G/A	cg26031613	chr14:104095156	KLC1	0.81	11.42	0.6	2.88e-24	Body mass index;
SARC	cis	rs611744	0.967	rs598022	chr8:109187759	C/T	cg21045802	chr8:109455806	TTC35	0.44	5.3	0.33	2.64e-7	Dupuytren's disease;
SARC	cis	rs1348850	0.914	rs12612857	chr2:178467144	A/G	cg23306229	chr2:178417860	TTC30B	0.55	6.13	0.37	3.69e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs3087591	0.683	rs2525564	chr17:29652531	A/G	cg24425628	chr17:29625626	OMG;NF1	0.44	5.61	0.35	5.64e-8	Hip circumference;
SARC	cis	rs208515	0.525	rs12215007	chr6:66671008	C/T	cg07460842	chr6:66804631	NA	-0.95	-10.93	-0.58	1.04e-22	Exhaled nitric oxide levels;
SARC	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg27286337	chr10:134555280	INPP5A	-0.66	-7.96	-0.46	7.37e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs3018712	0.532	rs2510396	chr11:68417652	G/C	cg01657329	chr11:68192670	LRP5	0.59	5.38	0.33	1.81e-7	Total body bone mineral density;
SARC	cis	rs6539267	1.000	rs6539267	chr12:106785554	T/C	cg00173435	chr12:106696525	TCP11L2	0.48	4.93	0.31	1.53e-6	Tourette syndrome;
SARC	cis	rs13191362	0.935	rs67084568	chr6:162988548	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.57	5.49	0.34	1.03e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	trans	rs79976124	0.837	rs75346757	chr6:66648386	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	7.87	0.46	1.33e-13	Type 2 diabetes;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg13357903	chr1:222790952	MIA3	-0.5	-6.71	-0.4	1.49e-10	Breast cancer;
SARC	cis	rs6752107	0.935	rs11688431	chr2:234147175	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.47	6.17	0.37	2.92e-9	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg05084668	chr3:125655381	ALG1L	-0.47	-5.03	-0.31	9.99e-7	Blood pressure (smoking interaction);
SARC	trans	rs3780486	0.846	rs10813950	chr9:33127640	A/G	cg04842962	chr6:43655489	MRPS18A	-0.99	-15.81	-0.72	9.39e-39	IgG glycosylation;
SARC	cis	rs11578119	1.000	rs12120764	chr1:170514229	G/A	cg09767346	chr1:170501363	GORAB	0.43	5.07	0.32	8.14e-7	Male-pattern baldness;
SARC	cis	rs10463554	0.759	rs461609	chr5:102447305	G/A	cg23492399	chr5:102201601	PAM	-0.51	-5.55	-0.34	7.77e-8	Parkinson's disease;
SARC	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg25894440	chr7:65020034	NA	-0.72	-5.46	-0.34	1.23e-7	Diabetic kidney disease;
SARC	cis	rs8114671	0.935	rs6060282	chr20:33767066	C/T	cg24642439	chr20:33292090	TP53INP2	0.51	5.88	0.36	1.4e-8	Height;
SARC	cis	rs9807841	0.544	rs10407692	chr19:10770783	A/G	cg17710535	chr19:10819994	QTRT1	0.41	4.98	0.31	1.26e-6	Inflammatory skin disease;
SARC	cis	rs9916302	0.904	rs11078897	chr17:37415870	C/T	cg00129232	chr17:37814104	STARD3	-0.59	-7.35	-0.43	3.37e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg15049968	chr18:44337910	ST8SIA5	0.39	6.29	0.38	1.53e-9	Personality dimensions;
SARC	cis	rs11785400	0.793	rs9297969	chr8:143723237	A/G	cg24634471	chr8:143751801	JRK	0.6	7.76	0.45	2.61e-13	Schizophrenia;
SARC	trans	rs9325144	0.555	rs6582576	chr12:38701230	C/T	cg23762105	chr12:34175262	ALG10	0.51	6.54	0.39	3.91e-10	Morning vs. evening chronotype;
SARC	cis	rs17666538	0.792	rs1979174	chr8:592274	C/A	cg23958373	chr8:599963	NA	0.84	6.88	0.41	5.46e-11	IgG glycosylation;
SARC	cis	rs1691799	0.899	rs1168304	chr12:66738667	A/C	cg16791601	chr12:66731901	HELB	-0.71	-10.67	-0.57	6.75e-22	White blood cell count (basophil);
SARC	cis	rs2916247	1.000	rs2920470	chr8:92977484	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.58	-6.0	-0.37	7.48e-9	Intelligence (multi-trait analysis);
SARC	trans	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg21659725	chr3:3221576	CRBN	0.52	6.74	0.4	1.23e-10	Intelligence (multi-trait analysis);
SARC	trans	rs9329221	0.682	rs6982308	chr8:10193772	C/G	cg06636001	chr8:8085503	FLJ10661	-0.68	-9.24	-0.52	1.56e-17	Neuroticism;
SARC	cis	rs1005277	0.522	rs289647	chr10:37968278	A/G	cg25427524	chr10:38739819	LOC399744	-0.5	-7.54	-0.44	1.05e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs11718455	0.960	rs11720974	chr3:43999111	G/C	cg21419209	chr3:44054225	NA	-0.42	-5.24	-0.32	3.61e-7	Coronary artery disease;
SARC	cis	rs72653721	0.877	rs72653723	chr6:10976218	G/A	cg13562911	chr6:11044106	ELOVL2	0.6	6.18	0.38	2.77e-9	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.48	5.75	0.35	2.71e-8	Tonsillectomy;
SARC	cis	rs3796352	1.000	rs34244302	chr3:53102236	C/G	cg15956490	chr3:53032818	SFMBT1	0.91	6.02	0.37	6.66e-9	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg11366901	chr6:160182831	ACAT2	1.02	9.89	0.54	1.79e-19	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.43	-5.44	-0.34	1.34e-7	Blood metabolite levels;
SARC	cis	rs611744	0.647	rs864166	chr8:109249300	C/G	cg21045802	chr8:109455806	TTC35	0.6	7.65	0.45	5.26e-13	Dupuytren's disease;
SARC	cis	rs1008375	0.863	rs7680984	chr4:17600884	A/G	cg27347728	chr4:17578864	LAP3	0.44	5.47	0.34	1.18e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs941408	1.000	rs1736180	chr19:2796021	C/T	cg06609049	chr19:2785107	THOP1	0.76	10.07	0.55	4.79e-20	Total cholesterol levels;
SARC	cis	rs3857067	0.806	rs12507575	chr4:95114920	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.05	-0.31	8.98e-7	QT interval;
SARC	cis	rs7481584	1.000	rs12798150	chr11:3019260	C/T	cg05729581	chr11:3078854	CARS	0.47	5.78	0.35	2.44e-8	Calcium levels;
SARC	cis	rs7084402	0.967	rs1620186	chr10:60314275	G/A	cg07615347	chr10:60278583	BICC1	0.59	8.39	0.48	4.85e-15	Refractive error;
SARC	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg11987759	chr7:65425863	GUSB	0.5	6.5	0.39	4.94e-10	Aortic root size;
SARC	cis	rs959260	0.614	rs930296	chr17:73404168	C/T	cg14668889	chr17:73230827	NUP85	0.47	4.71	0.3	4.19e-6	Systemic lupus erythematosus;
SARC	cis	rs2046867	0.908	rs68142603	chr3:72790220	A/C	cg25664220	chr3:72788482	NA	-0.29	-4.89	-0.3	1.9e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
SARC	trans	rs7752643	0.523	rs676962	chr6:84268501	C/T	cg14512089	chr1:160771850	LY9	0.31	6.44	0.39	6.92e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs17376456	0.877	rs34184666	chr5:93444584	T/C	cg21475434	chr5:93447410	FAM172A	0.86	7.77	0.45	2.57e-13	Diabetic retinopathy;
SARC	cis	rs13191362	0.935	rs34347104	chr6:163055716	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.59	4.99	0.31	1.19e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs7818345	0.967	rs13258090	chr8:19285726	A/G	cg11303988	chr8:19266685	CSGALNACT1	-0.43	-5.83	-0.36	1.81e-8	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs9788682	0.747	rs8043009	chr15:78908154	G/C	cg24631222	chr15:78858424	CHRNA5	0.71	9.65	0.53	9.2e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs11098499	0.863	rs17050695	chr4:120489527	G/T	cg24375607	chr4:120327624	NA	0.4	4.72	0.3	4.02e-6	Corneal astigmatism;
SARC	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg08677398	chr8:58056175	NA	0.44	5.25	0.33	3.38e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs3093024	0.904	rs3093019	chr6:167539655	C/G	cg07741184	chr6:167504864	NA	-0.31	-5.79	-0.35	2.29e-8	Rheumatoid arthritis;
SARC	cis	rs12586317	0.547	rs114371385	chr14:35503724	G/A	cg16230307	chr14:35515116	FAM177A1	1.03	11.88	0.61	9.41e-26	Psoriasis;
SARC	cis	rs644799	1.000	rs546809	chr11:95579938	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	14.87	0.7	1.29e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7264396	0.623	rs761827	chr20:34207897	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-7.25	-0.43	6.02e-12	Total cholesterol levels;
SARC	cis	rs8028182	0.501	rs11072553	chr15:75932777	C/T	cg20655648	chr15:75932815	IMP3	0.68	8.21	0.47	1.54e-14	Sudden cardiac arrest;
SARC	cis	rs56235845	0.694	rs12055081	chr5:176757191	C/T	cg06060754	chr5:176797920	RGS14	0.45	5.92	0.36	1.15e-8	Hemoglobin concentration;Hematocrit;
SARC	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg16606324	chr3:10149918	C3orf24	0.5	5.01	0.31	1.08e-6	Alzheimer's disease;
SARC	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg15448220	chr1:150897856	SETDB1	0.47	6.22	0.38	2.24e-9	Tonsillectomy;
SARC	trans	rs6601450	0.519	rs34906836	chr8:10288992	C/A	cg06636001	chr8:8085503	FLJ10661	0.52	7.05	0.42	2e-11	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs959260	1.000	rs4789186	chr17:73386086	C/T	cg14668889	chr17:73230827	NUP85	-0.44	-4.92	-0.31	1.67e-6	Systemic lupus erythematosus;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg14730097	chr2:233632281	GIGYF2;KCNJ13	0.54	7.74	0.45	3.03e-13	Thyroid stimulating hormone;
SARC	cis	rs4319547	0.698	rs4039670	chr12:122822655	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.59	-6.89	-0.41	5.18e-11	Body mass index;
SARC	cis	rs3806843	0.648	rs702399	chr5:140024432	C/T	cg16577123	chr5:140027231	NDUFA2;IK	-0.44	-5.21	-0.32	4.24e-7	Depressive symptoms (multi-trait analysis);
SARC	cis	rs3106136	0.843	rs1991316	chr4:95268272	G/T	cg11021082	chr4:95130006	SMARCAD1	0.33	5.17	0.32	5.09e-7	Capecitabine sensitivity;
SARC	cis	rs2479724	0.840	rs6925777	chr6:41750822	C/T	cg17623882	chr6:41773611	USP49	0.45	5.72	0.35	3.24e-8	Menarche (age at onset);
SARC	cis	rs7113850	0.541	rs78737372	chr11:24233984	G/A	ch.11.24196551F	chr11:24239977	NA	0.75	5.46	0.34	1.25e-7	Bone fracture in osteoporosis;
SARC	cis	rs9398803	0.865	rs2184968	chr6:126760994	A/G	cg19875578	chr6:126661172	C6orf173	0.56	7.5	0.44	1.3e-12	Male-pattern baldness;
SARC	cis	rs478304	0.627	rs1073602	chr11:65455386	G/C	cg27068330	chr11:65405492	SIPA1	-0.41	-4.75	-0.3	3.58e-6	Acne (severe);
SARC	cis	rs898097	0.812	rs72859941	chr17:80837459	G/A	cg15369054	chr17:80825471	TBCD	0.56	7.89	0.46	1.21e-13	Breast cancer;
SARC	cis	rs56235845	0.694	rs11749830	chr5:176766547	G/A	cg17509989	chr5:176798049	RGS14	0.58	7.78	0.45	2.37e-13	Hemoglobin concentration;Hematocrit;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22541679	chr13:78493666	EDNRB	0.48	6.49	0.39	5.02e-10	Smoking initiation;
SARC	cis	rs7520050	0.966	rs809775	chr1:46538040	A/T	cg06784218	chr1:46089804	CCDC17	-0.26	-4.83	-0.3	2.42e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs76419734	1.000	rs11736834	chr4:106708764	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.8	5.33	0.33	2.27e-7	Post bronchodilator FEV1;
SARC	cis	rs3796352	1.000	rs10510761	chr3:52965255	A/G	cg27565382	chr3:53032988	SFMBT1	-0.88	-6.44	-0.39	6.81e-10	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg17971929	chr21:40555470	PSMG1	0.99	13.51	0.66	4.14e-31	Cognitive function;
SARC	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg22800045	chr5:56110881	MAP3K1	0.76	8.02	0.47	5.09e-14	Initial pursuit acceleration;
SARC	cis	rs7429990	0.965	rs7426976	chr3:48022573	A/C	cg11946769	chr3:48343235	NME6	-0.45	-5.34	-0.33	2.17e-7	Educational attainment (years of education);
SARC	cis	rs7666738	0.830	rs6831219	chr4:98993576	C/A	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6840360	0.571	rs62327268	chr4:152522326	T/A	cg22705602	chr4:152727874	NA	-0.43	-6.79	-0.41	9.46e-11	Intelligence (multi-trait analysis);
SARC	cis	rs1865760	0.566	rs9358902	chr6:26058570	C/G	cg18357526	chr6:26021779	HIST1H4A	0.44	5.42	0.33	1.47e-7	Height;
SARC	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.95	-13.94	-0.67	1.6e-32	Gut microbiome composition (summer);
SARC	cis	rs7264396	0.887	rs224363	chr20:34062710	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-4.76	-0.3	3.46e-6	Total cholesterol levels;
SARC	cis	rs7412746	0.658	rs7521719	chr1:150913134	G/A	cg15448220	chr1:150897856	SETDB1	0.51	6.65	0.4	2.02e-10	Melanoma;
SARC	cis	rs12545109	0.800	rs2610052	chr8:57411316	C/A	cg21220214	chr8:57350948	NA	-0.41	-4.78	-0.3	3.11e-6	Obesity-related traits;
SARC	cis	rs9818758	0.607	rs9850917	chr3:49286983	A/G	cg07636037	chr3:49044803	WDR6	-0.75	-6.62	-0.4	2.39e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.68	6.83	0.41	7.31e-11	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs7953249	0.656	rs2178463	chr12:121389721	A/G	cg25281562	chr12:121454272	C12orf43	-0.45	-5.47	-0.34	1.17e-7	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs9660992	0.710	rs1668873	chr1:205235990	G/A	cg21545522	chr1:205238299	TMCC2	0.45	6.27	0.38	1.69e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.75	-7.65	-0.45	5.37e-13	Platelet count;
SARC	trans	rs66573146	1.000	rs55913461	chr4:7017509	C/T	cg07817883	chr1:32538562	TMEM39B	1.54	8.97	0.51	9.8e-17	Granulocyte percentage of myeloid white cells;
SARC	cis	rs10463316	0.928	rs10060441	chr5:150750006	A/G	cg03212797	chr5:150827313	SLC36A1	-0.46	-5.73	-0.35	3.13e-8	Metabolite levels (Pyroglutamine);
SARC	cis	rs77956314	0.515	rs12299065	chr12:117442304	A/G	cg16111737	chr12:117408163	FBXW8	-0.48	-6.31	-0.38	1.37e-9	Subcortical brain region volumes;Hippocampal volume;
SARC	cis	rs765787	0.530	rs4775835	chr15:45537553	T/C	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.51e-10	Uric acid levels;
SARC	cis	rs9858542	0.537	rs34915642	chr3:49358646	G/A	cg00383909	chr3:49044727	WDR6	0.51	5.41	0.33	1.53e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg07777115	chr5:623756	CEP72	-0.55	-4.97	-0.31	1.31e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs7589342	0.791	rs4438504	chr2:106461035	A/C	cg16077055	chr2:106428750	NCK2	0.39	7.12	0.42	1.33e-11	Addiction;
SARC	cis	rs3796352	0.881	rs35385050	chr3:52997945	C/A	cg12962167	chr3:53033115	SFMBT1	0.83	5.32	0.33	2.41e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs12421382	0.659	rs11604254	chr11:109392413	G/A	cg27471124	chr11:109292789	C11orf87	0.39	5.36	0.33	2.04e-7	Schizophrenia;
SARC	cis	rs8084125	0.832	rs2156646	chr18:74946660	C/T	cg05528293	chr18:74961138	GALR1	0.44	5.05	0.31	8.81e-7	Obesity-related traits;
SARC	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg05861140	chr6:150128134	PCMT1	-0.37	-4.84	-0.3	2.36e-6	Lung cancer;
SARC	cis	rs3617	0.652	rs60332615	chr3:52867595	C/A	cg04865290	chr3:52927548	TMEM110	0.34	4.93	0.31	1.57e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg07176514	chr1:185126191	C1orf25;C1orf26	-0.83	-7.3	-0.43	4.51e-12	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9325144	0.647	rs11168741	chr12:38989120	C/T	cg13010199	chr12:38710504	ALG10B	-0.51	-6.49	-0.39	5.12e-10	Morning vs. evening chronotype;
SARC	cis	rs7635838	0.684	rs2606750	chr3:11372151	T/C	cg00170343	chr3:11313890	ATG7	0.63	8.54	0.49	1.75e-15	HDL cholesterol;
SARC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg11494091	chr17:61959527	GH2	0.53	7.94	0.46	8.67e-14	Prudent dietary pattern;
SARC	cis	rs908922	0.676	rs528427	chr1:152511507	G/C	cg09873164	chr1:152488093	CRCT1	0.65	8.72	0.5	5.41e-16	Hair morphology;
SARC	cis	rs6701037	1.000	rs6659824	chr1:175125378	C/A	cg00321850	chr1:175162397	KIAA0040	-0.34	-5.02	-0.31	1.03e-6	Alcohol dependence;
SARC	cis	rs8114671	0.527	rs6060112	chr20:33489276	A/T	cg07148914	chr20:33460835	GGT7	0.47	5.78	0.35	2.34e-8	Height;
SARC	cis	rs11758351	1.000	rs79868973	chr6:26189312	C/G	cg01420254	chr6:26195488	NA	0.57	4.79	0.3	2.96e-6	Gout;Renal underexcretion gout;
SARC	cis	rs6723226	0.803	rs176415	chr2:32649778	G/A	cg02381751	chr2:32503542	YIPF4	-0.84	-12.2	-0.62	8.17e-27	Intelligence (multi-trait analysis);
SARC	cis	rs3733585	0.781	rs4292328	chr4:9970962	C/T	cg00071950	chr4:10020882	SLC2A9	-0.4	-6.45	-0.39	6.52e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg12463550	chr7:65579703	CRCP	-0.47	-5.17	-0.32	5.11e-7	Aortic root size;
SARC	cis	rs56330463	1.000	rs56330463	chr5:148200011	T/C	cg21580376	chr5:148206412	ADRB2	0.42	5.7	0.35	3.53e-8	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Monocyte percentage of white cells;Eosinophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;
SARC	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg11987759	chr7:65425863	GUSB	-0.61	-8.35	-0.48	5.95e-15	Aortic root size;
SARC	cis	rs709400	0.593	rs12898029	chr14:103877884	T/C	cg12935359	chr14:103987150	CKB	0.4	5.98	0.36	8.47e-9	Body mass index;
SARC	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6456156	0.565	rs7750209	chr6:167482895	T/G	cg07741184	chr6:167504864	NA	0.36	6.99	0.42	2.83e-11	Primary biliary cholangitis;
SARC	cis	rs782590	0.643	rs13009906	chr2:55739434	A/G	cg18811423	chr2:55921094	PNPT1	-0.59	-7.29	-0.43	4.92e-12	Metabolic syndrome;
SARC	cis	rs35110281	0.693	rs11089093	chr21:45121161	C/T	cg01579765	chr21:45077557	HSF2BP	-0.34	-5.47	-0.34	1.18e-7	Mean corpuscular volume;
SARC	cis	rs910316	0.763	rs175042	chr14:75470833	A/T	cg08847533	chr14:75593920	NEK9	-0.82	-11.57	-0.6	8.93e-25	Height;
SARC	cis	rs941408	0.515	rs7253128	chr19:2776982	C/T	cg06609049	chr19:2785107	THOP1	0.96	14.73	0.69	3.9e-35	Total cholesterol levels;
SARC	cis	rs8084125	0.832	rs62105178	chr18:74950635	C/T	cg07390210	chr18:74961196	GALR1	0.55	6.3	0.38	1.5e-9	Obesity-related traits;
SARC	cis	rs7607369	0.719	rs12613545	chr2:219623504	C/T	cg02176678	chr2:219576539	TTLL4	-0.32	-4.88	-0.3	1.93e-6	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs1569175	0.510	rs55852473	chr2:200709099	T/C	cg23649088	chr2:200775458	C2orf69	-0.74	-5.33	-0.33	2.34e-7	Response to treatment for acute lymphoblastic leukemia;
SARC	cis	rs1707322	0.752	rs11211152	chr1:46114157	C/T	cg03146154	chr1:46216737	IPP	0.52	6.25	0.38	1.92e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs57506017	0.585	rs2302633	chr7:12270815	C/T	cg23422036	chr7:12250390	TMEM106B	0.45	5.87	0.36	1.49e-8	Neuroticism;
SARC	cis	rs78487399	0.808	rs7556744	chr2:43672795	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.58	5.1	0.32	7.09e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs986417	0.681	rs1254329	chr14:60912870	G/A	cg27398547	chr14:60952738	C14orf39	-1.04	-9.78	-0.54	3.77e-19	Gut microbiota (bacterial taxa);
SARC	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg20102877	chr2:27665638	KRTCAP3	-0.39	-5.41	-0.33	1.54e-7	Total body bone mineral density;
SARC	cis	rs9916302	0.904	rs8079303	chr17:37530755	G/C	cg07936489	chr17:37558343	FBXL20	0.69	9.22	0.52	1.85e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs950776	0.593	rs621849	chr15:78872861	G/A	cg17108064	chr15:78857060	CHRNA5	-0.29	-4.97	-0.31	1.32e-6	Sudden cardiac arrest;
SARC	cis	rs6690583	0.623	rs7540706	chr1:85534645	A/G	cg22153463	chr1:85462885	MCOLN2	-0.68	-5.5	-0.34	1.02e-7	Serum sulfate level;
SARC	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg23758822	chr17:41437982	NA	0.91	11.54	0.6	1.16e-24	Menopause (age at onset);
SARC	cis	rs9398803	0.723	rs853981	chr6:127045460	C/T	cg19875578	chr6:126661172	C6orf173	-0.64	-8.82	-0.5	2.75e-16	Male-pattern baldness;
SARC	cis	rs7954584	0.560	rs745327	chr12:122456524	T/C	cg21171335	chr12:122356390	WDR66	-0.36	-5.14	-0.32	5.85e-7	Mean corpuscular volume;
SARC	cis	rs12142240	0.738	rs17361749	chr1:46806480	C/T	cg10495392	chr1:46806563	NSUN4	0.65	6.9	0.41	4.99e-11	Menopause (age at onset);
SARC	cis	rs4906332	1.000	rs10459573	chr14:103925457	A/C	cg26031613	chr14:104095156	KLC1	-0.49	-5.74	-0.35	2.88e-8	Coronary artery disease;
SARC	cis	rs9612	1.000	rs16976747	chr19:44238152	G/A	cg08581076	chr19:44259116	C19orf61	0.72	9.16	0.51	2.69e-17	Exhaled nitric oxide output;
SARC	trans	rs1910358	0.554	rs10057796	chr5:23759746	C/T	cg04655596	chr16:15248905	NA	0.54	6.32	0.38	1.31e-9	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs9814567	0.752	rs13098546	chr3:134333161	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.51	6.59	0.4	2.94e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs4268898	0.571	rs1986478	chr2:24468545	G/A	cg06627628	chr2:24431161	ITSN2	-0.81	-9.82	-0.54	2.85e-19	Asthma;
SARC	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg19671926	chr4:122722719	EXOSC9	-0.53	-6.09	-0.37	4.7e-9	Type 2 diabetes;
SARC	cis	rs10512697	0.803	rs36036519	chr5:3579493	G/A	cg19473799	chr5:3511975	NA	-0.63	-4.8	-0.3	2.84e-6	Immune response to smallpox vaccine (IL-6);
SARC	trans	rs208520	1.000	rs12193164	chr6:66978962	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.83	9.35	0.52	7.46e-18	Exhaled nitric oxide output;
SARC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg05863683	chr7:1912471	MAD1L1	0.36	5.4	0.33	1.63e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.44	0.53	4.08e-18	Prudent dietary pattern;
SARC	cis	rs9916302	0.861	rs7503514	chr17:37669884	G/C	cg00129232	chr17:37814104	STARD3	-0.65	-8.01	-0.46	5.61e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg12310025	chr6:25882481	NA	0.46	5.79	0.35	2.32e-8	Intelligence (multi-trait analysis);
SARC	cis	rs6938	0.534	rs11854704	chr15:75221015	C/T	cg17294928	chr15:75287854	SCAMP5	0.47	5.98	0.36	8.36e-9	Breast cancer;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg26030974	chr17:45266791	CDC27	0.5	6.48	0.39	5.55e-10	Chemerin levels;
SARC	cis	rs3820928	0.874	rs1917127	chr2:227895125	A/G	cg11843606	chr2:227700838	RHBDD1	-0.55	-6.84	-0.41	6.88e-11	Pulmonary function;
SARC	cis	rs2204008	0.807	rs8186948	chr12:38325101	C/G	cg26384229	chr12:38710491	ALG10B	0.87	12.62	0.64	3.71e-28	Bladder cancer;
SARC	cis	rs12594515	1.000	rs8029209	chr15:45993489	A/G	cg14863074	chr15:45997064	NA	0.35	5.31	0.33	2.58e-7	Waist circumference;Weight;
SARC	cis	rs950776	0.752	rs62010328	chr15:78894971	C/T	cg22563815	chr15:78856949	CHRNA5	0.34	5.29	0.33	2.84e-7	Sudden cardiac arrest;
SARC	cis	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg08045932	chr20:61659980	NA	0.49	6.67	0.4	1.84e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs10992471	0.603	rs10114912	chr9:95307863	C/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.45	-0.34	1.25e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs6088580	0.634	rs6088484	chr20:32985961	T/C	cg24642439	chr20:33292090	TP53INP2	-0.65	-8.43	-0.48	3.55e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs763121	0.853	rs3788544	chr22:39064966	C/T	cg14440974	chr22:39074834	NA	-0.33	-4.89	-0.3	1.92e-6	Menopause (age at onset);
SARC	cis	rs1008375	0.933	rs6449324	chr4:17694880	G/C	cg16339924	chr4:17578868	LAP3	0.55	6.96	0.42	3.35e-11	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6867032	1.000	rs2129471	chr5:2016236	C/G	cg26168224	chr5:2018326	NA	0.92	14.86	0.7	1.4e-35	Gut microbiome composition (winter);
SARC	cis	rs883565	0.542	rs6802490	chr3:39033907	T/A	cg01426195	chr3:39028469	NA	-0.35	-5.06	-0.31	8.37e-7	Handedness;
SARC	cis	rs4803468	0.967	rs7259900	chr19:41889429	A/T	cg09537434	chr19:41945824	ATP5SL	-0.93	-16.03	-0.72	1.78e-39	Height;
SARC	cis	rs4919087	0.748	rs701813	chr10:98975632	C/T	cg25902810	chr10:99078978	FRAT1	-0.54	-6.11	-0.37	4.04e-9	Monocyte count;
SARC	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg13206674	chr6:150067644	NUP43	0.39	5.18	0.32	4.91e-7	Lung cancer;
SARC	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg13699009	chr12:122356056	WDR66	0.69	11.5	0.6	1.53e-24	Mean corpuscular volume;
SARC	cis	rs9486719	1.000	rs13208422	chr6:96892119	C/T	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.01	-0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs7937682	0.883	rs1784776	chr11:111472392	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.87	-13.26	-0.66	2.92e-30	Primary sclerosing cholangitis;
SARC	cis	rs6484504	0.625	rs796341	chr11:31414151	G/A	cg02090638	chr11:31391270	DNAJC24;DCDC1	0.38	4.75	0.3	3.54e-6	Red blood cell count;
SARC	cis	rs6446731	0.636	rs2157091	chr4:3273099	G/A	cg06533319	chr4:3265114	C4orf44	-0.33	-5.36	-0.33	1.97e-7	Mean platelet volume;
SARC	cis	rs34779708	0.897	rs9787566	chr10:35279455	T/A	cg03585969	chr10:35415529	CREM	0.41	5.03	0.31	9.77e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs1843834	0.929	rs4674934	chr2:225516468	A/T	cg22509189	chr2:225307070	NA	0.49	6.47	0.39	5.68e-10	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs710216	0.957	rs841570	chr1:43435571	C/G	cg07803811	chr1:43423981	SLC2A1	0.51	5.0	0.31	1.13e-6	Red cell distribution width;
SARC	cis	rs6060717	0.536	rs6060666	chr20:34478954	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	5.16	0.32	5.29e-7	Hip circumference adjusted for BMI;
SARC	cis	rs7582720	0.943	rs72932575	chr2:203866857	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	7.36	0.43	3.09e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs2731664	0.792	rs335467	chr5:176890642	A/G	cg23176889	chr5:176863531	GRK6	-0.56	-8.31	-0.48	7.88e-15	Intelligence (multi-trait analysis);
SARC	cis	rs4555082	0.645	rs2816605	chr14:105715515	C/T	cg06808227	chr14:105710500	BRF1	-0.52	-6.51	-0.39	4.45e-10	Mean platelet volume;Platelet distribution width;
SARC	cis	rs1018697	0.518	rs284843	chr10:104553566	C/T	cg04362960	chr10:104952993	NT5C2	-0.52	-5.33	-0.33	2.37e-7	Colorectal adenoma (advanced);
SARC	cis	rs881375	0.678	rs10818488	chr9:123705087	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	6.25	0.38	1.97e-9	Rheumatoid arthritis;
SARC	cis	rs662064	0.852	rs2056417	chr1:10581658	G/A	cg01551238	chr1:11548576	PTCHD2	-0.36	-4.74	-0.3	3.8e-6	Asthma;
SARC	cis	rs11734570	0.581	rs4401459	chr4:38585268	G/T	cg18361445	chr4:38666374	KLF3;FLJ13197	-0.59	-6.93	-0.41	4.1e-11	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs11650494	0.516	rs13341862	chr17:47494203	A/G	cg08112188	chr17:47440006	ZNF652	-0.68	-6.56	-0.39	3.53e-10	Prostate cancer;
SARC	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.46	-5.87	-0.36	1.47e-8	Tonsillectomy;
SARC	cis	rs950169	0.887	rs35986397	chr15:84955107	G/A	cg17507749	chr15:85114479	UBE2QP1	0.78	9.63	0.53	1.06e-18	Schizophrenia;
SARC	trans	rs7937682	0.889	rs493865	chr11:111495178	A/C	cg18187862	chr3:45730750	SACM1L	0.58	7.27	0.43	5.53e-12	Primary sclerosing cholangitis;
SARC	cis	rs8044995	0.563	rs61746794	chr16:68387457	C/T	cg09835421	chr16:68378352	PRMT7	-0.69	-6.53	-0.39	4.17e-10	Schizophrenia;
SARC	cis	rs13256369	0.951	rs13270852	chr8:8566853	A/G	cg17143192	chr8:8559678	CLDN23	0.54	6.21	0.38	2.35e-9	Obesity-related traits;
SARC	cis	rs55823223	0.564	rs936396	chr17:73846829	C/G	cg14829360	chr17:73884958	NA	-0.59	-7.94	-0.46	8.3e-14	Psoriasis;
SARC	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	9.08	0.51	4.67e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs3796352	0.764	rs11714902	chr3:53101544	G/C	cg15956490	chr3:53032818	SFMBT1	0.88	6.07	0.37	5.25e-9	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg21782813	chr7:2030301	MAD1L1	0.37	5.75	0.35	2.72e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg03060546	chr3:49711283	APEH	0.47	6.13	0.37	3.7e-9	Menarche (age at onset);
SARC	cis	rs7223966	1.000	rs8081541	chr17:61812483	C/T	cg00588841	chr17:61851480	DDX42;CCDC47	-0.68	-7.6	-0.45	7.42e-13	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg04277193	chr17:41438351	NA	0.45	4.84	0.3	2.41e-6	Menopause (age at onset);
SARC	cis	rs6088590	1.000	rs6088590	chr20:33313566	T/C	cg08999081	chr20:33150536	PIGU	0.34	4.83	0.3	2.51e-6	Coronary artery disease;
SARC	cis	rs7666738	0.830	rs28451001	chr4:98924544	T/A	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs12048904	0.619	rs10875347	chr1:101333737	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.69	7.58	0.44	8.02e-13	Multiple sclerosis;
SARC	cis	rs12155623	1.000	rs12155623	chr8:49812201	A/T	cg22283653	chr8:49824208	NA	-0.38	-5.35	-0.33	2.14e-7	Sudden cardiac arrest;
SARC	cis	rs3771570	1.000	rs56383420	chr2:242219281	A/G	cg21155796	chr2:242212141	HDLBP	0.72	6.27	0.38	1.77e-9	Prostate cancer;
SARC	cis	rs9325144	0.647	rs7316392	chr12:39064381	T/G	cg26384229	chr12:38710491	ALG10B	-0.62	-8.02	-0.46	5.22e-14	Morning vs. evening chronotype;
SARC	cis	rs6604026	0.644	rs12069727	chr1:93399060	A/C	cg17283838	chr1:93427260	FAM69A	0.41	4.77	0.3	3.25e-6	Multiple sclerosis;
SARC	cis	rs1920116	0.744	rs12492658	chr3:169562083	C/T	cg08193579	chr3:169529701	LRRC34	0.39	4.72	0.3	3.98e-6	Glioma (high-grade);
SARC	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg00933542	chr6:150070202	PCMT1	0.34	5.83	0.36	1.83e-8	Lung cancer;
SARC	cis	rs6582630	0.502	rs1589390	chr12:38416139	C/T	cg13010199	chr12:38710504	ALG10B	-0.48	-5.86	-0.36	1.59e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs3733585	0.699	rs7676733	chr4:9966956	G/A	cg11266682	chr4:10021025	SLC2A9	-0.37	-6.48	-0.39	5.28e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7666738	0.830	rs11941961	chr4:99065654	G/T	cg05340658	chr4:99064831	C4orf37	0.63	8.4	0.48	4.4e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs12754538	0.739	rs2131679	chr1:8811768	G/A	cg13785123	chr1:8931135	ENO1	-0.51	-6.08	-0.37	4.8e-9	Subjective well-being;
SARC	cis	rs477692	1.000	rs477692	chr10:131426022	T/C	cg26102564	chr10:131424627	MGMT	0.29	4.72	0.3	4.09e-6	Response to temozolomide;
SARC	cis	rs936229	0.954	rs936230	chr15:75145098	C/T	cg10253484	chr15:75165896	SCAMP2	0.46	5.09	0.32	7.26e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg11952622	chr19:58962976	ZNF324B	0.53	6.99	0.42	2.82e-11	Uric acid clearance;
SARC	cis	rs16976116	0.951	rs6493768	chr15:55484294	T/A	cg11288833	chr15:55489084	RSL24D1	0.62	6.05	0.37	5.78e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2013441	0.965	rs2703790	chr17:20163209	G/A	cg13482628	chr17:19912719	NA	-0.47	-6.18	-0.38	2.87e-9	Obesity-related traits;
SARC	cis	rs1050631	0.592	rs1785927	chr18:33726447	C/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.55	6.41	0.39	8.08e-10	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg23758822	chr17:41437982	NA	0.88	11.59	0.6	8.03e-25	Menopause (age at onset);
SARC	cis	rs1707322	1.000	rs4073847	chr1:46463012	A/C	cg06784218	chr1:46089804	CCDC17	-0.34	-5.76	-0.35	2.67e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2197308	0.765	rs11182992	chr12:37935572	G/C	cg13010199	chr12:38710504	ALG10B	0.8	11.14	0.59	2.24e-23	Morning vs. evening chronotype;
SARC	cis	rs4243830	0.850	rs3761927	chr1:6601773	T/C	cg04093404	chr1:6614507	TAS1R1;NOL9	0.56	4.94	0.31	1.52e-6	Body mass index;
SARC	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg24829409	chr8:58192753	C8orf71	-0.62	-6.41	-0.39	8.1e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs11608355	0.552	rs2304549	chr12:109794875	A/G	cg05360138	chr12:110035743	NA	0.44	5.21	0.32	4.07e-7	Neuroticism;
SARC	cis	rs554111	0.634	rs1453265	chr1:21277711	C/T	cg08890418	chr1:21044141	KIF17	-0.34	-4.79	-0.3	2.99e-6	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs6788895	0.661	rs16862837	chr3:150469858	A/C	cg09723797	chr3:150481914	SIAH2	-0.74	-4.97	-0.31	1.28e-6	Breast cancer;
SARC	cis	rs17401966	0.838	rs7553935	chr1:10375179	G/A	cg15208524	chr1:10270712	KIF1B	0.5	5.91	0.36	1.23e-8	Hepatocellular carcinoma;
SARC	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg00149659	chr3:10157352	C3orf10	0.68	6.38	0.39	9.46e-10	Alzheimer's disease;
SARC	cis	rs9715521	0.691	rs60007977	chr4:59847637	T/C	cg11281224	chr4:60001000	NA	-0.4	-5.11	-0.32	6.65e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7829975	0.682	rs7013471	chr8:8687325	A/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.29	-0.43	4.84e-12	Mood instability;
SARC	cis	rs1018836	0.923	rs4734269	chr8:91635474	G/C	cg16814680	chr8:91681699	NA	-0.82	-13.45	-0.66	6.75e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs3815700	1.000	rs8100168	chr19:33093084	G/A	cg02997394	chr19:33096574	ANKRD27	0.73	6.45	0.39	6.5e-10	Eosinophilic esophagitis;
SARC	cis	rs35146811	0.844	rs34031156	chr7:99677917	T/A	cg22004693	chr7:99632812	ZKSCAN1	-0.45	-5.03	-0.31	9.69e-7	Coronary artery disease;
SARC	cis	rs4727027	0.737	rs10278971	chr7:148780659	A/T	cg23583168	chr7:148888333	NA	-0.72	-9.9	-0.54	1.59e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs7792596	1.000	rs7792596	chr7:94009634	T/C	cg20814616	chr7:94014465	NA	-0.44	-5.43	-0.33	1.44e-7	Intelligence;
SARC	cis	rs10779751	0.770	rs6701524	chr1:11198502	A/G	cg08854313	chr1:11322531	MTOR	-0.77	-10.17	-0.55	2.49e-20	Body mass index;
SARC	cis	rs7666738	0.830	rs6818045	chr4:99049374	G/A	cg05340658	chr4:99064831	C4orf37	0.66	8.87	0.5	1.91e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7644634	0.531	rs9883858	chr3:105383953	G/A	cg23051926	chr3:105466016	CBLB	0.47	5.4	0.33	1.68e-7	Itch intensity from mosquito bite;
SARC	cis	rs57221529	0.766	rs28563961	chr5:554498	C/G	cg09021430	chr5:549028	NA	-0.41	-5.2	-0.32	4.33e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs6003958	1	rs6003958	chr22:24264089	T/G	cg20007245	chr22:24372913	LOC391322	0.68	7.63	0.45	5.82e-13	S-phenylmercapturic acid levels in smokers;
SARC	cis	rs7560272	0.549	rs2421554	chr2:73806202	A/T	cg20560298	chr2:73613845	ALMS1	-0.47	-6.37	-0.39	1.01e-9	Schizophrenia;
SARC	cis	rs8114671	0.836	rs6141526	chr20:33615255	G/T	cg07148914	chr20:33460835	GGT7	-0.41	-4.75	-0.3	3.59e-6	Height;
SARC	cis	rs2425143	1.000	rs56904633	chr20:34400757	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-6.36	-0.38	1.06e-9	Blood protein levels;
SARC	cis	rs72781680	0.851	rs12612830	chr2:24134599	C/T	cg08917208	chr2:24149416	ATAD2B	0.79	7.64	0.45	5.66e-13	Lymphocyte counts;
SARC	cis	rs2952156	0.959	rs2941504	chr17:37830900	A/G	cg20243544	chr17:37824526	PNMT	0.5	6.32	0.38	1.29e-9	Asthma;
SARC	cis	rs2777491	0.957	rs3743038	chr15:41694743	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.83	-12.56	-0.64	5.5e-28	Ulcerative colitis;
SARC	cis	rs12477438	1.000	rs995617	chr2:99857904	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.85	10.13	0.55	3.21e-20	Chronic sinus infection;
SARC	cis	rs7621025	0.691	rs4678438	chr3:136344920	A/C	cg15507776	chr3:136538369	TMEM22	0.42	4.75	0.3	3.53e-6	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
SARC	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg22920501	chr2:26401640	FAM59B	-0.59	-7.55	-0.44	9.68e-13	Gut microbiome composition (summer);
SARC	cis	rs1707322	1.000	rs10890376	chr1:46406582	C/T	cg03146154	chr1:46216737	IPP	0.5	6.05	0.37	5.66e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs877282	1.000	rs12219807	chr10:772870	A/C	cg22713356	chr15:30763199	NA	1.04	10.32	0.56	8.5e-21	Uric acid levels;
SARC	cis	rs17030434	0.953	rs6535953	chr4:154728186	G/A	cg14289246	chr4:154710475	SFRP2	-0.78	-8.0	-0.46	5.94e-14	Electrocardiographic conduction measures;
SARC	cis	rs9457247	1.000	rs430293	chr6:167404958	A/G	cg23791538	chr6:167370224	RNASET2	-0.63	-8.74	-0.5	4.69e-16	Crohn's disease;
SARC	cis	rs3816788	0.792	rs729180	chr8:21817245	C/T	cg17168535	chr8:21777572	XPO7	0.86	13.54	0.66	3.37e-31	Lung cancer in ever smokers;
SARC	cis	rs7568458	0.684	rs7608074	chr2:85809703	T/G	cg02493740	chr2:85810744	VAMP5	-0.41	-5.08	-0.32	7.85e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs3808502	0.503	rs34190028	chr8:11417150	G/T	cg21775007	chr8:11205619	TDH	-0.43	-5.45	-0.34	1.29e-7	Neuroticism;
SARC	cis	rs3820928	0.874	rs4234064	chr2:227857497	G/T	cg05526886	chr2:227700861	RHBDD1	-0.51	-6.04	-0.37	6.12e-9	Pulmonary function;
SARC	cis	rs10927875	0.596	rs1806990	chr1:16129377	G/A	cg07117364	chr1:16154769	NA	-0.42	-4.89	-0.31	1.86e-6	Dilated cardiomyopathy;
SARC	cis	rs1943345	0.642	rs11233500	chr11:82881407	C/T	cg07047830	chr11:82868014	PCF11	-0.61	-7.96	-0.46	7.42e-14	Obesity-related traits;
SARC	cis	rs6582630	0.599	rs4882313	chr12:38454011	G/A	cg26384229	chr12:38710491	ALG10B	-0.55	-6.87	-0.41	5.84e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs17270561	0.583	rs9393661	chr6:25739080	C/T	cg16482183	chr6:26056742	HIST1H1C	0.43	5.22	0.32	3.92e-7	Iron status biomarkers;
SARC	cis	rs941873	0.868	rs1483733	chr10:81130036	A/G	cg09469691	chr10:81107165	PPIF	0.59	8.27	0.48	1e-14	Height;
SARC	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg22920501	chr2:26401640	FAM59B	-0.55	-7.03	-0.42	2.29e-11	Gut microbiome composition (summer);
SARC	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg18876405	chr7:65276391	NA	-0.46	-5.64	-0.35	4.87e-8	Aortic root size;
SARC	cis	rs6752107	0.967	rs11694081	chr2:234148586	A/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.47	6.17	0.37	2.92e-9	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs6058796	0.892	rs66897337	chr20:31256593	T/C	cg13636640	chr20:31349939	DNMT3B	0.56	4.94	0.31	1.48e-6	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.68	7.5	0.44	1.3e-12	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs7833790	0.553	rs9693128	chr8:82706128	A/G	cg27398817	chr8:82754497	SNX16	-0.53	-7.05	-0.42	2.01e-11	Diastolic blood pressure;
SARC	cis	rs644799	0.625	rs1255175	chr11:95471186	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.67	8.97	0.51	9.75e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7917772	0.536	rs4919667	chr10:104426011	A/G	cg22532475	chr10:104410764	TRIM8	0.26	5.11	0.32	6.62e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg23172400	chr8:95962367	TP53INP1	-0.35	-5.98	-0.36	8.44e-9	Type 2 diabetes;
SARC	cis	rs4595586	0.545	rs3858554	chr12:39381460	C/T	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.39	1.01e-9	Morning vs. evening chronotype;
SARC	cis	rs1355223	0.902	rs7130325	chr11:34750959	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-5.65	-0.35	4.73e-8	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs478304	0.593	rs4645927	chr11:65482827	C/T	cg27068330	chr11:65405492	SIPA1	-0.42	-4.88	-0.3	1.94e-6	Acne (severe);
SARC	trans	rs61931739	0.817	rs7963318	chr12:34244929	C/G	cg26384229	chr12:38710491	ALG10B	-0.53	-7.36	-0.43	3.06e-12	Morning vs. evening chronotype;
SARC	cis	rs240764	0.853	rs2062635	chr6:101002659	G/A	cg09795085	chr6:101329169	ASCC3	-0.46	-6.07	-0.37	5.12e-9	Neuroticism;
SARC	trans	rs1814175	0.585	rs4881661	chr11:50000117	A/G	cg15704280	chr7:45808275	SEPT13	-0.9	-14.33	-0.68	7.84e-34	Height;
SARC	cis	rs7681440	0.606	rs2619359	chr4:90754828	A/C	cg06632027	chr4:90757378	SNCA	-0.44	-5.44	-0.34	1.32e-7	Dementia with Lewy bodies;
SARC	cis	rs9354352	0.935	rs9345749	chr6:66699892	G/T	cg07460842	chr6:66804631	NA	-0.54	-7.34	-0.43	3.51e-12	Initial pursuit acceleration in psychotic disorders;
SARC	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg22496380	chr5:211416	CCDC127	-0.88	-9.35	-0.52	7.72e-18	Breast cancer;
SARC	cis	rs17376456	0.825	rs10053405	chr5:93275403	A/G	cg25358565	chr5:93447407	FAM172A	-1.34	-13.41	-0.66	8.78e-31	Diabetic retinopathy;
SARC	cis	rs6088590	1.000	rs910870	chr20:33292893	T/C	cg24642439	chr20:33292090	TP53INP2	0.82	11.82	0.61	1.4e-25	Coronary artery disease;
SARC	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg04944784	chr2:26401820	FAM59B	-0.47	-5.91	-0.36	1.18e-8	Gut microbiome composition (summer);
SARC	cis	rs7520050	0.966	rs1707304	chr1:46598269	C/A	cg06784218	chr1:46089804	CCDC17	-0.27	-4.85	-0.3	2.27e-6	Red blood cell count;Reticulocyte count;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg27627570	chr9:131183239	CERCAM	0.48	6.6	0.4	2.76e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs732765	1.000	rs709888	chr14:75369346	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.45	-5.26	-0.33	3.31e-7	Non-small cell lung cancer;
SARC	cis	rs34779708	0.931	rs6481935	chr10:35342959	C/T	cg03585969	chr10:35415529	CREM	0.38	4.79	0.3	3e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs765787	0.530	rs12440238	chr15:45512905	T/C	cg21132104	chr15:45694354	SPATA5L1	0.4	4.87	0.3	2.09e-6	Uric acid levels;
SARC	cis	rs11122272	0.735	rs2355873	chr1:231477442	A/G	cg06096015	chr1:231504339	EGLN1	0.39	5.93	0.36	1.11e-8	Hemoglobin concentration;
SARC	cis	rs9303401	0.614	rs3887355	chr17:56538639	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.05	11.4	0.6	3.25e-24	Cognitive test performance;
SARC	cis	rs6088580	0.634	rs6058051	chr20:33044862	G/A	cg08999081	chr20:33150536	PIGU	0.44	6.73	0.4	1.3100000000000001e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs1662342	1.000	rs16944555	chr18:3252130	T/C	cg14211874	chr18:3262499	MYL12B	-0.72	-5.41	-0.33	1.56e-7	QRS duration;
SARC	cis	rs6542838	0.646	rs17756034	chr2:99382810	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-5.16	-0.32	5.29e-7	Fear of minor pain;
SARC	cis	rs7590720	0.851	rs13006614	chr2:216876204	C/T	cg12620499	chr2:216877984	MREG	0.7	10.59	0.57	1.16e-21	Alcohol dependence;
SARC	trans	rs3774749	0.565	rs2518796	chr3:50207075	A/G	cg21659725	chr3:3221576	CRBN	0.49	6.41	0.39	7.8e-10	Intelligence (multi-trait analysis);
SARC	cis	rs4555082	0.957	rs10140586	chr14:105749582	A/G	cg10792982	chr14:105748885	BRF1	0.5	7.81	0.46	1.95e-13	Mean platelet volume;Platelet distribution width;
SARC	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	5.75	0.35	2.73e-8	Bipolar disorder;
SARC	cis	rs17600642	0.724	rs7478009	chr10:72453146	C/T	cg19779893	chr10:72451501	ADAMTS14	-0.37	-5.74	-0.35	2.89e-8	Bipolar disorder;
SARC	cis	rs116095464	0.558	rs9312957	chr5:202194	C/T	cg22857025	chr5:266934	NA	-1.15	-10.73	-0.58	4.38e-22	Breast cancer;
SARC	cis	rs4660306	1.000	rs10736426	chr1:45984353	A/G	cg24296786	chr1:45957014	TESK2	-0.53	-6.43	-0.39	6.96e-10	Homocysteine levels;
SARC	cis	rs11122272	0.735	rs2491407	chr1:231518928	G/A	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs7647973	0.626	rs11720705	chr3:49753788	A/G	cg07636037	chr3:49044803	WDR6	0.59	6.09	0.37	4.71e-9	Menarche (age at onset);
SARC	cis	rs4803468	1.000	rs878082	chr19:41897674	G/A	cg09537434	chr19:41945824	ATP5SL	-0.94	-16.3	-0.73	2.25e-40	Height;
SARC	cis	rs9303401	0.659	rs16943176	chr17:56769887	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	12.31	0.63	3.57e-27	Cognitive test performance;
SARC	cis	rs72781680	1.000	rs72781667	chr2:24225667	A/G	cg08917208	chr2:24149416	ATAD2B	0.85	8.26	0.48	1.06e-14	Lymphocyte counts;
SARC	cis	rs13006833	0.739	rs172366	chr2:191191233	G/T	cg25963032	chr2:191064776	C2orf88	0.36	5.01	0.31	1.1e-6	Urinary metabolites;
SARC	cis	rs73086581	1.000	rs56069856	chr20:3965709	A/C	cg02187196	chr20:3869020	PANK2	0.67	6.43	0.39	7.22e-10	Response to antidepressants in depression;
SARC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.08	0.37	4.93e-9	Prudent dietary pattern;
SARC	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.4	-5.05	-0.31	8.95e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9400467	0.537	rs12214886	chr6:111500081	C/T	cg15721981	chr6:111408429	SLC16A10	0.62	4.8	0.3	2.86e-6	Blood metabolite levels;Amino acid levels;
SARC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg13397359	chr6:42928475	GNMT	0.49	6.87	0.41	5.75e-11	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg11987759	chr7:65425863	GUSB	0.44	5.93	0.36	1.07e-8	Aortic root size;
SARC	cis	rs2916247	0.954	rs1126063	chr8:93120861	C/T	cg10183463	chr8:93005414	RUNX1T1	0.57	5.87	0.36	1.52e-8	Intelligence (multi-trait analysis);
SARC	cis	rs1801251	0.963	rs66549961	chr2:233602293	A/G	cg25237894	chr2:233734115	C2orf82	0.38	5.03	0.31	9.93e-7	Coronary artery disease;
SARC	trans	rs2727020	0.558	rs1164675	chr11:49325972	C/T	cg03929089	chr4:120376271	NA	0.72	10.27	0.56	1.19e-20	Coronary artery disease;
SARC	cis	rs11155671	0.530	rs9397398	chr6:150193603	G/A	cg09217309	chr6:150244204	RAET1G	0.41	5.12	0.32	6.45e-7	Testicular germ cell tumor;
SARC	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg17376030	chr22:41985996	PMM1	-0.72	-8.36	-0.48	5.85e-15	Vitiligo;
SARC	cis	rs2985684	0.894	rs7152110	chr14:50018218	T/C	cg04989706	chr14:50066350	PPIL5	-0.51	-5.57	-0.34	7.08e-8	Carotid intima media thickness;
SARC	cis	rs7582720	1.000	rs72932574	chr2:203866336	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	7.18	0.43	9.12e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg01765077	chr12:122356316	WDR66	0.32	4.97	0.31	1.32e-6	Mean corpuscular volume;
SARC	cis	rs698833	0.638	rs698785	chr2:44744389	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	6.27	0.38	1.78e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs9916302	0.904	rs801419	chr17:37466327	A/G	cg20243544	chr17:37824526	PNMT	-0.58	-7.17	-0.43	9.77e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs2070488	0.775	rs7644530	chr3:38558316	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.77	-11.41	-0.6	3.02e-24	Electrocardiographic conduction measures;
SARC	cis	rs526231	0.543	rs7709726	chr5:102327463	A/G	cg23492399	chr5:102201601	PAM	0.46	5.52	0.34	8.93e-8	Primary biliary cholangitis;
SARC	cis	rs7113874	0.545	rs2084187	chr11:8536941	G/C	cg09828998	chr11:8703972	RPL27A	0.5	5.45	0.34	1.31e-7	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg14893161	chr1:205819251	PM20D1	1.03	21.32	0.81	1.16e-56	Menarche (age at onset);
SARC	cis	rs6456156	0.792	rs2039321	chr6:167516299	C/T	cg23791538	chr6:167370224	RNASET2	-0.41	-5.2	-0.32	4.3e-7	Primary biliary cholangitis;
SARC	cis	rs2200578	1.000	rs116648076	chr2:99882347	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	0.67	6.57	0.4	3.25e-10	IgG glycosylation;
SARC	cis	rs17666538	0.591	rs2878547	chr8:603416	G/A	cg07234876	chr8:600039	NA	0.72	6.14	0.37	3.46e-9	IgG glycosylation;
SARC	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.62	7.45	0.44	1.8e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6866344	0.697	rs62392833	chr5:178135452	T/A	cg03877680	chr5:178157825	ZNF354A	1.03	12.65	0.64	2.88e-28	Neutrophil percentage of white cells;
SARC	cis	rs4780401	0.728	rs8191335	chr16:11771353	C/A	cg01061890	chr16:11836724	TXNDC11	-0.46	-5.86	-0.36	1.53e-8	Rheumatoid arthritis;
SARC	cis	rs1707322	1.000	rs10890380	chr1:46449469	A/G	cg03146154	chr1:46216737	IPP	0.45	5.41	0.33	1.57e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7539409	0.651	rs979757	chr1:84296605	T/C	cg10977910	chr1:84465055	TTLL7	0.52	4.83	0.3	2.5e-6	Alzheimer's disease;
SARC	cis	rs2228479	0.850	rs12598316	chr16:89916600	C/A	cg06558623	chr16:89946397	TCF25	0.93	6.61	0.4	2.59e-10	Skin colour saturation;
SARC	cis	rs1163251	0.837	rs660073	chr1:120245173	T/C	cg19096424	chr1:120255104	PHGDH	0.59	6.95	0.41	3.61e-11	Blood metabolite levels;
SARC	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg17376030	chr22:41985996	PMM1	-0.67	-8.74	-0.5	4.72e-16	Vitiligo;
SARC	cis	rs2191566	0.960	rs6509133	chr19:44522913	A/G	cg20607764	chr19:44506953	ZNF230	0.48	5.64	0.35	4.8e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs1348850	0.914	rs3813259	chr2:178257214	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.72	9.24	0.52	1.63e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7216064	1.000	rs12452511	chr17:65832576	A/G	cg12091567	chr17:66097778	LOC651250	-0.68	-6.83	-0.41	7.32e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg06872176	chr1:68697386	GPR177	-0.58	-6.71	-0.4	1.43e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs933688	0.536	rs332537	chr5:90794973	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.73	-6.27	-0.38	1.69e-9	Smoking behavior;
SARC	cis	rs2153535	0.580	rs5001324	chr6:8451604	A/T	cg07606381	chr6:8435919	SLC35B3	0.78	11.11	0.59	2.68e-23	Motion sickness;
SARC	cis	rs78487399	0.808	rs114563746	chr2:43760880	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-4.81	-0.3	2.67e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs4713118	0.591	rs2056924	chr6:27690174	G/A	cg17221315	chr6:27791827	HIST1H4J	0.4	4.92	0.31	1.67e-6	Parkinson's disease;
SARC	cis	rs9611565	0.921	rs2143695	chr22:41728620	A/G	cg17376030	chr22:41985996	PMM1	0.52	6.5	0.39	4.9e-10	Vitiligo;
SARC	cis	rs959260	0.614	rs8065441	chr17:73410447	C/G	cg00200289	chr17:73401734	GRB2	-0.58	-5.33	-0.33	2.27e-7	Systemic lupus erythematosus;
SARC	cis	rs10046574	0.561	rs17403528	chr7:135195531	C/T	cg27474649	chr7:135195673	CNOT4	0.83	7.67	0.45	4.56e-13	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs79149102	0.522	rs8023786	chr15:74822496	C/A	cg09165964	chr15:75287851	SCAMP5	-0.65	-5.12	-0.32	6.35e-7	Lung cancer;
SARC	cis	rs13040088	1.000	rs13040088	chr20:61549202	A/G	cg23096297	chr20:61557774	DIDO1	0.95	10.12	0.55	3.55e-20	Menopause (age at onset);
SARC	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg19077165	chr18:44547161	KATNAL2	-0.48	-6.53	-0.39	4.07e-10	Personality dimensions;
SARC	cis	rs17253792	0.822	rs74968702	chr14:56076818	A/T	cg01858014	chr14:56050164	KTN1	-0.69	-5.36	-0.33	2.02e-7	Putamen volume;
SARC	cis	rs34311866	0.808	rs11248060	chr4:964359	C/T	cg07828340	chr4:882639	GAK	0.71	5.48	0.34	1.12e-7	Parkinson's disease;
SARC	cis	rs7772486	0.875	rs1331639	chr6:146431869	A/G	cg05347473	chr6:146136440	FBXO30	-0.47	-6.45	-0.39	6.41e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs8078723	0.546	rs8067817	chr17:38163936	C/T	cg17467752	chr17:38218738	THRA	0.44	5.92	0.36	1.17e-8	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.82	12.52	0.63	7.89e-28	Personality dimensions;
SARC	trans	rs1814175	0.645	rs28436748	chr11:50046422	G/A	cg15704280	chr7:45808275	SEPT13	-0.91	-14.49	-0.69	2.43e-34	Height;
SARC	cis	rs7666738	0.830	rs9998582	chr4:98938949	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2077654	0.822	rs4148634	chr11:17429872	G/A	cg25308976	chr11:17434268	ABCC8	0.56	6.47	0.39	5.76e-10	Gout;
SARC	cis	rs11718455	0.960	rs11920021	chr3:44000856	T/C	cg21419209	chr3:44054225	NA	-0.41	-4.93	-0.31	1.55e-6	Coronary artery disease;
SARC	cis	rs17401966	0.931	rs12408430	chr1:10323339	T/A	cg15208524	chr1:10270712	KIF1B	0.48	5.62	0.35	5.38e-8	Hepatocellular carcinoma;
SARC	cis	rs981844	0.683	rs1037653	chr4:154749992	A/T	cg14289246	chr4:154710475	SFRP2	-0.45	-5.36	-0.33	1.96e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs4727027	0.704	rs12704083	chr7:148909759	G/A	cg23583168	chr7:148888333	NA	-0.81	-12.16	-0.62	1.12e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs6570726	0.846	rs4896824	chr6:145927048	C/T	cg05347473	chr6:146136440	FBXO30	0.5	6.85	0.41	6.71e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs144345632	1	rs144345632	chr6:96886894	T/TA	cg06623918	chr6:96969491	KIAA0776	-0.73	-7.79	-0.45	2.18e-13	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs67311347	0.544	rs9864664	chr3:40336226	T/C	cg09455208	chr3:40491958	NA	0.3	4.92	0.31	1.66e-6	Renal cell carcinoma;
SARC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg26338869	chr17:61819248	STRADA	0.81	10.89	0.58	1.38e-22	Prudent dietary pattern;
SARC	cis	rs7223966	1.000	rs11658175	chr17:61923838	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	7.39	0.44	2.54e-12	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs78487399	0.808	rs17030998	chr2:43758199	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-4.78	-0.3	3.06e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.92	9.25	0.52	1.46e-17	Platelet count;
SARC	cis	rs644799	0.930	rs2186782	chr11:95649543	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.61	7.71	0.45	3.64e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs72781680	0.821	rs116583405	chr2:24208221	T/C	cg06627628	chr2:24431161	ITSN2	-0.57	-6.12	-0.37	4.04e-9	Lymphocyte counts;
SARC	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg23172400	chr8:95962367	TP53INP1	-0.28	-4.89	-0.31	1.84e-6	Type 2 diabetes;
SARC	cis	rs11191205	0.865	rs11191161	chr10:103726528	C/T	cg15320455	chr10:103880129	LDB1	-0.83	-8.44	-0.48	3.49e-15	Intelligence (multi-trait analysis);
SARC	cis	rs2304069	0.837	rs10041451	chr5:149385197	A/C	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.69	6.68	0.4	1.78e-10	HIV-1 control;
SARC	cis	rs7043114	0.563	rs10820986	chr9:95312961	T/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-5.92	-0.36	1.16e-8	Height;
SARC	cis	rs11608355	0.846	rs12581637	chr12:109855429	G/A	cg05360138	chr12:110035743	NA	0.59	6.31	0.38	1.38e-9	Neuroticism;
SARC	cis	rs6831352	0.918	rs29001224	chr4:100047373	G/A	cg13256891	chr4:100009986	ADH5	-0.66	-8.28	-0.48	9.71e-15	Alcohol dependence;
SARC	cis	rs6759839	0.698	rs10856785	chr2:16650175	C/T	cg09580478	chr2:16689509	NA	0.49	6.54	0.39	3.76e-10	Mean platelet volume;
SARC	cis	rs6088590	1.000	rs6120705	chr20:33313740	T/C	cg06115741	chr20:33292138	TP53INP2	0.57	6.91	0.41	4.71e-11	Coronary artery disease;
SARC	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg05368731	chr17:41323189	NBR1	0.78	9.55	0.53	1.92e-18	Menopause (age at onset);
SARC	cis	rs2997447	0.744	rs2997442	chr1:26403530	T/G	cg19633962	chr1:26362018	EXTL1	-0.55	-5.17	-0.32	4.97e-7	QRS complex (12-leadsum);
SARC	cis	rs3784262	0.740	rs4646600	chr15:58295616	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.33	-4.8	-0.3	2.87e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs7086627	0.515	rs12245180	chr10:82211897	C/G	cg00277334	chr10:82204260	NA	-0.57	-9.42	-0.53	4.63e-18	Post bronchodilator FEV1;
SARC	cis	rs3733585	0.699	rs28837683	chr4:9959808	C/T	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.35	-0.33	2.06e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg22508957	chr16:3507546	NAT15	0.4	5.99	0.37	7.74e-9	Tuberculosis;
SARC	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.5	0.39	4.82e-10	Height;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg26405148	chr3:12525763	TSEN2	0.51	6.55	0.39	3.64e-10	Lung adenocarcinoma;
SARC	cis	rs9911578	0.967	rs6503893	chr17:57149695	G/A	cg12560992	chr17:57184187	TRIM37	0.87	12.54	0.63	6.5e-28	Intelligence (multi-trait analysis);
SARC	cis	rs3540	0.512	rs3862437	chr15:91084632	A/G	cg22089800	chr15:90895588	ZNF774	-0.59	-7.37	-0.44	2.87e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs1559088	0.847	rs2287680	chr19:33608566	A/G	cg17764715	chr19:33622953	WDR88	-0.48	-6.55	-0.39	3.6e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs9527	0.590	rs12355120	chr10:104852166	T/G	cg04362960	chr10:104952993	NT5C2	0.43	5.14	0.32	5.76e-7	Arsenic metabolism;
SARC	cis	rs6674176	0.660	rs6680421	chr1:44408969	A/C	cg12908607	chr1:44402522	ARTN	0.41	7.1	0.42	1.5e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs6450176	0.625	rs35027270	chr5:53289068	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.86	-10.05	-0.55	5.8e-20	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs1538970	1.000	rs1538970	chr1:45847562	G/A	cg05343316	chr1:45956843	TESK2	0.68	7.88	0.46	1.23e-13	Platelet count;
SARC	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg11952622	chr19:58962976	ZNF324B	0.57	7.55	0.44	9.95e-13	Uric acid clearance;
SARC	cis	rs3870371	1.000	rs4327433	chr8:122694160	C/T	cg21781600	chr8:122651575	HAS2;HAS2AS	0.48	5.5	0.34	9.97e-8	Periodontal disease-related phenotypes;
SARC	cis	rs3820928	0.874	rs13383070	chr2:227904939	C/T	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.83	-0.36	1.81e-8	Pulmonary function;
SARC	cis	rs9811216	1.000	rs9860874	chr3:169486271	C/A	cg14222479	chr3:169487675	ARPM1	0.44	5.29	0.33	2.86e-7	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs12911832	0.701	rs452698	chr15:59105571	A/G	cg05156742	chr15:59063176	FAM63B	0.83	12.74	0.64	1.47e-28	Schizophrenia;
SARC	cis	rs1153858	1.000	rs12594857	chr15:45667178	A/G	cg26924012	chr15:45694286	SPATA5L1	0.79	11.28	0.59	7.91e-24	Homoarginine levels;
SARC	cis	rs73206853	0.841	rs11829321	chr12:110864593	C/G	cg10860002	chr12:110842031	ANAPC7	0.6	4.75	0.3	3.61e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs9462027	0.651	rs34493158	chr6:34753339	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.79	-0.35	2.22e-8	Systemic lupus erythematosus;
SARC	cis	rs4586057	0.514	rs7089472	chr10:92663108	C/T	cg14313238	chr10:92632228	RPP30	0.41	5.17	0.32	5.11e-7	Economic and political preferences (time);
SARC	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg03351412	chr1:154909251	PMVK	-0.6	-7.71	-0.45	3.68e-13	Prostate cancer;
SARC	cis	rs763121	0.815	rs9306328	chr22:39028913	C/T	cg06022373	chr22:39101656	GTPBP1	0.79	9.96	0.55	1.03e-19	Menopause (age at onset);
SARC	cis	rs2439831	0.850	rs16963953	chr15:44081719	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.95	8.43	0.48	3.73e-15	Lung cancer in ever smokers;
SARC	cis	rs826838	0.868	rs864324	chr12:39122853	A/G	cg13010199	chr12:38710504	ALG10B	0.6	8.11	0.47	2.9e-14	Heart rate;
SARC	cis	rs1728785	0.688	rs7203363	chr16:68587692	T/A	cg02972257	chr16:68554789	NA	-0.45	-5.32	-0.33	2.48e-7	Ulcerative colitis;
SARC	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg04317338	chr11:64019027	PLCB3	0.82	8.84	0.5	2.47e-16	Mean platelet volume;
SARC	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	8.72	0.5	5.17e-16	Alzheimer's disease;
SARC	cis	rs6542838	0.641	rs883773	chr2:99491635	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-5.82	-0.36	1.92e-8	Fear of minor pain;
SARC	cis	rs7927771	0.832	rs935914	chr11:47387599	C/T	cg20307385	chr11:47447363	PSMC3	0.54	6.81	0.41	8.36e-11	Subjective well-being;
SARC	cis	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.75	-0.45	2.91e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs7824557	0.767	rs718427	chr8:11139038	C/G	cg21775007	chr8:11205619	TDH	0.52	5.96	0.36	9.37e-9	Retinal vascular caliber;
SARC	cis	rs1728785	1.000	rs889561	chr16:68605741	G/A	cg02972257	chr16:68554789	NA	-0.5	-5.86	-0.36	1.53e-8	Ulcerative colitis;
SARC	cis	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg25427524	chr10:38739819	LOC399744	-0.53	-8.46	-0.48	2.95e-15	Extrinsic epigenetic age acceleration;
SARC	cis	rs72945132	0.941	rs66803755	chr11:70117473	G/A	cg00319359	chr11:70116639	PPFIA1	0.7	6.71	0.4	1.46e-10	Coronary artery disease;
SARC	cis	rs7712401	0.601	rs431878	chr5:122261791	G/T	cg19412675	chr5:122181750	SNX24	-0.4	-5.12	-0.32	6.25e-7	Mean platelet volume;
SARC	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg20965017	chr5:231967	SDHA	-0.57	-5.57	-0.34	7.12e-8	Breast cancer;
SARC	trans	rs6076960	0.684	rs3852949	chr20:6264758	T/A	cg21095983	chr6:86352623	SYNCRIP	0.46	6.59	0.4	2.93e-10	Smooth-surface caries;
SARC	cis	rs79839061	0.610	rs11248051	chr4:858332	C/T	cg07828340	chr4:882639	GAK	0.77	5.84	0.36	1.75e-8	Intelligence (multi-trait analysis);
SARC	cis	rs1964356	0.967	rs17701675	chr8:8850633	A/G	cg08975724	chr8:8085496	FLJ10661	-0.39	-4.73	-0.3	3.94e-6	Mean corpuscular volume;
SARC	trans	rs9951602	0.512	rs9949512	chr18:76641845	T/C	cg02800362	chr5:177631904	HNRNPAB	0.68	8.61	0.49	1.13e-15	Obesity-related traits;
SARC	cis	rs6582630	0.519	rs1851130	chr12:38507819	C/T	cg13010199	chr12:38710504	ALG10B	0.75	10.23	0.56	1.61e-20	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs739401	0.611	rs417957	chr11:3046231	A/G	cg05729581	chr11:3078854	CARS	-0.49	-6.48	-0.39	5.51e-10	Longevity;
SARC	cis	rs9640161	0.673	rs34489187	chr7:150044379	G/A	cg21361702	chr7:150065534	REPIN1	0.51	5.24	0.32	3.63e-7	Blood protein levels;Circulating chemerin levels;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg27400282	chr2:201446673	SGOL2	0.51	7.34	0.43	3.6e-12	Thyroid stimulating hormone;
SARC	cis	rs9811216	1.000	rs1920123	chr3:169506173	C/T	cg14222479	chr3:169487675	ARPM1	0.42	5.22	0.32	4.03e-7	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs2250402	0.510	rs2291621	chr15:40324837	C/T	cg16127683	chr15:40268777	EIF2AK4	-0.57	-4.98	-0.31	1.25e-6	Corneal curvature;
SARC	cis	rs8068544	0.748	rs75881902	chr17:40156612	C/A	cg26502583	chr17:39992600	KLHL10;NT5C3L	-0.87	-6.46	-0.39	6.07e-10	Reticulocyte fraction of red cells;Reticulocyte count;
SARC	cis	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg20362242	chr5:692897	TPPP	0.53	4.73	0.3	3.87e-6	Obesity-related traits;
SARC	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.64	-6.88	-0.41	5.59e-11	Platelet count;
SARC	cis	rs155076	1.000	rs58519241	chr13:21845006	C/A	cg06138931	chr13:21896616	NA	-0.39	-5.08	-0.32	7.88e-7	White matter hyperintensity burden;
SARC	cis	rs35110281	0.837	rs7279968	chr21:45077398	C/G	cg01579765	chr21:45077557	HSF2BP	-0.32	-5.5	-0.34	1.01e-7	Mean corpuscular volume;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg09602577	chr11:124669905	C11orf61	0.52	7.01	0.42	2.56e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg25703541	chr22:24373054	LOC391322	-0.81	-10.99	-0.58	6.7e-23	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7296418	0.961	rs10848428	chr12:123572495	C/T	cg16085171	chr12:123569118	PITPNM2	-0.39	-5.01	-0.31	1.07e-6	Platelet count;
SARC	cis	rs7772486	0.754	rs4896839	chr6:146019689	T/G	cg05347473	chr6:146136440	FBXO30	-0.56	-7.8	-0.46	2.07e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7589342	0.899	rs879900	chr2:106494347	A/G	cg14210321	chr2:106509881	NCK2	-0.5	-5.94	-0.36	1.01e-8	Addiction;
SARC	cis	rs2153535	0.580	rs1414348	chr6:8471940	A/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg13699009	chr12:122356056	WDR66	0.62	10.0	0.55	8.26e-20	Mean corpuscular volume;
SARC	cis	rs7561149	0.528	rs10497523	chr2:179652802	A/G	cg17765952	chr2:179737173	CCDC141	-0.36	-4.93	-0.31	1.55e-6	QT interval;
SARC	cis	rs2486288	0.656	rs11637920	chr15:45550905	T/C	cg15395560	chr15:45543142	SLC28A2	0.29	5.63	0.35	5.17e-8	Glomerular filtration rate;
SARC	cis	rs4243830	0.850	rs932112	chr1:6591937	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.89	-9.19	-0.52	2.24e-17	Body mass index;
SARC	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	27.47	0.87	5.12e-75	Chronic sinus infection;
SARC	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg16479474	chr6:28041457	NA	0.36	5.45	0.34	1.25e-7	Depression;
SARC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg23034840	chr1:205782522	SLC41A1	-0.7	-10.45	-0.57	3.2e-21	Monocyte percentage of white cells;
SARC	cis	rs965469	0.779	rs6133031	chr20:3300857	A/C	cg25506879	chr20:3388711	C20orf194	-0.45	-4.96	-0.31	1.37e-6	IFN-related cytopenia;
SARC	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg21724239	chr8:58056113	NA	0.68	6.4	0.39	8.64e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs698813	0.674	rs11678787	chr2:44496315	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	5.91	0.36	1.22e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs1943345	1.000	rs1943345	chr11:82876270	G/T	cg07047830	chr11:82868014	PCF11	-0.58	-7.69	-0.45	4.11e-13	Obesity-related traits;
SARC	cis	rs12479064	0.724	rs2309618	chr2:99974473	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.46	-5.27	-0.33	3.07e-7	Chronic sinus infection;
SARC	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg06028808	chr11:68637592	NA	0.4	5.05	0.31	8.83e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs137603	1.000	rs137604	chr22:39694594	C/G	cg01093212	chr22:39715156	SNORD43;RPL3	-0.39	-4.73	-0.3	3.96e-6	Primary biliary cholangitis;
SARC	cis	rs7412746	0.587	rs11204722	chr1:150730184	A/C	cg13175981	chr1:150552382	MCL1	0.52	6.39	0.39	8.86e-10	Melanoma;
SARC	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg08677398	chr8:58056175	NA	0.42	5.07	0.32	8.07e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2153535	0.623	rs6597338	chr6:8533508	A/C	cg21535247	chr6:8435926	SLC35B3	0.51	6.48	0.39	5.5e-10	Motion sickness;
SARC	cis	rs7582180	0.764	rs1530028	chr2:100927910	A/C	cg14675211	chr2:100938903	LONRF2	0.52	7.62	0.45	6.2800000000000005e-13	Intelligence (multi-trait analysis);
SARC	trans	rs17221829	0.733	rs11018668	chr11:89356178	C/T	cg21336547	chr19:15490553	AKAP8	0.45	6.42	0.39	7.56e-10	Anxiety in major depressive disorder;
SARC	cis	rs922107	0.713	rs2061479	chr1:90044165	A/C	cg15422784	chr1:90023713	LRRC8B	-0.32	-4.82	-0.3	2.59e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
SARC	cis	rs854765	0.547	rs2955385	chr17:17939247	C/T	cg05444541	chr17:17804740	TOM1L2	-0.29	-4.78	-0.3	3.12e-6	Total body bone mineral density;
SARC	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg06558623	chr16:89946397	TCF25	0.67	5.59	0.34	6.48e-8	Skin colour saturation;
SARC	cis	rs6500602	0.727	rs6500607	chr16:4503631	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.36	6.06	0.37	5.35e-9	Schizophrenia;
SARC	cis	rs6545883	0.929	rs2593626	chr2:61665184	C/A	cg15711740	chr2:61764176	XPO1	-0.42	-5.19	-0.32	4.65e-7	Tuberculosis;
SARC	cis	rs76419734	1.000	rs72671873	chr4:106661194	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.84	5.41	0.33	1.59e-7	Post bronchodilator FEV1;
SARC	cis	rs9398803	0.687	rs4629706	chr6:126888331	A/T	cg19875578	chr6:126661172	C6orf173	0.63	8.71	0.5	5.59e-16	Male-pattern baldness;
SARC	cis	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg03213289	chr20:61660250	NA	-0.5	-6.68	-0.4	1.73e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs35955747	0.902	rs5997932	chr22:31668154	C/G	cg13145458	chr22:31556086	RNF185	0.4	4.91	0.31	1.73e-6	Neutrophil count;Sum basophil neutrophil counts;
SARC	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg00149659	chr3:10157352	C3orf10	0.57	5.05	0.31	9e-7	Alzheimer's disease;
SARC	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs16976116	0.619	rs10518801	chr15:55468617	G/A	cg17854078	chr15:55489399	RSL24D1	0.6	5.19	0.32	4.57e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs11997175	0.574	rs10954931	chr8:33631066	A/T	ch.8.33884649F	chr8:33765107	NA	0.51	6.75	0.4	1.17e-10	Body mass index;
SARC	cis	rs7408868	1.000	rs7247835	chr19:15262844	A/G	cg14696996	chr19:15285081	NOTCH3	1.06	8.56	0.49	1.56e-15	Pulse pressure;
SARC	cis	rs796364	0.951	rs12463436	chr2:201061962	C/G	cg23649088	chr2:200775458	C2orf69	0.65	7.23	0.43	7.02e-12	Schizophrenia;
SARC	cis	rs2354432	0.556	rs2353975	chr1:146837703	C/A	cg25205988	chr1:146714368	CHD1L	0.96	7.07	0.42	1.81e-11	Mitochondrial DNA levels;
SARC	cis	rs4727027	0.834	rs7811446	chr7:148773226	G/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.47	5.75	0.35	2.76e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs3741798	1.000	rs61922045	chr12:12494394	A/C	cg08615371	chr12:12503544	MANSC1	0.69	5.5	0.34	9.79e-8	Cerebrospinal fluid biomarker levels;
SARC	cis	rs2130604	1.000	rs2130604	chr6:126820561	T/G	cg19875578	chr6:126661172	C6orf173	0.47	5.23	0.32	3.74e-7	Bone mineral density (paediatric, skull);
SARC	cis	rs13088645	0.532	rs12695612	chr3:134161824	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.43	5.2	0.32	4.46e-7	Coronary artery disease;
SARC	cis	rs7000551	0.689	rs6997299	chr8:22324268	T/C	cg12081754	chr8:22256438	SLC39A14	0.58	8.29	0.48	8.98e-15	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs9443189	0.737	rs2842553	chr6:76456632	A/T	cg01950844	chr6:76311363	SENP6	-0.8	-7.15	-0.42	1.1e-11	Prostate cancer;
SARC	cis	rs8054556	0.787	rs12325539	chr16:30033633	T/C	cg06015834	chr16:30021696	DOC2A	-0.37	-4.96	-0.31	1.36e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs12497850	1.000	rs4858798	chr3:48727112	C/T	cg06212747	chr3:49208901	KLHDC8B	0.68	9.01	0.51	7.61e-17	Parkinson's disease;
SARC	cis	rs9302635	0.513	rs7198572	chr16:72183220	G/A	cg01557791	chr16:72042693	DHODH	-0.53	-5.37	-0.33	1.93e-7	Blood protein levels;
SARC	trans	rs3780486	0.757	rs10813949	chr9:33123464	G/A	cg04842962	chr6:43655489	MRPS18A	1.09	20.79	0.81	5.31e-55	IgG glycosylation;
SARC	cis	rs3936840	0.565	rs8006911	chr14:102975265	A/G	cg18135206	chr14:102964638	TECPR2	0.41	4.89	0.31	1.87e-6	Plateletcrit;
SARC	cis	rs763121	0.853	rs5757181	chr22:39013522	G/A	cg06022373	chr22:39101656	GTPBP1	0.88	10.94	0.58	9.12e-23	Menopause (age at onset);
SARC	cis	rs208520	0.690	rs12213928	chr6:66762978	G/A	cg07460842	chr6:66804631	NA	1.08	14.49	0.69	2.31e-34	Exhaled nitric oxide output;
SARC	cis	rs9303280	0.806	rs10445308	chr17:37938047	C/T	cg00129232	chr17:37814104	STARD3	-0.38	-4.92	-0.31	1.65e-6	Self-reported allergy;
SARC	cis	rs916888	0.610	rs199452	chr17:44801340	C/T	cg15921436	chr17:44337874	NA	0.47	5.52	0.34	8.99e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9457247	0.663	rs2301436	chr6:167437988	C/T	cg07741184	chr6:167504864	NA	0.36	6.99	0.42	2.81e-11	Crohn's disease;
SARC	cis	rs10078	0.515	rs2672739	chr5:443447	A/C	cg08916839	chr5:415575	AHRR	0.77	7.43	0.44	2.01e-12	Fat distribution (HIV);
SARC	cis	rs11630290	0.592	rs11634436	chr15:64158394	T/G	cg12036633	chr15:63758958	NA	0.5	5.27	0.33	3.14e-7	Iris characteristics;
SARC	cis	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg11266682	chr4:10021025	SLC2A9	0.41	7.32	0.43	3.99e-12	Bone mineral density;
SARC	cis	rs9603616	0.719	rs7999758	chr13:40236601	G/A	cg06101725	chr13:40230077	COG6	0.41	4.76	0.3	3.38e-6	Rheumatoid arthritis;
SARC	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg11987759	chr7:65425863	GUSB	0.49	6.04	0.37	6.17e-9	Aortic root size;
SARC	cis	rs55871839	0.643	rs10105665	chr8:59799367	A/G	cg07426533	chr8:59803705	TOX	-0.41	-5.35	-0.33	2.09e-7	Pneumonia;
SARC	cis	rs2180341	0.782	rs6912552	chr6:127722946	C/G	cg24812749	chr6:127587940	RNF146	-0.79	-10.19	-0.56	2.07e-20	Breast cancer;
SARC	trans	rs877282	0.947	rs4133015	chr10:774131	T/C	cg22713356	chr15:30763199	NA	0.98	10.09	0.55	4.29e-20	Uric acid levels;
SARC	cis	rs9902453	0.716	rs3098949	chr17:27978694	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	6.96	0.42	3.34e-11	Coffee consumption (cups per day);
SARC	cis	rs35110281	0.600	rs914198	chr21:45117456	A/C	cg04455712	chr21:45112962	RRP1B	0.35	4.89	0.31	1.88e-6	Mean corpuscular volume;
SARC	cis	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg22857025	chr5:266934	NA	-1.04	-11.62	-0.61	6.46e-25	Breast cancer;
SARC	cis	rs8058578	1.000	rs8058578	chr16:30726248	C/T	cg00531865	chr16:30841666	NA	-0.5	-5.67	-0.35	4.14e-8	Multiple myeloma;
SARC	trans	rs459571	0.959	rs408307	chr9:136892523	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	0.57	6.38	0.39	9.48e-10	Platelet distribution width;
SARC	cis	rs459571	0.629	rs441233	chr9:136876021	A/G	cg13789015	chr9:136890014	NCRNA00094	-0.46	-6.18	-0.38	2.88e-9	Platelet distribution width;
SARC	cis	rs73635312	0.850	rs406991	chr10:8930198	G/C	cg24467326	chr10:9646929	NA	-0.59	-5.05	-0.31	8.79e-7	Basal cell carcinoma;
SARC	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	11.73	0.61	2.91e-25	Alzheimer's disease;
SARC	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.46	5.39	0.33	1.7e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg11766577	chr21:47581405	C21orf56	-0.46	-5.54	-0.34	8.12e-8	Testicular germ cell tumor;
SARC	cis	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg12257692	chr3:49977190	RBM6	-0.27	-4.71	-0.3	4.18e-6	Body mass index;
SARC	cis	rs6142102	0.961	rs4911392	chr20:32570518	G/C	cg24642439	chr20:33292090	TP53INP2	0.44	4.81	0.3	2.69e-6	Skin pigmentation;
SARC	cis	rs763121	0.853	rs2281020	chr22:39064406	A/G	cg14440974	chr22:39074834	NA	-0.34	-5.07	-0.32	8.19e-7	Menopause (age at onset);
SARC	cis	rs7712401	0.601	rs442427	chr5:122322265	T/C	cg19412675	chr5:122181750	SNX24	-0.42	-5.41	-0.33	1.56e-7	Mean platelet volume;
SARC	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg22857025	chr5:266934	NA	-1.06	-11.8	-0.61	1.74e-25	Breast cancer;
SARC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.62	0.53	1.18e-18	Prudent dietary pattern;
SARC	cis	rs7149337	0.805	rs3007164	chr14:51646935	A/G	cg23942311	chr14:51606299	NA	0.37	6.71	0.4	1.47e-10	Cancer;
SARC	cis	rs6847149	0.929	rs4698798	chr4:110792629	C/T	cg07850274	chr4:110748770	RRH	-0.46	-5.35	-0.33	2.12e-7	Exercise treadmill test traits;
SARC	cis	rs2282802	0.651	rs13353827	chr5:139654537	T/C	cg26211634	chr5:139558579	C5orf32	0.37	4.84	0.3	2.38e-6	Intelligence (multi-trait analysis);
SARC	trans	rs9427116	0.502	rs12125166	chr1:154582129	A/G	cg17218495	chr19:11071743	SMARCA4	-0.5	-6.25	-0.38	1.98e-9	Blood protein levels;
SARC	cis	rs7647973	0.626	rs1463728	chr3:49647404	T/A	cg03060546	chr3:49711283	APEH	0.73	6.79	0.41	9.31e-11	Menarche (age at onset);
SARC	cis	rs2576037	0.901	rs6507719	chr18:44581310	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.49	6.51	0.39	4.56e-10	Personality dimensions;
SARC	cis	rs12681288	0.550	rs6989880	chr8:957209	A/G	cg15309053	chr8:964076	NA	0.47	7.82	0.46	1.82e-13	Schizophrenia;
SARC	cis	rs910316	0.967	rs175479	chr14:75561871	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.56	-8.13	-0.47	2.5e-14	Height;
SARC	cis	rs6087990	0.669	rs2424929	chr20:31389518	A/G	cg13636640	chr20:31349939	DNMT3B	0.77	12.01	0.62	3.49e-26	Ulcerative colitis;
SARC	trans	rs1546939	0.576	rs17490751	chr14:26666540	A/T	cg12167564	chr1:236047034	NA	0.41	6.36	0.38	1.03e-9	Mammographic density (non-dense area);
SARC	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg13012494	chr21:47604986	C21orf56	0.42	4.95	0.31	1.44e-6	Testicular germ cell tumor;
SARC	cis	rs11112613	0.713	rs11112589	chr12:105951226	C/G	cg03607813	chr12:105948248	NA	-0.51	-7.28	-0.43	5.04e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs10979	0.964	rs9496682	chr6:143898805	A/G	cg25407410	chr6:143891975	LOC285740	-0.63	-8.49	-0.49	2.43e-15	Hypospadias;
SARC	cis	rs4481887	0.893	rs4275482	chr1:248473506	T/C	cg01631408	chr1:248437212	OR2T33	-0.38	-4.92	-0.31	1.67e-6	Common traits (Other);
SARC	cis	rs9467773	0.595	rs2451736	chr6:26620544	G/A	cg11502198	chr6:26597334	ABT1	0.62	8.48	0.49	2.55e-15	Intelligence (multi-trait analysis);
SARC	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg06697600	chr4:7070879	GRPEL1	-0.38	-4.85	-0.3	2.21e-6	Monocyte percentage of white cells;
SARC	cis	rs9457247	1.000	rs415890	chr6:167406633	C/G	cg23791538	chr6:167370224	RNASET2	0.63	8.79	0.5	3.26e-16	Crohn's disease;
SARC	cis	rs2839186	0.508	rs12626873	chr21:47714848	G/T	cg09417038	chr21:47716443	C21orf57	-0.33	-4.78	-0.3	3.16e-6	Testicular germ cell tumor;
SARC	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg21442419	chr1:2182373	SKI	-0.39	-4.99	-0.31	1.16e-6	Height;
SARC	cis	rs2370759	1.000	rs11599522	chr10:32568434	G/C	cg18270830	chr10:32634957	EPC1	0.65	5.82	0.36	1.98e-8	Sexual dysfunction (female);
SARC	cis	rs1150668	0.830	rs2859365	chr6:28391465	C/T	cg13525197	chr6:28411240	ZSCAN23	0.42	5.08	0.32	7.7300000000000005e-07	Pubertal anthropometrics;
SARC	cis	rs995000	0.931	rs11207986	chr1:63018170	T/C	cg06896770	chr1:63153194	DOCK7	-0.9	-13.26	-0.66	2.87e-30	Triglyceride levels;
SARC	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.52	-5.94	-0.36	1.04e-8	Blood metabolite levels;
SARC	cis	rs9902453	0.765	rs2617883	chr17:28120488	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.19	-0.43	8.87e-12	Coffee consumption (cups per day);
SARC	cis	rs10189230	0.674	rs2710506	chr2:222379489	A/C	cg14652038	chr2:222343519	EPHA4	0.37	4.93	0.31	1.59e-6	Urate levels in lean individuals;
SARC	cis	rs2836974	0.545	rs8128901	chr21:40710419	G/A	cg17971929	chr21:40555470	PSMG1	0.64	8.33	0.48	6.81e-15	Cognitive function;
SARC	cis	rs644799	1.000	rs525404	chr11:95566520	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	15.04	0.7	3.37e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg12463550	chr7:65579703	CRCP	0.44	5.27	0.33	3.12e-7	Aortic root size;
SARC	cis	rs17023223	0.537	rs17023185	chr1:119610787	C/T	cg05756136	chr1:119680316	WARS2	-0.48	-5.49	-0.34	1.06e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs8077889	0.719	rs57227660	chr17:41858984	T/C	cg26893861	chr17:41843967	DUSP3	1.01	16.71	0.74	9.81e-42	Triglycerides;
SARC	cis	rs9399135	0.967	rs9389258	chr6:135361140	T/C	cg24558204	chr6:135376177	HBS1L	0.46	6.13	0.37	3.66e-9	Red blood cell count;
SARC	cis	rs611744	0.934	rs1452021	chr8:109207886	A/G	cg21045802	chr8:109455806	TTC35	0.44	5.23	0.32	3.81e-7	Dupuytren's disease;
SARC	cis	rs6088580	0.505	rs6058106	chr20:33278255	T/C	cg08999081	chr20:33150536	PIGU	-0.34	-4.95	-0.31	1.41e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs7474896	0.559	rs10740949	chr10:37978435	A/G	cg25427524	chr10:38739819	LOC399744	-0.42	-4.82	-0.3	2.61e-6	Obesity (extreme);
SARC	cis	rs826838	0.933	rs1906263	chr12:38653362	T/C	cg13010199	chr12:38710504	ALG10B	0.82	11.79	0.61	1.74e-25	Heart rate;
SARC	trans	rs61931739	0.517	rs12816423	chr12:34067736	G/A	cg26384229	chr12:38710491	ALG10B	0.87	12.36	0.63	2.53e-27	Morning vs. evening chronotype;
SARC	cis	rs908922	0.742	rs499913	chr1:152476743	T/A	cg09873164	chr1:152488093	CRCT1	0.68	7.82	0.46	1.82e-13	Hair morphology;
SARC	cis	rs1568889	1.000	rs1568889	chr11:28009463	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.73	8.35	0.48	6.2e-15	Bipolar disorder;
SARC	cis	rs13082711	0.522	rs9310842	chr3:27369765	A/T	cg02860705	chr3:27208620	NA	-0.48	-6.61	-0.4	2.6200000000000003e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs2764208	0.860	rs205286	chr6:34551334	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-6.09	-0.37	4.53e-9	Systemic lupus erythematosus;
SARC	cis	rs7659604	1.000	rs34952897	chr4:122664409	C/T	cg20573242	chr4:122745356	CCNA2	0.44	5.82	0.36	1.93e-8	Type 2 diabetes;
SARC	cis	rs861020	0.630	rs686582	chr1:210008673	A/C	cg23166289	chr1:210001082	C1orf107	0.39	4.74	0.3	3.67e-6	Orofacial clefts;
SARC	cis	rs2439831	1.000	rs2467740	chr15:43746792	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.04	10.9	0.58	1.23e-22	Lung cancer in ever smokers;
SARC	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-6.95	-0.41	3.57e-11	Personality dimensions;
SARC	cis	rs3870371	1.000	rs3870371	chr8:122697132	C/A	cg21781600	chr8:122651575	HAS2;HAS2AS	0.48	5.32	0.33	2.41e-7	Periodontal disease-related phenotypes;
SARC	cis	rs9815354	0.812	rs17283929	chr3:41941898	C/G	cg03022575	chr3:42003672	ULK4	-0.74	-6.18	-0.38	2.76e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs35110281	0.837	rs2838336	chr21:45071741	A/G	cg21573476	chr21:45109991	RRP1B	0.49	7.29	0.43	4.7e-12	Mean corpuscular volume;
SARC	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg06212747	chr3:49208901	KLHDC8B	0.66	8.8	0.5	3.19e-16	Parkinson's disease;
SARC	cis	rs10860964	0.746	rs7308725	chr12:103580090	A/G	cg11784990	chr12:103218665	NA	-0.31	-4.78	-0.3	3.12e-6	Schizophrenia;
SARC	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg20891283	chr12:69753455	YEATS4	0.55	7.55	0.44	9.74e-13	Blood protein levels;
SARC	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.9	9.7	0.54	6.67e-19	Platelet count;
SARC	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg12463550	chr7:65579703	CRCP	0.49	5.89	0.36	1.33e-8	Aortic root size;
SARC	cis	rs7712401	0.601	rs193539	chr5:122257617	C/G	cg19412675	chr5:122181750	SNX24	0.41	5.24	0.32	3.56e-7	Mean platelet volume;
SARC	cis	rs9303401	0.659	rs12935851	chr17:56600244	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	11.86	0.61	1.07e-25	Cognitive test performance;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg26106034	chr1:28974751	RNU11	-0.61	-6.5	-0.39	4.96e-10	Lung cancer in ever smokers;
SARC	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg25072359	chr17:41440525	NA	0.47	5.49	0.34	1.02e-7	Menopause (age at onset);
SARC	cis	rs9399135	0.967	rs4895436	chr6:135295001	G/A	cg24558204	chr6:135376177	HBS1L	0.44	5.97	0.36	8.77e-9	Red blood cell count;
SARC	cis	rs6500602	0.702	rs2270366	chr16:4558615	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.32	-5.51	-0.34	9.37e-8	Schizophrenia;
SARC	cis	rs16866061	1.000	rs72974222	chr2:225424143	C/T	cg12698349	chr2:225449008	CUL3	0.72	10.55	0.57	1.6e-21	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg13628971	chr7:2884303	GNA12	0.5	5.48	0.34	1.08e-7	Height;
SARC	cis	rs6759839	0.662	rs1430047	chr2:16646461	G/A	cg09580478	chr2:16689509	NA	0.46	6.09	0.37	4.66e-9	Mean platelet volume;
SARC	cis	rs6120849	0.754	rs6087666	chr20:33640242	G/A	cg24642439	chr20:33292090	TP53INP2	0.57	5.48	0.34	1.1e-7	Protein C levels;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg26582338	chr3:155523741	C3orf33	0.57	7.15	0.42	1.08e-11	Breast cancer;
SARC	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg11890956	chr21:40555474	PSMG1	1.18	19.47	0.79	8.8e-51	Cognitive function;
SARC	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	15.18	0.71	1.22e-36	Chronic sinus infection;
SARC	cis	rs4453791	0.505	rs11924818	chr3:38922323	G/A	cg15678707	chr3:39149194	GORASP1;TTC21A	0.48	5.28	0.33	3.03e-7	Social communication problems;
SARC	trans	rs11098499	1.000	rs28374891	chr4:120183550	G/A	cg25214090	chr10:38739885	LOC399744	0.52	6.89	0.41	5.07e-11	Corneal astigmatism;
SARC	cis	rs7659604	0.540	rs7676867	chr4:122671315	T/C	cg19671926	chr4:122722719	EXOSC9	0.56	6.87	0.41	5.72e-11	Type 2 diabetes;
SARC	cis	rs8141529	0.702	rs8137262	chr22:29292135	C/T	cg02153584	chr22:29168773	CCDC117	0.75	10.93	0.58	1.04e-22	Lymphocyte counts;
SARC	cis	rs916888	0.647	rs199524	chr17:44848438	G/T	cg15921436	chr17:44337874	NA	-0.5	-5.43	-0.34	1.42e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7772486	0.720	rs6931553	chr6:146112348	T/C	cg05347473	chr6:146136440	FBXO30	-0.56	-7.91	-0.46	1.01e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6568686	0.530	rs76540042	chr6:111937380	C/T	cg15721981	chr6:111408429	SLC16A10	0.7	5.67	0.35	4.16e-8	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	10.52	0.57	2.05e-21	Platelet count;
SARC	cis	rs2354432	0.607	rs10900350	chr1:146828017	T/G	cg25205988	chr1:146714368	CHD1L	0.96	7.4	0.44	2.45e-12	Mitochondrial DNA levels;
SARC	trans	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.57	-7.32	-0.43	3.91e-12	Brugada syndrome;
SARC	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg16606324	chr3:10149918	C3orf24	0.54	5.34	0.33	2.22e-7	Alzheimer's disease;
SARC	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg16325326	chr1:53192061	ZYG11B	-0.83	-13.35	-0.66	1.47e-30	Monocyte count;
SARC	trans	rs61931739	0.534	rs1586410	chr12:33999142	C/T	cg13010199	chr12:38710504	ALG10B	0.76	10.28	0.56	1.07e-20	Morning vs. evening chronotype;
SARC	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.41	-6.09	-0.37	4.6e-9	Total body bone mineral density;
SARC	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg13385521	chr17:29058706	SUZ12P	-0.7	-6.18	-0.38	2.85e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9457247	0.967	rs1794694	chr6:167404751	T/C	cg07741184	chr6:167504864	NA	0.29	5.55	0.34	7.72e-8	Crohn's disease;
SARC	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg11764359	chr7:65958608	NA	-0.78	-9.41	-0.52	4.86e-18	Aortic root size;
SARC	trans	rs9929218	0.581	rs4783676	chr16:68801077	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.77	11.96	0.62	5.25e-26	Colorectal cancer;
SARC	cis	rs9612	1.000	rs346528	chr19:44259232	G/T	cg08581076	chr19:44259116	C19orf61	0.65	7.93	0.46	9.08e-14	Exhaled nitric oxide output;
SARC	cis	rs2486288	0.656	rs1719232	chr15:45572072	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.57	-7.18	-0.43	9.09e-12	Glomerular filtration rate;
SARC	trans	rs7824557	0.564	rs7821459	chr8:11236681	T/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.0	-0.42	2.66e-11	Retinal vascular caliber;
SARC	cis	rs6582630	0.576	rs4882375	chr12:38371939	G/T	cg26384229	chr12:38710491	ALG10B	-0.58	-7.21	-0.43	7.87e-12	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg20757019	chr2:95873242	NA	0.51	7.12	0.42	1.29e-11	Tetralogy of Fallot;
SARC	cis	rs1865760	0.865	rs1541987	chr6:25950397	A/G	cg17691542	chr6:26056736	HIST1H1C	-0.59	-7.43	-0.44	2.07e-12	Height;
SARC	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg18404041	chr3:52824283	ITIH1	-0.44	-6.59	-0.4	2.82e-10	Bipolar disorder;
SARC	cis	rs9818758	0.607	rs9837625	chr3:49215966	C/T	cg01304814	chr3:48885189	PRKAR2A	0.6	4.92	0.31	1.63e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs6912958	0.559	rs369674	chr6:88043402	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.73	-10.96	-0.58	8.19e-23	Monocyte percentage of white cells;
SARC	cis	rs9815354	0.951	rs9817510	chr3:41813108	C/T	cg03022575	chr3:42003672	ULK4	0.6	5.77	0.35	2.51e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2276314	1.000	rs56050783	chr18:33553791	A/G	cg19628046	chr18:33552617	C18orf21	0.56	5.98	0.36	8.25e-9	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs933688	1.000	rs1964292	chr5:90743608	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.0	12.52	0.63	7.66e-28	Smoking behavior;
SARC	cis	rs3743266	0.507	rs34092508	chr15:60722979	C/T	cg22293140	chr15:60689852	ANXA2	-0.55	-5.09	-0.32	7.29e-7	Menarche (age at onset);
SARC	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.5	-6.35	-0.38	1.11e-9	Lymphocyte counts;
SARC	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg11062466	chr8:58055876	NA	0.55	5.51	0.34	9.67e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs950169	0.845	rs4502182	chr15:84923520	A/G	cg17507749	chr15:85114479	UBE2QP1	0.79	9.66	0.53	8.8e-19	Schizophrenia;
SARC	cis	rs2439831	0.850	rs524417	chr15:43772374	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.81	8.02	0.47	5.17e-14	Lung cancer in ever smokers;
SARC	cis	rs9902453	0.765	rs2874505	chr17:28037923	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	6.89	0.41	5.27e-11	Coffee consumption (cups per day);
SARC	cis	rs9398803	0.624	rs1591806	chr6:126641185	A/G	cg19875578	chr6:126661172	C6orf173	0.49	6.61	0.4	2.6e-10	Male-pattern baldness;
SARC	cis	rs7520050	0.966	rs6677007	chr1:46400590	A/G	cg24296786	chr1:45957014	TESK2	0.38	4.8	0.3	2.82e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg08280861	chr8:58055591	NA	0.61	5.96	0.36	9.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs8180040	0.800	rs56250009	chr3:47279497	G/C	cg27129171	chr3:47204927	SETD2	-0.73	-9.54	-0.53	1.96e-18	Colorectal cancer;
SARC	cis	rs7833986	0.534	rs72653928	chr8:56907735	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.67	6.66	0.4	1.98e-10	Height;
SARC	cis	rs7633857	0.512	rs1868109	chr3:160682500	G/A	cg04691961	chr3:161091175	C3orf57	-0.48	-5.91	-0.36	1.19e-8	Educational attainment (years of education);
SARC	cis	rs5753037	0.653	rs140121	chr22:30138689	C/T	cg01021169	chr22:30184971	ASCC2	-0.46	-6.31	-0.38	1.36e-9	Type 1 diabetes;
SARC	cis	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg12257692	chr3:49977190	RBM6	0.28	4.9	0.31	1.76e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg00933542	chr6:150070202	PCMT1	0.31	5.15	0.32	5.59e-7	Lung cancer;
SARC	cis	rs7937682	0.889	rs558736	chr11:111500760	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.93	-15.22	-0.71	8.88e-37	Primary sclerosing cholangitis;
SARC	cis	rs12142240	0.659	rs111723629	chr1:46853361	G/T	cg10495392	chr1:46806563	NSUN4	0.65	6.88	0.41	5.6e-11	Menopause (age at onset);
SARC	cis	rs933688	0.938	rs1477348	chr5:90707823	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.07	13.53	0.66	3.66e-31	Smoking behavior;
SARC	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg21724239	chr8:58056113	NA	0.55	5.91	0.36	1.22e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs17376456	0.877	rs12153506	chr5:93360953	T/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	6.12	0.37	3.99e-9	Diabetic retinopathy;
SARC	cis	rs16937	0.662	rs11240376	chr1:205146460	A/G	cg21643547	chr1:205240462	TMCC2	-0.42	-5.05	-0.31	9.02e-7	Schizophrenia;
SARC	cis	rs9457247	0.602	rs4710175	chr6:167467800	A/G	cg23791538	chr6:167370224	RNASET2	-0.54	-6.94	-0.41	3.88e-11	Crohn's disease;
SARC	cis	rs7914558	1.000	rs67908413	chr10:104764989	T/C	cg04362960	chr10:104952993	NT5C2	0.44	5.53	0.34	8.53e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	trans	rs10771431	0.597	rs10843144	chr12:9357577	C/T	cg27600084	chr12:12264075	NA	0.55	7.22	0.43	7.41e-12	Breast size;
SARC	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg04234412	chr22:24373322	LOC391322	0.52	6.12	0.37	3.85e-9	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg11987759	chr7:65425863	GUSB	0.57	7.57	0.44	8.71e-13	Cotinine glucuronidation;
SARC	cis	rs4891159	0.756	rs3892540	chr18:74118058	C/T	cg24786174	chr18:74118243	ZNF516	-0.67	-9.58	-0.53	1.49e-18	Longevity;
SARC	cis	rs17666538	0.591	rs2878547	chr8:603416	G/A	cg00450029	chr8:599525	NA	0.6	5.24	0.32	3.58e-7	IgG glycosylation;
SARC	cis	rs9815354	0.812	rs73077373	chr3:41852887	C/T	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6570726	0.935	rs421690	chr6:145834594	A/C	cg05347473	chr6:146136440	FBXO30	0.48	6.42	0.39	7.51e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs796364	0.806	rs4673634	chr2:200863349	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.77	6.78	0.41	9.78e-11	Schizophrenia;
SARC	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg14784868	chr12:69753453	YEATS4	0.65	9.07	0.51	5.01e-17	Cerebrospinal fluid biomarker levels;
SARC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg26338869	chr17:61819248	STRADA	0.8	10.82	0.58	2.2e-22	Prudent dietary pattern;
SARC	trans	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.75	-10.78	-0.58	3.03e-22	Intelligence (multi-trait analysis);
SARC	cis	rs7927592	0.871	rs11228284	chr11:68322767	A/T	cg01657329	chr11:68192670	LRP5	-0.41	-4.82	-0.3	2.55e-6	Total body bone mineral density;
SARC	cis	rs13392177	0.684	rs62185965	chr2:219073779	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.57	-7.33	-0.43	3.7e-12	Pyoderma gangrenosum in inflammatory bowel disease;
SARC	cis	rs9911578	0.835	rs723991	chr17:56482039	G/A	cg05425664	chr17:57184151	TRIM37	0.65	7.98	0.46	6.78e-14	Intelligence (multi-trait analysis);
SARC	cis	rs2354432	0.607	rs59689207	chr1:146722484	G/A	cg25205988	chr1:146714368	CHD1L	-1.04	-7.58	-0.44	8.14e-13	Mitochondrial DNA levels;
SARC	cis	rs7474896	0.559	rs2753880	chr10:38173338	G/A	cg00409905	chr10:38381863	ZNF37A	0.46	5.06	0.31	8.54e-7	Obesity (extreme);
SARC	cis	rs11997175	0.656	rs2350007	chr8:33585353	C/G	ch.8.33884649F	chr8:33765107	NA	0.49	6.33	0.38	1.27e-9	Body mass index;
SARC	cis	rs2304069	0.954	rs1433010	chr5:149383954	C/G	cg12661370	chr5:149340060	SLC26A2	-0.58	-5.64	-0.35	5e-8	HIV-1 control;
SARC	cis	rs9341808	0.538	rs688867	chr6:80939228	A/G	cg08355045	chr6:80787529	NA	0.32	5.01	0.31	1.07e-6	Sitting height ratio;
SARC	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg17221315	chr6:27791827	HIST1H4J	0.49	5.0	0.31	1.15e-6	Parkinson's disease;
SARC	cis	rs9911578	1.000	rs1494977	chr17:56863064	C/T	cg05425664	chr17:57184151	TRIM37	-0.66	-8.05	-0.47	4.33e-14	Intelligence (multi-trait analysis);
SARC	cis	rs7615952	0.688	rs12638224	chr3:125541320	C/T	cg05084668	chr3:125655381	ALG1L	-0.5	-5.25	-0.33	3.39e-7	Blood pressure (smoking interaction);
SARC	cis	rs3106136	0.843	rs11097414	chr4:95260301	A/T	cg11021082	chr4:95130006	SMARCAD1	0.35	5.39	0.33	1.75e-7	Capecitabine sensitivity;
SARC	cis	rs3087591	0.708	rs8067440	chr17:29708155	A/T	cg24425628	chr17:29625626	OMG;NF1	0.46	5.94	0.36	1.02e-8	Hip circumference;
SARC	cis	rs13031619	0.660	rs35668314	chr2:3702673	C/T	cg19052272	chr2:3704530	ALLC	-0.36	-4.74	-0.3	3.78e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
SARC	cis	rs2070488	0.965	rs35091896	chr3:38443320	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	14.44	0.69	3.36e-34	Electrocardiographic conduction measures;
SARC	cis	rs826838	0.935	rs11183940	chr12:38851642	A/G	cg26384229	chr12:38710491	ALG10B	0.93	14.91	0.7	9.31e-36	Heart rate;
SARC	cis	rs17023223	0.537	rs55836852	chr1:119725401	G/A	cg05756136	chr1:119680316	WARS2	-0.49	-5.62	-0.35	5.47e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs910316	1.000	rs4322591	chr14:75600697	C/T	cg08847533	chr14:75593920	NEK9	0.92	15.73	0.72	1.77e-38	Height;
SARC	cis	rs57244997	0.932	rs73026582	chr6:162406460	C/T	cg17173639	chr6:162384350	PARK2	-0.57	-5.48	-0.34	1.09e-7	Mosquito bite size;
SARC	cis	rs950776	0.531	rs12915652	chr15:78831928	G/A	cg22563815	chr15:78856949	CHRNA5	0.41	6.82	0.41	7.96e-11	Sudden cardiac arrest;
SARC	cis	rs10876993	0.928	rs2640629	chr12:58065448	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.39	-4.9	-0.31	1.78e-6	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs11098499	1.000	rs28419773	chr4:120211061	T/C	cg09307838	chr4:120376055	NA	0.84	11.48	0.6	1.76e-24	Corneal astigmatism;
SARC	trans	rs9329221	0.741	rs13264066	chr8:9804075	C/G	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.55	-0.39	3.58e-10	Neuroticism;
SARC	cis	rs796364	0.906	rs281766	chr2:200820505	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.78	7.57	0.44	8.72e-13	Schizophrenia;
SARC	cis	rs1046896	0.520	rs9895409	chr17:80902719	C/T	cg05255149	chr17:80675120	FN3KRP	0.46	5.1	0.32	6.87e-7	Glycated hemoglobin levels;
SARC	cis	rs950027	0.620	rs1346267	chr15:45690989	A/G	cg26924012	chr15:45694286	SPATA5L1	0.48	5.8	0.36	2.12e-8	Response to fenofibrate (adiponectin levels);
SARC	cis	rs7647973	1.000	rs6446275	chr3:49466871	A/G	cg07636037	chr3:49044803	WDR6	-0.76	-8.65	-0.49	8.36e-16	Menarche (age at onset);
SARC	cis	rs7769051	0.522	rs6569852	chr6:133108333	C/A	cg22852734	chr6:133119734	C6orf192	1.14	7.28	0.43	5.07e-12	Type 2 diabetes nephropathy;
SARC	cis	rs523522	0.962	rs4767912	chr12:120981202	A/G	cg27279351	chr12:120934652	DYNLL1	0.72	8.89	0.5	1.75e-16	High light scatter reticulocyte count;
SARC	cis	rs2120243	0.641	rs7639254	chr3:157141041	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.4	5.14	0.32	5.72e-7	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs12579753	0.833	rs1922566	chr12:82135030	T/C	cg07988820	chr12:82153109	PPFIA2	-0.6	-7.03	-0.42	2.3e-11	Resting heart rate;
SARC	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	15.58	0.71	5.4e-38	Chronic sinus infection;
SARC	cis	rs7918232	0.941	rs4749230	chr10:27441218	C/T	cg14442939	chr10:27389572	ANKRD26	0.6	5.39	0.33	1.7e-7	Breast cancer;
SARC	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg16405210	chr4:1374714	KIAA1530	-0.47	-5.64	-0.35	4.97e-8	Obesity-related traits;
SARC	cis	rs644799	0.710	rs473852	chr11:95568757	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.58	7.67	0.45	4.77e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg23131131	chr22:24373011	LOC391322	-0.48	-5.34	-0.33	2.17e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg00071950	chr4:10020882	SLC2A9	0.4	6.38	0.39	9.57e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs12079745	0.793	rs10919104	chr1:169209118	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.91	-5.85	-0.36	1.62e-8	QT interval;
SARC	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg08742575	chr21:47604166	C21orf56	-0.47	-5.97	-0.36	8.9e-9	Testicular germ cell tumor;
SARC	cis	rs2075371	0.897	rs1646702	chr7:134000177	C/G	cg00033643	chr7:134001901	SLC35B4	0.42	5.06	0.31	8.4e-7	Mean platelet volume;
SARC	cis	rs57083693	0.518	rs6538981	chr12:101702505	T/C	cg22051763	chr12:101673672	UTP20	-0.45	-5.37	-0.33	1.89e-7	Alcohol dependence (age at onset);
SARC	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg13939156	chr17:80058883	NA	0.4	6.25	0.38	1.92e-9	Life satisfaction;
SARC	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg26874164	chr19:58962979	ZNF324B	0.46	5.9	0.36	1.24e-8	Uric acid clearance;
SARC	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg19223190	chr17:80058835	NA	0.44	6.19	0.38	2.67e-9	Life satisfaction;
SARC	cis	rs763121	0.853	rs2281021	chr22:39064667	T/C	cg21395723	chr22:39101663	GTPBP1	0.54	6.03	0.37	6.24e-9	Menopause (age at onset);
SARC	cis	rs4727027	0.865	rs12154368	chr7:148862041	C/T	cg23583168	chr7:148888333	NA	-0.73	-11.03	-0.59	4.91e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs514024	0.672	rs578997	chr9:130489189	C/T	cg13643465	chr9:130375613	STXBP1	0.43	5.35	0.33	2.14e-7	Eating disorders (purging via substances);
SARC	cis	rs2236918	0.687	rs1776136	chr1:242026845	G/A	cg17736920	chr1:242011382	EXO1	0.66	9.02	0.51	7.17e-17	Menopause (age at onset);
SARC	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs13161895	0.591	rs12655422	chr5:179480825	C/A	cg06664874	chr5:179499304	RNF130	0.6	5.49	0.34	1.05e-7	LDL cholesterol;
SARC	cis	rs12701220	0.541	rs12535516	chr7:1114440	C/G	cg02733842	chr7:1102375	C7orf50	-0.59	-6.99	-0.42	2.9e-11	Bronchopulmonary dysplasia;
SARC	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg02725872	chr8:58115012	NA	-0.37	-6.55	-0.39	3.71e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg06634786	chr22:41940651	POLR3H	0.5	5.77	0.35	2.49e-8	Vitiligo;
SARC	cis	rs1865760	0.516	rs9393684	chr6:26075531	G/C	cg17691542	chr6:26056736	HIST1H1C	0.48	5.89	0.36	1.35e-8	Height;
SARC	cis	rs1728785	1.000	rs12925177	chr16:68569645	A/G	cg02972257	chr16:68554789	NA	0.48	5.74	0.35	2.87e-8	Ulcerative colitis;
SARC	cis	rs67460515	0.892	rs34016896	chr3:160992864	C/T	cg17135325	chr3:160939158	NMD3	0.63	7.97	0.46	7.02e-14	Parkinson's disease;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04802236	chr17:37010032	RPL23;SNORA21	0.55	6.62	0.4	2.46e-10	Fibrinogen levels;
SARC	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg00149659	chr3:10157352	C3orf10	1.09	10.0	0.55	7.87e-20	Alzheimer's disease;
SARC	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	22.9	0.83	1.38e-61	Chronic sinus infection;
SARC	trans	rs7824557	0.806	rs34171564	chr8:11095346	C/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.28	-0.38	1.6e-9	Retinal vascular caliber;
SARC	cis	rs787274	0.764	rs787281	chr9:115538568	C/T	cg13803584	chr9:115635662	SNX30	-0.83	-5.06	-0.31	8.34e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg01448562	chr3:133502909	NA	-0.51	-7.8	-0.46	2.03e-13	Iron status biomarkers;
SARC	cis	rs6495122	0.699	rs2168518	chr15:75081078	G/A	cg09165964	chr15:75287851	SCAMP5	0.4	4.79	0.3	3e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	cis	rs6782228	0.606	rs6787559	chr3:128381086	T/C	cg08795948	chr3:128337044	NA	0.37	5.07	0.32	8.06e-7	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
SARC	cis	rs6504663	0.525	rs557	chr17:48563234	C/T	cg22571038	chr17:48585470	MYCBPAP	0.47	5.49	0.34	1.03e-7	Visceral fat;
SARC	trans	rs61931739	0.500	rs11053268	chr12:34545121	T/C	cg13010199	chr12:38710504	ALG10B	0.78	11.07	0.59	3.68e-23	Morning vs. evening chronotype;
SARC	cis	rs9393692	0.905	rs6916289	chr6:26289122	A/T	cg00631329	chr6:26305371	NA	-0.6	-8.75	-0.5	4.37e-16	Educational attainment;
SARC	cis	rs634534	0.622	rs501353	chr11:65739549	T/G	cg26695010	chr11:65641043	EFEMP2	-0.58	-7.58	-0.44	8.39e-13	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs3796352	0.881	rs11710394	chr3:53015839	A/G	cg27565382	chr3:53032988	SFMBT1	0.88	6.16	0.37	3.18e-9	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs722599	0.748	rs1059326	chr14:75369385	C/T	cg08847533	chr14:75593920	NEK9	-0.42	-4.79	-0.3	3.02e-6	IgG glycosylation;
SARC	cis	rs6690583	0.623	rs11588160	chr1:85444226	T/G	cg22153463	chr1:85462885	MCOLN2	0.72	6.85	0.41	6.56e-11	Serum sulfate level;
SARC	cis	rs6831352	0.918	rs28987097	chr4:100049579	C/T	cg12011299	chr4:100065546	ADH4	-0.34	-5.74	-0.35	2.97e-8	Alcohol dependence;
SARC	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg12463550	chr7:65579703	CRCP	-0.49	-5.34	-0.33	2.21e-7	Aortic root size;
SARC	cis	rs7607369	0.559	rs4674340	chr2:219659799	A/G	cg02176678	chr2:219576539	TTLL4	-0.39	-6.08	-0.37	5e-9	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs2952156	0.959	rs2952151	chr17:37828496	T/C	cg20243544	chr17:37824526	PNMT	0.5	6.33	0.38	1.26e-9	Asthma;
SARC	cis	rs6456042	1.000	rs6456041	chr6:166534679	G/A	cg11088901	chr6:166572345	T	-0.35	-5.04	-0.31	9.56e-7	Asthma;
SARC	cis	rs668210	0.793	rs1192184	chr11:65773382	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.66	-6.46	-0.39	5.96e-10	Cerebrospinal fluid biomarker levels;
SARC	cis	rs28655083	1.000	rs1843457	chr16:77072400	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.42	-6.01	-0.37	7.05e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7208859	0.623	rs76633166	chr17:29113365	C/T	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg13939156	chr17:80058883	NA	0.35	5.43	0.34	1.39e-7	Life satisfaction;
SARC	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg11987759	chr7:65425863	GUSB	-0.5	-6.09	-0.37	4.6e-9	Aortic root size;
SARC	cis	rs6430585	0.583	rs7561565	chr2:136640787	A/C	cg07169764	chr2:136633963	MCM6	1.08	16.03	0.72	1.75e-39	Corneal structure;
SARC	cis	rs12922317	0.556	rs8062691	chr16:12091829	A/G	cg02368508	chr16:12060182	TNFRSF17	-0.33	-4.72	-0.3	4.11e-6	Schizophrenia;
SARC	cis	rs2282802	0.685	rs6580473	chr5:139646962	C/T	cg26211634	chr5:139558579	C5orf32	-0.39	-5.05	-0.31	9.08e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7772486	0.712	rs1292335	chr6:145967877	G/T	cg23711669	chr6:146136114	FBXO30	0.73	10.57	0.57	1.33e-21	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10876993	0.728	rs1082503	chr12:58036717	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.47	-5.92	-0.36	1.16e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs9733	0.744	rs2089081	chr1:150800117	T/C	cg15448220	chr1:150897856	SETDB1	-0.38	-5.09	-0.32	7.44e-7	Tonsillectomy;
SARC	cis	rs7582180	0.629	rs11684516	chr2:100949883	C/A	cg14675211	chr2:100938903	LONRF2	0.51	7.63	0.45	6.1e-13	Intelligence (multi-trait analysis);
SARC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg09373136	chr17:61933544	TCAM1	-0.46	-6.3	-0.38	1.5e-9	Prudent dietary pattern;
SARC	cis	rs2304069	0.954	rs2340463	chr5:149409294	C/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.7	6.95	0.41	3.69e-11	HIV-1 control;
SARC	cis	rs710216	0.843	rs3768043	chr1:43419354	C/A	cg07803811	chr1:43423981	SLC2A1	-0.58	-6.35	-0.38	1.15e-9	Red cell distribution width;
SARC	cis	rs6050267	0.556	rs62217177	chr20:25012178	A/G	cg26195577	chr20:24973756	C20orf3	0.71	5.1	0.32	7.17e-7	Cognitive performance;
SARC	cis	rs6866344	0.570	rs1079487	chr5:178136005	G/A	cg03877680	chr5:178157825	ZNF354A	1.04	14.68	0.69	5.67e-35	Neutrophil percentage of white cells;
SARC	cis	rs9399135	0.967	rs2327580	chr6:135364417	A/C	cg24558204	chr6:135376177	HBS1L	0.46	6.24	0.38	2.09e-9	Red blood cell count;
SARC	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg13206674	chr6:150067644	NUP43	0.46	6.1	0.37	4.29e-9	Lung cancer;
SARC	cis	rs7847628	0.587	rs12684934	chr9:123593159	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.69	9.51	0.53	2.57e-18	Birth weight;
SARC	cis	rs6723226	1.000	rs6723226	chr2:32849207	C/T	cg02381751	chr2:32503542	YIPF4	0.57	7.25	0.43	6.03e-12	Intelligence (multi-trait analysis);
SARC	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg22133161	chr19:49891603	CCDC155	0.43	4.72	0.3	4.14e-6	Multiple sclerosis;
SARC	cis	rs7264396	0.635	rs6060692	chr20:34517925	A/T	cg12579300	chr20:34535607	PHF20	0.43	5.02	0.31	1.04e-6	Total cholesterol levels;
SARC	cis	rs2985684	0.894	rs2354439	chr14:50019417	G/C	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.47	5.23	0.32	3.83e-7	Carotid intima media thickness;
SARC	cis	rs2635047	0.806	rs9962602	chr18:44599057	G/A	cg15049968	chr18:44337910	ST8SIA5	-0.32	-5.0	-0.31	1.1e-6	Educational attainment;
SARC	cis	rs12311304	1.000	rs114389628	chr12:15410504	G/T	cg08258403	chr12:15378311	NA	0.49	7.41	0.44	2.36e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs9517302	0.615	rs2274053	chr13:99098318	C/T	cg24044564	chr13:99115944	STK24	0.4	4.9	0.31	1.8e-6	Obesity-related traits;
SARC	cis	rs6752107	0.935	rs11690131	chr2:234148383	T/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.46	6.24	0.38	2.08e-9	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs7246760	0.867	rs12461215	chr19:9782461	G/A	cg16876255	chr19:9731953	ZNF561	0.82	5.05	0.31	8.72e-7	Pursuit maintenance gain;
SARC	cis	rs2859741	0.565	rs12031540	chr1:37513757	C/T	cg09363841	chr1:37513479	NA	-0.28	-4.92	-0.31	1.65e-6	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
SARC	cis	rs2213920	0.679	rs4979523	chr9:118177550	G/A	cg13918206	chr9:118159781	DEC1	0.83	6.82	0.41	7.93e-11	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs12079745	0.793	rs3766082	chr1:169215068	A/T	cg09363564	chr1:169337483	NME7;BLZF1	0.88	6.38	0.39	9.63e-10	QT interval;
SARC	cis	rs7020830	0.867	rs1339553	chr9:37266123	C/G	cg14294708	chr9:37120828	ZCCHC7	1.12	20.7	0.8	1.01e-54	Schizophrenia;
SARC	cis	rs13256369	0.802	rs11249883	chr8:8561537	G/A	cg18904891	chr8:8559673	CLDN23	0.47	5.32	0.33	2.45e-7	Obesity-related traits;
SARC	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg11062466	chr8:58055876	NA	0.56	5.14	0.32	5.71e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.35	4.84	0.3	2.39e-6	Obesity-related traits;
SARC	trans	rs6600671	1.000	rs4844616	chr1:121171208	A/G	cg00646200	chr1:148855367	NA	0.51	7.18	0.43	9.34e-12	Hip geometry;
SARC	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg05896524	chr21:47604654	C21orf56	0.42	5.04	0.31	9.35e-7	Testicular germ cell tumor;
SARC	cis	rs10791323	0.569	rs2282602	chr11:133714522	G/A	cg14349672	chr11:133703707	NA	-0.38	-5.55	-0.34	7.69e-8	Childhood ear infection;
SARC	cis	rs13191362	0.935	rs66923841	chr6:163177317	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.76	6.5	0.39	4.95e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs12079745	0.793	rs35037551	chr1:169105844	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.69	-4.87	-0.3	2.08e-6	QT interval;
SARC	cis	rs1800795	0.901	rs2069833	chr7:22767664	C/T	cg26061582	chr7:22766209	IL6	0.59	6.76	0.4	1.11e-10	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
SARC	cis	rs787274	0.718	rs7869100	chr9:115628533	T/C	cg13803584	chr9:115635662	SNX30	-0.96	-5.96	-0.36	9.43e-9	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs9304742	0.962	rs12461778	chr19:53454963	T/A	cg24044776	chr19:53454761	ZNF816A	-0.4	-5.6	-0.34	6.09e-8	Psoriasis;
SARC	cis	rs9381040	0.655	rs2268193	chr6:41024625	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-4.92	-0.31	1.64e-6	Alzheimer's disease (late onset);
SARC	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg12463550	chr7:65579703	CRCP	0.5	5.9	0.36	1.27e-8	Aortic root size;
SARC	trans	rs2727020	0.894	rs1917328	chr11:49359606	G/A	cg03929089	chr4:120376271	NA	-0.72	-9.06	-0.51	5.54e-17	Coronary artery disease;
SARC	cis	rs947211	0.800	rs1341249	chr1:205759876	T/C	cg14893161	chr1:205819251	PM20D1	0.53	5.53	0.34	8.65e-8	Parkinson's disease;
SARC	cis	rs6772849	0.775	rs66822528	chr3:128415097	G/A	cg08795948	chr3:128337044	NA	0.52	6.78	0.41	9.85e-11	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs11785400	1.000	rs3802232	chr8:143746701	A/G	cg10596483	chr8:143751796	JRK	0.65	8.66	0.49	7.81e-16	Schizophrenia;
SARC	cis	rs721399	0.512	rs4560828	chr8:18276294	A/T	cg18736775	chr8:18248649	NAT2	-0.52	-5.15	-0.32	5.54e-7	Blood metabolite levels;
SARC	cis	rs35146811	0.844	rs4729576	chr7:99692594	G/A	cg22004693	chr7:99632812	ZKSCAN1	-0.48	-5.07	-0.32	7.99e-7	Coronary artery disease;
SARC	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg24829409	chr8:58192753	C8orf71	-0.58	-5.16	-0.32	5.37e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs651907	0.535	rs34063583	chr3:101509948	C/T	cg12386194	chr3:101231763	SENP7	0.48	5.54	0.34	7.97e-8	Colorectal cancer;
SARC	cis	rs7870753	0.838	rs7867323	chr9:99248057	A/C	cg25260653	chr9:99212216	HABP4	0.5	4.72	0.3	4.04e-6	Height;
SARC	cis	rs8114671	0.562	rs4911163	chr20:33470694	C/T	cg24642439	chr20:33292090	TP53INP2	0.52	6.43	0.39	7.17e-10	Height;
SARC	cis	rs941408	1.000	rs1736176	chr19:2790394	G/A	cg00079169	chr19:2811669	THOP1	0.52	5.67	0.35	4.23e-8	Total cholesterol levels;
SARC	cis	rs9517320	0.534	rs3858778	chr13:99172249	A/C	cg07423050	chr13:99094983	FARP1	0.4	4.98	0.31	1.26e-6	Longevity;
SARC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg11203670	chr7:100026453	MEPCE;ZCWPW1	0.51	5.07	0.32	8.19e-7	Platelet count;
SARC	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg13939156	chr17:80058883	NA	0.4	6.25	0.38	1.92e-9	Life satisfaction;
SARC	cis	rs986417	0.688	rs8018111	chr14:60964347	A/G	cg27398547	chr14:60952738	C14orf39	0.88	8.66	0.49	7.84e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs1580019	0.587	rs6951955	chr7:32548761	A/T	cg07520158	chr7:32535189	LSM5;AVL9	0.61	7.97	0.46	6.84e-14	Cognitive ability;
SARC	cis	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg12463550	chr7:65579703	CRCP	-0.61	-4.84	-0.3	2.36e-6	Diabetic kidney disease;
SARC	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-9.33	-0.52	8.42e-18	Chronic sinus infection;
SARC	cis	rs17253792	0.822	rs112418863	chr14:56114079	G/A	cg01858014	chr14:56050164	KTN1	-0.64	-4.75	-0.3	3.57e-6	Putamen volume;
SARC	cis	rs17666538	1.000	rs73177066	chr8:585750	C/T	cg13264159	chr8:625131	ERICH1	0.7	4.72	0.3	4.13e-6	IgG glycosylation;
SARC	cis	rs116095464	1.000	rs56235400	chr5:312625	G/A	cg20965017	chr5:231967	SDHA	-0.7	-5.45	-0.34	1.28e-7	Breast cancer;
SARC	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg13770153	chr20:60521292	NA	-0.48	-6.43	-0.39	7.22e-10	Body mass index;
SARC	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg03264133	chr6:25882463	NA	-0.53	-6.67	-0.4	1.89e-10	Intelligence (multi-trait analysis);
SARC	cis	rs12586317	0.547	rs2038254	chr14:35462134	C/T	cg16230307	chr14:35515116	FAM177A1	1.02	11.85	0.61	1.18e-25	Psoriasis;
SARC	cis	rs9916302	0.706	rs9891892	chr17:37479856	A/C	cg15445000	chr17:37608096	MED1	-0.47	-5.08	-0.32	7.63e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs7684253	0.548	rs922570	chr4:57717358	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.4	-4.99	-0.31	1.18e-6	Migraine;
SARC	cis	rs66569888	0.523	rs4522599	chr2:106926004	G/C	cg15412446	chr2:106886593	NA	0.44	4.87	0.3	2.07e-6	Facial morphology (factor 23);
SARC	cis	rs10779751	0.686	rs1148478	chr1:11174067	A/T	cg08854313	chr1:11322531	MTOR	0.77	10.11	0.55	3.67e-20	Body mass index;
SARC	trans	rs1493916	0.748	rs4799355	chr18:31313124	G/T	cg27147174	chr7:100797783	AP1S1	-0.53	-6.55	-0.39	3.61e-10	Life satisfaction;
SARC	cis	rs806795	0.605	rs6935954	chr6:26255451	A/G	cg13736514	chr6:26305472	NA	-0.59	-6.91	-0.41	4.46e-11	Mosquito bite size;
SARC	cis	rs6500602	0.561	rs62039231	chr16:4519548	A/G	cg08645402	chr16:4508243	NA	0.48	6.48	0.39	5.33e-10	Schizophrenia;
SARC	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg19077165	chr18:44547161	KATNAL2	-0.51	-7.09	-0.42	1.58e-11	Personality dimensions;
SARC	cis	rs2235642	0.601	rs2235647	chr16:1601331	C/A	cg09065629	chr16:1709722	CRAMP1L	0.36	4.75	0.3	3.61e-6	Coronary artery disease;
SARC	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg09517075	chr8:22133004	PIWIL2	0.35	4.93	0.31	1.55e-6	Hypertriglyceridemia;
SARC	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.6	-6.31	-0.38	1.42e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs2718058	0.606	rs2718065	chr7:37859525	A/G	cg15028436	chr7:37888078	TXNDC3	0.39	4.93	0.31	1.54e-6	Alzheimer's disease (late onset);
SARC	cis	rs1387259	0.723	rs2732488	chr12:48771444	G/A	cg24011408	chr12:48396354	COL2A1	0.43	5.18	0.32	4.7e-7	Obstructive sleep apnea trait (apnea hypopnea index);
SARC	cis	rs10782582	0.593	rs12126155	chr1:76131555	C/G	cg03433033	chr1:76189801	ACADM	-0.41	-5.14	-0.32	5.69e-7	Daytime sleep phenotypes;
SARC	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg22968622	chr17:43663579	NA	-1.13	-14.9	-0.7	1.01e-35	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg21724239	chr8:58056113	NA	0.69	6.06	0.37	5.49e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs826838	1.000	rs34254519	chr12:39041235	G/A	cg26384229	chr12:38710491	ALG10B	0.9	14.24	0.68	1.57e-33	Heart rate;
SARC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.4	0.52	5.17e-18	Prudent dietary pattern;
SARC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg12419862	chr22:24373484	LOC391322	0.69	8.19	0.47	1.75e-14	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7666738	0.716	rs7656233	chr4:99079237	G/A	cg05340658	chr4:99064831	C4orf37	0.57	7.33	0.43	3.8e-12	Colonoscopy-negative controls vs population controls;
SARC	trans	rs904095	0.543	rs1789920	chr4:100268856	A/C	cg01588345	chr2:120023921	NA	0.43	6.28	0.38	1.62e-9	Alcohol dependence;
SARC	cis	rs1267303	0.642	rs61783087	chr1:46999955	T/C	cg25110126	chr1:46999211	NA	0.91	9.84	0.54	2.54e-19	Monobrow;
SARC	cis	rs11578119	0.933	rs12140161	chr1:170444010	A/G	cg09767346	chr1:170501363	GORAB	0.45	5.25	0.33	3.42e-7	Male-pattern baldness;
SARC	cis	rs11235843	0.929	rs72974866	chr11:73412291	C/T	cg18195628	chr11:73498948	MRPL48	0.61	4.86	0.3	2.2e-6	Hand grip strength;
SARC	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg24675658	chr1:53192096	ZYG11B	-0.58	-8.1	-0.47	3.09e-14	Monocyte count;
SARC	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg12648201	chr2:27665141	KRTCAP3	-0.32	-5.01	-0.31	1.06e-6	Total body bone mineral density;
SARC	trans	rs13098911	0.540	rs34766614	chr3:46107601	A/G	cg03842258	chr15:67135396	NA	0.79	6.41	0.39	8.07e-10	Celiac disease;
SARC	cis	rs2120243	0.539	rs1585080	chr3:157106982	A/G	cg24825693	chr3:157122686	VEPH1	-0.46	-6.28	-0.38	1.6e-9	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs9902453	0.868	rs9890075	chr17:28470464	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	6.88	0.41	5.46e-11	Coffee consumption (cups per day);
SARC	cis	rs9300255	0.506	rs61388686	chr12:123810873	G/A	cg00376283	chr12:123451042	ABCB9	0.57	6.95	0.41	3.55e-11	Neutrophil percentage of white cells;
SARC	cis	rs12995491	0.731	rs34991383	chr2:88500337	T/G	cg04511125	chr2:88470314	THNSL2	-0.4	-6.02	-0.37	6.79e-9	Response to metformin (IC50);
SARC	cis	rs9486719	1.000	rs2142653	chr6:96871520	C/A	cg06623918	chr6:96969491	KIAA0776	0.73	8.01	0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs5758659	0.714	rs5751216	chr22:42508937	G/T	cg15128208	chr22:42549153	NA	0.36	5.16	0.32	5.29e-7	Cognitive function;
SARC	cis	rs7296418	0.961	rs11608811	chr12:123529056	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.43	-5.93	-0.36	1.1e-8	Platelet count;
SARC	cis	rs12762955	0.677	rs11250267	chr10:1156487	A/G	cg18964960	chr10:1102726	WDR37	0.67	6.87	0.41	5.79e-11	Response to angiotensin II receptor blocker therapy;
SARC	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg16414030	chr3:133502952	NA	-0.37	-4.91	-0.31	1.69e-6	Iron status biomarkers;
SARC	cis	rs3008870	0.958	rs34367328	chr1:67445321	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.89	-11.03	-0.59	4.76e-23	Lymphocyte percentage of white cells;
SARC	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg12042659	chr19:58951599	ZNF132	0.41	5.49	0.34	1.03e-7	Uric acid clearance;
SARC	cis	rs1018836	0.632	rs7002775	chr8:91476765	C/T	cg16814680	chr8:91681699	NA	0.71	10.64	0.57	8.3e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs981844	0.740	rs10009844	chr4:154681576	C/T	cg14289246	chr4:154710475	SFRP2	-0.58	-7.01	-0.42	2.57e-11	Response to statins (LDL cholesterol change);
SARC	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs8017423	0.967	rs17188605	chr14:90722579	C/T	cg20276874	chr14:90721474	PSMC1	-0.39	-5.49	-0.34	1.06e-7	Mortality in heart failure;
SARC	cis	rs710216	0.957	rs859511	chr1:43430260	C/T	cg22176566	chr1:43424700	SLC2A1	0.52	5.12	0.32	6.46e-7	Red cell distribution width;
SARC	cis	rs2594989	0.779	rs2596815	chr3:11594930	A/G	cg00170343	chr3:11313890	ATG7	-0.52	-5.55	-0.34	7.93e-8	Circulating chemerin levels;
SARC	cis	rs67311347	0.869	rs7646899	chr3:40366982	A/G	cg24209194	chr3:40518798	ZNF619	0.58	7.41	0.44	2.29e-12	Renal cell carcinoma;
SARC	cis	rs12479064	0.724	rs10496336	chr2:99996165	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.56	-6.6	-0.4	2.8e-10	Chronic sinus infection;
SARC	cis	rs6459788	0.630	rs11977865	chr7:157234112	G/A	cg03453431	chr7:157225567	NA	-0.42	-6.23	-0.38	2.19e-9	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs1355223	0.902	rs7129089	chr11:34699699	T/C	cg18508148	chr11:34937573	PDHX;APIP	-0.41	-5.19	-0.32	4.55e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs10489202	1.000	rs12727036	chr1:167972147	A/G	cg24449463	chr1:168025552	DCAF6	-0.64	-6.95	-0.41	3.59e-11	Schizophrenia;
SARC	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg19346786	chr7:2764209	NA	-0.43	-6.35	-0.38	1.12e-9	Height;
SARC	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg10295955	chr4:187884368	NA	-1.05	-19.8	-0.79	7.71e-52	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9807989	0.801	rs72823663	chr2:102968738	G/C	cg09003973	chr2:102972529	NA	0.41	5.6	0.34	6.11e-8	Asthma;
SARC	cis	rs6831352	0.918	rs28987088	chr4:100059139	T/C	cg13256891	chr4:100009986	ADH5	-0.64	-8.0	-0.46	5.7e-14	Alcohol dependence;
SARC	cis	rs908922	0.743	rs10888499	chr1:152532742	C/A	cg09873164	chr1:152488093	CRCT1	0.6	7.14	0.42	1.15e-11	Hair morphology;
SARC	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.45	5.55	0.34	7.75e-8	Tonsillectomy;
SARC	cis	rs17253792	0.822	rs10149408	chr14:56046075	G/A	cg01858014	chr14:56050164	KTN1	-0.69	-5.25	-0.33	3.42e-7	Putamen volume;
SARC	trans	rs1814175	0.586	rs10769603	chr11:49688837	T/C	cg15704280	chr7:45808275	SEPT13	-0.82	-12.42	-0.63	1.63e-27	Height;
SARC	cis	rs1008375	0.966	rs28441502	chr4:17598384	G/A	cg02297831	chr4:17616191	MED28	0.47	5.8	0.35	2.2e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs870825	0.616	rs61539306	chr4:185650276	C/T	cg04058563	chr4:185651563	MLF1IP	0.8	11.37	0.6	3.9e-24	Blood protein levels;
SARC	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	10.56	0.57	1.49e-21	Alzheimer's disease;
SARC	cis	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg12064134	chr16:90016061	DEF8	-0.6	-5.11	-0.32	6.72e-7	Skin colour saturation;
SARC	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg02297831	chr4:17616191	MED28	0.51	6.59	0.4	2.97e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1153858	1.000	rs4775906	chr15:45638294	C/T	cg21132104	chr15:45694354	SPATA5L1	0.77	10.71	0.57	5.01e-22	Homoarginine levels;
SARC	cis	rs10876993	0.928	rs2640636	chr12:58077544	A/G	cg18357645	chr12:58087776	OS9	0.52	6.89	0.41	5.14e-11	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs6963495	0.818	rs6943132	chr7:105166776	C/T	cg19920283	chr7:105172520	RINT1	0.67	4.79	0.3	2.94e-6	Bipolar disorder (body mass index interaction);
SARC	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg06558623	chr16:89946397	TCF25	0.71	5.97	0.36	8.69e-9	Skin colour saturation;
SARC	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg11062466	chr8:58055876	NA	0.53	5.53	0.34	8.39e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs3808502	0.605	rs11784572	chr8:11174484	C/G	cg21775007	chr8:11205619	TDH	-0.54	-6.84	-0.41	7.1e-11	Neuroticism;
SARC	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.42	4.76	0.3	3.37e-6	Bipolar disorder;
SARC	cis	rs9467773	1.000	rs6903973	chr6:26499942	C/A	cg11502198	chr6:26597334	ABT1	0.49	6.0	0.37	7.6e-9	Intelligence (multi-trait analysis);
SARC	cis	rs1878931	0.582	rs9937267	chr16:3421073	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.68	7.72	0.45	3.36e-13	Body mass index (adult);
SARC	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg20735989	chr4:730612	PCGF3	-0.48	-5.59	-0.34	6.47e-8	White blood cell count;
SARC	cis	rs7089973	0.872	rs10490908	chr10:116616162	T/C	cg08188268	chr10:116634841	FAM160B1	0.36	5.8	0.36	2.13e-8	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs7666738	0.678	rs7670805	chr4:99008763	A/G	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	trans	rs7819412	0.811	rs2409691	chr8:10943276	C/T	cg15556689	chr8:8085844	FLJ10661	-0.48	-6.39	-0.39	8.82e-10	Triglycerides;
SARC	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg08280861	chr8:58055591	NA	0.68	5.83	0.36	1.81e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs883565	0.655	rs6599002	chr3:39076073	T/C	cg01426195	chr3:39028469	NA	-0.36	-5.24	-0.32	3.54e-7	Handedness;
SARC	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.34	-5.37	-0.33	1.89e-7	Longevity;Endometriosis;
SARC	cis	rs72945132	0.882	rs12294540	chr11:70118973	A/T	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.78	-0.35	2.39e-8	Coronary artery disease;
SARC	cis	rs7296418	0.738	rs10846489	chr12:123743927	A/G	cg00376283	chr12:123451042	ABCB9	-0.57	-6.93	-0.41	4.01e-11	Platelet count;
SARC	cis	rs6964587	1.000	rs11982047	chr7:91705274	G/A	cg17063962	chr7:91808500	NA	0.96	15.48	0.71	1.17e-37	Breast cancer;
SARC	cis	rs7666738	0.830	rs7689495	chr4:98920152	T/C	cg05340658	chr4:99064831	C4orf37	0.68	9.2	0.52	2.08e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg04155289	chr7:94953770	PON1	-0.36	-4.71	-0.3	4.2e-6	Paraoxonase activity;
SARC	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg04944784	chr2:26401820	FAM59B	0.61	7.99	0.46	6.27e-14	Gut microbiome composition (summer);
SARC	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg11366901	chr6:160182831	ACAT2	1.02	9.89	0.54	1.79e-19	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs9896052	0.614	rs4789201	chr17:73440579	A/G	cg27037648	chr17:73511087	CASKIN2	0.42	4.94	0.31	1.5e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg04166393	chr7:2884313	GNA12	0.48	5.59	0.34	6.26e-8	Height;
SARC	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg22508957	chr16:3507546	NAT15	0.38	5.45	0.34	1.29e-7	Tuberculosis;
SARC	cis	rs2273669	0.667	rs11153148	chr6:109304084	C/T	cg05315195	chr6:109294784	ARMC2	-0.57	-5.24	-0.32	3.62e-7	Prostate cancer;
SARC	cis	rs8114671	0.662	rs6058146	chr20:33540529	A/G	cg07148914	chr20:33460835	GGT7	0.43	5.16	0.32	5.17e-7	Height;
SARC	cis	rs12971120	0.891	rs12968731	chr18:72169708	G/T	cg25817165	chr18:72167213	CNDP2	-0.53	-7.59	-0.45	7.62e-13	Refractive error;
SARC	cis	rs2073499	1.000	rs10510755	chr3:50281168	C/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.61	5.78	0.35	2.41e-8	Schizophrenia;
SARC	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg03647317	chr4:187891568	NA	0.37	5.42	0.33	1.49e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs113835537	0.529	rs11824771	chr11:66262550	T/C	cg24851651	chr11:66362959	CCS	0.38	4.82	0.3	2.55e-6	Airway imaging phenotypes;
SARC	cis	rs7666738	0.830	rs72882693	chr4:98960804	T/A	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg18252515	chr7:66147081	NA	-1.34	-11.93	-0.62	6.47e-26	Diabetic kidney disease;
SARC	cis	rs77633900	0.614	rs2439992	chr15:76863023	T/G	cg21673338	chr15:77095150	SCAPER	-0.61	-5.12	-0.32	6.41e-7	Non-glioblastoma glioma;Glioma;
SARC	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg23758822	chr17:41437982	NA	0.89	11.28	0.59	7.77e-24	Menopause (age at onset);
SARC	cis	rs17095355	1.000	rs11194922	chr10:111695656	G/T	cg00817464	chr10:111662876	XPNPEP1	-0.41	-4.74	-0.3	3.74e-6	Biliary atresia;
SARC	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg13607699	chr17:42295918	UBTF	0.52	6.35	0.38	1.12e-9	Total body bone mineral density;
SARC	cis	rs11874712	1.000	rs9945751	chr18:43673265	G/A	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.46	5.49	0.34	1.06e-7	Migraine - clinic-based;
SARC	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg25894440	chr7:65020034	NA	-0.72	-5.46	-0.34	1.23e-7	Diabetic kidney disease;
SARC	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg22484793	chr3:52261325	TLR9	0.29	4.73	0.3	3.83e-6	Bipolar disorder;
SARC	cis	rs7312933	0.703	rs10492388	chr12:42608001	T/C	cg19980929	chr12:42632907	YAF2	0.43	5.86	0.36	1.58e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs6570726	0.935	rs424263	chr6:145840073	A/C	cg23711669	chr6:146136114	FBXO30	0.78	11.86	0.61	1.04e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1865760	0.865	rs9467651	chr6:25958257	C/G	cg16482183	chr6:26056742	HIST1H1C	0.52	6.69	0.4	1.63e-10	Height;
SARC	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg07343612	chr16:622815	PIGQ	-0.62	-8.71	-0.5	5.73e-16	Height;
SARC	cis	rs920590	0.573	rs6986456	chr8:19680562	A/G	cg17834443	chr8:19674713	INTS10	0.53	6.4	0.39	8.33e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs523522	0.673	rs643372	chr12:121022640	C/G	cg27279351	chr12:120934652	DYNLL1	0.7	8.49	0.49	2.37e-15	High light scatter reticulocyte count;
SARC	cis	rs3820928	0.845	rs4234065	chr2:227882006	C/T	cg11843606	chr2:227700838	RHBDD1	-0.57	-7.32	-0.43	3.95e-12	Pulmonary function;
SARC	cis	rs6963495	0.519	rs3892297	chr7:105152173	G/A	cg13798780	chr7:105162888	PUS7	0.58	5.2	0.32	4.42e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs3126085	0.935	rs11204937	chr1:152193851	C/T	cg26876637	chr1:152193138	HRNR	0.47	5.51	0.34	9.63e-8	Atopic dermatitis;
SARC	cis	rs9322817	0.607	rs9404572	chr6:105149439	T/C	cg02098413	chr6:105308735	HACE1	-0.38	-5.83	-0.36	1.81e-8	Thyroid stimulating hormone;
SARC	cis	rs7772486	0.754	rs9497434	chr6:146260753	C/T	cg05347473	chr6:146136440	FBXO30	-0.48	-6.54	-0.39	3.87e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs698813	0.572	rs4953076	chr2:44480950	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	6.18	0.38	2.88e-9	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg12373951	chr3:133503437	NA	-0.37	-5.43	-0.34	1.41e-7	Iron status biomarkers;
SARC	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg05368731	chr17:41323189	NBR1	0.8	9.52	0.53	2.4e-18	Menopause (age at onset);
SARC	cis	rs7043114	0.525	rs4744136	chr9:95275024	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.46	5.6	0.34	5.91e-8	Height;
SARC	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg12373951	chr3:133503437	NA	0.38	5.43	0.34	1.4e-7	Iron status biomarkers;
SARC	cis	rs2228479	0.850	rs17226980	chr16:89825065	G/A	cg00800038	chr16:89945340	TCF25	-0.74	-5.14	-0.32	5.75e-7	Skin colour saturation;
SARC	cis	rs9943753	0.525	rs6606708	chr12:109833146	T/C	cg19025524	chr12:109796872	NA	-0.39	-5.78	-0.35	2.39e-8	HDL cholesterol;
SARC	cis	rs7647973	0.593	rs7620848	chr3:49828021	G/C	cg07636037	chr3:49044803	WDR6	-0.62	-6.31	-0.38	1.41e-9	Menarche (age at onset);
SARC	cis	rs9916302	0.706	rs4795375	chr17:37662932	T/C	cg07936489	chr17:37558343	FBXL20	-0.75	-8.71	-0.5	5.74e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs35213789	0.768	rs726372	chr7:69320268	A/G	cg10619644	chr7:69149951	AUTS2	0.39	4.83	0.3	2.49e-6	Childhood ear infection;
SARC	cis	rs3617	0.625	rs3774364	chr3:52863605	G/A	cg18404041	chr3:52824283	ITIH1	-0.37	-5.4	-0.33	1.6e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs4481887	0.610	rs28763387	chr1:248559244	T/C	cg13385794	chr1:248469461	NA	0.33	5.45	0.34	1.31e-7	Common traits (Other);
SARC	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg00152838	chr16:24741724	TNRC6A	-0.58	-6.04	-0.37	5.98e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	trans	rs208520	0.874	rs208473	chr6:66917265	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.93	-11.11	-0.59	2.7e-23	Exhaled nitric oxide output;
SARC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.57	0.8	2.65e-54	Prudent dietary pattern;
SARC	cis	rs910316	0.763	rs175036	chr14:75464295	C/T	cg11812906	chr14:75593930	NEK9	-0.79	-11.1	-0.59	2.98e-23	Height;
SARC	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg16479474	chr6:28041457	NA	0.37	5.45	0.34	1.3e-7	Parkinson's disease;
SARC	cis	rs2439831	0.850	rs28578398	chr15:44075046	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	7.74	0.45	3.01e-13	Lung cancer in ever smokers;
SARC	cis	rs2075371	0.796	rs10954440	chr7:134005657	C/T	cg20476274	chr7:133979776	SLC35B4	0.54	7.0	0.42	2.72e-11	Mean platelet volume;
SARC	cis	rs4243830	0.649	rs11579888	chr1:6609896	G/A	cg04093404	chr1:6614507	TAS1R1;NOL9	0.62	5.23	0.32	3.76e-7	Body mass index;
SARC	cis	rs112374894	1.000	rs74077915	chr14:89025583	G/A	cg01020840	chr14:89016979	PTPN21	0.84	4.95	0.31	1.43e-6	Prudent dietary pattern;
SARC	cis	rs7044106	0.762	rs4837789	chr9:123426256	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	8.62	0.49	1.01e-15	Hip circumference adjusted for BMI;
SARC	cis	rs1448094	0.549	rs12308898	chr12:86233678	G/A	cg00310523	chr12:86230176	RASSF9	0.33	5.3	0.33	2.62e-7	Major depressive disorder;
SARC	cis	rs7740797	0.818	rs6906254	chr6:155074112	G/C	cg02865717	chr6:155053990	RBM16	-0.33	-4.83	-0.3	2.5e-6	Colorectal or endometrial cancer;
SARC	cis	rs7829975	0.509	rs2945269	chr8:8115578	G/C	cg06636001	chr8:8085503	FLJ10661	0.91	13.24	0.66	3.37e-30	Mood instability;
SARC	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg11247378	chr22:39784982	NA	-0.32	-5.18	-0.32	4.87e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg10971559	chr10:23287284	ARMC3	0.44	6.41	0.39	7.88e-10	Blood pressure;
SARC	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg06074448	chr4:187884817	NA	-0.41	-5.39	-0.33	1.76e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg21775007	chr8:11205619	TDH	-0.39	-4.94	-0.31	1.47e-6	Systolic blood pressure;
SARC	cis	rs8051517	1.000	rs77421912	chr16:68356008	A/G	cg01866162	chr16:67596514	CTCF	0.77	4.85	0.3	2.29e-6	Blood protein levels;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg07972983	chr1:205091412	RBBP5	-0.49	-6.54	-0.39	3.82e-10	Neuroticism;
SARC	cis	rs7249142	0.549	rs1858846	chr19:19281187	T/G	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.23	4.79	0.3	3e-6	IgG glycosylation;
SARC	cis	rs2011503	1.000	rs11670761	chr19:19649327	G/C	cg15839431	chr19:19639596	YJEFN3	-0.48	-4.77	-0.3	3.32e-6	Bipolar disorder;
SARC	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg08219700	chr8:58056026	NA	0.59	5.57	0.34	7.09e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2288073	0.965	rs13387930	chr2:24414400	A/G	cg26838691	chr2:24397539	C2orf84	-0.53	-6.54	-0.39	3.75e-10	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs950169	0.922	rs4338765	chr15:84916836	G/T	cg17507749	chr15:85114479	UBE2QP1	0.78	9.34	0.52	8.14e-18	Schizophrenia;
SARC	cis	rs9302635	0.513	rs13334151	chr16:72189727	A/C	cg01557791	chr16:72042693	DHODH	-0.55	-5.66	-0.35	4.44e-8	Blood protein levels;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg25934700	chr22:50644755	SELO	0.49	6.25	0.38	1.99e-9	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs12079745	0.590	rs41272453	chr1:169412011	T/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.89	-5.63	-0.35	5.03e-8	QT interval;
SARC	cis	rs453301	0.653	rs7853	chr8:8890814	A/G	cg06636001	chr8:8085503	FLJ10661	0.53	7.13	0.42	1.25e-11	Joint mobility (Beighton score);
SARC	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg22857025	chr5:266934	NA	-1.06	-11.82	-0.61	1.47e-25	Breast cancer;
SARC	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg22496380	chr5:211416	CCDC127	-0.87	-8.86	-0.5	2.06e-16	Breast cancer;
SARC	trans	rs11098499	0.908	rs12504149	chr4:120318577	G/A	cg25214090	chr10:38739885	LOC399744	0.57	7.43	0.44	2.01e-12	Corneal astigmatism;
SARC	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.03	12.03	0.62	3.06e-26	Alzheimer's disease;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg21321885	chr16:15744194	NDE1	-0.83	-6.7	-0.4	1.51e-10	Autism spectrum disorder or schizophrenia;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg06782692	chr10:134121419	STK32C	0.52	7.2	0.43	8.18e-12	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg24250549	chr1:154909240	PMVK	0.77	10.25	0.56	1.39e-20	Prostate cancer;
SARC	cis	rs9733	0.818	rs10888388	chr1:150687296	C/T	cg15448220	chr1:150897856	SETDB1	-0.36	-4.73	-0.3	3.86e-6	Tonsillectomy;
SARC	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg22535103	chr8:58192502	C8orf71	-0.66	-6.2	-0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6088580	0.634	rs2378134	chr20:32938085	C/T	cg24642439	chr20:33292090	TP53INP2	-0.64	-8.3	-0.48	8.24e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs2153535	0.580	rs2184586	chr6:8474182	A/G	cg21535247	chr6:8435926	SLC35B3	0.53	6.69	0.4	1.61e-10	Motion sickness;
SARC	cis	rs7772486	0.597	rs2246132	chr6:146182515	C/G	cg23711669	chr6:146136114	FBXO30	0.79	11.29	0.59	7.17e-24	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs1814175	0.645	rs847627	chr11:49927177	G/A	cg03929089	chr4:120376271	NA	-0.81	-11.69	-0.61	3.89e-25	Height;
SARC	cis	rs1707322	1.000	rs785517	chr1:46567535	A/T	cg03146154	chr1:46216737	IPP	-0.48	-5.73	-0.35	3.11e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2721811	0.738	rs2721795	chr7:24766614	G/T	cg17569154	chr7:24781545	DFNA5	0.44	5.97	0.36	8.65e-9	Depressive symptoms (multi-trait analysis);
SARC	cis	rs2120019	0.938	rs59094290	chr15:75308561	G/T	cg17294928	chr15:75287854	SCAMP5	-1.03	-15.07	-0.7	2.77e-36	Blood trace element (Zn levels);
SARC	cis	rs78320035	1.000	rs75920057	chr1:168099277	G/A	cg17113809	chr1:168148080	TIPRL	1.14	6.54	0.39	3.88e-10	Red cell distribution width;
SARC	cis	rs6910061	1.000	rs9468452	chr6:11121993	A/G	cg27233058	chr6:11094804	LOC221710	0.57	5.62	0.35	5.55e-8	Diabetic kidney disease;
SARC	cis	rs12142240	0.698	rs77185326	chr1:46818417	T/C	cg10495392	chr1:46806563	NSUN4	0.65	6.83	0.41	7.25e-11	Menopause (age at onset);
SARC	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-8.76	-0.5	4.15e-16	Alzheimer's disease;
SARC	cis	rs9910055	0.530	rs11652651	chr17:42302907	A/G	cg13607699	chr17:42295918	UBTF	-0.85	-13.64	-0.67	1.54e-31	Total body bone mineral density;
SARC	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg16606324	chr3:10149918	C3orf24	0.48	5.04	0.31	9.53e-7	Alzheimer's disease;
SARC	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg03264133	chr6:25882463	NA	-0.58	-7.42	-0.44	2.21e-12	Intelligence (multi-trait analysis);
SARC	cis	rs1348850	0.539	rs1453371	chr2:178227862	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	7.53	0.44	1.14e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs4713118	0.869	rs6914924	chr6:27711530	C/T	cg17221315	chr6:27791827	HIST1H4J	0.49	5.29	0.33	2.77e-7	Parkinson's disease;
SARC	cis	rs9309473	0.519	rs2421670	chr2:73886661	T/G	cg20560298	chr2:73613845	ALMS1	0.52	7.12	0.42	1.3e-11	Metabolite levels;
SARC	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg00149659	chr3:10157352	C3orf10	0.73	7.09	0.42	1.61e-11	Alzheimer's disease;
SARC	cis	rs11719291	0.833	rs11713694	chr3:48833615	G/T	cg06212747	chr3:49208901	KLHDC8B	-0.63	-5.4	-0.33	1.67e-7	Cognitive function;
SARC	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg11764359	chr7:65958608	NA	0.76	8.78	0.5	3.62e-16	Aortic root size;
SARC	cis	rs920590	0.573	rs12547934	chr8:19680736	T/C	cg17834443	chr8:19674713	INTS10	-0.51	-6.08	-0.37	4.84e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs2694528	0.844	rs2409824	chr5:60080418	G/T	cg11474532	chr5:59995715	DEPDC1B	0.78	5.43	0.34	1.39e-7	Parkinson's disease;
SARC	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.89	9.4	0.52	5.48e-18	Platelet count;
SARC	cis	rs910316	0.687	rs11627442	chr14:75669649	A/G	cg08847533	chr14:75593920	NEK9	-0.75	-10.59	-0.57	1.21e-21	Height;
SARC	cis	rs8038465	0.622	rs7182124	chr15:73915254	C/T	cg15420318	chr15:73925796	NPTN	0.61	6.87	0.41	5.68e-11	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9392918	0.690	rs7744088	chr6:7690275	G/A	cg23089261	chr6:7723385	NA	0.38	4.95	0.31	1.4e-6	Height;
SARC	cis	rs7246657	0.882	rs10422667	chr19:37937876	T/C	cg23950597	chr19:37808831	NA	-0.63	-6.07	-0.37	5.13e-9	Coronary artery calcification;
SARC	cis	rs713587	0.607	rs6725517	chr2:25129473	A/G	cg04586622	chr2:25135609	ADCY3	0.33	5.63	0.35	5.15e-8	Body mass index in non-asthmatics;
SARC	cis	rs12681366	0.614	rs2921385	chr8:95459348	C/T	cg26464482	chr8:95565502	KIAA1429	-0.44	-5.36	-0.33	1.97e-7	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs8014204	0.967	rs2359240	chr14:75328247	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.74	-10.72	-0.57	4.73e-22	Caffeine consumption;
SARC	cis	rs1348850	0.831	rs7606235	chr2:178401288	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.69	8.51	0.49	2.09e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9486719	1.000	rs13202675	chr6:97028427	C/T	cg06623918	chr6:96969491	KIAA0776	-0.79	-8.83	-0.5	2.51e-16	Migraine;Coronary artery disease;
SARC	cis	rs6088580	0.609	rs6059845	chr20:33036500	G/A	cg24642439	chr20:33292090	TP53INP2	0.65	8.48	0.49	2.55e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs2559856	1.000	rs2695284	chr12:102089318	A/G	cg12924262	chr12:102091054	CHPT1	-0.58	-7.89	-0.46	1.15e-13	Blood protein levels;
SARC	cis	rs7551222	0.752	rs10900597	chr1:204522489	C/T	cg20240347	chr1:204465584	NA	-0.33	-5.88	-0.36	1.4e-8	Schizophrenia;
SARC	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg03934478	chr11:495069	RNH1	0.56	5.32	0.33	2.46e-7	Body mass index;
SARC	cis	rs2204008	0.658	rs11495742	chr12:38395688	C/A	cg26384229	chr12:38710491	ALG10B	0.88	12.71	0.64	1.89e-28	Bladder cancer;
SARC	cis	rs875971	0.545	rs73376401	chr7:65639828	G/A	cg25894440	chr7:65020034	NA	0.51	4.76	0.3	3.41e-6	Aortic root size;
SARC	cis	rs834603	0.575	rs834592	chr7:47474328	T/C	cg23694490	chr7:47445681	TNS3	-0.33	-6.03	-0.37	6.29e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs6121246	0.697	rs6060912	chr20:30325755	C/A	cg13852791	chr20:30311386	BCL2L1	0.85	9.18	0.52	2.48e-17	Mean corpuscular hemoglobin;
SARC	cis	rs3741151	0.773	rs11820577	chr11:73261424	C/G	cg17517138	chr11:73019481	ARHGEF17	0.82	6.28	0.38	1.65e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg10295955	chr4:187884368	NA	-1.04	-18.25	-0.77	8.52e-47	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs13191362	0.938	rs13208970	chr6:163006368	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.57	5.51	0.34	9.61e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg12463550	chr7:65579703	CRCP	0.5	5.9	0.36	1.27e-8	Aortic root size;
SARC	cis	rs11697848	1.000	rs55994402	chr20:48467013	C/T	cg17849948	chr20:48532315	SPATA2	0.8	4.86	0.3	2.15e-6	Systemic lupus erythematosus;
SARC	cis	rs748404	0.690	rs2467737	chr15:43737188	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.49	5.46	0.34	1.2e-7	Lung cancer;
SARC	cis	rs2576037	0.521	rs4986227	chr18:44595031	G/C	cg19077165	chr18:44547161	KATNAL2	-0.41	-5.19	-0.32	4.66e-7	Personality dimensions;
SARC	cis	rs6696846	0.791	rs10158848	chr1:205061192	C/T	cg21545522	chr1:205238299	TMCC2	0.38	5.34	0.33	2.19e-7	Red blood cell count;
SARC	cis	rs35146811	0.844	rs10281368	chr7:99655897	A/G	cg22004693	chr7:99632812	ZKSCAN1	-0.45	-4.91	-0.31	1.71e-6	Coronary artery disease;
SARC	cis	rs2273669	0.667	rs111523655	chr6:109301664	G/A	cg05315195	chr6:109294784	ARMC2	-0.56	-5.14	-0.32	5.92e-7	Prostate cancer;
SARC	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	5.93	0.36	1.1e-8	Height;
SARC	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg20818283	chr2:191399100	TMEM194B	-0.46	-5.85	-0.36	1.68e-8	Pulse pressure;
SARC	cis	rs28374715	0.532	rs28463309	chr15:41666716	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.19	-20.29	-0.8	2.04e-53	Ulcerative colitis;
SARC	cis	rs8067545	0.641	rs203457	chr17:19818338	A/C	cg04132472	chr17:19861366	AKAP10	-0.39	-5.08	-0.32	7.56e-7	Schizophrenia;
SARC	cis	rs9341808	0.718	rs2322636	chr6:80897436	C/T	cg08355045	chr6:80787529	NA	0.33	5.34	0.33	2.24e-7	Sitting height ratio;
SARC	cis	rs12022452	0.591	rs6672398	chr1:41002177	A/T	cg25568243	chr1:40974465	DEM1	0.52	5.19	0.32	4.54e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs8114671	0.935	rs6058198	chr20:33748253	T/A	cg08999081	chr20:33150536	PIGU	0.34	4.74	0.3	3.72e-6	Height;
SARC	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg13395646	chr4:1353034	KIAA1530	-0.47	-5.65	-0.35	4.75e-8	Obesity-related traits;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg14950044	chr20:49457327	BCAS4	-0.8	-6.69	-0.4	1.62e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7512552	0.839	rs11590787	chr1:150398531	G/A	cg15654264	chr1:150340011	RPRD2	0.39	5.03	0.31	9.63e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs7715806	0.509	rs34349	chr5:74944868	A/G	cg19683494	chr5:74908142	NA	-0.55	-4.95	-0.31	1.43e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs796364	0.951	rs281776	chr2:200834282	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.76	7.15	0.42	1.11e-11	Schizophrenia;
SARC	cis	rs2011503	1.000	rs78883953	chr19:19630002	G/A	cg03709012	chr19:19516395	GATAD2A	0.6	5.29	0.33	2.8e-7	Bipolar disorder;
SARC	cis	rs72627123	0.867	rs74492048	chr14:74439895	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.73	5.53	0.34	8.48e-8	Morning vs. evening chronotype;
SARC	cis	rs698833	0.506	rs713448	chr2:44504877	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	5.07	0.32	7.92e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg24675658	chr1:53192096	ZYG11B	0.58	8.09	0.47	3.22e-14	Monocyte count;
SARC	cis	rs7178909	0.872	rs57715404	chr15:90433958	T/C	cg19708238	chr15:90437601	AP3S2	0.58	7.6	0.45	6.98e-13	Common traits (Other);
SARC	cis	rs1559088	0.649	rs4528686	chr19:33556074	A/G	cg17764715	chr19:33622953	WDR88	0.49	6.27	0.38	1.76e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs7312933	0.703	rs10880268	chr12:42599122	C/T	cg19980929	chr12:42632907	YAF2	0.44	6.04	0.37	6.04e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg17178900	chr1:205818956	PM20D1	0.65	9.34	0.52	7.8e-18	Menarche (age at onset);
SARC	cis	rs2204008	0.546	rs11519978	chr12:37998170	C/T	cg26384229	chr12:38710491	ALG10B	0.89	13.14	0.65	6.99e-30	Bladder cancer;
SARC	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.51	6.05	0.37	5.85e-9	Calcium levels;
SARC	cis	rs11098499	0.863	rs1552095	chr4:120460306	A/G	cg09160332	chr4:120329925	NA	-0.37	-5.09	-0.32	7.43e-7	Corneal astigmatism;
SARC	cis	rs34779708	0.931	rs12768019	chr10:35389843	T/C	cg03585969	chr10:35415529	CREM	0.41	4.98	0.31	1.21e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs870825	0.860	rs2696044	chr4:185595988	C/G	cg04058563	chr4:185651563	MLF1IP	0.72	8.96	0.51	1.05e-16	Blood protein levels;
SARC	cis	rs1468333	1.000	rs2906127	chr5:137539466	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.8	10.76	0.58	3.54e-22	Resting heart rate;
SARC	cis	rs898097	0.756	rs11655103	chr17:80813467	T/C	cg20578329	chr17:80767326	TBCD	-0.49	-6.63	-0.4	2.3e-10	Breast cancer;
SARC	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg17971929	chr21:40555470	PSMG1	-0.87	-11.14	-0.59	2.17e-23	Cognitive function;
SARC	cis	rs9393692	0.645	rs4145910	chr6:26313305	T/C	cg13736514	chr6:26305472	NA	-0.7	-9.04	-0.51	6.22e-17	Educational attainment;
SARC	cis	rs1865760	0.713	rs7766342	chr6:25990674	C/A	cg16482183	chr6:26056742	HIST1H1C	0.5	6.71	0.4	1.47e-10	Height;
SARC	cis	rs12421382	0.593	rs2118973	chr11:109389231	G/A	cg27471124	chr11:109292789	C11orf87	0.36	5.18	0.32	4.89e-7	Schizophrenia;
SARC	cis	rs6594499	0.872	rs10043631	chr5:110443228	C/T	cg04022379	chr5:110408740	TSLP	0.45	5.66	0.35	4.32e-8	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.71	-6.92	-0.41	4.32e-11	Platelet count;
SARC	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.4	-5.43	-0.34	1.4e-7	Personality dimensions;
SARC	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg11987759	chr7:65425863	GUSB	-0.64	-8.37	-0.48	5.21e-15	Aortic root size;
SARC	cis	rs6912958	0.781	rs3934838	chr6:88284699	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.43	-0.34	1.42e-7	Monocyte percentage of white cells;
SARC	cis	rs9815354	1.000	rs1717017	chr3:41915616	A/C	cg03022575	chr3:42003672	ULK4	0.55	5.24	0.32	3.65e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6582630	0.502	rs7312212	chr12:38274760	T/G	cg26384229	chr12:38710491	ALG10B	0.88	12.74	0.64	1.51e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs754466	0.606	rs11002310	chr10:79596030	A/C	cg17075019	chr10:79541650	NA	-0.8	-12.25	-0.63	5.79e-27	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs910316	1.000	rs28626045	chr14:75589195	G/C	cg06637938	chr14:75390232	RPS6KL1	0.5	7.15	0.42	1.09e-11	Height;
SARC	cis	rs9372253	1.000	rs11153232	chr6:110716252	G/T	cg19196401	chr6:110721138	DDO	0.39	5.2	0.32	4.33e-7	Platelet distribution width;
SARC	cis	rs4742903	0.904	rs7047747	chr9:106939922	G/A	cg14250997	chr9:106856677	SMC2	0.44	5.49	0.34	1.02e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs754466	0.606	rs11002315	chr10:79617385	T/G	cg17075019	chr10:79541650	NA	-0.78	-12.5	-0.63	8.75e-28	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6087990	0.806	rs992472	chr20:31385269	G/T	cg13636640	chr20:31349939	DNMT3B	0.79	12.34	0.63	3.04e-27	Ulcerative colitis;
SARC	cis	rs4919694	1.000	rs4917986	chr10:104630181	T/C	cg04362960	chr10:104952993	NT5C2	0.64	5.01	0.31	1.07e-6	Arsenic metabolism;
SARC	cis	rs7264396	0.563	rs73902913	chr20:34432784	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.56	4.75	0.3	3.49e-6	Total cholesterol levels;
SARC	cis	rs2463822	0.547	rs72917373	chr11:62024403	C/A	cg06239285	chr11:62104954	ASRGL1	-0.88	-7.94	-0.46	8.55e-14	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs9300255	0.602	rs1106241	chr12:123627016	T/C	cg00376283	chr12:123451042	ABCB9	0.57	6.66	0.4	1.93e-10	Neutrophil percentage of white cells;
SARC	cis	rs3820928	1.000	rs4675120	chr2:227774888	C/T	cg05526886	chr2:227700861	RHBDD1	-0.5	-6.14	-0.37	3.52e-9	Pulmonary function;
SARC	cis	rs9868809	0.505	rs13063223	chr3:48750340	G/A	cg07636037	chr3:49044803	WDR6	-0.69	-6.61	-0.4	2.58e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs12311304	0.965	rs7955309	chr12:15368198	T/C	cg08258403	chr12:15378311	NA	0.45	7.17	0.43	9.99e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs2286885	1.000	rs4837093	chr9:129254443	G/A	cg14319473	chr9:129242481	FAM125B	0.38	4.78	0.3	3.04e-6	Intraocular pressure;
SARC	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg01475735	chr3:40494733	NA	-0.49	-5.41	-0.33	1.57e-7	Renal cell carcinoma;
SARC	cis	rs2486288	0.656	rs8039138	chr15:45551592	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.45	-5.57	-0.34	7.07e-8	Glomerular filtration rate;
SARC	cis	rs1345301	0.518	rs1558624	chr2:102862233	A/G	cg12451869	chr2:102867685	NA	0.4	5.45	0.34	1.3e-7	Waist circumference;
SARC	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg13939156	chr17:80058883	NA	-0.41	-6.4	-0.39	8.28e-10	Life satisfaction;
SARC	cis	rs7474896	0.515	rs675628	chr10:38305331	C/G	cg25427524	chr10:38739819	LOC399744	0.47	5.74	0.35	2.95e-8	Obesity (extreme);
SARC	trans	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg20587970	chr11:113659929	NA	-1.22	-12.19	-0.62	9.18e-27	Hip circumference adjusted for BMI;
SARC	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg22105103	chr4:187893119	NA	0.49	6.57	0.4	3.25e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9470366	0.637	rs4151702	chr6:36645988	G/C	cg08179530	chr6:36648295	CDKN1A	0.53	5.21	0.32	4.08e-7	QRS duration;
SARC	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg11987759	chr7:65425863	GUSB	-0.5	-5.93	-0.36	1.06e-8	Aortic root size;
SARC	cis	rs501120	0.925	rs1657344	chr10:44781234	C/T	cg09554077	chr10:44749378	NA	0.52	5.95	0.36	9.9e-9	Coronary artery disease;Coronary heart disease;
SARC	cis	rs936229	0.954	rs936230	chr15:75145098	C/T	cg14664628	chr15:75095509	CSK	0.96	13.12	0.65	8.28e-30	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg15049968	chr18:44337910	ST8SIA5	-0.34	-5.25	-0.33	3.47e-7	Personality dimensions;
SARC	cis	rs7589728	0.925	rs78829281	chr2:88502293	T/A	cg04511125	chr2:88470314	THNSL2	0.69	6.2	0.38	2.61e-9	Plasma clusterin levels;
SARC	cis	rs8067545	0.578	rs62066870	chr17:20063758	A/C	cg13482628	chr17:19912719	NA	0.51	6.56	0.39	3.51e-10	Schizophrenia;
SARC	cis	rs4595586	0.545	rs7972590	chr12:39376615	A/G	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg21724239	chr8:58056113	NA	0.61	5.76	0.35	2.67e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs67311347	1.000	rs1466237	chr3:40462026	C/G	cg09455208	chr3:40491958	NA	0.43	6.91	0.41	4.53e-11	Renal cell carcinoma;
SARC	cis	rs9747201	0.862	rs11651738	chr17:80178691	A/T	cg09264619	chr17:80180166	NA	-0.57	-6.29	-0.38	1.52e-9	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs1865760	0.964	rs3799373	chr6:25929173	A/C	cg16482183	chr6:26056742	HIST1H1C	0.52	6.38	0.39	9.52e-10	Height;
SARC	cis	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg25894440	chr7:65020034	NA	-0.74	-5.72	-0.35	3.18e-8	Diabetic kidney disease;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg13510361	chr9:104161291	MRPL50;ZNF189	0.5	6.46	0.39	6.11e-10	Lung adenocarcinoma;
SARC	cis	rs282587	0.569	rs1278658	chr13:113386832	G/C	cg02820901	chr13:113351484	ATP11A	-0.49	-4.76	-0.3	3.35e-6	Glycated hemoglobin levels;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg06067032	chr13:26796571	RNF6	0.46	6.35	0.38	1.13e-9	Chemerin levels;
SARC	cis	rs734999	0.545	rs6698817	chr1:2564183	T/C	cg20673091	chr1:2541236	MMEL1	-0.33	-5.11	-0.32	6.56e-7	Ulcerative colitis;
SARC	cis	rs11690935	0.632	rs34531723	chr2:172564094	A/C	cg13550731	chr2:172543902	DYNC1I2	0.66	9.38	0.52	6.3e-18	Schizophrenia;
SARC	cis	rs3087591	0.922	rs12950506	chr17:29598392	A/G	cg24425628	chr17:29625626	OMG;NF1	0.55	6.75	0.4	1.19e-10	Hip circumference;
SARC	cis	rs73086581	0.947	rs67356712	chr20:3892886	A/G	cg02187196	chr20:3869020	PANK2	0.63	5.71	0.35	3.34e-8	Response to antidepressants in depression;
SARC	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg19500275	chr17:80737654	TBCD	0.41	4.73	0.3	3.93e-6	Glycated hemoglobin levels;
SARC	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg21782813	chr7:2030301	MAD1L1	0.41	6.24	0.38	2.09e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs7674212	0.507	rs223317	chr4:103802824	T/C	cg16532752	chr4:104119610	CENPE	-0.43	-4.91	-0.31	1.74e-6	Type 2 diabetes;
SARC	cis	rs11608355	0.515	rs11614551	chr12:109931630	G/A	cg05360138	chr12:110035743	NA	0.92	9.39	0.52	5.78e-18	Neuroticism;
SARC	cis	rs77956314	0.901	rs117425351	chr12:117409752	A/G	cg16111737	chr12:117408163	FBXW8	0.6	5.23	0.32	3.71e-7	Subcortical brain region volumes;Hippocampal volume;
SARC	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg06221963	chr1:154839813	KCNN3	-0.51	-8.24	-0.47	1.27e-14	Prostate cancer;
SARC	cis	rs2425143	1.000	rs57963833	chr20:34344225	T/A	cg01084648	chr20:34329383	RBM39	0.65	5.04	0.31	9.47e-7	Blood protein levels;
SARC	cis	rs57506017	0.585	rs4721059	chr7:12267495	C/G	cg23422036	chr7:12250390	TMEM106B	-0.43	-5.45	-0.34	1.25e-7	Neuroticism;
SARC	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.39	-5.03	-0.31	9.68e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7712401	0.598	rs367768	chr5:122191126	C/A	cg19412675	chr5:122181750	SNX24	0.38	4.9	0.31	1.81e-6	Mean platelet volume;
SARC	cis	rs6540556	0.769	rs6665715	chr1:209931353	A/C	cg23920097	chr1:209922102	NA	0.63	7.16	0.42	1.08e-11	Red blood cell count;
SARC	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg10591111	chr5:226296	SDHA	-0.51	-4.79	-0.3	3e-6	Breast cancer;
SARC	cis	rs6942407	0.592	rs2373389	chr7:86751777	C/A	cg02420886	chr7:86849541	C7orf23	0.6	5.44	0.34	1.32e-7	Food allergy;
SARC	cis	rs7412746	0.658	rs17660092	chr1:150797748	T/C	cg10589385	chr1:150898437	SETDB1	0.41	5.45	0.34	1.29e-7	Melanoma;
SARC	cis	rs950169	0.723	rs17589320	chr15:84919996	C/A	cg24253500	chr15:84953950	NA	0.36	5.19	0.32	4.54e-7	Schizophrenia;
SARC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg20102877	chr2:27665638	KRTCAP3	-0.37	-5.25	-0.33	3.44e-7	Total body bone mineral density;
SARC	cis	rs6964587	1.000	rs411	chr7:91557758	C/G	cg17063962	chr7:91808500	NA	-0.94	-14.8	-0.7	2.22e-35	Breast cancer;
SARC	cis	rs9768139	0.683	rs4909178	chr7:158117752	T/A	cg25566285	chr7:158114605	PTPRN2	0.31	5.04	0.31	9.38e-7	Calcium levels;
SARC	cis	rs1450679	0.843	rs1999153	chr9:106853504	G/A	cg21169611	chr9:106856078	SMC2	0.58	5.06	0.31	8.7e-7	Response to cytadine analogues (cytosine arabinoside);
SARC	cis	rs796364	0.951	rs769952	chr2:200734368	C/T	cg23649088	chr2:200775458	C2orf69	0.59	5.37	0.33	1.87e-7	Schizophrenia;
SARC	cis	rs72792276	0.818	rs3805610	chr5:127487719	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.61	5.0	0.31	1.11e-6	Red cell distribution width;
SARC	cis	rs72772090	0.634	rs10515246	chr5:96099265	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.62	-5.1	-0.32	6.96e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg05025164	chr4:1340916	KIAA1530	0.45	5.18	0.32	4.91e-7	Obesity-related traits;
SARC	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg05368731	chr17:41323189	NBR1	0.76	9.07	0.51	5.09e-17	Menopause (age at onset);
SARC	cis	rs9894429	0.608	rs8477	chr17:79618059	C/T	cg10661904	chr17:79619235	PDE6G	-0.45	-6.21	-0.38	2.38e-9	Eye color traits;
SARC	cis	rs7851660	0.527	rs7870795	chr9:100574120	A/G	cg13688889	chr9:100608707	NA	-0.45	-5.12	-0.32	6.5e-7	Strep throat;
SARC	cis	rs17376456	0.825	rs10054790	chr5:93272520	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.59	0.34	6.3e-8	Diabetic retinopathy;
SARC	cis	rs123509	0.687	rs73077220	chr3:42842340	T/C	cg12982090	chr3:42733453	KBTBD5	-0.53	-5.95	-0.36	9.96e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9290065	0.519	rs7626904	chr3:160672427	C/T	cg04691961	chr3:161091175	C3orf57	-0.52	-6.65	-0.4	2.09e-10	Kawasaki disease;
SARC	cis	rs35110281	0.840	rs2838331	chr21:45026728	A/G	cg01579765	chr21:45077557	HSF2BP	0.37	6.17	0.37	2.95e-9	Mean corpuscular volume;
SARC	cis	rs2153535	0.580	rs7767926	chr6:8453557	A/G	cg21535247	chr6:8435926	SLC35B3	0.54	6.83	0.41	7.19e-11	Motion sickness;
SARC	cis	rs1448094	0.512	rs7970081	chr12:86243392	G/T	cg02569458	chr12:86230093	RASSF9	0.39	5.44	0.34	1.34e-7	Major depressive disorder;
SARC	cis	rs3845702	0.736	rs72960660	chr2:180832482	A/G	cg01881094	chr2:180872142	CWC22	1.16	9.56	0.53	1.71e-18	Schizophrenia;
SARC	cis	rs1707322	0.963	rs10789484	chr1:46406978	G/C	cg03146154	chr1:46216737	IPP	0.46	5.53	0.34	8.66e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs2727020	0.576	rs12293522	chr11:49558425	T/A	cg15704280	chr7:45808275	SEPT13	-0.86	-14.59	-0.69	1.07e-34	Coronary artery disease;
SARC	cis	rs67311347	0.955	rs73080163	chr3:40533061	G/T	cg09455208	chr3:40491958	NA	0.33	5.05	0.31	8.92e-7	Renal cell carcinoma;
SARC	cis	rs17384381	1.000	rs35193119	chr1:85859265	T/C	cg16011679	chr1:85725395	C1orf52	0.61	5.77	0.35	2.49e-8	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs9329221	0.618	rs4314693	chr8:10258932	G/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-6.88	-0.41	5.56e-11	Neuroticism;
SARC	cis	rs9399135	0.967	rs6919862	chr6:135352443	C/A	cg24558204	chr6:135376177	HBS1L	0.45	6.15	0.37	3.33e-9	Red blood cell count;
SARC	cis	rs28374715	0.635	rs8023530	chr15:41647775	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.98	-15.66	-0.72	2.94e-38	Ulcerative colitis;
SARC	cis	rs9858542	1.000	rs13085791	chr3:49721798	C/A	cg07274523	chr3:49395745	GPX1	0.5	5.72	0.35	3.31e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs7520050	0.966	rs785494	chr1:46586626	C/A	cg24296786	chr1:45957014	TESK2	0.38	4.82	0.3	2.56e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs2153535	0.580	rs1335637	chr6:8465101	A/G	cg21535247	chr6:8435926	SLC35B3	0.54	6.79	0.41	9.19e-11	Motion sickness;
SARC	cis	rs3087591	1.000	rs2952982	chr17:29470646	A/C	cg24425628	chr17:29625626	OMG;NF1	0.57	7.21	0.43	7.71e-12	Hip circumference;
SARC	cis	rs2576037	0.901	rs2571021	chr18:44583498	A/G	cg19077165	chr18:44547161	KATNAL2	0.47	6.62	0.4	2.51e-10	Personality dimensions;
SARC	cis	rs7551222	0.752	rs2290854	chr1:204516025	A/G	cg20240347	chr1:204465584	NA	-0.33	-6.0	-0.37	7.31e-9	Schizophrenia;
SARC	cis	rs2624839	0.629	rs2526397	chr3:50187790	A/C	cg14019146	chr3:50243930	SLC38A3	0.3	4.8	0.3	2.77e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7666738	0.861	rs5010991	chr4:98972179	A/G	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2387326	0.680	rs11016097	chr10:129942948	T/C	cg16087940	chr10:129947807	NA	-0.45	-5.59	-0.34	6.29e-8	Select biomarker traits;
SARC	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg02725872	chr8:58115012	NA	-0.34	-5.46	-0.34	1.19e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs72781680	0.821	rs72790304	chr2:24108557	G/A	cg06627628	chr2:24431161	ITSN2	-0.58	-6.22	-0.38	2.29e-9	Lymphocyte counts;
SARC	cis	rs10504073	0.669	rs341801	chr8:50037784	A/G	cg00325661	chr8:49890786	NA	0.55	7.45	0.44	1.84e-12	Blood metabolite ratios;
SARC	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg27286337	chr10:134555280	INPP5A	0.66	8.31	0.48	8e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs1050631	0.592	rs1785921	chr18:33737196	A/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.56	6.52	0.39	4.41e-10	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs694739	0.892	rs647152	chr11:64109118	T/G	cg23796481	chr11:64053134	BAD;GPR137	0.68	8.79	0.5	3.45e-16	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.56	8.77	0.5	3.9e-16	Eosinophil percentage of white cells;
SARC	cis	rs2191566	0.960	rs11083733	chr19:44520919	G/C	cg20607764	chr19:44506953	ZNF230	-0.49	-5.66	-0.35	4.34e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs11608355	0.810	rs2217971	chr12:109857666	G/C	cg05360138	chr12:110035743	NA	0.59	6.28	0.38	1.65e-9	Neuroticism;
SARC	cis	rs6582630	0.502	rs11514371	chr12:38306306	G/C	cg26384229	chr12:38710491	ALG10B	0.86	12.55	0.64	6.16e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1318878	0.565	rs1304740	chr12:15506907	T/C	cg08258403	chr12:15378311	NA	0.48	6.67	0.4	1.87e-10	Intelligence (multi-trait analysis);
SARC	cis	rs11098499	0.955	rs1511018	chr4:120161580	G/T	cg09307838	chr4:120376055	NA	0.84	11.6	0.61	7.45e-25	Corneal astigmatism;
SARC	cis	rs7044106	0.762	rs7357638	chr9:123389204	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	5.01	0.31	1.05e-6	Hip circumference adjusted for BMI;
SARC	cis	rs6102059	0.503	rs6029179	chr20:39178679	C/T	cg06424997	chr20:39929561	ZHX3	0.37	4.89	0.3	1.92e-6	LDL cholesterol;
SARC	trans	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.04	-0.42	2.08e-11	Neuroticism;
SARC	cis	rs9420	0.961	rs7949841	chr11:57524700	G/C	cg19752551	chr11:57585705	CTNND1	-0.52	-7.19	-0.43	8.7e-12	Schizophrenia;
SARC	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.73	-7.16	-0.42	1.02e-11	Platelet count;
SARC	cis	rs7717697	0.797	rs10474101	chr5:82739803	T/C	cg19814134	chr5:82768288	VCAN	0.44	5.25	0.33	3.48e-7	Vertical cup-disc ratio;
SARC	cis	rs2865126	0.743	rs2865120	chr18:10754921	A/G	cg21165219	chr18:10698044	FAM38B	-0.5	-5.04	-0.31	9.28e-7	Metabolite levels (5-HIAA/ MHPG Ratio);
SARC	trans	rs208520	0.954	rs72884027	chr6:66995044	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	9.32	0.52	9.16e-18	Exhaled nitric oxide output;
SARC	cis	rs11676348	0.846	rs4674259	chr2:218991005	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.48	-6.22	-0.38	2.25e-9	Ulcerative colitis;
SARC	cis	rs8180040	0.654	rs6773521	chr3:47234419	A/G	cg27129171	chr3:47204927	SETD2	-0.69	-9.4	-0.52	5.33e-18	Colorectal cancer;
SARC	cis	rs8077889	0.672	rs1230397	chr17:41844689	A/G	cg26893861	chr17:41843967	DUSP3	1.01	17.06	0.75	6.96e-43	Triglycerides;
SARC	cis	rs208520	0.690	rs4386800	chr6:66755242	A/G	cg07460842	chr6:66804631	NA	1.03	13.88	0.67	2.57e-32	Exhaled nitric oxide output;
SARC	trans	rs982274	0.594	rs158038	chr21:19462131	A/C	cg09289712	chr7:139044435	LUC7L2	0.55	6.44	0.39	6.92e-10	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs7666738	0.830	rs6532720	chr4:99043781	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs13314892	0.764	rs62251009	chr3:69849835	T/C	cg17445875	chr3:69859618	MITF	-0.49	-5.09	-0.32	7.21e-7	QRS complex (12-leadsum);
SARC	cis	rs7917772	0.582	rs10786682	chr10:104318322	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.47	-6.25	-0.38	1.88e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.7	6.38	0.39	9.38e-10	Platelet count;
SARC	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg11644478	chr21:40555479	PSMG1	1.05	15.1	0.7	2.22e-36	Cognitive function;
SARC	cis	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg25894440	chr7:65020034	NA	-0.73	-5.51	-0.34	9.48e-8	Diabetic kidney disease;
SARC	cis	rs35146811	0.806	rs1534310	chr7:99699169	A/T	cg22004693	chr7:99632812	ZKSCAN1	-0.48	-5.28	-0.33	3.02e-7	Coronary artery disease;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg19715471	chr10:13344246	NA	0.52	6.55	0.39	3.58e-10	Height;
SARC	trans	rs1814175	0.817	rs12287396	chr11:49819798	G/C	cg03929089	chr4:120376271	NA	-0.9	-14.58	-0.69	1.14e-34	Height;
SARC	cis	rs7474896	0.537	rs1022449	chr10:38279467	T/A	cg25427524	chr10:38739819	LOC399744	0.45	5.47	0.34	1.18e-7	Obesity (extreme);
SARC	cis	rs3617	0.573	rs2336668	chr3:52919096	G/T	cg05564831	chr3:52568323	NT5DC2	-0.27	-4.76	-0.3	3.43e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg06108461	chr20:60628389	TAF4	-0.89	-11.79	-0.61	1.78e-25	Body mass index;
SARC	cis	rs6570726	0.935	rs419854	chr6:145844085	A/C	cg05347473	chr6:146136440	FBXO30	0.48	6.47	0.39	5.7e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg18876405	chr7:65276391	NA	-0.46	-5.51	-0.34	9.31e-8	Aortic root size;
SARC	cis	rs10782582	0.593	rs79552201	chr1:76215497	A/T	cg10523679	chr1:76189770	ACADM	-0.44	-5.41	-0.33	1.54e-7	Daytime sleep phenotypes;
SARC	cis	rs8005677	1.000	rs1951119	chr14:23388326	A/C	cg01529538	chr14:23388837	RBM23	0.46	5.72	0.35	3.25e-8	Cognitive ability (multi-trait analysis);
SARC	cis	rs3815700	1.000	rs8101356	chr19:33093402	C/T	cg24916020	chr19:33096688	ANKRD27	0.56	5.41	0.33	1.59e-7	Eosinophilic esophagitis;
SARC	trans	rs61931739	0.500	rs34997501	chr12:34549828	C/G	cg13010199	chr12:38710504	ALG10B	0.83	11.77	0.61	2.09e-25	Morning vs. evening chronotype;
SARC	cis	rs778371	0.871	rs2675954	chr2:233750627	C/G	cg16596103	chr2:233749413	NGEF	0.37	5.71	0.35	3.47e-8	Schizophrenia;
SARC	cis	rs3892630	0.878	rs2903759	chr19:33195947	A/G	cg22980127	chr19:33182716	NUDT19	1.03	9.52	0.53	2.39e-18	Red blood cell traits;
SARC	cis	rs8028182	0.725	rs74422833	chr15:75871521	C/T	cg20655648	chr15:75932815	IMP3	0.68	5.16	0.32	5.2e-7	Sudden cardiac arrest;
SARC	cis	rs7927592	0.913	rs2236708	chr11:68378045	G/A	cg01657329	chr11:68192670	LRP5	-0.43	-5.11	-0.32	6.73e-7	Total body bone mineral density;
SARC	cis	rs858239	0.899	rs858271	chr7:23278283	G/T	cg23682824	chr7:23144976	KLHL7	0.61	7.54	0.44	1.05e-12	Cerebrospinal fluid biomarker levels;
SARC	cis	rs13161895	1.000	rs3719	chr5:179435118	T/C	cg02702477	chr5:179499311	RNF130	-0.65	-6.46	-0.39	5.92e-10	LDL cholesterol;
SARC	cis	rs11098499	0.909	rs7681978	chr4:120383775	T/C	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs7429990	0.965	rs4296617	chr3:48068308	T/C	cg11946769	chr3:48343235	NME6	-0.47	-5.34	-0.33	2.2e-7	Educational attainment (years of education);
SARC	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg07636037	chr3:49044803	WDR6	1.01	17.85	0.76	1.69e-45	Parkinson's disease;
SARC	cis	rs9911578	0.967	rs2429369	chr17:56501420	A/G	cg12560992	chr17:57184187	TRIM37	0.77	10.02	0.55	7.03e-20	Intelligence (multi-trait analysis);
SARC	cis	rs9309473	0.687	rs6748040	chr2:73609928	A/G	cg20560298	chr2:73613845	ALMS1	0.55	7.19	0.43	8.61e-12	Metabolite levels;
SARC	cis	rs644799	0.635	rs10831428	chr11:95508404	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.61	8.15	0.47	2.28e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs10504073	0.584	rs55795863	chr8:49898055	A/G	cg00325661	chr8:49890786	NA	0.51	6.86	0.41	6.07e-11	Blood metabolite ratios;
SARC	cis	rs7044106	0.791	rs2416798	chr9:123480603	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	9.3	0.52	1.06e-17	Hip circumference adjusted for BMI;
SARC	cis	rs7639513	0.767	rs9878151	chr3:12703714	G/C	cg23032965	chr3:12705835	RAF1	0.84	12.27	0.63	5.13e-27	Itch intensity from mosquito bite;
SARC	cis	rs7208859	0.623	rs56163556	chr17:29101868	G/C	cg13385521	chr17:29058706	SUZ12P	0.84	7.02	0.42	2.44e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs7589342	0.536	rs17201484	chr2:106394809	C/G	cg16077055	chr2:106428750	NCK2	0.31	6.06	0.37	5.29e-9	Addiction;
SARC	cis	rs4481887	1.000	rs7517319	chr1:248466408	C/A	cg01631408	chr1:248437212	OR2T33	-0.44	-5.66	-0.35	4.35e-8	Common traits (Other);
SARC	cis	rs9467773	1.000	rs6940188	chr6:26562029	G/C	cg12292205	chr6:26970375	C6orf41	0.45	5.35	0.33	2.05e-7	Intelligence (multi-trait analysis);
SARC	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg14893161	chr1:205819251	PM20D1	0.51	5.77	0.35	2.54e-8	Parkinson's disease;
SARC	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg14664628	chr15:75095509	CSK	-0.49	-6.18	-0.38	2.84e-9	Breast cancer;
SARC	cis	rs1215050	0.791	rs1025201	chr4:98902938	A/G	cg05340658	chr4:99064831	C4orf37	-0.45	-6.08	-0.37	5e-9	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs7667	1.000	rs10753558	chr1:19697915	C/T	cg15311933	chr1:19638897	PQLC2;AKR7A2	-0.47	-5.39	-0.33	1.68e-7	Crohn's disease and psoriasis;
SARC	cis	rs116095464	0.558	rs10056628	chr5:279512	G/A	cg22496380	chr5:211416	CCDC127	-0.96	-8.86	-0.5	2.11e-16	Breast cancer;
SARC	cis	rs4911259	0.513	rs4287835	chr20:31457337	T/C	cg13636640	chr20:31349939	DNMT3B	-0.66	-9.07	-0.51	5.08e-17	Inflammatory bowel disease;
SARC	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg19680485	chr15:31195859	MTMR15	0.52	6.11	0.37	4.22e-9	Huntington's disease progression;
SARC	cis	rs12586317	0.513	rs11156871	chr14:35481196	G/A	cg16230307	chr14:35515116	FAM177A1	1.02	11.85	0.61	1.18e-25	Psoriasis;
SARC	cis	rs7520050	0.966	rs12405451	chr1:46384326	T/A	cg24296786	chr1:45957014	TESK2	0.39	4.9	0.31	1.77e-6	Red blood cell count;Reticulocyte count;
SARC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg15383120	chr6:291909	DUSP22	0.61	8.16	0.47	2.15e-14	Menopause (age at onset);
SARC	cis	rs634534	0.561	rs14157	chr11:65769780	T/G	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.44	-5.53	-0.34	8.54e-8	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.63	-7.61	-0.45	6.91e-13	Gut microbiome composition (summer);
SARC	cis	rs9393692	0.875	rs9393690	chr6:26271713	A/T	cg00631329	chr6:26305371	NA	-0.61	-8.94	-0.51	1.22e-16	Educational attainment;
SARC	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg09699651	chr6:150184138	LRP11	0.43	4.97	0.31	1.29e-6	Lung cancer;
SARC	cis	rs6088813	1.000	rs725908	chr20:33968067	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	-0.45	-5.44	-0.34	1.34e-7	Height;
SARC	cis	rs9549260	0.683	rs35594717	chr13:41240783	G/A	cg21288729	chr13:41239152	FOXO1	0.59	6.04	0.37	6.05e-9	Red blood cell count;
SARC	cis	rs1008375	0.931	rs10939734	chr4:17570709	C/T	cg02297831	chr4:17616191	MED28	0.46	5.72	0.35	3.33e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs208520	0.526	rs6913344	chr6:66754285	A/C	cg07460842	chr6:66804631	NA	-1.06	-19.43	-0.79	1.23e-50	Exhaled nitric oxide output;
SARC	cis	rs9916302	0.904	rs4794807	chr17:37531718	T/A	cg20243544	chr17:37824526	PNMT	-0.57	-6.98	-0.42	3.09e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs2425143	0.908	rs74784474	chr20:34422464	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	5.06	0.31	8.63e-7	Blood protein levels;
SARC	cis	rs8016982	0.634	rs1035948	chr14:81682392	C/T	cg01989461	chr14:81687754	GTF2A1	0.74	11.37	0.6	4.15e-24	Schizophrenia;
SARC	cis	rs400736	0.729	rs1546846	chr1:8004259	C/T	cg25007680	chr1:8021821	PARK7	-0.42	-5.39	-0.33	1.69e-7	Response to antidepressants and depression;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg24605529	chr2:203879461	NBEAL1	0.51	6.32	0.38	1.31e-9	Breast cancer;
SARC	cis	rs738322	0.967	rs133021	chr22:38573338	T/C	cg25457927	chr22:38595422	NA	-0.3	-6.24	-0.38	2.02e-9	Cutaneous nevi;
SARC	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg13803071	chr2:9771081	YWHAQ	-0.75	-6.47	-0.39	5.59e-10	Plasma thyroid-stimulating hormone levels;
SARC	cis	rs10089	1.000	rs10463838	chr5:127518305	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	9.1	0.51	4.25e-17	Ileal carcinoids;
SARC	cis	rs7077164	1.000	rs1227769	chr10:71586296	C/T	cg20696214	chr10:71583771	COL13A1	-0.4	-5.21	-0.32	4.06e-7	Non-alcoholic fatty liver disease histology (lobular);
SARC	cis	rs1957429	0.520	rs72625643	chr14:65340964	C/G	cg23373153	chr14:65346875	NA	-0.82	-5.63	-0.35	5.25e-8	Pediatric areal bone mineral density (radius);
SARC	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg06618935	chr21:46677482	NA	-0.4	-5.46	-0.34	1.21e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs11088226	0.581	rs2236430	chr21:33973408	A/G	cg09050820	chr6:167586206	TCP10L2	-0.54	-7.21	-0.43	7.67e-12	Gastritis;
SARC	cis	rs13082711	0.911	rs2172298	chr3:27425611	T/C	cg02860705	chr3:27208620	NA	0.46	5.98	0.36	8.27e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg04772025	chr11:68637568	NA	0.48	6.1	0.37	4.46e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs12681288	0.823	rs2701907	chr8:1003292	A/G	cg15309053	chr8:964076	NA	0.41	6.75	0.4	1.15e-10	Schizophrenia;
SARC	cis	rs2273669	0.588	rs75995854	chr6:109325624	C/A	cg05315195	chr6:109294784	ARMC2	-0.59	-5.45	-0.34	1.28e-7	Prostate cancer;
SARC	cis	rs57506017	0.585	rs5011432	chr7:12268668	A/C	cg23422036	chr7:12250390	TMEM106B	0.46	5.96	0.36	9.21e-9	Neuroticism;
SARC	cis	rs9486719	1.000	rs13207333	chr6:96882254	T/C	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.01	-0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs2342371	0.756	rs28712197	chr3:196107214	T/C	cg15048948	chr3:196158458	UBXN7	0.62	7.47	0.44	1.65e-12	Fat distribution (HIV);
SARC	cis	rs12134245	0.874	rs17501937	chr1:92021705	C/T	cg02896835	chr1:92012615	NA	0.44	6.07	0.37	5.04e-9	Breast cancer;
SARC	cis	rs10191773	0.584	rs72831633	chr2:112945932	T/G	cg07905836	chr2:113190072	RGPD8;RGPD5	0.96	7.97	0.46	6.88e-14	Yeast infection;
SARC	cis	rs3764563	1.000	rs2031062	chr19:15717573	T/C	cg20725493	chr19:15740067	CYP4F8	-0.67	-4.74	-0.3	3.69e-6	Inflammatory biomarkers;
SARC	cis	rs12142240	0.698	rs72677592	chr1:46818288	A/G	cg00530320	chr1:46809349	NSUN4	0.57	6.89	0.41	5.25e-11	Menopause (age at onset);
SARC	cis	rs2425143	1.000	rs11167275	chr20:34340275	T/C	cg01084648	chr20:34329383	RBM39	0.63	4.95	0.31	1.44e-6	Blood protein levels;
SARC	cis	rs365302	0.716	rs452651	chr6:159610946	C/T	cg14500486	chr6:159655392	FNDC1	0.41	5.02	0.31	1.04e-6	Coronary heart disease;
SARC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg22535103	chr8:58192502	C8orf71	-0.59	-6.21	-0.38	2.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs3008870	0.536	rs2208576	chr1:67513401	C/G	cg02640540	chr1:67518911	SLC35D1	-0.67	-8.34	-0.48	6.63e-15	Lymphocyte percentage of white cells;
SARC	cis	rs7818345	0.935	rs6990217	chr8:19276661	G/C	cg11303988	chr8:19266685	CSGALNACT1	0.42	5.7	0.35	3.64e-8	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs6570726	0.935	rs398060	chr6:145841515	C/T	cg05347473	chr6:146136440	FBXO30	-0.52	-7.03	-0.42	2.2e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.46	-5.77	-0.35	2.54e-8	Gut microbiome composition (summer);
SARC	trans	rs79976124	1.000	rs79976124	chr6:66618657	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	7.42	0.44	2.2e-12	Type 2 diabetes;
SARC	cis	rs2153535	0.601	rs9393030	chr6:8516489	C/G	cg07606381	chr6:8435919	SLC35B3	0.77	10.9	0.58	1.28e-22	Motion sickness;
SARC	cis	rs9612	1.000	rs346523	chr19:44260681	A/C	cg08581076	chr19:44259116	C19orf61	0.65	7.87	0.46	1.3e-13	Exhaled nitric oxide output;
SARC	cis	rs3733585	0.648	rs7378305	chr4:9954893	C/T	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.39	-0.33	1.76e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs11638352	1.000	rs2059628	chr15:44415271	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.77	-5.84	-0.36	1.78e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	cis	rs12142240	0.738	rs10489769	chr1:46806703	A/G	cg10495392	chr1:46806563	NSUN4	0.64	6.84	0.41	6.77e-11	Menopause (age at onset);
SARC	cis	rs7772486	0.654	rs1011597	chr6:146075672	A/C	cg23711669	chr6:146136114	FBXO30	-0.82	-13.44	-0.66	6.95e-31	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg20891283	chr12:69753455	YEATS4	-0.7	-10.28	-0.56	1.13e-20	Cerebrospinal fluid biomarker levels;
SARC	cis	rs8141529	0.529	rs35017742	chr22:29216585	C/T	cg02153584	chr22:29168773	CCDC117	0.65	6.49	0.39	5.07e-10	Lymphocyte counts;
SARC	cis	rs4481887	0.861	rs4486480	chr1:248449714	C/T	cg01631408	chr1:248437212	OR2T33	-0.46	-5.77	-0.35	2.55e-8	Common traits (Other);
SARC	cis	rs6977660	0.562	rs2189566	chr7:19768960	G/A	cg05791153	chr7:19748676	TWISTNB	0.9	7.53	0.44	1.1e-12	Thyroid stimulating hormone;
SARC	cis	rs8014204	0.544	rs2286913	chr14:75386576	G/A	cg06637938	chr14:75390232	RPS6KL1	0.92	15.01	0.7	4.47e-36	Caffeine consumption;
SARC	cis	rs9457247	1.000	rs2769352	chr6:167378619	A/G	cg23791538	chr6:167370224	RNASET2	0.62	8.55	0.49	1.63e-15	Crohn's disease;
SARC	cis	rs6088590	1.000	rs6119512	chr20:33306904	T/C	cg06115741	chr20:33292138	TP53INP2	0.57	6.94	0.41	3.96e-11	Coronary artery disease;
SARC	cis	rs9467711	0.606	rs9379875	chr6:26444732	C/T	cg12826209	chr6:26865740	GUSBL1	0.8	4.91	0.31	1.73e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1008375	0.931	rs2315558	chr4:17674558	C/A	cg02297831	chr4:17616191	MED28	0.43	5.56	0.34	7.42e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg18252515	chr7:66147081	NA	0.51	5.81	0.36	1.99e-8	Aortic root size;
SARC	cis	rs6988636	0.710	rs17315999	chr8:124153763	A/G	cg23067535	chr8:124195133	FAM83A	-0.64	-4.75	-0.3	3.54e-6	Urinary uromodulin levels;
SARC	cis	rs6502050	0.799	rs6502088	chr17:80169484	C/T	cg13939156	chr17:80058883	NA	-0.42	-6.4	-0.39	8.53e-10	Life satisfaction;
SARC	cis	rs9815354	0.812	rs17284472	chr3:41996304	A/G	cg03022575	chr3:42003672	ULK4	-0.66	-5.42	-0.33	1.48e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs7829975	0.811	rs7011229	chr8:8543324	T/C	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.15	-0.47	2.24e-14	Mood instability;
SARC	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.46	0.39	6.12e-10	Bipolar disorder;
SARC	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg10295955	chr4:187884368	NA	0.69	8.9	0.5	1.63e-16	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs561341	1.000	rs8077092	chr17:30281992	T/C	cg20587970	chr11:113659929	NA	-1.27	-12.5	-0.63	8.72e-28	Hip circumference adjusted for BMI;
SARC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.43	-5.6	-0.34	6.04e-8	Longevity;Endometriosis;
SARC	cis	rs9790314	0.628	rs4342141	chr3:160783922	T/C	cg03342759	chr3:160939853	NMD3	-0.53	-6.61	-0.4	2.64e-10	Morning vs. evening chronotype;
SARC	cis	rs7772486	0.754	rs4896838	chr6:146015451	T/C	cg05347473	chr6:146136440	FBXO30	-0.56	-7.82	-0.46	1.85e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9457247	0.967	rs2757054	chr6:167380501	A/G	cg23791538	chr6:167370224	RNASET2	0.63	8.68	0.49	6.8e-16	Crohn's disease;
SARC	cis	rs6674176	0.660	rs3791112	chr1:44379248	T/G	cg13606994	chr1:44402422	ARTN	-0.36	-5.92	-0.36	1.13e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs10992471	0.598	rs3174352	chr9:95219248	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.42	5.18	0.32	4.91e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs72945132	0.882	rs17160039	chr11:70145489	A/G	cg05964544	chr11:70165517	PPFIA1	-0.61	-5.87	-0.36	1.5e-8	Coronary artery disease;
SARC	cis	rs9815354	0.812	rs56332587	chr3:42012714	T/C	cg03022575	chr3:42003672	ULK4	0.71	5.98	0.36	8.48e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs986417	0.818	rs8008804	chr14:61082357	A/T	cg27398547	chr14:60952738	C14orf39	0.87	7.61	0.45	6.73e-13	Gut microbiota (bacterial taxa);
SARC	cis	rs2735413	0.881	rs11150036	chr16:78075687	C/G	cg04733911	chr16:78082701	NA	-0.31	-5.61	-0.34	5.78e-8	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg18225595	chr11:63971243	STIP1	0.53	7.73	0.45	3.12e-13	Platelet count;
SARC	cis	rs4664308	0.692	rs13009231	chr2:160964057	G/T	cg03641300	chr2:160917029	PLA2R1	-0.54	-7.09	-0.42	1.6e-11	Idiopathic membranous nephropathy;
SARC	cis	rs920590	0.523	rs4464983	chr8:19680979	C/T	cg03894339	chr8:19674705	INTS10	-0.51	-6.06	-0.37	5.36e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.72	8.27	0.48	1.01e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs501120	0.810	rs498810	chr10:44740776	A/C	cg09554077	chr10:44749378	NA	0.46	6.38	0.39	9.27e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs9547996	1.000	rs9548000	chr13:38224053	A/G	cg17979426	chr13:38220150	TRPC4	-0.55	-5.75	-0.35	2.82e-8	Diastolic blood pressure;
SARC	cis	rs743757	1.000	rs2236987	chr3:50504546	C/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.54	-5.36	-0.33	2.01e-7	Diastolic blood pressure;
SARC	cis	rs9911578	1.000	rs10401050	chr17:56953786	A/C	cg05425664	chr17:57184151	TRIM37	-0.65	-8.0	-0.46	5.84e-14	Intelligence (multi-trait analysis);
SARC	cis	rs853679	0.506	rs1150693	chr6:28174590	T/C	cg17221315	chr6:27791827	HIST1H4J	0.47	5.22	0.32	3.94e-7	Depression;
SARC	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg15049968	chr18:44337910	ST8SIA5	-0.34	-5.34	-0.33	2.21e-7	Personality dimensions;
SARC	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg06618935	chr21:46677482	NA	-0.41	-5.37	-0.33	1.92e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs838147	0.508	rs507766	chr19:49208543	T/C	cg21064579	chr19:49206444	FUT2	0.35	4.92	0.31	1.61e-6	Dietary macronutrient intake;
SARC	cis	rs208520	0.690	rs207118	chr6:66788948	T/A	cg07460842	chr6:66804631	NA	-1.08	-15.02	-0.7	4.17e-36	Exhaled nitric oxide output;
SARC	cis	rs6456042	1.000	rs3127417	chr6:166537734	A/G	cg11088901	chr6:166572345	T	-0.33	-4.79	-0.3	2.97e-6	Asthma;
SARC	cis	rs950169	0.887	rs3860265	chr15:84945185	C/T	cg24253500	chr15:84953950	NA	0.36	5.18	0.32	4.78e-7	Schizophrenia;
SARC	cis	rs2576037	0.566	rs2437854	chr18:44557613	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.83	-12.57	-0.64	5.42e-28	Personality dimensions;
SARC	cis	rs9487051	1.000	rs9487051	chr6:109617079	A/G	cg01475377	chr6:109611718	NA	-0.4	-5.6	-0.34	5.99e-8	Reticulocyte fraction of red cells;
SARC	cis	rs7647973	0.922	rs6809851	chr3:49309787	C/A	cg07636037	chr3:49044803	WDR6	0.72	7.89	0.46	1.15e-13	Menarche (age at onset);
SARC	cis	rs9807989	0.507	rs7605284	chr2:103044175	T/G	cg03938978	chr2:103052716	IL18RAP	0.32	5.18	0.32	4.72e-7	Asthma;
SARC	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg16339924	chr4:17578868	LAP3	0.66	8.76	0.5	4e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2439831	1.000	rs28628574	chr15:43802038	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	7.82	0.46	1.77e-13	Lung cancer in ever smokers;
SARC	cis	rs3859192	0.577	rs25645	chr17:38173143	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.39	7.15	0.42	1.12e-11	White blood cell count;
SARC	cis	rs7647973	1.000	rs3448	chr3:49396751	T/C	cg07636037	chr3:49044803	WDR6	0.75	8.18	0.47	1.88e-14	Menarche (age at onset);
SARC	cis	rs2749592	0.918	rs1208653	chr10:38253826	C/G	cg00409905	chr10:38381863	ZNF37A	0.56	6.42	0.39	7.37e-10	Age-related hearing impairment (SNP x SNP interaction);
SARC	trans	rs9929218	1.000	rs12446407	chr16:68804068	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.52	-6.72	-0.4	1.36e-10	Colorectal cancer;
SARC	cis	rs3820928	0.874	rs13385711	chr2:227830414	G/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-6.73	-0.4	1.27e-10	Pulmonary function;
SARC	cis	rs2486288	0.656	rs9921025	chr15:45546602	G/A	cg15395560	chr15:45543142	SLC28A2	0.29	5.57	0.34	6.85e-8	Glomerular filtration rate;
SARC	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg03354898	chr7:1950403	MAD1L1	-0.35	-4.86	-0.3	2.15e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs240764	0.658	rs3811078	chr6:101247503	T/C	cg09795085	chr6:101329169	ASCC3	-0.44	-5.67	-0.35	4.21e-8	Neuroticism;
SARC	cis	rs6665290	0.904	rs1045286	chr1:227179037	A/C	cg14016676	chr1:227182615	CDC42BPA	-0.34	-4.81	-0.3	2.75e-6	Myeloid white cell count;
SARC	trans	rs11098499	0.909	rs7681214	chr4:120385320	C/A	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg24209194	chr3:40518798	ZNF619	0.65	8.08	0.47	3.39e-14	Renal cell carcinoma;
SARC	cis	rs6912958	0.712	rs2754260	chr6:88397666	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.46	-5.91	-0.36	1.24e-8	Monocyte percentage of white cells;
SARC	cis	rs16976116	0.901	rs8028525	chr15:55492317	T/C	cg11288833	chr15:55489084	RSL24D1	0.65	6.14	0.37	3.54e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7223966	1.000	rs2665826	chr17:61944924	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	7.2	0.43	8.32e-12	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9381040	0.655	rs2268187	chr6:41042993	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.45	-5.27	-0.33	3.04e-7	Alzheimer's disease (late onset);
SARC	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.39	5.34	0.33	2.2e-7	Personality dimensions;
SARC	cis	rs2594989	0.943	rs2443713	chr3:11537540	T/G	cg00170343	chr3:11313890	ATG7	0.55	5.27	0.33	3.15e-7	Circulating chemerin levels;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg26465101	chr13:111367253	ING1	-0.95	-7.18	-0.43	9.05e-12	Obesity-related traits;
SARC	cis	rs2180341	0.960	rs9398839	chr6:127665863	G/A	cg27446573	chr6:127587934	RNF146	1.06	14.73	0.69	3.88e-35	Breast cancer;
SARC	cis	rs8141529	0.529	rs2267131	chr22:29190471	T/C	cg15103426	chr22:29168792	CCDC117	0.61	5.94	0.36	1.03e-8	Lymphocyte counts;
SARC	cis	rs853679	1.000	rs2799079	chr6:28235176	A/C	cg26450541	chr6:28235208	ZNF187	0.57	5.1	0.32	7.07e-7	Depression;
SARC	cis	rs35110281	0.744	rs162395	chr21:44945759	T/C	cg01579765	chr21:45077557	HSF2BP	-0.32	-5.37	-0.33	1.93e-7	Mean corpuscular volume;
SARC	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	11.07	0.59	3.54e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs57506017	0.585	rs7809700	chr7:12267734	G/A	cg23422036	chr7:12250390	TMEM106B	0.44	5.64	0.35	4.85e-8	Neuroticism;
SARC	cis	rs7312933	0.558	rs55702525	chr12:42814309	T/C	cg19980929	chr12:42632907	YAF2	-0.44	-6.52	-0.39	4.35e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs8114671	0.562	rs1060615	chr20:33478381	C/T	cg24642439	chr20:33292090	TP53INP2	-0.45	-5.6	-0.34	6.07e-8	Height;
SARC	cis	rs6089584	0.627	rs13045575	chr20:60565596	G/A	cg06108461	chr20:60628389	TAF4	-0.71	-9.32	-0.52	9.09e-18	Body mass index;
SARC	cis	rs1570884	0.516	rs7330830	chr13:50167929	T/A	cg03651054	chr13:50194643	NA	0.32	5.37	0.33	1.88e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg18876405	chr7:65276391	NA	-0.68	-8.47	-0.49	2.87e-15	Aortic root size;
SARC	cis	rs7644634	0.531	rs9877805	chr3:105388590	C/T	cg23051926	chr3:105466016	CBLB	0.47	5.4	0.33	1.68e-7	Itch intensity from mosquito bite;
SARC	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg24549020	chr5:56110836	MAP3K1	0.81	8.4	0.48	4.37e-15	Initial pursuit acceleration;
SARC	cis	rs735396	1.000	rs735396	chr12:121438844	T/C	cg15155738	chr12:121454335	C12orf43	0.5	6.09	0.37	4.73e-9	N-glycan levels;
SARC	cis	rs9611519	1.000	rs6002271	chr22:41566595	C/T	cg17376030	chr22:41985996	PMM1	0.46	5.01	0.31	1.08e-6	Neuroticism;
SARC	cis	rs3617	0.625	rs2240917	chr3:52851137	T/C	cg18404041	chr3:52824283	ITIH1	-0.36	-5.29	-0.33	2.85e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs9326248	1.000	rs7946257	chr11:117053165	A/G	cg11861562	chr11:117069780	TAGLN	0.24	5.03	0.31	9.73e-7	Blood protein levels;
SARC	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg18876405	chr7:65276391	NA	-0.46	-5.18	-0.32	4.8e-7	Aortic root size;
SARC	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg17221315	chr6:27791827	HIST1H4J	0.45	4.74	0.3	3.76e-6	Depression;
SARC	cis	rs76878669	0.561	rs905770	chr11:66156765	A/G	cg14036092	chr11:66035641	RAB1B	0.4	4.79	0.3	2.93e-6	Educational attainment (years of education);
SARC	cis	rs9303401	0.659	rs1864754	chr17:56688789	G/T	cg25039879	chr17:56429692	SUPT4H1	-0.67	-6.39	-0.39	9.03e-10	Cognitive test performance;
SARC	cis	rs73206853	0.640	rs35026231	chr12:110832125	A/G	cg10860002	chr12:110842031	ANAPC7	0.64	5.15	0.32	5.49e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs7824557	0.603	rs11250130	chr8:11214455	C/T	cg21775007	chr8:11205619	TDH	-0.64	-8.25	-0.48	1.19e-14	Retinal vascular caliber;
SARC	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg11764359	chr7:65958608	NA	0.88	12.58	0.64	4.89e-28	Aortic root size;
SARC	trans	rs9329221	0.683	rs814359	chr8:9883132	T/G	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.94	-0.41	3.76e-11	Neuroticism;
SARC	cis	rs67311347	1.000	rs951560	chr3:40463471	A/G	cg09455208	chr3:40491958	NA	0.43	6.8	0.41	8.86e-11	Renal cell carcinoma;
SARC	cis	rs7011049	1.000	rs72640863	chr8:53841706	A/T	cg26025543	chr8:53854495	NA	0.6	5.43	0.34	1.42e-7	Systolic blood pressure;
SARC	cis	rs10504073	0.647	rs12549138	chr8:50007203	C/T	cg00325661	chr8:49890786	NA	0.55	7.4	0.44	2.49e-12	Blood metabolite ratios;
SARC	cis	rs2908197	0.662	rs917423	chr7:75984717	A/G	cg24580635	chr7:76178542	LOC100133091	-0.42	-4.86	-0.3	2.19e-6	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs6834538	1.000	rs2171280	chr4:113472637	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	-0.4	-4.92	-0.31	1.62e-6	Free thyroxine concentration;
SARC	cis	rs911555	0.662	rs4906322	chr14:103879032	A/G	cg12935359	chr14:103987150	CKB	0.39	5.3	0.33	2.7e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg13939156	chr17:80058883	NA	-0.41	-6.4	-0.39	8.38e-10	Life satisfaction;
SARC	cis	rs9894429	0.646	rs7406828	chr17:79619226	A/G	cg18240062	chr17:79603768	NPLOC4	-0.59	-7.03	-0.42	2.3e-11	Eye color traits;
SARC	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.35	4.78	0.3	3.08e-6	Total body bone mineral density;
SARC	cis	rs7412746	0.611	rs111905669	chr1:150777565	T/C	cg10589385	chr1:150898437	SETDB1	0.4	5.38	0.33	1.78e-7	Melanoma;
SARC	cis	rs240764	0.658	rs9322182	chr6:101223295	G/A	cg09795085	chr6:101329169	ASCC3	-0.44	-5.64	-0.35	4.85e-8	Neuroticism;
SARC	cis	rs501120	0.925	rs535949	chr10:44752330	A/C	cg09554077	chr10:44749378	NA	-0.48	-6.79	-0.41	9.33e-11	Coronary artery disease;Coronary heart disease;
SARC	cis	rs6484504	0.600	rs942272	chr11:31364368	C/T	cg02090638	chr11:31391270	DNAJC24;DCDC1	0.4	5.09	0.32	7.49e-7	Red blood cell count;
SARC	cis	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg05623727	chr3:50126028	RBM5	-0.32	-4.74	-0.3	3.76e-6	Body mass index;
SARC	cis	rs11574514	1.000	rs76944074	chr16:67951827	G/A	cg01866162	chr16:67596514	CTCF	1.1	6.61	0.4	2.65e-10	Crohn's disease;
SARC	cis	rs7772486	0.686	rs1292336	chr6:145967818	T/C	cg23711669	chr6:146136114	FBXO30	-0.78	-12.19	-0.62	9.05e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9303401	0.659	rs12935851	chr17:56600244	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.09	12.17	0.62	1.05e-26	Cognitive test performance;
SARC	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg10523679	chr1:76189770	ACADM	0.54	7.38	0.44	2.73e-12	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs11098499	0.863	rs2170276	chr4:120485824	A/C	cg24375607	chr4:120327624	NA	0.42	4.92	0.31	1.64e-6	Corneal astigmatism;
SARC	cis	rs965469	1.000	rs6139088	chr20:3329063	G/A	cg25506879	chr20:3388711	C20orf194	-0.52	-5.34	-0.33	2.2e-7	IFN-related cytopenia;
SARC	cis	rs6582630	0.599	rs12824838	chr12:38373584	G/T	cg14851346	chr12:38532713	NA	-0.46	-5.6	-0.34	5.96e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs26232	0.551	rs26431	chr5:102365794	G/C	cg23492399	chr5:102201601	PAM	0.49	5.45	0.34	1.28e-7	Rheumatoid arthritis;
SARC	cis	rs11770686	0.692	rs2705796	chr7:75308988	A/C	cg17787366	chr7:75369077	HIP1	0.4	5.02	0.31	1.04e-6	Essential tremor;
SARC	cis	rs17376456	0.825	rs10056879	chr5:93282218	C/A	cg25358565	chr5:93447407	FAM172A	1.3	13.14	0.65	7.09e-30	Diabetic retinopathy;
SARC	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg24675658	chr1:53192096	ZYG11B	-0.61	-8.85	-0.5	2.3e-16	Monocyte count;
SARC	cis	rs2016266	0.855	rs1379610	chr12:53681683	A/G	cg26875137	chr12:53738046	NA	-0.43	-5.34	-0.33	2.25e-7	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs34311866	0.748	rs10029038	chr4:899352	T/C	cg07828340	chr4:882639	GAK	0.81	5.97	0.36	8.59e-9	Parkinson's disease;
SARC	cis	rs7178909	0.835	rs17241302	chr15:90406537	C/G	cg19708238	chr15:90437601	AP3S2	0.61	7.67	0.45	4.66e-13	Common traits (Other);
SARC	cis	rs6582630	0.573	rs12319414	chr12:38267440	T/C	cg13010199	chr12:38710504	ALG10B	-0.53	-6.43	-0.39	6.97e-10	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs12044355	0.927	rs61835384	chr1:231833422	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.59	7.93	0.46	8.95e-14	Alzheimer's disease;
SARC	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg21171335	chr12:122356390	WDR66	0.38	6.24	0.38	2.1e-9	Mean corpuscular volume;
SARC	trans	rs8020941	0.585	rs58955411	chr14:97497942	T/C	cg05136476	chr3:53190709	NA	-0.63	-6.39	-0.39	8.99e-10	Diabetic kidney disease;
SARC	cis	rs7644634	0.688	rs13059405	chr3:105465257	A/G	cg23051926	chr3:105466016	CBLB	0.44	5.54	0.34	8.07e-8	Itch intensity from mosquito bite;
SARC	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.73	10.85	0.58	1.76e-22	Menarche (age at onset);
SARC	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg22974920	chr21:40686053	BRWD1	-0.43	-4.89	-0.31	1.86e-6	Cognitive function;
SARC	cis	rs6750795	0.569	rs1667305	chr2:232403829	A/G	cg19187155	chr2:232395269	NMUR1	0.71	11.06	0.59	3.8e-23	Height;
SARC	cis	rs9858542	1.000	rs1131095	chr3:49714225	T/C	cg03060546	chr3:49711283	APEH	-0.63	-7.89	-0.46	1.16e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	trans	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.51	-6.48	-0.39	5.56e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7937682	0.632	rs3944619	chr11:111774743	A/G	cg09085632	chr11:111637200	PPP2R1B	0.8	10.64	0.57	8.05e-22	Primary sclerosing cholangitis;
SARC	cis	rs66573146	0.831	rs6851488	chr4:6987412	C/T	cg00086871	chr4:6988644	TBC1D14	0.8	5.12	0.32	6.28e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs34172651	0.837	rs1978451	chr16:24818286	C/G	cg00339695	chr16:24857497	SLC5A11	0.31	4.9	0.31	1.77e-6	Intelligence (multi-trait analysis);
SARC	cis	rs6121246	0.559	rs6060933	chr20:30351903	C/T	cg13852791	chr20:30311386	BCL2L1	0.89	11.01	0.58	5.74e-23	Mean corpuscular hemoglobin;
SARC	cis	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg06212747	chr3:49208901	KLHDC8B	0.72	6.46	0.39	6.03e-10	Menarche (age at onset);
SARC	cis	rs6456156	0.586	rs1358882	chr6:167467101	G/A	cg07741184	chr6:167504864	NA	0.36	7.09	0.42	1.62e-11	Primary biliary cholangitis;
SARC	cis	rs7872515	0.775	rs7024583	chr9:94824750	C/T	cg01248375	chr9:94877805	SPTLC1	0.56	5.28	0.33	2.93e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg01448562	chr3:133502909	NA	-0.49	-7.48	-0.44	1.47e-12	Iron status biomarkers;
SARC	cis	rs80130819	0.748	rs2732458	chr12:48758281	A/G	cg24011408	chr12:48396354	COL2A1	0.47	5.21	0.32	4.15e-7	Prostate cancer;
SARC	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.42	-5.2	-0.32	4.29e-7	Tonsillectomy;
SARC	cis	rs10791097	0.967	rs10894268	chr11:130717153	C/T	cg12179176	chr11:130786555	SNX19	0.6	8.22	0.47	1.4e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs67311347	1.000	rs7648952	chr3:40457038	C/T	cg24209194	chr3:40518798	ZNF619	-0.65	-8.62	-0.49	1.06e-15	Renal cell carcinoma;
SARC	cis	rs7310409	0.544	rs1169292	chr12:121426478	C/T	cg15155738	chr12:121454335	C12orf43	0.48	5.9	0.36	1.31e-8	Liver enzyme levels (gamma-glutamyl transferase);C-reactive protein;Pancreatic cancer;
SARC	cis	rs7552404	0.924	rs1146580	chr1:76209935	T/C	cg10523679	chr1:76189770	ACADM	0.45	6.13	0.37	3.64e-9	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs826838	0.868	rs12322306	chr12:39130021	A/G	cg13010199	chr12:38710504	ALG10B	-0.63	-8.88	-0.5	1.87e-16	Heart rate;
SARC	cis	rs870825	0.616	rs877276	chr4:185621249	C/T	cg04058563	chr4:185651563	MLF1IP	0.82	11.42	0.6	2.8e-24	Blood protein levels;
SARC	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.68	-8.77	-0.5	3.87e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs854765	0.583	rs4925123	chr17:17784374	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.42	-5.56	-0.34	7.31e-8	Total body bone mineral density;
SARC	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg05861140	chr6:150128134	PCMT1	-0.41	-5.18	-0.32	4.73e-7	Lung cancer;
SARC	cis	rs2721811	0.738	rs2521757	chr7:24761669	C/T	cg17569154	chr7:24781545	DFNA5	-0.45	-6.38	-0.39	9.53e-10	Depressive symptoms (multi-trait analysis);
SARC	cis	rs240764	0.621	rs6925316	chr6:101209137	C/G	cg09795085	chr6:101329169	ASCC3	-0.44	-5.7	-0.35	3.63e-8	Neuroticism;
SARC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg09373136	chr17:61933544	TCAM1	-0.45	-6.11	-0.37	4.08e-9	Prudent dietary pattern;
SARC	cis	rs7179456	0.557	rs446126	chr15:59113102	A/G	cg05156742	chr15:59063176	FAM63B	0.83	12.74	0.64	1.47e-28	Asperger disorder;
SARC	cis	rs2228479	0.681	rs10153055	chr16:89965842	C/T	cg06558623	chr16:89946397	TCF25	0.7	5.42	0.33	1.49e-7	Skin colour saturation;
SARC	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-5.45	-0.34	1.28e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs36051895	0.664	rs17425637	chr9:5110000	C/T	cg02405213	chr9:5042618	JAK2	-0.44	-5.14	-0.32	5.87e-7	Pediatric autoimmune diseases;
SARC	cis	rs9768139	0.935	rs7782393	chr7:158120486	G/A	cg25566285	chr7:158114605	PTPRN2	-0.32	-5.57	-0.34	7.14e-8	Calcium levels;
SARC	cis	rs11249608	0.600	rs6859767	chr5:178451107	T/C	cg21905437	chr5:178450457	ZNF879	0.58	7.91	0.46	1.02e-13	Pubertal anthropometrics;
SARC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.58	0.53	1.52e-18	Prudent dietary pattern;
SARC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg14159672	chr1:205819179	PM20D1	0.9	15.6	0.71	4.63e-38	Menarche (age at onset);
SARC	cis	rs9302635	0.640	rs9933009	chr16:72190650	G/A	cg16558253	chr16:72132732	DHX38	-0.53	-6.87	-0.41	5.87e-11	Blood protein levels;
SARC	cis	rs4481887	0.927	rs12039929	chr1:248482018	G/A	cg13385794	chr1:248469461	NA	0.34	5.14	0.32	5.78e-7	Common traits (Other);
SARC	cis	rs3126085	0.935	rs4845741	chr1:152183474	A/G	cg03465714	chr1:152285911	FLG	-0.48	-5.84	-0.36	1.78e-8	Atopic dermatitis;
SARC	cis	rs7582180	0.676	rs11691135	chr2:100934038	C/T	cg14675211	chr2:100938903	LONRF2	0.5	7.4	0.44	2.41e-12	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg08219700	chr8:58056026	NA	0.65	6.14	0.37	3.57e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1008375	1.000	rs7694020	chr4:17682597	C/T	cg16339924	chr4:17578868	LAP3	0.61	7.94	0.46	8.43e-14	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9393692	0.905	rs2393592	chr6:26285560	A/G	cg00631329	chr6:26305371	NA	-0.61	-8.87	-0.5	1.93e-16	Educational attainment;
SARC	cis	rs1957429	0.520	rs230723	chr14:65316017	C/T	cg23373153	chr14:65346875	NA	-0.65	-5.4	-0.33	1.64e-7	Pediatric areal bone mineral density (radius);
SARC	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs3733585	0.673	rs4292333	chr4:9953871	G/A	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.39	-0.33	1.76e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs2120243	0.510	rs10936087	chr3:157106628	T/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.39	5.07	0.32	8.25e-7	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-7.83	-0.46	1.71e-13	Alzheimer's disease;
SARC	cis	rs870825	0.616	rs9631782	chr4:185626379	A/G	cg04058563	chr4:185651563	MLF1IP	0.81	11.25	0.59	9.68e-24	Blood protein levels;
SARC	cis	rs67366981	1.000	rs55923743	chr14:77711454	G/A	cg06779847	chr14:77687015	TMEM63C	-0.47	-5.23	-0.32	3.84e-7	Obsessive-compulsive symptoms;
SARC	cis	rs7582720	1.000	rs76890136	chr2:203850011	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs459571	0.920	rs433402	chr9:136898627	A/G	cg01294253	chr9:136912663	BRD3	0.42	5.4	0.33	1.64e-7	Platelet distribution width;
SARC	cis	rs6893807	1.000	rs13163336	chr5:87943710	C/A	cg09002922	chr5:87956389	LOC645323	-0.42	-4.83	-0.3	2.44e-6	Body mass index;
SARC	cis	rs1707322	0.686	rs3014251	chr1:46077428	G/C	cg03146154	chr1:46216737	IPP	-0.52	-6.27	-0.38	1.69e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs3750965	0.959	rs4930264	chr11:68852181	C/T	cg06818126	chr11:68850279	TPCN2	-0.43	-5.01	-0.31	1.07e-6	Hair color;
SARC	cis	rs10791097	0.592	rs4936122	chr11:130734264	A/C	cg12179176	chr11:130786555	SNX19	0.73	10.51	0.57	2.2e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs7520050	0.966	rs12564541	chr1:46380237	G/A	cg06784218	chr1:46089804	CCDC17	-0.26	-4.79	-0.3	2.99e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg11141652	chr22:24348549	GSTTP1	-0.43	-4.99	-0.31	1.18e-6	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs1348850	0.958	rs4893965	chr2:178463852	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	7.64	0.45	5.64e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg01448562	chr3:133502909	NA	-0.55	-8.42	-0.48	3.95e-15	Iron status biomarkers;
SARC	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg12463550	chr7:65579703	CRCP	-0.49	-5.79	-0.35	2.29e-8	Aortic root size;
SARC	cis	rs1790761	0.692	rs10444362	chr11:67333090	G/A	cg24690094	chr11:67383802	NA	0.37	5.45	0.34	1.25e-7	Mean corpuscular volume;
SARC	cis	rs2072499	0.695	rs112223391	chr1:156156094	G/A	cg24450063	chr1:156163899	SLC25A44	1.09	14.15	0.68	3.09e-33	Testicular germ cell tumor;
SARC	cis	rs2742234	0.590	rs2742237	chr10:43621323	C/G	cg15436174	chr10:43711423	RASGEF1A	-0.39	-4.73	-0.3	3.89e-6	Hirschsprung disease;
SARC	cis	rs17376456	0.825	rs10054790	chr5:93272520	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.7	0.35	3.7e-8	Diabetic retinopathy;
SARC	cis	rs7568458	0.905	rs6714709	chr2:85756375	C/G	cg02493740	chr2:85810744	VAMP5	-0.34	-5.02	-0.31	1e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs10463316	0.817	rs13359941	chr5:150802118	C/T	cg03212797	chr5:150827313	SLC36A1	-0.44	-5.18	-0.32	4.82e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs2153535	0.580	rs6927589	chr6:8456632	A/G	cg07606381	chr6:8435919	SLC35B3	-0.76	-10.84	-0.58	2.01e-22	Motion sickness;
SARC	cis	rs365132	0.875	rs2962842	chr5:176338955	A/G	cg16309518	chr5:176445507	NA	-0.49	-6.25	-0.38	1.9e-9	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg03351412	chr1:154909251	PMVK	0.55	6.65	0.4	2.06e-10	Prostate cancer;
SARC	cis	rs950169	0.922	rs11633534	chr15:85124642	C/T	cg03959625	chr15:84868606	LOC388152	0.38	5.1	0.32	6.93e-7	Schizophrenia;
SARC	trans	rs17685	0.712	rs7794454	chr7:75776010	A/G	cg19862616	chr7:65841803	NCRNA00174	-0.59	-7.38	-0.44	2.79e-12	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs6570726	0.935	rs421268	chr6:145845558	A/T	cg23711669	chr6:146136114	FBXO30	0.78	12.08	0.62	2.13e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7208859	0.673	rs999797	chr17:29159329	G/A	cg13385521	chr17:29058706	SUZ12P	0.86	7.3	0.43	4.51e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	trans	rs9951602	0.512	rs9952372	chr18:76656295	A/G	cg02800362	chr5:177631904	HNRNPAB	0.71	8.95	0.51	1.17e-16	Obesity-related traits;
SARC	cis	rs10870270	1.000	rs7199	chr10:133769848	C/G	cg17892150	chr10:133769511	PPP2R2D	-0.84	-10.4	-0.56	4.62e-21	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg19318889	chr4:1322082	MAEA	0.39	4.88	0.3	1.95e-6	Longevity;
SARC	cis	rs599083	0.793	rs314750	chr11:68182028	G/A	cg24974729	chr11:67764320	UNC93B1	-0.32	-4.8	-0.3	2.88e-6	Bone mineral density (spine);
SARC	cis	rs7927771	0.839	rs11039308	chr11:47622412	G/A	cg05585544	chr11:47624801	NA	-0.33	-4.77	-0.3	3.29e-6	Subjective well-being;
SARC	cis	rs11687170	0.816	rs56306130	chr2:237057146	C/T	cg19324714	chr2:237145437	ASB18	0.49	4.89	0.31	1.89e-6	Educational attainment;Educational attainment (years of education);
SARC	cis	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg03403963	chr8:11986501	LOC392196;FAM66D	-0.35	-5.05	-0.31	9.12e-7	Triglycerides;
SARC	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg00149659	chr3:10157352	C3orf10	0.69	6.9	0.41	4.76e-11	Alzheimer's disease;
SARC	cis	rs10992471	0.603	rs12342019	chr9:95192508	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.26	-0.33	3.34e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg25894440	chr7:65020034	NA	-0.75	-5.64	-0.35	5e-8	Diabetic kidney disease;
SARC	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.76	11.16	0.59	1.95e-23	Personality dimensions;
SARC	cis	rs1198872	0.563	rs1686497	chr2:10961184	A/G	cg15705551	chr2:10952987	PDIA6	0.47	5.96	0.36	9.44e-9	Cardiac Troponin-T levels;
SARC	cis	rs11716531	0.574	rs62256311	chr3:27271505	G/A	cg02860705	chr3:27208620	NA	0.56	6.75	0.4	1.19e-10	Diastolic blood pressure;
SARC	cis	rs7246657	0.765	rs7247259	chr19:37851090	T/C	cg23950597	chr19:37808831	NA	-0.54	-5.47	-0.34	1.15e-7	Coronary artery calcification;
SARC	cis	rs3741404	0.620	rs12787945	chr11:63977546	G/A	cg04317338	chr11:64019027	PLCB3	0.42	5.0	0.31	1.12e-6	Platelet count;
SARC	cis	rs9902453	0.872	rs34698290	chr17:28500465	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	6.66	0.4	1.91e-10	Coffee consumption (cups per day);
SARC	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg00149659	chr3:10157352	C3orf10	0.68	6.72	0.4	1.38e-10	Alzheimer's disease;
SARC	cis	rs2120019	1.000	rs12903201	chr15:75370776	A/C	cg09165964	chr15:75287851	SCAMP5	-0.87	-13.08	-0.65	1.1e-29	Blood trace element (Zn levels);
SARC	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg25319279	chr11:5960081	NA	0.41	5.63	0.35	5.16e-8	DNA methylation (variation);
SARC	cis	rs1008375	0.931	rs10019482	chr4:17578079	G/A	cg16339924	chr4:17578868	LAP3	0.69	9.17	0.52	2.49e-17	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7589342	0.895	rs11901644	chr2:106432113	T/G	cg14210321	chr2:106509881	NCK2	-0.46	-5.39	-0.33	1.69e-7	Addiction;
SARC	trans	rs10771431	0.597	rs3759275	chr12:9353828	A/T	cg27600084	chr12:12264075	NA	0.52	6.87	0.41	5.96e-11	Breast size;
SARC	cis	rs1707322	0.717	rs3014237	chr1:46090252	A/G	cg06784218	chr1:46089804	CCDC17	-0.37	-6.35	-0.38	1.13e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6831352	0.918	rs13143133	chr4:100054970	A/G	cg13256891	chr4:100009986	ADH5	-0.64	-8.0	-0.46	5.7e-14	Alcohol dependence;
SARC	trans	rs12967884	0.892	rs4798979	chr18:76559384	T/A	cg10946435	chr1:154843044	KCNN3	0.57	6.36	0.38	1.06e-9	Subcutaneous adipose tissue;
SARC	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg01017244	chr2:74357527	NA	0.54	6.64	0.4	2.25e-10	Gestational age at birth (maternal effect);
SARC	cis	rs981844	0.961	rs56148270	chr4:154660874	C/T	cg14289246	chr4:154710475	SFRP2	0.59	6.74	0.4	1.25e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs2354432	0.607	rs6658763	chr1:146692373	C/T	cg25205988	chr1:146714368	CHD1L	-1.04	-8.05	-0.47	4.14e-14	Mitochondrial DNA levels;
SARC	cis	rs2635047	0.530	rs4986228	chr18:44595259	C/T	cg19077165	chr18:44547161	KATNAL2	-0.4	-5.14	-0.32	5.87e-7	Educational attainment;
SARC	cis	rs10197940	0.789	rs2444256	chr2:152280365	C/T	cg19508488	chr2:152266495	RIF1	0.6	6.99	0.42	2.95e-11	Lung cancer;
SARC	cis	rs2304069	0.909	rs2544931	chr5:149367837	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.88	-8.69	-0.49	6.63e-16	HIV-1 control;
SARC	cis	rs2153535	0.580	rs9379210	chr6:8461928	C/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.19	0.47	1.77e-14	Motion sickness;
SARC	cis	rs17376456	0.825	rs17372615	chr5:93124768	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.7	6.39	0.39	8.96e-10	Diabetic retinopathy;
SARC	cis	rs6500602	0.893	rs4786489	chr16:4485527	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.36	5.82	0.36	1.92e-8	Schizophrenia;
SARC	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.47	-5.93	-0.36	1.07e-8	Lymphocyte counts;
SARC	cis	rs12479064	0.724	rs62153852	chr2:99934713	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.68	-8.23	-0.47	1.3e-14	Chronic sinus infection;
SARC	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg12463550	chr7:65579703	CRCP	0.67	5.05	0.31	8.87e-7	Diabetic kidney disease;
SARC	cis	rs1153858	1.000	rs59889118	chr15:45618730	G/A	cg15395560	chr15:45543142	SLC28A2	-0.28	-5.25	-0.33	3.48e-7	Homoarginine levels;
SARC	trans	rs12310956	0.510	rs7965329	chr12:33868199	C/A	cg26384229	chr12:38710491	ALG10B	0.62	8.27	0.48	1.02e-14	Morning vs. evening chronotype;
SARC	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg13939156	chr17:80058883	NA	-0.43	-6.69	-0.4	1.65e-10	Life satisfaction;
SARC	cis	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.64	-0.45	5.55e-13	Extrinsic epigenetic age acceleration;
SARC	trans	rs79976124	0.879	rs12214948	chr6:66633603	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	7.93	0.46	9.08e-14	Type 2 diabetes;
SARC	cis	rs6665290	0.669	rs6426558	chr1:227175367	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.03	-20.71	-0.8	9.91e-55	Myeloid white cell count;
SARC	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg27170947	chr2:26402098	FAM59B	0.37	4.8	0.3	2.79e-6	Gut microbiome composition (summer);
SARC	cis	rs7208859	0.623	rs11657391	chr17:29194287	G/A	cg13385521	chr17:29058706	SUZ12P	0.86	7.34	0.43	3.54e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs6665290	0.935	rs17600627	chr1:227201449	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.08	-24.94	-0.85	1.03e-67	Myeloid white cell count;
SARC	cis	rs10504229	0.679	rs7840100	chr8:58036662	T/G	cg08219700	chr8:58056026	NA	0.58	6.05	0.37	5.69e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs916888	0.610	rs199436	chr17:44789285	C/T	cg15921436	chr17:44337874	NA	-0.48	-5.51	-0.34	9.46e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs3820928	0.874	rs6707265	chr2:227849255	T/A	cg05526886	chr2:227700861	RHBDD1	-0.55	-6.66	-0.4	1.96e-10	Pulmonary function;
SARC	cis	rs1387259	0.790	rs2732445	chr12:48645533	C/T	cg24011408	chr12:48396354	COL2A1	0.47	5.44	0.34	1.33e-7	Obstructive sleep apnea trait (apnea hypopnea index);
SARC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg24503407	chr1:205819492	PM20D1	0.81	12.67	0.64	2.51e-28	Menarche (age at onset);
SARC	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg05313129	chr8:58192883	C8orf71	-0.62	-6.37	-0.39	9.92e-10	Developmental language disorder (linguistic errors);
SARC	trans	rs11098499	0.618	rs28491261	chr4:120294900	C/A	cg25214090	chr10:38739885	LOC399744	0.54	7.12	0.42	1.33e-11	Corneal astigmatism;
SARC	cis	rs1003719	0.788	rs2040341	chr21:38489753	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.95	0.51	1.17e-16	Eye color traits;
SARC	cis	rs6963495	0.818	rs73192122	chr7:105171471	G/A	cg19920283	chr7:105172520	RINT1	0.69	5.9	0.36	1.29e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs9650657	0.501	rs3021500	chr8:11023997	G/C	cg12395012	chr8:11607386	GATA4	0.3	5.02	0.31	1.05e-6	Neuroticism;
SARC	cis	rs9899728	0.572	rs9915968	chr17:73059616	G/C	cg27626185	chr17:73056755	KCTD2	-0.53	-5.12	-0.32	6.32e-7	Alzheimer's disease or small vessel stroke;
SARC	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.77	11.13	0.59	2.33e-23	Personality dimensions;
SARC	cis	rs735396	0.770	rs1169315	chr12:121443753	T/G	cg04422896	chr12:121454269	C12orf43	0.41	5.01	0.31	1.07e-6	N-glycan levels;
SARC	cis	rs7551222	0.647	rs3014606	chr1:204464150	C/G	cg20240347	chr1:204465584	NA	0.3	5.06	0.31	8.6e-7	Schizophrenia;
SARC	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs8523	0.744	rs9348807	chr6:11082322	G/A	cg13562911	chr6:11044106	ELOVL2	0.41	5.37	0.33	1.87e-7	Red blood cell fatty acid levels;
SARC	cis	rs950027	0.620	rs1145080	chr15:45681338	C/T	cg15395560	chr15:45543142	SLC28A2	-0.27	-5.25	-0.33	3.36e-7	Response to fenofibrate (adiponectin levels);
SARC	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg19077165	chr18:44547161	KATNAL2	0.54	7.52	0.44	1.21e-12	Personality dimensions;
SARC	cis	rs1784581	0.569	rs9365357	chr6:162414913	A/G	cg17173639	chr6:162384350	PARK2	0.51	6.44	0.39	6.65e-10	Itch intensity from mosquito bite;
SARC	cis	rs10982256	1.000	rs10982256	chr9:117260834	A/G	cg21159778	chr9:117266918	DFNB31	0.32	4.75	0.3	3.62e-6	Bipolar disorder;
SARC	cis	rs10752881	0.839	rs6692207	chr1:183085304	T/C	cg13390022	chr1:182993471	LAMC1	0.32	4.83	0.3	2.52e-6	Colorectal cancer;
SARC	cis	rs2531992	0.800	rs2601782	chr16:4021051	T/C	cg05927578	chr16:4029543	ADCY9	0.43	4.83	0.3	2.46e-6	Waist circumference;
SARC	cis	rs933688	1.000	rs985434	chr5:90744509	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	13.03	0.65	1.61e-29	Smoking behavior;
SARC	trans	rs61931739	1.000	rs11052989	chr12:34057614	G/A	cg26384229	chr12:38710491	ALG10B	-0.57	-6.88	-0.41	5.5e-11	Morning vs. evening chronotype;
SARC	cis	rs6087990	0.835	rs4911106	chr20:31331330	A/G	cg13636640	chr20:31349939	DNMT3B	0.79	12.57	0.64	5.17e-28	Ulcerative colitis;
SARC	trans	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg16141378	chr3:129829833	LOC729375	-0.51	-6.27	-0.38	1.72e-9	Systolic blood pressure;
SARC	cis	rs10979	0.931	rs12191837	chr6:143898200	T/G	cg25407410	chr6:143891975	LOC285740	-0.64	-8.78	-0.5	3.67e-16	Hypospadias;
SARC	trans	rs10448080	0.879	rs240946	chr8:28568905	A/G	cg09742170	chr7:25021208	OSBPL3	0.47	6.36	0.38	1.08e-9	Height;
SARC	cis	rs9457247	0.967	rs430145	chr6:167410369	C/T	cg23791538	chr6:167370224	RNASET2	-0.6	-8.22	-0.47	1.39e-14	Crohn's disease;
SARC	cis	rs9527	0.590	rs2148200	chr10:104879847	C/A	cg04362960	chr10:104952993	NT5C2	0.43	4.94	0.31	1.47e-6	Arsenic metabolism;
SARC	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs929596	0.561	rs11891311	chr2:234639310	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.35	5.24	0.32	3.61e-7	Total bilirubin levels in HIV-1 infection;
SARC	cis	rs6582630	0.638	rs11182428	chr12:38526387	T/C	cg14851346	chr12:38532713	NA	-0.42	-4.96	-0.31	1.34e-6	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9640161	0.789	rs28439010	chr7:150046276	C/T	cg17279839	chr7:150038598	RARRES2	0.42	6.13	0.37	3.76e-9	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg05623727	chr3:50126028	RBM5	-0.33	-5.0	-0.31	1.15e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9457247	0.663	rs9459835	chr6:167417551	G/T	cg23791538	chr6:167370224	RNASET2	-0.55	-7.29	-0.43	4.67e-12	Crohn's disease;
SARC	cis	rs9902453	0.845	rs2321493	chr17:28230359	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	6.95	0.41	3.67e-11	Coffee consumption (cups per day);
SARC	trans	rs7980799	0.653	rs1384598	chr12:33622899	T/A	cg13010199	chr12:38710504	ALG10B	-0.53	-6.3	-0.38	1.46e-9	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs7296418	0.961	rs4275659	chr12:123447928	C/T	cg16085171	chr12:123569118	PITPNM2	0.38	4.89	0.31	1.85e-6	Platelet count;
SARC	cis	rs4727027	0.870	rs62507509	chr7:148795522	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	5.86	0.36	1.56e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs6582630	0.502	rs1607876	chr12:38355750	T/C	cg13010199	chr12:38710504	ALG10B	0.78	10.79	0.58	2.78e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs36051895	0.664	rs62541915	chr9:5151275	A/T	cg02405213	chr9:5042618	JAK2	-0.45	-5.07	-0.32	7.93e-7	Pediatric autoimmune diseases;
SARC	cis	rs4273100	1.000	rs16960158	chr17:19163052	A/C	cg18093559	chr17:18951025	GRAP	-0.41	-4.74	-0.3	3.65e-6	Schizophrenia;
SARC	cis	rs910316	1.000	rs10146482	chr14:75574087	C/T	cg08847533	chr14:75593920	NEK9	0.92	15.95	0.72	3.19e-39	Height;
SARC	cis	rs6815814	0.950	rs11725779	chr4:38811668	G/A	cg09316306	chr4:38807337	TLR1	0.5	5.22	0.32	3.93e-7	Breast cancer;
SARC	cis	rs4423214	1.000	rs4944956	chr11:71167765	C/T	cg24826892	chr11:71159390	DHCR7	0.48	6.12	0.37	3.92e-9	Vitamin D levels;
SARC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg12419862	chr22:24373484	LOC391322	-0.67	-8.12	-0.47	2.77e-14	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9486719	1.000	rs12210146	chr6:96903962	A/G	cg06623918	chr6:96969491	KIAA0776	0.71	7.39	0.44	2.56e-12	Migraine;Coronary artery disease;
SARC	cis	rs7561528	0.501	rs11689089	chr2:127887865	T/C	cg12632573	chr2:127783243	NA	0.65	5.85	0.36	1.63e-8	Alzheimer's disease;Alzheimer's disease (late onset);
SARC	cis	rs4919087	0.926	rs7072078	chr10:99026509	G/A	cg25902810	chr10:99078978	FRAT1	0.44	5.58	0.34	6.6e-8	Monocyte count;
SARC	cis	rs834603	0.575	rs1704968	chr7:47468231	T/C	cg23694490	chr7:47445681	TNS3	-0.32	-5.89	-0.36	1.36e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs12142240	0.698	rs6429599	chr1:46827871	G/A	cg10495392	chr1:46806563	NSUN4	0.64	6.83	0.41	7.39e-11	Menopause (age at onset);
SARC	cis	rs1348850	0.561	rs57986285	chr2:178468663	C/T	cg23306229	chr2:178417860	TTC30B	0.81	7.35	0.43	3.41e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs6456156	0.792	rs9366089	chr6:167512896	A/G	cg23791538	chr6:167370224	RNASET2	-0.42	-5.31	-0.33	2.59e-7	Primary biliary cholangitis;
SARC	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	16.73	0.74	8.77e-42	Height;
SARC	trans	rs7824557	0.767	rs11250127	chr8:11170209	G/A	cg06636001	chr8:8085503	FLJ10661	0.57	6.95	0.41	3.58e-11	Retinal vascular caliber;
SARC	cis	rs2120019	0.938	rs13056	chr15:75312187	A/G	cg09165964	chr15:75287851	SCAMP5	-0.95	-14.5	-0.69	2.24e-34	Blood trace element (Zn levels);
SARC	trans	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg21659725	chr3:3221576	CRBN	0.52	6.71	0.4	1.46e-10	Intelligence (multi-trait analysis);
SARC	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	11.34	0.6	5.12e-24	Alzheimer's disease;
SARC	cis	rs1971762	0.583	rs11170648	chr12:54089660	C/T	cg06632207	chr12:54070931	ATP5G2	0.43	5.7	0.35	3.6e-8	Height;
SARC	cis	rs2486288	0.656	rs11639349	chr15:45568260	C/T	cg15395560	chr15:45543142	SLC28A2	0.33	6.41	0.39	8.02e-10	Glomerular filtration rate;
SARC	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7833986	1.000	rs34037954	chr8:57096841	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.6	5.33	0.33	2.36e-7	Height;
SARC	cis	rs6545883	0.929	rs6545873	chr2:61733012	T/C	cg15711740	chr2:61764176	XPO1	-0.42	-5.25	-0.33	3.42e-7	Tuberculosis;
SARC	cis	rs55879323	1	rs55879323	chr1:152168740	C/T	cg09127314	chr1:152161683	NA	0.38	4.98	0.31	1.22e-6	Inflammatory skin disease;
SARC	cis	rs34779708	0.966	rs11010122	chr10:35493518	A/C	cg03585969	chr10:35415529	CREM	0.4	4.93	0.31	1.55e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs7635838	0.557	rs347615	chr3:11277284	T/A	cg00170343	chr3:11313890	ATG7	0.73	9.88	0.54	1.93e-19	HDL cholesterol;
SARC	cis	rs6504663	0.558	rs7627	chr17:48552154	G/C	cg22571038	chr17:48585470	MYCBPAP	0.45	5.0	0.31	1.14e-6	Visceral fat;
SARC	cis	rs734999	0.505	rs4278312	chr1:2539555	A/G	cg20673091	chr1:2541236	MMEL1	0.33	5.11	0.32	6.61e-7	Ulcerative colitis;
SARC	cis	rs911263	0.603	rs2180770	chr14:68773353	G/A	cg18825221	chr14:68749962	RAD51L1	0.41	7.36	0.43	3.06e-12	Primary biliary cholangitis;
SARC	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg24642844	chr7:1081250	C7orf50	-0.55	-5.71	-0.35	3.44e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg20607798	chr8:58055168	NA	0.73	6.16	0.37	3.22e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6540556	0.723	rs6752	chr1:209908100	G/A	cg23920097	chr1:209922102	NA	-0.51	-5.13	-0.32	6.16e-7	Red blood cell count;
SARC	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg25036284	chr2:26402008	FAM59B	0.43	5.42	0.33	1.52e-7	Gut microbiome composition (summer);
SARC	cis	rs7607369	0.536	rs12623740	chr2:219665715	T/A	cg02176678	chr2:219576539	TTLL4	-0.33	-4.82	-0.3	2.56e-6	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs9916302	0.904	rs68178216	chr17:37526241	A/C	cg15445000	chr17:37608096	MED1	-0.45	-5.46	-0.34	1.23e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs9916302	0.904	rs2338798	chr17:37547269	T/C	cg15445000	chr17:37608096	MED1	-0.4	-4.85	-0.3	2.25e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs11711311	0.747	rs11928494	chr3:113343219	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	7.16	0.42	1.03e-11	IgG glycosylation;
SARC	cis	rs7561528	0.501	rs11685593	chr2:127888121	C/T	cg12632573	chr2:127783243	NA	0.65	5.85	0.36	1.63e-8	Alzheimer's disease;Alzheimer's disease (late onset);
SARC	cis	rs7523050	0.730	rs34254854	chr1:109419875	C/T	cg08274380	chr1:109419600	GPSM2	1.11	8.77	0.5	3.73e-16	Fat distribution (HIV);
SARC	cis	rs6952809	0.532	rs6953297	chr7:2440874	C/G	cg23289794	chr7:2394357	EIF3B	-0.67	-6.33	-0.38	1.25e-9	Multiple sclerosis;
SARC	cis	rs28374715	0.662	rs10851403	chr15:41466087	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.0	-13.86	-0.67	2.89e-32	Ulcerative colitis;
SARC	cis	rs7953249	0.656	rs6489786	chr12:121397875	A/G	cg25281562	chr12:121454272	C12orf43	-0.45	-5.38	-0.33	1.84e-7	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs7089973	0.604	rs58587374	chr10:116597572	A/G	cg08188268	chr10:116634841	FAM160B1	0.28	4.86	0.3	2.13e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs2204008	0.775	rs2387809	chr12:38363338	T/A	cg13010199	chr12:38710504	ALG10B	0.78	10.77	0.58	3.24e-22	Bladder cancer;
SARC	cis	rs13256369	0.802	rs2280560	chr8:8560602	C/T	cg17143192	chr8:8559678	CLDN23	0.52	5.81	0.36	2.07e-8	Obesity-related traits;
SARC	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg12463550	chr7:65579703	CRCP	-0.47	-5.03	-0.31	9.64e-7	Aortic root size;
SARC	cis	rs4975616	0.869	rs466502	chr5:1325767	C/T	cg07493874	chr5:1342172	CLPTM1L	0.53	7.3	0.43	4.43e-12	Lung cancer;
SARC	cis	rs36051895	0.632	rs1360063	chr9:5167649	A/G	cg02405213	chr9:5042618	JAK2	-0.5	-5.8	-0.36	2.14e-8	Pediatric autoimmune diseases;
SARC	trans	rs61931739	0.517	rs11052964	chr12:34010996	G/C	cg13010199	chr12:38710504	ALG10B	0.75	9.95	0.55	1.11e-19	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg22535103	chr8:58192502	C8orf71	-0.73	-7.24	-0.43	6.52e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs2011503	0.882	rs4808933	chr19:19363812	T/A	cg03709012	chr19:19516395	GATAD2A	0.59	5.4	0.33	1.63e-7	Bipolar disorder;
SARC	cis	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg18252515	chr7:66147081	NA	-1.12	-9.81	-0.54	3.17e-19	Diabetic kidney disease;
SARC	cis	rs7712401	0.791	rs1870559	chr5:122116706	G/C	cg19412675	chr5:122181750	SNX24	0.38	5.0	0.31	1.14e-6	Mean platelet volume;
SARC	cis	rs7829975	0.511	rs1543238	chr8:8134809	A/G	cg08975724	chr8:8085496	FLJ10661	0.67	9.06	0.51	5.56e-17	Mood instability;
SARC	trans	rs2018683	0.870	rs13232487	chr7:28985119	C/A	cg19402173	chr7:128379420	CALU	-0.65	-8.4	-0.48	4.53e-15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg18876405	chr7:65276391	NA	0.69	9.05	0.51	5.93e-17	Aortic root size;
SARC	cis	rs6732160	0.967	rs6760964	chr2:73387386	C/G	cg01422370	chr2:73384389	NA	0.3	4.96	0.31	1.34e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9399135	0.967	rs12527683	chr6:135324534	C/T	cg24558204	chr6:135376177	HBS1L	0.46	6.12	0.37	3.92e-9	Red blood cell count;
SARC	cis	rs908922	0.676	rs11584191	chr1:152500428	A/T	cg09873164	chr1:152488093	CRCT1	-0.63	-7.96	-0.46	7.42e-14	Hair morphology;
SARC	cis	rs155076	0.938	rs9509633	chr13:21844482	G/C	cg25811766	chr13:21894605	NA	-0.51	-5.5	-0.34	9.92e-8	White matter hyperintensity burden;
SARC	trans	rs11098499	0.954	rs3890049	chr4:120326283	T/A	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	cis	rs6502050	0.761	rs13949	chr17:80059596	T/C	cg19223190	chr17:80058835	NA	-0.46	-6.69	-0.4	1.68e-10	Life satisfaction;
SARC	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg08109568	chr15:31115862	NA	-0.52	-6.71	-0.4	1.49e-10	Huntington's disease progression;
SARC	cis	rs208520	1.000	rs72884033	chr6:66995747	T/C	cg07460842	chr6:66804631	NA	0.9	10.25	0.56	1.39e-20	Exhaled nitric oxide output;
SARC	cis	rs80130819	0.515	rs72644846	chr12:48508283	A/G	cg05342945	chr12:48394962	COL2A1	0.52	5.62	0.35	5.38e-8	Prostate cancer;
SARC	cis	rs11122272	0.735	rs2790885	chr1:231529925	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.14	-0.55	2.99e-20	Hemoglobin concentration;
SARC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg22105103	chr4:187893119	NA	0.51	6.91	0.41	4.68e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs35160687	0.901	rs12622200	chr2:86498595	A/G	cg10973622	chr2:86423274	IMMT	-0.38	-4.9	-0.31	1.83e-6	Night sleep phenotypes;
SARC	cis	rs7223966	0.921	rs34699959	chr17:61960720	T/G	cg26338869	chr17:61819248	STRADA	0.5	5.64	0.35	5.01e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs763121	0.752	rs6001190	chr22:39073811	T/C	cg14440974	chr22:39074834	NA	-0.33	-4.8	-0.3	2.82e-6	Menopause (age at onset);
SARC	cis	rs7086627	0.515	rs2125040	chr10:82208422	G/C	cg01528321	chr10:82214614	TSPAN14	0.58	8.56	0.49	1.5e-15	Post bronchodilator FEV1;
SARC	cis	rs8028182	0.636	rs7495610	chr15:75784441	T/C	cg20655648	chr15:75932815	IMP3	0.63	7.26	0.43	5.91e-12	Sudden cardiac arrest;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg02263426	chr18:14378524	NA	0.53	6.85	0.41	6.48e-11	Breast cancer;
SARC	cis	rs2729354	1.000	rs2848630	chr11:57356907	T/C	cg02958346	chr11:57425731	CLP1	0.52	5.2	0.32	4.39e-7	Blood protein levels;
SARC	cis	rs10911232	0.507	rs10797814	chr1:182990929	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.71	0.57	5.09e-22	Hypertriglyceridemia;
SARC	cis	rs7561149	0.528	rs3816849	chr2:179667090	C/T	cg17765952	chr2:179737173	CCDC141	-0.38	-5.1	-0.32	7e-7	QT interval;
SARC	cis	rs12979813	0.901	rs10421795	chr19:11344406	C/T	cg00586551	chr19:11347513	LOC55908;DOCK6	0.41	5.0	0.31	1.15e-6	HDL cholesterol;
SARC	cis	rs9640161	0.789	rs34311995	chr7:150059255	T/C	cg17279839	chr7:150038598	RARRES2	0.34	5.04	0.31	9.23e-7	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs898097	0.812	rs72859941	chr17:80837459	G/A	cg15664640	chr17:80829946	TBCD	-0.55	-8.3	-0.48	8.26e-15	Breast cancer;
SARC	cis	rs6807306	1.000	rs7649555	chr3:167449369	C/T	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.52	5.24	0.32	3.57e-7	Mean platelet volume;
SARC	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg11878867	chr6:150167359	LRP11	-0.36	-4.71	-0.3	4.2e-6	Lung cancer;
SARC	cis	rs1568889	1.000	rs6484346	chr11:28040767	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	10.25	0.56	1.35e-20	Bipolar disorder;
SARC	cis	rs2251381	0.565	rs2832279	chr21:30613466	G/T	cg24692254	chr21:30365293	RNF160	0.68	8.78	0.5	3.67e-16	Selective IgA deficiency;
SARC	cis	rs754466	0.580	rs2579176	chr10:79529350	A/G	cg17075019	chr10:79541650	NA	-0.84	-13.18	-0.65	5.34e-30	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7582180	0.663	rs1114595	chr2:100960072	T/A	cg14675211	chr2:100938903	LONRF2	0.49	7.31	0.43	4.22e-12	Intelligence (multi-trait analysis);
SARC	cis	rs1559088	0.948	rs12610266	chr19:33581237	C/G	cg27124370	chr19:33622961	WDR88	-0.46	-6.0	-0.37	7.44e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg01448562	chr3:133502909	NA	-0.51	-7.83	-0.46	1.76e-13	Iron status biomarkers;
SARC	cis	rs501120	0.810	rs535176	chr10:44747059	C/T	cg09554077	chr10:44749378	NA	0.44	6.15	0.37	3.32e-9	Coronary artery disease;Coronary heart disease;
SARC	cis	rs9309473	0.950	rs2947860	chr2:73855386	A/G	cg20560298	chr2:73613845	ALMS1	-0.46	-5.57	-0.34	7.14e-8	Metabolite levels;
SARC	cis	rs9443189	0.855	rs1321161	chr6:76454182	G/A	cg01950844	chr6:76311363	SENP6	-0.84	-7.73	-0.45	3.22e-13	Prostate cancer;
SARC	cis	rs796364	1.000	rs71424239	chr2:200725473	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.73	-6.04	-0.37	6.19e-9	Schizophrenia;
SARC	cis	rs920590	0.796	rs10888170	chr8:19635328	C/T	cg03894339	chr8:19674705	INTS10	0.55	6.65	0.4	2.04e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs10078	0.571	rs890973	chr5:471494	T/C	cg26072250	chr5:443457	EXOC3;C5orf55	0.67	5.56	0.34	7.48e-8	Fat distribution (HIV);
SARC	cis	rs920590	0.879	rs67391684	chr8:19654642	A/T	cg17834443	chr8:19674713	INTS10	0.49	6.09	0.37	4.58e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs76419734	0.558	rs58412572	chr4:106518970	A/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.66	5.52	0.34	8.88e-8	Post bronchodilator FEV1;
SARC	cis	rs2153535	0.580	rs9379215	chr6:8481225	G/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.49	0.6	1.71e-24	Motion sickness;
SARC	trans	rs2727020	0.688	rs4929894	chr11:49196333	G/C	cg15704280	chr7:45808275	SEPT13	-0.82	-12.34	-0.63	2.96e-27	Coronary artery disease;
SARC	cis	rs7582180	0.676	rs4264577	chr2:100930662	T/C	cg14675211	chr2:100938903	LONRF2	0.49	7.22	0.43	7.37e-12	Intelligence (multi-trait analysis);
SARC	cis	rs8077889	0.871	rs8081101	chr17:41904332	C/T	cg26893861	chr17:41843967	DUSP3	0.83	10.1	0.55	3.97e-20	Triglycerides;
SARC	cis	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg00745463	chr17:30367425	LRRC37B	-0.68	-5.37	-0.33	1.86e-7	Hip circumference adjusted for BMI;
SARC	cis	rs1057510	0.790	rs73264846	chr12:6717258	A/G	cg13857086	chr12:6580257	VAMP1	0.59	4.75	0.3	3.56e-6	Myopia (pathological);
SARC	cis	rs12908161	0.515	rs12907646	chr15:85403496	G/A	cg24253500	chr15:84953950	NA	0.39	5.09	0.32	7.52e-7	Schizophrenia;
SARC	cis	rs11098499	0.955	rs1397608	chr4:120161744	A/G	cg24375607	chr4:120327624	NA	0.39	4.72	0.3	4.14e-6	Corneal astigmatism;
SARC	cis	rs7512552	0.839	rs7523428	chr1:150430472	G/A	cg15654264	chr1:150340011	RPRD2	0.39	5.13	0.32	6.09e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs6456156	0.792	rs4710183	chr6:167514083	A/G	cg23791538	chr6:167370224	RNASET2	0.4	5.14	0.32	5.88e-7	Primary biliary cholangitis;
SARC	cis	rs365132	1.000	rs353490	chr5:176433063	C/T	cg16309518	chr5:176445507	NA	-0.47	-6.07	-0.37	5.1e-9	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs1050631	0.592	rs1789546	chr18:33725874	A/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.56	6.65	0.4	2.11e-10	Esophageal squamous cell cancer (length of survival);
SARC	trans	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg00938859	chr5:1591904	SDHAP3	0.76	7.1	0.42	1.53e-11	Breast cancer;
SARC	cis	rs7937682	0.921	rs34584980	chr11:111441537	G/A	cg09085632	chr11:111637200	PPP2R1B	0.88	12.71	0.64	1.78e-28	Primary sclerosing cholangitis;
SARC	cis	rs6674176	0.561	rs12127226	chr1:44395309	C/T	cg13606994	chr1:44402422	ARTN	-0.34	-5.71	-0.35	3.44e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs7659604	0.502	rs28435300	chr4:122709412	T/C	cg19671926	chr4:122722719	EXOSC9	0.67	8.79	0.5	3.44e-16	Type 2 diabetes;
SARC	cis	rs12971120	0.947	rs8083001	chr18:72165058	A/G	cg25817165	chr18:72167213	CNDP2	-0.55	-10.37	-0.56	5.97e-21	Refractive error;
SARC	cis	rs17376456	0.825	rs34592268	chr5:93232751	G/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.65	5.99	0.37	7.71e-9	Diabetic retinopathy;
SARC	cis	rs796364	0.589	rs55700082	chr2:201135669	G/A	cg23649088	chr2:200775458	C2orf69	-0.64	-6.58	-0.4	3.04e-10	Schizophrenia;
SARC	cis	rs7953249	0.618	rs2650000	chr12:121388962	G/T	cg02403541	chr12:121454288	C12orf43	0.74	10.11	0.55	3.6e-20	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs5758511	0.680	rs5758692	chr22:42669029	T/A	cg00645731	chr22:42541494	CYP2D7P1	0.45	6.73	0.4	1.33e-10	Birth weight;
SARC	cis	rs116095464	1.000	rs7736	chr5:314935	T/C	cg22857025	chr5:266934	NA	-1.04	-8.49	-0.49	2.44e-15	Breast cancer;
SARC	cis	rs4689388	0.890	rs6838400	chr4:6295427	C/G	cg14416269	chr4:6271139	WFS1	0.32	4.92	0.31	1.61e-6	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs6141769	0.569	rs6119935	chr20:31270570	C/A	cg17884169	chr20:31446444	EFCAB8	-0.46	-4.9	-0.31	1.77e-6	Subjective well-being;
SARC	cis	rs2777491	0.957	rs16971798	chr15:41657144	A/T	cg18705301	chr15:41695430	NDUFAF1	0.74	11.11	0.59	2.77e-23	Ulcerative colitis;
SARC	cis	rs172166	0.769	rs149965	chr6:28018689	T/A	cg26335602	chr6:28129616	ZNF389	0.46	5.18	0.32	4.69e-7	Cardiac Troponin-T levels;
SARC	cis	rs694739	0.734	rs663743	chr11:64107735	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.62	7.66	0.45	4.81e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs765787	0.530	rs11636018	chr15:45539137	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.67e-7	Uric acid levels;
SARC	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg21132104	chr15:45694354	SPATA5L1	0.77	10.98	0.58	6.87e-23	Homoarginine levels;
SARC	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg08109568	chr15:31115862	NA	-0.52	-6.71	-0.4	1.46e-10	Huntington's disease progression;
SARC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.53	6.97	0.42	3.24e-11	Lymphocyte counts;
SARC	cis	rs1345301	0.518	rs56238602	chr2:102863095	G/T	cg12451869	chr2:102867685	NA	0.4	5.48	0.34	1.09e-7	Waist circumference;
SARC	cis	rs4780401	0.573	rs8045673	chr16:11804385	C/A	cg01061890	chr16:11836724	TXNDC11	-0.58	-8.05	-0.47	4.13e-14	Rheumatoid arthritis;
SARC	cis	rs7264396	0.635	rs6060685	chr20:34512023	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-7.47	-0.44	1.56e-12	Total cholesterol levels;
SARC	cis	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg24110177	chr3:50126178	RBM5	0.39	5.04	0.31	9.18e-7	Intelligence (multi-trait analysis);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg19155557	chr3:41240643	CTNNB1	0.49	6.41	0.39	8e-10	Breast cancer;
SARC	cis	rs67311347	1.000	rs4128740	chr3:40519532	C/A	cg01475735	chr3:40494733	NA	-0.47	-5.17	-0.32	5.15e-7	Renal cell carcinoma;
SARC	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg04267008	chr7:1944627	MAD1L1	-0.5	-5.73	-0.35	3.12e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg12463550	chr7:65579703	CRCP	0.47	5.51	0.34	9.32e-8	Aortic root size;
SARC	cis	rs17376456	0.877	rs10070390	chr5:93452345	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.79	0.35	2.3e-8	Diabetic retinopathy;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg24638722	chr8:105509494	LRP12	0.4	6.42	0.39	7.47e-10	Thyroid stimulating hormone;
SARC	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg11987759	chr7:65425863	GUSB	0.49	6.44	0.39	6.86e-10	Aortic root size;
SARC	cis	rs1318878	0.565	rs1304738	chr12:15506641	T/C	cg08258403	chr12:15378311	NA	0.48	6.67	0.4	1.87e-10	Intelligence (multi-trait analysis);
SARC	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg17221315	chr6:27791827	HIST1H4J	0.45	4.75	0.3	3.57e-6	Depression;
SARC	cis	rs8114671	0.562	rs2889861	chr20:33405664	C/T	cg24642439	chr20:33292090	TP53INP2	0.5	6.37	0.39	9.72e-10	Height;
SARC	cis	rs6815814	0.731	rs11096956	chr4:38776180	G/T	cg06935464	chr4:38784597	TLR10	0.5	5.23	0.32	3.78e-7	Breast cancer;
SARC	cis	rs7770848	1	rs7770848	chr6:44769237	A/C	cg19491151	chr6:45391088	RUNX2	0.78	6.98	0.42	3.09e-11	Asthma (childhood onset);
SARC	cis	rs9916302	0.706	rs28482878	chr17:37497100	A/G	cg20243544	chr17:37824526	PNMT	-0.54	-5.76	-0.35	2.67e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs1691799	0.899	rs1168305	chr12:66738714	A/G	cg16791601	chr12:66731901	HELB	-0.71	-10.67	-0.57	6.75e-22	White blood cell count (basophil);
SARC	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg24060327	chr5:131705240	SLC22A5	0.74	8.74	0.5	4.83e-16	Blood metabolite levels;
SARC	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg17376030	chr22:41985996	PMM1	-0.73	-9.06	-0.51	5.59e-17	Vitiligo;
SARC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg02581963	chr10:102133317	C10orf75	0.51	6.8	0.41	8.63e-11	Myopia (pathological);
SARC	cis	rs1865760	0.622	rs9295685	chr6:26071725	G/C	cg18357526	chr6:26021779	HIST1H4A	0.42	5.2	0.32	4.42e-7	Height;
SARC	cis	rs7412746	0.658	rs12067685	chr1:150952917	T/C	cg15448220	chr1:150897856	SETDB1	0.49	6.14	0.37	3.55e-9	Melanoma;
SARC	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg13939156	chr17:80058883	NA	-0.41	-6.39	-0.39	8.73e-10	Life satisfaction;
SARC	cis	rs12142240	0.698	rs56130131	chr1:46861306	A/C	cg10495392	chr1:46806563	NSUN4	0.65	6.9	0.41	5.01e-11	Menopause (age at onset);
SARC	cis	rs67460515	0.892	rs7648279	chr3:160979646	G/A	cg04691961	chr3:161091175	C3orf57	-0.47	-5.84	-0.36	1.71e-8	Parkinson's disease;
SARC	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.75	10.82	0.58	2.3e-22	Personality dimensions;
SARC	cis	rs1023500	0.573	rs133374	chr22:42465941	G/A	cg15557168	chr22:42548783	NA	-0.35	-4.87	-0.3	2.09e-6	Schizophrenia;
SARC	cis	rs12815613	1.000	rs12815613	chr12:121407256	A/G	cg02403541	chr12:121454288	C12orf43	-0.46	-4.8	-0.3	2.88e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs8112909	0.843	rs9967621	chr19:46415343	T/G	cg03583734	chr19:46390327	IRF2BP1	0.48	4.88	0.3	1.95e-6	Interferon gamma-induced protein 10 levels;
SARC	cis	rs9611519	0.828	rs9611460	chr22:41418297	T/C	cg17376030	chr22:41985996	PMM1	0.47	5.4	0.33	1.68e-7	Neuroticism;
SARC	cis	rs4919694	1.000	rs12242000	chr10:104702413	A/C	cg04362960	chr10:104952993	NT5C2	0.66	5.57	0.34	6.99e-8	Arsenic metabolism;
SARC	cis	rs1580019	0.563	rs10486509	chr7:32585443	C/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.96	-16.52	-0.73	4.28e-41	Cognitive ability;
SARC	cis	rs921968	0.541	rs687747	chr2:219399627	T/C	cg02176678	chr2:219576539	TTLL4	0.47	7.16	0.42	1.06e-11	Mean corpuscular hemoglobin concentration;
SARC	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg18402987	chr7:1209562	NA	0.57	4.83	0.3	2.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs72781680	0.898	rs7563564	chr2:23993404	T/C	cg08917208	chr2:24149416	ATAD2B	0.77	7.29	0.43	4.79e-12	Lymphocyte counts;
SARC	cis	rs10861342	1.000	rs11112380	chr12:105526695	C/T	cg23923672	chr12:105501055	KIAA1033	0.69	5.0	0.31	1.11e-6	IgG glycosylation;
SARC	cis	rs6732160	0.588	rs3891890	chr2:73378049	A/G	cg01422370	chr2:73384389	NA	0.37	5.65	0.35	4.61e-8	Intelligence (multi-trait analysis);
SARC	cis	rs986417	1.000	rs4243618	chr14:61067022	T/C	cg27398547	chr14:60952738	C14orf39	0.87	7.38	0.44	2.77e-12	Gut microbiota (bacterial taxa);
SARC	cis	rs11105298	0.891	rs1054807	chr12:89913419	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-5.43	-0.34	1.39e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg07414643	chr4:187882934	NA	-0.42	-5.95	-0.36	9.8e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs72653721	0.689	rs4713160	chr6:11057513	T/A	cg13562911	chr6:11044106	ELOVL2	0.52	5.91	0.36	1.23e-8	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	cis	rs763121	0.853	rs2413544	chr22:39059404	A/C	cg14440974	chr22:39074834	NA	-0.34	-4.89	-0.3	1.9e-6	Menopause (age at onset);
SARC	cis	rs898097	0.585	rs9892342	chr17:80893029	C/T	cg10494973	chr17:80897199	TBCD	-0.43	-5.88	-0.36	1.4e-8	Breast cancer;
SARC	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg26839252	chr6:160211577	TCP1;MRPL18	0.62	6.77	0.41	1.06e-10	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs58653258	0.568	rs6586430	chr1:235001591	G/A	cg14037484	chr1:235490207	ARID4B	-0.54	-4.77	-0.3	3.22e-6	Granulocyte percentage of myeloid white cells;
SARC	cis	rs7766436	0.614	rs2073030	chr6:22569634	A/T	cg13666174	chr6:22585274	NA	-0.59	-6.27	-0.38	1.77e-9	Coronary artery disease;
SARC	cis	rs9682041	0.808	rs9880558	chr3:170067771	A/G	cg11886554	chr3:170076028	SKIL	-0.59	-5.56	-0.34	7.32e-8	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg04267008	chr7:1944627	MAD1L1	-0.61	-7.1	-0.42	1.46e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs7829975	0.564	rs2921057	chr8:8318667	C/T	cg08975724	chr8:8085496	FLJ10661	0.57	7.62	0.45	6.37e-13	Mood instability;
SARC	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	16.84	0.74	3.62e-42	Height;
SARC	cis	rs1707322	1.000	rs6671754	chr1:46433990	A/G	cg03146154	chr1:46216737	IPP	0.45	5.41	0.33	1.57e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs870825	0.616	rs67641203	chr4:185623845	A/C	cg04058563	chr4:185651563	MLF1IP	0.82	11.42	0.6	2.8e-24	Blood protein levels;
SARC	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg02841227	chr6:26021843	HIST1H4A	0.6	6.77	0.41	1.03e-10	Intelligence (multi-trait analysis);
SARC	cis	rs67478160	0.634	rs2144079	chr14:104258884	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.36	-4.95	-0.31	1.42e-6	Schizophrenia;
SARC	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg04944784	chr2:26401820	FAM59B	0.6	7.95	0.46	8.14e-14	Gut microbiome composition (summer);
SARC	cis	rs1699337	0.740	rs709157	chr3:12462024	G/A	cg04748988	chr3:12329223	PPARG	-0.42	-5.16	-0.32	5.25e-7	Cholesterol, total;
SARC	cis	rs9341808	0.718	rs9359408	chr6:80820132	T/G	cg08355045	chr6:80787529	NA	0.34	5.48	0.34	1.09e-7	Sitting height ratio;
SARC	cis	rs3754214	0.823	rs494041	chr1:150270026	T/C	cg09579323	chr1:150459698	TARS2	-0.42	-5.43	-0.33	1.44e-7	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9302635	0.513	rs35460163	chr16:72177060	C/T	cg16558253	chr16:72132732	DHX38	-0.55	-6.53	-0.39	4.13e-10	Blood protein levels;
SARC	cis	rs7216064	0.906	rs78452260	chr17:65848522	G/T	cg12091567	chr17:66097778	LOC651250	-0.68	-6.81	-0.41	8.41e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	trans	rs8073060	0.544	rs8072676	chr17:33999517	C/T	cg19694781	chr19:47549865	TMEM160	-0.7	-6.98	-0.42	3.06e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs7553864	0.636	rs7543740	chr1:87609026	C/T	cg17420885	chr1:87600446	LOC339524	-0.35	-4.83	-0.3	2.49e-6	Smoking behavior;
SARC	cis	rs3796352	1.000	rs13072395	chr3:52980573	T/C	cg07884673	chr3:53033167	SFMBT1	0.82	5.03	0.31	1e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs9818758	0.607	rs9837237	chr3:49215583	G/T	cg01304814	chr3:48885189	PRKAR2A	0.6	4.92	0.31	1.63e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs9843304	0.528	rs9860963	chr3:149197465	A/G	cg08667024	chr3:149219783	TM4SF4	0.44	6.53	0.39	4.03e-10	Gallstone disease;
SARC	cis	rs9300255	0.537	rs2695482	chr12:123623174	C/T	cg00376283	chr12:123451042	ABCB9	0.56	6.58	0.4	2.99e-10	Neutrophil percentage of white cells;
SARC	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.03	12.03	0.62	3.06e-26	Alzheimer's disease;
SARC	cis	rs9818758	0.607	rs61729488	chr3:49067904	T/C	cg00383909	chr3:49044727	WDR6	0.78	6.77	0.41	1.04e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs10791097	0.678	rs10894272	chr11:130731081	A/G	cg09137382	chr11:130731461	NA	0.36	5.76	0.35	2.69e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs7586879	0.616	rs6545814	chr2:25131316	A/G	cg04586622	chr2:25135609	ADCY3	0.34	5.65	0.35	4.73e-8	Body mass index;
SARC	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg11764359	chr7:65958608	NA	0.81	10.52	0.57	1.96e-21	Aortic root size;
SARC	cis	rs6582630	0.519	rs11182021	chr12:38443709	A/T	cg13010199	chr12:38710504	ALG10B	-0.69	-9.46	-0.53	3.49e-18	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs34779708	0.931	rs11010101	chr10:35411045	T/A	cg03585969	chr10:35415529	CREM	0.42	5.37	0.33	1.91e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg07636037	chr3:49044803	WDR6	0.63	8.4	0.48	4.49e-15	Resting heart rate;
SARC	cis	rs7551222	0.752	rs12138846	chr1:204556478	T/A	cg20240347	chr1:204465584	NA	-0.28	-4.99	-0.31	1.21e-6	Schizophrenia;
SARC	cis	rs9381040	1.000	rs2093395	chr6:41155026	C/G	cg04346459	chr6:41068666	NFYA;LOC221442	0.45	5.28	0.33	2.89e-7	Alzheimer's disease (late onset);
SARC	cis	rs2553026	0.879	rs10164712	chr2:218152840	C/T	cg09170686	chr2:217309620	SMARCAL1	-0.37	-4.84	-0.3	2.38e-6	Height;
SARC	cis	rs524281	0.773	rs10791863	chr11:66027358	C/T	cg14036092	chr11:66035641	RAB1B	-0.59	-6.01	-0.37	7.02e-9	Electroencephalogram traits;
SARC	cis	rs282587	0.569	rs9604415	chr13:113393615	G/T	cg02820901	chr13:113351484	ATP11A	-0.5	-4.83	-0.3	2.51e-6	Glycated hemoglobin levels;
SARC	cis	rs9341808	0.528	rs2322753	chr6:81042865	C/G	cg08355045	chr6:80787529	NA	0.33	5.18	0.32	4.81e-7	Sitting height ratio;
SARC	cis	rs9902453	0.868	rs12944395	chr17:28323499	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.54	-6.95	-0.41	3.71e-11	Coffee consumption (cups per day);
SARC	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg04166393	chr7:2884313	GNA12	0.55	6.43	0.39	7.2e-10	Height;
SARC	cis	rs7666738	0.519	rs13136069	chr4:98819568	C/T	cg05340658	chr4:99064831	C4orf37	0.59	7.06	0.42	1.92e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9814567	0.762	rs13067564	chr3:134209956	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.52	5.58	0.34	6.53e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs9486719	0.948	rs11152970	chr6:96909077	A/G	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.01	-0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs2228479	0.850	rs1800344	chr16:89816367	T/G	cg06558623	chr16:89946397	TCF25	0.88	6.21	0.38	2.39e-9	Skin colour saturation;
SARC	cis	rs9393692	0.557	rs9379845	chr6:26291601	C/T	cg13736514	chr6:26305472	NA	-0.42	-4.98	-0.31	1.23e-6	Educational attainment;
SARC	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.59	0.34	6.34e-8	Bipolar disorder;
SARC	cis	rs7568458	0.870	rs1009	chr2:85808737	A/G	cg23752985	chr2:85803571	VAMP8	0.35	5.24	0.32	3.67e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs4280164	0.945	rs1131941	chr14:24760808	C/T	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.57	-5.31	-0.33	2.58e-7	Parent of origin effect on language impairment (paternal);
SARC	cis	rs3796352	0.527	rs11714793	chr3:52924930	A/G	cg27565382	chr3:53032988	SFMBT1	0.6	4.74	0.3	3.79e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs12134245	0.719	rs61798831	chr1:91996588	C/T	cg25838465	chr1:92012736	NA	-0.68	-9.89	-0.54	1.77e-19	Breast cancer;
SARC	cis	rs6604026	0.656	rs2774950	chr1:93353527	T/C	cg17283838	chr1:93427260	FAM69A	-0.42	-4.75	-0.3	3.59e-6	Multiple sclerosis;
SARC	trans	rs61931739	0.963	rs12307606	chr12:34016365	C/T	cg26384229	chr12:38710491	ALG10B	-0.57	-7.13	-0.42	1.23e-11	Morning vs. evening chronotype;
SARC	cis	rs453301	0.686	rs2409120	chr8:8882571	G/C	cg08975724	chr8:8085496	FLJ10661	-0.47	-6.14	-0.37	3.59e-9	Joint mobility (Beighton score);
SARC	cis	rs11098499	0.863	rs2127823	chr4:120485670	G/T	cg24375607	chr4:120327624	NA	0.4	4.82	0.3	2.64e-6	Corneal astigmatism;
SARC	cis	rs71277158	0.688	rs12492606	chr3:169808354	A/G	cg04067573	chr3:169899625	PHC3	-0.55	-4.99	-0.31	1.16e-6	Prostate cancer;
SARC	cis	rs10489202	0.644	rs11584210	chr1:167846853	A/G	cg24449463	chr1:168025552	DCAF6	-0.55	-5.04	-0.31	9.36e-7	Schizophrenia;
SARC	cis	rs208520	0.954	rs12190073	chr6:66983740	T/C	cg07460842	chr6:66804631	NA	0.9	10.32	0.56	8.16e-21	Exhaled nitric oxide output;
SARC	cis	rs10463554	0.857	rs3776873	chr5:102282472	T/A	cg23492399	chr5:102201601	PAM	-0.44	-5.31	-0.33	2.59e-7	Parkinson's disease;
SARC	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.78	7.44	0.44	1.91e-12	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	8.14	0.47	2.32e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1569175	0.522	rs2202923	chr2:200879804	C/T	cg23649088	chr2:200775458	C2orf69	-0.66	-5.56	-0.34	7.24e-8	Response to treatment for acute lymphoblastic leukemia;
SARC	cis	rs213599	0.579	rs9600625	chr13:31470643	C/T	cg00367615	chr13:31480979	C13orf33	-0.28	-4.76	-0.3	3.44e-6	Cognitive function;
SARC	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg04944784	chr2:26401820	FAM59B	0.64	8.39	0.48	4.62e-15	Gut microbiome composition (summer);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg08668662	chr20:30539908	PDRG1	-0.52	-6.42	-0.39	7.4e-10	Breast cancer;
SARC	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-9.18	-0.52	2.35e-17	Alzheimer's disease;
SARC	cis	rs1949733	1.000	rs2688233	chr4:8491885	T/C	cg13073564	chr4:8508604	NA	-0.47	-7.74	-0.45	2.94e-13	Response to antineoplastic agents;
SARC	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg16479474	chr6:28041457	NA	0.38	5.53	0.34	8.72e-8	Depression;
SARC	cis	rs3768617	0.510	rs10752900	chr1:183086238	G/A	cg13390022	chr1:182993471	LAMC1	0.32	4.83	0.3	2.52e-6	Fuchs's corneal dystrophy;
SARC	cis	rs78456975	1.000	rs11891809	chr2:1566001	A/G	cg26248373	chr2:1572462	NA	-0.64	-6.64	-0.4	2.15e-10	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs6840360	1.000	rs1105536	chr4:152605027	C/T	cg22705602	chr4:152727874	NA	-0.38	-6.5	-0.39	4.81e-10	Intelligence (multi-trait analysis);
SARC	cis	rs4148883	0.504	rs2000864	chr4:100123776	A/C	cg12011299	chr4:100065546	ADH4	0.3	5.53	0.34	8.57e-8	Alcohol dependence;
SARC	cis	rs8017423	0.900	rs7141887	chr14:90705364	G/T	cg20276874	chr14:90721474	PSMC1	-0.36	-5.03	-0.31	9.98e-7	Mortality in heart failure;
SARC	cis	rs8005677	1.000	rs7155857	chr14:23400059	C/A	cg01529538	chr14:23388837	RBM23	0.44	5.32	0.33	2.46e-7	Cognitive ability (multi-trait analysis);
SARC	cis	rs7818688	0.697	rs11784140	chr8:95987480	G/T	cg13393036	chr8:95962371	TP53INP1	0.39	4.77	0.3	3.24e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg02841227	chr6:26021843	HIST1H4A	-0.48	-5.86	-0.36	1.59e-8	Intelligence (multi-trait analysis);
SARC	cis	rs72949976	0.606	rs1922797	chr2:214027642	G/A	cg08319019	chr2:214017104	IKZF2	0.49	6.59	0.4	2.92e-10	Lung cancer;Squamous cell lung carcinoma;
SARC	cis	rs4969178	0.930	rs12601079	chr17:76400329	G/A	cg02836325	chr17:76403955	PGS1	0.34	5.21	0.32	4.2e-7	HDL cholesterol levels;
SARC	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg22535103	chr8:58192502	C8orf71	-0.58	-6.19	-0.38	2.71e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.18	0.8	4.72e-53	Prudent dietary pattern;
SARC	cis	rs10046574	0.831	rs77819442	chr7:135072552	C/T	cg27474649	chr7:135195673	CNOT4	0.87	7.0	0.42	2.73e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg13206674	chr6:150067644	NUP43	0.44	5.35	0.33	2.05e-7	Lung cancer;
SARC	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg22920501	chr2:26401640	FAM59B	0.5	6.23	0.38	2.16e-9	Gut microbiome composition (summer);
SARC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.46	0.57	3.12e-21	Prudent dietary pattern;
SARC	cis	rs6582630	0.599	rs12309369	chr12:38419683	C/G	cg26384229	chr12:38710491	ALG10B	-0.57	-7.05	-0.42	2.02e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs11098499	0.754	rs17049949	chr4:120255290	A/G	cg09307838	chr4:120376055	NA	0.81	11.03	0.59	4.84e-23	Corneal astigmatism;
SARC	cis	rs8180040	0.701	rs11917474	chr3:47010491	G/A	cg27129171	chr3:47204927	SETD2	0.65	8.91	0.5	1.47e-16	Colorectal cancer;
SARC	cis	rs9399135	0.967	rs6902438	chr6:135336587	C/T	cg24558204	chr6:135376177	HBS1L	0.45	6.03	0.37	6.24e-9	Red blood cell count;
SARC	cis	rs6087990	0.735	rs6058883	chr20:31365719	C/T	cg13636640	chr20:31349939	DNMT3B	-0.79	-12.31	-0.63	3.72e-27	Ulcerative colitis;
SARC	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg13175981	chr1:150552382	MCL1	-0.54	-6.82	-0.41	7.54e-11	Tonsillectomy;
SARC	cis	rs4423214	1.000	rs3794060	chr11:71187679	C/T	cg24826892	chr11:71159390	DHCR7	0.45	5.73	0.35	3.04e-8	Vitamin D levels;
SARC	cis	rs524281	0.861	rs11227403	chr11:65858428	T/C	cg14036092	chr11:66035641	RAB1B	-0.51	-5.34	-0.33	2.16e-7	Electroencephalogram traits;
SARC	cis	rs36051895	0.632	rs10815164	chr9:5131312	T/A	cg02405213	chr9:5042618	JAK2	-0.44	-5.22	-0.32	3.9e-7	Pediatric autoimmune diseases;
SARC	cis	rs1950500	0.545	rs724165	chr14:24806229	G/A	cg16194253	chr14:24768981	DHRS1;C14orf21	0.64	7.95	0.46	7.92e-14	Height;
SARC	cis	rs6060717	0.536	rs6060699	chr20:34523833	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	5.16	0.32	5.28e-7	Hip circumference adjusted for BMI;
SARC	cis	rs3093024	0.874	rs3093018	chr6:167539805	C/T	cg07741184	chr6:167504864	NA	-0.3	-5.73	-0.35	3.15e-8	Rheumatoid arthritis;
SARC	cis	rs9914988	0.613	rs12451190	chr17:27281877	C/G	cg10538030	chr17:27276405	PHF12	-0.62	-5.07	-0.32	8.01e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs1153858	1.000	rs66528868	chr15:45668547	A/C	cg21132104	chr15:45694354	SPATA5L1	0.78	11.01	0.59	5.55e-23	Homoarginine levels;
SARC	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg23172400	chr8:95962367	TP53INP1	-0.31	-5.3	-0.33	2.64e-7	Type 2 diabetes;
SARC	cis	rs1008375	0.932	rs11934968	chr4:17667766	A/G	cg16339924	chr4:17578868	LAP3	0.6	7.47	0.44	1.6e-12	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs295140	0.585	rs4233996	chr2:201131228	A/T	cg23649088	chr2:200775458	C2orf69	-0.46	-6.61	-0.4	2.6200000000000003e-10	QT interval;
SARC	cis	rs13202913	0.779	rs9383896	chr6:151768495	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.62	5.24	0.32	3.55e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs73206853	0.841	rs73191819	chr12:110920182	C/T	cg10860002	chr12:110842031	ANAPC7	0.59	4.79	0.3	2.95e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs11203032	0.831	rs10887921	chr10:90925667	T/G	cg16672925	chr10:90967113	CH25H	0.71	6.9	0.41	4.79e-11	Heart failure;
SARC	cis	rs9987353	0.566	rs34389718	chr8:9065525	A/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-7.68	-0.45	4.36e-13	Recombination measurement;
SARC	cis	rs6121246	0.567	rs6058187	chr20:30190923	T/C	cg21427119	chr20:30132790	HM13	-0.48	-5.29	-0.33	2.84e-7	Mean corpuscular hemoglobin;
SARC	cis	rs734999	0.505	rs10910107	chr1:2539181	C/T	cg20673091	chr1:2541236	MMEL1	0.33	5.09	0.32	7.49e-7	Ulcerative colitis;
SARC	cis	rs11102986	0.607	rs10776909	chr9:137288746	T/C	cg00753924	chr9:137298813	RXRA	-0.5	-5.67	-0.35	4.3e-8	Intelligence;
SARC	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg17376030	chr22:41985996	PMM1	0.74	9.18	0.52	2.35e-17	Vitiligo;
SARC	cis	rs9660992	0.649	rs12128229	chr1:205268014	C/A	cg00857998	chr1:205179979	DSTYK	0.43	4.93	0.31	1.54e-6	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg25894440	chr7:65020034	NA	-0.73	-5.54	-0.34	8.32e-8	Diabetic kidney disease;
SARC	cis	rs9436747	0.777	rs1475398	chr1:65983257	C/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.5	4.92	0.31	1.65e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	trans	rs9929218	0.954	rs9929239	chr16:68821126	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.52	-6.43	-0.39	6.99e-10	Colorectal cancer;
SARC	cis	rs7296418	0.663	rs28450974	chr12:123861420	G/A	cg05973401	chr12:123451056	ABCB9	0.48	5.62	0.35	5.5e-8	Platelet count;
SARC	cis	rs2295359	1.000	rs2295359	chr1:67635950	G/A	cg08029281	chr1:67600428	NA	0.39	5.38	0.33	1.8e-7	Psoriasis;
SARC	cis	rs6809651	0.524	rs4686730	chr3:185805993	C/T	cg00760338	chr3:185826511	ETV5	-0.83	-10.77	-0.58	3.21e-22	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
SARC	cis	rs9875589	0.957	rs4407395	chr3:13951673	A/G	cg19554555	chr3:13937349	NA	0.52	6.61	0.4	2.64e-10	Ovarian reserve;
SARC	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg11952622	chr19:58962976	ZNF324B	0.52	6.86	0.41	6.11e-11	Uric acid clearance;
SARC	cis	rs2832191	1.000	rs2832190	chr21:30488226	G/A	cg08807101	chr21:30365312	RNF160	-0.74	-10.3	-0.56	9.81e-21	Dental caries;
SARC	cis	rs6964587	0.967	rs10231350	chr7:91808499	G/T	cg17063962	chr7:91808500	NA	0.98	17.12	0.75	4.3e-43	Breast cancer;
SARC	cis	rs7553864	1.000	rs7515367	chr1:87615798	A/T	cg18153957	chr1:87613403	LOC339524	-0.44	-5.23	-0.32	3.79e-7	Smoking behavior;
SARC	cis	rs56176327	0.532	rs9849038	chr3:49771990	A/G	cg13072238	chr3:49761600	GMPPB	-0.61	-6.24	-0.38	2.08e-9	Intelligence (multi-trait analysis);
SARC	cis	rs1707322	0.721	rs4431884	chr1:46101323	C/T	cg06784218	chr1:46089804	CCDC17	0.35	6.14	0.37	3.54e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs11098499	0.863	rs9884402	chr4:120489982	A/G	cg24375607	chr4:120327624	NA	0.42	4.92	0.31	1.64e-6	Corneal astigmatism;
SARC	cis	rs2882667	0.858	rs11242448	chr5:138443154	C/A	cg04439458	chr5:138467593	SIL1	-0.29	-4.91	-0.31	1.68e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs1559088	0.803	rs10411529	chr19:33616256	A/C	cg27124370	chr19:33622961	WDR88	0.45	5.89	0.36	1.31e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.8	11.38	0.6	3.84e-24	Total body bone mineral density;
SARC	cis	rs7260598	0.539	rs115746110	chr19:24063975	G/A	cg27517351	chr19:23941871	ZNF681	0.54	4.73	0.3	3.86e-6	Response to taxane treatment (placlitaxel);
SARC	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg20607798	chr8:58055168	NA	0.48	4.84	0.3	2.32e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs2295359	0.963	rs12030867	chr1:67627620	T/C	cg12940439	chr1:67600707	NA	0.45	6.8	0.41	8.7e-11	Psoriasis;
SARC	cis	rs636291	0.517	rs670666	chr1:10549380	C/T	cg17425144	chr1:10567563	PEX14	-0.41	-6.69	-0.4	1.65e-10	Prostate cancer;
SARC	cis	rs6570726	0.935	rs374000	chr6:145855290	C/T	cg05347473	chr6:146136440	FBXO30	0.49	6.62	0.4	2.41e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6089584	0.893	rs2281735	chr20:60582540	T/A	cg06108461	chr20:60628389	TAF4	-0.88	-11.59	-0.6	7.87e-25	Body mass index;
SARC	trans	rs9354308	0.868	rs4392709	chr6:66547178	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.56	-6.64	-0.4	2.19e-10	Metabolite levels;
SARC	cis	rs4319547	0.508	rs10846826	chr12:122894987	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.53	-5.94	-0.36	1.01e-8	Body mass index;
SARC	cis	rs995000	0.931	rs10493322	chr1:62905893	C/T	cg06896770	chr1:63153194	DOCK7	0.99	15.48	0.71	1.16e-37	Triglyceride levels;
SARC	cis	rs10782582	0.609	rs1251584	chr1:76424440	C/T	cg10523679	chr1:76189770	ACADM	0.42	5.23	0.32	3.72e-7	Daytime sleep phenotypes;
SARC	cis	rs617219	0.574	rs7732681	chr5:78595246	C/T	cg24856658	chr5:78533917	JMY	0.3	4.78	0.3	3.09e-6	Betaine levels in individuals undergoing cardiac evaluation;
SARC	trans	rs1814175	0.607	rs11493324	chr11:50011304	T/C	cg15704280	chr7:45808275	SEPT13	-0.82	-13.02	-0.65	1.69e-29	Height;
SARC	cis	rs59112743	0.748	rs62395016	chr6:15693205	T/C	cg06375068	chr6:15849678	NA	0.53	4.75	0.3	3.63e-6	Multiple keratinocyte cancers;
SARC	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg18252515	chr7:66147081	NA	0.48	5.12	0.32	6.34e-7	Aortic root size;
SARC	cis	rs9916302	0.800	rs9892675	chr17:37549200	C/T	cg15445000	chr17:37608096	MED1	-0.48	-5.53	-0.34	8.66e-8	Glomerular filtration rate (creatinine);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg02004672	chr5:110074800	SLC25A46	0.54	6.27	0.38	1.75e-9	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg21724239	chr8:58056113	NA	0.57	5.84	0.36	1.79e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs883565	0.568	rs4616582	chr3:39028854	G/T	cg01426195	chr3:39028469	NA	0.35	5.31	0.33	2.6e-7	Handedness;
SARC	cis	rs6714710	0.580	rs11690737	chr2:98461953	C/T	cg26665480	chr2:98280029	ACTR1B	0.51	6.96	0.42	3.35e-11	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg18404041	chr3:52824283	ITIH1	0.32	4.83	0.3	2.46e-6	Electroencephalogram traits;
SARC	cis	rs13401104	0.716	rs1377443	chr2:237129648	G/T	cg19324714	chr2:237145437	ASB18	0.61	5.97	0.36	8.96e-9	Educational attainment;
SARC	cis	rs62432291	0.681	rs417719	chr6:159658042	C/T	cg14500486	chr6:159655392	FNDC1	-0.63	-6.19	-0.38	2.73e-9	Joint mobility (Beighton score);
SARC	cis	rs870825	0.616	rs1401359	chr4:185640216	T/C	cg04058563	chr4:185651563	MLF1IP	0.79	11.29	0.59	7.34e-24	Blood protein levels;
SARC	trans	rs2637266	1.000	rs2637266	chr10:78331318	C/T	cg01661307	chr16:4893705	GLYR1	0.44	6.39	0.39	8.95e-10	Pulmonary function;
SARC	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg00149659	chr3:10157352	C3orf10	0.8	7.55	0.44	9.91e-13	Alzheimer's disease;
SARC	cis	rs67460515	0.563	rs4494975	chr3:160866768	C/T	cg04691961	chr3:161091175	C3orf57	-0.41	-4.91	-0.31	1.7e-6	Parkinson's disease;
SARC	cis	rs11711311	1.000	rs9809850	chr3:113429010	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.7	8.67	0.49	7.34e-16	IgG glycosylation;
SARC	cis	rs10513432	0.655	rs77598898	chr3:152550872	G/A	cg04845053	chr3:152552877	P2RY1	0.81	4.73	0.3	3.96e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs6759839	0.761	rs7606503	chr2:16624447	G/A	cg09580478	chr2:16689509	NA	0.44	5.7	0.35	3.6e-8	Mean platelet volume;
SARC	cis	rs2952156	0.883	rs907089	chr17:37833600	C/T	cg20243544	chr17:37824526	PNMT	0.55	7.29	0.43	4.71e-12	Asthma;
SARC	cis	rs9462027	0.527	rs11755393	chr6:34824636	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.98	-0.36	8.24e-9	Systemic lupus erythematosus;
SARC	trans	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-6.25	-0.38	1.97e-9	Neuroticism;
SARC	cis	rs637571	0.522	rs606978	chr11:65711517	A/C	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.39	-4.77	-0.3	3.26e-6	Eosinophil percentage of white cells;
SARC	cis	rs3126085	0.935	rs3120661	chr1:152294402	A/G	cg03465714	chr1:152285911	FLG	0.45	5.34	0.33	2.24e-7	Atopic dermatitis;
SARC	cis	rs2908197	0.663	rs7802264	chr7:75985782	T/C	cg24580635	chr7:76178542	LOC100133091	-0.42	-4.86	-0.3	2.19e-6	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs6570726	0.818	rs398812	chr6:145817271	T/C	cg23711669	chr6:146136114	FBXO30	0.78	11.91	0.62	7.29e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12200782	1.000	rs12201802	chr6:26398664	G/A	cg11502198	chr6:26597334	ABT1	-0.69	-4.81	-0.3	2.69e-6	Small cell lung carcinoma;
SARC	cis	rs8038465	0.516	rs8037836	chr15:73859855	G/A	cg15420318	chr15:73925796	NPTN	0.73	8.67	0.49	7.52e-16	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs12421382	0.614	rs12575538	chr11:109390966	C/A	cg27471124	chr11:109292789	C11orf87	0.35	5.03	0.31	9.97e-7	Schizophrenia;
SARC	cis	rs11190604	1.000	rs2495755	chr10:102324649	A/C	cg07080220	chr10:102295463	HIF1AN	0.8	8.86	0.5	2.12e-16	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs7599312	0.534	rs6435711	chr2:213410065	G/A	cg16329650	chr2:213403929	ERBB4	0.7	10.56	0.57	1.52e-21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg05025164	chr4:1340916	KIAA1530	0.86	10.95	0.58	8.77e-23	Longevity;
SARC	cis	rs3772130	0.564	rs28760466	chr3:121601510	A/G	cg20356878	chr3:121714668	ILDR1	0.41	6.33	0.38	1.21e-9	Cognitive performance;
SARC	cis	rs41271473	0.898	rs3738073	chr1:228871693	C/T	cg10167378	chr1:228756711	NA	0.49	4.73	0.3	3.94e-6	Chronic lymphocytic leukemia;
SARC	cis	rs7178572	0.568	rs7175674	chr15:77670910	C/T	cg22256960	chr15:77711686	NA	-0.53	-5.88	-0.36	1.39e-8	Type 2 diabetes;
SARC	cis	rs7940866	0.903	rs11222411	chr11:130838682	A/G	cg12179176	chr11:130786555	SNX19	0.63	8.38	0.48	5.17e-15	Schizophrenia;
SARC	cis	rs3768617	0.510	rs2296300	chr1:183099701	G/A	cg13390022	chr1:182993471	LAMC1	0.31	4.79	0.3	3.01e-6	Fuchs's corneal dystrophy;
SARC	cis	rs13082711	0.911	rs34878935	chr3:27466123	A/C	cg02860705	chr3:27208620	NA	0.46	6.02	0.37	6.7e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs694739	0.536	rs11231740	chr11:64046641	C/T	cg23796481	chr11:64053134	BAD;GPR137	-0.53	-6.83	-0.41	7.21e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs262150	0.574	rs2730272	chr7:158798622	G/C	cg19418458	chr7:158789849	NA	-0.43	-6.02	-0.37	6.8e-9	Facial morphology (factor 20);
SARC	cis	rs10979	1.000	rs12211659	chr6:143898348	G/T	cg25407410	chr6:143891975	LOC285740	-0.64	-8.78	-0.5	3.67e-16	Hypospadias;
SARC	cis	rs7520050	0.931	rs7526678	chr1:46374159	A/G	cg24296786	chr1:45957014	TESK2	0.38	4.82	0.3	2.54e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.81	12.34	0.63	2.86e-27	Menarche (age at onset);
SARC	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg20607798	chr8:58055168	NA	0.57	5.53	0.34	8.58e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs908922	0.676	rs11205033	chr1:152527966	C/A	cg09873164	chr1:152488093	CRCT1	0.6	7.89	0.46	1.16e-13	Hair morphology;
SARC	cis	rs72781680	0.821	rs12623521	chr2:24181670	C/T	cg08917208	chr2:24149416	ATAD2B	0.58	6.0	0.37	7.32e-9	Lymphocyte counts;
SARC	cis	rs911263	0.603	rs12880109	chr14:68813032	C/T	cg18825221	chr14:68749962	RAD51L1	0.44	7.5	0.44	1.34e-12	Primary biliary cholangitis;
SARC	cis	rs2204008	0.806	rs11520229	chr12:38246448	C/A	cg26384229	chr12:38710491	ALG10B	0.91	13.64	0.67	1.61e-31	Bladder cancer;
SARC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.48	-6.19	-0.38	2.68e-9	Electroencephalogram traits;
SARC	cis	rs12681288	0.523	rs112307130	chr8:962483	G/A	cg15309053	chr8:964076	NA	0.47	7.71	0.45	3.58e-13	Schizophrenia;
SARC	cis	rs9612	1.000	rs1059	chr19:44268348	C/T	cg07522664	chr19:44259120	C19orf61	0.5	5.61	0.34	5.83e-8	Exhaled nitric oxide output;
SARC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.42	0.56	3.95e-21	Prudent dietary pattern;
SARC	trans	rs656319	0.513	rs688541	chr8:9818000	T/A	cg06636001	chr8:8085503	FLJ10661	-0.57	-6.55	-0.39	3.7e-10	Myopia (pathological);
SARC	cis	rs912057	0.965	rs1294409	chr6:6738355	A/G	cg06612196	chr6:6737390	NA	-0.65	-9.59	-0.53	1.43e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs1062177	1.000	rs2964612	chr5:151198750	G/A	cg00977110	chr5:151150581	G3BP1	0.57	5.59	0.34	6.19e-8	Preschool internalizing problems;
SARC	cis	rs7635838	0.892	rs9310383	chr3:11491305	A/G	cg00170343	chr3:11313890	ATG7	-0.61	-8.41	-0.48	4.1e-15	HDL cholesterol;
SARC	cis	rs17021463	0.807	rs6532480	chr4:95277038	T/C	cg11021082	chr4:95130006	SMARCAD1	0.36	5.34	0.33	2.18e-7	Testicular germ cell tumor;
SARC	cis	rs7412746	0.587	rs11204722	chr1:150730184	A/C	cg15448220	chr1:150897856	SETDB1	-0.49	-6.4	-0.39	8.54e-10	Melanoma;
SARC	cis	rs2070433	0.706	rs55696586	chr21:47733918	T/C	cg12379764	chr21:47803548	PCNT	0.59	4.9	0.31	1.81e-6	Lymphocyte counts;
SARC	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-6.48	-0.39	5.52e-10	Bipolar disorder;
SARC	cis	rs4820539	0.966	rs3788350	chr22:23468468	C/T	cg14186256	chr22:23484241	RTDR1	0.84	12.96	0.65	2.7e-29	Bone mineral density;
SARC	cis	rs11098499	0.874	rs12502503	chr4:120116255	C/T	cg09307838	chr4:120376055	NA	0.82	11.06	0.59	3.96e-23	Corneal astigmatism;
SARC	cis	rs910316	1.000	rs1043674	chr14:75549370	T/C	cg06637938	chr14:75390232	RPS6KL1	0.54	7.72	0.45	3.41e-13	Height;
SARC	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs7524258	0.868	rs7544314	chr1:7266744	G/C	cg07173049	chr1:7289937	CAMTA1	0.4	7.63	0.45	6.02e-13	Tourette's syndrome or obsessive-compulsive disorder;
SARC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg03452623	chr4:187889614	NA	-0.76	-11.88	-0.61	9e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs561341	0.609	rs11658984	chr17:30186612	C/T	cg13647721	chr17:30228624	UTP6	-0.73	-7.08	-0.42	1.73e-11	Hip circumference adjusted for BMI;
SARC	cis	rs644799	0.710	rs12272061	chr11:95524067	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.97	16.71	0.74	9.58e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs11105298	0.891	rs11105318	chr12:89926658	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.53	-5.26	-0.33	3.2e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs939574	1.000	rs56927225	chr2:220100922	A/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.63	4.98	0.31	1.22e-6	Platelet distribution width;
SARC	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg09035930	chr12:129282057	SLC15A4	0.56	7.99	0.46	6.12e-14	Systemic lupus erythematosus;
SARC	cis	rs17401966	1.000	rs3753037	chr1:10355834	C/T	cg15208524	chr1:10270712	KIF1B	0.59	6.68	0.4	1.7e-10	Hepatocellular carcinoma;
SARC	cis	rs787274	0.718	rs1711745	chr9:115452909	C/A	cg13803584	chr9:115635662	SNX30	0.68	5.23	0.32	3.78e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs6088580	0.634	rs3736762	chr20:33037336	C/T	cg08999081	chr20:33150536	PIGU	0.44	6.73	0.4	1.3100000000000001e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs6496932	0.563	rs2344083	chr15:85897432	T/C	cg19183879	chr15:85880815	NA	-0.41	-6.7	-0.4	1.57e-10	Central corneal thickness;Corneal structure;
SARC	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg07701084	chr6:150067640	NUP43	0.41	5.39	0.33	1.75e-7	Lung cancer;
SARC	cis	rs6841333	0.674	rs4859567	chr4:76852839	A/T	cg19999035	chr4:77355817	SHROOM3	0.35	4.89	0.31	1.88e-6	Monokine induced by gamma interferon levels;
SARC	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1008375	0.932	rs4698629	chr4:17608884	C/G	cg16339924	chr4:17578868	LAP3	0.65	8.16	0.47	2.09e-14	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2882667	0.755	rs55650316	chr5:138467292	C/G	cg04439458	chr5:138467593	SIL1	-0.28	-4.83	-0.3	2.5e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg15242686	chr22:24348715	GSTTP1	0.37	4.72	0.3	4e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2033711	0.811	rs9304814	chr19:58951811	C/A	cg00825309	chr19:58991885	ZNF446	-0.58	-7.96	-0.46	7.3e-14	Uric acid clearance;
SARC	cis	rs5771242	0.518	rs5771258	chr22:50675648	C/A	cg16473166	chr22:50639996	SELO	0.51	5.24	0.32	3.54e-7	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
SARC	cis	rs514406	0.505	rs405208	chr1:53176674	C/T	cg16325326	chr1:53192061	ZYG11B	0.95	17.84	0.76	1.79e-45	Monocyte count;
SARC	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg15448220	chr1:150897856	SETDB1	0.47	6.25	0.38	1.94e-9	Tonsillectomy;
SARC	cis	rs7223966	1.000	rs9899491	chr17:61934384	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	7.6	0.45	7.36e-13	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2197308	0.655	rs1971964	chr12:37870474	C/T	cg13010199	chr12:38710504	ALG10B	0.81	11.1	0.59	2.99e-23	Morning vs. evening chronotype;
SARC	cis	rs7772486	0.686	rs1004752	chr6:146037822	G/A	cg05347473	chr6:146136440	FBXO30	-0.5	-6.9	-0.41	4.85e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-15.26	-0.71	6.64e-37	Chronic sinus infection;
SARC	cis	rs12079745	0.793	rs12740226	chr1:169183257	T/C	cg09363564	chr1:169337483	NME7;BLZF1	-0.78	-5.14	-0.32	5.81e-7	QT interval;
SARC	cis	rs6487679	0.526	rs34362	chr12:9385425	C/T	cg08997352	chr12:9597637	DDX12	0.46	5.73	0.35	3.09e-8	Non-alcoholic fatty liver disease histology (AST);
SARC	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg25072359	chr17:41440525	NA	0.5	5.95	0.36	9.75e-9	Menopause (age at onset);
SARC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.09	12.63	0.64	3.25e-28	Platelet count;
SARC	cis	rs3733585	0.736	rs4543113	chr4:10008305	G/A	cg11266682	chr4:10021025	SLC2A9	0.4	6.85	0.41	6.58e-11	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs17376456	0.569	rs10476520	chr5:93058290	A/C	cg21475434	chr5:93447410	FAM172A	0.63	6.2	0.38	2.51e-9	Diabetic retinopathy;
SARC	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg01316550	chr5:56110833	MAP3K1	0.54	4.92	0.31	1.62e-6	Initial pursuit acceleration;
SARC	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg27266027	chr21:40555129	PSMG1	0.48	5.18	0.32	4.79e-7	Cognitive function;
SARC	cis	rs7223966	1.000	rs9899788	chr17:61756384	G/A	cg00588841	chr17:61851480	DDX42;CCDC47	-0.59	-6.86	-0.41	6.03e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs593982	0.920	rs488170	chr11:65481544	T/C	cg08755490	chr11:65554678	OVOL1	0.88	8.35	0.48	6.25e-15	Atopic dermatitis;
SARC	cis	rs4727027	0.866	rs10435245	chr7:148816081	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.48	5.7	0.35	3.63e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs4253772	0.688	rs113928699	chr22:46649344	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.63	4.94	0.31	1.47e-6	LDL cholesterol;Cholesterol, total;
SARC	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.679	rs16921677	chr8:58052431	T/C	cg20607798	chr8:58055168	NA	0.6	5.52	0.34	9.04e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs3857536	0.740	rs7773577	chr6:66892124	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.6	-7.14	-0.42	1.19e-11	Blood trace element (Cu levels);
SARC	cis	rs7937682	0.889	rs516263	chr11:111484719	A/C	cg22437258	chr11:111473054	SIK2	0.76	10.55	0.57	1.58e-21	Primary sclerosing cholangitis;
SARC	cis	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg09021430	chr5:549028	NA	-0.45	-5.7	-0.35	3.52e-8	Obesity-related traits;
SARC	cis	rs11098499	0.657	rs71614442	chr4:120379346	C/T	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	cis	rs881375	0.933	rs7031096	chr9:123694942	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	5.44	0.34	1.33e-7	Rheumatoid arthritis;
SARC	cis	rs75920871	0.588	rs4548653	chr11:116903316	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.52	-5.17	-0.32	5.06e-7	Subjective well-being;
SARC	cis	rs7904368	0.754	rs12246217	chr10:16853349	G/C	cg23933602	chr10:16859644	RSU1	0.58	5.88	0.36	1.38e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs5769765	1.000	rs2295409	chr22:50261060	G/C	cg03033257	chr22:50311977	ALG12;CRELD2	-0.53	-5.5	-0.34	9.76e-8	Schizophrenia;
SARC	cis	rs995000	0.899	rs35529421	chr1:62965621	T/A	cg06896770	chr1:63153194	DOCK7	0.98	14.53	0.69	1.72e-34	Triglyceride levels;
SARC	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg00933542	chr6:150070202	PCMT1	0.31	5.27	0.33	3.07e-7	Lung cancer;
SARC	cis	rs11690935	0.550	rs62183785	chr2:172866976	G/A	cg13550731	chr2:172543902	DYNC1I2	0.52	6.63	0.4	2.27e-10	Schizophrenia;
SARC	cis	rs9660992	0.674	rs56198325	chr1:205265450	G/A	cg19090574	chr1:205240910	TMCC2	-0.4	-4.89	-0.3	1.9e-6	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs2153535	0.580	rs1115078	chr6:8449638	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	8.4	0.48	4.42e-15	Motion sickness;
SARC	cis	rs503734	0.502	rs571391	chr3:100963154	C/T	cg12386194	chr3:101231763	SENP7	-0.42	-4.91	-0.31	1.7e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs11690935	1.000	rs312918	chr2:172569587	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.96	-15.02	-0.7	4.07e-36	Schizophrenia;
SARC	cis	rs208520	0.706	rs851601	chr6:66893853	G/A	cg07460842	chr6:66804631	NA	-1.03	-13.2	-0.65	4.48e-30	Exhaled nitric oxide output;
SARC	cis	rs7829975	0.871	rs7829826	chr8:8578120	T/A	cg08975724	chr8:8085496	FLJ10661	-0.5	-5.95	-0.36	9.71e-9	Mood instability;
SARC	trans	rs637571	0.522	rs493899	chr11:65747952	A/C	cg17712092	chr4:129076599	LARP1B	0.68	9.24	0.52	1.6e-17	Eosinophil percentage of white cells;
SARC	cis	rs7223966	1.000	rs7223412	chr17:61808172	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.53	-5.55	-0.34	7.66e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2467099	0.679	rs2608882	chr17:73934130	G/A	cg23806715	chr17:73775811	H3F3B	0.56	5.64	0.35	4.87e-8	Systolic blood pressure;
SARC	cis	rs2594989	1.000	rs2606742	chr3:11391717	G/A	cg00170343	chr3:11313890	ATG7	0.57	5.62	0.35	5.4e-8	Circulating chemerin levels;
SARC	cis	rs9399137	0.507	rs7771310	chr6:135272535	G/A	cg24558204	chr6:135376177	HBS1L	0.61	7.91	0.46	1.02e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs3106136	0.967	rs4693377	chr4:95157256	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.38	-5.95	-0.36	9.94e-9	Capecitabine sensitivity;
SARC	cis	rs9473924	0.505	rs9473921	chr6:50828072	C/T	cg14470998	chr6:50812995	TFAP2B	0.74	6.74	0.4	1.25e-10	Body mass index;
SARC	trans	rs56279505	0.629	rs33988198	chr4:100268132	A/C	cg21156590	chr1:3420848	MEGF6	-0.83	-6.41	-0.39	8.04e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9300255	0.602	rs1727316	chr12:123618603	C/T	cg00376283	chr12:123451042	ABCB9	0.56	6.7	0.4	1.51e-10	Neutrophil percentage of white cells;
SARC	cis	rs76419734	0.558	rs10019217	chr4:106588509	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.68	7.76	0.45	2.64e-13	Post bronchodilator FEV1;
SARC	cis	rs4888262	0.508	rs7193583	chr16:74649589	C/G	ch.16.1684049R	chr16:74565916	GLG1	0.35	4.72	0.3	4.1e-6	Testicular germ cell tumor;
SARC	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg11987759	chr7:65425863	GUSB	0.47	5.73	0.35	3.15e-8	Aortic root size;
SARC	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg13628971	chr7:2884303	GNA12	0.57	6.73	0.4	1.28e-10	Height;
SARC	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg26335602	chr6:28129616	ZNF389	0.48	5.47	0.34	1.17e-7	Cardiac Troponin-T levels;
SARC	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg19346786	chr7:2764209	NA	-0.41	-6.22	-0.38	2.22e-9	Height;
SARC	cis	rs6060717	0.536	rs6060670	chr20:34481143	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	5.16	0.32	5.29e-7	Hip circumference adjusted for BMI;
SARC	trans	rs9388451	0.868	rs10457467	chr6:126045148	T/A	cg05039488	chr6:79577232	IRAK1BP1	-0.58	-7.46	-0.44	1.66e-12	Brugada syndrome;
SARC	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg16479474	chr6:28041457	NA	0.38	5.58	0.34	6.78e-8	Depression;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg07512676	chr17:48785330	ANKRD40	-0.5	-6.26	-0.38	1.88e-9	Height;
SARC	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg12463550	chr7:65579703	CRCP	-0.71	-5.37	-0.33	1.9e-7	Diabetic kidney disease;
SARC	cis	rs1371867	0.810	rs2919470	chr8:101233301	C/A	cg11906718	chr8:101322791	RNF19A	-0.68	-8.69	-0.49	6.65e-16	Atrioventricular conduction;
SARC	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-6.36	-0.38	1.03e-9	Personality dimensions;
SARC	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.75	7.36	0.43	3.08e-12	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg03264133	chr6:25882463	NA	-0.39	-5.04	-0.31	9.52e-7	Intelligence (multi-trait analysis);
SARC	cis	rs79149102	0.579	rs7163390	chr15:75280426	T/C	cg09165964	chr15:75287851	SCAMP5	-0.94	-8.7	-0.5	6.17e-16	Lung cancer;
SARC	cis	rs9290065	0.519	rs1562465	chr3:160701442	G/A	cg04691961	chr3:161091175	C3orf57	-0.49	-6.23	-0.38	2.12e-9	Kawasaki disease;
SARC	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.78	11.64	0.61	5.61e-25	Personality dimensions;
SARC	cis	rs681343	1.000	rs679574	chr19:49206108	C/G	cg21064579	chr19:49206444	FUT2	0.36	5.1	0.32	6.92e-7	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
SARC	cis	rs8067545	0.532	rs17759041	chr17:19959966	A/G	cg13482628	chr17:19912719	NA	0.43	4.88	0.3	1.99e-6	Schizophrenia;
SARC	cis	rs709400	0.628	rs2010281	chr14:103862322	G/A	cg12935359	chr14:103987150	CKB	-0.38	-5.66	-0.35	4.44e-8	Body mass index;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg26390965	chr6:151670448	AKAP12	-0.37	-6.34	-0.38	1.19e-9	Breast cancer;
SARC	cis	rs6964587	1.000	rs2301559	chr7:91746727	T/C	cg17063962	chr7:91808500	NA	0.95	16.04	0.72	1.66e-39	Breast cancer;
SARC	cis	rs9303542	0.571	rs2202895	chr17:46584657	T/C	cg04904318	chr17:46607828	HOXB1	0.4	4.98	0.31	1.22e-6	Ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs6687430	0.526	rs7555790	chr1:10613167	A/G	cg17425144	chr1:10567563	PEX14	-0.35	-5.26	-0.33	3.34e-7	Hand grip strength;
SARC	cis	rs6909279	0.522	rs7741872	chr6:151893946	C/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.42	-5.25	-0.33	3.4e-7	Bone mineral density;
SARC	cis	rs6933660	0.512	rs9383905	chr6:151804296	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.76	6.45	0.39	6.54e-10	Menarche (age at onset);
SARC	cis	rs2976388	0.609	rs2572908	chr8:143802636	A/G	cg06565975	chr8:143823917	SLURP1	0.29	4.99	0.31	1.2e-6	Urinary tract infection frequency;
SARC	cis	rs11105298	0.891	rs10858889	chr12:89902604	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.52	-5.3	-0.33	2.67e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs10411936	0.682	rs8103805	chr19:16598433	T/G	cg10248733	chr19:16607483	C19orf44;CALR3	0.62	7.43	0.44	2.08e-12	White blood cell count;Multiple sclerosis;
SARC	cis	rs6570726	0.935	rs371744	chr6:145841024	C/T	cg05220968	chr6:146057943	EPM2A	-0.29	-4.86	-0.3	2.17e-6	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg18330675	chr4:180980172	NA	0.44	6.32	0.38	1.31e-9	Chemerin levels;
SARC	cis	rs6121246	0.522	rs6088736	chr20:30195166	C/G	cg13852791	chr20:30311386	BCL2L1	0.68	5.91	0.36	1.2e-8	Mean corpuscular hemoglobin;
SARC	cis	rs10463554	0.963	rs72785733	chr5:102374192	T/A	cg23492399	chr5:102201601	PAM	-0.52	-5.67	-0.35	4.18e-8	Parkinson's disease;
SARC	cis	rs1864400	0.641	rs61845681	chr10:43733180	T/C	cg15436174	chr10:43711423	RASGEF1A	0.48	5.49	0.34	1.03e-7	Hirschsprung disease;
SARC	cis	rs9868809	0.772	rs12107252	chr3:48691316	T/C	cg07636037	chr3:49044803	WDR6	-0.7	-6.62	-0.4	2.42e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs9309473	1.000	rs9653557	chr2:73795962	A/C	cg20560298	chr2:73613845	ALMS1	-0.48	-5.92	-0.36	1.14e-8	Metabolite levels;
SARC	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg00149659	chr3:10157352	C3orf10	0.68	6.38	0.39	9.46e-10	Alzheimer's disease;
SARC	cis	rs11574514	1.000	rs9928374	chr16:67811930	A/G	cg01866162	chr16:67596514	CTCF	-0.87	-5.53	-0.34	8.65e-8	Crohn's disease;
SARC	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg20607798	chr8:58055168	NA	0.68	5.88	0.36	1.43e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg18252515	chr7:66147081	NA	-0.47	-5.09	-0.32	7.32e-7	Aortic root size;
SARC	cis	rs3126085	0.935	rs1552993	chr1:152171483	A/G	cg03465714	chr1:152285911	FLG	-0.47	-5.56	-0.34	7.25e-8	Atopic dermatitis;
SARC	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.42	-4.99	-0.31	1.16e-6	Renal function-related traits (BUN);
SARC	cis	rs9858542	0.953	rs11922013	chr3:49458355	G/C	cg03060546	chr3:49711283	APEH	-0.57	-7.0	-0.42	2.67e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs514024	0.729	rs4836575	chr9:130446493	C/T	cg13643465	chr9:130375613	STXBP1	-0.51	-6.4	-0.39	8.27e-10	Eating disorders (purging via substances);
SARC	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg13607699	chr17:42295918	UBTF	-0.6	-7.23	-0.43	6.99e-12	Total body bone mineral density;
SARC	cis	rs344364	0.511	rs1657133	chr16:1950300	A/G	cg26617929	chr16:1858877	NA	-0.71	-6.06	-0.37	5.5e-9	Glomerular filtration rate in chronic kidney disease;
SARC	cis	rs12824058	0.831	rs12314111	chr12:130813663	G/T	cg26677194	chr12:130822605	PIWIL1	0.54	7.48	0.44	1.54e-12	Menopause (age at onset);
SARC	cis	rs826838	0.838	rs11183646	chr12:38799846	A/T	cg26384229	chr12:38710491	ALG10B	0.94	15.14	0.7	1.62e-36	Heart rate;
SARC	cis	rs9902453	0.904	rs8071742	chr17:28361669	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.53	-6.96	-0.41	3.52e-11	Coffee consumption (cups per day);
SARC	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg21724239	chr8:58056113	NA	0.58	5.69	0.35	3.74e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7847628	0.551	rs10818476	chr9:123572038	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.92	14.34	0.68	7.21e-34	Birth weight;
SARC	trans	rs12310956	0.532	rs11052952	chr12:33988048	G/A	cg26384229	chr12:38710491	ALG10B	0.85	12.42	0.63	1.57e-27	Morning vs. evening chronotype;
SARC	cis	rs9911578	0.967	rs7502208	chr17:57165097	G/A	cg05425664	chr17:57184151	TRIM37	-0.63	-7.79	-0.45	2.23e-13	Intelligence (multi-trait analysis);
SARC	cis	rs9462027	0.628	rs2814953	chr6:34697767	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.99	-0.37	8.1e-9	Systemic lupus erythematosus;
SARC	cis	rs8070128	0.534	rs2955350	chr17:17953548	G/A	cg05444541	chr17:17804740	TOM1L2	0.3	4.89	0.31	1.85e-6	Total body bone mineral density;
SARC	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg17158414	chr2:27665306	KRTCAP3	-0.35	-5.72	-0.35	3.24e-8	Total body bone mineral density;
SARC	cis	rs7927771	1.000	rs7947730	chr11:47786184	C/T	cg05585544	chr11:47624801	NA	-0.36	-4.82	-0.3	2.59e-6	Subjective well-being;
SARC	cis	rs7084402	0.967	rs1614258	chr10:60308407	C/T	cg07615347	chr10:60278583	BICC1	0.59	8.61	0.49	1.12e-15	Refractive error;
SARC	cis	rs3820928	0.874	rs6707265	chr2:227849255	T/A	cg11843606	chr2:227700838	RHBDD1	-0.56	-7.03	-0.42	2.29e-11	Pulmonary function;
SARC	cis	rs11098499	0.909	rs7681214	chr4:120385320	C/A	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	cis	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg16834496	chr10:115438884	CASP7	0.54	6.66	0.4	1.95e-10	Breast cancer;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg16757658	chr11:126138769	SRPR;FOXRED1	0.48	6.31	0.38	1.41e-9	Chemerin levels;
SARC	cis	rs72945132	0.882	rs12274436	chr11:70132204	T/C	cg05964544	chr11:70165517	PPFIA1	-0.6	-5.85	-0.36	1.66e-8	Coronary artery disease;
SARC	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg11366901	chr6:160182831	ACAT2	1.03	10.98	0.58	7.22e-23	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg18252515	chr7:66147081	NA	0.49	5.31	0.33	2.56e-7	Aortic root size;
SARC	cis	rs7659604	0.840	rs6821305	chr4:122713863	A/C	cg19748678	chr4:122722346	EXOSC9	0.53	6.43	0.39	7.32e-10	Type 2 diabetes;
SARC	cis	rs2075371	0.501	rs1646654	chr7:134027547	G/C	cg20476274	chr7:133979776	SLC35B4	0.43	5.43	0.34	1.4e-7	Mean platelet volume;
SARC	cis	rs1790761	0.667	rs11227837	chr11:67336424	A/T	cg00290607	chr11:67383545	NA	0.39	5.24	0.32	3.56e-7	Mean corpuscular volume;
SARC	cis	rs698813	0.774	rs2304769	chr2:44569474	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.66	7.65	0.45	5.16e-13	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	trans	rs61931739	0.513	rs4931760	chr12:33898361	T/C	cg26384229	chr12:38710491	ALG10B	0.62	8.13	0.47	2.47e-14	Morning vs. evening chronotype;
SARC	cis	rs7824557	0.701	rs4568582	chr8:11160495	A/T	cg21775007	chr8:11205619	TDH	0.53	6.28	0.38	1.63e-9	Retinal vascular caliber;
SARC	cis	rs9896052	0.535	rs35615150	chr17:73433560	G/A	cg25649188	chr17:73499917	CASKIN2	0.33	4.72	0.3	4.15e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs13256369	1.000	rs7004438	chr8:8574379	C/T	cg17143192	chr8:8559678	CLDN23	0.51	5.77	0.35	2.5e-8	Obesity-related traits;
SARC	cis	rs2070677	0.935	rs13376793	chr10:135421344	C/G	cg20169779	chr10:135381914	SYCE1	-0.52	-6.46	-0.39	6e-10	Gout;
SARC	cis	rs1008375	0.931	rs7435102	chr4:17571480	C/G	cg16339924	chr4:17578868	LAP3	0.68	8.81	0.5	2.95e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7264396	0.747	rs6058291	chr20:34247769	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-8.24	-0.47	1.25e-14	Total cholesterol levels;
SARC	cis	rs7937682	0.632	rs11214037	chr11:111773296	C/T	cg09085632	chr11:111637200	PPP2R1B	0.8	10.64	0.57	8.05e-22	Primary sclerosing cholangitis;
SARC	cis	rs9660992	0.710	rs1668873	chr1:205235990	G/A	cg00857998	chr1:205179979	DSTYK	0.5	6.21	0.38	2.35e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs12188164	0.543	rs2434695	chr5:464177	C/G	cg16584290	chr5:462447	EXOC3	0.41	6.23	0.38	2.15e-9	Cystic fibrosis severity;
SARC	cis	rs9309473	0.519	rs12991161	chr2:73871371	G/A	cg20560298	chr2:73613845	ALMS1	0.51	6.93	0.41	4.2e-11	Metabolite levels;
SARC	cis	rs9640161	0.750	rs4395803	chr7:150025367	A/C	cg10018233	chr7:150070692	REPIN1	0.72	9.39	0.52	5.72e-18	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs35110281	0.633	rs2329593	chr21:45121987	T/C	cg21573476	chr21:45109991	RRP1B	-0.59	-8.41	-0.48	4.01e-15	Mean corpuscular volume;
SARC	cis	rs12802200	0.561	rs746708	chr11:572129	C/T	cg16486109	chr11:613632	IRF7	0.35	4.95	0.31	1.44e-6	Systemic lupus erythematosus;
SARC	cis	rs9914988	0.673	rs9890212	chr17:27169890	G/C	cg20469991	chr17:27169893	C17orf63	-0.51	-5.07	-0.32	8.1e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs9911578	0.835	rs10853006	chr17:56489076	G/A	cg12560992	chr17:57184187	TRIM37	-0.75	-9.26	-0.52	1.36e-17	Intelligence (multi-trait analysis);
SARC	cis	rs12681288	0.523	rs11137122	chr8:954702	A/G	cg15309053	chr8:964076	NA	0.47	8.03	0.47	4.68e-14	Schizophrenia;
SARC	cis	rs9325144	0.555	rs28738714	chr12:38706912	G/A	cg26384229	chr12:38710491	ALG10B	-0.63	-8.46	-0.48	3.07e-15	Morning vs. evening chronotype;
SARC	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg20573242	chr4:122745356	CCNA2	0.59	7.38	0.44	2.8e-12	Type 2 diabetes;
SARC	cis	rs7568458	0.709	rs1446669	chr2:85762209	T/C	cg23752985	chr2:85803571	VAMP8	0.41	5.53	0.34	8.55e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs6815814	0.950	rs73236615	chr4:38786869	G/T	cg06935464	chr4:38784597	TLR10	0.62	6.19	0.38	2.68e-9	Breast cancer;
SARC	cis	rs16854884	0.657	rs1867608	chr3:143752938	G/A	cg06585982	chr3:143692056	C3orf58	0.68	9.25	0.52	1.51e-17	Economic and political preferences (feminism/equality);
SARC	trans	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg06838302	chr3:151066596	MED12L;P2RY12	0.57	6.28	0.38	1.67e-9	Cutaneous psoriasis;
SARC	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	6.64	0.4	2.23e-10	Bipolar disorder;
SARC	cis	rs7412746	0.658	rs6657388	chr1:150748786	A/G	cg10589385	chr1:150898437	SETDB1	0.39	5.06	0.31	8.47e-7	Melanoma;
SARC	cis	rs6908034	0.607	rs112659166	chr6:19807409	C/T	cg02682789	chr6:19804855	NA	0.69	5.41	0.33	1.53e-7	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs921968	0.565	rs6733892	chr2:219616002	C/A	cg02176678	chr2:219576539	TTLL4	-0.36	-5.59	-0.34	6.3e-8	Mean corpuscular hemoglobin concentration;
SARC	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg20607798	chr8:58055168	NA	0.61	5.41	0.33	1.57e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg25036284	chr2:26402008	FAM59B	0.46	5.7	0.35	3.59e-8	Gut microbiome composition (summer);
SARC	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg22496380	chr5:211416	CCDC127	-0.88	-9.59	-0.53	1.47e-18	Breast cancer;
SARC	cis	rs3008870	0.755	rs10749766	chr1:67376921	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.61	7.79	0.45	2.19e-13	Lymphocyte percentage of white cells;
SARC	cis	rs9457247	0.967	rs425039	chr6:167410527	C/T	cg23791538	chr6:167370224	RNASET2	-0.6	-8.22	-0.47	1.39e-14	Crohn's disease;
SARC	cis	rs66887589	0.592	rs2175383	chr4:120215836	C/A	cg09307838	chr4:120376055	NA	0.62	8.17	0.47	1.94e-14	Diastolic blood pressure;
SARC	cis	rs7819412	0.745	rs2898260	chr8:10939490	G/T	cg16664915	chr8:10907788	XKR6	-0.36	-4.98	-0.31	1.21e-6	Triglycerides;
SARC	cis	rs6866344	0.570	rs6896799	chr5:178147014	G/C	cg03877680	chr5:178157825	ZNF354A	1.05	13.99	0.68	1.08e-32	Neutrophil percentage of white cells;
SARC	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg13175981	chr1:150552382	MCL1	-0.54	-6.83	-0.41	7.26e-11	Tonsillectomy;
SARC	cis	rs826838	0.967	rs980572	chr12:39127673	A/C	cg26384229	chr12:38710491	ALG10B	0.8	11.83	0.61	1.32e-25	Heart rate;
SARC	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg21017887	chr14:105400489	NA	0.52	7.49	0.44	1.38e-12	Rheumatoid arthritis;
SARC	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs3092073	0.617	rs56324610	chr20:44564030	G/C	cg27529037	chr20:44575021	PCIF1	-0.34	-5.04	-0.31	9.55e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg15049968	chr18:44337910	ST8SIA5	-0.34	-5.1	-0.32	6.95e-7	Personality dimensions;
SARC	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg24060327	chr5:131705240	SLC22A5	-0.48	-5.84	-0.36	1.77e-8	Acylcarnitine levels;
SARC	cis	rs2594989	0.943	rs9830784	chr3:11434605	A/G	cg00170343	chr3:11313890	ATG7	0.57	5.53	0.34	8.36e-8	Circulating chemerin levels;
SARC	cis	rs11719291	0.584	rs13080725	chr3:49076092	G/A	cg01304814	chr3:48885189	PRKAR2A	0.65	5.25	0.33	3.46e-7	Cognitive function;
SARC	cis	rs637571	0.522	rs606978	chr11:65711517	A/C	cg04055107	chr11:65626734	MUS81;CFL1	0.39	4.85	0.3	2.28e-6	Eosinophil percentage of white cells;
SARC	cis	rs7246657	1.000	rs8110011	chr19:37745813	G/T	cg23950597	chr19:37808831	NA	-0.58	-5.34	-0.33	2.18e-7	Coronary artery calcification;
SARC	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg13699009	chr12:122356056	WDR66	0.62	10.0	0.55	8.26e-20	Mean corpuscular volume;
SARC	cis	rs7223966	0.921	rs11655493	chr17:61733052	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.14	0.37	3.61e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs4926611	0.795	rs12563871	chr1:54071610	A/G	cg08927728	chr1:54059983	GLIS1	-0.28	-4.84	-0.3	2.37e-6	Hand grip strength;
SARC	cis	rs79349575	0.749	rs519537	chr17:46971140	G/A	cg16584676	chr17:46985605	UBE2Z	0.55	6.64	0.4	2.13e-10	Type 2 diabetes;
SARC	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.95	-13.96	-0.67	1.32e-32	Gut microbiome composition (summer);
SARC	cis	rs807669	0.903	rs1018764	chr22:19172006	T/C	cg02655711	chr22:19163373	SLC25A1	0.56	7.95	0.46	7.9e-14	Metabolite levels;
SARC	cis	rs9818758	0.607	rs71324929	chr3:49044713	C/T	cg01304814	chr3:48885189	PRKAR2A	0.67	5.23	0.32	3.84e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs1801251	0.963	rs7562712	chr2:233606580	A/G	cg25237894	chr2:233734115	C2orf82	0.38	4.96	0.31	1.39e-6	Coronary artery disease;
SARC	cis	rs4481887	0.927	rs11204631	chr1:248479530	A/G	cg00666640	chr1:248458726	OR2T12	0.34	5.56	0.34	7.45e-8	Common traits (Other);
SARC	cis	rs3740540	0.507	rs2362500	chr10:126290431	T/C	cg04949429	chr10:126290192	LHPP	0.42	5.94	0.36	1.05e-8	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
SARC	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.47	-5.87	-0.36	1.48e-8	Tonsillectomy;
SARC	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg12373951	chr3:133503437	NA	-0.38	-5.56	-0.34	7.3900000000000007e-08	Iron status biomarkers;
SARC	cis	rs9916302	0.706	rs6503504	chr17:37514412	A/G	cg20243544	chr17:37824526	PNMT	-0.54	-5.81	-0.36	1.99e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs13082711	0.911	rs3736312	chr3:27442336	G/A	cg02860705	chr3:27208620	NA	0.47	6.19	0.38	2.7e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs7220711	1.000	rs6503470	chr17:41788360	A/C	cg26893861	chr17:41843967	DUSP3	0.4	5.06	0.31	8.37e-7	Bone mineral density (spine);Bone mineral density (hip);
SARC	trans	rs12310956	0.532	rs1525904	chr12:33962448	T/C	cg13010199	chr12:38710504	ALG10B	0.73	9.9	0.54	1.69e-19	Morning vs. evening chronotype;
SARC	cis	rs709400	0.659	rs7160366	chr14:103944137	C/T	cg12935359	chr14:103987150	CKB	-0.39	-5.68	-0.35	3.9e-8	Body mass index;
SARC	cis	rs9611519	0.603	rs9607764	chr22:41411804	G/C	cg03806693	chr22:41940476	POLR3H	-0.59	-7.93	-0.46	9.02e-14	Neuroticism;
SARC	trans	rs8073060	0.586	rs8077826	chr17:34001139	G/A	cg19694781	chr19:47549865	TMEM160	-0.71	-6.97	-0.42	3.32e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs11252926	0.598	rs4881256	chr10:453831	T/A	cg08603382	chr10:743973	NA	0.39	5.1	0.32	7.13e-7	Psychosis in Alzheimer's disease;
SARC	cis	rs6582630	0.555	rs12828034	chr12:38274249	C/T	cg14851346	chr12:38532713	NA	-0.47	-5.61	-0.35	5.65e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs870825	1.000	rs870823	chr4:185588195	G/A	cg04058563	chr4:185651563	MLF1IP	0.77	9.07	0.51	5.1e-17	Blood protein levels;
SARC	cis	rs7666738	0.753	rs13137152	chr4:98938044	A/T	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-5.44	-0.34	1.32e-7	Mood instability;
SARC	cis	rs3820928	0.874	rs6706802	chr2:227850776	A/G	cg05526886	chr2:227700861	RHBDD1	-0.56	-6.62	-0.4	2.46e-10	Pulmonary function;
SARC	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg22875332	chr1:76189707	ACADM	-0.44	-5.63	-0.35	5.08e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2576037	0.899	rs12955429	chr18:44585484	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.55	7.12	0.42	1.37e-11	Personality dimensions;
SARC	cis	rs6582630	0.555	rs11182422	chr12:38522833	A/G	cg26384229	chr12:38710491	ALG10B	0.84	12.57	0.64	5.06e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2288073	1.000	rs2288073	chr2:24413298	C/T	cg06627628	chr2:24431161	ITSN2	0.58	7.13	0.42	1.22e-11	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg26338869	chr17:61819248	STRADA	0.81	10.89	0.58	1.38e-22	Prudent dietary pattern;
SARC	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg06618935	chr21:46677482	NA	-0.38	-5.03	-0.31	9.84e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7618501	0.966	rs2246832	chr3:49881134	A/T	cg24110177	chr3:50126178	RBM5	-0.43	-5.34	-0.33	2.16e-7	Intelligence (multi-trait analysis);
SARC	cis	rs17666538	0.585	rs1037393	chr8:622634	G/C	cg02524346	chr8:600233	NA	0.7	5.84	0.36	1.74e-8	IgG glycosylation;
SARC	trans	rs6600671	1.000	rs2185281	chr1:121179991	A/G	cg00646200	chr1:148855367	NA	0.52	7.26	0.43	5.64e-12	Hip geometry;
SARC	cis	rs2153535	0.601	rs718504	chr6:8527512	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	10.59	0.57	1.15e-21	Motion sickness;
SARC	cis	rs501120	0.925	rs1632484	chr10:44773984	C/T	cg09554077	chr10:44749378	NA	0.41	5.47	0.34	1.18e-7	Coronary artery disease;Coronary heart disease;
SARC	cis	rs2235642	0.821	rs2281234	chr16:1602938	A/G	cg09065629	chr16:1709722	CRAMP1L	0.35	4.93	0.31	1.54e-6	Coronary artery disease;
SARC	cis	rs7666738	0.830	rs921522	chr4:98841608	C/T	cg05340658	chr4:99064831	C4orf37	0.68	9.01	0.51	7.73e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs116095464	1.000	rs55671190	chr5:287422	G/A	cg22857025	chr5:266934	NA	-0.97	-7.54	-0.44	1.03e-12	Breast cancer;
SARC	cis	rs72781680	1.000	rs72781643	chr2:24208746	G/A	cg08917208	chr2:24149416	ATAD2B	0.78	7.62	0.45	6.31e-13	Lymphocyte counts;
SARC	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg14983838	chr19:29218262	NA	0.77	10.52	0.57	2e-21	Methadone dose in opioid dependence;
SARC	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg01448562	chr3:133502909	NA	-0.44	-6.4	-0.39	8.39e-10	Iron status biomarkers;
SARC	cis	rs7551222	0.752	rs4252687	chr1:204497335	G/C	cg20240347	chr1:204465584	NA	-0.35	-6.2	-0.38	2.57e-9	Schizophrenia;
SARC	cis	rs5753618	0.583	rs5753631	chr22:31863022	A/C	cg13145458	chr22:31556086	RNF185	-0.46	-4.85	-0.3	2.26e-6	Colorectal cancer;
SARC	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg03433033	chr1:76189801	ACADM	-0.43	-5.64	-0.35	4.81e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs523522	0.962	rs509445	chr12:121017243	A/C	cg12219531	chr12:120966889	COQ5	0.8	10.77	0.58	3.27e-22	High light scatter reticulocyte count;
SARC	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg26335602	chr6:28129616	ZNF389	0.49	5.26	0.33	3.28e-7	Parkinson's disease;
SARC	cis	rs7589342	0.862	rs10469862	chr2:106509907	C/T	cg16077055	chr2:106428750	NCK2	0.36	6.57	0.4	3.18e-10	Addiction;
SARC	cis	rs1018836	0.923	rs6989123	chr8:91551234	A/T	cg16814680	chr8:91681699	NA	-0.77	-12.46	-0.63	1.22e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs2066819	1.000	rs2643626	chr12:56726518	C/T	cg26734620	chr12:56694298	CS	-0.89	-6.49	-0.39	5.14e-10	Psoriasis vulgaris;
SARC	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg26513180	chr16:89883248	FANCA	-0.82	-12.25	-0.63	5.77e-27	Vitiligo;
SARC	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg19774624	chr17:42201019	HDAC5	-0.79	-11.24	-0.59	1.05e-23	Total body bone mineral density;
SARC	cis	rs6450176	1.000	rs59061738	chr5:53296557	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.67	-7.71	-0.45	3.58e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7762018	0.655	rs2184194	chr6:170148394	C/T	cg13891659	chr6:170190454	C6orf122;C6orf208	0.55	4.88	0.3	2e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs6964587	0.626	rs2188841	chr7:91522641	A/G	cg17063962	chr7:91808500	NA	-0.77	-11.19	-0.59	1.57e-23	Breast cancer;
SARC	cis	rs2197308	0.765	rs12824529	chr12:37931656	T/C	cg26384229	chr12:38710491	ALG10B	0.9	13.38	0.66	1.18e-30	Morning vs. evening chronotype;
SARC	cis	rs1113500	0.836	rs1539553	chr1:108589998	C/T	cg06207961	chr1:108661230	NA	-0.38	-4.88	-0.3	1.94e-6	Growth-regulated protein alpha levels;
SARC	cis	rs6840360	1.000	rs2303866	chr4:152640387	C/T	cg22705602	chr4:152727874	NA	-0.38	-6.61	-0.4	2.55e-10	Intelligence (multi-trait analysis);
SARC	cis	rs344364	0.511	rs1742473	chr16:1953095	T/C	cg26617929	chr16:1858877	NA	-0.63	-5.27	-0.33	3.08e-7	Glomerular filtration rate in chronic kidney disease;
SARC	cis	rs763121	0.853	rs9306329	chr22:39072454	C/T	cg14440974	chr22:39074834	NA	-0.32	-4.73	-0.3	3.86e-6	Menopause (age at onset);
SARC	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg12042659	chr19:58951599	ZNF132	0.43	5.78	0.35	2.35e-8	Uric acid clearance;
SARC	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg20607798	chr8:58055168	NA	0.48	4.84	0.3	2.32e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs11971779	0.680	rs3924445	chr7:139044172	C/A	cg23387468	chr7:139079360	LUC7L2	0.33	4.71	0.3	4.2e-6	Diisocyanate-induced asthma;
SARC	cis	rs7412746	0.503	rs72704639	chr1:150798335	A/C	cg15448220	chr1:150897856	SETDB1	0.48	6.31	0.38	1.42e-9	Melanoma;
SARC	cis	rs9420	0.961	rs2847308	chr11:57498232	C/T	cg23127183	chr11:57508653	C11orf31	0.5	5.77	0.35	2.48e-8	Schizophrenia;
SARC	cis	rs6582630	0.638	rs7963994	chr12:38555535	G/A	cg26384229	chr12:38710491	ALG10B	-0.58	-7.44	-0.44	1.93e-12	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7208859	0.623	rs73269988	chr17:29118145	G/A	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9303401	0.614	rs8081058	chr17:57160513	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.98	10.26	0.56	1.25e-20	Cognitive test performance;
SARC	cis	rs1008375	0.902	rs7654332	chr4:17691778	A/T	cg02297831	chr4:17616191	MED28	0.39	4.86	0.3	2.14e-6	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg18404041	chr3:52824283	ITIH1	-0.41	-6.1	-0.37	4.44e-9	Bipolar disorder;
SARC	cis	rs6988636	1.000	rs16898097	chr8:124195034	G/C	cg23067535	chr8:124195133	FAM83A	-0.67	-5.57	-0.34	6.92e-8	Urinary uromodulin levels;
SARC	cis	rs7647973	1.000	rs3866330	chr3:49582994	T/C	cg06212747	chr3:49208901	KLHDC8B	0.58	6.05	0.37	5.83e-9	Menarche (age at onset);
SARC	cis	rs7666738	0.830	rs62318906	chr4:99037110	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs8114671	0.836	rs6142280	chr20:33622242	A/C	cg24642439	chr20:33292090	TP53INP2	-0.53	-6.23	-0.38	2.14e-9	Height;
SARC	cis	rs1348850	0.872	rs13004955	chr2:178398923	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.67	-8.04	-0.47	4.58e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9894429	0.608	rs7406382	chr17:79597786	T/C	cg18240062	chr17:79603768	NPLOC4	0.6	7.44	0.44	1.94e-12	Eye color traits;
SARC	cis	rs7607369	0.536	rs6436092	chr2:219669148	T/A	cg02176678	chr2:219576539	TTLL4	-0.38	-5.67	-0.35	4.2e-8	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs60695258	1.000	rs17605615	chr4:87996745	G/A	cg11209507	chr4:87813803	C4orf36	0.38	4.93	0.31	1.58e-6	Hematocrit;
SARC	cis	rs4141404	0.706	rs5753698	chr22:31970054	A/C	cg02404636	chr22:31891804	SFI1	0.47	5.19	0.32	4.68e-7	Paclitaxel-induced neuropathy;
SARC	cis	rs1348850	0.914	rs4893823	chr2:178285811	C/T	cg23306229	chr2:178417860	TTC30B	-0.54	-6.34	-0.38	1.2e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs4319547	0.695	rs11057797	chr12:122860732	G/A	cg05707623	chr12:122985044	ZCCHC8	0.57	6.43	0.39	6.96e-10	Body mass index;
SARC	cis	rs2273669	0.667	rs74582170	chr6:109312689	C/T	cg05315195	chr6:109294784	ARMC2	-0.59	-5.45	-0.34	1.28e-7	Prostate cancer;
SARC	cis	rs748404	0.588	rs506120	chr15:43802024	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	5.5	0.34	9.89e-8	Lung cancer;
SARC	cis	rs9303542	0.559	rs12939811	chr17:46607958	A/T	cg04904318	chr17:46607828	HOXB1	-0.44	-4.93	-0.31	1.54e-6	Ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg02018176	chr4:1364513	KIAA1530	-0.36	-5.09	-0.32	7.35e-7	Obesity-related traits;
SARC	cis	rs2361718	0.967	rs12942941	chr17:78103013	C/T	cg14949292	chr17:78079608	GAA	-0.33	-5.38	-0.33	1.8e-7	Yeast infection;
SARC	cis	rs6089584	0.527	rs927589	chr20:60606363	A/G	cg06108461	chr20:60628389	TAF4	-0.71	-9.27	-0.52	1.26e-17	Body mass index;
SARC	cis	rs17270561	0.609	rs7770037	chr6:25760591	G/A	cg17691542	chr6:26056736	HIST1H1C	0.57	7.0	0.42	2.78e-11	Iron status biomarkers;
SARC	cis	rs17666538	0.585	rs4333567	chr8:636611	C/T	cg19660806	chr8:588740	NA	0.61	4.79	0.3	2.92e-6	IgG glycosylation;
SARC	cis	rs9309473	0.607	rs7574291	chr2:73594941	A/G	cg20560298	chr2:73613845	ALMS1	-0.57	-7.09	-0.42	1.62e-11	Metabolite levels;
SARC	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg11987759	chr7:65425863	GUSB	-0.47	-5.88	-0.36	1.39e-8	Aortic root size;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg06996869	chr11:93474705	C11orf54;TAF1D	-0.48	-6.26	-0.38	1.86e-9	Neuroticism;
SARC	cis	rs711830	0.965	rs2857532	chr2:177033283	A/G	cg13092806	chr2:177043255	NA	0.62	6.32	0.38	1.34e-9	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
SARC	cis	rs6500395	1.000	rs7194570	chr16:48672986	A/G	cg04672837	chr16:48644449	N4BP1	-0.43	-5.53	-0.34	8.59e-8	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs13095912	0.962	rs7644758	chr3:185328197	G/T	cg11274856	chr3:185301563	NA	-0.36	-4.98	-0.31	1.24e-6	Systolic blood pressure;
SARC	cis	rs17125944	0.505	rs75838476	chr14:53242362	G/A	cg00686598	chr14:53173677	PSMC6	1.29	8.9	0.5	1.65e-16	Alzheimer's disease (late onset);
SARC	cis	rs854765	0.583	rs4925125	chr17:17794444	T/C	cg05444541	chr17:17804740	TOM1L2	0.3	5.02	0.31	1.05e-6	Total body bone mineral density;
SARC	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg13880726	chr7:1868755	MAD1L1	0.51	5.96	0.36	9.47e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg21724239	chr8:58056113	NA	0.61	5.93	0.36	1.1e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs60871478	0.947	rs7790823	chr7:788923	T/G	cg19087971	chr7:751233	PRKAR1B	-0.44	-5.0	-0.31	1.11e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg11987759	chr7:65425863	GUSB	0.62	8.24	0.48	1.25e-14	Aortic root size;
SARC	cis	rs9393692	0.905	rs7746807	chr6:26293338	C/A	cg13736514	chr6:26305472	NA	-0.65	-9.06	-0.51	5.33e-17	Educational attainment;
SARC	cis	rs11190604	1.000	rs7088512	chr10:102303498	G/T	cg07080220	chr10:102295463	HIF1AN	0.83	9.64	0.53	9.85e-19	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs13256369	0.756	rs13280759	chr8:8562995	G/T	cg18904891	chr8:8559673	CLDN23	0.48	5.41	0.33	1.55e-7	Obesity-related traits;
SARC	cis	rs9916302	0.904	rs634365	chr17:37436966	C/T	cg07936489	chr17:37558343	FBXL20	-0.66	-8.99	-0.51	8.68e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs7937682	0.921	rs10891280	chr11:111433609	A/T	cg09085632	chr11:111637200	PPP2R1B	0.85	12.08	0.62	2.03e-26	Primary sclerosing cholangitis;
SARC	cis	rs3796352	1.000	rs11718538	chr3:52975987	C/G	cg12962167	chr3:53033115	SFMBT1	0.75	4.9	0.31	1.8e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	15.05	0.7	3.18e-36	Chronic sinus infection;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg21263890	chr20:42839731	C20orf111	0.51	6.28	0.38	1.67e-9	Breast cancer;
SARC	cis	rs6582630	0.560	rs12315134	chr12:38419857	T/A	cg14851346	chr12:38532713	NA	-0.45	-5.31	-0.33	2.52e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs62064224	0.791	rs11656289	chr17:30761160	T/C	cg18200150	chr17:30822561	MYO1D	0.44	7.05	0.42	1.96e-11	Schizophrenia;
SARC	cis	rs9527	0.590	rs7901197	chr10:104840433	C/T	cg04362960	chr10:104952993	NT5C2	0.42	4.92	0.31	1.65e-6	Arsenic metabolism;
SARC	cis	rs10089	1.000	rs4835944	chr5:127490870	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.76	-8.94	-0.51	1.21e-16	Ileal carcinoids;
SARC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg02475777	chr4:1388615	CRIPAK	0.67	7.78	0.45	2.39e-13	Longevity;
SARC	trans	rs9888736	0.501	rs2164371	chr15:47900383	T/C	cg01357263	chr12:122459509	BCL7A	-0.49	-6.25	-0.38	1.92e-9	Body mass index;
SARC	cis	rs801193	0.742	rs9969300	chr7:65781646	G/A	cg11764359	chr7:65958608	NA	-0.57	-6.39	-0.39	9.04e-10	Aortic root size;
SARC	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg08280861	chr8:58055591	NA	0.55	4.79	0.3	2.95e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs898097	0.801	rs68141193	chr17:80878816	C/T	cg20578329	chr17:80767326	TBCD	-0.45	-6.04	-0.37	6.02e-9	Breast cancer;
SARC	cis	rs6690583	0.562	rs12024977	chr1:85531051	A/C	cg22153463	chr1:85462885	MCOLN2	0.67	5.64	0.35	5.03e-8	Serum sulfate level;
SARC	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg09323728	chr8:95962352	TP53INP1	-0.34	-5.68	-0.35	4.05e-8	Type 2 diabetes;
SARC	cis	rs10463316	0.894	rs10476769	chr5:150763970	A/G	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.28	-0.33	2.89e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg20965017	chr5:231967	SDHA	-0.55	-5.28	-0.33	3.03e-7	Breast cancer;
SARC	cis	rs9388451	0.903	rs7758115	chr6:126061502	C/T	cg05901451	chr6:126070800	HEY2	-0.68	-9.44	-0.53	4.04e-18	Brugada syndrome;
SARC	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.5	-6.24	-0.38	2e-9	Lymphocyte counts;
SARC	cis	rs644799	0.544	rs56298021	chr11:95545113	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	9.57	0.53	1.6e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs28386778	0.700	rs4968672	chr17:62011352	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.94	-13.42	-0.66	8.64e-31	Prudent dietary pattern;
SARC	trans	rs11098499	0.955	rs13114751	chr4:120156617	G/A	cg25214090	chr10:38739885	LOC399744	0.54	6.95	0.41	3.66e-11	Corneal astigmatism;
SARC	cis	rs17376456	1.000	rs34013242	chr5:93507947	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.49	0.34	1.03e-7	Diabetic retinopathy;
SARC	cis	rs2836950	0.501	rs13047518	chr21:40707307	G/A	cg17971929	chr21:40555470	PSMG1	-0.57	-7.15	-0.42	1.09e-11	Menarche (age at onset);
SARC	cis	rs950776	0.714	rs472054	chr15:78887994	A/G	cg06917634	chr15:78832804	PSMA4	-0.77	-10.32	-0.56	8.15e-21	Sudden cardiac arrest;
SARC	cis	rs12911832	0.958	rs12912003	chr15:58986001	A/T	cg05156742	chr15:59063176	FAM63B	0.64	8.03	0.47	4.84e-14	Schizophrenia;
SARC	cis	rs1865760	0.516	rs9295684	chr6:26069669	T/C	cg17691542	chr6:26056736	HIST1H1C	0.49	6.18	0.38	2.84e-9	Height;
SARC	cis	rs7312933	0.531	rs2406674	chr12:42720150	T/C	cg19980929	chr12:42632907	YAF2	-0.45	-6.73	-0.4	1.27e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs7772486	0.790	rs6924159	chr6:146267873	A/G	cg23711669	chr6:146136114	FBXO30	-0.81	-12.94	-0.65	3.15e-29	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs754466	0.580	rs2289309	chr10:79571108	C/T	cg17075019	chr10:79541650	NA	-0.81	-12.4	-0.63	1.82e-27	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.1	0.37	4.28e-9	Prudent dietary pattern;
SARC	cis	rs11098499	0.866	rs12374244	chr4:120281972	A/T	cg09307838	chr4:120376055	NA	0.83	11.82	0.61	1.46e-25	Corneal astigmatism;
SARC	cis	rs11997175	0.603	rs66828270	chr8:33790155	C/G	ch.8.33884649F	chr8:33765107	NA	0.52	6.98	0.42	3.11e-11	Body mass index;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg22606062	chr4:77996244	CCNI	-0.46	-6.36	-0.38	1.05e-9	Neuroticism;
SARC	cis	rs611744	0.967	rs630492	chr8:109215368	C/T	cg21045802	chr8:109455806	TTC35	-0.41	-4.89	-0.31	1.85e-6	Dupuytren's disease;
SARC	cis	rs10791097	0.720	rs4936121	chr11:130733878	A/G	cg12179176	chr11:130786555	SNX19	0.72	10.71	0.57	4.85e-22	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg17376030	chr22:41985996	PMM1	0.69	9.0	0.51	8.23e-17	Vitiligo;
SARC	cis	rs12762955	0.561	rs2620942	chr10:1048398	C/T	cg18964960	chr10:1102726	WDR37	0.71	8.79	0.5	3.37e-16	Response to angiotensin II receptor blocker therapy;
SARC	cis	rs514024	0.729	rs4837172	chr9:130384703	A/C	cg13643465	chr9:130375613	STXBP1	0.51	6.36	0.38	1.03e-9	Eating disorders (purging via substances);
SARC	cis	rs514024	0.672	rs482095	chr9:130493513	A/G	cg13643465	chr9:130375613	STXBP1	0.45	5.48	0.34	1.08e-7	Eating disorders (purging via substances);
SARC	trans	rs9325144	0.647	rs7487395	chr12:38865660	C/A	cg23762105	chr12:34175262	ALG10	0.5	6.55	0.39	3.56e-10	Morning vs. evening chronotype;
SARC	cis	rs870825	0.616	rs72703531	chr4:185611092	C/T	cg04058563	chr4:185651563	MLF1IP	0.84	11.19	0.59	1.57e-23	Blood protein levels;
SARC	cis	rs9486719	0.552	rs9399923	chr6:96850379	G/A	cg18709589	chr6:96969512	KIAA0776	0.45	4.91	0.31	1.71e-6	Migraine;Coronary artery disease;
SARC	cis	rs992157	0.764	rs4672886	chr2:219185545	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.57	-7.12	-0.42	1.29e-11	Colorectal cancer;
SARC	cis	rs288326	0.561	rs77184695	chr2:183802573	G/A	cg09997497	chr2:183902928	NCKAP1	0.75	5.13	0.32	6.18e-7	Blood protein levels;
SARC	cis	rs854765	0.547	rs2955377	chr17:17932818	G/A	cg04398451	chr17:18023971	MYO15A	-0.47	-6.63	-0.4	2.37e-10	Total body bone mineral density;
SARC	cis	rs1707322	1.000	rs7527079	chr1:46413450	C/G	cg06784218	chr1:46089804	CCDC17	0.35	6.05	0.37	5.72e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs3760982	0.585	rs67648499	chr19:44294055	G/A	cg11993925	chr19:44307056	LYPD5	0.3	4.78	0.3	3.14e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
SARC	cis	rs7824557	0.545	rs2736303	chr8:11236850	C/T	cg21775007	chr8:11205619	TDH	-0.65	-8.62	-0.49	1.01e-15	Retinal vascular caliber;
SARC	cis	rs67460515	0.892	rs1382429	chr3:161015153	T/C	cg17135325	chr3:160939158	NMD3	0.64	8.0	0.46	5.89e-14	Parkinson's disease;
SARC	cis	rs1448094	0.556	rs11611968	chr12:86168022	G/A	cg00310523	chr12:86230176	RASSF9	0.32	4.96	0.31	1.38e-6	Major depressive disorder;
SARC	cis	rs950169	0.545	rs4842841	chr15:84641125	G/A	cg17507749	chr15:85114479	UBE2QP1	0.67	7.03	0.42	2.33e-11	Schizophrenia;
SARC	cis	rs7044106	0.791	rs2416799	chr9:123480866	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.52	0.53	2.39e-18	Hip circumference adjusted for BMI;
SARC	cis	rs3540	1.000	rs6496678	chr15:91034456	A/G	cg22089800	chr15:90895588	ZNF774	0.51	5.7	0.35	3.52e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs2273669	0.915	rs4992384	chr6:109292806	A/G	cg05315195	chr6:109294784	ARMC2	-0.49	-4.82	-0.3	2.57e-6	Prostate cancer;
SARC	trans	rs7815944	1.000	rs16902875	chr8:129421904	G/A	cg17342469	chr22:46473074	NA	0.63	6.58	0.4	3.12e-10	Atopic dermatitis;
SARC	cis	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg05623727	chr3:50126028	RBM5	-0.32	-4.74	-0.3	3.76e-6	Body mass index;
SARC	cis	rs40363	0.523	rs757270	chr16:3534451	C/T	cg22508957	chr16:3507546	NAT15	-0.41	-5.6	-0.34	6.04e-8	Tuberculosis;
SARC	cis	rs6840360	0.615	rs6831810	chr4:152461995	A/G	cg22705602	chr4:152727874	NA	-0.42	-6.55	-0.39	3.67e-10	Intelligence (multi-trait analysis);
SARC	cis	rs13144136	0.664	rs6448177	chr4:10666272	C/T	cg10242279	chr4:10666415	CLNK	-0.44	-7.21	-0.43	7.72e-12	Resistance to antihypertensive treatment in hypertension;
SARC	cis	rs7647973	0.626	rs1078341	chr3:49685592	A/G	cg07636037	chr3:49044803	WDR6	0.6	6.11	0.37	4.23e-9	Menarche (age at onset);
SARC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg12419862	chr22:24373484	LOC391322	0.76	9.45	0.53	3.64e-18	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs10504229	0.679	rs4738574	chr8:58033771	T/C	cg08219700	chr8:58056026	NA	0.59	5.99	0.37	7.69e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2304069	0.954	rs9324640	chr5:149413186	C/T	cg12661370	chr5:149340060	SLC26A2	-0.55	-5.34	-0.33	2.22e-7	HIV-1 control;
SARC	cis	rs6732160	0.613	rs62151837	chr2:73390396	G/T	cg01422370	chr2:73384389	NA	0.38	5.93	0.36	1.1e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9462027	1.000	rs6457796	chr6:34828553	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.75	-0.35	2.73e-8	Systemic lupus erythematosus;
SARC	cis	rs4792901	0.802	rs76971300	chr17:41580588	A/G	cg22562494	chr17:41607896	ETV4	-0.31	-4.75	-0.3	3.64e-6	Dupuytren's disease;
SARC	cis	rs55962025	0.842	rs362306	chr4:3242100	C/T	cg06533319	chr4:3265114	C4orf44	0.32	4.78	0.3	3.07e-6	Parental longevity (mother's age at death);
SARC	cis	rs9911578	0.967	rs6503883	chr17:56917543	C/T	cg05425664	chr17:57184151	TRIM37	-0.64	-7.98	-0.46	6.52e-14	Intelligence (multi-trait analysis);
SARC	cis	rs936229	0.749	rs6495126	chr15:75175026	C/T	cg10253484	chr15:75165896	SCAMP2	0.52	5.63	0.35	5.16e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg25703541	chr22:24373054	LOC391322	0.77	8.86	0.5	2.16e-16	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg18252515	chr7:66147081	NA	0.43	4.77	0.3	3.3e-6	Aortic root size;
SARC	cis	rs11583043	0.872	rs1326380	chr1:101293753	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.45	5.39	0.33	1.73e-7	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs2153535	0.580	rs9406165	chr6:8488837	C/T	cg07606381	chr6:8435919	SLC35B3	0.79	11.13	0.59	2.33e-23	Motion sickness;
SARC	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg10435706	chr6:150039699	LATS1	0.36	4.8	0.3	2.88e-6	Lung cancer;
SARC	trans	rs61931739	0.534	rs10844816	chr12:34248533	C/A	cg13010199	chr12:38710504	ALG10B	0.74	10.06	0.55	5.14e-20	Morning vs. evening chronotype;
SARC	cis	rs282587	0.502	rs416018	chr13:113396488	G/A	cg02820901	chr13:113351484	ATP11A	-0.53	-5.08	-0.32	7.67e-7	Glycated hemoglobin levels;
SARC	cis	rs477692	0.583	rs12415589	chr10:131428336	C/G	cg05714579	chr10:131428358	MGMT	-0.68	-9.27	-0.52	1.26e-17	Response to temozolomide;
SARC	cis	rs12824058	0.831	rs12320318	chr12:130812335	T/C	cg24838063	chr12:130822603	PIWIL1	0.63	8.93	0.5	1.34e-16	Menopause (age at onset);
SARC	cis	rs10489202	1.000	rs12404574	chr1:167961235	C/T	cg24449463	chr1:168025552	DCAF6	0.62	6.83	0.41	7.14e-11	Schizophrenia;
SARC	cis	rs7666738	0.830	rs11935588	chr4:98979862	A/G	cg05340658	chr4:99064831	C4orf37	-0.67	-9.13	-0.51	3.3e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6860806	0.507	rs200837	chr5:131699958	G/A	cg04518342	chr5:131593106	PDLIM4	0.44	5.57	0.34	7.06e-8	Breast cancer;
SARC	cis	rs7666738	0.791	rs6853608	chr4:99047916	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs826838	0.967	rs1719852	chr12:39128531	A/G	cg13010199	chr12:38710504	ALG10B	-0.63	-8.68	-0.49	6.88e-16	Heart rate;
SARC	cis	rs4253772	0.872	rs4253776	chr22:46629479	C/T	cg24881330	chr22:46731750	TRMU	-0.53	-4.95	-0.31	1.4e-6	LDL cholesterol;Cholesterol, total;
SARC	cis	rs9682041	0.696	rs11927807	chr3:170096623	A/G	cg11886554	chr3:170076028	SKIL	0.84	7.76	0.45	2.72e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs9322817	1.000	rs6900902	chr6:105235757	A/G	cg02098413	chr6:105308735	HACE1	-0.33	-4.75	-0.3	3.5e-6	Thyroid stimulating hormone;
SARC	cis	rs7949030	1.000	rs7949030	chr11:62394881	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.39	5.65	0.35	4.74e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs3862260	0.509	rs2281493	chr1:120162787	T/C	cg16322792	chr1:120165303	ZNF697	0.29	6.09	0.37	4.51e-9	Systemic lupus erythematosus;
SARC	cis	rs2013441	1.000	rs2263175	chr17:20128029	C/G	cg13482628	chr17:19912719	NA	-0.46	-6.0	-0.37	7.47e-9	Obesity-related traits;
SARC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.76	9.95	0.55	1.12e-19	Prudent dietary pattern;
SARC	cis	rs2153535	0.601	rs2327059	chr6:8447071	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	8.38	0.48	5.16e-15	Motion sickness;
SARC	cis	rs2228479	0.681	rs7196840	chr16:89959647	A/G	cg06558623	chr16:89946397	TCF25	0.78	6.81	0.41	8.29e-11	Skin colour saturation;
SARC	cis	rs7828089	0.582	rs13259873	chr8:22266292	C/T	cg12081754	chr8:22256438	SLC39A14	0.64	8.69	0.49	6.69e-16	Verbal declarative memory;
SARC	cis	rs62103177	0.608	rs4442895	chr18:77826399	C/G	cg12964065	chr18:77638022	KCNG2	-0.39	-5.2	-0.32	4.32e-7	Opioid sensitivity;
SARC	cis	rs4595586	0.546	rs11169801	chr12:39241429	G/A	cg13010199	chr12:38710504	ALG10B	0.55	6.54	0.39	3.9e-10	Morning vs. evening chronotype;
SARC	cis	rs7617773	0.780	rs4511915	chr3:48343858	G/A	cg11946769	chr3:48343235	NME6	0.76	9.7	0.54	6.55e-19	Coronary artery disease;
SARC	cis	rs17401966	0.931	rs12137880	chr1:10388620	T/C	cg15208524	chr1:10270712	KIF1B	0.53	6.34	0.38	1.16e-9	Hepatocellular carcinoma;
SARC	cis	rs595982	0.501	rs112370206	chr19:49396623	C/T	cg03707168	chr19:49379127	PPP1R15A	0.44	5.76	0.35	2.68e-8	Red cell distribution width;
SARC	trans	rs36093844	0.800	rs1445504	chr11:85584879	G/A	cg15359163	chr5:122429178	PRDM6	-0.53	-6.33	-0.38	1.28e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs282587	0.502	rs416703	chr13:113399219	A/G	cg02820901	chr13:113351484	ATP11A	-0.48	-4.77	-0.3	3.21e-6	Glycated hemoglobin levels;
SARC	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-6.05	-0.37	5.68e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs3741151	0.686	rs7114376	chr11:73227361	T/C	cg17517138	chr11:73019481	ARHGEF17	0.69	5.87	0.36	1.48e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs17376456	0.825	rs12716454	chr5:93272279	A/C	cg25358565	chr5:93447407	FAM172A	1.3	14.13	0.68	3.7e-33	Diabetic retinopathy;
SARC	trans	rs7824557	0.527	rs2572449	chr8:11239137	A/G	cg15556689	chr8:8085844	FLJ10661	0.49	6.25	0.38	1.94e-9	Retinal vascular caliber;
SARC	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg11644478	chr21:40555479	PSMG1	1.06	15.22	0.71	8.95e-37	Cognitive function;
SARC	cis	rs918629	0.504	rs3777207	chr5:95231115	C/T	cg16656078	chr5:95278638	ELL2	-0.62	-5.34	-0.33	2.21e-7	IgG glycosylation;
SARC	cis	rs7666738	0.830	rs1967979	chr4:98966201	G/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6424115	0.594	rs10799802	chr1:24009544	C/T	cg15997130	chr1:24165203	NA	0.37	4.75	0.3	3.52e-6	Immature fraction of reticulocytes;
SARC	trans	rs2727020	0.521	rs1909220	chr11:49572109	T/C	cg03929089	chr4:120376271	NA	-0.68	-7.43	-0.44	2.04e-12	Coronary artery disease;
SARC	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.69	8.79	0.5	3.46e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6912958	0.703	rs9353483	chr6:88097180	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.35	6.03	0.37	6.42e-9	Monocyte percentage of white cells;
SARC	cis	rs12311304	1.000	rs16910711	chr12:15395799	C/T	cg08258403	chr12:15378311	NA	0.46	7.21	0.43	7.76e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs7762018	0.941	rs4716384	chr6:170109184	T/A	cg13891659	chr6:170190454	C6orf122;C6orf208	0.56	4.84	0.3	2.32e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	trans	rs7844647	0.530	rs10091301	chr8:34138591	C/T	cg26394233	chr7:157444480	PTPRN2	0.43	6.4	0.39	8.6e-10	Body mass index;
SARC	cis	rs6570726	0.791	rs6914203	chr6:145899975	C/A	cg23711669	chr6:146136114	FBXO30	0.79	12.75	0.64	1.35e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg22618164	chr12:122356400	WDR66	0.42	6.73	0.4	1.3e-10	Mean corpuscular volume;
SARC	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	12.72	0.64	1.67e-28	Smoking behavior;
SARC	cis	rs908922	0.676	rs525960	chr1:152497866	T/A	cg09873164	chr1:152488093	CRCT1	0.63	8.06	0.47	4.07e-14	Hair morphology;
SARC	cis	rs9457247	0.765	rs9457251	chr6:167426707	T/C	cg23791538	chr6:167370224	RNASET2	-0.54	-7.05	-0.42	1.96e-11	Crohn's disease;
SARC	cis	rs9325144	0.600	rs12227663	chr12:38734922	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-8.07	-0.47	3.63e-14	Morning vs. evening chronotype;
SARC	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg03264133	chr6:25882463	NA	-0.51	-6.58	-0.4	3.08e-10	Intelligence (multi-trait analysis);
SARC	cis	rs76419734	1.000	rs72673873	chr4:106780301	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.86	5.96	0.36	9.17e-9	Post bronchodilator FEV1;
SARC	cis	rs933688	1.000	rs2367526	chr5:90740525	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	13.03	0.65	1.61e-29	Smoking behavior;
SARC	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg02462569	chr6:150064036	NUP43	-0.4	-4.97	-0.31	1.29e-6	Lung cancer;
SARC	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	7.72	0.45	3.42e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9815354	1.000	rs9854838	chr3:41805670	C/A	cg03022575	chr3:42003672	ULK4	0.59	5.64	0.35	4.85e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg07157834	chr1:205819609	PM20D1	0.71	10.98	0.58	7e-23	Menarche (age at onset);
SARC	cis	rs9420	0.961	rs682503	chr11:57640994	C/G	cg19752551	chr11:57585705	CTNND1	0.52	6.97	0.42	3.27e-11	Schizophrenia;
SARC	cis	rs2404602	0.716	rs12441247	chr15:76812316	T/C	cg22467129	chr15:76604101	ETFA	-0.36	-4.73	-0.3	3.89e-6	Blood metabolite levels;
SARC	cis	rs1050631	0.564	rs12185396	chr18:33738496	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.52	6.28	0.38	1.61e-9	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	11.03	0.59	4.93e-23	Alzheimer's disease;
SARC	cis	rs10927875	0.864	rs12135073	chr1:16167799	C/T	cg21385522	chr1:16154831	NA	0.83	10.59	0.57	1.18e-21	Dilated cardiomyopathy;
SARC	cis	rs9420	0.961	rs77993055	chr11:57522840	C/T	cg23127183	chr11:57508653	C11orf31	-0.58	-6.74	-0.4	1.23e-10	Schizophrenia;
SARC	cis	rs365302	0.767	rs364581	chr6:159613190	G/A	cg14500486	chr6:159655392	FNDC1	0.4	4.91	0.31	1.68e-6	Coronary heart disease;
SARC	cis	rs2529049	0.537	rs2190439	chr7:24671468	G/A	cg17569154	chr7:24781545	DFNA5	0.49	7.09	0.42	1.58e-11	Urate levels in obese individuals;
SARC	cis	rs13256369	0.802	rs12153	chr8:8560909	G/C	cg18904891	chr8:8559673	CLDN23	0.48	5.38	0.33	1.79e-7	Obesity-related traits;
SARC	trans	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.75	10.83	0.58	2.07e-22	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs76419734	1.000	rs11726569	chr4:106606608	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.82	5.06	0.31	8.65e-7	Post bronchodilator FEV1;
SARC	cis	rs8077889	0.700	rs28571770	chr17:41904066	A/T	cg26893861	chr17:41843967	DUSP3	0.83	10.1	0.55	3.97e-20	Triglycerides;
SARC	cis	rs9911578	0.935	rs2302189	chr17:56584205	A/C	cg05425664	chr17:57184151	TRIM37	0.63	7.64	0.45	5.46e-13	Intelligence (multi-trait analysis);
SARC	cis	rs10089	1.000	rs3792866	chr5:127479900	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.79	9.48	0.53	3.13e-18	Ileal carcinoids;
SARC	cis	rs7089973	0.624	rs11196930	chr10:116583596	C/T	cg03647239	chr10:116582469	FAM160B1	0.49	6.31	0.38	1.42e-9	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg17971929	chr21:40555470	PSMG1	0.98	13.6	0.67	2.19e-31	Cognitive function;
SARC	cis	rs7681440	0.845	rs6843084	chr4:90766230	T/C	cg02192967	chr4:90758406	SNCA	0.36	5.13	0.32	6.11e-7	Dementia with Lewy bodies;
SARC	cis	rs7005606	0.905	rs2439304	chr8:32430371	A/G	cg14488905	chr8:32406789	NRG1	-0.4	-5.42	-0.33	1.48e-7	Hirschsprung disease;
SARC	cis	rs10791097	0.568	rs4411284	chr11:130738568	A/C	cg09137382	chr11:130731461	NA	0.31	4.76	0.3	3.39e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs7264396	0.512	rs2425072	chr20:34293686	T/C	cg01084648	chr20:34329383	RBM39	0.57	4.98	0.31	1.22e-6	Total cholesterol levels;
SARC	cis	rs7312933	0.703	rs10880264	chr12:42586535	A/G	cg17420585	chr12:42539391	GXYLT1	-0.33	-4.71	-0.3	4.18e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs9309711	0.666	rs6723101	chr2:3484443	T/C	cg15541040	chr2:3486749	NA	-0.43	-5.76	-0.35	2.6e-8	Neurofibrillary tangles;
SARC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.45	5.76	0.35	2.59e-8	Lymphocyte counts;
SARC	cis	rs1865760	1.000	rs2071299	chr6:25914801	G/A	cg17691542	chr6:26056736	HIST1H1C	0.56	6.83	0.41	7.18e-11	Height;
SARC	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.36	4.77	0.3	3.18e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs274567	0.711	rs404771	chr5:131635092	A/T	cg12564285	chr5:131593104	PDLIM4	0.43	5.77	0.35	2.46e-8	Blood metabolite levels;
SARC	cis	rs2997447	0.723	rs56241003	chr1:26435919	C/T	cg19633962	chr1:26362018	EXTL1	-0.57	-5.05	-0.31	8.95e-7	QRS complex (12-leadsum);
SARC	cis	rs4718428	1.000	rs4718428	chr7:66421446	T/G	cg18252515	chr7:66147081	NA	-0.46	-4.95	-0.31	1.42e-6	Corneal structure;
SARC	cis	rs10927875	0.632	rs7535248	chr1:16129598	C/T	cg21385522	chr1:16154831	NA	-0.92	-13.17	-0.65	5.55e-30	Dilated cardiomyopathy;
SARC	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg02725872	chr8:58115012	NA	-0.34	-5.37	-0.33	1.91e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs4713675	0.584	rs3818527	chr6:33661035	A/G	cg15676125	chr6:33679581	C6orf125	-0.53	-6.56	-0.4	3.38e-10	Plateletcrit;
SARC	cis	rs4141404	0.851	rs8135417	chr22:31559255	G/A	cg00478049	chr22:31556069	RNF185	0.46	5.58	0.34	6.61e-8	Paclitaxel-induced neuropathy;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg20962746	chr11:118436826	C11orf60	-0.49	-6.31	-0.38	1.36e-9	Height;
SARC	cis	rs858239	0.600	rs10241208	chr7:23144914	G/C	cg23682824	chr7:23144976	KLHL7	0.66	8.75	0.5	4.28e-16	Cerebrospinal fluid biomarker levels;
SARC	cis	rs2276314	0.857	rs28375959	chr18:33601534	T/G	cg19628046	chr18:33552617	C18orf21	0.61	6.29	0.38	1.54e-9	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg13175981	chr1:150552382	MCL1	-0.47	-5.8	-0.36	2.15e-8	Melanoma;
SARC	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	5.69	0.35	3.71e-8	Bipolar disorder;
SARC	cis	rs6963495	0.818	rs73190156	chr7:105153567	C/T	cg13798780	chr7:105162888	PUS7	0.6	5.5	0.34	9.98e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs9818758	0.556	rs11716614	chr3:49017208	C/G	cg07636037	chr3:49044803	WDR6	-0.69	-5.46	-0.34	1.23e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs2153535	0.580	rs9393025	chr6:8490618	G/A	cg23788917	chr6:8435910	SLC35B3	0.64	8.44	0.48	3.45e-15	Motion sickness;
SARC	cis	rs6831352	0.959	rs4699710	chr4:100051819	C/T	cg13256891	chr4:100009986	ADH5	0.66	8.75	0.5	4.46e-16	Alcohol dependence;
SARC	cis	rs1878931	0.582	rs40633	chr16:3425325	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.68	-7.73	-0.45	3.13e-13	Body mass index (adult);
SARC	cis	rs11190604	1.000	rs2489048	chr10:102348497	G/T	cg07080220	chr10:102295463	HIF1AN	0.79	8.5	0.49	2.34e-15	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg06634786	chr22:41940651	POLR3H	-0.64	-7.54	-0.44	1.05e-12	Vitiligo;
SARC	cis	rs6426558	0.537	rs6682642	chr1:227244600	G/T	cg10327440	chr1:227177885	CDC42BPA	0.42	4.99	0.31	1.2e-6	Neutrophil percentage of white cells;
SARC	cis	rs6088580	0.634	rs1890002	chr20:32919219	A/G	cg08999081	chr20:33150536	PIGU	-0.45	-6.75	-0.4	1.18e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs9916302	0.706	rs11078894	chr17:37396805	C/G	cg07936489	chr17:37558343	FBXL20	-0.79	-9.37	-0.52	6.73e-18	Glomerular filtration rate (creatinine);
SARC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.61	7.5	0.44	1.37e-12	Prudent dietary pattern;
SARC	cis	rs9309473	0.948	rs13391552	chr2:73818936	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-5.68	-0.35	3.93e-8	Metabolite levels;
SARC	cis	rs11112613	0.762	rs73184078	chr12:105950017	A/G	cg03607813	chr12:105948248	NA	0.56	7.54	0.44	1.06e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs1865760	0.602	rs2157050	chr6:26020431	C/T	cg17691542	chr6:26056736	HIST1H1C	0.53	6.46	0.39	6.14e-10	Height;
SARC	cis	rs12079745	0.793	rs12561922	chr1:169265794	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.81	-5.21	-0.32	4.14e-7	QT interval;
SARC	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg24642844	chr7:1081250	C7orf50	-0.59	-5.98	-0.36	8.18e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	trans	rs3942852	0.568	rs10769314	chr11:48097620	C/T	cg15704280	chr7:45808275	SEPT13	-0.66	-8.7	-0.5	6.08e-16	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg11987759	chr7:65425863	GUSB	-0.47	-6.28	-0.38	1.67e-9	Aortic root size;
SARC	cis	rs2075371	1.000	rs2598286	chr7:133976029	G/A	cg00033643	chr7:134001901	SLC35B4	0.41	4.98	0.31	1.25e-6	Mean platelet volume;
SARC	cis	rs7766436	0.767	rs62391062	chr6:22598736	G/A	cg13666174	chr6:22585274	NA	-0.48	-6.61	-0.4	2.55e-10	Coronary artery disease;
SARC	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg24531977	chr5:56204891	C5orf35	-0.5	-5.09	-0.32	7.48e-7	Initial pursuit acceleration;
SARC	cis	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg11266682	chr4:10021025	SLC2A9	0.41	7.34	0.43	3.52e-12	Bone mineral density;
SARC	cis	rs2070488	0.804	rs1870914	chr3:38494220	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	11.93	0.62	6.54e-26	Electrocardiographic conduction measures;
SARC	cis	rs981844	0.712	rs4538465	chr4:154746763	T/C	cg14289246	chr4:154710475	SFRP2	-0.45	-5.36	-0.33	1.96e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg03517284	chr6:25882590	NA	0.37	5.07	0.31	8.27e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7216064	0.953	rs11868959	chr17:65840810	T/C	cg12091567	chr17:66097778	LOC651250	-0.68	-6.87	-0.41	5.77e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs72781680	0.716	rs2712086	chr2:24004739	G/C	cg08917208	chr2:24149416	ATAD2B	0.6	6.04	0.37	6.17e-9	Lymphocyte counts;
SARC	cis	rs7772486	0.686	rs4896828	chr6:145953339	A/C	cg23711669	chr6:146136114	FBXO30	0.78	12.61	0.64	3.75e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9467773	1.000	rs9467796	chr6:26568411	A/G	cg12292205	chr6:26970375	C6orf41	0.45	5.43	0.33	1.45e-7	Intelligence (multi-trait analysis);
SARC	cis	rs796364	0.951	rs7565005	chr2:201013277	A/G	cg23649088	chr2:200775458	C2orf69	-0.61	-6.63	-0.4	2.31e-10	Schizophrenia;
SARC	cis	rs2288073	0.965	rs72789923	chr2:24394504	A/C	cg06627628	chr2:24431161	ITSN2	-0.64	-7.54	-0.44	1.03e-12	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg16606324	chr3:10149918	C3orf24	0.48	5.04	0.31	9.53e-7	Alzheimer's disease;
SARC	cis	rs11676348	0.772	rs7422358	chr2:218952778	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.43	-5.49	-0.34	1.05e-7	Ulcerative colitis;
SARC	cis	rs5753618	0.561	rs715510	chr22:31690528	T/A	cg07713946	chr22:31675144	LIMK2	-0.38	-5.25	-0.33	3.39e-7	Colorectal cancer;
SARC	trans	rs1814175	0.817	rs1996982	chr11:49972619	G/T	cg03929089	chr4:120376271	NA	-0.88	-14.05	-0.68	6.62e-33	Height;
SARC	cis	rs12134245	0.747	rs11164929	chr1:92012836	G/C	cg21854759	chr1:92012499	NA	-0.38	-5.07	-0.32	7.98e-7	Breast cancer;
SARC	trans	rs208520	0.770	rs1342960	chr6:66883514	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.03	-12.94	-0.65	3.22e-29	Exhaled nitric oxide output;
SARC	cis	rs7633857	0.595	rs7640874	chr3:160672617	T/A	cg17135325	chr3:160939158	NMD3	0.42	5.06	0.31	8.63e-7	Educational attainment (years of education);
SARC	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg03060546	chr3:49711283	APEH	0.42	5.19	0.32	4.47e-7	Parkinson's disease;
SARC	trans	rs56279505	0.629	rs17586023	chr4:100272950	A/G	cg18024358	chr1:3420815	MEGF6	-0.83	-6.4	-0.39	8.29e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9807841	0.670	rs2738042	chr19:10790143	C/G	cg17710535	chr19:10819994	QTRT1	0.43	4.78	0.3	3.12e-6	Inflammatory skin disease;
SARC	cis	rs1448094	0.520	rs12304244	chr12:86272823	C/T	cg00310523	chr12:86230176	RASSF9	0.31	4.76	0.3	3.36e-6	Major depressive disorder;
SARC	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg16434002	chr17:42200994	HDAC5	-0.41	-4.92	-0.31	1.66e-6	Total body bone mineral density;
SARC	cis	rs17376456	0.877	rs10040648	chr5:93490301	G/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.39	0.33	1.7e-7	Diabetic retinopathy;
SARC	cis	rs6545883	0.965	rs10186325	chr2:61757721	G/T	cg15711740	chr2:61764176	XPO1	-0.41	-5.04	-0.31	9.21e-7	Tuberculosis;
SARC	cis	rs10206020	0.885	rs6720797	chr2:1574340	T/C	cg01028140	chr2:1542097	TPO	-0.4	-5.41	-0.33	1.54e-7	IgG glycosylation;
SARC	cis	rs2834188	0.924	rs2834177	chr21:34676806	T/C	cg04842828	chr21:34696676	IFNAR1	0.42	4.98	0.31	1.26e-6	Narcolepsy;
SARC	cis	rs765787	0.530	rs2433229	chr15:45515235	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.43	-5.39	-0.33	1.73e-7	Uric acid levels;
SARC	cis	rs6942407	0.649	rs4727146	chr7:86856555	A/G	cg02420886	chr7:86849541	C7orf23	0.61	5.38	0.33	1.85e-7	Food allergy;
SARC	cis	rs9303401	0.614	rs35308719	chr17:57163501	C/T	cg25039879	chr17:56429692	SUPT4H1	0.58	5.22	0.32	3.88e-7	Cognitive test performance;
SARC	cis	rs4727027	0.704	rs7787753	chr7:148901779	A/T	cg23583168	chr7:148888333	NA	-0.81	-12.89	-0.65	4.5e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg09796886	chr4:39640558	C4orf34	0.48	6.34	0.38	1.2e-9	Chemerin levels;
SARC	cis	rs7681440	0.606	rs986609	chr4:90751415	C/G	cg06632027	chr4:90757378	SNCA	-0.42	-5.25	-0.33	3.35e-7	Dementia with Lewy bodies;
SARC	trans	rs36093844	0.752	rs1445505	chr11:85584722	A/G	cg15359163	chr5:122429178	PRDM6	-0.53	-6.33	-0.38	1.28e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs524281	0.861	rs1862005	chr11:65863402	T/C	cg14036092	chr11:66035641	RAB1B	-0.51	-5.34	-0.33	2.16e-7	Electroencephalogram traits;
SARC	cis	rs7937682	0.889	rs551825	chr11:111480116	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.88	-13.97	-0.68	1.3e-32	Primary sclerosing cholangitis;
SARC	trans	rs11098499	0.566	rs7664440	chr4:120578540	A/G	cg25214090	chr10:38739885	LOC399744	0.5	6.37	0.39	9.99e-10	Corneal astigmatism;
SARC	cis	rs9914988	0.943	rs4313850	chr17:27080768	T/C	cg20469991	chr17:27169893	C17orf63	-0.52	-5.45	-0.34	1.3e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs73206853	0.841	rs55741511	chr12:110880613	G/T	cg10860002	chr12:110842031	ANAPC7	0.69	4.76	0.3	3.38e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs7113850	0.541	rs7948382	chr11:24246608	T/C	ch.11.24196551F	chr11:24239977	NA	0.73	5.47	0.34	1.13e-7	Bone fracture in osteoporosis;
SARC	cis	rs7223966	1.000	rs61360320	chr17:61800392	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	6.88	0.41	5.45e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg02725872	chr8:58115012	NA	-0.35	-6.03	-0.37	6.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs58688157	0.739	rs56333810	chr11:575408	C/G	cg16486109	chr11:613632	IRF7	0.4	5.39	0.33	1.7e-7	Systemic lupus erythematosus;
SARC	cis	rs7084402	0.934	rs1658471	chr10:60291911	A/T	cg07615347	chr10:60278583	BICC1	0.61	8.99	0.51	8.99e-17	Refractive error;
SARC	cis	rs12079745	1.000	rs72637225	chr1:169129320	T/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.7	-5.23	-0.32	3.85e-7	QT interval;
SARC	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg19671926	chr4:122722719	EXOSC9	-0.58	-6.56	-0.4	3.36e-10	Type 2 diabetes;
SARC	cis	rs35110281	0.627	rs6518268	chr21:44967448	A/G	cg21573476	chr21:45109991	RRP1B	-0.4	-5.89	-0.36	1.37e-8	Mean corpuscular volume;
SARC	cis	rs6540556	0.521	rs9430015	chr1:209911734	G/A	cg05527609	chr1:210001259	C1orf107	-0.58	-6.06	-0.37	5.39e-9	Red blood cell count;
SARC	cis	rs6062302	0.522	rs2297427	chr20:62221364	G/A	cg09650180	chr20:62225654	GMEB2	-0.47	-5.81	-0.36	2.02e-8	Glioblastoma;
SARC	cis	rs7130144	0.541	rs73572230	chr11:130460843	G/A	cg26307797	chr11:130446613	NA	-0.7	-5.78	-0.35	2.33e-8	Urate levels in lean individuals;
SARC	cis	rs1008375	1.000	rs4698199	chr4:17656738	G/C	cg02297831	chr4:17616191	MED28	0.49	6.31	0.38	1.39e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4243830	0.850	rs12563717	chr1:6599557	T/G	cg22792644	chr1:6614718	TAS1R1;NOL9	1.04	10.25	0.56	1.37e-20	Body mass index;
SARC	cis	rs950169	0.887	rs71395453	chr15:85113490	G/C	cg03959625	chr15:84868606	LOC388152	0.36	4.93	0.31	1.53e-6	Schizophrenia;
SARC	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg07636037	chr3:49044803	WDR6	0.63	8.24	0.48	1.21e-14	Resting heart rate;
SARC	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg05368731	chr17:41323189	NBR1	0.76	8.93	0.51	1.27e-16	Menopause (age at onset);
SARC	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg19223190	chr17:80058835	NA	0.41	5.66	0.35	4.33e-8	Life satisfaction;
SARC	cis	rs79387448	0.745	rs7575867	chr2:103120179	C/T	cg09003973	chr2:102972529	NA	0.63	6.22	0.38	2.33e-9	Gut microbiota (bacterial taxa);
SARC	cis	rs965469	0.779	rs6139071	chr20:3299054	A/G	cg25506879	chr20:3388711	C20orf194	-0.47	-5.21	-0.32	4.1e-7	IFN-related cytopenia;
SARC	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg25894440	chr7:65020034	NA	-0.79	-5.99	-0.37	8.04e-9	Diabetic kidney disease;
SARC	cis	rs2304069	0.545	rs7445660	chr5:149413610	A/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.56	6.63	0.4	2.33e-10	HIV-1 control;
SARC	cis	rs4974559	0.895	rs57037487	chr4:1386652	A/G	cg02980000	chr4:1222292	CTBP1	0.6	6.24	0.38	2.03e-9	Systolic blood pressure;
SARC	cis	rs4595586	0.505	rs11611321	chr12:39390803	C/T	cg26384229	chr12:38710491	ALG10B	0.5	6.12	0.37	3.98e-9	Morning vs. evening chronotype;
SARC	cis	rs36051895	0.623	rs10975023	chr9:5239549	A/G	cg02405213	chr9:5042618	JAK2	0.42	4.79	0.3	2.9e-6	Pediatric autoimmune diseases;
SARC	cis	rs10206020	0.885	rs13411553	chr2:1574018	A/G	cg01028140	chr2:1542097	TPO	-0.38	-5.17	-0.32	4.98e-7	IgG glycosylation;
SARC	cis	rs2624839	0.639	rs2526389	chr3:50192826	C/T	cg14019146	chr3:50243930	SLC38A3	-0.31	-5.03	-0.31	9.91e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg00149659	chr3:10157352	C3orf10	0.69	6.44	0.39	6.6e-10	Alzheimer's disease;
SARC	cis	rs372883	0.564	rs766928	chr21:30753606	A/G	cg24692254	chr21:30365293	RNF160	0.6	7.54	0.44	1.05e-12	Pancreatic cancer;
SARC	cis	rs7851660	0.901	rs2401639	chr9:100607837	T/C	cg13688889	chr9:100608707	NA	-0.36	-4.72	-0.3	3.99e-6	Strep throat;
SARC	cis	rs9467711	0.591	rs17586553	chr6:25928775	C/T	cg21479132	chr6:26055353	NA	0.77	5.04	0.31	9.38e-7	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9300255	0.602	rs2510885	chr12:123614813	G/C	cg00376283	chr12:123451042	ABCB9	0.62	7.28	0.43	5.22e-12	Neutrophil percentage of white cells;
SARC	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg18876405	chr7:65276391	NA	0.69	8.33	0.48	6.91e-15	Aortic root size;
SARC	cis	rs453301	0.631	rs11780774	chr8:8799111	C/A	cg08975724	chr8:8085496	FLJ10661	-0.42	-5.08	-0.32	7.62e-7	Joint mobility (Beighton score);
SARC	cis	rs651907	0.557	rs2318090	chr3:101474933	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	6.48	0.39	5.37e-10	Colorectal cancer;
SARC	cis	rs2425143	1.000	rs11167275	chr20:34340275	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.68	5.67	0.35	4.3e-8	Blood protein levels;
SARC	cis	rs9815354	1.000	rs1716642	chr3:41965865	A/C	cg03022575	chr3:42003672	ULK4	-0.55	-5.27	-0.33	3.16e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6500602	0.627	rs709632	chr16:4587811	C/G	cg09269891	chr16:3843415	CREBBP	0.41	4.88	0.3	2.01e-6	Schizophrenia;
SARC	cis	rs7465272	1.000	rs36050651	chr8:143681796	A/G	cg24634471	chr8:143751801	JRK	0.6	6.77	0.41	1.05e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg16405210	chr4:1374714	KIAA1530	0.53	6.44	0.39	6.63e-10	Obesity-related traits;
SARC	cis	rs477895	0.568	rs12418035	chr11:63871558	G/A	cg18225595	chr11:63971243	STIP1	0.45	5.43	0.34	1.39e-7	Mean platelet volume;
SARC	cis	rs13082711	0.522	rs578501	chr3:27344963	A/G	cg02860705	chr3:27208620	NA	0.43	5.76	0.35	2.58e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg25427524	chr10:38739819	LOC399744	-0.54	-8.56	-0.49	1.52e-15	Extrinsic epigenetic age acceleration;
SARC	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.41	0.44	2.36e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.6	7.65	0.45	5.3e-13	Lymphocyte counts;
SARC	cis	rs2916247	0.954	rs2996058	chr8:93179441	G/C	cg10183463	chr8:93005414	RUNX1T1	0.49	5.25	0.33	3.45e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2290159	0.800	rs5746193	chr3:12658601	C/T	cg23032965	chr3:12705835	RAF1	0.73	7.89	0.46	1.18e-13	Cholesterol, total;
SARC	cis	rs17376456	0.825	rs74825443	chr5:93254973	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.67	6.14	0.37	3.48e-9	Diabetic retinopathy;
SARC	trans	rs7824557	0.564	rs12550129	chr8:11233917	C/T	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.84	-0.41	6.96e-11	Retinal vascular caliber;
SARC	cis	rs7582180	0.629	rs4851294	chr2:100941109	C/T	cg14675211	chr2:100938903	LONRF2	0.48	7.04	0.42	2.13e-11	Intelligence (multi-trait analysis);
SARC	cis	rs6582630	0.615	rs10880642	chr12:38554152	A/G	cg13010199	chr12:38710504	ALG10B	-0.51	-6.44	-0.39	6.92e-10	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9902453	1.000	rs62070270	chr17:28263980	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	6.56	0.39	3.54e-10	Coffee consumption (cups per day);
SARC	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg13699009	chr12:122356056	WDR66	0.59	9.72	0.54	5.6e-19	Mean corpuscular volume;
SARC	cis	rs910316	0.875	rs12588099	chr14:75594462	A/T	cg06637938	chr14:75390232	RPS6KL1	0.5	7.11	0.42	1.39e-11	Height;
SARC	cis	rs9297145	0.761	rs112155177	chr7:98747963	C/T	cg05967295	chr7:98741636	SMURF1	0.78	7.98	0.46	6.82e-14	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
SARC	cis	rs9916302	0.784	rs4795361	chr17:37573446	G/A	cg20243544	chr17:37824526	PNMT	0.55	6.56	0.39	3.39e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs4919087	0.683	rs7091162	chr10:99071242	G/T	cg25902810	chr10:99078978	FRAT1	-0.55	-6.56	-0.39	3.4e-10	Monocyte count;
SARC	cis	rs897984	0.568	rs4889651	chr16:30895545	C/T	cg00531865	chr16:30841666	NA	-0.45	-4.91	-0.31	1.7e-6	Dementia with Lewy bodies;
SARC	trans	rs634534	0.562	rs642293	chr11:65730217	G/A	cg17712092	chr4:129076599	LARP1B	0.69	9.39	0.52	5.88e-18	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg15966229	chr18:44337664	ST8SIA5	0.37	4.82	0.3	2.56e-6	Personality dimensions;
SARC	cis	rs6866344	0.697	rs11749438	chr5:178131245	C/T	cg03877680	chr5:178157825	ZNF354A	1.03	12.86	0.64	5.82e-29	Neutrophil percentage of white cells;
SARC	cis	rs11638352	1.000	rs890465	chr15:44356463	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.75	5.71	0.35	3.44e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	cis	rs6964587	0.967	rs10231496	chr7:91741132	T/C	cg17063962	chr7:91808500	NA	0.96	16.59	0.74	2.42e-41	Breast cancer;
SARC	cis	rs17376456	0.569	rs10067754	chr5:93093110	T/A	cg25358565	chr5:93447407	FAM172A	0.94	10.43	0.56	3.7e-21	Diabetic retinopathy;
SARC	cis	rs60871478	0.947	rs4074610	chr7:791755	G/A	cg05535760	chr7:792225	HEATR2	0.78	8.19	0.47	1.68e-14	Cerebrospinal P-tau181p levels;
SARC	cis	rs12579753	1.000	rs17749267	chr12:82178308	A/G	cg07988820	chr12:82153109	PPFIA2	0.59	6.91	0.41	4.65e-11	Resting heart rate;
SARC	cis	rs4423214	1.000	rs12797951	chr11:71143266	G/T	cg05163923	chr11:71159392	DHCR7	-0.66	-9.19	-0.52	2.19e-17	Vitamin D levels;
SARC	cis	rs7940866	0.845	rs10894294	chr11:130830748	G/T	cg12179176	chr11:130786555	SNX19	0.68	9.0	0.51	8.18e-17	Schizophrenia;
SARC	cis	rs9291683	0.530	rs6449196	chr4:9973660	C/T	cg11266682	chr4:10021025	SLC2A9	-0.39	-6.99	-0.42	2.85e-11	Bone mineral density;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg07827304	chr1:38005965	SNIP1	0.46	6.62	0.4	2.45e-10	Thyroid stimulating hormone;
SARC	cis	rs12950390	0.853	rs11079791	chr17:45859099	C/T	cg03474202	chr17:45855739	NA	-0.43	-6.73	-0.4	1.3e-10	IgG glycosylation;
SARC	cis	rs10493773	0.609	rs11161664	chr1:86185379	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.61	-9.96	-0.55	1.1e-19	Urate levels in overweight individuals;
SARC	cis	rs644799	0.965	rs2950522	chr11:95524719	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	15.34	0.71	3.56e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs6700896	0.864	rs11208718	chr1:66158995	G/A	cg04111102	chr1:66153794	NA	0.36	5.55	0.34	7.77e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs270601	0.817	rs460089	chr5:131629772	C/G	cg24060327	chr5:131705240	SLC22A5	-0.7	-8.23	-0.47	1.29e-14	Acylcarnitine levels;
SARC	cis	rs80130819	0.515	rs7315258	chr12:48572670	T/C	cg05342945	chr12:48394962	COL2A1	-0.5	-5.31	-0.33	2.54e-7	Prostate cancer;
SARC	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg22857025	chr5:266934	NA	1.03	11.17	0.59	1.8e-23	Breast cancer;
SARC	cis	rs8141529	0.702	rs469990	chr22:29304200	A/T	cg15103426	chr22:29168792	CCDC117	0.64	8.23	0.47	1.32e-14	Lymphocyte counts;
SARC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg09373136	chr17:61933544	TCAM1	-0.45	-6.13	-0.37	3.67e-9	Prudent dietary pattern;
SARC	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.95	9.97	0.55	1.03e-19	Platelet count;
SARC	cis	rs9303401	0.659	rs12602389	chr17:56779778	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	11.87	0.61	9.72e-26	Cognitive test performance;
SARC	cis	rs10089	1.000	rs13356473	chr5:127478250	T/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.82	10.2	0.56	1.97e-20	Ileal carcinoids;
SARC	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg11644478	chr21:40555479	PSMG1	-0.89	-11.73	-0.61	2.84e-25	Cognitive function;
SARC	cis	rs2070488	0.662	rs7652475	chr3:38481341	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.63	8.33	0.48	6.75e-15	Electrocardiographic conduction measures;
SARC	cis	rs10917477	0.576	rs10917476	chr1:19860840	C/G	cg12094543	chr1:19923282	C1orf151	0.62	7.18	0.43	9.43e-12	Thyroid function;
SARC	cis	rs35213789	0.878	rs17365333	chr7:69545958	A/T	cg10619644	chr7:69149951	AUTS2	0.42	5.13	0.32	5.97e-7	Childhood ear infection;
SARC	cis	rs796364	0.951	rs12463436	chr2:201061962	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.53	5.42	0.33	1.5e-7	Schizophrenia;
SARC	cis	rs2916247	0.954	rs2920940	chr8:93180965	T/C	cg10183463	chr8:93005414	RUNX1T1	0.5	5.27	0.33	3.05e-7	Intelligence (multi-trait analysis);
SARC	cis	rs3126085	0.935	rs991231	chr1:152211898	T/G	cg09127314	chr1:152161683	NA	-0.42	-4.79	-0.3	2.98e-6	Atopic dermatitis;
SARC	cis	rs1559088	0.948	rs7257858	chr19:33591231	T/C	cg17764715	chr19:33622953	WDR88	0.49	6.72	0.4	1.4e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs6952808	0.929	rs2280548	chr7:1976667	G/T	cg05863683	chr7:1912471	MAD1L1	0.34	4.94	0.31	1.47e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs62490346	1.000	rs10503407	chr8:10228633	C/G	cg21775007	chr8:11205619	TDH	-0.67	-5.54	-0.34	8.12e-8	Chickenpox;
SARC	cis	rs7020830	0.825	rs10973248	chr9:37197768	C/T	cg14294708	chr9:37120828	ZCCHC7	1.14	21.48	0.82	3.62e-57	Schizophrenia;
SARC	cis	rs854765	0.583	rs8075965	chr17:17853180	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	9.85	0.54	2.34e-19	Total body bone mineral density;
SARC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg15242686	chr22:24348715	GSTTP1	0.4	4.83	0.3	2.52e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7681440	1.000	rs7681440	chr4:90756550	C/G	cg06632027	chr4:90757378	SNCA	-0.38	-5.28	-0.33	3.02e-7	Dementia with Lewy bodies;
SARC	cis	rs8114671	0.528	rs6119542	chr20:33484545	G/T	cg07148914	chr20:33460835	GGT7	0.42	5.12	0.32	6.3e-7	Height;
SARC	cis	rs9290065	0.538	rs9860182	chr3:160768962	T/C	cg03342759	chr3:160939853	NMD3	-0.57	-6.94	-0.41	3.74e-11	Kawasaki disease;
SARC	cis	rs11122272	0.735	rs2749723	chr1:231493302	A/G	cg06096015	chr1:231504339	EGLN1	0.36	5.36	0.33	2.05e-7	Hemoglobin concentration;
SARC	cis	rs6493487	0.512	rs71471523	chr15:51197324	G/A	cg02338191	chr15:51200825	AP4E1	0.55	5.06	0.31	8.31e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg26039829	chr8:22132926	PIWIL2	0.44	6.46	0.39	6.17e-10	Hypertriglyceridemia;
SARC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg07414643	chr4:187882934	NA	0.5	7.41	0.44	2.29e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg01475735	chr3:40494733	NA	-0.49	-5.64	-0.35	4.98e-8	Renal cell carcinoma;
SARC	cis	rs7772486	0.681	rs9390343	chr6:146010527	A/T	cg05347473	chr6:146136440	FBXO30	-0.51	-6.89	-0.41	5.03e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7666738	0.830	rs13144771	chr4:99026935	G/C	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg25894440	chr7:65020034	NA	-0.73	-5.51	-0.34	9.25e-8	Diabetic kidney disease;
SARC	cis	rs1707322	0.717	rs28752166	chr1:46213309	G/A	cg06784218	chr1:46089804	CCDC17	0.36	6.37	0.38	1.03e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg06636001	chr8:8085503	FLJ10661	0.7	9.52	0.53	2.27e-18	Systolic blood pressure;
SARC	cis	rs644799	1.000	rs473148	chr11:95628606	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.66	8.34	0.48	6.38e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs57083693	0.518	rs10860710	chr12:101723467	A/G	cg22051763	chr12:101673672	UTP20	-0.46	-5.41	-0.33	1.57e-7	Alcohol dependence (age at onset);
SARC	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg12311346	chr5:56204834	C5orf35	-0.57	-5.82	-0.36	1.96e-8	Initial pursuit acceleration;
SARC	cis	rs473651	0.935	rs477041	chr2:239355995	C/G	cg21699342	chr2:239360505	ASB1	-0.49	-7.0	-0.42	2.78e-11	Multiple system atrophy;
SARC	cis	rs10463316	0.862	rs7720582	chr5:150776502	C/T	cg03212797	chr5:150827313	SLC36A1	0.44	5.23	0.32	3.8e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs7044106	0.762	rs13291660	chr9:123392748	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.71	9.01	0.51	7.5e-17	Hip circumference adjusted for BMI;
SARC	cis	rs7674212	0.507	rs223331	chr4:103793565	T/A	cg16532752	chr4:104119610	CENPE	-0.43	-4.85	-0.3	2.22e-6	Type 2 diabetes;
SARC	cis	rs7296418	0.961	rs1727307	chr12:123575742	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.36	-4.76	-0.3	3.39e-6	Platelet count;
SARC	cis	rs2153535	0.580	rs986060	chr6:8465428	T/C	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	cis	rs9843304	0.500	rs34358037	chr3:149201284	A/G	cg08667024	chr3:149219783	TM4SF4	-0.37	-5.55	-0.34	7.78e-8	Gallstone disease;
SARC	cis	rs10782582	0.586	rs1796813	chr1:76400403	G/A	cg10523679	chr1:76189770	ACADM	-0.42	-5.16	-0.32	5.23e-7	Daytime sleep phenotypes;
SARC	cis	rs1448094	0.511	rs17280643	chr12:86210154	C/T	cg02569458	chr12:86230093	RASSF9	-0.38	-5.4	-0.33	1.6e-7	Major depressive disorder;
SARC	cis	rs1008375	0.966	rs3775924	chr4:17585984	T/C	cg27347728	chr4:17578864	LAP3	0.49	6.06	0.37	5.46e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs3008870	0.755	rs11208974	chr1:67398119	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.59	7.54	0.44	1.07e-12	Lymphocyte percentage of white cells;
SARC	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg11987759	chr7:65425863	GUSB	-0.49	-6.21	-0.38	2.46e-9	Aortic root size;
SARC	cis	rs4144743	0.528	rs2292866	chr17:45356782	T/C	cg18085866	chr17:45331354	ITGB3	-0.82	-6.64	-0.4	2.2e-10	Body mass index;
SARC	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	12.4	0.63	1.9e-27	Personality dimensions;
SARC	cis	rs7481584	0.624	rs413368	chr11:3047646	C/G	cg25174290	chr11:3078921	CARS	-0.59	-8.27	-0.48	1.02e-14	Calcium levels;
SARC	cis	rs10927875	0.550	rs12121918	chr1:16183556	C/A	cg21385522	chr1:16154831	NA	-0.86	-9.58	-0.53	1.52e-18	Dilated cardiomyopathy;
SARC	cis	rs712039	0.617	rs36081240	chr17:35785054	G/A	cg16670864	chr17:35848621	DUSP14	0.48	5.25	0.33	3.44e-7	Tuberculosis;
SARC	cis	rs11809207	0.523	rs2783706	chr1:26504697	A/G	cg23602478	chr1:26503979	CNKSR1	0.27	5.0	0.31	1.15e-6	Height;
SARC	cis	rs981844	1.000	rs2606325	chr4:154652681	C/T	cg14289246	chr4:154710475	SFRP2	0.5	5.82	0.36	1.95e-8	Response to statins (LDL cholesterol change);
SARC	cis	rs11687170	0.882	rs11675094	chr2:237060060	C/T	cg19324714	chr2:237145437	ASB18	0.49	4.89	0.31	1.89e-6	Educational attainment;Educational attainment (years of education);
SARC	cis	rs865483	0.861	rs72828246	chr17:35766475	A/G	cg06561646	chr17:35873369	DUSP14	0.47	6.09	0.37	4.62e-9	Monocyte count;
SARC	cis	rs12887734	0.566	rs3742366	chr14:104198351	T/C	cg26031613	chr14:104095156	KLC1	-0.57	-6.68	-0.4	1.75e-10	Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	cis	rs13191362	1.000	rs1333963	chr6:163192571	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.43	5.3	0.33	2.71e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs9818758	0.556	rs9835439	chr3:49220330	G/C	cg01304814	chr3:48885189	PRKAR2A	0.6	4.84	0.3	2.37e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs881375	0.715	rs7858209	chr9:123645760	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	7.03	0.42	2.25e-11	Rheumatoid arthritis;
SARC	cis	rs2050392	0.630	rs303426	chr10:30740379	A/G	cg25182066	chr10:30743637	MAP3K8	-0.45	-6.19	-0.38	2.64e-9	Inflammatory bowel disease;
SARC	cis	rs11098499	0.954	rs10006706	chr4:120409152	A/G	cg09307838	chr4:120376055	NA	0.9	12.46	0.63	1.22e-27	Corneal astigmatism;
SARC	cis	rs7103648	0.838	rs11039244	chr11:47466442	G/A	cg20307385	chr11:47447363	PSMC3	0.83	12.21	0.62	7.6e-27	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg18357526	chr6:26021779	HIST1H4A	0.45	5.64	0.35	5.01e-8	Blood metabolite levels;
SARC	cis	rs240764	0.817	rs239201	chr6:101123993	T/A	cg09795085	chr6:101329169	ASCC3	0.45	5.91	0.36	1.19e-8	Neuroticism;
SARC	cis	rs12079745	0.590	rs7544446	chr1:169256524	T/C	cg09363564	chr1:169337483	NME7;BLZF1	-0.78	-4.99	-0.31	1.16e-6	QT interval;
SARC	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg19774624	chr17:42201019	HDAC5	-0.85	-13.37	-0.66	1.19e-30	Total body bone mineral density;
SARC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.62	0.53	1.18e-18	Prudent dietary pattern;
SARC	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg24250549	chr1:154909240	PMVK	0.71	9.4	0.52	5.19e-18	Prostate cancer;
SARC	cis	rs11697848	1.000	rs79663083	chr20:48534737	C/G	cg17849948	chr20:48532315	SPATA2	0.87	5.2	0.32	4.3e-7	Systemic lupus erythematosus;
SARC	cis	rs12971120	1.000	rs3829640	chr18:72174980	A/G	cg25817165	chr18:72167213	CNDP2	-0.48	-7.41	-0.44	2.27e-12	Refractive error;
SARC	cis	rs7582180	0.629	rs36103184	chr2:100942634	G/A	cg14675211	chr2:100938903	LONRF2	0.51	7.59	0.45	7.54e-13	Intelligence (multi-trait analysis);
SARC	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg25036284	chr2:26402008	FAM59B	0.46	5.7	0.35	3.59e-8	Gut microbiome composition (summer);
SARC	cis	rs6674176	0.628	rs7556565	chr1:44416090	C/T	cg12908607	chr1:44402522	ARTN	-0.4	-6.78	-0.41	1.01e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs7617773	0.817	rs13068265	chr3:48301614	A/C	cg11946769	chr3:48343235	NME6	0.71	9.26	0.52	1.37e-17	Coronary artery disease;
SARC	cis	rs1008375	0.646	rs13103430	chr4:17567355	A/C	cg16339924	chr4:17578868	LAP3	-0.58	-6.9	-0.41	4.98e-11	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.45	-7.34	-0.43	3.5e-12	Longevity;Endometriosis;
SARC	cis	rs9715521	0.775	rs11723682	chr4:59851969	C/T	cg11281224	chr4:60001000	NA	-0.4	-5.11	-0.32	6.63e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7084402	0.967	rs12569559	chr10:60312711	T/G	cg07615347	chr10:60278583	BICC1	-0.54	-7.81	-0.46	1.93e-13	Refractive error;
SARC	cis	rs1044826	1.000	rs12695700	chr3:139212098	C/G	cg15131784	chr3:139108705	COPB2	0.46	5.18	0.32	4.8e-7	Obesity-related traits;
SARC	cis	rs2075371	0.931	rs1646697	chr7:133999930	G/A	cg00033643	chr7:134001901	SLC35B4	0.42	5.06	0.31	8.4e-7	Mean platelet volume;
SARC	cis	rs634534	0.622	rs531612	chr11:65705432	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.53	-7.96	-0.46	7.5e-14	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs2204008	0.744	rs12099650	chr12:38317140	C/G	cg13010199	chr12:38710504	ALG10B	0.78	10.58	0.57	1.29e-21	Bladder cancer;
SARC	cis	rs1008375	0.931	rs4479701	chr4:17571496	G/A	cg16339924	chr4:17578868	LAP3	0.67	8.79	0.5	3.32e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg19729930	chr2:74357872	NA	0.71	10.24	0.56	1.52e-20	Gestational age at birth (maternal effect);
SARC	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9549367	0.789	rs12869947	chr13:113896156	A/G	cg18105134	chr13:113819100	PROZ	-0.39	-5.83	-0.36	1.84e-8	Platelet distribution width;
SARC	cis	rs4481887	0.741	rs7417519	chr1:248550370	C/T	cg13385794	chr1:248469461	NA	-0.31	-5.03	-0.31	9.66e-7	Common traits (Other);
SARC	cis	rs3796352	1.000	rs114562844	chr3:52991584	C/T	cg12962167	chr3:53033115	SFMBT1	0.75	4.9	0.31	1.8e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs7587476	0.906	rs16852750	chr2:215646683	A/G	cg04004882	chr2:215674386	BARD1	0.63	6.85	0.41	6.66e-11	Neuroblastoma;
SARC	cis	rs950169	0.580	rs35516100	chr15:85195430	C/T	cg17507749	chr15:85114479	UBE2QP1	0.59	6.85	0.41	6.41e-11	Schizophrenia;
SARC	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg13395646	chr4:1353034	KIAA1530	0.52	6.3	0.38	1.44e-9	Obesity-related traits;
SARC	cis	rs11585357	0.895	rs72646798	chr1:17614422	C/T	cg08277548	chr1:17600880	PADI3	-0.5	-5.56	-0.34	7.52e-8	Hair shape;
SARC	cis	rs2439831	0.867	rs2584702	chr15:43684914	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.06	11.44	0.6	2.43e-24	Lung cancer in ever smokers;
SARC	cis	rs3806933	0.522	rs13153937	chr5:110434307	C/T	cg04022379	chr5:110408740	TSLP	0.71	9.23	0.52	1.75e-17	Eosinophilic esophagitis;
SARC	cis	rs4944092	1.000	rs4944092	chr11:75909619	C/T	cg04588336	chr11:75916460	WNT11	-0.42	-5.63	-0.35	5.1e-8	PR interval;
SARC	cis	rs60871478	1.000	rs35488064	chr7:812722	G/C	cg19087971	chr7:751233	PRKAR1B	-0.43	-4.97	-0.31	1.32e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs2153535	0.580	rs4960423	chr6:8477210	C/T	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	cis	rs17401966	1.000	rs6700866	chr1:10306038	A/G	cg15208524	chr1:10270712	KIF1B	0.58	6.64	0.4	2.13e-10	Hepatocellular carcinoma;
SARC	cis	rs12911832	1.000	rs12911832	chr15:58985904	A/T	cg05156742	chr15:59063176	FAM63B	0.62	7.81	0.46	1.9e-13	Schizophrenia;
SARC	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg01341218	chr17:43662625	NA	1.02	11.67	0.61	4.29e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg24829409	chr8:58192753	C8orf71	-0.6	-6.35	-0.38	1.12e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7666738	0.830	rs3907021	chr4:99038668	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg17971929	chr21:40555470	PSMG1	-0.86	-11.35	-0.6	4.61e-24	Cognitive function;
SARC	cis	rs137603	0.502	rs137627	chr22:39716341	G/A	cg01093212	chr22:39715156	SNORD43;RPL3	-0.52	-6.03	-0.37	6.44e-9	Primary biliary cholangitis;
SARC	cis	rs6840360	1.000	rs6849050	chr4:152599902	C/T	cg22705602	chr4:152727874	NA	-0.37	-6.25	-0.38	1.89e-9	Intelligence (multi-trait analysis);
SARC	trans	rs36093844	0.747	rs17817314	chr11:85594972	T/C	cg27065003	chr5:122429449	PRDM6	-0.52	-6.25	-0.38	1.97e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs561341	1.000	rs548957	chr17:30302411	G/A	cg00745463	chr17:30367425	LRRC37B	-0.67	-5.32	-0.33	2.4e-7	Hip circumference adjusted for BMI;
SARC	cis	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg09021430	chr5:549028	NA	-0.43	-5.59	-0.34	6.43e-8	Obesity-related traits;
SARC	cis	rs35110281	0.565	rs7278003	chr21:44966069	T/C	cg21573476	chr21:45109991	RRP1B	-0.44	-6.32	-0.38	1.3e-9	Mean corpuscular volume;
SARC	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg05861140	chr6:150128134	PCMT1	-0.42	-5.49	-0.34	1.06e-7	Lung cancer;
SARC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg08219700	chr8:58056026	NA	0.62	6.56	0.4	3.37e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7326068	0.610	rs2314720	chr13:21313373	G/A	cg16922012	chr13:21400325	XPO4	-0.42	-5.72	-0.35	3.18e-8	Schizophrenia, bipolar disorder and depression (combined);
SARC	cis	rs244731	0.959	rs6872021	chr5:176610012	G/A	cg06060754	chr5:176797920	RGS14	-0.43	-5.0	-0.31	1.14e-6	Urate levels in lean individuals;
SARC	cis	rs2204008	0.837	rs11180821	chr12:38242843	A/G	cg26384229	chr12:38710491	ALG10B	0.89	13.06	0.65	1.31e-29	Bladder cancer;
SARC	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg09165964	chr15:75287851	SCAMP5	0.52	7.14	0.42	1.19e-11	Breast cancer;
SARC	cis	rs986417	1.000	rs8021347	chr14:60952773	G/C	cg27398547	chr14:60952738	C14orf39	1.0	9.44	0.53	4.04e-18	Gut microbiota (bacterial taxa);
SARC	cis	rs7020830	0.830	rs12554976	chr9:37244505	G/T	cg14294708	chr9:37120828	ZCCHC7	1.1	19.21	0.78	6.01e-50	Schizophrenia;
SARC	cis	rs12142240	0.698	rs72677600	chr1:46834449	G/A	cg10495392	chr1:46806563	NSUN4	0.66	6.91	0.41	4.69e-11	Menopause (age at onset);
SARC	cis	rs9329289	0.926	rs10903784	chr10:2541943	G/T	cg15501526	chr10:2543763	NA	-0.5	-7.7	-0.45	3.88e-13	Age-related hearing impairment;
SARC	cis	rs12681366	0.663	rs3099398	chr8:95479879	A/G	cg26464482	chr8:95565502	KIAA1429	0.42	5.24	0.32	3.64e-7	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs12291225	0.679	rs1043237	chr11:14289053	A/T	cg19336497	chr11:14380999	RRAS2	-0.36	-5.79	-0.35	2.3e-8	Sense of smell;
SARC	cis	rs912057	0.671	rs1294425	chr6:6744292	G/A	cg06612196	chr6:6737390	NA	0.63	9.53	0.53	2.1e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs11122272	0.735	rs910823	chr1:231498766	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.17	-0.55	2.42e-20	Hemoglobin concentration;
SARC	cis	rs380904	1.000	rs12543128	chr8:144595042	G/A	cg20583945	chr8:144636462	GSDMD	0.36	5.1	0.32	6.99e-7	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs9790314	0.586	rs11710916	chr3:161130070	A/G	cg03342759	chr3:160939853	NMD3	-0.62	-7.77	-0.45	2.5e-13	Morning vs. evening chronotype;
SARC	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg05368731	chr17:41323189	NBR1	0.8	9.59	0.53	1.43e-18	Menopause (age at onset);
SARC	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg05665937	chr4:1216051	CTBP1	0.35	4.96	0.31	1.34e-6	Obesity-related traits;
SARC	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg11878867	chr6:150167359	LRP11	-0.35	-4.77	-0.3	3.19e-6	Lung cancer;
SARC	cis	rs7772486	0.720	rs4896844	chr6:146075224	T/C	cg05347473	chr6:146136440	FBXO30	-0.56	-7.82	-0.46	1.87e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg11878867	chr6:150167359	LRP11	-0.35	-4.84	-0.3	2.35e-6	Lung cancer;
SARC	cis	rs910316	1.000	rs4903289	chr14:75623988	C/T	cg11812906	chr14:75593930	NEK9	-0.88	-13.99	-0.68	1.06e-32	Height;
SARC	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg03354898	chr7:1950403	MAD1L1	-0.35	-4.72	-0.3	4.1e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs8067545	0.641	rs203455	chr17:19821185	A/G	cg13482628	chr17:19912719	NA	0.54	6.84	0.41	6.97e-11	Schizophrenia;
SARC	cis	rs10504229	0.593	rs74760806	chr8:58024785	C/T	cg22535103	chr8:58192502	C8orf71	-0.6	-5.76	-0.35	2.61e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs796364	0.806	rs79725795	chr2:201083534	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.6	-4.84	-0.3	2.39e-6	Schizophrenia;
SARC	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg11987759	chr7:65425863	GUSB	-0.5	-6.53	-0.39	4.12e-10	Aortic root size;
SARC	cis	rs2241210	0.550	rs7486178	chr12:109980266	G/A	cg13986417	chr12:110012484	MVK;MMAB	-0.4	-6.24	-0.38	2.02e-9	HDL cholesterol levels;
SARC	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg11843238	chr5:131593191	PDLIM4	0.42	5.7	0.35	3.55e-8	Acylcarnitine levels;
SARC	cis	rs2439831	1.000	rs2245908	chr15:43731454	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.81	8.21	0.47	1.49e-14	Lung cancer in ever smokers;
SARC	cis	rs35110281	0.667	rs4819286	chr21:45120121	G/A	cg21573476	chr21:45109991	RRP1B	-0.62	-9.12	-0.51	3.62e-17	Mean corpuscular volume;
SARC	cis	rs10979	1.000	rs12738	chr6:143890049	A/G	cg25407410	chr6:143891975	LOC285740	-0.64	-8.68	-0.49	6.88e-16	Hypospadias;
SARC	cis	rs6964587	1.000	rs7791138	chr7:91686789	A/G	cg17063962	chr7:91808500	NA	0.97	16.79	0.74	5.2e-42	Breast cancer;
SARC	cis	rs60871478	0.947	rs62432239	chr7:794576	C/T	cg05535760	chr7:792225	HEATR2	0.77	8.01	0.46	5.31e-14	Cerebrospinal P-tau181p levels;
SARC	cis	rs477692	0.629	rs945231	chr10:131294827	A/G	cg02700606	chr10:131763134	EBF3	0.38	5.19	0.32	4.55e-7	Response to temozolomide;
SARC	cis	rs10489202	0.632	rs203781	chr1:167880518	A/C	cg24449463	chr1:168025552	DCAF6	-0.64	-8.82	-0.5	2.79e-16	Schizophrenia;
SARC	trans	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.73	10.35	0.56	6.59e-21	Intelligence (multi-trait analysis);
SARC	cis	rs933688	1.000	rs1895448	chr5:90743854	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.96	12.39	0.63	2.01e-27	Smoking behavior;
SARC	cis	rs7017697	0.642	rs3927029	chr8:19681933	G/A	cg17834443	chr8:19674713	INTS10	-0.43	-4.83	-0.3	2.42e-6	Breast cancer;
SARC	cis	rs9303401	0.573	rs34097494	chr17:57171917	C/T	cg25039879	chr17:56429692	SUPT4H1	0.58	5.24	0.32	3.51e-7	Cognitive test performance;
SARC	cis	rs3008870	1.000	rs2755245	chr1:67487964	C/G	cg08660285	chr1:67390436	MIER1;WDR78	0.86	10.93	0.58	1.04e-22	Lymphocyte percentage of white cells;
SARC	cis	rs7408868	0.520	rs1043994	chr19:15302844	T/C	cg14696996	chr19:15285081	NOTCH3	0.77	7.0	0.42	2.71e-11	Pulse pressure;
SARC	cis	rs9788682	0.747	rs2656073	chr15:78742276	G/T	cg24631222	chr15:78858424	CHRNA5	0.75	9.53	0.53	2.22e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs4727443	0.866	rs2897075	chr7:99630342	C/T	cg22004693	chr7:99632812	ZKSCAN1	0.59	7.23	0.43	6.68e-12	Interstitial lung disease;
SARC	cis	rs1318878	0.565	rs73057230	chr12:15497573	G/A	cg08258403	chr12:15378311	NA	0.47	6.67	0.4	1.83e-10	Intelligence (multi-trait analysis);
SARC	cis	rs59724122	0.542	rs28633173	chr8:27446980	A/G	cg24592790	chr8:27450047	NA	0.57	6.74	0.4	1.25e-10	Bipolar disorder lithium response (categorical) or schizophrenia;
SARC	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg11062466	chr8:58055876	NA	0.67	6.06	0.37	5.55e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2204008	0.652	rs11513964	chr12:37998214	C/G	cg26384229	chr12:38710491	ALG10B	0.89	13.14	0.65	6.99e-30	Bladder cancer;
SARC	cis	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg05340658	chr4:99064831	C4orf37	0.48	6.3	0.38	1.47e-9	Colonoscopy-negative controls vs population controls;
SARC	cis	rs644799	0.625	rs1255175	chr11:95471186	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.54	6.75	0.4	1.2e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs2637266	1.000	rs2637266	chr10:78331318	C/T	cg20547015	chr12:111165713	PPP1CC	0.44	6.84	0.41	7.1e-11	Pulmonary function;
SARC	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg22800045	chr5:56110881	MAP3K1	0.72	7.66	0.45	4.94e-13	Initial pursuit acceleration;
SARC	cis	rs611744	0.870	rs371878	chr8:109130620	T/G	cg21045802	chr8:109455806	TTC35	0.41	4.86	0.3	2.21e-6	Dupuytren's disease;
SARC	cis	rs992157	0.710	rs10167446	chr2:219056866	A/G	cg00012203	chr2:219082015	ARPC2	0.81	12.68	0.64	2.26e-28	Colorectal cancer;
SARC	cis	rs1256061	0.603	rs960069	chr14:64745002	C/T	cg23250157	chr14:64679961	SYNE2	0.45	6.3	0.38	1.44e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg11235426	chr6:292522	DUSP22	-0.61	-7.82	-0.46	1.79e-13	Menopause (age at onset);
SARC	cis	rs7584330	0.554	rs2325838	chr2:238386515	C/A	cg08992911	chr2:238395768	MLPH	0.68	5.79	0.35	2.23e-8	Prostate cancer;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	ch.7.2902493F	chr7:138945421	UBN2	-0.55	-7.47	-0.44	1.6e-12	Thyroid stimulating hormone;
SARC	cis	rs6060960	0.502	rs15817	chr20:30193538	A/G	cg21427119	chr20:30132790	HM13	-0.45	-4.98	-0.31	1.23e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
SARC	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg12379764	chr21:47803548	PCNT	0.59	6.48	0.39	5.42e-10	Testicular germ cell tumor;
SARC	cis	rs1707322	1.000	rs4641257	chr1:46353589	G/A	cg06784218	chr1:46089804	CCDC17	0.35	6.06	0.37	5.3300000000000004e-09	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9916302	0.706	rs7212621	chr17:37527911	T/G	cg20243544	chr17:37824526	PNMT	-0.55	-5.86	-0.36	1.56e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs9486715	0.830	rs2475023	chr6:96996833	G/A	cg06623918	chr6:96969491	KIAA0776	-0.93	-14.21	-0.68	2.02e-33	Headache;
SARC	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.82	12.55	0.64	6.06e-28	Personality dimensions;
SARC	cis	rs2504916	1.000	rs2504916	chr6:160824028	T/A	cg20340146	chr6:160172821	WTAP	0.45	4.72	0.3	4.04e-6	Response to hepatitis C treatment;
SARC	cis	rs9660992	0.710	rs1668869	chr1:205239779	G/C	cg21643547	chr1:205240462	TMCC2	-0.64	-8.25	-0.48	1.2e-14	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs3741404	0.583	rs640999	chr11:63869425	C/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	9.03	0.51	6.46e-17	Platelet count;
SARC	cis	rs17384381	0.953	rs12717763	chr1:85808164	A/T	cg16011679	chr1:85725395	C1orf52	0.68	6.17	0.37	3.06e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs5753037	0.547	rs140140	chr22:30166437	G/A	cg01021169	chr22:30184971	ASCC2	-0.53	-7.37	-0.43	2.94e-12	Type 1 diabetes;
SARC	cis	rs240764	0.658	rs1336251	chr6:101247698	C/T	cg09795085	chr6:101329169	ASCC3	-0.44	-5.67	-0.35	4.16e-8	Neuroticism;
SARC	cis	rs12950390	0.548	rs62076098	chr17:45860584	C/T	cg24803719	chr17:45855879	NA	-0.46	-7.76	-0.45	2.74e-13	IgG glycosylation;
SARC	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg05890377	chr2:74357713	NA	0.58	7.09	0.42	1.57e-11	Gestational age at birth (maternal effect);
SARC	cis	rs9814567	0.964	rs9815983	chr3:134222507	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-7.03	-0.42	2.3e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs7712401	0.601	rs246287	chr5:122245426	A/T	cg19412675	chr5:122181750	SNX24	0.42	5.4	0.33	1.65e-7	Mean platelet volume;
SARC	trans	rs17685	0.671	rs10274404	chr7:75706634	G/A	cg19862616	chr7:65841803	NCRNA00174	0.63	7.77	0.45	2.42e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg22708233	chr11:47198576	ARFGAP2	0.47	6.4	0.39	8.58e-10	Chemerin levels;
SARC	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg11843238	chr5:131593191	PDLIM4	0.4	4.97	0.31	1.27e-6	Breast cancer;
SARC	cis	rs1018836	0.770	rs12543806	chr8:91664011	C/T	cg16814680	chr8:91681699	NA	-0.97	-17.8	-0.76	2.42e-45	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg06074448	chr4:187884817	NA	-0.38	-5.18	-0.32	4.72e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1707322	0.964	rs7546237	chr1:46285610	A/C	cg03146154	chr1:46216737	IPP	0.47	5.62	0.35	5.38e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2180341	0.883	rs9388568	chr6:127690694	C/A	cg24812749	chr6:127587940	RNF146	1.02	13.46	0.66	6.06e-31	Breast cancer;
SARC	cis	rs11874712	1.000	rs28757346	chr18:43696540	C/T	cg25174615	chr18:43684699	ATP5A1;HAUS1	0.45	5.28	0.33	2.94e-7	Migraine - clinic-based;
SARC	cis	rs3768617	0.510	rs3768620	chr1:183092237	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.68	10.11	0.55	3.67e-20	Fuchs's corneal dystrophy;
SARC	cis	rs2463822	1.000	rs2513076	chr11:62103711	A/G	cg06239285	chr11:62104954	ASRGL1	0.9	9.65	0.53	9.5e-19	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs3858526	0.883	rs7481923	chr11:5933342	T/C	cg13902645	chr11:5959945	NA	-0.44	-5.16	-0.32	5.23e-7	DNA methylation (variation);
SARC	cis	rs17376456	0.877	rs7701974	chr5:93311417	C/T	cg25358565	chr5:93447407	FAM172A	1.29	14.58	0.69	1.2e-34	Diabetic retinopathy;
SARC	cis	rs9296092	0.538	rs62405942	chr6:33517346	G/A	cg13560919	chr6:33536144	NA	-0.51	-6.21	-0.38	2.4e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs9527	0.590	rs11191540	chr10:104822809	G/C	cg04362960	chr10:104952993	NT5C2	0.43	5.0	0.31	1.11e-6	Arsenic metabolism;
SARC	cis	rs826838	1.000	rs7953227	chr12:38946193	G/A	cg13010199	chr12:38710504	ALG10B	0.77	10.72	0.57	4.6e-22	Heart rate;
SARC	cis	rs2070488	1.000	rs36006749	chr3:38443312	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	14.46	0.69	2.97e-34	Electrocardiographic conduction measures;
SARC	cis	rs7592578	0.679	rs59929070	chr2:191327852	A/G	cg27211696	chr2:191398769	TMEM194B	-0.48	-5.07	-0.31	8.3e-7	Diastolic blood pressure;
SARC	cis	rs6582630	0.585	rs12422588	chr12:38478675	C/T	cg13010199	chr12:38710504	ALG10B	-0.48	-5.91	-0.36	1.2e-8	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs7819412	0.521	rs4451268	chr8:11034859	A/G	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.26	-0.38	1.81e-9	Triglycerides;
SARC	cis	rs11711311	0.955	rs2124105	chr3:113406003	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	8.2	0.47	1.59e-14	IgG glycosylation;
SARC	cis	rs11997175	0.624	rs4733175	chr8:33679744	T/A	ch.8.33884649F	chr8:33765107	NA	0.61	8.23	0.47	1.33e-14	Body mass index;
SARC	cis	rs11711311	1.000	rs12695295	chr3:113474866	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	8.37	0.48	5.21e-15	IgG glycosylation;
SARC	cis	rs1451375	0.583	rs7776816	chr7:50583534	G/A	cg18232548	chr7:50535776	DDC	0.48	4.8	0.3	2.78e-6	Malaria;
SARC	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg03351412	chr1:154909251	PMVK	0.59	7.19	0.43	8.68e-12	Prostate cancer;
SARC	cis	rs2153535	0.562	rs9379211	chr6:8463927	C/T	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	cis	rs17376456	0.877	rs114256265	chr5:93473130	T/A	cg25358565	chr5:93447407	FAM172A	1.34	15.05	0.7	3.15e-36	Diabetic retinopathy;
SARC	cis	rs9818758	0.505	rs67286839	chr3:49265744	C/T	cg01304814	chr3:48885189	PRKAR2A	0.63	5.18	0.32	4.72e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg08564027	chr20:61660810	NA	0.76	11.8	0.61	1.69e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs6582630	0.638	rs12231073	chr12:38526901	T/G	cg26384229	chr12:38710491	ALG10B	-0.62	-7.97	-0.46	7.27e-14	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg18252515	chr7:66147081	NA	0.45	4.97	0.31	1.3e-6	Aortic root size;
SARC	cis	rs447735	0.587	rs258335	chr16:89720944	G/A	cg03605463	chr16:89740564	NA	0.37	4.98	0.31	1.24e-6	Hemoglobin concentration;
SARC	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg21782813	chr7:2030301	MAD1L1	0.48	7.54	0.44	1.07e-12	Bipolar disorder and schizophrenia;
SARC	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg18758796	chr5:131593413	PDLIM4	0.38	4.93	0.31	1.55e-6	Acylcarnitine levels;
SARC	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg20607798	chr8:58055168	NA	0.61	5.41	0.33	1.57e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg11644478	chr21:40555479	PSMG1	-0.88	-11.31	-0.6	6.12e-24	Cognitive function;
SARC	cis	rs4474633	1	rs4474633	chr15:49260601	A/G	cg19135536	chr15:49267992	NA	-0.4	-4.89	-0.3	1.9e-6	Major depressive disorder;
SARC	cis	rs7914558	1.000	rs10883826	chr10:104830819	A/G	cg04362960	chr10:104952993	NT5C2	0.41	5.11	0.32	6.75e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs9467773	0.620	rs9461275	chr6:26590801	C/T	cg11502198	chr6:26597334	ABT1	0.66	8.89	0.5	1.66e-16	Intelligence (multi-trait analysis);
SARC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg01577475	chr2:114033581	PAX8;LOC440839	0.36	5.36	0.33	1.97e-7	Lymphocyte counts;
SARC	cis	rs959260	0.920	rs4789187	chr17:73394784	A/G	cg14668889	chr17:73230827	NUP85	-0.43	-4.83	-0.3	2.48e-6	Systemic lupus erythematosus;
SARC	cis	rs6670533	0.571	rs80091715	chr1:24860343	G/A	cg07475527	chr1:24864545	NA	-1.0	-5.65	-0.35	4.76e-8	Fasting blood insulin (BMI interaction);
SARC	cis	rs17376456	0.825	rs17314762	chr5:93231200	C/T	cg25358565	chr5:93447407	FAM172A	1.29	13.96	0.67	1.34e-32	Diabetic retinopathy;
SARC	cis	rs11792861	0.816	rs11788336	chr9:111688387	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.76	9.23	0.52	1.69e-17	Menarche (age at onset);
SARC	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg24675658	chr1:53192096	ZYG11B	-0.62	-8.75	-0.5	4.41e-16	Monocyte count;
SARC	cis	rs2282526	0.587	rs91424	chr21:44921161	A/G	cg21573476	chr21:45109991	RRP1B	0.38	5.24	0.32	3.63e-7	Mean corpuscular hemoglobin;
SARC	cis	rs9486715	0.867	rs9384585	chr6:96875664	C/T	cg18709589	chr6:96969512	KIAA0776	0.58	7.27	0.43	5.5e-12	Headache;
SARC	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg13206674	chr6:150067644	NUP43	0.48	6.36	0.38	1.07e-9	Lung cancer;
SARC	cis	rs9814567	0.929	rs9855013	chr3:134240414	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.14	-0.42	1.21e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs7819412	0.775	rs4841489	chr8:10936811	A/G	cg21775007	chr8:11205619	TDH	-0.45	-5.73	-0.35	3.02e-8	Triglycerides;
SARC	cis	rs11578119	0.933	rs10919416	chr1:170441709	T/C	cg09767346	chr1:170501363	GORAB	0.45	5.25	0.33	3.42e-7	Male-pattern baldness;
SARC	cis	rs9467603	1.000	rs9467613	chr6:25812641	T/C	cg21479132	chr6:26055353	NA	0.77	5.1	0.32	7.06e-7	Intelligence (multi-trait analysis);
SARC	cis	rs28374715	0.532	rs7168431	chr15:41672384	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.17	-18.76	-0.78	1.76e-48	Ulcerative colitis;
SARC	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg04267008	chr7:1944627	MAD1L1	-0.61	-7.11	-0.42	1.38e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs10865397	0.506	rs60764301	chr2:73384850	G/A	cg01422370	chr2:73384389	NA	0.37	6.13	0.37	3.66e-9	Intelligence (multi-trait analysis);
SARC	cis	rs4242434	0.927	rs720746	chr8:22471399	T/C	cg03733263	chr8:22462867	KIAA1967	1.05	18.1	0.76	2.66e-46	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs3768617	0.510	rs20557	chr1:183093875	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.82e-21	Fuchs's corneal dystrophy;
SARC	cis	rs12586317	0.547	rs10142667	chr14:35445090	A/G	cg16230307	chr14:35515116	FAM177A1	0.93	10.34	0.56	7.24e-21	Psoriasis;
SARC	cis	rs7546668	0.640	rs10803386	chr1:15811692	C/T	cg18192808	chr1:15853278	DNAJC16	0.43	4.85	0.3	2.26e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs12908161	0.959	rs17534709	chr15:85314397	G/C	cg17507749	chr15:85114479	UBE2QP1	0.57	6.47	0.39	5.6e-10	Schizophrenia;
SARC	cis	rs2841277	0.738	rs1036713	chr14:105396693	C/G	cg19901468	chr14:105411992	AHNAK2	0.58	8.05	0.47	4.35e-14	Rheumatoid arthritis;
SARC	cis	rs9815354	0.812	rs73073226	chr3:42005838	T/C	cg03022575	chr3:42003672	ULK4	0.65	5.61	0.34	5.72e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs7315438	0.600	rs10850515	chr12:115873190	C/G	cg00387115	chr12:115889598	NA	-0.35	-4.74	-0.3	3.73e-6	Colorectal cancer;
SARC	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.51	5.0	0.31	1.14e-6	Lung function (FEV1/FVC);
SARC	cis	rs9394841	0.667	rs9471653	chr6:41755410	C/G	cg08135965	chr6:41755394	TOMM6	0.62	6.55	0.39	3.7e-10	Mean corpuscular hemoglobin;Red cell distribution width;
SARC	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg13628971	chr7:2884303	GNA12	0.58	6.81	0.41	8.4e-11	Height;
SARC	trans	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-7.59	-0.45	7.48e-13	Intelligence (multi-trait analysis);
SARC	cis	rs1983891	0.955	rs6917270	chr6:41548755	A/G	cg15051332	chr6:41514432	FOXP4	0.52	5.76	0.35	2.59e-8	Prostate cancer;
SARC	cis	rs9640161	0.789	rs10282458	chr7:150045302	C/T	cg17279839	chr7:150038598	RARRES2	0.42	6.18	0.38	2.86e-9	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs1008375	0.863	rs4590022	chr4:17614434	T/C	cg02297831	chr4:17616191	MED28	0.5	6.39	0.39	9.15e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4919087	0.810	rs1572437	chr10:99029278	A/G	cg25902810	chr10:99078978	FRAT1	0.47	5.59	0.34	6.31e-8	Monocyte count;
SARC	trans	rs12554020	0.786	rs12553389	chr9:96263261	G/A	cg26442883	chr16:49686662	ZNF423	0.56	6.24	0.38	2.1e-9	Schizophrenia;
SARC	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg17971929	chr21:40555470	PSMG1	-0.86	-11.03	-0.59	4.8e-23	Cognitive function;
SARC	cis	rs11608355	0.545	rs35590455	chr12:109893514	A/G	cg05360138	chr12:110035743	NA	0.92	9.61	0.53	1.27e-18	Neuroticism;
SARC	cis	rs743757	1.000	rs2236964	chr3:50449062	C/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.54	-5.07	-0.32	8.22e-7	Diastolic blood pressure;
SARC	cis	rs17030434	0.749	rs1125228	chr4:154769052	C/T	cg14289246	chr4:154710475	SFRP2	-0.47	-5.48	-0.34	1.11e-7	Electrocardiographic conduction measures;
SARC	cis	rs2479724	0.905	rs2149274	chr6:41839092	T/C	cg17623882	chr6:41773611	USP49	-0.46	-5.71	-0.35	3.39e-8	Menarche (age at onset);
SARC	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg13393036	chr8:95962371	TP53INP1	-0.36	-6.21	-0.38	2.35e-9	Type 2 diabetes;
SARC	cis	rs7635838	0.827	rs9826044	chr3:11458075	A/G	cg00170343	chr3:11313890	ATG7	0.64	8.69	0.49	6.5e-16	HDL cholesterol;
SARC	cis	rs76419734	1.000	rs72671871	chr4:106660324	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.84	5.42	0.33	1.51e-7	Post bronchodilator FEV1;
SARC	cis	rs9457247	0.624	rs9457260	chr6:167466665	C/T	cg07741184	chr6:167504864	NA	0.37	7.07	0.42	1.77e-11	Crohn's disease;
SARC	cis	rs9325144	0.647	rs11169189	chr12:39097078	A/T	cg26384229	chr12:38710491	ALG10B	-0.58	-7.28	-0.43	5.24e-12	Morning vs. evening chronotype;
SARC	cis	rs7831492	0.564	rs7831530	chr8:41614567	G/A	cg17182837	chr8:41585554	ANK1	-0.37	-4.85	-0.3	2.28e-6	Colorectal cancer;
SARC	cis	rs933688	0.759	rs1423593	chr5:90752351	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.97	11.93	0.62	6.22e-26	Smoking behavior;
SARC	cis	rs2153535	0.601	rs4140584	chr6:8540614	C/G	cg07606381	chr6:8435919	SLC35B3	-0.75	-10.42	-0.56	4.17e-21	Motion sickness;
SARC	cis	rs921968	0.541	rs2710246	chr2:219533894	C/T	cg02176678	chr2:219576539	TTLL4	0.43	6.35	0.38	1.11e-9	Mean corpuscular hemoglobin concentration;
SARC	cis	rs7582720	1.000	rs3845800	chr2:203734365	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	-0.68	-6.79	-0.41	9.1e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs780096	0.778	rs780094	chr2:27741237	C/T	cg17158414	chr2:27665306	KRTCAP3	0.29	4.94	0.31	1.49e-6	Total body bone mineral density;
SARC	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg16325326	chr1:53192061	ZYG11B	-0.85	-14.04	-0.68	7.45e-33	Monocyte count;
SARC	cis	rs4727027	0.800	rs12530946	chr7:148887942	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	5.47	0.34	1.14e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs13191362	1.000	rs34725898	chr6:163127302	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.73	6.44	0.39	6.84e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs526231	0.543	rs62362544	chr5:102334247	C/T	cg23492399	chr5:102201601	PAM	-0.52	-6.36	-0.38	1.03e-9	Primary biliary cholangitis;
SARC	cis	rs62244186	0.683	rs6766334	chr3:44567065	T/C	cg15225532	chr3:44803084	KIF15;KIAA1143	0.43	5.32	0.33	2.46e-7	Depressive symptoms;
SARC	cis	rs9400467	0.506	rs10457238	chr6:111762593	C/G	cg15721981	chr6:111408429	SLC16A10	0.65	5.65	0.35	4.61e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs644799	0.544	rs499637	chr11:95569183	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	6.12	0.37	3.87e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg07234876	chr8:600039	NA	0.98	7.62	0.45	6.53e-13	IgG glycosylation;
SARC	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg13206674	chr6:150067644	NUP43	0.46	6.07	0.37	5.05e-9	Lung cancer;
SARC	cis	rs9467773	0.565	rs6925047	chr6:26521435	C/G	cg11502198	chr6:26597334	ABT1	0.58	7.49	0.44	1.39e-12	Intelligence (multi-trait analysis);
SARC	cis	rs912057	0.833	rs1294424	chr6:6744135	G/A	cg06612196	chr6:6737390	NA	0.66	9.46	0.53	3.57e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs8017423	0.967	rs4904663	chr14:90729565	G/T	cg20276874	chr14:90721474	PSMC1	-0.38	-5.25	-0.33	3.39e-7	Mortality in heart failure;
SARC	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg00933542	chr6:150070202	PCMT1	0.31	5.28	0.33	2.91e-7	Lung cancer;
SARC	cis	rs7829975	0.811	rs7011229	chr8:8543324	T/C	cg08975724	chr8:8085496	FLJ10661	-0.41	-5.0	-0.31	1.13e-6	Mood instability;
SARC	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg08859206	chr1:53392774	SCP2	0.41	5.95	0.36	9.87e-9	Monocyte count;
SARC	cis	rs7712401	0.791	rs6887101	chr5:122109207	C/T	cg19412675	chr5:122181750	SNX24	-0.37	-4.94	-0.31	1.52e-6	Mean platelet volume;
SARC	cis	rs72781680	0.948	rs113530757	chr2:24142500	G/A	cg08917208	chr2:24149416	ATAD2B	0.77	7.18	0.43	9.09e-12	Lymphocyte counts;
SARC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg23034840	chr1:205782522	SLC41A1	-0.76	-11.26	-0.59	8.96e-24	Monocyte percentage of white cells;
SARC	cis	rs734999	0.524	rs4648448	chr1:2695687	C/T	cg00980319	chr1:2560884	MMEL1	-0.37	-5.23	-0.32	3.74e-7	Ulcerative colitis;
SARC	cis	rs262150	0.503	rs11769917	chr7:158817498	C/T	cg04111992	chr7:158790115	NA	-0.34	-4.84	-0.3	2.33e-6	Facial morphology (factor 20);
SARC	cis	rs9894429	1.000	rs12948099	chr17:79600799	C/G	cg18240062	chr17:79603768	NPLOC4	0.74	10.13	0.55	3.25e-20	Eye color traits;
SARC	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg00933542	chr6:150070202	PCMT1	0.3	4.83	0.3	2.5e-6	Lung cancer;
SARC	cis	rs6120849	0.754	rs6088678	chr20:33607551	A/G	cg06115741	chr20:33292138	TP53INP2	-0.55	-5.29	-0.33	2.79e-7	Protein C levels;
SARC	cis	rs526231	0.543	rs34377	chr5:102400556	C/T	cg23492399	chr5:102201601	PAM	-0.51	-5.53	-0.34	8.78e-8	Primary biliary cholangitis;
SARC	cis	rs36051895	0.632	rs7849717	chr9:5170080	G/A	cg02405213	chr9:5042618	JAK2	-0.51	-5.82	-0.36	1.93e-8	Pediatric autoimmune diseases;
SARC	cis	rs2933343	0.951	rs789251	chr3:128576770	G/A	cg25356066	chr3:128598488	ACAD9	0.59	6.75	0.4	1.16e-10	IgG glycosylation;
SARC	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg22857025	chr5:266934	NA	-1.08	-11.86	-0.61	1.06e-25	Breast cancer;
SARC	cis	rs763121	0.853	rs3788544	chr22:39064966	C/T	cg06022373	chr22:39101656	GTPBP1	0.83	10.12	0.55	3.49e-20	Menopause (age at onset);
SARC	cis	rs6752107	0.936	rs6431660	chr2:234167234	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.48	6.24	0.38	2.01e-9	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg12064134	chr16:90016061	DEF8	-0.56	-4.79	-0.3	2.97e-6	Skin colour saturation;
SARC	cis	rs12142240	0.698	rs72677589	chr1:46817770	T/C	cg10495392	chr1:46806563	NSUN4	0.65	6.88	0.41	5.33e-11	Menopause (age at onset);
SARC	cis	rs10489202	0.608	rs7553238	chr1:168076768	G/A	cg24449463	chr1:168025552	DCAF6	-0.57	-7.26	-0.43	5.7e-12	Schizophrenia;
SARC	cis	rs57994353	0.828	rs11146021	chr9:139327858	A/G	cg14169450	chr9:139327907	INPP5E	-0.39	-5.04	-0.31	9.36e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg11494091	chr17:61959527	GH2	0.53	7.94	0.46	8.67e-14	Prudent dietary pattern;
SARC	cis	rs11098499	0.821	rs28665282	chr4:120384186	C/T	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	cis	rs9399135	0.933	rs41294852	chr6:135376379	T/G	cg24558204	chr6:135376177	HBS1L	0.46	6.22	0.38	2.22e-9	Red blood cell count;
SARC	cis	rs1056053	0.514	rs3127331	chr6:166572744	C/T	cg11088901	chr6:166572345	T	-0.42	-5.49	-0.34	1.04e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs2204008	0.623	rs4882302	chr12:38415608	T/A	cg13010199	chr12:38710504	ALG10B	-0.47	-5.75	-0.35	2.81e-8	Bladder cancer;
SARC	cis	rs941408	0.928	rs2260414	chr19:2796316	G/A	cg00079169	chr19:2811669	THOP1	0.48	5.29	0.33	2.86e-7	Total cholesterol levels;
SARC	cis	rs4642101	0.662	rs3901664	chr3:12824660	T/C	cg24848339	chr3:12840334	CAND2	0.36	5.72	0.35	3.28e-8	QRS complex (12-leadsum);
SARC	cis	rs733592	0.965	rs1978161	chr12:48467721	A/G	cg24011408	chr12:48396354	COL2A1	-0.46	-6.1	-0.37	4.34e-9	Plateletcrit;
SARC	cis	rs10463554	0.892	rs13340345	chr5:102339222	T/A	cg23492399	chr5:102201601	PAM	-0.47	-5.32	-0.33	2.43e-7	Parkinson's disease;
SARC	cis	rs1580019	0.587	rs10951338	chr7:32560089	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.99	18.08	0.76	2.9e-46	Cognitive ability;
SARC	cis	rs4803468	1.000	rs284657	chr19:41929915	G/C	cg09537434	chr19:41945824	ATP5SL	-0.99	-17.65	-0.76	7.69e-45	Height;
SARC	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg24250549	chr1:154909240	PMVK	0.74	9.77	0.54	4.02e-19	Prostate cancer;
SARC	cis	rs7843479	0.601	rs10866837	chr8:21861663	G/C	cg17168535	chr8:21777572	XPO7	0.85	13.2	0.65	4.62e-30	Mean corpuscular volume;
SARC	cis	rs10875746	0.951	rs2228500	chr12:48526712	A/G	cg26205652	chr12:48591994	NA	-0.55	-5.93	-0.36	1.1e-8	Longevity (90 years and older);
SARC	cis	rs7793919	0.652	rs10228886	chr7:4783224	C/T	cg09789173	chr7:4769017	FOXK1	-0.37	-5.02	-0.31	1.03e-6	Mosquito bite size;
SARC	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg21724239	chr8:58056113	NA	0.6	6.31	0.38	1.43e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7412746	0.621	rs11204749	chr1:150929563	G/A	cg10589385	chr1:150898437	SETDB1	0.39	5.23	0.32	3.77e-7	Melanoma;
SARC	cis	rs995000	0.931	rs583609	chr1:62916796	T/C	cg06896770	chr1:63153194	DOCK7	0.9	13.82	0.67	3.84e-32	Triglyceride levels;
SARC	cis	rs17600642	0.614	rs10823597	chr10:72442042	C/T	cg19779893	chr10:72451501	ADAMTS14	0.3	5.08	0.32	7.84e-7	Bipolar disorder;
SARC	cis	rs2204008	0.668	rs1619009	chr12:38120485	G/A	cg14851346	chr12:38532713	NA	-0.44	-5.33	-0.33	2.32e-7	Bladder cancer;
SARC	cis	rs35110281	0.811	rs2838339	chr21:45075750	A/G	cg21573476	chr21:45109991	RRP1B	0.56	8.31	0.48	8.05e-15	Mean corpuscular volume;
SARC	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg13699009	chr12:122356056	WDR66	-0.55	-8.9	-0.5	1.64e-16	Mean corpuscular volume;
SARC	cis	rs7260598	0.539	rs114482892	chr19:24063749	C/G	cg27517351	chr19:23941871	ZNF681	0.54	4.73	0.3	3.86e-6	Response to taxane treatment (placlitaxel);
SARC	cis	rs2425143	0.908	rs75331436	chr20:34391052	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	5.15	0.32	5.6e-7	Blood protein levels;
SARC	cis	rs778371	0.723	rs12619195	chr2:233678326	G/A	cg16596103	chr2:233749413	NGEF	0.35	5.32	0.33	2.49e-7	Schizophrenia;
SARC	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-6.7	-0.4	1.53e-10	Personality dimensions;
SARC	cis	rs55882075	0.690	rs12374485	chr5:179131395	G/C	cg14593053	chr5:179126677	CANX	0.52	7.2	0.43	8.45e-12	Monocyte percentage of white cells;
SARC	cis	rs6582630	0.555	rs10748382	chr12:38504529	C/T	cg13010199	chr12:38710504	ALG10B	0.76	10.48	0.57	2.62e-21	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs798554	0.704	rs709282	chr7:2769921	G/A	cg13628971	chr7:2884303	GNA12	0.47	5.8	0.36	2.17e-8	Height;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg05857826	chr20:30795350	POFUT1;PLAGL2	0.49	6.27	0.38	1.7e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg18252515	chr7:66147081	NA	-1.29	-11.06	-0.59	3.93e-23	Diabetic kidney disease;
SARC	cis	rs4727027	0.933	rs12532104	chr7:148864233	A/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	5.6	0.34	5.95e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs12586317	0.547	rs74462850	chr14:35500093	G/T	cg16230307	chr14:35515116	FAM177A1	1.02	11.85	0.61	1.18e-25	Psoriasis;
SARC	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg06558623	chr16:89946397	TCF25	0.98	8.13	0.47	2.6e-14	Skin colour saturation;
SARC	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.93	-15.22	-0.71	8.66e-37	Chronic sinus infection;
SARC	cis	rs12971120	0.891	rs71359051	chr18:72169723	G/A	cg26446133	chr18:72167187	CNDP2	-0.51	-7.23	-0.43	6.89e-12	Refractive error;
SARC	cis	rs2354432	0.607	rs58941651	chr1:146784919	T/C	cg25205988	chr1:146714368	CHD1L	-1.02	-7.73	-0.45	3.15e-13	Mitochondrial DNA levels;
SARC	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	5.93	0.36	1.1e-8	Height;
SARC	cis	rs922107	0.713	rs2061478	chr1:90044453	G/T	cg15422784	chr1:90023713	LRRC8B	-0.32	-4.82	-0.3	2.59e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
SARC	cis	rs3008870	0.755	rs2815368	chr1:67500778	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.6	7.71	0.45	3.55e-13	Lymphocyte percentage of white cells;
SARC	cis	rs9322193	0.543	rs9371533	chr6:150210681	G/A	cg09699651	chr6:150184138	LRP11	0.48	6.05	0.37	5.65e-9	Lung cancer;
SARC	cis	rs2303759	0.670	rs45549132	chr19:49794028	G/T	cg22590775	chr19:49891494	CCDC155	0.47	5.19	0.32	4.51e-7	Multiple sclerosis;
SARC	cis	rs2760061	0.626	rs591582	chr1:228117360	C/A	cg02753203	chr1:228287806	NA	-0.54	-7.45	-0.44	1.79e-12	Diastolic blood pressure;
SARC	cis	rs765787	0.530	rs12440238	chr15:45512905	T/C	cg24006582	chr15:45444508	DUOX1	0.43	5.5	0.34	9.82e-8	Uric acid levels;
SARC	cis	rs908922	0.676	rs12059256	chr1:152515431	G/A	cg09873164	chr1:152488093	CRCT1	0.64	8.6	0.49	1.16e-15	Hair morphology;
SARC	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	12.74	0.64	1.44e-28	Platelet count;
SARC	trans	rs9929218	0.906	rs9932679	chr16:68751904	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.65	-8.41	-0.48	4.21e-15	Colorectal cancer;
SARC	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg01017244	chr2:74357527	NA	0.54	6.7	0.4	1.55e-10	Gestational age at birth (maternal effect);
SARC	cis	rs12142240	0.731	rs6658556	chr1:46844180	A/C	cg10495392	chr1:46806563	NSUN4	0.67	6.96	0.41	3.45e-11	Menopause (age at onset);
SARC	cis	rs6088590	0.648	rs6059991	chr20:33280836	C/T	cg24642439	chr20:33292090	TP53INP2	0.76	10.34	0.56	7.1e-21	Coronary artery disease;
SARC	cis	rs76917914	0.589	rs6478563	chr9:100864919	T/C	cg03040243	chr9:100819229	NANS	0.56	6.04	0.37	5.91e-9	Immature fraction of reticulocytes;
SARC	cis	rs17854409	0.881	rs68066790	chr20:61487150	T/A	cg05147244	chr20:61493195	TCFL5	0.93	6.26	0.38	1.83e-9	Obesity-related traits;
SARC	cis	rs72945132	0.882	rs72945168	chr11:70131471	G/C	cg00319359	chr11:70116639	PPFIA1	0.68	6.37	0.39	1.01e-9	Coronary artery disease;
SARC	cis	rs7772486	0.658	rs9403737	chr6:145962193	G/T	cg23711669	chr6:146136114	FBXO30	0.86	14.16	0.68	3.03e-33	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg04317338	chr11:64019027	PLCB3	0.83	9.01	0.51	7.5e-17	Mean platelet volume;
SARC	cis	rs11190604	1.000	rs4919472	chr10:102315864	T/A	cg07080220	chr10:102295463	HIF1AN	0.81	8.82	0.5	2.65e-16	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs763121	0.925	rs5757165	chr22:38994577	C/T	cg06022373	chr22:39101656	GTPBP1	0.83	10.61	0.57	1.05e-21	Menopause (age at onset);
SARC	cis	rs1983891	0.954	rs1886816	chr6:41544494	A/G	cg15051332	chr6:41514432	FOXP4	0.52	5.69	0.35	3.72e-8	Prostate cancer;
SARC	cis	rs2576037	0.796	rs2576041	chr18:44580919	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.67	-9.69	-0.54	6.96e-19	Personality dimensions;
SARC	cis	rs9399137	0.507	rs28384513	chr6:135376209	T/G	cg22676075	chr6:135203613	NA	0.41	5.11	0.32	6.68e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs798554	0.686	rs2644298	chr7:2858448	G/C	cg04166393	chr7:2884313	GNA12	0.42	5.21	0.32	4.11e-7	Height;
SARC	cis	rs7666738	0.546	rs17546687	chr4:98769266	T/A	cg05340658	chr4:99064831	C4orf37	0.59	7.15	0.42	1.13e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2991971	0.782	rs10789463	chr1:45927848	C/A	cg05343316	chr1:45956843	TESK2	0.39	4.89	0.31	1.86e-6	High light scatter reticulocyte count;
SARC	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg11890956	chr21:40555474	PSMG1	-1.03	-15.28	-0.71	5.7e-37	Cognitive function;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg26151163	chr2:239079168	ILKAP	0.46	6.48	0.39	5.43e-10	Thyroid stimulating hormone;
SARC	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg03934478	chr11:495069	RNH1	0.56	5.32	0.33	2.46e-7	Body mass index;
SARC	cis	rs2963155	0.518	rs853184	chr5:142640901	C/T	cg17617527	chr5:142782415	NR3C1	0.86	6.08	0.37	4.86e-9	Breast cancer;
SARC	cis	rs9914988	0.832	rs12946132	chr17:27157362	T/C	cg20469991	chr17:27169893	C17orf63	-0.52	-5.39	-0.33	1.74e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs6582630	0.538	rs8189550	chr12:38333058	T/G	cg26384229	chr12:38710491	ALG10B	-0.58	-7.12	-0.42	1.35e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9859260	0.614	rs493661	chr3:195786489	T/A	cg03462622	chr3:195777018	TFRC	-0.47	-5.5	-0.34	1.01e-7	Mean corpuscular volume;
SARC	cis	rs908922	0.676	rs11205014	chr1:152483634	C/T	cg09873164	chr1:152488093	CRCT1	0.63	8.2	0.47	1.64e-14	Hair morphology;
SARC	cis	rs9326248	0.861	rs7120309	chr11:117042816	T/A	cg01368799	chr11:117014884	PAFAH1B2	0.55	5.5	0.34	9.94e-8	Blood protein levels;
SARC	cis	rs1707322	1.000	rs12060274	chr1:46291062	G/T	cg06784218	chr1:46089804	CCDC17	0.33	5.76	0.35	2.66e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs3540	0.920	rs7182658	chr15:91019248	A/T	cg24888049	chr15:91426667	FES;FURIN	0.36	5.1	0.32	7.12e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs9612	1.000	rs3786954	chr19:44272346	A/G	cg08581076	chr19:44259116	C19orf61	0.68	8.55	0.49	1.64e-15	Exhaled nitric oxide output;
SARC	cis	rs15676	0.783	rs2280845	chr9:131583170	T/C	cg00228799	chr9:131580591	ENDOG	0.58	7.24	0.43	6.44e-12	Blood metabolite levels;
SARC	cis	rs9660992	0.626	rs61823972	chr1:205201325	A/C	cg00857998	chr1:205179979	DSTYK	0.48	5.94	0.36	1.04e-8	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs9399135	0.933	rs9389262	chr6:135376409	G/T	cg24558204	chr6:135376177	HBS1L	0.46	6.12	0.37	3.99e-9	Red blood cell count;
SARC	cis	rs933688	1.000	rs11948075	chr5:90680579	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.06	13.47	0.66	5.91e-31	Smoking behavior;
SARC	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.78	12.02	0.62	3.23e-26	Personality dimensions;
SARC	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg16606324	chr3:10149918	C3orf24	0.48	5.04	0.31	9.53e-7	Alzheimer's disease;
SARC	cis	rs9296092	0.517	rs3912041	chr6:33521271	T/C	cg13560919	chr6:33536144	NA	-0.5	-6.31	-0.38	1.38e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg21724239	chr8:58056113	NA	0.61	6.43	0.39	7.16e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2645694	0.533	rs2645674	chr4:77818202	T/C	cg18351406	chr4:77819688	ANKRD56	0.44	6.09	0.37	4.59e-9	Emphysema distribution in smoking;
SARC	cis	rs1865760	0.865	rs9393677	chr6:25945815	G/A	cg17691542	chr6:26056736	HIST1H1C	0.58	7.3	0.43	4.62e-12	Height;
SARC	trans	rs17221829	0.733	rs11018668	chr11:89356178	C/T	cg00736283	chr19:14247601	ASF1B	-0.47	-6.29	-0.38	1.54e-9	Anxiety in major depressive disorder;
SARC	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg22903471	chr2:27725779	GCKR	-0.49	-7.42	-0.44	2.23e-12	Total body bone mineral density;
SARC	cis	rs477692	0.905	rs555545	chr10:131411586	G/A	cg05714579	chr10:131428358	MGMT	0.62	8.23	0.47	1.33e-14	Response to temozolomide;
SARC	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg03433033	chr1:76189801	ACADM	-0.52	-7.34	-0.43	3.61e-12	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2197308	0.765	rs10880643	chr12:37926452	C/T	cg26384229	chr12:38710491	ALG10B	-0.79	-11.38	-0.6	3.64e-24	Morning vs. evening chronotype;
SARC	cis	rs7712401	0.562	rs62377399	chr5:122324679	G/A	cg19412675	chr5:122181750	SNX24	-0.43	-5.43	-0.34	1.41e-7	Mean platelet volume;
SARC	cis	rs2439831	1.000	rs2467736	chr15:43784917	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	8.42	0.48	3.97e-15	Lung cancer in ever smokers;
SARC	cis	rs7824557	0.602	rs7820895	chr8:11206262	T/C	cg21775007	chr8:11205619	TDH	0.66	8.48	0.49	2.57e-15	Retinal vascular caliber;
SARC	cis	rs2882877	0.621	rs10189190	chr2:190371722	C/T	cg21926118	chr2:190387206	NA	0.39	4.93	0.31	1.6e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg20007245	chr22:24372913	LOC391322	-0.71	-9.62	-0.53	1.17e-18	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-8.98	-0.51	9.19e-17	Alzheimer's disease;
SARC	cis	rs17784882	0.524	rs7433300	chr3:47120640	G/A	cg27129171	chr3:47204927	SETD2	0.68	9.06	0.51	5.49e-17	QT interval;
SARC	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg11890956	chr21:40555474	PSMG1	1.17	19.17	0.78	8.67e-50	Cognitive function;
SARC	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg21782813	chr7:2030301	MAD1L1	-0.41	-6.63	-0.4	2.28e-10	Bipolar disorder and schizophrenia;
SARC	trans	rs2637266	1.000	rs2637266	chr10:78331318	C/T	cg21843347	chr2:33240386	LTBP1	0.41	6.27	0.38	1.72e-9	Pulmonary function;
SARC	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg03806693	chr22:41940476	POLR3H	-0.79	-10.59	-0.57	1.18e-21	Vitiligo;
SARC	cis	rs4808199	1.000	rs4808199	chr19:19545099	C/T	cg03709012	chr19:19516395	GATAD2A	1.13	13.15	0.65	6.71e-30	Nonalcoholic fatty liver disease;
SARC	cis	rs787274	0.718	rs2185768	chr9:115462645	C/T	cg13803584	chr9:115635662	SNX30	0.74	5.96	0.36	9.35e-9	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg04166393	chr7:2884313	GNA12	0.58	6.87	0.41	5.94e-11	Height;
SARC	cis	rs9462027	0.628	rs7739003	chr6:34800329	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-6.13	-0.37	3.64e-9	Systemic lupus erythematosus;
SARC	cis	rs72634258	0.503	rs697674	chr1:7837878	C/G	cg05338066	chr1:7812865	CAMTA1	0.66	5.65	0.35	4.76e-8	Inflammatory bowel disease;
SARC	cis	rs9858542	0.537	rs67882627	chr3:49380441	A/T	cg00383909	chr3:49044727	WDR6	0.53	5.23	0.32	3.84e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg13939156	chr17:80058883	NA	-0.42	-6.48	-0.39	5.51e-10	Life satisfaction;
SARC	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg06634786	chr22:41940651	POLR3H	-0.63	-7.58	-0.44	8.31e-13	Vitiligo;
SARC	cis	rs9902453	0.780	rs7210991	chr17:28190961	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	7.39	0.44	2.64e-12	Coffee consumption (cups per day);
SARC	cis	rs854765	0.583	rs7214536	chr17:17852446	G/A	cg04398451	chr17:18023971	MYO15A	-0.4	-5.51	-0.34	9.71e-8	Total body bone mineral density;
SARC	trans	rs61931739	0.534	rs11053131	chr12:34282109	A/G	cg26384229	chr12:38710491	ALG10B	0.72	9.85	0.54	2.3e-19	Morning vs. evening chronotype;
SARC	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	12.25	0.63	5.6e-27	Chronic sinus infection;
SARC	cis	rs3087591	0.960	rs2953009	chr17:29498387	A/C	cg24425628	chr17:29625626	OMG;NF1	0.51	6.3	0.38	1.49e-9	Hip circumference;
SARC	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg24209194	chr3:40518798	ZNF619	0.65	7.8	0.45	2.13e-13	Renal cell carcinoma;
SARC	cis	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg03213289	chr20:61660250	NA	0.46	6.43	0.39	7.22e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs2645694	0.626	rs2645684	chr4:77819892	A/C	cg10057126	chr4:77819792	ANKRD56	0.43	6.47	0.39	5.85e-10	Emphysema distribution in smoking;
SARC	cis	rs921968	0.608	rs11678428	chr2:219352598	C/T	cg02176678	chr2:219576539	TTLL4	0.38	5.66	0.35	4.36e-8	Mean corpuscular hemoglobin concentration;
SARC	cis	rs703842	1.000	rs10877012	chr12:58162085	G/T	cg00677455	chr12:58241039	CTDSP2	0.53	6.86	0.41	6.24e-11	Multiple sclerosis;
SARC	cis	rs9905704	0.647	rs7221274	chr17:57008128	A/G	cg12560992	chr17:57184187	TRIM37	0.4	4.8	0.3	2.88e-6	Testicular germ cell tumor;
SARC	cis	rs9300255	0.602	rs1716164	chr12:123663660	G/A	cg05973401	chr12:123451056	ABCB9	0.52	5.89	0.36	1.34e-8	Neutrophil percentage of white cells;
SARC	cis	rs2120019	1.000	rs7168680	chr15:75369212	G/A	cg09165964	chr15:75287851	SCAMP5	-0.87	-13.08	-0.65	1.1e-29	Blood trace element (Zn levels);
SARC	cis	rs7712401	0.562	rs30046	chr5:122271233	G/C	cg19412675	chr5:122181750	SNX24	0.4	5.2	0.32	4.32e-7	Mean platelet volume;
SARC	cis	rs4595586	0.545	rs925828	chr12:39364222	A/G	cg13010199	chr12:38710504	ALG10B	0.4	4.75	0.3	3.57e-6	Morning vs. evening chronotype;
SARC	cis	rs3099143	1.000	rs4886831	chr15:77106801	T/C	cg21673338	chr15:77095150	SCAPER	0.61	5.21	0.32	4.17e-7	Recalcitrant atopic dermatitis;
SARC	cis	rs7246657	0.508	rs1628959	chr19:37490376	G/A	cg23950597	chr19:37808831	NA	-0.54	-4.85	-0.3	2.24e-6	Coronary artery calcification;
SARC	cis	rs8141529	0.504	rs6005915	chr22:29233262	A/G	cg15103426	chr22:29168792	CCDC117	0.63	7.53	0.44	1.08e-12	Lymphocyte counts;
SARC	cis	rs2735413	0.514	rs7192129	chr16:78136414	A/G	cg04733911	chr16:78082701	NA	0.28	5.11	0.32	6.58e-7	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs7582180	0.629	rs4851298	chr2:100949827	G/A	cg14675211	chr2:100938903	LONRF2	0.51	7.63	0.45	6.1e-13	Intelligence (multi-trait analysis);
SARC	cis	rs7772486	0.686	rs9485019	chr6:146046381	C/G	cg23711669	chr6:146136114	FBXO30	-0.8	-12.55	-0.64	6e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9398803	0.723	rs4460221	chr6:127031221	G/A	cg20229609	chr6:126660872	C6orf173	-0.34	-4.83	-0.3	2.51e-6	Male-pattern baldness;
SARC	cis	rs3862030	0.720	rs11593526	chr10:104228017	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.46	-6.12	-0.37	3.9e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
SARC	cis	rs2276314	1.000	rs4799834	chr18:33566243	T/C	cg19628046	chr18:33552617	C18orf21	0.56	5.92	0.36	1.16e-8	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs2865116	0.855	rs11762075	chr7:68968288	T/C	cg10619644	chr7:69149951	AUTS2	0.34	4.72	0.3	4.02e-6	Positive affect;
SARC	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg16145915	chr7:1198662	ZFAND2A	-0.37	-5.54	-0.34	8.09e-8	Longevity;Endometriosis;
SARC	cis	rs796364	0.806	rs11689664	chr2:201099961	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.78	-6.59	-0.4	2.97e-10	Schizophrenia;
SARC	cis	rs12594515	1.000	rs11855562	chr15:45995659	C/T	cg14863074	chr15:45997064	NA	0.34	5.18	0.32	4.84e-7	Waist circumference;Weight;
SARC	cis	rs6831352	0.879	rs56222233	chr4:100069627	T/G	cg13256891	chr4:100009986	ADH5	-0.65	-7.8	-0.45	2.07e-13	Alcohol dependence;
SARC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.8	10.38	0.56	5.49e-21	Prudent dietary pattern;
SARC	cis	rs7644634	0.535	rs13064310	chr3:105439595	T/A	cg23051926	chr3:105466016	CBLB	0.47	5.27	0.33	3.18e-7	Itch intensity from mosquito bite;
SARC	cis	rs10791097	0.547	rs1050078	chr11:130746146	T/C	cg12179176	chr11:130786555	SNX19	0.73	10.73	0.58	4.22e-22	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg18370025	chr7:2749541	AMZ1	-0.29	-4.72	-0.3	4.08e-6	Height;
SARC	cis	rs1971762	0.563	rs10747679	chr12:54077750	C/T	cg06632207	chr12:54070931	ATP5G2	0.44	5.82	0.36	1.92e-8	Height;
SARC	cis	rs2999052	0.951	rs7355887	chr3:127808502	C/G	cg19755928	chr3:128723491	CCDC48	-0.38	-4.74	-0.3	3.69e-6	Hypospadias;
SARC	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg03264133	chr6:25882463	NA	0.55	7.18	0.43	9.33e-12	Blood metabolite levels;
SARC	cis	rs6866344	0.697	rs11748497	chr5:178130012	C/G	cg10224037	chr5:178157518	ZNF354A	1.0	12.73	0.64	1.59e-28	Neutrophil percentage of white cells;
SARC	cis	rs1003719	0.788	rs2156076	chr21:38452634	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.64	9.15	0.51	2.85e-17	Eye color traits;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg12930819	chr2:97405853	LMAN2L	-0.61	-6.28	-0.38	1.68e-9	Lung cancer in ever smokers;
SARC	cis	rs8031584	0.958	rs35256769	chr15:31237776	G/A	cg19680485	chr15:31195859	MTMR15	-0.51	-5.92	-0.36	1.16e-8	Huntington's disease progression;
SARC	cis	rs2180341	0.618	rs11154398	chr6:127654281	C/A	cg24812749	chr6:127587940	RNF146	0.59	7.28	0.43	5.1e-12	Breast cancer;
SARC	cis	rs9921222	0.500	rs11648673	chr16:377794	G/A	cg00101154	chr16:420108	MRPL28	-0.52	-7.04	-0.42	2.09e-11	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs6665290	0.839	rs6699400	chr1:227190497	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.09	-25.44	-0.86	3.45e-69	Myeloid white cell count;
SARC	cis	rs9389248	0.690	rs6939543	chr6:135255143	A/G	cg24558204	chr6:135376177	HBS1L	-0.52	-6.51	-0.39	4.64e-10	High light scatter reticulocyte percentage of red cells;
SARC	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg10591111	chr5:226296	SDHA	-0.56	-5.1	-0.32	7.03e-7	Breast cancer;
SARC	cis	rs7011049	1.000	rs72648410	chr8:53859225	G/A	cg26025543	chr8:53854495	NA	0.61	5.37	0.33	1.87e-7	Systolic blood pressure;
SARC	cis	rs16976116	0.901	rs1061870	chr15:55496769	G/T	cg11288833	chr15:55489084	RSL24D1	0.63	6.13	0.37	3.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs10754283	0.967	rs6428559	chr1:90099036	C/T	cg21401794	chr1:90099060	LRRC8C	0.62	8.57	0.49	1.42e-15	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs2288073	0.965	rs10185445	chr2:24410976	A/C	cg06627628	chr2:24431161	ITSN2	0.57	6.65	0.4	2.01e-10	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs7681440	0.904	rs58864428	chr4:90766986	T/C	cg02192967	chr4:90758406	SNCA	0.36	5.13	0.32	6.11e-7	Dementia with Lewy bodies;
SARC	cis	rs2718058	0.519	rs2722243	chr7:37873467	A/C	cg24998770	chr7:37888106	TXNDC3	0.36	5.49	0.34	1.07e-7	Alzheimer's disease (late onset);
SARC	cis	rs1443512	0.812	rs2044210	chr12:54335533	C/G	cg17410650	chr12:54324560	NA	-0.34	-5.32	-0.33	2.45e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
SARC	trans	rs7819412	0.838	rs3021494	chr8:10983534	A/G	cg08975724	chr8:8085496	FLJ10661	-0.55	-7.01	-0.42	2.61e-11	Triglycerides;
SARC	cis	rs6992848	0.824	rs34165847	chr8:141154185	T/C	cg24476153	chr8:142139938	DENND3	-0.31	-4.78	-0.3	3.07e-6	Response to amphetamines;
SARC	cis	rs9581857	0.556	rs9581861	chr13:28039991	C/T	cg22138327	chr13:27999177	GTF3A	0.55	5.65	0.35	4.56e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	trans	rs9929218	1.000	rs28549017	chr16:68758828	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.64	-8.19	-0.47	1.77e-14	Colorectal cancer;
SARC	cis	rs651907	0.617	rs797776	chr3:101610243	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.44	5.14	0.32	5.74e-7	Colorectal cancer;
SARC	cis	rs1707322	1.000	rs4134387	chr1:46395158	A/T	cg06784218	chr1:46089804	CCDC17	0.36	6.32	0.38	1.3e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9325144	0.752	rs12300353	chr12:39154492	G/C	cg26384229	chr12:38710491	ALG10B	-0.58	-7.2	-0.43	8.17e-12	Morning vs. evening chronotype;
SARC	cis	rs4423214	1.000	rs12792306	chr11:71166992	T/C	cg05163923	chr11:71159392	DHCR7	0.68	9.39	0.52	5.59e-18	Vitamin D levels;
SARC	cis	rs2153535	0.580	rs2152347	chr6:8474281	A/G	cg07606381	chr6:8435919	SLC35B3	0.77	10.83	0.58	2.14e-22	Motion sickness;
SARC	cis	rs8013055	0.846	rs10151805	chr14:105974781	T/C	cg19700328	chr14:106028568	NA	-0.6	-8.51	-0.49	2.19e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
SARC	cis	rs834603	0.575	rs834595	chr7:47472276	C/T	cg23694490	chr7:47445681	TNS3	-0.32	-5.89	-0.36	1.36e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs9300255	0.722	rs10846515	chr12:123801672	T/G	cg00376283	chr12:123451042	ABCB9	0.47	4.84	0.3	2.41e-6	Neutrophil percentage of white cells;
SARC	cis	rs8014204	0.604	rs11625594	chr14:75389833	G/A	cg11812906	chr14:75593930	NEK9	0.47	5.26	0.33	3.25e-7	Caffeine consumption;
SARC	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg13395646	chr4:1353034	KIAA1530	-0.48	-5.78	-0.35	2.39e-8	Obesity-related traits;
SARC	cis	rs6546550	0.867	rs1551374	chr2:70079633	C/T	cg02498382	chr2:70120550	SNRNP27	-0.4	-6.55	-0.39	3.63e-10	Prevalent atrial fibrillation;
SARC	cis	rs6988636	0.818	rs10111810	chr8:124169565	G/A	cg23067535	chr8:124195133	FAM83A	-0.68	-5.01	-0.31	1.08e-6	Urinary uromodulin levels;
SARC	cis	rs4689388	0.856	rs10016157	chr4:6294414	T/C	cg00701064	chr4:6280414	WFS1	0.54	8.58	0.49	1.38e-15	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	trans	rs1994135	0.669	rs2121831	chr12:33697674	G/A	cg26384229	chr12:38710491	ALG10B	0.79	9.96	0.55	1.09e-19	Resting heart rate;
SARC	cis	rs9911578	0.867	rs72628394	chr17:57121313	C/T	cg05425664	chr17:57184151	TRIM37	0.6	7.42	0.44	2.17e-12	Intelligence (multi-trait analysis);
SARC	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg11987759	chr7:65425863	GUSB	-0.5	-6.4	-0.39	8.69e-10	Aortic root size;
SARC	cis	rs2180341	0.596	rs12215298	chr6:127676833	C/T	cg24812749	chr6:127587940	RNF146	0.61	7.34	0.43	3.54e-12	Breast cancer;
SARC	cis	rs9300255	0.739	rs1980252	chr12:123745178	C/G	cg00376283	chr12:123451042	ABCB9	0.48	5.44	0.34	1.38e-7	Neutrophil percentage of white cells;
SARC	cis	rs12545912	0.909	rs12680098	chr8:9479540	C/T	cg21625330	chr8:9911636	MSRA	0.5	4.8	0.3	2.79e-6	Multiple myeloma (hyperdiploidy);
SARC	cis	rs6582630	0.555	rs10880607	chr12:38508184	A/G	cg26384229	chr12:38710491	ALG10B	0.89	13.22	0.65	3.76e-30	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9467711	0.606	rs9366656	chr6:26434630	T/C	cg12826209	chr6:26865740	GUSBL1	0.8	4.91	0.31	1.73e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.99	11.29	0.59	7.11e-24	Platelet count;
SARC	cis	rs372883	0.600	rs2832293	chr21:30738872	C/G	cg08807101	chr21:30365312	RNF160	0.54	6.78	0.41	9.95e-11	Pancreatic cancer;
SARC	cis	rs4926611	0.795	rs4927014	chr1:54072249	G/A	cg08927728	chr1:54059983	GLIS1	-0.27	-4.76	-0.3	3.45e-6	Hand grip strength;
SARC	cis	rs9985766	0.959	rs28642700	chr4:151051605	A/C	cg05926478	chr4:151174724	DCLK2	-0.49	-4.83	-0.3	2.46e-6	Coronary artery disease;Myocardial infarction;
SARC	cis	rs11697848	1.000	rs3210879	chr20:48506190	T/C	cg17849948	chr20:48532315	SPATA2	0.86	5.17	0.32	4.97e-7	Systemic lupus erythematosus;
SARC	cis	rs9462027	0.539	rs9469883	chr6:34758627	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.85	-0.36	1.63e-8	Systemic lupus erythematosus;
SARC	cis	rs1355223	1.000	rs11604069	chr11:34764251	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-5.65	-0.35	4.59e-8	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs1707322	0.721	rs4609469	chr1:46117185	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.25	0.38	1.93e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9457247	0.967	rs382009	chr6:167403121	G/C	cg07741184	chr6:167504864	NA	0.29	5.55	0.34	7.59e-8	Crohn's disease;
SARC	cis	rs6580649	0.941	rs72644844	chr12:48465425	A/C	cg24011408	chr12:48396354	COL2A1	-0.48	-5.38	-0.33	1.78e-7	Lung cancer;
SARC	cis	rs910316	0.967	rs10142770	chr14:75525449	G/A	cg11812906	chr14:75593930	NEK9	0.89	13.91	0.67	2.02e-32	Height;
SARC	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg22433210	chr17:43662623	NA	0.68	7.97	0.46	7.21e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7937682	0.883	rs568506	chr11:111466429	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.93	-14.06	-0.68	6.32e-33	Primary sclerosing cholangitis;
SARC	cis	rs4481887	0.893	rs1934544	chr1:248505582	G/A	cg01631408	chr1:248437212	OR2T33	-0.45	-6.02	-0.37	6.66e-9	Common traits (Other);
SARC	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg03709012	chr19:19516395	GATAD2A	0.95	14.76	0.7	2.9e-35	Tonsillectomy;
SARC	cis	rs892961	0.932	rs7222170	chr17:75413096	G/A	cg05865280	chr17:75406074	SEPT9	0.57	8.47	0.48	2.87e-15	Airflow obstruction;
SARC	cis	rs546131	0.642	rs512013	chr11:34842225	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.44	5.01	0.31	1.09e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs6088580	0.634	rs13041646	chr20:33082881	T/A	cg08999081	chr20:33150536	PIGU	0.44	6.84	0.41	6.79e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs11097912	0.632	rs4337799	chr4:107029199	G/A	cg09646026	chr4:107269030	AIMP1	-0.45	-4.74	-0.3	3.74e-6	Airflow obstruction;
SARC	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg23982607	chr1:1823379	GNB1	-0.66	-11.3	-0.59	6.78e-24	Body mass index;
SARC	cis	rs11711311	0.911	rs3773681	chr3:113523901	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	8.72	0.5	5.29e-16	IgG glycosylation;
SARC	cis	rs8084125	0.832	rs62105174	chr18:74948324	G/A	cg07390210	chr18:74961196	GALR1	0.55	6.25	0.38	1.97e-9	Obesity-related traits;
SARC	cis	rs2652822	1.000	rs2652822	chr15:63422772	C/T	cg02713581	chr15:63449717	RPS27L	-0.71	-9.79	-0.54	3.48e-19	Metabolic traits;
SARC	trans	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-7.07	-0.42	1.82e-11	Intelligence (multi-trait analysis);
SARC	cis	rs240764	0.555	rs6919283	chr6:101235769	C/T	cg09795085	chr6:101329169	ASCC3	0.45	5.66	0.35	4.42e-8	Neuroticism;
SARC	cis	rs2718058	0.630	rs2722227	chr7:37858610	G/A	cg24998770	chr7:37888106	TXNDC3	0.35	5.08	0.32	7.79e-7	Alzheimer's disease (late onset);
SARC	cis	rs2273669	0.588	rs111773102	chr6:109306480	C/T	cg05315195	chr6:109294784	ARMC2	-0.57	-5.11	-0.32	6.79e-7	Prostate cancer;
SARC	cis	rs2652822	0.525	rs58789072	chr15:63497553	G/A	cg02713581	chr15:63449717	RPS27L	0.54	6.5	0.39	4.76e-10	Metabolic traits;
SARC	cis	rs2425143	1.000	rs45595739	chr20:34320759	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-5.62	-0.35	5.31e-8	Blood protein levels;
SARC	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg16479474	chr6:28041457	NA	0.36	5.25	0.33	3.43e-7	Depression;
SARC	cis	rs459571	0.959	rs456205	chr9:136911146	G/A	cg01294253	chr9:136912663	BRD3	0.4	5.14	0.32	5.9e-7	Platelet distribution width;
SARC	cis	rs4919087	0.748	rs701819	chr10:98986316	C/A	cg25902810	chr10:99078978	FRAT1	-0.53	-5.98	-0.36	8.47e-9	Monocyte count;
SARC	cis	rs2230307	0.572	rs512999	chr1:100563330	A/G	cg24955406	chr1:100503596	HIAT1	0.73	7.18	0.43	9.4e-12	Carotid intima media thickness;
SARC	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg11644478	chr21:40555479	PSMG1	0.97	13.3	0.66	2.04e-30	Cognitive function;
SARC	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg03517284	chr6:25882590	NA	0.51	6.7	0.4	1.59e-10	Blood metabolite levels;
SARC	cis	rs9733	0.715	rs12402006	chr1:150869829	G/A	cg13175981	chr1:150552382	MCL1	0.57	7.53	0.44	1.1e-12	Tonsillectomy;
SARC	cis	rs2073300	0.609	rs56334525	chr20:23365812	A/G	cg12062639	chr20:23401060	NAPB	0.95	6.5	0.39	4.74e-10	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg08975724	chr8:8085496	FLJ10661	0.5	6.57	0.4	3.34e-10	Neuroticism;
SARC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	9.16	0.51	2.74e-17	Prudent dietary pattern;
SARC	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	5.49	0.34	1.06e-7	Personality dimensions;
SARC	cis	rs3733585	0.579	rs4235353	chr4:10122934	C/T	cg11266682	chr4:10021025	SLC2A9	-0.38	-6.14	-0.37	3.6e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg23188684	chr11:67383651	NA	-0.42	-5.7	-0.35	3.58e-8	Mean corpuscular volume;
SARC	cis	rs11997175	0.624	rs7464055	chr8:33679382	G/A	ch.8.33884649F	chr8:33765107	NA	0.61	8.23	0.47	1.33e-14	Body mass index;
SARC	trans	rs61931739	0.569	rs1872746	chr12:33985843	T/C	cg13010199	chr12:38710504	ALG10B	0.62	8.36	0.48	5.73e-15	Morning vs. evening chronotype;
SARC	cis	rs10992471	0.580	rs7020104	chr9:95416524	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.43	-4.76	-0.3	3.36e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg05872129	chr22:39784769	NA	-0.4	-5.62	-0.35	5.44e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2439831	0.850	rs10438303	chr15:44016417	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	7.53	0.44	1.12e-12	Lung cancer in ever smokers;
SARC	cis	rs1215050	0.776	rs1627946	chr4:98844416	G/A	cg05340658	chr4:99064831	C4orf37	-0.44	-5.9	-0.36	1.3e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg24675658	chr1:53192096	ZYG11B	0.59	8.28	0.48	9.42e-15	Monocyte count;
SARC	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg08067268	chr2:26466485	HADHB;HADHA	0.46	5.77	0.35	2.54e-8	Gut microbiome composition (summer);
SARC	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg13206674	chr6:150067644	NUP43	0.55	6.75	0.4	1.18e-10	Lung cancer;
SARC	cis	rs950169	0.887	rs35986397	chr15:84955107	G/A	cg24253500	chr15:84953950	NA	0.36	5.27	0.33	3.15e-7	Schizophrenia;
SARC	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg21724239	chr8:58056113	NA	0.6	6.37	0.38	1.03e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2043112	0.965	rs12659919	chr5:39072800	T/A	cg04869206	chr5:39074266	RICTOR	0.53	6.4	0.39	8.37e-10	Obesity-related traits;
SARC	cis	rs9815354	0.812	rs56728371	chr3:41999381	T/A	cg03022575	chr3:42003672	ULK4	0.7	5.95	0.36	9.58e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs72634258	0.786	rs12563704	chr1:8033837	G/A	cg00042356	chr1:8021962	PARK7	0.56	5.35	0.33	2.06e-7	Inflammatory bowel disease;
SARC	cis	rs9814567	1.000	rs6806417	chr3:134211446	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.53	6.62	0.4	2.38e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs7772486	0.754	rs1415747	chr6:146077249	A/G	cg05347473	chr6:146136440	FBXO30	0.52	7.26	0.43	5.9e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs274567	0.599	rs11242110	chr5:131743777	A/C	cg07395648	chr5:131743802	NA	0.56	7.05	0.42	1.98e-11	Blood metabolite levels;
SARC	cis	rs1018836	0.786	rs7016220	chr8:91606848	A/G	cg16814680	chr8:91681699	NA	-0.76	-11.96	-0.62	5.1e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs1801251	0.778	rs812383	chr2:233737132	C/A	cg25237894	chr2:233734115	C2orf82	-0.34	-4.86	-0.3	2.16e-6	Coronary artery disease;
SARC	cis	rs17412403	0.779	rs9661436	chr1:65953970	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.38	-4.95	-0.31	1.4e-6	Blood protein levels;
SARC	cis	rs2908197	0.737	rs6465096	chr7:75972872	T/G	cg07849177	chr7:76178544	LOC100133091	-0.43	-4.92	-0.31	1.66e-6	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg11062466	chr8:58055876	NA	0.56	5.58	0.34	6.66e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs3540	0.513	rs2589974	chr15:90891566	C/T	cg22089800	chr15:90895588	ZNF774	-0.76	-10.7	-0.57	5.52e-22	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.44	5.49	0.34	1.03e-7	Tonsillectomy;
SARC	cis	rs2952156	0.883	rs1495100	chr17:37832279	C/T	cg07936489	chr17:37558343	FBXL20	-0.41	-5.33	-0.33	2.31e-7	Asthma;
SARC	cis	rs2594989	1.000	rs2594986	chr3:11330964	G/A	cg00170343	chr3:11313890	ATG7	0.55	5.28	0.33	2.96e-7	Circulating chemerin levels;
SARC	cis	rs561341	0.740	rs11080174	chr17:30208521	C/A	cg13647721	chr17:30228624	UTP6	-0.69	-6.74	-0.4	1.26e-10	Hip circumference adjusted for BMI;
SARC	cis	rs7917772	0.636	rs2482499	chr10:104516246	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.59	6.96	0.41	3.46e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.47	5.51	0.34	9.48e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs1322639	0.614	rs9294967	chr6:169565406	C/T	cg04662567	chr6:169592167	NA	0.47	4.72	0.3	4.07e-6	Pulse pressure;
SARC	cis	rs362296	0.511	rs2051558	chr4:3324886	G/A	cg08741688	chr4:3415352	RGS12	-0.4	-5.18	-0.32	4.75e-7	Parental longevity (mother's age at death);
SARC	cis	rs3847687	1.000	rs11061303	chr12:131526322	A/G	cg25772418	chr12:131519998	GPR133	-0.33	-5.22	-0.32	3.95e-7	Longevity;
SARC	cis	rs10924970	0.503	rs1987092	chr1:235494235	C/G	cg26050004	chr1:235667680	B3GALNT2	0.52	6.31	0.38	1.36e-9	Asthma;
SARC	cis	rs11583043	0.918	rs6675403	chr1:101418569	T/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.49	5.99	0.37	7.95e-9	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs3762637	0.941	rs77599736	chr3:122179509	A/T	cg24169773	chr3:122142474	KPNA1	-0.56	-5.67	-0.35	4.18e-8	LDL cholesterol levels;
SARC	cis	rs262150	0.819	rs6956589	chr7:158769301	C/T	cg19418458	chr7:158789849	NA	-0.45	-6.04	-0.37	5.94e-9	Facial morphology (factor 20);
SARC	trans	rs61931739	0.517	rs10844738	chr12:34059503	T/A	cg13010199	chr12:38710504	ALG10B	0.64	8.68	0.49	7.1e-16	Morning vs. evening chronotype;
SARC	cis	rs2997447	0.748	rs112813126	chr1:26432239	A/T	cg19633962	chr1:26362018	EXTL1	-0.57	-5.05	-0.31	8.95e-7	QRS complex (12-leadsum);
SARC	cis	rs9715521	0.775	rs11931812	chr4:59844473	T/C	cg11281224	chr4:60001000	NA	-0.4	-5.12	-0.32	6.5e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9486719	0.948	rs2499817	chr6:96878321	C/T	cg06623918	chr6:96969491	KIAA0776	0.73	8.01	0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs9487051	1.000	rs9487052	chr6:109617086	C/T	cg01475377	chr6:109611718	NA	-0.4	-5.64	-0.35	4.9e-8	Reticulocyte fraction of red cells;
SARC	cis	rs9309473	1.000	rs10175180	chr2:73673123	C/T	cg20560298	chr2:73613845	ALMS1	-0.49	-5.97	-0.36	8.88e-9	Metabolite levels;
SARC	cis	rs908922	0.651	rs4845442	chr1:152485545	G/A	cg09873164	chr1:152488093	CRCT1	0.63	8.32	0.48	7.54e-15	Hair morphology;
SARC	cis	rs787274	1.000	rs2645994	chr9:115483322	C/T	cg13803584	chr9:115635662	SNX30	0.74	4.84	0.3	2.35e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs7666738	0.830	rs28516388	chr4:98987449	A/G	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7481584	0.962	rs2237905	chr11:2976584	T/C	cg25174290	chr11:3078921	CARS	-0.54	-7.11	-0.42	1.44e-11	Calcium levels;
SARC	cis	rs72949976	0.864	rs62186566	chr2:214024421	G/A	cg08319019	chr2:214017104	IKZF2	-0.52	-7.3	-0.43	4.5e-12	Lung cancer;Squamous cell lung carcinoma;
SARC	trans	rs11098499	0.954	rs9993199	chr4:120392873	A/G	cg25214090	chr10:38739885	LOC399744	-0.57	-7.54	-0.44	1.03e-12	Corneal astigmatism;
SARC	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg11987759	chr7:65425863	GUSB	0.48	5.88	0.36	1.42e-8	Aortic root size;
SARC	cis	rs1008375	1.000	rs10939744	chr4:17664473	G/T	cg02297831	chr4:17616191	MED28	0.43	5.34	0.33	2.19e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs67311347	1.000	rs6762997	chr3:40478151	C/T	cg09455208	chr3:40491958	NA	0.42	6.66	0.4	1.92e-10	Renal cell carcinoma;
SARC	cis	rs1355223	0.506	rs7131272	chr11:34869548	A/G	cg11622362	chr11:34938112	PDHX;APIP	-0.46	-6.06	-0.37	5.29e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs3796352	0.881	rs34238610	chr3:53026480	A/T	cg15956490	chr3:53032818	SFMBT1	0.87	5.73	0.35	3.14e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs3018712	0.532	rs948861	chr11:68420622	C/T	cg01657329	chr11:68192670	LRP5	0.6	5.55	0.34	7.87e-8	Total body bone mineral density;
SARC	cis	rs57920188	0.584	rs12062024	chr1:4089259	A/T	cg20703997	chr1:4087676	NA	-0.46	-5.0	-0.31	1.12e-6	Interleukin-17 levels;
SARC	cis	rs9341808	0.667	rs1408292	chr6:80883906	G/T	cg08355045	chr6:80787529	NA	0.37	5.9	0.36	1.25e-8	Sitting height ratio;
SARC	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg05368731	chr17:41323189	NBR1	0.76	8.99	0.51	8.64e-17	Menopause (age at onset);
SARC	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg08219700	chr8:58056026	NA	0.58	5.65	0.35	4.7e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg13901433	chr17:73285524	SLC25A19	0.45	6.25	0.38	1.89e-9	Immature fraction of reticulocytes;
SARC	cis	rs12971120	0.891	rs4891558	chr18:72170359	A/G	cg26446133	chr18:72167187	CNDP2	-0.46	-6.1	-0.37	4.27e-9	Refractive error;
SARC	cis	rs2075371	0.829	rs10954442	chr7:134007587	A/G	cg11752832	chr7:134001865	SLC35B4	-0.57	-7.42	-0.44	2.17e-12	Mean platelet volume;
SARC	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg13395646	chr4:1353034	KIAA1530	-0.56	-6.73	-0.4	1.29e-10	Obesity-related traits;
SARC	cis	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg05623727	chr3:50126028	RBM5	0.33	4.92	0.31	1.65e-6	Intelligence (multi-trait analysis);
SARC	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.33	-0.43	3.74e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs3816788	0.792	rs7013323	chr8:21869024	C/G	cg17168535	chr8:21777572	XPO7	0.84	11.7	0.61	3.48e-25	Lung cancer in ever smokers;
SARC	trans	rs1814175	0.645	rs1851850	chr11:50012168	G/A	cg03929089	chr4:120376271	NA	-0.84	-12.08	-0.62	2.02e-26	Height;
SARC	cis	rs8058578	0.832	rs3812999	chr16:30773605	G/T	cg00531865	chr16:30841666	NA	-0.54	-6.16	-0.37	3.1e-9	Multiple myeloma;
SARC	cis	rs7824557	0.806	rs10503418	chr8:11118983	C/T	cg21775007	chr8:11205619	TDH	-0.44	-5.29	-0.33	2.87e-7	Retinal vascular caliber;
SARC	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.61	-6.27	-0.38	1.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs7582180	0.614	rs4851309	chr2:100975390	C/T	cg14675211	chr2:100938903	LONRF2	0.52	7.79	0.45	2.26e-13	Intelligence (multi-trait analysis);
SARC	cis	rs995000	0.965	rs12047226	chr1:63105538	T/C	cg06896770	chr1:63153194	DOCK7	0.98	15.37	0.71	2.79e-37	Triglyceride levels;
SARC	cis	rs4268898	0.560	rs2384007	chr2:24514841	A/G	cg26838691	chr2:24397539	C2orf84	-0.49	-5.54	-0.34	8.26e-8	Asthma;
SARC	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg18252515	chr7:66147081	NA	-0.45	-4.98	-0.31	1.23e-6	Aortic root size;
SARC	cis	rs933688	1.000	rs10073935	chr5:90742188	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.0	12.59	0.64	4.38e-28	Smoking behavior;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg27366305	chr5:110075285	SLC25A46	0.55	6.57	0.4	3.29e-10	Alcohol dependence;
SARC	cis	rs11578119	0.933	rs12128573	chr1:170391126	C/T	cg09767346	chr1:170501363	GORAB	0.42	4.85	0.3	2.21e-6	Male-pattern baldness;
SARC	cis	rs67311347	1.000	rs951560	chr3:40463471	A/G	cg01475735	chr3:40494733	NA	-0.42	-4.84	-0.3	2.34e-6	Renal cell carcinoma;
SARC	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg11764359	chr7:65958608	NA	-0.62	-7.16	-0.42	1.03e-11	Aortic root size;
SARC	cis	rs7944584	0.511	rs10838725	chr11:47557871	T/C	cg20307385	chr11:47447363	PSMC3	0.78	11.2	0.59	1.37e-23	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg11494091	chr17:61959527	GH2	0.54	8.15	0.47	2.26e-14	Prudent dietary pattern;
SARC	cis	rs1348850	0.554	rs1374438	chr2:178376684	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	5.87	0.36	1.5e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs734999	0.588	rs6701238	chr1:2520500	G/A	cg18854424	chr1:2615690	NA	0.3	4.76	0.3	3.47e-6	Ulcerative colitis;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg00486604	chr3:43739515	ABHD5	0.42	6.26	0.38	1.79e-9	Thyroid stimulating hormone;
SARC	cis	rs10463554	0.759	rs34781	chr5:102454439	C/T	cg23492399	chr5:102201601	PAM	-0.51	-5.55	-0.34	7.77e-8	Parkinson's disease;
SARC	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg00933542	chr6:150070202	PCMT1	-0.32	-5.52	-0.34	9.04e-8	Lung cancer;
SARC	cis	rs7681440	0.904	rs7671549	chr4:90771147	T/A	cg02192967	chr4:90758406	SNCA	0.37	5.26	0.33	3.22e-7	Dementia with Lewy bodies;
SARC	cis	rs523522	0.923	rs1048830	chr12:120882217	G/T	cg12219531	chr12:120966889	COQ5	0.83	10.45	0.57	3.21e-21	High light scatter reticulocyte count;
SARC	trans	rs7815944	1.000	rs76344458	chr8:129396016	C/T	cg25487405	chr22:46473039	NA	0.64	6.35	0.38	1.09e-9	Atopic dermatitis;
SARC	cis	rs862034	0.531	rs11159084	chr14:74925144	G/A	cg16374328	chr14:74960395	NPC2;ISCA2	0.44	5.4	0.33	1.67e-7	Height;
SARC	cis	rs1832871	0.672	rs11751553	chr6:158774750	C/T	cg07165851	chr6:158734300	TULP4	-0.54	-6.34	-0.38	1.2e-9	Height;
SARC	cis	rs9399135	0.967	rs9389256	chr6:135331254	A/C	cg24558204	chr6:135376177	HBS1L	0.44	5.99	0.37	7.75e-9	Red blood cell count;
SARC	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg22920501	chr2:26401640	FAM59B	-0.57	-7.57	-0.44	8.81e-13	Gut microbiome composition (summer);
SARC	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg08742575	chr21:47604166	C21orf56	-0.45	-5.65	-0.35	4.78e-8	Testicular germ cell tumor;
SARC	cis	rs9948	0.786	rs62156233	chr2:97434061	C/G	cg01990225	chr2:97406019	LMAN2L	-0.8	-6.25	-0.38	1.89e-9	Erectile dysfunction and prostate cancer treatment;
SARC	trans	rs2727020	0.615	rs35423199	chr11:49514914	T/C	cg15704280	chr7:45808275	SEPT13	-0.87	-14.39	-0.69	5.05e-34	Coronary artery disease;
SARC	cis	rs2529049	0.537	rs2108303	chr7:24633333	T/G	cg17569154	chr7:24781545	DFNA5	0.49	7.1	0.42	1.54e-11	Urate levels in obese individuals;
SARC	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg05368731	chr17:41323189	NBR1	0.77	9.24	0.52	1.58e-17	Menopause (age at onset);
SARC	cis	rs9818758	0.607	rs35283189	chr3:49113668	T/C	cg00383909	chr3:49044727	WDR6	0.77	6.75	0.4	1.16e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs7829975	0.606	rs891570	chr8:8794454	G/A	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.35	-0.43	3.26e-12	Mood instability;
SARC	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg11764359	chr7:65958608	NA	0.86	12.33	0.63	3.29e-27	Aortic root size;
SARC	cis	rs9354308	0.834	rs9354307	chr6:66552953	A/G	cg07460842	chr6:66804631	NA	-0.45	-5.22	-0.32	3.92e-7	Metabolite levels;
SARC	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg13012494	chr21:47604986	C21orf56	0.41	4.83	0.3	2.45e-6	Testicular germ cell tumor;
SARC	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg01475735	chr3:40494733	NA	0.45	5.3	0.33	2.64e-7	Renal cell carcinoma;
SARC	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg02951883	chr7:2050386	MAD1L1	-0.42	-5.43	-0.34	1.41e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs12530134	0.519	rs3920484	chr6:170746081	A/G	cg16453901	chr6:170730693	NA	-0.86	-6.68	-0.4	1.75e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.78	10.1	0.55	3.87e-20	Prudent dietary pattern;
SARC	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg07701084	chr6:150067640	NUP43	0.4	5.37	0.33	1.93e-7	Lung cancer;
SARC	cis	rs8067545	0.611	rs2703777	chr17:20138891	C/T	cg13482628	chr17:19912719	NA	-0.56	-7.49	-0.44	1.38e-12	Schizophrenia;
SARC	cis	rs12421382	0.659	rs35527696	chr11:109379944	T/A	cg16359550	chr11:109292809	C11orf87	0.33	4.97	0.31	1.31e-6	Schizophrenia;
SARC	cis	rs57677839	1	rs57677839	chr11:17028189	G/A	cg15084286	chr11:17036142	PLEKHA7	0.77	11.6	0.61	7.42e-25	Coronary artery disease;
SARC	cis	rs703842	1.000	rs4646536	chr12:58157988	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.72	10.57	0.57	1.37e-21	Multiple sclerosis;
SARC	cis	rs2721195	0.549	rs2958492	chr8:145919126	C/T	cg11211951	chr8:145729740	GPT	0.38	4.96	0.31	1.34e-6	Age at first birth;
SARC	cis	rs4481887	0.927	rs4586010	chr1:248437568	G/A	cg13385794	chr1:248469461	NA	0.35	5.23	0.32	3.7e-7	Common traits (Other);
SARC	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg11890956	chr21:40555474	PSMG1	-1.05	-16.21	-0.73	4.5e-40	Cognitive function;
SARC	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg08219700	chr8:58056026	NA	0.6	5.71	0.35	3.49e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1395	0.744	rs11126935	chr2:27476740	G/T	cg21747090	chr2:27597821	SNX17	-0.46	-5.62	-0.35	5.42e-8	Blood metabolite levels;
SARC	cis	rs1707322	1.000	rs1707337	chr1:46508769	A/G	cg06784218	chr1:46089804	CCDC17	-0.38	-6.71	-0.4	1.48e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4969178	0.965	rs12451715	chr17:76397334	A/C	cg20026190	chr17:76395443	PGS1	0.4	5.37	0.33	1.94e-7	HDL cholesterol levels;
SARC	cis	rs1163251	0.869	rs629735	chr1:120206932	G/T	cg19096424	chr1:120255104	PHGDH	-0.51	-5.94	-0.36	1e-8	Blood metabolite levels;
SARC	cis	rs12479064	0.724	rs737094	chr2:100089078	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.65	-7.86	-0.46	1.43e-13	Chronic sinus infection;
SARC	cis	rs1580019	0.587	rs7806113	chr7:32553084	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.98	17.72	0.76	4.72e-45	Cognitive ability;
SARC	cis	rs9916302	0.904	rs801419	chr17:37466327	A/G	cg07936489	chr17:37558343	FBXL20	0.69	9.18	0.52	2.46e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs9322817	0.691	rs4299867	chr6:105325383	G/C	cg02098413	chr6:105308735	HACE1	0.38	5.92	0.36	1.13e-8	Thyroid stimulating hormone;
SARC	cis	rs2404602	0.716	rs8039545	chr15:76707247	A/G	cg22467129	chr15:76604101	ETFA	-0.36	-4.86	-0.3	2.15e-6	Blood metabolite levels;
SARC	cis	rs709400	0.628	rs1951392	chr14:103853367	T/G	cg12935359	chr14:103987150	CKB	-0.39	-5.71	-0.35	3.43e-8	Body mass index;
SARC	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs2832191	0.716	rs7509628	chr21:30454252	C/T	cg24692254	chr21:30365293	RNF160	1.04	18.49	0.77	1.4e-47	Dental caries;
SARC	cis	rs1401999	0.628	rs6798870	chr3:183740350	G/A	cg01324343	chr3:183735012	ABCC5	0.57	10.82	0.58	2.33e-22	Anterior chamber depth;
SARC	cis	rs7395581	0.879	rs3758673	chr11:47278917	C/T	cg25783544	chr11:47291846	MADD	0.48	5.02	0.31	1.02e-6	HDL cholesterol;
SARC	cis	rs11098499	0.820	rs11737395	chr4:120520704	C/G	cg24375607	chr4:120327624	NA	0.42	4.92	0.31	1.62e-6	Corneal astigmatism;
SARC	cis	rs270601	0.866	rs460271	chr5:131630062	C/G	cg24060327	chr5:131705240	SLC22A5	-0.69	-8.16	-0.47	2.08e-14	Acylcarnitine levels;
SARC	cis	rs1008375	1.000	rs11737138	chr4:17657986	G/A	cg27347728	chr4:17578864	LAP3	0.47	5.88	0.36	1.42e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs11098499	0.863	rs59732491	chr4:120489588	G/C	cg09307838	chr4:120376055	NA	0.91	12.25	0.63	5.66e-27	Corneal astigmatism;
SARC	cis	rs1003719	0.715	rs2051398	chr21:38550258	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.64	9.35	0.52	7.53e-18	Eye color traits;
SARC	cis	rs986417	1.000	rs4901985	chr14:60948318	A/C	cg27398547	chr14:60952738	C14orf39	1.0	9.23	0.52	1.75e-17	Gut microbiota (bacterial taxa);
SARC	cis	rs9354308	0.899	rs2814099	chr6:66555130	A/G	cg07460842	chr6:66804631	NA	0.48	5.6	0.34	6e-8	Metabolite levels;
SARC	cis	rs11209002	0.592	rs4655672	chr1:67553543	C/T	cg02640540	chr1:67518911	SLC35D1	0.57	6.68	0.4	1.76e-10	Crohn's disease;
SARC	cis	rs735396	1.000	rs1169306	chr12:121438311	C/T	cg02403541	chr12:121454288	C12orf43	0.72	9.46	0.53	3.46e-18	N-glycan levels;
SARC	cis	rs9549260	0.755	rs2721066	chr13:41156188	C/T	cg21288729	chr13:41239152	FOXO1	-0.61	-7.98	-0.46	6.73e-14	Red blood cell count;
SARC	cis	rs910187	0.678	rs6066229	chr20:45815341	A/G	cg27589058	chr20:45804311	EYA2	0.33	5.14	0.32	5.72e-7	Migraine;
SARC	cis	rs12421382	0.507	rs11600810	chr11:109356443	G/A	cg11473876	chr11:109292803	C11orf87	0.42	5.36	0.33	1.97e-7	Schizophrenia;
SARC	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg24829409	chr8:58192753	C8orf71	-0.62	-6.4	-0.39	8.61e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg07167872	chr1:205819463	PM20D1	0.74	11.1	0.59	2.93e-23	Menarche (age at onset);
SARC	cis	rs17023223	0.509	rs61806978	chr1:119713215	A/G	cg05756136	chr1:119680316	WARS2	-0.48	-5.49	-0.34	1.02e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg22484793	chr3:52261325	TLR9	0.29	4.76	0.3	3.38e-6	Bipolar disorder;
SARC	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg16479474	chr6:28041457	NA	0.37	5.47	0.34	1.17e-7	Depression;
SARC	cis	rs743757	1.000	rs2236984	chr3:50495487	A/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.51	4.85	0.3	2.29e-6	Diastolic blood pressure;
SARC	cis	rs11690935	1.000	rs1554166	chr2:172541609	G/T	cg13550731	chr2:172543902	DYNC1I2	-0.99	-15.38	-0.71	2.58e-37	Schizophrenia;
SARC	cis	rs554111	0.634	rs10799673	chr1:21274671	T/G	cg08890418	chr1:21044141	KIF17	-0.34	-4.76	-0.3	3.44e-6	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs2153535	0.935	rs11243254	chr6:8381242	C/T	cg07606381	chr6:8435919	SLC35B3	-0.51	-6.28	-0.38	1.64e-9	Motion sickness;
SARC	trans	rs208520	0.779	rs208451	chr6:66906155	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.93	-10.74	-0.58	4.13e-22	Exhaled nitric oxide output;
SARC	cis	rs4481887	0.636	rs10788761	chr1:248410663	C/T	cg00666640	chr1:248458726	OR2T12	0.35	5.15	0.32	5.45e-7	Common traits (Other);
SARC	cis	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg18252515	chr7:66147081	NA	-1.27	-11.31	-0.6	6.26e-24	Diabetic kidney disease;
SARC	cis	rs12681366	0.595	rs2450580	chr8:95363776	G/A	cg26464482	chr8:95565502	KIAA1429	-0.46	-5.78	-0.35	2.39e-8	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs6696846	0.749	rs6692170	chr1:205074019	G/A	cg21545522	chr1:205238299	TMCC2	0.36	5.0	0.31	1.15e-6	Red blood cell count;
SARC	cis	rs6943931	0.963	rs12531977	chr7:22425617	G/A	cg11052958	chr7:21583226	DNAH11	0.37	5.27	0.33	3.15e-7	Diabetic kidney disease;
SARC	cis	rs9914544	0.545	rs8078993	chr17:18797126	A/G	cg25390199	chr17:18761479	PRPSAP2	0.46	6.04	0.37	5.99e-9	Educational attainment (years of education);
SARC	trans	rs7824557	0.564	rs2736288	chr8:11228100	G/A	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.6	-0.4	2.75e-10	Retinal vascular caliber;
SARC	cis	rs440932	1.000	rs440932	chr8:9026929	T/C	cg06636001	chr8:8085503	FLJ10661	0.51	6.11	0.37	4.19e-9	High light scatter reticulocyte percentage of red cells;
SARC	cis	rs10513788	0.665	rs80295586	chr3:181992062	G/A	cg05977900	chr3:182512126	ATP11B	0.47	4.95	0.31	1.46e-6	Cognitive function;
SARC	cis	rs240764	0.817	rs239189	chr6:101128787	C/T	cg09795085	chr6:101329169	ASCC3	0.45	5.81	0.36	1.99e-8	Neuroticism;
SARC	cis	rs875971	0.545	rs73146609	chr7:65767464	A/G	cg11764359	chr7:65958608	NA	0.66	6.58	0.4	3.12e-10	Aortic root size;
SARC	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg08219700	chr8:58056026	NA	0.46	4.94	0.31	1.47e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.29	0.38	1.55e-9	Bipolar disorder;
SARC	cis	rs3008870	0.755	rs2815374	chr1:67507387	G/A	cg02640540	chr1:67518911	SLC35D1	0.46	5.32	0.33	2.46e-7	Lymphocyte percentage of white cells;
SARC	cis	rs1348850	0.958	rs1548067	chr2:178462914	C/T	cg23306229	chr2:178417860	TTC30B	0.54	6.22	0.38	2.24e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg12064134	chr16:90016061	DEF8	-0.59	-5.05	-0.31	8.75e-7	Skin colour saturation;
SARC	cis	rs2439831	1.000	rs565007	chr15:43716641	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.09	11.37	0.6	4.12e-24	Lung cancer in ever smokers;
SARC	trans	rs1577917	0.883	rs6454505	chr6:86592362	G/T	cg23236408	chr3:87039150	VGLL3	0.38	6.5	0.39	4.82e-10	Response to antipsychotic treatment;
SARC	cis	rs7937682	0.881	rs4936678	chr11:111625085	C/T	cg22437258	chr11:111473054	SIK2	-0.66	-7.96	-0.46	7.43e-14	Primary sclerosing cholangitis;
SARC	cis	rs11098499	0.909	rs1546504	chr4:120241179	C/T	cg09307838	chr4:120376055	NA	0.9	12.43	0.63	1.54e-27	Corneal astigmatism;
SARC	cis	rs5753618	0.561	rs2040533	chr22:31679110	G/C	cg02404636	chr22:31891804	SFI1	-0.49	-5.34	-0.33	2.18e-7	Colorectal cancer;
SARC	cis	rs62432291	0.681	rs365045	chr6:159632250	A/G	cg14500486	chr6:159655392	FNDC1	0.6	6.21	0.38	2.42e-9	Joint mobility (Beighton score);
SARC	cis	rs7223966	1.000	rs9899788	chr17:61756384	G/A	cg26338869	chr17:61819248	STRADA	0.44	5.14	0.32	5.82e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs8008758	1.000	rs8008758	chr14:101690045	A/C	cg26224664	chr14:101693935	NA	0.4	6.45	0.39	6.42e-10	Body mass index (alcohol intake interaction);
SARC	cis	rs13082711	0.911	rs66694067	chr3:27477337	C/T	cg02860705	chr3:27208620	NA	0.48	6.19	0.38	2.68e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs3540	0.576	rs10152871	chr15:91047469	G/A	cg22089800	chr15:90895588	ZNF774	-0.59	-7.63	-0.45	5.79e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs10089	0.953	rs1012851	chr5:127360241	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.85	9.96	0.55	1.1e-19	Ileal carcinoids;
SARC	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs12893668	0.572	rs34000399	chr14:104101417	T/C	cg26031613	chr14:104095156	KLC1	-0.53	-5.98	-0.36	8.42e-9	Reticulocyte count;
SARC	cis	rs7714584	1.000	rs11743488	chr5:150279218	A/G	cg22134413	chr5:150180641	NA	0.94	7.62	0.45	6.2800000000000005e-13	Crohn's disease;
SARC	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg22683308	chr4:1340831	KIAA1530	0.45	5.27	0.33	3.08e-7	Longevity;
SARC	cis	rs2916247	1.000	rs7830403	chr8:93008852	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.59	-6.26	-0.38	1.81e-9	Intelligence (multi-trait analysis);
SARC	cis	rs10782582	0.609	rs11588643	chr1:76255613	A/G	cg10523679	chr1:76189770	ACADM	-0.45	-5.58	-0.34	6.57e-8	Daytime sleep phenotypes;
SARC	cis	rs7208859	0.623	rs1061343	chr17:29114276	G/A	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg08280861	chr8:58055591	NA	0.61	5.81	0.36	2.02e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg12756686	chr19:29218302	NA	0.68	8.99	0.51	8.55e-17	Methadone dose in opioid dependence;
SARC	trans	rs6894249	1.000	rs6894249	chr5:131797547	A/G	cg14569778	chr17:28952111	LRRC37B2	-0.46	-6.58	-0.4	3.03e-10	Asthma;
SARC	cis	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg09021430	chr5:549028	NA	-0.44	-5.86	-0.36	1.58e-8	Obesity-related traits;
SARC	cis	rs1008375	1.000	rs1008374	chr4:17683219	G/A	cg16339924	chr4:17578868	LAP3	0.63	8.19	0.47	1.7e-14	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs17376456	0.741	rs12374432	chr5:93481348	C/A	cg21475434	chr5:93447410	FAM172A	0.91	7.83	0.46	1.71e-13	Diabetic retinopathy;
SARC	cis	rs644799	1.000	rs481630	chr11:95582447	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.67	9.11	0.51	3.97e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7582720	1.000	rs72926767	chr2:203796814	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs854765	0.647	rs854769	chr17:18019011	A/G	cg05444541	chr17:17804740	TOM1L2	0.33	5.57	0.34	6.89e-8	Total body bone mineral density;
SARC	cis	rs910316	0.737	rs108621	chr14:75480637	T/C	cg11812906	chr14:75593930	NEK9	-0.77	-10.33	-0.56	7.89e-21	Height;
SARC	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg23758822	chr17:41437982	NA	0.85	10.43	0.56	3.68e-21	Menopause (age at onset);
SARC	cis	rs11098499	0.820	rs6829903	chr4:120506884	C/T	cg09307838	chr4:120376055	NA	0.91	12.25	0.63	5.66e-27	Corneal astigmatism;
SARC	cis	rs9733	0.680	rs3738484	chr1:150552330	G/T	cg18016565	chr1:150552671	MCL1	-0.39	-5.41	-0.33	1.57e-7	Tonsillectomy;
SARC	cis	rs644799	0.582	rs473157	chr11:95596874	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.72	9.29	0.52	1.1e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7772486	0.658	rs4895683	chr6:146113654	T/A	cg05220968	chr6:146057943	EPM2A	0.28	4.87	0.3	2.03e-6	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg07884116	chr19:54663621	LENG1	0.57	6.96	0.41	3.5e-11	Breast cancer;
SARC	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg03806693	chr22:41940476	POLR3H	0.91	12.32	0.63	3.32e-27	Vitiligo;
SARC	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg14517863	chr17:44321492	NA	-0.34	-5.04	-0.31	9.3e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs3820928	0.605	rs13410141	chr2:227805529	A/G	cg05526886	chr2:227700861	RHBDD1	-0.48	-6.01	-0.37	7.08e-9	Pulmonary function;
SARC	cis	rs2361718	0.967	rs2361719	chr17:78103403	A/G	cg06718696	chr17:78121285	EIF4A3	-0.48	-5.67	-0.35	4.26e-8	Yeast infection;
SARC	cis	rs367943	0.933	rs451453	chr5:112808970	G/C	cg12552261	chr5:112820674	MCC	-0.45	-5.19	-0.32	4.65e-7	Type 2 diabetes;
SARC	cis	rs826838	1.000	rs7975243	chr12:38849220	C/T	cg13010199	chr12:38710504	ALG10B	0.78	11.03	0.59	4.74e-23	Heart rate;
SARC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg14159672	chr1:205819179	PM20D1	0.75	12.26	0.63	5.38e-27	Monocyte percentage of white cells;
SARC	cis	rs74417235	0.639	rs2396994	chr5:154052750	A/T	cg17344516	chr5:154026930	NA	-0.55	-5.59	-0.34	6.33e-8	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
SARC	cis	rs9309473	0.500	rs2421668	chr2:73885096	G/A	cg20560298	chr2:73613845	ALMS1	0.52	7.12	0.42	1.3e-11	Metabolite levels;
SARC	cis	rs4268898	0.662	rs72795832	chr2:24441855	C/A	cg06627628	chr2:24431161	ITSN2	-0.82	-9.92	-0.54	1.4e-19	Asthma;
SARC	cis	rs6840360	0.571	rs11726892	chr4:152555106	A/G	cg22705602	chr4:152727874	NA	-0.44	-6.81	-0.41	8.1e-11	Intelligence (multi-trait analysis);
SARC	cis	rs66573146	0.831	rs56081162	chr4:6989718	C/T	cg00086871	chr4:6988644	TBC1D14	0.9	5.39	0.33	1.72e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs1707322	1.000	rs7547189	chr1:46319514	C/A	cg06784218	chr1:46089804	CCDC17	0.33	5.78	0.35	2.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1448094	0.838	rs28509446	chr12:86312584	A/C	cg02569458	chr12:86230093	RASSF9	0.35	4.73	0.3	3.97e-6	Major depressive disorder;
SARC	cis	rs72945132	0.882	rs6592522	chr11:70128271	G/A	cg00319359	chr11:70116639	PPFIA1	0.68	6.18	0.38	2.8e-9	Coronary artery disease;
SARC	trans	rs3780486	0.846	rs7036812	chr9:33143822	T/C	cg20290983	chr6:43655470	MRPS18A	1.11	21.02	0.81	9.94e-56	IgG glycosylation;
SARC	cis	rs1707322	1.000	rs946527	chr1:46485970	C/T	cg03146154	chr1:46216737	IPP	0.48	5.78	0.35	2.41e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg07383130	chr1:16161673	FLJ37453	-0.51	-6.27	-0.38	1.7e-9	Height;
SARC	cis	rs668210	0.643	rs549334	chr11:65774659	C/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	5.29	0.33	2.82e-7	Cerebrospinal fluid biomarker levels;
SARC	cis	rs1401999	1.000	rs6805913	chr3:183662924	T/G	cg01324343	chr3:183735012	ABCC5	0.67	13.51	0.66	4.31e-31	Anterior chamber depth;
SARC	cis	rs8180040	0.587	rs1466741	chr3:47247214	C/T	cg27129171	chr3:47204927	SETD2	-0.68	-9.21	-0.52	1.98e-17	Colorectal cancer;
SARC	cis	rs7432375	0.610	rs28458819	chr3:136522314	A/G	cg15507776	chr3:136538369	TMEM22	0.62	7.74	0.45	2.93e-13	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	trans	rs13315871	1.000	rs74834816	chr3:58321828	G/A	cg23623270	chr17:42402962	SLC25A39	-0.86	-6.23	-0.38	2.14e-9	Cholesterol, total;
SARC	cis	rs5850	0.602	rs1005786	chr7:23145837	G/C	cg23682824	chr7:23144976	KLHL7	0.61	7.8	0.45	2.08e-13	Blood protein levels;
SARC	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg11644478	chr21:40555479	PSMG1	1.02	14.16	0.68	3.03e-33	Cognitive function;
SARC	trans	rs2727020	0.734	rs1164664	chr11:49295542	T/G	cg15704280	chr7:45808275	SEPT13	0.66	7.82	0.46	1.86e-13	Coronary artery disease;
SARC	cis	rs6665290	0.669	rs3795445	chr1:227180947	A/C	cg14016676	chr1:227182615	CDC42BPA	0.34	4.83	0.3	2.46e-6	Myeloid white cell count;
SARC	cis	rs559928	0.597	rs2186572	chr11:63895887	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	5.26	0.33	3.29e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	trans	rs1814175	0.647	rs4881649	chr11:49845560	A/G	cg15704280	chr7:45808275	SEPT13	-0.8	-12.78	-0.64	1.1e-28	Height;
SARC	cis	rs10754283	0.901	rs4520403	chr1:90112840	T/G	cg21401794	chr1:90099060	LRRC8C	0.59	8.09	0.47	3.24e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs34172651	0.797	rs12920941	chr16:24830866	T/A	cg00339695	chr16:24857497	SLC5A11	0.29	4.74	0.3	3.65e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7590720	0.704	rs7603645	chr2:216876949	C/G	cg12620499	chr2:216877984	MREG	0.75	11.69	0.61	3.79e-25	Alcohol dependence;
SARC	cis	rs950169	0.922	rs8037078	chr15:84818871	A/G	cg24253500	chr15:84953950	NA	-0.36	-5.02	-0.31	1.03e-6	Schizophrenia;
SARC	cis	rs981844	0.617	rs4077965	chr4:154710520	G/C	cg14289246	chr4:154710475	SFRP2	0.65	7.27	0.43	5.36e-12	Response to statins (LDL cholesterol change);
SARC	cis	rs9818758	0.607	rs80170003	chr3:48951640	T/C	cg01304814	chr3:48885189	PRKAR2A	0.65	5.28	0.33	3.02e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs11608355	0.545	rs1073780	chr12:109895143	T/C	cg05360138	chr12:110035743	NA	0.92	9.15	0.51	2.93e-17	Neuroticism;
SARC	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg01448562	chr3:133502909	NA	0.5	7.64	0.45	5.54e-13	Iron status biomarkers;
SARC	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg05368731	chr17:41323189	NBR1	0.79	9.46	0.53	3.5e-18	Menopause (age at onset);
SARC	cis	rs1153858	0.943	rs8038342	chr15:45651537	T/C	cg14582100	chr15:45693742	SPATA5L1	0.35	4.82	0.3	2.64e-6	Homoarginine levels;
SARC	cis	rs412050	0.594	rs113463481	chr22:22097230	G/A	cg17089214	chr22:22089827	YPEL1	0.72	6.35	0.38	1.15e-9	Attention deficit hyperactivity disorder;
SARC	cis	rs7089973	0.604	rs8181444	chr10:116588981	C/T	cg03647239	chr10:116582469	FAM160B1	0.49	6.3	0.38	1.48e-9	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg02725872	chr8:58115012	NA	-0.37	-6.42	-0.39	7.39e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1468333	0.667	rs11567972	chr5:137663093	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.71	8.52	0.49	2.01e-15	Resting heart rate;
SARC	cis	rs4919087	1.000	rs10882898	chr10:99087330	G/A	cg25902810	chr10:99078978	FRAT1	-0.46	-5.75	-0.35	2.74e-8	Monocyte count;
SARC	cis	rs8017423	0.935	rs4904661	chr14:90729332	T/C	cg20276874	chr14:90721474	PSMC1	-0.38	-5.25	-0.33	3.39e-7	Mortality in heart failure;
SARC	cis	rs2153535	0.541	rs9328471	chr6:8468842	T/C	cg21535247	chr6:8435926	SLC35B3	0.54	6.79	0.41	9.19e-11	Motion sickness;
SARC	cis	rs1524927	0.510	rs2922927	chr7:96412502	C/T	cg12459759	chr7:96762818	ACN9	0.35	4.79	0.3	3.01e-6	Total body bone mineral density;
SARC	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.01	-17.51	-0.75	2.16e-44	Chronic sinus infection;
SARC	cis	rs12586317	0.576	rs10146445	chr14:35631553	C/T	cg16230307	chr14:35515116	FAM177A1	0.46	5.83	0.36	1.81e-8	Psoriasis;
SARC	cis	rs36051895	0.623	rs7859361	chr9:5237479	C/T	cg02405213	chr9:5042618	JAK2	-0.42	-4.78	-0.3	3.13e-6	Pediatric autoimmune diseases;
SARC	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg05535760	chr7:792225	HEATR2	0.71	6.86	0.41	6.2e-11	Cerebrospinal P-tau181p levels;
SARC	cis	rs240764	0.658	rs12664626	chr6:101195720	A/G	cg09795085	chr6:101329169	ASCC3	-0.49	-6.42	-0.39	7.72e-10	Neuroticism;
SARC	cis	rs3768617	0.510	rs10752902	chr1:183090265	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.1	0.55	4.11e-20	Fuchs's corneal dystrophy;
SARC	cis	rs13256369	1.000	rs885000	chr8:8568875	G/T	cg18904891	chr8:8559673	CLDN23	0.48	5.54	0.34	8.31e-8	Obesity-related traits;
SARC	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg12463550	chr7:65579703	CRCP	0.48	5.79	0.35	2.23e-8	Aortic root size;
SARC	cis	rs9300255	0.566	rs10744150	chr12:123721614	A/C	cg00376283	chr12:123451042	ABCB9	0.56	6.58	0.4	3.1e-10	Neutrophil percentage of white cells;
SARC	cis	rs9388451	0.587	rs1739385	chr6:126099939	G/A	cg05901451	chr6:126070800	HEY2	-0.51	-6.4	-0.39	8.29e-10	Brugada syndrome;
SARC	cis	rs1707322	0.752	rs7529699	chr1:46134634	C/T	cg03146154	chr1:46216737	IPP	0.52	6.25	0.38	1.92e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2439831	0.850	rs8032649	chr15:44134922	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.88	-7.73	-0.45	3.25e-13	Lung cancer in ever smokers;
SARC	trans	rs208520	0.690	rs74707865	chr6:66717352	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	14.0	0.68	1.01e-32	Exhaled nitric oxide output;
SARC	cis	rs9640161	0.830	rs17173703	chr7:150068620	C/T	cg21361702	chr7:150065534	REPIN1	0.6	6.58	0.4	2.99e-10	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs40363	0.729	rs6501176	chr16:3522197	A/G	cg22508957	chr16:3507546	NAT15	-0.37	-4.82	-0.3	2.59e-6	Tuberculosis;
SARC	cis	rs11581859	0.613	rs12757095	chr1:99210758	C/T	cg20286094	chr1:99190917	SNX7	0.42	5.04	0.31	9.37e-7	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg13264159	chr8:625131	ERICH1	-0.64	-4.95	-0.31	1.4e-6	IgG glycosylation;
SARC	cis	rs3126085	0.935	rs12144058	chr1:152170216	C/T	cg26876637	chr1:152193138	HRNR	0.48	5.51	0.34	9.32e-8	Atopic dermatitis;
SARC	cis	rs7264396	0.563	rs2425088	chr20:34303902	C/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	5.7	0.35	3.66e-8	Total cholesterol levels;
SARC	cis	rs228769	1.000	rs12937692	chr17:42256430	G/A	cg13607699	chr17:42295918	UBTF	0.55	6.02	0.37	6.64e-9	Bone mineral density (hip);Bone mineral density (spine);
SARC	trans	rs3780486	0.834	rs75443249	chr9:33149207	A/G	cg04842962	chr6:43655489	MRPS18A	0.96	13.23	0.65	3.61e-30	IgG glycosylation;
SARC	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg08219700	chr8:58056026	NA	0.44	4.8	0.3	2.82e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs7236492	0.688	rs73494217	chr18:77186200	G/A	cg15644404	chr18:77186268	NFATC1	-0.66	-6.6	-0.4	2.71e-10	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs4253772	0.530	rs11090865	chr22:46731689	G/T	cg24881330	chr22:46731750	TRMU	0.7	5.7	0.35	3.55e-8	LDL cholesterol;Cholesterol, total;
SARC	cis	rs12451471	0.667	rs12942002	chr17:78101629	C/G	cg06718696	chr17:78121285	EIF4A3	0.93	10.96	0.58	7.95e-23	Plateletcrit;Mean corpuscular hemoglobin concentration;
SARC	cis	rs2832191	0.755	rs2832193	chr21:30493589	T/C	cg24692254	chr21:30365293	RNF160	-0.86	-12.02	-0.62	3.28e-26	Dental caries;
SARC	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg10144434	chr1:212209099	INTS7;DTL	-0.45	-6.62	-0.4	2.43e-10	Cancer;
SARC	cis	rs4148883	0.603	rs1893883	chr4:100124716	C/G	cg13256891	chr4:100009986	ADH5	0.5	6.49	0.39	5.12e-10	Alcohol dependence;
SARC	cis	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg12257692	chr3:49977190	RBM6	0.28	4.88	0.3	1.93e-6	Intelligence (multi-trait analysis);
SARC	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.46	-0.44	1.73e-12	Gut microbiome composition (summer);
SARC	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg13770153	chr20:60521292	NA	-0.45	-6.31	-0.38	1.39e-9	Body mass index;
SARC	cis	rs9398803	0.624	rs1338840	chr6:126629425	G/A	cg19875578	chr6:126661172	C6orf173	0.48	6.41	0.39	7.88e-10	Male-pattern baldness;
SARC	cis	rs77669868	0.929	rs76761091	chr11:114067058	A/G	cg01914181	chr11:114070210	ZBTB16	0.41	4.89	0.31	1.85e-6	Monocyte percentage of white cells;
SARC	cis	rs9393777	0.513	rs13210025	chr6:26654817	A/C	cg12826209	chr6:26865740	GUSBL1	0.66	5.95	0.36	9.98e-9	Intelligence (multi-trait analysis);
SARC	cis	rs17376456	0.877	rs7701974	chr5:93311417	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.46	0.34	1.24e-7	Diabetic retinopathy;
SARC	cis	rs11997175	0.574	rs9642707	chr8:33645789	C/G	ch.8.33884649F	chr8:33765107	NA	0.51	6.84	0.41	6.86e-11	Body mass index;
SARC	trans	rs3734266	0.527	rs9462001	chr6:34655563	G/A	cg08157914	chr7:2646478	IQCE	0.5	6.4	0.39	8.66e-10	Systemic lupus erythematosus;
SARC	cis	rs60871478	0.636	rs4276575	chr7:900035	C/T	cg05535760	chr7:792225	HEATR2	-0.69	-6.89	-0.41	5.29e-11	Cerebrospinal P-tau181p levels;
SARC	cis	rs76419734	1.000	rs17036225	chr4:106710092	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.77	5.12	0.32	6.27e-7	Post bronchodilator FEV1;
SARC	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7818345	1.000	rs11204041	chr8:19291371	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.4	5.37	0.33	1.94e-7	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs6570726	0.791	rs4332001	chr6:145934841	T/C	cg05347473	chr6:146136440	FBXO30	0.51	7.12	0.42	1.35e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg11644478	chr21:40555479	PSMG1	0.88	11.38	0.6	3.67e-24	Cognitive function;
SARC	cis	rs7336332	0.569	rs57724994	chr13:28010389	T/C	cg01674679	chr13:27998804	GTF3A	-0.48	-4.93	-0.31	1.56e-6	Weight;
SARC	cis	rs57561814	0.510	rs2066992	chr7:22768249	G/T	cg26061582	chr7:22766209	IL6	1.1	9.22	0.52	1.88e-17	Tonsillectomy;
SARC	cis	rs5753618	0.583	rs71324184	chr22:31752061	C/G	cg02404636	chr22:31891804	SFI1	0.63	8.07	0.47	3.69e-14	Colorectal cancer;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg24605529	chr2:203879461	NBEAL1	-0.89	-7.54	-0.44	1.07e-12	Autism spectrum disorder or schizophrenia;
SARC	cis	rs56176327	0.532	rs9849038	chr3:49771990	A/G	cg03060546	chr3:49711283	APEH	0.61	6.48	0.39	5.48e-10	Intelligence (multi-trait analysis);
SARC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.49	5.76	0.35	2.7e-8	Renal function-related traits (BUN);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	ch.2.180908690F	chr2:181200445	NA	-0.49	-6.66	-0.4	1.92e-10	Thyroid stimulating hormone;
SARC	cis	rs12971120	0.838	rs747176	chr18:72154931	G/A	cg25817165	chr18:72167213	CNDP2	-0.53	-8.22	-0.47	1.44e-14	Refractive error;
SARC	cis	rs7762018	0.607	rs3800544	chr6:170058374	C/T	cg19338460	chr6:170058176	WDR27	-0.82	-6.01	-0.37	6.92e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs262150	0.819	rs6956589	chr7:158769301	C/T	cg09640425	chr7:158790006	NA	-0.35	-4.72	-0.3	4.01e-6	Facial morphology (factor 20);
SARC	cis	rs9875589	0.509	rs4685061	chr3:14043823	G/A	cg19554555	chr3:13937349	NA	-0.41	-5.4	-0.33	1.64e-7	Ovarian reserve;
SARC	cis	rs36051895	0.632	rs10974987	chr9:5169302	G/T	cg02405213	chr9:5042618	JAK2	-0.55	-6.39	-0.39	9.14e-10	Pediatric autoimmune diseases;
SARC	cis	rs262150	0.546	rs7798337	chr7:158801089	G/A	cg19418458	chr7:158789849	NA	0.41	5.17	0.32	5.05e-7	Facial morphology (factor 20);
SARC	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.69	9.01	0.51	7.61e-17	Menarche (age at onset);
SARC	trans	rs1814175	0.645	rs4411280	chr11:49962750	A/G	cg03929089	chr4:120376271	NA	-0.82	-11.88	-0.61	9.2e-26	Height;
SARC	cis	rs7520050	0.778	rs2088102	chr1:46032974	T/C	cg24296786	chr1:45957014	TESK2	0.46	5.84	0.36	1.74e-8	Red blood cell count;Reticulocyte count;
SARC	cis	rs1707322	0.686	rs2991979	chr1:46055858	A/G	cg06784218	chr1:46089804	CCDC17	-0.38	-6.63	-0.4	2.32e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4901847	0.967	rs12433262	chr14:58552899	T/C	cg15908186	chr14:58618357	C14orf37	0.45	5.18	0.32	4.8e-7	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs2645694	0.651	rs2703144	chr4:77830505	C/G	cg10057126	chr4:77819792	ANKRD56	0.37	5.53	0.34	8.77e-8	Emphysema distribution in smoking;
SARC	cis	rs916888	0.647	rs199449	chr17:44808902	G/A	cg01570182	chr17:44337453	NA	0.63	7.71	0.45	3.7e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg07636037	chr3:49044803	WDR6	0.96	16.56	0.74	3.06e-41	Menarche (age at onset);
SARC	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg04772025	chr11:68637568	NA	0.5	6.32	0.38	1.28e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg05063339	chr4:54957980	NA	-0.55	-6.37	-0.39	1e-9	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs6088580	0.570	rs6058057	chr20:33065283	G/A	cg24642439	chr20:33292090	TP53INP2	0.69	8.85	0.5	2.17e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs7582180	0.652	rs12997725	chr2:100935136	A/G	cg14675211	chr2:100938903	LONRF2	0.5	7.41	0.44	2.27e-12	Intelligence (multi-trait analysis);
SARC	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg04166393	chr7:2884313	GNA12	0.55	6.61	0.4	2.6200000000000003e-10	Height;
SARC	trans	rs3779273	1.000	rs3807649	chr7:77828340	G/A	cg05596911	chr5:118502651	DMXL1	-0.53	-6.75	-0.4	1.14e-10	Body mass index;
SARC	cis	rs2952156	0.920	rs2517951	chr17:37853097	C/T	cg07936489	chr17:37558343	FBXL20	-0.42	-5.39	-0.33	1.74e-7	Asthma;
SARC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg06873352	chr17:61820015	STRADA	0.53	6.94	0.41	3.85e-11	Prudent dietary pattern;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg19265913	chr10:81154181	ZCCHC24	0.49	6.26	0.38	1.78e-9	Schizophrenia;
SARC	trans	rs208520	0.526	rs6913344	chr6:66754285	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.04	-18.52	-0.77	1.06e-47	Exhaled nitric oxide output;
SARC	cis	rs7786808	0.741	rs11765319	chr7:158226790	A/G	cg01191920	chr7:158217561	PTPRN2	-0.43	-8.27	-0.48	1.04e-14	Obesity-related traits;
SARC	cis	rs4900538	0.855	rs1210074	chr14:102889098	G/A	cg18135206	chr14:102964638	TECPR2	-0.6	-7.68	-0.45	4.39e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs2115536	0.967	rs934137	chr15:80211768	T/C	cg00225070	chr15:80189496	MTHFS	0.65	8.5	0.49	2.3e-15	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
SARC	cis	rs1401999	0.546	rs56889301	chr3:183675315	T/C	cg01324343	chr3:183735012	ABCC5	0.66	13.2	0.65	4.36e-30	Anterior chamber depth;
SARC	cis	rs78487399	0.808	rs17030835	chr2:43686245	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-4.82	-0.3	2.58e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs4568518	0.869	rs11531484	chr7:18035698	T/A	cg00911873	chr7:18067463	PRPS1L1	-0.33	-4.72	-0.3	4.08e-6	Measles;
SARC	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg22800045	chr5:56110881	MAP3K1	0.57	5.49	0.34	1.04e-7	Initial pursuit acceleration;
SARC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.46	0.57	3.12e-21	Prudent dietary pattern;
SARC	cis	rs10227331	0.692	rs34036749	chr7:157298870	T/C	cg04156418	chr7:157293606	NA	0.38	6.46	0.39	6e-10	Inattentive symptoms;
SARC	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg18252515	chr7:66147081	NA	0.43	4.74	0.3	3.68e-6	Aortic root size;
SARC	cis	rs7772486	0.754	rs1055212	chr6:146058315	A/T	cg05347473	chr6:146136440	FBXO30	-0.55	-7.59	-0.45	7.58e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7020830	1.000	rs7020830	chr9:37085184	A/T	cg14294708	chr9:37120828	ZCCHC7	1.14	21.05	0.81	8.16e-56	Schizophrenia;
SARC	cis	rs9902453	1.000	rs9897206	chr17:28406108	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.52	-6.88	-0.41	5.46e-11	Coffee consumption (cups per day);
SARC	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg16405210	chr4:1374714	KIAA1530	0.71	8.7	0.5	6.13e-16	Obesity-related traits;
SARC	cis	rs459571	0.920	rs2520094	chr9:136919985	A/T	cg13789015	chr9:136890014	NCRNA00094	0.61	8.42	0.48	3.89e-15	Platelet distribution width;
SARC	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg15049968	chr18:44337910	ST8SIA5	-0.34	-5.45	-0.34	1.3e-7	Personality dimensions;
SARC	cis	rs16976116	0.901	rs3759861	chr15:55473192	C/T	cg11288833	chr15:55489084	RSL24D1	0.61	6.14	0.37	3.59e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs3820928	0.874	rs1996998	chr2:227840294	C/A	cg11843606	chr2:227700838	RHBDD1	-0.55	-6.8	-0.41	8.51e-11	Pulmonary function;
SARC	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg10523679	chr1:76189770	ACADM	0.54	7.38	0.44	2.73e-12	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7123876	0.546	rs11604837	chr11:72360007	G/A	cg03713592	chr11:72463424	ARAP1	0.59	5.33	0.33	2.29e-7	Body mass index;
SARC	cis	rs4268898	0.931	rs2551121	chr2:24539967	T/C	cg26838691	chr2:24397539	C2orf84	-0.38	-5.15	-0.32	5.63e-7	Asthma;
SARC	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg11644478	chr21:40555479	PSMG1	-0.88	-11.29	-0.59	7.13e-24	Cognitive function;
SARC	cis	rs7103648	1.000	rs10838705	chr11:47424931	G/A	cg20307385	chr11:47447363	PSMC3	0.87	14.78	0.7	2.51e-35	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg09455208	chr3:40491958	NA	-0.37	-5.64	-0.35	4.94e-8	Renal cell carcinoma;
SARC	cis	rs1707322	0.686	rs2152078	chr1:46055600	C/T	cg06784218	chr1:46089804	CCDC17	-0.38	-6.63	-0.4	2.32e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1113500	0.787	rs10881502	chr1:108641819	C/T	cg06207961	chr1:108661230	NA	-0.38	-4.9	-0.31	1.8e-6	Growth-regulated protein alpha levels;
SARC	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg03185022	chr7:2884158	GNA12	0.45	4.99	0.31	1.19e-6	Height;
SARC	cis	rs910316	1.000	rs4899544	chr14:75546556	C/T	cg11812906	chr14:75593930	NEK9	0.87	13.66	0.67	1.39e-31	Height;
SARC	cis	rs35110281	0.782	rs9981790	chr21:45045052	G/C	cg01579765	chr21:45077557	HSF2BP	-0.34	-5.82	-0.36	1.89e-8	Mean corpuscular volume;
SARC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg06873352	chr17:61820015	STRADA	0.51	6.61	0.4	2.6200000000000003e-10	Prudent dietary pattern;
SARC	cis	rs918629	0.798	rs2161318	chr5:95288576	C/T	cg16656078	chr5:95278638	ELL2	0.61	7.58	0.44	8.19e-13	IgG glycosylation;
SARC	cis	rs798554	0.591	rs1713913	chr7:2895627	C/T	cg13628971	chr7:2884303	GNA12	0.51	6.15	0.37	3.42e-9	Height;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg16556111	chr5:92918829	NR2F1	0.44	6.35	0.38	1.09e-9	Lung adenocarcinoma;
SARC	cis	rs2180341	1.000	rs6569482	chr6:127631371	C/T	cg27446573	chr6:127587934	RNF146	1.02	14.46	0.69	2.89e-34	Breast cancer;
SARC	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.83	12.99	0.65	2.13e-29	Personality dimensions;
SARC	cis	rs7589342	0.839	rs35812588	chr2:106432201	C/T	cg14210321	chr2:106509881	NCK2	-0.42	-4.79	-0.3	2.98e-6	Addiction;
SARC	cis	rs9311474	0.598	rs1010554	chr3:52542919	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.37	-5.52	-0.34	9.14e-8	Electroencephalogram traits;
SARC	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg22590775	chr19:49891494	CCDC155	0.54	6.25	0.38	1.98e-9	Multiple sclerosis;
SARC	cis	rs7617773	0.746	rs6796343	chr3:48282021	C/A	cg11946769	chr3:48343235	NME6	0.72	9.4	0.52	5.35e-18	Coronary artery disease;
SARC	cis	rs9807989	0.765	rs6751977	chr2:102967430	T/C	cg09003973	chr2:102972529	NA	0.41	5.6	0.34	6.11e-8	Asthma;
SARC	cis	rs3126085	0.734	rs3120653	chr1:152284854	A/G	cg03465714	chr1:152285911	FLG	0.48	5.61	0.34	5.82e-8	Atopic dermatitis;
SARC	cis	rs8067545	0.750	rs4925079	chr17:19986861	T/A	cg13482628	chr17:19912719	NA	0.54	7.13	0.42	1.25e-11	Schizophrenia;
SARC	cis	rs2594989	0.945	rs2594969	chr3:11353399	C/G	cg00170343	chr3:11313890	ATG7	0.56	5.63	0.35	5.05e-8	Circulating chemerin levels;
SARC	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg24675658	chr1:53192096	ZYG11B	0.59	8.28	0.48	9.42e-15	Monocyte count;
SARC	cis	rs7826238	0.601	rs2976907	chr8:8345168	C/T	cg15556689	chr8:8085844	FLJ10661	0.39	4.94	0.31	1.48e-6	Systolic blood pressure;
SARC	cis	rs2236918	1.000	rs1635512	chr1:242024500	A/G	cg17736920	chr1:242011382	EXO1	-0.75	-10.65	-0.57	7.94e-22	Menopause (age at onset);
SARC	cis	rs6570726	0.846	rs6914304	chr6:145921017	T/C	cg23711669	chr6:146136114	FBXO30	0.78	12.25	0.63	5.73e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs8044995	0.563	rs7190134	chr16:68381516	A/G	cg09835421	chr16:68378352	PRMT7	0.68	6.45	0.39	6.41e-10	Schizophrenia;
SARC	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	7.84	0.46	1.59e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs992157	0.767	rs2382822	chr2:219173327	T/C	cg00012203	chr2:219082015	ARPC2	-0.64	-9.4	-0.52	5.39e-18	Colorectal cancer;
SARC	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg01475735	chr3:40494733	NA	-0.46	-5.12	-0.32	6.52e-7	Renal cell carcinoma;
SARC	cis	rs72781680	0.821	rs116583405	chr2:24208221	T/C	cg08917208	chr2:24149416	ATAD2B	0.58	6.08	0.37	4.76e-9	Lymphocyte counts;
SARC	cis	rs1865760	0.865	rs9467650	chr6:25958235	A/G	cg18357526	chr6:26021779	HIST1H4A	0.4	4.92	0.31	1.67e-6	Height;
SARC	cis	rs73198271	0.562	rs76960788	chr8:8674049	C/T	cg01851573	chr8:8652454	MFHAS1	0.45	5.49	0.34	1.03e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs1949733	0.917	rs10461079	chr4:8392724	G/A	cg13073564	chr4:8508604	NA	0.45	6.8	0.41	8.59e-11	Response to antineoplastic agents;
SARC	cis	rs2777491	1.000	rs316613	chr15:41747598	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.81	-12.13	-0.62	1.47e-26	Ulcerative colitis;
SARC	cis	rs9479482	0.967	rs9479478	chr6:150354608	T/G	cg03788504	chr6:150331562	NA	-0.32	-5.25	-0.33	3.41e-7	Alopecia areata;
SARC	cis	rs2073300	0.609	rs6137927	chr20:23372513	A/G	cg16736954	chr20:23401023	NAPB	0.79	4.99	0.31	1.16e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs3857536	0.904	rs979695	chr6:66896538	A/G	cg07460842	chr6:66804631	NA	-0.44	-5.21	-0.32	4.14e-7	Blood trace element (Cu levels);
SARC	cis	rs7582180	0.764	rs12999779	chr2:100924321	T/G	cg14675211	chr2:100938903	LONRF2	0.51	7.37	0.44	2.87e-12	Intelligence (multi-trait analysis);
SARC	cis	rs6582630	0.576	rs2387836	chr12:38560070	A/G	cg13010199	chr12:38710504	ALG10B	0.59	7.31	0.43	4.3e-12	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg02841227	chr6:26021843	HIST1H4A	0.48	5.29	0.33	2.83e-7	Intelligence (multi-trait analysis);
SARC	cis	rs10791097	0.694	rs1054869	chr11:130742630	G/A	cg12179176	chr11:130786555	SNX19	0.73	10.91	0.58	1.19e-22	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs11997175	0.646	rs66856932	chr8:33700782	A/G	ch.8.33884649F	chr8:33765107	NA	0.62	8.46	0.48	3.02e-15	Body mass index;
SARC	cis	rs7937682	0.737	rs682239	chr11:111425105	A/G	cg09085632	chr11:111637200	PPP2R1B	0.68	9.73	0.54	5.37e-19	Primary sclerosing cholangitis;
SARC	cis	rs787274	1.000	rs2645993	chr9:115536267	T/A	cg13803584	chr9:115635662	SNX30	-0.79	-6.14	-0.37	3.47e-9	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs6696846	0.630	rs6692706	chr1:205158561	G/T	cg21643547	chr1:205240462	TMCC2	-0.56	-7.23	-0.43	6.82e-12	Red blood cell count;
SARC	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg12311346	chr5:56204834	C5orf35	-0.58	-6.01	-0.37	7.24e-9	Initial pursuit acceleration;
SARC	cis	rs9902453	0.845	rs3102558	chr17:28023142	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	7.08	0.42	1.73e-11	Coffee consumption (cups per day);
SARC	trans	rs10771431	1.000	rs11611670	chr12:9385535	C/T	cg27600084	chr12:12264075	NA	0.58	7.93	0.46	8.97e-14	Breast size;
SARC	cis	rs651907	0.535	rs35810977	chr3:101531380	G/A	cg12386194	chr3:101231763	SENP7	0.48	5.43	0.33	1.44e-7	Colorectal cancer;
SARC	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.63e-10	Life satisfaction;
SARC	cis	rs1707322	1.000	rs6657720	chr1:46386269	G/A	cg03146154	chr1:46216737	IPP	0.46	5.54	0.34	7.97e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs193541	0.632	rs30063	chr5:122295693	G/A	cg19412675	chr5:122181750	SNX24	0.48	6.16	0.37	3.1e-9	Glucose homeostasis traits;
SARC	cis	rs1920116	0.961	rs6789970	chr3:169571810	T/C	cg14222479	chr3:169487675	ARPM1	0.44	5.34	0.33	2.24e-7	Glioma (high-grade);
SARC	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg07636037	chr3:49044803	WDR6	1.01	17.63	0.76	9.07e-45	Parkinson's disease;
SARC	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg19077165	chr18:44547161	KATNAL2	-0.52	-7.15	-0.42	1.11e-11	Personality dimensions;
SARC	cis	rs7635838	0.586	rs347617	chr3:11278211	C/T	cg00170343	chr3:11313890	ATG7	0.73	9.76	0.54	4.42e-19	HDL cholesterol;
SARC	cis	rs7223966	1.000	rs8081612	chr17:61724695	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	4.8	0.3	2.86e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7481584	0.603	rs399467	chr11:3072348	G/A	cg05729581	chr11:3078854	CARS	0.54	7.07	0.42	1.77e-11	Calcium levels;
SARC	cis	rs78545713	0.502	rs57145038	chr6:26311510	A/C	cg12826209	chr6:26865740	GUSBL1	-0.55	-4.89	-0.3	1.92e-6	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs2315504	0.626	rs757271	chr17:39003503	A/C	cg05063374	chr17:38953512	KRT28	0.28	4.86	0.3	2.13e-6	Height;
SARC	cis	rs7005606	1.000	rs4733130	chr8:32406994	T/C	cg14488905	chr8:32406789	NRG1	0.45	6.31	0.38	1.42e-9	Hirschsprung disease;
SARC	cis	rs7312774	0.881	rs7309260	chr12:107313254	T/A	cg16260113	chr12:107380972	MTERFD3	0.72	6.18	0.38	2.91e-9	Severe influenza A (H1N1) infection;
SARC	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg08280861	chr8:58055591	NA	0.61	5.96	0.36	9.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg14541582	chr5:601475	NA	-0.41	-5.06	-0.31	8.54e-7	Obesity-related traits;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg23752923	chr1:85513892	MCOLN3	0.47	6.56	0.39	3.47e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs710216	0.957	rs710215	chr1:43429105	T/C	cg07803811	chr1:43423981	SLC2A1	0.53	5.15	0.32	5.53e-7	Red cell distribution width;
SARC	cis	rs1467026	0.719	rs17037220	chr3:12818103	A/G	cg05775895	chr3:12838266	CAND2	0.77	12.93	0.65	3.42e-29	P wave duration;
SARC	cis	rs2073300	0.609	rs1076776	chr20:23427399	C/T	cg16736954	chr20:23401023	NAPB	-0.75	-4.76	-0.3	3.37e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs2074585	0.713	rs2589941	chr15:90931457	C/T	cg22089800	chr15:90895588	ZNF774	0.76	9.77	0.54	3.95e-19	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg06212747	chr3:49208901	KLHDC8B	0.88	13.64	0.67	1.56e-31	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs7582180	0.764	rs920269	chr2:100918363	G/A	cg14675211	chr2:100938903	LONRF2	0.53	7.89	0.46	1.15e-13	Intelligence (multi-trait analysis);
SARC	trans	rs78049276	0.512	rs6855875	chr4:148402737	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.63	-7.81	-0.46	1.96e-13	Pulse pressure;
SARC	cis	rs7005380	0.581	rs28546392	chr8:120931307	T/C	cg21744203	chr8:120868354	DSCC1	0.43	4.96	0.31	1.34e-6	Interstitial lung disease;
SARC	cis	rs9309711	0.689	rs4535075	chr2:3481716	T/C	cg15506890	chr2:3487001	NA	-0.46	-6.14	-0.37	3.59e-9	Neurofibrillary tangles;
SARC	cis	rs10870270	0.912	rs7079991	chr10:133736130	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.45	-5.37	-0.33	1.93e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs9911578	0.967	rs7222789	chr17:56819853	C/G	cg05425664	chr17:57184151	TRIM37	-0.66	-8.17	-0.47	1.99e-14	Intelligence (multi-trait analysis);
SARC	cis	rs963731	0.649	rs12620071	chr2:39345873	G/A	cg04010122	chr2:39346883	SOS1	1.11	6.38	0.39	9.36e-10	Corticobasal degeneration;
SARC	cis	rs7523050	0.558	rs35926243	chr1:109407712	T/A	cg08274380	chr1:109419600	GPSM2	1.06	7.99	0.46	6.34e-14	Fat distribution (HIV);
SARC	cis	rs732765	1.000	rs59159639	chr14:75351106	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.44	-5.18	-0.32	4.79e-7	Non-small cell lung cancer;
SARC	cis	rs752010	0.644	rs7541348	chr1:42113215	T/G	cg06885757	chr1:42089581	HIVEP3	0.39	5.95	0.36	9.87e-9	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs1691799	0.899	rs4762091	chr12:66747863	A/G	cg16791601	chr12:66731901	HELB	-0.71	-10.85	-0.58	1.89e-22	White blood cell count (basophil);
SARC	cis	rs739401	0.611	rs402276	chr11:3051404	C/G	cg05729581	chr11:3078854	CARS	-0.46	-5.91	-0.36	1.24e-8	Longevity;
SARC	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg16049864	chr8:95962084	TP53INP1	-0.46	-7.31	-0.43	4.34e-12	Type 2 diabetes;
SARC	cis	rs13256369	0.851	rs13271698	chr8:8567539	C/A	cg17143192	chr8:8559678	CLDN23	0.52	6.0	0.37	7.31e-9	Obesity-related traits;
SARC	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.91	9.68	0.54	7.63e-19	Platelet count;
SARC	cis	rs9581943	0.967	rs7999100	chr13:28477401	C/A	cg17352152	chr13:28491409	NA	0.37	5.02	0.31	1.03e-6	Pancreatic cancer;
SARC	cis	rs995000	0.931	rs10889354	chr1:63129082	T/C	cg06896770	chr1:63153194	DOCK7	0.97	15.32	0.71	3.94e-37	Triglyceride levels;
SARC	cis	rs9814567	1.000	rs7630874	chr3:134293291	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	7.01	0.42	2.54e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs7818688	0.745	rs11779282	chr8:95945487	A/G	cg13393036	chr8:95962371	TP53INP1	0.44	5.05	0.31	8.92e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs8028182	0.549	rs4886696	chr15:75664570	A/T	cg20655648	chr15:75932815	IMP3	-0.63	-7.39	-0.44	2.54e-12	Sudden cardiac arrest;
SARC	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg01276201	chr10:134613136	NA	0.3	5.11	0.32	6.73e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs41271473	0.526	rs10916344	chr1:228737489	C/T	cg10167378	chr1:228756711	NA	0.65	6.41	0.39	7.96e-10	Chronic lymphocytic leukemia;
SARC	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg02487422	chr3:49467188	NICN1	-0.51	-6.95	-0.41	3.65e-11	Resting heart rate;
SARC	cis	rs6141769	0.518	rs28378056	chr20:31298317	G/C	cg17884169	chr20:31446444	EFCAB8	-0.46	-4.88	-0.3	2.01e-6	Subjective well-being;
SARC	cis	rs6665290	0.904	rs6677602	chr1:227187838	G/T	cg10327440	chr1:227177885	CDC42BPA	-0.96	-18.34	-0.77	4.11e-47	Myeloid white cell count;
SARC	cis	rs9427116	0.502	rs12125166	chr1:154582129	A/G	cg14210872	chr1:155294935	RUSC1;C1orf104	-0.43	-5.41	-0.33	1.53e-7	Blood protein levels;
SARC	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg20965017	chr5:231967	SDHA	-0.58	-5.73	-0.35	3.14e-8	Breast cancer;
SARC	cis	rs10791323	0.511	rs4937837	chr11:133731134	T/C	cg15485101	chr11:133734466	NA	0.3	4.74	0.3	3.72e-6	Childhood ear infection;
SARC	cis	rs1355223	0.583	rs2941057	chr11:34882220	G/A	cg18508148	chr11:34937573	PDHX;APIP	0.51	6.5	0.39	4.74e-10	Systemic lupus erythematosus and Systemic sclerosis;
SARC	trans	rs7937682	0.889	rs1789359	chr11:111475995	T/A	cg18187862	chr3:45730750	SACM1L	0.55	6.97	0.42	3.29e-11	Primary sclerosing cholangitis;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg10141332	chr9:108282077	FSD1L	0.56	7.14	0.42	1.15e-11	Breast cancer;
SARC	cis	rs6728861	1	rs6728861	chr2:203873743	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	7.36	0.43	3.09e-12	Coronary artery disease;
SARC	cis	rs12477438	0.765	rs7605218	chr2:99593080	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-9.87	-0.54	1.98e-19	Chronic sinus infection;
SARC	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg17376030	chr22:41985996	PMM1	0.64	7.52	0.44	1.15e-12	Vitiligo;
SARC	cis	rs12497850	0.931	rs6442130	chr3:48778027	A/G	cg07636037	chr3:49044803	WDR6	0.92	14.48	0.69	2.56e-34	Parkinson's disease;
SARC	cis	rs2645694	0.533	rs2645681	chr4:77820949	G/A	cg10057126	chr4:77819792	ANKRD56	0.44	6.58	0.4	3.1e-10	Emphysema distribution in smoking;
SARC	cis	rs933688	0.532	rs973332	chr5:90555129	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.48	-5.22	-0.32	4e-7	Smoking behavior;
SARC	cis	rs9435341	0.826	rs17496332	chr1:107546375	C/T	cg09367891	chr1:107599246	PRMT6	-0.71	-8.66	-0.49	8.12e-16	Facial morphology (factor 21, depth of nasal alae);
SARC	cis	rs4780401	0.703	rs7193637	chr16:11764920	C/T	cg01061890	chr16:11836724	TXNDC11	-0.46	-5.91	-0.36	1.19e-8	Rheumatoid arthritis;
SARC	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg27286337	chr10:134555280	INPP5A	0.67	7.7	0.45	3.9e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs2439831	0.850	rs2957637	chr15:43951118	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.97	8.67	0.49	7.3e-16	Lung cancer in ever smokers;
SARC	cis	rs11190604	1.000	rs2489043	chr10:102334327	T/C	cg07080220	chr10:102295463	HIF1AN	0.83	10.75	0.58	3.65e-22	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs7474896	0.526	rs1208716	chr10:38089273	T/A	cg00409905	chr10:38381863	ZNF37A	-0.45	-4.83	-0.3	2.51e-6	Obesity (extreme);
SARC	cis	rs9303401	0.614	rs35308719	chr17:57163501	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.98	10.26	0.56	1.25e-20	Cognitive test performance;
SARC	cis	rs59918340	0.764	rs753779	chr8:142228809	T/C	cg16341495	chr8:142228727	SLC45A4	-0.37	-5.09	-0.32	7.51e-7	Immature fraction of reticulocytes;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg06646757	chr2:175211131	NA	0.47	6.98	0.42	3.02e-11	Thyroid stimulating hormone;
SARC	cis	rs11532322	1	rs11532322	chr12:123731423	A/G	cg00376283	chr12:123451042	ABCB9	0.55	6.54	0.39	3.78e-10	Schizophrenia;
SARC	cis	rs7624766	0.555	rs1455869	chr3:160475488	C/T	cg22637730	chr3:160473554	PPM1L	0.39	4.99	0.31	1.17e-6	Response to methotrexate in rheumatoid arthritis;
SARC	cis	rs2130392	0.924	rs873687	chr4:185638853	G/A	cg04058563	chr4:185651563	MLF1IP	-0.33	-4.74	-0.3	3.72e-6	Kawasaki disease;
SARC	cis	rs933688	1.000	rs9293568	chr5:90737845	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.0	12.52	0.63	7.66e-28	Smoking behavior;
SARC	cis	rs710216	0.843	rs3768043	chr1:43419354	C/A	cg22176566	chr1:43424700	SLC2A1	-0.47	-5.06	-0.31	8.69e-7	Red cell distribution width;
SARC	cis	rs3087591	0.708	rs10438801	chr17:29693785	G/A	cg24425628	chr17:29625626	OMG;NF1	0.41	5.23	0.32	3.74e-7	Hip circumference;
SARC	cis	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg11608241	chr8:8085544	FLJ10661	0.4	4.79	0.3	2.99e-6	Neuroticism;
SARC	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg11629889	chr17:40839022	CNTNAP1	0.46	6.74	0.4	1.25e-10	Colorectal or endometrial cancer;
SARC	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg08677398	chr8:58056175	NA	0.48	4.78	0.3	3.07e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs644799	0.763	rs2950521	chr11:95536870	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	15.09	0.7	2.3e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs965469	0.901	rs6139080	chr20:3314506	A/G	cg25506879	chr20:3388711	C20orf194	-0.51	-5.37	-0.33	1.94e-7	IFN-related cytopenia;
SARC	cis	rs6570726	0.935	rs419854	chr6:145844085	A/C	cg05220968	chr6:146057943	EPM2A	-0.31	-5.34	-0.33	2.23e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10791323	0.604	rs2853115	chr11:133707908	C/T	cg15485101	chr11:133734466	NA	-0.32	-4.93	-0.31	1.53e-6	Childhood ear infection;
SARC	cis	rs13166103	0.657	rs35345509	chr5:57677813	C/T	cg10487770	chr5:57879443	RAB3C	0.51	5.39	0.33	1.72e-7	Type 2 diabetes (age of onset);
SARC	cis	rs9788682	1.000	rs9788682	chr15:78802586	A/G	cg24631222	chr15:78858424	CHRNA5	-0.79	-10.5	-0.57	2.24e-21	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs4906332	0.782	rs2236281	chr14:104000518	G/T	cg19000871	chr14:103996768	TRMT61A	-0.39	-4.79	-0.3	2.96e-6	Coronary artery disease;
SARC	cis	rs1865760	0.566	rs1971509	chr6:26085777	T/C	cg17691542	chr6:26056736	HIST1H1C	0.52	6.41	0.39	8.05e-10	Height;
SARC	cis	rs11155671	0.530	rs7758020	chr6:150208111	T/C	cg00933542	chr6:150070202	PCMT1	0.29	4.9	0.31	1.79e-6	Testicular germ cell tumor;
SARC	trans	rs9951602	0.512	rs8097996	chr18:76648035	A/G	cg02800362	chr5:177631904	HNRNPAB	0.72	9.23	0.52	1.67e-17	Obesity-related traits;
SARC	trans	rs2898290	0.622	rs1600250	chr8:11345425	A/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.49	-0.44	1.44e-12	Systolic blood pressure;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg04240471	chr7:2420162	EIF3B	-0.78	-7.15	-0.42	1.13e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1949733	0.523	rs56053534	chr4:8542876	G/A	cg13073564	chr4:8508604	NA	0.49	7.34	0.43	3.47e-12	Response to antineoplastic agents;
SARC	cis	rs2153535	0.563	rs1796688	chr6:8536423	A/T	cg23788917	chr6:8435910	SLC35B3	0.62	8.19	0.47	1.68e-14	Motion sickness;
SARC	cis	rs449789	0.857	rs575681	chr6:159703534	G/A	cg14500486	chr6:159655392	FNDC1	-0.44	-5.02	-0.31	1.01e-6	Pulse pressure;
SARC	cis	rs4906332	1.000	rs55731474	chr14:103878481	G/A	cg20474699	chr14:102976161	ANKRD9	0.42	4.72	0.3	3.98e-6	Coronary artery disease;
SARC	cis	rs11758351	0.587	rs16891456	chr6:26234127	T/C	cg01420254	chr6:26195488	NA	0.55	4.75	0.3	3.49e-6	Gout;Renal underexcretion gout;
SARC	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg19774624	chr17:42201019	HDAC5	-0.78	-11.4	-0.6	3.33e-24	Total body bone mineral density;
SARC	cis	rs7223966	1.000	rs8075257	chr17:61728750	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.57	-6.21	-0.38	2.42e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs4319547	0.737	rs10846921	chr12:122943376	G/T	cg05707623	chr12:122985044	ZCCHC8	0.52	6.17	0.37	3.03e-9	Body mass index;
SARC	cis	rs17401966	0.800	rs12725210	chr1:10416993	G/A	cg15208524	chr1:10270712	KIF1B	0.48	5.67	0.35	4.12e-8	Hepatocellular carcinoma;
SARC	cis	rs7005380	0.581	rs6469866	chr8:120911297	G/T	cg21744203	chr8:120868354	DSCC1	-0.45	-5.32	-0.33	2.45e-7	Interstitial lung disease;
SARC	cis	rs7223966	1.000	rs8067064	chr17:61825984	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.45	4.76	0.3	3.39e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1345301	0.587	rs12464251	chr2:102867208	C/G	cg12451869	chr2:102867685	NA	0.42	5.82	0.36	1.96e-8	Waist circumference;
SARC	cis	rs6918586	0.658	rs198803	chr6:26135052	T/A	cg18357526	chr6:26021779	HIST1H4A	-0.44	-5.54	-0.34	8.34e-8	Schizophrenia;
SARC	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg12310025	chr6:25882481	NA	0.55	7.14	0.42	1.15e-11	Blood metabolite levels;
SARC	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg25894440	chr7:65020034	NA	-0.74	-5.57	-0.34	6.83e-8	Diabetic kidney disease;
SARC	cis	rs78132593	0.723	rs115291189	chr1:150675007	C/A	cg13175981	chr1:150552382	MCL1	0.47	4.99	0.31	1.2e-6	High light scatter reticulocyte count;
SARC	cis	rs4588572	0.643	rs2012562	chr5:77768088	T/A	cg11547950	chr5:77652471	NA	-0.41	-5.03	-0.31	9.86e-7	Triglycerides;
SARC	cis	rs16866061	0.515	rs13020268	chr2:225437923	C/T	cg22455342	chr2:225449267	CUL3	0.37	4.79	0.3	3.04e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	cis	rs17401966	0.931	rs1555849	chr1:10400602	G/T	cg15208524	chr1:10270712	KIF1B	-0.49	-5.92	-0.36	1.13e-8	Hepatocellular carcinoma;
SARC	cis	rs7937682	0.855	rs539693	chr11:111477387	A/G	cg22437258	chr11:111473054	SIK2	0.76	10.7	0.57	5.51e-22	Primary sclerosing cholangitis;
SARC	cis	rs4268898	0.662	rs17789375	chr2:24502554	G/T	cg06627628	chr2:24431161	ITSN2	-0.82	-9.88	-0.54	1.9e-19	Asthma;
SARC	cis	rs2120019	0.567	rs8037152	chr15:75156996	A/T	cg17294928	chr15:75287854	SCAMP5	-0.86	-9.04	-0.51	6.35e-17	Blood trace element (Zn levels);
SARC	cis	rs7089973	0.604	rs61596353	chr10:116597763	T/C	cg08188268	chr10:116634841	FAM160B1	0.28	4.86	0.3	2.13e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs3796352	1.000	rs34121720	chr3:53072167	C/T	cg07884673	chr3:53033167	SFMBT1	0.77	5.33	0.33	2.35e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs1707322	1.000	rs11211244	chr1:46456673	G/A	cg06784218	chr1:46089804	CCDC17	0.35	6.07	0.37	5.11e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1008375	0.966	rs758483	chr4:17703614	G/T	cg02297831	chr4:17616191	MED28	-0.4	-5.09	-0.32	7.42e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs722599	0.683	rs7160852	chr14:75239424	T/C	cg06637938	chr14:75390232	RPS6KL1	0.4	4.99	0.31	1.16e-6	IgG glycosylation;
SARC	cis	rs501120	0.657	rs583489	chr10:44738688	C/G	cg09554077	chr10:44749378	NA	0.39	5.01	0.31	1.08e-6	Coronary artery disease;Coronary heart disease;
SARC	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg05313129	chr8:58192883	C8orf71	-0.51	-4.77	-0.3	3.19e-6	Developmental language disorder (linguistic errors);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg07477928	chr9:113343166	SVEP1	0.41	6.36	0.38	1.05e-9	Thyroid stimulating hormone;
SARC	cis	rs6860806	0.531	rs270612	chr5:131637338	G/A	cg24060327	chr5:131705240	SLC22A5	-0.71	-8.5	-0.49	2.24e-15	Breast cancer;
SARC	cis	rs733592	0.894	rs886589	chr12:48477197	C/T	cg05342945	chr12:48394962	COL2A1	0.4	4.85	0.3	2.26e-6	Plateletcrit;
SARC	cis	rs9916302	0.706	rs8078599	chr17:37518660	C/T	cg15445000	chr17:37608096	MED1	-0.45	-4.83	-0.3	2.51e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs3784262	0.967	rs35511675	chr15:58266978	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.37	-5.61	-0.34	5.76e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	trans	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg00938859	chr5:1591904	SDHAP3	0.79	7.66	0.45	5.1e-13	Breast cancer;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg20448447	chr12:122255296	SETD1B	-0.43	-6.4	-0.39	8.32e-10	Chemerin levels;
SARC	cis	rs10046574	0.831	rs7785527	chr7:135063685	C/T	cg27474649	chr7:135195673	CNOT4	0.89	7.28	0.43	5.14e-12	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs9894429	0.646	rs7406825	chr17:79619188	C/T	cg10661904	chr17:79619235	PDE6G	-0.48	-6.68	-0.4	1.74e-10	Eye color traits;
SARC	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	5.69	0.35	3.81e-8	Bipolar disorder;
SARC	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg18850127	chr7:39170497	POU6F2	0.41	5.43	0.34	1.41e-7	IgG glycosylation;
SARC	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.91	-13.11	-0.65	8.98e-30	Gut microbiome composition (summer);
SARC	cis	rs9486715	0.867	rs9384602	chr6:96919561	G/A	cg06623918	chr6:96969491	KIAA0776	0.86	12.14	0.62	1.32e-26	Headache;
SARC	cis	rs897984	0.683	rs12926237	chr16:30837596	C/T	cg00531865	chr16:30841666	NA	0.47	5.63	0.35	5.25e-8	Dementia with Lewy bodies;
SARC	cis	rs9916302	0.904	rs8079560	chr17:37497661	C/T	cg20243544	chr17:37824526	PNMT	-0.53	-6.45	-0.39	6.43e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs11190604	1.000	rs11190578	chr10:102238953	C/T	cg07080220	chr10:102295463	HIF1AN	0.76	8.74	0.5	4.67e-16	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs11792861	0.962	rs11789624	chr9:111796231	T/C	cg13535736	chr9:111863775	C9orf5	-0.41	-5.05	-0.31	9.02e-7	Menarche (age at onset);
SARC	cis	rs950027	0.620	rs1719245	chr15:45623782	T/C	cg21132104	chr15:45694354	SPATA5L1	0.56	7.12	0.42	1.36e-11	Response to fenofibrate (adiponectin levels);
SARC	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg06634786	chr22:41940651	POLR3H	0.54	6.62	0.4	2.4e-10	Vitiligo;
SARC	trans	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.09	-0.42	1.56e-11	Retinal vascular caliber;
SARC	cis	rs7927771	0.965	rs34958982	chr11:47547046	T/C	cg20307385	chr11:47447363	PSMC3	-0.51	-6.28	-0.38	1.65e-9	Subjective well-being;
SARC	trans	rs3929778	0.959	rs13037119	chr20:6458525	C/T	cg27502912	chr22:51017001	CPT1B;CHKB-CPT1B	0.61	6.45	0.39	6.27e-10	QRS complex (Cornell);
SARC	cis	rs11625487	0.609	rs45493395	chr14:77976468	T/C	cg16049707	chr14:77965284	ISM2	-0.68	-5.32	-0.33	2.42e-7	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
SARC	cis	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg03213289	chr20:61660250	NA	0.46	6.43	0.39	7.22e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs778371	0.697	rs2344611	chr2:233581937	A/G	cg16596103	chr2:233749413	NGEF	-0.37	-5.57	-0.34	7.04e-8	Schizophrenia;
SARC	cis	rs7044106	0.708	rs991121	chr9:123370345	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	5.49	0.34	1.03e-7	Hip circumference adjusted for BMI;
SARC	cis	rs1371867	0.846	rs2453624	chr8:101230523	A/G	cg11906718	chr8:101322791	RNF19A	-0.69	-8.58	-0.49	1.37e-15	Atrioventricular conduction;
SARC	cis	rs4595586	0.546	rs2056159	chr12:39270417	C/G	cg13010199	chr12:38710504	ALG10B	0.57	6.69	0.4	1.61e-10	Morning vs. evening chronotype;
SARC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg07157834	chr1:205819609	PM20D1	0.7	11.13	0.59	2.44e-23	Menarche (age at onset);
SARC	cis	rs459571	0.920	rs2520094	chr9:136919985	A/T	cg01294253	chr9:136912663	BRD3	0.45	5.86	0.36	1.57e-8	Platelet distribution width;
SARC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	20.71	0.8	9.91e-55	Prudent dietary pattern;
SARC	cis	rs9875589	0.957	rs6778731	chr3:13947504	T/C	cg19554555	chr3:13937349	NA	0.51	6.62	0.4	2.39e-10	Ovarian reserve;
SARC	trans	rs2727020	0.576	rs1814175	chr11:49559172	T/C	cg15704280	chr7:45808275	SEPT13	-0.81	-13.2	-0.65	4.51e-30	Coronary artery disease;
SARC	cis	rs6964587	1.000	rs6952389	chr7:91657994	A/G	cg17063962	chr7:91808500	NA	0.93	15.78	0.72	1.19e-38	Breast cancer;
SARC	cis	rs9916302	0.904	rs12452880	chr17:37591149	G/C	cg07936489	chr17:37558343	FBXL20	-0.7	-9.15	-0.51	2.94e-17	Glomerular filtration rate (creatinine);
SARC	trans	rs1853207	1.000	rs111767681	chr10:96720169	A/G	cg02737782	chr1:8014393	NA	-0.89	-6.4	-0.39	8.69e-10	Blood metabolite levels;
SARC	cis	rs4664308	0.658	rs12987602	chr2:160960788	G/T	cg03641300	chr2:160917029	PLA2R1	-0.52	-6.86	-0.41	6.11e-11	Idiopathic membranous nephropathy;
SARC	cis	rs35146811	0.807	rs10228764	chr7:99608029	A/G	cg22004693	chr7:99632812	ZKSCAN1	-0.45	-4.87	-0.3	2.02e-6	Coronary artery disease;
SARC	cis	rs1878931	0.545	rs28603	chr16:3449479	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.65	-6.76	-0.4	1.12e-10	Body mass index (adult);
SARC	cis	rs35110281	0.807	rs1598206	chr21:45058776	A/G	cg21573476	chr21:45109991	RRP1B	-0.5	-7.24	-0.43	6.55e-12	Mean corpuscular volume;
SARC	cis	rs765787	0.530	rs4775835	chr15:45537553	T/C	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.81e-6	Uric acid levels;
SARC	cis	rs7644634	0.624	rs2301050	chr3:105401507	C/T	cg23051926	chr3:105466016	CBLB	0.47	5.96	0.36	9.14e-9	Itch intensity from mosquito bite;
SARC	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg03433033	chr1:76189801	ACADM	-0.52	-7.34	-0.43	3.61e-12	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs13390159	1.000	rs10207848	chr2:237155882	T/C	cg19324714	chr2:237145437	ASB18	0.49	4.85	0.3	2.28e-6	Response to statin therapy;
SARC	cis	rs9393692	0.840	rs9358915	chr6:26277268	G/A	cg05868516	chr6:26286170	HIST1H4H	0.56	7.37	0.43	2.9e-12	Educational attainment;
SARC	cis	rs748404	0.588	rs506120	chr15:43802024	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.41	4.83	0.3	2.49e-6	Lung cancer;
SARC	cis	rs9354308	0.933	rs2814134	chr6:66566658	C/G	cg07460842	chr6:66804631	NA	0.49	5.59	0.34	6.34e-8	Metabolite levels;
SARC	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6088580	0.634	rs6087588	chr20:33066369	T/C	cg08999081	chr20:33150536	PIGU	0.43	6.67	0.4	1.86e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs6701037	0.512	rs4650716	chr1:175128711	C/A	cg08873628	chr1:175162347	KIAA0040	0.35	4.86	0.3	2.21e-6	Alcohol dependence;
SARC	cis	rs7644634	0.624	rs1530420	chr3:105392392	T/C	cg23051926	chr3:105466016	CBLB	0.47	5.94	0.36	1.03e-8	Itch intensity from mosquito bite;
SARC	trans	rs2727020	0.619	rs1164665	chr11:49295630	T/C	cg15704280	chr7:45808275	SEPT13	0.66	7.76	0.45	2.69e-13	Coronary artery disease;
SARC	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg18252515	chr7:66147081	NA	-0.43	-4.79	-0.3	3.01e-6	Aortic root size;
SARC	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg06618935	chr21:46677482	NA	-0.4	-5.4	-0.33	1.63e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs3106136	0.967	rs2087170	chr4:95162960	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.4	-6.2	-0.38	2.54e-9	Capecitabine sensitivity;
SARC	cis	rs11122272	0.701	rs971533	chr1:231522097	T/C	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg11644478	chr21:40555479	PSMG1	-0.59	-7.28	-0.43	5.19e-12	Menarche (age at onset);
SARC	cis	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg11266682	chr4:10021025	SLC2A9	0.42	7.63	0.45	5.94e-13	Bone mineral density;
SARC	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	9.58	0.53	1.57e-18	Platelet count;
SARC	cis	rs2594989	0.721	rs9860504	chr3:11573615	G/T	cg00170343	chr3:11313890	ATG7	-0.57	-5.84	-0.36	1.75e-8	Circulating chemerin levels;
SARC	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs11098499	0.954	rs71614438	chr4:120371252	G/A	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	cis	rs7568458	0.709	rs2592551	chr2:85780131	G/A	cg02493740	chr2:85810744	VAMP5	-0.41	-5.1	-0.32	6.93e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs6964587	0.626	rs2106745	chr7:91506635	C/T	cg17063962	chr7:91808500	NA	-0.79	-11.69	-0.61	3.68e-25	Breast cancer;
SARC	cis	rs7513165	0.551	rs57406581	chr1:204141832	C/T	cg23788856	chr1:204159729	KISS1	-0.43	-5.42	-0.33	1.52e-7	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
SARC	cis	rs2404602	0.647	rs55778276	chr15:77136590	T/A	cg15268244	chr15:77196840	NA	0.45	5.22	0.32	4.02e-7	Blood metabolite levels;
SARC	cis	rs7020830	0.861	rs13295981	chr9:37330067	C/T	cg14294708	chr9:37120828	ZCCHC7	1.15	21.56	0.82	2.03e-57	Schizophrenia;
SARC	trans	rs61931739	0.635	rs3937819	chr12:33942715	A/G	cg26384229	chr12:38710491	ALG10B	0.58	7.47	0.44	1.63e-12	Morning vs. evening chronotype;
SARC	cis	rs3617	0.625	rs11715347	chr3:52883070	C/T	cg18404041	chr3:52824283	ITIH1	0.36	5.25	0.33	3.43e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs10979	0.964	rs35826562	chr6:143898672	G/A	cg25407410	chr6:143891975	LOC285740	-0.64	-8.55	-0.49	1.65e-15	Hypospadias;
SARC	cis	rs9640161	0.830	rs35840727	chr7:150063204	A/G	cg21361702	chr7:150065534	REPIN1	0.6	6.91	0.41	4.67e-11	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs3733585	0.664	rs17185870	chr4:9958214	C/A	cg11266682	chr4:10021025	SLC2A9	-0.34	-5.68	-0.35	3.91e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg16325326	chr1:53192061	ZYG11B	0.65	9.45	0.53	3.9e-18	Monocyte count;
SARC	cis	rs9309473	0.579	rs6728128	chr2:73595982	T/C	cg20560298	chr2:73613845	ALMS1	-0.57	-7.22	-0.43	7.38e-12	Metabolite levels;
SARC	cis	rs963731	0.649	rs10186762	chr2:39219361	A/G	cg04010122	chr2:39346883	SOS1	-1.06	-6.29	-0.38	1.58e-9	Corticobasal degeneration;
SARC	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg20818283	chr2:191399100	TMEM194B	0.43	5.46	0.34	1.24e-7	Pulse pressure;
SARC	cis	rs4718428	0.705	rs4718424	chr7:66376095	G/A	cg18252515	chr7:66147081	NA	-0.57	-6.25	-0.38	1.96e-9	Corneal structure;
SARC	cis	rs709400	1.000	rs3915733	chr14:104147353	G/A	cg26031613	chr14:104095156	KLC1	0.97	17.59	0.76	1.24e-44	Body mass index;
SARC	cis	rs9650657	0.615	rs1549796	chr8:10692359	C/T	cg21775007	chr8:11205619	TDH	-0.4	-4.92	-0.31	1.64e-6	Neuroticism;
SARC	cis	rs829661	0.532	rs9789517	chr2:30785824	C/G	cg12454169	chr2:30669597	LCLAT1	0.45	5.95	0.36	9.69e-9	Midgestational circulating levels of PBDEs (fetal genetic effect);
SARC	cis	rs12200560	0.505	rs9400167	chr6:97077192	G/T	cg06623918	chr6:96969491	KIAA0776	0.46	5.29	0.33	2.82e-7	Coronary heart disease;
SARC	cis	rs2153535	0.563	rs1796688	chr6:8536423	A/T	cg21535247	chr6:8435926	SLC35B3	0.53	6.65	0.4	2.09e-10	Motion sickness;
SARC	cis	rs7412746	0.611	rs2280627	chr1:150935872	A/G	cg13175981	chr1:150552382	MCL1	-0.53	-6.41	-0.39	7.98e-10	Melanoma;
SARC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg01238044	chr22:24384105	GSTT1	-0.66	-8.31	-0.48	8.01e-15	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs8523	0.774	rs61390967	chr6:11075200	A/G	cg13562911	chr6:11044106	ELOVL2	0.47	6.32	0.38	1.33e-9	Red blood cell fatty acid levels;
SARC	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg03575189	chr17:44344142	NA	0.6	5.84	0.36	1.71e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs12682352	0.602	rs635594	chr8:8613387	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.56	-0.4	3.35e-10	Neuroticism;
SARC	cis	rs4969178	0.930	rs11077363	chr17:76397309	C/T	cg20026190	chr17:76395443	PGS1	0.4	5.37	0.33	1.94e-7	HDL cholesterol levels;
SARC	cis	rs6831352	0.918	rs13113166	chr4:100050528	A/G	cg12011299	chr4:100065546	ADH4	-0.34	-5.74	-0.35	2.97e-8	Alcohol dependence;
SARC	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg26039829	chr8:22132926	PIWIL2	0.47	6.71	0.4	1.48e-10	Hypertriglyceridemia;
SARC	cis	rs986417	0.901	rs6573315	chr14:60996831	A/C	cg27398547	chr14:60952738	C14orf39	0.96	8.88	0.5	1.87e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs3857536	0.730	rs7761295	chr6:66932532	G/A	cg07460842	chr6:66804631	NA	-0.51	-5.86	-0.36	1.54e-8	Blood trace element (Cu levels);
SARC	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	5.36	0.33	1.95e-7	Electroencephalogram traits;
SARC	cis	rs3020736	0.519	rs5996116	chr22:42517492	G/A	cg15557168	chr22:42548783	NA	0.36	4.92	0.31	1.62e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9487051	0.676	rs7775206	chr6:109597222	A/G	cg01475377	chr6:109611718	NA	-0.35	-5.08	-0.32	7.8e-7	Reticulocyte fraction of red cells;
SARC	cis	rs7551222	0.646	rs4951382	chr1:204451495	T/C	cg20240347	chr1:204465584	NA	-0.3	-5.08	-0.32	7.7e-7	Schizophrenia;
SARC	cis	rs3733585	0.673	rs7375587	chr4:9954758	A/T	cg00071950	chr4:10020882	SLC2A9	0.38	5.89	0.36	1.34e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg02475777	chr4:1388615	CRIPAK	0.6	7.05	0.42	2.04e-11	Longevity;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg26664871	chr10:28032370	MKX	-0.8	-6.95	-0.41	3.63e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6704644	0.656	rs11681704	chr2:234338402	G/A	cg27060346	chr2:234359958	DGKD	-0.8	-5.71	-0.35	3.43e-8	Bilirubin levels;
SARC	cis	rs644799	1.000	rs12291986	chr11:95523030	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.71	9.72	0.54	5.86e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2985684	0.894	rs6572586	chr14:50021941	A/C	cg04989706	chr14:50066350	PPIL5	-0.51	-5.76	-0.35	2.7e-8	Carotid intima media thickness;
SARC	cis	rs568617	0.859	rs1204650	chr11:65645580	A/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.47	-5.47	-0.34	1.15e-7	Crohn's disease;
SARC	cis	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg09021430	chr5:549028	NA	-0.44	-5.71	-0.35	3.51e-8	Obesity-related traits;
SARC	trans	rs66573146	1.000	rs6812391	chr4:6963893	G/A	cg07817883	chr1:32538562	TMEM39B	1.45	9.08	0.51	4.59e-17	Granulocyte percentage of myeloid white cells;
SARC	cis	rs709400	0.663	rs17679475	chr14:103916958	A/G	cg26031613	chr14:104095156	KLC1	0.81	11.91	0.62	7.45e-26	Body mass index;
SARC	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg27266027	chr21:40555129	PSMG1	0.5	5.07	0.32	8.18e-7	Cognitive function;
SARC	cis	rs34375054	0.553	rs12581512	chr12:125622262	G/A	cg25124228	chr12:125621409	AACS	-0.68	-8.61	-0.49	1.12e-15	Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs3784262	0.669	rs12594082	chr15:58267779	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.33	-4.87	-0.3	2.04e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs9581857	0.579	rs3759434	chr13:27997700	A/C	cg22138327	chr13:27999177	GTF3A	0.59	5.96	0.36	9.38e-9	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	cis	rs6545883	0.929	rs1209434	chr2:61672958	G/A	cg15711740	chr2:61764176	XPO1	-0.42	-5.03	-0.31	9.64e-7	Tuberculosis;
SARC	cis	rs4430311	0.723	rs7548254	chr1:243891570	C/T	cg21452805	chr1:244014465	NA	-0.41	-5.36	-0.33	1.97e-7	Post-traumatic stress disorder (asjusted for relatedness);
SARC	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg10523679	chr1:76189770	ACADM	0.54	7.38	0.44	2.73e-12	Blood metabolite levels;Acylcarnitine levels;
SARC	trans	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg21659725	chr3:3221576	CRBN	-0.54	-7.02	-0.42	2.41e-11	Intelligence (multi-trait analysis);
SARC	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	11.38	0.6	3.68e-24	Platelet count;
SARC	cis	rs854765	0.583	rs5002487	chr17:17832460	A/G	cg16928487	chr17:17741425	SREBF1	-0.23	-4.88	-0.3	1.93e-6	Total body bone mineral density;
SARC	cis	rs733592	0.507	rs10747529	chr12:48473369	G/A	cg24011408	chr12:48396354	COL2A1	-0.52	-7.17	-0.42	1.01e-11	Plateletcrit;
SARC	cis	rs8014204	0.762	rs10139018	chr14:75274292	T/C	cg06637938	chr14:75390232	RPS6KL1	0.55	7.48	0.44	1.49e-12	Caffeine consumption;
SARC	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-8.16	-0.47	2.11e-14	Chronic sinus infection;
SARC	cis	rs2204008	0.837	rs7308714	chr12:38274307	T/C	cg26384229	chr12:38710491	ALG10B	0.91	13.79	0.67	4.83e-32	Bladder cancer;
SARC	cis	rs6738485	0.507	rs72819611	chr2:106845912	G/A	cg16099169	chr2:106886729	NA	-0.65	-6.94	-0.41	3.79e-11	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
SARC	trans	rs17367118	1.000	rs17464193	chr2:123629887	T/C	cg18647237	chr5:43017561	NA	-0.64	-6.3	-0.38	1.49e-9	Attention deficit hyperactivity disorder;
SARC	cis	rs2898681	0.618	rs116241740	chr4:53733523	A/G	cg00338735	chr4:53728038	RASL11B	0.49	5.0	0.31	1.15e-6	Optic nerve measurement (cup area);
SARC	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg23758822	chr17:41437982	NA	0.91	11.49	0.6	1.7e-24	Menopause (age at onset);
SARC	cis	rs35762459	1	rs35762459	chr11:8844653	T/TA	cg14711859	chr11:8959438	ASCL3	0.3	4.84	0.3	2.37e-6	Immature fraction of reticulocytes;
SARC	cis	rs10779751	1.000	rs7526649	chr1:11278163	C/T	cg08854313	chr1:11322531	MTOR	0.79	11.21	0.59	1.31e-23	Body mass index;
SARC	cis	rs10927875	0.597	rs61782184	chr1:16150976	G/A	cg07117364	chr1:16154769	NA	-0.45	-5.34	-0.33	2.19e-7	Dilated cardiomyopathy;
SARC	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.54	6.95	0.41	3.63e-11	Personality dimensions;
SARC	cis	rs7429990	0.932	rs6770477	chr3:48019258	A/G	cg11946769	chr3:48343235	NME6	-0.46	-5.39	-0.33	1.75e-7	Educational attainment (years of education);
SARC	cis	rs7412746	0.634	rs4451553	chr1:150937329	C/T	cg15448220	chr1:150897856	SETDB1	0.5	6.27	0.38	1.7e-9	Melanoma;
SARC	cis	rs12824058	0.831	rs4759655	chr12:130815740	A/G	cg24838063	chr12:130822603	PIWIL1	-0.59	-8.48	-0.49	2.55e-15	Menopause (age at onset);
SARC	cis	rs10411936	0.712	rs8103486	chr19:16603107	A/G	cg10248733	chr19:16607483	C19orf44;CALR3	0.62	7.24	0.43	6.34e-12	White blood cell count;Multiple sclerosis;
SARC	cis	rs7666738	0.783	rs10028584	chr4:98962404	C/T	cg05340658	chr4:99064831	C4orf37	0.67	9.08	0.51	4.79e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1003719	0.762	rs6517402	chr21:38447423	A/C	cg10648535	chr21:38446584	PIGP;TTC3	0.67	9.98	0.55	9.34e-20	Eye color traits;
SARC	cis	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg01579765	chr21:45077557	HSF2BP	-0.38	-6.52	-0.39	4.25e-10	Mean corpuscular volume;
SARC	cis	rs865483	0.860	rs12603185	chr17:35868304	T/C	cg06561646	chr17:35873369	DUSP14	-0.51	-6.69	-0.4	1.62e-10	Monocyte count;
SARC	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg02725872	chr8:58115012	NA	-0.37	-6.55	-0.39	3.71e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6831352	1.000	rs1126673	chr4:100045616	C/T	cg13256891	chr4:100009986	ADH5	0.68	9.13	0.51	3.43e-17	Alcohol dependence;
SARC	cis	rs981844	1.000	rs2118862	chr4:154657782	A/T	cg14289246	chr4:154710475	SFRP2	0.58	6.64	0.4	2.14e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg24110177	chr3:50126178	RBM5	0.61	8.09	0.47	3.21e-14	Body mass index;
SARC	cis	rs9611519	0.929	rs9611509	chr22:41565827	A/G	cg03806693	chr22:41940476	POLR3H	-0.54	-6.1	-0.37	4.49e-9	Neuroticism;
SARC	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.43	0.44	2.1e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4969178	0.965	rs3817294	chr17:76396963	A/G	cg02836325	chr17:76403955	PGS1	0.33	5.01	0.31	1.07e-6	HDL cholesterol levels;
SARC	cis	rs11098499	0.954	rs35091806	chr4:120325529	G/A	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	cis	rs611744	0.967	rs2212704	chr8:109198415	C/T	cg21045802	chr8:109455806	TTC35	0.44	5.23	0.32	3.81e-7	Dupuytren's disease;
SARC	cis	rs1008375	0.932	rs6835077	chr4:17653285	A/T	cg02297831	chr4:17616191	MED28	0.48	6.13	0.37	3.65e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.54	8.13	0.47	2.5e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs6866344	0.697	rs62392832	chr5:178134395	T/C	cg03877680	chr5:178157825	ZNF354A	1.03	12.74	0.64	1.42e-28	Neutrophil percentage of white cells;
SARC	trans	rs7824557	0.628	rs6601580	chr8:11193736	T/G	cg06636001	chr8:8085503	FLJ10661	0.52	6.33	0.38	1.28e-9	Retinal vascular caliber;
SARC	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg08355456	chr11:67383691	NA	-0.42	-5.54	-0.34	8.18e-8	Mean corpuscular volume;
SARC	cis	rs7769051	1.000	rs7765224	chr6:133101624	T/C	cg07930552	chr6:133119739	C6orf192	0.94	8.55	0.49	1.69e-15	Type 2 diabetes nephropathy;
SARC	cis	rs240764	0.584	rs11155653	chr6:101217123	G/A	cg09795085	chr6:101329169	ASCC3	-0.49	-6.56	-0.39	3.42e-10	Neuroticism;
SARC	cis	rs8031584	0.672	rs17815726	chr15:31313252	C/G	cg14298792	chr15:30685198	CHRFAM7A	0.51	5.01	0.31	1.1e-6	Huntington's disease progression;
SARC	cis	rs950169	0.920	rs12915390	chr15:84792069	T/C	cg24253500	chr15:84953950	NA	0.37	5.37	0.33	1.86e-7	Schizophrenia;
SARC	cis	rs114858855	1.000	rs9320292	chr6:109842965	G/A	cg26835506	chr6:109038353	NA	-0.61	-4.92	-0.31	1.61e-6	Plasma trimethylamine N-oxide levels;
SARC	cis	rs6141769	0.542	rs9421	chr20:31291161	C/T	cg17884169	chr20:31446444	EFCAB8	-0.47	-4.95	-0.31	1.41e-6	Subjective well-being;
SARC	cis	rs12367572	1.000	rs7304472	chr12:45262324	A/G	cg04608330	chr12:45269318	NELL2	-0.45	-5.65	-0.35	4.66e-8	Gut microbiome composition (summer);
SARC	cis	rs9788682	0.948	rs59683676	chr15:78833453	T/C	cg06917634	chr15:78832804	PSMA4	-0.6	-6.57	-0.4	3.33e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs477692	0.905	rs509041	chr10:131424948	A/G	cg05714579	chr10:131428358	MGMT	0.57	7.57	0.44	8.6e-13	Response to temozolomide;
SARC	cis	rs17253792	0.822	rs28478195	chr14:56047851	G/A	cg01858014	chr14:56050164	KTN1	-0.7	-5.39	-0.33	1.7e-7	Putamen volume;
SARC	cis	rs262150	0.714	rs2657397	chr7:158785095	C/T	cg04111992	chr7:158790115	NA	-0.35	-4.77	-0.3	3.25e-6	Facial morphology (factor 20);
SARC	cis	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg06558623	chr16:89946397	TCF25	0.88	5.83	0.36	1.84e-8	Skin colour saturation;
SARC	cis	rs17125944	0.505	rs10483617	chr14:53202605	A/G	cg13660082	chr14:53194042	PSMC6	0.73	4.92	0.31	1.66e-6	Alzheimer's disease (late onset);
SARC	cis	rs739401	0.611	rs2301140	chr11:3022629	C/T	cg25174290	chr11:3078921	CARS	0.55	7.28	0.43	5.07e-12	Longevity;
SARC	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4319547	0.695	rs55834409	chr12:122862560	C/G	cg05707623	chr12:122985044	ZCCHC8	0.56	6.42	0.39	7.61e-10	Body mass index;
SARC	cis	rs11711311	1.000	rs3806641	chr3:113465761	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.69	8.78	0.5	3.47e-16	IgG glycosylation;
SARC	cis	rs61935443	0.501	rs10777627	chr12:95211620	G/C	cg21533806	chr12:95267307	NA	0.4	5.04	0.31	9.56e-7	Schizophrenia;
SARC	cis	rs7917772	0.636	rs2863718	chr10:104519631	G/C	ch.10.2196322F	chr10:104248062	ACTR1A	-0.46	-5.39	-0.33	1.76e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	trans	rs208520	0.634	rs3909071	chr6:66836947	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.03	-13.88	-0.67	2.43e-32	Exhaled nitric oxide output;
SARC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg10295955	chr4:187884368	NA	-1.09	-21.04	-0.81	8.81e-56	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7772486	0.790	rs2249147	chr6:146184999	T/C	cg23711669	chr6:146136114	FBXO30	0.79	13.11	0.65	8.99e-30	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg03806693	chr22:41940476	POLR3H	-0.78	-10.33	-0.56	7.77e-21	Vitiligo;
SARC	cis	rs9291683	0.595	rs35250962	chr4:10048271	C/T	cg11266682	chr4:10021025	SLC2A9	0.4	7.13	0.42	1.23e-11	Bone mineral density;
SARC	cis	rs2071303	1.000	rs2071303	chr6:26091336	C/T	cg21479132	chr6:26055353	NA	-0.49	-5.86	-0.36	1.54e-8	Intelligence (multi-trait analysis);
SARC	trans	rs1853207	0.609	rs112194017	chr10:96598316	C/T	cg02737782	chr1:8014393	NA	-0.95	-6.37	-0.39	1.01e-9	Blood metabolite levels;
SARC	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg05872129	chr22:39784769	NA	-0.43	-6.11	-0.37	4.26e-9	Intelligence (multi-trait analysis);
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg09515097	chr16:4323120	TFAP4	-0.65	-6.76	-0.4	1.11e-10	Lung cancer in ever smokers;
SARC	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg16606324	chr3:10149918	C3orf24	0.49	4.72	0.3	4.12e-6	Alzheimer's disease;
SARC	cis	rs1044826	0.642	rs186103	chr3:139211942	C/A	cg15131784	chr3:139108705	COPB2	0.39	4.93	0.31	1.54e-6	Obesity-related traits;
SARC	cis	rs4780401	0.609	rs12927966	chr16:11814562	C/T	cg01061890	chr16:11836724	TXNDC11	-0.61	-8.68	-0.49	6.85e-16	Rheumatoid arthritis;
SARC	cis	rs6893300	0.542	rs7736300	chr5:179196898	G/A	cg14593053	chr5:179126677	CANX	0.51	7.37	0.44	2.87e-12	Resting heart rate;
SARC	cis	rs11098499	0.954	rs13151285	chr4:120314741	C/A	cg09307838	chr4:120376055	NA	0.91	12.88	0.65	4.9e-29	Corneal astigmatism;
SARC	cis	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg00800038	chr16:89945340	TCF25	-0.74	-5.1	-0.32	7.08e-7	Skin colour saturation;
SARC	cis	rs7769051	1.000	rs7761365	chr6:133101561	T/A	cg07930552	chr6:133119739	C6orf192	0.94	8.55	0.49	1.69e-15	Type 2 diabetes nephropathy;
SARC	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg12463550	chr7:65579703	CRCP	0.69	5.24	0.32	3.54e-7	Diabetic kidney disease;
SARC	cis	rs17209837	0.831	rs56223611	chr7:87083157	C/A	cg00919237	chr7:87102261	ABCB4	-0.47	-4.96	-0.31	1.38e-6	Gallbladder cancer;
SARC	cis	rs9430161	0.579	rs7542164	chr1:11040223	G/A	cg27631724	chr1:11040367	C1orf127	0.39	5.88	0.36	1.44e-8	Ewing sarcoma;
SARC	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg11890956	chr21:40555474	PSMG1	-1.05	-15.78	-0.72	1.19e-38	Cognitive function;
SARC	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg24829409	chr8:58192753	C8orf71	-0.56	-6.05	-0.37	5.68e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg16339924	chr4:17578868	LAP3	0.64	8.56	0.49	1.56e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs12249377	0.519	rs7087400	chr10:92587180	A/G	cg14313238	chr10:92632228	RPP30	0.43	5.14	0.32	5.91e-7	White matter microstructure (global fractional anisotropy);
SARC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg10963375	chr1:205815865	PM20D1	-0.4	-5.79	-0.35	2.31e-8	Menarche (age at onset);
SARC	cis	rs4689388	0.889	rs4629534	chr4:6294124	G/T	cg00701064	chr4:6280414	WFS1	0.53	8.46	0.48	2.9e-15	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg11764359	chr7:65958608	NA	0.86	12.33	0.63	3.29e-27	Aortic root size;
SARC	cis	rs12044355	0.929	rs11122322	chr1:231843962	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.53	-7.31	-0.43	4.18e-12	Alzheimer's disease;
SARC	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg18876405	chr7:65276391	NA	-0.67	-8.3	-0.48	8.63e-15	Aortic root size;
SARC	cis	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg27418564	chr15:44581614	CASC4	-0.49	-5.29	-0.33	2.84e-7	Lung cancer in ever smokers;
SARC	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg26335602	chr6:28129616	ZNF389	0.52	5.88	0.36	1.44e-8	Parkinson's disease;
SARC	cis	rs9786986	0.516	rs12401892	chr1:235701393	A/G	cg08848088	chr1:235714526	GNG4	0.53	5.56	0.34	7.36e-8	Body mass index;
SARC	cis	rs1941023	0.503	rs2233238	chr11:60145441	G/C	cg08716584	chr11:60157161	MS4A7	-0.4	-6.48	-0.39	5.52e-10	Congenital heart disease (maternal effect);
SARC	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg13939156	chr17:80058883	NA	-0.41	-6.27	-0.38	1.7e-9	Life satisfaction;
SARC	cis	rs11770686	0.871	rs2269889	chr7:75322878	C/T	cg17787366	chr7:75369077	HIP1	0.43	5.44	0.34	1.36e-7	Essential tremor;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg01510153	chr7:140620152	BRAF	0.48	6.34	0.38	1.19e-9	Thyroid stimulating hormone;
SARC	cis	rs876084	0.505	rs12680859	chr8:121118968	A/G	cg06265175	chr8:121136014	COL14A1	0.59	7.7	0.45	3.93e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs1003719	0.762	rs3787787	chr21:38463452	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.63	9.05	0.51	5.67e-17	Eye color traits;
SARC	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.62	-6.73	-0.4	1.29e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg07701084	chr6:150067640	NUP43	0.4	5.37	0.33	1.91e-7	Lung cancer;
SARC	cis	rs10489202	0.608	rs16828093	chr1:168078384	C/T	cg24449463	chr1:168025552	DCAF6	-0.58	-7.72	-0.45	3.47e-13	Schizophrenia;
SARC	cis	rs9303401	0.659	rs7223708	chr17:56896398	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.06	12.03	0.62	3.09e-26	Cognitive test performance;
SARC	cis	rs7644634	0.576	rs6437611	chr3:105391448	T/A	cg23051926	chr3:105466016	CBLB	0.49	5.56	0.34	7.4e-8	Itch intensity from mosquito bite;
SARC	cis	rs17376456	0.877	rs10070390	chr5:93452345	G/A	cg21475434	chr5:93447410	FAM172A	0.88	8.11	0.47	2.81e-14	Diabetic retinopathy;
SARC	cis	rs10861342	1.000	rs7136344	chr12:105528268	A/G	cg23923672	chr12:105501055	KIAA1033	0.7	5.58	0.34	6.54e-8	IgG glycosylation;
SARC	cis	rs3784262	0.967	rs4646612	chr15:58265077	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.37	-5.61	-0.34	5.76e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs6674176	0.597	rs12127737	chr1:44402565	G/A	cg13606994	chr1:44402422	ARTN	-0.33	-5.46	-0.34	1.19e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg15049968	chr18:44337910	ST8SIA5	-0.37	-6.14	-0.37	3.54e-9	Personality dimensions;
SARC	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.95	11.92	0.62	6.96e-26	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg02487422	chr3:49467188	NICN1	0.52	6.94	0.41	3.82e-11	Resting heart rate;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg10966500	chr12:110338339	TCHP	0.5	6.68	0.4	1.72e-10	Thyroid stimulating hormone;
SARC	cis	rs6733011	0.530	rs7608889	chr2:99481350	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.38	-4.83	-0.3	2.52e-6	Bipolar disorder;
SARC	cis	rs11098499	0.604	rs12642411	chr4:120580525	T/C	cg09307838	chr4:120376055	NA	0.82	10.84	0.58	2.01e-22	Corneal astigmatism;
SARC	cis	rs9467711	0.720	rs7749823	chr6:26158079	A/C	cg21479132	chr6:26055353	NA	0.68	5.45	0.34	1.28e-7	Autism spectrum disorder or schizophrenia;
SARC	cis	rs17401966	0.838	rs12737239	chr1:10323973	C/G	cg15208524	chr1:10270712	KIF1B	0.46	5.37	0.33	1.86e-7	Hepatocellular carcinoma;
SARC	cis	rs7264396	0.676	rs6060730	chr20:34558503	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-6.92	-0.41	4.41e-11	Total cholesterol levels;
SARC	cis	rs593982	0.688	rs3897552	chr11:65560880	C/T	cg08755490	chr11:65554678	OVOL1	-0.96	-10.14	-0.55	3.03e-20	Atopic dermatitis;
SARC	cis	rs7520050	0.966	rs785464	chr1:46523089	T/C	cg06784218	chr1:46089804	CCDC17	-0.28	-5.12	-0.32	6.39e-7	Red blood cell count;Reticulocyte count;
SARC	cis	rs5753618	0.519	rs5997939	chr22:31677130	C/G	cg02404636	chr22:31891804	SFI1	-0.49	-5.22	-0.32	3.99e-7	Colorectal cancer;
SARC	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg18252515	chr7:66147081	NA	1.29	11.12	0.59	2.48e-23	Diabetic kidney disease;
SARC	cis	rs2730245	0.550	rs2709860	chr7:158651156	A/T	cg11945929	chr7:158750384	NA	0.31	4.99	0.31	1.18e-6	Height;
SARC	cis	rs1008375	0.800	rs10008598	chr4:17607323	T/C	cg27347728	chr4:17578864	LAP3	0.46	5.59	0.34	6.19e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs12477438	0.765	rs12612688	chr2:99613091	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.67	-8.93	-0.5	1.35e-16	Chronic sinus infection;
SARC	cis	rs11711311	1.000	rs16861312	chr3:113492402	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.73	9.64	0.53	1.01e-18	IgG glycosylation;
SARC	cis	rs9894429	0.646	rs9904137	chr17:79613925	C/T	cg18240062	chr17:79603768	NPLOC4	0.59	7.31	0.43	4.15e-12	Eye color traits;
SARC	cis	rs4481887	0.927	rs10788765	chr1:248445642	A/G	cg01631408	chr1:248437212	OR2T33	0.4	5.01	0.31	1.06e-6	Common traits (Other);
SARC	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg08219700	chr8:58056026	NA	0.62	6.53	0.39	4.08e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs3126085	0.935	rs6681457	chr1:152297117	C/T	cg26876637	chr1:152193138	HRNR	-0.52	-5.68	-0.35	4.09e-8	Atopic dermatitis;
SARC	cis	rs6901004	0.803	rs11153272	chr6:111479539	C/T	cg15721981	chr6:111408429	SLC16A10	-0.44	-5.41	-0.33	1.57e-7	Blood metabolite levels;
SARC	cis	rs950027	0.620	rs1346267	chr15:45690989	A/G	cg21132104	chr15:45694354	SPATA5L1	0.51	6.2	0.38	2.55e-9	Response to fenofibrate (adiponectin levels);
SARC	cis	rs11711311	1.000	rs12631232	chr3:113497386	C/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	8.64	0.49	8.88e-16	IgG glycosylation;
SARC	cis	rs76917914	0.735	rs4742716	chr9:100851420	C/T	cg03040243	chr9:100819229	NANS	0.66	6.77	0.41	1.02e-10	Immature fraction of reticulocytes;
SARC	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg05623727	chr3:50126028	RBM5	0.32	4.87	0.3	2.06e-6	Intelligence (multi-trait analysis);
SARC	trans	rs2727020	0.757	rs7924526	chr11:49267043	G/A	cg03929089	chr4:120376271	NA	0.75	9.85	0.54	2.38e-19	Coronary artery disease;
SARC	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg24675658	chr1:53192096	ZYG11B	-0.62	-8.75	-0.5	4.44e-16	Monocyte count;
SARC	cis	rs854765	0.583	rs12603148	chr17:17865257	C/T	cg04398451	chr17:18023971	MYO15A	-0.44	-6.04	-0.37	6.06e-9	Total body bone mineral density;
SARC	cis	rs858239	0.932	rs858275	chr7:23294144	T/C	cg23682824	chr7:23144976	KLHL7	0.6	7.45	0.44	1.81e-12	Cerebrospinal fluid biomarker levels;
SARC	cis	rs7089973	0.966	rs55711292	chr10:116604870	T/G	cg08188268	chr10:116634841	FAM160B1	0.35	5.12	0.32	6.37e-7	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs6942407	0.546	rs4728686	chr7:86814784	G/A	cg02420886	chr7:86849541	C7orf23	0.71	6.11	0.37	4.04e-9	Food allergy;
SARC	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg01448562	chr3:133502909	NA	-0.44	-6.53	-0.39	4.13e-10	Iron status biomarkers;
SARC	trans	rs11098499	0.863	rs3822195	chr4:120471660	C/T	cg25214090	chr10:38739885	LOC399744	0.57	7.25	0.43	6.27e-12	Corneal astigmatism;
SARC	cis	rs4588572	0.644	rs7714871	chr5:77754268	G/T	cg18281939	chr5:77783895	LHFPL2	0.35	4.85	0.3	2.25e-6	Triglycerides;
SARC	cis	rs131777	0.708	rs131749	chr22:51024624	C/T	cg25309564	chr22:51001381	C22orf41	-0.51	-6.28	-0.38	1.64e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs2749592	0.513	rs9417249	chr10:37837155	C/T	cg25427524	chr10:38739819	LOC399744	0.41	6.0	0.37	7.65e-9	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs2576037	0.899	rs2246877	chr18:44577005	A/G	cg15049968	chr18:44337910	ST8SIA5	0.32	4.94	0.31	1.47e-6	Personality dimensions;
SARC	cis	rs607987	0.836	rs1222203	chr11:30336334	A/G	cg06241208	chr11:30344200	C11orf46	-0.39	-4.76	-0.3	3.4e-6	Body mass index;
SARC	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg04772025	chr11:68637568	NA	0.53	6.67	0.4	1.83e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs2033711	0.811	rs9304814	chr19:58951811	C/A	cg11952622	chr19:58962976	ZNF324B	0.58	7.52	0.44	1.21e-12	Uric acid clearance;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg04324509	chr3:101295624	PCNP	0.49	6.33	0.38	1.24e-9	Schizophrenia;
SARC	cis	rs644799	1.000	rs563653	chr11:95561488	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.9	14.03	0.68	7.82e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.45	6.65	0.4	2.1e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs7178572	0.568	rs12443386	chr15:77491389	C/T	cg22256960	chr15:77711686	NA	0.45	4.92	0.31	1.66e-6	Type 2 diabetes;
SARC	cis	rs2075371	0.933	rs432336	chr7:133949064	A/G	cg20476274	chr7:133979776	SLC35B4	0.62	8.56	0.49	1.53e-15	Mean platelet volume;
SARC	cis	rs644799	1.000	rs623191	chr11:95548359	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	15.35	0.71	3.21e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs66573146	0.831	rs56031152	chr4:6973832	C/A	cg00086871	chr4:6988644	TBC1D14	0.89	5.29	0.33	2.88e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs6426558	0.537	rs2813969	chr1:227404082	T/C	cg10327440	chr1:227177885	CDC42BPA	0.45	5.28	0.33	2.97e-7	Neutrophil percentage of white cells;
SARC	cis	rs1468333	0.824	rs4835673	chr5:137607680	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.74	9.65	0.53	9.22e-19	Resting heart rate;
SARC	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg22875332	chr1:76189707	ACADM	0.5	7.17	0.42	1.01e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs1865760	0.516	rs10807007	chr6:26048931	A/C	cg10373733	chr6:25993375	NA	0.39	4.85	0.3	2.22e-6	Height;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg14530993	chr4:882597	GAK	0.49	6.44	0.39	6.79e-10	Schizophrenia;
SARC	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg17971929	chr21:40555470	PSMG1	1.0	14.01	0.68	9.02e-33	Cognitive function;
SARC	cis	rs4253772	0.530	rs9615980	chr22:46791143	A/T	cg24881330	chr22:46731750	TRMU	0.73	5.31	0.33	2.5e-7	LDL cholesterol;Cholesterol, total;
SARC	cis	rs9322193	0.607	rs10457852	chr6:150201720	C/T	cg05036130	chr6:150231994	NA	0.34	5.1	0.32	6.96e-7	Lung cancer;
SARC	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	cis	rs6831352	0.703	rs2602862	chr4:100033221	A/G	cg13256891	chr4:100009986	ADH5	0.6	7.9	0.46	1.09e-13	Alcohol dependence;
SARC	cis	rs9517313	0.584	rs9556974	chr13:99216302	G/C	cg07423050	chr13:99094983	FARP1	-0.44	-5.83	-0.36	1.8e-8	Neuroticism;
SARC	cis	rs295137	0.836	rs10804097	chr2:201104924	A/T	cg23649088	chr2:200775458	C2orf69	0.48	6.76	0.41	1.08e-10	Asthma (bronchodilator response);
SARC	cis	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg24110177	chr3:50126178	RBM5	0.4	5.07	0.32	7.98e-7	Intelligence (multi-trait analysis);
SARC	cis	rs8180040	0.726	rs7610636	chr3:47064436	A/C	cg27129171	chr3:47204927	SETD2	-0.63	-8.48	-0.49	2.57e-15	Colorectal cancer;
SARC	cis	rs7084402	0.967	rs1649038	chr10:60330439	G/A	cg07615347	chr10:60278583	BICC1	0.58	8.49	0.49	2.37e-15	Refractive error;
SARC	cis	rs2120019	0.935	rs8042409	chr15:75350433	G/A	cg17294928	chr15:75287854	SCAMP5	-0.97	-14.24	-0.68	1.56e-33	Blood trace element (Zn levels);
SARC	cis	rs7552404	0.627	rs12127049	chr1:76353248	G/A	cg03433033	chr1:76189801	ACADM	0.44	5.55	0.34	7.89e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs965469	0.779	rs6051836	chr20:3386482	C/T	cg25506879	chr20:3388711	C20orf194	-0.47	-5.08	-0.32	7.86e-7	IFN-related cytopenia;
SARC	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	0.42	4.81	0.3	2.66e-6	Alzheimer's disease (late onset);
SARC	cis	rs2197308	0.631	rs4882308	chr12:38446252	G/C	cg26384229	chr12:38710491	ALG10B	-0.55	-6.86	-0.41	6.16e-11	Morning vs. evening chronotype;
SARC	cis	rs7917772	0.636	rs7079231	chr10:104527341	A/G	ch.10.2196322F	chr10:104248062	ACTR1A	0.53	6.55	0.39	3.68e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs634534	0.591	rs688862	chr11:65733393	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.47	7.06	0.42	1.92e-11	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs10216189	0.785	rs4623325	chr7:5526807	C/T	cg05318486	chr7:5553423	FBXL18	0.47	5.86	0.36	1.6e-8	Relative hand skill in reading disability;
SARC	cis	rs765787	0.530	rs11636410	chr15:45535913	A/C	cg26924012	chr15:45694286	SPATA5L1	0.44	5.41	0.33	1.53e-7	Uric acid levels;
SARC	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg21226059	chr5:178986404	RUFY1	-0.37	-5.25	-0.33	3.38e-7	Lung cancer;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg26220528	chr12:57623348	SHMT2	-0.59	-6.63	-0.4	2.34e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs2227564	0.649	rs2948689	chr10:75657860	A/G	cg16540259	chr10:75572220	NDST2	0.37	5.11	0.32	6.81e-7	Crohn's disease;Inflammatory bowel disease;
SARC	trans	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg07211511	chr3:129823064	LOC729375	-0.61	-6.58	-0.4	3.12e-10	Blood pressure (smoking interaction);
SARC	cis	rs2180341	0.961	rs910720	chr6:127619070	T/C	cg24812749	chr6:127587940	RNF146	0.97	12.89	0.65	4.63e-29	Breast cancer;
SARC	cis	rs9325144	0.723	rs1586373	chr12:39181582	G/A	cg13010199	chr12:38710504	ALG10B	-0.5	-6.03	-0.37	6.43e-9	Morning vs. evening chronotype;
SARC	cis	rs2011503	0.941	rs56278919	chr19:19367190	A/G	cg03709012	chr19:19516395	GATAD2A	0.64	5.57	0.34	7.18e-8	Bipolar disorder;
SARC	cis	rs2814982	0.605	rs114032116	chr6:34468333	C/T	cg14254433	chr6:34482411	PACSIN1	-0.5	-4.74	-0.3	3.75e-6	Cholesterol, total;Total cholesterol levels;
SARC	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg06212747	chr3:49208901	KLHDC8B	0.79	11.51	0.6	1.44e-24	Menarche (age at onset);
SARC	cis	rs950880	0.710	rs17027037	chr2:102994884	A/G	cg03938978	chr2:103052716	IL18RAP	-0.34	-4.85	-0.3	2.22e-6	Serum protein levels (sST2);
SARC	cis	rs4780401	0.755	rs2868981	chr16:11765518	T/C	cg01061890	chr16:11836724	TXNDC11	-0.46	-5.8	-0.36	2.12e-8	Rheumatoid arthritis;
SARC	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg11062466	chr8:58055876	NA	0.54	5.56	0.34	7.55e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9868809	0.505	rs28567949	chr3:48744560	G/A	cg00383909	chr3:49044727	WDR6	0.65	6.12	0.37	3.88e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs1008375	1.000	rs4698649	chr4:17692782	A/G	cg16339924	chr4:17578868	LAP3	0.56	7.03	0.42	2.24e-11	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7914558	0.966	rs12766205	chr10:104893568	A/G	cg04362960	chr10:104952993	NT5C2	0.42	4.99	0.31	1.16e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs4774830	0.661	rs62045239	chr15:56294642	G/A	cg24530489	chr15:56299380	NA	-0.83	-5.07	-0.32	7.94e-7	Delta-5 desaturase activity;
SARC	cis	rs4319547	0.956	rs9988963	chr12:122991478	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.62	-7.33	-0.43	3.82e-12	Body mass index;
SARC	cis	rs4481887	0.927	rs10157089	chr1:248488157	A/G	cg13385794	chr1:248469461	NA	0.34	5.1	0.32	6.89e-7	Common traits (Other);
SARC	cis	rs55823223	0.564	rs58363746	chr17:73850819	C/T	cg14829360	chr17:73884958	NA	-0.59	-7.89	-0.46	1.15e-13	Psoriasis;
SARC	cis	rs240764	0.817	rs58266877	chr6:101156284	C/T	cg09795085	chr6:101329169	ASCC3	-0.47	-6.08	-0.37	4.76e-9	Neuroticism;
SARC	cis	rs2933343	0.700	rs1680788	chr3:128625318	C/T	cg24203234	chr3:128598194	ACAD9	0.63	8.03	0.47	4.8e-14	IgG glycosylation;
SARC	cis	rs1800469	1.000	rs1982072	chr19:41864509	T/A	cg08477640	chr19:41863820	B9D2	0.72	9.25	0.52	1.46e-17	Colorectal cancer;
SARC	cis	rs7084402	0.967	rs1658463	chr10:60298208	C/T	cg07615347	chr10:60278583	BICC1	0.59	8.77	0.5	3.93e-16	Refractive error;
SARC	cis	rs7552404	0.727	rs6683437	chr1:76316619	G/A	cg10523679	chr1:76189770	ACADM	0.46	5.45	0.34	1.3e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs11690935	0.959	rs6433314	chr2:172660971	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.98	-15.73	-0.72	1.73e-38	Schizophrenia;
SARC	cis	rs72781680	0.821	rs17046004	chr2:24144873	A/G	cg06627628	chr2:24431161	ITSN2	-0.56	-5.85	-0.36	1.66e-8	Lymphocyte counts;
SARC	cis	rs2742234	0.541	rs10793422	chr10:43703874	G/A	cg15436174	chr10:43711423	RASGEF1A	0.41	4.81	0.3	2.7e-6	Hirschsprung disease;
SARC	cis	rs1059312	0.932	rs4760589	chr12:129284382	T/C	cg09035930	chr12:129282057	SLC15A4	0.62	8.93	0.5	1.32e-16	Systemic lupus erythematosus;
SARC	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg22496380	chr5:211416	CCDC127	-0.88	-9.35	-0.52	7.72e-18	Breast cancer;
SARC	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg11987759	chr7:65425863	GUSB	0.47	5.8	0.36	2.11e-8	Aortic root size;
SARC	cis	rs763121	0.819	rs3747173	chr22:39069045	A/G	cg21395723	chr22:39101663	GTPBP1	0.54	6.14	0.37	3.53e-9	Menopause (age at onset);
SARC	cis	rs7552404	0.696	rs67487205	chr1:76373756	T/C	cg22875332	chr1:76189707	ACADM	0.41	4.92	0.31	1.65e-6	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6121246	0.567	rs6088796	chr20:30213229	C/T	cg13852791	chr20:30311386	BCL2L1	0.64	5.64	0.35	4.79e-8	Mean corpuscular hemoglobin;
SARC	cis	rs6439153	0.901	rs2630263	chr3:128688318	A/G	cg25356066	chr3:128598488	ACAD9	0.46	5.52	0.34	9.2e-8	Pneumococcal bacteremia;
SARC	cis	rs2463822	1.000	rs2513052	chr11:62108248	C/G	cg06239285	chr11:62104954	ASRGL1	0.88	9.32	0.52	9.26e-18	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs986417	1.000	rs1254287	chr14:60861774	C/T	cg27398547	chr14:60952738	C14orf39	-0.99	-9.29	-0.52	1.17e-17	Gut microbiota (bacterial taxa);
SARC	cis	rs11122272	0.735	rs2250704	chr1:231486647	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-9.91	-0.54	1.5e-19	Hemoglobin concentration;
SARC	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg06212747	chr3:49208901	KLHDC8B	0.76	11.14	0.59	2.16e-23	Menarche (age at onset);
SARC	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg21171335	chr12:122356390	WDR66	0.39	6.35	0.38	1.13e-9	Mean corpuscular volume;
SARC	cis	rs12995491	0.763	rs1914735	chr2:88511953	A/T	cg07952391	chr2:88470173	THNSL2	-0.35	-4.71	-0.3	4.2e-6	Response to metformin (IC50);
SARC	cis	rs2658782	0.756	rs3019205	chr11:93109553	A/G	cg15737290	chr11:93063684	CCDC67	0.73	7.73	0.45	3.11e-13	Pulmonary function decline;
SARC	cis	rs713587	0.563	rs2033655	chr2:25101092	C/T	cg04586622	chr2:25135609	ADCY3	0.32	5.46	0.34	1.21e-7	Body mass index in non-asthmatics;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg23670563	chr7:767237	PRKAR1B;HEATR2	-0.5	-6.23	-0.38	2.11e-9	Breast cancer;
SARC	trans	rs61931739	0.517	rs10844738	chr12:34059503	T/A	cg26384229	chr12:38710491	ALG10B	0.73	10.28	0.56	1.11e-20	Morning vs. evening chronotype;
SARC	cis	rs13191362	1.000	rs73035012	chr6:162997279	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.49	0.34	1.04e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs12780845	0.522	rs10795457	chr10:17230150	A/G	cg11116878	chr10:17243438	TRDMT1	0.38	4.92	0.31	1.66e-6	Homocysteine levels;
SARC	cis	rs765787	0.530	rs1706831	chr15:45516230	T/C	cg24006582	chr15:45444508	DUOX1	-0.49	-6.47	-0.39	5.7e-10	Uric acid levels;
SARC	cis	rs7589342	0.509	rs10177819	chr2:106386640	G/A	cg16077055	chr2:106428750	NCK2	0.32	6.43	0.39	7.23e-10	Addiction;
SARC	cis	rs62191099	0.885	rs6741317	chr2:239862720	G/A	cg07215236	chr2:239865226	NA	0.36	4.81	0.3	2.74e-6	Alcohol dependence;
SARC	cis	rs2380220	1.000	rs2380222	chr6:95975395	C/T	cg04719120	chr6:96025338	MANEA	0.65	6.72	0.4	1.39e-10	Behavioural disinhibition (generation interaction);
SARC	cis	rs11785400	1.000	rs7002932	chr8:143738816	C/A	cg24634471	chr8:143751801	JRK	0.68	9.17	0.52	2.5e-17	Schizophrenia;
SARC	cis	rs546131	0.571	rs2421741	chr11:34856976	A/G	cg06937548	chr11:34938143	PDHX;APIP	-0.44	-4.73	-0.3	3.81e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs3617	0.598	rs56214994	chr3:52878600	G/C	cg04865290	chr3:52927548	TMEM110	0.34	5.0	0.31	1.13e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg15533434	chr14:39583459	SIP1	-0.55	-6.48	-0.39	5.33e-10	Alcohol dependence;
SARC	cis	rs8141529	1.000	rs132534	chr22:29299806	T/C	cg02153584	chr22:29168773	CCDC117	-0.75	-10.24	-0.56	1.52e-20	Lymphocyte counts;
SARC	cis	rs8523	0.774	rs12526913	chr6:11082924	A/G	cg13562911	chr6:11044106	ELOVL2	0.41	5.37	0.33	1.87e-7	Red blood cell fatty acid levels;
SARC	cis	rs3820928	0.874	rs4675132	chr2:227841792	A/C	cg05526886	chr2:227700861	RHBDD1	-0.57	-6.93	-0.41	4.16e-11	Pulmonary function;
SARC	cis	rs9486719	1.000	rs2179126	chr6:96871350	A/G	cg06623918	chr6:96969491	KIAA0776	0.73	8.01	0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs986417	0.748	rs1956552	chr14:60942685	A/G	cg27398547	chr14:60952738	C14orf39	0.98	8.85	0.5	2.24e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.67	8.49	0.49	2.4e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1448094	0.512	rs60986162	chr12:86247054	T/G	cg02569458	chr12:86230093	RASSF9	0.38	5.39	0.33	1.71e-7	Major depressive disorder;
SARC	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg08975724	chr8:8085496	FLJ10661	0.52	6.46	0.39	6.05e-10	Mood instability;
SARC	cis	rs3785574	0.705	rs2665856	chr17:61982721	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.79	-9.26	-0.52	1.36e-17	Height;
SARC	cis	rs2281636	0.754	rs7092699	chr10:101365302	G/A	cg22891862	chr10:101279697	NA	-0.3	-4.78	-0.3	3.14e-6	Obesity-related traits;
SARC	cis	rs870825	0.616	rs79884757	chr4:185621454	A/G	cg04058563	chr4:185651563	MLF1IP	0.82	11.42	0.6	2.8e-24	Blood protein levels;
SARC	cis	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg00071950	chr4:10020882	SLC2A9	0.39	6.31	0.38	1.4e-9	Bone mineral density;
SARC	cis	rs7681440	0.583	rs2737022	chr4:90739662	A/C	cg06632027	chr4:90757378	SNCA	-0.42	-5.23	-0.32	3.81e-7	Dementia with Lewy bodies;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg13154908	chr3:178869001	PIK3CA	0.43	6.36	0.38	1.07e-9	Thyroid stimulating hormone;
SARC	cis	rs9443189	0.774	rs2647405	chr6:76450023	C/T	cg01950844	chr6:76311363	SENP6	-0.71	-6.63	-0.4	2.34e-10	Prostate cancer;
SARC	cis	rs796364	0.755	rs6739563	chr2:201134216	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.63	4.8	0.3	2.82e-6	Schizophrenia;
SARC	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.38	4.71	0.3	4.2e-6	Tonsillectomy;
SARC	cis	rs112908525	1	rs112908525	chr7:80305278	T/TGAGGGTTGA	cg21369886	chr7:80305251	CD36	-0.39	-5.86	-0.36	1.54e-8	Mean corpuscular volume;
SARC	cis	rs7220401	0.789	rs4794859	chr17:27962393	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.46	-5.29	-0.33	2.85e-7	Coronary artery disease;
SARC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	19.74	0.79	1.22e-51	Prudent dietary pattern;
SARC	cis	rs72781680	0.846	rs55770503	chr2:24030126	A/T	cg06627628	chr2:24431161	ITSN2	-0.67	-6.41	-0.39	8.04e-10	Lymphocyte counts;
SARC	cis	rs763121	0.785	rs5757199	chr22:39040617	T/G	cg06022373	chr22:39101656	GTPBP1	0.9	11.56	0.6	9.96e-25	Menopause (age at onset);
SARC	cis	rs9611565	0.921	rs5751077	chr22:41720728	G/C	cg17376030	chr22:41985996	PMM1	0.52	6.6	0.4	2.7e-10	Vitiligo;
SARC	cis	rs7587476	0.601	rs17489363	chr2:215674341	A/G	cg04004882	chr2:215674386	BARD1	-0.6	-6.97	-0.42	3.22e-11	Neuroblastoma;
SARC	cis	rs12924604	1	rs12924604	chr16:74601486	G/A	cg08424188	chr16:75285647	BCAR1	-0.47	-4.72	-0.3	4.08e-6	Monocyte percentage of white cells;
SARC	cis	rs57221529	0.766	rs4527146	chr5:555236	A/G	cg07777115	chr5:623756	CEP72	-0.55	-4.92	-0.31	1.65e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg08219700	chr8:58056026	NA	0.63	5.99	0.37	7.78e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs722599	0.748	rs11623342	chr14:75347937	A/C	cg08847533	chr14:75593920	NEK9	-0.43	-4.88	-0.3	1.99e-6	IgG glycosylation;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg05162900	chr17:28808449	GOSR1	0.42	6.43	0.39	7.14e-10	Thyroid stimulating hormone;
SARC	cis	rs12762955	0.561	rs4880744	chr10:1012026	A/G	cg18964960	chr10:1102726	WDR37	-0.59	-6.91	-0.41	4.5e-11	Response to angiotensin II receptor blocker therapy;
SARC	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg00149659	chr3:10157352	C3orf10	0.64	5.91	0.36	1.22e-8	Alzheimer's disease;
SARC	cis	rs10791323	0.536	rs1944731	chr11:133726067	G/A	cg03690763	chr11:133734501	NA	-0.31	-4.98	-0.31	1.23e-6	Childhood ear infection;
SARC	cis	rs2273669	0.667	rs12204576	chr6:109318843	A/G	cg05315195	chr6:109294784	ARMC2	-0.6	-5.47	-0.34	1.13e-7	Prostate cancer;
SARC	cis	rs6582630	0.555	rs10880607	chr12:38508184	A/G	cg13010199	chr12:38710504	ALG10B	0.79	10.89	0.58	1.35e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg18252515	chr7:66147081	NA	0.55	5.82	0.36	1.89e-8	Aortic root size;
SARC	cis	rs8180040	0.729	rs11720439	chr3:47347003	T/G	cg27129171	chr3:47204927	SETD2	-0.66	-8.49	-0.49	2.47e-15	Colorectal cancer;
SARC	cis	rs9398803	0.687	rs853986	chr6:127023336	C/G	cg20229609	chr6:126660872	C6orf173	-0.35	-5.09	-0.32	7.54e-7	Male-pattern baldness;
SARC	cis	rs3812111	0.510	rs9372453	chr6:116583872	T/A	cg18828861	chr6:116576566	TSPYL4	0.33	4.85	0.3	2.21e-6	Age-related macular degeneration;
SARC	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg24675658	chr1:53192096	ZYG11B	-0.56	-7.78	-0.45	2.32e-13	Monocyte count;
SARC	cis	rs7553864	0.966	rs11161936	chr1:87614507	G/C	cg18153957	chr1:87613403	LOC339524	-0.51	-6.13	-0.37	3.65e-9	Smoking behavior;
SARC	cis	rs9611565	0.877	rs3817999	chr22:41747717	A/G	cg03806693	chr22:41940476	POLR3H	0.71	9.84	0.54	2.54e-19	Vitiligo;
SARC	cis	rs72781680	0.898	rs12623079	chr2:24103749	G/A	cg06627628	chr2:24431161	ITSN2	-0.67	-6.59	-0.4	2.95e-10	Lymphocyte counts;
SARC	cis	rs6484504	0.576	rs16922084	chr11:31371109	C/T	cg26647111	chr11:31128758	NA	0.39	4.98	0.31	1.23e-6	Red blood cell count;
SARC	cis	rs1008375	0.932	rs4235390	chr4:17696378	G/T	cg16339924	chr4:17578868	LAP3	0.52	6.64	0.4	2.24e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6840360	1.000	rs2007218	chr4:152643972	A/G	cg22705602	chr4:152727874	NA	0.38	6.56	0.39	3.43e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7937682	0.961	rs11601674	chr11:111634354	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.07	-19.37	-0.79	1.86e-50	Primary sclerosing cholangitis;
SARC	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg00149659	chr3:10157352	C3orf10	0.77	7.14	0.42	1.2e-11	Alzheimer's disease;
SARC	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg22903657	chr4:1355424	KIAA1530	-0.35	-4.74	-0.3	3.67e-6	Obesity-related traits;
SARC	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg26119090	chr2:26468346	HADHA;HADHB	0.95	13.96	0.67	1.32e-32	Gut microbiome composition (summer);
SARC	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-9.15	-0.51	2.85e-17	Alzheimer's disease;
SARC	cis	rs360798	0.656	rs1997246	chr2:62867347	T/C	cg16915676	chr2:62734870	TMEM17	0.48	5.91	0.36	1.24e-8	Coronary artery disease;
SARC	cis	rs6912958	0.516	rs242278	chr6:88047059	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	10.96	0.58	8.44e-23	Monocyte percentage of white cells;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg25818813	chr2:112656629	MERTK	0.47	6.41	0.39	7.96e-10	Thyroid stimulating hormone;
SARC	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg12756686	chr19:29218302	NA	0.68	8.99	0.51	8.47e-17	Methadone dose in opioid dependence;
SARC	cis	rs854765	0.552	rs11078407	chr17:17841083	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	9.98	0.55	9.16e-20	Total body bone mineral density;
SARC	cis	rs2479724	0.901	rs2185798	chr6:41773576	G/C	cg17623882	chr6:41773611	USP49	0.44	5.48	0.34	1.1e-7	Menarche (age at onset);
SARC	cis	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg12463550	chr7:65579703	CRCP	0.67	5.15	0.32	5.59e-7	Diabetic kidney disease;
SARC	cis	rs9902453	0.874	rs11653805	chr17:28378276	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.16	-0.42	1.02e-11	Coffee consumption (cups per day);
SARC	cis	rs9660992	0.573	rs12125276	chr1:205199440	C/T	cg21545522	chr1:205238299	TMCC2	0.39	5.34	0.33	2.25e-7	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs910316	0.591	rs7157158	chr14:75457238	A/G	cg23033748	chr14:75592666	NEK9	0.38	5.16	0.32	5.33e-7	Height;
SARC	cis	rs2425143	1.000	rs11696947	chr20:34312658	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.68	5.51	0.34	9.25e-8	Blood protein levels;
SARC	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg18404041	chr3:52824283	ITIH1	0.43	6.02	0.37	6.68e-9	Bipolar disorder;
SARC	cis	rs1580019	0.922	rs34545272	chr7:32460630	C/T	cg14728415	chr7:32535168	LSM5;AVL9	0.45	5.53	0.34	8.78e-8	Cognitive ability;
SARC	cis	rs897080	0.515	rs1067343	chr2:44621042	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.6	7.29	0.43	4.89e-12	Height;
SARC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	9.53	0.53	2.12e-18	Prudent dietary pattern;
SARC	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg22903471	chr2:27725779	GCKR	-0.45	-6.49	-0.39	4.99e-10	Total body bone mineral density;
SARC	cis	rs72781680	0.898	rs116113042	chr2:23960194	G/T	cg08917208	chr2:24149416	ATAD2B	0.76	7.25	0.43	5.95e-12	Lymphocyte counts;
SARC	cis	rs3847687	1.000	rs11061292	chr12:131518981	T/A	cg25772418	chr12:131519998	GPR133	-0.32	-5.02	-0.31	1.04e-6	Longevity;
SARC	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg01475735	chr3:40494733	NA	-0.47	-5.14	-0.32	5.91e-7	Renal cell carcinoma;
SARC	cis	rs78545713	1.000	rs77281308	chr6:26250029	C/T	cg13736514	chr6:26305472	NA	-0.6	-5.06	-0.31	8.67e-7	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs981844	0.857	rs62325140	chr4:154714161	C/A	cg14289246	chr4:154710475	SFRP2	0.66	7.05	0.42	1.99e-11	Response to statins (LDL cholesterol change);
SARC	cis	rs3796352	1.000	rs13076033	chr3:52898427	T/C	cg07884673	chr3:53033167	SFMBT1	0.79	4.92	0.31	1.62e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs838721	0.574	rs11681192	chr2:234258064	A/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.38	4.87	0.3	2.08e-6	Total body bone mineral density;
SARC	cis	rs9486715	1.000	rs11153082	chr6:97059666	A/G	cg18709589	chr6:96969512	KIAA0776	-0.63	-7.67	-0.45	4.71e-13	Headache;
SARC	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg22535103	chr8:58192502	C8orf71	-0.74	-8.69	-0.49	6.46e-16	Developmental language disorder (linguistic errors);
SARC	cis	rs11733284	0.515	rs10025104	chr4:47855999	T/C	cg21463140	chr4:47913142	NFXL1	-0.5	-5.67	-0.35	4.16e-8	Renal underexcretion gout;Gout;
SARC	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg18876405	chr7:65276391	NA	0.48	5.81	0.36	2.07e-8	Aortic root size;
SARC	cis	rs11214589	0.905	rs12805699	chr11:113241810	T/A	cg14159747	chr11:113255604	NA	0.34	4.86	0.3	2.12e-6	Neuroticism;
SARC	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg17178900	chr1:205818956	PM20D1	0.5	5.49	0.34	1.05e-7	Prostate-specific antigen levels;
SARC	cis	rs17401966	0.838	rs1013953	chr1:10319459	T/A	cg15208524	chr1:10270712	KIF1B	0.46	5.45	0.34	1.25e-7	Hepatocellular carcinoma;
SARC	cis	rs8027181	0.839	rs998020	chr15:72999635	C/T	cg25996835	chr15:72978165	BBS4;HIGD2B	0.39	5.17	0.32	4.99e-7	Triglyceride levels;
SARC	cis	rs8141529	0.732	rs5997408	chr22:29207915	G/A	cg15103426	chr22:29168792	CCDC117	0.68	8.95	0.51	1.13e-16	Lymphocyte counts;
SARC	cis	rs9660992	0.624	rs72745217	chr1:205261482	C/G	cg21643547	chr1:205240462	TMCC2	-0.58	-7.18	-0.43	9.34e-12	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg10207240	chr12:122356781	WDR66	0.36	6.08	0.37	4.98e-9	Mean corpuscular volume;
SARC	cis	rs9393692	0.875	rs6939589	chr6:26289203	C/T	cg00631329	chr6:26305371	NA	0.6	8.77	0.5	3.71e-16	Educational attainment;
SARC	cis	rs9815354	0.812	rs59138513	chr3:41908611	T/G	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs7208859	0.623	rs1061342	chr17:29114463	G/A	cg13385521	chr17:29058706	SUZ12P	0.89	7.67	0.45	4.57e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs12311304	1.000	rs12309172	chr12:15403226	C/T	cg08258403	chr12:15378311	NA	0.46	7.15	0.42	1.12e-11	Behavioural disinhibition (generation interaction);
SARC	cis	rs897984	0.520	rs4889534	chr16:30865440	T/C	cg02466173	chr16:30829666	NA	0.43	5.48	0.34	1.12e-7	Dementia with Lewy bodies;
SARC	cis	rs2268241	0.938	rs11088251	chr21:34770810	A/C	cg14850771	chr21:34775459	IFNGR2	0.85	8.54	0.49	1.8e-15	Obesity-related traits;
SARC	cis	rs1062177	1.000	rs62394155	chr5:151248069	G/A	cg00977110	chr5:151150581	G3BP1	0.54	5.08	0.32	7.58e-7	Preschool internalizing problems;
SARC	cis	rs13031619	0.660	rs34855424	chr2:3702780	C/A	cg19052272	chr2:3704530	ALLC	-0.36	-4.74	-0.3	3.78e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
SARC	cis	rs208515	0.525	rs1351866	chr6:66696969	A/G	cg07460842	chr6:66804631	NA	0.96	10.95	0.58	8.64e-23	Exhaled nitric oxide levels;
SARC	cis	rs1371867	0.810	rs2860518	chr8:101238120	G/T	cg11906718	chr8:101322791	RNF19A	-0.65	-8.61	-0.49	1.1e-15	Atrioventricular conduction;
SARC	cis	rs7027203	0.759	rs10761282	chr9:96586175	G/A	cg14598338	chr9:96623480	NA	-0.48	-6.69	-0.4	1.65e-10	DNA methylation (variation);
SARC	cis	rs911555	0.723	rs12436956	chr14:103852607	G/T	cg12935359	chr14:103987150	CKB	0.41	5.38	0.33	1.8e-7	Intelligence (multi-trait analysis);
SARC	cis	rs3820928	0.874	rs7605032	chr2:227847630	T/G	cg05526886	chr2:227700861	RHBDD1	-0.56	-6.73	-0.4	1.3100000000000001e-10	Pulmonary function;
SARC	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg19223190	chr17:80058835	NA	-0.42	-5.73	-0.35	3.09e-8	Life satisfaction;
SARC	cis	rs367615	0.506	rs2914684	chr5:108775110	C/T	cg17395555	chr5:108820864	NA	-0.41	-5.99	-0.37	8.07e-9	Colorectal cancer (SNP x SNP interaction);
SARC	trans	rs11098499	0.865	rs9996417	chr4:120295862	T/C	cg25214090	chr10:38739885	LOC399744	0.55	7.14	0.42	1.18e-11	Corneal astigmatism;
SARC	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg06558623	chr16:89946397	TCF25	-0.68	-6.28	-0.38	1.64e-9	Skin colour saturation;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg11995282	chr7:16746042	BZW2	0.51	6.97	0.42	3.16e-11	Thyroid stimulating hormone;
SARC	cis	rs72627123	0.749	rs10149956	chr14:74649106	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	-0.74	-5.83	-0.36	1.81e-8	Morning vs. evening chronotype;
SARC	cis	rs9611519	0.579	rs8136274	chr22:41415311	T/C	cg17376030	chr22:41985996	PMM1	0.39	4.85	0.3	2.29e-6	Neuroticism;
SARC	cis	rs9815354	1.000	rs7648357	chr3:41849670	A/G	cg03022575	chr3:42003672	ULK4	0.57	5.49	0.34	1.06e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.53	-6.09	-0.37	4.66e-9	Prudent dietary pattern;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg04278597	chr1:63154320	DOCK7	-0.61	-7.05	-0.42	1.99e-11	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs11785693	0.862	rs17435835	chr8:5000713	C/T	cg26367366	chr8:4980734	NA	-0.72	-6.54	-0.39	3.83e-10	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs79976124	0.842	rs7760550	chr6:66628788	T/C	cg07460842	chr6:66804631	NA	0.65	7.25	0.43	6.24e-12	Type 2 diabetes;
SARC	cis	rs963731	0.649	rs1377860	chr2:39290425	C/G	cg04010122	chr2:39346883	SOS1	1.0	6.29	0.38	1.56e-9	Corticobasal degeneration;
SARC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg24846343	chr22:24311635	DDTL	0.48	6.45	0.39	6.53e-10	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs3126085	0.825	rs11204933	chr1:152172185	C/T	cg09127314	chr1:152161683	NA	0.42	4.79	0.3	3.03e-6	Atopic dermatitis;
SARC	cis	rs2908197	0.843	rs2961041	chr7:75945944	C/T	cg22830091	chr7:75961684	YWHAG	-0.34	-5.04	-0.31	9.45e-7	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs7644634	0.634	rs1443105	chr3:105422024	T/C	cg23051926	chr3:105466016	CBLB	0.44	5.52	0.34	9.08e-8	Itch intensity from mosquito bite;
SARC	cis	rs950169	0.579	rs62027818	chr15:84661145	T/C	cg17507749	chr15:85114479	UBE2QP1	0.69	7.16	0.42	1.02e-11	Schizophrenia;
SARC	cis	rs6582630	0.555	rs11181053	chr12:38271364	T/C	cg14851346	chr12:38532713	NA	-0.42	-5.01	-0.31	1.08e-6	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9660992	0.710	rs1172138	chr1:205246019	G/A	cg21643547	chr1:205240462	TMCC2	-0.63	-8.04	-0.47	4.5e-14	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs910316	0.967	rs2024653	chr14:75595154	G/A	cg11812906	chr14:75593930	NEK9	0.86	13.44	0.66	7.34e-31	Height;
SARC	cis	rs6121246	0.567	rs6058197	chr20:30194899	A/G	cg13852791	chr20:30311386	BCL2L1	0.68	5.91	0.36	1.2e-8	Mean corpuscular hemoglobin;
SARC	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg04267008	chr7:1944627	MAD1L1	-0.48	-5.43	-0.33	1.44e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs4805272	0.512	rs4805279	chr19:29336966	A/G	cg12756686	chr19:29218302	NA	0.48	5.09	0.32	7.34e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs8114671	0.562	rs6087642	chr20:33468306	T/C	cg07148914	chr20:33460835	GGT7	0.45	5.58	0.34	6.59e-8	Height;
SARC	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.56	7.3	0.43	4.43e-12	Menarche (age at onset);
SARC	cis	rs751728	0.664	rs9394167	chr6:33754396	A/G	cg25922239	chr6:33757077	LEMD2	0.58	7.64	0.45	5.71e-13	Crohn's disease;
SARC	cis	rs8058578	1.000	rs6565201	chr16:30747191	C/T	cg02466173	chr16:30829666	NA	-0.41	-5.28	-0.33	3.02e-7	Multiple myeloma;
SARC	cis	rs6545883	0.831	rs9309336	chr2:61763165	T/C	cg15711740	chr2:61764176	XPO1	-0.45	-5.48	-0.34	1.09e-7	Tuberculosis;
SARC	cis	rs240764	0.595	rs1039033	chr6:101191397	C/T	cg09795085	chr6:101329169	ASCC3	-0.45	-5.8	-0.36	2.1e-8	Neuroticism;
SARC	cis	rs2180341	0.804	rs6902233	chr6:127555963	A/G	cg24812749	chr6:127587940	RNF146	0.95	10.75	0.58	3.71e-22	Breast cancer;
SARC	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.9	14.25	0.68	1.49e-33	Chronic sinus infection;
SARC	cis	rs7666738	0.791	rs2903151	chr4:99027218	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7582720	1.000	rs72936862	chr2:203786812	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs4660261	0.526	rs2906466	chr1:44322220	A/G	cg13606994	chr1:44402422	ARTN	-0.29	-4.77	-0.3	3.28e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9303280	0.806	rs12232497	chr17:38040119	T/C	cg20243544	chr17:37824526	PNMT	0.42	5.55	0.34	7.93e-8	Self-reported allergy;
SARC	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg23131131	chr22:24373011	LOC391322	-0.42	-4.74	-0.3	3.74e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg17691542	chr6:26056736	HIST1H1C	0.48	5.98	0.36	8.53e-9	Height;
SARC	cis	rs9815354	1.000	rs11923562	chr3:41760331	G/T	cg03022575	chr3:42003672	ULK4	0.61	5.42	0.33	1.52e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg07157834	chr1:205819609	PM20D1	0.51	6.97	0.42	3.16e-11	Menarche (age at onset);
SARC	cis	rs644799	0.965	rs687529	chr11:95545587	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	15.35	0.71	3.21e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2439831	0.702	rs3784275	chr15:44091386	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	7.64	0.45	5.54e-13	Lung cancer in ever smokers;
SARC	cis	rs9660992	0.548	rs1172152	chr1:205220718	T/A	cg07972983	chr1:205091412	RBBP5	0.53	6.78	0.41	9.94e-11	Mean corpuscular volume;Mean platelet volume;
SARC	trans	rs61931739	0.533	rs4270002	chr12:34313126	G/T	cg13010199	chr12:38710504	ALG10B	0.56	7.32	0.43	4.1e-12	Morning vs. evening chronotype;
SARC	trans	rs9929218	0.954	rs35444713	chr16:68824492	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.5	-6.34	-0.38	1.19e-9	Colorectal cancer;
SARC	cis	rs34779708	0.966	rs12769575	chr10:35435927	A/T	cg03585969	chr10:35415529	CREM	0.39	4.78	0.3	3.13e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs9486719	1.000	rs2472889	chr6:96866803	T/G	cg06623918	chr6:96969491	KIAA0776	0.73	8.01	0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs9660992	0.573	rs7368327	chr1:205214792	C/T	cg00857998	chr1:205179979	DSTYK	0.52	6.54	0.39	3.78e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs9810089	0.843	rs518972	chr3:136039268	C/A	cg15507776	chr3:136538369	TMEM22	0.43	4.8	0.3	2.8e-6	Gestational age at birth (child effect);
SARC	cis	rs9931543	0.596	rs730301	chr16:56293316	C/G	cg02433656	chr16:56322654	GNAO1	0.35	4.76	0.3	3.42e-6	Subjective well-being;
SARC	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg00933542	chr6:150070202	PCMT1	0.32	5.19	0.32	4.56e-7	Lung cancer;
SARC	cis	rs7605378	0.528	rs1704190	chr2:200760629	G/A	cg23649088	chr2:200775458	C2orf69	0.8	11.36	0.6	4.43e-24	Osteoporosis;
SARC	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg04277193	chr17:41438351	NA	0.47	5.04	0.31	9.3e-7	Menopause (age at onset);
SARC	cis	rs11203032	0.831	rs10887930	chr10:90950094	C/T	cg16672925	chr10:90967113	CH25H	-0.42	-4.96	-0.31	1.37e-6	Heart failure;
SARC	cis	rs2562456	0.833	rs2562487	chr19:21651382	C/T	cg00455402	chr19:21769736	NA	-0.38	-4.94	-0.31	1.49e-6	Pain;
SARC	cis	rs854765	0.547	rs4925135	chr17:17952868	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.41	-5.13	-0.32	6.16e-7	Total body bone mineral density;
SARC	cis	rs9467773	1.000	rs9467773	chr6:26498426	A/G	cg12292205	chr6:26970375	C6orf41	0.43	5.25	0.33	3.5e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg16339924	chr4:17578868	LAP3	0.66	8.76	0.5	4e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2073300	0.609	rs6132605	chr20:23354839	A/C	cg12062639	chr20:23401060	NAPB	1.01	6.9	0.41	4.88e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs950169	0.922	rs12911223	chr15:84831671	G/A	cg24253500	chr15:84953950	NA	-0.35	-4.97	-0.31	1.27e-6	Schizophrenia;
SARC	cis	rs7264396	0.563	rs2050729	chr20:34294409	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.73	7.21	0.43	7.62e-12	Total cholesterol levels;
SARC	trans	rs13130787	0.966	rs13105254	chr4:94842776	C/T	cg03916227	chr14:31676815	HECTD1	0.53	6.86	0.41	6.25e-11	Colorectal cancer;
SARC	cis	rs6696846	0.740	rs12125465	chr1:205074854	C/A	cg21643547	chr1:205240462	TMCC2	-0.57	-7.62	-0.45	6.4e-13	Red blood cell count;
SARC	cis	rs6456156	0.586	rs7762156	chr6:167485831	A/T	cg23791538	chr6:167370224	RNASET2	-0.53	-6.99	-0.42	2.86e-11	Primary biliary cholangitis;
SARC	cis	rs7772486	0.623	rs735535	chr6:146036829	C/T	cg05347473	chr6:146136440	FBXO30	-0.5	-6.91	-0.41	4.66e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs8064024	0.680	rs8056320	chr16:4918017	T/C	cg08329684	chr16:4932620	PPL	0.35	5.48	0.34	1.11e-7	Cancer;
SARC	cis	rs10463554	0.892	rs10463988	chr5:102249299	T/C	cg23492399	chr5:102201601	PAM	-0.45	-5.43	-0.33	1.45e-7	Parkinson's disease;
SARC	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg21724239	chr8:58056113	NA	0.6	6.27	0.38	1.72e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg00933542	chr6:150070202	PCMT1	0.3	4.87	0.3	2.05e-6	Lung cancer;
SARC	cis	rs1949733	1.000	rs3103072	chr4:8508431	C/T	cg13073564	chr4:8508604	NA	0.47	7.85	0.46	1.48e-13	Response to antineoplastic agents;
SARC	cis	rs76419734	1.000	rs112528936	chr4:106633029	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.84	5.56	0.34	7.44e-8	Post bronchodilator FEV1;
SARC	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg22535103	chr8:58192502	C8orf71	-0.73	-7.24	-0.43	6.52e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs1707322	0.752	rs28623463	chr1:46170758	A/C	cg03146154	chr1:46216737	IPP	0.52	6.28	0.38	1.6e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	5.98	0.36	8.43e-9	Prudent dietary pattern;
SARC	cis	rs7932354	0.710	rs2306032	chr11:46897253	G/C	cg03339077	chr11:47165057	C11orf49	-0.39	-5.33	-0.33	2.27e-7	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	22.95	0.83	9.94e-62	Chronic sinus infection;
SARC	cis	rs4803468	1.000	rs10413735	chr19:41921071	C/T	cg14132834	chr19:41945861	ATP5SL	-0.57	-7.53	-0.44	1.1e-12	Height;
SARC	cis	rs10078	0.515	rs2672739	chr5:443447	A/C	cg07599136	chr5:415885	AHRR	0.64	5.81	0.36	2.07e-8	Fat distribution (HIV);
SARC	cis	rs3824867	0.920	rs7105122	chr11:47449544	A/G	cg20307385	chr11:47447363	PSMC3	0.48	5.26	0.33	3.29e-7	Mean corpuscular hemoglobin;
SARC	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	7.4	0.44	2.42e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg02018176	chr4:1364513	KIAA1530	0.36	5.28	0.33	2.98e-7	Obesity-related traits;
SARC	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg18404041	chr3:52824283	ITIH1	-0.46	-7.1	-0.42	1.54e-11	Bipolar disorder;
SARC	cis	rs6087771	0.651	rs6060775	chr20:30286191	A/G	cg13852791	chr20:30311386	BCL2L1	0.55	6.79	0.41	9.41e-11	Subcortical brain region volumes;Putamen volume;
SARC	cis	rs1538970	0.816	rs11211124	chr1:45962409	T/C	cg05343316	chr1:45956843	TESK2	0.82	8.84	0.5	2.43e-16	Platelet count;
SARC	trans	rs7824557	0.767	rs2164272	chr8:11162496	A/C	cg06636001	chr8:8085503	FLJ10661	0.58	7.08	0.42	1.72e-11	Retinal vascular caliber;
SARC	cis	rs9814567	0.806	rs9857995	chr3:134316706	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.5	6.6	0.4	2.69e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs3820928	0.874	rs4234063	chr2:227828335	A/T	cg11843606	chr2:227700838	RHBDD1	0.54	6.74	0.4	1.25e-10	Pulmonary function;
SARC	cis	rs9303401	0.659	rs34426768	chr17:56683385	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.09	11.96	0.62	4.94e-26	Cognitive test performance;
SARC	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg16606324	chr3:10149918	C3orf24	0.52	5.11	0.32	6.74e-7	Alzheimer's disease;
SARC	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg07636037	chr3:49044803	WDR6	1.01	17.99	0.76	5.93e-46	Parkinson's disease;
SARC	cis	rs9303542	0.625	rs8066613	chr17:46583520	T/A	cg04904318	chr17:46607828	HOXB1	-0.46	-5.29	-0.33	2.8e-7	Ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs6121246	0.909	rs57726761	chr20:30314046	A/G	cg13852791	chr20:30311386	BCL2L1	0.84	9.04	0.51	6.31e-17	Mean corpuscular hemoglobin;
SARC	cis	rs1008375	0.933	rs6449324	chr4:17694880	G/C	cg27347728	chr4:17578864	LAP3	0.45	5.55	0.34	7.93e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2011503	1.000	rs55927782	chr19:19642032	T/C	cg03709012	chr19:19516395	GATAD2A	0.58	5.04	0.31	9.35e-7	Bipolar disorder;
SARC	cis	rs265548	0.646	rs36692	chr19:17906839	C/T	cg16744531	chr19:17905626	B3GNT3	0.39	5.13	0.32	6.17e-7	Tumor biomarkers;
SARC	cis	rs1153858	1.000	rs11858495	chr15:45637662	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.82	-11.6	-0.61	7.43e-25	Homoarginine levels;
SARC	cis	rs7937682	0.855	rs527078	chr11:111479713	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.91	-14.95	-0.7	6.72e-36	Primary sclerosing cholangitis;
SARC	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.5	-6.31	-0.38	1.39e-9	Lymphocyte counts;
SARC	cis	rs3087591	0.920	rs4795592	chr17:29612620	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.52	-6.43	-0.39	7.32e-10	Hip circumference;
SARC	cis	rs8141529	0.529	rs5752790	chr22:29152965	G/A	cg02153584	chr22:29168773	CCDC117	0.63	6.46	0.39	6.2e-10	Lymphocyte counts;
SARC	cis	rs4713118	0.955	rs9468200	chr6:27683063	T/A	cg17221315	chr6:27791827	HIST1H4J	0.49	4.94	0.31	1.47e-6	Parkinson's disease;
SARC	cis	rs57994353	0.865	rs34376913	chr9:139378914	T/C	cg14169450	chr9:139327907	INPP5E	0.42	5.38	0.33	1.79e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs3733585	0.699	rs17245723	chr4:9962218	A/T	cg00071950	chr4:10020882	SLC2A9	-0.38	-5.91	-0.36	1.2e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs2836950	0.840	rs12482317	chr21:40588241	A/G	cg11890956	chr21:40555474	PSMG1	-0.56	-6.84	-0.41	7.09e-11	Menarche (age at onset);
SARC	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg13939156	chr17:80058883	NA	-0.43	-6.68	-0.4	1.72e-10	Life satisfaction;
SARC	cis	rs79976124	0.797	rs77895756	chr6:66626782	C/T	cg07460842	chr6:66804631	NA	0.66	7.06	0.42	1.9e-11	Type 2 diabetes;
SARC	cis	rs7481584	0.581	rs366422	chr11:3053873	C/T	cg25174290	chr11:3078921	CARS	-0.6	-8.39	-0.48	4.67e-15	Calcium levels;
SARC	cis	rs644799	0.710	rs10831429	chr11:95508524	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.61	8.16	0.47	2.1e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs4242434	0.819	rs6558167	chr8:22473850	T/C	cg03733263	chr8:22462867	KIAA1967	0.98	16.3	0.73	2.21e-40	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs7255436	0.965	rs62117510	chr19:8452613	T/G	cg10174797	chr19:8464628	RAB11B	0.44	6.28	0.38	1.63e-9	HDL cholesterol;
SARC	cis	rs910316	1.000	rs11623413	chr14:75588824	C/T	cg08847533	chr14:75593920	NEK9	-0.94	-16.49	-0.73	5.15e-41	Height;
SARC	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	7.8	0.46	2.02e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs6716963	0.585	rs11687224	chr2:194568323	A/G	cg20947268	chr22:41682278	RANGAP1	0.53	6.55	0.39	3.7e-10	Schizophrenia;
SARC	cis	rs9843304	0.585	rs9847009	chr3:149208167	A/G	cg08667024	chr3:149219783	TM4SF4	0.42	6.43	0.39	6.98e-10	Gallstone disease;
SARC	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	11.96	0.62	5.28e-26	Chronic sinus infection;
SARC	cis	rs2354432	0.607	rs894469	chr1:146672906	C/T	cg25205988	chr1:146714368	CHD1L	1.04	8.94	0.51	1.2e-16	Mitochondrial DNA levels;
SARC	cis	rs694739	0.628	rs645078	chr11:64135298	A/C	cg23796481	chr11:64053134	BAD;GPR137	0.63	7.06	0.42	1.84e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs7312774	0.529	rs12314792	chr12:107333672	T/C	cg16260113	chr12:107380972	MTERFD3	0.86	7.11	0.42	1.39e-11	Severe influenza A (H1N1) infection;
SARC	cis	rs1707322	0.717	rs1972410	chr1:46080947	G/T	cg03146154	chr1:46216737	IPP	0.51	5.97	0.36	8.95e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2306786	0.558	rs76501863	chr15:59500346	C/T	cg23054309	chr15:59226205	SLTM	0.76	5.0	0.31	1.14e-6	Metabolite levels;
SARC	cis	rs910316	0.874	rs61980828	chr14:75630378	G/A	cg08847533	chr14:75593920	NEK9	-0.92	-14.25	-0.68	1.43e-33	Height;
SARC	cis	rs6088580	0.634	rs6059868	chr20:33079460	A/G	cg08999081	chr20:33150536	PIGU	0.42	6.47	0.39	5.81e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs910316	1.000	rs12879542	chr14:75507525	C/T	cg23033748	chr14:75592666	NEK9	0.36	4.96	0.31	1.36e-6	Height;
SARC	cis	rs2439831	0.867	rs4583210	chr15:43660925	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.07	11.41	0.6	3.09e-24	Lung cancer in ever smokers;
SARC	cis	rs9640161	0.830	rs12703061	chr7:150062545	T/C	cg10018233	chr7:150070692	REPIN1	0.69	10.18	0.56	2.18e-20	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs2592394	0.675	rs711819	chr2:176985696	C/T	cg03858756	chr2:176994637	HOXD8	-0.54	-5.67	-0.35	4.26e-8	Magnesium levels;Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs2952156	0.920	rs14050	chr17:37828072	C/T	cg20243544	chr17:37824526	PNMT	0.51	6.4	0.39	8.55e-10	Asthma;
SARC	cis	rs9640161	0.742	rs11983355	chr7:150016697	A/C	cg10018233	chr7:150070692	REPIN1	0.7	9.18	0.52	2.36e-17	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs6963495	0.818	rs6961233	chr7:105150469	C/T	cg13798780	chr7:105162888	PUS7	0.58	5.28	0.33	2.95e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs10911232	0.507	rs4642853	chr1:182996242	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.7	0.57	5.5e-22	Hypertriglyceridemia;
SARC	cis	rs796364	0.806	rs79897806	chr2:201073968	G/A	cg23649088	chr2:200775458	C2orf69	-0.64	-5.39	-0.33	1.7e-7	Schizophrenia;
SARC	cis	rs6121246	0.567	rs6120890	chr20:30207659	T/G	cg21427119	chr20:30132790	HM13	-0.44	-4.89	-0.3	1.9e-6	Mean corpuscular hemoglobin;
SARC	cis	rs6834538	0.597	rs4833414	chr4:113469913	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.54	7.33	0.43	3.86e-12	Free thyroxine concentration;
SARC	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg11247378	chr22:39784982	NA	-0.32	-5.2	-0.32	4.36e-7	Intelligence (multi-trait analysis);
SARC	cis	rs72772090	0.634	rs72773912	chr5:96107801	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-5.17	-0.32	4.99e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs77956314	0.515	rs4767490	chr12:117435016	A/G	cg16111737	chr12:117408163	FBXW8	-0.48	-6.29	-0.38	1.53e-9	Subcortical brain region volumes;Hippocampal volume;
SARC	cis	rs12145833	0.596	rs1060643	chr1:243429976	G/C	cg02356786	chr1:243265016	LOC731275	0.78	6.6	0.4	2.75e-10	Obesity (early onset extreme);
SARC	cis	rs72949976	0.898	rs6732233	chr2:214022834	C/T	cg08319019	chr2:214017104	IKZF2	-0.5	-6.61	-0.4	2.66e-10	Lung cancer;Squamous cell lung carcinoma;
SARC	cis	rs921968	0.540	rs646295	chr2:219408558	A/C	cg02176678	chr2:219576539	TTLL4	0.41	6.29	0.38	1.58e-9	Mean corpuscular hemoglobin concentration;
SARC	cis	rs3733585	0.673	rs4519796	chr4:9955936	A/G	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.39	-0.33	1.73e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs9291683	0.595	rs10939665	chr4:10037628	T/C	cg00071950	chr4:10020882	SLC2A9	0.4	6.29	0.38	1.54e-9	Bone mineral density;
SARC	cis	rs921968	0.643	rs4674305	chr2:219293326	C/T	cg02176678	chr2:219576539	TTLL4	0.36	5.28	0.33	2.98e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs17030434	0.911	rs17030490	chr4:154738340	C/T	cg14289246	chr4:154710475	SFRP2	-0.74	-7.85	-0.46	1.52e-13	Electrocardiographic conduction measures;
SARC	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg11890956	chr21:40555474	PSMG1	1.17	19.34	0.79	2.3e-50	Cognitive function;
SARC	cis	rs7103648	0.545	rs6485795	chr11:47929846	G/A	cg20307385	chr11:47447363	PSMC3	0.71	9.45	0.53	3.86e-18	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs9790314	0.747	rs1610158	chr3:160815050	A/G	cg03342759	chr3:160939853	NMD3	0.48	5.84	0.36	1.77e-8	Morning vs. evening chronotype;
SARC	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg18225595	chr11:63971243	STIP1	0.43	5.19	0.32	4.65e-7	Mean platelet volume;
SARC	cis	rs8072100	0.782	rs28507314	chr17:45551402	C/T	cg08085267	chr17:45401833	C17orf57	-0.49	-6.04	-0.37	6.17e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs11190604	0.697	rs12355942	chr10:102201320	T/C	cg07080220	chr10:102295463	HIF1AN	-0.74	-9.19	-0.52	2.21e-17	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs17376456	0.877	rs13185660	chr5:93336500	G/A	cg21475434	chr5:93447410	FAM172A	0.85	7.57	0.44	8.88e-13	Diabetic retinopathy;
SARC	cis	rs7674212	0.541	rs2720458	chr4:104052963	C/G	cg16532752	chr4:104119610	CENPE	-0.48	-5.68	-0.35	4.07e-8	Type 2 diabetes;
SARC	cis	rs7208859	0.673	rs216410	chr17:28903831	C/G	cg13385521	chr17:29058706	SUZ12P	-0.7	-6.62	-0.4	2.4e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg05036130	chr6:150231994	NA	0.29	5.08	0.32	7.92e-7	Testicular germ cell tumor;
SARC	cis	rs1707322	0.963	rs9787412	chr1:46371596	C/T	cg03146154	chr1:46216737	IPP	0.46	5.52	0.34	8.98e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs5753618	0.504	rs8138525	chr22:32011929	T/C	cg02404636	chr22:31891804	SFI1	-0.53	-5.75	-0.35	2.76e-8	Colorectal cancer;
SARC	cis	rs3820928	0.839	rs13404750	chr2:227876129	G/A	cg05526886	chr2:227700861	RHBDD1	-0.49	-5.8	-0.36	2.13e-8	Pulmonary function;
SARC	cis	rs6815814	0.851	rs11466617	chr4:38780471	T/C	cg02016764	chr4:38805732	TLR1	-0.42	-4.72	-0.3	3.98e-6	Breast cancer;
SARC	cis	rs7647973	0.554	rs13096480	chr3:49658084	A/G	cg06212747	chr3:49208901	KLHDC8B	0.59	5.82	0.36	1.94e-8	Menarche (age at onset);
SARC	cis	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.8	-0.46	2.01e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs950027	0.620	rs1153860	chr15:45636584	A/G	cg15395560	chr15:45543142	SLC28A2	0.27	5.22	0.32	3.93e-7	Response to fenofibrate (adiponectin levels);
SARC	cis	rs9916302	0.904	rs9944411	chr17:37483599	T/C	cg00129232	chr17:37814104	STARD3	0.58	7.24	0.43	6.36e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg07701084	chr6:150067640	NUP43	0.41	5.32	0.33	2.38e-7	Lung cancer;
SARC	cis	rs981844	0.712	rs1456398	chr4:154738266	G/A	cg14289246	chr4:154710475	SFRP2	-0.44	-5.16	-0.32	5.34e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg00684032	chr4:1343700	KIAA1530	0.38	5.52	0.34	9.14e-8	Obesity-related traits;
SARC	cis	rs10046574	0.634	rs77474267	chr7:135098679	G/A	cg27474649	chr7:135195673	CNOT4	0.86	6.95	0.41	3.61e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs4711350	0.765	rs2182658	chr6:33748831	G/T	cg13859433	chr6:33739653	LEMD2	0.33	4.8	0.3	2.82e-6	Schizophrenia;
SARC	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg27266027	chr21:40555129	PSMG1	0.53	5.75	0.35	2.8e-8	Cognitive function;
SARC	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg00149659	chr3:10157352	C3orf10	0.69	6.83	0.41	7.2e-11	Alzheimer's disease;
SARC	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg11301795	chr4:187892539	NA	0.72	10.67	0.57	6.87e-22	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg12311346	chr5:56204834	C5orf35	-0.68	-6.35	-0.38	1.09e-9	Initial pursuit acceleration;
SARC	cis	rs13034020	0.522	rs62150978	chr2:61256222	T/C	cg18625361	chr2:61244694	PEX13;PUS10	0.65	5.81	0.36	2.08e-8	Hodgkin's lymphoma;
SARC	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9905704	0.624	rs34718875	chr17:57072461	G/A	cg12560992	chr17:57184187	TRIM37	0.5	5.99	0.37	7.75e-9	Testicular germ cell tumor;
SARC	cis	rs6503863	1	rs6503863	chr17:56517034	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.4	4.98	0.31	1.24e-6	Intelligence (multi-trait analysis);
SARC	cis	rs6424115	1.000	rs6424115	chr1:24153231	A/G	cg15997130	chr1:24165203	NA	-0.48	-6.51	-0.39	4.45e-10	Immature fraction of reticulocytes;
SARC	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg08859206	chr1:53392774	SCP2	0.37	5.35	0.33	2.06e-7	Monocyte count;
SARC	cis	rs6570726	0.935	rs385134	chr6:145851005	C/T	cg05220968	chr6:146057943	EPM2A	-0.29	-5.04	-0.31	9.48e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg19223190	chr17:80058835	NA	-0.4	-5.56	-0.34	7.26e-8	Life satisfaction;
SARC	trans	rs9929218	0.501	rs12448999	chr16:68815549	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.77	11.71	0.61	3.28e-25	Colorectal cancer;
SARC	cis	rs9810259	0.582	rs12486170	chr3:12392296	A/G	cg04748988	chr3:12329223	PPARG	-0.4	-5.09	-0.32	7.33e-7	Platelet count;
SARC	cis	rs6752107	0.935	rs10929322	chr2:234149702	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	-0.51	-6.77	-0.41	1.03e-10	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs7312933	0.510	rs1907705	chr12:42451122	T/A	cg17420585	chr12:42539391	GXYLT1	-0.45	-6.99	-0.42	2.87e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs644799	0.526	rs568120	chr11:95578734	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.7	9.46	0.53	3.4e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2033732	0.706	rs7833023	chr8:85053241	A/C	cg05716166	chr8:85095498	RALYL	-0.49	-5.93	-0.36	1.08e-8	Body mass index;
SARC	cis	rs477692	0.624	rs880300	chr10:131329486	G/A	cg05714579	chr10:131428358	MGMT	0.55	7.07	0.42	1.74e-11	Response to temozolomide;
SARC	cis	rs1008375	0.966	rs10939736	chr4:17581617	T/A	cg02297831	chr4:17616191	MED28	0.49	6.22	0.38	2.31e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg13206674	chr6:150067644	NUP43	0.41	5.36	0.33	1.96e-7	Lung cancer;
SARC	cis	rs1008375	0.966	rs3775927	chr4:17599894	G/T	cg02297831	chr4:17616191	MED28	0.47	5.75	0.35	2.78e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs3815700	1.000	rs8109990	chr19:33095636	A/G	cg24916020	chr19:33096688	ANKRD27	0.55	5.32	0.33	2.4e-7	Eosinophilic esophagitis;
SARC	cis	rs73198271	0.681	rs35457364	chr8:8649790	T/A	cg06636001	chr8:8085503	FLJ10661	-0.51	-5.58	-0.34	6.53e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs7481584	0.624	rs375579	chr11:3065300	G/C	cg25174290	chr11:3078921	CARS	-0.58	-8.1	-0.47	3.02e-14	Calcium levels;
SARC	cis	rs9400467	0.506	rs12190135	chr6:111698204	T/C	cg15721981	chr6:111408429	SLC16A10	0.65	5.65	0.35	4.61e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs9612	0.718	rs346522	chr19:44262545	C/T	cg08581076	chr19:44259116	C19orf61	-0.58	-7.43	-0.44	2.03e-12	Exhaled nitric oxide output;
SARC	trans	rs9388451	0.839	rs3757217	chr6:126069636	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.56	-7.24	-0.43	6.6e-12	Brugada syndrome;
SARC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg11494091	chr17:61959527	GH2	0.57	8.59	0.49	1.25e-15	Prudent dietary pattern;
SARC	cis	rs2013441	1.000	rs2165897	chr17:20209721	T/C	cg13482628	chr17:19912719	NA	-0.49	-6.33	-0.38	1.23e-9	Obesity-related traits;
SARC	cis	rs10875746	0.951	rs2286021	chr12:48528220	C/T	cg27446233	chr12:48516484	PFKM	-0.42	-4.78	-0.3	3.17e-6	Longevity (90 years and older);
SARC	cis	rs6120849	0.754	rs752448	chr20:33592248	C/T	cg24642439	chr20:33292090	TP53INP2	0.57	5.54	0.34	7.99e-8	Protein C levels;
SARC	cis	rs9341808	0.590	rs4706841	chr6:81057827	T/A	cg08355045	chr6:80787529	NA	0.34	5.22	0.32	3.89e-7	Sitting height ratio;
SARC	cis	rs9911578	1.000	rs8071916	chr17:56660279	A/G	cg12560992	chr17:57184187	TRIM37	0.79	10.69	0.57	5.63e-22	Intelligence (multi-trait analysis);
SARC	cis	rs15676	0.947	rs2293968	chr9:131587240	G/A	cg00228799	chr9:131580591	ENDOG	0.61	7.71	0.45	3.53e-13	Blood metabolite levels;
SARC	cis	rs9815354	1.000	rs17062109	chr3:41810364	C/T	cg03022575	chr3:42003672	ULK4	0.57	5.52	0.34	9.21e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs4481887	1.000	rs4244182	chr1:248471174	A/G	cg01631408	chr1:248437212	OR2T33	-0.41	-5.16	-0.32	5.18e-7	Common traits (Other);
SARC	cis	rs7843479	1.000	rs7821592	chr8:21811530	C/G	cg17168535	chr8:21777572	XPO7	0.62	7.8	0.46	2.07e-13	Mean corpuscular volume;
SARC	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg13939156	chr17:80058883	NA	-0.42	-6.61	-0.4	2.52e-10	Life satisfaction;
SARC	cis	rs2439831	0.850	rs7179388	chr15:44123945	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.93	8.04	0.47	4.56e-14	Lung cancer in ever smokers;
SARC	cis	rs735539	0.521	rs2585896	chr13:21398861	A/G	cg16922012	chr13:21400325	XPO4	-0.43	-5.95	-0.36	9.94e-9	Dental caries;
SARC	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg12311346	chr5:56204834	C5orf35	-0.55	-5.76	-0.35	2.69e-8	Initial pursuit acceleration;
SARC	cis	rs1545257	0.505	rs2584950	chr2:24632762	A/G	cg06627628	chr2:24431161	ITSN2	-0.55	-7.09	-0.42	1.56e-11	Sjögren's syndrome;
SARC	cis	rs7582720	1.000	rs72926802	chr2:203830228	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs3796352	1.000	rs13069006	chr3:52973305	G/C	cg27565382	chr3:53032988	SFMBT1	0.95	6.34	0.38	1.17e-9	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	6.08	0.37	4.98e-9	Prudent dietary pattern;
SARC	cis	rs4481887	0.720	rs4543835	chr1:248468608	A/T	cg00666640	chr1:248458726	OR2T12	0.38	6.35	0.38	1.14e-9	Common traits (Other);
SARC	cis	rs17376456	0.825	rs6877030	chr5:93201841	C/A	cg25358565	chr5:93447407	FAM172A	1.23	12.61	0.64	3.94e-28	Diabetic retinopathy;
SARC	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs61931739	0.635	rs1525895	chr12:33966496	A/G	cg13010199	chr12:38710504	ALG10B	0.5	6.47	0.39	5.87e-10	Morning vs. evening chronotype;
SARC	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.79	-11.56	-0.6	1.01e-24	Personality dimensions;
SARC	trans	rs7395662	0.571	rs10838947	chr11:48568693	G/T	cg15704280	chr7:45808275	SEPT13	-0.5	-6.81	-0.41	8.14e-11	HDL cholesterol;
SARC	cis	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg15556689	chr8:8085844	FLJ10661	0.39	4.92	0.31	1.6e-6	Mood instability;
SARC	cis	rs6484504	0.532	rs10835756	chr11:31267622	C/T	cg02090638	chr11:31391270	DNAJC24;DCDC1	-0.43	-5.39	-0.33	1.72e-7	Red blood cell count;
SARC	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg13699009	chr12:122356056	WDR66	0.59	9.57	0.53	1.68e-18	Mean corpuscular volume;
SARC	cis	rs9858542	0.953	rs9859556	chr3:49455986	G/T	cg03060546	chr3:49711283	APEH	-0.58	-7.2	-0.43	8.27e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs703842	1.000	rs10877014	chr12:58167661	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.78	11.47	0.6	1.92e-24	Multiple sclerosis;
SARC	cis	rs763121	0.815	rs4821799	chr22:39021326	T/G	cg21395723	chr22:39101663	GTPBP1	0.54	6.45	0.39	6.24e-10	Menopause (age at onset);
SARC	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	8.4	0.48	4.36e-15	Mean platelet volume;
SARC	cis	rs7223966	0.921	rs2727300	chr17:61965398	G/A	cg00588841	chr17:61851480	DDX42;CCDC47	-0.61	-6.39	-0.39	8.84e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9341808	0.667	rs2490241	chr6:80846342	T/C	cg08355045	chr6:80787529	NA	0.36	5.76	0.35	2.69e-8	Sitting height ratio;
SARC	cis	rs4668356	0.687	rs7563109	chr2:172047280	A/C	cg13882835	chr2:172017928	TLK1	0.63	5.21	0.32	4.16e-7	Cognitive performance;
SARC	cis	rs9916302	0.851	rs9904919	chr17:37556431	G/C	cg00129232	chr17:37814104	STARD3	0.62	7.7	0.45	3.76e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs10484885	0.775	rs72919985	chr6:90534641	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.6	-5.16	-0.32	5.29e-7	QRS interval (sulfonylurea treatment interaction);
SARC	cis	rs13166103	0.657	rs35917227	chr5:57678197	G/A	cg10487770	chr5:57879443	RAB3C	0.53	5.57	0.34	7.06e-8	Type 2 diabetes (age of onset);
SARC	cis	rs3862030	0.720	rs11593583	chr10:104228149	A/G	ch.10.2196322F	chr10:104248062	ACTR1A	0.49	6.53	0.39	4.01e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
SARC	cis	rs6582630	0.519	rs8186992	chr12:38325848	C/T	cg26384229	chr12:38710491	ALG10B	0.86	12.36	0.63	2.63e-27	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs3758785	0.641	rs10831207	chr11:94089363	G/A	cg13023536	chr11:94226537	MRE11A;ANKRD49	-0.45	-5.82	-0.36	1.9e-8	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
SARC	cis	rs7998202	0.667	rs914018	chr13:113354819	A/G	cg02820901	chr13:113351484	ATP11A	0.56	5.04	0.31	9.19e-7	Glycated hemoglobin levels;
SARC	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg20965017	chr5:231967	SDHA	-0.55	-5.26	-0.33	3.23e-7	Breast cancer;
SARC	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg06420487	chr17:61919686	SMARCD2	0.49	5.71	0.35	3.46e-8	Height;
SARC	trans	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg06437703	chr8:37914619	EIF4EBP1	0.56	6.79	0.41	9.21e-11	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg15482792	chr1:91870014	HFM1	-0.95	-8.38	-0.48	5.12e-15	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1790761	0.692	rs674783	chr11:67339076	C/T	cg24690094	chr11:67383802	NA	0.37	5.52	0.34	8.98e-8	Mean corpuscular volume;
SARC	cis	rs7149337	0.837	rs10132658	chr14:51677599	C/T	cg23942311	chr14:51606299	NA	0.33	5.9	0.36	1.26e-8	Cancer;
SARC	trans	rs988958	0.848	rs13431388	chr2:42304967	G/A	cg02435573	chr1:94712239	NA	-0.51	-6.72	-0.4	1.4e-10	Hypospadias;
SARC	trans	rs12097821	0.627	rs4409683	chr1:107121173	A/G	cg24684357	chr21:43188367	RIPK4	-0.66	-6.67	-0.4	1.82e-10	Non-obstructive azoospermia;
SARC	cis	rs477692	1.000	rs554792	chr10:131423181	A/G	cg05714579	chr10:131428358	MGMT	0.55	7.13	0.42	1.23e-11	Response to temozolomide;
SARC	cis	rs28374715	0.681	rs11629979	chr15:41626579	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.96	-14.98	-0.7	5.42e-36	Ulcerative colitis;
SARC	cis	rs526231	0.511	rs12109860	chr5:102393112	A/T	cg23492399	chr5:102201601	PAM	-0.51	-5.55	-0.34	7.61e-8	Primary biliary cholangitis;
SARC	trans	rs10209086	0.736	rs1584436	chr2:138298878	A/G	cg07391498	chr1:205290332	NUAK2	-0.45	-6.33	-0.38	1.25e-9	Multiple system atrophy;
SARC	cis	rs1971762	0.583	rs12319789	chr12:54090450	G/C	cg06632207	chr12:54070931	ATP5G2	0.43	5.42	0.33	1.52e-7	Height;
SARC	cis	rs10463554	0.526	rs114525197	chr5:102443045	T/C	cg23492399	chr5:102201601	PAM	-0.52	-5.58	-0.34	6.67e-8	Parkinson's disease;
SARC	cis	rs11190604	1.000	rs7078799	chr10:102301447	G/A	cg07080220	chr10:102295463	HIF1AN	0.83	9.82	0.54	2.9e-19	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs10875746	0.903	rs12306451	chr12:48483241	T/C	cg26205652	chr12:48591994	NA	0.56	6.1	0.37	4.37e-9	Longevity (90 years and older);
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg13350481	chr3:38537876	EXOG	0.53	7.07	0.42	1.78e-11	Lung adenocarcinoma;
SARC	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.43	5.93	0.36	1.11e-8	Personality dimensions;
SARC	trans	rs747334	0.846	rs7897603	chr10:92708759	C/G	cg03518179	chr1:156470915	MEF2D	-0.49	-6.4	-0.39	8.57e-10	Fibroblast growth factor basic levels;
SARC	cis	rs2635047	0.713	rs9950812	chr18:44765943	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	6.3	0.38	1.47e-9	Educational attainment;
SARC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg02018176	chr4:1364513	KIAA1530	0.43	6.27	0.38	1.73e-9	Longevity;
SARC	trans	rs61931739	0.534	rs1608911	chr12:34010249	T/C	cg13010199	chr12:38710504	ALG10B	0.75	10.07	0.55	4.77e-20	Morning vs. evening chronotype;
SARC	cis	rs7647973	0.593	rs7652179	chr3:49808618	T/A	cg13072238	chr3:49761600	GMPPB	0.66	6.39	0.39	8.95e-10	Menarche (age at onset);
SARC	cis	rs4642101	0.824	rs9825233	chr3:12843368	A/G	cg05775895	chr3:12838266	CAND2	-0.74	-12.08	-0.62	2.01e-26	QRS complex (12-leadsum);
SARC	cis	rs9303401	0.659	rs72828726	chr17:56951217	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	11.09	0.59	3.23e-23	Cognitive test performance;
SARC	cis	rs1385374	0.563	rs12299194	chr12:129264838	A/G	cg09035930	chr12:129282057	SLC15A4	-0.51	-4.72	-0.3	4.13e-6	Systemic lupus erythematosus;
SARC	trans	rs9392653	0.847	rs9405255	chr6:5066039	A/T	cg17170942	chr3:124452405	UMPS	0.51	6.26	0.38	1.85e-9	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs2251381	0.750	rs2251087	chr21:30527999	C/T	cg08807101	chr21:30365312	RNF160	0.76	10.23	0.56	1.58e-20	Selective IgA deficiency;
SARC	cis	rs8180040	0.620	rs7373821	chr3:47080127	A/C	cg27129171	chr3:47204927	SETD2	0.7	9.5	0.53	2.59e-18	Colorectal cancer;
SARC	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg24531977	chr5:56204891	C5orf35	-0.54	-5.46	-0.34	1.24e-7	Initial pursuit acceleration;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg02062953	chr8:17088077	CNOT7	-0.74	-6.29	-0.38	1.59e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs965469	0.947	rs965470	chr20:3381588	C/G	cg25506879	chr20:3388711	C20orf194	-0.54	-5.47	-0.34	1.17e-7	IFN-related cytopenia;
SARC	cis	rs11648796	0.757	rs66649828	chr16:766078	A/G	cg07343612	chr16:622815	PIGQ	-0.41	-4.82	-0.3	2.57e-6	Height;
SARC	cis	rs7178572	0.568	rs12909924	chr15:77551445	T/G	cg22256960	chr15:77711686	NA	-0.51	-5.61	-0.34	5.71e-8	Type 2 diabetes;
SARC	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg11987759	chr7:65425863	GUSB	0.51	6.55	0.39	3.69e-10	Aortic root size;
SARC	cis	rs751728	0.717	rs3763258	chr6:33773744	A/G	cg25922239	chr6:33757077	LEMD2	0.64	7.52	0.44	1.21e-12	Crohn's disease;
SARC	cis	rs12142240	0.698	rs932816	chr1:46859749	G/A	cg00530320	chr1:46809349	NSUN4	0.57	7.0	0.42	2.74e-11	Menopause (age at onset);
SARC	cis	rs4423214	0.879	rs10898144	chr11:71151540	A/T	cg05163923	chr11:71159392	DHCR7	-0.56	-6.61	-0.4	2.57e-10	Vitamin D levels;
SARC	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.83	-0.41	7.28e-11	Mood instability;
SARC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg10150615	chr22:24372951	LOC391322	0.44	4.86	0.3	2.11e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2153535	0.580	rs1832100	chr6:8446956	G/A	cg07606381	chr6:8435919	SLC35B3	0.77	11.03	0.59	5.01e-23	Motion sickness;
SARC	cis	rs9840812	0.522	rs699165	chr3:136224697	A/G	cg15507776	chr3:136538369	TMEM22	0.54	6.0	0.37	7.55e-9	Fibrinogen levels;
SARC	cis	rs2933343	1.000	rs2630252	chr3:128624772	T/C	cg24203234	chr3:128598194	ACAD9	0.54	5.99	0.37	8e-9	IgG glycosylation;
SARC	cis	rs933688	0.877	rs1477349	chr5:90707773	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.02	12.78	0.64	1.09e-28	Smoking behavior;
SARC	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg13880726	chr7:1868755	MAD1L1	0.43	4.99	0.31	1.2e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs6815814	0.950	rs73236618	chr4:38794041	T/C	cg06935464	chr4:38784597	TLR10	0.56	5.25	0.32	3.5e-7	Breast cancer;
SARC	cis	rs67133203	0.606	rs1056897	chr12:51566541	G/A	cg15029631	chr12:52078762	SCN8A	-0.42	-4.9	-0.31	1.79e-6	Urinary tract infection frequency;
SARC	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg11987759	chr7:65425863	GUSB	0.48	6.23	0.38	2.16e-9	Aortic root size;
SARC	cis	rs10924309	0.737	rs6700721	chr1:245854173	C/T	cg00036263	chr1:245852353	KIF26B	-0.39	-4.87	-0.3	2.05e-6	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
SARC	cis	rs2268241	0.938	rs7283827	chr21:34769904	A/G	cg14850771	chr21:34775459	IFNGR2	0.95	9.4	0.52	5.47e-18	Obesity-related traits;
SARC	cis	rs9420	0.961	rs7938083	chr11:57493622	C/A	cg19752551	chr11:57585705	CTNND1	-0.48	-6.48	-0.39	5.49e-10	Schizophrenia;
SARC	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.97	14.01	0.68	9.52e-33	Height;
SARC	cis	rs9886651	0.935	rs13248719	chr8:128802751	T/C	cg24514600	chr8:128805414	PVT1	-0.44	-5.85	-0.36	1.7e-8	Epithelial ovarian cancer;Serous invasive ovarian cancer;
SARC	cis	rs926392	0.965	rs714108	chr20:37687838	G/A	cg16355469	chr20:37678765	NA	0.58	7.54	0.44	1.06e-12	Dialysis-related mortality;
SARC	cis	rs4481887	0.893	rs7528645	chr1:248427291	T/A	cg00666640	chr1:248458726	OR2T12	0.3	4.98	0.31	1.23e-6	Common traits (Other);
SARC	cis	rs116095464	0.558	rs9312979	chr5:222057	A/C	cg22857025	chr5:266934	NA	-1.11	-10.4	-0.56	4.74e-21	Breast cancer;
SARC	cis	rs17345786	0.906	rs58835747	chr3:101243634	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.46	-4.94	-0.31	1.5e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9920506	0.536	rs12441998	chr15:78929372	G/A	cg04896959	chr15:78267971	NA	0.42	5.01	0.31	1.09e-6	Post bronchodilator FEV1;
SARC	cis	rs6484504	0.553	rs413067	chr11:31223497	T/C	cg26647111	chr11:31128758	NA	-0.39	-5.1	-0.32	7.11e-7	Red blood cell count;
SARC	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2486288	0.656	rs2271438	chr15:45557468	A/G	cg15395560	chr15:45543142	SLC28A2	0.29	5.68	0.35	3.91e-8	Glomerular filtration rate;
SARC	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg11764359	chr7:65958608	NA	0.59	7.09	0.42	1.56e-11	Aortic root size;
SARC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.35	-5.41	-0.33	1.57e-7	Longevity;Endometriosis;
SARC	cis	rs9325144	0.560	rs11182930	chr12:38633693	A/T	cg13010199	chr12:38710504	ALG10B	-0.55	-6.83	-0.41	7.47e-11	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.679	rs72649131	chr8:58054288	G/T	cg11062466	chr8:58055876	NA	0.53	5.15	0.32	5.42e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs11098499	0.909	rs28632018	chr4:120386730	T/C	cg09307838	chr4:120376055	NA	0.9	12.45	0.63	1.31e-27	Corneal astigmatism;
SARC	cis	rs9902453	0.740	rs2254414	chr17:28061130	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.28	-0.43	4.97e-12	Coffee consumption (cups per day);
SARC	trans	rs66573146	0.572	rs67750430	chr4:6957266	T/G	cg07817883	chr1:32538562	TMEM39B	1.07	8.31	0.48	8e-15	Granulocyte percentage of myeloid white cells;
SARC	cis	rs7223966	1.000	rs8081612	chr17:61724695	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.42	-4.73	-0.3	3.83e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7246760	0.867	rs55846005	chr19:9796709	T/A	cg16876255	chr19:9731953	ZNF561	0.82	5.05	0.31	8.72e-7	Pursuit maintenance gain;
SARC	cis	rs4243830	0.850	rs12030607	chr1:6601007	T/A	cg22792644	chr1:6614718	TAS1R1;NOL9	0.92	9.54	0.53	2.02e-18	Body mass index;
SARC	cis	rs79349575	0.783	rs61576918	chr17:46985593	A/C	cg16584676	chr17:46985605	UBE2Z	0.54	6.59	0.4	2.95e-10	Type 2 diabetes;
SARC	cis	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg25833597	chr17:30823145	MYO1D	0.52	4.79	0.3	3e-6	Hip circumference adjusted for BMI;
SARC	trans	rs9354308	0.933	rs55672811	chr6:66571730	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.58	6.82	0.41	7.77e-11	Metabolite levels;
SARC	cis	rs72781680	1.000	rs72796329	chr2:24141912	G/A	cg06627628	chr2:24431161	ITSN2	-0.68	-6.44	-0.39	6.58e-10	Lymphocyte counts;
SARC	cis	rs9300255	0.602	rs10744147	chr12:123643729	A/G	cg00376283	chr12:123451042	ABCB9	0.59	5.91	0.36	1.22e-8	Neutrophil percentage of white cells;
SARC	cis	rs9843304	0.508	rs11926459	chr3:149212082	T/C	cg08667024	chr3:149219783	TM4SF4	0.47	7.15	0.42	1.1e-11	Gallstone disease;
SARC	cis	rs1355223	0.545	rs7111695	chr11:34874906	T/G	cg11058730	chr11:34937778	PDHX;APIP	-0.5	-6.36	-0.38	1.06e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs6782228	0.606	rs2811497	chr3:128363332	C/T	cg08795948	chr3:128337044	NA	0.37	5.03	0.31	9.79e-7	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
SARC	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg04944784	chr2:26401820	FAM59B	0.6	7.95	0.46	8.14e-14	Gut microbiome composition (summer);
SARC	cis	rs4253772	0.551	rs9615936	chr22:46686328	C/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.64	4.75	0.3	3.57e-6	LDL cholesterol;Cholesterol, total;
SARC	cis	rs11122272	0.735	rs2491403	chr1:231511185	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg01316550	chr5:56110833	MAP3K1	0.54	4.92	0.31	1.62e-6	Initial pursuit acceleration;
SARC	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg21442419	chr1:2182373	SKI	0.46	5.96	0.36	9.4e-9	Height;
SARC	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg06212747	chr3:49208901	KLHDC8B	0.78	11.39	0.6	3.61e-24	Menarche (age at onset);
SARC	cis	rs9462027	0.628	rs2814991	chr6:34615443	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-6.13	-0.37	3.79e-9	Systemic lupus erythematosus;
SARC	cis	rs6582630	0.593	rs12816835	chr12:38533304	C/T	cg26384229	chr12:38710491	ALG10B	-0.6	-7.6	-0.45	7.11e-13	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs12579753	0.719	rs4418884	chr12:82277006	C/T	cg07988820	chr12:82153109	PPFIA2	-0.44	-5.37	-0.33	1.91e-7	Resting heart rate;
SARC	cis	rs1580019	0.922	rs766658	chr7:32499391	C/T	cg14728415	chr7:32535168	LSM5;AVL9	0.44	5.18	0.32	4.9e-7	Cognitive ability;
SARC	cis	rs7772486	0.754	rs697054	chr6:146003770	C/T	cg05347473	chr6:146136440	FBXO30	0.55	7.5	0.44	1.31e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg22857025	chr5:266934	NA	-1.07	-11.54	-0.6	1.15e-24	Breast cancer;
SARC	trans	rs6716963	0.585	rs11687224	chr2:194568323	A/G	cg08648041	chr20:2633689	NOP56;SNORD110	0.54	6.46	0.39	6.09e-10	Schizophrenia;
SARC	cis	rs9858542	1.000	rs9822268	chr3:49719729	G/A	cg03060546	chr3:49711283	APEH	-0.63	-7.86	-0.46	1.42e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs5753618	0.561	rs4820963	chr22:31698166	C/T	cg13145458	chr22:31556086	RNF185	0.47	5.07	0.32	8.23e-7	Colorectal cancer;
SARC	cis	rs7772486	0.790	rs7753092	chr6:146248863	C/T	cg23711669	chr6:146136114	FBXO30	-0.84	-13.4	-0.66	9.4e-31	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg02733842	chr7:1102375	C7orf50	-0.52	-6.39	-0.39	9.16e-10	Bronchopulmonary dysplasia;
SARC	cis	rs1949733	1.000	rs6858542	chr4:8511547	C/G	cg13073564	chr4:8508604	NA	0.48	7.82	0.46	1.77e-13	Response to antineoplastic agents;
SARC	cis	rs2304069	0.826	rs245076	chr5:149350648	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.62	6.97	0.42	3.23e-11	HIV-1 control;
SARC	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg18252515	chr7:66147081	NA	-1.33	-11.96	-0.62	5.03e-26	Diabetic kidney disease;
SARC	cis	rs858239	0.600	rs6956595	chr7:23134256	A/G	cg23682824	chr7:23144976	KLHL7	0.71	9.42	0.53	4.53e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs35110281	0.774	rs2838321	chr21:44995488	A/T	cg01579765	chr21:45077557	HSF2BP	-0.32	-5.38	-0.33	1.81e-7	Mean corpuscular volume;
SARC	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg22920501	chr2:26401640	FAM59B	0.61	7.93	0.46	8.99e-14	Gut microbiome composition (summer);
SARC	cis	rs78545713	0.502	rs3823157	chr6:26272039	A/G	cg13736514	chr6:26305472	NA	-0.51	-5.03	-0.31	9.94e-7	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs7772486	0.686	rs9390349	chr6:146054430	T/G	cg05347473	chr6:146136440	FBXO30	-0.51	-7.06	-0.42	1.95e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs17253792	0.822	rs28392709	chr14:56093685	G/A	cg01858014	chr14:56050164	KTN1	-0.67	-5.15	-0.32	5.5e-7	Putamen volume;
SARC	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg11644478	chr21:40555479	PSMG1	1.0	12.21	0.62	8.15e-27	Cognitive function;
SARC	trans	rs10862219	0.927	rs11615137	chr12:81416403	T/A	cg03835158	chr8:52773607	PCMTD1	-0.5	-6.84	-0.41	7.03e-11	Neuroticism;
SARC	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg06713675	chr4:122721982	EXOSC9	-0.51	-6.72	-0.4	1.39e-10	Type 2 diabetes;
SARC	cis	rs854765	0.533	rs2955354	chr17:17948716	G/C	cg04398451	chr17:18023971	MYO15A	0.47	6.55	0.39	3.55e-10	Total body bone mineral density;
SARC	cis	rs11098499	0.955	rs6815725	chr4:120158410	C/A	cg24375607	chr4:120327624	NA	0.39	4.73	0.3	3.89e-6	Corneal astigmatism;
SARC	cis	rs13161895	1.000	rs12654148	chr5:179438920	T/A	cg04265672	chr5:179402240	RNF130	0.52	5.15	0.32	5.48e-7	LDL cholesterol;
SARC	trans	rs11098499	0.863	rs11098532	chr4:120490726	C/A	cg25214090	chr10:38739885	LOC399744	0.57	7.25	0.43	6.27e-12	Corneal astigmatism;
SARC	cis	rs2204008	0.715	rs11495369	chr12:38238673	T/C	cg13010199	chr12:38710504	ALG10B	0.81	11.21	0.59	1.3e-23	Bladder cancer;
SARC	cis	rs7829975	0.686	rs907180	chr8:8702827	A/G	cg06636001	chr8:8085503	FLJ10661	0.59	8.08	0.47	3.52e-14	Mood instability;
SARC	cis	rs77372450	0.636	rs73305048	chr5:157017847	A/G	cg23851860	chr5:157002805	ADAM19	0.51	4.91	0.31	1.72e-6	Bipolar disorder (body mass index interaction);
SARC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg03452623	chr4:187889614	NA	-0.77	-12.35	-0.63	2.65e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4713118	0.699	rs200969	chr6:27859453	T/C	cg10876282	chr6:28092338	ZSCAN16	0.51	4.8	0.3	2.79e-6	Parkinson's disease;
SARC	cis	rs9300255	0.602	rs1716168	chr12:123651966	C/G	cg05973401	chr12:123451056	ABCB9	-0.54	-6.18	-0.38	2.89e-9	Neutrophil percentage of white cells;
SARC	cis	rs11997175	0.838	rs7836762	chr8:33667153	A/G	ch.8.33884649F	chr8:33765107	NA	0.49	6.71	0.4	1.47e-10	Body mass index;
SARC	cis	rs2120243	0.539	rs1563420	chr3:157119326	A/G	cg24825693	chr3:157122686	VEPH1	-0.46	-6.42	-0.39	7.36e-10	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs67311347	0.911	rs6776044	chr3:40377503	T/G	cg09455208	chr3:40491958	NA	0.39	6.12	0.37	3.93e-9	Renal cell carcinoma;
SARC	cis	rs8014204	0.804	rs34956813	chr14:75254167	G/A	cg17347104	chr14:75034677	LTBP2	-0.43	-5.35	-0.33	2.11e-7	Caffeine consumption;
SARC	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg16325326	chr1:53192061	ZYG11B	-0.82	-13.46	-0.66	6.13e-31	Monocyte count;
SARC	cis	rs7927771	1.000	rs7947730	chr11:47786184	C/T	cg20307385	chr11:47447363	PSMC3	-0.47	-5.59	-0.34	6.3e-8	Subjective well-being;
SARC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.62	-6.59	-0.4	2.82e-10	Platelet count;
SARC	cis	rs67311347	1.000	rs28491638	chr3:40496263	T/C	cg09455208	chr3:40491958	NA	0.4	5.9	0.36	1.29e-8	Renal cell carcinoma;
SARC	cis	rs72781680	0.611	rs72783636	chr2:24328706	C/T	cg06627628	chr2:24431161	ITSN2	-0.5	-5.34	-0.33	2.18e-7	Lymphocyte counts;
SARC	cis	rs10791097	0.667	rs4937584	chr11:130741761	A/G	cg09137382	chr11:130731461	NA	0.31	4.78	0.3	3.15e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs17270561	0.636	rs7453371	chr6:25719256	A/G	cg17691542	chr6:26056736	HIST1H1C	0.59	7.21	0.43	7.66e-12	Iron status biomarkers;
SARC	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg19077165	chr18:44547161	KATNAL2	-0.5	-6.73	-0.4	1.3100000000000001e-10	Personality dimensions;
SARC	cis	rs7647973	1.000	rs1982861	chr3:49577665	A/G	cg06212747	chr3:49208901	KLHDC8B	0.57	6.01	0.37	6.96e-9	Menarche (age at onset);
SARC	cis	rs7223966	1.000	rs6504171	chr17:61710010	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.59	-6.72	-0.4	1.41e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs13191362	0.507	rs2846566	chr6:163059714	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.44	-4.78	-0.3	3.07e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	trans	rs2816316	0.559	rs2816313	chr1:192539337	G/A	cg02079908	chr2:42411760	EML4	0.55	6.47	0.39	5.82e-10	Celiac disease;
SARC	cis	rs6901004	0.803	rs9387000	chr6:111459941	A/C	cg15721981	chr6:111408429	SLC16A10	-0.44	-5.35	-0.33	2.06e-7	Blood metabolite levels;
SARC	cis	rs739401	0.611	rs7130841	chr11:3043658	A/G	cg08508325	chr11:3079039	CARS	-0.32	-7.88	-0.46	1.28e-13	Longevity;
SARC	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs4141404	0.851	rs5997893	chr22:31556103	A/G	cg00478049	chr22:31556069	RNF185	0.46	5.57	0.34	6.85e-8	Paclitaxel-induced neuropathy;
SARC	cis	rs25645	0.800	rs11078935	chr17:38192137	T/G	cg17344932	chr17:38183730	MED24;SNORD124	0.4	7.25	0.43	6.05e-12	Myeloid white cell count;
SARC	cis	rs2153535	0.541	rs5026687	chr6:8473957	A/T	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg20682991	chr2:74981952	NA	-0.51	-6.79	-0.41	9.02e-11	Height;
SARC	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg03806693	chr22:41940476	POLR3H	-0.87	-11.91	-0.62	7.27e-26	Vitiligo;
SARC	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg25405998	chr7:65216604	CCT6P1	-0.48	-5.76	-0.35	2.7e-8	Calcium levels;
SARC	cis	rs9393692	0.645	rs766406	chr6:26319588	G/T	cg13736514	chr6:26305472	NA	-0.74	-9.43	-0.53	4.26e-18	Educational attainment;
SARC	cis	rs595982	0.510	rs3826817	chr19:49401444	C/T	cg03707168	chr19:49379127	PPP1R15A	0.47	6.31	0.38	1.42e-9	Red cell distribution width;
SARC	cis	rs10911232	0.507	rs4397624	chr1:183053131	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.35	0.56	6.82e-21	Hypertriglyceridemia;
SARC	cis	rs17401966	0.838	rs12132134	chr1:10378428	A/G	cg15208524	chr1:10270712	KIF1B	0.5	5.91	0.36	1.23e-8	Hepatocellular carcinoma;
SARC	cis	rs4660306	0.744	rs11211113	chr1:45923668	T/C	cg24296786	chr1:45957014	TESK2	-0.57	-5.61	-0.34	5.79e-8	Homocysteine levels;
SARC	cis	rs3741151	0.773	rs73546720	chr11:73252409	C/T	cg17517138	chr11:73019481	ARHGEF17	0.93	6.88	0.41	5.4e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs12579753	0.917	rs12372724	chr12:82193628	C/T	cg07988820	chr12:82153109	PPFIA2	-0.52	-6.06	-0.37	5.55e-9	Resting heart rate;
SARC	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10465746	0.780	rs11163872	chr1:84421969	G/T	cg10977910	chr1:84465055	TTLL7	0.41	4.97	0.31	1.28e-6	Obesity-related traits;
SARC	cis	rs3772130	0.583	rs12695415	chr3:121398853	C/T	cg20356878	chr3:121714668	ILDR1	0.39	6.11	0.37	4.15e-9	Cognitive performance;
SARC	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9611519	1.000	rs9611510	chr22:41569124	T/C	cg17376030	chr22:41985996	PMM1	0.51	6.02	0.37	6.81e-9	Neuroticism;
SARC	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg21782813	chr7:2030301	MAD1L1	0.39	5.91	0.36	1.2e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs34172651	0.517	rs2303083	chr16:24835168	G/A	cg06028605	chr16:24865363	SLC5A11	0.35	4.91	0.31	1.7e-6	Intelligence (multi-trait analysis);
SARC	cis	rs1044826	1.000	rs9835241	chr3:139234555	A/G	cg15131784	chr3:139108705	COPB2	0.44	5.08	0.32	7.72e-7	Obesity-related traits;
SARC	cis	rs2273669	0.588	rs11153151	chr6:109316754	C/G	cg05315195	chr6:109294784	ARMC2	-0.59	-5.45	-0.34	1.28e-7	Prostate cancer;
SARC	cis	rs9868809	0.772	rs9811318	chr3:48702606	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.55	-4.91	-0.31	1.69e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs1348850	0.789	rs2197611	chr2:178369036	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.71	8.82	0.5	2.78e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7223966	0.881	rs3020608	chr17:61979993	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-4.81	-0.3	2.72e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg25427524	chr10:38739819	LOC399744	-0.52	-8.25	-0.48	1.17e-14	Extrinsic epigenetic age acceleration;
SARC	cis	rs9303401	0.614	rs3087762	chr17:56568680	C/T	cg25039879	chr17:56429692	SUPT4H1	0.63	5.77	0.35	2.51e-8	Cognitive test performance;
SARC	cis	rs1348850	0.645	rs11889272	chr2:178432378	C/T	cg23306229	chr2:178417860	TTC30B	0.82	8.49	0.49	2.42e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg27266027	chr21:40555129	PSMG1	0.49	5.27	0.33	3.17e-7	Cognitive function;
SARC	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg11489262	chr17:43973426	MAPT;LOC100128977;LOC100130148	0.46	4.82	0.3	2.56e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7011049	1.000	rs72643576	chr8:53845016	A/T	cg26025543	chr8:53854495	NA	0.6	5.39	0.33	1.73e-7	Systolic blood pressure;
SARC	cis	rs9814567	0.762	rs13093893	chr3:134292131	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.52	5.43	0.33	1.45e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs10056811	0.527	rs55798253	chr5:74380957	A/G	cg06933384	chr5:74808293	COL4A3BP;POLK	0.49	4.85	0.3	2.22e-6	Coronary artery disease;
SARC	cis	rs1215050	0.743	rs6532692	chr4:98648005	C/A	cg05340658	chr4:99064831	C4orf37	-0.46	-6.0	-0.37	7.57e-9	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs2408955	0.568	rs12099462	chr12:48503104	T/C	cg24011408	chr12:48396354	COL2A1	-0.43	-5.37	-0.33	1.87e-7	Glycated hemoglobin levels;
SARC	cis	rs16933812	0.510	rs4880049	chr9:36989333	C/T	cg14294708	chr9:37120828	ZCCHC7	0.43	4.78	0.3	3.07e-6	Obesity-related traits;
SARC	cis	rs992157	0.560	rs6436047	chr2:219108913	A/C	cg00012203	chr2:219082015	ARPC2	0.75	11.6	0.61	7.38e-25	Colorectal cancer;
SARC	cis	rs11122272	0.735	rs2749705	chr1:231526696	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.95	-0.55	1.17e-19	Hemoglobin concentration;
SARC	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg04944784	chr2:26401820	FAM59B	-0.5	-6.14	-0.37	3.49e-9	Gut microbiome composition (summer);
SARC	cis	rs514406	0.536	rs878957	chr1:53197559	C/T	cg16325326	chr1:53192061	ZYG11B	-0.89	-15.61	-0.72	4.38e-38	Monocyte count;
SARC	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg21724239	chr8:58056113	NA	0.57	6.15	0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7208859	0.623	rs9900144	chr17:29208389	T/C	cg13385521	chr17:29058706	SUZ12P	0.86	7.34	0.43	3.54e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs17270561	0.583	rs6937800	chr6:25765943	A/G	cg16482183	chr6:26056742	HIST1H1C	0.48	5.95	0.36	9.58e-9	Iron status biomarkers;
SARC	cis	rs136211	0.895	rs755470	chr22:36774904	C/T	cg16924664	chr22:36878180	TXN2	0.43	5.37	0.33	1.95e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs916888	0.610	rs199442	chr17:44820122	G/A	cg01570182	chr17:44337453	NA	0.63	7.71	0.45	3.7e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs6831352	0.877	rs2602890	chr4:100043179	C/T	cg12011299	chr4:100065546	ADH4	0.34	5.71	0.35	3.43e-8	Alcohol dependence;
SARC	trans	rs10929159	0.928	rs9636243	chr2:236925259	C/T	cg09017434	chr5:16179660	MARCH11	-0.34	-6.43	-0.39	7.05e-10	Parkinson's disease;
SARC	cis	rs9354308	0.868	rs1938063	chr6:66559098	T/G	cg07460842	chr6:66804631	NA	-0.45	-5.19	-0.32	4.6e-7	Metabolite levels;
SARC	cis	rs7296418	0.961	rs4148863	chr12:123569375	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.42	-5.74	-0.35	2.91e-8	Platelet count;
SARC	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg16325326	chr1:53192061	ZYG11B	0.81	12.75	0.64	1.31e-28	Monocyte count;
SARC	cis	rs6120849	0.663	rs13041792	chr20:33545055	G/A	cg24642439	chr20:33292090	TP53INP2	0.6	6.02	0.37	6.77e-9	Protein C levels;
SARC	cis	rs910316	0.934	rs8016330	chr14:75657507	G/T	cg08847533	chr14:75593920	NEK9	-0.84	-12.74	-0.64	1.5e-28	Height;
SARC	cis	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg12463550	chr7:65579703	CRCP	0.69	5.29	0.33	2.86e-7	Diabetic kidney disease;
SARC	cis	rs995000	0.931	rs642845	chr1:62908235	T/C	cg06896770	chr1:63153194	DOCK7	0.89	13.58	0.66	2.52e-31	Triglyceride levels;
SARC	cis	rs6500602	0.702	rs6500606	chr16:4502514	A/G	cg08645402	chr16:4508243	NA	-0.46	-5.93	-0.36	1.11e-8	Schizophrenia;
SARC	cis	rs7647973	0.710	rs12637313	chr3:49645458	A/G	cg13072238	chr3:49761600	GMPPB	-0.61	-5.32	-0.33	2.38e-7	Menarche (age at onset);
SARC	cis	rs2562456	0.917	rs11085463	chr19:21751302	G/T	cg00455402	chr19:21769736	NA	-0.37	-4.84	-0.3	2.36e-6	Pain;
SARC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg09373136	chr17:61933544	TCAM1	0.44	5.97	0.36	8.57e-9	Prudent dietary pattern;
SARC	cis	rs6834538	0.597	rs6822451	chr4:113463265	G/A	cg05193411	chr4:113558554	LARP7;C4orf21	0.4	4.93	0.31	1.53e-6	Free thyroxine concentration;
SARC	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.9	9.7	0.54	6.67e-19	Platelet count;
SARC	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg25894440	chr7:65020034	NA	-0.79	-5.96	-0.36	9.49e-9	Diabetic kidney disease;
SARC	cis	rs9911578	0.967	rs12603238	chr17:57130785	C/T	cg05425664	chr17:57184151	TRIM37	0.64	7.93	0.46	9e-14	Intelligence (multi-trait analysis);
SARC	cis	rs1371867	0.846	rs2083499	chr8:101230534	T/A	cg11906718	chr8:101322791	RNF19A	-0.69	-8.58	-0.49	1.37e-15	Atrioventricular conduction;
SARC	cis	rs7937682	0.889	rs541198	chr11:111475340	A/G	cg22437258	chr11:111473054	SIK2	0.76	10.7	0.57	5.51e-22	Primary sclerosing cholangitis;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg12050434	chr12:43030949	NA	-0.54	-6.93	-0.41	4.05e-11	Height;
SARC	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg22535103	chr8:58192502	C8orf71	0.77	7.74	0.45	2.93e-13	Developmental language disorder (linguistic errors);
SARC	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg16329197	chr12:53359506	NA	-0.49	-6.03	-0.37	6.46e-9	Cancer (pleiotropy);
SARC	cis	rs7428	0.527	rs1061782	chr2:85546615	A/G	cg03728395	chr2:85555865	TGOLN2	0.49	7.01	0.42	2.49e-11	Ear protrusion;
SARC	cis	rs7208859	0.623	rs9894709	chr17:29078454	G/A	cg13385521	chr17:29058706	SUZ12P	0.88	7.75	0.45	2.9e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs7264396	0.666	rs1536147	chr20:34173046	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.53	6.17	0.37	3.07e-9	Total cholesterol levels;
SARC	cis	rs10513788	0.665	rs72622587	chr3:181994809	C/T	cg05977900	chr3:182512126	ATP11B	0.49	5.09	0.32	7.48e-7	Cognitive function;
SARC	cis	rs611744	0.608	rs1448152	chr8:109278249	C/T	cg21045802	chr8:109455806	TTC35	0.62	7.7	0.45	3.94e-13	Dupuytren's disease;
SARC	cis	rs240764	0.658	rs705585	chr6:101262409	A/G	cg09795085	chr6:101329169	ASCC3	0.49	6.46	0.39	5.88e-10	Neuroticism;
SARC	cis	rs9462027	0.561	rs2814972	chr6:34566975	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-6.02	-0.37	6.81e-9	Systemic lupus erythematosus;
SARC	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg26335602	chr6:28129616	ZNF389	0.47	5.68	0.35	4.09e-8	Depression;
SARC	cis	rs35306767	0.903	rs11813210	chr10:919796	G/A	cg20503657	chr10:835505	NA	0.89	8.25	0.48	1.18e-14	Eosinophil percentage of granulocytes;
SARC	cis	rs1153858	1.000	rs7171577	chr15:45627979	G/A	cg21132104	chr15:45694354	SPATA5L1	0.8	11.18	0.59	1.65e-23	Homoarginine levels;
SARC	cis	rs262150	0.567	rs2527177	chr7:158804737	T/C	cg04111992	chr7:158790115	NA	-0.36	-5.18	-0.32	4.8e-7	Facial morphology (factor 20);
SARC	cis	rs7223966	0.961	rs17631394	chr17:61646000	A/G	cg00588841	chr17:61851480	DDX42;CCDC47	0.58	5.68	0.35	4.07e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2425143	1.000	rs45595739	chr20:34320759	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	5.11	0.32	6.74e-7	Blood protein levels;
SARC	cis	rs8054556	0.787	rs1140239	chr16:30021402	C/T	cg06015834	chr16:30021696	DOC2A	-0.36	-4.85	-0.3	2.23e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9467773	1.000	rs6932156	chr6:26571506	T/G	cg12292205	chr6:26970375	C6orf41	0.45	5.43	0.33	1.45e-7	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg20607798	chr8:58055168	NA	0.57	5.42	0.33	1.45e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	8.93	0.5	1.31e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs240764	0.541	rs9390693	chr6:101239935	T/C	cg09795085	chr6:101329169	ASCC3	0.45	5.66	0.35	4.42e-8	Neuroticism;
SARC	cis	rs739401	0.595	rs6578304	chr11:2998279	A/G	cg08508325	chr11:3079039	CARS	0.32	7.7	0.45	3.9e-13	Longevity;
SARC	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg12463550	chr7:65579703	CRCP	0.42	4.97	0.31	1.32e-6	Aortic root size;
SARC	cis	rs2777491	0.957	rs919961	chr15:41651721	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.75	-11.19	-0.59	1.49e-23	Ulcerative colitis;
SARC	cis	rs10504229	0.636	rs114725691	chr8:58054292	C/T	cg11062466	chr8:58055876	NA	0.52	5.13	0.32	5.99e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6964587	1.000	rs7806157	chr7:91601930	A/G	cg17063962	chr7:91808500	NA	0.95	15.33	0.71	3.72e-37	Breast cancer;
SARC	cis	rs8014204	0.935	rs1799900	chr14:75367740	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.74	-11.05	-0.59	4.36e-23	Caffeine consumption;
SARC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	9.05	0.51	5.9e-17	Prudent dietary pattern;
SARC	trans	rs57046232	0.502	rs13041415	chr20:6463095	T/C	cg00270625	chr22:51017019	CPT1B;CHKB-CPT1B	0.61	6.82	0.41	7.94e-11	Colorectal cancer;
SARC	cis	rs4253772	0.530	rs11090865	chr22:46731689	G/T	cg23346237	chr22:46685655	TTC38	0.39	4.81	0.3	2.77e-6	LDL cholesterol;Cholesterol, total;
SARC	trans	rs9929218	1.000	rs12930371	chr16:68802936	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.55	6.91	0.41	4.58e-11	Colorectal cancer;
SARC	cis	rs11792861	0.781	rs874864	chr9:111728718	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.77	9.58	0.53	1.48e-18	Menarche (age at onset);
SARC	cis	rs826838	0.967	rs4768330	chr12:39129399	T/C	cg13010199	chr12:38710504	ALG10B	-0.63	-8.88	-0.5	1.87e-16	Heart rate;
SARC	cis	rs7011049	1.000	rs72643579	chr8:53846705	C/A	cg26025543	chr8:53854495	NA	0.6	5.43	0.34	1.42e-7	Systolic blood pressure;
SARC	cis	rs13161895	1.000	rs1102191	chr5:179416210	C/T	cg04265672	chr5:179402240	RNF130	-0.53	-5.07	-0.32	8.22e-7	LDL cholesterol;
SARC	cis	rs6570726	0.791	rs6900040	chr6:145893134	C/T	cg05347473	chr6:146136440	FBXO30	0.51	7.17	0.43	9.59e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9309473	0.607	rs10196402	chr2:73572081	A/C	cg20560298	chr2:73613845	ALMS1	-0.55	-6.88	-0.41	5.59e-11	Metabolite levels;
SARC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg06873352	chr17:61820015	STRADA	0.51	6.55	0.39	3.71e-10	Prudent dietary pattern;
SARC	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg24209194	chr3:40518798	ZNF619	-0.65	-8.08	-0.47	3.47e-14	Renal cell carcinoma;
SARC	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg20090690	chr10:134436459	INPP5A	0.45	5.0	0.31	1.12e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs1153858	1.000	rs2467863	chr15:45641880	G/A	cg21132104	chr15:45694354	SPATA5L1	0.78	10.77	0.58	3.26e-22	Homoarginine levels;
SARC	cis	rs7103648	0.545	rs6485795	chr11:47929846	G/A	cg10504702	chr11:47789108	FNBP4	0.71	8.97	0.51	1.01e-16	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs2380220	1.000	rs2380220	chr6:95967412	T/C	cg23517279	chr6:96025343	MANEA	0.53	5.43	0.34	1.39e-7	Behavioural disinhibition (generation interaction);
SARC	cis	rs1348850	0.831	rs1345139	chr2:178449791	G/T	cg23306229	chr2:178417860	TTC30B	0.57	6.54	0.39	3.85e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9840812	0.690	rs1618069	chr3:136027145	A/G	cg15507776	chr3:136538369	TMEM22	0.45	4.84	0.3	2.34e-6	Fibrinogen levels;
SARC	trans	rs208520	0.837	rs208509	chr6:66941706	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.87	-10.1	-0.55	3.99e-20	Exhaled nitric oxide output;
SARC	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg12463550	chr7:65579703	CRCP	-0.47	-5.03	-0.31	9.64e-7	Aortic root size;
SARC	cis	rs7412746	0.658	rs12067685	chr1:150952917	T/C	cg13175981	chr1:150552382	MCL1	-0.46	-5.32	-0.33	2.38e-7	Melanoma;
SARC	cis	rs13191362	0.810	rs34714603	chr6:163008078	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.57	5.51	0.34	9.35e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs10464366	0.544	rs34866559	chr7:39166071	G/A	cg15212455	chr7:39170539	POU6F2	0.39	4.96	0.31	1.34e-6	IgG glycosylation;
SARC	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg15049968	chr18:44337910	ST8SIA5	-0.35	-5.32	-0.33	2.46e-7	Personality dimensions;
SARC	cis	rs6570726	0.935	rs425731	chr6:145834151	A/G	cg23711669	chr6:146136114	FBXO30	0.78	11.86	0.61	1.04e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs72634258	0.945	rs397349	chr1:8074872	A/C	cg00042356	chr1:8021962	PARK7	0.55	5.38	0.33	1.81e-7	Inflammatory bowel disease;
SARC	cis	rs7786808	0.579	rs4045391	chr7:158181826	T/C	cg01191920	chr7:158217561	PTPRN2	-0.29	-4.89	-0.3	1.91e-6	Obesity-related traits;
SARC	cis	rs6582630	0.634	rs10748443	chr12:38734062	G/T	cg13010199	chr12:38710504	ALG10B	0.52	6.54	0.39	3.76e-10	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs7615952	0.932	rs11922218	chr3:125631289	C/T	cg07211511	chr3:129823064	LOC729375	-0.94	-10.46	-0.57	2.96e-21	Blood pressure (smoking interaction);
SARC	cis	rs7666738	0.830	rs4619898	chr4:98959646	G/A	cg05340658	chr4:99064831	C4orf37	0.66	9.0	0.51	8.07e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg03060546	chr3:49711283	APEH	0.43	5.34	0.33	2.21e-7	Parkinson's disease;
SARC	cis	rs7937682	0.924	rs10891288	chr11:111552053	G/T	cg09085632	chr11:111637200	PPP2R1B	0.9	14.93	0.7	8.25e-36	Primary sclerosing cholangitis;
SARC	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg13395646	chr4:1353034	KIAA1530	0.4	4.79	0.3	2.92e-6	Obesity-related traits;
SARC	cis	rs10191773	0.589	rs72831634	chr2:112946796	A/G	cg07905836	chr2:113190072	RGPD8;RGPD5	0.96	7.97	0.46	6.88e-14	Yeast infection;
SARC	cis	rs10875746	0.903	rs11168386	chr12:48467977	C/T	cg26205652	chr12:48591994	NA	0.56	6.05	0.37	5.72e-9	Longevity (90 years and older);
SARC	cis	rs10861342	1.000	rs10861350	chr12:105484913	G/A	cg23923672	chr12:105501055	KIAA1033	0.73	5.3	0.33	2.74e-7	IgG glycosylation;
SARC	cis	rs2729354	0.953	rs2649663	chr11:57357305	C/T	cg02958346	chr11:57425731	CLP1	0.48	4.82	0.3	2.56e-6	Blood protein levels;
SARC	cis	rs854765	0.547	rs7212167	chr17:17913504	G/A	cg04398451	chr17:18023971	MYO15A	-0.45	-6.33	-0.38	1.27e-9	Total body bone mineral density;
SARC	cis	rs9303401	0.615	rs7502342	chr17:56922629	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	11.58	0.6	8.42e-25	Cognitive test performance;
SARC	cis	rs7647973	1.000	rs56127630	chr3:49438036	C/G	cg06212747	chr3:49208901	KLHDC8B	-0.56	-5.75	-0.35	2.8e-8	Menarche (age at onset);
SARC	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg10523679	chr1:76189770	ACADM	0.54	7.38	0.44	2.73e-12	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs16974263	1.000	rs16974263	chr19:40913539	A/G	cg14150973	chr19:40950431	SERTAD3	-0.66	-5.87	-0.36	1.5e-8	Otitis media;Otitis media (chronic);Otitis media (recurrent);
SARC	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg02725872	chr8:58115012	NA	-0.37	-6.55	-0.39	3.71e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg02725872	chr8:58115012	NA	-0.37	-6.54	-0.39	3.94e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9611519	0.780	rs5751071	chr22:41656332	G/A	cg03806693	chr22:41940476	POLR3H	-0.67	-9.03	-0.51	6.84e-17	Neuroticism;
SARC	cis	rs17666538	1.000	rs17666538	chr8:566207	T/C	cg02524346	chr8:600233	NA	-0.9	-6.34	-0.38	1.15e-9	IgG glycosylation;
SARC	cis	rs6963495	0.818	rs73192141	chr7:105201129	T/G	cg13798780	chr7:105162888	PUS7	0.57	5.14	0.32	5.94e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs1448094	0.967	rs10863115	chr12:86332586	T/C	cg02569458	chr12:86230093	RASSF9	0.4	5.83	0.36	1.84e-8	Major depressive disorder;
SARC	cis	rs9916302	0.629	rs9972882	chr17:37807698	A/C	cg07936489	chr17:37558343	FBXL20	-0.41	-4.96	-0.31	1.33e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs4803468	1.000	rs2241709	chr19:41912250	C/T	cg08477640	chr19:41863820	B9D2	0.41	5.22	0.32	3.9e-7	Height;
SARC	trans	rs561341	1.000	rs55643307	chr17:30263074	T/C	cg20587970	chr11:113659929	NA	-1.38	-13.55	-0.66	3.22e-31	Hip circumference adjusted for BMI;
SARC	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.5	0.39	4.82e-10	Height;
SARC	cis	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg13072238	chr3:49761600	GMPPB	-0.64	-5.6	-0.34	5.9e-8	Menarche (age at onset);
SARC	cis	rs11252926	0.550	rs10795122	chr10:466830	C/T	cg16386425	chr10:429943	DIP2C	-0.56	-6.22	-0.38	2.26e-9	Psychosis in Alzheimer's disease;
SARC	cis	rs3096299	0.933	rs2965824	chr16:89455306	A/G	cg02187348	chr16:89574699	SPG7	0.49	6.48	0.39	5.27e-10	Multiple myeloma (IgH translocation);
SARC	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg16680214	chr1:154839983	KCNN3	-0.34	-5.37	-0.33	1.9e-7	Prostate cancer;
SARC	cis	rs9479482	1.000	rs9478354	chr6:150334366	G/A	cg03788504	chr6:150331562	NA	-0.32	-5.09	-0.32	7.31e-7	Alopecia areata;
SARC	cis	rs9290065	0.558	rs9846254	chr3:160770370	C/T	cg04691961	chr3:161091175	C3orf57	-0.48	-5.94	-0.36	1.02e-8	Kawasaki disease;
SARC	cis	rs9325144	0.624	rs12231544	chr12:38901956	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-7.07	-0.42	1.81e-11	Morning vs. evening chronotype;
SARC	cis	rs2481665	0.739	rs6674622	chr1:62534938	A/G	cg18591186	chr1:62594603	INADL	-0.41	-5.55	-0.34	7.55e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	trans	rs4332037	0.539	rs34809719	chr7:2028968	G/T	cg11693508	chr17:37793320	STARD3	0.66	6.54	0.39	3.93e-10	Bipolar disorder;
SARC	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.61	-7.75	-0.45	2.85e-13	Prudent dietary pattern;
SARC	cis	rs55692411	0.517	rs13095697	chr3:50136463	G/A	cg24110177	chr3:50126178	RBM5	-0.47	-5.2	-0.32	4.3e-7	Intelligence (multi-trait analysis);
SARC	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg12564285	chr5:131593104	PDLIM4	0.42	6.16	0.37	3.24e-9	Acylcarnitine levels;
SARC	trans	rs11039798	0.588	rs10160381	chr11:48599491	A/G	cg15704280	chr7:45808275	SEPT13	0.63	6.71	0.4	1.46e-10	Axial length;
SARC	cis	rs6558174	0.930	rs12676084	chr8:22493350	C/T	cg03733263	chr8:22462867	KIAA1967	0.58	6.75	0.4	1.16e-10	Breast cancer;
SARC	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg04166393	chr7:2884313	GNA12	0.54	6.25	0.38	1.98e-9	Height;
SARC	cis	rs6840360	1.000	rs6841783	chr4:152598876	C/G	cg22705602	chr4:152727874	NA	-0.38	-6.54	-0.39	3.91e-10	Intelligence (multi-trait analysis);
SARC	cis	rs4780401	0.933	rs12926451	chr16:11819569	A/C	cg01061890	chr16:11836724	TXNDC11	0.52	6.93	0.41	4.18e-11	Rheumatoid arthritis;
SARC	cis	rs6688613	0.729	rs2072742	chr1:166929673	A/G	cg07049167	chr1:166818506	POGK	0.5	5.2	0.32	4.39e-7	Refractive astigmatism;
SARC	cis	rs644799	0.710	rs10831429	chr11:95508524	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	13.92	0.67	1.89e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs143699489	1	rs143699489	chr3:140927121	A/G	cg16418163	chr3:140950828	ACPL2	0.6	4.71	0.3	4.19e-6	White blood cell count;Granulocyte count;Sum neutrophil eosinophil counts;
SARC	cis	rs911555	0.570	rs11625397	chr14:104027557	A/G	cg26031613	chr14:104095156	KLC1	-0.63	-8.8	-0.5	3.21e-16	Intelligence (multi-trait analysis);
SARC	cis	rs2832191	0.791	rs2832202	chr21:30501342	G/A	cg08807101	chr21:30365312	RNF160	-0.81	-11.21	-0.59	1.31e-23	Dental caries;
SARC	cis	rs3947	0.906	rs709822	chr8:11702313	C/G	cg00262122	chr8:11665843	FDFT1	-0.45	-5.12	-0.32	6.29e-7	Blood protein levels;
SARC	cis	rs10934753	0.632	rs13070856	chr3:125909415	A/G	cg01346077	chr3:125931526	NA	-0.38	-5.04	-0.31	9.21e-7	Plasma homocysteine levels (post-methionine load test);
SARC	cis	rs709400	0.567	rs1961600	chr14:103862144	G/A	cg26031613	chr14:104095156	KLC1	0.81	11.84	0.61	1.26e-25	Body mass index;
SARC	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.39	-5.34	-0.33	2.18e-7	Personality dimensions;
SARC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg16132339	chr22:24313637	DDTL;DDT	0.4	5.11	0.32	6.56e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1008375	1.000	rs28552744	chr4:17620165	A/G	cg27347728	chr4:17578864	LAP3	0.47	5.81	0.36	2.01e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2594989	0.673	rs1046593	chr3:11596402	C/T	cg00170343	chr3:11313890	ATG7	-0.53	-4.73	-0.3	3.92e-6	Circulating chemerin levels;
SARC	cis	rs826838	0.967	rs7299170	chr12:38789536	G/A	cg26384229	chr12:38710491	ALG10B	0.94	14.91	0.7	9.81e-36	Heart rate;
SARC	cis	rs4927850	1.000	rs6799572	chr3:195740408	C/T	cg00031303	chr3:195681400	NA	0.51	5.88	0.36	1.43e-8	Pancreatic cancer;
SARC	cis	rs10416265	0.527	rs6510337	chr19:33545701	C/T	cg27124370	chr19:33622961	WDR88	0.47	6.18	0.38	2.91e-9	Bone properties (heel);
SARC	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg18876405	chr7:65276391	NA	-0.72	-9.0	-0.51	8.24e-17	Aortic root size;
SARC	cis	rs644799	0.965	rs11021305	chr11:95498269	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.65	8.78	0.5	3.5e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs4891159	0.548	rs689902	chr18:74119969	C/T	cg24786174	chr18:74118243	ZNF516	-0.76	-13.07	-0.65	1.24e-29	Longevity;
SARC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg06873352	chr17:61820015	STRADA	0.54	6.91	0.41	4.71e-11	Prudent dietary pattern;
SARC	cis	rs67311347	0.955	rs11717036	chr3:40379578	G/T	cg09455208	chr3:40491958	NA	-0.39	-6.09	-0.37	4.58e-9	Renal cell carcinoma;
SARC	cis	rs2153535	0.580	rs7341382	chr6:8470549	A/G	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	cis	rs4332037	0.950	rs7807014	chr7:1939021	T/C	cg23422044	chr7:1970798	MAD1L1	-0.46	-4.86	-0.3	2.19e-6	Bipolar disorder;
SARC	cis	rs7617773	0.746	rs4130995	chr3:48358255	C/T	cg11946769	chr3:48343235	NME6	0.69	9.25	0.52	1.5e-17	Coronary artery disease;
SARC	cis	rs6060717	0.536	rs11697024	chr20:34546500	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-5.4	-0.33	1.67e-7	Hip circumference adjusted for BMI;
SARC	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg12419862	chr22:24373484	LOC391322	0.67	8.14	0.47	2.4e-14	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs11625487	0.957	rs10145540	chr14:77957354	C/T	cg20045696	chr14:77926864	AHSA1	-0.47	-5.44	-0.34	1.34e-7	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
SARC	cis	rs7582720	1.000	rs76461893	chr2:203865515	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs7937682	0.575	rs7950926	chr11:111776437	G/C	cg09085632	chr11:111637200	PPP2R1B	0.77	10.1	0.55	4.07e-20	Primary sclerosing cholangitis;
SARC	cis	rs344364	0.511	rs62040571	chr16:1948514	C/G	cg26617929	chr16:1858877	NA	-0.71	-6.06	-0.37	5.5e-9	Glomerular filtration rate in chronic kidney disease;
SARC	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg13944838	chr5:179740914	GFPT2	-0.56	-7.22	-0.43	7.16e-12	Height;
SARC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg04267008	chr7:1944627	MAD1L1	-0.46	-5.28	-0.33	2.98e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs7586879	0.616	rs10203386	chr2:25136866	T/A	cg04586622	chr2:25135609	ADCY3	0.3	5.07	0.32	8.23e-7	Body mass index;
SARC	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg19500275	chr17:80737654	TBCD	0.45	5.42	0.33	1.45e-7	Glycated hemoglobin levels;
SARC	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg12311346	chr5:56204834	C5orf35	-0.57	-6.1	-0.37	4.48e-9	Initial pursuit acceleration;
SARC	cis	rs8005677	0.962	rs11157931	chr14:23403193	A/C	cg01529538	chr14:23388837	RBM23	0.43	5.2	0.32	4.41e-7	Cognitive ability (multi-trait analysis);
SARC	cis	rs854765	0.583	rs9635697	chr17:17870394	T/A	cg05444541	chr17:17804740	TOM1L2	-0.3	-4.88	-0.3	1.96e-6	Total body bone mineral density;
SARC	cis	rs10782582	0.609	rs78748984	chr1:76340467	G/A	cg10523679	chr1:76189770	ACADM	-0.39	-4.88	-0.3	1.93e-6	Daytime sleep phenotypes;
SARC	cis	rs2227564	0.729	rs2633303	chr10:75645882	G/T	cg16540259	chr10:75572220	NDST2	0.36	5.01	0.31	1.09e-6	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg08859206	chr1:53392774	SCP2	0.39	5.65	0.35	4.74e-8	Monocyte count;
SARC	cis	rs1008375	0.966	rs1476836	chr4:17585014	G/C	cg16339924	chr4:17578868	LAP3	0.69	9.17	0.51	2.59e-17	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg05861140	chr6:150128134	PCMT1	-0.4	-5.18	-0.32	4.91e-7	Lung cancer;
SARC	cis	rs13108904	0.517	rs7671242	chr4:1339875	G/A	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.13	-0.32	6.09e-7	Obesity-related traits;
SARC	cis	rs7833790	0.676	rs7834555	chr8:82697625	A/G	cg17211192	chr8:82754475	SNX16	-0.49	-5.88	-0.36	1.41e-8	Diastolic blood pressure;
SARC	cis	rs611744	0.967	rs660816	chr8:109178048	C/T	cg21045802	chr8:109455806	TTC35	0.44	5.3	0.33	2.64e-7	Dupuytren's disease;
SARC	cis	rs1387259	0.690	rs1601985	chr12:48761914	A/G	cg24011408	chr12:48396354	COL2A1	0.43	5.12	0.32	6.46e-7	Obstructive sleep apnea trait (apnea hypopnea index);
SARC	cis	rs7937682	0.883	rs12804962	chr11:111442683	A/T	cg22437258	chr11:111473054	SIK2	-0.72	-9.46	-0.53	3.47e-18	Primary sclerosing cholangitis;
SARC	cis	rs8067545	0.611	rs7222984	chr17:20019694	A/C	cg13482628	chr17:19912719	NA	0.57	7.51	0.44	1.28e-12	Schizophrenia;
SARC	cis	rs1318878	1.000	rs77362355	chr12:15547710	G/A	cg08258403	chr12:15378311	NA	0.46	6.07	0.37	5.26e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7828089	0.875	rs6998575	chr8:22254499	C/T	cg12081754	chr8:22256438	SLC39A14	0.55	7.33	0.43	3.83e-12	Verbal declarative memory;
SARC	cis	rs7589342	0.862	rs6745887	chr2:106468039	G/A	cg16077055	chr2:106428750	NCK2	0.4	7.38	0.44	2.79e-12	Addiction;
SARC	cis	rs11209002	0.524	rs982131	chr1:67542360	T/C	cg02640540	chr1:67518911	SLC35D1	0.59	6.66	0.4	1.99e-10	Crohn's disease;
SARC	cis	rs9660992	0.789	rs1768584	chr1:205240145	A/G	cg00857998	chr1:205179979	DSTYK	0.48	6.02	0.37	6.67e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs10870270	0.912	rs7079991	chr10:133736130	A/G	cg26149184	chr10:133730230	NA	0.47	5.39	0.33	1.68e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs7327064	0.510	rs9547565	chr13:36962622	G/T	cg13455704	chr13:36871754	C13orf38	-0.54	-5.86	-0.36	1.53e-8	Economic and political preferences;
SARC	cis	rs644799	1.000	rs611020	chr11:95567905	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.89	13.93	0.67	1.77e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2075371	1.000	rs432487	chr7:133990114	T/G	cg00033643	chr7:134001901	SLC35B4	0.39	4.77	0.3	3.25e-6	Mean platelet volume;
SARC	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg13902645	chr11:5959945	NA	0.42	5.85	0.36	1.67e-8	DNA methylation (variation);
SARC	cis	rs4919087	0.715	rs2484880	chr10:98998355	T/C	cg25902810	chr10:99078978	FRAT1	-0.52	-6.2	-0.38	2.52e-9	Monocyte count;
SARC	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg12463550	chr7:65579703	CRCP	0.66	5.07	0.32	8.09e-7	Diabetic kidney disease;
SARC	cis	rs35110281	0.744	rs230644	chr21:44917183	C/T	cg01579765	chr21:45077557	HSF2BP	0.31	5.27	0.33	3.11e-7	Mean corpuscular volume;
SARC	cis	rs2075371	0.933	rs1421481	chr7:133964380	A/C	cg20476274	chr7:133979776	SLC35B4	0.59	7.94	0.46	8.47e-14	Mean platelet volume;
SARC	cis	rs11786130	0.544	rs4733823	chr8:129014697	C/T	cg01765152	chr8:129005526	PVT1	0.38	5.82	0.36	1.94e-8	Eosinophil counts;Sum eosinophil basophil counts;
SARC	cis	rs9790314	0.875	rs462514	chr3:161092809	C/T	cg03342759	chr3:160939853	NMD3	-0.6	-7.69	-0.45	4.05e-13	Morning vs. evening chronotype;
SARC	cis	rs2834188	0.924	rs6517160	chr21:34683512	A/G	cg14352951	chr21:34696688	IFNAR1	0.45	5.57	0.34	7.04e-8	Narcolepsy;
SARC	cis	rs35110281	0.687	rs4819284	chr21:45084548	C/T	cg21573476	chr21:45109991	RRP1B	-0.54	-7.56	-0.44	8.96e-13	Mean corpuscular volume;
SARC	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg00825309	chr19:58991885	ZNF446	-0.54	-7.63	-0.45	6.05e-13	Uric acid clearance;
SARC	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg26335602	chr6:28129616	ZNF389	0.46	5.29	0.33	2.8e-7	Cardiac Troponin-T levels;
SARC	cis	rs3740540	0.530	rs2362506	chr10:126290751	C/G	cg04949429	chr10:126290192	LHPP	0.42	5.92	0.36	1.16e-8	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
SARC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg26338869	chr17:61819248	STRADA	0.75	9.94	0.55	1.27e-19	Prudent dietary pattern;
SARC	cis	rs9388451	0.874	rs7739566	chr6:126094757	A/T	cg06289844	chr6:126071538	HEY2	0.35	5.67	0.35	4.18e-8	Brugada syndrome;
SARC	cis	rs2075371	0.673	rs35290398	chr7:134011773	C/T	cg11752832	chr7:134001865	SLC35B4	0.56	7.02	0.42	2.44e-11	Mean platelet volume;
SARC	cis	rs208520	1.000	rs12191598	chr6:66983962	T/C	cg07460842	chr6:66804631	NA	0.9	10.32	0.56	8.16e-21	Exhaled nitric oxide output;
SARC	cis	rs9291683	0.588	rs4280729	chr4:10013861	C/T	cg00071950	chr4:10020882	SLC2A9	0.41	6.47	0.39	5.6e-10	Bone mineral density;
SARC	cis	rs523522	0.923	rs2235217	chr12:120884328	C/T	cg27279351	chr12:120934652	DYNLL1	0.71	8.41	0.48	4.25e-15	High light scatter reticulocyte count;
SARC	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg16414030	chr3:133502952	NA	-0.46	-6.22	-0.38	2.24e-9	Iron status biomarkers;
SARC	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg22618164	chr12:122356400	WDR66	0.42	6.5	0.39	4.76e-10	Mean corpuscular volume;
SARC	trans	rs3942852	0.545	rs10838798	chr11:48091303	T/G	cg03929089	chr4:120376271	NA	-0.56	-6.87	-0.41	5.73e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs709400	0.859	rs7693	chr14:104023704	C/T	cg26031613	chr14:104095156	KLC1	1.03	19.25	0.78	4.7e-50	Body mass index;
SARC	cis	rs524281	0.861	rs12049852	chr11:65884702	T/C	cg14036092	chr11:66035641	RAB1B	-0.48	-5.04	-0.31	9.51e-7	Electroencephalogram traits;
SARC	cis	rs11719291	0.915	rs11557629	chr3:48732223	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.6	-5.53	-0.34	8.69e-8	Cognitive function;
SARC	cis	rs459571	0.920	rs460154	chr9:136909309	C/T	cg13789015	chr9:136890014	NCRNA00094	0.59	8.29	0.48	9.16e-15	Platelet distribution width;
SARC	cis	rs12950390	0.853	rs12450733	chr17:45855404	A/G	cg03474202	chr17:45855739	NA	-0.44	-6.91	-0.41	4.7e-11	IgG glycosylation;
SARC	cis	rs1971762	0.583	rs1864448	chr12:54087856	T/G	cg06632207	chr12:54070931	ATP5G2	0.44	5.73	0.35	3.16e-8	Height;
SARC	cis	rs3892630	0.818	rs80137870	chr19:33182750	C/T	cg22980127	chr19:33182716	NUDT19	1.06	9.7	0.54	6.48e-19	Red blood cell traits;
SARC	cis	rs7772486	0.754	rs6570708	chr6:145989428	C/T	cg05347473	chr6:146136440	FBXO30	-0.5	-6.94	-0.41	3.91e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10089	1.000	rs4835943	chr5:127457569	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	10.23	0.56	1.56e-20	Ileal carcinoids;
SARC	cis	rs7408868	1.000	rs10406754	chr19:15274201	T/A	cg14696996	chr19:15285081	NOTCH3	1.06	8.68	0.49	6.85e-16	Pulse pressure;
SARC	cis	rs826838	0.935	rs10875816	chr12:38955014	C/A	cg26384229	chr12:38710491	ALG10B	0.92	14.4	0.69	4.79e-34	Heart rate;
SARC	cis	rs7666738	0.688	rs4632667	chr4:98748299	A/G	cg05340658	chr4:99064831	C4orf37	0.51	5.52	0.34	9.02e-8	Colonoscopy-negative controls vs population controls;
SARC	cis	rs5758511	0.514	rs5758586	chr22:42517471	A/T	cg00645731	chr22:42541494	CYP2D7P1	0.42	6.04	0.37	6.11e-9	Birth weight;
SARC	cis	rs9733	0.650	rs12125672	chr1:150554470	A/T	cg13175981	chr1:150552382	MCL1	0.7	9.45	0.53	3.74e-18	Tonsillectomy;
SARC	cis	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg07777115	chr5:623756	CEP72	-0.56	-4.81	-0.3	2.68e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg10523679	chr1:76189770	ACADM	0.52	6.89	0.41	5.02e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs1059312	1.000	rs3825180	chr12:129279242	A/G	cg23521905	chr12:129298690	SLC15A4;MGC16384	-0.5	-7.21	-0.43	7.97e-12	Systemic lupus erythematosus;
SARC	cis	rs4713118	0.869	rs9461401	chr6:27703291	G/A	cg17221315	chr6:27791827	HIST1H4J	0.49	5.29	0.33	2.77e-7	Parkinson's disease;
SARC	cis	rs12711979	0.509	rs10187740	chr2:3823965	A/G	cg17052675	chr2:3827356	NA	0.51	7.53	0.44	1.12e-12	Itch intensity from mosquito bite adjusted by bite size;
SARC	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg05368731	chr17:41323189	NBR1	0.79	9.57	0.53	1.59e-18	Menopause (age at onset);
SARC	cis	rs1348850	0.567	rs12994392	chr2:178536640	A/G	cg22681709	chr2:178499509	PDE11A	-0.37	-5.22	-0.32	3.98e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg10631515	chr10:52167630	SGMS1	0.53	7.35	0.43	3.24e-12	Thyroid stimulating hormone;
SARC	cis	rs6582630	0.598	rs10880645	chr12:38556172	G/A	cg13010199	chr12:38710504	ALG10B	-0.52	-6.5	-0.39	4.9e-10	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg08975724	chr8:8085496	FLJ10661	-0.45	-5.56	-0.34	7.41e-8	Neuroticism;
SARC	cis	rs2952156	0.920	rs2517958	chr17:37838751	G/A	cg07936489	chr17:37558343	FBXL20	-0.45	-5.75	-0.35	2.76e-8	Asthma;
SARC	cis	rs4727027	0.901	rs12671341	chr7:148805282	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.48	5.64	0.35	4.84e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs11785400	0.793	rs9297970	chr8:143723386	C/T	cg24634471	chr8:143751801	JRK	0.6	7.76	0.45	2.61e-13	Schizophrenia;
SARC	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg04277193	chr17:41438351	NA	0.44	4.73	0.3	3.83e-6	Menopause (age at onset);
SARC	cis	rs12979813	1.000	rs10406522	chr19:11341635	T/C	cg00586551	chr19:11347513	LOC55908;DOCK6	0.41	4.93	0.31	1.54e-6	HDL cholesterol;
SARC	cis	rs9916302	0.706	rs12947506	chr17:37707592	A/G	cg20243544	chr17:37824526	PNMT	0.52	5.41	0.33	1.56e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs2439831	0.850	rs10163054	chr15:44047638	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	7.55	0.44	1.01e-12	Lung cancer in ever smokers;
SARC	cis	rs921968	0.643	rs13431399	chr2:219469498	G/C	cg02176678	chr2:219576539	TTLL4	-0.49	-7.35	-0.43	3.3e-12	Mean corpuscular hemoglobin concentration;
SARC	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg27541892	chr1:1571801	CDK11B	0.41	5.57	0.34	6.93e-8	Body mass index;
SARC	cis	rs2439831	0.867	rs6493082	chr15:43634808	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.04	10.9	0.58	1.25e-22	Lung cancer in ever smokers;
SARC	cis	rs9810259	0.525	rs310749	chr3:12273768	A/C	cg04748988	chr3:12329223	PPARG	-0.42	-5.4	-0.33	1.6e-7	Platelet count;
SARC	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.98	-16.17	-0.73	6.02e-40	Chronic sinus infection;
SARC	cis	rs908922	0.676	rs4240884	chr1:152529792	C/T	cg09873164	chr1:152488093	CRCT1	-0.59	-7.68	-0.45	4.26e-13	Hair morphology;
SARC	cis	rs2288884	0.579	rs6509609	chr19:52473606	G/A	cg24732339	chr19:52471368	ZNF350	-0.6	-5.58	-0.34	6.59e-8	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
SARC	cis	rs8180040	0.966	rs3816779	chr3:47543389	C/T	cg27129171	chr3:47204927	SETD2	0.67	9.28	0.52	1.21e-17	Colorectal cancer;
SARC	cis	rs933688	1.000	rs2839728	chr5:90727412	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.95	12.14	0.62	1.31e-26	Smoking behavior;
SARC	cis	rs314370	0.818	rs13245899	chr7:100497131	A/G	cg10426581	chr7:100472382	SRRT	0.59	6.73	0.4	1.3100000000000001e-10	Resting heart rate;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg09400392	chr16:84150674	MBTPS1	0.49	6.4	0.39	8.33e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs9394841	0.692	rs9357371	chr6:41885319	A/C	cg08135965	chr6:41755394	TOMM6	0.67	7.1	0.42	1.53e-11	Mean corpuscular hemoglobin;Red cell distribution width;
SARC	cis	rs9581943	0.967	rs9581927	chr13:28462645	G/T	cg25299895	chr13:28498091	PDX1	0.38	5.13	0.32	6.03e-7	Pancreatic cancer;
SARC	cis	rs4975709	1.000	rs4975709	chr5:1877280	A/C	cg15595755	chr5:1867978	NA	0.38	4.76	0.3	3.36e-6	Cardiovascular disease risk factors;
SARC	cis	rs7762018	0.943	rs7772889	chr6:170142458	T/C	cg13891659	chr6:170190454	C6orf122;C6orf208	0.55	4.88	0.3	2e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs950776	0.518	rs952216	chr15:78819202	C/T	cg22563815	chr15:78856949	CHRNA5	0.41	6.87	0.41	5.76e-11	Sudden cardiac arrest;
SARC	cis	rs734999	0.572	rs3748816	chr1:2526746	A/G	cg00980319	chr1:2560884	MMEL1	-0.35	-4.91	-0.31	1.69e-6	Ulcerative colitis;
SARC	cis	rs1976403	0.659	rs10799701	chr1:21820990	A/G	cg17800788	chr1:21766015	NBPF3	0.31	5.04	0.31	9.33e-7	Liver enzyme levels (alkaline phosphatase);
SARC	trans	rs2736337	0.530	rs2003422	chr8:11303137	G/C	cg06636001	chr8:8085503	FLJ10661	0.52	6.38	0.39	9.52e-10	Rheumatoid arthritis;
SARC	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg04166393	chr7:2884313	GNA12	0.57	6.74	0.4	1.21e-10	Height;
SARC	trans	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg00938859	chr5:1591904	SDHAP3	-0.7	-6.63	-0.4	2.33e-10	Breast cancer;
SARC	cis	rs7937682	0.883	rs472465	chr11:111468962	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.93	-14.06	-0.68	6.32e-33	Primary sclerosing cholangitis;
SARC	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg12463550	chr7:65579703	CRCP	0.51	5.74	0.35	2.94e-8	Aortic root size;
SARC	cis	rs568617	0.953	rs658938	chr11:65651830	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.47	-5.45	-0.34	1.31e-7	Crohn's disease;
SARC	cis	rs12291225	0.679	rs10832240	chr11:14304744	C/T	cg19336497	chr11:14380999	RRAS2	-0.41	-6.78	-0.41	9.87e-11	Sense of smell;
SARC	cis	rs7824557	0.767	rs28507159	chr8:11166076	C/T	cg21775007	chr8:11205619	TDH	0.52	6.18	0.38	2.79e-9	Retinal vascular caliber;
SARC	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg13880726	chr7:1868755	MAD1L1	0.5	6.07	0.37	5.24e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs36715	1.000	rs181850	chr5:127547487	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	7.19	0.43	8.57e-12	Breast cancer;
SARC	cis	rs2204008	0.614	rs4578492	chr12:38036350	T/C	cg13010199	chr12:38710504	ALG10B	0.78	10.69	0.57	5.8e-22	Bladder cancer;
SARC	cis	rs7000551	0.688	rs2948145	chr8:22367792	T/C	cg12081754	chr8:22256438	SLC39A14	0.55	7.79	0.45	2.21e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg12463550	chr7:65579703	CRCP	0.69	5.24	0.32	3.54e-7	Diabetic kidney disease;
SARC	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.61	7.33	0.43	3.7e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	10.98	0.58	6.89e-23	Platelet count;
SARC	cis	rs208520	0.565	rs1385222	chr6:66753013	C/T	cg07460842	chr6:66804631	NA	1.06	18.86	0.78	8.84e-49	Exhaled nitric oxide output;
SARC	cis	rs950169	0.650	rs12902052	chr15:85125838	A/T	cg24253500	chr15:84953950	NA	0.39	5.55	0.34	7.67e-8	Schizophrenia;
SARC	cis	rs208520	0.874	rs208470	chr6:66916402	G/A	cg07460842	chr6:66804631	NA	-1.01	-11.9	-0.61	7.68e-26	Exhaled nitric oxide output;
SARC	cis	rs17253792	0.822	rs12100753	chr14:56042870	G/A	cg01858014	chr14:56050164	KTN1	-0.65	-4.76	-0.3	3.43e-6	Putamen volume;
SARC	cis	rs4722166	0.630	rs4722169	chr7:22785419	C/T	cg26061582	chr7:22766209	IL6	0.55	6.11	0.37	4.09e-9	Lung cancer;
SARC	cis	rs6723226	0.739	rs2069213	chr2:32743084	C/T	cg02381751	chr2:32503542	YIPF4	0.71	9.61	0.53	1.27e-18	Intelligence (multi-trait analysis);
SARC	trans	rs10825741	0.825	rs12266026	chr10:57921687	T/G	cg12948920	chr4:8609706	CPZ	0.53	6.34	0.38	1.17e-9	Night sleep phenotypes;
SARC	cis	rs72945132	0.714	rs72947077	chr11:70197431	A/G	cg05964544	chr11:70165517	PPFIA1	-0.58	-5.45	-0.34	1.3e-7	Coronary artery disease;
SARC	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg08219700	chr8:58056026	NA	0.49	5.01	0.31	1.05e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.12	0.37	3.91e-9	Prudent dietary pattern;
SARC	cis	rs17270561	0.609	rs9366629	chr6:25741216	G/A	cg16482183	chr6:26056742	HIST1H1C	0.43	5.08	0.32	7.76e-7	Iron status biomarkers;
SARC	cis	rs1153858	0.943	rs4774580	chr15:45652086	G/A	cg21132104	chr15:45694354	SPATA5L1	0.77	10.88	0.58	1.44e-22	Homoarginine levels;
SARC	cis	rs6546550	0.901	rs6546556	chr2:70139001	A/G	cg02498382	chr2:70120550	SNRNP27	-0.33	-5.27	-0.33	3.04e-7	Prevalent atrial fibrillation;
SARC	cis	rs2204008	0.837	rs12366727	chr12:38365748	A/C	cg26384229	chr12:38710491	ALG10B	0.91	13.46	0.66	6.11e-31	Bladder cancer;
SARC	cis	rs7635838	0.617	rs346071	chr3:11305584	A/T	cg00170343	chr3:11313890	ATG7	-0.72	-9.69	-0.54	7.1e-19	HDL cholesterol;
SARC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg09033563	chr22:24373618	LOC391322	-0.53	-6.6	-0.4	2.7e-10	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9462027	0.628	rs9296127	chr6:34719628	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.81	-0.36	2.03e-8	Systemic lupus erythematosus;
SARC	cis	rs875971	0.545	rs3735147	chr7:65970528	A/C	cg11764359	chr7:65958608	NA	0.63	6.17	0.37	2.92e-9	Aortic root size;
SARC	cis	rs12311304	0.965	rs11056399	chr12:15365510	C/T	cg08258403	chr12:15378311	NA	0.48	7.5	0.44	1.36e-12	Behavioural disinhibition (generation interaction);
SARC	trans	rs2257129	1.000	rs10886863	chr10:122929493	C/T	cg25685359	chr22:46473721	NA	0.6	6.23	0.38	2.15e-9	Coronary artery disease;Body mass index;
SARC	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg17971929	chr21:40555470	PSMG1	0.99	14.22	0.68	1.86e-33	Cognitive function;
SARC	cis	rs2729354	1.000	rs2511983	chr11:57346874	A/G	cg02958346	chr11:57425731	CLP1	0.49	5.01	0.31	1.07e-6	Blood protein levels;
SARC	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg19077165	chr18:44547161	KATNAL2	0.51	7.1	0.42	1.49e-11	Personality dimensions;
SARC	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg13939156	chr17:80058883	NA	-0.44	-6.79	-0.41	9.27e-11	Life satisfaction;
SARC	cis	rs17030434	0.953	rs10014299	chr4:154700858	A/G	cg14289246	chr4:154710475	SFRP2	-0.8	-7.97	-0.46	7.13e-14	Electrocardiographic conduction measures;
SARC	cis	rs9398803	0.830	rs9401885	chr6:126825837	C/G	cg19875578	chr6:126661172	C6orf173	0.63	8.53	0.49	1.82e-15	Male-pattern baldness;
SARC	cis	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.8	-0.46	2.01e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs7766436	0.583	rs72831211	chr6:22560161	C/T	cg13666174	chr6:22585274	NA	-0.59	-6.04	-0.37	6e-9	Coronary artery disease;
SARC	trans	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg21659725	chr3:3221576	CRBN	-0.55	-7.19	-0.43	8.59e-12	Intelligence (multi-trait analysis);
SARC	cis	rs763121	0.853	rs5750672	chr22:39104168	C/T	cg06022373	chr22:39101656	GTPBP1	-0.88	-11.34	-0.6	5.22e-24	Menopause (age at onset);
SARC	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg05313129	chr8:58192883	C8orf71	-0.48	-5.7	-0.35	3.52e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4974559	0.790	rs6850727	chr4:1323273	G/C	cg02980000	chr4:1222292	CTBP1	0.63	6.14	0.37	3.48e-9	Systolic blood pressure;
SARC	cis	rs17270561	0.609	rs1892248	chr6:25768914	C/T	cg16482183	chr6:26056742	HIST1H1C	0.5	6.05	0.37	5.58e-9	Iron status biomarkers;
SARC	cis	rs8072100	0.713	rs4968228	chr17:45497548	T/C	cg08085267	chr17:45401833	C17orf57	-0.43	-5.03	-0.31	9.66e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg02725872	chr8:58115012	NA	-0.37	-6.55	-0.39	3.71e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.8	-0.41	8.49e-11	Total body bone mineral density;
SARC	cis	rs9660992	0.512	rs12123773	chr1:205122420	C/G	cg00857998	chr1:205179979	DSTYK	0.52	6.74	0.4	1.22e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg08975724	chr8:8085496	FLJ10661	0.52	6.5	0.39	4.79e-10	Systolic blood pressure;
SARC	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg07636037	chr3:49044803	WDR6	0.99	17.31	0.75	1.02e-43	Parkinson's disease;
SARC	cis	rs854765	0.583	rs62064158	chr17:17826935	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.43	5.67	0.35	4.18e-8	Total body bone mineral density;
SARC	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	9.01	0.51	7.42e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg11987759	chr7:65425863	GUSB	-0.48	-6.54	-0.39	3.9e-10	Aortic root size;
SARC	cis	rs6484504	0.576	rs208083	chr11:31196880	C/T	cg14844989	chr11:31128820	NA	-0.33	-4.8	-0.3	2.78e-6	Red blood cell count;
SARC	cis	rs6121246	0.529	rs6060359	chr20:30209740	A/G	cg13852791	chr20:30311386	BCL2L1	0.66	5.62	0.35	5.5e-8	Mean corpuscular hemoglobin;
SARC	cis	rs7429990	0.965	rs13075795	chr3:48024629	A/T	cg11946769	chr3:48343235	NME6	-0.46	-5.39	-0.33	1.75e-7	Educational attainment (years of education);
SARC	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg06618935	chr21:46677482	NA	-0.37	-4.89	-0.31	1.85e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg09021430	chr5:549028	NA	-0.45	-5.69	-0.35	3.74e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs2070997	0.607	rs4504691	chr9:133663852	T/C	cg11464064	chr9:133710261	ABL1	0.58	5.38	0.33	1.85e-7	Response to amphetamines;
SARC	cis	rs2594989	0.779	rs2437685	chr3:11593013	A/G	cg00170343	chr3:11313890	ATG7	0.54	5.82	0.36	1.96e-8	Circulating chemerin levels;
SARC	cis	rs2230307	0.536	rs11166409	chr1:100641411	T/C	cg24955406	chr1:100503596	HIAT1	-0.61	-5.82	-0.36	1.96e-8	Carotid intima media thickness;
SARC	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg18252515	chr7:66147081	NA	1.33	11.84	0.61	1.22e-25	Diabetic kidney disease;
SARC	cis	rs8141529	0.843	rs1065497	chr22:29279991	C/T	cg15103426	chr22:29168792	CCDC117	0.64	8.11	0.47	2.89e-14	Lymphocyte counts;
SARC	cis	rs9790314	1.000	rs4350933	chr3:160955879	G/T	cg03342759	chr3:160939853	NMD3	-0.63	-8.03	-0.47	4.77e-14	Morning vs. evening chronotype;
SARC	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg03517284	chr6:25882590	NA	0.48	6.34	0.38	1.15e-9	Blood metabolite levels;
SARC	cis	rs8067545	0.611	rs8066143	chr17:20048355	A/C	cg13482628	chr17:19912719	NA	0.52	6.8	0.41	8.78e-11	Schizophrenia;
SARC	cis	rs4481887	1.000	rs4360553	chr1:248467092	A/G	cg00666640	chr1:248458726	OR2T12	0.37	6.3	0.38	1.49e-9	Common traits (Other);
SARC	trans	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg20587970	chr11:113659929	NA	-1.38	-13.71	-0.67	8.88e-32	Hip circumference adjusted for BMI;
SARC	cis	rs9916302	0.904	rs2061342	chr17:37405657	T/G	cg20243544	chr17:37824526	PNMT	0.54	6.53	0.39	3.98e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs4851250	0.559	rs13023088	chr2:100576304	A/G	cg04109781	chr2:100722022	AFF3	-0.43	-4.9	-0.31	1.78e-6	Intelligence (multi-trait analysis);
SARC	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg18252515	chr7:66147081	NA	-0.42	-4.72	-0.3	4.03e-6	Aortic root size;
SARC	trans	rs11098499	1.000	rs13116504	chr4:120209412	A/C	cg25214090	chr10:38739885	LOC399744	0.54	7.09	0.42	1.58e-11	Corneal astigmatism;
SARC	cis	rs2976388	0.587	rs2717606	chr8:143799496	G/A	cg06565975	chr8:143823917	SLURP1	0.28	4.73	0.3	3.97e-6	Urinary tract infection frequency;
SARC	cis	rs3845702	0.877	rs12693216	chr2:180839793	T/A	cg01881094	chr2:180872142	CWC22	-0.74	-6.79	-0.41	9.46e-11	Schizophrenia;
SARC	trans	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg21659725	chr3:3221576	CRBN	-0.81	-12.44	-0.63	1.38e-27	Intelligence (multi-trait analysis);
SARC	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.03	12.36	0.63	2.47e-27	Platelet count;
SARC	trans	rs9650657	0.547	rs11250099	chr8:10818657	C/T	cg06636001	chr8:8085503	FLJ10661	0.64	8.72	0.5	5.17e-16	Neuroticism;
SARC	cis	rs6807306	1.000	rs16851302	chr3:167353211	A/T	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.5	5.05	0.31	8.99e-7	Mean platelet volume;
SARC	cis	rs611744	0.816	rs626211	chr8:109189448	A/C	cg21045802	chr8:109455806	TTC35	0.5	6.12	0.37	3.87e-9	Dupuytren's disease;
SARC	cis	rs6459788	0.527	rs6980250	chr7:157228710	C/T	cg06271696	chr7:157225062	NA	-0.29	-5.0	-0.31	1.12e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs12458462	0.851	rs3859317	chr18:77443093	A/C	cg23301140	chr18:77439876	CTDP1	0.62	7.99	0.46	6.36e-14	Monocyte count;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26308425	chr1:29508658	SFRS4	-0.57	-6.83	-0.41	7.45e-11	Fibrinogen levels;
SARC	cis	rs757978	0.733	rs41342147	chr2:242407588	C/T	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.55	-5.16	-0.32	5.18e-7	Chronic lymphocytic leukemia;
SARC	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg05368731	chr17:41323189	NBR1	0.79	9.6	0.53	1.34e-18	Menopause (age at onset);
SARC	cis	rs7005380	0.581	rs28461628	chr8:120940867	G/A	cg21744203	chr8:120868354	DSCC1	0.45	5.3	0.33	2.71e-7	Interstitial lung disease;
SARC	cis	rs10463316	0.817	rs2112419	chr5:150797804	T/C	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.49	-0.34	1.06e-7	Metabolite levels (Pyroglutamine);
SARC	trans	rs11767400	0.745	rs13222449	chr7:122220781	G/A	cg04856042	chr3:115752704	LSAMP	0.44	6.23	0.38	2.13e-9	Menarche (age at onset);
SARC	cis	rs6060717	0.536	rs6058364	chr20:34507890	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-5.72	-0.35	3.27e-8	Hip circumference adjusted for BMI;
SARC	cis	rs7566780	0.516	rs12710703	chr2:16665425	C/G	cg09580478	chr2:16689509	NA	-0.58	-7.4	-0.44	2.38e-12	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs17384381	0.634	rs11801146	chr1:85915374	C/T	cg16011679	chr1:85725395	C1orf52	0.61	5.98	0.36	8.46e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs875971	0.965	rs697968	chr7:65535033	G/A	cg12463550	chr7:65579703	CRCP	-0.48	-5.67	-0.35	4.28e-8	Aortic root size;
SARC	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.41	-6.68	-0.4	1.72e-10	Total body bone mineral density;
SARC	cis	rs7106204	0.590	rs7115417	chr11:24247696	A/G	ch.11.24196551F	chr11:24239977	NA	0.59	6.12	0.37	3.83e-9	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs1865760	0.623	rs12216125	chr6:25997458	C/T	cg16482183	chr6:26056742	HIST1H1C	0.46	5.53	0.34	8.74e-8	Height;
SARC	cis	rs6570726	0.791	rs952406	chr6:145925616	C/A	cg05220968	chr6:146057943	EPM2A	-0.28	-4.91	-0.31	1.7e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2361718	0.521	rs2361724	chr17:78099114	G/A	cg27427491	chr17:78079615	GAA	-0.34	-4.92	-0.31	1.66e-6	Yeast infection;
SARC	cis	rs17376456	0.825	rs56108532	chr5:93276342	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	5.84	0.36	1.75e-8	Diabetic retinopathy;
SARC	cis	rs524281	0.861	rs10750780	chr11:65974592	G/A	cg14036092	chr11:66035641	RAB1B	-0.5	-5.3	-0.33	2.74e-7	Electroencephalogram traits;
SARC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg24503407	chr1:205819492	PM20D1	-0.7	-11.7	-0.61	3.58e-25	Monocyte percentage of white cells;
SARC	cis	rs1707322	1.000	rs10890365	chr1:46359348	C/T	cg03146154	chr1:46216737	IPP	0.47	5.72	0.35	3.25e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6964587	0.872	rs57969083	chr7:91665627	A/T	cg17063962	chr7:91808500	NA	0.97	16.79	0.74	5.47e-42	Breast cancer;
SARC	cis	rs524281	0.637	rs7126075	chr11:65940563	T/G	cg14036092	chr11:66035641	RAB1B	-0.49	-5.16	-0.32	5.24e-7	Electroencephalogram traits;
SARC	cis	rs6732160	0.588	rs1430344	chr2:73373344	G/A	cg01422370	chr2:73384389	NA	0.37	5.78	0.35	2.33e-8	Intelligence (multi-trait analysis);
SARC	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg09455208	chr3:40491958	NA	-0.36	-5.48	-0.34	1.11e-7	Renal cell carcinoma;
SARC	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg22920501	chr2:26401640	FAM59B	-0.55	-7.26	-0.43	5.77e-12	Gut microbiome composition (summer);
SARC	trans	rs7824557	0.564	rs2736293	chr8:11234613	T/A	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.72	-0.5	5.4e-16	Retinal vascular caliber;
SARC	cis	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg20965017	chr5:231967	SDHA	-0.55	-5.27	-0.33	3.13e-7	Breast cancer;
SARC	cis	rs2933343	0.630	rs75824035	chr3:128652985	T/C	cg24203234	chr3:128598194	ACAD9	0.64	7.93	0.46	9.25e-14	IgG glycosylation;
SARC	cis	rs992157	0.585	rs62182795	chr2:219100202	C/T	cg00012203	chr2:219082015	ARPC2	-0.73	-10.74	-0.58	3.92e-22	Colorectal cancer;
SARC	cis	rs644799	0.965	rs545342	chr11:95545369	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	14.15	0.68	3.08e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs6138458	1.000	rs227632	chr20:24913729	G/A	cg26195577	chr20:24973756	C20orf3	0.89	10.08	0.55	4.54e-20	Blood protein levels;
SARC	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.48	5.42	0.33	1.52e-7	Renal function-related traits (BUN);
SARC	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg15212455	chr7:39170539	POU6F2	0.42	5.25	0.33	3.36e-7	IgG glycosylation;
SARC	cis	rs950027	0.620	rs2453533	chr15:45641225	C/A	cg15395560	chr15:45543142	SLC28A2	-0.27	-5.17	-0.32	5.14e-7	Response to fenofibrate (adiponectin levels);
SARC	cis	rs2486288	0.656	rs12440356	chr15:45567529	T/C	cg26924012	chr15:45694286	SPATA5L1	0.54	6.8	0.41	8.95e-11	Glomerular filtration rate;
SARC	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg05025164	chr4:1340916	KIAA1530	0.52	6.32	0.38	1.32e-9	Longevity;
SARC	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg16405210	chr4:1374714	KIAA1530	-0.45	-5.62	-0.35	5.48e-8	Longevity;
SARC	cis	rs7223966	1.000	rs11657120	chr17:61857218	G/A	cg00588841	chr17:61851480	DDX42;CCDC47	-0.67	-7.46	-0.44	1.69e-12	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6963495	0.818	rs73190181	chr7:105162907	A/C	cg13798780	chr7:105162888	PUS7	0.6	5.45	0.34	1.31e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs2011503	1.000	rs45631651	chr19:19638743	A/G	cg15839431	chr19:19639596	YJEFN3	-0.48	-4.77	-0.3	3.32e-6	Bipolar disorder;
SARC	trans	rs11098499	0.955	rs11944880	chr4:120159334	A/G	cg25214090	chr10:38739885	LOC399744	-0.52	-6.89	-0.41	5.13e-11	Corneal astigmatism;
SARC	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg24531977	chr5:56204891	C5orf35	-0.54	-5.45	-0.34	1.26e-7	Initial pursuit acceleration;
SARC	cis	rs875971	0.545	rs73142265	chr7:65699497	G/A	cg11764359	chr7:65958608	NA	0.67	6.71	0.4	1.48e-10	Aortic root size;
SARC	cis	rs17376456	0.504	rs7702649	chr5:93065149	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.57	5.9	0.36	1.26e-8	Diabetic retinopathy;
SARC	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	12.74	0.64	1.44e-28	Platelet count;
SARC	cis	rs7937682	0.824	rs11213962	chr11:111506027	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.93	-15.22	-0.71	8.48e-37	Primary sclerosing cholangitis;
SARC	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg24531977	chr5:56204891	C5orf35	-0.52	-5.3	-0.33	2.73e-7	Initial pursuit acceleration;
SARC	cis	rs10883723	0.810	rs2296586	chr10:104245575	C/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.53	6.84	0.41	6.89e-11	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs7762018	0.607	rs79355059	chr6:170062157	T/C	cg14662283	chr6:170068385	WDR27	-0.66	-4.74	-0.3	3.7e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg06221963	chr1:154839813	KCNN3	-0.51	-8.37	-0.48	5.38e-15	Prostate cancer;
SARC	cis	rs77633900	0.772	rs2078437	chr15:76669580	A/G	cg21673338	chr15:77095150	SCAPER	0.76	4.8	0.3	2.9e-6	Non-glioblastoma glioma;Glioma;
SARC	cis	rs747650	0.884	rs7128325	chr11:47046554	G/A	cg03339077	chr11:47165057	C11orf49	-0.39	-5.25	-0.33	3.44e-7	Acne (severe);
SARC	cis	rs7560272	0.512	rs12998980	chr2:73930726	A/C	cg20560298	chr2:73613845	ALMS1	0.47	6.2	0.38	2.54e-9	Schizophrenia;
SARC	cis	rs9916302	0.706	rs8078599	chr17:37518660	C/T	cg20243544	chr17:37824526	PNMT	-0.52	-5.48	-0.34	1.12e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg26818010	chr10:134567672	INPP5A	-0.65	-6.92	-0.41	4.21e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg06618935	chr21:46677482	NA	-0.4	-5.3	-0.33	2.73e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg20607798	chr8:58055168	NA	0.58	5.57	0.34	6.9e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs924607	1.000	rs12523022	chr5:598643	C/T	cg09021430	chr5:549028	NA	0.34	6.33	0.38	1.24e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	trans	rs7824557	0.606	rs2736264	chr8:11186639	G/C	cg06636001	chr8:8085503	FLJ10661	0.6	7.84	0.46	1.56e-13	Retinal vascular caliber;
SARC	cis	rs7772486	0.790	rs4075694	chr6:146251108	G/C	cg23711669	chr6:146136114	FBXO30	-0.81	-12.93	-0.65	3.43e-29	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1355223	0.902	rs1539251	chr11:34742772	A/G	cg18508148	chr11:34937573	PDHX;APIP	-0.38	-4.83	-0.3	2.46e-6	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs61935443	0.614	rs61935662	chr12:95313296	A/G	cg21533806	chr12:95267307	NA	0.6	6.91	0.41	4.52e-11	Schizophrenia;
SARC	cis	rs4481887	0.893	rs10888348	chr1:248448610	C/G	cg13385794	chr1:248469461	NA	0.33	4.91	0.31	1.73e-6	Common traits (Other);
SARC	cis	rs6686643	0.762	rs6672982	chr1:165612815	T/A	cg19407955	chr1:165599744	MGST3	-0.59	-6.05	-0.37	5.59e-9	Total ventricular volume;
SARC	cis	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg00409905	chr10:38381863	ZNF37A	-0.5	-6.9	-0.41	4.93e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs820218	0.926	rs820200	chr17:73632030	C/A	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.65	8.72	0.5	5.43e-16	Rotator cuff tears;
SARC	cis	rs1865760	0.516	rs9393683	chr6:26066198	A/G	cg10373733	chr6:25993375	NA	0.39	4.81	0.3	2.69e-6	Height;
SARC	cis	rs7666738	0.830	rs4292342	chr4:98959870	A/T	cg05340658	chr4:99064831	C4orf37	0.67	9.08	0.51	4.75e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7312774	0.748	rs7966019	chr12:107297502	G/T	cg16260113	chr12:107380972	MTERFD3	0.76	6.48	0.39	5.37e-10	Severe influenza A (H1N1) infection;
SARC	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg16414030	chr3:133502952	NA	-0.36	-4.82	-0.3	2.56e-6	Iron status biomarkers;
SARC	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg08959305	chr17:26646465	TMEM97	0.52	6.34	0.38	1.19e-9	Migraine with aura;
SARC	cis	rs3749237	0.595	rs2878298	chr3:49406080	T/C	cg03060546	chr3:49711283	APEH	0.75	10.52	0.57	2.01e-21	Resting heart rate;
SARC	cis	rs3782089	0.546	rs76146604	chr11:65277512	G/T	cg21890820	chr11:65308645	LTBP3	0.85	5.3	0.33	2.74e-7	Height;
SARC	cis	rs12709013	0.636	rs257628	chr16:58792828	T/C	cg04273148	chr16:57808038	KIFC3	0.32	4.72	0.3	4.08e-6	Blood metabolite ratios;
SARC	cis	rs7824557	0.614	rs4394351	chr8:11212875	G/C	cg21775007	chr8:11205619	TDH	0.72	9.54	0.53	2.05e-18	Retinal vascular caliber;
SARC	cis	rs15676	0.947	rs2805103	chr9:131598897	T/A	cg00228799	chr9:131580591	ENDOG	0.6	7.31	0.43	4.37e-12	Blood metabolite levels;
SARC	cis	rs7819412	0.749	rs11991118	chr8:10939273	A/C	cg00262122	chr8:11665843	FDFT1	0.39	4.97	0.31	1.27e-6	Triglycerides;
SARC	cis	rs611744	0.967	rs688746	chr8:109225725	G/A	cg21045802	chr8:109455806	TTC35	0.44	5.26	0.33	3.18e-7	Dupuytren's disease;
SARC	cis	rs11190604	0.943	rs11190581	chr10:102243387	T/G	cg07080220	chr10:102295463	HIF1AN	0.75	8.79	0.5	3.4e-16	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs9902453	0.726	rs3115088	chr17:28031275	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	6.98	0.42	3e-11	Coffee consumption (cups per day);
SARC	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg05332525	chr7:65337924	VKORC1L1	-0.44	-4.86	-0.3	2.19e-6	Aortic root size;
SARC	cis	rs7020830	0.898	rs7857936	chr9:37078491	T/C	cg14294708	chr9:37120828	ZCCHC7	1.14	21.07	0.81	7.24e-56	Schizophrenia;
SARC	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg08219700	chr8:58056026	NA	0.58	6.19	0.38	2.71e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs865483	0.895	rs2522966	chr17:35816616	A/G	cg06561646	chr17:35873369	DUSP14	0.47	6.26	0.38	1.85e-9	Monocyte count;
SARC	cis	rs2070997	0.756	rs3808820	chr9:133726956	A/T	cg03924115	chr9:133768966	QRFP	0.47	5.29	0.33	2.86e-7	Response to amphetamines;
SARC	cis	rs10791097	0.694	rs10894275	chr11:130756251	C/T	cg09137382	chr11:130731461	NA	0.31	4.73	0.3	3.97e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs8028182	0.636	rs4886707	chr15:75755467	C/T	cg20655648	chr15:75932815	IMP3	0.6	7.35	0.43	3.38e-12	Sudden cardiac arrest;
SARC	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg14820908	chr5:178986412	RUFY1	-0.33	-4.73	-0.3	3.94e-6	Lung cancer;
SARC	cis	rs17384381	1.000	rs12129502	chr1:85900727	T/C	cg16011679	chr1:85725395	C1orf52	0.6	5.52	0.34	8.87e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11249608	0.636	rs6868893	chr5:178449826	C/A	cg21905437	chr5:178450457	ZNF879	0.58	7.7	0.45	3.79e-13	Pubertal anthropometrics;
SARC	cis	rs1451375	0.550	rs2242042	chr7:50529852	T/G	cg18232548	chr7:50535776	DDC	-0.48	-4.72	-0.3	3.99e-6	Malaria;
SARC	cis	rs9300255	0.602	rs1727313	chr12:123640853	C/G	cg00376283	chr12:123451042	ABCB9	0.57	5.55	0.34	7.7e-8	Neutrophil percentage of white cells;
SARC	cis	rs546131	0.642	rs12808574	chr11:34852120	A/C	cg06937548	chr11:34938143	PDHX;APIP	0.44	4.83	0.3	2.53e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs17270561	0.609	rs9348692	chr6:25720812	A/G	cg17691542	chr6:26056736	HIST1H1C	0.59	7.24	0.43	6.65e-12	Iron status biomarkers;
SARC	cis	rs2760061	0.583	rs697763	chr1:228192622	G/C	cg02753203	chr1:228287806	NA	0.81	11.43	0.6	2.62e-24	Diastolic blood pressure;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg05730215	chr2:27435253	SLC5A6;C2orf28	0.5	6.47	0.39	5.65e-10	Chemerin levels;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg21066290	chr5:176757391	NA	-0.65	-6.35	-0.38	1.14e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs79976124	0.800	rs6918860	chr6:66637741	G/C	cg07460842	chr6:66804631	NA	0.63	7.01	0.42	2.5e-11	Type 2 diabetes;
SARC	cis	rs4481887	0.927	rs4603165	chr1:248473799	T/A	cg01631408	chr1:248437212	OR2T33	-0.38	-4.92	-0.31	1.67e-6	Common traits (Other);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg00382463	chr19:30718424	NA	-0.47	-6.44	-0.39	6.88e-10	Chemerin levels;
SARC	cis	rs654950	0.901	rs607586	chr1:42004379	C/T	cg06885757	chr1:42089581	HIVEP3	-0.45	-6.43	-0.39	7.12e-10	Airway imaging phenotypes;
SARC	cis	rs4565302	1.000	rs4580846	chr6:38400255	A/G	cg26053840	chr6:38644662	GLO1	-0.5	-4.77	-0.3	3.26e-6	Mammographic density;
SARC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg02469487	chr2:96874652	STARD7	-0.58	-6.43	-0.39	7e-10	Hepatitis;
SARC	cis	rs6484504	0.600	rs7122895	chr11:31346620	G/C	cg02090638	chr11:31391270	DNAJC24;DCDC1	0.41	5.1	0.32	6.95e-7	Red blood cell count;
SARC	cis	rs12579753	1.000	rs10862374	chr12:82250809	G/C	cg07988820	chr12:82153109	PPFIA2	-0.55	-6.55	-0.39	3.61e-10	Resting heart rate;
SARC	cis	rs6496667	0.683	rs1869180	chr15:90895467	T/C	cg22089800	chr15:90895588	ZNF774	0.64	7.6	0.45	7.41e-13	Rheumatoid arthritis;
SARC	cis	rs7828089	0.935	rs896378	chr8:22262321	T/C	cg12081754	chr8:22256438	SLC39A14	0.44	5.76	0.35	2.64e-8	Verbal declarative memory;
SARC	cis	rs9747201	1.000	rs9747201	chr17:80177852	A/C	cg09264619	chr17:80180166	NA	-0.5	-5.62	-0.35	5.41e-8	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs8114671	0.562	rs6088636	chr20:33469746	C/T	cg07148914	chr20:33460835	GGT7	0.45	5.58	0.34	6.59e-8	Height;
SARC	cis	rs57506017	0.585	rs1042949	chr7:12272116	C/G	cg23422036	chr7:12250390	TMEM106B	0.45	5.87	0.36	1.49e-8	Neuroticism;
SARC	cis	rs1832871	0.711	rs9459769	chr6:158666493	T/C	cg07165851	chr6:158734300	TULP4	0.56	6.79	0.41	9.29e-11	Height;
SARC	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-7.93	-0.46	9.03e-14	Chronic sinus infection;
SARC	cis	rs8114671	0.836	rs1885114	chr20:33577361	A/G	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.54	-0.34	7.97e-8	Height;
SARC	cis	rs9814567	1.000	rs9856693	chr3:134306913	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-6.93	-0.41	4.14e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg01475735	chr3:40494733	NA	0.48	5.47	0.34	1.14e-7	Renal cell carcinoma;
SARC	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg25894440	chr7:65020034	NA	-0.73	-5.48	-0.34	1.09e-7	Diabetic kidney disease;
SARC	cis	rs10254118	0.730	rs6961517	chr7:133130940	G/T	cg10665199	chr7:133106180	EXOC4	0.45	5.81	0.36	2.09e-8	Intelligence (multi-trait analysis);
SARC	cis	rs412050	0.547	rs5999842	chr22:22214889	G/A	cg17089214	chr22:22089827	YPEL1	0.88	7.03	0.42	2.33e-11	Attention deficit hyperactivity disorder;
SARC	cis	rs765787	0.530	rs2668737	chr15:45522799	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.24	-0.32	3.62e-7	Uric acid levels;
SARC	cis	rs72634258	0.503	rs707457	chr1:7831064	C/A	cg05338066	chr1:7812865	CAMTA1	0.66	5.46	0.34	1.24e-7	Inflammatory bowel disease;
SARC	cis	rs6977660	0.652	rs58559474	chr7:19751569	C/T	cg07541023	chr7:19748670	TWISTNB	0.97	7.78	0.45	2.35e-13	Thyroid stimulating hormone;
SARC	cis	rs1008375	0.966	rs2315645	chr4:17579678	G/C	cg02297831	chr4:17616191	MED28	0.49	6.22	0.38	2.31e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7560272	0.723	rs6722867	chr2:73816285	A/G	cg20560298	chr2:73613845	ALMS1	-0.52	-6.97	-0.42	3.2e-11	Schizophrenia;
SARC	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg16405210	chr4:1374714	KIAA1530	-0.51	-6.07	-0.37	5.28e-9	Obesity-related traits;
SARC	trans	rs1814175	0.935	rs7925863	chr11:49615802	C/A	cg03929089	chr4:120376271	NA	-0.83	-12.97	-0.65	2.5e-29	Height;
SARC	cis	rs1983170	0.808	rs10874789	chr1:92017990	T/C	cg25838465	chr1:92012736	NA	0.45	5.49	0.34	1.04e-7	Eosinophil percentage of white cells;
SARC	cis	rs1046896	0.553	rs1044661	chr17:80901020	G/A	cg02711726	chr17:80685570	FN3KRP	-0.55	-6.76	-0.41	1.07e-10	Glycated hemoglobin levels;
SARC	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg22496380	chr5:211416	CCDC127	-0.88	-9.35	-0.52	7.72e-18	Breast cancer;
SARC	cis	rs6121246	0.909	rs6060870	chr20:30303299	C/T	cg13852791	chr20:30311386	BCL2L1	0.86	9.16	0.51	2.76e-17	Mean corpuscular hemoglobin;
SARC	cis	rs2011503	1.000	rs56280531	chr19:19585788	A/C	cg15839431	chr19:19639596	YJEFN3	-0.47	-4.73	-0.3	3.84e-6	Bipolar disorder;
SARC	cis	rs2425143	1.000	rs7273174	chr20:34350306	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-5.91	-0.36	1.19e-8	Blood protein levels;
SARC	cis	rs568617	0.953	rs583887	chr11:65644027	T/C	cg26695010	chr11:65641043	EFEMP2	0.49	5.75	0.35	2.82e-8	Crohn's disease;
SARC	cis	rs1707322	0.752	rs28550303	chr1:46188914	G/T	cg03146154	chr1:46216737	IPP	0.52	6.3	0.38	1.44e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1559088	0.948	rs7259333	chr19:33579128	T/C	cg17764715	chr19:33622953	WDR88	0.49	6.57	0.4	3.18e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs2806561	0.704	rs1757039	chr1:23508657	A/G	cg12483005	chr1:23474871	LUZP1	0.43	5.72	0.35	3.23e-8	Height;
SARC	cis	rs1832871	0.683	rs6908487	chr6:158713047	G/T	cg07165851	chr6:158734300	TULP4	0.54	6.51	0.39	4.65e-10	Height;
SARC	cis	rs12984174	0.877	rs408484	chr19:18139771	C/T	cg21649277	chr19:18117794	ARRDC2	0.7	5.65	0.35	4.69e-8	Pulmonary function in asthmatics;
SARC	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-7.06	-0.42	1.87e-11	Gut microbiome composition (summer);
SARC	cis	rs4785204	0.618	rs55830064	chr16:50032641	G/A	cg26500707	chr16:50100227	HEATR3	0.71	5.26	0.33	3.27e-7	Esophageal cancer (squamous cell);
SARC	cis	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg18252515	chr7:66147081	NA	-1.39	-12.23	-0.63	6.97e-27	Gout;
SARC	cis	rs34330	0.562	rs10492235	chr12:12851339	T/G	cg04607235	chr12:12878440	APOLD1	-0.56	-5.42	-0.33	1.47e-7	Systemic lupus erythematosus;
SARC	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg23985595	chr17:80112537	CCDC57	-0.33	-4.95	-0.31	1.45e-6	Life satisfaction;
SARC	cis	rs1153858	1.000	rs4625670	chr15:45652926	C/T	cg26924012	chr15:45694286	SPATA5L1	0.78	11.14	0.59	2.18e-23	Homoarginine levels;
SARC	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.27	-4.87	-0.3	2.02e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg26818010	chr10:134567672	INPP5A	0.61	6.73	0.4	1.27e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs4481887	1.000	rs6697735	chr1:248465315	G/C	cg01631408	chr1:248437212	OR2T33	-0.41	-5.25	-0.33	3.35e-7	Common traits (Other);
SARC	cis	rs9467160	1.000	rs9467162	chr6:24442047	T/C	cg16211469	chr6:24423932	MRS2	0.39	4.89	0.3	1.91e-6	Liver enzyme levels;
SARC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg06873352	chr17:61820015	STRADA	0.53	6.92	0.41	4.3e-11	Prudent dietary pattern;
SARC	cis	rs10489202	0.634	rs6427119	chr1:168074145	A/G	cg24449463	chr1:168025552	DCAF6	0.59	7.53	0.44	1.11e-12	Schizophrenia;
SARC	cis	rs7659604	1.000	rs35901586	chr4:122664757	T/A	cg19671926	chr4:122722719	EXOSC9	-0.49	-5.97	-0.36	8.79e-9	Type 2 diabetes;
SARC	cis	rs1124769	0.871	rs2614793	chr15:51209674	A/G	cg21246271	chr15:51200259	AP4E1	0.57	5.35	0.33	2.14e-7	Cognitive performance;
SARC	cis	rs11997175	0.624	rs4621768	chr8:33677452	T/C	ch.8.33884649F	chr8:33765107	NA	0.61	8.23	0.47	1.33e-14	Body mass index;
SARC	cis	rs2153535	0.580	rs6926759	chr6:8456176	G/A	cg21535247	chr6:8435926	SLC35B3	0.53	6.6	0.4	2.71e-10	Motion sickness;
SARC	cis	rs2070488	0.804	rs13092539	chr3:38458725	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.81	12.47	0.63	1.15e-27	Electrocardiographic conduction measures;
SARC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg20007245	chr22:24372913	LOC391322	-0.7	-8.6	-0.49	1.21e-15	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2749592	0.725	rs9417245	chr10:37826322	C/T	cg25427524	chr10:38739819	LOC399744	0.45	5.96	0.36	9.16e-9	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs1707322	0.648	rs4439382	chr1:46150805	C/T	cg03146154	chr1:46216737	IPP	0.52	6.24	0.38	2.07e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg06028808	chr11:68637592	NA	-0.42	-5.48	-0.34	1.11e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs12791968	1.000	rs1005935	chr11:45002498	A/C	cg11846598	chr11:44996168	LOC221122	-0.36	-5.65	-0.35	4.59e-8	Inhibitory control;
SARC	trans	rs7824557	0.806	rs6601574	chr8:11094885	G/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.26	-0.38	1.84e-9	Retinal vascular caliber;
SARC	cis	rs3796352	1.000	rs71299622	chr3:52917038	G/A	cg12962167	chr3:53033115	SFMBT1	0.84	5.72	0.35	3.18e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs13314892	0.692	rs62253174	chr3:69898414	C/T	cg17445875	chr3:69859618	MITF	-0.56	-5.71	-0.35	3.42e-8	QRS complex (12-leadsum);
SARC	cis	rs644799	0.965	rs499076	chr11:95546341	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	14.15	0.68	3.08e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs710216	0.797	rs841856	chr1:43400113	G/T	cg03128534	chr1:43423976	SLC2A1	0.61	5.81	0.36	2.07e-8	Red cell distribution width;
SARC	cis	rs76917914	0.780	rs16912622	chr9:100843660	A/C	cg03040243	chr9:100819229	NANS	-0.67	-7.2	-0.43	8.27e-12	Immature fraction of reticulocytes;
SARC	cis	rs751728	0.965	rs2013381	chr6:33763837	C/T	cg25922239	chr6:33757077	LEMD2	0.77	10.26	0.56	1.25e-20	Crohn's disease;
SARC	trans	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg21659725	chr3:3221576	CRBN	-0.54	-7.01	-0.42	2.58e-11	Intelligence (multi-trait analysis);
SARC	cis	rs2658782	1.000	rs2658781	chr11:93166368	C/T	cg15737290	chr11:93063684	CCDC67	-0.72	-7.79	-0.45	2.23e-13	Pulmonary function decline;
SARC	cis	rs73206853	0.841	rs7967246	chr12:110756569	G/A	cg10860002	chr12:110842031	ANAPC7	0.61	4.81	0.3	2.76e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs35213789	0.762	rs2533441	chr7:69107979	T/A	cg10619644	chr7:69149951	AUTS2	-0.36	-4.85	-0.3	2.25e-6	Childhood ear infection;
SARC	cis	rs6933660	0.646	rs6915598	chr6:151778664	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.62	7.56	0.44	9.31e-13	Menarche (age at onset);
SARC	cis	rs1580019	0.587	rs10951338	chr7:32560089	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.61	8.15	0.47	2.24e-14	Cognitive ability;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg18264383	chr3:45730917	SACM1L	-0.51	-6.66	-0.4	1.91e-10	Schizophrenia;
SARC	cis	rs73206853	0.841	rs4131851	chr12:110812345	T/C	cg10860002	chr12:110842031	ANAPC7	0.63	5.03	0.31	9.95e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs13401104	0.796	rs61160252	chr2:237119074	A/G	cg19324714	chr2:237145437	ASB18	0.57	5.66	0.35	4.32e-8	Educational attainment;
SARC	cis	rs3741151	0.686	rs7118982	chr11:73110668	T/C	cg17517138	chr11:73019481	ARHGEF17	0.65	5.35	0.33	2.11e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	trans	rs561341	0.882	rs504887	chr17:30322881	T/A	cg20587970	chr11:113659929	NA	-1.24	-12.68	-0.64	2.28e-28	Hip circumference adjusted for BMI;
SARC	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg19901468	chr14:105411992	AHNAK2	-0.73	-10.79	-0.58	2.74e-22	Rheumatoid arthritis;
SARC	cis	rs7566780	0.602	rs1346754	chr2:16683606	G/A	cg09580478	chr2:16689509	NA	0.57	7.0	0.42	2.78e-11	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs2908197	0.737	rs6465096	chr7:75972872	T/G	cg22830091	chr7:75961684	YWHAG	-0.35	-5.22	-0.32	3.98e-7	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs9300255	0.602	rs2510885	chr12:123614813	G/C	cg05973401	chr12:123451056	ABCB9	0.59	6.72	0.4	1.35e-10	Neutrophil percentage of white cells;
SARC	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg12463550	chr7:65579703	CRCP	0.67	5.06	0.31	8.43e-7	Diabetic kidney disease;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14552663	chr20:49347896	PARD6B	-0.49	-6.25	-0.38	1.91e-9	Smoking initiation;
SARC	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	5.34	0.33	2.17e-7	Tonsillectomy;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg02604939	chr3:50330083	IFRD2	0.48	6.37	0.39	1.01e-9	Chemerin levels;
SARC	cis	rs13256369	0.755	rs11776987	chr8:8559401	C/G	cg18904891	chr8:8559673	CLDN23	0.5	5.6	0.34	5.95e-8	Obesity-related traits;
SARC	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg05313129	chr8:58192883	C8orf71	-0.57	-6.31	-0.38	1.41e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2180341	1.000	rs2038378	chr6:127590400	C/T	cg27446573	chr6:127587934	RNF146	1.01	14.01	0.68	9.13e-33	Breast cancer;
SARC	cis	rs4742903	0.967	rs4742904	chr9:106856952	C/T	cg21169611	chr9:106856078	SMC2	0.39	4.71	0.3	4.18e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs9911578	1.000	rs8071280	chr17:57010225	T/C	cg12560992	chr17:57184187	TRIM37	0.85	11.7	0.61	3.63e-25	Intelligence (multi-trait analysis);
SARC	cis	rs3764563	0.660	rs8107923	chr19:15737899	A/T	cg20725493	chr19:15740067	CYP4F8	-0.76	-5.92	-0.36	1.12e-8	Inflammatory biomarkers;
SARC	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg12463550	chr7:65579703	CRCP	-0.48	-5.55	-0.34	7.58e-8	Aortic root size;
SARC	cis	rs9303280	0.901	rs883770	chr17:38063381	C/T	cg20243544	chr17:37824526	PNMT	0.45	6.07	0.37	5.01e-9	Self-reported allergy;
SARC	cis	rs9303280	0.837	rs907092	chr17:37922259	A/G	cg19468946	chr17:37922297	IKZF3	0.35	5.92	0.36	1.13e-8	Self-reported allergy;
SARC	trans	rs79976124	0.800	rs6918860	chr6:66637741	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	7.98	0.46	6.52e-14	Type 2 diabetes;
SARC	trans	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.57	-7.44	-0.44	1.92e-12	Brugada syndrome;
SARC	cis	rs7191439	0.674	rs4782429	chr16:88792097	A/G	cg27087555	chr16:88793112	FAM38A	-1.2	-9.72	-0.54	5.7e-19	Plateletcrit;
SARC	cis	rs965469	0.895	rs6051843	chr20:3400538	A/G	cg25506879	chr20:3388711	C20orf194	-0.57	-5.92	-0.36	1.16e-8	IFN-related cytopenia;
SARC	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg24829409	chr8:58192753	C8orf71	-0.56	-6.05	-0.37	5.68e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs1814175	0.754	rs10219245	chr11:49645052	C/T	cg03929089	chr4:120376271	NA	-0.9	-14.65	-0.69	6.79e-35	Height;
SARC	cis	rs921968	0.565	rs2272191	chr2:219609776	G/A	cg02176678	chr2:219576539	TTLL4	-0.32	-4.94	-0.31	1.48e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.44	-5.56	-0.34	7.32e-8	Intelligence (multi-trait analysis);
SARC	trans	rs11098499	0.818	rs55825515	chr4:120486402	A/G	cg25214090	chr10:38739885	LOC399744	0.57	7.01	0.42	2.57e-11	Corneal astigmatism;
SARC	cis	rs3820928	1.000	rs3820928	chr2:227773466	A/G	cg11843606	chr2:227700838	RHBDD1	-0.5	-6.16	-0.37	3.08e-9	Pulmonary function;
SARC	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg06618935	chr21:46677482	NA	-0.44	-5.8	-0.35	2.2e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs1814175	0.647	rs10839394	chr11:49844747	T/C	cg15704280	chr7:45808275	SEPT13	-0.95	-16.97	-0.74	1.31e-42	Height;
SARC	cis	rs796364	0.806	rs79725795	chr2:201083534	C/T	cg23649088	chr2:200775458	C2orf69	-0.61	-5.32	-0.33	2.46e-7	Schizophrenia;
SARC	cis	rs9914988	0.613	rs12941884	chr17:27284443	A/G	cg10538030	chr17:27276405	PHF12	-0.6	-4.92	-0.31	1.66e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg24399712	chr22:39784796	NA	-0.45	-6.02	-0.37	6.72e-9	Intelligence (multi-trait analysis);
SARC	cis	rs6087990	0.863	rs1569686	chr20:31367079	G/T	cg13636640	chr20:31349939	DNMT3B	0.8	12.66	0.64	2.7e-28	Ulcerative colitis;
SARC	cis	rs7614311	0.731	rs56126667	chr3:63866286	A/G	cg22134162	chr3:63841271	THOC7	-0.47	-5.04	-0.31	9.26e-7	Lung function (FVC);Lung function (FEV1);
SARC	cis	rs6456042	1.000	rs3127416	chr6:166537412	G/A	cg11088901	chr6:166572345	T	-0.34	-4.85	-0.3	2.31e-6	Asthma;
SARC	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg26116260	chr4:7069785	GRPEL1	-0.8	-8.77	-0.5	3.83e-16	Monocyte percentage of white cells;
SARC	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg23262073	chr20:60523788	NA	-0.39	-5.63	-0.35	5.17e-8	Body mass index;
SARC	cis	rs8141529	0.509	rs7287124	chr22:29239157	A/G	cg02153584	chr22:29168773	CCDC117	0.67	8.51	0.49	2.21e-15	Lymphocyte counts;
SARC	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg16482183	chr6:26056742	HIST1H1C	0.42	5.34	0.33	2.26e-7	Height;
SARC	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg08280861	chr8:58055591	NA	0.7	6.02	0.37	6.73e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs61931739	0.658	rs10772149	chr12:34285498	A/G	cg26384229	chr12:38710491	ALG10B	0.6	8.05	0.47	4.3e-14	Morning vs. evening chronotype;
SARC	cis	rs6772849	0.896	rs9816260	chr3:128352083	A/T	cg01163369	chr3:128370232	RPN1	-0.33	-4.75	-0.3	3.63e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg19901468	chr14:105411992	AHNAK2	-0.73	-10.79	-0.58	2.74e-22	Rheumatoid arthritis;
SARC	cis	rs6570726	0.791	rs10872577	chr6:145900560	G/T	cg23711669	chr6:146136114	FBXO30	0.83	13.94	0.67	1.53e-32	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1348850	0.574	rs12988366	chr2:178417945	A/C	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.61	-5.89	-0.36	1.32e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs6772849	0.930	rs4857914	chr3:128350684	C/T	cg08795948	chr3:128337044	NA	0.53	7.32	0.43	3.94e-12	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs9814567	1.000	rs2177601	chr3:134245434	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	7.08	0.42	1.73e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs3106136	0.843	rs7438414	chr4:95265822	T/C	cg11021082	chr4:95130006	SMARCAD1	0.38	5.85	0.36	1.66e-8	Capecitabine sensitivity;
SARC	cis	rs4268898	0.610	rs72791170	chr2:24449776	C/T	cg26838691	chr2:24397539	C2orf84	-0.51	-5.79	-0.35	2.29e-8	Asthma;
SARC	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg00152838	chr16:24741724	TNRC6A	-0.59	-6.24	-0.38	1.99e-9	Intelligence (multi-trait analysis);
SARC	cis	rs1483890	0.642	rs1010315	chr3:69402165	C/T	cg22125112	chr3:69402811	FRMD4B	0.28	4.78	0.3	3.04e-6	Resting heart rate;
SARC	cis	rs7624766	0.508	rs1598495	chr3:160497731	G/A	cg22637730	chr3:160473554	PPM1L	0.38	4.87	0.3	2.07e-6	Response to methotrexate in rheumatoid arthritis;
SARC	cis	rs66887589	0.934	rs6817317	chr4:120542827	A/G	cg09307838	chr4:120376055	NA	-0.54	-7.45	-0.44	1.81e-12	Diastolic blood pressure;
SARC	cis	rs1983891	1.000	rs9296365	chr6:41535379	A/G	cg15051332	chr6:41514432	FOXP4	0.54	5.96	0.36	9.49e-9	Prostate cancer;
SARC	cis	rs6963495	0.799	rs73190201	chr7:105165891	A/C	cg13798780	chr7:105162888	PUS7	0.6	5.56	0.34	7.22e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs2153535	0.563	rs1737585	chr6:8536594	A/G	cg23788917	chr6:8435910	SLC35B3	-0.63	-8.4	-0.48	4.44e-15	Motion sickness;
SARC	cis	rs6952808	0.635	rs6952727	chr7:1947958	A/G	cg13880726	chr7:1868755	MAD1L1	0.43	4.97	0.31	1.33e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg16680214	chr1:154839983	KCNN3	-0.36	-5.52	-0.34	8.82e-8	Prostate cancer;
SARC	cis	rs7618915	0.501	rs55678971	chr3:52717229	T/A	cg22484793	chr3:52261325	TLR9	0.31	5.02	0.31	1.02e-6	Bipolar disorder;
SARC	cis	rs3018712	0.547	rs4930583	chr11:68411179	G/A	cg01657329	chr11:68192670	LRP5	0.58	5.28	0.33	3.01e-7	Total body bone mineral density;
SARC	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg06697600	chr4:7070879	GRPEL1	-0.37	-4.77	-0.3	3.18e-6	Monocyte percentage of white cells;
SARC	cis	rs36051895	0.623	rs10975033	chr9:5262567	C/T	cg02405213	chr9:5042618	JAK2	-0.42	-5.2	-0.32	4.36e-7	Pediatric autoimmune diseases;
SARC	cis	rs8028182	0.636	rs4075522	chr15:75864335	G/A	cg20655648	chr15:75932815	IMP3	0.62	7.19	0.43	8.75e-12	Sudden cardiac arrest;
SARC	cis	rs76419734	0.850	rs10516528	chr4:106739593	G/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.79	5.34	0.33	2.23e-7	Post bronchodilator FEV1;
SARC	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg11062466	chr8:58055876	NA	0.54	5.56	0.34	7.55e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs854765	0.693	rs8079321	chr17:17760789	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	9.56	0.53	1.8e-18	Total body bone mineral density;
SARC	cis	rs9660992	0.573	rs4400674	chr1:205218425	A/C	cg21545522	chr1:205238299	TMCC2	-0.41	-5.87	-0.36	1.52e-8	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs11719291	0.833	rs73080361	chr3:48832146	G/A	cg00383909	chr3:49044727	WDR6	0.8	6.53	0.39	4.13e-10	Cognitive function;
SARC	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	8.71	0.5	5.56e-16	Alzheimer's disease;
SARC	cis	rs7647973	0.626	rs9870858	chr3:49769071	C/T	cg07636037	chr3:49044803	WDR6	0.59	6.09	0.37	4.62e-9	Menarche (age at onset);
SARC	cis	rs6495122	0.699	rs3784789	chr15:75082552	C/G	cg09165964	chr15:75287851	SCAMP5	0.4	4.79	0.3	3e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.57	5.48	0.34	1.11e-7	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg24209194	chr3:40518798	ZNF619	0.65	8.17	0.47	1.99e-14	Renal cell carcinoma;
SARC	cis	rs1691799	0.867	rs6581677	chr12:66770379	C/G	cg16791601	chr12:66731901	HELB	-0.69	-10.23	-0.56	1.54e-20	White blood cell count (basophil);
SARC	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg16414030	chr3:133502952	NA	-0.36	-4.82	-0.3	2.56e-6	Iron status biomarkers;
SARC	cis	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg02487422	chr3:49467188	NICN1	0.5	6.83	0.41	7.5e-11	Resting heart rate;
SARC	cis	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.42	-5.23	-0.32	3.77e-7	Eosinophil percentage of white cells;
SARC	cis	rs995000	0.931	rs116405518	chr1:63036807	G/A	cg06896770	chr1:63153194	DOCK7	-0.92	-13.65	-0.67	1.48e-31	Triglyceride levels;
SARC	cis	rs9399135	0.967	rs1023179	chr6:135343829	T/A	cg24558204	chr6:135376177	HBS1L	0.45	6.07	0.37	5.25e-9	Red blood cell count;
SARC	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg25894440	chr7:65020034	NA	-0.72	-5.46	-0.34	1.2e-7	Diabetic kidney disease;
SARC	cis	rs7729447	0.841	rs10941021	chr5:32691144	C/T	cg16267343	chr5:32710456	NPR3	0.64	8.46	0.48	2.96e-15	Blood pressure;
SARC	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg18876405	chr7:65276391	NA	0.74	9.42	0.53	4.63e-18	Aortic root size;
SARC	cis	rs7589342	0.839	rs35812588	chr2:106432201	C/T	cg16077055	chr2:106428750	NCK2	0.34	6.14	0.37	3.6e-9	Addiction;
SARC	cis	rs3812565	0.506	rs8413	chr9:139323311	T/C	cg14169450	chr9:139327907	INPP5E	0.43	5.7	0.35	3.54e-8	Granulocyte percentage of myeloid white cells;
SARC	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg22496380	chr5:211416	CCDC127	-0.88	-9.35	-0.52	7.72e-18	Breast cancer;
SARC	cis	rs35955747	0.902	rs5997919	chr22:31623442	A/G	cg13145458	chr22:31556086	RNF185	0.39	4.74	0.3	3.74e-6	Neutrophil count;Sum basophil neutrophil counts;
SARC	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg19748678	chr4:122722346	EXOSC9	0.76	9.69	0.54	7.21e-19	Type 2 diabetes;
SARC	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg15921436	chr17:44337874	NA	0.52	5.2	0.32	4.29e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg25036284	chr2:26402008	FAM59B	-0.43	-5.31	-0.33	2.53e-7	Gut microbiome composition (summer);
SARC	cis	rs2180341	1.000	rs2057223	chr6:127637374	T/C	cg27446573	chr6:127587934	RNF146	1.02	14.02	0.68	8.55e-33	Breast cancer;
SARC	cis	rs9790314	0.581	rs6806054	chr3:160724978	C/T	cg04691961	chr3:161091175	C3orf57	-0.58	-8.03	-0.47	4.71e-14	Morning vs. evening chronotype;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg26551417	chr13:52586451	ALG11;ATP7B	0.52	6.24	0.38	1.99e-9	Blood pressure;
SARC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg09373136	chr17:61933544	TCAM1	-0.42	-5.78	-0.35	2.38e-8	Prudent dietary pattern;
SARC	cis	rs1215050	0.791	rs260889	chr4:98742340	A/G	cg05340658	chr4:99064831	C4orf37	0.44	5.85	0.36	1.62e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs796364	0.760	rs74993507	chr2:201068684	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-5.91	-0.36	1.21e-8	Schizophrenia;
SARC	cis	rs7772486	0.686	rs6570701	chr6:145954090	A/G	cg05347473	chr6:146136440	FBXO30	0.5	7.1	0.42	1.48e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6088580	0.634	rs6120642	chr20:33012531	A/G	cg08999081	chr20:33150536	PIGU	0.44	6.59	0.4	2.93e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg08219700	chr8:58056026	NA	0.46	4.96	0.31	1.34e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs986417	1.000	rs6573312	chr14:60952536	G/T	cg27398547	chr14:60952738	C14orf39	1.03	9.89	0.54	1.74e-19	Gut microbiota (bacterial taxa);
SARC	cis	rs7584330	0.737	rs12465714	chr2:238365637	C/T	cg14458575	chr2:238380390	NA	0.45	5.56	0.34	7.38e-8	Prostate cancer;
SARC	cis	rs2562456	0.917	rs2562471	chr19:21715819	C/T	cg00806126	chr19:22604979	ZNF98	0.49	5.03	0.31	9.61e-7	Pain;
SARC	cis	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg22496380	chr5:211416	CCDC127	-0.88	-9.35	-0.52	7.72e-18	Breast cancer;
SARC	cis	rs6696846	0.905	rs11240349	chr1:205041015	G/A	cg00857998	chr1:205179979	DSTYK	0.4	4.91	0.31	1.72e-6	Red blood cell count;
SARC	cis	rs1153858	1.000	rs10519022	chr15:45663684	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.79	-11.06	-0.59	4.06e-23	Homoarginine levels;
SARC	cis	rs7264396	0.563	rs2425122	chr20:34328848	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.59	5.48	0.34	1.12e-7	Total cholesterol levels;
SARC	cis	rs7592578	0.771	rs62181034	chr2:191354963	C/A	cg25963032	chr2:191064776	C2orf88	-0.44	-4.86	-0.3	2.16e-6	Diastolic blood pressure;
SARC	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg10591111	chr5:226296	SDHA	-0.57	-5.13	-0.32	6.17e-7	Breast cancer;
SARC	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg24642844	chr7:1081250	C7orf50	-0.54	-6.27	-0.38	1.77e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs10791097	0.667	rs2155358	chr11:130740357	T/C	cg12179176	chr11:130786555	SNX19	0.73	10.92	0.58	1.08e-22	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs2882667	0.858	rs11951899	chr5:138374310	A/G	cg04439458	chr5:138467593	SIL1	-0.29	-4.73	-0.3	3.81e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs1008375	1.000	rs10939738	chr4:17604295	G/C	cg02297831	chr4:17616191	MED28	0.51	6.45	0.39	6.53e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7144547	0.803	rs8008602	chr14:81890171	T/A	cg23690444	chr14:81902736	NA	0.56	6.66	0.4	1.91e-10	Prudent dietary pattern;
SARC	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg13206674	chr6:150067644	NUP43	0.43	5.55	0.34	7.62e-8	Lung cancer;
SARC	cis	rs3820928	1.000	rs2396433	chr2:227772502	A/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-6.81	-0.41	8.13e-11	Pulmonary function;
SARC	cis	rs72634258	0.503	rs697674	chr1:7837878	C/G	cg26816564	chr1:7831052	VAMP3	0.58	5.2	0.32	4.36e-7	Inflammatory bowel disease;
SARC	cis	rs244731	0.959	rs4976677	chr5:176629546	G/A	cg17509989	chr5:176798049	RGS14	-0.68	-8.48	-0.49	2.68e-15	Urate levels in lean individuals;
SARC	cis	rs6484504	0.576	rs176373	chr11:31136026	G/T	cg26647111	chr11:31128758	NA	-0.37	-4.79	-0.3	2.95e-6	Red blood cell count;
SARC	trans	rs61931739	0.500	rs11513287	chr12:34584351	G/A	cg13010199	chr12:38710504	ALG10B	0.83	11.69	0.61	3.9e-25	Morning vs. evening chronotype;
SARC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg13397359	chr6:42928475	GNMT	0.57	7.96	0.46	7.37e-14	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs7927592	0.913	rs3824850	chr11:68341873	A/G	cg01657329	chr11:68192670	LRP5	-0.43	-5.11	-0.32	6.59e-7	Total body bone mineral density;
SARC	cis	rs8084125	0.832	rs7238522	chr18:74948730	A/C	cg05528293	chr18:74961138	GALR1	-0.48	-5.35	-0.33	2.11e-7	Obesity-related traits;
SARC	cis	rs7412746	0.587	rs3849279	chr1:150944707	T/C	cg15448220	chr1:150897856	SETDB1	0.52	6.79	0.41	9.19e-11	Melanoma;
SARC	cis	rs9682041	0.622	rs7640791	chr3:170155726	G/C	cg11886554	chr3:170076028	SKIL	0.84	6.06	0.37	5.29e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs9611565	0.921	rs5758297	chr22:41720697	A/G	cg03806693	chr22:41940476	POLR3H	-0.68	-9.32	-0.52	9.09e-18	Vitiligo;
SARC	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg24675658	chr1:53192096	ZYG11B	-0.64	-9.57	-0.53	1.67e-18	Monocyte count;
SARC	cis	rs7513165	0.932	rs11240694	chr1:204157973	C/T	cg23788856	chr1:204159729	KISS1	-0.33	-5.24	-0.32	3.66e-7	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
SARC	cis	rs1865760	0.892	rs6456705	chr6:25936056	G/A	cg16482183	chr6:26056742	HIST1H1C	0.53	6.68	0.4	1.72e-10	Height;
SARC	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg11987759	chr7:65425863	GUSB	0.45	6.03	0.37	6.22e-9	Aortic root size;
SARC	cis	rs763121	0.853	rs5757253	chr22:39104320	C/T	cg21395723	chr22:39101663	GTPBP1	0.57	6.89	0.41	5.16e-11	Menopause (age at onset);
SARC	cis	rs208520	0.690	rs3843513	chr6:66836797	A/G	cg07460842	chr6:66804631	NA	-1.04	-14.38	-0.69	5.61e-34	Exhaled nitric oxide output;
SARC	cis	rs950027	0.620	rs1617984	chr15:45622662	A/G	cg21132104	chr15:45694354	SPATA5L1	0.56	7.12	0.42	1.36e-11	Response to fenofibrate (adiponectin levels);
SARC	cis	rs897080	0.515	rs2850290	chr2:44636055	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	6.7	0.4	1.52e-10	Height;
SARC	cis	rs1008375	0.932	rs11941874	chr4:17666416	C/T	cg02297831	chr4:17616191	MED28	-0.42	-5.2	-0.32	4.42e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs5744897	0.708	rs4883582	chr12:133242733	C/A	cg16945633	chr12:133170342	NA	0.62	6.43	0.39	7.3e-10	Urate levels in overweight individuals;
SARC	cis	rs644799	0.710	rs56384142	chr11:95502075	G/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.61	8.27	0.48	1.05e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9916302	0.861	rs752314	chr17:37410700	C/T	cg20243544	chr17:37824526	PNMT	0.56	6.95	0.41	3.53e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs7647973	0.710	rs11130207	chr3:49611666	T/G	cg06212747	chr3:49208901	KLHDC8B	0.73	6.49	0.39	5.02e-10	Menarche (age at onset);
SARC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg17178900	chr1:205818956	PM20D1	0.75	11.9	0.61	8.02e-26	Menarche (age at onset);
SARC	cis	rs7760949	0.963	rs9475771	chr6:13914869	A/G	cg27413430	chr6:13925136	RNF182	-0.48	-6.03	-0.37	6.3e-9	Mean corpuscular hemoglobin concentration;
SARC	trans	rs8073060	0.544	rs225249	chr17:33942540	T/C	cg19694781	chr19:47549865	TMEM160	-0.64	-6.66	-0.4	1.97e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg15595755	chr5:1867978	NA	0.48	6.56	0.4	3.37e-10	Cardiovascular disease risk factors;
SARC	cis	rs1580019	0.961	rs766657	chr7:32499510	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.74	9.9	0.54	1.68e-19	Cognitive ability;
SARC	cis	rs7959452	0.640	rs12370042	chr12:69692420	C/G	cg22834771	chr12:69754056	YEATS4	-0.41	-5.47	-0.34	1.19e-7	Blood protein levels;
SARC	cis	rs2342371	0.848	rs5016648	chr3:196207989	A/G	cg15048948	chr3:196158458	UBXN7	-0.53	-6.62	-0.4	2.42e-10	Fat distribution (HIV);
SARC	cis	rs41271473	0.526	rs942853	chr1:228730949	G/T	cg10167378	chr1:228756711	NA	0.61	5.41	0.33	1.6e-7	Chronic lymphocytic leukemia;
SARC	cis	rs11655198	1	rs11655198	chr17:38026169	C/T	cg20243544	chr17:37824526	PNMT	0.44	5.89	0.36	1.35e-8	Asthma;
SARC	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.94	9.51	0.53	2.52e-18	Platelet count;
SARC	cis	rs6840258	1.000	rs56406125	chr4:87940205	G/T	cg11209507	chr4:87813803	C4orf36	0.44	4.72	0.3	4.1e-6	Mean corpuscular volume;Basophil percentage of granulocytes;
SARC	trans	rs7944735	0.507	rs10838802	chr11:48102478	A/G	cg15704280	chr7:45808275	SEPT13	0.6	6.98	0.42	3.06e-11	Intraocular pressure;
SARC	cis	rs11758351	0.866	rs2022448	chr6:26207928	C/T	cg01420254	chr6:26195488	NA	0.51	4.9	0.31	1.83e-6	Gout;Renal underexcretion gout;
SARC	cis	rs7828089	0.582	rs3817445	chr8:22266054	G/T	cg12081754	chr8:22256438	SLC39A14	0.63	8.62	0.49	1.05e-15	Verbal declarative memory;
SARC	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg18876405	chr7:65276391	NA	-0.67	-8.63	-0.49	9.59e-16	Aortic root size;
SARC	cis	rs2228479	0.557	rs11641726	chr16:89891619	G/A	cg12064134	chr16:90016061	DEF8	-0.56	-4.79	-0.3	2.91e-6	Skin colour saturation;
SARC	cis	rs6539267	0.748	rs1921953	chr12:106721012	C/T	cg02476566	chr12:106696527	TCP11L2	0.51	5.1	0.32	6.96e-7	Tourette syndrome;
SARC	cis	rs933688	1.000	rs1035476	chr5:90745976	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.04	12.87	0.64	5.6e-29	Smoking behavior;
SARC	cis	rs2213920	0.522	rs7847118	chr9:118199763	T/C	cg13918206	chr9:118159781	DEC1	0.82	6.54	0.39	3.77e-10	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs7412746	0.611	rs12410869	chr1:150856153	G/T	cg15448220	chr1:150897856	SETDB1	0.51	6.6	0.4	2.67e-10	Melanoma;
SARC	cis	rs9309473	0.718	rs10175529	chr2:73606093	A/G	cg20560298	chr2:73613845	ALMS1	-0.54	-6.97	-0.42	3.17e-11	Metabolite levels;
SARC	cis	rs7208859	0.623	rs7220289	chr17:29103762	G/T	cg13385521	chr17:29058706	SUZ12P	0.89	7.73	0.45	3.24e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs6582630	0.598	rs10880614	chr12:38509766	G/A	cg26384229	chr12:38710491	ALG10B	-0.59	-7.48	-0.44	1.47e-12	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs11574514	1.000	rs9939085	chr16:67733237	C/T	cg01866162	chr16:67596514	CTCF	0.87	5.39	0.33	1.74e-7	Crohn's disease;
SARC	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.92	10.24	0.56	1.46e-20	Platelet count;
SARC	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg27266027	chr21:40555129	PSMG1	-0.5	-5.43	-0.34	1.4e-7	Cognitive function;
SARC	cis	rs9611565	0.802	rs132916	chr22:41806768	C/G	cg17376030	chr22:41985996	PMM1	-0.6	-7.87	-0.46	1.29e-13	Vitiligo;
SARC	cis	rs15676	0.561	rs10739736	chr9:131577981	A/T	cg00228799	chr9:131580591	ENDOG	0.59	7.33	0.43	3.82e-12	Blood metabolite levels;
SARC	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg02725872	chr8:58115012	NA	-0.34	-5.37	-0.33	1.91e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg20677814	chr7:16656054	ANKMY2	0.54	7.54	0.44	1.03e-12	Thyroid stimulating hormone;
SARC	cis	rs3767633	0.925	rs2055539	chr1:161807866	T/C	cg09175582	chr1:161736000	ATF6	0.68	5.95	0.36	9.52e-9	IgG glycosylation;
SARC	cis	rs67460515	0.665	rs28384382	chr3:160939141	C/T	cg03342759	chr3:160939853	NMD3	-0.72	-9.15	-0.51	2.96e-17	Parkinson's disease;
SARC	cis	rs9818758	0.607	rs66991555	chr3:49228643	A/G	cg01304814	chr3:48885189	PRKAR2A	0.58	4.82	0.3	2.64e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs11112613	0.818	rs73184099	chr12:106018143	A/G	cg03607813	chr12:105948248	NA	0.5	5.6	0.34	6.15e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg12667521	chr19:29218732	NA	0.39	5.26	0.33	3.27e-7	Methadone dose in opioid dependence;
SARC	cis	rs10489202	1.000	rs34774552	chr1:168032245	G/A	cg24449463	chr1:168025552	DCAF6	-0.63	-6.96	-0.42	3.33e-11	Schizophrenia;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg11923054	chr4:4250051	TMEM128	0.6	7.56	0.44	9e-13	Breast cancer;
SARC	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg09263875	chr16:632152	PIGQ	0.52	7.98	0.46	6.48e-14	Height;
SARC	cis	rs6772849	0.775	rs12486377	chr3:128414853	G/C	cg08795948	chr3:128337044	NA	0.51	6.71	0.4	1.49e-10	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs854765	0.619	rs1101727	chr17:18016148	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.41	5.09	0.32	7.55e-7	Total body bone mineral density;
SARC	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg17221315	chr6:27791827	HIST1H4J	-0.48	-5.02	-0.31	1.02e-6	Parkinson's disease;
SARC	cis	rs7714584	1.000	rs12652003	chr5:150231945	T/C	cg22134413	chr5:150180641	NA	0.87	6.95	0.41	3.73e-11	Crohn's disease;
SARC	cis	rs3733585	0.534	rs7375642	chr4:9955236	A/G	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.95	-0.36	9.9e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg03060546	chr3:49711283	APEH	-0.67	-8.31	-0.48	8e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs2742234	0.541	rs10793424	chr10:43717116	G/T	cg15436174	chr10:43711423	RASGEF1A	0.43	5.01	0.31	1.08e-6	Hirschsprung disease;
SARC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg14893161	chr1:205819251	PM20D1	0.94	16.56	0.74	3.11e-41	Menarche (age at onset);
SARC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg15796911	chr2:118594622	NA	0.44	6.38	0.39	9.29e-10	HDL cholesterol;
SARC	cis	rs73071352	0.588	rs55744136	chr3:41812293	A/C	cg03022575	chr3:42003672	ULK4	0.72	5.99	0.37	7.83e-9	Multiple myeloma and monoclonal gammopathy;Multiple myeloma;
SARC	cis	rs7681440	0.804	rs1442140	chr4:90816023	A/G	cg06632027	chr4:90757378	SNCA	0.42	5.94	0.36	1.05e-8	Dementia with Lewy bodies;
SARC	cis	rs644799	0.511	rs1016030	chr11:95472693	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.74	9.81	0.54	3.1400000000000002e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg14586887	chr7:28966691	NA	0.78	6.49	0.39	5.23e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6570726	0.791	rs11759979	chr6:145918881	C/T	cg05347473	chr6:146136440	FBXO30	0.53	7.31	0.43	4.36e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9300255	0.602	rs2695476	chr12:123694206	T/C	cg05973401	chr12:123451056	ABCB9	0.55	5.22	0.32	3.89e-7	Neutrophil percentage of white cells;
SARC	cis	rs5769765	0.908	rs9616390	chr22:50314289	G/C	cg03033257	chr22:50311977	ALG12;CRELD2	0.62	5.9	0.36	1.25e-8	Schizophrenia;
SARC	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg00825309	chr19:58991885	ZNF446	-0.95	-14.24	-0.68	1.61e-33	Mean platelet volume;
SARC	trans	rs61931739	0.635	rs1852225	chr12:33963004	C/T	cg26384229	chr12:38710491	ALG10B	0.57	7.37	0.43	2.93e-12	Morning vs. evening chronotype;
SARC	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg03452623	chr4:187889614	NA	-0.76	-12.04	-0.62	2.75e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs765787	0.530	rs3759895	chr15:45543870	G/A	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.81e-6	Uric acid levels;
SARC	cis	rs3733585	0.605	rs7656624	chr4:10121097	T/C	cg00071950	chr4:10020882	SLC2A9	-0.34	-5.02	-0.31	1.03e-6	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg11987759	chr7:65425863	GUSB	-0.49	-6.21	-0.38	2.46e-9	Aortic root size;
SARC	cis	rs7017697	0.507	rs10112790	chr8:19684414	A/T	cg03894339	chr8:19674705	INTS10	-0.52	-5.49	-0.34	1.05e-7	Breast cancer;
SARC	cis	rs3796352	0.568	rs11713376	chr3:52958927	A/G	cg04865290	chr3:52927548	TMEM110	-0.62	-5.33	-0.33	2.26e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs76419734	0.850	rs11734568	chr4:106703543	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.81	5.48	0.34	1.08e-7	Post bronchodilator FEV1;
SARC	cis	rs2204008	0.837	rs11495548	chr12:38076756	C/T	cg26384229	chr12:38710491	ALG10B	0.88	12.92	0.65	3.79e-29	Bladder cancer;
SARC	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg11890956	chr21:40555474	PSMG1	1.16	17.01	0.74	1.03e-42	Cognitive function;
SARC	cis	rs78456975	1.000	rs72778004	chr2:1571892	T/A	cg01028140	chr2:1542097	TPO	-0.48	-4.79	-0.3	2.95e-6	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs9916302	0.861	rs4795377	chr17:37669056	C/T	cg07936489	chr17:37558343	FBXL20	-0.69	-8.9	-0.5	1.63e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs3862260	0.509	rs3862262	chr1:120161841	G/T	cg16322792	chr1:120165303	ZNF697	0.29	6.08	0.37	4.77e-9	Systemic lupus erythematosus;
SARC	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.01	12.2	0.62	8.73e-27	Platelet count;
SARC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg06074448	chr4:187884817	NA	-0.41	-5.39	-0.33	1.76e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg22903471	chr2:27725779	GCKR	-0.44	-6.44	-0.39	6.81e-10	Total body bone mineral density;
SARC	cis	rs4509693	0.782	rs12268880	chr10:102495285	G/C	cg15234845	chr10:102496500	NA	0.33	4.82	0.3	2.63e-6	Alzheimer's disease;
SARC	cis	rs9290065	0.519	rs6763532	chr3:160701816	G/A	cg04691961	chr3:161091175	C3orf57	-0.49	-6.23	-0.38	2.12e-9	Kawasaki disease;
SARC	cis	rs5167	0.533	rs55778858	chr19:45485465	G/A	cg10169327	chr19:45448959	APOC2	0.33	4.86	0.3	2.18e-6	Blood protein levels;
SARC	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg18827097	chr2:3522506	ADI1	0.44	6.44	0.39	6.65e-10	Cancer;
SARC	cis	rs12311304	0.965	rs58368403	chr12:15359047	C/A	cg08258403	chr12:15378311	NA	0.48	7.48	0.44	1.48e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs1018836	0.631	rs9987164	chr8:91470910	T/G	cg16814680	chr8:91681699	NA	-0.68	-9.79	-0.54	3.5e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs898097	0.812	rs56405605	chr17:80843663	T/C	cg15664640	chr17:80829946	TBCD	-0.56	-8.36	-0.48	5.88e-15	Breast cancer;
SARC	cis	rs7714584	1.000	rs10051924	chr5:150226639	T/C	cg22134413	chr5:150180641	NA	0.78	6.54	0.39	3.82e-10	Crohn's disease;
SARC	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg07061783	chr6:25882402	NA	-0.42	-5.1	-0.32	7.15e-7	Intelligence (multi-trait analysis);
SARC	cis	rs10046574	0.634	rs10266715	chr7:135155366	C/T	cg27474649	chr7:135195673	CNOT4	-0.88	-7.31	-0.43	4.36e-12	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs3760982	0.585	rs61013802	chr19:44292142	A/T	cg11993925	chr19:44307056	LYPD5	0.3	4.77	0.3	3.22e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
SARC	cis	rs6088580	0.543	rs4911158	chr20:33239512	T/C	cg08999081	chr20:33150536	PIGU	-0.35	-5.13	-0.32	6.11e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg17376030	chr22:41985996	PMM1	0.59	7.41	0.44	2.3e-12	Vitiligo;
SARC	cis	rs6429082	0.811	rs291348	chr1:235667690	A/G	cg26050004	chr1:235667680	B3GALNT2	0.82	13.46	0.66	6.35e-31	Adiposity;
SARC	cis	rs7560272	0.564	rs10496190	chr2:73638823	C/G	cg20560298	chr2:73613845	ALMS1	0.49	6.6	0.4	2.8e-10	Schizophrenia;
SARC	cis	rs698833	0.828	rs4952710	chr2:44524575	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.65	8.41	0.48	4.08e-15	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg12463550	chr7:65579703	CRCP	0.7	5.31	0.33	2.51e-7	Diabetic kidney disease;
SARC	cis	rs2832077	0.506	rs2832085	chr21:30155258	G/T	cg24692254	chr21:30365293	RNF160	-0.54	-5.86	-0.36	1.6e-8	Cognitive test performance;
SARC	cis	rs950169	0.840	rs72748702	chr15:84915246	A/G	cg17507749	chr15:85114479	UBE2QP1	0.78	9.33	0.52	8.36e-18	Schizophrenia;
SARC	cis	rs13161895	0.713	rs76315806	chr5:179485515	C/G	cg02702477	chr5:179499311	RNF130	0.7	6.34	0.38	1.19e-9	LDL cholesterol;
SARC	cis	rs1707322	0.682	rs28508523	chr1:46189625	G/A	cg06784218	chr1:46089804	CCDC17	0.37	6.43	0.39	7.15e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg22535103	chr8:58192502	C8orf71	-0.7	-7.06	-0.42	1.93e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs4427176	0.543	rs7837054	chr8:9652735	A/G	cg21625330	chr8:9911636	MSRA	0.64	5.21	0.32	4.22e-7	Mosquito bite size;
SARC	cis	rs11608355	0.506	rs11066471	chr12:109828039	T/C	cg19025524	chr12:109796872	NA	-0.41	-5.15	-0.32	5.44e-7	Neuroticism;
SARC	trans	rs61931739	0.500	rs7965679	chr12:34542494	T/C	cg26384229	chr12:38710491	ALG10B	0.85	12.63	0.64	3.4e-28	Morning vs. evening chronotype;
SARC	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg21782813	chr7:2030301	MAD1L1	0.38	5.96	0.36	9.37e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs1318878	0.565	rs2417434	chr12:15449761	T/C	cg08258403	chr12:15378311	NA	0.49	6.97	0.42	3.3e-11	Intelligence (multi-trait analysis);
SARC	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg11764359	chr7:65958608	NA	0.88	12.58	0.64	4.89e-28	Aortic root size;
SARC	cis	rs5167	0.781	rs909134	chr19:45493061	T/C	cg09555818	chr19:45449301	APOC2	0.41	5.87	0.36	1.5e-8	Blood protein levels;
SARC	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	12.7	0.64	2e-28	Personality dimensions;
SARC	cis	rs8141529	0.748	rs7287918	chr22:29281710	G/A	cg15103426	chr22:29168792	CCDC117	0.63	8.2	0.47	1.63e-14	Lymphocyte counts;
SARC	cis	rs67460515	0.506	rs935497	chr3:160600563	A/G	cg17135325	chr3:160939158	NMD3	0.54	5.92	0.36	1.13e-8	Parkinson's disease;
SARC	cis	rs7647973	0.626	rs9835157	chr3:49797769	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.58	-5.81	-0.36	2e-8	Menarche (age at onset);
SARC	cis	rs9814567	0.727	rs7641798	chr3:134345719	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.49	-6.33	-0.38	1.24e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs722599	0.683	rs8008475	chr14:75291900	C/T	cg06637938	chr14:75390232	RPS6KL1	0.38	4.73	0.3	3.81e-6	IgG glycosylation;
SARC	cis	rs7113850	0.541	rs80031332	chr11:24211553	A/G	ch.11.24196551F	chr11:24239977	NA	0.77	6.02	0.37	6.84e-9	Bone fracture in osteoporosis;
SARC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg03395511	chr6:291903	DUSP22	-0.54	-6.82	-0.41	7.88e-11	Menopause (age at onset);
SARC	cis	rs72781680	0.800	rs72790306	chr2:24111311	T/G	cg06627628	chr2:24431161	ITSN2	-0.71	-6.84	-0.41	7e-11	Lymphocyte counts;
SARC	cis	rs17209837	1.000	rs998671	chr7:87123275	C/T	cg00919237	chr7:87102261	ABCB4	-0.49	-4.76	-0.3	3.41e-6	Gallbladder cancer;
SARC	cis	rs950169	0.922	rs4842939	chr15:84827966	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.69	-8.22	-0.47	1.38e-14	Schizophrenia;
SARC	cis	rs12135062	1.000	rs12135062	chr1:3103312	A/C	cg21609526	chr1:3105151	PRDM16	0.38	6.56	0.39	3.44e-10	Migraine;
SARC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.46	0.8	5.92e-54	Prudent dietary pattern;
SARC	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg26839252	chr6:160211577	TCP1;MRPL18	-0.63	-6.77	-0.41	1.03e-10	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg17376030	chr22:41985996	PMM1	-0.64	-8.25	-0.48	1.19e-14	Vitiligo;
SARC	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg00933542	chr6:150070202	PCMT1	0.3	5.08	0.32	7.56e-7	Lung cancer;
SARC	cis	rs4906332	1.000	rs12147655	chr14:103850906	G/C	cg26031613	chr14:104095156	KLC1	-0.56	-6.56	-0.39	3.43e-10	Coronary artery disease;
SARC	cis	rs3749237	0.964	rs2352975	chr3:49891885	T/C	cg07636037	chr3:49044803	WDR6	0.49	5.32	0.33	2.43e-7	Resting heart rate;
SARC	cis	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg25427524	chr10:38739819	LOC399744	-0.53	-8.32	-0.48	7.33e-15	Extrinsic epigenetic age acceleration;
SARC	cis	rs9640161	0.742	rs2108854	chr7:150017408	C/T	cg21361702	chr7:150065534	REPIN1	-0.46	-4.93	-0.31	1.55e-6	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg18876405	chr7:65276391	NA	-0.67	-8.16	-0.47	2.09e-14	Aortic root size;
SARC	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg11987759	chr7:65425863	GUSB	0.47	5.71	0.35	3.51e-8	Aortic root size;
SARC	cis	rs17345786	1.000	rs11715368	chr3:101336380	G/A	cg12386194	chr3:101231763	SENP7	0.72	8.48	0.49	2.67e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs698833	0.886	rs698766	chr2:44574277	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.69	8.67	0.49	7.3e-16	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs7178572	0.568	rs11858641	chr15:77585820	C/T	cg22256960	chr15:77711686	NA	-0.51	-5.54	-0.34	8.14e-8	Type 2 diabetes;
SARC	trans	rs75804782	0.641	rs3769123	chr2:239349328	C/G	cg01134436	chr17:81009848	B3GNTL1	0.86	6.23	0.38	2.11e-9	Morning vs. evening chronotype;Chronotype;
SARC	trans	rs4295623	0.789	rs12541318	chr8:11594970	G/T	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.23	-0.38	2.11e-9	Morning vs. evening chronotype;
SARC	cis	rs2153535	0.580	rs9406143	chr6:8444583	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.97e-8	Aortic root size;
SARC	cis	rs2120243	0.533	rs62278578	chr3:157055867	C/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.42	5.54	0.34	8.11e-8	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs3771570	0.901	rs6757876	chr2:242245570	T/C	cg21155796	chr2:242212141	HDLBP	0.53	4.98	0.31	1.25e-6	Prostate cancer;
SARC	cis	rs5753618	0.539	rs5997933	chr22:31672752	A/C	cg02404636	chr22:31891804	SFI1	-0.49	-5.3	-0.33	2.67e-7	Colorectal cancer;
SARC	cis	rs7178909	0.866	rs3784388	chr15:90437301	C/T	cg19708238	chr15:90437601	AP3S2	0.62	8.47	0.49	2.73e-15	Common traits (Other);
SARC	cis	rs2273669	0.667	rs10457185	chr6:109322477	G/C	cg05315195	chr6:109294784	ARMC2	-0.6	-5.43	-0.34	1.38e-7	Prostate cancer;
SARC	cis	rs17384381	1.000	rs12135333	chr1:85890494	C/A	cg16011679	chr1:85725395	C1orf52	0.61	5.66	0.35	4.32e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.05	15.8	0.72	1.02e-38	Height;
SARC	cis	rs950169	0.881	rs4842852	chr15:84941961	A/G	cg24253500	chr15:84953950	NA	0.36	5.1	0.32	6.9e-7	Schizophrenia;
SARC	cis	rs2916247	1.000	rs2920465	chr8:92996143	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.56	-5.73	-0.35	3.13e-8	Intelligence (multi-trait analysis);
SARC	cis	rs10791323	0.569	rs2282601	chr11:133712594	C/G	cg14349672	chr11:133703707	NA	-0.38	-5.42	-0.33	1.47e-7	Childhood ear infection;
SARC	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg13770153	chr20:60521292	NA	-0.46	-6.44	-0.39	6.66e-10	Body mass index;
SARC	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg20007245	chr22:24372913	LOC391322	0.64	7.66	0.45	5.03e-13	Liver enzyme levels (gamma-glutamyl transferase);
SARC	trans	rs56279505	0.629	rs17526590	chr4:100269045	G/A	cg21156590	chr1:3420848	MEGF6	-0.83	-6.41	-0.39	8.04e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs834603	0.541	rs1704965	chr7:47470215	C/T	cg23694490	chr7:47445681	TNS3	-0.32	-5.89	-0.36	1.36e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs10512697	0.803	rs13170862	chr5:3582216	A/G	cg19473799	chr5:3511975	NA	0.6	4.93	0.31	1.56e-6	Immune response to smallpox vaccine (IL-6);
SARC	cis	rs17270561	0.666	rs4711099	chr6:25741809	C/G	cg16482183	chr6:26056742	HIST1H1C	0.43	5.08	0.32	7.76e-7	Iron status biomarkers;
SARC	cis	rs4780401	0.933	rs4439779	chr16:11826841	A/G	cg01061890	chr16:11836724	TXNDC11	-0.51	-6.69	-0.4	1.61e-10	Rheumatoid arthritis;
SARC	cis	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg07274523	chr3:49395745	GPX1	0.5	5.71	0.35	3.4e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs12142240	0.698	rs17361950	chr1:46864150	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-5.33	-0.33	2.33e-7	Menopause (age at onset);
SARC	cis	rs10421328	0.821	rs4808976	chr19:19759299	A/T	cg03709012	chr19:19516395	GATAD2A	0.55	5.84	0.36	1.79e-8	Parental longevity (combined parental age at death);
SARC	cis	rs12594515	1.000	rs8038320	chr15:45990267	G/C	cg14863074	chr15:45997064	NA	0.34	5.24	0.32	3.57e-7	Waist circumference;Weight;
SARC	cis	rs8114671	0.562	rs2378292	chr20:33485178	T/C	cg24642439	chr20:33292090	TP53INP2	0.47	5.62	0.35	5.36e-8	Height;
SARC	cis	rs818427	0.681	rs469523	chr5:112294680	A/G	cg07820702	chr5:112228657	REEP5	0.41	4.73	0.3	3.98e-6	Total body bone mineral density;
SARC	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg07061783	chr6:25882402	NA	0.38	4.83	0.3	2.48e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2236918	1.000	rs735943	chr1:242030151	C/T	cg17736920	chr1:242011382	EXO1	-0.75	-10.56	-0.57	1.5e-21	Menopause (age at onset);
SARC	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg05332525	chr7:65337924	VKORC1L1	0.44	4.94	0.31	1.49e-6	Aortic root size;
SARC	cis	rs17253792	0.687	rs10137995	chr14:56173687	A/G	cg01858014	chr14:56050164	KTN1	-0.59	-5.31	-0.33	2.52e-7	Putamen volume;
SARC	cis	rs7940866	0.874	rs1433979	chr11:130871617	G/A	cg12179176	chr11:130786555	SNX19	0.65	8.63	0.49	9.56e-16	Schizophrenia;
SARC	cis	rs748404	0.697	rs504417	chr15:43554226	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	6.69	0.4	1.61e-10	Lung cancer;
SARC	cis	rs798554	1.000	rs798562	chr7:2757938	C/T	cg04166393	chr7:2884313	GNA12	0.58	6.93	0.41	4.19e-11	Height;
SARC	cis	rs7520050	0.966	rs1707335	chr1:46571921	C/T	cg24296786	chr1:45957014	TESK2	0.38	4.83	0.3	2.44e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs734999	0.545	rs7368105	chr1:2556548	C/T	cg18854424	chr1:2615690	NA	0.31	4.91	0.31	1.73e-6	Ulcerative colitis;
SARC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg17178900	chr1:205818956	PM20D1	0.4	5.24	0.32	3.59e-7	Menarche (age at onset);
SARC	trans	rs11227306	0.934	rs7102454	chr11:65594820	C/T	cg17712092	chr4:129076599	LARP1B	-0.51	-6.31	-0.38	1.43e-9	DNA methylation (variation);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg10208649	chr14:96858368	AK7	0.49	6.6	0.4	2.67e-10	Chemerin levels;
SARC	cis	rs9300255	0.602	rs949142	chr12:123634043	T/C	cg00376283	chr12:123451042	ABCB9	0.57	6.67	0.4	1.81e-10	Neutrophil percentage of white cells;
SARC	trans	rs61931739	0.534	rs814669	chr12:34102459	C/T	cg13010199	chr12:38710504	ALG10B	0.67	8.91	0.5	1.51e-16	Morning vs. evening chronotype;
SARC	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg22920501	chr2:26401640	FAM59B	0.61	8.19	0.47	1.71e-14	Gut microbiome composition (summer);
SARC	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	8.96	0.51	1.08e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6840360	0.615	rs4696266	chr4:152463421	A/G	cg22705602	chr4:152727874	NA	-0.42	-6.51	-0.39	4.59e-10	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs13191362	0.935	rs67673890	chr6:163107647	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.76	6.62	0.4	2.46e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs9788682	0.747	rs2656073	chr15:78742276	G/T	cg06917634	chr15:78832804	PSMA4	-0.49	-5.15	-0.32	5.45e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs6545883	0.929	rs12617911	chr2:61740825	A/G	cg15711740	chr2:61764176	XPO1	-0.42	-5.27	-0.33	3.03e-7	Tuberculosis;
SARC	cis	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg11754259	chr11:130184488	ZBTB44	-0.38	-4.84	-0.3	2.35e-6	Breast cancer;Type 2 diabetes;
SARC	cis	rs7020830	0.825	rs66684257	chr9:37199087	G/T	cg14294708	chr9:37120828	ZCCHC7	1.11	20.42	0.8	7.92e-54	Schizophrenia;
SARC	cis	rs9325144	0.560	rs10506127	chr12:39126686	C/G	cg26384229	chr12:38710491	ALG10B	-0.61	-8.27	-0.48	1.06e-14	Morning vs. evening chronotype;
SARC	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg22800045	chr5:56110881	MAP3K1	0.74	7.83	0.46	1.74e-13	Initial pursuit acceleration;
SARC	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg21442419	chr1:2182373	SKI	-0.48	-6.29	-0.38	1.53e-9	Height;
SARC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	19.57	0.79	4.3e-51	Prudent dietary pattern;
SARC	trans	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.55	-7.2	-0.43	8.24e-12	Intelligence (multi-trait analysis);
SARC	cis	rs6963495	0.818	rs73190151	chr7:105152887	C/T	cg19920283	chr7:105172520	RINT1	0.65	5.53	0.34	8.62e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs4481887	1.000	rs4360555	chr1:248468591	G/T	cg13385794	chr1:248469461	NA	0.36	5.59	0.34	6.44e-8	Common traits (Other);
SARC	cis	rs637571	0.522	rs538954	chr11:65756808	A/G	cg26695010	chr11:65641043	EFEMP2	-0.52	-6.81	-0.41	8.06e-11	Eosinophil percentage of white cells;
SARC	cis	rs739401	0.595	rs6578305	chr11:3001120	C/T	cg25174290	chr11:3078921	CARS	0.56	7.93	0.46	9.12e-14	Longevity;
SARC	cis	rs870825	0.581	rs7675106	chr4:185652388	C/G	cg04058563	chr4:185651563	MLF1IP	-0.79	-11.11	-0.59	2.8e-23	Blood protein levels;
SARC	cis	rs6912958	0.781	rs6454632	chr6:88231824	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-5.76	-0.35	2.65e-8	Monocyte percentage of white cells;
SARC	cis	rs9638182	1.000	rs35659126	chr7:72988069	C/T	cg07467649	chr7:72856462	BAZ1B	0.46	4.87	0.3	2.03e-6	Triglycerides;
SARC	cis	rs2732480	0.500	rs11168468	chr12:48612465	C/T	cg24011408	chr12:48396354	COL2A1	0.45	5.26	0.33	3.24e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs7539409	0.651	rs10747407	chr1:84314754	G/A	cg10977910	chr1:84465055	TTLL7	0.65	6.17	0.37	2.94e-9	Alzheimer's disease;
SARC	cis	rs35213789	0.683	rs12531914	chr7:69014936	G/A	cg10619644	chr7:69149951	AUTS2	0.39	5.17	0.32	5.14e-7	Childhood ear infection;
SARC	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.09	12.8	0.64	9e-29	Platelet count;
SARC	cis	rs12682352	0.602	rs635594	chr8:8613387	C/T	cg08975724	chr8:8085496	FLJ10661	-0.39	-4.73	-0.3	3.88e-6	Neuroticism;
SARC	cis	rs7647973	0.593	rs62262730	chr3:49808274	T/G	cg06212747	chr3:49208901	KLHDC8B	-0.59	-5.61	-0.35	5.66e-8	Menarche (age at onset);
SARC	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg18252515	chr7:66147081	NA	-0.45	-4.81	-0.3	2.65e-6	Aortic root size;
SARC	cis	rs10028773	0.515	rs9994651	chr4:120587803	C/T	cg09307838	chr4:120376055	NA	0.71	10.14	0.55	3.06e-20	Educational attainment;
SARC	cis	rs9398803	0.687	rs4626447	chr6:126964675	G/A	cg20229609	chr6:126660872	C6orf173	0.37	5.39	0.33	1.74e-7	Male-pattern baldness;
SARC	cis	rs2730245	0.636	rs2657382	chr7:158650941	G/A	cg17136484	chr7:158649327	WDR60	0.49	5.29	0.33	2.76e-7	Height;
SARC	cis	rs7937682	0.889	rs493865	chr11:111495178	A/C	cg22437258	chr11:111473054	SIK2	0.73	9.88	0.54	1.9e-19	Primary sclerosing cholangitis;
SARC	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg24399712	chr22:39784796	NA	-0.45	-6.03	-0.37	6.31e-9	Intelligence (multi-trait analysis);
SARC	cis	rs3796352	0.881	rs11710394	chr3:53015839	A/G	cg12962167	chr3:53033115	SFMBT1	0.75	5.06	0.31	8.45e-7	Immune reponse to smallpox (secreted IL-2);
SARC	trans	rs1814175	0.791	rs10839468	chr11:49986288	A/G	cg15704280	chr7:45808275	SEPT13	-0.97	-18.54	-0.77	9.52e-48	Height;
SARC	cis	rs11690462	0.963	rs12471849	chr2:26559825	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.39	-5.06	-0.31	8.6e-7	Coronary artery disease;
SARC	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg19729930	chr2:74357872	NA	0.72	10.83	0.58	2.05e-22	Gestational age at birth (maternal effect);
SARC	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.63e-10	Life satisfaction;
SARC	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg09263875	chr16:632152	PIGQ	0.55	8.27	0.48	1.03e-14	Height;
SARC	cis	rs5995756	0.736	rs9611204	chr22:40010383	G/A	cg10455938	chr22:40058150	CACNA1I	-0.48	-6.21	-0.38	2.4e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs796364	0.806	rs11689664	chr2:201099961	A/G	cg23649088	chr2:200775458	C2orf69	-0.67	-5.88	-0.36	1.38e-8	Schizophrenia;
SARC	cis	rs7582180	0.629	rs12620139	chr2:100943446	A/G	cg14675211	chr2:100938903	LONRF2	0.51	7.68	0.45	4.41e-13	Intelligence (multi-trait analysis);
SARC	cis	rs8068544	0.818	rs78333491	chr17:40163138	A/G	cg26502583	chr17:39992600	KLHL10;NT5C3L	-0.87	-6.46	-0.39	6.07e-10	Reticulocyte fraction of red cells;Reticulocyte count;
SARC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg10295955	chr4:187884368	NA	-1.09	-21.04	-0.81	8.81e-56	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg22857025	chr5:266934	NA	-1.06	-11.8	-0.61	1.74e-25	Breast cancer;
SARC	cis	rs6582630	0.519	rs11495699	chr12:38286219	G/T	cg13010199	chr12:38710504	ALG10B	0.82	11.39	0.6	3.58e-24	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs870825	0.929	rs72689258	chr4:185590550	G/C	cg04058563	chr4:185651563	MLF1IP	0.79	8.8	0.5	3.22e-16	Blood protein levels;
SARC	cis	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg08975724	chr8:8085496	FLJ10661	-0.55	-7.25	-0.43	6.17e-12	Mood instability;
SARC	cis	rs6772849	0.708	rs12491942	chr3:128421469	C/G	cg08795948	chr3:128337044	NA	0.51	6.84	0.41	6.87e-11	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs7726839	0.526	rs11960158	chr5:568665	C/T	cg09021430	chr5:549028	NA	-0.46	-6.21	-0.38	2.36e-9	Obesity-related traits;
SARC	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg06634786	chr22:41940651	POLR3H	0.49	6.09	0.37	4.68e-9	Vitiligo;
SARC	cis	rs7662987	0.517	rs1154405	chr4:100008750	G/A	cg12011299	chr4:100065546	ADH4	0.32	5.24	0.32	3.6e-7	Smoking initiation;
SARC	cis	rs72781680	0.716	rs2712065	chr2:23973603	C/T	cg08917208	chr2:24149416	ATAD2B	-0.57	-5.95	-0.36	9.68e-9	Lymphocyte counts;
SARC	cis	rs2204008	0.715	rs12815986	chr12:38343869	G/A	cg26384229	chr12:38710491	ALG10B	0.92	13.39	0.66	1.02e-30	Bladder cancer;
SARC	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg18876405	chr7:65276391	NA	-0.43	-4.72	-0.3	4.07e-6	Aortic root size;
SARC	cis	rs36051895	0.658	rs7875265	chr9:5033882	C/A	cg02405213	chr9:5042618	JAK2	-0.55	-6.56	-0.39	3.44e-10	Pediatric autoimmune diseases;
SARC	cis	rs9790314	1.000	rs28515190	chr3:161028605	G/A	cg04691961	chr3:161091175	C3orf57	-0.79	-11.61	-0.61	7e-25	Morning vs. evening chronotype;
SARC	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg06221963	chr1:154839813	KCNN3	0.47	7.27	0.43	5.54e-12	Prostate cancer;
SARC	cis	rs4423214	1.000	rs12419334	chr11:71139472	T/C	cg05163923	chr11:71159392	DHCR7	0.66	8.71	0.5	5.82e-16	Vitamin D levels;
SARC	cis	rs3750965	0.959	rs2253658	chr11:68856804	C/G	cg06818126	chr11:68850279	TPCN2	-0.41	-4.74	-0.3	3.71e-6	Hair color;
SARC	cis	rs2412459	1.000	rs8023482	chr15:40307095	A/C	cg01081584	chr15:40268610	EIF2AK4	-0.64	-4.79	-0.3	3.01e-6	Response to haloperidol in psychosis;
SARC	cis	rs2307121	0.512	rs2367496	chr5:64712122	T/C	cg11190754	chr5:64858552	CENPK;PPWD1	0.37	4.8	0.3	2.83e-6	Corneal structure;
SARC	cis	rs7520050	0.931	rs11576305	chr1:46460046	C/T	cg24296786	chr1:45957014	TESK2	0.38	4.87	0.3	2.03e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs7246760	0.867	rs56377135	chr19:9820116	C/T	cg16876255	chr19:9731953	ZNF561	0.79	4.88	0.3	1.96e-6	Pursuit maintenance gain;
SARC	cis	rs9815354	1.000	rs9875083	chr3:41775786	T/A	cg03022575	chr3:42003672	ULK4	0.65	5.58	0.34	6.57e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs861020	0.710	rs7516902	chr1:210022179	A/G	cg05527609	chr1:210001259	C1orf107	1.06	12.77	0.64	1.15e-28	Orofacial clefts;
SARC	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg08859206	chr1:53392774	SCP2	0.37	5.37	0.33	1.93e-7	Monocyte count;
SARC	cis	rs35213789	0.881	rs13236841	chr7:69389859	A/G	cg10619644	chr7:69149951	AUTS2	0.49	5.99	0.37	7.85e-9	Childhood ear infection;
SARC	cis	rs9788721	0.836	rs17484524	chr15:78772676	A/G	cg06917634	chr15:78832804	PSMA4	-0.51	-5.28	-0.33	3.01e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	16.42	0.73	9.18e-41	Prudent dietary pattern;
SARC	cis	rs73195822	0.614	rs7309777	chr12:111213964	A/G	cg10860002	chr12:110842031	ANAPC7	0.58	4.98	0.31	1.24e-6	Itch intensity from mosquito bite;
SARC	cis	rs2439831	0.681	rs526450	chr15:43599325	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.74	8.22	0.47	1.45e-14	Lung cancer in ever smokers;
SARC	cis	rs9814567	0.806	rs2888670	chr3:134326684	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.53	-6.89	-0.41	5.13e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs1953600	0.837	rs2573352	chr10:81939813	T/C	cg00277334	chr10:82204260	NA	0.36	5.29	0.33	2.77e-7	Sarcoidosis;
SARC	cis	rs7937682	0.889	rs564086	chr11:111501079	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.93	-15.22	-0.71	8.48e-37	Primary sclerosing cholangitis;
SARC	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg12310025	chr6:25882481	NA	-0.47	-5.79	-0.35	2.26e-8	Intelligence (multi-trait analysis);
SARC	cis	rs1538970	0.924	rs11211108	chr1:45891152	C/T	cg05343316	chr1:45956843	TESK2	0.77	8.82	0.5	2.75e-16	Platelet count;
SARC	cis	rs782590	0.902	rs782595	chr2:55845596	C/G	cg18811423	chr2:55921094	PNPT1	0.68	10.55	0.57	1.65e-21	Metabolic syndrome;
SARC	cis	rs79149102	0.579	rs9673012	chr15:75293737	C/T	cg17294928	chr15:75287854	SCAMP5	-0.99	-8.87	-0.5	1.91e-16	Lung cancer;
SARC	cis	rs17001868	1.000	rs73167022	chr22:40797256	A/T	cg07138101	chr22:40742427	ADSL	0.52	4.8	0.3	2.78e-6	Mammographic density (dense area);
SARC	cis	rs8017423	0.935	rs3742667	chr14:90767856	T/C	cg20276874	chr14:90721474	PSMC1	0.37	4.95	0.31	1.42e-6	Mortality in heart failure;
SARC	cis	rs1322639	0.657	rs12203887	chr6:169572252	C/T	cg04662567	chr6:169592167	NA	-0.53	-5.23	-0.32	3.73e-7	Pulse pressure;
SARC	cis	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.8	-0.46	2.01e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs12545109	0.800	rs1996105	chr8:57413123	A/G	cg19413350	chr8:57351067	NA	-0.43	-4.83	-0.3	2.45e-6	Obesity-related traits;
SARC	cis	rs193541	0.632	rs119449	chr5:122283741	T/G	cg19412675	chr5:122181750	SNX24	0.48	6.09	0.37	4.61e-9	Glucose homeostasis traits;
SARC	cis	rs5753037	0.702	rs9614055	chr22:30187702	C/T	cg01021169	chr22:30184971	ASCC2	-0.43	-5.95	-0.36	1e-8	Type 1 diabetes;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg13503067	chr12:58176460	TSFM	0.48	6.33	0.38	1.24e-9	Chemerin levels;
SARC	cis	rs3008870	1.000	rs4655663	chr1:67430103	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.9	10.96	0.58	8.13e-23	Lymphocyte percentage of white cells;
SARC	cis	rs3820928	0.967	rs4675118	chr2:227773157	C/A	cg05526886	chr2:227700861	RHBDD1	-0.5	-6.11	-0.37	4.2e-9	Pulmonary function;
SARC	cis	rs4711336	1.000	rs764752	chr6:33658066	G/C	cg15676125	chr6:33679581	C6orf125	0.57	6.81	0.41	8.1e-11	Height;
SARC	cis	rs11673344	0.566	rs7254009	chr19:37918609	C/T	cg14683738	chr19:37701593	ZNF585B	0.46	5.48	0.34	1.08e-7	Obesity-related traits;
SARC	cis	rs9436747	0.748	rs1782754	chr1:65993348	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	-0.5	-4.87	-0.3	2.06e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs7659604	0.521	rs13130789	chr4:122690166	G/A	cg19671926	chr4:122722719	EXOSC9	0.66	8.66	0.49	8.14e-16	Type 2 diabetes;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg05898602	chr17:26646107	TMEM97	0.56	7.02	0.42	2.39e-11	Fibrinogen levels;
SARC	trans	rs11098499	0.780	rs7680914	chr4:120563053	A/G	cg25214090	chr10:38739885	LOC399744	0.52	6.69	0.4	1.68e-10	Corneal astigmatism;
SARC	cis	rs763121	0.752	rs5757222	chr22:39060473	C/T	cg21395723	chr22:39101663	GTPBP1	0.58	6.43	0.39	7.23e-10	Menopause (age at onset);
SARC	cis	rs1371867	0.875	rs7830342	chr8:101327738	T/A	cg11906718	chr8:101322791	RNF19A	0.66	8.62	0.49	1.01e-15	Atrioventricular conduction;
SARC	cis	rs34172651	0.917	rs11646987	chr16:24832408	G/T	cg00152838	chr16:24741724	TNRC6A	-0.41	-5.08	-0.32	7.69e-7	Intelligence (multi-trait analysis);
SARC	trans	rs9325144	0.555	rs4882284	chr12:38710459	C/T	cg23762105	chr12:34175262	ALG10	0.53	6.96	0.41	3.43e-11	Morning vs. evening chronotype;
SARC	cis	rs6696846	0.740	rs12125465	chr1:205074854	C/A	cg00857998	chr1:205179979	DSTYK	0.49	6.29	0.38	1.54e-9	Red blood cell count;
SARC	cis	rs7666738	0.924	rs13124368	chr4:99039615	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.91	0.5	1.47e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs765787	0.556	rs2413778	chr15:45539397	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.67e-7	Uric acid levels;
SARC	cis	rs1981331	0.609	rs3088287	chr21:48079669	G/A	cg17243659	chr21:48055224	PRMT2	1.09	6.13	0.37	3.63e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;
SARC	trans	rs11098499	0.820	rs13128602	chr4:120459366	C/T	cg25214090	chr10:38739885	LOC399744	-0.54	-6.8	-0.41	8.62e-11	Corneal astigmatism;
SARC	cis	rs6570726	0.791	rs9322029	chr6:145906683	A/G	cg23711669	chr6:146136114	FBXO30	0.85	14.24	0.68	1.55e-33	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs72781680	0.898	rs72782126	chr2:24039901	A/C	cg08917208	chr2:24149416	ATAD2B	0.78	7.32	0.43	3.96e-12	Lymphocyte counts;
SARC	cis	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg00409905	chr10:38381863	ZNF37A	0.53	7.45	0.44	1.86e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg07414643	chr4:187882934	NA	0.46	6.66	0.4	1.92e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg24101359	chr6:42928495	GNMT	0.43	5.91	0.36	1.2e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs6693567	0.545	rs35705743	chr1:150451832	G/A	cg09579323	chr1:150459698	TARS2	0.43	5.52	0.34	9.1e-8	Migraine;
SARC	cis	rs921968	0.643	rs10187066	chr2:219514759	A/G	cg02176678	chr2:219576539	TTLL4	0.37	5.55	0.34	7.87e-8	Mean corpuscular hemoglobin concentration;
SARC	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg13206674	chr6:150067644	NUP43	0.41	5.19	0.32	4.51e-7	Lung cancer;
SARC	cis	rs595982	0.559	rs73061643	chr19:49368151	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.65	-7.34	-0.43	3.65e-12	Red cell distribution width;
SARC	cis	rs6087771	0.714	rs6058259	chr20:30235302	A/G	cg13852791	chr20:30311386	BCL2L1	0.8	9.61	0.53	1.22e-18	Subcortical brain region volumes;Putamen volume;
SARC	trans	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.1	-0.42	1.51e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.45	5.42	0.33	1.51e-7	Calcium levels;
SARC	cis	rs644799	0.603	rs1255180	chr11:95472134	G/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	6.2	0.38	2.59e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg18252515	chr7:66147081	NA	0.6	6.3	0.38	1.44e-9	Aortic root size;
SARC	cis	rs1707322	0.721	rs11211158	chr1:46132850	C/G	cg03146154	chr1:46216737	IPP	0.52	6.32	0.38	1.33e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4808199	1.000	rs12977524	chr19:19568244	A/G	cg03709012	chr19:19516395	GATAD2A	1.2	13.19	0.65	4.79e-30	Nonalcoholic fatty liver disease;
SARC	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg06618935	chr21:46677482	NA	-0.41	-5.37	-0.33	1.92e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs17384381	0.953	rs11161597	chr1:85784936	G/A	cg16011679	chr1:85725395	C1orf52	0.62	5.31	0.33	2.54e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7178572	1.000	rs8034133	chr15:77763712	C/G	cg22256960	chr15:77711686	NA	-0.56	-6.59	-0.4	2.94e-10	Type 2 diabetes;
SARC	cis	rs17600642	0.622	rs17600495	chr10:72457578	T/C	cg19779893	chr10:72451501	ADAMTS14	-0.39	-6.24	-0.38	2.06e-9	Bipolar disorder;
SARC	trans	rs9329221	0.621	rs522483	chr8:9812969	C/G	cg21775007	chr8:11205619	TDH	-0.53	-6.78	-0.41	9.53e-11	Neuroticism;
SARC	cis	rs9733	0.818	rs7520022	chr1:150659173	C/G	cg17724175	chr1:150552817	MCL1	-0.36	-4.8	-0.3	2.8e-6	Tonsillectomy;
SARC	cis	rs17270561	0.636	rs9393671	chr6:25789189	G/C	cg17691542	chr6:26056736	HIST1H1C	-0.45	-5.49	-0.34	1.05e-7	Iron status biomarkers;
SARC	cis	rs6570726	0.791	rs7765675	chr6:145915077	A/C	cg23711669	chr6:146136114	FBXO30	0.88	14.58	0.69	1.2e-34	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7681440	0.606	rs2583969	chr4:90746133	T/C	cg06632027	chr4:90757378	SNCA	-0.44	-5.44	-0.34	1.36e-7	Dementia with Lewy bodies;
SARC	cis	rs4144743	1.000	rs35704663	chr17:45327321	T/G	cg18085866	chr17:45331354	ITGB3	-0.73	-7.41	-0.44	2.29e-12	Body mass index;
SARC	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg20102877	chr2:27665638	KRTCAP3	-0.36	-5.04	-0.31	9.55e-7	Total body bone mineral density;
SARC	cis	rs427394	0.659	rs274674	chr5:6755460	C/T	cg10857441	chr5:6722123	POLS	-0.34	-4.89	-0.3	1.9e-6	Menopause (age at onset);
SARC	cis	rs2882877	0.648	rs11682165	chr2:190401523	T/C	cg21926118	chr2:190387206	NA	-0.43	-5.36	-0.33	2.03e-7	Mean corpuscular hemoglobin concentration;
SARC	trans	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.1	-0.42	1.51e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg11987759	chr7:65425863	GUSB	0.47	5.77	0.35	2.51e-8	Aortic root size;
SARC	cis	rs1008375	0.966	rs10939735	chr4:17578891	A/G	cg27347728	chr4:17578864	LAP3	0.53	6.47	0.39	5.62e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2732480	0.577	rs2634684	chr12:48730875	C/T	cg24011408	chr12:48396354	COL2A1	-0.42	-4.9	-0.31	1.79e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs9790314	0.612	rs9875200	chr3:160733708	A/G	cg04691961	chr3:161091175	C3orf57	-0.58	-8.03	-0.47	4.71e-14	Morning vs. evening chronotype;
SARC	cis	rs7769051	0.522	rs3736725	chr6:133095172	A/G	cg22852734	chr6:133119734	C6orf192	1.02	7.32	0.43	4.12e-12	Type 2 diabetes nephropathy;
SARC	cis	rs11098699	0.784	rs11947137	chr4:124205966	C/G	cg09941581	chr4:124220074	SPATA5	0.39	4.73	0.3	3.98e-6	Mosquito bite size;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg19817544	chr15:37109747	CSNK1A1P	0.5	6.98	0.42	3.09e-11	Thyroid stimulating hormone;
SARC	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg13880726	chr7:1868755	MAD1L1	0.43	4.97	0.31	1.3e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg13206674	chr6:150067644	NUP43	0.48	6.36	0.38	1.07e-9	Lung cancer;
SARC	cis	rs918629	0.761	rs3777175	chr5:95277555	A/G	cg16656078	chr5:95278638	ELL2	-0.69	-8.09	-0.47	3.22e-14	IgG glycosylation;
SARC	cis	rs7945718	0.967	rs7930077	chr11:12778769	C/T	ch.11.340609R	chr11:12831013	TEAD1	-0.37	-4.9	-0.31	1.79e-6	Educational attainment (years of education);
SARC	cis	rs9660992	0.547	rs12143121	chr1:205199142	A/G	cg00857998	chr1:205179979	DSTYK	0.51	6.31	0.38	1.39e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg02462569	chr6:150064036	NUP43	-0.37	-4.83	-0.3	2.44e-6	Lung cancer;
SARC	cis	rs9467711	0.538	rs9467626	chr6:25873746	C/A	cg21479132	chr6:26055353	NA	0.77	4.75	0.3	3.5e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9309473	0.904	rs79145598	chr2:73821382	T/A	cg20560298	chr2:73613845	ALMS1	-0.47	-5.64	-0.35	4.9e-8	Metabolite levels;
SARC	cis	rs1008375	0.931	rs1860592	chr4:17577028	C/G	cg27347728	chr4:17578864	LAP3	0.49	6.06	0.37	5.46e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs11098499	0.909	rs79704848	chr4:120309351	T/A	cg09160332	chr4:120329925	NA	-0.33	-4.77	-0.3	3.27e-6	Corneal astigmatism;
SARC	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg04944784	chr2:26401820	FAM59B	0.42	5.08	0.32	7.86e-7	Gut microbiome composition (summer);
SARC	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.37	-5.08	-0.32	7.83e-7	Total body bone mineral density;
SARC	cis	rs3126085	0.935	rs6666382	chr1:152217226	C/G	cg26876637	chr1:152193138	HRNR	-0.49	-5.59	-0.34	6.23e-8	Atopic dermatitis;
SARC	cis	rs950169	0.881	rs34591918	chr15:84950833	C/T	cg17507749	chr15:85114479	UBE2QP1	0.77	9.42	0.53	4.67e-18	Schizophrenia;
SARC	cis	rs7005380	0.581	rs869341	chr8:120932805	G/C	cg21744203	chr8:120868354	DSCC1	0.46	5.29	0.33	2.79e-7	Interstitial lung disease;
SARC	cis	rs6912958	0.781	rs1051148	chr6:88221892	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.52	-7.03	-0.42	2.22e-11	Monocyte percentage of white cells;
SARC	cis	rs2522056	0.808	rs7704457	chr5:131744790	C/T	cg24060327	chr5:131705240	SLC22A5	-0.61	-6.29	-0.38	1.52e-9	Lymphocyte counts;Fibrinogen;
SARC	cis	rs9902453	0.967	rs4533341	chr17:28495672	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	6.66	0.4	1.91e-10	Coffee consumption (cups per day);
SARC	cis	rs5753618	0.583	rs8141150	chr22:31800336	C/T	cg02404636	chr22:31891804	SFI1	0.5	5.33	0.33	2.29e-7	Colorectal cancer;
SARC	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg16606324	chr3:10149918	C3orf24	0.46	4.8	0.3	2.79e-6	Alzheimer's disease;
SARC	cis	rs4642101	0.824	rs9852222	chr3:12848491	G/T	cg05775895	chr3:12838266	CAND2	0.73	11.9	0.61	7.91e-26	QRS complex (12-leadsum);
SARC	cis	rs826838	0.967	rs1352123	chr12:39130992	T/C	cg13010199	chr12:38710504	ALG10B	-0.63	-8.88	-0.5	1.87e-16	Heart rate;
SARC	cis	rs6582630	0.638	rs4882309	chr12:38448595	A/G	cg26384229	chr12:38710491	ALG10B	-0.55	-6.91	-0.41	4.57e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs61409971	0.920	rs10131276	chr14:93015364	C/T	cg04718702	chr14:93020195	RIN3	-0.37	-4.88	-0.3	1.96e-6	Lymphocyte percentage of white cells;
SARC	cis	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg24110177	chr3:50126178	RBM5	0.38	4.83	0.3	2.42e-6	Intelligence (multi-trait analysis);
SARC	trans	rs17685	0.712	rs7778735	chr7:75770237	T/C	cg19862616	chr7:65841803	NCRNA00174	0.62	7.72	0.45	3.44e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs3008870	1.000	rs3008856	chr1:67387901	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.93	11.49	0.6	1.62e-24	Lymphocyte percentage of white cells;
SARC	cis	rs74417235	0.684	rs7723312	chr5:154053249	A/G	cg08893839	chr5:154027129	NA	-0.51	-4.73	-0.3	3.81e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
SARC	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg19223190	chr17:80058835	NA	0.45	6.35	0.38	1.13e-9	Life satisfaction;
SARC	cis	rs7582180	0.790	rs13020451	chr2:100927131	T/G	cg14675211	chr2:100938903	LONRF2	0.51	7.37	0.44	2.87e-12	Intelligence (multi-trait analysis);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg05335107	chr2:109400084	RANBP2	0.51	6.79	0.41	9.35e-11	Thyroid stimulating hormone;
SARC	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg13206674	chr6:150067644	NUP43	0.43	5.64	0.35	4.84e-8	Lung cancer;
SARC	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg18404041	chr3:52824283	ITIH1	-0.46	-7.02	-0.42	2.38e-11	Bipolar disorder;
SARC	cis	rs7940866	0.874	rs10894306	chr11:130873882	A/C	cg12179176	chr11:130786555	SNX19	0.65	8.97	0.51	1.02e-16	Schizophrenia;
SARC	cis	rs6089584	0.606	rs7270666	chr20:60577598	C/T	cg23262073	chr20:60523788	NA	-0.36	-5.6	-0.34	5.91e-8	Body mass index;
SARC	cis	rs9660992	0.539	rs113699533	chr1:205122895	G/A	cg00857998	chr1:205179979	DSTYK	0.52	6.74	0.4	1.22e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs13401104	0.680	rs11894606	chr2:237114834	T/G	cg19324714	chr2:237145437	ASB18	0.56	5.8	0.36	2.16e-8	Educational attainment;
SARC	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg19223190	chr17:80058835	NA	0.39	5.51	0.34	9.28e-8	Life satisfaction;
SARC	cis	rs3754214	0.836	rs12023277	chr1:150466737	A/G	cg09579323	chr1:150459698	TARS2	0.43	5.52	0.34	9.03e-8	Cerebrospinal fluid biomarker levels;
SARC	cis	rs4076764	0.958	rs10917748	chr1:163400377	T/C	cg06092702	chr1:163392909	NA	-0.29	-4.74	-0.3	3.68e-6	Motion sickness;
SARC	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg12463550	chr7:65579703	CRCP	-0.46	-5.29	-0.33	2.78e-7	Aortic root size;
SARC	cis	rs897080	0.552	rs1067377	chr2:44648239	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.69	0.4	1.61e-10	Height;
SARC	cis	rs1348850	0.526	rs4243389	chr2:178379783	G/C	cg23306229	chr2:178417860	TTC30B	0.76	7.37	0.43	3e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7223966	1.000	rs8078862	chr17:61854068	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.52	-5.44	-0.34	1.35e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg13939156	chr17:80058883	NA	-0.4	-6.03	-0.37	6.45e-9	Life satisfaction;
SARC	cis	rs8014204	0.804	rs7154845	chr14:75247746	A/G	cg06637938	chr14:75390232	RPS6KL1	0.72	10.47	0.57	2.78e-21	Caffeine consumption;
SARC	trans	rs3857536	0.706	rs1418854	chr6:66893284	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.6	-7.1	-0.42	1.51e-11	Blood trace element (Cu levels);
SARC	cis	rs3892630	0.824	rs35654350	chr19:33223766	T/C	cg22980127	chr19:33182716	NUDT19	1.01	8.55	0.49	1.62e-15	Red blood cell traits;
SARC	trans	rs61931739	0.500	rs7977194	chr12:34408459	G/A	cg13010199	chr12:38710504	ALG10B	0.82	11.43	0.6	2.62e-24	Morning vs. evening chronotype;
SARC	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg11890956	chr21:40555474	PSMG1	1.18	19.61	0.79	3.1e-51	Cognitive function;
SARC	cis	rs1109861	0.593	rs658681	chr10:11218580	A/G	cg17290701	chr10:11059714	CUGBP2	0.38	4.89	0.31	1.88e-6	Urinary albumin-to-creatinine ratio;
SARC	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.46	-5.72	-0.35	3.33e-8	Gut microbiome composition (summer);
SARC	cis	rs796364	0.789	rs176008	chr2:200814720	A/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.8	7.36	0.43	3.15e-12	Schizophrenia;
SARC	cis	rs6430585	0.528	rs75524146	chr2:136725459	C/T	cg07169764	chr2:136633963	MCM6	1.02	13.66	0.67	1.37e-31	Corneal structure;
SARC	cis	rs6714710	0.603	rs7583868	chr2:98588372	C/A	cg26665480	chr2:98280029	ACTR1B	0.49	6.48	0.39	5.32e-10	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg08280861	chr8:58055591	NA	0.68	5.69	0.35	3.75e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.593	rs74760806	chr8:58024785	C/T	cg11062466	chr8:58055876	NA	0.58	5.5	0.34	1e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9300255	0.508	rs1716176	chr12:123655467	T/G	cg00376283	chr12:123451042	ABCB9	0.6	6.79	0.41	9.43e-11	Neutrophil percentage of white cells;
SARC	cis	rs9911578	1.000	rs9915935	chr17:56843048	A/G	cg12560992	chr17:57184187	TRIM37	0.88	12.23	0.63	6.65e-27	Intelligence (multi-trait analysis);
SARC	cis	rs11648796	0.757	rs6600231	chr16:766485	A/G	cg07343612	chr16:622815	PIGQ	0.41	4.81	0.3	2.71e-6	Height;
SARC	cis	rs12220238	1.000	rs10824103	chr10:75949415	A/T	cg19889307	chr10:75911429	ADK;AP3M1	0.57	5.72	0.35	3.27e-8	Soluble interleukin-2 receptor subunit alpha;
SARC	cis	rs35213789	0.887	rs608796	chr7:69190197	C/T	cg10619644	chr7:69149951	AUTS2	-0.44	-5.89	-0.36	1.34e-8	Childhood ear infection;
SARC	cis	rs17376456	0.825	rs10036024	chr5:93074804	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.72	6.12	0.37	3.83e-9	Diabetic retinopathy;
SARC	cis	rs2228479	0.702	rs78331410	chr16:89917775	C/T	cg06558623	chr16:89946397	TCF25	0.93	6.61	0.4	2.59e-10	Skin colour saturation;
SARC	cis	rs995000	0.931	rs1168018	chr1:63001120	A/C	cg06896770	chr1:63153194	DOCK7	-0.9	-13.49	-0.66	5.08e-31	Triglyceride levels;
SARC	cis	rs7937682	0.737	rs542275	chr11:111431614	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.69	-9.71	-0.54	6e-19	Primary sclerosing cholangitis;
SARC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	11.32	0.6	5.71e-24	Platelet count;
SARC	trans	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg17830980	chr10:43048298	ZNF37B	-0.49	-6.43	-0.39	7.23e-10	Extrinsic epigenetic age acceleration;
SARC	cis	rs7264396	0.747	rs2425112	chr20:34319775	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-8.44	-0.48	3.47e-15	Total cholesterol levels;
SARC	cis	rs7044106	0.762	rs10739570	chr9:123381222	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	5.39	0.33	1.7e-7	Hip circumference adjusted for BMI;
SARC	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.98	10.69	0.57	5.78e-22	Platelet count;
SARC	cis	rs7714584	1.000	rs4579248	chr5:150268151	C/T	cg22134413	chr5:150180641	NA	0.93	7.27	0.43	5.4e-12	Crohn's disease;
SARC	cis	rs13191362	0.810	rs66921603	chr6:162996982	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.57	5.38	0.33	1.85e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	trans	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg16829450	chr12:96184020	NTN4	-0.67	-6.32	-0.38	1.31e-9	Cutaneous psoriasis;
SARC	cis	rs10875746	0.904	rs11168422	chr12:48519505	T/G	cg26205652	chr12:48591994	NA	0.55	6.03	0.37	6.27e-9	Longevity (90 years and older);
SARC	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg00933542	chr6:150070202	PCMT1	0.3	5.07	0.32	8.07e-7	Lung cancer;
SARC	cis	rs858239	0.539	rs6949363	chr7:23192394	A/G	cg23682824	chr7:23144976	KLHL7	0.73	9.65	0.53	9.37e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs8027181	0.839	rs2304597	chr15:73052431	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	0.44	5.75	0.35	2.73e-8	Triglyceride levels;
SARC	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg19223190	chr17:80058835	NA	0.44	6.19	0.38	2.67e-9	Life satisfaction;
SARC	cis	rs74181299	0.927	rs2723064	chr2:65279805	T/C	cg20592124	chr2:65290738	CEP68	0.48	7.03	0.42	2.25e-11	Pulse pressure;
SARC	cis	rs12545109	1.000	rs2217957	chr8:57313360	T/C	cg21220214	chr8:57350948	NA	-0.41	-4.76	-0.3	3.33e-6	Obesity-related traits;
SARC	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg17971929	chr21:40555470	PSMG1	0.87	11.42	0.6	2.79e-24	Cognitive function;
SARC	cis	rs4453791	0.505	rs13099628	chr3:38927854	T/G	cg15678707	chr3:39149194	GORASP1;TTC21A	0.47	5.06	0.31	8.37e-7	Social communication problems;
SARC	cis	rs734999	0.588	rs2843401	chr1:2528133	T/C	cg00980319	chr1:2560884	MMEL1	0.35	4.95	0.31	1.44e-6	Ulcerative colitis;
SARC	cis	rs7113850	0.541	rs7129631	chr11:24208560	A/G	ch.11.24196551F	chr11:24239977	NA	0.77	6.04	0.37	5.98e-9	Bone fracture in osteoporosis;
SARC	cis	rs644799	0.965	rs602512	chr11:95561682	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	14.87	0.7	1.3e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs17376456	0.825	rs56108532	chr5:93276342	C/T	cg21475434	chr5:93447410	FAM172A	0.86	7.72	0.45	3.37e-13	Diabetic retinopathy;
SARC	trans	rs116095464	0.558	rs55833259	chr5:286728	G/A	cg00938859	chr5:1591904	SDHAP3	0.77	6.36	0.38	1.08e-9	Breast cancer;
SARC	cis	rs9457247	1.000	rs389956	chr6:167407254	T/G	cg23791538	chr6:167370224	RNASET2	-0.62	-8.59	-0.49	1.27e-15	Crohn's disease;
SARC	cis	rs7819412	0.740	rs11250119	chr8:11037034	C/T	cg03403963	chr8:11986501	LOC392196;FAM66D	-0.33	-4.8	-0.3	2.9e-6	Triglycerides;
SARC	cis	rs1559088	0.600	rs10421769	chr19:33605312	T/C	cg27124370	chr19:33622961	WDR88	0.5	6.61	0.4	2.54e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs3796352	1.000	rs3796352	chr3:52913279	C/T	cg27565382	chr3:53032988	SFMBT1	1.0	7.01	0.42	2.57e-11	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs8014204	0.816	rs28426374	chr14:75346740	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.56	-7.99	-0.46	6.39e-14	Caffeine consumption;
SARC	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg12463550	chr7:65579703	CRCP	0.49	5.82	0.36	1.91e-8	Aortic root size;
SARC	cis	rs4453791	0.505	rs11924818	chr3:38922323	G/A	cg26331595	chr3:39149181	GORASP1;TTC21A	0.46	4.91	0.31	1.7e-6	Social communication problems;
SARC	cis	rs2075371	0.734	rs13225086	chr7:134011411	C/T	cg20476274	chr7:133979776	SLC35B4	0.45	5.56	0.34	7.53e-8	Mean platelet volume;
SARC	cis	rs4417855	0.761	rs1523468	chr3:187416253	C/T	cg08969912	chr3:187456781	BCL6	-0.4	-4.78	-0.3	3.11e-6	Granulocyte percentage of myeloid white cells;
SARC	cis	rs3796352	1.000	rs71299622	chr3:52917038	G/A	cg27565382	chr3:53032988	SFMBT1	1.03	7.43	0.44	2.04e-12	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs721399	0.962	rs2410558	chr8:18263484	T/C	cg18736775	chr8:18248649	NAT2	0.4	5.09	0.32	7.26e-7	Blood metabolite levels;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg12675942	chr10:71160999	HK1	0.47	6.46	0.39	5.89e-10	Thyroid stimulating hormone;
SARC	cis	rs6088590	1.000	rs10048849	chr20:33419680	C/T	cg06115741	chr20:33292138	TP53INP2	0.54	6.51	0.39	4.68e-10	Coronary artery disease;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg24980700	chr20:30410739	MYLK2	0.48	6.25	0.38	1.91e-9	Chemerin levels;
SARC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.48	5.64	0.35	5.01e-8	Renal function-related traits (BUN);
SARC	cis	rs9486715	0.809	rs9486467	chr6:96971803	C/T	cg18709589	chr6:96969512	KIAA0776	0.62	7.79	0.45	2.18e-13	Headache;
SARC	cis	rs9399137	0.507	rs12663810	chr6:135289782	G/C	cg24558204	chr6:135376177	HBS1L	0.61	7.91	0.46	1.04e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs9397240	0.789	rs9397801	chr6:155614192	C/T	cg07943832	chr6:155568918	TIAM2	-0.58	-5.53	-0.34	8.59e-8	Life satisfaction;
SARC	cis	rs7186908	0.711	rs9923344	chr16:72190653	T/C	cg16558253	chr16:72132732	DHX38	-0.52	-6.37	-0.39	9.74e-10	Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs10744422	1.000	rs897385	chr12:123341297	A/G	cg25930673	chr12:123319894	HIP1R	-0.64	-4.8	-0.3	2.84e-6	Schizophrenia;
SARC	cis	rs17057640	0.892	rs1041915	chr6:130014253	C/T	cg08633085	chr6:130031345	ARHGAP18	0.67	5.43	0.34	1.42e-7	Cognitive function;
SARC	cis	rs854765	0.619	rs6502636	chr17:17983817	A/T	cg05444541	chr17:17804740	TOM1L2	-0.33	-5.43	-0.34	1.4e-7	Total body bone mineral density;
SARC	cis	rs1707322	0.647	rs6686944	chr1:46156308	G/T	cg06784218	chr1:46089804	CCDC17	0.36	6.2	0.38	2.59e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs9388451	0.872	rs2008027	chr6:126052359	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.57	-7.31	-0.43	4.26e-12	Brugada syndrome;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16740166	chr10:12110759	DHTKD1	-0.52	-6.34	-0.38	1.2e-9	Fibrinogen levels;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg14256840	chr7:64197047	NA	-0.7	-6.56	-0.39	3.51e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.44	5.41	0.33	1.54e-7	Tonsillectomy;
SARC	trans	rs9329221	0.905	rs28712068	chr8:10251145	G/C	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.58	-0.4	3.06e-10	Neuroticism;
SARC	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg12463550	chr7:65579703	CRCP	-0.73	-5.54	-0.34	8.18e-8	Diabetic kidney disease;
SARC	cis	rs11608355	0.515	rs7136048	chr12:109903926	A/G	cg05360138	chr12:110035743	NA	0.92	9.68	0.54	7.88e-19	Neuroticism;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg01154392	chr12:48167362	SLC48A1	0.52	6.31	0.38	1.36e-9	Breast cancer;
SARC	cis	rs7223966	1.000	rs7223966	chr17:61893398	G/A	cg26338869	chr17:61819248	STRADA	0.47	5.09	0.32	7.5e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs950027	0.620	rs1153857	chr15:45659095	G/T	cg15395560	chr15:45543142	SLC28A2	-0.27	-5.26	-0.33	3.29e-7	Response to fenofibrate (adiponectin levels);
SARC	cis	rs1488864	0.536	rs1159431	chr11:6339984	A/G	cg18450930	chr11:5444223	OR51Q1	0.48	5.31	0.33	2.58e-7	Smooth-surface caries;
SARC	cis	rs9303401	0.580	rs12603808	chr17:56578508	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.04	10.97	0.58	7.47e-23	Cognitive test performance;
SARC	cis	rs4555082	0.834	rs2735826	chr14:105710866	G/A	cg13114125	chr14:105738426	BRF1	-0.8	-11.97	-0.62	4.76e-26	Mean platelet volume;Platelet distribution width;
SARC	cis	rs1008375	1.000	rs56308330	chr4:17643050	G/A	cg02297831	chr4:17616191	MED28	0.51	6.49	0.39	5.19e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4481887	0.720	rs4543835	chr1:248468608	A/T	cg01631408	chr1:248437212	OR2T33	-0.41	-5.18	-0.32	4.79e-7	Common traits (Other);
SARC	trans	rs7927370	1.000	rs7112787	chr11:55342155	C/T	cg07162727	chr16:4848039	ROGDI	0.84	6.28	0.38	1.67e-9	Systemic lupus erythematosus;
SARC	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.44	-5.7	-0.35	3.57e-8	Intelligence (multi-trait analysis);
SARC	cis	rs17666538	1.000	rs57255985	chr8:574131	C/T	cg02524346	chr8:600233	NA	-0.88	-6.26	-0.38	1.85e-9	IgG glycosylation;
SARC	cis	rs4642101	0.793	rs13320486	chr3:12822069	C/A	cg12400702	chr3:12838781	CAND2	-0.26	-5.1	-0.32	7.04e-7	QRS complex (12-leadsum);
SARC	cis	rs4595586	0.545	rs4438082	chr12:39363870	C/T	cg26384229	chr12:38710491	ALG10B	0.51	6.25	0.38	1.9e-9	Morning vs. evening chronotype;
SARC	cis	rs875971	0.545	rs316324	chr7:65610614	A/G	cg11764359	chr7:65958608	NA	-0.65	-6.42	-0.39	7.5e-10	Aortic root size;
SARC	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.61	7.29	0.43	4.66e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2933343	1.000	rs1683776	chr3:128622760	G/T	cg25356066	chr3:128598488	ACAD9	0.59	6.6	0.4	2.79e-10	IgG glycosylation;
SARC	cis	rs11997175	0.587	rs72612118	chr8:33695225	T/C	ch.8.33884649F	chr8:33765107	NA	0.63	8.6	0.49	1.21e-15	Body mass index;
SARC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg26996656	chr16:880371	NA	0.33	6.41	0.39	7.82e-10	HDL cholesterol;
SARC	cis	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.42	-5.16	-0.32	5.32e-7	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs892961	0.867	rs6501955	chr17:75414443	A/G	cg05865280	chr17:75406074	SEPT9	0.56	8.25	0.48	1.18e-14	Airflow obstruction;
SARC	cis	rs7044106	0.791	rs2900177	chr9:123497645	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	6.71	0.4	1.46e-10	Hip circumference adjusted for BMI;
SARC	cis	rs7412746	0.658	rs11589458	chr1:150792616	A/G	cg15448220	chr1:150897856	SETDB1	0.48	6.3	0.38	1.5e-9	Melanoma;
SARC	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg16606324	chr3:10149918	C3orf24	0.48	5.04	0.31	9.53e-7	Alzheimer's disease;
SARC	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.41	-5.15	-0.32	5.48e-7	Lymphocyte counts;
SARC	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.41	-5.32	-0.33	2.42e-7	Intelligence (multi-trait analysis);
SARC	cis	rs55962025	0.883	rs61792530	chr4:3145866	T/C	cg06533319	chr4:3265114	C4orf44	0.32	4.84	0.3	2.4e-6	Parental longevity (mother's age at death);
SARC	cis	rs738322	0.553	rs28718653	chr22:38570698	C/A	cg25457927	chr22:38595422	NA	-0.25	-4.78	-0.3	3.11e-6	Cutaneous nevi;
SARC	cis	rs453301	0.686	rs6601281	chr8:8911004	A/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.14	-0.42	1.19e-11	Joint mobility (Beighton score);
SARC	cis	rs4803468	0.763	rs17318596	chr19:41937095	A/G	cg09537434	chr19:41945824	ATP5SL	-0.86	-13.47	-0.66	5.86e-31	Height;
SARC	cis	rs2948294	0.588	rs7011221	chr8:8114246	C/T	cg08975724	chr8:8085496	FLJ10661	0.53	6.01	0.37	6.98e-9	Red cell distribution width;
SARC	cis	rs17741873	0.779	rs17631000	chr10:75602500	C/T	cg07699608	chr10:75541558	CHCHD1	-0.51	-4.95	-0.31	1.46e-6	Paclitaxel disposition in epithelial ovarian cancer;
SARC	cis	rs9359856	0.564	rs72913921	chr6:90328692	A/T	cg13799429	chr6:90582589	CASP8AP2	-0.66	-5.17	-0.32	4.94e-7	Bipolar disorder;
SARC	cis	rs55962025	0.846	rs16843836	chr4:3113337	G/A	cg06533319	chr4:3265114	C4orf44	0.36	5.4	0.33	1.68e-7	Parental longevity (mother's age at death);
SARC	cis	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg14343924	chr8:8086146	FLJ10661	0.42	5.12	0.32	6.35e-7	Mood instability;
SARC	cis	rs55883249	1.000	rs62119428	chr2:9743332	T/C	cg23886495	chr2:9695866	ADAM17	0.66	6.73	0.4	1.33e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs9325144	0.650	rs6582624	chr12:38733475	A/T	cg13010199	chr12:38710504	ALG10B	-0.55	-6.84	-0.41	6.73e-11	Morning vs. evening chronotype;
SARC	trans	rs1411916	0.841	rs56084216	chr9:80973960	G/A	cg22801675	chr5:175971121	NA	-0.8	-6.23	-0.38	2.15e-9	Visceral fat;
SARC	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.5	5.66	0.35	4.43e-8	Renal function-related traits (BUN);
SARC	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.75	10.75	0.58	3.85e-22	Personality dimensions;
SARC	cis	rs747650	0.926	rs11039119	chr11:47201924	G/A	cg03339077	chr11:47165057	C11orf49	0.44	5.92	0.36	1.13e-8	Acne (severe);
SARC	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.38	6.22	0.38	2.27e-9	Schizophrenia;
SARC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg23042612	chr1:8613264	RERE	0.45	6.23	0.38	2.14e-9	Colonoscopy-negative controls vs population controls;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg02362017	chr9:131154347	NA	0.53	7.33	0.43	3.67e-12	Thyroid stimulating hormone;
SARC	cis	rs11625487	0.522	rs11845884	chr14:77966268	C/T	cg16049707	chr14:77965284	ISM2	0.55	7.29	0.43	4.84e-12	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
SARC	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg21171335	chr12:122356390	WDR66	0.47	7.55	0.44	9.81e-13	Mean corpuscular volume;
SARC	cis	rs9911578	1.000	rs1631237	chr17:56734695	A/G	cg12560992	chr17:57184187	TRIM37	0.83	11.32	0.6	5.91e-24	Intelligence (multi-trait analysis);
SARC	cis	rs6570726	0.755	rs451699	chr6:145830594	C/G	cg23711669	chr6:146136114	FBXO30	0.87	14.58	0.69	1.18e-34	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7566780	0.656	rs4452143	chr2:16679171	G/A	cg09580478	chr2:16689509	NA	0.46	6.14	0.37	3.55e-9	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs6714710	0.603	rs55776387	chr2:98405034	T/C	cg26665480	chr2:98280029	ACTR1B	0.48	6.32	0.38	1.3e-9	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs2236918	1.000	rs2797605	chr1:242025245	A/T	cg17736920	chr1:242011382	EXO1	0.77	10.64	0.57	8.4e-22	Menopause (age at onset);
SARC	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.78	8.8	0.5	3.2e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg22903471	chr2:27725779	GCKR	-0.51	-7.68	-0.45	4.26e-13	Total body bone mineral density;
SARC	cis	rs9388451	0.626	rs1343115	chr6:126069817	C/G	cg06289844	chr6:126071538	HEY2	0.36	5.54	0.34	8.2e-8	Brugada syndrome;
SARC	cis	rs1048238	0.506	rs7552077	chr1:16196759	A/G	cg21385522	chr1:16154831	NA	0.49	6.2	0.38	2.55e-9	Systolic blood pressure;
SARC	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg05861140	chr6:150128134	PCMT1	-0.42	-5.41	-0.33	1.53e-7	Lung cancer;
SARC	cis	rs2120243	0.539	rs7618737	chr3:157095621	G/A	cg24825693	chr3:157122686	VEPH1	-0.46	-6.19	-0.38	2.74e-9	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg11987759	chr7:65425863	GUSB	0.48	5.94	0.36	1.03e-8	Aortic root size;
SARC	cis	rs4595586	0.679	rs7955725	chr12:39322903	C/T	cg26384229	chr12:38710491	ALG10B	0.46	5.64	0.35	4.79e-8	Morning vs. evening chronotype;
SARC	cis	rs9325144	0.560	rs12424821	chr12:38649951	C/T	cg13010199	chr12:38710504	ALG10B	-0.56	-6.97	-0.42	3.3e-11	Morning vs. evening chronotype;
SARC	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg20573242	chr4:122745356	CCNA2	0.66	8.47	0.49	2.85e-15	Type 2 diabetes;
SARC	cis	rs9399135	0.622	rs3817776	chr6:135256756	C/T	cg24558204	chr6:135376177	HBS1L	-0.37	-4.77	-0.3	3.18e-6	Red blood cell count;
SARC	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg07701084	chr6:150067640	NUP43	0.41	5.46	0.34	1.23e-7	Lung cancer;
SARC	cis	rs4742903	0.904	rs2417487	chr9:106887581	A/G	cg14250997	chr9:106856677	SMC2	0.55	7.25	0.43	6.06e-12	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs9303401	0.592	rs12936771	chr17:56725052	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	12.09	0.62	2e-26	Cognitive test performance;
SARC	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg16680214	chr1:154839983	KCNN3	-0.36	-5.83	-0.36	1.87e-8	Prostate cancer;
SARC	cis	rs4319547	0.656	rs9788145	chr12:122899522	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.54	-6.18	-0.38	2.76e-9	Body mass index;
SARC	cis	rs7927771	0.725	rs11039265	chr11:47523214	C/A	cg05585544	chr11:47624801	NA	-0.37	-4.96	-0.31	1.35e-6	Subjective well-being;
SARC	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg08219700	chr8:58056026	NA	0.74	6.46	0.39	6.15e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs10782582	0.593	rs77208152	chr1:76124255	T/C	cg10523679	chr1:76189770	ACADM	-0.4	-5.02	-0.31	1.02e-6	Daytime sleep phenotypes;
SARC	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg25072359	chr17:41440525	NA	0.5	5.94	0.36	1.04e-8	Menopause (age at onset);
SARC	cis	rs9911578	0.967	rs4598970	chr17:57076893	T/A	cg05425664	chr17:57184151	TRIM37	0.64	7.86	0.46	1.43e-13	Intelligence (multi-trait analysis);
SARC	cis	rs5762813	0.566	rs28360615	chr22:29338656	G/C	cg15103426	chr22:29168792	CCDC117	0.58	5.81	0.36	2.01e-8	Hematocrit;Hemoglobin concentration;
SARC	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg02725872	chr8:58115012	NA	0.33	5.21	0.32	4.23e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2832191	0.740	rs2832168	chr21:30463695	G/A	cg24692254	chr21:30365293	RNF160	1.03	18.7	0.77	2.87e-48	Dental caries;
SARC	cis	rs4975616	0.836	rs460073	chr5:1336459	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.58	-8.69	-0.49	6.46e-16	Lung cancer;
SARC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg26338869	chr17:61819248	STRADA	0.8	10.65	0.57	7.56e-22	Prudent dietary pattern;
SARC	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg16606324	chr3:10149918	C3orf24	0.48	4.75	0.3	3.57e-6	Alzheimer's disease;
SARC	cis	rs9815354	0.904	rs4621303	chr3:41839370	T/A	cg03022575	chr3:42003672	ULK4	0.58	5.61	0.35	5.63e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs11792861	0.926	rs58795279	chr9:111851902	A/T	cg13535736	chr9:111863775	C9orf5	-0.4	-4.88	-0.3	1.97e-6	Menarche (age at onset);
SARC	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.37	-4.85	-0.3	2.26e-6	Bronchopulmonary dysplasia;
SARC	cis	rs2985684	0.948	rs4900925	chr14:50012325	A/G	cg15316458	chr14:50087796	RPL36AL;MGAT2	-0.58	-5.76	-0.35	2.69e-8	Carotid intima media thickness;
SARC	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg00149659	chr3:10157352	C3orf10	1.09	10.0	0.55	7.87e-20	Alzheimer's disease;
SARC	cis	rs2933343	1.000	rs1680784	chr3:128644458	A/G	cg24203234	chr3:128598194	ACAD9	0.55	6.04	0.37	6.17e-9	IgG glycosylation;
SARC	cis	rs7481584	0.624	rs2106229	chr11:3041195	G/A	cg25174290	chr11:3078921	CARS	-0.59	-7.97	-0.46	7.07e-14	Calcium levels;
SARC	cis	rs7223966	1.000	rs11871767	chr17:61698723	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.53	-5.71	-0.35	3.44e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6493487	0.512	rs12911270	chr15:51166326	C/T	cg02338191	chr15:51200825	AP4E1	0.55	5.06	0.31	8.33e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs2836633	0.931	rs2836635	chr21:40069850	A/G	cg12884169	chr21:40033163	ERG	0.44	7.57	0.44	8.6e-13	Coronary artery disease;
SARC	cis	rs367615	0.552	rs10042721	chr5:108713970	C/T	cg17395555	chr5:108820864	NA	-0.34	-4.91	-0.31	1.72e-6	Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs858239	0.932	rs199355	chr7:23296533	C/T	cg23682824	chr7:23144976	KLHL7	0.57	7.24	0.43	6.61e-12	Cerebrospinal fluid biomarker levels;
SARC	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-5.96	-0.36	9.37e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs11509153	0.687	rs12671250	chr7:12284475	C/G	cg23422036	chr7:12250390	TMEM106B	0.46	5.95	0.36	9.77e-9	Residual cognition;
SARC	cis	rs1167827	0.805	rs809439	chr7:75161318	T/A	cg16384552	chr7:74938386	SPDYE8P	0.51	6.36	0.38	1.08e-9	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs1395	0.744	rs11126929	chr2:27472027	C/T	cg21747090	chr2:27597821	SNX17	0.45	5.63	0.35	5.28e-8	Blood metabolite levels;
SARC	cis	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg08975724	chr8:8085496	FLJ10661	0.46	6.0	0.37	7.67e-9	Mood instability;
SARC	cis	rs60871478	0.685	rs34421533	chr7:816638	A/G	cg05535760	chr7:792225	HEATR2	0.85	7.88	0.46	1.28e-13	Cerebrospinal P-tau181p levels;
SARC	cis	rs763121	0.853	rs5757193	chr22:39034867	A/G	cg06022373	chr22:39101656	GTPBP1	-0.9	-11.07	-0.59	3.7e-23	Menopause (age at onset);
SARC	cis	rs56011263	0.687	rs11734460	chr4:705074	C/T	cg17689763	chr4:710664	PCGF3	-0.64	-9.06	-0.51	5.33e-17	White blood cell count;
SARC	cis	rs3126085	0.935	rs10749669	chr1:152177289	A/C	cg26876637	chr1:152193138	HRNR	-0.48	-5.59	-0.34	6.2e-8	Atopic dermatitis;
SARC	cis	rs2439831	0.867	rs12324572	chr15:43636200	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	8.32	0.48	7.2e-15	Lung cancer in ever smokers;
SARC	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg19346786	chr7:2764209	NA	-0.37	-5.23	-0.32	3.83e-7	Height;
SARC	cis	rs4820539	0.966	rs2301554	chr22:23484254	A/C	cg14186256	chr22:23484241	RTDR1	0.89	14.6	0.69	1.04e-34	Bone mineral density;
SARC	cis	rs477692	0.905	rs693402	chr10:131422882	G/A	cg05714579	chr10:131428358	MGMT	0.56	7.48	0.44	1.48e-12	Response to temozolomide;
SARC	cis	rs1580019	0.523	rs9791770	chr7:32582252	C/A	cg06627557	chr7:32535165	LSM5;AVL9	0.96	15.94	0.72	3.65e-39	Cognitive ability;
SARC	cis	rs7927771	0.864	rs11600581	chr11:47448497	T/C	cg05585544	chr11:47624801	NA	-0.37	-4.98	-0.31	1.25e-6	Subjective well-being;
SARC	cis	rs7756236	0.521	rs6907437	chr6:36625021	A/G	cg08179530	chr6:36648295	CDKN1A	0.53	6.45	0.39	6.32e-10	QRS duration;
SARC	cis	rs17209837	0.920	rs4148817	chr7:87087397	C/G	cg00919237	chr7:87102261	ABCB4	-0.5	-5.47	-0.34	1.14e-7	Gallbladder cancer;
SARC	cis	rs7568458	0.905	rs17026396	chr2:85759127	C/T	cg02493740	chr2:85810744	VAMP5	0.35	5.18	0.32	4.86e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs9858542	0.953	rs9837027	chr3:49597013	C/T	cg03060546	chr3:49711283	APEH	-0.61	-7.78	-0.45	2.3e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs3741151	1.000	rs3741149	chr11:73021084	A/G	cg17517138	chr11:73019481	ARHGEF17	-0.87	-7.75	-0.45	2.89e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg04944784	chr2:26401820	FAM59B	-0.47	-5.77	-0.35	2.47e-8	Gut microbiome composition (summer);
SARC	cis	rs709400	0.663	rs72710714	chr14:103981849	T/G	cg26031613	chr14:104095156	KLC1	0.82	11.74	0.61	2.64e-25	Body mass index;
SARC	cis	rs3106136	0.872	rs10030713	chr4:95238536	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.85	-0.36	1.66e-8	Capecitabine sensitivity;
SARC	trans	rs800082	0.698	rs1178943	chr3:144391772	T/G	cg24215973	chr2:240111563	HDAC4	-0.53	-6.3	-0.38	1.45e-9	Smoking behavior;
SARC	cis	rs9325144	0.600	rs1825807	chr12:38737007	T/C	cg26384229	chr12:38710491	ALG10B	0.61	7.97	0.46	6.88e-14	Morning vs. evening chronotype;
SARC	cis	rs11098499	0.690	rs34818745	chr4:120257055	T/C	cg24375607	chr4:120327624	NA	0.4	4.72	0.3	4.14e-6	Corneal astigmatism;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg00859888	chr10:34795865	PARD3	0.5	6.7	0.4	1.59e-10	Thyroid stimulating hormone;
SARC	cis	rs9916302	0.610	rs11078902	chr17:37631883	C/G	cg00129232	chr17:37814104	STARD3	-0.64	-7.77	-0.45	2.51e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs13191362	0.872	rs67712738	chr6:163245768	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.38	5.3	0.33	2.68e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	trans	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg17830980	chr10:43048298	ZNF37B	-0.5	-6.54	-0.39	3.92e-10	Extrinsic epigenetic age acceleration;
SARC	cis	rs9916302	0.706	rs7212621	chr17:37527911	T/G	cg07936489	chr17:37558343	FBXL20	0.77	9.17	0.51	2.66e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs9303280	0.806	rs4795395	chr17:37962987	T/A	cg00129232	chr17:37814104	STARD3	-0.38	-4.92	-0.31	1.65e-6	Self-reported allergy;
SARC	cis	rs2439831	0.850	rs7183809	chr15:44120868	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.76	7.51	0.44	1.27e-12	Lung cancer in ever smokers;
SARC	cis	rs6546550	0.935	rs60207187	chr2:70093910	G/A	cg02498382	chr2:70120550	SNRNP27	-0.37	-6.04	-0.37	6.06e-9	Prevalent atrial fibrillation;
SARC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.42	0.56	3.95e-21	Prudent dietary pattern;
SARC	cis	rs4268898	0.722	rs7564420	chr2:24414002	C/T	cg26838691	chr2:24397539	C2orf84	-0.43	-5.8	-0.36	2.15e-8	Asthma;
SARC	cis	rs2590816	0.691	rs2572291	chr4:54493383	A/G	cg16252889	chr4:54487027	NA	-0.41	-4.83	-0.3	2.47e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2304069	0.545	rs4705404	chr5:149381952	A/C	cg12661370	chr5:149340060	SLC26A2	0.57	6.71	0.4	1.42e-10	HIV-1 control;
SARC	cis	rs7726839	0.540	rs11738281	chr5:662547	T/C	cg09021430	chr5:549028	NA	-0.43	-5.54	-0.34	8.25e-8	Obesity-related traits;
SARC	cis	rs35110281	0.627	rs6518268	chr21:44967448	A/G	cg01579765	chr21:45077557	HSF2BP	-0.28	-4.85	-0.3	2.27e-6	Mean corpuscular volume;
SARC	cis	rs72781680	0.898	rs72782138	chr2:24048162	T/C	cg06627628	chr2:24431161	ITSN2	-0.67	-6.37	-0.38	1.02e-9	Lymphocyte counts;
SARC	cis	rs910316	1.000	rs12588240	chr14:75612083	C/A	cg23033748	chr14:75592666	NEK9	0.37	5.31	0.33	2.54e-7	Height;
SARC	cis	rs12586317	0.547	rs112510746	chr14:35491833	T/G	cg26967526	chr14:35346199	BAZ1A	-0.57	-5.71	-0.35	3.4e-8	Psoriasis;
SARC	cis	rs4713118	0.513	rs149962	chr6:28015918	G/A	cg17221315	chr6:27791827	HIST1H4J	0.45	4.86	0.3	2.14e-6	Parkinson's disease;
SARC	cis	rs5758659	0.622	rs129856	chr22:42399396	C/G	cg04733989	chr22:42467013	NAGA	0.51	6.82	0.41	7.7e-11	Cognitive function;
SARC	cis	rs1707322	1.000	rs785493	chr1:46584859	A/G	cg03146154	chr1:46216737	IPP	-0.48	-5.6	-0.34	6.03e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs10754283	0.967	rs7523518	chr1:90110010	G/A	cg21401794	chr1:90099060	LRRC8C	0.58	8.02	0.46	5.22e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs6120849	0.754	rs6120788	chr20:33583716	C/T	cg24642439	chr20:33292090	TP53INP2	0.59	5.69	0.35	3.79e-8	Protein C levels;
SARC	cis	rs3741404	0.620	rs2236648	chr11:63964657	C/T	cg18225595	chr11:63971243	STIP1	0.47	7.22	0.43	7.3e-12	Platelet count;
SARC	cis	rs28374715	0.532	rs28897479	chr15:41690851	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.17	-18.27	-0.77	7.1500000000000005e-47	Ulcerative colitis;
SARC	cis	rs9902453	0.817	rs67206808	chr17:28190096	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	7.26	0.43	5.71e-12	Coffee consumption (cups per day);
SARC	cis	rs2463822	1.000	rs2513074	chr11:62100880	A/C	cg06239285	chr11:62104954	ASRGL1	0.9	9.65	0.53	9.5e-19	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg04756594	chr16:24857601	SLC5A11	0.44	6.11	0.37	4.19e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs57506017	0.540	rs7781670	chr7:12251560	C/G	cg23422036	chr7:12250390	TMEM106B	0.49	6.43	0.39	7.14e-10	Neuroticism;
SARC	cis	rs17666538	1.000	rs73177066	chr8:585750	C/T	cg00450029	chr8:599525	NA	-0.78	-5.81	-0.36	2.05e-8	IgG glycosylation;
SARC	cis	rs4711350	1.000	rs2182659	chr6:33751767	A/G	cg18005901	chr6:33739558	LEMD2	-0.44	-4.72	-0.3	4.04e-6	Schizophrenia;
SARC	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg17376030	chr22:41985996	PMM1	-0.62	-7.98	-0.46	6.44e-14	Vitiligo;
SARC	cis	rs1707322	0.686	rs2991977	chr1:46053683	G/A	cg03146154	chr1:46216737	IPP	-0.5	-5.92	-0.36	1.13e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6831352	0.819	rs896992	chr4:100002372	C/T	cg12011299	chr4:100065546	ADH4	0.3	5.44	0.34	1.35e-7	Alcohol dependence;
SARC	cis	rs4268898	0.608	rs72793980	chr2:24428859	T/C	cg26838691	chr2:24397539	C2orf84	-0.43	-5.05	-0.31	8.76e-7	Asthma;
SARC	cis	rs10927875	0.632	rs4481843	chr1:16128205	G/A	cg21385522	chr1:16154831	NA	-0.92	-13.17	-0.65	5.55e-30	Dilated cardiomyopathy;
SARC	cis	rs7402982	0.625	rs4966011	chr15:99204006	G/A	cg03437748	chr15:99193247	IGF1R	0.64	8.03	0.47	4.75e-14	Birth weight;
SARC	cis	rs651907	0.557	rs1031710	chr3:101463895	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	6.39	0.39	8.85e-10	Colorectal cancer;
SARC	cis	rs2502731	0.561	rs3003606	chr9:130982416	C/T	cg13642260	chr9:130955380	CIZ1	0.36	4.85	0.3	2.21e-6	Attention deficit hyperactivity disorder;
SARC	trans	rs61931739	0.500	rs10772154	chr12:34373271	A/C	cg13010199	chr12:38710504	ALG10B	0.73	10.4	0.56	4.61e-21	Morning vs. evening chronotype;
SARC	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg05872129	chr22:39784769	NA	-0.44	-6.18	-0.38	2.86e-9	Intelligence (multi-trait analysis);
SARC	cis	rs9733	0.818	rs11204702	chr1:150663507	C/A	cg13175981	chr1:150552382	MCL1	0.65	8.99	0.51	8.45e-17	Tonsillectomy;
SARC	trans	rs747334	0.846	rs7897603	chr10:92708759	C/G	cg20294640	chr3:150332279	SELT	-0.46	-6.35	-0.38	1.13e-9	Fibroblast growth factor basic levels;
SARC	cis	rs10875746	0.903	rs11168427	chr12:48538979	A/G	cg27446233	chr12:48516484	PFKM	-0.46	-5.24	-0.32	3.59e-7	Longevity (90 years and older);
SARC	cis	rs35110281	0.633	rs4819292	chr21:45125223	A/G	cg01579765	chr21:45077557	HSF2BP	-0.37	-5.77	-0.35	2.51e-8	Mean corpuscular volume;
SARC	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg18876405	chr7:65276391	NA	-0.72	-9.18	-0.52	2.4e-17	Aortic root size;
SARC	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg24675658	chr1:53192096	ZYG11B	-0.56	-7.78	-0.45	2.32e-13	Monocyte count;
SARC	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg07636037	chr3:49044803	WDR6	1.0	17.66	0.76	6.92e-45	Parkinson's disease;
SARC	cis	rs2204008	0.837	rs7974888	chr12:37945215	A/G	cg26384229	chr12:38710491	ALG10B	0.88	12.58	0.64	5.01e-28	Bladder cancer;
SARC	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg22974920	chr21:40686053	BRWD1	0.44	4.78	0.3	3.17e-6	Cognitive function;
SARC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	5.94	0.36	1.06e-8	Prudent dietary pattern;
SARC	cis	rs12249377	0.519	rs35987367	chr10:92591992	C/T	cg14313238	chr10:92632228	RPP30	0.42	5.1	0.32	7.16e-7	White matter microstructure (global fractional anisotropy);
SARC	cis	rs7818345	1.000	rs4618712	chr8:19302621	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.41	5.58	0.34	6.59e-8	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs6088813	1.000	rs6088823	chr20:33994265	G/T	cg23207816	chr20:34252616	CPNE1;RBM12	-0.45	-5.39	-0.33	1.75e-7	Height;
SARC	cis	rs282587	0.569	rs373653	chr13:113406699	A/G	cg02820901	chr13:113351484	ATP11A	-0.46	-4.79	-0.3	2.96e-6	Glycated hemoglobin levels;
SARC	cis	rs2408955	0.521	rs11168437	chr12:48566156	C/T	cg24011408	chr12:48396354	COL2A1	0.43	5.09	0.32	7.22e-7	Glycated hemoglobin levels;
SARC	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs11711311	0.747	rs9882193	chr3:113349451	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.49	-5.92	-0.36	1.13e-8	IgG glycosylation;
SARC	cis	rs7223966	1.000	rs8081541	chr17:61812483	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-5.86	-0.36	1.6e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1034435	0.962	rs1894542	chr22:48890335	G/C	cg05992904	chr22:48892994	FAM19A5	-0.45	-6.72	-0.4	1.38e-10	Late-onset Alzheimer's disease;
SARC	cis	rs78320035	1.000	rs115530478	chr1:168130127	C/A	cg17113809	chr1:168148080	TIPRL	1.32	7.13	0.42	1.23e-11	Red cell distribution width;
SARC	trans	rs61931739	0.500	rs34167298	chr12:34534338	G/A	cg26384229	chr12:38710491	ALG10B	0.91	13.78	0.67	5.4e-32	Morning vs. evening chronotype;
SARC	cis	rs832540	0.806	rs10039322	chr5:56260259	A/C	cg14703610	chr5:56206110	C5orf35	0.47	5.81	0.36	2.05e-8	Coronary artery disease;
SARC	cis	rs6570726	0.818	rs9399555	chr6:145877554	T/C	cg05347473	chr6:146136440	FBXO30	0.51	7.25	0.43	5.99e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs8067545	0.750	rs28603224	chr17:19985052	G/A	cg13482628	chr17:19912719	NA	0.53	7.12	0.42	1.35e-11	Schizophrenia;
SARC	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.79	11.29	0.59	7.54e-24	Total body bone mineral density;
SARC	cis	rs875971	0.545	rs11767262	chr7:65767224	T/A	cg11764359	chr7:65958608	NA	0.67	6.71	0.4	1.46e-10	Aortic root size;
SARC	cis	rs9303401	0.659	rs17222691	chr17:56771096	C/T	cg25039879	chr17:56429692	SUPT4H1	0.71	6.5	0.39	4.94e-10	Cognitive test performance;
SARC	trans	rs208520	0.586	rs208442	chr6:66900618	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.76	-9.11	-0.51	3.91e-17	Exhaled nitric oxide output;
SARC	cis	rs12142240	0.698	rs17413701	chr1:46818452	A/G	cg10495392	chr1:46806563	NSUN4	0.65	6.83	0.41	7.25e-11	Menopause (age at onset);
SARC	cis	rs10782582	0.593	rs17647178	chr1:76210524	A/G	cg03433033	chr1:76189801	ACADM	-0.43	-5.62	-0.35	5.34e-8	Daytime sleep phenotypes;
SARC	cis	rs2380220	0.516	rs7748108	chr6:96008082	T/C	cg23517279	chr6:96025343	MANEA	0.59	7.06	0.42	1.92e-11	Behavioural disinhibition (generation interaction);
SARC	cis	rs897080	0.552	rs1067392	chr2:44639097	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.69	0.4	1.61e-10	Height;
SARC	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	11.54	0.6	1.19e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs11761408	0.585	rs76950470	chr7:5252801	G/A	cg17652756	chr7:5252759	WIPI2	0.49	4.8	0.3	2.81e-6	Mean corpuscular volume;
SARC	cis	rs6580649	0.831	rs4760620	chr12:48559642	A/G	cg05342945	chr12:48394962	COL2A1	-0.54	-5.98	-0.36	8.35e-9	Lung cancer;
SARC	trans	rs7937682	1.000	rs11213980	chr11:111562692	A/T	cg18187862	chr3:45730750	SACM1L	-0.53	-6.56	-0.39	3.53e-10	Primary sclerosing cholangitis;
SARC	cis	rs9916302	0.706	rs57933226	chr17:37412829	C/T	cg20243544	chr17:37824526	PNMT	0.5	5.31	0.33	2.6e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs4580814	0.869	rs4535497	chr5:1107428	G/T	cg18655438	chr5:1077845	SLC12A7	0.37	4.99	0.31	1.2e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs2439831	0.867	rs4583210	chr15:43660925	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	8.36	0.48	5.82e-15	Lung cancer in ever smokers;
SARC	cis	rs6912958	0.781	rs9450732	chr6:88249826	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.37	-0.33	1.88e-7	Monocyte percentage of white cells;
SARC	cis	rs4268898	0.679	rs2543666	chr2:24446042	C/T	cg26838691	chr2:24397539	C2orf84	0.41	4.91	0.31	1.74e-6	Asthma;
SARC	cis	rs713477	0.967	rs4243600	chr14:55910679	A/G	cg13175173	chr14:55914753	NA	-0.3	-4.75	-0.3	3.63e-6	Pediatric bone mineral content (femoral neck);
SARC	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg13175981	chr1:150552382	MCL1	-0.5	-6.06	-0.37	5.3e-9	Melanoma;
SARC	cis	rs7264396	0.676	rs1341603	chr20:34556216	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-6.92	-0.41	4.41e-11	Total cholesterol levels;
SARC	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg03264133	chr6:25882463	NA	0.51	6.54	0.39	3.85e-10	Intelligence (multi-trait analysis);
SARC	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg24549020	chr5:56110836	MAP3K1	0.81	8.29	0.48	9.03e-15	Initial pursuit acceleration;
SARC	cis	rs6570726	0.791	rs6923074	chr6:145893332	T/C	cg23711669	chr6:146136114	FBXO30	0.84	13.98	0.68	1.14e-32	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg16339924	chr4:17578868	LAP3	0.66	8.76	0.5	4e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg09373136	chr17:61933544	TCAM1	-0.45	-6.17	-0.37	2.95e-9	Prudent dietary pattern;
SARC	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg18876405	chr7:65276391	NA	-0.46	-5.04	-0.31	9.38e-7	Aortic root size;
SARC	cis	rs7824557	0.614	rs2293858	chr8:11213881	G/C	cg21775007	chr8:11205619	TDH	0.73	9.65	0.53	9.36e-19	Retinal vascular caliber;
SARC	cis	rs6674176	0.628	rs3791119	chr1:44431362	C/G	cg12908607	chr1:44402522	ARTN	-0.38	-6.51	-0.39	4.63e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs910187	0.678	rs6122562	chr20:45813847	A/G	cg27589058	chr20:45804311	EYA2	-0.32	-5.08	-0.32	7.7e-7	Migraine;
SARC	cis	rs17345786	0.906	rs56171035	chr3:101111108	G/C	cg11279151	chr3:101281821	RG9MTD1	-0.45	-4.75	-0.3	3.57e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg09359103	chr1:154839909	KCNN3	-0.43	-7.03	-0.42	2.24e-11	Prostate cancer;
SARC	cis	rs710216	0.957	rs841570	chr1:43435571	C/G	cg03128534	chr1:43423976	SLC2A1	0.65	6.54	0.39	3.87e-10	Red cell distribution width;
SARC	cis	rs11105298	0.891	rs3825330	chr12:89933710	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.57	-5.72	-0.35	3.2e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs66573146	1.000	rs7686168	chr4:6986057	C/A	cg00086871	chr4:6988644	TBC1D14	0.99	5.28	0.33	2.99e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs9462027	0.583	rs9469862	chr6:34729848	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.81	-0.36	2.03e-8	Systemic lupus erythematosus;
SARC	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.45	-5.76	-0.35	2.61e-8	Personality dimensions;
SARC	trans	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg07211511	chr3:129823064	LOC729375	-0.61	-6.46	-0.39	6.08e-10	Blood pressure (smoking interaction);
SARC	cis	rs4727027	0.933	rs757738	chr7:148872351	T/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.47	5.83	0.36	1.85e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs13006833	0.668	rs291449	chr2:191177467	A/G	cg25963032	chr2:191064776	C2orf88	-0.37	-5.14	-0.32	5.77e-7	Urinary metabolites;
SARC	cis	rs74417235	0.517	rs13179034	chr5:154059487	C/A	cg17344516	chr5:154026930	NA	0.52	5.25	0.33	3.39e-7	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
SARC	cis	rs36051895	0.625	rs12340333	chr9:5176215	C/G	cg02405213	chr9:5042618	JAK2	-0.46	-5.56	-0.34	7.53e-8	Pediatric autoimmune diseases;
SARC	cis	rs2997457	0.515	rs2992064	chr1:26278253	G/T	cg24596570	chr1:26146463	FAM54B;LOC646471	-0.55	-5.18	-0.32	4.87e-7	Facial morphology (factor 16);
SARC	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg15242686	chr22:24348715	GSTTP1	-0.47	-5.82	-0.36	1.89e-8	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs739401	0.572	rs12276060	chr11:3015572	A/T	cg25174290	chr11:3078921	CARS	0.58	8.21	0.47	1.53e-14	Longevity;
SARC	cis	rs2213920	0.679	rs7862261	chr9:118187677	A/G	cg13918206	chr9:118159781	DEC1	0.79	6.28	0.38	1.61e-9	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg14784868	chr12:69753453	YEATS4	0.63	8.8	0.5	3.22e-16	Cerebrospinal fluid biomarker levels;
SARC	cis	rs10754283	0.901	rs10922683	chr1:90116068	G/A	cg21401794	chr1:90099060	LRRC8C	0.61	8.35	0.48	6.11e-15	Amyotrophic lateral sclerosis (sporadic);
SARC	trans	rs1814175	0.645	rs1963215	chr11:49931486	G/A	cg03929089	chr4:120376271	NA	-0.81	-11.69	-0.61	3.89e-25	Height;
SARC	cis	rs3617	0.573	rs13072537	chr3:52896032	C/A	cg18404041	chr3:52824283	ITIH1	-0.36	-5.22	-0.32	3.94e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg12463550	chr7:65579703	CRCP	-0.7	-5.34	-0.33	2.21e-7	Diabetic kidney disease;
SARC	cis	rs910316	1.000	rs7147118	chr14:75610170	G/C	cg06637938	chr14:75390232	RPS6KL1	0.5	7.2	0.43	8.28e-12	Height;
SARC	cis	rs2197308	0.765	rs12370231	chr12:37917881	T/C	cg13010199	chr12:38710504	ALG10B	0.8	11.02	0.59	5.3e-23	Morning vs. evening chronotype;
SARC	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg05368731	chr17:41323189	NBR1	0.78	9.31	0.52	9.95e-18	Menopause (age at onset);
SARC	cis	rs1153858	1.000	rs4775937	chr15:45678614	C/A	cg26924012	chr15:45694286	SPATA5L1	0.79	11.28	0.59	7.91e-24	Homoarginine levels;
SARC	cis	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.8	-0.46	2.01e-13	Extrinsic epigenetic age acceleration;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg23330710	chr20:44044709	PIGT	-0.49	-6.34	-0.38	1.16e-9	Chemerin levels;
SARC	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg11764359	chr7:65958608	NA	-0.82	-10.37	-0.56	5.7e-21	Aortic root size;
SARC	cis	rs7552404	0.883	rs2185436	chr1:76203783	A/G	cg10523679	chr1:76189770	ACADM	0.51	7.01	0.42	2.55e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg06873352	chr17:61820015	STRADA	0.54	7.03	0.42	2.31e-11	Prudent dietary pattern;
SARC	cis	rs763121	0.853	rs5757166	chr22:38995385	G/T	cg06022373	chr22:39101656	GTPBP1	0.9	12.05	0.62	2.56e-26	Menopause (age at onset);
SARC	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg12564285	chr5:131593104	PDLIM4	0.42	6.16	0.37	3.24e-9	Acylcarnitine levels;
SARC	cis	rs7829975	0.511	rs1401390	chr8:8136410	C/T	cg11608241	chr8:8085544	FLJ10661	0.42	5.15	0.32	5.6e-7	Mood instability;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg05580181	chr2:66802583	NA	-0.45	-6.31	-0.38	1.39e-9	Thyroid stimulating hormone;
SARC	cis	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg24110177	chr3:50126178	RBM5	-0.54	-7.23	-0.43	6.7e-12	Intelligence (multi-trait analysis);
SARC	cis	rs73198271	0.729	rs66564323	chr8:8604996	G/A	cg06636001	chr8:8085503	FLJ10661	-0.49	-4.83	-0.3	2.46e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs765787	0.530	rs11070451	chr15:45533541	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.67e-7	Uric acid levels;
SARC	cis	rs7647973	0.710	rs2029591	chr3:49646981	C/T	cg03060546	chr3:49711283	APEH	-0.71	-6.66	-0.4	1.91e-10	Menarche (age at onset);
SARC	cis	rs4819052	0.679	rs28623526	chr21:46712324	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.59	7.23	0.43	6.71e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs11758351	0.789	rs2069020	chr6:26205500	C/T	cg23601095	chr6:26197514	HIST1H3D	0.55	4.86	0.3	2.19e-6	Gout;Renal underexcretion gout;
SARC	cis	rs4242434	0.927	rs11136092	chr8:22466488	T/G	cg03733263	chr8:22462867	KIAA1967	1.04	17.62	0.76	9.61e-45	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs7666738	0.830	rs13119913	chr4:98977983	G/T	cg05340658	chr4:99064831	C4orf37	0.64	8.6	0.49	1.18e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs3768617	0.510	rs7549768	chr1:183097382	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.2	0.56	1.95e-20	Fuchs's corneal dystrophy;
SARC	cis	rs9341808	0.558	rs2322635	chr6:80897210	A/G	cg08355045	chr6:80787529	NA	0.34	5.24	0.32	3.52e-7	Sitting height ratio;
SARC	cis	rs2439831	0.850	rs12441127	chr15:44021175	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	7.53	0.44	1.12e-12	Lung cancer in ever smokers;
SARC	cis	rs60871478	0.636	rs61441144	chr7:897784	C/T	cg05535760	chr7:792225	HEATR2	-0.74	-6.86	-0.41	6.07e-11	Cerebrospinal P-tau181p levels;
SARC	cis	rs7833790	0.963	rs28823280	chr8:82777716	G/A	cg27398817	chr8:82754497	SNX16	0.51	5.63	0.35	5.03e-8	Diastolic blood pressure;
SARC	cis	rs10193935	0.901	rs222469	chr2:42640235	T/C	cg27598129	chr2:42591480	NA	-0.39	-5.62	-0.35	5.55e-8	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9815354	0.812	rs73830532	chr3:41898814	T/C	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs4555082	0.957	rs2816628	chr14:105736134	T/G	cg10792982	chr14:105748885	BRF1	0.48	7.44	0.44	1.89e-12	Mean platelet volume;Platelet distribution width;
SARC	cis	rs1707322	0.964	rs10890358	chr1:46319025	T/A	cg06784218	chr1:46089804	CCDC17	0.33	5.78	0.35	2.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7937682	0.793	rs4581484	chr11:111415822	G/A	cg09085632	chr11:111637200	PPP2R1B	0.64	8.56	0.49	1.49e-15	Primary sclerosing cholangitis;
SARC	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg13770153	chr20:60521292	NA	-0.52	-7.37	-0.43	3.02e-12	Body mass index;
SARC	cis	rs72781680	0.898	rs72788214	chr2:24087621	A/C	cg08917208	chr2:24149416	ATAD2B	0.75	7.33	0.43	3.77e-12	Lymphocyte counts;
SARC	trans	rs1973993	0.567	rs2800431	chr1:97000998	C/T	cg10631902	chr5:14652156	NA	0.45	7.41	0.44	2.26e-12	Weight;
SARC	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	5.91	0.36	1.21e-8	Bipolar disorder;
SARC	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg20887711	chr4:1340912	KIAA1530	-0.62	-7.28	-0.43	5.1e-12	Obesity-related traits;
SARC	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg05025164	chr4:1340916	KIAA1530	-0.46	-5.41	-0.33	1.54e-7	Obesity-related traits;
SARC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg09373136	chr17:61933544	TCAM1	-0.44	-5.99	-0.37	7.94e-9	Prudent dietary pattern;
SARC	cis	rs17125944	0.505	rs10483618	chr14:53203590	T/C	cg00686598	chr14:53173677	PSMC6	1.3	8.95	0.51	1.11e-16	Alzheimer's disease (late onset);
SARC	cis	rs2228479	0.702	rs3819574	chr16:89826630	G/A	cg06558623	chr16:89946397	TCF25	0.89	6.23	0.38	2.14e-9	Skin colour saturation;
SARC	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg25072359	chr17:41440525	NA	0.48	5.63	0.35	5.24e-8	Menopause (age at onset);
SARC	trans	rs3808502	0.526	rs7822958	chr8:11422442	C/A	cg06636001	chr8:8085503	FLJ10661	-0.65	-9.21	-0.52	1.97e-17	Neuroticism;
SARC	cis	rs3733585	0.624	rs58130873	chr4:9972081	T/C	cg11266682	chr4:10021025	SLC2A9	-0.38	-6.39	-0.39	9.06e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs722599	0.715	rs2300598	chr14:75359229	T/C	cg08847533	chr14:75593920	NEK9	-0.44	-4.98	-0.31	1.27e-6	IgG glycosylation;
SARC	cis	rs208520	0.909	rs62414636	chr6:67015723	T/G	cg07460842	chr6:66804631	NA	0.84	8.59	0.49	1.29e-15	Exhaled nitric oxide output;
SARC	trans	rs9329221	0.905	rs13252982	chr8:10255105	C/G	cg06636001	chr8:8085503	FLJ10661	-0.69	-9.36	-0.52	6.96e-18	Neuroticism;
SARC	cis	rs7726839	0.540	rs74553517	chr5:665671	C/T	cg14541582	chr5:601475	NA	-0.42	-5.06	-0.31	8.69e-7	Obesity-related traits;
SARC	cis	rs9948	0.529	rs62156222	chr2:97410988	C/A	cg01990225	chr2:97406019	LMAN2L	-0.94	-6.38	-0.39	9.49e-10	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs778371	0.522	rs10205801	chr2:233597196	G/A	cg16596103	chr2:233749413	NGEF	-0.36	-5.96	-0.36	9.48e-9	Schizophrenia;
SARC	cis	rs28669119	0.778	rs80043958	chr5:88179575	A/G	cg18498987	chr5:88179539	MEF2C	0.56	5.31	0.33	2.62e-7	Schizophrenia;
SARC	cis	rs17376456	0.877	rs17083460	chr5:93462354	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	6.14	0.37	3.45e-9	Diabetic retinopathy;
SARC	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg12463550	chr7:65579703	CRCP	0.71	5.37	0.33	1.9e-7	Diabetic kidney disease;
SARC	cis	rs448720	0.840	rs399755	chr15:68161587	T/A	cg05925327	chr15:68127851	NA	0.36	5.07	0.32	8.25e-7	Cognitive performance;
SARC	trans	rs11098499	0.863	rs6858777	chr4:120475966	A/G	cg25214090	chr10:38739885	LOC399744	0.57	7.25	0.43	6.27e-12	Corneal astigmatism;
SARC	cis	rs72781680	0.898	rs72782106	chr2:24022009	A/G	cg08917208	chr2:24149416	ATAD2B	0.93	8.76	0.5	4.07e-16	Lymphocyte counts;
SARC	cis	rs7582720	1.000	rs72936834	chr2:203771260	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.31	0.43	4.24e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg17651973	chr2:162095248	NA	-0.5	-6.66	-0.4	1.91e-10	Thyroid stimulating hormone;
SARC	cis	rs713587	0.935	rs11676272	chr2:25141538	A/G	cg01884057	chr2:25150051	NA	0.29	4.73	0.3	3.86e-6	Body mass index in non-asthmatics;
SARC	trans	rs61931739	0.534	rs10844729	chr12:34022919	A/G	cg26384229	chr12:38710491	ALG10B	0.82	11.77	0.61	2.13e-25	Morning vs. evening chronotype;
SARC	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg14159672	chr1:205819179	PM20D1	0.55	6.34	0.38	1.17e-9	Prostate-specific antigen levels;
SARC	cis	rs2153535	0.580	rs4960412	chr6:8438261	G/C	cg23788917	chr6:8435910	SLC35B3	0.63	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs992157	0.835	rs4674282	chr2:219144230	A/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.69	-10.31	-0.56	8.82e-21	Colorectal cancer;
SARC	cis	rs2425143	1.000	rs10485510	chr20:34445164	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-5.46	-0.34	1.21e-7	Blood protein levels;
SARC	cis	rs7246657	0.943	rs10415937	chr19:37830064	T/G	cg23950597	chr19:37808831	NA	-0.54	-5.47	-0.34	1.15e-7	Coronary artery calcification;
SARC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg09033563	chr22:24373618	LOC391322	-0.44	-4.93	-0.31	1.56e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7582180	0.591	rs62148360	chr2:101006319	C/T	cg14675211	chr2:100938903	LONRF2	0.53	7.94	0.46	8.36e-14	Intelligence (multi-trait analysis);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg13617782	chr21:34915953	GART;SON	-0.46	-6.33	-0.38	1.23e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs957448	1.000	rs1055797	chr8:95523233	G/T	cg26464482	chr8:95565502	KIAA1429	0.43	4.83	0.3	2.45e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs8180040	0.764	rs11718795	chr3:47218727	G/A	cg02527881	chr3:46936655	PTH1R	-0.31	-4.96	-0.31	1.35e-6	Colorectal cancer;
SARC	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg24642844	chr7:1081250	C7orf50	-0.62	-6.39	-0.39	8.77e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	trans	rs7395662	0.500	rs1605360	chr11:48685714	G/A	cg15704280	chr7:45808275	SEPT13	-0.53	-7.19	-0.43	8.66e-12	HDL cholesterol;
SARC	cis	rs2153535	0.580	rs9406161	chr6:8466144	G/T	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs2153535	0.580	rs7450817	chr6:8481421	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	8.24	0.48	1.24e-14	Motion sickness;
SARC	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-10.5	-0.57	2.35e-21	Chronic sinus infection;
SARC	cis	rs6748734	0.553	rs7340215	chr2:241805851	A/G	cg26084005	chr2:241760190	KIF1A	-0.39	-4.95	-0.31	1.42e-6	Urinary metabolites;
SARC	cis	rs7582180	0.629	rs11686842	chr2:100956139	C/T	cg14675211	chr2:100938903	LONRF2	0.51	7.51	0.44	1.24e-12	Intelligence (multi-trait analysis);
SARC	cis	rs10875746	0.903	rs11168427	chr12:48538979	A/G	cg26205652	chr12:48591994	NA	0.57	6.23	0.38	2.14e-9	Longevity (90 years and older);
SARC	cis	rs80130819	0.748	rs901962	chr12:48741219	A/T	cg24011408	chr12:48396354	COL2A1	0.48	5.38	0.33	1.78e-7	Prostate cancer;
SARC	cis	rs7659604	0.605	rs2071486	chr4:122740162	C/T	cg06713675	chr4:122721982	EXOSC9	-0.39	-5.11	-0.32	6.64e-7	Type 2 diabetes;
SARC	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg23758822	chr17:41437982	NA	0.89	11.4	0.6	3.2e-24	Menopause (age at onset);
SARC	cis	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg24110177	chr3:50126178	RBM5	0.57	7.71	0.45	3.64e-13	Intelligence (multi-trait analysis);
SARC	cis	rs911263	0.603	rs1108590	chr14:68772610	A/G	cg18825221	chr14:68749962	RAD51L1	0.43	7.65	0.45	5.43e-13	Primary biliary cholangitis;
SARC	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg06634786	chr22:41940651	POLR3H	-0.5	-6.13	-0.37	3.78e-9	Vitiligo;
SARC	cis	rs1468333	0.667	rs17538215	chr5:137752868	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.73	8.51	0.49	2.21e-15	Resting heart rate;
SARC	cis	rs2777491	0.507	rs34040639	chr15:41760807	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.15	-18.05	-0.76	3.8e-46	Ulcerative colitis;
SARC	cis	rs7481584	1.000	rs2239898	chr11:3024462	G/A	cg25174290	chr11:3078921	CARS	-0.48	-6.31	-0.38	1.42e-9	Calcium levels;
SARC	cis	rs1044826	1.000	rs13089052	chr3:139227472	C/T	cg15131784	chr3:139108705	COPB2	0.46	5.3	0.33	2.68e-7	Obesity-related traits;
SARC	cis	rs6570726	0.967	rs1396648	chr6:145785248	C/A	cg05347473	chr6:146136440	FBXO30	-0.45	-6.12	-0.37	3.99e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12458462	0.859	rs2242177	chr18:77477379	G/A	cg11879182	chr18:77439856	CTDP1	0.86	12.55	0.64	6.12e-28	Monocyte count;
SARC	trans	rs2727020	0.521	rs7101761	chr11:49598178	G/A	cg15704280	chr7:45808275	SEPT13	-0.72	-7.94	-0.46	8.44e-14	Coronary artery disease;
SARC	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg16479474	chr6:28041457	NA	0.37	5.39	0.33	1.73e-7	Depression;
SARC	cis	rs3771570	1.000	rs73020143	chr2:242261240	T/A	cg21155796	chr2:242212141	HDLBP	0.68	5.89	0.36	1.31e-8	Prostate cancer;
SARC	cis	rs1943345	0.556	rs606381	chr11:82907249	G/A	cg07047830	chr11:82868014	PCF11	0.46	5.81	0.36	2.04e-8	Obesity-related traits;
SARC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg08219700	chr8:58056026	NA	0.62	6.56	0.4	3.37e-10	Developmental language disorder (linguistic errors);
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg17378273	chr11:45169082	PRDM11	-0.47	-6.39	-0.39	9.07e-10	Electrocardiographic conduction measures;
SARC	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.48	-0.39	5.4e-10	Total body bone mineral density;
SARC	cis	rs1550582	1.000	rs1550582	chr8:135542084	A/G	cg17885191	chr8:135476712	NA	-0.55	-5.58	-0.34	6.73e-8	Educational attainment;
SARC	cis	rs911555	0.755	rs8014013	chr14:103937372	A/G	cg12935359	chr14:103987150	CKB	0.35	4.84	0.3	2.42e-6	Intelligence (multi-trait analysis);
SARC	trans	rs12310956	0.510	rs10772109	chr12:33839548	A/C	cg13010199	chr12:38710504	ALG10B	-0.59	-7.75	-0.45	2.76e-13	Morning vs. evening chronotype;
SARC	cis	rs477692	0.569	rs1711670	chr10:131281115	A/G	cg05714579	chr10:131428358	MGMT	0.57	7.64	0.45	5.68e-13	Response to temozolomide;
SARC	cis	rs9790314	0.905	rs7611367	chr3:161003182	A/G	cg04691961	chr3:161091175	C3orf57	0.65	8.17	0.47	1.92e-14	Morning vs. evening chronotype;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg24457521	chr20:57607420	ATP5E	0.55	7.46	0.44	1.75e-12	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs13401104	0.796	rs35819191	chr2:237119051	T/C	cg19324714	chr2:237145437	ASB18	0.57	5.66	0.35	4.32e-8	Educational attainment;
SARC	cis	rs735539	0.521	rs9552281	chr13:21365407	A/G	cg16922012	chr13:21400325	XPO4	-0.42	-5.72	-0.35	3.22e-8	Dental caries;
SARC	trans	rs7922314	0.571	rs16917988	chr10:64735314	T/C	cg25304107	chr2:177017331	HOXD4	-0.78	-6.31	-0.38	1.36e-9	Cutaneous psoriasis;
SARC	cis	rs505401	0.570	rs11879285	chr19:6118289	T/C	cg18109231	chr19:6110877	RFX2	0.9	5.5	0.34	1.02e-7	Mean platelet volume;
SARC	cis	rs9443189	0.806	rs9359139	chr6:76487269	C/G	cg01950844	chr6:76311363	SENP6	0.75	6.52	0.39	4.32e-10	Prostate cancer;
SARC	cis	rs9381040	0.626	rs2272986	chr6:41037778	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-5.16	-0.32	5.23e-7	Alzheimer's disease (late onset);
SARC	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.56	-7.08	-0.42	1.66e-11	Personality dimensions;
SARC	cis	rs7635838	0.718	rs2606736	chr3:11400249	C/T	cg00170343	chr3:11313890	ATG7	0.63	8.78	0.5	3.53e-16	HDL cholesterol;
SARC	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.42	-4.77	-0.3	3.29e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs644799	0.687	rs11021318	chr11:95522996	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.88	13.99	0.68	1.09e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg22004693	chr7:99632812	ZKSCAN1	0.54	5.44	0.34	1.34e-7	Lung function (FEV1/FVC);
SARC	cis	rs67311347	0.544	rs2278930	chr3:40351092	C/T	cg09455208	chr3:40491958	NA	0.29	4.75	0.3	3.53e-6	Renal cell carcinoma;
SARC	cis	rs79976124	1.000	rs79976124	chr6:66618657	G/A	cg07460842	chr6:66804631	NA	0.64	6.66	0.4	1.99e-10	Type 2 diabetes;
SARC	cis	rs6484504	0.625	rs4922859	chr11:31382517	A/G	cg02090638	chr11:31391270	DNAJC24;DCDC1	0.4	5.05	0.31	8.89e-7	Red blood cell count;
SARC	cis	rs2916247	0.954	rs7014794	chr8:93164893	A/C	cg10183463	chr8:93005414	RUNX1T1	0.51	5.21	0.32	4.19e-7	Intelligence (multi-trait analysis);
SARC	cis	rs11690935	0.959	rs1474074	chr2:172659852	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.97	-15.33	-0.71	3.78e-37	Schizophrenia;
SARC	cis	rs2814982	0.605	rs35429796	chr6:34474639	G/T	cg17674042	chr6:34482479	PACSIN1	-0.57	-4.89	-0.3	1.9e-6	Cholesterol, total;Total cholesterol levels;
SARC	cis	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg21775007	chr8:11205619	TDH	-0.42	-4.91	-0.31	1.69e-6	Neuroticism;
SARC	cis	rs950027	0.620	rs1145077	chr15:45683795	A/C	cg21132104	chr15:45694354	SPATA5L1	-0.51	-6.3	-0.38	1.46e-9	Response to fenofibrate (adiponectin levels);
SARC	cis	rs4805272	0.512	rs7245724	chr19:29341679	C/T	cg14983838	chr19:29218262	NA	0.55	5.97	0.36	8.83e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs10911232	0.507	rs4652767	chr1:183002483	G/C	cg13390022	chr1:182993471	LAMC1	0.35	5.34	0.33	2.24e-7	Hypertriglyceridemia;
SARC	cis	rs7374004	0.655	rs7374826	chr3:38635589	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.51	5.91	0.36	1.22e-8	PR interval;
SARC	cis	rs7712401	0.541	rs42537	chr5:122274688	A/G	cg19412675	chr5:122181750	SNX24	0.4	5.09	0.32	7.55e-7	Mean platelet volume;
SARC	cis	rs9457247	0.510	rs6456151	chr6:167471851	A/C	cg07741184	chr6:167504864	NA	0.36	7.09	0.42	1.62e-11	Crohn's disease;
SARC	cis	rs7644634	0.688	rs3772513	chr3:105488572	A/G	cg23051926	chr3:105466016	CBLB	0.44	5.02	0.31	1.01e-6	Itch intensity from mosquito bite;
SARC	cis	rs362272	0.545	rs3135146	chr4:3307638	C/G	cg08741688	chr4:3415352	RGS12	0.45	5.73	0.35	3.04e-8	Serum sulfate level;
SARC	cis	rs9916302	0.904	rs11654018	chr17:37703740	C/T	cg07936489	chr17:37558343	FBXL20	0.7	9.01	0.51	7.5e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs7696431	0.870	rs869396	chr4:169688000	A/C	cg07840446	chr4:169690674	PALLD	-0.35	-4.93	-0.31	1.58e-6	Coronary artery disease;
SARC	trans	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	7.04	0.42	2.17e-11	Intelligence (multi-trait analysis);
SARC	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg24549020	chr5:56110836	MAP3K1	0.53	5.83	0.36	1.82e-8	Initial pursuit acceleration;
SARC	cis	rs7666738	0.830	rs13141752	chr4:98893128	G/A	cg05340658	chr4:99064831	C4orf37	0.64	8.45	0.48	3.18e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs870825	0.860	rs72703525	chr4:185605154	T/C	cg04058563	chr4:185651563	MLF1IP	0.76	9.26	0.52	1.4e-17	Blood protein levels;
SARC	cis	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg14541582	chr5:601475	NA	-0.4	-4.93	-0.31	1.54e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs6570726	0.935	rs399169	chr6:145836353	C/A	cg05220968	chr6:146057943	EPM2A	-0.29	-4.99	-0.31	1.19e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg17328964	chr8:145687451	CYHR1	0.44	5.96	0.36	9.3e-9	Age at first birth;
SARC	cis	rs6546324	0.592	rs9309402	chr2:67869338	T/C	cg18237512	chr2:67827392	NA	-0.56	-6.71	-0.4	1.49e-10	Endometriosis;
SARC	cis	rs57506017	0.585	rs3800843	chr7:12264297	G/A	cg23422036	chr7:12250390	TMEM106B	0.46	6.01	0.37	7.15e-9	Neuroticism;
SARC	cis	rs4319547	0.741	rs4758644	chr12:122943915	A/C	cg23029597	chr12:123009494	RSRC2	-0.37	-4.93	-0.31	1.55e-6	Body mass index;
SARC	cis	rs8058578	1.000	rs8051050	chr16:30687909	A/G	cg00531865	chr16:30841666	NA	-0.49	-5.48	-0.34	1.12e-7	Multiple myeloma;
SARC	cis	rs1950500	0.509	rs12882558	chr14:24819233	G/A	cg22990158	chr14:24802150	ADCY4	-0.33	-5.6	-0.34	6.03e-8	Height;
SARC	cis	rs892961	0.932	rs35657663	chr17:75412482	T/C	cg05865280	chr17:75406074	SEPT9	0.57	8.47	0.48	2.87e-15	Airflow obstruction;
SARC	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	17.66	0.76	7.16e-45	Height;
SARC	cis	rs11608355	0.515	rs12818537	chr12:109902150	C/T	cg05360138	chr12:110035743	NA	0.92	9.65	0.53	9.69e-19	Neuroticism;
SARC	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg27286337	chr10:134555280	INPP5A	0.68	7.93	0.46	9.33e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs11719291	0.833	rs13074318	chr3:48816725	C/T	cg00383909	chr3:49044727	WDR6	0.76	6.82	0.41	7.67e-11	Cognitive function;
SARC	cis	rs2180341	1.000	rs6569483	chr6:127658855	G/A	cg17762328	chr6:126965162	NA	-0.45	-5.11	-0.32	6.78e-7	Breast cancer;
SARC	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg18404041	chr3:52824283	ITIH1	-0.44	-6.57	-0.4	3.31e-10	Bipolar disorder;
SARC	cis	rs765787	0.530	rs2413776	chr15:45544170	A/G	cg24006582	chr15:45444508	DUOX1	-0.52	-6.85	-0.41	6.5e-11	Uric acid levels;
SARC	cis	rs11209002	0.592	rs6672126	chr1:67558063	C/G	cg02640540	chr1:67518911	SLC35D1	0.54	6.28	0.38	1.67e-9	Crohn's disease;
SARC	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.4	-4.83	-0.3	2.44e-6	Lymphocyte counts;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg09724427	chr17:47866462	MYST2	0.59	7.74	0.45	3.09e-13	Lung adenocarcinoma;
SARC	cis	rs13401104	0.786	rs11677411	chr2:237110028	T/C	cg19324714	chr2:237145437	ASB18	0.57	5.6	0.34	5.92e-8	Educational attainment;
SARC	cis	rs4555082	0.830	rs3803319	chr14:105752458	G/A	cg10792982	chr14:105748885	BRF1	0.55	8.19	0.47	1.76e-14	Mean platelet volume;Platelet distribution width;
SARC	cis	rs644799	0.601	rs662168	chr11:95586982	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	12.82	0.64	7.81e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg25427524	chr10:38739819	LOC399744	0.58	9.22	0.52	1.84e-17	Extrinsic epigenetic age acceleration;
SARC	cis	rs2290416	0.681	rs3793371	chr8:144664299	C/T	cg10810860	chr8:144639591	GSDMD	-0.71	-4.78	-0.3	3.18e-6	Attention deficit hyperactivity disorder;
SARC	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg22496380	chr5:211416	CCDC127	-0.87	-8.86	-0.5	2.06e-16	Breast cancer;
SARC	cis	rs7769051	0.522	rs7738256	chr6:133113066	C/G	cg22852734	chr6:133119734	C6orf192	1.25	8.38	0.48	4.9e-15	Type 2 diabetes nephropathy;
SARC	cis	rs11122272	0.735	rs971534	chr1:231521971	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs422249	0.512	rs174566	chr11:61592362	A/G	cg19610905	chr11:61596333	FADS2	-0.4	-4.76	-0.3	3.47e-6	Trans fatty acid levels;
SARC	cis	rs10078	0.515	rs1053299	chr5:470760	G/A	cg24955955	chr5:415729	AHRR	0.73	6.66	0.4	1.93e-10	Fat distribution (HIV);
SARC	cis	rs5758659	0.714	rs5758578	chr22:42490292	A/C	cg04733989	chr22:42467013	NAGA	-0.5	-6.26	-0.38	1.88e-9	Cognitive function;
SARC	cis	rs17001868	0.568	rs9611310	chr22:40733777	A/G	cg07138101	chr22:40742427	ADSL	0.54	5.94	0.36	1.01e-8	Mammographic density (dense area);
SARC	cis	rs2933343	0.951	rs7648327	chr3:128570708	A/G	cg24203234	chr3:128598194	ACAD9	0.52	5.86	0.36	1.58e-8	IgG glycosylation;
SARC	cis	rs910316	1.000	rs876402	chr14:75601862	C/T	cg11812906	chr14:75593930	NEK9	-0.87	-13.35	-0.66	1.48e-30	Height;
SARC	cis	rs9341808	0.519	rs59232999	chr6:81018783	T/C	cg08355045	chr6:80787529	NA	-0.36	-5.38	-0.33	1.83e-7	Sitting height ratio;
SARC	cis	rs936229	0.749	rs8031937	chr15:75181121	A/G	cg14664628	chr15:75095509	CSK	-0.85	-10.27	-0.56	1.22e-20	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs820218	0.847	rs1661745	chr17:73647139	A/G	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.66	9.18	0.52	2.34e-17	Rotator cuff tears;
SARC	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg11644478	chr21:40555479	PSMG1	1.05	15.13	0.7	1.75e-36	Cognitive function;
SARC	cis	rs72829446	0.530	rs4796422	chr17:7380004	T/C	cg07168214	chr17:7380112	ZBTB4	-0.4	-4.71	-0.3	4.17e-6	Androgen levels;
SARC	cis	rs7937682	0.924	rs1784782	chr11:111525764	A/C	cg22437258	chr11:111473054	SIK2	0.74	10.3	0.56	9.9e-21	Primary sclerosing cholangitis;
SARC	cis	rs3733585	0.699	rs28613263	chr4:9964880	C/T	cg11266682	chr4:10021025	SLC2A9	-0.34	-5.76	-0.35	2.65e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs473651	0.935	rs559579	chr2:239339501	G/C	cg21699342	chr2:239360505	ASB1	0.49	5.95	0.36	9.57e-9	Multiple system atrophy;
SARC	cis	rs4689388	0.926	rs10010131	chr4:6292915	A/G	cg25554036	chr4:6271136	WFS1	0.39	6.42	0.39	7.48e-10	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs4588572	0.686	rs10078289	chr5:77670793	T/G	cg11547950	chr5:77652471	NA	0.41	4.93	0.31	1.59e-6	Triglycerides;
SARC	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg23758822	chr17:41437982	NA	0.9	11.51	0.6	1.45e-24	Menopause (age at onset);
SARC	cis	rs523522	0.962	rs3213565	chr12:120992401	C/T	cg27279351	chr12:120934652	DYNLL1	0.72	8.87	0.5	2.02e-16	High light scatter reticulocyte count;
SARC	cis	rs1865760	0.551	rs9461230	chr6:26019240	G/C	cg02841227	chr6:26021843	HIST1H4A	0.42	5.24	0.32	3.61e-7	Height;
SARC	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg03806693	chr22:41940476	POLR3H	-0.95	-13.66	-0.67	1.3e-31	Vitiligo;
SARC	cis	rs7918232	0.800	rs7907981	chr10:27444329	T/C	cg14442939	chr10:27389572	ANKRD26	0.79	7.93	0.46	9.31e-14	Breast cancer;
SARC	cis	rs11122272	0.735	rs2808601	chr1:231536571	A/G	cg06096015	chr1:231504339	EGLN1	0.36	5.42	0.33	1.51e-7	Hemoglobin concentration;
SARC	cis	rs899997	0.862	rs11072787	chr15:78972977	T/C	cg24631222	chr15:78858424	CHRNA5	0.4	4.73	0.3	3.88e-6	Coronary artery disease or large artery stroke;
SARC	cis	rs7027203	0.828	rs4743934	chr9:96581893	A/G	cg13679303	chr9:96623674	NA	-0.35	-5.07	-0.32	7.94e-7	DNA methylation (variation);
SARC	cis	rs6570726	0.935	rs432086	chr6:145841593	C/T	cg05347473	chr6:146136440	FBXO30	-0.45	-5.96	-0.36	9.04e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6429082	0.715	rs2153204	chr1:235580382	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.58	-7.55	-0.44	9.58e-13	Adiposity;
SARC	cis	rs2916247	1.000	rs2976506	chr8:92998874	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.63	-6.12	-0.37	3.94e-9	Intelligence (multi-trait analysis);
SARC	cis	rs829880	0.858	rs733180	chr12:98842588	C/T	cg25150519	chr12:98850993	NA	0.7	10.26	0.56	1.23e-20	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4820539	1.000	rs4822360	chr22:23482460	A/G	cg14186256	chr22:23484241	RTDR1	0.84	13.48	0.66	5.27e-31	Bone mineral density;
SARC	cis	rs9420	0.884	rs589914	chr11:57661032	A/G	cg19752551	chr11:57585705	CTNND1	0.51	6.56	0.39	3.51e-10	Schizophrenia;
SARC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg11905131	chr22:24372483	LOC391322	-0.52	-5.68	-0.35	4.07e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs12477438	0.765	rs7605218	chr2:99593080	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.95	-15.47	-0.71	1.34e-37	Chronic sinus infection;
SARC	cis	rs11105298	0.891	rs11105319	chr12:89927177	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.55	-5.51	-0.34	9.48e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	10.64	0.57	8.51e-22	Platelet count;
SARC	cis	rs2976388	0.578	rs3736010	chr8:143817503	T/C	cg06565975	chr8:143823917	SLURP1	-0.31	-4.82	-0.3	2.56e-6	Urinary tract infection frequency;
SARC	cis	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg26513180	chr16:89883248	FANCA	0.72	4.79	0.3	2.94e-6	Skin colour saturation;
SARC	cis	rs7084402	1.000	rs7074778	chr10:60272248	C/T	cg07615347	chr10:60278583	BICC1	-0.6	-8.8	-0.5	3.15e-16	Refractive error;
SARC	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg17211192	chr8:82754475	SNX16	0.51	6.37	0.39	9.85e-10	Diastolic blood pressure;
SARC	cis	rs9326248	0.581	rs7106437	chr11:116992076	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.66	8.74	0.5	4.61e-16	Blood protein levels;
SARC	trans	rs3780486	0.846	rs2209948	chr9:33138247	G/A	cg04842962	chr6:43655489	MRPS18A	1.09	19.73	0.79	1.33e-51	IgG glycosylation;
SARC	cis	rs7953249	0.564	rs11065385	chr12:121423386	A/G	cg02403541	chr12:121454288	C12orf43	-0.78	-10.71	-0.57	5.04e-22	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	trans	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg21659725	chr3:3221576	CRBN	-0.79	-11.96	-0.62	5.19e-26	Intelligence (multi-trait analysis);
SARC	cis	rs6542838	0.673	rs13005148	chr2:99467538	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-5.67	-0.35	4.26e-8	Fear of minor pain;
SARC	cis	rs12579753	0.879	rs11115007	chr12:82164673	A/T	cg07988820	chr12:82153109	PPFIA2	-0.61	-7.26	-0.43	5.8e-12	Resting heart rate;
SARC	cis	rs637571	0.726	rs669371	chr11:65674153	G/T	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.53	-5.88	-0.36	1.44e-8	Eosinophil percentage of white cells;
SARC	cis	rs9303401	0.614	rs28687626	chr17:57191904	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.99	10.15	0.55	2.8e-20	Cognitive test performance;
SARC	cis	rs7712401	0.580	rs439739	chr5:122318421	G/C	cg19412675	chr5:122181750	SNX24	-0.43	-5.47	-0.34	1.15e-7	Mean platelet volume;
SARC	cis	rs17401966	0.928	rs11121531	chr1:10277357	G/A	cg15208524	chr1:10270712	KIF1B	0.58	6.61	0.4	2.54e-10	Hepatocellular carcinoma;
SARC	cis	rs1832871	0.672	rs9456285	chr6:158732819	T/G	cg07165851	chr6:158734300	TULP4	0.57	6.6	0.4	2.8e-10	Height;
SARC	cis	rs523522	0.962	rs7471	chr12:120941215	T/C	cg27279351	chr12:120934652	DYNLL1	0.72	8.91	0.5	1.5e-16	High light scatter reticulocyte count;
SARC	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg05665937	chr4:1216051	CTBP1	0.37	5.37	0.33	1.94e-7	Obesity-related traits;
SARC	cis	rs1050631	0.556	rs4267398	chr18:33767749	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.51	5.53	0.34	8.44e-8	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs1878931	0.582	rs27231	chr16:3434966	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.65	7.21	0.43	7.65e-12	Body mass index (adult);
SARC	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg03185022	chr7:2884158	GNA12	0.51	5.49	0.34	1.04e-7	Height;
SARC	cis	rs2549003	0.966	rs839	chr5:131819126	C/T	cg21138405	chr5:131827807	IRF1	0.27	5.44	0.34	1.32e-7	Asthma (sex interaction);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg26029744	chr1:163291534	NUF2	0.54	7.2	0.43	8.13e-12	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg15320075	chr8:145703422	NA	-0.69	-9.62	-0.53	1.19e-18	Age at first birth;
SARC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg14893161	chr1:205819251	PM20D1	0.82	13.53	0.66	3.62e-31	Monocyte percentage of white cells;
SARC	cis	rs9467773	1.000	rs1321481	chr6:26538210	A/T	cg12292205	chr6:26970375	C6orf41	0.45	5.42	0.33	1.45e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9467773	1.000	rs10214634	chr6:26564582	T/A	cg12292205	chr6:26970375	C6orf41	0.45	5.41	0.33	1.6e-7	Intelligence (multi-trait analysis);
SARC	cis	rs10465746	0.725	rs4907185	chr1:84336047	T/C	cg10977910	chr1:84465055	TTLL7	0.47	5.79	0.35	2.26e-8	Obesity-related traits;
SARC	cis	rs2153535	0.505	rs1335629	chr6:8491863	C/T	cg07606381	chr6:8435919	SLC35B3	0.79	11.12	0.59	2.5e-23	Motion sickness;
SARC	cis	rs17539620	0.565	rs61225515	chr6:154841625	A/G	cg17771515	chr6:154831774	CNKSR3	0.53	4.98	0.31	1.23e-6	Lipoprotein (a) levels;
SARC	cis	rs826838	0.935	rs3886109	chr12:39189243	C/T	cg26384229	chr12:38710491	ALG10B	0.87	12.47	0.63	1.11e-27	Heart rate;
SARC	cis	rs6938	0.618	rs12912839	chr15:75221245	C/T	cg09165964	chr15:75287851	SCAMP5	0.58	7.76	0.45	2.61e-13	Breast cancer;
SARC	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg15448220	chr1:150897856	SETDB1	0.47	6.25	0.38	1.94e-9	Tonsillectomy;
SARC	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg27266027	chr21:40555129	PSMG1	0.48	5.14	0.32	5.69e-7	Cognitive function;
SARC	cis	rs7647973	0.848	rs4955411	chr3:49145304	A/G	cg07636037	chr3:49044803	WDR6	0.9	10.5	0.57	2.36e-21	Menarche (age at onset);
SARC	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	5.35	0.33	2.05e-7	Tonsillectomy;
SARC	cis	rs17376456	0.877	rs28575883	chr5:93346035	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.74	0.35	2.96e-8	Diabetic retinopathy;
SARC	cis	rs6138458	0.620	rs2151462	chr20:24911823	T/C	cg26195577	chr20:24973756	C20orf3	0.88	9.75	0.54	4.69e-19	Blood protein levels;
SARC	cis	rs3126085	0.877	rs57597406	chr1:152246619	C/G	cg03465714	chr1:152285911	FLG	-0.45	-5.45	-0.34	1.25e-7	Atopic dermatitis;
SARC	cis	rs10876993	0.749	rs703832	chr12:58024626	G/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.52	-6.44	-0.39	6.8e-10	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs6977660	0.652	rs10267417	chr7:19843797	C/T	cg05791153	chr7:19748676	TWISTNB	0.63	5.15	0.32	5.64e-7	Thyroid stimulating hormone;
SARC	cis	rs4664308	1.000	rs17831251	chr2:160914156	C/T	cg03641300	chr2:160917029	PLA2R1	-0.7	-9.41	-0.52	4.82e-18	Idiopathic membranous nephropathy;
SARC	cis	rs2153535	0.580	rs2184583	chr6:8447808	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	8.38	0.48	5.16e-15	Motion sickness;
SARC	cis	rs854765	0.533	rs2955354	chr17:17948716	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-9.75	-0.54	4.63e-19	Total body bone mineral density;
SARC	cis	rs920590	0.523	rs4464983	chr8:19680979	C/T	cg17834443	chr8:19674713	INTS10	-0.5	-6.01	-0.37	7.01e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2075371	0.933	rs432336	chr7:133949064	A/G	cg11752832	chr7:134001865	SLC35B4	0.53	6.81	0.41	8.12e-11	Mean platelet volume;
SARC	cis	rs910187	0.605	rs3787239	chr20:45802729	T/C	cg27589058	chr20:45804311	EYA2	-0.3	-4.78	-0.3	3.06e-6	Migraine;
SARC	cis	rs240764	0.817	rs239211	chr6:101144965	A/C	cg09795085	chr6:101329169	ASCC3	0.46	5.98	0.36	8.3e-9	Neuroticism;
SARC	cis	rs397969	0.596	rs4925064	chr17:19901405	T/C	cg13482628	chr17:19912719	NA	0.43	4.73	0.3	3.97e-6	Platelet count;
SARC	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg06713675	chr4:122721982	EXOSC9	-0.51	-6.6	-0.4	2.75e-10	Type 2 diabetes;
SARC	cis	rs804280	0.509	rs13276433	chr8:11783036	A/G	cg00262122	chr8:11665843	FDFT1	0.41	5.02	0.31	1.01e-6	Myopia (pathological);
SARC	cis	rs7833790	0.963	rs72686466	chr8:82758928	G/T	cg17211192	chr8:82754475	SNX16	0.59	6.43	0.39	7.2e-10	Diastolic blood pressure;
SARC	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg02297831	chr4:17616191	MED28	0.51	6.63	0.4	2.36e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9911578	1.000	rs437732	chr17:56675861	A/C	cg12560992	chr17:57184187	TRIM37	0.84	11.4	0.6	3.14e-24	Intelligence (multi-trait analysis);
SARC	cis	rs12130219	0.500	rs1552991	chr1:152165878	C/T	cg25272121	chr1:152190972	HRNR	-0.4	-5.29	-0.33	2.76e-7	Inflammatory skin disease;
SARC	cis	rs2997447	0.668	rs59978831	chr1:26446351	T/A	cg19633962	chr1:26362018	EXTL1	-0.56	-5.06	-0.31	8.55e-7	QRS complex (12-leadsum);
SARC	cis	rs34172651	0.571	rs9922156	chr16:24704329	C/A	cg00339695	chr16:24857497	SLC5A11	-0.4	-5.62	-0.35	5.51e-8	Intelligence (multi-trait analysis);
SARC	cis	rs1023500	0.573	rs6002592	chr22:42476754	A/C	cg15557168	chr22:42548783	NA	0.35	4.81	0.3	2.67e-6	Schizophrenia;
SARC	cis	rs1707322	1.000	rs1707322	chr1:46505147	C/T	cg03146154	chr1:46216737	IPP	0.5	6.07	0.37	5.02e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs11083475	0.714	rs1471432	chr19:39260282	G/A	cg07905965	chr19:39260460	NA	0.49	8.03	0.47	4.83e-14	Heart rate;
SARC	cis	rs3857067	0.806	rs6532472	chr4:95110113	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.05	-0.31	8.98e-7	QT interval;
SARC	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg07701084	chr6:150067640	NUP43	0.41	5.43	0.34	1.38e-7	Lung cancer;
SARC	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg04287289	chr16:89883240	FANCA	-0.75	-10.72	-0.57	4.69e-22	Vitiligo;
SARC	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg08219700	chr8:58056026	NA	0.57	5.51	0.34	9.69e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs11098499	0.909	rs1546504	chr4:120241179	C/T	cg25214090	chr10:38739885	LOC399744	0.55	7.17	0.43	9.85e-12	Corneal astigmatism;
SARC	cis	rs981844	0.689	rs7666762	chr4:154684197	C/T	cg14289246	chr4:154710475	SFRP2	-0.61	-7.12	-0.42	1.37e-11	Response to statins (LDL cholesterol change);
SARC	cis	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg11764359	chr7:65958608	NA	0.65	7.21	0.43	7.77e-12	Aortic root size;
SARC	cis	rs6759839	0.844	rs16982394	chr2:16624749	A/C	cg09580478	chr2:16689509	NA	0.44	5.7	0.35	3.6e-8	Mean platelet volume;
SARC	cis	rs17445774	1.000	rs1509833	chr2:200865225	G/A	cg23649088	chr2:200775458	C2orf69	0.6	7.99	0.46	6.19e-14	LDL cholesterol to HDL cholesterol ratio;
SARC	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg16405210	chr4:1374714	KIAA1530	-0.5	-5.8	-0.36	2.13e-8	Obesity-related traits;
SARC	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg18252515	chr7:66147081	NA	1.35	12.11	0.62	1.7e-26	Diabetic kidney disease;
SARC	cis	rs2070488	0.932	rs1841776	chr3:38480727	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	14.64	0.69	7.76e-35	Electrocardiographic conduction measures;
SARC	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg02896835	chr1:92012615	NA	-0.5	-6.98	-0.42	2.97e-11	Breast cancer;
SARC	trans	rs61931739	0.929	rs10844730	chr12:34026721	C/G	cg13010199	chr12:38710504	ALG10B	-0.56	-7.5	-0.44	1.34e-12	Morning vs. evening chronotype;
SARC	cis	rs56104184	0.830	rs17272658	chr19:49355405	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.97	-8.86	-0.5	2.03e-16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs2952156	0.920	rs1476278	chr17:37836243	C/T	cg07936489	chr17:37558343	FBXL20	-0.42	-5.45	-0.34	1.25e-7	Asthma;
SARC	cis	rs637571	0.522	rs566590	chr11:65754062	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.83	12.28	0.63	4.65e-27	Eosinophil percentage of white cells;
SARC	cis	rs1865760	0.566	rs9379825	chr6:26083871	C/A	cg17691542	chr6:26056736	HIST1H1C	0.52	6.41	0.39	8.05e-10	Height;
SARC	cis	rs739401	0.611	rs2239900	chr11:3030992	C/T	cg25174290	chr11:3078921	CARS	0.54	7.26	0.43	5.91e-12	Longevity;
SARC	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg05872129	chr22:39784769	NA	-0.44	-5.97	-0.36	8.67e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs2361718	1.000	rs2361718	chr17:78103466	C/T	cg27427491	chr17:78079615	GAA	-0.31	-5.19	-0.32	4.68e-7	Yeast infection;
SARC	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg06028808	chr11:68637592	NA	0.41	5.12	0.32	6.29e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7833790	0.929	rs10958048	chr8:82792914	C/T	cg27398817	chr8:82754497	SNX16	0.5	5.54	0.34	8.13e-8	Diastolic blood pressure;
SARC	cis	rs3126085	0.935	rs4421596	chr1:152181673	G/A	cg03465714	chr1:152285911	FLG	-0.46	-5.51	-0.34	9.24e-8	Atopic dermatitis;
SARC	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg24549020	chr5:56110836	MAP3K1	0.71	7.47	0.44	1.59e-12	Initial pursuit acceleration;
SARC	cis	rs10870270	0.957	rs9971084	chr10:133788747	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.43	-4.77	-0.3	3.21e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg11987759	chr7:65425863	GUSB	-0.58	-7.64	-0.45	5.63e-13	Aortic root size;
SARC	cis	rs453301	0.624	rs2288671	chr8:8860894	T/C	cg11995313	chr8:8860691	ERI1	-0.38	-5.01	-0.31	1.1e-6	Joint mobility (Beighton score);
SARC	cis	rs9902453	0.765	rs12601647	chr17:28164953	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	7.19	0.43	8.98e-12	Coffee consumption (cups per day);
SARC	cis	rs9322193	0.607	rs3798763	chr6:150211100	T/C	cg11878867	chr6:150167359	LRP11	-0.41	-4.86	-0.3	2.18e-6	Lung cancer;
SARC	trans	rs3804024	1.000	rs55692551	chr21:41984050	G/T	cg03228353	chr1:161520094	FCGR3A	0.57	7.05	0.42	2.03e-11	Obesity-related traits;
SARC	cis	rs3750965	0.959	rs3376	chr11:68856680	G/A	cg06818126	chr11:68850279	TPCN2	-0.41	-4.74	-0.3	3.71e-6	Hair color;
SARC	cis	rs11098499	0.863	rs1552092	chr4:120488496	C/T	cg24375607	chr4:120327624	NA	0.42	4.92	0.31	1.64e-6	Corneal astigmatism;
SARC	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg02841227	chr6:26021843	HIST1H4A	0.63	7.28	0.43	5e-12	Intelligence (multi-trait analysis);
SARC	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg23262073	chr20:60523788	NA	-0.38	-5.12	-0.32	6.29e-7	Body mass index;
SARC	cis	rs1865760	1.000	rs7739966	chr6:25906040	T/C	cg16482183	chr6:26056742	HIST1H1C	0.5	6.22	0.38	2.27e-9	Height;
SARC	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg08677398	chr8:58056175	NA	0.43	5.09	0.32	7.42e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs4803468	1.000	rs2288871	chr19:41917868	C/T	cg09537434	chr19:41945824	ATP5SL	-0.98	-17.56	-0.75	1.59e-44	Height;
SARC	trans	rs61931739	0.929	rs1844524	chr12:34094709	A/T	cg26384229	chr12:38710491	ALG10B	-0.53	-7.16	-0.42	1.02e-11	Morning vs. evening chronotype;
SARC	cis	rs9815354	0.680	rs79211428	chr3:41921810	C/T	cg03022575	chr3:42003672	ULK4	0.61	5.26	0.33	3.3e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs4268898	0.552	rs12620938	chr2:24367122	C/A	cg06627628	chr2:24431161	ITSN2	0.48	6.22	0.38	2.29e-9	Asthma;
SARC	cis	rs9303401	0.614	rs34683543	chr17:56520036	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.03	11.16	0.59	1.89e-23	Cognitive test performance;
SARC	cis	rs7647973	0.626	rs1491985	chr3:49739507	G/C	cg03060546	chr3:49711283	APEH	0.61	6.47	0.39	5.6e-10	Menarche (age at onset);
SARC	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg12288994	chr5:1860383	NA	0.35	5.78	0.35	2.43e-8	Cardiovascular disease risk factors;
SARC	cis	rs6062302	0.522	rs2872810	chr20:62241931	C/T	cg09650180	chr20:62225654	GMEB2	0.42	5.14	0.32	5.71e-7	Glioblastoma;
SARC	cis	rs208515	0.525	rs4145045	chr6:66678949	T/C	cg07460842	chr6:66804631	NA	0.86	9.87	0.54	2.02e-19	Exhaled nitric oxide levels;
SARC	cis	rs453301	0.686	rs1045527	chr8:8890041	A/G	cg06636001	chr8:8085503	FLJ10661	-0.6	-8.09	-0.47	3.35e-14	Joint mobility (Beighton score);
SARC	cis	rs6831352	0.918	rs2602896	chr4:100046207	C/T	cg13256891	chr4:100009986	ADH5	-0.68	-8.48	-0.49	2.67e-15	Alcohol dependence;
SARC	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg02951883	chr7:2050386	MAD1L1	-0.49	-6.91	-0.41	4.66e-11	Schizophrenia;
SARC	cis	rs9309473	0.898	rs6546852	chr2:73833431	G/A	cg07208825	chr2:73871855	ALMS1P	0.35	5.14	0.32	5.87e-7	Metabolite levels;
SARC	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg06618935	chr21:46677482	NA	-0.39	-5.13	-0.32	6.02e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7824557	0.628	rs11250129	chr8:11202154	G/A	cg21775007	chr8:11205619	TDH	0.65	8.53	0.49	1.91e-15	Retinal vascular caliber;
SARC	cis	rs995000	0.895	rs11208001	chr1:63130431	C/T	cg06896770	chr1:63153194	DOCK7	0.92	14.18	0.68	2.49e-33	Triglyceride levels;
SARC	trans	rs1973993	0.691	rs1980684	chr1:96890636	A/G	cg10631902	chr5:14652156	NA	0.5	8.65	0.49	8.76e-16	Weight;
SARC	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg21782813	chr7:2030301	MAD1L1	-0.32	-5.02	-0.31	1.02e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs7667	1.000	rs7667	chr1:19718824	C/T	cg15311933	chr1:19638897	PQLC2;AKR7A2	-0.46	-5.45	-0.34	1.31e-7	Crohn's disease and psoriasis;
SARC	cis	rs3768617	0.510	rs3768624	chr1:183079252	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.8e-21	Fuchs's corneal dystrophy;
SARC	cis	rs7772486	0.790	rs2247666	chr6:146220409	C/A	cg05347473	chr6:146136440	FBXO30	0.49	6.63	0.4	2.33e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6942407	0.546	rs10228392	chr7:86799673	A/T	cg02420886	chr7:86849541	C7orf23	0.72	6.32	0.38	1.3e-9	Food allergy;
SARC	cis	rs3126085	0.867	rs36033453	chr1:152221226	T/G	cg09127314	chr1:152161683	NA	-0.42	-4.79	-0.3	2.98e-6	Atopic dermatitis;
SARC	cis	rs7336332	0.628	rs9581855	chr13:28018014	G/A	cg01674679	chr13:27998804	GTF3A	-0.5	-4.85	-0.3	2.27e-6	Weight;
SARC	cis	rs1865760	0.566	rs3752419	chr6:26027433	C/T	cg02841227	chr6:26021843	HIST1H4A	0.41	4.96	0.31	1.39e-6	Height;
SARC	cis	rs2531992	1.000	rs710893	chr16:4014964	A/G	cg05927578	chr16:4029543	ADCY9	0.43	4.96	0.31	1.34e-6	Waist circumference;
SARC	cis	rs2120243	0.504	rs1824058	chr3:157124780	C/A	cg24825693	chr3:157122686	VEPH1	-0.46	-6.38	-0.39	9.19e-10	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg22974920	chr21:40686053	BRWD1	0.45	4.88	0.3	1.94e-6	Cognitive function;
SARC	cis	rs1728785	1.000	rs3203684	chr16:68600440	C/T	cg02972257	chr16:68554789	NA	0.46	5.35	0.33	2.06e-7	Ulcerative colitis;
SARC	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg08742575	chr21:47604166	C21orf56	-0.42	-5.32	-0.33	2.44e-7	Testicular germ cell tumor;
SARC	trans	rs6894249	1.000	rs6894249	chr5:131797547	A/G	cg04671329	chr10:105614985	SH3PXD2A	0.51	6.27	0.38	1.76e-9	Asthma;
SARC	cis	rs11608355	0.515	rs11609630	chr12:109918934	C/T	cg05360138	chr12:110035743	NA	0.94	9.47	0.53	3.36e-18	Neuroticism;
SARC	cis	rs981844	0.922	rs75543972	chr4:154664792	G/C	cg14289246	chr4:154710475	SFRP2	0.58	6.68	0.4	1.71e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg05863683	chr7:1912471	MAD1L1	0.33	5.0	0.31	1.15e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs7819412	0.539	rs11250131	chr8:11251175	C/T	cg21775007	chr8:11205619	TDH	-0.57	-7.61	-0.45	6.6e-13	Triglycerides;
SARC	cis	rs924607	1.000	rs4045344	chr5:595870	G/T	cg09021430	chr5:549028	NA	0.34	6.39	0.39	8.84e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs1949733	0.675	rs2688235	chr4:8450546	T/C	cg13073564	chr4:8508604	NA	-0.44	-7.02	-0.42	2.42e-11	Response to antineoplastic agents;
SARC	cis	rs9987353	0.544	rs2929469	chr8:9062656	T/G	cg06636001	chr8:8085503	FLJ10661	0.6	7.84	0.46	1.56e-13	Recombination measurement;
SARC	cis	rs3796352	1.000	rs114562844	chr3:52991584	C/T	cg27565382	chr3:53032988	SFMBT1	0.83	5.57	0.34	7.16e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs12311304	0.965	rs73055263	chr12:15417595	A/C	cg08258403	chr12:15378311	NA	0.48	7.09	0.42	1.56e-11	Behavioural disinhibition (generation interaction);
SARC	cis	rs6580649	0.941	rs72644847	chr12:48516093	C/A	cg24011408	chr12:48396354	COL2A1	-0.47	-5.16	-0.32	5.2e-7	Lung cancer;
SARC	cis	rs1865721	0.656	rs724765	chr18:73139794	A/G	cg26385618	chr18:73139727	C18orf62	-0.34	-4.95	-0.31	1.4e-6	Intelligence;
SARC	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-7.12	-0.42	1.37e-11	Alzheimer's disease;
SARC	cis	rs9640161	0.830	rs17173682	chr7:150059602	A/G	cg10018233	chr7:150070692	REPIN1	0.69	10.12	0.55	3.58e-20	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs16976116	0.951	rs13733	chr15:55489104	A/G	cg11288833	chr15:55489084	RSL24D1	0.6	5.9	0.36	1.3e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9916302	0.706	rs9906612	chr17:37547631	A/C	cg15445000	chr17:37608096	MED1	-0.46	-4.91	-0.31	1.7e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs7264396	0.747	rs6058291	chr20:34247769	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	5.9	0.36	1.24e-8	Total cholesterol levels;
SARC	trans	rs9650657	0.655	rs10093774	chr8:10703293	C/T	cg06636001	chr8:8085503	FLJ10661	0.59	7.81	0.46	1.96e-13	Neuroticism;
SARC	cis	rs4423214	1.000	rs4944062	chr11:71187294	G/T	cg24826892	chr11:71159390	DHCR7	0.47	6.0	0.37	7.59e-9	Vitamin D levels;
SARC	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg12310025	chr6:25882481	NA	0.49	6.31	0.38	1.38e-9	Blood metabolite levels;
SARC	cis	rs3106136	0.681	rs6847590	chr4:95311787	C/T	cg11021082	chr4:95130006	SMARCAD1	0.32	4.87	0.3	2.06e-6	Capecitabine sensitivity;
SARC	cis	rs7617480	0.648	rs14018	chr3:48784270	G/A	cg07636037	chr3:49044803	WDR6	0.87	8.93	0.51	1.28e-16	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs826838	0.802	rs10785619	chr12:38742897	T/A	cg26384229	chr12:38710491	ALG10B	0.83	12.5	0.63	9.21e-28	Heart rate;
SARC	cis	rs1144333	0.655	rs12401729	chr1:76336586	T/G	cg03433033	chr1:76189801	ACADM	0.61	4.94	0.31	1.46e-6	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs66573146	1.000	rs7686186	chr4:6986094	C/T	cg00086871	chr4:6988644	TBC1D14	0.99	5.28	0.33	2.99e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs73001065	0.818	rs10500212	chr19:19723215	C/T	cg03709012	chr19:19516395	GATAD2A	0.84	5.87	0.36	1.48e-8	LDL cholesterol;
SARC	cis	rs9660992	0.573	rs12126439	chr1:205200720	C/T	cg00857998	chr1:205179979	DSTYK	0.51	6.31	0.38	1.39e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg25427524	chr10:38739819	LOC399744	0.59	9.07	0.51	4.99e-17	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs1971762	0.545	rs10783585	chr12:53977317	T/G	cg06632207	chr12:54070931	ATP5G2	0.56	7.56	0.44	9.36e-13	Height;
SARC	cis	rs672059	0.806	rs3754524	chr1:183153267	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.56	7.74	0.45	3.02e-13	Hypertriglyceridemia;
SARC	cis	rs6582630	0.615	rs11182380	chr12:38511735	G/T	cg14851346	chr12:38532713	NA	-0.43	-5.13	-0.32	5.97e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7872515	0.887	rs58129324	chr9:94839105	T/C	cg01248375	chr9:94877805	SPTLC1	0.66	5.96	0.36	9.26e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs17666538	0.591	rs1669716	chr8:593707	C/T	cg02524346	chr8:600233	NA	0.58	5.13	0.32	5.97e-7	IgG glycosylation;
SARC	cis	rs6831352	0.589	rs2924584	chr4:99988208	A/G	cg13256891	chr4:100009986	ADH5	0.65	9.5	0.53	2.7e-18	Alcohol dependence;
SARC	cis	rs10463554	1.000	rs10463554	chr5:102318974	T/C	cg23492399	chr5:102201601	PAM	-0.51	-6.41	-0.39	8.01e-10	Parkinson's disease;
SARC	cis	rs9309473	0.660	rs17349321	chr2:73643753	C/T	cg07208825	chr2:73871855	ALMS1P	0.38	4.97	0.31	1.3e-6	Metabolite levels;
SARC	cis	rs11718455	0.883	rs4682926	chr3:44006170	C/T	cg08738300	chr3:44038990	NA	0.54	5.94	0.36	1.01e-8	Coronary artery disease;
SARC	cis	rs73198271	0.813	rs17697237	chr8:8615874	A/C	cg01851573	chr8:8652454	MFHAS1	-0.36	-5.08	-0.32	7.59e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg12463550	chr7:65579703	CRCP	0.48	5.24	0.32	3.65e-7	Aortic root size;
SARC	cis	rs7772486	0.720	rs1890171	chr6:146072114	T/C	cg23711669	chr6:146136114	FBXO30	-0.92	-16.53	-0.73	3.75e-41	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs208520	1.000	rs208523	chr6:66954195	G/C	cg07460842	chr6:66804631	NA	-0.86	-9.56	-0.53	1.79e-18	Exhaled nitric oxide output;
SARC	cis	rs9381040	0.655	rs4140578	chr6:41041829	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-5.16	-0.32	5.23e-7	Alzheimer's disease (late onset);
SARC	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	14.0	0.68	9.94e-33	Chronic sinus infection;
SARC	cis	rs4972806	0.849	rs2857541	chr2:177029086	C/T	cg14236662	chr2:176988284	HOXD9	0.37	5.18	0.32	4.76e-7	IgG glycosylation;
SARC	cis	rs10791323	0.572	rs10791334	chr11:133735810	A/C	cg13461336	chr11:133711254	SPATA19	-0.27	-4.79	-0.3	2.98e-6	Childhood ear infection;
SARC	cis	rs360798	1.000	rs6758263	chr2:62909466	G/T	cg16915676	chr2:62734870	TMEM17	0.43	4.91	0.31	1.72e-6	Coronary artery disease;
SARC	cis	rs10992471	0.598	rs1175788	chr9:95117798	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.4	-4.87	-0.3	2.02e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs2380220	0.541	rs9285413	chr6:96023439	G/A	cg04719120	chr6:96025338	MANEA	0.7	7.9	0.46	1.13e-13	Behavioural disinhibition (generation interaction);
SARC	cis	rs9467711	0.591	rs10484435	chr6:26031811	A/C	cg21479132	chr6:26055353	NA	0.9	5.98	0.37	8.11e-9	Autism spectrum disorder or schizophrenia;
SARC	trans	rs11039798	0.588	rs10838979	chr11:48626810	T/G	cg15704280	chr7:45808275	SEPT13	0.6	6.34	0.38	1.19e-9	Axial length;
SARC	cis	rs738322	0.935	rs4384	chr22:38572440	G/C	cg25457927	chr22:38595422	NA	-0.31	-6.58	-0.4	3.01e-10	Cutaneous nevi;
SARC	cis	rs17270561	0.583	rs9393661	chr6:25739080	C/T	cg17691542	chr6:26056736	HIST1H1C	0.58	7.09	0.42	1.6e-11	Iron status biomarkers;
SARC	cis	rs4727027	0.933	rs12667123	chr7:148850621	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	5.55	0.34	7.58e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs67478160	0.643	rs3742369	chr14:104251276	T/C	cg08213375	chr14:104286397	PPP1R13B	0.26	4.72	0.3	4.02e-6	Schizophrenia;
SARC	cis	rs9513627	0.749	rs73556143	chr13:100116907	G/A	cg25919922	chr13:100150906	NA	-0.76	-5.44	-0.34	1.33e-7	Obesity-related traits;
SARC	cis	rs6788895	1.000	rs73010930	chr3:150469735	G/A	cg09723797	chr3:150481914	SIAH2	0.76	4.8	0.3	2.86e-6	Breast cancer;
SARC	cis	rs763121	0.853	rs2413544	chr22:39059404	A/C	cg06022373	chr22:39101656	GTPBP1	0.91	11.32	0.6	5.9e-24	Menopause (age at onset);
SARC	cis	rs9814567	0.806	rs4955534	chr3:134319723	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.51	-6.63	-0.4	2.36e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	trans	rs61931739	0.517	rs2636073	chr12:34063049	C/T	cg26384229	chr12:38710491	ALG10B	0.74	10.17	0.55	2.49e-20	Morning vs. evening chronotype;
SARC	cis	rs1728785	1.000	rs1728780	chr16:68567642	G/C	cg02972257	chr16:68554789	NA	-0.44	-5.15	-0.32	5.43e-7	Ulcerative colitis;
SARC	cis	rs2204008	0.694	rs1672436	chr12:38132547	G/T	cg13010199	chr12:38710504	ALG10B	-0.59	-7.49	-0.44	1.41e-12	Bladder cancer;
SARC	cis	rs6840360	0.571	rs62327274	chr4:152548012	C/T	cg22705602	chr4:152727874	NA	-0.44	-6.84	-0.41	7.02e-11	Intelligence (multi-trait analysis);
SARC	trans	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg19474418	chr3:9834677	ARPC4;TADA3	-0.52	-6.4	-0.39	8.53e-10	Colonoscopy-negative controls vs population controls;
SARC	cis	rs765787	0.530	rs4774550	chr15:45542312	C/T	cg25801113	chr15:45476975	SHF	0.28	4.73	0.3	3.89e-6	Uric acid levels;
SARC	cis	rs709400	0.628	rs7155014	chr14:103863970	C/G	cg12935359	chr14:103987150	CKB	-0.38	-5.6	-0.34	5.93e-8	Body mass index;
SARC	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg04181038	chr4:183730758	NA	0.57	6.52	0.39	4.34e-10	Pediatric autoimmune diseases;
SARC	cis	rs796364	0.951	rs35618222	chr2:201065777	C/G	cg05691004	chr2:201170426	SPATS2L	-0.44	-4.76	-0.3	3.35e-6	Schizophrenia;
SARC	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg07061783	chr6:25882402	NA	-0.43	-5.3	-0.33	2.68e-7	Intelligence (multi-trait analysis);
SARC	trans	rs1814175	0.645	rs847632	chr11:49926097	C/T	cg15704280	chr7:45808275	SEPT13	-0.89	-14.11	-0.68	4.34e-33	Height;
SARC	trans	rs17221829	0.733	rs11018668	chr11:89356178	C/T	cg05498379	chr10:28821244	WAC	-0.51	-6.95	-0.41	3.55e-11	Anxiety in major depressive disorder;
SARC	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	5.43	0.34	1.41e-7	Personality dimensions;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg18067644	chr22:46932066	CELSR1	-0.52	-6.71	-0.4	1.5e-10	Blood pressure;
SARC	cis	rs4253772	0.591	rs6007747	chr22:46657261	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.65	7.01	0.42	2.62e-11	LDL cholesterol;Cholesterol, total;
SARC	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg20607798	chr8:58055168	NA	0.58	5.57	0.34	6.9e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10779751	0.734	rs2791657	chr1:11128001	A/G	cg04508216	chr1:11107452	MASP2	0.34	4.75	0.3	3.52e-6	Body mass index;
SARC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-4.93	-0.31	1.59e-6	Total body bone mineral density;
SARC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg07362569	chr17:61921086	SMARCD2	-0.39	-5.13	-0.32	5.98e-7	Prudent dietary pattern;
SARC	cis	rs73086581	0.787	rs67633417	chr20:3868257	C/G	cg02187196	chr20:3869020	PANK2	0.67	5.88	0.36	1.38e-8	Response to antidepressants in depression;
SARC	trans	rs34421088	0.560	rs2248315	chr8:11397086	T/A	cg06636001	chr8:8085503	FLJ10661	-0.66	-9.15	-0.51	3e-17	Neuroticism;
SARC	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg24549020	chr5:56110836	MAP3K1	-0.51	-5.66	-0.35	4.38e-8	Initial pursuit acceleration;
SARC	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg11890956	chr21:40555474	PSMG1	-0.72	-9.53	-0.53	2.13e-18	Menarche (age at onset);
SARC	cis	rs9916302	0.861	rs10491129	chr17:37461643	T/G	cg20243544	chr17:37824526	PNMT	-0.55	-6.57	-0.4	3.21e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs3734905	0.656	rs2902923	chr6:169813336	G/A	cg15038512	chr6:170123185	PHF10	0.58	5.25	0.33	3.43e-7	HIV-1 control;
SARC	cis	rs13256369	0.802	rs4840350	chr8:8561442	A/G	cg18904891	chr8:8559673	CLDN23	0.47	5.32	0.33	2.45e-7	Obesity-related traits;
SARC	cis	rs3820928	0.709	rs10178202	chr2:227914561	C/T	cg11843606	chr2:227700838	RHBDD1	-0.49	-5.6	-0.34	5.92e-8	Pulmonary function;
SARC	trans	rs897080	0.515	rs1067366	chr2:44655094	T/C	cg19364021	chr13:53776396	NA	0.47	6.34	0.38	1.15e-9	Height;
SARC	cis	rs3091242	0.933	rs3093584	chr1:25668714	T/C	cg23205692	chr1:25664452	TMEM50A	-0.46	-5.56	-0.34	7.21e-8	Erythrocyte sedimentation rate;
SARC	cis	rs881375	0.678	rs1014530	chr9:123685092	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	6.68	0.4	1.7e-10	Rheumatoid arthritis;
SARC	cis	rs6693567	0.507	rs4970964	chr1:150458029	A/G	cg09579323	chr1:150459698	TARS2	0.44	5.61	0.34	5.76e-8	Migraine;
SARC	cis	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg13647721	chr17:30228624	UTP6	0.69	6.29	0.38	1.59e-9	Hip circumference adjusted for BMI;
SARC	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg11965913	chr1:205819406	PM20D1	0.43	4.85	0.3	2.31e-6	Parkinson's disease;
SARC	cis	rs698813	0.763	rs786615	chr2:44590608	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.65	7.74	0.45	3e-13	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg03433033	chr1:76189801	ACADM	0.52	7.42	0.44	2.21e-12	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6500602	0.727	rs4786515	chr16:4578133	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.32	5.24	0.32	3.68e-7	Schizophrenia;
SARC	cis	rs6772849	0.930	rs12487604	chr3:128337075	T/A	cg08795948	chr3:128337044	NA	0.55	7.58	0.44	8.12e-13	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs9810259	0.588	rs7620165	chr3:12344441	C/T	cg04748988	chr3:12329223	PPARG	0.41	5.27	0.33	3.14e-7	Platelet count;
SARC	cis	rs11833313	1	rs11833313	chr12:110510470	A/G	cg08946844	chr12:110511112	NA	0.63	5.02	0.31	1.03e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7223966	0.921	rs2854207	chr17:61947107	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-5.18	-0.32	4.81e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2832077	0.943	rs2832099	chr21:30173460	A/G	cg24692254	chr21:30365293	RNF160	-0.51	-4.77	-0.3	3.28e-6	Cognitive test performance;
SARC	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.67	-8.05	-0.47	4.35e-14	Gut microbiome composition (summer);
SARC	cis	rs12291225	0.679	rs11369	chr11:14288096	A/G	cg19336497	chr11:14380999	RRAS2	-0.4	-6.72	-0.4	1.34e-10	Sense of smell;
SARC	cis	rs13034020	0.641	rs12996153	chr2:61222736	A/G	cg18625361	chr2:61244694	PEX13;PUS10	-0.63	-5.28	-0.33	2.9e-7	Hodgkin's lymphoma;
SARC	cis	rs10754283	0.871	rs72712569	chr1:90125657	G/C	cg21401794	chr1:90099060	LRRC8C	-0.56	-7.34	-0.43	3.45e-12	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs11098499	0.754	rs1980025	chr4:120252806	A/G	cg09307838	chr4:120376055	NA	-0.8	-10.81	-0.58	2.41e-22	Corneal astigmatism;
SARC	cis	rs57221529	0.766	rs56278696	chr5:582669	A/G	cg07777115	chr5:623756	CEP72	-0.56	-4.83	-0.3	2.49e-6	Lung disease severity in cystic fibrosis;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg11266921	chr6:38608106	BTBD9	-0.61	-7.05	-0.42	2.04e-11	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs7000551	0.505	rs73227818	chr8:22243325	T/C	cg12081754	chr8:22256438	SLC39A14	0.77	10.29	0.56	1.01e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg06873352	chr17:61820015	STRADA	0.53	6.86	0.41	6.24e-11	Prudent dietary pattern;
SARC	cis	rs12044355	0.927	rs17748239	chr1:231834901	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-7.88	-0.46	1.25e-13	Alzheimer's disease;
SARC	cis	rs61935443	0.720	rs10859783	chr12:95285339	A/G	cg21533806	chr12:95267307	NA	0.7	8.35	0.48	6.01e-15	Schizophrenia;
SARC	cis	rs826838	1.000	rs1963562	chr12:38662896	C/T	cg26384229	chr12:38710491	ALG10B	0.93	14.73	0.69	3.88e-35	Heart rate;
SARC	cis	rs2066819	0.901	rs773665	chr12:56717466	C/T	cg26734620	chr12:56694298	CS	-0.86	-6.37	-0.39	1.01e-9	Psoriasis vulgaris;
SARC	cis	rs9457247	1.000	rs422094	chr6:167397033	C/G	cg23791538	chr6:167370224	RNASET2	-0.63	-8.73	-0.5	4.9e-16	Crohn's disease;
SARC	cis	rs754466	0.580	rs2579178	chr10:79529215	A/G	cg17075019	chr10:79541650	NA	0.81	11.83	0.61	1.39e-25	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7714584	1.000	rs11749391	chr5:150229066	T/C	cg22134413	chr5:150180641	NA	0.75	6.33	0.38	1.27e-9	Crohn's disease;
SARC	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg16049864	chr8:95962084	TP53INP1	-0.48	-7.83	-0.46	1.72e-13	Type 2 diabetes;
SARC	cis	rs1580019	0.922	rs1466147	chr7:32486262	C/T	cg07520158	chr7:32535189	LSM5;AVL9	0.42	4.99	0.31	1.16e-6	Cognitive ability;
SARC	cis	rs9400467	0.537	rs12195305	chr6:111449228	G/A	cg15721981	chr6:111408429	SLC16A10	0.69	5.96	0.36	9.46e-9	Blood metabolite levels;Amino acid levels;
SARC	cis	rs12594515	0.967	rs67854274	chr15:45990518	A/G	cg14863074	chr15:45997064	NA	0.34	5.24	0.32	3.57e-7	Waist circumference;Weight;
SARC	cis	rs4253772	0.550	rs6007819	chr22:46704916	C/G	cg24881330	chr22:46731750	TRMU	0.67	5.68	0.35	3.91e-8	LDL cholesterol;Cholesterol, total;
SARC	cis	rs739401	0.527	rs418832	chr11:3072236	C/T	cg20651018	chr11:3035856	CARS	-0.46	-7.07	-0.42	1.83e-11	Longevity;
SARC	cis	rs11673344	0.566	rs2385180	chr19:37922356	T/C	cg14683738	chr19:37701593	ZNF585B	0.46	5.48	0.34	1.08e-7	Obesity-related traits;
SARC	trans	rs656319	0.513	rs6985941	chr8:9983179	C/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.1	-0.42	1.47e-11	Myopia (pathological);
SARC	cis	rs73086581	1.000	rs6052218	chr20:3970212	A/G	cg02187196	chr20:3869020	PANK2	0.67	6.46	0.39	6.21e-10	Response to antidepressants in depression;
SARC	trans	rs747334	0.846	rs7897603	chr10:92708759	C/G	cg21107223	chr15:75182455	MPI	-0.47	-6.35	-0.38	1.11e-9	Fibroblast growth factor basic levels;
SARC	cis	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg03213289	chr20:61660250	NA	0.46	6.43	0.39	7.22e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs7084402	0.967	rs1649035	chr10:60332701	A/T	cg07615347	chr10:60278583	BICC1	0.57	8.08	0.47	3.58e-14	Refractive error;
SARC	cis	rs12446492	1.000	rs12446492	chr16:20408377	A/T	cg07222434	chr16:20395031	PDILT	0.28	4.8	0.3	2.81e-6	Urinary uromodulin levels;
SARC	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg27170947	chr2:26402098	FAM59B	-0.37	-4.77	-0.3	3.23e-6	Gut microbiome composition (summer);
SARC	trans	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg06636001	chr8:8085503	FLJ10661	-0.72	-10.06	-0.55	5.23e-20	Neuroticism;
SARC	cis	rs965469	1.000	rs6037526	chr20:3251248	T/C	cg25506879	chr20:3388711	C20orf194	-0.5	-5.11	-0.32	6.73e-7	IFN-related cytopenia;
SARC	cis	rs2180341	0.961	rs910720	chr6:127619070	T/C	cg17762328	chr6:126965162	NA	-0.46	-5.24	-0.32	3.55e-7	Breast cancer;
SARC	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg10435706	chr6:150039699	LATS1	0.36	4.78	0.3	3.04e-6	Lung cancer;
SARC	cis	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg25427524	chr10:38739819	LOC399744	-0.55	-8.74	-0.5	4.69e-16	Extrinsic epigenetic age acceleration;
SARC	cis	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg11987759	chr7:65425863	GUSB	-0.64	-8.14	-0.47	2.43e-14	Aortic root size;
SARC	trans	rs1635	0.655	rs58019071	chr6:28304016	T/C	cg08080395	chr15:65488966	CILP	0.66	6.47	0.39	5.71e-10	Schizophrenia;
SARC	cis	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg01579765	chr21:45077557	HSF2BP	-0.37	-6.31	-0.38	1.38e-9	Mean corpuscular volume;
SARC	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.38	-4.8	-0.3	2.86e-6	Lymphocyte counts;
SARC	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg22433210	chr17:43662623	NA	-0.96	-11.3	-0.59	6.64e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs5758511	0.680	rs5758681	chr22:42645091	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.45	6.73	0.4	1.34e-10	Birth weight;
SARC	cis	rs10911232	0.507	rs4422969	chr1:183020762	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.11	0.55	3.63e-20	Hypertriglyceridemia;
SARC	cis	rs9473924	0.542	rs9473925	chr6:50834565	T/C	cg14470998	chr6:50812995	TFAP2B	0.74	6.72	0.4	1.36e-10	Body mass index;
SARC	cis	rs9616064	0.506	rs6008944	chr22:47060976	C/T	cg25730555	chr22:47059586	GRAMD4	0.37	4.88	0.3	1.99e-6	Urate levels in obese individuals;
SARC	cis	rs10982256	0.904	rs4527950	chr9:117267472	G/T	cg21159778	chr9:117266918	DFNB31	0.4	5.8	0.36	2.14e-8	Bipolar disorder;
SARC	cis	rs981844	0.796	rs13140722	chr4:154712203	T/A	cg14289246	chr4:154710475	SFRP2	-0.63	-7.04	-0.42	2.19e-11	Response to statins (LDL cholesterol change);
SARC	cis	rs611744	0.647	rs10106246	chr8:109268710	T/C	cg21045802	chr8:109455806	TTC35	0.57	7.1	0.42	1.45e-11	Dupuytren's disease;
SARC	cis	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg12257692	chr3:49977190	RBM6	-0.27	-4.83	-0.3	2.47e-6	Body mass index;
SARC	cis	rs2070677	0.935	rs4351775	chr10:135402200	C/T	cg20169779	chr10:135381914	SYCE1	-0.56	-6.55	-0.39	3.63e-10	Gout;
SARC	cis	rs614226	1.000	rs1167726	chr12:120967364	A/C	cg01236616	chr12:121019343	POP5	-1.27	-18.39	-0.77	2.85e-47	Type 1 diabetes nephropathy;
SARC	trans	rs2727020	0.521	rs7930855	chr11:49521660	C/T	cg03929089	chr4:120376271	NA	0.7	7.86	0.46	1.46e-13	Coronary artery disease;
SARC	cis	rs4481887	0.927	rs10749651	chr1:248472930	T/C	cg13385794	chr1:248469461	NA	0.35	5.45	0.34	1.29e-7	Common traits (Other);
SARC	trans	rs7819412	0.775	rs4841490	chr8:10936891	T/C	cg08975724	chr8:8085496	FLJ10661	-0.58	-7.81	-0.46	1.99e-13	Triglycerides;
SARC	trans	rs7615952	0.611	rs79405914	chr3:125723623	C/T	cg07211511	chr3:129823064	LOC729375	-0.83	-6.53	-0.39	4e-10	Blood pressure (smoking interaction);
SARC	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg17221315	chr6:27791827	HIST1H4J	0.48	4.94	0.31	1.47e-6	Parkinson's disease;
SARC	cis	rs11105298	0.891	rs11105287	chr12:89829470	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.51	-5.1	-0.32	6.97e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs8042680	0.688	rs4244883	chr15:91546497	T/G	cg08919649	chr15:91565780	VPS33B	0.43	5.01	0.31	1.09e-6	Type 2 diabetes;
SARC	cis	rs748404	0.697	rs475261	chr15:43546456	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.53	6.27	0.38	1.78e-9	Lung cancer;
SARC	cis	rs4481887	1.000	rs7525344	chr1:248467565	C/T	cg13385794	chr1:248469461	NA	-0.36	-5.5	-0.34	1.02e-7	Common traits (Other);
SARC	cis	rs11098499	0.588	rs6534149	chr4:120559292	T/G	cg09307838	chr4:120376055	NA	-0.72	-9.81	-0.54	3.04e-19	Corneal astigmatism;
SARC	cis	rs9291683	0.632	rs13101785	chr4:10042915	T/A	cg00071950	chr4:10020882	SLC2A9	0.39	6.29	0.38	1.52e-9	Bone mineral density;
SARC	cis	rs8114671	0.562	rs1060615	chr20:33478381	C/T	cg07148914	chr20:33460835	GGT7	-0.42	-5.23	-0.32	3.84e-7	Height;
SARC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg07414643	chr4:187882934	NA	0.52	7.82	0.46	1.83e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg00933542	chr6:150070202	PCMT1	0.31	5.29	0.33	2.83e-7	Lung cancer;
SARC	cis	rs1003719	0.762	rs1015551	chr21:38449510	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.67	9.98	0.55	9.34e-20	Eye color traits;
SARC	cis	rs4713118	0.866	rs2179094	chr6:27741825	T/C	cg17221315	chr6:27791827	HIST1H4J	0.49	5.36	0.33	2e-7	Parkinson's disease;
SARC	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg25894440	chr7:65020034	NA	-0.75	-5.67	-0.35	4.13e-8	Diabetic kidney disease;
SARC	cis	rs9916302	0.904	rs2338798	chr17:37547269	T/C	cg00129232	chr17:37814104	STARD3	0.61	7.55	0.44	1e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs3820928	0.874	rs6728239	chr2:227856552	A/G	cg05526886	chr2:227700861	RHBDD1	-0.49	-5.87	-0.36	1.5e-8	Pulmonary function;
SARC	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg08859206	chr1:53392774	SCP2	-0.4	-5.71	-0.35	3.41e-8	Monocyte count;
SARC	cis	rs912057	0.671	rs1294435	chr6:6745455	G/A	cg06612196	chr6:6737390	NA	0.63	9.56	0.53	1.8e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	trans	rs17453880	0.929	rs11948856	chr5:151983819	G/T	cg25372841	chr8:145675454	CYHR1	-0.46	-6.36	-0.38	1.05e-9	Subjective well-being;
SARC	trans	rs17685	0.712	rs28506984	chr7:75763484	A/G	cg19862616	chr7:65841803	NCRNA00174	0.63	7.78	0.45	2.35e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs7772486	0.603	rs2223411	chr6:146028767	T/C	cg05347473	chr6:146136440	FBXO30	-0.7	-9.91	-0.54	1.47e-19	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7560272	0.723	rs780391	chr2:73703904	C/T	cg20560298	chr2:73613845	ALMS1	0.55	7.44	0.44	1.88e-12	Schizophrenia;
SARC	cis	rs7552404	0.731	rs11588578	chr1:76400539	T/G	cg10523679	chr1:76189770	ACADM	0.44	4.99	0.31	1.17e-6	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg21016266	chr12:122356598	WDR66	0.42	6.5	0.39	4.91e-10	Mean corpuscular volume;
SARC	cis	rs3762637	1.000	rs7644540	chr3:122210052	C/T	cg24169773	chr3:122142474	KPNA1	-0.57	-5.79	-0.35	2.29e-8	LDL cholesterol levels;
SARC	cis	rs11105298	0.891	rs10858872	chr12:89872932	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.49	-5.0	-0.31	1.11e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs10883723	0.810	rs12162	chr10:104240498	A/G	ch.10.2196322F	chr10:104248062	ACTR1A	0.54	5.96	0.36	9.5e-9	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg15049968	chr18:44337910	ST8SIA5	-0.37	-6.03	-0.37	6.33e-9	Personality dimensions;
SARC	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.42	6.33	0.38	1.28e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs4481887	0.800	rs4514268	chr1:248444600	T/G	cg13385794	chr1:248469461	NA	0.31	4.73	0.3	3.94e-6	Common traits (Other);
SARC	cis	rs834603	0.546	rs1534138	chr7:47482750	T/C	cg23694490	chr7:47445681	TNS3	-0.32	-5.82	-0.36	1.94e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs4727027	0.704	rs13229244	chr7:148898219	A/C	cg23583168	chr7:148888333	NA	0.8	12.72	0.64	1.74e-28	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs2153535	0.580	rs7767926	chr6:8453557	A/G	cg23788917	chr6:8435910	SLC35B3	0.64	8.52	0.49	1.95e-15	Motion sickness;
SARC	cis	rs2230307	0.536	rs834278	chr1:100510882	T/C	cg24955406	chr1:100503596	HIAT1	0.66	6.38	0.39	9.42e-10	Carotid intima media thickness;
SARC	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg04518342	chr5:131593106	PDLIM4	-0.42	-5.25	-0.33	3.45e-7	Breast cancer;
SARC	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs992157	0.835	rs7559416	chr2:219150211	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.69	-10.08	-0.55	4.66e-20	Colorectal cancer;
SARC	cis	rs8141529	0.764	rs5762824	chr22:29222930	C/T	cg15103426	chr22:29168792	CCDC117	0.67	8.66	0.49	8.19e-16	Lymphocyte counts;
SARC	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	9.12	0.51	3.65e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg08677398	chr8:58056175	NA	0.42	4.99	0.31	1.2e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs2046867	0.818	rs17010188	chr3:72870351	T/C	cg25664220	chr3:72788482	NA	-0.29	-4.77	-0.3	3.27e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
SARC	cis	rs7769051	0.711	rs7758531	chr6:133085302	T/C	cg07930552	chr6:133119739	C6orf192	0.85	7.07	0.42	1.76e-11	Type 2 diabetes nephropathy;
SARC	cis	rs12421382	0.659	rs1837397	chr11:109389803	A/C	cg27471124	chr11:109292789	C11orf87	0.39	5.4	0.33	1.65e-7	Schizophrenia;
SARC	cis	rs7089973	0.624	rs1359080	chr10:116582419	C/A	cg08188268	chr10:116634841	FAM160B1	0.29	4.92	0.31	1.64e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	trans	rs2736345	0.516	rs9657551	chr8:11398183	A/G	cg06636001	chr8:8085503	FLJ10661	0.6	7.98	0.46	6.79e-14	Sjögren's syndrome;Systemic lupus erythematosus;
SARC	cis	rs644799	0.526	rs568120	chr11:95578734	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.48	5.85	0.36	1.62e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs690037	0.551	rs690522	chr3:16377067	C/T	cg23474789	chr3:16306055	DPH3;OXNAD1	-0.46	-5.24	-0.32	3.67e-7	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);
SARC	cis	rs6920965	0.507	rs4285341	chr6:126205589	T/G	cg05901451	chr6:126070800	HEY2	-0.48	-5.86	-0.36	1.56e-8	High light scatter reticulocyte count;
SARC	cis	rs3768617	0.528	rs10737242	chr1:183098249	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.66e-21	Fuchs's corneal dystrophy;
SARC	cis	rs35110281	0.508	rs2838351	chr21:45110784	A/G	cg21573476	chr21:45109991	RRP1B	-0.57	-7.99	-0.46	6.33e-14	Mean corpuscular volume;
SARC	cis	rs17376456	0.825	rs13155452	chr5:93164449	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.71	-6.48	-0.39	5.49e-10	Diabetic retinopathy;
SARC	cis	rs11723261	0.582	rs6814287	chr4:122323	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.42	5.46	0.34	1.19e-7	Immune response to smallpox vaccine (IL-6);
SARC	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	-0.53	-6.75	-0.4	1.17e-10	Menarche (age at onset);
SARC	cis	rs763121	0.853	rs5750671	chr22:39094619	A/C	cg21395723	chr22:39101663	GTPBP1	0.56	6.73	0.4	1.29e-10	Menopause (age at onset);
SARC	cis	rs10876993	0.928	rs2169988	chr12:58071165	G/A	cg18357645	chr12:58087776	OS9	0.46	6.05	0.37	5.82e-9	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs35110281	0.591	rs162366	chr21:44935383	C/T	cg21573476	chr21:45109991	RRP1B	0.49	7.28	0.43	5.08e-12	Mean corpuscular volume;
SARC	cis	rs1865760	0.532	rs2006736	chr6:26086017	C/T	cg16482183	chr6:26056742	HIST1H1C	0.47	5.91	0.36	1.22e-8	Height;
SARC	cis	rs11864453	0.826	rs12708928	chr16:72137227	C/A	cg01557791	chr16:72042693	DHODH	-0.62	-8.55	-0.49	1.64e-15	Fibrinogen levels;
SARC	cis	rs9322817	0.691	rs2290515	chr6:105232204	C/T	cg02098413	chr6:105308735	HACE1	-0.39	-6.13	-0.37	3.69e-9	Thyroid stimulating hormone;
SARC	cis	rs372883	0.648	rs1153291	chr21:30689070	G/T	cg24692254	chr21:30365293	RNF160	-0.59	-7.36	-0.43	3.1e-12	Pancreatic cancer;
SARC	cis	rs6060717	0.536	rs6058356	chr20:34491530	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.14	0.32	5.87e-7	Hip circumference adjusted for BMI;
SARC	cis	rs1957429	0.731	rs1951495	chr14:65336690	T/C	cg23373153	chr14:65346875	NA	1.0	9.53	0.53	2.2e-18	Pediatric areal bone mineral density (radius);
SARC	trans	rs117850870	0.536	rs7923735	chr10:50513443	C/T	cg15310637	chr12:14927542	H2AFJ	-0.78	-6.3	-0.38	1.45e-9	Alzheimer disease and age of onset;
SARC	cis	rs1355223	0.583	rs1396881	chr11:34870506	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.76	10.87	0.58	1.62e-22	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg24829409	chr8:58192753	C8orf71	-0.61	-6.28	-0.38	1.63e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg16479474	chr6:28041457	NA	0.37	5.44	0.34	1.37e-7	Depression;
SARC	cis	rs1865760	0.964	rs6932113	chr6:25913098	C/T	cg10373733	chr6:25993375	NA	0.43	5.08	0.32	7.67e-7	Height;
SARC	cis	rs7617773	0.817	rs17647717	chr3:48305456	C/T	cg11946769	chr3:48343235	NME6	0.7	8.62	0.49	1.06e-15	Coronary artery disease;
SARC	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.48	-6.03	-0.37	6.29e-9	Lymphocyte counts;
SARC	cis	rs17376456	0.825	rs28705226	chr5:93233135	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.65	5.99	0.37	7.71e-9	Diabetic retinopathy;
SARC	cis	rs9916302	0.904	rs602688	chr17:37439496	C/T	cg07936489	chr17:37558343	FBXL20	-0.68	-9.16	-0.51	2.84e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg20965017	chr5:231967	SDHA	0.57	5.49	0.34	1.03e-7	Breast cancer;
SARC	cis	rs2933343	1.000	rs1683811	chr3:128612113	A/C	cg25356066	chr3:128598488	ACAD9	0.6	6.91	0.41	4.64e-11	IgG glycosylation;
SARC	cis	rs2016266	0.964	rs61754164	chr12:53684619	A/G	cg06632207	chr12:54070931	ATP5G2	-0.44	-5.01	-0.31	1.06e-6	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs198851	0.915	rs111663960	chr6:26082220	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.38	-4.95	-0.31	1.42e-6	Red cell distribution width;High light scatter reticulocyte percentage of red cells;Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg00409905	chr10:38381863	ZNF37A	-0.52	-7.36	-0.43	3.09e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg24675658	chr1:53192096	ZYG11B	-0.58	-8.1	-0.47	3.09e-14	Monocyte count;
SARC	cis	rs7223966	1.000	rs15637	chr17:61772050	C/G	cg26338869	chr17:61819248	STRADA	0.44	5.14	0.32	5.82e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs57221529	0.600	rs11750269	chr5:666270	G/A	cg09021430	chr5:549028	NA	-0.41	-5.03	-0.31	9.67e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs79149102	0.522	rs6495112	chr15:74832798	A/C	cg09165964	chr15:75287851	SCAMP5	-0.66	-5.1	-0.32	7.06e-7	Lung cancer;
SARC	cis	rs763121	0.819	rs4560233	chr22:38982442	A/T	cg06022373	chr22:39101656	GTPBP1	0.87	10.4	0.56	4.84e-21	Menopause (age at onset);
SARC	cis	rs1044826	0.647	rs4683463	chr3:139196946	T/G	cg15131784	chr3:139108705	COPB2	0.4	5.03	0.31	9.72e-7	Obesity-related traits;
SARC	cis	rs35213789	0.762	rs210606	chr7:69234928	G/A	cg10619644	chr7:69149951	AUTS2	0.35	4.83	0.3	2.45e-6	Childhood ear infection;
SARC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg12419862	chr22:24373484	LOC391322	-0.82	-11.44	-0.6	2.5e-24	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs12079745	0.793	rs12565852	chr1:169369330	T/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.81	-5.31	-0.33	2.62e-7	QT interval;
SARC	cis	rs73242632	0.881	rs17182939	chr4:57926791	A/G	cg20415529	chr4:57845134	POLR2B;C4orf14	0.87	5.35	0.33	2.12e-7	Congenital heart disease (maternal effect);
SARC	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg05861140	chr6:150128134	PCMT1	-0.41	-5.24	-0.32	3.6e-7	Lung cancer;
SARC	cis	rs4423214	0.650	rs7940244	chr11:71221574	C/T	cg24826892	chr11:71159390	DHCR7	-0.46	-5.18	-0.32	4.77e-7	Vitamin D levels;
SARC	cis	rs11676348	0.774	rs11683524	chr2:218984604	G/A	cg00012203	chr2:219082015	ARPC2	-0.4	-5.06	-0.31	8.62e-7	Ulcerative colitis;
SARC	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg16414030	chr3:133502952	NA	0.43	5.86	0.36	1.58e-8	Iron status biomarkers;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg13674316	chr14:55518174	MAPK1IP1L	0.48	6.24	0.38	2.04e-9	Chemerin levels;
SARC	cis	rs698761	0.519	rs2005202	chr2:44541706	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.63	7.08	0.42	1.71e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs765787	0.530	rs2413775	chr15:45544288	T/A	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.15	-0.32	5.63e-7	Uric acid levels;
SARC	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.45	-5.79	-0.35	2.25e-8	Personality dimensions;
SARC	cis	rs6582630	0.638	rs12831496	chr12:38552604	G/A	cg14851346	chr12:38532713	NA	-0.48	-5.85	-0.36	1.63e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg12463550	chr7:65579703	CRCP	-0.49	-5.23	-0.32	3.74e-7	Aortic root size;
SARC	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg04944784	chr2:26401820	FAM59B	-0.47	-5.76	-0.35	2.66e-8	Gut microbiome composition (summer);
SARC	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg03647317	chr4:187891568	NA	-0.35	-5.13	-0.32	6.17e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg24060327	chr5:131705240	SLC22A5	-0.5	-5.98	-0.36	8.28e-9	Acylcarnitine levels;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg12769566	chr4:47487497	ATP10D	-0.52	-7.14	-0.42	1.15e-11	Thyroid stimulating hormone;
SARC	cis	rs2742234	0.541	rs11238476	chr10:43711436	G/T	cg15436174	chr10:43711423	RASGEF1A	0.43	5.01	0.31	1.08e-6	Hirschsprung disease;
SARC	cis	rs9916302	0.904	rs35285898	chr17:37555872	A/C	cg20243544	chr17:37824526	PNMT	-0.56	-6.64	-0.4	2.19e-10	Glomerular filtration rate (creatinine);
SARC	trans	rs11039798	0.588	rs3924476	chr11:48581733	T/C	cg15704280	chr7:45808275	SEPT13	0.62	6.61	0.4	2.57e-10	Axial length;
SARC	cis	rs4132509	0.793	rs10927046	chr1:243801190	T/C	cg21452805	chr1:244014465	NA	0.57	5.69	0.35	3.71e-8	RR interval (heart rate);
SARC	cis	rs752010	0.746	rs10890146	chr1:42089389	G/A	cg06885757	chr1:42089581	HIVEP3	0.43	6.79	0.41	9.22e-11	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs1318878	0.565	rs12580434	chr12:15473696	C/T	cg08258403	chr12:15378311	NA	0.49	6.85	0.41	6.41e-11	Intelligence (multi-trait analysis);
SARC	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg22875332	chr1:76189707	ACADM	0.49	6.58	0.4	3.07e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs116095464	0.558	rs113796397	chr5:246503	A/G	cg22857025	chr5:266934	NA	-1.03	-11.07	-0.59	3.73e-23	Breast cancer;
SARC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.43	5.6	0.34	5.93e-8	Lymphocyte counts;
SARC	cis	rs870825	0.616	rs2090590	chr4:185647850	A/C	cg04058563	chr4:185651563	MLF1IP	0.8	11.35	0.6	4.56e-24	Blood protein levels;
SARC	cis	rs2342371	0.756	rs4916492	chr3:196106306	G/A	cg15048948	chr3:196158458	UBXN7	0.63	7.66	0.45	4.95e-13	Fat distribution (HIV);
SARC	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	5.9	0.36	1.24e-8	Electroencephalogram traits;
SARC	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg07701084	chr6:150067640	NUP43	0.41	5.42	0.33	1.5e-7	Lung cancer;
SARC	cis	rs9467711	0.651	rs72834677	chr6:26106604	C/A	cg21479132	chr6:26055353	NA	0.96	6.97	0.42	3.2e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2072499	0.750	rs55675376	chr1:156165881	C/T	cg25208724	chr1:156163844	SLC25A44	0.87	9.89	0.54	1.74e-19	Testicular germ cell tumor;
SARC	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.72	-8.99	-0.51	8.91e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2304069	0.955	rs4288106	chr5:149394872	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.89	9.6	0.53	1.3e-18	HIV-1 control;
SARC	trans	rs1973993	0.745	rs6683508	chr1:96955038	T/C	cg10631902	chr5:14652156	NA	-0.43	-6.98	-0.42	3.08e-11	Weight;
SARC	cis	rs899997	1.000	rs11072794	chr15:79006582	A/G	cg04896959	chr15:78267971	NA	0.5	6.0	0.37	7.52e-9	Coronary artery disease or large artery stroke;
SARC	cis	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg12463550	chr7:65579703	CRCP	0.67	5.15	0.32	5.59e-7	Diabetic kidney disease;
SARC	cis	rs1904096	0.506	rs6532476	chr4:95192461	C/A	cg11021082	chr4:95130006	SMARCAD1	-0.48	-7.26	-0.43	5.65e-12	Type 2 diabetes;
SARC	trans	rs4332037	0.901	rs11767040	chr7:1945468	C/T	cg11693508	chr17:37793320	STARD3	0.72	6.5	0.39	4.74e-10	Bipolar disorder;
SARC	cis	rs2075371	0.611	rs1862045	chr7:134023412	A/G	cg11752832	chr7:134001865	SLC35B4	0.52	6.4	0.39	8.39e-10	Mean platelet volume;
SARC	cis	rs9290065	0.519	rs7626904	chr3:160672427	C/T	cg03342759	chr3:160939853	NMD3	-0.48	-5.82	-0.36	1.9e-8	Kawasaki disease;
SARC	cis	rs1018836	0.828	rs10086462	chr8:91558089	A/G	cg16814680	chr8:91681699	NA	-0.75	-11.64	-0.61	5.6e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs4481887	0.927	rs10888344	chr1:248446655	T/C	cg01631408	chr1:248437212	OR2T33	-0.43	-5.4	-0.33	1.61e-7	Common traits (Other);
SARC	cis	rs12950390	0.853	rs11658511	chr17:45856918	T/C	cg24803719	chr17:45855879	NA	-0.47	-7.63	-0.45	6.05e-13	IgG glycosylation;
SARC	cis	rs244731	0.959	rs7721671	chr5:176630984	A/G	cg17509989	chr5:176798049	RGS14	-0.68	-8.57	-0.49	1.45e-15	Urate levels in lean individuals;
SARC	cis	rs36715	1.000	rs36702	chr5:127552723	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.59	6.43	0.39	7.06e-10	Breast cancer;
SARC	cis	rs17270561	0.609	rs4145216	chr6:25743559	G/A	cg16482183	chr6:26056742	HIST1H1C	0.43	5.08	0.32	7.76e-7	Iron status biomarkers;
SARC	cis	rs4742903	0.904	rs4743691	chr9:106931541	G/A	cg14250997	chr9:106856677	SMC2	0.44	5.5	0.34	1.01e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg08020962	chr6:80714156	TTK	0.5	6.3	0.38	1.5e-9	Breast cancer;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg21146272	chr6:42858716	C6orf226	0.51	6.51	0.39	4.53e-10	Lung adenocarcinoma;
SARC	trans	rs11098499	0.908	rs71614449	chr4:120387055	C/T	cg25214090	chr10:38739885	LOC399744	0.56	7.32	0.43	4.04e-12	Corneal astigmatism;
SARC	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg26335602	chr6:28129616	ZNF389	0.47	5.64	0.35	4.94e-8	Depression;
SARC	trans	rs3857536	0.740	rs4710572	chr6:66890361	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.6	-7.14	-0.42	1.19e-11	Blood trace element (Cu levels);
SARC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg12419862	chr22:24373484	LOC391322	-0.88	-13.05	-0.65	1.41e-29	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2236918	0.664	rs1776158	chr1:242017658	C/T	cg17736920	chr1:242011382	EXO1	0.66	8.96	0.51	1.07e-16	Menopause (age at onset);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg05020822	chr8:144373356	ZNF696	0.48	6.24	0.38	2.02e-9	Chemerin levels;
SARC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg06873352	chr17:61820015	STRADA	0.53	6.94	0.41	3.85e-11	Prudent dietary pattern;
SARC	cis	rs5753037	0.653	rs140133	chr22:30152522	G/C	cg01021169	chr22:30184971	ASCC2	-0.45	-6.31	-0.38	1.38e-9	Type 1 diabetes;
SARC	cis	rs3617	0.573	rs2336668	chr3:52919096	G/T	cg18404041	chr3:52824283	ITIH1	0.33	4.82	0.3	2.65e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg17101226	chr11:64794859	SNX15	0.53	6.85	0.41	6.45e-11	Chemerin levels;
SARC	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg02461776	chr11:598696	PHRF1	0.48	5.28	0.33	2.89e-7	Systemic lupus erythematosus;
SARC	cis	rs8067545	0.611	rs8071274	chr17:20216928	T/C	cg13482628	chr17:19912719	NA	-0.56	-7.3	-0.43	4.51e-12	Schizophrenia;
SARC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg21747090	chr2:27597821	SNX17	-0.55	-7.75	-0.45	2.9e-13	Total body bone mineral density;
SARC	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg08219700	chr8:58056026	NA	0.6	5.83	0.36	1.81e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg04277193	chr17:41438351	NA	0.45	4.73	0.3	3.85e-6	Menopause (age at onset);
SARC	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg04944784	chr2:26401820	FAM59B	-0.47	-5.77	-0.35	2.47e-8	Gut microbiome composition (summer);
SARC	cis	rs7586879	0.593	rs10198275	chr2:25130542	A/C	cg01884057	chr2:25150051	NA	0.3	4.87	0.3	2.1e-6	Body mass index;
SARC	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.97e-8	Aortic root size;
SARC	cis	rs2997447	0.846	rs55912918	chr1:26409801	C/T	cg19633962	chr1:26362018	EXTL1	-0.67	-5.78	-0.35	2.43e-8	QRS complex (12-leadsum);
SARC	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-6.37	-0.39	9.84e-10	Personality dimensions;
SARC	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	7.77	0.45	2.5e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6456156	0.526	rs3093025	chr6:167532731	A/G	cg07741184	chr6:167504864	NA	-0.32	-6.43	-0.39	6.98e-10	Primary biliary cholangitis;
SARC	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg18357526	chr6:26021779	HIST1H4A	0.46	5.72	0.35	3.18e-8	Blood metabolite levels;
SARC	cis	rs73206853	0.841	rs73191815	chr12:110914698	G/A	cg10860002	chr12:110842031	ANAPC7	0.67	5.13	0.32	6.07e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs76419734	1.000	rs76419734	chr4:106624285	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.81	4.9	0.31	1.76e-6	Post bronchodilator FEV1;
SARC	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg06634786	chr22:41940651	POLR3H	-0.61	-7.25	-0.43	6.27e-12	Vitiligo;
SARC	cis	rs10979	1.000	rs1416206	chr6:143889385	T/C	cg25407410	chr6:143891975	LOC285740	-0.64	-8.68	-0.49	6.88e-16	Hypospadias;
SARC	cis	rs1003719	0.788	rs9981226	chr21:38452127	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.65	9.46	0.53	3.52e-18	Eye color traits;
SARC	cis	rs4065321	0.522	rs3744245	chr17:38146542	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.39	7.17	0.42	1.01e-11	White blood cell count (basophil);White blood cell count;
SARC	cis	rs2361710	0.669	rs12940486	chr17:78118569	T/C	cg20811857	chr17:78079795	GAA	-0.32	-5.12	-0.32	6.49e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
SARC	cis	rs2153535	0.580	rs1119689	chr6:8460754	C/G	cg21535247	chr6:8435926	SLC35B3	0.53	6.61	0.4	2.59e-10	Motion sickness;
SARC	cis	rs9788682	0.748	rs2456020	chr15:78868398	C/T	cg24631222	chr15:78858424	CHRNA5	0.71	9.48	0.53	3.12e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs10078	0.528	rs2434697	chr5:466811	T/C	cg08916839	chr5:415575	AHRR	0.84	8.0	0.46	5.66e-14	Fat distribution (HIV);
SARC	cis	rs9768139	0.634	rs11762383	chr7:158113889	C/T	cg06219351	chr7:158114137	PTPRN2	-0.29	-4.86	-0.3	2.2e-6	Calcium levels;
SARC	cis	rs7296418	0.663	rs11057276	chr12:123820397	C/T	cg05973401	chr12:123451056	ABCB9	-0.46	-5.39	-0.33	1.72e-7	Platelet count;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg09321614	chr16:31885091	ZNF267	-0.54	-6.5	-0.39	4.91e-10	Breast cancer;
SARC	cis	rs8102137	0.706	rs17599450	chr19:30328753	C/T	cg27475126	chr19:30303651	CCNE1	-0.34	-4.72	-0.3	4.14e-6	Bladder cancer;
SARC	cis	rs3126085	0.935	rs877776	chr1:152178018	C/G	cg03465714	chr1:152285911	FLG	-0.47	-5.91	-0.36	1.23e-8	Atopic dermatitis;
SARC	cis	rs992157	0.798	rs4674284	chr2:219161241	C/T	cg00012203	chr2:219082015	ARPC2	-0.65	-9.27	-0.52	1.3e-17	Colorectal cancer;
SARC	cis	rs35110281	0.540	rs55840436	chr21:45118541	G/T	cg01579765	chr21:45077557	HSF2BP	-0.36	-5.77	-0.35	2.47e-8	Mean corpuscular volume;
SARC	cis	rs8078723	0.714	rs9915252	chr17:38145088	C/G	cg17467752	chr17:38218738	THRA	-0.38	-4.91	-0.31	1.69e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs7599312	0.534	rs7607363	chr2:213402705	A/G	cg16329650	chr2:213403929	ERBB4	0.7	10.61	0.57	1.03e-21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2730245	0.505	rs1188956	chr7:158690576	G/A	cg00815399	chr7:158750607	NA	0.36	5.15	0.32	5.59e-7	Height;
SARC	cis	rs7412746	0.658	rs11589458	chr1:150792616	A/G	cg13175981	chr1:150552382	MCL1	-0.5	-6.13	-0.37	3.73e-9	Melanoma;
SARC	cis	rs6964587	1.000	rs10264666	chr7:91578639	G/A	cg17063962	chr7:91808500	NA	-0.95	-14.91	-0.7	9.58e-36	Breast cancer;
SARC	cis	rs10504229	0.680	rs16921675	chr8:58052082	A/G	cg08280861	chr8:58055591	NA	0.55	5.03	0.31	9.82e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs933688	1.000	rs10041402	chr5:90738948	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	12.61	0.64	3.86e-28	Smoking behavior;
SARC	cis	rs9916302	0.904	rs4239222	chr17:37696235	A/C	cg15445000	chr17:37608096	MED1	-0.43	-5.08	-0.32	7.79e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs1348850	0.608	rs2364845	chr2:178226240	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.65	8.42	0.48	3.93e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg23758822	chr17:41437982	NA	0.91	12.34	0.63	2.86e-27	Menopause (age at onset);
SARC	cis	rs9796	0.553	rs2925343	chr15:41306493	T/C	cg18705301	chr15:41695430	NDUFAF1	0.51	6.95	0.41	3.56e-11	Menopause (age at onset);
SARC	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg01316550	chr5:56110833	MAP3K1	0.53	4.81	0.3	2.74e-6	Initial pursuit acceleration;
SARC	cis	rs72945132	0.882	rs55738915	chr11:70190019	C/T	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.58	-0.34	6.81e-8	Coronary artery disease;
SARC	cis	rs2011503	1.000	rs4808206	chr19:19645645	C/A	cg15839431	chr19:19639596	YJEFN3	-0.48	-4.77	-0.3	3.32e-6	Bipolar disorder;
SARC	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg04267008	chr7:1944627	MAD1L1	-0.47	-5.18	-0.32	4.81e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs735539	0.521	rs2763002	chr13:21369982	T/C	cg16922012	chr13:21400325	XPO4	-0.42	-5.7	-0.35	3.6e-8	Dental caries;
SARC	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg11062466	chr8:58055876	NA	0.53	5.51	0.34	9.46e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg23971995	chr6:158039297	ZDHHC14	-0.52	-6.88	-0.41	5.61e-11	Electrocardiographic conduction measures;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg21813470	chr12:59797287	NA	-0.47	-6.34	-0.38	1.18e-9	Thyroid stimulating hormone;
SARC	cis	rs362296	0.671	rs3095074	chr4:3261152	G/A	cg06533319	chr4:3265114	C4orf44	0.34	5.15	0.32	5.57e-7	Parental longevity (mother's age at death);
SARC	trans	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg08975724	chr8:8085496	FLJ10661	-0.57	-7.6	-0.45	7.18e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs10512697	0.803	rs13172912	chr5:3578445	A/G	cg19473799	chr5:3511975	NA	-0.68	-4.86	-0.3	2.11e-6	Immune response to smallpox vaccine (IL-6);
SARC	cis	rs7914558	0.901	rs35525740	chr10:104941112	A/T	cg04362960	chr10:104952993	NT5C2	0.4	4.8	0.3	2.83e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs677665	0.537	rs72641831	chr1:9335173	G/T	cg25755851	chr1:9335794	NA	0.61	8.64	0.49	9.28e-16	Eosinophil percentage of white cells;
SARC	cis	rs941408	1.000	rs1736183	chr19:2809672	A/G	cg06609049	chr19:2785107	THOP1	0.8	10.98	0.58	7.25e-23	Total cholesterol levels;
SARC	cis	rs854765	0.547	rs2955372	chr17:17970229	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.4	-4.97	-0.31	1.28e-6	Total body bone mineral density;
SARC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg09373136	chr17:61933544	TCAM1	-0.45	-6.16	-0.37	3.23e-9	Prudent dietary pattern;
SARC	cis	rs7666738	0.830	rs10009206	chr4:99056900	A/C	cg05340658	chr4:99064831	C4orf37	-0.49	-6.28	-0.38	1.61e-9	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2204008	0.571	rs7970136	chr12:38531951	G/C	cg14851346	chr12:38532713	NA	-0.44	-5.29	-0.33	2.81e-7	Bladder cancer;
SARC	cis	rs12477438	0.834	rs1563107	chr2:99701276	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.94	14.76	0.7	2.92e-35	Chronic sinus infection;
SARC	cis	rs367943	1.000	rs348946	chr5:112822814	C/T	cg12552261	chr5:112820674	MCC	-0.46	-5.27	-0.33	3.05e-7	Type 2 diabetes;
SARC	cis	rs10876993	0.928	rs1689587	chr12:58075398	A/G	cg18357645	chr12:58087776	OS9	0.52	6.89	0.41	5.14e-11	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg00933542	chr6:150070202	PCMT1	0.31	5.31	0.33	2.6e-7	Lung cancer;
SARC	cis	rs208520	1.000	rs9453671	chr6:66991208	A/G	cg07460842	chr6:66804631	NA	0.81	9.37	0.52	6.74e-18	Exhaled nitric oxide output;
SARC	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg22433210	chr17:43662623	NA	0.69	8.18	0.47	1.82e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg08426951	chr19:46521569	CCDC61;MIR769	0.48	6.26	0.38	1.8e-9	Schizophrenia;
SARC	cis	rs412050	0.696	rs113366054	chr22:22267184	A/C	cg17089214	chr22:22089827	YPEL1	0.62	5.76	0.35	2.65e-8	Attention deficit hyperactivity disorder;
SARC	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg18357526	chr6:26021779	HIST1H4A	0.46	5.85	0.36	1.65e-8	Blood metabolite levels;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg14087004	chr18:30050818	FAM59A	0.53	6.42	0.39	7.42e-10	Blood pressure;
SARC	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg21747090	chr2:27597821	SNX17	-0.5	-6.9	-0.41	4.76e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs1008375	0.618	rs6842764	chr4:17568420	C/T	cg16339924	chr4:17578868	LAP3	-0.62	-7.43	-0.44	1.99e-12	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2204008	0.605	rs4608149	chr12:38132057	G/C	cg13010199	chr12:38710504	ALG10B	0.78	10.64	0.57	8.61e-22	Bladder cancer;
SARC	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg16479474	chr6:28041457	NA	0.36	5.45	0.34	1.25e-7	Depression;
SARC	cis	rs2290159	0.800	rs11128607	chr3:12673275	A/G	cg23032965	chr3:12705835	RAF1	0.74	8.1	0.47	3.1e-14	Cholesterol, total;
SARC	cis	rs2120019	1.000	rs12901243	chr15:75374233	C/T	cg00629941	chr15:75287862	SCAMP5	-0.6	-7.27	-0.43	5.46e-12	Blood trace element (Zn levels);
SARC	cis	rs8523	0.901	rs61624919	chr6:10997823	G/A	cg13562911	chr6:11044106	ELOVL2	0.38	5.02	0.31	1.02e-6	Red blood cell fatty acid levels;
SARC	trans	rs11039798	0.512	rs3974936	chr11:49005012	C/T	cg15704280	chr7:45808275	SEPT13	0.71	7.34	0.43	3.59e-12	Axial length;
SARC	cis	rs6495122	0.699	rs1378941	chr15:75080150	C/A	cg09165964	chr15:75287851	SCAMP5	0.4	4.79	0.3	3e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	cis	rs7766436	0.614	rs7775936	chr6:22566151	T/C	cg13666174	chr6:22585274	NA	-0.56	-5.86	-0.36	1.59e-8	Coronary artery disease;
SARC	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg05025164	chr4:1340916	KIAA1530	0.69	8.65	0.49	8.46e-16	Longevity;
SARC	cis	rs8014131	0.667	rs7146465	chr14:85990943	C/G	cg10406690	chr14:85995726	FLRT2	0.39	5.05	0.31	8.98e-7	Menarche (age at onset);
SARC	cis	rs8017423	0.904	rs11159963	chr14:90805358	C/T	cg20276874	chr14:90721474	PSMC1	0.41	5.28	0.33	2.91e-7	Mortality in heart failure;
SARC	cis	rs4881340	1.000	rs7076213	chr10:4790557	C/T	cg12223502	chr10:5658492	NA	0.28	4.77	0.3	3.3e-6	Major depressive disorder;
SARC	cis	rs3768617	0.811	rs4366285	chr1:183013672	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	8.26	0.48	1.09e-14	Fuchs's corneal dystrophy;
SARC	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg21171335	chr12:122356390	WDR66	-0.4	-6.47	-0.39	5.69e-10	Mean corpuscular volume;
SARC	cis	rs9303401	0.659	rs34818467	chr17:56643109	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.94	-11.06	-0.59	3.84e-23	Cognitive test performance;
SARC	cis	rs6910061	1.000	rs6456868	chr6:11115183	G/A	cg27233058	chr6:11094804	LOC221710	0.58	5.66	0.35	4.42e-8	Diabetic kidney disease;
SARC	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.36	-5.84	-0.36	1.73e-8	Schizophrenia;
SARC	cis	rs936229	1.000	rs936229	chr15:75132319	A/G	cg14664628	chr15:75095509	CSK	-1.03	-12.99	-0.65	2.14e-29	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs4972806	0.814	rs1446575	chr2:177047801	A/C	cg14324370	chr2:177042789	NA	0.45	5.98	0.36	8.47e-9	IgG glycosylation;
SARC	cis	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg03060546	chr3:49711283	APEH	0.73	10.7	0.57	5.32e-22	Resting heart rate;
SARC	cis	rs875971	0.545	rs73150604	chr7:65945532	T/A	cg11764359	chr7:65958608	NA	0.64	6.18	0.38	2.89e-9	Aortic root size;
SARC	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg22168489	chr12:122356033	WDR66	0.54	7.75	0.45	2.89e-13	Mean corpuscular volume;
SARC	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg03433033	chr1:76189801	ACADM	0.55	7.69	0.45	4.12e-13	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9393692	0.846	rs7771202	chr6:26279907	A/G	cg00631329	chr6:26305371	NA	-0.62	-9.05	-0.51	5.82e-17	Educational attainment;
SARC	cis	rs1355223	0.506	rs11032894	chr11:34865544	T/C	cg18508148	chr11:34937573	PDHX;APIP	-0.37	-4.74	-0.3	3.74e-6	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs4803468	1.000	rs284652	chr19:41928652	C/T	cg08477640	chr19:41863820	B9D2	0.44	5.53	0.34	8.62e-8	Height;
SARC	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg22535103	chr8:58192502	C8orf71	0.6	6.29	0.38	1.56e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7300001	0.538	rs7968848	chr12:110941059	T/A	cg10860002	chr12:110842031	ANAPC7	0.59	4.76	0.3	3.44e-6	Headache;
SARC	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg12463550	chr7:65579703	CRCP	-0.71	-5.42	-0.33	1.47e-7	Diabetic kidney disease;
SARC	cis	rs79149102	0.579	rs7181942	chr15:75300623	G/C	cg09165964	chr15:75287851	SCAMP5	-0.95	-8.86	-0.5	2.03e-16	Lung cancer;
SARC	trans	rs3942852	0.774	rs924715	chr11:48181060	G/A	cg15704280	chr7:45808275	SEPT13	-0.62	-7.2	-0.43	8.05e-12	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9916302	0.768	rs62077464	chr17:37656056	C/G	cg07936489	chr17:37558343	FBXL20	-0.65	-8.45	-0.48	3.21e-15	Glomerular filtration rate (creatinine);
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg25886382	chr13:26760664	NA	-0.51	-6.3	-0.38	1.48e-9	Fibrinogen levels;
SARC	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg26119090	chr2:26468346	HADHA;HADHB	0.93	13.87	0.67	2.78e-32	Gut microbiome composition (summer);
SARC	cis	rs10779751	0.770	rs11585553	chr1:11233814	G/A	cg08854313	chr1:11322531	MTOR	-0.84	-10.62	-0.57	9.91e-22	Body mass index;
SARC	cis	rs17666538	0.585	rs6559063	chr8:623051	C/T	cg07234876	chr8:600039	NA	0.7	5.44	0.34	1.32e-7	IgG glycosylation;
SARC	cis	rs992157	0.710	rs12612347	chr2:219057338	C/T	cg00012203	chr2:219082015	ARPC2	-0.87	-13.8	-0.67	4.46e-32	Colorectal cancer;
SARC	cis	rs344364	0.511	rs2982455	chr16:1950498	T/G	cg26617929	chr16:1858877	NA	-0.71	-5.85	-0.36	1.62e-8	Glomerular filtration rate in chronic kidney disease;
SARC	cis	rs1008375	0.932	rs9283698	chr4:17662471	T/C	cg27347728	chr4:17578864	LAP3	0.47	5.66	0.35	4.46e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs1814175	0.935	rs6485999	chr11:49658986	G/C	cg03929089	chr4:120376271	NA	-0.84	-12.91	-0.65	4.14e-29	Height;
SARC	cis	rs8070624	0.574	rs9914127	chr17:17875836	A/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.39	4.73	0.3	3.89e-6	Total body bone mineral density;
SARC	cis	rs11098499	0.863	rs11098531	chr4:120465001	G/A	cg24375607	chr4:120327624	NA	0.42	4.92	0.31	1.64e-6	Corneal astigmatism;
SARC	cis	rs9462027	0.628	rs9296131	chr6:34776361	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.82	-0.36	1.98e-8	Systemic lupus erythematosus;
SARC	cis	rs6496667	0.865	rs13329288	chr15:90897451	C/T	cg22089800	chr15:90895588	ZNF774	0.51	4.75	0.3	3.53e-6	Rheumatoid arthritis;
SARC	trans	rs7615952	0.866	rs11922276	chr3:125631326	G/T	cg07211511	chr3:129823064	LOC729375	-0.94	-10.46	-0.57	2.96e-21	Blood pressure (smoking interaction);
SARC	cis	rs7833790	1.000	rs7833790	chr8:82731157	T/C	cg17211192	chr8:82754475	SNX16	-0.58	-6.53	-0.39	4.05e-10	Diastolic blood pressure;
SARC	cis	rs9640161	0.830	rs13307276	chr7:150061525	T/C	cg10018233	chr7:150070692	REPIN1	0.7	10.4	0.56	4.8e-21	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs9354308	0.899	rs2802056	chr6:66546219	C/A	cg07460842	chr6:66804631	NA	0.48	5.48	0.34	1.12e-7	Metabolite levels;
SARC	cis	rs9807989	0.524	rs6759479	chr2:103040047	A/C	cg03938978	chr2:103052716	IL18RAP	0.32	5.11	0.32	6.56e-7	Asthma;
SARC	cis	rs778371	0.723	rs6710294	chr2:233579634	T/C	cg20388707	chr2:233749442	NGEF	-0.36	-5.26	-0.33	3.32e-7	Schizophrenia;
SARC	cis	rs11122272	0.701	rs2474628	chr1:231526000	C/T	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs7666738	0.753	rs34164013	chr4:98976333	A/G	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs72781680	0.898	rs2879640	chr2:24043573	T/C	cg06627628	chr2:24431161	ITSN2	-0.68	-6.38	-0.39	9.38e-10	Lymphocyte counts;
SARC	cis	rs6570726	0.599	rs4398765	chr6:145935006	C/A	cg23711669	chr6:146136114	FBXO30	0.82	11.86	0.61	1.07e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs5753618	0.583	rs5753612	chr22:31821479	T/C	cg02404636	chr22:31891804	SFI1	0.49	5.22	0.32	3.88e-7	Colorectal cancer;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01113084	chr7:158649018	WDR60	-0.53	-6.79	-0.41	9.18e-11	Smoking initiation;
SARC	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg07648498	chr16:89883185	FANCA	0.43	5.76	0.35	2.63e-8	Vitiligo;
SARC	trans	rs9325144	0.647	rs61930266	chr12:38922048	A/G	cg23762105	chr12:34175262	ALG10	0.49	6.26	0.38	1.86e-9	Morning vs. evening chronotype;
SARC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	20.42	0.8	8.2e-54	Prudent dietary pattern;
SARC	cis	rs10875746	0.903	rs17122666	chr12:48502574	C/T	cg26205652	chr12:48591994	NA	0.57	6.47	0.39	5.67e-10	Longevity (90 years and older);
SARC	cis	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg12463550	chr7:65579703	CRCP	0.68	5.09	0.32	7.53e-7	Gout;
SARC	cis	rs2153535	0.580	rs2327061	chr6:8447231	G/C	cg21535247	chr6:8435926	SLC35B3	0.57	7.24	0.43	6.41e-12	Motion sickness;
SARC	cis	rs1008375	0.966	rs3796812	chr4:17582051	G/A	cg27347728	chr4:17578864	LAP3	0.46	5.65	0.35	4.6e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs644799	0.965	rs602512	chr11:95561682	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.9	14.14	0.68	3.54e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs501120	0.925	rs1746052	chr10:44778546	G/T	cg09554077	chr10:44749378	NA	-0.53	-7.25	-0.43	5.96e-12	Coronary artery disease;Coronary heart disease;
SARC	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg27266027	chr21:40555129	PSMG1	0.49	5.26	0.33	3.23e-7	Cognitive function;
SARC	cis	rs79149102	0.579	rs7342591	chr15:75306863	C/T	cg00629941	chr15:75287862	SCAMP5	0.59	5.0	0.31	1.11e-6	Lung cancer;
SARC	cis	rs911555	0.755	rs975892	chr14:103883349	A/T	cg12935359	chr14:103987150	CKB	-0.4	-5.55	-0.34	7.75e-8	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg21724239	chr8:58056113	NA	0.43	4.74	0.3	3.71e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs611744	0.967	rs639059	chr8:109236119	G/A	cg21045802	chr8:109455806	TTC35	0.47	5.58	0.34	6.72e-8	Dupuytren's disease;
SARC	cis	rs9303280	0.806	rs12936409	chr17:38043649	C/T	cg20243544	chr17:37824526	PNMT	0.43	5.66	0.35	4.47e-8	Self-reported allergy;
SARC	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.19	-0.56	2.08e-20	Chronic sinus infection;
SARC	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg18252515	chr7:66147081	NA	1.25	10.56	0.57	1.52e-21	Diabetic kidney disease;
SARC	cis	rs6964587	0.900	rs6465352	chr7:91775117	A/G	cg17063962	chr7:91808500	NA	0.98	17.35	0.75	7.27e-44	Breast cancer;
SARC	cis	rs7178572	0.568	rs12900433	chr15:77495028	T/C	cg22256960	chr15:77711686	NA	-0.5	-5.53	-0.34	8.67e-8	Type 2 diabetes;
SARC	cis	rs2028299	0.920	rs4932261	chr15:90430396	A/G	cg19708238	chr15:90437601	AP3S2	0.45	5.03	0.31	9.83e-7	Type 2 diabetes;
SARC	cis	rs11122272	0.735	rs2474625	chr1:231519331	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs10463554	0.818	rs2241564	chr5:102302251	A/G	cg23492399	chr5:102201601	PAM	-0.47	-5.62	-0.35	5.46e-8	Parkinson's disease;
SARC	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	14.04	0.68	7.52e-33	Chronic sinus infection;
SARC	cis	rs1023500	0.573	rs1807494	chr22:42474138	C/G	cg15557168	chr22:42548783	NA	0.35	4.8	0.3	2.85e-6	Schizophrenia;
SARC	cis	rs8114671	0.562	rs1018447	chr20:33401707	A/G	cg07148914	chr20:33460835	GGT7	-0.43	-5.46	-0.34	1.2e-7	Height;
SARC	cis	rs10979	1.000	rs1416207	chr6:143889275	G/A	cg25407410	chr6:143891975	LOC285740	-0.64	-8.68	-0.49	6.88e-16	Hypospadias;
SARC	cis	rs7044106	0.791	rs4836831	chr9:123496570	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	9.69	0.54	7.25e-19	Hip circumference adjusted for BMI;
SARC	cis	rs6815814	0.950	rs73236617	chr4:38793860	C/G	cg06935464	chr4:38784597	TLR10	0.61	6.0	0.37	7.64e-9	Breast cancer;
SARC	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg04756594	chr16:24857601	SLC5A11	-0.43	-5.92	-0.36	1.14e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	trans	rs12310956	0.532	rs11494810	chr12:33952881	C/A	cg26384229	chr12:38710491	ALG10B	0.74	10.34	0.56	7.25e-21	Morning vs. evening chronotype;
SARC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.62	7.97	0.46	6.91e-14	Lymphocyte counts;
SARC	cis	rs11169225	0.756	rs3759124	chr12:50343166	G/A	cg23855989	chr12:50355821	AQP5	0.47	6.05	0.37	5.84e-9	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs2075371	0.796	rs12672752	chr7:134007382	C/T	cg20476274	chr7:133979776	SLC35B4	0.51	6.53	0.39	4.08e-10	Mean platelet volume;
SARC	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg18876405	chr7:65276391	NA	0.49	6.04	0.37	6e-9	Aortic root size;
SARC	cis	rs883565	0.654	rs7642737	chr3:39032469	T/C	cg01426195	chr3:39028469	NA	-0.36	-5.19	-0.32	4.51e-7	Handedness;
SARC	cis	rs11098499	0.954	rs13113483	chr4:120309039	C/T	cg09307838	chr4:120376055	NA	0.91	12.88	0.65	4.9e-29	Corneal astigmatism;
SARC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg21747090	chr2:27597821	SNX17	-0.55	-7.68	-0.45	4.44e-13	Total body bone mineral density;
SARC	cis	rs7223966	1.000	rs17549954	chr17:61707032	A/G	cg00588841	chr17:61851480	DDX42;CCDC47	-0.65	-6.94	-0.41	3.78e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg20891283	chr12:69753455	YEATS4	0.55	7.55	0.44	9.74e-13	Blood protein levels;
SARC	cis	rs4689388	0.824	rs4467645	chr4:6294305	C/T	cg00701064	chr4:6280414	WFS1	0.53	8.54	0.49	1.78e-15	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs16986825	0.599	rs34751572	chr22:29170138	C/G	cg02153584	chr22:29168773	CCDC117	0.65	6.58	0.4	3.11e-10	Pancreatic cancer;
SARC	trans	rs6600671	1.000	rs10794671	chr1:121168242	A/C	cg00646200	chr1:148855367	NA	0.48	6.63	0.4	2.29e-10	Hip geometry;
SARC	cis	rs748404	0.650	rs518261	chr15:43573429	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.43	5.24	0.32	3.53e-7	Lung cancer;
SARC	cis	rs3741798	1.000	rs2160588	chr12:12487447	C/T	cg08615371	chr12:12503544	MANSC1	0.83	6.84	0.41	6.93e-11	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9788721	1.000	rs8031948	chr15:78816057	G/T	cg06917634	chr15:78832804	PSMA4	-0.49	-5.25	-0.33	3.49e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs3771570	0.786	rs62186396	chr2:242221219	A/G	cg21155796	chr2:242212141	HDLBP	0.73	6.36	0.38	1.05e-9	Prostate cancer;
SARC	cis	rs449789	0.857	rs1553482	chr6:159722147	T/G	cg14500486	chr6:159655392	FNDC1	-0.45	-5.07	-0.32	8.07e-7	Pulse pressure;
SARC	cis	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg07274523	chr3:49395745	GPX1	0.49	5.46	0.34	1.21e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs7772486	0.790	rs2814879	chr6:146201743	T/C	cg23711669	chr6:146136114	FBXO30	0.8	13.13	0.65	7.67e-30	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg19223190	chr17:80058835	NA	0.45	6.18	0.38	2.83e-9	Life satisfaction;
SARC	cis	rs644799	0.710	rs10831427	chr11:95508383	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.94	16.0	0.72	2.32e-39	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.54	6.14	0.37	3.48e-9	Prudent dietary pattern;
SARC	cis	rs9902453	1.000	rs60967688	chr17:28437052	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	6.65	0.4	2.08e-10	Coffee consumption (cups per day);
SARC	cis	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg15556689	chr8:8085844	FLJ10661	-0.42	-5.17	-0.32	5.08e-7	Mood instability;
SARC	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg08219700	chr8:58056026	NA	0.47	5.08	0.32	7.82e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2273669	0.667	rs12200531	chr6:109320441	T/C	cg05315195	chr6:109294784	ARMC2	-0.6	-5.47	-0.34	1.13e-7	Prostate cancer;
SARC	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg01316550	chr5:56110833	MAP3K1	0.54	4.86	0.3	2.17e-6	Initial pursuit acceleration;
SARC	cis	rs10752881	1.000	rs4593781	chr1:182984983	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.72	10.89	0.58	1.32e-22	Colorectal cancer;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg11330941	chr2:17934879	GEN1;SMC6	0.6	7.59	0.45	7.77e-13	Breast cancer;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg14373456	chr4:55094337	PDGFRA	-0.54	-6.97	-0.42	3.15e-11	Gallstone disease;
SARC	cis	rs826838	0.935	rs11169508	chr12:39173385	C/T	cg26384229	chr12:38710491	ALG10B	0.9	13.18	0.65	5.35e-30	Heart rate;
SARC	cis	rs1215050	0.904	rs9307215	chr4:98813965	A/G	cg05340658	chr4:99064831	C4orf37	0.41	5.28	0.33	2.99e-7	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs1707322	0.752	rs28890893	chr1:46186576	T/G	cg03146154	chr1:46216737	IPP	0.52	6.28	0.38	1.6e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs11758351	1.000	rs2143346	chr6:26198449	C/G	cg01420254	chr6:26195488	NA	-0.6	-5.28	-0.33	2.93e-7	Gout;Renal underexcretion gout;
SARC	cis	rs2439831	0.850	rs694985	chr15:43813387	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	8.43	0.48	3.54e-15	Lung cancer in ever smokers;
SARC	cis	rs526231	0.543	rs7714539	chr5:102328878	G/A	cg23492399	chr5:102201601	PAM	-0.52	-6.36	-0.38	1.03e-9	Primary biliary cholangitis;
SARC	cis	rs10782582	0.617	rs1846233	chr1:76159354	C/T	cg03433033	chr1:76189801	ACADM	-0.42	-5.43	-0.33	1.44e-7	Daytime sleep phenotypes;
SARC	cis	rs67460515	0.563	rs11720263	chr3:160848293	T/C	cg17135325	chr3:160939158	NMD3	0.62	7.68	0.45	4.46e-13	Parkinson's disease;
SARC	cis	rs72627123	0.530	rs79371463	chr14:74474856	T/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.74	5.59	0.34	6.39e-8	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg08677398	chr8:58056175	NA	0.43	4.81	0.3	2.72e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg08219700	chr8:58056026	NA	0.57	5.1	0.32	7.16e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9807989	0.839	rs10192036	chr2:102968211	C/A	cg09003973	chr2:102972529	NA	0.41	5.56	0.34	7.26e-8	Asthma;
SARC	cis	rs7617773	0.780	rs3731489	chr3:48228906	C/A	cg11946769	chr3:48343235	NME6	0.72	9.33	0.52	8.8e-18	Coronary artery disease;
SARC	cis	rs78487399	0.808	rs17039133	chr2:43694570	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-4.86	-0.3	2.16e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs3018712	0.590	rs4930584	chr11:68411296	T/C	cg01657329	chr11:68192670	LRP5	0.58	5.28	0.33	3.01e-7	Total body bone mineral density;
SARC	cis	rs4481887	0.741	rs6674078	chr1:248543026	G/A	cg13385794	chr1:248469461	NA	0.35	5.62	0.35	5.4e-8	Common traits (Other);
SARC	cis	rs17376456	1.000	rs56046246	chr5:93531545	T/G	cg25358565	chr5:93447407	FAM172A	1.35	14.06	0.68	6.12e-33	Diabetic retinopathy;
SARC	cis	rs854765	0.583	rs4077198	chr17:17834563	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	9.75	0.54	4.62e-19	Total body bone mineral density;
SARC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	10.46	0.57	2.97e-21	Platelet count;
SARC	cis	rs7769051	0.803	rs34334052	chr6:133231829	C/T	cg07930552	chr6:133119739	C6orf192	0.79	6.46	0.39	5.99e-10	Type 2 diabetes nephropathy;
SARC	cis	rs12908161	0.959	rs62019472	chr15:85331493	A/G	cg17507749	chr15:85114479	UBE2QP1	0.53	6.04	0.37	6.03e-9	Schizophrenia;
SARC	cis	rs1046896	0.553	rs1044661	chr17:80901020	G/A	cg05255149	chr17:80675120	FN3KRP	0.46	5.1	0.32	7.16e-7	Glycated hemoglobin levels;
SARC	trans	rs2715157	0.647	rs6959361	chr7:82389249	A/C	cg10215185	chr8:50756867	NA	0.49	6.54	0.39	3.8e-10	Major depressive disorder;
SARC	cis	rs9640161	0.871	rs56156367	chr7:150047201	A/T	cg10018233	chr7:150070692	REPIN1	0.62	8.21	0.47	1.49e-14	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs1538970	0.962	rs4660849	chr1:45819872	A/G	cg05343316	chr1:45956843	TESK2	-0.71	-8.58	-0.49	1.33e-15	Platelet count;
SARC	cis	rs9372253	0.678	rs9372251	chr6:110700656	A/G	cg19196401	chr6:110721138	DDO	-0.41	-5.42	-0.33	1.45e-7	Platelet distribution width;
SARC	cis	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg02487422	chr3:49467188	NICN1	0.51	6.83	0.41	7.34e-11	Resting heart rate;
SARC	cis	rs7512552	0.966	rs2147324	chr1:150255587	T/C	cg15654264	chr1:150340011	RPRD2	-0.37	-4.79	-0.3	3e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs2153535	0.580	rs1414351	chr6:8476634	T/C	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	cis	rs12950390	1.000	rs8068453	chr17:45852354	A/G	cg03474202	chr17:45855739	NA	0.4	5.72	0.35	3.19e-8	IgG glycosylation;
SARC	cis	rs8020289	0.560	rs7142548	chr14:77250908	C/T	cg23436960	chr14:77239540	VASH1	-0.33	-5.05	-0.31	8.78e-7	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);
SARC	trans	rs61931739	0.534	rs11053020	chr12:34111092	C/G	cg26384229	chr12:38710491	ALG10B	0.87	12.43	0.63	1.5e-27	Morning vs. evening chronotype;
SARC	cis	rs288326	0.561	rs79804181	chr2:183710898	T/C	cg09997497	chr2:183902928	NCKAP1	0.7	4.8	0.3	2.85e-6	Blood protein levels;
SARC	cis	rs6542838	0.641	rs4850890	chr2:99535426	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-4.88	-0.3	1.96e-6	Fear of minor pain;
SARC	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg11168104	chr5:1857477	NA	-0.34	-4.87	-0.3	2.03e-6	Cardiovascular disease risk factors;
SARC	trans	rs7819412	0.875	rs6981523	chr8:11061792	C/T	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.78	-0.45	2.29e-13	Triglycerides;
SARC	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.93	14.75	0.69	3.31e-35	Chronic sinus infection;
SARC	cis	rs2916247	0.909	rs7009009	chr8:93170665	T/A	cg10183463	chr8:93005414	RUNX1T1	0.46	4.94	0.31	1.51e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2070488	0.965	rs7642472	chr3:38525567	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	13.69	0.67	1.04e-31	Electrocardiographic conduction measures;
SARC	cis	rs793571	0.543	rs11854073	chr15:58972995	G/A	cg05156742	chr15:59063176	FAM63B	0.7	9.42	0.53	4.51e-18	Schizophrenia;
SARC	cis	rs4742903	0.791	rs6479226	chr9:106972872	T/G	cg14250997	chr9:106856677	SMC2	0.43	5.48	0.34	1.12e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs2153535	0.580	rs7341381	chr6:8470537	A/G	cg21535247	chr6:8435926	SLC35B3	0.56	7.09	0.42	1.55e-11	Motion sickness;
SARC	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6815814	0.950	rs5743556	chr4:38806851	A/G	cg06935464	chr4:38784597	TLR10	0.63	6.31	0.38	1.41e-9	Breast cancer;
SARC	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg21724239	chr8:58056113	NA	-0.6	-5.66	-0.35	4.39e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs854765	0.547	rs8069811	chr17:17922280	G/A	cg04398451	chr17:18023971	MYO15A	-0.44	-6.29	-0.38	1.53e-9	Total body bone mineral density;
SARC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg02018176	chr4:1364513	KIAA1530	0.65	9.91	0.54	1.54e-19	Longevity;
SARC	cis	rs3768617	0.510	rs4651145	chr1:183098900	T/C	cg13390022	chr1:182993471	LAMC1	0.31	4.79	0.3	3.01e-6	Fuchs's corneal dystrophy;
SARC	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-6.23	-0.38	2.13e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7412746	0.588	rs10305664	chr1:150839686	A/C	cg13175981	chr1:150552382	MCL1	-0.51	-6.12	-0.37	3.84e-9	Melanoma;
SARC	cis	rs9650657	0.615	rs11986935	chr8:10691549	T/A	cg21775007	chr8:11205619	TDH	-0.4	-4.93	-0.31	1.55e-6	Neuroticism;
SARC	cis	rs1062177	0.901	rs1549622	chr5:151266049	A/G	cg00977110	chr5:151150581	G3BP1	0.54	5.42	0.33	1.51e-7	Preschool internalizing problems;
SARC	cis	rs7223966	1.000	rs8066719	chr17:61825764	C/T	cg00588841	chr17:61851480	DDX42;CCDC47	-0.68	-7.41	-0.44	2.32e-12	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7666738	0.830	rs28594127	chr4:99001121	T/G	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg13206674	chr6:150067644	NUP43	0.46	6.03	0.37	6.45e-9	Lung cancer;
SARC	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg00152838	chr16:24741724	TNRC6A	-0.62	-6.32	-0.38	1.3e-9	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg20203395	chr5:56204925	C5orf35	0.62	5.49	0.34	1.07e-7	Initial pursuit acceleration;
SARC	cis	rs7819412	0.668	rs4841507	chr8:11046394	C/G	cg21775007	chr8:11205619	TDH	-0.46	-5.91	-0.36	1.21e-8	Triglycerides;
SARC	cis	rs2635047	1.000	rs2635045	chr18:44668417	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.54	7.36	0.43	3.12e-12	Educational attainment;
SARC	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-5.59	-0.34	6.45e-8	Bipolar disorder;
SARC	cis	rs7178909	0.872	rs28468074	chr15:90435600	C/T	cg19708238	chr15:90437601	AP3S2	0.62	8.41	0.48	4.15e-15	Common traits (Other);
SARC	cis	rs17376456	0.569	rs6879620	chr5:93119893	G/A	cg21475434	chr5:93447410	FAM172A	-0.6	-5.86	-0.36	1.57e-8	Diabetic retinopathy;
SARC	cis	rs12586317	0.576	rs10130047	chr14:35633580	C/A	cg16230307	chr14:35515116	FAM177A1	0.44	5.55	0.34	7.87e-8	Psoriasis;
SARC	cis	rs712039	0.652	rs11656503	chr17:35772021	G/T	cg16670864	chr17:35848621	DUSP14	0.51	5.68	0.35	3.94e-8	Tuberculosis;
SARC	cis	rs12142240	0.698	rs17357759	chr1:46832534	A/G	cg10495392	chr1:46806563	NSUN4	0.61	6.42	0.39	7.4e-10	Menopause (age at onset);
SARC	cis	rs981844	0.813	rs72731678	chr4:154671476	T/C	cg14289246	chr4:154710475	SFRP2	0.59	6.62	0.4	2.43e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs6752107	1.000	rs3792112	chr2:234176609	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.45	6.02	0.37	6.84e-9	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs476633	0.691	rs28735224	chr15:41537539	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.58	-8.12	-0.47	2.75e-14	Glomerular filtration rate (creatinine);
SARC	trans	rs56279505	0.629	rs34774688	chr4:100274464	A/T	cg18024358	chr1:3420815	MEGF6	-0.83	-6.4	-0.39	8.29e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-6.82	-0.41	7.94e-11	Personality dimensions;
SARC	cis	rs3540	0.597	rs11639150	chr15:91042071	C/G	cg22089800	chr15:90895588	ZNF774	-0.59	-7.49	-0.44	1.39e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg13939156	chr17:80058883	NA	0.37	5.66	0.35	4.45e-8	Life satisfaction;
SARC	cis	rs6831352	0.879	rs29001229	chr4:100046823	A/G	cg12011299	chr4:100065546	ADH4	-0.34	-5.7	-0.35	3.52e-8	Alcohol dependence;
SARC	cis	rs9389248	0.690	rs728030	chr6:135246294	G/T	cg22676075	chr6:135203613	NA	-0.46	-5.95	-0.36	9.68e-9	High light scatter reticulocyte percentage of red cells;
SARC	cis	rs72781680	0.898	rs72796166	chr2:23939311	G/C	cg06627628	chr2:24431161	ITSN2	-0.66	-6.06	-0.37	5.51e-9	Lymphocyte counts;
SARC	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg13939156	chr17:80058883	NA	-0.44	-6.71	-0.4	1.46e-10	Life satisfaction;
SARC	cis	rs526231	0.512	rs28022	chr5:102464367	T/C	cg23492399	chr5:102201601	PAM	-0.52	-5.62	-0.35	5.5e-8	Primary biliary cholangitis;
SARC	cis	rs9916302	0.904	rs4795355	chr17:37427382	C/T	cg20243544	chr17:37824526	PNMT	0.56	6.82	0.41	7.65e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs1153858	0.725	rs74572151	chr15:45647526	T/G	cg26924012	chr15:45694286	SPATA5L1	0.77	10.99	0.58	6.8e-23	Homoarginine levels;
SARC	trans	rs1422110	0.543	rs10035841	chr5:85419597	T/C	cg01787110	chr1:109008453	NBPF6	0.45	6.39	0.39	8.96e-10	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs13144136	0.748	rs4697773	chr4:10668379	C/T	cg10242279	chr4:10666415	CLNK	-0.34	-5.18	-0.32	4.89e-7	Resistance to antihypertensive treatment in hypertension;
SARC	cis	rs2120019	0.567	rs8025170	chr15:75170983	A/G	cg00629941	chr15:75287862	SCAMP5	0.57	5.39	0.33	1.68e-7	Blood trace element (Zn levels);
SARC	cis	rs2777491	0.915	rs7180418	chr15:41629502	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.74	-10.99	-0.58	6.61e-23	Ulcerative colitis;
SARC	cis	rs11792861	0.926	rs72607173	chr9:111879398	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.65	7.57	0.44	8.85e-13	Menarche (age at onset);
SARC	cis	rs7937682	0.883	rs1784775	chr11:111472460	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.87	-13.26	-0.66	2.92e-30	Primary sclerosing cholangitis;
SARC	cis	rs12200560	0.505	rs211171	chr6:97070579	T/G	cg06623918	chr6:96969491	KIAA0776	0.43	4.85	0.3	2.21e-6	Coronary heart disease;
SARC	cis	rs796364	0.664	rs3106089	chr2:200884615	A/C	cg23649088	chr2:200775458	C2orf69	0.6	5.38	0.33	1.85e-7	Schizophrenia;
SARC	trans	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg13565492	chr6:43139072	SRF	-0.55	-6.41	-0.39	8.06e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs8014204	0.566	rs12587457	chr14:75164141	C/T	cg06637938	chr14:75390232	RPS6KL1	0.55	7.89	0.46	1.14e-13	Caffeine consumption;
SARC	cis	rs17125944	0.686	rs7158555	chr14:53362006	G/A	cg00686598	chr14:53173677	PSMC6	-0.65	-5.04	-0.31	9.13e-7	Alzheimer's disease (late onset);
SARC	cis	rs734999	0.549	rs6667564	chr1:2520302	T/C	cg00980319	chr1:2560884	MMEL1	-0.34	-4.84	-0.3	2.33e-6	Ulcerative colitis;
SARC	cis	rs9467711	0.606	rs34273322	chr6:26415409	T/A	cg12826209	chr6:26865740	GUSBL1	0.83	5.07	0.32	8.17e-7	Autism spectrum disorder or schizophrenia;
SARC	cis	rs907683	0.570	rs3755056	chr2:220281016	T/A	cg15015639	chr2:220282977	DES	0.4	6.03	0.37	6.45e-9	Resting heart rate;
SARC	cis	rs8017423	0.647	rs4904674	chr14:90817412	G/A	cg20276874	chr14:90721474	PSMC1	0.36	4.77	0.3	3.25e-6	Mortality in heart failure;
SARC	cis	rs3008870	0.755	rs10749766	chr1:67376921	A/G	cg02640540	chr1:67518911	SLC35D1	0.44	5.05	0.31	9.1e-7	Lymphocyte percentage of white cells;
SARC	cis	rs9840812	0.623	rs9854084	chr3:136194743	A/T	cg15507776	chr3:136538369	TMEM22	0.51	5.78	0.35	2.44e-8	Fibrinogen levels;
SARC	cis	rs9486719	0.857	rs4265039	chr6:96878929	T/C	cg06623918	chr6:96969491	KIAA0776	0.75	8.76	0.5	4.17e-16	Migraine;Coronary artery disease;
SARC	cis	rs7582180	0.764	rs11689439	chr2:100925399	T/C	cg14675211	chr2:100938903	LONRF2	0.54	7.84	0.46	1.61e-13	Intelligence (multi-trait analysis);
SARC	cis	rs8180040	0.726	rs2305634	chr3:47043538	A/G	cg27129171	chr3:47204927	SETD2	-0.67	-9.15	-0.51	3.05e-17	Colorectal cancer;
SARC	cis	rs644799	0.648	rs1255182	chr11:95472391	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.59	7.63	0.45	6.08e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9393777	0.545	rs56303243	chr6:26485727	G/A	cg12826209	chr6:26865740	GUSBL1	0.8	7.27	0.43	5.42e-12	Intelligence (multi-trait analysis);
SARC	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg16479474	chr6:28041457	NA	0.36	5.25	0.33	3.43e-7	Depression;
SARC	cis	rs3771570	1.000	rs12619369	chr2:242282957	A/T	cg21155796	chr2:242212141	HDLBP	0.57	5.3	0.33	2.7e-7	Prostate cancer;
SARC	cis	rs9911578	0.785	rs10853008	chr17:56993407	T/C	cg12560992	chr17:57184187	TRIM37	-0.75	-8.64	-0.49	9.38e-16	Intelligence (multi-trait analysis);
SARC	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg11987759	chr7:65425863	GUSB	-0.5	-6.57	-0.4	3.18e-10	Aortic root size;
SARC	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.46	5.43	0.34	1.41e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7179456	0.654	rs12905081	chr15:59250000	G/A	cg05156742	chr15:59063176	FAM63B	0.57	7.31	0.43	4.31e-12	Asperger disorder;
SARC	cis	rs9788721	0.836	rs2656065	chr15:78750549	G/A	cg18825076	chr15:78729989	IREB2	-0.49	-6.07	-0.37	5.11e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs7666738	0.830	rs7657497	chr4:99044028	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.33e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg05623727	chr3:50126028	RBM5	0.35	5.13	0.32	6.06e-7	Body mass index;
SARC	trans	rs877282	1.000	rs877282	chr10:771532	G/A	cg22713356	chr15:30763199	NA	1.05	10.15	0.55	2.77e-20	Uric acid levels;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg26342734	chr17:7211307	EIF5A	-0.5	-6.63	-0.4	2.36e-10	Schizophrenia;
SARC	cis	rs9896933	0.832	rs75552659	chr17:80804630	G/A	cg20578329	chr17:80767326	TBCD	-0.7	-8.14	-0.47	2.34e-14	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
SARC	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg18402987	chr7:1209562	NA	0.56	5.09	0.32	7.47e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs7106204	0.764	rs4508205	chr11:24218850	C/T	ch.11.24196551F	chr11:24239977	NA	0.7	6.81	0.41	8.07e-11	Response to Homoharringtonine (cytotoxicity);
SARC	trans	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg21659725	chr3:3221576	CRBN	-0.64	-6.3	-0.38	1.43e-9	Menarche (age at onset);
SARC	cis	rs3126085	0.877	rs7537633	chr1:152223333	T/G	cg03465714	chr1:152285911	FLG	-0.44	-5.34	-0.33	2.26e-7	Atopic dermatitis;
SARC	cis	rs992157	0.835	rs4674283	chr2:219144254	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.7	-10.25	-0.56	1.35e-20	Colorectal cancer;
SARC	cis	rs995000	0.931	rs1168089	chr1:63113719	T/C	cg06896770	chr1:63153194	DOCK7	-0.89	-13.41	-0.66	9.23e-31	Triglyceride levels;
SARC	cis	rs11651000	0.761	rs11657388	chr17:45820707	C/G	cg24803719	chr17:45855879	NA	-0.45	-6.89	-0.41	5.3e-11	IgG glycosylation;
SARC	cis	rs2652822	0.525	rs35594365	chr15:63520154	T/C	cg02713581	chr15:63449717	RPS27L	0.53	6.38	0.39	9.47e-10	Metabolic traits;
SARC	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.31	0.43	4.17e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs8060686	0.545	rs55897859	chr16:68286748	G/C	cg27539214	chr16:67997921	SLC12A4	-0.61	-5.72	-0.35	3.29e-8	HDL cholesterol;Metabolic syndrome;
SARC	cis	rs6831352	0.819	rs13832	chr4:99993075	C/A	cg13256891	chr4:100009986	ADH5	0.62	8.42	0.48	3.79e-15	Alcohol dependence;
SARC	cis	rs55692411	0.537	rs7648652	chr3:50135412	A/C	cg24110177	chr3:50126178	RBM5	-0.48	-5.29	-0.33	2.84e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7103648	0.712	rs10838703	chr11:47422861	C/G	cg10504702	chr11:47789108	FNBP4	0.61	7.49	0.44	1.45e-12	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs6815814	0.950	rs55830619	chr4:38807364	G/A	cg02016764	chr4:38805732	TLR1	-0.42	-4.89	-0.31	1.89e-6	Breast cancer;
SARC	cis	rs9290065	0.519	rs7616249	chr3:160679422	T/C	cg03342759	chr3:160939853	NMD3	-0.47	-5.64	-0.35	4.87e-8	Kawasaki disease;
SARC	cis	rs2425143	0.730	rs7263640	chr20:34314725	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.09	-0.37	4.6e-9	Blood protein levels;
SARC	cis	rs2361718	1.000	rs2361718	chr17:78103466	C/T	cg06718696	chr17:78121285	EIF4A3	0.49	5.76	0.35	2.66e-8	Yeast infection;
SARC	cis	rs9916302	0.861	rs11078896	chr17:37415544	C/T	cg00129232	chr17:37814104	STARD3	-0.59	-7.4	-0.44	2.39e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs2011013	0.956	rs2277849	chr15:84639350	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.5	-5.27	-0.33	3.17e-7	Sitting height ratio;
SARC	cis	rs9549367	0.789	rs9549716	chr13:113908478	G/A	cg18105134	chr13:113819100	PROZ	-0.36	-5.48	-0.34	1.11e-7	Platelet distribution width;
SARC	cis	rs6991838	0.584	rs7812446	chr8:66505988	G/T	cg13398993	chr8:66546079	ARMC1	-0.62	-8.37	-0.48	5.33e-15	Intelligence (multi-trait analysis);
SARC	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg05793240	chr7:2802953	GNA12	-0.38	-5.47	-0.34	1.17e-7	Height;
SARC	cis	rs4319547	0.695	rs6488939	chr12:122858250	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.55	-6.22	-0.38	2.26e-9	Body mass index;
SARC	cis	rs7769051	1.000	rs9493443	chr6:133121349	C/T	cg07930552	chr6:133119739	C6orf192	0.93	8.61	0.49	1.14e-15	Type 2 diabetes nephropathy;
SARC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg26338869	chr17:61819248	STRADA	0.8	10.82	0.58	2.2e-22	Prudent dietary pattern;
SARC	cis	rs931812	1.000	rs4734494	chr8:101917721	T/C	cg07585502	chr8:101912084	NA	-0.41	-4.8	-0.3	2.84e-6	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs6964587	0.869	rs2374519	chr7:91541481	T/C	cg17063962	chr7:91808500	NA	-0.91	-14.0	-0.68	9.98e-33	Breast cancer;
SARC	cis	rs11785693	0.862	rs62491191	chr8:4993460	G/A	cg26367366	chr8:4980734	NA	0.73	6.47	0.39	5.67e-10	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg25072359	chr17:41440525	NA	0.51	6.02	0.37	6.83e-9	Menopause (age at onset);
SARC	cis	rs11608355	0.515	rs11611012	chr12:109945203	G/A	cg05360138	chr12:110035743	NA	0.91	8.86	0.5	2.03e-16	Neuroticism;
SARC	cis	rs10463554	0.824	rs60588319	chr5:102324360	G/A	cg23492399	chr5:102201601	PAM	-0.51	-6.16	-0.37	3.15e-9	Parkinson's disease;
SARC	cis	rs600231	0.706	rs4244811	chr11:65320780	G/A	cg17120908	chr11:65337727	SSSCA1	0.51	6.36	0.38	1.07e-9	Bone mineral density;
SARC	trans	rs61931739	0.500	rs10844864	chr12:34532468	A/G	cg13010199	chr12:38710504	ALG10B	0.78	11.07	0.59	3.68e-23	Morning vs. evening chronotype;
SARC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg01238044	chr22:24384105	GSTT1	-0.75	-10.04	-0.55	6.08e-20	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9987353	0.519	rs13276350	chr8:9063157	T/C	cg15556689	chr8:8085844	FLJ10661	-0.48	-5.68	-0.35	3.92e-8	Recombination measurement;
SARC	cis	rs9902453	0.967	rs55744550	chr17:28475729	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	6.62	0.4	2.5e-10	Coffee consumption (cups per day);
SARC	cis	rs2439831	0.850	rs3816792	chr15:44116986	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.95	-8.49	-0.49	2.49e-15	Lung cancer in ever smokers;
SARC	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg23758822	chr17:41437982	NA	0.87	10.64	0.57	8.54e-22	Menopause (age at onset);
SARC	cis	rs7635838	0.826	rs9867963	chr3:11469126	C/T	cg00170343	chr3:11313890	ATG7	0.55	7.28	0.43	5.11e-12	HDL cholesterol;
SARC	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg18252515	chr7:66147081	NA	0.6	6.57	0.4	3.3e-10	Aortic root size;
SARC	cis	rs2797160	0.651	rs6569437	chr6:126034540	T/G	cg05901451	chr6:126070800	HEY2	0.44	5.39	0.33	1.69e-7	Endometrial cancer;
SARC	cis	rs7729447	0.804	rs4867471	chr5:32693456	A/T	cg16267343	chr5:32710456	NPR3	0.65	8.59	0.49	1.24e-15	Blood pressure;
SARC	cis	rs4742903	0.904	rs4373581	chr9:106977463	C/T	cg14250997	chr9:106856677	SMC2	0.4	5.02	0.31	1.02e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	trans	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg06437703	chr8:37914619	EIF4EBP1	-0.54	-6.46	-0.39	6.1e-10	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg12373951	chr3:133503437	NA	0.36	5.28	0.33	2.97e-7	Iron status biomarkers;
SARC	cis	rs2213920	0.749	rs4637918	chr9:118258247	G/T	cg13918206	chr9:118159781	DEC1	0.8	6.21	0.38	2.44e-9	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg11644478	chr21:40555479	PSMG1	1.06	15.22	0.71	8.95e-37	Cognitive function;
SARC	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.57	7.51	0.44	1.27e-12	Menarche (age at onset);
SARC	cis	rs858239	0.601	rs73272048	chr7:23152653	C/G	cg23682824	chr7:23144976	KLHL7	0.72	9.84	0.54	2.49e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs1800469	1.000	rs2241714	chr19:41869392	C/T	cg09537434	chr19:41945824	ATP5SL	0.57	6.97	0.42	3.17e-11	Colorectal cancer;
SARC	cis	rs7223966	1.000	rs7220892	chr17:61908316	G/A	cg00588841	chr17:61851480	DDX42;CCDC47	-0.63	-6.78	-0.41	9.88e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7264396	0.563	rs2425079	chr20:34298191	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	5.69	0.35	3.71e-8	Total cholesterol levels;
SARC	cis	rs554111	0.656	rs12021529	chr1:21306161	C/T	cg08890418	chr1:21044141	KIF17	0.35	4.87	0.3	2.06e-6	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg09373136	chr17:61933544	TCAM1	-0.45	-6.23	-0.38	2.18e-9	Prudent dietary pattern;
SARC	cis	rs1550582	0.662	rs4909628	chr8:135502380	A/T	cg17885191	chr8:135476712	NA	-0.77	-7.95	-0.46	8e-14	Educational attainment;
SARC	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg19346786	chr7:2764209	NA	-0.39	-5.86	-0.36	1.59e-8	Height;
SARC	cis	rs4268898	0.527	rs72789910	chr2:24388609	T/G	cg26838691	chr2:24397539	C2orf84	-0.56	-6.33	-0.38	1.23e-9	Asthma;
SARC	cis	rs13191362	1.000	rs13218900	chr6:163081638	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.72	6.38	0.39	9.33e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2033732	0.706	rs9298418	chr8:85066831	T/C	cg05716166	chr8:85095498	RALYL	0.47	5.62	0.35	5.51e-8	Body mass index;
SARC	cis	rs7481584	0.624	rs511990	chr11:3052936	A/G	cg05729581	chr11:3078854	CARS	0.57	7.41	0.44	2.38e-12	Calcium levels;
SARC	cis	rs3008870	1.000	rs2985818	chr1:67398916	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.91	11.38	0.6	3.78e-24	Lymphocyte percentage of white cells;
SARC	cis	rs995000	0.965	rs1168022	chr1:63007721	A/T	cg06896770	chr1:63153194	DOCK7	-0.9	-13.49	-0.66	5.08e-31	Triglyceride levels;
SARC	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.9	-0.5	1.61e-16	Alzheimer's disease;
SARC	cis	rs1124376	0.882	rs7639282	chr3:20133873	G/A	cg05072819	chr3:20081367	KAT2B	0.49	4.81	0.3	2.66e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-5.76	-0.35	2.69e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg16606324	chr3:10149918	C3orf24	0.5	5.01	0.31	1.08e-6	Alzheimer's disease;
SARC	cis	rs9435341	0.930	rs12408634	chr1:107579540	G/A	cg09367891	chr1:107599246	PRMT6	0.75	9.41	0.52	5.12e-18	Facial morphology (factor 21, depth of nasal alae);
SARC	cis	rs4926611	0.729	rs17382457	chr1:54071428	A/G	cg08927728	chr1:54059983	GLIS1	-0.33	-5.49	-0.34	1.07e-7	Hand grip strength;
SARC	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg22903471	chr2:27725779	GCKR	-0.49	-7.48	-0.44	1.49e-12	Total body bone mineral density;
SARC	cis	rs2985684	0.901	rs7146248	chr14:50112067	C/T	cg23565292	chr14:50234668	KLHDC2	-0.47	-4.87	-0.3	2.06e-6	Carotid intima media thickness;
SARC	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg20891283	chr12:69753455	YEATS4	0.66	9.54	0.53	2.09e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg18230493	chr5:56204884	C5orf35	0.53	4.8	0.3	2.79e-6	Initial pursuit acceleration;
SARC	cis	rs4423214	0.959	rs12793224	chr11:71168710	G/A	cg24826892	chr11:71159390	DHCR7	0.46	5.76	0.35	2.69e-8	Vitamin D levels;
SARC	cis	rs7520050	0.807	rs4660312	chr1:46110572	A/G	cg24296786	chr1:45957014	TESK2	-0.43	-5.54	-0.34	7.98e-8	Red blood cell count;Reticulocyte count;
SARC	trans	rs1814175	0.781	rs1851872	chr11:50009770	A/G	cg15704280	chr7:45808275	SEPT13	-0.97	-18.31	-0.77	5.28e-47	Height;
SARC	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg24060327	chr5:131705240	SLC22A5	-0.5	-5.98	-0.36	8.28e-9	Acylcarnitine levels;
SARC	cis	rs11098499	0.954	rs6838814	chr4:120392443	G/A	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	trans	rs925098	0.577	rs981209	chr4:18027239	C/T	cg08521178	chr6:170491202	NA	0.43	6.8	0.41	8.79e-11	Birth weight;Height;
SARC	cis	rs7572733	0.555	rs7600269	chr2:198923468	C/G	cg00792783	chr2:198669748	PLCL1	0.43	4.76	0.3	3.33e-6	Dermatomyositis;
SARC	cis	rs9894429	0.646	rs9902264	chr17:79613828	G/A	cg10661904	chr17:79619235	PDE6G	-0.44	-6.25	-0.38	1.91e-9	Eye color traits;
SARC	trans	rs12310956	0.532	rs10844719	chr12:33987714	A/G	cg26384229	chr12:38710491	ALG10B	0.75	10.56	0.57	1.45e-21	Morning vs. evening chronotype;
SARC	cis	rs3733585	0.683	rs6449140	chr4:9936437	G/C	cg00071950	chr4:10020882	SLC2A9	-0.4	-6.42	-0.39	7.43e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.9	11.95	0.62	5.38e-26	Gut microbiome composition (summer);
SARC	cis	rs765787	0.530	rs11854294	chr15:45527996	A/G	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.81e-6	Uric acid levels;
SARC	cis	rs7084402	0.967	rs1658442	chr10:60318897	G/A	cg07615347	chr10:60278583	BICC1	0.58	8.33	0.48	7.16e-15	Refractive error;
SARC	cis	rs13314892	0.689	rs62252226	chr3:69885246	G/A	cg17445875	chr3:69859618	MITF	-0.5	-5.24	-0.32	3.6e-7	QRS complex (12-leadsum);
SARC	cis	rs4924935	0.798	rs1737940	chr17:18845320	T/G	cg26306683	chr17:18585705	ZNF286B	0.45	5.29	0.33	2.8e-7	Pancreatic cancer;
SARC	cis	rs7246760	0.867	rs67634928	chr19:9802397	C/G	cg16876255	chr19:9731953	ZNF561	0.82	5.05	0.31	8.72e-7	Pursuit maintenance gain;
SARC	cis	rs3126085	0.935	rs1858479	chr1:152294823	A/T	cg03465714	chr1:152285911	FLG	0.48	5.62	0.35	5.42e-8	Atopic dermatitis;
SARC	cis	rs9467773	0.523	rs2498399	chr6:26706544	T/C	cg12292205	chr6:26970375	C6orf41	0.41	4.77	0.3	3.26e-6	Intelligence (multi-trait analysis);
SARC	cis	rs6582630	0.555	rs11182202	chr12:38476451	C/G	cg26384229	chr12:38710491	ALG10B	0.84	12.0	0.62	3.64e-26	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7833790	1.000	rs28696138	chr8:82770794	G/A	cg27398817	chr8:82754497	SNX16	0.52	5.73	0.35	3.17e-8	Diastolic blood pressure;
SARC	cis	rs4481887	0.893	rs10888347	chr1:248448566	T/C	cg01631408	chr1:248437212	OR2T33	-0.41	-5.21	-0.32	4.17e-7	Common traits (Other);
SARC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg09373136	chr17:61933544	TCAM1	0.39	5.55	0.34	7.6e-8	Prudent dietary pattern;
SARC	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.69	8.81	0.5	2.92e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs939574	0.720	rs6714820	chr2:220071803	C/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.53	-4.87	-0.3	2.03e-6	Platelet distribution width;
SARC	cis	rs9788682	0.748	rs637137	chr15:78873976	T/A	cg24631222	chr15:78858424	CHRNA5	0.75	10.02	0.55	6.84e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg11987759	chr7:65425863	GUSB	-0.48	-6.52	-0.39	4.3e-10	Aortic root size;
SARC	cis	rs10463554	0.927	rs34824	chr5:102438931	A/C	cg23492399	chr5:102201601	PAM	-0.52	-5.71	-0.35	3.43e-8	Parkinson's disease;
SARC	cis	rs7944584	0.545	rs7118178	chr11:47659135	G/A	cg10504702	chr11:47789108	FNBP4	0.67	8.15	0.47	2.27e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs10089	0.953	rs4836358	chr5:127376869	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	10.19	0.56	2.04e-20	Ileal carcinoids;
SARC	cis	rs11792861	0.962	rs3750452	chr9:111801353	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.68	7.79	0.45	2.21e-13	Menarche (age at onset);
SARC	cis	rs10992471	0.651	rs7043984	chr9:95529408	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.41	-4.79	-0.3	2.91e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs60733400	0.818	rs10909839	chr1:2708430	G/A	cg00980319	chr1:2560884	MMEL1	-0.34	-4.92	-0.31	1.66e-6	Multiple sclerosis;
SARC	cis	rs8067545	0.611	rs1974745	chr17:20059824	C/G	cg13482628	chr17:19912719	NA	0.51	6.45	0.39	6.23e-10	Schizophrenia;
SARC	cis	rs2549003	1.000	rs10214312	chr5:131821866	T/G	cg21138405	chr5:131827807	IRF1	0.27	5.32	0.33	2.4e-7	Asthma (sex interaction);
SARC	cis	rs7681440	0.904	rs3806789	chr4:90759556	C/T	cg06632027	chr4:90757378	SNCA	0.41	5.95	0.36	9.71e-9	Dementia with Lewy bodies;
SARC	cis	rs2180341	0.814	rs6569488	chr6:127726256	C/T	cg24812749	chr6:127587940	RNF146	0.79	10.11	0.55	3.71e-20	Breast cancer;
SARC	cis	rs2075371	0.501	rs1646652	chr7:134024515	A/T	cg20476274	chr7:133979776	SLC35B4	0.38	4.82	0.3	2.62e-6	Mean platelet volume;
SARC	cis	rs7647973	0.559	rs9586	chr3:49213637	C/T	cg06212747	chr3:49208901	KLHDC8B	0.85	9.08	0.51	4.77e-17	Menarche (age at onset);
SARC	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg04267008	chr7:1944627	MAD1L1	-0.6	-6.85	-0.41	6.46e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs7772486	0.840	rs854144	chr6:146360880	G/T	cg23711669	chr6:146136114	FBXO30	-0.77	-10.83	-0.58	2.16e-22	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1008375	0.898	rs7670500	chr4:17586957	A/G	cg27347728	chr4:17578864	LAP3	0.49	6.06	0.37	5.46e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.03	0.37	6.27e-9	Prudent dietary pattern;
SARC	cis	rs17023223	0.537	rs2361271	chr1:119603405	A/G	cg05756136	chr1:119680316	WARS2	-0.43	-5.03	-0.31	9.81e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs1784581	0.588	rs9458428	chr6:162424579	A/G	cg17173639	chr6:162384350	PARK2	-0.5	-6.48	-0.39	5.47e-10	Itch intensity from mosquito bite;
SARC	cis	rs4660261	0.562	rs3011223	chr1:44318286	T/C	cg09903430	chr1:44172605	ST3GAL3	0.36	4.75	0.3	3.62e-6	Intelligence (multi-trait analysis);
SARC	cis	rs6456156	0.586	rs12529876	chr6:167461501	G/A	cg23791538	chr6:167370224	RNASET2	-0.52	-6.79	-0.41	9.49e-11	Primary biliary cholangitis;
SARC	cis	rs7582180	0.764	rs12622318	chr2:100927375	T/C	cg14675211	chr2:100938903	LONRF2	0.52	7.62	0.45	6.2800000000000005e-13	Intelligence (multi-trait analysis);
SARC	cis	rs7647973	0.925	rs7429661	chr3:49228800	G/A	cg07636037	chr3:49044803	WDR6	0.75	8.04	0.47	4.64e-14	Menarche (age at onset);
SARC	cis	rs11711311	1.000	rs9865965	chr3:113450495	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.69	8.9	0.5	1.64e-16	IgG glycosylation;
SARC	cis	rs80130819	0.748	rs2732474	chr12:48700817	A/T	cg24011408	chr12:48396354	COL2A1	0.52	5.89	0.36	1.32e-8	Prostate cancer;
SARC	cis	rs651907	0.535	rs9830943	chr3:101428899	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	6.29	0.38	1.59e-9	Colorectal cancer;
SARC	cis	rs2043112	1.000	rs13177882	chr5:39021493	G/A	cg04869206	chr5:39074266	RICTOR	0.49	5.94	0.36	1.02e-8	Obesity-related traits;
SARC	cis	rs7592578	0.825	rs12477369	chr2:191455624	G/T	cg25963032	chr2:191064776	C2orf88	0.45	4.97	0.31	1.27e-6	Diastolic blood pressure;
SARC	trans	rs61931739	0.500	rs11053271	chr12:34545407	C/A	cg13010199	chr12:38710504	ALG10B	0.83	11.73	0.61	2.89e-25	Morning vs. evening chronotype;
SARC	trans	rs561341	1.000	rs501312	chr17:30329066	A/G	cg20587970	chr11:113659929	NA	-1.29	-13.65	-0.67	1.47e-31	Hip circumference adjusted for BMI;
SARC	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg06713675	chr4:122721982	EXOSC9	-0.5	-6.59	-0.4	2.96e-10	Type 2 diabetes;
SARC	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7772486	0.686	rs10872579	chr6:145966012	C/G	cg05347473	chr6:146136440	FBXO30	0.49	6.83	0.41	7.43e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs67311347	1.000	rs28536038	chr3:40496382	A/C	cg01475735	chr3:40494733	NA	-0.46	-5.16	-0.32	5.33e-7	Renal cell carcinoma;
SARC	cis	rs7208859	0.673	rs999796	chr17:29159404	G/C	cg13385521	chr17:29058706	SUZ12P	0.77	6.79	0.41	9.01e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg13264159	chr8:625131	ERICH1	-0.72	-4.84	-0.3	2.33e-6	IgG glycosylation;
SARC	cis	rs36051895	0.659	rs10121491	chr9:5046935	T/C	cg02405213	chr9:5042618	JAK2	-0.5	-5.81	-0.36	2.07e-8	Pediatric autoimmune diseases;
SARC	cis	rs9354308	0.764	rs4476812	chr6:66594554	A/C	cg07460842	chr6:66804631	NA	0.41	4.77	0.3	3.27e-6	Metabolite levels;
SARC	cis	rs35146811	0.586	rs10267212	chr7:99595422	T/C	cg22004693	chr7:99632812	ZKSCAN1	-0.44	-4.73	-0.3	3.9e-6	Coronary artery disease;
SARC	cis	rs6807306	1.000	rs9823325	chr3:167363212	A/G	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.53	5.36	0.33	2e-7	Mean platelet volume;
SARC	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg16049864	chr8:95962084	TP53INP1	0.47	8.04	0.47	4.38e-14	Type 2 diabetes;
SARC	cis	rs3733585	0.563	rs881971	chr4:9930962	A/G	cg11266682	chr4:10021025	SLC2A9	-0.36	-6.3	-0.38	1.5e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg04155687	chr1:202830475	LOC148709	0.75	6.34	0.38	1.15e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs832540	0.552	rs252924	chr5:56205643	A/G	cg14703610	chr5:56206110	C5orf35	0.42	4.74	0.3	3.67e-6	Coronary artery disease;
SARC	cis	rs6963495	0.745	rs68153235	chr7:105184832	A/C	cg13798780	chr7:105162888	PUS7	0.47	4.76	0.3	3.4e-6	Bipolar disorder (body mass index interaction);
SARC	cis	rs3087591	0.708	rs2854311	chr17:29671327	C/T	cg24425628	chr17:29625626	OMG;NF1	0.44	5.72	0.35	3.2e-8	Hip circumference;
SARC	cis	rs12579753	0.810	rs10862350	chr12:82156202	G/A	cg07988820	chr12:82153109	PPFIA2	-0.47	-5.97	-0.36	8.62e-9	Resting heart rate;
SARC	cis	rs6542838	0.554	rs4311103	chr2:99538362	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.5	-6.36	-0.38	1.05e-9	Fear of minor pain;
SARC	cis	rs870825	0.929	rs1405941	chr4:185591518	A/C	cg04058563	chr4:185651563	MLF1IP	-0.68	-7.29	-0.43	4.69e-12	Blood protein levels;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg24688926	chr19:6737877	GPR108	0.5	6.27	0.38	1.74e-9	Lung adenocarcinoma;
SARC	cis	rs59918340	0.764	rs4961339	chr8:142231504	A/G	cg16341495	chr8:142228727	SLC45A4	-0.36	-5.17	-0.32	5.01e-7	Immature fraction of reticulocytes;
SARC	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg13877915	chr19:58951672	ZNF132	0.66	9.97	0.55	1.02e-19	Uric acid clearance;
SARC	cis	rs4268898	0.636	rs76172309	chr2:24458911	G/C	cg06627628	chr2:24431161	ITSN2	-0.82	-10.04	-0.55	6.21e-20	Asthma;
SARC	cis	rs7824557	0.583	rs4448232	chr8:11231354	G/T	cg21775007	chr8:11205619	TDH	0.63	8.39	0.48	4.74e-15	Retinal vascular caliber;
SARC	cis	rs67311347	1.000	rs2168111	chr3:40395325	T/G	cg09455208	chr3:40491958	NA	0.4	6.1	0.37	4.45e-9	Renal cell carcinoma;
SARC	cis	rs7914558	0.966	rs10786721	chr10:104654383	C/A	cg04362960	chr10:104952993	NT5C2	0.41	4.96	0.31	1.38e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs1448094	1.000	rs1448094	chr12:86343135	G/T	cg02569458	chr12:86230093	RASSF9	0.39	5.74	0.35	2.92e-8	Major depressive disorder;
SARC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.54	6.97	0.42	3.16e-11	Lymphocyte counts;
SARC	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg16405210	chr4:1374714	KIAA1530	-0.63	-7.8	-0.46	2.06e-13	Obesity-related traits;
SARC	cis	rs734999	0.566	rs10752747	chr1:2524915	G/T	cg18854424	chr1:2615690	NA	0.33	5.17	0.32	5e-7	Ulcerative colitis;
SARC	cis	rs9611519	0.780	rs2235850	chr22:41657626	C/T	cg17376030	chr22:41985996	PMM1	0.53	6.69	0.4	1.65e-10	Neuroticism;
SARC	cis	rs57083693	0.556	rs6538984	chr12:101725669	T/G	cg22051763	chr12:101673672	UTP20	-0.44	-5.19	-0.32	4.63e-7	Alcohol dependence (age at onset);
SARC	cis	rs7084402	0.935	rs1658492	chr10:60281267	C/T	cg07615347	chr10:60278583	BICC1	-0.6	-8.82	-0.5	2.71e-16	Refractive error;
SARC	cis	rs1707322	0.686	rs2991987	chr1:46081422	C/G	cg06784218	chr1:46089804	CCDC17	-0.38	-6.68	-0.4	1.79e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs73195822	0.667	rs117806977	chr12:111235324	C/T	cg10860002	chr12:110842031	ANAPC7	0.67	5.0	0.31	1.15e-6	Itch intensity from mosquito bite;
SARC	cis	rs6714710	0.557	rs17490429	chr2:98449024	G/A	cg26665480	chr2:98280029	ACTR1B	0.48	6.45	0.39	6.37e-10	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs6089584	0.606	rs6089599	chr20:60576992	A/G	cg06108461	chr20:60628389	TAF4	0.7	9.11	0.51	3.77e-17	Body mass index;
SARC	cis	rs56235845	0.694	rs12055081	chr5:176757191	C/T	cg17509989	chr5:176798049	RGS14	0.57	7.68	0.45	4.29e-13	Hemoglobin concentration;Hematocrit;
SARC	cis	rs3126085	0.935	rs41267154	chr1:152286367	C/A	cg03465714	chr1:152285911	FLG	0.48	5.62	0.35	5.42e-8	Atopic dermatitis;
SARC	cis	rs6142102	0.961	rs2284379	chr20:32594642	T/C	cg24642439	chr20:33292090	TP53INP2	0.43	4.73	0.3	3.88e-6	Skin pigmentation;
SARC	cis	rs6964587	0.626	rs10280301	chr7:91524258	A/T	cg17063962	chr7:91808500	NA	-0.78	-11.47	-0.6	1.95e-24	Breast cancer;
SARC	cis	rs8078723	1.000	rs8078723	chr17:38166879	A/G	cg17467752	chr17:38218738	THRA	0.45	5.76	0.35	2.62e-8	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs921968	0.565	rs1078803	chr2:219606538	A/C	cg02176678	chr2:219576539	TTLL4	0.34	5.18	0.32	4.73e-7	Mean corpuscular hemoglobin concentration;
SARC	trans	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg04863568	chr16:28936502	RABEP2	0.47	6.36	0.38	1.08e-9	Immature fraction of reticulocytes;
SARC	cis	rs6963495	0.818	rs9769403	chr7:105163091	G/A	cg19920283	chr7:105172520	RINT1	0.65	5.48	0.34	1.09e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs2075371	1.000	rs2505	chr7:133979552	C/T	cg11752832	chr7:134001865	SLC35B4	0.56	7.39	0.44	2.64e-12	Mean platelet volume;
SARC	cis	rs7833986	0.501	rs2668007	chr8:56944111	C/T	cg26371346	chr8:56986568	SNORD54;RPS20	0.76	6.47	0.39	5.87e-10	Height;
SARC	cis	rs7617773	0.817	rs3731555	chr3:48206102	G/A	cg11946769	chr3:48343235	NME6	0.72	9.38	0.52	6.07e-18	Coronary artery disease;
SARC	cis	rs7312933	1.000	rs7957213	chr12:42475438	T/G	cg19980929	chr12:42632907	YAF2	0.33	4.72	0.3	4.07e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs9916302	0.752	rs8071300	chr17:37508524	G/C	cg00129232	chr17:37814104	STARD3	0.53	5.69	0.35	3.85e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	7.34	0.43	3.43e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9987353	0.519	rs13276350	chr8:9063157	T/C	cg06636001	chr8:8085503	FLJ10661	-0.62	-7.76	-0.45	2.64e-13	Recombination measurement;
SARC	cis	rs2354432	0.607	rs2297752	chr1:146765454	C/G	cg25205988	chr1:146714368	CHD1L	-0.97	-9.27	-0.52	1.26e-17	Mitochondrial DNA levels;
SARC	cis	rs6088580	0.634	rs6579165	chr20:32994715	A/G	cg24642439	chr20:33292090	TP53INP2	-0.68	-8.73	-0.5	4.96e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.1	20.49	0.8	5e-54	Chronic sinus infection;
SARC	cis	rs7635838	0.892	rs7644968	chr3:11489493	C/T	cg00170343	chr3:11313890	ATG7	0.63	8.44	0.48	3.32e-15	HDL cholesterol;
SARC	cis	rs2387326	0.717	rs12252256	chr10:129944616	C/T	cg16087940	chr10:129947807	NA	-0.46	-5.85	-0.36	1.64e-8	Select biomarker traits;
SARC	cis	rs8044995	0.501	rs73613952	chr16:68352808	G/C	cg09835421	chr16:68378352	PRMT7	-0.65	-5.69	-0.35	3.75e-8	Schizophrenia;
SARC	cis	rs240764	0.658	rs2050549	chr6:101216645	A/G	cg09795085	chr6:101329169	ASCC3	-0.44	-5.64	-0.35	4.87e-8	Neuroticism;
SARC	cis	rs995000	0.868	rs1007205	chr1:62936912	T/C	cg06896770	chr1:63153194	DOCK7	-0.89	-13.31	-0.66	2.01e-30	Triglyceride levels;
SARC	cis	rs12477438	0.677	rs12475034	chr2:99699464	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-6.86	-0.41	6.04e-11	Chronic sinus infection;
SARC	cis	rs11758351	0.660	rs55848726	chr6:26224434	T/C	cg01420254	chr6:26195488	NA	0.55	4.75	0.3	3.49e-6	Gout;Renal underexcretion gout;
SARC	cis	rs6546550	0.901	rs6736408	chr2:70137774	C/T	cg02498382	chr2:70120550	SNRNP27	-0.32	-5.13	-0.32	6.02e-7	Prevalent atrial fibrillation;
SARC	cis	rs10752881	0.935	rs10911235	chr1:183053746	G/A	cg13390022	chr1:182993471	LAMC1	0.33	5.06	0.31	8.49e-7	Colorectal cancer;
SARC	cis	rs2070488	1.000	rs762317	chr3:38497659	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	14.68	0.69	5.62e-35	Electrocardiographic conduction measures;
SARC	cis	rs9303401	0.661	rs9902820	chr17:56637545	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.42	5.14	0.32	5.69e-7	Cognitive test performance;
SARC	cis	rs870825	0.929	rs72689262	chr4:185590950	C/G	cg04058563	chr4:185651563	MLF1IP	0.79	8.8	0.5	3.22e-16	Blood protein levels;
SARC	cis	rs2268241	0.938	rs9978223	chr21:34770358	G/A	cg14850771	chr21:34775459	IFNGR2	0.95	9.4	0.52	5.47e-18	Obesity-related traits;
SARC	cis	rs8078723	0.668	rs3859191	chr17:38128714	G/A	cg17467752	chr17:38218738	THRA	0.41	5.31	0.33	2.58e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs7260598	0.539	rs116780835	chr19:24063516	G/A	cg27517351	chr19:23941871	ZNF681	0.54	4.73	0.3	3.86e-6	Response to taxane treatment (placlitaxel);
SARC	cis	rs41278232	0.557	rs817338	chr20:62604201	T/C	cg07620230	chr20:62328084	TNFRSF6B	0.33	4.72	0.3	4.13e-6	Tonsillectomy;
SARC	cis	rs9527	0.590	rs7074395	chr10:104844928	A/C	cg04362960	chr10:104952993	NT5C2	-0.42	-5.07	-0.32	8.02e-7	Arsenic metabolism;
SARC	cis	rs10465746	0.967	rs12118434	chr1:84328629	C/T	cg10977910	chr1:84465055	TTLL7	0.41	4.96	0.31	1.39e-6	Obesity-related traits;
SARC	cis	rs644799	0.710	rs12273579	chr11:95524421	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.97	16.71	0.74	9.58e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.57	-7.39	-0.44	2.6e-12	Lymphocyte counts;
SARC	cis	rs16976116	0.643	rs12440420	chr15:55517432	C/T	cg17854078	chr15:55489399	RSL24D1	-0.51	-4.93	-0.31	1.53e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs826838	0.967	rs73096706	chr12:38860563	G/A	cg26384229	chr12:38710491	ALG10B	0.92	14.39	0.69	5.19e-34	Heart rate;
SARC	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.74	8.73	0.5	5.14e-16	Height;
SARC	cis	rs12477438	0.765	rs13390672	chr2:99589829	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.95	-15.47	-0.71	1.34e-37	Chronic sinus infection;
SARC	cis	rs11722228	0.549	rs55848383	chr4:10081117	C/A	cg11266682	chr4:10021025	SLC2A9	0.32	4.73	0.3	3.97e-6	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg08677398	chr8:58056175	NA	0.44	5.24	0.32	3.59e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9790314	0.690	rs7633857	chr3:160844942	C/G	cg04691961	chr3:161091175	C3orf57	-0.56	-7.35	-0.43	3.27e-12	Morning vs. evening chronotype;
SARC	cis	rs7647973	1.000	rs13088309	chr3:49368317	A/G	cg06212747	chr3:49208901	KLHDC8B	0.55	5.94	0.36	1.02e-8	Menarche (age at onset);
SARC	cis	rs270601	0.909	rs2569265	chr5:131704519	T/C	cg12564285	chr5:131593104	PDLIM4	-0.46	-6.26	-0.38	1.79e-9	Acylcarnitine levels;
SARC	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg21724239	chr8:58056113	NA	0.6	6.37	0.39	9.97e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg04772025	chr11:68637568	NA	0.47	5.72	0.35	3.34e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs1034435	0.755	rs713923	chr22:48891519	C/T	cg05992904	chr22:48892994	FAM19A5	0.45	6.58	0.4	3.1e-10	Late-onset Alzheimer's disease;
SARC	cis	rs7672847	0.547	rs4692723	chr4:170346090	C/T	cg00846720	chr4:170533756	NEK1	-0.57	-4.72	-0.3	4.06e-6	Subjective well-being;
SARC	cis	rs1008375	0.966	rs28750296	chr4:17685826	A/T	cg16339924	chr4:17578868	LAP3	0.62	8.1	0.47	3.05e-14	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs208520	0.545	rs6899712	chr6:66749670	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	18.56	0.77	7.87e-48	Exhaled nitric oxide output;
SARC	cis	rs17023223	0.537	rs2765534	chr1:119597792	A/C	cg05756136	chr1:119680316	WARS2	-0.43	-5.06	-0.31	8.38e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs7833986	0.501	rs2719227	chr8:57043794	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	-0.77	-7.72	-0.45	3.5e-13	Height;
SARC	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg07636037	chr3:49044803	WDR6	1.0	17.66	0.76	6.92e-45	Parkinson's disease;
SARC	cis	rs6912958	0.712	rs2307379	chr6:88366771	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.24	-0.32	3.57e-7	Monocyte percentage of white cells;
SARC	cis	rs9916302	0.752	rs11078895	chr17:37401051	A/G	cg20243544	chr17:37824526	PNMT	0.51	5.45	0.34	1.29e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs835154	0.845	rs835158	chr5:14873254	C/G	cg18064842	chr5:14874549	NA	-0.67	-10.42	-0.56	4.07e-21	Blood metabolite levels;
SARC	cis	rs79149102	0.649	rs12443172	chr15:75119671	G/C	cg17294928	chr15:75287854	SCAMP5	-0.99	-5.42	-0.33	1.46e-7	Lung cancer;
SARC	trans	rs9329221	0.638	rs7460436	chr8:10254322	C/T	cg06636001	chr8:8085503	FLJ10661	0.6	7.33	0.43	3.66e-12	Neuroticism;
SARC	cis	rs4566357	0.539	rs10933164	chr2:227860671	A/G	cg05526886	chr2:227700861	RHBDD1	-0.55	-6.23	-0.38	2.2e-9	Coronary artery disease;
SARC	cis	rs6120849	0.754	rs6088691	chr20:33633758	C/T	cg06115741	chr20:33292138	TP53INP2	0.54	5.16	0.32	5.3e-7	Protein C levels;
SARC	cis	rs11792861	0.505	rs12377869	chr9:111907803	C/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	7.52	0.44	1.18e-12	Menarche (age at onset);
SARC	cis	rs7264396	0.635	rs6058363	chr20:34505054	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-6.85	-0.41	6.4e-11	Total cholesterol levels;
SARC	cis	rs6540556	0.723	rs7539852	chr1:209898539	A/G	cg23920097	chr1:209922102	NA	-0.51	-4.94	-0.31	1.51e-6	Red blood cell count;
SARC	cis	rs240764	0.764	rs10457800	chr6:100936628	C/T	cg09795085	chr6:101329169	ASCC3	-0.4	-5.1	-0.32	7.15e-7	Neuroticism;
SARC	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg11987759	chr7:65425863	GUSB	-0.48	-6.54	-0.39	3.9e-10	Aortic root size;
SARC	cis	rs6087990	0.899	rs998382	chr20:31384136	C/T	cg13636640	chr20:31349939	DNMT3B	-0.79	-12.04	-0.62	2.82e-26	Ulcerative colitis;
SARC	cis	rs8112909	0.790	rs888950	chr19:46418089	T/C	cg03583734	chr19:46390327	IRF2BP1	0.48	4.91	0.31	1.73e-6	Interferon gamma-induced protein 10 levels;
SARC	cis	rs2066819	0.818	rs703830	chr12:56701872	T/C	cg26316697	chr12:56727976	PAN2	-0.9	-6.37	-0.39	9.89e-10	Psoriasis vulgaris;
SARC	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg19223190	chr17:80058835	NA	-0.43	-6.02	-0.37	6.57e-9	Life satisfaction;
SARC	cis	rs1728785	1.000	rs1170426	chr16:68603798	C/T	cg02972257	chr16:68554789	NA	-0.47	-5.56	-0.34	7.2e-8	Ulcerative colitis;
SARC	cis	rs1568889	0.938	rs6484358	chr11:28260364	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	10.14	0.55	2.91e-20	Bipolar disorder;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg02909592	chr3:149181944	NA	0.48	6.33	0.38	1.24e-9	Schizophrenia;
SARC	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg05861140	chr6:150128134	PCMT1	-0.42	-5.44	-0.34	1.32e-7	Lung cancer;
SARC	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg03806693	chr22:41940476	POLR3H	-0.9	-13.05	-0.65	1.37e-29	Vitiligo;
SARC	cis	rs3768617	0.811	rs12738377	chr1:183031256	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.6	7.97	0.46	7.28e-14	Fuchs's corneal dystrophy;
SARC	cis	rs9815354	0.597	rs80066790	chr3:42000843	A/G	cg03022575	chr3:42003672	ULK4	0.68	5.86	0.36	1.56e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs240764	0.659	rs240772	chr6:101007895	C/T	cg09795085	chr6:101329169	ASCC3	-0.38	-4.73	-0.3	3.82e-6	Neuroticism;
SARC	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg22834771	chr12:69754056	YEATS4	-0.44	-5.77	-0.35	2.49e-8	Blood protein levels;
SARC	cis	rs3008870	0.755	rs2815380	chr1:67510857	A/G	cg02640540	chr1:67518911	SLC35D1	-0.66	-8.41	-0.48	4.05e-15	Lymphocyte percentage of white cells;
SARC	cis	rs6545883	0.772	rs1186709	chr2:61689380	G/A	cg15711740	chr2:61764176	XPO1	-0.44	-5.23	-0.32	3.72e-7	Tuberculosis;
SARC	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg03806693	chr22:41940476	POLR3H	0.83	11.73	0.61	2.8e-25	Vitiligo;
SARC	cis	rs35110281	0.626	rs162367	chr21:44934857	A/G	cg01579765	chr21:45077557	HSF2BP	-0.3	-5.03	-0.31	9.8e-7	Mean corpuscular volume;
SARC	cis	rs9840812	0.639	rs610860	chr3:136052816	A/G	cg15507776	chr3:136538369	TMEM22	0.52	5.14	0.32	5.82e-7	Fibrinogen levels;
SARC	cis	rs9399137	0.507	rs7748708	chr6:135275142	G/A	cg24558204	chr6:135376177	HBS1L	0.6	7.84	0.46	1.58e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg05863683	chr7:1912471	MAD1L1	0.34	4.94	0.31	1.48e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs9815354	1.000	rs2683696	chr3:41914898	T/C	cg03022575	chr3:42003672	ULK4	0.56	5.25	0.33	3.37e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9398803	0.678	rs4621655	chr6:126896107	G/A	cg19875578	chr6:126661172	C6orf173	0.6	8.22	0.47	1.39e-14	Male-pattern baldness;
SARC	cis	rs8064024	0.620	rs9923349	chr16:4905124	A/G	cg08329684	chr16:4932620	PPL	0.37	5.81	0.36	1.99e-8	Cancer;
SARC	trans	rs9463078	0.547	rs764397	chr6:44710771	C/A	cg03948781	chr1:205179583	DSTYK	0.39	6.26	0.38	1.83e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
SARC	cis	rs13166103	0.657	rs1396503	chr5:57696039	A/G	cg10487770	chr5:57879443	RAB3C	0.52	5.45	0.34	1.27e-7	Type 2 diabetes (age of onset);
SARC	cis	rs9457247	0.935	rs427824	chr6:167403918	T/G	cg07741184	chr6:167504864	NA	0.3	5.68	0.35	4e-8	Crohn's disease;
SARC	cis	rs2841277	0.834	rs2841281	chr14:105394669	C/T	cg15352829	chr14:105391018	PLD4	0.35	6.6	0.4	2.7e-10	Rheumatoid arthritis;
SARC	cis	rs995000	0.931	rs2131926	chr1:63026011	C/T	cg06896770	chr1:63153194	DOCK7	-0.9	-13.26	-0.66	2.87e-30	Triglyceride levels;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg12707693	chr11:6652106	DCHS1	0.57	6.76	0.4	1.1e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs617791	0.530	rs10791835	chr11:65750924	C/A	cg26695010	chr11:65641043	EFEMP2	0.58	7.13	0.42	1.25e-11	Breast cancer;
SARC	cis	rs7178572	0.568	rs12907847	chr15:77493174	C/T	cg22256960	chr15:77711686	NA	-0.5	-5.53	-0.34	8.67e-8	Type 2 diabetes;
SARC	cis	rs1008375	0.966	rs2010053	chr4:17583806	A/C	cg27347728	chr4:17578864	LAP3	0.49	6.06	0.37	5.46e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2153535	0.580	rs9378552	chr6:8463748	G/A	cg23788917	chr6:8435910	SLC35B3	0.62	8.23	0.47	1.34e-14	Motion sickness;
SARC	cis	rs10932679	0.654	rs35169442	chr2:217679427	G/C	cg05032264	chr2:217675019	NA	0.58	5.66	0.35	4.41e-8	Pulse pressure;
SARC	cis	rs722599	0.748	rs741096	chr14:75351487	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.41	-5.17	-0.32	5.13e-7	IgG glycosylation;
SARC	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg04166393	chr7:2884313	GNA12	0.54	6.45	0.39	6.48e-10	Height;
SARC	cis	rs62191099	0.819	rs9308909	chr2:239865163	T/C	cg07215236	chr2:239865226	NA	0.34	4.74	0.3	3.7e-6	Alcohol dependence;
SARC	cis	rs11711311	1.000	rs13073843	chr3:113449150	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.69	8.9	0.5	1.64e-16	IgG glycosylation;
SARC	cis	rs61935443	0.614	rs11107792	chr12:95317126	G/C	cg21533806	chr12:95267307	NA	0.68	7.64	0.45	5.71e-13	Schizophrenia;
SARC	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg13395646	chr4:1353034	KIAA1530	-0.44	-5.44	-0.34	1.34e-7	Longevity;
SARC	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg08564027	chr20:61660810	NA	0.76	11.8	0.61	1.69e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs4711336	0.967	rs4711338	chr6:33660188	T/C	cg15676125	chr6:33679581	C6orf125	0.57	6.98	0.42	3.13e-11	Height;
SARC	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg19223190	chr17:80058835	NA	-0.43	-6.02	-0.37	6.57e-9	Life satisfaction;
SARC	cis	rs6582630	0.638	rs1829584	chr12:38526299	G/T	cg13010199	chr12:38710504	ALG10B	-0.52	-6.46	-0.39	5.98e-10	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs12310956	0.532	rs6488186	chr12:33974122	G/A	cg13010199	chr12:38710504	ALG10B	0.65	8.66	0.49	7.86e-16	Morning vs. evening chronotype;
SARC	cis	rs11574514	1.000	rs8061384	chr16:67911874	T/G	cg01866162	chr16:67596514	CTCF	0.87	5.63	0.35	5.09e-8	Crohn's disease;
SARC	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg21782813	chr7:2030301	MAD1L1	-0.36	-5.65	-0.35	4.64e-8	Bipolar disorder and schizophrenia;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg24008893	chr2:39627269	MAP4K3	0.51	6.83	0.41	7.29e-11	Thyroid stimulating hormone;
SARC	cis	rs2303759	0.676	rs7248378	chr19:49908144	C/A	cg22307029	chr19:49891270	CCDC155	0.44	5.29	0.33	2.78e-7	Multiple sclerosis;
SARC	cis	rs7595412	0.877	rs989056	chr2:198991275	G/C	cg00208931	chr2:198669586	PLCL1	-0.75	-5.97	-0.36	8.56e-9	Hip bone size;
SARC	cis	rs7584330	0.868	rs13386290	chr2:238393136	G/C	cg14458575	chr2:238380390	NA	0.45	5.49	0.34	1.07e-7	Prostate cancer;
SARC	cis	rs367615	0.660	rs10477972	chr5:108831951	C/A	cg17395555	chr5:108820864	NA	0.47	6.59	0.4	2.98e-10	Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs6840360	0.967	rs7695162	chr4:152510541	G/A	cg22705602	chr4:152727874	NA	-0.37	-6.29	-0.38	1.55e-9	Intelligence (multi-trait analysis);
SARC	cis	rs11098499	0.780	rs12504773	chr4:120562149	G/C	cg09307838	chr4:120376055	NA	0.88	11.95	0.62	5.44e-26	Corneal astigmatism;
SARC	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg24642844	chr7:1081250	C7orf50	-0.4	-5.43	-0.34	1.41e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs739401	0.611	rs7130841	chr11:3043658	A/G	cg05729581	chr11:3078854	CARS	-0.45	-5.74	-0.35	2.96e-8	Longevity;
SARC	cis	rs2594989	0.943	rs62245869	chr3:11439820	G/A	cg00170343	chr3:11313890	ATG7	0.63	6.1	0.37	4.46e-9	Circulating chemerin levels;
SARC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg21747090	chr2:27597821	SNX17	-0.55	-7.68	-0.45	4.44e-13	Total body bone mineral density;
SARC	cis	rs208520	0.874	rs208514	chr6:66945520	G/A	cg07460842	chr6:66804631	NA	-0.85	-10.02	-0.55	7.1e-20	Exhaled nitric oxide output;
SARC	cis	rs7772486	0.720	rs6901888	chr6:146023144	A/G	cg23711669	chr6:146136114	FBXO30	-0.91	-15.59	-0.71	5.22e-38	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1348850	0.526	rs4893829	chr2:178399810	A/G	cg23306229	chr2:178417860	TTC30B	-0.81	-7.86	-0.46	1.4e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-9.08	-0.51	4.64e-17	Alzheimer's disease;
SARC	cis	rs9303401	0.614	rs2240719	chr17:56582477	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.05	11.47	0.6	2e-24	Cognitive test performance;
SARC	cis	rs910316	0.726	rs175040	chr14:75469555	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.41	-5.51	-0.34	9.67e-8	Height;
SARC	cis	rs4819052	0.788	rs13049700	chr21:46701909	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.6	6.93	0.41	4.09e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7847628	0.587	rs1060817	chr9:123583192	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.67	9.09	0.51	4.33e-17	Birth weight;
SARC	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg10589385	chr1:150898437	SETDB1	0.39	5.26	0.33	3.21e-7	Melanoma;
SARC	cis	rs79149102	0.579	rs12593542	chr15:75282147	C/G	cg09165964	chr15:75287851	SCAMP5	-0.87	-8.58	-0.49	1.37e-15	Lung cancer;
SARC	trans	rs8073060	0.586	rs117573546	chr17:33909588	G/A	cg19694781	chr19:47549865	TMEM160	0.65	6.37	0.39	1.02e-9	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs6121246	0.559	rs6060944	chr20:30372114	G/A	cg13852791	chr20:30311386	BCL2L1	0.89	10.76	0.58	3.44e-22	Mean corpuscular hemoglobin;
SARC	cis	rs7927771	1.000	rs7120333	chr11:47817441	C/T	cg05585544	chr11:47624801	NA	-0.36	-4.82	-0.3	2.59e-6	Subjective well-being;
SARC	cis	rs10022260	1	rs10022260	chr4:83793921	C/T	cg00595051	chr4:83955429	COPS4	-0.48	-5.25	-0.33	3.35e-7	Adult asthma;
SARC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.99	11.91	0.62	7.58e-26	Platelet count;
SARC	cis	rs7927771	0.832	rs6485753	chr11:47410200	C/T	cg20307385	chr11:47447363	PSMC3	0.58	7.22	0.43	7.12e-12	Subjective well-being;
SARC	cis	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.48	-0.39	5.49e-10	Joint mobility (Beighton score);
SARC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg22105103	chr4:187893119	NA	0.51	6.91	0.41	4.68e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11209002	0.545	rs2093332	chr1:67531974	G/A	cg02640540	chr1:67518911	SLC35D1	0.59	6.66	0.4	1.99e-10	Crohn's disease;
SARC	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg27266027	chr21:40555129	PSMG1	0.5	5.48	0.34	1.12e-7	Cognitive function;
SARC	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	trans	rs2727020	0.595	rs10466496	chr11:49501514	C/T	cg15704280	chr7:45808275	SEPT13	-0.87	-14.4	-0.69	4.67e-34	Coronary artery disease;
SARC	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg07701084	chr6:150067640	NUP43	0.41	5.29	0.33	2.81e-7	Lung cancer;
SARC	cis	rs765787	0.530	rs1631533	chr15:45518628	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.43	-5.28	-0.33	2.96e-7	Uric acid levels;
SARC	cis	rs7666738	0.830	rs13138051	chr4:99050367	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg05313129	chr8:58192883	C8orf71	-0.49	-5.77	-0.35	2.48e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.44	-5.43	-0.33	1.45e-7	Lymphocyte counts;
SARC	cis	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg19404757	chr15:45003832	B2M	0.55	5.31	0.33	2.5e-7	Lung cancer in ever smokers;
SARC	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg17221315	chr6:27791827	HIST1H4J	-0.46	-5.28	-0.33	3.02e-7	Depression;
SARC	cis	rs7937682	0.924	rs6589244	chr11:111534333	T/C	cg22437258	chr11:111473054	SIK2	0.74	9.84	0.54	2.48e-19	Primary sclerosing cholangitis;
SARC	cis	rs981844	0.857	rs56198877	chr4:154718970	A/G	cg14289246	chr4:154710475	SFRP2	0.59	6.34	0.38	1.16e-9	Response to statins (LDL cholesterol change);
SARC	cis	rs6843082	0.531	rs1448817	chr4:111641053	A/G	cg25750389	chr4:111544016	PITX2	0.37	4.82	0.3	2.65e-6	Stroke (ischemic);Incident atrial fibrillation;Atrial fibrillation;
SARC	cis	rs12447804	0.734	rs9926693	chr16:58097357	C/T	cg03859792	chr16:58121049	NA	-0.34	-4.98	-0.31	1.24e-6	Pulmonary function;Pulmonary function (smoking interaction);
SARC	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg18876405	chr7:65276391	NA	-0.43	-4.72	-0.3	4.06e-6	Aortic root size;
SARC	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg13939156	chr17:80058883	NA	-0.42	-6.48	-0.39	5.51e-10	Life satisfaction;
SARC	cis	rs7772486	0.774	rs6930181	chr6:146180974	A/T	cg05347473	chr6:146136440	FBXO30	-0.48	-6.54	-0.39	3.81e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3126085	0.935	rs74127901	chr1:152195579	G/A	cg09127314	chr1:152161683	NA	-0.44	-4.91	-0.31	1.7e-6	Atopic dermatitis;
SARC	cis	rs2180341	1.000	rs2180341	chr6:127600630	C/T	cg27446573	chr6:127587934	RNF146	1.01	13.93	0.67	1.67e-32	Breast cancer;
SARC	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg06221963	chr1:154839813	KCNN3	-0.45	-6.66	-0.4	2e-10	Prostate cancer;
SARC	cis	rs7592578	0.679	rs4287794	chr2:191327147	T/C	cg27211696	chr2:191398769	TMEM194B	-0.5	-5.22	-0.32	3.87e-7	Diastolic blood pressure;
SARC	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg05368731	chr17:41323189	NBR1	0.8	9.59	0.53	1.43e-18	Menopause (age at onset);
SARC	cis	rs8072100	0.840	rs4968319	chr17:45464967	A/G	cg08085267	chr17:45401833	C17orf57	-0.42	-5.18	-0.32	4.9e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	trans	rs7615952	0.800	rs35390120	chr3:125599809	G/A	cg07211511	chr3:129823064	LOC729375	-0.81	-8.09	-0.47	3.24e-14	Blood pressure (smoking interaction);
SARC	cis	rs6088590	1.000	rs6088607	chr20:33378733	C/T	cg06115741	chr20:33292138	TP53INP2	0.57	6.83	0.41	7.46e-11	Coronary artery disease;
SARC	cis	rs28374715	0.635	rs28557159	chr15:41657353	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.98	-15.67	-0.72	2.86e-38	Ulcerative colitis;
SARC	cis	rs4589502	1.000	rs16950284	chr15:67154184	A/G	cg12317470	chr15:67143691	NA	-0.7	-5.15	-0.32	5.63e-7	Lung cancer (smoking interaction);
SARC	cis	rs9398803	0.636	rs1262542	chr6:127032008	T/A	cg19875578	chr6:126661172	C6orf173	-0.61	-8.43	-0.48	3.58e-15	Male-pattern baldness;
SARC	cis	rs7843479	0.509	rs899428	chr8:21770763	T/C	cg17168535	chr8:21777572	XPO7	0.8	10.82	0.58	2.34e-22	Mean corpuscular volume;
SARC	cis	rs644799	0.710	rs12272061	chr11:95524067	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.88	13.98	0.68	1.14e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs748404	0.697	rs498227	chr15:43573052	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.43	5.21	0.32	4.14e-7	Lung cancer;
SARC	cis	rs6871536	1.000	rs6596090	chr5:131988415	G/A	cg11797159	chr5:131991491	NA	0.35	4.72	0.3	4.1e-6	Asthma (childhood onset);
SARC	cis	rs11574514	1.000	rs28655136	chr16:68001447	T/C	cg01866162	chr16:67596514	CTCF	0.92	5.56	0.34	7.47e-8	Crohn's disease;
SARC	cis	rs7833790	0.927	rs61020899	chr8:82757090	C/T	cg27398817	chr8:82754497	SNX16	0.52	5.64	0.35	5e-8	Diastolic blood pressure;
SARC	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg04944784	chr2:26401820	FAM59B	-0.51	-6.15	-0.37	3.33e-9	Gut microbiome composition (summer);
SARC	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	12.12	0.62	1.5e-26	Chronic sinus infection;
SARC	cis	rs4566357	0.615	rs12474622	chr2:227912793	A/G	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.86	-0.36	1.61e-8	Coronary artery disease;
SARC	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg13206674	chr6:150067644	NUP43	0.41	5.28	0.33	2.94e-7	Lung cancer;
SARC	cis	rs12042938	0.837	rs1417584	chr1:231819050	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.5	-6.52	-0.39	4.26e-10	Neuranatomic and neurocognitive phenotypes;
SARC	cis	rs16976116	0.901	rs62020097	chr15:55491007	A/T	cg17854078	chr15:55489399	RSL24D1	0.66	6.46	0.39	6.14e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg06634786	chr22:41940651	POLR3H	-0.59	-7.0	-0.42	2.72e-11	Vitiligo;
SARC	cis	rs9611565	0.512	rs139572	chr22:42214532	C/T	cg06634786	chr22:41940651	POLR3H	-0.51	-5.18	-0.32	4.81e-7	Vitiligo;
SARC	cis	rs17376456	0.877	rs28539612	chr5:93499099	C/T	cg21475434	chr5:93447410	FAM172A	0.89	7.4	0.44	2.4e-12	Diabetic retinopathy;
SARC	cis	rs7246760	0.737	rs60584926	chr19:9797014	C/T	cg16876255	chr19:9731953	ZNF561	0.82	5.05	0.31	8.72e-7	Pursuit maintenance gain;
SARC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.65	0.53	9.21e-19	Prudent dietary pattern;
SARC	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg08219700	chr8:58056026	NA	0.74	6.81	0.41	8.35e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs1318878	0.565	rs12582073	chr12:15473750	T/C	cg08258403	chr12:15378311	NA	0.5	6.77	0.41	1.04e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7772486	0.658	rs4895683	chr6:146113654	T/A	cg05347473	chr6:146136440	FBXO30	-0.51	-7.16	-0.42	1.05e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg03264133	chr6:25882463	NA	0.56	7.29	0.43	4.93e-12	Intelligence (multi-trait analysis);
SARC	cis	rs1707322	0.506	rs2991983	chr1:46079391	T/C	cg03146154	chr1:46216737	IPP	-0.52	-6.24	-0.38	2e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1448094	0.967	rs7978132	chr12:86323484	T/C	cg02569458	chr12:86230093	RASSF9	0.4	5.82	0.36	1.92e-8	Major depressive disorder;
SARC	cis	rs35306767	0.903	rs11253475	chr10:907262	C/A	cg26597838	chr10:835615	NA	0.83	8.4	0.48	4.52e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs17600642	0.724	rs748164	chr10:72460799	A/T	cg19779893	chr10:72451501	ADAMTS14	-0.4	-6.31	-0.38	1.36e-9	Bipolar disorder;
SARC	cis	rs9815354	0.812	rs59146151	chr3:41949301	T/C	cg03022575	chr3:42003672	ULK4	0.7	5.7	0.35	3.66e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs854765	0.552	rs6502624	chr17:17847936	G/A	cg04398451	chr17:18023971	MYO15A	-0.4	-5.6	-0.34	5.94e-8	Total body bone mineral density;
SARC	cis	rs74417235	0.684	rs13185173	chr5:154055081	A/G	cg08754654	chr5:154026448	NA	0.48	4.8	0.3	2.86e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
SARC	cis	rs10276381	1.000	rs7796417	chr7:28186119	G/C	cg23620719	chr7:28220237	JAZF1	0.71	5.87	0.36	1.5e-8	Crohn's disease;
SARC	cis	rs7829975	0.633	rs2979181	chr8:8323088	A/T	cg06636001	chr8:8085503	FLJ10661	0.71	10.26	0.56	1.24e-20	Mood instability;
SARC	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg23758822	chr17:41437982	NA	0.89	10.96	0.58	8.18e-23	Menopause (age at onset);
SARC	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg26769984	chr7:1090371	C7orf50	0.49	5.18	0.32	4.8e-7	Bronchopulmonary dysplasia;
SARC	cis	rs13202913	0.837	rs6906678	chr6:151772395	A/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.63	5.29	0.33	2.84e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg17348667	chr6:45346345	SUPT3H;RUNX2	-0.47	-6.25	-0.38	1.95e-9	Thyroid stimulating hormone;
SARC	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.33	4.73	0.3	3.84e-6	Obesity-related traits;
SARC	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg00933542	chr6:150070202	PCMT1	0.33	5.63	0.35	5.13e-8	Lung cancer;
SARC	cis	rs72627509	0.904	rs781663	chr4:57781754	A/G	cg26694713	chr4:57773883	REST	0.65	6.79	0.41	9.15e-11	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	trans	rs7937682	0.924	rs10891288	chr11:111552053	G/T	cg18187862	chr3:45730750	SACM1L	-0.56	-7.14	-0.42	1.17e-11	Primary sclerosing cholangitis;
SARC	cis	rs9807989	0.708	rs6543124	chr2:102987459	T/A	cg09003973	chr2:102972529	NA	0.38	5.12	0.32	6.5e-7	Asthma;
SARC	cis	rs4481887	1.000	rs7517319	chr1:248466408	C/A	cg00666640	chr1:248458726	OR2T12	0.37	6.3	0.38	1.43e-9	Common traits (Other);
SARC	cis	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg05623727	chr3:50126028	RBM5	-0.36	-5.29	-0.33	2.78e-7	Body mass index;
SARC	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.76	9.13	0.51	3.45e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9291683	0.527	rs3822241	chr4:10094931	G/A	cg00071950	chr4:10020882	SLC2A9	-0.39	-5.8	-0.36	2.18e-8	Bone mineral density;
SARC	cis	rs7264396	0.790	rs6058288	chr20:34228680	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.57	-5.92	-0.36	1.13e-8	Total cholesterol levels;
SARC	cis	rs7408868	0.563	rs10404382	chr19:15301389	C/A	cg14696996	chr19:15285081	NOTCH3	0.79	7.44	0.44	1.9e-12	Pulse pressure;
SARC	trans	rs9929218	1.000	rs9936621	chr16:68798682	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.53	-6.69	-0.4	1.63e-10	Colorectal cancer;
SARC	cis	rs2832191	0.716	rs8132085	chr21:30501389	G/T	cg08807101	chr21:30365312	RNF160	-0.86	-12.78	-0.64	1.1e-28	Dental caries;
SARC	cis	rs12893668	0.572	rs4906356	chr14:104138701	C/T	cg26031613	chr14:104095156	KLC1	-0.52	-5.85	-0.36	1.62e-8	Reticulocyte count;
SARC	cis	rs2075371	0.611	rs62462979	chr7:134019379	G/T	cg00033643	chr7:134001901	SLC35B4	0.46	5.66	0.35	4.32e-8	Mean platelet volume;
SARC	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg13395646	chr4:1353034	KIAA1530	-0.56	-6.69	-0.4	1.66e-10	Obesity-related traits;
SARC	cis	rs2153535	0.580	rs4960422	chr6:8459309	T/C	cg07606381	chr6:8435919	SLC35B3	0.75	10.66	0.57	7.43e-22	Motion sickness;
SARC	cis	rs6942407	0.592	rs17766011	chr7:86749169	C/A	cg02420886	chr7:86849541	C7orf23	0.59	5.41	0.33	1.55e-7	Food allergy;
SARC	cis	rs7264396	0.747	rs73283043	chr20:34383863	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	5.23	0.32	3.7e-7	Total cholesterol levels;
SARC	cis	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg00409905	chr10:38381863	ZNF37A	-0.58	-8.19	-0.47	1.73e-14	Extrinsic epigenetic age acceleration;
SARC	cis	rs2239547	0.522	rs6445550	chr3:52983434	G/A	cg07507251	chr3:52567010	NT5DC2	0.39	5.06	0.31	8.34e-7	Schizophrenia;
SARC	cis	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg20965017	chr5:231967	SDHA	-0.51	-4.72	-0.3	4.07e-6	Breast cancer;
SARC	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg24531977	chr5:56204891	C5orf35	-0.54	-5.45	-0.34	1.26e-7	Initial pursuit acceleration;
SARC	cis	rs2425143	0.908	rs58448091	chr20:34325470	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	5.11	0.32	6.74e-7	Blood protein levels;
SARC	cis	rs4481887	0.927	rs10888343	chr1:248446642	A/G	cg01631408	chr1:248437212	OR2T33	-0.44	-5.61	-0.35	5.68e-8	Common traits (Other);
SARC	trans	rs7937682	1.000	rs11608122	chr11:111535105	C/T	cg18187862	chr3:45730750	SACM1L	-0.59	-7.15	-0.42	1.12e-11	Primary sclerosing cholangitis;
SARC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg04013093	chr6:42928303	GNMT	-0.33	-4.73	-0.3	3.83e-6	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs7772486	0.686	rs4896828	chr6:145953339	A/C	cg05220968	chr6:146057943	EPM2A	-0.28	-4.88	-0.3	1.93e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg11494091	chr17:61959527	GH2	0.55	8.38	0.48	5.12e-15	Prudent dietary pattern;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg11794625	chr2:223521104	FARSB	0.76	6.26	0.38	1.84e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs501120	1.000	rs573141	chr10:44758587	G/A	cg09554077	chr10:44749378	NA	0.48	6.49	0.39	5.12e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs7647973	0.588	rs62262675	chr3:49673662	A/G	cg03060546	chr3:49711283	APEH	-0.62	-5.69	-0.35	3.86e-8	Menarche (age at onset);
SARC	cis	rs7086627	0.515	rs11202960	chr10:82209807	G/A	cg00277334	chr10:82204260	NA	-0.56	-9.34	-0.52	7.82e-18	Post bronchodilator FEV1;
SARC	cis	rs4761669	0.959	rs10777625	chr12:95204452	G/C	cg21533806	chr12:95267307	NA	0.38	4.92	0.31	1.61e-6	Common carotid intima-media thickness in HIV infection;
SARC	cis	rs4975616	0.686	rs37011	chr5:1348798	A/T	cg06550200	chr5:1325588	CLPTM1L	-0.44	-6.26	-0.38	1.83e-9	Lung cancer;
SARC	cis	rs12464559	0.522	rs10180065	chr2:152619007	A/G	cg01189475	chr2:152685088	ARL5A	-0.65	-5.14	-0.32	5.85e-7	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs1044826	0.692	rs188421	chr3:139234066	A/C	cg15131784	chr3:139108705	COPB2	-0.41	-5.25	-0.33	3.35e-7	Obesity-related traits;
SARC	cis	rs6582630	0.519	rs10880194	chr12:38302836	G/A	cg26384229	chr12:38710491	ALG10B	0.87	12.74	0.64	1.45e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9905704	0.846	rs302851	chr17:56685424	G/A	cg12560992	chr17:57184187	TRIM37	0.44	5.16	0.32	5.24e-7	Testicular germ cell tumor;
SARC	cis	rs739401	0.572	rs389128	chr11:3083873	G/T	cg20651018	chr11:3035856	CARS	-0.45	-7.01	-0.42	2.57e-11	Longevity;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg19294256	chr13:46627018	ZC3H13	-0.45	-6.35	-0.38	1.11e-9	Thyroid stimulating hormone;
SARC	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg21724239	chr8:58056113	NA	0.61	5.93	0.36	1.1e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs16912285	0.688	rs59246618	chr11:24315201	G/T	ch.11.24196551F	chr11:24239977	NA	0.58	5.79	0.35	2.24e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	10.75	0.58	3.69e-22	Alzheimer's disease;
SARC	cis	rs9796	0.621	rs11858678	chr15:41467932	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.56	-8.06	-0.47	3.9e-14	Menopause (age at onset);
SARC	trans	rs11722228	0.508	rs3796825	chr4:10092879	T/A	cg26043149	chr18:55253948	FECH	0.67	7.54	0.44	1.01e-12	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg13939156	chr17:80058883	NA	-0.4	-6.25	-0.38	1.98e-9	Life satisfaction;
SARC	cis	rs2180341	0.814	rs6905553	chr6:127727407	A/G	cg27446573	chr6:127587934	RNF146	0.79	10.27	0.56	1.21e-20	Breast cancer;
SARC	cis	rs6901250	0.632	rs339355	chr6:117196503	A/T	cg12892004	chr6:117198278	RFX6	-0.37	-5.32	-0.33	2.46e-7	C-reactive protein levels;
SARC	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg03934478	chr11:495069	RNH1	0.6	5.44	0.34	1.36e-7	Body mass index;
SARC	cis	rs73198271	0.694	rs114184516	chr8:8647082	A/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-4.97	-0.31	1.3e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs875971	0.502	rs11769702	chr7:65720516	A/C	cg11764359	chr7:65958608	NA	0.65	6.48	0.39	5.45e-10	Aortic root size;
SARC	cis	rs9868809	0.772	rs28452701	chr3:48708575	C/T	cg00383909	chr3:49044727	WDR6	0.57	4.79	0.3	3.02e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs12479064	0.724	rs11885942	chr2:100004165	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.68	-8.38	-0.48	4.88e-15	Chronic sinus infection;
SARC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.76	9.54	0.53	1.96e-18	Prudent dietary pattern;
SARC	cis	rs2011503	0.882	rs56144632	chr19:19368310	G/A	cg03709012	chr19:19516395	GATAD2A	0.64	5.57	0.34	7.18e-8	Bipolar disorder;
SARC	cis	rs79149102	0.522	rs8028893	chr15:74845923	C/A	cg09165964	chr15:75287851	SCAMP5	-0.65	-5.02	-0.31	1.04e-6	Lung cancer;
SARC	cis	rs270601	0.913	rs273899	chr5:131695178	G/A	cg11843238	chr5:131593191	PDLIM4	0.4	4.97	0.31	1.29e-6	Acylcarnitine levels;
SARC	cis	rs72781680	0.898	rs72782137	chr2:24047805	C/T	cg08917208	chr2:24149416	ATAD2B	0.78	7.41	0.44	2.26e-12	Lymphocyte counts;
SARC	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg20965017	chr5:231967	SDHA	-0.56	-5.3	-0.33	2.71e-7	Breast cancer;
SARC	cis	rs11098499	0.754	rs714899	chr4:120243035	G/A	cg09307838	chr4:120376055	NA	0.81	11.2	0.59	1.36e-23	Corneal astigmatism;
SARC	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg05165339	chr4:1420672	NA	-0.22	-4.91	-0.31	1.73e-6	Longevity;
SARC	trans	rs629535	0.859	rs55803226	chr8:70108965	T/C	cg21567404	chr3:27674614	NA	-1.04	-13.02	-0.65	1.76e-29	Dupuytren's disease;
SARC	cis	rs2361718	0.603	rs12951255	chr17:78085597	A/G	cg27427491	chr17:78079615	GAA	-0.31	-4.79	-0.3	3.03e-6	Yeast infection;
SARC	cis	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg14541582	chr5:601475	NA	-0.41	-5.15	-0.32	5.42e-7	Obesity-related traits;
SARC	cis	rs8141529	0.509	rs12628211	chr22:29239250	T/C	cg15103426	chr22:29168792	CCDC117	0.58	7.2	0.43	8.47e-12	Lymphocyte counts;
SARC	cis	rs73198271	0.562	rs3827810	chr8:8659040	T/G	cg01851573	chr8:8652454	MFHAS1	0.46	5.69	0.35	3.87e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs6912958	0.712	rs4707383	chr6:88330602	T/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-6.46	-0.39	6.16e-10	Monocyte percentage of white cells;
SARC	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg19223190	chr17:80058835	NA	0.43	6.05	0.37	5.72e-9	Life satisfaction;
SARC	cis	rs2011503	0.941	rs112253053	chr19:19425145	T/A	cg03709012	chr19:19516395	GATAD2A	0.64	5.7	0.35	3.69e-8	Bipolar disorder;
SARC	trans	rs3779273	1.000	rs3807648	chr7:77828434	T/C	cg05596911	chr5:118502651	DMXL1	-0.53	-6.92	-0.41	4.23e-11	Body mass index;
SARC	cis	rs17401966	0.838	rs11121551	chr1:10435170	T/C	cg15208524	chr1:10270712	KIF1B	0.47	5.56	0.34	7.28e-8	Hepatocellular carcinoma;
SARC	cis	rs9790314	0.747	rs9820825	chr3:160848155	A/G	cg04691961	chr3:161091175	C3orf57	-0.62	-8.47	-0.49	2.77e-15	Morning vs. evening chronotype;
SARC	cis	rs67311347	0.668	rs73071710	chr3:40288587	A/G	cg24209194	chr3:40518798	ZNF619	0.53	6.26	0.38	1.79e-9	Renal cell carcinoma;
SARC	trans	rs2727020	0.576	rs1814175	chr11:49559172	T/C	cg03929089	chr4:120376271	NA	-0.75	-11.24	-0.59	1.02e-23	Coronary artery disease;
SARC	trans	rs11098499	0.954	rs34858317	chr4:120387110	A/C	cg25214090	chr10:38739885	LOC399744	0.56	7.32	0.43	4.04e-12	Corneal astigmatism;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg11023075	chr5:60633617	ZSWIM6	-0.51	-6.28	-0.38	1.62e-9	Alcohol dependence;
SARC	cis	rs524281	0.814	rs1055615	chr11:65846922	C/G	cg14036092	chr11:66035641	RAB1B	-0.51	-5.32	-0.33	2.43e-7	Electroencephalogram traits;
SARC	cis	rs2241210	0.550	rs7486178	chr12:109980266	G/A	cg08884029	chr12:110012500	MVK;MMAB	-0.35	-5.2	-0.32	4.38e-7	HDL cholesterol levels;
SARC	cis	rs12702595	0.818	rs10259085	chr7:7268431	C/T	cg04827551	chr7:7268805	C1GALT1	0.44	5.4	0.33	1.63e-7	Serum dimethylarginine levels (asymmetric/symetric ratio);Symmetrical dimethylarginine levels;
SARC	cis	rs920590	0.876	rs3907477	chr8:19657744	C/T	cg17834443	chr8:19674713	INTS10	0.5	6.33	0.38	1.28e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs2832191	0.720	rs2832200	chr21:30499165	G/A	cg08807101	chr21:30365312	RNF160	-0.79	-10.93	-0.58	1.04e-22	Dental caries;
SARC	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg25072359	chr17:41440525	NA	0.51	6.13	0.37	3.72e-9	Menopause (age at onset);
SARC	trans	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.1	-0.42	1.51e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs11881751	0.876	rs34009962	chr19:5020474	G/A	cg04571196	chr19:4910051	UHRF1	0.47	5.12	0.32	6.26e-7	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg18876405	chr7:65276391	NA	-0.44	-4.83	-0.3	2.43e-6	Aortic root size;
SARC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg15242686	chr22:24348715	GSTTP1	0.47	5.96	0.36	9.03e-9	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7599312	0.534	rs10182996	chr2:213404834	T/C	cg20637307	chr2:213403960	ERBB4	0.8	12.5	0.63	8.9e-28	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs11578119	0.933	rs12135326	chr1:170490570	G/A	cg09767346	chr1:170501363	GORAB	0.4	4.73	0.3	3.91e-6	Male-pattern baldness;
SARC	cis	rs2276314	0.762	rs3826600	chr18:33609053	A/G	cg19628046	chr18:33552617	C18orf21	0.6	6.23	0.38	2.11e-9	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.73	-9.52	-0.53	2.29e-18	Gut microbiome composition (summer);
SARC	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg03806693	chr22:41940476	POLR3H	0.84	11.8	0.61	1.68e-25	Vitiligo;
SARC	trans	rs7615952	0.800	rs12489350	chr3:125644116	T/C	cg07211511	chr3:129823064	LOC729375	-0.95	-11.04	-0.59	4.41e-23	Blood pressure (smoking interaction);
SARC	cis	rs4689388	0.926	rs5018648	chr4:6292818	C/G	cg25554036	chr4:6271136	WFS1	-0.4	-6.52	-0.39	4.35e-10	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs7089973	0.604	rs11196939	chr10:116593175	A/G	cg03647239	chr10:116582469	FAM160B1	-0.49	-5.9	-0.36	1.25e-8	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs9398803	0.865	rs9375441	chr6:126778600	G/A	cg20229609	chr6:126660872	C6orf173	0.4	5.81	0.36	2.09e-8	Male-pattern baldness;
SARC	cis	rs67460515	0.596	rs4856700	chr3:160922951	A/C	cg04691961	chr3:161091175	C3orf57	-0.42	-5.06	-0.31	8.36e-7	Parkinson's disease;
SARC	cis	rs7264396	0.635	rs6058344	chr20:34475038	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	5.41	0.33	1.6e-7	Total cholesterol levels;
SARC	cis	rs7762018	0.556	rs78864023	chr6:170059755	T/A	cg19338460	chr6:170058176	WDR27	-0.82	-6.02	-0.37	6.74e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs7937682	1.000	rs7937682	chr11:111579939	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.99	-17.39	-0.75	5.45e-44	Primary sclerosing cholangitis;
SARC	cis	rs4481887	0.927	rs4460676	chr1:248431781	G/A	cg13385794	chr1:248469461	NA	0.35	5.13	0.32	6.01e-7	Common traits (Other);
SARC	cis	rs6732160	0.932	rs768851	chr2:73378241	G/A	cg01422370	chr2:73384389	NA	0.3	4.81	0.3	2.74e-6	Intelligence (multi-trait analysis);
SARC	trans	rs6894249	1.000	rs6894249	chr5:131797547	A/G	cg11309891	chr11:73388802	RAB6A	-0.49	-6.65	-0.4	2.06e-10	Asthma;
SARC	cis	rs6088580	0.524	rs1321306	chr20:33266379	T/A	cg24642439	chr20:33292090	TP53INP2	-0.54	-6.65	-0.4	2.07e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs523522	1.000	rs1563333	chr12:120934407	C/T	cg27279351	chr12:120934652	DYNLL1	0.71	8.85	0.5	2.22e-16	High light scatter reticulocyte count;
SARC	cis	rs425277	1.000	rs421992	chr1:2077260	C/T	cg24578937	chr1:2090814	PRKCZ	0.31	5.85	0.36	1.63e-8	Height;
SARC	cis	rs6582630	0.539	rs12308081	chr12:38342881	C/G	cg14851346	chr12:38532713	NA	-0.47	-5.57	-0.34	7.09e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.44	5.61	0.35	5.67e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.66	-9.03	-0.51	6.67e-17	Age at first birth;
SARC	cis	rs7666738	0.830	rs34916200	chr4:98851593	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.59	0.49	1.24e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg18252515	chr7:66147081	NA	0.48	5.14	0.32	5.88e-7	Aortic root size;
SARC	cis	rs6500602	0.702	rs56895104	chr16:4548132	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.32	5.57	0.34	7.15e-8	Schizophrenia;
SARC	cis	rs10782582	0.609	rs11584577	chr1:76242378	A/G	cg10523679	chr1:76189770	ACADM	-0.45	-5.39	-0.33	1.7e-7	Daytime sleep phenotypes;
SARC	cis	rs9399137	0.507	rs12664898	chr6:135288663	T/C	cg22676075	chr6:135203613	NA	0.39	4.97	0.31	1.32e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs3126085	0.935	rs10788824	chr1:152161694	A/G	cg03465714	chr1:152285911	FLG	-0.48	-5.51	-0.34	9.41e-8	Atopic dermatitis;
SARC	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.72	8.54	0.49	1.75e-15	Height;
SARC	cis	rs9581857	0.556	rs1885990	chr13:28040502	C/T	cg01674679	chr13:27998804	GTF3A	-0.62	-6.18	-0.38	2.91e-9	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	cis	rs6582630	0.519	rs12819814	chr12:38332568	G/C	cg26384229	chr12:38710491	ALG10B	0.88	12.75	0.64	1.3e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg26839252	chr6:160211577	TCP1;MRPL18	0.59	5.6	0.34	6.03e-8	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg26338869	chr17:61819248	STRADA	0.81	10.89	0.58	1.38e-22	Prudent dietary pattern;
SARC	cis	rs2594989	0.639	rs2442781	chr3:11483769	A/G	cg00170343	chr3:11313890	ATG7	-0.58	-6.36	-0.38	1.05e-9	Circulating chemerin levels;
SARC	cis	rs7084402	0.934	rs1158212	chr10:60318276	G/A	cg07615347	chr10:60278583	BICC1	0.59	8.58	0.49	1.31e-15	Refractive error;
SARC	cis	rs2273669	0.588	rs6568555	chr6:109331777	A/G	cg05315195	chr6:109294784	ARMC2	-0.63	-5.7	-0.35	3.6e-8	Prostate cancer;
SARC	cis	rs12311304	0.965	rs17835113	chr12:15369665	G/A	cg08258403	chr12:15378311	NA	0.49	7.48	0.44	1.54e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs6582630	0.576	rs4882372	chr12:38356609	C/A	cg13010199	chr12:38710504	ALG10B	-0.49	-5.95	-0.36	9.62e-9	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg20607798	chr8:58055168	NA	0.56	5.33	0.33	2.31e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	10.23	0.56	1.62e-20	Alzheimer's disease;
SARC	cis	rs1008375	0.966	rs4698642	chr4:17679174	A/T	cg27347728	chr4:17578864	LAP3	0.44	5.53	0.34	8.5e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9467773	0.595	rs13207371	chr6:26591074	G/A	cg11502198	chr6:26597334	ABT1	0.63	7.98	0.46	6.75e-14	Intelligence (multi-trait analysis);
SARC	cis	rs17376456	0.877	rs10476596	chr5:93367074	C/T	cg21475434	chr5:93447410	FAM172A	-0.84	-7.43	-0.44	2.1e-12	Diabetic retinopathy;
SARC	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg11987759	chr7:65425863	GUSB	-0.48	-6.54	-0.39	3.9e-10	Aortic root size;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg06972998	chr10:76585851	MYST4	-0.53	-6.8	-0.41	8.74e-11	Height;
SARC	cis	rs870825	0.860	rs72703519	chr4:185602707	G/A	cg04058563	chr4:185651563	MLF1IP	0.76	9.26	0.52	1.4e-17	Blood protein levels;
SARC	cis	rs9815354	0.904	rs7647561	chr3:41848627	T/A	cg03022575	chr3:42003672	ULK4	0.56	5.41	0.33	1.57e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9325144	0.647	rs1875609	chr12:39018259	C/T	cg26384229	chr12:38710491	ALG10B	-0.61	-7.91	-0.46	1e-13	Morning vs. evening chronotype;
SARC	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	17.63	0.76	9e-45	Height;
SARC	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg23131131	chr22:24373011	LOC391322	-0.48	-5.1	-0.32	6.9e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6456156	0.586	rs10946209	chr6:167480991	G/A	cg23791538	chr6:167370224	RNASET2	-0.54	-7.1	-0.42	1.51e-11	Primary biliary cholangitis;
SARC	cis	rs3806843	0.676	rs2245640	chr5:140029958	A/G	cg16577123	chr5:140027231	NDUFA2;IK	-0.46	-5.36	-0.33	1.97e-7	Depressive symptoms (multi-trait analysis);
SARC	cis	rs3126085	0.935	rs12045496	chr1:152253910	A/G	cg26876637	chr1:152193138	HRNR	0.45	5.21	0.32	4.07e-7	Atopic dermatitis;
SARC	cis	rs6062302	0.545	rs2297430	chr20:62229244	T/C	cg16989086	chr20:62203971	PRIC285	0.47	4.79	0.3	2.93e-6	Glioblastoma;
SARC	cis	rs12142240	0.698	rs56049453	chr1:46835468	A/G	cg10495392	chr1:46806563	NSUN4	0.65	6.88	0.41	5.6e-11	Menopause (age at onset);
SARC	cis	rs6964587	1.000	rs12531366	chr7:91683849	C/G	cg17063962	chr7:91808500	NA	0.94	15.92	0.72	4.2e-39	Breast cancer;
SARC	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg13939156	chr17:80058883	NA	0.4	6.22	0.38	2.23e-9	Life satisfaction;
SARC	cis	rs672059	1.000	rs1760621	chr1:183156006	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.52	7.03	0.42	2.33e-11	Hypertriglyceridemia;
SARC	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg00684032	chr4:1343700	KIAA1530	0.38	5.48	0.34	1.1e-7	Obesity-related traits;
SARC	cis	rs7589342	0.507	rs6543338	chr2:106403911	C/G	cg16077055	chr2:106428750	NCK2	0.28	5.26	0.33	3.22e-7	Addiction;
SARC	cis	rs2933343	0.903	rs2638846	chr3:128587163	A/T	cg25356066	chr3:128598488	ACAD9	0.58	6.61	0.4	2.65e-10	IgG glycosylation;
SARC	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg22535103	chr8:58192502	C8orf71	-0.57	-5.64	-0.35	4.88e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2425143	1.000	rs7267759	chr20:34257284	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-5.75	-0.35	2.78e-8	Blood protein levels;
SARC	cis	rs10992471	0.603	rs10992349	chr9:95233887	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.25	-0.33	3.37e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs2120243	0.592	rs1869857	chr3:157123357	G/T	cg24825693	chr3:157122686	VEPH1	0.47	6.58	0.4	2.99e-10	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg04267008	chr7:1944627	MAD1L1	-0.46	-4.91	-0.31	1.71e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg26850624	chr5:429559	AHRR	-0.31	-4.77	-0.3	3.21e-6	Cystic fibrosis severity;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg25166381	chr11:110167568	RDX	0.5	6.6	0.4	2.75e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs5753618	0.583	rs7285619	chr22:31842554	C/T	cg07713946	chr22:31675144	LIMK2	0.37	5.13	0.32	5.96e-7	Colorectal cancer;
SARC	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg13206674	chr6:150067644	NUP43	0.42	5.53	0.34	8.42e-8	Lung cancer;
SARC	cis	rs2806561	0.765	rs652783	chr1:23514313	G/T	cg12483005	chr1:23474871	LUZP1	0.45	5.9	0.36	1.29e-8	Height;
SARC	cis	rs1044826	1.000	rs9289577	chr3:139200327	C/G	cg15131784	chr3:139108705	COPB2	0.45	5.19	0.32	4.69e-7	Obesity-related traits;
SARC	cis	rs9894429	0.634	rs9709130	chr17:79583948	C/T	cg10661904	chr17:79619235	PDE6G	-0.45	-6.4	-0.39	8.67e-10	Eye color traits;
SARC	trans	rs36093844	0.800	rs17817331	chr11:85595338	A/G	cg27065003	chr5:122429449	PRDM6	0.52	6.38	0.39	9.23e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs3008870	1.000	rs2009319	chr1:67481070	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.91	11.08	0.59	3.49e-23	Lymphocyte percentage of white cells;
SARC	cis	rs1448094	0.802	rs11513957	chr12:86435551	C/T	cg02569458	chr12:86230093	RASSF9	0.35	4.94	0.31	1.47e-6	Major depressive disorder;
SARC	cis	rs2576037	0.899	rs7233515	chr18:44585955	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	5.16	0.32	5.2e-7	Personality dimensions;
SARC	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg12463550	chr7:65579703	CRCP	0.48	5.79	0.35	2.23e-8	Aortic root size;
SARC	cis	rs72781680	0.848	rs55725028	chr2:23966447	A/G	cg08917208	chr2:24149416	ATAD2B	0.92	8.9	0.5	1.64e-16	Lymphocyte counts;
SARC	cis	rs9902453	1.000	rs9890886	chr17:28391076	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.52	-6.87	-0.41	5.83e-11	Coffee consumption (cups per day);
SARC	cis	rs8014204	0.753	rs6574199	chr14:75356103	T/C	cg17347104	chr14:75034677	LTBP2	0.4	4.93	0.31	1.55e-6	Caffeine consumption;
SARC	cis	rs10876993	0.890	rs810204	chr12:58075733	T/C	cg18357645	chr12:58087776	OS9	0.46	6.05	0.37	5.81e-9	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg04944784	chr2:26401820	FAM59B	-0.48	-6.0	-0.37	7.54e-9	Gut microbiome composition (summer);
SARC	cis	rs12291225	0.679	rs11023170	chr11:14294909	A/G	cg19336497	chr11:14380999	RRAS2	-0.41	-6.81	-0.41	8.46e-11	Sense of smell;
SARC	cis	rs2228479	0.850	rs11648689	chr16:89806732	G/A	cg00800038	chr16:89945340	TCF25	-0.74	-5.08	-0.32	7.86e-7	Skin colour saturation;
SARC	cis	rs2070997	0.548	rs7868336	chr9:133668926	T/C	cg11464064	chr9:133710261	ABL1	0.57	5.62	0.35	5.48e-8	Response to amphetamines;
SARC	cis	rs11039216	1	rs11039216	chr11:47406592	C/T	cg20307385	chr11:47447363	PSMC3	0.66	9.44	0.53	3.99e-18	Neuroticism;
SARC	cis	rs7766436	0.848	rs16901663	chr6:22598054	T/C	cg13666174	chr6:22585274	NA	-0.6	-7.65	-0.45	5.41e-13	Coronary artery disease;
SARC	cis	rs9329221	0.682	rs6982308	chr8:10193772	C/G	cg27411982	chr8:10470053	RP1L1	-0.31	-4.99	-0.31	1.2e-6	Neuroticism;
SARC	cis	rs11792861	0.781	rs11789252	chr9:111762010	A/T	cg13535736	chr9:111863775	C9orf5	-0.38	-4.71	-0.3	4.2e-6	Menarche (age at onset);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg01304440	chr3:32726769	CNOT10	0.5	6.24	0.38	2.06e-9	Breast cancer;
SARC	cis	rs9309711	0.544	rs9752130	chr2:3488502	A/G	cg15506890	chr2:3487001	NA	-0.5	-6.47	-0.39	5.77e-10	Neurofibrillary tangles;
SARC	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg06221963	chr1:154839813	KCNN3	-0.54	-8.58	-0.49	1.34e-15	Prostate cancer;
SARC	cis	rs826838	0.834	rs826874	chr12:39122599	C/A	cg26384229	chr12:38710491	ALG10B	-0.7	-10.18	-0.55	2.33e-20	Heart rate;
SARC	cis	rs7011049	1.000	rs72643599	chr8:53854434	A/G	cg26025543	chr8:53854495	NA	0.6	5.37	0.33	1.91e-7	Systolic blood pressure;
SARC	cis	rs2439831	0.681	rs3742971	chr15:43622916	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.76	-8.69	-0.49	6.72e-16	Lung cancer in ever smokers;
SARC	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg21747090	chr2:27597821	SNX17	-0.55	-7.62	-0.45	6.44e-13	Total body bone mineral density;
SARC	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-5.45	-0.34	1.28e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs9322817	0.902	rs7773123	chr6:105173726	A/G	cg02098413	chr6:105308735	HACE1	0.34	4.91	0.31	1.68e-6	Thyroid stimulating hormone;
SARC	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-6.45	-0.39	6.46e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9581857	0.615	rs9581848	chr13:28003997	C/T	cg01674679	chr13:27998804	GTF3A	-0.68	-5.31	-0.33	2.5e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	cis	rs4969178	0.965	rs2292643	chr17:76395421	G/A	cg20026190	chr17:76395443	PGS1	0.4	5.36	0.33	2.03e-7	HDL cholesterol levels;
SARC	trans	rs11722228	0.522	rs7662229	chr4:10133014	A/T	cg26043149	chr18:55253948	FECH	0.75	8.9	0.5	1.65e-16	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs35306767	0.953	rs11253517	chr10:970524	A/G	cg25019033	chr10:957182	NA	0.49	5.19	0.32	4.63e-7	Eosinophil percentage of granulocytes;
SARC	cis	rs7568458	0.870	rs6719046	chr2:85757371	G/A	cg17127132	chr2:85788382	GGCX	0.41	5.35	0.33	2.09e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	trans	rs7615952	0.576	rs2276726	chr3:125826287	C/G	cg07211511	chr3:129823064	LOC729375	-0.61	-6.85	-0.41	6.59e-11	Blood pressure (smoking interaction);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg21389394	chr3:101498216	FAM55C	0.54	6.75	0.4	1.14e-10	Breast cancer;
SARC	cis	rs5753618	0.561	rs4603880	chr22:31744721	T/C	cg07713946	chr22:31675144	LIMK2	0.38	5.46	0.34	1.23e-7	Colorectal cancer;
SARC	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg11890956	chr21:40555474	PSMG1	-1.04	-15.98	-0.72	2.56e-39	Cognitive function;
SARC	cis	rs75059851	0.756	rs7122746	chr11:133838808	A/G	cg03326252	chr11:133821166	IGSF9B	0.35	4.79	0.3	2.92e-6	Schizophrenia;
SARC	cis	rs10512697	1.000	rs11741276	chr5:3577135	C/G	cg19473799	chr5:3511975	NA	-0.66	-4.78	-0.3	3.08e-6	Immune response to smallpox vaccine (IL-6);
SARC	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg25703541	chr22:24373054	LOC391322	0.69	8.57	0.49	1.4e-15	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg17221315	chr6:27791827	HIST1H4J	0.43	4.75	0.3	3.59e-6	Cardiac Troponin-T levels;
SARC	cis	rs62344088	0.590	rs6882234	chr5:177389	C/G	cg22857025	chr5:266934	NA	-0.76	-5.56	-0.34	7.26e-8	Asthma (childhood onset);
SARC	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg22509189	chr2:225307070	NA	-0.67	-8.57	-0.49	1.44e-15	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs2115630	1.000	rs10220733	chr15:85280864	G/A	cg17507749	chr15:85114479	UBE2QP1	-0.46	-5.46	-0.34	1.24e-7	P wave terminal force;
SARC	cis	rs9815354	1.000	rs9823254	chr3:41894768	G/C	cg03022575	chr3:42003672	ULK4	0.67	5.73	0.35	3.13e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs7412746	0.658	rs4970986	chr1:150907955	A/G	cg10589385	chr1:150898437	SETDB1	0.42	5.64	0.35	4.91e-8	Melanoma;
SARC	cis	rs787274	0.867	rs786977	chr9:115459708	A/G	cg13803584	chr9:115635662	SNX30	0.69	4.74	0.3	3.67e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs9291683	0.679	rs2241483	chr4:10099831	A/G	cg11266682	chr4:10021025	SLC2A9	-0.46	-8.27	-0.48	1.06e-14	Bone mineral density;
SARC	cis	rs3820928	0.839	rs13413292	chr2:227893747	G/C	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.67	-0.35	4.12e-8	Pulmonary function;
SARC	cis	rs11122272	0.766	rs2808608	chr1:231543175	A/G	cg06096015	chr1:231504339	EGLN1	0.38	5.59	0.34	6.26e-8	Hemoglobin concentration;
SARC	cis	rs76419734	0.850	rs17036156	chr4:106663234	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.81	5.48	0.34	1.08e-7	Post bronchodilator FEV1;
SARC	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg13939156	chr17:80058883	NA	-0.43	-6.7	-0.4	1.55e-10	Life satisfaction;
SARC	trans	rs11722228	0.508	rs3796826	chr4:10092728	G/A	cg26043149	chr18:55253948	FECH	0.67	7.54	0.44	1.01e-12	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs2732480	0.577	rs2732466	chr12:48732459	A/G	cg21466736	chr12:48725269	NA	-0.33	-5.19	-0.32	4.47e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs6696846	0.749	rs6692170	chr1:205074019	G/A	cg00857998	chr1:205179979	DSTYK	0.4	4.92	0.31	1.65e-6	Red blood cell count;
SARC	cis	rs2180341	1.000	rs4895822	chr6:127642703	T/C	cg27446573	chr6:127587934	RNF146	1.03	14.54	0.69	1.56e-34	Breast cancer;
SARC	cis	rs9303401	0.580	rs12946396	chr17:57164195	T/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	10.79	0.58	2.88e-22	Cognitive test performance;
SARC	cis	rs2048656	0.501	rs13276750	chr8:9474209	C/T	cg21625330	chr8:9911636	MSRA	0.5	4.81	0.3	2.66e-6	Schizophrenia;
SARC	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	8.8	0.5	3.1e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2749592	0.531	rs994804	chr10:37900140	A/C	cg00409905	chr10:38381863	ZNF37A	0.54	7.52	0.44	1.2e-12	Age-related hearing impairment (SNP x SNP interaction);
SARC	trans	rs7980799	0.682	rs10161491	chr12:33623806	T/C	cg13010199	chr12:38710504	ALG10B	-0.53	-6.35	-0.38	1.13e-9	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs5753618	0.583	rs34545960	chr22:31812462	G/A	cg02404636	chr22:31891804	SFI1	0.49	5.17	0.32	4.93e-7	Colorectal cancer;
SARC	cis	rs2857078	0.720	rs9901595	chr17:42305699	G/A	cg19774624	chr17:42201019	HDAC5	-0.44	-5.84	-0.36	1.73e-8	Red cell distribution width;Reticulocyte count;
SARC	cis	rs9902453	0.808	rs12452288	chr17:28235220	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	6.95	0.41	3.67e-11	Coffee consumption (cups per day);
SARC	cis	rs1707322	1.000	rs34694458	chr1:46332696	G/A	cg03146154	chr1:46216737	IPP	0.47	5.63	0.35	5.03e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs13082711	1.000	rs73050029	chr3:27514760	C/A	cg02860705	chr3:27208620	NA	0.49	5.97	0.36	8.58e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs1707322	0.682	rs12037459	chr1:46094959	T/G	cg06784218	chr1:46089804	CCDC17	0.37	6.37	0.39	1.01e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1018836	0.545	rs4236827	chr8:91688943	A/T	cg16814680	chr8:91681699	NA	-0.98	-20.6	-0.8	2.14e-54	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg22394521	chr20:61569754	DIDO1;C20orf11	-0.49	-6.39	-0.39	9.19e-10	Gallstone disease;
SARC	cis	rs62244186	0.566	rs3762636	chr3:44854563	A/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.55	7.2	0.43	8.39e-12	Depressive symptoms;
SARC	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg24642844	chr7:1081250	C7orf50	-0.59	-6.22	-0.38	2.25e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs2120019	0.938	rs8036573	chr15:75308690	C/T	cg17294928	chr15:75287854	SCAMP5	-1.02	-14.75	-0.69	3.26e-35	Blood trace element (Zn levels);
SARC	cis	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.45	5.65	0.35	4.68e-8	Sum eosinophil basophil counts;Eosinophil counts;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg26056104	chr20:2188127	NA	0.47	6.48	0.39	5.53e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg21552701	chr13:111090453	COL4A2	0.71	5.43	0.34	1.41e-7	Obesity-related traits;
SARC	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg13880726	chr7:1868755	MAD1L1	-0.51	-6.02	-0.37	6.59e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs6772849	0.896	rs4857859	chr3:128348014	G/T	cg08795948	chr3:128337044	NA	0.55	7.74	0.45	3.01e-13	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs929354	0.742	rs62491945	chr7:156955580	G/A	cg05182265	chr7:156933206	UBE3C	-0.34	-5.19	-0.32	4.49e-7	Body mass index;
SARC	cis	rs2644899	0.750	rs2607414	chr19:41267129	C/T	cg24958765	chr19:41283667	RAB4B	0.58	6.73	0.4	1.28e-10	Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs1832871	0.630	rs11754501	chr6:158710451	A/G	cg07165851	chr6:158734300	TULP4	0.45	5.41	0.33	1.56e-7	Height;
SARC	cis	rs883565	0.528	rs4428122	chr3:38972603	C/A	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.44	-5.12	-0.32	6.25e-7	Handedness;
SARC	cis	rs898097	0.756	rs56249965	chr17:80806603	C/G	cg20578329	chr17:80767326	TBCD	-0.51	-6.74	-0.4	1.21e-10	Breast cancer;
SARC	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg22105103	chr4:187893119	NA	-0.52	-6.92	-0.41	4.31e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6693567	0.526	rs3818978	chr1:150266338	T/A	cg09579323	chr1:150459698	TARS2	-0.43	-5.45	-0.34	1.3e-7	Migraine;
SARC	cis	rs7520050	0.931	rs6688365	chr1:46329884	G/C	cg24296786	chr1:45957014	TESK2	0.39	4.92	0.31	1.63e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs854765	0.583	rs4925123	chr17:17784374	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.62	-9.25	-0.52	1.53e-17	Total body bone mineral density;
SARC	cis	rs72945132	0.882	rs7116059	chr11:70159690	G/T	cg00319359	chr11:70116639	PPFIA1	0.67	6.08	0.37	4.85e-9	Coronary artery disease;
SARC	cis	rs7412746	0.658	rs7521719	chr1:150913134	G/A	cg13175981	chr1:150552382	MCL1	-0.48	-5.86	-0.36	1.57e-8	Melanoma;
SARC	cis	rs5771069	0.933	rs137848	chr22:50440296	A/G	cg03721641	chr22:50451245	IL17REL	0.32	4.86	0.3	2.16e-6	Ulcerative colitis;
SARC	cis	rs12142240	0.692	rs7532149	chr1:46824932	A/C	cg00530320	chr1:46809349	NSUN4	0.57	6.79	0.41	9.05e-11	Menopause (age at onset);
SARC	cis	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg14541582	chr5:601475	NA	-0.4	-4.8	-0.3	2.89e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs1355223	0.506	rs7130774	chr11:34869267	A/G	cg11622362	chr11:34938112	PDHX;APIP	0.46	6.04	0.37	6.11e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	trans	rs78810706	0.541	rs1281598	chr1:82883310	C/T	cg02794784	chr15:99646736	SYNM	-0.66	-6.31	-0.38	1.41e-9	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
SARC	cis	rs6429082	0.715	rs2131923	chr1:235580821	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.58	-7.55	-0.44	9.58e-13	Adiposity;
SARC	cis	rs12142240	0.698	rs17361763	chr1:46810670	T/C	cg10495392	chr1:46806563	NSUN4	0.64	6.76	0.4	1.09e-10	Menopause (age at onset);
SARC	cis	rs12142240	0.698	rs7525309	chr1:46809025	G/T	cg00530320	chr1:46809349	NSUN4	0.58	7.07	0.42	1.74e-11	Menopause (age at onset);
SARC	cis	rs11997175	0.624	rs17700425	chr8:33691467	T/G	ch.8.33884649F	chr8:33765107	NA	0.63	8.44	0.48	3.46e-15	Body mass index;
SARC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg11494091	chr17:61959527	GH2	0.53	8.02	0.47	5.12e-14	Prudent dietary pattern;
SARC	cis	rs11098499	1.000	rs35643470	chr4:120184948	T/C	cg09307838	chr4:120376055	NA	0.84	11.41	0.6	3.03e-24	Corneal astigmatism;
SARC	cis	rs6912958	0.712	rs2246113	chr6:88410050	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.4	-4.96	-0.31	1.38e-6	Monocyte percentage of white cells;
SARC	cis	rs9486719	1.000	rs2971608	chr6:97039757	T/C	cg18709589	chr6:96969512	KIAA0776	-0.49	-5.49	-0.34	1.04e-7	Migraine;Coronary artery disease;
SARC	cis	rs7647973	1.000	rs9842132	chr3:49427933	G/A	cg07636037	chr3:49044803	WDR6	-0.75	-8.18	-0.47	1.88e-14	Menarche (age at onset);
SARC	cis	rs1008375	0.966	rs11947836	chr4:17697187	A/G	cg27347728	chr4:17578864	LAP3	-0.47	-6.05	-0.37	5.72e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9914544	0.545	rs4510081	chr17:18798846	A/C	cg25390199	chr17:18761479	PRPSAP2	0.44	5.8	0.36	2.11e-8	Educational attainment (years of education);
SARC	cis	rs57502260	0.764	rs7105218	chr11:68222461	C/A	cg01657329	chr11:68192670	LRP5	-0.47	-4.86	-0.3	2.2e-6	Total body bone mineral density (age 45-60);
SARC	cis	rs2594989	0.691	rs2596816	chr3:11581200	A/C	cg00170343	chr3:11313890	ATG7	0.57	6.34	0.38	1.16e-9	Circulating chemerin levels;
SARC	cis	rs3768617	0.966	rs10911253	chr1:183086190	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.57	7.45	0.44	1.84e-12	Fuchs's corneal dystrophy;
SARC	cis	rs2204008	0.570	rs12318341	chr12:38251087	T/C	cg26384229	chr12:38710491	ALG10B	-0.6	-7.63	-0.45	5.8e-13	Bladder cancer;
SARC	cis	rs12048904	1.000	rs12048904	chr1:101331536	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.41	-5.26	-0.33	3.24e-7	Multiple sclerosis;
SARC	cis	rs807669	0.500	rs5746668	chr22:19149151	T/G	cg02655711	chr22:19163373	SLC25A1	0.45	5.48	0.34	1.08e-7	Metabolite levels;
SARC	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg15448220	chr1:150897856	SETDB1	0.47	6.24	0.38	2.06e-9	Tonsillectomy;
SARC	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg22590775	chr19:49891494	CCDC155	0.53	6.16	0.37	3.14e-9	Multiple sclerosis;
SARC	cis	rs7520050	0.966	rs10789481	chr1:46383583	C/G	cg24296786	chr1:45957014	TESK2	0.39	4.93	0.31	1.59e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs7044106	0.708	rs991121	chr9:123370345	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	8.96	0.51	1.07e-16	Hip circumference adjusted for BMI;
SARC	cis	rs7223966	1.000	rs9901112	chr17:61730617	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	5.66	0.35	4.35e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs12681366	0.663	rs2043987	chr8:95469693	G/C	cg13257157	chr8:95487014	RAD54B	0.39	4.92	0.31	1.65e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs2832191	0.791	rs8134407	chr21:30476586	G/A	cg08807101	chr21:30365312	RNF160	0.83	11.42	0.6	2.79e-24	Dental caries;
SARC	cis	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg25894440	chr7:65020034	NA	0.75	5.97	0.36	8.65e-9	Diabetic kidney disease;
SARC	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.43	6.71	0.4	1.48e-10	Schizophrenia;
SARC	cis	rs4443100	0.917	rs725984	chr22:23387642	A/G	cg14186256	chr22:23484241	RTDR1	0.47	4.92	0.31	1.63e-6	Serum parathyroid hormone levels;
SARC	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.65	-0.4	2.03e-10	Total body bone mineral density;
SARC	cis	rs804292	1.000	rs804292	chr8:11643915	C/T	cg26752888	chr8:11627280	NEIL2	-0.84	-10.15	-0.55	2.69e-20	Alcohol dependence;Nicotine use;
SARC	cis	rs2011503	1.000	rs34067609	chr19:19653524	G/A	cg15839431	chr19:19639596	YJEFN3	-0.48	-4.77	-0.3	3.32e-6	Bipolar disorder;
SARC	cis	rs2120243	0.647	rs1456099	chr3:157146307	A/T	cg01018701	chr3:157155998	VEPH1;PTX3	-0.47	-6.05	-0.37	5.76e-9	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs7264396	0.528	rs6058370	chr20:34518592	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	5.1	0.32	6.9e-7	Total cholesterol levels;
SARC	cis	rs35306767	0.903	rs11253485	chr10:919362	C/T	cg20503657	chr10:835505	NA	0.89	8.25	0.48	1.18e-14	Eosinophil percentage of granulocytes;
SARC	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg00149659	chr3:10157352	C3orf10	0.64	6.01	0.37	7.21e-9	Alzheimer's disease;
SARC	cis	rs300703	0.935	rs300704	chr2:240255	A/C	cg21211680	chr2:198530	NA	0.52	5.21	0.32	4.11e-7	Blood protein levels;
SARC	trans	rs7824557	0.638	rs4413734	chr8:11212778	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	6.72	0.4	1.39e-10	Retinal vascular caliber;
SARC	cis	rs6582630	0.560	rs11504462	chr12:38440379	G/A	cg26384229	chr12:38710491	ALG10B	-0.56	-7.01	-0.42	2.54e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg06634786	chr22:41940651	POLR3H	-0.58	-6.75	-0.4	1.18e-10	Vitiligo;
SARC	cis	rs1580019	0.510	rs4723162	chr7:32543804	C/A	cg14728415	chr7:32535168	LSM5;AVL9	0.53	6.83	0.41	7.51e-11	Cognitive ability;
SARC	cis	rs1008375	1.000	rs28552744	chr4:17620165	A/G	cg02297831	chr4:17616191	MED28	0.47	5.86	0.36	1.56e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg22535103	chr8:58192502	C8orf71	-0.67	-5.94	-0.36	1.05e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg07167872	chr1:205819463	PM20D1	0.86	15.4	0.71	2.19e-37	Menarche (age at onset);
SARC	cis	rs13390159	0.943	rs13416480	chr2:237156676	C/T	cg19324714	chr2:237145437	ASB18	0.48	4.73	0.3	3.84e-6	Response to statin therapy;
SARC	cis	rs2070433	0.948	rs2839304	chr21:47952650	C/G	cg12379764	chr21:47803548	PCNT	-0.5	-4.88	-0.3	2e-6	Lymphocyte counts;
SARC	cis	rs1843834	0.838	rs6436506	chr2:225558242	T/C	cg22455342	chr2:225449267	CUL3	0.52	6.84	0.41	6.74e-11	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg20607798	chr8:58055168	NA	0.72	5.88	0.36	1.43e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10883723	0.518	rs10786679	chr10:104315667	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.58	7.3	0.43	4.39e-12	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs2204008	0.837	rs8189467	chr12:38241956	T/C	cg26384229	chr12:38710491	ALG10B	0.89	13.06	0.65	1.31e-29	Bladder cancer;
SARC	cis	rs1497406	0.744	rs12057222	chr1:16508534	A/G	cg20430773	chr1:16534157	ARHGEF19	0.53	7.96	0.46	7.62e-14	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg17827154	chr12:41323612	CNTN1	0.42	6.35	0.38	1.14e-9	Thyroid stimulating hormone;
SARC	cis	rs7833986	0.501	rs2953901	chr8:56981824	C/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.72	7.24	0.43	6.48e-12	Height;
SARC	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	7.7	0.45	3.75e-13	Mean platelet volume;
SARC	cis	rs9303401	0.659	rs7210432	chr17:56668170	C/T	cg25039879	chr17:56429692	SUPT4H1	0.67	6.21	0.38	2.4e-9	Cognitive test performance;
SARC	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg11644478	chr21:40555479	PSMG1	-0.88	-11.57	-0.6	9.56e-25	Cognitive function;
SARC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.05	0.8	1.27e-52	Prudent dietary pattern;
SARC	cis	rs41278232	0.557	rs817340	chr20:62606024	C/A	cg07620230	chr20:62328084	TNFRSF6B	0.33	4.72	0.3	4.13e-6	Tonsillectomy;
SARC	cis	rs2016266	0.855	rs1056692	chr12:53687387	A/G	cg26875137	chr12:53738046	NA	-0.43	-5.39	-0.33	1.76e-7	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs1401999	0.966	rs2037379	chr3:183650330	T/C	cg01324343	chr3:183735012	ABCC5	0.68	13.95	0.67	1.46e-32	Anterior chamber depth;
SARC	cis	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg13072238	chr3:49761600	GMPPB	-0.42	-5.54	-0.34	8.33e-8	Intelligence (multi-trait analysis);
SARC	trans	rs877282	0.853	rs7079450	chr10:755932	T/A	cg22713356	chr15:30763199	NA	0.99	9.88	0.54	1.92e-19	Uric acid levels;
SARC	cis	rs1371867	0.810	rs1618528	chr8:101259134	T/C	cg11906718	chr8:101322791	RNF19A	-0.71	-8.83	-0.5	2.62e-16	Atrioventricular conduction;
SARC	cis	rs60843830	0.662	rs6721594	chr2:305203	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	-0.55	-7.94	-0.46	8.37e-14	Spherical equivalent (joint analysis main effects and education interaction);
SARC	cis	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg18252515	chr7:66147081	NA	-1.36	-12.11	-0.62	1.61e-26	Diabetic kidney disease;
SARC	cis	rs7740797	0.875	rs6557370	chr6:155081163	C/T	cg02865717	chr6:155053990	RBM16	-0.33	-4.73	-0.3	3.96e-6	Colorectal or endometrial cancer;
SARC	cis	rs910316	0.737	rs175055	chr14:75488946	T/G	cg06637938	chr14:75390232	RPS6KL1	-0.51	-6.85	-0.41	6.61e-11	Height;
SARC	trans	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg21659725	chr3:3221576	CRBN	-0.55	-7.33	-0.43	3.71e-12	Intelligence (multi-trait analysis);
SARC	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg07701084	chr6:150067640	NUP43	0.4	5.23	0.32	3.68e-7	Lung cancer;
SARC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.46	0.8	5.92e-54	Prudent dietary pattern;
SARC	cis	rs7223966	1.000	rs15637	chr17:61772050	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.45	5.03	0.31	9.75e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs1814175	0.645	rs7103554	chr11:50027612	G/A	cg03929089	chr4:120376271	NA	-0.84	-12.08	-0.62	2.02e-26	Height;
SARC	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg18876405	chr7:65276391	NA	-0.72	-9.19	-0.52	2.25e-17	Aortic root size;
SARC	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg18876405	chr7:65276391	NA	0.47	5.75	0.35	2.85e-8	Aortic root size;
SARC	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg24642844	chr7:1081250	C7orf50	-0.57	-6.05	-0.37	5.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	trans	rs208520	1.000	rs9453663	chr6:66976077	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.76	8.51	0.49	2.21e-15	Exhaled nitric oxide output;
SARC	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs34684276	1	rs34684276	chr15:78813155	G/A	cg18825076	chr15:78729989	IREB2	-0.46	-5.34	-0.33	2.26e-7	Nicotine dependence;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg02725872	chr8:58115012	NA	-0.37	-6.55	-0.39	3.71e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg21171335	chr12:122356390	WDR66	0.42	6.52	0.39	4.26e-10	Mean corpuscular volume;
SARC	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.38	-4.83	-0.3	2.5e-6	Lymphocyte counts;
SARC	cis	rs7662987	0.517	rs2924580	chr4:100032168	C/G	cg12011299	chr4:100065546	ADH4	0.33	5.53	0.34	8.55e-8	Smoking initiation;
SARC	cis	rs7312933	0.533	rs3747557	chr12:42717961	G/T	cg19980929	chr12:42632907	YAF2	-0.45	-6.73	-0.4	1.27e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs7336332	0.598	rs9581850	chr13:28012265	A/G	cg01674679	chr13:27998804	GTF3A	-0.54	-4.97	-0.31	1.3e-6	Weight;
SARC	cis	rs9886651	0.935	rs36157705	chr8:128797938	A/G	cg24514600	chr8:128805414	PVT1	-0.43	-5.68	-0.35	4.05e-8	Epithelial ovarian cancer;Serous invasive ovarian cancer;
SARC	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg09417038	chr21:47716443	C21orf57	-0.35	-5.05	-0.31	8.93e-7	Testicular germ cell tumor;
SARC	trans	rs7824557	0.591	rs2736283	chr8:11225910	A/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.34	-0.43	3.56e-12	Retinal vascular caliber;
SARC	cis	rs4742903	0.740	rs4596709	chr9:106978756	G/C	cg14250997	chr9:106856677	SMC2	0.4	4.98	0.31	1.22e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg12257692	chr3:49977190	RBM6	-0.27	-4.72	-0.3	3.99e-6	Body mass index;
SARC	cis	rs282587	0.569	rs403530	chr13:113396380	G/A	cg02820901	chr13:113351484	ATP11A	-0.53	-5.08	-0.32	7.58e-7	Glycated hemoglobin levels;
SARC	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	15.35	0.71	3.17e-37	Chronic sinus infection;
SARC	cis	rs34779708	0.931	rs12268745	chr10:35305989	C/G	cg03585969	chr10:35415529	CREM	0.39	4.98	0.31	1.24e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs2153535	0.580	rs6927589	chr6:8456632	A/G	cg23788917	chr6:8435910	SLC35B3	-0.63	-8.34	-0.48	6.46e-15	Motion sickness;
SARC	cis	rs3820928	0.967	rs4675118	chr2:227773157	C/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-6.68	-0.4	1.78e-10	Pulmonary function;
SARC	cis	rs447735	0.566	rs258337	chr16:89720710	T/A	cg03605463	chr16:89740564	NA	0.38	5.04	0.31	9.53e-7	Hemoglobin concentration;
SARC	cis	rs595982	0.527	rs73061659	chr19:49373556	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.64	-7.15	-0.42	1.09e-11	Red cell distribution width;
SARC	cis	rs7746199	0.668	rs7749305	chr6:27446566	T/C	cg12826209	chr6:26865740	GUSBL1	0.86	4.87	0.3	2.08e-6	Gait speed in old age;Autism spectrum disorder or schizophrenia;
SARC	cis	rs8141529	0.719	rs132561	chr22:29351179	C/T	cg15103426	chr22:29168792	CCDC117	-0.65	-8.01	-0.46	5.49e-14	Lymphocyte counts;
SARC	trans	rs3780486	0.801	rs56687083	chr9:33132134	A/G	cg04842962	chr6:43655489	MRPS18A	1.1	20.63	0.8	1.68e-54	IgG glycosylation;
SARC	cis	rs2834188	1.000	rs4408796	chr21:34698741	C/G	cg15382669	chr21:34697036	IFNAR1	-0.43	-4.91	-0.31	1.74e-6	Narcolepsy;
SARC	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	9.0	0.51	7.96e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs936229	0.705	rs936227	chr15:75131959	A/G	cg17294928	chr15:75287854	SCAMP5	0.42	4.93	0.31	1.55e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs870825	0.616	rs6419939	chr4:185642869	C/T	cg04058563	chr4:185651563	MLF1IP	0.81	11.52	0.6	1.31e-24	Blood protein levels;
SARC	cis	rs2933343	0.649	rs789214	chr3:128594995	A/G	cg25356066	chr3:128598488	ACAD9	0.71	9.53	0.53	2.1e-18	IgG glycosylation;
SARC	cis	rs9916302	0.904	rs8081338	chr17:37406139	C/T	cg07936489	chr17:37558343	FBXL20	-0.68	-9.04	-0.51	6.12e-17	Glomerular filtration rate (creatinine);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg10707110	chr22:38227306	ANKRD54	0.73	6.69	0.4	1.63e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7474896	0.515	rs2738208	chr10:38306128	A/G	cg00409905	chr10:38381863	ZNF37A	0.42	4.75	0.3	3.48e-6	Obesity (extreme);
SARC	cis	rs11785400	1.000	rs10108059	chr8:143750028	G/T	cg24634471	chr8:143751801	JRK	-0.66	-8.76	-0.5	4.05e-16	Schizophrenia;
SARC	cis	rs7666738	0.830	rs1426663	chr4:98990092	T/G	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs8180040	0.934	rs4858811	chr3:47480524	G/C	cg27129171	chr3:47204927	SETD2	-0.68	-9.53	-0.53	2.15e-18	Colorectal cancer;
SARC	cis	rs1707322	0.686	rs1547924	chr1:46085112	C/T	cg06784218	chr1:46089804	CCDC17	0.39	7.05	0.42	2e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2370759	1.000	rs11594963	chr10:32625736	G/A	cg18270830	chr10:32634957	EPC1	0.68	6.22	0.38	2.22e-9	Sexual dysfunction (female);
SARC	cis	rs5758659	0.652	rs133321	chr22:42405322	A/G	cg04733989	chr22:42467013	NAGA	0.5	6.7	0.4	1.52e-10	Cognitive function;
SARC	cis	rs262150	0.579	rs4481540	chr7:158785846	A/G	cg19418458	chr7:158789849	NA	0.45	4.98	0.31	1.22e-6	Facial morphology (factor 20);
SARC	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg13877915	chr19:58951672	ZNF132	0.66	9.9	0.54	1.63e-19	Uric acid clearance;
SARC	cis	rs7408868	1.000	rs10420466	chr19:15261371	G/T	cg14696996	chr19:15285081	NOTCH3	1.13	8.94	0.51	1.2e-16	Pulse pressure;
SARC	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg24675658	chr1:53192096	ZYG11B	-0.59	-8.11	-0.47	2.87e-14	Monocyte count;
SARC	cis	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg25427524	chr10:38739819	LOC399744	-0.57	-8.93	-0.5	1.33e-16	Extrinsic epigenetic age acceleration;
SARC	cis	rs4737010	0.501	rs1579274	chr8:41658923	T/G	cg08923054	chr8:41654455	ANK1	0.7	8.12	0.47	2.66e-14	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
SARC	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg13395646	chr4:1353034	KIAA1530	-0.56	-6.72	-0.4	1.35e-10	Obesity-related traits;
SARC	cis	rs6430585	0.528	rs7573555	chr2:136694905	C/T	cg07169764	chr2:136633963	MCM6	-1.06	-16.19	-0.73	5.05e-40	Corneal structure;
SARC	cis	rs3857067	0.806	rs17302467	chr4:95112056	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.05	-0.31	8.98e-7	QT interval;
SARC	cis	rs8180040	1.000	rs2159400	chr3:47375890	T/C	cg27129171	chr3:47204927	SETD2	-0.7	-9.9	-0.54	1.58e-19	Colorectal cancer;
SARC	cis	rs651907	0.535	rs34161138	chr3:101510388	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	5.91	0.36	1.22e-8	Colorectal cancer;
SARC	cis	rs11098499	0.818	rs10008791	chr4:120431469	A/C	cg24375607	chr4:120327624	NA	0.41	4.79	0.3	2.97e-6	Corneal astigmatism;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg18289490	chr20:48532070	SPATA2	0.53	7.02	0.42	2.44e-11	Chemerin levels;
SARC	trans	rs208520	0.690	rs1563929	chr6:66702108	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.09	14.12	0.68	4.08e-33	Exhaled nitric oxide output;
SARC	cis	rs7216064	1.000	rs9912770	chr17:65868233	C/T	cg12091567	chr17:66097778	LOC651250	-0.7	-7.64	-0.45	5.5e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg05025164	chr4:1340916	KIAA1530	0.62	7.69	0.45	4.07e-13	Longevity;
SARC	cis	rs6456156	0.586	rs10946209	chr6:167480991	G/A	cg07741184	chr6:167504864	NA	0.37	7.08	0.42	1.71e-11	Primary biliary cholangitis;
SARC	cis	rs1545257	0.514	rs7581577	chr2:24638107	C/T	cg06627628	chr2:24431161	ITSN2	-0.55	-6.97	-0.42	3.18e-11	Sjögren's syndrome;
SARC	cis	rs6088580	0.634	rs4911419	chr20:32995873	G/A	cg08999081	chr20:33150536	PIGU	-0.44	-6.65	-0.4	2.07e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs60871478	0.898	rs4720929	chr7:808009	T/C	cg19087971	chr7:751233	PRKAR1B	-0.43	-4.88	-0.3	2.01e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs3008870	0.583	rs2147838	chr1:67399466	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.83	8.91	0.5	1.46e-16	Lymphocyte percentage of white cells;
SARC	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg18225595	chr11:63971243	STIP1	0.47	5.64	0.35	4.89e-8	Mean platelet volume;
SARC	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg08219700	chr8:58056026	NA	0.6	5.71	0.35	3.49e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7927771	0.965	rs35184771	chr11:47475189	G/T	cg05585544	chr11:47624801	NA	-0.37	-4.95	-0.31	1.43e-6	Subjective well-being;
SARC	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg11890956	chr21:40555474	PSMG1	1.17	19.92	0.79	3.17e-52	Cognitive function;
SARC	cis	rs4919087	0.683	rs7074896	chr10:99071282	T/C	cg25902810	chr10:99078978	FRAT1	-0.55	-6.56	-0.39	3.4e-10	Monocyte count;
SARC	cis	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg14343924	chr8:8086146	FLJ10661	0.46	5.55	0.34	7.84e-8	Mood instability;
SARC	cis	rs6496667	1.000	rs7178496	chr15:90896959	C/T	cg22089800	chr15:90895588	ZNF774	0.51	4.75	0.3	3.53e-6	Rheumatoid arthritis;
SARC	cis	rs950776	0.642	rs12905641	chr15:78964362	A/G	cg06917634	chr15:78832804	PSMA4	-0.47	-5.37	-0.33	1.95e-7	Sudden cardiac arrest;
SARC	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg18876405	chr7:65276391	NA	0.49	6.04	0.37	6e-9	Aortic root size;
SARC	cis	rs941408	0.515	rs2110118	chr19:2775144	T/C	cg06609049	chr19:2785107	THOP1	0.96	14.11	0.68	4.21e-33	Total cholesterol levels;
SARC	cis	rs6831352	0.879	rs56222233	chr4:100069627	T/G	cg12011299	chr4:100065546	ADH4	-0.32	-5.09	-0.32	7.33e-7	Alcohol dependence;
SARC	trans	rs61931739	0.817	rs1705754	chr12:34145569	A/G	cg26384229	chr12:38710491	ALG10B	0.61	8.21	0.47	1.47e-14	Morning vs. evening chronotype;
SARC	cis	rs644799	0.623	rs17207890	chr11:95490754	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.8	10.91	0.58	1.16e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs3820928	0.874	rs6717168	chr2:227901342	C/T	cg05526886	chr2:227700861	RHBDD1	-0.5	-5.84	-0.36	1.71e-8	Pulmonary function;
SARC	trans	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg21659725	chr3:3221576	CRBN	-0.55	-7.19	-0.43	8.59e-12	Intelligence (multi-trait analysis);
SARC	cis	rs2273669	0.667	rs11153156	chr6:109365911	C/T	cg05315195	chr6:109294784	ARMC2	-0.63	-5.7	-0.35	3.6e-8	Prostate cancer;
SARC	cis	rs9858542	0.903	rs11917431	chr3:49644012	C/T	cg07274523	chr3:49395745	GPX1	0.5	5.69	0.35	3.73e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs7551222	0.752	rs12039454	chr1:204542580	C/T	cg20240347	chr1:204465584	NA	0.32	5.68	0.35	4.01e-8	Schizophrenia;
SARC	cis	rs1873147	1.000	rs1873147	chr15:63312632	G/A	cg05507819	chr15:63340323	TPM1	-0.47	-5.13	-0.32	6.15e-7	Orofacial clefts;
SARC	cis	rs2832191	0.791	rs2832182	chr21:30481612	G/A	cg08807101	chr21:30365312	RNF160	-0.84	-11.81	-0.61	1.6e-25	Dental caries;
SARC	trans	rs3779273	0.776	rs1969441	chr7:77835255	G/T	cg05596911	chr5:118502651	DMXL1	-0.58	-7.36	-0.43	3.17e-12	Body mass index;
SARC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg02353165	chr6:42928485	GNMT	0.61	8.41	0.48	4.21e-15	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs651907	1.000	rs665211	chr3:101600028	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.4	4.8	0.3	2.85e-6	Colorectal cancer;
SARC	cis	rs752010	0.695	rs11210509	chr1:42109311	A/G	cg06885757	chr1:42089581	HIVEP3	0.32	4.9	0.31	1.78e-6	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs611744	0.870	rs416611	chr8:109124593	T/C	cg21045802	chr8:109455806	TTC35	0.41	4.86	0.3	2.21e-6	Dupuytren's disease;
SARC	cis	rs4642101	0.618	rs9877079	chr3:12821287	A/G	cg05775895	chr3:12838266	CAND2	0.84	15.68	0.72	2.67e-38	QRS complex (12-leadsum);
SARC	cis	rs1468333	1.000	rs1468333	chr5:137552970	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.82	11.73	0.61	2.81e-25	Resting heart rate;
SARC	cis	rs9325144	0.647	rs7957185	chr12:38909710	G/A	cg13010199	chr12:38710504	ALG10B	-0.46	-5.89	-0.36	1.33e-8	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs554111	0.656	rs4654900	chr1:21422021	G/C	cg08890418	chr1:21044141	KIF17	-0.36	-5.1	-0.32	7.17e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg26119090	chr2:26468346	HADHA;HADHB	0.65	7.74	0.45	3.08e-13	Gut microbiome composition (summer);
SARC	cis	rs7786877	0.521	rs4729606	chr7:100321790	T/C	cg03098644	chr7:100410630	EPHB4	0.45	5.02	0.31	1.02e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs4713675	0.546	rs10947434	chr6:33691501	G/T	cg15676125	chr6:33679581	C6orf125	0.52	6.26	0.38	1.88e-9	Plateletcrit;
SARC	cis	rs910316	0.763	rs175016	chr14:75459633	C/T	cg08847533	chr14:75593920	NEK9	-0.86	-13.07	-0.65	1.21e-29	Height;
SARC	cis	rs34779708	0.897	rs7897827	chr10:35386237	C/T	cg03585969	chr10:35415529	CREM	0.41	5.12	0.32	6.25e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg05368731	chr17:41323189	NBR1	0.8	9.68	0.54	7.71e-19	Menopause (age at onset);
SARC	cis	rs17376456	1.000	rs56046246	chr5:93531545	T/G	cg21475434	chr5:93447410	FAM172A	0.92	7.81	0.46	1.91e-13	Diabetic retinopathy;
SARC	cis	rs986417	0.606	rs7156375	chr14:61110627	G/A	cg27398547	chr14:60952738	C14orf39	0.77	7.12	0.42	1.35e-11	Gut microbiota (bacterial taxa);
SARC	cis	rs7582720	1.000	rs114527590	chr2:203787405	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg27487021	chr2:160597953	MARCH7	0.46	6.58	0.4	3.02e-10	Thyroid stimulating hormone;
SARC	cis	rs17376456	0.877	rs13156865	chr5:93390908	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.76	0.35	2.64e-8	Diabetic retinopathy;
SARC	cis	rs875971	0.545	rs2173571	chr7:65770379	G/A	cg11764359	chr7:65958608	NA	0.66	6.58	0.4	3.12e-10	Aortic root size;
SARC	cis	rs2742234	0.541	rs7096500	chr10:43712095	C/T	cg15436174	chr10:43711423	RASGEF1A	0.43	5.01	0.31	1.08e-6	Hirschsprung disease;
SARC	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg14983838	chr19:29218262	NA	0.78	10.33	0.56	7.62e-21	Methadone dose in opioid dependence;
SARC	cis	rs2075371	0.611	rs12707154	chr7:134015832	C/T	cg00033643	chr7:134001901	SLC35B4	0.43	5.17	0.32	5.02e-7	Mean platelet volume;
SARC	cis	rs17666538	0.591	rs7818950	chr8:643831	C/T	cg07685180	chr8:600429	NA	0.61	5.38	0.33	1.79e-7	IgG glycosylation;
SARC	cis	rs12142240	0.698	rs17361763	chr1:46810670	T/C	cg00530320	chr1:46809349	NSUN4	0.58	7.07	0.42	1.74e-11	Menopause (age at onset);
SARC	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg24209194	chr3:40518798	ZNF619	0.58	7.45	0.44	1.76e-12	Renal cell carcinoma;
SARC	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg22004693	chr7:99632812	ZKSCAN1	0.55	5.47	0.34	1.18e-7	Lung function (FEV1/FVC);
SARC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.44	-6.72	-0.4	1.4e-10	Longevity;Endometriosis;
SARC	cis	rs2933343	0.621	rs789241	chr3:128585752	G/A	cg25356066	chr3:128598488	ACAD9	0.7	9.39	0.52	5.65e-18	IgG glycosylation;
SARC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg06873352	chr17:61820015	STRADA	0.55	6.87	0.41	5.69e-11	Prudent dietary pattern;
SARC	cis	rs7223966	0.960	rs2319990	chr17:61705397	T/C	cg00588841	chr17:61851480	DDX42;CCDC47	-0.61	-7.1	-0.42	1.53e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs8258	0.501	rs474490	chr11:117287794	T/G	cg15227623	chr11:117232454	CEP164	0.46	5.6	0.34	5.99e-8	Pulse pressure;
SARC	cis	rs17376456	0.569	rs2045021	chr5:93224222	G/A	cg21475434	chr5:93447410	FAM172A	-0.68	-7.0	-0.42	2.71e-11	Diabetic retinopathy;
SARC	cis	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg06212747	chr3:49208901	KLHDC8B	0.51	6.48	0.39	5.37e-10	Resting heart rate;
SARC	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg20573242	chr4:122745356	CCNA2	0.64	8.11	0.47	2.93e-14	Type 2 diabetes;
SARC	cis	rs477692	0.669	rs12265939	chr10:131445398	A/G	cg05714579	chr10:131428358	MGMT	-0.58	-7.58	-0.44	7.99e-13	Response to temozolomide;
SARC	cis	rs40363	0.723	rs2736	chr16:3536872	G/A	cg22508957	chr16:3507546	NAT15	-0.59	-5.03	-0.31	9.76e-7	Tuberculosis;
SARC	cis	rs763121	0.853	rs1062687	chr22:39134715	T/C	cg06544989	chr22:39130855	UNC84B	0.28	4.76	0.3	3.33e-6	Menopause (age at onset);
SARC	cis	rs7769051	0.522	rs73550455	chr6:133096633	A/G	cg07930552	chr6:133119739	C6orf192	0.89	5.34	0.33	2.19e-7	Type 2 diabetes nephropathy;
SARC	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.07	0.59	3.73e-23	Alzheimer's disease;
SARC	cis	rs7666738	0.830	rs4699593	chr4:98980628	A/G	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6495122	0.699	rs1378942	chr15:75077367	A/C	cg09165964	chr15:75287851	SCAMP5	-0.42	-5.23	-0.32	3.79e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	cis	rs12421382	1.000	rs12421382	chr11:109378071	C/T	cg15948088	chr11:109293068	C11orf87	0.38	4.88	0.3	1.97e-6	Schizophrenia;
SARC	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg03433033	chr1:76189801	ACADM	0.58	7.97	0.46	6.99e-14	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7113850	0.541	rs74832028	chr11:24232359	A/T	ch.11.24196551F	chr11:24239977	NA	0.73	5.37	0.33	1.91e-7	Bone fracture in osteoporosis;
SARC	cis	rs2013441	1.000	rs9897328	chr17:20174852	G/A	cg13482628	chr17:19912719	NA	-0.47	-6.08	-0.37	4.9e-9	Obesity-related traits;
SARC	cis	rs6568686	0.627	rs117205661	chr6:111624557	T/A	cg15721981	chr6:111408429	SLC16A10	0.69	5.85	0.36	1.67e-8	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs9790314	1.000	rs4273380	chr3:160950314	A/G	cg03342759	chr3:160939853	NMD3	-0.61	-7.73	-0.45	3.22e-13	Morning vs. evening chronotype;
SARC	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg24675658	chr1:53192096	ZYG11B	0.67	9.85	0.54	2.29e-19	Monocyte count;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg04677295	chr13:100153866	TM9SF2	-0.77	-6.57	-0.4	3.27e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs526231	0.543	rs26258	chr5:102549721	A/C	cg23492399	chr5:102201601	PAM	-0.52	-5.61	-0.35	5.62e-8	Primary biliary cholangitis;
SARC	cis	rs10782582	0.593	rs11579752	chr1:76178694	C/T	cg10523679	chr1:76189770	ACADM	-0.41	-5.02	-0.31	1.01e-6	Daytime sleep phenotypes;
SARC	cis	rs734999	0.505	rs10797439	chr1:2540364	G/A	cg20673091	chr1:2541236	MMEL1	0.33	5.08	0.32	7.7e-7	Ulcerative colitis;
SARC	cis	rs6964587	1.000	rs57816416	chr7:91736078	A/C	cg17063962	chr7:91808500	NA	0.95	16.04	0.72	1.66e-39	Breast cancer;
SARC	trans	rs61931739	0.534	rs4931783	chr12:34115322	G/A	cg26384229	chr12:38710491	ALG10B	0.87	12.56	0.64	5.57e-28	Morning vs. evening chronotype;
SARC	cis	rs7945705	0.902	rs2568059	chr11:8884161	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.46	-6.58	-0.4	3.11e-10	Hemoglobin concentration;
SARC	cis	rs981844	0.826	rs1545604	chr4:154682733	C/T	cg14289246	chr4:154710475	SFRP2	0.63	7.35	0.43	3.28e-12	Response to statins (LDL cholesterol change);
SARC	cis	rs4423214	0.570	rs7118246	chr11:71231124	G/C	cg05163923	chr11:71159392	DHCR7	0.59	6.9	0.41	4.89e-11	Vitamin D levels;
SARC	cis	rs34779708	0.966	rs17591163	chr10:35465279	G/C	cg03585969	chr10:35415529	CREM	0.39	4.8	0.3	2.88e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg04756594	chr16:24857601	SLC5A11	0.43	5.86	0.36	1.55e-8	Intelligence (multi-trait analysis);
SARC	trans	rs1200821	0.535	rs1208789	chr10:37722472	A/G	cg25427524	chr10:38739819	LOC399744	-0.47	-7.03	-0.42	2.27e-11	Hemostatic factors and hematological phenotypes;
SARC	cis	rs9470366	0.848	rs9470361	chr6:36623379	G/A	cg08179530	chr6:36648295	CDKN1A	0.55	5.94	0.36	1.05e-8	QRS duration;
SARC	cis	rs918629	0.530	rs11739652	chr5:95238582	C/G	cg16656078	chr5:95278638	ELL2	-0.58	-6.98	-0.42	3.08e-11	IgG glycosylation;
SARC	cis	rs9303401	0.580	rs34076823	chr17:57114497	C/G	cg25039879	chr17:56429692	SUPT4H1	0.55	4.94	0.31	1.52e-6	Cognitive test performance;
SARC	cis	rs554111	0.656	rs17450813	chr1:21264308	T/C	cg08890418	chr1:21044141	KIF17	-0.34	-4.76	-0.3	3.44e-6	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs6714710	0.603	rs11692010	chr2:98397301	C/T	cg26665480	chr2:98280029	ACTR1B	0.49	6.49	0.39	5.15e-10	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs739401	1.000	rs739401	chr11:3036324	C/T	cg25174290	chr11:3078921	CARS	-0.55	-7.61	-0.45	6.62e-13	Longevity;
SARC	trans	rs56341938	0.757	rs1420465	chr3:168715138	C/G	cg05085101	chr17:4890696	CAMTA2	-0.51	-6.38	-0.39	9.69e-10	Lung function (FEV1/FVC);
SARC	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg13175981	chr1:150552382	MCL1	-0.5	-6.02	-0.37	6.75e-9	Melanoma;
SARC	cis	rs13082711	0.911	rs73050094	chr3:27519552	T/A	cg02860705	chr3:27208620	NA	0.46	5.78	0.35	2.43e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs67460515	0.892	rs73026976	chr3:160964271	G/A	cg04691961	chr3:161091175	C3orf57	-0.47	-5.82	-0.36	1.89e-8	Parkinson's disease;
SARC	cis	rs10227331	0.846	rs10807647	chr7:157298007	A/G	cg04156418	chr7:157293606	NA	-0.42	-7.02	-0.42	2.43e-11	Inattentive symptoms;
SARC	cis	rs4423214	1.000	rs2040323	chr11:71172783	A/C	cg24826892	chr11:71159390	DHCR7	0.48	6.11	0.37	4.18e-9	Vitamin D levels;
SARC	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.73	8.8	0.5	3.1e-16	Height;
SARC	cis	rs8067354	0.609	rs1292066	chr17:57932314	T/A	cg02344993	chr17:57696989	CLTC	0.63	6.45	0.39	6.25e-10	Hemoglobin concentration;
SARC	cis	rs9388451	0.537	rs1739383	chr6:126098915	G/T	cg06289844	chr6:126071538	HEY2	0.32	5.14	0.32	5.73e-7	Brugada syndrome;
SARC	cis	rs7772486	0.727	rs11155442	chr6:146140725	T/C	cg05347473	chr6:146136440	FBXO30	0.53	7.4	0.44	2.39e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs8064299	0.574	rs1879455	chr17:72774738	C/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.82	11.03	0.59	4.83e-23	Monocyte count;
SARC	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	trans	rs61931739	0.534	rs4931775	chr12:34050729	G/A	cg26384229	chr12:38710491	ALG10B	0.86	12.43	0.63	1.55e-27	Morning vs. evening chronotype;
SARC	cis	rs7084402	0.967	rs1649085	chr10:60292042	T/C	cg07615347	chr10:60278583	BICC1	0.61	8.99	0.51	8.99e-17	Refractive error;
SARC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.4	4.93	0.31	1.55e-6	Electroencephalogram traits;
SARC	cis	rs7179456	0.547	rs6494036	chr15:59015961	A/T	cg05156742	chr15:59063176	FAM63B	0.63	7.86	0.46	1.44e-13	Asperger disorder;
SARC	cis	rs4901847	0.901	rs8019367	chr14:58553750	A/G	cg15908186	chr14:58618357	C14orf37	0.46	5.25	0.33	3.38e-7	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	7.76	0.45	2.65e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg01579765	chr21:45077557	HSF2BP	-0.36	-6.02	-0.37	6.78e-9	Mean corpuscular volume;
SARC	cis	rs76419734	1.000	rs72671856	chr4:106647366	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.84	5.56	0.34	7.44e-8	Post bronchodilator FEV1;
SARC	cis	rs936229	0.749	rs7497201	chr15:75190690	A/G	cg14664628	chr15:75095509	CSK	-0.84	-10.15	-0.55	2.85e-20	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs61935443	0.832	rs11107768	chr12:95274182	A/T	cg21533806	chr12:95267307	NA	-0.67	-8.08	-0.47	3.4e-14	Schizophrenia;
SARC	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg22535103	chr8:58192502	C8orf71	-0.83	-9.5	-0.53	2.68e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg24110177	chr3:50126178	RBM5	0.63	8.44	0.48	3.41e-15	Body mass index;
SARC	cis	rs67311347	0.955	rs6764102	chr3:40378153	C/G	cg24209194	chr3:40518798	ZNF619	0.58	7.29	0.43	4.74e-12	Renal cell carcinoma;
SARC	cis	rs873946	0.689	rs2803993	chr10:134550606	T/C	cg26818010	chr10:134567672	INPP5A	-0.44	-5.0	-0.31	1.14e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs25645	0.830	rs4072639	chr17:38189049	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.39	7.18	0.43	9.49e-12	Myeloid white cell count;
SARC	cis	rs6439153	0.933	rs34193129	chr3:128691407	G/A	cg25356066	chr3:128598488	ACAD9	0.46	5.52	0.34	9.2e-8	Pneumococcal bacteremia;
SARC	trans	rs561341	0.739	rs7213369	chr17:30211878	G/A	cg20587970	chr11:113659929	NA	0.7	7.06	0.42	1.86e-11	Hip circumference adjusted for BMI;
SARC	cis	rs35146811	0.844	rs13223792	chr7:99675659	T/G	cg22004693	chr7:99632812	ZKSCAN1	-0.46	-5.13	-0.32	5.97e-7	Coronary artery disease;
SARC	cis	rs7092929	0.941	rs615019	chr10:3563318	T/C	cg14308648	chr10:3568949	NA	0.48	4.81	0.3	2.71e-6	Coronary artery calcification;
SARC	cis	rs8031584	0.958	rs61997079	chr15:31238271	G/C	cg19680485	chr15:31195859	MTMR15	-0.52	-5.95	-0.36	9.62e-9	Huntington's disease progression;
SARC	cis	rs7829975	0.510	rs332037	chr8:8722675	C/T	cg08975724	chr8:8085496	FLJ10661	0.46	5.84	0.36	1.72e-8	Mood instability;
SARC	cis	rs11190604	1.000	rs11190570	chr10:102227702	G/C	cg07080220	chr10:102295463	HIF1AN	0.78	9.59	0.53	1.41e-18	Palmitoleic acid (16:1n-7) levels;
SARC	trans	rs8073060	0.544	rs7210966	chr17:33986334	G/C	cg19694781	chr19:47549865	TMEM160	-0.72	-7.4	-0.44	2.53e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs2380220	0.574	rs9374322	chr6:95998994	G/A	cg15832292	chr6:96025679	MANEA	0.5	5.55	0.34	7.71e-8	Behavioural disinhibition (generation interaction);
SARC	cis	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg15556689	chr8:8085844	FLJ10661	0.47	5.75	0.35	2.83e-8	Systolic blood pressure;
SARC	cis	rs9443189	0.502	rs6453843	chr6:76558485	T/G	cg01950844	chr6:76311363	SENP6	-0.76	-4.78	-0.3	3.12e-6	Prostate cancer;
SARC	cis	rs7255436	0.965	rs7249624	chr19:8446135	G/A	cg10174797	chr19:8464628	RAB11B	0.45	6.5	0.39	4.91e-10	HDL cholesterol;
SARC	cis	rs739401	0.595	rs6578305	chr11:3001120	C/T	cg20651018	chr11:3035856	CARS	-0.46	-7.25	-0.43	5.98e-12	Longevity;
SARC	cis	rs11711311	1.000	rs12637066	chr3:113527574	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	8.72	0.5	5.29e-16	IgG glycosylation;
SARC	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg15448220	chr1:150897856	SETDB1	0.47	6.24	0.38	2.06e-9	Tonsillectomy;
SARC	cis	rs9296092	0.538	rs62405953	chr6:33524760	C/T	cg13560919	chr6:33536144	NA	-0.5	-5.92	-0.36	1.13e-8	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs2916247	1.000	rs9297901	chr8:93036795	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.59	-6.18	-0.38	2.87e-9	Intelligence (multi-trait analysis);
SARC	cis	rs67311347	0.866	rs1454491	chr3:40352647	C/G	cg09455208	chr3:40491958	NA	0.38	6.0	0.37	7.53e-9	Renal cell carcinoma;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg04514556	chr3:71113948	FOXP1	0.5	6.29	0.38	1.57e-9	Lung adenocarcinoma;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg00993799	chr7:104653126	LOC100216545	-0.64	-7.28	-0.43	5.2e-12	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs2762353	0.505	rs2096386	chr6:25787817	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.41	-5.19	-0.32	4.59e-7	Blood metabolite levels;
SARC	cis	rs7659604	0.540	rs9998385	chr4:122676673	C/T	cg19671926	chr4:122722719	EXOSC9	0.55	6.99	0.42	2.87e-11	Type 2 diabetes;
SARC	cis	rs10046574	0.831	rs7455447	chr7:135062056	C/T	cg27474649	chr7:135195673	CNOT4	0.89	7.19	0.43	8.96e-12	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs4906332	1.000	rs4900574	chr14:103879024	G/A	cg26031613	chr14:104095156	KLC1	0.52	6.15	0.37	3.29e-9	Coronary artery disease;
SARC	cis	rs4074493	1.000	rs11122198	chr1:231171139	G/A	cg22172038	chr1:231176991	FAM89A	0.33	4.8	0.3	2.86e-6	Carotid plaque burden (smoking interaction);
SARC	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg02931644	chr1:25747376	RHCE	0.45	7.6	0.45	7.18e-13	Erythrocyte sedimentation rate;
SARC	cis	rs9902453	0.780	rs62068621	chr17:28170382	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	7.22	0.43	7.39e-12	Coffee consumption (cups per day);
SARC	cis	rs7647973	1.000	rs7613491	chr3:49508976	T/C	cg07636037	chr3:49044803	WDR6	-0.75	-7.99	-0.46	6.22e-14	Menarche (age at onset);
SARC	cis	rs12311304	1.000	rs1120565	chr12:15401796	A/T	cg08258403	chr12:15378311	NA	0.4	6.27	0.38	1.75e-9	Behavioural disinhibition (generation interaction);
SARC	cis	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg20965017	chr5:231967	SDHA	-0.55	-5.28	-0.33	2.98e-7	Breast cancer;
SARC	cis	rs6685188	0.925	rs12752037	chr1:205661614	A/C	cg11965913	chr1:205819406	PM20D1	-0.53	-6.19	-0.38	2.76e-9	White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs7264396	0.790	rs6060582	chr20:34313297	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.58	-6.0	-0.37	7.38e-9	Total cholesterol levels;
SARC	cis	rs4253772	0.637	rs6008357	chr22:46652104	T/G	cg24881330	chr22:46731750	TRMU	0.62	6.72	0.4	1.41e-10	LDL cholesterol;Cholesterol, total;
SARC	cis	rs6121246	0.609	rs2377317	chr20:30402502	A/G	cg13852791	chr20:30311386	BCL2L1	-0.83	-10.3	-0.56	9.53e-21	Mean corpuscular hemoglobin;
SARC	cis	rs8078723	0.738	rs8066582	chr17:38146929	A/G	cg17467752	chr17:38218738	THRA	-0.4	-5.11	-0.32	6.65e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.67	0.54	8.17e-19	Prudent dietary pattern;
SARC	cis	rs2645694	0.626	rs2703118	chr4:77823672	A/G	cg10057126	chr4:77819792	ANKRD56	0.45	6.87	0.41	5.84e-11	Emphysema distribution in smoking;
SARC	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg05025164	chr4:1340916	KIAA1530	0.85	11.09	0.59	3.19e-23	Longevity;
SARC	cis	rs113835537	0.597	rs57288351	chr11:66307489	C/T	cg24851651	chr11:66362959	CCS	0.41	5.16	0.32	5.27e-7	Airway imaging phenotypes;
SARC	cis	rs4253772	0.591	rs113101219	chr22:46659186	C/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.63	4.94	0.31	1.47e-6	LDL cholesterol;Cholesterol, total;
SARC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg04234412	chr22:24373322	LOC391322	-0.54	-6.6	-0.4	2.78e-10	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs13191362	1.000	rs4260737	chr6:163137746	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.75	6.38	0.39	9.54e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg10435706	chr6:150039699	LATS1	0.37	4.87	0.3	2.07e-6	Lung cancer;
SARC	cis	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg14541582	chr5:601475	NA	-0.4	-4.95	-0.31	1.4e-6	Obesity-related traits;
SARC	cis	rs66573146	1.000	rs55833486	chr4:6978729	C/A	cg15105060	chr4:7024189	TBC1D14	-0.69	-4.92	-0.31	1.63e-6	Granulocyte percentage of myeloid white cells;
SARC	trans	rs8073060	0.614	rs72829932	chr17:34055935	A/G	cg19694781	chr19:47549865	TMEM160	0.69	6.83	0.41	7.34e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs9916302	0.706	rs11657153	chr17:37699729	A/G	cg00129232	chr17:37814104	STARD3	-0.57	-6.07	-0.37	5.26e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs1395	0.922	rs13404327	chr2:27519153	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.35	-5.09	-0.32	7.43e-7	Blood metabolite levels;
SARC	cis	rs9443189	0.865	rs2133190	chr6:76443493	A/G	cg01950844	chr6:76311363	SENP6	-0.73	-7.05	-0.42	2.06e-11	Prostate cancer;
SARC	cis	rs13191362	0.872	rs56404230	chr6:163252863	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.37	5.15	0.32	5.44e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs11675119	0.517	rs12619851	chr2:3492747	T/C	cg08493051	chr2:3487164	NA	-0.4	-4.77	-0.3	3.2e-6	Neurofibrillary tangles;
SARC	cis	rs4555082	0.834	rs28846738	chr14:105745781	A/G	cg13114125	chr14:105738426	BRF1	-0.73	-10.78	-0.58	3.05e-22	Mean platelet volume;Platelet distribution width;
SARC	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg26335602	chr6:28129616	ZNF389	0.52	5.7	0.35	3.61e-8	Parkinson's disease;
SARC	cis	rs8141529	0.529	rs2301428	chr22:29214606	G/C	cg15103426	chr22:29168792	CCDC117	0.61	5.73	0.35	3.06e-8	Lymphocyte counts;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg15482792	chr1:91870014	HFM1	0.55	7.14	0.42	1.17e-11	Breast cancer;
SARC	cis	rs6141769	0.569	rs6058807	chr20:31264608	T/C	cg17884169	chr20:31446444	EFCAB8	-0.46	-4.86	-0.3	2.16e-6	Subjective well-being;
SARC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg03452623	chr4:187889614	NA	-0.76	-11.87	-0.61	9.77e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10979	0.557	rs9390117	chr6:143907590	C/T	cg25407410	chr6:143891975	LOC285740	-0.52	-6.0	-0.37	7.63e-9	Hypospadias;
SARC	cis	rs9911578	0.967	rs7222789	chr17:56819853	C/G	cg12560992	chr17:57184187	TRIM37	0.88	12.14	0.62	1.31e-26	Intelligence (multi-trait analysis);
SARC	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg02463440	chr8:22132932	PIWIL2	0.46	6.51	0.39	4.49e-10	Hypertriglyceridemia;
SARC	trans	rs7615952	0.688	rs4422259	chr3:125545831	C/T	cg07211511	chr3:129823064	LOC729375	-0.74	-8.86	-0.5	2.13e-16	Blood pressure (smoking interaction);
SARC	cis	rs6835098	0.924	rs2332669	chr4:174163398	G/A	cg08422745	chr4:174089978	GALNT7	-0.65	-8.59	-0.49	1.25e-15	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs9660992	0.624	rs72745217	chr1:205261482	C/G	cg19090574	chr1:205240910	TMCC2	-0.4	-4.75	-0.3	3.49e-6	Mean corpuscular volume;Mean platelet volume;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg18891090	chr8:68167394	ARFGEF1	0.5	6.88	0.41	5.54e-11	Thyroid stimulating hormone;
SARC	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.79	8.12	0.47	2.74e-14	Alzheimer's disease;
SARC	cis	rs72781680	0.898	rs72798041	chr2:23953076	T/C	cg08917208	chr2:24149416	ATAD2B	0.9	8.62	0.49	1.04e-15	Lymphocyte counts;
SARC	cis	rs1707322	1.000	rs10158032	chr1:46332701	T/C	cg06784218	chr1:46089804	CCDC17	0.33	5.75	0.35	2.84e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg21747090	chr2:27597821	SNX17	0.53	7.14	0.42	1.2e-11	Total body bone mineral density;
SARC	cis	rs6582630	0.502	rs11520279	chr12:38360871	A/G	cg26384229	chr12:38710491	ALG10B	0.87	12.85	0.64	6.2e-29	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7617773	0.780	rs79089926	chr3:48348564	A/C	cg11946769	chr3:48343235	NME6	0.76	9.7	0.54	6.55e-19	Coronary artery disease;
SARC	cis	rs12291225	0.585	rs12270374	chr11:14375079	T/C	cg19336497	chr11:14380999	RRAS2	-0.45	-8.01	-0.46	5.56e-14	Sense of smell;
SARC	cis	rs3106136	0.934	rs2902979	chr4:95177874	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.39	-6.05	-0.37	5.83e-9	Capecitabine sensitivity;
SARC	cis	rs9341808	0.500	rs2322629	chr6:80811540	C/T	cg08355045	chr6:80787529	NA	0.41	6.14	0.37	3.62e-9	Sitting height ratio;
SARC	cis	rs7223966	1.000	rs6504168	chr17:61697469	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.51	-5.29	-0.33	2.75e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9381040	0.655	rs2268187	chr6:41042993	G/A	cg02167203	chr6:41068553	NFYA;LOC221442	-0.42	-4.74	-0.3	3.69e-6	Alzheimer's disease (late onset);
SARC	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg11764359	chr7:65958608	NA	-0.82	-11.07	-0.59	3.54e-23	Aortic root size;
SARC	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg04772025	chr11:68637568	NA	0.51	6.38	0.39	9.27e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs2066819	1.000	rs17118439	chr12:56667604	C/T	cg26804944	chr12:56660921	COQ10A	0.9	5.33	0.33	2.28e-7	Psoriasis vulgaris;
SARC	cis	rs4319547	0.656	rs7975747	chr12:122816995	C/T	cg23029597	chr12:123009494	RSRC2	-0.41	-5.14	-0.32	5.71e-7	Body mass index;
SARC	cis	rs2043112	0.965	rs7724222	chr5:38931313	A/T	cg04869206	chr5:39074266	RICTOR	0.51	6.4	0.39	8.23e-10	Obesity-related traits;
SARC	cis	rs17376456	0.825	rs10057130	chr5:93282557	C/T	cg21475434	chr5:93447410	FAM172A	0.85	7.53	0.44	1.13e-12	Diabetic retinopathy;
SARC	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg11987759	chr7:65425863	GUSB	-0.57	-7.73	-0.45	3.15e-13	Aortic root size;
SARC	cis	rs11190604	1.000	rs2495743	chr10:102329739	G/C	cg07080220	chr10:102295463	HIF1AN	0.79	9.16	0.51	2.76e-17	Palmitoleic acid (16:1n-7) levels;
SARC	trans	rs9929218	0.871	rs1862748	chr16:68832943	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.52	-6.67	-0.4	1.84e-10	Colorectal cancer;
SARC	cis	rs1707322	0.752	rs28507722	chr1:46206540	A/G	cg06784218	chr1:46089804	CCDC17	0.36	6.37	0.38	1.03e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs8058578	1.000	rs8058578	chr16:30726248	C/T	cg02466173	chr16:30829666	NA	-0.44	-5.82	-0.36	1.97e-8	Multiple myeloma;
SARC	cis	rs17270561	0.609	rs1892254	chr6:25750530	T/C	cg16482183	chr6:26056742	HIST1H1C	0.43	5.14	0.32	5.72e-7	Iron status biomarkers;
SARC	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg05535760	chr7:792225	HEATR2	0.84	8.32	0.48	7.31e-15	Cerebrospinal P-tau181p levels;
SARC	cis	rs2011503	1.000	rs75667002	chr19:19592232	T/A	cg15839431	chr19:19639596	YJEFN3	-0.47	-4.76	-0.3	3.45e-6	Bipolar disorder;
SARC	cis	rs11971779	0.590	rs6944104	chr7:139051120	T/A	cg23387468	chr7:139079360	LUC7L2	0.33	4.71	0.3	4.2e-6	Diisocyanate-induced asthma;
SARC	cis	rs16912285	0.688	rs59797575	chr11:24315536	A/T	ch.11.24196551F	chr11:24239977	NA	0.52	4.99	0.31	1.2e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs17030434	0.654	rs10021447	chr4:154646459	A/C	cg14289246	chr4:154710475	SFRP2	-0.55	-5.47	-0.34	1.16e-7	Electrocardiographic conduction measures;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg09436067	chr3:185689507	NA	-0.68	-6.27	-0.38	1.77e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs734999	0.545	rs4648356	chr1:2709164	C/A	cg20673091	chr1:2541236	MMEL1	0.32	4.89	0.31	1.87e-6	Ulcerative colitis;
SARC	cis	rs1348850	0.526	rs78587445	chr2:178461339	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.7	-6.25	-0.38	1.92e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7633770	0.664	rs7373994	chr3:46701114	C/G	cg11219411	chr3:46661640	NA	-0.41	-6.52	-0.39	4.31e-10	Coronary artery disease;
SARC	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg11965913	chr1:205819406	PM20D1	0.48	5.44	0.34	1.35e-7	Parkinson's disease;
SARC	cis	rs11583043	0.575	rs658861	chr1:101584241	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.47	-5.22	-0.32	3.88e-7	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg22535103	chr8:58192502	C8orf71	-0.64	-6.54	-0.39	3.91e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg00684032	chr4:1343700	KIAA1530	0.33	4.75	0.3	3.52e-6	Obesity-related traits;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg17499041	chr6:35310257	PPARD	0.52	6.95	0.41	3.57e-11	Tetralogy of Fallot;
SARC	cis	rs7927771	0.832	rs1317164	chr11:47419757	G/T	cg20307385	chr11:47447363	PSMC3	-0.6	-7.54	-0.44	1.06e-12	Subjective well-being;
SARC	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-7.06	-0.42	1.87e-11	Gut microbiome composition (summer);
SARC	cis	rs7223966	1.000	rs2854219	chr17:61942682	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-4.84	-0.3	2.31e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg08859206	chr1:53392774	SCP2	-0.39	-5.66	-0.35	4.38e-8	Monocyte count;
SARC	cis	rs17376456	0.825	rs1470150	chr5:93138654	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.65	-6.33	-0.38	1.26e-9	Diabetic retinopathy;
SARC	cis	rs7568458	0.905	rs6547620	chr2:85755928	C/T	cg23752985	chr2:85803571	VAMP8	0.33	4.73	0.3	3.98e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	trans	rs9951602	0.512	rs9958376	chr18:76655167	G/T	cg02800362	chr5:177631904	HNRNPAB	0.7	8.91	0.5	1.49e-16	Obesity-related traits;
SARC	cis	rs4646312	0.555	rs1800706	chr22:19928022	G/A	cg07194846	chr22:19930177	COMT;TXNRD2	0.51	6.63	0.4	2.26e-10	Schizophrenia;
SARC	cis	rs672059	1.000	rs672119	chr1:183162506	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.5	6.93	0.41	4.01e-11	Hypertriglyceridemia;
SARC	cis	rs9381040	0.655	rs7738684	chr6:41038552	G/A	cg02167203	chr6:41068553	NFYA;LOC221442	-0.41	-4.73	-0.3	3.81e-6	Alzheimer's disease (late onset);
SARC	cis	rs6456156	0.603	rs2345754	chr6:167484361	T/C	cg07741184	chr6:167504864	NA	0.36	6.99	0.42	2.83e-11	Primary biliary cholangitis;
SARC	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7572733	0.555	rs6434954	chr2:198929716	T/C	cg00792783	chr2:198669748	PLCL1	0.43	4.87	0.3	2.1e-6	Dermatomyositis;
SARC	cis	rs2153535	0.580	rs9392220	chr6:8457946	G/A	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.04e-14	Motion sickness;
SARC	cis	rs3733585	0.699	rs12498956	chr4:9950705	G/T	cg11266682	chr4:10021025	SLC2A9	-0.35	-6.03	-0.37	6.37e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-9.79	-0.54	3.57e-19	Alzheimer's disease;
SARC	cis	rs7223966	1.000	rs6504171	chr17:61710010	G/A	cg26338869	chr17:61819248	STRADA	0.43	4.83	0.3	2.42e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs854765	0.547	rs8069811	chr17:17922280	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.46	5.99	0.37	7.81e-9	Total body bone mineral density;
SARC	cis	rs9393692	0.905	rs989134	chr6:26336224	A/C	cg13736514	chr6:26305472	NA	-0.64	-8.83	-0.5	2.53e-16	Educational attainment;
SARC	cis	rs9790314	0.663	rs10513562	chr3:160743579	G/A	cg04691961	chr3:161091175	C3orf57	-0.58	-8.04	-0.47	4.66e-14	Morning vs. evening chronotype;
SARC	cis	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg18252515	chr7:66147081	NA	1.23	11.08	0.59	3.5e-23	Diabetic kidney disease;
SARC	trans	rs6600671	0.934	rs7528274	chr1:121286901	A/T	cg00646200	chr1:148855367	NA	0.5	7.05	0.42	2.06e-11	Hip geometry;
SARC	cis	rs9660992	0.573	rs12140422	chr1:205187981	G/A	cg21545522	chr1:205238299	TMCC2	0.4	5.39	0.33	1.73e-7	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs8064299	0.655	rs12797	chr17:72766993	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.45	5.45	0.34	1.27e-7	Monocyte count;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18458295	chr11:46722285	ZNF408;ARHGAP1	0.55	7.28	0.43	5.24e-12	Smoking initiation;
SARC	cis	rs6933660	0.683	rs8180642	chr6:151756612	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.64	8.27	0.48	1.01e-14	Menarche (age at onset);
SARC	cis	rs9398803	0.865	rs9385401	chr6:126789472	C/T	cg20229609	chr6:126660872	C6orf173	0.4	5.82	0.36	1.96e-8	Male-pattern baldness;
SARC	cis	rs6568686	0.627	rs174387	chr6:111915023	C/T	cg15721981	chr6:111408429	SLC16A10	0.58	4.98	0.31	1.22e-6	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs9443189	0.570	rs6903448	chr6:76173832	C/T	cg01950844	chr6:76311363	SENP6	0.75	6.48	0.39	5.4e-10	Prostate cancer;
SARC	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg26850624	chr5:429559	AHRR	-0.33	-5.23	-0.32	3.7e-7	Cystic fibrosis severity;
SARC	cis	rs2769264	0.505	rs4246526	chr1:151403916	G/T	cg18801370	chr1:151430492	POGZ	0.83	8.96	0.51	1.05e-16	Blood trace element (Cu levels);
SARC	trans	rs9354308	0.866	rs2814092	chr6:66547346	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.57	6.66	0.4	1.92e-10	Metabolite levels;
SARC	cis	rs748404	0.697	rs530683	chr15:43568999	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.42	-5.25	-0.33	3.45e-7	Lung cancer;
SARC	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg18876405	chr7:65276391	NA	0.49	6.04	0.37	6e-9	Aortic root size;
SARC	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg16479474	chr6:28041457	NA	0.37	5.44	0.34	1.37e-7	Parkinson's disease;
SARC	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg11843238	chr5:131593191	PDLIM4	0.38	5.28	0.33	2.91e-7	Breast cancer;
SARC	cis	rs3087591	0.960	rs9807077	chr17:29634457	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.54	-6.65	-0.4	2.07e-10	Hip circumference;
SARC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg23696834	chr6:42928345	GNMT	-0.32	-4.73	-0.3	3.89e-6	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg03033257	chr22:50311977	ALG12;CRELD2	0.6	5.67	0.35	4.15e-8	Schizophrenia;
SARC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg24829409	chr8:58192753	C8orf71	-0.59	-5.12	-0.32	6.49e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7084402	1.000	rs28426375	chr10:60285478	T/A	cg07615347	chr10:60278583	BICC1	0.59	8.51	0.49	2.16e-15	Refractive error;
SARC	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg15049968	chr18:44337910	ST8SIA5	-0.34	-5.25	-0.33	3.47e-7	Personality dimensions;
SARC	cis	rs2153535	0.580	rs1119689	chr6:8460754	C/G	cg07606381	chr6:8435919	SLC35B3	0.75	10.63	0.57	9.19e-22	Motion sickness;
SARC	cis	rs9457247	1.000	rs430477	chr6:167389851	T/C	cg23791538	chr6:167370224	RNASET2	-0.62	-8.66	-0.49	8.17e-16	Crohn's disease;
SARC	cis	rs13082711	0.522	rs4973760	chr3:27349047	G/A	cg02860705	chr3:27208620	NA	0.45	5.93	0.36	1.1e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs9392918	0.902	rs9392172	chr6:7723962	C/G	cg23089261	chr6:7723385	NA	0.37	4.86	0.3	2.11e-6	Height;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg09959495	chr2:237029385	AGAP1	0.45	6.28	0.38	1.64e-9	Thyroid stimulating hormone;
SARC	cis	rs4481887	1.000	rs7511706	chr1:248467360	G/A	cg13385794	chr1:248469461	NA	0.36	5.59	0.34	6.44e-8	Common traits (Other);
SARC	cis	rs72945132	0.882	rs17425511	chr11:70183737	C/G	cg00319359	chr11:70116639	PPFIA1	0.69	6.28	0.38	1.68e-9	Coronary artery disease;
SARC	cis	rs2013441	1.000	rs2703778	chr17:20138900	T/C	cg13482628	chr17:19912719	NA	-0.47	-6.18	-0.38	2.82e-9	Obesity-related traits;
SARC	cis	rs2425143	1.000	rs17093026	chr20:34318911	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.66	-5.15	-0.32	5.65e-7	Blood protein levels;
SARC	cis	rs757081	0.667	rs17473243	chr11:17266259	G/A	cg15432903	chr11:17409602	KCNJ11	-0.36	-4.74	-0.3	3.68e-6	Systolic blood pressure;
SARC	cis	rs13191362	1.000	rs34655790	chr6:163202739	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.65	5.75	0.35	2.72e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs3106136	0.527	rs2632411	chr4:95149434	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.49	-7.39	-0.44	2.55e-12	Capecitabine sensitivity;
SARC	cis	rs7927771	0.524	rs4752865	chr11:47759841	G/A	cg10504702	chr11:47789108	FNBP4	-0.43	-5.62	-0.35	5.48e-8	Subjective well-being;
SARC	cis	rs478304	0.654	rs11601509	chr11:65456864	T/C	cg27068330	chr11:65405492	SIPA1	-0.41	-4.82	-0.3	2.54e-6	Acne (severe);
SARC	cis	rs4820539	1.000	rs13054985	chr22:23458577	G/A	cg14186256	chr22:23484241	RTDR1	0.86	13.04	0.65	1.55e-29	Bone mineral density;
SARC	cis	rs9399135	0.967	rs9389254	chr6:135330709	C/T	cg24558204	chr6:135376177	HBS1L	0.45	6.04	0.37	6.04e-9	Red blood cell count;
SARC	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg02018176	chr4:1364513	KIAA1530	-0.36	-5.1	-0.32	7.09e-7	Obesity-related traits;
SARC	cis	rs9462027	0.562	rs2814946	chr6:34651180	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.98	-0.36	8.35e-9	Systemic lupus erythematosus;
SARC	cis	rs6912958	0.678	rs9450733	chr6:88250081	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.52	-7.09	-0.42	1.6e-11	Monocyte percentage of white cells;
SARC	cis	rs2153535	0.580	rs718502	chr6:8527400	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	10.6	0.57	1.12e-21	Motion sickness;
SARC	cis	rs477692	1.000	rs508303	chr10:131424996	A/T	cg05714579	chr10:131428358	MGMT	-0.54	-6.81	-0.41	8.46e-11	Response to temozolomide;
SARC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg11494091	chr17:61959527	GH2	0.53	7.94	0.46	8.72e-14	Prudent dietary pattern;
SARC	cis	rs9828933	0.938	rs9809432	chr3:64002953	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	-0.68	-5.84	-0.36	1.7e-8	Type 2 diabetes;
SARC	cis	rs9916302	0.851	rs6503518	chr17:37660469	A/G	cg20243544	chr17:37824526	PNMT	0.55	6.45	0.39	6.26e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs7829975	0.514	rs2920991	chr8:8259117	T/A	cg08975724	chr8:8085496	FLJ10661	0.56	6.67	0.4	1.83e-10	Mood instability;
SARC	cis	rs769267	0.566	rs7249692	chr19:19670688	T/C	cg03709012	chr19:19516395	GATAD2A	-0.76	-10.0	-0.55	8.1e-20	Tonsillectomy;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg06456538	chr6:87967386	ZNF292	0.45	6.25	0.38	1.9e-9	Thyroid stimulating hormone;
SARC	cis	rs796364	0.662	rs11688415	chr2:201143409	C/T	cg23649088	chr2:200775458	C2orf69	0.63	5.3	0.33	2.65e-7	Schizophrenia;
SARC	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg22903471	chr2:27725779	GCKR	-0.51	-7.68	-0.45	4.26e-13	Total body bone mineral density;
SARC	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg20891558	chr2:74357851	NA	0.69	9.54	0.53	1.97e-18	Gestational age at birth (maternal effect);
SARC	cis	rs72634258	0.554	rs12745962	chr1:7919825	C/T	cg00042356	chr1:8021962	PARK7	0.66	5.49	0.34	1.03e-7	Inflammatory bowel disease;
SARC	cis	rs12474201	0.862	rs7562173	chr2:46976217	C/G	cg06386533	chr2:46925753	SOCS5	-0.84	-12.67	-0.64	2.38e-28	Height;
SARC	cis	rs6908034	0.607	rs114146042	chr6:19807229	G/A	cg02682789	chr6:19804855	NA	0.69	5.41	0.33	1.53e-7	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs1865760	0.519	rs4360119	chr6:25815074	C/G	cg17691542	chr6:26056736	HIST1H1C	0.61	7.38	0.44	2.82e-12	Height;
SARC	cis	rs6546550	0.901	rs11902198	chr2:70144596	C/A	cg02498382	chr2:70120550	SNRNP27	-0.32	-5.22	-0.32	4e-7	Prevalent atrial fibrillation;
SARC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg11301795	chr4:187892539	NA	-0.7	-10.35	-0.56	6.76e-21	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg16325326	chr1:53192061	ZYG11B	-0.97	-18.69	-0.77	3.09e-48	Monocyte count;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg05771398	chr17:66031830	KPNA2	0.52	6.94	0.41	3.77e-11	Thyroid stimulating hormone;
SARC	cis	rs13161895	0.941	rs438050	chr5:179414645	T/C	cg02702477	chr5:179499311	RNF130	0.63	5.92	0.36	1.15e-8	LDL cholesterol;
SARC	cis	rs9911578	0.934	rs58092632	chr17:57111101	T/C	cg12560992	chr17:57184187	TRIM37	-0.87	-12.54	-0.63	6.5e-28	Intelligence (multi-trait analysis);
SARC	cis	rs4481887	0.861	rs4644528	chr1:248472508	T/A	cg13385794	chr1:248469461	NA	0.35	5.45	0.34	1.29e-7	Common traits (Other);
SARC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg20007245	chr22:24372913	LOC391322	-0.64	-7.7	-0.45	3.81e-13	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg18404041	chr3:52824283	ITIH1	0.44	6.63	0.4	2.3e-10	Bipolar disorder;
SARC	cis	rs75804782	0.641	rs3769125	chr2:239349562	A/G	cg21699342	chr2:239360505	ASB1	-0.58	-4.81	-0.3	2.68e-6	Morning vs. evening chronotype;Chronotype;
SARC	cis	rs6088580	0.524	rs11167241	chr20:33250835	C/T	cg08999081	chr20:33150536	PIGU	-0.34	-4.99	-0.31	1.17e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs4843747	0.671	rs9933794	chr16:88116981	T/C	cg01573921	chr16:88061006	BANP	-0.45	-4.77	-0.3	3.23e-6	Menopause (age at onset);
SARC	cis	rs13256369	0.590	rs10113115	chr8:8559588	A/G	cg18904891	chr8:8559673	CLDN23	0.46	5.43	0.34	1.42e-7	Obesity-related traits;
SARC	cis	rs10078	0.515	rs1053299	chr5:470760	G/A	cg26072250	chr5:443457	EXOC3;C5orf55	0.67	5.56	0.34	7.48e-8	Fat distribution (HIV);
SARC	cis	rs6665290	0.935	rs6659424	chr1:227197875	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.09	-25.76	-0.86	4.12e-70	Myeloid white cell count;
SARC	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg08859206	chr1:53392774	SCP2	-0.39	-5.66	-0.35	4.36e-8	Monocyte count;
SARC	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.74	-7.32	-0.43	3.97e-12	Platelet count;
SARC	cis	rs7700895	0.554	rs154460	chr5:95217430	A/T	cg16656078	chr5:95278638	ELL2	0.42	5.3	0.33	2.71e-7	IgG glycosylation;
SARC	cis	rs7432375	0.566	rs835636	chr3:136674500	A/C	cg15507776	chr3:136538369	TMEM22	0.67	8.55	0.49	1.6e-15	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	cis	rs889312	0.961	rs1862626	chr5:56032940	G/T	cg14703610	chr5:56206110	C5orf35	0.41	4.75	0.3	3.61e-6	Breast cancer;Breast cancer (early onset);
SARC	cis	rs10911232	0.507	rs4652766	chr1:182994336	A/G	cg13390022	chr1:182993471	LAMC1	0.33	4.97	0.31	1.29e-6	Hypertriglyceridemia;
SARC	cis	rs55986470	0.763	rs10188853	chr2:239430558	G/C	cg21699342	chr2:239360505	ASB1	-0.47	-4.97	-0.31	1.3e-6	Chronotype;
SARC	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg11764359	chr7:65958608	NA	0.75	8.59	0.49	1.22e-15	Aortic root size;
SARC	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg03060546	chr3:49711283	APEH	0.42	5.31	0.33	2.5e-7	Parkinson's disease;
SARC	cis	rs7103648	0.712	rs10838703	chr11:47422861	C/G	cg20307385	chr11:47447363	PSMC3	0.76	10.48	0.57	2.59e-21	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs986417	0.818	rs4278669	chr14:60982075	T/C	cg27398547	chr14:60952738	C14orf39	0.99	9.02	0.51	6.89e-17	Gut microbiota (bacterial taxa);
SARC	cis	rs9487051	0.676	rs9400267	chr6:109600164	T/C	cg01475377	chr6:109611718	NA	-0.35	-5.16	-0.32	5.17e-7	Reticulocyte fraction of red cells;
SARC	cis	rs1538970	0.781	rs34768551	chr1:46020408	G/A	cg05343316	chr1:45956843	TESK2	0.83	9.04	0.51	6.34e-17	Platelet count;
SARC	cis	rs2304069	0.614	rs216140	chr5:149443298	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.51	5.63	0.35	5.24e-8	HIV-1 control;
SARC	cis	rs703842	1.000	rs703842	chr12:58162739	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.72	-10.42	-0.56	4.03e-21	Multiple sclerosis;
SARC	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg11987759	chr7:65425863	GUSB	-0.47	-6.31	-0.38	1.39e-9	Aortic root size;
SARC	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg10523679	chr1:76189770	ACADM	-0.5	-6.72	-0.4	1.36e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg07308232	chr7:1071921	C7orf50	-0.46	-5.71	-0.35	3.48e-8	Longevity;Endometriosis;
SARC	cis	rs7428	0.527	rs3184780	chr2:85549547	C/T	cg03728395	chr2:85555865	TGOLN2	-0.45	-6.3	-0.38	1.47e-9	Ear protrusion;
SARC	cis	rs9303401	0.659	rs12600349	chr17:57054245	A/G	cg25039879	chr17:56429692	SUPT4H1	-0.63	-5.97	-0.36	8.81e-9	Cognitive test performance;
SARC	cis	rs240764	0.583	rs6905113	chr6:101209368	A/G	cg09795085	chr6:101329169	ASCC3	-0.44	-5.7	-0.35	3.63e-8	Neuroticism;
SARC	cis	rs8114671	0.562	rs8116657	chr20:33476474	C/G	cg07148914	chr20:33460835	GGT7	0.44	5.41	0.33	1.55e-7	Height;
SARC	cis	rs796364	0.806	rs35200468	chr2:201110368	G/C	cg23649088	chr2:200775458	C2orf69	-0.66	-5.5	-0.34	1.01e-7	Schizophrenia;
SARC	cis	rs9388451	0.874	rs1159974	chr6:126090277	C/T	cg06289844	chr6:126071538	HEY2	-0.35	-5.65	-0.35	4.55e-8	Brugada syndrome;
SARC	cis	rs709400	0.567	rs1961600	chr14:103862144	G/A	cg12935359	chr14:103987150	CKB	-0.38	-5.66	-0.35	4.44e-8	Body mass index;
SARC	cis	rs585510	1	rs585510	chr12:121000133	A/G	cg12219531	chr12:120966889	COQ5	0.83	11.11	0.59	2.8e-23	Reticulocyte fraction of red cells;
SARC	cis	rs801193	0.742	rs9969300	chr7:65781646	G/A	cg18876405	chr7:65276391	NA	-0.66	-7.79	-0.45	2.18e-13	Aortic root size;
SARC	cis	rs523522	0.962	rs10849758	chr12:120971149	C/T	cg12219531	chr12:120966889	COQ5	0.84	11.36	0.6	4.3e-24	High light scatter reticulocyte count;
SARC	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg04277193	chr17:41438351	NA	0.44	4.78	0.3	3.04e-6	Menopause (age at onset);
SARC	cis	rs6448317	1.000	rs7698504	chr4:24939386	A/T	cg21108841	chr4:24914750	CCDC149	-0.52	-5.43	-0.34	1.39e-7	Heschl's gyrus morphology;
SARC	cis	rs4642101	0.737	rs4299468	chr3:12825559	G/A	cg05775895	chr3:12838266	CAND2	0.75	12.09	0.62	1.9e-26	QRS complex (12-leadsum);
SARC	cis	rs2297440	0.527	rs4809318	chr20:62264760	G/A	cg09650180	chr20:62225654	GMEB2	-0.45	-5.11	-0.32	6.56e-7	Glioma;Non-glioblastoma glioma;Glioblastoma;
SARC	cis	rs910316	1.000	rs4903281	chr14:75554361	G/C	cg08847533	chr14:75593920	NEK9	0.95	15.92	0.72	3.98e-39	Height;
SARC	cis	rs10492096	0.853	rs7300092	chr12:6607364	T/C	cg13857086	chr12:6580257	VAMP1	0.62	6.11	0.37	4.17e-9	Hip geometry;
SARC	cis	rs1341267	0.529	rs6492721	chr13:95258944	A/G	cg18412871	chr13:95254051	GPR180	-0.45	-6.06	-0.37	5.56e-9	Triglyceride levels;
SARC	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg11062466	chr8:58055876	NA	0.56	5.67	0.35	4.19e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs3126085	0.935	rs6675889	chr1:152213066	G/A	cg03465714	chr1:152285911	FLG	-0.44	-5.3	-0.33	2.67e-7	Atopic dermatitis;
SARC	cis	rs2050392	0.624	rs303449	chr10:30726845	G/A	cg25182066	chr10:30743637	MAP3K8	0.41	5.59	0.34	6.27e-8	Inflammatory bowel disease;
SARC	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg00149659	chr3:10157352	C3orf10	0.8	7.48	0.44	1.53e-12	Alzheimer's disease;
SARC	cis	rs600231	0.706	rs10896016	chr11:65335705	C/T	cg17120908	chr11:65337727	SSSCA1	0.52	6.54	0.39	3.9e-10	Bone mineral density;
SARC	trans	rs1973993	0.691	rs1989141	chr1:96898520	C/T	cg10631902	chr5:14652156	NA	0.51	8.81	0.5	2.85e-16	Weight;
SARC	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg06618935	chr21:46677482	NA	-0.37	-5.0	-0.31	1.11e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs5758659	0.652	rs133303	chr22:42395242	C/G	cg04733989	chr22:42467013	NAGA	0.51	6.82	0.41	7.82e-11	Cognitive function;
SARC	cis	rs910316	1.000	rs4903284	chr14:75592483	G/C	cg11812906	chr14:75593930	NEK9	0.86	13.44	0.66	7.34e-31	Height;
SARC	cis	rs1008375	0.932	rs6449321	chr4:17644472	A/G	cg27347728	chr4:17578864	LAP3	0.47	5.89	0.36	1.32e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg16339924	chr4:17578868	LAP3	0.66	8.76	0.5	4e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg11494091	chr17:61959527	GH2	-0.53	-7.99	-0.46	6.07e-14	Prudent dietary pattern;
SARC	cis	rs2180341	1.000	rs9385419	chr6:127597591	A/G	cg24812749	chr6:127587940	RNF146	0.96	12.68	0.64	2.3e-28	Breast cancer;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg22797735	chr12:115122157	TBX3	0.54	6.72	0.4	1.35e-10	Blood pressure;
SARC	cis	rs2153535	0.580	rs2183112	chr6:8528212	G/A	cg23788917	chr6:8435910	SLC35B3	0.62	8.31	0.48	8.11e-15	Motion sickness;
SARC	cis	rs6733011	0.578	rs10172158	chr2:99509605	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-5.41	-0.33	1.57e-7	Bipolar disorder;
SARC	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg00149659	chr3:10157352	C3orf10	0.69	6.9	0.41	4.76e-11	Alzheimer's disease;
SARC	cis	rs796364	1.000	rs281771	chr2:200812202	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.74	-6.66	-0.4	1.9e-10	Schizophrenia;
SARC	cis	rs7927771	1.000	rs4752856	chr11:47648042	C/T	cg20307385	chr11:47447363	PSMC3	-0.51	-6.27	-0.38	1.73e-9	Subjective well-being;
SARC	cis	rs9894429	1.000	rs9748176	chr17:79584043	C/G	cg18240062	chr17:79603768	NPLOC4	0.71	9.76	0.54	4.27e-19	Eye color traits;
SARC	cis	rs273218	1.000	rs273218	chr5:53380555	T/C	ch.5.1024479R	chr5:53302184	ARL15	0.66	7.11	0.42	1.39e-11	Migraine;
SARC	cis	rs2153535	0.504	rs4493781	chr6:8473941	G/C	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs6882046	0.513	rs447801	chr5:88002653	T/C	cg22951263	chr5:87985283	NA	-0.36	-4.79	-0.3	2.9e-6	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
SARC	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.49	0.39	5.23e-10	Bipolar disorder;
SARC	cis	rs453301	0.686	rs6748	chr8:8890802	C/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.86	-0.41	6.22e-11	Joint mobility (Beighton score);
SARC	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.76	7.77	0.45	2.57e-13	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs7769051	1.000	rs9493446	chr6:133125643	C/T	cg22852734	chr6:133119734	C6orf192	1.09	11.3	0.59	6.88e-24	Type 2 diabetes nephropathy;
SARC	cis	rs473651	0.935	rs508483	chr2:239339709	T/C	cg21699342	chr2:239360505	ASB1	0.47	7.01	0.42	2.56e-11	Multiple system atrophy;
SARC	cis	rs1448094	0.621	rs10863089	chr12:86279699	C/T	cg02569458	chr12:86230093	RASSF9	0.41	5.58	0.34	6.67e-8	Major depressive disorder;
SARC	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg02574844	chr11:5959923	NA	-0.38	-5.13	-0.32	6.2e-7	DNA methylation (variation);
SARC	trans	rs61931739	0.635	rs3937819	chr12:33942715	A/G	cg13010199	chr12:38710504	ALG10B	0.52	6.52	0.39	4.39e-10	Morning vs. evening chronotype;
SARC	cis	rs17253792	0.822	rs11546	chr14:56146357	G/A	cg01858014	chr14:56050164	KTN1	-0.71	-5.58	-0.34	6.78e-8	Putamen volume;
SARC	cis	rs920590	0.643	rs2083641	chr8:19660217	A/C	cg03894339	chr8:19674705	INTS10	0.43	5.13	0.32	6.15e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs6062509	0.965	rs6062504	chr20:62348907	A/G	cg27236539	chr20:62289627	RTEL1	0.51	5.86	0.36	1.53e-8	Prostate cancer;
SARC	cis	rs3857536	0.741	rs9363556	chr6:66934399	T/C	cg07460842	chr6:66804631	NA	-0.51	-5.83	-0.36	1.82e-8	Blood trace element (Cu levels);
SARC	cis	rs8192482	1	rs8192482	chr15:78886198	C/T	cg06917634	chr15:78832804	PSMA4	-0.58	-6.04	-0.37	6.18e-9	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg19680485	chr15:31195859	MTMR15	-0.58	-6.88	-0.41	5.42e-11	Huntington's disease progression;
SARC	cis	rs80130819	0.591	rs10875783	chr12:48649736	G/A	cg05342945	chr12:48394962	COL2A1	-0.53	-5.69	-0.35	3.7e-8	Prostate cancer;
SARC	cis	rs1707322	0.963	rs10890373	chr1:46393755	A/C	cg06784218	chr1:46089804	CCDC17	0.35	6.19	0.38	2.64e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2985684	0.894	rs4581611	chr14:50043520	A/T	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.46	5.07	0.32	8.22e-7	Carotid intima media thickness;
SARC	cis	rs9858542	0.953	rs11711485	chr3:49491983	G/T	cg07274523	chr3:49395745	GPX1	0.52	5.93	0.36	1.07e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs950169	1.000	rs35297609	chr15:84772896	A/G	cg17507749	chr15:85114479	UBE2QP1	0.76	9.25	0.52	1.47e-17	Schizophrenia;
SARC	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg04267008	chr7:1944627	MAD1L1	-0.53	-6.18	-0.38	2.83e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs11155671	0.530	rs9383577	chr6:150207195	C/T	cg09699651	chr6:150184138	LRP11	0.51	6.55	0.39	3.7e-10	Testicular germ cell tumor;
SARC	cis	rs57994353	0.760	rs4413892	chr9:139330158	G/A	cg14169450	chr9:139327907	INPP5E	0.4	5.12	0.32	6.39e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg00990874	chr7:1149470	C7orf50	-0.61	-6.34	-0.38	1.15e-9	Bronchopulmonary dysplasia;
SARC	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg10295955	chr4:187884368	NA	-1.05	-17.53	-0.75	1.93e-44	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg18404041	chr3:52824283	ITIH1	-0.44	-6.7	-0.4	1.58e-10	Bipolar disorder;
SARC	cis	rs2153535	0.541	rs1414352	chr6:8485547	A/C	cg07606381	chr6:8435919	SLC35B3	0.78	11.07	0.59	3.71e-23	Motion sickness;
SARC	cis	rs72634258	0.945	rs1883679	chr1:8100451	T/G	cg00042356	chr1:8021962	PARK7	0.91	8.4	0.48	4.38e-15	Inflammatory bowel disease;
SARC	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg25427524	chr10:38739819	LOC399744	-0.54	-8.38	-0.48	5.16e-15	Extrinsic epigenetic age acceleration;
SARC	cis	rs7714584	1.000	rs4958842	chr5:150224877	G/A	cg22134413	chr5:150180641	NA	0.87	6.97	0.42	3.16e-11	Crohn's disease;
SARC	cis	rs2439831	0.867	rs2245715	chr15:43818052	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.95	8.87	0.5	1.93e-16	Lung cancer in ever smokers;
SARC	cis	rs8014204	0.566	rs12587457	chr14:75164141	C/T	cg17347104	chr14:75034677	LTBP2	-0.5	-6.79	-0.41	9.12e-11	Caffeine consumption;
SARC	cis	rs62344088	0.590	rs60845955	chr5:185094	C/T	cg20965017	chr5:231967	SDHA	-0.7	-5.22	-0.32	4.04e-7	Asthma (childhood onset);
SARC	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg26335602	chr6:28129616	ZNF389	0.52	5.88	0.36	1.44e-8	Depression;
SARC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.0	12.26	0.63	5.27e-27	Platelet count;
SARC	cis	rs11252926	0.527	rs10904093	chr10:436848	A/G	cg08603382	chr10:743973	NA	-0.39	-5.06	-0.31	8.3e-7	Psychosis in Alzheimer's disease;
SARC	cis	rs709400	0.628	rs10141120	chr14:103923008	T/C	cg26031613	chr14:104095156	KLC1	0.82	11.95	0.62	5.63e-26	Body mass index;
SARC	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.8	-11.3	-0.59	6.77e-24	Chronic sinus infection;
SARC	trans	rs61931739	1.000	rs12424741	chr12:34022771	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-6.83	-0.41	7.35e-11	Morning vs. evening chronotype;
SARC	trans	rs61931739	0.534	rs11053016	chr12:34104372	C/T	cg13010199	chr12:38710504	ALG10B	0.77	10.37	0.56	5.83e-21	Morning vs. evening chronotype;
SARC	cis	rs1568889	1.000	rs16917689	chr11:28064466	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	10.33	0.56	7.9e-21	Bipolar disorder;
SARC	cis	rs9309473	0.950	rs6546853	chr2:73833739	G/A	cg07208825	chr2:73871855	ALMS1P	0.35	5.14	0.32	5.87e-7	Metabolite levels;
SARC	cis	rs662064	0.963	rs10864459	chr1:10563609	C/T	cg07384165	chr1:10488281	NA	0.41	4.81	0.3	2.75e-6	Asthma;
SARC	cis	rs9467773	1.000	rs1884946	chr6:26545308	C/G	cg11502198	chr6:26597334	ABT1	0.46	5.55	0.34	7.63e-8	Intelligence (multi-trait analysis);
SARC	cis	rs10876993	0.806	rs1689598	chr12:58050500	G/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.48	-6.08	-0.37	4.99e-9	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs7084402	0.967	rs1658424	chr10:60331588	G/A	cg07615347	chr10:60278583	BICC1	0.57	8.42	0.48	3.91e-15	Refractive error;
SARC	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg24549020	chr5:56110836	MAP3K1	0.81	8.4	0.48	4.37e-15	Initial pursuit acceleration;
SARC	cis	rs10791323	0.569	rs10791328	chr11:133713730	A/G	cg15485101	chr11:133734466	NA	0.35	5.28	0.33	2.96e-7	Childhood ear infection;
SARC	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg07636037	chr3:49044803	WDR6	0.81	7.47	0.44	1.64e-12	Menarche (age at onset);
SARC	cis	rs2370759	1.000	rs16933177	chr10:32565705	G/A	cg18270830	chr10:32634957	EPC1	0.65	5.8	0.35	2.2e-8	Sexual dysfunction (female);
SARC	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg00149659	chr3:10157352	C3orf10	-0.64	-6.02	-0.37	6.85e-9	Alzheimer's disease;
SARC	cis	rs7223966	0.960	rs113155878	chr17:61706560	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	6.53	0.39	3.98e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg11168104	chr5:1857477	NA	-0.35	-5.22	-0.32	4.02e-7	Cardiovascular disease risk factors;
SARC	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg04317338	chr11:64019027	PLCB3	-0.83	-9.21	-0.52	2e-17	Mean platelet volume;
SARC	cis	rs2486288	0.656	rs12904150	chr15:45547605	T/C	cg15395560	chr15:45543142	SLC28A2	0.29	5.59	0.34	6.44e-8	Glomerular filtration rate;
SARC	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg11987759	chr7:65425863	GUSB	0.43	5.71	0.35	3.37e-8	Calcium levels;
SARC	trans	rs4915077	0.504	rs10494071	chr1:108202879	C/T	cg02129737	chr3:17131888	PLCL2	0.82	6.35	0.38	1.12e-9	Hypothyroidism;
SARC	cis	rs643506	1.000	rs1788955	chr11:111630998	C/G	cg09085632	chr11:111637200	PPP2R1B	0.52	5.86	0.36	1.54e-8	Breast cancer;
SARC	cis	rs7586879	1.000	rs7586879	chr2:25116977	C/T	cg04586622	chr2:25135609	ADCY3	0.29	4.76	0.3	3.41e-6	Body mass index;
SARC	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg11489262	chr17:43973426	MAPT;LOC100128977;LOC100130148	0.44	4.73	0.3	3.83e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg05368731	chr17:41323189	NBR1	0.81	9.93	0.55	1.36e-19	Menopause (age at onset);
SARC	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg17294928	chr15:75287854	SCAMP5	0.48	6.11	0.37	4.25e-9	Breast cancer;
SARC	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg24675658	chr1:53192096	ZYG11B	0.58	8.09	0.47	3.22e-14	Monocyte count;
SARC	cis	rs9296092	0.538	rs112113649	chr6:33524529	A/G	cg13560919	chr6:33536144	NA	-0.51	-6.24	-0.38	2e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs1008375	0.897	rs67455495	chr4:17665238	A/T	cg02297831	chr4:17616191	MED28	-0.43	-5.28	-0.33	2.93e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9326248	0.954	rs521171	chr11:117064693	C/G	cg01368799	chr11:117014884	PAFAH1B2	0.48	5.5	0.34	9.95e-8	Blood protein levels;
SARC	cis	rs2230307	0.656	rs114775204	chr1:100463030	T/C	cg24955406	chr1:100503596	HIAT1	0.71	5.83	0.36	1.83e-8	Carotid intima media thickness;
SARC	cis	rs7624766	0.743	rs6805905	chr3:160496362	G/A	cg22637730	chr3:160473554	PPM1L	0.44	5.72	0.35	3.2e-8	Response to methotrexate in rheumatoid arthritis;
SARC	cis	rs80130819	0.748	rs2732446	chr12:48690177	T/C	cg05342945	chr12:48394962	COL2A1	-0.54	-5.66	-0.35	4.34e-8	Prostate cancer;
SARC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg07308232	chr7:1071921	C7orf50	-0.65	-8.36	-0.48	5.55e-15	Longevity;Endometriosis;
SARC	cis	rs4803468	1.000	rs2241709	chr19:41912250	C/T	cg09537434	chr19:41945824	ATP5SL	-0.97	-17.07	-0.75	6.11e-43	Height;
SARC	cis	rs9322193	0.607	rs4869755	chr6:150207483	G/A	cg05036130	chr6:150231994	NA	0.33	4.92	0.31	1.62e-6	Lung cancer;
SARC	cis	rs11191193	0.555	rs5003331	chr10:103754150	G/A	cg15320455	chr10:103880129	LDB1	0.58	6.05	0.37	5.79e-9	Educational attainment;
SARC	cis	rs9815354	1.000	rs9874513	chr3:41909508	G/A	cg03022575	chr3:42003672	ULK4	0.67	5.73	0.35	3.13e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs35213789	0.878	rs12698835	chr7:69479123	T/C	cg10619644	chr7:69149951	AUTS2	0.44	5.42	0.33	1.45e-7	Childhood ear infection;
SARC	cis	rs12545109	0.800	rs2670055	chr8:57421575	T/C	cg21220214	chr8:57350948	NA	-0.4	-4.82	-0.3	2.53e-6	Obesity-related traits;
SARC	cis	rs9916302	0.706	rs2338799	chr17:37513941	G/A	cg07936489	chr17:37558343	FBXL20	0.76	9.22	0.52	1.85e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs7617773	0.780	rs13081169	chr3:48356797	G/A	cg11946769	chr3:48343235	NME6	0.76	9.7	0.54	6.55e-19	Coronary artery disease;
SARC	cis	rs448720	0.776	rs1001870	chr15:68151448	C/T	cg05925327	chr15:68127851	NA	-0.35	-5.05	-0.31	9.08e-7	Cognitive performance;
SARC	cis	rs9660992	0.573	rs12126439	chr1:205200720	C/T	cg21545522	chr1:205238299	TMCC2	0.39	5.34	0.33	2.25e-7	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs11764590	0.694	rs60626033	chr7:2099719	A/G	cg23043544	chr7:2124092	MAD1L1	-0.35	-4.85	-0.3	2.27e-6	Neuroticism;
SARC	cis	rs8180040	0.715	rs6772670	chr3:47191349	G/A	cg02527881	chr3:46936655	PTH1R	-0.32	-4.97	-0.31	1.28e-6	Colorectal cancer;
SARC	cis	rs9911578	1.000	rs304270	chr17:56802141	A/G	cg05425664	chr17:57184151	TRIM37	0.67	8.31	0.48	7.79e-15	Intelligence (multi-trait analysis);
SARC	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg00933542	chr6:150070202	PCMT1	0.31	4.96	0.31	1.34e-6	Lung cancer;
SARC	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg11987759	chr7:65425863	GUSB	-0.59	-7.96	-0.46	7.73e-14	Aortic root size;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg21878890	chr14:75725895	NA	0.53	6.56	0.39	3.49e-10	Breast cancer;
SARC	cis	rs34779708	0.931	rs68039650	chr10:35385499	C/A	cg03585969	chr10:35415529	CREM	0.41	4.98	0.31	1.21e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs754466	0.580	rs2289311	chr10:79565655	G/A	cg17075019	chr10:79541650	NA	-0.82	-12.52	-0.63	7.52e-28	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg07308232	chr7:1071921	C7orf50	-0.49	-5.69	-0.35	3.73e-8	Longevity;Endometriosis;
SARC	cis	rs35213789	0.853	rs7796857	chr7:69271347	T/G	cg10619644	chr7:69149951	AUTS2	0.37	4.77	0.3	3.21e-6	Childhood ear infection;
SARC	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg26874164	chr19:58962979	ZNF324B	0.48	6.22	0.38	2.29e-9	Uric acid clearance;
SARC	cis	rs1983891	0.874	rs3747744	chr6:41516351	A/G	cg15051332	chr6:41514432	FOXP4	0.55	5.92	0.36	1.17e-8	Prostate cancer;
SARC	cis	rs1008375	0.931	rs6831211	chr4:17697009	G/A	cg16339924	chr4:17578868	LAP3	0.52	6.67	0.4	1.8e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg08219700	chr8:58056026	NA	0.62	6.52	0.39	4.42e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9790314	0.613	rs13086250	chr3:160631965	G/A	cg04691961	chr3:161091175	C3orf57	0.54	7.5	0.44	1.32e-12	Morning vs. evening chronotype;
SARC	cis	rs7312933	0.618	rs7954523	chr12:42681508	A/G	cg19980929	chr12:42632907	YAF2	0.45	6.52	0.39	4.24e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg26338869	chr17:61819248	STRADA	0.77	10.04	0.55	6.07e-20	Prudent dietary pattern;
SARC	trans	rs9650657	0.836	rs4841438	chr8:10606756	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.63	-0.4	2.28e-10	Neuroticism;
SARC	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg24829409	chr8:58192753	C8orf71	-0.61	-6.57	-0.4	3.34e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg12463550	chr7:65579703	CRCP	0.69	5.24	0.32	3.57e-7	Diabetic kidney disease;
SARC	cis	rs6831352	0.918	rs17817359	chr4:100054197	G/T	cg12011299	chr4:100065546	ADH4	-0.34	-5.74	-0.35	2.95e-8	Alcohol dependence;
SARC	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg04267008	chr7:1944627	MAD1L1	-0.5	-5.78	-0.35	2.33e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs4588572	0.601	rs6867673	chr5:77779125	A/G	cg11547950	chr5:77652471	NA	-0.42	-5.13	-0.32	6.13e-7	Triglycerides;
SARC	cis	rs6540556	0.608	rs2205985	chr1:209912100	A/G	cg23920097	chr1:209922102	NA	-0.5	-5.95	-0.36	9.93e-9	Red blood cell count;
SARC	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg18252515	chr7:66147081	NA	-1.33	-11.82	-0.61	1.46e-25	Diabetic kidney disease;
SARC	cis	rs1401999	1.000	rs2872249	chr3:183636273	T/A	cg01324343	chr3:183735012	ABCC5	0.68	13.97	0.68	1.29e-32	Anterior chamber depth;
SARC	cis	rs8114671	0.562	rs2064454	chr20:33496169	C/T	cg08999081	chr20:33150536	PIGU	0.33	4.74	0.3	3.76e-6	Height;
SARC	cis	rs9943753	0.525	rs7952909	chr12:109808573	A/T	cg19025524	chr12:109796872	NA	0.39	5.66	0.35	4.43e-8	HDL cholesterol;
SARC	cis	rs9435341	0.762	rs2878349	chr1:107549245	G/A	cg09367891	chr1:107599246	PRMT6	0.68	8.27	0.48	1.04e-14	Facial morphology (factor 21, depth of nasal alae);
SARC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	21.1	0.81	5.74e-56	Prudent dietary pattern;
SARC	cis	rs1003719	0.788	rs2835599	chr21:38466937	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.7	0.5	5.92e-16	Eye color traits;
SARC	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg22857025	chr5:266934	NA	-1.1	-12.02	-0.62	3.17e-26	Breast cancer;
SARC	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg05896524	chr21:47604654	C21orf56	0.55	6.61	0.4	2.55e-10	Testicular germ cell tumor;
SARC	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg17221315	chr6:27791827	HIST1H4J	0.45	4.75	0.3	3.57e-6	Depression;
SARC	cis	rs9435341	0.930	rs61798463	chr1:107565934	G/A	cg09367891	chr1:107599246	PRMT6	0.73	9.34	0.52	7.81e-18	Facial morphology (factor 21, depth of nasal alae);
SARC	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg10207240	chr12:122356781	WDR66	0.3	4.96	0.31	1.35e-6	Mean corpuscular volume;
SARC	trans	rs61931739	0.793	rs609886	chr12:34138160	T/G	cg26384229	chr12:38710491	ALG10B	0.6	7.93	0.46	9.2e-14	Morning vs. evening chronotype;
SARC	cis	rs36051895	0.658	rs72699568	chr9:5007138	C/T	cg02405213	chr9:5042618	JAK2	-0.55	-6.36	-0.38	1.07e-9	Pediatric autoimmune diseases;
SARC	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg18876405	chr7:65276391	NA	0.7	8.7	0.5	6.12e-16	Aortic root size;
SARC	cis	rs36051895	0.664	rs3780369	chr9:5095095	A/C	cg02405213	chr9:5042618	JAK2	-0.47	-5.69	-0.35	3.74e-8	Pediatric autoimmune diseases;
SARC	cis	rs4253772	0.550	rs6007779	chr22:46678615	A/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.73	7.52	0.44	1.21e-12	LDL cholesterol;Cholesterol, total;
SARC	cis	rs921968	0.565	rs6436070	chr2:219597960	A/G	cg02176678	chr2:219576539	TTLL4	-0.34	-5.14	-0.32	5.83e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs2658782	0.688	rs2658768	chr11:93250827	T/C	cg15737290	chr11:93063684	CCDC67	0.77	8.47	0.49	2.82e-15	Pulmonary function decline;
SARC	cis	rs9393692	0.875	rs9358917	chr6:26284417	T/C	cg13736514	chr6:26305472	NA	-0.6	-8.35	-0.48	5.94e-15	Educational attainment;
SARC	cis	rs7647973	1.000	rs7644148	chr3:49545241	G/A	cg07636037	chr3:49044803	WDR6	-0.76	-8.65	-0.49	8.36e-16	Menarche (age at onset);
SARC	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg07343612	chr16:622815	PIGQ	-0.62	-8.65	-0.49	8.38e-16	Height;
SARC	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.6	-6.31	-0.38	1.42e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs78487399	0.808	rs17030800	chr2:43671003	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.14	-0.32	5.7e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	trans	rs8073060	0.586	rs4795086	chr17:34042190	G/A	cg19694781	chr19:47549865	TMEM160	0.71	6.91	0.41	4.64e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs6545883	0.929	rs10200055	chr2:61628017	T/A	cg15711740	chr2:61764176	XPO1	0.41	5.06	0.31	8.68e-7	Tuberculosis;
SARC	cis	rs7296418	0.961	rs1790094	chr12:123586688	T/C	cg05973401	chr12:123451056	ABCB9	0.62	7.6	0.45	7.26e-13	Platelet count;
SARC	cis	rs6693567	0.565	rs834243	chr1:150339290	C/A	cg09579323	chr1:150459698	TARS2	0.45	5.83	0.36	1.83e-8	Migraine;
SARC	cis	rs4926611	0.698	rs10888795	chr1:54061446	A/G	cg08927728	chr1:54059983	GLIS1	-0.31	-5.17	-0.32	5.1e-7	Hand grip strength;
SARC	cis	rs16937	0.711	rs10751429	chr1:205107478	C/T	cg00857998	chr1:205179979	DSTYK	0.4	4.72	0.3	4.16e-6	Schizophrenia;
SARC	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg22508957	chr16:3507546	NAT15	0.37	5.39	0.33	1.73e-7	Tuberculosis;
SARC	cis	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg14541582	chr5:601475	NA	-0.41	-5.15	-0.32	5.42e-7	Obesity-related traits;
SARC	cis	rs17253792	0.822	rs10148983	chr14:56051879	A/G	cg01858014	chr14:56050164	KTN1	-0.68	-4.9	-0.31	1.81e-6	Putamen volume;
SARC	cis	rs8180040	0.701	rs7617689	chr3:46996442	C/T	cg27129171	chr3:47204927	SETD2	-0.64	-9.11	-0.51	3.84e-17	Colorectal cancer;
SARC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.54	6.14	0.37	3.56e-9	Prudent dietary pattern;
SARC	cis	rs10512697	0.803	rs11742420	chr5:3579874	A/C	cg19473799	chr5:3511975	NA	-0.63	-4.8	-0.3	2.84e-6	Immune response to smallpox vaccine (IL-6);
SARC	cis	rs7584330	0.737	rs13397017	chr2:238361241	G/A	cg14458575	chr2:238380390	NA	0.46	5.73	0.35	3.03e-8	Prostate cancer;
SARC	cis	rs2228479	0.717	rs1061647	chr16:89806063	G/C	cg00800038	chr16:89945340	TCF25	-0.74	-5.03	-0.31	9.61e-7	Skin colour saturation;
SARC	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg21782813	chr7:2030301	MAD1L1	0.44	7.0	0.42	2.76e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs6446731	0.593	rs2157090	chr4:3273110	C/T	cg06533319	chr4:3265114	C4orf44	-0.33	-5.36	-0.33	1.97e-7	Mean platelet volume;
SARC	cis	rs17376456	0.877	rs55832164	chr5:93436579	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.71	0.35	3.39e-8	Diabetic retinopathy;
SARC	cis	rs35110281	0.548	rs2838350	chr21:45109972	T/C	cg01579765	chr21:45077557	HSF2BP	-0.39	-6.37	-0.39	9.73e-10	Mean corpuscular volume;
SARC	cis	rs2180341	0.824	rs9321076	chr6:127655614	G/A	cg24812749	chr6:127587940	RNF146	0.98	13.14	0.65	7.1e-30	Breast cancer;
SARC	cis	rs4253772	0.591	rs6008384	chr22:46655948	T/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.64	7.09	0.42	1.61e-11	LDL cholesterol;Cholesterol, total;
SARC	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg11764359	chr7:65958608	NA	0.86	12.33	0.63	3.29e-27	Aortic root size;
SARC	cis	rs1059312	0.966	rs12370194	chr12:129277250	A/T	cg09035930	chr12:129282057	SLC15A4	0.57	8.25	0.48	1.14e-14	Systemic lupus erythematosus;
SARC	cis	rs798554	0.591	rs1182156	chr7:2901084	G/T	cg04166393	chr7:2884313	GNA12	0.5	6.11	0.37	4.04e-9	Height;
SARC	cis	rs1707322	0.686	rs1541131	chr1:46084934	G/A	cg03146154	chr1:46216737	IPP	-0.51	-6.12	-0.37	4.02e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs11098499	0.954	rs10017371	chr4:120293776	A/G	cg09307838	chr4:120376055	NA	0.87	11.92	0.62	7.06e-26	Corneal astigmatism;
SARC	cis	rs3741404	0.537	rs1123251	chr11:63917601	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.54	-7.12	-0.42	1.32e-11	Platelet count;
SARC	cis	rs875971	0.545	rs10950025	chr7:65623933	G/A	cg25894440	chr7:65020034	NA	0.51	4.74	0.3	3.69e-6	Aortic root size;
SARC	cis	rs9640161	0.789	rs10952250	chr7:150025966	T/C	cg10018233	chr7:150070692	REPIN1	0.7	9.9	0.54	1.68e-19	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs2273669	0.667	rs3734649	chr6:109294752	C/T	cg05315195	chr6:109294784	ARMC2	-0.59	-5.33	-0.33	2.34e-7	Prostate cancer;
SARC	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg12705353	chr12:122356852	WDR66	0.4	5.79	0.35	2.24e-8	Mean corpuscular volume;
SARC	cis	rs2239547	0.563	rs9876403	chr3:52916916	C/T	cg11645453	chr3:52864694	ITIH4	0.33	5.13	0.32	6.05e-7	Schizophrenia;
SARC	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg03351412	chr1:154909251	PMVK	0.62	8.06	0.47	4.07e-14	Prostate cancer;
SARC	cis	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg12064134	chr16:90016061	DEF8	-0.59	-5.05	-0.31	8.75e-7	Skin colour saturation;
SARC	cis	rs7208859	0.614	rs216474	chr17:28865091	C/T	cg13385521	chr17:29058706	SUZ12P	-0.59	-4.96	-0.31	1.37e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs747650	0.892	rs7111764	chr11:47233209	G/A	cg03339077	chr11:47165057	C11orf49	-0.45	-6.2	-0.38	2.55e-9	Acne (severe);
SARC	cis	rs765787	0.530	rs16941017	chr15:45543281	T/C	cg25801113	chr15:45476975	SHF	0.29	4.88	0.3	2e-6	Uric acid levels;
SARC	cis	rs72945132	0.882	rs7935969	chr11:70194175	G/A	cg00319359	chr11:70116639	PPFIA1	0.67	6.17	0.37	2.95e-9	Coronary artery disease;
SARC	cis	rs2652834	1.000	rs2729780	chr15:63404639	C/G	cg05507819	chr15:63340323	TPM1	0.57	5.67	0.35	4.16e-8	HDL cholesterol;
SARC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.54	6.21	0.38	2.43e-9	Prudent dietary pattern;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg13690003	chr13:45767909	GTF2F2;KCTD4	0.48	6.77	0.41	1.06e-10	Thyroid stimulating hormone;
SARC	cis	rs12044355	0.865	rs2487453	chr1:231863204	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.52	6.86	0.41	6.11e-11	Alzheimer's disease;
SARC	cis	rs910316	1.000	rs4322591	chr14:75600697	C/T	cg23033748	chr14:75592666	NEK9	0.37	5.3	0.33	2.73e-7	Height;
SARC	cis	rs933688	1.000	rs35712350	chr5:90679519	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.04	13.23	0.65	3.51e-30	Smoking behavior;
SARC	trans	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	7.03	0.42	2.21e-11	Intelligence (multi-trait analysis);
SARC	cis	rs921968	0.643	rs645796	chr2:219389236	A/G	cg02176678	chr2:219576539	TTLL4	0.36	5.59	0.34	6.18e-8	Mean corpuscular hemoglobin concentration;
SARC	cis	rs35849525	0.814	rs35491931	chr3:49993462	T/A	cg14019146	chr3:50243930	SLC38A3	-0.39	-5.52	-0.34	8.96e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7592578	0.771	rs10432434	chr2:191387079	T/G	cg10560079	chr2:191398806	TMEM194B	-0.77	-8.55	-0.49	1.64e-15	Diastolic blood pressure;
SARC	cis	rs10927875	0.800	rs1627145	chr1:16328116	C/T	cg21385522	chr1:16154831	NA	0.7	9.07	0.51	5.19e-17	Dilated cardiomyopathy;
SARC	cis	rs2072499	0.966	rs11587860	chr1:156156951	G/C	cg24450063	chr1:156163899	SLC25A44	1.15	20.02	0.8	1.55e-52	Testicular germ cell tumor;
SARC	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg11062466	chr8:58055876	NA	0.52	5.4	0.33	1.64e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7561149	0.768	rs6709708	chr2:179729081	C/T	cg17765952	chr2:179737173	CCDC141	-0.46	-6.25	-0.38	1.91e-9	QT interval;
SARC	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-8.17	-0.47	2.01e-14	Alzheimer's disease;
SARC	cis	rs2439831	0.614	rs2467733	chr15:43693328	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.75	7.82	0.46	1.88e-13	Lung cancer in ever smokers;
SARC	cis	rs2070488	0.662	rs7375040	chr3:38469116	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.62	8.2	0.47	1.66e-14	Electrocardiographic conduction measures;
SARC	cis	rs2832191	0.791	rs9983651	chr21:30491227	T/A	cg24692254	chr21:30365293	RNF160	-0.88	-12.46	-0.63	1.2e-27	Dental caries;
SARC	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg25894440	chr7:65020034	NA	-0.69	-5.3	-0.33	2.69e-7	Diabetic kidney disease;
SARC	cis	rs739401	0.588	rs10219272	chr11:3020789	G/A	cg05729581	chr11:3078854	CARS	-0.5	-6.67	-0.4	1.87e-10	Longevity;
SARC	cis	rs9640161	0.789	rs6964110	chr7:150041836	A/C	cg10018233	chr7:150070692	REPIN1	0.58	7.74	0.45	3.08e-13	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg11764359	chr7:65958608	NA	0.88	12.58	0.64	4.89e-28	Aortic root size;
SARC	cis	rs1055129	0.516	rs7218498	chr17:73931847	C/G	cg06969265	chr17:73775802	H3F3B	0.45	5.55	0.34	7.66e-8	White matter hyperintensity burden;
SARC	cis	rs7582180	0.627	rs2241811	chr2:101011724	C/T	cg14675211	chr2:100938903	LONRF2	0.54	7.89	0.46	1.15e-13	Intelligence (multi-trait analysis);
SARC	cis	rs2228479	0.717	rs34027607	chr16:89808939	T/C	cg00800038	chr16:89945340	TCF25	-0.66	-5.1	-0.32	7.1e-7	Skin colour saturation;
SARC	cis	rs2841277	0.834	rs2841281	chr14:105394669	C/T	cg21017887	chr14:105400489	NA	-0.54	-7.5	-0.44	1.34e-12	Rheumatoid arthritis;
SARC	cis	rs7208859	0.623	rs9916727	chr17:29107472	A/G	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	trans	rs3945119	0.808	rs1335734	chr1:91155742	G/A	cg01730148	chr2:3698421	NA	0.34	6.42	0.39	7.7e-10	Intelligence (multi-trait analysis);
SARC	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg14582100	chr15:45693742	SPATA5L1	0.35	4.91	0.31	1.69e-6	Homoarginine levels;
SARC	cis	rs9815354	0.812	rs73830516	chr3:41876056	A/G	cg03022575	chr3:42003672	ULK4	0.7	5.76	0.35	2.69e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2115630	0.764	rs11073716	chr15:85335774	C/T	cg12501888	chr15:85177176	SCAND2	-0.46	-5.36	-0.33	2.02e-7	P wave terminal force;
SARC	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg24503407	chr1:205819492	PM20D1	0.43	4.99	0.31	1.17e-6	Parkinson's disease;
SARC	cis	rs7918232	0.882	rs10829190	chr10:27409555	C/T	cg14442939	chr10:27389572	ANKRD26	0.64	5.73	0.35	3.1e-8	Breast cancer;
SARC	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg03982820	chr1:40723960	ZMPSTE24	0.48	6.29	0.38	1.56e-9	Thyroid stimulating hormone;
SARC	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg18404041	chr3:52824283	ITIH1	-0.43	-6.53	-0.39	4.04e-10	Bipolar disorder;
SARC	cis	rs6815814	0.950	rs113465719	chr4:38808045	A/T	cg02016764	chr4:38805732	TLR1	-0.42	-4.89	-0.31	1.89e-6	Breast cancer;
SARC	cis	rs9790314	0.718	rs9847866	chr3:160758275	A/G	cg03342759	chr3:160939853	NMD3	-0.42	-5.02	-0.31	1.01e-6	Morning vs. evening chronotype;
SARC	cis	rs3008870	0.755	rs2755271	chr1:67474977	C/T	cg02640540	chr1:67518911	SLC35D1	0.46	5.28	0.33	2.98e-7	Lymphocyte percentage of white cells;
SARC	cis	rs7639513	0.767	rs6784168	chr3:12702847	T/G	cg23032965	chr3:12705835	RAF1	0.84	12.29	0.63	4.17e-27	Itch intensity from mosquito bite;
SARC	cis	rs8078723	1.000	rs2227336	chr17:38174855	T/G	cg17467752	chr17:38218738	THRA	0.47	5.96	0.36	9.44e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs478304	0.580	rs11606947	chr11:65508237	A/C	cg27068330	chr11:65405492	SIPA1	-0.39	-4.77	-0.3	3.3e-6	Acne (severe);
SARC	cis	rs1003719	0.679	rs2246285	chr21:38582431	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-8.76	-0.5	4.05e-16	Eye color traits;
SARC	trans	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg20587970	chr11:113659929	NA	-1.38	-13.71	-0.67	8.88e-32	Hip circumference adjusted for BMI;
SARC	cis	rs12142240	0.660	rs112560929	chr1:46822297	A/G	cg14993813	chr1:46806288	NSUN4	-0.51	-5.34	-0.33	2.19e-7	Menopause (age at onset);
SARC	cis	rs4481887	0.861	rs6669290	chr1:248476804	G/A	cg00666640	chr1:248458726	OR2T12	0.34	5.7	0.35	3.65e-8	Common traits (Other);
SARC	cis	rs4481887	0.927	rs4381224	chr1:248456826	A/T	cg00666640	chr1:248458726	OR2T12	0.35	5.73	0.35	3.14e-8	Common traits (Other);
SARC	trans	rs9329221	0.537	rs13282106	chr8:9981900	G/T	cg06636001	chr8:8085503	FLJ10661	0.53	7.32	0.43	3.95e-12	Neuroticism;
SARC	cis	rs4820539	1.000	rs4820539	chr22:23477970	C/T	cg14186256	chr22:23484241	RTDR1	-0.83	-13.09	-0.65	1e-29	Bone mineral density;
SARC	cis	rs72627123	0.867	rs118113209	chr14:74432158	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.73	5.53	0.34	8.48e-8	Morning vs. evening chronotype;
SARC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg01238044	chr22:24384105	GSTT1	-0.52	-5.92	-0.36	1.15e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7584330	0.868	rs67071074	chr2:238395429	T/C	cg11271282	chr2:238384023	NA	0.48	5.48	0.34	1.12e-7	Prostate cancer;
SARC	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg00149659	chr3:10157352	C3orf10	0.64	5.91	0.36	1.22e-8	Alzheimer's disease;
SARC	cis	rs1408799	0.695	rs10756395	chr9:12723937	G/A	cg05274944	chr9:12693694	TYRP1	0.35	5.2	0.32	4.28e-7	Eye color;Blue vs. green eyes;
SARC	cis	rs929354	1.000	rs1182385	chr7:157040583	C/T	cg05182265	chr7:156933206	UBE3C	0.32	4.93	0.31	1.53e-6	Body mass index;
SARC	cis	rs3820928	0.804	rs4144327	chr2:227790262	C/T	cg05526886	chr2:227700861	RHBDD1	-0.54	-6.64	-0.4	2.19e-10	Pulmonary function;
SARC	cis	rs73086581	0.787	rs67724338	chr20:3869057	A/G	cg02187196	chr20:3869020	PANK2	0.67	5.88	0.36	1.38e-8	Response to antidepressants in depression;
SARC	cis	rs5758659	0.569	rs133293	chr22:42382797	G/A	cg04733989	chr22:42467013	NAGA	0.49	6.65	0.4	2.06e-10	Cognitive function;
SARC	cis	rs7216064	0.906	rs8074644	chr17:65878217	G/C	cg12091567	chr17:66097778	LOC651250	-0.7	-7.64	-0.45	5.5e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs950776	0.518	rs2869055	chr15:78822388	G/C	cg06917634	chr15:78832804	PSMA4	-0.86	-13.38	-0.66	1.11e-30	Sudden cardiac arrest;
SARC	cis	rs7264396	0.563	rs6060592	chr20:34352414	C/G	cg01084648	chr20:34329383	RBM39	0.61	4.92	0.31	1.65e-6	Total cholesterol levels;
SARC	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.15	-0.55	2.75e-20	Chronic sinus infection;
SARC	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg12310025	chr6:25882481	NA	0.39	5.21	0.32	4.08e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg18404041	chr3:52824283	ITIH1	-0.42	-6.29	-0.38	1.53e-9	Bipolar disorder;
SARC	cis	rs13256369	0.851	rs13266562	chr8:8564065	T/C	cg18904891	chr8:8559673	CLDN23	0.49	5.55	0.34	7.83e-8	Obesity-related traits;
SARC	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6089584	0.927	rs2281734	chr20:60582401	C/A	cg06108461	chr20:60628389	TAF4	-0.89	-11.84	-0.61	1.21e-25	Body mass index;
SARC	cis	rs7412746	0.621	rs72704656	chr1:150828307	A/G	cg13175981	chr1:150552382	MCL1	-0.55	-6.77	-0.41	1.06e-10	Melanoma;
SARC	cis	rs55794721	0.509	rs909834	chr1:25757996	A/G	cg27572855	chr1:25598939	RHD	0.51	8.63	0.49	9.770000000000001e-16	Plateletcrit;Mean corpuscular volume;
SARC	cis	rs10504229	0.593	rs7000752	chr8:58026980	C/G	cg08219700	chr8:58056026	NA	0.63	6.4	0.39	8.42e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs17030434	0.654	rs1530105	chr4:154646994	C/T	cg14289246	chr4:154710475	SFRP2	0.55	5.56	0.34	7.3e-8	Electrocardiographic conduction measures;
SARC	cis	rs4234284	0.556	rs4679147	chr3:126955702	C/T	cg27326032	chr3:127006922	NA	-0.51	-5.74	-0.35	2.92e-8	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
SARC	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg06212747	chr3:49208901	KLHDC8B	0.66	8.73	0.5	5.12e-16	Parkinson's disease;
SARC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.54	6.14	0.37	3.48e-9	Prudent dietary pattern;
SARC	cis	rs1318878	0.589	rs12297543	chr12:15512864	T/G	cg08258403	chr12:15378311	NA	0.48	6.67	0.4	1.87e-10	Intelligence (multi-trait analysis);
SARC	cis	rs9916302	0.904	rs11078897	chr17:37415870	C/T	cg07936489	chr17:37558343	FBXL20	-0.68	-9.2	-0.52	2.04e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs11997175	0.692	rs6995075	chr8:33673816	G/A	ch.8.33884649F	chr8:33765107	NA	0.53	7.08	0.42	1.71e-11	Body mass index;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg13457403	chr21:44313401	NDUFV3	0.63	6.49	0.39	5.17e-10	Lung cancer in ever smokers;
SARC	cis	rs4780401	0.587	rs9931332	chr16:11807517	G/C	cg01061890	chr16:11836724	TXNDC11	-0.61	-8.7	-0.5	6.01e-16	Rheumatoid arthritis;
SARC	cis	rs1448094	0.556	rs61930626	chr12:86167445	A/G	cg00310523	chr12:86230176	RASSF9	0.32	4.96	0.31	1.38e-6	Major depressive disorder;
SARC	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg16405210	chr4:1374714	KIAA1530	-0.52	-6.45	-0.39	6.26e-10	Longevity;
SARC	cis	rs7264396	0.563	rs2425089	chr20:34304036	G/A	cg01084648	chr20:34329383	RBM39	0.57	4.95	0.31	1.45e-6	Total cholesterol levels;
SARC	trans	rs1994135	0.630	rs11052760	chr12:33724949	A/T	cg26384229	chr12:38710491	ALG10B	0.85	10.48	0.57	2.72e-21	Resting heart rate;
SARC	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg11644478	chr21:40555479	PSMG1	-0.9	-11.73	-0.61	2.83e-25	Cognitive function;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg06458092	chr7:120497559	TSPAN12	0.51	6.37	0.39	9.8e-10	Lung adenocarcinoma;
SARC	cis	rs73206853	0.841	rs57821814	chr12:110829254	A/C	cg10860002	chr12:110842031	ANAPC7	0.64	5.02	0.31	1.04e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	trans	rs1814175	0.791	rs7395713	chr11:49877887	A/G	cg03929089	chr4:120376271	NA	-0.89	-14.53	-0.69	1.73e-34	Height;
SARC	cis	rs3857536	0.776	rs9294687	chr6:66942919	C/T	cg07460842	chr6:66804631	NA	-0.51	-5.83	-0.36	1.86e-8	Blood trace element (Cu levels);
SARC	cis	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg05623727	chr3:50126028	RBM5	-0.32	-4.74	-0.3	3.76e-6	Body mass index;
SARC	cis	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg26850624	chr5:429559	AHRR	-0.31	-4.77	-0.3	3.21e-6	Cystic fibrosis severity;
SARC	cis	rs4276643	0.531	rs2685410	chr8:27813096	G/A	cg25028855	chr8:28560486	EXTL3	0.31	4.84	0.3	2.38e-6	Low vWF levels;
SARC	cis	rs7208859	0.623	rs1054397	chr17:29110196	T/C	cg13385521	chr17:29058706	SUZ12P	0.89	7.75	0.45	2.84e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs12824058	0.767	rs4759654	chr12:130815559	A/G	cg26677194	chr12:130822605	PIWIL1	0.55	7.57	0.44	8.59e-13	Menopause (age at onset);
SARC	cis	rs2718058	0.639	rs2597270	chr7:37762014	A/G	cg15028436	chr7:37888078	TXNDC3	-0.35	-4.91	-0.31	1.73e-6	Alzheimer's disease (late onset);
SARC	trans	rs9858542	0.903	rs9875617	chr3:49634696	G/A	cg21659725	chr3:3221576	CRBN	-0.55	-6.38	-0.39	9.23e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs41271473	0.500	rs4440831	chr1:228887522	C/T	cg16512390	chr1:228756714	NA	-0.38	-4.81	-0.3	2.76e-6	Chronic lymphocytic leukemia;
SARC	cis	rs208520	0.690	rs207740	chr6:66764132	T/G	cg07460842	chr6:66804631	NA	1.08	14.49	0.69	2.31e-34	Exhaled nitric oxide output;
SARC	cis	rs72634258	0.554	rs35123409	chr1:7878568	C/T	cg26816564	chr1:7831052	VAMP3	0.55	4.78	0.3	3.15e-6	Inflammatory bowel disease;
SARC	cis	rs4737010	0.570	rs7823138	chr8:41644861	C/T	cg08923054	chr8:41654455	ANK1	-0.66	-8.14	-0.47	2.34e-14	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
SARC	cis	rs78545713	1.000	rs41266821	chr6:26247198	A/G	cg00631329	chr6:26305371	NA	-0.73	-6.4	-0.39	8.56e-10	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg11764359	chr7:65958608	NA	-0.6	-6.88	-0.41	5.49e-11	Aortic root size;
SARC	cis	rs4919694	0.572	rs12261294	chr10:104934952	C/T	cg04362960	chr10:104952993	NT5C2	0.59	5.43	0.34	1.41e-7	Arsenic metabolism;
SARC	cis	rs832540	0.931	rs33318	chr5:56208414	G/T	cg14703610	chr5:56206110	C5orf35	0.54	6.95	0.41	3.55e-11	Coronary artery disease;
SARC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	9.23	0.52	1.67e-17	Prudent dietary pattern;
SARC	cis	rs56330463	0.967	rs11948371	chr5:148203108	T/A	cg21580376	chr5:148206412	ADRB2	0.4	5.55	0.34	7.78e-8	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Monocyte percentage of white cells;Eosinophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;
SARC	cis	rs7635838	0.892	rs9310379	chr3:11434143	C/T	cg00170343	chr3:11313890	ATG7	-0.61	-8.3	-0.48	8.47e-15	HDL cholesterol;
SARC	cis	rs763121	0.853	rs2284073	chr22:39105948	T/C	cg21395723	chr22:39101663	GTPBP1	0.57	6.94	0.41	3.96e-11	Menopause (age at onset);
SARC	cis	rs7824557	0.564	rs2736294	chr8:11234626	T/C	cg21775007	chr8:11205619	TDH	-0.65	-8.64	-0.49	9.24e-16	Retinal vascular caliber;
SARC	cis	rs7666738	0.830	rs62321564	chr4:98976496	C/G	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg10029411	chr13:50746245	FAM10A4	-0.76	-6.79	-0.41	9.22e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs13191362	1.000	rs4489133	chr6:163137793	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.72	6.11	0.37	4.25e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs449789	0.857	rs579533	chr6:159715203	C/T	cg14500486	chr6:159655392	FNDC1	-0.44	-5.02	-0.31	1.01e-6	Pulse pressure;
SARC	trans	rs208515	0.525	rs10455593	chr6:66691341	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.99	11.59	0.6	8.2e-25	Exhaled nitric oxide levels;
SARC	cis	rs2230307	0.536	rs496798	chr1:100507990	G/A	cg24955406	chr1:100503596	HIAT1	0.67	6.32	0.38	1.34e-9	Carotid intima media thickness;
SARC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg06873352	chr17:61820015	STRADA	0.53	6.88	0.41	5.32e-11	Prudent dietary pattern;
SARC	cis	rs4595586	0.505	rs12826314	chr12:39379435	A/C	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	cis	rs1395	0.744	rs11686131	chr2:27508710	C/T	cg21747090	chr2:27597821	SNX17	-0.54	-6.31	-0.38	1.42e-9	Blood metabolite levels;
SARC	cis	rs6831352	0.918	rs35662508	chr4:100050974	C/G	cg13256891	chr4:100009986	ADH5	-0.65	-8.11	-0.47	2.83e-14	Alcohol dependence;
SARC	cis	rs7553864	1.000	rs4551570	chr1:87614019	C/A	cg17420885	chr1:87600446	LOC339524	-0.32	-4.74	-0.3	3.76e-6	Smoking behavior;
SARC	cis	rs473651	0.935	rs520765	chr2:239354712	C/T	cg21699342	chr2:239360505	ASB1	0.47	6.52	0.39	4.24e-10	Multiple system atrophy;
SARC	cis	rs9818758	0.607	rs10049462	chr3:49309684	C/T	cg00383909	chr3:49044727	WDR6	0.72	6.24	0.38	2.04e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs16976116	0.901	rs2899580	chr15:55491571	A/G	cg17854078	chr15:55489399	RSL24D1	0.66	6.46	0.39	6.14e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1865760	0.508	rs9379820	chr6:26049924	T/C	cg17691542	chr6:26056736	HIST1H1C	0.54	6.83	0.41	7.13e-11	Height;
SARC	cis	rs7824557	0.527	rs2736298	chr8:11235136	C/G	cg21775007	chr8:11205619	TDH	-0.65	-8.61	-0.49	1.12e-15	Retinal vascular caliber;
SARC	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg18357526	chr6:26021779	HIST1H4A	0.45	5.64	0.35	4.97e-8	Blood metabolite levels;
SARC	cis	rs6988636	1.000	rs28670850	chr8:124189125	A/G	cg23067535	chr8:124195133	FAM83A	-0.69	-5.46	-0.34	1.24e-7	Urinary uromodulin levels;
SARC	cis	rs9611519	0.929	rs9611474	chr22:41434858	G/A	cg03806693	chr22:41940476	POLR3H	-0.61	-7.52	-0.44	1.2e-12	Neuroticism;
SARC	cis	rs1707322	1.000	rs1612419	chr1:46546945	T/C	cg03146154	chr1:46216737	IPP	-0.47	-5.58	-0.34	6.79e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2075371	0.501	rs1643057	chr7:134027521	A/G	cg11752832	chr7:134001865	SLC35B4	0.47	5.92	0.36	1.17e-8	Mean platelet volume;
SARC	cis	rs1008375	1.000	rs2215450	chr4:17675394	T/G	cg02297831	chr4:17616191	MED28	0.43	5.56	0.34	7.42e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg22903471	chr2:27725779	GCKR	-0.48	-7.0	-0.42	2.75e-11	Menopause (age at onset);
SARC	cis	rs611744	0.647	rs615126	chr8:109247619	C/T	cg21045802	chr8:109455806	TTC35	0.61	7.7	0.45	3.89e-13	Dupuytren's disease;
SARC	trans	rs7815944	1.000	rs16902863	chr8:129415706	T/G	cg17342469	chr22:46473074	NA	0.71	6.7	0.4	1.51e-10	Atopic dermatitis;
SARC	cis	rs10504073	0.584	rs11786103	chr8:49904077	A/G	cg00325661	chr8:49890786	NA	0.49	6.66	0.4	2e-10	Blood metabolite ratios;
SARC	cis	rs4727027	0.901	rs1137432	chr7:148801658	C/T	cg23583168	chr7:148888333	NA	-0.74	-10.24	-0.56	1.5e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs13191362	0.872	rs73017702	chr6:163257695	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.62	5.96	0.36	9.45e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2439831	0.867	rs2927072	chr15:43922398	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	7.5	0.44	1.35e-12	Lung cancer in ever smokers;
SARC	cis	rs6088590	1.000	rs11696546	chr20:33452999	C/G	cg24642439	chr20:33292090	TP53INP2	0.79	10.69	0.57	5.93e-22	Coronary artery disease;
SARC	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg12292205	chr6:26970375	C6orf41	-0.56	-6.2	-0.38	2.6e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs713477	1.000	rs28478984	chr14:55911326	C/A	cg13175173	chr14:55914753	NA	-0.3	-4.75	-0.3	3.63e-6	Pediatric bone mineral content (femoral neck);
SARC	cis	rs11579220	1	rs11579220	chr1:205144363	G/T	cg21643547	chr1:205240462	TMCC2	-0.58	-7.37	-0.43	2.93e-12	White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs7607369	0.679	rs6751527	chr2:219630965	C/G	cg02176678	chr2:219576539	TTLL4	0.49	7.74	0.45	2.99e-13	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg04944784	chr2:26401820	FAM59B	-0.48	-5.99	-0.37	7.95e-9	Gut microbiome composition (summer);
SARC	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg25427524	chr10:38739819	LOC399744	-0.61	-9.92	-0.54	1.41e-19	Extrinsic epigenetic age acceleration;
SARC	cis	rs3796352	1.000	rs71301804	chr3:53073314	C/A	cg15956490	chr3:53032818	SFMBT1	0.76	5.35	0.33	2.05e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs15676	1.000	rs15676	chr9:131572027	A/G	cg00228799	chr9:131580591	ENDOG	-0.55	-6.88	-0.41	5.38e-11	Blood metabolite levels;
SARC	cis	rs9905704	0.671	rs4337355	chr17:56950920	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.4	-4.89	-0.3	1.89e-6	Testicular germ cell tumor;
SARC	cis	rs13082711	0.555	rs73038733	chr3:27263537	C/G	cg02860705	chr3:27208620	NA	0.6	7.78	0.45	2.3e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs2243480	1.000	rs709607	chr7:65449541	C/G	cg25894440	chr7:65020034	NA	0.63	4.72	0.3	4.1e-6	Diabetic kidney disease;
SARC	cis	rs751728	1.000	rs3793079	chr6:33767788	T/A	cg15252951	chr6:33757062	LEMD2	0.58	6.87	0.41	5.97e-11	Crohn's disease;
SARC	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg04944784	chr2:26401820	FAM59B	-0.58	-7.73	-0.45	3.1400000000000003e-13	Gut microbiome composition (summer);
SARC	cis	rs1018836	0.608	rs6998106	chr8:91479755	G/T	cg16814680	chr8:91681699	NA	-0.65	-9.3	-0.52	1.03e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	trans	rs6819266	0.636	rs13148734	chr4:63330858	A/G	cg09567670	chr8:103251664	RRM2B	0.48	6.57	0.4	3.17e-10	Age-related macular degeneration;
SARC	cis	rs1707322	1.000	rs785478	chr1:46491635	C/T	cg03146154	chr1:46216737	IPP	-0.45	-5.39	-0.33	1.71e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs5758659	1.000	rs134869	chr22:42652074	G/A	cg15128208	chr22:42549153	NA	-0.37	-5.3	-0.33	2.7e-7	Cognitive function;
SARC	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg22168489	chr12:122356033	WDR66	0.63	9.06	0.51	5.48e-17	Mean corpuscular volume;
SARC	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg06618935	chr21:46677482	NA	-0.42	-5.65	-0.35	4.7e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.41	-6.24	-0.38	2.04e-9	Total body bone mineral density;
SARC	trans	rs1814175	0.817	rs10839465	chr11:49981554	C/A	cg03929089	chr4:120376271	NA	-0.88	-14.05	-0.68	6.62e-33	Height;
SARC	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	27.53	0.87	3.44e-75	Chronic sinus infection;
SARC	cis	rs12586317	0.553	rs3809448	chr14:35515096	C/T	cg16230307	chr14:35515116	FAM177A1	1.03	11.91	0.62	7.28e-26	Psoriasis;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg19723775	chr5:179050963	HNRNPH1	0.51	6.31	0.38	1.38e-9	Blood pressure;
SARC	cis	rs6570726	0.875	rs373313	chr6:145857791	T/C	cg05347473	chr6:146136440	FBXO30	0.49	6.58	0.4	3.04e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9790314	1.000	rs1382426	chr3:161045933	G/A	cg04691961	chr3:161091175	C3orf57	-0.79	-11.9	-0.61	7.81e-26	Morning vs. evening chronotype;
SARC	cis	rs1957429	0.808	rs4902325	chr14:65330843	A/G	cg23373153	chr14:65346875	NA	-0.98	-10.08	-0.55	4.48e-20	Pediatric areal bone mineral density (radius);
SARC	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg08859206	chr1:53392774	SCP2	-0.35	-4.98	-0.31	1.26e-6	Monocyte count;
SARC	cis	rs8180040	0.654	rs6791062	chr3:47174343	T/A	cg27129171	chr3:47204927	SETD2	0.68	9.48	0.53	2.97e-18	Colorectal cancer;
SARC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg24846343	chr22:24311635	DDTL	0.51	6.91	0.41	4.67e-11	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs672059	0.967	rs514183	chr1:183163174	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.5	6.86	0.41	6.29e-11	Hypertriglyceridemia;
SARC	cis	rs7336332	0.628	rs9581854	chr13:28017782	C/T	cg01674679	chr13:27998804	GTF3A	-0.5	-4.93	-0.31	1.55e-6	Weight;
SARC	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg06634786	chr22:41940651	POLR3H	-0.61	-7.37	-0.43	2.98e-12	Vitiligo;
SARC	cis	rs3768617	0.510	rs10911242	chr1:183072147	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	9.81	0.54	3.01e-19	Fuchs's corneal dystrophy;
SARC	cis	rs7647973	1.000	rs9871024	chr3:49554241	T/C	cg07636037	chr3:49044803	WDR6	-0.75	-8.43	-0.48	3.58e-15	Menarche (age at onset);
SARC	cis	rs77686669	1	rs77686669	chr7:99744572	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.47	4.99	0.31	1.18e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
SARC	cis	rs4851313	0.527	rs10183150	chr2:100939117	A/G	cg14675211	chr2:100938903	LONRF2	0.47	6.77	0.41	1.01e-10	Intelligence (multi-trait analysis);
SARC	cis	rs12479064	0.724	rs3087403	chr2:100058870	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.57	-6.29	-0.38	1.52e-9	Chronic sinus infection;
SARC	cis	rs3784262	0.740	rs12898976	chr15:58276358	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.33	-4.75	-0.3	3.63e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	trans	rs1373453	0.908	rs61747221	chr12:70037520	G/A	cg03128133	chr1:1072839	NA	-0.73	-6.29	-0.38	1.53e-9	Orofacial clefts;
SARC	cis	rs6570726	0.935	rs585292	chr6:145862228	T/C	cg05220968	chr6:146057943	EPM2A	-0.3	-5.08	-0.32	7.76e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4919694	1.000	rs78893207	chr10:104796138	T/C	cg04362960	chr10:104952993	NT5C2	0.66	5.46	0.34	1.21e-7	Arsenic metabolism;
SARC	cis	rs3733585	0.673	rs4627861	chr4:9954238	T/G	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.94	-0.36	1.06e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs11583043	0.918	rs6675403	chr1:101418569	T/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.51	6.04	0.37	5.96e-9	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs17376456	0.825	rs36042718	chr5:93180997	C/T	cg21475434	chr5:93447410	FAM172A	0.78	6.66	0.4	1.96e-10	Diabetic retinopathy;
SARC	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg18404041	chr3:52824283	ITIH1	-0.44	-6.7	-0.4	1.58e-10	Bipolar disorder;
SARC	cis	rs12421382	0.881	rs1808843	chr11:109389471	A/G	cg27471124	chr11:109292789	C11orf87	0.52	7.02	0.42	2.46e-11	Schizophrenia;
SARC	cis	rs524281	0.731	rs476551	chr11:66006323	G/C	cg14036092	chr11:66035641	RAB1B	-0.58	-6.27	-0.38	1.73e-9	Electroencephalogram traits;
SARC	cis	rs8038734	0.636	rs11631125	chr15:72776126	T/A	cg10943348	chr15:72668568	HEXA;C15orf34	0.64	4.8	0.3	2.77e-6	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs8031584	0.918	rs34331396	chr15:31248736	C/G	cg14829155	chr15:31115871	NA	-0.43	-5.28	-0.33	2.98e-7	Huntington's disease progression;
SARC	cis	rs9894429	0.816	rs9747093	chr17:79584280	G/A	cg18240062	chr17:79603768	NPLOC4	0.72	9.82	0.54	2.83e-19	Eye color traits;
SARC	cis	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg03060546	chr3:49711283	APEH	0.73	10.59	0.57	1.23e-21	Resting heart rate;
SARC	cis	rs79976124	0.879	rs17432710	chr6:66621744	T/C	cg07460842	chr6:66804631	NA	0.63	6.68	0.4	1.7e-10	Type 2 diabetes;
SARC	cis	rs9916302	0.861	rs632202	chr17:37453294	C/A	cg07936489	chr17:37558343	FBXL20	0.68	8.95	0.51	1.13e-16	Glomerular filtration rate (creatinine);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg11141692	chr4:111866916	NA	-0.48	-6.7	-0.4	1.59e-10	Height;
SARC	cis	rs9303401	0.592	rs12936771	chr17:56725052	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	12.63	0.64	3.28e-28	Cognitive test performance;
SARC	cis	rs2425143	0.908	rs11697087	chr20:34427583	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.78	-5.79	-0.35	2.26e-8	Blood protein levels;
SARC	cis	rs4975616	0.869	rs452932	chr5:1330253	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.55	-7.53	-0.44	1.12e-12	Lung cancer;
SARC	cis	rs7666738	0.830	rs6848397	chr4:98946738	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7589342	0.536	rs1367404	chr2:106386865	G/T	cg16077055	chr2:106428750	NCK2	0.3	6.06	0.37	5.3300000000000004e-09	Addiction;
SARC	trans	rs7937682	0.889	rs1940529	chr11:111498523	G/C	cg18187862	chr3:45730750	SACM1L	0.57	7.11	0.42	1.45e-11	Primary sclerosing cholangitis;
SARC	cis	rs2120019	0.938	rs2304903	chr15:75315778	A/G	cg12414181	chr15:75287860	SCAMP5	-0.48	-5.52	-0.34	9.01e-8	Blood trace element (Zn levels);
SARC	cis	rs12134245	0.776	rs625525	chr1:91997593	C/T	cg02896835	chr1:92012615	NA	-0.51	-7.04	-0.42	2.16e-11	Breast cancer;
SARC	cis	rs6582630	0.502	rs11520234	chr12:38255005	G/A	cg13010199	chr12:38710504	ALG10B	0.81	11.31	0.6	6.33e-24	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs858239	0.669	rs1618339	chr7:23229774	T/C	cg23682824	chr7:23144976	KLHL7	0.68	8.82	0.5	2.73e-16	Cerebrospinal fluid biomarker levels;
SARC	cis	rs3106136	0.681	rs11097423	chr4:95303161	G/A	cg11021082	chr4:95130006	SMARCAD1	0.33	4.91	0.31	1.73e-6	Capecitabine sensitivity;
SARC	cis	rs2820315	0.540	rs10920259	chr1:201797696	C/T	cg06775570	chr1:201857621	SHISA4	-0.33	-5.31	-0.33	2.55e-7	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
SARC	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg22535103	chr8:58192502	C8orf71	-0.6	-6.15	-0.37	3.42e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs3749237	0.595	rs1568661	chr3:49520958	A/G	cg07636037	chr3:49044803	WDR6	0.62	8.01	0.46	5.33e-14	Resting heart rate;
SARC	cis	rs8141529	0.764	rs5752812	chr22:29225603	T/A	cg02153584	chr22:29168773	CCDC117	0.79	11.65	0.61	5e-25	Lymphocyte counts;
SARC	cis	rs921968	0.643	rs611203	chr2:219472325	G/A	cg02176678	chr2:219576539	TTLL4	0.4	6.04	0.37	6.11e-9	Mean corpuscular hemoglobin concentration;
SARC	cis	rs854765	0.647	rs854791	chr17:18029857	C/T	cg04398451	chr17:18023971	MYO15A	-0.56	-7.72	-0.45	3.44e-13	Total body bone mineral density;
SARC	cis	rs240764	0.717	rs6904959	chr6:101157916	C/T	cg09795085	chr6:101329169	ASCC3	-0.46	-5.85	-0.36	1.61e-8	Neuroticism;
SARC	cis	rs10927875	1.000	rs12138117	chr1:16305279	T/C	cg21385522	chr1:16154831	NA	-0.76	-9.66	-0.53	8.99e-19	Dilated cardiomyopathy;
SARC	cis	rs244731	0.959	rs918459	chr5:176669030	C/T	cg16006841	chr5:176797999	RGS14	-0.55	-6.79	-0.41	9.06e-11	Urate levels in lean individuals;
SARC	cis	rs11690935	0.595	rs788171	chr2:172921832	A/G	cg13550731	chr2:172543902	DYNC1I2	0.67	9.51	0.53	2.43e-18	Schizophrenia;
SARC	trans	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	7.03	0.42	2.21e-11	Intelligence (multi-trait analysis);
SARC	cis	rs2644899	0.859	rs2545757	chr19:41297302	A/G	cg24958765	chr19:41283667	RAB4B	-0.58	-6.43	-0.39	7.22e-10	Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.45	-5.69	-0.35	3.7e-8	Electroencephalogram traits;
SARC	trans	rs1814175	0.817	rs7946556	chr11:49944874	G/A	cg15704280	chr7:45808275	SEPT13	-0.97	-18.24	-0.77	8.77e-47	Height;
SARC	cis	rs7766436	0.848	rs13200143	chr6:22586212	T/G	cg13666174	chr6:22585274	NA	-0.59	-7.41	-0.44	2.32e-12	Coronary artery disease;
SARC	cis	rs7264396	0.563	rs2425131	chr20:34337074	T/C	cg01084648	chr20:34329383	RBM39	0.57	5.0	0.31	1.13e-6	Total cholesterol levels;
SARC	trans	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg21659725	chr3:3221576	CRBN	0.52	7.0	0.42	2.67e-11	Intelligence (multi-trait analysis);
SARC	cis	rs12681288	0.676	rs2701923	chr8:994605	A/G	cg15309053	chr8:964076	NA	0.45	7.34	0.43	3.55e-12	Schizophrenia;
SARC	cis	rs11874712	0.932	rs34907121	chr18:43677793	G/A	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	6.34	0.38	1.21e-9	Migraine - clinic-based;
SARC	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg12463550	chr7:65579703	CRCP	0.48	5.79	0.35	2.23e-8	Aortic root size;
SARC	cis	rs1055129	0.560	rs2305913	chr17:73922941	T/C	cg14829360	chr17:73884958	NA	-0.57	-8.43	-0.48	3.65e-15	White matter hyperintensity burden;
SARC	cis	rs2576037	0.796	rs2576041	chr18:44580919	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.35	-4.93	-0.31	1.55e-6	Personality dimensions;
SARC	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg25072359	chr17:41440525	NA	0.48	5.63	0.35	5.24e-8	Menopause (age at onset);
SARC	cis	rs6582630	0.599	rs8189525	chr12:38424982	A/C	cg14851346	chr12:38532713	NA	0.46	5.53	0.34	8.44e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7103648	0.669	rs7927445	chr11:47780754	G/T	cg10504702	chr11:47789108	FNBP4	0.77	10.07	0.55	4.85e-20	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs7615952	0.799	rs13315434	chr3:125641394	T/G	cg05084668	chr3:125655381	ALG1L	-0.62	-6.23	-0.38	2.18e-9	Blood pressure (smoking interaction);
SARC	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg08280861	chr8:58055591	NA	0.59	5.22	0.32	4.02e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2072499	0.868	rs2758600	chr1:156195205	C/T	cg24450063	chr1:156163899	SLC25A44	1.09	15.77	0.72	1.28e-38	Testicular germ cell tumor;
SARC	cis	rs7555523	0.943	rs4537525	chr1:165711089	T/G	cg24409356	chr1:165738333	TMCO1	0.8	6.67	0.4	1.88e-10	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	cis	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg12463550	chr7:65579703	CRCP	0.65	5.04	0.31	9.53e-7	Diabetic kidney disease;
SARC	cis	rs3011225	0.710	rs3011224	chr1:44318483	C/T	cg13606994	chr1:44402422	ARTN	-0.29	-4.77	-0.3	3.3e-6	Amyotrophic lateral sclerosis (age of onset);
SARC	cis	rs9487051	1.000	rs9400272	chr6:109616762	A/G	cg01475377	chr6:109611718	NA	-0.4	-5.55	-0.34	7.62e-8	Reticulocyte fraction of red cells;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg06640206	chr3:69985594	MITF	0.48	7.28	0.43	5.08e-12	Thyroid stimulating hormone;
SARC	cis	rs7644634	0.649	rs28532512	chr3:105378473	G/A	cg23051926	chr3:105466016	CBLB	0.47	5.93	0.36	1.08e-8	Itch intensity from mosquito bite;
SARC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg06873352	chr17:61820015	STRADA	0.54	7.11	0.42	1.44e-11	Prudent dietary pattern;
SARC	cis	rs9875589	0.509	rs1488377	chr3:14073178	C/G	cg19554555	chr3:13937349	NA	-0.41	-5.14	-0.32	5.7e-7	Ovarian reserve;
SARC	cis	rs1707322	0.752	rs28719889	chr1:46202283	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.29	0.38	1.55e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.66	6.36	0.38	1.03e-9	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg13699009	chr12:122356056	WDR66	0.57	8.69	0.49	6.7e-16	Mean corpuscular volume;
SARC	cis	rs2439831	0.867	rs16957630	chr15:43642780	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.76	7.92	0.46	9.46e-14	Lung cancer in ever smokers;
SARC	cis	rs861020	1.000	rs642961	chr1:209989270	A/G	cg05527609	chr1:210001259	C1orf107	1.01	11.23	0.59	1.14e-23	Orofacial clefts;
SARC	cis	rs1057510	0.858	rs78742502	chr12:6712759	C/T	cg13857086	chr12:6580257	VAMP1	0.62	4.94	0.31	1.51e-6	Myopia (pathological);
SARC	cis	rs12458130	1.000	rs598417	chr18:8666881	C/T	cg25899954	chr18:8660164	NA	-0.65	-5.77	-0.35	2.5e-8	Inflammatory skin disease;
SARC	cis	rs2377585	0.524	rs11612882	chr12:8843133	A/G	cg03761649	chr12:8850719	RIMKLB	-0.5	-5.57	-0.34	7.15e-8	Reticulocyte fraction of red cells;
SARC	cis	rs9733	0.680	rs3738484	chr1:150552330	G/T	cg17724175	chr1:150552817	MCL1	-0.39	-5.01	-0.31	1.08e-6	Tonsillectomy;
SARC	cis	rs6782228	0.606	rs1697	chr3:128356852	C/T	cg08795948	chr3:128337044	NA	0.37	5.01	0.31	1.1e-6	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
SARC	cis	rs9902453	0.765	rs3115087	chr17:28030267	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	7.15	0.42	1.11e-11	Coffee consumption (cups per day);
SARC	cis	rs9486719	0.857	rs1157316	chr6:96869710	G/A	cg18709589	chr6:96969512	KIAA0776	0.49	5.35	0.33	2.11e-7	Migraine;Coronary artery disease;
SARC	cis	rs4972806	0.849	rs2857541	chr2:177029086	C/T	cg14324370	chr2:177042789	NA	0.55	7.42	0.44	2.22e-12	IgG glycosylation;
SARC	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg22834771	chr12:69754056	YEATS4	-0.44	-5.78	-0.35	2.42e-8	Blood protein levels;
SARC	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.53	6.02	0.37	6.57e-9	Renal function-related traits (BUN);
SARC	cis	rs1215050	0.904	rs2903153	chr4:99057457	C/T	cg05340658	chr4:99064831	C4orf37	0.43	5.47	0.34	1.13e-7	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs9788682	1.000	rs12441426	chr15:78812329	T/C	cg06917634	chr15:78832804	PSMA4	-0.58	-6.43	-0.39	7.18e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs35110281	0.715	rs2838353	chr21:45119228	C/T	cg04455712	chr21:45112962	RRP1B	0.33	4.76	0.3	3.36e-6	Mean corpuscular volume;
SARC	cis	rs262150	0.522	rs2527182	chr7:158813812	A/G	cg04111992	chr7:158790115	NA	-0.36	-5.12	-0.32	6.46e-7	Facial morphology (factor 20);
SARC	cis	rs11122272	0.701	rs971533	chr1:231522097	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg16743903	chr16:89593216	SPG7	0.38	5.22	0.32	4.05e-7	Multiple myeloma (IgH translocation);
SARC	cis	rs2760061	0.583	rs1745413	chr1:228212456	A/G	cg01200585	chr1:228362443	C1orf69	0.44	5.51	0.34	9.46e-8	Diastolic blood pressure;
SARC	cis	rs4742903	0.509	rs7019494	chr9:106943054	T/C	cg14250997	chr9:106856677	SMC2	0.42	5.16	0.32	5.37e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs72781680	0.821	rs72796369	chr2:24162663	G/T	cg08917208	chr2:24149416	ATAD2B	0.58	5.89	0.36	1.34e-8	Lymphocyte counts;
SARC	cis	rs9747201	1.000	rs55638685	chr17:80107566	G/C	cg09264619	chr17:80180166	NA	0.49	5.76	0.35	2.64e-8	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs6493487	0.512	rs71471584	chr15:51261229	T/A	cg02338191	chr15:51200825	AP4E1	0.55	5.09	0.32	7.21e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs9398803	0.723	rs861237	chr6:127073798	C/T	cg19875578	chr6:126661172	C6orf173	-0.6	-8.29	-0.48	8.89e-15	Male-pattern baldness;
SARC	cis	rs870825	0.860	rs72703529	chr4:185607351	T/C	cg04058563	chr4:185651563	MLF1IP	0.8	9.65	0.53	9.29e-19	Blood protein levels;
SARC	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg19077165	chr18:44547161	KATNAL2	-0.49	-6.79	-0.41	9.33e-11	Personality dimensions;
SARC	cis	rs7312933	0.584	rs6582391	chr12:42634686	G/A	cg19980929	chr12:42632907	YAF2	0.48	6.89	0.41	5.01e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg20007245	chr22:24372913	LOC391322	-0.63	-7.49	-0.44	1.45e-12	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg06636001	chr8:8085503	FLJ10661	-0.81	-11.91	-0.62	7.22e-26	Schizophrenia;
SARC	cis	rs6088580	0.608	rs1205342	chr20:32921842	C/T	cg08999081	chr20:33150536	PIGU	-0.45	-6.78	-0.41	9.73e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs4481887	0.962	rs5009868	chr1:248474495	A/G	cg13385794	chr1:248469461	NA	0.36	5.39	0.33	1.72e-7	Common traits (Other);
SARC	cis	rs11105298	0.891	rs8181784	chr12:89828591	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.51	-5.17	-0.32	5.03e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs8072100	0.713	rs9895776	chr17:45486003	A/G	cg08085267	chr17:45401833	C17orf57	-0.44	-5.18	-0.32	4.76e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs2694528	0.844	rs10471496	chr5:60068347	G/A	cg11474532	chr5:59995715	DEPDC1B	0.76	5.32	0.33	2.43e-7	Parkinson's disease;
SARC	cis	rs9916302	0.904	rs8079355	chr17:37473018	G/A	cg00129232	chr17:37814104	STARD3	0.59	7.27	0.43	5.32e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg10523679	chr1:76189770	ACADM	0.45	5.45	0.34	1.27e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7762018	0.556	rs80250989	chr6:170105553	T/C	cg13015042	chr6:170102002	WDR27;C6orf120	0.68	4.81	0.3	2.73e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs950169	1.000	rs35658069	chr15:84780146	C/T	cg17507749	chr15:85114479	UBE2QP1	0.76	9.25	0.52	1.47e-17	Schizophrenia;
SARC	cis	rs1843834	0.539	rs6749402	chr2:225443901	T/G	cg22455342	chr2:225449267	CUL3	0.69	8.68	0.49	6.82e-16	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg11890956	chr21:40555474	PSMG1	-0.7	-9.31	-0.52	1.02e-17	Menarche (age at onset);
SARC	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg02297831	chr4:17616191	MED28	0.51	6.58	0.4	3.1e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6841898	1.000	rs6841898	chr4:24578097	A/G	cg26992952	chr4:24981949	CCDC149	-0.72	-4.94	-0.31	1.46e-6	Myopia (pathological);
SARC	trans	rs877282	0.898	rs11253344	chr10:765162	C/T	cg22713356	chr15:30763199	NA	1.04	10.06	0.55	5.37e-20	Uric acid levels;
SARC	cis	rs1008375	0.618	rs13129002	chr4:17567513	A/G	cg27347728	chr4:17578864	LAP3	0.54	6.36	0.38	1.04e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4481887	0.741	rs6682957	chr1:248535639	T/G	cg00666640	chr1:248458726	OR2T12	0.34	5.97	0.36	8.87e-9	Common traits (Other);
SARC	cis	rs35306767	0.859	rs11817793	chr10:878895	C/T	cg20503657	chr10:835505	NA	0.76	7.21	0.43	7.69e-12	Eosinophil percentage of granulocytes;
SARC	cis	rs1050631	1.000	rs1785916	chr18:33696156	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.42	5.06	0.31	8.67e-7	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs7523050	0.643	rs35665867	chr1:109395436	G/A	cg08274380	chr1:109419600	GPSM2	1.09	7.82	0.46	1.88e-13	Fat distribution (HIV);
SARC	cis	rs1200821	0.535	rs1938417	chr10:37687520	A/C	cg00409905	chr10:38381863	ZNF37A	0.42	5.89	0.36	1.33e-8	Hemostatic factors and hematological phenotypes;
SARC	cis	rs2236918	0.932	rs1635501	chr1:242040775	C/T	cg17736920	chr1:242011382	EXO1	0.71	9.5	0.53	2.71e-18	Menopause (age at onset);
SARC	cis	rs9309473	1.000	rs10187416	chr2:73713741	T/G	cg20560298	chr2:73613845	ALMS1	-0.51	-6.1	-0.37	4.33e-9	Metabolite levels;
SARC	cis	rs2120019	1.000	rs12910644	chr15:75358388	A/G	cg12414181	chr15:75287860	SCAMP5	-0.45	-5.06	-0.31	8.48e-7	Blood trace element (Zn levels);
SARC	cis	rs12908161	1.000	rs12903134	chr15:85337699	T/A	cg17507749	chr15:85114479	UBE2QP1	0.54	6.1	0.37	4.39e-9	Schizophrenia;
SARC	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg18876405	chr7:65276391	NA	0.49	6.04	0.37	6e-9	Aortic root size;
SARC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg24503407	chr1:205819492	PM20D1	0.92	17.08	0.75	5.82e-43	Menarche (age at onset);
SARC	cis	rs67460515	0.892	rs1478566	chr3:161030335	A/T	cg04691961	chr3:161091175	C3orf57	-0.49	-6.08	-0.37	4.91e-9	Parkinson's disease;
SARC	cis	rs6450176	0.909	rs3776721	chr5:53292522	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.64	-7.22	-0.43	7.11e-12	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	trans	rs12554020	0.892	rs78816659	chr9:96337423	C/T	cg26442883	chr16:49686662	ZNF423	0.6	6.58	0.4	3.01e-10	Schizophrenia;
SARC	cis	rs3540	0.597	rs3743409	chr15:91045539	T/A	cg22089800	chr15:90895588	ZNF774	-0.59	-7.63	-0.45	5.79e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	trans	rs7615952	0.551	rs6438945	chr3:125634473	G/A	cg07211511	chr3:129823064	LOC729375	-0.96	-10.53	-0.57	1.86e-21	Blood pressure (smoking interaction);
SARC	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg21724239	chr8:58056113	NA	0.6	6.31	0.38	1.43e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs12545109	0.571	rs1370306	chr8:57299137	C/G	cg19413350	chr8:57351067	NA	-0.4	-5.04	-0.31	9.15e-7	Obesity-related traits;
SARC	cis	rs8523	0.774	rs9295764	chr6:11045196	A/G	cg13562911	chr6:11044106	ELOVL2	0.48	6.46	0.39	6.21e-10	Red blood cell fatty acid levels;
SARC	cis	rs981844	0.712	rs4434231	chr4:154746293	G/T	cg14289246	chr4:154710475	SFRP2	-0.49	-5.82	-0.36	1.9e-8	Response to statins (LDL cholesterol change);
SARC	cis	rs2645694	0.626	rs2703121	chr4:77822328	C/G	cg06046430	chr4:77819534	ANKRD56	0.54	7.78	0.45	2.35e-13	Emphysema distribution in smoking;
SARC	cis	rs11676348	0.846	rs7594532	chr2:219008000	T/C	cg00012203	chr2:219082015	ARPC2	-0.52	-6.91	-0.41	4.64e-11	Ulcerative colitis;
SARC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.32	-4.83	-0.3	2.44e-6	Longevity;Endometriosis;
SARC	cis	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg24110177	chr3:50126178	RBM5	0.54	7.23	0.43	7.07e-12	Intelligence (multi-trait analysis);
SARC	cis	rs10982256	0.811	rs10759713	chr9:117254214	G/A	cg15903421	chr9:117267460	DFNB31	-0.36	-4.73	-0.3	3.91e-6	Bipolar disorder;
SARC	cis	rs17376456	0.542	rs10476588	chr5:93208330	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.56	-5.84	-0.36	1.73e-8	Diabetic retinopathy;
SARC	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.43	5.84	0.36	1.75e-8	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg11843238	chr5:131593191	PDLIM4	0.38	5.38	0.33	1.85e-7	Breast cancer;
SARC	trans	rs1814175	0.935	rs7950947	chr11:49668369	C/T	cg03929089	chr4:120376271	NA	-0.85	-13.4	-0.66	9.4e-31	Height;
SARC	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10744422	0.925	rs3825143	chr12:123352179	C/T	cg22842854	chr12:123319900	HIP1R	-0.63	-4.72	-0.3	4.16e-6	Schizophrenia;
SARC	cis	rs1419980	0.673	rs2377086	chr12:7753798	C/T	cg10578777	chr12:7781093	NA	0.55	5.87	0.36	1.53e-8	HDL cholesterol levels;
SARC	cis	rs7772486	0.754	rs864148	chr6:145976675	T/C	cg05347473	chr6:146136440	FBXO30	-0.54	-7.59	-0.45	7.86e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9828933	0.752	rs28675788	chr3:63942188	C/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.87	-7.55	-0.44	1.01e-12	Type 2 diabetes;
SARC	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg24250549	chr1:154909240	PMVK	0.82	11.5	0.6	1.59e-24	Prostate cancer;
SARC	cis	rs123509	0.913	rs339685	chr3:42782952	C/G	cg12982090	chr3:42733453	KBTBD5	0.52	6.36	0.38	1.07e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs6448317	0.863	rs2695228	chr4:24901985	C/T	cg21108841	chr4:24914750	CCDC149	0.55	6.27	0.38	1.69e-9	Heschl's gyrus morphology;
SARC	cis	rs2594989	0.943	rs2454512	chr3:11487506	A/G	cg00170343	chr3:11313890	ATG7	0.54	5.28	0.33	2.97e-7	Circulating chemerin levels;
SARC	cis	rs2880765	0.835	rs7174323	chr15:86049719	A/C	cg10818794	chr15:86012489	AKAP13	-0.37	-4.71	-0.3	4.18e-6	Coronary artery disease;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg10362113	chr14:96978537	PAPOLA	0.48	6.24	0.38	2e-9	Thyroid stimulating hormone;
SARC	cis	rs2180341	0.640	rs11154395	chr6:127629138	T/C	cg27446573	chr6:127587934	RNF146	0.69	9.04	0.51	6.36e-17	Breast cancer;
SARC	cis	rs1451375	0.572	rs11575463	chr7:50547173	A/G	cg14593290	chr7:50529359	DDC	-0.45	-4.99	-0.31	1.2e-6	Malaria;
SARC	cis	rs4280164	0.943	rs2516564	chr14:24778643	C/T	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.59	-5.58	-0.34	6.6e-8	Parent of origin effect on language impairment (paternal);
SARC	cis	rs910187	0.631	rs62201431	chr20:45810994	G/A	cg27589058	chr20:45804311	EYA2	-0.32	-5.09	-0.32	7.43e-7	Migraine;
SARC	cis	rs17376456	0.877	rs10076052	chr5:93317762	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.8	0.35	2.2e-8	Diabetic retinopathy;
SARC	cis	rs2204008	0.805	rs11180825	chr12:38242916	G/T	cg26384229	chr12:38710491	ALG10B	0.91	13.64	0.67	1.61e-31	Bladder cancer;
SARC	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg20607798	chr8:58055168	NA	0.52	4.93	0.31	1.54e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs4792901	0.959	rs72833148	chr17:41629163	G/A	cg22562494	chr17:41607896	ETV4	-0.31	-4.89	-0.31	1.89e-6	Dupuytren's disease;
SARC	cis	rs950776	0.752	rs2869546	chr15:78907345	C/T	cg22563815	chr15:78856949	CHRNA5	-0.35	-5.56	-0.34	7.55e-8	Sudden cardiac arrest;
SARC	cis	rs240764	0.614	rs12210312	chr6:101170849	A/G	cg09795085	chr6:101329169	ASCC3	-0.41	-5.03	-0.31	1e-6	Neuroticism;
SARC	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg15049968	chr18:44337910	ST8SIA5	-0.32	-5.04	-0.31	9.43e-7	Personality dimensions;
SARC	cis	rs7819412	0.540	rs2409725	chr8:11041661	T/C	cg12395012	chr8:11607386	GATA4	0.32	5.49	0.34	1.04e-7	Triglycerides;
SARC	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.73	-7.38	-0.44	2.72e-12	Platelet count;
SARC	cis	rs9682041	1.000	rs6444920	chr3:170090374	A/G	cg11886554	chr3:170076028	SKIL	1.07	8.49	0.49	2.41e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs9291683	0.546	rs6829727	chr4:10051672	A/C	cg00071950	chr4:10020882	SLC2A9	0.34	5.03	0.31	9.72e-7	Bone mineral density;
SARC	cis	rs1852985	0.659	rs12526484	chr6:45292279	C/A	cg11115867	chr6:45345767	RUNX2;SUPT3H	0.52	4.82	0.3	2.6e-6	middle facial morphology traits (quantitative measurement);facial morphology traits (multivariate analysis);
SARC	cis	rs9486719	1.000	rs6923212	chr6:97061940	A/G	cg18709589	chr6:96969512	KIAA0776	-0.47	-4.79	-0.3	2.98e-6	Migraine;Coronary artery disease;
SARC	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg12463550	chr7:65579703	CRCP	0.5	5.9	0.36	1.27e-8	Aortic root size;
SARC	cis	rs3087591	0.553	rs2854334	chr17:29715500	A/G	cg24425628	chr17:29625626	OMG;NF1	0.42	5.3	0.33	2.66e-7	Hip circumference;
SARC	cis	rs748404	0.578	rs512628	chr15:43618734	A/G	cg08831455	chr15:43942014	CATSPER2	-0.4	-4.77	-0.3	3.19e-6	Lung cancer;
SARC	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg13175981	chr1:150552382	MCL1	-0.46	-5.49	-0.34	1.06e-7	Melanoma;
SARC	cis	rs992157	0.560	rs7578940	chr2:219083318	G/T	cg00012203	chr2:219082015	ARPC2	-0.73	-10.73	-0.58	4.28e-22	Colorectal cancer;
SARC	trans	rs3808502	0.526	rs1042701	chr8:11422045	G/A	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.51	-0.39	4.54e-10	Neuroticism;
SARC	cis	rs9398803	0.687	rs6569469	chr6:127008431	C/T	cg19875578	chr6:126661172	C6orf173	-0.63	-8.71	-0.5	5.59e-16	Male-pattern baldness;
SARC	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg17691542	chr6:26056736	HIST1H1C	0.48	5.39	0.33	1.73e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-5.43	-0.33	1.44e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs7772486	0.686	rs1569540	chr6:146069112	A/G	cg23711669	chr6:146136114	FBXO30	-0.8	-12.99	-0.65	2.26e-29	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.41	-6.25	-0.38	1.93e-9	Menopause (age at onset);
SARC	cis	rs7644634	0.512	rs1545304	chr3:105421823	G/A	cg23051926	chr3:105466016	CBLB	0.46	5.28	0.33	2.97e-7	Itch intensity from mosquito bite;
SARC	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg18404041	chr3:52824283	ITIH1	-0.4	-6.17	-0.37	3.06e-9	Bipolar disorder;
SARC	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg00339695	chr16:24857497	SLC5A11	0.37	5.15	0.32	5.62e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs1318878	0.639	rs56029389	chr12:15517379	T/G	cg08258403	chr12:15378311	NA	0.48	6.63	0.4	2.36e-10	Intelligence (multi-trait analysis);
SARC	trans	rs61931739	0.513	rs10772116	chr12:33897795	G/C	cg26384229	chr12:38710491	ALG10B	0.69	9.44	0.53	4.15e-18	Morning vs. evening chronotype;
SARC	cis	rs6693567	0.545	rs2275246	chr1:150460168	A/G	cg09579323	chr1:150459698	TARS2	0.43	5.51	0.34	9.7e-8	Migraine;
SARC	trans	rs2018683	0.899	rs10479816	chr7:28978021	G/A	cg19402173	chr7:128379420	CALU	-0.66	-8.58	-0.49	1.35e-15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs1355223	0.902	rs1773908	chr11:34743380	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.34	-0.33	2.21e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	trans	rs1853207	0.609	rs17110310	chr10:96626682	C/T	cg02737782	chr1:8014393	NA	-0.97	-6.42	-0.39	7.44e-10	Blood metabolite levels;
SARC	cis	rs7582180	0.629	rs4851296	chr2:100949570	T/C	cg14675211	chr2:100938903	LONRF2	0.47	7.0	0.42	2.73e-11	Intelligence (multi-trait analysis);
SARC	cis	rs6963495	0.818	rs6973974	chr7:105170629	C/T	cg13798780	chr7:105162888	PUS7	0.6	5.55	0.34	7.84e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs933688	1.000	rs6869717	chr5:90694797	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.01	12.81	0.64	8.3e-29	Smoking behavior;
SARC	cis	rs35213789	1.000	rs7808773	chr7:69297622	A/C	cg10619644	chr7:69149951	AUTS2	0.45	5.67	0.35	4.17e-8	Childhood ear infection;
SARC	cis	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg24110177	chr3:50126178	RBM5	0.4	5.12	0.32	6.51e-7	Intelligence (multi-trait analysis);
SARC	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.45	-5.13	-0.32	5.99e-7	Renal function-related traits (BUN);
SARC	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.66	-6.89	-0.41	5.03e-11	Platelet count;
SARC	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg22800045	chr5:56110881	MAP3K1	0.65	6.84	0.41	6.74e-11	Initial pursuit acceleration;
SARC	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg11890956	chr21:40555474	PSMG1	1.18	16.89	0.74	2.51e-42	Cognitive function;
SARC	cis	rs778371	0.958	rs778341	chr2:233728801	C/A	cg16596103	chr2:233749413	NGEF	0.36	5.05	0.31	8.73e-7	Schizophrenia;
SARC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg15242686	chr22:24348715	GSTTP1	-0.37	-4.72	-0.3	4.03e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs67460515	0.563	rs9883566	chr3:160770323	C/T	cg03342759	chr3:160939853	NMD3	0.58	6.68	0.4	1.7e-10	Parkinson's disease;
SARC	cis	rs3733585	0.699	rs7663079	chr4:9966771	T/C	cg11266682	chr4:10021025	SLC2A9	-0.37	-6.48	-0.39	5.28e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs10791323	0.559	rs10750549	chr11:133730820	A/G	cg03690763	chr11:133734501	NA	-0.29	-4.74	-0.3	3.64e-6	Childhood ear infection;
SARC	cis	rs7659604	1.000	rs7689722	chr4:122665955	T/C	cg19671926	chr4:122722719	EXOSC9	-0.51	-6.14	-0.37	3.44e-9	Type 2 diabetes;
SARC	cis	rs1941023	0.584	rs2233252	chr11:60157107	T/G	cg08716584	chr11:60157161	MS4A7	-0.39	-6.29	-0.38	1.52e-9	Congenital heart disease (maternal effect);
SARC	trans	rs1814175	0.708	rs10839464	chr11:49981386	T/C	cg03929089	chr4:120376271	NA	-0.82	-11.88	-0.61	9.2e-26	Height;
SARC	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg17221315	chr6:27791827	HIST1H4J	0.52	5.33	0.33	2.3e-7	Parkinson's disease;
SARC	cis	rs1008375	1.000	rs2315560	chr4:17677305	C/G	cg16339924	chr4:17578868	LAP3	0.64	8.39	0.48	4.6e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4423214	1.000	rs12808368	chr11:71170817	C/T	cg05163923	chr11:71159392	DHCR7	0.64	8.92	0.5	1.44e-16	Vitamin D levels;
SARC	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg00933542	chr6:150070202	PCMT1	0.3	5.09	0.32	7.29e-7	Lung cancer;
SARC	trans	rs826838	0.654	rs7977738	chr12:38722460	G/A	cg23762105	chr12:34175262	ALG10	-0.53	-6.92	-0.41	4.29e-11	Heart rate;
SARC	cis	rs7647973	0.593	rs55997059	chr3:49858661	A/T	cg06212747	chr3:49208901	KLHDC8B	-0.59	-5.88	-0.36	1.41e-8	Menarche (age at onset);
SARC	cis	rs7208859	0.623	rs9912440	chr17:29148772	A/G	cg13385521	chr17:29058706	SUZ12P	0.91	7.65	0.45	5.17e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs8180040	0.739	rs11719306	chr3:47184182	G/A	cg27129171	chr3:47204927	SETD2	0.69	9.93	0.55	1.28e-19	Colorectal cancer;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg02025192	chr11:115375385	CADM1	-0.73	-6.27	-0.38	1.69e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9325144	0.560	rs7971313	chr12:38653413	A/G	cg26384229	chr12:38710491	ALG10B	-0.66	-8.86	-0.5	2.06e-16	Morning vs. evening chronotype;
SARC	cis	rs1318878	1.000	rs983799	chr12:15544073	A/C	cg08258403	chr12:15378311	NA	-0.45	-5.17	-0.32	4.92e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7011049	1.000	rs11993171	chr8:53832898	C/A	cg26025543	chr8:53854495	NA	0.61	5.59	0.34	6.42e-8	Systolic blood pressure;
SARC	cis	rs921968	0.565	rs6436072	chr2:219598095	C/T	cg02176678	chr2:219576539	TTLL4	-0.34	-5.14	-0.32	5.86e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg05863683	chr7:1912471	MAD1L1	0.35	5.19	0.32	4.5e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs6815814	0.950	rs55903115	chr4:38786474	C/A	cg06935464	chr4:38784597	TLR10	0.62	6.19	0.38	2.68e-9	Breast cancer;
SARC	cis	rs910316	1.000	rs175442	chr14:75603564	T/C	cg11812906	chr14:75593930	NEK9	-0.83	-12.49	-0.63	9.4e-28	Height;
SARC	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.38	-4.8	-0.3	2.86e-6	Lymphocyte counts;
SARC	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg11764359	chr7:65958608	NA	-0.71	-8.09	-0.47	3.24e-14	Aortic root size;
SARC	cis	rs8114671	0.562	rs6088653	chr20:33520321	T/C	cg07148914	chr20:33460835	GGT7	0.43	5.28	0.33	2.89e-7	Height;
SARC	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg09373136	chr17:61933544	TCAM1	0.44	5.82	0.36	1.94e-8	Prudent dietary pattern;
SARC	cis	rs2795502	0.938	rs3121324	chr10:43379515	C/T	cg20628663	chr10:43360327	NA	0.36	4.76	0.3	3.39e-6	Blood protein levels;
SARC	cis	rs2645694	0.626	rs2703116	chr4:77824289	C/T	cg10057126	chr4:77819792	ANKRD56	-0.46	-7.15	-0.42	1.12e-11	Emphysema distribution in smoking;
SARC	cis	rs9790314	0.638	rs17236746	chr3:160646743	A/G	cg04691961	chr3:161091175	C3orf57	0.61	8.4	0.48	4.38e-15	Morning vs. evening chronotype;
SARC	cis	rs1018836	0.923	rs10956720	chr8:91576222	C/T	cg16814680	chr8:91681699	NA	-0.81	-12.66	-0.64	2.67e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs7582180	0.629	rs893416	chr2:100957443	G/A	cg14675211	chr2:100938903	LONRF2	0.51	7.51	0.44	1.24e-12	Intelligence (multi-trait analysis);
SARC	cis	rs2816062	0.710	rs2816052	chr1:18895536	T/C	cg10574377	chr1:18908098	NA	0.35	4.93	0.31	1.55e-6	Urate levels in lean individuals;
SARC	trans	rs11098499	0.908	rs9995234	chr4:120321827	A/G	cg25214090	chr10:38739885	LOC399744	0.56	7.32	0.43	3.9e-12	Corneal astigmatism;
SARC	cis	rs11105298	0.786	rs10858867	chr12:89851166	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.49	-5.0	-0.31	1.11e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	8.84	0.5	2.36e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2204008	0.580	rs36118148	chr12:38411812	G/A	cg14851346	chr12:38532713	NA	-0.44	-5.3	-0.33	2.73e-7	Bladder cancer;
SARC	cis	rs2072499	0.966	rs1137703	chr1:156184458	T/C	cg24450063	chr1:156163899	SLC25A44	1.14	19.4	0.79	1.5e-50	Testicular germ cell tumor;
SARC	cis	rs4969178	0.965	rs4969186	chr17:76398404	C/G	cg20026190	chr17:76395443	PGS1	0.41	5.61	0.34	5.75e-8	HDL cholesterol levels;
SARC	cis	rs2120243	0.539	rs2047649	chr3:157085605	G/C	cg24825693	chr3:157122686	VEPH1	-0.45	-6.04	-0.37	6.19e-9	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs9916302	0.752	rs676882	chr17:37433424	A/T	cg07936489	chr17:37558343	FBXL20	0.74	8.01	0.46	5.41e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs642803	1.000	rs642803	chr11:65560620	C/T	cg10518572	chr11:65560635	OVOL1	0.29	5.28	0.33	3.03e-7	Urate levels;
SARC	cis	rs7000551	0.663	rs7827093	chr8:22334610	A/G	cg12081754	chr8:22256438	SLC39A14	0.64	8.99	0.51	8.79e-17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs2282802	0.685	rs2116790	chr5:139654115	G/A	cg26211634	chr5:139558579	C5orf32	0.39	4.98	0.31	1.24e-6	Intelligence (multi-trait analysis);
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg13208492	chr2:122513376	TSN	0.54	6.38	0.39	9.2e-10	Blood pressure;
SARC	cis	rs4988958	0.565	rs6732138	chr2:103009662	G/A	cg03938978	chr2:103052716	IL18RAP	0.32	5.23	0.32	3.69e-7	Asthma (childhood onset);
SARC	cis	rs735396	0.770	rs1169300	chr12:121431225	G/A	cg25281562	chr12:121454272	C12orf43	0.55	6.78	0.41	9.79e-11	N-glycan levels;
SARC	cis	rs4481887	0.741	rs7417519	chr1:248550370	C/T	cg00666640	chr1:248458726	OR2T12	-0.31	-5.5	-0.34	9.86e-8	Common traits (Other);
SARC	cis	rs876084	0.505	rs10738134	chr8:121168145	T/C	cg06265175	chr8:121136014	COL14A1	0.57	7.22	0.43	7.21e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs7927771	0.524	rs7116346	chr11:47883880	G/A	cg20307385	chr11:47447363	PSMC3	-0.48	-6.54	-0.39	3.96e-10	Subjective well-being;
SARC	cis	rs96067	0.805	rs4652902	chr1:36612955	C/A	cg24686825	chr1:36642396	MAP7D1	-0.56	-6.73	-0.4	1.3e-10	Corneal structure;
SARC	trans	rs7819412	0.775	rs34094119	chr8:10935898	A/G	cg06636001	chr8:8085503	FLJ10661	-0.7	-9.85	-0.54	2.35e-19	Triglycerides;
SARC	cis	rs7520050	0.966	rs2275426	chr1:46487552	G/A	cg24296786	chr1:45957014	TESK2	0.39	5.02	0.31	1.04e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs9879311	0.966	rs6442165	chr3:10415108	A/C	cg11030744	chr3:10328490	GHRL;GHRLOS	0.43	5.31	0.33	2.61e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	cis	rs6963495	0.872	rs73190193	chr7:105164852	A/G	cg13798780	chr7:105162888	PUS7	0.6	5.45	0.34	1.31e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs62158211	1.000	rs4618068	chr2:114109355	C/T	cg17784749	chr2:114082611	LOC440839	0.63	6.77	0.41	1.06e-10	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
SARC	cis	rs6430585	0.528	rs721765	chr2:136748779	C/A	cg07169764	chr2:136633963	MCM6	1.01	12.7	0.64	2.01e-28	Corneal structure;
SARC	cis	rs2985684	1.000	rs7142457	chr14:50097862	C/T	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.47	4.91	0.31	1.69e-6	Carotid intima media thickness;
SARC	cis	rs9858542	0.953	rs6446272	chr3:49463287	G/A	cg03060546	chr3:49711283	APEH	-0.57	-7.0	-0.42	2.67e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs710865	0.627	rs10799710	chr1:19483209	A/G	cg13387374	chr1:19411106	UBR4	0.56	7.76	0.45	2.67e-13	Brain structure;
SARC	cis	rs1023500	0.596	rs5751204	chr22:42433801	C/T	cg04733989	chr22:42467013	NAGA	0.69	9.19	0.52	2.2e-17	Schizophrenia;
SARC	cis	rs9916302	0.800	rs8081220	chr17:37473157	A/C	cg00129232	chr17:37814104	STARD3	0.59	7.27	0.43	5.47e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs240764	0.817	rs240115	chr6:101053069	T/C	cg09795085	chr6:101329169	ASCC3	0.44	5.69	0.35	3.82e-8	Neuroticism;
SARC	trans	rs1493916	0.967	rs9953768	chr18:31399468	A/G	cg27147174	chr7:100797783	AP1S1	-0.58	-7.49	-0.44	1.45e-12	Life satisfaction;
SARC	cis	rs17270561	0.609	rs9358885	chr6:25758024	T/C	cg16482183	chr6:26056742	HIST1H1C	0.42	5.04	0.31	9.32e-7	Iron status biomarkers;
SARC	cis	rs30380	0.632	rs26497	chr5:96138767	T/C	cg16492584	chr5:96139282	ERAP1	-0.46	-5.26	-0.33	3.33e-7	Cerebrospinal fluid biomarker levels;
SARC	cis	rs4925386	1.000	rs4925382	chr20:60918542	G/C	cg22633769	chr20:60982531	CABLES2	-0.45	-4.95	-0.31	1.41e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs9902453	0.780	rs10445384	chr17:28182685	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	7.4	0.44	2.41e-12	Coffee consumption (cups per day);
SARC	cis	rs9815354	1.000	rs9820192	chr3:41889281	G/A	cg03022575	chr3:42003672	ULK4	0.56	5.29	0.33	2.81e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs7589342	0.839	rs1465641	chr2:106438936	C/T	cg16077055	chr2:106428750	NCK2	0.33	5.96	0.36	9.24e-9	Addiction;
SARC	cis	rs3820928	0.904	rs2396432	chr2:227765891	C/T	cg05526886	chr2:227700861	RHBDD1	-0.51	-6.08	-0.37	4.88e-9	Pulmonary function;
SARC	cis	rs6714710	0.603	rs34974566	chr2:98552299	C/G	cg26665480	chr2:98280029	ACTR1B	0.47	6.29	0.38	1.54e-9	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs11650494	0.831	rs7216993	chr17:47454263	A/G	cg08112188	chr17:47440006	ZNF652	0.76	7.22	0.43	7.34e-12	Prostate cancer;
SARC	cis	rs858239	0.600	rs7787110	chr7:23138474	C/T	cg23682824	chr7:23144976	KLHL7	0.71	9.61	0.53	1.22e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs13191362	1.000	rs34619021	chr6:163029767	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.55	5.32	0.33	2.48e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs858239	0.601	rs2068459	chr7:23154313	A/C	cg23682824	chr7:23144976	KLHL7	0.66	8.55	0.49	1.68e-15	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9916302	0.861	rs8081033	chr17:37506650	A/G	cg20243544	chr17:37824526	PNMT	-0.53	-6.45	-0.39	6.43e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs6963495	0.818	rs73192113	chr7:105169603	C/T	cg13798780	chr7:105162888	PUS7	0.6	5.55	0.34	7.84e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs9470366	0.545	rs4711457	chr6:36633160	T/C	cg08179530	chr6:36648295	CDKN1A	-0.64	-8.58	-0.49	1.32e-15	QRS duration;
SARC	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg05861140	chr6:150128134	PCMT1	0.42	5.45	0.34	1.25e-7	Lung cancer;
SARC	cis	rs7932354	0.502	rs11600668	chr11:47193566	G/A	cg03339077	chr11:47165057	C11orf49	0.4	5.27	0.33	3.07e-7	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs6141769	0.542	rs28612490	chr20:31297568	G/A	cg17884169	chr20:31446444	EFCAB8	-0.45	-4.8	-0.3	2.83e-6	Subjective well-being;
SARC	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-8.98	-0.51	9.19e-17	Alzheimer's disease;
SARC	cis	rs13082711	0.689	rs34641383	chr3:27320210	G/A	cg02860705	chr3:27208620	NA	0.74	8.38	0.48	5.13e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs12079745	0.590	rs12065030	chr1:169258201	A/G	cg09363564	chr1:169337483	NME7;BLZF1	0.86	5.4	0.33	1.64e-7	QT interval;
SARC	cis	rs12586317	0.547	rs74243586	chr14:35477325	C/T	cg26967526	chr14:35346199	BAZ1A	-0.57	-5.71	-0.35	3.4e-8	Psoriasis;
SARC	cis	rs6570726	0.764	rs9403726	chr6:145901686	G/T	cg23711669	chr6:146136114	FBXO30	0.79	12.75	0.64	1.35e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg07157834	chr1:205819609	PM20D1	0.7	11.13	0.59	2.44e-23	Menarche (age at onset);
SARC	cis	rs7027203	0.576	rs11792101	chr9:96535470	C/T	cg14598338	chr9:96623480	NA	0.34	4.76	0.3	3.42e-6	DNA methylation (variation);
SARC	trans	rs1814175	0.616	rs28417656	chr11:50040152	C/T	cg03929089	chr4:120376271	NA	-0.83	-11.84	-0.61	1.24e-25	Height;
SARC	cis	rs7666738	0.830	rs62318471	chr4:98925848	G/A	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs8180040	0.967	rs4858856	chr3:47565424	G/A	cg27129171	chr3:47204927	SETD2	0.67	9.1	0.51	4.13e-17	Colorectal cancer;
SARC	cis	rs7216064	1.000	rs8074078	chr17:65838743	A/C	cg12091567	chr17:66097778	LOC651250	-0.7	-7.7	-0.45	3.86e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg06212747	chr3:49208901	KLHDC8B	0.76	11.04	0.59	4.47e-23	Menarche (age at onset);
SARC	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.56	-5.6	-0.34	6.1e-8	Lung function (FEV1/FVC);
SARC	cis	rs7615952	0.599	rs67575510	chr3:125742355	C/G	cg05084668	chr3:125655381	ALG1L	-0.49	-5.14	-0.32	5.75e-7	Blood pressure (smoking interaction);
SARC	cis	rs3008870	0.755	rs2815362	chr1:67496803	C/T	cg02640540	chr1:67518911	SLC35D1	0.46	5.22	0.32	4.03e-7	Lymphocyte percentage of white cells;
SARC	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg24549020	chr5:56110836	MAP3K1	-0.46	-5.08	-0.32	7.91e-7	Initial pursuit acceleration;
SARC	cis	rs6964587	0.773	rs2097810	chr7:91977226	G/A	cg17063962	chr7:91808500	NA	0.91	12.84	0.64	6.94e-29	Breast cancer;
SARC	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg21782813	chr7:2030301	MAD1L1	0.42	6.71	0.4	1.5e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg06212747	chr3:49208901	KLHDC8B	0.67	8.87	0.5	1.98e-16	Parkinson's disease;
SARC	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg26818010	chr10:134567672	INPP5A	-0.5	-5.6	-0.34	6.01e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs11249608	0.548	rs6860309	chr5:178451428	T/C	cg21905437	chr5:178450457	ZNF879	0.58	7.92	0.46	9.53e-14	Pubertal anthropometrics;
SARC	cis	rs7312933	0.645	rs11181404	chr12:42683840	T/C	cg19980929	chr12:42632907	YAF2	0.47	6.76	0.41	1.07e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs787274	1.000	rs7030795	chr9:115558962	G/A	cg13803584	chr9:115635662	SNX30	-0.83	-4.98	-0.31	1.25e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs6582630	0.519	rs11181294	chr12:38312787	C/T	cg13010199	chr12:38710504	ALG10B	0.77	10.59	0.57	1.16e-21	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9467711	0.591	rs68149500	chr6:26111271	C/T	cg21479132	chr6:26055353	NA	0.97	7.0	0.42	2.74e-11	Autism spectrum disorder or schizophrenia;
SARC	trans	rs7824557	0.606	rs2736270	chr8:11192593	G/A	cg06636001	chr8:8085503	FLJ10661	0.62	8.12	0.47	2.66e-14	Retinal vascular caliber;
SARC	trans	rs1814175	0.791	rs10219223	chr11:49791468	A/T	cg03929089	chr4:120376271	NA	-0.9	-14.74	-0.69	3.46e-35	Height;
SARC	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg24829409	chr8:58192753	C8orf71	-0.61	-6.26	-0.38	1.81e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1153858	1.000	rs4775906	chr15:45638294	C/T	cg03999130	chr15:45571217	NA	0.39	4.93	0.31	1.58e-6	Homoarginine levels;
SARC	cis	rs13314892	0.764	rs79151317	chr3:69872713	G/A	cg17445875	chr3:69859618	MITF	-0.48	-5.08	-0.32	7.89e-7	QRS complex (12-leadsum);
SARC	cis	rs36051895	0.632	rs12337904	chr9:5144606	C/G	cg02405213	chr9:5042618	JAK2	-0.5	-6.2	-0.38	2.58e-9	Pediatric autoimmune diseases;
SARC	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg25036284	chr2:26402008	FAM59B	0.5	6.04	0.37	6.13e-9	Mean corpuscular hemoglobin;
SARC	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7084402	0.967	rs1649072	chr10:60298112	G/A	cg07615347	chr10:60278583	BICC1	0.59	8.77	0.5	3.93e-16	Refractive error;
SARC	cis	rs1348850	0.914	rs4893823	chr2:178285811	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.7	-8.9	-0.5	1.62e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs651907	0.514	rs12636047	chr3:101434449	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	6.39	0.39	8.85e-10	Colorectal cancer;
SARC	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg06634786	chr22:41940651	POLR3H	0.49	5.77	0.35	2.52e-8	Crohn's disease;Inflammatory bowel disease;
SARC	trans	rs208520	0.955	rs208532	chr6:66961280	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.82	-8.98	-0.51	9.32e-17	Exhaled nitric oxide output;
SARC	trans	rs9329221	0.710	rs11785061	chr8:10259528	G/C	cg06636001	chr8:8085503	FLJ10661	0.6	7.27	0.43	5.45e-12	Neuroticism;
SARC	cis	rs72781680	0.821	rs55948613	chr2:24094787	A/G	cg06627628	chr2:24431161	ITSN2	-0.55	-5.9	-0.36	1.26e-8	Lymphocyte counts;
SARC	cis	rs7666738	0.830	rs13147768	chr4:98833675	A/T	cg05340658	chr4:99064831	C4orf37	0.66	8.76	0.5	4.2e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10489202	0.608	rs4657733	chr1:168086434	G/A	cg24449463	chr1:168025552	DCAF6	-0.59	-7.72	-0.45	3.36e-13	Schizophrenia;
SARC	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg05861140	chr6:150128134	PCMT1	-0.37	-4.85	-0.3	2.29e-6	Lung cancer;
SARC	cis	rs71636778	0.631	rs113312820	chr1:27213079	A/G	cg04852280	chr1:26496234	ZNF593	0.58	5.14	0.32	5.79e-7	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs667920	0.575	rs9861150	chr3:136183320	G/T	cg15507776	chr3:136538369	TMEM22	0.65	6.76	0.41	1.07e-10	Coronary artery disease;
SARC	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg24829409	chr8:58192753	C8orf71	-0.55	-6.17	-0.37	2.94e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg09731288	chr10:112632370	PDCD4	0.49	6.42	0.39	7.39e-10	Chemerin levels;
SARC	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg00933542	chr6:150070202	PCMT1	0.34	5.92	0.36	1.16e-8	Lung cancer;
SARC	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg03709012	chr19:19516395	GATAD2A	1.0	17.43	0.75	3.97e-44	Tonsillectomy;
SARC	cis	rs7980687	0.550	rs1727324	chr12:123698603	A/T	cg05973401	chr12:123451056	ABCB9	0.55	5.16	0.32	5.32e-7	Height;Educational attainment;Head circumference (infant);
SARC	cis	rs911555	0.755	rs1116095	chr14:103931879	A/G	cg12935359	chr14:103987150	CKB	0.38	5.28	0.33	2.99e-7	Intelligence (multi-trait analysis);
SARC	cis	rs847851	0.583	rs3823437	chr6:35009809	A/G	cg04594399	chr6:34941065	ANKS1A	-0.43	-4.72	-0.3	4.15e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6665290	0.904	rs1186	chr1:227177731	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.07	-25.78	-0.86	3.44e-70	Myeloid white cell count;
SARC	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg18876405	chr7:65276391	NA	0.46	5.11	0.32	6.58e-7	Aortic root size;
SARC	cis	rs2072438	0.503	rs10739590	chr9:123871481	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.41	5.26	0.33	3.25e-7	Rheumatoid arthritis;
SARC	cis	rs2153535	0.563	rs1737585	chr6:8536594	A/G	cg07606381	chr6:8435919	SLC35B3	-0.78	-11.29	-0.59	7.12e-24	Motion sickness;
SARC	cis	rs2075371	0.966	rs2244690	chr7:133987039	A/G	cg20476274	chr7:133979776	SLC35B4	0.62	8.49	0.49	2.43e-15	Mean platelet volume;
SARC	cis	rs992157	0.560	rs6436047	chr2:219108913	A/C	cg20019365	chr2:219134978	PNKD;AAMP	0.6	8.26	0.48	1.09e-14	Colorectal cancer;
SARC	cis	rs11758351	1.000	rs76329209	chr6:26196430	A/G	cg23601095	chr6:26197514	HIST1H3D	0.62	5.39	0.33	1.68e-7	Gout;Renal underexcretion gout;
SARC	cis	rs6964587	0.839	rs62466809	chr7:91472801	A/G	cg17063962	chr7:91808500	NA	0.85	12.11	0.62	1.71e-26	Breast cancer;
SARC	cis	rs2952156	0.920	rs9303274	chr17:37836353	T/C	cg00129232	chr17:37814104	STARD3	-0.72	-10.21	-0.56	1.81e-20	Asthma;
SARC	cis	rs1345301	1.000	rs12474199	chr2:102868980	G/A	cg12451869	chr2:102867685	NA	0.39	5.52	0.34	9.24e-8	Waist circumference;
SARC	cis	rs765787	0.530	rs3759893	chr15:45542950	G/T	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.51e-10	Uric acid levels;
SARC	cis	rs123509	0.731	rs73087348	chr3:42811571	C/T	cg12982090	chr3:42733453	KBTBD5	-0.52	-5.72	-0.35	3.32e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	11.47	0.6	1.89e-24	Alzheimer's disease;
SARC	cis	rs9398803	1.000	rs9398803	chr6:126683594	A/G	cg20229609	chr6:126660872	C6orf173	0.4	5.81	0.36	2e-8	Male-pattern baldness;
SARC	cis	rs76419734	1.000	rs11722225	chr4:106766430	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	5.31	0.33	2.52e-7	Post bronchodilator FEV1;
SARC	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg11987759	chr7:65425863	GUSB	0.53	7.07	0.42	1.78e-11	Calcium levels;
SARC	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.54	-4.72	-0.3	4.03e-6	Schizophrenia;
SARC	cis	rs193541	0.501	rs3943379	chr5:122056137	A/G	cg19412675	chr5:122181750	SNX24	0.52	6.74	0.4	1.22e-10	Glucose homeostasis traits;
SARC	cis	rs1008375	1.000	rs2872958	chr4:17665032	A/G	cg27347728	chr4:17578864	LAP3	0.45	5.48	0.34	1.09e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg03709012	chr19:19516395	GATAD2A	0.97	15.48	0.71	1.19e-37	Tonsillectomy;
SARC	cis	rs929354	0.772	rs1182432	chr7:157029176	A/G	cg05182265	chr7:156933206	UBE3C	-0.32	-5.02	-0.31	1.03e-6	Body mass index;
SARC	cis	rs818427	0.964	rs463229	chr5:112201284	G/A	cg07820702	chr5:112228657	REEP5	0.44	4.89	0.3	1.89e-6	Total body bone mineral density;
SARC	cis	rs2933343	1.000	rs1683811	chr3:128612113	A/C	cg24203234	chr3:128598194	ACAD9	0.53	5.93	0.36	1.11e-8	IgG glycosylation;
SARC	cis	rs4690686	0.500	rs3921993	chr4:177263284	A/G	cg17059388	chr4:177262070	NA	0.36	4.78	0.3	3.09e-6	Essential tremor;
SARC	cis	rs11711311	1.000	rs2603792	chr3:113509187	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	8.09	0.47	3.26e-14	IgG glycosylation;
SARC	cis	rs239198	0.602	rs4840157	chr6:101326375	C/T	cg09795085	chr6:101329169	ASCC3	-0.49	-6.29	-0.38	1.57e-9	Menarche (age at onset);
SARC	cis	rs6570726	0.818	rs437147	chr6:145875423	A/T	cg05347473	chr6:146136440	FBXO30	0.53	7.34	0.43	3.59e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2562456	0.682	rs11085464	chr19:21751778	C/G	cg00455402	chr19:21769736	NA	-0.39	-4.95	-0.31	1.41e-6	Pain;
SARC	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg06028808	chr11:68637592	NA	0.43	5.69	0.35	3.89e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9300255	0.639	rs941306	chr12:123715113	C/T	cg00376283	chr12:123451042	ABCB9	0.52	6.03	0.37	6.37e-9	Neutrophil percentage of white cells;
SARC	cis	rs6728642	1.000	rs116171118	chr2:97695036	C/A	cg26665480	chr2:98280029	ACTR1B	-0.64	-5.07	-0.32	8.2e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs72717009	0.825	rs7529425	chr1:161479599	G/A	cg23840854	chr1:161414152	NA	-0.54	-5.04	-0.31	9.44e-7	Rheumatoid arthritis;
SARC	cis	rs6496667	0.865	rs1971899	chr15:90890664	C/A	cg22089800	chr15:90895588	ZNF774	0.5	4.79	0.3	2.92e-6	Rheumatoid arthritis;
SARC	cis	rs2920503	1.000	rs2920503	chr3:12324230	C/T	cg04748988	chr3:12329223	PPARG	0.62	7.37	0.43	2.99e-12	LDL cholesterol;
SARC	cis	rs924607	1.000	rs924607	chr5:610093	C/T	cg09021430	chr5:549028	NA	0.33	6.16	0.37	3.11e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg19223190	chr17:80058835	NA	-0.42	-5.73	-0.35	3.09e-8	Life satisfaction;
SARC	cis	rs79349575	0.715	rs11657238	chr17:46985634	A/G	cg16584676	chr17:46985605	UBE2Z	0.55	7.06	0.42	1.92e-11	Type 2 diabetes;
SARC	trans	rs80052780	0.579	rs298487	chr4:139258573	C/T	cg09529783	chr8:1958930	NA	0.62	6.5	0.39	4.73e-10	Response to paliperidone in schizophrenia (Multivariate);
SARC	trans	rs61931739	0.534	rs4547187	chr12:34041259	T/C	cg13010199	chr12:38710504	ALG10B	0.67	9.22	0.52	1.81e-17	Morning vs. evening chronotype;
SARC	cis	rs1904096	0.506	rs10024642	chr4:95179295	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.47	-6.95	-0.41	3.58e-11	Type 2 diabetes;
SARC	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg09359103	chr1:154839909	KCNN3	-0.46	-7.71	-0.45	3.72e-13	Prostate cancer;
SARC	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg18252515	chr7:66147081	NA	1.29	11.21	0.59	1.32e-23	Diabetic kidney disease;
SARC	cis	rs763121	0.819	rs5757237	chr22:39073835	G/C	cg06022373	chr22:39101656	GTPBP1	0.84	10.39	0.56	4.96e-21	Menopause (age at onset);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg11653675	chr2:46811648	RHOQ;PIGF	0.45	6.27	0.38	1.75e-9	Thyroid stimulating hormone;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg10576516	chr17:73663407	RECQL5;SAP30BP	0.51	6.46	0.39	5.9e-10	Tetralogy of Fallot;
SARC	cis	rs67460515	0.563	rs11713441	chr3:160906855	T/C	cg04691961	chr3:161091175	C3orf57	-0.4	-4.78	-0.3	3.17e-6	Parkinson's disease;
SARC	cis	rs10504229	0.679	rs16921683	chr8:58053270	T/C	cg11062466	chr8:58055876	NA	0.51	5.05	0.31	8.85e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.57	-0.4	3.19e-10	Total body bone mineral density;
SARC	trans	rs9325144	0.555	rs1813392	chr12:38692203	C/T	cg23762105	chr12:34175262	ALG10	0.48	6.35	0.38	1.12e-9	Morning vs. evening chronotype;
SARC	cis	rs7223966	1.000	rs16947042	chr17:61766457	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.48	-5.35	-0.33	2.07e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg11987759	chr7:65425863	GUSB	0.61	8.28	0.48	9.39e-15	Aortic root size;
SARC	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg09323728	chr8:95962352	TP53INP1	-0.33	-5.41	-0.33	1.59e-7	Type 2 diabetes;
SARC	cis	rs72781680	1.000	rs72796358	chr2:24160132	T/A	cg08917208	chr2:24149416	ATAD2B	0.77	7.15	0.42	1.12e-11	Lymphocyte counts;
SARC	cis	rs12586317	0.547	rs112138868	chr14:35444385	C/T	cg26967526	chr14:35346199	BAZ1A	-0.57	-5.7	-0.35	3.53e-8	Psoriasis;
SARC	cis	rs6701037	0.566	rs10489326	chr1:175134677	A/G	cg00321850	chr1:175162397	KIAA0040	0.38	5.92	0.36	1.13e-8	Alcohol dependence;
SARC	cis	rs9300255	0.544	rs1716157	chr12:123670473	T/C	cg05973401	chr12:123451056	ABCB9	0.52	5.89	0.36	1.34e-8	Neutrophil percentage of white cells;
SARC	cis	rs9921192	0.967	rs3747571	chr16:4323983	A/G	cg07945448	chr16:4304224	NA	0.55	7.04	0.42	2.12e-11	Prostate-specific antigen levels;
SARC	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg13393036	chr8:95962371	TP53INP1	-0.39	-6.58	-0.4	3.04e-10	Type 2 diabetes;
SARC	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg07343612	chr16:622815	PIGQ	-0.56	-7.68	-0.45	4.26e-13	Height;
SARC	cis	rs10504229	0.871	rs56048296	chr8:58163781	C/T	cg08219700	chr8:58056026	NA	0.43	4.77	0.3	3.22e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.520	rs55967509	chr8:57992448	A/G	cg11062466	chr8:58055876	NA	0.55	5.06	0.31	8.4e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg20887711	chr4:1340912	KIAA1530	0.77	9.85	0.54	2.34e-19	Longevity;
SARC	cis	rs9911578	0.835	rs9788975	chr17:56460800	G/A	cg12560992	chr17:57184187	TRIM37	-0.73	-9.19	-0.52	2.29e-17	Intelligence (multi-trait analysis);
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg06026548	chr3:184529869	VPS8	-0.59	-7.81	-0.46	1.96e-13	Gallstone disease;
SARC	cis	rs12586317	0.586	rs74243591	chr14:35520917	C/T	cg26967526	chr14:35346199	BAZ1A	-0.57	-5.74	-0.35	3e-8	Psoriasis;
SARC	cis	rs11249608	0.548	rs2132672	chr5:178457742	A/C	cg21905437	chr5:178450457	ZNF879	0.57	7.59	0.45	7.54e-13	Pubertal anthropometrics;
SARC	cis	rs10875746	0.951	rs61918826	chr12:48543978	T/C	cg26205652	chr12:48591994	NA	0.57	6.23	0.38	2.14e-9	Longevity (90 years and older);
SARC	cis	rs8014204	0.967	rs1319171	chr14:75334096	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.74	-10.77	-0.58	3.27e-22	Caffeine consumption;
SARC	cis	rs35110281	0.693	rs4819290	chr21:45122713	C/T	cg21573476	chr21:45109991	RRP1B	-0.58	-8.22	-0.47	1.46e-14	Mean corpuscular volume;
SARC	cis	rs2075371	1.000	rs1421485	chr7:133985181	C/T	cg20476274	chr7:133979776	SLC35B4	0.62	8.49	0.49	2.43e-15	Mean platelet volume;
SARC	cis	rs77106637	0.932	rs74439784	chr11:72649396	A/T	cg03713592	chr11:72463424	ARAP1	0.86	8.04	0.47	4.44e-14	Type 2 diabetes;
SARC	cis	rs2075371	0.611	rs11762920	chr7:134018514	C/T	cg11752832	chr7:134001865	SLC35B4	0.5	6.22	0.38	2.3e-9	Mean platelet volume;
SARC	cis	rs10927875	1.000	rs3979179	chr1:16306846	A/G	cg21385522	chr1:16154831	NA	0.79	9.84	0.54	2.44e-19	Dilated cardiomyopathy;
SARC	cis	rs12421382	0.636	rs60266280	chr11:109387766	A/C	cg27471124	chr11:109292789	C11orf87	0.36	5.02	0.31	1.05e-6	Schizophrenia;
SARC	cis	rs9902453	0.967	rs6505155	chr17:28372783	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.53	-6.96	-0.41	3.47e-11	Coffee consumption (cups per day);
SARC	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg14784868	chr12:69753453	YEATS4	0.63	8.8	0.5	3.21e-16	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9611565	0.921	rs2143695	chr22:41728620	A/G	cg03806693	chr22:41940476	POLR3H	-0.69	-9.29	-0.52	1.1e-17	Vitiligo;
SARC	cis	rs6089584	1.000	rs6089580	chr20:60558976	G/A	cg13770153	chr20:60521292	NA	-0.55	-7.78	-0.45	2.37e-13	Body mass index;
SARC	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-5.56	-0.34	7.23e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs8070128	0.534	rs2955350	chr17:17953548	G/A	cg04398451	chr17:18023971	MYO15A	0.47	6.55	0.39	3.55e-10	Total body bone mineral density;
SARC	cis	rs12142240	0.698	rs45517837	chr1:46859225	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-5.56	-0.34	7.46e-8	Menopause (age at onset);
SARC	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg03806693	chr22:41940476	POLR3H	-0.91	-12.41	-0.63	1.69e-27	Vitiligo;
SARC	cis	rs2652834	0.851	rs16946416	chr15:63356721	A/T	cg05507819	chr15:63340323	TPM1	-0.61	-6.14	-0.37	3.57e-9	HDL cholesterol;
SARC	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg02841227	chr6:26021843	HIST1H4A	-0.44	-5.17	-0.32	5.05e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6840360	0.593	rs6847844	chr4:152693246	C/T	cg22705602	chr4:152727874	NA	-0.5	-8.81	-0.5	2.98e-16	Intelligence (multi-trait analysis);
SARC	cis	rs950169	1.000	rs12903820	chr15:84723820	A/G	cg24253500	chr15:84953950	NA	0.35	5.08	0.32	7.66e-7	Schizophrenia;
SARC	trans	rs3857536	0.740	rs7756519	chr6:66892275	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.6	-7.14	-0.42	1.19e-11	Blood trace element (Cu levels);
SARC	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg02574844	chr11:5959923	NA	0.44	6.12	0.37	3.9e-9	DNA methylation (variation);
SARC	cis	rs11583043	0.958	rs12746722	chr1:101464789	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.49	5.74	0.35	2.97e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs2276314	0.857	rs9304155	chr18:33585710	A/C	cg19628046	chr18:33552617	C18orf21	0.58	5.95	0.36	9.62e-9	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg13939156	chr17:80058883	NA	0.4	6.25	0.38	1.92e-9	Life satisfaction;
SARC	cis	rs1728785	0.901	rs1170444	chr16:68573287	T/C	cg02972257	chr16:68554789	NA	-0.44	-5.15	-0.32	5.43e-7	Ulcerative colitis;
SARC	cis	rs8031584	0.958	rs11629793	chr15:31238423	G/A	cg08109568	chr15:31115862	NA	-0.47	-5.8	-0.35	2.2e-8	Huntington's disease progression;
SARC	trans	rs9325144	0.647	rs11169222	chr12:39105210	C/T	cg23762105	chr12:34175262	ALG10	0.49	6.25	0.38	1.96e-9	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs17125944	0.686	rs7144029	chr14:53333616	G/T	cg00686598	chr14:53173677	PSMC6	-0.72	-5.46	-0.34	1.19e-7	Alzheimer's disease (late onset);
SARC	cis	rs7246760	0.867	rs1115825	chr19:9786121	C/G	cg16876255	chr19:9731953	ZNF561	0.82	5.05	0.31	8.72e-7	Pursuit maintenance gain;
SARC	cis	rs10046574	0.831	rs7810503	chr7:135142285	T/C	cg27474649	chr7:135195673	CNOT4	0.87	7.2	0.43	8.45e-12	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg06634786	chr22:41940651	POLR3H	-0.65	-7.75	-0.45	2.86e-13	Vitiligo;
SARC	cis	rs9291683	0.507	rs6849273	chr4:10021595	C/T	cg11266682	chr4:10021025	SLC2A9	0.39	6.82	0.41	7.94e-11	Bone mineral density;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg26156301	chr20:30193024	ID1	-0.51	-6.23	-0.38	2.15e-9	Schizophrenia;
SARC	cis	rs17376456	0.825	rs6877030	chr5:93201841	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.7	6.34	0.38	1.19e-9	Diabetic retinopathy;
SARC	cis	rs6570726	0.905	rs419575	chr6:145840174	A/G	cg05220968	chr6:146057943	EPM2A	-0.29	-4.99	-0.31	1.19e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7927771	1.000	rs11039390	chr11:47796295	C/G	cg05585544	chr11:47624801	NA	-0.36	-4.82	-0.3	2.59e-6	Subjective well-being;
SARC	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg24675658	chr1:53192096	ZYG11B	0.6	8.35	0.48	6.11e-15	Monocyte count;
SARC	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	11.03	0.59	4.93e-23	Alzheimer's disease;
SARC	cis	rs9443189	0.901	rs2038624	chr6:76560707	T/C	cg01950844	chr6:76311363	SENP6	-0.76	-6.4	-0.39	8.38e-10	Prostate cancer;
SARC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.72	7.38	0.44	2.84e-12	Platelet count;
SARC	cis	rs9303401	0.659	rs12946397	chr17:56769979	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	11.87	0.61	9.72e-26	Cognitive test performance;
SARC	cis	rs10193935	0.892	rs7574609	chr2:42388468	C/A	cg27598129	chr2:42591480	NA	-0.36	-5.0	-0.31	1.13e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6831352	0.569	rs4148883	chr4:100066332	T/C	cg13256891	chr4:100009986	ADH5	0.47	6.03	0.37	6.24e-9	Alcohol dependence;
SARC	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg27104117	chr17:27276789	PHF12	0.5	6.25	0.38	1.91e-9	Migraine with aura;
SARC	cis	rs7927771	0.929	rs12787646	chr11:47669665	T/C	cg20307385	chr11:47447363	PSMC3	-0.46	-5.52	-0.34	8.96e-8	Subjective well-being;
SARC	cis	rs4689388	0.853	rs6446479	chr4:6291737	G/C	cg25554036	chr4:6271136	WFS1	0.4	6.43	0.39	7.33e-10	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs11711311	0.955	rs12630833	chr3:113390883	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	8.19	0.47	1.72e-14	IgG glycosylation;
SARC	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg00149659	chr3:10157352	C3orf10	0.69	6.9	0.41	4.76e-11	Alzheimer's disease;
SARC	cis	rs7582180	0.627	rs4149517	chr2:101014247	C/A	cg14675211	chr2:100938903	LONRF2	0.52	7.67	0.45	4.61e-13	Intelligence (multi-trait analysis);
SARC	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg00933542	chr6:150070202	PCMT1	0.32	5.34	0.33	2.23e-7	Lung cancer;
SARC	trans	rs61931739	0.621	rs843785	chr12:33729308	C/T	cg26384229	chr12:38710491	ALG10B	-0.51	-6.32	-0.38	1.34e-9	Morning vs. evening chronotype;
SARC	cis	rs7927771	0.524	rs1563820	chr11:47833398	A/T	cg10504702	chr11:47789108	FNBP4	-0.43	-5.62	-0.35	5.52e-8	Subjective well-being;
SARC	cis	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg08045932	chr20:61659980	NA	0.51	6.96	0.42	3.35e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs67311347	0.568	rs9864544	chr3:40336204	T/C	cg24209194	chr3:40518798	ZNF619	0.48	6.42	0.39	7.46e-10	Renal cell carcinoma;
SARC	cis	rs4969178	0.965	rs11653305	chr17:76386918	T/C	cg20026190	chr17:76395443	PGS1	0.4	5.34	0.33	2.24e-7	HDL cholesterol levels;
SARC	cis	rs2273669	0.667	rs12198088	chr6:109338433	C/T	cg05315195	chr6:109294784	ARMC2	-0.63	-5.7	-0.35	3.6e-8	Prostate cancer;
SARC	cis	rs7617773	0.817	rs35456569	chr3:48250899	T/A	cg11946769	chr3:48343235	NME6	0.72	9.36	0.52	7.22e-18	Coronary artery disease;
SARC	cis	rs763121	0.853	rs5757226	chr22:39070550	T/C	cg21395723	chr22:39101663	GTPBP1	0.54	6.14	0.37	3.53e-9	Menopause (age at onset);
SARC	cis	rs4481887	0.708	rs6696691	chr1:248539720	T/C	cg13385794	chr1:248469461	NA	0.35	5.57	0.34	6.97e-8	Common traits (Other);
SARC	cis	rs7762018	0.607	rs75438963	chr6:170047695	G/A	cg13891659	chr6:170190454	C6orf122;C6orf208	0.76	5.02	0.31	1.03e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg10591111	chr5:226296	SDHA	-0.55	-4.97	-0.31	1.31e-6	Breast cancer;
SARC	cis	rs9513593	1.000	rs2182954	chr13:99937082	A/G	cg21788972	chr13:99853209	UBAC2	0.5	5.14	0.32	5.72e-7	Psoriasis;
SARC	cis	rs3741404	0.609	rs669913	chr11:63869879	A/G	cg04317338	chr11:64019027	PLCB3	0.48	5.52	0.34	8.86e-8	Platelet count;
SARC	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	10.45	0.56	3.3e-21	Platelet count;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg22898145	chr2:162096490	NA	0.48	7.2	0.43	8.23e-12	Thyroid stimulating hormone;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg05087722	chr2:241404981	GPC1	0.51	6.82	0.41	7.59e-11	Schizophrenia;
SARC	cis	rs7020830	0.931	rs7034554	chr9:37081301	A/G	cg14294708	chr9:37120828	ZCCHC7	1.15	21.49	0.82	3.29e-57	Schizophrenia;
SARC	cis	rs4481887	0.927	rs4341391	chr1:248475720	A/G	cg13385794	chr1:248469461	NA	0.35	5.46	0.34	1.21e-7	Common traits (Other);
SARC	cis	rs9486715	1.000	rs6905737	chr6:97066659	A/T	cg06623918	chr6:96969491	KIAA0776	-0.82	-11.32	-0.6	5.65e-24	Headache;
SARC	cis	rs11583043	1.000	rs6675353	chr1:101459625	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.49	6.0	0.37	7.41e-9	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs208515	0.592	rs10944862	chr6:66674215	C/T	cg07460842	chr6:66804631	NA	0.96	11.1	0.59	2.97e-23	Exhaled nitric oxide levels;
SARC	cis	rs2228479	0.850	rs62056063	chr16:89903680	C/T	cg12064134	chr16:90016061	DEF8	-0.56	-4.79	-0.3	2.91e-6	Skin colour saturation;
SARC	cis	rs981844	0.712	rs10009854	chr4:154741785	C/T	cg14289246	chr4:154710475	SFRP2	-0.44	-5.07	-0.32	8.03e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs3796352	1.000	rs34979715	chr3:53048960	G/A	cg12962167	chr3:53033115	SFMBT1	0.82	5.36	0.33	2.04e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs7119	0.717	rs12898281	chr15:77786903	C/T	cg17802220	chr15:77601643	NA	0.45	5.97	0.36	8.88e-9	Type 2 diabetes;
SARC	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg04756594	chr16:24857601	SLC5A11	0.43	5.8	0.36	2.18e-8	Intelligence (multi-trait analysis);
SARC	trans	rs3942852	0.545	rs10838798	chr11:48091303	T/G	cg15704280	chr7:45808275	SEPT13	-0.66	-8.71	-0.5	5.74e-16	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs10752881	0.967	rs6695746	chr1:182991355	T/C	cg13390022	chr1:182993471	LAMC1	0.34	5.23	0.32	3.79e-7	Colorectal cancer;
SARC	cis	rs12887734	0.569	rs66953418	chr14:104271470	G/A	cg26031613	chr14:104095156	KLC1	-0.47	-5.45	-0.34	1.31e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.39	-6.28	-0.38	1.67e-9	Longevity;Endometriosis;
SARC	cis	rs13091206	1	rs13091206	chr3:49238718	A/G	cg07636037	chr3:49044803	WDR6	0.82	8.11	0.47	2.95e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg20607798	chr8:58055168	NA	0.54	4.76	0.3	3.43e-6	Developmental language disorder (linguistic errors);
SARC	trans	rs7752643	0.760	rs7752899	chr6:84287712	C/T	cg14512089	chr1:160771850	LY9	0.31	6.32	0.38	1.31e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg03213289	chr20:61660250	NA	0.46	6.43	0.39	7.22e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs965469	0.779	rs57373308	chr20:3314715	G/C	cg25506879	chr20:3388711	C20orf194	-0.46	-4.82	-0.3	2.61e-6	IFN-related cytopenia;
SARC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg04267008	chr7:1944627	MAD1L1	0.66	8.05	0.47	4.3e-14	Bipolar disorder and schizophrenia;
SARC	cis	rs2228479	0.850	rs3785279	chr16:89824562	G/C	cg06558623	chr16:89946397	TCF25	0.88	6.21	0.38	2.39e-9	Skin colour saturation;
SARC	cis	rs240764	0.528	rs964223	chr6:101250982	T/A	cg09795085	chr6:101329169	ASCC3	0.39	4.83	0.3	2.49e-6	Neuroticism;
SARC	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg11987759	chr7:65425863	GUSB	0.47	5.87	0.36	1.49e-8	Aortic root size;
SARC	cis	rs7681440	0.904	rs6816305	chr4:90772902	C/G	cg02192967	chr4:90758406	SNCA	0.37	5.26	0.33	3.22e-7	Dementia with Lewy bodies;
SARC	cis	rs9325144	0.555	rs4882359	chr12:38726679	T/C	cg26384229	chr12:38710491	ALG10B	0.6	7.86	0.46	1.39e-13	Morning vs. evening chronotype;
SARC	cis	rs9911578	0.967	rs12938821	chr17:56959422	T/C	cg05425664	chr17:57184151	TRIM37	-0.65	-7.99	-0.46	6.29e-14	Intelligence (multi-trait analysis);
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg00554614	chr7:127225750	GCC1	-0.5	-6.31	-0.38	1.35e-9	Gallstone disease;
SARC	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	8.86	0.5	2.16e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs13082711	0.522	rs653886	chr3:27343549	C/T	cg02860705	chr3:27208620	NA	0.41	5.43	0.34	1.43e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs3126085	0.935	rs6587647	chr1:152192631	C/T	cg03465714	chr1:152285911	FLG	-0.46	-5.51	-0.34	9.24e-8	Atopic dermatitis;
SARC	cis	rs7647973	0.925	rs7429661	chr3:49228800	G/A	cg06212747	chr3:49208901	KLHDC8B	0.6	6.1	0.37	4.39e-9	Menarche (age at onset);
SARC	cis	rs9398803	0.865	rs9388495	chr6:126782457	G/A	cg19875578	chr6:126661172	C6orf173	0.6	8.1	0.47	3.17e-14	Male-pattern baldness;
SARC	cis	rs9916302	0.653	rs11657058	chr17:37699378	T/G	cg20243544	chr17:37824526	PNMT	0.53	5.46	0.34	1.23e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs763121	0.925	rs5757251	chr22:39100128	G/A	cg21395723	chr22:39101663	GTPBP1	0.46	5.37	0.33	1.86e-7	Menopause (age at onset);
SARC	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg24531977	chr5:56204891	C5orf35	-0.54	-5.45	-0.34	1.26e-7	Initial pursuit acceleration;
SARC	cis	rs7818345	0.935	rs7016592	chr8:19277735	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.43	5.92	0.36	1.12e-8	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs742614	0.533	rs6059497	chr20:32446960	C/G	cg06304546	chr20:32448765	NA	-0.58	-7.6	-0.45	7.01e-13	Stearic acid (18:0) levels;
SARC	cis	rs3857536	0.740	rs4710571	chr6:66890250	T/C	cg07460842	chr6:66804631	NA	-0.6	-7.16	-0.42	1.04e-11	Blood trace element (Cu levels);
SARC	cis	rs1008375	0.932	rs9291660	chr4:17663414	A/G	cg27347728	chr4:17578864	LAP3	0.47	5.66	0.35	4.46e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7560272	0.512	rs4530394	chr2:73929650	T/C	cg20560298	chr2:73613845	ALMS1	0.49	6.44	0.39	6.76e-10	Schizophrenia;
SARC	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg08859206	chr1:53392774	SCP2	-0.39	-5.55	-0.34	7.87e-8	Monocyte count;
SARC	cis	rs1113500	0.932	rs1343205	chr1:108597873	C/G	cg06207961	chr1:108661230	NA	0.42	5.45	0.34	1.25e-7	Growth-regulated protein alpha levels;
SARC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg07161166	chr1:84543374	PRKACB	-0.59	-6.34	-0.38	1.15e-9	Hepatitis;
SARC	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	10.9	0.58	1.25e-22	Platelet count;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg05210131	chr2:182757482	SSFA2	-0.54	-6.68	-0.4	1.73e-10	Schizophrenia;
SARC	cis	rs722599	0.683	rs10144845	chr14:75237770	C/T	cg06637938	chr14:75390232	RPS6KL1	0.44	5.48	0.34	1.09e-7	IgG glycosylation;
SARC	cis	rs920590	0.758	rs1817836	chr8:19664852	T/C	cg01411142	chr8:19674711	INTS10	0.5	5.88	0.36	1.44e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs6088580	0.634	rs6059856	chr20:33057954	G/C	cg24642439	chr20:33292090	TP53INP2	0.67	8.77	0.5	3.9e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs76419734	1.000	rs72671835	chr4:106631356	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.84	5.56	0.34	7.44e-8	Post bronchodilator FEV1;
SARC	cis	rs644799	0.511	rs10831420	chr11:95478209	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.76	10.25	0.56	1.38e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9393692	0.557	rs56763414	chr6:26286468	T/C	cg13736514	chr6:26305472	NA	-0.41	-4.81	-0.3	2.7e-6	Educational attainment;
SARC	cis	rs10927875	0.632	rs2862162	chr1:16142960	A/C	cg21385522	chr1:16154831	NA	0.91	13.24	0.66	3.37e-30	Dilated cardiomyopathy;
SARC	cis	rs5753618	0.561	rs2040533	chr22:31679110	G/C	cg07713946	chr22:31675144	LIMK2	-0.37	-5.23	-0.32	3.82e-7	Colorectal cancer;
SARC	trans	rs2727020	0.729	rs1164685	chr11:49293660	G/A	cg03929089	chr4:120376271	NA	0.77	11.6	0.61	7.15e-25	Coronary artery disease;
SARC	cis	rs7568458	0.660	rs55692129	chr2:85792404	A/T	cg02493740	chr2:85810744	VAMP5	-0.41	-4.98	-0.31	1.25e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs10752881	0.652	rs10911262	chr1:183114956	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.67	9.41	0.52	4.96e-18	Colorectal cancer;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg10491652	chr1:156052205	MEX3A	0.5	6.64	0.4	2.21e-10	Thyroid stimulating hormone;
SARC	cis	rs1401999	0.898	rs6443928	chr3:183729487	C/T	cg01324343	chr3:183735012	ABCC5	0.66	13.23	0.65	3.67e-30	Anterior chamber depth;
SARC	cis	rs2354432	1.000	rs10900325	chr1:146692174	C/T	cg25205988	chr1:146714368	CHD1L	-1.09	-11.1	-0.59	2.93e-23	Mitochondrial DNA levels;
SARC	cis	rs4280164	0.551	rs3212242	chr14:24810401	C/T	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.53	-5.41	-0.33	1.53e-7	Parent of origin effect on language impairment (paternal);
SARC	trans	rs1853207	0.737	rs9332098	chr10:96697459	G/A	cg02737782	chr1:8014393	NA	-0.92	-6.55	-0.39	3.72e-10	Blood metabolite levels;
SARC	trans	rs1411916	0.688	rs56276800	chr9:80974061	A/G	cg22801675	chr5:175971121	NA	-0.8	-6.23	-0.38	2.15e-9	Visceral fat;
SARC	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	10.68	0.57	6.06e-22	Platelet count;
SARC	cis	rs10875746	0.859	rs4760622	chr12:48591960	C/A	cg26205652	chr12:48591994	NA	0.48	5.51	0.34	9.57e-8	Longevity (90 years and older);
SARC	cis	rs3106136	0.967	rs2171381	chr4:95224768	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.89	-0.36	1.35e-8	Capecitabine sensitivity;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg13606015	chr3:43732015	ABHD5	0.56	7.18	0.43	9.44e-12	Blood pressure;
SARC	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	16.7	0.74	1.06e-41	Height;
SARC	cis	rs10911232	0.507	rs7547953	chr1:183031641	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.1	0.55	3.92e-20	Hypertriglyceridemia;
SARC	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg04277193	chr17:41438351	NA	0.47	5.04	0.31	9.3e-7	Menopause (age at onset);
SARC	trans	rs1994135	0.617	rs1384590	chr12:33734271	C/T	cg26384229	chr12:38710491	ALG10B	0.71	8.71	0.5	5.86e-16	Resting heart rate;
SARC	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg01475735	chr3:40494733	NA	-0.49	-5.43	-0.34	1.39e-7	Renal cell carcinoma;
SARC	cis	rs9916302	0.752	rs12150047	chr17:37601755	A/G	cg20243544	chr17:37824526	PNMT	0.54	5.61	0.35	5.69e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs2635047	0.935	rs2576031	chr18:44658146	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.58	7.86	0.46	1.45e-13	Educational attainment;
SARC	cis	rs1865760	0.865	rs9467651	chr6:25958257	C/G	cg17691542	chr6:26056736	HIST1H1C	0.58	7.37	0.43	2.91e-12	Height;
SARC	cis	rs2731664	0.792	rs335435	chr5:176867943	A/G	cg23176889	chr5:176863531	GRK6	-0.56	-8.13	-0.47	2.54e-14	Intelligence (multi-trait analysis);
SARC	cis	rs6429082	0.523	rs704718	chr1:235666159	A/T	cg26050004	chr1:235667680	B3GALNT2	0.8	13.19	0.65	4.72e-30	Adiposity;
SARC	cis	rs9487051	0.676	rs6568560	chr6:109592851	G/A	cg01475377	chr6:109611718	NA	-0.35	-5.08	-0.32	7.66e-7	Reticulocyte fraction of red cells;
SARC	cis	rs9399135	0.660	rs4472368	chr6:135274232	A/G	cg24558204	chr6:135376177	HBS1L	0.45	6.12	0.37	3.97e-9	Red blood cell count;
SARC	cis	rs9435341	0.965	rs9435441	chr1:107603330	C/G	cg09367891	chr1:107599246	PRMT6	-0.63	-7.91	-0.46	1.06e-13	Facial morphology (factor 21, depth of nasal alae);
SARC	cis	rs2153535	0.580	rs1414340	chr6:8491139	G/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.45	0.6	2.26e-24	Motion sickness;
SARC	cis	rs6665290	0.904	rs10495273	chr1:227183359	T/G	cg10327440	chr1:227177885	CDC42BPA	-1.08	-24.77	-0.85	3.19e-67	Myeloid white cell count;
SARC	trans	rs11098499	0.908	rs11729050	chr4:120300066	T/C	cg25214090	chr10:38739885	LOC399744	0.55	7.14	0.42	1.15e-11	Corneal astigmatism;
SARC	cis	rs11166927	0.548	rs2100803	chr8:140839371	A/C	cg16909799	chr8:140841666	TRAPPC9	-0.4	-5.64	-0.35	4.83e-8	Pediatric non-alcoholic fatty liver disease activity score;
SARC	cis	rs4479964	0.605	rs62421091	chr6:129962590	C/A	cg27192990	chr6:129479024	LAMA2	0.29	4.82	0.3	2.56e-6	Gut microbiome composition (summer);
SARC	cis	rs7792596	0.964	rs2374717	chr7:93992345	C/T	cg20814616	chr7:94014465	NA	-0.46	-5.77	-0.35	2.51e-8	Intelligence;
SARC	cis	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg13072238	chr3:49761600	GMPPB	0.42	5.35	0.33	2.1e-7	Intelligence (multi-trait analysis);
SARC	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg04944784	chr2:26401820	FAM59B	-0.52	-6.53	-0.39	4.15e-10	Gut microbiome composition (summer);
SARC	cis	rs2200578	0.732	rs56143125	chr2:99565143	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.61	5.59	0.34	6.3e-8	IgG glycosylation;
SARC	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7945705	0.782	rs2742545	chr11:8884308	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.45	-6.44	-0.39	6.8e-10	Hemoglobin concentration;
SARC	cis	rs4561483	0.801	rs4511557	chr16:11949458	T/C	cg08843971	chr16:11963173	GSPT1	0.42	5.21	0.32	4.24e-7	Testicular germ cell tumor;
SARC	cis	rs3087591	0.922	rs2905879	chr17:29545431	T/A	cg24425628	chr17:29625626	OMG;NF1	0.5	6.19	0.38	2.7e-9	Hip circumference;
SARC	cis	rs6674176	0.628	rs3828146	chr1:44428715	C/T	cg12908607	chr1:44402522	ARTN	-0.38	-6.51	-0.39	4.44e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	trans	rs1493916	0.777	rs1941685	chr18:31304318	G/T	cg27147174	chr7:100797783	AP1S1	-0.51	-6.27	-0.38	1.77e-9	Life satisfaction;
SARC	cis	rs8014204	0.804	rs2287403	chr14:75259140	C/T	cg06637938	chr14:75390232	RPS6KL1	0.7	10.08	0.55	4.45e-20	Caffeine consumption;
SARC	cis	rs7647973	0.848	rs4292260	chr3:49148890	T/C	cg07636037	chr3:49044803	WDR6	0.9	10.5	0.57	2.36e-21	Menarche (age at onset);
SARC	cis	rs11018904	0.906	rs17227345	chr11:89954685	A/T	cg26028595	chr11:89956573	CHORDC1	0.49	4.76	0.3	3.39e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7552404	0.727	rs61770533	chr1:76306490	C/G	cg10523679	chr1:76189770	ACADM	0.46	5.37	0.33	1.89e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs17253792	0.822	rs10147431	chr14:56091841	G/A	cg01858014	chr14:56050164	KTN1	-0.67	-5.11	-0.32	6.86e-7	Putamen volume;
SARC	cis	rs6570726	0.935	rs414646	chr6:145831685	T/C	cg23711669	chr6:146136114	FBXO30	0.78	11.86	0.61	1.04e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2290402	0.536	rs17165130	chr4:875339	A/C	cg00846425	chr4:957561	DGKQ	0.42	4.83	0.3	2.52e-6	Type 2 diabetes;
SARC	cis	rs743757	1.000	rs743756	chr3:50481717	C/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.51	4.85	0.3	2.29e-6	Diastolic blood pressure;
SARC	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg18876405	chr7:65276391	NA	-0.45	-5.15	-0.32	5.56e-7	Aortic root size;
SARC	trans	rs61931739	0.534	rs1608912	chr12:34008574	C/T	cg13010199	chr12:38710504	ALG10B	0.64	8.39	0.48	4.79e-15	Morning vs. evening chronotype;
SARC	cis	rs11731606	0.508	rs12108452	chr4:95300688	A/C	cg00507259	chr4:95128692	SMARCAD1	0.5	5.02	0.31	1.03e-6	Mean platelet volume;
SARC	cis	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg03213289	chr20:61660250	NA	0.45	6.16	0.37	3.11e-9	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.36	-0.52	6.88e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs2228479	0.702	rs62053702	chr16:89860688	G/T	cg06558623	chr16:89946397	TCF25	0.94	6.6	0.4	2.67e-10	Skin colour saturation;
SARC	trans	rs9929218	1.000	rs8044058	chr16:68807088	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.54	-6.77	-0.41	1.05e-10	Colorectal cancer;
SARC	cis	rs12930096	1.000	rs55947021	chr16:11678949	C/A	cg07439791	chr16:11680400	LITAF	0.57	5.71	0.35	3.46e-8	QT interval;
SARC	cis	rs2120019	1.000	rs7168680	chr15:75369212	G/A	cg12414181	chr15:75287860	SCAMP5	-0.42	-4.89	-0.31	1.87e-6	Blood trace element (Zn levels);
SARC	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg03033257	chr22:50311977	ALG12;CRELD2	0.61	5.8	0.36	2.1e-8	Schizophrenia;
SARC	trans	rs2727020	0.521	rs7126835	chr11:49594658	T/C	cg03929089	chr4:120376271	NA	-0.69	-7.59	-0.45	7.66e-13	Coronary artery disease;
SARC	cis	rs1062177	1.000	rs2915869	chr5:151171509	C/T	cg00977110	chr5:151150581	G3BP1	0.58	5.92	0.36	1.14e-8	Preschool internalizing problems;
SARC	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg00339695	chr16:24857497	SLC5A11	0.41	5.78	0.35	2.32e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9843304	0.772	rs4681515	chr3:149212076	A/G	cg08667024	chr3:149219783	TM4SF4	0.36	5.55	0.34	7.78e-8	Gallstone disease;
SARC	cis	rs1580019	0.539	rs11769109	chr7:32571352	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.55	7.19	0.43	8.54e-12	Cognitive ability;
SARC	cis	rs734999	0.588	rs2843402	chr1:2528682	T/C	cg20673091	chr1:2541236	MMEL1	-0.33	-5.09	-0.32	7.54e-7	Ulcerative colitis;
SARC	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	11.44	0.6	2.46e-24	Platelet count;
SARC	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg03517284	chr6:25882590	NA	-0.6	-7.43	-0.44	2.03e-12	Intelligence (multi-trait analysis);
SARC	cis	rs3767633	0.925	rs1806594	chr1:161858860	T/C	cg09175582	chr1:161736000	ATF6	0.65	5.5	0.34	9.86e-8	IgG glycosylation;
SARC	cis	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg03213289	chr20:61660250	NA	0.45	6.08	0.37	4.87e-9	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs9300255	0.568	rs1727300	chr12:123664205	C/T	cg05973401	chr12:123451056	ABCB9	0.52	5.89	0.36	1.34e-8	Neutrophil percentage of white cells;
SARC	cis	rs6582630	0.537	rs7299661	chr12:38527713	C/T	cg13010199	chr12:38710504	ALG10B	0.75	10.4	0.56	4.79e-21	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg24503407	chr1:205819492	PM20D1	0.45	5.12	0.32	6.31e-7	Parkinson's disease;
SARC	cis	rs72781680	1.000	rs72796357	chr2:24160131	A/G	cg06627628	chr2:24431161	ITSN2	-0.68	-6.32	-0.38	1.35e-9	Lymphocyte counts;
SARC	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	16.12	0.73	8.93e-40	Chronic sinus infection;
SARC	cis	rs7769051	0.522	rs6569852	chr6:133108333	C/A	cg07930552	chr6:133119739	C6orf192	0.88	5.24	0.32	3.54e-7	Type 2 diabetes nephropathy;
SARC	cis	rs3818285	0.885	rs10787217	chr10:111621103	A/T	cg00817464	chr10:111662876	XPNPEP1	0.38	5.1	0.32	7.16e-7	Superior crus of antihelix expression;
SARC	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs67460515	0.563	rs13256	chr3:160796505	G/A	cg03342759	chr3:160939853	NMD3	-0.66	-7.63	-0.45	5.79e-13	Parkinson's disease;
SARC	cis	rs1800469	1.000	rs1549933	chr19:41871142	A/G	cg08477640	chr19:41863820	B9D2	0.69	9.09	0.51	4.32e-17	Colorectal cancer;
SARC	cis	rs116095464	0.558	rs9312979	chr5:222057	A/C	cg22496380	chr5:211416	CCDC127	-0.89	-7.97	-0.46	7.24e-14	Breast cancer;
SARC	cis	rs1401999	0.714	rs1533683	chr3:183635488	C/T	cg01324343	chr3:183735012	ABCC5	0.6	10.98	0.58	7.29e-23	Anterior chamber depth;
SARC	cis	rs17401966	0.838	rs4846207	chr1:10313811	T/C	cg15208524	chr1:10270712	KIF1B	0.46	5.37	0.33	1.91e-7	Hepatocellular carcinoma;
SARC	trans	rs17685	0.753	rs10262501	chr7:75668172	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.59	-7.35	-0.43	3.32e-12	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg19723775	chr5:179050963	HNRNPH1	-0.4	-5.1	-0.32	6.89e-7	Lung cancer;
SARC	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg00149659	chr3:10157352	C3orf10	0.69	6.9	0.41	4.76e-11	Alzheimer's disease;
SARC	cis	rs6570726	0.791	rs436498	chr6:145876347	G/A	cg05347473	chr6:146136440	FBXO30	0.55	7.67	0.45	4.64e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg11890956	chr21:40555474	PSMG1	1.16	19.69	0.79	1.79e-51	Cognitive function;
SARC	cis	rs3091242	0.967	rs3091240	chr1:25676935	G/T	cg02931644	chr1:25747376	RHCE	0.48	7.99	0.46	6.1e-14	Erythrocyte sedimentation rate;
SARC	cis	rs4664308	1.000	rs10929965	chr2:160906931	C/T	cg03641300	chr2:160917029	PLA2R1	0.68	9.12	0.51	3.73e-17	Idiopathic membranous nephropathy;
SARC	cis	rs10752881	1.000	rs10752881	chr1:182973491	A/G	cg13390022	chr1:182993471	LAMC1	0.33	5.09	0.32	7.29e-7	Colorectal cancer;
SARC	cis	rs9325144	0.600	rs6582630	chr12:38743508	A/G	cg04568710	chr12:38710424	ALG10B	-0.4	-4.97	-0.31	1.27e-6	Morning vs. evening chronotype;
SARC	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg14983838	chr19:29218262	NA	0.64	7.29	0.43	4.68e-12	Methadone dose in opioid dependence;
SARC	cis	rs992157	0.798	rs1017698	chr2:219170525	A/G	cg00012203	chr2:219082015	ARPC2	-0.65	-9.63	-0.53	1.11e-18	Colorectal cancer;
SARC	cis	rs6484504	0.512	rs2774402	chr11:31312897	G/C	cg02090638	chr11:31391270	DNAJC24;DCDC1	0.43	5.43	0.34	1.39e-7	Red blood cell count;
SARC	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg11890956	chr21:40555474	PSMG1	-0.72	-9.41	-0.52	4.92e-18	Menarche (age at onset);
SARC	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg27266027	chr21:40555129	PSMG1	0.48	5.24	0.32	3.61e-7	Cognitive function;
SARC	cis	rs9457247	0.602	rs12209395	chr6:167463914	C/T	cg23791538	chr6:167370224	RNASET2	-0.53	-6.86	-0.41	6.19e-11	Crohn's disease;
SARC	cis	rs1318878	0.565	rs9788092	chr12:15422843	A/T	cg08258403	chr12:15378311	NA	0.48	6.79	0.41	9.27e-11	Intelligence (multi-trait analysis);
SARC	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg13393036	chr8:95962371	TP53INP1	-0.36	-6.21	-0.38	2.38e-9	Type 2 diabetes;
SARC	cis	rs3845702	0.736	rs72962517	chr2:180861452	G/A	cg01881094	chr2:180872142	CWC22	1.04	8.14	0.47	2.43e-14	Schizophrenia;
SARC	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg17376030	chr22:41985996	PMM1	-0.67	-8.41	-0.48	4.23e-15	Vitiligo;
SARC	cis	rs3126085	0.935	rs1552995	chr1:152171427	A/G	cg03465714	chr1:152285911	FLG	-0.47	-5.56	-0.34	7.45e-8	Atopic dermatitis;
SARC	cis	rs7729447	0.776	rs17442964	chr5:32693916	G/A	cg16267343	chr5:32710456	NPR3	0.65	8.59	0.49	1.24e-15	Blood pressure;
SARC	cis	rs6912958	0.754	rs2268994	chr6:88185386	A/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.29	-4.97	-0.31	1.32e-6	Monocyte percentage of white cells;
SARC	trans	rs2727020	0.658	rs4980442	chr11:49445016	G/T	cg15704280	chr7:45808275	SEPT13	-0.86	-14.07	-0.68	5.67e-33	Coronary artery disease;
SARC	trans	rs11098499	1.000	rs1011054	chr4:120202387	A/G	cg25214090	chr10:38739885	LOC399744	-0.53	-6.85	-0.41	6.34e-11	Corneal astigmatism;
SARC	cis	rs9486719	0.522	rs4839683	chr6:96851933	A/G	cg06623918	chr6:96969491	KIAA0776	0.62	7.03	0.42	2.23e-11	Migraine;Coronary artery disease;
SARC	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg06420487	chr17:61919686	SMARCD2	0.43	4.73	0.3	3.84e-6	Height;
SARC	cis	rs1008375	0.932	rs7697329	chr4:17657853	C/A	cg27347728	chr4:17578864	LAP3	0.5	6.27	0.38	1.72e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs523522	0.962	rs2168319	chr12:120933217	C/T	cg12219531	chr12:120966889	COQ5	0.82	11.15	0.59	1.99e-23	High light scatter reticulocyte count;
SARC	cis	rs7149337	0.805	rs2999361	chr14:51605358	G/A	cg23942311	chr14:51606299	NA	0.31	5.78	0.35	2.42e-8	Cancer;
SARC	cis	rs2075371	0.932	rs2598290	chr7:133987736	C/G	cg20476274	chr7:133979776	SLC35B4	0.62	8.41	0.48	4.18e-15	Mean platelet volume;
SARC	cis	rs4481887	0.741	rs11488133	chr1:248548380	T/C	cg00666640	chr1:248458726	OR2T12	0.32	5.81	0.36	2.08e-8	Common traits (Other);
SARC	cis	rs7666738	0.830	rs17027090	chr4:98897923	G/T	cg05340658	chr4:99064831	C4orf37	0.64	8.46	0.48	3.06e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg03033257	chr22:50311977	ALG12;CRELD2	0.61	5.8	0.36	2.1e-8	Schizophrenia;
SARC	cis	rs7762018	1.000	rs6942332	chr6:170131934	A/G	cg15038512	chr6:170123185	PHF10	0.51	4.97	0.31	1.29e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs453301	0.658	rs12114954	chr8:8904862	T/G	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.49	-0.49	2.44e-15	Joint mobility (Beighton score);
SARC	cis	rs6831352	0.918	rs2851246	chr4:100046104	A/G	cg12011299	chr4:100065546	ADH4	0.33	5.55	0.34	7.66e-8	Alcohol dependence;
SARC	cis	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg13072238	chr3:49761600	GMPPB	0.43	5.65	0.35	4.57e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7712401	0.598	rs446116	chr5:122191130	G/A	cg19412675	chr5:122181750	SNX24	0.38	4.9	0.31	1.81e-6	Mean platelet volume;
SARC	cis	rs11724804	0.532	rs73207782	chr4:848764	G/C	cg08222618	chr4:941054	TMEM175	0.44	5.17	0.32	5.15e-7	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
SARC	cis	rs17376456	0.877	rs10476598	chr5:93367281	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.64	-5.65	-0.35	4.6e-8	Diabetic retinopathy;
SARC	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg14784868	chr12:69753453	YEATS4	0.65	9.07	0.51	5.01e-17	Cerebrospinal fluid biomarker levels;
SARC	cis	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.67	-0.45	4.53e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs8141529	0.732	rs3788409	chr22:29198151	T/G	cg02153584	chr22:29168773	CCDC117	0.82	12.64	0.64	3.02e-28	Lymphocyte counts;
SARC	cis	rs7666738	0.830	rs35685312	chr4:98858521	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.59	0.49	1.24e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9381040	1.000	rs2093395	chr6:41155026	C/G	cg03644281	chr6:41068752	NFYA;LOC221442	0.46	5.4	0.33	1.65e-7	Alzheimer's disease (late onset);
SARC	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg08048268	chr3:133502702	NA	-0.43	-5.73	-0.35	3.03e-8	Iron status biomarkers;
SARC	cis	rs3784262	0.757	rs74655564	chr15:58325512	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.39	-5.88	-0.36	1.42e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05382305	chr1:91869782	HFM1	-0.47	-6.47	-0.39	5.7e-10	Smoking initiation;
SARC	cis	rs651907	0.535	rs12633089	chr3:101528763	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	5.84	0.36	1.72e-8	Colorectal cancer;
SARC	cis	rs4423214	0.592	rs10898191	chr11:71194601	G/A	cg05163923	chr11:71159392	DHCR7	-0.56	-5.75	-0.35	2.73e-8	Vitamin D levels;
SARC	cis	rs11581859	0.613	rs1384157	chr1:99226477	A/G	cg20286094	chr1:99190917	SNX7	-0.42	-4.92	-0.31	1.63e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs4969178	0.932	rs3744219	chr17:76400236	G/A	cg02836325	chr17:76403955	PGS1	0.34	5.21	0.32	4.16e-7	HDL cholesterol levels;
SARC	cis	rs11098499	0.954	rs6849561	chr4:120409694	C/G	cg24375607	chr4:120327624	NA	-0.4	-4.77	-0.3	3.27e-6	Corneal astigmatism;
SARC	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg22535103	chr8:58192502	C8orf71	-0.59	-6.21	-0.38	2.35e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs11711311	0.712	rs3773684	chr3:113334488	A/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.57	-7.07	-0.42	1.75e-11	IgG glycosylation;
SARC	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg27266027	chr21:40555129	PSMG1	-0.5	-5.42	-0.33	1.5e-7	Cognitive function;
SARC	cis	rs7582180	0.629	rs13004216	chr2:100945402	G/A	cg14675211	chr2:100938903	LONRF2	0.51	7.63	0.45	6.1e-13	Intelligence (multi-trait analysis);
SARC	cis	rs7824557	0.527	rs2736305	chr8:11237773	T/C	cg21775007	chr8:11205619	TDH	-0.56	-7.3	-0.43	4.38e-12	Retinal vascular caliber;
SARC	cis	rs644799	1.000	rs487609	chr11:95588102	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	14.6	0.69	1.05e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs6952809	0.532	rs10272548	chr7:2439467	G/A	cg05083358	chr7:2394359	EIF3B	-0.57	-5.29	-0.33	2.85e-7	Multiple sclerosis;
SARC	cis	rs644148	0.836	rs2686776	chr19:45000366	T/C	cg15540054	chr19:45004280	ZNF180	-0.44	-5.03	-0.31	9.64e-7	Personality dimensions;
SARC	cis	rs3764563	0.935	rs10408443	chr19:15715973	C/T	cg20725493	chr19:15740067	CYP4F8	-0.67	-4.74	-0.3	3.69e-6	Inflammatory biomarkers;
SARC	trans	rs208520	0.690	rs1351867	chr6:66760995	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.07	14.1	0.68	4.62e-33	Exhaled nitric oxide output;
SARC	cis	rs4969178	0.930	rs2292644	chr17:76394449	C/T	cg20026190	chr17:76395443	PGS1	0.39	5.3	0.33	2.71e-7	HDL cholesterol levels;
SARC	cis	rs2153535	0.540	rs9378557	chr6:8517381	T/C	cg07606381	chr6:8435919	SLC35B3	0.77	10.9	0.58	1.28e-22	Motion sickness;
SARC	cis	rs892961	0.899	rs312911	chr17:75414585	A/C	cg05865280	chr17:75406074	SEPT9	0.57	8.6	0.49	1.2e-15	Airflow obstruction;
SARC	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-9.14	-0.51	3.2e-17	Alzheimer's disease;
SARC	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg13206674	chr6:150067644	NUP43	0.48	6.36	0.38	1.07e-9	Lung cancer;
SARC	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg26039829	chr8:22132926	PIWIL2	0.47	6.77	0.41	1.05e-10	Hypertriglyceridemia;
SARC	cis	rs6831352	1.000	rs1126671	chr4:100048414	T/C	cg13256891	chr4:100009986	ADH5	0.67	8.93	0.51	1.28e-16	Alcohol dependence;
SARC	cis	rs36051895	0.632	rs12115301	chr9:5180548	A/G	cg02405213	chr9:5042618	JAK2	0.52	6.19	0.38	2.65e-9	Pediatric autoimmune diseases;
SARC	cis	rs7084402	0.967	rs1658425	chr10:60331547	G/C	cg07615347	chr10:60278583	BICC1	0.53	7.56	0.44	9.45e-13	Refractive error;
SARC	cis	rs1008375	1.000	rs555	chr4:17625658	A/G	cg16339924	chr4:17578868	LAP3	0.65	8.5	0.49	2.25e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10484885	0.775	rs17584945	chr6:90512776	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.59	-4.91	-0.31	1.68e-6	QRS interval (sulfonylurea treatment interaction);
SARC	cis	rs7584330	0.657	rs10202599	chr2:238352465	A/C	cg14458575	chr2:238380390	NA	0.54	6.46	0.39	5.91e-10	Prostate cancer;
SARC	cis	rs2013441	1.000	rs1561974	chr17:20196144	G/A	cg13482628	chr17:19912719	NA	-0.49	-6.36	-0.38	1.07e-9	Obesity-related traits;
SARC	cis	rs6484504	0.532	rs11031330	chr11:31275073	G/A	cg19308365	chr11:31391254	DNAJC24;DCDC1	-0.38	-4.76	-0.3	3.4e-6	Red blood cell count;
SARC	cis	rs847851	0.630	rs9469905	chr6:34797747	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-6.17	-0.37	2.92e-9	Colonoscopy-negative controls vs population controls;
SARC	cis	rs13191362	1.000	rs34443622	chr6:163208214	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.65	5.66	0.35	4.39e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs30380	0.632	rs26495	chr5:96137840	A/G	cg16492584	chr5:96139282	ERAP1	-0.48	-5.5	-0.34	1.01e-7	Cerebrospinal fluid biomarker levels;
SARC	cis	rs950169	0.724	rs11632668	chr15:84948687	T/C	cg24253500	chr15:84953950	NA	0.36	5.18	0.32	4.78e-7	Schizophrenia;
SARC	cis	rs1468333	0.567	rs10072318	chr5:137646221	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.66	8.04	0.47	4.63e-14	Resting heart rate;
SARC	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9815354	0.953	rs1716641	chr3:41921681	C/T	cg03022575	chr3:42003672	ULK4	-0.54	-5.11	-0.32	6.58e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs7833790	0.676	rs7834555	chr8:82697625	A/G	cg27398817	chr8:82754497	SNX16	-0.43	-5.12	-0.32	6.3e-7	Diastolic blood pressure;
SARC	cis	rs9815354	1.000	rs13325965	chr3:41914942	G/T	cg03022575	chr3:42003672	ULK4	0.65	5.67	0.35	4.19e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs7465272	1.000	rs13258638	chr8:143683582	C/T	cg10596483	chr8:143751796	JRK	0.56	6.04	0.37	6.07e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg18252515	chr7:66147081	NA	0.52	5.59	0.34	6.44e-8	Aortic root size;
SARC	cis	rs2486288	0.656	rs7167146	chr15:45571386	A/G	cg26924012	chr15:45694286	SPATA5L1	0.57	6.72	0.4	1.42e-10	Glomerular filtration rate;
SARC	cis	rs9814567	0.929	rs9838834	chr3:134207077	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-7.09	-0.42	1.57e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs6582630	0.519	rs4405392	chr12:38293661	A/C	cg13010199	chr12:38710504	ALG10B	0.79	11.02	0.59	5.26e-23	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2602836	0.830	rs2602874	chr4:100039396	A/T	cg13256891	chr4:100009986	ADH5	0.71	10.88	0.58	1.47e-22	HDL cholesterol;HDL cholesterol levels;
SARC	trans	rs1814175	0.817	rs10128730	chr11:50023369	G/T	cg03929089	chr4:120376271	NA	-0.87	-13.86	-0.67	2.91e-32	Height;
SARC	cis	rs7523050	0.643	rs36047249	chr1:109401499	T/C	cg08274380	chr1:109419600	GPSM2	1.03	7.67	0.45	4.7e-13	Fat distribution (HIV);
SARC	cis	rs6693567	0.586	rs875514	chr1:150484555	C/G	cg09579323	chr1:150459698	TARS2	0.41	5.25	0.33	3.43e-7	Migraine;
SARC	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg17376030	chr22:41985996	PMM1	-0.69	-8.54	-0.49	1.81e-15	Vitiligo;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg14610915	chr17:75243296	NA	-0.5	-6.52	-0.39	4.31e-10	Schizophrenia;
SARC	cis	rs9916302	0.653	rs11657058	chr17:37699378	T/G	cg07936489	chr17:37558343	FBXL20	-0.74	-8.58	-0.49	1.37e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs7614311	0.636	rs73117041	chr3:63896266	A/T	cg22134162	chr3:63841271	THOC7	-0.46	-4.95	-0.31	1.44e-6	Lung function (FVC);Lung function (FEV1);
SARC	cis	rs72717751	0.504	rs17128143	chr14:55533588	C/G	cg01858014	chr14:56050164	KTN1	0.79	5.37	0.33	1.92e-7	Platelet distribution width;
SARC	cis	rs72781680	0.716	rs2712061	chr2:24026411	G/A	cg08917208	chr2:24149416	ATAD2B	0.57	5.87	0.36	1.52e-8	Lymphocyte counts;
SARC	cis	rs826838	1.000	rs10875991	chr12:39108886	G/C	cg26384229	chr12:38710491	ALG10B	0.9	13.75	0.67	6.55e-32	Heart rate;
SARC	cis	rs2115630	0.645	rs2292463	chr15:85175750	A/G	cg17507749	chr15:85114479	UBE2QP1	-0.51	-6.17	-0.37	3e-9	P wave terminal force;
SARC	cis	rs1050631	0.564	rs10153377	chr18:33727984	G/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.59	7.16	0.42	1.06e-11	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs12956009	0.518	rs4574017	chr18:44891703	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	7.64	0.45	5.68e-13	Educational attainment (years of education);
SARC	cis	rs17600642	0.724	rs1477070	chr10:72445630	A/G	cg19779893	chr10:72451501	ADAMTS14	-0.37	-5.88	-0.36	1.44e-8	Bipolar disorder;
SARC	cis	rs12586317	0.586	rs74243590	chr14:35513246	G/A	cg26967526	chr14:35346199	BAZ1A	-0.58	-5.82	-0.36	1.94e-8	Psoriasis;
SARC	cis	rs6542838	0.641	rs6724477	chr2:99537074	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.49	6.24	0.38	2.06e-9	Fear of minor pain;
SARC	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg05896524	chr21:47604654	C21orf56	0.56	6.88	0.41	5.54e-11	Testicular germ cell tumor;
SARC	cis	rs6456156	0.586	rs7742305	chr6:167485723	C/T	cg23791538	chr6:167370224	RNASET2	-0.53	-6.99	-0.42	2.86e-11	Primary biliary cholangitis;
SARC	cis	rs9902453	0.967	rs62070344	chr17:28476997	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	6.6	0.4	2.71e-10	Coffee consumption (cups per day);
SARC	cis	rs7762018	0.607	rs77392231	chr6:170057634	G/A	cg13015042	chr6:170102002	WDR27;C6orf120	0.69	5.01	0.31	1.07e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	8.06	0.47	4.08e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs864537	0.676	rs1773560	chr1:167421763	A/G	cg09179987	chr1:167433047	CD247	0.39	6.11	0.37	4.15e-9	Celiac disease or Rheumatoid arthritis;Celiac disease;
SARC	cis	rs9462027	0.628	rs2764208	chr6:34714322	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.86	-0.36	1.55e-8	Systemic lupus erythematosus;
SARC	cis	rs9399135	0.967	rs4388304	chr6:135309597	T/A	cg24558204	chr6:135376177	HBS1L	0.45	5.95	0.36	9.68e-9	Red blood cell count;
SARC	cis	rs2204008	0.654	rs1733410	chr12:38132172	G/A	cg14851346	chr12:38532713	NA	-0.44	-5.33	-0.33	2.32e-7	Bladder cancer;
SARC	cis	rs2290720	0.930	rs7314205	chr12:101722293	A/G	cg22051763	chr12:101673672	UTP20	-0.43	-5.09	-0.32	7.36e-7	Brain structure (hippocampal volume);
SARC	cis	rs9916302	0.904	rs8077104	chr17:37530510	A/G	cg15445000	chr17:37608096	MED1	-0.42	-5.14	-0.32	5.86e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs787274	1.000	rs787302	chr9:115543839	G/A	cg13803584	chr9:115635662	SNX30	-0.83	-5.06	-0.31	8.34e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg24829409	chr8:58192753	C8orf71	0.64	6.15	0.37	3.31e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs11690935	0.798	rs13018768	chr2:172598592	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.0	-16.16	-0.73	6.45e-40	Schizophrenia;
SARC	cis	rs651907	0.557	rs11917682	chr3:101355427	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	6.29	0.38	1.57e-9	Colorectal cancer;
SARC	cis	rs10791323	0.628	rs1893850	chr11:133705356	T/C	cg13461336	chr11:133711254	SPATA19	-0.28	-4.8	-0.3	2.84e-6	Childhood ear infection;
SARC	cis	rs3768617	0.528	rs6672093	chr1:183079853	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.67	9.85	0.54	2.33e-19	Fuchs's corneal dystrophy;
SARC	cis	rs17270561	0.609	rs9358871	chr6:25726675	G/A	cg16482183	chr6:26056742	HIST1H1C	0.43	5.25	0.33	3.49e-7	Iron status biomarkers;
SARC	trans	rs12310956	0.532	rs10772114	chr12:33853970	G/A	cg13010199	chr12:38710504	ALG10B	0.51	6.35	0.38	1.1e-9	Morning vs. evening chronotype;
SARC	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg22484793	chr3:52261325	TLR9	0.3	4.87	0.3	2.05e-6	Bipolar disorder;
SARC	cis	rs12142240	0.698	rs6696777	chr1:46810970	A/G	cg10495392	chr1:46806563	NSUN4	0.65	6.8	0.41	8.47e-11	Menopause (age at onset);
SARC	cis	rs7595412	1.000	rs2859982	chr2:198971623	C/T	cg00208931	chr2:198669586	PLCL1	-0.85	-6.37	-0.38	1.02e-9	Hip bone size;
SARC	cis	rs6714710	0.603	rs6738389	chr2:98386731	A/G	cg26665480	chr2:98280029	ACTR1B	0.49	6.5	0.39	4.81e-10	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs7084402	0.967	rs1582827	chr10:60297102	T/C	cg07615347	chr10:60278583	BICC1	0.6	8.91	0.5	1.45e-16	Refractive error;
SARC	cis	rs9894429	0.646	rs58398000	chr17:79576923	G/A	cg10661904	chr17:79619235	PDE6G	0.45	6.3	0.38	1.48e-9	Eye color traits;
SARC	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg02297831	chr4:17616191	MED28	0.51	6.63	0.4	2.36e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs1814175	0.746	rs10839429	chr11:49906845	G/A	cg15704280	chr7:45808275	SEPT13	-0.98	-18.28	-0.77	6.55e-47	Height;
SARC	cis	rs607987	0.871	rs4244552	chr11:30282274	C/T	cg06241208	chr11:30344200	C11orf46	0.42	5.03	0.31	9.7e-7	Body mass index;
SARC	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.35	-4.72	-0.3	4.02e-6	Personality dimensions;
SARC	cis	rs55794721	0.509	rs4649085	chr1:25778832	G/A	cg27572855	chr1:25598939	RHD	0.54	9.04	0.51	6.32e-17	Plateletcrit;Mean corpuscular volume;
SARC	cis	rs936229	0.871	rs2290574	chr15:75135447	T/C	cg14664628	chr15:75095509	CSK	-1.04	-13.2	-0.65	4.39e-30	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs35110281	0.506	rs13051661	chr21:45111518	A/T	cg01579765	chr21:45077557	HSF2BP	-0.34	-5.47	-0.34	1.15e-7	Mean corpuscular volume;
SARC	cis	rs826838	0.651	rs1843892	chr12:38616965	A/G	cg26384229	chr12:38710491	ALG10B	0.75	10.03	0.55	6.41e-20	Heart rate;
SARC	cis	rs17331151	0.512	rs9637477	chr3:52891426	G/C	cg04865290	chr3:52927548	TMEM110	0.57	5.82	0.36	1.89e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs1707322	0.721	rs28501477	chr1:46199084	A/G	cg06784218	chr1:46089804	CCDC17	0.37	6.33	0.38	1.22e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4713675	0.584	rs749847	chr6:33665001	G/C	cg15676125	chr6:33679581	C6orf125	0.53	6.46	0.39	6.12e-10	Plateletcrit;
SARC	cis	rs7561149	0.902	rs6715406	chr2:179650701	C/T	cg17765952	chr2:179737173	CCDC141	-0.36	-4.77	-0.3	3.23e-6	QT interval;
SARC	cis	rs11676348	0.774	rs11683524	chr2:218984604	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.47	-6.0	-0.37	7.62e-9	Ulcerative colitis;
SARC	cis	rs4803468	1.000	rs6508977	chr19:41909346	A/G	cg09537434	chr19:41945824	ATP5SL	-0.95	-16.27	-0.73	2.94e-40	Height;
SARC	cis	rs7223966	1.000	rs11657120	chr17:61857218	G/A	cg26338869	chr17:61819248	STRADA	0.45	4.85	0.3	2.23e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs981844	0.683	rs1037647	chr4:154737991	A/G	cg14289246	chr4:154710475	SFRP2	-0.45	-5.2	-0.32	4.29e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs78487399	0.808	rs17406646	chr2:43678617	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-5.01	-0.31	1.09e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs4925386	0.959	rs6121989	chr20:60916713	A/T	cg22541963	chr20:60982533	CABLES2	-0.44	-4.91	-0.31	1.74e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
SARC	trans	rs7395662	0.571	rs4882020	chr11:48615658	C/T	cg15704280	chr7:45808275	SEPT13	-0.49	-6.49	-0.39	5.08e-10	HDL cholesterol;
SARC	cis	rs4132509	0.603	rs12408951	chr1:243679364	A/G	cg21452805	chr1:244014465	NA	0.52	5.45	0.34	1.28e-7	RR interval (heart rate);
SARC	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	11.63	0.61	5.84e-25	Alzheimer's disease;
SARC	cis	rs11785693	0.862	rs62491196	chr8:4995690	C/T	cg26367366	chr8:4980734	NA	0.75	6.62	0.4	2.46e-10	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs9916302	0.851	rs7225096	chr17:37664443	T/C	cg07936489	chr17:37558343	FBXL20	-0.69	-8.94	-0.51	1.2e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs9640161	0.673	rs11773351	chr7:150030963	T/C	cg10018233	chr7:150070692	REPIN1	0.63	7.4	0.44	2.52e-12	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg18252515	chr7:66147081	NA	-1.3	-11.63	-0.61	5.98e-25	Diabetic kidney disease;
SARC	cis	rs9814567	0.722	rs13083717	chr3:134348796	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.5	5.43	0.34	1.43e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg04944784	chr2:26401820	FAM59B	-0.52	-6.37	-0.39	9.8e-10	Gut microbiome composition (summer);
SARC	cis	rs10463316	0.817	rs7713109	chr5:150789284	A/G	cg03212797	chr5:150827313	SLC36A1	-0.42	-4.97	-0.31	1.3e-6	Metabolite levels (Pyroglutamine);
SARC	cis	rs11605924	1.000	rs1401419	chr11:45879739	T/C	ch.11.939596F	chr11:45881766	CRY2	-0.51	-6.06	-0.37	5.32e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	trans	rs9395865	0.520	rs6903708	chr6:53332940	A/G	cg17966709	chr11:57435952	ZDHHC5	-0.51	-6.24	-0.38	2.01e-9	Electroencephalographic traits in alcoholism;
SARC	cis	rs3126085	0.935	rs2184951	chr1:152273168	T/G	cg03465714	chr1:152285911	FLG	0.51	5.76	0.35	2.6e-8	Atopic dermatitis;
SARC	cis	rs11770686	0.812	rs10226578	chr7:75321824	T/C	cg17787366	chr7:75369077	HIP1	0.44	5.47	0.34	1.17e-7	Essential tremor;
SARC	cis	rs7666738	0.830	rs957742	chr4:99029409	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs17376456	1.000	rs17376207	chr5:93545524	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.62	-5.72	-0.35	3.28e-8	Diabetic retinopathy;
SARC	cis	rs3796352	1.000	rs34121720	chr3:53072167	C/T	cg27565382	chr3:53032988	SFMBT1	0.86	6.3	0.38	1.49e-9	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	13.12	0.65	8.35e-30	Chronic sinus infection;
SARC	cis	rs2115536	0.967	rs3826008	chr15:80189805	G/T	cg00225070	chr15:80189496	MTHFS	0.66	8.83	0.5	2.5e-16	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
SARC	cis	rs1345301	1.000	rs1345301	chr2:102875587	A/G	cg12451869	chr2:102867685	NA	0.38	5.41	0.33	1.58e-7	Waist circumference;
SARC	cis	rs7043114	0.525	rs6479419	chr9:95110002	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.81	-0.36	2.02e-8	Height;
SARC	cis	rs9457247	0.765	rs1322077	chr6:167424293	T/C	cg07741184	chr6:167504864	NA	0.34	6.55	0.39	3.64e-10	Crohn's disease;
SARC	cis	rs751728	0.965	rs2296743	chr6:33740025	C/T	cg25922239	chr6:33757077	LEMD2	0.78	10.29	0.56	1.02e-20	Crohn's disease;
SARC	cis	rs2070997	0.667	rs2260323	chr9:133700786	C/T	cg11464064	chr9:133710261	ABL1	-0.62	-5.7	-0.35	3.52e-8	Response to amphetamines;
SARC	cis	rs6450176	0.909	rs67721004	chr5:53290571	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.63	-7.13	-0.42	1.25e-11	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs1881797	1.000	rs10925069	chr1:247681313	C/T	cg11166453	chr1:247681781	NA	-0.47	-5.25	-0.33	3.45e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs10216189	0.785	rs4352753	chr7:5527223	A/C	cg05318486	chr7:5553423	FBXL18	-0.48	-5.88	-0.36	1.39e-8	Relative hand skill in reading disability;
SARC	cis	rs9326248	0.539	rs7120565	chr11:117042949	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.7	9.17	0.51	2.6e-17	Blood protein levels;
SARC	cis	rs6912958	0.754	rs4707374	chr6:88255438	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.38	-0.33	1.8e-7	Monocyte percentage of white cells;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg02718654	chr19:40971802	SPTBN4;BLVRB	0.52	6.37	0.39	9.76e-10	Fibrinogen levels;
SARC	cis	rs9807989	0.507	rs4479442	chr2:103054074	A/T	cg03938978	chr2:103052716	IL18RAP	0.3	4.83	0.3	2.46e-6	Asthma;
SARC	trans	rs1814175	0.817	rs7924619	chr11:49620632	G/A	cg15704280	chr7:45808275	SEPT13	-0.97	-17.82	-0.76	2.12e-45	Height;
SARC	cis	rs1691799	0.899	rs1168314	chr12:66746937	A/G	cg16791601	chr12:66731901	HELB	-0.71	-10.85	-0.58	1.89e-22	White blood cell count (basophil);
SARC	cis	rs9660992	0.789	rs1768584	chr1:205240145	A/G	cg21643547	chr1:205240462	TMCC2	-0.6	-8.03	-0.47	4.84e-14	Mean corpuscular volume;Mean platelet volume;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg08815745	chr17:36828454	C17orf96	0.52	7.52	0.44	1.19e-12	Thyroid stimulating hormone;
SARC	cis	rs1707322	1.000	rs4660896	chr1:46372416	A/G	cg03146154	chr1:46216737	IPP	0.46	5.52	0.34	8.98e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg24829409	chr8:58192753	C8orf71	-0.56	-6.05	-0.37	5.68e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6831352	1.000	rs10017466	chr4:100055800	C/T	cg12011299	chr4:100065546	ADH4	0.33	5.9	0.36	1.28e-8	Alcohol dependence;
SARC	cis	rs854765	0.583	rs5002487	chr17:17832460	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.62	9.39	0.52	5.59e-18	Total body bone mineral density;
SARC	cis	rs427394	0.659	rs274695	chr5:6732252	G/C	cg10857441	chr5:6722123	POLS	-0.33	-4.85	-0.3	2.29e-6	Menopause (age at onset);
SARC	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg19346786	chr7:2764209	NA	-0.38	-5.63	-0.35	5.13e-8	Height;
SARC	cis	rs7587476	0.861	rs3768716	chr2:215635794	T/C	cg04004882	chr2:215674386	BARD1	0.59	6.19	0.38	2.68e-9	Neuroblastoma;
SARC	cis	rs8141529	0.664	rs5762861	chr22:29250505	T/G	cg15103426	chr22:29168792	CCDC117	0.56	6.64	0.4	2.17e-10	Lymphocyte counts;
SARC	cis	rs35164067	1.000	rs34953890	chr19:10526854	C/A	cg21868191	chr19:10515988	NA	-0.43	-5.37	-0.33	1.91e-7	Inflammatory bowel disease;
SARC	cis	rs7937682	0.632	rs10789850	chr11:111750829	C/T	cg09085632	chr11:111637200	PPP2R1B	0.76	9.99	0.55	8.94e-20	Primary sclerosing cholangitis;
SARC	cis	rs2425143	0.687	rs6119649	chr20:34369596	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	-0.64	-5.23	-0.32	3.83e-7	Blood protein levels;
SARC	cis	rs6500395	0.775	rs7185541	chr16:48664681	A/G	cg04672837	chr16:48644449	N4BP1	0.41	5.63	0.35	5.04e-8	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs155076	1.000	rs261432	chr13:21865915	G/C	cg11317459	chr13:21872234	NA	-0.95	-11.65	-0.61	4.96e-25	White matter hyperintensity burden;
SARC	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.41	-0.44	2.33e-12	Gut microbiome composition (summer);
SARC	cis	rs7647973	0.769	rs11130181	chr3:49109919	G/A	cg06212747	chr3:49208901	KLHDC8B	0.49	5.04	0.31	9.47e-7	Menarche (age at onset);
SARC	trans	rs7824557	0.564	rs2572400	chr8:11234367	T/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.87	-0.41	5.91e-11	Retinal vascular caliber;
SARC	cis	rs1008375	1.000	rs10805358	chr4:17652450	A/C	cg16339924	chr4:17578868	LAP3	0.66	8.81	0.5	2.96e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg17376030	chr22:41985996	PMM1	-0.73	-9.01	-0.51	7.45e-17	Vitiligo;
SARC	cis	rs2288073	1.000	rs2288073	chr2:24413298	C/T	cg26838691	chr2:24397539	C2orf84	0.53	6.82	0.41	7.64e-11	Venous thromboembolism (SNP x SNP interaction);
SARC	trans	rs1814175	0.645	rs4625470	chr11:49983769	T/C	cg03929089	chr4:120376271	NA	-0.82	-11.88	-0.61	9.2e-26	Height;
SARC	cis	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg03060546	chr3:49711283	APEH	0.75	11.06	0.59	3.81e-23	Resting heart rate;
SARC	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg11644478	chr21:40555479	PSMG1	1.02	14.38	0.69	5.5e-34	Cognitive function;
SARC	cis	rs2427308	0.607	rs1741635	chr20:60938197	C/G	cg24112000	chr20:60950667	NA	0.34	4.8	0.3	2.8e-6	Colorectal cancer;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg25565376	chr6:99842092	COQ3	-0.49	-6.79	-0.41	8.97e-11	Thyroid stimulating hormone;
SARC	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg02931644	chr1:25747376	RHCE	0.41	7.01	0.42	2.48e-11	Erythrocyte sedimentation rate;
SARC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2295359	1.000	rs736197	chr1:67607135	G/T	cg08029281	chr1:67600428	NA	0.38	5.49	0.34	1.03e-7	Psoriasis;
SARC	cis	rs929354	0.772	rs6969244	chr7:157004012	A/G	cg05182265	chr7:156933206	UBE3C	-0.31	-4.73	-0.3	3.91e-6	Body mass index;
SARC	cis	rs995000	0.839	rs1168026	chr1:62970996	T/C	cg06896770	chr1:63153194	DOCK7	-0.89	-12.99	-0.65	2.12e-29	Triglyceride levels;
SARC	cis	rs7100689	0.577	rs756208	chr10:82041751	A/G	cg01528321	chr10:82214614	TSPAN14	0.66	8.6	0.49	1.19e-15	Post bronchodilator FEV1;
SARC	cis	rs9325144	0.647	rs11168741	chr12:38989120	C/T	cg26384229	chr12:38710491	ALG10B	-0.61	-7.97	-0.46	7.09e-14	Morning vs. evening chronotype;
SARC	cis	rs921968	0.565	rs1529382	chr2:219626489	C/T	cg02176678	chr2:219576539	TTLL4	-0.32	-4.95	-0.31	1.41e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs910316	1.000	rs12435391	chr14:75601737	A/G	cg23033748	chr14:75592666	NEK9	0.37	5.05	0.31	8.99e-7	Height;
SARC	cis	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg25894440	chr7:65020034	NA	-0.77	-5.95	-0.36	9.84e-9	Diabetic kidney disease;
SARC	cis	rs9527	0.641	rs10786732	chr10:104762535	T/C	cg04362960	chr10:104952993	NT5C2	0.45	5.4	0.33	1.63e-7	Arsenic metabolism;
SARC	cis	rs2658782	0.547	rs3133454	chr11:93059019	A/C	cg15737290	chr11:93063684	CCDC67	0.97	13.71	0.67	8.98e-32	Pulmonary function decline;
SARC	cis	rs79349575	0.756	rs3848460	chr17:47047114	A/G	cg16584676	chr17:46985605	UBE2Z	-0.45	-5.38	-0.33	1.78e-7	Type 2 diabetes;
SARC	cis	rs13082711	0.522	rs674303	chr3:27332177	T/C	cg02860705	chr3:27208620	NA	0.47	6.26	0.38	1.86e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs7005606	0.870	rs6996585	chr8:32400803	A/G	cg14488905	chr8:32406789	NRG1	0.45	5.99	0.37	8.08e-9	Hirschsprung disease;
SARC	cis	rs8016982	0.633	rs8019108	chr14:81716781	A/T	cg01989461	chr14:81687754	GTF2A1	0.72	10.88	0.58	1.44e-22	Schizophrenia;
SARC	cis	rs4805272	0.539	rs11883172	chr19:29318536	C/T	cg04546413	chr19:29218101	NA	0.55	6.39	0.39	8.75e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs6704644	0.651	rs6753242	chr2:234329419	G/T	cg27060346	chr2:234359958	DGKD	-0.73	-5.54	-0.34	7.96e-8	Bilirubin levels;
SARC	cis	rs1003719	0.788	rs2835592	chr21:38464387	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.63	9.05	0.51	5.67e-17	Eye color traits;
SARC	cis	rs3120667	0.790	rs3829868	chr1:152382120	A/G	cg26876637	chr1:152193138	HRNR	0.46	4.73	0.3	3.85e-6	Eating disorders;
SARC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg05896524	chr21:47604654	C21orf56	-0.59	-7.23	-0.43	6.69e-12	Testicular germ cell tumor;
SARC	cis	rs13326165	0.543	rs7643913	chr3:52303213	G/A	cg16894138	chr3:53270350	TKT	-0.54	-4.87	-0.3	2.02e-6	HDL cholesterol;HDL cholesterol levels;
SARC	cis	rs13166103	0.628	rs11959784	chr5:57722288	C/A	cg10487770	chr5:57879443	RAB3C	0.5	4.96	0.31	1.36e-6	Type 2 diabetes (age of onset);
SARC	cis	rs7772486	0.754	rs6915718	chr6:146100676	A/G	cg23711669	chr6:146136114	FBXO30	-0.92	-16.21	-0.73	4.61e-40	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7927771	1.000	rs4752797	chr11:47874364	C/T	cg20307385	chr11:47447363	PSMC3	-0.48	-5.89	-0.36	1.31e-8	Subjective well-being;
SARC	cis	rs4243830	0.826	rs3908553	chr1:6621921	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	0.96	7.19	0.43	8.72e-12	Body mass index;
SARC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	10.64	0.57	8.51e-22	Platelet count;
SARC	cis	rs6088590	1.000	rs2295353	chr20:33356511	C/T	cg06115741	chr20:33292138	TP53INP2	0.57	6.85	0.41	6.57e-11	Coronary artery disease;
SARC	cis	rs7843479	0.562	rs2127206	chr8:21786989	C/T	cg17168535	chr8:21777572	XPO7	0.85	12.61	0.64	3.82e-28	Mean corpuscular volume;
SARC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	6.08	0.37	5e-9	Prudent dietary pattern;
SARC	cis	rs2832077	0.527	rs9980449	chr21:30224889	G/C	cg24692254	chr21:30365293	RNF160	-0.65	-7.62	-0.45	6.52e-13	Cognitive test performance;
SARC	cis	rs796364	0.806	rs1509832	chr2:200874443	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.71	6.04	0.37	6.12e-9	Schizophrenia;
SARC	cis	rs12479064	0.604	rs11893359	chr2:99954608	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.46	-5.29	-0.33	2.79e-7	Chronic sinus infection;
SARC	cis	rs908922	0.676	rs11205018	chr1:152496249	T/G	cg09873164	chr1:152488093	CRCT1	0.63	8.06	0.47	4.07e-14	Hair morphology;
SARC	cis	rs10242455	0.571	rs28365067	chr7:99272310	G/A	cg03695448	chr7:99016977	BUD31;PTCD1	0.91	4.88	0.3	2e-6	Blood metabolite levels;
SARC	cis	rs2718058	0.606	rs2722247	chr7:37869308	C/T	cg24998770	chr7:37888106	TXNDC3	-0.33	-4.85	-0.3	2.31e-6	Alzheimer's disease (late onset);
SARC	cis	rs7772486	0.790	rs2247429	chr6:146217769	T/C	cg23711669	chr6:146136114	FBXO30	0.81	13.07	0.65	1.23e-29	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1008375	0.866	rs12233712	chr4:17570063	T/A	cg16339924	chr4:17578868	LAP3	0.66	8.43	0.48	3.59e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2486288	0.656	rs11639349	chr15:45568260	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.54	-6.85	-0.41	6.45e-11	Glomerular filtration rate;
SARC	cis	rs11585357	0.895	rs72633814	chr1:17626456	T/C	cg08277548	chr1:17600880	PADI3	-0.49	-5.62	-0.35	5.37e-8	Hair shape;
SARC	cis	rs12451471	0.529	rs2278620	chr17:78083565	G/A	cg24585782	chr17:78113791	EIF4A3	-0.52	-5.85	-0.36	1.68e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
SARC	cis	rs2180341	0.751	rs9388553	chr6:127574044	A/G	cg27446573	chr6:127587934	RNF146	0.94	13.2	0.65	4.61e-30	Breast cancer;
SARC	cis	rs9467773	1.000	rs1321479	chr6:26501897	C/T	cg12292205	chr6:26970375	C6orf41	-0.43	-5.19	-0.32	4.57e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2075371	1.000	rs447266	chr7:133989543	A/G	cg11752832	chr7:134001865	SLC35B4	0.59	7.66	0.45	5.02e-13	Mean platelet volume;
SARC	cis	rs4132509	1.000	rs10927076	chr1:243958293	A/G	cg21452805	chr1:244014465	NA	0.48	4.91	0.31	1.7e-6	RR interval (heart rate);
SARC	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg24829409	chr8:58192753	C8orf71	-0.62	-5.88	-0.36	1.39e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg16479474	chr6:28041457	NA	0.37	5.47	0.34	1.17e-7	Depression;
SARC	cis	rs7223966	0.921	rs7225092	chr17:61864005	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	7.41	0.44	2.31e-12	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs61409971	0.920	rs10131588	chr14:93015834	A/G	cg04718702	chr14:93020195	RIN3	-0.37	-4.88	-0.3	1.96e-6	Lymphocyte percentage of white cells;
SARC	cis	rs7586879	0.616	rs12713422	chr2:25134497	A/C	cg04586622	chr2:25135609	ADCY3	0.3	5.1	0.32	7.2e-7	Body mass index;
SARC	cis	rs1448094	0.506	rs61930640	chr12:86173333	T/C	cg00310523	chr12:86230176	RASSF9	0.36	5.48	0.34	1.09e-7	Major depressive disorder;
SARC	trans	rs11088226	0.645	rs2833917	chr21:33957544	C/T	cg09050820	chr6:167586206	TCP10L2	0.62	6.67	0.4	1.85e-10	Gastritis;
SARC	cis	rs634534	0.561	rs655744	chr11:65776585	G/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.46	5.86	0.36	1.53e-8	Sum eosinophil basophil counts;Eosinophil counts;
SARC	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg17646418	chr6:166911767	RPS6KA2	-0.49	-6.89	-0.41	5.3e-11	Body mass index;
SARC	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg25703541	chr22:24373054	LOC391322	0.76	8.77	0.5	3.79e-16	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg13939156	chr17:80058883	NA	0.4	6.25	0.38	1.92e-9	Life satisfaction;
SARC	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg00933542	chr6:150070202	PCMT1	0.29	5.09	0.32	7.37e-7	Lung cancer;
SARC	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg10295955	chr4:187884368	NA	-1.05	-17.53	-0.75	1.93e-44	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs8067545	0.641	rs850623	chr17:19837130	C/T	cg13482628	chr17:19912719	NA	0.54	6.84	0.41	6.97e-11	Schizophrenia;
SARC	cis	rs3741151	1.000	rs7122825	chr11:73061324	C/T	cg17517138	chr11:73019481	ARHGEF17	0.9	6.75	0.4	1.16e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg25894440	chr7:65020034	NA	-0.73	-5.54	-0.34	8.32e-8	Diabetic kidney disease;
SARC	cis	rs9733	0.650	rs9803935	chr1:150552622	T/G	cg13175981	chr1:150552382	MCL1	0.7	9.46	0.53	3.4e-18	Tonsillectomy;
SARC	cis	rs818427	0.929	rs153550	chr5:112234957	C/T	cg07820702	chr5:112228657	REEP5	-0.54	-6.09	-0.37	4.72e-9	Total body bone mineral density;
SARC	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg11890956	chr21:40555474	PSMG1	-0.71	-9.22	-0.52	1.89e-17	Menarche (age at onset);
SARC	cis	rs7666738	0.830	rs17550735	chr4:99014076	T/G	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.42	-5.25	-0.33	3.45e-7	Uric acid levels;
SARC	cis	rs870825	0.860	rs11132253	chr4:185595472	C/T	cg04058563	chr4:185651563	MLF1IP	0.74	9.24	0.52	1.6e-17	Blood protein levels;
SARC	cis	rs17001868	0.892	rs73167023	chr22:40799954	T/C	cg07138101	chr22:40742427	ADSL	0.54	4.94	0.31	1.51e-6	Mammographic density (dense area);
SARC	cis	rs7772486	0.597	rs7746618	chr6:146281367	T/C	cg23711669	chr6:146136114	FBXO30	-0.85	-12.09	-0.62	1.96e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2370759	1.000	rs76467481	chr10:32610740	T/G	cg01819863	chr10:32635814	EPC1	1.01	10.17	0.55	2.34e-20	Sexual dysfunction (female);
SARC	cis	rs7216064	0.651	rs12947658	chr17:65903006	A/G	cg12091567	chr17:66097778	LOC651250	0.51	5.98	0.36	8.18e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs3008870	1.000	rs2755250	chr1:67495283	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.9	11.27	0.59	8.39e-24	Lymphocyte percentage of white cells;
SARC	cis	rs7084402	0.764	rs2393455	chr10:60374898	C/A	cg07615347	chr10:60278583	BICC1	0.59	8.59	0.49	1.3e-15	Refractive error;
SARC	cis	rs3540	0.557	rs11634314	chr15:91042066	A/C	cg22089800	chr15:90895588	ZNF774	-0.6	-7.61	-0.45	6.87e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg11644478	chr21:40555479	PSMG1	-0.55	-6.83	-0.41	7.11e-11	Menarche (age at onset);
SARC	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg05872129	chr22:39784769	NA	-0.38	-5.09	-0.32	7.26e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs2011503	1.000	rs2905422	chr19:19460703	A/G	cg03709012	chr19:19516395	GATAD2A	-0.64	-5.37	-0.33	1.94e-7	Bipolar disorder;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg25883261	chr11:34937992	PDHX;APIP	0.77	6.4	0.39	8.31e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2120243	0.539	rs7629293	chr3:157114462	C/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.39	4.95	0.31	1.44e-6	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg06558623	chr16:89946397	TCF25	0.91	6.17	0.37	3.02e-9	Skin colour saturation;
SARC	cis	rs9457247	1.000	rs393727	chr6:167398632	T/A	cg07741184	chr6:167504864	NA	0.29	5.55	0.34	7.59e-8	Crohn's disease;
SARC	cis	rs8077889	0.917	rs72836556	chr17:41911824	G/T	cg26893861	chr17:41843967	DUSP3	0.89	11.13	0.59	2.41e-23	Triglycerides;
SARC	cis	rs2439831	0.681	rs7175434	chr15:43628542	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.07	12.45	0.63	1.3e-27	Lung cancer in ever smokers;
SARC	cis	rs9329289	0.603	rs2458705	chr10:2541377	A/G	cg15501526	chr10:2543763	NA	0.59	8.93	0.5	1.34e-16	Age-related hearing impairment;
SARC	cis	rs112591243	0.685	rs2839341	chr21:47990008	A/G	cg26904215	chr21:47823096	PCNT	0.8	5.51	0.34	9.53e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs6893300	0.524	rs12374446	chr5:179131143	A/G	cg14593053	chr5:179126677	CANX	0.48	6.56	0.39	3.52e-10	Resting heart rate;
SARC	cis	rs172166	0.694	rs203892	chr6:28067196	T/C	cg17221315	chr6:27791827	HIST1H4J	0.45	4.95	0.31	1.41e-6	Cardiac Troponin-T levels;
SARC	cis	rs4975616	0.804	rs459961	chr5:1337106	T/A	cg07493874	chr5:1342172	CLPTM1L	-0.58	-7.89	-0.46	1.19e-13	Lung cancer;
SARC	cis	rs6545883	0.899	rs1562309	chr2:61770126	C/A	cg15711740	chr2:61764176	XPO1	-0.44	-5.44	-0.34	1.35e-7	Tuberculosis;
SARC	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg03433033	chr1:76189801	ACADM	0.47	5.93	0.36	1.1e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9303401	0.659	rs12150536	chr17:56640834	C/T	cg25039879	chr17:56429692	SUPT4H1	0.67	6.21	0.38	2.4e-9	Cognitive test performance;
SARC	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg11644478	chr21:40555479	PSMG1	-0.56	-6.81	-0.41	8.37e-11	Menarche (age at onset);
SARC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.64	-7.86	-0.46	1.43e-13	Longevity;Endometriosis;
SARC	cis	rs73206853	0.688	rs55805203	chr12:110819142	G/T	cg08946844	chr12:110511112	NA	0.59	4.75	0.3	3.56e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg09373136	chr17:61933544	TCAM1	-0.44	-6.05	-0.37	5.88e-9	Prudent dietary pattern;
SARC	cis	rs7959452	0.640	rs12370042	chr12:69692420	C/G	cg14784868	chr12:69753453	YEATS4	0.4	5.24	0.32	3.58e-7	Blood protein levels;
SARC	cis	rs6840360	0.571	rs62327269	chr4:152527973	G/C	cg22705602	chr4:152727874	NA	-0.42	-6.64	-0.4	2.15e-10	Intelligence (multi-trait analysis);
SARC	trans	rs9395865	0.520	rs6903708	chr6:53332940	A/G	cg18718234	chr5:175874660	FAF2	-0.51	-6.25	-0.38	1.93e-9	Electroencephalographic traits in alcoholism;
SARC	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs3204955	0.802	rs12402684	chr1:116245655	C/G	cg20810993	chr1:116250018	CASQ2	0.51	5.26	0.33	3.22e-7	Itch intensity from mosquito bite adjusted by bite size;
SARC	cis	rs78487399	0.808	rs6717636	chr2:43703684	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-5.28	-0.33	2.9e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs6964587	0.967	rs10279210	chr7:91616891	G/A	cg17063962	chr7:91808500	NA	0.96	16.31	0.73	2.04e-40	Breast cancer;
SARC	cis	rs7326068	0.596	rs4505167	chr13:21341096	T/C	cg16922012	chr13:21400325	XPO4	-0.43	-5.68	-0.35	3.9e-8	Schizophrenia, bipolar disorder and depression (combined);
SARC	cis	rs34779708	0.897	rs4934716	chr10:35369299	A/G	cg03585969	chr10:35415529	CREM	0.39	4.92	0.31	1.67e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs899997	0.814	rs28661610	chr15:78985317	G/A	cg04896959	chr15:78267971	NA	-0.44	-5.21	-0.32	4.2e-7	Coronary artery disease or large artery stroke;
SARC	cis	rs11574514	0.661	rs9940402	chr16:67830338	T/A	cg01866162	chr16:67596514	CTCF	0.98	5.97	0.36	8.6e-9	Crohn's disease;
SARC	cis	rs6484504	0.625	rs7112412	chr11:31370271	T/C	cg26647111	chr11:31128758	NA	0.39	5.0	0.31	1.13e-6	Red blood cell count;
SARC	cis	rs2115630	1.000	rs2115630	chr15:85364516	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.45	-5.49	-0.34	1.03e-7	P wave terminal force;
SARC	cis	rs1185460	0.565	rs584115	chr11:118938880	A/G	cg23280166	chr11:118938394	VPS11	-0.58	-7.32	-0.43	4.03e-12	Coronary artery disease;
SARC	cis	rs910316	0.967	rs175505	chr14:75529619	C/T	cg08847533	chr14:75593920	NEK9	-0.87	-13.34	-0.66	1.55e-30	Height;
SARC	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg24250549	chr1:154909240	PMVK	0.78	11.09	0.59	3.11e-23	Prostate cancer;
SARC	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg22535103	chr8:58192502	C8orf71	-0.69	-8.36	-0.48	5.81e-15	Developmental language disorder (linguistic errors);
SARC	cis	rs17023223	0.509	rs6668960	chr1:119600812	C/T	cg05756136	chr1:119680316	WARS2	-0.43	-5.03	-0.31	9.81e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs818427	0.896	rs430665	chr5:112228667	G/A	cg07820702	chr5:112228657	REEP5	-0.5	-5.65	-0.35	4.57e-8	Total body bone mineral density;
SARC	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg08859206	chr1:53392774	SCP2	-0.41	-5.81	-0.36	1.99e-8	Monocyte count;
SARC	cis	rs4555082	0.834	rs11622165	chr14:105759761	C/A	cg13114125	chr14:105738426	BRF1	-0.78	-10.8	-0.58	2.7e-22	Mean platelet volume;Platelet distribution width;
SARC	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg26681399	chr22:41777847	TEF	0.43	4.94	0.31	1.47e-6	Vitiligo;
SARC	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg11987759	chr7:65425863	GUSB	0.47	5.85	0.36	1.64e-8	Aortic root size;
SARC	cis	rs10493773	1.000	rs3767163	chr1:86121895	T/G	cg17807903	chr1:86174739	ZNHIT6	-0.48	-6.96	-0.41	3.51e-11	Urate levels in overweight individuals;
SARC	cis	rs17345786	0.667	rs7622940	chr3:101133155	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.43	-4.83	-0.3	2.47e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9393692	0.905	rs7450556	chr6:26299900	C/T	cg05868516	chr6:26286170	HIST1H4H	0.58	7.76	0.45	2.67e-13	Educational attainment;
SARC	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.47	-5.32	-0.33	2.49e-7	Height;
SARC	cis	rs41264869	0.628	rs16855154	chr1:205111275	T/C	cg21643547	chr1:205240462	TMCC2	0.47	5.22	0.32	3.93e-7	Blood protein levels;
SARC	cis	rs7584330	0.554	rs7587496	chr2:238387632	A/G	cg08992911	chr2:238395768	MLPH	0.68	5.72	0.35	3.33e-8	Prostate cancer;
SARC	cis	rs4595586	0.679	rs1156706	chr12:39372641	G/A	cg26384229	chr12:38710491	ALG10B	0.43	5.41	0.33	1.6e-7	Morning vs. evening chronotype;
SARC	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg22920501	chr2:26401640	FAM59B	-0.55	-7.03	-0.42	2.29e-11	Gut microbiome composition (summer);
SARC	cis	rs7246657	0.943	rs4417644	chr19:37852472	A/G	cg23950597	chr19:37808831	NA	-0.6	-5.85	-0.36	1.67e-8	Coronary artery calcification;
SARC	cis	rs748404	0.660	rs2467738	chr15:43739936	T/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	5.52	0.34	8.9e-8	Lung cancer;
SARC	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg25036284	chr2:26402008	FAM59B	-0.46	-5.7	-0.35	3.59e-8	Gut microbiome composition (summer);
SARC	cis	rs7178572	0.568	rs4886866	chr15:77696166	A/T	cg22256960	chr15:77711686	NA	-0.5	-5.4	-0.33	1.62e-7	Type 2 diabetes;
SARC	cis	rs1545257	0.538	rs729921	chr2:24633124	T/G	cg06627628	chr2:24431161	ITSN2	-0.55	-7.09	-0.42	1.56e-11	Sjögren's syndrome;
SARC	cis	rs8067545	0.611	rs12938355	chr17:20195217	A/G	cg13482628	chr17:19912719	NA	-0.58	-7.7	-0.45	3.8e-13	Schizophrenia;
SARC	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.95	-15.2	-0.71	1.01e-36	Chronic sinus infection;
SARC	trans	rs1814175	0.676	rs11040647	chr11:49935947	A/C	cg15704280	chr7:45808275	SEPT13	-0.88	-14.0	-0.68	1.02e-32	Height;
SARC	cis	rs2120243	0.539	rs2168430	chr3:157120408	T/C	cg24825693	chr3:157122686	VEPH1	-0.46	-6.42	-0.39	7.36e-10	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs2421770	0.530	rs4756218	chr11:35370113	G/A	cg13971030	chr11:35366721	SLC1A2	-0.34	-5.29	-0.33	2.82e-7	Staphylococcus aureus nasal carriage (persistent);
SARC	cis	rs17376456	0.877	rs10476597	chr5:93367172	C/T	cg21475434	chr5:93447410	FAM172A	-0.82	-7.19	-0.43	9.01e-12	Diabetic retinopathy;
SARC	cis	rs11098499	0.863	rs3822191	chr4:120428101	A/T	cg09307838	chr4:120376055	NA	0.88	11.06	0.59	3.91e-23	Corneal astigmatism;
SARC	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg16606324	chr3:10149918	C3orf24	0.49	4.82	0.3	2.56e-6	Alzheimer's disease;
SARC	cis	rs7766436	0.524	rs66992531	chr6:22511065	T/C	cg13666174	chr6:22585274	NA	-0.57	-6.42	-0.39	7.4e-10	Coronary artery disease;
SARC	cis	rs17023223	0.537	rs12081198	chr1:119686104	A/C	cg05756136	chr1:119680316	WARS2	-0.48	-5.55	-0.34	7.84e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs9814567	1.000	rs1917130	chr3:134313773	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	6.89	0.41	5.31e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs1153858	0.725	rs74572151	chr15:45647526	T/G	cg14582100	chr15:45693742	SPATA5L1	0.35	4.91	0.31	1.69e-6	Homoarginine levels;
SARC	cis	rs1348850	0.632	rs1358328	chr2:178517532	G/A	cg22681709	chr2:178499509	PDE11A	-0.42	-5.78	-0.35	2.39e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs950169	1.000	rs1848093	chr15:84755527	G/C	cg24253500	chr15:84953950	NA	0.36	5.24	0.32	3.66e-7	Schizophrenia;
SARC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg10295955	chr4:187884368	NA	-1.07	-20.18	-0.8	4.55e-53	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs1493916	0.748	rs1941684	chr18:31304421	C/G	cg27147174	chr7:100797783	AP1S1	-0.51	-6.27	-0.38	1.77e-9	Life satisfaction;
SARC	cis	rs477692	0.699	rs576175	chr10:131386408	A/T	cg05714579	chr10:131428358	MGMT	0.55	7.26	0.43	5.67e-12	Response to temozolomide;
SARC	cis	rs1538970	0.962	rs9429077	chr1:45820667	C/A	cg05343316	chr1:45956843	TESK2	0.67	7.83	0.46	1.76e-13	Platelet count;
SARC	cis	rs739401	0.572	rs739400	chr11:3016520	G/A	cg25174290	chr11:3078921	CARS	0.57	8.06	0.47	4.09e-14	Longevity;
SARC	cis	rs526231	0.543	rs246916	chr5:102557515	T/C	cg23492399	chr5:102201601	PAM	-0.52	-5.63	-0.35	5.18e-8	Primary biliary cholangitis;
SARC	cis	rs1267303	0.642	rs2404611	chr1:46997127	C/G	cg25110126	chr1:46999211	NA	0.9	9.78	0.54	3.7e-19	Monobrow;
SARC	cis	rs72781680	0.821	rs11894756	chr2:24170214	A/G	cg06627628	chr2:24431161	ITSN2	0.56	6.01	0.37	7.14e-9	Lymphocyte counts;
SARC	cis	rs6665290	0.582	rs72764213	chr1:227207391	C/T	cg14016676	chr1:227182615	CDC42BPA	0.36	5.26	0.33	3.2e-7	Myeloid white cell count;
SARC	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg15448220	chr1:150897856	SETDB1	0.47	6.22	0.38	2.23e-9	Tonsillectomy;
SARC	cis	rs12142240	0.698	rs55670684	chr1:46835139	C/T	cg10495392	chr1:46806563	NSUN4	0.67	6.96	0.41	3.45e-11	Menopause (age at onset);
SARC	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg18357526	chr6:26021779	HIST1H4A	0.6	6.87	0.41	5.66e-11	Intelligence (multi-trait analysis);
SARC	cis	rs709400	0.930	rs2274268	chr14:104029378	C/G	cg26031613	chr14:104095156	KLC1	1.03	20.5	0.8	4.44e-54	Body mass index;
SARC	cis	rs12586317	0.547	rs28395170	chr14:35506988	C/T	cg16230307	chr14:35515116	FAM177A1	0.95	11.21	0.59	1.3e-23	Psoriasis;
SARC	cis	rs6860806	0.531	rs270612	chr5:131637338	G/A	cg04518342	chr5:131593106	PDLIM4	0.43	5.39	0.33	1.72e-7	Breast cancer;
SARC	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg08742575	chr21:47604166	C21orf56	0.47	6.01	0.37	7.07e-9	Testicular germ cell tumor;
SARC	cis	rs6484504	0.532	rs1929019	chr11:31267030	C/T	cg02090638	chr11:31391270	DNAJC24;DCDC1	-0.44	-5.53	-0.34	8.58e-8	Red blood cell count;
SARC	cis	rs9790314	0.695	rs7630763	chr3:160864865	T/C	cg04691961	chr3:161091175	C3orf57	-0.54	-7.19	-0.43	8.51e-12	Morning vs. evening chronotype;
SARC	cis	rs240764	0.658	rs7768210	chr6:101261494	C/T	cg09795085	chr6:101329169	ASCC3	0.44	5.62	0.35	5.29e-8	Neuroticism;
SARC	cis	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg25427524	chr10:38739819	LOC399744	-0.54	-8.46	-0.48	2.97e-15	Extrinsic epigenetic age acceleration;
SARC	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg03433033	chr1:76189801	ACADM	0.53	7.42	0.44	2.12e-12	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2180341	1.000	rs9385419	chr6:127597591	A/G	cg27446573	chr6:127587934	RNF146	1.01	14.18	0.68	2.45e-33	Breast cancer;
SARC	cis	rs9457247	1.000	rs409356	chr6:167405226	T/A	cg23791538	chr6:167370224	RNASET2	-0.63	-8.74	-0.5	4.69e-16	Crohn's disease;
SARC	cis	rs9611519	0.929	rs73174657	chr22:41434158	G/A	cg17376030	chr22:41985996	PMM1	0.5	6.06	0.37	5.45e-9	Neuroticism;
SARC	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.88	11.13	0.59	2.28e-23	Multiple sclerosis;
SARC	cis	rs17376456	0.825	rs13165400	chr5:93091427	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.71	6.3	0.38	1.48e-9	Diabetic retinopathy;
SARC	cis	rs9790314	0.690	rs1903423	chr3:160842252	A/G	cg03342759	chr3:160939853	NMD3	-0.57	-7.22	-0.43	7.37e-12	Morning vs. evening chronotype;
SARC	trans	rs7824557	0.767	rs3808513	chr8:11157460	G/T	cg06636001	chr8:8085503	FLJ10661	-0.6	-7.57	-0.44	8.69e-13	Retinal vascular caliber;
SARC	cis	rs9462027	0.628	rs9469892	chr6:34769101	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.91	-0.36	1.23e-8	Systemic lupus erythematosus;
SARC	cis	rs7000551	0.700	rs2469761	chr8:22367274	A/G	cg12081754	chr8:22256438	SLC39A14	0.54	7.57	0.44	8.61e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs362272	0.524	rs10937924	chr4:3374898	T/C	cg08741688	chr4:3415352	RGS12	-0.48	-6.27	-0.38	1.72e-9	Serum sulfate level;
SARC	cis	rs2425143	0.915	rs74355238	chr20:34441541	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-5.57	-0.34	6.92e-8	Blood protein levels;
SARC	cis	rs17376456	0.877	rs10044139	chr5:93407803	T/C	cg21475434	chr5:93447410	FAM172A	0.85	7.56	0.44	9.4e-13	Diabetic retinopathy;
SARC	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg18252515	chr7:66147081	NA	-0.5	-5.36	-0.33	2.02e-7	Aortic root size;
SARC	cis	rs7539542	0.556	rs6427979	chr1:202869503	T/C	cg08940984	chr1:202857613	RABIF	0.39	5.34	0.33	2.17e-7	Mean platelet volume;
SARC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.51	5.78	0.35	2.33e-8	Prudent dietary pattern;
SARC	cis	rs3768617	0.510	rs6424884	chr1:183065904	C/T	cg13390022	chr1:182993471	LAMC1	0.33	4.94	0.31	1.47e-6	Fuchs's corneal dystrophy;
SARC	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.47	-5.93	-0.36	1.1e-8	Lymphocyte counts;
SARC	cis	rs57502260	0.680	rs7104806	chr11:68222188	C/T	cg01657329	chr11:68192670	LRP5	-0.49	-4.81	-0.3	2.75e-6	Total body bone mineral density (age 45-60);
SARC	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg10435706	chr6:150039699	LATS1	0.37	4.87	0.3	2.04e-6	Lung cancer;
SARC	cis	rs2013441	1.000	rs2013441	chr17:20023099	G/A	cg13482628	chr17:19912719	NA	0.46	5.94	0.36	1.05e-8	Obesity-related traits;
SARC	cis	rs9443189	0.950	rs1280039	chr6:76514940	C/T	cg01950844	chr6:76311363	SENP6	0.78	6.78	0.41	1e-10	Prostate cancer;
SARC	cis	rs17030434	0.953	rs11099905	chr4:154686183	A/G	cg14289246	chr4:154710475	SFRP2	0.61	5.7	0.35	3.59e-8	Electrocardiographic conduction measures;
SARC	cis	rs798554	0.610	rs2644297	chr7:2858906	A/C	cg04166393	chr7:2884313	GNA12	0.44	5.45	0.34	1.28e-7	Height;
SARC	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg18876405	chr7:65276391	NA	0.68	8.13	0.47	2.52e-14	Aortic root size;
SARC	cis	rs1949733	0.585	rs2631768	chr4:8473050	A/G	cg11789530	chr4:8429930	ACOX3	-0.59	-6.99	-0.42	2.89e-11	Response to antineoplastic agents;
SARC	trans	rs629535	0.547	rs62513420	chr8:70122597	G/A	cg21567404	chr3:27674614	NA	-0.97	-10.7	-0.57	5.22e-22	Dupuytren's disease;
SARC	cis	rs4820539	1.000	rs5759596	chr22:23475750	G/A	cg14186256	chr22:23484241	RTDR1	0.91	14.96	0.7	6.32e-36	Bone mineral density;
SARC	cis	rs4268898	0.931	rs34504814	chr2:24503766	C/T	cg06627628	chr2:24431161	ITSN2	-0.66	-9.21	-0.52	1.95e-17	Asthma;
SARC	cis	rs3087591	0.920	rs2905881	chr17:29547862	T/C	cg24425628	chr17:29625626	OMG;NF1	0.5	6.19	0.38	2.69e-9	Hip circumference;
SARC	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg03161606	chr19:29218774	NA	0.47	6.93	0.41	4.07e-11	Methadone dose in opioid dependence;
SARC	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg01017244	chr2:74357527	NA	0.56	7.2	0.43	8.45e-12	Gestational age at birth (maternal effect);
SARC	cis	rs7216064	1.000	rs59950564	chr17:65860859	A/G	cg12091567	chr17:66097778	LOC651250	-0.64	-6.45	-0.39	6.56e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs2235642	0.821	rs8051895	chr16:1602811	A/G	cg09065629	chr16:1709722	CRAMP1L	0.35	4.93	0.31	1.54e-6	Coronary artery disease;
SARC	cis	rs9682041	0.736	rs34237232	chr3:170063753	C/T	cg11886554	chr3:170076028	SKIL	-0.83	-7.05	-0.42	2.01e-11	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs523522	0.962	rs655530	chr12:121022275	T/C	cg12219531	chr12:120966889	COQ5	0.82	11.01	0.59	5.52e-23	High light scatter reticulocyte count;
SARC	cis	rs9486719	1.000	rs2273622	chr6:97058567	A/G	cg18709589	chr6:96969512	KIAA0776	-0.56	-5.62	-0.35	5.44e-8	Migraine;Coronary artery disease;
SARC	cis	rs7647973	0.925	rs9834003	chr3:49216472	T/C	cg06212747	chr3:49208901	KLHDC8B	0.61	6.48	0.39	5.53e-10	Menarche (age at onset);
SARC	cis	rs4927850	0.829	rs6768483	chr3:195745963	C/G	cg00031303	chr3:195681400	NA	0.7	7.73	0.45	3.29e-13	Pancreatic cancer;
SARC	cis	rs4906332	1.000	rs12889703	chr14:103872951	T/A	cg20474699	chr14:102976161	ANKRD9	0.42	4.75	0.3	3.62e-6	Coronary artery disease;
SARC	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.42	-6.95	-0.41	3.58e-11	Total body bone mineral density;
SARC	cis	rs11690935	0.686	rs10165126	chr2:172820315	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.7	-9.07	-0.51	4.99e-17	Schizophrenia;
SARC	cis	rs6580649	0.941	rs11612578	chr12:48414798	T/C	cg05342945	chr12:48394962	COL2A1	0.56	6.12	0.37	3.85e-9	Lung cancer;
SARC	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg11366901	chr6:160182831	ACAT2	0.98	10.0	0.55	7.96e-20	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs2286503	0.650	rs1990279	chr7:22890742	A/G	cg04907244	chr7:22894795	SNORD93	-0.36	-5.04	-0.31	9.46e-7	Fibrinogen;
SARC	cis	rs7829975	0.572	rs28446104	chr8:8795901	C/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.95	-0.41	3.55e-11	Mood instability;
SARC	cis	rs2576037	0.796	rs2576041	chr18:44580919	C/T	cg19077165	chr18:44547161	KATNAL2	0.45	6.24	0.38	2.02e-9	Personality dimensions;
SARC	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg19223190	chr17:80058835	NA	0.46	6.33	0.38	1.28e-9	Life satisfaction;
SARC	cis	rs9640161	0.789	rs2159234	chr7:150020422	A/T	cg21361702	chr7:150065534	REPIN1	0.5	5.14	0.32	5.95e-7	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs7681440	0.606	rs2583971	chr4:90747207	C/T	cg06632027	chr4:90757378	SNCA	-0.43	-5.32	-0.33	2.4e-7	Dementia with Lewy bodies;
SARC	cis	rs17270561	0.609	rs4711096	chr6:25727054	A/G	cg16482183	chr6:26056742	HIST1H1C	0.43	5.23	0.32	3.85e-7	Iron status biomarkers;
SARC	cis	rs2645694	0.608	rs60247484	chr4:77835480	C/T	cg06046430	chr4:77819534	ANKRD56	0.55	5.18	0.32	4.82e-7	Emphysema distribution in smoking;
SARC	cis	rs950169	0.881	rs62029599	chr15:84956565	A/C	cg17507749	chr15:85114479	UBE2QP1	0.77	9.42	0.53	4.67e-18	Schizophrenia;
SARC	cis	rs2303759	0.709	rs8102574	chr19:49828897	A/G	cg24324837	chr19:49891574	CCDC155	0.4	4.77	0.3	3.28e-6	Multiple sclerosis;
SARC	cis	rs9381040	0.655	rs2268188	chr6:41042590	T/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.45	-5.16	-0.32	5.17e-7	Alzheimer's disease (late onset);
SARC	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg04277193	chr17:41438351	NA	0.44	4.78	0.3	3.04e-6	Menopause (age at onset);
SARC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg07092213	chr7:1199455	ZFAND2A	-0.43	-5.82	-0.36	1.9e-8	Longevity;Endometriosis;
SARC	cis	rs7106204	0.702	rs11826172	chr11:24233998	G/A	ch.11.24196551F	chr11:24239977	NA	0.54	5.56	0.34	7.47e-8	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs8067545	0.611	rs2703771	chr17:20130154	C/G	cg13482628	chr17:19912719	NA	-0.54	-7.26	-0.43	5.91e-12	Schizophrenia;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg17417198	chr5:77590955	AP3B1	0.49	6.36	0.38	1.07e-9	Chemerin levels;
SARC	cis	rs2463822	1.000	rs2513071	chr11:62098387	A/C	cg06239285	chr11:62104954	ASRGL1	0.9	9.65	0.53	9.5e-19	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs10760158	0.510	rs7020643	chr9:123861856	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.41	4.78	0.3	3.16e-6	Pulse pressure;
SARC	cis	rs617219	0.698	rs10514159	chr5:78596044	T/C	cg24856658	chr5:78533917	JMY	0.3	4.73	0.3	3.89e-6	Betaine levels in individuals undergoing cardiac evaluation;
SARC	cis	rs2303759	0.709	rs8102574	chr19:49828897	A/G	cg22307029	chr19:49891270	CCDC155	0.59	6.64	0.4	2.17e-10	Multiple sclerosis;
SARC	cis	rs7568458	0.660	rs2289972	chr2:85766545	C/T	cg23752985	chr2:85803571	VAMP8	0.45	5.68	0.35	4.01e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs7937682	0.924	rs1784782	chr11:111525764	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.93	-15.22	-0.71	8.48e-37	Primary sclerosing cholangitis;
SARC	cis	rs6493487	0.512	rs28430533	chr15:51256012	T/C	cg02338191	chr15:51200825	AP4E1	0.5	4.74	0.3	3.8e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg03517284	chr6:25882590	NA	-0.43	-5.84	-0.36	1.79e-8	Intelligence (multi-trait analysis);
SARC	cis	rs6495122	0.501	rs6495151	chr15:75385990	A/G	cg09165964	chr15:75287851	SCAMP5	-0.49	-6.59	-0.4	2.95e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg24846343	chr22:24311635	DDTL	-0.49	-7.25	-0.43	6.28e-12	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2842992	0.747	rs4709379	chr6:160227530	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.8	7.43	0.44	1.98e-12	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs17021463	0.902	rs36099342	chr4:95239783	T/C	cg11021082	chr4:95130006	SMARCAD1	0.43	6.43	0.39	7.34e-10	Testicular germ cell tumor;
SARC	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg18252515	chr7:66147081	NA	-0.57	-6.09	-0.37	4.63e-9	Aortic root size;
SARC	cis	rs918629	0.530	rs9314162	chr5:95252594	C/A	cg16656078	chr5:95278638	ELL2	-0.6	-7.16	-0.42	1.07e-11	IgG glycosylation;
SARC	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg22535103	chr8:58192502	C8orf71	-0.71	-6.83	-0.41	7.18e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg03806693	chr22:41940476	POLR3H	-0.96	-13.26	-0.66	2.78e-30	Vitiligo;
SARC	cis	rs10504073	0.647	rs10435574	chr8:49996028	G/A	cg00325661	chr8:49890786	NA	0.54	7.27	0.43	5.57e-12	Blood metabolite ratios;
SARC	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg11494091	chr17:61959527	GH2	0.37	5.18	0.32	4.88e-7	Height;
SARC	cis	rs67311347	1.000	rs11714912	chr3:40494065	A/G	cg01475735	chr3:40494733	NA	0.45	5.4	0.33	1.66e-7	Renal cell carcinoma;
SARC	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg11301795	chr4:187892539	NA	-0.77	-12.17	-0.62	1.06e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10162002	1.000	rs10162002	chr13:24042510	G/A	cg00158254	chr13:24040743	NA	0.51	4.89	0.31	1.86e-6	Hypothyroidism;
SARC	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg09165964	chr15:75287851	SCAMP5	0.59	8.03	0.47	4.68e-14	Breast cancer;
SARC	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-5.74	-0.35	2.92e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg18876405	chr7:65276391	NA	0.45	5.08	0.32	7.82e-7	Aortic root size;
SARC	cis	rs7714584	0.793	rs12653039	chr5:150252631	G/A	cg22134413	chr5:150180641	NA	0.93	7.28	0.43	5.05e-12	Crohn's disease;
SARC	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.72	-7.17	-0.43	9.79e-12	Platelet count;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg04674581	chr9:136283438	ADAMTS13;REXO4	0.5	6.39	0.39	8.87e-10	Breast cancer;
SARC	cis	rs17666538	0.636	rs62486234	chr8:589157	G/T	cg23958373	chr8:599963	NA	-0.64	-5.66	-0.35	4.32e-8	IgG glycosylation;
SARC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.76	-7.97	-0.46	6.85e-14	Platelet count;
SARC	trans	rs13247936	0.574	rs12702800	chr7:8965291	A/G	cg27292588	chr1:45285892	PTCH2	0.49	6.93	0.41	4.12e-11	Schizophrenia;
SARC	cis	rs1355223	0.583	rs2941041	chr11:34874734	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.78	11.23	0.59	1.12e-23	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs8044995	0.563	rs55968019	chr16:68398111	G/A	cg09835421	chr16:68378352	PRMT7	-0.64	-6.04	-0.37	6.1e-9	Schizophrenia;
SARC	cis	rs17270561	0.609	rs1892246	chr6:25764408	C/T	cg17691542	chr6:26056736	HIST1H1C	0.57	7.11	0.42	1.45e-11	Iron status biomarkers;
SARC	cis	rs3923518	0.956	rs33985936	chr3:38936134	C/T	cg15678707	chr3:39149194	GORASP1;TTC21A	0.47	5.05	0.31	8.84e-7	Migraine;
SARC	cis	rs11809207	0.568	rs1892494	chr1:26497626	C/G	cg23602478	chr1:26503979	CNKSR1	0.28	5.04	0.31	9.15e-7	Height;
SARC	cis	rs2239547	0.523	rs6803486	chr3:53098209	T/A	cg11645453	chr3:52864694	ITIH4	0.3	4.72	0.3	4.13e-6	Schizophrenia;
SARC	cis	rs8180040	0.903	rs13094438	chr3:47277885	G/A	cg27129171	chr3:47204927	SETD2	0.7	9.54	0.53	1.99e-18	Colorectal cancer;
SARC	cis	rs73086581	1.000	rs3746666	chr20:3910861	A/G	cg02187196	chr20:3869020	PANK2	0.64	6.23	0.38	2.12e-9	Response to antidepressants in depression;
SARC	cis	rs908922	0.676	rs569032	chr1:152508615	C/T	cg09873164	chr1:152488093	CRCT1	0.66	8.62	0.49	1.03e-15	Hair morphology;
SARC	cis	rs6088580	0.524	rs6088567	chr20:33263872	A/T	cg08999081	chr20:33150536	PIGU	-0.34	-4.99	-0.31	1.17e-6	Glomerular filtration rate (creatinine);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg08793459	chr17:57784647	PTRH2;TMEM49	-0.64	-7.33	-0.43	3.67e-12	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg11987759	chr7:65425863	GUSB	0.57	7.43	0.44	2.04e-12	Aortic root size;
SARC	cis	rs9916302	0.904	rs7223438	chr17:37521355	T/C	cg15445000	chr17:37608096	MED1	-0.45	-5.6	-0.34	5.98e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	11.66	0.61	4.57e-25	Alzheimer's disease;
SARC	cis	rs4765905	0.610	rs4765902	chr12:2312965	C/T	cg10668781	chr12:2307325	CACNA1C	-0.35	-5.46	-0.34	1.2e-7	Schizophrenia;
SARC	cis	rs7408868	0.764	rs12610803	chr19:15260682	A/C	cg14696996	chr19:15285081	NOTCH3	1.13	8.94	0.51	1.2e-16	Pulse pressure;
SARC	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg20607798	chr8:58055168	NA	0.61	5.79	0.35	2.27e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10979	0.679	rs35914889	chr6:143886392	A/T	cg25407410	chr6:143891975	LOC285740	-0.57	-6.92	-0.41	4.44e-11	Hypospadias;
SARC	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg12373951	chr3:133503437	NA	0.37	5.38	0.33	1.8e-7	Iron status biomarkers;
SARC	cis	rs6704644	0.932	rs11675858	chr2:234440053	G/A	cg27060346	chr2:234359958	DGKD	-0.61	-4.77	-0.3	3.21e-6	Bilirubin levels;
SARC	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.73	-7.62	-0.45	6.21e-13	Platelet count;
SARC	cis	rs710865	0.527	rs2275403	chr1:19557713	C/G	cg13387374	chr1:19411106	UBR4	-0.69	-10.07	-0.55	4.94e-20	Brain structure;
SARC	cis	rs28655083	0.500	rs9972728	chr16:77064484	A/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.33	4.75	0.3	3.52e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9875589	0.509	rs6775534	chr3:14051001	C/T	cg19554555	chr3:13937349	NA	-0.41	-5.4	-0.33	1.64e-7	Ovarian reserve;
SARC	cis	rs6693567	0.565	rs1260407	chr1:150306125	T/C	cg09579323	chr1:150459698	TARS2	0.42	5.31	0.33	2.56e-7	Migraine;
SARC	cis	rs11098499	0.909	rs79704848	chr4:120309351	T/A	cg09307838	chr4:120376055	NA	0.91	12.88	0.65	4.9e-29	Corneal astigmatism;
SARC	cis	rs9633740	1.000	rs7900536	chr10:82253701	G/T	cg01528321	chr10:82214614	TSPAN14	0.91	10.58	0.57	1.25e-21	Post bronchodilator FEV1;
SARC	cis	rs7178909	0.872	rs28865973	chr15:90435178	T/G	cg19708238	chr15:90437601	AP3S2	0.59	7.89	0.46	1.19e-13	Common traits (Other);
SARC	cis	rs1801251	0.893	rs11687128	chr2:233608901	T/C	cg25237894	chr2:233734115	C2orf82	0.38	4.96	0.31	1.39e-6	Coronary artery disease;
SARC	cis	rs2865116	0.851	rs10265771	chr7:68991726	C/G	cg10619644	chr7:69149951	AUTS2	0.34	4.76	0.3	3.34e-6	Positive affect;
SARC	cis	rs73206853	0.841	rs55864430	chr12:110932355	G/T	cg10860002	chr12:110842031	ANAPC7	0.63	4.96	0.31	1.35e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	trans	rs2243123	0.602	rs2133310	chr3:159716352	A/G	cg03901886	chr1:9600115	SLC25A33	0.49	6.25	0.38	1.95e-9	Multiple sclerosis;
SARC	cis	rs7589342	0.929	rs13024715	chr2:106433950	A/G	cg16077055	chr2:106428750	NCK2	0.4	7.45	0.44	1.79e-12	Addiction;
SARC	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg02725872	chr8:58115012	NA	-0.31	-4.88	-0.3	1.96e-6	Developmental language disorder (linguistic errors);
SARC	trans	rs8073060	0.586	rs4796098	chr17:33913436	T/C	cg19694781	chr19:47549865	TMEM160	0.65	6.37	0.39	1.02e-9	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs2120243	0.539	rs2305622	chr3:157122504	C/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.38	4.88	0.3	1.99e-6	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs7520050	0.966	rs6675726	chr1:46560643	A/G	cg24296786	chr1:45957014	TESK2	0.38	4.82	0.3	2.56e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg13770153	chr20:60521292	NA	-0.48	-6.45	-0.39	6.49e-10	Body mass index;
SARC	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.53	4.88	0.3	1.99e-6	Lung function (FEV1/FVC);
SARC	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg18404041	chr3:52824283	ITIH1	-0.44	-6.58	-0.4	3.05e-10	Bipolar disorder;
SARC	cis	rs72627509	1.000	rs72627509	chr4:57839051	C/G	cg26694713	chr4:57773883	REST	0.68	6.61	0.4	2.61e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs710216	0.917	rs900837	chr1:43412793	A/G	cg22176566	chr1:43424700	SLC2A1	-0.53	-5.39	-0.33	1.75e-7	Red cell distribution width;
SARC	cis	rs9916302	0.660	rs665413	chr17:37455678	T/A	cg20243544	chr17:37824526	PNMT	-0.56	-5.96	-0.36	9.3e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs193541	0.593	rs246309	chr5:122269719	A/C	cg19412675	chr5:122181750	SNX24	0.47	6.04	0.37	5.91e-9	Glucose homeostasis traits;
SARC	cis	rs2279817	0.913	rs11203436	chr1:18019016	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.46	4.82	0.3	2.62e-6	Neuroticism;
SARC	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg03806693	chr22:41940476	POLR3H	0.83	10.8	0.58	2.66e-22	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs763121	0.853	rs11704021	chr22:39074716	G/A	cg21395723	chr22:39101663	GTPBP1	0.52	5.8	0.36	2.17e-8	Menopause (age at onset);
SARC	cis	rs7647973	0.826	rs9834535	chr3:49378797	A/T	cg07636037	chr3:49044803	WDR6	0.78	8.63	0.49	9.87e-16	Menarche (age at onset);
SARC	cis	rs918629	0.567	rs1458018	chr5:95253295	G/T	cg16656078	chr5:95278638	ELL2	-0.54	-6.75	-0.4	1.16e-10	IgG glycosylation;
SARC	cis	rs71636778	0.722	rs71636784	chr1:27169200	T/G	cg04852280	chr1:26496234	ZNF593	0.58	5.33	0.33	2.36e-7	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs7197653	0.667	rs12599876	chr16:68393405	C/T	cg05110241	chr16:68378359	PRMT7	-0.59	-5.03	-0.31	9.81e-7	Magnesium levels;
SARC	cis	rs12477438	0.834	rs11903311	chr2:99701807	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-9.82	-0.54	2.89e-19	Chronic sinus infection;
SARC	cis	rs5758511	0.680	rs5758698	chr22:42684818	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.49	7.31	0.43	4.24e-12	Birth weight;
SARC	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg12463550	chr7:65579703	CRCP	0.46	5.17	0.32	5e-7	Aortic root size;
SARC	cis	rs6570726	0.577	rs9497315	chr6:145791967	C/T	cg05347473	chr6:146136440	FBXO30	-0.68	-9.26	-0.52	1.35e-17	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7178572	0.568	rs4886856	chr15:77510585	A/G	cg22256960	chr15:77711686	NA	-0.51	-5.58	-0.34	6.56e-8	Type 2 diabetes;
SARC	cis	rs796364	1.000	rs281762	chr2:200799201	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.78	7.15	0.42	1.12e-11	Schizophrenia;
SARC	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg18876405	chr7:65276391	NA	0.71	8.86	0.5	2.13e-16	Aortic root size;
SARC	cis	rs7772486	0.754	rs12199362	chr6:146118225	A/G	cg23711669	chr6:146136114	FBXO30	0.91	16.04	0.72	1.67e-39	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg13012494	chr21:47604986	C21orf56	-0.45	-5.25	-0.33	3.37e-7	Testicular germ cell tumor;
SARC	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg03735888	chr19:58951602	ZNF132	0.41	5.47	0.34	1.14e-7	Uric acid clearance;
SARC	cis	rs595982	0.546	rs12461075	chr19:49399821	G/A	cg03707168	chr19:49379127	PPP1R15A	0.44	5.77	0.35	2.5e-8	Red cell distribution width;
SARC	cis	rs644799	0.544	rs56298021	chr11:95545113	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	6.03	0.37	6.29e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs11098699	0.821	rs4833887	chr4:124208033	T/C	cg09941581	chr4:124220074	SPATA5	0.39	4.73	0.3	3.98e-6	Mosquito bite size;
SARC	cis	rs6700896	0.931	rs4655574	chr1:66135328	T/A	cg04111102	chr1:66153794	NA	0.37	5.72	0.35	3.2e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs9814567	0.964	rs9820150	chr3:134223011	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.08	-0.42	1.7e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs7582180	0.629	rs10202326	chr2:100950237	A/G	cg14675211	chr2:100938903	LONRF2	0.47	7.0	0.42	2.67e-11	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-6.31	-0.38	1.36e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9399135	0.967	rs4142299	chr6:135377186	G/T	cg22676075	chr6:135203613	NA	0.35	4.76	0.3	3.45e-6	Red blood cell count;
SARC	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg13175981	chr1:150552382	MCL1	-0.54	-6.9	-0.41	4.97e-11	Urate levels;
SARC	cis	rs7084402	0.967	rs12259990	chr10:60297574	A/G	cg07615347	chr10:60278583	BICC1	-0.55	-8.09	-0.47	3.35e-14	Refractive error;
SARC	cis	rs1707322	0.721	rs10890341	chr1:46147240	C/A	cg06784218	chr1:46089804	CCDC17	0.36	6.2	0.38	2.56e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg26354017	chr1:205819088	PM20D1	-0.44	-4.84	-0.3	2.32e-6	White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs9457247	0.765	rs10484531	chr6:167454434	G/A	cg07741184	chr6:167504864	NA	0.38	7.35	0.43	3.41e-12	Crohn's disease;
SARC	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg25072359	chr17:41440525	NA	0.5	5.94	0.36	1.04e-8	Menopause (age at onset);
SARC	cis	rs2812378	1.000	rs11574914	chr9:34710338	G/A	cg13525804	chr9:33857698	UBE2R2	0.33	4.86	0.3	2.18e-6	Rheumatoid arthritis;
SARC	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg21856205	chr7:94953877	PON1	-0.32	-4.94	-0.31	1.51e-6	Paraoxonase activity;
SARC	cis	rs67311347	1.000	rs7617989	chr3:40512463	A/G	cg01475735	chr3:40494733	NA	0.44	5.06	0.31	8.7e-7	Renal cell carcinoma;
SARC	cis	rs1468333	0.567	rs2240334	chr5:137763615	A/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.61	7.41	0.44	2.32e-12	Resting heart rate;
SARC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.36	0.8	1.22e-53	Prudent dietary pattern;
SARC	cis	rs4481887	0.708	rs28729425	chr1:248563027	T/C	cg00666640	chr1:248458726	OR2T12	0.32	5.77	0.35	2.57e-8	Common traits (Other);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg20932348	chr4:26862197	STIM2	-0.81	-6.48	-0.39	5.55e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9818758	0.607	rs13077498	chr3:49313978	C/T	cg00383909	chr3:49044727	WDR6	0.72	6.24	0.38	2.04e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs7560272	0.501	rs2421676	chr2:73966087	G/A	cg20560298	chr2:73613845	ALMS1	0.43	5.74	0.35	2.98e-8	Schizophrenia;
SARC	cis	rs7223966	1.000	rs8068603	chr17:61755211	T/A	cg00588841	chr17:61851480	DDX42;CCDC47	-0.59	-6.86	-0.41	6.03e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.42	0.53	4.71e-18	Prudent dietary pattern;
SARC	cis	rs2651899	0.867	rs207200	chr1:3073555	T/C	cg22674798	chr1:3096360	PRDM16	0.27	5.4	0.33	1.65e-7	Migraine;
SARC	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6088590	0.687	rs73106933	chr20:33287425	T/C	cg24642439	chr20:33292090	TP53INP2	0.78	10.42	0.56	4.03e-21	Coronary artery disease;
SARC	trans	rs9951602	0.512	rs12455566	chr18:76655926	A/G	cg02800362	chr5:177631904	HNRNPAB	0.7	8.91	0.5	1.49e-16	Obesity-related traits;
SARC	cis	rs62344088	1.000	rs28409618	chr5:160289	C/T	cg20965017	chr5:231967	SDHA	-0.74	-4.94	-0.31	1.47e-6	Asthma (childhood onset);
SARC	cis	rs7220711	0.967	rs4792909	chr17:41798824	G/T	cg26893861	chr17:41843967	DUSP3	0.39	4.91	0.31	1.72e-6	Bone mineral density (spine);Bone mineral density (hip);
SARC	cis	rs4927850	0.521	rs4927679	chr3:195658360	C/T	cg12923728	chr3:195709715	SDHAP1	0.41	5.2	0.32	4.4e-7	Pancreatic cancer;
SARC	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg12463550	chr7:65579703	CRCP	0.49	5.32	0.33	2.49e-7	Aortic root size;
SARC	cis	rs6674176	0.660	rs12726706	chr1:44399942	G/A	cg12908607	chr1:44402522	ARTN	-0.4	-6.78	-0.41	9.8e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs67460515	0.528	rs11915989	chr3:160902259	A/G	cg03342759	chr3:160939853	NMD3	-0.64	-7.95	-0.46	7.99e-14	Parkinson's disease;
SARC	cis	rs34779708	0.966	rs4934730	chr10:35415555	A/G	cg03585969	chr10:35415529	CREM	0.43	5.24	0.32	3.63e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs1008375	0.966	rs6449325	chr4:17699509	C/T	cg27347728	chr4:17578864	LAP3	-0.44	-5.48	-0.34	1.11e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7223966	1.000	rs6504173	chr17:61735056	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.58	-6.67	-0.4	1.81e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg07076661	chr18:9136556	ANKRD12	-0.71	-6.72	-0.4	1.36e-10	Cutaneous psoriasis;
SARC	cis	rs1865760	0.892	rs2328903	chr6:25935765	T/C	cg16482183	chr6:26056742	HIST1H1C	0.53	6.68	0.4	1.72e-10	Height;
SARC	cis	rs7666738	0.962	rs11728816	chr4:98951767	C/T	cg05340658	chr4:99064831	C4orf37	0.56	6.99	0.42	2.95e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs3617	0.573	rs9880978	chr3:52923251	C/G	cg18404041	chr3:52824283	ITIH1	-0.33	-4.75	-0.3	3.62e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	trans	rs61931739	0.500	rs10844862	chr12:34531965	A/T	cg26384229	chr12:38710491	ALG10B	0.85	12.63	0.64	3.4e-28	Morning vs. evening chronotype;
SARC	cis	rs6500602	0.627	rs841231	chr16:4583147	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.37	-6.01	-0.37	7.18e-9	Schizophrenia;
SARC	cis	rs1865760	0.865	rs10946800	chr6:25957773	C/T	cg16482183	chr6:26056742	HIST1H1C	0.52	6.69	0.4	1.63e-10	Height;
SARC	cis	rs6991838	0.778	rs7843724	chr8:66462816	G/T	cg13398993	chr8:66546079	ARMC1	0.42	5.22	0.32	4.03e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9467603	1.000	rs9467607	chr6:25809477	G/A	cg21479132	chr6:26055353	NA	0.77	5.1	0.32	7.06e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7408868	0.706	rs7257550	chr19:15292088	C/G	cg14696996	chr19:15285081	NOTCH3	0.71	6.76	0.4	1.11e-10	Pulse pressure;
SARC	cis	rs943466	0.911	rs111352628	chr6:33742490	A/G	cg04676172	chr6:33757040	LEMD2	0.45	4.76	0.3	3.47e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
SARC	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	13.02	0.65	1.75e-29	Chronic sinus infection;
SARC	cis	rs477692	0.837	rs543454	chr10:131420536	T/C	cg05714579	chr10:131428358	MGMT	0.58	7.77	0.45	2.46e-13	Response to temozolomide;
SARC	cis	rs7833790	0.963	rs6473312	chr8:82732515	C/A	cg27398817	chr8:82754497	SNX16	-0.51	-5.63	-0.35	5.24e-8	Diastolic blood pressure;
SARC	cis	rs2197308	0.703	rs10880251	chr12:37903297	G/A	cg26384229	chr12:38710491	ALG10B	0.9	13.3	0.66	2.04e-30	Morning vs. evening chronotype;
SARC	cis	rs8141529	0.764	rs8137969	chr22:29228484	G/C	cg15103426	chr22:29168792	CCDC117	0.68	8.84	0.5	2.32e-16	Lymphocyte counts;
SARC	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	9.01	0.51	7.42e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs76419734	1.000	rs11728716	chr4:106755996	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	-0.81	-5.26	-0.33	3.29e-7	Post bronchodilator FEV1;
SARC	cis	rs9326248	1.000	rs10790175	chr11:117034729	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.56	6.19	0.38	2.65e-9	Blood protein levels;
SARC	cis	rs6570726	0.791	rs374478	chr6:145840022	C/T	cg23711669	chr6:146136114	FBXO30	0.87	14.58	0.69	1.18e-34	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs858239	0.601	rs10239760	chr7:23149950	C/T	cg23682824	chr7:23144976	KLHL7	0.66	8.51	0.49	2.09e-15	Cerebrospinal fluid biomarker levels;
SARC	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	9.6	0.53	1.36e-18	Platelet count;
SARC	cis	rs7511006	1.000	rs17836662	chr22:50672154	A/G	cg15134628	chr22:50699649	MAPK12	-0.4	-4.81	-0.3	2.67e-6	Obesity-related traits;
SARC	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg06634786	chr22:41940651	POLR3H	-0.57	-6.77	-0.41	1.05e-10	Vitiligo;
SARC	cis	rs11098499	0.754	rs12711071	chr4:120240934	A/G	cg09307838	chr4:120376055	NA	0.83	11.41	0.6	3.12e-24	Corneal astigmatism;
SARC	cis	rs6540556	0.769	rs2272867	chr1:209929579	C/A	cg05527609	chr1:210001259	C1orf107	-0.77	-7.0	-0.42	2.76e-11	Red blood cell count;
SARC	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg01341218	chr17:43662625	NA	1.02	11.64	0.61	5.36e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs877282	0.628	rs11253435	chr10:824169	T/C	cg15764593	chr10:829463	NA	-0.43	-4.75	-0.3	3.59e-6	Uric acid levels;
SARC	cis	rs7481584	0.924	rs12805661	chr11:3020740	C/T	cg05729581	chr11:3078854	CARS	0.48	5.73	0.35	3.06e-8	Calcium levels;
SARC	cis	rs3092073	0.624	rs11906879	chr20:44591324	C/T	cg27529037	chr20:44575021	PCIF1	-0.38	-6.14	-0.37	3.57e-9	Intelligence (multi-trait analysis);
SARC	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg03060546	chr3:49711283	APEH	0.43	5.33	0.33	2.31e-7	Parkinson's disease;
SARC	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg08677398	chr8:58056175	NA	0.43	5.05	0.31	8.92e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10512697	0.803	rs71594962	chr5:3578127	A/G	cg19473799	chr5:3511975	NA	-0.68	-4.86	-0.3	2.11e-6	Immune response to smallpox vaccine (IL-6);
SARC	cis	rs7029536	0.551	rs11794990	chr9:130171020	A/G	cg09445097	chr9:130186736	ZNF79	0.53	4.92	0.31	1.67e-6	Metabolite levels (HVA);
SARC	cis	rs67311347	1.000	rs11129876	chr3:40401636	C/T	cg09455208	chr3:40491958	NA	-0.4	-6.01	-0.37	7.1e-9	Renal cell carcinoma;
SARC	cis	rs2839627	0.561	rs6586248	chr21:44257812	C/T	cg03543861	chr21:44258195	NA	0.45	5.01	0.31	1.07e-6	Information processing speed;
SARC	cis	rs7246657	0.943	rs1373991	chr19:37838911	T/C	cg23950597	chr19:37808831	NA	-0.54	-5.47	-0.34	1.15e-7	Coronary artery calcification;
SARC	cis	rs947211	1.000	rs1775151	chr1:205745684	C/T	cg14893161	chr1:205819251	PM20D1	0.45	4.97	0.31	1.31e-6	Parkinson's disease;
SARC	cis	rs4713118	0.869	rs6901520	chr6:27714575	G/T	cg17221315	chr6:27791827	HIST1H4J	0.49	5.33	0.33	2.26e-7	Parkinson's disease;
SARC	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.49	-5.62	-0.35	5.52e-8	Blood metabolite levels;
SARC	cis	rs1949733	0.675	rs2688219	chr4:8444631	T/C	cg11789530	chr4:8429930	ACOX3	0.81	10.58	0.57	1.28e-21	Response to antineoplastic agents;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg07991600	chr17:7589380	TP53;WRAP53	-0.61	-7.24	-0.43	6.54e-12	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs1018836	0.923	rs2105967	chr8:91587522	A/G	cg16814680	chr8:91681699	NA	-0.84	-13.5	-0.66	4.55e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs15676	0.783	rs10988119	chr9:131564585	T/C	cg00228799	chr9:131580591	ENDOG	-0.56	-7.09	-0.42	1.59e-11	Blood metabolite levels;
SARC	cis	rs965469	0.947	rs6139087	chr20:3329062	T/C	cg25506879	chr20:3388711	C20orf194	-0.51	-5.21	-0.32	4.1e-7	IFN-related cytopenia;
SARC	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.74	8.95	0.51	1.17e-16	Height;
SARC	cis	rs2197308	0.619	rs4002730	chr12:37876400	T/C	cg26384229	chr12:38710491	ALG10B	0.9	13.3	0.66	2.04e-30	Morning vs. evening chronotype;
SARC	cis	rs7523050	0.908	rs17621644	chr1:109399023	C/T	cg08274380	chr1:109419600	GPSM2	0.79	6.61	0.4	2.55e-10	Fat distribution (HIV);
SARC	trans	rs7824557	0.614	rs2293860	chr8:11219386	G/T	cg06636001	chr8:8085503	FLJ10661	0.52	6.33	0.38	1.22e-9	Retinal vascular caliber;
SARC	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.62	-6.62	-0.4	2.46e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs35123781	0.696	rs356429	chr5:139073143	C/T	cg10513866	chr5:139070639	NA	0.35	4.76	0.3	3.39e-6	Schizophrenia;
SARC	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg01448562	chr3:133502909	NA	-0.5	-7.13	-0.42	1.22e-11	Iron status biomarkers;
SARC	trans	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg00938859	chr5:1591904	SDHAP3	0.74	7.18	0.43	9.17e-12	Breast cancer;
SARC	cis	rs12142240	0.698	rs41294476	chr1:46818374	C/A	cg14993813	chr1:46806288	NSUN4	-0.52	-5.46	-0.34	1.22e-7	Menopause (age at onset);
SARC	cis	rs1153858	0.621	rs1719237	chr15:45579822	G/A	cg14582100	chr15:45693742	SPATA5L1	0.41	5.52	0.34	9.04e-8	Homoarginine levels;
SARC	cis	rs72781680	1.000	rs72781689	chr2:24256349	C/T	cg08917208	chr2:24149416	ATAD2B	0.88	8.28	0.48	9.36e-15	Lymphocyte counts;
SARC	cis	rs854765	0.647	rs854790	chr17:18028318	C/G	cg04398451	chr17:18023971	MYO15A	-0.53	-7.47	-0.44	1.58e-12	Total body bone mineral density;
SARC	cis	rs6815814	0.861	rs4833095	chr4:38799710	T/C	cg06935464	chr4:38784597	TLR10	0.44	4.86	0.3	2.19e-6	Breast cancer;
SARC	cis	rs1865760	0.713	rs6928951	chr6:25995554	C/T	cg10373733	chr6:25993375	NA	0.46	5.86	0.36	1.58e-8	Height;
SARC	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg12667521	chr19:29218732	NA	0.39	5.27	0.33	3.09e-7	Methadone dose in opioid dependence;
SARC	cis	rs4280164	0.887	rs2748543	chr14:24778674	C/A	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.59	-5.54	-0.34	8.21e-8	Parent of origin effect on language impairment (paternal);
SARC	cis	rs2916247	0.909	rs7004147	chr8:93024405	G/C	cg10183463	chr8:93005414	RUNX1T1	-0.58	-6.04	-0.37	5.91e-9	Intelligence (multi-trait analysis);
SARC	cis	rs2120019	1.000	rs12324912	chr15:75361006	G/A	cg09165964	chr15:75287851	SCAMP5	-0.91	-13.65	-0.67	1.4e-31	Blood trace element (Zn levels);
SARC	trans	rs1853207	1.000	rs113251361	chr10:96626220	A/G	cg02737782	chr1:8014393	NA	-0.97	-6.43	-0.39	7.21e-10	Blood metabolite levels;
SARC	cis	rs950169	0.840	rs2896002	chr15:84945121	A/G	cg24253500	chr15:84953950	NA	0.36	5.22	0.32	3.93e-7	Schizophrenia;
SARC	cis	rs911555	0.755	rs55742283	chr14:103942965	A/G	cg12935359	chr14:103987150	CKB	0.38	5.28	0.33	2.99e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg12395012	chr8:11607386	GATA4	-0.28	-4.74	-0.3	3.72e-6	Retinal vascular caliber;
SARC	cis	rs4595586	0.546	rs2056159	chr12:39270417	C/G	cg26384229	chr12:38710491	ALG10B	0.7	8.58	0.49	1.39e-15	Morning vs. evening chronotype;
SARC	cis	rs9303401	0.646	rs8067682	chr17:57219391	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	7.59	0.45	7.82e-13	Cognitive test performance;
SARC	cis	rs787274	1.000	rs4549852	chr9:115584223	G/A	cg13803584	chr9:115635662	SNX30	-0.83	-5.03	-0.31	9.96e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs11098499	0.954	rs4577559	chr4:120404043	T/G	cg24375607	chr4:120327624	NA	0.42	4.97	0.31	1.28e-6	Corneal astigmatism;
SARC	cis	rs3087591	0.960	rs12942479	chr17:29461912	T/A	cg24425628	chr17:29625626	OMG;NF1	0.55	6.95	0.41	3.66e-11	Hip circumference;
SARC	cis	rs72781680	0.898	rs112985192	chr2:24102797	G/A	cg08917208	chr2:24149416	ATAD2B	0.79	7.72	0.45	3.44e-13	Lymphocyte counts;
SARC	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg22875332	chr1:76189707	ACADM	0.48	6.67	0.4	1.85e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7186908	0.793	rs7191623	chr16:72212044	G/A	cg01557791	chr16:72042693	DHODH	-0.59	-6.13	-0.37	3.77e-9	Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.8	-10.85	-0.58	1.78e-22	Chronic sinus infection;
SARC	cis	rs9486719	1.000	rs2472886	chr6:96864876	C/T	cg06623918	chr6:96969491	KIAA0776	0.73	8.01	0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	trans	rs877282	0.755	rs2790388	chr10:786084	T/C	cg22713356	chr15:30763199	NA	0.93	9.61	0.53	1.26e-18	Uric acid levels;
SARC	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.98	9.78	0.54	3.73e-19	Platelet count;
SARC	trans	rs9650657	0.740	rs6980805	chr8:10679842	G/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.88	-0.41	5.46e-11	Neuroticism;
SARC	cis	rs6879260	1.000	rs1035411	chr5:179729519	A/G	cg23248424	chr5:179741104	GFPT2	-0.51	-6.15	-0.37	3.32e-9	Height;
SARC	cis	rs11098499	0.863	rs28718422	chr4:120466304	C/A	cg24375607	chr4:120327624	NA	0.42	4.92	0.31	1.64e-6	Corneal astigmatism;
SARC	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg13175981	chr1:150552382	MCL1	-0.52	-6.65	-0.4	2.12e-10	Tonsillectomy;
SARC	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.06	17.7	0.76	5.38e-45	Height;
SARC	cis	rs7089973	0.872	rs7094072	chr10:116627160	T/G	cg08188268	chr10:116634841	FAM160B1	0.37	5.89	0.36	1.33e-8	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs9325144	0.602	rs10785590	chr12:38694145	C/T	cg10518543	chr12:38710700	ALG10B	0.39	4.94	0.31	1.5e-6	Morning vs. evening chronotype;
SARC	cis	rs2624839	0.704	rs1046956	chr3:50222926	T/A	cg24110177	chr3:50126178	RBM5	0.56	7.05	0.42	1.99e-11	Intelligence (multi-trait analysis);
SARC	cis	rs7224737	1.000	rs12603327	chr17:40290552	T/C	cg20291162	chr17:40259547	DHX58	-0.33	-4.85	-0.3	2.23e-6	Fibrinogen levels;
SARC	cis	rs9733	0.519	rs11800855	chr1:150800995	G/A	cg15448220	chr1:150897856	SETDB1	0.5	6.55	0.39	3.57e-10	Tonsillectomy;
SARC	cis	rs2273669	0.667	rs7759680	chr6:109310649	C/T	cg05315195	chr6:109294784	ARMC2	-0.49	-4.89	-0.31	1.89e-6	Prostate cancer;
SARC	cis	rs910316	0.783	rs11850751	chr14:75590113	A/T	cg23033748	chr14:75592666	NEK9	0.36	5.15	0.32	5.53e-7	Height;
SARC	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg11764359	chr7:65958608	NA	-0.86	-11.0	-0.58	5.98e-23	Aortic root size;
SARC	cis	rs9815354	0.812	rs17215589	chr3:41831203	C/T	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs1707322	0.686	rs2050376	chr1:46078630	C/T	cg06784218	chr1:46089804	CCDC17	0.41	7.11	0.42	1.42e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs911555	0.504	rs8021368	chr14:104074810	G/A	cg17925084	chr14:104152323	KLC1	0.39	5.51	0.34	9.32e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg05861140	chr6:150128134	PCMT1	-0.41	-5.34	-0.33	2.15e-7	Lung cancer;
SARC	cis	rs503734	0.502	rs348879	chr3:100979826	A/T	cg27318481	chr3:100970896	IMPG2	-0.46	-5.52	-0.34	9.21e-8	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg00933542	chr6:150070202	PCMT1	0.32	5.53	0.34	8.36e-8	Lung cancer;
SARC	cis	rs6450176	0.564	rs406621	chr5:53326232	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.54	-6.19	-0.38	2.63e-9	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs6570726	0.764	rs451108	chr6:145844309	T/C	cg23711669	chr6:146136114	FBXO30	0.88	14.89	0.7	1.14e-35	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg13939156	chr17:80058883	NA	0.4	6.22	0.38	2.23e-9	Life satisfaction;
SARC	cis	rs9831754	0.865	rs9842838	chr3:78387904	A/C	cg06138941	chr3:78371609	NA	-0.59	-6.97	-0.42	3.31e-11	Calcium levels;
SARC	cis	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg03213289	chr20:61660250	NA	0.46	6.37	0.39	9.84e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg11644478	chr21:40555479	PSMG1	-0.87	-11.42	-0.6	2.82e-24	Cognitive function;
SARC	cis	rs9457247	1.000	rs400176	chr6:167406238	T/C	cg23791538	chr6:167370224	RNASET2	-0.62	-8.6	-0.49	1.2e-15	Crohn's disease;
SARC	cis	rs2070997	0.607	rs4740371	chr9:133673777	G/C	cg11464064	chr9:133710261	ABL1	0.59	5.85	0.36	1.68e-8	Response to amphetamines;
SARC	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg06221963	chr1:154839813	KCNN3	-0.53	-8.57	-0.49	1.44e-15	Prostate cancer;
SARC	cis	rs9527	0.590	rs7898770	chr10:104756636	A/G	cg04362960	chr10:104952993	NT5C2	-0.42	-5.1	-0.32	7.16e-7	Arsenic metabolism;
SARC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg06873352	chr17:61820015	STRADA	0.55	7.13	0.42	1.27e-11	Prudent dietary pattern;
SARC	cis	rs9916302	0.653	rs4239223	chr17:37717004	T/C	cg00129232	chr17:37814104	STARD3	-0.58	-6.16	-0.37	3.19e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs3204955	0.876	rs10923246	chr1:116253668	G/C	cg20810993	chr1:116250018	CASQ2	-0.52	-5.38	-0.33	1.81e-7	Itch intensity from mosquito bite adjusted by bite size;
SARC	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg06634786	chr22:41940651	POLR3H	0.51	6.17	0.37	3.07e-9	Vitiligo;
SARC	cis	rs9513627	0.920	rs16956607	chr13:100120220	A/G	cg25919922	chr13:100150906	NA	-0.61	-4.77	-0.3	3.21e-6	Obesity-related traits;
SARC	cis	rs1105228	0.580	rs6909361	chr6:165691210	A/G	cg20535254	chr6:165714960	C6orf118	-0.34	-4.87	-0.3	2.03e-6	Number of pregnancies;Number of children;
SARC	cis	rs12477438	1.000	rs6542873	chr2:99824965	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.83	-9.44	-0.53	3.91e-18	Chronic sinus infection;
SARC	cis	rs787274	1.000	rs4979153	chr9:115554984	G/A	cg13803584	chr9:115635662	SNX30	-0.77	-5.88	-0.36	1.38e-8	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs367943	1.000	rs348944	chr5:112822925	C/T	cg12552261	chr5:112820674	MCC	-0.46	-5.27	-0.33	3.05e-7	Type 2 diabetes;
SARC	cis	rs7560272	0.501	rs2421675	chr2:73955301	C/A	cg20560298	chr2:73613845	ALMS1	0.43	5.67	0.35	4.17e-8	Schizophrenia;
SARC	cis	rs7560272	0.501	rs6755500	chr2:73942233	C/T	cg20560298	chr2:73613845	ALMS1	0.45	6.19	0.38	2.7e-9	Schizophrenia;
SARC	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg18252515	chr7:66147081	NA	-1.3	-11.62	-0.61	6.33e-25	Diabetic kidney disease;
SARC	trans	rs11039798	0.660	rs717897	chr11:48375604	A/G	cg15704280	chr7:45808275	SEPT13	-0.62	-6.39	-0.39	9.03e-10	Axial length;
SARC	cis	rs9303401	0.661	rs9902820	chr17:56637545	A/C	cg12560992	chr17:57184187	TRIM37	0.48	5.89	0.36	1.32e-8	Cognitive test performance;
SARC	cis	rs7223966	1.000	rs2013288	chr17:61785904	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	6.72	0.4	1.34e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9479482	0.967	rs11752529	chr6:150347971	C/T	cg03788504	chr6:150331562	NA	-0.34	-5.5	-0.34	9.81e-8	Alopecia areata;
SARC	cis	rs503734	0.502	rs571391	chr3:100963154	C/T	cg27318481	chr3:100970896	IMPG2	-0.41	-4.82	-0.3	2.57e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs75920871	0.528	rs12279066	chr11:116913909	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.46	-4.75	-0.3	3.49e-6	Subjective well-being;
SARC	cis	rs9462027	0.628	rs9368832	chr6:34679587	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.42	5.99	0.37	7.84e-9	Systemic lupus erythematosus;
SARC	cis	rs11252926	0.673	rs7096559	chr10:499188	C/T	cg08603382	chr10:743973	NA	0.39	4.98	0.31	1.24e-6	Psychosis in Alzheimer's disease;
SARC	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg22535103	chr8:58192502	C8orf71	-0.73	-7.31	-0.43	4.37e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs17270561	0.609	rs1937132	chr6:25757017	A/G	cg16482183	chr6:26056742	HIST1H1C	0.42	5.03	0.31	9.6e-7	Iron status biomarkers;
SARC	cis	rs826838	0.616	rs1601746	chr12:38626195	G/T	cg14851346	chr12:38532713	NA	-0.41	-5.02	-0.31	1.03e-6	Heart rate;
SARC	trans	rs454510	0.542	rs10754417	chr1:120177454	G/T	cg03354009	chr12:69080458	NUP107	-0.49	-6.3	-0.38	1.46e-9	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
SARC	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg11890956	chr21:40555474	PSMG1	1.17	19.17	0.78	8.44e-50	Cognitive function;
SARC	cis	rs13256369	0.802	rs11249887	chr8:8562184	T/C	cg18904891	chr8:8559673	CLDN23	0.49	5.53	0.34	8.66e-8	Obesity-related traits;
SARC	cis	rs4901847	0.643	rs7153396	chr14:58596356	C/T	cg15908186	chr14:58618357	C14orf37	-0.59	-7.62	-0.45	6.49e-13	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.93	13.19	0.65	4.88e-30	Height;
SARC	cis	rs7927592	0.913	rs67605986	chr11:68300955	C/T	cg01657329	chr11:68192670	LRP5	-0.4	-4.94	-0.31	1.51e-6	Total body bone mineral density;
SARC	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg15049968	chr18:44337910	ST8SIA5	-0.34	-5.4	-0.33	1.62e-7	Personality dimensions;
SARC	cis	rs950776	0.667	rs57728226	chr15:78929350	G/C	cg06917634	chr15:78832804	PSMA4	0.66	8.39	0.48	4.73e-15	Sudden cardiac arrest;
SARC	cis	rs9326248	0.559	rs4938334	chr11:116931042	G/C	cg01368799	chr11:117014884	PAFAH1B2	0.65	8.3	0.48	8.38e-15	Blood protein levels;
SARC	cis	rs9517320	0.534	rs61969451	chr13:99167654	A/T	cg07423050	chr13:99094983	FARP1	-0.41	-5.52	-0.34	8.79e-8	Longevity;
SARC	cis	rs2066819	1.000	rs116535779	chr12:56739261	A/G	cg26734620	chr12:56694298	CS	0.85	6.27	0.38	1.77e-9	Psoriasis vulgaris;
SARC	cis	rs1355223	0.506	rs1509660	chr11:34865017	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.25	-0.38	1.89e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs6459788	0.934	rs10237947	chr7:157258109	G/T	cg06271696	chr7:157225062	NA	0.28	4.96	0.31	1.33e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg13443385	chr2:192245185	MYO1B	0.49	6.97	0.42	3.22e-11	Thyroid stimulating hormone;
SARC	cis	rs34891900	0.507	rs12167823	chr22:18124362	G/A	cg19898043	chr22:18121309	BCL2L13	0.66	7.37	0.43	2.93e-12	Sum neutrophil eosinophil counts;
SARC	cis	rs2153535	0.580	rs763376	chr6:8492776	G/A	cg21535247	chr6:8435926	SLC35B3	0.56	6.97	0.42	3.24e-11	Motion sickness;
SARC	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.39	4.8	0.3	2.89e-6	Total body bone mineral density;
SARC	cis	rs7220711	1.000	rs9897313	chr17:41787558	G/A	cg26893861	chr17:41843967	DUSP3	0.38	4.79	0.3	2.91e-6	Bone mineral density (spine);Bone mineral density (hip);
SARC	cis	rs4481887	0.893	rs6681339	chr1:248482761	C/G	cg00666640	chr1:248458726	OR2T12	0.35	5.63	0.35	5.09e-8	Common traits (Other);
SARC	trans	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg21659725	chr3:3221576	CRBN	0.79	11.85	0.61	1.17e-25	Intelligence (multi-trait analysis);
SARC	cis	rs2061333	0.557	rs10410306	chr19:44601537	T/C	cg18700516	chr19:44507157	ZNF230	-0.56	-5.15	-0.32	5.51e-7	Alzheimer's disease;
SARC	cis	rs6952808	0.858	rs12671113	chr7:1965255	G/A	cg21782813	chr7:2030301	MAD1L1	0.41	6.5	0.39	4.76e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs3796352	0.667	rs3755805	chr3:52866299	G/A	cg27565382	chr3:53032988	SFMBT1	0.85	5.63	0.35	5.24e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs12995491	0.731	rs55705009	chr2:88500718	T/G	cg04511125	chr2:88470314	THNSL2	-0.4	-6.02	-0.37	6.79e-9	Response to metformin (IC50);
SARC	cis	rs858239	0.600	rs10235786	chr7:23139940	T/C	cg23682824	chr7:23144976	KLHL7	0.7	9.52	0.53	2.26e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg24549020	chr5:56110836	MAP3K1	0.79	8.08	0.47	3.57e-14	Initial pursuit acceleration;
SARC	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg13175981	chr1:150552382	MCL1	-0.54	-6.82	-0.41	7.54e-11	Tonsillectomy;
SARC	cis	rs10849893	0.595	rs6489811	chr12:121893626	C/T	cg01154721	chr12:121881891	KDM2B	0.35	4.88	0.3	1.96e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg24209194	chr3:40518798	ZNF619	0.64	7.71	0.45	3.56e-13	Renal cell carcinoma;
SARC	cis	rs9443189	1.000	rs1280047	chr6:76527791	A/G	cg01950844	chr6:76311363	SENP6	0.78	6.74	0.4	1.24e-10	Prostate cancer;
SARC	cis	rs561341	1.000	rs72821952	chr17:30248133	T/A	cg00745463	chr17:30367425	LRRC37B	-0.68	-5.09	-0.32	7.52e-7	Hip circumference adjusted for BMI;
SARC	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg12564285	chr5:131593104	PDLIM4	0.45	6.29	0.38	1.57e-9	Breast cancer;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg17383024	chr4:87797556	C4orf36	0.55	6.53	0.39	4.18e-10	Blood pressure;
SARC	cis	rs7000551	0.751	rs2449348	chr8:22359572	C/T	cg12081754	chr8:22256438	SLC39A14	0.52	7.26	0.43	5.63e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.33	4.72	0.3	4.06e-6	Bipolar disorder;
SARC	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg12463550	chr7:65579703	CRCP	-0.48	-5.55	-0.34	7.58e-8	Aortic root size;
SARC	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg16405210	chr4:1374714	KIAA1530	-0.46	-5.4	-0.33	1.63e-7	Obesity-related traits;
SARC	cis	rs2652822	1.000	rs1126309	chr15:63429062	A/G	cg02713581	chr15:63449717	RPS27L	0.72	9.81	0.54	3.04e-19	Metabolic traits;
SARC	cis	rs13161895	0.702	rs73810942	chr5:179499267	C/A	cg06664874	chr5:179499304	RNF130	0.7	6.49	0.39	5.08e-10	LDL cholesterol;
SARC	trans	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg17830980	chr10:43048298	ZNF37B	-0.53	-7.24	-0.43	6.47e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs9814567	1.000	rs7371896	chr3:134249769	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.1	-0.42	1.49e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs12709013	0.561	rs727484	chr16:58790472	G/C	cg04273148	chr16:57808038	KIFC3	0.32	4.72	0.3	4.08e-6	Blood metabolite ratios;
SARC	cis	rs2204008	0.749	rs10880692	chr12:38592918	C/G	cg26384229	chr12:38710491	ALG10B	-0.91	-13.58	-0.66	2.5e-31	Bladder cancer;
SARC	cis	rs9914988	0.943	rs4794838	chr17:27131095	T/C	cg20469991	chr17:27169893	C17orf63	-0.5	-5.25	-0.33	3.36e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs3820928	0.935	rs12151597	chr2:227859224	A/G	cg11843606	chr2:227700838	RHBDD1	-0.5	-6.12	-0.37	3.84e-9	Pulmonary function;
SARC	cis	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg24110177	chr3:50126178	RBM5	0.61	8.12	0.47	2.73e-14	Body mass index;
SARC	cis	rs13191362	1.000	rs34637087	chr6:163004064	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.57	5.38	0.33	1.85e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2710642	0.962	rs1828398	chr2:63034870	A/G	cg17519650	chr2:63277830	OTX1	-0.39	-4.95	-0.31	1.4e-6	LDL cholesterol levels;LDL cholesterol;
SARC	cis	rs7811142	1.000	rs6972167	chr7:100080013	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.98	11.73	0.61	2.74e-25	Platelet count;
SARC	cis	rs12478296	0.792	rs6738361	chr2:243014257	C/T	cg06360820	chr2:242988706	NA	-0.62	-5.06	-0.31	8.7e-7	Obesity-related traits;
SARC	cis	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg24110177	chr3:50126178	RBM5	-0.62	-8.03	-0.47	4.95e-14	Intelligence (multi-trait analysis);
SARC	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg17376030	chr22:41985996	PMM1	0.72	8.49	0.49	2.42e-15	Vitiligo;
SARC	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg14582100	chr15:45693742	SPATA5L1	0.35	4.91	0.31	1.69e-6	Homoarginine levels;
SARC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.34	-5.1	-0.32	7.05e-7	Total body bone mineral density;
SARC	cis	rs5753618	0.509	rs1034589	chr22:31579233	C/T	cg07713946	chr22:31675144	LIMK2	-0.39	-5.53	-0.34	8.63e-8	Colorectal cancer;
SARC	cis	rs1949733	0.701	rs4696828	chr4:8455604	G/A	cg13073564	chr4:8508604	NA	0.43	6.71	0.4	1.43e-10	Response to antineoplastic agents;
SARC	cis	rs9921222	1.000	rs10794639	chr16:377367	A/G	cg12437481	chr16:420112	MRPL28	-0.45	-7.44	-0.44	1.88e-12	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs7474896	0.515	rs2505233	chr10:38340265	C/T	cg25427524	chr10:38739819	LOC399744	-0.46	-5.81	-0.36	2e-8	Obesity (extreme);
SARC	cis	rs3741404	0.609	rs635139	chr11:63872210	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	9.05	0.51	5.95e-17	Platelet count;
SARC	cis	rs55883249	0.958	rs113937820	chr2:9746668	A/G	cg23886495	chr2:9695866	ADAM17	0.68	6.82	0.41	7.92e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg14541582	chr5:601475	NA	-0.38	-4.82	-0.3	2.54e-6	Obesity-related traits;
SARC	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg12016809	chr21:47604291	C21orf56	0.47	5.37	0.33	1.91e-7	Testicular germ cell tumor;
SARC	cis	rs9868809	0.772	rs9821797	chr3:48718253	T/A	cg03060546	chr3:49711283	APEH	-0.54	-4.97	-0.31	1.31e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg11987759	chr7:65425863	GUSB	-0.48	-5.98	-0.36	8.44e-9	Aortic root size;
SARC	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg08859206	chr1:53392774	SCP2	-0.34	-4.96	-0.31	1.38e-6	Monocyte count;
SARC	cis	rs4919087	0.715	rs2484881	chr10:98998266	C/T	cg25902810	chr10:99078978	FRAT1	-0.52	-6.2	-0.38	2.52e-9	Monocyte count;
SARC	cis	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg07636037	chr3:49044803	WDR6	0.46	5.38	0.33	1.82e-7	Resting heart rate;
SARC	cis	rs8067354	0.645	rs9901606	chr17:57811407	A/C	cg02344993	chr17:57696989	CLTC	0.65	6.71	0.4	1.49e-10	Hemoglobin concentration;
SARC	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs5762430	0.736	rs5762404	chr22:28314330	C/G	cg02153584	chr22:29168773	CCDC117	0.55	4.76	0.3	3.36e-6	Obesity;
SARC	cis	rs7223966	1.000	rs7217982	chr17:61832150	C/T	cg26338869	chr17:61819248	STRADA	0.44	4.75	0.3	3.52e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2033732	0.673	rs920226	chr8:85054989	A/T	cg05716166	chr8:85095498	RALYL	0.47	5.63	0.35	5.1e-8	Body mass index;
SARC	cis	rs17539620	0.519	rs4077066	chr6:154838448	C/G	cg20019720	chr6:154832845	CNKSR3	0.43	5.23	0.32	3.86e-7	Lipoprotein (a) levels;
SARC	cis	rs9660992	0.547	rs12143121	chr1:205199142	A/G	cg21643547	chr1:205240462	TMCC2	-0.6	-7.83	-0.46	1.76e-13	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs11638352	0.661	rs2706488	chr15:44389897	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.71	-5.29	-0.33	2.79e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-6.37	-0.38	1.02e-9	Personality dimensions;
SARC	cis	rs6815814	0.950	rs5743563	chr4:38806019	A/G	cg06935464	chr4:38784597	TLR10	0.63	6.25	0.38	1.95e-9	Breast cancer;
SARC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg26338869	chr17:61819248	STRADA	0.81	10.89	0.58	1.38e-22	Prudent dietary pattern;
SARC	cis	rs6429082	0.608	rs903348	chr1:235571343	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.6	-7.05	-0.42	2e-11	Adiposity;
SARC	cis	rs62344088	0.590	rs62345236	chr5:283519	G/A	cg22496380	chr5:211416	CCDC127	-0.81	-5.92	-0.36	1.17e-8	Asthma (childhood onset);
SARC	cis	rs1215050	0.716	rs11940331	chr4:99054041	G/C	cg05340658	chr4:99064831	C4orf37	0.49	6.65	0.4	2.09e-10	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg04267008	chr7:1944627	MAD1L1	-0.6	-6.85	-0.41	6.46e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs11785400	0.793	rs7017851	chr8:143722038	G/T	cg10596483	chr8:143751796	JRK	0.58	7.53	0.44	1.08e-12	Schizophrenia;
SARC	cis	rs6088580	0.608	rs8114616	chr20:32969092	G/T	cg08999081	chr20:33150536	PIGU	-0.42	-6.23	-0.38	2.11e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs11098499	0.955	rs1511019	chr4:120166007	T/G	cg09307838	chr4:120376055	NA	0.84	11.66	0.61	4.76e-25	Corneal astigmatism;
SARC	cis	rs9309473	1.000	rs6755217	chr2:73641285	C/T	cg20560298	chr2:73613845	ALMS1	-0.49	-5.85	-0.36	1.64e-8	Metabolite levels;
SARC	cis	rs4713118	0.662	rs149961	chr6:28015569	A/C	cg26335602	chr6:28129616	ZNF389	0.5	5.29	0.33	2.77e-7	Parkinson's disease;
SARC	trans	rs7824557	0.564	rs1435275	chr8:11235735	T/C	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.0	-0.42	2.69e-11	Retinal vascular caliber;
SARC	cis	rs2908197	0.737	rs6465097	chr7:75972914	T/C	cg22830091	chr7:75961684	YWHAG	-0.35	-5.22	-0.32	3.98e-7	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg21775007	chr8:11205619	TDH	-0.43	-5.4	-0.33	1.62e-7	Triglycerides;
SARC	cis	rs4975709	0.569	rs4975742	chr5:1858612	T/C	cg11168104	chr5:1857477	NA	-0.35	-4.87	-0.3	2.09e-6	Cardiovascular disease risk factors;
SARC	cis	rs12421382	0.614	rs11213104	chr11:109391297	G/T	cg16359550	chr11:109292809	C11orf87	0.34	5.19	0.32	4.67e-7	Schizophrenia;
SARC	cis	rs9398803	0.965	rs9491624	chr6:126679106	A/T	cg20229609	chr6:126660872	C6orf173	0.4	5.85	0.36	1.62e-8	Male-pattern baldness;
SARC	cis	rs2354432	0.556	rs6593777	chr1:146884013	C/G	cg25205988	chr1:146714368	CHD1L	0.95	7.05	0.42	2.04e-11	Mitochondrial DNA levels;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16791216	chr8:17104201	CNOT7;VPS37A	-0.51	-6.5	-0.39	4.7e-10	Smoking initiation;
SARC	cis	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.8	-0.41	8.78e-11	Joint mobility (Beighton score);
SARC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.65	0.53	9.21e-19	Prudent dietary pattern;
SARC	cis	rs10744422	0.925	rs897391	chr12:123326374	G/A	cg25930673	chr12:123319894	HIP1R	-0.65	-5.06	-0.31	8.53e-7	Schizophrenia;
SARC	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg08219700	chr8:58056026	NA	0.6	5.71	0.35	3.49e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg16479474	chr6:28041457	NA	0.37	5.47	0.34	1.17e-7	Depression;
SARC	cis	rs2997447	0.723	rs2259849	chr1:26474251	A/T	cg19633962	chr1:26362018	EXTL1	-0.55	-4.91	-0.31	1.72e-6	QRS complex (12-leadsum);
SARC	cis	rs1401999	0.628	rs7639048	chr3:183746044	A/G	cg01324343	chr3:183735012	ABCC5	0.57	10.82	0.58	2.31e-22	Anterior chamber depth;
SARC	cis	rs6582630	0.519	rs11520262	chr12:38333051	A/G	cg13010199	chr12:38710504	ALG10B	0.79	10.83	0.58	2.12e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs559928	0.606	rs11231710	chr11:63925743	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	5.07	0.32	8.03e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs17666538	0.792	rs115204727	chr8:676639	G/A	cg00450029	chr8:599525	NA	-0.87	-5.64	-0.35	5.01e-8	IgG glycosylation;
SARC	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg13866156	chr1:1669148	SLC35E2	0.6	9.04	0.51	6.42e-17	Body mass index;
SARC	cis	rs12048904	0.505	rs11166508	chr1:101233511	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.73	-8.21	-0.47	1.55e-14	Multiple sclerosis;
SARC	trans	rs1814175	0.817	rs4084376	chr11:49831160	T/C	cg03929089	chr4:120376271	NA	-0.89	-14.38	-0.69	5.28e-34	Height;
SARC	trans	rs11098499	0.779	rs10011097	chr4:120310359	T/G	cg25214090	chr10:38739885	LOC399744	0.55	7.14	0.42	1.15e-11	Corneal astigmatism;
SARC	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg08564027	chr20:61660810	NA	0.76	11.8	0.61	1.69e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg16479474	chr6:28041457	NA	0.37	5.44	0.34	1.37e-7	Depression;
SARC	cis	rs7296418	0.961	rs11608811	chr12:123529056	A/G	cg16085171	chr12:123569118	PITPNM2	-0.38	-4.85	-0.3	2.23e-6	Platelet count;
SARC	cis	rs11098499	0.954	rs6849561	chr4:120409694	C/G	cg09307838	chr4:120376055	NA	-0.9	-12.29	-0.63	4.46e-27	Corneal astigmatism;
SARC	cis	rs910316	0.967	rs175498	chr14:75536369	G/A	cg11812906	chr14:75593930	NEK9	-0.85	-12.53	-0.63	7.22e-28	Height;
SARC	cis	rs273218	1.000	rs156440	chr5:53373656	A/T	ch.5.1024479R	chr5:53302184	ARL15	0.65	7.04	0.42	2.13e-11	Migraine;
SARC	cis	rs7666738	0.830	rs3852123	chr4:98697586	A/G	cg05340658	chr4:99064831	C4orf37	0.6	7.52	0.44	1.2e-12	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg13770153	chr20:60521292	NA	0.74	10.74	0.58	4.11e-22	Obesity-related traits;
SARC	cis	rs2228479	0.541	rs13335395	chr16:89952843	T/A	cg06558623	chr16:89946397	TCF25	0.77	6.79	0.41	9.29e-11	Skin colour saturation;
SARC	cis	rs7208859	0.573	rs58920731	chr17:29191746	G/T	cg13385521	chr17:29058706	SUZ12P	0.86	7.34	0.43	3.54e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs5760092	0.755	rs11090298	chr22:24262061	G/A	cg11141652	chr22:24348549	GSTTP1	-0.52	-5.55	-0.34	7.71e-8	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs854765	0.655	rs4470201	chr17:17844870	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.44	5.7	0.35	3.57e-8	Total body bone mineral density;
SARC	cis	rs2075371	1.000	rs1868783	chr7:133975087	A/G	cg20476274	chr7:133979776	SLC35B4	0.6	8.19	0.47	1.7e-14	Mean platelet volume;
SARC	cis	rs7264396	0.790	rs3787166	chr20:34229072	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-6.57	-0.4	3.23e-10	Total cholesterol levels;
SARC	cis	rs79839061	0.610	rs11726280	chr4:864077	C/T	cg07828340	chr4:882639	GAK	0.77	5.79	0.35	2.22e-8	Intelligence (multi-trait analysis);
SARC	cis	rs72781680	0.799	rs2551332	chr2:23988950	T/C	cg08917208	chr2:24149416	ATAD2B	0.58	5.91	0.36	1.22e-8	Lymphocyte counts;
SARC	cis	rs1062177	1.000	rs1062177	chr5:151184701	C/T	cg00977110	chr5:151150581	G3BP1	0.55	5.49	0.34	1.02e-7	Preschool internalizing problems;
SARC	cis	rs6831352	0.918	rs29001232	chr4:100046654	G/C	cg13256891	chr4:100009986	ADH5	-0.66	-8.4	-0.48	4.51e-15	Alcohol dependence;
SARC	cis	rs10911232	0.507	rs10911212	chr1:183024469	C/T	cg13390022	chr1:182993471	LAMC1	0.36	5.41	0.33	1.6e-7	Hypertriglyceridemia;
SARC	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg14664628	chr15:75095509	CSK	-0.49	-6.09	-0.37	4.65e-9	Breast cancer;
SARC	cis	rs6570726	0.599	rs426371	chr6:145886469	A/G	cg05347473	chr6:146136440	FBXO30	-0.7	-9.3	-0.52	1.08e-17	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg01341218	chr17:43662625	NA	0.7	8.18	0.47	1.86e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs698833	0.852	rs4953092	chr2:44565293	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.7	9.39	0.52	5.72e-18	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs9633740	0.545	rs2343306	chr10:82230146	A/G	cg01528321	chr10:82214614	TSPAN14	-1.01	-11.09	-0.59	3.17e-23	Post bronchodilator FEV1;
SARC	cis	rs2075371	0.829	rs727202	chr7:133947942	A/G	cg20476274	chr7:133979776	SLC35B4	0.58	7.57	0.44	8.47e-13	Mean platelet volume;
SARC	cis	rs11758351	0.866	rs2022448	chr6:26207928	C/T	cg23601095	chr6:26197514	HIST1H3D	0.51	4.83	0.3	2.48e-6	Gout;Renal underexcretion gout;
SARC	trans	rs9858542	0.953	rs9811982	chr3:49624377	A/C	cg21659725	chr3:3221576	CRBN	-0.54	-6.28	-0.38	1.66e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs2729354	0.779	rs2454663	chr11:57358083	T/C	cg02958346	chr11:57425731	CLP1	0.5	5.01	0.31	1.06e-6	Blood protein levels;
SARC	cis	rs6963495	0.818	rs6943132	chr7:105166776	C/T	cg13798780	chr7:105162888	PUS7	0.68	5.33	0.33	2.3e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs7937682	0.575	rs1346180	chr11:111715570	G/C	cg22437258	chr11:111473054	SIK2	-0.49	-5.58	-0.34	6.5e-8	Primary sclerosing cholangitis;
SARC	cis	rs5167	0.504	rs7258345	chr19:45453151	T/G	cg20090143	chr19:45452003	APOC2	0.3	4.89	0.31	1.85e-6	Blood protein levels;
SARC	cis	rs1538970	0.924	rs1007858	chr1:45912005	C/T	cg05343316	chr1:45956843	TESK2	0.78	8.86	0.5	2.1e-16	Platelet count;
SARC	cis	rs2380220	0.808	rs72922390	chr6:95934317	G/A	cg23517279	chr6:96025343	MANEA	-0.54	-5.39	-0.33	1.76e-7	Behavioural disinhibition (generation interaction);
SARC	cis	rs4253772	0.591	rs6008595	chr22:46703860	A/T	cg24881330	chr22:46731750	TRMU	0.65	5.55	0.34	7.82e-8	LDL cholesterol;Cholesterol, total;
SARC	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg01448562	chr3:133502909	NA	-0.45	-6.65	-0.4	2.08e-10	Iron status biomarkers;
SARC	cis	rs4481887	0.927	rs4347240	chr1:248475403	C/G	cg13385794	chr1:248469461	NA	0.34	5.32	0.33	2.46e-7	Common traits (Other);
SARC	cis	rs4319547	0.656	rs1553179	chr12:122831073	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.57	-6.64	-0.4	2.17e-10	Body mass index;
SARC	cis	rs16854884	0.657	rs7642774	chr3:143723272	T/A	cg06585982	chr3:143692056	C3orf58	0.67	9.15	0.51	2.91e-17	Economic and political preferences (feminism/equality);
SARC	cis	rs2204008	0.754	rs11181244	chr12:38302454	T/C	cg13010199	chr12:38710504	ALG10B	0.78	10.82	0.58	2.18e-22	Bladder cancer;
SARC	cis	rs6089584	1.000	rs3787424	chr20:60559219	G/A	cg13770153	chr20:60521292	NA	-0.55	-7.66	-0.45	5.08e-13	Body mass index;
SARC	cis	rs2153535	0.580	rs6597325	chr6:8461053	A/C	cg21535247	chr6:8435926	SLC35B3	0.53	6.7	0.4	1.58e-10	Motion sickness;
SARC	cis	rs820218	0.847	rs820190	chr17:73625286	G/A	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.56	6.96	0.41	3.45e-11	Rotator cuff tears;
SARC	cis	rs9443189	1.000	rs9443189	chr6:76495882	A/G	cg01950844	chr6:76311363	SENP6	0.77	6.59	0.4	2.98e-10	Prostate cancer;
SARC	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-5.98	-0.36	8.15e-9	Personality dimensions;
SARC	cis	rs7635838	0.503	rs9853547	chr3:11396101	C/G	cg00170343	chr3:11313890	ATG7	0.57	7.62	0.45	6.43e-13	HDL cholesterol;
SARC	cis	rs910316	0.967	rs175451	chr14:75589729	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.51	-7.23	-0.43	6.92e-12	Height;
SARC	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg03709012	chr19:19516395	GATAD2A	0.97	15.48	0.71	1.19e-37	Tonsillectomy;
SARC	cis	rs933688	0.941	rs2887007	chr5:90740531	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	13.18	0.65	5.03e-30	Smoking behavior;
SARC	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg22535103	chr8:58192502	C8orf71	-0.78	-9.12	-0.51	3.63e-17	Developmental language disorder (linguistic errors);
SARC	cis	rs9660992	0.573	rs1172139	chr1:205213962	G/A	cg07972983	chr1:205091412	RBBP5	0.54	6.8	0.41	8.75e-11	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs568617	0.716	rs77779142	chr11:65599656	C/T	cg00576331	chr11:65640516	EFEMP2	-0.48	-4.82	-0.3	2.58e-6	Crohn's disease;
SARC	cis	rs7568458	0.837	rs3770098	chr2:85805367	C/A	cg02493740	chr2:85810744	VAMP5	-0.34	-5.03	-0.31	9.94e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg21724239	chr8:58056113	NA	0.58	6.14	0.37	3.49e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2228479	0.557	rs2293584	chr16:89888686	C/G	cg00800038	chr16:89945340	TCF25	-0.82	-5.79	-0.35	2.31e-8	Skin colour saturation;
SARC	cis	rs2236918	0.932	rs1776131	chr1:242024245	T/A	cg17736920	chr1:242011382	EXO1	0.77	10.65	0.57	7.93e-22	Menopause (age at onset);
SARC	cis	rs79349575	0.716	rs46522	chr17:46988597	C/T	cg16584676	chr17:46985605	UBE2Z	0.49	5.67	0.35	4.25e-8	Type 2 diabetes;
SARC	cis	rs939574	1.000	rs6712442	chr2:220117333	T/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.56	-5.26	-0.33	3.21e-7	Platelet distribution width;
SARC	cis	rs7264396	0.635	rs7263302	chr20:34545858	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.48	4.72	0.3	4.13e-6	Total cholesterol levels;
SARC	cis	rs9486719	1.000	rs11153058	chr6:97012746	C/T	cg06623918	chr6:96969491	KIAA0776	-0.8	-8.88	-0.5	1.78e-16	Migraine;Coronary artery disease;
SARC	cis	rs911555	0.755	rs2756135	chr14:103962579	G/A	cg24130564	chr14:104152367	KLC1	0.49	5.77	0.35	2.48e-8	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs72945132	0.882	rs55905028	chr11:70127750	G/A	cg00319359	chr11:70116639	PPFIA1	0.68	6.37	0.39	1.01e-9	Coronary artery disease;
SARC	cis	rs1865760	0.566	rs9348706	chr6:26065481	G/C	cg10373733	chr6:25993375	NA	0.41	5.02	0.31	1.02e-6	Height;
SARC	cis	rs7644634	0.649	rs1042852	chr3:105377515	C/T	cg23051926	chr3:105466016	CBLB	0.48	5.96	0.36	9.37e-9	Itch intensity from mosquito bite;
SARC	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.6	-6.31	-0.38	1.42e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg11987759	chr7:65425863	GUSB	-0.49	-6.21	-0.38	2.46e-9	Aortic root size;
SARC	cis	rs9916302	0.904	rs9944411	chr17:37483599	T/C	cg15445000	chr17:37608096	MED1	-0.46	-5.69	-0.35	3.78e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs79149102	0.579	rs7168638	chr15:75280826	T/C	cg17294928	chr15:75287854	SCAMP5	-1.07	-9.23	-0.52	1.74e-17	Lung cancer;
SARC	cis	rs13082711	0.863	rs13062327	chr3:27495573	G/A	cg02860705	chr3:27208620	NA	0.46	5.89	0.36	1.33e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs4819052	0.565	rs35776291	chr21:46706142	T/C	cg06618935	chr21:46677482	NA	-0.36	-4.85	-0.3	2.3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7000551	0.689	rs6984908	chr8:22316901	A/G	cg12081754	chr8:22256438	SLC39A14	-0.6	-8.33	-0.48	6.78e-15	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs2658782	0.901	rs7116173	chr11:93222311	C/T	cg15737290	chr11:93063684	CCDC67	-0.6	-6.47	-0.39	5.59e-10	Pulmonary function decline;
SARC	cis	rs9612	1.000	rs346534	chr19:44250831	A/G	cg08581076	chr19:44259116	C19orf61	0.66	8.17	0.47	1.99e-14	Exhaled nitric oxide output;
SARC	trans	rs17221829	0.733	rs11018668	chr11:89356178	C/T	cg14287923	chr19:4791411	FEM1A	0.47	6.48	0.39	5.44e-10	Anxiety in major depressive disorder;
SARC	cis	rs34779708	0.897	rs9665538	chr10:35461038	T/C	cg03585969	chr10:35415529	CREM	0.38	4.84	0.3	2.33e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg12419862	chr22:24373484	LOC391322	-0.69	-8.27	-0.48	1.01e-14	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs76419734	0.850	rs72669998	chr4:106590288	A/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.76	4.76	0.3	3.46e-6	Post bronchodilator FEV1;
SARC	cis	rs34172651	0.917	rs11642302	chr16:24770856	G/A	cg04756594	chr16:24857601	SLC5A11	0.36	5.91	0.36	1.22e-8	Intelligence (multi-trait analysis);
SARC	cis	rs12681366	0.614	rs3099397	chr8:95479319	A/G	cg26464482	chr8:95565502	KIAA1429	0.43	5.23	0.32	3.77e-7	Nonsyndromic cleft lip with cleft palate;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg02206636	chr2:73612757	ALMS1	0.49	6.32	0.38	1.3e-9	Lung adenocarcinoma;
SARC	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg06634786	chr22:41940651	POLR3H	-0.55	-6.61	-0.4	2.56e-10	Vitiligo;
SARC	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.03	12.36	0.63	2.47e-27	Platelet count;
SARC	cis	rs4727027	0.933	rs2158633	chr7:148832652	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	5.38	0.33	1.82e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs7617773	0.815	rs9825637	chr3:48372282	T/C	cg11946769	chr3:48343235	NME6	0.75	9.66	0.53	8.5e-19	Coronary artery disease;
SARC	cis	rs6831352	1.000	rs6532798	chr4:100054827	C/T	cg12011299	chr4:100065546	ADH4	0.34	6.0	0.37	7.51e-9	Alcohol dependence;
SARC	cis	rs1707322	0.927	rs6690386	chr1:46253011	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.3	0.38	1.45e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg18116217	chr10:3215066	PITRM1	-0.56	-6.25	-0.38	1.96e-9	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg19729930	chr2:74357872	NA	0.71	10.53	0.57	1.87e-21	Gestational age at birth (maternal effect);
SARC	cis	rs2834188	0.961	rs8130807	chr21:34690013	A/G	cg14352951	chr21:34696688	IFNAR1	0.46	5.56	0.34	7.2e-8	Narcolepsy;
SARC	trans	rs11098499	1.000	rs11726229	chr4:120211580	C/T	cg25214090	chr10:38739885	LOC399744	0.53	7.01	0.42	2.5e-11	Corneal astigmatism;
SARC	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg00933542	chr6:150070202	PCMT1	0.31	5.29	0.33	2.83e-7	Lung cancer;
SARC	cis	rs2327429	0.519	rs4895388	chr6:134150561	G/A	cg25632230	chr6:134101081	NA	-0.4	-5.12	-0.32	6.37e-7	Coronary artery disease;
SARC	cis	rs11997175	0.603	rs6468205	chr8:33778642	T/A	ch.8.33884649F	chr8:33765107	NA	0.42	5.45	0.34	1.28e-7	Body mass index;
SARC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.53	6.72	0.4	1.35e-10	Lymphocyte counts;
SARC	cis	rs6942407	0.640	rs17698411	chr7:86749197	C/T	cg02420886	chr7:86849541	C7orf23	0.59	5.41	0.33	1.55e-7	Food allergy;
SARC	cis	rs2153535	0.541	rs6932434	chr6:8467679	G/A	cg23788917	chr6:8435910	SLC35B3	0.64	8.39	0.48	4.57e-15	Motion sickness;
SARC	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg11062466	chr8:58055876	NA	0.54	5.56	0.34	7.55e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs8073060	0.559	rs72829925	chr17:34049778	C/A	cg19694781	chr19:47549865	TMEM160	0.72	6.95	0.41	3.67e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg19734201	chr4:39699603	UBE2K	0.46	6.28	0.38	1.6e-9	Tetralogy of Fallot;
SARC	cis	rs8180040	0.726	rs2305638	chr3:47046842	G/C	cg27129171	chr3:47204927	SETD2	0.67	9.28	0.52	1.24e-17	Colorectal cancer;
SARC	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-10.79	-0.58	2.85e-22	Chronic sinus infection;
SARC	cis	rs614226	1.000	rs1614223	chr12:120964043	T/C	cg01236616	chr12:121019343	POP5	1.27	18.35	0.77	4.03e-47	Type 1 diabetes nephropathy;
SARC	cis	rs17209837	1.000	rs45526438	chr7:87089927	G/A	cg00919237	chr7:87102261	ABCB4	-0.47	-4.96	-0.31	1.38e-6	Gallbladder cancer;
SARC	cis	rs2991971	0.967	rs937291	chr1:45957039	G/T	cg24296786	chr1:45957014	TESK2	0.64	9.27	0.52	1.28e-17	High light scatter reticulocyte count;
SARC	cis	rs2295359	1.000	rs2295359	chr1:67635950	G/A	cg12940439	chr1:67600707	NA	0.46	6.97	0.42	3.24e-11	Psoriasis;
SARC	cis	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg20965017	chr5:231967	SDHA	-0.55	-5.32	-0.33	2.41e-7	Breast cancer;
SARC	cis	rs7582720	1.000	rs115953525	chr2:203744445	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.31	0.43	4.24e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs698833	0.962	rs786409	chr2:44731344	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.67	8.34	0.48	6.39e-15	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	trans	rs2727020	0.729	rs34647977	chr11:49195543	G/A	cg15704280	chr7:45808275	SEPT13	-0.81	-12.35	-0.63	2.69e-27	Coronary artery disease;
SARC	cis	rs7512552	0.839	rs11587116	chr1:150451898	A/T	cg15654264	chr1:150340011	RPRD2	0.38	4.84	0.3	2.38e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs34779708	0.750	rs35032841	chr10:35312687	G/A	cg03585969	chr10:35415529	CREM	0.39	4.8	0.3	2.81e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs3126085	0.597	rs12047544	chr1:152169922	C/T	cg03465714	chr1:152285911	FLG	-0.46	-5.48	-0.34	1.07e-7	Atopic dermatitis;
SARC	cis	rs8017423	0.967	rs11845329	chr14:90727749	C/T	cg20276874	chr14:90721474	PSMC1	-0.38	-5.25	-0.33	3.39e-7	Mortality in heart failure;
SARC	cis	rs12479064	0.703	rs28382977	chr2:100018304	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.56	-6.47	-0.39	5.73e-10	Chronic sinus infection;
SARC	cis	rs9790314	0.715	rs980975	chr3:160771410	G/A	cg03342759	chr3:160939853	NMD3	-0.42	-5.04	-0.31	9.13e-7	Morning vs. evening chronotype;
SARC	cis	rs7647973	1.000	rs940045	chr3:49449638	G/A	cg07636037	chr3:49044803	WDR6	0.76	8.55	0.49	1.64e-15	Menarche (age at onset);
SARC	cis	rs2153535	0.580	rs2327058	chr6:8447018	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	8.38	0.48	5.16e-15	Motion sickness;
SARC	cis	rs7772486	0.905	rs9373486	chr6:146446024	C/G	cg05347473	chr6:146136440	FBXO30	-0.44	-5.85	-0.36	1.69e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7312933	0.526	rs1669892	chr12:42811305	G/A	cg19980929	chr12:42632907	YAF2	-0.44	-6.52	-0.39	4.35e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs7223966	1.000	rs17549954	chr17:61707032	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.5	-5.08	-0.32	7.82e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg20587970	chr11:113659929	NA	-0.95	-9.49	-0.53	2.77e-18	Hip circumference adjusted for BMI;
SARC	cis	rs9393777	0.513	rs9393737	chr6:26617306	A/G	cg12826209	chr6:26865740	GUSBL1	-0.68	-6.07	-0.37	5.06e-9	Intelligence (multi-trait analysis);
SARC	cis	rs8017423	0.605	rs3742673	chr14:90735707	C/T	cg20276874	chr14:90721474	PSMC1	-0.37	-4.83	-0.3	2.52e-6	Mortality in heart failure;
SARC	cis	rs2120243	0.538	rs4680360	chr3:157094479	C/T	cg24825693	chr3:157122686	VEPH1	0.49	6.31	0.38	1.4e-9	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg04586622	chr2:25135609	ADCY3	-0.31	-4.76	-0.3	3.44e-6	Body mass index;
SARC	cis	rs9807989	0.765	rs13424006	chr2:102967236	T/C	cg09003973	chr2:102972529	NA	0.41	5.6	0.34	6.11e-8	Asthma;
SARC	cis	rs9326248	0.861	rs7931335	chr11:117036805	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.52	5.2	0.32	4.37e-7	Blood protein levels;
SARC	cis	rs10463554	0.963	rs11242484	chr5:102381876	C/T	cg23492399	chr5:102201601	PAM	-0.51	-5.65	-0.35	4.78e-8	Parkinson's disease;
SARC	cis	rs3741151	0.773	rs113465107	chr11:73210416	T/G	cg17517138	chr11:73019481	ARHGEF17	0.96	7.55	0.44	9.89e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs5995756	0.736	rs5995755	chr22:39999013	A/G	cg10455938	chr22:40058150	CACNA1I	-0.49	-6.5	-0.39	4.86e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs765787	0.556	rs12915965	chr15:45512647	T/C	cg26924012	chr15:45694286	SPATA5L1	0.43	5.36	0.33	1.98e-7	Uric acid levels;
SARC	cis	rs11098499	0.863	rs11098532	chr4:120490726	C/A	cg09307838	chr4:120376055	NA	0.91	12.25	0.63	5.66e-27	Corneal astigmatism;
SARC	cis	rs6790105	1	rs6790105	chr3:49393409	C/T	cg06212747	chr3:49208901	KLHDC8B	0.62	6.32	0.38	1.33e-9	Childhood ear infection;
SARC	cis	rs1691799	0.899	rs1168327	chr12:66728842	G/A	cg16791601	chr12:66731901	HELB	-0.72	-11.02	-0.59	5.4e-23	White blood cell count (basophil);
SARC	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg04772025	chr11:68637568	NA	0.49	6.22	0.38	2.32e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg03033257	chr22:50311977	ALG12;CRELD2	0.61	5.8	0.36	2.1e-8	Schizophrenia;
SARC	cis	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg12463550	chr7:65579703	CRCP	0.68	5.09	0.32	7.53e-7	Gout;
SARC	cis	rs7208859	0.623	rs8079891	chr17:29058863	G/A	cg13385521	chr17:29058706	SUZ12P	0.85	7.36	0.43	3.19e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9300255	0.510	rs1790086	chr12:123672518	A/G	cg00376283	chr12:123451042	ABCB9	0.55	6.36	0.38	1.08e-9	Neutrophil percentage of white cells;
SARC	cis	rs933688	1.000	rs61612071	chr5:90741470	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	13.03	0.65	1.61e-29	Smoking behavior;
SARC	cis	rs9910055	0.530	rs8072954	chr17:42294722	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	0.46	6.14	0.37	3.44e-9	Total body bone mineral density;
SARC	cis	rs6866344	0.697	rs17184302	chr5:178127676	C/T	cg03877680	chr5:178157825	ZNF354A	1.02	12.35	0.63	2.74e-27	Neutrophil percentage of white cells;
SARC	cis	rs8180040	0.620	rs56217494	chr3:47048452	T/G	cg27129171	chr3:47204927	SETD2	-0.71	-9.4	-0.52	5.49e-18	Colorectal cancer;
SARC	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg21782813	chr7:2030301	MAD1L1	0.34	5.32	0.33	2.45e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs9300255	0.602	rs1616131	chr12:123619838	G/A	cg05973401	chr12:123451056	ABCB9	0.52	5.85	0.36	1.68e-8	Neutrophil percentage of white cells;
SARC	cis	rs9660992	0.710	rs1768587	chr1:205236432	C/T	cg07972983	chr1:205091412	RBBP5	0.56	6.71	0.4	1.46e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg27266027	chr21:40555129	PSMG1	-0.5	-5.39	-0.33	1.71e-7	Cognitive function;
SARC	cis	rs6831352	0.877	rs28987101	chr4:100049253	T/G	cg12011299	chr4:100065546	ADH4	-0.34	-5.74	-0.35	2.97e-8	Alcohol dependence;
SARC	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg01475735	chr3:40494733	NA	-0.47	-5.15	-0.32	5.45e-7	Renal cell carcinoma;
SARC	cis	rs1707322	1.000	rs34444543	chr1:46358862	G/A	cg06784218	chr1:46089804	CCDC17	0.34	6.03	0.37	6.51e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs7824557	0.583	rs2263512	chr8:11233419	T/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.68	-0.4	1.77e-10	Retinal vascular caliber;
SARC	cis	rs72627123	0.656	rs17096208	chr14:74555269	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.74	5.87	0.36	1.48e-8	Morning vs. evening chronotype;
SARC	cis	rs1784581	1.000	rs1784582	chr6:162400712	A/G	cg17173639	chr6:162384350	PARK2	-0.8	-11.03	-0.59	4.75e-23	Itch intensity from mosquito bite;
SARC	cis	rs1144333	0.655	rs114457542	chr1:76449314	A/C	cg03433033	chr1:76189801	ACADM	0.57	4.74	0.3	3.65e-6	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs3099143	1.000	rs3110378	chr15:77127983	G/A	cg21673338	chr15:77095150	SCAPER	-0.6	-4.99	-0.31	1.18e-6	Recalcitrant atopic dermatitis;
SARC	cis	rs13256369	1.000	rs9329166	chr8:8576655	C/T	cg17143192	chr8:8559678	CLDN23	0.5	5.89	0.36	1.35e-8	Obesity-related traits;
SARC	cis	rs981844	0.775	rs72733610	chr4:154732336	A/G	cg14289246	chr4:154710475	SFRP2	0.57	6.3	0.38	1.44e-9	Response to statins (LDL cholesterol change);
SARC	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg25894440	chr7:65020034	NA	-0.78	-6.04	-0.37	6.1e-9	Diabetic kidney disease;
SARC	cis	rs7582720	0.511	rs116219813	chr2:204081675	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	7.88	0.46	1.21e-13	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs9486719	1.000	rs11152959	chr6:96900272	C/T	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.01	-0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs11098499	1.000	rs1011054	chr4:120202387	A/G	cg09307838	chr4:120376055	NA	-0.83	-11.15	-0.59	2.08e-23	Corneal astigmatism;
SARC	cis	rs1669338	0.588	rs73005226	chr3:3195369	A/G	cg16797762	chr3:3221439	CRBN	-0.91	-9.37	-0.52	6.43e-18	White matter integrity;
SARC	trans	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.53	-6.87	-0.41	5.71e-11	Intelligence (multi-trait analysis);
SARC	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg13206674	chr6:150067644	NUP43	0.48	6.36	0.38	1.07e-9	Lung cancer;
SARC	cis	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg26695010	chr11:65641043	EFEMP2	-0.53	-6.74	-0.4	1.27e-10	Eosinophil percentage of white cells;
SARC	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg18252515	chr7:66147081	NA	0.47	5.21	0.32	4.1e-7	Aortic root size;
SARC	cis	rs17376456	0.825	rs55947981	chr5:93278104	G/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.85	0.36	1.65e-8	Diabetic retinopathy;
SARC	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg20891283	chr12:69753455	YEATS4	0.54	7.42	0.44	2.22e-12	Blood protein levels;
SARC	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg21747090	chr2:27597821	SNX17	-0.55	-7.61	-0.45	6.75e-13	Total body bone mineral density;
SARC	cis	rs7614311	0.731	rs56263032	chr3:63863022	G/A	cg22134162	chr3:63841271	THOC7	-0.45	-5.0	-0.31	1.13e-6	Lung function (FVC);Lung function (FEV1);
SARC	cis	rs861020	0.883	rs680331	chr1:209959872	G/A	cg05527609	chr1:210001259	C1orf107	1.01	11.3	0.6	6.61e-24	Orofacial clefts;
SARC	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7336332	0.800	rs9805452	chr13:28047908	C/T	cg01674679	chr13:27998804	GTF3A	-0.51	-5.1	-0.32	6.91e-7	Weight;
SARC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg05863683	chr7:1912471	MAD1L1	0.36	5.33	0.33	2.33e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs2073300	0.609	rs6137913	chr20:23357725	C/T	cg16736954	chr20:23401023	NAPB	0.78	5.52	0.34	9.07e-8	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs17401966	1.000	rs12132635	chr1:10430479	G/A	cg15208524	chr1:10270712	KIF1B	0.59	6.48	0.39	5.37e-10	Hepatocellular carcinoma;
SARC	cis	rs611744	0.647	rs11785776	chr8:109264933	C/T	cg21045802	chr8:109455806	TTC35	0.57	7.1	0.42	1.45e-11	Dupuytren's disease;
SARC	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg02725872	chr8:58115012	NA	-0.36	-5.52	-0.34	9.23e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1976403	0.633	rs1780324	chr1:21821757	A/G	cg21906605	chr1:21766650	NBPF3	0.44	5.88	0.36	1.43e-8	Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs3087591	0.922	rs2953013	chr17:29496343	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.53	-6.52	-0.39	4.4e-10	Hip circumference;
SARC	cis	rs2180341	1.000	rs6569478	chr6:127598619	G/A	cg27446573	chr6:127587934	RNF146	1.01	14.22	0.68	1.88e-33	Breast cancer;
SARC	cis	rs7829975	0.617	rs4841071	chr8:8791144	G/T	cg06636001	chr8:8085503	FLJ10661	0.52	6.53	0.39	4.13e-10	Mood instability;
SARC	cis	rs910316	0.967	rs8007539	chr14:75664953	T/C	cg11812906	chr14:75593930	NEK9	-0.81	-12.28	-0.63	4.55e-27	Height;
SARC	cis	rs4689388	0.926	rs10010131	chr4:6292915	A/G	cg00701064	chr4:6280414	WFS1	0.54	8.58	0.49	1.38e-15	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs734999	0.566	rs4648563	chr1:2536002	C/G	cg18854424	chr1:2615690	NA	0.32	4.98	0.31	1.23e-6	Ulcerative colitis;
SARC	cis	rs4243830	0.850	rs4908912	chr1:6599558	A/C	cg05709478	chr1:6581295	PLEKHG5	-0.48	-4.8	-0.3	2.87e-6	Body mass index;
SARC	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg24549020	chr5:56110836	MAP3K1	0.81	8.44	0.48	3.34e-15	Initial pursuit acceleration;
SARC	cis	rs4588572	0.643	rs3885254	chr5:77686468	G/A	cg11547950	chr5:77652471	NA	0.4	4.76	0.3	3.36e-6	Triglycerides;
SARC	cis	rs2463822	1.000	rs72921501	chr11:62115622	A/T	cg06239285	chr11:62104954	ASRGL1	-0.86	-8.36	-0.48	5.71e-15	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg05313129	chr8:58192883	C8orf71	-0.63	-6.51	-0.39	4.44e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs580438	1.000	rs184793	chr3:13343360	C/T	cg05446471	chr3:13522740	HDAC11	0.31	4.93	0.31	1.53e-6	Myringotomy;
SARC	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg11952622	chr19:58962976	ZNF324B	-0.59	-7.8	-0.45	2.09e-13	Uric acid clearance;
SARC	cis	rs2204008	0.837	rs73112346	chr12:38357606	C/T	cg13010199	chr12:38710504	ALG10B	0.8	11.05	0.59	4.21e-23	Bladder cancer;
SARC	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg04267008	chr7:1944627	MAD1L1	-0.51	-5.65	-0.35	4.59e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs6504663	0.586	rs60117965	chr17:48569755	G/A	cg22571038	chr17:48585470	MYCBPAP	0.49	5.53	0.34	8.76e-8	Visceral fat;
SARC	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.44	-5.47	-0.34	1.18e-7	Blood metabolite levels;
SARC	cis	rs2795502	0.630	rs2914988	chr10:43509354	A/T	cg08461752	chr10:43522343	NA	-0.43	-4.78	-0.3	3.08e-6	Blood protein levels;
SARC	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg10591111	chr5:226296	SDHA	-0.51	-4.79	-0.3	3e-6	Breast cancer;
SARC	cis	rs9549260	0.753	rs9549238	chr13:41179321	G/A	cg21288729	chr13:41239152	FOXO1	0.55	5.28	0.33	2.95e-7	Red blood cell count;
SARC	cis	rs9733	0.621	rs12746899	chr1:150579678	A/T	cg18016565	chr1:150552671	MCL1	-0.39	-5.38	-0.33	1.79e-7	Tonsillectomy;
SARC	cis	rs9910055	0.530	rs11656758	chr17:42301541	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.44	5.95	0.36	9.51e-9	Total body bone mineral density;
SARC	trans	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-10.59	-0.57	1.18e-21	Intelligence (multi-trait analysis);
SARC	cis	rs4737010	0.578	rs4466386	chr8:41679853	A/G	cg08923054	chr8:41654455	ANK1	0.55	6.73	0.4	1.29e-10	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
SARC	cis	rs739401	0.611	rs402276	chr11:3051404	C/G	cg08508325	chr11:3079039	CARS	-0.32	-7.84	-0.46	1.59e-13	Longevity;
SARC	cis	rs78456975	1.000	rs13414537	chr2:1556330	C/T	cg26248373	chr2:1572462	NA	-0.62	-6.27	-0.38	1.72e-9	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg18404041	chr3:52824283	ITIH1	-0.38	-5.63	-0.35	5.06e-8	Bipolar disorder;
SARC	cis	rs7552404	0.731	rs7523573	chr1:76372020	G/T	cg03433033	chr1:76189801	ACADM	0.47	5.6	0.34	5.92e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs11809207	0.523	rs2783628	chr1:26501827	A/C	cg23602478	chr1:26503979	CNKSR1	0.28	5.03	0.31	9.98e-7	Height;
SARC	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg04277193	chr17:41438351	NA	0.46	4.97	0.31	1.3e-6	Menopause (age at onset);
SARC	cis	rs504918	0.524	rs2272486	chr3:123988039	T/C	cg05766129	chr3:123988013	KALRN	0.32	5.23	0.32	3.72e-7	Schizophrenia;
SARC	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg04166393	chr7:2884313	GNA12	0.54	6.17	0.37	2.99e-9	Height;
SARC	cis	rs11158198	0.559	rs12881190	chr14:58607284	A/C	cg15908186	chr14:58618357	C14orf37	0.4	4.74	0.3	3.7e-6	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs8114671	0.967	rs6058202	chr20:33777983	A/G	cg24642439	chr20:33292090	TP53INP2	0.5	5.7	0.35	3.59e-8	Height;
SARC	cis	rs4243830	0.522	rs10864614	chr1:6596008	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.9	-9.28	-0.52	1.19e-17	Body mass index;
SARC	cis	rs2273669	0.667	rs6899723	chr6:109362749	T/G	cg05315195	chr6:109294784	ARMC2	-0.61	-5.57	-0.34	6.99e-8	Prostate cancer;
SARC	cis	rs11651000	0.857	rs11658383	chr17:45842354	A/C	cg03474202	chr17:45855739	NA	-0.43	-6.06	-0.37	5.35e-9	IgG glycosylation;
SARC	cis	rs6121246	0.567	rs6060399	chr20:30220823	C/T	cg21427119	chr20:30132790	HM13	-0.46	-5.11	-0.32	6.71e-7	Mean corpuscular hemoglobin;
SARC	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg11764359	chr7:65958608	NA	-0.72	-8.45	-0.48	3.08e-15	Aortic root size;
SARC	cis	rs10979	1.000	rs9386037	chr6:143891950	T/C	cg25407410	chr6:143891975	LOC285740	-0.65	-8.8	-0.5	3.12e-16	Hypospadias;
SARC	cis	rs367615	0.704	rs11747622	chr5:108844720	G/A	cg17395555	chr5:108820864	NA	0.48	6.88	0.41	5.51e-11	Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg22974920	chr21:40686053	BRWD1	0.46	5.15	0.32	5.52e-7	Cognitive function;
SARC	cis	rs763121	0.962	rs6001159	chr22:38966487	A/G	cg21395723	chr22:39101663	GTPBP1	0.52	6.4	0.39	8.56e-10	Menopause (age at onset);
SARC	cis	rs7223966	0.883	rs2727317	chr17:61961302	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-5.91	-0.36	1.23e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs709400	1.000	rs7150141	chr14:104129352	G/A	cg12935359	chr14:103987150	CKB	-0.32	-4.81	-0.3	2.72e-6	Body mass index;
SARC	cis	rs12612619	0.689	rs10181551	chr2:27277274	G/A	cg17611932	chr2:27505586	TRIM54	0.28	4.96	0.31	1.37e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
SARC	cis	rs9951602	0.920	rs4799257	chr18:76664054	C/T	cg00806245	chr18:76673096	NA	-0.37	-4.72	-0.3	4.05e-6	Obesity-related traits;
SARC	cis	rs7568458	0.709	rs11895399	chr2:85753806	C/A	cg23752985	chr2:85803571	VAMP8	0.4	5.28	0.33	3.02e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs6496667	0.533	rs7172909	chr15:90991416	C/T	cg22089800	chr15:90895588	ZNF774	0.43	4.92	0.31	1.65e-6	Rheumatoid arthritis;
SARC	cis	rs2153535	0.580	rs6597318	chr6:8437289	G/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.47	0.49	2.7e-15	Motion sickness;
SARC	cis	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg12463550	chr7:65579703	CRCP	0.66	4.95	0.31	1.4e-6	Diabetic kidney disease;
SARC	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg06028605	chr16:24865363	SLC5A11	0.36	5.57	0.34	7.06e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7829975	0.514	rs2976926	chr8:8261624	T/C	cg08975724	chr8:8085496	FLJ10661	0.56	6.82	0.41	7.98e-11	Mood instability;
SARC	cis	rs6813479	0.523	rs2932114	chr4:137744095	G/A	cg16185213	chr4:137733633	NA	0.39	5.41	0.33	1.58e-7	Longevity;
SARC	cis	rs9815354	1.000	rs1716984	chr3:41965532	G/A	cg03022575	chr3:42003672	ULK4	-0.54	-5.16	-0.32	5.2e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs4555082	0.957	rs2816608	chr14:105718407	A/G	cg06808227	chr14:105710500	BRF1	0.55	7.23	0.43	6.97e-12	Mean platelet volume;Platelet distribution width;
SARC	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg13206674	chr6:150067644	NUP43	0.42	5.46	0.34	1.2e-7	Lung cancer;
SARC	cis	rs7681440	0.904	rs10004413	chr4:90769479	T/C	cg06632027	chr4:90757378	SNCA	0.39	5.66	0.35	4.49e-8	Dementia with Lewy bodies;
SARC	cis	rs79349575	0.749	rs957557	chr17:47003221	G/T	cg16584676	chr17:46985605	UBE2Z	0.53	6.37	0.39	9.89e-10	Type 2 diabetes;
SARC	cis	rs17666538	1.000	rs61122136	chr8:585027	G/C	cg23958373	chr8:599963	NA	-0.99	-7.45	-0.44	1.79e-12	IgG glycosylation;
SARC	cis	rs709400	0.628	rs6575983	chr14:103869849	C/G	cg26031613	chr14:104095156	KLC1	0.73	10.52	0.57	1.93e-21	Body mass index;
SARC	cis	rs6429082	0.783	rs291385	chr1:235646613	T/C	cg26050004	chr1:235667680	B3GALNT2	0.65	7.99	0.46	6.07e-14	Adiposity;
SARC	cis	rs8005677	1.000	rs1043209	chr14:23373986	A/G	cg01529538	chr14:23388837	RBM23	-0.47	-5.81	-0.36	2e-8	Cognitive ability (multi-trait analysis);
SARC	cis	rs9858542	0.903	rs11921590	chr3:49644193	T/C	cg07274523	chr3:49395745	GPX1	0.5	5.69	0.35	3.73e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg11062466	chr8:58055876	NA	0.54	5.56	0.34	7.55e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs933688	0.532	rs11740007	chr5:90545498	C/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.46	-5.31	-0.33	2.59e-7	Smoking behavior;
SARC	cis	rs698833	0.537	rs698826	chr2:44728418	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.7	0.35	3.64e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs9486715	0.867	rs9373907	chr6:96981189	G/A	cg06623918	chr6:96969491	KIAA0776	0.9	13.24	0.66	3.39e-30	Headache;
SARC	cis	rs950776	0.518	rs3813571	chr15:78832792	G/T	cg22563815	chr15:78856949	CHRNA5	0.41	7.07	0.42	1.84e-11	Sudden cardiac arrest;
SARC	cis	rs9818758	0.607	rs35060561	chr3:49255503	T/C	cg01304814	chr3:48885189	PRKAR2A	0.62	5.12	0.32	6.4e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	trans	rs629535	0.590	rs55988608	chr8:70133619	A/G	cg21567404	chr3:27674614	NA	-0.93	-10.12	-0.55	3.4e-20	Dupuytren's disease;
SARC	cis	rs55823223	0.618	rs11867339	chr17:73862093	A/G	cg10935138	chr17:73851978	WBP2	0.51	5.31	0.33	2.52e-7	Psoriasis;
SARC	cis	rs2658782	1.000	rs2658779	chr11:93163137	G/T	cg15737290	chr11:93063684	CCDC67	-0.7	-7.59	-0.45	7.73e-13	Pulmonary function decline;
SARC	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.95	11.92	0.62	6.96e-26	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs11608355	0.618	rs60819157	chr12:109795766	G/A	cg19025524	chr12:109796872	NA	-0.48	-6.85	-0.41	6.64e-11	Neuroticism;
SARC	cis	rs6089584	0.546	rs6089308	chr20:60583529	C/T	cg06108461	chr20:60628389	TAF4	-0.66	-8.54	-0.49	1.72e-15	Body mass index;
SARC	cis	rs7512552	0.839	rs1260405	chr1:150304781	A/G	cg15654264	chr1:150340011	RPRD2	0.37	4.77	0.3	3.32e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.63	-7.57	-0.44	8.82e-13	Gut microbiome composition (summer);
SARC	cis	rs270601	0.909	rs2569265	chr5:131704519	T/C	cg04518342	chr5:131593106	PDLIM4	-0.43	-5.55	-0.34	7.79e-8	Acylcarnitine levels;
SARC	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg07234876	chr8:600039	NA	0.76	5.98	0.36	8.19e-9	IgG glycosylation;
SARC	cis	rs11190604	1.000	rs3793772	chr10:102222825	A/G	cg07080220	chr10:102295463	HIF1AN	0.75	9.09	0.51	4.46e-17	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs6570726	0.902	rs973855	chr6:145781850	C/T	cg05347473	chr6:146136440	FBXO30	-0.46	-6.2	-0.38	2.61e-9	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg13272839	chr2:203241107	BMPR2	-0.52	-6.51	-0.39	4.46e-10	Schizophrenia;
SARC	cis	rs12134245	0.776	rs61548854	chr1:92001536	C/T	cg02896835	chr1:92012615	NA	-0.52	-7.15	-0.42	1.09e-11	Breast cancer;
SARC	cis	rs921968	0.565	rs6723334	chr2:219629303	C/T	cg02176678	chr2:219576539	TTLL4	0.32	4.94	0.31	1.5e-6	Mean corpuscular hemoglobin concentration;
SARC	trans	rs61931739	0.500	rs34703942	chr12:34583776	T/C	cg13010199	chr12:38710504	ALG10B	-0.78	-11.12	-0.59	2.47e-23	Morning vs. evening chronotype;
SARC	cis	rs9359856	0.564	rs7682	chr6:90352862	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.62	-4.9	-0.31	1.8e-6	Bipolar disorder;
SARC	cis	rs11098499	0.954	rs11098525	chr4:120390152	G/A	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	cis	rs10089	0.552	rs17607942	chr5:127555435	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.56	5.9	0.36	1.28e-8	Ileal carcinoids;
SARC	cis	rs9309473	0.950	rs6546849	chr2:73831037	A/G	cg20560298	chr2:73613845	ALMS1	-0.46	-5.4	-0.33	1.64e-7	Metabolite levels;
SARC	cis	rs17741873	0.779	rs12572101	chr10:75600651	A/G	cg07699608	chr10:75541558	CHCHD1	0.56	5.31	0.33	2.58e-7	Paclitaxel disposition in epithelial ovarian cancer;
SARC	cis	rs11864453	0.826	rs2074627	chr16:72136769	C/T	cg16558253	chr16:72132732	DHX38	-0.59	-9.62	-0.53	1.17e-18	Fibrinogen levels;
SARC	cis	rs67460515	0.563	rs6772723	chr3:160895074	C/G	cg17135325	chr3:160939158	NMD3	0.66	8.51	0.49	2.19e-15	Parkinson's disease;
SARC	cis	rs9815354	1.000	rs3934103	chr3:41977214	C/T	cg03022575	chr3:42003672	ULK4	-0.61	-5.73	-0.35	3.04e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg11644478	chr21:40555479	PSMG1	-0.88	-11.39	-0.6	3.49e-24	Cognitive function;
SARC	cis	rs3812049	0.611	rs251393	chr5:127533085	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	7.38	0.44	2.84e-12	Lymphocyte counts;Red cell distribution width;
SARC	cis	rs9467773	0.933	rs35355150	chr6:26526039	G/A	cg11502198	chr6:26597334	ABT1	0.42	5.08	0.32	7.67e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.31	-0.43	4.28e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs2120019	1.000	rs35577967	chr15:75354621	G/A	cg12414181	chr15:75287860	SCAMP5	-0.45	-5.11	-0.32	6.8e-7	Blood trace element (Zn levels);
SARC	cis	rs6570726	0.935	rs376991	chr6:145828073	G/C	cg05347473	chr6:146136440	FBXO30	0.48	6.42	0.39	7.51e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6991838	0.584	rs66486920	chr8:66486693	C/T	cg13398993	chr8:66546079	ARMC1	-0.62	-8.36	-0.48	5.88e-15	Intelligence (multi-trait analysis);
SARC	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg16606324	chr3:10149918	C3orf24	0.51	4.95	0.31	1.39e-6	Alzheimer's disease;
SARC	cis	rs1008375	0.646	rs4235387	chr4:17569327	T/G	cg16339924	chr4:17578868	LAP3	0.65	7.92	0.46	9.44e-14	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6807306	1.000	rs2420025	chr3:167368802	A/C	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.57	5.72	0.35	3.25e-8	Mean platelet volume;
SARC	cis	rs17401966	0.898	rs11587495	chr1:10448999	T/C	cg15208524	chr1:10270712	KIF1B	0.49	5.89	0.36	1.36e-8	Hepatocellular carcinoma;
SARC	cis	rs2204008	0.744	rs11495519	chr12:38060546	C/A	cg13010199	chr12:38710504	ALG10B	0.78	10.73	0.57	4.45e-22	Bladder cancer;
SARC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.41	0.52	5.05e-18	Prudent dietary pattern;
SARC	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.77	10.99	0.58	6.7e-23	Personality dimensions;
SARC	cis	rs17376456	1.000	rs61132622	chr5:93539684	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.47	0.34	1.14e-7	Diabetic retinopathy;
SARC	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg24675658	chr1:53192096	ZYG11B	-0.66	-9.87	-0.54	2.06e-19	Monocyte count;
SARC	cis	rs2033732	0.673	rs1550211	chr8:85057571	G/A	cg05716166	chr8:85095498	RALYL	0.47	5.63	0.35	5.1e-8	Body mass index;
SARC	cis	rs6964587	1.000	rs9784993	chr7:91672403	G/A	cg17063962	chr7:91808500	NA	0.93	15.8	0.72	1.07e-38	Breast cancer;
SARC	cis	rs2952156	0.883	rs2941505	chr17:37832704	A/G	cg00129232	chr17:37814104	STARD3	-0.69	-9.9	-0.54	1.58e-19	Asthma;
SARC	cis	rs288326	0.561	rs75936972	chr2:183756989	C/T	cg09997497	chr2:183902928	NCKAP1	0.72	4.83	0.3	2.43e-6	Blood protein levels;
SARC	cis	rs7552404	0.924	rs3818855	chr1:76198785	C/T	cg22875332	chr1:76189707	ACADM	0.46	6.76	0.4	1.12e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9611519	0.603	rs4821999	chr22:41470001	A/G	cg03806693	chr22:41940476	POLR3H	-0.53	-6.8	-0.41	8.76e-11	Neuroticism;
SARC	cis	rs9840812	0.769	rs4678428	chr3:135988412	C/T	cg15507776	chr3:136538369	TMEM22	0.46	5.16	0.32	5.3e-7	Fibrinogen levels;
SARC	cis	rs7089973	0.604	rs11196947	chr10:116601372	G/A	cg03647239	chr10:116582469	FAM160B1	0.51	6.51	0.39	4.49e-10	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs17376456	0.877	rs9885329	chr5:93380278	G/A	cg21475434	chr5:93447410	FAM172A	0.85	7.5	0.44	1.34e-12	Diabetic retinopathy;
SARC	cis	rs72634258	0.945	rs225131	chr1:8095486	T/C	cg00042356	chr1:8021962	PARK7	0.66	6.56	0.4	3.38e-10	Inflammatory bowel disease;
SARC	cis	rs11098499	0.618	rs6858383	chr4:120296772	T/C	cg09160332	chr4:120329925	NA	-0.33	-4.77	-0.3	3.27e-6	Corneal astigmatism;
SARC	cis	rs908922	0.887	rs1538084	chr1:152496012	A/C	cg09873164	chr1:152488093	CRCT1	0.72	8.41	0.48	4.11e-15	Hair morphology;
SARC	cis	rs5167	0.525	rs11083752	chr19:45454363	G/A	cg20090143	chr19:45452003	APOC2	0.31	4.99	0.31	1.18e-6	Blood protein levels;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg14214706	chr13:103052943	FGF14	0.47	6.29	0.38	1.52e-9	Lung adenocarcinoma;
SARC	cis	rs2278491	0.528	rs4145242	chr8:117728296	C/T	cg23513447	chr8:117778558	UTP23	-0.45	-4.84	-0.3	2.35e-6	Body mass index;
SARC	cis	rs11155671	0.530	rs7774787	chr6:150209432	G/A	cg05036130	chr6:150231994	NA	0.28	4.87	0.3	2.04e-6	Testicular germ cell tumor;
SARC	cis	rs3820928	0.874	rs2177593	chr2:227833869	G/A	cg11843606	chr2:227700838	RHBDD1	-0.56	-6.88	-0.41	5.63e-11	Pulmonary function;
SARC	trans	rs656319	0.729	rs671370	chr8:9813317	T/C	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.48	-0.39	5.42e-10	Myopia (pathological);
SARC	cis	rs73206853	0.764	rs7960705	chr12:111084540	G/A	cg10860002	chr12:110842031	ANAPC7	0.59	5.08	0.32	7.77e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs6484504	0.625	rs672396	chr11:31386165	A/G	cg02090638	chr11:31391270	DNAJC24;DCDC1	0.39	4.89	0.31	1.88e-6	Red blood cell count;
SARC	cis	rs3617	0.625	rs2071042	chr3:52864584	A/G	cg18404041	chr3:52824283	ITIH1	-0.36	-5.22	-0.32	3.92e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs7772486	0.790	rs1133832	chr6:146205604	C/T	cg05347473	chr6:146136440	FBXO30	-0.45	-6.06	-0.37	5.38e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg14541582	chr5:601475	NA	-0.4	-4.95	-0.31	1.4e-6	Obesity-related traits;
SARC	cis	rs6500602	0.727	rs55939215	chr16:4541390	C/G	cg08645402	chr16:4508243	NA	0.38	4.84	0.3	2.32e-6	Schizophrenia;
SARC	cis	rs2120019	0.935	rs8043181	chr15:75380424	T/C	cg17294928	chr15:75287854	SCAMP5	-0.9	-13.17	-0.65	5.48e-30	Blood trace element (Zn levels);
SARC	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg25072359	chr17:41440525	NA	0.53	6.3	0.38	1.49e-9	Menopause (age at onset);
SARC	cis	rs55962025	0.804	rs3775061	chr4:3238754	A/G	cg06533319	chr4:3265114	C4orf44	0.33	4.89	0.3	1.91e-6	Parental longevity (mother's age at death);
SARC	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg11764359	chr7:65958608	NA	0.65	7.6	0.45	7.08e-13	Aortic root size;
SARC	cis	rs864537	0.622	rs2949661	chr1:167424924	C/T	cg09179987	chr1:167433047	CD247	0.39	6.15	0.37	3.43e-9	Celiac disease or Rheumatoid arthritis;Celiac disease;
SARC	cis	rs9302635	0.513	rs12928732	chr16:72188683	C/T	cg16558253	chr16:72132732	DHX38	-0.53	-6.27	-0.38	1.76e-9	Blood protein levels;
SARC	cis	rs12477438	1.000	rs57846982	chr2:99921574	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.9	-10.51	-0.57	2.08e-21	Chronic sinus infection;
SARC	cis	rs4689592	0.554	rs66925245	chr4:7071999	C/T	cg26116260	chr4:7069785	GRPEL1	-0.82	-8.61	-0.49	1.13e-15	Monocyte percentage of white cells;
SARC	cis	rs11758351	0.660	rs11759904	chr6:26231443	T/C	cg01420254	chr6:26195488	NA	0.55	4.75	0.3	3.49e-6	Gout;Renal underexcretion gout;
SARC	cis	rs6901004	0.685	rs354550	chr6:111546484	G/A	cg15721981	chr6:111408429	SLC16A10	-0.43	-5.13	-0.32	6.23e-7	Blood metabolite levels;
SARC	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg11168104	chr5:1857477	NA	-0.35	-4.93	-0.31	1.6e-6	Cardiovascular disease risk factors;
SARC	cis	rs10056811	0.538	rs2035191	chr5:74413713	T/C	cg06933384	chr5:74808293	COL4A3BP;POLK	0.47	4.72	0.3	4.12e-6	Coronary artery disease;
SARC	cis	rs3126085	0.935	rs10888467	chr1:152171707	C/T	cg03465714	chr1:152285911	FLG	-0.45	-5.47	-0.34	1.13e-7	Atopic dermatitis;
SARC	cis	rs7246657	0.525	rs10410594	chr19:37477758	C/T	cg23950597	chr19:37808831	NA	-0.56	-5.11	-0.32	6.68e-7	Coronary artery calcification;
SARC	cis	rs853679	1.000	rs1778508	chr6:28229881	C/T	cg26450541	chr6:28235208	ZNF187	-0.59	-4.81	-0.3	2.66e-6	Depression;
SARC	cis	rs1707322	0.656	rs2991981	chr1:46057144	A/G	cg03146154	chr1:46216737	IPP	-0.5	-5.95	-0.36	9.85e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs13256369	0.802	rs34762800	chr8:8559294	G/A	cg17143192	chr8:8559678	CLDN23	0.52	5.81	0.36	2.07e-8	Obesity-related traits;
SARC	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.67	6.41	0.39	8.06e-10	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs1568889	1.000	rs12803716	chr11:28055111	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	10.33	0.56	7.9e-21	Bipolar disorder;
SARC	cis	rs79057730	0.599	rs4721086	chr7:821123	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.61	4.87	0.3	2.02e-6	Initial pursuit acceleration;
SARC	cis	rs2718058	0.630	rs2718051	chr7:37824790	G/A	cg15028436	chr7:37888078	TXNDC3	0.4	5.08	0.32	7.83e-7	Alzheimer's disease (late onset);
SARC	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg22549504	chr19:17448937	GTPBP3	0.48	4.88	0.3	1.94e-6	Systemic lupus erythematosus;
SARC	cis	rs3820928	0.874	rs13419455	chr2:227850465	C/G	cg05526886	chr2:227700861	RHBDD1	-0.55	-6.59	-0.4	2.97e-10	Pulmonary function;
SARC	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg26681399	chr22:41777847	TEF	0.41	4.77	0.3	3.18e-6	Vitiligo;
SARC	cis	rs7584330	0.738	rs4402703	chr2:238374957	T/A	cg11271282	chr2:238384023	NA	0.49	5.57	0.34	6.93e-8	Prostate cancer;
SARC	cis	rs2075371	0.966	rs1646646	chr7:133996905	G/T	cg11752832	chr7:134001865	SLC35B4	0.57	7.28	0.43	5.03e-12	Mean platelet volume;
SARC	cis	rs796364	0.568	rs11890894	chr2:201072055	C/T	cg05691004	chr2:201170426	SPATS2L	-0.43	-5.2	-0.32	4.27e-7	Schizophrenia;
SARC	cis	rs6840360	0.571	rs11939356	chr4:152505234	G/C	cg22705602	chr4:152727874	NA	-0.44	-6.82	-0.41	7.54e-11	Intelligence (multi-trait analysis);
SARC	cis	rs1005277	0.505	rs200931	chr10:38128434	A/C	cg00409905	chr10:38381863	ZNF37A	-0.53	-7.41	-0.44	2.25e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs1008375	1.000	rs4698200	chr4:17657051	G/A	cg02297831	chr4:17616191	MED28	0.5	6.32	0.38	1.3e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7520050	0.966	rs9429183	chr1:46524582	G/A	cg24296786	chr1:45957014	TESK2	0.38	4.8	0.3	2.84e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4319547	0.915	rs7316734	chr12:123117425	A/G	cg23029597	chr12:123009494	RSRC2	-0.43	-5.5	-0.34	9.76e-8	Body mass index;
SARC	cis	rs7772486	0.682	rs1337840	chr6:146042558	T/C	cg23711669	chr6:146136114	FBXO30	-0.8	-12.29	-0.63	4.15e-27	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs11174478	0.531	rs7313231	chr12:40418224	C/T	cg17715141	chr4:182609697	NA	-0.41	-6.26	-0.38	1.82e-9	Insomnia;
SARC	cis	rs7587476	0.906	rs62201985	chr2:215658638	A/G	cg04004882	chr2:215674386	BARD1	0.68	7.28	0.43	5.08e-12	Neuroblastoma;
SARC	cis	rs2439831	0.702	rs16977724	chr15:44151299	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	8.01	0.46	5.3e-14	Lung cancer in ever smokers;
SARC	cis	rs7178572	0.568	rs7167794	chr15:77635875	T/C	cg22256960	chr15:77711686	NA	-0.52	-5.76	-0.35	2.69e-8	Type 2 diabetes;
SARC	cis	rs950776	0.684	rs11637635	chr15:78877150	A/G	cg17108064	chr15:78857060	CHRNA5	-0.29	-4.86	-0.3	2.17e-6	Sudden cardiac arrest;
SARC	cis	rs3087591	0.919	rs9913470	chr17:29566575	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.52	-6.41	-0.39	8.18e-10	Hip circumference;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	ch.11.721876F	chr11:34163014	NAT10	-0.58	-7.03	-0.42	2.31e-11	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs2013441	1.000	rs4588033	chr17:20029901	C/G	cg13482628	chr17:19912719	NA	-0.46	-6.11	-0.37	4.05e-9	Obesity-related traits;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg04466995	chr11:65421839	RELA	-0.68	-6.36	-0.38	1.04e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2204008	0.748	rs8186658	chr12:38301461	A/C	cg13010199	chr12:38710504	ALG10B	0.76	10.22	0.56	1.75e-20	Bladder cancer;
SARC	cis	rs17376456	0.569	rs7735009	chr5:93260865	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.5	-5.58	-0.34	6.65e-8	Diabetic retinopathy;
SARC	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.62	7.45	0.44	1.8e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs208520	0.526	rs9354370	chr6:66808209	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.09	21.38	0.81	7.3e-57	Exhaled nitric oxide output;
SARC	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg13393036	chr8:95962371	TP53INP1	-0.36	-6.15	-0.37	3.29e-9	Type 2 diabetes;
SARC	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.33	-4.79	-0.3	3.03e-6	Bipolar disorder;
SARC	cis	rs1044826	0.642	rs295478	chr3:139223135	G/A	cg15131784	chr3:139108705	COPB2	0.4	5.06	0.31	8.66e-7	Obesity-related traits;
SARC	cis	rs7246657	0.943	rs34603719	chr19:37794528	T/G	cg14683738	chr19:37701593	ZNF585B	0.6	5.26	0.33	3.34e-7	Coronary artery calcification;
SARC	cis	rs5766691	0.644	rs6007607	chr22:47529288	C/G	cg15757745	chr22:47558489	TBC1D22A	-0.5	-6.77	-0.41	1.03e-10	Longevity;
SARC	cis	rs7772486	0.686	rs9485019	chr6:146046381	C/G	cg05347473	chr6:146136440	FBXO30	-0.5	-6.89	-0.41	5.25e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg25427524	chr10:38739819	LOC399744	0.56	8.97	0.51	9.98e-17	Extrinsic epigenetic age acceleration;
SARC	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg16405210	chr4:1374714	KIAA1530	0.53	6.43	0.39	7e-10	Obesity-related traits;
SARC	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg11890956	chr21:40555474	PSMG1	1.17	19.24	0.78	4.84e-50	Cognitive function;
SARC	cis	rs6570726	0.846	rs439035	chr6:145887990	G/C	cg23711669	chr6:146136114	FBXO30	0.79	12.63	0.64	3.42e-28	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs10209086	0.736	rs1584436	chr2:138298878	A/G	cg10180764	chr2:128284465	IWS1	-0.46	-6.23	-0.38	2.11e-9	Multiple system atrophy;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg13375479	chr7:133984347	SLC35B4	0.47	6.31	0.38	1.37e-9	Thyroid stimulating hormone;
SARC	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg11366901	chr6:160182831	ACAT2	1.0	10.19	0.56	2.07e-20	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs198851	0.833	rs7766267	chr6:25990474	G/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.37	-4.73	-0.3	3.87e-6	Red cell distribution width;High light scatter reticulocyte percentage of red cells;Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9931543	0.714	rs9923469	chr16:56289608	T/C	cg02433656	chr16:56322654	GNAO1	0.37	5.21	0.32	4.12e-7	Subjective well-being;
SARC	cis	rs4841097	0.876	rs6601288	chr8:8943430	A/T	cg11995313	chr8:8860691	ERI1	-0.41	-4.99	-0.31	1.16e-6	Platelet distribution width;
SARC	cis	rs1707322	0.685	rs56177313	chr1:46225806	A/C	cg03146154	chr1:46216737	IPP	0.5	5.98	0.36	8.19e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg04995826	chr11:43333458	API5	-0.6	-7.37	-0.43	3.01e-12	Fibrinogen levels;
SARC	cis	rs835154	0.817	rs835157	chr5:14874533	T/C	cg18064842	chr5:14874549	NA	-0.67	-10.68	-0.57	6.02e-22	Blood metabolite levels;
SARC	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg00933542	chr6:150070202	PCMT1	0.3	5.08	0.32	7.56e-7	Lung cancer;
SARC	cis	rs4927850	0.501	rs9881504	chr3:195656614	A/G	cg01181863	chr3:195395398	SDHAP2	-0.6	-6.93	-0.41	4.04e-11	Pancreatic cancer;
SARC	cis	rs6580649	0.941	rs72644844	chr12:48465425	A/C	cg05342945	chr12:48394962	COL2A1	0.56	6.03	0.37	6.35e-9	Lung cancer;
SARC	cis	rs9796	0.866	rs2928148	chr15:41401550	G/A	cg18705301	chr15:41695430	NDUFAF1	0.45	6.14	0.37	3.48e-9	Menopause (age at onset);
SARC	cis	rs7635838	0.964	rs7624086	chr3:11412620	C/G	cg00170343	chr3:11313890	ATG7	0.5	6.59	0.4	2.86e-10	HDL cholesterol;
SARC	trans	rs1814175	0.509	rs60698301	chr11:49877672	G/A	cg03929089	chr4:120376271	NA	-0.83	-12.22	-0.62	7.28e-27	Height;
SARC	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg24829409	chr8:58192753	C8orf71	-0.58	-5.16	-0.32	5.37e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2832191	1.000	rs2832191	chr21:30489300	A/C	cg24692254	chr21:30365293	RNF160	-0.75	-10.49	-0.57	2.54e-21	Dental caries;
SARC	cis	rs12579753	0.917	rs4842410	chr12:82219225	A/T	cg07988820	chr12:82153109	PPFIA2	-0.52	-5.86	-0.36	1.58e-8	Resting heart rate;
SARC	cis	rs1707322	1.000	rs7517560	chr1:46425943	A/G	cg06784218	chr1:46089804	CCDC17	0.34	5.83	0.36	1.88e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs2736345	0.516	rs9657551	chr8:11398183	A/G	cg08975724	chr8:8085496	FLJ10661	0.49	6.39	0.39	8.77e-10	Sjögren's syndrome;Systemic lupus erythematosus;
SARC	cis	rs2467099	0.679	rs59867239	chr17:73931787	G/A	cg23806715	chr17:73775811	H3F3B	0.56	5.66	0.35	4.51e-8	Systolic blood pressure;
SARC	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg16405210	chr4:1374714	KIAA1530	-0.48	-5.64	-0.35	4.92e-8	Obesity-related traits;
SARC	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg24829409	chr8:58192753	C8orf71	-0.65	-6.15	-0.37	3.28e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs490234	0.588	rs35278449	chr9:128172963	C/G	cg14078157	chr9:128172775	NA	-0.36	-4.95	-0.31	1.41e-6	Mean arterial pressure;
SARC	cis	rs11098499	0.863	rs3775849	chr4:120450908	G/C	cg09307838	chr4:120376055	NA	0.91	12.31	0.63	3.63e-27	Corneal astigmatism;
SARC	cis	rs9503598	0.778	rs10155771	chr6:3465930	G/A	cg00476032	chr6:3446245	SLC22A23	0.4	6.41	0.39	7.95e-10	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
SARC	trans	rs9325144	0.600	rs7312522	chr12:38730423	A/G	cg23762105	chr12:34175262	ALG10	-0.55	-7.17	-0.43	9.69e-12	Morning vs. evening chronotype;
SARC	cis	rs921968	0.565	rs35594672	chr2:219589280	T/A	cg02176678	chr2:219576539	TTLL4	-0.33	-5.07	-0.32	8.2e-7	Mean corpuscular hemoglobin concentration;
SARC	trans	rs629535	0.773	rs630235	chr8:70033529	T/G	cg21567404	chr3:27674614	NA	1.04	13.82	0.67	3.98e-32	Dupuytren's disease;
SARC	cis	rs1345301	0.518	rs1035131	chr2:102862641	A/C	cg12451869	chr2:102867685	NA	0.4	5.55	0.34	7.86e-8	Waist circumference;
SARC	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg04267008	chr7:1944627	MAD1L1	-0.6	-6.85	-0.41	6.46e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg06808227	chr14:105710500	BRF1	-0.55	-7.52	-0.44	1.2e-12	Mean platelet volume;Platelet distribution width;
SARC	cis	rs10504073	0.647	rs11997959	chr8:50014044	C/T	cg00325661	chr8:49890786	NA	0.53	7.35	0.43	3.36e-12	Blood metabolite ratios;
SARC	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg04315214	chr1:2043799	PRKCZ	0.29	4.73	0.3	3.97e-6	Height;
SARC	cis	rs4642101	0.765	rs4321514	chr3:12825901	C/T	cg12400702	chr3:12838781	CAND2	-0.26	-5.27	-0.33	3.06e-7	QRS complex (12-leadsum);
SARC	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg07701084	chr6:150067640	NUP43	0.41	5.4	0.33	1.62e-7	Lung cancer;
SARC	cis	rs10876993	0.890	rs7963927	chr12:58046272	T/G	cg18357645	chr12:58087776	OS9	0.48	6.31	0.38	1.42e-9	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs17600642	0.694	rs72814529	chr10:72444698	T/C	cg19779893	chr10:72451501	ADAMTS14	-0.35	-5.48	-0.34	1.11e-7	Bipolar disorder;
SARC	cis	rs9399135	0.967	rs2150681	chr6:135375232	A/G	cg24558204	chr6:135376177	HBS1L	-0.47	-6.23	-0.38	2.17e-9	Red blood cell count;
SARC	cis	rs1707322	0.721	rs12045096	chr1:46114428	A/G	cg06784218	chr1:46089804	CCDC17	0.36	6.25	0.38	1.93e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs11676348	0.846	rs13009946	chr2:219007752	A/C	cg00012203	chr2:219082015	ARPC2	-0.49	-6.42	-0.39	7.51e-10	Ulcerative colitis;
SARC	cis	rs9814567	0.896	rs2177602	chr3:134245866	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.1	-0.42	1.49e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg11366901	chr6:160182831	ACAT2	0.61	6.37	0.39	1.01e-9	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs28655083	0.785	rs7404856	chr16:77130339	A/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.46	6.57	0.4	3.28e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs13392177	0.660	rs62185964	chr2:219073745	A/G	cg00012203	chr2:219082015	ARPC2	-0.69	-9.61	-0.53	1.23e-18	Pyoderma gangrenosum in inflammatory bowel disease;
SARC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg11494091	chr17:61959527	GH2	0.53	7.94	0.46	8.72e-14	Prudent dietary pattern;
SARC	cis	rs16866061	0.515	rs11695326	chr2:225415134	A/G	cg22455342	chr2:225449267	CUL3	0.37	4.82	0.3	2.56e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg22535103	chr8:58192502	C8orf71	-0.73	-7.24	-0.43	6.52e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs16976116	0.502	rs7165565	chr15:55452689	T/C	cg11288833	chr15:55489084	RSL24D1	-0.62	-5.32	-0.33	2.46e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4713118	0.662	rs149947	chr6:27972433	A/T	cg26335602	chr6:28129616	ZNF389	0.48	5.06	0.31	8.38e-7	Parkinson's disease;
SARC	cis	rs4555082	0.830	rs3803319	chr14:105752458	G/A	cg13114125	chr14:105738426	BRF1	-0.78	-11.21	-0.59	1.28e-23	Mean platelet volume;Platelet distribution width;
SARC	cis	rs7027203	0.828	rs7037960	chr9:96584028	G/A	cg14598338	chr9:96623480	NA	-0.55	-7.95	-0.46	7.9e-14	DNA methylation (variation);
SARC	cis	rs7729447	0.813	rs1031648	chr5:32692105	T/A	cg16267343	chr5:32710456	NPR3	0.65	8.59	0.49	1.24e-15	Blood pressure;
SARC	cis	rs818427	0.964	rs818425	chr5:112226655	C/T	cg07820702	chr5:112228657	REEP5	-0.46	-5.14	-0.32	5.73e-7	Total body bone mineral density;
SARC	cis	rs921968	0.643	rs711186	chr2:219346102	A/G	cg02176678	chr2:219576539	TTLL4	-0.37	-5.65	-0.35	4.71e-8	Mean corpuscular hemoglobin concentration;
SARC	cis	rs6089584	0.586	rs2296087	chr20:60584328	T/A	cg23262073	chr20:60523788	NA	-0.36	-5.52	-0.34	9.08e-8	Body mass index;
SARC	cis	rs2153535	0.601	rs2015281	chr6:8539673	G/A	cg07606381	chr6:8435919	SLC35B3	0.76	10.69	0.57	5.72e-22	Motion sickness;
SARC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg07167872	chr1:205819463	PM20D1	0.88	15.6	0.71	4.65e-38	Menarche (age at onset);
SARC	cis	rs826838	0.967	rs826870	chr12:39120250	G/A	cg13010199	chr12:38710504	ALG10B	-0.7	-9.86	-0.54	2.16e-19	Heart rate;
SARC	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-14.98	-0.7	5.45e-36	Chronic sinus infection;
SARC	cis	rs5758511	0.680	rs1001586	chr22:42670293	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.45	6.73	0.4	1.33e-10	Birth weight;
SARC	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg03060546	chr3:49711283	APEH	0.43	5.33	0.33	2.31e-7	Parkinson's disease;
SARC	cis	rs1832871	0.711	rs9456266	chr6:158714422	A/G	cg07165851	chr6:158734300	TULP4	0.54	6.51	0.39	4.65e-10	Height;
SARC	cis	rs7520050	0.966	rs946529	chr1:46485548	G/T	cg24296786	chr1:45957014	TESK2	0.39	5.02	0.31	1.04e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs992157	0.764	rs10932774	chr2:219191569	A/G	cg00012203	chr2:219082015	ARPC2	0.62	8.4	0.48	4.53e-15	Colorectal cancer;
SARC	cis	rs3126085	0.935	rs10749670	chr1:152220467	G/A	cg03465714	chr1:152285911	FLG	-0.46	-5.6	-0.34	6.03e-8	Atopic dermatitis;
SARC	cis	rs9302635	0.626	rs34508528	chr16:72215115	C/T	cg16558253	chr16:72132732	DHX38	-0.51	-5.98	-0.36	8.19e-9	Blood protein levels;
SARC	trans	rs7937682	0.883	rs659529	chr11:111436896	T/A	cg18187862	chr3:45730750	SACM1L	0.56	6.95	0.41	3.67e-11	Primary sclerosing cholangitis;
SARC	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg05872129	chr22:39784769	NA	-0.42	-5.88	-0.36	1.44e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg06634786	chr22:41940651	POLR3H	-0.65	-7.65	-0.45	5.36e-13	Vitiligo;
SARC	cis	rs7769051	0.522	rs34688576	chr6:133118214	C/T	cg07930552	chr6:133119739	C6orf192	1.01	5.99	0.37	7.7e-9	Type 2 diabetes nephropathy;
SARC	cis	rs8180040	0.966	rs11914795	chr3:47557722	G/A	cg27129171	chr3:47204927	SETD2	0.65	8.89	0.5	1.67e-16	Colorectal cancer;
SARC	cis	rs4566357	0.615	rs12621808	chr2:227909522	A/C	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.86	-0.36	1.53e-8	Coronary artery disease;
SARC	cis	rs6696846	0.765	rs61822568	chr1:205081166	C/G	cg07972983	chr1:205091412	RBBP5	0.58	7.52	0.44	1.16e-12	Red blood cell count;
SARC	cis	rs440932	1.000	rs378974	chr8:9026639	C/T	cg08975724	chr8:8085496	FLJ10661	0.44	5.15	0.32	5.47e-7	High light scatter reticulocyte percentage of red cells;
SARC	cis	rs7617773	0.746	rs4371540	chr3:48353543	G/A	cg11946769	chr3:48343235	NME6	0.76	9.7	0.54	6.55e-19	Coronary artery disease;
SARC	cis	rs4853036	0.951	rs13393656	chr2:70119255	C/A	cg02498382	chr2:70120550	SNRNP27	-0.38	-5.34	-0.33	2.22e-7	Colorectal or endometrial cancer;
SARC	cis	rs12142240	0.667	rs45524035	chr1:46862780	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-5.49	-0.34	1.06e-7	Menopause (age at onset);
SARC	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg04267008	chr7:1944627	MAD1L1	-0.5	-5.79	-0.35	2.24e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs4803468	0.967	rs3213860	chr19:41920211	T/C	cg09537434	chr19:41945824	ATP5SL	-0.98	-17.48	-0.75	2.73e-44	Height;
SARC	cis	rs7726839	0.540	rs28364691	chr5:664084	G/A	cg09021430	chr5:549028	NA	-0.41	-5.09	-0.32	7.35e-7	Obesity-related traits;
SARC	cis	rs2304069	0.545	rs6866616	chr5:149415401	A/G	cg12661370	chr5:149340060	SLC26A2	0.56	6.44	0.39	6.72e-10	HIV-1 control;
SARC	cis	rs2153535	0.580	rs4587214	chr6:8454119	T/C	cg07606381	chr6:8435919	SLC35B3	0.76	10.77	0.58	3.33e-22	Motion sickness;
SARC	cis	rs4713118	0.666	rs2893930	chr6:27738806	T/C	cg17221315	chr6:27791827	HIST1H4J	0.56	5.75	0.35	2.84e-8	Parkinson's disease;
SARC	cis	rs11585357	1.000	rs72646785	chr1:17603472	G/T	cg08277548	chr1:17600880	PADI3	-0.52	-5.74	-0.35	2.86e-8	Hair shape;
SARC	cis	rs28829049	0.597	rs34219832	chr1:19502432	C/T	cg13387374	chr1:19411106	UBR4	0.43	5.05	0.31	8.85e-7	QRS duration in Tripanosoma cruzi seropositivity;
SARC	cis	rs2276314	0.857	rs8097597	chr18:33619448	A/G	cg19628046	chr18:33552617	C18orf21	0.57	6.06	0.37	5.54e-9	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs644799	0.648	rs1255182	chr11:95472391	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.49	6.11	0.37	4.17e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs911263	0.961	rs3784099	chr14:68749927	A/G	cg18825221	chr14:68749962	RAD51L1	0.47	7.92	0.46	9.41e-14	Primary biliary cholangitis;
SARC	cis	rs13401104	0.716	rs57014724	chr2:237127936	G/A	cg19324714	chr2:237145437	ASB18	0.61	5.88	0.36	1.43e-8	Educational attainment;
SARC	cis	rs763121	0.819	rs5757161	chr22:38990662	G/A	cg21395723	chr22:39101663	GTPBP1	0.53	6.17	0.37	2.98e-9	Menopause (age at onset);
SARC	trans	rs11039798	0.588	rs6485869	chr11:48576903	G/T	cg15704280	chr7:45808275	SEPT13	0.62	6.61	0.4	2.66e-10	Axial length;
SARC	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg12016809	chr21:47604291	C21orf56	0.46	5.57	0.34	6.84e-8	Testicular germ cell tumor;
SARC	cis	rs2991971	0.967	rs2275276	chr1:45973928	C/T	cg24296786	chr1:45957014	TESK2	0.63	9.18	0.52	2.33e-17	High light scatter reticulocyte count;
SARC	cis	rs9818758	0.607	rs9880088	chr3:49178990	G/A	cg07636037	chr3:49044803	WDR6	-0.77	-6.78	-0.41	9.75e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	trans	rs1493916	0.870	rs8083723	chr18:31384398	C/T	cg27147174	chr7:100797783	AP1S1	-0.53	-6.62	-0.4	2.44e-10	Life satisfaction;
SARC	cis	rs6582630	0.638	rs12231073	chr12:38526901	T/G	cg04568710	chr12:38710424	ALG10B	-0.42	-5.05	-0.31	8.84e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs35213789	0.762	rs646233	chr7:69161943	C/T	cg10619644	chr7:69149951	AUTS2	-0.36	-4.95	-0.31	1.44e-6	Childhood ear infection;
SARC	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg07701084	chr6:150067640	NUP43	0.48	6.19	0.38	2.7e-9	Lung cancer;
SARC	cis	rs6450176	1.000	rs3776706	chr5:53304933	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-7.97	-0.46	6.84e-14	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs9902453	0.933	rs4470197	chr17:28464474	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	6.64	0.4	2.23e-10	Coffee consumption (cups per day);
SARC	cis	rs4481887	1.000	rs4508046	chr1:248488988	T/C	cg13385794	chr1:248469461	NA	0.36	5.35	0.33	2.14e-7	Common traits (Other);
SARC	cis	rs6977660	0.660	rs61670426	chr7:19790460	A/G	cg07541023	chr7:19748670	TWISTNB	0.75	6.72	0.4	1.35e-10	Thyroid stimulating hormone;
SARC	cis	rs3815700	1.000	rs8104729	chr19:33093979	C/T	cg02997394	chr19:33096574	ANKRD27	0.8	8.23	0.47	1.36e-14	Eosinophilic esophagitis;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg15421363	chr5:131826865	IRF1	0.48	6.35	0.38	1.13e-9	Chemerin levels;
SARC	cis	rs4588572	0.645	rs10059940	chr5:77680873	T/C	cg11547950	chr5:77652471	NA	0.4	4.86	0.3	2.16e-6	Triglycerides;
SARC	cis	rs7666738	0.830	rs62321598	chr4:99014237	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7223966	1.000	rs112143304	chr17:61822401	T/A	cg26338869	chr17:61819248	STRADA	0.49	5.06	0.31	8.5e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg07777115	chr5:623756	CEP72	-0.56	-4.81	-0.3	2.68e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs910316	1.000	rs4899546	chr14:75594946	G/C	cg23033748	chr14:75592666	NEK9	0.38	5.32	0.33	2.47e-7	Height;
SARC	cis	rs1707322	0.964	rs785508	chr1:46527159	G/A	cg06784218	chr1:46089804	CCDC17	-0.37	-6.39	-0.39	8.76e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7264396	0.563	rs6058312	chr20:34324484	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	5.68	0.35	4.03e-8	Total cholesterol levels;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg15120477	chr2:220252832	DNPEP	-0.54	-7.03	-0.42	2.31e-11	Breast cancer;
SARC	cis	rs870825	0.746	rs1107908	chr4:185620113	T/C	cg04058563	chr4:185651563	MLF1IP	0.82	11.44	0.6	2.35e-24	Blood protein levels;
SARC	cis	rs3749237	0.595	rs4955412	chr3:49418168	A/C	cg06212747	chr3:49208901	KLHDC8B	0.51	6.24	0.38	1.99e-9	Resting heart rate;
SARC	cis	rs16976116	0.951	rs9300	chr15:55489065	G/A	cg11288833	chr15:55489084	RSL24D1	0.61	6.0	0.37	7.51e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs3106136	1.000	rs2632401	chr4:95147055	C/G	cg11021082	chr4:95130006	SMARCAD1	0.4	6.13	0.37	3.71e-9	Capecitabine sensitivity;
SARC	cis	rs7760949	0.888	rs6939712	chr6:13897246	T/C	cg27413430	chr6:13925136	RNF182	0.4	4.93	0.31	1.57e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs10876993	0.890	rs2619441	chr12:58083015	C/A	cg18357645	chr12:58087776	OS9	0.54	7.25	0.43	6.27e-12	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs6840360	0.533	rs13121178	chr4:152729047	T/C	cg22705602	chr4:152727874	NA	0.48	8.21	0.47	1.55e-14	Intelligence (multi-trait analysis);
SARC	trans	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg17830980	chr10:43048298	ZNF37B	-0.51	-6.71	-0.4	1.5e-10	Extrinsic epigenetic age acceleration;
SARC	cis	rs2486288	0.656	rs12910009	chr15:45572408	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.55	-6.86	-0.41	5.98e-11	Glomerular filtration rate;
SARC	cis	rs12586317	0.548	rs12590678	chr14:35602956	C/T	cg26967526	chr14:35346199	BAZ1A	-0.54	-5.59	-0.34	6.32e-8	Psoriasis;
SARC	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.09	0.37	4.57e-9	Height;
SARC	trans	rs656319	0.559	rs55683917	chr8:9976479	C/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.55	-0.44	9.54e-13	Myopia (pathological);
SARC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg02353165	chr6:42928485	GNMT	-0.46	-6.01	-0.37	7.26e-9	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg13880726	chr7:1868755	MAD1L1	0.43	4.96	0.31	1.35e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg01475735	chr3:40494733	NA	-0.47	-5.15	-0.32	5.45e-7	Renal cell carcinoma;
SARC	cis	rs950169	0.800	rs4099846	chr15:84956894	C/G	cg24253500	chr15:84953950	NA	0.36	5.21	0.32	4.19e-7	Schizophrenia;
SARC	cis	rs4919087	0.590	rs61569149	chr10:99073879	A/G	cg25902810	chr10:99078978	FRAT1	-0.56	-6.57	-0.4	3.2e-10	Monocyte count;
SARC	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg13939156	chr17:80058883	NA	-0.42	-6.48	-0.39	5.51e-10	Life satisfaction;
SARC	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg18252515	chr7:66147081	NA	-0.65	-6.81	-0.41	8.16e-11	Aortic root size;
SARC	cis	rs2153904	0.793	rs12132270	chr1:205660940	C/T	cg26354017	chr1:205819088	PM20D1	-0.56	-4.91	-0.31	1.68e-6	Prostate-specific antigen levels;
SARC	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	8.67	0.49	7.62e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs36051895	0.632	rs7022901	chr9:5177680	C/G	cg02405213	chr9:5042618	JAK2	-0.46	-5.51	-0.34	9.59e-8	Pediatric autoimmune diseases;
SARC	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg17747265	chr1:1875780	NA	-0.36	-5.32	-0.33	2.47e-7	Body mass index;
SARC	cis	rs7296418	0.699	rs11057254	chr12:123794581	A/C	cg05973401	chr12:123451056	ABCB9	0.47	5.41	0.33	1.59e-7	Platelet count;
SARC	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg21724239	chr8:58056113	NA	0.59	6.31	0.38	1.42e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.75	-0.45	2.91e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs10779751	0.770	rs2258621	chr1:11141187	C/G	cg08854313	chr1:11322531	MTOR	0.76	9.68	0.54	7.48e-19	Body mass index;
SARC	trans	rs7859245	0.819	rs10117157	chr9:138490836	T/C	cg02665744	chr19:50223325	NA	-0.56	-6.92	-0.41	4.4e-11	Response to paliperidone in schizophrenia (negative Marder score);
SARC	cis	rs10744422	1.000	rs4759381	chr12:123348480	G/A	cg25930673	chr12:123319894	HIP1R	-0.69	-4.82	-0.3	2.62e-6	Schizophrenia;
SARC	cis	rs9398803	0.687	rs853986	chr6:127023336	C/G	cg19875578	chr6:126661172	C6orf173	-0.64	-8.9	-0.5	1.56e-16	Male-pattern baldness;
SARC	cis	rs7980687	0.628	rs1727332	chr12:123718301	C/T	cg00376283	chr12:123451042	ABCB9	0.56	6.63	0.4	2.29e-10	Height;Educational attainment;Head circumference (infant);
SARC	cis	rs910316	0.591	rs7157158	chr14:75457238	A/G	cg11812906	chr14:75593930	NEK9	0.8	11.13	0.59	2.41e-23	Height;
SARC	cis	rs208520	0.690	rs864314	chr6:66814830	G/A	cg07460842	chr6:66804631	NA	-1.12	-22.07	-0.82	5.21e-59	Exhaled nitric oxide output;
SARC	cis	rs7246657	0.943	rs4803347	chr19:37848017	G/A	cg14683738	chr19:37701593	ZNF585B	0.51	4.87	0.3	2.07e-6	Coronary artery calcification;
SARC	cis	rs965469	1.000	rs2236123	chr20:3305305	C/G	cg25506879	chr20:3388711	C20orf194	0.53	5.43	0.33	1.44e-7	IFN-related cytopenia;
SARC	cis	rs7412746	0.611	rs4970931	chr1:150910727	G/A	cg10589385	chr1:150898437	SETDB1	0.4	5.31	0.33	2.54e-7	Melanoma;
SARC	cis	rs1971762	0.527	rs6580953	chr12:54021138	T/C	cg06632207	chr12:54070931	ATP5G2	0.6	8.38	0.48	5.15e-15	Height;
SARC	cis	rs9790314	0.613	rs2121718	chr3:160603511	C/T	cg04691961	chr3:161091175	C3orf57	0.55	7.47	0.44	1.6e-12	Morning vs. evening chronotype;
SARC	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.48	5.92	0.36	1.17e-8	Tonsillectomy;
SARC	cis	rs6060717	0.536	rs6060666	chr20:34478954	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-5.78	-0.35	2.42e-8	Hip circumference adjusted for BMI;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg24751538	chr10:70167018	RUFY2	-0.48	-6.24	-0.38	2.09e-9	Chemerin levels;
SARC	cis	rs2228479	0.702	rs12600047	chr16:89831630	G/A	cg12064134	chr16:90016061	DEF8	-0.59	-4.82	-0.3	2.59e-6	Skin colour saturation;
SARC	cis	rs611744	0.967	rs645070	chr8:109216345	A/C	cg21045802	chr8:109455806	TTC35	0.46	5.48	0.34	1.09e-7	Dupuytren's disease;
SARC	cis	rs11608355	0.515	rs11611011	chr12:109936948	C/T	cg05360138	chr12:110035743	NA	0.92	9.39	0.52	5.78e-18	Neuroticism;
SARC	cis	rs6964587	0.869	rs11769726	chr7:91485231	A/G	cg17063962	chr7:91808500	NA	-0.9	-13.15	-0.65	6.73e-30	Breast cancer;
SARC	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg08280861	chr8:58055591	NA	0.55	5.13	0.32	5.98e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg01570182	chr17:44337453	NA	-0.82	-9.75	-0.54	4.71e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9858542	0.953	rs9878943	chr3:49434654	G/A	cg03060546	chr3:49711283	APEH	-0.58	-7.17	-0.43	9.67e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs12134245	0.747	rs11164929	chr1:92012836	G/C	cg25838465	chr1:92012736	NA	-0.73	-10.67	-0.57	6.89e-22	Breast cancer;
SARC	cis	rs367615	0.506	rs1428932	chr5:108792479	A/G	cg17395555	chr5:108820864	NA	-0.43	-6.19	-0.38	2.72e-9	Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs62432291	0.681	rs404435	chr6:159654487	G/T	cg14500486	chr6:159655392	FNDC1	-0.62	-6.09	-0.37	4.52e-9	Joint mobility (Beighton score);
SARC	cis	rs7027203	0.688	rs4075733	chr9:96624645	C/T	cg14396892	chr9:96623032	NA	-0.33	-4.93	-0.31	1.54e-6	DNA methylation (variation);
SARC	cis	rs7246760	0.737	rs73501268	chr19:9803081	G/A	cg16876255	chr19:9731953	ZNF561	0.82	5.05	0.31	8.72e-7	Pursuit maintenance gain;
SARC	cis	rs1448094	0.802	rs12369634	chr12:86406792	C/G	cg02569458	chr12:86230093	RASSF9	0.38	5.67	0.35	4.18e-8	Major depressive disorder;
SARC	cis	rs10791097	0.765	rs7943757	chr11:130716157	C/T	cg12179176	chr11:130786555	SNX19	0.5	6.77	0.41	1.03e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs6088590	0.603	rs6579186	chr20:33282198	G/C	cg24642439	chr20:33292090	TP53INP2	0.72	9.76	0.54	4.47e-19	Coronary artery disease;
SARC	cis	rs2228479	0.867	rs17784386	chr16:89947457	A/G	cg06558623	chr16:89946397	TCF25	0.98	8.13	0.47	2.6e-14	Skin colour saturation;
SARC	cis	rs12893668	0.572	rs35011804	chr14:104151400	C/T	cg26031613	chr14:104095156	KLC1	-0.53	-5.82	-0.36	1.98e-8	Reticulocyte count;
SARC	cis	rs2836974	0.549	rs34160989	chr21:40554118	C/G	cg11890956	chr21:40555474	PSMG1	0.87	7.65	0.45	5.16e-13	Cognitive function;
SARC	cis	rs2933343	0.729	rs1680781	chr3:128612830	C/A	cg25356066	chr3:128598488	ACAD9	0.74	9.7	0.54	6.43e-19	IgG glycosylation;
SARC	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg22535103	chr8:58192502	C8orf71	-0.59	-6.21	-0.38	2.35e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9399137	0.507	rs6940258	chr6:135366132	C/T	cg24558204	chr6:135376177	HBS1L	0.62	7.87	0.46	1.32e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg08859206	chr1:53392774	SCP2	-0.37	-5.32	-0.33	2.44e-7	Monocyte count;
SARC	cis	rs4780401	0.609	rs35649585	chr16:11813899	G/A	cg01061890	chr16:11836724	TXNDC11	-0.61	-8.7	-0.5	5.98e-16	Rheumatoid arthritis;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg11547334	chr20:34287314	ROMO1;NFS1	-0.51	-6.3	-0.38	1.46e-9	Schizophrenia;
SARC	cis	rs672059	0.565	rs525410	chr1:183176430	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.39	-5.06	-0.31	8.61e-7	Hypertriglyceridemia;
SARC	cis	rs137603	0.644	rs137635	chr22:39720656	G/C	cg01093212	chr22:39715156	SNORD43;RPL3	-0.54	-6.28	-0.38	1.63e-9	Primary biliary cholangitis;
SARC	trans	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg15556689	chr8:8085844	FLJ10661	0.52	6.73	0.4	1.3100000000000001e-10	Retinal vascular caliber;
SARC	cis	rs11098499	0.863	rs10018280	chr4:120478139	T/G	cg24375607	chr4:120327624	NA	0.4	4.82	0.3	2.64e-6	Corneal astigmatism;
SARC	cis	rs55879323	1	rs55879323	chr1:152168740	C/T	cg17718321	chr1:152188247	HRNR	-0.34	-4.87	-0.3	2.08e-6	Inflammatory skin disease;
SARC	cis	rs7520050	0.966	rs11810993	chr1:46478793	A/G	cg24296786	chr1:45957014	TESK2	0.39	5.03	0.31	9.75e-7	Red blood cell count;Reticulocyte count;
SARC	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg13206674	chr6:150067644	NUP43	0.46	6.1	0.37	4.29e-9	Lung cancer;
SARC	cis	rs7312933	0.592	rs1551210	chr12:42865874	C/T	cg19980929	chr12:42632907	YAF2	0.49	7.16	0.42	1.04e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs734999	0.588	rs11585048	chr1:2534087	C/T	cg18854424	chr1:2615690	NA	0.3	4.8	0.3	2.79e-6	Ulcerative colitis;
SARC	cis	rs11644362	1.000	rs35972357	chr16:12987664	C/T	cg06890432	chr16:12997467	SHISA9	-0.54	-7.1	-0.42	1.51e-11	Positive affect;Subjective well-being;
SARC	cis	rs4319547	0.794	rs61954972	chr12:123074167	T/G	cg23029597	chr12:123009494	RSRC2	-0.41	-5.17	-0.32	5.05e-7	Body mass index;
SARC	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg11843238	chr5:131593191	PDLIM4	0.4	5.53	0.34	8.43e-8	Breast cancer;
SARC	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg22535103	chr8:58192502	C8orf71	-0.7	-6.64	-0.4	2.17e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9790314	0.791	rs6809256	chr3:161026513	G/A	cg04691961	chr3:161091175	C3orf57	-0.64	-8.73	-0.5	4.93e-16	Morning vs. evening chronotype;
SARC	cis	rs600231	0.508	rs17146964	chr11:65249145	C/T	cg17120908	chr11:65337727	SSSCA1	0.47	5.34	0.33	2.17e-7	Bone mineral density;
SARC	cis	rs27434	0.583	rs26653	chr5:96139250	C/G	cg16492584	chr5:96139282	ERAP1	-0.59	-7.74	-0.45	2.93e-13	Ankylosing spondylitis;
SARC	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg15052019	chr19:19431593	KIAA0892;SF4	0.39	4.73	0.3	3.92e-6	Tonsillectomy;
SARC	cis	rs2033711	0.654	rs734380	chr19:58898963	A/C	cg00825309	chr19:58991885	ZNF446	-0.39	-4.99	-0.31	1.17e-6	Uric acid clearance;
SARC	cis	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg18252515	chr7:66147081	NA	-1.37	-12.45	-0.63	1.25e-27	Gout;
SARC	cis	rs4810479	0.513	rs3746506	chr20:44586036	G/A	cg27529037	chr20:44575021	PCIF1	0.29	4.77	0.3	3.23e-6	Metabolite levels;
SARC	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg04166393	chr7:2884313	GNA12	0.56	6.53	0.39	4.19e-10	Height;
SARC	cis	rs804280	0.525	rs1004712	chr8:11622293	C/T	cg00262122	chr8:11665843	FDFT1	0.43	5.28	0.33	2.89e-7	Myopia (pathological);
SARC	cis	rs448720	0.811	rs383041	chr15:68184481	C/G	cg05925327	chr15:68127851	NA	-0.37	-5.31	-0.33	2.58e-7	Cognitive performance;
SARC	cis	rs9916302	0.851	rs6503518	chr17:37660469	A/G	cg00129232	chr17:37814104	STARD3	-0.65	-7.99	-0.46	6.36e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs6500602	0.702	rs2058812	chr16:4524443	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.34	5.87	0.36	1.47e-8	Schizophrenia;
SARC	cis	rs561341	0.883	rs2074102	chr17:30228884	G/A	cg25833597	chr17:30823145	MYO1D	-0.55	-5.06	-0.31	8.48e-7	Hip circumference adjusted for BMI;
SARC	cis	rs6582630	0.519	rs11181526	chr12:38360230	A/G	cg26384229	chr12:38710491	ALG10B	0.87	12.85	0.64	6.2e-29	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7937682	0.562	rs630002	chr11:111377758	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.56	-7.29	-0.43	4.66e-12	Primary sclerosing cholangitis;
SARC	cis	rs896854	0.738	rs509594	chr8:95967156	C/G	cg16049864	chr8:95962084	TP53INP1	0.4	6.28	0.38	1.6e-9	Type 2 diabetes;
SARC	cis	rs16976116	0.901	rs11852763	chr15:55494606	T/C	cg17854078	chr15:55489399	RSL24D1	0.64	6.28	0.38	1.62e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.83	-11.56	-0.6	1.01e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs11098499	0.821	rs10032151	chr4:120391628	C/T	cg24375607	chr4:120327624	NA	0.4	4.76	0.3	3.36e-6	Corneal astigmatism;
SARC	cis	rs8180040	0.701	rs12491473	chr3:46989904	G/A	cg27129171	chr3:47204927	SETD2	-0.69	-9.82	-0.54	2.82e-19	Colorectal cancer;
SARC	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-5.62	-0.35	5.3e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs6912958	0.781	rs9444504	chr6:88181046	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.52	-6.78	-0.41	9.55e-11	Monocyte percentage of white cells;
SARC	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg06713675	chr4:122721982	EXOSC9	-0.52	-7.3	-0.43	4.38e-12	Type 2 diabetes;
SARC	cis	rs36051895	0.659	rs7046511	chr9:5045695	C/T	cg02405213	chr9:5042618	JAK2	-0.52	-6.06	-0.37	5.47e-9	Pediatric autoimmune diseases;
SARC	cis	rs6088580	0.634	rs6059878	chr20:33087166	A/T	cg24642439	chr20:33292090	TP53INP2	0.68	8.88	0.5	1.87e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs55962025	0.846	rs363066	chr4:3135953	G/T	cg06533319	chr4:3265114	C4orf44	-0.34	-4.8	-0.3	2.78e-6	Parental longevity (mother's age at death);
SARC	cis	rs8177253	0.632	rs6782523	chr3:133438917	C/T	cg16414030	chr3:133502952	NA	-0.37	-4.94	-0.31	1.46e-6	Iron status biomarkers;
SARC	cis	rs1635	0.512	rs73742545	chr6:28319023	T/G	cg15743358	chr6:28303923	ZNF323	-0.76	-4.86	-0.3	2.18e-6	Schizophrenia;
SARC	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg02725872	chr8:58115012	NA	-0.36	-6.12	-0.37	3.91e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10791097	0.703	rs11222360	chr11:130730871	C/T	cg09137382	chr11:130731461	NA	0.35	5.46	0.34	1.22e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs7666738	0.830	rs35915560	chr4:98978649	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs708547	0.647	rs781666	chr4:57830981	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.42	-4.94	-0.31	1.48e-6	Response to bleomycin (chromatid breaks);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg01113040	chr17:42440939	FAM171A2	0.48	6.3	0.38	1.48e-9	Thyroid stimulating hormone;
SARC	cis	rs9325144	0.836	rs7489197	chr12:38750065	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-5.89	-0.36	1.36e-8	Morning vs. evening chronotype;
SARC	cis	rs77633900	0.614	rs2469242	chr15:76876710	A/G	cg21673338	chr15:77095150	SCAPER	-0.77	-6.38	-0.39	9.37e-10	Non-glioblastoma glioma;Glioma;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg14527802	chr6:138188823	TNFAIP3	-0.46	-6.35	-0.38	1.13e-9	Neuroticism;
SARC	cis	rs858239	0.539	rs2390757	chr7:23191492	A/G	cg23682824	chr7:23144976	KLHL7	0.66	8.1	0.47	3.17e-14	Cerebrospinal fluid biomarker levels;
SARC	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg00450029	chr8:599525	NA	0.61	5.15	0.32	5.61e-7	IgG glycosylation;
SARC	cis	rs12142240	0.698	rs12385695	chr1:46819021	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-5.46	-0.34	1.22e-7	Menopause (age at onset);
SARC	cis	rs10875746	0.551	rs12322348	chr12:48707699	T/A	cg26205652	chr12:48591994	NA	0.45	4.78	0.3	3.04e-6	Longevity (90 years and older);
SARC	cis	rs854765	0.547	rs7223696	chr17:17915791	G/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.46	5.99	0.37	7.81e-9	Total body bone mineral density;
SARC	cis	rs10089	1.000	rs11957052	chr5:127524055	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	9.18	0.52	2.36e-17	Ileal carcinoids;
SARC	cis	rs9457247	0.637	rs9459846	chr6:167441023	T/G	cg23791538	chr6:167370224	RNASET2	-0.53	-7.06	-0.42	1.89e-11	Crohn's disease;
SARC	cis	rs67460515	0.563	rs11922957	chr3:160828865	A/C	cg17135325	chr3:160939158	NMD3	0.63	7.74	0.45	3.01e-13	Parkinson's disease;
SARC	cis	rs62432291	0.681	rs404461	chr6:159640709	T/C	cg14500486	chr6:159655392	FNDC1	0.61	6.1	0.37	4.35e-9	Joint mobility (Beighton score);
SARC	cis	rs1949733	0.523	rs55977448	chr4:8542918	G/T	cg05004818	chr4:8539015	NA	0.37	4.75	0.3	3.63e-6	Response to antineoplastic agents;
SARC	cis	rs13144136	0.664	rs12501252	chr4:10661563	A/G	cg10242279	chr4:10666415	CLNK	-0.45	-7.41	-0.44	2.38e-12	Resistance to antihypertensive treatment in hypertension;
SARC	cis	rs76419734	1.000	rs72673813	chr4:106710653	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.8	5.33	0.33	2.27e-7	Post bronchodilator FEV1;
SARC	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg23758822	chr17:41437982	NA	0.91	11.44	0.6	2.42e-24	Menopause (age at onset);
SARC	cis	rs2180341	0.618	rs4502958	chr6:127593113	G/A	cg24812749	chr6:127587940	RNF146	0.57	7.12	0.42	1.32e-11	Breast cancer;
SARC	cis	rs6910061	1.000	rs9468416	chr6:11100978	T/C	cg27233058	chr6:11094804	LOC221710	0.58	5.56	0.34	7.5e-8	Diabetic kidney disease;
SARC	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg11301795	chr4:187892539	NA	0.43	5.49	0.34	1.05e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs73198271	0.562	rs11774860	chr8:8651879	C/T	cg01851573	chr8:8652454	MFHAS1	0.43	5.19	0.32	4.47e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs7246657	0.943	rs10414904	chr19:37830088	G/A	cg14683738	chr19:37701593	ZNF585B	0.51	4.99	0.31	1.16e-6	Coronary artery calcification;
SARC	cis	rs829883	0.659	rs4762495	chr12:98934105	C/T	cg25150519	chr12:98850993	NA	-0.59	-7.3	-0.43	4.42e-12	Colorectal adenoma (advanced);
SARC	trans	rs9329221	0.620	rs6601427	chr8:10156025	A/G	cg08975724	chr8:8085496	FLJ10661	-0.53	-7.27	-0.43	5.46e-12	Neuroticism;
SARC	cis	rs9916302	0.706	rs11655972	chr17:37407072	C/T	cg00129232	chr17:37814104	STARD3	-0.56	-6.06	-0.37	5.37e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs10875746	0.951	rs2269935	chr12:48516464	G/T	cg26205652	chr12:48591994	NA	0.54	5.8	0.36	2.14e-8	Longevity (90 years and older);
SARC	cis	rs614226	0.688	rs75111771	chr12:121009943	T/C	cg01236616	chr12:121019343	POP5	-1.24	-16.84	-0.74	3.79e-42	Type 1 diabetes nephropathy;
SARC	cis	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg07636037	chr3:49044803	WDR6	0.63	8.4	0.48	4.49e-15	Resting heart rate;
SARC	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	10.38	0.56	5.22e-21	Platelet count;
SARC	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	9.6	0.53	1.31e-18	Platelet count;
SARC	cis	rs7582720	1.000	rs72936870	chr2:203789679	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs6910061	0.830	rs35281611	chr6:11103232	G/T	cg27233058	chr6:11094804	LOC221710	0.62	5.48	0.34	1.08e-7	Diabetic kidney disease;
SARC	cis	rs561341	0.700	rs8079471	chr17:30218317	A/G	cg25833597	chr17:30823145	MYO1D	-0.4	-4.73	-0.3	3.97e-6	Hip circumference adjusted for BMI;
SARC	cis	rs55962025	0.842	rs73193303	chr4:3192200	A/G	cg06533319	chr4:3265114	C4orf44	0.33	4.94	0.31	1.47e-6	Parental longevity (mother's age at death);
SARC	cis	rs739401	0.566	rs7931504	chr11:3026712	C/T	cg05729581	chr11:3078854	CARS	-0.48	-6.07	-0.37	5.08e-9	Longevity;
SARC	cis	rs1355223	0.583	rs1549789	chr11:34867947	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.75	10.91	0.58	1.2e-22	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs12458462	0.787	rs56006341	chr18:77439844	G/T	cg11879182	chr18:77439856	CTDP1	0.9	13.28	0.66	2.5e-30	Monocyte count;
SARC	trans	rs61931739	0.500	rs11519398	chr12:34473553	C/T	cg13010199	chr12:38710504	ALG10B	0.79	10.8	0.58	2.58e-22	Morning vs. evening chronotype;
SARC	cis	rs6840360	0.615	rs1561916	chr4:152479234	C/T	cg22705602	chr4:152727874	NA	-0.42	-6.51	-0.39	4.59e-10	Intelligence (multi-trait analysis);
SARC	cis	rs9916302	0.904	rs2338755	chr17:37419317	C/T	cg00129232	chr17:37814104	STARD3	0.58	7.27	0.43	5.52e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs7520050	0.931	rs1707333	chr1:46547035	C/G	cg06784218	chr1:46089804	CCDC17	-0.26	-4.82	-0.3	2.57e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs1059312	0.966	rs12368452	chr12:129277164	C/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.49	7.23	0.43	6.93e-12	Systemic lupus erythematosus;
SARC	cis	rs9894429	0.789	rs6565611	chr17:79598319	T/C	cg18240062	chr17:79603768	NPLOC4	0.88	13.71	0.67	9.24e-32	Eye color traits;
SARC	cis	rs2742234	0.590	rs2435383	chr10:43675671	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.4	-4.74	-0.3	3.67e-6	Hirschsprung disease;
SARC	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg08280861	chr8:58055591	NA	0.59	5.22	0.32	4.02e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs698833	0.663	rs1223165	chr2:44747044	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.54	-6.91	-0.41	4.71e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs3793683	0.965	rs3829131	chr10:134564627	A/G	cg01276201	chr10:134613136	NA	-0.26	-4.88	-0.3	1.95e-6	Migraine;
SARC	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg13628971	chr7:2884303	GNA12	0.55	6.09	0.37	4.58e-9	Height;
SARC	cis	rs7246657	0.943	rs7257672	chr19:37823859	G/C	cg14683738	chr19:37701593	ZNF585B	0.51	4.94	0.31	1.52e-6	Coronary artery calcification;
SARC	cis	rs1707322	0.721	rs12045096	chr1:46114428	A/G	cg03146154	chr1:46216737	IPP	0.52	6.32	0.38	1.33e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.4	-4.99	-0.31	1.18e-6	Lymphocyte counts;
SARC	cis	rs7847628	0.587	rs12684934	chr9:123593159	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.94	14.75	0.69	3.18e-35	Birth weight;
SARC	cis	rs116095464	0.558	rs6879656	chr5:264428	T/C	cg22857025	chr5:266934	NA	-1.11	-11.3	-0.6	6.53e-24	Breast cancer;
SARC	cis	rs9399135	0.967	rs4376365	chr6:135307740	T/C	cg24558204	chr6:135376177	HBS1L	0.46	6.15	0.37	3.41e-9	Red blood cell count;
SARC	cis	rs7412746	0.658	rs3843843	chr1:150918084	C/T	cg15448220	chr1:150897856	SETDB1	0.51	6.66	0.4	1.89e-10	Melanoma;
SARC	cis	rs4481887	0.927	rs4564179	chr1:248472422	T/C	cg13385794	chr1:248469461	NA	0.35	5.45	0.34	1.29e-7	Common traits (Other);
SARC	cis	rs17376456	0.825	rs28412976	chr5:93248377	T/C	cg21475434	chr5:93447410	FAM172A	0.85	7.47	0.44	1.61e-12	Diabetic retinopathy;
SARC	cis	rs7551222	0.752	rs4252685	chr1:204496856	C/A	cg20240347	chr1:204465584	NA	-0.34	-5.92	-0.36	1.14e-8	Schizophrenia;
SARC	trans	rs1814175	0.781	rs28681334	chr11:50051177	C/T	cg03929089	chr4:120376271	NA	-0.89	-14.58	-0.69	1.16e-34	Height;
SARC	cis	rs9611519	1.000	rs2273085	chr22:41615376	C/T	cg17376030	chr22:41985996	PMM1	0.47	5.74	0.35	2.97e-8	Neuroticism;
SARC	trans	rs12460587	0.587	rs10415150	chr19:52604625	C/G	cg14851496	chr14:105850307	PACS2	-0.51	-6.58	-0.4	3.13e-10	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
SARC	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.71	6.95	0.41	3.54e-11	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs2749592	1.000	rs2749592	chr10:38258842	A/C	cg00409905	chr10:38381863	ZNF37A	-0.54	-6.2	-0.38	2.6e-9	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs7672847	0.547	rs4334719	chr4:170362151	A/G	cg00846720	chr4:170533756	NEK1	0.6	5.07	0.32	8.1e-7	Subjective well-being;
SARC	cis	rs2816062	0.786	rs2745320	chr1:18893592	G/A	cg10574377	chr1:18908098	NA	0.36	5.24	0.32	3.66e-7	Urate levels in lean individuals;
SARC	cis	rs2033732	0.706	rs1370419	chr8:85068424	G/A	cg05716166	chr8:85095498	RALYL	0.47	5.62	0.35	5.51e-8	Body mass index;
SARC	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg27266027	chr21:40555129	PSMG1	0.47	4.96	0.31	1.38e-6	Cognitive function;
SARC	cis	rs9790314	0.747	rs1841526	chr3:160834682	A/G	cg03342759	chr3:160939853	NMD3	-0.46	-5.67	-0.35	4.11e-8	Morning vs. evening chronotype;
SARC	cis	rs11758351	0.588	rs2050948	chr6:26234952	A/G	cg01420254	chr6:26195488	NA	0.55	4.75	0.3	3.49e-6	Gout;Renal underexcretion gout;
SARC	cis	rs910316	1.000	rs12589815	chr14:75544101	C/T	cg23033748	chr14:75592666	NEK9	0.38	5.31	0.33	2.52e-7	Height;
SARC	cis	rs12971120	0.891	rs4891558	chr18:72170359	A/G	cg25817165	chr18:72167213	CNDP2	-0.51	-6.91	-0.41	4.66e-11	Refractive error;
SARC	cis	rs360798	0.512	rs2430388	chr2:63106784	T/C	cg17519650	chr2:63277830	OTX1	0.41	5.26	0.33	3.19e-7	Coronary artery disease;
SARC	cis	rs11677370	0.561	rs12711973	chr2:3825339	C/G	cg17052675	chr2:3827356	NA	-0.51	-6.24	-0.38	1.99e-9	Type 2 diabetes;
SARC	cis	rs1144333	0.655	rs968018	chr1:76395662	G/A	cg03433033	chr1:76189801	ACADM	0.64	5.23	0.32	3.71e-7	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs8014204	0.533	rs12889955	chr14:75172999	G/A	cg06637938	chr14:75390232	RPS6KL1	0.59	8.68	0.49	7.2e-16	Caffeine consumption;
SARC	cis	rs73206853	0.841	rs56017652	chr12:110931054	C/T	cg10860002	chr12:110842031	ANAPC7	0.59	4.79	0.3	2.95e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	trans	rs3942852	0.774	rs2270990	chr11:48184983	G/T	cg15704280	chr7:45808275	SEPT13	-0.61	-7.11	-0.42	1.42e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs1023500	0.505	rs134878	chr22:42663874	A/G	cg15557168	chr22:42548783	NA	-0.37	-5.09	-0.32	7.36e-7	Schizophrenia;
SARC	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg04518342	chr5:131593106	PDLIM4	0.42	5.76	0.35	2.71e-8	Acylcarnitine levels;
SARC	cis	rs9325144	0.647	rs870431	chr12:38953073	T/C	cg13010199	chr12:38710504	ALG10B	-0.51	-6.45	-0.39	6.35e-10	Morning vs. evening chronotype;
SARC	cis	rs9309473	1.000	rs6745368	chr2:73809974	C/T	cg20560298	chr2:73613845	ALMS1	-0.48	-5.91	-0.36	1.21e-8	Metabolite levels;
SARC	cis	rs3784262	0.669	rs3784257	chr15:58262974	C/T	cg12031962	chr15:58353849	ALDH1A2	0.34	5.14	0.32	5.75e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg10591111	chr5:226296	SDHA	-0.53	-4.76	-0.3	3.39e-6	Breast cancer;
SARC	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg19500275	chr17:80737654	TBCD	0.44	5.13	0.32	5.98e-7	Glycated hemoglobin levels;
SARC	cis	rs2075371	0.796	rs35336643	chr7:134010640	G/A	cg20476274	chr7:133979776	SLC35B4	0.52	6.47	0.39	5.79e-10	Mean platelet volume;
SARC	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg14773178	chr5:1868261	NA	0.34	5.32	0.33	2.38e-7	Cardiovascular disease risk factors;
SARC	cis	rs367943	1.000	rs348955	chr5:112821643	C/T	cg12552261	chr5:112820674	MCC	-0.45	-5.23	-0.32	3.86e-7	Type 2 diabetes;
SARC	cis	rs8180040	0.764	rs11716539	chr3:47186503	G/T	cg02527881	chr3:46936655	PTH1R	-0.31	-4.82	-0.3	2.56e-6	Colorectal cancer;
SARC	trans	rs3808502	0.647	rs7821302	chr8:11236572	T/A	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.72	-0.5	5.49e-16	Neuroticism;
SARC	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg18252515	chr7:66147081	NA	-0.53	-5.69	-0.35	3.86e-8	Aortic root size;
SARC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.0	0.79	1.72e-52	Prudent dietary pattern;
SARC	cis	rs10927875	0.632	rs904911	chr1:16126932	C/T	cg21385522	chr1:16154831	NA	-0.92	-13.17	-0.65	5.55e-30	Dilated cardiomyopathy;
SARC	cis	rs832540	0.931	rs2591960	chr5:56238811	A/T	cg12311346	chr5:56204834	C5orf35	0.46	5.5	0.34	9.73e-8	Coronary artery disease;
SARC	cis	rs8014204	0.575	rs1045430	chr14:75130235	T/G	cg17347104	chr14:75034677	LTBP2	-0.47	-6.3	-0.38	1.48e-9	Caffeine consumption;
SARC	cis	rs4481887	1.000	rs6681423	chr1:248482834	C/A	cg01631408	chr1:248437212	OR2T33	-0.43	-5.32	-0.33	2.38e-7	Common traits (Other);
SARC	cis	rs4713675	0.524	rs4713672	chr6:33705066	G/A	cg15676125	chr6:33679581	C6orf125	0.57	7.03	0.42	2.21e-11	Plateletcrit;
SARC	cis	rs554111	0.656	rs10753514	chr1:21492531	T/C	cg08890418	chr1:21044141	KIF17	-0.36	-5.08	-0.32	7.78e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs372883	0.600	rs1236460	chr21:30615513	G/A	cg08807101	chr21:30365312	RNF160	-0.59	-7.38	-0.44	2.8e-12	Pancreatic cancer;
SARC	cis	rs3796352	1.000	rs71617204	chr3:53042951	G/A	cg12962167	chr3:53033115	SFMBT1	0.82	5.4	0.33	1.61e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2153535	0.580	rs1414345	chr6:8471537	T/G	cg21535247	chr6:8435926	SLC35B3	0.53	6.61	0.4	2.64e-10	Motion sickness;
SARC	cis	rs79149102	0.649	rs2305667	chr15:75144543	G/A	cg17294928	chr15:75287854	SCAMP5	-1.01	-5.9	-0.36	1.24e-8	Lung cancer;
SARC	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg11987759	chr7:65425863	GUSB	-0.49	-5.8	-0.36	2.17e-8	Aortic root size;
SARC	trans	rs61931739	0.817	rs2203086	chr12:34232590	T/C	cg13010199	chr12:38710504	ALG10B	0.58	7.42	0.44	2.12e-12	Morning vs. evening chronotype;
SARC	cis	rs4820294	1.000	rs62236668	chr22:38063870	G/A	cg21798802	chr22:38057573	PDXP	0.38	5.62	0.35	5.57e-8	Fat distribution (HIV);
SARC	cis	rs17600642	0.724	rs72814536	chr10:72451583	C/T	cg19779893	chr10:72451501	ADAMTS14	-0.37	-5.77	-0.35	2.53e-8	Bipolar disorder;
SARC	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.12	24.57	0.85	1.28e-66	Chronic sinus infection;
SARC	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg18252515	chr7:66147081	NA	0.45	4.91	0.31	1.68e-6	Aortic root size;
SARC	cis	rs372883	0.506	rs2832301	chr21:30749712	G/A	cg08807101	chr21:30365312	RNF160	0.53	6.65	0.4	2.06e-10	Pancreatic cancer;
SARC	cis	rs314370	0.855	rs17883557	chr7:100494949	G/T	cg10426581	chr7:100472382	SRRT	0.58	6.13	0.37	3.78e-9	Resting heart rate;
SARC	cis	rs11098499	0.754	rs12513083	chr4:120249612	A/T	cg09307838	chr4:120376055	NA	0.81	11.03	0.59	4.84e-23	Corneal astigmatism;
SARC	cis	rs12142240	0.698	rs6683192	chr1:46830257	C/T	cg10495392	chr1:46806563	NSUN4	0.64	6.83	0.41	7.39e-11	Menopause (age at onset);
SARC	cis	rs7481584	1.000	rs7481584	chr11:3029089	G/A	cg25174290	chr11:3078921	CARS	-0.51	-6.61	-0.4	2.6e-10	Calcium levels;
SARC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.73	-9.5	-0.53	2.73e-18	Prudent dietary pattern;
SARC	cis	rs13392177	0.684	rs11682371	chr2:219079513	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.57	-7.28	-0.43	5.24e-12	Pyoderma gangrenosum in inflammatory bowel disease;
SARC	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg04944784	chr2:26401820	FAM59B	-0.58	-7.55	-0.44	9.6e-13	Gut microbiome composition (summer);
SARC	cis	rs2439831	1.000	rs690316	chr15:43737880	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.06	10.75	0.58	3.82e-22	Lung cancer in ever smokers;
SARC	cis	rs453301	0.598	rs2921383	chr8:8892221	C/T	cg11995313	chr8:8860691	ERI1	-0.37	-4.74	-0.3	3.78e-6	Joint mobility (Beighton score);
SARC	cis	rs4975616	0.869	rs370348	chr5:1331219	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.58	-8.61	-0.49	1.11e-15	Lung cancer;
SARC	cis	rs965469	1.000	rs6051718	chr20:3270370	C/T	cg25506879	chr20:3388711	C20orf194	-0.5	-5.04	-0.31	9.37e-7	IFN-related cytopenia;
SARC	cis	rs6714710	0.580	rs11692470	chr2:98520564	T/C	cg26665480	chr2:98280029	ACTR1B	0.49	6.72	0.4	1.38e-10	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs7927592	0.871	rs17603185	chr11:68376241	C/T	cg01657329	chr11:68192670	LRP5	-0.42	-5.05	-0.31	8.73e-7	Total body bone mineral density;
SARC	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs459571	0.959	rs461462	chr9:136911272	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.61	-7.08	-0.42	1.64e-11	Platelet distribution width;
SARC	cis	rs9911578	0.900	rs8067264	chr17:57182793	G/C	cg12560992	chr17:57184187	TRIM37	0.87	12.41	0.63	1.71e-27	Intelligence (multi-trait analysis);
SARC	cis	rs2645694	0.626	rs2703119	chr4:77823640	C/T	cg06046430	chr4:77819534	ANKRD56	0.54	7.98	0.46	6.82e-14	Emphysema distribution in smoking;
SARC	cis	rs11997175	0.574	rs4733453	chr8:33650745	A/G	ch.8.33884649F	chr8:33765107	NA	0.48	6.33	0.38	1.23e-9	Body mass index;
SARC	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	11.64	0.61	5.7e-25	Alzheimer's disease;
SARC	cis	rs11992162	0.933	rs10108075	chr8:11832079	A/G	cg21775007	chr8:11205619	TDH	0.39	4.78	0.3	3.09e-6	Monocyte count;
SARC	trans	rs2727020	0.553	rs4103567	chr11:49255389	C/T	cg00717180	chr2:96193071	NA	-0.39	-6.69	-0.4	1.6e-10	Coronary artery disease;
SARC	cis	rs7635838	0.617	rs13071193	chr3:11284226	G/T	cg00170343	chr3:11313890	ATG7	-0.75	-10.13	-0.55	3.14e-20	HDL cholesterol;
SARC	cis	rs6831352	0.918	rs34071486	chr4:100051087	A/G	cg12011299	chr4:100065546	ADH4	-0.34	-5.74	-0.35	2.97e-8	Alcohol dependence;
SARC	cis	rs611744	1.000	rs611744	chr8:109228008	A/G	cg21045802	chr8:109455806	TTC35	0.44	5.26	0.33	3.18e-7	Dupuytren's disease;
SARC	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg08677398	chr8:58056175	NA	0.43	5.12	0.32	6.55e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg03060546	chr3:49711283	APEH	0.75	11.17	0.59	1.7e-23	Resting heart rate;
SARC	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg19077165	chr18:44547161	KATNAL2	-0.52	-7.27	-0.43	5.27e-12	Personality dimensions;
SARC	cis	rs6580649	0.771	rs1034762	chr12:48389643	G/T	cg24011408	chr12:48396354	COL2A1	-0.52	-5.95	-0.36	9.68e-9	Lung cancer;
SARC	cis	rs7264396	0.635	rs2064724	chr20:34522520	T/C	cg12579300	chr20:34535607	PHF20	-0.42	-4.93	-0.31	1.58e-6	Total cholesterol levels;
SARC	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg04518342	chr5:131593106	PDLIM4	0.42	5.77	0.35	2.49e-8	Acylcarnitine levels;
SARC	cis	rs67366981	1.000	rs17105547	chr14:77698358	G/A	cg06779847	chr14:77687015	TMEM63C	-0.55	-5.95	-0.36	9.99e-9	Obsessive-compulsive symptoms;
SARC	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg05279229	chr7:1896384	MAD1L1	-0.35	-4.77	-0.3	3.23e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs6580649	0.941	rs11612970	chr12:48451009	T/C	cg05342945	chr12:48394962	COL2A1	0.57	6.15	0.37	3.42e-9	Lung cancer;
SARC	cis	rs6963495	0.818	rs6956249	chr7:105149743	A/T	cg19920283	chr7:105172520	RINT1	0.67	5.8	0.36	2.14e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs11191193	0.686	rs11191162	chr10:103732143	G/A	cg15320455	chr10:103880129	LDB1	0.56	5.9	0.36	1.3e-8	Educational attainment;
SARC	cis	rs2991971	0.901	rs11211122	chr1:45954650	C/T	cg24296786	chr1:45957014	TESK2	0.66	9.48	0.53	2.98e-18	High light scatter reticulocyte count;
SARC	cis	rs10504229	0.679	rs72649107	chr8:58030453	C/A	cg22535103	chr8:58192502	C8orf71	-0.54	-5.48	-0.34	1.08e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9297145	0.916	rs6969140	chr7:98753900	G/A	cg05967295	chr7:98741636	SMURF1	-0.86	-10.45	-0.56	3.31e-21	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
SARC	cis	rs2721195	0.626	rs59464125	chr8:145857786	G/A	cg12270520	chr8:146023939	ZNF517	-0.4	-4.87	-0.3	2.1e-6	Age at first birth;
SARC	cis	rs4910157	1	rs4910157	chr11:8941215	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.39	5.58	0.34	6.7e-8	Tonsillectomy;
SARC	cis	rs4974559	0.501	rs1250096	chr4:1238836	G/C	cg02980000	chr4:1222292	CTBP1	-0.81	-6.6	-0.4	2.7e-10	Systolic blood pressure;
SARC	cis	rs4803468	0.967	rs4803461	chr19:41908871	G/A	cg08477640	chr19:41863820	B9D2	0.43	5.48	0.34	1.12e-7	Height;
SARC	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg10523679	chr1:76189770	ACADM	-0.43	-5.31	-0.33	2.61e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs751728	1.000	rs4713684	chr6:33766488	T/C	cg15252951	chr6:33757062	LEMD2	0.56	6.62	0.4	2.39e-10	Crohn's disease;
SARC	cis	rs35955747	0.902	rs12166373	chr22:31700508	A/G	cg13145458	chr22:31556086	RNF185	0.39	4.78	0.3	3.14e-6	Neutrophil count;Sum basophil neutrophil counts;
SARC	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg06634786	chr22:41940651	POLR3H	0.45	5.17	0.32	5.09e-7	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg00750074	chr16:89608354	SPG7	0.33	5.04	0.31	9.14e-7	Multiple myeloma (IgH translocation);
SARC	cis	rs9682041	0.696	rs11709437	chr3:170085568	T/G	cg11886554	chr3:170076028	SKIL	0.83	7.75	0.45	2.91e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs6709815	0.902	rs13020432	chr2:219668211	C/T	cg02176678	chr2:219576539	TTLL4	-0.38	-5.67	-0.35	4.2e-8	Reticulocyte count;High light scatter reticulocyte count;
SARC	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg06028808	chr11:68637592	NA	0.44	5.45	0.34	1.3e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs6831352	0.918	rs29001195	chr4:100054244	G/T	cg12011299	chr4:100065546	ADH4	-0.34	-5.74	-0.35	2.95e-8	Alcohol dependence;
SARC	cis	rs72781680	0.665	rs72788298	chr2:24104293	T/C	cg06627628	chr2:24431161	ITSN2	-0.57	-6.16	-0.37	3.23e-9	Lymphocyte counts;
SARC	cis	rs9790314	0.905	rs6789388	chr3:160970437	G/A	cg03342759	chr3:160939853	NMD3	-0.63	-8.09	-0.47	3.32e-14	Morning vs. evening chronotype;
SARC	cis	rs10078	0.510	rs2278248	chr5:469570	G/T	cg07599136	chr5:415885	AHRR	0.6	5.67	0.35	4.13e-8	Fat distribution (HIV);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg04678989	chr19:39138551	ACTN4	0.52	6.36	0.38	1.05e-9	Height;
SARC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg06873352	chr17:61820015	STRADA	0.54	6.99	0.42	2.8e-11	Prudent dietary pattern;
SARC	cis	rs501120	1.000	rs493874	chr10:44764077	C/T	cg09554077	chr10:44749378	NA	0.47	6.4	0.39	8.69e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg00149659	chr3:10157352	C3orf10	0.7	6.56	0.39	3.47e-10	Alzheimer's disease;
SARC	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg11062466	chr8:58055876	NA	0.66	6.04	0.37	6.14e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9341808	0.538	rs613588	chr6:80978928	A/C	cg08355045	chr6:80787529	NA	-0.36	-5.47	-0.34	1.17e-7	Sitting height ratio;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg13289463	chr2:161273519	RBMS1	0.51	6.96	0.41	3.33e-11	Thyroid stimulating hormone;
SARC	cis	rs9788682	1.000	rs7163730	chr15:78814681	A/G	cg06917634	chr15:78832804	PSMA4	-0.56	-6.26	-0.38	1.82e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs17376456	0.877	rs7701011	chr5:93311456	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.8	0.35	2.2e-8	Diabetic retinopathy;
SARC	cis	rs911555	0.755	rs12432803	chr14:103930032	C/T	cg24130564	chr14:104152367	KLC1	0.5	5.96	0.36	9.3e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7599312	0.534	rs2371615	chr2:213405660	G/T	cg20637307	chr2:213403960	ERBB4	0.8	12.58	0.64	4.96e-28	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg21016266	chr12:122356598	WDR66	0.31	4.74	0.3	3.67e-6	Mean corpuscular volume;
SARC	cis	rs1153858	0.621	rs2413769	chr15:45561868	A/C	cg21132104	chr15:45694354	SPATA5L1	0.74	9.63	0.53	1.05e-18	Homoarginine levels;
SARC	cis	rs9325144	0.560	rs1601745	chr12:38647828	G/A	cg13010199	chr12:38710504	ALG10B	-0.58	-7.52	-0.44	1.2e-12	Morning vs. evening chronotype;
SARC	cis	rs34172651	0.917	rs11640931	chr16:24797919	A/G	cg04756594	chr16:24857601	SLC5A11	0.35	5.61	0.35	5.65e-8	Intelligence (multi-trait analysis);
SARC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.34	-5.11	-0.32	6.77e-7	Total body bone mineral density;
SARC	cis	rs41271473	0.526	rs12143098	chr1:228720965	A/C	cg10167378	chr1:228756711	NA	0.6	5.3	0.33	2.69e-7	Chronic lymphocytic leukemia;
SARC	trans	rs3945119	0.808	rs7517238	chr1:91152258	G/A	cg01730148	chr2:3698421	NA	0.34	6.24	0.38	2.07e-9	Intelligence (multi-trait analysis);
SARC	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg03806693	chr22:41940476	POLR3H	0.84	11.81	0.61	1.54e-25	Vitiligo;
SARC	cis	rs365132	1.000	rs402511	chr5:176434440	G/A	cg16309518	chr5:176445507	NA	-0.47	-6.07	-0.37	5.09e-9	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg13114125	chr14:105738426	BRF1	-0.72	-10.53	-0.57	1.84e-21	Mean platelet volume;Platelet distribution width;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg21551132	chr17:53046152	COX11;STXBP4	0.65	6.83	0.41	7.14e-11	Lung cancer in ever smokers;
SARC	cis	rs9467711	0.651	rs17587597	chr6:25986451	G/A	cg21479132	chr6:26055353	NA	0.82	4.87	0.3	2.02e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg13395646	chr4:1353034	KIAA1530	0.42	4.96	0.31	1.38e-6	Obesity-related traits;
SARC	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.77	7.65	0.45	5.44e-13	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg03188948	chr7:1209495	NA	0.41	5.24	0.32	3.56e-7	Longevity;Endometriosis;
SARC	cis	rs6840360	0.550	rs7683134	chr4:152503362	A/C	cg22705602	chr4:152727874	NA	-0.43	-6.66	-0.4	1.91e-10	Intelligence (multi-trait analysis);
SARC	cis	rs11098499	0.863	rs10034450	chr4:120455649	A/G	cg09307838	chr4:120376055	NA	0.91	12.31	0.63	3.63e-27	Corneal astigmatism;
SARC	cis	rs1580019	0.563	rs2392071	chr7:32572536	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.62	8.36	0.48	5.73e-15	Cognitive ability;
SARC	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.31	-4.76	-0.3	3.4e-6	Menopause (age at onset);
SARC	cis	rs6088580	0.634	rs4911151	chr20:32932273	T/C	cg08999081	chr20:33150536	PIGU	-0.43	-6.51	-0.39	4.47e-10	Glomerular filtration rate (creatinine);
SARC	trans	rs9929218	0.551	rs4783663	chr16:68720271	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.86	14.34	0.68	7.44e-34	Colorectal cancer;
SARC	cis	rs7432375	0.610	rs56163507	chr3:136516056	C/T	cg15507776	chr3:136538369	TMEM22	0.61	7.58	0.44	8.18e-13	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	cis	rs1538970	0.961	rs4660854	chr1:45854087	A/T	cg05343316	chr1:45956843	TESK2	0.68	8.32	0.48	7.61e-15	Platelet count;
SARC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.8	10.35	0.56	6.69e-21	Prudent dietary pattern;
SARC	cis	rs4253772	0.515	rs74766656	chr22:46662497	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.63	4.92	0.31	1.62e-6	LDL cholesterol;Cholesterol, total;
SARC	cis	rs896854	0.517	rs1011796	chr8:95951273	A/G	cg16049864	chr8:95962084	TP53INP1	0.32	4.77	0.3	3.29e-6	Type 2 diabetes;
SARC	cis	rs7005380	0.531	rs9649948	chr8:120913535	A/G	cg21744203	chr8:120868354	DSCC1	-0.43	-4.78	-0.3	3.06e-6	Interstitial lung disease;
SARC	cis	rs13191362	1.000	rs34591938	chr6:163087003	C/G	cg18825119	chr6:163149453	PACRG;PARK2	0.39	4.83	0.3	2.46e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs9611519	0.964	rs2179744	chr22:41621714	G/A	cg03806693	chr22:41940476	POLR3H	-0.56	-6.84	-0.41	6.82e-11	Neuroticism;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg02037518	chr11:57283212	SLC43A1	-0.85	-7.24	-0.43	6.38e-12	Autism spectrum disorder or schizophrenia;
SARC	cis	rs8114671	0.836	rs17404569	chr20:33674077	A/C	cg24642439	chr20:33292090	TP53INP2	-0.52	-6.03	-0.37	6.27e-9	Height;
SARC	cis	rs6546550	0.901	rs897119	chr2:70160658	T/C	cg02498382	chr2:70120550	SNRNP27	-0.33	-5.4	-0.33	1.66e-7	Prevalent atrial fibrillation;
SARC	cis	rs7927771	1.000	rs7105282	chr11:47805614	C/A	cg05585544	chr11:47624801	NA	-0.36	-4.84	-0.3	2.36e-6	Subjective well-being;
SARC	cis	rs3892630	0.824	rs34425841	chr19:33231619	C/T	cg22980127	chr19:33182716	NUDT19	1.01	8.49	0.49	2.39e-15	Red blood cell traits;
SARC	cis	rs6582630	0.555	rs10880625	chr12:38526612	A/C	cg13010199	chr12:38710504	ALG10B	0.77	10.75	0.58	3.81e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs12134245	0.776	rs61548854	chr1:92001536	C/T	cg25838465	chr1:92012736	NA	-0.69	-9.93	-0.55	1.29e-19	Breast cancer;
SARC	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg14403583	chr14:105418241	AHNAK2	-0.58	-7.63	-0.45	6.09e-13	Rheumatoid arthritis;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg09560911	chr6:47276890	TNFRSF21	-0.74	-6.34	-0.38	1.21e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs8031584	0.958	rs7176569	chr15:31244495	G/T	cg14298792	chr15:30685198	CHRFAM7A	0.46	5.15	0.32	5.55e-7	Huntington's disease progression;
SARC	cis	rs7020830	0.931	rs13288178	chr9:37107799	A/G	cg14294708	chr9:37120828	ZCCHC7	1.14	20.51	0.8	4.19e-54	Schizophrenia;
SARC	cis	rs6003958	1	rs6003958	chr22:24264089	T/G	cg11141652	chr22:24348549	GSTTP1	-0.49	-5.26	-0.33	3.18e-7	S-phenylmercapturic acid levels in smokers;
SARC	cis	rs1020064	0.945	rs1030878	chr2:105910598	T/G	cg02079111	chr2:105885981	TGFBRAP1	0.54	6.25	0.38	1.99e-9	AIDS;
SARC	cis	rs9326248	0.581	rs7121898	chr11:116796846	A/T	cg01368799	chr11:117014884	PAFAH1B2	0.61	7.69	0.45	4.1e-13	Blood protein levels;
SARC	cis	rs17345786	0.911	rs10936707	chr3:101324063	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.45	5.0	0.31	1.11e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs501120	1.000	rs604674	chr10:44756894	G/T	cg09554077	chr10:44749378	NA	0.48	6.49	0.39	5.12e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs921968	0.643	rs613539	chr2:219455967	G/T	cg02176678	chr2:219576539	TTLL4	0.36	5.27	0.33	3.05e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs9290065	0.519	rs9857743	chr3:160677732	G/A	cg03342759	chr3:160939853	NMD3	-0.49	-5.95	-0.36	9.87e-9	Kawasaki disease;
SARC	cis	rs9467711	0.651	rs9467623	chr6:25860580	G/A	cg21479132	chr6:26055353	NA	0.78	5.0	0.31	1.1e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg18357526	chr6:26021779	HIST1H4A	0.46	5.84	0.36	1.71e-8	Blood metabolite levels;
SARC	cis	rs6138458	1.000	rs2387361	chr20:24899905	C/T	cg26195577	chr20:24973756	C20orf3	-0.86	-9.47	-0.53	3.25e-18	Blood protein levels;
SARC	cis	rs77633900	0.614	rs280029	chr15:77031235	A/G	cg21673338	chr15:77095150	SCAPER	-0.76	-6.35	-0.38	1.11e-9	Non-glioblastoma glioma;Glioma;
SARC	cis	rs7662987	0.517	rs1453874	chr4:100022724	G/A	cg12011299	chr4:100065546	ADH4	0.32	5.26	0.33	3.23e-7	Smoking initiation;
SARC	cis	rs11098499	0.955	rs1551	chr4:120158500	T/G	cg09307838	chr4:120376055	NA	0.85	11.68	0.61	3.97e-25	Corneal astigmatism;
SARC	cis	rs763121	0.853	rs6001175	chr22:39018334	T/C	cg06022373	chr22:39101656	GTPBP1	0.92	12.65	0.64	2.86e-28	Menopause (age at onset);
SARC	cis	rs72781680	0.898	rs17462670	chr2:24026579	T/C	cg08917208	chr2:24149416	ATAD2B	0.76	7.11	0.42	1.4e-11	Lymphocyte counts;
SARC	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg18252515	chr7:66147081	NA	-1.34	-11.85	-0.61	1.15e-25	Diabetic kidney disease;
SARC	cis	rs1754541	1.000	rs1188752	chr1:101632277	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.42	-4.74	-0.3	3.74e-6	Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;
SARC	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg18758796	chr5:131593413	PDLIM4	0.37	4.81	0.3	2.68e-6	Acylcarnitine levels;
SARC	cis	rs2916247	0.954	rs28475789	chr8:93128465	C/T	cg10183463	chr8:93005414	RUNX1T1	0.55	5.68	0.35	3.96e-8	Intelligence (multi-trait analysis);
SARC	cis	rs10089	1.000	rs4836367	chr5:127482592	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.81	10.17	0.55	2.39e-20	Ileal carcinoids;
SARC	cis	rs6752107	1.000	rs2241880	chr2:234183368	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.5	6.65	0.4	2.11e-10	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg06028808	chr11:68637592	NA	0.44	5.64	0.35	5.01e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs2425143	0.730	rs2095819	chr20:34353278	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-6.38	-0.39	9.66e-10	Blood protein levels;
SARC	cis	rs933688	0.938	rs6866923	chr5:90669352	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.08	13.94	0.67	1.57e-32	Smoking behavior;
SARC	cis	rs526821	0.595	rs532278	chr11:55344983	A/G	cg04317927	chr11:55418816	OR4S2	0.41	6.09	0.37	4.71e-9	Pediatric bone mineral density (spine);
SARC	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg25072359	chr17:41440525	NA	0.48	5.62	0.35	5.43e-8	Menopause (age at onset);
SARC	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg07343612	chr16:622815	PIGQ	-0.6	-8.4	-0.48	4.34e-15	Height;
SARC	cis	rs748404	0.697	rs491804	chr15:43560825	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.41	5.13	0.32	6.02e-7	Lung cancer;
SARC	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg22535103	chr8:58192502	C8orf71	-0.6	-6.15	-0.37	3.42e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2742234	0.541	rs1254959	chr10:43700979	C/G	cg15436174	chr10:43711423	RASGEF1A	0.41	4.81	0.3	2.7e-6	Hirschsprung disease;
SARC	cis	rs7672847	0.500	rs7677603	chr4:170330085	G/C	cg00846720	chr4:170533756	NEK1	-0.62	-4.79	-0.3	2.97e-6	Subjective well-being;
SARC	cis	rs79149102	0.579	rs73438569	chr15:75354486	T/A	cg17294928	chr15:75287854	SCAMP5	-1.11	-9.26	-0.52	1.41e-17	Lung cancer;
SARC	cis	rs17376456	0.597	rs7733142	chr5:93322795	C/A	cg25358565	chr5:93447407	FAM172A	-0.83	-9.74	-0.54	4.97e-19	Diabetic retinopathy;
SARC	cis	rs4642101	0.662	rs1969154	chr3:12829156	A/G	cg05775895	chr3:12838266	CAND2	0.73	11.58	0.6	8.37e-25	QRS complex (12-leadsum);
SARC	cis	rs826838	0.510	rs17523988	chr12:39222785	A/C	cg26384229	chr12:38710491	ALG10B	0.72	9.02	0.51	7.26e-17	Heart rate;
SARC	cis	rs4566357	0.595	rs6707286	chr2:227911400	A/G	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.87	-0.36	1.51e-8	Coronary artery disease;
SARC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg05195085	chr7:157951403	PTPRN2	0.35	5.86	0.36	1.56e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
SARC	cis	rs7520050	0.966	rs1085244	chr1:46563680	C/A	cg24296786	chr1:45957014	TESK2	0.38	4.83	0.3	2.44e-6	Red blood cell count;Reticulocyte count;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg14870062	chr19:10207170	ANGPTL6	0.51	7.26	0.43	5.84e-12	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs17600642	0.724	rs17528468	chr10:72459184	A/C	cg19779893	chr10:72451501	ADAMTS14	-0.39	-6.16	-0.37	3.22e-9	Bipolar disorder;
SARC	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg18305652	chr10:134549665	INPP5A	0.33	4.88	0.3	1.93e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs1008375	1.000	rs11724495	chr4:17621310	G/A	cg02297831	chr4:17616191	MED28	0.47	5.93	0.36	1.09e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs17376456	0.741	rs7718842	chr5:93480568	G/A	cg21475434	chr5:93447410	FAM172A	0.89	7.33	0.43	3.73e-12	Diabetic retinopathy;
SARC	cis	rs2439831	0.850	rs68079546	chr15:44136957	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.76	7.53	0.44	1.14e-12	Lung cancer in ever smokers;
SARC	cis	rs9420	0.961	rs17455520	chr11:57540458	C/A	cg19752551	chr11:57585705	CTNND1	-0.53	-7.23	-0.43	6.92e-12	Schizophrenia;
SARC	cis	rs9815354	1.000	rs1716987	chr3:41970516	A/G	cg03022575	chr3:42003672	ULK4	-0.62	-5.81	-0.36	2.09e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs3764563	0.877	rs4646526	chr19:15729773	A/G	cg20725493	chr19:15740067	CYP4F8	-0.73	-5.73	-0.35	3.07e-8	Inflammatory biomarkers;
SARC	cis	rs3126085	0.935	rs2291770	chr1:152179792	G/C	cg26876637	chr1:152193138	HRNR	0.49	5.61	0.35	5.67e-8	Atopic dermatitis;
SARC	cis	rs1707322	0.928	rs10732844	chr1:46372688	T/C	cg03146154	chr1:46216737	IPP	0.46	5.52	0.34	8.98e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2916247	1.000	rs11776021	chr8:93025183	A/G	cg10183463	chr8:93005414	RUNX1T1	0.59	6.21	0.38	2.35e-9	Intelligence (multi-trait analysis);
SARC	cis	rs6570726	0.935	rs390252	chr6:145856896	A/G	cg05220968	chr6:146057943	EPM2A	-0.3	-5.08	-0.32	7.76e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7639513	0.767	rs7648488	chr3:12708946	T/C	cg23032965	chr3:12705835	RAF1	0.85	12.42	0.63	1.59e-27	Itch intensity from mosquito bite;
SARC	cis	rs34779708	0.931	rs4934524	chr10:35270921	G/C	cg03585969	chr10:35415529	CREM	0.4	5.01	0.31	1.07e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs6121246	0.559	rs6058465	chr20:30397691	G/A	cg13852791	chr20:30311386	BCL2L1	0.87	10.91	0.58	1.14e-22	Mean corpuscular hemoglobin;
SARC	cis	rs7740797	0.818	rs9375	chr6:155155039	C/T	cg02865717	chr6:155053990	RBM16	0.33	4.72	0.3	4.08e-6	Colorectal or endometrial cancer;
SARC	cis	rs1468333	0.724	rs7726580	chr5:137608666	A/G	cg27119451	chr5:137514611	BRD8;KIF20A	-0.75	-10.31	-0.56	8.73e-21	Resting heart rate;
SARC	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs3741404	0.620	rs882147	chr11:63976689	T/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	9.77	0.54	3.97e-19	Platelet count;
SARC	cis	rs875971	0.545	rs73142245	chr7:65691649	A/G	cg11764359	chr7:65958608	NA	0.66	6.41	0.39	7.9e-10	Aortic root size;
SARC	cis	rs7084402	0.967	rs1593678	chr10:60291548	A/G	cg07615347	chr10:60278583	BICC1	0.61	8.99	0.51	8.84e-17	Refractive error;
SARC	cis	rs12200560	0.505	rs211172	chr6:97070691	C/A	cg06623918	chr6:96969491	KIAA0776	0.43	4.85	0.3	2.21e-6	Coronary heart disease;
SARC	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs763121	0.853	rs5750627	chr22:38982321	A/G	cg06022373	chr22:39101656	GTPBP1	0.91	12.1	0.62	1.74e-26	Menopause (age at onset);
SARC	cis	rs17376456	0.825	rs6898842	chr5:93213221	T/C	cg21475434	chr5:93447410	FAM172A	0.79	6.71	0.4	1.49e-10	Diabetic retinopathy;
SARC	cis	rs17384381	0.953	rs12138621	chr1:85783970	T/C	cg16011679	chr1:85725395	C1orf52	0.62	5.31	0.33	2.54e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6450176	1.000	rs3776717	chr5:53298762	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.67	-7.8	-0.46	2.06e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs6089584	1.000	rs6089587	chr20:60564829	C/T	cg06108461	chr20:60628389	TAF4	-0.91	-11.96	-0.62	5.27e-26	Body mass index;
SARC	cis	rs950776	0.507	rs12912673	chr15:78810216	T/C	cg06917634	chr15:78832804	PSMA4	0.87	12.9	0.65	4.47e-29	Sudden cardiac arrest;
SARC	cis	rs9303401	0.614	rs3087762	chr17:56568680	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.05	11.45	0.6	2.3e-24	Cognitive test performance;
SARC	cis	rs17270561	0.636	rs2070642	chr6:25831212	G/A	cg17691542	chr6:26056736	HIST1H1C	0.54	6.86	0.41	6.01e-11	Iron status biomarkers;
SARC	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg01181863	chr3:195395398	SDHAP2	-0.61	-6.96	-0.42	3.35e-11	Pancreatic cancer;
SARC	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg08219700	chr8:58056026	NA	0.49	5.01	0.31	1.05e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs7084402	0.935	rs12264028	chr10:60278140	C/T	cg07615347	chr10:60278583	BICC1	-0.6	-8.98	-0.51	9.22e-17	Refractive error;
SARC	cis	rs7044106	0.734	rs10491784	chr9:123432289	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	5.44	0.34	1.32e-7	Hip circumference adjusted for BMI;
SARC	cis	rs6964587	0.626	rs10243083	chr7:91552530	G/A	cg17063962	chr7:91808500	NA	-0.78	-11.2	-0.59	1.44e-23	Breast cancer;
SARC	cis	rs12451471	0.637	rs12452616	chr17:78090081	A/G	cg06718696	chr17:78121285	EIF4A3	-0.86	-9.68	-0.54	7.87e-19	Plateletcrit;Mean corpuscular hemoglobin concentration;
SARC	cis	rs4481887	0.927	rs10158431	chr1:248481253	A/G	cg00666640	chr1:248458726	OR2T12	0.39	6.45	0.39	6.29e-10	Common traits (Other);
SARC	cis	rs1873147	1.000	rs12440411	chr15:63313581	T/G	cg05507819	chr15:63340323	TPM1	-0.45	-4.89	-0.31	1.84e-6	Orofacial clefts;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg02730843	chr10:13251406	MCM10	0.46	6.38	0.39	9.46e-10	Thyroid stimulating hormone;
SARC	cis	rs11249608	0.548	rs10479519	chr5:178450693	T/C	cg21905437	chr5:178450457	ZNF879	0.59	8.02	0.47	5.05e-14	Pubertal anthropometrics;
SARC	trans	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg21659725	chr3:3221576	CRBN	0.54	6.86	0.41	6.06e-11	Intelligence (multi-trait analysis);
SARC	cis	rs763121	0.853	rs1062687	chr22:39134715	T/C	cg21395723	chr22:39101663	GTPBP1	0.58	7.11	0.42	1.38e-11	Menopause (age at onset);
SARC	trans	rs2637266	1.000	rs2637266	chr10:78331318	C/T	cg02067430	chr17:79679069	SLC25A10	0.5	6.76	0.4	1.11e-10	Pulmonary function;
SARC	cis	rs12311304	1.000	rs11056403	chr12:15377717	G/T	cg08258403	chr12:15378311	NA	-0.44	-6.4	-0.39	8.56e-10	Behavioural disinhibition (generation interaction);
SARC	cis	rs7296418	0.961	rs11613937	chr12:123520071	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.44	-6.0	-0.37	7.47e-9	Platelet count;
SARC	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg15448220	chr1:150897856	SETDB1	0.47	6.25	0.38	1.94e-9	Tonsillectomy;
SARC	cis	rs546131	0.642	rs12293044	chr11:34851049	T/G	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-4.81	-0.3	2.72e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs11098499	0.697	rs11941899	chr4:120382758	C/A	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg04192019	chr6:47555018	CD2AP	-0.53	-6.33	-0.38	1.28e-9	Gut microbiota (bacterial taxa);
SARC	trans	rs890100	0.642	rs1989593	chr2:56668109	G/A	cg26233084	chr5:15510258	FBXL7	-0.31	-6.38	-0.39	9.24e-10	Gut microbiome composition (summer);
SARC	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg24642844	chr7:1081250	C7orf50	-0.59	-6.05	-0.37	5.79e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs7106204	0.514	rs10834307	chr11:24272516	G/A	ch.11.24196551F	chr11:24239977	NA	-0.56	-5.52	-0.34	8.97e-8	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs240764	0.631	rs9386250	chr6:101204126	A/G	cg09795085	chr6:101329169	ASCC3	-0.44	-5.64	-0.35	4.99e-8	Neuroticism;
SARC	cis	rs9911578	0.967	rs12938821	chr17:56959422	T/C	cg12560992	chr17:57184187	TRIM37	0.85	11.74	0.61	2.68e-25	Intelligence (multi-trait analysis);
SARC	cis	rs950776	0.518	rs12907169	chr15:78825498	G/C	cg06917634	chr15:78832804	PSMA4	0.91	14.24	0.68	1.6e-33	Sudden cardiac arrest;
SARC	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.47	-5.27	-0.33	3.12e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs208520	0.690	rs12189780	chr6:66759619	G/A	cg07460842	chr6:66804631	NA	1.09	14.71	0.69	4.45e-35	Exhaled nitric oxide output;
SARC	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg22974920	chr21:40686053	BRWD1	-0.43	-4.83	-0.3	2.47e-6	Cognitive function;
SARC	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg18876405	chr7:65276391	NA	0.44	4.91	0.31	1.71e-6	Aortic root size;
SARC	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg17376030	chr22:41985996	PMM1	-0.73	-9.01	-0.51	7.45e-17	Vitiligo;
SARC	cis	rs548181	1.000	rs548181	chr11:125461709	A/G	cg03464685	chr11:125439445	EI24	1.05	9.76	0.54	4.36e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs2303759	0.709	rs10422677	chr19:49824290	C/T	cg22307029	chr19:49891270	CCDC155	0.59	6.71	0.4	1.43e-10	Multiple sclerosis;
SARC	cis	rs8067545	0.717	rs34401389	chr17:19989436	A/T	cg13482628	chr17:19912719	NA	0.56	7.35	0.43	3.37e-12	Schizophrenia;
SARC	cis	rs6860806	0.507	rs200837	chr5:131699958	G/A	cg11843238	chr5:131593191	PDLIM4	0.4	4.97	0.31	1.29e-6	Breast cancer;
SARC	cis	rs365132	0.840	rs58400555	chr5:176454081	A/T	cg16309518	chr5:176445507	NA	-0.45	-5.8	-0.36	2.15e-8	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	trans	rs7980799	0.649	rs1601003	chr12:33689436	A/T	cg13010199	chr12:38710504	ALG10B	0.57	6.59	0.4	2.93e-10	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs9486719	1.000	rs2472880	chr6:96860130	G/A	cg18709589	chr6:96969512	KIAA0776	0.48	4.88	0.3	1.93e-6	Migraine;Coronary artery disease;
SARC	cis	rs9840812	0.773	rs1154988	chr3:135925191	A/T	cg15507776	chr3:136538369	TMEM22	-0.51	-5.42	-0.33	1.45e-7	Fibrinogen levels;
SARC	cis	rs250677	0.522	rs3763022	chr5:148381078	A/G	cg18129178	chr5:148520854	ABLIM3	-0.37	-4.85	-0.3	2.29e-6	Breast cancer;
SARC	trans	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg00938859	chr5:1591904	SDHAP3	0.69	6.36	0.38	1.03e-9	Breast cancer;
SARC	cis	rs2075371	0.501	rs1643043	chr7:134013902	C/T	cg11752832	chr7:134001865	SLC35B4	0.45	5.53	0.34	8.71e-8	Mean platelet volume;
SARC	cis	rs7740797	0.818	rs9371352	chr6:155133680	C/G	cg02865717	chr6:155053990	RBM16	0.33	4.86	0.3	2.13e-6	Colorectal or endometrial cancer;
SARC	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg27266027	chr21:40555129	PSMG1	-0.5	-5.61	-0.35	5.58e-8	Cognitive function;
SARC	cis	rs6964587	0.933	rs13230837	chr7:91779017	A/G	cg17063962	chr7:91808500	NA	0.95	15.55	0.71	6.91e-38	Breast cancer;
SARC	cis	rs8177253	0.633	rs10935073	chr3:133439184	T/C	cg16414030	chr3:133502952	NA	-0.38	-4.96	-0.31	1.33e-6	Iron status biomarkers;
SARC	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg00149659	chr3:10157352	C3orf10	1.09	10.0	0.55	7.87e-20	Alzheimer's disease;
SARC	cis	rs7084402	0.967	rs1658494	chr10:60280323	C/T	cg07615347	chr10:60278583	BICC1	-0.6	-8.82	-0.5	2.78e-16	Refractive error;
SARC	cis	rs57244997	0.725	rs61574422	chr6:162425056	T/C	cg17173639	chr6:162384350	PARK2	-0.52	-5.29	-0.33	2.85e-7	Mosquito bite size;
SARC	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg11764359	chr7:65958608	NA	-0.79	-9.75	-0.54	4.53e-19	Aortic root size;
SARC	cis	rs425277	0.958	rs262639	chr1:2107061	G/T	cg24578937	chr1:2090814	PRKCZ	0.3	5.43	0.34	1.39e-7	Height;
SARC	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1707322	1.000	rs785470	chr1:46519622	C/A	cg03146154	chr1:46216737	IPP	-0.46	-5.46	-0.34	1.2e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9486715	1.000	rs9386670	chr6:97060688	C/A	cg06623918	chr6:96969491	KIAA0776	-0.8	-10.2	-0.56	1.93e-20	Headache;
SARC	cis	rs66569888	0.789	rs1317569	chr2:106735490	C/A	cg16099169	chr2:106886729	NA	-0.44	-4.73	-0.3	3.84e-6	Facial morphology (factor 23);
SARC	cis	rs6840360	0.554	rs61308159	chr4:152728941	G/A	cg22705602	chr4:152727874	NA	0.48	8.55	0.49	1.68e-15	Intelligence (multi-trait analysis);
SARC	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg17971929	chr21:40555470	PSMG1	0.84	11.2	0.59	1.37e-23	Cognitive function;
SARC	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg12463550	chr7:65579703	CRCP	0.66	5.06	0.31	8.64e-7	Diabetic kidney disease;
SARC	trans	rs17221829	0.733	rs11018668	chr11:89356178	C/T	cg10795359	chr7:134143988	AKR1B1	-0.48	-6.55	-0.39	3.56e-10	Anxiety in major depressive disorder;
SARC	trans	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg06437703	chr8:37914619	EIF4EBP1	-0.55	-6.58	-0.4	3.09e-10	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs3818285	0.610	rs642938	chr10:111633025	A/C	cg00817464	chr10:111662876	XPNPEP1	0.5	8.09	0.47	3.34e-14	Superior crus of antihelix expression;
SARC	cis	rs11098499	1.000	rs13435802	chr4:120177960	A/T	cg09307838	chr4:120376055	NA	-0.81	-11.29	-0.59	7.09e-24	Corneal astigmatism;
SARC	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	11.63	0.61	5.96e-25	Alzheimer's disease;
SARC	cis	rs9814567	0.712	rs4306900	chr3:134334327	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.52	6.76	0.41	1.08e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg04391736	chr16:69373674	COG8;NIP7	-0.53	-6.91	-0.41	4.55e-11	Chemerin levels;
SARC	cis	rs10875746	0.903	rs11168418	chr12:48515754	C/A	cg26205652	chr12:48591994	NA	0.56	6.21	0.38	2.45e-9	Longevity (90 years and older);
SARC	cis	rs7264396	0.733	rs6060515	chr20:34211779	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.56	5.58	0.34	6.67e-8	Total cholesterol levels;
SARC	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg22496380	chr5:211416	CCDC127	-0.89	-9.32	-0.52	9.5e-18	Breast cancer;
SARC	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg06634786	chr22:41940651	POLR3H	0.49	6.15	0.37	3.38e-9	Vitiligo;
SARC	cis	rs6598955	0.543	rs6698557	chr1:26561220	G/C	cg04990556	chr1:26633338	UBXN11	0.76	7.87	0.46	1.3e-13	Obesity-related traits;
SARC	cis	rs13191362	1.000	rs35818596	chr6:163001874	C/G	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.49	0.34	1.04e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-7.12	-0.42	1.32e-11	Alzheimer's disease;
SARC	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg25036284	chr2:26402008	FAM59B	-0.45	-5.61	-0.34	5.83e-8	Gut microbiome composition (summer);
SARC	cis	rs155076	1.000	rs2478824	chr13:21844144	G/C	cg11317459	chr13:21872234	NA	-0.98	-12.36	-0.63	2.52e-27	White matter hyperintensity burden;
SARC	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg17221315	chr6:27791827	HIST1H4J	0.51	5.28	0.33	2.97e-7	Parkinson's disease;
SARC	cis	rs4423214	1.000	rs2282620	chr11:71183477	C/T	cg24826892	chr11:71159390	DHCR7	0.48	6.11	0.37	4.13e-9	Vitamin D levels;
SARC	cis	rs7429990	0.965	rs7431572	chr3:48027851	G/T	cg11946769	chr3:48343235	NME6	-0.46	-5.39	-0.33	1.75e-7	Educational attainment (years of education);
SARC	cis	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg14541582	chr5:601475	NA	-0.4	-4.8	-0.3	2.85e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs208520	0.507	rs3903670	chr6:66812183	T/C	cg07460842	chr6:66804631	NA	-1.12	-22.45	-0.83	3.48e-60	Exhaled nitric oxide output;
SARC	cis	rs7552404	0.731	rs1770885	chr1:76402212	C/T	cg10523679	chr1:76189770	ACADM	-0.43	-5.11	-0.32	6.63e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg24642844	chr7:1081250	C7orf50	-0.4	-5.49	-0.34	1.02e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs523522	0.962	rs3759394	chr12:120933173	C/A	cg27279351	chr12:120934652	DYNLL1	0.72	8.91	0.5	1.5e-16	High light scatter reticulocyte count;
SARC	cis	rs2250402	0.510	rs8031319	chr15:40323692	A/G	cg09159619	chr15:40331526	SRP14	0.69	4.71	0.3	4.2e-6	Corneal curvature;
SARC	cis	rs2304069	0.545	rs6866616	chr5:149415401	A/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.45	5.0	0.31	1.11e-6	HIV-1 control;
SARC	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg22903471	chr2:27725779	GCKR	-0.47	-6.94	-0.41	3.79e-11	Menopause (age at onset);
SARC	cis	rs2153535	0.580	rs9406170	chr6:8514153	T/C	cg07606381	chr6:8435919	SLC35B3	0.77	10.87	0.58	1.55e-22	Motion sickness;
SARC	cis	rs3962382	1	rs3962382	chr1:68165693	A/C	cg10018272	chr1:67519814	SLC35D1	0.45	4.77	0.3	3.21e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs56077333	1	rs56077333	chr15:78899003	C/A	cg18825076	chr15:78729989	IREB2	-0.43	-4.99	-0.31	1.16e-6	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs7582720	1.000	rs1541853	chr2:203835177	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs9894429	0.646	rs6565609	chr17:79592267	G/A	cg10661904	chr17:79619235	PDE6G	-0.46	-6.42	-0.39	7.61e-10	Eye color traits;
SARC	cis	rs4073582	0.595	rs801736	chr11:65928430	A/T	cg14036092	chr11:66035641	RAB1B	0.6	8.44	0.48	3.49e-15	Gout;
SARC	cis	rs11098499	0.863	rs7678400	chr4:120461957	G/A	cg24375607	chr4:120327624	NA	0.42	4.94	0.31	1.52e-6	Corneal astigmatism;
SARC	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg20607798	chr8:58055168	NA	0.58	5.57	0.34	6.9e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1215050	0.782	rs6853916	chr4:98653387	C/T	cg05340658	chr4:99064831	C4orf37	-0.43	-5.67	-0.35	4.27e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	trans	rs629535	0.814	rs549643	chr8:70062884	C/T	cg21567404	chr3:27674614	NA	1.04	13.17	0.65	5.78e-30	Dupuytren's disease;
SARC	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg01181863	chr3:195395398	SDHAP2	-0.57	-6.4	-0.39	8.24e-10	Pancreatic cancer;
SARC	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg09359103	chr1:154839909	KCNN3	-0.45	-7.71	-0.45	3.66e-13	Prostate cancer;
SARC	cis	rs6669008	1.000	rs6669008	chr1:114166561	A/G	cg13572289	chr1:114447746	DCLRE1B;AP4B1	-0.44	-5.15	-0.32	5.5e-7	Bacteremia;
SARC	cis	rs8058578	1.000	rs13338946	chr16:30700858	T/C	cg00531865	chr16:30841666	NA	-0.49	-5.55	-0.34	7.7e-8	Multiple myeloma;
SARC	cis	rs9303401	0.614	rs34843288	chr17:57103140	T/C	cg25039879	chr17:56429692	SUPT4H1	0.68	5.82	0.36	1.9e-8	Cognitive test performance;
SARC	cis	rs11190604	1.000	rs2489034	chr10:102319192	C/T	cg07080220	chr10:102295463	HIF1AN	0.83	8.75	0.5	4.33e-16	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs6988636	1.000	rs4377946	chr8:124185887	T/C	cg23067535	chr8:124195133	FAM83A	-0.64	-5.3	-0.33	2.72e-7	Urinary uromodulin levels;
SARC	cis	rs3784262	0.967	rs12148907	chr15:58296450	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.39	-5.88	-0.36	1.44e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs2153535	0.580	rs6921964	chr6:8446395	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.1	0.59	2.96e-23	Motion sickness;
SARC	cis	rs713587	0.525	rs11675457	chr2:25079770	C/T	cg04586622	chr2:25135609	ADCY3	0.32	5.4	0.33	1.64e-7	Body mass index in non-asthmatics;
SARC	cis	rs2075371	0.611	rs12531769	chr7:134016899	C/G	cg11752832	chr7:134001865	SLC35B4	0.51	6.35	0.38	1.12e-9	Mean platelet volume;
SARC	cis	rs561341	0.505	rs28708703	chr17:30386845	C/G	cg13647721	chr17:30228624	UTP6	0.56	4.79	0.3	3e-6	Hip circumference adjusted for BMI;
SARC	cis	rs1185460	0.967	rs1307145	chr11:118950217	C/G	cg01677386	chr11:118938358	VPS11	-0.4	-4.78	-0.3	3.14e-6	Coronary artery disease;
SARC	cis	rs10911251	0.546	rs20560	chr1:183105534	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.21	0.56	1.79e-20	Colorectal cancer;
SARC	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg08859206	chr1:53392774	SCP2	0.39	5.68	0.35	3.99e-8	Monocyte count;
SARC	cis	rs1707322	0.827	rs12125508	chr1:46246010	A/G	cg06784218	chr1:46089804	CCDC17	0.35	6.31	0.38	1.4e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6570726	0.643	rs9403735	chr6:145936591	C/T	cg05347473	chr6:146136440	FBXO30	0.54	7.4	0.44	2.52e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1475911	0.708	rs11701371	chr21:43523972	C/G	cg19766460	chr21:43528205	UMODL1;C21orf128	0.6	7.41	0.44	2.27e-12	IgG glycosylation;
SARC	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.9	14.55	0.69	1.51e-34	Chronic sinus infection;
SARC	cis	rs1712790	0.729	rs10891742	chr11:114611756	C/G	cg01161204	chr11:115530932	NA	-0.33	-4.91	-0.31	1.75e-6	Urinary albumin excretion;
SARC	cis	rs4727027	0.933	rs10277119	chr7:148849942	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.47	5.74	0.35	3e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg18357526	chr6:26021779	HIST1H4A	-0.49	-5.72	-0.35	3.25e-8	Blood metabolite levels;
SARC	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg12463550	chr7:65579703	CRCP	0.66	5.05	0.31	9.09e-7	Diabetic kidney disease;
SARC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg11301795	chr4:187892539	NA	-0.7	-10.09	-0.55	4.21e-20	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg18876405	chr7:65276391	NA	0.45	5.36	0.33	2.02e-7	Aortic root size;
SARC	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg15537850	chr8:144661051	NAPRT1	-0.45	-4.82	-0.3	2.56e-6	Attention deficit hyperactivity disorder;
SARC	cis	rs13095912	1.000	rs4686666	chr3:185342847	T/C	cg11274856	chr3:185301563	NA	0.35	4.84	0.3	2.34e-6	Systolic blood pressure;
SARC	cis	rs2243123	0.602	rs11927521	chr3:159717085	A/G	cg20712415	chr3:159570903	SCHIP1	0.34	5.25	0.33	3.44e-7	Multiple sclerosis;
SARC	cis	rs2694528	0.686	rs7723165	chr5:59876715	A/G	cg11474532	chr5:59995715	DEPDC1B	0.94	6.5	0.39	4.76e-10	Parkinson's disease;
SARC	cis	rs796364	1.000	rs11895190	chr2:200838613	A/G	cg23649088	chr2:200775458	C2orf69	-0.54	-5.09	-0.32	7.44e-7	Schizophrenia;
SARC	cis	rs870825	0.616	rs6844146	chr4:185636396	G/A	cg04058563	chr4:185651563	MLF1IP	0.84	11.36	0.6	4.49e-24	Blood protein levels;
SARC	cis	rs9549260	0.753	rs9549246	chr13:41220755	G/A	cg21288729	chr13:41239152	FOXO1	0.65	6.25	0.38	1.9e-9	Red blood cell count;
SARC	trans	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-7.17	-0.43	1e-11	Intelligence (multi-trait analysis);
SARC	cis	rs7560272	0.501	rs11126417	chr2:73974315	A/G	cg20560298	chr2:73613845	ALMS1	-0.48	-6.42	-0.39	7.7e-10	Schizophrenia;
SARC	cis	rs1008375	0.932	rs6814465	chr4:17659034	C/T	cg16339924	chr4:17578868	LAP3	0.65	8.51	0.49	2.12e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6121246	0.609	rs4453755	chr20:30331047	G/A	cg13852791	chr20:30311386	BCL2L1	0.81	9.97	0.55	9.89e-20	Mean corpuscular hemoglobin;
SARC	trans	rs2637266	1.000	rs2637266	chr10:78331318	C/T	cg01390082	chr15:85365662	ALPK3	0.42	6.24	0.38	2.1e-9	Pulmonary function;
SARC	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg22903657	chr4:1355424	KIAA1530	-0.43	-6.04	-0.37	6.08e-9	Obesity-related traits;
SARC	trans	rs10506458	0.915	rs12424908	chr12:63402364	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.72	-6.38	-0.39	9.58e-10	Hemostatic factors and hematological phenotypes;
SARC	cis	rs459571	0.959	rs2810491	chr9:136923331	C/T	cg13789015	chr9:136890014	NCRNA00094	-0.61	-8.33	-0.48	7.12e-15	Platelet distribution width;
SARC	cis	rs2916247	0.865	rs2920467	chr8:93001261	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.57	-5.83	-0.36	1.86e-8	Intelligence (multi-trait analysis);
SARC	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg20007245	chr22:24372913	LOC391322	0.67	7.43	0.44	1.99e-12	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs12497850	0.931	rs7616815	chr3:48779715	C/T	cg06212747	chr3:49208901	KLHDC8B	0.64	8.47	0.49	2.84e-15	Parkinson's disease;
SARC	cis	rs4253772	0.591	rs8135363	chr22:46651713	T/C	cg24881330	chr22:46731750	TRMU	0.62	6.72	0.4	1.41e-10	LDL cholesterol;Cholesterol, total;
SARC	cis	rs17209837	1.000	rs4148815	chr7:87087834	A/T	cg00919237	chr7:87102261	ABCB4	-0.5	-5.47	-0.34	1.14e-7	Gallbladder cancer;
SARC	cis	rs72717009	0.825	rs7539468	chr1:161477066	G/A	cg23840854	chr1:161414152	NA	-0.54	-5.07	-0.32	8.2e-7	Rheumatoid arthritis;
SARC	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1008375	1.000	rs1121091	chr4:17676386	A/C	cg16339924	chr4:17578868	LAP3	0.64	8.39	0.48	4.6e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs11235843	0.636	rs10736793	chr11:73402576	A/C	cg18195628	chr11:73498948	MRPL48	-0.56	-5.68	-0.35	4e-8	Hand grip strength;
SARC	cis	rs372883	0.901	rs13048365	chr21:30740394	T/C	cg24692254	chr21:30365293	RNF160	0.41	5.0	0.31	1.14e-6	Pancreatic cancer;
SARC	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg06212747	chr3:49208901	KLHDC8B	0.65	8.64	0.49	9.19e-16	Parkinson's disease;
SARC	cis	rs2180341	0.960	rs3756996	chr6:127664258	G/C	cg27446573	chr6:127587934	RNF146	1.03	14.64	0.69	7.75e-35	Breast cancer;
SARC	cis	rs761746	0.960	rs5998042	chr22:31953962	T/C	cg15162869	chr22:32027605	PISD	-0.34	-4.77	-0.3	3.25e-6	Intelligence;
SARC	trans	rs7819412	0.521	rs10100660	chr8:11038885	T/A	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.43	-0.39	7.31e-10	Triglycerides;
SARC	cis	rs6582630	0.519	rs12366667	chr12:38332632	C/T	cg26384229	chr12:38710491	ALG10B	0.85	12.21	0.62	7.84e-27	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg16049864	chr8:95962084	TP53INP1	-0.49	-8.21	-0.47	1.53e-14	Type 2 diabetes;
SARC	cis	rs854765	0.647	rs721669	chr17:18005073	A/G	cg05444541	chr17:17804740	TOM1L2	-0.32	-5.2	-0.32	4.35e-7	Total body bone mineral density;
SARC	cis	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg12923728	chr3:195709715	SDHAP1	0.41	4.99	0.31	1.17e-6	Bronchopulmonary dysplasia;
SARC	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg05872129	chr22:39784769	NA	-0.43	-6.01	-0.37	6.93e-9	Intelligence (multi-trait analysis);
SARC	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg06618935	chr21:46677482	NA	-0.41	-5.31	-0.33	2.56e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.8	10.35	0.56	6.69e-21	Prudent dietary pattern;
SARC	cis	rs3820928	0.904	rs2396432	chr2:227765891	C/T	cg11843606	chr2:227700838	RHBDD1	-0.56	-6.88	-0.41	5.4e-11	Pulmonary function;
SARC	cis	rs2213920	0.516	rs71505546	chr9:118158372	G/A	cg13918206	chr9:118159781	DEC1	-0.85	-7.08	-0.42	1.7e-11	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs8141529	0.702	rs469990	chr22:29304200	A/T	cg02153584	chr22:29168773	CCDC117	0.76	10.91	0.58	1.2e-22	Lymphocyte counts;
SARC	cis	rs3820928	0.874	rs4675128	chr2:227814757	T/C	cg11843606	chr2:227700838	RHBDD1	-0.57	-7.27	-0.43	5.32e-12	Pulmonary function;
SARC	cis	rs11676855	0.924	rs11680626	chr2:235927511	A/T	cg14917874	chr2:235941519	SH3BP4	-0.38	-4.79	-0.3	2.94e-6	Dialysis-related mortality;
SARC	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-9.68	-0.54	7.76e-19	Chronic sinus infection;
SARC	cis	rs9650657	0.547	rs11250099	chr8:10818657	C/T	cg00262122	chr8:11665843	FDFT1	0.45	5.65	0.35	4.67e-8	Neuroticism;
SARC	cis	rs10870270	0.956	rs10870293	chr10:133771413	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.47	-5.36	-0.33	1.96e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs710216	0.912	rs11537640	chr1:43424519	T/G	cg07803811	chr1:43423981	SLC2A1	0.54	5.4	0.33	1.67e-7	Red cell distribution width;
SARC	cis	rs11719291	0.833	rs13074318	chr3:48816725	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.64	-5.45	-0.34	1.28e-7	Cognitive function;
SARC	cis	rs9916302	0.904	rs9892055	chr17:37510402	C/T	cg15445000	chr17:37608096	MED1	-0.45	-5.48	-0.34	1.1e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs9818758	0.545	rs11717978	chr3:48969036	T/A	cg07636037	chr3:49044803	WDR6	-0.74	-6.49	-0.39	5.12e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs829883	1.000	rs2908843	chr12:98889332	C/G	cg25150519	chr12:98850993	NA	-0.71	-9.62	-0.53	1.18e-18	Colorectal adenoma (advanced);
SARC	cis	rs7511006	0.893	rs5771104	chr22:50651839	C/T	cg08875078	chr22:50639485	SELO	0.44	5.19	0.32	4.56e-7	Obesity-related traits;
SARC	trans	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.55	-7.09	-0.42	1.63e-11	Intelligence (multi-trait analysis);
SARC	cis	rs748404	0.697	rs572959	chr15:43550502	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	6.69	0.4	1.61e-10	Lung cancer;
SARC	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	8.97	0.51	1.03e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.43	-0.44	2.07e-12	Gut microbiome composition (summer);
SARC	cis	rs7772486	0.558	rs62435775	chr6:146136415	G/C	cg05347473	chr6:146136440	FBXO30	0.73	10.27	0.56	1.21e-20	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs72781680	0.611	rs72783636	chr2:24328706	C/T	cg08917208	chr2:24149416	ATAD2B	0.59	6.2	0.38	2.53e-9	Lymphocyte counts;
SARC	trans	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg00938859	chr5:1591904	SDHAP3	0.79	7.66	0.45	5.1e-13	Breast cancer;
SARC	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg12463550	chr7:65579703	CRCP	0.53	5.63	0.35	5.14e-8	Aortic root size;
SARC	cis	rs6062509	1.000	rs6062509	chr20:62362563	G/T	cg27236539	chr20:62289627	RTEL1	0.52	5.72	0.35	3.32e-8	Prostate cancer;
SARC	cis	rs9326248	0.768	rs4936366	chr11:117026885	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.59	5.91	0.36	1.18e-8	Blood protein levels;
SARC	cis	rs2153535	0.580	rs2327060	chr6:8447111	G/A	cg07606381	chr6:8435919	SLC35B3	0.78	11.06	0.59	4.04e-23	Motion sickness;
SARC	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.94	10.19	0.56	2.09e-20	Platelet count;
SARC	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg11062466	chr8:58055876	NA	0.56	5.67	0.35	4.19e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7681440	0.904	rs2301135	chr4:90758389	G/C	cg02192967	chr4:90758406	SNCA	0.36	5.12	0.32	6.28e-7	Dementia with Lewy bodies;
SARC	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg19077165	chr18:44547161	KATNAL2	-0.55	-7.6	-0.45	7.25e-13	Personality dimensions;
SARC	cis	rs7178572	1.000	rs7178572	chr15:77747190	A/G	cg22256960	chr15:77711686	NA	-0.57	-6.71	-0.4	1.51e-10	Type 2 diabetes;
SARC	cis	rs6500602	0.702	rs6500606	chr16:4502514	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.39	-6.59	-0.4	2.91e-10	Schizophrenia;
SARC	cis	rs9788682	0.895	rs3813570	chr15:78832832	T/C	cg06917634	chr15:78832804	PSMA4	-0.59	-6.56	-0.39	3.51e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs11098499	0.754	rs4443261	chr4:120249301	T/C	cg09307838	chr4:120376055	NA	0.82	11.14	0.59	2.19e-23	Corneal astigmatism;
SARC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg01238044	chr22:24384105	GSTT1	0.71	9.05	0.51	5.83e-17	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7520050	0.966	rs1707304	chr1:46598269	C/A	cg24296786	chr1:45957014	TESK2	0.39	4.94	0.31	1.51e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs372883	0.506	rs2832300	chr21:30749315	A/G	cg24692254	chr21:30365293	RNF160	0.55	6.91	0.41	4.66e-11	Pancreatic cancer;
SARC	cis	rs10464366	0.746	rs12674262	chr7:39141728	G/T	cg15212455	chr7:39170539	POU6F2	0.45	5.28	0.33	3.02e-7	IgG glycosylation;
SARC	cis	rs9326248	1.000	rs7946257	chr11:117053165	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.5	5.42	0.33	1.5e-7	Blood protein levels;
SARC	cis	rs11249608	0.548	rs7732719	chr5:178463054	A/G	cg01312482	chr5:178451176	ZNF879	-0.37	-4.74	-0.3	3.69e-6	Pubertal anthropometrics;
SARC	cis	rs617791	0.530	rs735942	chr11:65749337	A/G	cg09783858	chr11:65769428	EIF1AD;BANF1	0.59	7.23	0.43	6.7e-12	Breast cancer;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg03758674	chr11:644361	DEAF1	0.47	6.26	0.38	1.8e-9	Blood pressure;
SARC	cis	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg18252515	chr7:66147081	NA	-1.38	-12.57	-0.64	5.19e-28	Diabetic kidney disease;
SARC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.44	0.53	4.06e-18	Prudent dietary pattern;
SARC	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.8	0.36	2.11e-8	Electroencephalogram traits;
SARC	cis	rs7666738	0.716	rs13136721	chr4:99085602	G/A	cg05340658	chr4:99064831	C4orf37	0.57	7.28	0.43	5.16e-12	Colonoscopy-negative controls vs population controls;
SARC	trans	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg06437703	chr8:37914619	EIF4EBP1	-0.73	-10.29	-0.56	1.03e-20	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs858239	0.509	rs6962213	chr7:23188109	G/A	cg23682824	chr7:23144976	KLHL7	0.7	8.89	0.5	1.68e-16	Cerebrospinal fluid biomarker levels;
SARC	cis	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg00409905	chr10:38381863	ZNF37A	-0.52	-7.1	-0.42	1.52e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs473651	0.935	rs477041	chr2:239355995	C/G	cg18131467	chr2:239335373	ASB1	-1.0	-16.98	-0.74	1.28e-42	Multiple system atrophy;
SARC	cis	rs9486719	0.857	rs13208321	chr6:96860354	C/T	cg06623918	chr6:96969491	KIAA0776	-0.64	-7.43	-0.44	2.07e-12	Migraine;Coronary artery disease;
SARC	cis	rs10791323	0.538	rs1105494	chr11:133698733	A/C	cg14349672	chr11:133703707	NA	0.41	5.55	0.34	7.61e-8	Childhood ear infection;
SARC	cis	rs763121	0.853	rs35565791	chr22:39063011	C/A	cg14440974	chr22:39074834	NA	-0.35	-5.11	-0.32	6.58e-7	Menopause (age at onset);
SARC	cis	rs6570726	0.846	rs409553	chr6:145886963	C/T	cg23711669	chr6:146136114	FBXO30	0.8	12.67	0.64	2.5e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3008870	1.000	rs12117131	chr1:67451922	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.89	-11.03	-0.59	4.76e-23	Lymphocyte percentage of white cells;
SARC	cis	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg03060546	chr3:49711283	APEH	0.74	10.67	0.57	6.93e-22	Resting heart rate;
SARC	cis	rs6674176	0.597	rs9326136	chr1:44390392	A/G	cg13606994	chr1:44402422	ARTN	0.32	5.2	0.32	4.3e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs9902453	0.817	rs59420007	chr17:28196114	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	7.5	0.44	1.37e-12	Coffee consumption (cups per day);
SARC	cis	rs11077998	0.967	rs7502945	chr17:80495039	T/C	cg10255544	chr17:80519551	FOXK2	0.45	6.52	0.39	4.25e-10	Reticulocyte fraction of red cells;
SARC	cis	rs1003719	0.715	rs4261789	chr21:38503762	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-8.87	-0.5	1.95e-16	Eye color traits;
SARC	cis	rs4819052	0.679	rs2838860	chr21:46684904	A/G	cg06618935	chr21:46677482	NA	-0.37	-4.99	-0.31	1.17e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9911578	1.000	rs368186	chr17:56736659	A/G	cg05425664	chr17:57184151	TRIM37	-0.66	-8.22	-0.47	1.44e-14	Intelligence (multi-trait analysis);
SARC	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg16680214	chr1:154839983	KCNN3	-0.36	-5.69	-0.35	3.7e-8	Prostate cancer;
SARC	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg06212747	chr3:49208901	KLHDC8B	0.7	9.53	0.53	2.23e-18	Parkinson's disease;
SARC	cis	rs2387326	1.000	rs945221	chr10:129932954	C/T	cg16087940	chr10:129947807	NA	-0.43	-5.7	-0.35	3.63e-8	Select biomarker traits;
SARC	cis	rs1348850	0.526	rs4144278	chr2:178412378	C/T	cg23306229	chr2:178417860	TTC30B	0.84	7.79	0.45	2.24e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs4664308	1.000	rs4664308	chr2:160917497	A/G	cg03641300	chr2:160917029	PLA2R1	-0.67	-9.03	-0.51	6.88e-17	Idiopathic membranous nephropathy;
SARC	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg17330251	chr7:94953956	PON1	0.44	6.3	0.38	1.47e-9	Paraoxonase activity;
SARC	cis	rs7870753	0.838	rs1590971	chr9:99246217	C/T	cg25260653	chr9:99212216	HABP4	0.51	4.77	0.3	3.21e-6	Height;
SARC	cis	rs6426558	0.572	rs2670471	chr1:227454328	T/C	cg10327440	chr1:227177885	CDC42BPA	0.44	5.11	0.32	6.72e-7	Neutrophil percentage of white cells;
SARC	cis	rs10870270	0.956	rs11146425	chr10:133734261	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.45	-5.33	-0.33	2.27e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg02951883	chr7:2050386	MAD1L1	0.49	6.51	0.39	4.64e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs1018836	0.923	rs13262354	chr8:91635731	G/A	cg16814680	chr8:91681699	NA	-0.83	-13.63	-0.67	1.65e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs1707322	1.000	rs4641257	chr1:46353589	G/A	cg03146154	chr1:46216737	IPP	0.47	5.69	0.35	3.76e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs8072100	0.840	rs56952963	chr17:45493826	T/C	cg08085267	chr17:45401833	C17orf57	-0.41	-4.88	-0.3	2.01e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg11890956	chr21:40555474	PSMG1	-1.04	-15.98	-0.72	2.56e-39	Cognitive function;
SARC	cis	rs8072100	0.582	rs3826536	chr17:45501967	T/A	cg08085267	chr17:45401833	C17orf57	-0.42	-4.94	-0.31	1.49e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg24580076	chr7:915073	C7orf20	0.38	5.23	0.32	3.77e-7	Subjective well-being;
SARC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg10295955	chr4:187884368	NA	-1.09	-21.04	-0.81	8.81e-56	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10979	0.597	rs9403516	chr6:143908139	A/T	cg25407410	chr6:143891975	LOC285740	0.53	5.85	0.36	1.66e-8	Hypospadias;
SARC	cis	rs911555	0.755	rs4143998	chr14:103955247	T/C	cg12935359	chr14:103987150	CKB	-0.37	-5.18	-0.32	4.91e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6714710	0.603	rs1470483	chr2:98393894	C/T	cg26665480	chr2:98280029	ACTR1B	0.54	7.2	0.43	8.21e-12	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg05793240	chr7:2802953	GNA12	-0.36	-5.21	-0.32	4.19e-7	Height;
SARC	cis	rs2645694	0.626	rs2703143	chr4:77830441	A/G	cg18351406	chr4:77819688	ANKRD56	0.37	5.14	0.32	5.77e-7	Emphysema distribution in smoking;
SARC	cis	rs3011225	0.710	rs3011222	chr1:44317545	C/T	cg12908607	chr1:44402522	ARTN	-0.33	-5.83	-0.36	1.88e-8	Amyotrophic lateral sclerosis (age of onset);
SARC	cis	rs6665290	0.594	rs17592479	chr1:227173892	T/A	cg10327440	chr1:227177885	CDC42BPA	-1.0	-19.72	-0.79	1.38e-51	Myeloid white cell count;
SARC	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.87	-13.4	-0.66	9.66e-31	Chronic sinus infection;
SARC	cis	rs986417	0.818	rs761557	chr14:61077484	C/T	cg27398547	chr14:60952738	C14orf39	-0.55	-5.11	-0.32	6.59e-7	Gut microbiota (bacterial taxa);
SARC	cis	rs9902453	0.904	rs7219456	chr17:28374112	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.16	-0.42	1.02e-11	Coffee consumption (cups per day);
SARC	cis	rs2635047	0.656	rs1355594	chr18:44763994	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	6.46	0.39	5.95e-10	Educational attainment;
SARC	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.97e-8	Aortic root size;
SARC	cis	rs7264396	0.790	rs6121026	chr20:34266883	A/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	5.78	0.35	2.33e-8	Total cholesterol levels;
SARC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg20102877	chr2:27665638	KRTCAP3	-0.37	-5.25	-0.33	3.44e-7	Total body bone mineral density;
SARC	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.4	-4.82	-0.3	2.6e-6	Longevity;Endometriosis;
SARC	cis	rs8114671	0.836	rs6142294	chr20:33671497	A/G	cg24642439	chr20:33292090	TP53INP2	-0.53	-6.11	-0.37	4.17e-9	Height;
SARC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg16145915	chr7:1198662	ZFAND2A	-0.39	-5.67	-0.35	4.27e-8	Longevity;Endometriosis;
SARC	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg01316550	chr5:56110833	MAP3K1	0.53	4.8	0.3	2.86e-6	Initial pursuit acceleration;
SARC	cis	rs9788682	0.747	rs12910984	chr15:78891627	G/A	cg06917634	chr15:78832804	PSMA4	0.46	5.13	0.32	6.22e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg05623727	chr3:50126028	RBM5	0.34	5.08	0.32	7.68e-7	Intelligence (multi-trait analysis);
SARC	cis	rs78487399	0.808	rs12104615	chr2:43676938	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-5.01	-0.31	1.08e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg11764359	chr7:65958608	NA	0.56	6.55	0.39	3.64e-10	Calcium levels;
SARC	cis	rs2120243	0.508	rs1965246	chr3:157111586	G/A	cg24825693	chr3:157122686	VEPH1	-0.46	-6.4	-0.39	8.25e-10	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs10463316	0.817	rs11167545	chr5:150778076	C/T	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.31	-0.33	2.59e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs9487051	0.872	rs9480922	chr6:109607211	G/A	cg01475377	chr6:109611718	NA	-0.42	-5.97	-0.36	9e-9	Reticulocyte fraction of red cells;
SARC	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg16325326	chr1:53192061	ZYG11B	0.78	12.14	0.62	1.29e-26	Monocyte count;
SARC	cis	rs11155671	0.530	rs7742993	chr6:150205095	G/A	cg05036130	chr6:150231994	NA	0.3	5.17	0.32	5.04e-7	Testicular germ cell tumor;
SARC	cis	rs79149102	0.649	rs75985113	chr15:75379312	C/T	cg17294928	chr15:75287854	SCAMP5	-0.96	-8.08	-0.47	3.47e-14	Lung cancer;
SARC	cis	rs7113850	0.541	rs77699762	chr11:24236448	C/T	ch.11.24196551F	chr11:24239977	NA	0.74	5.53	0.34	8.37e-8	Bone fracture in osteoporosis;
SARC	cis	rs11792861	0.926	rs11787878	chr9:111866749	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.69	7.9	0.46	1.08e-13	Menarche (age at onset);
SARC	cis	rs2288073	0.965	rs36101491	chr2:24387532	C/T	cg26838691	chr2:24397539	C2orf84	-0.59	-7.26	-0.43	5.78e-12	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs2251381	0.750	rs2776250	chr21:30528094	T/G	cg24692254	chr21:30365293	RNF160	0.87	12.54	0.63	6.61e-28	Selective IgA deficiency;
SARC	trans	rs7824557	0.603	rs2246606	chr8:11219334	G/A	cg06636001	chr8:8085503	FLJ10661	0.63	8.12	0.47	2.74e-14	Retinal vascular caliber;
SARC	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg22433210	chr17:43662623	NA	-0.66	-7.55	-0.44	9.85e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs6545883	0.929	rs2121660	chr2:61653058	T/C	cg15711740	chr2:61764176	XPO1	0.42	5.09	0.32	7.27e-7	Tuberculosis;
SARC	cis	rs8031584	0.918	rs34331396	chr15:31248736	C/G	cg08109568	chr15:31115862	NA	-0.48	-5.77	-0.35	2.53e-8	Huntington's disease progression;
SARC	cis	rs72634258	0.554	rs17374292	chr1:7881234	C/T	cg05338066	chr1:7812865	CAMTA1	0.64	5.57	0.34	7.17e-8	Inflammatory bowel disease;
SARC	cis	rs7824557	0.591	rs2736283	chr8:11225910	A/G	cg21775007	chr8:11205619	TDH	-0.7	-9.53	-0.53	2.21e-18	Retinal vascular caliber;
SARC	cis	rs67311347	1.000	rs67680017	chr3:40533164	C/T	cg01475735	chr3:40494733	NA	-0.44	-5.11	-0.32	6.77e-7	Renal cell carcinoma;
SARC	cis	rs2075371	1.000	rs2504	chr7:133979545	A/T	cg11752832	chr7:134001865	SLC35B4	0.56	7.39	0.44	2.64e-12	Mean platelet volume;
SARC	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.9	-0.5	1.61e-16	Alzheimer's disease;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg04921814	chr1:145575587	PIAS3	-0.62	-7.02	-0.42	2.45e-11	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg18876405	chr7:65276391	NA	-0.74	-9.42	-0.53	4.63e-18	Aortic root size;
SARC	cis	rs6500602	0.929	rs6500603	chr16:4497537	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.37	6.11	0.37	4.2e-9	Schizophrenia;
SARC	cis	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg12463550	chr7:65579703	CRCP	-0.68	-5.09	-0.32	7.53e-7	Gout;
SARC	cis	rs6598955	0.724	rs884533	chr1:26585657	G/T	cg04990556	chr1:26633338	UBXN11	-0.59	-8.27	-0.48	1.06e-14	Obesity-related traits;
SARC	cis	rs35661897	0.920	rs62190939	chr2:227336387	C/T	cg03426602	chr2:227312417	NA	-0.53	-5.02	-0.31	1.03e-6	Urinary tract infection frequency;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24501027	chr1:92764777	RPAP2;GLMN	-0.51	-6.27	-0.38	1.74e-9	Smoking initiation;
SARC	cis	rs793571	0.774	rs4775096	chr15:59140329	A/G	cg05156742	chr15:59063176	FAM63B	0.54	5.56	0.34	7.31e-8	Schizophrenia;
SARC	cis	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg05623727	chr3:50126028	RBM5	-0.33	-5.02	-0.31	1.03e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9902453	0.619	rs2617866	chr17:28076217	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.26	-0.43	5.67e-12	Coffee consumption (cups per day);
SARC	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg12751644	chr20:60527061	NA	-0.48	-6.27	-0.38	1.69e-9	Obesity-related traits;
SARC	cis	rs9818758	0.607	rs71324929	chr3:49044713	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.72	-5.91	-0.36	1.18e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs9381040	0.610	rs742495	chr6:41018233	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.41	-4.8	-0.3	2.9e-6	Alzheimer's disease (late onset);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg08289323	chr8:62588462	ASPH	0.41	6.28	0.38	1.69e-9	Thyroid stimulating hormone;
SARC	cis	rs1062177	1.000	rs2964578	chr5:151147198	T/A	cg00977110	chr5:151150581	G3BP1	0.62	6.11	0.37	4.05e-9	Preschool internalizing problems;
SARC	cis	rs13256369	1.000	rs12545771	chr8:8567977	C/G	cg17143192	chr8:8559678	CLDN23	0.52	6.0	0.37	7.31e-9	Obesity-related traits;
SARC	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg11764359	chr7:65958608	NA	-0.79	-9.75	-0.54	4.53e-19	Aortic root size;
SARC	cis	rs910316	0.935	rs175448	chr14:75591071	G/A	cg08847533	chr14:75593920	NEK9	-0.86	-13.54	-0.66	3.39e-31	Height;
SARC	cis	rs3749237	0.595	rs1464567	chr3:49459252	C/G	cg03060546	chr3:49711283	APEH	-0.73	-9.87	-0.54	1.99e-19	Resting heart rate;
SARC	trans	rs11039798	0.588	rs12278284	chr11:48612063	G/C	cg15704280	chr7:45808275	SEPT13	0.63	6.81	0.41	8.1e-11	Axial length;
SARC	cis	rs2075371	0.965	rs2544216	chr7:133987902	G/A	cg11752832	chr7:134001865	SLC35B4	0.57	7.43	0.44	1.99e-12	Mean platelet volume;
SARC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg27588902	chr6:42928151	GNMT	-0.38	-6.12	-0.37	3.89e-9	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs9325144	0.560	rs1601745	chr12:38647828	G/A	cg26384229	chr12:38710491	ALG10B	-0.66	-8.84	-0.5	2.39e-16	Morning vs. evening chronotype;
SARC	cis	rs10267417	0.544	rs2072185	chr7:19748700	G/A	cg07541023	chr7:19748670	TWISTNB	0.93	10.06	0.55	5.15e-20	Night sleep phenotypes;
SARC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.34	-4.95	-0.31	1.44e-6	Longevity;Endometriosis;
SARC	cis	rs2658782	0.789	rs3020073	chr11:93103830	T/C	cg15737290	chr11:93063684	CCDC67	0.72	7.69	0.45	4.21e-13	Pulmonary function decline;
SARC	cis	rs1073160	1.000	rs1073160	chr12:9058562	A/G	cg26114124	chr12:9217669	LOC144571	-0.22	-4.81	-0.3	2.76e-6	Small cell lung carcinoma;
SARC	cis	rs8078723	1.000	rs4795415	chr17:38157995	C/T	cg17467752	chr17:38218738	THRA	0.46	5.89	0.36	1.31e-8	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs2859741	0.546	rs3845491	chr1:37497521	C/T	cg09363841	chr1:37513479	NA	-0.31	-5.37	-0.33	1.92e-7	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
SARC	cis	rs6542838	0.703	rs7593332	chr2:99467991	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.39	-4.87	-0.3	2.02e-6	Fear of minor pain;
SARC	cis	rs4443100	0.670	rs13054331	chr22:23407063	G/A	cg14186256	chr22:23484241	RTDR1	0.58	5.87	0.36	1.5e-8	Serum parathyroid hormone levels;
SARC	cis	rs10463554	0.963	rs34828	chr5:102442913	C/A	cg23492399	chr5:102201601	PAM	-0.5	-5.54	-0.34	8.2e-8	Parkinson's disease;
SARC	cis	rs7647973	1.000	rs74471041	chr3:49542543	T/G	cg07636037	chr3:49044803	WDR6	-0.76	-8.65	-0.49	8.36e-16	Menarche (age at onset);
SARC	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg22484793	chr3:52261325	TLR9	0.29	4.8	0.3	2.81e-6	Bipolar disorder;
SARC	cis	rs6088580	0.524	rs6088568	chr20:33265971	A/C	cg08999081	chr20:33150536	PIGU	-0.34	-4.99	-0.31	1.17e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg06221963	chr1:154839813	KCNN3	-0.47	-7.17	-0.42	1.01e-11	Prostate cancer;
SARC	cis	rs7582180	0.652	rs4851311	chr2:100980398	C/T	cg14675211	chr2:100938903	LONRF2	0.53	7.85	0.46	1.47e-13	Intelligence (multi-trait analysis);
SARC	cis	rs35110281	0.782	rs1584917	chr21:45042365	A/G	cg21573476	chr21:45109991	RRP1B	-0.54	-7.97	-0.46	6.95e-14	Mean corpuscular volume;
SARC	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg11878867	chr6:150167359	LRP11	-0.35	-4.82	-0.3	2.62e-6	Lung cancer;
SARC	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg10523679	chr1:76189770	ACADM	0.52	6.8	0.41	8.76e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs916888	0.610	rs199446	chr17:44813169	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.57	-6.62	-0.4	2.51e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs2295359	0.892	rs2064689	chr1:67653010	G/A	cg08029281	chr1:67600428	NA	0.37	4.77	0.3	3.25e-6	Psoriasis;
SARC	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.0	15.41	0.71	2e-37	Height;
SARC	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg06028808	chr11:68637592	NA	-0.45	-5.72	-0.35	3.3e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.67	6.46	0.39	5.98e-10	Platelet count;
SARC	cis	rs2153535	0.580	rs9505454	chr6:8478532	T/G	cg23788917	chr6:8435910	SLC35B3	0.64	8.59	0.49	1.25e-15	Motion sickness;
SARC	cis	rs818427	0.964	rs495794	chr5:112201094	A/G	cg07820702	chr5:112228657	REEP5	0.52	5.88	0.36	1.43e-8	Total body bone mineral density;
SARC	cis	rs1982346	0.579	rs2256746	chr4:106742263	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	-0.67	-4.82	-0.3	2.54e-6	Lung function (FEV1);
SARC	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-9.15	-0.51	2.85e-17	Alzheimer's disease;
SARC	cis	rs9911578	0.967	rs1267542	chr17:56654690	T/C	cg12560992	chr17:57184187	TRIM37	-0.82	-11.2	-0.59	1.36e-23	Intelligence (multi-trait analysis);
SARC	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-8.89	-0.5	1.75e-16	Alzheimer's disease;
SARC	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.97e-8	Aortic root size;
SARC	cis	rs7772486	0.754	rs702319	chr6:146006117	T/C	cg23711669	chr6:146136114	FBXO30	-0.91	-16.12	-0.73	9.23e-40	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg08219700	chr8:58056026	NA	0.62	6.56	0.4	3.37e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs12142240	0.698	rs41294458	chr1:46810304	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-5.45	-0.34	1.28e-7	Menopause (age at onset);
SARC	cis	rs9747201	0.926	rs34153075	chr17:80135728	C/A	cg09264619	chr17:80180166	NA	0.5	5.92	0.36	1.14e-8	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs1538970	0.851	rs2055145	chr1:45926495	C/G	cg05343316	chr1:45956843	TESK2	0.76	8.54	0.49	1.8e-15	Platelet count;
SARC	cis	rs9324022	0.584	rs72698722	chr14:101181881	C/T	cg18089426	chr14:101175970	NA	0.56	6.17	0.37	3e-9	Plateletcrit;
SARC	cis	rs1578862	0.966	rs56124448	chr1:247484918	G/A	cg22704608	chr1:247479546	ZNF496	-0.33	-4.77	-0.3	3.31e-6	Monocyte percentage of white cells;
SARC	cis	rs12142240	0.698	rs6683192	chr1:46830257	C/T	cg14993813	chr1:46806288	NSUN4	-0.53	-5.62	-0.35	5.48e-8	Menopause (age at onset);
SARC	cis	rs7696431	0.933	rs6823685	chr4:169690820	C/A	cg07840446	chr4:169690674	PALLD	0.36	5.26	0.33	3.24e-7	Coronary artery disease;
SARC	cis	rs13161895	1.000	rs6873781	chr5:179436734	A/C	cg04265672	chr5:179402240	RNF130	0.52	5.15	0.32	5.48e-7	LDL cholesterol;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14916095	chr14:52118110	FRMD6	-0.51	-6.39	-0.39	8.73e-10	Smoking initiation;
SARC	cis	rs72781680	1.000	rs61739076	chr2:24149439	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	8.7	0.5	6.18e-16	Lymphocyte counts;
SARC	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg22535103	chr8:58192502	C8orf71	-0.69	-6.22	-0.38	2.25e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs5758511	0.633	rs5758689	chr22:42664972	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.45	6.69	0.4	1.63e-10	Birth weight;
SARC	cis	rs6570726	0.791	rs11155435	chr6:145938545	T/C	cg05347473	chr6:146136440	FBXO30	0.55	7.55	0.44	1.01e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7666738	0.830	rs4502686	chr4:98765117	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.54	0.49	1.74e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6546550	0.901	rs7573442	chr2:70154037	G/A	cg02498382	chr2:70120550	SNRNP27	-0.32	-5.24	-0.32	3.6e-7	Prevalent atrial fibrillation;
SARC	cis	rs13077101	0.893	rs4676827	chr3:120452898	C/T	cg24332942	chr3:120408071	RABL3	-0.43	-5.33	-0.33	2.3e-7	Obesity-related traits;
SARC	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg03264133	chr6:25882463	NA	0.52	6.79	0.41	9.37e-11	Blood metabolite levels;
SARC	cis	rs7843479	0.582	rs13439690	chr8:21778082	T/C	cg17168535	chr8:21777572	XPO7	0.89	13.61	0.67	1.95e-31	Mean corpuscular volume;
SARC	cis	rs7666738	0.830	rs28515641	chr4:98726419	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.54	0.49	1.74e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs11105298	0.891	rs10858869	chr12:89857611	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.49	-5.0	-0.31	1.11e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs10484885	0.824	rs72919982	chr6:90532600	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.6	-5.17	-0.32	5.02e-7	QRS interval (sulfonylurea treatment interaction);
SARC	cis	rs910316	0.763	rs175450	chr14:75590340	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.47	-6.34	-0.38	1.17e-9	Height;
SARC	cis	rs7208859	0.623	rs11657662	chr17:29076347	A/G	cg13385521	chr17:29058706	SUZ12P	-0.82	-7.07	-0.42	1.77e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs6691722	0.506	rs11587667	chr1:24715435	C/G	cg18323236	chr1:24743029	NIPAL3	0.37	5.09	0.32	7.36e-7	Response to interferon beta in multiple sclerosis;
SARC	cis	rs9457247	0.663	rs1894603	chr6:167434686	C/T	cg23791538	chr6:167370224	RNASET2	0.51	6.88	0.41	5.45e-11	Crohn's disease;
SARC	cis	rs651907	0.535	rs11716558	chr3:101528481	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	5.84	0.36	1.72e-8	Colorectal cancer;
SARC	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg14893161	chr1:205819251	PM20D1	-0.5	-5.58	-0.34	6.49e-8	White blood cell count (basophil);Basophil percentage of white cells;
SARC	trans	rs194045	0.609	rs252344	chr16:29184882	G/A	cg17334114	chr3:133646504	NA	0.59	6.7	0.4	1.51e-10	Yu-Zhi constitution type in type 2 diabetes;
SARC	cis	rs12554020	0.681	rs80062429	chr9:96371112	T/C	cg21184699	chr9:96277131	FAM120A	-0.5	-4.73	-0.3	3.97e-6	Schizophrenia;
SARC	cis	rs72781680	1.000	rs72796388	chr2:24171509	A/C	cg08917208	chr2:24149416	ATAD2B	0.79	7.54	0.44	1.05e-12	Lymphocyte counts;
SARC	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg27286337	chr10:134555280	INPP5A	0.71	8.17	0.47	2.02e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs7474896	0.583	rs1208770	chr10:38044683	C/T	cg25427524	chr10:38739819	LOC399744	-0.5	-6.07	-0.37	5.19e-9	Obesity (extreme);
SARC	cis	rs10782582	0.609	rs5745547	chr1:76378275	G/C	cg03433033	chr1:76189801	ACADM	-0.4	-5.12	-0.32	6.3e-7	Daytime sleep phenotypes;
SARC	cis	rs76917914	0.820	rs7846880	chr9:100822940	G/A	cg03040243	chr9:100819229	NANS	0.73	8.03	0.47	4.78e-14	Immature fraction of reticulocytes;
SARC	cis	rs9790314	0.586	rs35713426	chr3:161131271	A/G	cg04691961	chr3:161091175	C3orf57	-0.47	-5.97	-0.36	8.64e-9	Morning vs. evening chronotype;
SARC	cis	rs992157	0.560	rs4674274	chr2:219089131	A/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.59	-7.89	-0.46	1.14e-13	Colorectal cancer;
SARC	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg21782813	chr7:2030301	MAD1L1	0.32	4.91	0.31	1.7e-6	Schizophrenia;
SARC	trans	rs561341	0.883	rs72821942	chr17:30234460	C/T	cg20587970	chr11:113659929	NA	-1.03	-9.65	-0.53	9.56e-19	Hip circumference adjusted for BMI;
SARC	trans	rs7824557	0.527	rs2409756	chr8:11242025	A/C	cg06636001	chr8:8085503	FLJ10661	-0.6	-7.68	-0.45	4.24e-13	Retinal vascular caliber;
SARC	cis	rs10895275	0.510	rs11225155	chr11:102043400	G/A	cg00496961	chr11:102638706	NA	-0.34	-4.93	-0.31	1.55e-6	Migraine;
SARC	cis	rs67133203	0.606	rs11169727	chr12:51557964	G/A	cg15029631	chr12:52078762	SCN8A	-0.42	-4.84	-0.3	2.39e-6	Urinary tract infection frequency;
SARC	cis	rs2120019	0.938	rs8040169	chr15:75370958	C/A	cg00629941	chr15:75287862	SCAMP5	-0.6	-7.27	-0.43	5.46e-12	Blood trace element (Zn levels);
SARC	cis	rs6500395	1.000	rs7187513	chr16:48591638	T/C	cg04672837	chr16:48644449	N4BP1	0.46	6.13	0.37	3.71e-9	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs7772486	0.654	rs4896829	chr6:145953675	T/A	cg05220968	chr6:146057943	EPM2A	-0.29	-4.86	-0.3	2.16e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.78	-0.5	3.56e-16	Alzheimer's disease;
SARC	cis	rs2228479	0.850	rs62056065	chr16:89905115	C/G	cg12064134	chr16:90016061	DEF8	-0.56	-4.79	-0.3	2.91e-6	Skin colour saturation;
SARC	cis	rs4803468	0.967	rs4803462	chr19:41908936	T/A	cg08477640	chr19:41863820	B9D2	0.49	6.27	0.38	1.76e-9	Height;
SARC	cis	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg25894440	chr7:65020034	NA	-0.74	-5.55	-0.34	7.85e-8	Diabetic kidney disease;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg06061892	chr20:17948694	C20orf72;SNX5	-0.47	-6.24	-0.38	2.02e-9	Neuroticism;
SARC	cis	rs1008375	0.606	rs6828925	chr4:17561139	C/T	cg02297831	chr4:17616191	MED28	0.42	5.15	0.32	5.45e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2230307	0.536	rs687513	chr1:100598867	C/T	cg24955406	chr1:100503596	HIAT1	-0.66	-6.42	-0.39	7.5e-10	Carotid intima media thickness;
SARC	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg04944784	chr2:26401820	FAM59B	-0.5	-6.21	-0.38	2.41e-9	Gut microbiome composition (summer);
SARC	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg10591111	chr5:226296	SDHA	-0.51	-4.79	-0.3	3e-6	Breast cancer;
SARC	cis	rs10504073	0.506	rs7007271	chr8:49941897	T/C	cg00325661	chr8:49890786	NA	0.51	6.8	0.41	8.75e-11	Blood metabolite ratios;
SARC	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg11987759	chr7:65425863	GUSB	-0.6	-7.71	-0.45	3.69e-13	Aortic root size;
SARC	cis	rs7520050	0.966	rs1707321	chr1:46505309	A/G	cg06784218	chr1:46089804	CCDC17	-0.26	-4.82	-0.3	2.58e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs10752881	0.967	rs6695837	chr1:182991462	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.71	0.57	5.09e-22	Colorectal cancer;
SARC	cis	rs2576037	0.796	rs6507718	chr18:44581284	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.49	6.51	0.39	4.59e-10	Personality dimensions;
SARC	cis	rs72945132	0.714	rs115143889	chr11:70150122	G/T	cg00319359	chr11:70116639	PPFIA1	0.68	6.19	0.38	2.66e-9	Coronary artery disease;
SARC	cis	rs7216064	1.000	rs56148300	chr17:65892752	T/C	cg12091567	chr17:66097778	LOC651250	-0.74	-8.14	-0.47	2.4e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs1707322	0.717	rs2275086	chr1:46085879	C/G	cg03146154	chr1:46216737	IPP	-0.5	-6.04	-0.37	6.03e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs13390159	0.714	rs116252704	chr2:237155262	G/A	cg19324714	chr2:237145437	ASB18	0.5	4.9	0.31	1.78e-6	Response to statin therapy;
SARC	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.46	5.77	0.35	2.54e-8	Gut microbiome composition (summer);
SARC	cis	rs699371	0.550	rs11851117	chr14:74921559	T/G	cg16374328	chr14:74960395	NPC2;ISCA2	0.42	5.32	0.33	2.41e-7	Height;
SARC	cis	rs2204008	0.627	rs10878488	chr12:38148666	G/A	cg13010199	chr12:38710504	ALG10B	0.77	10.31	0.56	9.05e-21	Bladder cancer;
SARC	cis	rs9858542	0.953	rs3811699	chr3:49396360	T/C	cg07274523	chr3:49395745	GPX1	0.53	6.26	0.38	1.8e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg11494091	chr17:61959527	GH2	0.53	8.03	0.47	4.96e-14	Prudent dietary pattern;
SARC	cis	rs13082711	0.595	rs34453788	chr3:27330153	T/C	cg02860705	chr3:27208620	NA	0.66	8.0	0.46	5.67e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs11098499	0.863	rs10034450	chr4:120455649	A/G	cg24375607	chr4:120327624	NA	0.42	4.9	0.31	1.76e-6	Corneal astigmatism;
SARC	cis	rs883565	0.654	rs6779880	chr3:39022926	G/T	cg01426195	chr3:39028469	NA	0.35	4.87	0.3	2.09e-6	Handedness;
SARC	cis	rs9329221	0.527	rs4841352	chr8:10327590	A/C	cg21775007	chr8:11205619	TDH	0.38	5.01	0.31	1.1e-6	Neuroticism;
SARC	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.54	-6.14	-0.37	3.54e-9	Height;
SARC	cis	rs2834188	1.000	rs2026254	chr21:34688032	C/T	cg15382669	chr21:34697036	IFNAR1	0.41	4.76	0.3	3.34e-6	Narcolepsy;
SARC	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg01475735	chr3:40494733	NA	-0.47	-5.14	-0.32	5.91e-7	Renal cell carcinoma;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg14339287	chr19:14640339	TECR;MIR639	0.51	6.96	0.41	3.45e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg01448562	chr3:133502909	NA	0.47	7.64	0.45	5.62e-13	Iron status biomarkers;
SARC	cis	rs5995756	0.761	rs5995759	chr22:40006626	T/C	cg10455938	chr22:40058150	CACNA1I	-0.48	-6.18	-0.38	2.89e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1878931	0.513	rs35160989	chr16:3405506	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.87	13.55	0.66	3.02e-31	Body mass index (adult);
SARC	cis	rs11792861	0.555	rs4978767	chr9:111762925	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.73	9.08	0.51	4.6e-17	Menarche (age at onset);
SARC	cis	rs9325144	0.560	rs7980358	chr12:38640396	C/G	cg26384229	chr12:38710491	ALG10B	0.63	8.08	0.47	3.49e-14	Morning vs. evening chronotype;
SARC	cis	rs4555082	0.834	rs2816607	chr14:105718385	A/T	cg10792982	chr14:105748885	BRF1	0.54	7.93	0.46	9.01e-14	Mean platelet volume;Platelet distribution width;
SARC	cis	rs2204008	0.744	rs11180504	chr12:38236313	C/T	cg26384229	chr12:38710491	ALG10B	0.92	13.59	0.66	2.33e-31	Bladder cancer;
SARC	cis	rs6540556	0.635	rs17389184	chr1:209916789	C/T	cg23920097	chr1:209922102	NA	-0.57	-5.61	-0.34	5.8e-8	Red blood cell count;
SARC	cis	rs6424115	1.000	rs2179395	chr1:24148365	T/C	cg15997130	chr1:24165203	NA	0.48	6.46	0.39	6.16e-10	Immature fraction of reticulocytes;
SARC	cis	rs2839627	0.598	rs2246573	chr21:44253016	C/T	cg03543861	chr21:44258195	NA	-0.45	-5.11	-0.32	6.56e-7	Information processing speed;
SARC	cis	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg05623727	chr3:50126028	RBM5	-0.35	-5.27	-0.33	3.15e-7	Intelligence (multi-trait analysis);
SARC	cis	rs4727027	0.933	rs12540094	chr7:148847178	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.48	-5.87	-0.36	1.52e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg01454612	chr17:57693600	NA	0.48	6.83	0.41	7.35e-11	Thyroid stimulating hormone;
SARC	cis	rs3762637	1.000	rs7642869	chr3:122190786	T/C	cg24169773	chr3:122142474	KPNA1	-0.57	-5.85	-0.36	1.67e-8	LDL cholesterol levels;
SARC	cis	rs477692	0.571	rs10764890	chr10:131347163	G/A	cg05714579	chr10:131428358	MGMT	0.5	6.6	0.4	2.75e-10	Response to temozolomide;
SARC	cis	rs526821	0.595	rs499446	chr11:55355722	A/G	cg04317927	chr11:55418816	OR4S2	0.41	6.12	0.37	4e-9	Pediatric bone mineral density (spine);
SARC	cis	rs41271473	0.898	rs55730631	chr1:228865663	C/A	cg10167378	chr1:228756711	NA	0.49	4.73	0.3	3.94e-6	Chronic lymphocytic leukemia;
SARC	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg20887711	chr4:1340912	KIAA1530	0.54	6.58	0.4	3.03e-10	Longevity;
SARC	cis	rs7089973	0.604	rs2420067	chr10:116590348	A/G	cg08188268	chr10:116634841	FAM160B1	0.28	4.77	0.3	3.18e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs7607369	0.536	rs4674345	chr2:219671598	A/G	cg02176678	chr2:219576539	TTLL4	-0.4	-6.06	-0.37	5.49e-9	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs57506017	0.540	rs11974335	chr7:12263378	G/T	cg23422036	chr7:12250390	TMEM106B	0.49	6.41	0.39	8.02e-10	Neuroticism;
SARC	cis	rs875971	0.545	rs4718325	chr7:65680310	G/A	cg11764359	chr7:65958608	NA	0.67	6.53	0.39	4.12e-10	Aortic root size;
SARC	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg19223190	chr17:80058835	NA	0.44	6.19	0.38	2.67e-9	Life satisfaction;
SARC	cis	rs9400467	0.537	rs17606672	chr6:111546833	G/C	cg15721981	chr6:111408429	SLC16A10	0.7	5.85	0.36	1.7e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs7937682	0.602	rs11214036	chr11:111773169	C/T	cg22437258	chr11:111473054	SIK2	0.49	5.75	0.35	2.84e-8	Primary sclerosing cholangitis;
SARC	cis	rs79349575	0.783	rs4793995	chr17:47019399	A/C	cg16584676	chr17:46985605	UBE2Z	0.55	6.66	0.4	1.91e-10	Type 2 diabetes;
SARC	trans	rs7824557	0.603	rs11250130	chr8:11214455	C/T	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.4	-0.44	2.46e-12	Retinal vascular caliber;
SARC	cis	rs13191362	1.000	rs66789102	chr6:163104432	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.39	4.81	0.3	2.76e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs1707322	0.896	rs809774	chr1:46560244	T/A	cg06784218	chr1:46089804	CCDC17	-0.35	-6.13	-0.37	3.64e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6502050	0.626	rs11868521	chr17:80100195	T/G	cg19223190	chr17:80058835	NA	-0.45	-6.27	-0.38	1.74e-9	Life satisfaction;
SARC	cis	rs3845702	1.000	rs259808	chr2:180791419	T/G	cg01881094	chr2:180872142	CWC22	-0.59	-5.48	-0.34	1.1e-7	Schizophrenia;
SARC	cis	rs10504229	0.680	rs16921675	chr8:58052082	A/G	cg21724239	chr8:58056113	NA	0.57	5.75	0.35	2.79e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg04944784	chr2:26401820	FAM59B	-0.5	-6.14	-0.37	3.55e-9	Gut microbiome composition (summer);
SARC	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg00684032	chr4:1343700	KIAA1530	0.35	5.06	0.31	8.6e-7	Obesity-related traits;
SARC	cis	rs9790314	0.632	rs55672403	chr3:160681026	C/A	cg04691961	chr3:161091175	C3orf57	0.57	7.63	0.45	5.86e-13	Morning vs. evening chronotype;
SARC	cis	rs34172651	0.917	rs12923476	chr16:24798079	G/A	cg00152838	chr16:24741724	TNRC6A	-0.5	-5.96	-0.36	9.39e-9	Intelligence (multi-trait analysis);
SARC	cis	rs796364	1.000	rs35594306	chr2:200775125	T/C	cg23649088	chr2:200775458	C2orf69	-0.58	-4.99	-0.31	1.2e-6	Schizophrenia;
SARC	cis	rs4969178	0.965	rs8071889	chr17:76398101	A/G	cg20026190	chr17:76395443	PGS1	0.4	5.32	0.33	2.47e-7	HDL cholesterol levels;
SARC	cis	rs10504229	0.679	rs10504217	chr8:58037522	A/G	cg08219700	chr8:58056026	NA	0.58	6.0	0.37	7.52e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg01341218	chr17:43662625	NA	0.81	9.09	0.51	4.49e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg22920501	chr2:26401640	FAM59B	-0.61	-8.19	-0.47	1.71e-14	Gut microbiome composition (summer);
SARC	cis	rs10504229	0.679	rs4738574	chr8:58033771	T/C	cg11062466	chr8:58055876	NA	0.51	5.02	0.31	1.03e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs2658782	0.789	rs2658775	chr11:93126799	C/T	cg15737290	chr11:93063684	CCDC67	0.72	7.55	0.44	9.6e-13	Pulmonary function decline;
SARC	cis	rs131777	0.575	rs963980	chr22:51022117	C/A	cg01081346	chr22:51017151	CPT1B;CHKB-CPT1B	0.32	4.77	0.3	3.18e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg19774624	chr17:42201019	HDAC5	0.87	13.87	0.67	2.77e-32	Total body bone mineral density;
SARC	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs4917300	0.650	rs6981779	chr8:143071927	A/G	cg06573787	chr8:143070187	NA	-0.37	-5.64	-0.35	5.01e-8	Amyotrophic lateral sclerosis;
SARC	cis	rs4568518	0.903	rs12699940	chr7:18037037	G/A	cg00911873	chr7:18067463	PRPS1L1	-0.33	-4.87	-0.3	2.1e-6	Measles;
SARC	cis	rs2213920	0.679	rs4978638	chr9:118232778	G/C	cg13918206	chr9:118159781	DEC1	0.78	6.24	0.38	2.05e-9	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs9818758	0.607	rs12715434	chr3:49295025	G/C	cg06212747	chr3:49208901	KLHDC8B	-0.69	-5.9	-0.36	1.29e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs9341808	0.622	rs684283	chr6:80967317	T/G	cg08355045	chr6:80787529	NA	-0.34	-5.43	-0.34	1.4e-7	Sitting height ratio;
SARC	cis	rs734999	0.505	rs60687045	chr1:2539603	G/A	cg18854424	chr1:2615690	NA	0.32	5.07	0.32	8.08e-7	Ulcerative colitis;
SARC	cis	rs9322817	0.653	rs4132193	chr6:105168358	C/T	cg02098413	chr6:105308735	HACE1	-0.38	-5.81	-0.36	1.99e-8	Thyroid stimulating hormone;
SARC	cis	rs1865760	0.929	rs1816546	chr6:25938252	C/T	cg17691542	chr6:26056736	HIST1H1C	0.61	7.7	0.45	3.85e-13	Height;
SARC	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg11062466	chr8:58055876	NA	0.61	5.64	0.35	5.01e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg03490073	chr3:176806812	TBL1XR1	0.45	6.39	0.39	9.12e-10	Thyroid stimulating hormone;
SARC	cis	rs35110281	0.633	rs4819289	chr21:45120237	A/G	cg01579765	chr21:45077557	HSF2BP	-0.33	-5.15	-0.32	5.43e-7	Mean corpuscular volume;
SARC	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg05861140	chr6:150128134	PCMT1	-0.42	-5.44	-0.34	1.32e-7	Lung cancer;
SARC	cis	rs4242434	0.699	rs878051	chr8:22483836	T/C	cg03733263	chr8:22462867	KIAA1967	0.88	13.93	0.67	1.72e-32	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg26338869	chr17:61819248	STRADA	0.81	10.86	0.58	1.68e-22	Prudent dietary pattern;
SARC	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg05025164	chr4:1340916	KIAA1530	-0.68	-8.1	-0.47	3.08e-14	Obesity-related traits;
SARC	cis	rs854765	0.618	rs8066982	chr17:17851377	T/C	cg04398451	chr17:18023971	MYO15A	-0.4	-5.51	-0.34	9.71e-8	Total body bone mineral density;
SARC	cis	rs3741404	0.609	rs666497	chr11:63869821	G/C	cg18225595	chr11:63971243	STIP1	0.4	5.67	0.35	4.24e-8	Platelet count;
SARC	trans	rs208520	0.690	rs12198297	chr6:66714665	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	14.0	0.68	1.01e-32	Exhaled nitric oxide output;
SARC	cis	rs2153535	0.580	rs9393022	chr6:8466588	T/C	cg07606381	chr6:8435919	SLC35B3	0.77	10.83	0.58	2.14e-22	Motion sickness;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg17895363	chr1:193070292	GLRX2	0.47	7.06	0.42	1.92e-11	Thyroid stimulating hormone;
SARC	cis	rs2153535	0.580	rs7745043	chr6:8513507	T/C	cg23788917	chr6:8435910	SLC35B3	0.64	8.27	0.48	9.97e-15	Motion sickness;
SARC	cis	rs6580649	0.941	rs6580651	chr12:48429933	A/T	cg05342945	chr12:48394962	COL2A1	0.57	6.13	0.37	3.81e-9	Lung cancer;
SARC	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg21747090	chr2:27597821	SNX17	-0.55	-7.62	-0.45	6.44e-13	Total body bone mineral density;
SARC	cis	rs372883	0.967	rs2832290	chr21:30728863	C/T	cg08807101	chr21:30365312	RNF160	-0.4	-4.91	-0.31	1.75e-6	Pancreatic cancer;
SARC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.38	-4.73	-0.3	3.89e-6	Longevity;Endometriosis;
SARC	cis	rs240764	0.658	rs7747014	chr6:101201898	T/G	cg09795085	chr6:101329169	ASCC3	-0.5	-6.68	-0.4	1.74e-10	Neuroticism;
SARC	cis	rs672059	1.000	rs566625	chr1:183161441	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.51	6.84	0.41	6.94e-11	Hypertriglyceridemia;
SARC	cis	rs9916302	0.861	rs7503514	chr17:37669884	G/C	cg07936489	chr17:37558343	FBXL20	-0.65	-8.39	-0.48	4.58e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs36051895	0.664	rs10815157	chr9:5108771	C/G	cg02405213	chr9:5042618	JAK2	-0.46	-5.57	-0.34	6.95e-8	Pediatric autoimmune diseases;
SARC	cis	rs7666738	0.830	rs2903150	chr4:99027184	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs826838	0.967	rs11183622	chr12:38792849	T/C	cg26384229	chr12:38710491	ALG10B	0.94	15.14	0.7	1.62e-36	Heart rate;
SARC	cis	rs7667	0.919	rs6702374	chr1:19755388	C/A	cg15311933	chr1:19638897	PQLC2;AKR7A2	-0.42	-4.92	-0.31	1.66e-6	Crohn's disease and psoriasis;
SARC	cis	rs1215050	0.791	rs984940	chr4:98811756	T/A	cg05340658	chr4:99064831	C4orf37	0.44	5.86	0.36	1.53e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs734999	0.588	rs4648653	chr1:2535895	C/T	cg18854424	chr1:2615690	NA	0.32	5.04	0.31	9.16e-7	Ulcerative colitis;
SARC	cis	rs7647973	0.848	rs4292260	chr3:49148890	T/C	cg06212747	chr3:49208901	KLHDC8B	0.5	5.0	0.31	1.15e-6	Menarche (age at onset);
SARC	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg18252515	chr7:66147081	NA	0.48	5.12	0.32	6.38e-7	Aortic root size;
SARC	cis	rs2486288	0.656	rs12904150	chr15:45547605	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.45	-5.55	-0.34	7.66e-8	Glomerular filtration rate;
SARC	cis	rs7829975	0.509	rs2945269	chr8:8115578	G/C	cg08975724	chr8:8085496	FLJ10661	0.73	9.44	0.53	3.99e-18	Mood instability;
SARC	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg04944784	chr2:26401820	FAM59B	0.6	7.95	0.46	8.14e-14	Gut microbiome composition (summer);
SARC	cis	rs6439153	0.933	rs6799008	chr3:128717387	G/T	cg25356066	chr3:128598488	ACAD9	0.46	5.46	0.34	1.24e-7	Pneumococcal bacteremia;
SARC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg25703541	chr22:24373054	LOC391322	-0.74	-9.43	-0.53	4.37e-18	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg00933542	chr6:150070202	PCMT1	0.3	5.08	0.32	7.56e-7	Lung cancer;
SARC	cis	rs28655083	0.956	rs35848061	chr16:77101327	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.37	-5.15	-0.32	5.56e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs67311347	1.000	rs9842564	chr3:40405810	A/G	cg09455208	chr3:40491958	NA	-0.4	-6.37	-0.39	9.96e-10	Renal cell carcinoma;
SARC	cis	rs4481887	0.927	rs10788779	chr1:248481661	C/G	cg01631408	chr1:248437212	OR2T33	-0.38	-4.81	-0.3	2.73e-6	Common traits (Other);
SARC	cis	rs9916302	0.706	rs7208252	chr17:37584368	A/G	cg00129232	chr17:37814104	STARD3	-0.55	-5.83	-0.36	1.82e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs35213789	0.562	rs2533455	chr7:69056899	G/A	cg10619644	chr7:69149951	AUTS2	-0.34	-4.81	-0.3	2.7e-6	Childhood ear infection;
SARC	cis	rs7617480	0.648	rs4858830	chr3:48734002	T/C	cg07636037	chr3:49044803	WDR6	0.77	8.15	0.47	2.19e-14	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs1153858	0.725	rs74572151	chr15:45647526	T/G	cg03999130	chr15:45571217	NA	0.39	5.09	0.32	7.55e-7	Homoarginine levels;
SARC	trans	rs61931739	0.500	rs11053193	chr12:34438838	G/T	cg26384229	chr12:38710491	ALG10B	0.92	13.84	0.67	3.3e-32	Morning vs. evening chronotype;
SARC	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg08859206	chr1:53392774	SCP2	0.45	6.19	0.38	2.66e-9	Monocyte count;
SARC	cis	rs4242434	0.927	rs11778693	chr8:22462852	T/C	cg03733263	chr8:22462867	KIAA1967	1.05	17.98	0.76	6.49e-46	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs2380220	0.606	rs7754906	chr6:95992429	C/T	cg04719120	chr6:96025338	MANEA	0.53	6.01	0.37	7.01e-9	Behavioural disinhibition (generation interaction);
SARC	trans	rs1814175	0.654	rs1164676	chr11:49324868	T/C	cg15704280	chr7:45808275	SEPT13	0.78	12.28	0.63	4.68e-27	Height;
SARC	cis	rs9462027	0.651	rs7748203	chr6:34812054	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-6.09	-0.37	4.69e-9	Systemic lupus erythematosus;
SARC	cis	rs2694528	0.686	rs6864253	chr5:59862743	A/G	cg11474532	chr5:59995715	DEPDC1B	0.84	5.84	0.36	1.78e-8	Parkinson's disease;
SARC	cis	rs1878931	0.559	rs11643501	chr16:3392752	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.75	9.95	0.55	1.12e-19	Body mass index (adult);
SARC	cis	rs9807841	0.592	rs3810154	chr19:10764914	G/A	cg17710535	chr19:10819994	QTRT1	0.4	4.86	0.3	2.15e-6	Inflammatory skin disease;
SARC	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg08645402	chr16:4508243	NA	0.44	5.58	0.34	6.81e-8	Schizophrenia;
SARC	cis	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg15556689	chr8:8085844	FLJ10661	0.48	5.96	0.36	9.43e-9	Mood instability;
SARC	cis	rs6815814	0.731	rs4504266	chr4:38773754	G/A	cg06935464	chr4:38784597	TLR10	0.5	5.19	0.32	4.66e-7	Breast cancer;
SARC	cis	rs477692	0.692	rs7905095	chr10:131448143	C/T	cg05714579	chr10:131428358	MGMT	-0.57	-7.34	-0.43	3.61e-12	Response to temozolomide;
SARC	cis	rs733592	0.524	rs10875744	chr12:48498440	G/C	cg21466736	chr12:48725269	NA	-0.32	-5.65	-0.35	4.72e-8	Plateletcrit;
SARC	cis	rs1153858	0.945	rs7182300	chr15:45634928	G/A	cg21132104	chr15:45694354	SPATA5L1	0.78	11.03	0.59	4.99e-23	Homoarginine levels;
SARC	cis	rs6568686	0.577	rs174391	chr6:111917948	C/A	cg15721981	chr6:111408429	SLC16A10	0.62	5.13	0.32	6.22e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs1559088	1.000	rs1559087	chr19:33551041	A/G	cg27124370	chr19:33622961	WDR88	0.42	5.25	0.33	3.44e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs17125944	0.505	rs76219229	chr14:53178346	G/A	cg00686598	chr14:53173677	PSMC6	1.33	9.44	0.53	4.08e-18	Alzheimer's disease (late onset);
SARC	cis	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg14019146	chr3:50243930	SLC38A3	-0.31	-4.91	-0.31	1.74e-6	Body mass index;
SARC	cis	rs748404	0.631	rs1133395	chr15:43650384	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	5.83	0.36	1.87e-8	Lung cancer;
SARC	cis	rs9486719	1.000	rs2205755	chr6:96864704	A/G	cg06623918	chr6:96969491	KIAA0776	0.73	8.01	0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs9309473	0.948	rs13392691	chr2:73748980	G/A	cg20560298	chr2:73613845	ALMS1	-0.53	-6.16	-0.37	3.18e-9	Metabolite levels;
SARC	cis	rs1707322	0.963	rs4553121	chr1:46375253	G/A	cg03146154	chr1:46216737	IPP	0.46	5.52	0.34	8.98e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs12142240	0.698	rs9661240	chr1:46827050	G/A	cg14993813	chr1:46806288	NSUN4	-0.51	-5.34	-0.33	2.19e-7	Menopause (age at onset);
SARC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg22105103	chr4:187893119	NA	-0.47	-6.04	-0.37	6.12e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg14159672	chr1:205819179	PM20D1	0.45	5.21	0.32	4.1e-7	Parkinson's disease;
SARC	cis	rs6570726	0.935	rs447247	chr6:145812678	G/T	cg23711669	chr6:146136114	FBXO30	0.78	11.91	0.62	7.29e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9290065	0.519	rs7626904	chr3:160672427	C/T	cg17135325	chr3:160939158	NMD3	0.42	5.1	0.32	7.03e-7	Kawasaki disease;
SARC	cis	rs2522056	1.000	rs2057655	chr5:131807624	A/G	cg24060327	chr5:131705240	SLC22A5	-0.48	-5.0	-0.31	1.11e-6	Lymphocyte counts;Fibrinogen;
SARC	cis	rs7712401	0.601	rs246320	chr5:122308581	A/G	cg19412675	chr5:122181750	SNX24	0.4	5.13	0.32	5.98e-7	Mean platelet volume;
SARC	cis	rs1912483	0.505	rs11079772	chr17:45393739	A/C	cg08085267	chr17:45401833	C17orf57	0.55	6.6	0.4	2.68e-10	Coronary artery disease;
SARC	cis	rs703842	0.642	rs11536137	chr12:58056426	C/A	cg00677455	chr12:58241039	CTDSP2	0.52	5.8	0.35	2.2e-8	Multiple sclerosis;
SARC	cis	rs7615952	0.932	rs7629977	chr3:125649573	T/G	cg05084668	chr3:125655381	ALG1L	-0.69	-6.95	-0.41	3.56e-11	Blood pressure (smoking interaction);
SARC	cis	rs12681366	0.663	rs2919662	chr8:95470272	C/A	cg13257157	chr8:95487014	RAD54B	0.39	4.92	0.31	1.65e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs6540556	0.521	rs1337531	chr1:209911988	T/G	cg05527609	chr1:210001259	C1orf107	-0.58	-6.01	-0.37	7.05e-9	Red blood cell count;
SARC	cis	rs8031584	1.000	rs1474380	chr15:31269235	T/C	cg19680485	chr15:31195859	MTMR15	-0.51	-5.95	-0.36	9.62e-9	Huntington's disease progression;
SARC	cis	rs7818688	0.697	rs77805255	chr8:95983566	G/A	cg13393036	chr8:95962371	TP53INP1	0.4	4.85	0.3	2.27e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs11874712	1.000	rs11874712	chr18:43688576	C/A	cg25174615	chr18:43684699	ATP5A1;HAUS1	0.42	4.91	0.31	1.68e-6	Migraine - clinic-based;
SARC	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg11644478	chr21:40555479	PSMG1	-0.88	-11.87	-0.61	9.64e-26	Cognitive function;
SARC	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.59e-6	Depression;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg27081973	chr5:64921186	C5orf44;TRIM23	-0.45	-6.27	-0.38	1.78e-9	Thyroid stimulating hormone;
SARC	cis	rs11864453	0.826	rs12448315	chr16:72147242	G/T	cg16558253	chr16:72132732	DHX38	-0.57	-9.25	-0.52	1.46e-17	Fibrinogen levels;
SARC	cis	rs9309473	0.950	rs17009149	chr2:73790368	T/C	cg20560298	chr2:73613845	ALMS1	-0.48	-5.89	-0.36	1.31e-8	Metabolite levels;
SARC	cis	rs2832191	1.000	rs2832189	chr21:30487414	C/T	cg24692254	chr21:30365293	RNF160	-0.78	-10.9	-0.58	1.28e-22	Dental caries;
SARC	cis	rs2204008	0.583	rs12820907	chr12:37990931	T/C	cg26384229	chr12:38710491	ALG10B	0.86	12.42	0.63	1.62e-27	Bladder cancer;
SARC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.53	6.17	0.37	2.96e-9	Renal function-related traits (BUN);
SARC	cis	rs722599	0.748	rs20578	chr14:75367807	C/T	cg08847533	chr14:75593920	NEK9	-0.42	-4.79	-0.3	3.02e-6	IgG glycosylation;
SARC	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg07234876	chr8:600039	NA	0.79	6.6	0.4	2.68e-10	IgG glycosylation;
SARC	cis	rs7666738	0.791	rs6840669	chr4:99016020	G/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.41	-0.44	2.32e-12	Gut microbiome composition (summer);
SARC	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg04944784	chr2:26401820	FAM59B	-0.5	-6.14	-0.37	3.49e-9	Gut microbiome composition (summer);
SARC	cis	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg26513180	chr16:89883248	FANCA	0.72	4.79	0.3	2.92e-6	Skin colour saturation;
SARC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg10862848	chr6:42927986	GNMT	-0.45	-7.49	-0.44	1.46e-12	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs7587476	0.906	rs17487827	chr2:215644335	C/G	cg04530015	chr2:215796436	ABCA12	-0.37	-5.5	-0.34	9.98e-8	Neuroblastoma;
SARC	cis	rs2180341	0.960	rs6900074	chr6:127685893	A/G	cg27446573	chr6:127587934	RNF146	1.06	14.75	0.69	3.18e-35	Breast cancer;
SARC	cis	rs12368653	0.591	rs1038914	chr12:58011066	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.42	5.58	0.34	6.53e-8	Multiple sclerosis;
SARC	cis	rs4555082	0.834	rs11622165	chr14:105759761	C/A	cg06808227	chr14:105710500	BRF1	-0.51	-6.28	-0.38	1.67e-9	Mean platelet volume;Platelet distribution width;
SARC	cis	rs1843834	0.838	rs6436506	chr2:225558242	T/C	cg12698349	chr2:225449008	CUL3	0.39	5.0	0.31	1.13e-6	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg27572855	chr1:25598939	RHD	0.53	9.08	0.51	4.79e-17	Erythrocyte sedimentation rate;
SARC	cis	rs9790314	0.846	rs9815222	chr3:160994897	C/T	cg04691961	chr3:161091175	C3orf57	-0.64	-8.7	-0.5	6.2e-16	Morning vs. evening chronotype;
SARC	cis	rs4242434	0.819	rs2306518	chr8:22470308	A/G	cg03733263	chr8:22462867	KIAA1967	0.93	15.2	0.71	1.04e-36	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs10992471	0.580	rs10992366	chr9:95317214	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.51	-0.34	9.36e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs734999	0.545	rs4074789	chr1:2537464	A/G	cg20673091	chr1:2541236	MMEL1	0.33	5.09	0.32	7.49e-7	Ulcerative colitis;
SARC	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg12463550	chr7:65579703	CRCP	-0.71	-5.42	-0.33	1.47e-7	Diabetic kidney disease;
SARC	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg24531977	chr5:56204891	C5orf35	-0.5	-5.09	-0.32	7.48e-7	Initial pursuit acceleration;
SARC	cis	rs1971256	0.500	rs1971255	chr6:151816094	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.55	-4.87	-0.3	2.05e-6	Endometriosis;
SARC	cis	rs2197308	0.740	rs11182251	chr12:37919611	C/T	cg13010199	chr12:38710504	ALG10B	-0.69	-9.28	-0.52	1.23e-17	Morning vs. evening chronotype;
SARC	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg21782813	chr7:2030301	MAD1L1	0.48	7.83	0.46	1.76e-13	Bipolar disorder and schizophrenia;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg06343869	chr13:115079967	ZNF828	0.59	7.8	0.46	2.1e-13	Tetralogy of Fallot;
SARC	cis	rs7524258	0.868	rs8179413	chr1:7267729	T/G	cg07173049	chr1:7289937	CAMTA1	0.4	7.58	0.44	8.38e-13	Tourette's syndrome or obsessive-compulsive disorder;
SARC	trans	rs11165623	0.564	rs9887897	chr1:96996671	T/C	cg10631902	chr5:14652156	NA	-0.43	-6.54	-0.39	3.89e-10	Hip circumference;Waist circumference;
SARC	cis	rs453301	0.574	rs10081437	chr8:8948979	T/C	cg15556689	chr8:8085844	FLJ10661	-0.4	-4.82	-0.3	2.54e-6	Joint mobility (Beighton score);
SARC	cis	rs11168351	0.864	rs10875743	chr12:48498413	C/T	cg24011408	chr12:48396354	COL2A1	-0.42	-5.16	-0.32	5.18e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs7786877	0.761	rs11772705	chr7:100298904	T/C	cg16850897	chr7:100343110	ZAN	-0.53	-5.92	-0.36	1.13e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg03060546	chr3:49711283	APEH	0.48	6.39	0.39	8.85e-10	Menarche (age at onset);
SARC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg11203670	chr7:100026453	MEPCE;ZCWPW1	0.48	4.83	0.3	2.47e-6	Platelet count;
SARC	cis	rs2213920	0.679	rs10759786	chr9:118241188	A/G	cg13918206	chr9:118159781	DEC1	0.73	6.68	0.4	1.78e-10	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs2180341	1.000	rs9388561	chr6:127634921	C/T	cg27446573	chr6:127587934	RNF146	1.03	14.58	0.69	1.15e-34	Breast cancer;
SARC	cis	rs933688	0.532	rs2367292	chr5:90556785	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.49	-5.47	-0.34	1.16e-7	Smoking behavior;
SARC	cis	rs11112613	0.713	rs73184083	chr12:105952593	T/A	cg03607813	chr12:105948248	NA	0.54	7.74	0.45	3.01e-13	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	trans	rs3942852	0.806	rs4752893	chr11:48118604	C/T	cg15704280	chr7:45808275	SEPT13	-0.57	-6.64	-0.4	2.2e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs10876993	0.672	rs2640611	chr12:58037757	T/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.47	-6.01	-0.37	7.13e-9	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs9303401	0.659	rs34426768	chr17:56683385	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	11.64	0.61	5.66e-25	Cognitive test performance;
SARC	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	9.84	0.54	2.45e-19	Alzheimer's disease;
SARC	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg18252515	chr7:66147081	NA	0.47	5.13	0.32	6.22e-7	Aortic root size;
SARC	cis	rs2933343	0.951	rs1055128	chr3:128591048	C/T	cg25356066	chr3:128598488	ACAD9	0.58	6.62	0.4	2.49e-10	IgG glycosylation;
SARC	cis	rs763121	0.853	rs2076028	chr22:39150450	G/A	cg06022373	chr22:39101656	GTPBP1	0.87	11.11	0.59	2.76e-23	Menopause (age at onset);
SARC	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg02018176	chr4:1364513	KIAA1530	0.34	5.1	0.32	7.1e-7	Longevity;
SARC	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg08219700	chr8:58056026	NA	0.71	6.61	0.4	2.61e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2050392	0.544	rs598672	chr10:30742388	C/T	cg25182066	chr10:30743637	MAP3K8	0.53	7.56	0.44	9.36e-13	Inflammatory bowel disease;
SARC	cis	rs6456156	0.586	rs10946208	chr6:167459596	C/T	cg23791538	chr6:167370224	RNASET2	-0.54	-7.1	-0.42	1.53e-11	Primary biliary cholangitis;
SARC	trans	rs9329221	0.537	rs2062331	chr8:9979992	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.32	-0.43	3.98e-12	Neuroticism;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg14771734	chr5:79703670	ZFYVE16	0.52	6.41	0.39	7.96e-10	Breast cancer;
SARC	cis	rs734999	0.588	rs2260976	chr1:2527678	A/G	cg00980319	chr1:2560884	MMEL1	0.35	4.95	0.31	1.44e-6	Ulcerative colitis;
SARC	trans	rs75804782	0.641	rs3769125	chr2:239349562	A/G	cg01134436	chr17:81009848	B3GNTL1	0.86	6.23	0.38	2.11e-9	Morning vs. evening chronotype;Chronotype;
SARC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg02592271	chr2:27665507	KRTCAP3	-0.42	-6.42	-0.39	7.6e-10	Total body bone mineral density;
SARC	cis	rs12596210	0.599	rs11646488	chr16:54033075	A/G	cg00542139	chr16:53088674	CHD9	0.51	4.72	0.3	4.15e-6	Sex hormone-binding globulin levels;
SARC	cis	rs2439831	0.681	rs2278859	chr15:43632960	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	8.43	0.48	3.59e-15	Lung cancer in ever smokers;
SARC	cis	rs2019216	0.564	rs907707	chr17:21910083	G/C	cg22648282	chr17:21454238	C17orf51	-0.3	-4.75	-0.3	3.6e-6	Pelvic organ prolapse;
SARC	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg12463550	chr7:65579703	CRCP	0.54	5.76	0.35	2.68e-8	Aortic root size;
SARC	cis	rs6088590	1.000	rs3787222	chr20:33333040	T/A	cg08999081	chr20:33150536	PIGU	0.35	4.98	0.31	1.22e-6	Coronary artery disease;
SARC	cis	rs6089584	0.566	rs11699442	chr20:60623268	A/G	cg13770153	chr20:60521292	NA	-0.4	-5.72	-0.35	3.28e-8	Body mass index;
SARC	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg16680214	chr1:154839983	KCNN3	-0.35	-5.67	-0.35	4.17e-8	Prostate cancer;
SARC	cis	rs748404	0.697	rs475227	chr15:43546446	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	6.61	0.4	2.61e-10	Lung cancer;
SARC	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg03709012	chr19:19516395	GATAD2A	1.03	18.37	0.77	3.25e-47	Tonsillectomy;
SARC	cis	rs76419734	1.000	rs72673834	chr4:106739374	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	5.2	0.32	4.29e-7	Post bronchodilator FEV1;
SARC	trans	rs2727020	0.857	rs1917324	chr11:49371759	G/C	cg15704280	chr7:45808275	SEPT13	-0.74	-9.67	-0.54	8.17e-19	Coronary artery disease;
SARC	cis	rs644799	0.965	rs10831425	chr11:95500628	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.88	13.95	0.67	1.45e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7666738	0.791	rs6833691	chr4:98951508	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6772849	1.000	rs2713605	chr3:128307460	A/T	cg08795948	chr3:128337044	NA	0.37	4.88	0.3	1.96e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs35306767	0.903	rs35968821	chr10:910225	A/G	cg26597838	chr10:835615	NA	0.83	8.49	0.49	2.51e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs4803468	0.967	rs11670583	chr19:41920440	A/T	cg09537434	chr19:41945824	ATP5SL	-0.98	-17.48	-0.75	2.73e-44	Height;
SARC	cis	rs12908161	1.000	rs12908161	chr15:85207825	A/G	cg17507749	chr15:85114479	UBE2QP1	0.59	6.79	0.41	9.04e-11	Schizophrenia;
SARC	cis	rs2658782	0.654	rs2605620	chr11:93247646	C/T	cg15737290	chr11:93063684	CCDC67	0.71	8.42	0.48	3.97e-15	Pulmonary function decline;
SARC	cis	rs7582720	1.000	rs72926771	chr2:203801226	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs35213789	0.703	rs59585486	chr7:69257234	G/T	cg10619644	chr7:69149951	AUTS2	0.35	4.77	0.3	3.26e-6	Childhood ear infection;
SARC	cis	rs6450176	0.638	rs3822497	chr5:53299693	C/G	ch.5.1024479R	chr5:53302184	ARL15	-1.07	-12.53	-0.63	7.27e-28	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs9393692	0.676	rs806977	chr6:26189615	A/G	cg00631329	chr6:26305371	NA	-0.62	-8.38	-0.48	4.89e-15	Educational attainment;
SARC	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg08219700	chr8:58056026	NA	0.77	6.99	0.42	2.8e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs7582720	1.000	rs115810193	chr2:203943168	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	7.78	0.45	2.39e-13	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs5758511	0.633	rs5751258	chr22:42663871	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.45	6.69	0.4	1.63e-10	Birth weight;
SARC	cis	rs765787	0.530	rs2554453	chr15:45522107	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.41	-4.9	-0.31	1.82e-6	Uric acid levels;
SARC	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg04277193	chr17:41438351	NA	0.45	4.86	0.3	2.2e-6	Menopause (age at onset);
SARC	cis	rs2227564	0.729	rs2675674	chr10:75652682	G/A	cg16540259	chr10:75572220	NDST2	0.35	4.97	0.31	1.32e-6	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg04267008	chr7:1944627	MAD1L1	-0.51	-5.81	-0.36	2.07e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs2228479	0.850	rs74251568	chr16:89903416	A/C	cg00800038	chr16:89945340	TCF25	-0.82	-5.77	-0.35	2.46e-8	Skin colour saturation;
SARC	cis	rs9309711	0.666	rs4321399	chr2:3481659	G/A	cg15506890	chr2:3487001	NA	-0.44	-5.83	-0.36	1.84e-8	Neurofibrillary tangles;
SARC	cis	rs12681288	0.550	rs4637864	chr8:959761	C/T	cg15309053	chr8:964076	NA	0.47	7.81	0.46	1.91e-13	Schizophrenia;
SARC	cis	rs9467711	0.720	rs1417998	chr6:26162019	T/A	cg21479132	chr6:26055353	NA	0.64	5.09	0.32	7.27e-7	Autism spectrum disorder or schizophrenia;
SARC	cis	rs709400	0.628	rs6575984	chr14:103876454	A/G	cg26031613	chr14:104095156	KLC1	-0.76	-10.54	-0.57	1.67e-21	Body mass index;
SARC	cis	rs6942407	0.744	rs10273853	chr7:86863060	A/G	cg02420886	chr7:86849541	C7orf23	-0.52	-4.83	-0.3	2.51e-6	Food allergy;
SARC	cis	rs2153535	0.542	rs6905925	chr6:8440030	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs7089973	0.526	rs61869272	chr10:116732900	C/A	cg08188268	chr10:116634841	FAM160B1	0.4	5.11	0.32	6.71e-7	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg07701084	chr6:150067640	NUP43	0.4	5.24	0.32	3.64e-7	Lung cancer;
SARC	cis	rs1843834	0.838	rs6436506	chr2:225558242	T/C	cg22509189	chr2:225307070	NA	-0.5	-6.42	-0.39	7.75e-10	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs2425143	1.000	rs17093026	chr20:34318911	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.61	4.89	0.3	1.92e-6	Blood protein levels;
SARC	cis	rs2624839	0.704	rs1046956	chr3:50222926	T/A	cg19755318	chr3:50243323	SLC38A3	0.29	5.02	0.31	1.04e-6	Intelligence (multi-trait analysis);
SARC	cis	rs11583043	0.918	rs6577216	chr1:101409972	C/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.46	5.7	0.35	3.64e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs9388451	0.839	rs9401845	chr6:126104118	A/G	cg05901451	chr6:126070800	HEY2	-0.67	-9.17	-0.52	2.55e-17	Brugada syndrome;
SARC	cis	rs1348850	0.526	rs6718769	chr2:178450909	T/C	cg23306229	chr2:178417860	TTC30B	0.75	7.75	0.45	2.83e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs16866061	1.000	rs72974205	chr2:225408468	C/T	cg12698349	chr2:225449008	CUL3	0.72	10.55	0.57	1.6e-21	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	cis	rs9486719	1.000	rs9486719	chr6:97060124	G/A	cg18709589	chr6:96969512	KIAA0776	-0.6	-6.44	-0.39	6.94e-10	Migraine;Coronary artery disease;
SARC	cis	rs568617	1.000	rs568617	chr11:65653242	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.47	5.45	0.34	1.31e-7	Crohn's disease;
SARC	cis	rs9814567	1.000	rs9841212	chr3:134191938	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-6.9	-0.41	4.75e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg22535103	chr8:58192502	C8orf71	-0.7	-6.64	-0.4	2.17e-10	Developmental language disorder (linguistic errors);
SARC	trans	rs17685	0.712	rs4732578	chr7:75721532	A/G	cg19862616	chr7:65841803	NCRNA00174	0.63	7.77	0.45	2.42e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs35110281	0.805	rs4818843	chr21:45006607	C/T	cg01579765	chr21:45077557	HSF2BP	-0.32	-5.48	-0.34	1.1e-7	Mean corpuscular volume;
SARC	cis	rs8068544	0.818	rs8079958	chr17:40155467	C/T	cg26502583	chr17:39992600	KLHL10;NT5C3L	-0.87	-6.46	-0.39	6.07e-10	Reticulocyte fraction of red cells;Reticulocyte count;
SARC	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg22535103	chr8:58192502	C8orf71	-0.73	-8.66	-0.49	8.02e-16	Developmental language disorder (linguistic errors);
SARC	cis	rs2043112	0.691	rs10941418	chr5:39080694	A/G	cg04869206	chr5:39074266	RICTOR	0.51	6.43	0.39	7.22e-10	Obesity-related traits;
SARC	cis	rs9788682	0.668	rs2036529	chr15:78726272	A/T	cg06917634	chr15:78832804	PSMA4	0.57	5.69	0.35	3.74e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs7103648	0.808	rs7103835	chr11:47461693	G/A	cg10504702	chr11:47789108	FNBP4	0.62	7.48	0.44	1.55e-12	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs16973500	0.808	rs61523290	chr16:71943556	A/G	cg09427745	chr16:71932006	KIAA0174	-0.55	-5.28	-0.33	3e-7	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg19357499	chr8:144660631	NAPRT1	-0.6	-5.44	-0.34	1.34e-7	Attention deficit hyperactivity disorder;
SARC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg08677398	chr8:58056175	NA	0.44	5.27	0.33	3.14e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs1814175	0.669	rs12416837	chr11:49669761	G/T	cg03929089	chr4:120376271	NA	-0.68	-9.47	-0.53	3.34e-18	Height;
SARC	cis	rs4243830	0.850	rs7536908	chr1:6607814	C/T	cg04093404	chr1:6614507	TAS1R1;NOL9	0.57	4.85	0.3	2.24e-6	Body mass index;
SARC	cis	rs11809207	0.523	rs12565756	chr1:26498196	G/T	cg23602478	chr1:26503979	CNKSR1	0.29	5.05	0.31	8.92e-7	Height;
SARC	cis	rs2193412	0.704	rs7584445	chr2:51173811	T/A	cg00345522	chr2:51260399	NRXN1	0.37	5.29	0.33	2.81e-7	Response to zileuton treatment in asthma (FEV1 change interaction);
SARC	cis	rs6815814	0.950	rs11727978	chr4:38811051	T/A	cg06935464	chr4:38784597	TLR10	0.63	6.34	0.38	1.16e-9	Breast cancer;
SARC	cis	rs9640161	0.711	rs60268791	chr7:150023800	G/T	cg21361702	chr7:150065534	REPIN1	0.46	4.98	0.31	1.22e-6	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.47	6.16	0.37	3.25e-9	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs2916247	1.000	rs36005889	chr8:93058638	A/C	cg10183463	chr8:93005414	RUNX1T1	-0.56	-5.83	-0.36	1.81e-8	Intelligence (multi-trait analysis);
SARC	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg04546413	chr19:29218101	NA	0.64	8.99	0.51	8.9e-17	Methadone dose in opioid dependence;
SARC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg10862848	chr6:42927986	GNMT	-0.43	-6.82	-0.41	7.73e-11	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-7.47	-0.44	1.58e-12	Alzheimer's disease;
SARC	cis	rs2806561	0.765	rs9426692	chr1:23508426	C/T	cg12483005	chr1:23474871	LUZP1	0.43	5.72	0.35	3.23e-8	Height;
SARC	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg22974920	chr21:40686053	BRWD1	-0.43	-4.74	-0.3	3.74e-6	Cognitive function;
SARC	cis	rs8180040	0.701	rs11917474	chr3:47010491	G/A	cg02527881	chr3:46936655	PTH1R	-0.31	-4.78	-0.3	3.07e-6	Colorectal cancer;
SARC	cis	rs910187	0.678	rs7352690	chr20:45815352	C/G	cg27589058	chr20:45804311	EYA2	-0.31	-4.96	-0.31	1.34e-6	Migraine;
SARC	cis	rs6496667	0.565	rs7162107	chr15:90889046	A/G	cg22089800	chr15:90895588	ZNF774	0.44	4.82	0.3	2.59e-6	Rheumatoid arthritis;
SARC	cis	rs17376456	1.000	rs12187701	chr5:93522290	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.61	5.23	0.32	3.75e-7	Diabetic retinopathy;
SARC	cis	rs2273669	0.667	rs76249006	chr6:109366740	G/A	cg05315195	chr6:109294784	ARMC2	-0.63	-5.7	-0.35	3.6e-8	Prostate cancer;
SARC	cis	rs9303401	0.659	rs34878689	chr17:56694330	G/A	cg25039879	chr17:56429692	SUPT4H1	0.71	6.64	0.4	2.25e-10	Cognitive test performance;
SARC	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.74	8.49	0.49	2.45e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs13166103	0.657	rs11739498	chr5:57692163	A/G	cg10487770	chr5:57879443	RAB3C	0.52	5.51	0.34	9.57e-8	Type 2 diabetes (age of onset);
SARC	cis	rs1322639	0.614	rs6908401	chr6:169564716	A/C	cg03254818	chr6:169586852	NA	-0.73	-7.64	-0.45	5.74e-13	Pulse pressure;
SARC	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg11987759	chr7:65425863	GUSB	0.5	6.07	0.37	5.27e-9	Aortic root size;
SARC	cis	rs7208859	0.623	rs80355557	chr17:29154421	C/T	cg13385521	chr17:29058706	SUZ12P	0.85	7.66	0.45	4.88e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs78545713	0.892	rs113432940	chr6:26256324	T/A	cg13736514	chr6:26305472	NA	-0.6	-5.22	-0.32	3.96e-7	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg08742575	chr21:47604166	C21orf56	0.49	6.2	0.38	2.56e-9	Testicular germ cell tumor;
SARC	cis	rs2204008	0.806	rs35534445	chr12:38279093	C/T	cg26384229	chr12:38710491	ALG10B	0.9	13.53	0.66	3.58e-31	Bladder cancer;
SARC	cis	rs3768617	0.510	rs2333620	chr1:183100555	T/C	cg13390022	chr1:182993471	LAMC1	0.31	4.79	0.3	3.01e-6	Fuchs's corneal dystrophy;
SARC	cis	rs12545109	0.800	rs2221919	chr8:57412541	A/C	cg19413350	chr8:57351067	NA	-0.43	-5.37	-0.33	1.88e-7	Obesity-related traits;
SARC	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.36	0.38	1.07e-9	Bipolar disorder;
SARC	cis	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg17357698	chr6:26322488	NA	0.43	5.42	0.33	1.52e-7	Schizophrenia;
SARC	cis	rs274567	0.501	rs272855	chr5:131687175	C/T	cg24060327	chr5:131705240	SLC22A5	-0.7	-8.17	-0.47	1.96e-14	Blood metabolite levels;
SARC	cis	rs7777484	0.500	rs757787	chr7:2836355	G/A	cg13628971	chr7:2884303	GNA12	0.43	5.03	0.31	9.68e-7	Height;
SARC	cis	rs74417235	0.684	rs13186731	chr5:154056002	C/T	cg08754654	chr5:154026448	NA	0.48	4.8	0.3	2.86e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
SARC	cis	rs933688	1.000	rs6869717	chr5:90694797	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.01	12.57	0.64	5.2e-28	Smoking behavior;
SARC	cis	rs7772486	0.719	rs2206141	chr6:146086192	A/G	cg23711669	chr6:146136114	FBXO30	-0.91	-16.19	-0.73	5.21e-40	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg06634786	chr22:41940651	POLR3H	0.55	6.43	0.39	7.01e-10	Vitiligo;
SARC	cis	rs8014204	0.604	rs11159109	chr14:75389074	G/A	cg11812906	chr14:75593930	NEK9	0.47	5.31	0.33	2.58e-7	Caffeine consumption;
SARC	cis	rs6540556	0.954	rs611861	chr1:209937251	C/G	cg23920097	chr1:209922102	NA	-0.45	-5.12	-0.32	6.41e-7	Red blood cell count;
SARC	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg13866156	chr1:1669148	SLC35E2	-0.64	-9.69	-0.54	7.33e-19	Body mass index;
SARC	cis	rs950027	0.620	rs1426932	chr15:45687256	T/C	cg26924012	chr15:45694286	SPATA5L1	0.52	6.44	0.39	6.66e-10	Response to fenofibrate (adiponectin levels);
SARC	cis	rs12142240	0.698	rs4372193	chr1:46853233	G/T	cg14993813	chr1:46806288	NSUN4	-0.52	-5.56	-0.34	7.46e-8	Menopause (age at onset);
SARC	cis	rs1401999	0.966	rs2313212	chr3:183700928	A/G	cg01324343	chr3:183735012	ABCC5	0.67	13.33	0.66	1.72e-30	Anterior chamber depth;
SARC	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.74	10.05	0.55	5.66e-20	Total body bone mineral density;
SARC	cis	rs939574	1.000	rs7574937	chr2:220099331	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.64	5.11	0.32	6.85e-7	Platelet distribution width;
SARC	cis	rs10504229	0.593	rs2317990	chr8:58024168	G/T	cg11062466	chr8:58055876	NA	0.58	5.5	0.34	1e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6759839	0.591	rs12463697	chr2:16686128	A/G	cg09580478	chr2:16689509	NA	0.43	5.92	0.36	1.15e-8	Mean platelet volume;
SARC	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg24829409	chr8:58192753	C8orf71	-0.62	-6.66	-0.4	1.96e-10	Developmental language disorder (linguistic errors);
SARC	trans	rs61931739	0.500	rs3924705	chr12:34557825	A/T	cg26384229	chr12:38710491	ALG10B	0.85	12.64	0.64	3.01e-28	Morning vs. evening chronotype;
SARC	cis	rs1150668	0.796	rs213237	chr6:28323938	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.46	-5.54	-0.34	8.19e-8	Pubertal anthropometrics;
SARC	cis	rs6570726	0.875	rs373313	chr6:145857791	T/C	cg05220968	chr6:146057943	EPM2A	-0.3	-5.08	-0.32	7.76e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9916302	0.904	rs634365	chr17:37436966	C/T	cg20243544	chr17:37824526	PNMT	0.55	6.85	0.41	6.61e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs73195822	0.667	rs55799214	chr12:111229700	G/T	cg10860002	chr12:110842031	ANAPC7	0.67	5.0	0.31	1.15e-6	Itch intensity from mosquito bite;
SARC	cis	rs6831352	0.589	rs2924584	chr4:99988208	A/G	cg12011299	chr4:100065546	ADH4	0.29	5.46	0.34	1.22e-7	Alcohol dependence;
SARC	cis	rs9486719	1.000	rs2499804	chr6:96861216	A/G	cg18709589	chr6:96969512	KIAA0776	0.48	4.72	0.3	3.99e-6	Migraine;Coronary artery disease;
SARC	cis	rs6831352	0.918	rs13112733	chr4:100050319	A/T	cg12011299	chr4:100065546	ADH4	-0.34	-5.74	-0.35	2.97e-8	Alcohol dependence;
SARC	cis	rs11249608	0.548	rs7709054	chr5:178462757	C/T	cg21905437	chr5:178450457	ZNF879	0.57	7.47	0.44	1.63e-12	Pubertal anthropometrics;
SARC	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg22004693	chr7:99632812	ZKSCAN1	0.55	5.48	0.34	1.09e-7	Lung function (FEV1/FVC);
SARC	cis	rs4808199	0.947	rs10401193	chr19:19591066	A/G	cg03709012	chr19:19516395	GATAD2A	1.15	13.08	0.65	1.11e-29	Nonalcoholic fatty liver disease;
SARC	cis	rs6580649	0.941	rs1635529	chr12:48395102	T/G	cg05342945	chr12:48394962	COL2A1	-0.61	-6.32	-0.38	1.32e-9	Lung cancer;
SARC	cis	rs4891159	0.790	rs72975925	chr18:74143902	G/A	cg24786174	chr18:74118243	ZNF516	-0.64	-8.89	-0.5	1.67e-16	Longevity;
SARC	cis	rs7011049	1.000	rs72640850	chr8:53836681	A/C	cg26025543	chr8:53854495	NA	0.61	5.53	0.34	8.77e-8	Systolic blood pressure;
SARC	cis	rs12586317	0.547	rs77780729	chr14:35496176	C/A	cg26967526	chr14:35346199	BAZ1A	-0.57	-5.72	-0.35	3.22e-8	Psoriasis;
SARC	cis	rs6120849	0.707	rs6088690	chr20:33633326	A/G	cg06115741	chr20:33292138	TP53INP2	0.54	5.16	0.32	5.3e-7	Protein C levels;
SARC	cis	rs9487051	0.872	rs9480923	chr6:109607369	G/C	cg01475377	chr6:109611718	NA	-0.42	-5.97	-0.36	9e-9	Reticulocyte fraction of red cells;
SARC	cis	rs4242434	0.597	rs4066629	chr8:22529073	A/C	cg03733263	chr8:22462867	KIAA1967	-0.82	-12.64	-0.64	3.05e-28	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs11723261	0.582	rs6599293	chr4:133027	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.39	5.25	0.33	3.48e-7	Immune response to smallpox vaccine (IL-6);
SARC	cis	rs7566780	0.631	rs7605021	chr2:16664068	G/C	cg09580478	chr2:16689509	NA	0.44	5.94	0.36	1.01e-8	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs5753037	0.543	rs131284	chr22:30157589	T/C	cg01021169	chr22:30184971	ASCC2	-0.49	-6.82	-0.41	7.82e-11	Type 1 diabetes;
SARC	cis	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg05084668	chr3:125655381	ALG1L	-0.48	-4.93	-0.31	1.54e-6	Blood pressure (smoking interaction);
SARC	cis	rs75920871	0.588	rs4620758	chr11:116945718	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-5.11	-0.32	6.63e-7	Subjective well-being;
SARC	cis	rs7582720	1.000	rs79633844	chr2:203683990	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.71	7.13	0.42	1.29e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs4242434	0.819	rs6999893	chr8:22465427	T/C	cg03733263	chr8:22462867	KIAA1967	0.93	15.34	0.71	3.61e-37	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs9796	0.689	rs692153	chr15:41452681	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.47	-6.37	-0.39	9.87e-10	Menopause (age at onset);
SARC	cis	rs2204008	0.537	rs11170128	chr12:38006632	G/A	cg13010199	chr12:38710504	ALG10B	0.78	10.73	0.57	4.45e-22	Bladder cancer;
SARC	cis	rs8017423	0.967	rs12896540	chr14:90729392	T/C	cg20276874	chr14:90721474	PSMC1	0.38	5.19	0.32	4.47e-7	Mortality in heart failure;
SARC	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.76	7.28	0.43	5.22e-12	Age-related macular degeneration (geographic atrophy);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg14895945	chr19:12889086	NA	-0.5	-6.29	-0.38	1.52e-9	Height;
SARC	cis	rs1799949	0.587	rs1824890	chr17:41421904	T/C	cg23758822	chr17:41437982	NA	0.84	8.78	0.5	3.67e-16	Menopause (age at onset);
SARC	cis	rs2414059	0.518	rs8026653	chr15:50736620	G/C	cg05456662	chr15:50716270	USP8	-0.45	-5.47	-0.34	1.15e-7	QT interval;
SARC	cis	rs4642101	0.534	rs13316229	chr3:12807371	C/T	cg24848339	chr3:12840334	CAND2	0.34	5.15	0.32	5.67e-7	QRS complex (12-leadsum);
SARC	cis	rs11874712	0.965	rs8083998	chr18:43673144	A/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.46	5.49	0.34	1.06e-7	Migraine - clinic-based;
SARC	cis	rs240764	0.621	rs11752659	chr6:101212241	A/G	cg09795085	chr6:101329169	ASCC3	-0.5	-6.74	-0.4	1.25e-10	Neuroticism;
SARC	cis	rs1468333	0.582	rs13154749	chr5:137573519	C/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.69	7.7	0.45	3.94e-13	Resting heart rate;
SARC	cis	rs9879311	0.966	rs7619385	chr3:10414909	G/A	cg11030744	chr3:10328490	GHRL;GHRLOS	0.41	5.02	0.31	1.01e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	cis	rs7829975	0.686	rs907180	chr8:8702827	A/G	cg08975724	chr8:8085496	FLJ10661	0.47	6.15	0.37	3.39e-9	Mood instability;
SARC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg01238044	chr22:24384105	GSTT1	-0.73	-9.29	-0.52	1.14e-17	Liver enzyme levels (gamma-glutamyl transferase);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg05933803	chr17:27895641	TP53I13	0.49	6.28	0.38	1.64e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs35213789	0.762	rs2533430	chr7:69138567	A/C	cg10619644	chr7:69149951	AUTS2	-0.36	-4.95	-0.31	1.44e-6	Childhood ear infection;
SARC	cis	rs753778	0.748	rs56767156	chr8:142216476	G/C	cg18755752	chr8:142205143	DENND3	-0.51	-7.32	-0.43	4.02e-12	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs3820928	0.904	rs4439949	chr2:227764954	T/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-6.74	-0.4	1.21e-10	Pulmonary function;
SARC	cis	rs1784581	0.588	rs7758559	chr6:162438635	G/T	cg17173639	chr6:162384350	PARK2	0.54	6.8	0.41	8.95e-11	Itch intensity from mosquito bite;
SARC	cis	rs7833986	0.501	rs17815934	chr8:57038395	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.74	7.59	0.45	7.75e-13	Height;
SARC	cis	rs6582630	0.516	rs8186746	chr12:38347638	G/T	cg13010199	chr12:38710504	ALG10B	-0.5	-6.01	-0.37	7.24e-9	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1865760	0.566	rs9358902	chr6:26058570	C/G	cg16482183	chr6:26056742	HIST1H1C	0.49	6.21	0.38	2.46e-9	Height;
SARC	cis	rs1046896	0.594	rs8070403	chr17:80865404	A/G	cg19500275	chr17:80737654	TBCD	0.45	5.24	0.32	3.53e-7	Glycated hemoglobin levels;
SARC	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.42	-0.44	2.12e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg12419862	chr22:24373484	LOC391322	-0.88	-12.84	-0.64	6.92e-29	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg06634786	chr22:41940651	POLR3H	-0.52	-6.08	-0.37	4.81e-9	Vitiligo;
SARC	cis	rs3733585	0.673	rs4292332	chr4:9953830	C/A	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.39	-0.33	1.76e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	11.07	0.59	3.59e-23	Alzheimer's disease;
SARC	cis	rs7772486	0.790	rs4896852	chr6:146284621	T/C	cg05347473	chr6:146136440	FBXO30	-0.5	-6.74	-0.4	1.21e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs453301	0.598	rs10104303	chr8:8834528	A/T	cg15556689	chr8:8085844	FLJ10661	0.38	4.92	0.31	1.61e-6	Joint mobility (Beighton score);
SARC	cis	rs3087591	0.708	rs10445402	chr17:29661340	G/T	cg24425628	chr17:29625626	OMG;NF1	0.44	5.61	0.35	5.64e-8	Hip circumference;
SARC	trans	rs9427116	0.502	rs12125166	chr1:154582129	A/G	cg06787431	chr3:185827293	ETV5	-0.51	-6.38	-0.39	9.35e-10	Blood protein levels;
SARC	cis	rs6088580	0.634	rs6059851	chr20:33047945	G/A	cg08999081	chr20:33150536	PIGU	0.42	6.47	0.39	5.81e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs7412746	0.611	rs2271076	chr1:150916657	C/T	cg10589385	chr1:150898437	SETDB1	0.4	5.31	0.33	2.54e-7	Melanoma;
SARC	cis	rs35398779	1	rs35398779	chr17:19853094	GA/G	cg13482628	chr17:19912719	NA	0.52	6.26	0.38	1.82e-9	Platelet count;
SARC	cis	rs72945132	0.882	rs72945194	chr11:70138621	A/G	cg00319359	chr11:70116639	PPFIA1	0.68	6.19	0.38	2.66e-9	Coronary artery disease;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg12043807	chr9:99180432	ZNF367	0.53	6.47	0.39	5.63e-10	Breast cancer;
SARC	cis	rs2011503	0.941	rs998732	chr19:19378671	A/G	cg03709012	chr19:19516395	GATAD2A	0.62	5.34	0.33	2.17e-7	Bipolar disorder;
SARC	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	10.24	0.56	1.5e-20	Alzheimer's disease;
SARC	cis	rs9457247	0.663	rs7749278	chr6:167435325	C/T	cg23791538	chr6:167370224	RNASET2	0.51	6.75	0.4	1.14e-10	Crohn's disease;
SARC	cis	rs4975616	0.804	rs462608	chr5:1336626	T/A	cg07493874	chr5:1342172	CLPTM1L	-0.52	-6.83	-0.41	7.44e-11	Lung cancer;
SARC	cis	rs4805272	0.512	rs8106166	chr19:29339578	A/G	cg12756686	chr19:29218302	NA	-0.48	-5.02	-0.31	1.05e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg05535760	chr7:792225	HEATR2	0.84	8.23	0.47	1.32e-14	Cerebrospinal P-tau181p levels;
SARC	cis	rs2050392	0.590	rs2065723	chr10:30720462	A/T	cg25182066	chr10:30743637	MAP3K8	0.43	5.8	0.36	2.17e-8	Inflammatory bowel disease;
SARC	cis	rs9818758	0.607	rs73074866	chr3:49626666	C/T	cg01304814	chr3:48885189	PRKAR2A	0.65	5.07	0.31	8.26e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg08219700	chr8:58056026	NA	0.48	5.29	0.33	2.88e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs11122272	0.735	rs2250734	chr1:231485958	G/A	cg06096015	chr1:231504339	EGLN1	0.36	5.43	0.34	1.39e-7	Hemoglobin concentration;
SARC	cis	rs1949733	0.598	rs869602	chr4:8535371	G/T	cg05004818	chr4:8539015	NA	0.37	5.01	0.31	1.07e-6	Response to antineoplastic agents;
SARC	cis	rs9322817	0.583	rs9391226	chr6:105158405	T/C	cg02098413	chr6:105308735	HACE1	-0.38	-5.84	-0.36	1.71e-8	Thyroid stimulating hormone;
SARC	cis	rs4794106	0.792	rs847682	chr17:48208274	C/T	cg13127421	chr17:48202128	SAMD14	-0.57	-8.02	-0.47	5.2e-14	Temporomandibular joint disorder;
SARC	cis	rs9905704	0.624	rs8080071	chr17:57093825	C/T	cg12560992	chr17:57184187	TRIM37	-0.43	-5.09	-0.32	7.45e-7	Testicular germ cell tumor;
SARC	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg23172400	chr8:95962367	TP53INP1	-0.31	-5.24	-0.32	3.61e-7	Type 2 diabetes;
SARC	cis	rs2070488	0.804	rs35463537	chr3:38498248	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.81	12.58	0.64	4.69e-28	Electrocardiographic conduction measures;
SARC	cis	rs10791097	0.739	rs11222358	chr11:130730497	G/A	cg09137382	chr11:130731461	NA	0.33	5.13	0.32	6.14e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs17345786	0.861	rs11707689	chr3:101086475	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.45	-4.75	-0.3	3.57e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg13395646	chr4:1353034	KIAA1530	-0.5	-5.98	-0.36	8.15e-9	Obesity-related traits;
SARC	cis	rs807669	0.548	rs5748028	chr22:19172281	G/A	cg02655711	chr22:19163373	SLC25A1	0.51	7.56	0.44	9.49e-13	Metabolite levels;
SARC	cis	rs2354432	0.556	rs2275249	chr1:146759320	C/G	cg25205988	chr1:146714368	CHD1L	0.92	7.72	0.45	3.36e-13	Mitochondrial DNA levels;
SARC	cis	rs8114671	0.869	rs66535333	chr20:33656666	G/A	cg08999081	chr20:33150536	PIGU	-0.34	-4.84	-0.3	2.38e-6	Height;
SARC	cis	rs123509	0.913	rs339682	chr3:42791123	A/G	cg12982090	chr3:42733453	KBTBD5	0.52	6.3	0.38	1.43e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs10411936	0.682	rs6512113	chr19:16598269	C/T	cg10248733	chr19:16607483	C19orf44;CALR3	0.62	7.48	0.44	1.52e-12	White blood cell count;Multiple sclerosis;
SARC	cis	rs6582630	0.519	rs12368889	chr12:38315160	G/A	cg26384229	chr12:38710491	ALG10B	0.89	12.99	0.65	2.11e-29	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9611565	0.512	rs139572	chr22:42214532	C/T	cg17376030	chr22:41985996	PMM1	0.74	7.84	0.46	1.5700000000000001e-13	Vitiligo;
SARC	cis	rs11098499	0.863	rs28718422	chr4:120466304	C/A	cg09307838	chr4:120376055	NA	0.91	12.25	0.63	5.66e-27	Corneal astigmatism;
SARC	cis	rs60752752	0.852	rs2916218	chr1:153353169	G/A	cg26882115	chr1:153603048	S100A1;S100A13	-0.63	-4.83	-0.3	2.49e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg13939156	chr17:80058883	NA	-0.41	-6.27	-0.38	1.7e-9	Life satisfaction;
SARC	cis	rs6456042	0.829	rs3127419	chr6:166538527	A/G	cg11088901	chr6:166572345	T	-0.33	-4.82	-0.3	2.59e-6	Asthma;
SARC	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg22535103	chr8:58192502	C8orf71	-0.6	-6.33	-0.38	1.24e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs7615952	0.515	rs7630575	chr3:125682330	A/G	cg07211511	chr3:129823064	LOC729375	-0.67	-7.09	-0.42	1.54e-11	Blood pressure (smoking interaction);
SARC	cis	rs2239815	0.515	rs5762829	chr22:29228130	A/G	cg02153584	chr22:29168773	CCDC117	0.65	6.83	0.41	7.36e-11	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
SARC	cis	rs7592578	0.679	rs59929070	chr2:191327852	A/G	cg10560079	chr2:191398806	TMEM194B	-0.75	-8.34	-0.48	6.42e-15	Diastolic blood pressure;
SARC	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg11987759	chr7:65425863	GUSB	0.45	5.38	0.33	1.82e-7	Aortic root size;
SARC	cis	rs6696846	0.740	rs17344537	chr1:205091427	T/G	cg07972983	chr1:205091412	RBBP5	0.57	7.37	0.43	3.03e-12	Red blood cell count;
SARC	cis	rs9660992	0.548	rs1172152	chr1:205220718	T/A	cg00857998	chr1:205179979	DSTYK	0.51	6.56	0.39	3.5e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs2120243	0.539	rs6801110	chr3:157084731	C/G	cg24825693	chr3:157122686	VEPH1	-0.45	-5.93	-0.36	1.09e-8	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs921968	0.541	rs58650092	chr2:219304851	C/A	cg02176678	chr2:219576539	TTLL4	-0.41	-6.21	-0.38	2.38e-9	Mean corpuscular hemoglobin concentration;
SARC	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg02018176	chr4:1364513	KIAA1530	0.49	7.24	0.43	6.58e-12	Obesity-related traits;
SARC	cis	rs2952156	0.834	rs903503	chr17:37829571	C/A	cg07936489	chr17:37558343	FBXL20	-0.43	-5.62	-0.35	5.49e-8	Asthma;
SARC	cis	rs9457247	1.000	rs2769352	chr6:167378619	A/G	cg07741184	chr6:167504864	NA	-0.3	-5.74	-0.35	2.93e-8	Crohn's disease;
SARC	cis	rs1550582	1.000	rs754234	chr8:135512875	A/G	cg17885191	chr8:135476712	NA	0.59	6.12	0.37	3.93e-9	Educational attainment;
SARC	cis	rs651907	0.535	rs11717638	chr3:101505468	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	5.86	0.36	1.61e-8	Colorectal cancer;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg19386714	chr18:71825760	C18orf55	0.46	6.34	0.38	1.16e-9	Thyroid stimulating hormone;
SARC	cis	rs7819412	0.521	rs11777887	chr8:11036799	C/G	cg12395012	chr8:11607386	GATA4	-0.32	-5.55	-0.34	7.7e-8	Triglycerides;
SARC	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg07930192	chr7:1003750	NA	0.42	5.79	0.35	2.22e-8	Longevity;Endometriosis;
SARC	cis	rs6840360	0.571	rs4696110	chr4:152671325	G/A	cg22705602	chr4:152727874	NA	-0.47	-8.13	-0.47	2.52e-14	Intelligence (multi-trait analysis);
SARC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg06873352	chr17:61820015	STRADA	0.53	6.81	0.41	8.27e-11	Prudent dietary pattern;
SARC	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg25894440	chr7:65020034	NA	0.75	5.66	0.35	4.46e-8	Diabetic kidney disease;
SARC	cis	rs10992471	0.598	rs2031262	chr9:95170368	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.4	-4.86	-0.3	2.11e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg03806693	chr22:41940476	POLR3H	-0.87	-11.71	-0.61	3.18e-25	Vitiligo;
SARC	cis	rs6429082	0.749	rs291362	chr1:235686690	T/A	cg26050004	chr1:235667680	B3GALNT2	0.65	8.41	0.48	4.07e-15	Adiposity;
SARC	cis	rs10870270	0.957	rs7074604	chr10:133740373	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.8	-10.37	-0.56	5.78e-21	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs17826219	0.500	rs2449749	chr17:29078298	C/T	cg13385521	chr17:29058706	SUZ12P	0.88	7.75	0.45	2.9e-13	Body mass index;
SARC	trans	rs17685	0.753	rs1637044	chr7:75703744	T/C	cg19862616	chr7:65841803	NCRNA00174	0.63	7.77	0.45	2.42e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs9733	0.687	rs11204735	chr1:150841667	T/C	cg15448220	chr1:150897856	SETDB1	-0.39	-5.17	-0.32	4.95e-7	Tonsillectomy;
SARC	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg21171335	chr12:122356390	WDR66	0.42	6.66	0.4	1.99e-10	Mean corpuscular volume;
SARC	trans	rs36093844	0.800	rs75605851	chr11:85580031	T/G	cg15359163	chr5:122429178	PRDM6	-0.53	-6.38	-0.39	9.19e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg25517427	chr17:12921477	ELAC2	0.78	6.7	0.4	1.56e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6141769	0.542	rs28548540	chr20:31294655	A/G	cg17884169	chr20:31446444	EFCAB8	-0.46	-4.88	-0.3	2.01e-6	Subjective well-being;
SARC	cis	rs2832191	1.000	rs6516891	chr21:30483070	C/T	cg08807101	chr21:30365312	RNF160	-0.75	-10.39	-0.56	4.97e-21	Dental caries;
SARC	cis	rs1707322	0.717	rs3014245	chr1:46086913	C/T	cg03146154	chr1:46216737	IPP	-0.49	-5.89	-0.36	1.36e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6582630	0.537	rs1829579	chr12:38420555	A/G	cg26384229	chr12:38710491	ALG10B	0.84	12.04	0.62	2.79e-26	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6088580	0.634	rs1205345	chr20:32914699	A/G	cg08999081	chr20:33150536	PIGU	-0.44	-6.66	-0.4	1.99e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg09699651	chr6:150184138	LRP11	-0.41	-5.04	-0.31	9.38e-7	Lung cancer;
SARC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg11165626	chr10:21786221	MIR1915;C10orf114	0.54	7.18	0.43	9.09e-12	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.6	8.1	0.47	3.15e-14	Menarche (age at onset);
SARC	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg08280861	chr8:58055591	NA	0.6	5.87	0.36	1.48e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1707322	1.000	rs785510	chr1:46528618	T/C	cg03146154	chr1:46216737	IPP	-0.47	-5.48	-0.34	1.12e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg14403583	chr14:105418241	AHNAK2	0.58	7.61	0.45	6.71e-13	Rheumatoid arthritis;
SARC	cis	rs78487399	0.808	rs112387154	chr2:43763231	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-5.11	-0.32	6.6e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs2153535	0.541	rs6908504	chr6:8456778	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	6.55	0.39	3.66e-10	Motion sickness;
SARC	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg13114125	chr14:105738426	BRF1	-0.73	-11.0	-0.58	6.04e-23	Mean platelet volume;Platelet distribution width;
SARC	cis	rs35146811	0.844	rs13232115	chr7:99670932	T/C	cg22004693	chr7:99632812	ZKSCAN1	-0.45	-4.83	-0.3	2.43e-6	Coronary artery disease;
SARC	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg05025164	chr4:1340916	KIAA1530	0.53	6.14	0.37	3.6e-9	Obesity-related traits;
SARC	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg12311346	chr5:56204834	C5orf35	-0.58	-6.01	-0.37	7.24e-9	Initial pursuit acceleration;
SARC	cis	rs7772486	0.686	rs9373473	chr6:146082282	A/G	cg23711669	chr6:146136114	FBXO30	0.79	12.42	0.63	1.65e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6582630	0.555	rs10880611	chr12:38509316	C/G	cg13010199	chr12:38710504	ALG10B	0.76	10.49	0.57	2.39e-21	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1034435	0.755	rs5768680	chr22:48892919	T/C	cg05992904	chr22:48892994	FAM19A5	-0.48	-7.04	-0.42	2.14e-11	Late-onset Alzheimer's disease;
SARC	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg26839252	chr6:160211577	TCP1;MRPL18	0.56	5.11	0.32	6.63e-7	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg22903657	chr4:1355424	KIAA1530	-0.36	-4.89	-0.31	1.84e-6	Obesity-related traits;
SARC	cis	rs12142240	0.698	rs9661240	chr1:46827050	G/A	cg00530320	chr1:46809349	NSUN4	0.57	6.79	0.41	9.05e-11	Menopause (age at onset);
SARC	cis	rs67478160	0.619	rs3742365	chr14:104198251	A/G	cg26031613	chr14:104095156	KLC1	-0.48	-6.22	-0.38	2.33e-9	Schizophrenia;
SARC	cis	rs6831352	0.918	rs29001202	chr4:100053782	T/A	cg13256891	chr4:100009986	ADH5	-0.64	-8.0	-0.46	5.7e-14	Alcohol dependence;
SARC	cis	rs1707322	0.963	rs6666763	chr1:46436451	C/A	cg06784218	chr1:46089804	CCDC17	0.34	5.95	0.36	9.76e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs3764563	1.000	rs4239617	chr19:15741537	C/T	cg20725493	chr19:15740067	CYP4F8	-0.77	-5.96	-0.36	9.12e-9	Inflammatory biomarkers;
SARC	cis	rs3020736	0.500	rs2839708	chr22:42500745	A/G	cg04733989	chr22:42467013	NAGA	-0.76	-10.7	-0.57	5.23e-22	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6831352	0.918	rs17218239	chr4:100057020	G/A	cg13256891	chr4:100009986	ADH5	-0.64	-8.0	-0.46	5.7e-14	Alcohol dependence;
SARC	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg13206674	chr6:150067644	NUP43	0.48	6.17	0.37	3.03e-9	Lung cancer;
SARC	trans	rs36093844	0.752	rs57534090	chr11:85573020	C/T	cg15359163	chr5:122429178	PRDM6	-0.52	-6.36	-0.38	1.05e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs1044826	1.000	rs1044826	chr3:139073011	A/G	cg15131784	chr3:139108705	COPB2	-0.42	-4.89	-0.31	1.88e-6	Obesity-related traits;
SARC	trans	rs208520	0.690	rs12213928	chr6:66762978	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.07	14.08	0.68	5.37e-33	Exhaled nitric oxide output;
SARC	cis	rs6121246	0.529	rs750144	chr20:30179027	C/T	cg13852791	chr20:30311386	BCL2L1	-0.63	-5.53	-0.34	8.37e-8	Mean corpuscular hemoglobin;
SARC	trans	rs61931739	0.534	rs11053073	chr12:34202412	C/T	cg13010199	chr12:38710504	ALG10B	0.74	10.02	0.55	6.89e-20	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.36	-0.52	6.88e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg09177884	chr7:1199841	ZFAND2A	-0.63	-7.82	-0.46	1.79e-13	Longevity;Endometriosis;
SARC	cis	rs1707322	0.963	rs12022335	chr1:46402732	C/A	cg03146154	chr1:46216737	IPP	0.46	5.53	0.34	8.66e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7949030	0.688	rs2849031	chr11:62365665	G/A	cg22862634	chr11:62369728	EML3;MTA2	-0.55	-8.69	-0.49	6.4e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg16132339	chr22:24313637	DDTL;DDT	-0.4	-5.21	-0.32	4.12e-7	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs2153535	0.580	rs718502	chr6:8527400	T/C	cg23788917	chr6:8435910	SLC35B3	0.62	8.31	0.48	8.11e-15	Motion sickness;
SARC	cis	rs360798	0.553	rs7562734	chr2:63047973	G/C	cg17519650	chr2:63277830	OTX1	-0.4	-5.11	-0.32	6.72e-7	Coronary artery disease;
SARC	cis	rs11112613	0.713	rs12580741	chr12:105941328	A/G	cg03607813	chr12:105948248	NA	-0.51	-6.72	-0.4	1.39e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs9660992	0.710	rs1768587	chr1:205236432	C/T	cg00857998	chr1:205179979	DSTYK	0.52	6.29	0.38	1.57e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs6598955	0.670	rs7522905	chr1:26609259	C/T	cg21300267	chr1:26547059	NA	-0.25	-4.78	-0.3	3.15e-6	Obesity-related traits;
SARC	cis	rs651907	0.557	rs2288272	chr3:101378476	C/T	cg12386194	chr3:101231763	SENP7	0.53	6.27	0.38	1.7e-9	Colorectal cancer;
SARC	cis	rs3020736	0.500	rs1801311	chr22:42486723	G/A	cg15557168	chr22:42548783	NA	0.35	4.8	0.3	2.85e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg10150615	chr22:24372951	LOC391322	-0.47	-5.35	-0.33	2.07e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs3741151	1.000	rs7941454	chr11:73085336	C/T	cg17517138	chr11:73019481	ARHGEF17	0.71	5.82	0.36	1.94e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs818427	0.929	rs431287	chr5:112197986	A/T	cg07820702	chr5:112228657	REEP5	0.46	5.07	0.32	8.01e-7	Total body bone mineral density;
SARC	cis	rs9436747	0.748	rs1171269	chr1:65996802	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	-0.52	-5.09	-0.32	7.46e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs1018836	0.663	rs4735190	chr8:91509601	A/G	cg16814680	chr8:91681699	NA	-0.75	-11.46	-0.6	2.14e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs1215050	0.740	rs6855827	chr4:99065706	G/A	cg05340658	chr4:99064831	C4orf37	0.49	6.51	0.39	4.47e-10	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs6964587	1.000	rs10235941	chr7:91587050	T/G	cg17063962	chr7:91808500	NA	0.91	15.2	0.71	9.95e-37	Breast cancer;
SARC	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.33	-4.97	-0.31	1.32e-6	Total body bone mineral density;
SARC	cis	rs4969178	0.965	rs3817295	chr17:76394526	T/A	cg02836325	chr17:76403955	PGS1	0.32	4.99	0.31	1.17e-6	HDL cholesterol levels;
SARC	cis	rs7647973	0.961	rs62259943	chr3:49425167	A/G	cg07636037	chr3:49044803	WDR6	-0.74	-7.53	-0.44	1.08e-12	Menarche (age at onset);
SARC	cis	rs9303280	0.806	rs10445308	chr17:37938047	C/T	cg19468946	chr17:37922297	IKZF3	-0.31	-5.23	-0.32	3.81e-7	Self-reported allergy;
SARC	cis	rs6570726	0.935	rs384453	chr6:145815145	G/C	cg05347473	chr6:146136440	FBXO30	0.49	6.48	0.39	5.27e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs734999	0.588	rs3748817	chr1:2525665	T/C	cg20673091	chr1:2541236	MMEL1	0.33	5.13	0.32	6.14e-7	Ulcerative colitis;
SARC	cis	rs9612	1.000	rs12611034	chr19:44268678	C/T	cg07522664	chr19:44259120	C19orf61	0.5	5.61	0.34	5.83e-8	Exhaled nitric oxide output;
SARC	cis	rs2354432	0.505	rs4424556	chr1:146863973	G/C	cg25205988	chr1:146714368	CHD1L	0.95	7.04	0.42	2.09e-11	Mitochondrial DNA levels;
SARC	cis	rs4566357	0.615	rs3769643	chr2:227917270	T/C	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.97	-0.36	8.81e-9	Coronary artery disease;
SARC	cis	rs894734	0.535	rs2366142	chr12:54323148	T/C	cg17410650	chr12:54324560	NA	-0.33	-4.96	-0.31	1.39e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
SARC	cis	rs734999	0.588	rs6689711	chr1:2531467	T/C	cg20673091	chr1:2541236	MMEL1	-0.33	-5.09	-0.32	7.54e-7	Ulcerative colitis;
SARC	cis	rs2549003	0.870	rs10053046	chr5:131821558	A/G	cg21138405	chr5:131827807	IRF1	0.27	5.32	0.33	2.4e-7	Asthma (sex interaction);
SARC	cis	rs10463316	0.894	rs6579864	chr5:150762181	G/A	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.28	-0.33	2.89e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs3815700	1.000	rs8104726	chr19:33094675	G/A	cg02997394	chr19:33096574	ANKRD27	0.8	8.25	0.48	1.15e-14	Eosinophilic esophagitis;
SARC	cis	rs698833	0.798	rs4953082	chr2:44524064	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.59	7.36	0.43	3.11e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs10088262	0.629	rs12549683	chr8:124798276	G/C	cg02993010	chr8:124780839	FAM91A1	-0.79	-9.28	-0.52	1.24e-17	Pancreatic cancer;
SARC	cis	rs2832270	0.562	rs73192155	chr21:30455919	A/G	cg24692254	chr21:30365293	RNF160	-0.62	-4.82	-0.3	2.61e-6	Response to mTOR inhibitor (everolimus);
SARC	trans	rs826838	0.709	rs4882355	chr12:38721462	A/T	cg23762105	chr12:34175262	ALG10	-0.52	-6.82	-0.41	7.91e-11	Heart rate;
SARC	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.46	5.43	0.34	1.41e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg25281171	chr1:111149507	KCNA2	0.49	6.74	0.4	1.26e-10	Lung adenocarcinoma;
SARC	cis	rs2439831	1.000	rs690002	chr15:43729349	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	8.19	0.47	1.77e-14	Lung cancer in ever smokers;
SARC	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg18252515	chr7:66147081	NA	0.53	5.7	0.35	3.55e-8	Aortic root size;
SARC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg26354017	chr1:205819088	PM20D1	0.85	13.71	0.67	9.14e-32	Menarche (age at onset);
SARC	trans	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg21659725	chr3:3221576	CRBN	-0.8	-12.22	-0.62	7.09e-27	Intelligence (multi-trait analysis);
SARC	cis	rs9325144	0.647	rs11168819	chr12:39011082	C/A	cg26384229	chr12:38710491	ALG10B	-0.62	-8.1	-0.47	3.17e-14	Morning vs. evening chronotype;
SARC	cis	rs761746	0.672	rs5753684	chr22:31939973	A/G	cg15162869	chr22:32027605	PISD	-0.37	-4.74	-0.3	3.78e-6	Intelligence;
SARC	cis	rs11644362	0.932	rs3848239	chr16:12996642	A/G	cg06890432	chr16:12997467	SHISA9	-0.47	-6.02	-0.37	6.61e-9	Positive affect;Subjective well-being;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg00502533	chr1:113498761	SLC16A1	-0.87	-7.26	-0.43	5.62e-12	Autism spectrum disorder or schizophrenia;
SARC	cis	rs17095355	1.000	rs12263915	chr10:111744664	G/C	cg00817464	chr10:111662876	XPNPEP1	-0.42	-4.73	-0.3	3.84e-6	Biliary atresia;
SARC	cis	rs2130392	0.926	rs7677893	chr4:185625523	T/C	cg04058563	chr4:185651563	MLF1IP	0.39	5.67	0.35	4.28e-8	Kawasaki disease;
SARC	cis	rs6690583	0.560	rs1542427	chr1:85554402	T/C	cg22153463	chr1:85462885	MCOLN2	-0.56	-5.52	-0.34	9.19e-8	Serum sulfate level;
SARC	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs11792861	0.564	rs3816237	chr9:111718348	T/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.79	10.31	0.56	8.78e-21	Menarche (age at onset);
SARC	cis	rs60752752	0.852	rs61803339	chr1:153364926	G/T	cg26882115	chr1:153603048	S100A1;S100A13	-0.6	-4.72	-0.3	4.11e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs3540	0.920	rs7182658	chr15:91019248	A/T	cg22089800	chr15:90895588	ZNF774	0.49	5.54	0.34	8.01e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs6582630	0.533	rs11181379	chr12:38332381	C/T	cg26384229	chr12:38710491	ALG10B	0.57	7.18	0.43	9.35e-12	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6908034	0.607	rs111533721	chr6:19803745	C/G	cg02682789	chr6:19804855	NA	0.72	5.23	0.32	3.82e-7	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs72653721	0.715	rs4711162	chr6:10993079	T/A	cg13562911	chr6:11044106	ELOVL2	0.45	5.0	0.31	1.13e-6	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	cis	rs910316	1.000	rs12589815	chr14:75544101	C/T	cg08847533	chr14:75593920	NEK9	0.92	15.61	0.72	4.29e-38	Height;
SARC	cis	rs826838	0.935	rs980571	chr12:39127532	C/G	cg26384229	chr12:38710491	ALG10B	-0.77	-11.64	-0.61	5.62e-25	Heart rate;
SARC	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg17376030	chr22:41985996	PMM1	0.6	7.27	0.43	5.29e-12	Vitiligo;
SARC	cis	rs4481887	1.000	rs4508046	chr1:248488988	T/C	cg01631408	chr1:248437212	OR2T33	-0.44	-5.34	-0.33	2.15e-7	Common traits (Other);
SARC	cis	rs651907	0.557	rs13081846	chr3:101383321	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	6.43	0.39	6.98e-10	Colorectal cancer;
SARC	cis	rs6831352	0.918	rs13140423	chr4:100050400	T/C	cg13256891	chr4:100009986	ADH5	-0.65	-8.11	-0.47	2.83e-14	Alcohol dependence;
SARC	cis	rs72781680	0.898	rs12620558	chr2:23936022	G/A	cg06627628	chr2:24431161	ITSN2	-0.63	-5.59	-0.34	6.42e-8	Lymphocyte counts;
SARC	cis	rs7917772	0.582	rs10786682	chr10:104318322	A/C	ch.10.2196322F	chr10:104248062	ACTR1A	-0.46	-6.37	-0.39	9.98e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs2204008	0.837	rs11168504	chr12:37964922	G/T	cg26384229	chr12:38710491	ALG10B	0.9	13.37	0.66	1.22e-30	Bladder cancer;
SARC	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg16325326	chr1:53192061	ZYG11B	-0.83	-13.35	-0.66	1.47e-30	Monocyte count;
SARC	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg07157834	chr1:205819609	PM20D1	-0.39	-5.18	-0.32	4.72e-7	Menarche (age at onset);
SARC	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg11987759	chr7:65425863	GUSB	-0.62	-8.24	-0.48	1.25e-14	Aortic root size;
SARC	cis	rs9796	0.870	rs7162992	chr15:41290861	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.42	-5.83	-0.36	1.85e-8	Menopause (age at onset);
SARC	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg20102877	chr2:27665638	KRTCAP3	-0.34	-4.72	-0.3	4.04e-6	Total body bone mineral density;
SARC	cis	rs2288073	0.965	rs10199334	chr2:24392618	T/C	cg06627628	chr2:24431161	ITSN2	-0.64	-7.55	-0.44	9.69e-13	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs6674176	0.569	rs34830883	chr1:44405339	T/C	cg13606994	chr1:44402422	ARTN	-0.33	-5.49	-0.34	1.03e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg22800045	chr5:56110881	MAP3K1	0.73	7.85	0.46	1.52e-13	Initial pursuit acceleration;
SARC	cis	rs875971	0.545	rs313828	chr7:65552614	T/C	cg11764359	chr7:65958608	NA	-0.64	-6.18	-0.38	2.87e-9	Aortic root size;
SARC	cis	rs7918232	0.574	rs10458708	chr10:27455605	C/T	cg14442939	chr10:27389572	ANKRD26	0.85	11.73	0.61	2.92e-25	Breast cancer;
SARC	cis	rs6831352	0.879	rs2602879	chr4:100040652	G/A	cg13256891	chr4:100009986	ADH5	0.68	8.6	0.49	1.18e-15	Alcohol dependence;
SARC	cis	rs1559088	0.948	rs9304844	chr19:33579935	G/T	cg17764715	chr19:33622953	WDR88	0.49	6.57	0.4	3.18e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs6840360	0.550	rs4696288	chr4:152621150	A/C	cg22705602	chr4:152727874	NA	-0.48	-7.27	-0.43	5.51e-12	Intelligence (multi-trait analysis);
SARC	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg13175981	chr1:150552382	MCL1	-0.48	-5.97	-0.36	8.78e-9	Tonsillectomy;
SARC	cis	rs4148883	0.675	rs34511427	chr4:100105405	G/T	cg13256891	chr4:100009986	ADH5	0.56	7.39	0.44	2.6e-12	Alcohol dependence;
SARC	cis	rs11608355	0.545	rs12822974	chr12:109909154	G/T	cg05360138	chr12:110035743	NA	0.93	9.71	0.54	6.21e-19	Neuroticism;
SARC	cis	rs1580019	0.922	rs59938271	chr7:32484844	T/C	cg14728415	chr7:32535168	LSM5;AVL9	0.45	5.43	0.33	1.44e-7	Cognitive ability;
SARC	cis	rs4689388	0.890	rs3821941	chr4:6286954	A/G	cg00701064	chr4:6280414	WFS1	0.59	9.61	0.53	1.24e-18	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg00684032	chr4:1343700	KIAA1530	0.37	5.34	0.33	2.16e-7	Obesity-related traits;
SARC	cis	rs13082711	0.953	rs13096477	chr3:27490194	T/C	cg02860705	chr3:27208620	NA	0.51	6.39	0.39	8.8e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs546131	0.642	rs561477	chr11:34852152	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.42	4.83	0.3	2.49e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-8.66	-0.49	8.01e-16	Chronic sinus infection;
SARC	cis	rs4689388	0.926	rs4308429	chr4:6294001	A/G	cg00701064	chr4:6280414	WFS1	0.54	8.58	0.49	1.38e-15	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs71636778	0.631	rs60314236	chr1:27155166	C/T	cg04852280	chr1:26496234	ZNF593	0.58	5.27	0.33	3.12e-7	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs13191362	1.000	rs13214516	chr6:163121583	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.71	6.22	0.38	2.26e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs763121	0.853	rs35522482	chr22:39063015	C/A	cg21395723	chr22:39101663	GTPBP1	0.56	6.36	0.38	1.06e-9	Menopause (age at onset);
SARC	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg11987759	chr7:65425863	GUSB	0.46	5.84	0.36	1.74e-8	Aortic root size;
SARC	cis	rs1707322	1.000	rs7538978	chr1:46505054	C/T	cg03146154	chr1:46216737	IPP	-0.44	-5.2	-0.32	4.31e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6568686	0.527	rs174409	chr6:111932384	C/T	cg15721981	chr6:111408429	SLC16A10	0.71	5.98	0.36	8.21e-9	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg12064134	chr16:90016061	DEF8	-0.57	-4.78	-0.3	3.14e-6	Skin colour saturation;
SARC	cis	rs6088580	0.524	rs6088552	chr20:33226491	A/G	cg24642439	chr20:33292090	TP53INP2	-0.53	-6.52	-0.39	4.31e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs9914988	0.943	rs9890155	chr17:27125467	A/G	cg20469991	chr17:27169893	C17orf63	-0.5	-5.21	-0.32	4.1e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg08109568	chr15:31115862	NA	-0.49	-5.87	-0.36	1.51e-8	Huntington's disease progression;
SARC	cis	rs926392	0.589	rs2019032	chr20:37680326	C/A	cg16355469	chr20:37678765	NA	0.77	10.06	0.55	5.12e-20	Dialysis-related mortality;
SARC	cis	rs10782582	0.609	rs78776851	chr1:76424845	T/C	cg10523679	chr1:76189770	ACADM	-0.43	-5.34	-0.33	2.2e-7	Daytime sleep phenotypes;
SARC	cis	rs11098499	0.866	rs12374352	chr4:120281977	C/T	cg09307838	chr4:120376055	NA	0.83	11.82	0.61	1.46e-25	Corneal astigmatism;
SARC	trans	rs3780486	0.846	rs6476402	chr9:33148552	G/A	cg20290983	chr6:43655470	MRPS18A	1.09	20.23	0.8	3.38e-53	IgG glycosylation;
SARC	cis	rs3796352	1.000	rs13072818	chr3:53074263	C/T	cg12962167	chr3:53033115	SFMBT1	0.72	5.0	0.31	1.14e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs9816226	0.938	rs55742087	chr3:185830488	C/T	cg00760338	chr3:185826511	ETV5	-0.88	-9.72	-0.54	5.73e-19	Obesity;Body mass index;
SARC	trans	rs629535	0.814	rs477200	chr8:70059584	A/G	cg21567404	chr3:27674614	NA	1.05	13.61	0.67	2.04e-31	Dupuytren's disease;
SARC	cis	rs9790314	0.637	rs778654	chr3:160716078	G/A	cg04691961	chr3:161091175	C3orf57	-0.59	-8.14	-0.47	2.4e-14	Morning vs. evening chronotype;
SARC	cis	rs1707322	1.000	rs11211205	chr1:46321874	C/T	cg03146154	chr1:46216737	IPP	0.47	5.67	0.35	4.31e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4423214	1.000	rs12806844	chr11:71170770	G/A	cg05163923	chr11:71159392	DHCR7	0.64	8.92	0.5	1.44e-16	Vitamin D levels;
SARC	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg02725872	chr8:58115012	NA	-0.32	-4.89	-0.31	1.89e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs2204008	0.571	rs8175738	chr12:38311234	C/T	cg13010199	chr12:38710504	ALG10B	-0.51	-6.14	-0.37	3.61e-9	Bladder cancer;
SARC	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.62	7.45	0.44	1.8e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs10189230	0.868	rs5002064	chr2:222353508	G/A	cg14652038	chr2:222343519	EPHA4	0.45	6.05	0.37	5.72e-9	Urate levels in lean individuals;
SARC	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg15049968	chr18:44337910	ST8SIA5	-0.38	-6.15	-0.37	3.42e-9	Personality dimensions;
SARC	cis	rs10865397	0.539	rs13414338	chr2:73383375	C/T	cg01422370	chr2:73384389	NA	0.37	6.06	0.37	5.35e-9	Intelligence (multi-trait analysis);
SARC	cis	rs709400	0.628	rs11622320	chr14:103912194	A/T	cg12935359	chr14:103987150	CKB	-0.4	-5.88	-0.36	1.45e-8	Body mass index;
SARC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg02475777	chr4:1388615	CRIPAK	0.64	7.43	0.44	2.08e-12	Longevity;
SARC	cis	rs10191773	0.589	rs72831641	chr2:112955815	A/G	cg07905836	chr2:113190072	RGPD8;RGPD5	0.85	7.5	0.44	1.3e-12	Yeast infection;
SARC	cis	rs10927875	0.632	rs4481843	chr1:16128205	G/A	cg07117364	chr1:16154769	NA	-0.42	-4.89	-0.31	1.86e-6	Dilated cardiomyopathy;
SARC	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.95	-15.39	-0.71	2.45e-37	Chronic sinus infection;
SARC	cis	rs708547	0.697	rs67479587	chr4:57878884	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.57	7.18	0.43	9.05e-12	Response to bleomycin (chromatid breaks);
SARC	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg26116260	chr4:7069785	GRPEL1	0.89	11.17	0.59	1.77e-23	Monocyte percentage of white cells;
SARC	cis	rs1348850	0.634	rs1534304	chr2:178489264	C/T	cg23306229	chr2:178417860	TTC30B	0.62	6.47	0.39	5.63e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs6815814	0.950	rs73236618	chr4:38794041	T/C	cg02016764	chr4:38805732	TLR1	-0.44	-4.94	-0.31	1.52e-6	Breast cancer;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg07990511	chr6:36853609	C6orf89	0.54	6.86	0.41	6.32e-11	Electrocardiographic conduction measures;
SARC	cis	rs7044106	0.791	rs4836829	chr9:123482747	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	9.52	0.53	2.3e-18	Hip circumference adjusted for BMI;
SARC	cis	rs9300255	0.602	rs1106240	chr12:123626982	C/T	cg00376283	chr12:123451042	ABCB9	0.56	5.47	0.34	1.18e-7	Neutrophil percentage of white cells;
SARC	cis	rs2997447	0.761	rs17257093	chr1:26436231	C/A	cg19633962	chr1:26362018	EXTL1	-0.57	-5.05	-0.31	8.95e-7	QRS complex (12-leadsum);
SARC	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.36	0.38	1.07e-9	Bipolar disorder;
SARC	cis	rs778371	0.722	rs1996342	chr2:233805499	A/G	cg16596103	chr2:233749413	NGEF	-0.33	-4.92	-0.31	1.62e-6	Schizophrenia;
SARC	cis	rs651907	0.557	rs3806654	chr3:101396529	G/C	cg12386194	chr3:101231763	SENP7	0.5	6.02	0.37	6.79e-9	Colorectal cancer;
SARC	cis	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg12463550	chr7:65579703	CRCP	0.61	4.74	0.3	3.73e-6	Diabetic kidney disease;
SARC	cis	rs17125944	0.505	rs28568967	chr14:53223060	A/G	cg00686598	chr14:53173677	PSMC6	1.3	9.08	0.51	4.65e-17	Alzheimer's disease (late onset);
SARC	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-8.72	-0.5	5.32e-16	Alzheimer's disease;
SARC	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg13175981	chr1:150552382	MCL1	-0.47	-5.89	-0.36	1.32e-8	Tonsillectomy;
SARC	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg08859206	chr1:53392774	SCP2	-0.4	-5.66	-0.35	4.34e-8	Monocyte count;
SARC	cis	rs4975616	0.804	rs381949	chr5:1322468	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.5	-6.56	-0.4	3.35e-10	Lung cancer;
SARC	cis	rs9527	0.615	rs7899622	chr10:104727333	C/T	cg04362960	chr10:104952993	NT5C2	0.42	4.92	0.31	1.65e-6	Arsenic metabolism;
SARC	cis	rs782590	0.774	rs782630	chr2:55899425	T/C	cg18811423	chr2:55921094	PNPT1	0.7	10.7	0.57	5.42e-22	Metabolic syndrome;
SARC	cis	rs3784262	0.740	rs4646598	chr15:58300328	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.34	-5.0	-0.31	1.11e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs12956009	0.583	rs9653016	chr18:44894189	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	7.64	0.45	5.6e-13	Educational attainment (years of education);
SARC	cis	rs3733585	0.673	rs6850143	chr4:9958924	T/C	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.55	-0.34	7.65e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs1784581	0.588	rs6415086	chr6:162418147	C/T	cg17173639	chr6:162384350	PARK2	0.51	6.5	0.39	4.82e-10	Itch intensity from mosquito bite;
SARC	cis	rs5758659	0.652	rs6519301	chr22:42385967	A/G	cg04733989	chr22:42467013	NAGA	0.49	6.56	0.39	3.41e-10	Cognitive function;
SARC	cis	rs4713118	0.513	rs149959	chr6:28013854	T/C	cg26450541	chr6:28235208	ZNF187	0.48	4.9	0.31	1.82e-6	Parkinson's disease;
SARC	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg16606324	chr3:10149918	C3orf24	0.49	4.82	0.3	2.63e-6	Alzheimer's disease;
SARC	cis	rs7772486	0.790	rs2247206	chr6:146216184	C/T	cg23711669	chr6:146136114	FBXO30	0.76	11.9	0.61	8.07e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs765787	0.530	rs4238376	chr15:45541887	T/C	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.51e-10	Uric acid levels;
SARC	cis	rs11098499	0.908	rs7695996	chr4:120322033	C/T	cg09307838	chr4:120376055	NA	0.9	12.47	0.63	1.08e-27	Corneal astigmatism;
SARC	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg06074448	chr4:187884817	NA	-0.46	-6.52	-0.39	4.34e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs858239	0.539	rs10225608	chr7:23188908	A/G	cg23682824	chr7:23144976	KLHL7	0.71	9.28	0.52	1.23e-17	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9303401	0.659	rs714959	chr17:56628601	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.13	12.27	0.63	4.87e-27	Cognitive test performance;
SARC	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg22857025	chr5:266934	NA	-1.04	-11.74	-0.61	2.61e-25	Breast cancer;
SARC	cis	rs7621025	0.675	rs34602896	chr3:136346385	A/G	cg15507776	chr3:136538369	TMEM22	-0.47	-5.01	-0.31	1.06e-6	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
SARC	cis	rs7589342	0.791	rs4438504	chr2:106461035	A/C	cg14210321	chr2:106509881	NCK2	-0.48	-5.46	-0.34	1.25e-7	Addiction;
SARC	cis	rs2073300	0.536	rs6137947	chr20:23414630	C/A	cg12062639	chr20:23401060	NAPB	0.98	6.65	0.4	2.03e-10	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs9911578	1.000	rs9898916	chr17:57048660	C/T	cg12560992	chr17:57184187	TRIM37	0.84	11.53	0.6	1.23e-24	Intelligence (multi-trait analysis);
SARC	cis	rs78487399	0.808	rs17031005	chr2:43761299	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.58	-5.05	-0.31	9.06e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg26513180	chr16:89883248	FANCA	0.74	4.78	0.3	3.11e-6	Skin colour saturation;
SARC	cis	rs763121	0.853	rs5750626	chr22:38977890	G/C	cg06022373	chr22:39101656	GTPBP1	0.87	10.84	0.58	1.98e-22	Menopause (age at onset);
SARC	trans	rs1814175	0.534	rs1983448	chr11:49933856	C/A	cg03929089	chr4:120376271	NA	-0.83	-11.53	-0.6	1.22e-24	Height;
SARC	cis	rs796364	0.806	rs55985986	chr2:201120987	A/C	cg23649088	chr2:200775458	C2orf69	-0.66	-5.57	-0.34	7.09e-8	Schizophrenia;
SARC	cis	rs7560272	0.723	rs12995433	chr2:73641326	C/T	cg20560298	chr2:73613845	ALMS1	0.52	7.14	0.42	1.19e-11	Schizophrenia;
SARC	cis	rs11574514	1.000	rs78563448	chr16:67731204	A/G	cg01866162	chr16:67596514	CTCF	1.13	6.68	0.4	1.7e-10	Crohn's disease;
SARC	cis	rs9916302	0.706	rs4332770	chr17:37704712	T/C	cg00129232	chr17:37814104	STARD3	-0.57	-6.07	-0.37	5.26e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs4713118	0.955	rs9380011	chr6:27683924	A/G	cg17221315	chr6:27791827	HIST1H4J	0.49	4.97	0.31	1.3e-6	Parkinson's disease;
SARC	cis	rs7932354	0.502	rs10769233	chr11:47072655	T/C	cg03339077	chr11:47165057	C11orf49	-0.41	-5.43	-0.34	1.38e-7	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs6598955	0.543	rs60676610	chr1:26543421	G/C	cg04990556	chr1:26633338	UBXN11	0.75	7.53	0.44	1.08e-12	Obesity-related traits;
SARC	cis	rs2153535	0.580	rs6421949	chr6:8531769	G/A	cg21535247	chr6:8435926	SLC35B3	0.54	6.86	0.41	6.27e-11	Motion sickness;
SARC	cis	rs4481887	0.893	rs6681339	chr1:248482761	C/G	cg13385794	chr1:248469461	NA	0.35	5.29	0.33	2.83e-7	Common traits (Other);
SARC	cis	rs10463554	0.927	rs11952361	chr5:102287920	A/G	cg23492399	chr5:102201601	PAM	-0.48	-5.71	-0.35	3.48e-8	Parkinson's disease;
SARC	cis	rs708547	0.830	rs1713994	chr4:57868367	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.74	10.04	0.55	6.15e-20	Response to bleomycin (chromatid breaks);
SARC	cis	rs9436747	0.748	rs1751486	chr1:66020840	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	-0.52	-5.13	-0.32	6.22e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs7666738	0.830	rs6833822	chr4:98951354	G/A	cg05340658	chr4:99064831	C4orf37	0.66	8.98	0.51	9.36e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs11997175	0.766	rs4733176	chr8:33685334	A/T	ch.8.33884649F	chr8:33765107	NA	0.56	7.55	0.44	9.51e-13	Body mass index;
SARC	cis	rs763121	0.626	rs5757236	chr22:39073824	T/C	cg06022373	chr22:39101656	GTPBP1	0.84	10.39	0.56	4.96e-21	Menopause (age at onset);
SARC	cis	rs2425143	1.000	rs12480408	chr20:34234800	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	5.02	0.31	1.01e-6	Blood protein levels;
SARC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg26338869	chr17:61819248	STRADA	0.79	10.69	0.57	5.78e-22	Prudent dietary pattern;
SARC	cis	rs8038465	0.638	rs12594175	chr15:73973186	C/T	cg15420318	chr15:73925796	NPTN	0.52	6.0	0.37	7.31e-9	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1729951	0.546	rs12054219	chr3:136677472	G/A	cg15507776	chr3:136538369	TMEM22	0.52	5.79	0.35	2.3e-8	Neuroticism;
SARC	cis	rs2732480	0.577	rs2732448	chr12:48730600	T/C	cg24011408	chr12:48396354	COL2A1	0.43	5.04	0.31	9.5e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs17376456	0.877	rs10476597	chr5:93367172	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.59	-5.26	-0.33	3.22e-7	Diabetic retinopathy;
SARC	cis	rs986417	1.000	rs1950319	chr14:61048844	T/C	cg27398547	chr14:60952738	C14orf39	0.89	8.22	0.47	1.45e-14	Gut microbiota (bacterial taxa);
SARC	cis	rs1874252	0.559	rs6495988	chr15:38969545	C/T	cg01338139	chr15:38987640	C15orf53	-0.49	-4.79	-0.3	3e-6	Alcohol dependence (age at onset);
SARC	cis	rs761746	0.960	rs5753686	chr22:31947948	G/A	cg15162869	chr22:32027605	PISD	-0.35	-4.81	-0.3	2.74e-6	Intelligence;
SARC	cis	rs1008375	0.966	rs4698636	chr4:17632834	T/C	cg27347728	chr4:17578864	LAP3	0.47	5.88	0.36	1.39e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6750795	0.641	rs10933375	chr2:232367296	A/T	cg19187155	chr2:232395269	NMUR1	-0.63	-7.12	-0.42	1.37e-11	Height;
SARC	cis	rs897984	0.568	rs56083427	chr16:30881298	C/T	cg00531865	chr16:30841666	NA	-0.51	-5.28	-0.33	2.96e-7	Dementia with Lewy bodies;
SARC	cis	rs67460515	0.892	rs6780536	chr3:161058726	T/C	cg04691961	chr3:161091175	C3orf57	-0.5	-6.25	-0.38	1.94e-9	Parkinson's disease;
SARC	cis	rs2816062	0.965	rs2816061	chr1:18903819	A/G	cg18795169	chr1:18902165	NA	0.79	12.3	0.63	3.95e-27	Urate levels in lean individuals;
SARC	cis	rs796364	0.806	rs74938253	chr2:201008386	T/G	cg23649088	chr2:200775458	C2orf69	-0.64	-6.49	-0.39	5.01e-10	Schizophrenia;
SARC	trans	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg06437703	chr8:37914619	EIF4EBP1	0.67	7.77	0.45	2.56e-13	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs35955747	0.934	rs131200	chr22:31703272	T/C	cg13145458	chr22:31556086	RNF185	-0.4	-4.94	-0.31	1.49e-6	Neutrophil count;Sum basophil neutrophil counts;
SARC	cis	rs2832191	0.646	rs2832210	chr21:30508723	T/G	cg08807101	chr21:30365312	RNF160	-0.71	-8.63	-0.49	9.62e-16	Dental caries;
SARC	cis	rs2120019	0.935	rs34913788	chr15:75372617	A/C	cg00629941	chr15:75287862	SCAMP5	-0.6	-7.27	-0.43	5.46e-12	Blood trace element (Zn levels);
SARC	cis	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg22857025	chr5:266934	NA	-1.06	-11.77	-0.61	2.16e-25	Breast cancer;
SARC	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.59	0.34	6.34e-8	Bipolar disorder;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg19721680	chr1:244816665	PPPDE1	-0.53	-6.76	-0.4	1.1e-10	Height;
SARC	cis	rs7086627	0.515	rs10887896	chr10:82210144	A/C	cg00277334	chr10:82204260	NA	-0.57	-9.34	-0.52	7.79e-18	Post bronchodilator FEV1;
SARC	cis	rs9902453	0.765	rs2729447	chr17:28099002	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.15	-0.42	1.13e-11	Coffee consumption (cups per day);
SARC	cis	rs9309473	1.000	rs7604682	chr2:73788026	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-5.55	-0.34	7.78e-8	Metabolite levels;
SARC	trans	rs208520	0.874	rs208491	chr6:66928459	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-11.06	-0.59	3.85e-23	Exhaled nitric oxide output;
SARC	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg00409905	chr10:38381863	ZNF37A	-0.56	-7.51	-0.44	1.24e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg24503407	chr1:205819492	PM20D1	0.79	12.27	0.63	4.99e-27	Menarche (age at onset);
SARC	cis	rs6912958	0.559	rs451829	chr6:88041919	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.33	5.85	0.36	1.63e-8	Monocyte percentage of white cells;
SARC	cis	rs9303401	0.573	rs34097494	chr17:57171917	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.99	10.36	0.56	6.1e-21	Cognitive test performance;
SARC	cis	rs9291683	0.632	rs11734375	chr4:10046298	A/G	cg11266682	chr4:10021025	SLC2A9	0.4	7.27	0.43	5.35e-12	Bone mineral density;
SARC	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg22920501	chr2:26401640	FAM59B	-0.57	-7.45	-0.44	1.82e-12	Gut microbiome composition (summer);
SARC	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg16743903	chr16:89593216	SPG7	-0.4	-5.51	-0.34	9.62e-8	Multiple myeloma (IgH translocation);
SARC	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg13206674	chr6:150067644	NUP43	0.41	5.28	0.33	2.94e-7	Lung cancer;
SARC	cis	rs73206853	0.841	rs56130410	chr12:110824112	C/T	cg10860002	chr12:110842031	ANAPC7	0.61	4.76	0.3	3.39e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs76917914	0.589	rs7022455	chr9:100866872	C/T	cg03040243	chr9:100819229	NANS	-0.53	-5.73	-0.35	3.15e-8	Immature fraction of reticulocytes;
SARC	cis	rs672059	1.000	rs563026	chr1:183161037	A/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.5	-6.93	-0.41	4.1e-11	Hypertriglyceridemia;
SARC	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg26818010	chr10:134567672	INPP5A	-0.63	-6.84	-0.41	7.04e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs9843304	0.616	rs67576825	chr3:149202683	A/C	cg08667024	chr3:149219783	TM4SF4	-0.36	-5.25	-0.33	3.46e-7	Gallstone disease;
SARC	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg11644478	chr21:40555479	PSMG1	0.89	11.2	0.59	1.4e-23	Cognitive function;
SARC	cis	rs7250872	0.647	rs7259484	chr19:1813207	A/G	cg18850929	chr19:1828978	REXO1	0.43	5.24	0.32	3.52e-7	Bipolar disorder;
SARC	cis	rs1348850	0.914	rs2060929	chr2:178280031	T/C	cg23306229	chr2:178417860	TTC30B	0.52	5.99	0.37	7.83e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs10193935	1.000	rs72796507	chr2:42409840	A/G	cg27598129	chr2:42591480	NA	-0.35	-4.72	-0.3	4e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg07234876	chr8:600039	NA	0.79	6.6	0.4	2.68e-10	IgG glycosylation;
SARC	cis	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg05623727	chr3:50126028	RBM5	0.33	4.8	0.3	2.88e-6	Intelligence (multi-trait analysis);
SARC	cis	rs1355223	0.816	rs2136506	chr11:34748260	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-5.65	-0.35	4.73e-8	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg02018176	chr4:1364513	KIAA1530	0.45	6.7	0.4	1.53e-10	Longevity;
SARC	cis	rs11718455	0.960	rs11921942	chr3:44007957	T/C	cg08738300	chr3:44038990	NA	0.53	5.91	0.36	1.2e-8	Coronary artery disease;
SARC	cis	rs9790314	0.875	rs336568	chr3:161072763	G/C	cg04691961	chr3:161091175	C3orf57	-0.75	-11.06	-0.59	3.85e-23	Morning vs. evening chronotype;
SARC	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg22004693	chr7:99632812	ZKSCAN1	0.55	5.49	0.34	1.04e-7	Lung function (FEV1/FVC);
SARC	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg22968622	chr17:43663579	NA	1.26	17.12	0.75	4.32e-43	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs17376456	0.569	rs6879620	chr5:93119893	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.51	-5.23	-0.32	3.75e-7	Diabetic retinopathy;
SARC	cis	rs1691799	0.867	rs1027401	chr12:66760892	C/G	cg16791601	chr12:66731901	HELB	-0.71	-10.69	-0.57	5.79e-22	White blood cell count (basophil);
SARC	cis	rs1790761	0.520	rs4930461	chr11:67394895	A/G	cg24690094	chr11:67383802	NA	0.45	6.34	0.38	1.18e-9	Mean corpuscular volume;
SARC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg26338869	chr17:61819248	STRADA	0.8	10.72	0.57	4.8e-22	Prudent dietary pattern;
SARC	cis	rs208520	0.507	rs9453585	chr6:66796668	C/T	cg07460842	chr6:66804631	NA	-1.12	-22.38	-0.83	5.7e-60	Exhaled nitric oxide output;
SARC	cis	rs138341189	1	rs138341189	chr11:68224411	GATTGTGCCAAT/G	cg01657329	chr11:68192670	LRP5	-0.48	-4.78	-0.3	3.13e-6	Monobrow;
SARC	cis	rs3858526	0.883	rs7481882	chr11:5944221	A/G	cg13902645	chr11:5959945	NA	-0.44	-4.99	-0.31	1.18e-6	DNA methylation (variation);
SARC	cis	rs2736337	0.530	rs11782375	chr8:11294934	C/T	cg21775007	chr8:11205619	TDH	0.42	4.77	0.3	3.19e-6	Rheumatoid arthritis;
SARC	cis	rs12142240	0.698	rs45449893	chr1:46859024	A/G	cg00530320	chr1:46809349	NSUN4	0.57	7.0	0.42	2.74e-11	Menopause (age at onset);
SARC	cis	rs554111	0.891	rs671905	chr1:21047092	A/T	cg08890418	chr1:21044141	KIF17	0.54	7.56	0.44	9.31e-13	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg08742575	chr21:47604166	C21orf56	0.47	5.93	0.36	1.07e-8	Testicular germ cell tumor;
SARC	cis	rs28829049	0.565	rs2182197	chr1:19369527	C/T	cg13387374	chr1:19411106	UBR4	0.38	5.02	0.31	1.02e-6	QRS duration in Tripanosoma cruzi seropositivity;
SARC	cis	rs992157	0.661	rs17653757	chr2:219109364	G/C	cg00012203	chr2:219082015	ARPC2	0.86	14.09	0.68	5.2e-33	Colorectal cancer;
SARC	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.45	5.13	0.32	6.21e-7	Renal function-related traits (BUN);
SARC	cis	rs2197308	0.715	rs11181816	chr12:37911626	A/G	cg26384229	chr12:38710491	ALG10B	-0.79	-11.38	-0.6	3.64e-24	Morning vs. evening chronotype;
SARC	cis	rs10513788	0.665	rs55994251	chr3:181992492	A/G	cg05977900	chr3:182512126	ATP11B	0.47	4.91	0.31	1.72e-6	Cognitive function;
SARC	cis	rs10089	1.000	rs3805606	chr5:127470813	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.81	-9.96	-0.55	1.1e-19	Ileal carcinoids;
SARC	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg11987759	chr7:65425863	GUSB	-0.47	-6.27	-0.38	1.7e-9	Aortic root size;
SARC	cis	rs6670533	0.571	rs61358817	chr1:24864789	G/A	cg07475527	chr1:24864545	NA	-0.89	-5.35	-0.33	2.07e-7	Fasting blood insulin (BMI interaction);
SARC	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	8.62	0.49	1.06e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs393155	0.517	rs330050	chr8:9087679	G/C	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.46	-0.39	6.03e-10	Neuroticism;
SARC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg25703541	chr22:24373054	LOC391322	-0.86	-12.52	-0.63	7.64e-28	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs10465746	0.570	rs11163886	chr1:84473445	C/A	cg04407776	chr1:84465009	TTLL7	-0.42	-5.06	-0.31	8.62e-7	Obesity-related traits;
SARC	cis	rs4664308	0.875	rs7593593	chr2:160933811	C/T	cg03641300	chr2:160917029	PLA2R1	-0.71	-9.54	-0.53	2.02e-18	Idiopathic membranous nephropathy;
SARC	cis	rs208520	0.690	rs6929762	chr6:66709277	C/T	cg07460842	chr6:66804631	NA	1.06	14.43	0.69	3.63e-34	Exhaled nitric oxide output;
SARC	cis	rs1153858	0.621	rs2413769	chr15:45561868	A/C	cg26924012	chr15:45694286	SPATA5L1	0.71	9.17	0.51	2.57e-17	Homoarginine levels;
SARC	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg06221963	chr1:154839813	KCNN3	-0.49	-7.57	-0.44	8.53e-13	Prostate cancer;
SARC	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg22535103	chr8:58192502	C8orf71	-0.6	-6.33	-0.38	1.24e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2153535	0.542	rs6912740	chr6:8439959	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs10791097	0.547	rs11222371	chr11:130745719	C/T	cg12179176	chr11:130786555	SNX19	0.73	10.76	0.58	3.41e-22	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs35213789	0.762	rs2851506	chr7:69114734	T/G	cg10619644	chr7:69149951	AUTS2	-0.36	-4.89	-0.31	1.89e-6	Childhood ear infection;
SARC	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg19077165	chr18:44547161	KATNAL2	-0.56	-7.94	-0.46	8.57e-14	Personality dimensions;
SARC	cis	rs1008375	0.932	rs11935124	chr4:17668200	G/A	cg02297831	chr4:17616191	MED28	-0.42	-5.24	-0.32	3.53e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs3820928	0.874	rs10183633	chr2:227887828	A/G	cg05526886	chr2:227700861	RHBDD1	-0.47	-5.46	-0.34	1.2e-7	Pulmonary function;
SARC	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg11494091	chr17:61959527	GH2	0.38	5.41	0.33	1.57e-7	Height;
SARC	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg14403583	chr14:105418241	AHNAK2	-0.58	-7.63	-0.45	6.09e-13	Rheumatoid arthritis;
SARC	cis	rs1707322	0.789	rs10789473	chr1:46248131	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.35	0.38	1.15e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7615952	0.551	rs12695470	chr3:125635718	C/A	cg05084668	chr3:125655381	ALG1L	-0.66	-6.41	-0.39	8.14e-10	Blood pressure (smoking interaction);
SARC	cis	rs10782582	0.593	rs12131493	chr1:76139172	G/A	cg03433033	chr1:76189801	ACADM	-0.42	-5.39	-0.33	1.7e-7	Daytime sleep phenotypes;
SARC	cis	rs7818345	0.967	rs4549789	chr8:19284015	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.42	5.61	0.34	5.84e-8	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs7520050	0.966	rs785489	chr1:46576390	A/G	cg06784218	chr1:46089804	CCDC17	-0.26	-4.82	-0.3	2.56e-6	Red blood cell count;Reticulocyte count;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg01553063	chr11:560751	RASSF7;C11orf35	-0.76	-6.32	-0.38	1.31e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1790761	0.520	rs12805884	chr11:67387977	G/A	cg24690094	chr11:67383802	NA	-0.44	-6.27	-0.38	1.71e-9	Mean corpuscular volume;
SARC	cis	rs9916302	0.904	rs3964723	chr17:37403979	C/T	cg00129232	chr17:37814104	STARD3	-0.61	-7.51	-0.44	1.23e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	10.53	0.57	1.87e-21	Platelet count;
SARC	cis	rs56283067	0.887	rs9463042	chr6:44770527	T/C	cg18551225	chr6:44695536	NA	-0.36	-4.95	-0.31	1.45e-6	Total body bone mineral density;
SARC	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg19223190	chr17:80058835	NA	0.46	6.23	0.38	2.1e-9	Life satisfaction;
SARC	cis	rs2197308	0.692	rs67352173	chr12:37906912	A/T	cg13010199	chr12:38710504	ALG10B	0.77	10.27	0.56	1.16e-20	Morning vs. evening chronotype;
SARC	cis	rs76419734	0.558	rs4235415	chr4:106593850	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.73	8.06	0.47	4.07e-14	Post bronchodilator FEV1;
SARC	cis	rs9911578	1.000	rs7223955	chr17:56917053	C/A	cg05425664	chr17:57184151	TRIM37	-0.64	-7.98	-0.46	6.52e-14	Intelligence (multi-trait analysis);
SARC	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.44	6.81	0.41	8.18e-11	Schizophrenia;
SARC	cis	rs3741404	0.665	rs594461	chr11:63872543	A/G	cg04317338	chr11:64019027	PLCB3	0.48	5.51	0.34	9.63e-8	Platelet count;
SARC	cis	rs10513432	0.826	rs16864605	chr3:152551071	T/C	cg04845053	chr3:152552877	P2RY1	0.81	4.73	0.3	3.96e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs13191362	0.573	rs9365499	chr6:163271833	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.42	4.89	0.3	1.9e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs4803468	1.000	rs2241711	chr19:41911980	T/C	cg09537434	chr19:41945824	ATP5SL	-0.97	-16.94	-0.74	1.74e-42	Height;
SARC	cis	rs6088590	0.502	rs6059861	chr20:33068563	A/T	cg08999081	chr20:33150536	PIGU	0.42	6.37	0.39	9.9e-10	Coronary artery disease;
SARC	cis	rs7247513	0.759	rs73002392	chr19:12768391	G/A	cg06417478	chr19:12876846	HOOK2	0.41	5.02	0.31	1.04e-6	Bipolar disorder;
SARC	cis	rs3126085	0.935	rs6666382	chr1:152217226	C/G	cg03465714	chr1:152285911	FLG	0.48	5.81	0.36	2.07e-8	Atopic dermatitis;
SARC	cis	rs2200578	1.000	rs12053519	chr2:99875018	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	0.66	6.44	0.39	6.69e-10	IgG glycosylation;
SARC	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg03060546	chr3:49711283	APEH	0.41	5.21	0.32	4.24e-7	Parkinson's disease;
SARC	cis	rs10791323	0.693	rs10750544	chr11:133718740	A/G	cg13461336	chr11:133711254	SPATA19	-0.3	-5.48	-0.34	1.09e-7	Childhood ear infection;
SARC	cis	rs10489202	0.955	rs17557162	chr1:167985950	A/T	cg24449463	chr1:168025552	DCAF6	0.65	7.28	0.43	5.03e-12	Schizophrenia;
SARC	cis	rs2236918	1.000	rs2526699	chr1:242022130	T/C	cg17736920	chr1:242011382	EXO1	0.77	10.68	0.57	6.15e-22	Menopause (age at onset);
SARC	cis	rs6061231	1.000	rs11908473	chr20:60957770	C/G	cg24112000	chr20:60950667	NA	-0.38	-5.96	-0.36	9.21e-9	Colorectal cancer;
SARC	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg02725872	chr8:58115012	NA	-0.37	-6.54	-0.39	3.94e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs950776	0.684	rs692780	chr15:78876505	C/G	cg22563815	chr15:78856949	CHRNA5	-0.35	-5.48	-0.34	1.09e-7	Sudden cardiac arrest;
SARC	cis	rs981844	0.740	rs6858578	chr4:154682058	G/T	cg14289246	chr4:154710475	SFRP2	-0.59	-6.98	-0.42	3.05e-11	Response to statins (LDL cholesterol change);
SARC	cis	rs7220711	1.000	rs1881107	chr17:41786076	A/G	cg26893861	chr17:41843967	DUSP3	0.39	4.94	0.31	1.53e-6	Bone mineral density (spine);Bone mineral density (hip);
SARC	cis	rs9640161	0.750	rs11538922	chr7:150035183	C/T	cg10018233	chr7:150070692	REPIN1	0.68	8.16	0.47	2.04e-14	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs7772486	0.754	rs9386132	chr6:146140751	T/C	cg05347473	chr6:146136440	FBXO30	0.57	7.97	0.46	6.94e-14	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg03351412	chr1:154909251	PMVK	0.6	7.48	0.44	1.51e-12	Prostate cancer;
SARC	cis	rs3733585	0.699	rs7435196	chr4:9967556	A/C	cg11266682	chr4:10021025	SLC2A9	-0.36	-6.31	-0.38	1.43e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7089973	0.604	rs2420067	chr10:116590348	A/G	cg03647239	chr10:116582469	FAM160B1	0.49	6.3	0.38	1.48e-9	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs778371	0.723	rs737027	chr2:233641083	G/C	cg16596103	chr2:233749413	NGEF	-0.38	-5.88	-0.36	1.42e-8	Schizophrenia;
SARC	trans	rs1910358	0.554	rs10057796	chr5:23759746	C/T	cg11694119	chr1:145611008	POLR3C;RNF115	0.54	6.25	0.38	1.96e-9	Venous thromboembolism (SNP x SNP interaction);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg01113680	chr13:43842067	ENOX1	0.5	6.85	0.41	6.64e-11	Thyroid stimulating hormone;
SARC	cis	rs9303401	0.659	rs7225896	chr17:56637337	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.07	11.43	0.6	2.64e-24	Cognitive test performance;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg11208313	chr17:27276484	PHF12	0.51	6.49	0.39	5.04e-10	Breast cancer;
SARC	trans	rs8073060	0.586	rs72829927	chr17:34049992	A/G	cg19694781	chr19:47549865	TMEM160	0.72	6.95	0.41	3.67e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs3733585	0.726	rs4306953	chr4:9955776	G/A	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.95	-0.36	9.9e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs11098499	0.954	rs12505469	chr4:120249585	C/T	cg09307838	chr4:120376055	NA	0.9	12.31	0.63	3.69e-27	Corneal astigmatism;
SARC	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	11.17	0.59	1.73e-23	Alzheimer's disease;
SARC	cis	rs6988636	1.000	rs10096350	chr8:124184470	T/C	cg23067535	chr8:124195133	FAM83A	-0.65	-4.97	-0.31	1.29e-6	Urinary uromodulin levels;
SARC	cis	rs7633770	0.664	rs11130101	chr3:46685895	T/A	cg11219411	chr3:46661640	NA	-0.4	-6.26	-0.38	1.84e-9	Coronary artery disease;
SARC	cis	rs11098499	0.954	rs17046116	chr4:120387259	G/A	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	cis	rs3784262	0.692	rs12907125	chr15:58282621	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.36	-5.34	-0.33	2.25e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs7568458	0.870	rs2366639	chr2:85809955	A/G	cg17127132	chr2:85788382	GGCX	0.4	5.26	0.33	3.19e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg05623727	chr3:50126028	RBM5	0.33	4.91	0.31	1.69e-6	Intelligence (multi-trait analysis);
SARC	cis	rs1865760	0.568	rs2032450	chr6:25993114	C/G	cg10373733	chr6:25993375	NA	0.46	5.86	0.36	1.58e-8	Height;
SARC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg20607798	chr8:58055168	NA	0.68	7.94	0.46	8.35e-14	Developmental language disorder (linguistic errors);
SARC	cis	rs2014572	0.967	rs7259978	chr19:57756129	C/T	cg24459738	chr19:57751996	ZNF805	-0.47	-5.58	-0.34	6.62e-8	Hyperactive-impulsive symptoms;
SARC	cis	rs9611519	0.964	rs2092563	chr22:41592677	G/A	cg17376030	chr22:41985996	PMM1	0.49	5.77	0.35	2.52e-8	Neuroticism;
SARC	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.59	0.34	6.34e-8	Bipolar disorder;
SARC	cis	rs11992162	0.551	rs13268217	chr8:11782609	T/A	cg02127589	chr8:12458309	NA	-0.32	-4.77	-0.3	3.26e-6	Monocyte count;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg18675616	chr4:1962842	WHSC1	0.48	6.39	0.39	8.73e-10	Chemerin levels;
SARC	cis	rs7412746	0.658	rs4970986	chr1:150907955	A/G	cg13175981	chr1:150552382	MCL1	-0.48	-5.86	-0.36	1.57e-8	Melanoma;
SARC	cis	rs2836950	0.545	rs11700813	chr21:40517469	T/G	cg17971929	chr21:40555470	PSMG1	-0.55	-6.72	-0.4	1.42e-10	Menarche (age at onset);
SARC	trans	rs3780486	0.846	rs4584234	chr9:33147479	G/A	cg20290983	chr6:43655470	MRPS18A	1.09	20.19	0.8	4.5e-53	IgG glycosylation;
SARC	cis	rs7959452	0.901	rs1384	chr12:69747834	C/T	cg14784868	chr12:69753453	YEATS4	0.4	5.2	0.32	4.45e-7	Blood protein levels;
SARC	cis	rs554111	0.660	rs1985278	chr1:21091861	G/T	cg08890418	chr1:21044141	KIF17	-0.43	-5.94	-0.36	1.04e-8	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs9814567	0.963	rs36006513	chr3:134291913	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	7.01	0.42	2.54e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs568617	1.000	rs693824	chr11:65654783	A/G	cg00576331	chr11:65640516	EFEMP2	-0.46	-5.41	-0.33	1.53e-7	Crohn's disease;
SARC	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg05313129	chr8:58192883	C8orf71	-0.62	-6.5	-0.39	4.79e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9611519	0.558	rs8137906	chr22:41442566	A/G	cg17376030	chr22:41985996	PMM1	0.44	5.63	0.35	5.24e-8	Neuroticism;
SARC	cis	rs765787	0.530	rs2433227	chr15:45517119	A/T	cg24006582	chr15:45444508	DUOX1	-0.49	-6.47	-0.39	5.7e-10	Uric acid levels;
SARC	cis	rs734999	0.588	rs78506337	chr1:2537095	G/A	cg18854424	chr1:2615690	NA	0.34	5.37	0.33	1.87e-7	Ulcerative colitis;
SARC	cis	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg07777115	chr5:623756	CEP72	-0.62	-5.58	-0.34	6.66e-8	Obesity-related traits;
SARC	cis	rs79149102	0.579	rs7172715	chr15:75287375	C/G	cg17294928	chr15:75287854	SCAMP5	-1.08	-8.85	-0.5	2.29e-16	Lung cancer;
SARC	cis	rs9916302	0.904	rs11078915	chr17:37715426	T/C	cg20243544	chr17:37824526	PNMT	0.54	6.36	0.38	1.08e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs10751667	0.600	rs4076915	chr11:1012464	C/G	cg20946044	chr11:1010712	AP2A2	-0.42	-6.05	-0.37	5.59e-9	Alzheimer's disease (late onset);
SARC	cis	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg15556689	chr8:8085844	FLJ10661	0.43	5.4	0.33	1.64e-7	Mood instability;
SARC	cis	rs7084402	0.935	rs4141671	chr10:60338753	T/C	cg07615347	chr10:60278583	BICC1	-0.51	-7.06	-0.42	1.95e-11	Refractive error;
SARC	cis	rs7561528	0.501	rs55646068	chr2:127869366	A/G	cg12632573	chr2:127783243	NA	0.72	6.55	0.39	3.65e-10	Alzheimer's disease;Alzheimer's disease (late onset);
SARC	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.78	-0.5	3.56e-16	Alzheimer's disease;
SARC	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg06212747	chr3:49208901	KLHDC8B	0.76	11.14	0.59	2.16e-23	Menarche (age at onset);
SARC	cis	rs2635047	0.638	rs2668761	chr18:44673049	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	6.59	0.4	2.84e-10	Educational attainment;
SARC	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg26924012	chr15:45694286	SPATA5L1	0.77	10.99	0.58	6.8e-23	Homoarginine levels;
SARC	cis	rs7223966	0.921	rs7225092	chr17:61864005	G/T	cg26338869	chr17:61819248	STRADA	0.49	5.18	0.32	4.75e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1215050	0.904	rs260898	chr4:98706492	C/G	cg05340658	chr4:99064831	C4orf37	-0.41	-5.08	-0.32	7.72e-7	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs2153535	0.580	rs9393016	chr6:8458573	T/A	cg07606381	chr6:8435919	SLC35B3	0.75	10.66	0.57	7.43e-22	Motion sickness;
SARC	cis	rs6448317	0.597	rs3843416	chr4:24903822	T/C	cg21108841	chr4:24914750	CCDC149	0.49	4.78	0.3	3.07e-6	Heschl's gyrus morphology;
SARC	cis	rs1878931	0.555	rs27228	chr16:3431933	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.66	-7.14	-0.42	1.15e-11	Body mass index (adult);
SARC	cis	rs9325144	0.555	rs4882279	chr12:38688918	C/A	cg13010199	chr12:38710504	ALG10B	0.55	7.22	0.43	7.12e-12	Morning vs. evening chronotype;
SARC	cis	rs13314892	0.764	rs62251040	chr3:69869384	T/C	cg17445875	chr3:69859618	MITF	-0.49	-5.12	-0.32	6.44e-7	QRS complex (12-leadsum);
SARC	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg06028808	chr11:68637592	NA	0.44	5.42	0.33	1.51e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs6735179	0.688	rs2382562	chr2:1763509	G/A	cg08534653	chr2:1747700	PXDN	0.38	4.72	0.3	4.01e-6	Response to antipsychotic treatment;
SARC	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg07308232	chr7:1071921	C7orf50	-0.55	-6.96	-0.42	3.36e-11	Longevity;Endometriosis;
SARC	cis	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg12463550	chr7:65579703	CRCP	0.64	5.33	0.33	2.32e-7	Diabetic kidney disease;
SARC	cis	rs6582630	0.504	rs4882367	chr12:38330878	A/T	cg26384229	chr12:38710491	ALG10B	-0.58	-7.12	-0.42	1.35e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6570726	0.935	rs421268	chr6:145845558	A/T	cg05347473	chr6:146136440	FBXO30	0.49	6.55	0.39	3.56e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs644799	0.710	rs519511	chr11:95538270	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.6	7.87	0.46	1.29e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs3733585	0.631	rs4697707	chr4:10119787	G/T	cg11266682	chr4:10021025	SLC2A9	-0.39	-6.39	-0.39	8.94e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs72781680	1.000	rs12620594	chr2:24194490	G/A	cg06627628	chr2:24431161	ITSN2	-0.7	-6.71	-0.4	1.49e-10	Lymphocyte counts;
SARC	trans	rs61931739	0.679	rs10844831	chr12:34311245	G/T	cg13010199	chr12:38710504	ALG10B	0.56	7.32	0.43	4.1e-12	Morning vs. evening chronotype;
SARC	trans	rs9329221	0.662	rs9650650	chr8:10247976	C/T	cg06636001	chr8:8085503	FLJ10661	0.61	7.49	0.44	1.44e-12	Neuroticism;
SARC	cis	rs858239	0.600	rs7776649	chr7:23119317	C/T	cg23682824	chr7:23144976	KLHL7	0.72	9.68	0.54	7.7e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs7084402	1.000	rs34774248	chr10:60269691	A/G	cg07615347	chr10:60278583	BICC1	-0.58	-8.47	-0.49	2.84e-15	Refractive error;
SARC	cis	rs9462027	0.628	rs3734268	chr6:34716028	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.4	-5.7	-0.35	3.67e-8	Systemic lupus erythematosus;
SARC	cis	rs4319547	0.695	rs4758643	chr12:122924819	A/T	cg23029597	chr12:123009494	RSRC2	-0.41	-5.01	-0.31	1.06e-6	Body mass index;
SARC	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg22004693	chr7:99632812	ZKSCAN1	0.55	5.5	0.34	1e-7	Lung function (FEV1/FVC);
SARC	cis	rs4148883	0.689	rs1869458	chr4:100024728	C/G	cg13256891	chr4:100009986	ADH5	0.61	8.41	0.48	4.12e-15	Alcohol dependence;
SARC	cis	rs4727027	0.704	rs12535115	chr7:148895087	C/T	cg23583168	chr7:148888333	NA	-0.82	-13.46	-0.66	6.25e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs1983891	1.000	rs2104506	chr6:41533579	C/A	cg15051332	chr6:41514432	FOXP4	0.54	5.96	0.36	9.49e-9	Prostate cancer;
SARC	trans	rs79976124	0.797	rs74995761	chr6:66640216	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	7.86	0.46	1.41e-13	Type 2 diabetes;
SARC	cis	rs9916302	0.800	rs11869259	chr17:37518141	C/A	cg00129232	chr17:37814104	STARD3	0.6	7.36	0.43	3.15e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs372883	0.600	rs2832298	chr21:30743863	C/G	cg24692254	chr21:30365293	RNF160	0.65	8.65	0.49	8.3e-16	Pancreatic cancer;
SARC	cis	rs11122272	0.735	rs2572254	chr1:231512593	T/C	cg06096015	chr1:231504339	EGLN1	0.38	5.72	0.35	3.28e-8	Hemoglobin concentration;
SARC	cis	rs1044826	1.000	rs9849578	chr3:139089602	C/T	cg15131784	chr3:139108705	COPB2	0.45	5.21	0.32	4.24e-7	Obesity-related traits;
SARC	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg05861140	chr6:150128134	PCMT1	-0.42	-5.44	-0.34	1.32e-7	Lung cancer;
SARC	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg21724239	chr8:58056113	NA	0.45	4.88	0.3	1.99e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs3820928	0.967	rs2396435	chr2:227778397	G/A	cg05526886	chr2:227700861	RHBDD1	-0.52	-6.25	-0.38	1.93e-9	Pulmonary function;
SARC	cis	rs10861342	1.000	rs2888841	chr12:105493750	C/T	cg23923672	chr12:105501055	KIAA1033	0.74	5.01	0.31	1.06e-6	IgG glycosylation;
SARC	cis	rs7208859	0.673	rs9899943	chr17:29223925	G/A	cg13385521	chr17:29058706	SUZ12P	0.85	7.23	0.43	7.08e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg18715318	chr22:19420067	HIRA;MRPL40	0.75	6.47	0.39	5.78e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9747201	1.000	rs36048409	chr17:80096961	T/A	cg09264619	chr17:80180166	NA	0.49	5.76	0.35	2.64e-8	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs7103648	0.966	rs10838702	chr11:47410888	G/T	cg10504702	chr11:47789108	FNBP4	0.55	6.91	0.41	4.57e-11	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg14403583	chr14:105418241	AHNAK2	-0.58	-7.63	-0.45	6.09e-13	Rheumatoid arthritis;
SARC	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg02592271	chr2:27665507	KRTCAP3	0.41	6.26	0.38	1.79e-9	Total body bone mineral density;
SARC	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.65	5.91	0.36	1.24e-8	Platelet count;
SARC	cis	rs9355610	0.892	rs2247314	chr6:167370230	T/C	cg23791538	chr6:167370224	RNASET2	0.66	9.24	0.52	1.58e-17	Graves' disease;
SARC	cis	rs10752881	1.000	rs8179283	chr1:182974602	C/T	cg13390022	chr1:182993471	LAMC1	0.33	5.06	0.31	8.36e-7	Colorectal cancer;
SARC	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg20965017	chr5:231967	SDHA	0.53	5.0	0.31	1.14e-6	Breast cancer;
SARC	cis	rs4073582	0.595	rs1115508	chr11:65923149	A/G	cg14036092	chr11:66035641	RAB1B	0.58	8.06	0.47	3.93e-14	Gout;
SARC	cis	rs7044106	0.791	rs4836830	chr9:123483668	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	5.93	0.36	1.08e-8	Hip circumference adjusted for BMI;
SARC	cis	rs4073054	0.564	rs10797094	chr1:161182672	G/A	cg13853198	chr1:161185092	FCER1G	0.29	4.82	0.3	2.53e-6	Blood metabolite levels;
SARC	cis	rs6446731	0.614	rs7661630	chr4:3280106	G/A	cg06533319	chr4:3265114	C4orf44	-0.32	-5.12	-0.32	6.48e-7	Mean platelet volume;
SARC	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg04518342	chr5:131593106	PDLIM4	0.41	5.62	0.35	5.42e-8	Acylcarnitine levels;
SARC	cis	rs9473924	0.542	rs2857514	chr6:50811283	C/T	cg14470998	chr6:50812995	TFAP2B	0.68	5.57	0.34	7.11e-8	Body mass index;
SARC	cis	rs7027203	0.576	rs11790754	chr9:96535709	T/G	cg14598338	chr9:96623480	NA	0.34	4.76	0.3	3.42e-6	DNA methylation (variation);
SARC	cis	rs6831352	0.879	rs56295995	chr4:100060899	C/T	cg12011299	chr4:100065546	ADH4	-0.35	-5.75	-0.35	2.8e-8	Alcohol dependence;
SARC	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg22974920	chr21:40686053	BRWD1	0.45	4.79	0.3	3e-6	Cognitive function;
SARC	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg16479474	chr6:28041457	NA	0.36	5.25	0.33	3.43e-7	Depression;
SARC	cis	rs778371	0.522	rs6704768	chr2:233592501	C/T	cg20388707	chr2:233749442	NGEF	-0.35	-5.38	-0.33	1.83e-7	Schizophrenia;
SARC	cis	rs9486715	0.838	rs6928442	chr6:96870118	A/G	cg06623918	chr6:96969491	KIAA0776	0.88	12.7	0.64	1.95e-28	Headache;
SARC	trans	rs2727020	0.729	rs1917325	chr11:49370004	G/A	cg15704280	chr7:45808275	SEPT13	-0.82	-13.26	-0.66	2.83e-30	Coronary artery disease;
SARC	cis	rs7584330	0.738	rs4402703	chr2:238374957	T/A	cg14458575	chr2:238380390	NA	0.4	4.75	0.3	3.54e-6	Prostate cancer;
SARC	cis	rs986417	1.000	rs1268621	chr14:60921571	G/A	cg27398547	chr14:60952738	C14orf39	-1.02	-9.54	-0.53	2.06e-18	Gut microbiota (bacterial taxa);
SARC	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg20965017	chr5:231967	SDHA	-0.55	-5.26	-0.33	3.23e-7	Breast cancer;
SARC	cis	rs13144136	0.687	rs11725559	chr4:10654270	A/G	cg10242279	chr4:10666415	CLNK	0.39	6.39	0.39	8.76e-10	Resistance to antihypertensive treatment in hypertension;
SARC	cis	rs7429990	0.965	rs1137524	chr3:47956424	C/T	cg11946769	chr3:48343235	NME6	0.44	5.06	0.31	8.47e-7	Educational attainment (years of education);
SARC	cis	rs9815354	0.812	rs73071330	chr3:41810553	T/G	cg03022575	chr3:42003672	ULK4	0.72	5.99	0.37	7.83e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9818758	0.505	rs11716159	chr3:49631585	G/A	cg07636037	chr3:49044803	WDR6	-0.8	-6.62	-0.4	2.41e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs7578035	0.935	rs13000014	chr2:99383330	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.38	-4.84	-0.3	2.35e-6	Bipolar disorder;
SARC	cis	rs11690935	0.959	rs7597387	chr2:172577116	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.98	-15.72	-0.72	1.85e-38	Schizophrenia;
SARC	cis	rs448720	0.806	rs11071966	chr15:68163774	G/A	cg05925327	chr15:68127851	NA	0.36	5.1	0.32	7.15e-7	Cognitive performance;
SARC	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg19223190	chr17:80058835	NA	-0.4	-5.56	-0.34	7.44e-8	Life satisfaction;
SARC	cis	rs7011049	1.000	rs7011049	chr8:53834012	C/A	cg26025543	chr8:53854495	NA	0.6	5.47	0.34	1.15e-7	Systolic blood pressure;
SARC	cis	rs2624839	0.704	rs14321	chr3:50226151	T/C	cg14019146	chr3:50243930	SLC38A3	0.45	7.26	0.43	5.92e-12	Intelligence (multi-trait analysis);
SARC	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.07	0.59	3.73e-23	Alzheimer's disease;
SARC	trans	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg07211511	chr3:129823064	LOC729375	-0.62	-6.66	-0.4	1.92e-10	Blood pressure (smoking interaction);
SARC	cis	rs9303401	0.614	rs2007993	chr17:56590643	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	11.68	0.61	4.19e-25	Cognitive test performance;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg07508260	chr11:111742291	ALG9	0.51	6.65	0.4	2.07e-10	Lung adenocarcinoma;
SARC	cis	rs2153535	0.601	rs2143353	chr6:8530111	T/G	cg07606381	chr6:8435919	SLC35B3	0.74	10.6	0.57	1.12e-21	Motion sickness;
SARC	cis	rs6831352	0.918	rs4699712	chr4:100060490	A/T	cg12011299	chr4:100065546	ADH4	-0.35	-5.75	-0.35	2.8e-8	Alcohol dependence;
SARC	cis	rs17376456	0.825	rs10064368	chr5:93266396	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.67	6.14	0.37	3.48e-9	Diabetic retinopathy;
SARC	cis	rs3888647	0.622	rs4758618	chr11:2995186	A/T	cg20651018	chr11:3035856	CARS	-0.45	-7.13	-0.42	1.27e-11	Type 2 diabetes;
SARC	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	5.42	0.33	1.47e-7	Bipolar disorder;
SARC	cis	rs7666738	0.830	rs13147195	chr4:98893334	G/T	cg05340658	chr4:99064831	C4orf37	0.64	8.45	0.48	3.18e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.43	5.98	0.36	8.49e-9	Personality dimensions;
SARC	cis	rs7647973	1.000	rs6446268	chr3:49445695	G/A	cg07636037	chr3:49044803	WDR6	-0.78	-8.64	-0.49	9.04e-16	Menarche (age at onset);
SARC	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.99	-11.14	-0.59	2.12e-23	Alzheimer's disease;
SARC	cis	rs9807989	0.839	rs11695627	chr2:102970105	A/G	cg09003973	chr2:102972529	NA	0.41	5.6	0.34	6.11e-8	Asthma;
SARC	cis	rs7005380	0.581	rs6469876	chr8:120935251	G/T	cg21744203	chr8:120868354	DSCC1	0.45	5.29	0.33	2.75e-7	Interstitial lung disease;
SARC	cis	rs10504229	0.679	rs12679920	chr8:58051710	G/T	cg21724239	chr8:58056113	NA	0.56	5.67	0.35	4.28e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg17342834	chr11:535396	HRAS	-0.52	-6.29	-0.38	1.51e-9	Height;
SARC	cis	rs995000	0.895	rs597076	chr1:62917865	T/A	cg06896770	chr1:63153194	DOCK7	0.9	13.85	0.67	3.23e-32	Triglyceride levels;
SARC	cis	rs2213920	0.619	rs4979529	chr9:118197686	T/A	cg13918206	chr9:118159781	DEC1	0.82	6.54	0.39	3.77e-10	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs17376456	0.569	rs2045020	chr5:93224466	T/C	cg21475434	chr5:93447410	FAM172A	-0.67	-6.86	-0.41	6.28e-11	Diabetic retinopathy;
SARC	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg05861140	chr6:150128134	PCMT1	-0.42	-5.24	-0.32	3.57e-7	Lung cancer;
SARC	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.97	11.13	0.59	2.35e-23	Platelet count;
SARC	trans	rs1814175	0.935	rs11040462	chr11:49683158	G/A	cg03929089	chr4:120376271	NA	-0.86	-13.53	-0.66	3.54e-31	Height;
SARC	cis	rs2816062	0.813	rs742485	chr1:18900943	A/T	cg10574377	chr1:18908098	NA	0.35	4.94	0.31	1.52e-6	Urate levels in lean individuals;
SARC	cis	rs7264396	0.635	rs6119672	chr20:34479767	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-7.65	-0.45	5.16e-13	Total cholesterol levels;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg07179770	chr16:84681994	KLHL36	0.57	7.71	0.45	3.68e-13	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg00262122	chr8:11665843	FDFT1	0.42	5.21	0.32	4.2e-7	Retinal vascular caliber;
SARC	cis	rs10791323	0.593	rs2156676	chr11:133715791	G/C	cg15485101	chr11:133734466	NA	0.33	5.12	0.32	6.5e-7	Childhood ear infection;
SARC	cis	rs78487399	0.710	rs57696714	chr2:43626521	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-5.03	-0.31	9.83e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs8084125	1.000	rs72978665	chr18:74953641	A/G	cg05528293	chr18:74961138	GALR1	0.5	5.65	0.35	4.73e-8	Obesity-related traits;
SARC	cis	rs7927592	0.763	rs7129248	chr11:68263276	A/T	cg01657329	chr11:68192670	LRP5	-0.37	-5.14	-0.32	5.76e-7	Total body bone mineral density;
SARC	cis	rs6938	0.563	rs12917376	chr15:75116167	C/T	cg00629941	chr15:75287862	SCAMP5	0.48	5.99	0.37	8.04e-9	Breast cancer;
SARC	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg16325326	chr1:53192061	ZYG11B	0.95	18.15	0.77	1.75e-46	Monocyte count;
SARC	cis	rs17376456	1.000	rs9968749	chr5:93509559	A/G	cg21475434	chr5:93447410	FAM172A	0.92	7.93	0.46	9.34e-14	Diabetic retinopathy;
SARC	cis	rs1881797	0.932	rs10925071	chr1:247686521	C/T	cg11166453	chr1:247681781	NA	-0.49	-5.79	-0.35	2.26e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg13114125	chr14:105738426	BRF1	0.72	10.41	0.56	4.24e-21	Mean platelet volume;Platelet distribution width;
SARC	cis	rs6484504	0.532	rs1929019	chr11:31267030	C/T	cg14844989	chr11:31128820	NA	-0.34	-4.78	-0.3	3.11e-6	Red blood cell count;
SARC	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs11792861	0.525	rs2417975	chr9:111860185	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	5.4	0.33	1.64e-7	Menarche (age at onset);
SARC	cis	rs123509	0.913	rs339661	chr3:42753904	G/A	cg10144569	chr3:42726640	KBTBD5	0.46	4.76	0.3	3.4e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1348850	0.526	rs2178017	chr2:178374788	G/T	cg23306229	chr2:178417860	TTC30B	0.84	7.66	0.45	4.88e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg05025164	chr4:1340916	KIAA1530	0.85	11.02	0.59	5.45e-23	Longevity;
SARC	cis	rs1355223	0.583	rs1553757	chr11:34867089	G/A	cg18508148	chr11:34937573	PDHX;APIP	0.52	6.79	0.41	9.3e-11	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs4566357	0.615	rs10184991	chr2:227916533	G/A	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.97	-0.36	8.81e-9	Coronary artery disease;
SARC	cis	rs2120019	0.938	rs2304903	chr15:75315778	A/G	cg09165964	chr15:75287851	SCAMP5	-0.95	-14.37	-0.69	5.71e-34	Blood trace element (Zn levels);
SARC	cis	rs3733585	0.604	rs73215003	chr4:10126317	C/G	cg11266682	chr4:10021025	SLC2A9	-0.41	-6.82	-0.41	7.67e-11	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7520050	0.966	rs7540325	chr1:46338217	A/T	cg24296786	chr1:45957014	TESK2	0.39	4.92	0.31	1.63e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs4689388	0.890	rs13130845	chr4:6297646	A/C	cg25554036	chr4:6271136	WFS1	0.38	6.01	0.37	7.19e-9	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs9916302	0.904	rs3744348	chr17:37417575	C/G	cg20243544	chr17:37824526	PNMT	0.56	6.84	0.41	6.78e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs6840360	0.593	rs10033405	chr4:152474489	A/G	cg22705602	chr4:152727874	NA	-0.4	-6.25	-0.38	1.92e-9	Intelligence (multi-trait analysis);
SARC	cis	rs9398803	0.678	rs1844593	chr6:126897827	G/A	cg20229609	chr6:126660872	C6orf173	0.35	5.07	0.31	8.26e-7	Male-pattern baldness;
SARC	cis	rs16976116	0.851	rs28889339	chr15:55503205	T/G	cg17854078	chr15:55489399	RSL24D1	0.66	6.53	0.39	4.18e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs929354	0.742	rs7801905	chr7:156940111	T/C	cg05182265	chr7:156933206	UBE3C	-0.34	-5.19	-0.32	4.49e-7	Body mass index;
SARC	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg11766577	chr21:47581405	C21orf56	0.42	5.15	0.32	5.6e-7	Testicular germ cell tumor;
SARC	cis	rs1559088	0.847	rs2287680	chr19:33608566	A/G	cg03563238	chr19:33554763	RHPN2	0.26	4.76	0.3	3.39e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs7223966	1.000	rs9899788	chr17:61756384	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.48	-5.35	-0.33	2.07e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9399135	1.000	rs35123050	chr6:135302740	G/A	cg24558204	chr6:135376177	HBS1L	0.44	5.95	0.36	9.58e-9	Red blood cell count;
SARC	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.55	6.3	0.38	1.5e-9	Renal function-related traits (BUN);
SARC	cis	rs9814567	1.000	rs9813774	chr3:134227100	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-7.02	-0.42	2.38e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg20891558	chr2:74357851	NA	0.68	9.55	0.53	1.89e-18	Gestational age at birth (maternal effect);
SARC	cis	rs9388451	0.626	rs1343116	chr6:126069702	C/A	cg06289844	chr6:126071538	HEY2	0.36	5.54	0.34	8.2e-8	Brugada syndrome;
SARC	cis	rs6570726	0.738	rs6925594	chr6:145898454	T/C	cg23711669	chr6:146136114	FBXO30	0.83	13.94	0.67	1.53e-32	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10782582	0.593	rs115291524	chr1:76141811	A/G	cg10523679	chr1:76189770	ACADM	-0.42	-5.05	-0.31	9.06e-7	Daytime sleep phenotypes;
SARC	cis	rs79387448	0.638	rs74731686	chr2:103043981	G/A	cg09003973	chr2:102972529	NA	0.77	7.48	0.44	1.5e-12	Gut microbiota (bacterial taxa);
SARC	cis	rs11581859	0.613	rs1545836	chr1:99234825	G/A	cg20286094	chr1:99190917	SNX7	-0.43	-5.08	-0.32	7.68e-7	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs2204008	0.805	rs12146846	chr12:37985847	C/T	cg13010199	chr12:38710504	ALG10B	0.78	10.73	0.57	4.45e-22	Bladder cancer;
SARC	cis	rs4727027	0.835	rs11767810	chr7:148774433	T/A	cg23583168	chr7:148888333	NA	-0.73	-10.56	-0.57	1.52e-21	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs3008870	0.958	rs12143044	chr1:67460054	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.89	-11.03	-0.59	4.76e-23	Lymphocyte percentage of white cells;
SARC	cis	rs865483	0.895	rs853211	chr17:35828164	T/C	cg06561646	chr17:35873369	DUSP14	-0.49	-6.55	-0.39	3.6e-10	Monocyte count;
SARC	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg13385521	chr17:29058706	SUZ12P	0.64	5.87	0.36	1.53e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs7246760	0.867	rs68041339	chr19:9818851	A/G	cg16876255	chr19:9731953	ZNF561	0.79	4.88	0.3	1.96e-6	Pursuit maintenance gain;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg17470723	chr8:74884337	TCEB1	-0.52	-6.29	-0.38	1.58e-9	Schizophrenia;
SARC	cis	rs734999	0.545	rs10910106	chr1:2538886	G/T	cg20673091	chr1:2541236	MMEL1	0.34	5.13	0.32	6.15e-7	Ulcerative colitis;
SARC	cis	rs7635838	0.587	rs347591	chr3:11290122	G/T	cg00170343	chr3:11313890	ATG7	0.73	9.69	0.54	7.23e-19	HDL cholesterol;
SARC	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg14784868	chr12:69753453	YEATS4	0.64	8.93	0.5	1.3e-16	Cerebrospinal fluid biomarker levels;
SARC	cis	rs2425143	1.000	rs7261284	chr20:34244104	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-5.75	-0.35	2.78e-8	Blood protein levels;
SARC	cis	rs6570726	0.935	rs411641	chr6:145827532	G/A	cg05220968	chr6:146057943	EPM2A	-0.29	-4.97	-0.31	1.27e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg13395646	chr4:1353034	KIAA1530	-0.45	-5.31	-0.33	2.58e-7	Obesity-related traits;
SARC	cis	rs7086627	0.515	rs11202957	chr10:82209592	A/G	cg01528321	chr10:82214614	TSPAN14	0.57	8.41	0.48	4.07e-15	Post bronchodilator FEV1;
SARC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg26354017	chr1:205819088	PM20D1	-0.73	-11.42	-0.6	2.82e-24	Monocyte percentage of white cells;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg12548088	chr19:12777567	MORG1;MAN2B1	-0.54	-6.83	-0.41	7.33e-11	Gallstone disease;
SARC	cis	rs981844	0.890	rs56184506	chr4:154685889	G/T	cg14289246	chr4:154710475	SFRP2	0.63	7.05	0.42	2.04e-11	Response to statins (LDL cholesterol change);
SARC	cis	rs8067545	0.750	rs4925069	chr17:19953531	C/G	cg13482628	chr17:19912719	NA	0.54	7.25	0.43	5.95e-12	Schizophrenia;
SARC	cis	rs2153535	0.580	rs4960411	chr6:8438231	C/G	cg23788917	chr6:8435910	SLC35B3	0.63	8.27	0.48	1.05e-14	Motion sickness;
SARC	trans	rs1994135	0.630	rs11052757	chr12:33719879	A/G	cg13010199	chr12:38710504	ALG10B	0.76	8.92	0.5	1.41e-16	Resting heart rate;
SARC	cis	rs10425738	0.830	rs3844444	chr19:41434047	A/G	cg17435250	chr19:41386441	CYP2A7	-0.41	-4.85	-0.3	2.23e-6	nicotine metabolite ratio in current smokers;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
SARC	cis	rs9303401	0.921	rs34102441	chr17:56877414	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.68	7.91	0.46	1.01e-13	Cognitive test performance;
SARC	cis	rs9902453	0.765	rs8071576	chr17:28188554	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	7.45	0.44	1.82e-12	Coffee consumption (cups per day);
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg24508409	chr1:112298175	DDX20;C1orf183	-0.5	-6.23	-0.38	2.12e-9	Schizophrenia;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg01566242	chr1:150266242	MRPS21	0.52	6.71	0.4	1.45e-10	Height;
SARC	cis	rs9787249	0.957	rs11206754	chr1:40216234	A/G	cg02773041	chr1:40204384	PPIE	0.52	6.34	0.38	1.16e-9	Blood protein levels;
SARC	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg25894440	chr7:65020034	NA	-0.75	-5.62	-0.35	5.47e-8	Diabetic kidney disease;
SARC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg17330251	chr7:94953956	PON1	-0.45	-6.42	-0.39	7.42e-10	Paraoxonase activity;
SARC	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs11214589	0.774	rs10891544	chr11:113256152	A/C	cg14159747	chr11:113255604	NA	-0.36	-5.24	-0.32	3.55e-7	Neuroticism;
SARC	cis	rs7769051	0.615	rs12209144	chr6:133191064	A/T	cg22852734	chr6:133119734	C6orf192	0.88	7.42	0.44	2.18e-12	Type 2 diabetes nephropathy;
SARC	cis	rs1008375	0.932	rs6857678	chr4:17696964	A/T	cg16339924	chr4:17578868	LAP3	0.52	6.67	0.4	1.8e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6834538	0.894	rs4383675	chr4:113572619	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.46	5.35	0.33	2.14e-7	Free thyroxine concentration;
SARC	cis	rs9420	0.961	rs11607056	chr11:57496820	C/T	cg19752551	chr11:57585705	CTNND1	-0.5	-6.79	-0.41	9.24e-11	Schizophrenia;
SARC	cis	rs2439831	0.850	rs7169322	chr15:44131014	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	7.59	0.45	7.57e-13	Lung cancer in ever smokers;
SARC	trans	rs61931739	0.500	rs6416261	chr12:34540377	T/C	cg13010199	chr12:38710504	ALG10B	0.78	11.07	0.59	3.68e-23	Morning vs. evening chronotype;
SARC	cis	rs2952156	1.000	rs2934971	chr17:37854507	G/T	cg00129232	chr17:37814104	STARD3	-0.68	-8.68	-0.49	7.03e-16	Asthma;
SARC	cis	rs7587476	0.689	rs78989396	chr2:215714816	C/T	cg04530015	chr2:215796436	ABCA12	-0.41	-6.62	-0.4	2.51e-10	Neuroblastoma;
SARC	cis	rs3099143	1.000	rs2011635	chr15:77134891	T/A	cg21673338	chr15:77095150	SCAPER	-0.76	-6.25	-0.38	1.93e-9	Recalcitrant atopic dermatitis;
SARC	cis	rs9420	0.809	rs11600169	chr11:57464945	T/A	cg19752551	chr11:57585705	CTNND1	-0.48	-6.41	-0.39	7.88e-10	Schizophrenia;
SARC	cis	rs887829	0.570	rs6753320	chr2:234595615	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.33	4.78	0.3	3.16e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
SARC	cis	rs995000	0.839	rs12090886	chr1:62981440	G/A	cg06896770	chr1:63153194	DOCK7	-0.89	-12.99	-0.65	2.12e-29	Triglyceride levels;
SARC	cis	rs11097912	0.632	rs7688008	chr4:107216896	G/C	cg09646026	chr4:107269030	AIMP1	-0.43	-4.79	-0.3	2.96e-6	Airflow obstruction;
SARC	cis	rs2197308	0.740	rs11182967	chr12:37935140	A/C	cg26384229	chr12:38710491	ALG10B	0.9	13.38	0.66	1.18e-30	Morning vs. evening chronotype;
SARC	cis	rs760805	1.000	rs10903115	chr1:25261696	A/G	cg22509179	chr1:25234806	RUNX3	-0.49	-6.82	-0.41	7.55e-11	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs7927771	0.542	rs7122217	chr11:47777920	G/C	cg10504702	chr11:47789108	FNBP4	-0.43	-5.62	-0.35	5.45e-8	Subjective well-being;
SARC	trans	rs877282	0.700	rs816311	chr10:796490	C/A	cg22713356	chr15:30763199	NA	0.94	9.61	0.53	1.22e-18	Uric acid levels;
SARC	cis	rs35213789	0.762	rs2851501	chr7:69110858	G/A	cg10619644	chr7:69149951	AUTS2	-0.36	-4.85	-0.3	2.25e-6	Childhood ear infection;
SARC	cis	rs6429082	0.702	rs10802797	chr1:235705673	A/G	cg26050004	chr1:235667680	B3GALNT2	0.48	5.48	0.34	1.08e-7	Adiposity;
SARC	cis	rs1109501	0.734	rs34066179	chr4:71418908	C/T	cg22786090	chr4:71381880	NA	-0.37	-4.81	-0.3	2.68e-6	Alcoholism (heaviness of drinking);
SARC	cis	rs4713118	0.869	rs6922574	chr6:27693003	A/T	cg17221315	chr6:27791827	HIST1H4J	0.49	5.34	0.33	2.26e-7	Parkinson's disease;
SARC	cis	rs9815354	0.812	rs113300894	chr3:41984243	G/C	cg03022575	chr3:42003672	ULK4	0.69	5.65	0.35	4.69e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs668210	0.947	rs610497	chr11:65765551	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.56	6.06	0.37	5.46e-9	Cerebrospinal fluid biomarker levels;
SARC	cis	rs12926788	0.689	rs34365165	chr16:24856208	G/A	cg00339695	chr16:24857497	SLC5A11	0.38	5.2	0.32	4.34e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs7826238	0.623	rs2976893	chr8:8338219	G/T	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.81	-0.41	8.23e-11	Systolic blood pressure;
SARC	cis	rs372883	0.648	rs2832297	chr21:30742996	A/C	cg08807101	chr21:30365312	RNF160	0.54	6.82	0.41	7.63e-11	Pancreatic cancer;
SARC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg02600494	chr17:73257794	MRPS7;GGA3	-0.51	-6.27	-0.38	1.69e-9	HDL cholesterol;
SARC	cis	rs11252926	1.000	rs11252926	chr10:566379	C/T	cg08603382	chr10:743973	NA	-0.63	-8.11	-0.47	2.87e-14	Psychosis in Alzheimer's disease;
SARC	cis	rs7666738	0.830	rs10007872	chr4:99001904	T/C	cg05340658	chr4:99064831	C4orf37	0.64	8.59	0.49	1.22e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs921968	0.508	rs72965103	chr2:219312469	T/C	cg02176678	chr2:219576539	TTLL4	-0.5	-7.57	-0.44	8.87e-13	Mean corpuscular hemoglobin concentration;
SARC	cis	rs6963495	0.818	rs73190149	chr7:105152793	C/T	cg19920283	chr7:105172520	RINT1	0.63	5.3	0.33	2.75e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs912057	0.526	rs737449	chr6:6733729	A/G	cg06612196	chr6:6737390	NA	-0.72	-11.84	-0.61	1.28e-25	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs6964587	0.585	rs10266481	chr7:91554338	T/C	cg17063962	chr7:91808500	NA	-0.78	-11.2	-0.59	1.44e-23	Breast cancer;
SARC	cis	rs72653721	0.838	rs911196	chr6:10990751	T/G	cg13562911	chr6:11044106	ELOVL2	0.55	6.24	0.38	2.03e-9	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	cis	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg00745463	chr17:30367425	LRRC37B	-0.63	-5.02	-0.31	1.05e-6	Hip circumference adjusted for BMI;
SARC	cis	rs7726839	0.578	rs10080150	chr5:593160	C/T	cg09021430	chr5:549028	NA	0.53	10.64	0.57	8.44e-22	Obesity-related traits;
SARC	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.63	-6.41	-0.39	8.13e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg22875332	chr1:76189707	ACADM	-0.42	-5.53	-0.34	8.5e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6484504	0.532	rs2616799	chr11:31319044	T/C	cg02090638	chr11:31391270	DNAJC24;DCDC1	0.42	5.31	0.33	2.51e-7	Red blood cell count;
SARC	trans	rs7815944	1.000	rs80294477	chr8:129424138	G/A	cg25487405	chr22:46473039	NA	0.64	6.35	0.38	1.09e-9	Atopic dermatitis;
SARC	cis	rs3847687	1.000	rs3847687	chr12:131525053	C/T	cg25772418	chr12:131519998	GPR133	-0.3	-4.79	-0.3	2.97e-6	Longevity;
SARC	cis	rs11687170	0.882	rs6757833	chr2:237053514	A/T	cg19324714	chr2:237145437	ASB18	0.46	4.73	0.3	3.97e-6	Educational attainment;Educational attainment (years of education);
SARC	cis	rs11190604	1.000	rs2489043	chr10:102334327	T/C	cg14256752	chr10:102295592	HIF1AN	0.41	4.76	0.3	3.45e-6	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs314370	0.951	rs12705095	chr7:100484381	T/G	cg10426581	chr7:100472382	SRRT	0.62	6.56	0.39	3.53e-10	Resting heart rate;
SARC	cis	rs10927875	0.632	rs7535248	chr1:16129598	C/T	cg07117364	chr1:16154769	NA	-0.42	-4.89	-0.31	1.86e-6	Dilated cardiomyopathy;
SARC	cis	rs8077889	1.000	rs17674998	chr17:41879544	A/G	cg26893861	chr17:41843967	DUSP3	0.86	9.92	0.55	1.37e-19	Triglycerides;
SARC	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg13264159	chr8:625131	ERICH1	-0.63	-4.79	-0.3	2.96e-6	IgG glycosylation;
SARC	cis	rs11122272	0.735	rs2790880	chr1:231534259	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-9.93	-0.55	1.35e-19	Hemoglobin concentration;
SARC	cis	rs7000551	0.751	rs2449341	chr8:22390937	C/A	cg12081754	chr8:22256438	SLC39A14	0.57	7.9	0.46	1.09e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs4930561	0.714	rs7950452	chr11:67962407	C/A	cg16338278	chr11:67432957	ALDH3B2	0.34	5.6	0.34	6.12e-8	Breast cancer in childhood cancer survivors;IgG glycosylation;
SARC	cis	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg16662139	chr6:27806254	HIST1H2BN;HIST1H2AK	-0.4	-4.91	-0.31	1.69e-6	Schizophrenia;
SARC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg09373136	chr17:61933544	TCAM1	-0.44	-5.93	-0.36	1.09e-8	Prudent dietary pattern;
SARC	cis	rs3768617	0.740	rs28533496	chr1:183019885	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	7.98	0.46	6.5e-14	Fuchs's corneal dystrophy;
SARC	cis	rs798554	0.731	rs2283779	chr7:2815140	G/A	cg13628971	chr7:2884303	GNA12	0.43	5.24	0.32	3.56e-7	Height;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg01813026	chr11:809279	RPLP2	0.5	6.45	0.39	6.52e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg03351412	chr1:154909251	PMVK	0.63	8.22	0.47	1.42e-14	Prostate cancer;
SARC	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg06618935	chr21:46677482	NA	-0.41	-5.43	-0.34	1.4e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg17774634	chr6:97730494	C6orf167;MIR548H3	-0.56	-7.93	-0.46	9.12e-14	Thyroid stimulating hormone;
SARC	cis	rs79149102	0.579	rs74023935	chr15:75359184	T/C	cg09165964	chr15:75287851	SCAMP5	-1.08	-9.29	-0.52	1.12e-17	Lung cancer;
SARC	cis	rs17600642	0.724	rs1079352	chr10:72453565	C/T	cg19779893	chr10:72451501	ADAMTS14	-0.38	-5.86	-0.36	1.59e-8	Bipolar disorder;
SARC	cis	rs7264396	0.563	rs56941405	chr20:34313426	C/T	cg01084648	chr20:34329383	RBM39	0.56	4.93	0.31	1.57e-6	Total cholesterol levels;
SARC	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg02841227	chr6:26021843	HIST1H4A	0.45	4.74	0.3	3.76e-6	Intelligence (multi-trait analysis);
SARC	cis	rs4727027	0.933	rs757738	chr7:148872351	T/G	cg23583168	chr7:148888333	NA	-0.73	-10.84	-0.58	1.99e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs17666538	1.000	rs61064968	chr8:587933	T/C	cg23958373	chr8:599963	NA	-0.85	-6.73	-0.4	1.3e-10	IgG glycosylation;
SARC	cis	rs10504073	0.605	rs62507176	chr8:49930321	G/A	cg00325661	chr8:49890786	NA	0.52	6.9	0.41	4.88e-11	Blood metabolite ratios;
SARC	cis	rs2425143	1.000	rs6060639	chr20:34438183	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	4.84	0.3	2.35e-6	Blood protein levels;
SARC	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg06212747	chr3:49208901	KLHDC8B	0.66	8.74	0.5	4.62e-16	Parkinson's disease;
SARC	trans	rs208520	1.000	rs208529	chr6:66957549	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.76	-8.44	-0.48	3.38e-15	Exhaled nitric oxide output;
SARC	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg22800045	chr5:56110881	MAP3K1	-0.64	-6.0	-0.37	7.63e-9	Initial pursuit acceleration;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg16553134	chr10:1034401	GTPBP4	0.49	6.24	0.38	2.01e-9	Lung adenocarcinoma;
SARC	cis	rs9660992	0.710	rs1151787	chr1:205254238	G/A	cg21545522	chr1:205238299	TMCC2	0.47	6.49	0.39	5.19e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs6864727	1.000	rs217267	chr5:137421274	A/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.56	6.24	0.38	2e-9	Atrial fibrillation;
SARC	cis	rs425277	0.958	rs262687	chr1:2117155	G/A	cg21442419	chr1:2182373	SKI	-0.54	-6.7	-0.4	1.56e-10	Height;
SARC	cis	rs35110281	0.807	rs1598206	chr21:45058776	A/G	cg01579765	chr21:45077557	HSF2BP	-0.32	-5.42	-0.33	1.47e-7	Mean corpuscular volume;
SARC	cis	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg05084668	chr3:125655381	ALG1L	-0.48	-4.93	-0.31	1.54e-6	Blood pressure (smoking interaction);
SARC	cis	rs17376456	0.877	rs10476596	chr5:93367074	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.62	-5.68	-0.35	4.08e-8	Diabetic retinopathy;
SARC	cis	rs34375054	0.687	rs12303572	chr12:125611271	G/T	cg25124228	chr12:125621409	AACS	-0.46	-4.95	-0.31	1.45e-6	Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs28437878	1	rs28437878	chr15:78807872	C/T	cg24631222	chr15:78858424	CHRNA5	0.75	9.67	0.54	8.11e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs9660992	0.710	rs1668872	chr1:205236069	G/A	cg21643547	chr1:205240462	TMCC2	-0.64	-8.25	-0.48	1.16e-14	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs11122272	0.735	rs2790886	chr1:231529491	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.14	-0.55	2.99e-20	Hemoglobin concentration;
SARC	cis	rs6582630	0.555	rs12372536	chr12:38400864	C/G	cg26384229	chr12:38710491	ALG10B	0.85	12.08	0.62	2.08e-26	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7429990	0.965	rs13074973	chr3:48028144	T/A	cg11946769	chr3:48343235	NME6	-0.46	-5.39	-0.33	1.75e-7	Educational attainment (years of education);
SARC	cis	rs614226	1.000	rs591992	chr12:121019323	T/C	cg01236616	chr12:121019343	POP5	1.25	18.78	0.78	1.57e-48	Type 1 diabetes nephropathy;
SARC	cis	rs1497406	0.744	rs10907282	chr1:16510139	A/G	cg20430773	chr1:16534157	ARHGEF19	0.46	7.09	0.42	1.6e-11	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9911578	1.000	rs2531734	chr17:56550804	T/C	cg12560992	chr17:57184187	TRIM37	-0.81	-10.75	-0.58	3.84e-22	Intelligence (multi-trait analysis);
SARC	cis	rs35110281	0.633	rs762400	chr21:45113629	C/G	cg04455712	chr21:45112962	RRP1B	-0.35	-5.07	-0.32	8.16e-7	Mean corpuscular volume;
SARC	cis	rs7568458	0.709	rs2028898	chr2:85777270	G/A	cg02493740	chr2:85810744	VAMP5	-0.41	-5.1	-0.32	6.93e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg21132104	chr15:45694354	SPATA5L1	0.75	10.44	0.56	3.56e-21	Homoarginine levels;
SARC	cis	rs7084402	0.935	rs10740732	chr10:60352888	G/A	cg07615347	chr10:60278583	BICC1	0.6	8.68	0.49	7.06e-16	Refractive error;
SARC	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg24060327	chr5:131705240	SLC22A5	-0.73	-8.83	-0.5	2.51e-16	Breast cancer;
SARC	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg08219700	chr8:58056026	NA	0.58	5.68	0.35	4.04e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7666738	0.830	rs34628820	chr4:99004764	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg12463550	chr7:65579703	CRCP	0.48	5.79	0.35	2.23e-8	Aortic root size;
SARC	cis	rs8051517	0.661	rs36087213	chr16:68394763	C/T	cg01866162	chr16:67596514	CTCF	1.08	6.23	0.38	2.15e-9	Blood protein levels;
SARC	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg10295955	chr4:187884368	NA	-1.06	-18.33	-0.77	4.58e-47	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10876993	0.890	rs774888	chr12:58036506	A/G	cg18357645	chr12:58087776	OS9	0.44	5.81	0.36	2.09e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs2645694	0.626	rs2703140	chr4:77830057	C/G	cg18351406	chr4:77819688	ANKRD56	0.4	5.6	0.34	6.14e-8	Emphysema distribution in smoking;
SARC	cis	rs524281	0.861	rs11227426	chr11:65971951	T/C	cg14036092	chr11:66035641	RAB1B	-0.51	-5.4	-0.33	1.62e-7	Electroencephalogram traits;
SARC	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg08048268	chr3:133502702	NA	-0.49	-6.41	-0.39	7.83e-10	Iron status biomarkers;
SARC	cis	rs2153904	0.590	rs823106	chr1:205656453	G/C	cg26354017	chr1:205819088	PM20D1	0.63	5.63	0.35	5.28e-8	Prostate-specific antigen levels;
SARC	cis	rs950880	0.710	rs66919607	chr2:103008969	C/G	cg03938978	chr2:103052716	IL18RAP	-0.34	-4.84	-0.3	2.36e-6	Serum protein levels (sST2);
SARC	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg22857025	chr5:266934	NA	-1.08	-11.84	-0.61	1.25e-25	Breast cancer;
SARC	cis	rs7659604	0.540	rs28672860	chr4:122705051	G/A	cg19748678	chr4:122722346	EXOSC9	-0.42	-5.15	-0.32	5.55e-7	Type 2 diabetes;
SARC	cis	rs910316	1.000	rs12589876	chr14:75544189	G/A	cg11812906	chr14:75593930	NEK9	0.89	13.48	0.66	5.48e-31	Height;
SARC	cis	rs7617773	0.780	rs4511916	chr3:48350366	G/A	cg11946769	chr3:48343235	NME6	0.76	9.7	0.54	6.55e-19	Coronary artery disease;
SARC	cis	rs6120849	0.901	rs6088737	chr20:33745938	A/G	cg24642439	chr20:33292090	TP53INP2	0.49	4.83	0.3	2.44e-6	Protein C levels;
SARC	trans	rs7824557	0.564	rs2437152	chr8:11235497	G/A	cg15556689	chr8:8085844	FLJ10661	-0.55	-6.99	-0.42	2.8e-11	Retinal vascular caliber;
SARC	cis	rs28680850	1.000	rs28680850	chr8:1373720	G/A	cg06035437	chr8:1398411	NA	-0.33	-4.86	-0.3	2.14e-6	Triglycerides;
SARC	cis	rs2404602	0.716	rs17461634	chr15:76764107	G/A	cg22467129	chr15:76604101	ETFA	-0.36	-4.75	-0.3	3.64e-6	Blood metabolite levels;
SARC	cis	rs10490913	0.836	rs10886233	chr10:120160063	G/A	cg23160142	chr10:120154512	NA	0.32	4.76	0.3	3.39e-6	Cancer;
SARC	cis	rs2303759	0.830	rs7257053	chr19:49894456	C/G	cg22307029	chr19:49891270	CCDC155	0.59	7.12	0.42	1.33e-11	Multiple sclerosis;
SARC	cis	rs4746818	0.793	rs2805913	chr10:70858062	A/G	cg11621586	chr10:70884670	VPS26A	0.59	6.72	0.4	1.38e-10	Left atrial antero-posterior diameter;
SARC	cis	rs950027	0.620	rs1145080	chr15:45681338	C/T	cg21132104	chr15:45694354	SPATA5L1	0.55	7.05	0.42	1.96e-11	Response to fenofibrate (adiponectin levels);
SARC	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg12288994	chr5:1860383	NA	0.39	6.36	0.38	1.06e-9	Cardiovascular disease risk factors;
SARC	cis	rs9300255	0.770	rs12299125	chr12:123862447	C/T	cg00376283	chr12:123451042	ABCB9	-0.48	-5.02	-0.31	1.03e-6	Neutrophil percentage of white cells;
SARC	cis	rs73086581	0.787	rs73084505	chr20:3856874	C/T	cg02187196	chr20:3869020	PANK2	0.7	6.03	0.37	6.45e-9	Response to antidepressants in depression;
SARC	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg20573242	chr4:122745356	CCNA2	0.58	7.52	0.44	1.16e-12	Type 2 diabetes;
SARC	cis	rs1008375	1.000	rs28497813	chr4:17685503	A/G	cg02297831	chr4:17616191	MED28	0.43	5.43	0.33	1.44e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7635838	0.586	rs379241	chr3:11291565	G/A	cg00170343	chr3:11313890	ATG7	0.75	10.01	0.55	7.4e-20	HDL cholesterol;
SARC	cis	rs10504229	0.593	rs80174614	chr8:58024631	G/A	cg08280861	chr8:58055591	NA	0.61	5.41	0.33	1.59e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs910316	0.737	rs175055	chr14:75488946	T/G	cg11812906	chr14:75593930	NEK9	-0.76	-10.11	-0.55	3.68e-20	Height;
SARC	cis	rs920590	0.679	rs58556504	chr8:19653674	A/G	cg17834443	chr8:19674713	INTS10	0.4	5.1	0.32	6.91e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs2361718	0.501	rs12944619	chr17:78144109	T/C	cg23534315	chr17:78082725	GAA	0.44	5.51	0.34	9.28e-8	Yeast infection;
SARC	cis	rs11969893	0.737	rs1856131	chr6:101407104	C/G	cg12253828	chr6:101329408	ASCC3	0.92	6.21	0.38	2.46e-9	Economic and political preferences (immigration/crime);
SARC	cis	rs9436747	0.667	rs4655518	chr1:66039858	G/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.49	-5.31	-0.33	2.6e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-9.17	-0.51	2.59e-17	Alzheimer's disease;
SARC	cis	rs611744	0.583	rs1448148	chr8:109333074	T/A	cg21045802	chr8:109455806	TTC35	0.7	9.21	0.52	1.99e-17	Dupuytren's disease;
SARC	cis	rs12709013	0.597	rs11076259	chr16:58783764	A/G	cg04273148	chr16:57808038	KIFC3	0.32	4.72	0.3	4.08e-6	Blood metabolite ratios;
SARC	cis	rs1008375	0.931	rs6449309	chr4:17573208	C/T	cg16339924	chr4:17578868	LAP3	0.69	8.88	0.5	1.89e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg08815785	chr3:178970966	KCNMB3	0.54	7.65	0.45	5.13e-13	Thyroid stimulating hormone;
SARC	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg13902645	chr11:5959945	NA	-0.4	-5.3	-0.33	2.72e-7	DNA methylation (variation);
SARC	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	trans	rs61931739	0.500	rs11053251	chr12:34520743	A/G	cg13010199	chr12:38710504	ALG10B	0.78	11.07	0.59	3.76e-23	Morning vs. evening chronotype;
SARC	cis	rs1008375	1.000	rs11727312	chr4:17669185	C/T	cg02297831	chr4:17616191	MED28	0.43	5.41	0.33	1.55e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs11690935	0.959	rs6754817	chr2:172663394	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.98	-14.87	-0.7	1.33e-35	Schizophrenia;
SARC	cis	rs2439831	1.000	rs689781	chr15:43792097	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.05	10.85	0.58	1.78e-22	Lung cancer in ever smokers;
SARC	cis	rs9399135	0.660	rs4440481	chr6:135276696	A/G	cg24558204	chr6:135376177	HBS1L	0.46	6.35	0.38	1.1e-9	Red blood cell count;
SARC	cis	rs2882667	0.756	rs11957953	chr5:138479377	G/T	cg04439458	chr5:138467593	SIL1	-0.29	-4.91	-0.31	1.71e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs7223966	1.000	rs7209758	chr17:61913621	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.47	5.03	0.31	9.97e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg20573242	chr4:122745356	CCNA2	0.66	8.38	0.48	4.91e-15	Type 2 diabetes;
SARC	cis	rs13314892	0.728	rs55735918	chr3:69874297	A/G	cg17445875	chr3:69859618	MITF	-0.49	-5.12	-0.32	6.44e-7	QRS complex (12-leadsum);
SARC	cis	rs9818758	0.607	rs67060340	chr3:48915321	C/T	cg00383909	chr3:49044727	WDR6	0.75	6.7	0.4	1.54e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs2290159	0.800	rs5746195	chr3:12653800	A/G	cg23032965	chr3:12705835	RAF1	0.77	8.58	0.49	1.36e-15	Cholesterol, total;
SARC	cis	rs7818345	1.000	rs7011602	chr8:19308915	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.4	5.23	0.32	3.76e-7	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs2354432	0.607	rs7516430	chr1:146767062	A/G	cg25205988	chr1:146714368	CHD1L	-0.97	-9.27	-0.52	1.26e-17	Mitochondrial DNA levels;
SARC	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.77	7.61	0.45	6.57e-13	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs7223966	1.000	rs8081612	chr17:61724695	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.46	-5.16	-0.32	5.25e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs8114671	0.967	rs2069945	chr20:33761837	C/G	cg24642439	chr20:33292090	TP53INP2	0.42	4.97	0.31	1.3e-6	Height;
SARC	cis	rs9394841	0.692	rs9394837	chr6:41848088	G/A	cg08135965	chr6:41755394	TOMM6	0.61	6.5	0.39	4.8e-10	Mean corpuscular hemoglobin;Red cell distribution width;
SARC	cis	rs7953249	0.594	rs11065384	chr12:121423285	T/C	cg15155738	chr12:121454335	C12orf43	-0.47	-5.72	-0.35	3.33e-8	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs9875589	0.533	rs12490233	chr3:13977365	G/A	cg19554555	chr3:13937349	NA	-0.42	-5.33	-0.33	2.3e-7	Ovarian reserve;
SARC	cis	rs9291683	0.561	rs3733584	chr4:10036506	T/C	cg11266682	chr4:10021025	SLC2A9	0.4	7.09	0.42	1.55e-11	Bone mineral density;
SARC	cis	rs778371	0.788	rs4973569	chr2:233767037	A/G	cg16596103	chr2:233749413	NGEF	0.34	5.0	0.31	1.11e-6	Schizophrenia;
SARC	cis	rs2191566	0.922	rs7245749	chr19:44513932	G/A	cg20607764	chr19:44506953	ZNF230	-0.5	-5.71	-0.35	3.42e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9640161	0.702	rs1962004	chr7:150020381	G/A	cg10018233	chr7:150070692	REPIN1	0.71	8.7	0.5	5.95e-16	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs600231	0.577	rs12269965	chr11:65232087	C/T	cg17120908	chr11:65337727	SSSCA1	-0.46	-5.1	-0.32	6.88e-7	Bone mineral density;
SARC	cis	rs6500395	0.926	rs8057777	chr16:48565643	T/C	cg04672837	chr16:48644449	N4BP1	0.42	5.45	0.34	1.31e-7	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs9815354	1.000	rs9815354	chr3:41912651	G/A	cg03022575	chr3:42003672	ULK4	0.67	5.73	0.35	3.13e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6089584	0.927	rs11697597	chr20:60584748	C/T	cg13770153	chr20:60521292	NA	-0.52	-7.38	-0.44	2.83e-12	Body mass index;
SARC	cis	rs898097	0.690	rs12452304	chr17:80811659	G/A	cg15664640	chr17:80829946	TBCD	-0.53	-8.28	-0.48	9.87e-15	Breast cancer;
SARC	cis	rs10992471	0.603	rs7850528	chr9:95208992	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.43	-4.9	-0.31	1.83e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs6133127	0.671	rs6139441	chr20:4486601	C/A	cg14606382	chr20:4573199	NA	-0.46	-4.99	-0.31	1.19e-6	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
SARC	cis	rs9616064	0.506	rs2073275	chr22:47070432	G/C	cg05621596	chr22:47072043	GRAMD4	-0.62	-8.66	-0.49	8.15e-16	Urate levels in obese individuals;
SARC	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg03433033	chr1:76189801	ACADM	0.51	7.4	0.44	2.42e-12	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2073499	1.000	rs4141060	chr3:50300117	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.52	6.65	0.4	2.07e-10	Schizophrenia;
SARC	cis	rs17376456	0.935	rs10036891	chr5:93171738	T/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.69	5.46	0.34	1.25e-7	Diabetic retinopathy;
SARC	cis	rs3796352	1.000	rs71301804	chr3:53073314	C/A	cg12962167	chr3:53033115	SFMBT1	0.72	5.0	0.31	1.14e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2295359	1.000	rs9729046	chr1:67607082	C/G	cg11235152	chr1:67600687	NA	0.47	7.17	0.43	9.86e-12	Psoriasis;
SARC	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg22496380	chr5:211416	CCDC127	-0.88	-9.28	-0.52	1.21e-17	Breast cancer;
SARC	cis	rs888194	0.568	rs10850141	chr12:109876128	C/T	cg05360138	chr12:110035743	NA	0.47	5.62	0.35	5.34e-8	Neuroticism;
SARC	cis	rs7592578	0.766	rs35818159	chr2:191409616	C/G	cg10560079	chr2:191398806	TMEM194B	-0.8	-8.91	-0.5	1.54e-16	Diastolic blood pressure;
SARC	cis	rs11997175	0.935	rs6990082	chr8:33708034	C/A	ch.8.33884649F	chr8:33765107	NA	0.61	8.27	0.48	1.04e-14	Body mass index;
SARC	cis	rs910316	1.000	rs12435391	chr14:75601737	A/G	cg08847533	chr14:75593920	NEK9	0.93	15.06	0.7	2.92e-36	Height;
SARC	cis	rs228437	1.000	rs1535118	chr6:134912447	C/T	cg24504307	chr6:134963096	NA	0.52	5.94	0.36	1.01e-8	Melanoma;
SARC	cis	rs6866344	0.570	rs59259518	chr5:178142628	C/T	cg03877680	chr5:178157825	ZNF354A	1.04	14.37	0.69	6.1e-34	Neutrophil percentage of white cells;
SARC	cis	rs66887589	0.777	rs2017058	chr4:120257739	T/C	cg09307838	chr4:120376055	NA	0.53	7.16	0.42	1.03e-11	Diastolic blood pressure;
SARC	cis	rs6665290	0.904	rs2297418	chr1:227192579	A/C	cg14016676	chr1:227182615	CDC42BPA	0.37	5.37	0.33	1.91e-7	Myeloid white cell count;
SARC	cis	rs4595586	0.545	rs6580894	chr12:39371951	A/G	cg13010199	chr12:38710504	ALG10B	0.41	4.9	0.31	1.83e-6	Morning vs. evening chronotype;
SARC	cis	rs7584330	0.666	rs60671275	chr2:238374318	C/A	cg11271282	chr2:238384023	NA	0.48	4.86	0.3	2.13e-6	Prostate cancer;
SARC	cis	rs6484504	0.516	rs1999250	chr11:31287455	C/T	cg02090638	chr11:31391270	DNAJC24;DCDC1	-0.41	-5.22	-0.32	3.87e-7	Red blood cell count;
SARC	cis	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg15556689	chr8:8085844	FLJ10661	0.46	5.74	0.35	2.89e-8	Mood instability;
SARC	cis	rs9513627	1.000	rs2390279	chr13:100208705	A/G	cg25919922	chr13:100150906	NA	-0.63	-4.83	-0.3	2.51e-6	Obesity-related traits;
SARC	trans	rs7824557	0.564	rs11782430	chr8:11226071	A/G	cg06636001	chr8:8085503	FLJ10661	-0.6	-7.82	-0.46	1.82e-13	Retinal vascular caliber;
SARC	cis	rs13191362	1.000	rs67094146	chr6:163145412	G/C	cg06582575	chr6:163149167	PACRG;PARK2	0.61	5.4	0.33	1.68e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg02018176	chr4:1364513	KIAA1530	0.45	6.7	0.4	1.51e-10	Longevity;
SARC	cis	rs7727544	0.735	rs4705933	chr5:131678412	G/A	cg07395648	chr5:131743802	NA	-0.42	-4.9	-0.31	1.77e-6	Blood metabolite levels;
SARC	cis	rs710216	0.957	rs3806401	chr1:43426212	G/T	cg07803811	chr1:43423981	SLC2A1	-0.59	-5.66	-0.35	4.32e-8	Red cell distribution width;
SARC	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg19223190	chr17:80058835	NA	0.45	6.18	0.38	2.79e-9	Life satisfaction;
SARC	cis	rs3741151	0.686	rs12291233	chr11:73272946	T/G	cg17517138	chr11:73019481	ARHGEF17	0.72	6.16	0.37	3.11e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs9818758	0.556	rs13086240	chr3:49001409	G/A	cg00383909	chr3:49044727	WDR6	0.75	6.7	0.4	1.54e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	trans	rs9929218	0.551	rs1886697	chr16:68716179	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.86	14.57	0.69	1.29e-34	Colorectal cancer;
SARC	cis	rs1008375	1.000	rs2315556	chr4:17670861	T/C	cg27347728	chr4:17578864	LAP3	0.45	5.64	0.35	4.78e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs2727020	0.566	rs10839234	chr11:49185524	C/T	cg03929089	chr4:120376271	NA	-0.72	-10.05	-0.55	5.73e-20	Coronary artery disease;
SARC	trans	rs4295623	0.531	rs2898295	chr8:11595969	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.69	-0.4	1.67e-10	Morning vs. evening chronotype;
SARC	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg22875332	chr1:76189707	ACADM	0.45	5.73	0.35	3.15e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7522061	0.546	rs2785665	chr1:157623017	C/A	cg18268488	chr1:157545234	FCRL4	0.26	4.77	0.3	3.18e-6	Blood protein levels;
SARC	cis	rs1018836	0.892	rs10105142	chr8:91547420	C/T	cg16814680	chr8:91681699	NA	-0.69	-10.63	-0.57	9e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs10504229	0.679	rs73681882	chr8:58030038	A/G	cg20607798	chr8:58055168	NA	0.6	5.49	0.34	1.04e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10791097	0.694	rs10160281	chr11:130742788	T/C	cg09137382	chr11:130731461	NA	0.31	4.78	0.3	3.15e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs6570726	0.935	rs416987	chr6:145847005	G/C	cg05220968	chr6:146057943	EPM2A	-0.29	-5.04	-0.31	9.48e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg12463550	chr7:65579703	CRCP	0.47	5.16	0.32	5.3e-7	Aortic root size;
SARC	cis	rs73198271	0.737	rs565203	chr8:8632957	T/C	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.38	-0.39	9.7e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs8017423	0.838	rs11845950	chr14:90723962	T/A	cg20276874	chr14:90721474	PSMC1	-0.39	-5.49	-0.34	1.06e-7	Mortality in heart failure;
SARC	cis	rs4148883	0.675	rs11724783	chr4:100099688	C/A	cg13256891	chr4:100009986	ADH5	0.56	7.39	0.44	2.6e-12	Alcohol dependence;
SARC	cis	rs3126085	0.935	rs3126094	chr1:152308243	T/C	cg26876637	chr1:152193138	HRNR	-0.46	-5.31	-0.33	2.52e-7	Atopic dermatitis;
SARC	cis	rs7904368	0.951	rs7905776	chr10:16853609	C/T	cg14835575	chr10:16859367	RSU1	0.7	7.69	0.45	4.14e-13	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs9326248	0.954	rs8521	chr11:117067699	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.49	5.47	0.34	1.18e-7	Blood protein levels;
SARC	cis	rs12291225	0.883	rs1864658	chr11:14256444	C/T	cg19336497	chr11:14380999	RRAS2	0.31	4.87	0.3	2.03e-6	Sense of smell;
SARC	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg12564285	chr5:131593104	PDLIM4	-0.47	-6.38	-0.39	9.59e-10	Breast cancer;
SARC	cis	rs17345786	0.906	rs72940399	chr3:101122575	A/T	cg12386194	chr3:101231763	SENP7	0.81	9.48	0.53	3.14e-18	Colonoscopy-negative controls vs population controls;
SARC	trans	rs9951602	0.512	rs4799244	chr18:76649763	T/C	cg02800362	chr5:177631904	HNRNPAB	0.71	9.0	0.51	8.26e-17	Obesity-related traits;
SARC	cis	rs11105298	0.786	rs3803128	chr12:89860319	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.49	-5.0	-0.31	1.11e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs4891159	0.790	rs689885	chr18:74110563	T/G	cg24786174	chr18:74118243	ZNF516	0.65	9.22	0.52	1.82e-17	Longevity;
SARC	cis	rs1008375	0.902	rs12503164	chr4:17656107	C/T	cg27347728	chr4:17578864	LAP3	0.47	5.88	0.36	1.42e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs477692	0.905	rs570967	chr10:131421330	T/G	cg05714579	chr10:131428358	MGMT	0.58	7.77	0.45	2.46e-13	Response to temozolomide;
SARC	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	8.8	0.5	3.1e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg14541582	chr5:601475	NA	-0.4	-4.93	-0.31	1.54e-6	Obesity-related traits;
SARC	cis	rs981844	0.775	rs1037656	chr4:154750786	A/G	cg14289246	chr4:154710475	SFRP2	-0.47	-5.49	-0.34	1.02e-7	Response to statins (LDL cholesterol change);
SARC	trans	rs9951602	0.512	rs7237214	chr18:76657394	C/G	cg02800362	chr5:177631904	HNRNPAB	0.72	8.93	0.5	1.3e-16	Obesity-related traits;
SARC	cis	rs7246657	0.524	rs28542490	chr19:37456584	C/A	cg14683738	chr19:37701593	ZNF585B	0.56	5.05	0.31	9.05e-7	Coronary artery calcification;
SARC	cis	rs9462027	0.606	rs2744959	chr6:34616654	T/A	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-5.97	-0.36	8.65e-9	Systemic lupus erythematosus;
SARC	cis	rs3771570	1.000	rs62193208	chr2:242322430	G/A	cg21155796	chr2:242212141	HDLBP	0.68	6.06	0.37	5.34e-9	Prostate cancer;
SARC	cis	rs113835537	0.529	rs74869459	chr11:66296569	T/C	cg24851651	chr11:66362959	CCS	0.37	4.75	0.3	3.61e-6	Airway imaging phenotypes;
SARC	cis	rs9818758	0.607	rs3923475	chr3:49055788	G/T	cg01304814	chr3:48885189	PRKAR2A	0.65	5.28	0.33	2.99e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs651907	0.514	rs10936744	chr3:101433440	C/T	cg12386194	chr3:101231763	SENP7	0.48	5.74	0.35	2.96e-8	Colorectal cancer;
SARC	cis	rs9902453	0.817	rs55758314	chr17:28173978	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	7.22	0.43	7.39e-12	Coffee consumption (cups per day);
SARC	cis	rs9896052	0.614	rs34042490	chr17:73452956	T/C	cg04121983	chr17:73511085	CASKIN2	0.44	5.02	0.31	1.04e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg14664628	chr15:75095509	CSK	-0.51	-6.33	-0.38	1.27e-9	Breast cancer;
SARC	cis	rs2635047	1.000	rs2684826	chr18:44679147	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.57	7.49	0.44	1.45e-12	Educational attainment;
SARC	cis	rs9393692	0.645	rs2179152	chr6:26325888	T/C	cg05868516	chr6:26286170	HIST1H4H	0.48	5.41	0.33	1.6e-7	Educational attainment;
SARC	cis	rs7647973	0.925	rs6769821	chr3:49244657	G/A	cg06212747	chr3:49208901	KLHDC8B	0.63	6.19	0.38	2.75e-9	Menarche (age at onset);
SARC	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-9.15	-0.51	2.85e-17	Alzheimer's disease;
SARC	cis	rs6908034	0.607	rs73376650	chr6:19805506	T/G	cg02682789	chr6:19804855	NA	0.72	5.45	0.34	1.31e-7	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg18404041	chr3:52824283	ITIH1	-0.33	-4.97	-0.31	1.3e-6	Hemoglobin concentration;
SARC	cis	rs6450176	1.000	rs4334835	chr5:53300612	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.68	-7.82	-0.46	1.84e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg16006841	chr5:176797999	RGS14	-0.72	-9.54	-0.53	2.05e-18	Hemoglobin concentration;Hematocrit;
SARC	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg16325326	chr1:53192061	ZYG11B	-0.97	-18.69	-0.77	3.09e-48	Monocyte count;
SARC	cis	rs9398803	0.723	rs853972	chr6:127068293	C/G	cg19875578	chr6:126661172	C6orf173	-0.59	-8.03	-0.47	4.73e-14	Male-pattern baldness;
SARC	cis	rs709400	0.628	rs3783394	chr14:103858673	G/A	cg12935359	chr14:103987150	CKB	-0.39	-5.66	-0.35	4.38e-8	Body mass index;
SARC	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg24829409	chr8:58192753	C8orf71	-0.62	-6.51	-0.39	4.69e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1865760	0.663	rs9348704	chr6:26000393	A/C	cg10373733	chr6:25993375	NA	0.46	5.98	0.36	8.4e-9	Height;
SARC	trans	rs61931739	0.500	rs6488211	chr12:34375620	A/T	cg26384229	chr12:38710491	ALG10B	-0.83	-11.82	-0.61	1.43e-25	Morning vs. evening chronotype;
SARC	cis	rs3106136	0.527	rs2865345	chr4:95156565	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.48	-7.09	-0.42	1.59e-11	Capecitabine sensitivity;
SARC	cis	rs2933343	1.000	rs1680795	chr3:128620388	T/C	cg25356066	chr3:128598488	ACAD9	0.59	6.6	0.4	2.79e-10	IgG glycosylation;
SARC	cis	rs34172651	0.917	rs7202252	chr16:24741686	T/C	cg00339695	chr16:24857497	SLC5A11	-0.32	-5.08	-0.32	7.74e-7	Intelligence (multi-trait analysis);
SARC	cis	rs66573146	1.000	rs6838250	chr4:6973184	C/G	cg00086871	chr4:6988644	TBC1D14	0.93	5.04	0.31	9.21e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs6840360	0.837	rs4696294	chr4:152713089	C/A	cg22705602	chr4:152727874	NA	0.37	6.46	0.39	6.08e-10	Intelligence (multi-trait analysis);
SARC	trans	rs7615952	0.515	rs4441610	chr3:125681307	C/G	cg07211511	chr3:129823064	LOC729375	-0.63	-7.02	-0.42	2.36e-11	Blood pressure (smoking interaction);
SARC	cis	rs6871536	1.000	rs58760622	chr5:131908112	A/T	cg11797159	chr5:131991491	NA	0.38	4.82	0.3	2.61e-6	Asthma (childhood onset);
SARC	trans	rs1493916	0.905	rs12455290	chr18:31398778	A/G	cg27147174	chr7:100797783	AP1S1	-0.57	-7.25	-0.43	6.2e-12	Life satisfaction;
SARC	cis	rs9916302	0.904	rs12952384	chr17:37669536	T/C	cg15445000	chr17:37608096	MED1	0.4	4.74	0.3	3.8e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs11690935	0.921	rs7355523	chr2:172744421	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.99	-14.87	-0.7	1.25e-35	Schizophrenia;
SARC	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg04317338	chr11:64019027	PLCB3	0.83	8.72	0.5	5.46e-16	Mean platelet volume;
SARC	cis	rs11792861	0.566	rs966466	chr9:111851333	T/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.44	5.45	0.34	1.28e-7	Menarche (age at onset);
SARC	cis	rs9322817	0.583	rs7741733	chr6:105182839	T/C	cg02098413	chr6:105308735	HACE1	-0.39	-6.09	-0.37	4.54e-9	Thyroid stimulating hormone;
SARC	cis	rs2073300	0.609	rs6137910	chr20:23346515	C/G	cg12062639	chr20:23401060	NAPB	1.01	6.97	0.42	3.31e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs7208859	0.623	rs73267858	chr17:29059737	A/G	cg13385521	chr17:29058706	SUZ12P	0.85	7.36	0.43	3.19e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg23172400	chr8:95962367	TP53INP1	-0.28	-4.86	-0.3	2.16e-6	Type 2 diabetes;
SARC	cis	rs6964587	0.967	rs34574955	chr7:91847550	A/C	cg17063962	chr7:91808500	NA	0.98	15.9	0.72	4.67e-39	Breast cancer;
SARC	cis	rs2273669	0.831	rs11153152	chr6:109343340	A/T	cg01304950	chr6:109416612	SESN1;C6orf182	0.56	5.03	0.31	9.77e-7	Prostate cancer;
SARC	cis	rs13314892	0.734	rs79366329	chr3:69854698	G/A	cg17445875	chr3:69859618	MITF	-0.58	-5.7	-0.35	3.56e-8	QRS complex (12-leadsum);
SARC	cis	rs11871801	0.517	rs34855406	chr17:40731411	G/C	cg14558262	chr17:40713999	COASY	0.58	6.0	0.37	7.58e-9	Crohn's disease;
SARC	cis	rs10752881	0.901	rs10911201	chr1:183001622	G/T	cg13390022	chr1:182993471	LAMC1	0.34	5.23	0.32	3.81e-7	Colorectal cancer;
SARC	cis	rs1594829	0.500	rs4871973	chr8:26199883	A/G	cg11498726	chr8:26250323	BNIP3L	-0.47	-6.01	-0.37	7.1e-9	Height;
SARC	cis	rs9341808	0.667	rs2490239	chr6:80826289	G/A	cg08355045	chr6:80787529	NA	0.36	5.7	0.35	3.52e-8	Sitting height ratio;
SARC	cis	rs1348850	0.651	rs1901824	chr2:178225466	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.61	7.88	0.46	1.28e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs12893668	0.637	rs12892038	chr14:104068629	G/A	cg26031613	chr14:104095156	KLC1	-0.56	-6.04	-0.37	6.03e-9	Reticulocyte count;
SARC	cis	rs2204008	0.548	rs2320740	chr12:38166421	G/A	cg13010199	chr12:38710504	ALG10B	0.78	10.64	0.57	8.11e-22	Bladder cancer;
SARC	cis	rs76419734	1.000	rs72673812	chr4:106710454	G/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.8	5.36	0.33	2.02e-7	Post bronchodilator FEV1;
SARC	cis	rs870825	0.616	rs7680639	chr4:185652915	C/T	cg04058563	chr4:185651563	MLF1IP	-0.79	-11.11	-0.59	2.8e-23	Blood protein levels;
SARC	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg12311346	chr5:56204834	C5orf35	-0.58	-6.01	-0.37	7.24e-9	Initial pursuit acceleration;
SARC	cis	rs7659604	0.967	rs34949254	chr4:122664344	G/A	cg20573242	chr4:122745356	CCNA2	0.45	5.94	0.36	1.03e-8	Type 2 diabetes;
SARC	cis	rs12079745	0.793	rs12076519	chr1:169283540	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.83	-5.15	-0.32	5.46e-7	QT interval;
SARC	cis	rs10911232	0.507	rs10752888	chr1:182993751	A/G	cg13390022	chr1:182993471	LAMC1	0.33	4.96	0.31	1.34e-6	Hypertriglyceridemia;
SARC	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.77	-11.24	-0.59	1.07e-23	Personality dimensions;
SARC	cis	rs9457247	0.756	rs1811123	chr6:167403443	T/C	cg07741184	chr6:167504864	NA	0.31	5.91	0.36	1.21e-8	Crohn's disease;
SARC	cis	rs3813567	0.759	rs12594550	chr15:78959037	C/G	cg04896959	chr15:78267971	NA	0.54	5.59	0.34	6.41e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
SARC	cis	rs10131894	0.611	rs175002	chr14:75436466	C/G	cg08847533	chr14:75593920	NEK9	0.76	10.45	0.56	3.28e-21	Coronary artery disease;
SARC	cis	rs7659604	1.000	rs10016433	chr4:122664771	A/G	cg19671926	chr4:122722719	EXOSC9	-0.49	-5.97	-0.36	8.79e-9	Type 2 diabetes;
SARC	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg06028605	chr16:24865363	SLC5A11	0.37	5.45	0.34	1.28e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.61	-6.27	-0.38	1.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.49	-5.94	-0.36	1.05e-8	Urate levels;
SARC	cis	rs2797160	0.651	rs1268092	chr6:126029043	A/G	cg05901451	chr6:126070800	HEY2	-0.46	-5.66	-0.35	4.34e-8	Endometrial cancer;
SARC	cis	rs372883	0.638	rs371432	chr21:30710876	G/A	cg08807101	chr21:30365312	RNF160	-0.59	-7.3	-0.43	4.5e-12	Pancreatic cancer;
SARC	cis	rs9486715	1.000	rs9398148	chr6:97063555	A/G	cg06623918	chr6:96969491	KIAA0776	-0.82	-11.37	-0.6	4.07e-24	Headache;
SARC	cis	rs6088590	1.000	rs3787222	chr20:33333040	T/A	cg06115741	chr20:33292138	TP53INP2	0.57	6.86	0.41	6.09e-11	Coronary artery disease;
SARC	cis	rs1003719	0.688	rs2835662	chr21:38568967	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-8.88	-0.5	1.88e-16	Eye color traits;
SARC	cis	rs6840360	1.000	rs6535813	chr4:152599652	A/T	cg22705602	chr4:152727874	NA	-0.38	-6.54	-0.39	3.91e-10	Intelligence (multi-trait analysis);
SARC	cis	rs17345786	0.861	rs74768235	chr3:101142821	T/C	cg12386194	chr3:101231763	SENP7	0.82	9.62	0.53	1.17e-18	Colonoscopy-negative controls vs population controls;
SARC	cis	rs617219	0.552	rs6891335	chr5:78623110	G/A	cg24856658	chr5:78533917	JMY	0.3	4.81	0.3	2.67e-6	Betaine levels in individuals undergoing cardiac evaluation;
SARC	cis	rs17401966	1.000	rs17401966	chr1:10385471	C/T	cg15208524	chr1:10270712	KIF1B	-0.59	-6.61	-0.4	2.6200000000000003e-10	Hepatocellular carcinoma;
SARC	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg04944784	chr2:26401820	FAM59B	0.64	8.27	0.48	1.03e-14	Gut microbiome composition (summer);
SARC	cis	rs1055129	0.681	rs7221792	chr17:73834690	T/G	cg14829360	chr17:73884958	NA	-0.43	-5.96	-0.36	9.44e-9	White matter hyperintensity burden;
SARC	cis	rs6582630	0.537	rs1851124	chr12:38516404	G/A	cg26384229	chr12:38710491	ALG10B	0.84	12.37	0.63	2.31e-27	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.44	4.99	0.31	1.17e-6	Height;
SARC	cis	rs13256369	1.000	rs13267501	chr8:8574058	G/A	cg17143192	chr8:8559678	CLDN23	0.51	5.77	0.35	2.5e-8	Obesity-related traits;
SARC	cis	rs2380220	0.720	rs9398251	chr6:95984709	C/T	cg23517279	chr6:96025343	MANEA	0.5	5.67	0.35	4.2e-8	Behavioural disinhibition (generation interaction);
SARC	cis	rs6918586	0.658	rs13161	chr6:26114702	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.45	-5.82	-0.36	1.97e-8	Schizophrenia;
SARC	cis	rs2075371	1.000	rs2241336	chr7:133979578	A/G	cg00033643	chr7:134001901	SLC35B4	0.4	4.91	0.31	1.68e-6	Mean platelet volume;
SARC	cis	rs6568686	0.730	rs6936935	chr6:111845774	T/C	cg15721981	chr6:111408429	SLC16A10	-0.61	-5.07	-0.32	8.09e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs4141404	0.706	rs5753698	chr22:31970054	A/C	cg07713946	chr22:31675144	LIMK2	0.34	4.89	0.31	1.85e-6	Paclitaxel-induced neuropathy;
SARC	cis	rs4356932	1.000	rs4616778	chr4:76981206	C/T	cg24176760	chr4:76958061	ART3;CXCL11	0.3	4.88	0.3	2e-6	Blood protein levels;
SARC	cis	rs61823972	0.547	rs12048743	chr1:205114873	C/G	cg21643547	chr1:205240462	TMCC2	-0.51	-6.85	-0.41	6.43e-11	Immature fraction of reticulocytes;Mean corpuscular volume;Mean corpuscular hemoglobin;Mean corpuscular hemoglobin concentration;High light scatter reticulocyte count;
SARC	cis	rs3923518	1.000	rs3923518	chr3:38886413	C/A	cg15678707	chr3:39149194	GORASP1;TTC21A	0.46	4.86	0.3	2.17e-6	Migraine;
SARC	cis	rs35146811	0.586	rs6964754	chr7:99589404	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.42	5.06	0.31	8.68e-7	Coronary artery disease;
SARC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg06873352	chr17:61820015	STRADA	0.45	5.97	0.36	8.87e-9	Prudent dietary pattern;
SARC	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.42	5.15	0.32	5.67e-7	Electroencephalogram traits;
SARC	cis	rs6088580	0.634	rs7271970	chr20:32987666	A/G	cg08999081	chr20:33150536	PIGU	-0.43	-6.58	-0.4	3.15e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs9768139	1.000	rs9768139	chr7:158120731	G/A	cg25566285	chr7:158114605	PTPRN2	-0.32	-5.56	-0.34	7.51e-8	Calcium levels;
SARC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg26668828	chr6:292823	DUSP22	-0.65	-8.44	-0.48	3.48e-15	Menopause (age at onset);
SARC	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg11987759	chr7:65425863	GUSB	-0.61	-8.0	-0.46	5.89e-14	Aortic root size;
SARC	cis	rs6088580	0.634	rs6059896	chr20:33111783	T/C	cg08999081	chr20:33150536	PIGU	0.43	6.75	0.4	1.14e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs10089	1.000	rs1559263	chr5:127512873	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	9.01	0.51	7.68e-17	Ileal carcinoids;
SARC	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg04267008	chr7:1944627	MAD1L1	-0.54	-6.23	-0.38	2.16e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs1371867	0.817	rs1788185	chr8:101335529	T/C	cg11906718	chr8:101322791	RNF19A	0.71	9.13	0.51	3.37e-17	Atrioventricular conduction;
SARC	cis	rs9314323	0.592	rs12165	chr8:26269412	C/T	cg11498726	chr8:26250323	BNIP3L	-0.48	-6.39	-0.39	9.03e-10	Red cell distribution width;
SARC	cis	rs78487399	0.808	rs13395290	chr2:43706319	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-4.81	-0.3	2.67e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs8067354	0.645	rs2102507	chr17:57875907	A/G	cg13753209	chr17:57696993	CLTC	0.68	7.55	0.44	9.66e-13	Hemoglobin concentration;
SARC	cis	rs734999	0.545	rs10910111	chr1:2542653	A/G	cg18854424	chr1:2615690	NA	0.31	4.87	0.3	2.06e-6	Ulcerative colitis;
SARC	cis	rs9902453	0.934	rs11080120	chr17:28507021	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	6.71	0.4	1.44e-10	Coffee consumption (cups per day);
SARC	cis	rs6456156	0.565	rs12529238	chr6:167465576	G/A	cg23791538	chr6:167370224	RNASET2	-0.52	-6.79	-0.41	9.49e-11	Primary biliary cholangitis;
SARC	cis	rs6061231	0.724	rs1570027	chr20:60968596	A/G	cg22601191	chr20:60968625	CABLES2	0.4	4.87	0.3	2.02e-6	Colorectal cancer;
SARC	cis	rs4974559	0.501	rs730830	chr4:1240091	T/C	cg02980000	chr4:1222292	CTBP1	-0.82	-6.63	-0.4	2.3e-10	Systolic blood pressure;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg18014789	chr12:123717788	C12orf65	-0.76	-6.35	-0.38	1.14e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6977660	0.714	rs10251774	chr7:19790489	T/C	cg05791153	chr7:19748676	TWISTNB	0.72	6.28	0.38	1.65e-9	Thyroid stimulating hormone;
SARC	cis	rs698833	0.926	rs1067367	chr2:44654905	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.69	9.18	0.52	2.4e-17	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs34779708	0.931	rs12242882	chr10:35347860	G/C	cg03585969	chr10:35415529	CREM	0.38	4.79	0.3	3e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs2549003	0.933	rs3846731	chr5:131814264	T/C	cg21138405	chr5:131827807	IRF1	0.27	5.44	0.34	1.32e-7	Asthma (sex interaction);
SARC	cis	rs2486288	0.656	rs12911861	chr15:45566718	T/C	cg19305227	chr15:45544335	SLC28A2	0.31	5.78	0.35	2.41e-8	Glomerular filtration rate;
SARC	cis	rs787274	0.681	rs787270	chr9:115549092	C/T	cg13803584	chr9:115635662	SNX30	-0.77	-5.69	-0.35	3.78e-8	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg03999130	chr15:45571217	NA	0.39	5.09	0.32	7.55e-7	Homoarginine levels;
SARC	cis	rs11098499	0.955	rs1511019	chr4:120166007	T/G	cg24375607	chr4:120327624	NA	0.39	4.83	0.3	2.53e-6	Corneal astigmatism;
SARC	cis	rs7843479	0.582	rs11135743	chr8:21803008	A/G	cg17168535	chr8:21777572	XPO7	0.86	13.47	0.66	5.51e-31	Mean corpuscular volume;
SARC	cis	rs79149102	0.579	rs12593542	chr15:75282147	C/G	cg00629941	chr15:75287862	SCAMP5	-0.59	-5.07	-0.32	8.19e-7	Lung cancer;
SARC	cis	rs6568686	0.786	rs6927920	chr6:111820382	A/T	cg15721981	chr6:111408429	SLC16A10	-0.6	-4.72	-0.3	4.16e-6	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs11874712	1.000	rs28699609	chr18:43674879	A/T	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.46	5.49	0.34	1.06e-7	Migraine - clinic-based;
SARC	cis	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg03213289	chr20:61660250	NA	0.45	6.16	0.37	3.11e-9	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs10911232	0.507	rs4652772	chr1:183023696	C/G	cg13390022	chr1:182993471	LAMC1	-0.33	-4.97	-0.31	1.31e-6	Hypertriglyceridemia;
SARC	cis	rs7647973	0.626	rs1463728	chr3:49647404	T/A	cg07636037	chr3:49044803	WDR6	0.81	7.4	0.44	2.39e-12	Menarche (age at onset);
SARC	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.35	4.8	0.3	2.87e-6	Total body bone mineral density;
SARC	cis	rs6831352	0.879	rs29001215	chr4:100051722	T/C	cg13256891	chr4:100009986	ADH5	-0.65	-8.09	-0.47	3.18e-14	Alcohol dependence;
SARC	trans	rs1945213	0.694	rs17149976	chr11:55839746	T/C	cg15704280	chr7:45808275	SEPT13	0.66	6.87	0.41	5.94e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs910316	0.737	rs175049	chr14:75481368	C/T	cg08847533	chr14:75593920	NEK9	-0.81	-11.55	-0.6	1.09e-24	Height;
SARC	cis	rs2013441	1.000	rs2107566	chr17:20103252	C/T	cg13482628	chr17:19912719	NA	-0.46	-5.82	-0.36	1.91e-8	Obesity-related traits;
SARC	cis	rs17270561	0.609	rs9358879	chr6:25742918	C/G	cg17691542	chr6:26056736	HIST1H1C	0.61	7.36	0.43	3.06e-12	Iron status biomarkers;
SARC	cis	rs17209837	1.000	rs12673662	chr7:87110351	C/G	cg00919237	chr7:87102261	ABCB4	0.46	4.81	0.3	2.71e-6	Gallbladder cancer;
SARC	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg07701084	chr6:150067640	NUP43	0.45	5.54	0.34	8.02e-8	Lung cancer;
SARC	cis	rs3099143	0.901	rs3764244	chr15:77223740	T/C	cg21673338	chr15:77095150	SCAPER	-0.68	-5.37	-0.33	1.91e-7	Recalcitrant atopic dermatitis;
SARC	cis	rs7583236	0.500	rs7601899	chr2:70335973	C/G	cg19638749	chr2:70312615	NA	0.59	5.6	0.34	5.88e-8	Obesity-related traits;
SARC	cis	rs67460515	0.892	rs73026974	chr3:160963231	A/C	cg17135325	chr3:160939158	NMD3	0.63	7.94	0.46	8.51e-14	Parkinson's disease;
SARC	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg19223190	chr17:80058835	NA	-0.42	-5.73	-0.35	3.09e-8	Life satisfaction;
SARC	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg24531977	chr5:56204891	C5orf35	0.66	6.33	0.38	1.24e-9	Initial pursuit acceleration;
SARC	cis	rs67311347	0.955	rs73080163	chr3:40533061	G/T	cg01475735	chr3:40494733	NA	-0.42	-4.88	-0.3	1.99e-6	Renal cell carcinoma;
SARC	cis	rs9660992	0.700	rs1172125	chr1:205258442	A/T	cg00857998	chr1:205179979	DSTYK	0.43	5.45	0.34	1.28e-7	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs7223966	1.000	rs8067431	chr17:61817048	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	7.11	0.42	1.43e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs208520	0.690	rs12201156	chr6:66720874	G/T	cg07460842	chr6:66804631	NA	1.07	14.64	0.69	7.58e-35	Exhaled nitric oxide output;
SARC	cis	rs7590720	1.000	rs934156	chr2:216901482	C/T	cg12620499	chr2:216877984	MREG	-0.56	-7.69	-0.45	4.14e-13	Alcohol dependence;
SARC	cis	rs2228479	0.618	rs17233623	chr16:89811209	C/T	cg00800038	chr16:89945340	TCF25	-0.66	-5.13	-0.32	6.2e-7	Skin colour saturation;
SARC	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg25072359	chr17:41440525	NA	0.5	5.92	0.36	1.15e-8	Menopause (age at onset);
SARC	cis	rs889312	0.500	rs252905	chr5:56118875	C/T	cg14703610	chr5:56206110	C5orf35	0.48	5.98	0.36	8.41e-9	Breast cancer;Breast cancer (early onset);
SARC	cis	rs6582630	0.555	rs61932279	chr12:38349096	C/T	cg26384229	chr12:38710491	ALG10B	-0.59	-7.29	-0.43	4.69e-12	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs748404	0.697	rs546722	chr15:43580819	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.43	5.17	0.32	4.99e-7	Lung cancer;
SARC	cis	rs7412746	0.658	rs11204750	chr1:150939744	C/A	cg15448220	chr1:150897856	SETDB1	0.52	6.67	0.4	1.85e-10	Melanoma;
SARC	cis	rs3126085	0.935	rs4845423	chr1:152184950	T/G	cg03465714	chr1:152285911	FLG	-0.48	-5.84	-0.36	1.79e-8	Atopic dermatitis;
SARC	cis	rs2952156	0.920	rs1018246	chr17:37835240	C/T	cg00129232	chr17:37814104	STARD3	-0.71	-10.13	-0.55	3.18e-20	Asthma;
SARC	cis	rs11608355	0.618	rs2075435	chr12:109796832	C/T	cg05360138	chr12:110035743	NA	0.44	5.29	0.33	2.81e-7	Neuroticism;
SARC	cis	rs7944584	0.632	rs7116451	chr11:47322327	G/A	cg20307385	chr11:47447363	PSMC3	0.55	6.93	0.41	4.02e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs11098499	0.954	rs10031665	chr4:120422852	T/C	cg24375607	chr4:120327624	NA	0.41	4.86	0.3	2.12e-6	Corneal astigmatism;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg20685431	chr4:186347356	UFSP2	0.52	6.32	0.38	1.35e-9	Blood pressure;
SARC	cis	rs5769765	1.000	rs768619	chr22:50287266	C/T	cg03033257	chr22:50311977	ALG12;CRELD2	0.54	5.55	0.34	7.94e-8	Schizophrenia;
SARC	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg05793240	chr7:2802953	GNA12	-0.37	-5.31	-0.33	2.53e-7	Height;
SARC	cis	rs9916302	0.752	rs8071300	chr17:37508524	G/C	cg07936489	chr17:37558343	FBXL20	0.76	9.12	0.51	3.63e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs2806561	0.765	rs2776815	chr1:23510584	C/T	cg12483005	chr1:23474871	LUZP1	-0.43	-5.62	-0.35	5.35e-8	Height;
SARC	cis	rs7216064	0.953	rs10445361	chr17:65962238	G/T	cg12091567	chr17:66097778	LOC651250	0.62	6.67	0.4	1.81e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs6687430	0.526	rs12117392	chr1:10608583	T/C	cg17425144	chr1:10567563	PEX14	0.39	5.77	0.35	2.56e-8	Hand grip strength;
SARC	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg22508957	chr16:3507546	NAT15	-0.35	-5.13	-0.32	6.15e-7	Tuberculosis;
SARC	cis	rs9303401	0.659	rs12602389	chr17:56779778	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	12.31	0.63	3.57e-27	Cognitive test performance;
SARC	cis	rs7870753	0.838	rs10761035	chr9:99236092	G/A	cg25260653	chr9:99212216	HABP4	0.51	4.77	0.3	3.21e-6	Height;
SARC	cis	rs7772486	0.754	rs6570718	chr6:146088443	T/G	cg23711669	chr6:146136114	FBXO30	-0.91	-16.19	-0.73	5.21e-40	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.47	0.39	5.63e-10	Bipolar disorder;
SARC	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg24250549	chr1:154909240	PMVK	0.83	12.22	0.62	7.36e-27	Prostate cancer;
SARC	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.39	-0.56	4.87e-21	Chronic sinus infection;
SARC	cis	rs56011263	0.687	rs73221103	chr4:706740	T/C	cg17689763	chr4:710664	PCGF3	-0.64	-8.99	-0.51	8.86e-17	White blood cell count;
SARC	cis	rs8087995	0.591	rs79655297	chr18:65735424	A/G	cg12487792	chr18:66383213	TMX3;CCDC102B	0.51	4.71	0.3	4.2e-6	Dysphagia;
SARC	cis	rs2268241	0.877	rs17885509	chr21:34779630	C/T	cg14850771	chr21:34775459	IFNGR2	0.97	9.33	0.52	8.64e-18	Obesity-related traits;
SARC	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg22168489	chr12:122356033	WDR66	-0.61	-9.49	-0.53	2.81e-18	Mean corpuscular volume;
SARC	cis	rs17666538	0.585	rs6559064	chr8:623061	G/A	cg02524346	chr8:600233	NA	0.7	5.84	0.36	1.74e-8	IgG glycosylation;
SARC	cis	rs477692	0.637	rs10829598	chr10:131319774	C/G	cg05714579	chr10:131428358	MGMT	0.58	7.57	0.44	8.58e-13	Response to temozolomide;
SARC	cis	rs5753618	0.561	rs1858821	chr22:31676454	T/C	cg13145458	chr22:31556086	RNF185	0.47	5.01	0.31	1.06e-6	Colorectal cancer;
SARC	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg04317338	chr11:64019027	PLCB3	0.81	8.61	0.49	1.12e-15	Mean platelet volume;
SARC	cis	rs3126085	0.877	rs6662450	chr1:152191709	C/G	cg03465714	chr1:152285911	FLG	-0.49	-5.96	-0.36	9.41e-9	Atopic dermatitis;
SARC	cis	rs9503598	0.636	rs6596975	chr6:3465925	G/A	cg00476032	chr6:3446245	SLC22A23	0.4	6.43	0.39	7.22e-10	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
SARC	cis	rs8067545	0.611	rs12949481	chr17:20190974	C/A	cg13482628	chr17:19912719	NA	-0.57	-7.54	-0.44	1.02e-12	Schizophrenia;
SARC	cis	rs56235845	0.694	rs36102285	chr5:176774018	C/T	cg06060754	chr5:176797920	RGS14	0.47	6.15	0.37	3.4e-9	Hemoglobin concentration;Hematocrit;
SARC	cis	rs2635047	0.638	rs2571008	chr18:44649950	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	6.48	0.39	5.46e-10	Educational attainment;
SARC	cis	rs10489202	1.000	rs1060041	chr1:167973976	C/T	cg24449463	chr1:168025552	DCAF6	-0.64	-7.0	-0.42	2.74e-11	Schizophrenia;
SARC	cis	rs7940866	0.874	rs7111478	chr11:130819628	A/G	cg12179176	chr11:130786555	SNX19	0.68	9.58	0.53	1.54e-18	Schizophrenia;
SARC	cis	rs1153858	1.000	rs16942568	chr15:45677390	T/C	cg21132104	chr15:45694354	SPATA5L1	0.78	11.01	0.59	5.55e-23	Homoarginine levels;
SARC	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg26818010	chr10:134567672	INPP5A	-0.51	-5.46	-0.34	1.19e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	trans	rs1910358	0.554	rs10057796	chr5:23759746	C/T	cg16626280	chr5:128430255	ISOC1	0.57	6.43	0.39	7.2e-10	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs10791323	0.660	rs10791330	chr11:133727535	C/T	cg14349672	chr11:133703707	NA	-0.34	-5.14	-0.32	5.87e-7	Childhood ear infection;
SARC	cis	rs11997175	0.603	rs4739381	chr8:33806892	C/A	ch.8.33884649F	chr8:33765107	NA	0.44	5.63	0.35	5.19e-8	Body mass index;
SARC	cis	rs73195822	0.614	rs73194061	chr12:111221941	T/C	cg10860002	chr12:110842031	ANAPC7	0.58	5.05	0.31	8.84e-7	Itch intensity from mosquito bite;
SARC	trans	rs11098499	0.909	rs11098530	chr4:120413154	C/T	cg25214090	chr10:38739885	LOC399744	0.58	7.47	0.44	1.63e-12	Corneal astigmatism;
SARC	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg06221963	chr1:154839813	KCNN3	-0.52	-8.26	-0.48	1.1e-14	Prostate cancer;
SARC	cis	rs6700896	0.931	rs1938498	chr1:66098653	T/C	cg04111102	chr1:66153794	NA	0.35	5.53	0.34	8.41e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs7149337	0.805	rs2999354	chr14:51607179	C/G	cg23942311	chr14:51606299	NA	0.3	5.48	0.34	1.1e-7	Cancer;
SARC	trans	rs61931739	0.534	rs10844728	chr12:34020109	G/C	cg26384229	chr12:38710491	ALG10B	0.85	12.24	0.63	6.08e-27	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.34e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg27541892	chr1:1571801	CDK11B	-0.41	-5.67	-0.35	4.26e-8	Body mass index;
SARC	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg02524346	chr8:600233	NA	0.71	5.96	0.36	9.39e-9	IgG glycosylation;
SARC	cis	rs6834538	0.964	rs4834280	chr4:113396655	C/T	cg05166686	chr4:113558556	LARP7;C4orf21	0.47	5.71	0.35	3.46e-8	Free thyroxine concentration;
SARC	cis	rs7666738	0.962	rs2865985	chr4:99068009	T/C	cg05340658	chr4:99064831	C4orf37	0.56	6.81	0.41	8.11e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs8180040	0.676	rs7633698	chr3:47013452	A/T	cg02527881	chr3:46936655	PTH1R	-0.31	-4.78	-0.3	3.07e-6	Colorectal cancer;
SARC	cis	rs11792861	0.890	rs3750465	chr9:111900677	T/C	cg13535736	chr9:111863775	C9orf5	-0.4	-4.87	-0.3	2.09e-6	Menarche (age at onset);
SARC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.38	0.52	6.17e-18	Prudent dietary pattern;
SARC	cis	rs918629	0.716	rs6881355	chr5:95274795	C/T	cg16656078	chr5:95278638	ELL2	-0.62	-7.54	-0.44	1.03e-12	IgG glycosylation;
SARC	cis	rs526231	0.543	rs257302	chr5:102416130	G/T	cg23492399	chr5:102201601	PAM	-0.51	-5.52	-0.34	8.81e-8	Primary biliary cholangitis;
SARC	trans	rs9929218	0.529	rs8059194	chr16:68749663	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.79	13.08	0.65	1.13e-29	Colorectal cancer;
SARC	cis	rs4974559	0.739	rs10029534	chr4:1322908	C/A	cg02980000	chr4:1222292	CTBP1	0.74	5.48	0.34	1.12e-7	Systolic blood pressure;
SARC	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg24549020	chr5:56110836	MAP3K1	0.81	8.4	0.48	4.37e-15	Initial pursuit acceleration;
SARC	cis	rs523522	0.962	rs11065149	chr12:120956963	G/A	cg27279351	chr12:120934652	DYNLL1	0.73	9.05	0.51	5.73e-17	High light scatter reticulocyte count;
SARC	cis	rs4555082	0.874	rs113291192	chr14:105738181	C/T	cg10792982	chr14:105748885	BRF1	0.54	7.93	0.46	9.08e-14	Mean platelet volume;Platelet distribution width;
SARC	trans	rs208515	0.556	rs1872309	chr6:66660432	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.92	10.23	0.56	1.56e-20	Exhaled nitric oxide levels;
SARC	cis	rs2070488	0.775	rs2051214	chr3:38560303	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.77	-11.22	-0.59	1.22e-23	Electrocardiographic conduction measures;
SARC	cis	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg24110177	chr3:50126178	RBM5	-0.54	-7.17	-0.43	1e-11	Intelligence (multi-trait analysis);
SARC	cis	rs78545713	1.000	rs41266821	chr6:26247198	A/G	cg13736514	chr6:26305472	NA	-0.59	-4.8	-0.3	2.9e-6	Iron status biomarkers (total iron binding capacity);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg15202251	chr7:100183972	FBXO24;LRCH4	-0.51	-6.29	-0.38	1.58e-9	Height;
SARC	cis	rs6062302	0.522	rs6090476	chr20:62248001	G/A	cg09650180	chr20:62225654	GMEB2	-0.45	-5.55	-0.34	7.75e-8	Glioblastoma;
SARC	cis	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg05623727	chr3:50126028	RBM5	-0.33	-5.15	-0.32	5.66e-7	Intelligence (multi-trait analysis);
SARC	cis	rs16976116	0.901	rs3179664	chr15:55496853	G/A	cg17854078	chr15:55489399	RSL24D1	0.64	6.28	0.38	1.62e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg04518342	chr5:131593106	PDLIM4	0.36	5.14	0.32	5.82e-7	Breast cancer;
SARC	cis	rs116095464	1.000	rs7723693	chr5:306032	G/A	cg20965017	chr5:231967	SDHA	-0.7	-5.41	-0.33	1.58e-7	Breast cancer;
SARC	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg11890956	chr21:40555474	PSMG1	-0.69	-9.05	-0.51	5.87e-17	Menarche (age at onset);
SARC	cis	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg25894440	chr7:65020034	NA	-0.77	-5.83	-0.36	1.88e-8	Diabetic kidney disease;
SARC	cis	rs11697848	1.000	rs79547786	chr20:48555820	C/T	cg17849948	chr20:48532315	SPATA2	0.87	5.2	0.32	4.3e-7	Systemic lupus erythematosus;
SARC	cis	rs9291683	0.588	rs34501273	chr4:9996996	C/T	cg00071950	chr4:10020882	SLC2A9	0.42	6.65	0.4	2.04e-10	Bone mineral density;
SARC	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg26516362	chr5:178986906	RUFY1	0.34	4.77	0.3	3.25e-6	Lung cancer;
SARC	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs3126085	0.825	rs4845428	chr1:152225261	T/C	cg26876637	chr1:152193138	HRNR	0.45	5.34	0.33	2.24e-7	Atopic dermatitis;
SARC	cis	rs9325144	0.647	rs12822023	chr12:39097964	T/C	cg13010199	chr12:38710504	ALG10B	-0.51	-6.38	-0.39	9.59e-10	Morning vs. evening chronotype;
SARC	cis	rs853679	0.506	rs1150693	chr6:28174590	T/C	cg16479474	chr6:28041457	NA	0.36	5.61	0.34	5.82e-8	Depression;
SARC	cis	rs7674212	0.539	rs2866635	chr4:104121576	G/A	cg16532752	chr4:104119610	CENPE	-0.49	-6.08	-0.37	4.81e-9	Type 2 diabetes;
SARC	cis	rs7587476	0.954	rs3768708	chr2:215645046	C/T	cg04004882	chr2:215674386	BARD1	-0.58	-6.57	-0.4	3.22e-10	Neuroblastoma;
SARC	trans	rs61931739	0.500	rs10844845	chr12:34381117	C/T	cg26384229	chr12:38710491	ALG10B	0.83	12.5	0.63	8.92e-28	Morning vs. evening chronotype;
SARC	cis	rs4718428	0.705	rs12698547	chr7:66278258	T/C	cg12165864	chr7:66369176	NA	-0.44	-4.83	-0.3	2.45e-6	Corneal structure;
SARC	cis	rs637571	0.522	rs542332	chr11:65744421	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.83	12.35	0.63	2.71e-27	Eosinophil percentage of white cells;
SARC	cis	rs57506017	0.585	rs3823612	chr7:12258755	C/G	cg23422036	chr7:12250390	TMEM106B	0.48	6.33	0.38	1.22e-9	Neuroticism;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg08374732	chr10:97889046	ZNF518A	0.53	7.68	0.45	4.48e-13	Thyroid stimulating hormone;
SARC	cis	rs10089	1.000	rs4836368	chr5:127486330	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.81	10.17	0.55	2.39e-20	Ileal carcinoids;
SARC	cis	rs4720575	1.000	rs4724535	chr7:47100396	G/A	cg00036614	chr7:47093842	NA	-0.47	-6.54	-0.39	3.95e-10	Angiotensin-converting enzyme inhibitor intolerance;
SARC	cis	rs7481584	1.000	rs12789474	chr11:3024139	T/G	cg25174290	chr11:3078921	CARS	-0.5	-6.55	-0.39	3.72e-10	Calcium levels;
SARC	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg17971929	chr21:40555470	PSMG1	0.85	10.67	0.57	6.95e-22	Cognitive function;
SARC	cis	rs1057239	0.739	rs1014554	chr1:175133626	A/G	cg00321850	chr1:175162397	KIAA0040	0.37	5.89	0.36	1.33e-8	Diastolic blood pressure;
SARC	cis	rs760805	1.000	rs7517302	chr1:25254317	C/T	cg22509179	chr1:25234806	RUNX3	-0.5	-6.96	-0.41	3.48e-11	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs7647973	0.560	rs62262671	chr3:49649873	A/G	cg03060546	chr3:49711283	APEH	-0.64	-5.23	-0.32	3.79e-7	Menarche (age at onset);
SARC	cis	rs858239	0.632	rs6952947	chr7:23121042	C/G	cg23682824	chr7:23144976	KLHL7	-0.71	-9.49	-0.53	2.85e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs5753037	0.504	rs140114	chr22:30133881	C/T	cg01021169	chr22:30184971	ASCC2	-0.47	-6.23	-0.38	2.11e-9	Type 1 diabetes;
SARC	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg08048268	chr3:133502702	NA	-0.45	-6.2	-0.38	2.61e-9	Iron status biomarkers;
SARC	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg18252515	chr7:66147081	NA	0.58	6.23	0.38	2.16e-9	Aortic root size;
SARC	cis	rs9309473	0.950	rs6735946	chr2:73790058	A/G	cg20560298	chr2:73613845	ALMS1	-0.48	-5.92	-0.36	1.14e-8	Metabolite levels;
SARC	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg11987759	chr7:65425863	GUSB	0.46	6.01	0.37	7.26e-9	Aortic root size;
SARC	cis	rs4689388	0.926	rs3821940	chr4:6286711	C/A	cg00701064	chr4:6280414	WFS1	0.58	9.42	0.53	4.73e-18	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg11644478	chr21:40555479	PSMG1	1.03	14.39	0.69	5.14e-34	Cognitive function;
SARC	cis	rs11880706	0.831	rs28718730	chr19:6091237	G/A	cg18109231	chr19:6110877	RFX2	0.8	5.36	0.33	1.97e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg04944784	chr2:26401820	FAM59B	-0.6	-7.95	-0.46	8.14e-14	Gut microbiome composition (summer);
SARC	cis	rs4805272	0.512	rs8105613	chr19:29339151	C/T	cg14983838	chr19:29218262	NA	0.54	5.83	0.36	1.83e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	trans	rs10209086	0.736	rs1584436	chr2:138298878	A/G	cg16323843	chr3:49711263	APEH	-0.48	-6.26	-0.38	1.8e-9	Multiple system atrophy;
SARC	cis	rs66887589	0.776	rs10518337	chr4:120574874	A/C	cg09307838	chr4:120376055	NA	-0.53	-7.11	-0.42	1.4e-11	Diastolic blood pressure;
SARC	trans	rs208520	0.690	rs3843513	chr6:66836797	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-13.77	-0.67	5.95e-32	Exhaled nitric oxide output;
SARC	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg03806693	chr22:41940476	POLR3H	-0.94	-12.82	-0.64	8e-29	Vitiligo;
SARC	cis	rs548181	0.673	rs12288034	chr11:125570941	A/T	cg03464685	chr11:125439445	EI24	-1.03	-10.55	-0.57	1.58e-21	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg12463550	chr7:65579703	CRCP	0.55	5.86	0.36	1.54e-8	Aortic root size;
SARC	cis	rs2439831	0.618	rs8023508	chr15:44176103	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.68	-6.93	-0.41	4.14e-11	Lung cancer in ever smokers;
SARC	cis	rs501120	0.925	rs1657345	chr10:44779078	A/G	cg09554077	chr10:44749378	NA	0.51	6.38	0.39	9.47e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs925228	0.504	rs6729231	chr2:24292597	A/T	cg01493198	chr2:24299560	SF3B14	0.87	5.05	0.31	8.99e-7	Reticulocyte fraction of red cells;Reticulocyte count;
SARC	cis	rs1008375	0.931	rs6449326	chr4:17699790	G/T	cg16339924	chr4:17578868	LAP3	0.52	6.67	0.4	1.8e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg11890956	chr21:40555474	PSMG1	-1.05	-15.78	-0.72	1.19e-38	Cognitive function;
SARC	cis	rs7578035	0.935	rs7561818	chr2:99384070	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.38	-4.83	-0.3	2.43e-6	Bipolar disorder;
SARC	cis	rs8114671	0.804	rs3803936	chr20:33632775	T/C	cg08999081	chr20:33150536	PIGU	-0.35	-4.93	-0.31	1.54e-6	Height;
SARC	cis	rs7208859	0.524	rs77498725	chr17:29063986	C/T	cg13385521	chr17:29058706	SUZ12P	0.84	7.31	0.43	4.29e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs77972916	0.536	rs11679731	chr2:43589064	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.5	-5.02	-0.31	1.02e-6	Granulocyte percentage of myeloid white cells;
SARC	cis	rs4727027	0.716	rs4727020	chr7:148837317	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.52	6.04	0.37	6.13e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs2204008	0.774	rs3910796	chr12:38230660	G/T	cg26384229	chr12:38710491	ALG10B	0.88	12.94	0.65	3.26e-29	Bladder cancer;
SARC	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg13395646	chr4:1353034	KIAA1530	-0.53	-6.28	-0.38	1.64e-9	Obesity-related traits;
SARC	cis	rs644799	1.000	rs580255	chr11:95577929	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.89	13.95	0.67	1.5e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs965604	0.965	rs36146269	chr15:78779510	T/A	cg24631222	chr15:78858424	CHRNA5	-0.46	-5.94	-0.36	1.05e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs78545713	1.000	rs16891484	chr6:26242930	G/A	cg13736514	chr6:26305472	NA	-0.61	-5.14	-0.32	5.89e-7	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs79149102	1.000	rs78940327	chr15:75152480	G/A	cg09165964	chr15:75287851	SCAMP5	-1.16	-6.97	-0.42	3.26e-11	Lung cancer;
SARC	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg11890956	chr21:40555474	PSMG1	1.16	19.35	0.79	2.15e-50	Cognitive function;
SARC	cis	rs6500602	0.647	rs4786519	chr16:4584406	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.31	5.06	0.31	8.48e-7	Schizophrenia;
SARC	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg11766577	chr21:47581405	C21orf56	0.5	6.12	0.37	3.89e-9	Testicular germ cell tumor;
SARC	cis	rs2529049	0.560	rs6943306	chr7:24701995	A/G	cg17569154	chr7:24781545	DFNA5	0.51	7.31	0.43	4.16e-12	Urate levels in obese individuals;
SARC	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg03452623	chr4:187889614	NA	-0.76	-11.83	-0.61	1.32e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.57	-7.43	-0.44	2.04e-12	Mean platelet volume;
SARC	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg03709012	chr19:19516395	GATAD2A	-0.94	-15.08	-0.7	2.5e-36	Tonsillectomy;
SARC	cis	rs4925386	0.840	rs6142738	chr20:60919960	C/T	cg24112000	chr20:60950667	NA	0.36	5.4	0.33	1.67e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs6500602	0.727	rs12443748	chr16:4541831	C/T	cg08645402	chr16:4508243	NA	0.38	4.84	0.3	2.32e-6	Schizophrenia;
SARC	cis	rs11225247	0.536	rs11605915	chr11:102237187	C/T	cg11690896	chr11:102217788	BIRC2	0.73	5.21	0.32	4.15e-7	Vein graft stenosis in coronary artery bypass grafting;
SARC	cis	rs950169	0.881	rs62029599	chr15:84956565	A/C	cg24253500	chr15:84953950	NA	0.36	5.21	0.32	4.19e-7	Schizophrenia;
SARC	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg26513180	chr16:89883248	FANCA	0.74	4.78	0.3	3.11e-6	Skin colour saturation;
SARC	cis	rs9486715	0.867	rs3860243	chr6:96905303	T/G	cg18709589	chr6:96969512	KIAA0776	0.54	6.66	0.4	1.95e-10	Headache;
SARC	cis	rs17376456	0.542	rs1982439	chr5:93160560	C/G	cg21475434	chr5:93447410	FAM172A	-0.61	-5.95	-0.36	9.87e-9	Diabetic retinopathy;
SARC	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg22968622	chr17:43663579	NA	1.25	16.81	0.74	4.44e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs10483282	1.000	rs6573382	chr14:24254208	G/T	cg02879798	chr14:24800305	ADCY4	-0.33	-5.07	-0.32	7.96e-7	Alcohol dependence;
SARC	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg09359103	chr1:154839909	KCNN3	-0.47	-7.99	-0.46	6.06e-14	Prostate cancer;
SARC	cis	rs11098499	0.697	rs35280960	chr4:120257059	G/A	cg09307838	chr4:120376055	NA	0.8	10.7	0.57	5.3e-22	Corneal astigmatism;
SARC	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg18876405	chr7:65276391	NA	-0.73	-9.46	-0.53	3.51e-18	Aortic root size;
SARC	cis	rs5167	0.536	rs1882752	chr19:45461342	G/C	cg10169327	chr19:45448959	APOC2	0.34	4.93	0.31	1.53e-6	Blood protein levels;
SARC	cis	rs7044106	0.791	rs10985004	chr9:123484937	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.77	10.25	0.56	1.41e-20	Hip circumference adjusted for BMI;
SARC	cis	rs17445774	1.000	rs1509833	chr2:200865225	G/A	cg17644776	chr2:200775616	C2orf69	0.44	5.62	0.35	5.53e-8	LDL cholesterol to HDL cholesterol ratio;
SARC	trans	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg00938859	chr5:1591904	SDHAP3	0.79	7.55	0.44	9.95e-13	Breast cancer;
SARC	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg01276201	chr10:134613136	NA	0.31	5.31	0.33	2.57e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs2425143	1.000	rs2425093	chr20:34306875	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-7.17	-0.43	9.99e-12	Blood protein levels;
SARC	cis	rs644799	0.635	rs10831428	chr11:95508404	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.87	14.1	0.68	4.78e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs62244186	0.748	rs6441861	chr3:44652287	A/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.44	5.5	0.34	9.74e-8	Depressive symptoms;
SARC	cis	rs2304069	0.913	rs7734382	chr5:149383241	A/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.89	9.42	0.53	4.58e-18	HIV-1 control;
SARC	cis	rs2387326	0.629	rs12261739	chr10:129945520	A/G	cg16087940	chr10:129947807	NA	-0.45	-5.79	-0.35	2.31e-8	Select biomarker traits;
SARC	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg09455208	chr3:40491958	NA	0.41	6.28	0.38	1.66e-9	Renal cell carcinoma;
SARC	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs17376456	0.877	rs17316137	chr5:93456577	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.77	0.35	2.5e-8	Diabetic retinopathy;
SARC	cis	rs2120019	1.000	rs1867146	chr15:75354971	C/G	cg09165964	chr15:75287851	SCAMP5	-0.93	-13.71	-0.67	9.36e-32	Blood trace element (Zn levels);
SARC	cis	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg02836830	chr20:3767452	CENPB	0.37	4.94	0.31	1.48e-6	Immature fraction of reticulocytes;
SARC	cis	rs9470366	0.816	rs7774130	chr6:36623756	C/T	cg08179530	chr6:36648295	CDKN1A	0.57	6.08	0.37	4.91e-9	QRS duration;
SARC	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg11366901	chr6:160182831	ACAT2	0.95	9.83	0.54	2.66e-19	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg25072359	chr17:41440525	NA	0.52	6.47	0.39	5.59e-10	Menopause (age at onset);
SARC	cis	rs9467773	0.620	rs2451744	chr6:26633463	G/T	cg11502198	chr6:26597334	ABT1	0.63	8.63	0.49	9.91e-16	Intelligence (multi-trait analysis);
SARC	cis	rs2304069	0.565	rs13183261	chr5:149421847	T/G	cg12661370	chr5:149340060	SLC26A2	0.56	6.48	0.39	5.44e-10	HIV-1 control;
SARC	cis	rs13161895	0.941	rs6876648	chr5:179441842	T/C	cg04265672	chr5:179402240	RNF130	0.51	5.06	0.31	8.52e-7	LDL cholesterol;
SARC	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg05313129	chr8:58192883	C8orf71	-0.58	-6.5	-0.39	4.83e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs3824867	0.920	rs9734013	chr11:47451517	G/T	cg20307385	chr11:47447363	PSMC3	-0.47	-5.14	-0.32	5.71e-7	Mean corpuscular hemoglobin;
SARC	cis	rs2239547	0.657	rs4687672	chr3:52880543	G/A	cg18404041	chr3:52824283	ITIH1	-0.41	-5.09	-0.32	7.3e-7	Schizophrenia;
SARC	trans	rs9951602	0.512	rs9958497	chr18:76655296	G/C	cg02800362	chr5:177631904	HNRNPAB	0.7	8.92	0.5	1.4e-16	Obesity-related traits;
SARC	cis	rs7113850	0.541	rs78048500	chr11:24217764	T/G	ch.11.24196551F	chr11:24239977	NA	0.77	6.04	0.37	6.18e-9	Bone fracture in osteoporosis;
SARC	cis	rs6545883	0.894	rs35292974	chr2:61522047	T/C	cg15711740	chr2:61764176	XPO1	0.4	4.78	0.3	3.11e-6	Tuberculosis;
SARC	cis	rs17331151	0.573	rs76029595	chr3:52868523	C/T	cg04865290	chr3:52927548	TMEM110	-0.62	-5.81	-0.36	2.07e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs7766436	0.583	rs6936809	chr6:22559825	T/G	cg13666174	chr6:22585274	NA	-0.59	-6.04	-0.37	6e-9	Coronary artery disease;
SARC	cis	rs67311347	1.000	rs7633809	chr3:40517737	A/G	cg09455208	chr3:40491958	NA	-0.35	-5.35	-0.33	2.1e-7	Renal cell carcinoma;
SARC	cis	rs9916302	0.851	rs11870631	chr17:37645129	C/T	cg00129232	chr17:37814104	STARD3	-0.65	-7.98	-0.46	6.57e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs1878931	0.501	rs17136359	chr16:3420814	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.75	-9.75	-0.54	4.79e-19	Body mass index (adult);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg01260541	chr6:119499554	MAN1A1	0.51	7.16	0.42	1.06e-11	Thyroid stimulating hormone;
SARC	cis	rs7945705	0.875	rs10769957	chr11:8809016	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.37	-5.0	-0.31	1.13e-6	Hemoglobin concentration;
SARC	cis	rs17030434	1.000	rs78249279	chr4:154718783	C/T	cg14289246	chr4:154710475	SFRP2	-0.77	-7.02	-0.42	2.39e-11	Electrocardiographic conduction measures;
SARC	cis	rs8058578	0.943	rs7197770	chr16:30715908	T/C	cg02466173	chr16:30829666	NA	-0.39	-5.18	-0.32	4.74e-7	Multiple myeloma;
SARC	cis	rs8114671	0.562	rs8117491	chr20:33510120	T/C	cg07148914	chr20:33460835	GGT7	0.45	5.49	0.34	1.04e-7	Height;
SARC	cis	rs6088590	1.000	rs6088607	chr20:33378733	C/T	cg24642439	chr20:33292090	TP53INP2	0.88	12.36	0.63	2.45e-27	Coronary artery disease;
SARC	cis	rs10504229	0.512	rs77289815	chr8:57995242	A/G	cg08219700	chr8:58056026	NA	0.7	4.87	0.3	2.03e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg00825309	chr19:58991885	ZNF446	-0.55	-7.7	-0.45	3.88e-13	Uric acid clearance;
SARC	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg03264133	chr6:25882463	NA	-0.45	-5.95	-0.36	9.94e-9	Intelligence (multi-trait analysis);
SARC	cis	rs1163251	0.837	rs2764886	chr1:120241771	C/T	cg19096424	chr1:120255104	PHGDH	0.59	6.95	0.41	3.61e-11	Blood metabolite levels;
SARC	cis	rs829883	0.664	rs829876	chr12:98842138	A/G	cg25150519	chr12:98850993	NA	0.8	13.21	0.65	4.15e-30	Colorectal adenoma (advanced);
SARC	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.44	5.04	0.31	9.25e-7	Bipolar disorder;
SARC	cis	rs7481584	0.669	rs12793371	chr11:3034709	A/G	cg20651018	chr11:3035856	CARS	0.4	5.81	0.36	2.04e-8	Calcium levels;
SARC	cis	rs79149102	0.850	rs78646589	chr15:75170580	C/T	cg09165964	chr15:75287851	SCAMP5	-1.06	-6.87	-0.41	5.67e-11	Lung cancer;
SARC	cis	rs240764	0.817	rs239221	chr6:101113085	G/A	cg09795085	chr6:101329169	ASCC3	0.44	5.72	0.35	3.32e-8	Neuroticism;
SARC	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	5.42	0.33	1.47e-7	Bipolar disorder;
SARC	cis	rs11209002	0.876	rs7517744	chr1:67570879	T/C	cg02640540	chr1:67518911	SLC35D1	0.47	4.85	0.3	2.25e-6	Crohn's disease;
SARC	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs1532331	0.898	rs4498259	chr5:43165943	A/G	cg04007151	chr5:43193035	MGC42105	0.38	4.73	0.3	3.96e-6	Menarche (age at onset);
SARC	cis	rs748404	0.723	rs573169	chr15:43550581	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.53	6.37	0.39	9.92e-10	Lung cancer;
SARC	cis	rs7760949	0.963	rs9367699	chr6:13894635	A/C	cg27413430	chr6:13925136	RNF182	0.41	5.01	0.31	1.09e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg25072359	chr17:41440525	NA	0.52	6.51	0.39	4.48e-10	Menopause (age at onset);
SARC	cis	rs7511006	0.895	rs5771270	chr22:50682865	G/A	cg15134628	chr22:50699649	MAPK12	0.44	5.15	0.32	5.63e-7	Obesity-related traits;
SARC	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg19729930	chr2:74357872	NA	0.74	10.62	0.57	9.51e-22	Gestational age at birth (maternal effect);
SARC	cis	rs7998202	0.667	rs914017	chr13:113355037	G/A	cg02820901	chr13:113351484	ATP11A	0.56	5.06	0.31	8.58e-7	Glycated hemoglobin levels;
SARC	cis	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg01579765	chr21:45077557	HSF2BP	-0.38	-6.46	-0.39	5.92e-10	Mean corpuscular volume;
SARC	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg06028808	chr11:68637592	NA	0.45	5.83	0.36	1.88e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg26335602	chr6:28129616	ZNF389	0.53	5.92	0.36	1.12e-8	Depression;
SARC	cis	rs9300255	0.544	rs1727309	chr12:123658258	A/G	cg00376283	chr12:123451042	ABCB9	0.58	5.7	0.35	3.55e-8	Neutrophil percentage of white cells;
SARC	cis	rs9354308	0.868	rs4388276	chr6:66546565	G/A	cg07460842	chr6:66804631	NA	-0.42	-4.85	-0.3	2.27e-6	Metabolite levels;
SARC	cis	rs3768617	0.706	rs4129858	chr1:183004334	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.65	9.06	0.51	5.36e-17	Fuchs's corneal dystrophy;
SARC	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg13206674	chr6:150067644	NUP43	0.41	5.37	0.33	1.95e-7	Lung cancer;
SARC	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.17	-0.47	1.92e-14	Chronic sinus infection;
SARC	cis	rs2380220	1.000	rs2380220	chr6:95967412	T/C	cg04719120	chr6:96025338	MANEA	0.63	6.55	0.39	3.71e-10	Behavioural disinhibition (generation interaction);
SARC	cis	rs916888	0.647	rs199449	chr17:44808902	G/A	cg15921436	chr17:44337874	NA	0.47	5.38	0.33	1.83e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs751728	0.664	rs12196293	chr6:33749151	A/G	cg25922239	chr6:33757077	LEMD2	0.58	7.59	0.45	7.62e-13	Crohn's disease;
SARC	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg06108461	chr20:60628389	TAF4	-0.89	-11.9	-0.61	7.81e-26	Body mass index;
SARC	cis	rs698833	0.521	rs35627501	chr2:44506971	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.45	5.43	0.34	1.42e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs9916302	0.800	rs8069451	chr17:37504933	C/T	cg07936489	chr17:37558343	FBXL20	-0.67	-8.8	-0.5	3.2e-16	Glomerular filtration rate (creatinine);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg15156614	chr1:59248148	JUN	0.49	6.33	0.38	1.23e-9	Breast cancer;
SARC	cis	rs9513627	0.748	rs61525545	chr13:100118261	T/C	cg25919922	chr13:100150906	NA	-0.65	-5.01	-0.31	1.06e-6	Obesity-related traits;
SARC	cis	rs858239	0.932	rs1624451	chr7:23262435	A/T	cg23682824	chr7:23144976	KLHL7	-0.6	-7.45	-0.44	1.86e-12	Cerebrospinal fluid biomarker levels;
SARC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	9.6	0.53	1.32e-18	Prudent dietary pattern;
SARC	cis	rs13090388	1	rs13090388	chr3:49391082	C/T	cg03060546	chr3:49711283	APEH	-0.57	-7.09	-0.42	1.55e-11	Intelligence (multi-trait analysis);Educational attainment (years of education);
SARC	cis	rs7937682	0.889	rs551825	chr11:111480116	C/G	cg22437258	chr11:111473054	SIK2	0.76	10.68	0.57	6.13e-22	Primary sclerosing cholangitis;
SARC	cis	rs4713118	0.662	rs149961	chr6:28015569	A/C	cg16479474	chr6:28041457	NA	0.36	5.16	0.32	5.32e-7	Parkinson's disease;
SARC	cis	rs644799	1.000	rs12786522	chr11:95522858	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	15.44	0.71	1.64e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs677665	0.918	rs11590326	chr1:9339205	A/G	cg25755851	chr1:9335794	NA	-0.36	-5.31	-0.33	2.61e-7	Eosinophil percentage of white cells;
SARC	cis	rs13095912	1.000	rs13340181	chr3:185325612	T/C	cg11274856	chr3:185301563	NA	0.36	4.98	0.31	1.24e-6	Systolic blood pressure;
SARC	cis	rs61935443	0.501	rs7311211	chr12:95191189	A/C	cg21533806	chr12:95267307	NA	0.38	4.81	0.3	2.74e-6	Schizophrenia;
SARC	cis	rs4128725	1.000	rs12118628	chr1:159409884	G/A	cg25076881	chr1:159409836	OR10J1	0.4	4.8	0.3	2.86e-6	Select biomarker traits;
SARC	cis	rs2997447	0.655	rs11247852	chr1:26383125	C/G	cg19633962	chr1:26362018	EXTL1	0.76	7.53	0.44	1.12e-12	QRS complex (12-leadsum);
SARC	cis	rs11098499	0.863	rs6534139	chr4:120449456	A/G	cg09307838	chr4:120376055	NA	-0.9	-12.09	-0.62	1.94e-26	Corneal astigmatism;
SARC	cis	rs7626444	0.625	rs1718410	chr3:196477660	A/G	cg12930392	chr3:196481615	PAK2	0.25	5.0	0.31	1.13e-6	Monocyte count;
SARC	cis	rs6570726	0.935	rs442254	chr6:145849118	T/C	cg05347473	chr6:146136440	FBXO30	0.49	6.55	0.39	3.56e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs763121	0.853	rs2413547	chr22:39107338	A/G	cg06022373	chr22:39101656	GTPBP1	0.85	10.6	0.57	1.12e-21	Menopause (age at onset);
SARC	cis	rs11785400	0.793	rs4336593	chr8:143739647	A/C	cg10596483	chr8:143751796	JRK	-0.55	-6.93	-0.41	4.15e-11	Schizophrenia;
SARC	cis	rs6831352	1.000	rs1126670	chr4:100052733	C/A	cg12011299	chr4:100065546	ADH4	0.34	5.95	0.36	1e-8	Alcohol dependence;
SARC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg20102877	chr2:27665638	KRTCAP3	-0.36	-5.09	-0.32	7.24e-7	Total body bone mineral density;
SARC	cis	rs1707322	1.000	rs10890375	chr1:46406581	G/A	cg03146154	chr1:46216737	IPP	0.46	5.53	0.34	8.66e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs854765	0.583	rs8078105	chr17:17853782	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.43	5.52	0.34	9.04e-8	Total body bone mineral density;
SARC	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-6.48	-0.39	5.35e-10	Bipolar disorder;
SARC	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg10523679	chr1:76189770	ACADM	0.5	6.45	0.39	6.24e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs112374894	1.000	rs117770243	chr14:88996726	C/A	cg01020840	chr14:89016979	PTPN21	0.84	4.95	0.31	1.43e-6	Prudent dietary pattern;
SARC	cis	rs7772486	0.654	rs702321	chr6:146006695	A/G	cg23711669	chr6:146136114	FBXO30	-0.8	-12.76	-0.64	1.23e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9303401	0.659	rs34170300	chr17:56789905	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	11.87	0.61	9.72e-26	Cognitive test performance;
SARC	cis	rs3870371	1.000	rs7816221	chr8:122696143	A/G	cg21781600	chr8:122651575	HAS2;HAS2AS	-0.49	-5.54	-0.34	8.34e-8	Periodontal disease-related phenotypes;
SARC	cis	rs6484504	0.600	rs208063	chr11:31159777	C/T	cg26647111	chr11:31128758	NA	-0.38	-5.04	-0.31	9.31e-7	Red blood cell count;
SARC	cis	rs9914544	0.545	rs9914914	chr17:18787780	G/A	cg25390199	chr17:18761479	PRPSAP2	0.46	6.05	0.37	5.66e-9	Educational attainment (years of education);
SARC	cis	rs4595586	0.525	rs3914597	chr12:39388693	G/A	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	cis	rs9314323	0.798	rs12682345	chr8:26218332	A/G	cg11498726	chr8:26250323	BNIP3L	0.6	7.8	0.45	2.13e-13	Red cell distribution width;
SARC	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg20891283	chr12:69753455	YEATS4	0.55	7.55	0.44	9.74e-13	Blood protein levels;
SARC	cis	rs7412746	0.611	rs7556661	chr1:150892009	C/T	cg15448220	chr1:150897856	SETDB1	0.51	6.65	0.4	2.02e-10	Melanoma;
SARC	cis	rs56775891	1.000	rs34945223	chr18:77575871	A/G	cg24058013	chr18:77568902	NA	-0.37	-4.88	-0.3	2e-6	Schizophrenia;
SARC	cis	rs6089584	0.507	rs6061999	chr20:60637429	G/A	cg06108461	chr20:60628389	TAF4	-0.67	-8.49	-0.49	2.41e-15	Body mass index;
SARC	cis	rs9291683	0.610	rs993172	chr4:10324361	G/T	cg11266682	chr4:10021025	SLC2A9	0.31	5.15	0.32	5.52e-7	Bone mineral density;
SARC	cis	rs459571	0.920	rs417142	chr9:136891370	G/T	cg01294253	chr9:136912663	BRD3	0.43	5.62	0.35	5.55e-8	Platelet distribution width;
SARC	cis	rs12478296	1.000	rs113129906	chr2:243004253	C/T	cg06360820	chr2:242988706	NA	-0.82	-6.43	-0.39	7.21e-10	Obesity-related traits;
SARC	cis	rs11122272	0.735	rs1076804	chr1:231498460	T/C	cg06096015	chr1:231504339	EGLN1	0.37	5.56	0.34	7.48e-8	Hemoglobin concentration;
SARC	cis	rs2153535	0.505	rs9405395	chr6:8468622	T/A	cg07606381	chr6:8435919	SLC35B3	0.73	10.14	0.55	3.07e-20	Motion sickness;
SARC	cis	rs9309473	0.607	rs6716776	chr2:73587713	T/C	cg20560298	chr2:73613845	ALMS1	-0.57	-7.09	-0.42	1.57e-11	Metabolite levels;
SARC	trans	rs6894249	1.000	rs6894249	chr5:131797547	A/G	cg02553987	chr17:58754813	BCAS3	0.49	6.25	0.38	1.93e-9	Asthma;
SARC	cis	rs546131	0.963	rs539044	chr11:34841542	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.45	5.54	0.34	8.29e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg11062466	chr8:58055876	NA	0.6	5.71	0.35	3.44e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs55871839	0.559	rs66954327	chr8:59825133	A/G	cg07426533	chr8:59803705	TOX	0.47	5.4	0.33	1.62e-7	Pneumonia;
SARC	cis	rs1003719	0.762	rs3787786	chr21:38463436	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.63	9.05	0.51	5.67e-17	Eye color traits;
SARC	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg27266027	chr21:40555129	PSMG1	-0.46	-5.04	-0.31	9.33e-7	Cognitive function;
SARC	cis	rs6580649	0.883	rs4075913	chr12:48537624	A/G	cg05342945	chr12:48394962	COL2A1	-0.51	-5.54	-0.34	8.29e-8	Lung cancer;
SARC	cis	rs6121246	0.697	rs6120970	chr20:30232452	C/T	cg13852791	chr20:30311386	BCL2L1	0.82	8.74	0.5	4.67e-16	Mean corpuscular hemoglobin;
SARC	cis	rs523522	0.962	rs509445	chr12:121017243	A/C	cg27279351	chr12:120934652	DYNLL1	0.7	8.62	0.49	1.03e-15	High light scatter reticulocyte count;
SARC	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs1215050	0.791	rs783969	chr4:98906504	C/T	cg05340658	chr4:99064831	C4orf37	0.46	6.06	0.37	5.36e-9	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs79149102	0.579	rs7167415	chr15:75302570	C/T	cg00629941	chr15:75287862	SCAMP5	-0.65	-5.26	-0.33	3.2e-7	Lung cancer;
SARC	trans	rs79976124	0.797	rs78317899	chr6:66652896	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	7.89	0.46	1.16e-13	Type 2 diabetes;
SARC	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg22307029	chr19:49891270	CCDC155	0.65	7.67	0.45	4.54e-13	Multiple sclerosis;
SARC	cis	rs9916302	0.706	rs4488484	chr17:37717377	A/T	cg20243544	chr17:37824526	PNMT	-0.57	-5.86	-0.36	1.53e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.54	4.91	0.31	1.72e-6	Lung function (FEV1/FVC);
SARC	cis	rs35110281	0.782	rs1584917	chr21:45042365	A/G	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.01	-0.37	7.01e-9	Mean corpuscular volume;
SARC	cis	rs2303745	0.589	rs1965717	chr19:17398559	C/T	cg22549504	chr19:17448937	GTPBP3	0.49	4.99	0.31	1.19e-6	Systemic lupus erythematosus;
SARC	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg21782813	chr7:2030301	MAD1L1	0.48	7.44	0.44	1.94e-12	Bipolar disorder and schizophrenia;
SARC	cis	rs9790314	0.846	rs899275	chr3:161042104	T/C	cg04691961	chr3:161091175	C3orf57	-0.64	-8.79	-0.5	3.34e-16	Morning vs. evening chronotype;
SARC	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg18876405	chr7:65276391	NA	-0.69	-8.6	-0.49	1.22e-15	Aortic root size;
SARC	cis	rs12142240	0.698	rs72886907	chr1:46814265	C/T	cg10495392	chr1:46806563	NSUN4	0.65	6.79	0.41	9.18e-11	Menopause (age at onset);
SARC	cis	rs7264396	0.690	rs2425172	chr20:34443893	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.51	5.08	0.32	7.84e-7	Total cholesterol levels;
SARC	trans	rs61931739	0.534	rs11052986	chr12:34052578	T/C	cg13010199	chr12:38710504	ALG10B	0.66	9.11	0.51	3.85e-17	Morning vs. evening chronotype;
SARC	cis	rs17125944	0.556	rs7152229	chr14:53313405	T/C	cg00686598	chr14:53173677	PSMC6	-0.72	-5.32	-0.33	2.43e-7	Alzheimer's disease (late onset);
SARC	cis	rs2439831	0.681	rs2278858	chr15:43632755	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.75	7.07	0.42	1.78e-11	Lung cancer in ever smokers;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg14303833	chr7:120590659	ING3	-0.48	-6.28	-0.38	1.6e-9	Neuroticism;
SARC	cis	rs1580019	0.563	rs34201720	chr7:32568935	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.55	7.19	0.43	8.97e-12	Cognitive ability;
SARC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg08219700	chr8:58056026	NA	0.62	6.56	0.4	3.37e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs4713118	0.513	rs156738	chr6:28014025	G/C	cg17221315	chr6:27791827	HIST1H4J	0.45	4.84	0.3	2.4e-6	Parkinson's disease;
SARC	cis	rs76419734	1.000	rs17036258	chr4:106737382	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	5.2	0.32	4.29e-7	Post bronchodilator FEV1;
SARC	cis	rs7584330	0.628	rs7591065	chr2:238390739	G/T	cg08992911	chr2:238395768	MLPH	0.5	4.86	0.3	2.18e-6	Prostate cancer;
SARC	trans	rs1814175	0.791	rs11040513	chr11:49778153	G/C	cg15704280	chr7:45808275	SEPT13	-0.97	-18.04	-0.76	3.96e-46	Height;
SARC	cis	rs3858526	0.920	rs11039698	chr11:5950907	C/T	cg05234568	chr11:5960015	NA	-0.42	-4.89	-0.31	1.86e-6	DNA methylation (variation);
SARC	cis	rs698813	0.674	rs11680456	chr2:44497544	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	6.31	0.38	1.4e-9	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg21724239	chr8:58056113	NA	0.6	6.31	0.38	1.43e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7582720	1.000	rs72932573	chr2:203861113	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs12579753	0.810	rs10862355	chr12:82162698	C/T	cg07988820	chr12:82153109	PPFIA2	-0.51	-6.13	-0.37	3.7e-9	Resting heart rate;
SARC	cis	rs735396	1.000	rs1169311	chr12:121440731	C/T	cg25281562	chr12:121454272	C12orf43	0.5	6.06	0.37	5.55e-9	N-glycan levels;
SARC	cis	rs453301	0.686	rs11785819	chr8:8870378	T/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.04	-0.42	2.15e-11	Joint mobility (Beighton score);
SARC	cis	rs35110281	0.591	rs86139	chr21:44932802	G/A	cg01579765	chr21:45077557	HSF2BP	-0.34	-5.78	-0.35	2.44e-8	Mean corpuscular volume;
SARC	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg24675658	chr1:53192096	ZYG11B	-0.59	-8.1	-0.47	3.15e-14	Monocyte count;
SARC	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg27286337	chr10:134555280	INPP5A	0.67	7.34	0.43	3.53e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs6840360	0.554	rs13108359	chr4:152727852	T/C	cg22705602	chr4:152727874	NA	0.48	8.56	0.49	1.53e-15	Intelligence (multi-trait analysis);
SARC	cis	rs7412746	0.563	rs3768013	chr1:150815411	G/A	cg13175981	chr1:150552382	MCL1	-0.56	-6.98	-0.42	3.09e-11	Melanoma;
SARC	cis	rs10791097	0.739	rs12279359	chr11:130730544	G/A	cg12179176	chr11:130786555	SNX19	0.65	9.0	0.51	8.36e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs9487051	0.898	rs882072	chr6:109611806	A/G	cg01475377	chr6:109611718	NA	-0.41	-5.88	-0.36	1.39e-8	Reticulocyte fraction of red cells;
SARC	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg16606324	chr3:10149918	C3orf24	0.52	4.96	0.31	1.34e-6	Alzheimer's disease;
SARC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg25703541	chr22:24373054	LOC391322	-0.87	-13.27	-0.66	2.54e-30	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2858942	0.575	rs2858011	chr16:247938	C/T	cg08400316	chr16:204221	HBZ	0.52	6.67	0.4	1.79e-10	Mean corpuscular hemoglobin;
SARC	cis	rs7927771	0.864	rs4752838	chr11:47466006	G/A	cg05585544	chr11:47624801	NA	-0.36	-4.8	-0.3	2.8e-6	Subjective well-being;
SARC	cis	rs6964587	0.967	rs58673519	chr7:91823887	T/G	cg17063962	chr7:91808500	NA	0.98	15.9	0.72	4.67e-39	Breast cancer;
SARC	trans	rs2018683	0.711	rs2158788	chr7:28971958	G/A	cg19402173	chr7:128379420	CALU	-0.56	-7.13	-0.42	1.22e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	trans	rs1865760	0.929	rs9461224	chr6:25936402	G/T	cg13799898	chr9:136858673	VAV2	-0.54	-6.32	-0.38	1.34e-9	Height;
SARC	cis	rs2594989	1.000	rs2595002	chr3:11373700	G/A	cg00170343	chr3:11313890	ATG7	0.58	5.65	0.35	4.64e-8	Circulating chemerin levels;
SARC	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.76	6.99	0.42	2.9100000000000002e-11	Platelet count;
SARC	cis	rs12971120	0.891	rs2303463	chr18:72168608	G/A	cg26446133	chr18:72167187	CNDP2	-0.51	-7.23	-0.43	6.89e-12	Refractive error;
SARC	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.59e-6	Depression;
SARC	cis	rs3733585	0.805	rs882222	chr4:9981294	G/A	cg11266682	chr4:10021025	SLC2A9	0.39	7.04	0.42	2.15e-11	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs1670533	1.000	rs6836350	chr4:1069973	C/T	cg27284194	chr4:1044797	NA	0.43	4.72	0.3	4.01e-6	Recombination rate (females);
SARC	cis	rs9911578	0.935	rs9911753	chr17:56983174	G/A	cg05425664	chr17:57184151	TRIM37	-0.57	-6.9	-0.41	4.96e-11	Intelligence (multi-trait analysis);
SARC	cis	rs72634258	0.554	rs13306061	chr1:7913445	C/T	cg05338066	chr1:7812865	CAMTA1	0.56	4.9	0.31	1.82e-6	Inflammatory bowel disease;
SARC	cis	rs910187	0.571	rs6512428	chr20:45807822	T/C	cg27589058	chr20:45804311	EYA2	-0.3	-4.96	-0.31	1.36e-6	Migraine;
SARC	cis	rs6912958	0.935	rs6454629	chr6:88165515	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.62	-8.71	-0.5	5.79e-16	Monocyte percentage of white cells;
SARC	cis	rs644799	0.965	rs3016295	chr11:95554311	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	15.16	0.7	1.35e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2074585	0.839	rs11638780	chr15:91041896	G/T	cg22089800	chr15:90895588	ZNF774	-0.59	-7.57	-0.44	8.72e-13	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg07701084	chr6:150067640	NUP43	0.42	5.53	0.34	8.75e-8	Lung cancer;
SARC	cis	rs832540	0.656	rs6893754	chr5:56100006	G/A	cg12311346	chr5:56204834	C5orf35	-0.39	-4.83	-0.3	2.45e-6	Coronary artery disease;
SARC	cis	rs1348850	0.914	rs12469386	chr2:178358281	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.63	-7.87	-0.46	1.36e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs10875746	0.669	rs10783244	chr12:48664989	A/C	cg26205652	chr12:48591994	NA	0.47	5.11	0.32	6.85e-7	Longevity (90 years and older);
SARC	cis	rs7084402	0.967	rs1649028	chr10:60280428	A/G	cg07615347	chr10:60278583	BICC1	-0.6	-8.82	-0.5	2.78e-16	Refractive error;
SARC	cis	rs2486288	0.656	rs2413773	chr15:45549442	C/A	cg15395560	chr15:45543142	SLC28A2	0.29	5.63	0.35	5.17e-8	Glomerular filtration rate;
SARC	cis	rs4595586	0.545	rs4623945	chr12:39364572	A/T	cg26384229	chr12:38710491	ALG10B	0.51	6.25	0.38	1.9e-9	Morning vs. evening chronotype;
SARC	trans	rs1814175	0.765	rs1721990	chr11:49912154	G/C	cg03929089	chr4:120376271	NA	-0.88	-13.97	-0.68	1.25e-32	Height;
SARC	cis	rs57502260	0.704	rs12286536	chr11:68290234	C/G	cg01657329	chr11:68192670	LRP5	-0.5	-5.11	-0.32	6.65e-7	Total body bone mineral density (age 45-60);
SARC	cis	rs3820928	0.874	rs7576081	chr2:227843634	C/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-6.76	-0.4	1.09e-10	Pulmonary function;
SARC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg02951883	chr7:2050386	MAD1L1	-0.51	-6.52	-0.39	4.4e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs11792861	0.926	rs17628095	chr9:111889172	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.62	-7.0	-0.42	2.78e-11	Menarche (age at onset);
SARC	cis	rs9325144	0.671	rs35817541	chr12:38975001	T/C	cg13010199	chr12:38710504	ALG10B	-0.51	-6.43	-0.39	7.22e-10	Morning vs. evening chronotype;
SARC	cis	rs4889855	0.505	rs8077626	chr17:78600552	G/C	cg17956530	chr17:78667699	RPTOR	-0.47	-5.4	-0.33	1.65e-7	Fractional excretion of uric acid;
SARC	cis	rs2153535	0.580	rs9379222	chr6:8514788	T/C	cg07606381	chr6:8435919	SLC35B3	0.77	10.87	0.58	1.55e-22	Motion sickness;
SARC	cis	rs12048904	0.964	rs17123467	chr1:101331760	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.43	5.43	0.33	1.44e-7	Multiple sclerosis;
SARC	cis	rs12824058	0.831	rs4759657	chr12:130815818	G/A	cg24838063	chr12:130822603	PIWIL1	0.63	9.06	0.51	5.5e-17	Menopause (age at onset);
SARC	cis	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg07777115	chr5:623756	CEP72	-0.56	-4.83	-0.3	2.49e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs6866344	0.570	rs56236920	chr5:178144617	C/T	cg03877680	chr5:178157825	ZNF354A	1.04	14.5	0.69	2.19e-34	Neutrophil percentage of white cells;
SARC	cis	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg15556689	chr8:8085844	FLJ10661	0.47	5.87	0.36	1.52e-8	Systolic blood pressure;
SARC	cis	rs7179456	0.654	rs8038504	chr15:59249516	T/A	cg05156742	chr15:59063176	FAM63B	0.57	7.31	0.43	4.31e-12	Asperger disorder;
SARC	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg12564285	chr5:131593104	PDLIM4	-0.48	-6.37	-0.39	1e-9	Blood metabolite levels;
SARC	cis	rs9914988	0.943	rs2874253	chr17:27157863	A/T	cg20469991	chr17:27169893	C17orf63	-0.52	-5.39	-0.33	1.74e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.48	-6.01	-0.37	7.23e-9	Lymphocyte counts;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg18223896	chr14:89081931	EML5	0.44	6.25	0.38	1.96e-9	Thyroid stimulating hormone;
SARC	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg05861140	chr6:150128134	PCMT1	-0.42	-5.44	-0.34	1.32e-7	Lung cancer;
SARC	cis	rs4727027	0.933	rs13225884	chr7:148857795	A/G	cg23583168	chr7:148888333	NA	-0.73	-11.15	-0.59	2.07e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	trans	rs1814175	0.645	rs10839382	chr11:49823172	C/T	cg03929089	chr4:120376271	NA	-0.84	-12.32	-0.63	3.52e-27	Height;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg26492833	chr12:112451189	TMEM116;ERP29	0.53	6.96	0.41	3.52e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg27426447	chr16:83947913	MLYCD	-0.5	-6.29	-0.38	1.56e-9	Migraine with aura;
SARC	cis	rs1728785	1.000	rs864741	chr16:68576577	C/T	cg02972257	chr16:68554789	NA	-0.43	-5.01	-0.31	1.08e-6	Ulcerative colitis;
SARC	cis	rs8058578	1.000	rs13338946	chr16:30700858	T/C	cg02466173	chr16:30829666	NA	-0.42	-5.45	-0.34	1.26e-7	Multiple myeloma;
SARC	cis	rs11608355	0.597	rs10850070	chr12:109793882	A/G	cg19025524	chr12:109796872	NA	-0.47	-6.75	-0.4	1.18e-10	Neuroticism;
SARC	cis	rs453301	0.719	rs34004903	chr8:8892604	C/T	cg06636001	chr8:8085503	FLJ10661	-0.61	-8.27	-0.48	9.97e-15	Joint mobility (Beighton score);
SARC	cis	rs910316	1.000	rs12588240	chr14:75612083	C/A	cg08847533	chr14:75593920	NEK9	0.92	15.79	0.72	1.14e-38	Height;
SARC	cis	rs950169	0.724	rs11632668	chr15:84948687	T/C	cg17507749	chr15:85114479	UBE2QP1	0.78	9.49	0.53	2.84e-18	Schizophrenia;
SARC	cis	rs6493487	0.512	rs17521789	chr15:51271177	G/A	cg02338191	chr15:51200825	AP4E1	0.55	5.09	0.32	7.21e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs11676348	0.846	rs4674257	chr2:218988774	A/G	cg00012203	chr2:219082015	ARPC2	-0.55	-7.32	-0.43	3.92e-12	Ulcerative colitis;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg15150615	chr19:45681664	BLOC1S3;TRAPPC6A	-0.52	-6.62	-0.4	2.51e-10	Gallstone disease;
SARC	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg11644478	chr21:40555479	PSMG1	-0.86	-10.61	-0.57	1.04e-21	Cognitive function;
SARC	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg11644478	chr21:40555479	PSMG1	1.06	15.16	0.7	1.35e-36	Cognitive function;
SARC	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg22857025	chr5:266934	NA	-1.08	-11.86	-0.61	1.06e-25	Breast cancer;
SARC	cis	rs35110281	0.591	rs162390	chr21:44936826	C/T	cg01579765	chr21:45077557	HSF2BP	-0.32	-5.52	-0.34	9.16e-8	Mean corpuscular volume;
SARC	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	13.66	0.67	1.39e-31	Chronic sinus infection;
SARC	cis	rs820218	0.886	rs820186	chr17:73619920	G/A	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.56	7.03	0.42	2.23e-11	Rotator cuff tears;
SARC	cis	rs67311347	1.000	rs6762997	chr3:40478151	C/T	cg24209194	chr3:40518798	ZNF619	0.63	8.24	0.48	1.22e-14	Renal cell carcinoma;
SARC	cis	rs2624839	0.704	rs13064381	chr3:50233317	C/T	cg14019146	chr3:50243930	SLC38A3	-0.44	-7.16	-0.42	1.04e-11	Intelligence (multi-trait analysis);
SARC	cis	rs6570726	0.791	rs6913727	chr6:145899826	A/G	cg23711669	chr6:146136114	FBXO30	0.83	13.94	0.67	1.53e-32	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs9951602	0.512	rs6506874	chr18:76653467	G/T	cg02800362	chr5:177631904	HNRNPAB	0.7	8.91	0.5	1.49e-16	Obesity-related traits;
SARC	cis	rs637571	0.522	rs491973	chr11:65727301	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.81	11.96	0.62	5.22e-26	Eosinophil percentage of white cells;
SARC	cis	rs16854884	0.632	rs35629416	chr3:143748424	C/T	cg06585982	chr3:143692056	C3orf58	0.63	8.44	0.48	3.36e-15	Economic and political preferences (feminism/equality);
SARC	cis	rs6424115	0.708	rs12755062	chr1:24185025	T/A	cg15997130	chr1:24165203	NA	-0.43	-5.22	-0.32	3.94e-7	Immature fraction of reticulocytes;
SARC	trans	rs11098499	0.954	rs10024844	chr4:120311528	A/G	cg25214090	chr10:38739885	LOC399744	0.55	7.14	0.42	1.15e-11	Corneal astigmatism;
SARC	cis	rs2228479	0.850	rs11642010	chr16:89845111	T/C	cg06558623	chr16:89946397	TCF25	0.91	6.2	0.38	2.51e-9	Skin colour saturation;
SARC	cis	rs9397240	0.789	rs9384308	chr6:155615948	C/T	cg07943832	chr6:155568918	TIAM2	-0.58	-5.62	-0.35	5.56e-8	Life satisfaction;
SARC	cis	rs9487051	0.872	rs9487038	chr6:109610152	T/C	cg01475377	chr6:109611718	NA	-0.42	-5.94	-0.36	1.01e-8	Reticulocyte fraction of red cells;
SARC	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg13175981	chr1:150552382	MCL1	-0.53	-6.81	-0.41	8.15e-11	Tonsillectomy;
SARC	cis	rs13314892	0.806	rs56007401	chr3:69861186	G/A	cg17445875	chr3:69859618	MITF	-0.49	-5.1	-0.32	6.98e-7	QRS complex (12-leadsum);
SARC	cis	rs804280	0.565	rs1466785	chr8:11623456	C/T	cg00262122	chr8:11665843	FDFT1	0.39	4.83	0.3	2.5e-6	Myopia (pathological);
SARC	cis	rs3796352	1.000	rs61172708	chr3:52996052	T/G	cg12962167	chr3:53033115	SFMBT1	0.75	4.9	0.31	1.8e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs16866061	1.000	rs10498163	chr2:225434445	A/G	cg12698349	chr2:225449008	CUL3	0.73	10.71	0.57	5.12e-22	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	cis	rs8114671	0.562	rs6087649	chr20:33510662	A/G	cg24642439	chr20:33292090	TP53INP2	0.49	5.94	0.36	1e-8	Height;
SARC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg26338869	chr17:61819248	STRADA	0.79	10.57	0.57	1.39e-21	Prudent dietary pattern;
SARC	cis	rs4689388	0.819	rs12649341	chr4:6294759	G/A	cg14416269	chr4:6271139	WFS1	0.32	4.92	0.31	1.61e-6	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs365132	0.875	rs353476	chr5:176424035	A/G	cg16309518	chr5:176445507	NA	-0.48	-6.29	-0.38	1.53e-9	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs9815354	0.812	rs113772069	chr3:41933389	T/C	cg03022575	chr3:42003672	ULK4	0.7	5.7	0.35	3.66e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs17376456	1.000	rs13163610	chr5:93548877	A/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.62	5.4	0.33	1.68e-7	Diabetic retinopathy;
SARC	cis	rs9815354	0.812	rs73071356	chr3:41829486	C/T	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6690583	0.623	rs74689037	chr1:85439268	C/T	cg22153463	chr1:85462885	MCOLN2	0.71	6.76	0.4	1.11e-10	Serum sulfate level;
SARC	cis	rs965469	1.000	rs2281503	chr20:3263636	G/A	cg25506879	chr20:3388711	C20orf194	-0.49	-4.91	-0.31	1.7e-6	IFN-related cytopenia;
SARC	trans	rs2727020	0.729	rs4315497	chr11:49214499	G/A	cg03929089	chr4:120376271	NA	0.77	10.7	0.57	5.33e-22	Coronary artery disease;
SARC	cis	rs9790314	0.715	rs7622047	chr3:160770505	G/A	cg03342759	chr3:160939853	NMD3	-0.42	-5.04	-0.31	9.13e-7	Morning vs. evening chronotype;
SARC	cis	rs3820928	0.934	rs1366756	chr2:227772038	G/A	cg05526886	chr2:227700861	RHBDD1	-0.5	-6.11	-0.37	4.08e-9	Pulmonary function;
SARC	cis	rs34172651	0.917	rs1075987	chr16:24794957	G/A	cg04756594	chr16:24857601	SLC5A11	0.35	5.57	0.34	6.89e-8	Intelligence (multi-trait analysis);
SARC	cis	rs4242434	0.672	rs2404654	chr8:22484949	T/C	cg03733263	chr8:22462867	KIAA1967	0.87	13.58	0.66	2.44e-31	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs16895831	0.519	rs16895863	chr6:42571346	A/T	cg10605015	chr6:42532144	UBR2	-0.53	-5.27	-0.33	3.14e-7	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
SARC	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs10046574	0.561	rs11505984	chr7:135208359	G/A	cg27474649	chr7:135195673	CNOT4	0.81	7.74	0.45	3e-13	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs9858542	0.903	rs9875617	chr3:49634696	G/A	cg03060546	chr3:49711283	APEH	-0.62	-7.88	-0.46	1.28e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.03	0.37	6.27e-9	Prudent dietary pattern;
SARC	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg07636037	chr3:49044803	WDR6	0.98	17.16	0.75	3.15e-43	Parkinson's disease;
SARC	cis	rs2439831	0.867	rs11856184	chr15:43919162	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	8.21	0.47	1.53e-14	Lung cancer in ever smokers;
SARC	cis	rs7659604	0.540	rs11098643	chr4:122701507	C/A	cg19671926	chr4:122722719	EXOSC9	0.66	8.81	0.5	2.84e-16	Type 2 diabetes;
SARC	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg23172400	chr8:95962367	TP53INP1	-0.34	-5.9	-0.36	1.29e-8	Type 2 diabetes;
SARC	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg12463550	chr7:65579703	CRCP	0.5	5.9	0.36	1.27e-8	Aortic root size;
SARC	trans	rs9929218	0.954	rs72785165	chr16:68755635	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.63	-8.07	-0.47	3.67e-14	Colorectal cancer;
SARC	cis	rs10927875	0.722	rs945425	chr1:16348412	T/C	cg21385522	chr1:16154831	NA	0.71	9.1	0.51	4.23e-17	Dilated cardiomyopathy;
SARC	cis	rs4077515	0.806	rs11145839	chr9:139285137	A/C	cg14169450	chr9:139327907	INPP5E	0.36	4.77	0.3	3.19e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg18404041	chr3:52824283	ITIH1	-0.44	-6.68	-0.4	1.73e-10	Bipolar disorder;
SARC	cis	rs3771570	1.000	rs56222556	chr2:242364119	G/A	cg21155796	chr2:242212141	HDLBP	0.7	6.27	0.38	1.74e-9	Prostate cancer;
SARC	trans	rs61931739	1.000	rs11052989	chr12:34057614	G/A	cg13010199	chr12:38710504	ALG10B	-0.53	-6.38	-0.39	9.58e-10	Morning vs. evening chronotype;
SARC	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.64	-7.78	-0.45	2.28e-13	Gut microbiome composition (summer);
SARC	cis	rs356220	0.509	rs356212	chr4:90636472	A/G	cg06632027	chr4:90757378	SNCA	0.39	5.0	0.31	1.13e-6	Parkinson's disease;
SARC	cis	rs765787	0.530	rs11639403	chr15:45538350	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.67e-7	Uric acid levels;
SARC	cis	rs4664308	0.935	rs4520994	chr2:160937750	G/A	cg03641300	chr2:160917029	PLA2R1	-0.71	-9.54	-0.53	2.02e-18	Idiopathic membranous nephropathy;
SARC	cis	rs10489202	0.954	rs11586522	chr1:168091031	G/T	cg24449463	chr1:168025552	DCAF6	-0.59	-6.63	-0.4	2.37e-10	Schizophrenia;
SARC	cis	rs7208859	0.623	rs28433704	chr17:29084285	G/C	cg13385521	chr17:29058706	SUZ12P	0.89	7.89	0.46	1.18e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs2425143	1.000	rs7273174	chr20:34350306	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.67	5.33	0.33	2.3e-7	Blood protein levels;
SARC	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg23758822	chr17:41437982	NA	0.86	10.56	0.57	1.52e-21	Menopause (age at onset);
SARC	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg11987759	chr7:65425863	GUSB	0.62	8.23	0.47	1.3e-14	Aortic root size;
SARC	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-9.6	-0.53	1.3e-18	Chronic sinus infection;
SARC	cis	rs1008375	1.000	rs10939746	chr4:17684951	A/G	cg27347728	chr4:17578864	LAP3	-0.45	-5.6	-0.34	5.88e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs367943	0.966	rs455435	chr5:112799412	T/C	cg12552261	chr5:112820674	MCC	-0.45	-5.19	-0.32	4.65e-7	Type 2 diabetes;
SARC	cis	rs3820928	0.839	rs10197773	chr2:227824835	G/A	cg05526886	chr2:227700861	RHBDD1	-0.57	-6.89	-0.41	5.13e-11	Pulmonary function;
SARC	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg24675658	chr1:53192096	ZYG11B	-0.6	-8.39	-0.48	4.63e-15	Monocyte count;
SARC	cis	rs112591243	0.570	rs2839340	chr21:47989804	C/T	cg26904215	chr21:47823096	PCNT	-0.83	-5.87	-0.36	1.5e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs2295359	0.892	rs56920441	chr1:67652012	A/G	cg12940439	chr1:67600707	NA	0.45	6.64	0.4	2.12e-10	Psoriasis;
SARC	cis	rs13191362	1.000	rs13213408	chr6:162998049	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.59	5.71	0.35	3.45e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs854765	0.663	rs12941550	chr17:17753828	C/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.61	-8.92	-0.5	1.41e-16	Total body bone mineral density;
SARC	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg24250549	chr1:154909240	PMVK	0.76	10.04	0.55	5.95e-20	Prostate cancer;
SARC	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg25072359	chr17:41440525	NA	0.54	6.84	0.41	6.99e-11	Menopause (age at onset);
SARC	cis	rs2197308	0.623	rs1672426	chr12:38118671	C/T	cg26384229	chr12:38710491	ALG10B	-0.68	-8.75	-0.5	4.25e-16	Morning vs. evening chronotype;
SARC	cis	rs17376456	0.569	rs7701114	chr5:93096028	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.56	5.89	0.36	1.37e-8	Diabetic retinopathy;
SARC	cis	rs4969178	1.000	rs7212201	chr17:76393896	C/A	cg20026190	chr17:76395443	PGS1	0.39	5.3	0.33	2.71e-7	HDL cholesterol levels;
SARC	cis	rs6088813	0.961	rs878639	chr20:33894463	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.43	5.05	0.31	8.76e-7	Height;
SARC	cis	rs6952809	0.516	rs6952959	chr7:2440722	C/T	cg23289794	chr7:2394357	EIF3B	-0.71	-6.8	-0.41	8.94e-11	Multiple sclerosis;
SARC	cis	rs11579220	1	rs11579220	chr1:205144363	G/T	cg07972983	chr1:205091412	RBBP5	0.55	6.72	0.4	1.42e-10	White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs854765	0.655	rs4470201	chr17:17844870	G/A	cg04398451	chr17:18023971	MYO15A	-0.4	-5.68	-0.35	4.02e-8	Total body bone mineral density;
SARC	cis	rs6918586	0.636	rs198857	chr6:26102417	G/C	cg18357526	chr6:26021779	HIST1H4A	-0.45	-5.81	-0.36	2.08e-8	Schizophrenia;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg19726959	chr15:75094782	CSK	0.5	7.29	0.43	4.65e-12	Schizophrenia;
SARC	cis	rs854765	0.618	rs8068820	chr17:17834119	A/G	cg05444541	chr17:17804740	TOM1L2	-0.3	-5.06	-0.31	8.38e-7	Total body bone mineral density;
SARC	cis	rs12754538	0.739	rs12567502	chr1:8808820	A/T	cg13785123	chr1:8931135	ENO1	0.48	5.79	0.35	2.27e-8	Subjective well-being;
SARC	cis	rs35110281	0.641	rs4819283	chr21:45083011	T/A	cg01579765	chr21:45077557	HSF2BP	-0.39	-6.37	-0.39	9.85e-10	Mean corpuscular volume;
SARC	cis	rs12545109	0.879	rs1975285	chr8:57358682	G/C	cg19413350	chr8:57351067	NA	-0.45	-4.92	-0.31	1.61e-6	Obesity-related traits;
SARC	cis	rs251130	0.709	rs114667405	chr5:110849504	T/C	cg13674042	chr5:110848180	STARD4	0.47	5.3	0.33	2.63e-7	Menarche (age at onset);
SARC	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg02733842	chr7:1102375	C7orf50	-0.62	-7.23	-0.43	6.98e-12	Bronchopulmonary dysplasia;
SARC	cis	rs8014204	0.806	rs11159105	chr14:75298052	C/T	cg06637938	chr14:75390232	RPS6KL1	0.69	10.1	0.55	4.11e-20	Caffeine consumption;
SARC	cis	rs524281	0.773	rs10896105	chr11:66002260	A/G	cg14036092	chr11:66035641	RAB1B	-0.59	-6.28	-0.38	1.67e-9	Electroencephalogram traits;
SARC	cis	rs2228479	0.557	rs11648881	chr16:89862434	T/C	cg00800038	chr16:89945340	TCF25	-0.83	-5.76	-0.35	2.65e-8	Skin colour saturation;
SARC	cis	rs2230307	0.572	rs11166408	chr1:100641350	A/T	cg24955406	chr1:100503596	HIAT1	-0.64	-5.93	-0.36	1.08e-8	Carotid intima media thickness;
SARC	cis	rs72792276	1.000	rs78529289	chr5:127405378	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	6.03	0.37	6.3e-9	Red cell distribution width;
SARC	cis	rs9818758	0.607	rs3923475	chr3:49055788	G/T	cg07636037	chr3:49044803	WDR6	-0.78	-6.77	-0.41	1.04e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg20607798	chr8:58055168	NA	0.6	5.33	0.33	2.29e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2153535	0.580	rs6938071	chr6:8464845	A/T	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg25072359	chr17:41440525	NA	0.5	5.96	0.36	9.33e-9	Menopause (age at onset);
SARC	cis	rs7149337	1.000	rs8006432	chr14:51731306	A/T	cg23942311	chr14:51606299	NA	0.32	5.71	0.35	3.43e-8	Cancer;
SARC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.78	10.07	0.55	5.05e-20	Prudent dietary pattern;
SARC	cis	rs6088590	0.582	rs6059909	chr20:33139691	C/A	cg24642439	chr20:33292090	TP53INP2	0.65	8.35	0.48	5.97e-15	Coronary artery disease;
SARC	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.79	-11.97	-0.62	4.79e-26	Personality dimensions;
SARC	cis	rs1003719	0.628	rs2252402	chr21:38520720	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.57	7.87	0.46	1.34e-13	Eye color traits;
SARC	cis	rs6582630	0.576	rs4403871	chr12:38292193	G/A	cg13010199	chr12:38710504	ALG10B	-0.55	-6.77	-0.41	1.07e-10	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg18435900	chr10:44101962	ZNF485	0.6	6.81	0.41	8.29e-11	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs11155671	0.530	rs7764376	chr6:150210344	A/G	cg05036130	chr6:150231994	NA	0.28	4.87	0.3	2.04e-6	Testicular germ cell tumor;
SARC	cis	rs2153535	0.580	rs6597326	chr6:8482019	A/C	cg21535247	chr6:8435926	SLC35B3	0.58	7.33	0.43	3.7e-12	Motion sickness;
SARC	cis	rs7520050	0.667	rs11211176	chr1:46223086	C/T	cg24296786	chr1:45957014	TESK2	0.41	5.09	0.32	7.54e-7	Red blood cell count;Reticulocyte count;
SARC	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg09323728	chr8:95962352	TP53INP1	-0.29	-4.96	-0.31	1.35e-6	Type 2 diabetes;
SARC	cis	rs12479064	0.724	rs2309618	chr2:99974473	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.68	-8.44	-0.48	3.44e-15	Chronic sinus infection;
SARC	cis	rs6696846	0.765	rs3738155	chr1:205074424	C/T	cg00857998	chr1:205179979	DSTYK	0.48	6.18	0.38	2.91e-9	Red blood cell count;
SARC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg12000995	chr2:27665139	KRTCAP3	-0.3	-4.77	-0.3	3.24e-6	Total body bone mineral density;
SARC	cis	rs9300255	0.739	rs1402275	chr12:123750895	A/G	cg00376283	chr12:123451042	ABCB9	0.51	5.73	0.35	3.13e-8	Neutrophil percentage of white cells;
SARC	cis	rs4561483	0.619	rs12597429	chr16:12062396	A/G	cg08843971	chr16:11963173	GSPT1	-0.4	-4.76	-0.3	3.37e-6	Testicular germ cell tumor;
SARC	cis	rs7927592	0.913	rs11228268	chr11:68287447	A/T	cg01657329	chr11:68192670	LRP5	-0.4	-4.94	-0.31	1.48e-6	Total body bone mineral density;
SARC	cis	rs9300255	0.602	rs1716164	chr12:123663660	G/A	cg00376283	chr12:123451042	ABCB9	0.55	6.53	0.39	4.09e-10	Neutrophil percentage of white cells;
SARC	cis	rs9323205	0.798	rs11157805	chr14:51658390	C/G	cg23942311	chr14:51606299	NA	0.31	5.09	0.32	7.36e-7	Cancer;
SARC	cis	rs6060717	0.536	rs6060676	chr20:34498551	T/C	cg01084648	chr20:34329383	RBM39	0.62	4.76	0.3	3.41e-6	Hip circumference adjusted for BMI;
SARC	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg11062466	chr8:58055876	NA	0.64	6.03	0.37	6.52e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1545257	0.505	rs894466	chr2:24633771	T/C	cg06627628	chr2:24431161	ITSN2	-0.57	-7.22	-0.43	7.13e-12	Sjögren's syndrome;
SARC	cis	rs9811216	0.917	rs10936599	chr3:169492101	C/T	cg14222479	chr3:169487675	ARPM1	0.47	5.34	0.33	2.25e-7	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs748404	0.723	rs565658	chr15:43556307	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.53	6.37	0.39	9.92e-10	Lung cancer;
SARC	cis	rs6696846	0.765	rs11577406	chr1:205065733	G/T	cg00857998	chr1:205179979	DSTYK	0.5	6.39	0.39	8.87e-10	Red blood cell count;
SARC	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg18876405	chr7:65276391	NA	-0.45	-5.01	-0.31	1.05e-6	Aortic root size;
SARC	cis	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg24110177	chr3:50126178	RBM5	-0.55	-7.28	-0.43	5.15e-12	Intelligence (multi-trait analysis);
SARC	cis	rs832540	1.000	rs832540	chr5:56199202	G/A	cg14703610	chr5:56206110	C5orf35	0.55	6.92	0.41	4.21e-11	Coronary artery disease;
SARC	cis	rs7666738	0.830	rs35938349	chr4:98974998	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1691799	0.899	rs903590	chr12:66745777	C/G	cg16791601	chr12:66731901	HELB	-0.73	-11.13	-0.59	2.38e-23	White blood cell count (basophil);
SARC	cis	rs60871478	1.000	rs34086011	chr7:805430	C/T	cg05535760	chr7:792225	HEATR2	0.77	8.01	0.46	5.42e-14	Cerebrospinal P-tau181p levels;
SARC	cis	rs7829975	0.510	rs2921073	chr8:8307643	C/T	cg06636001	chr8:8085503	FLJ10661	0.77	10.8	0.58	2.71e-22	Mood instability;
SARC	cis	rs7336332	0.662	rs9581862	chr13:28039993	T/G	cg22138327	chr13:27999177	GTF3A	0.55	5.65	0.35	4.56e-8	Weight;
SARC	cis	rs3768617	0.782	rs12143211	chr1:182990172	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.63	8.67	0.49	7.55e-16	Fuchs's corneal dystrophy;
SARC	cis	rs6582630	0.537	rs8189533	chr12:38391068	A/G	cg13010199	chr12:38710504	ALG10B	0.84	11.35	0.6	4.58e-24	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7100689	0.577	rs10749550	chr10:82031197	A/G	cg01528321	chr10:82214614	TSPAN14	0.68	8.66	0.49	7.96e-16	Post bronchodilator FEV1;
SARC	cis	rs9911578	0.935	rs117819974	chr17:57002324	C/T	cg12560992	chr17:57184187	TRIM37	0.85	11.7	0.61	3.63e-25	Intelligence (multi-trait analysis);
SARC	cis	rs9486719	0.901	rs13206547	chr6:97006942	T/C	cg06623918	chr6:96969491	KIAA0776	-0.8	-8.93	-0.5	1.32e-16	Migraine;Coronary artery disease;
SARC	cis	rs3870371	0.955	rs58702755	chr8:122702478	A/G	cg21781600	chr8:122651575	HAS2;HAS2AS	0.49	5.44	0.34	1.35e-7	Periodontal disease-related phenotypes;
SARC	cis	rs6840360	0.718	rs2136960	chr4:152746189	A/G	cg22705602	chr4:152727874	NA	0.33	5.29	0.33	2.84e-7	Intelligence (multi-trait analysis);
SARC	cis	rs11214589	0.651	rs11214596	chr11:113264511	C/G	cg14159747	chr11:113255604	NA	0.37	5.34	0.33	2.21e-7	Neuroticism;
SARC	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg12463550	chr7:65579703	CRCP	-0.71	-5.42	-0.33	1.47e-7	Diabetic kidney disease;
SARC	cis	rs433852	0.904	rs8102492	chr19:49140809	A/C	cg21547979	chr19:49141364	SEC1;DBP;CA11	0.48	5.34	0.33	2.22e-7	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg02524346	chr8:600233	NA	-0.67	-4.98	-0.31	1.25e-6	IgG glycosylation;
SARC	cis	rs8078723	0.966	rs57065891	chr17:38168227	C/T	cg17467752	chr17:38218738	THRA	0.47	5.94	0.36	1.01e-8	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg12311346	chr5:56204834	C5orf35	0.74	7.25	0.43	5.95e-12	Initial pursuit acceleration;
SARC	cis	rs1865760	1.000	rs3799371	chr6:25912816	A/G	cg17691542	chr6:26056736	HIST1H1C	-0.59	-7.33	-0.43	3.8e-12	Height;
SARC	cis	rs477692	0.699	rs528549	chr10:131381574	A/G	cg14263093	chr10:131365266	MGMT	0.37	5.23	0.32	3.86e-7	Response to temozolomide;
SARC	cis	rs9911578	1.000	rs2567911	chr17:56734977	A/G	cg12560992	chr17:57184187	TRIM37	0.83	11.32	0.6	5.91e-24	Intelligence (multi-trait analysis);
SARC	cis	rs4141404	0.851	rs5997893	chr22:31556103	A/G	cg02404636	chr22:31891804	SFI1	-0.46	-5.52	-0.34	9.12e-8	Paclitaxel-induced neuropathy;
SARC	cis	rs854765	0.583	rs11078406	chr17:17840823	G/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.41	5.3	0.33	2.63e-7	Total body bone mineral density;
SARC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.19	0.8	4.45e-53	Prudent dietary pattern;
SARC	cis	rs7260598	0.581	rs116653454	chr19:24063556	A/G	cg27517351	chr19:23941871	ZNF681	0.54	4.73	0.3	3.86e-6	Response to taxane treatment (placlitaxel);
SARC	trans	rs208520	0.955	rs12216176	chr6:67005130	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.82	9.07	0.51	5.08e-17	Exhaled nitric oxide output;
SARC	cis	rs3784262	0.669	rs4646609	chr15:58274989	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.34	-5.07	-0.32	7.93e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs10782582	0.609	rs1498311	chr1:76254726	A/C	cg10523679	chr1:76189770	ACADM	0.44	5.48	0.34	1.08e-7	Daytime sleep phenotypes;
SARC	cis	rs2594989	0.887	rs2443717	chr3:11521493	T/C	cg00170343	chr3:11313890	ATG7	0.52	5.18	0.32	4.69e-7	Circulating chemerin levels;
SARC	cis	rs1707322	0.752	rs6658700	chr1:46160260	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.24	0.38	2.03e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs763121	0.853	rs2064088	chr22:39053382	A/G	cg06022373	chr22:39101656	GTPBP1	0.9	11.56	0.6	9.96e-25	Menopause (age at onset);
SARC	cis	rs73242632	1.000	rs12511480	chr4:57748143	C/T	cg20415529	chr4:57845134	POLR2B;C4orf14	-0.89	-5.92	-0.36	1.16e-8	Congenital heart disease (maternal effect);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg14395546	chr16:66730808	CMTM4	0.56	7.71	0.45	3.62e-13	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs910316	0.763	rs175016	chr14:75459633	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.44	-5.88	-0.36	1.43e-8	Height;
SARC	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg11502198	chr6:26597334	ABT1	-0.63	-8.44	-0.48	3.39e-15	Intelligence (multi-trait analysis);
SARC	cis	rs10791323	0.628	rs2851118	chr11:133705995	A/C	cg14349672	chr11:133703707	NA	-0.39	-5.84	-0.36	1.73e-8	Childhood ear infection;
SARC	cis	rs7524258	0.903	rs4908450	chr1:7292756	T/C	cg07173049	chr1:7289937	CAMTA1	0.41	7.97	0.46	7.07e-14	Tourette's syndrome or obsessive-compulsive disorder;
SARC	cis	rs10189230	0.967	rs13012429	chr2:222350788	C/T	cg14652038	chr2:222343519	EPHA4	0.44	5.85	0.36	1.65e-8	Urate levels in lean individuals;
SARC	cis	rs7589342	0.839	rs6747023	chr2:106431856	A/G	cg14210321	chr2:106509881	NCK2	-0.42	-4.79	-0.3	2.98e-6	Addiction;
SARC	trans	rs2018683	0.711	rs917214	chr7:28968293	T/C	cg19402173	chr7:128379420	CALU	-0.59	-7.61	-0.45	6.87e-13	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs11098499	0.954	rs9993199	chr4:120392873	A/G	cg24375607	chr4:120327624	NA	-0.4	-4.78	-0.3	3.05e-6	Corneal astigmatism;
SARC	cis	rs981844	0.683	rs4696191	chr4:154740668	G/A	cg14289246	chr4:154710475	SFRP2	-0.44	-5.07	-0.32	8.03e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs56011263	0.687	rs4690187	chr4:703813	C/T	cg20735989	chr4:730612	PCGF3	-0.46	-5.26	-0.33	3.25e-7	White blood cell count;
SARC	cis	rs9517302	0.615	rs9517306	chr13:99097962	T/C	cg24044564	chr13:99115944	STK24	0.43	5.41	0.33	1.6e-7	Obesity-related traits;
SARC	cis	rs6439153	0.967	rs12695513	chr3:128722312	T/C	cg25356066	chr3:128598488	ACAD9	0.46	5.51	0.34	9.37e-8	Pneumococcal bacteremia;
SARC	cis	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg09021430	chr5:549028	NA	-0.45	-5.77	-0.35	2.57e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs4065321	0.522	rs11078930	chr17:38141955	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.4	7.31	0.43	4.21e-12	White blood cell count (basophil);White blood cell count;
SARC	cis	rs7937682	0.889	rs521155	chr11:111492563	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.89	-14.18	-0.68	2.61e-33	Primary sclerosing cholangitis;
SARC	cis	rs72634258	0.699	rs2493214	chr1:7994420	A/G	cg05338066	chr1:7812865	CAMTA1	0.42	4.86	0.3	2.14e-6	Inflammatory bowel disease;
SARC	cis	rs62064224	0.560	rs12162135	chr17:30805795	A/C	cg09324608	chr17:30823087	MYO1D	0.32	4.72	0.3	3.99e-6	Schizophrenia;
SARC	cis	rs477692	1.000	rs4750759	chr10:131436603	G/A	cg05714579	chr10:131428358	MGMT	-0.54	-6.99	-0.42	2.82e-11	Response to temozolomide;
SARC	cis	rs10895987	1.000	rs11227126	chr11:64908062	A/T	cg21152694	chr11:64885413	ZNHIT2	-0.44	-4.76	-0.3	3.32e-6	Blood protein levels;
SARC	cis	rs17125944	0.615	rs12590862	chr14:53297008	A/G	cg00686598	chr14:53173677	PSMC6	-0.76	-5.85	-0.36	1.62e-8	Alzheimer's disease (late onset);
SARC	cis	rs30380	0.632	rs30186	chr5:96124447	G/C	cg16492584	chr5:96139282	ERAP1	-0.48	-5.51	-0.34	9.68e-8	Cerebrospinal fluid biomarker levels;
SARC	cis	rs7644634	0.559	rs2301029	chr3:105469130	C/T	cg23051926	chr3:105466016	CBLB	0.47	5.43	0.34	1.43e-7	Itch intensity from mosquito bite;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg20095390	chr2:187373473	ZC3H15	-0.52	-6.51	-0.39	4.47e-10	Alcohol dependence;
SARC	trans	rs7819412	0.740	rs28633434	chr8:11053922	G/A	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.7	-0.45	3.98e-13	Triglycerides;
SARC	cis	rs1448094	0.512	rs57278040	chr12:86237886	A/G	cg02569458	chr12:86230093	RASSF9	0.4	5.63	0.35	5.08e-8	Major depressive disorder;
SARC	cis	rs11025523	0.848	rs10833309	chr11:20378045	A/G	cg04101203	chr11:20408940	PRMT3	0.52	4.84	0.3	2.33e-6	Obesity-related traits;
SARC	cis	rs2228479	0.850	rs62056061	chr16:89901767	G/A	cg12064134	chr16:90016061	DEF8	-0.56	-4.79	-0.3	2.91e-6	Skin colour saturation;
SARC	cis	rs703842	1.000	rs11172343	chr12:58188157	T/C	cg00677455	chr12:58241039	CTDSP2	0.51	6.6	0.4	2.73e-10	Multiple sclerosis;
SARC	cis	rs6484504	0.576	rs438578	chr11:31222579	A/G	cg02090638	chr11:31391270	DNAJC24;DCDC1	0.38	4.8	0.3	2.78e-6	Red blood cell count;
SARC	cis	rs2204008	0.754	rs11514074	chr12:38401128	C/T	cg26384229	chr12:38710491	ALG10B	0.89	12.6	0.64	4.29e-28	Bladder cancer;
SARC	cis	rs10779751	0.770	rs2261434	chr1:11170131	A/C	cg08854313	chr1:11322531	MTOR	0.88	13.1	0.65	9.82e-30	Body mass index;
SARC	cis	rs2832191	0.716	rs2692625	chr21:30446360	C/G	cg08807101	chr21:30365312	RNF160	0.89	13.68	0.67	1.14e-31	Dental caries;
SARC	cis	rs73242632	0.867	rs4596307	chr4:57932174	C/T	cg20415529	chr4:57845134	POLR2B;C4orf14	0.97	5.83	0.36	1.87e-8	Congenital heart disease (maternal effect);
SARC	cis	rs910316	0.789	rs4899552	chr14:75667921	C/A	cg11812906	chr14:75593930	NEK9	-0.74	-9.87	-0.54	2.05e-19	Height;
SARC	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.79	-8.47	-0.49	2.86e-15	Alzheimer's disease;
SARC	cis	rs7904368	0.806	rs45495501	chr10:16861476	G/A	cg23933602	chr10:16859644	RSU1	0.54	5.3	0.33	2.74e-7	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs6693567	0.565	rs834235	chr1:150362154	C/T	cg09579323	chr1:150459698	TARS2	0.46	5.8	0.36	2.11e-8	Migraine;
SARC	cis	rs9473924	0.580	rs67092917	chr6:50815333	G/T	cg14470998	chr6:50812995	TFAP2B	0.66	6.02	0.37	6.73e-9	Body mass index;
SARC	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg09455208	chr3:40491958	NA	-0.36	-5.4	-0.33	1.62e-7	Renal cell carcinoma;
SARC	cis	rs654950	0.806	rs1815257	chr1:42041479	A/C	cg06885757	chr1:42089581	HIVEP3	-0.41	-5.89	-0.36	1.33e-8	Airway imaging phenotypes;
SARC	cis	rs7250849	1.000	rs7250849	chr19:52158316	A/C	cg03965138	chr19:52134393	SIGLEC5	-0.46	-4.91	-0.31	1.7e-6	Blood protein levels;
SARC	cis	rs2153535	0.580	rs1335633	chr6:8448800	C/T	cg07606381	chr6:8435919	SLC35B3	0.77	11.03	0.59	5.01e-23	Motion sickness;
SARC	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg16405210	chr4:1374714	KIAA1530	-0.47	-5.76	-0.35	2.7e-8	Longevity;
SARC	cis	rs7100689	0.577	rs1417219	chr10:82041409	C/T	cg01528321	chr10:82214614	TSPAN14	0.66	8.6	0.49	1.19e-15	Post bronchodilator FEV1;
SARC	cis	rs698833	0.962	rs698828	chr2:44730577	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.63	8.03	0.47	4.76e-14	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs7264396	0.790	rs6060530	chr20:34227663	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.34	-0.43	3.62e-12	Total cholesterol levels;
SARC	cis	rs1124769	0.502	rs28565448	chr15:51079970	C/T	cg21246271	chr15:51200259	AP4E1	-0.44	-4.73	-0.3	3.91e-6	Cognitive performance;
SARC	cis	rs72781680	1.000	rs55773155	chr2:24255081	A/G	cg06627628	chr2:24431161	ITSN2	-0.7	-6.47	-0.39	5.6e-10	Lymphocyte counts;
SARC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg07308232	chr7:1071921	C7orf50	-0.46	-5.49	-0.34	1.03e-7	Longevity;Endometriosis;
SARC	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg13939156	chr17:80058883	NA	-0.41	-6.45	-0.39	6.3e-10	Life satisfaction;
SARC	cis	rs7172118	1	rs7172118	chr15:78862453	C/A	cg18825076	chr15:78729989	IREB2	-0.44	-5.28	-0.33	3.03e-7	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs3857536	0.904	rs979697	chr6:66896671	C/A	cg07460842	chr6:66804631	NA	-0.44	-5.27	-0.33	3.08e-7	Blood trace element (Cu levels);
SARC	cis	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg21775007	chr8:11205619	TDH	-0.43	-5.38	-0.33	1.83e-7	Triglycerides;
SARC	cis	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg09021430	chr5:549028	NA	-0.43	-5.59	-0.34	6.31e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs8044868	0.530	rs2288000	chr16:72058881	A/G	cg01557791	chr16:72042693	DHODH	-0.38	-4.8	-0.3	2.82e-6	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
SARC	cis	rs3136516	0.935	rs11038993	chr11:46810916	A/C	cg03339077	chr11:47165057	C11orf49	0.34	4.96	0.31	1.35e-6	Venous thromboembolism;
SARC	cis	rs9398803	0.865	rs2050644	chr6:126805255	A/G	cg20229609	chr6:126660872	C6orf173	0.4	5.71	0.35	3.42e-8	Male-pattern baldness;
SARC	cis	rs12586317	0.511	rs11540758	chr14:35498485	C/T	cg26967526	chr14:35346199	BAZ1A	-0.57	-5.71	-0.35	3.4e-8	Psoriasis;
SARC	cis	rs6964587	0.626	rs10234074	chr7:91520119	C/T	cg17063962	chr7:91808500	NA	-0.78	-11.48	-0.6	1.78e-24	Breast cancer;
SARC	cis	rs12142240	0.731	rs6658556	chr1:46844180	A/C	cg14993813	chr1:46806288	NSUN4	-0.5	-5.13	-0.32	6.01e-7	Menopause (age at onset);
SARC	cis	rs372883	0.600	rs2832295	chr21:30739843	C/T	cg24692254	chr21:30365293	RNF160	0.67	8.67	0.49	7.36e-16	Pancreatic cancer;
SARC	cis	rs9513593	1.000	rs7323390	chr13:99997968	A/G	cg21788972	chr13:99853209	UBAC2	0.49	4.95	0.31	1.43e-6	Psoriasis;
SARC	cis	rs11758351	1.000	rs77957229	chr6:26185226	A/G	cg23601095	chr6:26197514	HIST1H3D	0.63	5.17	0.32	5.11e-7	Gout;Renal underexcretion gout;
SARC	cis	rs3540	0.533	rs2256097	chr15:90971331	A/T	cg22089800	chr15:90895588	ZNF774	0.68	8.71	0.5	5.89e-16	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs2832191	0.671	rs2832212	chr21:30511417	G/A	cg08807101	chr21:30365312	RNF160	-0.7	-8.54	-0.49	1.76e-15	Dental caries;
SARC	cis	rs7000551	0.646	rs2979302	chr8:22359156	G/A	cg12081754	chr8:22256438	SLC39A14	0.54	7.64	0.45	5.6e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg19223190	chr17:80058835	NA	0.45	6.24	0.38	1.99e-9	Life satisfaction;
SARC	cis	rs3796352	1.000	rs11710292	chr3:53117798	T/C	cg27565382	chr3:53032988	SFMBT1	0.99	6.8	0.41	8.62e-11	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs8180040	0.652	rs13077398	chr3:47011120	G/C	cg02527881	chr3:46936655	PTH1R	-0.31	-4.78	-0.3	3.07e-6	Colorectal cancer;
SARC	cis	rs7712401	0.601	rs30022	chr5:122285716	T/A	cg19412675	chr5:122181750	SNX24	0.4	5.13	0.32	5.98e-7	Mean platelet volume;
SARC	cis	rs1707322	0.964	rs7512395	chr1:46361177	G/A	cg06784218	chr1:46089804	CCDC17	0.36	6.41	0.39	8.05e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg13206674	chr6:150067644	NUP43	0.41	5.37	0.33	1.95e-7	Lung cancer;
SARC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg09436375	chr6:42928200	GNMT	-0.36	-5.5	-0.34	1e-7	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.75	-0.45	2.87e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs9400467	0.537	rs449308	chr6:111480395	A/C	cg15721981	chr6:111408429	SLC16A10	-0.64	-5.69	-0.35	3.79e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs9303401	0.659	rs34351230	chr17:56782555	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	11.87	0.61	9.72e-26	Cognitive test performance;
SARC	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1568889	1.000	rs35697240	chr11:28287342	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.72	9.46	0.53	3.58e-18	Bipolar disorder;
SARC	cis	rs918629	0.679	rs72656689	chr5:95270872	A/G	cg16656078	chr5:95278638	ELL2	-0.62	-7.12	-0.42	1.36e-11	IgG glycosylation;
SARC	cis	rs2011503	1.000	rs4808951	chr19:19550306	C/G	cg15839431	chr19:19639596	YJEFN3	-0.51	-4.94	-0.31	1.49e-6	Bipolar disorder;
SARC	cis	rs7937682	1.000	rs505372	chr11:111507189	A/C	cg22437258	chr11:111473054	SIK2	0.74	10.1	0.55	4.01e-20	Primary sclerosing cholangitis;
SARC	cis	rs155076	1.000	rs658244	chr13:21850976	T/C	cg06138931	chr13:21896616	NA	-0.39	-5.12	-0.32	6.44e-7	White matter hyperintensity burden;
SARC	cis	rs62344088	0.744	rs76038312	chr5:229005	A/G	cg22496380	chr5:211416	CCDC127	-0.91	-5.61	-0.35	5.67e-8	Asthma (childhood onset);
SARC	cis	rs9325144	0.510	rs7952795	chr12:38720686	C/T	cg13010199	chr12:38710504	ALG10B	0.57	7.4	0.44	2.45e-12	Morning vs. evening chronotype;
SARC	cis	rs7216064	1.000	rs4318247	chr17:65882172	A/G	cg12091567	chr17:66097778	LOC651250	-0.64	-6.45	-0.39	6.56e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	trans	rs9354308	0.838	rs7769057	chr6:66540229	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.56	-6.64	-0.4	2.19e-10	Metabolite levels;
SARC	cis	rs9341808	0.519	rs684251	chr6:80967337	G/A	cg08355045	chr6:80787529	NA	-0.32	-4.92	-0.31	1.63e-6	Sitting height ratio;
SARC	cis	rs4319547	0.695	rs4758662	chr12:122924778	G/A	cg23029597	chr12:123009494	RSRC2	-0.41	-5.01	-0.31	1.06e-6	Body mass index;
SARC	cis	rs2976388	0.967	rs2976397	chr8:143764613	G/T	cg06565975	chr8:143823917	SLURP1	-0.28	-4.72	-0.3	4.09e-6	Urinary tract infection frequency;
SARC	cis	rs829661	0.532	rs12621663	chr2:30784540	G/A	cg17749961	chr2:30669863	LCLAT1	-0.39	-4.81	-0.3	2.72e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
SARC	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.43	-0.56	3.88e-21	Chronic sinus infection;
SARC	cis	rs73086581	0.838	rs73088426	chr20:4003283	A/T	cg02187196	chr20:3869020	PANK2	0.57	5.34	0.33	2.17e-7	Response to antidepressants in depression;
SARC	cis	rs2153535	0.580	rs6597318	chr6:8437289	G/A	cg21535247	chr6:8435926	SLC35B3	0.56	6.86	0.41	6.29e-11	Motion sickness;
SARC	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg21361702	chr7:150065534	REPIN1	-0.5	-5.37	-0.33	1.86e-7	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg00409905	chr10:38381863	ZNF37A	-0.53	-7.37	-0.43	2.93e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs754466	0.606	rs11002308	chr10:79594796	A/T	cg17075019	chr10:79541650	NA	-0.82	-12.67	-0.64	2.43e-28	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7103648	1.000	rs11039225	chr11:47430599	G/A	cg20307385	chr11:47447363	PSMC3	0.87	14.78	0.7	2.51e-35	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg25894440	chr7:65020034	NA	-0.73	-5.54	-0.34	8.32e-8	Diabetic kidney disease;
SARC	cis	rs1023500	0.505	rs2143139	chr22:42614401	G/C	cg15557168	chr22:42548783	NA	-0.41	-5.7	-0.35	3.59e-8	Schizophrenia;
SARC	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg24642844	chr7:1081250	C7orf50	-0.55	-6.1	-0.37	4.35e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs6120849	0.663	rs6088662	chr20:33547633	A/C	cg24642439	chr20:33292090	TP53INP2	0.56	5.72	0.35	3.18e-8	Protein C levels;
SARC	cis	rs6582630	0.555	rs10880544	chr12:38473464	G/C	cg13010199	chr12:38710504	ALG10B	0.75	10.21	0.56	1.79e-20	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs1814175	0.791	rs10769593	chr11:49616217	T/C	cg03929089	chr4:120376271	NA	-0.86	-13.24	-0.66	3.19e-30	Height;
SARC	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg18252515	chr7:66147081	NA	-0.57	-6.2	-0.38	2.51e-9	Aortic root size;
SARC	cis	rs7374004	1.000	rs7374004	chr3:38625709	A/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.46	-5.43	-0.34	1.41e-7	PR interval;
SARC	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg23758822	chr17:41437982	NA	0.88	11.19	0.59	1.55e-23	Menopause (age at onset);
SARC	cis	rs6121246	0.529	rs6060359	chr20:30209740	A/G	cg21427119	chr20:30132790	HM13	-0.48	-5.22	-0.32	4e-7	Mean corpuscular hemoglobin;
SARC	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg22903471	chr2:27725779	GCKR	-0.46	-6.77	-0.41	1.04e-10	Total body bone mineral density;
SARC	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg26818010	chr10:134567672	INPP5A	-0.45	-5.05	-0.31	8.93e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.33	-4.94	-0.31	1.51e-6	Total body bone mineral density;
SARC	cis	rs796364	1.000	rs35594306	chr2:200775125	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.68	-5.71	-0.35	3.45e-8	Schizophrenia;
SARC	cis	rs193541	0.530	rs1466371	chr5:122083788	T/C	cg19412675	chr5:122181750	SNX24	0.45	5.98	0.36	8.53e-9	Glucose homeostasis traits;
SARC	cis	rs10892173	0.846	rs12790243	chr11:117678543	C/T	cg21640587	chr11:117668038	DSCAML1	0.5	6.86	0.41	6.18e-11	Myopia;
SARC	cis	rs6687430	0.526	rs12120962	chr1:10609505	G/A	cg17425144	chr1:10567563	PEX14	0.38	5.55	0.34	7.8e-8	Hand grip strength;
SARC	trans	rs61931739	0.534	rs11052991	chr12:34059018	G/T	cg26384229	chr12:38710491	ALG10B	-0.72	-10.32	-0.56	8.04e-21	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1569175	1.000	rs3115424	chr2:200932296	A/G	cg23649088	chr2:200775458	C2orf69	-0.77	-5.53	-0.34	8.5e-8	Response to treatment for acute lymphoblastic leukemia;
SARC	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg14517863	chr17:44321492	NA	-0.32	-4.76	-0.3	3.46e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs6665290	0.904	rs3795451	chr1:227181923	C/T	cg14016676	chr1:227182615	CDC42BPA	0.33	4.83	0.3	2.5e-6	Myeloid white cell count;
SARC	cis	rs12479064	0.703	rs28382977	chr2:100018304	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.65	-7.93	-0.46	9.2e-14	Chronic sinus infection;
SARC	cis	rs9660992	0.674	rs72745219	chr1:205262271	G/A	cg21643547	chr1:205240462	TMCC2	-0.58	-7.18	-0.43	9.34e-12	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg07777115	chr5:623756	CEP72	-0.64	-5.95	-0.36	9.89e-9	Obesity-related traits;
SARC	cis	rs2841277	0.676	rs10438247	chr14:105411781	G/A	cg19901468	chr14:105411992	AHNAK2	-0.73	-10.79	-0.58	2.91e-22	Rheumatoid arthritis;
SARC	cis	rs6089584	0.606	rs2296082	chr20:60573983	A/G	cg23262073	chr20:60523788	NA	-0.37	-5.66	-0.35	4.42e-8	Body mass index;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg24605529	chr2:203879461	NBEAL1	0.55	6.31	0.38	1.39e-9	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs7586879	0.616	rs6545809	chr2:25126715	C/T	cg04586622	chr2:25135609	ADCY3	0.32	5.39	0.33	1.71e-7	Body mass index;
SARC	cis	rs9916302	0.706	rs9908131	chr17:37520449	T/C	cg00129232	chr17:37814104	STARD3	0.54	5.76	0.35	2.66e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs73198271	0.562	rs55961293	chr8:8675478	T/C	cg01851573	chr8:8652454	MFHAS1	0.45	5.46	0.34	1.19e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs9435341	0.965	rs1730862	chr1:107614003	G/A	cg09367891	chr1:107599246	PRMT6	-0.7	-8.27	-0.48	1.06e-14	Facial morphology (factor 21, depth of nasal alae);
SARC	cis	rs743757	1.000	rs2282752	chr3:50433967	G/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.55	5.12	0.32	6.26e-7	Diastolic blood pressure;
SARC	cis	rs920590	0.679	rs58556504	chr8:19653674	A/G	cg03894339	chr8:19674705	INTS10	0.39	4.78	0.3	3.06e-6	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs6674970	0.541	rs2902811	chr1:151010521	G/C	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.57	-5.83	-0.36	1.88e-8	Childhood ear infection;
SARC	cis	rs17376456	0.877	rs17316137	chr5:93456577	C/T	cg25358565	chr5:93447407	FAM172A	1.29	14.92	0.7	8.68e-36	Diabetic retinopathy;
SARC	cis	rs11098499	0.863	rs1480940	chr4:120457682	T/C	cg24375607	chr4:120327624	NA	0.42	4.92	0.31	1.61e-6	Corneal astigmatism;
SARC	cis	rs2832077	0.506	rs2832093	chr21:30164855	C/T	cg24692254	chr21:30365293	RNF160	-0.54	-5.89	-0.36	1.31e-8	Cognitive test performance;
SARC	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10911232	0.507	rs10752890	chr1:183021910	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.11	0.55	3.63e-20	Hypertriglyceridemia;
SARC	cis	rs1018836	0.663	rs12674903	chr8:91475774	T/C	cg16814680	chr8:91681699	NA	-0.75	-11.54	-0.6	1.14e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs11697848	1.000	rs79598075	chr20:48562116	T/C	cg17849948	chr20:48532315	SPATA2	0.87	5.2	0.32	4.3e-7	Systemic lupus erythematosus;
SARC	cis	rs7520050	0.807	rs4274104	chr1:46217941	T/C	cg06784218	chr1:46089804	CCDC17	0.26	4.76	0.3	3.38e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs8014131	0.689	rs6574828	chr14:85979237	A/G	cg10406690	chr14:85995726	FLRT2	0.39	5.07	0.32	8.21e-7	Menarche (age at onset);
SARC	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg11764359	chr7:65958608	NA	0.75	8.59	0.49	1.22e-15	Aortic root size;
SARC	cis	rs79149102	0.579	rs3812943	chr15:75312715	C/G	cg00629941	chr15:75287862	SCAMP5	-0.76	-5.63	-0.35	5.13e-8	Lung cancer;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg13617248	chr21:38640479	DSCR3	-0.77	-6.65	-0.4	2.11e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1008375	0.863	rs10003291	chr4:17600728	A/C	cg27347728	chr4:17578864	LAP3	0.48	5.81	0.36	2.06e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.52	7.99	0.46	6.33e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-7.93	-0.46	8.82e-14	Chronic sinus infection;
SARC	cis	rs2841277	0.509	rs11850949	chr14:105408827	A/C	cg15352829	chr14:105391018	PLD4	-0.32	-6.21	-0.38	2.42e-9	Rheumatoid arthritis;
SARC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg09373136	chr17:61933544	TCAM1	-0.45	-6.17	-0.37	2.95e-9	Prudent dietary pattern;
SARC	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg22920501	chr2:26401640	FAM59B	0.61	8.19	0.47	1.71e-14	Gut microbiome composition (summer);
SARC	cis	rs2072499	0.750	rs10159384	chr1:156160822	C/T	cg25208724	chr1:156163844	SLC25A44	0.86	9.9	0.54	1.67e-19	Testicular germ cell tumor;
SARC	cis	rs2836950	0.762	rs8134638	chr21:40644170	T/C	cg11890956	chr21:40555474	PSMG1	-0.59	-7.24	-0.43	6.42e-12	Menarche (age at onset);
SARC	cis	rs7223966	1.000	rs2854218	chr17:61942940	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	5.33	0.33	2.28e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg17221315	chr6:27791827	HIST1H4J	0.45	4.75	0.3	3.57e-6	Depression;
SARC	cis	rs4481887	0.893	rs4576683	chr1:248472390	T/C	cg01631408	chr1:248437212	OR2T33	-0.39	-5.06	-0.31	8.56e-7	Common traits (Other);
SARC	trans	rs6076960	0.684	rs6054058	chr20:6262187	T/C	cg21095983	chr6:86352623	SYNCRIP	0.46	6.56	0.39	3.44e-10	Smooth-surface caries;
SARC	cis	rs35306767	0.903	rs12763396	chr10:927357	C/A	cg26597838	chr10:835615	NA	0.82	8.5	0.49	2.22e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg05025164	chr4:1340916	KIAA1530	0.44	5.34	0.33	2.26e-7	Obesity-related traits;
SARC	cis	rs9303401	0.659	rs12952325	chr17:56899371	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.06	11.88	0.61	9.07e-26	Cognitive test performance;
SARC	trans	rs7465272	1.000	rs35900184	chr8:143693411	C/T	cg16922340	chr20:33873526	FAM83C;EIF6	0.48	6.39	0.39	8.97e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs1878931	0.624	rs27241	chr16:3447282	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.71	-8.0	-0.46	5.93e-14	Body mass index (adult);
SARC	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg00684032	chr4:1343700	KIAA1530	0.37	5.36	0.33	1.99e-7	Obesity-related traits;
SARC	cis	rs10751667	0.600	rs7394783	chr11:1005108	C/T	cg20946044	chr11:1010712	AP2A2	0.38	5.7	0.35	3.68e-8	Alzheimer's disease (late onset);
SARC	cis	rs96067	0.711	rs11263861	chr1:36628033	G/A	cg24686825	chr1:36642396	MAP7D1	-0.54	-6.57	-0.4	3.26e-10	Corneal structure;
SARC	cis	rs7247513	0.930	rs35275129	chr19:12716493	G/A	cg04657146	chr19:12876947	HOOK2	0.4	4.76	0.3	3.34e-6	Bipolar disorder;
SARC	cis	rs876084	0.505	rs10955953	chr8:121106381	C/T	cg06265175	chr8:121136014	COL14A1	-0.61	-7.98	-0.46	6.52e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs4144743	1.000	rs2317385	chr17:45329682	G/A	cg18085866	chr17:45331354	ITGB3	-0.73	-7.41	-0.44	2.29e-12	Body mass index;
SARC	cis	rs8077889	1.000	rs2880329	chr17:41866168	T/A	cg26893861	chr17:41843967	DUSP3	0.9	10.81	0.58	2.48e-22	Triglycerides;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg23371655	chr17:4225165	UBE2G1	0.52	6.97	0.42	3.19e-11	Thyroid stimulating hormone;
SARC	cis	rs7666738	0.791	rs7658177	chr4:99035192	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6088580	0.634	rs6058073	chr20:33116483	T/C	cg24642439	chr20:33292090	TP53INP2	0.68	8.84	0.5	2.39e-16	Glomerular filtration rate (creatinine);
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg25104716	chr18:45936047	NA	-0.54	-6.88	-0.41	5.45e-11	Schizophrenia;
SARC	cis	rs1018836	0.632	rs9642910	chr8:91475724	G/T	cg16814680	chr8:91681699	NA	-0.7	-10.44	-0.56	3.62e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg13699009	chr12:122356056	WDR66	0.6	9.51	0.53	2.43e-18	Mean corpuscular volume;
SARC	cis	rs4974559	0.790	rs11933855	chr4:1315183	C/T	cg02980000	chr4:1222292	CTBP1	0.56	5.3	0.33	2.63e-7	Systolic blood pressure;
SARC	cis	rs874628	0.851	rs4808765	chr19:18334443	C/T	cg13670957	chr19:18329801	PDE4C	0.5	5.74	0.35	2.86e-8	Multiple sclerosis;
SARC	cis	rs10875746	0.859	rs12305647	chr12:48582961	T/C	cg27446233	chr12:48516484	PFKM	-0.39	-4.74	-0.3	3.71e-6	Longevity (90 years and older);
SARC	cis	rs1395	0.922	rs4665376	chr2:27509032	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.34	-4.92	-0.31	1.62e-6	Blood metabolite levels;
SARC	cis	rs453301	0.658	rs12114954	chr8:8904862	T/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.98	-0.42	2.96e-11	Joint mobility (Beighton score);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg00031340	chr16:81130212	GCSH;LOC100329108	0.78	6.77	0.41	1.02e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg22920501	chr2:26401640	FAM59B	-0.57	-7.45	-0.44	1.82e-12	Gut microbiome composition (summer);
SARC	cis	rs9875589	0.509	rs9836573	chr3:14065239	G/A	cg19554555	chr3:13937349	NA	-0.4	-5.14	-0.32	5.95e-7	Ovarian reserve;
SARC	cis	rs11711311	0.955	rs67550112	chr3:113401988	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	8.19	0.47	1.67e-14	IgG glycosylation;
SARC	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-8.03	-0.47	4.67e-14	Chronic sinus infection;
SARC	cis	rs113835537	0.935	rs117131621	chr11:66422334	C/T	cg24851651	chr11:66362959	CCS	0.48	5.17	0.32	5.15e-7	Airway imaging phenotypes;
SARC	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg23262073	chr20:60523788	NA	-0.37	-5.12	-0.32	6.31e-7	Body mass index;
SARC	cis	rs986417	1.000	rs1254322	chr14:60906976	G/A	cg27398547	chr14:60952738	C14orf39	-1.01	-9.11	-0.51	3.86e-17	Gut microbiota (bacterial taxa);
SARC	cis	rs2562456	0.876	rs11085468	chr19:21751889	C/T	cg00806126	chr19:22604979	ZNF98	-0.46	-4.78	-0.3	3.07e-6	Pain;
SARC	cis	rs477895	1.000	rs66968227	chr11:64070930	T/C	cg04317338	chr11:64019027	PLCB3	0.62	5.05	0.31	8.86e-7	Mean platelet volume;
SARC	cis	rs11792861	0.926	rs77567374	chr9:111835034	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.67	7.64	0.45	5.51e-13	Menarche (age at onset);
SARC	cis	rs1580019	0.961	rs1580021	chr7:32497702	T/G	cg06627557	chr7:32535165	LSM5;AVL9	0.73	9.78	0.54	3.93e-19	Cognitive ability;
SARC	cis	rs992157	0.560	rs6738394	chr2:219110625	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.6	-8.18	-0.47	1.8e-14	Colorectal cancer;
SARC	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-9.15	-0.51	2.85e-17	Alzheimer's disease;
SARC	cis	rs6542838	0.641	rs6757098	chr2:99471399	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-5.66	-0.35	4.53e-8	Fear of minor pain;
SARC	cis	rs9398803	0.931	rs9375435	chr6:126661858	C/T	cg20229609	chr6:126660872	C6orf173	0.4	5.7	0.35	3.54e-8	Male-pattern baldness;
SARC	cis	rs6484504	0.576	rs438578	chr11:31222579	A/G	cg26647111	chr11:31128758	NA	0.4	5.23	0.32	3.85e-7	Red blood cell count;
SARC	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	13.88	0.67	2.59e-32	Chronic sinus infection;
SARC	cis	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg05623727	chr3:50126028	RBM5	-0.35	-5.25	-0.33	3.47e-7	Body mass index;
SARC	cis	rs4891159	0.790	rs11150953	chr18:74145491	G/A	cg24786174	chr18:74118243	ZNF516	-0.64	-8.93	-0.5	1.35e-16	Longevity;
SARC	cis	rs7100689	0.646	rs7081889	chr10:82165427	C/A	cg01528321	chr10:82214614	TSPAN14	0.7	9.75	0.54	4.54e-19	Post bronchodilator FEV1;
SARC	cis	rs1865760	1.000	rs3799371	chr6:25912816	A/G	cg16482183	chr6:26056742	HIST1H1C	-0.51	-6.38	-0.39	9.32e-10	Height;
SARC	cis	rs11690935	0.959	rs3770451	chr2:172668715	T/G	cg13550731	chr2:172543902	DYNC1I2	-0.96	-14.9	-0.7	1.04e-35	Schizophrenia;
SARC	cis	rs9914988	0.832	rs9903248	chr17:27127439	G/T	cg20469991	chr17:27169893	C17orf63	-0.5	-5.21	-0.32	4.1e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs6011674	1.000	rs59784306	chr20:61859596	C/T	cg06763829	chr20:61885236	FLJ16779;NKAIN4	0.62	4.73	0.3	3.83e-6	Response to cytadine analogues (cytosine arabinoside);
SARC	cis	rs7937682	0.881	rs4936678	chr11:111625085	C/T	cg09085632	chr11:111637200	PPP2R1B	1.0	15.43	0.71	1.79e-37	Primary sclerosing cholangitis;
SARC	cis	rs3087591	0.708	rs7503922	chr17:29641935	C/A	cg24425628	chr17:29625626	OMG;NF1	0.42	5.45	0.34	1.3e-7	Hip circumference;
SARC	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg26119090	chr2:26468346	HADHA;HADHB	0.95	12.52	0.63	7.36e-28	Gut microbiome composition (summer);
SARC	trans	rs1635	0.655	rs2281041	chr6:28303845	G/C	cg08080395	chr15:65488966	CILP	0.66	6.47	0.39	5.71e-10	Schizophrenia;
SARC	cis	rs11122272	0.735	rs2491408	chr1:231519248	C/G	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs911555	0.574	rs34251103	chr14:103860063	A/G	cg12935359	chr14:103987150	CKB	0.39	5.38	0.33	1.83e-7	Intelligence (multi-trait analysis);
SARC	cis	rs72781680	0.716	rs2712068	chr2:23984000	A/G	cg08917208	chr2:24149416	ATAD2B	0.55	5.69	0.35	3.73e-8	Lymphocyte counts;
SARC	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.38	5.35	0.33	2.14e-7	Total body bone mineral density;
SARC	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg22433210	chr17:43662623	NA	0.73	8.32	0.48	7.39e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs1008375	0.932	rs6449317	chr4:17631253	T/C	cg27347728	chr4:17578864	LAP3	0.5	6.27	0.38	1.72e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg26874164	chr19:58962979	ZNF324B	0.52	6.78	0.41	9.81e-11	Uric acid clearance;
SARC	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg07685180	chr8:600429	NA	0.76	6.0	0.37	7.5e-9	IgG glycosylation;
SARC	cis	rs36051895	0.632	rs12349918	chr9:5125250	A/G	cg02405213	chr9:5042618	JAK2	-0.43	-5.07	-0.32	8.22e-7	Pediatric autoimmune diseases;
SARC	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg13047869	chr3:10149882	C3orf24	0.43	4.73	0.3	3.82e-6	Alzheimer's disease;
SARC	cis	rs9916302	0.904	rs9898773	chr17:37532507	C/G	cg07936489	chr17:37558343	FBXL20	0.69	9.27	0.52	1.28e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs2033711	0.870	rs4801583	chr19:58918405	A/G	cg12042659	chr19:58951599	ZNF132	0.42	5.6	0.34	5.97e-8	Uric acid clearance;
SARC	cis	rs1153858	1.000	rs7179743	chr15:45638331	G/C	cg03999130	chr15:45571217	NA	0.39	4.93	0.31	1.58e-6	Homoarginine levels;
SARC	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg14784868	chr12:69753453	YEATS4	0.5	6.58	0.4	3.06e-10	Blood protein levels;
SARC	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.53	-6.28	-0.38	1.62e-9	Renal function-related traits (BUN);
SARC	cis	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg00800038	chr16:89945340	TCF25	-0.74	-5.14	-0.32	5.79e-7	Skin colour saturation;
SARC	cis	rs7666738	0.830	rs17558193	chr4:99049593	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs11098499	0.863	rs6858592	chr4:120458692	G/A	cg24375607	chr4:120327624	NA	0.41	4.81	0.3	2.65e-6	Corneal astigmatism;
SARC	cis	rs920590	0.643	rs7012694	chr8:19662732	C/T	cg01411142	chr8:19674711	INTS10	0.39	4.75	0.3	3.5e-6	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg27572855	chr1:25598939	RHD	-0.54	-9.1	-0.51	4.24e-17	Erythrocyte sedimentation rate;
SARC	cis	rs796364	0.806	rs112305133	chr2:201010380	A/G	cg23649088	chr2:200775458	C2orf69	-0.64	-6.49	-0.39	5.01e-10	Schizophrenia;
SARC	cis	rs9858542	0.953	rs11706370	chr3:49441091	G/A	cg07274523	chr3:49395745	GPX1	0.53	6.25	0.38	1.94e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.62	7.45	0.44	1.8e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs3812831	0.654	rs9314900	chr13:114937618	A/C	cg22348356	chr13:114891224	RASA3	0.35	4.95	0.31	1.39e-6	Schizophrenia;
SARC	cis	rs7216064	1.000	rs11079706	chr17:65835470	G/T	cg12091567	chr17:66097778	LOC651250	-0.69	-6.99	-0.42	2.89e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs9987353	0.566	rs13260067	chr8:9071033	A/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.54	-0.44	1.02e-12	Recombination measurement;
SARC	cis	rs2075371	0.829	rs9641970	chr7:134004887	C/A	cg20476274	chr7:133979776	SLC35B4	0.56	7.12	0.42	1.3e-11	Mean platelet volume;
SARC	cis	rs7208859	0.623	rs7223404	chr17:29107363	C/T	cg13385521	chr17:29058706	SUZ12P	0.84	7.27	0.43	5.28e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs826838	0.709	rs4882355	chr12:38721462	A/T	cg10518543	chr12:38710700	ALG10B	0.38	4.79	0.3	2.99e-6	Heart rate;
SARC	cis	rs7592578	0.766	rs62182885	chr2:191437024	A/G	cg25963032	chr2:191064776	C2orf88	-0.45	-4.91	-0.31	1.75e-6	Diastolic blood pressure;
SARC	cis	rs137603	0.602	rs9611146	chr22:39718120	G/T	cg01093212	chr22:39715156	SNORD43;RPL3	-0.54	-6.22	-0.38	2.29e-9	Primary biliary cholangitis;
SARC	cis	rs10089	0.951	rs56066100	chr5:127460571	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	10.26	0.56	1.31e-20	Ileal carcinoids;
SARC	cis	rs4891159	0.548	rs690082	chr18:74116668	C/T	cg24786174	chr18:74118243	ZNF516	0.77	13.31	0.66	1.92e-30	Longevity;
SARC	cis	rs1865760	0.516	rs9358903	chr6:26061949	A/C	cg17691542	chr6:26056736	HIST1H1C	0.49	6.14	0.37	3.47e-9	Height;
SARC	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg11764359	chr7:65958608	NA	0.88	12.58	0.64	4.89e-28	Aortic root size;
SARC	cis	rs9398803	0.713	rs4621657	chr6:126896227	G/A	cg19875578	chr6:126661172	C6orf173	0.6	8.22	0.47	1.39e-14	Male-pattern baldness;
SARC	trans	rs2727020	0.521	rs11040408	chr11:49534880	A/T	cg15704280	chr7:45808275	SEPT13	0.68	7.85	0.46	1.53e-13	Coronary artery disease;
SARC	cis	rs7264396	0.563	rs2425121	chr20:34326186	A/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	5.68	0.35	4.03e-8	Total cholesterol levels;
SARC	cis	rs9790314	0.586	rs11710086	chr3:161125858	A/T	cg04691961	chr3:161091175	C3orf57	-0.47	-5.89	-0.36	1.33e-8	Morning vs. evening chronotype;
SARC	cis	rs9398803	0.931	rs2045258	chr6:126674354	A/G	cg20229609	chr6:126660872	C6orf173	0.4	5.85	0.36	1.62e-8	Male-pattern baldness;
SARC	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg19223190	chr17:80058835	NA	0.47	6.44	0.39	6.62e-10	Life satisfaction;
SARC	cis	rs12477438	0.834	rs1563106	chr2:99701381	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-9.82	-0.54	2.89e-19	Chronic sinus infection;
SARC	cis	rs2439831	0.681	rs540031	chr15:43608855	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.05	12.09	0.62	1.9e-26	Lung cancer in ever smokers;
SARC	cis	rs7474896	0.583	rs12776092	chr10:38015795	G/C	cg25427524	chr10:38739819	LOC399744	-0.5	-5.92	-0.36	1.16e-8	Obesity (extreme);
SARC	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	12.45	0.63	1.33e-27	Platelet count;
SARC	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg12463550	chr7:65579703	CRCP	-0.48	-5.25	-0.33	3.44e-7	Aortic root size;
SARC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg03647317	chr4:187891568	NA	0.41	5.64	0.35	4.91e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg06873352	chr17:61820015	STRADA	0.53	6.86	0.41	6.24e-11	Prudent dietary pattern;
SARC	cis	rs12824058	0.831	rs11060826	chr12:130809931	G/C	cg26677194	chr12:130822605	PIWIL1	0.54	7.4	0.44	2.4e-12	Menopause (age at onset);
SARC	cis	rs908922	0.676	rs1053590	chr1:152488428	T/C	cg09873164	chr1:152488093	CRCT1	0.65	8.55	0.49	1.63e-15	Hair morphology;
SARC	cis	rs950776	0.518	rs4887062	chr15:78837801	G/A	cg22563815	chr15:78856949	CHRNA5	-0.4	-6.58	-0.4	3.03e-10	Sudden cardiac arrest;
SARC	cis	rs360798	0.512	rs4461246	chr2:63027671	C/T	cg17519650	chr2:63277830	OTX1	-0.43	-5.45	-0.34	1.28e-7	Coronary artery disease;
SARC	cis	rs2120243	0.501	rs1456107	chr3:157119520	A/C	cg24825693	chr3:157122686	VEPH1	-0.46	-6.46	-0.39	6e-10	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs9392653	0.847	rs9405255	chr6:5066039	A/T	cg17025484	chr7:99102690	ZKSCAN5	-0.54	-6.5	-0.39	4.75e-10	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs965469	0.779	rs6037568	chr20:3333245	C/T	cg25506879	chr20:3388711	C20orf194	-0.46	-4.99	-0.31	1.17e-6	IFN-related cytopenia;
SARC	cis	rs7927771	0.832	rs7940536	chr11:47395240	G/A	cg20307385	chr11:47447363	PSMC3	0.54	6.81	0.41	8.14e-11	Subjective well-being;
SARC	cis	rs6840360	0.615	rs4696268	chr4:152464723	G/A	cg22705602	chr4:152727874	NA	-0.4	-6.25	-0.38	1.92e-9	Intelligence (multi-trait analysis);
SARC	cis	rs2952156	0.920	rs732083	chr17:37834367	G/A	cg00129232	chr17:37814104	STARD3	-0.71	-10.1	-0.55	4.02e-20	Asthma;
SARC	cis	rs9341808	0.690	rs6930534	chr6:80896050	C/T	cg08355045	chr6:80787529	NA	0.33	5.34	0.33	2.24e-7	Sitting height ratio;
SARC	cis	rs7264396	0.635	rs6060719	chr20:34546013	A/C	cg12579300	chr20:34535607	PHF20	-0.43	-4.94	-0.31	1.49e-6	Total cholesterol levels;
SARC	cis	rs7264396	0.635	rs2024854	chr20:34511189	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	5.27	0.33	3.09e-7	Total cholesterol levels;
SARC	cis	rs15676	0.947	rs2977994	chr9:131585216	G/T	cg00228799	chr9:131580591	ENDOG	0.61	7.69	0.45	4.08e-13	Blood metabolite levels;
SARC	cis	rs3087591	0.922	rs12939969	chr17:29463577	A/G	cg24425628	chr17:29625626	OMG;NF1	0.53	6.59	0.4	2.88e-10	Hip circumference;
SARC	cis	rs7940866	0.838	rs10750455	chr11:130800330	C/T	cg12179176	chr11:130786555	SNX19	0.67	9.5	0.53	2.74e-18	Schizophrenia;
SARC	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg12463550	chr7:65579703	CRCP	-0.49	-5.29	-0.33	2.8e-7	Aortic root size;
SARC	cis	rs1018836	0.828	rs7816023	chr8:91567398	T/C	cg16814680	chr8:91681699	NA	-0.74	-11.45	-0.6	2.24e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs734999	0.505	rs4648659	chr1:2560903	T/G	cg20673091	chr1:2541236	MMEL1	-0.32	-4.98	-0.31	1.23e-6	Ulcerative colitis;
SARC	cis	rs9916302	0.706	rs1874226	chr17:37729031	C/T	cg07936489	chr17:37558343	FBXL20	0.73	8.5	0.49	2.29e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs13256369	0.802	rs11249887	chr8:8562184	T/C	cg17143192	chr8:8559678	CLDN23	0.52	5.83	0.36	1.86e-8	Obesity-related traits;
SARC	cis	rs870825	0.616	rs6552806	chr4:185638231	C/T	cg04058563	chr4:185651563	MLF1IP	0.84	11.36	0.6	4.49e-24	Blood protein levels;
SARC	cis	rs262150	0.659	rs2527237	chr7:158798494	A/G	cg04111992	chr7:158790115	NA	0.36	5.02	0.31	1.02e-6	Facial morphology (factor 20);
SARC	cis	rs35849525	0.814	rs7635601	chr3:50044006	A/T	cg14019146	chr3:50243930	SLC38A3	-0.38	-5.28	-0.33	2.9e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6700896	0.931	rs12035753	chr1:66116691	T/G	cg04111102	chr1:66153794	NA	0.35	5.55	0.34	7.6e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs7659604	1.000	rs7689714	chr4:122665943	T/A	cg20573242	chr4:122745356	CCNA2	0.44	5.74	0.35	3e-8	Type 2 diabetes;
SARC	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg18876405	chr7:65276391	NA	-0.65	-8.11	-0.47	2.97e-14	Aortic root size;
SARC	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-6.96	-0.41	3.46e-11	Gut microbiome composition (summer);
SARC	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.33	-5.46	-0.34	1.23e-7	Total body bone mineral density;
SARC	cis	rs9916302	0.904	rs587343	chr17:37440603	C/T	cg15445000	chr17:37608096	MED1	-0.44	-5.41	-0.33	1.59e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs2204008	0.744	rs11181337	chr12:38322083	C/A	cg13010199	chr12:38710504	ALG10B	0.76	10.2	0.56	1.99e-20	Bladder cancer;
SARC	cis	rs3126085	1.000	rs3126098	chr1:152311923	T/C	cg03465714	chr1:152285911	FLG	0.44	4.9	0.31	1.81e-6	Atopic dermatitis;
SARC	cis	rs1008375	1.000	rs10939749	chr4:17692319	A/C	cg02297831	chr4:17616191	MED28	0.39	4.86	0.3	2.14e-6	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs67478160	0.679	rs7156834	chr14:104211180	G/A	cg26031613	chr14:104095156	KLC1	-0.4	-4.78	-0.3	3.12e-6	Schizophrenia;
SARC	cis	rs1008375	0.932	rs7677212	chr4:17675932	A/G	cg02297831	chr4:17616191	MED28	-0.42	-5.22	-0.32	3.96e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs3942852	0.774	rs10838811	chr11:48186795	A/G	cg15704280	chr7:45808275	SEPT13	-0.62	-7.2	-0.43	8.05e-12	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.41	0.44	2.36e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9788682	0.747	rs2656069	chr15:78745707	C/T	cg06917634	chr15:78832804	PSMA4	0.51	5.35	0.33	2.09e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs941408	1.000	rs1736184	chr19:2810248	G/A	cg00079169	chr19:2811669	THOP1	0.47	5.15	0.32	5.52e-7	Total cholesterol levels;
SARC	cis	rs7089973	0.646	rs35453961	chr10:116638166	T/C	cg03647239	chr10:116582469	FAM160B1	0.41	5.05	0.31	9.02e-7	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg04277193	chr17:41438351	NA	0.47	5.04	0.31	9.44e-7	Menopause (age at onset);
SARC	cis	rs7712401	0.601	rs246274	chr5:122280803	A/C	cg19412675	chr5:122181750	SNX24	0.39	4.95	0.31	1.45e-6	Mean platelet volume;
SARC	cis	rs2153535	0.563	rs1796688	chr6:8536423	A/T	cg07606381	chr6:8435919	SLC35B3	0.75	10.53	0.57	1.88e-21	Motion sickness;
SARC	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg05861140	chr6:150128134	PCMT1	-0.38	-4.94	-0.31	1.5e-6	Lung cancer;
SARC	cis	rs4969178	0.965	rs2292643	chr17:76395421	G/A	cg02836325	chr17:76403955	PGS1	0.33	5.01	0.31	1.07e-6	HDL cholesterol levels;
SARC	cis	rs2032447	0.613	rs6456708	chr6:26032847	G/C	cg05027125	chr6:25961768	TRIM38	-0.39	-4.72	-0.3	4.04e-6	Intelligence (multi-trait analysis);
SARC	cis	rs3011225	0.683	rs4660753	chr1:44321044	G/A	cg12908607	chr1:44402522	ARTN	-0.33	-5.83	-0.36	1.88e-8	Amyotrophic lateral sclerosis (age of onset);
SARC	cis	rs10791097	0.694	rs4457753	chr11:130755575	A/G	cg09137382	chr11:130731461	NA	0.33	5.05	0.31	8.97e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg00149659	chr3:10157352	C3orf10	0.64	6.01	0.37	7.21e-9	Alzheimer's disease;
SARC	cis	rs12188164	0.965	rs56146525	chr5:442571	A/C	cg21144161	chr5:423903	AHRR	0.31	4.84	0.3	2.39e-6	Cystic fibrosis severity;
SARC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg20887711	chr4:1340912	KIAA1530	0.8	10.03	0.55	6.51e-20	Longevity;
SARC	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs3768617	0.966	rs6669796	chr1:183082825	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.57	7.4	0.44	2.5e-12	Fuchs's corneal dystrophy;
SARC	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg03735888	chr19:58951602	ZNF132	0.4	5.22	0.32	4e-7	Uric acid clearance;
SARC	cis	rs11166927	0.524	rs2035087	chr8:140831320	A/G	cg16909799	chr8:140841666	TRAPPC9	-0.39	-5.45	-0.34	1.3e-7	Pediatric non-alcoholic fatty liver disease activity score;
SARC	cis	rs12421382	0.659	rs1837397	chr11:109389803	A/C	cg16359550	chr11:109292809	C11orf87	0.38	5.66	0.35	4.47e-8	Schizophrenia;
SARC	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	12.49	0.63	9.73e-28	Personality dimensions;
SARC	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	8.95	0.51	1.11e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7937682	0.793	rs7130440	chr11:111417779	A/G	cg22437258	chr11:111473054	SIK2	-0.5	-6.18	-0.38	2.8e-9	Primary sclerosing cholangitis;
SARC	cis	rs67311347	1.000	rs7633809	chr3:40517737	A/G	cg24209194	chr3:40518798	ZNF619	-0.63	-8.04	-0.47	4.48e-14	Renal cell carcinoma;
SARC	cis	rs9831754	0.906	rs6782626	chr3:78406178	T/C	cg06138941	chr3:78371609	NA	-0.58	-6.79	-0.41	9.42e-11	Calcium levels;
SARC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.65	0.53	9.46e-19	Prudent dietary pattern;
SARC	cis	rs9916302	0.904	rs2061338	chr17:37421767	T/C	cg07936489	chr17:37558343	FBXL20	-0.68	-9.23	-0.52	1.69e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg04944784	chr2:26401820	FAM59B	-0.6	-7.95	-0.46	8.14e-14	Gut microbiome composition (summer);
SARC	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg11764359	chr7:65958608	NA	-0.72	-8.42	-0.48	3.77e-15	Aortic root size;
SARC	cis	rs12044355	0.858	rs1538975	chr1:231828372	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.62	8.41	0.48	4.01e-15	Alzheimer's disease;
SARC	cis	rs1801251	1.000	rs11679079	chr2:233612656	C/T	cg25237894	chr2:233734115	C2orf82	0.38	4.96	0.31	1.39e-6	Coronary artery disease;
SARC	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg06420487	chr17:61919686	SMARCD2	0.44	4.97	0.31	1.32e-6	Height;
SARC	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg22800045	chr5:56110881	MAP3K1	0.67	6.22	0.38	2.24e-9	Initial pursuit acceleration;
SARC	cis	rs4919694	0.908	rs11191523	chr10:104792400	A/G	cg04362960	chr10:104952993	NT5C2	0.66	5.46	0.34	1.21e-7	Arsenic metabolism;
SARC	cis	rs12142240	0.698	rs28578741	chr1:46825176	T/C	cg00530320	chr1:46809349	NSUN4	0.57	6.79	0.41	9.05e-11	Menopause (age at onset);
SARC	cis	rs12421382	0.511	rs2212430	chr11:109289538	C/T	cg11473876	chr11:109292803	C11orf87	0.41	5.75	0.35	2.86e-8	Schizophrenia;
SARC	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg11764359	chr7:65958608	NA	-0.66	-7.88	-0.46	1.23e-13	Aortic root size;
SARC	cis	rs459571	0.959	rs378740	chr9:136890876	C/A	cg01294253	chr9:136912663	BRD3	0.43	5.53	0.34	8.42e-8	Platelet distribution width;
SARC	cis	rs11792861	0.816	rs2275637	chr9:111696043	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.73	8.72	0.5	5.33e-16	Menarche (age at onset);
SARC	cis	rs698833	0.892	rs786618	chr2:44593929	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.64	7.83	0.46	1.72e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs2651899	0.934	rs1627080	chr1:3081309	T/C	cg22674798	chr1:3096360	PRDM16	0.26	5.16	0.32	5.16e-7	Migraine;
SARC	trans	rs1973993	0.745	rs6593606	chr1:96968005	C/T	cg10631902	chr5:14652156	NA	-0.42	-6.68	-0.4	1.71e-10	Weight;
SARC	cis	rs7833790	1.000	rs7833384	chr8:82730915	T/C	cg17211192	chr8:82754475	SNX16	-0.58	-6.37	-0.39	1.01e-9	Diastolic blood pressure;
SARC	cis	rs6700896	0.522	rs12030543	chr1:66155027	C/T	cg04111102	chr1:66153794	NA	0.44	4.74	0.3	3.7e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs4988958	0.565	rs6760621	chr2:102999952	T/C	cg03938978	chr2:103052716	IL18RAP	0.32	5.17	0.32	5.14e-7	Asthma (childhood onset);
SARC	cis	rs11690935	0.632	rs34242651	chr2:172553999	G/A	cg13550731	chr2:172543902	DYNC1I2	0.65	9.18	0.52	2.35e-17	Schizophrenia;
SARC	cis	rs72945132	0.882	rs11235755	chr11:70136323	A/G	cg05964544	chr11:70165517	PPFIA1	-0.58	-5.72	-0.35	3.32e-8	Coronary artery disease;
SARC	cis	rs6665290	0.904	rs12409428	chr1:227189969	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.09	-25.56	-0.86	1.54e-69	Myeloid white cell count;
SARC	cis	rs986417	0.901	rs9743622	chr14:61037163	A/T	cg27398547	chr14:60952738	C14orf39	0.87	7.98	0.46	6.41e-14	Gut microbiota (bacterial taxa);
SARC	cis	rs12079745	1.000	rs74967728	chr1:169202731	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.8	-5.35	-0.33	2.06e-7	QT interval;
SARC	cis	rs10791323	0.628	rs10750543	chr11:133718467	G/A	cg13461336	chr11:133711254	SPATA19	-0.27	-4.81	-0.3	2.77e-6	Childhood ear infection;
SARC	cis	rs11711311	0.826	rs13077644	chr3:113467777	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	8.18	0.47	1.88e-14	IgG glycosylation;
SARC	cis	rs965469	0.553	rs6051767	chr20:3324521	C/T	cg25506879	chr20:3388711	C20orf194	-0.43	-5.12	-0.32	6.45e-7	IFN-related cytopenia;
SARC	cis	rs7296418	0.580	rs78455769	chr12:123856443	G/A	cg05973401	chr12:123451056	ABCB9	0.48	5.58	0.34	6.66e-8	Platelet count;
SARC	cis	rs10791097	0.506	rs10750446	chr11:130706918	T/C	cg12179176	chr11:130786555	SNX19	-0.41	-5.26	-0.33	3.29e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs2204008	0.583	rs12307593	chr12:38317803	A/G	cg26384229	chr12:38710491	ALG10B	0.54	6.58	0.4	2.99e-10	Bladder cancer;
SARC	cis	rs9733	0.818	rs4970926	chr1:150673684	T/C	cg13175981	chr1:150552382	MCL1	0.64	8.92	0.5	1.42e-16	Tonsillectomy;
SARC	cis	rs9341808	0.667	rs2476826	chr6:80876064	C/T	cg08355045	chr6:80787529	NA	0.37	5.8	0.36	2.11e-8	Sitting height ratio;
SARC	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg18252515	chr7:66147081	NA	0.59	6.4	0.39	8.53e-10	Aortic root size;
SARC	trans	rs634534	0.591	rs688862	chr11:65733393	A/G	cg17712092	chr4:129076599	LARP1B	0.61	8.14	0.47	2.42e-14	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs208520	0.661	rs6937856	chr6:66867468	A/G	cg07460842	chr6:66804631	NA	-1.09	-15.3	-0.71	4.9e-37	Exhaled nitric oxide output;
SARC	cis	rs6988636	1.000	rs16898095	chr8:124193523	T/C	cg23067535	chr8:124195133	FAM83A	-0.71	-5.75	-0.35	2.83e-8	Urinary uromodulin levels;
SARC	cis	rs861020	0.606	rs657844	chr1:210006873	T/G	cg23166289	chr1:210001082	C1orf107	0.39	4.74	0.3	3.66e-6	Orofacial clefts;
SARC	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg16405210	chr4:1374714	KIAA1530	-0.49	-5.8	-0.36	2.14e-8	Obesity-related traits;
SARC	cis	rs7412746	0.634	rs2124952	chr1:150923774	T/A	cg10589385	chr1:150898437	SETDB1	0.42	5.64	0.35	4.91e-8	Melanoma;
SARC	cis	rs2033732	0.826	rs12546578	chr8:85085268	A/T	cg05716166	chr8:85095498	RALYL	-0.55	-7.1	-0.42	1.49e-11	Body mass index;
SARC	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.62	-6.74	-0.4	1.24e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs1707322	0.964	rs785508	chr1:46527159	G/A	cg03146154	chr1:46216737	IPP	-0.48	-5.65	-0.35	4.78e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.34	-5.07	-0.32	8.2e-7	Total body bone mineral density;
SARC	cis	rs921968	0.541	rs562510	chr2:219443001	A/C	cg02176678	chr2:219576539	TTLL4	0.47	7.13	0.42	1.28e-11	Mean corpuscular hemoglobin concentration;
SARC	cis	rs7647973	0.626	rs4855849	chr3:49653378	A/G	cg13072238	chr3:49761600	GMPPB	-0.61	-6.14	-0.37	3.48e-9	Menarche (age at onset);
SARC	cis	rs763121	0.776	rs5757177	chr22:39007174	A/C	cg06022373	chr22:39101656	GTPBP1	0.88	11.31	0.6	6.49e-24	Menopause (age at onset);
SARC	cis	rs9807989	0.839	rs4988957	chr2:102968075	C/T	cg09003973	chr2:102972529	NA	-0.42	-5.68	-0.35	3.92e-8	Asthma;
SARC	cis	rs72781680	1.000	rs72796327	chr2:24140372	T/C	cg08917208	chr2:24149416	ATAD2B	0.85	8.04	0.47	4.51e-14	Lymphocyte counts;
SARC	cis	rs1057510	1.000	rs1057510	chr12:6683287	C/T	cg22370296	chr12:6798801	ZNF384	0.52	5.46	0.34	1.22e-7	Myopia (pathological);
SARC	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg13939156	chr17:80058883	NA	-0.42	-6.48	-0.39	5.51e-10	Life satisfaction;
SARC	cis	rs6582630	0.615	rs3914894	chr12:38480280	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-6.91	-0.41	4.57e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs17384381	0.859	rs28529751	chr1:85910951	G/A	cg16011679	chr1:85725395	C1orf52	0.59	5.64	0.35	4.81e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7520050	0.778	rs3014238	chr1:46090214	A/G	cg24296786	chr1:45957014	TESK2	0.42	5.39	0.33	1.7e-7	Red blood cell count;Reticulocyte count;
SARC	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg05025164	chr4:1340916	KIAA1530	-0.46	-5.24	-0.32	3.52e-7	Obesity-related traits;
SARC	cis	rs7819412	0.805	rs2409710	chr8:10979821	A/G	cg21775007	chr8:11205619	TDH	-0.48	-5.74	-0.35	3e-8	Triglycerides;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg02081051	chr20:18488312	SEC23B	0.5	6.31	0.38	1.4e-9	Lung adenocarcinoma;
SARC	cis	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg05084668	chr3:125655381	ALG1L	-0.48	-4.87	-0.3	2.02e-6	Blood pressure (smoking interaction);
SARC	trans	rs11098499	1.000	rs28419773	chr4:120211061	T/C	cg25214090	chr10:38739885	LOC399744	0.54	7.07	0.42	1.75e-11	Corneal astigmatism;
SARC	cis	rs12421382	0.543	rs11213094	chr11:109357926	G/A	cg16359550	chr11:109292809	C11orf87	0.44	5.95	0.36	9.58e-9	Schizophrenia;
SARC	cis	rs1538970	0.962	rs9429072	chr1:45810091	C/T	cg16078521	chr1:45672383	ZSWIM5	-0.46	-5.03	-0.31	9.74e-7	Platelet count;
SARC	cis	rs6952808	0.929	rs4721217	chr7:1973579	C/T	cg05863683	chr7:1912471	MAD1L1	0.35	5.2	0.32	4.27e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs7833790	0.700	rs7825180	chr8:82723991	T/A	cg17211192	chr8:82754475	SNX16	-0.49	-6.21	-0.38	2.35e-9	Diastolic blood pressure;
SARC	cis	rs9322817	0.617	rs9391242	chr6:105231257	G/A	cg02098413	chr6:105308735	HACE1	-0.39	-6.13	-0.37	3.68e-9	Thyroid stimulating hormone;
SARC	cis	rs981844	1.000	rs17371021	chr4:154664295	A/G	cg14289246	chr4:154710475	SFRP2	-0.59	-6.72	-0.4	1.37e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg18252515	chr7:66147081	NA	-1.29	-11.31	-0.6	6.31e-24	Diabetic kidney disease;
SARC	trans	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.74	-10.81	-0.58	2.44e-22	Intelligence (multi-trait analysis);
SARC	cis	rs2718058	0.560	rs2709109	chr7:37832852	G/A	cg15028436	chr7:37888078	TXNDC3	0.42	5.23	0.32	3.73e-7	Alzheimer's disease (late onset);
SARC	cis	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg06212747	chr3:49208901	KLHDC8B	0.51	6.38	0.39	9.49e-10	Resting heart rate;
SARC	trans	rs9329221	0.741	rs13264066	chr8:9804075	C/G	cg06636001	chr8:8085503	FLJ10661	-0.69	-9.29	-0.52	1.13e-17	Neuroticism;
SARC	cis	rs2153535	0.580	rs9406161	chr6:8466144	G/T	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	cis	rs7586879	0.639	rs2033653	chr2:25103446	C/T	cg04586622	chr2:25135609	ADCY3	-0.31	-5.26	-0.33	3.29e-7	Body mass index;
SARC	cis	rs35160687	0.901	rs35762338	chr2:86513553	G/A	cg10973622	chr2:86423274	IMMT	0.38	4.91	0.31	1.68e-6	Night sleep phenotypes;
SARC	cis	rs10782582	0.593	rs12130832	chr1:76234294	T/C	cg03433033	chr1:76189801	ACADM	-0.42	-5.29	-0.33	2.77e-7	Daytime sleep phenotypes;
SARC	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg15847926	chr7:2749597	AMZ1	-0.3	-4.92	-0.31	1.62e-6	Height;
SARC	cis	rs7584330	0.737	rs12469894	chr2:238365528	T/C	cg14458575	chr2:238380390	NA	0.45	5.56	0.34	7.38e-8	Prostate cancer;
SARC	cis	rs6088590	1.000	rs28542147	chr20:33376323	G/A	cg24642439	chr20:33292090	TP53INP2	0.88	12.36	0.63	2.45e-27	Coronary artery disease;
SARC	cis	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg25427524	chr10:38739819	LOC399744	-0.55	-8.59	-0.49	1.27e-15	Extrinsic epigenetic age acceleration;
SARC	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.79	5.61	0.34	5.77e-8	Initial pursuit acceleration;
SARC	cis	rs11105298	0.891	rs6538190	chr12:89885942	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-5.42	-0.33	1.49e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs9660992	0.700	rs7547565	chr1:205259402	G/A	cg00857998	chr1:205179979	DSTYK	-0.42	-5.05	-0.31	8.93e-7	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs11651000	0.817	rs11657479	chr17:45822901	T/C	cg03474202	chr17:45855739	NA	-0.36	-4.96	-0.31	1.33e-6	IgG glycosylation;
SARC	cis	rs10911232	0.507	rs10797814	chr1:182990929	C/A	cg13390022	chr1:182993471	LAMC1	0.34	5.23	0.32	3.79e-7	Hypertriglyceridemia;
SARC	cis	rs3087591	0.853	rs2953003	chr17:29502731	T/C	cg24425628	chr17:29625626	OMG;NF1	0.5	6.26	0.38	1.88e-9	Hip circumference;
SARC	trans	rs7824557	0.564	rs2736288	chr8:11228100	G/A	cg06636001	chr8:8085503	FLJ10661	-0.61	-7.98	-0.46	6.53e-14	Retinal vascular caliber;
SARC	cis	rs367615	0.704	rs4320313	chr5:108828687	A/G	cg17395555	chr5:108820864	NA	0.47	6.68	0.4	1.73e-10	Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.98	10.59	0.57	1.23e-21	Platelet count;
SARC	cis	rs10197940	0.624	rs13393122	chr2:152413315	A/G	cg19508488	chr2:152266495	RIF1	0.46	5.04	0.31	9.46e-7	Lung cancer;
SARC	cis	rs4481887	1.000	rs6683717	chr1:248476792	A/G	cg01631408	chr1:248437212	OR2T33	-0.42	-5.31	-0.33	2.61e-7	Common traits (Other);
SARC	cis	rs4927850	0.794	rs2019472	chr3:195735371	T/C	cg18569988	chr3:195679450	NA	0.32	4.82	0.3	2.54e-6	Pancreatic cancer;
SARC	cis	rs67460515	0.892	rs34016896	chr3:160992864	C/T	cg04691961	chr3:161091175	C3orf57	-0.5	-6.19	-0.38	2.71e-9	Parkinson's disease;
SARC	cis	rs7772486	0.686	rs9376961	chr6:146048737	C/T	cg23711669	chr6:146136114	FBXO30	0.78	12.22	0.62	7.34e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs60733400	0.500	rs72644697	chr1:2533605	G/A	cg00980319	chr1:2560884	MMEL1	-0.33	-4.75	-0.3	3.55e-6	Multiple sclerosis;
SARC	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg16339924	chr4:17578868	LAP3	0.62	8.21	0.47	1.53e-14	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7833790	0.724	rs4739627	chr8:82734657	A/G	cg17211192	chr8:82754475	SNX16	-0.49	-6.21	-0.38	2.35e-9	Diastolic blood pressure;
SARC	cis	rs2153535	0.580	rs9328483	chr6:8521295	A/G	cg23788917	chr6:8435910	SLC35B3	0.64	8.66	0.49	7.75e-16	Motion sickness;
SARC	cis	rs9916302	0.784	rs4795361	chr17:37573446	G/A	cg07936489	chr17:37558343	FBXL20	-0.7	-9.15	-0.51	2.94e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg00149659	chr3:10157352	C3orf10	0.68	6.28	0.38	1.63e-9	Alzheimer's disease;
SARC	cis	rs2204008	0.805	rs10881112	chr12:37956611	G/A	cg26384229	chr12:38710491	ALG10B	-0.77	-10.94	-0.58	9.57e-23	Bladder cancer;
SARC	cis	rs2055729	0.591	rs6987670	chr8:9883177	C/T	cg21625330	chr8:9911636	MSRA	-0.45	-5.04	-0.31	9.14e-7	Multiple myeloma (hyperdiploidy);
SARC	cis	rs7044106	0.791	rs10985001	chr9:123484232	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	6.22	0.38	2.25e-9	Hip circumference adjusted for BMI;
SARC	cis	rs1568889	1.000	rs7951681	chr11:28273894	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	10.21	0.56	1.79e-20	Bipolar disorder;
SARC	cis	rs3126085	0.935	rs4361987	chr1:152229701	A/G	cg03465714	chr1:152285911	FLG	-0.45	-5.48	-0.34	1.13e-7	Atopic dermatitis;
SARC	cis	rs911555	0.692	rs7146215	chr14:103915908	A/G	cg24130564	chr14:104152367	KLC1	0.49	5.75	0.35	2.73e-8	Intelligence (multi-trait analysis);
SARC	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg23758822	chr17:41437982	NA	0.88	11.19	0.59	1.55e-23	Menopause (age at onset);
SARC	cis	rs5753618	0.539	rs4820962	chr22:31689951	A/G	cg13145458	chr22:31556086	RNF185	0.46	4.83	0.3	2.51e-6	Colorectal cancer;
SARC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg20665002	chr13:25946220	ATP8A2	0.47	6.58	0.4	3.04e-10	Colonoscopy-negative controls vs population controls;
SARC	cis	rs826838	0.900	rs1403523	chr12:39130570	T/A	cg13010199	chr12:38710504	ALG10B	-0.63	-8.88	-0.5	1.87e-16	Heart rate;
SARC	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg18252515	chr7:66147081	NA	1.34	11.82	0.61	1.44e-25	Diabetic kidney disease;
SARC	cis	rs16854884	0.683	rs6766544	chr3:143736659	G/T	cg06585982	chr3:143692056	C3orf58	0.67	9.14	0.51	3.13e-17	Economic and political preferences (feminism/equality);
SARC	cis	rs10861342	1.000	rs10861346	chr12:105473245	G/T	cg23923672	chr12:105501055	KIAA1033	0.65	4.8	0.3	2.85e-6	IgG glycosylation;
SARC	cis	rs1448094	0.512	rs12314318	chr12:86249238	T/C	cg02569458	chr12:86230093	RASSF9	0.38	5.39	0.33	1.71e-7	Major depressive disorder;
SARC	cis	rs4481887	0.927	rs4427440	chr1:248480337	T/A	cg00666640	chr1:248458726	OR2T12	0.33	5.54	0.34	7.95e-8	Common traits (Other);
SARC	cis	rs9462027	0.628	rs9469863	chr6:34739649	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.84	-0.36	1.71e-8	Systemic lupus erythematosus;
SARC	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg22834771	chr12:69754056	YEATS4	-0.48	-6.33	-0.38	1.25e-9	Cerebrospinal fluid biomarker levels;
SARC	cis	rs7937682	0.824	rs11213962	chr11:111506027	G/A	cg22437258	chr11:111473054	SIK2	0.74	10.3	0.56	9.9e-21	Primary sclerosing cholangitis;
SARC	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg11987759	chr7:65425863	GUSB	-0.6	-7.96	-0.46	7.38e-14	Aortic root size;
SARC	cis	rs3770081	1.000	rs73943920	chr2:86186195	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.79	-4.81	-0.3	2.71e-6	Facial emotion recognition (sad faces);
SARC	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg11062466	chr8:58055876	NA	0.64	5.98	0.36	8.43e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9858542	0.953	rs7646366	chr3:49470668	G/A	cg07274523	chr3:49395745	GPX1	0.53	6.11	0.37	4.1e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs7043114	0.525	rs10820969	chr9:95106678	G/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.82	-0.36	1.97e-8	Height;
SARC	cis	rs10875746	0.903	rs2158516	chr12:48490834	T/A	cg26205652	chr12:48591994	NA	0.55	6.0	0.37	7.52e-9	Longevity (90 years and older);
SARC	cis	rs722599	0.683	rs10144845	chr14:75237770	C/T	cg08847533	chr14:75593920	NEK9	0.42	4.71	0.3	4.17e-6	IgG glycosylation;
SARC	cis	rs78456975	1.000	rs72776298	chr2:1570163	C/G	cg12573674	chr2:1569213	NA	-0.54	-4.79	-0.3	2.96e-6	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs2073300	0.609	rs3746733	chr20:23349749	C/T	cg12062639	chr20:23401060	NAPB	1.04	6.75	0.4	1.17e-10	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs9341808	0.538	rs623048	chr6:80981916	C/T	cg08355045	chr6:80787529	NA	-0.32	-4.91	-0.31	1.69e-6	Sitting height ratio;
SARC	cis	rs11613048	0.897	rs12826253	chr12:30323114	C/T	cg12718339	chr12:29936407	TMTC1	-0.36	-4.91	-0.31	1.7e-6	Major depressive disorder;
SARC	cis	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg15556689	chr8:8085844	FLJ10661	-0.43	-5.0	-0.31	1.12e-6	Mood instability;
SARC	cis	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg14019146	chr3:50243930	SLC38A3	-0.3	-4.73	-0.3	3.92e-6	Body mass index;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg18807049	chr1:112532978	KCND3	-0.59	-6.48	-0.39	5.39e-10	Lung cancer in ever smokers;
SARC	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg18357526	chr6:26021779	HIST1H4A	-0.7	-9.24	-0.52	1.62e-17	Intelligence (multi-trait analysis);
SARC	cis	rs858239	0.601	rs3735228	chr7:23170427	T/G	cg23682824	chr7:23144976	KLHL7	0.73	9.85	0.54	2.33e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs3126085	0.877	rs4456098	chr1:152176034	C/T	cg26876637	chr1:152193138	HRNR	0.48	5.52	0.34	9.22e-8	Atopic dermatitis;
SARC	cis	rs7927592	0.912	rs55767696	chr11:68375120	C/G	cg01657329	chr11:68192670	LRP5	-0.4	-4.85	-0.3	2.24e-6	Total body bone mineral density;
SARC	cis	rs11098499	0.779	rs80242894	chr4:120375752	G/A	cg24375607	chr4:120327624	NA	0.39	4.73	0.3	3.94e-6	Corneal astigmatism;
SARC	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg03647317	chr4:187891568	NA	-0.41	-6.11	-0.37	4.26e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7624766	0.594	rs12494732	chr3:160578374	C/T	cg22637730	chr3:160473554	PPM1L	0.39	4.86	0.3	2.17e-6	Response to methotrexate in rheumatoid arthritis;
SARC	cis	rs908922	0.676	rs498184	chr1:152501423	G/C	cg09873164	chr1:152488093	CRCT1	0.66	8.56	0.49	1.53e-15	Hair morphology;
SARC	cis	rs11225247	0.881	rs12282486	chr11:102253554	C/G	cg11690896	chr11:102217788	BIRC2	0.77	5.44	0.34	1.33e-7	Vein graft stenosis in coronary artery bypass grafting;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08858875	chr6:86388188	SNHG5;SNORD50B;SNORD50A	0.55	6.99	0.42	2.95e-11	Smoking initiation;
SARC	cis	rs17345786	0.798	rs4257518	chr3:101281709	C/T	cg12386194	chr3:101231763	SENP7	-0.58	-7.11	-0.42	1.38e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.68	7.44	0.44	1.97e-12	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg24675658	chr1:53192096	ZYG11B	-0.59	-8.31	-0.48	8.04e-15	Monocyte count;
SARC	cis	rs9309473	0.500	rs12997018	chr2:73912899	A/G	cg20560298	chr2:73613845	ALMS1	0.47	6.27	0.38	1.69e-9	Metabolite levels;
SARC	cis	rs881375	0.867	rs6478487	chr9:123672777	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	4.85	0.3	2.24e-6	Rheumatoid arthritis;
SARC	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg17376030	chr22:41985996	PMM1	-0.74	-9.14	-0.51	3.13e-17	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs4737010	0.591	rs13282514	chr8:41619713	A/G	cg08923054	chr8:41654455	ANK1	0.42	5.08	0.32	7.85e-7	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
SARC	cis	rs8114671	0.836	rs745849	chr20:33572178	G/A	cg24642439	chr20:33292090	TP53INP2	-0.49	-5.7	-0.35	3.56e-8	Height;
SARC	cis	rs2354432	0.556	rs2883319	chr1:146838177	A/G	cg25205988	chr1:146714368	CHD1L	-0.95	-6.83	-0.41	7.16e-11	Mitochondrial DNA levels;
SARC	cis	rs11122272	0.735	rs2247132	chr1:231493359	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.22	-0.56	1.7e-20	Hemoglobin concentration;
SARC	cis	rs888194	0.966	rs7313797	chr12:109896165	A/G	cg08884029	chr12:110012500	MVK;MMAB	-0.33	-5.04	-0.31	9.29e-7	Neuroticism;
SARC	cis	rs2153535	0.541	rs9505456	chr6:8479001	T/C	cg23788917	chr6:8435910	SLC35B3	0.64	8.59	0.49	1.25e-15	Motion sickness;
SARC	cis	rs2273669	0.667	rs77002235	chr6:109321497	G/A	cg05315195	chr6:109294784	ARMC2	-0.6	-5.43	-0.34	1.38e-7	Prostate cancer;
SARC	trans	rs11165623	0.543	rs6656866	chr1:97002238	T/C	cg10631902	chr5:14652156	NA	-0.42	-6.36	-0.38	1.04e-9	Hip circumference;Waist circumference;
SARC	cis	rs4319547	0.695	rs10846699	chr12:122853073	A/G	cg23029597	chr12:123009494	RSRC2	0.38	4.93	0.31	1.59e-6	Body mass index;
SARC	cis	rs3784262	0.709	rs4080	chr15:58201341	C/G	cg12031962	chr15:58353849	ALDH1A2	0.37	5.46	0.34	1.2e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.49	-6.12	-0.37	3.97e-9	Lymphocyte counts;
SARC	cis	rs7312774	0.618	rs57361179	chr12:107337483	T/C	cg16260113	chr12:107380972	MTERFD3	0.91	7.5	0.44	1.31e-12	Severe influenza A (H1N1) infection;
SARC	cis	rs4243830	1.000	rs12046884	chr1:6594561	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	1.04	8.63	0.49	9.5e-16	Body mass index;
SARC	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg25036284	chr2:26402008	FAM59B	-0.46	-5.7	-0.35	3.59e-8	Gut microbiome composition (summer);
SARC	cis	rs17376456	0.877	rs17083455	chr5:93446380	A/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	6.14	0.37	3.45e-9	Diabetic retinopathy;
SARC	cis	rs9868809	0.505	rs28567949	chr3:48744560	G/A	cg03060546	chr3:49711283	APEH	-0.51	-4.74	-0.3	3.73e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg07013326	chr6:57037090	BAG2	0.51	6.53	0.39	4.1e-10	Height;
SARC	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	12.74	0.64	1.44e-28	Platelet count;
SARC	cis	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg25427524	chr10:38739819	LOC399744	-0.52	-8.12	-0.47	2.64e-14	Extrinsic epigenetic age acceleration;
SARC	cis	rs4253772	0.530	rs6008623	chr22:46710024	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.61	4.79	0.3	3e-6	LDL cholesterol;Cholesterol, total;
SARC	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg17376030	chr22:41985996	PMM1	-0.62	-7.98	-0.46	6.44e-14	Vitiligo;
SARC	cis	rs2303759	0.914	rs2288481	chr19:49878196	G/A	cg22590775	chr19:49891494	CCDC155	0.48	4.92	0.31	1.67e-6	Multiple sclerosis;
SARC	cis	rs6701037	1.000	rs12747817	chr1:175118895	C/T	cg00321850	chr1:175162397	KIAA0040	-0.36	-5.47	-0.34	1.16e-7	Alcohol dependence;
SARC	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg20573242	chr4:122745356	CCNA2	0.55	7.04	0.42	2.08e-11	Type 2 diabetes;
SARC	cis	rs7592578	0.766	rs62182885	chr2:191437024	A/G	cg27211696	chr2:191398769	TMEM194B	-0.56	-5.78	-0.35	2.44e-8	Diastolic blood pressure;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg22665089	chr10:97320867	SORBS1	-0.53	-6.41	-0.39	8.12e-10	Fibrinogen levels;
SARC	cis	rs4803468	1.000	rs2241711	chr19:41911980	T/C	cg14132834	chr19:41945861	ATP5SL	-0.56	-7.32	-0.43	4.06e-12	Height;
SARC	cis	rs796364	0.664	rs3106089	chr2:200884615	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.71	6.04	0.37	6.12e-9	Schizophrenia;
SARC	trans	rs1994135	0.617	rs2200155	chr12:33734935	G/A	cg13010199	chr12:38710504	ALG10B	0.59	6.94	0.41	3.79e-11	Resting heart rate;
SARC	cis	rs11264799	0.581	rs2758680	chr1:157543746	C/T	cg18268488	chr1:157545234	FCRL4	0.29	4.81	0.3	2.68e-6	IgA nephropathy;
SARC	cis	rs4727027	0.933	rs10277119	chr7:148849942	T/C	cg23583168	chr7:148888333	NA	-0.73	-10.84	-0.58	1.91e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs17376456	0.877	rs10059230	chr5:93450347	A/G	cg25358565	chr5:93447407	FAM172A	1.31	15.17	0.7	1.33e-36	Diabetic retinopathy;
SARC	cis	rs4481887	0.927	rs7519334	chr1:248472076	C/T	cg01631408	chr1:248437212	OR2T33	-0.4	-5.1	-0.32	7.03e-7	Common traits (Other);
SARC	cis	rs929354	0.742	rs2107863	chr7:156963731	T/C	cg05182265	chr7:156933206	UBE3C	-0.33	-5.08	-0.32	7.67e-7	Body mass index;
SARC	cis	rs8017423	0.935	rs12884698	chr14:90750566	G/A	cg20276874	chr14:90721474	PSMC1	0.36	4.79	0.3	2.96e-6	Mortality in heart failure;
SARC	cis	rs3540	0.960	rs8040585	chr15:91026477	T/C	cg22089800	chr15:90895588	ZNF774	0.48	5.57	0.34	7.07e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	trans	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg24575169	chr11:70244414	CTTN	0.46	6.4	0.39	8.56e-10	Immature fraction of reticulocytes;
SARC	cis	rs2197308	0.623	rs1672426	chr12:38118671	C/T	cg14851346	chr12:38532713	NA	-0.43	-5.12	-0.32	6.25e-7	Morning vs. evening chronotype;
SARC	cis	rs10276381	0.786	rs10272155	chr7:28246989	A/G	cg23620719	chr7:28220237	JAZF1	0.71	5.56	0.34	7.27e-8	Crohn's disease;
SARC	cis	rs8038465	0.594	rs55816897	chr15:73869767	G/T	cg15420318	chr15:73925796	NPTN	0.61	7.05	0.42	2.02e-11	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9303280	0.806	rs9907088	chr17:38035116	G/A	cg20243544	chr17:37824526	PNMT	0.43	5.63	0.35	5.08e-8	Self-reported allergy;
SARC	cis	rs2439831	0.702	rs16977724	chr15:44151299	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	7.67	0.45	4.56e-13	Lung cancer in ever smokers;
SARC	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg11764359	chr7:65958608	NA	0.77	9.94	0.55	1.26e-19	Aortic root size;
SARC	cis	rs4819052	0.679	rs4819053	chr21:46711357	C/T	cg06618935	chr21:46677482	NA	0.36	4.79	0.3	2.91e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9303401	0.614	rs3803753	chr17:56540110	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.05	11.4	0.6	3.25e-24	Cognitive test performance;
SARC	cis	rs826838	0.967	rs1719856	chr12:39127201	C/T	cg13010199	chr12:38710504	ALG10B	-0.63	-8.88	-0.5	1.87e-16	Heart rate;
SARC	cis	rs3753242	1.000	rs3753242	chr1:2069681	A/G	cg24700472	chr1:2118131	C1orf86	-0.58	-4.86	-0.3	2.15e-6	Response to antipsychotic treatment in schizophrenia (reasoning);
SARC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg13397359	chr6:42928475	GNMT	0.58	8.08	0.47	3.46e-14	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs10875746	0.859	rs11168371	chr12:48437686	C/T	cg26205652	chr12:48591994	NA	0.47	5.15	0.32	5.47e-7	Longevity (90 years and older);
SARC	trans	rs7742915	0.548	rs12206712	chr6:38139748	T/C	cg23109359	chr1:229730475	TAF5L	0.46	6.38	0.39	9.37e-10	Colorectal cancer;
SARC	cis	rs7089973	0.604	rs11196941	chr10:116596258	A/G	cg03647239	chr10:116582469	FAM160B1	0.5	6.45	0.39	6.5e-10	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs6061231	1.000	rs11696991	chr20:60959694	G/T	cg24112000	chr20:60950667	NA	-0.42	-6.83	-0.41	7.37e-11	Colorectal cancer;
SARC	cis	rs6981523	0.553	rs11989369	chr8:11055385	A/G	cg12395012	chr8:11607386	GATA4	-0.33	-5.71	-0.35	3.39e-8	Neuroticism;
SARC	cis	rs2286885	1.000	rs10760438	chr9:129245334	C/A	cg14319473	chr9:129242481	FAM125B	0.39	4.88	0.3	2.01e-6	Intraocular pressure;
SARC	cis	rs112591243	0.570	rs17393980	chr21:47971060	C/T	cg10657630	chr21:48055338	PRMT2	0.81	4.76	0.3	3.47e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs3126085	0.935	rs11204980	chr1:152296191	G/C	cg03465714	chr1:152285911	FLG	0.48	5.59	0.34	6.32e-8	Atopic dermatitis;
SARC	cis	rs7666738	0.962	rs13147921	chr4:99069296	C/G	cg05340658	chr4:99064831	C4orf37	0.57	6.79	0.41	9.36e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs66573146	0.572	rs67922134	chr4:6955772	G/A	cg26116260	chr4:7069785	GRPEL1	-0.68	-5.02	-0.31	1.03e-6	Granulocyte percentage of myeloid white cells;
SARC	cis	rs651907	0.557	rs56291106	chr3:101377474	C/T	cg12386194	chr3:101231763	SENP7	0.51	6.1	0.37	4.43e-9	Colorectal cancer;
SARC	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg04267008	chr7:1944627	MAD1L1	-0.56	-6.34	-0.38	1.21e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs2014572	0.967	rs10411941	chr19:57762886	C/T	cg24459738	chr19:57751996	ZNF805	-0.45	-5.13	-0.32	5.99e-7	Hyperactive-impulsive symptoms;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg00385906	chr1:117910225	MAN1A2	0.52	6.48	0.39	5.32e-10	Height;
SARC	cis	rs7829975	0.617	rs4841071	chr8:8791144	G/T	cg08975724	chr8:8085496	FLJ10661	0.39	4.78	0.3	3.06e-6	Mood instability;
SARC	cis	rs9309473	0.948	rs10170849	chr2:73747932	G/A	cg07208825	chr2:73871855	ALMS1P	0.32	4.78	0.3	3.13e-6	Metabolite levels;
SARC	cis	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg07777115	chr5:623756	CEP72	-0.59	-5.25	-0.33	3.48e-7	Obesity-related traits;
SARC	cis	rs10463554	0.892	rs62362519	chr5:102301463	C/T	cg23492399	chr5:102201601	PAM	-0.46	-5.5	-0.34	1.01e-7	Parkinson's disease;
SARC	cis	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg12463550	chr7:65579703	CRCP	0.7	5.34	0.33	2.21e-7	Gout;
SARC	cis	rs644799	0.544	rs1622515	chr11:95523433	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.74	9.63	0.53	1.12e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs710216	0.536	rs710221	chr1:43414200	G/A	cg07803811	chr1:43423981	SLC2A1	0.63	8.69	0.49	6.35e-16	Red cell distribution width;
SARC	cis	rs2797160	0.651	rs6939969	chr6:126034563	C/T	cg05901451	chr6:126070800	HEY2	0.45	5.52	0.34	8.85e-8	Endometrial cancer;
SARC	cis	rs17081231	0.590	rs17081545	chr13:67165163	A/T	cg09985739	chr13:67621714	PCDH9	-0.66	-4.9	-0.31	1.76e-6	Obesity;
SARC	cis	rs4803468	0.967	rs11670583	chr19:41920440	A/T	cg08477640	chr19:41863820	B9D2	0.45	5.68	0.35	3.94e-8	Height;
SARC	cis	rs787274	1.000	rs1891403	chr9:115527183	C/T	cg13803584	chr9:115635662	SNX30	-0.81	-6.33	-0.38	1.23e-9	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs1067327	1	rs1067327	chr2:44628529	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.71	9.12	0.51	3.55e-17	Anxiety disorder (factor score);
SARC	cis	rs4720575	1.000	rs4720575	chr7:47086805	A/G	cg00036614	chr7:47093842	NA	-0.42	-5.86	-0.36	1.6e-8	Angiotensin-converting enzyme inhibitor intolerance;
SARC	cis	rs1355223	0.545	rs7123029	chr11:34874815	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.5	-6.36	-0.38	1.06e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs924840	0.634	rs2869030	chr15:78711803	A/C	cg06917634	chr15:78832804	PSMA4	-0.43	-4.72	-0.3	4.07e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
SARC	cis	rs9462027	0.583	rs2814947	chr6:34653268	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-6.01	-0.37	6.96e-9	Systemic lupus erythematosus;
SARC	cis	rs2153535	0.580	rs9406158	chr6:8464152	C/T	cg23788917	chr6:8435910	SLC35B3	0.64	8.39	0.48	4.57e-15	Motion sickness;
SARC	cis	rs6570726	0.846	rs441575	chr6:145849205	A/C	cg05347473	chr6:146136440	FBXO30	0.49	6.55	0.39	3.56e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs694739	1.000	rs694739	chr11:64097233	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.67	8.54	0.49	1.71e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs13343954	0.518	rs8106293	chr19:33536376	C/T	cg17764715	chr19:33622953	WDR88	0.51	6.8	0.41	8.55e-11	Colorectal cancer;
SARC	cis	rs12586317	0.620	rs7147571	chr14:35530236	T/C	cg26967526	chr14:35346199	BAZ1A	-0.64	-6.77	-0.41	1.04e-10	Psoriasis;
SARC	cis	rs3091242	0.728	rs706845	chr1:25730713	G/A	cg23205692	chr1:25664452	TMEM50A	0.4	4.82	0.3	2.58e-6	Erythrocyte sedimentation rate;
SARC	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg03354898	chr7:1950403	MAD1L1	-0.36	-4.87	-0.3	2.03e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs6992848	0.791	rs11774304	chr8:141160226	C/T	cg24476153	chr8:142139938	DENND3	-0.32	-4.73	-0.3	3.82e-6	Response to amphetamines;
SARC	cis	rs763121	0.853	rs1569492	chr22:38975511	A/G	cg21395723	chr22:39101663	GTPBP1	-0.49	-5.77	-0.35	2.46e-8	Menopause (age at onset);
SARC	trans	rs3942852	0.696	rs4597030	chr11:48176573	G/A	cg03929089	chr4:120376271	NA	-0.61	-6.92	-0.41	4.3e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg18252515	chr7:66147081	NA	-1.33	-11.84	-0.61	1.22e-25	Diabetic kidney disease;
SARC	cis	rs870825	0.616	rs2141258	chr4:185609576	A/C	cg04058563	chr4:185651563	MLF1IP	-0.79	-10.55	-0.57	1.6e-21	Blood protein levels;
SARC	cis	rs6558174	0.630	rs6558176	chr8:22522502	C/T	cg03733263	chr8:22462867	KIAA1967	-0.59	-6.9	-0.41	4.95e-11	Breast cancer;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg02454053	chr15:85327774	ZNF592	0.5	6.63	0.4	2.26e-10	Schizophrenia;
SARC	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg12696929	chr3:195401817	SDHAP2	0.39	5.26	0.33	3.33e-7	Pancreatic cancer;
SARC	cis	rs2766692	1.000	rs34680851	chr14:100723154	A/G	cg14866419	chr14:100704911	YY1	0.59	6.95	0.41	3.53e-11	Electroencephalographic traits in alcoholism;
SARC	cis	rs2273669	0.915	rs6568554	chr6:109290319	C/A	cg01304950	chr6:109416612	SESN1;C6orf182	0.56	4.91	0.31	1.73e-6	Prostate cancer;
SARC	cis	rs748404	0.578	rs512628	chr15:43618734	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.41	5.19	0.32	4.53e-7	Lung cancer;
SARC	cis	rs3018712	0.532	rs7116363	chr11:68412798	G/A	cg01657329	chr11:68192670	LRP5	0.6	5.44	0.34	1.31e-7	Total body bone mineral density;
SARC	cis	rs796364	0.806	rs11688194	chr2:200916239	C/T	cg23649088	chr2:200775458	C2orf69	-0.6	-5.29	-0.33	2.77e-7	Schizophrenia;
SARC	cis	rs72945132	0.882	rs66989619	chr11:70202127	G/C	cg00319359	chr11:70116639	PPFIA1	0.67	6.19	0.38	2.66e-9	Coronary artery disease;
SARC	cis	rs67311347	0.955	rs6599100	chr3:40447362	C/T	cg09455208	chr3:40491958	NA	0.41	6.41	0.39	7.86e-10	Renal cell carcinoma;
SARC	cis	rs4555082	0.915	rs2816632	chr14:105741355	C/T	cg06808227	chr14:105710500	BRF1	0.56	7.74	0.45	3.02e-13	Mean platelet volume;Platelet distribution width;
SARC	cis	rs7592578	0.771	rs12053190	chr2:191383348	A/G	cg27211696	chr2:191398769	TMEM194B	-0.55	-5.74	-0.35	2.91e-8	Diastolic blood pressure;
SARC	cis	rs995000	0.640	rs4915853	chr1:63191577	C/A	cg06896770	chr1:63153194	DOCK7	-0.56	-7.49	-0.44	1.4e-12	Triglyceride levels;
SARC	cis	rs155076	1.000	rs261406	chr13:21855854	G/A	cg14456004	chr13:21872349	NA	-0.99	-12.51	-0.63	8.42e-28	White matter hyperintensity burden;
SARC	cis	rs739401	0.572	rs384490	chr11:3078885	A/C	cg08508325	chr11:3079039	CARS	-0.31	-7.72	-0.45	3.39e-13	Longevity;
SARC	cis	rs1044826	1.000	rs10935323	chr3:139110135	T/G	cg15131784	chr3:139108705	COPB2	0.45	5.15	0.32	5.55e-7	Obesity-related traits;
SARC	cis	rs3733346	0.553	rs2290403	chr4:942006	G/A	cg23939001	chr4:940644	TMEM175	0.49	7.62	0.45	6.3e-13	Sjögren's syndrome;
SARC	cis	rs7264396	0.635	rs6060682	chr20:34506331	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-7.6	-0.45	7.05e-13	Total cholesterol levels;
SARC	cis	rs9300255	0.602	rs1402274	chr12:123686224	T/C	cg00376283	chr12:123451042	ABCB9	0.55	6.53	0.39	4.09e-10	Neutrophil percentage of white cells;
SARC	trans	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.55	-7.27	-0.43	5.44e-12	Intelligence (multi-trait analysis);
SARC	trans	rs1814175	0.935	rs7950947	chr11:49668369	C/T	cg15704280	chr7:45808275	SEPT13	-0.92	-16.41	-0.73	9.66e-41	Height;
SARC	cis	rs7615952	0.673	rs7632557	chr3:125634881	G/C	cg05084668	chr3:125655381	ALG1L	-0.66	-6.41	-0.39	8.14e-10	Blood pressure (smoking interaction);
SARC	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-7.06	-0.42	1.87e-11	Gut microbiome composition (summer);
SARC	cis	rs6570726	0.935	rs392014	chr6:145843691	A/C	cg05347473	chr6:146136440	FBXO30	0.48	6.5	0.39	4.71e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs13401104	0.796	rs1377447	chr2:237119709	C/T	cg19324714	chr2:237145437	ASB18	0.57	5.93	0.36	1.1e-8	Educational attainment;
SARC	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg06212747	chr3:49208901	KLHDC8B	0.65	8.63	0.49	9.91e-16	Parkinson's disease;
SARC	cis	rs7659604	0.791	rs57316471	chr4:122663939	A/G	cg19671926	chr4:122722719	EXOSC9	-0.51	-6.11	-0.37	4.12e-9	Type 2 diabetes;
SARC	cis	rs7522061	0.546	rs10796982	chr1:157643196	C/T	cg18268488	chr1:157545234	FCRL4	0.26	4.79	0.3	2.9e-6	Blood protein levels;
SARC	cis	rs8114671	0.967	rs2065979	chr20:33767690	T/C	cg24642439	chr20:33292090	TP53INP2	0.51	5.88	0.36	1.4e-8	Height;
SARC	cis	rs17253792	0.822	rs77761669	chr14:56034216	G/A	cg01858014	chr14:56050164	KTN1	-0.68	-5.28	-0.33	3.03e-7	Putamen volume;
SARC	cis	rs56011263	0.687	rs11734460	chr4:705074	C/T	cg05835009	chr4:710272	PCGF3	0.56	6.57	0.4	3.33e-10	White blood cell count;
SARC	cis	rs76419734	1.000	rs72671874	chr4:106661970	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.84	5.56	0.34	7.44e-8	Post bronchodilator FEV1;
SARC	cis	rs2075371	0.897	rs1646733	chr7:134002228	C/A	cg11752832	chr7:134001865	SLC35B4	0.66	8.62	0.49	1.03e-15	Mean platelet volume;
SARC	cis	rs11190604	1.000	rs4919470	chr10:102298920	C/T	cg07080220	chr10:102295463	HIF1AN	0.78	8.81	0.5	2.92e-16	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs6582630	0.537	rs3942440	chr12:38459672	A/G	cg13010199	chr12:38710504	ALG10B	0.75	10.21	0.56	1.79e-20	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg03806693	chr22:41940476	POLR3H	0.88	12.16	0.62	1.15e-26	Vitiligo;
SARC	cis	rs6142102	0.812	rs6059554	chr20:32514092	A/T	cg24642439	chr20:33292090	TP53INP2	0.44	4.74	0.3	3.79e-6	Skin pigmentation;
SARC	cis	rs7819412	0.811	rs2409691	chr8:10943276	C/T	cg00262122	chr8:11665843	FDFT1	-0.4	-5.06	-0.31	8.61e-7	Triglycerides;
SARC	cis	rs10927875	0.619	rs7537101	chr1:16150384	T/C	cg21385522	chr1:16154831	NA	-0.62	-8.48	-0.49	2.61e-15	Dilated cardiomyopathy;
SARC	cis	rs950776	0.518	rs4886572	chr15:78837452	A/G	cg22563815	chr15:78856949	CHRNA5	-0.4	-6.6	-0.4	2.82e-10	Sudden cardiac arrest;
SARC	trans	rs7980799	0.682	rs10437795	chr12:33635336	C/G	cg26384229	chr12:38710491	ALG10B	-0.62	-7.6	-0.45	7.4e-13	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs7089973	0.604	rs61596353	chr10:116597763	T/C	cg03647239	chr10:116582469	FAM160B1	0.5	6.48	0.39	5.49e-10	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg18305652	chr10:134549665	INPP5A	0.36	5.15	0.32	5.46e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs8114671	0.528	rs6119542	chr20:33484545	G/T	cg24642439	chr20:33292090	TP53INP2	0.5	6.14	0.37	3.45e-9	Height;
SARC	cis	rs1008375	1.000	rs10805358	chr4:17652450	A/C	cg27347728	chr4:17578864	LAP3	0.47	5.9	0.36	1.3e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2505675	1.000	rs2479013	chr6:2356979	C/T	cg16550324	chr6:2245327	GMDS	0.42	5.23	0.32	3.68e-7	Tuberculosis;
SARC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg06873352	chr17:61820015	STRADA	0.53	6.94	0.41	3.85e-11	Prudent dietary pattern;
SARC	cis	rs56313388	0.751	rs8057553	chr16:56334990	A/G	cg02433656	chr16:56322654	GNAO1	0.39	5.77	0.35	2.55e-8	Pulse pressure;
SARC	cis	rs4925386	1.000	rs6089351	chr20:60916153	G/A	cg22541963	chr20:60982533	CABLES2	-0.45	-4.93	-0.31	1.57e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs995000	0.899	rs1168045	chr1:62982891	C/T	cg06896770	chr1:63153194	DOCK7	-0.86	-12.54	-0.63	6.66e-28	Triglyceride levels;
SARC	cis	rs7512552	0.839	rs6662108	chr1:150420541	G/T	cg15654264	chr1:150340011	RPRD2	0.39	4.98	0.31	1.25e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs1267303	0.798	rs1267304	chr1:46990426	C/T	cg25110126	chr1:46999211	NA	-0.71	-7.79	-0.45	2.26e-13	Monobrow;
SARC	cis	rs4911259	0.552	rs13037833	chr20:31459562	C/T	cg13636640	chr20:31349939	DNMT3B	-0.7	-9.67	-0.54	8.25e-19	Inflammatory bowel disease;
SARC	cis	rs7824557	0.767	rs6985460	chr8:11171087	A/C	cg21775007	chr8:11205619	TDH	0.49	5.82	0.36	1.98e-8	Retinal vascular caliber;
SARC	trans	rs11098499	0.954	rs3733524	chr4:120423729	T/C	cg25214090	chr10:38739885	LOC399744	0.57	7.33	0.43	3.75e-12	Corneal astigmatism;
SARC	cis	rs13401104	0.796	rs10929165	chr2:237111187	C/G	cg19324714	chr2:237145437	ASB18	0.58	6.02	0.37	6.73e-9	Educational attainment;
SARC	cis	rs7178572	0.568	rs62008452	chr15:77591007	A/G	cg22256960	chr15:77711686	NA	-0.51	-5.6	-0.34	5.87e-8	Type 2 diabetes;
SARC	cis	rs6793245	0.810	rs7429945	chr3:38591689	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.46	-5.44	-0.34	1.31e-7	QT interval;
SARC	cis	rs644799	0.965	rs573758	chr11:95539591	G/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.7	9.55	0.53	1.87e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg03098644	chr7:100410630	EPHB4	0.46	5.1	0.32	6.91e-7	Other erythrocyte phenotypes;
SARC	cis	rs9790314	0.846	rs6791213	chr3:161033721	A/G	cg04691961	chr3:161091175	C3orf57	-0.64	-8.79	-0.5	3.26e-16	Morning vs. evening chronotype;
SARC	cis	rs9399135	1.000	rs4895435	chr6:135293463	C/A	cg24558204	chr6:135376177	HBS1L	0.44	5.79	0.35	2.23e-8	Red blood cell count;
SARC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	11.37	0.6	3.9e-24	Platelet count;
SARC	cis	rs9300255	0.739	rs10846491	chr12:123753492	C/G	cg00376283	chr12:123451042	ABCB9	0.49	5.56	0.34	7.24e-8	Neutrophil percentage of white cells;
SARC	cis	rs7412746	0.634	rs3754212	chr1:150738200	A/G	cg13175981	chr1:150552382	MCL1	-0.48	-5.66	-0.35	4.42e-8	Melanoma;
SARC	cis	rs11792861	0.816	rs7027263	chr9:111699569	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.74	8.7	0.5	5.95e-16	Menarche (age at onset);
SARC	cis	rs7246657	0.943	rs6508711	chr19:37815134	G/T	cg14683738	chr19:37701593	ZNF585B	0.51	4.94	0.31	1.52e-6	Coronary artery calcification;
SARC	cis	rs8114671	0.839	rs6142290	chr20:33654672	A/C	cg24642439	chr20:33292090	TP53INP2	-0.51	-5.96	-0.36	9.12e-9	Height;
SARC	cis	rs4919087	0.923	rs12357266	chr10:98978045	G/A	cg25902810	chr10:99078978	FRAT1	0.47	5.65	0.35	4.64e-8	Monocyte count;
SARC	cis	rs4938330	0.608	rs2239011	chr11:117088994	A/G	cg01368799	chr11:117014884	PAFAH1B2	-0.52	-5.51	-0.34	9.61e-8	Blood protein levels;
SARC	cis	rs11676348	0.729	rs13013361	chr2:218947515	A/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-5.99	-0.37	7.75e-9	Ulcerative colitis;
SARC	cis	rs9790314	1.000	rs9870059	chr3:161017240	T/C	cg03342759	chr3:160939853	NMD3	-0.59	-7.36	-0.43	3.18e-12	Morning vs. evening chronotype;
SARC	cis	rs7772486	0.790	rs9386141	chr6:146268623	T/A	cg23711669	chr6:146136114	FBXO30	-0.76	-11.77	-0.61	2.12e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg09455208	chr3:40491958	NA	0.4	5.84	0.36	1.76e-8	Renal cell carcinoma;
SARC	cis	rs2444240	0.967	rs470645	chr11:120007889	G/T	cg07435449	chr11:120005650	TRIM29	0.29	4.85	0.3	2.29e-6	Corneal curvature;
SARC	cis	rs12142240	0.698	rs1057534	chr1:46815880	A/C	cg00530320	chr1:46809349	NSUN4	0.57	6.92	0.41	4.4e-11	Menopause (age at onset);
SARC	cis	rs9303401	0.614	rs62084387	chr17:57148027	C/T	cg25039879	chr17:56429692	SUPT4H1	0.66	5.6	0.34	6.09e-8	Cognitive test performance;
SARC	cis	rs2777491	1.000	rs2777491	chr15:41735710	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.82	-12.19	-0.62	9.25e-27	Ulcerative colitis;
SARC	cis	rs9486719	1.000	rs11756315	chr6:97008678	A/G	cg06623918	chr6:96969491	KIAA0776	0.79	8.94	0.51	1.21e-16	Migraine;Coronary artery disease;
SARC	cis	rs9436747	0.748	rs1171263	chr1:66001933	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	-0.53	-5.19	-0.32	4.49e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg04166393	chr7:2884313	GNA12	-0.67	-8.03	-0.47	4.68e-14	Height;
SARC	cis	rs4242434	0.819	rs1059592	chr8:22477778	G/A	cg03733263	chr8:22462867	KIAA1967	0.99	16.38	0.73	1.26e-40	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs10489202	1.000	rs3767474	chr1:168062398	C/T	cg24449463	chr1:168025552	DCAF6	-0.6	-6.62	-0.4	2.4e-10	Schizophrenia;
SARC	cis	rs6582630	0.638	rs12425379	chr12:38523705	G/A	cg26384229	chr12:38710491	ALG10B	-0.57	-7.3	-0.43	4.5e-12	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs12134245	0.776	rs12124682	chr1:91995542	A/G	cg25838465	chr1:92012736	NA	-0.68	-9.85	-0.54	2.38e-19	Breast cancer;
SARC	cis	rs116095464	1.000	rs62331562	chr5:349298	G/C	cg22857025	chr5:266934	NA	-1.02	-6.2	-0.38	2.59e-9	Breast cancer;
SARC	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg03934478	chr11:495069	RNH1	0.52	4.86	0.3	2.2e-6	Body mass index;
SARC	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg03453431	chr7:157225567	NA	-0.51	-7.79	-0.45	2.22e-13	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs9462027	0.628	rs6929567	chr6:34692735	T/C	cg07306190	chr6:34760872	UHRF1BP1	0.42	5.91	0.36	1.19e-8	Systemic lupus erythematosus;
SARC	cis	rs6540556	0.723	rs6702301	chr1:209923154	C/T	cg05527609	chr1:210001259	C1orf107	-0.47	-4.87	-0.3	2.1e-6	Red blood cell count;
SARC	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg12463550	chr7:65579703	CRCP	0.47	5.51	0.34	9.32e-8	Aortic root size;
SARC	trans	rs11098499	0.820	rs28535956	chr4:120536858	C/T	cg25214090	chr10:38739885	LOC399744	-0.48	-6.31	-0.38	1.39e-9	Corneal astigmatism;
SARC	trans	rs34421088	0.560	rs2245250	chr8:11400680	G/A	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.49	-0.39	5.02e-10	Neuroticism;
SARC	cis	rs7481584	0.624	rs377765	chr11:3046298	C/T	cg05729581	chr11:3078854	CARS	0.57	7.44	0.44	1.96e-12	Calcium levels;
SARC	cis	rs3806843	0.619	rs2569160	chr5:140028774	T/C	cg16577123	chr5:140027231	NDUFA2;IK	-0.46	-5.33	-0.33	2.29e-7	Depressive symptoms (multi-trait analysis);
SARC	cis	rs763121	0.853	rs9610993	chr22:39042818	C/A	cg06022373	chr22:39101656	GTPBP1	0.9	11.56	0.6	9.96e-25	Menopause (age at onset);
SARC	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg11987759	chr7:65425863	GUSB	-0.58	-7.66	-0.45	4.85e-13	Aortic root size;
SARC	cis	rs9309473	0.500	rs2421582	chr2:73898420	A/G	cg20560298	chr2:73613845	ALMS1	0.51	6.92	0.41	4.42e-11	Metabolite levels;
SARC	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg17971929	chr21:40555470	PSMG1	0.99	13.74	0.67	7.16e-32	Cognitive function;
SARC	trans	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg00938859	chr5:1591904	SDHAP3	0.69	6.36	0.38	1.03e-9	Breast cancer;
SARC	trans	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg17712092	chr4:129076599	LARP1B	0.71	9.61	0.53	1.28e-18	Eosinophil percentage of white cells;
SARC	cis	rs7772486	0.754	rs702319	chr6:146006117	T/C	cg05347473	chr6:146136440	FBXO30	-0.56	-7.86	-0.46	1.43e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2228479	0.867	rs62052168	chr16:89947203	G/A	cg06558623	chr16:89946397	TCF25	0.89	6.28	0.38	1.67e-9	Skin colour saturation;
SARC	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.76	10.71	0.57	4.85e-22	Personality dimensions;
SARC	cis	rs9660992	0.512	rs12142402	chr1:205128215	A/T	cg00857998	chr1:205179979	DSTYK	0.53	6.91	0.41	4.67e-11	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs7264396	0.790	rs761826	chr20:34194243	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.52	-5.57	-0.34	6.85e-8	Total cholesterol levels;
SARC	cis	rs56104184	0.830	rs28556985	chr19:49351149	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.92	-9.68	-0.54	7.77e-19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg16049864	chr8:95962084	TP53INP1	-0.47	-7.69	-0.45	4.04e-13	Type 2 diabetes;
SARC	cis	rs4555082	0.834	rs2816652	chr14:105712493	C/T	cg10792982	chr14:105748885	BRF1	0.54	8.14	0.47	2.36e-14	Mean platelet volume;Platelet distribution width;
SARC	cis	rs12048904	0.505	rs10493936	chr1:101213335	A/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.45	-4.75	-0.3	3.53e-6	Multiple sclerosis;
SARC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.64	-7.83	-0.46	1.67e-13	Longevity;Endometriosis;
SARC	cis	rs6138458	0.962	rs6036976	chr20:24901567	T/G	cg26195577	chr20:24973756	C20orf3	-0.86	-9.46	-0.53	3.56e-18	Blood protein levels;
SARC	cis	rs4742903	0.509	rs7873500	chr9:106965334	T/C	cg14250997	chr9:106856677	SMC2	0.39	4.8	0.3	2.77e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs7607369	0.536	rs13013510	chr2:219667227	A/G	cg02176678	chr2:219576539	TTLL4	-0.38	-5.67	-0.35	4.2e-8	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs7223966	1.000	rs11654335	chr17:61797579	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-5.86	-0.36	1.6e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs28374715	0.635	rs112547435	chr15:41648737	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.03	-16.56	-0.74	3.04e-41	Ulcerative colitis;
SARC	cis	rs2370759	0.945	rs74625866	chr10:32597618	A/T	cg01819863	chr10:32635814	EPC1	1.01	9.95	0.55	1.17e-19	Sexual dysfunction (female);
SARC	cis	rs13077101	0.530	rs11709002	chr3:120471429	G/A	cg24332942	chr3:120408071	RABL3	-0.36	-4.76	-0.3	3.47e-6	Obesity-related traits;
SARC	cis	rs7582720	0.943	rs72934546	chr2:203980033	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	7.8	0.45	2.11e-13	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs6690583	0.623	rs61768853	chr1:85455707	T/C	cg22153463	chr1:85462885	MCOLN2	0.72	6.96	0.42	3.33e-11	Serum sulfate level;
SARC	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg11062466	chr8:58055876	NA	0.52	5.32	0.33	2.43e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.69	-8.89	-0.5	1.72e-16	Longevity;Endometriosis;
SARC	cis	rs143111788	1	rs143111788	chr6:41919175	CCAGCTACT/C	cg17623882	chr6:41773611	USP49	-0.45	-5.75	-0.35	2.72e-8	Red cell distribution width;
SARC	cis	rs834603	0.687	rs13231464	chr7:47481211	A/G	cg23694490	chr7:47445681	TNS3	0.34	6.03	0.37	6.54e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs870825	0.616	rs72705689	chr4:185639894	A/G	cg04058563	chr4:185651563	MLF1IP	0.79	11.24	0.59	1.03e-23	Blood protein levels;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg10663503	chr17:8126298	C17orf44	0.51	6.39	0.39	9.15e-10	Lung adenocarcinoma;
SARC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg12419862	chr22:24373484	LOC391322	-0.66	-8.09	-0.47	3.34e-14	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1538970	0.816	rs12029322	chr1:45970446	C/T	cg05343316	chr1:45956843	TESK2	0.81	8.78	0.5	3.47e-16	Platelet count;
SARC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg09373136	chr17:61933544	TCAM1	-0.45	-6.2	-0.38	2.48e-9	Prudent dietary pattern;
SARC	cis	rs55986470	0.763	rs2280034	chr2:239438298	C/T	cg18131467	chr2:239335373	ASB1	-0.52	-4.85	-0.3	2.27e-6	Chronotype;
SARC	cis	rs7178572	0.568	rs1602925	chr15:77685857	T/C	cg22256960	chr15:77711686	NA	-0.51	-5.59	-0.34	6.36e-8	Type 2 diabetes;
SARC	cis	rs876084	0.505	rs7834024	chr8:121103053	T/C	cg06265175	chr8:121136014	COL14A1	0.57	7.48	0.44	1.47e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.46	-5.42	-0.33	1.45e-7	Renal function-related traits (BUN);
SARC	cis	rs12079745	0.590	rs9628661	chr1:169310283	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.98	-5.75	-0.35	2.79e-8	QT interval;
SARC	cis	rs6964587	0.900	rs6972027	chr7:91781380	T/C	cg17063962	chr7:91808500	NA	0.98	17.34	0.75	7.95e-44	Breast cancer;
SARC	cis	rs17376456	0.542	rs1453003	chr5:93151611	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.51	-5.11	-0.32	6.63e-7	Diabetic retinopathy;
SARC	cis	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg07274523	chr3:49395745	GPX1	0.49	5.59	0.34	6.24e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs2239547	0.522	rs2581801	chr3:52972907	G/T	cg11645453	chr3:52864694	ITIH4	-0.34	-5.32	-0.33	2.4e-7	Schizophrenia;
SARC	cis	rs3737883	1.000	rs10753933	chr1:203026214	T/G	cg03900565	chr1:203031815	PPFIA4	0.35	5.47	0.34	1.13e-7	Early onset atrial fibrillation;
SARC	cis	rs3087591	0.922	rs2905801	chr17:29524974	C/T	cg24425628	chr17:29625626	OMG;NF1	0.54	6.64	0.4	2.14e-10	Hip circumference;
SARC	cis	rs7772486	0.701	rs11155438	chr6:145950112	C/G	cg05347473	chr6:146136440	FBXO30	0.54	7.62	0.45	6.48e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs911555	0.504	rs8006526	chr14:104075015	T/C	cg17925084	chr14:104152323	KLC1	0.39	5.5	0.34	9.94e-8	Intelligence (multi-trait analysis);
SARC	cis	rs11098499	0.865	rs1112817	chr4:120297800	T/C	cg09160332	chr4:120329925	NA	-0.33	-4.77	-0.3	3.27e-6	Corneal astigmatism;
SARC	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.75	8.86	0.5	2.11e-16	Height;
SARC	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg05368731	chr17:41323189	NBR1	0.67	7.91	0.46	1.03e-13	Menopause (age at onset);
SARC	cis	rs8078723	0.714	rs8070444	chr17:38151960	A/G	cg17467752	chr17:38218738	THRA	-0.37	-4.76	-0.3	3.4e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	trans	rs9325144	0.650	rs6582631	chr12:38744135	T/C	cg23762105	chr12:34175262	ALG10	-0.54	-7.1	-0.42	1.45e-11	Morning vs. evening chronotype;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg21789620	chr15:49170180	SHC4;EID1	0.52	6.75	0.4	1.13e-10	Breast cancer;
SARC	cis	rs1609391	0.561	rs6439675	chr3:136625436	G/A	cg15507776	chr3:136538369	TMEM22	0.83	11.54	0.6	1.17e-24	Neuroticism;
SARC	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg18252515	chr7:66147081	NA	1.29	11.17	0.59	1.7e-23	Diabetic kidney disease;
SARC	cis	rs2204008	0.806	rs35534445	chr12:38279093	C/T	cg13010199	chr12:38710504	ALG10B	0.8	11.16	0.59	1.84e-23	Bladder cancer;
SARC	cis	rs7408868	0.908	rs62113794	chr19:15277337	C/A	cg14696996	chr19:15285081	NOTCH3	1.01	8.51	0.49	2.08e-15	Pulse pressure;
SARC	cis	rs7909074	0.899	rs2026428	chr10:45389452	T/C	cg04218760	chr10:45406644	TMEM72	-0.24	-4.83	-0.3	2.53e-6	Mean corpuscular volume;
SARC	cis	rs11190604	1.000	rs3750627	chr10:102275642	G/T	cg14256752	chr10:102295592	HIF1AN	0.43	4.82	0.3	2.64e-6	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-9.15	-0.51	2.85e-17	Alzheimer's disease;
SARC	trans	rs7937682	0.961	rs7119563	chr11:111543916	T/A	cg18187862	chr3:45730750	SACM1L	-0.58	-7.29	-0.43	4.92e-12	Primary sclerosing cholangitis;
SARC	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg02461776	chr11:598696	PHRF1	0.46	4.75	0.3	3.52e-6	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg27266027	chr21:40555129	PSMG1	-0.48	-5.21	-0.32	4.24e-7	Cognitive function;
SARC	trans	rs116095464	0.558	rs7356535	chr5:284117	G/T	cg00938859	chr5:1591904	SDHAP3	0.77	6.36	0.38	1.08e-9	Breast cancer;
SARC	cis	rs644799	0.601	rs662168	chr11:95586982	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.72	10.34	0.56	7.36e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs62344088	0.590	rs6889904	chr5:177264	A/C	cg22496380	chr5:211416	CCDC127	-0.68	-5.23	-0.32	3.84e-7	Asthma (childhood onset);
SARC	cis	rs7772486	0.806	rs4243478	chr6:146284560	A/G	cg23711669	chr6:146136114	FBXO30	-0.76	-11.56	-0.6	9.66e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2290416	0.786	rs77951814	chr8:144657152	C/G	cg10810860	chr8:144639591	GSDMD	-0.72	-4.9	-0.31	1.78e-6	Attention deficit hyperactivity disorder;
SARC	cis	rs3768617	0.510	rs10752899	chr1:183081241	T/G	cg13390022	chr1:182993471	LAMC1	0.32	4.76	0.3	3.47e-6	Fuchs's corneal dystrophy;
SARC	cis	rs4737010	0.501	rs990174	chr8:41632230	A/G	cg08923054	chr8:41654455	ANK1	0.53	6.13	0.37	3.72e-9	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
SARC	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs8141529	0.748	rs715531	chr22:29282679	A/G	cg15103426	chr22:29168792	CCDC117	0.67	8.77	0.5	3.79e-16	Lymphocyte counts;
SARC	cis	rs2806561	0.765	rs2806557	chr1:23503372	T/A	cg12483005	chr1:23474871	LUZP1	0.42	5.54	0.34	8.33e-8	Height;
SARC	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.23e-9	Life satisfaction;
SARC	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7666738	0.753	rs13122897	chr4:98936185	C/A	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9309473	0.948	rs2421577	chr2:73840998	G/T	cg07208825	chr2:73871855	ALMS1P	0.33	4.82	0.3	2.61e-6	Metabolite levels;
SARC	cis	rs7666738	0.830	rs7672901	chr4:98938781	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.83	0.5	2.48e-16	Colonoscopy-negative controls vs population controls;
SARC	trans	rs3780486	0.957	rs10971434	chr9:33168891	C/A	cg04842962	chr6:43655489	MRPS18A	0.97	13.24	0.66	3.29e-30	IgG glycosylation;
SARC	cis	rs10140922	0.966	rs4982260	chr14:35822105	T/A	cg26967526	chr14:35346199	BAZ1A	-0.4	-4.91	-0.31	1.7e-6	Hip circumference adjusted for BMI;
SARC	cis	rs6714710	0.603	rs35255677	chr2:98567820	G/A	cg26665480	chr2:98280029	ACTR1B	0.49	6.58	0.4	3.16e-10	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs4073582	0.555	rs521109	chr11:66030948	G/A	cg14036092	chr11:66035641	RAB1B	0.62	8.92	0.5	1.41e-16	Gout;
SARC	cis	rs11122272	0.525	rs61835222	chr1:231537917	C/A	cg06096015	chr1:231504339	EGLN1	0.37	5.54	0.34	8.27e-8	Hemoglobin concentration;
SARC	cis	rs2645694	0.533	rs2703125	chr4:77819900	T/C	cg18351406	chr4:77819688	ANKRD56	0.45	6.26	0.38	1.81e-9	Emphysema distribution in smoking;
SARC	cis	rs796364	1.000	rs35594306	chr2:200775125	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.74	-6.2	-0.38	2.58e-9	Schizophrenia;
SARC	cis	rs10504229	0.679	rs60869047	chr8:58053221	G/A	cg20607798	chr8:58055168	NA	0.6	5.58	0.34	6.63e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg06028808	chr11:68637592	NA	0.47	5.93	0.36	1.08e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg11203670	chr7:100026453	MEPCE;ZCWPW1	0.48	4.75	0.3	3.55e-6	Platelet count;
SARC	cis	rs7666738	0.546	rs7699578	chr4:98838893	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.75	0.35	2.83e-8	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4919694	0.808	rs4918001	chr10:105013147	G/T	cg04362960	chr10:104952993	NT5C2	-0.68	-5.46	-0.34	1.22e-7	Arsenic metabolism;
SARC	cis	rs372883	0.648	rs368322	chr21:30717151	C/T	cg24692254	chr21:30365293	RNF160	-0.65	-8.28	-0.48	9.76e-15	Pancreatic cancer;
SARC	cis	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg09021430	chr5:549028	NA	-0.44	-5.81	-0.36	2.09e-8	Obesity-related traits;
SARC	cis	rs644799	0.965	rs545342	chr11:95545369	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.7	9.55	0.53	1.87e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg26116260	chr4:7069785	GRPEL1	-0.81	-8.78	-0.5	3.48e-16	Monocyte percentage of white cells;
SARC	cis	rs1538970	0.924	rs12037201	chr1:45941349	G/T	cg05343316	chr1:45956843	TESK2	0.77	8.63	0.49	9.49e-16	Platelet count;
SARC	cis	rs9818758	0.607	rs11719220	chr3:49245201	A/G	cg01304814	chr3:48885189	PRKAR2A	0.61	5.0	0.31	1.13e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.62	7.75	0.45	2.75e-13	Lymphocyte counts;
SARC	trans	rs804280	0.518	rs34266352	chr8:11791462	G/A	cg06636001	chr8:8085503	FLJ10661	0.5	6.28	0.38	1.64e-9	Myopia (pathological);
SARC	cis	rs3767633	0.748	rs6667896	chr1:161837407	G/A	cg09175582	chr1:161736000	ATF6	0.68	5.91	0.36	1.21e-8	IgG glycosylation;
SARC	cis	rs9916302	0.904	rs7221875	chr17:37543328	G/A	cg00129232	chr17:37814104	STARD3	0.61	7.6	0.45	7.17e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs7829975	0.744	rs2409092	chr8:8682192	A/T	cg15556689	chr8:8085844	FLJ10661	0.44	5.5	0.34	1.01e-7	Mood instability;
SARC	cis	rs4901847	0.967	rs4901846	chr14:58553582	G/C	cg15908186	chr14:58618357	C14orf37	0.45	5.07	0.31	8.26e-7	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs9393777	0.546	rs35589403	chr6:27219491	C/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.36	-4.84	-0.3	2.34e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7917772	0.599	rs2863717	chr10:104519829	A/G	ch.10.2196322F	chr10:104248062	ACTR1A	-0.46	-5.39	-0.33	1.76e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.33	-5.02	-0.31	1.03e-6	Total body bone mineral density;
SARC	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg00908189	chr16:619842	PIGQ	0.84	12.3	0.63	4.01e-27	Height;
SARC	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg22484793	chr3:52261325	TLR9	0.29	4.77	0.3	3.31e-6	Bipolar disorder;
SARC	cis	rs2072499	0.966	rs2842882	chr1:156165342	T/G	cg24450063	chr1:156163899	SLC25A44	1.18	21.2	0.81	2.66e-56	Testicular germ cell tumor;
SARC	cis	rs6795744	0.908	rs9864031	chr3:13908071	T/G	cg19554555	chr3:13937349	NA	0.52	4.76	0.3	3.46e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs710216	0.763	rs698046	chr1:43446606	C/T	cg03128534	chr1:43423976	SLC2A1	0.5	5.1	0.32	7.11e-7	Red cell distribution width;
SARC	cis	rs7481584	1.000	rs12789474	chr11:3024139	T/G	cg05729581	chr11:3078854	CARS	0.47	5.77	0.35	2.56e-8	Calcium levels;
SARC	cis	rs2239547	0.657	rs4687554	chr3:52864135	T/C	cg18404041	chr3:52824283	ITIH1	-0.42	-5.07	-0.32	8.09e-7	Schizophrenia;
SARC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg17178900	chr1:205818956	PM20D1	0.74	11.2	0.59	1.39e-23	Menarche (age at onset);
SARC	cis	rs3768617	0.811	rs12138049	chr1:182979546	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.64	8.73	0.5	4.89e-16	Fuchs's corneal dystrophy;
SARC	cis	rs12142240	0.698	rs66911505	chr1:46823298	A/G	cg14993813	chr1:46806288	NSUN4	-0.51	-5.34	-0.33	2.19e-7	Menopause (age at onset);
SARC	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg11890956	chr21:40555474	PSMG1	-0.69	-8.96	-0.51	1.04e-16	Menarche (age at onset);
SARC	cis	rs858239	0.600	rs4321896	chr7:23128056	G/A	cg23682824	chr7:23144976	KLHL7	0.71	9.42	0.53	4.53e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg07701084	chr6:150067640	NUP43	0.39	5.15	0.32	5.56e-7	Lung cancer;
SARC	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg07685180	chr8:600429	NA	0.74	5.81	0.36	2.04e-8	IgG glycosylation;
SARC	cis	rs6570726	0.967	rs373527	chr6:145801861	C/T	cg23711669	chr6:146136114	FBXO30	0.71	10.61	0.57	1.07e-21	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11203032	0.831	rs61853069	chr10:90935641	C/G	cg16672925	chr10:90967113	CH25H	0.53	5.8	0.36	2.16e-8	Heart failure;
SARC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg17158414	chr2:27665306	KRTCAP3	0.39	6.64	0.4	2.17e-10	Total body bone mineral density;
SARC	cis	rs9341808	0.754	rs10733162	chr6:81023389	G/A	cg08355045	chr6:80787529	NA	0.37	5.95	0.36	9.6e-9	Sitting height ratio;
SARC	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg24399712	chr22:39784796	NA	-0.41	-5.49	-0.34	1.05e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9682041	0.561	rs7643214	chr3:170144281	C/T	cg11886554	chr3:170076028	SKIL	0.84	7.67	0.45	4.61e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs2916247	1.000	rs2976510	chr8:93005015	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.52	-5.57	-0.34	6.98e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9291683	0.507	rs3775940	chr4:10025163	A/T	cg11266682	chr4:10021025	SLC2A9	0.4	7.07	0.42	1.76e-11	Bone mineral density;
SARC	cis	rs733592	0.507	rs10747529	chr12:48473369	G/A	cg21466736	chr12:48725269	NA	0.31	5.37	0.33	1.95e-7	Plateletcrit;
SARC	cis	rs1008375	0.843	rs59112113	chr4:17685336	A/T	cg27347728	chr4:17578864	LAP3	0.46	5.68	0.35	3.92e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	8.51	0.49	2.13e-15	Mean platelet volume;
SARC	cis	rs4308124	0.708	rs28766030	chr2:111962429	T/C	cg04571233	chr2:111982156	NA	-0.48	-5.59	-0.34	6.46e-8	Vitiligo;
SARC	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg12310025	chr6:25882481	NA	0.49	6.31	0.38	1.38e-9	Blood metabolite levels;
SARC	cis	rs7084402	0.967	rs1658454	chr10:60306770	G/A	cg07615347	chr10:60278583	BICC1	0.59	8.61	0.49	1.12e-15	Refractive error;
SARC	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg24846343	chr22:24311635	DDTL	0.53	7.05	0.42	2.03e-11	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2425143	1.000	rs55761608	chr20:34344226	A/C	cg01084648	chr20:34329383	RBM39	0.65	5.04	0.31	9.47e-7	Blood protein levels;
SARC	cis	rs2839627	0.561	rs6586250	chr21:44270229	C/T	cg03543861	chr21:44258195	NA	0.46	5.06	0.31	8.55e-7	Information processing speed;
SARC	trans	rs7980799	0.682	rs1601005	chr12:33634658	A/G	cg26384229	chr12:38710491	ALG10B	-0.62	-7.55	-0.44	9.98e-13	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs7223966	1.000	rs6504173	chr17:61735056	T/C	cg00588841	chr17:61851480	DDX42;CCDC47	-0.58	-6.59	-0.4	2.88e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs11112613	0.762	rs17037312	chr12:105950085	C/T	cg03607813	chr12:105948248	NA	0.56	7.54	0.44	1.06e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs2576037	0.796	rs2247021	chr18:44578794	A/C	cg15049968	chr18:44337910	ST8SIA5	-0.33	-5.37	-0.33	1.93e-7	Personality dimensions;
SARC	cis	rs9916302	0.706	rs8073907	chr17:37424149	C/T	cg00129232	chr17:37814104	STARD3	-0.56	-6.06	-0.37	5.37e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs8141529	0.778	rs763073	chr22:29215542	G/A	cg02153584	chr22:29168773	CCDC117	0.79	11.72	0.61	3.15e-25	Lymphocyte counts;
SARC	cis	rs7927771	1.000	rs34128973	chr11:47851376	C/T	cg05585544	chr11:47624801	NA	-0.36	-4.82	-0.3	2.59e-6	Subjective well-being;
SARC	cis	rs6466055	0.748	rs10266871	chr7:104812129	G/A	cg04380332	chr7:105027541	SRPK2	-0.39	-4.74	-0.3	3.66e-6	Schizophrenia;
SARC	cis	rs611744	0.934	rs672591	chr8:109192453	T/A	cg21045802	chr8:109455806	TTC35	0.44	5.3	0.33	2.63e-7	Dupuytren's disease;
SARC	cis	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg06212747	chr3:49208901	KLHDC8B	0.58	5.82	0.36	1.95e-8	Menarche (age at onset);
SARC	cis	rs2180341	1.000	rs2180341	chr6:127600630	C/T	cg24812749	chr6:127587940	RNF146	0.97	12.65	0.64	2.79e-28	Breast cancer;
SARC	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg18876405	chr7:65276391	NA	0.46	5.21	0.32	4.22e-7	Aortic root size;
SARC	cis	rs2718058	0.519	rs2722242	chr7:37873610	A/G	cg15028436	chr7:37888078	TXNDC3	-0.39	-5.42	-0.33	1.51e-7	Alzheimer's disease (late onset);
SARC	cis	rs28374715	0.662	rs691906	chr15:41474636	T/A	cg18705301	chr15:41695430	NDUFAF1	0.95	14.14	0.68	3.4e-33	Ulcerative colitis;
SARC	cis	rs1057510	1.000	rs1057510	chr12:6683287	C/T	cg25922808	chr12:6862832	MLF2	0.46	4.73	0.3	3.82e-6	Myopia (pathological);
SARC	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg00933542	chr6:150070202	PCMT1	0.32	5.31	0.33	2.6e-7	Lung cancer;
SARC	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.64	-7.41	-0.44	2.37e-12	Gut microbiome composition (summer);
SARC	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg19077165	chr18:44547161	KATNAL2	-0.55	-7.57	-0.44	8.67e-13	Personality dimensions;
SARC	cis	rs7662987	0.517	rs1311617	chr4:100012425	T/G	cg12011299	chr4:100065546	ADH4	0.32	5.24	0.32	3.6e-7	Smoking initiation;
SARC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg11203670	chr7:100026453	MEPCE;ZCWPW1	0.48	4.76	0.3	3.43e-6	Platelet count;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg00333315	chr19:4670412	C19orf10	0.47	6.34	0.38	1.18e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	trans	rs1973993	0.691	rs2985636	chr1:96889884	T/A	cg10631902	chr5:14652156	NA	0.5	8.65	0.49	8.61e-16	Weight;
SARC	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg01316550	chr5:56110833	MAP3K1	0.54	4.92	0.31	1.62e-6	Initial pursuit acceleration;
SARC	cis	rs7568458	0.905	rs6714709	chr2:85756375	C/G	cg23752985	chr2:85803571	VAMP8	0.33	4.81	0.3	2.76e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs8016982	0.633	rs72695758	chr14:81720146	T/C	cg01989461	chr14:81687754	GTF2A1	0.73	11.03	0.59	4.74e-23	Schizophrenia;
SARC	cis	rs3820928	0.692	rs2396434	chr2:227775223	G/T	cg05526886	chr2:227700861	RHBDD1	-0.46	-5.87	-0.36	1.5e-8	Pulmonary function;
SARC	cis	rs7712401	0.601	rs404442	chr5:122344931	C/T	cg19412675	chr5:122181750	SNX24	-0.42	-5.35	-0.33	2.09e-7	Mean platelet volume;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27622633	chr4:120133607	USP53	-0.51	-6.27	-0.38	1.7e-9	Fibrinogen levels;
SARC	cis	rs7264396	0.513	rs3787169	chr20:34419884	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	5.23	0.32	3.75e-7	Total cholesterol levels;
SARC	cis	rs9790314	1.000	rs336579	chr3:161086610	G/A	cg04691961	chr3:161091175	C3orf57	-0.81	-12.45	-0.63	1.28e-27	Morning vs. evening chronotype;
SARC	cis	rs3815700	1.000	rs2287670	chr19:33095057	G/A	cg24916020	chr19:33096688	ANKRD27	0.57	5.47	0.34	1.15e-7	Eosinophilic esophagitis;
SARC	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg05793240	chr7:2802953	GNA12	-0.37	-5.09	-0.32	7.39e-7	Height;
SARC	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg11062466	chr8:58055876	NA	0.7	6.14	0.37	3.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7953249	0.656	rs2251468	chr12:121405126	A/C	cg15155738	chr12:121454335	C12orf43	0.45	5.67	0.35	4.11e-8	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs72781680	0.560	rs72781698	chr2:24271506	C/T	cg06627628	chr2:24431161	ITSN2	-0.61	-6.04	-0.37	6.18e-9	Lymphocyte counts;
SARC	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg09455208	chr3:40491958	NA	-0.36	-5.52	-0.34	8.85e-8	Renal cell carcinoma;
SARC	cis	rs910316	1.000	rs8003506	chr14:75586288	A/C	cg08847533	chr14:75593920	NEK9	-0.92	-15.0	-0.7	4.72e-36	Height;
SARC	cis	rs6580649	0.843	rs3803184	chr12:48398002	G/C	cg24011408	chr12:48396354	COL2A1	0.55	6.23	0.38	2.12e-9	Lung cancer;
SARC	cis	rs1044826	0.692	rs176987	chr3:139233001	G/A	cg15131784	chr3:139108705	COPB2	-0.4	-5.12	-0.32	6.51e-7	Obesity-related traits;
SARC	cis	rs765787	0.530	rs2554453	chr15:45522107	A/G	cg25801113	chr15:45476975	SHF	0.31	5.12	0.32	6.38e-7	Uric acid levels;
SARC	cis	rs597539	0.727	rs632984	chr11:68620271	C/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.44	4.95	0.31	1.46e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs1707322	0.963	rs6429581	chr1:46319096	G/A	cg03146154	chr1:46216737	IPP	0.51	6.12	0.37	3.9e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs17376456	0.825	rs34967135	chr5:93221785	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.62	5.64	0.35	4.83e-8	Diabetic retinopathy;
SARC	trans	rs1910358	0.554	rs10057796	chr5:23759746	C/T	cg11843502	chr1:7843515	PER3	-0.56	-6.38	-0.39	9.52e-10	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs1545257	0.505	rs7595372	chr2:24632122	A/C	cg06627628	chr2:24431161	ITSN2	-0.57	-7.37	-0.43	2.91e-12	Sjögren's syndrome;
SARC	cis	rs9814567	1.000	rs7637227	chr3:134244155	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.1	-0.42	1.49e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs761746	0.804	rs5749304	chr22:31967775	A/G	cg15162869	chr22:32027605	PISD	0.38	5.34	0.33	2.21e-7	Intelligence;
SARC	cis	rs2594989	0.943	rs4580536	chr3:11422319	A/G	cg00170343	chr3:11313890	ATG7	0.58	5.66	0.35	4.33e-8	Circulating chemerin levels;
SARC	cis	rs2239547	0.563	rs6797399	chr3:52905917	G/A	cg18404041	chr3:52824283	ITIH1	-0.39	-4.73	-0.3	3.94e-6	Schizophrenia;
SARC	cis	rs11676348	0.703	rs6737563	chr2:218945674	T/C	cg00012203	chr2:219082015	ARPC2	-0.53	-6.95	-0.41	3.53e-11	Ulcerative colitis;
SARC	cis	rs6570726	0.764	rs366673	chr6:145814628	T/A	cg23711669	chr6:146136114	FBXO30	0.87	14.62	0.69	8.73e-35	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg18876405	chr7:65276391	NA	-0.44	-4.93	-0.31	1.56e-6	Aortic root size;
SARC	cis	rs9790314	0.613	rs34297047	chr3:160631478	A/G	cg04691961	chr3:161091175	C3orf57	0.53	7.3	0.43	4.61e-12	Morning vs. evening chronotype;
SARC	cis	rs34172651	0.917	rs2112786	chr16:24778944	C/T	cg00152838	chr16:24741724	TNRC6A	-0.43	-5.38	-0.33	1.8e-7	Intelligence (multi-trait analysis);
SARC	cis	rs244731	0.920	rs244707	chr5:176555636	A/T	cg17509989	chr5:176798049	RGS14	0.68	8.33	0.48	7.09e-15	Urate levels in lean individuals;
SARC	cis	rs6807306	1.000	rs6769769	chr3:167443156	T/C	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.56	5.48	0.34	1.1e-7	Mean platelet volume;
SARC	cis	rs76419734	1.000	rs72673872	chr4:106779925	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	5.31	0.33	2.52e-7	Post bronchodilator FEV1;
SARC	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg11764359	chr7:65958608	NA	-0.78	-9.41	-0.52	4.93e-18	Aortic root size;
SARC	cis	rs10504229	0.679	rs12375445	chr8:58040082	A/G	cg08280861	chr8:58055591	NA	0.56	5.22	0.32	4.01e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2228479	0.850	rs17227064	chr16:89816314	A/G	cg06558623	chr16:89946397	TCF25	0.88	6.21	0.38	2.39e-9	Skin colour saturation;
SARC	cis	rs11792861	0.781	rs72607159	chr9:111764270	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.73	8.54	0.49	1.78e-15	Menarche (age at onset);
SARC	cis	rs8067354	0.645	rs2665403	chr17:57889985	G/A	cg13753209	chr17:57696993	CLTC	0.62	6.28	0.38	1.62e-9	Hemoglobin concentration;
SARC	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg06212747	chr3:49208901	KLHDC8B	0.88	13.79	0.67	5.09e-32	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs7659604	0.540	rs4240264	chr4:122683818	A/G	cg19671926	chr4:122722719	EXOSC9	0.59	7.75	0.45	2.8e-13	Type 2 diabetes;
SARC	cis	rs858239	0.571	rs2390755	chr7:23190716	A/T	cg23682824	chr7:23144976	KLHL7	0.74	9.66	0.53	8.86e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs4141404	0.787	rs4820042	chr22:31589056	T/C	cg07713946	chr22:31675144	LIMK2	-0.38	-5.29	-0.33	2.76e-7	Paclitaxel-induced neuropathy;
SARC	cis	rs4481887	0.893	rs28451623	chr1:248509783	G/A	cg01631408	chr1:248437212	OR2T33	-0.44	-5.89	-0.36	1.34e-8	Common traits (Other);
SARC	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg22834771	chr12:69754056	YEATS4	-0.44	-5.78	-0.35	2.42e-8	Blood protein levels;
SARC	cis	rs17125944	0.505	rs74642116	chr14:53213507	A/G	cg00686598	chr14:53173677	PSMC6	1.3	9.0	0.51	8.31e-17	Alzheimer's disease (late onset);
SARC	cis	rs10463554	0.963	rs1552916	chr5:102337740	A/G	cg23492399	chr5:102201601	PAM	-0.47	-5.46	-0.34	1.2e-7	Parkinson's disease;
SARC	cis	rs1971762	0.563	rs7975862	chr12:54078427	A/C	cg02675414	chr12:54089240	NA	-0.31	-4.8	-0.3	2.85e-6	Height;
SARC	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg03709012	chr19:19516395	GATAD2A	-0.96	-15.36	-0.71	2.92e-37	Tonsillectomy;
SARC	cis	rs11758351	0.660	rs11757754	chr6:26219744	A/C	cg01420254	chr6:26195488	NA	0.55	4.75	0.3	3.49e-6	Gout;Renal underexcretion gout;
SARC	cis	rs9398803	0.687	rs7743860	chr6:126927717	T/G	cg20229609	chr6:126660872	C6orf173	0.37	5.39	0.33	1.74e-7	Male-pattern baldness;
SARC	cis	rs9911578	0.933	rs11868348	chr17:57179238	C/T	cg05425664	chr17:57184151	TRIM37	-0.63	-7.9	-0.46	1.07e-13	Intelligence (multi-trait analysis);
SARC	cis	rs73001065	0.591	rs56273306	chr19:19621004	T/C	cg03709012	chr19:19516395	GATAD2A	1.09	7.49	0.44	1.44e-12	LDL cholesterol;
SARC	cis	rs9309473	0.948	rs10173534	chr2:73813432	C/T	cg20560298	chr2:73613845	ALMS1	-0.48	-5.85	-0.36	1.67e-8	Metabolite levels;
SARC	cis	rs6696846	0.703	rs112653854	chr1:205079251	G/T	cg21643547	chr1:205240462	TMCC2	-0.58	-7.73	-0.45	3.12e-13	Red blood cell count;
SARC	cis	rs2153535	0.547	rs9505475	chr6:8542890	A/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.64	0.49	9.03e-16	Motion sickness;
SARC	cis	rs910316	0.712	rs175015	chr14:75457075	A/C	cg08847533	chr14:75593920	NEK9	-0.82	-11.41	-0.6	3.09e-24	Height;
SARC	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg03351412	chr1:154909251	PMVK	0.61	7.91	0.46	1.03e-13	Prostate cancer;
SARC	cis	rs651907	0.557	rs13069443	chr3:101373305	C/T	cg12386194	chr3:101231763	SENP7	0.51	6.1	0.37	4.43e-9	Colorectal cancer;
SARC	cis	rs7412746	0.611	rs12410869	chr1:150856153	G/T	cg10589385	chr1:150898437	SETDB1	0.39	5.11	0.32	6.62e-7	Melanoma;
SARC	cis	rs6831352	1.000	rs6822348	chr4:100053894	A/T	cg13256891	chr4:100009986	ADH5	0.65	8.54	0.49	1.77e-15	Alcohol dependence;
SARC	cis	rs453301	0.624	rs2915251	chr8:8867411	G/C	cg11995313	chr8:8860691	ERI1	-0.38	-5.12	-0.32	6.44e-7	Joint mobility (Beighton score);
SARC	cis	rs6696846	0.740	rs17344537	chr1:205091427	T/G	cg00857998	chr1:205179979	DSTYK	0.49	6.13	0.37	3.73e-9	Red blood cell count;
SARC	cis	rs2694528	0.844	rs4541610	chr5:60065941	A/C	cg11474532	chr5:59995715	DEPDC1B	-0.71	-5.04	-0.31	9.31e-7	Parkinson's disease;
SARC	cis	rs13272623	0.502	rs268628	chr8:71560505	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.46	-4.77	-0.3	3.2e-6	IgG glycosylation;
SARC	cis	rs7568458	0.870	rs1562323	chr2:85809711	T/C	cg17127132	chr2:85788382	GGCX	0.43	5.8	0.36	2.13e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs959260	0.557	rs12936583	chr17:73304710	A/C	cg14668889	chr17:73230827	NUP85	0.56	7.12	0.42	1.31e-11	Systemic lupus erythematosus;
SARC	cis	rs9905704	0.756	rs302860	chr17:56695008	C/A	cg12560992	chr17:57184187	TRIM37	0.42	4.87	0.3	2.03e-6	Testicular germ cell tumor;
SARC	cis	rs8067545	0.641	rs169412	chr17:19851875	G/T	cg04132472	chr17:19861366	AKAP10	0.38	5.04	0.31	9.29e-7	Schizophrenia;
SARC	cis	rs9814567	1.000	rs7356093	chr3:134238753	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.03	-0.42	2.24e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs11710088	0.599	rs4681509	chr3:149201444	A/G	cg08667024	chr3:149219783	TM4SF4	-0.37	-5.55	-0.34	7.78e-8	QRS duration;
SARC	cis	rs6142102	0.812	rs725478	chr20:32518354	A/G	cg24642439	chr20:33292090	TP53INP2	-0.45	-4.86	-0.3	2.13e-6	Skin pigmentation;
SARC	cis	rs710216	0.957	rs841563	chr1:43429520	C/T	cg03128534	chr1:43423976	SLC2A1	0.66	6.64	0.4	2.17e-10	Red cell distribution width;
SARC	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	12.03	0.62	3.06e-26	Chronic sinus infection;
SARC	cis	rs9788682	1.000	rs7164594	chr15:78803057	C/T	cg06917634	chr15:78832804	PSMA4	-0.56	-6.33	-0.38	1.27e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs4481887	0.927	rs4453080	chr1:248474671	T/C	cg01631408	chr1:248437212	OR2T33	-0.39	-5.06	-0.31	8.56e-7	Common traits (Other);
SARC	cis	rs9916302	0.904	rs2338800	chr17:37498149	C/G	cg20243544	chr17:37824526	PNMT	-0.53	-6.26	-0.38	1.87e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs9392918	0.934	rs12194650	chr6:7720539	T/C	cg23089261	chr6:7723385	NA	0.37	4.98	0.31	1.22e-6	Height;
SARC	trans	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg21659725	chr3:3221576	CRBN	0.8	11.9	0.61	7.82e-26	Intelligence (multi-trait analysis);
SARC	cis	rs728616	0.614	rs10887199	chr10:81702834	T/C	cg05935833	chr10:81318306	SFTPA2	-0.42	-5.01	-0.31	1.07e-6	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg18099408	chr3:52552593	STAB1	-0.4	-5.22	-0.32	3.99e-7	Electroencephalogram traits;
SARC	cis	rs826838	1.000	rs4575342	chr12:38663831	G/A	cg26384229	chr12:38710491	ALG10B	0.93	14.73	0.69	3.88e-35	Heart rate;
SARC	cis	rs1215050	0.740	rs1084784	chr4:98961711	T/G	cg05340658	chr4:99064831	C4orf37	-0.46	-6.22	-0.38	2.26e-9	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs2576037	0.796	rs2247021	chr18:44578794	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-6.58	-0.4	3.05e-10	Personality dimensions;
SARC	cis	rs854765	0.616	rs8076747	chr17:17853595	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.42	5.22	0.32	3.97e-7	Total body bone mineral density;
SARC	cis	rs1949733	0.628	rs2688231	chr4:8490981	G/A	cg11789530	chr4:8429930	ACOX3	0.76	9.92	0.55	1.4e-19	Response to antineoplastic agents;
SARC	cis	rs8141529	0.719	rs6005916	chr22:29233342	T/C	cg15103426	chr22:29168792	CCDC117	0.67	8.88	0.5	1.8e-16	Lymphocyte counts;
SARC	trans	rs9329221	0.683	rs658385	chr8:9892177	C/T	cg06636001	chr8:8085503	FLJ10661	-0.69	-10.03	-0.55	6.51e-20	Neuroticism;
SARC	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	14.0	0.68	9.94e-33	Chronic sinus infection;
SARC	cis	rs2952156	0.959	rs2952151	chr17:37828496	T/C	cg00129232	chr17:37814104	STARD3	-0.7	-9.68	-0.54	7.43e-19	Asthma;
SARC	cis	rs9392918	0.967	rs6927500	chr6:7706004	A/G	cg23089261	chr6:7723385	NA	-0.4	-5.39	-0.33	1.71e-7	Height;
SARC	cis	rs7326068	0.543	rs2785740	chr13:21423525	C/G	cg16922012	chr13:21400325	XPO4	-0.42	-5.55	-0.34	7.62e-8	Schizophrenia, bipolar disorder and depression (combined);
SARC	cis	rs7474896	0.515	rs662928	chr10:38316216	G/T	cg00409905	chr10:38381863	ZNF37A	0.44	4.93	0.31	1.57e-6	Obesity (extreme);
SARC	cis	rs3733585	0.781	rs57250714	chr4:9984529	C/T	cg00071950	chr4:10020882	SLC2A9	0.39	5.97	0.36	8.69e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs3733585	0.699	rs7437120	chr4:9967683	T/A	cg11266682	chr4:10021025	SLC2A9	-0.39	-6.77	-0.41	1.05e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs2075371	0.966	rs1619682	chr7:133996703	T/G	cg11752832	chr7:134001865	SLC35B4	0.56	7.1	0.42	1.47e-11	Mean platelet volume;
SARC	cis	rs981844	0.645	rs72731677	chr4:154671475	C/G	cg14289246	chr4:154710475	SFRP2	0.59	6.62	0.4	2.43e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.76	8.66	0.49	8.14e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4561483	0.831	rs2018199	chr16:11940968	C/T	cg08843971	chr16:11963173	GSPT1	-0.41	-4.75	-0.3	3.61e-6	Testicular germ cell tumor;
SARC	cis	rs13031619	0.517	rs10864995	chr2:3683557	C/T	cg26479022	chr2:3695865	NA	0.42	5.21	0.32	4.14e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
SARC	cis	rs793571	0.662	rs964285	chr15:59170964	A/G	cg05156742	chr15:59063176	FAM63B	-0.5	-5.93	-0.36	1.11e-8	Schizophrenia;
SARC	cis	rs4713118	0.540	rs469227	chr6:27970705	A/C	cg17221315	chr6:27791827	HIST1H4J	0.48	4.94	0.31	1.47e-6	Parkinson's disease;
SARC	cis	rs6665290	0.904	rs1343743	chr1:227183125	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.08	-24.92	-0.85	1.15e-67	Myeloid white cell count;
SARC	cis	rs2304069	0.954	rs2340462	chr5:149415219	G/A	cg12661370	chr5:149340060	SLC26A2	0.48	4.87	0.3	2.06e-6	HIV-1 control;
SARC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg11494091	chr17:61959527	GH2	-0.6	-9.74	-0.54	5.05e-19	Prudent dietary pattern;
SARC	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.76	11.2	0.59	1.36e-23	Personality dimensions;
SARC	cis	rs1865760	0.566	rs2051544	chr6:26071093	C/T	cg16482183	chr6:26056742	HIST1H1C	0.48	6.01	0.37	7.1e-9	Height;
SARC	cis	rs644799	0.710	rs10765771	chr11:95521044	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.61	8.19	0.47	1.77e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg26681399	chr22:41777847	TEF	-0.48	-5.2	-0.32	4.34e-7	Vitiligo;
SARC	cis	rs72627123	0.867	rs113257091	chr14:74461121	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.77	5.86	0.36	1.6e-8	Morning vs. evening chronotype;
SARC	trans	rs7980799	0.653	rs10844613	chr12:33605362	A/G	cg26384229	chr12:38710491	ALG10B	-0.58	-6.95	-0.41	3.68e-11	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg25072359	chr17:41440525	NA	0.51	6.04	0.37	6.2e-9	Menopause (age at onset);
SARC	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7274811	0.681	rs293733	chr20:31975976	C/T	cg21523528	chr20:32077966	CBFA2T2	-0.42	-4.95	-0.31	1.4e-6	Height;
SARC	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg23172400	chr8:95962367	TP53INP1	-0.35	-5.96	-0.36	9.5e-9	Type 2 diabetes;
SARC	cis	rs6964587	1.000	rs17164263	chr7:91581566	T/A	cg17063962	chr7:91808500	NA	-0.94	-15.25	-0.71	6.82e-37	Breast cancer;
SARC	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg19223190	chr17:80058835	NA	0.44	6.19	0.38	2.67e-9	Life satisfaction;
SARC	cis	rs2963155	0.518	rs72801090	chr5:142774692	C/T	cg17617527	chr5:142782415	NR3C1	0.78	6.27	0.38	1.77e-9	Breast cancer;
SARC	cis	rs12701220	0.590	rs1881124	chr7:1096766	A/C	cg02733842	chr7:1102375	C7orf50	-0.6	-6.97	-0.42	3.23e-11	Bronchopulmonary dysplasia;
SARC	cis	rs9951698	0.518	rs475438	chr18:13073641	C/T	cg12848697	chr18:13133368	NA	0.38	4.91	0.31	1.7e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg18404041	chr3:52824283	ITIH1	-0.44	-6.59	-0.4	2.82e-10	Bipolar disorder;
SARC	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg16405210	chr4:1374714	KIAA1530	-0.44	-5.45	-0.34	1.29e-7	Longevity;
SARC	cis	rs3087591	1.000	rs2854322	chr17:29699416	C/T	cg24425628	chr17:29625626	OMG;NF1	0.53	6.43	0.39	7.17e-10	Hip circumference;
SARC	cis	rs9611519	1.000	rs5758267	chr22:41619350	A/T	cg17376030	chr22:41985996	PMM1	-0.44	-5.31	-0.33	2.53e-7	Neuroticism;
SARC	cis	rs2153535	0.580	rs9392224	chr6:8472614	G/A	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	cis	rs6952808	0.636	rs73048162	chr7:1949328	T/C	cg04267008	chr7:1944627	MAD1L1	-0.49	-5.57	-0.34	7e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg24549020	chr5:56110836	MAP3K1	-0.79	-8.14	-0.47	2.43e-14	Initial pursuit acceleration;
SARC	cis	rs80130819	0.688	rs2634672	chr12:48649640	G/A	cg24011408	chr12:48396354	COL2A1	0.52	5.87	0.36	1.46e-8	Prostate cancer;
SARC	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	0.38	4.71	0.3	4.2e-6	Tonsillectomy;
SARC	cis	rs9916302	0.851	rs12936996	chr17:37665554	A/G	cg00129232	chr17:37814104	STARD3	0.63	7.71	0.45	3.65e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.76	9.64	0.53	9.91e-19	Height;
SARC	cis	rs6598955	0.724	rs12732295	chr1:26602251	C/T	cg04990556	chr1:26633338	UBXN11	-0.59	-8.11	-0.47	2.94e-14	Obesity-related traits;
SARC	cis	rs10791323	0.581	rs2723608	chr11:133710149	A/G	cg15485101	chr11:133734466	NA	0.33	5.07	0.32	8.08e-7	Childhood ear infection;
SARC	cis	rs9790314	0.905	rs1154701	chr3:161008025	T/A	cg03342759	chr3:160939853	NMD3	-0.63	-8.03	-0.47	4.72e-14	Morning vs. evening chronotype;
SARC	cis	rs1707322	0.963	rs4459051	chr1:46451203	A/G	cg06784218	chr1:46089804	CCDC17	0.34	5.95	0.36	9.76e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9796	0.516	rs28473405	chr15:41293170	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.52	-7.09	-0.42	1.59e-11	Menopause (age at onset);
SARC	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg23172400	chr8:95962367	TP53INP1	-0.35	-5.98	-0.36	8.43e-9	Type 2 diabetes;
SARC	cis	rs1371867	0.875	rs1619759	chr8:101337560	T/C	cg11906718	chr8:101322791	RNF19A	0.71	8.91	0.5	1.45e-16	Atrioventricular conduction;
SARC	cis	rs6918586	0.616	rs1056314	chr6:26114653	G/A	cg18357526	chr6:26021779	HIST1H4A	0.45	5.82	0.36	1.97e-8	Schizophrenia;
SARC	cis	rs4819052	0.679	rs8132135	chr21:46694782	C/T	cg06618935	chr21:46677482	NA	-0.35	-4.82	-0.3	2.61e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs963731	0.649	rs4670903	chr2:39220975	G/A	cg04010122	chr2:39346883	SOS1	-0.88	-5.46	-0.34	1.21e-7	Corticobasal degeneration;
SARC	cis	rs7589342	0.660	rs11124058	chr2:106400749	A/G	cg16077055	chr2:106428750	NCK2	0.3	5.72	0.35	3.33e-8	Addiction;
SARC	cis	rs2380220	0.606	rs4559095	chr6:95994154	A/C	cg15832292	chr6:96025679	MANEA	0.5	5.58	0.34	6.54e-8	Behavioural disinhibition (generation interaction);
SARC	cis	rs9640161	0.789	rs60283368	chr7:150023258	G/A	cg17279839	chr7:150038598	RARRES2	0.49	7.39	0.44	2.64e-12	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs10779751	0.655	rs1884429	chr1:11112836	T/C	cg08854313	chr1:11322531	MTOR	0.82	9.76	0.54	4.33e-19	Body mass index;
SARC	cis	rs6752107	1.000	rs10165561	chr2:234172915	G/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.48	6.36	0.38	1.04e-9	Crohn's disease;Inflammatory bowel disease;
SARC	trans	rs36093844	0.800	rs75605851	chr11:85580031	T/G	cg27065003	chr5:122429449	PRDM6	-0.54	-6.42	-0.39	7.74e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	trans	rs9951602	0.512	rs77157626	chr18:76644771	C/T	cg02800362	chr5:177631904	HNRNPAB	0.68	8.61	0.49	1.13e-15	Obesity-related traits;
SARC	cis	rs1707322	0.650	rs4660879	chr1:46105401	C/A	cg06784218	chr1:46089804	CCDC17	0.35	6.14	0.37	3.54e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs79149102	0.522	rs117774781	chr15:74772450	G/C	cg09165964	chr15:75287851	SCAMP5	-0.63	-5.06	-0.31	8.39e-7	Lung cancer;
SARC	cis	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg22496380	chr5:211416	CCDC127	-0.88	-9.47	-0.53	3.3e-18	Breast cancer;
SARC	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-8.98	-0.51	9.19e-17	Alzheimer's disease;
SARC	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg22903471	chr2:27725779	GCKR	-0.5	-7.61	-0.45	6.97e-13	Total body bone mineral density;
SARC	trans	rs11098499	0.909	rs78332141	chr4:120375782	C/T	cg25214090	chr10:38739885	LOC399744	0.55	7.02	0.42	2.41e-11	Corneal astigmatism;
SARC	cis	rs6597981	0.675	rs4963120	chr11:825777	A/G	cg21775979	chr11:780331	NA	0.35	5.2	0.32	4.4e-7	Breast cancer;
SARC	cis	rs7208859	0.623	rs56095789	chr17:29060170	A/G	cg13385521	chr17:29058706	SUZ12P	0.85	7.36	0.43	3.19e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs477692	1.000	rs522891	chr10:131430916	T/C	cg05714579	chr10:131428358	MGMT	-0.56	-7.34	-0.43	3.63e-12	Response to temozolomide;
SARC	trans	rs7937682	0.961	rs491937	chr11:111494947	A/T	cg18187862	chr3:45730750	SACM1L	0.54	6.81	0.41	8.41e-11	Primary sclerosing cholangitis;
SARC	cis	rs11098499	0.954	rs4345162	chr4:120312959	G/A	cg09160332	chr4:120329925	NA	-0.33	-4.77	-0.3	3.27e-6	Corneal astigmatism;
SARC	cis	rs950776	0.648	rs57945453	chr15:78862845	C/T	cg22563815	chr15:78856949	CHRNA5	0.36	5.58	0.34	6.59e-8	Sudden cardiac arrest;
SARC	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg04267008	chr7:1944627	MAD1L1	-0.44	-4.93	-0.31	1.56e-6	Schizophrenia;
SARC	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg18876405	chr7:65276391	NA	0.44	4.94	0.31	1.5e-6	Aortic root size;
SARC	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	8.08	0.47	3.4e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg13607699	chr17:42295918	UBTF	-0.56	-6.67	-0.4	1.84e-10	Total body bone mineral density;
SARC	cis	rs7223966	1.000	rs8077265	chr17:61732727	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.27	0.38	1.7e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg11987759	chr7:65425863	GUSB	0.57	7.54	0.44	1.03e-12	Aortic root size;
SARC	cis	rs2425143	1.000	rs11700256	chr20:34372941	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-5.89	-0.36	1.33e-8	Blood protein levels;
SARC	cis	rs7246760	0.867	rs35416342	chr19:9779058	A/G	cg16876255	chr19:9731953	ZNF561	0.82	5.05	0.31	8.72e-7	Pursuit maintenance gain;
SARC	cis	rs12216125	0.801	rs56107510	chr6:25987436	C/A	cg16482183	chr6:26056742	HIST1H1C	0.47	5.54	0.34	8.04e-8	Iron status biomarkers;
SARC	cis	rs5762813	0.566	rs4055	chr22:29352495	A/C	cg15103426	chr22:29168792	CCDC117	0.58	5.79	0.35	2.3e-8	Hematocrit;Hemoglobin concentration;
SARC	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.37	-5.8	-0.36	2.16e-8	Longevity;Endometriosis;
SARC	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg10523679	chr1:76189770	ACADM	-0.5	-6.75	-0.4	1.17e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs1568889	0.838	rs11030206	chr11:28099747	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.85	14.14	0.68	3.49e-33	Bipolar disorder;
SARC	cis	rs9527	0.590	rs10786741	chr10:104939182	G/A	cg04362960	chr10:104952993	NT5C2	0.43	5.12	0.32	6.5e-7	Arsenic metabolism;
SARC	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg08742575	chr21:47604166	C21orf56	0.46	5.91	0.36	1.24e-8	Testicular germ cell tumor;
SARC	cis	rs1881797	0.932	rs2387038	chr1:247674919	G/A	cg11166453	chr1:247681781	NA	0.44	4.72	0.3	4.04e-6	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs76419734	1.000	rs74568699	chr4:106665995	T/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.76	4.95	0.31	1.4e-6	Post bronchodilator FEV1;
SARC	cis	rs9398803	0.865	rs1572569	chr6:126771687	G/A	cg20229609	chr6:126660872	C6orf173	0.38	5.47	0.34	1.16e-7	Male-pattern baldness;
SARC	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg21132104	chr15:45694354	SPATA5L1	0.79	11.27	0.59	8.18e-24	Homoarginine levels;
SARC	cis	rs2832077	0.943	rs11701777	chr21:30155828	T/C	cg24692254	chr21:30365293	RNF160	-0.52	-4.79	-0.3	3.03e-6	Cognitive test performance;
SARC	cis	rs11770686	0.632	rs2285872	chr7:75310887	C/T	cg17787366	chr7:75369077	HIP1	0.39	4.85	0.3	2.28e-6	Essential tremor;
SARC	cis	rs11574514	1.000	rs76649027	chr16:67905994	G/A	cg01866162	chr16:67596514	CTCF	1.11	6.4	0.39	8.22e-10	Crohn's disease;
SARC	cis	rs9815354	0.767	rs61283393	chr3:41854135	T/G	cg03022575	chr3:42003672	ULK4	0.7	5.79	0.35	2.3e-8	Pulse pressure;Diastolic blood pressure;
SARC	trans	rs10829156	0.732	rs1917823	chr10:18817113	G/A	cg21448875	chr7:44104584	PGAM2	0.45	6.32	0.38	1.33e-9	Sudden cardiac arrest;
SARC	cis	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg00800038	chr16:89945340	TCF25	-0.79	-5.45	-0.34	1.26e-7	Skin colour saturation;
SARC	cis	rs4148883	0.675	rs116265877	chr4:100096896	G/A	cg12011299	chr4:100065546	ADH4	0.36	6.77	0.41	1.03e-10	Alcohol dependence;
SARC	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg13395646	chr4:1353034	KIAA1530	0.54	6.55	0.39	3.74e-10	Obesity-related traits;
SARC	cis	rs155076	1.000	rs261407	chr13:21855213	C/A	cg14456004	chr13:21872349	NA	-0.99	-12.51	-0.63	8.42e-28	White matter hyperintensity burden;
SARC	cis	rs11997175	0.595	rs6468204	chr8:33774748	T/C	ch.8.33884649F	chr8:33765107	NA	0.48	6.01	0.37	7.19e-9	Body mass index;
SARC	cis	rs4900538	0.787	rs11704	chr14:102808655	C/G	cg18135206	chr14:102964638	TECPR2	0.59	8.0	0.46	5.69e-14	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	trans	rs9525927	0.670	rs2246478	chr13:44829300	G/T	cg15777261	chr2:73462569	CCT7	0.44	6.25	0.38	1.98e-9	Dupuytren's disease;
SARC	cis	rs9815354	1.000	rs9864217	chr3:41762206	G/A	cg03022575	chr3:42003672	ULK4	0.63	5.35	0.33	2.05e-7	Pulse pressure;Diastolic blood pressure;
SARC	trans	rs61931739	0.500	rs7296061	chr12:34435009	A/G	cg13010199	chr12:38710504	ALG10B	-0.78	-10.72	-0.57	4.54e-22	Morning vs. evening chronotype;
SARC	cis	rs62244186	0.545	rs9284880	chr3:44759389	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.57	7.36	0.43	3.18e-12	Depressive symptoms;
SARC	cis	rs709400	0.663	rs62007681	chr14:103884651	G/A	cg26031613	chr14:104095156	KLC1	0.81	11.42	0.6	2.88e-24	Body mass index;
SARC	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg20102877	chr2:27665638	KRTCAP3	-0.38	-5.28	-0.33	2.96e-7	Total body bone mineral density;
SARC	cis	rs6545883	0.894	rs12997538	chr2:61564249	A/C	cg15711740	chr2:61764176	XPO1	0.4	4.78	0.3	3.07e-6	Tuberculosis;
SARC	cis	rs6912958	0.535	rs1753154	chr6:88032843	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.36	6.22	0.38	2.25e-9	Monocyte percentage of white cells;
SARC	cis	rs1882538	0.569	rs11562036	chr7:133076862	T/C	cg10665199	chr7:133106180	EXOC4	0.38	4.77	0.3	3.26e-6	Intelligence (multi-trait analysis);
SARC	cis	rs6570726	0.791	rs6570694	chr6:145911204	C/G	cg05347473	chr6:146136440	FBXO30	0.51	7.13	0.42	1.29e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7633857	0.537	rs9813700	chr3:160683279	G/T	cg03342759	chr3:160939853	NMD3	-0.46	-5.41	-0.33	1.55e-7	Educational attainment (years of education);
SARC	cis	rs883565	0.655	rs6777651	chr3:39143599	G/C	cg01426195	chr3:39028469	NA	-0.32	-4.79	-0.3	3.03e-6	Handedness;
SARC	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	11.35	0.6	4.58e-24	Platelet count;
SARC	cis	rs2070488	0.730	rs2268759	chr3:38514327	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	11.83	0.61	1.38e-25	Electrocardiographic conduction measures;
SARC	cis	rs2180341	0.960	rs9401953	chr6:127687574	G/A	cg17762328	chr6:126965162	NA	-0.45	-4.98	-0.31	1.21e-6	Breast cancer;
SARC	cis	rs6545883	0.965	rs9989775	chr2:61761774	A/G	cg15711740	chr2:61764176	XPO1	-0.45	-5.48	-0.34	1.09e-7	Tuberculosis;
SARC	cis	rs9297145	0.565	rs941001	chr7:98735185	A/T	cg05967295	chr7:98741636	SMURF1	-0.51	-5.73	-0.35	3.17e-8	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
SARC	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.52	6.18	0.38	2.81e-9	Calcium levels;
SARC	cis	rs9910055	0.529	rs615070	chr17:42176591	A/G	cg19774624	chr17:42201019	HDAC5	-0.54	-6.28	-0.38	1.6e-9	Total body bone mineral density;
SARC	cis	rs8044995	0.563	rs2279540	chr16:68395061	T/C	cg09835421	chr16:68378352	PRMT7	-0.67	-6.3	-0.38	1.45e-9	Schizophrenia;
SARC	cis	rs7712401	0.601	rs34233716	chr5:122316365	C/G	cg19412675	chr5:122181750	SNX24	-0.43	-5.5	-0.34	9.81e-8	Mean platelet volume;
SARC	cis	rs6969780	1.000	rs73071550	chr7:27149099	T/C	cg26364809	chr7:27145159	NA	-0.58	-4.82	-0.3	2.58e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
SARC	cis	rs2594989	0.779	rs7647622	chr3:11590871	G/A	cg00170343	chr3:11313890	ATG7	-0.54	-5.88	-0.36	1.45e-8	Circulating chemerin levels;
SARC	cis	rs7178909	0.902	rs28372736	chr15:90437858	T/C	cg19708238	chr15:90437601	AP3S2	0.62	8.47	0.49	2.73e-15	Common traits (Other);
SARC	cis	rs11249608	0.789	rs6868425	chr5:178446708	A/G	cg21905437	chr5:178450457	ZNF879	0.55	7.24	0.43	6.39e-12	Pubertal anthropometrics;
SARC	cis	rs12142240	0.660	rs7520497	chr1:46824919	C/A	cg10495392	chr1:46806563	NSUN4	0.65	6.8	0.41	8.89e-11	Menopause (age at onset);
SARC	trans	rs656319	0.638	rs670044	chr8:9892529	G/T	cg08975724	chr8:8085496	FLJ10661	0.59	7.3	0.43	4.51e-12	Myopia (pathological);
SARC	cis	rs76419734	1.000	rs17036123	chr4:106622190	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.8	4.9	0.31	1.8e-6	Post bronchodilator FEV1;
SARC	cis	rs950776	0.531	rs12915652	chr15:78831928	G/A	cg06917634	chr15:78832804	PSMA4	0.91	14.24	0.68	1.63e-33	Sudden cardiac arrest;
SARC	cis	rs2153535	0.541	rs6905934	chr6:8440043	C/A	cg21535247	chr6:8435926	SLC35B3	0.56	7.01	0.42	2.6e-11	Motion sickness;
SARC	cis	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg13147721	chr7:65941812	NA	-0.52	-4.76	-0.3	3.38e-6	Diabetic kidney disease;
SARC	cis	rs7927592	0.913	rs11228262	chr11:68274907	G/T	cg01657329	chr11:68192670	LRP5	-0.41	-5.01	-0.31	1.08e-6	Total body bone mineral density;
SARC	cis	rs708547	0.874	rs1718869	chr4:57880232	A/C	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.46	-5.07	-0.32	8.1e-7	Response to bleomycin (chromatid breaks);
SARC	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg11062466	chr8:58055876	NA	0.67	5.87	0.36	1.49e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6912958	0.781	rs9444524	chr6:88311260	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.54	-0.34	8.32e-8	Monocyte percentage of white cells;
SARC	cis	rs16976116	0.901	rs1061823	chr15:55496043	T/A	cg17854078	chr15:55489399	RSL24D1	0.66	6.53	0.39	4.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg12463550	chr7:65579703	CRCP	0.48	5.79	0.35	2.23e-8	Aortic root size;
SARC	cis	rs7326068	0.576	rs34880311	chr13:21329255	A/T	cg16922012	chr13:21400325	XPO4	-0.44	-6.12	-0.37	3.92e-9	Schizophrenia, bipolar disorder and depression (combined);
SARC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg09373136	chr17:61933544	TCAM1	0.39	5.41	0.33	1.56e-7	Prudent dietary pattern;
SARC	cis	rs7829975	0.606	rs891570	chr8:8794454	G/A	cg08975724	chr8:8085496	FLJ10661	-0.42	-5.23	-0.32	3.71e-7	Mood instability;
SARC	cis	rs11874712	1.000	rs13381709	chr18:43670988	C/T	cg25174615	chr18:43684699	ATP5A1;HAUS1	0.4	4.75	0.3	3.52e-6	Migraine - clinic-based;
SARC	cis	rs3093024	0.935	rs10946216	chr6:167538897	T/C	cg07741184	chr6:167504864	NA	-0.32	-6.22	-0.38	2.32e-9	Rheumatoid arthritis;
SARC	cis	rs79149102	0.649	rs3743487	chr15:75122856	C/T	cg09165964	chr15:75287851	SCAMP5	-1.13	-6.78	-0.41	9.65e-11	Lung cancer;
SARC	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs34172651	0.837	rs12596793	chr16:24823667	C/G	cg00152838	chr16:24741724	TNRC6A	-0.41	-4.95	-0.31	1.41e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9325144	0.513	rs7977596	chr12:38649067	C/A	cg13010199	chr12:38710504	ALG10B	-0.56	-6.98	-0.42	3.02e-11	Morning vs. evening chronotype;
SARC	cis	rs1920116	0.778	rs34058457	chr3:169554741	G/T	cg14222479	chr3:169487675	ARPM1	0.44	4.96	0.31	1.39e-6	Glioma (high-grade);
SARC	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg16325326	chr1:53192061	ZYG11B	0.78	12.14	0.62	1.29e-26	Monocyte count;
SARC	trans	rs11098499	0.954	rs1022145	chr4:120230979	A/G	cg25214090	chr10:38739885	LOC399744	0.54	6.98	0.42	3.11e-11	Corneal astigmatism;
SARC	cis	rs2282802	0.685	rs7717576	chr5:139623591	G/A	cg26211634	chr5:139558579	C5orf32	0.38	4.88	0.3	2.01e-6	Intelligence (multi-trait analysis);
SARC	cis	rs3733585	0.699	rs57574512	chr4:9960182	T/C	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.55	-0.34	7.65e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs12579753	0.917	rs10129029	chr12:82180324	G/A	cg07988820	chr12:82153109	PPFIA2	-0.54	-6.42	-0.39	7.48e-10	Resting heart rate;
SARC	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.62	7.63	0.45	6.09e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7959452	0.535	rs10784771	chr12:69621264	A/G	cg20891283	chr12:69753455	YEATS4	0.4	5.21	0.32	4.08e-7	Blood protein levels;
SARC	cis	rs751728	0.865	rs751726	chr6:33764386	G/A	cg15252951	chr6:33757062	LEMD2	0.57	6.81	0.41	8.32e-11	Crohn's disease;
SARC	cis	rs6840360	0.571	rs72730104	chr4:152543857	A/G	cg22705602	chr4:152727874	NA	-0.42	-6.62	-0.4	2.46e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7223966	1.000	rs9909992	chr17:61731931	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.24	0.38	2.08e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1018836	0.545	rs7840203	chr8:91701223	A/G	cg16814680	chr8:91681699	NA	-1.02	-21.34	-0.81	9.8e-57	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg09323728	chr8:95962352	TP53INP1	-0.32	-5.34	-0.33	2.19e-7	Type 2 diabetes;
SARC	cis	rs826838	0.834	rs826874	chr12:39122599	C/A	cg13010199	chr12:38710504	ALG10B	-0.58	-7.92	-0.46	9.89e-14	Heart rate;
SARC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg19318889	chr4:1322082	MAEA	-0.44	-5.46	-0.34	1.2e-7	Longevity;
SARC	cis	rs7772486	0.743	rs2092262	chr6:146037105	C/T	cg23711669	chr6:146136114	FBXO30	-0.8	-12.29	-0.63	4.15e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12079745	0.793	rs75487543	chr1:169339382	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.92	-5.9	-0.36	1.29e-8	QT interval;
SARC	cis	rs7098414	0.511	rs10749592	chr10:82150891	C/T	cg01528321	chr10:82214614	TSPAN14	0.57	7.97	0.46	7.19e-14	Post bronchodilator FEV1;
SARC	cis	rs11098499	0.954	rs11722872	chr4:120233030	G/C	cg09307838	chr4:120376055	NA	0.9	12.25	0.63	5.65e-27	Corneal astigmatism;
SARC	cis	rs4253772	0.530	rs6008662	chr22:46713917	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.75	7.35	0.43	3.24e-12	LDL cholesterol;Cholesterol, total;
SARC	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg08280861	chr8:58055591	NA	0.59	5.22	0.32	4.02e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6815814	0.847	rs11725309	chr4:38783848	T/C	cg09316306	chr4:38807337	TLR1	0.51	5.27	0.33	3.18e-7	Breast cancer;
SARC	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg13939156	chr17:80058883	NA	-0.42	-6.48	-0.39	5.51e-10	Life satisfaction;
SARC	cis	rs9611519	0.566	rs4821981	chr22:41415644	A/C	cg06634786	chr22:41940651	POLR3H	0.41	5.14	0.32	5.83e-7	Neuroticism;
SARC	cis	rs6545883	0.895	rs7588814	chr2:61695589	A/T	cg15711740	chr2:61764176	XPO1	-0.43	-5.14	-0.32	5.9e-7	Tuberculosis;
SARC	cis	rs13256369	0.802	rs1060107	chr8:8561399	G/T	cg17143192	chr8:8559678	CLDN23	0.52	5.74	0.35	2.9e-8	Obesity-related traits;
SARC	cis	rs2933343	1.000	rs2933343	chr3:128658492	G/A	cg25356066	chr3:128598488	ACAD9	0.61	6.9	0.41	4.78e-11	IgG glycosylation;
SARC	cis	rs67311347	1.000	rs67680017	chr3:40533164	C/T	cg24209194	chr3:40518798	ZNF619	0.6	7.65	0.45	5.27e-13	Renal cell carcinoma;
SARC	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg16606324	chr3:10149918	C3orf24	0.49	4.82	0.3	2.56e-6	Alzheimer's disease;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg06965122	chr4:174089515	GALNT7	-0.53	-6.53	-0.39	4.07e-10	Breast cancer;
SARC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg09373136	chr17:61933544	TCAM1	-0.43	-5.92	-0.36	1.14e-8	Prudent dietary pattern;
SARC	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.04	15.53	0.71	8.12e-38	Height;
SARC	trans	rs208520	0.690	rs7764570	chr6:66827600	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-13.1	-0.65	9.28e-30	Exhaled nitric oxide output;
SARC	cis	rs897080	0.515	rs698800	chr2:44690787	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.58	6.22	0.38	2.28e-9	Height;
SARC	cis	rs10046574	0.831	rs7797208	chr7:135137729	C/T	cg27474649	chr7:135195673	CNOT4	0.88	7.17	0.43	9.89e-12	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs1008375	1.000	rs10939746	chr4:17684951	A/G	cg02297831	chr4:17616191	MED28	-0.44	-5.57	-0.34	7.05e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs72781680	1.000	rs72796359	chr2:24160545	T/C	cg08917208	chr2:24149416	ATAD2B	0.93	8.7	0.5	6.18e-16	Lymphocyte counts;
SARC	cis	rs941408	0.515	rs1640262	chr19:2779134	C/T	cg00079169	chr19:2811669	THOP1	-0.45	-4.97	-0.31	1.28e-6	Total cholesterol levels;
SARC	cis	rs3087591	0.708	rs2285894	chr17:29654876	T/A	cg24425628	chr17:29625626	OMG;NF1	0.42	5.39	0.33	1.73e-7	Hip circumference;
SARC	cis	rs10046574	0.831	rs78220593	chr7:135166787	T/C	cg27474649	chr7:135195673	CNOT4	0.87	7.13	0.42	1.27e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg04277193	chr17:41438351	NA	0.44	4.82	0.3	2.59e-6	Menopause (age at onset);
SARC	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg26752003	chr8:145688521	CYHR1	-0.66	-9.04	-0.51	6.23e-17	Age at first birth;
SARC	cis	rs9291683	0.530	rs998675	chr4:9948829	A/G	cg00071950	chr4:10020882	SLC2A9	0.45	7.18	0.43	9.46e-12	Bone mineral density;
SARC	cis	rs9660992	0.508	rs113817010	chr1:205104581	C/A	cg07972983	chr1:205091412	RBBP5	0.6	7.74	0.45	3.1e-13	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs7927771	0.965	rs3817335	chr11:47643891	T/A	cg05585544	chr11:47624801	NA	-0.42	-5.73	-0.35	3.16e-8	Subjective well-being;
SARC	cis	rs1580019	0.587	rs34488151	chr7:32548146	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.53	6.84	0.41	7.05e-11	Cognitive ability;
SARC	cis	rs6570726	0.935	rs446242	chr6:145843866	A/G	cg23711669	chr6:146136114	FBXO30	0.78	11.98	0.62	4.52e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7626444	0.625	rs1798634	chr3:196474287	G/A	cg12930392	chr3:196481615	PAK2	0.26	5.2	0.32	4.44e-7	Monocyte count;
SARC	cis	rs2276314	0.857	rs3737474	chr18:33613595	T/C	cg19628046	chr18:33552617	C18orf21	0.61	6.28	0.38	1.68e-9	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.68	6.53	0.39	4.09e-10	Platelet count;
SARC	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.68	6.53	0.39	4.09e-10	Platelet count;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg09104720	chr17:45727790	KPNB1	0.49	6.37	0.39	9.9e-10	Lung adenocarcinoma;
SARC	cis	rs35213789	0.887	rs2851517	chr7:69141402	A/G	cg10619644	chr7:69149951	AUTS2	0.41	5.53	0.34	8.37e-8	Childhood ear infection;
SARC	cis	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg24110177	chr3:50126178	RBM5	0.62	8.12	0.47	2.73e-14	Body mass index;
SARC	cis	rs2070488	0.861	rs2067082	chr3:38438182	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.83	13.11	0.65	8.5e-30	Electrocardiographic conduction measures;
SARC	cis	rs11098499	0.789	rs12498994	chr4:120250818	A/C	cg09307838	chr4:120376055	NA	0.81	11.03	0.59	4.84e-23	Corneal astigmatism;
SARC	cis	rs7208859	0.623	rs12006	chr17:29110652	G/A	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs76419734	1.000	rs75156726	chr4:106677999	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.76	5.11	0.32	6.56e-7	Post bronchodilator FEV1;
SARC	cis	rs7904368	0.806	rs7099178	chr10:16862578	C/G	cg23933602	chr10:16859644	RSU1	0.54	5.44	0.34	1.34e-7	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.68	-8.82	-0.5	2.66e-16	Chronic sinus infection;
SARC	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.46	5.28	0.33	2.97e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs6495122	0.699	rs34862454	chr15:75101530	C/T	cg14664628	chr15:75095509	CSK	-0.8	-10.49	-0.57	2.42e-21	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	cis	rs7589342	0.862	rs12613864	chr2:106515869	G/A	cg14210321	chr2:106509881	NCK2	-0.47	-5.59	-0.34	6.37e-8	Addiction;
SARC	cis	rs709400	0.633	rs7160208	chr14:103965528	G/A	cg26031613	chr14:104095156	KLC1	0.82	11.95	0.62	5.3e-26	Body mass index;
SARC	cis	rs7829975	0.684	rs546603	chr8:8595838	T/G	cg08975724	chr8:8085496	FLJ10661	-0.46	-5.57	-0.34	7.15e-8	Mood instability;
SARC	cis	rs10411936	1.000	rs1870071	chr19:16505106	A/G	cg10248733	chr19:16607483	C19orf44;CALR3	-0.41	-4.71	-0.3	4.18e-6	White blood cell count;Multiple sclerosis;
SARC	cis	rs4481887	0.893	rs1934543	chr1:248505602	C/G	cg01631408	chr1:248437212	OR2T33	-0.45	-6.02	-0.37	6.66e-9	Common traits (Other);
SARC	cis	rs11630290	0.806	rs11631544	chr15:64098557	A/G	cg12036633	chr15:63758958	NA	-0.48	-4.88	-0.3	1.96e-6	Iris characteristics;
SARC	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg08048268	chr3:133502702	NA	-0.46	-6.2	-0.38	2.61e-9	Iron status biomarkers;
SARC	cis	rs1797081	0.542	rs2603796	chr10:16871456	C/T	cg23933602	chr10:16859644	RSU1	0.76	12.1	0.62	1.84e-26	Platelet distribution width;
SARC	cis	rs7937682	0.924	rs12791699	chr11:111505880	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.93	-15.22	-0.71	8.48e-37	Primary sclerosing cholangitis;
SARC	cis	rs6088813	1.000	rs4911494	chr20:33971914	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	-0.43	-5.24	-0.32	3.67e-7	Height;
SARC	cis	rs1865721	0.771	rs7231277	chr18:73136724	A/G	cg26385618	chr18:73139727	C18orf62	-0.4	-5.53	-0.34	8.56e-8	Intelligence;
SARC	cis	rs6088580	0.602	rs6059834	chr20:33019299	A/G	cg08999081	chr20:33150536	PIGU	0.44	6.59	0.4	2.97e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs614226	0.744	rs787832	chr12:120986801	A/G	cg01236616	chr12:121019343	POP5	1.3	19.08	0.78	1.61e-49	Type 1 diabetes nephropathy;
SARC	cis	rs2361710	0.611	rs3816257	chr17:78074446	G/T	cg06718696	chr17:78121285	EIF4A3	-0.61	-7.07	-0.42	1.8e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
SARC	cis	rs6088580	0.713	rs1884669	chr20:33171287	G/A	cg24642439	chr20:33292090	TP53INP2	0.66	8.51	0.49	2.18e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs1982346	0.850	rs2553457	chr4:106738805	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	-0.67	-4.74	-0.3	3.74e-6	Lung function (FEV1);
SARC	cis	rs5997397	0.934	rs6005863	chr22:29156448	A/G	cg02153584	chr22:29168773	CCDC117	0.56	7.74	0.45	2.98e-13	Red cell distribution width;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg03433329	chr17:33446705	RAD51L3	0.56	7.56	0.44	9.46e-13	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs7582180	0.715	rs1866198	chr2:100917739	C/A	cg14675211	chr2:100938903	LONRF2	0.52	7.72	0.45	3.45e-13	Intelligence (multi-trait analysis);
SARC	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg27286337	chr10:134555280	INPP5A	0.65	7.49	0.44	1.42e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs5758659	0.714	rs5751220	chr22:42516205	A/C	cg04733989	chr22:42467013	NAGA	-0.49	-5.83	-0.36	1.85e-8	Cognitive function;
SARC	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs12956009	0.518	rs953291	chr18:44870499	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.57	7.38	0.44	2.79e-12	Educational attainment (years of education);
SARC	cis	rs9790314	0.747	rs9990242	chr3:160838461	T/C	cg03342759	chr3:160939853	NMD3	-0.46	-5.67	-0.35	4.11e-8	Morning vs. evening chronotype;
SARC	cis	rs2439831	0.764	rs12324584	chr15:43683446	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	10.8	0.58	2.68e-22	Lung cancer in ever smokers;
SARC	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg10435706	chr6:150039699	LATS1	0.36	4.8	0.3	2.88e-6	Lung cancer;
SARC	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	10.15	0.55	2.76e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs898097	0.756	rs56249965	chr17:80806603	C/G	cg05255149	chr17:80675120	FN3KRP	-0.42	-4.95	-0.31	1.46e-6	Breast cancer;
SARC	cis	rs80282103	0.867	rs11250242	chr10:1100064	A/C	cg08668510	chr10:1095578	IDI1	-0.77	-4.86	-0.3	2.2e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs898097	1.000	rs898098	chr17:80904564	G/A	cg15369054	chr17:80825471	TBCD	-0.45	-6.42	-0.39	7.42e-10	Breast cancer;
SARC	cis	rs10078	0.571	rs2671890	chr5:456457	A/G	cg08916839	chr5:415575	AHRR	0.82	7.76	0.45	2.67e-13	Fat distribution (HIV);
SARC	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg22800045	chr5:56110881	MAP3K1	0.74	7.83	0.46	1.74e-13	Initial pursuit acceleration;
SARC	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg06420487	chr17:61919686	SMARCD2	0.48	5.61	0.35	5.62e-8	Height;
SARC	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg26335602	chr6:28129616	ZNF389	0.53	5.92	0.36	1.12e-8	Depression;
SARC	cis	rs7044106	0.762	rs1158554	chr9:123400898	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	9.01	0.51	7.8e-17	Hip circumference adjusted for BMI;
SARC	cis	rs796364	0.806	rs188102	chr2:200903189	T/A	cg23649088	chr2:200775458	C2orf69	-0.66	-5.76	-0.35	2.68e-8	Schizophrenia;
SARC	cis	rs1707322	1.000	rs10789486	chr1:46408667	A/G	cg06784218	chr1:46089804	CCDC17	0.34	5.86	0.36	1.6e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2075371	0.965	rs2544216	chr7:133987902	G/A	cg20476274	chr7:133979776	SLC35B4	0.62	8.41	0.48	4.18e-15	Mean platelet volume;
SARC	cis	rs7568458	0.684	rs3731828	chr2:85806266	C/T	cg23752985	chr2:85803571	VAMP8	0.48	6.15	0.37	3.26e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg14893161	chr1:205819251	PM20D1	0.92	15.9	0.72	4.68e-39	Menarche (age at onset);
SARC	cis	rs7681440	0.838	rs1348224	chr4:90761946	G/A	cg06632027	chr4:90757378	SNCA	0.4	5.8	0.36	2.1e-8	Dementia with Lewy bodies;
SARC	cis	rs858239	0.730	rs10255155	chr7:23402147	A/T	cg23682824	chr7:23144976	KLHL7	-0.55	-6.9	-0.41	4.97e-11	Cerebrospinal fluid biomarker levels;
SARC	cis	rs752010	0.806	rs11210500	chr1:42089737	A/G	cg06885757	chr1:42089581	HIVEP3	0.43	6.77	0.41	1.03e-10	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs9611519	0.828	rs9611460	chr22:41418297	T/C	cg03806693	chr22:41940476	POLR3H	-0.56	-6.55	-0.39	3.63e-10	Neuroticism;
SARC	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg17221315	chr6:27791827	HIST1H4J	0.47	4.81	0.3	2.76e-6	Depression;
SARC	cis	rs5753618	0.509	rs2079431	chr22:31564334	C/T	cg02404636	chr22:31891804	SFI1	-0.51	-5.77	-0.35	2.51e-8	Colorectal cancer;
SARC	trans	rs61931739	0.500	rs73103774	chr12:34482279	C/T	cg26384229	chr12:38710491	ALG10B	0.91	13.62	0.67	1.86e-31	Morning vs. evening chronotype;
SARC	cis	rs35123781	0.696	rs4912756	chr5:139070780	A/T	cg10513866	chr5:139070639	NA	0.35	4.76	0.3	3.39e-6	Schizophrenia;
SARC	cis	rs9790314	1.000	rs4273380	chr3:160950314	A/G	cg04691961	chr3:161091175	C3orf57	-0.79	-11.72	-0.61	3.09e-25	Morning vs. evening chronotype;
SARC	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg00450029	chr8:599525	NA	-0.55	-4.92	-0.31	1.61e-6	IgG glycosylation;
SARC	cis	rs4430311	0.723	rs1973284	chr1:243856681	A/G	cg21452805	chr1:244014465	NA	-0.45	-5.72	-0.35	3.23e-8	Post-traumatic stress disorder (asjusted for relatedness);
SARC	cis	rs9462027	0.628	rs9462020	chr6:34751265	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.84	-0.36	1.71e-8	Systemic lupus erythematosus;
SARC	cis	rs2777491	0.915	rs16971767	chr15:41623308	T/C	cg01768344	chr15:41576519	LOC729082	0.45	4.97	0.31	1.31e-6	Ulcerative colitis;
SARC	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg23262073	chr20:60523788	NA	-0.38	-5.41	-0.33	1.53e-7	Body mass index;
SARC	cis	rs898097	0.585	rs9893200	chr17:80893028	A/C	cg02711726	chr17:80685570	FN3KRP	-0.38	-5.38	-0.33	1.84e-7	Breast cancer;
SARC	cis	rs12421382	0.811	rs11602639	chr11:109472829	C/T	cg27471124	chr11:109292789	C11orf87	0.54	7.24	0.43	6.4e-12	Schizophrenia;
SARC	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg11211951	chr8:145729740	GPT	-0.49	-7.29	-0.43	4.76e-12	Age at first birth;
SARC	cis	rs12142240	0.667	rs41293287	chr1:46808852	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-5.45	-0.34	1.28e-7	Menopause (age at onset);
SARC	cis	rs73086581	1.000	rs73086544	chr20:3950928	C/A	cg02187196	chr20:3869020	PANK2	0.67	6.4	0.39	8.3e-10	Response to antidepressants in depression;
SARC	cis	rs765787	0.556	rs2413778	chr15:45539397	C/A	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.81e-6	Uric acid levels;
SARC	cis	rs13256369	0.802	rs13280101	chr8:8562773	G/A	cg18904891	chr8:8559673	CLDN23	0.49	5.55	0.34	7.9e-8	Obesity-related traits;
SARC	cis	rs6840360	0.571	rs4696278	chr4:152558978	A/G	cg22705602	chr4:152727874	NA	-0.43	-6.69	-0.4	1.66e-10	Intelligence (multi-trait analysis);
SARC	cis	rs2204008	0.668	rs1619009	chr12:38120485	G/A	cg13010199	chr12:38710504	ALG10B	-0.59	-7.53	-0.44	1.12e-12	Bladder cancer;
SARC	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.56	7.25	0.43	6.03e-12	Menarche (age at onset);
SARC	cis	rs2153535	0.580	rs6913100	chr6:8456855	A/G	cg21535247	chr6:8435926	SLC35B3	0.49	6.13	0.37	3.79e-9	Motion sickness;
SARC	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg04944784	chr2:26401820	FAM59B	-0.51	-6.39	-0.39	8.74e-10	Gut microbiome composition (summer);
SARC	cis	rs3126085	0.935	rs72696997	chr1:152257099	A/C	cg03465714	chr1:152285911	FLG	0.46	4.84	0.3	2.31e-6	Atopic dermatitis;
SARC	cis	rs9388451	0.591	rs1268792	chr6:126042124	G/A	cg05901451	chr6:126070800	HEY2	0.46	5.72	0.35	3.24e-8	Brugada syndrome;
SARC	cis	rs2120243	0.539	rs9878474	chr3:157123147	A/G	cg24825693	chr3:157122686	VEPH1	0.46	6.45	0.39	6.37e-10	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs2498796	0.635	rs6644	chr14:105213343	A/G	cg07523784	chr14:105186699	NA	-0.37	-5.38	-0.33	1.81e-7	Endometrial cancer;Endometrial endometrioid carcinoma;
SARC	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg06028808	chr11:68637592	NA	0.48	6.23	0.38	2.15e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs1267303	0.675	rs1267313	chr1:46986322	G/T	cg25110126	chr1:46999211	NA	-0.69	-7.8	-0.45	2.1e-13	Monobrow;
SARC	cis	rs4853036	0.859	rs10196546	chr2:70157158	T/C	cg02498382	chr2:70120550	SNRNP27	-0.4	-5.56	-0.34	7.23e-8	Colorectal or endometrial cancer;
SARC	cis	rs992157	0.710	rs10169718	chr2:219103580	C/T	cg00012203	chr2:219082015	ARPC2	-0.85	-13.71	-0.67	9.46e-32	Colorectal cancer;
SARC	cis	rs1008375	0.966	rs11733730	chr4:17625209	G/C	cg27347728	chr4:17578864	LAP3	0.48	6.08	0.37	4.84e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs56279505	0.629	rs2866153	chr4:100263695	A/T	cg18024358	chr1:3420815	MEGF6	-0.83	-6.4	-0.39	8.29e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs11098499	0.657	rs7664458	chr4:120371967	A/G	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	cis	rs11097912	0.603	rs75814353	chr4:107200154	C/T	cg09646026	chr4:107269030	AIMP1	-0.45	-4.86	-0.3	2.13e-6	Airflow obstruction;
SARC	cis	rs9527	0.615	rs7096452	chr10:104736563	G/A	cg04362960	chr10:104952993	NT5C2	0.42	4.99	0.31	1.2e-6	Arsenic metabolism;
SARC	cis	rs1790761	0.658	rs666328	chr11:67335538	G/A	cg24690094	chr11:67383802	NA	0.37	5.45	0.34	1.25e-7	Mean corpuscular volume;
SARC	cis	rs2387326	0.717	rs11016102	chr10:129945154	A/G	cg16087940	chr10:129947807	NA	-0.45	-5.68	-0.35	4.01e-8	Select biomarker traits;
SARC	trans	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg00938859	chr5:1591904	SDHAP3	0.69	6.36	0.38	1.03e-9	Breast cancer;
SARC	cis	rs4689388	0.926	rs11725500	chr4:6293919	C/G	cg14416269	chr4:6271139	WFS1	0.32	4.92	0.31	1.61e-6	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg11987759	chr7:65425863	GUSB	-0.6	-7.96	-0.46	7.64e-14	Aortic root size;
SARC	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg17971929	chr21:40555470	PSMG1	0.94	11.47	0.6	1.9e-24	Cognitive function;
SARC	cis	rs524281	0.861	rs7935336	chr11:65865325	C/T	cg14036092	chr11:66035641	RAB1B	-0.51	-5.34	-0.33	2.16e-7	Electroencephalogram traits;
SARC	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg16405210	chr4:1374714	KIAA1530	-0.49	-5.75	-0.35	2.77e-8	Obesity-related traits;
SARC	cis	rs4713118	0.629	rs203888	chr6:28021589	C/T	cg26335602	chr6:28129616	ZNF389	0.51	5.32	0.33	2.44e-7	Parkinson's disease;
SARC	cis	rs16854884	0.632	rs1466941	chr3:143670131	A/G	cg06585982	chr3:143692056	C3orf58	0.69	9.56	0.53	1.75e-18	Economic and political preferences (feminism/equality);
SARC	cis	rs7586879	0.575	rs6721750	chr2:25128719	A/G	cg04586622	chr2:25135609	ADCY3	0.31	5.29	0.33	2.8e-7	Body mass index;
SARC	cis	rs2797685	1.000	rs2797685	chr1:7879063	C/T	cg00864860	chr1:7907996	UTS2	-0.35	-4.84	-0.3	2.32e-6	Crohn's disease;
SARC	cis	rs10085978	0.583	rs13258478	chr8:143235330	C/G	cg10596483	chr8:143751796	JRK	0.42	4.78	0.3	3.1e-6	Mosquito bite size;
SARC	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg18876405	chr7:65276391	NA	0.48	5.69	0.35	3.89e-8	Calcium levels;
SARC	cis	rs12135062	0.851	rs2651926	chr1:3101820	C/T	cg21609526	chr1:3105151	PRDM16	-0.4	-6.87	-0.41	5.71e-11	Migraine;
SARC	cis	rs9303401	0.659	rs34878689	chr17:56694330	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	11.52	0.6	1.34e-24	Cognitive test performance;
SARC	cis	rs4642101	0.793	rs6763619	chr3:12822147	T/G	cg05775895	chr3:12838266	CAND2	0.75	11.88	0.61	9.18e-26	QRS complex (12-leadsum);
SARC	cis	rs7927771	0.965	rs56400411	chr11:47586376	T/G	cg20307385	chr11:47447363	PSMC3	-0.51	-6.31	-0.38	1.37e-9	Subjective well-being;
SARC	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg14983838	chr19:29218262	NA	0.78	10.59	0.57	1.2e-21	Methadone dose in opioid dependence;
SARC	cis	rs3540	0.618	rs11609	chr15:91043765	C/G	cg22089800	chr15:90895588	ZNF774	-0.6	-7.6	-0.45	7.02e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs3126085	0.935	rs10888483	chr1:152252789	T/A	cg03465714	chr1:152285911	FLG	0.46	4.84	0.3	2.31e-6	Atopic dermatitis;
SARC	cis	rs12681288	0.676	rs34435811	chr8:990630	T/A	cg15309053	chr8:964076	NA	0.46	7.29	0.43	4.94e-12	Schizophrenia;
SARC	cis	rs2153535	0.601	rs9393030	chr6:8516489	C/G	cg23788917	chr6:8435910	SLC35B3	0.63	8.21	0.47	1.56e-14	Motion sickness;
SARC	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2933343	0.661	rs2630259	chr3:128606322	C/T	cg24203234	chr3:128598194	ACAD9	0.62	7.77	0.45	2.49e-13	IgG glycosylation;
SARC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg11235426	chr6:292522	DUSP22	-0.6	-7.8	-0.46	2.08e-13	Menopause (age at onset);
SARC	cis	rs17376456	0.825	rs35426871	chr5:93291613	C/T	cg25358565	chr5:93447407	FAM172A	1.31	14.54	0.69	1.57e-34	Diabetic retinopathy;
SARC	cis	rs9611519	0.531	rs1967708	chr22:41444444	G/C	cg03806693	chr22:41940476	POLR3H	-0.59	-7.75	-0.45	2.88e-13	Neuroticism;
SARC	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg08677398	chr8:58056175	NA	0.43	5.05	0.31	8.92e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs965469	0.779	rs6051830	chr20:3373397	T/C	cg25506879	chr20:3388711	C20orf194	-0.44	-4.8	-0.3	2.88e-6	IFN-related cytopenia;
SARC	cis	rs2718058	0.630	rs2722290	chr7:37820403	C/G	cg24998770	chr7:37888106	TXNDC3	0.36	5.25	0.33	3.42e-7	Alzheimer's disease (late onset);
SARC	cis	rs7412746	0.658	rs897815	chr1:150879101	C/T	cg15448220	chr1:150897856	SETDB1	-0.51	-6.71	-0.4	1.42e-10	Melanoma;
SARC	cis	rs910316	0.763	rs175057	chr14:75489632	C/T	cg08847533	chr14:75593920	NEK9	-0.83	-11.65	-0.61	5e-25	Height;
SARC	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg07636037	chr3:49044803	WDR6	1.01	17.84	0.76	1.85e-45	Parkinson's disease;
SARC	cis	rs6908034	0.769	rs6916589	chr6:19761363	T/G	cg02682789	chr6:19804855	NA	0.8	6.84	0.41	6.78e-11	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	13.57	0.66	2.68e-31	Chronic sinus infection;
SARC	cis	rs9303401	0.614	rs3803752	chr17:56540267	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.04	10.97	0.58	7.47e-23	Cognitive test performance;
SARC	cis	rs412050	0.547	rs61763401	chr22:22139847	C/T	cg17089214	chr22:22089827	YPEL1	0.79	6.51	0.39	4.64e-10	Attention deficit hyperactivity disorder;
SARC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg09373136	chr17:61933544	TCAM1	-0.43	-5.79	-0.35	2.21e-8	Prudent dietary pattern;
SARC	cis	rs72781680	0.898	rs72786276	chr2:24062566	G/A	cg08917208	chr2:24149416	ATAD2B	0.95	9.18	0.52	2.4e-17	Lymphocyte counts;
SARC	cis	rs4319547	0.741	rs4758644	chr12:122943915	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.46	-5.47	-0.34	1.18e-7	Body mass index;
SARC	cis	rs2629540	0.847	rs10901807	chr10:126384610	G/A	cg08799069	chr10:126477246	METTL10	0.6	6.55	0.39	3.54e-10	Cocaine dependence;
SARC	cis	rs751728	0.638	rs4607416	chr6:33784998	G/C	cg15252951	chr6:33757062	LEMD2	0.46	5.13	0.32	6e-7	Crohn's disease;
SARC	cis	rs36051895	0.659	rs62541538	chr9:5038164	G/A	cg02405213	chr9:5042618	JAK2	-0.53	-5.98	-0.36	8.31e-9	Pediatric autoimmune diseases;
SARC	cis	rs15676	0.947	rs2759009	chr9:131599008	C/T	cg00228799	chr9:131580591	ENDOG	0.6	7.31	0.43	4.37e-12	Blood metabolite levels;
SARC	cis	rs35110281	0.667	rs7282122	chr21:45082365	G/A	cg04455712	chr21:45112962	RRP1B	0.33	4.81	0.3	2.74e-6	Mean corpuscular volume;
SARC	cis	rs4555082	0.645	rs2816605	chr14:105715515	C/T	cg10792982	chr14:105748885	BRF1	0.54	8.01	0.46	5.54e-14	Mean platelet volume;Platelet distribution width;
SARC	cis	rs36051895	0.664	rs7851455	chr9:5100501	G/C	cg02405213	chr9:5042618	JAK2	-0.49	-5.97	-0.36	8.84e-9	Pediatric autoimmune diseases;
SARC	cis	rs12893668	0.603	rs61637848	chr14:104096031	C/T	cg26031613	chr14:104095156	KLC1	-0.54	-5.99	-0.37	7.75e-9	Reticulocyte count;
SARC	cis	rs6088580	0.570	rs6058057	chr20:33065283	G/A	cg08999081	chr20:33150536	PIGU	0.44	6.63	0.4	2.27e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg18876405	chr7:65276391	NA	0.72	9.42	0.53	4.52e-18	Calcium levels;
SARC	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg22535103	chr8:58192502	C8orf71	-0.71	-7.22	-0.43	7.52e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs2204008	0.837	rs11172728	chr12:38070042	C/A	cg26384229	chr12:38710491	ALG10B	0.86	12.3	0.63	4.03e-27	Bladder cancer;
SARC	cis	rs3820928	0.605	rs4675124	chr2:227802354	G/A	cg05526886	chr2:227700861	RHBDD1	-0.49	-6.15	-0.37	3.28e-9	Pulmonary function;
SARC	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg18404041	chr3:52824283	ITIH1	-0.38	-5.68	-0.35	3.93e-8	Bipolar disorder;
SARC	cis	rs7786808	0.741	rs11767875	chr7:158228923	A/G	cg01191920	chr7:158217561	PTPRN2	-0.42	-7.99	-0.46	6.15e-14	Obesity-related traits;
SARC	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg17376030	chr22:41985996	PMM1	-0.74	-9.24	-0.52	1.62e-17	Vitiligo;
SARC	cis	rs9300255	0.739	rs4759415	chr12:123743674	C/T	cg05973401	chr12:123451056	ABCB9	-0.45	-4.91	-0.31	1.75e-6	Neutrophil percentage of white cells;
SARC	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg11987759	chr7:65425863	GUSB	0.47	5.77	0.35	2.51e-8	Aortic root size;
SARC	cis	rs898097	0.625	rs898095	chr17:80890638	T/C	cg15664640	chr17:80829946	TBCD	0.34	5.35	0.33	2.14e-7	Breast cancer;
SARC	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.84	-13.01	-0.65	1.95e-29	Personality dimensions;
SARC	cis	rs4595586	0.545	rs2388179	chr12:39364036	T/A	cg26384229	chr12:38710491	ALG10B	0.51	6.25	0.38	1.9e-9	Morning vs. evening chronotype;
SARC	cis	rs11585357	0.557	rs17378462	chr1:17595702	C/T	cg08277548	chr1:17600880	PADI3	-0.44	-4.78	-0.3	3.13e-6	Hair shape;
SARC	cis	rs17376456	0.597	rs10064158	chr5:93095186	C/T	cg25358565	chr5:93447407	FAM172A	0.94	10.43	0.56	3.7e-21	Diabetic retinopathy;
SARC	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg22862634	chr11:62369728	EML3;MTA2	0.53	8.41	0.48	4.11e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7762018	1.000	rs73242927	chr6:170129573	T/A	cg13891659	chr6:170190454	C6orf122;C6orf208	0.53	4.96	0.31	1.37e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs1348850	0.872	rs4893824	chr2:178298104	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.68	8.32	0.48	7.28e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs10046574	0.831	rs75959757	chr7:135170755	G/A	cg27474649	chr7:135195673	CNOT4	0.85	6.86	0.41	6.11e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg27121462	chr16:89883253	FANCA	0.74	11.56	0.6	9.98e-25	Vitiligo;
SARC	cis	rs9462027	0.628	rs2814967	chr6:34712838	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.4	-5.7	-0.35	3.67e-8	Systemic lupus erythematosus;
SARC	cis	rs763121	0.853	rs2413547	chr22:39107338	A/G	cg21395723	chr22:39101663	GTPBP1	0.54	6.08	0.37	4.86e-9	Menopause (age at onset);
SARC	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg04944784	chr2:26401820	FAM59B	-0.49	-6.25	-0.38	1.89e-9	Gut microbiome composition (summer);
SARC	cis	rs11608355	0.515	rs7310945	chr12:109946012	G/A	cg05360138	chr12:110035743	NA	0.92	9.39	0.52	5.78e-18	Neuroticism;
SARC	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.66	-6.98	-0.42	3.04e-11	Platelet count;
SARC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg24503407	chr1:205819492	PM20D1	0.79	12.26	0.63	5.24e-27	Menarche (age at onset);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg15894103	chr7:130664631	FLJ43663	0.49	6.84	0.41	6.94e-11	Thyroid stimulating hormone;
SARC	cis	rs3762637	0.823	rs9849013	chr3:122250605	A/G	cg24169773	chr3:122142474	KPNA1	-0.57	-5.77	-0.35	2.55e-8	LDL cholesterol levels;
SARC	cis	rs4253772	0.513	rs12171124	chr22:46710693	A/C	cg24881330	chr22:46731750	TRMU	0.67	5.53	0.34	8.72e-8	LDL cholesterol;Cholesterol, total;
SARC	cis	rs12681366	0.708	rs2515165	chr8:95364844	A/G	cg26464482	chr8:95565502	KIAA1429	-0.46	-5.78	-0.35	2.32e-8	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg13647721	chr17:30228624	UTP6	-0.65	-5.95	-0.36	9.7e-9	Hip circumference adjusted for BMI;
SARC	cis	rs539096	0.540	rs3011217	chr1:44303266	C/T	cg12908607	chr1:44402522	ARTN	0.31	5.51	0.34	9.51e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9341808	0.683	rs7771449	chr6:80919977	C/T	cg08355045	chr6:80787529	NA	0.33	5.25	0.33	3.4e-7	Sitting height ratio;
SARC	cis	rs1728785	0.892	rs1103955	chr16:68588488	T/G	cg02972257	chr16:68554789	NA	-0.45	-5.32	-0.33	2.48e-7	Ulcerative colitis;
SARC	cis	rs2304069	0.507	rs7728264	chr5:149394954	C/G	cg12661370	chr5:149340060	SLC26A2	0.55	6.38	0.39	9.62e-10	HIV-1 control;
SARC	cis	rs35306767	0.903	rs11253493	chr10:936931	T/C	cg26597838	chr10:835615	NA	0.77	7.87	0.46	1.37e-13	Eosinophil percentage of granulocytes;
SARC	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg04277193	chr17:41438351	NA	0.44	4.72	0.3	3.99e-6	Menopause (age at onset);
SARC	cis	rs12545109	0.800	rs1440747	chr8:57417924	G/T	cg19413350	chr8:57351067	NA	0.43	4.83	0.3	2.45e-6	Obesity-related traits;
SARC	cis	rs7412746	0.658	rs1546376	chr1:150937661	A/G	cg10589385	chr1:150898437	SETDB1	0.41	5.46	0.34	1.2e-7	Melanoma;
SARC	cis	rs6582630	0.519	rs8189549	chr12:38245752	A/G	cg26384229	chr12:38710491	ALG10B	0.91	13.64	0.67	1.61e-31	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs4808199	0.948	rs757000	chr19:19448301	A/G	cg03709012	chr19:19516395	GATAD2A	1.13	11.33	0.6	5.5e-24	Nonalcoholic fatty liver disease;
SARC	cis	rs1401999	0.932	rs4148557	chr3:183733784	A/G	cg01324343	chr3:183735012	ABCC5	0.66	13.36	0.66	1.33e-30	Anterior chamber depth;
SARC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	6.0	0.37	7.37e-9	Prudent dietary pattern;
SARC	cis	rs995000	0.931	rs2366638	chr1:63099577	G/A	cg06896770	chr1:63153194	DOCK7	0.89	13.36	0.66	1.34e-30	Triglyceride levels;
SARC	cis	rs80282103	0.618	rs17155886	chr10:1145182	A/G	cg08668510	chr10:1095578	IDI1	0.71	4.92	0.31	1.61e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs668210	0.793	rs622779	chr11:65744247	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.64	-6.37	-0.39	9.87e-10	Cerebrospinal fluid biomarker levels;
SARC	cis	rs6582630	0.538	rs8189550	chr12:38333058	T/G	cg13010199	chr12:38710504	ALG10B	-0.51	-6.08	-0.37	4.95e-9	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs778371	0.624	rs6733495	chr2:233616709	A/G	cg20388707	chr2:233749442	NGEF	-0.34	-4.89	-0.3	1.9e-6	Schizophrenia;
SARC	cis	rs2732480	0.500	rs2732461	chr12:48692802	C/A	cg24011408	chr12:48396354	COL2A1	0.48	5.68	0.35	4e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs3845702	0.736	rs12693214	chr2:180825685	G/A	cg01881094	chr2:180872142	CWC22	-1.12	-9.33	-0.52	8.56e-18	Schizophrenia;
SARC	cis	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg07777115	chr5:623756	CEP72	-0.56	-4.81	-0.3	2.68e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-8.76	-0.5	4.15e-16	Alzheimer's disease;
SARC	cis	rs12545109	0.879	rs1581129	chr8:57377476	T/C	cg19413350	chr8:57351067	NA	-0.45	-4.92	-0.31	1.61e-6	Obesity-related traits;
SARC	cis	rs1318878	0.840	rs11056457	chr12:15545128	A/C	cg08258403	chr12:15378311	NA	-0.48	-6.51	-0.39	4.51e-10	Intelligence (multi-trait analysis);
SARC	cis	rs2645694	0.626	rs2703126	chr4:77819842	T/C	cg06046430	chr4:77819534	ANKRD56	0.53	7.54	0.44	1.02e-12	Emphysema distribution in smoking;
SARC	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg18876405	chr7:65276391	NA	0.48	5.47	0.34	1.14e-7	Aortic root size;
SARC	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg03033257	chr22:50311977	ALG12;CRELD2	0.61	5.74	0.35	2.9e-8	Schizophrenia;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg14313443	chr15:66995985	SMAD6	-0.74	-6.36	-0.38	1.06e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs10916814	0.704	rs4655221	chr1:20899265	C/A	cg24502330	chr1:20914028	CDA	-0.3	-5.27	-0.33	3.16e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg13939156	chr17:80058883	NA	-0.44	-6.8	-0.41	8.86e-11	Life satisfaction;
SARC	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg11062466	chr8:58055876	NA	0.53	5.07	0.32	8e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg02524346	chr8:600233	NA	0.67	5.09	0.32	7.52e-7	IgG glycosylation;
SARC	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg14664628	chr15:75095509	CSK	-0.49	-6.11	-0.37	4.09e-9	Breast cancer;
SARC	cis	rs7666738	0.830	rs34671152	chr4:98978177	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6835098	0.962	rs6851632	chr4:174109611	A/G	cg08422745	chr4:174089978	GALNT7	-0.73	-9.31	-0.52	9.57e-18	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs3106136	0.527	rs2883	chr4:95158610	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.47	-7.05	-0.42	2.06e-11	Capecitabine sensitivity;
SARC	cis	rs6582630	0.503	rs4882293	chr12:38388200	G/C	cg13010199	chr12:38710504	ALG10B	-0.48	-5.85	-0.36	1.62e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs11581859	0.613	rs6683097	chr1:99237347	T/C	cg20286094	chr1:99190917	SNX7	-0.43	-5.06	-0.31	8.37e-7	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs240764	0.817	rs239226	chr6:101107969	G/C	cg09795085	chr6:101329169	ASCC3	0.44	5.71	0.35	3.39e-8	Neuroticism;
SARC	cis	rs9790314	0.967	rs1382427	chr3:161032576	T/C	cg04691961	chr3:161091175	C3orf57	-0.79	-11.61	-0.61	7e-25	Morning vs. evening chronotype;
SARC	cis	rs208520	0.754	rs851594	chr6:66876695	A/G	cg07460842	chr6:66804631	NA	-1.12	-15.12	-0.7	1.91e-36	Exhaled nitric oxide output;
SARC	cis	rs1048238	0.506	rs10737911	chr1:16167855	C/T	cg21385522	chr1:16154831	NA	-0.5	-6.49	-0.39	5.07e-10	Systolic blood pressure;
SARC	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.76	10.88	0.58	1.52e-22	Personality dimensions;
SARC	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg02841227	chr6:26021843	HIST1H4A	0.51	6.3	0.38	1.48e-9	Intelligence (multi-trait analysis);
SARC	cis	rs950776	0.790	rs2067808	chr15:78911780	G/A	cg22563815	chr15:78856949	CHRNA5	0.33	5.14	0.32	5.75e-7	Sudden cardiac arrest;
SARC	cis	rs644799	0.710	rs11021311	chr11:95505227	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.94	16.13	0.73	8.51e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs1707322	0.717	rs3014245	chr1:46086913	C/T	cg06784218	chr1:46089804	CCDC17	-0.38	-6.56	-0.39	3.44e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs3858526	0.839	rs10466484	chr11:5943696	A/G	cg13902645	chr11:5959945	NA	-0.43	-4.92	-0.31	1.65e-6	DNA methylation (variation);
SARC	cis	rs8141529	0.529	rs2301428	chr22:29214606	G/C	cg02153584	chr22:29168773	CCDC117	0.67	6.65	0.4	2.03e-10	Lymphocyte counts;
SARC	cis	rs12911832	1.000	rs4774310	chr15:58985164	T/G	cg05156742	chr15:59063176	FAM63B	0.61	7.77	0.45	2.56e-13	Schizophrenia;
SARC	cis	rs3741404	0.609	rs651855	chr11:63870810	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	9.07	0.51	5.25e-17	Platelet count;
SARC	cis	rs10911232	0.507	rs10797815	chr1:182996827	A/G	cg13390022	chr1:182993471	LAMC1	0.33	4.97	0.31	1.31e-6	Hypertriglyceridemia;
SARC	cis	rs57221529	0.766	rs12521051	chr5:560440	A/G	cg09021430	chr5:549028	NA	0.38	5.11	0.32	6.85e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs67311347	1.000	rs1119179	chr3:40424929	A/C	cg09455208	chr3:40491958	NA	-0.36	-5.4	-0.33	1.65e-7	Renal cell carcinoma;
SARC	cis	rs6813479	0.523	rs1585402	chr4:137744395	A/G	cg16185213	chr4:137733633	NA	0.38	5.2	0.32	4.41e-7	Longevity;
SARC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg24846343	chr22:24311635	DDTL	0.51	6.92	0.41	4.29e-11	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9868809	0.772	rs12107418	chr3:48689787	A/G	cg12468774	chr3:49236860	CCDC36	0.44	4.74	0.3	3.7e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	15.02	0.7	4.1e-36	Chronic sinus infection;
SARC	cis	rs11190604	1.000	rs2489045	chr10:102344754	C/T	cg07080220	chr10:102295463	HIF1AN	0.77	8.17	0.47	1.92e-14	Palmitoleic acid (16:1n-7) levels;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg13893584	chr12:28123068	PTHLH	-0.48	-6.42	-0.39	7.56e-10	Thyroid stimulating hormone;
SARC	cis	rs10040989	0.749	rs78702109	chr5:137705715	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.76	4.86	0.3	2.14e-6	QT interval;
SARC	trans	rs9929218	0.551	rs3785134	chr16:68728938	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.8	13.67	0.67	1.26e-31	Colorectal cancer;
SARC	cis	rs838147	0.844	rs8111208	chr19:49248022	A/C	cg13540341	chr19:49222985	MAMSTR	0.28	4.73	0.3	3.83e-6	Dietary macronutrient intake;
SARC	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.47	5.24	0.32	3.51e-7	Renal function-related traits (BUN);
SARC	cis	rs8177253	0.665	rs4525863	chr3:133436136	C/A	cg01448562	chr3:133502909	NA	-0.44	-6.2	-0.38	2.58e-9	Iron status biomarkers;
SARC	cis	rs3820928	0.605	rs4281898	chr2:227855493	A/C	cg11843606	chr2:227700838	RHBDD1	-0.48	-6.23	-0.38	2.16e-9	Pulmonary function;
SARC	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg04166393	chr7:2884313	GNA12	0.53	6.34	0.38	1.17e-9	Height;
SARC	cis	rs3092073	0.617	rs17448680	chr20:44594726	T/C	cg27529037	chr20:44575021	PCIF1	-0.34	-5.02	-0.31	1.02e-6	Intelligence (multi-trait analysis);
SARC	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg12463550	chr7:65579703	CRCP	-0.45	-5.42	-0.33	1.48e-7	Aortic root size;
SARC	cis	rs7666738	0.791	rs1896155	chr4:99020948	C/A	cg05340658	chr4:99064831	C4orf37	0.66	9.04	0.51	6.35e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs73086581	1.000	rs6107393	chr20:3987738	C/T	cg02187196	chr20:3869020	PANK2	0.64	6.32	0.38	1.3e-9	Response to antidepressants in depression;
SARC	cis	rs17270561	0.609	rs9348694	chr6:25753640	C/T	cg16482183	chr6:26056742	HIST1H1C	0.43	5.03	0.31	9.85e-7	Iron status biomarkers;
SARC	cis	rs9389248	0.737	rs56358308	chr6:135306980	A/T	cg24558204	chr6:135376177	HBS1L	0.62	8.1	0.47	3.16e-14	High light scatter reticulocyte percentage of red cells;
SARC	cis	rs6815814	0.904	rs7664239	chr4:38786304	T/C	cg06935464	chr4:38784597	TLR10	0.49	5.6	0.34	6.01e-8	Breast cancer;
SARC	cis	rs67311347	0.713	rs114569261	chr3:40314580	G/A	cg24209194	chr3:40518798	ZNF619	0.54	6.67	0.4	1.86e-10	Renal cell carcinoma;
SARC	cis	rs9640161	0.830	rs11768108	chr7:150064150	C/T	cg17279839	chr7:150038598	RARRES2	0.34	4.91	0.31	1.73e-6	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg24675658	chr1:53192096	ZYG11B	0.74	11.28	0.59	7.93e-24	Monocyte count;
SARC	cis	rs6582630	0.502	rs11495393	chr12:38341194	T/C	cg13010199	chr12:38710504	ALG10B	0.79	10.85	0.58	1.8e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.49	-6.14	-0.37	3.52e-9	Lymphocyte counts;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg21878890	chr14:75725895	NA	0.59	7.22	0.43	7.46e-12	Blood pressure;
SARC	cis	rs1008375	0.932	rs11941874	chr4:17666416	C/T	cg27347728	chr4:17578864	LAP3	-0.48	-5.84	-0.36	1.76e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg11987759	chr7:65425863	GUSB	-0.48	-5.87	-0.36	1.51e-8	Aortic root size;
SARC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.67	8.93	0.51	1.29e-16	Prudent dietary pattern;
SARC	cis	rs12681366	0.537	rs2919659	chr8:95471772	T/C	cg13257157	chr8:95487014	RAD54B	0.4	4.81	0.3	2.67e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs7296418	0.961	rs1790106	chr12:123591596	G/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.42	-5.72	-0.35	3.33e-8	Platelet count;
SARC	cis	rs2486288	0.586	rs12909625	chr15:45572053	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.53	-6.65	-0.4	2.03e-10	Glomerular filtration rate;
SARC	cis	rs7107356	1	rs7107356	chr11:47676170	A/G	cg10504702	chr11:47789108	FNBP4	0.38	4.75	0.3	3.49e-6	Neuroticism;Neuroticism (multi-trait analysis);
SARC	trans	rs1814175	0.817	rs4881658	chr11:49941123	G/A	cg15704280	chr7:45808275	SEPT13	-0.96	-17.71	-0.76	4.73e-45	Height;
SARC	cis	rs5753618	0.583	rs8138596	chr22:31786961	T/A	cg13145458	chr22:31556086	RNF185	-0.45	-4.71	-0.3	4.19e-6	Colorectal cancer;
SARC	cis	rs2153535	0.580	rs9505458	chr6:8479215	A/G	cg23788917	chr6:8435910	SLC35B3	0.64	8.59	0.49	1.25e-15	Motion sickness;
SARC	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg04518342	chr5:131593106	PDLIM4	0.37	5.2	0.32	4.36e-7	Breast cancer;
SARC	cis	rs910316	0.967	rs11159116	chr14:75550584	G/T	cg23033748	chr14:75592666	NEK9	0.37	5.15	0.32	5.46e-7	Height;
SARC	cis	rs916888	0.531	rs183211	chr17:44788310	G/A	cg01570182	chr17:44337453	NA	0.62	7.45	0.44	1.83e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs4588572	0.561	rs7727592	chr5:77804547	G/A	cg11547950	chr5:77652471	NA	-0.38	-4.77	-0.3	3.24e-6	Triglycerides;
SARC	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-6.53	-0.39	4.04e-10	Bipolar disorder;
SARC	cis	rs41278232	0.557	rs817341	chr20:62606765	C/T	cg07620230	chr20:62328084	TNFRSF6B	0.33	4.72	0.3	4.13e-6	Tonsillectomy;
SARC	cis	rs72634258	0.836	rs9658012	chr1:7989022	C/T	cg00042356	chr1:8021962	PARK7	0.72	6.13	0.37	3.76e-9	Inflammatory bowel disease;
SARC	cis	rs11605924	0.766	rs12419690	chr11:45858584	G/A	ch.11.939596F	chr11:45881766	CRY2	-0.45	-5.54	-0.34	8.21e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-6.48	-0.39	5.37e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs55882075	0.722	rs10903245	chr5:179133608	T/C	cg14593053	chr5:179126677	CANX	0.52	7.19	0.43	8.5e-12	Monocyte percentage of white cells;
SARC	cis	rs12579753	0.917	rs12311988	chr12:82177209	C/A	cg07988820	chr12:82153109	PPFIA2	-0.54	-6.35	-0.38	1.14e-9	Resting heart rate;
SARC	cis	rs6582630	0.563	rs923281	chr12:38590241	G/A	cg14851346	chr12:38532713	NA	-0.44	-5.32	-0.33	2.43e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg08975724	chr8:8085496	FLJ10661	0.42	5.38	0.33	1.8e-7	Joint mobility (Beighton score);
SARC	cis	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg24110177	chr3:50126178	RBM5	0.54	7.28	0.43	4.95e-12	Intelligence (multi-trait analysis);
SARC	cis	rs9517320	0.515	rs4771307	chr13:99221879	A/G	cg07423050	chr13:99094983	FARP1	-0.42	-5.29	-0.33	2.87e-7	Longevity;
SARC	cis	rs6088580	0.634	rs1205338	chr20:32925625	C/G	cg24642439	chr20:33292090	TP53INP2	-0.64	-8.31	-0.48	8.16e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs7766436	0.885	rs13198355	chr6:22577119	C/G	cg13666174	chr6:22585274	NA	-0.58	-7.06	-0.42	1.93e-11	Coronary artery disease;
SARC	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg27170947	chr2:26402098	FAM59B	0.37	4.8	0.3	2.79e-6	Gut microbiome composition (summer);
SARC	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg23531748	chr20:60969906	CABLES2	-0.49	-6.11	-0.37	4.1e-9	Colorectal cancer;
SARC	cis	rs7635838	0.596	rs347598	chr3:11258289	G/C	cg00170343	chr3:11313890	ATG7	0.66	8.85	0.5	2.31e-16	HDL cholesterol;
SARC	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg02788857	chr8:22132959	PIWIL2	0.35	4.98	0.31	1.22e-6	Hypertriglyceridemia;
SARC	cis	rs7937682	0.632	rs14133	chr11:111782697	C/G	cg09085632	chr11:111637200	PPP2R1B	0.78	10.49	0.57	2.48e-21	Primary sclerosing cholangitis;
SARC	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg19223190	chr17:80058835	NA	-0.4	-5.5	-0.34	1.01e-7	Life satisfaction;
SARC	cis	rs2180341	0.538	rs11154402	chr6:127711932	C/A	cg27446573	chr6:127587934	RNF146	0.51	6.35	0.38	1.09e-9	Breast cancer;
SARC	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg17971929	chr21:40555470	PSMG1	-0.59	-7.44	-0.44	1.89e-12	Menarche (age at onset);
SARC	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.68	-8.75	-0.5	4.34e-16	Chronic sinus infection;
SARC	cis	rs4423214	0.819	rs7938885	chr11:71170043	T/C	cg24826892	chr11:71159390	DHCR7	0.48	6.16	0.37	3.09e-9	Vitamin D levels;
SARC	cis	rs7264396	0.790	rs6060519	chr20:34217383	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-7.75	-0.45	2.82e-13	Total cholesterol levels;
SARC	cis	rs11871801	0.517	rs34855406	chr17:40731411	G/C	cg20126647	chr17:40714003	COASY	0.53	5.29	0.33	2.84e-7	Crohn's disease;
SARC	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg25072359	chr17:41440525	NA	0.51	6.0	0.37	7.33e-9	Menopause (age at onset);
SARC	trans	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg00938859	chr5:1591904	SDHAP3	0.78	7.53	0.44	1.1e-12	Breast cancer;
SARC	cis	rs6732160	0.564	rs2043096	chr2:73375723	T/C	cg01422370	chr2:73384389	NA	0.38	5.81	0.36	2.01e-8	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1707322	0.691	rs11211174	chr1:46220816	C/G	cg06784218	chr1:46089804	CCDC17	0.37	6.29	0.38	1.59e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs11613048	0.897	rs7136950	chr12:30321100	G/A	cg12718339	chr12:29936407	TMTC1	-0.36	-5.0	-0.31	1.11e-6	Major depressive disorder;
SARC	cis	rs2204008	0.652	rs11513964	chr12:37998214	C/G	cg13010199	chr12:38710504	ALG10B	0.78	10.73	0.57	4.45e-22	Bladder cancer;
SARC	cis	rs7833790	0.927	rs61020899	chr8:82757090	C/T	cg17211192	chr8:82754475	SNX16	0.59	6.43	0.39	7.2e-10	Diastolic blood pressure;
SARC	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg04944784	chr2:26401820	FAM59B	-0.48	-6.07	-0.37	5.06e-9	Gut microbiome composition (summer);
SARC	cis	rs7429990	0.965	rs7642590	chr3:48099750	G/A	cg11946769	chr3:48343235	NME6	-0.49	-5.48	-0.34	1.09e-7	Educational attainment (years of education);
SARC	cis	rs10752881	0.809	rs3768613	chr1:183106296	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.04	0.55	6e-20	Colorectal cancer;
SARC	cis	rs6840360	0.550	rs7689266	chr4:152561048	T/C	cg22705602	chr4:152727874	NA	-0.44	-6.81	-0.41	8.1e-11	Intelligence (multi-trait analysis);
SARC	cis	rs995000	0.839	rs12403207	chr1:62993620	T/C	cg06896770	chr1:63153194	DOCK7	-0.88	-12.57	-0.64	5.16e-28	Triglyceride levels;
SARC	cis	rs1865760	0.713	rs9461229	chr6:25992279	G/T	cg10373733	chr6:25993375	NA	0.46	5.95	0.36	9.84e-9	Height;
SARC	cis	rs7927771	0.524	rs10742820	chr11:47781057	C/T	cg20307385	chr11:47447363	PSMC3	-0.49	-6.63	-0.4	2.36e-10	Subjective well-being;
SARC	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.79	11.43	0.6	2.55e-24	Total body bone mineral density;
SARC	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg26335602	chr6:28129616	ZNF389	-0.49	-5.33	-0.33	2.35e-7	Parkinson's disease;
SARC	cis	rs6570726	0.764	rs448258	chr6:145869145	C/A	cg05347473	chr6:146136440	FBXO30	0.54	7.45	0.44	1.82e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1562975	0.722	rs17583662	chr4:109461985	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.43	5.08	0.32	7.79e-7	Height;
SARC	trans	rs7937682	0.889	rs558736	chr11:111500760	C/G	cg18187862	chr3:45730750	SACM1L	0.57	7.19	0.43	8.81e-12	Primary sclerosing cholangitis;
SARC	cis	rs7927771	0.524	rs10838771	chr11:47831332	A/G	cg20307385	chr11:47447363	PSMC3	-0.49	-6.61	-0.4	2.63e-10	Subjective well-being;
SARC	cis	rs8180040	0.966	rs922957	chr3:47422152	G/C	cg27129171	chr3:47204927	SETD2	-0.68	-9.5	-0.53	2.68e-18	Colorectal cancer;
SARC	cis	rs2303759	0.551	rs7249040	chr19:49790602	C/T	cg22307029	chr19:49891270	CCDC155	0.54	5.95	0.36	9.95e-9	Multiple sclerosis;
SARC	cis	rs969413	0.624	rs7213540	chr17:79255912	C/T	cg25342872	chr17:79175132	AZI1	-0.37	-5.2	-0.32	4.31e-7	Frontotemporal dementia;
SARC	cis	rs7552404	0.731	rs5745491	chr1:76350159	T/G	cg03433033	chr1:76189801	ACADM	-0.42	-5.37	-0.33	1.87e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs2011503	0.941	rs11670775	chr19:19649636	A/G	cg15839431	chr19:19639596	YJEFN3	-0.48	-4.77	-0.3	3.32e-6	Bipolar disorder;
SARC	cis	rs9427116	0.502	rs12125166	chr1:154582129	A/G	cg17833341	chr1:154947313	SHC1;CKS1B	-0.41	-5.02	-0.31	1.02e-6	Blood protein levels;
SARC	cis	rs7246657	0.943	rs4801759	chr19:37954985	G/A	cg23950597	chr19:37808831	NA	-0.63	-6.05	-0.37	5.72e-9	Coronary artery calcification;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg18739800	chr6:27806020	HIST1H2BN;HIST1H2AK	0.52	7.02	0.42	2.42e-11	Chemerin levels;
SARC	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.45	-5.2	-0.32	4.32e-7	Longevity;Endometriosis;
SARC	cis	rs2115630	1.000	rs11854313	chr15:85304048	G/C	cg17507749	chr15:85114479	UBE2QP1	-0.45	-5.29	-0.33	2.79e-7	P wave terminal force;
SARC	cis	rs644799	0.544	rs56298021	chr11:95545113	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.74	9.87	0.54	2.09e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs1153858	1.000	rs4775937	chr15:45678614	C/A	cg03999130	chr15:45571217	NA	0.39	4.98	0.31	1.25e-6	Homoarginine levels;
SARC	cis	rs6908034	0.607	rs34109983	chr6:19808042	G/A	cg02682789	chr6:19804855	NA	0.72	5.71	0.35	3.37e-8	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs9309473	0.519	rs2421545	chr2:73639476	T/C	cg20560298	chr2:73613845	ALMS1	0.52	7.14	0.42	1.19e-11	Metabolite levels;
SARC	cis	rs2486288	0.656	rs2413772	chr15:45549862	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.52	-6.53	-0.39	3.99e-10	Glomerular filtration rate;
SARC	cis	rs3733585	0.781	rs6449183	chr4:9970691	C/A	cg11266682	chr4:10021025	SLC2A9	-0.36	-6.39	-0.39	8.85e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg25894440	chr7:65020034	NA	-0.75	-5.67	-0.35	4.13e-8	Diabetic kidney disease;
SARC	cis	rs10489202	0.608	rs6659593	chr1:168072152	A/T	cg24449463	chr1:168025552	DCAF6	-0.61	-8.15	-0.47	2.16e-14	Schizophrenia;
SARC	cis	rs12824058	0.678	rs11614163	chr12:130814621	C/G	cg26677194	chr12:130822605	PIWIL1	0.57	7.76	0.45	2.64e-13	Menopause (age at onset);
SARC	cis	rs7552404	0.924	rs1251075	chr1:76190569	C/G	cg22875332	chr1:76189707	ACADM	0.41	5.91	0.36	1.2e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg04267008	chr7:1944627	MAD1L1	-0.5	-5.69	-0.35	3.85e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs950776	0.518	rs12907169	chr15:78825498	G/C	cg22563815	chr15:78856949	CHRNA5	0.41	6.82	0.41	7.56e-11	Sudden cardiac arrest;
SARC	cis	rs9325144	0.647	rs1875609	chr12:39018259	C/T	cg13010199	chr12:38710504	ALG10B	-0.52	-6.64	-0.4	2.23e-10	Morning vs. evening chronotype;
SARC	cis	rs8141529	0.732	rs2347447	chr22:29179739	C/A	cg15103426	chr22:29168792	CCDC117	0.69	9.21	0.52	1.94e-17	Lymphocyte counts;
SARC	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg13395646	chr4:1353034	KIAA1530	-0.58	-6.87	-0.41	5.95e-11	Obesity-related traits;
SARC	cis	rs9733	0.621	rs6669122	chr1:150591732	A/G	cg18016565	chr1:150552671	MCL1	-0.39	-5.32	-0.33	2.41e-7	Tonsillectomy;
SARC	trans	rs208520	0.690	rs10455194	chr6:66743356	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	13.79	0.67	5.04e-32	Exhaled nitric oxide output;
SARC	cis	rs7589342	0.929	rs6725519	chr2:106445209	A/G	cg14210321	chr2:106509881	NCK2	0.42	4.99	0.31	1.18e-6	Addiction;
SARC	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg03517284	chr6:25882590	NA	-0.53	-6.96	-0.41	3.43e-11	Intelligence (multi-trait analysis);
SARC	cis	rs9682041	0.660	rs34158232	chr3:170115360	T/C	cg11886554	chr3:170076028	SKIL	0.84	7.77	0.45	2.51e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs738322	0.742	rs4821767	chr22:38614129	G/T	cg25457927	chr22:38595422	NA	0.31	6.25	0.38	1.91e-9	Cutaneous nevi;
SARC	cis	rs9814567	0.964	rs1534028	chr3:134284639	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.04	-0.42	2.19e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs2303759	0.676	rs10426452	chr19:49907690	G/A	cg22307029	chr19:49891270	CCDC155	0.43	5.14	0.32	5.88e-7	Multiple sclerosis;
SARC	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg22875332	chr1:76189707	ACADM	0.48	5.82	0.36	1.91e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs11122272	0.701	rs2011383	chr1:231479788	T/A	cg06096015	chr1:231504339	EGLN1	0.38	5.61	0.34	5.71e-8	Hemoglobin concentration;
SARC	cis	rs2439831	0.850	rs558656	chr15:43723514	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	8.09	0.47	3.35e-14	Lung cancer in ever smokers;
SARC	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.69	-8.9	-0.5	1.61e-16	Chronic sinus infection;
SARC	trans	rs7615952	0.611	rs12488771	chr3:125700526	A/G	cg07211511	chr3:129823064	LOC729375	-0.83	-6.53	-0.39	4.05e-10	Blood pressure (smoking interaction);
SARC	cis	rs6964587	0.773	rs13223564	chr7:91932666	A/G	cg17063962	chr7:91808500	NA	0.92	12.81	0.64	8.67e-29	Breast cancer;
SARC	cis	rs4792901	0.759	rs9907813	chr17:41602858	T/G	cg22562494	chr17:41607896	ETV4	-0.32	-4.98	-0.31	1.25e-6	Dupuytren's disease;
SARC	cis	rs4555082	0.834	rs2735826	chr14:105710866	G/A	cg06808227	chr14:105710500	BRF1	-0.51	-6.51	-0.39	4.46e-10	Mean platelet volume;Platelet distribution width;
SARC	cis	rs12956009	0.518	rs3902716	chr18:44889441	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.58	7.49	0.44	1.44e-12	Educational attainment (years of education);
SARC	cis	rs1003719	0.645	rs8131944	chr21:38547215	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.48	-0.53	3.11e-18	Eye color traits;
SARC	cis	rs6088580	0.543	rs4911158	chr20:33239512	T/C	cg24642439	chr20:33292090	TP53INP2	-0.55	-6.74	-0.4	1.22e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs473651	0.935	rs541013	chr2:239336492	G/A	cg18131467	chr2:239335373	ASB1	0.96	16.21	0.73	4.55e-40	Multiple system atrophy;
SARC	cis	rs9611519	0.929	rs9611469	chr22:41433319	T/C	cg17376030	chr22:41985996	PMM1	0.5	6.05	0.37	5.85e-9	Neuroticism;
SARC	cis	rs9400467	0.506	rs12199656	chr6:111675143	A/C	cg15721981	chr6:111408429	SLC16A10	0.64	5.51	0.34	9.48e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs9457247	0.646	rs239934	chr6:167412048	G/A	cg07741184	chr6:167504864	NA	0.31	5.95	0.36	9.65e-9	Crohn's disease;
SARC	cis	rs10979	0.965	rs7754452	chr6:143889028	G/A	cg25407410	chr6:143891975	LOC285740	-0.64	-8.68	-0.49	6.88e-16	Hypospadias;
SARC	cis	rs3733585	0.673	rs4235348	chr4:9951968	T/C	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.39	-0.33	1.76e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs6964587	1.000	rs9690778	chr7:91735299	A/G	cg17063962	chr7:91808500	NA	0.95	16.04	0.72	1.66e-39	Breast cancer;
SARC	cis	rs77106637	0.929	rs77464186	chr11:72460398	A/C	cg03713592	chr11:72463424	ARAP1	1.09	10.42	0.56	4.16e-21	Type 2 diabetes;
SARC	cis	rs796364	0.951	rs3098341	chr2:200792498	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.78	7.15	0.42	1.12e-11	Schizophrenia;
SARC	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9916302	0.800	rs9892675	chr17:37549200	C/T	cg20243544	chr17:37824526	PNMT	-0.58	-6.58	-0.4	3.1e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs7520050	0.966	rs10789481	chr1:46383583	C/G	cg06784218	chr1:46089804	CCDC17	-0.26	-4.76	-0.3	3.4e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs9300255	0.550	rs10772997	chr12:123719880	C/A	cg00376283	chr12:123451042	ABCB9	0.56	6.58	0.4	3.1e-10	Neutrophil percentage of white cells;
SARC	cis	rs9393692	0.875	rs9393690	chr6:26271713	A/T	cg13736514	chr6:26305472	NA	-0.61	-8.56	-0.49	1.56e-15	Educational attainment;
SARC	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg22535103	chr8:58192502	C8orf71	-0.7	-7.12	-0.42	1.31e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs7223966	1.000	rs12325866	chr17:61755974	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	6.59	0.4	2.94e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.73	-7.58	-0.44	7.9e-13	Platelet count;
SARC	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg24675658	chr1:53192096	ZYG11B	-0.56	-7.78	-0.45	2.32e-13	Monocyte count;
SARC	cis	rs7647973	0.925	rs4955439	chr3:49245645	G/T	cg07636037	chr3:49044803	WDR6	-0.76	-8.17	-0.47	1.95e-14	Menarche (age at onset);
SARC	cis	rs554111	0.571	rs4537519	chr1:21461370	T/C	cg04902671	chr1:21058625	SH2D5	0.46	5.71	0.35	3.45e-8	Facial morphology (factor 17, height of vermillion upper lip);
SARC	trans	rs8073060	0.586	rs7214742	chr17:33981969	C/A	cg19694781	chr19:47549865	TMEM160	-0.68	-6.85	-0.41	6.48e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg27541892	chr1:1571801	CDK11B	0.4	5.45	0.34	1.29e-7	Body mass index;
SARC	cis	rs5753618	0.607	rs5753621	chr22:31847647	T/C	cg07713946	chr22:31675144	LIMK2	0.36	5.01	0.31	1.08e-6	Colorectal cancer;
SARC	cis	rs1059312	1.000	rs7135854	chr12:129279988	G/C	cg09035930	chr12:129282057	SLC15A4	0.61	8.74	0.5	4.7e-16	Systemic lupus erythematosus;
SARC	cis	rs7246657	0.882	rs6508716	chr19:37819010	T/C	cg23950597	chr19:37808831	NA	-0.54	-5.46	-0.34	1.24e-7	Coronary artery calcification;
SARC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg22903471	chr2:27725779	GCKR	-0.49	-7.42	-0.44	2.21e-12	Total body bone mineral density;
SARC	cis	rs1153858	1.000	rs16942000	chr15:45633003	C/T	cg21132104	chr15:45694354	SPATA5L1	0.79	11.15	0.59	2.03e-23	Homoarginine levels;
SARC	cis	rs9303280	0.806	rs36038753	chr17:38035370	G/T	cg20243544	chr17:37824526	PNMT	0.43	5.63	0.35	5.08e-8	Self-reported allergy;
SARC	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg05872129	chr22:39784769	NA	-0.43	-6.11	-0.37	4.26e-9	Intelligence (multi-trait analysis);
SARC	cis	rs2576037	0.566	rs2437854	chr18:44557613	T/C	cg15049968	chr18:44337910	ST8SIA5	0.32	4.99	0.31	1.21e-6	Personality dimensions;
SARC	cis	rs73198271	0.531	rs3748142	chr8:8655355	G/A	cg01851573	chr8:8652454	MFHAS1	0.41	4.89	0.31	1.84e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs10911232	0.507	rs12037623	chr1:183000148	G/A	cg13390022	chr1:182993471	LAMC1	0.33	4.97	0.31	1.31e-6	Hypertriglyceridemia;
SARC	cis	rs3741151	0.773	rs73542952	chr11:73108556	A/G	cg17517138	chr11:73019481	ARHGEF17	0.86	6.41	0.39	7.94e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	trans	rs208520	0.661	rs704519	chr6:66801136	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-14.36	-0.69	6.43e-34	Exhaled nitric oxide output;
SARC	cis	rs4481887	0.893	rs4244186	chr1:248493319	A/G	cg13385794	chr1:248469461	NA	0.33	4.98	0.31	1.21e-6	Common traits (Other);
SARC	cis	rs3784262	0.631	rs3742961	chr15:58247977	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.32	-4.76	-0.3	3.36e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs1348850	0.567	rs3770005	chr2:178528874	A/G	cg22681709	chr2:178499509	PDE11A	-0.38	-5.4	-0.33	1.64e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2228479	0.850	rs3785279	chr16:89824562	G/C	cg26513180	chr16:89883248	FANCA	0.72	4.79	0.3	2.99e-6	Skin colour saturation;
SARC	cis	rs72781680	0.898	rs55841168	chr2:24007926	T/C	cg08917208	chr2:24149416	ATAD2B	0.75	7.09	0.42	1.56e-11	Lymphocyte counts;
SARC	cis	rs13191362	0.935	rs67084568	chr6:162988548	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.59	0.34	6.28e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg21393986	chr3:196159244	UBXN7	0.53	6.55	0.39	3.68e-10	Breast cancer;
SARC	cis	rs9486715	0.838	rs6928442	chr6:96870118	A/G	cg18709589	chr6:96969512	KIAA0776	0.58	7.27	0.43	5.5e-12	Headache;
SARC	cis	rs13191362	1.000	rs34931503	chr6:163003876	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.49	0.34	1.04e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs9790314	0.521	rs2122527	chr3:161091636	G/A	cg04691961	chr3:161091175	C3orf57	-0.54	-7.17	-0.43	1e-11	Morning vs. evening chronotype;
SARC	cis	rs735396	1.000	rs1169309	chr12:121439192	G/T	cg15155738	chr12:121454335	C12orf43	0.5	6.09	0.37	4.73e-9	N-glycan levels;
SARC	cis	rs2070677	0.935	rs12245492	chr10:135419727	A/G	cg20169779	chr10:135381914	SYCE1	-0.52	-6.46	-0.39	6e-10	Gout;
SARC	cis	rs9467773	0.620	rs2498351	chr6:26659642	C/T	cg11502198	chr6:26597334	ABT1	0.63	8.48	0.49	2.58e-15	Intelligence (multi-trait analysis);
SARC	cis	rs6840360	0.934	rs6817058	chr4:152603865	T/C	cg22705602	chr4:152727874	NA	-0.38	-6.54	-0.39	3.9e-10	Intelligence (multi-trait analysis);
SARC	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg11644478	chr21:40555479	PSMG1	-0.56	-6.95	-0.41	3.64e-11	Menarche (age at onset);
SARC	cis	rs7223966	1.000	rs13380863	chr17:61780793	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.51	-5.31	-0.33	2.54e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.67	6.41	0.39	8.06e-10	Age-related macular degeneration (geographic atrophy);
SARC	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg01341218	chr17:43662625	NA	-0.85	-9.63	-0.53	1.11e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg12419862	chr22:24373484	LOC391322	-0.51	-5.89	-0.36	1.34e-8	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs10046574	0.831	rs10239457	chr7:135116926	A/G	cg27474649	chr7:135195673	CNOT4	-0.83	-6.86	-0.41	6.05e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg13699009	chr12:122356056	WDR66	0.59	9.32	0.52	9.14e-18	Mean corpuscular volume;
SARC	cis	rs11098499	0.505	rs75122014	chr4:120362426	G/C	cg24375607	chr4:120327624	NA	0.43	5.12	0.32	6.44e-7	Corneal astigmatism;
SARC	cis	rs34779708	0.931	rs17591135	chr10:35465190	T/A	cg03585969	chr10:35415529	CREM	0.39	4.78	0.3	3.16e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs6952808	0.929	rs12699483	chr7:1975624	C/G	cg21782813	chr7:2030301	MAD1L1	0.43	6.45	0.39	6.51e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs8114671	0.562	rs6088622	chr20:33419977	C/A	cg07148914	chr20:33460835	GGT7	0.43	5.17	0.32	5.02e-7	Height;
SARC	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg01316550	chr5:56110833	MAP3K1	0.54	4.92	0.31	1.62e-6	Initial pursuit acceleration;
SARC	cis	rs6089584	0.546	rs4925337	chr20:60637637	T/C	cg06108461	chr20:60628389	TAF4	-0.67	-8.37	-0.48	5.22e-15	Body mass index;
SARC	cis	rs13082711	0.911	rs13086867	chr3:27529937	G/A	cg02860705	chr3:27208620	NA	0.45	5.69	0.35	3.84e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs35110281	0.776	rs229357	chr21:44982717	T/C	cg21573476	chr21:45109991	RRP1B	-0.53	-7.72	-0.45	3.44e-13	Mean corpuscular volume;
SARC	cis	rs3106136	0.967	rs66581998	chr4:95196901	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.38	-5.71	-0.35	3.4e-8	Capecitabine sensitivity;
SARC	cis	rs448720	0.806	rs4306451	chr15:68157881	A/G	cg05925327	chr15:68127851	NA	-0.36	-5.05	-0.31	8.94e-7	Cognitive performance;
SARC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg09373136	chr17:61933544	TCAM1	-0.45	-6.23	-0.38	2.18e-9	Prudent dietary pattern;
SARC	trans	rs208520	0.690	rs207096	chr6:66797287	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-14.36	-0.69	6.28e-34	Exhaled nitric oxide output;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg06475972	chr17:34842357	ZNHIT3	-0.61	-6.25	-0.38	1.94e-9	Lung cancer in ever smokers;
SARC	cis	rs7474896	0.537	rs598857	chr10:38302926	A/G	cg00409905	chr10:38381863	ZNF37A	0.42	4.75	0.3	3.48e-6	Obesity (extreme);
SARC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg01516881	chr6:292596	DUSP22	0.67	8.63	0.49	9.78e-16	Menopause (age at onset);
SARC	cis	rs10911232	0.507	rs4652764	chr1:182994115	C/T	cg13390022	chr1:182993471	LAMC1	0.34	5.07	0.32	8.16e-7	Hypertriglyceridemia;
SARC	cis	rs11098499	0.908	rs71614449	chr4:120387055	C/T	cg09307838	chr4:120376055	NA	0.9	12.47	0.63	1.13e-27	Corneal astigmatism;
SARC	cis	rs2075371	0.796	rs1978504	chr7:134006933	C/T	cg11752832	chr7:134001865	SLC35B4	-0.57	-7.33	-0.43	3.71e-12	Mean platelet volume;
SARC	cis	rs9916302	0.904	rs12452509	chr17:37574722	G/A	cg07936489	chr17:37558343	FBXL20	-0.69	-9.17	-0.52	2.52e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg22875332	chr1:76189707	ACADM	0.49	6.83	0.41	7.16e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs4268898	0.865	rs13021828	chr2:24439276	G/C	cg06627628	chr2:24431161	ITSN2	-0.65	-8.49	-0.49	2.46e-15	Asthma;
SARC	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg03709012	chr19:19516395	GATAD2A	-0.94	-15.04	-0.7	3.61e-36	Tonsillectomy;
SARC	cis	rs2730245	0.527	rs2527205	chr7:158706393	G/T	cg24397884	chr7:158709396	WDR60	-1.09	-9.71	-0.54	6.02e-19	Height;
SARC	cis	rs17572109	0.666	rs11696005	chr2:219229641	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.55	-5.61	-0.34	5.76e-8	Platelet count;Platelet distribution width;Mean platelet volume;
SARC	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg06697600	chr4:7070879	GRPEL1	-0.38	-4.77	-0.3	3.22e-6	Monocyte percentage of white cells;
SARC	trans	rs453301	0.571	rs330057	chr8:9089793	C/T	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.38	-0.39	9.59e-10	Joint mobility (Beighton score);
SARC	cis	rs3771570	0.901	rs62190413	chr2:242417950	G/A	cg21155796	chr2:242212141	HDLBP	0.64	5.99	0.37	7.87e-9	Prostate cancer;
SARC	cis	rs1707322	1.000	rs12097799	chr1:46459886	C/A	cg03146154	chr1:46216737	IPP	0.46	5.59	0.34	6.25e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs981844	0.775	rs17371545	chr4:154763980	A/G	cg14289246	chr4:154710475	SFRP2	-0.57	-6.59	-0.4	2.83e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.53	-6.47	-0.39	5.84e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs11864453	0.826	rs6499560	chr16:72147666	G/T	cg01557791	chr16:72042693	DHODH	0.64	8.96	0.51	1.1e-16	Fibrinogen levels;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg07615839	chr2:231921515	PSMD1	0.76	6.29	0.38	1.52e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs67460515	0.528	rs11915989	chr3:160902259	A/G	cg04691961	chr3:161091175	C3orf57	-0.4	-4.79	-0.3	2.98e-6	Parkinson's disease;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg09612423	chr7:120596469	ING3	0.49	6.9	0.41	4.95e-11	Thyroid stimulating hormone;
SARC	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg06634786	chr22:41940651	POLR3H	0.53	6.41	0.39	7.81e-10	Vitiligo;
SARC	cis	rs941873	0.835	rs4246944	chr10:81105684	C/T	cg09469691	chr10:81107165	PPIF	0.61	9.17	0.52	2.54e-17	Height;
SARC	cis	rs6429082	0.806	rs2382570	chr1:235570523	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.4	-5.1	-0.32	7.04e-7	Adiposity;
SARC	cis	rs920590	0.876	rs3907477	chr8:19657744	C/T	cg03894339	chr8:19674705	INTS10	0.56	7.1	0.42	1.51e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs737337	0.623	rs3826815	chr19:11332505	C/T	cg00586551	chr19:11347513	LOC55908;DOCK6	0.55	6.02	0.37	6.61e-9	HDL cholesterol;HDL cholesterol levels;
SARC	cis	rs79149102	0.579	rs8034149	chr15:75311842	G/C	cg17294928	chr15:75287854	SCAMP5	-1.08	-9.3	-0.52	1.07e-17	Lung cancer;
SARC	cis	rs4988958	0.584	rs7589142	chr2:103024660	T/C	cg03938978	chr2:103052716	IL18RAP	0.31	4.91	0.31	1.72e-6	Asthma (childhood onset);
SARC	cis	rs920590	0.684	rs57462676	chr8:19670848	G/C	cg03894339	chr8:19674705	INTS10	0.65	7.46	0.44	1.71e-12	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs1113500	0.933	rs11185260	chr1:108635079	A/T	cg06207961	chr1:108661230	NA	-0.46	-6.16	-0.37	3.18e-9	Growth-regulated protein alpha levels;
SARC	cis	rs7923609	0.871	rs6479905	chr10:65315231	A/G	cg01631684	chr10:65280961	REEP3	0.35	4.72	0.3	4.07e-6	Educational attainment;Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs11997175	0.740	rs4467902	chr8:33693415	G/T	ch.8.33884649F	chr8:33765107	NA	0.57	7.72	0.45	3.31e-13	Body mass index;
SARC	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg16405210	chr4:1374714	KIAA1530	-0.9	-12.63	-0.64	3.25e-28	Longevity;
SARC	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg18252515	chr7:66147081	NA	-0.63	-6.76	-0.41	1.07e-10	Aortic root size;
SARC	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1950500	0.509	rs12879087	chr14:24826900	A/T	cg16194253	chr14:24768981	DHRS1;C14orf21	0.59	7.28	0.43	5.08e-12	Height;
SARC	cis	rs933688	1.000	rs9293568	chr5:90737845	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	12.57	0.64	5.35e-28	Smoking behavior;
SARC	trans	rs890100	0.736	rs13413915	chr2:56693898	T/C	cg26233084	chr5:15510258	FBXL7	-0.32	-6.51	-0.39	4.68e-10	Gut microbiome composition (summer);
SARC	cis	rs7465272	0.500	rs7463655	chr8:143731034	G/C	cg24634471	chr8:143751801	JRK	0.6	7.74	0.45	2.98e-13	Bipolar disorder and schizophrenia;
SARC	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg02592271	chr2:27665507	KRTCAP3	-0.42	-6.42	-0.39	7.71e-10	Total body bone mineral density;
SARC	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg24829409	chr8:58192753	C8orf71	-0.62	-5.91	-0.36	1.2e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg12463550	chr7:65579703	CRCP	0.48	5.79	0.35	2.23e-8	Aortic root size;
SARC	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg16325326	chr1:53192061	ZYG11B	0.73	10.77	0.58	3.31e-22	Monocyte count;
SARC	cis	rs2075371	0.933	rs2244548	chr7:133986234	A/G	cg11752832	chr7:134001865	SLC35B4	0.57	7.43	0.44	1.99e-12	Mean platelet volume;
SARC	cis	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg05084668	chr3:125655381	ALG1L	-0.46	-4.86	-0.3	2.18e-6	Blood pressure (smoking interaction);
SARC	cis	rs2963155	0.518	rs853177	chr5:142635460	A/G	cg17617527	chr5:142782415	NR3C1	0.79	5.55	0.34	7.68e-8	Breast cancer;
SARC	trans	rs9354308	0.868	rs2351729	chr6:66537291	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.56	-6.67	-0.4	1.89e-10	Metabolite levels;
SARC	cis	rs7674212	0.570	rs6813563	chr4:104099110	G/A	cg16532752	chr4:104119610	CENPE	-0.47	-5.84	-0.36	1.76e-8	Type 2 diabetes;
SARC	cis	rs7223966	1.000	rs16947014	chr17:61719032	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.52	-5.41	-0.33	1.53e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9650657	0.812	rs6601522	chr8:10629061	G/T	cg21775007	chr8:11205619	TDH	-0.38	-4.78	-0.3	3.06e-6	Neuroticism;
SARC	cis	rs11190604	1.000	rs7905961	chr10:102297391	G/C	cg07080220	chr10:102295463	HIF1AN	0.8	9.26	0.52	1.39e-17	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs2070488	1.000	rs13089394	chr3:38446309	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	14.49	0.69	2.44e-34	Electrocardiographic conduction measures;
SARC	cis	rs9916302	0.861	rs11078912	chr17:37671490	A/G	cg20243544	chr17:37824526	PNMT	0.54	6.05	0.37	5.74e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs12579753	0.692	rs11115064	chr12:82278683	G/A	cg07988820	chr12:82153109	PPFIA2	-0.47	-5.68	-0.35	4.08e-8	Resting heart rate;
SARC	cis	rs35995292	0.963	rs7803397	chr7:38905686	C/T	cg19327137	chr7:38886074	VPS41	-0.36	-5.13	-0.32	6.17e-7	Subjective well-being (multi-trait analysis);
SARC	cis	rs7626444	0.563	rs2686598	chr3:196487719	C/T	cg12930392	chr3:196481615	PAK2	0.25	4.82	0.3	2.61e-6	Monocyte count;
SARC	cis	rs4654899	0.897	rs6670897	chr1:21066376	T/C	cg04902671	chr1:21058625	SH2D5	-0.41	-4.87	-0.3	2.07e-6	Superior frontal gyrus grey matter volume;
SARC	cis	rs3758785	0.619	rs2096763	chr11:94114694	T/G	cg13023536	chr11:94226537	MRE11A;ANKRD49	-0.42	-5.41	-0.33	1.58e-7	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
SARC	trans	rs12310956	0.532	rs2171534	chr12:33838998	C/T	cg13010199	chr12:38710504	ALG10B	0.6	7.51	0.44	1.25e-12	Morning vs. evening chronotype;
SARC	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg13206674	chr6:150067644	NUP43	0.42	5.41	0.33	1.59e-7	Lung cancer;
SARC	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg11987759	chr7:65425863	GUSB	-0.49	-6.02	-0.37	6.86e-9	Aortic root size;
SARC	cis	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg03213289	chr20:61660250	NA	0.46	6.29	0.38	1.56e-9	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs7824557	0.603	rs2246606	chr8:11219334	G/A	cg21775007	chr8:11205619	TDH	0.64	8.35	0.48	6.26e-15	Retinal vascular caliber;
SARC	cis	rs11338569	1	rs11338569	chr9:100763456	CT/C	cg03040243	chr9:100819229	NANS	0.58	6.07	0.37	5.27e-9	Red blood cell count;Mean corpuscular hemoglobin;
SARC	trans	rs988958	0.883	rs10153941	chr2:42304417	G/T	cg02435573	chr1:94712239	NA	-0.51	-6.72	-0.4	1.4e-10	Hypospadias;
SARC	cis	rs854765	0.583	rs8065970	chr17:17858771	A/G	cg05444541	chr17:17804740	TOM1L2	-0.29	-4.82	-0.3	2.56e-6	Total body bone mineral density;
SARC	cis	rs1707322	0.716	rs6694889	chr1:46101806	A/C	cg03146154	chr1:46216737	IPP	0.51	6.11	0.37	4.04e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2200578	1.000	rs7566277	chr2:99916242	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.65	6.17	0.37	2.98e-9	IgG glycosylation;
SARC	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.46	-5.81	-0.36	2.08e-8	Personality dimensions;
SARC	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg03188948	chr7:1209495	NA	0.41	5.19	0.32	4.68e-7	Longevity;Endometriosis;
SARC	cis	rs3008870	1.000	rs3008874	chr1:67431365	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.92	11.37	0.6	3.93e-24	Lymphocyte percentage of white cells;
SARC	cis	rs6088813	1.000	rs6141549	chr20:33974051	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	-0.43	-5.24	-0.32	3.67e-7	Height;
SARC	cis	rs4268898	0.552	rs12620938	chr2:24367122	C/A	cg26838691	chr2:24397539	C2orf84	0.38	5.05	0.31	9.11e-7	Asthma;
SARC	cis	rs6674970	0.518	rs6587552	chr1:151018861	C/T	cg04469105	chr1:151031679	CDC42SE1;MLLT11	0.53	5.63	0.35	5.12e-8	Childhood ear infection;
SARC	trans	rs7980799	0.682	rs1384599	chr12:33624579	G/A	cg13010199	chr12:38710504	ALG10B	-0.53	-6.35	-0.38	1.13e-9	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.71	-8.75	-0.5	4.31e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg02773640	chr10:6135633	RBM17	0.51	7.24	0.43	6.58e-12	Thyroid stimulating hormone;
SARC	cis	rs5758659	1.000	rs5758659	chr22:42622003	C/T	cg15128208	chr22:42549153	NA	-0.36	-5.2	-0.32	4.34e-7	Cognitive function;
SARC	cis	rs7621025	0.690	rs11715257	chr3:136182053	C/T	cg15507776	chr3:136538369	TMEM22	0.56	6.13	0.37	3.67e-9	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
SARC	cis	rs9660992	0.710	rs1180721	chr1:205232696	T/C	cg19090574	chr1:205240910	TMCC2	-0.39	-4.89	-0.3	1.91e-6	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs2985684	0.894	rs2354439	chr14:50019417	G/C	cg04989706	chr14:50066350	PPIL5	-0.51	-5.72	-0.35	3.29e-8	Carotid intima media thickness;
SARC	cis	rs910316	1.000	rs7145159	chr14:75583268	A/G	cg08847533	chr14:75593920	NEK9	0.93	15.59	0.71	5.03e-38	Height;
SARC	cis	rs722599	0.748	rs11623342	chr14:75347937	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.42	-5.2	-0.32	4.26e-7	IgG glycosylation;
SARC	cis	rs992157	0.835	rs6729058	chr2:219148369	G/A	cg00012203	chr2:219082015	ARPC2	-0.63	-9.11	-0.51	3.96e-17	Colorectal cancer;
SARC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.57	-6.53	-0.39	4.13e-10	Prudent dietary pattern;
SARC	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg08280861	chr8:58055591	NA	0.57	4.88	0.3	1.95e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6963495	0.818	rs73190166	chr7:105159955	G/A	cg19920283	chr7:105172520	RINT1	0.66	5.55	0.34	7.81e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs1215050	0.716	rs356549	chr4:98699344	A/G	cg05340658	chr4:99064831	C4orf37	0.43	5.8	0.36	2.11e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs6542838	0.582	rs6542845	chr2:99537600	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.55	-7.08	-0.42	1.73e-11	Fear of minor pain;
SARC	cis	rs2421770	0.532	rs2901605	chr11:35340431	A/T	cg13971030	chr11:35366721	SLC1A2	-0.36	-4.81	-0.3	2.75e-6	Staphylococcus aureus nasal carriage (persistent);
SARC	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg27286337	chr10:134555280	INPP5A	0.69	7.72	0.45	3.51e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs7582720	1.000	rs114702158	chr2:203821793	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs858239	0.539	rs4295546	chr7:23191021	C/T	cg23682824	chr7:23144976	KLHL7	0.73	9.38	0.52	6.18e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs1153858	1.000	rs12437840	chr15:45669055	C/A	cg03999130	chr15:45571217	NA	0.39	4.98	0.31	1.25e-6	Homoarginine levels;
SARC	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg16325326	chr1:53192061	ZYG11B	0.71	10.45	0.56	3.25e-21	Monocyte count;
SARC	cis	rs926392	0.572	rs6129156	chr20:37672209	A/C	cg16355469	chr20:37678765	NA	0.72	8.85	0.5	2.24e-16	Dialysis-related mortality;
SARC	cis	rs9788721	0.934	rs1051730	chr15:78894339	G/A	cg18825076	chr15:78729989	IREB2	-0.45	-5.23	-0.32	3.84e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs9906944	0.707	rs4794019	chr17:47107290	G/T	cg16584676	chr17:46985605	UBE2Z	-0.41	-4.91	-0.31	1.75e-6	Intelligence (multi-trait analysis);Body fat percentage;
SARC	cis	rs3768617	0.528	rs2027082	chr1:183084608	C/A	cg13390022	chr1:182993471	LAMC1	0.32	4.83	0.3	2.52e-6	Fuchs's corneal dystrophy;
SARC	cis	rs2908197	0.663	rs7802264	chr7:75985782	T/C	cg07849177	chr7:76178544	LOC100133091	-0.43	-4.89	-0.31	1.86e-6	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs526231	0.511	rs26255	chr5:102554100	T/A	cg23492399	chr5:102201601	PAM	-0.52	-5.58	-0.34	6.75e-8	Primary biliary cholangitis;
SARC	cis	rs12142240	0.698	rs56358525	chr1:46849520	C/T	cg00530320	chr1:46809349	NSUN4	0.57	6.97	0.42	3.29e-11	Menopause (age at onset);
SARC	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg17971929	chr21:40555470	PSMG1	-0.86	-11.17	-0.59	1.72e-23	Cognitive function;
SARC	cis	rs7659604	0.643	rs6839054	chr4:122663628	C/T	cg20573242	chr4:122745356	CCNA2	0.39	4.73	0.3	3.81e-6	Type 2 diabetes;
SARC	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg02733842	chr7:1102375	C7orf50	-0.6	-7.36	-0.43	3.08e-12	Bronchopulmonary dysplasia;
SARC	cis	rs79349575	0.783	rs58591767	chr17:47026076	G/A	cg16584676	chr17:46985605	UBE2Z	0.55	6.58	0.4	3.01e-10	Type 2 diabetes;
SARC	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg11965913	chr1:205819406	PM20D1	-0.44	-4.96	-0.31	1.37e-6	Parkinson's disease;
SARC	cis	rs9682041	0.627	rs3772173	chr3:170078232	C/T	cg11886554	chr3:170076028	SKIL	0.63	6.21	0.38	2.45e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs6570726	0.791	rs6915094	chr6:145883540	C/G	cg05347473	chr6:146136440	FBXO30	0.54	7.51	0.44	1.24e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4481887	0.927	rs7521689	chr1:248435831	G/T	cg13385794	chr1:248469461	NA	0.35	5.13	0.32	6.01e-7	Common traits (Other);
SARC	cis	rs561341	0.623	rs4795665	chr17:30233657	C/T	cg13647721	chr17:30228624	UTP6	0.67	6.4	0.39	8.36e-10	Hip circumference adjusted for BMI;
SARC	cis	rs7566780	0.541	rs4645016	chr2:16664292	G/A	cg09580478	chr2:16689509	NA	0.55	6.92	0.41	4.42e-11	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs453301	0.686	rs1045527	chr8:8890041	A/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-7.02	-0.42	2.45e-11	Joint mobility (Beighton score);
SARC	cis	rs7011049	0.778	rs72648436	chr8:53881267	G/C	cg26025543	chr8:53854495	NA	0.51	4.74	0.3	3.77e-6	Systolic blood pressure;
SARC	cis	rs6835098	1.000	rs6835098	chr4:174089238	T/C	cg08422745	chr4:174089978	GALNT7	-0.77	-10.37	-0.56	5.62e-21	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	trans	rs61931739	0.500	rs9919726	chr12:34510783	A/G	cg13010199	chr12:38710504	ALG10B	0.76	10.85	0.58	1.77e-22	Morning vs. evening chronotype;
SARC	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg22875332	chr1:76189707	ACADM	-0.42	-5.53	-0.34	8.5e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg22800045	chr5:56110881	MAP3K1	0.42	5.04	0.31	9.15e-7	Coronary artery disease;
SARC	cis	rs4243830	0.850	rs12029123	chr1:6607142	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.9	8.33	0.48	7.1e-15	Body mass index;
SARC	cis	rs2985684	0.894	rs4900928	chr14:50020817	A/G	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.47	5.22	0.32	3.93e-7	Carotid intima media thickness;
SARC	cis	rs12541335	0.639	rs68063696	chr8:22153236	A/G	cg18135555	chr8:22132992	PIWIL2	0.37	5.39	0.33	1.71e-7	Hypertriglyceridemia;
SARC	cis	rs710216	0.571	rs11210772	chr1:43448499	A/G	cg07803811	chr1:43423981	SLC2A1	-0.43	-4.74	-0.3	3.7e-6	Red cell distribution width;
SARC	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg00149659	chr3:10157352	C3orf10	0.72	6.46	0.39	5.95e-10	Alzheimer's disease;
SARC	cis	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg13072238	chr3:49761600	GMPPB	-0.43	-5.57	-0.34	6.87e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7712401	0.715	rs385996	chr5:122355228	T/G	cg19412675	chr5:122181750	SNX24	-0.42	-5.3	-0.33	2.65e-7	Mean platelet volume;
SARC	cis	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg03060546	chr3:49711283	APEH	0.59	7.33	0.43	3.8e-12	Resting heart rate;
SARC	cis	rs2013441	1.000	rs2703810	chr17:20113715	C/T	cg13482628	chr17:19912719	NA	-0.46	-5.98	-0.36	8.48e-9	Obesity-related traits;
SARC	trans	rs12486865	0.522	rs11707768	chr3:99920920	G/A	cg21934772	chr13:110198949	NA	0.51	6.94	0.41	3.93e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs9398803	0.865	rs2326451	chr6:126811928	A/T	cg20229609	chr6:126660872	C6orf173	0.39	5.58	0.34	6.56e-8	Male-pattern baldness;
SARC	cis	rs6570726	0.935	rs397418	chr6:145842362	C/T	cg23711669	chr6:146136114	FBXO30	0.77	11.79	0.61	1.79e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg12419862	chr22:24373484	LOC391322	-0.67	-8.99	-0.51	8.46e-17	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs933688	1.000	rs2367526	chr5:90740525	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	12.57	0.64	5.35e-28	Smoking behavior;
SARC	cis	rs5762813	0.561	rs5762821	chr22:29219472	G/A	cg02153584	chr22:29168773	CCDC117	0.65	6.65	0.4	2.02e-10	Hematocrit;Hemoglobin concentration;
SARC	cis	rs6456156	0.792	rs7775443	chr6:167513252	A/C	cg07741184	chr6:167504864	NA	-0.35	-6.74	-0.4	1.21e-10	Primary biliary cholangitis;
SARC	cis	rs2295359	1.000	rs12043240	chr1:67624304	C/T	cg08029281	chr1:67600428	NA	0.37	5.05	0.31	8.88e-7	Psoriasis;
SARC	cis	rs9486715	1.000	rs9486725	chr6:97061159	C/T	cg18709589	chr6:96969512	KIAA0776	-0.61	-7.53	-0.44	1.09e-12	Headache;
SARC	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9462027	0.561	rs3798348	chr6:34771892	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.92	-0.36	1.16e-8	Systemic lupus erythematosus;
SARC	cis	rs3733585	0.699	rs6844787	chr4:9959233	A/G	cg11266682	chr4:10021025	SLC2A9	-0.35	-6.03	-0.37	6.35e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs9393692	0.875	rs9358917	chr6:26284417	T/C	cg00631329	chr6:26305371	NA	-0.59	-8.58	-0.49	1.32e-15	Educational attainment;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg02400139	chr5:145890299	TCERG1	-0.56	-6.89	-0.41	5.28e-11	Alcohol dependence;
SARC	cis	rs8180040	0.764	rs11130115	chr3:47181661	C/A	cg02527881	chr3:46936655	PTH1R	-0.31	-4.9	-0.31	1.77e-6	Colorectal cancer;
SARC	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg07308232	chr7:1071921	C7orf50	-0.65	-7.96	-0.46	7.4e-14	Longevity;Endometriosis;
SARC	cis	rs9790314	0.586	rs16832279	chr3:161120483	C/T	cg03342759	chr3:160939853	NMD3	-0.58	-7.19	-0.43	8.93e-12	Morning vs. evening chronotype;
SARC	cis	rs763121	0.853	rs2281019	chr22:39064378	T/A	cg14440974	chr22:39074834	NA	-0.34	-5.07	-0.32	8.19e-7	Menopause (age at onset);
SARC	cis	rs735539	0.521	rs2762998	chr13:21375752	A/G	cg16922012	chr13:21400325	XPO4	-0.4	-5.62	-0.35	5.42e-8	Dental caries;
SARC	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9914544	0.505	rs4924774	chr17:18794920	A/C	cg25390199	chr17:18761479	PRPSAP2	0.46	6.05	0.37	5.66e-9	Educational attainment (years of education);
SARC	cis	rs16854884	0.770	rs7621079	chr3:143814500	G/C	cg06585982	chr3:143692056	C3orf58	0.61	8.07	0.47	3.74e-14	Economic and political preferences (feminism/equality);
SARC	trans	rs9354308	0.901	rs55832318	chr6:66560086	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.56	6.58	0.4	2.99e-10	Metabolite levels;
SARC	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg11764359	chr7:65958608	NA	0.86	12.33	0.63	3.29e-27	Aortic root size;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg06900676	chr2:61293330	KIAA1841	0.51	6.91	0.41	4.5e-11	Tetralogy of Fallot;
SARC	cis	rs1008375	0.966	rs7658240	chr4:17588950	A/G	cg16339924	chr4:17578868	LAP3	-0.71	-9.41	-0.52	5.07e-18	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg12373951	chr3:133503437	NA	-0.42	-5.99	-0.37	7.76e-9	Iron status biomarkers;
SARC	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg13175981	chr1:150552382	MCL1	-0.54	-6.82	-0.41	7.54e-11	Tonsillectomy;
SARC	cis	rs911555	0.755	rs10148970	chr14:103892000	G/A	cg24130564	chr14:104152367	KLC1	-0.5	-5.8	-0.36	2.12e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2204008	0.775	rs3900361	chr12:38238936	A/G	cg13010199	chr12:38710504	ALG10B	-0.75	-10.34	-0.56	7e-21	Bladder cancer;
SARC	cis	rs113835537	0.935	rs79106199	chr11:66420518	T/C	cg24851651	chr11:66362959	CCS	0.48	5.17	0.32	5.15e-7	Airway imaging phenotypes;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg05558578	chr10:5487785	NET1	0.5	6.87	0.41	5.78e-11	Thyroid stimulating hormone;
SARC	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg13880726	chr7:1868755	MAD1L1	0.56	6.87	0.41	5.8e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs12421382	0.881	rs1808843	chr11:109389471	A/G	cg11473876	chr11:109292803	C11orf87	0.42	5.6	0.34	5.92e-8	Schizophrenia;
SARC	cis	rs6840360	0.533	rs13145446	chr4:152729035	G/A	cg22705602	chr4:152727874	NA	0.48	8.21	0.47	1.55e-14	Intelligence (multi-trait analysis);
SARC	cis	rs4764124	0.646	rs10744078	chr12:14978535	T/G	cg19759883	chr12:14956454	WBP11;C12orf60	-0.73	-10.36	-0.56	6.42e-21	Pubertal anthropometrics;
SARC	cis	rs1971762	0.563	rs7958775	chr12:54077556	T/C	cg06632207	chr12:54070931	ATP5G2	0.44	5.7	0.35	3.67e-8	Height;
SARC	cis	rs4276643	0.531	rs2726943	chr8:27817484	A/G	cg26001764	chr8:28560637	EXTL3	-0.34	-4.75	-0.3	3.52e-6	Low vWF levels;
SARC	cis	rs9868809	0.505	rs13316551	chr3:48745167	A/C	cg06212747	chr3:49208901	KLHDC8B	-0.55	-5.05	-0.31	8.91e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs6717918	0.620	rs7570112	chr2:233150452	A/G	cg17539151	chr2:232235334	NA	0.36	4.86	0.3	2.13e-6	Height;
SARC	cis	rs7667	0.881	rs12034426	chr1:19750871	C/A	cg15311933	chr1:19638897	PQLC2;AKR7A2	-0.43	-5.14	-0.32	5.82e-7	Crohn's disease and psoriasis;
SARC	cis	rs672059	0.966	rs689375	chr1:183160973	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.51	6.97	0.42	3.21e-11	Hypertriglyceridemia;
SARC	trans	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.07	-0.42	1.77e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs950027	0.572	rs12910764	chr15:45609360	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.51	-6.34	-0.38	1.16e-9	Response to fenofibrate (adiponectin levels);
SARC	cis	rs56235845	0.694	rs9313758	chr5:176773091	T/G	cg16006841	chr5:176797999	RGS14	0.56	7.59	0.45	7.72e-13	Hemoglobin concentration;Hematocrit;
SARC	cis	rs9290065	0.519	rs7635796	chr3:160674689	G/C	cg03342759	chr3:160939853	NMD3	-0.47	-5.64	-0.35	4.87e-8	Kawasaki disease;
SARC	cis	rs5167	0.525	rs10402642	chr19:45453878	G/A	cg20090143	chr19:45452003	APOC2	0.31	4.99	0.31	1.18e-6	Blood protein levels;
SARC	cis	rs6831352	0.840	rs35073321	chr4:100053276	G/A	cg12011299	chr4:100065546	ADH4	-0.34	-5.74	-0.35	2.95e-8	Alcohol dependence;
SARC	cis	rs601339	1.000	rs525215	chr12:123179771	G/A	cg18578876	chr12:123200353	GPR109B	0.43	4.84	0.3	2.35e-6	Adiponectin levels;
SARC	cis	rs9291683	0.546	rs4575994	chr4:9997979	G/A	cg00071950	chr4:10020882	SLC2A9	0.36	5.57	0.34	7.01e-8	Bone mineral density;
SARC	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg20607798	chr8:58055168	NA	0.49	5.0	0.31	1.11e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs9875589	0.509	rs2731332	chr3:14110083	G/C	cg19554555	chr3:13937349	NA	-0.4	-5.08	-0.32	7.65e-7	Ovarian reserve;
SARC	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.68	9.13	0.51	3.45e-17	Menarche (age at onset);
SARC	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg03650068	chr1:25596491	NA	-0.33	-5.14	-0.32	5.75e-7	Erythrocyte sedimentation rate;
SARC	cis	rs1355223	0.552	rs2421743	chr11:34882840	C/T	cg18508148	chr11:34937573	PDHX;APIP	0.51	6.5	0.39	4.74e-10	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg05368731	chr17:41323189	NBR1	0.79	9.6	0.53	1.34e-18	Menopause (age at onset);
SARC	cis	rs995000	0.931	rs656297	chr1:62907595	A/G	cg06896770	chr1:63153194	DOCK7	0.89	13.58	0.66	2.52e-31	Triglyceride levels;
SARC	cis	rs3126085	0.932	rs11204949	chr1:152219797	A/C	cg26876637	chr1:152193138	HRNR	-0.51	-5.22	-0.32	3.95e-7	Atopic dermatitis;
SARC	cis	rs2228479	0.850	rs17233455	chr16:89816407	A/G	cg06558623	chr16:89946397	TCF25	0.88	6.21	0.38	2.39e-9	Skin colour saturation;
SARC	trans	rs3942852	0.568	rs10838800	chr11:48094879	C/T	cg15704280	chr7:45808275	SEPT13	-0.66	-8.71	-0.5	5.74e-16	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs3741404	0.620	rs12787945	chr11:63977546	G/A	cg18225595	chr11:63971243	STIP1	0.47	7.25	0.43	6.06e-12	Platelet count;
SARC	cis	rs1538970	0.924	rs4660855	chr1:45899795	A/G	cg05343316	chr1:45956843	TESK2	0.78	8.92	0.5	1.44e-16	Platelet count;
SARC	cis	rs2718058	0.519	rs2598071	chr7:37875347	G/A	cg15028436	chr7:37888078	TXNDC3	0.48	6.3	0.38	1.45e-9	Alzheimer's disease (late onset);
SARC	cis	rs193541	0.502	rs2061511	chr5:122056727	A/G	cg19412675	chr5:122181750	SNX24	0.52	6.74	0.4	1.22e-10	Glucose homeostasis traits;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg12268991	chr3:136471127	STAG1	0.53	6.43	0.39	7.28e-10	Breast cancer;
SARC	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg08219700	chr8:58056026	NA	0.71	6.75	0.4	1.16e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs4805272	0.539	rs7256211	chr19:29333063	C/G	cg14983838	chr19:29218262	NA	0.55	6.26	0.38	1.85e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs4242434	0.698	rs10104039	chr8:22538384	A/G	cg03733263	chr8:22462867	KIAA1967	-0.85	-13.5	-0.66	4.56e-31	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs7647973	1.000	rs9842132	chr3:49427933	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.56	-5.75	-0.35	2.8e-8	Menarche (age at onset);
SARC	cis	rs4243830	0.677	rs6693922	chr1:6584804	A/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.83	8.29	0.48	9.28e-15	Body mass index;
SARC	cis	rs3845702	0.736	rs6433821	chr2:180837806	T/A	cg01881094	chr2:180872142	CWC22	-1.12	-9.3	-0.52	1.07e-17	Schizophrenia;
SARC	cis	rs6840258	1.000	rs55787557	chr4:87950825	A/G	cg11209507	chr4:87813803	C4orf36	0.43	4.74	0.3	3.74e-6	Mean corpuscular volume;Basophil percentage of granulocytes;
SARC	cis	rs2562456	0.617	rs34203148	chr19:21773545	T/A	cg03331224	chr19:21860916	NA	-0.33	-5.01	-0.31	1.1e-6	Pain;
SARC	cis	rs4742903	0.935	rs10820602	chr9:106861282	C/T	cg14250997	chr9:106856677	SMC2	0.53	7.08	0.42	1.68e-11	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg08859206	chr1:53392774	SCP2	0.38	5.43	0.34	1.43e-7	Monocyte count;
SARC	cis	rs240764	0.717	rs180963	chr6:101127213	T/C	cg09795085	chr6:101329169	ASCC3	0.43	5.46	0.34	1.2e-7	Neuroticism;
SARC	trans	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.07	-0.42	1.77e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs4711336	1.000	rs2229642	chr6:33659472	C/G	cg15676125	chr6:33679581	C6orf125	0.57	7.0	0.42	2.64e-11	Height;
SARC	cis	rs72781680	0.821	rs72781644	chr2:24209348	T/C	cg06627628	chr2:24431161	ITSN2	-0.57	-6.13	-0.37	3.63e-9	Lymphocyte counts;
SARC	cis	rs73206853	0.841	rs56017468	chr12:110653857	T/C	cg08946844	chr12:110511112	NA	0.59	4.81	0.3	2.67e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs995000	0.931	rs11207992	chr1:63041800	T/G	cg06896770	chr1:63153194	DOCK7	1.0	15.5	0.71	1.02e-37	Triglyceride levels;
SARC	cis	rs2535633	0.820	rs7626551	chr3:52938092	C/G	cg18404041	chr3:52824283	ITIH1	0.33	4.77	0.3	3.24e-6	Body mass index;
SARC	cis	rs6674176	0.660	rs6801	chr1:44396646	C/G	cg13606994	chr1:44402422	ARTN	0.34	5.54	0.34	8.26e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs911263	0.603	rs2145423	chr14:68796930	A/G	cg18825221	chr14:68749962	RAD51L1	0.39	6.88	0.41	5.61e-11	Primary biliary cholangitis;
SARC	cis	rs7523050	0.643	rs12741194	chr1:109400390	T/C	cg08274380	chr1:109419600	GPSM2	1.07	8.3	0.48	8.22e-15	Fat distribution (HIV);
SARC	cis	rs4780401	0.609	rs11639945	chr16:11824056	T/G	cg01061890	chr16:11836724	TXNDC11	-0.59	-8.22	-0.47	1.41e-14	Rheumatoid arthritis;
SARC	cis	rs2120243	0.534	rs35004310	chr3:157113800	C/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.39	5.06	0.31	8.57e-7	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg11644478	chr21:40555479	PSMG1	-0.87	-11.38	-0.6	3.86e-24	Cognitive function;
SARC	cis	rs11792861	0.589	rs2176692	chr9:111927723	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.61	6.57	0.4	3.28e-10	Menarche (age at onset);
SARC	cis	rs17125944	0.686	rs7147258	chr14:53337664	G/T	cg00686598	chr14:53173677	PSMC6	-0.61	-4.86	-0.3	2.15e-6	Alzheimer's disease (late onset);
SARC	cis	rs875971	0.545	rs12670811	chr7:65823019	C/A	cg11764359	chr7:65958608	NA	0.69	6.92	0.41	4.33e-11	Aortic root size;
SARC	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg21724239	chr8:58056113	NA	0.6	5.85	0.36	1.64e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4132509	0.696	rs12023642	chr1:243767826	T/G	cg21452805	chr1:244014465	NA	0.55	5.44	0.34	1.37e-7	RR interval (heart rate);
SARC	trans	rs6560039	1	rs6560039	chr9:90474946	C/T	cg24436365	chr6:63940138	NA	0.59	10.5	0.57	2.34e-21	Gait variability;
SARC	cis	rs12142240	0.698	rs17361936	chr1:46862893	C/T	cg10495392	chr1:46806563	NSUN4	0.65	6.88	0.41	5.6e-11	Menopause (age at onset);
SARC	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg17971929	chr21:40555470	PSMG1	0.99	14.22	0.68	1.86e-33	Cognitive function;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg02500152	chr12:48357316	TMEM106C	-0.52	-6.59	-0.4	2.98e-10	Schizophrenia;
SARC	cis	rs1059312	0.808	rs10847694	chr12:129292457	C/A	cg09035930	chr12:129282057	SLC15A4	0.56	8.04	0.47	4.57e-14	Systemic lupus erythematosus;
SARC	cis	rs79349575	0.783	rs4793991	chr17:47001801	A/G	cg07967210	chr17:47022446	SNF8	0.37	4.72	0.3	4.02e-6	Type 2 diabetes;
SARC	cis	rs3796352	1.000	rs71301814	chr3:53117663	G/A	cg12962167	chr3:53033115	SFMBT1	0.76	4.96	0.31	1.37e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg23034840	chr1:205782522	SLC41A1	0.62	7.95	0.46	8.08e-14	Menarche (age at onset);
SARC	cis	rs561341	0.700	rs6505266	chr17:30225813	G/A	cg13647721	chr17:30228624	UTP6	0.74	8.91	0.5	1.47e-16	Hip circumference adjusted for BMI;
SARC	cis	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg13072238	chr3:49761600	GMPPB	-0.62	-6.23	-0.38	2.14e-9	Menarche (age at onset);
SARC	cis	rs12681366	0.683	rs2450572	chr8:95424335	A/G	cg26464482	chr8:95565502	KIAA1429	-0.45	-5.6	-0.34	6.09e-8	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.18	0.38	2.83e-9	Bipolar disorder;
SARC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.78	-10.08	-0.55	4.46e-20	Prudent dietary pattern;
SARC	cis	rs7772486	0.624	rs9485018	chr6:146025731	T/C	cg05347473	chr6:146136440	FBXO30	-0.5	-6.86	-0.41	6.03e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs61409971	0.920	rs66906591	chr14:93014911	C/T	cg04718702	chr14:93020195	RIN3	-0.37	-4.92	-0.31	1.64e-6	Lymphocyte percentage of white cells;
SARC	cis	rs3771570	1.000	rs62190370	chr2:242384194	C/G	cg21155796	chr2:242212141	HDLBP	0.7	6.4	0.39	8.61e-10	Prostate cancer;
SARC	cis	rs3820928	0.874	rs4675130	chr2:227827740	G/T	cg05526886	chr2:227700861	RHBDD1	-0.55	-6.64	-0.4	2.25e-10	Pulmonary function;
SARC	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-9.15	-0.51	2.85e-17	Alzheimer's disease;
SARC	cis	rs4595586	0.545	rs58154430	chr12:39386649	C/T	cg26384229	chr12:38710491	ALG10B	0.52	6.21	0.38	2.4e-9	Morning vs. evening chronotype;
SARC	cis	rs11122272	0.735	rs2739516	chr1:231505527	G/A	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs12973672	1.000	rs12975284	chr19:35770962	G/C	cg12095397	chr19:35769544	USF2	0.38	4.79	0.3	2.9e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs2295359	0.963	rs12030867	chr1:67627620	T/C	cg11235152	chr1:67600687	NA	0.48	6.97	0.42	3.21e-11	Psoriasis;
SARC	trans	rs1814175	0.618	rs1851843	chr11:50021846	T/C	cg15704280	chr7:45808275	SEPT13	-0.9	-14.33	-0.68	7.84e-34	Height;
SARC	cis	rs3858526	0.959	rs4559671	chr11:5923419	C/T	cg02574844	chr11:5959923	NA	-0.4	-4.88	-0.3	1.93e-6	DNA methylation (variation);
SARC	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg13393036	chr8:95962371	TP53INP1	-0.37	-6.37	-0.39	9.75e-10	Type 2 diabetes;
SARC	cis	rs7727544	0.735	rs270605	chr5:131651811	C/T	cg24060327	chr5:131705240	SLC22A5	-0.68	-8.79	-0.5	3.37e-16	Blood metabolite levels;
SARC	cis	rs2718058	0.613	rs2597272	chr7:37759710	C/G	cg15028436	chr7:37888078	TXNDC3	-0.36	-4.92	-0.31	1.66e-6	Alzheimer's disease (late onset);
SARC	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	10.22	0.56	1.7e-20	Platelet count;
SARC	cis	rs1801251	0.964	rs7589201	chr2:233724536	A/G	cg25237894	chr2:233734115	C2orf82	-0.36	-4.78	-0.3	3.11e-6	Coronary artery disease;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg27323088	chr5:89770393	MBLAC2;POLR3G	0.79	6.47	0.39	5.71e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6539267	0.741	rs7314289	chr12:106686260	A/C	cg02476566	chr12:106696527	TCP11L2	0.51	5.35	0.33	2.12e-7	Tourette syndrome;
SARC	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg17328964	chr8:145687451	CYHR1	0.41	5.47	0.34	1.17e-7	Age at first birth;
SARC	cis	rs748404	0.631	rs8042688	chr15:43638525	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.52	5.97	0.36	8.59e-9	Lung cancer;
SARC	cis	rs138857	0.515	rs9616375	chr22:50310600	G/A	cg03033257	chr22:50311977	ALG12;CRELD2	0.66	5.01	0.31	1.06e-6	Mean platelet volume;
SARC	cis	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg00409905	chr10:38381863	ZNF37A	-0.53	-7.5	-0.44	1.34e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg06212747	chr3:49208901	KLHDC8B	0.66	8.73	0.5	4.89e-16	Parkinson's disease;
SARC	cis	rs174601	0.668	rs174559	chr11:61581656	G/A	cg19610905	chr11:61596333	FADS2	-0.44	-4.98	-0.31	1.22e-6	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
SARC	cis	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg07636037	chr3:49044803	WDR6	0.81	7.47	0.44	1.64e-12	Menarche (age at onset);
SARC	cis	rs17253792	0.822	rs78522049	chr14:56071203	A/C	cg01858014	chr14:56050164	KTN1	-0.71	-5.63	-0.35	5.25e-8	Putamen volume;
SARC	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg18404041	chr3:52824283	ITIH1	-0.46	-6.85	-0.41	6.71e-11	Bipolar disorder;
SARC	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg23758822	chr17:41437982	NA	0.8	8.7	0.5	5.94e-16	Menopause (age at onset);
SARC	cis	rs7953249	0.618	rs2650000	chr12:121388962	G/T	cg15155738	chr12:121454335	C12orf43	0.46	5.64	0.35	4.85e-8	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg12311346	chr5:56204834	C5orf35	-0.58	-6.01	-0.37	7.24e-9	Initial pursuit acceleration;
SARC	cis	rs910316	0.712	rs175015	chr14:75457075	A/C	cg11812906	chr14:75593930	NEK9	-0.75	-9.69	-0.54	7.18e-19	Height;
SARC	cis	rs270601	0.817	rs460089	chr5:131629772	C/G	cg04518342	chr5:131593106	PDLIM4	0.4	4.95	0.31	1.42e-6	Acylcarnitine levels;
SARC	cis	rs3617	0.573	rs12492391	chr3:52912296	C/A	cg05564831	chr3:52568323	NT5DC2	0.29	4.86	0.3	2.16e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs7103648	1.000	rs10838705	chr11:47424931	G/A	cg10504702	chr11:47789108	FNBP4	0.58	7.58	0.44	8.01e-13	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs7818688	0.697	rs11784212	chr8:95976995	G/A	cg13393036	chr8:95962371	TP53INP1	0.41	4.87	0.3	2.1e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs1949733	0.666	rs3103070	chr4:8508825	A/G	cg11789530	chr4:8429930	ACOX3	-0.79	-10.48	-0.57	2.61e-21	Response to antineoplastic agents;
SARC	cis	rs6456042	1.000	rs3127408	chr6:166530659	T/A	cg11088901	chr6:166572345	T	-0.35	-5.1	-0.32	7.02e-7	Asthma;
SARC	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg04944784	chr2:26401820	FAM59B	-0.48	-5.95	-0.36	9.94e-9	Gut microbiome composition (summer);
SARC	cis	rs17253792	0.915	rs78498383	chr14:56177585	C/T	cg01858014	chr14:56050164	KTN1	-0.62	-4.86	-0.3	2.19e-6	Putamen volume;
SARC	cis	rs11785400	0.793	rs13255558	chr8:143748080	C/T	cg24634471	chr8:143751801	JRK	0.57	7.17	0.42	1.01e-11	Schizophrenia;
SARC	trans	rs17685	0.712	rs4552844	chr7:75718095	A/G	cg19862616	chr7:65841803	NCRNA00174	0.63	7.77	0.45	2.42e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs7474896	0.515	rs2505233	chr10:38340265	C/T	cg00409905	chr10:38381863	ZNF37A	-0.45	-5.1	-0.32	6.94e-7	Obesity (extreme);
SARC	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg16606324	chr3:10149918	C3orf24	0.54	5.34	0.33	2.22e-7	Alzheimer's disease;
SARC	cis	rs7828089	0.582	rs13282084	chr8:22266280	T/C	cg12081754	chr8:22256438	SLC39A14	0.64	8.77	0.5	3.85e-16	Verbal declarative memory;
SARC	cis	rs155076	1.000	rs564685	chr13:21846879	A/G	cg25811766	chr13:21894605	NA	-0.51	-5.5	-0.34	9.92e-8	White matter hyperintensity burden;
SARC	cis	rs666930	0.519	rs483180	chr1:120267505	C/G	cg19096424	chr1:120255104	PHGDH	-0.85	-10.14	-0.55	2.91e-20	Breast cancer;
SARC	cis	rs9486715	0.838	rs9400034	chr6:96954566	C/T	cg06623918	chr6:96969491	KIAA0776	0.89	12.91	0.65	3.96e-29	Headache;
SARC	cis	rs96067	0.711	rs272811	chr1:36634414	G/A	cg24686825	chr1:36642396	MAP7D1	-0.65	-8.18	-0.47	1.86e-14	Corneal structure;
SARC	cis	rs4595586	0.525	rs7972595	chr12:39338000	G/A	cg13010199	chr12:38710504	ALG10B	0.43	4.91	0.31	1.74e-6	Morning vs. evening chronotype;
SARC	cis	rs826838	0.935	rs1601579	chr12:39178606	G/C	cg26384229	chr12:38710491	ALG10B	0.89	12.84	0.64	6.61e-29	Heart rate;
SARC	cis	rs7932354	0.528	rs7103581	chr11:47072805	G/T	cg03339077	chr11:47165057	C11orf49	-0.4	-5.45	-0.34	1.25e-7	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs7252505	1.000	rs12460349	chr19:33584491	C/T	cg17764715	chr19:33622953	WDR88	0.57	4.82	0.3	2.55e-6	Colorectal cancer;
SARC	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg21724239	chr8:58056113	NA	0.6	6.31	0.38	1.43e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs599083	0.793	rs471966	chr11:68173861	C/T	cg01657329	chr11:68192670	LRP5	0.41	5.74	0.35	2.91e-8	Bone mineral density (spine);
SARC	cis	rs6701037	0.566	rs729675	chr1:175136946	T/C	cg08873628	chr1:175162347	KIAA0040	0.34	4.82	0.3	2.64e-6	Alcohol dependence;
SARC	cis	rs1468333	1.000	rs4552585	chr5:137533159	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.8	10.76	0.58	3.54e-22	Resting heart rate;
SARC	cis	rs910316	1.000	rs1043674	chr14:75549370	T/C	cg08847533	chr14:75593920	NEK9	0.94	16.23	0.73	3.78e-40	Height;
SARC	cis	rs9914544	0.545	rs3826380	chr17:18793225	A/G	cg25390199	chr17:18761479	PRPSAP2	0.46	6.05	0.37	5.66e-9	Educational attainment (years of education);
SARC	cis	rs9302635	0.513	rs3812987	chr16:72158920	C/A	cg01557791	chr16:72042693	DHODH	-0.55	-6.11	-0.37	4.09e-9	Blood protein levels;
SARC	cis	rs10782582	0.632	rs77099976	chr1:76240524	T/C	cg03433033	chr1:76189801	ACADM	-0.39	-4.91	-0.31	1.68e-6	Daytime sleep phenotypes;
SARC	cis	rs9660992	0.573	rs1318187	chr1:205206172	T/A	cg00857998	chr1:205179979	DSTYK	0.51	6.31	0.38	1.39e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	23.05	0.83	5.02e-62	Chronic sinus infection;
SARC	cis	rs735396	1.000	rs1169313	chr12:121442670	C/T	cg25281562	chr12:121454272	C12orf43	-0.49	-6.02	-0.37	6.83e-9	N-glycan levels;
SARC	cis	rs709400	0.633	rs7160208	chr14:103965528	G/A	cg12935359	chr14:103987150	CKB	-0.4	-5.85	-0.36	1.67e-8	Body mass index;
SARC	cis	rs965469	0.779	rs6139048	chr20:3239753	T/G	cg25506879	chr20:3388711	C20orf194	-0.47	-4.94	-0.31	1.49e-6	IFN-related cytopenia;
SARC	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg09699651	chr6:150184138	LRP11	0.41	5.11	0.32	6.6e-7	Lung cancer;
SARC	cis	rs6088580	0.634	rs9789792	chr20:32957709	G/A	cg24642439	chr20:33292090	TP53INP2	-0.64	-8.19	-0.47	1.77e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs7223966	0.960	rs11659013	chr17:61869559	C/G	cg00588841	chr17:61851480	DDX42;CCDC47	-0.64	-6.93	-0.41	4.06e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs12044355	0.927	rs11585981	chr1:231833962	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.55	7.42	0.44	2.16e-12	Alzheimer's disease;
SARC	cis	rs8114671	0.562	rs2076667	chr20:33506964	G/A	cg07148914	chr20:33460835	GGT7	0.42	5.1	0.32	6.98e-7	Height;
SARC	cis	rs3087591	0.708	rs2525574	chr17:29705947	T/C	cg24425628	chr17:29625626	OMG;NF1	0.42	5.4	0.33	1.61e-7	Hip circumference;
SARC	cis	rs9747201	0.925	rs8072670	chr17:80159566	T/C	cg17462356	chr17:80056334	FASN	-0.44	-4.94	-0.31	1.49e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-6.89	-0.41	5.05e-11	Personality dimensions;
SARC	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg22875332	chr1:76189707	ACADM	-0.46	-6.51	-0.39	4.57e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs11122272	0.735	rs2790882	chr1:231532783	A/G	cg06096015	chr1:231504339	EGLN1	-0.41	-6.16	-0.37	3.09e-9	Hemoglobin concentration;
SARC	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg03806693	chr22:41940476	POLR3H	-0.81	-10.52	-0.57	2.01e-21	Vitiligo;
SARC	cis	rs1865760	0.827	rs9461227	chr6:25960815	C/T	cg17691542	chr6:26056736	HIST1H1C	0.57	7.25	0.43	6.11e-12	Height;
SARC	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.73	8.8	0.5	3.12e-16	Height;
SARC	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg02725872	chr8:58115012	NA	-0.36	-5.52	-0.34	9.23e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg15448220	chr1:150897856	SETDB1	0.45	5.99	0.37	7.81e-9	Melanoma;
SARC	cis	rs10932679	0.708	rs741382	chr2:217682247	C/T	cg05032264	chr2:217675019	NA	0.58	5.79	0.35	2.25e-8	Pulse pressure;
SARC	cis	rs4243830	0.850	rs57203351	chr1:6601319	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	0.92	9.5	0.53	2.7e-18	Body mass index;
SARC	cis	rs13191362	1.000	rs34655790	chr6:163202739	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.4	5.17	0.32	5.11e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs748404	0.578	rs573615	chr15:43614281	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	5.7	0.35	3.65e-8	Lung cancer;
SARC	cis	rs2839627	0.561	rs2839601	chr21:44317381	A/G	cg03543861	chr21:44258195	NA	0.45	4.99	0.31	1.19e-6	Information processing speed;
SARC	cis	rs7246657	0.943	rs6508733	chr19:38000548	A/T	cg23950597	chr19:37808831	NA	-0.54	-5.36	-0.33	2.01e-7	Coronary artery calcification;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg21540437	chr4:46391737	GABRA2	0.62	6.78	0.41	9.93e-11	Lung cancer in ever smokers;
SARC	cis	rs7626444	0.627	rs5021326	chr3:196477628	A/T	cg12930392	chr3:196481615	PAK2	0.25	5.0	0.31	1.12e-6	Monocyte count;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg12955121	chr20:33680750	TRPC4AP	-0.51	-6.66	-0.4	2e-10	Electrocardiographic conduction measures;
SARC	cis	rs9486715	1.000	rs3798297	chr6:97062835	C/T	cg18709589	chr6:96969512	KIAA0776	-0.58	-7.29	-0.43	4.75e-12	Headache;
SARC	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg10523679	chr1:76189770	ACADM	0.51	6.71	0.4	1.42e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6570726	0.935	rs387965	chr6:145869366	A/G	cg05347473	chr6:146136440	FBXO30	0.47	6.24	0.38	2.08e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2120019	1.000	rs67544533	chr15:75361539	A/G	cg12414181	chr15:75287860	SCAMP5	-0.43	-4.93	-0.31	1.6e-6	Blood trace element (Zn levels);
SARC	cis	rs11098499	0.909	rs9994810	chr4:120381590	A/G	cg09160332	chr4:120329925	NA	-0.33	-4.74	-0.3	3.75e-6	Corneal astigmatism;
SARC	cis	rs1055129	0.537	rs2467100	chr17:73949038	C/G	cg14829360	chr17:73884958	NA	-0.57	-8.66	-0.49	8.06e-16	White matter hyperintensity burden;
SARC	cis	rs1448094	0.556	rs61930632	chr12:86168937	A/C	cg00310523	chr12:86230176	RASSF9	0.32	5.02	0.31	1.04e-6	Major depressive disorder;
SARC	cis	rs826838	1.000	rs7315028	chr12:38710523	G/A	cg13010199	chr12:38710504	ALG10B	0.82	11.91	0.62	7.44e-26	Heart rate;
SARC	trans	rs66573146	1.000	rs55688389	chr4:7030689	C/G	cg07817883	chr1:32538562	TMEM39B	1.47	8.69	0.49	6.56e-16	Granulocyte percentage of myeloid white cells;
SARC	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg03060546	chr3:49711283	APEH	0.58	7.95	0.46	8.1e-14	Parkinson's disease;
SARC	cis	rs9916302	0.706	rs3744349	chr17:37414842	C/T	cg20243544	chr17:37824526	PNMT	0.56	6.09	0.37	4.71e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs6582630	0.519	rs10880576	chr12:38497693	T/C	cg26384229	chr12:38710491	ALG10B	0.82	11.75	0.61	2.36e-25	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg23131131	chr22:24373011	LOC391322	-0.47	-5.22	-0.32	3.95e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs17376456	0.877	rs17083460	chr5:93462354	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.79	0.35	2.3e-8	Diabetic retinopathy;
SARC	cis	rs35110281	0.720	rs162393	chr21:44942692	G/A	cg21573476	chr21:45109991	RRP1B	-0.5	-7.4	-0.44	2.48e-12	Mean corpuscular volume;
SARC	cis	rs9911578	1.000	rs6503866	chr17:56619581	C/T	cg05425664	chr17:57184151	TRIM37	0.65	8.0	0.46	5.97e-14	Intelligence (multi-trait analysis);
SARC	cis	rs1957429	0.520	rs66511472	chr14:65330330	C/A	cg23373153	chr14:65346875	NA	-0.66	-5.52	-0.34	9.09e-8	Pediatric areal bone mineral density (radius);
SARC	cis	rs644799	0.763	rs2950521	chr11:95536870	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.7	9.53	0.53	2.16e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs892961	0.932	rs7207891	chr17:75413922	G/C	cg05865280	chr17:75406074	SEPT9	0.55	8.02	0.47	5.11e-14	Airflow obstruction;
SARC	cis	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg09021430	chr5:549028	NA	-0.45	-5.7	-0.35	3.69e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs7149337	0.836	rs11622116	chr14:51670744	C/T	cg23942311	chr14:51606299	NA	0.34	6.05	0.37	5.74e-9	Cancer;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg18014789	chr12:123717788	C12orf65	0.52	6.62	0.4	2.46e-10	Breast cancer;
SARC	cis	rs9296092	0.538	rs75082458	chr6:33524792	C/T	cg13560919	chr6:33536144	NA	-0.48	-5.54	-0.34	8.34e-8	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg07234876	chr8:600039	NA	0.77	5.84	0.36	1.73e-8	IgG glycosylation;
SARC	cis	rs58365910	1	rs58365910	chr15:78849034	T/C	cg18825076	chr15:78729989	IREB2	-0.42	-5.08	-0.32	7.69e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs9325144	0.555	rs7977200	chr12:38713745	C/T	cg10518543	chr12:38710700	ALG10B	0.4	5.01	0.31	1.09e-6	Morning vs. evening chronotype;
SARC	cis	rs1401999	0.724	rs1016752	chr3:183665062	C/G	cg01324343	chr3:183735012	ABCC5	-0.58	-9.68	-0.54	7.57e-19	Anterior chamber depth;
SARC	cis	rs12142240	0.731	rs6681857	chr1:46850124	T/C	cg14993813	chr1:46806288	NSUN4	-0.56	-5.84	-0.36	1.75e-8	Menopause (age at onset);
SARC	cis	rs8014204	0.773	rs2241275	chr14:75251440	C/T	cg17347104	chr14:75034677	LTBP2	0.4	4.84	0.3	2.34e-6	Caffeine consumption;
SARC	cis	rs460214	0.564	rs458465	chr21:40024644	A/T	cg12884169	chr21:40033163	ERG	-0.33	-4.98	-0.31	1.24e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs3820928	0.904	rs2217359	chr2:227759892	C/T	cg11843606	chr2:227700838	RHBDD1	-0.55	-6.97	-0.42	3.15e-11	Pulmonary function;
SARC	cis	rs72634258	0.786	rs6577468	chr1:8183921	T/C	cg00042356	chr1:8021962	PARK7	0.61	5.47	0.34	1.18e-7	Inflammatory bowel disease;
SARC	cis	rs7819412	0.521	rs10100660	chr8:11038885	T/A	cg12395012	chr8:11607386	GATA4	0.33	5.64	0.35	5.03e-8	Triglycerides;
SARC	trans	rs7615952	0.611	rs35321002	chr3:125612065	G/C	cg07211511	chr3:129823064	LOC729375	-0.81	-8.09	-0.47	3.24e-14	Blood pressure (smoking interaction);
SARC	cis	rs11809207	0.523	rs2783707	chr1:26504196	C/G	cg00300879	chr1:26503847	CNKSR1	0.31	4.78	0.3	3.07e-6	Height;
SARC	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-10.73	-0.58	4.38e-22	Chronic sinus infection;
SARC	cis	rs6693567	0.565	rs1776273	chr1:150270209	C/T	cg09579323	chr1:150459698	TARS2	0.38	4.93	0.31	1.56e-6	Migraine;
SARC	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg13114125	chr14:105738426	BRF1	-0.74	-10.73	-0.58	4.2e-22	Mean platelet volume;Platelet distribution width;
SARC	cis	rs12701220	0.739	rs2293523	chr7:1098518	G/A	cg02733842	chr7:1102375	C7orf50	-0.58	-6.82	-0.41	7.84e-11	Bronchopulmonary dysplasia;
SARC	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg09455208	chr3:40491958	NA	-0.36	-5.55	-0.34	7.79e-8	Renal cell carcinoma;
SARC	cis	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg07636037	chr3:49044803	WDR6	0.63	8.37	0.48	5.38e-15	Resting heart rate;
SARC	cis	rs11731606	0.508	rs17021533	chr4:95280587	C/T	cg20625393	chr4:95128694	SMARCAD1	0.57	5.6	0.34	6.12e-8	Mean platelet volume;
SARC	cis	rs644799	1.000	rs494829	chr11:95571750	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.89	13.95	0.67	1.5e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg18357526	chr6:26021779	HIST1H4A	0.63	8.06	0.47	3.9e-14	Intelligence (multi-trait analysis);
SARC	cis	rs17666538	0.636	rs62486234	chr8:589157	G/T	cg00450029	chr8:599525	NA	-0.57	-5.14	-0.32	5.88e-7	IgG glycosylation;
SARC	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg24399712	chr22:39784796	NA	-0.42	-5.75	-0.35	2.85e-8	Intelligence (multi-trait analysis);
SARC	cis	rs1144333	0.655	rs7418941	chr1:76436020	A/G	cg03433033	chr1:76189801	ACADM	0.61	4.9	0.31	1.77e-6	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg15847926	chr7:2749597	AMZ1	-0.3	-4.95	-0.31	1.43e-6	Height;
SARC	cis	rs3845702	0.736	rs1904850	chr2:180852767	A/G	cg01881094	chr2:180872142	CWC22	-1.13	-9.12	-0.51	3.54e-17	Schizophrenia;
SARC	cis	rs3733585	0.781	rs57250714	chr4:9984529	C/T	cg11266682	chr4:10021025	SLC2A9	0.39	6.58	0.4	3.06e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs35995292	0.500	rs6945239	chr7:38932208	C/T	cg19327137	chr7:38886074	VPS41	0.49	7.24	0.43	6.36e-12	Subjective well-being (multi-trait analysis);
SARC	cis	rs7644634	0.559	rs2301043	chr3:105429152	G/T	cg23051926	chr3:105466016	CBLB	0.44	4.77	0.3	3.2e-6	Itch intensity from mosquito bite;
SARC	cis	rs9393777	0.513	rs11967852	chr6:26612870	G/T	cg12826209	chr6:26865740	GUSBL1	0.67	5.97	0.36	8.68e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7615952	0.576	rs17523380	chr3:125802874	C/T	cg15145296	chr3:125709740	NA	-0.54	-5.71	-0.35	3.49e-8	Blood pressure (smoking interaction);
SARC	cis	rs473651	0.503	rs515342	chr2:239367296	A/G	cg00800569	chr2:239229395	TRAF3IP1	-0.67	-6.93	-0.41	3.97e-11	Multiple system atrophy;
SARC	cis	rs2153535	0.580	rs9505446	chr6:8448691	T/C	cg07606381	chr6:8435919	SLC35B3	0.77	11.03	0.59	5.01e-23	Motion sickness;
SARC	cis	rs1670533	1.000	rs7669399	chr4:1058478	T/G	cg27284194	chr4:1044797	NA	0.47	4.97	0.31	1.29e-6	Recombination rate (females);
SARC	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg16606324	chr3:10149918	C3orf24	0.49	4.82	0.3	2.56e-6	Alzheimer's disease;
SARC	cis	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg00071950	chr4:10020882	SLC2A9	0.39	6.35	0.38	1.14e-9	Bone mineral density;
SARC	cis	rs2408955	0.504	rs11168441	chr12:48576054	G/A	cg24011408	chr12:48396354	COL2A1	0.42	4.98	0.31	1.26e-6	Glycated hemoglobin levels;
SARC	cis	rs10916814	0.632	rs12089623	chr1:20903643	G/A	cg24502330	chr1:20914028	CDA	-0.28	-4.94	-0.31	1.49e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg12648201	chr2:27665141	KRTCAP3	-0.33	-5.0	-0.31	1.11e-6	Total body bone mineral density;
SARC	cis	rs1707322	0.721	rs4415615	chr1:46132109	C/T	cg03146154	chr1:46216737	IPP	0.52	6.25	0.38	1.92e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7772486	0.655	rs2142981	chr6:146071695	G/C	cg23711669	chr6:146136114	FBXO30	-0.92	-16.55	-0.74	3.29e-41	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7100689	0.577	rs10788545	chr10:82034675	A/G	cg01528321	chr10:82214614	TSPAN14	0.67	8.51	0.49	2.12e-15	Post bronchodilator FEV1;
SARC	trans	rs17685	0.753	rs6976532	chr7:75681094	A/G	cg19862616	chr7:65841803	NCRNA00174	0.63	7.9	0.46	1.13e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs17376456	0.569	rs6556834	chr5:93123067	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.56	-5.92	-0.36	1.12e-8	Diabetic retinopathy;
SARC	cis	rs3771570	1.000	rs73002111	chr2:242277833	C/T	cg21155796	chr2:242212141	HDLBP	0.67	5.74	0.35	2.99e-8	Prostate cancer;
SARC	cis	rs11997175	0.626	rs6468189	chr8:33648189	C/A	ch.8.33884649F	chr8:33765107	NA	0.51	6.72	0.4	1.4e-10	Body mass index;
SARC	cis	rs1152591	0.543	rs1152590	chr14:64681193	C/T	cg23250157	chr14:64679961	SYNE2	0.39	5.2	0.32	4.4e-7	Atrial fibrillation;
SARC	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg13206674	chr6:150067644	NUP43	0.45	5.75	0.35	2.73e-8	Lung cancer;
SARC	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg27266027	chr21:40555129	PSMG1	0.51	5.57	0.34	6.84e-8	Cognitive function;
SARC	cis	rs765787	0.530	rs2413776	chr15:45544170	A/G	cg25801113	chr15:45476975	SHF	0.29	4.88	0.3	2e-6	Uric acid levels;
SARC	cis	rs240764	0.604	rs9373590	chr6:101212001	A/T	cg09795085	chr6:101329169	ASCC3	0.44	5.61	0.35	5.66e-8	Neuroticism;
SARC	cis	rs7819412	0.775	rs34094119	chr8:10935898	A/G	cg21775007	chr8:11205619	TDH	-0.47	-5.99	-0.37	7.69e-9	Triglycerides;
SARC	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg04267008	chr7:1944627	MAD1L1	-0.66	-7.66	-0.45	4.96e-13	Bipolar disorder and schizophrenia;
SARC	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.8	-9.99	-0.55	8.89e-20	Height;
SARC	cis	rs6840360	0.571	rs11940881	chr4:152501050	C/G	cg22705602	chr4:152727874	NA	-0.43	-6.71	-0.4	1.5e-10	Intelligence (multi-trait analysis);
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg23614229	chr17:48638594	CACNA1G	-0.52	-6.59	-0.4	2.97e-10	Schizophrenia;
SARC	cis	rs9868809	0.505	rs9877685	chr3:48748588	C/T	cg00383909	chr3:49044727	WDR6	0.65	6.21	0.38	2.36e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs1318878	0.956	rs73301698	chr12:15539771	G/A	cg08258403	chr12:15378311	NA	0.5	6.4	0.39	8.62e-10	Intelligence (multi-trait analysis);
SARC	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg09699651	chr6:150184138	LRP11	0.4	4.94	0.31	1.49e-6	Lung cancer;
SARC	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9398803	0.865	rs9372840	chr6:126822635	A/C	cg20229609	chr6:126660872	C6orf173	0.41	5.94	0.36	1.03e-8	Male-pattern baldness;
SARC	cis	rs865483	0.895	rs853191	chr17:35821758	A/T	cg06561646	chr17:35873369	DUSP14	-0.48	-6.45	-0.39	6.36e-10	Monocyte count;
SARC	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg22535103	chr8:58192502	C8orf71	-0.59	-5.59	-0.34	6.45e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs66573146	0.831	rs73088564	chr4:6984553	G/C	cg15105060	chr4:7024189	TBC1D14	-0.69	-4.92	-0.31	1.63e-6	Granulocyte percentage of myeloid white cells;
SARC	cis	rs854765	0.583	rs12603148	chr17:17865257	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.69	10.04	0.55	5.92e-20	Total body bone mineral density;
SARC	cis	rs10791097	0.677	rs11222359	chr11:130730648	A/G	cg12179176	chr11:130786555	SNX19	0.65	9.0	0.51	8.36e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs10463554	0.963	rs1011454	chr5:102368255	A/G	cg23492399	chr5:102201601	PAM	-0.47	-5.16	-0.32	5.38e-7	Parkinson's disease;
SARC	cis	rs6977660	0.714	rs12386623	chr7:19791875	A/G	cg05791153	chr7:19748676	TWISTNB	-0.72	-6.59	-0.4	2.99e-10	Thyroid stimulating hormone;
SARC	cis	rs2576037	0.566	rs2437854	chr18:44557613	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.53	6.7	0.4	1.52e-10	Personality dimensions;
SARC	cis	rs9790314	0.905	rs7613358	chr3:160949296	T/C	cg03342759	chr3:160939853	NMD3	-0.71	-9.5	-0.53	2.6e-18	Morning vs. evening chronotype;
SARC	cis	rs6570726	0.905	rs396492	chr6:145816180	C/G	cg23711669	chr6:146136114	FBXO30	0.76	11.39	0.6	3.59e-24	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6450176	0.857	rs1541680	chr5:53304725	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-8.01	-0.46	5.3e-14	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs7769051	0.708	rs62426668	chr6:133225021	C/T	cg22852734	chr6:133119734	C6orf192	0.89	5.61	0.35	5.68e-8	Type 2 diabetes nephropathy;
SARC	cis	rs7106204	0.748	rs4636667	chr11:24238615	T/C	ch.11.24196551F	chr11:24239977	NA	0.56	5.77	0.35	2.54e-8	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs9467773	0.534	rs34453863	chr6:26628005	T/C	cg11502198	chr6:26597334	ABT1	0.6	7.41	0.44	2.34e-12	Intelligence (multi-trait analysis);
SARC	cis	rs16976116	0.951	rs8043029	chr15:55486011	C/G	cg17854078	chr15:55489399	RSL24D1	0.66	6.59	0.4	2.89e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2180341	1.000	rs6937287	chr6:127645719	T/A	cg27446573	chr6:127587934	RNF146	1.03	14.54	0.69	1.56e-34	Breast cancer;
SARC	trans	rs11722228	0.522	rs2241468	chr4:10113905	G/A	cg26043149	chr18:55253948	FECH	0.72	8.18	0.47	1.84e-14	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs478304	0.651	rs10896038	chr11:65505528	G/C	cg26695010	chr11:65641043	EFEMP2	0.39	4.78	0.3	3.1e-6	Acne (severe);
SARC	cis	rs7429990	0.965	rs7653368	chr3:47985361	C/T	cg11946769	chr3:48343235	NME6	0.43	4.86	0.3	2.11e-6	Educational attainment (years of education);
SARC	cis	rs9910055	0.530	rs11656758	chr17:42301541	A/G	cg13607699	chr17:42295918	UBTF	0.85	13.57	0.66	2.71e-31	Total body bone mineral density;
SARC	cis	rs7327064	1.000	rs7995669	chr13:36762986	C/T	cg13455704	chr13:36871754	C13orf38	-0.52	-5.72	-0.35	3.22e-8	Economic and political preferences;
SARC	cis	rs3540	0.554	rs12443252	chr15:91064690	C/T	cg22089800	chr15:90895588	ZNF774	-0.61	-7.61	-0.45	6.56e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg00149659	chr3:10157352	C3orf10	0.69	7.2	0.43	8.12e-12	Alzheimer's disease;
SARC	cis	rs3126085	0.935	rs1390485	chr1:152182168	C/T	cg26876637	chr1:152193138	HRNR	-0.48	-5.57	-0.34	6.97e-8	Atopic dermatitis;
SARC	cis	rs12586317	0.547	rs13379372	chr14:35483882	A/C	cg16230307	chr14:35515116	FAM177A1	1.02	11.85	0.61	1.18e-25	Psoriasis;
SARC	cis	rs8028182	1.000	rs8028182	chr15:75718669	G/T	cg20655648	chr15:75932815	IMP3	0.56	6.0	0.37	7.48e-9	Sudden cardiac arrest;
SARC	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.71	7.43	0.44	2.04e-12	Platelet count;
SARC	cis	rs9682041	0.696	rs35177863	chr3:170090006	A/G	cg11886554	chr3:170076028	SKIL	0.83	7.75	0.45	2.91e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg05368731	chr17:41323189	NBR1	0.79	9.57	0.53	1.59e-18	Menopause (age at onset);
SARC	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.69	0.54	7.15e-19	Hip circumference adjusted for BMI;
SARC	cis	rs2191566	0.821	rs62119173	chr19:44518073	G/A	cg20607764	chr19:44506953	ZNF230	-0.49	-5.66	-0.35	4.34e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs920590	0.684	rs57462676	chr8:19670848	G/C	cg17834443	chr8:19674713	INTS10	0.65	7.71	0.45	3.71e-13	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs7582180	0.700	rs4640404	chr2:100980523	C/T	cg14675211	chr2:100938903	LONRF2	-0.49	-7.04	-0.42	2.14e-11	Intelligence (multi-trait analysis);
SARC	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg17971929	chr21:40555470	PSMG1	-0.85	-11.47	-0.6	1.97e-24	Cognitive function;
SARC	cis	rs911263	0.581	rs12890110	chr14:68781595	C/T	cg18825221	chr14:68749962	RAD51L1	0.42	7.41	0.44	2.28e-12	Primary biliary cholangitis;
SARC	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.53	4.98	0.31	1.25e-6	Lung function (FEV1/FVC);
SARC	cis	rs870825	0.616	rs7659101	chr4:185632158	C/T	cg04058563	chr4:185651563	MLF1IP	0.83	11.16	0.59	1.91e-23	Blood protein levels;
SARC	cis	rs7223966	1.000	rs6504170	chr17:61709168	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.48	-5.09	-0.32	7.51e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1865760	0.551	rs9461230	chr6:26019240	G/C	cg10373733	chr6:25993375	NA	0.42	5.11	0.32	6.82e-7	Height;
SARC	cis	rs7644634	0.531	rs11713094	chr3:105389153	A/G	cg23051926	chr3:105466016	CBLB	0.47	5.4	0.33	1.68e-7	Itch intensity from mosquito bite;
SARC	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg00933542	chr6:150070202	PCMT1	0.3	5.1	0.32	7.1e-7	Lung cancer;
SARC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.04	0.37	6.05e-9	Prudent dietary pattern;
SARC	cis	rs2011503	1.000	rs2011503	chr19:19443986	C/T	cg03709012	chr19:19516395	GATAD2A	0.63	5.65	0.35	4.67e-8	Bipolar disorder;
SARC	cis	rs2997447	0.846	rs7520344	chr1:26397286	C/T	cg19633962	chr1:26362018	EXTL1	-0.64	-5.21	-0.32	4.07e-7	QRS complex (12-leadsum);
SARC	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg11764359	chr7:65958608	NA	-0.65	-7.69	-0.45	4.11e-13	Aortic root size;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg11988203	chr2:198272801	SF3B1	0.5	7.1	0.42	1.5e-11	Thyroid stimulating hormone;
SARC	cis	rs10227331	0.585	rs10240671	chr7:157298637	G/T	cg04156418	chr7:157293606	NA	-0.36	-5.89	-0.36	1.31e-8	Inattentive symptoms;
SARC	cis	rs950169	0.922	rs11633075	chr15:85113972	C/A	cg03959625	chr15:84868606	LOC388152	0.36	4.93	0.31	1.53e-6	Schizophrenia;
SARC	cis	rs12142240	0.698	rs17413694	chr1:46818416	A/C	cg00530320	chr1:46809349	NSUN4	0.57	6.92	0.41	4.4e-11	Menopause (age at onset);
SARC	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg20891283	chr12:69753455	YEATS4	0.54	7.42	0.44	2.22e-12	Blood protein levels;
SARC	cis	rs1983891	0.865	rs10947980	chr6:41525739	A/G	cg15051332	chr6:41514432	FOXP4	0.48	5.02	0.31	1.01e-6	Prostate cancer;
SARC	cis	rs6912958	0.678	rs9450733	chr6:88250081	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.37	-0.33	1.88e-7	Monocyte percentage of white cells;
SARC	cis	rs7264396	0.563	rs56941405	chr20:34313426	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	5.69	0.35	3.71e-8	Total cholesterol levels;
SARC	cis	rs12421382	0.507	rs11600810	chr11:109356443	G/A	cg16359550	chr11:109292809	C11orf87	0.44	6.06	0.37	5.47e-9	Schizophrenia;
SARC	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg06420487	chr17:61919686	SMARCD2	0.46	5.2	0.32	4.31e-7	Height;
SARC	cis	rs7808935	0.591	rs62451117	chr7:27942357	T/C	cg05786569	chr7:27702416	HIBADH	0.69	7.63	0.45	6.12e-13	Prostate cancer;
SARC	cis	rs7927771	1.000	rs12418852	chr11:47868853	C/G	cg05585544	chr11:47624801	NA	-0.36	-4.82	-0.3	2.59e-6	Subjective well-being;
SARC	cis	rs7223966	1.000	rs752621	chr17:61901880	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-4.97	-0.31	1.29e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs4727027	0.933	rs917123	chr7:148848358	G/A	cg23583168	chr7:148888333	NA	-0.73	-11.06	-0.59	3.98e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs7582720	1.000	rs72926794	chr2:203827432	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs554111	0.891	rs646786	chr1:21054726	A/G	cg04902671	chr1:21058625	SH2D5	-0.44	-5.08	-0.32	7.8e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs12995491	0.731	rs17435439	chr2:88511391	A/G	cg04511125	chr2:88470314	THNSL2	-0.39	-5.84	-0.36	1.72e-8	Response to metformin (IC50);
SARC	cis	rs11122272	0.735	rs2437147	chr1:231516756	T/C	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs698813	0.674	rs6759891	chr2:44496005	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	6.28	0.38	1.62e-9	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	trans	rs1478897	0.898	rs2248696	chr8:11393803	C/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.33	-0.43	3.77e-12	Systemic lupus erythematosus;
SARC	cis	rs737337	1.000	rs3760782	chr19:11346550	C/T	cg00586551	chr19:11347513	LOC55908;DOCK6	0.67	6.46	0.39	6.05e-10	HDL cholesterol;HDL cholesterol levels;
SARC	trans	rs11767400	0.745	rs4521704	chr7:122246992	A/G	cg04856042	chr3:115752704	LSAMP	-0.44	-6.36	-0.38	1.06e-9	Menarche (age at onset);
SARC	trans	rs61931739	0.534	rs2636072	chr12:34062386	C/T	cg26384229	chr12:38710491	ALG10B	0.74	10.17	0.55	2.49e-20	Morning vs. evening chronotype;
SARC	cis	rs11098499	0.754	rs9999724	chr4:120239944	C/T	cg09307838	chr4:120376055	NA	0.81	11.2	0.59	1.36e-23	Corneal astigmatism;
SARC	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg16405210	chr4:1374714	KIAA1530	-0.43	-5.11	-0.32	6.77e-7	Obesity-related traits;
SARC	cis	rs2594989	0.831	rs2443703	chr3:11564191	C/T	cg00170343	chr3:11313890	ATG7	-0.57	-5.79	-0.35	2.25e-8	Circulating chemerin levels;
SARC	cis	rs2280018	0.526	rs2966128	chr16:15153389	G/T	cg27102117	chr16:15229624	NA	0.53	6.3	0.38	1.5e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	trans	rs73376981	0.660	rs13219910	chr6:471619	C/T	cg03622371	chr11:73000436	P2RY6	-0.53	-6.57	-0.4	3.24e-10	Plantar warts;
SARC	cis	rs752010	0.967	rs6703597	chr1:42097904	C/T	cg06885757	chr1:42089581	HIVEP3	0.35	5.46	0.34	1.21e-7	Lupus nephritis in systemic lupus erythematosus;
SARC	trans	rs1853207	1.000	rs78441737	chr10:96693563	G/A	cg02737782	chr1:8014393	NA	-0.91	-6.52	-0.39	4.4e-10	Blood metabolite levels;
SARC	cis	rs7666738	0.830	rs13133355	chr4:98919415	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.31e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6570726	0.967	rs439017	chr6:145806123	T/C	cg23711669	chr6:146136114	FBXO30	0.76	11.62	0.61	6.15e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7528419	1.000	rs646776	chr1:109818530	C/T	cg00908766	chr1:109817496	CELSR2	0.6	7.66	0.45	5.08e-13	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
SARC	cis	rs2806561	0.765	rs652706	chr1:23514246	G/A	cg12483005	chr1:23474871	LUZP1	0.45	5.9	0.36	1.29e-8	Height;
SARC	cis	rs4253772	0.637	rs9627295	chr22:46650100	C/T	cg24881330	chr22:46731750	TRMU	0.62	6.72	0.4	1.41e-10	LDL cholesterol;Cholesterol, total;
SARC	cis	rs9916302	0.652	rs9903269	chr17:37742383	A/T	cg20243544	chr17:37824526	PNMT	0.53	5.47	0.34	1.17e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg02018176	chr4:1364513	KIAA1530	0.36	5.08	0.32	7.87e-7	Obesity-related traits;
SARC	cis	rs3008870	1.000	rs2755248	chr1:67492624	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.9	11.27	0.59	8.24e-24	Lymphocyte percentage of white cells;
SARC	cis	rs7246657	1.000	rs7246657	chr19:37747108	C/T	cg14683738	chr19:37701593	ZNF585B	-0.6	-5.61	-0.34	5.75e-8	Coronary artery calcification;
SARC	cis	rs7829975	0.606	rs891570	chr8:8794454	G/A	cg15556689	chr8:8085844	FLJ10661	-0.41	-5.04	-0.31	9.16e-7	Mood instability;
SARC	cis	rs910316	1.000	rs2098297	chr14:75619118	G/T	cg08847533	chr14:75593920	NEK9	-0.92	-15.87	-0.72	5.89e-39	Height;
SARC	cis	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.43	-0.39	6.99e-10	Joint mobility (Beighton score);
SARC	cis	rs9788682	0.747	rs8043009	chr15:78908154	G/C	cg06917634	chr15:78832804	PSMA4	-0.47	-5.37	-0.33	1.89e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs6430585	0.528	rs16832440	chr2:136754183	G/A	cg07169764	chr2:136633963	MCM6	1.01	12.82	0.64	7.73e-29	Corneal structure;
SARC	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.37	-4.73	-0.3	3.92e-6	Lymphocyte counts;
SARC	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg02841227	chr6:26021843	HIST1H4A	0.63	7.67	0.45	4.57e-13	Intelligence (multi-trait analysis);
SARC	trans	rs61931739	0.517	rs4931771	chr12:34044557	G/A	cg26384229	chr12:38710491	ALG10B	0.85	12.34	0.63	2.98e-27	Morning vs. evening chronotype;
SARC	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg21016266	chr12:122356598	WDR66	0.42	6.49	0.39	5.23e-10	Mean corpuscular volume;
SARC	cis	rs7246657	0.882	rs10412043	chr19:37826626	A/C	cg23950597	chr19:37808831	NA	-0.54	-5.46	-0.34	1.24e-7	Coronary artery calcification;
SARC	cis	rs3126085	0.935	rs10749670	chr1:152220467	G/A	cg26876637	chr1:152193138	HRNR	0.48	5.6	0.34	6.14e-8	Atopic dermatitis;
SARC	cis	rs7106204	0.534	rs76397001	chr11:24254188	A/C	ch.11.24196551F	chr11:24239977	NA	0.73	6.26	0.38	1.84e-9	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg25894440	chr7:65020034	NA	0.71	5.33	0.33	2.28e-7	Diabetic kidney disease;
SARC	cis	rs8141529	0.551	rs34578331	chr22:29347215	G/T	cg15103426	chr22:29168792	CCDC117	0.6	5.83	0.36	1.79e-8	Lymphocyte counts;
SARC	cis	rs11608355	0.618	rs4486687	chr12:109790741	T/A	cg05360138	chr12:110035743	NA	0.42	5.06	0.31	8.48e-7	Neuroticism;
SARC	cis	rs11252926	0.589	rs12359901	chr10:475068	A/G	cg16386425	chr10:429943	DIP2C	0.45	5.05	0.31	9.1e-7	Psychosis in Alzheimer's disease;
SARC	cis	rs113835537	0.529	rs11227509	chr11:66281194	T/C	cg24851651	chr11:66362959	CCS	0.37	4.76	0.3	3.36e-6	Airway imaging phenotypes;
SARC	cis	rs2153904	0.793	rs12132270	chr1:205660940	C/T	cg23034840	chr1:205782522	SLC41A1	-0.78	-6.86	-0.41	6.03e-11	Prostate-specific antigen levels;
SARC	cis	rs11605924	0.967	rs7121611	chr11:45864142	A/T	ch.11.939596F	chr11:45881766	CRY2	-0.47	-5.44	-0.34	1.31e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs10463554	0.963	rs257319	chr5:102445827	T/A	cg23492399	chr5:102201601	PAM	-0.52	-5.72	-0.35	3.2e-8	Parkinson's disease;
SARC	trans	rs2243123	0.602	rs2133310	chr3:159716352	A/G	cg15822908	chr1:33502755	AK2	0.51	6.6	0.4	2.78e-10	Multiple sclerosis;
SARC	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg26335602	chr6:28129616	ZNF389	0.43	5.26	0.33	3.27e-7	Cardiac Troponin-T levels;
SARC	cis	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg25427524	chr10:38739819	LOC399744	-0.53	-8.32	-0.48	7.33e-15	Extrinsic epigenetic age acceleration;
SARC	cis	rs1044826	0.619	rs6439856	chr3:139134868	A/T	cg15131784	chr3:139108705	COPB2	-0.4	-5.14	-0.32	5.7e-7	Obesity-related traits;
SARC	cis	rs7617773	0.817	rs6806112	chr3:48276077	A/T	cg11946769	chr3:48343235	NME6	0.64	8.54	0.49	1.73e-15	Coronary artery disease;
SARC	cis	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg25358081	chr4:146402752	SMAD1	-0.46	-4.97	-0.31	1.3e-6	Hip circumference;
SARC	cis	rs7927592	0.956	rs12365160	chr11:68250419	A/G	cg01657329	chr11:68192670	LRP5	-0.41	-5.09	-0.32	7.55e-7	Total body bone mineral density;
SARC	cis	rs2153219	1.000	rs2789493	chr6:149756862	T/A	cg18043157	chr6:150390308	ULBP3	-0.53	-5.08	-0.32	7.74e-7	Coronary artery disease;
SARC	cis	rs13088645	0.532	rs12695613	chr3:134166572	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.46	5.45	0.34	1.29e-7	Coronary artery disease;
SARC	cis	rs72945132	0.825	rs72947052	chr11:70188575	A/G	cg00319359	chr11:70116639	PPFIA1	0.69	6.06	0.37	5.46e-9	Coronary artery disease;
SARC	cis	rs11676348	0.710	rs11894169	chr2:219046846	T/C	cg00012203	chr2:219082015	ARPC2	0.44	5.58	0.34	6.52e-8	Ulcerative colitis;
SARC	trans	rs6600671	1.000	rs1832558	chr1:121177380	A/G	cg00646200	chr1:148855367	NA	0.49	6.93	0.41	4.12e-11	Hip geometry;
SARC	trans	rs61931739	0.517	rs11053067	chr12:34191391	T/C	cg13010199	chr12:38710504	ALG10B	0.73	9.71	0.54	6.21e-19	Morning vs. evening chronotype;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg15086788	chr17:8152811	PFAS;C17orf68	0.57	7.28	0.43	5.2e-12	Breast cancer;
SARC	cis	rs9325144	0.560	rs7980635	chr12:38668355	G/T	cg26384229	chr12:38710491	ALG10B	-0.63	-8.11	-0.47	2.91e-14	Morning vs. evening chronotype;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg09058860	chr1:173837788	SNORD74;ZBTB37;GAS5	-0.74	-6.45	-0.39	6.5e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs911555	0.511	rs8007489	chr14:104054572	A/G	cg17925084	chr14:104152323	KLC1	-0.35	-5.02	-0.31	1e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg07636037	chr3:49044803	WDR6	0.93	15.32	0.71	4.04e-37	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs11792861	1.000	rs11792861	chr9:111809295	A/C	cg13535736	chr9:111863775	C9orf5	-0.4	-4.99	-0.31	1.16e-6	Menarche (age at onset);
SARC	cis	rs11025559	0.812	rs16906280	chr11:20472242	T/C	cg19653624	chr11:20408972	PRMT3	-0.6	-6.62	-0.4	2.5e-10	Pursuit maintenance gain;
SARC	cis	rs881375	1.000	rs10117059	chr9:123653477	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.44	5.3	0.33	2.63e-7	Rheumatoid arthritis;
SARC	trans	rs11165623	0.564	rs6673207	chr1:96999259	C/G	cg10631902	chr5:14652156	NA	-0.44	-6.58	-0.4	3.16e-10	Hip circumference;Waist circumference;
SARC	cis	rs9916302	0.861	rs9903363	chr17:37499604	C/G	cg00129232	chr17:37814104	STARD3	0.59	7.31	0.43	4.18e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg22496380	chr5:211416	CCDC127	-0.91	-9.08	-0.51	4.66e-17	Breast cancer;
SARC	cis	rs698833	1.000	rs698833	chr2:44735438	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.66	7.84	0.46	1.63e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs7089973	0.872	rs7072356	chr10:116634651	T/C	cg08188268	chr10:116634841	FAM160B1	0.37	5.9	0.36	1.27e-8	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs11997175	0.575	rs56942690	chr8:33820308	G/A	ch.8.33884649F	chr8:33765107	NA	0.46	5.95	0.36	9.77e-9	Body mass index;
SARC	cis	rs67460515	0.500	rs6806015	chr3:160724766	G/A	cg04691961	chr3:161091175	C3orf57	-0.43	-5.28	-0.33	3.03e-7	Parkinson's disease;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg27005053	chr16:75467374	CFDP1	0.55	6.78	0.41	1e-10	Breast cancer;
SARC	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg02725872	chr8:58115012	NA	-0.34	-5.35	-0.33	2.08e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs1814175	0.586	rs2866862	chr11:49954588	T/C	cg15704280	chr7:45808275	SEPT13	-0.9	-14.28	-0.68	1.15e-33	Height;
SARC	trans	rs8020941	0.585	rs75993804	chr14:97497690	C/A	cg05136476	chr3:53190709	NA	-0.63	-6.39	-0.39	8.99e-10	Diabetic kidney disease;
SARC	trans	rs7819412	0.561	rs2001328	chr8:10987199	T/C	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.75	-0.45	2.82e-13	Triglycerides;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg16204710	chr13:41707021	KBTBD6	0.49	6.47	0.39	5.68e-10	Chemerin levels;
SARC	cis	rs3733346	0.529	rs6842493	chr4:914638	T/C	cg15105011	chr4:940614	TMEM175	0.36	4.93	0.31	1.55e-6	Sjögren's syndrome;
SARC	cis	rs644799	0.540	rs10831419	chr11:95478037	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.57	6.91	0.41	4.7e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs10771431	0.935	rs1988852	chr12:9372862	G/A	cg27600084	chr12:12264075	NA	0.55	7.71	0.45	3.54e-13	Breast size;
SARC	cis	rs262150	0.544	rs2428780	chr7:158812471	T/A	cg04111992	chr7:158790115	NA	-0.34	-4.85	-0.3	2.21e-6	Facial morphology (factor 20);
SARC	cis	rs11910985	0.546	rs9977877	chr21:48080493	G/A	cg23283320	chr21:48055893	PRMT2	0.98	5.78	0.35	2.39e-8	Cerebrospinal fluid t-tau:AB1-42 ratio;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg14412639	chr9:34098451	DCAF12	0.48	6.96	0.41	3.46e-11	Chemerin levels;
SARC	cis	rs17376456	0.877	rs13173952	chr5:93307557	A/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.65	6.1	0.37	4.49e-9	Diabetic retinopathy;
SARC	cis	rs7223966	1.000	rs7211213	chr17:61769456	A/G	cg00588841	chr17:61851480	DDX42;CCDC47	-0.59	-6.91	-0.41	4.49e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs17030434	0.911	rs75822357	chr4:154738258	T/C	cg14289246	chr4:154710475	SFRP2	-0.74	-7.85	-0.46	1.52e-13	Electrocardiographic conduction measures;
SARC	cis	rs79349575	0.783	rs12601858	chr17:47017477	T/C	cg16584676	chr17:46985605	UBE2Z	0.55	6.66	0.4	1.91e-10	Type 2 diabetes;
SARC	cis	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg07777115	chr5:623756	CEP72	-0.57	-5.15	-0.32	5.55e-7	Obesity-related traits;
SARC	cis	rs9611519	0.780	rs2284079	chr22:41658632	C/T	cg17376030	chr22:41985996	PMM1	0.53	6.68	0.4	1.7e-10	Neuroticism;
SARC	cis	rs16976116	0.619	rs11071172	chr15:55467185	A/C	cg11288833	chr15:55489084	RSL24D1	-0.62	-5.28	-0.33	3.02e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg06636001	chr8:8085503	FLJ10661	0.59	8.02	0.46	5.24e-14	Neuroticism;
SARC	cis	rs1670533	1.000	rs10007978	chr4:1060984	A/T	cg27284194	chr4:1044797	NA	0.45	4.76	0.3	3.42e-6	Recombination rate (females);
SARC	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg01017244	chr2:74357527	NA	0.51	5.91	0.36	1.22e-8	Gestational age at birth (maternal effect);
SARC	cis	rs858239	0.508	rs2390754	chr7:23190494	A/G	cg23682824	chr7:23144976	KLHL7	0.67	8.31	0.48	7.73e-15	Cerebrospinal fluid biomarker levels;
SARC	cis	rs2204008	0.774	rs11520273	chr12:38354075	A/T	cg13010199	chr12:38710504	ALG10B	0.78	10.79	0.58	2.78e-22	Bladder cancer;
SARC	cis	rs472402	0.623	rs8192133	chr5:6636645	A/G	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.4	-4.9	-0.31	1.78e-6	Response to amphetamines;
SARC	cis	rs2486288	0.586	rs12909883	chr15:45572054	G/C	cg15395560	chr15:45543142	SLC28A2	0.3	5.78	0.35	2.41e-8	Glomerular filtration rate;
SARC	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg27266027	chr21:40555129	PSMG1	0.48	4.83	0.3	2.51e-6	Cognitive function;
SARC	trans	rs9325144	0.581	rs2653758	chr12:38946233	G/T	cg23762105	chr12:34175262	ALG10	0.51	6.5	0.39	4.89e-10	Morning vs. evening chronotype;
SARC	cis	rs9911578	0.967	rs2333410	chr17:57137129	G/A	cg05425664	chr17:57184151	TRIM37	0.62	7.76	0.45	2.59e-13	Intelligence (multi-trait analysis);
SARC	cis	rs9296092	0.500	rs4376348	chr6:33521097	A/G	cg13560919	chr6:33536144	NA	-0.49	-5.95	-0.36	9.74e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs870825	0.860	rs72703526	chr4:185605676	A/T	cg04058563	chr4:185651563	MLF1IP	0.76	9.26	0.52	1.4e-17	Blood protein levels;
SARC	trans	rs9929218	0.954	rs9925923	chr16:68819614	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.53	-6.87	-0.41	5.68e-11	Colorectal cancer;
SARC	cis	rs79349575	0.783	rs4255820	chr17:46996583	T/A	cg16584676	chr17:46985605	UBE2Z	0.53	6.38	0.39	9.28e-10	Type 2 diabetes;
SARC	trans	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg00938859	chr5:1591904	SDHAP3	0.8	7.65	0.45	5.22e-13	Breast cancer;
SARC	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg25072359	chr17:41440525	NA	0.51	6.04	0.37	6.2e-9	Menopause (age at onset);
SARC	cis	rs73157695	1.000	rs2839072	chr21:47369535	A/G	cg00682050	chr21:47343716	PCBP3	-0.41	-4.89	-0.3	1.9e-6	Myopia;
SARC	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-5.62	-0.35	5.3e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg07167872	chr1:205819463	PM20D1	0.46	6.11	0.37	4.12e-9	Menarche (age at onset);
SARC	cis	rs7178572	0.889	rs907388	chr15:77828668	G/A	cg22256960	chr15:77711686	NA	-0.53	-6.03	-0.37	6.33e-9	Type 2 diabetes;
SARC	cis	rs9815354	1.000	rs56121764	chr3:41883975	T/C	cg03022575	chr3:42003672	ULK4	0.62	5.43	0.34	1.39e-7	Pulse pressure;Diastolic blood pressure;
SARC	trans	rs208520	0.909	rs55813840	chr6:67012508	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.82	8.32	0.48	7.56e-15	Exhaled nitric oxide output;
SARC	cis	rs473651	0.935	rs515412	chr2:239345394	A/T	cg21699342	chr2:239360505	ASB1	0.43	6.22	0.38	2.28e-9	Multiple system atrophy;
SARC	cis	rs2070997	0.607	rs10901284	chr9:133668799	T/C	cg11464064	chr9:133710261	ABL1	0.59	5.67	0.35	4.12e-8	Response to amphetamines;
SARC	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg08219700	chr8:58056026	NA	0.59	6.3	0.38	1.46e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7659604	1.000	rs72678650	chr4:122666000	A/G	cg19748678	chr4:122722346	EXOSC9	0.41	5.04	0.31	9.17e-7	Type 2 diabetes;
SARC	cis	rs7659604	1.000	rs28433617	chr4:122664138	C/A	cg19748678	chr4:122722346	EXOSC9	0.44	5.49	0.34	1.03e-7	Type 2 diabetes;
SARC	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg22920501	chr2:26401640	FAM59B	-0.6	-8.25	-0.48	1.19e-14	Gut microbiome composition (summer);
SARC	cis	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg25894440	chr7:65020034	NA	-0.73	-5.55	-0.34	7.84e-8	Diabetic kidney disease;
SARC	cis	rs10992471	0.535	rs10117041	chr9:95282331	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.38	-0.33	1.78e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs4242434	0.927	rs10095121	chr8:22538426	A/G	cg03733263	chr8:22462867	KIAA1967	0.88	13.98	0.68	1.19e-32	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs9457247	0.765	rs9457259	chr6:167444281	C/T	cg07741184	chr6:167504864	NA	0.38	7.49	0.44	1.39e-12	Crohn's disease;
SARC	cis	rs7552404	0.731	rs5745445	chr1:76344332	G/A	cg03433033	chr1:76189801	ACADM	0.45	5.53	0.34	8.68e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs10752881	1.000	rs10752883	chr1:182980963	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.76	0.58	3.38e-22	Colorectal cancer;
SARC	cis	rs2463822	1.000	rs1881534	chr11:62085083	A/G	cg06239285	chr11:62104954	ASRGL1	0.88	8.81	0.5	2.88e-16	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs2762353	0.524	rs3923	chr6:25783315	T/C	cg17691542	chr6:26056736	HIST1H1C	-0.44	-5.51	-0.34	9.42e-8	Blood metabolite levels;
SARC	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.8	8.31	0.48	7.83e-15	Mean platelet volume;
SARC	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg22800045	chr5:56110881	MAP3K1	0.73	7.81	0.46	2e-13	Initial pursuit acceleration;
SARC	cis	rs6570726	0.846	rs6570700	chr6:145931552	A/G	cg05347473	chr6:146136440	FBXO30	0.51	7.12	0.42	1.35e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1559088	0.948	rs6510346	chr19:33598526	T/A	cg27124370	chr19:33622961	WDR88	0.44	5.86	0.36	1.6e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs9843304	0.568	rs10935763	chr3:149219070	A/C	cg08667024	chr3:149219783	TM4SF4	0.33	4.74	0.3	3.73e-6	Gallstone disease;
SARC	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg18252515	chr7:66147081	NA	-0.47	-5.09	-0.32	7.32e-7	Aortic root size;
SARC	cis	rs11690935	0.632	rs6433323	chr2:172873060	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.68	-9.39	-0.52	5.69e-18	Schizophrenia;
SARC	cis	rs9399135	0.967	rs7766189	chr6:135353851	A/C	cg24558204	chr6:135376177	HBS1L	0.46	6.2	0.38	2.56e-9	Red blood cell count;
SARC	cis	rs826838	0.933	rs980573	chr12:39127811	T/C	cg26384229	chr12:38710491	ALG10B	-0.76	-11.59	-0.6	7.97e-25	Heart rate;
SARC	cis	rs6450176	0.909	rs7732139	chr5:53292017	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.64	-7.22	-0.43	7.11e-12	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs7727544	0.709	rs441969	chr5:131702120	G/A	cg24060327	chr5:131705240	SLC22A5	-0.67	-8.43	-0.48	3.7e-15	Blood metabolite levels;
SARC	cis	rs1267303	0.642	rs6696219	chr1:47000408	T/C	cg25110126	chr1:46999211	NA	0.84	9.05	0.51	6e-17	Monobrow;
SARC	cis	rs7084402	0.967	rs2842083	chr10:60329230	A/C	cg07615347	chr10:60278583	BICC1	0.58	8.58	0.49	1.36e-15	Refractive error;
SARC	cis	rs10823500	0.777	rs10509321	chr10:71985733	A/G	cg04118878	chr10:71993077	PPA1	-0.58	-6.64	-0.4	2.23e-10	Blood protein levels;
SARC	cis	rs35306767	0.903	rs12260800	chr10:927933	T/C	cg20503657	chr10:835505	NA	0.88	8.48	0.49	2.64e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs9309473	0.687	rs6706235	chr2:73613558	C/G	cg20560298	chr2:73613845	ALMS1	-0.52	-6.74	-0.4	1.23e-10	Metabolite levels;
SARC	trans	rs9395865	0.520	rs6903708	chr6:53332940	A/G	cg01037673	chr19:11485375	C19orf39	-0.51	-6.34	-0.38	1.15e-9	Electroencephalographic traits in alcoholism;
SARC	cis	rs6688613	0.729	rs10918603	chr1:166936503	T/C	cg07049167	chr1:166818506	POGK	0.5	5.2	0.32	4.39e-7	Refractive astigmatism;
SARC	cis	rs56235845	0.694	rs4532376	chr5:176774403	G/A	cg16006841	chr5:176797999	RGS14	0.56	7.35	0.43	3.32e-12	Hemoglobin concentration;Hematocrit;
SARC	cis	rs10782582	0.545	rs12138018	chr1:76186794	T/C	cg03433033	chr1:76189801	ACADM	-0.41	-5.35	-0.33	2.09e-7	Daytime sleep phenotypes;
SARC	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg11764359	chr7:65958608	NA	0.65	7.58	0.44	7.92e-13	Aortic root size;
SARC	cis	rs651907	0.535	rs34743741	chr3:101532448	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.49	5.7	0.35	3.63e-8	Colorectal cancer;
SARC	cis	rs9381040	0.610	rs4140579	chr6:41041752	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.45	-5.16	-0.32	5.17e-7	Alzheimer's disease (late onset);
SARC	cis	rs7408868	1.000	rs10410514	chr19:15277610	C/T	cg14696996	chr19:15285081	NOTCH3	1.01	8.93	0.5	1.32e-16	Pulse pressure;
SARC	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.0	11.56	0.6	9.97e-25	Platelet count;
SARC	trans	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg21659725	chr3:3221576	CRBN	0.56	6.46	0.39	6.06e-10	Resting heart rate;
SARC	cis	rs72945132	0.882	rs113472486	chr11:70194945	C/G	cg00319359	chr11:70116639	PPFIA1	0.67	6.17	0.37	2.95e-9	Coronary artery disease;
SARC	cis	rs76693355	0.512	rs11217875	chr11:120325559	C/A	cg15690696	chr11:120217718	ARHGEF12	-0.39	-4.8	-0.3	2.86e-6	Intraocular pressure;
SARC	cis	rs9325144	0.555	rs10748433	chr12:38696352	C/G	cg13010199	chr12:38710504	ALG10B	0.56	7.33	0.43	3.73e-12	Morning vs. evening chronotype;
SARC	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg22875332	chr1:76189707	ACADM	0.48	6.72	0.4	1.4e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs832540	0.864	rs832576	chr5:56163255	C/A	cg14703610	chr5:56206110	C5orf35	0.52	6.46	0.39	6.11e-10	Coronary artery disease;
SARC	cis	rs9894429	1.000	rs7223613	chr17:79574803	C/T	cg18240062	chr17:79603768	NPLOC4	-0.71	-9.81	-0.54	3.03e-19	Eye color traits;
SARC	cis	rs2425143	0.908	rs74784474	chr20:34422464	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-6.27	-0.38	1.69e-9	Blood protein levels;
SARC	cis	rs637571	0.565	rs570387	chr11:65637076	T/C	cg26695010	chr11:65641043	EFEMP2	0.79	12.36	0.63	2.55e-27	Eosinophil percentage of white cells;
SARC	cis	rs2635047	0.682	rs9960932	chr18:44792445	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	6.28	0.38	1.6e-9	Educational attainment;
SARC	cis	rs539096	0.500	rs803678	chr1:44350898	G/T	cg12908607	chr1:44402522	ARTN	-0.31	-5.58	-0.34	6.5e-8	Intelligence (multi-trait analysis);
SARC	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg04518342	chr5:131593106	PDLIM4	0.36	5.06	0.31	8.51e-7	Breast cancer;
SARC	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.65	7.87	0.46	1.35e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg22535103	chr8:58192502	C8orf71	-0.72	-6.61	-0.4	2.6e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg13206674	chr6:150067644	NUP43	0.43	5.58	0.34	6.59e-8	Lung cancer;
SARC	cis	rs2658782	1.000	rs2658778	chr11:93148948	C/G	cg15737290	chr11:93063684	CCDC67	0.69	7.18	0.43	9.13e-12	Pulmonary function decline;
SARC	cis	rs12586317	0.553	rs78124218	chr14:35570606	G/A	cg26967526	chr14:35346199	BAZ1A	-0.64	-6.86	-0.41	6.1e-11	Psoriasis;
SARC	cis	rs9389248	0.737	rs12664956	chr6:135384188	T/C	cg24558204	chr6:135376177	HBS1L	0.62	7.77	0.45	2.49e-13	High light scatter reticulocyte percentage of red cells;
SARC	cis	rs7178572	0.524	rs1473922	chr15:77656798	G/T	cg22256960	chr15:77711686	NA	-0.52	-5.77	-0.35	2.52e-8	Type 2 diabetes;
SARC	cis	rs11581859	0.562	rs1982704	chr1:99242884	T/A	cg20286094	chr1:99190917	SNX7	-0.44	-5.21	-0.32	4.06e-7	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-8.71	-0.5	5.79e-16	Chronic sinus infection;
SARC	cis	rs514406	0.505	rs395169	chr1:53174071	G/A	cg08859206	chr1:53392774	SCP2	-0.35	-5.07	-0.32	8.19e-7	Monocyte count;
SARC	cis	rs1003719	0.715	rs7282195	chr21:38508619	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-9.13	-0.51	3.35e-17	Eye color traits;
SARC	cis	rs10911251	0.528	rs10911255	chr1:183088868	G/C	cg13390022	chr1:182993471	LAMC1	0.32	4.83	0.3	2.44e-6	Colorectal cancer;
SARC	cis	rs1008375	1.000	rs10019856	chr4:17615742	T/A	cg16339924	chr4:17578868	LAP3	0.65	8.46	0.48	2.92e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4423214	0.592	rs11233977	chr11:71221605	C/T	cg05163923	chr11:71159392	DHCR7	-0.49	-4.94	-0.31	1.48e-6	Vitamin D levels;
SARC	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg08021120	chr3:195498017	MUC4	0.42	5.25	0.33	3.49e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs708547	0.676	rs11133470	chr4:57864926	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.66	8.98	0.51	9.53e-17	Response to bleomycin (chromatid breaks);
SARC	cis	rs4689388	0.926	rs11732178	chr4:6292643	G/C	cg00701064	chr4:6280414	WFS1	0.57	9.55	0.53	1.82e-18	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs2153535	0.580	rs9405390	chr6:8466209	T/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.52	-5.33	-0.33	2.3e-7	Lung function (FEV1/FVC);
SARC	cis	rs2985684	0.948	rs2883437	chr14:50031666	A/G	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.47	5.17	0.32	5.05e-7	Carotid intima media thickness;
SARC	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs11190604	1.000	rs11190541	chr10:102203071	A/G	cg07080220	chr10:102295463	HIF1AN	0.77	9.5	0.53	2.71e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs1865760	0.927	rs6915834	chr6:25935427	A/C	cg17691542	chr6:26056736	HIST1H1C	0.61	7.56	0.44	9.04e-13	Height;
SARC	cis	rs5758659	0.714	rs5751220	chr22:42516205	A/C	cg15128208	chr22:42549153	NA	0.36	4.97	0.31	1.28e-6	Cognitive function;
SARC	cis	rs34311866	0.808	rs11728344	chr4:963755	T/C	cg07828340	chr4:882639	GAK	0.7	5.49	0.34	1.04e-7	Parkinson's disease;
SARC	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg09455208	chr3:40491958	NA	0.4	5.81	0.36	2.05e-8	Renal cell carcinoma;
SARC	cis	rs7937682	0.883	rs659529	chr11:111436896	T/A	cg22437258	chr11:111473054	SIK2	0.72	9.58	0.53	1.56e-18	Primary sclerosing cholangitis;
SARC	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg08859206	chr1:53392774	SCP2	-0.42	-5.9	-0.36	1.28e-8	Monocyte count;
SARC	cis	rs8054556	0.760	rs11642740	chr16:30060655	C/T	cg06015834	chr16:30021696	DOC2A	0.35	4.74	0.3	3.81e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs918629	0.798	rs6877821	chr5:95289502	C/T	cg16656078	chr5:95278638	ELL2	-0.64	-7.74	-0.45	3.03e-13	IgG glycosylation;
SARC	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg22974920	chr21:40686053	BRWD1	0.44	4.79	0.3	2.99e-6	Cognitive function;
SARC	cis	rs6977660	0.652	rs10274428	chr7:19850592	C/T	cg05791153	chr7:19748676	TWISTNB	0.59	5.2	0.32	4.28e-7	Thyroid stimulating hormone;
SARC	cis	rs2549003	0.934	rs2549006	chr5:131827065	A/G	cg21138405	chr5:131827807	IRF1	-0.28	-5.52	-0.34	9.16e-8	Asthma (sex interaction);
SARC	cis	rs826838	1.000	rs11514441	chr12:38775190	C/T	cg13010199	chr12:38710504	ALG10B	0.8	11.45	0.6	2.31e-24	Heart rate;
SARC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.42	0.53	4.53e-18	Prudent dietary pattern;
SARC	cis	rs1044826	1.000	rs3821545	chr3:139182971	C/G	cg15131784	chr3:139108705	COPB2	0.46	5.2	0.32	4.34e-7	Obesity-related traits;
SARC	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg02524346	chr8:600233	NA	0.68	5.74	0.35	2.89e-8	IgG glycosylation;
SARC	cis	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg22857025	chr5:266934	NA	-1.04	-11.38	-0.6	3.73e-24	Breast cancer;
SARC	cis	rs1983891	0.955	rs7753653	chr6:41548430	C/T	cg15051332	chr6:41514432	FOXP4	-0.51	-5.71	-0.35	3.4e-8	Prostate cancer;
SARC	cis	rs58785573	0.504	rs9522	chr4:38666972	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.47	6.22	0.38	2.25e-9	Lymphocyte percentage of white cells;
SARC	cis	rs2153535	0.580	rs4639392	chr6:8446547	A/G	cg21535247	chr6:8435926	SLC35B3	0.55	6.89	0.41	5.25e-11	Motion sickness;
SARC	cis	rs2327429	0.519	rs6906375	chr6:134152627	C/G	cg25632230	chr6:134101081	NA	-0.41	-5.11	-0.32	6.61e-7	Coronary artery disease;
SARC	cis	rs4555082	0.834	rs28489970	chr14:105748862	T/C	cg10792982	chr14:105748885	BRF1	0.55	8.22	0.47	1.45e-14	Mean platelet volume;Platelet distribution width;
SARC	trans	rs9325144	0.505	rs901635	chr12:38646572	A/C	cg23762105	chr12:34175262	ALG10	0.51	6.5	0.39	4.94e-10	Morning vs. evening chronotype;
SARC	cis	rs2153535	0.546	rs1335640	chr6:8485325	A/C	cg21535247	chr6:8435926	SLC35B3	0.55	6.88	0.41	5.45e-11	Motion sickness;
SARC	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.62	-0.4	2.41e-10	Total body bone mineral density;
SARC	cis	rs9470366	0.637	rs730506	chr6:36645968	G/C	cg08179530	chr6:36648295	CDKN1A	0.53	5.21	0.32	4.08e-7	QRS duration;
SARC	cis	rs9394841	0.692	rs9349202	chr6:41805581	A/C	cg08135965	chr6:41755394	TOMM6	0.6	6.26	0.38	1.87e-9	Mean corpuscular hemoglobin;Red cell distribution width;
SARC	cis	rs10464366	0.544	rs9639812	chr7:39192058	C/T	cg15212455	chr7:39170539	POU6F2	0.39	4.89	0.31	1.84e-6	IgG glycosylation;
SARC	cis	rs9640161	0.830	rs17173681	chr7:150059414	A/G	cg21361702	chr7:150065534	REPIN1	-0.57	-6.75	-0.4	1.15e-10	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs787274	0.850	rs10733599	chr9:115634234	A/T	cg13803584	chr9:115635662	SNX30	-0.9	-5.62	-0.35	5.54e-8	Age-related hearing impairment (SNP x SNP interaction);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg16480539	chr9:88897556	ISCA1	0.52	6.53	0.39	4.1e-10	Breast cancer;
SARC	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg12658694	chr1:38397304	INPP5B	0.78	11.0	0.58	6.02e-23	Coronary artery disease;
SARC	cis	rs796364	0.760	rs56225698	chr2:200910653	A/C	cg23649088	chr2:200775458	C2orf69	-0.64	-5.54	-0.34	8.17e-8	Schizophrenia;
SARC	cis	rs10754283	0.967	rs2185195	chr1:90106697	T/C	cg21401794	chr1:90099060	LRRC8C	0.59	8.09	0.47	3.24e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs17209837	1.000	rs17149647	chr7:87086931	T/C	cg00919237	chr7:87102261	ABCB4	-0.48	-5.12	-0.32	6.33e-7	Gallbladder cancer;
SARC	cis	rs3768617	0.510	rs4651139	chr1:183091963	C/T	cg13390022	chr1:182993471	LAMC1	0.31	4.73	0.3	3.89e-6	Fuchs's corneal dystrophy;
SARC	cis	rs4689388	0.889	rs13128674	chr4:6294517	C/T	cg25554036	chr4:6271136	WFS1	0.39	6.42	0.39	7.48e-10	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg07701084	chr6:150067640	NUP43	0.4	5.2	0.32	4.31e-7	Lung cancer;
SARC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg02475777	chr4:1388615	CRIPAK	0.62	6.84	0.41	6.88e-11	Longevity;
SARC	cis	rs2016266	0.859	rs10783575	chr12:53742885	C/T	cg26875137	chr12:53738046	NA	-0.44	-5.34	-0.33	2.16e-7	Bone mineral density (spine);Bone mineral density;
SARC	trans	rs208520	0.526	rs7771233	chr6:66819784	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-19.63	-0.79	2.85e-51	Exhaled nitric oxide output;
SARC	cis	rs9650657	0.655	rs1991651	chr8:10706411	C/G	cg21775007	chr8:11205619	TDH	0.41	5.0	0.31	1.14e-6	Neuroticism;
SARC	cis	rs9399135	0.967	rs9376077	chr6:135299713	C/G	cg24558204	chr6:135376177	HBS1L	0.45	6.06	0.37	5.41e-9	Red blood cell count;
SARC	cis	rs17401966	0.931	rs1002076	chr1:10438892	G/A	cg15208524	chr1:10270712	KIF1B	0.5	5.99	0.37	7.88e-9	Hepatocellular carcinoma;
SARC	cis	rs1003719	0.762	rs1155786	chr21:38448025	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.66	9.7	0.54	6.71e-19	Eye color traits;
SARC	cis	rs7264396	0.676	rs58372200	chr20:34555445	C/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	5.3	0.33	2.71e-7	Total cholesterol levels;
SARC	cis	rs7772486	0.754	rs702323	chr6:146008274	A/G	cg05347473	chr6:146136440	FBXO30	-0.52	-7.22	-0.43	7.32e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11097912	0.632	rs7654865	chr4:107279450	C/T	cg09646026	chr4:107269030	AIMP1	-0.43	-4.84	-0.3	2.37e-6	Airflow obstruction;
SARC	cis	rs9858542	0.953	rs4625	chr3:49572140	A/G	cg03060546	chr3:49711283	APEH	-0.61	-7.78	-0.45	2.3e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs9611565	0.592	rs12484467	chr22:41957610	T/C	cg06634786	chr22:41940651	POLR3H	-0.57	-6.53	-0.39	4.01e-10	Vitiligo;
SARC	cis	rs35306767	0.855	rs61830932	chr10:934183	T/C	cg26597838	chr10:835615	NA	0.81	8.33	0.48	6.99e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs2061333	0.557	rs28446946	chr19:44607619	T/C	cg18700516	chr19:44507157	ZNF230	-0.56	-5.28	-0.33	3.01e-7	Alzheimer's disease;
SARC	cis	rs6714710	0.603	rs11684749	chr2:98420142	G/C	cg26665480	chr2:98280029	ACTR1B	0.51	6.84	0.41	6.93e-11	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs898097	1.000	rs898098	chr17:80904564	G/A	cg15664640	chr17:80829946	TBCD	0.52	8.22	0.47	1.45e-14	Breast cancer;
SARC	cis	rs950776	0.648	rs57945453	chr15:78862845	C/T	cg06917634	chr15:78832804	PSMA4	0.79	10.66	0.57	7.14e-22	Sudden cardiac arrest;
SARC	cis	rs2180341	0.781	rs877102	chr6:127587086	T/C	cg27446573	chr6:127587934	RNF146	0.89	12.78	0.64	1.07e-28	Breast cancer;
SARC	trans	rs7819412	0.775	rs4841489	chr8:10936811	A/G	cg08975724	chr8:8085496	FLJ10661	-0.58	-7.81	-0.46	1.99e-13	Triglycerides;
SARC	cis	rs752010	0.967	rs2038978	chr1:42094719	A/G	cg06885757	chr1:42089581	HIVEP3	0.31	4.95	0.31	1.43e-6	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg11890956	chr21:40555474	PSMG1	-1.06	-15.55	-0.71	6.98e-38	Cognitive function;
SARC	cis	rs72634258	0.740	rs4489581	chr1:8174495	A/C	cg00042356	chr1:8021962	PARK7	-0.65	-6.1	-0.37	4.36e-9	Inflammatory bowel disease;
SARC	cis	rs832540	0.593	rs96844	chr5:56196604	G/A	cg14703610	chr5:56206110	C5orf35	0.46	5.2	0.32	4.29e-7	Coronary artery disease;
SARC	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg05861140	chr6:150128134	PCMT1	-0.41	-5.41	-0.33	1.53e-7	Lung cancer;
SARC	cis	rs12701220	0.553	rs34062359	chr7:1139076	C/T	cg02733842	chr7:1102375	C7orf50	-0.54	-6.13	-0.37	3.75e-9	Bronchopulmonary dysplasia;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg14787260	chr17:40428794	STAT5B	-0.8	-6.7	-0.4	1.52e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2273669	0.504	rs79374607	chr6:109398257	C/T	cg05315195	chr6:109294784	ARMC2	-0.58	-4.81	-0.3	2.76e-6	Prostate cancer;
SARC	cis	rs10782582	0.609	rs2029680	chr1:76363505	A/C	cg03433033	chr1:76189801	ACADM	-0.39	-4.93	-0.31	1.58e-6	Daytime sleep phenotypes;
SARC	cis	rs55962025	0.842	rs363088	chr4:3210330	A/T	cg06533319	chr4:3265114	C4orf44	0.35	5.33	0.33	2.37e-7	Parental longevity (mother's age at death);
SARC	trans	rs7824557	0.815	rs958648	chr8:11103895	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.48	-0.39	5.44e-10	Retinal vascular caliber;
SARC	cis	rs2658782	0.826	rs2925355	chr11:93090887	T/C	cg15737290	chr11:93063684	CCDC67	0.7	7.14	0.42	1.2e-11	Pulmonary function decline;
SARC	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg11890956	chr21:40555474	PSMG1	1.17	19.07	0.78	1.8e-49	Cognitive function;
SARC	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg10253484	chr15:75165896	SCAMP2	-0.39	-4.78	-0.3	3.1e-6	Breast cancer;
SARC	cis	rs4253772	0.591	rs6007740	chr22:46654323	A/G	cg24881330	chr22:46731750	TRMU	-0.62	-6.98	-0.42	3.01e-11	LDL cholesterol;Cholesterol, total;
SARC	cis	rs950169	0.800	rs34302901	chr15:85110943	C/G	cg03959625	chr15:84868606	LOC388152	0.36	4.85	0.3	2.29e-6	Schizophrenia;
SARC	cis	rs9325144	0.647	rs34963631	chr12:38912260	T/A	cg26384229	chr12:38710491	ALG10B	-0.54	-7.07	-0.42	1.81e-11	Morning vs. evening chronotype;
SARC	cis	rs9790314	0.663	rs1599379	chr3:160860665	A/G	cg03342759	chr3:160939853	NMD3	-0.57	-7.28	-0.43	4.99e-12	Morning vs. evening chronotype;
SARC	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg09263875	chr16:632152	PIGQ	0.55	8.52	0.49	2.02e-15	Height;
SARC	cis	rs644799	1.000	rs627568	chr11:95569253	A/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.89	13.84	0.67	3.48e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs950169	0.922	rs11630507	chr15:85095725	A/G	cg17507749	chr15:85114479	UBE2QP1	0.77	9.43	0.53	4.27e-18	Schizophrenia;
SARC	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.45	5.07	0.32	8.2e-7	Renal function-related traits (BUN);
SARC	cis	rs989128	0.600	rs73338243	chr17:48631324	T/C	cg20467136	chr17:48638190	CACNA1G	0.46	5.36	0.33	2e-7	Type 2 diabetes;
SARC	cis	rs10979	1.000	rs9386033	chr6:143888520	T/C	cg25407410	chr6:143891975	LOC285740	-0.64	-8.66	-0.49	8.14e-16	Hypospadias;
SARC	cis	rs9436747	0.626	rs7516763	chr1:65972550	C/A	cg14976592	chr1:65886160	LEPROT;LEPR	-0.42	-5.37	-0.33	1.93e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs9747201	0.889	rs4789784	chr17:80179213	G/A	cg09264619	chr17:80180166	NA	-0.54	-6.15	-0.37	3.36e-9	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs9612	1.000	rs346544	chr19:44256205	A/G	cg08581076	chr19:44259116	C19orf61	0.63	7.85	0.46	1.47e-13	Exhaled nitric oxide output;
SARC	cis	rs6500602	0.627	rs860891	chr16:4586529	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.34	-5.62	-0.35	5.36e-8	Schizophrenia;
SARC	cis	rs7566780	0.656	rs2163217	chr2:16673773	C/T	cg09580478	chr2:16689509	NA	-0.42	-5.8	-0.36	2.12e-8	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs12142240	0.698	rs41534051	chr1:46828734	A/G	cg14993813	chr1:46806288	NSUN4	-0.51	-5.36	-0.33	2.03e-7	Menopause (age at onset);
SARC	cis	rs9790314	0.690	rs7614375	chr3:160851331	A/T	cg03342759	chr3:160939853	NMD3	-0.52	-6.56	-0.39	3.44e-10	Morning vs. evening chronotype;
SARC	cis	rs9788682	0.706	rs924840	chr15:78731808	A/T	cg06917634	chr15:78832804	PSMA4	-0.5	-5.25	-0.33	3.35e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs1448094	0.512	rs11117061	chr12:86250916	G/A	cg00310523	chr12:86230176	RASSF9	0.31	4.88	0.3	1.95e-6	Major depressive disorder;
SARC	cis	rs35828350	1	rs35828350	chr15:85355841	G/A	cg17507749	chr15:85114479	UBE2QP1	0.57	6.52	0.39	4.29e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg11987759	chr7:65425863	GUSB	-0.58	-7.66	-0.45	4.85e-13	Calcium levels;
SARC	cis	rs2120019	0.938	rs2120020	chr15:75316845	T/C	cg09165964	chr15:75287851	SCAMP5	-0.95	-14.3	-0.68	1.02e-33	Blood trace element (Zn levels);
SARC	cis	rs8014204	0.720	rs34752362	chr14:75232306	G/A	cg06637938	chr14:75390232	RPS6KL1	0.75	10.95	0.58	9.03e-23	Caffeine consumption;
SARC	cis	rs12579753	0.913	rs7965664	chr12:82237340	G/T	cg07988820	chr12:82153109	PPFIA2	-0.52	-6.07	-0.37	5.24e-9	Resting heart rate;
SARC	cis	rs9790314	0.687	rs1037888	chr3:160775251	A/T	cg04691961	chr3:161091175	C3orf57	-0.6	-8.14	-0.47	2.31e-14	Morning vs. evening chronotype;
SARC	cis	rs644799	0.931	rs496305	chr11:95567035	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	14.86	0.7	1.4e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs17345786	0.906	rs72946021	chr3:101250008	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.46	-4.93	-0.31	1.58e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7523050	0.643	rs71655970	chr1:109403895	A/G	cg08274380	chr1:109419600	GPSM2	1.0	7.6	0.45	7.21e-13	Fat distribution (HIV);
SARC	cis	rs11225247	0.772	rs11225222	chr11:102230129	T/A	cg11690896	chr11:102217788	BIRC2	0.72	5.19	0.32	4.65e-7	Vein graft stenosis in coronary artery bypass grafting;
SARC	cis	rs7552404	0.883	rs2185436	chr1:76203783	A/G	cg22875332	chr1:76189707	ACADM	0.46	6.65	0.4	2.09e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-6.66	-0.4	1.93e-10	Personality dimensions;
SARC	cis	rs1048238	0.506	rs7525608	chr1:16141901	A/G	cg21385522	chr1:16154831	NA	0.46	5.76	0.35	2.65e-8	Systolic blood pressure;
SARC	cis	rs9303401	0.659	rs3809724	chr17:57061238	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	10.89	0.58	1.36e-22	Cognitive test performance;
SARC	cis	rs6752107	1.000	rs12994971	chr2:234178453	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.44	5.88	0.36	1.43e-8	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs6582630	0.576	rs3900594	chr12:38272429	C/T	cg13010199	chr12:38710504	ALG10B	-0.53	-6.43	-0.39	6.97e-10	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs12142240	0.698	rs57267378	chr1:46816644	A/G	cg10495392	chr1:46806563	NSUN4	0.65	6.83	0.41	7.25e-11	Menopause (age at onset);
SARC	cis	rs7412746	0.621	rs72704656	chr1:150828307	A/G	cg15448220	chr1:150897856	SETDB1	0.51	6.59	0.4	2.83e-10	Melanoma;
SARC	cis	rs12142240	0.698	rs68112720	chr1:46813888	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-5.46	-0.34	1.22e-7	Menopause (age at onset);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg27617225	chr8:145625612	CPSF1;MIR1234	-0.37	-6.28	-0.38	1.64e-9	Chemerin levels;
SARC	cis	rs9611565	0.921	rs5751081	chr22:41742788	A/T	cg03806693	chr22:41940476	POLR3H	-0.69	-9.52	-0.53	2.32e-18	Vitiligo;
SARC	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg22920501	chr2:26401640	FAM59B	-0.55	-7.06	-0.42	1.92e-11	Gut microbiome composition (summer);
SARC	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg14773178	chr5:1868261	NA	0.35	5.45	0.34	1.26e-7	Cardiovascular disease risk factors;
SARC	cis	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg22496380	chr5:211416	CCDC127	-0.82	-8.3	-0.48	8.53e-15	Breast cancer;
SARC	cis	rs9527	0.544	rs1572578	chr10:104822431	C/G	cg04362960	chr10:104952993	NT5C2	0.43	5.0	0.31	1.11e-6	Arsenic metabolism;
SARC	cis	rs11608355	1.000	rs930356	chr12:109852372	T/C	cg05360138	chr12:110035743	NA	0.43	4.78	0.3	3.04e-6	Neuroticism;
SARC	cis	rs13191362	1.000	rs34192365	chr6:163012382	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.55	5.25	0.33	3.46e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs765787	0.530	rs2458224	chr15:45522130	T/C	cg25801113	chr15:45476975	SHF	0.31	5.12	0.32	6.38e-7	Uric acid levels;
SARC	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg10351095	chr21:47802916	PCNT	0.46	5.37	0.33	1.95e-7	Testicular germ cell tumor;
SARC	cis	rs12142240	0.698	rs13374893	chr1:46843800	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-5.56	-0.34	7.46e-8	Menopause (age at onset);
SARC	cis	rs11690935	0.959	rs75922913	chr2:172620152	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.99	-14.79	-0.7	2.39e-35	Schizophrenia;
SARC	cis	rs1448094	0.512	rs7313278	chr12:86250263	C/T	cg02569458	chr12:86230093	RASSF9	0.37	5.15	0.32	5.54e-7	Major depressive disorder;
SARC	cis	rs3105593	0.605	rs3131562	chr15:50772479	C/T	cg05456662	chr15:50716270	USP8	0.42	5.11	0.32	6.66e-7	QT interval;
SARC	cis	rs6060717	0.536	rs6060669	chr20:34480557	G/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.29	0.33	2.86e-7	Hip circumference adjusted for BMI;
SARC	cis	rs1153858	1.000	rs2056493	chr15:45648272	A/G	cg26924012	chr15:45694286	SPATA5L1	0.76	10.72	0.57	4.81e-22	Homoarginine levels;
SARC	cis	rs2836974	0.583	rs2776306	chr21:40713754	A/G	cg11890956	chr21:40555474	PSMG1	0.72	9.7	0.54	6.75e-19	Cognitive function;
SARC	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.65	-6.91	-0.41	4.63e-11	Platelet count;
SARC	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg04518342	chr5:131593106	PDLIM4	-0.45	-5.68	-0.35	3.9e-8	Breast cancer;
SARC	trans	rs877282	0.583	rs11253425	chr10:815173	G/A	cg22713356	chr15:30763199	NA	0.92	8.71	0.5	5.58e-16	Uric acid levels;
SARC	cis	rs12477438	0.520	rs11695751	chr2:99708247	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	13.66	0.67	1.38e-31	Chronic sinus infection;
SARC	cis	rs13401104	0.796	rs7584847	chr2:237119457	T/C	cg19324714	chr2:237145437	ASB18	0.57	5.93	0.36	1.1e-8	Educational attainment;
SARC	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg11764359	chr7:65958608	NA	0.86	12.33	0.63	3.29e-27	Aortic root size;
SARC	cis	rs6500602	0.702	rs11076835	chr16:4549618	G/A	cg08645402	chr16:4508243	NA	0.42	5.68	0.35	3.95e-8	Schizophrenia;
SARC	cis	rs6580649	0.941	rs17122613	chr12:48460016	T/C	cg05342945	chr12:48394962	COL2A1	0.56	6.03	0.37	6.35e-9	Lung cancer;
SARC	cis	rs2732480	0.577	rs2634693	chr12:48706498	C/T	cg24011408	chr12:48396354	COL2A1	0.43	4.97	0.31	1.29e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	trans	rs9325144	0.671	rs7485963	chr12:38768254	C/G	cg23762105	chr12:34175262	ALG10	0.49	6.35	0.38	1.1e-9	Morning vs. evening chronotype;
SARC	cis	rs981844	0.740	rs10024619	chr4:154684441	A/T	cg14289246	chr4:154710475	SFRP2	-0.61	-7.18	-0.43	9.54e-12	Response to statins (LDL cholesterol change);
SARC	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg20916646	chr4:852691	GAK	0.55	6.96	0.42	3.33e-11	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
SARC	cis	rs9381040	0.655	rs879491	chr6:41026953	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.44	-5.06	-0.31	8.67e-7	Alzheimer's disease (late onset);
SARC	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg12042659	chr19:58951599	ZNF132	0.4	5.13	0.32	6.03e-7	Uric acid clearance;
SARC	cis	rs2251381	0.778	rs722013	chr21:30549245	G/T	cg08807101	chr21:30365312	RNF160	0.73	10.03	0.55	6.49e-20	Selective IgA deficiency;
SARC	trans	rs9329221	0.905	rs6601451	chr8:10243681	C/G	cg06636001	chr8:8085503	FLJ10661	-0.68	-9.25	-0.52	1.46e-17	Neuroticism;
SARC	cis	rs34172651	0.876	rs2112785	chr16:24781176	C/T	cg04756594	chr16:24857601	SLC5A11	0.35	5.8	0.36	2.13e-8	Intelligence (multi-trait analysis);
SARC	cis	rs769267	0.631	rs7252981	chr19:19692579	T/C	cg03709012	chr19:19516395	GATAD2A	-0.75	-10.06	-0.55	5.28e-20	Tonsillectomy;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg26218466	chr11:1968643	MRPL23	0.53	7.03	0.42	2.23e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs57506017	0.585	rs28549831	chr7:12268117	C/T	cg23422036	chr7:12250390	TMEM106B	0.45	5.87	0.36	1.46e-8	Neuroticism;
SARC	cis	rs897080	0.793	rs55951536	chr2:44770733	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.43	4.79	0.3	2.94e-6	Height;
SARC	cis	rs478304	0.651	rs948493	chr11:65552154	C/T	cg26695010	chr11:65641043	EFEMP2	0.4	4.81	0.3	2.75e-6	Acne (severe);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg00812502	chr22:19109875	DGCR2	0.49	6.72	0.4	1.36e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs35213789	0.887	rs917616	chr7:69149969	G/A	cg10619644	chr7:69149951	AUTS2	-0.44	-5.89	-0.36	1.35e-8	Childhood ear infection;
SARC	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.57	-7.36	-0.43	3.12e-12	Mean platelet volume;
SARC	cis	rs3092073	0.617	rs3893276	chr20:44591089	G/C	cg00981651	chr20:44574847	PCIF1	-0.33	-5.23	-0.32	3.84e-7	Intelligence (multi-trait analysis);
SARC	cis	rs921968	0.565	rs3770220	chr2:219619550	C/T	cg02176678	chr2:219576539	TTLL4	-0.32	-4.88	-0.3	1.93e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs910316	0.789	rs175444	chr14:75601782	G/C	cg08847533	chr14:75593920	NEK9	-0.78	-11.39	-0.6	3.38e-24	Height;
SARC	cis	rs11651000	0.947	rs59216876	chr17:45832965	G/A	cg03474202	chr17:45855739	NA	-0.42	-5.12	-0.32	6.27e-7	IgG glycosylation;
SARC	cis	rs3126085	0.935	rs3126048	chr1:152260165	T/C	cg03465714	chr1:152285911	FLG	0.46	5.47	0.34	1.16e-7	Atopic dermatitis;
SARC	trans	rs9987353	0.518	rs4841110	chr8:9086023	C/T	cg06636001	chr8:8085503	FLJ10661	0.64	8.59	0.49	1.29e-15	Recombination measurement;
SARC	cis	rs1448094	0.842	rs12809288	chr12:86455427	C/T	cg02569458	chr12:86230093	RASSF9	-0.39	-5.71	-0.35	3.39e-8	Major depressive disorder;
SARC	cis	rs7953249	0.618	rs7954331	chr12:121398657	G/T	cg15155738	chr12:121454335	C12orf43	-0.45	-5.48	-0.34	1.13e-7	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg11366901	chr6:160182831	ACAT2	1.04	10.57	0.57	1.38e-21	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs7246657	0.943	rs4802766	chr19:37981933	T/C	cg23950597	chr19:37808831	NA	-0.58	-5.45	-0.34	1.28e-7	Coronary artery calcification;
SARC	cis	rs356220	0.632	rs2736991	chr4:90671670	A/T	cg06632027	chr4:90757378	SNCA	0.41	5.15	0.32	5.51e-7	Parkinson's disease;
SARC	cis	rs16858210	0.520	rs34190894	chr3:183550412	A/T	cg03417191	chr3:183542750	MAP6D1	-0.5	-4.8	-0.3	2.82e-6	Menopause (age at onset);
SARC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg09033563	chr22:24373618	LOC391322	0.61	8.02	0.47	5.07e-14	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs34779708	0.658	rs4934715	chr10:35364992	G/T	cg03585969	chr10:35415529	CREM	0.39	5.01	0.31	1.08e-6	Inflammatory bowel disease;Crohn's disease;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg06347499	chr1:9599419	SLC25A33	0.51	7.2	0.43	8.12e-12	Thyroid stimulating hormone;
SARC	cis	rs1865760	0.663	rs9379815	chr6:25980116	T/A	cg10373733	chr6:25993375	NA	0.47	6.0	0.37	7.44e-9	Height;
SARC	cis	rs2439831	0.717	rs2470132	chr15:43835481	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.78	7.78	0.45	2.3e-13	Lung cancer in ever smokers;
SARC	trans	rs2553026	0.879	rs10164712	chr2:218152840	C/T	cg19988958	chr2:208576137	CCNYL1	0.59	7.32	0.43	4.08e-12	Height;
SARC	cis	rs72653721	0.689	rs17697089	chr6:11065856	C/T	cg13562911	chr6:11044106	ELOVL2	0.54	6.11	0.37	4.15e-9	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg09455208	chr3:40491958	NA	-0.35	-5.41	-0.33	1.55e-7	Renal cell carcinoma;
SARC	cis	rs2421770	0.504	rs7943314	chr11:35363823	A/G	cg13971030	chr11:35366721	SLC1A2	-0.34	-5.25	-0.33	3.39e-7	Staphylococcus aureus nasal carriage (persistent);
SARC	cis	rs16976116	0.951	rs13733	chr15:55489104	A/G	cg17854078	chr15:55489399	RSL24D1	0.61	6.04	0.37	6.16e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs3110496	0.751	rs3115096	chr17:27907486	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.46	4.79	0.3	3.02e-6	Height;
SARC	cis	rs7178572	0.568	rs4886862	chr15:77652368	T/C	cg22256960	chr15:77711686	NA	-0.49	-5.36	-0.33	2.05e-7	Type 2 diabetes;
SARC	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.59	4.95	0.31	1.43e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs9916302	0.706	rs4794808	chr17:37531916	C/T	cg07936489	chr17:37558343	FBXL20	0.77	9.26	0.52	1.38e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.67	-0.4	1.82e-10	Joint mobility (Beighton score);
SARC	cis	rs4742903	0.935	rs10991182	chr9:106983578	T/C	cg14250997	chr9:106856677	SMC2	0.39	4.93	0.31	1.54e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs7949030	0.688	rs2849031	chr11:62365665	G/A	cg11742103	chr11:62369870	EML3;MTA2	-0.42	-6.5	-0.39	4.89e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs9914988	0.613	rs2277664	chr17:27286662	C/G	cg10538030	chr17:27276405	PHF12	0.58	4.97	0.31	1.28e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10716835	chr10:94834582	CYP26A1	-0.45	-6.28	-0.38	1.66e-9	Fibrinogen levels;
SARC	cis	rs6969780	1.000	rs6461985	chr7:27150634	T/C	cg26364809	chr7:27145159	NA	-0.58	-4.82	-0.3	2.58e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
SARC	cis	rs7312933	0.558	rs11181507	chr12:42844763	T/A	cg19980929	chr12:42632907	YAF2	0.46	6.55	0.39	3.69e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs807669	0.903	rs2800974	chr22:19168087	C/T	cg02655711	chr22:19163373	SLC25A1	0.56	7.86	0.46	1.4e-13	Metabolite levels;
SARC	cis	rs644799	0.930	rs2186782	chr11:95649543	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.87	12.99	0.65	2.24e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9303401	0.527	rs12946522	chr17:56768103	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.09	11.65	0.61	4.96e-25	Cognitive test performance;
SARC	cis	rs7914558	0.966	rs10883817	chr10:104755431	C/T	cg04362960	chr10:104952993	NT5C2	0.43	5.22	0.32	4.05e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg15383120	chr6:291909	DUSP22	-0.6	-7.88	-0.46	1.26e-13	Menopause (age at onset);
SARC	cis	rs11676348	0.808	rs61700947	chr2:219046171	C/G	cg00012203	chr2:219082015	ARPC2	0.44	5.63	0.35	5.08e-8	Ulcerative colitis;
SARC	cis	rs7474896	0.583	rs10827818	chr10:38000856	T/C	cg00409905	chr10:38381863	ZNF37A	-0.44	-4.82	-0.3	2.59e-6	Obesity (extreme);
SARC	cis	rs6121246	0.529	rs6060145	chr20:30178631	T/C	cg13852791	chr20:30311386	BCL2L1	0.63	4.89	0.31	1.84e-6	Mean corpuscular hemoglobin;
SARC	trans	rs78266804	0.640	rs13157524	chr5:8770573	C/T	cg11584246	chr13:113676726	MCF2L	-0.46	-6.57	-0.4	3.16e-10	Pediatric bone mineral content (femoral neck);
SARC	cis	rs9372253	1.000	rs9374170	chr6:110712991	A/G	cg19196401	chr6:110721138	DDO	-0.37	-4.76	-0.3	3.34e-6	Platelet distribution width;
SARC	cis	rs17376456	0.877	rs28637444	chr5:93495548	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.02	0.31	1.01e-6	Diabetic retinopathy;
SARC	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg10523679	chr1:76189770	ACADM	0.51	6.81	0.41	8.08e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs57920188	0.513	rs4290031	chr1:4094701	A/G	cg20703997	chr1:4087676	NA	0.52	5.49	0.34	1.05e-7	Interleukin-17 levels;
SARC	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg20607798	chr8:58055168	NA	0.71	6.18	0.38	2.87e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg16083429	chr3:49237500	CCDC36	-0.38	-5.17	-0.32	5.09e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs1580019	0.522	rs10951340	chr7:32562408	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.55	7.07	0.42	1.79e-11	Cognitive ability;
SARC	cis	rs713477	0.967	rs61976571	chr14:55908774	T/C	cg13175173	chr14:55914753	NA	-0.3	-4.75	-0.3	3.63e-6	Pediatric bone mineral content (femoral neck);
SARC	cis	rs870825	0.860	rs2705899	chr4:185596219	A/G	cg04058563	chr4:185651563	MLF1IP	0.73	9.08	0.51	4.82e-17	Blood protein levels;
SARC	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg06108461	chr20:60628389	TAF4	-0.98	-13.24	-0.66	3.34e-30	Body mass index;
SARC	cis	rs41271473	0.526	rs56043220	chr1:228783474	G/C	cg10167378	chr1:228756711	NA	0.63	5.56	0.34	7.46e-8	Chronic lymphocytic leukemia;
SARC	cis	rs6867032	1.000	rs6867032	chr5:2015103	G/T	cg26168224	chr5:2018326	NA	-0.92	-15.28	-0.71	5.45e-37	Gut microbiome composition (winter);
SARC	cis	rs6860806	0.507	rs270608	chr5:131648406	C/T	cg11843238	chr5:131593191	PDLIM4	0.41	4.97	0.31	1.27e-6	Breast cancer;
SARC	cis	rs2153535	0.601	rs4960414	chr6:8438541	A/G	cg21535247	chr6:8435926	SLC35B3	0.56	7.01	0.42	2.6e-11	Motion sickness;
SARC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.97	10.66	0.57	7.33e-22	Platelet count;
SARC	cis	rs6484504	0.532	rs1929019	chr11:31267030	C/T	cg26647111	chr11:31128758	NA	-0.39	-5.09	-0.32	7.34e-7	Red blood cell count;
SARC	cis	rs1559088	0.948	rs12608825	chr19:33581219	C/T	cg17764715	chr19:33622953	WDR88	-0.46	-5.86	-0.36	1.54e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs644799	0.710	rs473852	chr11:95568757	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.83	13.24	0.66	3.35e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs282587	0.569	rs192530	chr13:113388303	A/G	cg02820901	chr13:113351484	ATP11A	-0.52	-4.92	-0.31	1.63e-6	Glycated hemoglobin levels;
SARC	cis	rs72945132	0.882	rs6592537	chr11:70172975	C/T	cg00319359	chr11:70116639	PPFIA1	0.68	6.18	0.38	2.78e-9	Coronary artery disease;
SARC	cis	rs910316	0.967	rs2268619	chr14:75640354	C/G	cg08847533	chr14:75593920	NEK9	-0.87	-12.36	-0.63	2.52e-27	Height;
SARC	cis	rs939574	0.818	rs6744146	chr2:220070597	T/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.53	-4.87	-0.3	2.03e-6	Platelet distribution width;
SARC	cis	rs1882538	0.564	rs10488164	chr7:133106199	A/G	cg10665199	chr7:133106180	EXOC4	0.4	5.35	0.33	2.14e-7	Intelligence (multi-trait analysis);
SARC	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.46	5.87	0.36	1.53e-8	Gut microbiome composition (summer);
SARC	cis	rs1023500	0.505	rs134886	chr22:42673856	C/T	cg15557168	chr22:42548783	NA	0.38	5.39	0.33	1.75e-7	Schizophrenia;
SARC	cis	rs7412746	0.611	rs4970985	chr1:150887442	C/T	cg13175981	chr1:150552382	MCL1	0.5	6.17	0.37	3.06e-9	Melanoma;
SARC	cis	rs765787	0.530	rs55920042	chr15:45541577	G/A	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.81e-6	Uric acid levels;
SARC	cis	rs74781061	0.585	rs7161990	chr15:74735664	C/T	cg09165964	chr15:75287851	SCAMP5	-0.62	-4.93	-0.31	1.55e-6	Endometriosis;
SARC	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg11644478	chr21:40555479	PSMG1	-0.56	-6.81	-0.41	8.37e-11	Menarche (age at onset);
SARC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg14159672	chr1:205819179	PM20D1	0.98	17.9	0.76	1.13e-45	Menarche (age at onset);
SARC	cis	rs7662987	0.517	rs2034696	chr4:100024322	C/G	cg13256891	chr4:100009986	ADH5	0.66	8.13	0.47	2.55e-14	Smoking initiation;
SARC	cis	rs7296418	0.663	rs11057284	chr12:123830692	G/C	cg05973401	chr12:123451056	ABCB9	0.48	5.61	0.35	5.69e-8	Platelet count;
SARC	cis	rs6964587	0.900	rs62467794	chr7:91850578	C/T	cg17063962	chr7:91808500	NA	0.92	13.7	0.67	9.55e-32	Breast cancer;
SARC	cis	rs9457247	1.000	rs444988	chr6:167389674	A/T	cg23791538	chr6:167370224	RNASET2	-0.61	-8.47	-0.49	2.72e-15	Crohn's disease;
SARC	cis	rs67311347	1.000	rs9874006	chr3:40471596	G/A	cg24209194	chr3:40518798	ZNF619	0.61	7.88	0.46	1.24e-13	Renal cell carcinoma;
SARC	cis	rs10791097	1.000	rs10791097	chr11:130718630	G/T	cg12179176	chr11:130786555	SNX19	-0.63	-8.6	-0.49	1.18e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg22920501	chr2:26401640	FAM59B	-0.6	-8.1	-0.47	3.11e-14	Gut microbiome composition (summer);
SARC	cis	rs6121246	0.559	rs6121172	chr20:30296095	A/C	cg13852791	chr20:30311386	BCL2L1	0.88	10.86	0.58	1.7e-22	Mean corpuscular hemoglobin;
SARC	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg00339695	chr16:24857497	SLC5A11	-0.42	-6.14	-0.37	3.59e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs9814567	0.928	rs6768323	chr3:134268737	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	7.08	0.42	1.73e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs1669338	0.588	rs55959448	chr3:3204000	C/T	cg16797762	chr3:3221439	CRBN	-0.94	-9.64	-0.53	1.04e-18	White matter integrity;
SARC	cis	rs737337	0.623	rs4804155	chr19:11334295	C/G	cg00586551	chr19:11347513	LOC55908;DOCK6	0.61	6.85	0.41	6.35e-11	HDL cholesterol;HDL cholesterol levels;
SARC	cis	rs9905704	0.846	rs304268	chr17:56799907	T/C	cg12560992	chr17:57184187	TRIM37	0.43	4.93	0.31	1.58e-6	Testicular germ cell tumor;
SARC	cis	rs35110281	0.720	rs162392	chr21:44941406	A/G	cg21573476	chr21:45109991	RRP1B	-0.5	-7.39	-0.44	2.66e-12	Mean corpuscular volume;
SARC	cis	rs2270221	0.673	rs73092480	chr7:31921337	C/G	cg02147443	chr7:31232861	NA	-0.47	-4.78	-0.3	3.07e-6	Endometriosis;
SARC	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6570726	0.764	rs9322028	chr6:145895797	G/T	cg05347473	chr6:146136440	FBXO30	0.51	7.17	0.43	9.59e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg18404041	chr3:52824283	ITIH1	-0.38	-5.72	-0.35	3.23e-8	Electroencephalogram traits;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg09688763	chr10:114206798	VTI1A;ZDHHC6	-0.5	-6.87	-0.41	5.74e-11	Neuroticism;
SARC	cis	rs10911363	0.549	rs12742245	chr1:183446922	T/A	cg09173681	chr1:183549694	NCF2	0.32	5.05	0.31	8.86e-7	Systemic lupus erythematosus;
SARC	cis	rs11122272	0.735	rs2808596	chr1:231530723	A/G	cg06096015	chr1:231504339	EGLN1	0.38	5.63	0.35	5.12e-8	Hemoglobin concentration;
SARC	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.66	0.35	4.44e-8	Bipolar disorder;
SARC	cis	rs17539620	0.624	rs62432739	chr6:154835926	A/G	cg20019720	chr6:154832845	CNKSR3	0.41	4.84	0.3	2.39e-6	Lipoprotein (a) levels;
SARC	cis	rs2153535	0.580	rs6905242	chr6:8471799	A/C	cg07606381	chr6:8435919	SLC35B3	0.77	10.82	0.58	2.19e-22	Motion sickness;
SARC	cis	rs6426558	0.537	rs6699828	chr1:227274591	T/C	cg10327440	chr1:227177885	CDC42BPA	0.42	5.01	0.31	1.08e-6	Neutrophil percentage of white cells;
SARC	cis	rs734999	0.588	rs2843404	chr1:2530558	T/C	cg00980319	chr1:2560884	MMEL1	0.35	4.95	0.31	1.42e-6	Ulcerative colitis;
SARC	cis	rs9398803	0.965	rs6919397	chr6:126659043	A/C	cg20229609	chr6:126660872	C6orf173	0.38	5.5	0.34	1.02e-7	Male-pattern baldness;
SARC	cis	rs7666738	0.830	rs4323111	chr4:98952276	A/G	cg05340658	chr4:99064831	C4orf37	0.65	8.73	0.5	5.13e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs11122272	0.735	rs2808592	chr1:231523757	G/A	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs6732160	0.588	rs13407363	chr2:73372558	T/C	cg01422370	chr2:73384389	NA	0.37	5.76	0.35	2.67e-8	Intelligence (multi-trait analysis);
SARC	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	7.72	0.45	3.42e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg05623727	chr3:50126028	RBM5	-0.34	-5.27	-0.33	3.18e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9660992	0.710	rs7367930	chr1:205235512	A/G	cg21643547	chr1:205240462	TMCC2	-0.64	-8.25	-0.48	1.16e-14	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg13206674	chr6:150067644	NUP43	0.4	5.38	0.33	1.82e-7	Lung cancer;
SARC	cis	rs1395	0.922	rs13404446	chr2:27519254	C/T	cg21747090	chr2:27597821	SNX17	-0.45	-5.53	-0.34	8.54e-8	Blood metabolite levels;
SARC	cis	rs995000	0.965	rs1979722	chr1:62940097	G/A	cg06896770	chr1:63153194	DOCK7	0.99	15.29	0.71	5.12e-37	Triglyceride levels;
SARC	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.76	11.01	0.58	5.81e-23	Personality dimensions;
SARC	cis	rs34172651	0.917	rs11646987	chr16:24832408	G/T	cg06028605	chr16:24865363	SLC5A11	0.28	4.95	0.31	1.4e-6	Intelligence (multi-trait analysis);
SARC	cis	rs17376456	0.741	rs10036829	chr5:93309897	G/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.46	0.34	1.24e-7	Diabetic retinopathy;
SARC	cis	rs9309473	0.851	rs6546850	chr2:73831147	A/T	cg07208825	chr2:73871855	ALMS1P	0.35	5.14	0.32	5.87e-7	Metabolite levels;
SARC	cis	rs4925386	0.959	rs6121989	chr20:60916713	A/T	cg22633769	chr20:60982531	CABLES2	-0.47	-5.24	-0.32	3.6e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs910316	1.000	rs175442	chr14:75603564	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.52	-7.31	-0.43	4.16e-12	Height;
SARC	cis	rs11122272	0.735	rs2808602	chr1:231537303	A/G	cg06096015	chr1:231504339	EGLN1	0.38	5.7	0.35	3.54e-8	Hemoglobin concentration;
SARC	cis	rs765787	0.530	rs28815867	chr15:45526805	G/C	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.81e-6	Uric acid levels;
SARC	cis	rs16912285	0.688	rs12801480	chr11:24270146	G/A	ch.11.24196551F	chr11:24239977	NA	0.52	4.78	0.3	3.04e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg05368731	chr17:41323189	NBR1	0.8	9.84	0.54	2.52e-19	Menopause (age at onset);
SARC	cis	rs240764	0.658	rs7753317	chr6:101220433	G/A	cg09795085	chr6:101329169	ASCC3	-0.44	-5.64	-0.35	4.85e-8	Neuroticism;
SARC	cis	rs2153535	0.601	rs330105	chr6:8543981	A/C	cg23788917	chr6:8435910	SLC35B3	0.66	8.71	0.5	5.57e-16	Motion sickness;
SARC	cis	rs920590	0.643	rs6982084	chr8:19669333	G/A	cg17834443	chr8:19674713	INTS10	-0.5	-6.21	-0.38	2.35e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs11249608	0.548	rs13156530	chr5:178475017	C/T	cg21905437	chr5:178450457	ZNF879	0.52	6.42	0.39	7.45e-10	Pubertal anthropometrics;
SARC	trans	rs78382112	0.731	rs73057733	chr1:181582147	T/C	cg23731742	chr1:879958	NOC2L;SAMD11	0.7	6.5	0.39	4.88e-10	Intelligence (multi-trait analysis);
SARC	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg12667521	chr19:29218732	NA	0.4	5.48	0.34	1.08e-7	Methadone dose in opioid dependence;
SARC	cis	rs7089973	0.872	rs7072364	chr10:116620840	G/A	cg08188268	chr10:116634841	FAM160B1	0.37	5.89	0.36	1.33e-8	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs3733585	0.781	rs13103690	chr4:9972778	T/G	cg00071950	chr4:10020882	SLC2A9	-0.37	-5.87	-0.36	1.5e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs9398803	0.835	rs59698523	chr6:126733094	T/C	cg20229609	chr6:126660872	C6orf173	0.4	5.75	0.35	2.73e-8	Male-pattern baldness;
SARC	cis	rs921968	0.619	rs1554623	chr2:219606177	C/T	cg02176678	chr2:219576539	TTLL4	-0.33	-5.03	-0.31	9.93e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs3771570	0.901	rs56129392	chr2:242242439	C/T	cg21155796	chr2:242212141	HDLBP	0.63	5.48	0.34	1.09e-7	Prostate cancer;
SARC	cis	rs11122272	0.735	rs2491404	chr1:231512127	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs959260	0.588	rs9894003	chr17:73405860	T/G	cg14668889	chr17:73230827	NUP85	-0.52	-5.29	-0.33	2.85e-7	Systemic lupus erythematosus;
SARC	cis	rs897080	0.515	rs1145519	chr2:44708709	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	6.29	0.38	1.59e-9	Height;
SARC	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.74	-7.72	-0.45	3.33e-13	Platelet count;
SARC	trans	rs1994135	0.692	rs7297538	chr12:33693438	T/C	cg26384229	chr12:38710491	ALG10B	0.81	9.83	0.54	2.66e-19	Resting heart rate;
SARC	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	cis	rs3099143	1.000	rs2063542	chr15:77149498	A/G	cg21673338	chr15:77095150	SCAPER	-0.6	-5.02	-0.31	1.01e-6	Recalcitrant atopic dermatitis;
SARC	cis	rs2486288	0.656	rs7166580	chr15:45571209	C/G	cg21132104	chr15:45694354	SPATA5L1	-0.55	-6.91	-0.41	4.62e-11	Glomerular filtration rate;
SARC	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.85	9.21	0.52	1.99e-17	Alzheimer's disease;
SARC	trans	rs11098499	0.865	rs1112817	chr4:120297800	T/C	cg25214090	chr10:38739885	LOC399744	0.55	7.14	0.42	1.15e-11	Corneal astigmatism;
SARC	cis	rs1707322	0.752	rs6662164	chr1:46146230	T/A	cg06784218	chr1:46089804	CCDC17	0.34	5.95	0.36	9.73e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7216064	1.000	rs9912084	chr17:65868035	A/C	cg12091567	chr17:66097778	LOC651250	-0.7	-7.64	-0.45	5.5e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs11112613	0.762	rs17037308	chr12:105949847	T/G	cg03607813	chr12:105948248	NA	0.56	7.54	0.44	1.06e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs6456156	0.586	rs12213683	chr6:167460718	G/A	cg23791538	chr6:167370224	RNASET2	-0.52	-6.79	-0.41	9.49e-11	Primary biliary cholangitis;
SARC	cis	rs7635838	0.686	rs347589	chr3:11288419	A/G	cg00170343	chr3:11313890	ATG7	0.65	8.1	0.47	3.14e-14	HDL cholesterol;
SARC	trans	rs3942852	0.806	rs10769317	chr11:48150712	T/C	cg15704280	chr7:45808275	SEPT13	-0.57	-6.61	-0.4	2.55e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs7635838	0.619	rs347614	chr3:11276399	T/C	cg00170343	chr3:11313890	ATG7	0.61	7.73	0.45	3.17e-13	HDL cholesterol;
SARC	cis	rs7149337	0.836	rs12588488	chr14:51660217	C/A	cg23942311	chr14:51606299	NA	0.37	6.66	0.4	1.98e-10	Cancer;
SARC	cis	rs9677476	0.863	rs5018532	chr2:232077075	A/G	cg23338755	chr2:231921595	PSMD1	0.44	5.36	0.33	1.97e-7	Food antigen IgG levels;
SARC	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg21548813	chr6:291882	DUSP22	-0.5	-6.39	-0.39	9.1e-10	Menopause (age at onset);
SARC	trans	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.42	-0.39	7.72e-10	Neuroticism;
SARC	cis	rs1578862	0.934	rs61838684	chr1:247473889	C/T	cg22704608	chr1:247479546	ZNF496	-0.33	-4.72	-0.3	4.08e-6	Monocyte percentage of white cells;
SARC	trans	rs561341	1.000	rs564714	chr17:30318404	C/T	cg20587970	chr11:113659929	NA	-1.36	-14.02	-0.68	8.31e-33	Hip circumference adjusted for BMI;
SARC	cis	rs73086581	1.000	rs73086535	chr20:3944150	T/C	cg02187196	chr20:3869020	PANK2	0.67	6.43	0.39	7.22e-10	Response to antidepressants in depression;
SARC	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg18252515	chr7:66147081	NA	-0.51	-5.77	-0.35	2.54e-8	Aortic root size;
SARC	cis	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg06636001	chr8:8085503	FLJ10661	0.65	8.7	0.5	5.95e-16	Mood instability;
SARC	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg11890956	chr21:40555474	PSMG1	-1.06	-15.63	-0.72	3.88e-38	Cognitive function;
SARC	cis	rs748404	0.560	rs689797	chr15:43826557	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.45	4.84	0.3	2.38e-6	Lung cancer;
SARC	cis	rs372883	0.901	rs407463	chr21:30722440	G/A	cg24692254	chr21:30365293	RNF160	-0.4	-5.02	-0.31	1.02e-6	Pancreatic cancer;
SARC	cis	rs7818688	0.697	rs58314911	chr8:95985111	G/A	cg13393036	chr8:95962371	TP53INP1	0.4	4.85	0.3	2.23e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs1568889	0.877	rs17310076	chr11:28147590	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.72	8.32	0.48	7.22e-15	Bipolar disorder;
SARC	cis	rs473651	0.935	rs508483	chr2:239339709	T/C	cg18131467	chr2:239335373	ASB1	0.93	15.37	0.71	2.89e-37	Multiple system atrophy;
SARC	cis	rs7374004	0.655	rs13099365	chr3:38635787	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.51	5.9	0.36	1.29e-8	PR interval;
SARC	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg06108461	chr20:60628389	TAF4	-0.98	-13.47	-0.66	5.65e-31	Body mass index;
SARC	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg22535103	chr8:58192502	C8orf71	-0.7	-8.15	-0.47	2.21e-14	Developmental language disorder (linguistic errors);
SARC	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg15352829	chr14:105391018	PLD4	-0.33	-6.33	-0.38	1.24e-9	Rheumatoid arthritis;
SARC	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg06634786	chr22:41940651	POLR3H	0.58	7.04	0.42	2.08e-11	Vitiligo;
SARC	cis	rs2279817	1.000	rs1339800	chr1:18020201	C/G	cg21791023	chr1:18019539	ARHGEF10L	-0.47	-4.97	-0.31	1.29e-6	Neuroticism;
SARC	cis	rs1801251	1.000	rs895430	chr2:233725483	C/A	cg25237894	chr2:233734115	C2orf82	-0.38	-5.04	-0.31	9.23e-7	Coronary artery disease;
SARC	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg09359103	chr1:154839909	KCNN3	-0.46	-7.7	-0.45	3.87e-13	Prostate cancer;
SARC	cis	rs1920116	0.778	rs16854453	chr3:169559234	G/A	cg14222479	chr3:169487675	ARPM1	0.44	5.08	0.32	7.8e-7	Glioma (high-grade);
SARC	cis	rs55823223	0.646	rs55868394	chr17:73851113	C/A	cg06969265	chr17:73775802	H3F3B	1.03	9.51	0.53	2.54e-18	Psoriasis;
SARC	cis	rs12950390	0.853	rs11079791	chr17:45859099	C/T	cg24803719	chr17:45855879	NA	-0.46	-7.44	-0.44	1.97e-12	IgG glycosylation;
SARC	cis	rs4689388	0.926	rs4688987	chr4:6287329	C/T	cg00701064	chr4:6280414	WFS1	0.56	9.08	0.51	4.84e-17	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs7223966	1.000	rs7209758	chr17:61913621	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-5.18	-0.32	4.81e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg23758822	chr17:41437982	NA	0.89	11.4	0.6	3.2e-24	Menopause (age at onset);
SARC	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg16405210	chr4:1374714	KIAA1530	-0.48	-5.57	-0.34	6.83e-8	Obesity-related traits;
SARC	cis	rs911555	0.504	rs8006526	chr14:104075015	T/C	cg26031613	chr14:104095156	KLC1	0.61	7.99	0.46	6.39e-14	Intelligence (multi-trait analysis);
SARC	cis	rs6963495	0.745	rs73192151	chr7:105211876	A/G	cg19920283	chr7:105172520	RINT1	0.68	5.77	0.35	2.46e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs35110281	0.774	rs2838323	chr21:44999086	G/A	cg01579765	chr21:45077557	HSF2BP	-0.31	-5.23	-0.32	3.68e-7	Mean corpuscular volume;
SARC	cis	rs1401999	0.510	rs3749438	chr3:183705184	G/A	cg01324343	chr3:183735012	ABCC5	0.47	8.17	0.47	1.96e-14	Anterior chamber depth;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg11239695	chr6:26458489	BTN2A1	0.79	6.48	0.39	5.46e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9462027	1.000	rs9689160	chr6:34749849	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.4	-5.41	-0.33	1.58e-7	Systemic lupus erythematosus;
SARC	cis	rs8114671	0.562	rs6120758	chr20:33492523	C/T	cg24642439	chr20:33292090	TP53INP2	0.5	6.14	0.37	3.45e-9	Height;
SARC	cis	rs3768617	0.754	rs6673768	chr1:182983396	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.64	8.8	0.5	3.12e-16	Fuchs's corneal dystrophy;
SARC	cis	rs7551222	0.752	rs11240755	chr1:204478649	C/T	cg20240347	chr1:204465584	NA	-0.35	-6.18	-0.38	2.78e-9	Schizophrenia;
SARC	cis	rs2230307	0.505	rs571579	chr1:100617372	G/A	cg24955406	chr1:100503596	HIAT1	-0.67	-6.63	-0.4	2.34e-10	Carotid intima media thickness;
SARC	cis	rs2562456	0.876	rs11085465	chr19:21751790	A/G	cg00806126	chr19:22604979	ZNF98	0.49	4.93	0.31	1.54e-6	Pain;
SARC	trans	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg21659725	chr3:3221576	CRBN	0.79	11.85	0.61	1.17e-25	Intelligence (multi-trait analysis);
SARC	cis	rs10752881	1.000	rs12133714	chr1:182988252	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.7	0.57	5.56e-22	Colorectal cancer;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg21786873	chr4:4250096	TMEM128	0.48	6.36	0.38	1.05e-9	Chemerin levels;
SARC	cis	rs2153535	0.580	rs6597318	chr6:8437289	G/A	cg07606381	chr6:8435919	SLC35B3	0.81	11.47	0.6	1.92e-24	Motion sickness;
SARC	cis	rs6964587	1.000	rs28584017	chr7:91719168	G/A	cg17063962	chr7:91808500	NA	0.96	16.21	0.73	4.62e-40	Breast cancer;
SARC	cis	rs2180341	1.000	rs4897207	chr6:127605898	C/T	cg17762328	chr6:126965162	NA	-0.46	-5.22	-0.32	3.95e-7	Breast cancer;
SARC	cis	rs9682041	0.800	rs7643085	chr3:170070371	A/G	cg11886554	chr3:170076028	SKIL	0.79	6.84	0.41	6.96e-11	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs4253772	0.637	rs41279831	chr22:46651623	T/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.63	4.94	0.31	1.47e-6	LDL cholesterol;Cholesterol, total;
SARC	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg18252515	chr7:66147081	NA	0.56	5.92	0.36	1.16e-8	Aortic root size;
SARC	trans	rs61931739	0.817	rs1705772	chr12:34174756	G/A	cg13010199	chr12:38710504	ALG10B	0.57	7.5	0.44	1.36e-12	Morning vs. evening chronotype;
SARC	cis	rs9796	0.870	rs8023345	chr15:41338348	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.42	-5.83	-0.36	1.85e-8	Menopause (age at onset);
SARC	cis	rs7412746	0.621	rs11204749	chr1:150929563	G/A	cg15448220	chr1:150897856	SETDB1	0.52	6.76	0.4	1.1e-10	Melanoma;
SARC	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg09323728	chr8:95962352	TP53INP1	-0.29	-4.91	-0.31	1.72e-6	Type 2 diabetes;
SARC	cis	rs1215050	0.791	rs783959	chr4:98893476	C/T	cg05340658	chr4:99064831	C4orf37	-0.46	-6.18	-0.38	2.81e-9	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs9916302	0.752	rs8071300	chr17:37508524	G/C	cg20243544	chr17:37824526	PNMT	-0.54	-5.81	-0.36	1.99e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs79149102	0.649	rs3803568	chr15:75108636	G/A	cg17294928	chr15:75287854	SCAMP5	-0.89	-4.74	-0.3	3.75e-6	Lung cancer;
SARC	cis	rs6570726	0.935	rs379164	chr6:145829093	A/T	cg05220968	chr6:146057943	EPM2A	-0.29	-4.99	-0.31	1.19e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg20607798	chr8:58055168	NA	0.65	5.13	0.32	6e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2242194	0.816	rs6671688	chr1:154994265	T/C	cg06221963	chr1:154839813	KCNN3	-0.4	-6.04	-0.37	5.93e-9	Schizophrenia;
SARC	cis	rs712039	0.652	rs853224	chr17:35791328	A/T	cg16670864	chr17:35848621	DUSP14	0.48	5.25	0.33	3.44e-7	Tuberculosis;
SARC	cis	rs7647973	0.593	rs58339610	chr3:49845006	T/A	cg03060546	chr3:49711283	APEH	-0.66	-6.95	-0.41	3.73e-11	Menarche (age at onset);
SARC	trans	rs61931739	0.500	rs11053235	chr12:34507899	G/A	cg13010199	chr12:38710504	ALG10B	0.82	11.58	0.6	8.37e-25	Morning vs. evening chronotype;
SARC	cis	rs3824867	0.676	rs7104366	chr11:47462115	G/A	cg20307385	chr11:47447363	PSMC3	0.48	5.21	0.32	4.25e-7	Mean corpuscular hemoglobin;
SARC	cis	rs7949030	0.653	rs2516634	chr11:62367186	G/A	cg13298116	chr11:62369859	EML3;MTA2	-0.47	-7.42	-0.44	2.21e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs1153858	1.000	rs8032904	chr15:45651309	C/T	cg21132104	chr15:45694354	SPATA5L1	0.77	10.97	0.58	7.49e-23	Homoarginine levels;
SARC	cis	rs959260	0.541	rs58935635	chr17:73357744	C/T	cg14668889	chr17:73230827	NUP85	0.53	5.16	0.32	5.27e-7	Systemic lupus erythematosus;
SARC	cis	rs912057	0.632	rs1294429	chr6:6744652	G/A	cg06612196	chr6:6737390	NA	0.63	9.53	0.53	2.1e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs9818758	0.607	rs67831908	chr3:49313513	T/G	cg00383909	chr3:49044727	WDR6	0.72	6.24	0.38	2.04e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs9341808	0.791	rs1324122	chr6:80946061	G/A	cg08355045	chr6:80787529	NA	0.34	5.5	0.34	9.89e-8	Sitting height ratio;
SARC	cis	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg24110177	chr3:50126178	RBM5	-0.68	-9.46	-0.53	3.55e-18	Body mass index;
SARC	cis	rs35213789	0.887	rs10237145	chr7:69230066	T/A	cg10619644	chr7:69149951	AUTS2	-0.42	-5.69	-0.35	3.8e-8	Childhood ear infection;
SARC	cis	rs6964587	0.967	rs4729015	chr7:91561592	T/G	cg17063962	chr7:91808500	NA	-0.93	-14.77	-0.7	2.86e-35	Breast cancer;
SARC	cis	rs7829975	0.846	rs1879957	chr8:8544808	T/C	cg08975724	chr8:8085496	FLJ10661	-0.43	-5.24	-0.32	3.64e-7	Mood instability;
SARC	cis	rs10752881	0.905	rs10797830	chr1:183036274	A/T	cg13390022	chr1:182993471	LAMC1	0.33	5.03	0.31	9.72e-7	Colorectal cancer;
SARC	cis	rs11630290	1.000	rs72750987	chr15:63999112	G/C	cg12036633	chr15:63758958	NA	-0.58	-5.56	-0.34	7.29e-8	Iris characteristics;
SARC	cis	rs172166	0.694	rs203892	chr6:28067196	T/C	cg26335602	chr6:28129616	ZNF389	0.47	5.43	0.34	1.42e-7	Cardiac Troponin-T levels;
SARC	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.06	-0.42	1.88e-11	Gut microbiome composition (summer);
SARC	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	23.05	0.83	5.02e-62	Chronic sinus infection;
SARC	cis	rs11209002	0.567	rs2224501	chr1:67532526	G/T	cg02640540	chr1:67518911	SLC35D1	0.59	6.66	0.4	1.99e-10	Crohn's disease;
SARC	trans	rs981844	0.712	rs11099915	chr4:154743624	A/G	cg25721732	chr2:74602550	DCTN1	-0.51	-6.32	-0.38	1.32e-9	Response to statins (LDL cholesterol change);
SARC	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.39	-4.76	-0.3	3.4e-6	Lymphocyte counts;
SARC	cis	rs3087591	1.000	rs7216033	chr17:29574642	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.49	-6.03	-0.37	6.36e-9	Hip circumference;
SARC	cis	rs4808199	0.895	rs12981405	chr19:19651577	C/T	cg03709012	chr19:19516395	GATAD2A	1.1	11.71	0.61	3.24e-25	Nonalcoholic fatty liver disease;
SARC	cis	rs61935443	0.832	rs12367920	chr12:95280752	T/A	cg21533806	chr12:95267307	NA	0.75	8.32	0.48	7.64e-15	Schizophrenia;
SARC	cis	rs35306767	0.903	rs12769431	chr10:922633	T/C	cg26597838	chr10:835615	NA	0.83	8.39	0.48	4.83e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs4803468	0.967	rs4803462	chr19:41908936	T/A	cg14132834	chr19:41945861	ATP5SL	-0.55	-7.18	-0.43	9.34e-12	Height;
SARC	cis	rs6693567	0.545	rs11205375	chr1:150412474	C/T	cg09579323	chr1:150459698	TARS2	0.44	5.58	0.34	6.5e-8	Migraine;
SARC	cis	rs6570726	0.837	rs636894	chr6:145864122	T/C	cg23711669	chr6:146136114	FBXO30	0.75	11.29	0.59	7.15e-24	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9486719	0.749	rs1009596	chr6:96843688	A/G	cg06623918	chr6:96969491	KIAA0776	0.75	7.39	0.44	2.65e-12	Migraine;Coronary artery disease;
SARC	cis	rs2153535	0.580	rs7742794	chr6:8459723	C/A	cg21535247	chr6:8435926	SLC35B3	0.52	6.55	0.39	3.66e-10	Motion sickness;
SARC	cis	rs12142240	0.698	rs6684274	chr1:46810842	A/G	cg14993813	chr1:46806288	NSUN4	0.54	5.93	0.36	1.1e-8	Menopause (age at onset);
SARC	cis	rs3820928	1.000	rs7579961	chr2:227776976	T/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-6.88	-0.41	5.56e-11	Pulmonary function;
SARC	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg05861140	chr6:150128134	PCMT1	-0.42	-5.44	-0.34	1.32e-7	Lung cancer;
SARC	cis	rs6733011	0.578	rs12712038	chr2:99497710	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.41	-5.28	-0.33	2.94e-7	Bipolar disorder;
SARC	cis	rs9916302	0.706	rs9908131	chr17:37520449	T/C	cg07936489	chr17:37558343	FBXL20	0.77	9.2	0.52	2.04e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs870825	0.860	rs56180712	chr4:185600223	A/G	cg04058563	chr4:185651563	MLF1IP	0.8	9.84	0.54	2.51e-19	Blood protein levels;
SARC	cis	rs9916302	0.718	rs7219909	chr17:37706243	C/T	cg00129232	chr17:37814104	STARD3	-0.63	-7.71	-0.45	3.69e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs1348850	0.632	rs1405718	chr2:178499809	C/T	cg22681709	chr2:178499509	PDE11A	-0.42	-5.6	-0.34	6.11e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs910316	0.763	rs4556	chr14:75476071	G/C	cg23033748	chr14:75592666	NEK9	0.39	5.24	0.32	3.64e-7	Height;
SARC	cis	rs9325144	0.555	rs2387843	chr12:38711203	T/C	cg10518543	chr12:38710700	ALG10B	0.39	5.04	0.31	9.36e-7	Morning vs. evening chronotype;
SARC	cis	rs3784262	0.669	rs34226780	chr15:58280168	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.33	-4.87	-0.3	2.05e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg20203395	chr5:56204925	C5orf35	0.55	4.91	0.31	1.72e-6	Initial pursuit acceleration;
SARC	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.32	-4.93	-0.31	1.56e-6	Total body bone mineral density;
SARC	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg08280861	chr8:58055591	NA	0.69	5.64	0.35	4.93e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs17376456	0.542	rs35672980	chr5:93284877	A/T	cg21475434	chr5:93447410	FAM172A	-0.61	-6.6	-0.4	2.82e-10	Diabetic retinopathy;
SARC	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg18225595	chr11:63971243	STIP1	0.46	5.6	0.34	6.17e-8	Mean platelet volume;
SARC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg21280719	chr6:42927975	GNMT	-0.45	-7.61	-0.45	6.8e-13	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs2576037	0.763	rs2060418	chr18:44576535	A/C	cg19077165	chr18:44547161	KATNAL2	0.44	6.21	0.38	2.37e-9	Personality dimensions;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg16714616	chr20:40247229	CHD6	-0.52	-6.94	-0.41	3.96e-11	Electrocardiographic conduction measures;
SARC	cis	rs9790314	0.638	rs1374793	chr3:160638505	G/A	cg04691961	chr3:161091175	C3orf57	0.58	8.06	0.47	4.06e-14	Morning vs. evening chronotype;
SARC	cis	rs7274811	0.711	rs291700	chr20:31981849	C/T	cg21523528	chr20:32077966	CBFA2T2	0.41	4.75	0.3	3.52e-6	Height;
SARC	cis	rs1008375	1.000	rs10939747	chr4:17691166	C/A	cg02297831	chr4:17616191	MED28	0.41	5.09	0.32	7.32e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs3105593	0.543	rs28582911	chr15:50729629	G/A	cg05456662	chr15:50716270	USP8	0.44	5.39	0.33	1.76e-7	QT interval;
SARC	cis	rs17253792	0.822	rs76555508	chr14:56071868	A/G	cg01858014	chr14:56050164	KTN1	-0.71	-5.63	-0.35	5.25e-8	Putamen volume;
SARC	cis	rs6998277	1.000	rs4734648	chr8:103635994	G/A	cg10187029	chr8:103597600	NA	0.64	6.25	0.38	1.91e-9	Migraine;
SARC	cis	rs4423214	1.000	rs11546509	chr11:71162785	A/G	cg24826892	chr11:71159390	DHCR7	0.43	5.24	0.32	3.64e-7	Vitamin D levels;
SARC	trans	rs61931739	0.817	rs7297799	chr12:34260142	T/C	cg13010199	chr12:38710504	ALG10B	0.57	7.28	0.43	5.06e-12	Morning vs. evening chronotype;
SARC	cis	rs2013441	1.000	rs2703815	chr17:20118499	C/T	cg13482628	chr17:19912719	NA	0.44	5.7	0.35	3.7e-8	Obesity-related traits;
SARC	cis	rs2204008	0.837	rs11180549	chr12:38236950	A/G	cg26384229	chr12:38710491	ALG10B	0.91	13.43	0.66	7.61e-31	Bladder cancer;
SARC	cis	rs7005606	1.000	rs2466098	chr8:32429916	A/G	cg14488905	chr8:32406789	NRG1	-0.42	-5.9	-0.36	1.27e-8	Hirschsprung disease;
SARC	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg05313129	chr8:58192883	C8orf71	-0.55	-6.02	-0.37	6.59e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1707322	1.000	rs10890360	chr1:46338444	C/T	cg03146154	chr1:46216737	IPP	0.47	5.67	0.35	4.31e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs17253792	0.822	rs77990307	chr14:56070049	T/C	cg01858014	chr14:56050164	KTN1	-0.67	-5.16	-0.32	5.38e-7	Putamen volume;
SARC	cis	rs7020830	0.898	rs7038219	chr9:37182892	C/A	cg14294708	chr9:37120828	ZCCHC7	1.11	20.73	0.81	8.41e-55	Schizophrenia;
SARC	cis	rs6840360	0.533	rs13119490	chr4:152713412	A/G	cg22705602	chr4:152727874	NA	0.47	8.08	0.47	3.39e-14	Intelligence (multi-trait analysis);
SARC	cis	rs72781680	0.784	rs72798406	chr2:24180144	T/C	cg06627628	chr2:24431161	ITSN2	-0.57	-6.05	-0.37	5.69e-9	Lymphocyte counts;
SARC	cis	rs4481887	1.000	rs4244178	chr1:248468441	A/G	cg00666640	chr1:248458726	OR2T12	0.37	6.23	0.38	2.17e-9	Common traits (Other);
SARC	cis	rs9868809	0.505	rs13434258	chr3:48738491	T/C	cg00383909	chr3:49044727	WDR6	0.65	6.21	0.38	2.36e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	trans	rs561341	0.882	rs111484028	chr17:30287701	G/A	cg20587970	chr11:113659929	NA	-1.26	-12.41	-0.63	1.72e-27	Hip circumference adjusted for BMI;
SARC	cis	rs7552404	0.920	rs2788654	chr1:76219569	C/T	cg10523679	chr1:76189770	ACADM	0.44	5.92	0.36	1.16e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9470361	0.524	rs7740181	chr6:36624111	C/T	cg08179530	chr6:36648295	CDKN1A	0.52	6.31	0.38	1.39e-9	QRS complex (Cornell);QRS duration;Left ventricular fractional shortening;
SARC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg19318889	chr4:1322082	MAEA	0.44	5.38	0.33	1.84e-7	Longevity;
SARC	cis	rs12701220	0.503	rs12531999	chr7:1181601	T/A	cg16145915	chr7:1198662	ZFAND2A	-0.38	-4.88	-0.3	1.97e-6	Bronchopulmonary dysplasia;
SARC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.58	6.9	0.41	4.75e-11	Renal function-related traits (BUN);
SARC	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg21782813	chr7:2030301	MAD1L1	0.41	6.16	0.37	3.17e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs1707322	0.686	rs2230659	chr1:46078884	C/T	cg03146154	chr1:46216737	IPP	-0.52	-6.29	-0.38	1.54e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs709400	0.593	rs12898029	chr14:103877884	T/C	cg26031613	chr14:104095156	KLC1	-0.76	-10.63	-0.57	8.79e-22	Body mass index;
SARC	cis	rs861020	1.000	rs632746	chr1:209982515	C/T	cg05527609	chr1:210001259	C1orf107	0.96	11.13	0.59	2.38e-23	Orofacial clefts;
SARC	cis	rs2070997	0.667	rs13287613	chr9:133715291	T/C	cg11464064	chr9:133710261	ABL1	0.62	5.99	0.37	7.99e-9	Response to amphetamines;
SARC	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg25405998	chr7:65216604	CCT6P1	-0.48	-5.74	-0.35	2.95e-8	Calcium levels;
SARC	cis	rs7937682	0.575	rs7114617	chr11:111768173	A/T	cg09085632	chr11:111637200	PPP2R1B	0.84	11.37	0.6	4.02e-24	Primary sclerosing cholangitis;
SARC	cis	rs765787	0.530	rs2554457	chr15:45520926	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.41	-5.08	-0.32	7.58e-7	Uric acid levels;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13472656	chr22:25960710	ADRBK2	0.58	7.4	0.44	2.43e-12	Smoking initiation;
SARC	cis	rs2153219	1.000	rs1074495	chr6:149759325	C/A	cg18043157	chr6:150390308	ULBP3	-0.54	-5.18	-0.32	4.8e-7	Coronary artery disease;
SARC	cis	rs2718058	0.630	rs2709120	chr7:37809412	T/C	cg15028436	chr7:37888078	TXNDC3	0.39	4.96	0.31	1.33e-6	Alzheimer's disease (late onset);
SARC	cis	rs4619890	0.528	rs62289335	chr4:7877655	G/C	cg18538662	chr4:7941764	AFAP1	-0.42	-5.42	-0.33	1.47e-7	Glaucoma (primary open-angle);
SARC	cis	rs4481887	0.708	rs6696691	chr1:248539720	T/C	cg00666640	chr1:248458726	OR2T12	0.35	6.12	0.37	3.88e-9	Common traits (Other);
SARC	cis	rs3617	0.591	rs2276823	chr3:52869263	C/A	cg18404041	chr3:52824283	ITIH1	0.37	5.47	0.34	1.18e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs2120019	0.935	rs8043181	chr15:75380424	T/C	cg09165964	chr15:75287851	SCAMP5	-0.87	-13.13	-0.65	7.3e-30	Blood trace element (Zn levels);
SARC	cis	rs27434	0.583	rs468130	chr5:96156029	A/G	cg16492584	chr5:96139282	ERAP1	-0.56	-7.02	-0.42	2.43e-11	Ankylosing spondylitis;
SARC	trans	rs1814175	0.791	rs10769625	chr11:49869887	G/A	cg03929089	chr4:120376271	NA	-0.89	-14.53	-0.69	1.73e-34	Height;
SARC	cis	rs7178909	0.902	rs3853640	chr15:90443720	A/C	cg19708238	chr15:90437601	AP3S2	0.62	8.76	0.5	4e-16	Common traits (Other);
SARC	cis	rs751728	0.638	rs4607416	chr6:33784998	G/C	cg25922239	chr6:33757077	LEMD2	0.6	7.26	0.43	5.58e-12	Crohn's disease;
SARC	cis	rs3020736	0.500	rs6002618	chr22:42507859	G/C	cg04733989	chr22:42467013	NAGA	-0.76	-10.57	-0.57	1.4e-21	Autism spectrum disorder or schizophrenia;
SARC	cis	rs11122272	0.766	rs2739511	chr1:231526490	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-9.65	-0.53	9.22e-19	Hemoglobin concentration;
SARC	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg02018176	chr4:1364513	KIAA1530	-0.46	-6.56	-0.4	3.36e-10	Obesity-related traits;
SARC	cis	rs6456156	0.586	rs9459862	chr6:167487011	A/G	cg07741184	chr6:167504864	NA	-0.27	-5.09	-0.32	7.25e-7	Primary biliary cholangitis;
SARC	cis	rs870825	0.929	rs72689261	chr4:185590897	C/A	cg04058563	chr4:185651563	MLF1IP	0.79	8.8	0.5	3.22e-16	Blood protein levels;
SARC	cis	rs7098414	0.511	rs7899545	chr10:82150635	G/C	cg00277334	chr10:82204260	NA	-0.36	-5.17	-0.32	4.99e-7	Post bronchodilator FEV1;
SARC	cis	rs13191362	1.000	rs67646369	chr6:163003233	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.57	5.38	0.33	1.85e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg01238044	chr22:24384105	GSTT1	-0.58	-6.72	-0.4	1.36e-10	Liver enzyme levels (gamma-glutamyl transferase);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg24801210	chr3:101293432	PCNP	0.55	7.01	0.42	2.58e-11	Breast cancer;
SARC	trans	rs629535	0.814	rs55873935	chr8:70081646	G/A	cg21567404	chr3:27674614	NA	-1.05	-13.65	-0.67	1.47e-31	Dupuytren's disease;
SARC	cis	rs820218	0.962	rs707707	chr17:73669521	C/T	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.72	9.75	0.54	4.58e-19	Rotator cuff tears;
SARC	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg13298116	chr11:62369859	EML3;MTA2	0.44	5.93	0.36	1.1e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs986417	0.818	rs767603	chr14:61098683	T/C	cg27398547	chr14:60952738	C14orf39	0.74	7.01	0.42	2.56e-11	Gut microbiota (bacterial taxa);
SARC	cis	rs2070488	0.775	rs6599204	chr3:38525734	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.77	11.22	0.59	1.24e-23	Electrocardiographic conduction measures;
SARC	cis	rs155076	1.000	rs261430	chr13:21865242	C/T	cg14456004	chr13:21872349	NA	-0.99	-12.13	-0.62	1.38e-26	White matter hyperintensity burden;
SARC	cis	rs6840360	1.000	rs9995704	chr4:152619069	C/A	cg22705602	chr4:152727874	NA	-0.39	-6.72	-0.4	1.38e-10	Intelligence (multi-trait analysis);
SARC	cis	rs4356932	1.000	rs7674409	chr4:76958334	C/G	cg24176760	chr4:76958061	ART3;CXCL11	0.29	4.96	0.31	1.37e-6	Blood protein levels;
SARC	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg11878867	chr6:150167359	LRP11	-0.35	-4.81	-0.3	2.72e-6	Lung cancer;
SARC	cis	rs11718455	0.960	rs35869565	chr3:44002394	G/C	cg08738300	chr3:44038990	NA	0.54	5.97	0.36	8.73e-9	Coronary artery disease;
SARC	cis	rs6815814	0.950	rs5743571	chr4:38805489	C/T	cg06935464	chr4:38784597	TLR10	0.63	6.31	0.38	1.41e-9	Breast cancer;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg17154313	chr10:71562511	COL13A1	0.51	6.45	0.39	6.48e-10	Lung adenocarcinoma;
SARC	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg02463440	chr8:22132932	PIWIL2	0.48	6.85	0.41	6.52e-11	Hypertriglyceridemia;
SARC	cis	rs5769765	0.773	rs4075331	chr22:50302850	A/G	cg03033257	chr22:50311977	ALG12;CRELD2	0.5	5.07	0.32	8.17e-7	Schizophrenia;
SARC	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg05313129	chr8:58192883	C8orf71	0.63	6.41	0.39	7.94e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs11690935	0.843	rs9784070	chr2:172785007	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.96	-13.95	-0.67	1.46e-32	Schizophrenia;
SARC	cis	rs208346	1.000	rs208346	chr7:2799686	G/T	cg19346786	chr7:2764209	NA	0.29	4.72	0.3	4.16e-6	Loneliness (linear analysis);
SARC	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg27266027	chr21:40555129	PSMG1	-0.4	-4.76	-0.3	3.35e-6	Menarche (age at onset);
SARC	cis	rs1865760	1.000	rs2071299	chr6:25914801	G/A	cg10373733	chr6:25993375	NA	0.41	4.83	0.3	2.42e-6	Height;
SARC	cis	rs1348850	0.567	rs880899	chr2:178532416	A/G	cg22681709	chr2:178499509	PDE11A	-0.37	-5.21	-0.32	4.08e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg25072359	chr17:41440525	NA	0.5	5.97	0.36	8.94e-9	Menopause (age at onset);
SARC	cis	rs62064224	0.791	rs11653160	chr17:30717222	A/G	cg25809561	chr17:30822961	MYO1D	0.37	5.63	0.35	5.19e-8	Schizophrenia;
SARC	cis	rs986417	0.818	rs10143831	chr14:61081961	G/T	cg27398547	chr14:60952738	C14orf39	0.75	7.06	0.42	1.87e-11	Gut microbiota (bacterial taxa);
SARC	cis	rs9640161	0.830	rs3757423	chr7:150067714	A/G	cg17279839	chr7:150038598	RARRES2	-0.32	-5.13	-0.32	6.13e-7	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs9309473	0.950	rs6756885	chr2:73805172	A/G	cg20560298	chr2:73613845	ALMS1	-0.47	-5.74	-0.35	2.91e-8	Metabolite levels;
SARC	cis	rs344364	0.511	rs2982446	chr16:1947153	C/T	cg26617929	chr16:1858877	NA	-0.71	-6.05	-0.37	5.88e-9	Glomerular filtration rate in chronic kidney disease;
SARC	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg13628971	chr7:2884303	GNA12	0.67	8.17	0.47	1.95e-14	Height;
SARC	cis	rs3092073	1.000	rs3092073	chr20:44595649	G/A	cg27529037	chr20:44575021	PCIF1	-0.3	-4.79	-0.3	2.97e-6	Intelligence (multi-trait analysis);
SARC	trans	rs1814175	0.817	rs11040651	chr11:49938395	G/A	cg15704280	chr7:45808275	SEPT13	-0.97	-18.24	-0.77	8.77e-47	Height;
SARC	cis	rs13191362	1.000	rs34931503	chr6:163003876	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.57	5.38	0.33	1.85e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs9467160	0.871	rs13205780	chr6:24448687	C/T	cg16211469	chr6:24423932	MRS2	0.37	4.83	0.3	2.51e-6	Liver enzyme levels;
SARC	cis	rs920590	0.758	rs35896770	chr8:19665616	G/C	cg17834443	chr8:19674713	INTS10	0.62	7.61	0.45	6.63e-13	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs1832871	0.616	rs55675950	chr6:158773994	T/A	cg07165851	chr6:158734300	TULP4	0.53	6.34	0.38	1.16e-9	Height;
SARC	cis	rs2204008	0.712	rs12371182	chr12:38321143	A/C	cg13010199	chr12:38710504	ALG10B	0.82	11.11	0.59	2.79e-23	Bladder cancer;
SARC	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg18252515	chr7:66147081	NA	-1.29	-11.04	-0.59	4.48e-23	Diabetic kidney disease;
SARC	cis	rs861020	0.630	rs655712	chr1:210006437	G/A	cg05527609	chr1:210001259	C1orf107	0.78	10.12	0.55	3.37e-20	Orofacial clefts;
SARC	cis	rs7772486	0.790	rs1062067	chr6:146207563	A/G	cg23711669	chr6:146136114	FBXO30	0.8	12.61	0.64	3.91e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs910316	1.000	rs4903281	chr14:75554361	G/C	cg06637938	chr14:75390232	RPS6KL1	0.55	7.72	0.45	3.36e-13	Height;
SARC	trans	rs7819412	0.775	rs4841490	chr8:10936891	T/C	cg06636001	chr8:8085503	FLJ10661	-0.7	-9.92	-0.54	1.47e-19	Triglycerides;
SARC	cis	rs7149337	1.000	rs35567150	chr14:51725944	A/G	cg23942311	chr14:51606299	NA	0.32	5.73	0.35	3.07e-8	Cancer;
SARC	cis	rs1691799	0.899	rs1168320	chr12:66744849	C/T	cg16791601	chr12:66731901	HELB	-0.71	-10.66	-0.57	7.05e-22	White blood cell count (basophil);
SARC	cis	rs1538970	0.884	rs781226	chr1:45872662	T/C	cg05343316	chr1:45956843	TESK2	-0.68	-8.26	-0.48	1.1e-14	Platelet count;
SARC	cis	rs559928	0.557	rs7122408	chr11:63898826	G/T	cg05555928	chr11:63887634	MACROD1	-0.51	-4.85	-0.3	2.26e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs11697848	1.000	rs117447227	chr20:48552370	C/T	cg17849948	chr20:48532315	SPATA2	0.87	5.2	0.32	4.3e-7	Systemic lupus erythematosus;
SARC	cis	rs1355223	1.000	rs1396883	chr11:34757447	C/T	cg18508148	chr11:34937573	PDHX;APIP	-0.42	-5.27	-0.33	3.08e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs6448317	1.000	rs11938296	chr4:24938861	A/G	cg21108841	chr4:24914750	CCDC149	-0.53	-5.47	-0.34	1.15e-7	Heschl's gyrus morphology;
SARC	cis	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.8	-0.46	2.01e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.94	-13.49	-0.66	4.75e-31	Gut microbiome composition (summer);
SARC	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg07308232	chr7:1071921	C7orf50	-0.61	-7.78	-0.45	2.32e-13	Longevity;Endometriosis;
SARC	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg23758822	chr17:41437982	NA	0.89	11.34	0.6	4.95e-24	Menopause (age at onset);
SARC	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg13902645	chr11:5959945	NA	-0.44	-6.01	-0.37	7.27e-9	DNA methylation (variation);
SARC	cis	rs8141529	0.529	rs5762814	chr22:29203964	G/A	cg15103426	chr22:29168792	CCDC117	0.61	5.91	0.36	1.19e-8	Lymphocyte counts;
SARC	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg26335602	chr6:28129616	ZNF389	0.53	5.95	0.36	9.59e-9	Depression;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg06623899	chr8:142161840	DENND3	-0.42	-6.32	-0.38	1.35e-9	Chemerin levels;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg04815758	chr6:43423089	DLK2	0.49	6.67	0.4	1.83e-10	Tetralogy of Fallot;
SARC	cis	rs7633857	0.512	rs745707	chr3:160652672	G/T	cg04691961	chr3:161091175	C3orf57	-0.46	-5.77	-0.35	2.57e-8	Educational attainment (years of education);
SARC	cis	rs7607369	0.626	rs4672892	chr2:219278630	A/G	cg02176678	chr2:219576539	TTLL4	-0.51	-7.57	-0.44	8.79e-13	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs7927592	0.913	rs12285993	chr11:68302538	A/G	cg01657329	chr11:68192670	LRP5	-0.4	-4.94	-0.31	1.51e-6	Total body bone mineral density;
SARC	cis	rs1448094	0.845	rs11117129	chr12:86349390	A/G	cg02569458	chr12:86230093	RASSF9	0.43	6.21	0.38	2.43e-9	Major depressive disorder;
SARC	cis	rs8180040	0.654	rs9837343	chr3:47177388	C/T	cg27129171	chr3:47204927	SETD2	0.68	9.41	0.52	4.92e-18	Colorectal cancer;
SARC	cis	rs2832191	0.692	rs2254872	chr21:30414724	C/T	cg08807101	chr21:30365312	RNF160	0.87	13.16	0.65	5.9e-30	Dental caries;
SARC	cis	rs78545713	0.892	rs113432940	chr6:26256324	T/A	cg00436476	chr6:26240505	HIST1H4F	-0.51	-4.91	-0.31	1.69e-6	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs9790314	1.000	rs62279921	chr3:161065441	T/C	cg03342759	chr3:160939853	NMD3	-0.61	-7.63	-0.45	5.95e-13	Morning vs. evening chronotype;
SARC	trans	rs13240504	0.557	rs10230565	chr7:126176516	T/A	cg12155036	chr3:194015171	NA	-0.55	-6.31	-0.38	1.38e-9	Anti-saccade response;
SARC	cis	rs9303542	0.592	rs34378400	chr17:46589265	A/G	cg04904318	chr17:46607828	HOXB1	-0.46	-5.35	-0.33	2.06e-7	Ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs1707322	1.000	rs10890381	chr1:46451771	T/G	cg06784218	chr1:46089804	CCDC17	0.36	6.31	0.38	1.37e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7662987	0.517	rs2602845	chr4:100023944	T/C	cg12011299	chr4:100065546	ADH4	0.32	5.26	0.33	3.23e-7	Smoking initiation;
SARC	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg12463550	chr7:65579703	CRCP	0.5	5.9	0.36	1.27e-8	Aortic root size;
SARC	cis	rs7772486	0.790	rs4435956	chr6:146232403	G/C	cg05347473	chr6:146136440	FBXO30	-0.48	-6.55	-0.39	3.63e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg11494091	chr17:61959527	GH2	0.53	7.83	0.46	1.75e-13	Prudent dietary pattern;
SARC	trans	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg20587970	chr11:113659929	NA	1.0	8.95	0.51	1.12e-16	Hip circumference adjusted for BMI;
SARC	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg02725872	chr8:58115012	NA	-0.34	-5.38	-0.33	1.78e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg06634786	chr22:41940651	POLR3H	0.53	6.4	0.39	8.27e-10	Vitiligo;
SARC	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg25072359	chr17:41440525	NA	0.51	6.08	0.37	4.92e-9	Menopause (age at onset);
SARC	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg02725872	chr8:58115012	NA	-0.34	-5.37	-0.33	1.91e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg06634786	chr22:41940651	POLR3H	-0.63	-7.21	-0.43	7.75e-12	Vitiligo;
SARC	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-8.57	-0.49	1.44e-15	Chronic sinus infection;
SARC	cis	rs12681366	0.683	rs2470746	chr8:95395808	A/G	cg26464482	chr8:95565502	KIAA1429	-0.43	-5.24	-0.32	3.54e-7	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs2200578	0.732	rs56271621	chr2:99658200	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.63	5.9	0.36	1.27e-8	IgG glycosylation;
SARC	cis	rs7560272	0.538	rs4852972	chr2:73916672	C/T	cg20560298	chr2:73613845	ALMS1	0.47	6.34	0.38	1.16e-9	Schizophrenia;
SARC	cis	rs13314892	0.764	rs74945202	chr3:69872697	C/T	cg17445875	chr3:69859618	MITF	-0.49	-5.12	-0.32	6.44e-7	QRS complex (12-leadsum);
SARC	cis	rs9398803	0.931	rs2045258	chr6:126674354	A/G	cg19875578	chr6:126661172	C6orf173	0.6	8.17	0.47	1.96e-14	Male-pattern baldness;
SARC	cis	rs4595586	0.545	rs1588970	chr12:39403122	C/A	cg26384229	chr12:38710491	ALG10B	0.5	6.12	0.37	3.98e-9	Morning vs. evening chronotype;
SARC	cis	rs11690935	0.589	rs6729945	chr2:172864695	C/G	cg13550731	chr2:172543902	DYNC1I2	0.51	6.5	0.39	4.84e-10	Schizophrenia;
SARC	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg03806693	chr22:41940476	POLR3H	-0.93	-11.63	-0.61	5.91e-25	Crohn's disease;Inflammatory bowel disease;
SARC	trans	rs8020941	0.585	rs76103642	chr14:97501149	C/T	cg05136476	chr3:53190709	NA	-0.64	-6.45	-0.39	6.29e-10	Diabetic kidney disease;
SARC	cis	rs2425143	0.643	rs6058324	chr20:34388789	G/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	5.15	0.32	5.6e-7	Blood protein levels;
SARC	cis	rs526231	0.615	rs26818	chr5:102529719	T/C	cg23492399	chr5:102201601	PAM	-0.53	-5.61	-0.34	5.75e-8	Primary biliary cholangitis;
SARC	trans	rs9329221	0.967	rs7005363	chr8:10283748	C/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.39	-0.44	2.55e-12	Neuroticism;
SARC	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg24829409	chr8:58192753	C8orf71	-0.55	-6.17	-0.37	2.94e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs796364	0.806	rs188102	chr2:200903189	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-5.23	-0.32	3.82e-7	Schizophrenia;
SARC	cis	rs9868809	0.505	rs13316551	chr3:48745167	A/C	cg07636037	chr3:49044803	WDR6	-0.69	-6.55	-0.39	3.7e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg06873352	chr17:61820015	STRADA	0.53	6.88	0.41	5.32e-11	Prudent dietary pattern;
SARC	cis	rs10911363	0.573	rs2702181	chr1:183516985	T/A	cg09173681	chr1:183549694	NCF2	0.32	5.09	0.32	7.46e-7	Systemic lupus erythematosus;
SARC	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg22800045	chr5:56110881	MAP3K1	0.74	7.83	0.46	1.74e-13	Initial pursuit acceleration;
SARC	cis	rs4268898	0.662	rs72795824	chr2:24435837	T/C	cg06627628	chr2:24431161	ITSN2	-0.84	-10.12	-0.55	3.39e-20	Asthma;
SARC	cis	rs7654585	0.782	rs2309288	chr4:25947097	C/A	cg10409131	chr4:25915609	C4orf52	0.5	6.17	0.37	3.04e-9	Obesity-related traits;
SARC	cis	rs9309473	0.500	rs7608328	chr2:73914019	G/A	cg20560298	chr2:73613845	ALMS1	0.49	6.55	0.39	3.59e-10	Metabolite levels;
SARC	cis	rs6570726	0.935	rs436212	chr6:145849400	G/A	cg05347473	chr6:146136440	FBXO30	0.49	6.55	0.39	3.56e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6456156	0.526	rs1854853	chr6:167533062	A/G	cg07741184	chr6:167504864	NA	-0.29	-5.63	-0.35	5.15e-8	Primary biliary cholangitis;
SARC	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg15966229	chr18:44337664	ST8SIA5	-0.37	-4.86	-0.3	2.15e-6	Personality dimensions;
SARC	cis	rs2228479	0.717	rs1800358	chr16:89809319	T/C	cg06558623	chr16:89946397	TCF25	0.87	6.94	0.41	3.78e-11	Skin colour saturation;
SARC	cis	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg18252515	chr7:66147081	NA	-1.34	-11.93	-0.62	6.47e-26	Diabetic kidney disease;
SARC	cis	rs11719291	0.833	rs11709246	chr3:48859498	G/A	cg01304814	chr3:48885189	PRKAR2A	0.63	5.21	0.32	4.2e-7	Cognitive function;
SARC	cis	rs6060960	0.502	rs6057968	chr20:30082779	A/T	cg21427119	chr20:30132790	HM13	-0.48	-5.34	-0.33	2.23e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
SARC	cis	rs73001065	0.892	rs58542926	chr19:19379549	C/T	cg03709012	chr19:19516395	GATAD2A	0.93	4.87	0.3	2.02e-6	LDL cholesterol;
SARC	cis	rs6456156	0.586	rs2001115	chr6:167486218	A/C	cg23791538	chr6:167370224	RNASET2	-0.53	-6.99	-0.42	2.86e-11	Primary biliary cholangitis;
SARC	cis	rs7583236	1.000	rs7583236	chr2:70182805	A/G	cg08479476	chr2:70313163	PCBP1	0.48	4.86	0.3	2.2e-6	Obesity-related traits;
SARC	trans	rs9354308	0.868	rs9453450	chr6:66545431	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.56	-6.64	-0.4	2.19e-10	Metabolite levels;
SARC	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg08048268	chr3:133502702	NA	0.49	6.61	0.4	2.53e-10	Iron status biomarkers;
SARC	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg22535103	chr8:58192502	C8orf71	-0.83	-8.03	-0.47	4.92e-14	Developmental language disorder (linguistic errors);
SARC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg09436375	chr6:42928200	GNMT	0.36	5.62	0.35	5.3e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs9911578	0.967	rs9907940	chr17:56663842	A/G	cg12560992	chr17:57184187	TRIM37	0.82	11.05	0.59	4.1000000000000003e-23	Intelligence (multi-trait analysis);
SARC	cis	rs4727027	0.933	rs28767030	chr7:148825918	T/G	cg23583168	chr7:148888333	NA	-0.73	-10.69	-0.57	5.97e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs2239547	0.603	rs6805298	chr3:53096552	A/G	cg05564831	chr3:52568323	NT5DC2	-0.32	-5.09	-0.32	7.45e-7	Schizophrenia;
SARC	cis	rs10845606	1.000	rs10845605	chr12:12833468	T/C	cg04607235	chr12:12878440	APOLD1	-0.56	-5.56	-0.34	7.22e-8	Systemic lupus erythematosus;
SARC	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg06634786	chr22:41940651	POLR3H	-0.66	-7.82	-0.46	1.77e-13	Vitiligo;
SARC	cis	rs1594829	0.655	rs111283523	chr8:26143503	C/T	cg11498726	chr8:26250323	BNIP3L	0.59	5.46	0.34	1.2e-7	Height;
SARC	cis	rs9814567	0.806	rs9857242	chr3:134316378	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.51	6.82	0.41	7.94e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	10.98	0.58	6.95e-23	Platelet count;
SARC	cis	rs9788721	0.835	rs72743158	chr15:78926445	T/C	cg06917634	chr15:78832804	PSMA4	-0.47	-5.16	-0.32	5.33e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs8180040	0.620	rs6442055	chr3:47110722	A/G	cg27129171	chr3:47204927	SETD2	0.71	9.71	0.54	6.27e-19	Colorectal cancer;
SARC	cis	rs10504073	0.647	rs4493918	chr8:50015937	C/G	cg00325661	chr8:49890786	NA	0.54	7.39	0.44	2.67e-12	Blood metabolite ratios;
SARC	trans	rs78901727	0.614	rs17666314	chr2:194361358	C/T	cg02889647	chr1:152879586	IVL	0.82	6.46	0.39	6.12e-10	Schizophrenia;
SARC	cis	rs2153535	0.607	rs9502722	chr6:8541483	C/T	cg23788917	chr6:8435910	SLC35B3	0.64	8.35	0.48	6.23e-15	Motion sickness;
SARC	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg25072359	chr17:41440525	NA	0.49	6.08	0.37	4.79e-9	Menopause (age at onset);
SARC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg09373136	chr17:61933544	TCAM1	-0.45	-6.13	-0.37	3.74e-9	Prudent dietary pattern;
SARC	cis	rs1144333	0.655	rs12402347	chr1:76447986	C/T	cg03433033	chr1:76189801	ACADM	0.61	4.9	0.31	1.77e-6	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs9325144	0.600	rs10785615	chr12:38733627	G/C	cg13010199	chr12:38710504	ALG10B	0.53	6.92	0.41	4.41e-11	Morning vs. evening chronotype;
SARC	cis	rs3820928	0.605	rs4281898	chr2:227855493	A/C	cg05526886	chr2:227700861	RHBDD1	-0.4	-4.95	-0.31	1.41e-6	Pulmonary function;
SARC	cis	rs7005380	0.581	rs12677306	chr8:120916082	G/C	cg21744203	chr8:120868354	DSCC1	-0.48	-5.56	-0.34	7.48e-8	Interstitial lung disease;
SARC	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.5	0.39	4.96e-10	Intelligence (multi-trait analysis);
SARC	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg02951883	chr7:2050386	MAD1L1	-0.52	-6.77	-0.41	1.03e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs798554	0.591	rs1182156	chr7:2901084	G/T	cg13628971	chr7:2884303	GNA12	0.49	5.99	0.37	8.05e-9	Height;
SARC	cis	rs1153858	1.000	rs28679834	chr15:45616206	C/T	cg03999130	chr15:45571217	NA	0.4	5.02	0.31	1.03e-6	Homoarginine levels;
SARC	cis	rs7824557	0.679	rs7004362	chr8:11135974	G/A	cg21775007	chr8:11205619	TDH	-0.54	-6.41	-0.39	7.87e-10	Retinal vascular caliber;
SARC	trans	rs7922314	0.571	rs16917991	chr10:64737762	A/C	cg25304107	chr2:177017331	HOXD4	-0.78	-6.29	-0.38	1.52e-9	Cutaneous psoriasis;
SARC	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg11301795	chr4:187892539	NA	-0.7	-10.28	-0.56	1.13e-20	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg12257692	chr3:49977190	RBM6	-0.27	-4.83	-0.3	2.45e-6	Body mass index;
SARC	cis	rs9916302	0.660	rs665413	chr17:37455678	T/A	cg07936489	chr17:37558343	FBXL20	0.77	9.2	0.52	2.04e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs17023223	0.581	rs2765529	chr1:119581900	C/T	cg05756136	chr1:119680316	WARS2	-0.45	-5.44	-0.34	1.35e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg18153499	chr19:47142459	NA	0.51	6.43	0.39	7.12e-10	Height;
SARC	cis	rs981844	0.753	rs1105491	chr4:154726634	A/C	cg14289246	chr4:154710475	SFRP2	0.51	5.96	0.36	9.11e-9	Response to statins (LDL cholesterol change);
SARC	cis	rs4742903	0.527	rs1450672	chr9:106944271	A/C	cg14250997	chr9:106856677	SMC2	0.39	4.85	0.3	2.3e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs28386778	0.700	rs4968672	chr17:62011352	G/A	cg26338869	chr17:61819248	STRADA	-0.68	-8.43	-0.48	3.64e-15	Prudent dietary pattern;
SARC	cis	rs2204008	0.583	rs12820907	chr12:37990931	T/C	cg13010199	chr12:38710504	ALG10B	0.74	9.81	0.54	3.15e-19	Bladder cancer;
SARC	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg26119090	chr2:26468346	HADHA;HADHB	0.95	13.25	0.66	3.02e-30	Gut microbiome composition (summer);
SARC	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg00431813	chr7:1051703	C7orf50	-0.33	-4.99	-0.31	1.17e-6	Longevity;Endometriosis;
SARC	cis	rs7412746	0.658	rs4970982	chr1:150865084	G/C	cg15448220	chr1:150897856	SETDB1	0.51	6.65	0.4	2.02e-10	Melanoma;
SARC	cis	rs12220238	1.000	rs10824106	chr10:75958408	C/T	cg19889307	chr10:75911429	ADK;AP3M1	-0.54	-5.26	-0.33	3.2e-7	Soluble interleukin-2 receptor subunit alpha;
SARC	cis	rs9399135	0.967	rs6923765	chr6:135335176	C/G	cg24558204	chr6:135376177	HBS1L	-0.46	-6.19	-0.38	2.69e-9	Red blood cell count;
SARC	cis	rs3820928	0.874	rs7576081	chr2:227843634	C/G	cg05526886	chr2:227700861	RHBDD1	-0.56	-6.77	-0.41	1.01e-10	Pulmonary function;
SARC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg09373136	chr17:61933544	TCAM1	-0.45	-6.12	-0.37	3.83e-9	Prudent dietary pattern;
SARC	cis	rs2043112	0.691	rs10057281	chr5:39090078	G/A	cg04869206	chr5:39074266	RICTOR	0.52	6.36	0.38	1.06e-9	Obesity-related traits;
SARC	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg01448562	chr3:133502909	NA	-0.49	-7.63	-0.45	6.08e-13	Iron status biomarkers;
SARC	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg05332525	chr7:65337924	VKORC1L1	-0.43	-4.83	-0.3	2.49e-6	Aortic root size;
SARC	cis	rs4803468	1.000	rs284651	chr19:41928336	T/C	cg09537434	chr19:41945824	ATP5SL	-0.98	-17.35	-0.75	7.28e-44	Height;
SARC	cis	rs6912958	0.712	rs9444526	chr6:88326402	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-6.46	-0.39	6.16e-10	Monocyte percentage of white cells;
SARC	cis	rs7219021	0.774	rs9909916	chr17:46961493	C/T	cg16584676	chr17:46985605	UBE2Z	-0.45	-4.78	-0.3	3.14e-6	Schizophrenia or bipolar disorder;
SARC	cis	rs12142240	0.698	rs67276232	chr1:46825484	T/G	cg00530320	chr1:46809349	NSUN4	0.57	6.79	0.41	9.05e-11	Menopause (age at onset);
SARC	cis	rs36715	1.000	rs251212	chr5:127545910	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	7.19	0.43	8.57e-12	Breast cancer;
SARC	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg13939156	chr17:80058883	NA	-0.43	-6.62	-0.4	2.45e-10	Life satisfaction;
SARC	cis	rs7252981	0.632	rs8101679	chr19:19733877	T/C	cg03709012	chr19:19516395	GATAD2A	-0.59	-6.34	-0.38	1.16e-9	Perceived unattractiveness to mosquitoes;
SARC	cis	rs763121	0.925	rs9611008	chr22:39098787	T/C	cg21395723	chr22:39101663	GTPBP1	0.51	6.01	0.37	6.95e-9	Menopause (age at onset);
SARC	cis	rs986417	0.901	rs1955693	chr14:61012331	T/C	cg27398547	chr14:60952738	C14orf39	0.96	8.75	0.5	4.38e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs193541	0.593	rs30042	chr5:122272641	A/G	cg19412675	chr5:122181750	SNX24	0.49	6.32	0.38	1.31e-9	Glucose homeostasis traits;
SARC	cis	rs2731664	0.792	rs2731662	chr5:176872494	C/T	cg23176889	chr5:176863531	GRK6	0.54	7.99	0.46	6.39e-14	Intelligence (multi-trait analysis);
SARC	cis	rs3091242	0.935	rs4233043	chr1:25765483	A/G	cg02931644	chr1:25747376	RHCE	0.44	7.44	0.44	1.89e-12	Erythrocyte sedimentation rate;
SARC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg24503407	chr1:205819492	PM20D1	0.79	11.96	0.62	5.17e-26	Menarche (age at onset);
SARC	cis	rs1448094	0.785	rs6539941	chr12:86452813	G/T	cg02569458	chr12:86230093	RASSF9	-0.39	-5.71	-0.35	3.46e-8	Major depressive disorder;
SARC	cis	rs17376456	0.825	rs10038828	chr5:93124056	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.71	6.57	0.4	3.3e-10	Diabetic retinopathy;
SARC	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg11987759	chr7:65425863	GUSB	0.5	6.22	0.38	2.3e-9	Aortic root size;
SARC	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg09060608	chr5:178986726	RUFY1	0.35	4.96	0.31	1.37e-6	Lung cancer;
SARC	cis	rs453301	0.658	rs6986044	chr8:8874786	G/C	cg11608241	chr8:8085544	FLJ10661	-0.46	-5.84	-0.36	1.79e-8	Joint mobility (Beighton score);
SARC	trans	rs9329221	0.905	rs4610752	chr8:10248962	A/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.27	-0.38	1.75e-9	Neuroticism;
SARC	cis	rs193541	0.621	rs898391	chr5:122082166	T/C	cg19412675	chr5:122181750	SNX24	0.48	6.42	0.39	7.46e-10	Glucose homeostasis traits;
SARC	cis	rs1843834	0.505	rs4674911	chr2:225345254	A/G	cg12698349	chr2:225449008	CUL3	0.62	7.94	0.46	8.55e-14	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs6696846	0.765	rs3738155	chr1:205074424	C/T	cg07972983	chr1:205091412	RBBP5	0.57	7.41	0.44	2.37e-12	Red blood cell count;
SARC	cis	rs35110281	0.667	rs9941787	chr21:45116042	A/G	cg21573476	chr21:45109991	RRP1B	-0.57	-8.0	-0.46	5.9e-14	Mean corpuscular volume;
SARC	cis	rs9457247	1.000	rs364451	chr6:167384756	G/A	cg07741184	chr6:167504864	NA	0.3	5.74	0.35	2.93e-8	Crohn's disease;
SARC	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg18404041	chr3:52824283	ITIH1	-0.38	-5.79	-0.35	2.21e-8	Electroencephalogram traits;
SARC	cis	rs9660992	0.710	rs55671824	chr1:205249814	G/A	cg21545522	chr1:205238299	TMCC2	0.49	6.61	0.4	2.58e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs6831352	0.879	rs34360292	chr4:100051303	T/C	cg13256891	chr4:100009986	ADH5	-0.65	-8.11	-0.47	2.83e-14	Alcohol dependence;
SARC	cis	rs6942407	0.592	rs2057984	chr7:86826540	C/T	cg02420886	chr7:86849541	C7orf23	0.7	6.23	0.38	2.21e-9	Food allergy;
SARC	cis	rs17401966	1.000	rs11576866	chr1:10414432	A/G	cg15208524	chr1:10270712	KIF1B	0.6	6.58	0.4	3.1e-10	Hepatocellular carcinoma;
SARC	cis	rs7666738	0.830	rs13137808	chr4:99047095	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg17691542	chr6:26056736	HIST1H1C	0.48	5.27	0.33	3.1e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2120019	0.938	rs59094290	chr15:75308561	G/T	cg12414181	chr15:75287860	SCAMP5	-0.52	-5.76	-0.35	2.65e-8	Blood trace element (Zn levels);
SARC	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg23262073	chr20:60523788	NA	-0.39	-5.71	-0.35	3.43e-8	Body mass index;
SARC	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg12463550	chr7:65579703	CRCP	0.55	5.86	0.36	1.54e-8	Aortic root size;
SARC	cis	rs11997175	0.902	rs7462610	chr8:33693318	A/T	ch.8.33884649F	chr8:33765107	NA	0.61	8.29	0.48	8.84e-15	Body mass index;
SARC	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg27170947	chr2:26402098	FAM59B	0.37	4.72	0.3	4.03e-6	Gut microbiome composition (summer);
SARC	cis	rs4689388	0.926	rs4416547	chr4:6293967	G/A	cg14416269	chr4:6271139	WFS1	0.32	4.92	0.31	1.61e-6	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	trans	rs2243123	0.602	rs2133310	chr3:159716352	A/G	cg13204435	chr8:95731830	DPY19L4	-0.51	-6.42	-0.39	7.57e-10	Multiple sclerosis;
SARC	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg11764359	chr7:65958608	NA	-0.75	-8.74	-0.5	4.7e-16	Aortic root size;
SARC	cis	rs2729354	0.909	rs2729374	chr11:57326927	C/T	cg02958346	chr11:57425731	CLP1	0.48	4.83	0.3	2.42e-6	Blood protein levels;
SARC	cis	rs7223966	1.000	rs11079511	chr17:61858537	C/G	cg26338869	chr17:61819248	STRADA	0.5	5.17	0.32	5.16e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg02018176	chr4:1364513	KIAA1530	0.36	5.27	0.33	3.17e-7	Obesity-related traits;
SARC	cis	rs11098499	0.954	rs6834796	chr4:120414693	A/C	cg09307838	chr4:120376055	NA	0.93	12.73	0.64	1.6e-28	Corneal astigmatism;
SARC	trans	rs9325144	0.554	rs1906264	chr12:38739490	A/G	cg23762105	chr12:34175262	ALG10	-0.54	-7.03	-0.42	2.22e-11	Morning vs. evening chronotype;
SARC	cis	rs933688	1.000	rs332529	chr5:90789470	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.98	11.53	0.6	1.23e-24	Smoking behavior;
SARC	cis	rs7264396	0.563	rs2425103	chr20:34312329	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-7.17	-0.43	9.99e-12	Total cholesterol levels;
SARC	cis	rs7412746	0.658	rs6656535	chr1:150940357	G/T	cg10589385	chr1:150898437	SETDB1	0.41	5.46	0.34	1.2e-7	Melanoma;
SARC	cis	rs367943	0.966	rs364738	chr5:112808329	A/G	cg12552261	chr5:112820674	MCC	-0.45	-5.19	-0.32	4.65e-7	Type 2 diabetes;
SARC	cis	rs12142240	0.698	rs66972124	chr1:46807445	A/G	cg10495392	chr1:46806563	NSUN4	0.65	6.96	0.41	3.41e-11	Menopause (age at onset);
SARC	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg05861140	chr6:150128134	PCMT1	-0.37	-4.88	-0.3	2.01e-6	Lung cancer;
SARC	cis	rs9790314	0.967	rs339101	chr3:161064193	A/T	cg03342759	chr3:160939853	NMD3	-0.6	-7.71	-0.45	3.57e-13	Morning vs. evening chronotype;
SARC	cis	rs7712401	0.601	rs30059	chr5:122297509	G/A	cg19412675	chr5:122181750	SNX24	0.4	5.13	0.32	5.98e-7	Mean platelet volume;
SARC	trans	rs1814175	0.654	rs1164676	chr11:49324868	T/C	cg03929089	chr4:120376271	NA	0.72	10.34	0.56	7.03e-21	Height;
SARC	cis	rs34172651	0.517	rs2303083	chr16:24835168	G/A	cg00152838	chr16:24741724	TNRC6A	-0.6	-5.98	-0.36	8.31e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7296418	0.518	rs28825193	chr12:123878262	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-5.33	-0.33	2.32e-7	Platelet count;
SARC	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg23982607	chr1:1823379	GNB1	0.38	4.83	0.3	2.46e-6	Body mass index;
SARC	cis	rs300703	0.515	rs364431	chr2:191399	C/A	cg21211680	chr2:198530	NA	0.42	4.8	0.3	2.83e-6	Blood protein levels;
SARC	cis	rs6493487	0.512	rs16953045	chr15:51251122	A/C	cg02338191	chr15:51200825	AP4E1	0.53	4.95	0.31	1.44e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.74	10.04	0.55	6e-20	Menarche (age at onset);
SARC	cis	rs9843304	0.616	rs4131174	chr3:149203910	C/T	cg08667024	chr3:149219783	TM4SF4	-0.35	-5.0	-0.31	1.12e-6	Gallstone disease;
SARC	cis	rs1865760	0.865	rs9467652	chr6:25959127	A/G	cg10373733	chr6:25993375	NA	0.4	4.79	0.3	2.96e-6	Height;
SARC	cis	rs1865760	1.000	rs2071301	chr6:25914263	G/T	cg10373733	chr6:25993375	NA	0.47	5.64	0.35	4.92e-8	Height;
SARC	cis	rs6540556	0.954	rs6685077	chr1:209933331	A/G	cg05527609	chr1:210001259	C1orf107	-0.58	-5.85	-0.36	1.68e-8	Red blood cell count;
SARC	trans	rs1814175	0.817	rs10769618	chr11:49822336	A/G	cg15704280	chr7:45808275	SEPT13	-0.97	-18.13	-0.76	2.05e-46	Height;
SARC	cis	rs13401104	0.796	rs10929170	chr2:237115591	A/G	cg19324714	chr2:237145437	ASB18	0.56	5.44	0.34	1.36e-7	Educational attainment;
SARC	cis	rs9388451	0.805	rs1028481	chr6:126106573	G/T	cg05901451	chr6:126070800	HEY2	-0.67	-9.32	-0.52	9.5e-18	Brugada syndrome;
SARC	cis	rs6493487	0.512	rs7166600	chr15:51161379	T/C	cg02338191	chr15:51200825	AP4E1	0.52	5.0	0.31	1.12e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs7954584	0.560	rs745327	chr12:122456524	T/C	cg22618164	chr12:122356400	WDR66	-0.41	-5.92	-0.36	1.16e-8	Mean corpuscular volume;
SARC	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg08219700	chr8:58056026	NA	0.78	7.03	0.42	2.21e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs939574	0.799	rs1109867	chr2:220083453	G/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.53	-4.87	-0.3	2.03e-6	Platelet distribution width;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg16700620	chr16:54963754	IRX5	-0.48	-6.53	-0.39	4e-10	Chemerin levels;
SARC	cis	rs7223966	0.960	rs8082651	chr17:61675292	A/G	cg00588841	chr17:61851480	DDX42;CCDC47	-0.46	-4.72	-0.3	4.13e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.5	5.96	0.36	9.48e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs17154702	0.524	rs2664041	chr8:8593144	A/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-4.72	-0.3	4.07e-6	Neurocognitive impairment in HIV-1 infection (continuous);
SARC	cis	rs1046896	1.000	rs1046875	chr17:80685426	A/G	cg02711726	chr17:80685570	FN3KRP	0.67	8.52	0.49	2.03e-15	Glycated hemoglobin levels;
SARC	trans	rs61931739	0.500	rs11053207	chr12:34459827	A/G	cg13010199	chr12:38710504	ALG10B	0.75	10.57	0.57	1.36e-21	Morning vs. evening chronotype;
SARC	cis	rs9462027	0.628	rs1998702	chr6:34741917	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.96	-0.36	9.08e-9	Systemic lupus erythematosus;
SARC	cis	rs6424115	0.867	rs11588187	chr1:24145047	T/A	cg15997130	chr1:24165203	NA	0.49	6.72	0.4	1.39e-10	Immature fraction of reticulocytes;
SARC	cis	rs554111	0.656	rs3121071	chr1:21128420	C/T	cg04902671	chr1:21058625	SH2D5	0.44	5.28	0.33	3.03e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	trans	rs36093844	0.752	rs79734467	chr11:85571953	C/T	cg15359163	chr5:122429178	PRDM6	-0.52	-6.36	-0.38	1.05e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs6831352	0.851	rs1230164	chr4:99986023	C/G	cg13256891	chr4:100009986	ADH5	0.65	8.19	0.47	1.73e-14	Alcohol dependence;
SARC	cis	rs7615952	0.515	rs7637246	chr3:125678706	A/G	cg05084668	chr3:125655381	ALG1L	-0.61	-6.03	-0.37	6.41e-9	Blood pressure (smoking interaction);
SARC	cis	rs7247513	0.701	rs8107642	chr19:12766370	C/T	cg04657146	chr19:12876947	HOOK2	0.46	5.69	0.35	3.78e-8	Bipolar disorder;
SARC	cis	rs4132509	1.000	rs10927078	chr1:243983830	C/T	cg21452805	chr1:244014465	NA	0.48	4.89	0.31	1.87e-6	RR interval (heart rate);
SARC	cis	rs11690935	0.918	rs11757	chr2:172641045	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.0	-15.95	-0.72	3.15e-39	Schizophrenia;
SARC	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg13770153	chr20:60521292	NA	-0.48	-6.45	-0.39	6.51e-10	Body mass index;
SARC	cis	rs2594989	0.748	rs9653970	chr3:11412754	A/G	cg00170343	chr3:11313890	ATG7	0.49	4.81	0.3	2.74e-6	Circulating chemerin levels;
SARC	cis	rs7513165	0.932	rs12040580	chr1:204148168	T/C	cg23788856	chr1:204159729	KISS1	-0.32	-4.82	-0.3	2.63e-6	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
SARC	trans	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg21659725	chr3:3221576	CRBN	-0.55	-7.19	-0.43	8.59e-12	Intelligence (multi-trait analysis);
SARC	cis	rs916888	0.610	rs199454	chr17:44800110	G/A	cg15921436	chr17:44337874	NA	-0.49	-5.53	-0.34	8.52e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7223966	0.691	rs9893518	chr17:62006997	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	6.46	0.39	5.95e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1865721	0.804	rs1319789	chr18:73161157	C/A	cg26385618	chr18:73139727	C18orf62	-0.37	-5.09	-0.32	7.26e-7	Intelligence;
SARC	cis	rs911263	0.603	rs11158730	chr14:68812756	A/G	cg18825221	chr14:68749962	RAD51L1	0.42	7.4	0.44	2.42e-12	Primary biliary cholangitis;
SARC	cis	rs9341808	0.754	rs9341810	chr6:80974838	G/A	cg08355045	chr6:80787529	NA	0.35	5.65	0.35	4.77e-8	Sitting height ratio;
SARC	cis	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg14541582	chr5:601475	NA	-0.4	-4.8	-0.3	2.89e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg16680214	chr1:154839983	KCNN3	-0.39	-6.19	-0.38	2.74e-9	Prostate cancer;
SARC	cis	rs2120019	0.567	rs28844983	chr15:75178088	T/A	cg00629941	chr15:75287862	SCAMP5	-0.59	-5.5	-0.34	9.94e-8	Blood trace element (Zn levels);
SARC	cis	rs27434	0.821	rs28337	chr5:96125314	A/T	cg16492584	chr5:96139282	ERAP1	-0.48	-5.46	-0.34	1.24e-7	Ankylosing spondylitis;
SARC	cis	rs607987	0.841	rs12363576	chr11:30301607	G/A	cg06241208	chr11:30344200	C11orf46	0.42	5.03	0.31	9.7e-7	Body mass index;
SARC	cis	rs66573146	1.000	rs55913461	chr4:7017509	C/T	cg00086871	chr4:6988644	TBC1D14	1.0	5.23	0.32	3.81e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs12899811	0.512	rs7164916	chr15:91561446	T/C	cg08919649	chr15:91565780	VPS33B	0.43	5.2	0.32	4.3e-7	Type 2 diabetes;
SARC	cis	rs6912958	0.874	rs9294381	chr6:88152681	A/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.62	-8.72	-0.5	5.41e-16	Monocyte percentage of white cells;
SARC	cis	rs5753618	0.561	rs715510	chr22:31690528	T/A	cg00478049	chr22:31556069	RNF185	0.44	4.78	0.3	3.07e-6	Colorectal cancer;
SARC	cis	rs7223966	1.000	rs9908044	chr17:61747032	A/C	cg26338869	chr17:61819248	STRADA	0.44	5.14	0.32	5.82e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7552404	0.924	rs1313071	chr1:76195542	C/G	cg10523679	chr1:76189770	ACADM	0.45	6.26	0.38	1.86e-9	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg12064134	chr16:90016061	DEF8	-0.57	-4.76	-0.3	3.38e-6	Skin colour saturation;
SARC	cis	rs9393777	0.557	rs7759741	chr6:27241043	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.37	-4.85	-0.3	2.28e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2191566	1.000	rs390369	chr19:44506984	C/T	cg20607764	chr19:44506953	ZNF230	0.54	6.38	0.39	9.34e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg12311346	chr5:56204834	C5orf35	0.67	6.47	0.39	5.61e-10	Initial pursuit acceleration;
SARC	cis	rs2658782	0.547	rs10765602	chr11:93048165	G/T	cg15737290	chr11:93063684	CCDC67	0.95	12.84	0.64	6.66e-29	Pulmonary function decline;
SARC	trans	rs2816316	0.583	rs2816314	chr1:192538530	C/T	cg02079908	chr2:42411760	EML4	0.52	6.3	0.38	1.5e-9	Celiac disease;
SARC	cis	rs9300255	0.509	rs641760	chr12:123518866	T/C	cg00376283	chr12:123451042	ABCB9	0.56	5.98	0.37	8.12e-9	Neutrophil percentage of white cells;
SARC	cis	rs240764	0.604	rs9322173	chr6:101203889	G/A	cg09795085	chr6:101329169	ASCC3	0.44	5.55	0.34	7.69e-8	Neuroticism;
SARC	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg23172400	chr8:95962367	TP53INP1	-0.33	-5.77	-0.35	2.54e-8	Type 2 diabetes;
SARC	cis	rs9640161	0.659	rs77354576	chr7:150013300	A/C	cg21361702	chr7:150065534	REPIN1	0.43	4.75	0.3	3.64e-6	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs3892630	0.878	rs8108621	chr19:33183291	G/A	cg22980127	chr19:33182716	NUDT19	1.07	9.96	0.55	1.11e-19	Red blood cell traits;
SARC	cis	rs1003719	0.788	rs2835582	chr21:38458773	C/G	cg10648535	chr21:38446584	PIGP;TTC3	0.66	9.49	0.53	2.78e-18	Eye color traits;
SARC	cis	rs986417	1.000	rs1254296	chr14:60870389	T/C	cg27398547	chr14:60952738	C14orf39	-0.97	-8.69	-0.49	6.71e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs2120243	0.592	rs7618502	chr3:157095544	C/G	cg24825693	chr3:157122686	VEPH1	-0.42	-5.7	-0.35	3.54e-8	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs137603	0.966	rs137616	chr22:39703883	A/G	cg01093212	chr22:39715156	SNORD43;RPL3	-0.43	-5.1	-0.32	7.02e-7	Primary biliary cholangitis;
SARC	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg05863683	chr7:1912471	MAD1L1	0.36	5.52	0.34	8.85e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs4481887	0.927	rs11204637	chr1:248492581	G/A	cg00666640	chr1:248458726	OR2T12	0.34	5.68	0.35	4.08e-8	Common traits (Other);
SARC	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg08280861	chr8:58055591	NA	0.59	5.74	0.35	2.94e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs611744	0.870	rs429315	chr8:109094068	A/G	cg21045802	chr8:109455806	TTC35	-0.45	-5.22	-0.32	3.96e-7	Dupuytren's disease;
SARC	cis	rs3087591	1.000	rs7406983	chr17:29703374	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.54	-6.69	-0.4	1.66e-10	Hip circumference;
SARC	cis	rs8102732	1.000	rs8102732	chr19:1023867	C/G	cg13770691	chr19:1021866	C19orf6	0.34	4.8	0.3	2.87e-6	Eosinophil percentage of granulocytes;
SARC	cis	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg12395012	chr8:11607386	GATA4	-0.29	-4.89	-0.31	1.89e-6	Retinal vascular caliber;
SARC	cis	rs57994353	0.865	rs35857370	chr9:139354097	G/A	cg13611204	chr9:139324423	INPP5E	-0.28	-4.88	-0.3	1.93e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg16265557	chr4:8443089	ACOX3	0.51	6.63	0.4	2.36e-10	Breast cancer;
SARC	cis	rs3770770	0.859	rs6753260	chr2:37238516	C/G	cg14987922	chr2:37194071	STRN	-0.5	-4.9	-0.31	1.78e-6	QRS duration;
SARC	cis	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg26695010	chr11:65641043	EFEMP2	-0.52	-6.69	-0.4	1.68e-10	Eosinophil percentage of white cells;
SARC	cis	rs12586317	0.547	rs2038254	chr14:35462134	C/T	cg26967526	chr14:35346199	BAZ1A	-0.57	-5.71	-0.35	3.4e-8	Psoriasis;
SARC	cis	rs11630290	1.000	rs11630290	chr15:63915786	C/T	cg12036633	chr15:63758958	NA	-0.47	-4.73	-0.3	3.91e-6	Iris characteristics;
SARC	cis	rs2153535	0.580	rs1577471	chr6:8485905	T/A	cg07606381	chr6:8435919	SLC35B3	0.78	11.07	0.59	3.71e-23	Motion sickness;
SARC	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg23758822	chr17:41437982	NA	0.9	11.63	0.61	5.8e-25	Menopause (age at onset);
SARC	cis	rs7208859	0.623	rs11658945	chr17:29122509	T/C	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs12956009	0.559	rs12607072	chr18:44839888	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	7.54	0.44	1.03e-12	Educational attainment (years of education);
SARC	cis	rs17376456	0.569	rs10476520	chr5:93058290	A/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.49	4.96	0.31	1.37e-6	Diabetic retinopathy;
SARC	cis	rs17270561	0.609	rs6941933	chr6:25745702	T/C	cg16482183	chr6:26056742	HIST1H1C	0.43	5.08	0.32	7.76e-7	Iron status biomarkers;
SARC	cis	rs372883	0.600	rs2832295	chr21:30739843	C/T	cg08807101	chr21:30365312	RNF160	0.59	7.56	0.44	9.44e-13	Pancreatic cancer;
SARC	cis	rs911263	0.603	rs3784104	chr14:68773469	A/G	cg18825221	chr14:68749962	RAD51L1	0.42	7.49	0.44	1.4e-12	Primary biliary cholangitis;
SARC	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg13939156	chr17:80058883	NA	0.37	5.65	0.35	4.6e-8	Life satisfaction;
SARC	cis	rs10779751	0.734	rs2791649	chr1:11132561	A/G	cg08854313	chr1:11322531	MTOR	0.82	11.29	0.59	7.2e-24	Body mass index;
SARC	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg21724239	chr8:58056113	NA	0.62	5.81	0.36	2.09e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg25894440	chr7:65020034	NA	0.53	4.92	0.31	1.61e-6	Aortic root size;
SARC	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg01324507	chr7:1177794	C7orf50	0.46	5.16	0.32	5.25e-7	Bronchopulmonary dysplasia;
SARC	cis	rs898097	0.625	rs6502017	chr17:80891135	C/T	cg10494973	chr17:80897199	TBCD	-0.42	-5.62	-0.35	5.52e-8	Breast cancer;
SARC	cis	rs115056730	0.520	rs114113305	chr2:98189209	A/T	cg26665480	chr2:98280029	ACTR1B	-0.67	-5.02	-0.31	1.03e-6	Monocyte chemoattractant protein-3 levels;
SARC	trans	rs6981523	0.517	rs13251510	chr8:10916974	A/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.29	-0.43	4.8e-12	Neuroticism;
SARC	cis	rs3087591	0.919	rs2952993	chr17:29539998	G/A	cg24425628	chr17:29625626	OMG;NF1	0.54	6.66	0.4	1.99e-10	Hip circumference;
SARC	cis	rs6570726	0.935	rs411641	chr6:145827532	G/A	cg23711669	chr6:146136114	FBXO30	0.79	12.09	0.62	2e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs708547	0.915	rs28605409	chr4:57766261	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.59	6.26	0.38	1.82e-9	Response to bleomycin (chromatid breaks);
SARC	cis	rs4727027	0.834	rs7811446	chr7:148773226	G/T	cg23583168	chr7:148888333	NA	-0.73	-10.58	-0.57	1.32e-21	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg20607798	chr8:58055168	NA	0.61	5.45	0.34	1.27e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs4253772	0.637	rs11703173	chr22:46660367	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.62	4.86	0.3	2.14e-6	LDL cholesterol;Cholesterol, total;
SARC	cis	rs4481887	0.927	rs4390209	chr1:248472613	A/T	cg01631408	chr1:248437212	OR2T33	-0.39	-5.06	-0.31	8.56e-7	Common traits (Other);
SARC	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg27347728	chr4:17578864	LAP3	0.48	6.1	0.37	4.5e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10463554	0.892	rs257313	chr5:102420647	A/G	cg23492399	chr5:102201601	PAM	-0.47	-5.18	-0.32	4.86e-7	Parkinson's disease;
SARC	cis	rs7772486	0.754	rs9386133	chr6:146141213	A/G	cg23711669	chr6:146136114	FBXO30	0.79	12.55	0.64	6.14e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11098499	0.866	rs13125526	chr4:120288019	G/A	cg09307838	chr4:120376055	NA	0.83	11.82	0.61	1.46e-25	Corneal astigmatism;
SARC	trans	rs11165623	0.564	rs9887887	chr1:96996930	A/G	cg10631902	chr5:14652156	NA	-0.43	-6.54	-0.39	3.89e-10	Hip circumference;Waist circumference;
SARC	cis	rs12824058	0.831	rs11609362	chr12:130810526	T/C	cg24838063	chr12:130822603	PIWIL1	0.63	8.94	0.51	1.25e-16	Menopause (age at onset);
SARC	cis	rs9341808	0.667	rs806783	chr6:80942943	A/C	cg08355045	chr6:80787529	NA	-0.35	-5.66	-0.35	4.53e-8	Sitting height ratio;
SARC	cis	rs17376456	0.877	rs34184666	chr5:93444584	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.71	0.35	3.39e-8	Diabetic retinopathy;
SARC	cis	rs3087591	0.960	rs4263003	chr17:29438508	G/T	cg24425628	chr17:29625626	OMG;NF1	0.56	6.95	0.41	3.55e-11	Hip circumference;
SARC	cis	rs10911232	0.507	rs4651137	chr1:182994300	T/C	cg13390022	chr1:182993471	LAMC1	0.33	4.97	0.31	1.29e-6	Hypertriglyceridemia;
SARC	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg05025164	chr4:1340916	KIAA1530	0.44	5.46	0.34	1.2e-7	Obesity-related traits;
SARC	cis	rs6700896	0.931	rs12042807	chr1:66134052	T/C	cg04111102	chr1:66153794	NA	0.36	5.66	0.35	4.49e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg03351412	chr1:154909251	PMVK	-0.63	-7.97	-0.46	6.85e-14	Prostate cancer;
SARC	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg21724239	chr8:58056113	NA	0.69	6.57	0.4	3.22e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7914558	1.000	rs12780843	chr10:104769335	G/C	cg04362960	chr10:104952993	NT5C2	0.44	5.48	0.34	1.12e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs1949733	0.523	rs4619877	chr4:8543235	G/A	cg13073564	chr4:8508604	NA	0.49	7.34	0.43	3.47e-12	Response to antineoplastic agents;
SARC	cis	rs8031584	0.958	rs7176569	chr15:31244495	G/T	cg14829155	chr15:31115871	NA	0.4	5.02	0.31	1.04e-6	Huntington's disease progression;
SARC	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-9.6	-0.53	1.3e-18	Chronic sinus infection;
SARC	cis	rs6120849	0.663	rs6088662	chr20:33547633	A/C	cg06115741	chr20:33292138	TP53INP2	0.5	5.0	0.31	1.14e-6	Protein C levels;
SARC	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg11987759	chr7:65425863	GUSB	0.47	5.87	0.36	1.49e-8	Aortic root size;
SARC	cis	rs77372450	0.636	rs6889203	chr5:156993871	G/C	cg23851860	chr5:157002805	ADAM19	0.5	4.75	0.3	3.51e-6	Bipolar disorder (body mass index interaction);
SARC	cis	rs4988958	0.527	rs11465641	chr2:103000868	T/G	cg03938978	chr2:103052716	IL18RAP	0.32	5.17	0.32	5.14e-7	Asthma (childhood onset);
SARC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.62	7.97	0.46	6.87e-14	Lymphocyte counts;
SARC	cis	rs1983891	1.000	rs913074	chr6:41538545	T/C	cg15051332	chr6:41514432	FOXP4	0.52	5.72	0.35	3.32e-8	Prostate cancer;
SARC	cis	rs9309473	0.500	rs12996463	chr2:73655496	T/C	cg20560298	chr2:73613845	ALMS1	0.53	7.23	0.43	6.79e-12	Metabolite levels;
SARC	cis	rs9436747	0.516	rs6656451	chr1:65990422	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.41	-5.09	-0.32	7.25e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs9486719	1.000	rs12530462	chr6:97053514	C/T	cg06623918	chr6:96969491	KIAA0776	-0.75	-8.05	-0.47	4.17e-14	Migraine;Coronary artery disease;
SARC	cis	rs9309473	0.632	rs6546825	chr2:73592253	G/C	cg20560298	chr2:73613845	ALMS1	-0.6	-7.62	-0.45	6.24e-13	Metabolite levels;
SARC	cis	rs11673344	0.566	rs8109103	chr19:37994111	C/T	cg14683738	chr19:37701593	ZNF585B	-0.41	-4.83	-0.3	2.51e-6	Obesity-related traits;
SARC	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg13939156	chr17:80058883	NA	0.4	6.25	0.38	1.92e-9	Life satisfaction;
SARC	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg04166393	chr7:2884313	GNA12	0.56	6.44	0.39	6.84e-10	Height;
SARC	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg01448562	chr3:133502909	NA	0.5	7.68	0.45	4.33e-13	Iron status biomarkers;
SARC	cis	rs6088580	0.634	rs4911420	chr20:32998654	A/G	cg24642439	chr20:33292090	TP53INP2	-0.61	-7.84	-0.46	1.63e-13	Glomerular filtration rate (creatinine);
SARC	trans	rs11098499	1.000	rs3749591	chr4:120214030	T/G	cg25214090	chr10:38739885	LOC399744	0.53	6.95	0.41	3.63e-11	Corneal astigmatism;
SARC	cis	rs7829975	0.606	rs6422352	chr8:8794193	A/G	cg14343924	chr8:8086146	FLJ10661	-0.4	-4.82	-0.3	2.61e-6	Mood instability;
SARC	trans	rs925098	0.556	rs2251890	chr4:17966548	T/C	cg08521178	chr6:170491202	NA	0.42	6.58	0.4	3.02e-10	Birth weight;Height;
SARC	cis	rs9815354	0.556	rs55953604	chr3:42004428	A/G	cg03022575	chr3:42003672	ULK4	0.65	5.61	0.34	5.72e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs1707322	0.752	rs28812624	chr1:46203736	T/A	cg06784218	chr1:46089804	CCDC17	0.36	6.29	0.38	1.55e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7408868	0.563	rs11085949	chr19:15296917	G/T	cg14696996	chr19:15285081	NOTCH3	0.76	6.87	0.41	5.94e-11	Pulse pressure;
SARC	cis	rs950027	0.549	rs1719250	chr15:45609773	A/G	cg26924012	chr15:45694286	SPATA5L1	0.51	6.5	0.39	4.75e-10	Response to fenofibrate (adiponectin levels);
SARC	cis	rs9457247	0.515	rs2757039	chr6:167370353	G/T	cg23791538	chr6:167370224	RNASET2	0.73	10.59	0.57	1.2e-21	Crohn's disease;
SARC	cis	rs644799	1.000	rs500054	chr11:95593806	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.68	8.8	0.5	3.23e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9329221	0.527	rs4841351	chr8:10327367	G/A	cg21775007	chr8:11205619	TDH	-0.38	-5.05	-0.31	8.86e-7	Neuroticism;
SARC	cis	rs6088813	1.000	rs6142379	chr20:33999267	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.45	-5.39	-0.33	1.75e-7	Height;
SARC	cis	rs2762353	0.526	rs9461203	chr6:25710555	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.44	-5.4	-0.33	1.61e-7	Blood metabolite levels;
SARC	cis	rs11997175	0.625	rs2882300	chr8:33585323	G/A	ch.8.33884649F	chr8:33765107	NA	0.48	6.27	0.38	1.75e-9	Body mass index;
SARC	cis	rs1878931	0.501	rs42329	chr16:3425524	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.74	-8.99	-0.51	8.6e-17	Body mass index (adult);
SARC	cis	rs2412208	0.664	rs12025462	chr1:7107665	C/T	cg20434152	chr1:7120926	CAMTA1	0.32	4.88	0.3	1.97e-6	Survival in sporadic amyotrophic lateral sclerosis;
SARC	cis	rs3008870	0.755	rs4655661	chr1:67408828	A/C	cg02640540	chr1:67518911	SLC35D1	0.45	5.19	0.32	4.55e-7	Lymphocyte percentage of white cells;
SARC	cis	rs2832191	0.791	rs2832197	chr21:30497790	T/C	cg24692254	chr21:30365293	RNF160	-0.84	-11.9	-0.61	8.25e-26	Dental caries;
SARC	cis	rs3126085	0.867	rs12748016	chr1:152197235	T/C	cg09127314	chr1:152161683	NA	-0.43	-4.88	-0.3	2.01e-6	Atopic dermatitis;
SARC	cis	rs7223966	1.000	rs9903897	chr17:61716705	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.59	-6.78	-0.41	9.63e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7819412	0.805	rs2409710	chr8:10979821	A/G	cg12395012	chr8:11607386	GATA4	0.3	4.86	0.3	2.17e-6	Triglycerides;
SARC	cis	rs6088590	1.000	rs10048849	chr20:33419680	C/T	cg24642439	chr20:33292090	TP53INP2	0.85	11.82	0.61	1.48e-25	Coronary artery disease;
SARC	cis	rs6669008	1.000	rs55912359	chr1:114167099	C/T	cg13572289	chr1:114447746	DCLRE1B;AP4B1	-0.43	-5.1	-0.32	6.94e-7	Bacteremia;
SARC	cis	rs62064224	0.791	rs17806082	chr17:30705346	G/C	cg18200150	chr17:30822561	MYO1D	0.43	6.85	0.41	6.36e-11	Schizophrenia;
SARC	cis	rs2645694	0.626	rs904050	chr4:77826089	T/G	cg03477792	chr4:77819574	ANKRD56	0.47	6.96	0.41	3.38e-11	Emphysema distribution in smoking;
SARC	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg09165964	chr15:75287851	SCAMP5	0.54	7.15	0.42	1.09e-11	Breast cancer;
SARC	cis	rs6977660	0.714	rs10228783	chr7:19789290	C/T	cg05791153	chr7:19748676	TWISTNB	0.73	6.43	0.39	7.21e-10	Thyroid stimulating hormone;
SARC	cis	rs11155671	0.546	rs1999633	chr6:150187712	C/T	cg11878867	chr6:150167359	LRP11	-0.45	-5.24	-0.32	3.62e-7	Testicular germ cell tumor;
SARC	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9359856	0.564	rs61739327	chr6:90340446	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.63	-4.95	-0.31	1.41e-6	Bipolar disorder;
SARC	cis	rs8114671	0.869	rs66535333	chr20:33656666	G/A	cg24642439	chr20:33292090	TP53INP2	-0.51	-5.96	-0.36	9.12e-9	Height;
SARC	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg03264133	chr6:25882463	NA	-0.48	-6.26	-0.38	1.8e-9	Intelligence (multi-trait analysis);
SARC	cis	rs4423214	1.000	rs12422045	chr11:71154820	C/T	cg05163923	chr11:71159392	DHCR7	0.67	8.88	0.5	1.85e-16	Vitamin D levels;
SARC	cis	rs12545109	1.000	rs12545109	chr8:57313906	A/C	cg19413350	chr8:57351067	NA	-0.45	-5.59	-0.34	6.46e-8	Obesity-related traits;
SARC	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg13395646	chr4:1353034	KIAA1530	-0.43	-5.19	-0.32	4.59e-7	Longevity;
SARC	cis	rs244731	0.959	rs7724098	chr5:176659570	G/A	cg06060754	chr5:176797920	RGS14	-0.43	-5.04	-0.31	9.37e-7	Urate levels in lean individuals;
SARC	cis	rs950027	0.620	rs1617984	chr15:45622662	A/G	cg26924012	chr15:45694286	SPATA5L1	0.51	6.47	0.39	5.74e-10	Response to fenofibrate (adiponectin levels);
SARC	cis	rs9788721	0.836	rs72738732	chr15:78752188	C/G	cg18825076	chr15:78729989	IREB2	-0.53	-6.37	-0.39	1.01e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg09323728	chr8:95962352	TP53INP1	-0.31	-5.17	-0.32	5.12e-7	Type 2 diabetes;
SARC	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.44	-5.61	-0.35	5.63e-8	Personality dimensions;
SARC	cis	rs6964587	0.869	rs6946764	chr7:91539003	A/G	cg17063962	chr7:91808500	NA	-0.91	-14.0	-0.68	9.98e-33	Breast cancer;
SARC	trans	rs1994135	0.617	rs10844644	chr12:33735871	A/G	cg26384229	chr12:38710491	ALG10B	0.71	8.79	0.5	3.33e-16	Resting heart rate;
SARC	cis	rs10046574	0.519	rs7810403	chr7:135216172	G/A	cg27474649	chr7:135195673	CNOT4	0.79	7.57	0.44	8.67e-13	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs2153535	0.541	rs945304	chr6:8442892	A/G	cg07606381	chr6:8435919	SLC35B3	0.8	11.46	0.6	2.07e-24	Motion sickness;
SARC	cis	rs2153535	0.580	rs6929206	chr6:8447961	A/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.5	0.49	2.33e-15	Motion sickness;
SARC	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg24060327	chr5:131705240	SLC22A5	-0.5	-6.11	-0.37	4.21e-9	Blood metabolite levels;
SARC	cis	rs992157	0.798	rs10932772	chr2:219177148	C/T	cg00012203	chr2:219082015	ARPC2	0.66	9.63	0.53	1.09e-18	Colorectal cancer;
SARC	cis	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg00071950	chr4:10020882	SLC2A9	0.4	6.39	0.39	8.75e-10	Bone mineral density;
SARC	cis	rs9399135	0.933	rs4559100	chr6:135324085	T/C	cg24558204	chr6:135376177	HBS1L	0.45	6.11	0.37	4.1e-9	Red blood cell count;
SARC	cis	rs950169	0.922	rs2033284	chr15:84946273	C/T	cg17507749	chr15:85114479	UBE2QP1	0.78	9.49	0.53	2.84e-18	Schizophrenia;
SARC	cis	rs55823223	0.648	rs11869977	chr17:73857382	C/G	cg10935138	chr17:73851978	WBP2	0.52	5.62	0.35	5.51e-8	Psoriasis;
SARC	cis	rs2228479	0.850	rs17226973	chr16:89825248	T/C	cg00800038	chr16:89945340	TCF25	-0.74	-5.14	-0.32	5.75e-7	Skin colour saturation;
SARC	trans	rs1814175	0.817	rs4881645	chr11:49791168	G/A	cg15704280	chr7:45808275	SEPT13	-0.97	-18.04	-0.76	3.96e-46	Height;
SARC	cis	rs77956314	0.515	rs10850741	chr12:117432004	A/G	cg16111737	chr12:117408163	FBXW8	-0.49	-6.36	-0.38	1.03e-9	Subcortical brain region volumes;Hippocampal volume;
SARC	cis	rs2486288	0.656	rs11629859	chr15:45547121	T/G	cg26924012	chr15:45694286	SPATA5L1	-0.44	-5.45	-0.34	1.26e-7	Glomerular filtration rate;
SARC	cis	rs637571	0.522	rs528736	chr11:65705108	A/G	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.41	-4.98	-0.31	1.24e-6	Eosinophil percentage of white cells;
SARC	cis	rs1046896	0.594	rs67813226	chr17:80851134	G/A	cg02711726	chr17:80685570	FN3KRP	-0.58	-7.09	-0.42	1.63e-11	Glycated hemoglobin levels;
SARC	cis	rs17153755	0.931	rs12677897	chr8:11612963	G/A	cg00262122	chr8:11665843	FDFT1	0.44	5.05	0.31	8.72e-7	Testicular germ cell tumor;
SARC	cis	rs6582630	0.502	rs11520279	chr12:38360871	A/G	cg13010199	chr12:38710504	ALG10B	0.78	10.79	0.58	2.78e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg11608241	chr8:8085544	FLJ10661	0.44	5.4	0.33	1.62e-7	Mood instability;
SARC	cis	rs6456156	0.565	rs6456153	chr6:167472167	T/C	cg23791538	chr6:167370224	RNASET2	-0.52	-6.81	-0.41	8.22e-11	Primary biliary cholangitis;
SARC	cis	rs9916302	0.904	rs8070695	chr17:37478062	C/T	cg00129232	chr17:37814104	STARD3	0.61	7.15	0.42	1.14e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs7089973	0.604	rs11196924	chr10:116571796	A/C	cg03647239	chr10:116582469	FAM160B1	-0.45	-5.42	-0.33	1.47e-7	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg11965913	chr1:205819406	PM20D1	0.87	14.59	0.69	1.1e-34	Menarche (age at onset);
SARC	cis	rs765787	0.530	rs28733848	chr15:45516047	C/T	cg25801113	chr15:45476975	SHF	0.28	4.72	0.3	4.06e-6	Uric acid levels;
SARC	cis	rs7772486	0.754	rs4896839	chr6:146019689	T/G	cg23711669	chr6:146136114	FBXO30	-0.91	-15.87	-0.72	5.98e-39	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6976053	0.564	rs314347	chr7:100399149	G/A	cg03098644	chr7:100410630	EPHB4	-0.44	-6.26	-0.38	1.87e-9	Plasminogen activator inhibitor type 1 levels (PAI-1);
SARC	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.7	0.35	3.54e-8	Bipolar disorder;
SARC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg22535103	chr8:58192502	C8orf71	-0.59	-6.21	-0.38	2.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1580019	0.563	rs34319173	chr7:32585904	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.5	6.18	0.38	2.83e-9	Cognitive ability;
SARC	cis	rs2130392	0.926	rs7680323	chr4:185652871	A/T	cg04058563	chr4:185651563	MLF1IP	-0.4	-5.72	-0.35	3.3e-8	Kawasaki disease;
SARC	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	8.88	0.5	1.89e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9715521	0.718	rs62301190	chr4:59842351	A/G	cg11281224	chr4:60001000	NA	-0.42	-5.25	-0.33	3.48e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs6540556	0.517	rs61820570	chr1:209884953	C/T	cg05527609	chr1:210001259	C1orf107	-0.54	-4.73	-0.3	3.96e-6	Red blood cell count;
SARC	cis	rs4919694	1.000	rs11191473	chr10:104710710	C/G	cg04362960	chr10:104952993	NT5C2	0.66	5.57	0.34	6.99e-8	Arsenic metabolism;
SARC	cis	rs9611519	0.565	rs8135524	chr22:41436442	T/C	cg06634786	chr22:41940651	POLR3H	-0.37	-4.78	-0.3	3.14e-6	Neuroticism;
SARC	cis	rs3857067	0.806	rs2171384	chr4:95103545	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.07	-0.32	8.15e-7	QT interval;
SARC	cis	rs9815354	0.812	rs17218103	chr3:41943724	A/G	cg03022575	chr3:42003672	ULK4	0.7	5.7	0.35	3.66e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg09373136	chr17:61933544	TCAM1	-0.45	-6.12	-0.37	3.83e-9	Prudent dietary pattern;
SARC	cis	rs2354432	0.556	rs7525622	chr1:146774116	G/A	cg25205988	chr1:146714368	CHD1L	-1.0	-7.56	-0.44	9.4e-13	Mitochondrial DNA levels;
SARC	cis	rs17376456	0.825	rs55724660	chr5:93276636	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.85	0.36	1.65e-8	Diabetic retinopathy;
SARC	cis	rs611744	0.647	rs2594358	chr8:109256018	A/G	cg21045802	chr8:109455806	TTC35	0.6	7.67	0.45	4.78e-13	Dupuytren's disease;
SARC	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg09455208	chr3:40491958	NA	0.42	6.43	0.39	7.12e-10	Renal cell carcinoma;
SARC	cis	rs4751006	0.543	rs9794336	chr10:128777873	C/T	cg05702161	chr10:128779687	DOCK1	0.64	5.15	0.32	5.53e-7	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2997447	0.846	rs61775431	chr1:26411275	T/G	cg19633962	chr1:26362018	EXTL1	-0.67	-5.78	-0.35	2.42e-8	QRS complex (12-leadsum);
SARC	cis	rs34779708	0.966	rs12762493	chr10:35471873	G/A	cg03585969	chr10:35415529	CREM	0.4	5.04	0.31	9.39e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs79349575	0.811	rs1057897	chr17:47005509	T/G	cg16584676	chr17:46985605	UBE2Z	0.52	6.29	0.38	1.57e-9	Type 2 diabetes;
SARC	cis	rs9916302	0.861	rs10491129	chr17:37461643	T/G	cg07936489	chr17:37558343	FBXL20	0.68	9.05	0.51	5.66e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs3733589	0.590	rs7657096	chr4:10004000	A/G	cg16430538	chr4:10459836	ZNF518B	0.61	5.47	0.34	1.16e-7	Renal overload gout;
SARC	cis	rs1395	0.744	rs11126932	chr2:27476282	G/A	cg21747090	chr2:27597821	SNX17	-0.46	-5.62	-0.35	5.42e-8	Blood metabolite levels;
SARC	cis	rs6665290	0.935	rs17600627	chr1:227201449	A/G	cg14016676	chr1:227182615	CDC42BPA	0.36	5.2	0.32	4.44e-7	Myeloid white cell count;
SARC	cis	rs12479064	0.724	rs2305352	chr2:100015124	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.65	-7.93	-0.46	9.2e-14	Chronic sinus infection;
SARC	cis	rs986417	0.818	rs7153263	chr14:61099261	G/A	cg27398547	chr14:60952738	C14orf39	0.76	7.3	0.43	4.54e-12	Gut microbiota (bacterial taxa);
SARC	cis	rs1030877	0.889	rs2576746	chr2:105909559	G/A	cg02079111	chr2:105885981	TGFBRAP1	0.63	9.55	0.53	1.89e-18	Obesity-related traits;
SARC	cis	rs10489202	0.633	rs4657734	chr1:168086743	C/T	cg24449463	chr1:168025552	DCAF6	-0.62	-7.95	-0.46	7.93e-14	Schizophrenia;
SARC	cis	rs1957429	0.901	rs2884308	chr14:65350406	A/T	cg23373153	chr14:65346875	NA	-0.93	-8.94	-0.51	1.23e-16	Pediatric areal bone mineral density (radius);
SARC	cis	rs10504229	0.593	rs74760806	chr8:58024785	C/T	cg08280861	chr8:58055591	NA	0.61	5.41	0.33	1.59e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg00990874	chr7:1149470	C7orf50	-0.57	-6.2	-0.38	2.49e-9	Bronchopulmonary dysplasia;
SARC	cis	rs1580019	0.520	rs13228793	chr7:32711465	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.87	11.7	0.61	3.61e-25	Cognitive ability;
SARC	cis	rs12618769	0.597	rs3754892	chr2:99063318	T/A	cg18455616	chr2:99124870	INPP4A	0.43	5.24	0.32	3.54e-7	Bipolar disorder;
SARC	cis	rs73635312	0.850	rs11814404	chr10:8992453	T/C	cg24467326	chr10:9646929	NA	0.59	5.05	0.31	9.02e-7	Basal cell carcinoma;
SARC	trans	rs10085978	0.781	rs13280419	chr8:143225596	G/C	cg12891252	chr10:43902500	HNRNPF	0.51	6.39	0.39	9.11e-10	Mosquito bite size;
SARC	cis	rs7312933	0.558	rs1796388	chr12:42785987	G/C	cg19980929	chr12:42632907	YAF2	-0.45	-6.67	-0.4	1.89e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs1878931	0.697	rs10048148	chr16:3417450	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.93	15.51	0.71	9.28e-38	Body mass index (adult);
SARC	cis	rs57506017	0.540	rs7804433	chr7:12266706	G/A	cg23422036	chr7:12250390	TMEM106B	0.48	6.16	0.37	3.18e-9	Neuroticism;
SARC	cis	rs1865760	0.820	rs9348697	chr6:25890834	C/T	cg17691542	chr6:26056736	HIST1H1C	0.57	7.08	0.42	1.73e-11	Height;
SARC	cis	rs76419734	0.510	rs2216516	chr4:106749857	G/C	cg24545054	chr4:106630052	GSTCD;INTS12	-0.74	-7.55	-0.44	9.63e-13	Post bronchodilator FEV1;
SARC	cis	rs2668423	0.502	rs2074898	chr19:1391361	A/G	cg02639931	chr19:1387894	NDUFS7	-0.49	-9.5	-0.53	2.63e-18	Nonalcoholic fatty liver disease;
SARC	trans	rs7824557	0.564	rs2572389	chr8:11236392	T/C	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.72	-0.5	5.49e-16	Retinal vascular caliber;
SARC	trans	rs61931739	0.534	rs1352206	chr12:34036668	G/A	cg26384229	chr12:38710491	ALG10B	0.75	10.62	0.57	9.96e-22	Morning vs. evening chronotype;
SARC	cis	rs1008375	0.932	rs12500912	chr4:17603318	C/T	cg16339924	chr4:17578868	LAP3	0.64	8.34	0.48	6.37e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2599510	0.755	rs67257914	chr2:32804018	G/A	cg02381751	chr2:32503542	YIPF4	0.44	5.18	0.32	4.77e-7	Interleukin-18 levels;
SARC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg16132339	chr22:24313637	DDTL;DDT	0.38	4.8	0.3	2.9e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs910316	0.967	rs175432	chr14:75615246	C/G	cg11812906	chr14:75593930	NEK9	-0.85	-12.61	-0.64	4.03e-28	Height;
SARC	cis	rs908922	0.676	rs4240887	chr1:152530510	C/T	cg09873164	chr1:152488093	CRCT1	-0.63	-8.16	-0.47	2.08e-14	Hair morphology;
SARC	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg02841227	chr6:26021843	HIST1H4A	-0.46	-5.47	-0.34	1.18e-7	Intelligence (multi-trait analysis);
SARC	cis	rs3812831	0.654	rs367312	chr13:114930195	G/A	cg15896084	chr13:114927664	NA	0.37	5.07	0.32	7.95e-7	Schizophrenia;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg21982490	chr5:124845866	NA	0.47	6.64	0.4	2.13e-10	Thyroid stimulating hormone;
SARC	cis	rs67311347	1.000	rs2276868	chr3:40498845	C/T	cg09455208	chr3:40491958	NA	-0.42	-6.46	-0.39	6.13e-10	Renal cell carcinoma;
SARC	cis	rs4481887	0.861	rs7412034	chr1:248434150	G/C	cg00666640	chr1:248458726	OR2T12	0.29	4.79	0.3	3e-6	Common traits (Other);
SARC	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	6.24	0.38	2.09e-9	Platelet count;
SARC	cis	rs77956314	0.515	rs10850733	chr12:117380961	G/A	cg02017074	chr12:117425053	FBXW8	0.58	7.3	0.43	4.44e-12	Subcortical brain region volumes;Hippocampal volume;
SARC	cis	rs2013441	1.000	rs17686798	chr17:20029170	A/C	cg13482628	chr17:19912719	NA	-0.47	-6.24	-0.38	1.99e-9	Obesity-related traits;
SARC	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	16.47	0.73	6.27e-41	Height;
SARC	cis	rs4423214	0.879	rs736894	chr11:71152258	A/G	cg05163923	chr11:71159392	DHCR7	0.58	6.92	0.41	4.32e-11	Vitamin D levels;
SARC	cis	rs8014204	0.816	rs10083386	chr14:75347585	C/A	cg06637938	chr14:75390232	RPS6KL1	-0.56	-7.9	-0.46	1.13e-13	Caffeine consumption;
SARC	cis	rs9948	0.655	rs17119591	chr2:97435557	G/A	cg15007626	chr2:97405879	LMAN2L	0.72	4.81	0.3	2.72e-6	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs250677	0.522	rs1432798	chr5:148383345	C/G	cg18129178	chr5:148520854	ABLIM3	-0.36	-4.75	-0.3	3.54e-6	Breast cancer;
SARC	cis	rs8053891	1.000	rs8053891	chr16:71997789	A/C	cg16558253	chr16:72132732	DHX38	-0.41	-5.32	-0.33	2.44e-7	Coronary artery disease;
SARC	cis	rs16854884	0.633	rs6779321	chr3:143736676	T/C	cg06585982	chr3:143692056	C3orf58	0.67	9.14	0.51	3.13e-17	Economic and political preferences (feminism/equality);
SARC	cis	rs7582720	1.000	rs72936882	chr2:203794439	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.63	8.2	0.47	1.57e-14	Lymphocyte counts;
SARC	trans	rs9951602	0.541	rs7243702	chr18:76645637	G/A	cg02800362	chr5:177631904	HNRNPAB	0.68	8.44	0.48	3.37e-15	Obesity-related traits;
SARC	trans	rs1814175	0.645	rs1874969	chr11:49826700	G/A	cg03929089	chr4:120376271	NA	-0.83	-12.16	-0.62	1.17e-26	Height;
SARC	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg23262073	chr20:60523788	NA	-0.4	-5.78	-0.35	2.36e-8	Body mass index;
SARC	cis	rs4805272	0.512	rs7260055	chr19:29341599	G/A	cg14983838	chr19:29218262	NA	0.55	5.97	0.36	8.83e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs9790314	0.905	rs4518145	chr3:160950030	T/C	cg03342759	chr3:160939853	NMD3	-0.63	-8.09	-0.47	3.32e-14	Morning vs. evening chronotype;
SARC	cis	rs7712401	0.601	rs30028	chr5:122283269	G/T	cg19412675	chr5:122181750	SNX24	0.39	5.05	0.31	8.82e-7	Mean platelet volume;
SARC	cis	rs10513788	0.855	rs4343618	chr3:182029013	C/T	cg05977900	chr3:182512126	ATP11B	0.46	4.75	0.3	3.56e-6	Cognitive function;
SARC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg05552183	chr6:42928497	GNMT	0.52	7.11	0.42	1.4e-11	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs1881797	0.932	rs41305741	chr1:247689543	A/G	cg11166453	chr1:247681781	NA	0.49	5.47	0.34	1.17e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs864537	0.676	rs2056626	chr1:167420425	T/G	cg09179987	chr1:167433047	CD247	0.4	6.14	0.37	3.47e-9	Celiac disease or Rheumatoid arthritis;Celiac disease;
SARC	cis	rs8028182	0.549	rs10775209	chr15:75634759	G/A	cg20655648	chr15:75932815	IMP3	-0.63	-7.22	-0.43	7.18e-12	Sudden cardiac arrest;
SARC	cis	rs7312933	0.701	rs10880260	chr12:42561398	A/G	cg17420585	chr12:42539391	GXYLT1	-0.34	-4.77	-0.3	3.29e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs60871478	0.947	rs62432255	chr7:804219	G/A	cg19087971	chr7:751233	PRKAR1B	-0.42	-4.85	-0.3	2.26e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg13206674	chr6:150067644	NUP43	0.47	6.12	0.37	3.99e-9	Lung cancer;
SARC	cis	rs9388451	0.839	rs3966775	chr6:126067655	C/A	cg05901451	chr6:126070800	HEY2	-0.69	-9.51	-0.53	2.53e-18	Brugada syndrome;
SARC	cis	rs7113850	0.541	rs56679749	chr11:24235649	G/A	ch.11.24196551F	chr11:24239977	NA	0.72	5.44	0.34	1.36e-7	Bone fracture in osteoporosis;
SARC	cis	rs8017423	0.935	rs11624246	chr14:90734826	A/G	cg20276874	chr14:90721474	PSMC1	0.35	4.83	0.3	2.49e-6	Mortality in heart failure;
SARC	cis	rs7659604	0.702	rs6815790	chr4:122695385	A/C	cg19748678	chr4:122722346	EXOSC9	0.77	10.41	0.56	4.4e-21	Type 2 diabetes;
SARC	cis	rs57994353	0.897	rs3812595	chr9:139369062	C/T	cg14169450	chr9:139327907	INPP5E	0.42	5.38	0.33	1.79e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs8114671	0.836	rs4911461	chr20:33629993	A/C	cg08999081	chr20:33150536	PIGU	-0.34	-4.89	-0.31	1.86e-6	Height;
SARC	cis	rs6456156	0.586	rs13210649	chr6:167473193	T/G	cg23791538	chr6:167370224	RNASET2	-0.51	-6.78	-0.41	1.01e-10	Primary biliary cholangitis;
SARC	cis	rs3733585	0.648	rs7376155	chr4:9952588	C/T	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.39	-0.33	1.76e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg22968622	chr17:43663579	NA	-0.87	-11.07	-0.59	3.65e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs11098499	0.863	rs3775845	chr4:120432447	T/C	cg09307838	chr4:120376055	NA	0.9	12.13	0.62	1.43e-26	Corneal astigmatism;
SARC	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg03060546	chr3:49711283	APEH	0.77	11.27	0.59	8.25e-24	Resting heart rate;
SARC	cis	rs17173637	1.000	rs73165526	chr7:150531275	T/C	cg26935020	chr7:151217007	RHEB	-0.73	-4.83	-0.3	2.45e-6	HDL cholesterol;HDL cholesterol levels;
SARC	cis	rs1580019	0.563	rs764483	chr7:32578150	A/T	cg14728415	chr7:32535168	LSM5;AVL9	0.52	6.5	0.39	4.79e-10	Cognitive ability;
SARC	cis	rs11719291	0.584	rs13080725	chr3:49076092	G/A	cg07636037	chr3:49044803	WDR6	-0.78	-6.72	-0.4	1.37e-10	Cognitive function;
SARC	cis	rs2425143	1.000	rs8124505	chr20:34307247	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.68	5.51	0.34	9.25e-8	Blood protein levels;
SARC	cis	rs76419734	0.850	rs72671879	chr4:106663657	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.76	4.98	0.31	1.23e-6	Post bronchodilator FEV1;
SARC	trans	rs561341	0.883	rs886224	chr17:30229902	T/C	cg20587970	chr11:113659929	NA	-1.05	-9.82	-0.54	2.78e-19	Hip circumference adjusted for BMI;
SARC	cis	rs7662987	0.517	rs1377689	chr4:100021787	A/G	cg12011299	chr4:100065546	ADH4	0.32	5.26	0.33	3.23e-7	Smoking initiation;
SARC	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg24531977	chr5:56204891	C5orf35	-0.54	-5.45	-0.34	1.26e-7	Initial pursuit acceleration;
SARC	cis	rs2836974	0.565	rs2836939	chr21:40578546	C/T	cg11644478	chr21:40555479	PSMG1	0.77	6.77	0.41	1.04e-10	Cognitive function;
SARC	cis	rs7568458	0.684	rs1048739	chr2:85764968	T/G	cg23752985	chr2:85803571	VAMP8	0.45	5.76	0.35	2.64e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs7824557	0.606	rs1435277	chr8:11196970	C/T	cg21775007	chr8:11205619	TDH	0.68	9.04	0.51	6.36e-17	Retinal vascular caliber;
SARC	cis	rs6426558	0.559	rs7549520	chr1:227258858	G/C	cg10327440	chr1:227177885	CDC42BPA	0.41	4.92	0.31	1.64e-6	Neutrophil percentage of white cells;
SARC	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg22834771	chr12:69754056	YEATS4	-0.44	-5.78	-0.35	2.42e-8	Blood protein levels;
SARC	cis	rs1044826	0.642	rs2118981	chr3:139178853	A/G	cg15131784	chr3:139108705	COPB2	0.4	5.03	0.31	1e-6	Obesity-related traits;
SARC	cis	rs548181	0.668	rs579661	chr11:125474766	A/G	cg03464685	chr11:125439445	EI24	1.22	11.01	0.59	5.65e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs1062177	0.855	rs6884630	chr5:151268997	A/T	cg00977110	chr5:151150581	G3BP1	0.53	5.62	0.35	5.3e-8	Preschool internalizing problems;
SARC	cis	rs360798	0.656	rs11125934	chr2:62856099	C/T	cg16915676	chr2:62734870	TMEM17	0.45	5.53	0.34	8.55e-8	Coronary artery disease;
SARC	cis	rs644799	0.965	rs2508713	chr11:95547927	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.7	9.53	0.53	2.16e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg16405210	chr4:1374714	KIAA1530	-0.46	-5.66	-0.35	4.39e-8	Longevity;
SARC	cis	rs17376456	1.000	rs34068652	chr5:93563319	G/A	cg21475434	chr5:93447410	FAM172A	0.94	8.63	0.49	9.56e-16	Diabetic retinopathy;
SARC	cis	rs673253	0.650	rs2819335	chr1:44014825	A/G	cg10881128	chr1:44031826	PTPRF	-0.36	-4.75	-0.3	3.54e-6	Intelligence (multi-trait analysis);
SARC	cis	rs459571	1.000	rs459571	chr9:136912626	C/T	cg13789015	chr9:136890014	NCRNA00094	0.62	8.57	0.49	1.43e-15	Platelet distribution width;
SARC	cis	rs7044106	0.791	rs2900177	chr9:123497645	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	9.69	0.54	7.33e-19	Hip circumference adjusted for BMI;
SARC	cis	rs57561814	1.000	rs6949149	chr7:22749157	G/T	cg01770232	chr7:22766155	IL6	0.63	4.99	0.31	1.18e-6	Tonsillectomy;
SARC	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg04518342	chr5:131593106	PDLIM4	0.42	5.76	0.35	2.64e-8	Acylcarnitine levels;
SARC	cis	rs1448094	0.512	rs6539933	chr12:86247611	T/C	cg02569458	chr12:86230093	RASSF9	0.38	5.39	0.33	1.71e-7	Major depressive disorder;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg14504697	chr2:177190235	MTX2	0.58	8.58	0.49	1.35e-15	Thyroid stimulating hormone;
SARC	cis	rs6580649	0.941	rs12580764	chr12:48453882	G/A	cg24011408	chr12:48396354	COL2A1	-0.48	-5.31	-0.33	2.56e-7	Lung cancer;
SARC	cis	rs2176263	1.000	rs2176263	chr2:24092773	G/C	cg08063864	chr2:24346004	PFN4;LOC375190	-0.48	-6.21	-0.38	2.42e-9	Intelligence (multi-trait analysis);
SARC	cis	rs3820928	0.874	rs10207404	chr2:227794420	T/C	cg11843606	chr2:227700838	RHBDD1	-0.56	-7.12	-0.42	1.33e-11	Pulmonary function;
SARC	cis	rs73157695	1.000	rs11908910	chr21:47332948	C/T	cg00682050	chr21:47343716	PCBP3	-0.43	-5.04	-0.31	9.48e-7	Myopia;
SARC	cis	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg01579765	chr21:45077557	HSF2BP	-0.37	-6.18	-0.38	2.91e-9	Mean corpuscular volume;
SARC	cis	rs1348850	0.634	rs2293471	chr2:178487729	T/G	cg23306229	chr2:178417860	TTC30B	0.61	6.26	0.38	1.85e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7103648	0.669	rs7131262	chr11:47836302	T/A	cg10504702	chr11:47789108	FNBP4	0.77	10.09	0.55	4.38e-20	Diastolic blood pressure;Systolic blood pressure;
SARC	trans	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg00938859	chr5:1591904	SDHAP3	0.76	7.39	0.44	2.55e-12	Breast cancer;
SARC	trans	rs9532669	0.963	rs9532662	chr13:41500351	A/C	cg13688329	chr9:114557390	NA	-0.47	-6.42	-0.39	7.52e-10	Cervical cancer;
SARC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.14	0.37	3.57e-9	Prudent dietary pattern;
SARC	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg02951883	chr7:2050386	MAD1L1	-0.52	-6.73	-0.4	1.34e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs10927875	0.632	rs6677321	chr1:16149301	A/C	cg07117364	chr1:16154769	NA	-0.45	-5.34	-0.33	2.19e-7	Dilated cardiomyopathy;
SARC	cis	rs7666738	0.830	rs11932887	chr4:99072965	C/G	cg05340658	chr4:99064831	C4orf37	0.63	8.43	0.48	3.73e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg04518342	chr5:131593106	PDLIM4	0.35	5.06	0.31	8.48e-7	Breast cancer;
SARC	cis	rs8044995	0.563	rs3785127	chr16:68399590	C/G	cg05110241	chr16:68378359	PRMT7	-0.67	-6.57	-0.4	3.28e-10	Schizophrenia;
SARC	cis	rs244293	0.730	rs12945579	chr17:53022714	A/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.4	-4.87	-0.3	2.05e-6	Menarche (age at onset);
SARC	cis	rs7666738	0.830	rs13138063	chr4:99050438	A/C	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7824557	0.806	rs34171564	chr8:11095346	C/A	cg21775007	chr8:11205619	TDH	-0.44	-5.23	-0.32	3.77e-7	Retinal vascular caliber;
SARC	cis	rs2594989	0.673	rs9854573	chr3:11602577	C/T	cg00170343	chr3:11313890	ATG7	-0.55	-5.55	-0.34	7.69e-8	Circulating chemerin levels;
SARC	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg05872129	chr22:39784769	NA	-0.44	-6.34	-0.38	1.2e-9	Intelligence (multi-trait analysis);
SARC	cis	rs2354432	0.556	rs7516165	chr1:146866418	G/T	cg25205988	chr1:146714368	CHD1L	0.95	7.05	0.42	2.04e-11	Mitochondrial DNA levels;
SARC	cis	rs9303401	0.659	rs7216648	chr17:56790858	C/T	cg25039879	chr17:56429692	SUPT4H1	0.68	6.4	0.39	8.57e-10	Cognitive test performance;
SARC	cis	rs6831352	0.918	rs29001194	chr4:100054844	A/G	cg12011299	chr4:100065546	ADH4	-0.34	-5.74	-0.35	2.95e-8	Alcohol dependence;
SARC	cis	rs4243830	0.522	rs10157142	chr1:6618785	A/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.89	-8.07	-0.47	3.74e-14	Body mass index;
SARC	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.95	-13.94	-0.67	1.6e-32	Gut microbiome composition (summer);
SARC	cis	rs1707322	1.000	rs785478	chr1:46491635	C/T	cg06784218	chr1:46089804	CCDC17	-0.36	-6.31	-0.38	1.41e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9660992	0.626	rs61823972	chr1:205201325	A/C	cg21643547	chr1:205240462	TMCC2	-0.55	-7.15	-0.42	1.12e-11	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs4727027	0.933	rs1044358	chr7:148879951	C/A	cg23583168	chr7:148888333	NA	-0.73	-10.76	-0.58	3.53e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs981844	0.857	rs72731698	chr4:154716353	T/C	cg14289246	chr4:154710475	SFRP2	0.66	7.04	0.42	2.15e-11	Response to statins (LDL cholesterol change);
SARC	cis	rs79149102	0.579	rs7181942	chr15:75300623	G/C	cg00629941	chr15:75287862	SCAMP5	-0.65	-5.26	-0.33	3.2e-7	Lung cancer;
SARC	cis	rs11155671	0.530	rs4869763	chr6:150211684	T/C	cg00933542	chr6:150070202	PCMT1	0.29	4.81	0.3	2.77e-6	Testicular germ cell tumor;
SARC	cis	rs3820928	0.874	rs3769646	chr2:227896330	C/T	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.76	-0.35	2.69e-8	Pulmonary function;
SARC	cis	rs1941023	0.584	rs6591578	chr11:60158649	G/A	cg08716584	chr11:60157161	MS4A7	-0.38	-6.04	-0.37	5.97e-9	Congenital heart disease (maternal effect);
SARC	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg05368731	chr17:41323189	NBR1	0.8	9.59	0.53	1.43e-18	Menopause (age at onset);
SARC	trans	rs1994135	0.669	rs11052747	chr12:33697913	C/G	cg13010199	chr12:38710504	ALG10B	0.62	7.33	0.43	3.66e-12	Resting heart rate;
SARC	cis	rs6971211	0.655	rs754469	chr7:155671277	G/A	cg14601210	chr7:155671264	NA	-0.25	-4.77	-0.3	3.19e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs7507204	0.530	rs4807470	chr19:3443470	A/T	cg08380311	chr19:3435252	NFIC	0.45	5.54	0.34	8.35e-8	Height;
SARC	cis	rs875971	0.545	rs1796219	chr7:66110964	A/G	cg11764359	chr7:65958608	NA	-0.55	-5.06	-0.31	8.69e-7	Aortic root size;
SARC	trans	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.65	8.65	0.49	8.46e-16	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs11785400	0.793	rs4736364	chr8:143742113	C/T	cg10596483	chr8:143751796	JRK	0.58	7.47	0.44	1.61e-12	Schizophrenia;
SARC	cis	rs2594989	0.779	rs56053623	chr3:11592153	T/C	cg00170343	chr3:11313890	ATG7	-0.54	-5.88	-0.36	1.45e-8	Circulating chemerin levels;
SARC	cis	rs7937682	0.889	rs497111	chr11:111499512	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.92	-14.73	-0.69	3.72e-35	Primary sclerosing cholangitis;
SARC	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg18876405	chr7:65276391	NA	-0.46	-5.04	-0.31	9.38e-7	Aortic root size;
SARC	cis	rs7662987	0.540	rs2851278	chr4:100021253	G/C	cg12011299	chr4:100065546	ADH4	0.32	5.26	0.33	3.23e-7	Smoking initiation;
SARC	cis	rs7481584	0.624	rs12417389	chr11:3035304	G/C	cg08508325	chr11:3079039	CARS	0.24	5.46	0.34	1.25e-7	Calcium levels;
SARC	cis	rs5769765	0.865	rs10854860	chr22:50320029	G/T	cg03033257	chr22:50311977	ALG12;CRELD2	0.48	4.71	0.3	4.18e-6	Schizophrenia;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg18468176	chr14:95623969	FLJ45244;DICER1	-0.8	-6.58	-0.4	3.05e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs11792861	0.890	rs2900481	chr9:111831825	G/A	cg13535736	chr9:111863775	C9orf5	-0.4	-5.03	-0.31	9.92e-7	Menarche (age at onset);
SARC	cis	rs2228479	0.850	rs11641147	chr16:89813589	C/T	cg06558623	chr16:89946397	TCF25	0.91	6.4	0.39	8.49e-10	Skin colour saturation;
SARC	cis	rs2043112	0.691	rs13165383	chr5:39089342	G/A	cg04869206	chr5:39074266	RICTOR	0.51	6.35	0.38	1.12e-9	Obesity-related traits;
SARC	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg11608241	chr8:8085544	FLJ10661	0.44	5.29	0.33	2.81e-7	Neuroticism;
SARC	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg07414643	chr4:187882934	NA	0.5	7.62	0.45	6.22e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4478037	0.822	rs9883177	chr3:33123354	T/C	cg19404215	chr3:33155277	CRTAP	0.53	4.74	0.3	3.69e-6	Major depressive disorder;
SARC	cis	rs11190604	1.000	rs4917901	chr10:102201773	A/C	cg07080220	chr10:102295463	HIF1AN	0.77	9.5	0.53	2.71e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg13395646	chr4:1353034	KIAA1530	-0.43	-5.05	-0.31	8.95e-7	Obesity-related traits;
SARC	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg18876405	chr7:65276391	NA	0.42	4.93	0.31	1.53e-6	Aortic root size;
SARC	cis	rs4243830	0.826	rs12565181	chr1:6620545	G/A	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.62	-4.77	-0.3	3.28e-6	Body mass index;
SARC	cis	rs4988958	0.527	rs3771155	chr2:103037826	A/G	cg03938978	chr2:103052716	IL18RAP	0.32	5.12	0.32	6.49e-7	Asthma (childhood onset);
SARC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg20007245	chr22:24372913	LOC391322	-0.61	-7.36	-0.43	3.07e-12	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9325144	0.647	rs61937754	chr12:39060543	T/C	cg26384229	chr12:38710491	ALG10B	-0.61	-7.9	-0.46	1.09e-13	Morning vs. evening chronotype;
SARC	cis	rs933688	0.532	rs12514092	chr5:90540522	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.46	-5.31	-0.33	2.5e-7	Smoking behavior;
SARC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg24846343	chr22:24311635	DDTL	0.51	6.99	0.42	2.85e-11	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7617773	0.780	rs11714944	chr3:48366971	C/A	cg11946769	chr3:48343235	NME6	0.77	9.81	0.54	2.97e-19	Coronary artery disease;
SARC	cis	rs6723226	0.721	rs3769600	chr2:32616879	G/A	cg02381751	chr2:32503542	YIPF4	-0.62	-8.12	-0.47	2.7e-14	Intelligence (multi-trait analysis);
SARC	cis	rs735396	1.000	rs1169311	chr12:121440731	C/T	cg15155738	chr12:121454335	C12orf43	0.5	6.09	0.37	4.73e-9	N-glycan levels;
SARC	trans	rs12310956	0.527	rs1608910	chr12:33895414	T/C	cg26384229	chr12:38710491	ALG10B	0.69	9.44	0.53	4.15e-18	Morning vs. evening chronotype;
SARC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg06873352	chr17:61820015	STRADA	0.5	6.56	0.39	3.46e-10	Prudent dietary pattern;
SARC	cis	rs5753618	0.504	rs9606846	chr22:31897571	C/T	cg02404636	chr22:31891804	SFI1	0.49	5.1	0.32	7.1e-7	Colorectal cancer;
SARC	cis	rs62191099	0.885	rs6741318	chr2:239862727	G/T	cg07215236	chr2:239865226	NA	0.36	4.81	0.3	2.74e-6	Alcohol dependence;
SARC	cis	rs2180341	0.960	rs7773484	chr6:127670779	T/C	cg24812749	chr6:127587940	RNF146	1.01	13.21	0.65	4.13e-30	Breast cancer;
SARC	cis	rs9322193	0.607	rs6925151	chr6:150210723	C/T	cg09699651	chr6:150184138	LRP11	0.44	4.89	0.31	1.88e-6	Lung cancer;
SARC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg15383120	chr6:291909	DUSP22	-0.61	-8.02	-0.47	5.26e-14	Menopause (age at onset);
SARC	cis	rs6580649	0.941	rs60681522	chr12:48464195	T/C	cg24011408	chr12:48396354	COL2A1	-0.48	-5.38	-0.33	1.78e-7	Lung cancer;
SARC	cis	rs66573146	0.572	rs67750430	chr4:6957266	T/G	cg26116260	chr4:7069785	GRPEL1	-0.68	-5.02	-0.31	1.05e-6	Granulocyte percentage of myeloid white cells;
SARC	cis	rs910316	0.967	rs4899551	chr14:75660246	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.46	-6.26	-0.38	1.83e-9	Height;
SARC	cis	rs2486288	0.656	rs2413768	chr15:45561984	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.49	-6.1	-0.37	4.39e-9	Glomerular filtration rate;
SARC	cis	rs7103648	0.897	rs35032070	chr11:47408592	G/A	cg10504702	chr11:47789108	FNBP4	0.54	6.49	0.39	5.21e-10	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs56161922	0.908	rs78159416	chr1:207820375	C/A	cg11752769	chr1:207818423	CR1L	-0.58	-4.72	-0.3	3.99e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
SARC	cis	rs453301	0.624	rs2915251	chr8:8867411	G/C	cg06636001	chr8:8085503	FLJ10661	0.37	4.8	0.3	2.78e-6	Joint mobility (Beighton score);
SARC	cis	rs7597155	0.935	rs4852988	chr2:69978290	A/C	cg02498382	chr2:70120550	SNRNP27	-0.33	-5.51	-0.34	9.41e-8	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg22920501	chr2:26401640	FAM59B	0.49	6.45	0.39	6.47e-10	Gut microbiome composition (summer);
SARC	cis	rs17376456	0.825	rs67328989	chr5:93243133	T/A	cg21475434	chr5:93447410	FAM172A	0.86	7.67	0.45	4.52e-13	Diabetic retinopathy;
SARC	cis	rs10088262	0.629	rs7827665	chr8:124804190	G/A	cg02993010	chr8:124780839	FAM91A1	-0.77	-9.15	-0.51	2.98e-17	Pancreatic cancer;
SARC	cis	rs35160687	0.901	rs11127026	chr2:86531748	C/T	cg10973622	chr2:86423274	IMMT	0.38	4.9	0.31	1.77e-6	Night sleep phenotypes;
SARC	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg27266027	chr21:40555129	PSMG1	0.48	5.18	0.32	4.79e-7	Cognitive function;
SARC	cis	rs3020736	0.500	rs6002616	chr22:42504679	A/G	cg15557168	chr22:42548783	NA	0.36	4.94	0.31	1.51e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1401999	1.000	rs939337	chr3:183701147	G/C	cg01324343	chr3:183735012	ABCC5	0.67	13.33	0.66	1.72e-30	Anterior chamber depth;
SARC	cis	rs11155671	0.530	rs7774787	chr6:150209432	G/A	cg09699651	chr6:150184138	LRP11	0.52	6.59	0.4	2.86e-10	Testicular germ cell tumor;
SARC	cis	rs80130819	0.748	rs1387255	chr12:48648943	C/T	cg24011408	chr12:48396354	COL2A1	0.53	5.69	0.35	3.71e-8	Prostate cancer;
SARC	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg17376030	chr22:41985996	PMM1	-0.68	-8.73	-0.5	5.08e-16	Vitiligo;
SARC	cis	rs698833	0.962	rs698832	chr2:44734823	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.67	-8.48	-0.49	2.62e-15	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg20607798	chr8:58055168	NA	0.68	5.89	0.36	1.33e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2204008	0.754	rs11514074	chr12:38401128	C/T	cg13010199	chr12:38710504	ALG10B	0.79	10.56	0.57	1.5e-21	Bladder cancer;
SARC	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-5.68	-0.35	4.08e-8	Bipolar disorder;
SARC	cis	rs950169	0.922	rs12915832	chr15:85111457	C/T	cg24253500	chr15:84953950	NA	0.37	5.33	0.33	2.35e-7	Schizophrenia;
SARC	cis	rs9818758	0.607	rs9862483	chr3:49195441	G/A	cg00383909	chr3:49044727	WDR6	0.72	6.27	0.38	1.73e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs722599	0.683	rs11848876	chr14:75224626	C/G	cg06637938	chr14:75390232	RPS6KL1	0.43	5.33	0.33	2.32e-7	IgG glycosylation;
SARC	cis	rs8067545	0.641	rs397969	chr17:19804247	T/C	cg13482628	chr17:19912719	NA	0.52	6.56	0.4	3.37e-10	Schizophrenia;
SARC	cis	rs2439831	0.850	rs2439832	chr15:43779686	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.81	7.99	0.46	6.25e-14	Lung cancer in ever smokers;
SARC	cis	rs67460515	0.892	rs11710489	chr3:161093332	G/A	cg03342759	chr3:160939853	NMD3	-0.64	-7.88	-0.46	1.22e-13	Parkinson's disease;
SARC	cis	rs73242632	1.000	rs56798906	chr4:57875725	A/G	cg20415529	chr4:57845134	POLR2B;C4orf14	1.07	6.6	0.4	2.74e-10	Congenital heart disease (maternal effect);
SARC	cis	rs12545912	0.909	rs10903315	chr8:9483921	G/A	cg21625330	chr8:9911636	MSRA	0.53	5.03	0.31	9.73e-7	Multiple myeloma (hyperdiploidy);
SARC	cis	rs854765	0.583	rs4413022	chr17:17858280	G/C	cg05444541	chr17:17804740	TOM1L2	-0.29	-4.82	-0.3	2.56e-6	Total body bone mineral density;
SARC	cis	rs2153535	0.580	rs1832101	chr6:8460177	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	10.61	0.57	1.01e-21	Motion sickness;
SARC	cis	rs826838	0.585	rs12296822	chr12:38625829	A/T	cg26384229	chr12:38710491	ALG10B	-0.59	-7.54	-0.44	1.04e-12	Heart rate;
SARC	cis	rs7808935	0.914	rs67746093	chr7:27985524	C/G	cg05786569	chr7:27702416	HIBADH	0.55	5.64	0.35	4.82e-8	Prostate cancer;
SARC	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg08109568	chr15:31115862	NA	0.55	7.03	0.42	2.31e-11	Huntington's disease progression;
SARC	cis	rs965469	1.000	rs2236089	chr20:3257194	C/A	cg25506879	chr20:3388711	C20orf194	-0.5	-5.11	-0.32	6.73e-7	IFN-related cytopenia;
SARC	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg23262073	chr20:60523788	NA	-0.43	-5.98	-0.36	8.29e-9	Body mass index;
SARC	trans	rs11098499	0.863	rs12508173	chr4:120318526	T/C	cg25214090	chr10:38739885	LOC399744	0.57	7.43	0.44	2.01e-12	Corneal astigmatism;
SARC	cis	rs6570726	1.000	rs1935617	chr6:145943326	C/T	cg05347473	chr6:146136440	FBXO30	0.45	6.02	0.37	6.69e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6991838	0.733	rs7822627	chr8:66626374	C/A	cg13398993	chr8:66546079	ARMC1	0.43	5.6	0.34	6.03e-8	Intelligence (multi-trait analysis);
SARC	trans	rs61931739	0.500	rs11053242	chr12:34511625	A/G	cg13010199	chr12:38710504	ALG10B	0.76	10.85	0.58	1.77e-22	Morning vs. evening chronotype;
SARC	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg05890377	chr2:74357713	NA	0.56	6.87	0.41	5.9e-11	Gestational age at birth (maternal effect);
SARC	cis	rs8068544	0.818	rs7209012	chr17:40161323	C/T	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.06	-8.41	-0.48	4.15e-15	Reticulocyte fraction of red cells;Reticulocyte count;
SARC	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg03433033	chr1:76189801	ACADM	0.41	5.73	0.35	3.11e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg12575583	chr6:43484804	POLR1C;YIPF3	0.8	6.7	0.4	1.51e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.97	-15.81	-0.72	9.26e-39	Chronic sinus infection;
SARC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.44	-5.53	-0.34	8.37e-8	Longevity;Endometriosis;
SARC	cis	rs7412746	0.611	rs11204726	chr1:150743492	T/C	cg15448220	chr1:150897856	SETDB1	0.48	6.25	0.38	1.99e-9	Melanoma;
SARC	cis	rs73198271	0.562	rs76702427	chr8:8660141	G/T	cg01851573	chr8:8652454	MFHAS1	0.46	5.72	0.35	3.33e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	trans	rs9929218	0.906	rs4783565	chr16:68750190	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.65	-8.41	-0.48	4.06e-15	Colorectal cancer;
SARC	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg09359103	chr1:154839909	KCNN3	-0.46	-7.8	-0.46	2e-13	Prostate cancer;
SARC	cis	rs17376456	0.877	rs10476599	chr5:93383423	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.86	0.36	1.59e-8	Diabetic retinopathy;
SARC	cis	rs9715521	0.712	rs58171535	chr4:59847742	T/A	cg11281224	chr4:60001000	NA	-0.4	-5.11	-0.32	6.65e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs4805272	0.626	rs12610050	chr19:29331324	A/T	cg04546413	chr19:29218101	NA	0.5	6.19	0.38	2.74e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	trans	rs9329221	0.905	rs4841329	chr8:10253098	A/G	cg06636001	chr8:8085503	FLJ10661	-0.69	-9.44	-0.53	4.08e-18	Neuroticism;
SARC	cis	rs7264396	0.635	rs6060681	chr20:34506147	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-7.74	-0.45	3.08e-13	Total cholesterol levels;
SARC	cis	rs3617	0.598	rs56214994	chr3:52878600	G/C	cg18404041	chr3:52824283	ITIH1	0.36	5.32	0.33	2.37e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs116095464	0.558	rs10059907	chr5:205360	G/C	cg22857025	chr5:266934	NA	-1.13	-10.64	-0.57	8.44e-22	Breast cancer;
SARC	cis	rs11586313	1.000	rs11586313	chr1:152890470	C/T	cg07796016	chr1:152779584	LCE1C	-0.35	-4.74	-0.3	3.72e-6	Vitamin D levels;
SARC	cis	rs2228479	0.850	rs11641147	chr16:89813589	C/T	cg00800038	chr16:89945340	TCF25	-0.74	-5.1	-0.32	7.19e-7	Skin colour saturation;
SARC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg09436375	chr6:42928200	GNMT	-0.35	-5.39	-0.33	1.72e-7	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg17376030	chr22:41985996	PMM1	0.77	9.57	0.53	1.66e-18	Vitiligo;
SARC	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg22535103	chr8:58192502	C8orf71	-0.73	-7.24	-0.43	6.52e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs9487051	0.676	rs13210693	chr6:109598964	A/G	cg01475377	chr6:109611718	NA	0.36	5.23	0.32	3.73e-7	Reticulocyte fraction of red cells;
SARC	cis	rs8067354	0.645	rs2271304	chr17:57814641	A/G	cg02344993	chr17:57696989	CLTC	0.65	6.24	0.38	2.02e-9	Hemoglobin concentration;
SARC	cis	rs8031584	0.958	rs7176569	chr15:31244495	G/T	cg08109568	chr15:31115862	NA	0.44	5.52	0.34	8.83e-8	Huntington's disease progression;
SARC	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg08219700	chr8:58056026	NA	0.46	4.96	0.31	1.34e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs17270561	0.609	rs9366629	chr6:25741216	G/A	cg17691542	chr6:26056736	HIST1H1C	0.61	7.36	0.43	3.06e-12	Iron status biomarkers;
SARC	cis	rs7772486	0.790	rs2265469	chr6:146219049	T/C	cg23711669	chr6:146136114	FBXO30	0.8	12.59	0.64	4.55e-28	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs1853207	1.000	rs17110314	chr10:96633434	G/A	cg02737782	chr1:8014393	NA	-0.97	-6.42	-0.39	7.44e-10	Blood metabolite levels;
SARC	cis	rs3857536	0.842	rs2188590	chr6:66939534	A/G	cg07460842	chr6:66804631	NA	-0.51	-5.83	-0.36	1.86e-8	Blood trace element (Cu levels);
SARC	cis	rs7843479	0.601	rs10453141	chr8:21847235	T/C	cg17168535	chr8:21777572	XPO7	0.86	13.4	0.66	9.6e-31	Mean corpuscular volume;
SARC	cis	rs9549260	1.000	rs9549260	chr13:41254104	G/T	cg21288729	chr13:41239152	FOXO1	0.52	6.02	0.37	6.82e-9	Red blood cell count;
SARC	cis	rs9325144	0.555	rs1973292	chr12:38679626	T/C	cg04568710	chr12:38710424	ALG10B	0.38	4.74	0.3	3.69e-6	Morning vs. evening chronotype;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg01769037	chr6:15246613	JARID2	0.52	6.69	0.4	1.61e-10	Electrocardiographic conduction measures;
SARC	cis	rs6831352	0.918	rs2602894	chr4:100045647	A/G	cg13256891	chr4:100009986	ADH5	0.66	8.4	0.48	4.51e-15	Alcohol dependence;
SARC	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg02725872	chr8:58115012	NA	-0.36	-5.52	-0.34	9.21e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9388451	0.657	rs4895799	chr6:126052729	C/T	cg05901451	chr6:126070800	HEY2	-0.51	-6.37	-0.38	1.02e-9	Brugada syndrome;
SARC	cis	rs2832191	0.935	rs11910475	chr21:30519702	T/C	cg08807101	chr21:30365312	RNF160	-0.75	-10.21	-0.56	1.8e-20	Dental caries;
SARC	cis	rs7208859	0.673	rs9915139	chr17:29158515	A/G	cg13385521	chr17:29058706	SUZ12P	0.85	7.63	0.45	6.15e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs11574514	1.000	rs73591936	chr16:67761825	G/A	cg01866162	chr16:67596514	CTCF	0.82	5.13	0.32	6e-7	Crohn's disease;
SARC	cis	rs8067545	0.611	rs4925090	chr17:20066631	C/T	cg13482628	chr17:19912719	NA	0.55	7.18	0.43	9.03e-12	Schizophrenia;
SARC	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg05861140	chr6:150128134	PCMT1	-0.42	-5.44	-0.34	1.32e-7	Lung cancer;
SARC	cis	rs11190604	1.000	rs2495736	chr10:102338410	T/C	cg07080220	chr10:102295463	HIF1AN	0.79	9.06	0.51	5.47e-17	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs7833986	1.000	rs66796428	chr8:57094797	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.6	5.33	0.33	2.36e-7	Height;
SARC	cis	rs62244186	0.748	rs4682987	chr3:44674996	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.46	5.76	0.35	2.63e-8	Depressive symptoms;
SARC	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg16479474	chr6:28041457	NA	0.37	5.44	0.34	1.37e-7	Depression;
SARC	cis	rs6121246	0.559	rs10439608	chr20:30258814	T/C	cg13852791	chr20:30311386	BCL2L1	0.88	10.92	0.58	1.1e-22	Mean corpuscular hemoglobin;
SARC	cis	rs3733585	0.673	rs7377578	chr4:9952775	T/C	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.94	-0.36	1.06e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs4803468	1.000	rs284654	chr19:41928724	G/A	cg14132834	chr19:41945861	ATP5SL	-0.58	-7.59	-0.45	7.51e-13	Height;
SARC	cis	rs9381040	0.655	rs7775972	chr6:41038116	A/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.42	-4.81	-0.3	2.69e-6	Alzheimer's disease (late onset);
SARC	cis	rs7223966	1.000	rs6504182	chr17:61823672	T/C	cg26338869	chr17:61819248	STRADA	0.43	4.94	0.31	1.46e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7264396	0.563	rs2050729	chr20:34294409	A/G	cg01084648	chr20:34329383	RBM39	-0.57	-4.98	-0.31	1.21e-6	Total cholesterol levels;
SARC	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.78	11.63	0.61	6.08e-25	Personality dimensions;
SARC	cis	rs9611519	0.580	rs7286603	chr22:41440061	T/C	cg17376030	chr22:41985996	PMM1	0.44	5.63	0.35	5.24e-8	Neuroticism;
SARC	cis	rs17270561	0.609	rs2154218	chr6:25776290	T/C	cg17691542	chr6:26056736	HIST1H1C	0.57	6.95	0.41	3.7e-11	Iron status biomarkers;
SARC	cis	rs9457247	1.000	rs444988	chr6:167389674	A/T	cg07741184	chr6:167504864	NA	0.3	5.62	0.35	5.47e-8	Crohn's disease;
SARC	cis	rs1008375	0.932	rs2302391	chr4:17660237	T/C	cg27347728	chr4:17578864	LAP3	0.46	5.78	0.35	2.44e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4660306	1.000	rs7534467	chr1:45988691	G/A	cg24296786	chr1:45957014	TESK2	0.58	6.79	0.41	9.22e-11	Homocysteine levels;
SARC	cis	rs6964587	1.000	rs6952671	chr7:91597934	C/A	cg17063962	chr7:91808500	NA	0.95	15.95	0.72	3.15e-39	Breast cancer;
SARC	cis	rs7044106	0.734	rs1981020	chr9:123388464	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	8.99	0.51	8.91e-17	Hip circumference adjusted for BMI;
SARC	cis	rs7264396	0.790	rs6060541	chr20:34248066	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	5.91	0.36	1.21e-8	Total cholesterol levels;
SARC	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.55	-6.93	-0.41	4.13e-11	Chronic sinus infection;
SARC	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg13877915	chr19:58951672	ZNF132	0.66	9.97	0.55	1.02e-19	Uric acid clearance;
SARC	cis	rs921968	0.643	rs596076	chr2:219451015	T/G	cg02176678	chr2:219576539	TTLL4	0.36	5.27	0.33	3.05e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs7264396	0.635	rs6058365	chr20:34508092	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-7.41	-0.44	2.33e-12	Total cholesterol levels;
SARC	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.76	11.14	0.59	2.19e-23	Personality dimensions;
SARC	cis	rs4555082	0.834	rs2735825	chr14:105710900	G/A	cg10792982	chr14:105748885	BRF1	0.55	8.22	0.47	1.46e-14	Mean platelet volume;Platelet distribution width;
SARC	cis	rs559928	0.606	rs12417635	chr11:63912728	C/T	cg05555928	chr11:63887634	MACROD1	-0.51	-4.85	-0.3	2.26e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs7208859	0.673	rs61348930	chr17:29221763	C/T	cg13385521	chr17:29058706	SUZ12P	0.85	7.23	0.43	7.08e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs1707322	1.000	rs10789479	chr1:46352500	T/C	cg03146154	chr1:46216737	IPP	0.5	6.14	0.37	3.5e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg24324837	chr19:49891574	CCDC155	0.43	5.26	0.33	3.3e-7	Multiple sclerosis;
SARC	cis	rs12145833	1.000	rs12145004	chr1:243483365	T/G	cg02356786	chr1:243265016	LOC731275	0.73	5.94	0.36	1.02e-8	Obesity (early onset extreme);
SARC	cis	rs2380220	0.574	rs9400526	chr6:95998441	T/C	cg04719120	chr6:96025338	MANEA	0.54	6.06	0.37	5.45e-9	Behavioural disinhibition (generation interaction);
SARC	cis	rs941408	1.000	rs1076447	chr19:2792128	C/G	cg06609049	chr19:2785107	THOP1	0.82	10.51	0.57	2.2e-21	Total cholesterol levels;
SARC	cis	rs262150	0.574	rs2730272	chr7:158798622	G/C	cg09640425	chr7:158790006	NA	-0.4	-5.63	-0.35	5.09e-8	Facial morphology (factor 20);
SARC	cis	rs7615952	0.641	rs7632497	chr3:125783086	A/C	cg05084668	chr3:125655381	ALG1L	-0.47	-4.89	-0.31	1.88e-6	Blood pressure (smoking interaction);
SARC	cis	rs13427251	0.692	rs17765112	chr2:100149336	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-6.28	-0.38	1.67e-9	Chronic sinus infection;
SARC	cis	rs637571	0.780	rs677029	chr11:65683531	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.47	6.84	0.41	6.99e-11	Eosinophil percentage of white cells;
SARC	cis	rs2153535	0.580	rs9379216	chr6:8481235	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	8.24	0.48	1.24e-14	Motion sickness;
SARC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg22535103	chr8:58192502	C8orf71	-0.59	-6.21	-0.38	2.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9398803	0.713	rs9401891	chr6:126894135	G/T	cg20229609	chr6:126660872	C6orf173	0.37	5.4	0.33	1.67e-7	Male-pattern baldness;
SARC	cis	rs7255436	0.965	rs11666003	chr19:8452102	G/A	cg10174797	chr19:8464628	RAB11B	0.45	6.44	0.39	6.84e-10	HDL cholesterol;
SARC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg06873352	chr17:61820015	STRADA	0.53	6.85	0.41	6.67e-11	Prudent dietary pattern;
SARC	cis	rs763121	0.853	rs5995610	chr22:39064681	C/T	cg06022373	chr22:39101656	GTPBP1	0.87	10.87	0.58	1.61e-22	Menopause (age at onset);
SARC	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.44	4.93	0.31	1.56e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg11987759	chr7:65425863	GUSB	-0.47	-6.27	-0.38	1.7e-9	Aortic root size;
SARC	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg11987759	chr7:65425863	GUSB	0.49	6.06	0.37	5.48e-9	Aortic root size;
SARC	cis	rs4243830	0.850	rs7536908	chr1:6607814	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.82	-7.93	-0.46	9.37e-14	Body mass index;
SARC	cis	rs4689388	0.890	rs6838400	chr4:6295427	C/G	cg25554036	chr4:6271136	WFS1	0.39	6.42	0.39	7.48e-10	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg05313129	chr8:58192883	C8orf71	-0.51	-4.95	-0.31	1.42e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg11987759	chr7:65425863	GUSB	-0.48	-6.04	-0.37	5.99e-9	Aortic root size;
SARC	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg13206674	chr6:150067644	NUP43	0.44	5.68	0.35	4e-8	Lung cancer;
SARC	cis	rs72945132	0.882	rs7929271	chr11:70165749	A/G	cg05964544	chr11:70165517	PPFIA1	-0.61	-5.87	-0.36	1.5e-8	Coronary artery disease;
SARC	cis	rs9332653	0.569	rs12120904	chr1:169478042	T/C	cg02837999	chr1:169338281	NME7;BLZF1	0.71	5.11	0.32	6.63e-7	Blood protein levels;
SARC	cis	rs710216	0.917	rs4660691	chr1:43417150	T/G	cg07803811	chr1:43423981	SLC2A1	-0.55	-5.66	-0.35	4.41e-8	Red cell distribution width;
SARC	cis	rs7647973	1.000	rs6446262	chr3:49401153	T/C	cg07636037	chr3:49044803	WDR6	0.74	7.53	0.44	1.08e-12	Menarche (age at onset);
SARC	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.46	-5.77	-0.35	2.56e-8	Personality dimensions;
SARC	cis	rs3768617	0.510	rs10911242	chr1:183072147	C/T	cg13390022	chr1:182993471	LAMC1	0.33	4.91	0.31	1.68e-6	Fuchs's corneal dystrophy;
SARC	cis	rs7729447	0.813	rs7715779	chr5:32690199	T/G	cg16267343	chr5:32710456	NPR3	0.64	8.46	0.48	2.96e-15	Blood pressure;
SARC	cis	rs2070488	0.736	rs2070988	chr3:38437835	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.59	7.72	0.45	3.52e-13	Electrocardiographic conduction measures;
SARC	cis	rs9309473	1.000	rs58603761	chr2:73726605	A/G	cg20560298	chr2:73613845	ALMS1	-0.49	-5.93	-0.36	1.07e-8	Metabolite levels;
SARC	cis	rs2306786	0.558	rs11852359	chr15:59498881	A/C	cg23054309	chr15:59226205	SLTM	-0.71	-5.01	-0.31	1.06e-6	Metabolite levels;
SARC	cis	rs2204008	0.630	rs7314669	chr12:38203602	G/A	cg13010199	chr12:38710504	ALG10B	-0.61	-7.52	-0.44	1.15e-12	Bladder cancer;
SARC	cis	rs607987	0.836	rs7108615	chr11:30297809	T/C	cg06241208	chr11:30344200	C11orf46	0.41	5.08	0.32	7.85e-7	Body mass index;
SARC	cis	rs10982256	0.817	rs10817628	chr9:117259538	A/C	cg21159778	chr9:117266918	DFNB31	0.37	5.07	0.32	7.97e-7	Bipolar disorder;
SARC	cis	rs116095464	0.558	rs9654453	chr5:299621	T/C	cg22496380	chr5:211416	CCDC127	-0.93	-8.37	-0.48	5.29e-15	Breast cancer;
SARC	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg13939156	chr17:80058883	NA	0.37	5.65	0.35	4.6e-8	Life satisfaction;
SARC	cis	rs5762813	0.566	rs16987027	chr22:29215703	G/A	cg15103426	chr22:29168792	CCDC117	0.64	6.32	0.38	1.35e-9	Hematocrit;Hemoglobin concentration;
SARC	cis	rs2115630	0.645	rs3825878	chr15:85174755	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.52	-6.25	-0.38	1.91e-9	P wave terminal force;
SARC	cis	rs2273669	0.915	rs7753554	chr6:109292133	G/C	cg01304950	chr6:109416612	SESN1;C6orf182	0.54	4.74	0.3	3.75e-6	Prostate cancer;
SARC	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg21226059	chr5:178986404	RUFY1	0.35	4.92	0.31	1.65e-6	Lung cancer;
SARC	cis	rs9911578	0.935	rs2302189	chr17:56584205	A/C	cg12560992	chr17:57184187	TRIM37	-0.82	-10.96	-0.58	8.42e-23	Intelligence (multi-trait analysis);
SARC	cis	rs5753618	0.583	rs9606839	chr22:31802710	A/C	cg07713946	chr22:31675144	LIMK2	0.36	4.92	0.31	1.63e-6	Colorectal cancer;
SARC	cis	rs2645694	0.626	rs2645705	chr4:77830434	G/A	cg10057126	chr4:77819792	ANKRD56	0.37	5.59	0.34	6.31e-8	Emphysema distribution in smoking;
SARC	cis	rs1707322	0.721	rs10890337	chr1:46124527	C/T	cg03146154	chr1:46216737	IPP	0.52	6.32	0.38	1.33e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9916302	0.706	rs8078599	chr17:37518660	C/T	cg07936489	chr17:37558343	FBXL20	0.75	8.83	0.5	2.56e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs1003719	0.788	rs9977602	chr21:38450650	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.67	9.66	0.53	8.81e-19	Eye color traits;
SARC	cis	rs7772486	0.686	rs4896828	chr6:145953339	A/C	cg05347473	chr6:146136440	FBXO30	0.5	7.1	0.42	1.48e-11	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg05764960	chr4:119631674	METTL14	0.49	6.62	0.4	2.42e-10	Thyroid stimulating hormone;
SARC	cis	rs57506017	0.606	rs3807866	chr7:12250378	G/A	cg23422036	chr7:12250390	TMEM106B	0.49	6.26	0.38	1.81e-9	Neuroticism;
SARC	cis	rs4727027	0.901	rs4727017	chr7:148822062	A/G	cg23583168	chr7:148888333	NA	-0.74	-11.16	-0.59	1.9e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg11211951	chr8:145729740	GPT	-0.48	-6.93	-0.41	3.97e-11	Age at first birth;
SARC	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg13770153	chr20:60521292	NA	-0.47	-6.2	-0.38	2.5e-9	Body mass index;
SARC	cis	rs9309473	0.519	rs2421584	chr2:73898852	G/A	cg20560298	chr2:73613845	ALMS1	0.51	6.92	0.41	4.42e-11	Metabolite levels;
SARC	trans	rs12351590	0.614	rs7024240	chr9:12165146	A/C	cg16711517	chr16:2570260	AMDHD2	0.68	6.53	0.39	4.03e-10	Reading and spelling;Word reading;
SARC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg26338869	chr17:61819248	STRADA	0.8	10.83	0.58	2.04e-22	Prudent dietary pattern;
SARC	trans	rs7395662	0.525	rs1945189	chr11:48418889	A/G	cg15704280	chr7:45808275	SEPT13	-0.5	-6.74	-0.4	1.22e-10	HDL cholesterol;
SARC	cis	rs1023500	0.507	rs6002600	chr22:42488906	G/A	cg04733989	chr22:42467013	NAGA	-0.76	-10.7	-0.57	5.23e-22	Schizophrenia;
SARC	cis	rs6835098	0.816	rs13111572	chr4:174159788	G/A	cg08422745	chr4:174089978	GALNT7	0.72	9.17	0.51	2.63e-17	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg13395646	chr4:1353034	KIAA1530	-0.42	-5.06	-0.31	8.6e-7	Longevity;
SARC	cis	rs72634258	0.786	rs7537362	chr1:8177564	C/T	cg00042356	chr1:8021962	PARK7	0.64	5.83	0.36	1.84e-8	Inflammatory bowel disease;
SARC	cis	rs453301	0.506	rs476845	chr8:8622877	A/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.82	-0.41	7.54e-11	Joint mobility (Beighton score);
SARC	cis	rs240764	0.817	rs240145	chr6:101079610	A/C	cg09795085	chr6:101329169	ASCC3	0.45	5.77	0.35	2.55e-8	Neuroticism;
SARC	cis	rs1832871	0.672	rs7750011	chr6:158746802	A/C	cg07165851	chr6:158734300	TULP4	0.58	6.77	0.41	1.05e-10	Height;
SARC	cis	rs9326248	0.861	rs7120449	chr11:117042899	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.54	5.39	0.33	1.76e-7	Blood protein levels;
SARC	cis	rs9462027	0.628	rs10807141	chr6:34693111	A/G	cg07306190	chr6:34760872	UHRF1BP1	0.42	5.91	0.36	1.19e-8	Systemic lupus erythematosus;
SARC	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6061231	0.740	rs11698650	chr20:60958374	A/T	cg24112000	chr20:60950667	NA	-0.43	-7.28	-0.43	5.14e-12	Colorectal cancer;
SARC	cis	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg07777115	chr5:623756	CEP72	-0.55	-4.83	-0.3	2.48e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs10791097	0.694	rs2236717	chr11:130739887	G/T	cg12179176	chr11:130786555	SNX19	0.73	10.92	0.58	1.08e-22	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.45	-7.25	-0.43	6.18e-12	Longevity;Endometriosis;
SARC	cis	rs7617480	0.648	rs6806356	chr3:48727636	G/A	cg06212747	chr3:49208901	KLHDC8B	0.5	4.87	0.3	2.06e-6	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs910316	1.000	rs4903275	chr14:75512509	C/T	cg11812906	chr14:75593930	NEK9	0.89	13.72	0.67	8.51e-32	Height;
SARC	cis	rs9359856	0.510	rs6937244	chr6:90468465	C/A	cg13799429	chr6:90582589	CASP8AP2	0.52	4.75	0.3	3.57e-6	Bipolar disorder;
SARC	cis	rs67311347	0.866	rs56331709	chr3:40356558	A/C	cg24209194	chr3:40518798	ZNF619	0.54	6.79	0.41	9.49e-11	Renal cell carcinoma;
SARC	cis	rs7843479	0.601	rs10101881	chr8:21830158	A/G	cg17168535	chr8:21777572	XPO7	0.78	10.72	0.57	4.55e-22	Mean corpuscular volume;
SARC	cis	rs2120019	0.567	rs8025170	chr15:75170983	A/G	cg12414181	chr15:75287860	SCAMP5	0.51	4.88	0.3	1.94e-6	Blood trace element (Zn levels);
SARC	cis	rs995000	0.868	rs11208007	chr1:63176083	A/T	cg06896770	chr1:63153194	DOCK7	0.93	14.24	0.68	1.66e-33	Triglyceride levels;
SARC	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg16405210	chr4:1374714	KIAA1530	-0.9	-12.63	-0.64	3.25e-28	Longevity;
SARC	cis	rs2718058	0.519	rs2598054	chr7:37884640	C/T	cg24998770	chr7:37888106	TXNDC3	0.42	6.16	0.37	3.25e-9	Alzheimer's disease (late onset);
SARC	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg04277193	chr17:41438351	NA	0.45	4.84	0.3	2.39e-6	Menopause (age at onset);
SARC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.73	7.52	0.44	1.16e-12	Platelet count;
SARC	cis	rs11608355	0.545	rs34737994	chr12:109901621	C/T	cg05360138	chr12:110035743	NA	0.92	9.65	0.53	9.69e-19	Neuroticism;
SARC	cis	rs7264396	0.563	rs2425094	chr20:34306974	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-7.17	-0.43	9.99e-12	Total cholesterol levels;
SARC	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg17971929	chr21:40555470	PSMG1	-0.85	-11.04	-0.59	4.51e-23	Cognitive function;
SARC	trans	rs1994135	0.617	rs2200155	chr12:33734935	G/A	cg26384229	chr12:38710491	ALG10B	0.71	8.7	0.5	6.22e-16	Resting heart rate;
SARC	cis	rs818427	0.964	rs459102	chr5:112228765	C/A	cg07820702	chr5:112228657	REEP5	-0.55	-6.16	-0.37	3.24e-9	Total body bone mineral density;
SARC	cis	rs12602172	1	rs12602172	chr17:38163567	G/A	cg17467752	chr17:38218738	THRA	0.47	5.94	0.36	1.01e-8	Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs7223966	1.000	rs7209435	chr17:61712964	T/C	cg26338869	chr17:61819248	STRADA	0.43	4.83	0.3	2.42e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7633857	0.532	rs1580254	chr3:160767278	C/T	cg03342759	chr3:160939853	NMD3	-0.58	-7.2	-0.43	8.48e-12	Educational attainment (years of education);
SARC	cis	rs622217	0.541	rs10755578	chr6:160969738	C/G	cg12345982	chr6:160389645	IGF2R	0.35	5.29	0.33	2.77e-7	Type 2 diabetes;
SARC	cis	rs7084402	0.967	rs1649037	chr10:60331135	C/T	cg07615347	chr10:60278583	BICC1	0.57	8.42	0.48	3.91e-15	Refractive error;
SARC	cis	rs11190604	1.000	rs2495741	chr10:102331795	A/G	cg07510080	chr10:102295549	HIF1AN	0.44	4.83	0.3	2.43e-6	Palmitoleic acid (16:1n-7) levels;
SARC	trans	rs2018683	0.707	rs1021691	chr7:28974496	C/T	cg19402173	chr7:128379420	CALU	-0.5	-6.43	-0.39	7.13e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs4427176	0.714	rs62491544	chr8:9511555	G/A	cg21625330	chr8:9911636	MSRA	-0.59	-4.95	-0.31	1.44e-6	Mosquito bite size;
SARC	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.36	6.03	0.37	6.38e-9	Schizophrenia;
SARC	cis	rs77956314	0.901	rs117425351	chr12:117409752	A/G	cg02017074	chr12:117425053	FBXW8	-0.6	-4.83	-0.3	2.44e-6	Subcortical brain region volumes;Hippocampal volume;
SARC	cis	rs698833	0.926	rs1065786	chr2:44660616	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.68	-9.05	-0.51	6.01e-17	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs7681440	0.606	rs2737001	chr4:90753477	G/A	cg06632027	chr4:90757378	SNCA	-0.42	-5.25	-0.33	3.35e-7	Dementia with Lewy bodies;
SARC	cis	rs9324022	0.860	rs72698720	chr14:101178715	C/G	cg18089426	chr14:101175970	NA	0.57	5.44	0.34	1.38e-7	Plateletcrit;
SARC	cis	rs698833	0.561	rs698820	chr2:44716323	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	5.78	0.35	2.41e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs78487399	0.808	rs7599799	chr2:43685493	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-4.95	-0.31	1.45e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	trans	rs2727020	0.675	rs7929401	chr11:49350832	C/A	cg03929089	chr4:120376271	NA	-0.68	-7.48	-0.44	1.48e-12	Coronary artery disease;
SARC	cis	rs503734	0.504	rs348873	chr3:100930665	C/T	cg27318481	chr3:100970896	IMPG2	-0.46	-5.37	-0.33	1.86e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg08219700	chr8:58056026	NA	0.48	5.05	0.31	9.05e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1832871	0.672	rs62437361	chr6:158728759	C/T	cg07165851	chr6:158734300	TULP4	0.57	6.55	0.39	3.61e-10	Height;
SARC	cis	rs9790314	0.779	rs1609688	chr3:160877096	T/G	cg04691961	chr3:161091175	C3orf57	-0.69	-9.31	-0.52	1.02e-17	Morning vs. evening chronotype;
SARC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg06873352	chr17:61820015	STRADA	0.53	6.88	0.41	5.32e-11	Prudent dietary pattern;
SARC	cis	rs7582720	1.000	rs72934753	chr2:203750272	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.31	0.43	4.24e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs11608355	0.545	rs61941585	chr12:109905222	C/T	cg05360138	chr12:110035743	NA	0.92	9.22	0.52	1.8e-17	Neuroticism;
SARC	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg17971929	chr21:40555470	PSMG1	0.98	13.77	0.67	5.75e-32	Cognitive function;
SARC	cis	rs6062509	0.965	rs1056441	chr20:62370349	T/C	cg27236539	chr20:62289627	RTEL1	0.5	5.41	0.33	1.59e-7	Prostate cancer;
SARC	cis	rs3091242	1.000	rs3091242	chr1:25674785	C/T	cg23205692	chr1:25664452	TMEM50A	0.44	5.33	0.33	2.33e-7	Erythrocyte sedimentation rate;
SARC	cis	rs9393777	0.623	rs3757150	chr6:26476782	T/A	cg12826209	chr6:26865740	GUSBL1	0.81	7.39	0.44	2.59e-12	Intelligence (multi-trait analysis);
SARC	cis	rs7582720	0.725	rs72934725	chr2:203725983	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.76	7.4	0.44	2.38e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs17331151	0.573	rs28552648	chr3:52865593	G/A	cg04865290	chr3:52927548	TMEM110	-0.6	-5.93	-0.36	1.11e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs116095464	1.000	rs28416084	chr5:217640	G/A	cg22857025	chr5:266934	NA	-1.11	-10.4	-0.56	4.74e-21	Breast cancer;
SARC	cis	rs6840360	0.615	rs72728171	chr4:152469372	C/A	cg22705602	chr4:152727874	NA	-0.42	-6.55	-0.39	3.67e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7937682	0.632	rs11603779	chr11:111781047	A/C	cg09085632	chr11:111637200	PPP2R1B	0.8	10.6	0.57	1.09e-21	Primary sclerosing cholangitis;
SARC	cis	rs8070128	0.534	rs2955350	chr17:17953548	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-9.75	-0.54	4.63e-19	Total body bone mineral density;
SARC	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg18876405	chr7:65276391	NA	-0.43	-5.26	-0.33	3.25e-7	Aortic root size;
SARC	cis	rs4906332	1.000	rs7155980	chr14:103922419	C/G	cg26031613	chr14:104095156	KLC1	-0.49	-5.78	-0.35	2.42e-8	Coronary artery disease;
SARC	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg04267008	chr7:1944627	MAD1L1	-0.49	-5.55	-0.34	7.83e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs59227481	1	rs59227481	chr12:110007993	A/G	cg13986417	chr12:110012484	MVK;MMAB	-0.43	-6.64	-0.4	2.21e-10	Age-related nuclear cataracts;
SARC	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg09517075	chr8:22133004	PIWIL2	0.36	4.89	0.31	1.84e-6	Hypertriglyceridemia;
SARC	cis	rs8028182	0.501	rs7166281	chr15:75928192	G/T	cg20655648	chr15:75932815	IMP3	-0.62	-7.58	-0.44	8.22e-13	Sudden cardiac arrest;
SARC	cis	rs9905704	0.918	rs11656666	chr17:56929840	A/G	cg12560992	chr17:57184187	TRIM37	0.41	4.77	0.3	3.29e-6	Testicular germ cell tumor;
SARC	cis	rs76419734	0.702	rs114432567	chr4:106781636	T/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.86	5.96	0.36	9.17e-9	Post bronchodilator FEV1;
SARC	cis	rs743757	1.000	rs2073496	chr3:50431142	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.53	4.85	0.3	2.25e-6	Diastolic blood pressure;
SARC	cis	rs6831352	0.918	rs7694646	chr4:100059732	T/A	cg13256891	chr4:100009986	ADH5	-0.65	-8.0	-0.46	5.94e-14	Alcohol dependence;
SARC	cis	rs1215050	0.740	rs700740	chr4:98976003	A/C	cg05340658	chr4:99064831	C4orf37	-0.46	-6.22	-0.38	2.26e-9	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs9916302	0.904	rs2338798	chr17:37547269	T/C	cg20243544	chr17:37824526	PNMT	-0.57	-6.92	-0.41	4.32e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs7582720	0.887	rs72934591	chr2:204019762	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.76	7.84	0.46	1.65e-13	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs7412746	0.658	rs2864869	chr1:150734655	G/A	cg10589385	chr1:150898437	SETDB1	0.39	5.06	0.31	8.49e-7	Melanoma;
SARC	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg23188684	chr11:67383651	NA	0.45	6.31	0.38	1.4e-9	Mean corpuscular volume;
SARC	cis	rs13202913	0.652	rs9383578	chr6:151838192	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.65	6.16	0.37	3.21e-9	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs6088813	1.000	rs2425066	chr20:33927006	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.44	5.35	0.33	2.07e-7	Height;
SARC	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg22800045	chr5:56110881	MAP3K1	0.41	4.99	0.31	1.18e-6	Coronary artery disease;
SARC	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg27266027	chr21:40555129	PSMG1	-0.45	-4.88	-0.3	1.93e-6	Cognitive function;
SARC	cis	rs9388451	0.531	rs9401850	chr6:126151000	T/G	cg05901451	chr6:126070800	HEY2	-0.5	-6.04	-0.37	5.89e-9	Brugada syndrome;
SARC	cis	rs483180	0.531	rs541503	chr1:120208297	A/G	cg19096424	chr1:120255104	PHGDH	-0.51	-5.94	-0.36	1.01e-8	Macular telangiectasia type 2;
SARC	cis	rs4727027	0.870	rs11524138	chr7:148799125	G/A	cg23583168	chr7:148888333	NA	-0.74	-10.79	-0.58	2.91e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg19748678	chr4:122722346	EXOSC9	0.78	9.76	0.54	4.43e-19	Type 2 diabetes;
SARC	cis	rs7243790	0.807	rs13380938	chr18:51895547	T/C	cg04730925	chr18:51795821	POLI	-0.43	-5.13	-0.32	6.17e-7	Diastolic blood pressure;
SARC	cis	rs897080	0.515	rs1085444	chr2:44624155	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.7	0.4	1.59e-10	Height;
SARC	cis	rs11792861	0.816	rs3763643	chr9:111695607	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.73	8.72	0.5	5.33e-16	Menarche (age at onset);
SARC	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg13385521	chr17:29058706	SUZ12P	0.69	5.71	0.35	3.44e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs7953249	0.542	rs1169284	chr12:121419926	T/C	cg02403541	chr12:121454288	C12orf43	0.75	10.35	0.56	6.91e-21	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg20786058	chr5:52774812	NA	0.49	6.4	0.39	8.24e-10	Lung adenocarcinoma;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg07645194	chr3:194407045	FAM43A	-0.54	-6.24	-0.38	2.08e-9	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs7264396	0.690	rs2425170	chr20:34442672	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-6.56	-0.39	3.44e-10	Total cholesterol levels;
SARC	cis	rs7617773	0.817	rs11130163	chr3:48312658	T/C	cg11946769	chr3:48343235	NME6	0.65	8.8	0.5	3.06e-16	Coronary artery disease;
SARC	cis	rs10883723	0.810	rs10883728	chr10:104269301	A/G	ch.10.2196322F	chr10:104248062	ACTR1A	-0.55	-7.14	-0.42	1.2e-11	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs73206853	0.764	rs17682012	chr12:111094454	A/G	cg08946844	chr12:110511112	NA	-0.57	-4.78	-0.3	3.15e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs2180341	1.000	rs3798853	chr6:127636823	C/T	cg27446573	chr6:127587934	RNF146	-1.03	-14.25	-0.68	1.5e-33	Breast cancer;
SARC	cis	rs4919694	1.000	rs3740394	chr10:104634474	A/G	cg04362960	chr10:104952993	NT5C2	0.66	5.48	0.34	1.08e-7	Arsenic metabolism;
SARC	cis	rs10781543	0.810	rs11145756	chr9:139364585	A/G	cg14169450	chr9:139327907	INPP5E	0.47	6.73	0.4	1.27e-10	Monocyte percentage of white cells;
SARC	cis	rs10078	0.571	rs2721028	chr5:443849	A/G	cg24955955	chr5:415729	AHRR	0.7	6.3	0.38	1.48e-9	Fat distribution (HIV);
SARC	cis	rs9896052	0.649	rs6501797	chr17:73444312	G/A	cg25649188	chr17:73499917	CASKIN2	0.35	5.11	0.32	6.65e-7	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs9549367	0.789	rs3764124	chr13:113897320	C/T	cg18105134	chr13:113819100	PROZ	-0.41	-5.99	-0.37	7.81e-9	Platelet distribution width;
SARC	cis	rs561341	1.000	rs535151	chr17:30317405	C/T	cg00745463	chr17:30367425	LRRC37B	-0.56	-4.77	-0.3	3.28e-6	Hip circumference adjusted for BMI;
SARC	cis	rs10870270	1.000	rs10781564	chr10:133757922	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.48	-5.64	-0.35	4.86e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs9291683	0.527	rs3822247	chr4:10094671	G/A	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.84	-0.5	2.42e-16	Bone mineral density;
SARC	cis	rs6089584	1.000	rs6089583	chr20:60563624	G/A	cg06108461	chr20:60628389	TAF4	-0.91	-11.96	-0.62	5.27e-26	Body mass index;
SARC	cis	rs6121246	0.567	rs6060249	chr20:30190944	G/A	cg13852791	chr20:30311386	BCL2L1	0.68	5.91	0.36	1.2e-8	Mean corpuscular hemoglobin;
SARC	cis	rs71191701	1.000	rs71191701	chr9:139322257	G/C	cg14169450	chr9:139327907	INPP5E	0.47	6.06	0.37	5.4e-9	Myeloid white cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
SARC	cis	rs834603	0.575	rs834608	chr7:47451918	A/T	cg23694490	chr7:47445681	TNS3	0.34	6.1	0.37	4.31e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs1957429	0.901	rs1957435	chr14:65349697	G/A	cg23373153	chr14:65346875	NA	1.07	11.5	0.6	1.53e-24	Pediatric areal bone mineral density (radius);
SARC	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg09359103	chr1:154839909	KCNN3	0.45	7.71	0.45	3.72e-13	Prostate cancer;
SARC	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg06618935	chr21:46677482	NA	-0.38	-5.21	-0.32	4.23e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7824557	0.614	rs2736277	chr8:11218893	C/T	cg21775007	chr8:11205619	TDH	-0.62	-8.39	-0.48	4.83e-15	Retinal vascular caliber;
SARC	cis	rs9911578	0.933	rs74370218	chr17:57095212	C/T	cg12560992	chr17:57184187	TRIM37	-0.87	-12.54	-0.63	6.5e-28	Intelligence (multi-trait analysis);
SARC	cis	rs2180341	0.960	rs1964130	chr6:127677391	C/G	cg27446573	chr6:127587934	RNF146	1.06	14.08	0.68	5.38e-33	Breast cancer;
SARC	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg21782813	chr7:2030301	MAD1L1	0.39	6.21	0.38	2.38e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs3820928	0.874	rs1949807	chr2:227891861	A/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-6.34	-0.38	1.18e-9	Pulmonary function;
SARC	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg08219700	chr8:58056026	NA	0.59	6.27	0.38	1.76e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs3796352	0.667	rs11720228	chr3:52877270	G/A	cg27565382	chr3:53032988	SFMBT1	0.87	5.72	0.35	3.25e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg17221315	chr6:27791827	HIST1H4J	0.45	4.84	0.3	2.32e-6	Cardiac Troponin-T levels;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18481137	chr3:71631744	FOXP1	-0.51	-6.52	-0.39	4.22e-10	Smoking initiation;
SARC	cis	rs6540556	0.723	rs6752	chr1:209908100	G/A	cg05527609	chr1:210001259	C1orf107	-0.67	-6.35	-0.38	1.09e-9	Red blood cell count;
SARC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg11494091	chr17:61959527	GH2	0.53	7.98	0.46	6.66e-14	Prudent dietary pattern;
SARC	cis	rs1801251	1.000	rs2100053	chr2:233719516	G/T	cg25237894	chr2:233734115	C2orf82	-0.36	-4.73	-0.3	3.81e-6	Coronary artery disease;
SARC	cis	rs11574514	1.000	rs28367503	chr16:67854534	A/G	cg01866162	chr16:67596514	CTCF	0.79	5.24	0.32	3.51e-7	Crohn's disease;
SARC	cis	rs6121246	0.954	rs7266148	chr20:30431070	G/T	cg13852791	chr20:30311386	BCL2L1	0.89	9.43	0.53	4.23e-18	Mean corpuscular hemoglobin;
SARC	cis	rs7937682	0.883	rs2212520	chr11:111462096	C/T	cg22437258	chr11:111473054	SIK2	0.76	9.87	0.54	2.07e-19	Primary sclerosing cholangitis;
SARC	cis	rs73198271	0.565	rs575895	chr8:8594247	G/A	cg06636001	chr8:8085503	FLJ10661	-0.45	-4.76	-0.3	3.35e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	12.37	0.63	2.38e-27	Chronic sinus infection;
SARC	cis	rs17376456	0.741	rs12374432	chr5:93481348	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.29	0.33	2.81e-7	Diabetic retinopathy;
SARC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.46	0.53	3.5e-18	Prudent dietary pattern;
SARC	cis	rs6728642	0.908	rs13400545	chr2:97871626	A/G	cg26665480	chr2:98280029	ACTR1B	-0.72	-6.53	-0.39	3.97e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs7208859	0.623	rs8081299	chr17:29104296	G/A	cg13385521	chr17:29058706	SUZ12P	0.89	7.77	0.45	2.53e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg22496380	chr5:211416	CCDC127	-0.9	-9.61	-0.53	1.23e-18	Breast cancer;
SARC	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg18404041	chr3:52824283	ITIH1	-0.42	-6.29	-0.38	1.56e-9	Bipolar disorder;
SARC	cis	rs6840360	0.615	rs12641441	chr4:152607623	A/G	cg22705602	chr4:152727874	NA	-0.49	-8.47	-0.49	2.76e-15	Intelligence (multi-trait analysis);
SARC	cis	rs3020736	0.500	rs7292241	chr22:42492063	G/A	cg15557168	chr22:42548783	NA	0.37	4.96	0.31	1.36e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7216064	1.000	rs3935969	chr17:65881959	A/G	cg12091567	chr17:66097778	LOC651250	-0.7	-7.64	-0.45	5.5e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs6459788	0.720	rs11974772	chr7:157250645	G/A	cg03453431	chr7:157225567	NA	-0.42	-6.43	-0.39	7.32e-10	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs62432291	0.681	rs386818	chr6:159660255	T/C	cg14500486	chr6:159655392	FNDC1	-0.62	-6.16	-0.37	3.14e-9	Joint mobility (Beighton score);
SARC	cis	rs735396	0.770	rs1169314	chr12:121443116	A/G	cg15155738	chr12:121454335	C12orf43	0.51	6.49	0.39	5.07e-10	N-glycan levels;
SARC	cis	rs617791	0.508	rs10896074	chr11:65776304	C/T	cg09462587	chr11:65769444	EIF1AD;BANF1	0.41	4.72	0.3	4.05e-6	Breast cancer;
SARC	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg18876405	chr7:65276391	NA	-0.44	-5.03	-0.31	9.8e-7	Aortic root size;
SARC	cis	rs11098499	0.863	rs10019674	chr4:120443489	C/T	cg09307838	chr4:120376055	NA	-0.92	-12.78	-0.64	1.1e-28	Corneal astigmatism;
SARC	cis	rs9486719	0.857	rs1157316	chr6:96869710	G/A	cg06623918	chr6:96969491	KIAA0776	0.72	8.47	0.48	2.88e-15	Migraine;Coronary artery disease;
SARC	cis	rs2153535	0.542	rs9378553	chr6:8472632	T/C	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs8180040	0.620	rs9875235	chr3:47083621	G/A	cg27129171	chr3:47204927	SETD2	0.7	9.5	0.53	2.59e-18	Colorectal cancer;
SARC	cis	rs9815354	0.812	rs17214987	chr3:41810481	C/T	cg03022575	chr3:42003672	ULK4	-0.74	-5.96	-0.36	9.15e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg22496380	chr5:211416	CCDC127	-0.89	-9.3	-0.52	1.06e-17	Breast cancer;
SARC	cis	rs9300255	0.679	rs12817892	chr12:123728702	G/A	cg00376283	chr12:123451042	ABCB9	-0.5	-4.78	-0.3	3.17e-6	Neutrophil percentage of white cells;
SARC	cis	rs4742903	0.904	rs1605448	chr9:106976405	T/G	cg14250997	chr9:106856677	SMC2	0.4	4.95	0.31	1.41e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg16550656	chr5:61874017	LRRC70;IPO11	0.49	7.84	0.46	1.5700000000000001e-13	Thyroid stimulating hormone;
SARC	cis	rs3768617	0.510	rs2027075	chr1:183073266	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.31	0.56	8.74e-21	Fuchs's corneal dystrophy;
SARC	cis	rs6831352	0.918	rs2851251	chr4:100044111	A/G	cg13256891	chr4:100009986	ADH5	0.67	8.36	0.48	5.85e-15	Alcohol dependence;
SARC	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg16479474	chr6:28041457	NA	0.38	5.58	0.34	6.78e-8	Depression;
SARC	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg11965913	chr1:205819406	PM20D1	0.48	5.34	0.33	2.26e-7	Parkinson's disease;
SARC	cis	rs6540556	0.954	rs7536882	chr1:209936673	C/G	cg05527609	chr1:210001259	C1orf107	-0.64	-6.48	-0.39	5.46e-10	Red blood cell count;
SARC	cis	rs7772486	0.790	rs2247666	chr6:146220409	C/A	cg23711669	chr6:146136114	FBXO30	0.81	13.07	0.65	1.23e-29	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs7615952	0.932	rs13325495	chr3:125637416	T/G	cg07211511	chr3:129823064	LOC729375	-0.98	-10.72	-0.57	4.83e-22	Blood pressure (smoking interaction);
SARC	cis	rs620875	1.000	rs646236	chr11:126851452	A/G	cg17273911	chr11:126872863	NA	0.43	4.78	0.3	3.17e-6	Response to antipsychotic treatment;
SARC	cis	rs7726839	0.578	rs112516582	chr5:584319	G/A	cg23206463	chr5:561769	NA	-0.43	-6.12	-0.37	3.99e-9	Obesity-related traits;
SARC	cis	rs12142240	0.621	rs13374968	chr1:46843908	T/G	cg00530320	chr1:46809349	NSUN4	0.57	7.0	0.42	2.74e-11	Menopause (age at onset);
SARC	cis	rs3096299	0.606	rs8052103	chr16:89541243	A/T	cg16743903	chr16:89593216	SPG7	0.53	6.54	0.39	3.96e-10	Multiple myeloma (IgH translocation);
SARC	cis	rs146671954	1	rs146671954	chr9:136934203	G/A	cg13789015	chr9:136890014	NCRNA00094	0.59	6.4	0.39	8.38e-10	Red cell distribution width;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg19100453	chr3:112280678	ATG3;SLC35A5	0.55	7.39	0.44	2.56e-12	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs796364	1.000	rs35220450	chr2:200780737	T/C	cg23649088	chr2:200775458	C2orf69	-0.58	-4.99	-0.31	1.2e-6	Schizophrenia;
SARC	cis	rs820218	0.576	rs1661674	chr17:73725298	C/T	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.61	6.92	0.41	4.43e-11	Rotator cuff tears;
SARC	cis	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg08975724	chr8:8085496	FLJ10661	-0.37	-4.82	-0.3	2.59e-6	Joint mobility (Beighton score);
SARC	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.62	5.69	0.35	3.86e-8	Lung function (FEV1/FVC);
SARC	cis	rs73198271	0.960	rs73198290	chr8:8616009	A/T	cg01851573	chr8:8652454	MFHAS1	0.44	5.82	0.36	1.94e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	trans	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.56	-7.41	-0.44	2.25e-12	Intelligence (multi-trait analysis);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg18747265	chr6:57306409	PRIM2	0.52	7.32	0.43	3.98e-12	Thyroid stimulating hormone;
SARC	cis	rs8170	0.603	rs8110408	chr19:17440542	C/G	cg04749549	chr19:17459798	NA	-0.36	-4.72	-0.3	4.07e-6	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
SARC	cis	rs17666538	0.585	rs1037393	chr8:622634	G/C	cg00450029	chr8:599525	NA	0.6	5.1	0.32	7.13e-7	IgG glycosylation;
SARC	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg19223190	chr17:80058835	NA	-0.43	-6.02	-0.37	6.57e-9	Life satisfaction;
SARC	cis	rs1059312	0.966	rs12368452	chr12:129277164	C/A	cg09035930	chr12:129282057	SLC15A4	0.57	8.25	0.48	1.14e-14	Systemic lupus erythematosus;
SARC	cis	rs4481887	0.893	rs9651175	chr1:248446888	G/T	cg00666640	chr1:248458726	OR2T12	0.34	5.62	0.35	5.47e-8	Common traits (Other);
SARC	cis	rs73086581	1.000	rs6052217	chr20:3970211	A/G	cg02187196	chr20:3869020	PANK2	0.67	6.46	0.39	6.21e-10	Response to antidepressants in depression;
SARC	cis	rs9303401	0.659	rs17222691	chr17:56771096	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.08	11.61	0.61	6.68e-25	Cognitive test performance;
SARC	cis	rs6088580	0.634	rs6088498	chr20:33020446	A/G	cg24642439	chr20:33292090	TP53INP2	0.61	7.72	0.45	3.42e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs7659604	1.000	rs73844281	chr4:122664688	A/G	cg20573242	chr4:122745356	CCNA2	0.44	5.72	0.35	3.18e-8	Type 2 diabetes;
SARC	cis	rs10197940	0.578	rs2432956	chr2:152287831	C/T	cg26121113	chr2:153191532	FMNL2	-0.45	-4.72	-0.3	4.12e-6	Lung cancer;
SARC	trans	rs61931739	0.500	rs11053273	chr12:34547255	C/T	cg26384229	chr12:38710491	ALG10B	0.91	13.78	0.67	5.4e-32	Morning vs. evening chronotype;
SARC	cis	rs72781680	1.000	rs55773155	chr2:24255081	A/G	cg08917208	chr2:24149416	ATAD2B	0.88	8.28	0.48	9.36e-15	Lymphocyte counts;
SARC	cis	rs11758351	1.000	rs3734530	chr6:26195408	G/C	cg01420254	chr6:26195488	NA	0.55	4.8	0.3	2.79e-6	Gout;Renal underexcretion gout;
SARC	cis	rs6840360	0.615	rs9996320	chr4:152610587	T/G	cg22705602	chr4:152727874	NA	-0.52	-8.96	-0.51	1.08e-16	Intelligence (multi-trait analysis);
SARC	cis	rs826838	0.935	rs11169547	chr12:39185625	C/A	cg26384229	chr12:38710491	ALG10B	0.87	12.47	0.63	1.11e-27	Heart rate;
SARC	cis	rs4748857	0.947	rs9888000	chr10:23606391	A/G	cg12804278	chr10:23633326	C10orf67	0.39	4.73	0.3	3.96e-6	Systemic lupus erythematosus;
SARC	cis	rs546131	0.642	rs12272777	chr11:34850902	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-4.81	-0.3	2.72e-6	Lung disease severity in cystic fibrosis;
SARC	trans	rs7395662	0.591	rs7482521	chr11:48609735	G/A	cg15704280	chr7:45808275	SEPT13	-0.49	-6.49	-0.39	5.1e-10	HDL cholesterol;
SARC	cis	rs79149102	0.522	rs74925675	chr15:74905756	A/C	cg09165964	chr15:75287851	SCAMP5	-0.6	-4.76	-0.3	3.45e-6	Lung cancer;
SARC	cis	rs9790314	1.000	rs9790314	chr3:161019558	T/C	cg04691961	chr3:161091175	C3orf57	-0.75	-10.78	-0.58	2.93e-22	Morning vs. evening chronotype;
SARC	trans	rs208520	0.802	rs1342959	chr6:66883329	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.03	-12.94	-0.65	3.22e-29	Exhaled nitric oxide output;
SARC	cis	rs35110281	0.517	rs11089020	chr21:44939991	C/T	cg21573476	chr21:45109991	RRP1B	-0.43	-6.05	-0.37	5.62e-9	Mean corpuscular volume;
SARC	cis	rs6545883	1.000	rs778758	chr2:61782161	T/C	cg15711740	chr2:61764176	XPO1	-0.45	-5.47	-0.34	1.18e-7	Tuberculosis;
SARC	cis	rs2016266	0.819	rs6580942	chr12:53662624	C/A	cg26875137	chr12:53738046	NA	0.42	5.46	0.34	1.2e-7	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs6089584	0.606	rs7270666	chr20:60577598	C/T	cg06108461	chr20:60628389	TAF4	-0.67	-8.65	-0.49	8.53e-16	Body mass index;
SARC	cis	rs4268898	0.965	rs4665673	chr2:24459737	A/T	cg26838691	chr2:24397539	C2orf84	0.37	5.02	0.31	1.04e-6	Asthma;
SARC	cis	rs870825	0.616	rs28524599	chr4:185647414	A/G	cg04058563	chr4:185651563	MLF1IP	0.8	11.35	0.6	4.56e-24	Blood protein levels;
SARC	cis	rs981844	0.683	rs1105496	chr4:154756755	T/C	cg14289246	chr4:154710475	SFRP2	-0.47	-5.62	-0.35	5.39e-8	Response to statins (LDL cholesterol change);
SARC	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg26681399	chr22:41777847	TEF	-0.48	-5.39	-0.33	1.72e-7	Vitiligo;
SARC	cis	rs7582180	0.627	rs4851312	chr2:101011241	G/A	cg14675211	chr2:100938903	LONRF2	0.55	7.93	0.46	9.25e-14	Intelligence (multi-trait analysis);
SARC	cis	rs9788721	0.836	rs72738736	chr15:78765122	G/T	cg06917634	chr15:78832804	PSMA4	-0.49	-5.27	-0.33	3.09e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs12682352	0.535	rs12677550	chr8:8644322	A/G	cg06636001	chr8:8085503	FLJ10661	-0.41	-5.09	-0.32	7.42e-7	Neuroticism;
SARC	cis	rs6831352	0.918	rs1042365	chr4:100045500	G/T	cg13256891	chr4:100009986	ADH5	-0.68	-8.57	-0.49	1.43e-15	Alcohol dependence;
SARC	cis	rs9914544	0.545	rs57035178	chr17:18797767	C/T	cg25390199	chr17:18761479	PRPSAP2	0.46	6.04	0.37	5.99e-9	Educational attainment (years of education);
SARC	cis	rs7772486	0.701	rs697056	chr6:146003897	C/T	cg23711669	chr6:146136114	FBXO30	-0.91	-15.87	-0.72	5.98e-39	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg09699651	chr6:150184138	LRP11	0.39	4.98	0.31	1.26e-6	Lung cancer;
SARC	cis	rs911263	0.603	rs3784109	chr14:68789911	T/G	cg18825221	chr14:68749962	RAD51L1	0.41	7.28	0.43	5.21e-12	Primary biliary cholangitis;
SARC	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg07414643	chr4:187882934	NA	0.49	7.32	0.43	4.01e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10465746	0.570	rs2147950	chr1:84465545	C/T	cg04407776	chr1:84465009	TTLL7	-0.44	-5.34	-0.33	2.21e-7	Obesity-related traits;
SARC	cis	rs763121	0.853	rs5750621	chr22:38956166	C/T	cg14440974	chr22:39074834	NA	-0.32	-4.73	-0.3	3.95e-6	Menopause (age at onset);
SARC	cis	rs1348850	0.645	rs10181259	chr2:178428256	C/A	cg23306229	chr2:178417860	TTC30B	0.7	7.88	0.46	1.23e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs6088590	1.000	rs1998028	chr20:33344595	A/T	cg24642439	chr20:33292090	TP53INP2	0.89	12.76	0.64	1.26e-28	Coronary artery disease;
SARC	cis	rs1185460	1.000	rs1614264	chr11:118942638	A/C	cg01677386	chr11:118938358	VPS11	-0.39	-4.72	-0.3	4.02e-6	Coronary artery disease;
SARC	cis	rs17600642	0.622	rs17600495	chr10:72457578	T/C	cg18679544	chr10:72432482	ADAMTS14	0.46	4.86	0.3	2.14e-6	Bipolar disorder;
SARC	cis	rs1580019	0.562	rs4720064	chr7:32559638	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.62	8.17	0.47	1.92e-14	Cognitive ability;
SARC	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.57	-7.3	-0.43	4.51e-12	Mean platelet volume;
SARC	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg22800045	chr5:56110881	MAP3K1	0.66	7.63	0.45	5.88e-13	Type 2 diabetes;
SARC	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg06221963	chr1:154839813	KCNN3	-0.52	-8.14	-0.47	2.37e-14	Prostate cancer;
SARC	cis	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg05623727	chr3:50126028	RBM5	0.35	5.16	0.32	5.22e-7	Intelligence (multi-trait analysis);
SARC	cis	rs910316	0.874	rs61980828	chr14:75630378	G/A	cg23033748	chr14:75592666	NEK9	-0.36	-4.81	-0.3	2.7e-6	Height;
SARC	cis	rs6582630	0.555	rs2090785	chr12:38424342	G/A	cg26384229	chr12:38710491	ALG10B	0.84	12.04	0.62	2.79e-26	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs897080	0.516	rs1067393	chr2:44638832	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.62	0.4	2.4e-10	Height;
SARC	cis	rs34293785	1.000	rs34293785	chr1:66137192	T/C	cg04111102	chr1:66153794	NA	0.37	5.61	0.35	5.63e-8	Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;
SARC	cis	rs17401966	1.000	rs12118323	chr1:10469641	A/G	cg15208524	chr1:10270712	KIF1B	0.43	4.96	0.31	1.39e-6	Hepatocellular carcinoma;
SARC	cis	rs2991971	0.810	rs2036021	chr1:45901370	G/A	cg24296786	chr1:45957014	TESK2	0.6	7.99	0.46	6.24e-14	High light scatter reticulocyte count;
SARC	cis	rs1707322	1.000	rs7527079	chr1:46413450	C/G	cg03146154	chr1:46216737	IPP	0.46	5.53	0.34	8.63e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7827545	0.644	rs4909452	chr8:135521053	C/G	cg17885191	chr8:135476712	NA	-0.45	-5.06	-0.31	8.44e-7	Hypertension (SNP x SNP interaction);
SARC	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg24846343	chr22:24311635	DDTL	0.58	8.26	0.48	1.11e-14	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-8.19	-0.47	1.74e-14	Chronic sinus infection;
SARC	cis	rs7659604	1.000	rs6816071	chr4:122665185	G/A	cg19671926	chr4:122722719	EXOSC9	-0.49	-5.98	-0.36	8.52e-9	Type 2 diabetes;
SARC	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg16482183	chr6:26056742	HIST1H1C	0.43	5.34	0.33	2.17e-7	Height;
SARC	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg13395646	chr4:1353034	KIAA1530	-0.42	-4.99	-0.31	1.19e-6	Obesity-related traits;
SARC	cis	rs11785400	1.000	rs4327844	chr8:143733540	C/T	cg10596483	chr8:143751796	JRK	-0.61	-8.12	-0.47	2.76e-14	Schizophrenia;
SARC	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg23205692	chr1:25664452	TMEM50A	0.4	4.88	0.3	1.97e-6	Erythrocyte sedimentation rate;
SARC	cis	rs7923609	0.871	rs2393984	chr10:65314971	A/G	cg01631684	chr10:65280961	REEP3	0.35	4.72	0.3	4.07e-6	Educational attainment;Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg21724239	chr8:58056113	NA	0.69	6.57	0.4	3.22e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1468333	1.000	rs34927605	chr5:137580418	T/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.86	12.08	0.62	2.08e-26	Resting heart rate;
SARC	cis	rs2645694	0.533	rs2645680	chr4:77820956	T/C	cg03477792	chr4:77819574	ANKRD56	0.5	7.5	0.44	1.35e-12	Emphysema distribution in smoking;
SARC	cis	rs1800562	1	rs1800562	chr6:26093141	C/T	cg16482183	chr6:26056742	HIST1H1C	0.9	5.29	0.33	2.8e-7	Hematocrit;Iron status biomarkers (transferrin levels);Diastolic blood pressure;Hemoglobin;Red blood cell count;Cholesterol, total;Hematology traits;Alcohol consumption (transferrin glycosylation);Iron status biomarkers (ferritin levels);LDL cholesterol;Iron status biomarkers;Mean corpuscular hemoglobin;Iron status biomarkers (transferrin saturation);Mean corpuscular volume;Iron status biomarkers (iron levels);Red blood cell traits;Iron status biomarkers (total iron binding capacity);Glycated hemoglobin levels;Hematological parameters;Hepcidin levels;Cardiovascular disease risk factors;
SARC	cis	rs7553864	0.614	rs10493796	chr1:87614175	A/G	cg17420885	chr1:87600446	LOC339524	0.38	5.41	0.33	1.58e-7	Smoking behavior;
SARC	cis	rs7566780	0.772	rs12468063	chr2:16725869	A/G	cg09580478	chr2:16689509	NA	-0.52	-5.63	-0.35	5.03e-8	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	trans	rs9354308	0.834	rs12212376	chr6:66598879	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.58	6.77	0.41	1.04e-10	Metabolite levels;
SARC	cis	rs947211	0.800	rs1341249	chr1:205759876	T/C	cg11965913	chr1:205819406	PM20D1	0.46	4.76	0.3	3.46e-6	Parkinson's disease;
SARC	cis	rs1881797	1.000	rs12071797	chr1:247686871	A/G	cg11166453	chr1:247681781	NA	0.46	5.18	0.32	4.74e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg00409905	chr10:38381863	ZNF37A	0.5	6.59	0.4	2.98e-10	Age-related hearing impairment (SNP x SNP interaction);
SARC	trans	rs1814175	0.754	rs10219245	chr11:49645052	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-17.82	-0.76	2.12e-45	Height;
SARC	cis	rs2075371	1.000	rs2598291	chr7:133988313	C/G	cg00033643	chr7:134001901	SLC35B4	0.4	4.84	0.3	2.41e-6	Mean platelet volume;
SARC	cis	rs3768617	0.510	rs2093984	chr1:183094314	T/C	cg13390022	chr1:182993471	LAMC1	0.31	4.71	0.3	4.18e-6	Fuchs's corneal dystrophy;
SARC	cis	rs2839627	0.561	rs7281655	chr21:44269743	A/G	cg03543861	chr21:44258195	NA	0.46	5.06	0.31	8.55e-7	Information processing speed;
SARC	cis	rs9807989	0.801	rs7558339	chr2:102970243	T/G	cg09003973	chr2:102972529	NA	0.41	5.6	0.34	6.11e-8	Asthma;
SARC	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg03735888	chr19:58951602	ZNF132	0.39	5.19	0.32	4.58e-7	Uric acid clearance;
SARC	cis	rs4566357	0.557	rs6707158	chr2:227911269	A/G	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.87	-0.36	1.51e-8	Coronary artery disease;
SARC	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.72	-7.58	-0.44	8e-13	Platelet count;
SARC	cis	rs11792861	0.816	rs28361186	chr9:111704064	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.74	8.7	0.5	5.95e-16	Menarche (age at onset);
SARC	cis	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg00071950	chr4:10020882	SLC2A9	0.41	6.58	0.4	3.09e-10	Bone mineral density;
SARC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg26354017	chr1:205819088	PM20D1	0.89	14.45	0.69	3.23e-34	Menarche (age at onset);
SARC	cis	rs9467773	1.000	rs6925703	chr6:26521589	G/A	cg11502198	chr6:26597334	ABT1	0.47	5.93	0.36	1.1e-8	Intelligence (multi-trait analysis);
SARC	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg19346786	chr7:2764209	NA	-0.38	-5.8	-0.36	2.1e-8	Height;
SARC	cis	rs9807989	0.801	rs6752482	chr2:102967858	T/C	cg09003973	chr2:102972529	NA	0.41	5.6	0.34	6.11e-8	Asthma;
SARC	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg11890956	chr21:40555474	PSMG1	1.16	19.35	0.79	2.15e-50	Cognitive function;
SARC	cis	rs1707322	0.721	rs11211178	chr1:46227566	G/T	cg03146154	chr1:46216737	IPP	0.5	5.98	0.36	8.19e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2276314	0.802	rs9963714	chr18:33592056	T/C	cg05985134	chr18:33552581	C18orf21	0.67	6.74	0.4	1.25e-10	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs7374004	0.601	rs13062931	chr3:38637160	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.5	5.76	0.35	2.7e-8	PR interval;
SARC	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg13072238	chr3:49761600	GMPPB	-0.42	-5.54	-0.34	8.33e-8	Intelligence (multi-trait analysis);
SARC	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg11764359	chr7:65958608	NA	0.66	7.91	0.46	1.04e-13	Aortic root size;
SARC	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg16479474	chr6:28041457	NA	0.34	5.19	0.32	4.68e-7	Cardiac Troponin-T levels;
SARC	cis	rs172166	0.652	rs476167	chr6:28065888	T/C	cg16479474	chr6:28041457	NA	0.33	5.09	0.32	7.48e-7	Cardiac Troponin-T levels;
SARC	cis	rs17376456	0.877	rs10476597	chr5:93367172	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.61	-5.45	-0.34	1.29e-7	Diabetic retinopathy;
SARC	cis	rs4961252	0.545	rs1107258	chr8:142104071	G/A	cg06401414	chr8:141599436	EIF2C2	0.37	4.75	0.3	3.55e-6	Isovolumetric relaxation time;Response to interferon beta therapy;
SARC	cis	rs1920116	1.000	rs11709840	chr3:169570241	A/C	cg14222479	chr3:169487675	ARPM1	0.43	5.12	0.32	6.36e-7	Glioma (high-grade);
SARC	cis	rs6570726	1.000	rs444564	chr6:145859795	G/C	cg05347473	chr6:146136440	FBXO30	0.48	6.5	0.39	4.96e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3213545	0.700	rs2260399	chr12:121469653	C/T	cg25281562	chr12:121454272	C12orf43	0.51	6.43	0.39	7.23e-10	Subjective well-being;Cardiovascular disease risk factors;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg13960493	chr9:113658492	LPAR1	0.46	6.32	0.38	1.35e-9	Thyroid stimulating hormone;
SARC	cis	rs7224737	1.000	rs7214921	chr17:40294025	T/C	cg20291162	chr17:40259547	DHX58	-0.33	-4.85	-0.3	2.24e-6	Fibrinogen levels;
SARC	cis	rs2204008	0.693	rs12372025	chr12:38202028	G/A	cg26384229	chr12:38710491	ALG10B	0.88	12.94	0.65	3.26e-29	Bladder cancer;
SARC	cis	rs733592	1.000	rs733592	chr12:48429776	C/T	cg21466736	chr12:48725269	NA	0.3	5.2	0.32	4.27e-7	Plateletcrit;
SARC	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg20887711	chr4:1340912	KIAA1530	0.41	5.02	0.31	1.01e-6	Longevity;
SARC	cis	rs9296092	0.538	rs7761268	chr6:33519300	C/T	cg13560919	chr6:33536144	NA	-0.51	-6.24	-0.38	2.08e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs17376456	0.877	rs10040648	chr5:93490301	G/C	cg21475434	chr5:93447410	FAM172A	0.91	7.79	0.45	2.18e-13	Diabetic retinopathy;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg25019564	chr18:9475492	RALBP1	0.48	6.44	0.39	6.84e-10	Tetralogy of Fallot;
SARC	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg05861140	chr6:150128134	PCMT1	0.4	5.13	0.32	6.15e-7	Lung cancer;
SARC	cis	rs10840133	1	rs10840133	chr11:8846369	G/A	cg14711859	chr11:8959438	ASCL3	-0.33	-5.25	-0.33	3.47e-7	Reticulocyte fraction of red cells;
SARC	cis	rs2997447	0.846	rs3008420	chr1:26401403	C/T	cg19633962	chr1:26362018	EXTL1	-0.56	-4.85	-0.3	2.28e-6	QRS complex (12-leadsum);
SARC	cis	rs25645	0.800	rs34003767	chr17:38194296	A/G	cg17467752	chr17:38218738	THRA	-0.47	-6.1	-0.37	4.32e-9	Myeloid white cell count;
SARC	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg19748678	chr4:122722346	EXOSC9	0.76	9.43	0.53	4.18e-18	Type 2 diabetes;
SARC	cis	rs1153858	1.000	rs4775907	chr15:45638647	G/A	cg21132104	chr15:45694354	SPATA5L1	0.77	10.71	0.57	5.01e-22	Homoarginine levels;
SARC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.43	0.56	3.8e-21	Prudent dietary pattern;
SARC	cis	rs2228479	0.702	rs62056092	chr16:89930426	A/G	cg00800038	chr16:89945340	TCF25	-0.72	-5.22	-0.32	3.97e-7	Skin colour saturation;
SARC	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg18252515	chr7:66147081	NA	-0.48	-5.24	-0.32	3.55e-7	Aortic root size;
SARC	cis	rs7223966	1.000	rs9747164	chr17:61864787	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	7.19	0.43	8.52e-12	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg20007245	chr22:24372913	LOC391322	-0.67	-8.46	-0.48	3.03e-15	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg18404041	chr3:52824283	ITIH1	-0.38	-5.59	-0.34	6.45e-8	Bipolar disorder;
SARC	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg15448220	chr1:150897856	SETDB1	0.47	6.17	0.37	3.05e-9	Tonsillectomy;
SARC	cis	rs4481887	0.893	rs4297335	chr1:248473421	C/T	cg13385794	chr1:248469461	NA	0.34	5.32	0.33	2.46e-7	Common traits (Other);
SARC	cis	rs7647973	0.626	rs1586827	chr3:49671224	T/C	cg07636037	chr3:49044803	WDR6	0.63	6.5	0.39	4.76e-10	Menarche (age at onset);
SARC	cis	rs10782582	0.546	rs79652169	chr1:76233882	G/A	cg03433033	chr1:76189801	ACADM	-0.42	-5.37	-0.33	1.92e-7	Daytime sleep phenotypes;
SARC	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg15556689	chr8:8085844	FLJ10661	-0.62	-8.15	-0.47	2.3e-14	Neuroticism;
SARC	cis	rs9303401	0.659	rs35103007	chr17:56900738	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.07	12.11	0.62	1.62e-26	Cognitive test performance;
SARC	cis	rs651907	0.535	rs34263427	chr3:101507805	A/G	cg12386194	chr3:101231763	SENP7	0.49	5.62	0.35	5.36e-8	Colorectal cancer;
SARC	cis	rs9325144	0.560	rs11182979	chr12:38642562	C/A	cg13010199	chr12:38710504	ALG10B	-0.56	-6.97	-0.42	3.31e-11	Morning vs. evening chronotype;
SARC	cis	rs1568889	0.838	rs11030230	chr11:28174631	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	14.58	0.69	1.18e-34	Bipolar disorder;
SARC	trans	rs7937682	1.000	rs7128353	chr11:111538875	A/G	cg18187862	chr3:45730750	SACM1L	0.55	6.84	0.41	7.05e-11	Primary sclerosing cholangitis;
SARC	cis	rs1707322	1.000	rs10890359	chr1:46336635	A/G	cg03146154	chr1:46216737	IPP	0.47	5.67	0.35	4.31e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7260598	0.539	rs114301360	chr19:24065052	G/A	cg27517351	chr19:23941871	ZNF681	0.54	4.73	0.3	3.86e-6	Response to taxane treatment (placlitaxel);
SARC	cis	rs11098499	0.708	rs10005237	chr4:120237897	T/C	cg09307838	chr4:120376055	NA	0.81	11.15	0.59	2.11e-23	Corneal astigmatism;
SARC	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg03517284	chr6:25882590	NA	-0.58	-7.46	-0.44	1.66e-12	Intelligence (multi-trait analysis);
SARC	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg19223190	chr17:80058835	NA	0.46	6.33	0.38	1.28e-9	Life satisfaction;
SARC	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg08645402	chr16:4508243	NA	0.44	5.58	0.34	6.81e-8	Schizophrenia;
SARC	cis	rs2303745	0.589	rs10401700	chr19:17397700	A/C	cg22549504	chr19:17448937	GTPBP3	0.5	5.09	0.32	7.39e-7	Systemic lupus erythematosus;
SARC	cis	rs9309711	0.666	rs6723126	chr2:3484500	T/C	cg15506890	chr2:3487001	NA	-0.46	-6.14	-0.37	3.59e-9	Neurofibrillary tangles;
SARC	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	11.07	0.59	3.59e-23	Alzheimer's disease;
SARC	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg16325326	chr1:53192061	ZYG11B	-0.9	-16.27	-0.73	2.82e-40	Monocyte count;
SARC	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg04772025	chr11:68637568	NA	0.55	7.0	0.42	2.72e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs523522	0.923	rs3916065	chr12:120934624	A/C	cg12219531	chr12:120966889	COQ5	0.83	11.18	0.59	1.61e-23	High light scatter reticulocyte count;
SARC	cis	rs2075371	0.933	rs1868784	chr7:133945932	A/G	cg20476274	chr7:133979776	SLC35B4	0.6	8.18	0.47	1.85e-14	Mean platelet volume;
SARC	cis	rs4423214	0.840	rs1790340	chr11:71182589	T/C	cg05163923	chr11:71159392	DHCR7	-0.58	-6.41	-0.39	7.85e-10	Vitamin D levels;
SARC	cis	rs9325144	0.624	rs10783333	chr12:39118931	A/T	cg26384229	chr12:38710491	ALG10B	0.57	7.18	0.43	9.54e-12	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg08280861	chr8:58055591	NA	0.58	5.71	0.35	3.35e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg09021430	chr5:549028	NA	-0.43	-5.58	-0.34	6.64e-8	Obesity-related traits;
SARC	cis	rs2239547	0.657	rs12496077	chr3:52886241	G/A	cg18404041	chr3:52824283	ITIH1	-0.41	-5.07	-0.32	7.92e-7	Schizophrenia;
SARC	trans	rs9325144	0.555	rs1973292	chr12:38679626	T/C	cg23762105	chr12:34175262	ALG10	-0.53	-7.07	-0.42	1.81e-11	Morning vs. evening chronotype;
SARC	cis	rs950776	0.518	rs11636131	chr15:78821606	C/T	cg06917634	chr15:78832804	PSMA4	0.91	14.24	0.68	1.6e-33	Sudden cardiac arrest;
SARC	cis	rs9297145	0.916	rs4236540	chr7:98769025	A/C	cg05967295	chr7:98741636	SMURF1	0.76	9.52	0.53	2.29e-18	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
SARC	cis	rs926392	0.572	rs6129158	chr20:37673967	A/G	cg16355469	chr20:37678765	NA	0.76	9.75	0.54	4.69e-19	Dialysis-related mortality;
SARC	cis	rs67460515	0.892	rs7648279	chr3:160979646	G/A	cg03342759	chr3:160939853	NMD3	-0.71	-9.18	-0.52	2.33e-17	Parkinson's disease;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg15289658	chr9:80912121	PSAT1	-0.5	-6.31	-0.38	1.41e-9	Schizophrenia;
SARC	cis	rs709400	0.663	rs7145113	chr14:103945414	A/G	cg12935359	chr14:103987150	CKB	-0.39	-5.68	-0.35	3.9e-8	Body mass index;
SARC	cis	rs5167	0.504	rs7248162	chr19:45454686	T/C	cg20090143	chr19:45452003	APOC2	0.31	4.99	0.31	1.18e-6	Blood protein levels;
SARC	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg02725872	chr8:58115012	NA	-0.35	-6.03	-0.37	6.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1790761	0.607	rs656652	chr11:67343957	C/T	cg24690094	chr11:67383802	NA	0.37	5.5	0.34	1.01e-7	Mean corpuscular volume;
SARC	cis	rs9300255	0.516	rs6488868	chr12:123799974	A/G	cg00376283	chr12:123451042	ABCB9	0.44	4.99	0.31	1.21e-6	Neutrophil percentage of white cells;
SARC	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg10207240	chr12:122356781	WDR66	0.36	6.02	0.37	6.57e-9	Mean corpuscular volume;
SARC	trans	rs11039798	0.544	rs114343057	chr11:48558172	C/T	cg15704280	chr7:45808275	SEPT13	0.64	6.62	0.4	2.38e-10	Axial length;
SARC	cis	rs3733585	0.699	rs4588456	chr4:9963895	A/T	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.55	-0.34	7.65e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs1348850	0.632	rs1405718	chr2:178499809	C/T	cg23306229	chr2:178417860	TTC30B	0.5	5.55	0.34	7.79e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg14893161	chr1:205819251	PM20D1	0.94	16.56	0.74	3.11e-41	Menarche (age at onset);
SARC	cis	rs12950390	0.853	rs12451815	chr17:45855956	A/G	cg24803719	chr17:45855879	NA	-0.48	-7.66	-0.45	4.83e-13	IgG glycosylation;
SARC	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg08219700	chr8:58056026	NA	0.6	5.71	0.35	3.49e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg22857025	chr5:266934	NA	-1.05	-11.66	-0.61	4.62e-25	Breast cancer;
SARC	cis	rs12079745	0.793	rs10919110	chr1:169214293	G/C	cg09363564	chr1:169337483	NME7;BLZF1	-0.81	-5.41	-0.33	1.6e-7	QT interval;
SARC	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg20887711	chr4:1340912	KIAA1530	0.79	9.74	0.54	5.13e-19	Longevity;
SARC	cis	rs473651	0.904	rs472247	chr2:239362573	G/A	cg18131467	chr2:239335373	ASB1	0.96	16.15	0.73	7.06e-40	Multiple system atrophy;
SARC	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.9	-0.5	1.61e-16	Alzheimer's disease;
SARC	cis	rs17253792	0.822	rs10143002	chr14:56074278	G/A	cg01858014	chr14:56050164	KTN1	-0.69	-5.36	-0.33	2.02e-7	Putamen volume;
SARC	cis	rs17125944	0.686	rs78623109	chr14:53383077	G/T	cg00686598	chr14:53173677	PSMC6	0.84	5.86	0.36	1.57e-8	Alzheimer's disease (late onset);
SARC	cis	rs11997175	0.545	rs4733458	chr8:33661542	G/T	ch.8.33884649F	chr8:33765107	NA	0.49	6.22	0.38	2.25e-9	Body mass index;
SARC	cis	rs72781680	0.898	rs72780191	chr2:24007122	T/C	cg06627628	chr2:24431161	ITSN2	-0.7	-6.43	-0.39	7.32e-10	Lymphocyte counts;
SARC	cis	rs9816226	0.587	rs9863591	chr3:185841624	C/G	cg00760338	chr3:185826511	ETV5	-0.84	-10.25	-0.56	1.41e-20	Obesity;Body mass index;
SARC	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg08109568	chr15:31115862	NA	-0.5	-6.02	-0.37	6.6e-9	Huntington's disease progression;
SARC	cis	rs7568458	0.811	rs3755015	chr2:85764041	G/A	cg02493740	chr2:85810744	VAMP5	-0.38	-5.58	-0.34	6.57e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs240764	0.817	rs6905221	chr6:101151537	G/A	cg09795085	chr6:101329169	ASCC3	-0.46	-5.94	-0.36	1.01e-8	Neuroticism;
SARC	cis	rs7904368	0.754	rs7076955	chr10:16852781	G/A	cg23933602	chr10:16859644	RSU1	0.6	6.03	0.37	6.38e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs72781680	1.000	rs12623496	chr2:24181583	C/T	cg08917208	chr2:24149416	ATAD2B	0.79	7.54	0.44	1.05e-12	Lymphocyte counts;
SARC	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg11644478	chr21:40555479	PSMG1	1.04	14.22	0.68	1.9e-33	Cognitive function;
SARC	cis	rs3749237	0.595	rs4855877	chr3:49448527	T/C	cg07636037	chr3:49044803	WDR6	0.64	8.23	0.47	1.36e-14	Resting heart rate;
SARC	cis	rs73242632	0.867	rs73242634	chr4:57935521	G/A	cg20415529	chr4:57845134	POLR2B;C4orf14	0.97	5.81	0.36	2.09e-8	Congenital heart disease (maternal effect);
SARC	cis	rs7246657	0.943	rs1559229	chr19:37876197	T/C	cg14683738	chr19:37701593	ZNF585B	0.49	4.76	0.3	3.47e-6	Coronary artery calcification;
SARC	cis	rs2729385	1.000	rs2729385	chr11:57262993	C/T	cg17237962	chr11:57479805	MED19;TMX2	0.45	5.04	0.31	9.15e-7	Interleukin-18 levels;
SARC	cis	rs6558174	1.000	rs6558174	chr8:22492129	A/G	cg03733263	chr8:22462867	KIAA1967	0.55	6.14	0.37	3.55e-9	Breast cancer;
SARC	cis	rs79349575	0.749	rs957557	chr17:47003221	G/T	cg07967210	chr17:47022446	SNF8	0.37	4.72	0.3	4.02e-6	Type 2 diabetes;
SARC	cis	rs2204008	0.774	rs8186954	chr12:38318566	C/A	cg26384229	chr12:38710491	ALG10B	0.87	12.62	0.64	3.71e-28	Bladder cancer;
SARC	cis	rs4557101	0.526	rs7627890	chr3:73532069	C/T	cg24173753	chr3:73529447	PDZRN3	-0.56	-8.78	-0.5	3.59e-16	QT interval;
SARC	cis	rs763121	0.925	rs4821797	chr22:39016182	T/C	cg21395723	chr22:39101663	GTPBP1	0.54	6.32	0.38	1.32e-9	Menopause (age at onset);
SARC	cis	rs7552404	0.731	rs11161836	chr1:76354333	C/T	cg03433033	chr1:76189801	ACADM	0.45	5.49	0.34	1.03e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg19223190	chr17:80058835	NA	0.46	6.36	0.38	1.04e-9	Life satisfaction;
SARC	cis	rs7264396	0.563	rs2425131	chr20:34337074	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	5.32	0.33	2.49e-7	Total cholesterol levels;
SARC	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg04166393	chr7:2884313	GNA12	0.59	7.04	0.42	2.09e-11	Height;
SARC	cis	rs1878931	0.580	rs4578649	chr16:3407258	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.88	-13.66	-0.67	1.36e-31	Body mass index (adult);
SARC	cis	rs1003719	0.680	rs2835630	chr21:38521842	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-9.01	-0.51	7.85e-17	Eye color traits;
SARC	cis	rs9640161	0.830	rs35635199	chr7:150063342	C/T	cg21361702	chr7:150065534	REPIN1	0.59	6.68	0.4	1.7e-10	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.98	11.19	0.59	1.47e-23	Platelet count;
SARC	cis	rs66887589	0.616	rs13113885	chr4:120221176	G/C	cg09307838	chr4:120376055	NA	0.61	8.2	0.47	1.61e-14	Diastolic blood pressure;
SARC	cis	rs7084402	0.967	rs7099881	chr10:60316211	A/G	cg07615347	chr10:60278583	BICC1	-0.53	-7.54	-0.44	1.07e-12	Refractive error;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg21736089	chr19:3110171	GNA11	0.54	6.96	0.41	3.4e-11	Schizophrenia;
SARC	cis	rs920590	0.758	rs7010174	chr8:19661930	G/C	cg01411142	chr8:19674711	INTS10	0.48	5.55	0.34	7.86e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs10791097	0.694	rs7942621	chr11:130751308	C/G	cg09137382	chr11:130731461	NA	0.31	4.78	0.3	3.07e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	trans	rs561341	0.609	rs9906443	chr17:30185565	C/T	cg20587970	chr11:113659929	NA	0.74	6.92	0.41	4.34e-11	Hip circumference adjusted for BMI;
SARC	trans	rs9354308	0.933	rs2814134	chr6:66566658	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.58	6.82	0.41	7.77e-11	Metabolite levels;
SARC	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg13206674	chr6:150067644	NUP43	0.46	5.98	0.36	8.37e-9	Lung cancer;
SARC	cis	rs4253772	0.637	rs8139035	chr22:46651367	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.64	6.81	0.41	8.27e-11	LDL cholesterol;Cholesterol, total;
SARC	cis	rs4319547	0.760	rs61954973	chr12:123074168	T/C	cg23029597	chr12:123009494	RSRC2	-0.41	-5.17	-0.32	5.05e-7	Body mass index;
SARC	cis	rs7511006	0.895	rs5771270	chr22:50682865	G/A	cg08875078	chr22:50639485	SELO	0.44	4.87	0.3	2.02e-6	Obesity-related traits;
SARC	cis	rs1920116	0.710	rs6772936	chr3:169566453	C/G	cg14222479	chr3:169487675	ARPM1	0.45	5.26	0.33	3.18e-7	Glioma (high-grade);
SARC	cis	rs7208859	0.623	rs56812022	chr17:29068733	A/G	cg13385521	chr17:29058706	SUZ12P	0.84	7.31	0.43	4.29e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs4319547	1.000	rs6489071	chr12:123025576	C/G	cg23029597	chr12:123009494	RSRC2	-0.39	-5.0	-0.31	1.15e-6	Body mass index;
SARC	cis	rs751728	0.605	rs1535950	chr6:33785827	A/G	cg25922239	chr6:33757077	LEMD2	0.54	6.58	0.4	3.08e-10	Crohn's disease;
SARC	cis	rs9807989	0.811	rs11688573	chr2:102969971	C/A	cg09003973	chr2:102972529	NA	0.41	5.57	0.34	7.03e-8	Asthma;
SARC	cis	rs3806843	0.676	rs1583005	chr5:140031537	G/A	cg16577123	chr5:140027231	NDUFA2;IK	-0.45	-5.31	-0.33	2.56e-7	Depressive symptoms (multi-trait analysis);
SARC	cis	rs9341808	0.600	rs590641	chr6:80966483	A/G	cg08355045	chr6:80787529	NA	0.32	5.07	0.32	7.95e-7	Sitting height ratio;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg26561342	chr1:45241260	SNORD55;RPS8;SNORD46	0.74	6.32	0.38	1.33e-9	Autism spectrum disorder or schizophrenia;
SARC	trans	rs12310956	0.510	rs6488178	chr12:33885251	C/G	cg26384229	chr12:38710491	ALG10B	0.6	7.92	0.46	9.47e-14	Morning vs. evening chronotype;
SARC	cis	rs8005150	0.737	rs10220371	chr14:88501852	C/T	cg18866806	chr14:89259551	EML5	-0.47	-4.88	-0.3	1.96e-6	Hepatitis B;
SARC	cis	rs1318878	0.565	rs12299598	chr12:15454217	A/T	cg08258403	chr12:15378311	NA	0.48	6.84	0.41	6.91e-11	Intelligence (multi-trait analysis);
SARC	cis	rs477692	1.000	rs485576	chr10:131425496	G/C	cg05714579	chr10:131428358	MGMT	0.55	7.26	0.43	5.59e-12	Response to temozolomide;
SARC	cis	rs10131894	0.611	rs174994	chr14:75434102	A/G	cg11812906	chr14:75593930	NEK9	-0.63	-7.81	-0.46	1.93e-13	Coronary artery disease;
SARC	cis	rs6688613	0.545	rs10800270	chr1:166827602	A/T	cg07049167	chr1:166818506	POGK	0.45	4.76	0.3	3.4e-6	Refractive astigmatism;
SARC	cis	rs78487399	0.808	rs7599781	chr2:43678726	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-5.01	-0.31	1.08e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs7769051	1.000	rs12203977	chr6:133122760	A/G	cg22852734	chr6:133119734	C6orf192	1.09	11.3	0.59	6.88e-24	Type 2 diabetes nephropathy;
SARC	cis	rs3749237	0.595	rs17595772	chr3:49409704	G/A	cg07636037	chr3:49044803	WDR6	0.64	8.25	0.48	1.2e-14	Resting heart rate;
SARC	trans	rs6600671	1.000	rs12047116	chr1:121185770	G/A	cg00646200	chr1:148855367	NA	0.53	7.39	0.44	2.58e-12	Hip geometry;
SARC	cis	rs9354352	0.935	rs9354354	chr6:66699333	A/G	cg07460842	chr6:66804631	NA	-0.59	-7.83	-0.46	1.73e-13	Initial pursuit acceleration in psychotic disorders;
SARC	cis	rs4803468	0.967	rs4802116	chr19:41905540	C/T	cg14132834	chr19:41945861	ATP5SL	-0.56	-7.51	-0.44	1.24e-12	Height;
SARC	cis	rs73206853	0.841	rs59698293	chr12:111054455	C/G	cg08946844	chr12:110511112	NA	0.56	4.72	0.3	4.05e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs2529049	0.727	rs886235	chr7:24769241	C/G	cg17569154	chr7:24781545	DFNA5	0.41	5.57	0.34	6.84e-8	Urate levels in obese individuals;
SARC	cis	rs950169	0.580	rs11636189	chr15:85193554	G/A	cg17507749	chr15:85114479	UBE2QP1	0.58	6.76	0.41	1.09e-10	Schizophrenia;
SARC	cis	rs950027	0.620	rs1617634	chr15:45615578	A/G	cg26924012	chr15:45694286	SPATA5L1	0.51	6.38	0.39	9.52e-10	Response to fenofibrate (adiponectin levels);
SARC	cis	rs7552404	0.924	rs1146588	chr1:76229787	C/G	cg10523679	chr1:76189770	ACADM	0.44	5.89	0.36	1.33e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.58	-6.91	-0.41	4.69e-11	Gut microbiome composition (summer);
SARC	cis	rs765787	0.530	rs4775837	chr15:45537684	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.67e-7	Uric acid levels;
SARC	cis	rs240764	0.853	rs11155496	chr6:100988939	T/C	cg09795085	chr6:101329169	ASCC3	-0.46	-6.04	-0.37	6.19e-9	Neuroticism;
SARC	cis	rs6964587	0.626	rs35849169	chr7:91507313	A/G	cg17063962	chr7:91808500	NA	0.78	11.26	0.59	9.38e-24	Breast cancer;
SARC	cis	rs1018836	0.651	rs2339175	chr8:91565805	A/T	cg16814680	chr8:91681699	NA	-0.84	-13.2	-0.65	4.36e-30	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs7917772	0.503	rs11191347	chr10:104351617	C/T	cg22532475	chr10:104410764	TRIM8	-0.24	-4.78	-0.3	3.14e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs2635047	0.638	rs2684840	chr18:44737230	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	6.01	0.37	7.22e-9	Educational attainment;
SARC	cis	rs6964587	0.869	rs7793946	chr7:91520628	T/C	cg17063962	chr7:91808500	NA	-0.93	-13.79	-0.67	4.86e-32	Breast cancer;
SARC	cis	rs10744422	1.000	rs7972447	chr12:123354545	C/G	cg25930673	chr12:123319894	HIP1R	-0.64	-4.75	-0.3	3.52e-6	Schizophrenia;
SARC	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs950169	0.840	rs62019457	chr15:85102142	T/C	cg24253500	chr15:84953950	NA	0.38	5.47	0.34	1.18e-7	Schizophrenia;
SARC	cis	rs12142240	0.698	rs6697123	chr1:46811310	A/C	cg10495392	chr1:46806563	NSUN4	0.65	6.8	0.41	8.47e-11	Menopause (age at onset);
SARC	cis	rs73206853	0.620	rs17682482	chr12:111154788	C/G	cg10860002	chr12:110842031	ANAPC7	0.58	4.8	0.3	2.84e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs7927771	0.832	rs11039212	chr11:47393303	A/T	cg20307385	chr11:47447363	PSMC3	0.56	6.84	0.41	7.05e-11	Subjective well-being;
SARC	trans	rs9325144	0.555	rs4550281	chr12:38689937	A/G	cg23762105	chr12:34175262	ALG10	-0.53	-7.07	-0.42	1.81e-11	Morning vs. evening chronotype;
SARC	cis	rs703842	1.000	rs8181644	chr12:58173466	A/G	cg00677455	chr12:58241039	CTDSP2	0.51	6.57	0.4	3.24e-10	Multiple sclerosis;
SARC	cis	rs7712401	0.562	rs2927639	chr5:122279666	G/C	cg19412675	chr5:122181750	SNX24	0.39	4.95	0.31	1.45e-6	Mean platelet volume;
SARC	cis	rs4820294	1.000	rs62236667	chr22:38061520	C/G	cg21798802	chr22:38057573	PDXP	0.37	5.65	0.35	4.69e-8	Fat distribution (HIV);
SARC	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg01570182	chr17:44337453	NA	0.85	9.69	0.54	7.29e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg20014441	chr20:42086101	SFRS6	-0.53	-7.31	-0.43	4.25e-12	Neuroticism;
SARC	cis	rs17376456	0.825	rs10476590	chr5:93244884	A/T	cg25358565	chr5:93447407	FAM172A	1.3	14.36	0.69	6.63e-34	Diabetic retinopathy;
SARC	cis	rs13095912	0.889	rs35917986	chr3:185310041	G/A	cg11274856	chr3:185301563	NA	0.35	4.81	0.3	2.76e-6	Systolic blood pressure;
SARC	cis	rs8051517	0.744	rs74024438	chr16:68327519	T/C	cg01866162	chr16:67596514	CTCF	0.86	5.4	0.33	1.64e-7	Blood protein levels;
SARC	cis	rs2016266	0.752	rs10783562	chr12:53657467	G/A	cg26875137	chr12:53738046	NA	0.4	5.23	0.32	3.74e-7	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs7264396	1.000	rs224430	chr20:34153341	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-5.4	-0.33	1.63e-7	Total cholesterol levels;
SARC	cis	rs7412746	0.658	rs11581757	chr1:150892244	A/G	cg15448220	chr1:150897856	SETDB1	0.51	6.65	0.4	2.02e-10	Melanoma;
SARC	cis	rs7408868	1.000	rs7254735	chr19:15263385	A/G	cg14696996	chr19:15285081	NOTCH3	0.95	8.01	0.46	5.33e-14	Pulse pressure;
SARC	cis	rs17376456	0.825	rs12716453	chr5:93271697	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.67	6.14	0.37	3.48e-9	Diabetic retinopathy;
SARC	cis	rs6840360	0.615	rs1877188	chr4:152607931	T/C	cg22705602	chr4:152727874	NA	-0.48	-8.3	-0.48	8.21e-15	Intelligence (multi-trait analysis);
SARC	cis	rs6121246	0.542	rs76513665	chr20:30450232	T/C	cg13852791	chr20:30311386	BCL2L1	0.76	6.21	0.38	2.44e-9	Mean corpuscular hemoglobin;
SARC	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg10295955	chr4:187884368	NA	-1.06	-19.91	-0.79	3.49e-52	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4588572	0.644	rs10061149	chr5:77744201	G/A	cg18281939	chr5:77783895	LHFPL2	0.34	4.74	0.3	3.69e-6	Triglycerides;
SARC	cis	rs6693567	0.545	rs7411534	chr1:150447269	C/T	cg09579323	chr1:150459698	TARS2	0.44	5.61	0.34	5.73e-8	Migraine;
SARC	cis	rs3733585	0.578	rs4466042	chr4:9955367	T/C	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.95	-0.36	9.9e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7546668	0.640	rs3766160	chr1:15808872	G/A	cg21858823	chr1:15850916	CASP9	0.49	5.95	0.36	9.81e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.38	4.71	0.3	4.2e-6	Tonsillectomy;
SARC	cis	rs1538970	0.924	rs6657284	chr1:45879088	T/C	cg05343316	chr1:45956843	TESK2	0.72	8.56	0.49	1.5e-15	Platelet count;
SARC	cis	rs472402	0.623	rs8192135	chr5:6636757	T/A	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.39	-4.86	-0.3	2.17e-6	Response to amphetamines;
SARC	cis	rs10463554	0.892	rs257307	chr5:102417509	A/G	cg23492399	chr5:102201601	PAM	-0.52	-5.7	-0.35	3.63e-8	Parkinson's disease;
SARC	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg18404041	chr3:52824283	ITIH1	-0.41	-6.13	-0.37	3.81e-9	Bipolar disorder;
SARC	cis	rs2361718	0.500	rs4889970	chr17:78096086	C/T	cg23534315	chr17:78082725	GAA	-0.39	-4.9	-0.31	1.82e-6	Yeast infection;
SARC	cis	rs17376456	0.825	rs28645862	chr5:93233128	G/C	cg25358565	chr5:93447407	FAM172A	1.29	14.31	0.68	9.44e-34	Diabetic retinopathy;
SARC	cis	rs920590	0.600	rs4921678	chr8:19663449	A/G	cg01411142	chr8:19674711	INTS10	0.39	4.75	0.3	3.61e-6	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg18357526	chr6:26021779	HIST1H4A	0.75	9.07	0.51	5.12e-17	Intelligence (multi-trait analysis);
SARC	cis	rs9487051	0.872	rs1111864	chr6:109611138	A/G	cg01475377	chr6:109611718	NA	-0.42	-5.94	-0.36	1.01e-8	Reticulocyte fraction of red cells;
SARC	cis	rs826838	1.000	rs10880785	chr12:38655405	T/G	cg13010199	chr12:38710504	ALG10B	0.82	11.85	0.61	1.17e-25	Heart rate;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg03779880	chr21:44395779	PKNOX1	-0.53	-6.6	-0.4	2.72e-10	Breast cancer;
SARC	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg23991368	chr14:102414729	NA	-0.53	-7.08	-0.42	1.65e-11	Thyroid cancer;
SARC	cis	rs10276381	0.901	rs73300638	chr7:28187344	A/C	cg23620719	chr7:28220237	JAZF1	0.71	5.69	0.35	3.76e-8	Crohn's disease;
SARC	trans	rs7937682	0.961	rs4935790	chr11:111633014	T/C	cg18187862	chr3:45730750	SACM1L	-0.58	-7.14	-0.42	1.16e-11	Primary sclerosing cholangitis;
SARC	cis	rs6500602	0.702	rs3761680	chr16:4524060	C/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.35	5.98	0.36	8.52e-9	Schizophrenia;
SARC	cis	rs995000	0.931	rs1168050	chr1:62986955	C/T	cg06896770	chr1:63153194	DOCK7	-0.88	-12.57	-0.64	5.16e-28	Triglyceride levels;
SARC	cis	rs12681366	0.614	rs3099401	chr8:95485531	T/C	cg26464482	chr8:95565502	KIAA1429	0.41	5.06	0.31	8.7e-7	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg05025164	chr4:1340916	KIAA1530	0.49	5.76	0.35	2.59e-8	Obesity-related traits;
SARC	cis	rs9457247	1.000	rs389946	chr6:167407268	T/C	cg23791538	chr6:167370224	RNASET2	-0.62	-8.52	-0.49	2e-15	Crohn's disease;
SARC	cis	rs6060717	0.536	rs7271036	chr20:34467215	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	-0.62	-4.92	-0.31	1.62e-6	Hip circumference adjusted for BMI;
SARC	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg06618935	chr21:46677482	NA	-0.4	-4.89	-0.3	1.9e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9291683	0.588	rs4280729	chr4:10013861	C/T	cg11266682	chr4:10021025	SLC2A9	0.42	7.65	0.45	5.26e-13	Bone mineral density;
SARC	cis	rs72945132	0.882	rs55905028	chr11:70127750	G/A	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.78	-0.35	2.39e-8	Coronary artery disease;
SARC	cis	rs5753618	0.509	rs5749229	chr22:31587218	T/C	cg00478049	chr22:31556069	RNF185	0.44	4.74	0.3	3.65e-6	Colorectal cancer;
SARC	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg18252515	chr7:66147081	NA	-1.3	-11.62	-0.61	6.33e-25	Diabetic kidney disease;
SARC	cis	rs6701037	0.566	rs4344281	chr1:175135376	C/T	cg00321850	chr1:175162397	KIAA0040	0.38	5.93	0.36	1.11e-8	Alcohol dependence;
SARC	cis	rs3820928	1.000	rs10167422	chr2:227777554	G/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-6.88	-0.41	5.56e-11	Pulmonary function;
SARC	trans	rs2847476	0.690	rs7929497	chr11:114192132	C/G	cg04509559	chr14:69864994	ERH;SLC39A9	-0.49	-6.29	-0.38	1.58e-9	Volumetric brain MRI;
SARC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.63	-7.69	-0.45	4.21e-13	Longevity;Endometriosis;
SARC	cis	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg12463550	chr7:65579703	CRCP	0.65	4.8	0.3	2.87e-6	Gout;
SARC	cis	rs7481584	0.581	rs366422	chr11:3053873	C/T	cg08508325	chr11:3079039	CARS	0.23	5.09	0.32	7.33e-7	Calcium levels;
SARC	cis	rs9341808	0.655	rs9350846	chr6:80865481	T/A	cg08355045	chr6:80787529	NA	0.34	5.35	0.33	2.14e-7	Sitting height ratio;
SARC	cis	rs2153904	0.793	rs12132270	chr1:205660940	C/T	cg14893161	chr1:205819251	PM20D1	-0.59	-5.25	-0.33	3.39e-7	Prostate-specific antigen levels;
SARC	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg21724239	chr8:58056113	NA	0.6	6.37	0.38	1.03e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2841277	0.834	rs2841281	chr14:105394669	C/T	cg19901468	chr14:105411992	AHNAK2	0.75	10.76	0.58	3.5e-22	Rheumatoid arthritis;
SARC	cis	rs7520050	0.966	rs12561806	chr1:46396776	C/T	cg06784218	chr1:46089804	CCDC17	-0.26	-4.75	-0.3	3.57e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs9916302	0.904	rs55689507	chr17:37404436	G/C	cg20243544	chr17:37824526	PNMT	0.54	6.44	0.39	6.75e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg15448220	chr1:150897856	SETDB1	0.43	5.73	0.35	3.01e-8	Tonsillectomy;
SARC	cis	rs986417	0.818	rs1950311	chr14:60989604	A/C	cg27398547	chr14:60952738	C14orf39	0.96	8.88	0.5	1.87e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg24531977	chr5:56204891	C5orf35	0.6	5.65	0.35	4.75e-8	Initial pursuit acceleration;
SARC	cis	rs713477	0.967	rs10150617	chr14:55916225	A/C	cg13175173	chr14:55914753	NA	0.34	5.15	0.32	5.43e-7	Pediatric bone mineral content (femoral neck);
SARC	cis	rs61935443	0.832	rs7308359	chr12:95272904	G/T	cg21533806	chr12:95267307	NA	0.7	8.46	0.48	2.97e-15	Schizophrenia;
SARC	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg26335602	chr6:28129616	ZNF389	0.49	5.2	0.32	4.38e-7	Parkinson's disease;
SARC	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg06108461	chr20:60628389	TAF4	0.61	6.57	0.4	3.28e-10	Obesity-related traits;
SARC	trans	rs12310956	0.510	rs4931758	chr12:33871870	C/T	cg26384229	chr12:38710491	ALG10B	0.63	8.33	0.48	6.88e-15	Morning vs. evening chronotype;
SARC	cis	rs7208859	0.673	rs73265624	chr17:29232066	G/A	cg13385521	chr17:29058706	SUZ12P	0.85	7.23	0.43	7.08e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs6570726	0.738	rs4495284	chr6:145916617	T/A	cg23711669	chr6:146136114	FBXO30	0.86	13.94	0.67	1.61e-32	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11098499	0.954	rs6822679	chr4:120402702	A/C	cg24375607	chr4:120327624	NA	0.42	4.97	0.31	1.28e-6	Corneal astigmatism;
SARC	cis	rs1707322	1.000	rs4489497	chr1:46438698	C/T	cg03146154	chr1:46216737	IPP	0.45	5.41	0.33	1.57e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9916302	0.904	rs4357971	chr17:37717280	C/T	cg15445000	chr17:37608096	MED1	0.41	4.82	0.3	2.57e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs2997447	0.761	rs17257127	chr1:26452386	C/T	cg19633962	chr1:26362018	EXTL1	-0.55	-4.72	-0.3	4.04e-6	QRS complex (12-leadsum);
SARC	cis	rs72945132	0.882	rs60917762	chr11:70211384	C/T	cg00319359	chr11:70116639	PPFIA1	0.67	6.2	0.38	2.61e-9	Coronary artery disease;
SARC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg05863683	chr7:1912471	MAD1L1	0.34	5.05	0.31	8.71e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs7582720	1.000	rs35212307	chr2:203765756	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.31	0.43	4.24e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs73206853	0.764	rs55929416	chr12:110622543	C/T	cg10860002	chr12:110842031	ANAPC7	0.64	5.27	0.33	3.06e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs73206853	0.764	rs7960988	chr12:110749918	G/A	cg10860002	chr12:110842031	ANAPC7	0.62	4.99	0.31	1.17e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg03161606	chr19:29218774	NA	0.47	6.67	0.4	1.79e-10	Methadone dose in opioid dependence;
SARC	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg00629941	chr15:75287862	SCAMP5	0.43	5.37	0.33	1.9e-7	Breast cancer;
SARC	cis	rs2204008	0.748	rs11180579	chr12:38237830	A/G	cg13010199	chr12:38710504	ALG10B	0.81	11.19	0.59	1.51e-23	Bladder cancer;
SARC	cis	rs63406760	1	rs63406760	chr12:123742692	TG/T	cg05973401	chr12:123451056	ABCB9	0.44	4.86	0.3	2.19e-6	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs9757252	0.580	rs7649306	chr3:86964922	C/T	cg12894142	chr3:86979205	NA	0.33	4.98	0.31	1.26e-6	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs4253772	0.513	rs6008612	chr22:46707907	G/A	cg24881330	chr22:46731750	TRMU	0.81	8.5	0.49	2.24e-15	LDL cholesterol;Cholesterol, total;
SARC	cis	rs8028182	0.636	rs8036884	chr15:75862893	T/C	cg20655648	chr15:75932815	IMP3	0.62	7.18	0.43	9.2e-12	Sudden cardiac arrest;
SARC	cis	rs6964587	0.839	rs13246743	chr7:91453945	G/T	cg17063962	chr7:91808500	NA	0.83	11.84	0.61	1.27e-25	Breast cancer;
SARC	cis	rs820218	0.717	rs9910627	chr17:73655529	C/T	cg01592526	chr17:73663357	RECQL5;SAP30BP	-0.59	-7.81	-0.46	1.88e-13	Rotator cuff tears;
SARC	cis	rs1538970	0.810	rs12067642	chr1:45927517	G/T	cg05343316	chr1:45956843	TESK2	0.75	8.5	0.49	2.25e-15	Platelet count;
SARC	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg12463550	chr7:65579703	CRCP	-0.48	-5.53	-0.34	8.39e-8	Aortic root size;
SARC	cis	rs208520	0.690	rs2797693	chr6:66868985	T/C	cg07460842	chr6:66804631	NA	-1.09	-15.3	-0.71	4.9e-37	Exhaled nitric oxide output;
SARC	cis	rs9303401	0.659	rs35082010	chr17:56936867	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	11.27	0.59	8.61e-24	Cognitive test performance;
SARC	cis	rs6542838	0.641	rs4499468	chr2:99475204	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.41	-5.19	-0.32	4.64e-7	Fear of minor pain;
SARC	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.76	11.28	0.59	7.76e-24	Menarche (age at onset);
SARC	cis	rs2304069	0.909	rs2544931	chr5:149367837	C/G	cg12661370	chr5:149340060	SLC26A2	-0.56	-5.12	-0.32	6.3e-7	HIV-1 control;
SARC	cis	rs73206853	0.620	rs73194027	chr12:111144317	C/A	cg10860002	chr12:110842031	ANAPC7	0.63	5.18	0.32	4.7e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	trans	rs1814175	0.817	rs7481230	chr11:49772235	G/A	cg15704280	chr7:45808275	SEPT13	-0.97	-18.15	-0.77	1.71e-46	Height;
SARC	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg03354898	chr7:1950403	MAD1L1	-0.38	-5.18	-0.32	4.72e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs9393777	0.513	rs9295702	chr6:26634040	T/C	cg12826209	chr6:26865740	GUSBL1	0.63	5.67	0.35	4.21e-8	Intelligence (multi-trait analysis);
SARC	cis	rs453301	0.522	rs2929309	chr8:9083771	C/A	cg11995313	chr8:8860691	ERI1	0.39	4.78	0.3	3.05e-6	Joint mobility (Beighton score);
SARC	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg14750844	chr3:154797592	MME	-0.52	-6.83	-0.41	7.22e-11	Parental extreme longevity (95 years and older);
SARC	cis	rs3812831	0.669	rs7327370	chr13:114946858	A/G	cg08824895	chr13:115047677	UPF3A	0.54	7.38	0.44	2.77e-12	Schizophrenia;
SARC	cis	rs1865760	0.964	rs1324084	chr6:25915134	C/T	cg10373733	chr6:25993375	NA	0.41	4.83	0.3	2.42e-6	Height;
SARC	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg18876405	chr7:65276391	NA	-0.44	-5.38	-0.33	1.85e-7	Aortic root size;
SARC	cis	rs11252926	0.931	rs4881399	chr10:567325	A/G	cg08603382	chr10:743973	NA	0.51	6.55	0.39	3.61e-10	Psychosis in Alzheimer's disease;
SARC	cis	rs72781680	0.821	rs12616257	chr2:24135034	A/G	cg08917208	chr2:24149416	ATAD2B	0.6	6.22	0.38	2.27e-9	Lymphocyte counts;
SARC	cis	rs4689388	0.926	rs10012946	chr4:6293350	C/T	cg25554036	chr4:6271136	WFS1	-0.4	-6.25	-0.38	1.88e-9	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs6493487	0.512	rs8032550	chr15:51178313	A/C	cg02338191	chr15:51200825	AP4E1	0.55	5.09	0.32	7.27e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	trans	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.43	-0.39	7.21e-10	Neuroticism;
SARC	cis	rs9916302	0.660	rs4795379	chr17:37674683	T/G	cg20243544	chr17:37824526	PNMT	0.53	5.45	0.34	1.28e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs6690583	0.560	rs7522046	chr1:85544410	A/G	cg22153463	chr1:85462885	MCOLN2	-0.55	-5.46	-0.34	1.25e-7	Serum sulfate level;
SARC	cis	rs1113500	0.933	rs1414674	chr1:108625947	A/G	cg06207961	chr1:108661230	NA	0.46	6.07	0.37	5.2e-9	Growth-regulated protein alpha levels;
SARC	cis	rs57506017	0.848	rs11509880	chr7:12261911	G/A	cg23422036	chr7:12250390	TMEM106B	0.4	4.92	0.31	1.6e-6	Neuroticism;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg18598016	chr22:39641127	PDGFB	-0.51	-6.65	-0.4	2.09e-10	Gallstone disease;
SARC	cis	rs9467773	1.000	rs9467774	chr6:26505036	C/A	cg12292205	chr6:26970375	C6orf41	0.43	5.24	0.32	3.66e-7	Intelligence (multi-trait analysis);
SARC	cis	rs3011225	0.710	rs3011222	chr1:44317545	C/T	cg13606994	chr1:44402422	ARTN	-0.29	-4.77	-0.3	3.3e-6	Amyotrophic lateral sclerosis (age of onset);
SARC	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg18357526	chr6:26021779	HIST1H4A	0.49	6.14	0.37	3.61e-9	Blood metabolite levels;
SARC	cis	rs7605378	1.000	rs769958	chr2:200695901	G/A	cg23649088	chr2:200775458	C2orf69	0.52	5.99	0.37	7.77e-9	Osteoporosis;
SARC	cis	rs7582720	1.000	rs72934751	chr2:203747522	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.31	0.43	4.24e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs3741404	0.560	rs12362602	chr11:63908660	G/A	cg05555928	chr11:63887634	MACROD1	0.35	5.4	0.33	1.63e-7	Platelet count;
SARC	cis	rs9462027	0.606	rs7759227	chr6:34728230	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.84	-0.36	1.71e-8	Systemic lupus erythematosus;
SARC	cis	rs6430585	0.528	rs499483	chr2:136652524	G/A	cg07169764	chr2:136633963	MCM6	1.05	13.37	0.66	1.23e-30	Corneal structure;
SARC	cis	rs6088590	0.561	rs6059932	chr20:33175466	C/T	cg08999081	chr20:33150536	PIGU	0.45	6.82	0.41	7.78e-11	Coronary artery disease;
SARC	cis	rs6484504	0.532	rs11031332	chr11:31278962	T/C	cg26647111	chr11:31128758	NA	-0.39	-5.05	-0.31	9.01e-7	Red blood cell count;
SARC	cis	rs11785400	1.000	rs4327844	chr8:143733540	C/T	cg24634471	chr8:143751801	JRK	-0.64	-8.52	-0.49	2.05e-15	Schizophrenia;
SARC	cis	rs6570726	0.791	rs11155433	chr6:145907831	A/G	cg05347473	chr6:146136440	FBXO30	-0.54	-7.46	-0.44	1.73e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6546324	0.625	rs1023693	chr2:67868732	T/C	cg18237512	chr2:67827392	NA	-0.57	-6.86	-0.41	6.02e-11	Endometriosis;
SARC	cis	rs523522	0.673	rs643372	chr12:121022640	C/G	cg12219531	chr12:120966889	COQ5	0.82	11.0	0.58	6.24e-23	High light scatter reticulocyte count;
SARC	cis	rs897984	0.520	rs4889622	chr16:30870957	A/G	cg00531865	chr16:30841666	NA	0.45	4.76	0.3	3.47e-6	Dementia with Lewy bodies;
SARC	cis	rs826838	0.559	rs4882276	chr12:38611994	T/C	cg13010199	chr12:38710504	ALG10B	0.52	6.58	0.4	3.09e-10	Heart rate;
SARC	cis	rs2404602	0.716	rs8025134	chr15:76781729	C/T	cg22467129	chr15:76604101	ETFA	-0.36	-4.73	-0.3	3.87e-6	Blood metabolite levels;
SARC	cis	rs2933343	0.700	rs6787833	chr3:128656184	A/G	cg25356066	chr3:128598488	ACAD9	0.69	9.15	0.51	3.05e-17	IgG glycosylation;
SARC	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.93	-13.85	-0.67	3.15e-32	Chronic sinus infection;
SARC	cis	rs754466	0.580	rs10824577	chr10:79577408	G/C	cg17075019	chr10:79541650	NA	-0.81	-12.4	-0.63	1.82e-27	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7223966	1.000	rs8075257	chr17:61728750	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.27	0.38	1.77e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs4900538	0.855	rs12586378	chr14:102853150	T/C	cg18135206	chr14:102964638	TECPR2	-0.6	-7.7	-0.45	3.94e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs2624839	0.704	rs2624833	chr3:50212512	G/T	cg19755318	chr3:50243323	SLC38A3	-0.3	-5.11	-0.32	6.57e-7	Intelligence (multi-trait analysis);
SARC	cis	rs10752881	1.000	rs4304541	chr1:182970238	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.3	0.56	9.62e-21	Colorectal cancer;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg18851932	chr19:45867053	ERCC2	-0.48	-6.4	-0.39	8.46e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs2073300	0.609	rs6132605	chr20:23354839	A/C	cg16736954	chr20:23401023	NAPB	0.79	4.89	0.31	1.86e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs7644634	0.559	rs2399054	chr3:105461250	G/C	cg23051926	chr3:105466016	CBLB	0.46	5.16	0.32	5.16e-7	Itch intensity from mosquito bite;
SARC	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.46	-5.85	-0.36	1.69e-8	Intelligence (multi-trait analysis);
SARC	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg17294928	chr15:75287854	SCAMP5	0.49	6.26	0.38	1.81e-9	Breast cancer;
SARC	cis	rs12586317	0.547	rs74243586	chr14:35477325	C/T	cg16230307	chr14:35515116	FAM177A1	1.02	11.85	0.61	1.18e-25	Psoriasis;
SARC	cis	rs2836950	0.545	rs2836922	chr21:40516308	C/T	cg11890956	chr21:40555474	PSMG1	-0.69	-8.61	-0.49	1.14e-15	Menarche (age at onset);
SARC	cis	rs4865169	0.967	rs10023088	chr4:57884435	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.4	4.8	0.3	2.78e-6	Breast cancer;
SARC	cis	rs6700896	0.897	rs11208696	chr1:66121781	T/G	cg04111102	chr1:66153794	NA	0.36	5.66	0.35	4.49e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs7223966	1.000	rs8078462	chr17:61857937	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.46	4.75	0.3	3.58e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg01475735	chr3:40494733	NA	0.45	5.07	0.32	8.24e-7	Renal cell carcinoma;
SARC	cis	rs8523	0.779	rs3798713	chr6:11008622	G/C	cg13562911	chr6:11044106	ELOVL2	0.45	5.82	0.36	1.96e-8	Red blood cell fatty acid levels;
SARC	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.43	0.44	2.1e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7542091	0.748	rs2357231	chr1:210028454	A/C	cg05527609	chr1:210001259	C1orf107	0.56	7.24	0.43	6.59e-12	Monobrow;
SARC	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg11987759	chr7:65425863	GUSB	0.48	6.02	0.37	6.7e-9	Aortic root size;
SARC	trans	rs61931739	0.500	rs3922568	chr12:34560107	A/C	cg13010199	chr12:38710504	ALG10B	0.78	11.05	0.59	4.14e-23	Morning vs. evening chronotype;
SARC	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.62	-6.33	-0.38	1.24e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs317689	0.718	rs160827	chr12:69770147	G/A	cg20891283	chr12:69753455	YEATS4	0.49	5.56	0.34	7.44e-8	Response to diuretic therapy;
SARC	cis	rs1008375	1.000	rs2315561	chr4:17679695	C/T	cg02297831	chr4:17616191	MED28	0.44	5.6	0.34	6.15e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs35995292	0.534	rs11980627	chr7:38907533	T/C	cg19327137	chr7:38886074	VPS41	0.51	7.51	0.44	1.28e-12	Subjective well-being (multi-trait analysis);
SARC	cis	rs807669	0.548	rs5746685	chr22:19192596	C/G	cg02655711	chr22:19163373	SLC25A1	-0.4	-5.46	-0.34	1.2e-7	Metabolite levels;
SARC	cis	rs11711311	1.000	rs2603793	chr3:113496418	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	8.58	0.49	1.31e-15	IgG glycosylation;
SARC	cis	rs13202913	0.652	rs9371528	chr6:151832668	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.57	5.46	0.34	1.2e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg06558623	chr16:89946397	TCF25	0.93	7.0	0.42	2.69e-11	Skin colour saturation;
SARC	cis	rs9457247	0.765	rs9457259	chr6:167444281	C/T	cg23791538	chr6:167370224	RNASET2	-0.55	-7.31	-0.43	4.24e-12	Crohn's disease;
SARC	cis	rs6840360	0.615	rs12647586	chr4:152607568	G/C	cg22705602	chr4:152727874	NA	-0.48	-8.38	-0.48	5.05e-15	Intelligence (multi-trait analysis);
SARC	cis	rs7044106	0.791	rs2416797	chr9:123480600	C/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	9.3	0.52	1.06e-17	Hip circumference adjusted for BMI;
SARC	cis	rs72781680	0.678	rs872169	chr2:24259188	C/G	cg08917208	chr2:24149416	ATAD2B	0.67	6.54	0.39	3.78e-10	Lymphocyte counts;
SARC	cis	rs6815814	0.950	rs5743557	chr4:38806827	G/A	cg09316306	chr4:38807337	TLR1	0.5	5.16	0.32	5.23e-7	Breast cancer;
SARC	cis	rs2213920	0.680	rs7863450	chr9:118242611	G/C	cg13918206	chr9:118159781	DEC1	0.76	5.92	0.36	1.13e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs2280018	0.963	rs12928424	chr16:15150773	C/G	cg07549590	chr16:15018862	NA	-0.35	-4.86	-0.3	2.2e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs7607369	0.637	rs3731866	chr2:219288899	C/T	cg02176678	chr2:219576539	TTLL4	-0.52	-7.46	-0.44	1.75e-12	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs681343	0.746	rs633372	chr19:49209226	G/A	cg21064579	chr19:49206444	FUT2	0.34	4.81	0.3	2.72e-6	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
SARC	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg13395646	chr4:1353034	KIAA1530	-0.6	-7.28	-0.43	5.19e-12	Obesity-related traits;
SARC	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6807915	0.541	rs310757	chr3:12281063	C/T	cg04748988	chr3:12329223	PPARG	0.35	4.89	0.31	1.88e-6	Leprosy;
SARC	cis	rs7520050	0.778	rs2934857	chr1:46039612	A/G	cg24296786	chr1:45957014	TESK2	-0.46	-5.73	-0.35	3.16e-8	Red blood cell count;Reticulocyte count;
SARC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.54	5.98	0.36	8.44e-9	Prudent dietary pattern;
SARC	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg10435706	chr6:150039699	LATS1	0.36	4.8	0.3	2.88e-6	Lung cancer;
SARC	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg19077165	chr18:44547161	KATNAL2	-0.52	-7.04	-0.42	2.17e-11	Personality dimensions;
SARC	cis	rs6840360	1.000	rs4696104	chr4:152600451	A/G	cg22705602	chr4:152727874	NA	-0.38	-6.54	-0.39	3.91e-10	Intelligence (multi-trait analysis);
SARC	cis	rs3213545	0.659	rs2259690	chr12:121457914	T/G	cg25281562	chr12:121454272	C12orf43	0.5	6.29	0.38	1.56e-9	Subjective well-being;Cardiovascular disease risk factors;
SARC	cis	rs10934753	0.632	rs1447661	chr3:125924981	A/G	cg01346077	chr3:125931526	NA	0.38	4.86	0.3	2.14e-6	Plasma homocysteine levels (post-methionine load test);
SARC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg07507251	chr3:52567010	NT5DC2	0.33	5.18	0.32	4.71e-7	Electroencephalogram traits;
SARC	cis	rs17345786	1.000	rs3804778	chr3:101294572	C/T	cg12386194	chr3:101231763	SENP7	0.72	8.56	0.49	1.51e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg00990874	chr7:1149470	C7orf50	-0.54	-5.88	-0.36	1.43e-8	Bronchopulmonary dysplasia;
SARC	cis	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg16384552	chr7:74938386	SPDYE8P	-0.47	-6.1	-0.37	4.29e-9	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs950776	0.518	rs12914694	chr15:78814444	G/A	cg06917634	chr15:78832804	PSMA4	0.88	13.47	0.66	5.85e-31	Sudden cardiac arrest;
SARC	cis	rs7833790	0.963	rs2400473	chr8:82703403	C/T	cg27398817	chr8:82754497	SNX16	-0.51	-5.53	-0.34	8.41e-8	Diastolic blood pressure;
SARC	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-8.66	-0.49	8.01e-16	Chronic sinus infection;
SARC	cis	rs10782582	0.593	rs2147039	chr1:76143166	C/T	cg10523679	chr1:76189770	ACADM	-0.42	-5.19	-0.32	4.6e-7	Daytime sleep phenotypes;
SARC	cis	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg22496380	chr5:211416	CCDC127	-0.88	-9.55	-0.53	1.95e-18	Breast cancer;
SARC	cis	rs9788682	1.000	rs9788682	chr15:78802586	A/G	cg06917634	chr15:78832804	PSMA4	0.48	5.16	0.32	5.31e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs9462027	0.628	rs7739771	chr6:34779801	C/A	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.91	-0.36	1.22e-8	Systemic lupus erythematosus;
SARC	cis	rs9790314	0.580	rs10936227	chr3:161043869	A/C	cg17135325	chr3:160939158	NMD3	0.52	6.5	0.39	4.78e-10	Morning vs. evening chronotype;
SARC	trans	rs7937682	0.889	rs1784786	chr11:111486043	A/G	cg18187862	chr3:45730750	SACM1L	-0.59	-7.3	-0.43	4.41e-12	Primary sclerosing cholangitis;
SARC	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg07157834	chr1:205819609	PM20D1	0.41	4.86	0.3	2.14e-6	Parkinson's disease;
SARC	cis	rs910316	1.000	rs2268617	chr14:75608728	G/A	cg06637938	chr14:75390232	RPS6KL1	0.51	7.14	0.42	1.15e-11	Height;
SARC	cis	rs9398803	0.687	rs7743860	chr6:126927717	T/G	cg19875578	chr6:126661172	C6orf173	0.63	8.7	0.5	5.9e-16	Male-pattern baldness;
SARC	cis	rs4792901	0.802	rs2279191	chr17:41570427	A/G	cg22562494	chr17:41607896	ETV4	-0.31	-4.86	-0.3	2.2e-6	Dupuytren's disease;
SARC	cis	rs6807306	1.000	rs6805980	chr3:167443548	C/T	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.56	5.48	0.34	1.1e-7	Mean platelet volume;
SARC	cis	rs9291683	0.609	rs3796836	chr4:10011345	A/G	cg11266682	chr4:10021025	SLC2A9	0.44	7.85	0.46	1.55e-13	Bone mineral density;
SARC	cis	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg01579765	chr21:45077557	HSF2BP	-0.37	-6.22	-0.38	2.3e-9	Mean corpuscular volume;
SARC	cis	rs708547	0.647	rs781668	chr4:57825140	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	0.41	4.84	0.3	2.37e-6	Response to bleomycin (chromatid breaks);
SARC	cis	rs9807989	0.801	rs11123925	chr2:102977511	G/A	cg09003973	chr2:102972529	NA	0.41	5.64	0.35	4.86e-8	Asthma;
SARC	cis	rs72781680	0.950	rs56128748	chr2:24126809	T/G	cg06627628	chr2:24431161	ITSN2	-0.65	-6.15	-0.37	3.33e-9	Lymphocyte counts;
SARC	cis	rs9790314	0.875	rs7615592	chr3:160981548	A/C	cg03342759	chr3:160939853	NMD3	-0.62	-7.7	-0.45	3.81e-13	Morning vs. evening chronotype;
SARC	cis	rs6831352	0.918	rs29001202	chr4:100053782	T/A	cg12011299	chr4:100065546	ADH4	-0.34	-5.74	-0.35	2.95e-8	Alcohol dependence;
SARC	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg02018176	chr4:1364513	KIAA1530	-0.34	-4.88	-0.3	1.94e-6	Obesity-related traits;
SARC	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg11987759	chr7:65425863	GUSB	0.48	6.3	0.38	1.51e-9	Aortic root size;
SARC	trans	rs9329221	0.655	rs4292737	chr8:10259115	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.63	-0.4	2.31e-10	Neuroticism;
SARC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg15242686	chr22:24348715	GSTTP1	0.42	5.46	0.34	1.23e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs76419734	1.000	rs11733093	chr4:106765063	G/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.77	5.19	0.32	4.53e-7	Post bronchodilator FEV1;
SARC	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg19223190	chr17:80058835	NA	0.44	6.19	0.38	2.67e-9	Life satisfaction;
SARC	cis	rs72945132	0.882	rs56368270	chr11:70162590	A/G	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.59	-0.34	6.41e-8	Coronary artery disease;
SARC	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg04944784	chr2:26401820	FAM59B	-0.47	-5.78	-0.35	2.43e-8	Gut microbiome composition (summer);
SARC	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg08048268	chr3:133502702	NA	0.43	6.08	0.37	5e-9	Iron status biomarkers;
SARC	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg00933542	chr6:150070202	PCMT1	0.31	5.14	0.32	5.88e-7	Lung cancer;
SARC	trans	rs116095464	0.558	rs113796397	chr5:246503	A/G	cg00938859	chr5:1591904	SDHAP3	0.77	7.34	0.43	3.49e-12	Breast cancer;
SARC	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg20607798	chr8:58055168	NA	0.57	5.42	0.33	1.45e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs765787	0.530	rs11636395	chr15:45535684	G/C	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.9e-6	Uric acid levels;
SARC	cis	rs11105298	0.891	rs10858909	chr12:89935387	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.55	-5.53	-0.34	8.4e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg17971929	chr21:40555470	PSMG1	0.98	13.7	0.67	9.88e-32	Cognitive function;
SARC	cis	rs7270101	0.749	rs61261378	chr20:3172807	G/T	cg25506879	chr20:3388711	C20orf194	-0.59	-4.74	-0.3	3.72e-6	Chronic hepatitis C infection;
SARC	cis	rs17608059	0.504	rs11656981	chr17:13978777	A/G	cg27005118	chr17:13972210	COX10	-0.55	-8.47	-0.49	2.71e-15	Temperament;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg08352268	chr17:6947337	SLC16A11	-0.51	-6.51	-0.39	4.49e-10	Height;
SARC	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg00149659	chr3:10157352	C3orf10	0.69	6.9	0.41	4.76e-11	Alzheimer's disease;
SARC	cis	rs2153535	0.580	rs9505457	chr6:8479142	C/T	cg23788917	chr6:8435910	SLC35B3	0.64	8.36	0.48	5.74e-15	Motion sickness;
SARC	cis	rs2072499	1.000	rs2253809	chr1:156172125	T/C	cg25208724	chr1:156163844	SLC25A44	0.87	11.61	0.61	7.06e-25	Testicular germ cell tumor;
SARC	cis	rs13256369	1.000	rs10095733	chr8:8574646	A/G	cg18904891	chr8:8559673	CLDN23	0.5	5.76	0.35	2.69e-8	Obesity-related traits;
SARC	cis	rs9916302	0.851	rs11657899	chr17:37626963	G/A	cg15445000	chr17:37608096	MED1	0.4	4.73	0.3	3.86e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs9715521	0.900	rs4860450	chr4:59827819	G/A	cg11281224	chr4:60001000	NA	-0.38	-4.83	-0.3	2.47e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9843304	0.585	rs9837351	chr3:149210099	C/G	cg08667024	chr3:149219783	TM4SF4	0.47	7.1	0.42	1.45e-11	Gallstone disease;
SARC	cis	rs7681440	0.869	rs894280	chr4:90760883	C/T	cg02192967	chr4:90758406	SNCA	0.36	5.11	0.32	6.56e-7	Dementia with Lewy bodies;
SARC	cis	rs11155671	0.530	rs9383577	chr6:150207195	C/T	cg00933542	chr6:150070202	PCMT1	0.29	4.91	0.31	1.73e-6	Testicular germ cell tumor;
SARC	cis	rs10861342	1.000	rs10861342	chr12:105458797	C/T	cg23923672	chr12:105501055	KIAA1033	-0.74	-5.1	-0.32	7.08e-7	IgG glycosylation;
SARC	cis	rs2645694	0.626	rs2645708	chr4:77822682	G/A	cg06046430	chr4:77819534	ANKRD56	0.55	7.9	0.46	1.08e-13	Emphysema distribution in smoking;
SARC	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg08067268	chr2:26466485	HADHB;HADHA	0.49	6.07	0.37	5.23e-9	Gut microbiome composition (summer);
SARC	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg22535103	chr8:58192502	C8orf71	-0.6	-6.33	-0.38	1.24e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9291683	0.588	rs3796842	chr4:9995851	A/T	cg00071950	chr4:10020882	SLC2A9	0.42	6.74	0.4	1.21e-10	Bone mineral density;
SARC	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg07414643	chr4:187882934	NA	0.46	6.57	0.4	3.28e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg18404041	chr3:52824283	ITIH1	-0.38	-5.72	-0.35	3.23e-8	Electroencephalogram traits;
SARC	cis	rs2153535	0.580	rs7748455	chr6:8453625	C/T	cg07606381	chr6:8435919	SLC35B3	0.77	11.05	0.59	4.35e-23	Motion sickness;
SARC	cis	rs2529049	0.560	rs2721783	chr7:24652955	C/T	cg17569154	chr7:24781545	DFNA5	0.49	7.09	0.42	1.58e-11	Urate levels in obese individuals;
SARC	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg00800038	chr16:89945340	TCF25	-0.76	-5.06	-0.31	8.3e-7	Skin colour saturation;
SARC	cis	rs2549003	1.000	rs2070723	chr5:131823187	A/G	cg21138405	chr5:131827807	IRF1	0.27	5.35	0.33	2.1e-7	Asthma (sex interaction);
SARC	cis	rs9951602	0.651	rs2959408	chr18:76681702	T/C	cg00806245	chr18:76673096	NA	0.4	5.17	0.32	4.98e-7	Obesity-related traits;
SARC	cis	rs5753618	0.583	rs5753639	chr22:31870400	A/G	cg07713946	chr22:31675144	LIMK2	-0.32	-4.87	-0.3	2.04e-6	Colorectal cancer;
SARC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.37	0.52	6.44e-18	Prudent dietary pattern;
SARC	cis	rs12912251	0.500	rs2643204	chr15:39007171	C/T	cg10631289	chr15:39006617	NA	-0.41	-4.76	-0.3	3.33e-6	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
SARC	cis	rs7769051	1.000	rs6910639	chr6:133120553	A/G	cg22852734	chr6:133119734	C6orf192	1.06	10.42	0.56	4.09e-21	Type 2 diabetes nephropathy;
SARC	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg13699009	chr12:122356056	WDR66	0.61	9.85	0.54	2.29e-19	Mean corpuscular volume;
SARC	trans	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg21659725	chr3:3221576	CRBN	-0.8	-12.22	-0.62	7.07e-27	Intelligence (multi-trait analysis);
SARC	cis	rs11098499	0.909	rs11723757	chr4:120299669	C/T	cg09307838	chr4:120376055	NA	0.9	12.63	0.64	3.26e-28	Corneal astigmatism;
SARC	cis	rs2916247	0.955	rs2920462	chr8:92985508	G/A	cg10183463	chr8:93005414	RUNX1T1	0.63	6.23	0.38	2.19e-9	Intelligence (multi-trait analysis);
SARC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg11494091	chr17:61959527	GH2	0.54	8.15	0.47	2.26e-14	Prudent dietary pattern;
SARC	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg11890956	chr21:40555474	PSMG1	1.16	19.42	0.79	1.32e-50	Cognitive function;
SARC	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg11062466	chr8:58055876	NA	0.53	5.53	0.34	8.39e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs986417	0.688	rs965454	chr14:60960251	T/C	cg27398547	chr14:60952738	C14orf39	0.88	8.66	0.49	7.84e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.34	-5.01	-0.31	1.07e-6	Longevity;Endometriosis;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg11698548	chr7:43769233	C7orf44	0.51	6.72	0.4	1.37e-10	Chemerin levels;
SARC	cis	rs9309473	0.950	rs13391258	chr2:73848933	C/T	cg20560298	chr2:73613845	ALMS1	-0.45	-5.48	-0.34	1.08e-7	Metabolite levels;
SARC	cis	rs5760092	0.755	rs11090298	chr22:24262061	G/A	cg04234412	chr22:24373322	LOC391322	0.59	6.49	0.39	5.02e-10	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs4742903	0.765	rs4743700	chr9:107005468	C/T	cg14250997	chr9:106856677	SMC2	0.38	4.76	0.3	3.44e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs1018836	0.544	rs10112371	chr8:91457626	C/T	cg16814680	chr8:91681699	NA	0.57	7.71	0.45	3.56e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg08045932	chr20:61659980	NA	0.5	6.67	0.4	1.89e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs6495122	0.501	rs12904227	chr15:75387048	A/C	cg09165964	chr15:75287851	SCAMP5	-0.49	-6.59	-0.4	2.95e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	cis	rs644799	0.965	rs2508713	chr11:95547927	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	14.22	0.68	1.83e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs17209837	1.000	rs45593435	chr7:87088772	A/G	cg00919237	chr7:87102261	ABCB4	-0.5	-5.47	-0.34	1.14e-7	Gallbladder cancer;
SARC	cis	rs9916302	0.784	rs34473775	chr17:37396201	G/T	cg07936489	chr17:37558343	FBXL20	-0.68	-8.97	-0.51	1.02e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs616147	0.627	rs9871799	chr3:39484320	G/A	cg17944282	chr3:39448217	RPSA	0.41	4.9	0.31	1.76e-6	Amyotrophic lateral sclerosis;Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs6088580	0.634	rs6088488	chr20:32992631	T/C	cg08999081	chr20:33150536	PIGU	-0.44	-6.65	-0.4	2.07e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs7587476	0.822	rs6726763	chr2:215681580	T/G	cg04530015	chr2:215796436	ABCA12	-0.41	-6.72	-0.4	1.42e-10	Neuroblastoma;
SARC	trans	rs11039798	0.512	rs1988465	chr11:49011303	C/T	cg15704280	chr7:45808275	SEPT13	0.7	6.96	0.41	3.42e-11	Axial length;
SARC	cis	rs941408	0.515	rs1005556	chr19:2778543	G/T	cg06609049	chr19:2785107	THOP1	0.95	14.12	0.68	3.94e-33	Total cholesterol levels;
SARC	cis	rs56116382	0.604	rs9858428	chr3:49877585	G/T	cg07636037	chr3:49044803	WDR6	-0.75	-5.8	-0.36	2.12e-8	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
SARC	cis	rs2380220	0.720	rs9400397	chr6:95980623	C/A	cg15832292	chr6:96025679	MANEA	0.5	5.54	0.34	8.02e-8	Behavioural disinhibition (generation interaction);
SARC	cis	rs1008375	1.000	rs917665	chr4:17668504	A/C	cg02297831	chr4:17616191	MED28	-0.38	-4.74	-0.3	3.78e-6	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg12463550	chr7:65579703	CRCP	-0.49	-5.79	-0.35	2.25e-8	Aortic root size;
SARC	cis	rs11608355	0.521	rs11066503	chr12:109842434	A/G	cg19025524	chr12:109796872	NA	-0.42	-6.05	-0.37	5.85e-9	Neuroticism;
SARC	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg11764359	chr7:65958608	NA	-0.77	-9.16	-0.51	2.79e-17	Aortic root size;
SARC	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg20102877	chr2:27665638	KRTCAP3	-0.36	-5.09	-0.32	7.24e-7	Total body bone mineral density;
SARC	cis	rs4481887	0.927	rs10749651	chr1:248472930	T/C	cg00666640	chr1:248458726	OR2T12	0.34	5.7	0.35	3.65e-8	Common traits (Other);
SARC	cis	rs34330	0.562	rs10845615	chr12:12863470	C/T	cg09462578	chr12:12878428	APOLD1	-0.57	-5.46	-0.34	1.22e-7	Systemic lupus erythematosus;
SARC	cis	rs3008870	1.000	rs12132068	chr1:67451924	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.89	-10.93	-0.58	9.86e-23	Lymphocyte percentage of white cells;
SARC	cis	rs9324022	0.929	rs1004574	chr14:101178067	C/G	cg18089426	chr14:101175970	NA	0.58	5.54	0.34	8.16e-8	Plateletcrit;
SARC	cis	rs6840360	0.615	rs4696094	chr4:152465501	C/T	cg22705602	chr4:152727874	NA	-0.43	-6.65	-0.4	2.01e-10	Intelligence (multi-trait analysis);
SARC	cis	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg25894440	chr7:65020034	NA	-0.75	-5.77	-0.35	2.56e-8	Diabetic kidney disease;
SARC	cis	rs12142240	0.698	rs17357683	chr1:46815378	C/T	cg00530320	chr1:46809349	NSUN4	0.57	6.92	0.41	4.4e-11	Menopause (age at onset);
SARC	cis	rs72781680	0.716	rs2712056	chr2:23959131	C/T	cg06627628	chr2:24431161	ITSN2	-0.52	-5.35	-0.33	2.11e-7	Lymphocyte counts;
SARC	trans	rs208520	0.690	rs7739253	chr6:66861052	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-13.93	-0.67	1.73e-32	Exhaled nitric oxide output;
SARC	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg16325326	chr1:53192061	ZYG11B	-0.95	-18.5	-0.77	1.23e-47	Monocyte count;
SARC	cis	rs12824058	0.831	rs7485200	chr12:130811641	C/T	cg24838063	chr12:130822603	PIWIL1	0.63	9.2	0.52	2.13e-17	Menopause (age at onset);
SARC	cis	rs11718455	0.960	rs35711021	chr3:44004791	G/A	cg08738300	chr3:44038990	NA	0.53	5.9	0.36	1.3e-8	Coronary artery disease;
SARC	cis	rs2841277	0.676	rs10438247	chr14:105411781	G/A	cg14403583	chr14:105418241	AHNAK2	-0.57	-7.38	-0.44	2.72e-12	Rheumatoid arthritis;
SARC	cis	rs3768617	0.510	rs1886501	chr1:183095234	A/G	cg13390022	chr1:182993471	LAMC1	0.31	4.79	0.3	3.01e-6	Fuchs's corneal dystrophy;
SARC	cis	rs2718058	0.560	rs2709109	chr7:37832852	G/A	cg24998770	chr7:37888106	TXNDC3	0.37	5.2	0.32	4.44e-7	Alzheimer's disease (late onset);
SARC	cis	rs9640161	0.789	rs13223702	chr7:150058968	G/A	cg21361702	chr7:150065534	REPIN1	0.58	6.41	0.39	8.02e-10	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs67311347	1.000	rs73080165	chr3:40533062	G/T	cg09455208	chr3:40491958	NA	0.33	5.05	0.31	8.92e-7	Renal cell carcinoma;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg00094036	chr12:72057474	THAP2;ZFC3H1	0.78	6.32	0.38	1.31e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6597981	0.592	rs10902218	chr11:743813	C/T	cg01741372	chr11:783889	NA	-0.48	-7.79	-0.45	2.23e-13	Breast cancer;
SARC	cis	rs1957429	0.614	rs17767870	chr14:65321737	G/A	cg23373153	chr14:65346875	NA	-0.69	-4.87	-0.3	2.11e-6	Pediatric areal bone mineral density (radius);
SARC	cis	rs7216064	0.861	rs62084252	chr17:65879578	G/C	cg12091567	chr17:66097778	LOC651250	-0.71	-7.9	-0.46	1.13e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg10591111	chr5:226296	SDHA	-0.51	-4.79	-0.3	3e-6	Breast cancer;
SARC	cis	rs4971059	0.654	rs4971073	chr1:155113104	G/T	cg22049894	chr1:155113146	DPM3	0.51	6.32	0.38	1.31e-9	Breast cancer;
SARC	cis	rs910316	1.000	rs910316	chr14:75626042	A/C	cg06637938	chr14:75390232	RPS6KL1	0.51	6.86	0.41	6.16e-11	Height;
SARC	cis	rs4253772	0.678	rs9627281	chr22:46644168	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.49	5.25	0.33	3.47e-7	LDL cholesterol;Cholesterol, total;
SARC	cis	rs11203032	0.831	rs12250945	chr10:90935206	A/G	cg16672925	chr10:90967113	CH25H	0.51	5.44	0.34	1.36e-7	Heart failure;
SARC	cis	rs9322817	0.691	rs7769270	chr6:105230729	C/A	cg02098413	chr6:105308735	HACE1	-0.39	-6.13	-0.37	3.69e-9	Thyroid stimulating hormone;
SARC	cis	rs12586317	0.576	rs6571696	chr14:35630175	A/G	cg16230307	chr14:35515116	FAM177A1	0.45	5.78	0.35	2.43e-8	Psoriasis;
SARC	cis	rs1008375	0.932	rs9291660	chr4:17663414	A/G	cg02297831	chr4:17616191	MED28	0.44	5.45	0.34	1.27e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs13256369	0.851	rs12541477	chr8:8563895	G/A	cg17143192	chr8:8559678	CLDN23	0.53	5.87	0.36	1.46e-8	Obesity-related traits;
SARC	cis	rs28595532	1.000	rs11938970	chr4:119660152	A/G	cg14228332	chr4:119757509	SEC24D	0.87	5.13	0.32	6.09e-7	Cannabis dependence symptom count;
SARC	cis	rs13191362	1.000	rs13206253	chr6:163166902	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.36	4.74	0.3	3.79e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9486719	0.790	rs2499790	chr6:96845078	G/A	cg06623918	chr6:96969491	KIAA0776	0.75	7.39	0.44	2.65e-12	Migraine;Coronary artery disease;
SARC	cis	rs2204008	0.905	rs7294297	chr12:38442573	T/C	cg26384229	chr12:38710491	ALG10B	0.82	10.96	0.58	7.9e-23	Bladder cancer;
SARC	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg20607798	chr8:58055168	NA	0.61	5.41	0.33	1.57e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2295359	0.824	rs4655679	chr1:67599657	A/G	cg08029281	chr1:67600428	NA	-0.4	-5.11	-0.32	6.84e-7	Psoriasis;
SARC	cis	rs4336470	0.504	rs62418774	chr6:105175132	G/A	cg02098413	chr6:105308735	HACE1	-0.39	-6.04	-0.37	6.11e-9	Neuroblastoma;
SARC	cis	rs7666738	0.830	rs62321570	chr4:98984276	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs8058578	1.000	rs7198250	chr16:30746822	C/A	cg02466173	chr16:30829666	NA	-0.42	-5.54	-0.34	8.03e-8	Multiple myeloma;
SARC	cis	rs11608355	0.846	rs60945232	chr12:109854401	A/G	cg05360138	chr12:110035743	NA	0.59	6.3	0.38	1.46e-9	Neuroticism;
SARC	trans	rs61931739	0.534	rs28548399	chr12:34188151	G/A	cg13010199	chr12:38710504	ALG10B	0.73	9.71	0.54	6.21e-19	Morning vs. evening chronotype;
SARC	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg20887711	chr4:1340912	KIAA1530	0.56	6.88	0.41	5.58e-11	Longevity;
SARC	trans	rs7618501	0.966	rs13085679	chr3:49869631	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.72	10.12	0.55	3.49e-20	Intelligence (multi-trait analysis);
SARC	cis	rs514406	0.505	rs387436	chr1:53179376	C/T	cg24675658	chr1:53192096	ZYG11B	0.65	9.54	0.53	1.98e-18	Monocyte count;
SARC	cis	rs9911578	1.000	rs9898916	chr17:57048660	C/T	cg05425664	chr17:57184151	TRIM37	-0.64	-7.89	-0.46	1.17e-13	Intelligence (multi-trait analysis);
SARC	cis	rs2075371	1.000	rs2241335	chr7:133979368	C/T	cg11752832	chr7:134001865	SLC35B4	0.55	7.25	0.43	6.04e-12	Mean platelet volume;
SARC	cis	rs7769051	0.711	rs9493435	chr6:133088205	A/G	cg07930552	chr6:133119739	C6orf192	0.86	7.74	0.45	2.94e-13	Type 2 diabetes nephropathy;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg14256840	chr7:64197047	NA	0.45	6.41	0.39	7.84e-10	Breast cancer;
SARC	cis	rs765787	0.530	rs2554453	chr15:45522107	A/G	cg24006582	chr15:45444508	DUOX1	-0.5	-6.41	-0.39	8.17e-10	Uric acid levels;
SARC	cis	rs11098499	0.954	rs7437420	chr4:120312903	A/G	cg09160332	chr4:120329925	NA	-0.33	-4.77	-0.3	3.27e-6	Corneal astigmatism;
SARC	cis	rs6908034	0.505	rs77880623	chr6:19819454	T/C	cg02682789	chr6:19804855	NA	0.67	5.36	0.33	2.03e-7	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs35110281	0.616	rs2236666	chr21:45109856	T/C	cg01579765	chr21:45077557	HSF2BP	-0.39	-6.24	-0.38	2.02e-9	Mean corpuscular volume;
SARC	cis	rs78487399	0.808	rs7570242	chr2:43706002	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-4.81	-0.3	2.67e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs6088580	0.634	rs6059875	chr20:33086090	T/G	cg08999081	chr20:33150536	PIGU	0.43	6.75	0.4	1.14e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs10463554	0.927	rs34800	chr5:102426503	C/T	cg23492399	chr5:102201601	PAM	-0.54	-5.91	-0.36	1.23e-8	Parkinson's disease;
SARC	cis	rs2562456	0.876	rs11085467	chr19:21751843	A/G	cg00455402	chr19:21769736	NA	-0.39	-4.95	-0.31	1.41e-6	Pain;
SARC	cis	rs7552404	0.924	rs2173378	chr1:76201992	G/T	cg03433033	chr1:76189801	ACADM	0.48	6.99	0.42	2.82e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg06212747	chr3:49208901	KLHDC8B	0.76	11.07	0.59	3.64e-23	Menarche (age at onset);
SARC	cis	rs9486715	0.809	rs9486467	chr6:96971803	C/T	cg06623918	chr6:96969491	KIAA0776	0.94	14.14	0.68	3.42e-33	Headache;
SARC	cis	rs9303280	0.517	rs12939566	chr17:38038390	A/T	cg17467752	chr17:38218738	THRA	-0.37	-4.77	-0.3	3.25e-6	Self-reported allergy;
SARC	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg21782813	chr7:2030301	MAD1L1	0.36	5.69	0.35	3.89e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs3796352	1.000	rs13072457	chr3:53102389	G/A	cg15956490	chr3:53032818	SFMBT1	0.91	6.02	0.37	6.66e-9	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs4242434	0.854	rs4872007	chr8:22538879	G/A	cg03733263	chr8:22462867	KIAA1967	-0.94	-15.12	-0.7	1.85e-36	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs1059312	0.772	rs11609637	chr12:129300202	T/G	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.5	7.35	0.43	3.37e-12	Systemic lupus erythematosus;
SARC	cis	rs10911232	0.507	rs10911198	chr1:182997318	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.67	0.57	6.63e-22	Hypertriglyceridemia;
SARC	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg13628971	chr7:2884303	GNA12	0.66	7.83	0.46	1.66e-13	Height;
SARC	trans	rs3942852	0.806	rs10734562	chr11:48128189	A/T	cg15704280	chr7:45808275	SEPT13	0.59	6.91	0.41	4.51e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.45	-5.7	-0.35	3.61e-8	Personality dimensions;
SARC	cis	rs4555082	0.915	rs66527719	chr14:105750523	C/G	cg06808227	chr14:105710500	BRF1	-0.47	-6.08	-0.37	4.83e-9	Mean platelet volume;Platelet distribution width;
SARC	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.97	-15.81	-0.72	9.26e-39	Chronic sinus infection;
SARC	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.63e-10	Life satisfaction;
SARC	cis	rs2816062	0.813	rs2745321	chr1:18889198	G/C	cg18795169	chr1:18902165	NA	-0.79	-12.43	-0.63	1.56e-27	Urate levels in lean individuals;
SARC	cis	rs1008375	0.966	rs6449329	chr4:17703677	T/C	cg16339924	chr4:17578868	LAP3	0.55	7.02	0.42	2.36e-11	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10782582	0.609	rs5745394	chr1:76311731	G/A	cg03433033	chr1:76189801	ACADM	-0.39	-4.98	-0.31	1.24e-6	Daytime sleep phenotypes;
SARC	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.45	5.58	0.34	6.78e-8	Tonsillectomy;
SARC	cis	rs11770686	0.740	rs2868137	chr7:75345175	T/C	cg17787366	chr7:75369077	HIP1	0.44	5.44	0.34	1.37e-7	Essential tremor;
SARC	cis	rs698833	0.859	rs1302175	chr2:44657024	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.67	8.77	0.5	3.91e-16	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs554111	0.593	rs7540023	chr1:21310092	T/C	cg04902671	chr1:21058625	SH2D5	0.45	5.49	0.34	1.04e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs473651	0.935	rs10170056	chr2:239339291	G/C	cg18131467	chr2:239335373	ASB1	0.98	12.45	0.63	1.28e-27	Multiple system atrophy;
SARC	cis	rs6701037	0.566	rs10489326	chr1:175134677	A/G	cg08873628	chr1:175162347	KIAA0040	0.34	4.82	0.3	2.64e-6	Alcohol dependence;
SARC	cis	rs1707322	0.963	rs4459051	chr1:46451203	A/G	cg03146154	chr1:46216737	IPP	0.45	5.41	0.33	1.57e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1707322	1.000	rs12124291	chr1:46432132	G/A	cg06784218	chr1:46089804	CCDC17	0.34	5.98	0.36	8.31e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs477692	0.673	rs487120	chr10:131367552	C/T	cg05714579	chr10:131428358	MGMT	0.57	7.21	0.43	7.96e-12	Response to temozolomide;
SARC	cis	rs7617480	0.648	rs6801211	chr3:48774420	C/G	cg07636037	chr3:49044803	WDR6	0.88	10.29	0.56	1.02e-20	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg07414643	chr4:187882934	NA	0.46	6.57	0.4	3.28e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2439831	0.867	rs4075674	chr15:43650230	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.77	7.99	0.46	6.26e-14	Lung cancer in ever smokers;
SARC	cis	rs78545713	0.892	rs113432940	chr6:26256324	T/A	cg00631329	chr6:26305371	NA	-0.69	-6.41	-0.39	8.11e-10	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs3126085	0.935	rs4845736	chr1:152175551	G/A	cg09127314	chr1:152161683	NA	0.42	4.79	0.3	3.03e-6	Atopic dermatitis;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg13861908	chr20:62290376	RTEL1	0.5	6.43	0.39	7.1e-10	Breast cancer;
SARC	cis	rs67460515	0.563	rs35914913	chr3:160826561	A/G	cg03342759	chr3:160939853	NMD3	-0.63	-7.56	-0.44	9.46e-13	Parkinson's disease;
SARC	cis	rs4722166	0.630	rs4722168	chr7:22779002	G/A	cg26061582	chr7:22766209	IL6	0.57	6.16	0.37	3.17e-9	Lung cancer;
SARC	cis	rs7927592	0.913	rs4316515	chr11:68308840	A/T	cg01657329	chr11:68192670	LRP5	0.41	5.03	0.31	1e-6	Total body bone mineral density;
SARC	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.56	7.25	0.43	6.03e-12	Menarche (age at onset);
SARC	trans	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-7.71	-0.45	3.62e-13	Intelligence (multi-trait analysis);
SARC	trans	rs459571	1.000	rs459571	chr9:136912626	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.62	-7.03	-0.42	2.25e-11	Platelet distribution width;
SARC	cis	rs8051517	1.000	rs74024440	chr16:68330989	G/A	cg01866162	chr16:67596514	CTCF	0.86	5.44	0.34	1.36e-7	Blood protein levels;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg07159286	chr12:133779169	ZNF268	-0.51	-6.66	-0.4	1.94e-10	Height;
SARC	cis	rs3796352	1.000	rs34979715	chr3:53048960	G/A	cg15956490	chr3:53032818	SFMBT1	0.86	5.7	0.35	3.66e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs7666738	0.830	rs1813251	chr4:98921170	A/G	cg05340658	chr4:99064831	C4orf37	0.68	9.2	0.52	2.08e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7666738	0.791	rs7657399	chr4:98851861	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.59	0.49	1.24e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs240764	0.853	rs2062634	chr6:101002618	G/C	cg09795085	chr6:101329169	ASCC3	-0.46	-6.07	-0.37	5.12e-9	Neuroticism;
SARC	cis	rs7607369	0.559	rs6741592	chr2:219658609	C/T	cg02176678	chr2:219576539	TTLL4	-0.33	-4.82	-0.3	2.54e-6	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg05896524	chr21:47604654	C21orf56	-0.42	-5.09	-0.32	7.23e-7	Testicular germ cell tumor;
SARC	cis	rs3018712	0.532	rs948863	chr11:68420974	G/A	cg01657329	chr11:68192670	LRP5	0.6	5.55	0.34	7.87e-8	Total body bone mineral density;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg02674662	chr11:62599661	STX5	0.54	6.76	0.4	1.08e-10	Blood pressure;
SARC	cis	rs425277	0.958	rs626479	chr1:2110260	A/G	cg24578937	chr1:2090814	PRKCZ	-0.3	-5.62	-0.35	5.38e-8	Height;
SARC	cis	rs950027	0.549	rs2899375	chr15:45598335	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.48	-5.75	-0.35	2.83e-8	Response to fenofibrate (adiponectin levels);
SARC	trans	rs453301	0.571	rs330048	chr8:9087278	A/C	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.44	-0.39	6.63e-10	Joint mobility (Beighton score);
SARC	cis	rs7666738	0.830	rs10049985	chr4:99023517	C/T	cg05340658	chr4:99064831	C4orf37	0.66	9.04	0.51	6.35e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7584330	0.666	rs72620816	chr2:238353604	C/T	cg14458575	chr2:238380390	NA	0.59	6.5	0.39	4.78e-10	Prostate cancer;
SARC	cis	rs9362426	1.000	rs406900	chr6:88085447	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.41	4.97	0.31	1.3e-6	Depressive episodes in bipolar disorder;
SARC	cis	rs79839061	0.518	rs3755961	chr4:895059	A/G	cg07828340	chr4:882639	GAK	0.79	5.94	0.36	1.06e-8	Intelligence (multi-trait analysis);
SARC	cis	rs4737010	0.570	rs2111804	chr8:41644266	A/T	cg17182837	chr8:41585554	ANK1	-0.44	-4.93	-0.31	1.57e-6	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
SARC	cis	rs13191362	0.935	rs73008456	chr6:163013697	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.55	5.25	0.33	3.46e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs7084402	0.967	rs1649048	chr10:60324282	C/T	cg07615347	chr10:60278583	BICC1	0.58	8.16	0.47	2.14e-14	Refractive error;
SARC	cis	rs9807989	0.811	rs67088699	chr2:102968751	C/T	cg09003973	chr2:102972529	NA	0.41	5.6	0.34	6.11e-8	Asthma;
SARC	cis	rs7824557	0.592	rs2572371	chr8:11223793	G/T	cg21775007	chr8:11205619	TDH	0.69	9.82	0.54	2.89e-19	Retinal vascular caliber;
SARC	cis	rs1559088	0.744	rs12462426	chr19:33536683	A/C	cg17764715	chr19:33622953	WDR88	0.4	4.95	0.31	1.42e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg02725872	chr8:58115012	NA	-0.37	-6.55	-0.39	3.71e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1468333	1.000	rs7735635	chr5:137508336	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	-0.75	-9.65	-0.53	9.43e-19	Resting heart rate;
SARC	cis	rs7927592	0.956	rs12274114	chr11:68255577	A/C	cg01657329	chr11:68192670	LRP5	-0.39	-4.91	-0.31	1.7e-6	Total body bone mineral density;
SARC	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1055129	0.655	rs7216615	chr17:73833910	T/C	cg06969265	chr17:73775802	H3F3B	0.44	5.1	0.32	7.03e-7	White matter hyperintensity burden;
SARC	cis	rs4481887	0.830	rs4474289	chr1:248474972	T/A	cg01631408	chr1:248437212	OR2T33	-0.38	-4.8	-0.3	2.78e-6	Common traits (Other);
SARC	cis	rs7020830	0.867	rs55845273	chr9:37362219	C/T	cg14294708	chr9:37120828	ZCCHC7	1.1	19.45	0.79	1.06e-50	Schizophrenia;
SARC	cis	rs2952156	0.652	rs11869286	chr17:37813856	C/G	cg00129232	chr17:37814104	STARD3	-0.81	-12.14	-0.62	1.34e-26	Asthma;
SARC	cis	rs11098499	0.908	rs1002152	chr4:120273387	C/A	cg09307838	chr4:120376055	NA	0.89	12.28	0.63	4.81e-27	Corneal astigmatism;
SARC	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg02297831	chr4:17616191	MED28	0.52	6.79	0.41	9.4e-11	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg06636001	chr8:8085503	FLJ10661	0.65	8.8	0.5	3.11e-16	Mood instability;
SARC	cis	rs4646312	0.555	rs737866	chr22:19930109	T/C	cg07194846	chr22:19930177	COMT;TXNRD2	0.52	6.8	0.41	8.56e-11	Schizophrenia;
SARC	cis	rs9818758	0.607	rs13087930	chr3:48961726	A/G	cg07636037	chr3:49044803	WDR6	-0.74	-6.49	-0.39	5.12e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs11583043	1.000	rs17100939	chr1:101443701	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	5.91	0.36	1.24e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-6.35	-0.38	1.11e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4713675	0.565	rs9348924	chr6:33705436	A/G	cg15676125	chr6:33679581	C6orf125	0.57	7.03	0.42	2.21e-11	Plateletcrit;
SARC	cis	rs1538970	0.924	rs1006216	chr1:45909994	A/G	cg05343316	chr1:45956843	TESK2	0.78	9.01	0.51	7.82e-17	Platelet count;
SARC	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg12463550	chr7:65579703	CRCP	0.67	5.06	0.31	8.43e-7	Diabetic kidney disease;
SARC	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg19346786	chr7:2764209	NA	-0.36	-5.19	-0.32	4.48e-7	Height;
SARC	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.39	5.67	0.35	4.13e-8	Total body bone mineral density;
SARC	cis	rs2439831	0.867	rs2255440	chr15:43830467	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	7.91	0.46	1.06e-13	Lung cancer in ever smokers;
SARC	cis	rs8141529	0.509	rs5762863	chr22:29253335	A/C	cg02153584	chr22:29168773	CCDC117	0.7	9.45	0.53	3.82e-18	Lymphocyte counts;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg11600721	chr5:72861436	ANKRA2;UTP15	-0.47	-6.26	-0.38	1.83e-9	Neuroticism;
SARC	cis	rs12950390	0.512	rs11655306	chr17:45858744	C/T	cg24803719	chr17:45855879	NA	-0.43	-5.33	-0.33	2.31e-7	IgG glycosylation;
SARC	cis	rs9611565	0.921	rs5751080	chr22:41736267	A/G	cg17376030	chr22:41985996	PMM1	0.52	6.66	0.4	1.99e-10	Vitiligo;
SARC	cis	rs4481887	0.927	rs4244184	chr1:248486895	G/T	cg00666640	chr1:248458726	OR2T12	0.35	5.75	0.35	2.83e-8	Common traits (Other);
SARC	cis	rs6952808	0.609	rs34967784	chr7:1949507	T/G	cg03354898	chr7:1950403	MAD1L1	-0.38	-5.12	-0.32	6.48e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs9388451	0.807	rs1268065	chr6:126042783	G/A	cg06289844	chr6:126071538	HEY2	-0.37	-6.06	-0.37	5.31e-9	Brugada syndrome;
SARC	cis	rs3784262	1.000	rs4646586	chr15:58305344	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.39	-5.88	-0.36	1.44e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs9393692	0.905	rs9357004	chr6:26303319	A/G	cg13736514	chr6:26305472	NA	-0.7	-9.78	-0.54	3.76e-19	Educational attainment;
SARC	trans	rs11098499	0.955	rs1397608	chr4:120161744	A/G	cg25214090	chr10:38739885	LOC399744	0.52	6.86	0.41	6.19e-11	Corneal astigmatism;
SARC	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg25072359	chr17:41440525	NA	0.49	5.8	0.36	2.15e-8	Menopause (age at onset);
SARC	cis	rs751728	0.626	rs57150921	chr6:33737518	T/C	cg15252951	chr6:33757062	LEMD2	0.42	4.94	0.31	1.52e-6	Crohn's disease;
SARC	cis	rs526231	0.511	rs10434793	chr5:102389815	A/T	cg23492399	chr5:102201601	PAM	-0.51	-5.55	-0.34	7.61e-8	Primary biliary cholangitis;
SARC	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg24250549	chr1:154909240	PMVK	0.83	11.95	0.62	5.56e-26	Prostate cancer;
SARC	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg10253484	chr15:75165896	SCAMP2	-0.39	-4.73	-0.3	3.83e-6	Breast cancer;
SARC	cis	rs7617773	0.780	rs6442111	chr3:48312060	G/C	cg11946769	chr3:48343235	NME6	0.68	8.97	0.51	9.74e-17	Coronary artery disease;
SARC	cis	rs1635	0.826	rs4711167	chr6:28294888	C/T	cg24154054	chr6:28220253	ZKSCAN4	-0.7	-4.72	-0.3	3.99e-6	Schizophrenia;
SARC	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.91	11.13	0.59	2.36e-23	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs7103648	0.966	rs10838702	chr11:47410888	G/T	cg20307385	chr11:47447363	PSMC3	0.83	12.91	0.65	3.98e-29	Diastolic blood pressure;Systolic blood pressure;
SARC	trans	rs208520	1.000	rs208527	chr6:66957209	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.82	-8.98	-0.51	9.32e-17	Exhaled nitric oxide output;
SARC	cis	rs1348850	0.915	rs10930798	chr2:178446141	G/A	cg23306229	chr2:178417860	TTC30B	0.59	7.11	0.42	1.43e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs644799	0.710	rs564480	chr11:95561741	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.94	16.0	0.72	2.26e-39	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs10905065	0.610	rs4748307	chr10:5747701	C/T	cg09072322	chr10:5726702	C10orf18	0.42	4.78	0.3	3.06e-6	Menopause (age at onset);
SARC	cis	rs6665290	0.669	rs3768423	chr1:227177293	G/A	cg14016676	chr1:227182615	CDC42BPA	0.35	5.13	0.32	6.02e-7	Myeloid white cell count;
SARC	cis	rs941873	0.772	rs1892498	chr10:81103862	A/G	cg09469691	chr10:81107165	PPIF	0.65	9.38	0.52	6.05e-18	Height;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg27558594	chr6:91006613	BACH2	-0.79	-6.44	-0.39	6.7e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs11098499	0.818	rs7688802	chr4:120451668	G/A	cg24375607	chr4:120327624	NA	0.42	4.9	0.31	1.76e-6	Corneal astigmatism;
SARC	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg12463550	chr7:65579703	CRCP	0.47	5.24	0.32	3.55e-7	Aortic root size;
SARC	cis	rs703842	1.000	rs11172342	chr12:58187758	G/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.77	11.14	0.59	2.16e-23	Multiple sclerosis;
SARC	cis	rs2652834	0.821	rs7174174	chr15:63372327	A/G	cg05507819	chr15:63340323	TPM1	-0.52	-5.58	-0.34	6.72e-8	HDL cholesterol;
SARC	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg21782813	chr7:2030301	MAD1L1	0.32	4.94	0.31	1.5e-6	Schizophrenia;
SARC	cis	rs1468333	0.567	rs10073922	chr5:137717213	A/G	cg27119451	chr5:137514611	BRD8;KIF20A	-0.61	-7.7	-0.45	3.76e-13	Resting heart rate;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg23233673	chr19:54693846	MBOAT7;TSEN34	0.54	6.65	0.4	2.12e-10	Breast cancer;
SARC	cis	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg07274523	chr3:49395745	GPX1	0.49	5.46	0.34	1.21e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs1483890	0.723	rs13075664	chr3:69411365	G/A	cg22125112	chr3:69402811	FRMD4B	0.29	4.78	0.3	3.12e-6	Resting heart rate;
SARC	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg08219700	chr8:58056026	NA	0.61	6.27	0.38	1.75e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs644799	0.735	rs10831432	chr11:95516040	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.6	8.17	0.47	2e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg23242017	chr7:97736138	LMTK2	0.54	6.92	0.41	4.38e-11	Lung adenocarcinoma;
SARC	cis	rs4727027	0.866	rs1405124	chr7:148779618	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	5.68	0.35	3.94e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs9398803	0.965	rs4895807	chr6:126686513	C/G	cg19875578	chr6:126661172	C6orf173	0.57	7.67	0.45	4.7e-13	Male-pattern baldness;
SARC	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg08219700	chr8:58056026	NA	0.62	6.52	0.39	4.28e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9914544	0.524	rs7209853	chr17:18798600	G/A	cg25390199	chr17:18761479	PRPSAP2	0.46	6.04	0.37	5.99e-9	Educational attainment (years of education);
SARC	cis	rs5753618	0.539	rs1034588	chr22:31616301	A/G	cg02404636	chr22:31891804	SFI1	-0.47	-4.98	-0.31	1.26e-6	Colorectal cancer;
SARC	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg08280861	chr8:58055591	NA	0.62	5.68	0.35	4.06e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg21775007	chr8:11205619	TDH	-0.64	-8.51	-0.49	2.08e-15	Retinal vascular caliber;
SARC	cis	rs1559088	0.576	rs7251626	chr19:33578470	C/A	cg17764715	chr19:33622953	WDR88	0.59	8.17	0.47	1.91e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs6693567	0.565	rs543179	chr1:150274610	G/A	cg09579323	chr1:150459698	TARS2	-0.44	-5.71	-0.35	3.45e-8	Migraine;
SARC	cis	rs11809207	0.523	rs2186232	chr1:26502676	T/A	cg23602478	chr1:26503979	CNKSR1	0.29	5.1	0.32	7.15e-7	Height;
SARC	cis	rs526231	0.578	rs10463553	chr5:102249207	T/C	cg23492399	chr5:102201601	PAM	-0.44	-5.21	-0.32	4.21e-7	Primary biliary cholangitis;
SARC	cis	rs17428076	0.556	rs12692976	chr2:172684403	G/T	cg13550731	chr2:172543902	DYNC1I2	-0.53	-6.5	-0.39	4.88e-10	Myopia;
SARC	cis	rs208520	0.754	rs7753158	chr6:66875633	A/C	cg07460842	chr6:66804631	NA	-1.05	-13.25	-0.66	3.13e-30	Exhaled nitric oxide output;
SARC	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.59e-6	Depression;
SARC	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg03806693	chr22:41940476	POLR3H	0.83	11.73	0.61	2.8e-25	Vitiligo;
SARC	cis	rs1018836	0.923	rs9693182	chr8:91621876	T/C	cg16814680	chr8:91681699	NA	-0.86	-14.05	-0.68	6.71e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg18357526	chr6:26021779	HIST1H4A	0.46	5.85	0.36	1.64e-8	Blood metabolite levels;
SARC	cis	rs9890032	0.532	rs1808257	chr17:29039966	A/G	cg13385521	chr17:29058706	SUZ12P	0.49	5.35	0.33	2.08e-7	Hip circumference adjusted for BMI;
SARC	cis	rs6831352	0.840	rs35073321	chr4:100053276	G/A	cg13256891	chr4:100009986	ADH5	-0.64	-8.0	-0.46	5.7e-14	Alcohol dependence;
SARC	cis	rs7597155	0.935	rs7563401	chr2:69980193	C/T	cg02498382	chr2:70120550	SNRNP27	-0.31	-5.26	-0.33	3.23e-7	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs73198271	0.562	rs964773	chr8:8651314	T/C	cg01851573	chr8:8652454	MFHAS1	0.41	5.12	0.32	6.33e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs9790314	0.540	rs35462273	chr3:160991877	C/T	cg03342759	chr3:160939853	NMD3	-0.71	-8.98	-0.51	9.09e-17	Morning vs. evening chronotype;
SARC	cis	rs72945132	0.882	rs7116059	chr11:70159690	G/T	cg05964544	chr11:70165517	PPFIA1	-0.61	-5.87	-0.36	1.5e-8	Coronary artery disease;
SARC	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg18876405	chr7:65276391	NA	0.63	7.61	0.45	6.59e-13	Aortic root size;
SARC	trans	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.68	-0.49	6.94e-16	Triglycerides;
SARC	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg12463550	chr7:65579703	CRCP	-0.48	-5.25	-0.33	3.44e-7	Aortic root size;
SARC	cis	rs986417	0.901	rs10139995	chr14:60947177	G/T	cg27398547	chr14:60952738	C14orf39	0.98	8.85	0.5	2.24e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs561341	0.739	rs9906455	chr17:30215669	G/A	cg13647721	chr17:30228624	UTP6	-0.7	-6.92	-0.41	4.3e-11	Hip circumference adjusted for BMI;
SARC	cis	rs9788682	0.947	rs12439240	chr15:78829091	T/C	cg24631222	chr15:78858424	CHRNA5	0.75	10.06	0.55	5.3e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs2115630	0.645	rs3825877	chr15:85174631	G/A	cg12501888	chr15:85177176	SCAND2	-0.49	-6.0	-0.37	7.62e-9	P wave terminal force;
SARC	cis	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg06636001	chr8:8085503	FLJ10661	0.64	8.44	0.48	3.31e-15	Mood instability;
SARC	cis	rs1003719	0.688	rs2000413	chr21:38539718	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.43	-0.53	4.44e-18	Eye color traits;
SARC	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg27266027	chr21:40555129	PSMG1	0.49	5.01	0.31	1.08e-6	Cognitive function;
SARC	trans	rs12310956	0.510	rs11612987	chr12:33879130	T/C	cg26384229	chr12:38710491	ALG10B	0.6	7.92	0.46	9.47e-14	Morning vs. evening chronotype;
SARC	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg14403583	chr14:105418241	AHNAK2	-0.58	-7.63	-0.45	5.95e-13	Rheumatoid arthritis;
SARC	cis	rs13082711	0.911	rs4973770	chr3:27425815	C/T	cg02860705	chr3:27208620	NA	0.47	6.24	0.38	2.05e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs5757673	1	rs5757673	chr22:39837920	T/C	cg05872129	chr22:39784769	NA	-0.39	-5.08	-0.32	7.77e-7	Post bronchodilator FEV1;
SARC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg09373136	chr17:61933544	TCAM1	-0.45	-6.19	-0.38	2.73e-9	Prudent dietary pattern;
SARC	cis	rs7666738	0.546	rs13148080	chr4:98680947	A/G	cg05340658	chr4:99064831	C4orf37	0.61	7.38	0.44	2.78e-12	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1971762	0.527	rs1247957	chr12:53961493	G/T	cg06632207	chr12:54070931	ATP5G2	-0.59	-7.98	-0.46	6.58e-14	Height;
SARC	cis	rs9660992	0.573	rs1172147	chr1:205225457	G/A	cg21545522	chr1:205238299	TMCC2	0.41	5.78	0.35	2.41e-8	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg02841227	chr6:26021843	HIST1H4A	-0.63	-7.36	-0.43	3.18e-12	Intelligence (multi-trait analysis);
SARC	cis	rs3020736	0.500	rs2413669	chr22:42507748	A/C	cg15557168	chr22:42548783	NA	0.36	4.92	0.31	1.62e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg24549020	chr5:56110836	MAP3K1	0.83	8.58	0.49	1.36e-15	Initial pursuit acceleration;
SARC	cis	rs1355223	0.902	rs11819839	chr11:34715778	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.4	-5.07	-0.32	8.21e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs9398803	0.687	rs7740134	chr6:127009669	T/A	cg19875578	chr6:126661172	C6orf173	-0.64	-8.86	-0.5	2.09e-16	Male-pattern baldness;
SARC	cis	rs55692411	0.537	rs71326904	chr3:49991060	C/T	cg14019146	chr3:50243930	SLC38A3	-0.38	-5.41	-0.33	1.53e-7	Intelligence (multi-trait analysis);
SARC	cis	rs13082711	0.911	rs17682229	chr3:27443067	T/C	cg02860705	chr3:27208620	NA	0.47	6.19	0.38	2.7e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg17971929	chr21:40555470	PSMG1	0.85	11.12	0.59	2.48e-23	Cognitive function;
SARC	cis	rs2832191	0.755	rs2832192	chr21:30491173	G/T	cg08807101	chr21:30365312	RNF160	-0.77	-10.25	-0.56	1.38e-20	Dental caries;
SARC	cis	rs17376456	0.569	rs2045019	chr5:93201971	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.49	-5.02	-0.31	1.04e-6	Diabetic retinopathy;
SARC	trans	rs2018683	0.770	rs10951208	chr7:29022504	G/T	cg19402173	chr7:128379420	CALU	-0.56	-6.79	-0.41	9.36e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs673253	0.686	rs2819336	chr1:44015809	T/C	cg10881128	chr1:44031826	PTPRF	-0.41	-5.13	-0.32	6.02e-7	Intelligence (multi-trait analysis);
SARC	cis	rs4906332	1.000	rs12885234	chr14:103889181	A/G	cg26031613	chr14:104095156	KLC1	-0.5	-5.84	-0.36	1.72e-8	Coronary artery disease;
SARC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.52	6.65	0.4	2.03e-10	Lymphocyte counts;
SARC	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	12.02	0.62	3.2e-26	Chronic sinus infection;
SARC	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg13628971	chr7:2884303	GNA12	0.59	6.91	0.41	4.71e-11	Height;
SARC	cis	rs6963495	0.818	rs6961233	chr7:105150469	C/T	cg19920283	chr7:105172520	RINT1	0.63	5.3	0.33	2.75e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs9818758	0.607	rs9311439	chr3:49310408	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.7	-5.94	-0.36	1.05e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg25072359	chr17:41440525	NA	0.5	6.0	0.37	7.48e-9	Menopause (age at onset);
SARC	cis	rs7246657	0.943	rs3803895	chr19:37898669	A/G	cg23950597	chr19:37808831	NA	-0.56	-5.68	-0.35	3.9e-8	Coronary artery calcification;
SARC	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg18225595	chr11:63971243	STIP1	0.52	7.63	0.45	6.06e-13	Platelet count;
SARC	cis	rs9303280	0.901	rs12950743	chr17:38049233	T/C	cg20243544	chr17:37824526	PNMT	0.43	5.76	0.35	2.61e-8	Self-reported allergy;
SARC	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg14784868	chr12:69753453	YEATS4	0.65	9.07	0.51	5.02e-17	Cerebrospinal fluid biomarker levels;
SARC	cis	rs4820539	0.708	rs5751591	chr22:23489042	G/A	cg14186256	chr22:23484241	RTDR1	0.73	9.95	0.55	1.13e-19	Bone mineral density;
SARC	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg17376030	chr22:41985996	PMM1	-0.71	-8.94	-0.51	1.26e-16	Vitiligo;
SARC	cis	rs10865397	0.506	rs6546807	chr2:73386212	C/T	cg01422370	chr2:73384389	NA	0.37	6.13	0.37	3.7e-9	Intelligence (multi-trait analysis);
SARC	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg20965017	chr5:231967	SDHA	-0.58	-5.52	-0.34	8.82e-8	Breast cancer;
SARC	cis	rs1008375	1.000	rs4642241	chr4:17617111	T/C	cg02297831	chr4:17616191	MED28	0.47	5.99	0.37	7.69e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs933688	1.000	rs6452953	chr5:90723034	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.95	12.14	0.62	1.31e-26	Smoking behavior;
SARC	cis	rs62064224	0.606	rs61390192	chr17:30837447	C/T	cg09324608	chr17:30823087	MYO1D	0.36	5.11	0.32	6.81e-7	Schizophrenia;
SARC	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.0	11.29	0.59	7.1e-24	Platelet count;
SARC	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg12463550	chr7:65579703	CRCP	0.52	5.8	0.36	2.18e-8	Aortic root size;
SARC	cis	rs79149102	0.579	rs12591994	chr15:75320306	A/G	cg00629941	chr15:75287862	SCAMP5	-0.78	-5.84	-0.36	1.74e-8	Lung cancer;
SARC	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg18404041	chr3:52824283	ITIH1	-0.37	-5.39	-0.33	1.72e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg14664628	chr15:75095509	CSK	-0.46	-5.61	-0.34	5.78e-8	Breast cancer;
SARC	cis	rs7681440	0.904	rs7680761	chr4:90763510	A/T	cg02192967	chr4:90758406	SNCA	0.36	5.14	0.32	5.76e-7	Dementia with Lewy bodies;
SARC	cis	rs12142240	0.698	rs72677599	chr1:46834251	G/A	cg14993813	chr1:46806288	NSUN4	-0.53	-5.62	-0.35	5.48e-8	Menopause (age at onset);
SARC	cis	rs1712517	0.873	rs1891292	chr10:105001510	A/G	cg05636881	chr10:105038444	INA	-0.34	-5.13	-0.32	6.1e-7	Migraine;
SARC	cis	rs7397814	0.558	rs4764447	chr12:9579109	C/T	cg08997352	chr12:9597637	DDX12	-0.55	-6.4	-0.39	8.37e-10	IgG glycosylation;
SARC	cis	rs6570726	0.935	rs374000	chr6:145855290	C/T	cg05220968	chr6:146057943	EPM2A	-0.3	-5.17	-0.32	5.07e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9467773	1.000	rs10946834	chr6:26533664	G/C	cg12292205	chr6:26970375	C6orf41	0.45	5.43	0.34	1.41e-7	Intelligence (multi-trait analysis);
SARC	cis	rs554111	0.656	rs4654893	chr1:21305596	G/C	cg08890418	chr1:21044141	KIF17	-0.34	-4.8	-0.3	2.78e-6	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs854765	0.647	rs741782	chr17:18019712	T/C	cg05444541	chr17:17804740	TOM1L2	-0.32	-5.29	-0.33	2.88e-7	Total body bone mineral density;
SARC	cis	rs2916247	1.000	rs2979854	chr8:92978039	G/A	cg10183463	chr8:93005414	RUNX1T1	0.47	4.76	0.3	3.36e-6	Intelligence (multi-trait analysis);
SARC	cis	rs6912958	0.781	rs3934838	chr6:88284699	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-6.8	-0.41	8.58e-11	Monocyte percentage of white cells;
SARC	cis	rs1355223	0.902	rs4465347	chr11:34727333	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-5.2	-0.32	4.38e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs5167	0.586	rs4803774	chr19:45450872	A/G	cg09555818	chr19:45449301	APOC2	0.57	9.04	0.51	6.2e-17	Blood protein levels;
SARC	cis	rs6860806	0.507	rs2631371	chr5:131703691	G/A	cg04518342	chr5:131593106	PDLIM4	-0.44	-5.58	-0.34	6.74e-8	Breast cancer;
SARC	cis	rs883565	0.569	rs1274969	chr3:39169712	T/C	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.46	-5.3	-0.33	2.74e-7	Handedness;
SARC	cis	rs651907	0.557	rs3864012	chr3:101397623	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	6.59	0.4	2.97e-10	Colorectal cancer;
SARC	cis	rs561341	0.629	rs7216107	chr17:30224419	G/A	cg13647721	chr17:30228624	UTP6	0.68	8.18	0.47	1.86e-14	Hip circumference adjusted for BMI;
SARC	cis	rs11785400	0.793	rs1056012	chr8:143740167	A/G	cg24634471	chr8:143751801	JRK	0.59	7.45	0.44	1.83e-12	Schizophrenia;
SARC	cis	rs13191362	1.000	rs35575481	chr6:163007746	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.57	5.38	0.33	1.85e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs16944613	0.588	rs6496698	chr15:91135558	A/G	cg26821196	chr15:91095069	CRTC3	0.52	5.35	0.33	2.13e-7	Colorectal cancer;
SARC	cis	rs3815700	1.000	rs7248273	chr19:33096816	C/T	cg24916020	chr19:33096688	ANKRD27	0.53	4.79	0.3	2.91e-6	Eosinophilic esophagitis;
SARC	cis	rs2153535	0.580	rs6597335	chr6:8527714	T/C	cg23788917	chr6:8435910	SLC35B3	0.62	8.31	0.48	8.11e-15	Motion sickness;
SARC	cis	rs11098499	0.863	rs10030660	chr4:120436704	G/A	cg09307838	chr4:120376055	NA	0.91	12.31	0.63	3.63e-27	Corneal astigmatism;
SARC	cis	rs10227331	0.617	rs55977076	chr7:157301739	A/G	cg04156418	chr7:157293606	NA	0.37	5.93	0.36	1.06e-8	Inattentive symptoms;
SARC	cis	rs72945132	1.000	rs72945129	chr11:70110808	C/T	cg05964544	chr11:70165517	PPFIA1	-0.57	-5.36	-0.33	2.04e-7	Coronary artery disease;
SARC	cis	rs637571	0.522	rs491973	chr11:65727301	A/G	cg26695010	chr11:65641043	EFEMP2	-0.55	-7.19	-0.43	8.91e-12	Eosinophil percentage of white cells;
SARC	cis	rs2075371	0.501	rs1646652	chr7:134024515	A/T	cg11752832	chr7:134001865	SLC35B4	0.48	6.17	0.37	3e-9	Mean platelet volume;
SARC	cis	rs4642101	0.662	rs9874893	chr3:12833079	C/G	cg24848339	chr3:12840334	CAND2	0.35	5.69	0.35	3.76e-8	QRS complex (12-leadsum);
SARC	cis	rs9894429	1.000	rs7406003	chr17:79597597	C/T	cg10661904	chr17:79619235	PDE6G	-0.34	-4.76	-0.3	3.45e-6	Eye color traits;
SARC	cis	rs3762637	0.941	rs79493664	chr3:122109546	T/A	cg24169773	chr3:122142474	KPNA1	-0.57	-5.61	-0.35	5.6e-8	LDL cholesterol levels;
SARC	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg08219700	chr8:58056026	NA	0.64	6.33	0.38	1.21e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1707322	0.964	rs785496	chr1:46588006	T/C	cg03146154	chr1:46216737	IPP	-0.48	-5.6	-0.34	6.03e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2481665	0.617	rs12732781	chr1:62518459	T/C	cg18591186	chr1:62594603	INADL	-0.44	-5.87	-0.36	1.49e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs453301	0.686	rs28482034	chr8:8869664	G/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.04	-0.42	2.15e-11	Joint mobility (Beighton score);
SARC	cis	rs876084	0.505	rs35529075	chr8:121143623	C/G	cg06265175	chr8:121136014	COL14A1	0.57	7.37	0.43	2.9e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs7119167	0.851	rs12295744	chr11:73279296	C/T	cg17517138	chr11:73019481	ARHGEF17	0.45	4.75	0.3	3.57e-6	Blood protein levels;
SARC	cis	rs9303401	0.659	rs12602808	chr17:56698420	A/G	cg25039879	chr17:56429692	SUPT4H1	0.69	6.55	0.39	3.71e-10	Cognitive test performance;
SARC	cis	rs6831352	0.851	rs1230164	chr4:99986023	C/G	cg12011299	chr4:100065546	ADH4	0.36	6.22	0.38	2.29e-9	Alcohol dependence;
SARC	cis	rs9914988	0.887	rs4795456	chr17:27072463	G/A	cg20469991	chr17:27169893	C17orf63	-0.55	-5.48	-0.34	1.13e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs9398803	0.687	rs9401897	chr6:126940641	A/G	cg19875578	chr6:126661172	C6orf173	0.63	8.7	0.5	5.9e-16	Male-pattern baldness;
SARC	cis	rs17253792	0.822	rs75663029	chr14:56092385	T/C	cg01858014	chr14:56050164	KTN1	-0.67	-5.11	-0.32	6.86e-7	Putamen volume;
SARC	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg12463550	chr7:65579703	CRCP	-0.46	-4.82	-0.3	2.61e-6	Aortic root size;
SARC	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.32	-4.91	-0.31	1.74e-6	Total body bone mineral density;
SARC	cis	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg22496380	chr5:211416	CCDC127	-0.88	-9.32	-0.52	9.29e-18	Breast cancer;
SARC	cis	rs4974559	0.739	rs28573879	chr4:1285910	C/T	cg02980000	chr4:1222292	CTBP1	0.73	5.6	0.34	5.97e-8	Systolic blood pressure;
SARC	cis	rs17854409	0.764	rs8116995	chr20:61475824	A/G	cg05147244	chr20:61493195	TCFL5	0.92	6.17	0.37	2.99e-9	Obesity-related traits;
SARC	cis	rs1467026	0.691	rs9985266	chr3:12803162	C/T	cg24848339	chr3:12840334	CAND2	-0.32	-4.86	-0.3	2.11e-6	P wave duration;
SARC	cis	rs7103648	0.695	rs7933019	chr11:47509137	G/C	cg10504702	chr11:47789108	FNBP4	0.7	9.16	0.51	2.79e-17	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	8.28	0.48	9.57e-15	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs854765	0.547	rs4925135	chr17:17952868	T/C	cg05444541	chr17:17804740	TOM1L2	0.3	4.89	0.31	1.85e-6	Total body bone mineral density;
SARC	cis	rs7512552	0.839	rs1260386	chr1:150369622	G/T	cg15654264	chr1:150340011	RPRD2	0.38	4.81	0.3	2.7e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs9398803	0.687	rs7740134	chr6:127009669	T/A	cg20229609	chr6:126660872	C6orf173	-0.37	-5.25	-0.33	3.38e-7	Male-pattern baldness;
SARC	cis	rs12791968	1.000	rs11038237	chr11:45001880	C/T	cg11846598	chr11:44996168	LOC221122	-0.36	-5.65	-0.35	4.75e-8	Inhibitory control;
SARC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg20607798	chr8:58055168	NA	0.58	5.55	0.34	7.69e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg25315252	chr10:81839033	LOC219347;C10orf57	0.49	6.6	0.4	2.73e-10	Chemerin levels;
SARC	cis	rs3796352	1.000	rs33999310	chr3:52883332	G/A	cg15956490	chr3:53032818	SFMBT1	0.81	5.21	0.32	4.13e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs7647973	1.000	rs2177268	chr3:49439725	A/T	cg07636037	chr3:49044803	WDR6	-0.75	-8.18	-0.47	1.88e-14	Menarche (age at onset);
SARC	cis	rs2115536	0.730	rs4238512	chr15:80183898	A/C	cg00225070	chr15:80189496	MTHFS	-0.54	-7.04	-0.42	2.14e-11	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
SARC	cis	rs898097	0.691	rs7222745	chr17:80907253	C/T	cg15369054	chr17:80825471	TBCD	0.35	4.93	0.31	1.54e-6	Breast cancer;
SARC	cis	rs60871478	0.704	rs62432895	chr7:822050	C/G	cg05535760	chr7:792225	HEATR2	0.77	7.88	0.46	1.26e-13	Cerebrospinal P-tau181p levels;
SARC	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg21724239	chr8:58056113	NA	0.61	5.93	0.36	1.1e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg03517284	chr6:25882590	NA	0.48	6.23	0.38	2.21e-9	Intelligence (multi-trait analysis);
SARC	cis	rs4780401	0.933	rs1592572	chr16:11810382	T/C	cg01061890	chr16:11836724	TXNDC11	-0.52	-6.73	-0.4	1.3e-10	Rheumatoid arthritis;
SARC	cis	rs6582630	0.502	rs11522899	chr12:38270637	T/C	cg13010199	chr12:38710504	ALG10B	0.81	11.31	0.6	6.33e-24	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg07030336	chr10:114206784	VTI1A;ZDHHC6	-0.48	-6.56	-0.39	3.36e-10	Neuroticism;
SARC	cis	rs4853036	1.000	rs3732269	chr2:70046255	G/C	cg02498382	chr2:70120550	SNRNP27	-0.42	-5.66	-0.35	4.44e-8	Colorectal or endometrial cancer;
SARC	cis	rs4273100	1.000	rs12602286	chr17:19236954	G/T	cg18093559	chr17:18951025	GRAP	0.38	4.85	0.3	2.24e-6	Schizophrenia;
SARC	cis	rs7220711	1.000	rs8072333	chr17:41793893	C/T	cg26893861	chr17:41843967	DUSP3	0.42	5.3	0.33	2.67e-7	Bone mineral density (spine);Bone mineral density (hip);
SARC	cis	rs9611519	0.929	rs4820423	chr22:41430338	A/T	cg03806693	chr22:41940476	POLR3H	-0.61	-7.54	-0.44	1.03e-12	Neuroticism;
SARC	cis	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg24110177	chr3:50126178	RBM5	-0.61	-7.86	-0.46	1.38e-13	Body mass index;
SARC	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg17221315	chr6:27791827	HIST1H4J	0.45	4.75	0.3	3.57e-6	Depression;
SARC	cis	rs7772486	0.806	rs4075696	chr6:146250947	T/C	cg23711669	chr6:146136114	FBXO30	-0.76	-11.61	-0.61	6.87e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9303542	0.559	rs12602539	chr17:46617459	T/A	cg04904318	chr17:46607828	HOXB1	-0.45	-4.95	-0.31	1.41e-6	Ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.71	-6.92	-0.41	4.32e-11	Platelet count;
SARC	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg24209194	chr3:40518798	ZNF619	0.67	8.13	0.47	2.49e-14	Renal cell carcinoma;
SARC	cis	rs2415984	0.562	rs12895104	chr14:46972736	G/A	cg14871534	chr14:47121158	RPL10L	0.41	5.36	0.33	1.97e-7	Number of children ever born;
SARC	cis	rs8031584	0.958	rs61997079	chr15:31238271	G/C	cg08109568	chr15:31115862	NA	-0.46	-5.75	-0.35	2.78e-8	Huntington's disease progression;
SARC	cis	rs8114671	0.869	rs1407202	chr20:33651967	C/T	cg08999081	chr20:33150536	PIGU	-0.35	-4.89	-0.3	1.9e-6	Height;
SARC	cis	rs7727544	0.740	rs419291	chr5:131633355	T/C	cg07395648	chr5:131743802	NA	-0.41	-4.73	-0.3	3.86e-6	Blood metabolite levels;
SARC	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg11987759	chr7:65425863	GUSB	-0.58	-7.96	-0.46	7.3e-14	Calcium levels;
SARC	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.58	-6.9	-0.41	4.84e-11	Gut microbiome composition (summer);
SARC	cis	rs10504229	0.680	rs16921675	chr8:58052082	A/G	cg20607798	chr8:58055168	NA	0.59	5.43	0.34	1.4e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs13401104	0.587	rs7581196	chr2:237151098	A/C	cg19324714	chr2:237145437	ASB18	-0.59	-6.1	-0.37	4.31e-9	Educational attainment;
SARC	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.65	-7.82	-0.46	1.78e-13	Gut microbiome composition (summer);
SARC	cis	rs6840360	0.638	rs6816002	chr4:152589439	C/T	cg22705602	chr4:152727874	NA	-0.46	-7.83	-0.46	1.69e-13	Intelligence (multi-trait analysis);
SARC	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg12311346	chr5:56204834	C5orf35	-0.58	-6.01	-0.37	7.24e-9	Initial pursuit acceleration;
SARC	cis	rs72781680	0.716	rs72788206	chr2:24084989	T/C	cg08917208	chr2:24149416	ATAD2B	0.61	6.65	0.4	2.1e-10	Lymphocyte counts;
SARC	cis	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg21775007	chr8:11205619	TDH	0.45	5.58	0.34	6.68e-8	Triglycerides;
SARC	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs921968	0.509	rs7571743	chr2:219352572	C/T	cg02176678	chr2:219576539	TTLL4	0.46	7.12	0.42	1.33e-11	Mean corpuscular hemoglobin concentration;
SARC	trans	rs12967884	0.892	rs907282	chr18:76563207	G/A	cg10946435	chr1:154843044	KCNN3	0.57	6.31	0.38	1.38e-9	Subcutaneous adipose tissue;
SARC	cis	rs57994353	0.897	rs11999532	chr9:139371405	G/C	cg14169450	chr9:139327907	INPP5E	0.41	5.22	0.32	3.93e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs1707322	1.000	rs7526369	chr1:46390560	G/C	cg06784218	chr1:46089804	CCDC17	0.34	5.97	0.36	8.8e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2439831	0.850	rs3816792	chr15:44116986	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.82	-7.67	-0.45	4.51e-13	Lung cancer in ever smokers;
SARC	cis	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg21573476	chr21:45109991	RRP1B	-0.55	-8.3	-0.48	8.51e-15	Mean corpuscular volume;
SARC	trans	rs7824557	0.564	rs35009431	chr8:11232788	G/A	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.56	-0.39	3.44e-10	Retinal vascular caliber;
SARC	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg22920501	chr2:26401640	FAM59B	0.61	8.19	0.47	1.71e-14	Gut microbiome composition (summer);
SARC	trans	rs9811216	0.606	rs1881984	chr3:169464459	A/G	cg02552189	chr2:223891284	NA	0.53	6.87	0.41	5.81e-11	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg21747090	chr2:27597821	SNX17	-0.55	-7.58	-0.44	8.03e-13	Total body bone mineral density;
SARC	cis	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg05623727	chr3:50126028	RBM5	0.33	4.99	0.31	1.21e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.48	7.48	0.44	1.52e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs9815354	0.812	rs73071304	chr3:41797504	G/C	cg03022575	chr3:42003672	ULK4	0.72	5.99	0.37	7.83e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs1707322	0.893	rs9919275	chr1:46441360	A/C	cg03146154	chr1:46216737	IPP	0.45	5.41	0.33	1.57e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9549260	0.564	rs9315784	chr13:41289166	G/A	cg21288729	chr13:41239152	FOXO1	0.44	5.21	0.32	4.22e-7	Red blood cell count;
SARC	cis	rs2204008	0.713	rs2320522	chr12:38251438	C/T	cg13010199	chr12:38710504	ALG10B	0.81	11.31	0.6	6.33e-24	Bladder cancer;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg17753496	chr6:108881018	FOXO3	0.55	6.34	0.38	1.21e-9	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs2408955	0.522	rs4760679	chr12:48461635	G/T	cg24011408	chr12:48396354	COL2A1	-0.41	-5.01	-0.31	1.08e-6	Glycated hemoglobin levels;
SARC	cis	rs2303745	0.589	rs6512179	chr19:17399105	T/C	cg04248312	chr19:17393744	ANKLE1	-0.6	-7.61	-0.45	6.84e-13	Systemic lupus erythematosus;
SARC	cis	rs7208859	0.573	rs73277974	chr17:29189869	A/G	cg13385521	chr17:29058706	SUZ12P	0.86	7.34	0.43	3.54e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs400736	0.702	rs225134	chr1:8098730	A/G	cg25007680	chr1:8021821	PARK7	0.49	6.22	0.38	2.24e-9	Response to antidepressants and depression;
SARC	cis	rs11792861	0.781	rs28361106	chr9:111762385	T/C	cg13535736	chr9:111863775	C9orf5	-0.38	-4.71	-0.3	4.2e-6	Menarche (age at onset);
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg12605564	chr3:129035140	H1FX;C3orf47	0.49	6.4	0.39	8.3e-10	Tetralogy of Fallot;
SARC	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg09455208	chr3:40491958	NA	0.4	5.88	0.36	1.39e-8	Renal cell carcinoma;
SARC	trans	rs7615952	0.673	rs115942855	chr3:125601960	G/A	cg07211511	chr3:129823064	LOC729375	-0.83	-7.42	-0.44	2.11e-12	Blood pressure (smoking interaction);
SARC	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg03060546	chr3:49711283	APEH	0.43	5.33	0.33	2.31e-7	Parkinson's disease;
SARC	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg11843238	chr5:131593191	PDLIM4	0.43	5.82	0.36	1.93e-8	Acylcarnitine levels;
SARC	cis	rs4268898	0.965	rs13033241	chr2:24476118	G/C	cg26838691	chr2:24397539	C2orf84	0.36	4.88	0.3	2e-6	Asthma;
SARC	cis	rs981844	1.000	rs10517579	chr4:154666321	T/C	cg14289246	chr4:154710475	SFRP2	0.57	6.43	0.39	7.08e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg11366901	chr6:160182831	ACAT2	1.03	10.98	0.58	7.22e-23	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs9420	0.961	rs11604325	chr11:57497011	C/A	cg23127183	chr11:57508653	C11orf31	-0.55	-6.28	-0.38	1.61e-9	Schizophrenia;
SARC	cis	rs1707322	0.638	rs1416706	chr1:46602844	G/A	cg06784218	chr1:46089804	CCDC17	-0.29	-4.82	-0.3	2.59e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7264396	0.790	rs3787168	chr20:34233278	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-8.14	-0.47	2.35e-14	Total cholesterol levels;
SARC	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg18252515	chr7:66147081	NA	0.51	5.81	0.36	1.99e-8	Aortic root size;
SARC	cis	rs7582180	0.591	rs12991577	chr2:101010867	C/A	cg14675211	chr2:100938903	LONRF2	0.53	7.93	0.46	8.91e-14	Intelligence (multi-trait analysis);
SARC	cis	rs2115630	1.000	rs11854291	chr15:85363708	T/C	cg12501888	chr15:85177176	SCAND2	-0.47	-5.83	-0.36	1.87e-8	P wave terminal force;
SARC	cis	rs1153858	1.000	rs2114501	chr15:45670316	G/A	cg21132104	chr15:45694354	SPATA5L1	0.78	10.98	0.58	7.11e-23	Homoarginine levels;
SARC	cis	rs6963495	0.818	rs55983796	chr7:105170941	C/T	cg19920283	chr7:105172520	RINT1	0.67	5.76	0.35	2.59e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs3126085	0.935	rs12408581	chr1:152175211	A/G	cg03465714	chr1:152285911	FLG	0.45	4.86	0.3	2.2e-6	Atopic dermatitis;
SARC	cis	rs79149102	0.579	rs7166105	chr15:75343942	A/G	cg17294928	chr15:75287854	SCAMP5	1.0	9.33	0.52	8.91e-18	Lung cancer;
SARC	cis	rs34779708	0.931	rs35136660	chr10:35385973	C/A	cg03585969	chr10:35415529	CREM	0.41	4.98	0.31	1.21e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.33	-5.0	-0.31	1.11e-6	Total body bone mineral density;
SARC	cis	rs35110281	0.805	rs3788062	chr21:44991159	C/T	cg21573476	chr21:45109991	RRP1B	-0.47	-6.85	-0.41	6.49e-11	Mean corpuscular volume;
SARC	cis	rs55692411	0.537	rs71326904	chr3:49991060	C/T	cg24110177	chr3:50126178	RBM5	-0.51	-5.66	-0.35	4.34e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg17328964	chr8:145687451	CYHR1	-0.47	-6.64	-0.4	2.14e-10	Age at first birth;
SARC	cis	rs7826238	0.623	rs2976893	chr8:8338219	G/T	cg06636001	chr8:8085503	FLJ10661	-0.62	-8.63	-0.49	1e-15	Systolic blood pressure;
SARC	trans	rs61931739	0.500	rs7979482	chr12:34542877	C/A	cg13010199	chr12:38710504	ALG10B	0.83	11.73	0.61	2.89e-25	Morning vs. evening chronotype;
SARC	cis	rs10876993	0.789	rs1689600	chr12:58049645	A/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.49	-6.12	-0.37	3.87e-9	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs9915657	0.840	rs10512582	chr17:70139393	A/C	cg06234051	chr17:70120541	SOX9	-0.36	-5.15	-0.32	5.64e-7	Thyroid hormone levels;
SARC	cis	rs9814567	1.000	rs62271513	chr3:134298412	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	6.89	0.41	5.31e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs1669338	0.588	rs3864050	chr3:3186769	T/C	cg16797762	chr3:3221439	CRBN	-0.94	-9.54	-0.53	2.07e-18	White matter integrity;
SARC	cis	rs76419734	1.000	rs11733654	chr4:106730710	C/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	5.35	0.33	2.11e-7	Post bronchodilator FEV1;
SARC	cis	rs4566357	0.615	rs2894626	chr2:227916039	T/C	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.98	-0.36	8.44e-9	Coronary artery disease;
SARC	cis	rs10875746	0.903	rs11168401	chr12:48481519	T/C	cg26205652	chr12:48591994	NA	0.56	6.1	0.37	4.37e-9	Longevity (90 years and older);
SARC	cis	rs739401	0.588	rs10219272	chr11:3020789	G/A	cg08508325	chr11:3079039	CARS	-0.34	-8.55	-0.49	1.65e-15	Longevity;
SARC	cis	rs6963495	0.556	rs818481	chr7:105158467	G/C	cg19920283	chr7:105172520	RINT1	0.55	5.6	0.34	6.11e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs78320035	0.737	rs116238489	chr1:168134486	G/A	cg17113809	chr1:168148080	TIPRL	1.32	7.13	0.42	1.23e-11	Red cell distribution width;
SARC	cis	rs1957429	0.614	rs117316280	chr14:65388641	T/C	cg23373153	chr14:65346875	NA	-1.03	-6.42	-0.39	7.58e-10	Pediatric areal bone mineral density (radius);
SARC	cis	rs9486719	1.000	rs12207570	chr6:96987884	A/C	cg06623918	chr6:96969491	KIAA0776	-0.76	-8.29	-0.48	9.16e-15	Migraine;Coronary artery disease;
SARC	cis	rs17030434	0.784	rs11099896	chr4:154664697	T/G	cg14289246	chr4:154710475	SFRP2	-0.49	-5.7	-0.35	3.66e-8	Electrocardiographic conduction measures;
SARC	cis	rs1182196	0.533	rs2527521	chr7:2904928	A/G	cg04166393	chr7:2884313	GNA12	-0.38	-4.92	-0.31	1.66e-6	Plateletcrit;
SARC	cis	rs4805272	0.512	rs765484	chr19:29344663	A/G	cg14983838	chr19:29218262	NA	0.54	5.8	0.36	2.09e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg03087855	chr10:92661845	RPP30	0.53	7.42	0.44	2.24e-12	Thyroid stimulating hormone;
SARC	cis	rs6733011	0.508	rs925887	chr2:99514671	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.48	6.32	0.38	1.35e-9	Bipolar disorder;
SARC	cis	rs9814567	0.963	rs9844537	chr3:134238341	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-7.06	-0.42	1.94e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs12142240	0.698	rs72679807	chr1:46846490	G/A	cg00530320	chr1:46809349	NSUN4	0.57	7.0	0.42	2.74e-11	Menopause (age at onset);
SARC	cis	rs76935404	0.811	rs12150973	chr19:41434524	T/C	cg17435250	chr19:41386441	CYP2A7	-0.37	-4.85	-0.3	2.21e-6	nicotine metabolite ratio in current smokers;
SARC	cis	rs4481887	1.000	rs4244182	chr1:248471174	A/G	cg13385794	chr1:248469461	NA	0.36	5.46	0.34	1.19e-7	Common traits (Other);
SARC	cis	rs8028182	0.613	rs28433871	chr15:75897733	C/T	cg20655648	chr15:75932815	IMP3	0.71	5.31	0.33	2.61e-7	Sudden cardiac arrest;
SARC	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg13770153	chr20:60521292	NA	-0.45	-6.31	-0.38	1.39e-9	Body mass index;
SARC	trans	rs61931739	0.500	rs56056630	chr12:34543465	T/C	cg26384229	chr12:38710491	ALG10B	0.85	12.63	0.64	3.4e-28	Morning vs. evening chronotype;
SARC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg11494091	chr17:61959527	GH2	0.56	8.16	0.47	2.06e-14	Prudent dietary pattern;
SARC	cis	rs36051895	0.664	rs10974963	chr9:5101305	G/A	cg02405213	chr9:5042618	JAK2	-0.46	-5.39	-0.33	1.74e-7	Pediatric autoimmune diseases;
SARC	cis	rs7429990	0.965	rs796566	chr3:47938354	G/C	cg11946769	chr3:48343235	NME6	0.44	5.06	0.31	8.47e-7	Educational attainment (years of education);
SARC	cis	rs1865760	0.519	rs4360119	chr6:25815074	C/G	cg16482183	chr6:26056742	HIST1H1C	0.52	6.3	0.38	1.51e-9	Height;
SARC	cis	rs9911578	0.757	rs8081906	chr17:56631907	A/T	cg05425664	chr17:57184151	TRIM37	0.67	7.7	0.45	3.77e-13	Intelligence (multi-trait analysis);
SARC	cis	rs7089973	0.872	rs12773943	chr10:116631184	G/A	cg08188268	chr10:116634841	FAM160B1	0.36	5.7	0.35	3.53e-8	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs965469	0.843	rs6139122	chr20:3395871	T/G	cg25506879	chr20:3388711	C20orf194	-0.59	-6.15	-0.37	3.36e-9	IFN-related cytopenia;
SARC	cis	rs2070488	0.965	rs2284820	chr3:38562579	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.82	-13.17	-0.65	5.73e-30	Electrocardiographic conduction measures;
SARC	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg07414643	chr4:187882934	NA	0.5	7.55	0.44	1e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7264396	0.790	rs12480622	chr20:34234620	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.29	-0.43	4.86e-12	Total cholesterol levels;
SARC	cis	rs67460515	0.563	rs1585481	chr3:160901481	C/T	cg17135325	chr3:160939158	NMD3	0.68	8.71	0.5	5.63e-16	Parkinson's disease;
SARC	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg11062466	chr8:58055876	NA	0.58	5.61	0.35	5.65e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7223966	1.000	rs8067431	chr17:61817048	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.46	4.8	0.3	2.87e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg11878867	chr6:150167359	LRP11	-0.34	-4.72	-0.3	4.01e-6	Lung cancer;
SARC	cis	rs9303280	0.651	rs59716545	chr17:38031857	T/G	cg20243544	chr17:37824526	PNMT	0.42	5.39	0.33	1.71e-7	Self-reported allergy;
SARC	cis	rs17376456	0.597	rs6869110	chr5:93355531	G/A	cg25358565	chr5:93447407	FAM172A	-0.83	-9.65	-0.53	9.46e-19	Diabetic retinopathy;
SARC	cis	rs10911363	0.592	rs10911354	chr1:183489278	G/A	cg09173681	chr1:183549694	NCF2	0.34	5.38	0.33	1.84e-7	Systemic lupus erythematosus;
SARC	cis	rs11098499	0.863	rs3775858	chr4:120486028	A/G	cg09307838	chr4:120376055	NA	0.92	12.75	0.64	1.33e-28	Corneal astigmatism;
SARC	cis	rs986417	0.818	rs2092722	chr14:61062890	T/A	cg27398547	chr14:60952738	C14orf39	0.75	7.05	0.42	2.06e-11	Gut microbiota (bacterial taxa);
SARC	cis	rs2193412	0.645	rs35903458	chr2:51186587	A/T	cg00345522	chr2:51260399	NRXN1	0.36	4.97	0.31	1.28e-6	Response to zileuton treatment in asthma (FEV1 change interaction);
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg11692477	chr2:190445477	SLC40A1	0.48	6.56	0.39	3.44e-10	Tetralogy of Fallot;
SARC	cis	rs11638352	1.000	rs2733203	chr15:44415602	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.77	-5.84	-0.36	1.78e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	cis	rs2077654	0.822	rs4148627	chr11:17436271	G/A	cg25308976	chr11:17434268	ABCC8	0.53	6.54	0.39	3.81e-10	Gout;
SARC	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg11843238	chr5:131593191	PDLIM4	-0.37	-5.11	-0.32	6.67e-7	Breast cancer;
SARC	cis	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg06636001	chr8:8085503	FLJ10661	0.65	8.36	0.48	5.69e-15	Mood instability;
SARC	cis	rs668210	0.793	rs522553	chr11:65771669	T/C	cg02202077	chr11:65769826	EIF1AD;BANF1	0.71	7.68	0.45	4.34e-13	Cerebrospinal fluid biomarker levels;
SARC	cis	rs4727027	0.716	rs4727020	chr7:148837317	C/T	cg23583168	chr7:148888333	NA	-0.74	-10.04	-0.55	6.03e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs7932354	0.528	rs7125807	chr11:47041163	G/T	cg03339077	chr11:47165057	C11orf49	0.42	5.8	0.36	2.12e-8	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs6840360	0.593	rs59350867	chr4:152695935	G/A	cg22705602	chr4:152727874	NA	-0.5	-8.77	-0.5	3.91e-16	Intelligence (multi-trait analysis);
SARC	cis	rs1707322	1.000	rs11211239	chr1:46451947	A/G	cg06784218	chr1:46089804	CCDC17	0.34	5.95	0.36	9.76e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg11987759	chr7:65425863	GUSB	-0.49	-6.11	-0.37	4.06e-9	Aortic root size;
SARC	trans	rs208520	0.608	rs3846803	chr6:66805743	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.06	-14.37	-0.69	6.07e-34	Exhaled nitric oxide output;
SARC	cis	rs12142240	0.698	rs1057534	chr1:46815880	A/C	cg14993813	chr1:46806288	NSUN4	-0.52	-5.46	-0.34	1.22e-7	Menopause (age at onset);
SARC	cis	rs55665837	0.559	rs11023209	chr11:14422600	T/C	cg19336497	chr11:14380999	RRAS2	-0.34	-5.7	-0.35	3.68e-8	Vitamin D levels;
SARC	cis	rs1153858	1.000	rs7169587	chr15:45640379	A/G	cg21132104	chr15:45694354	SPATA5L1	0.78	10.82	0.58	2.33e-22	Homoarginine levels;
SARC	cis	rs6062302	0.522	rs6089929	chr20:62219679	C/T	cg09650180	chr20:62225654	GMEB2	-0.47	-5.76	-0.35	2.62e-8	Glioblastoma;
SARC	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg13395646	chr4:1353034	KIAA1530	-0.45	-5.33	-0.33	2.29e-7	Obesity-related traits;
SARC	cis	rs9399135	0.816	rs4134030	chr6:135354094	G/T	cg24558204	chr6:135376177	HBS1L	0.45	6.15	0.37	3.31e-9	Red blood cell count;
SARC	cis	rs1348850	0.914	rs7587604	chr2:178309848	T/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.63	8.01	0.46	5.5e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs698833	0.518	rs7560807	chr2:44557089	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.67	7.68	0.45	4.3e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs13201294	1	rs13201294	chr6:27556141	A/T	cg19592336	chr6:28129416	ZNF389	0.77	5.34	0.33	2.16e-7	Squamous cell lung carcinoma;
SARC	cis	rs782590	0.774	rs782637	chr2:55894247	T/C	cg18811423	chr2:55921094	PNPT1	0.7	10.66	0.57	7.02e-22	Metabolic syndrome;
SARC	cis	rs1056053	0.514	rs1056051	chr6:166571579	T/G	cg11088901	chr6:166572345	T	-0.41	-5.36	-0.33	2.01e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs4132509	0.515	rs76243949	chr1:243674094	G/A	cg21452805	chr1:244014465	NA	0.5	5.29	0.33	2.82e-7	RR interval (heart rate);
SARC	cis	rs11997175	0.574	rs58858314	chr8:33658221	T/C	ch.8.33884649F	chr8:33765107	NA	0.49	6.48	0.39	5.55e-10	Body mass index;
SARC	cis	rs453301	0.597	rs7001187	chr8:8792782	G/A	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.37	-0.38	1.01e-9	Joint mobility (Beighton score);
SARC	cis	rs1878931	0.567	rs7196196	chr16:3411855	C/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.91	14.8	0.7	2.12e-35	Body mass index (adult);
SARC	cis	rs709400	0.628	rs72708854	chr14:103864885	T/C	cg12935359	chr14:103987150	CKB	-0.39	-5.72	-0.35	3.25e-8	Body mass index;
SARC	cis	rs748404	0.697	rs555001	chr15:43545728	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.42	5.25	0.33	3.37e-7	Lung cancer;
SARC	cis	rs12950390	0.853	rs67441169	chr17:45854462	T/G	cg03474202	chr17:45855739	NA	-0.43	-6.72	-0.4	1.4e-10	IgG glycosylation;
SARC	cis	rs7772486	0.754	rs702318	chr6:146005873	G/T	cg23711669	chr6:146136114	FBXO30	-0.91	-15.89	-0.72	5.29e-39	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7312933	0.558	rs1796381	chr12:42842475	C/T	cg19980929	chr12:42632907	YAF2	0.4	5.6	0.34	6.07e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg19223190	chr17:80058835	NA	0.43	6.03	0.37	6.35e-9	Life satisfaction;
SARC	cis	rs9814567	0.806	rs13076825	chr3:134317239	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.51	6.62	0.4	2.51e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs4780401	0.967	rs11075011	chr16:11828282	T/A	cg01061890	chr16:11836724	TXNDC11	-0.53	-6.88	-0.41	5.62e-11	Rheumatoid arthritis;
SARC	cis	rs10463554	0.963	rs26817	chr5:102540366	C/T	cg23492399	chr5:102201601	PAM	0.46	4.98	0.31	1.25e-6	Parkinson's disease;
SARC	cis	rs356220	0.632	rs168552	chr4:90643144	C/T	cg06632027	chr4:90757378	SNCA	0.41	5.15	0.32	5.51e-7	Parkinson's disease;
SARC	cis	rs7666738	0.830	rs6848404	chr4:98946750	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs861020	1.000	rs622832	chr1:209974232	A/C	cg05527609	chr1:210001259	C1orf107	0.94	10.47	0.57	2.75e-21	Orofacial clefts;
SARC	cis	rs7044106	0.762	rs3903886	chr9:123383646	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.67	-8.87	-0.5	1.92e-16	Hip circumference adjusted for BMI;
SARC	cis	rs35110281	0.837	rs7279958	chr21:45016016	C/A	cg21573476	chr21:45109991	RRP1B	-0.5	-7.29	-0.43	4.93e-12	Mean corpuscular volume;
SARC	cis	rs9462027	0.628	rs2744957	chr6:34618516	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-6.13	-0.37	3.79e-9	Systemic lupus erythematosus;
SARC	cis	rs6860806	0.531	rs274556	chr5:131722075	A/G	cg24060327	chr5:131705240	SLC22A5	0.74	8.94	0.51	1.2e-16	Breast cancer;
SARC	cis	rs365132	1.000	rs353467	chr5:176445698	T/C	cg16309518	chr5:176445507	NA	-0.46	-5.89	-0.36	1.32e-8	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs12048904	0.533	rs1590580	chr1:101292668	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.88	10.28	0.56	1.08e-20	Multiple sclerosis;
SARC	cis	rs611744	0.631	rs681963	chr8:109255032	C/A	cg21045802	chr8:109455806	TTC35	0.6	7.65	0.45	5.26e-13	Dupuytren's disease;
SARC	trans	rs3734266	0.702	rs6934741	chr6:34730049	C/T	cg08157914	chr7:2646478	IQCE	0.52	6.24	0.38	2.1e-9	Systemic lupus erythematosus;
SARC	cis	rs1707322	0.928	rs7527244	chr1:46368772	A/G	cg03146154	chr1:46216737	IPP	0.47	5.64	0.35	4.94e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg18357526	chr6:26021779	HIST1H4A	0.77	10.71	0.57	5.2e-22	Intelligence (multi-trait analysis);
SARC	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg24642844	chr7:1081250	C7orf50	-0.59	-6.21	-0.38	2.41e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg13293756	chr2:172778961	HAT1	0.49	6.34	0.38	1.19e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs79839061	0.610	rs12651271	chr4:854071	C/T	cg07828340	chr4:882639	GAK	0.76	5.78	0.35	2.37e-8	Intelligence (multi-trait analysis);
SARC	cis	rs933688	1.000	rs10059163	chr5:90742444	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.0	12.59	0.64	4.38e-28	Smoking behavior;
SARC	cis	rs9513627	1.000	rs6491512	chr13:100199741	C/T	cg25919922	chr13:100150906	NA	0.62	4.76	0.3	3.4e-6	Obesity-related traits;
SARC	cis	rs6570726	0.791	rs414600	chr6:145879606	G/A	cg23711669	chr6:146136114	FBXO30	0.87	14.68	0.69	5.43e-35	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs72781680	0.799	rs2551332	chr2:23988950	T/C	cg06627628	chr2:24431161	ITSN2	-0.53	-5.5	-0.34	9.9e-8	Lymphocyte counts;
SARC	cis	rs2832191	0.903	rs11700687	chr21:30486767	A/G	cg08807101	chr21:30365312	RNF160	-0.75	-10.39	-0.56	4.97e-21	Dental caries;
SARC	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg24549020	chr5:56110836	MAP3K1	-0.63	-5.78	-0.35	2.43e-8	Initial pursuit acceleration;
SARC	cis	rs9879311	0.966	rs4684685	chr3:10411553	C/T	cg11030744	chr3:10328490	GHRL;GHRLOS	0.44	5.49	0.34	1.05e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	cis	rs17376456	0.877	rs10072592	chr5:93405989	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.7	0.35	3.55e-8	Diabetic retinopathy;
SARC	cis	rs2075371	0.966	rs2544223	chr7:133995787	A/G	cg11752832	chr7:134001865	SLC35B4	0.58	7.44	0.44	1.92e-12	Mean platelet volume;
SARC	cis	rs965469	0.895	rs6051841	chr20:3392871	A/G	cg25506879	chr20:3388711	C20orf194	-0.58	-5.97	-0.36	8.84e-9	IFN-related cytopenia;
SARC	cis	rs11112613	0.775	rs12371537	chr12:105971425	T/C	cg03607813	chr12:105948248	NA	0.54	7.4	0.44	2.39e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg18876405	chr7:65276391	NA	-0.47	-5.42	-0.33	1.5e-7	Aortic root size;
SARC	cis	rs10754283	0.967	rs2002883	chr1:90105838	A/G	cg21401794	chr1:90099060	LRRC8C	0.59	8.1	0.47	2.99e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs6088590	0.561	rs6088527	chr20:33155841	C/T	cg24642439	chr20:33292090	TP53INP2	0.66	8.51	0.49	2.12e-15	Coronary artery disease;
SARC	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg04277193	chr17:41438351	NA	0.44	4.73	0.3	3.83e-6	Menopause (age at onset);
SARC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg25934064	chr3:52569026	NT5DC2	0.3	4.72	0.3	4.06e-6	Bipolar disorder;
SARC	cis	rs5995756	1.000	rs5995756	chr22:40000313	A/G	cg10455938	chr22:40058150	CACNA1I	-0.43	-5.53	-0.34	8.74e-8	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6696846	0.765	rs4394715	chr1:205108393	T/G	cg21643547	chr1:205240462	TMCC2	-0.61	-8.42	-0.48	3.83e-15	Red blood cell count;
SARC	cis	rs10504073	0.669	rs12548464	chr8:50023867	C/T	cg00325661	chr8:49890786	NA	0.53	7.16	0.42	1.02e-11	Blood metabolite ratios;
SARC	cis	rs6831352	0.879	rs29001208	chr4:100052539	A/C	cg13256891	chr4:100009986	ADH5	-0.64	-7.95	-0.46	8.17e-14	Alcohol dependence;
SARC	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg17221315	chr6:27791827	HIST1H4J	0.43	4.75	0.3	3.59e-6	Cardiac Troponin-T levels;
SARC	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg18252515	chr7:66147081	NA	-1.34	-11.85	-0.61	1.15e-25	Diabetic kidney disease;
SARC	cis	rs1008375	1.000	rs1008375	chr4:17682834	T/C	cg27347728	chr4:17578864	LAP3	0.45	5.59	0.34	6.23e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg22535103	chr8:58192502	C8orf71	-0.82	-9.44	-0.53	3.92e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg21724239	chr8:58056113	NA	0.6	6.37	0.38	1.03e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs12369179	0.737	rs116896792	chr12:122948907	T/C	cg18578876	chr12:123200353	GPR109B	-0.91	-6.47	-0.39	5.77e-10	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;
SARC	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg13607699	chr17:42295918	UBTF	0.59	7.22	0.43	7.31e-12	Total body bone mineral density;
SARC	cis	rs2180341	0.814	rs6919277	chr6:127738050	T/C	cg27446573	chr6:127587934	RNF146	0.8	10.21	0.56	1.81e-20	Breast cancer;
SARC	cis	rs1448094	0.512	rs6539929	chr12:86244932	T/C	cg02569458	chr12:86230093	RASSF9	0.38	5.4	0.33	1.64e-7	Major depressive disorder;
SARC	trans	rs208520	0.779	rs208446	chr6:66903515	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.93	-10.74	-0.58	4.13e-22	Exhaled nitric oxide output;
SARC	cis	rs9902453	0.967	rs4493117	chr17:28489770	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	7.0	0.42	2.73e-11	Coffee consumption (cups per day);
SARC	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg05025164	chr4:1340916	KIAA1530	0.62	7.69	0.45	4.12e-13	Longevity;
SARC	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg04944784	chr2:26401820	FAM59B	0.47	5.64	0.35	4.89e-8	Gut microbiome composition (summer);
SARC	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg18252515	chr7:66147081	NA	-0.53	-5.69	-0.35	3.86e-8	Aortic root size;
SARC	cis	rs9790314	1.000	rs1993891	chr3:161047467	A/G	cg03342759	chr3:160939853	NMD3	-0.57	-7.23	-0.43	6.78e-12	Morning vs. evening chronotype;
SARC	cis	rs13343954	0.825	rs7259371	chr19:33534641	G/A	cg17764715	chr19:33622953	WDR88	0.5	5.46	0.34	1.19e-7	Colorectal cancer;
SARC	cis	rs9325144	1.000	rs7963123	chr12:38976617	C/T	cg26384229	chr12:38710491	ALG10B	-0.56	-6.3	-0.38	1.43e-9	Morning vs. evening chronotype;
SARC	trans	rs9329221	0.662	rs4240645	chr8:10254463	C/G	cg06636001	chr8:8085503	FLJ10661	-0.6	-7.33	-0.43	3.66e-12	Neuroticism;
SARC	cis	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg01579765	chr21:45077557	HSF2BP	-0.37	-6.34	-0.38	1.21e-9	Mean corpuscular volume;
SARC	cis	rs9398803	0.651	rs9388509	chr6:126989977	G/A	cg20229609	chr6:126660872	C6orf173	0.34	4.85	0.3	2.25e-6	Male-pattern baldness;
SARC	cis	rs3820928	1.000	rs10193316	chr2:227777650	A/G	cg11843606	chr2:227700838	RHBDD1	-0.55	-6.95	-0.41	3.58e-11	Pulmonary function;
SARC	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	-0.95	-11.73	-0.61	2.73e-25	Age-related macular degeneration (geographic atrophy);
SARC	trans	rs11098499	0.954	rs13151285	chr4:120314741	C/A	cg25214090	chr10:38739885	LOC399744	0.55	7.14	0.42	1.15e-11	Corneal astigmatism;
SARC	cis	rs3733585	0.682	rs13124563	chr4:9927553	A/G	cg11266682	chr4:10021025	SLC2A9	0.4	7.1	0.42	1.49e-11	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7044106	0.734	rs10491784	chr9:123432289	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	8.99	0.51	9.01e-17	Hip circumference adjusted for BMI;
SARC	cis	rs478304	0.934	rs610037	chr11:65546857	A/C	cg08755490	chr11:65554678	OVOL1	0.38	5.37	0.33	1.92e-7	Acne (severe);
SARC	cis	rs765787	0.530	rs12592055	chr15:45514477	C/T	cg24006582	chr15:45444508	DUOX1	0.46	5.94	0.36	1.03e-8	Uric acid levels;
SARC	cis	rs595982	0.527	rs73061656	chr19:49372355	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.64	-7.15	-0.42	1.09e-11	Red cell distribution width;
SARC	cis	rs7412746	0.658	rs6660845	chr1:150841066	G/A	cg13175981	chr1:150552382	MCL1	-0.51	-6.07	-0.37	5.1e-9	Melanoma;
SARC	cis	rs2153535	0.525	rs1335644	chr6:8488041	A/G	cg23788917	chr6:8435910	SLC35B3	0.64	8.44	0.48	3.45e-15	Motion sickness;
SARC	cis	rs2732480	0.500	rs7315820	chr12:48598938	C/T	cg24011408	chr12:48396354	COL2A1	0.46	5.4	0.33	1.63e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs7223966	1.000	rs2874121	chr17:61731024	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.51	-5.28	-0.33	2.95e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.31	-4.76	-0.3	3.38e-6	Total body bone mineral density;
SARC	cis	rs228437	0.913	rs1467434	chr6:134925349	C/T	cg24504307	chr6:134963096	NA	0.46	5.21	0.32	4.08e-7	Melanoma;
SARC	cis	rs11150038	0.826	rs7203483	chr16:78085836	C/T	cg04733911	chr16:78082701	NA	0.41	4.74	0.3	3.67e-6	Colorectal or endometrial cancer;
SARC	cis	rs4865169	0.934	rs12650737	chr4:57892475	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.43	-5.05	-0.31	8.82e-7	Breast cancer;
SARC	cis	rs9486719	1.000	rs2472882	chr6:96863474	C/T	cg06623918	chr6:96969491	KIAA0776	0.73	8.01	0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs11122272	0.735	rs2790884	chr1:231531932	A/G	cg06096015	chr1:231504339	EGLN1	0.38	5.7	0.35	3.54e-8	Hemoglobin concentration;
SARC	cis	rs870825	0.616	rs7678849	chr4:185648868	T/C	cg04058563	chr4:185651563	MLF1IP	0.8	11.35	0.6	4.56e-24	Blood protein levels;
SARC	cis	rs2952156	1.000	rs2088126	chr17:37879030	A/G	cg20243544	chr17:37824526	PNMT	0.44	5.13	0.32	6.15e-7	Asthma;
SARC	cis	rs10870270	1.000	rs11146338	chr10:133770291	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.48	-5.41	-0.33	1.53e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg08219700	chr8:58056026	NA	0.59	5.98	0.37	8.12e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9398803	0.678	rs9401892	chr6:126895368	G/A	cg19875578	chr6:126661172	C6orf173	0.6	8.22	0.47	1.39e-14	Male-pattern baldness;
SARC	cis	rs870825	0.616	rs7678616	chr4:185648714	T/G	cg04058563	chr4:185651563	MLF1IP	0.8	11.35	0.6	4.56e-24	Blood protein levels;
SARC	cis	rs7818345	1.000	rs6981898	chr8:19305705	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.39	5.29	0.33	2.77e-7	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg07701084	chr6:150067640	NUP43	0.43	5.66	0.35	4.4e-8	Lung cancer;
SARC	cis	rs8180040	0.966	rs1872164	chr3:47415100	G/A	cg27129171	chr3:47204927	SETD2	-0.67	-9.42	-0.53	4.5e-18	Colorectal cancer;
SARC	cis	rs7666738	0.830	rs13125432	chr4:98961253	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg11301795	chr4:187892539	NA	0.71	10.32	0.56	8.27e-21	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7520050	0.771	rs4660882	chr1:46116292	C/T	cg24296786	chr1:45957014	TESK2	-0.43	-5.57	-0.34	6.94e-8	Red blood cell count;Reticulocyte count;
SARC	cis	rs13082711	0.522	rs479302	chr3:27363033	A/G	cg02860705	chr3:27208620	NA	0.43	5.66	0.35	4.5e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg21573476	chr21:45109991	RRP1B	-0.55	-8.27	-0.48	1.01e-14	Mean corpuscular volume;
SARC	cis	rs1580019	0.713	rs2167274	chr7:32524844	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.55	7.11	0.42	1.39e-11	Cognitive ability;
SARC	cis	rs2952156	1.000	rs2643195	chr17:37853118	A/G	cg20243544	chr17:37824526	PNMT	0.4	4.82	0.3	2.58e-6	Asthma;
SARC	cis	rs12311304	1.000	rs1479405	chr12:15387519	C/T	cg08258403	chr12:15378311	NA	0.46	7.2	0.43	8.46e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs11509153	0.687	rs1435526	chr7:12262654	A/G	cg23422036	chr7:12250390	TMEM106B	0.47	6.04	0.37	6.14e-9	Residual cognition;
SARC	cis	rs11711311	0.911	rs28577577	chr3:113447276	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.69	8.9	0.5	1.64e-16	IgG glycosylation;
SARC	trans	rs61931739	0.635	rs6488185	chr12:33933127	G/C	cg26384229	chr12:38710491	ALG10B	0.56	7.25	0.43	6.01e-12	Morning vs. evening chronotype;
SARC	cis	rs9660992	0.710	rs1172111	chr1:205232980	C/T	cg00857998	chr1:205179979	DSTYK	0.5	6.19	0.38	2.62e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs77106637	0.858	rs117819392	chr11:72514503	C/T	cg03713592	chr11:72463424	ARAP1	1.03	9.86	0.54	2.2e-19	Type 2 diabetes;
SARC	cis	rs2304069	0.826	rs2244195	chr5:149403528	C/A	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.68	6.89	0.41	5.12e-11	HIV-1 control;
SARC	cis	rs9322817	0.607	rs7772567	chr6:105155782	C/A	cg02098413	chr6:105308735	HACE1	-0.37	-5.67	-0.35	4.31e-8	Thyroid stimulating hormone;
SARC	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg23958373	chr8:599963	NA	-0.6	-5.26	-0.33	3.29e-7	IgG glycosylation;
SARC	cis	rs7216064	1.000	rs11870068	chr17:65944515	A/C	cg12091567	chr17:66097778	LOC651250	-0.72	-7.47	-0.44	1.61e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs9399137	0.529	rs7739722	chr6:135282225	T/C	cg24558204	chr6:135376177	HBS1L	0.6	7.87	0.46	1.37e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs6831352	1.000	rs6837685	chr4:100049145	G/A	cg13256891	chr4:100009986	ADH5	0.66	8.75	0.5	4.46e-16	Alcohol dependence;
SARC	trans	rs453301	0.624	rs330058	chr8:9089809	G/A	cg21775007	chr8:11205619	TDH	-0.51	-6.47	-0.39	5.64e-10	Joint mobility (Beighton score);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg24990968	chr12:64784626	C12orf56	0.48	6.86	0.41	6.19e-11	Chemerin levels;
SARC	cis	rs7703051	0.520	rs13354746	chr5:74619132	C/T	cg19683494	chr5:74908142	NA	0.52	5.77	0.35	2.54e-8	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
SARC	trans	rs36093844	0.800	rs78681528	chr11:85588156	T/G	cg15359163	chr5:122429178	PRDM6	-0.54	-6.44	-0.39	6.72e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs35306767	0.855	rs61830932	chr10:934183	T/C	cg20503657	chr10:835505	NA	0.86	8.3	0.48	8.21e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs6439153	0.933	rs2630262	chr3:128677098	C/T	cg25356066	chr3:128598488	ACAD9	-0.42	-4.94	-0.31	1.49e-6	Pneumococcal bacteremia;
SARC	cis	rs9435341	0.929	rs1762509	chr1:107592959	A/G	cg09367891	chr1:107599246	PRMT6	-0.76	-9.29	-0.52	1.1e-17	Facial morphology (factor 21, depth of nasal alae);
SARC	cis	rs7659604	1.000	rs28618203	chr4:122663935	T/C	cg20573242	chr4:122745356	CCNA2	0.42	5.49	0.34	1.03e-7	Type 2 diabetes;
SARC	cis	rs4727027	0.901	rs4727019	chr7:148822266	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	5.85	0.36	1.61e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs9388451	0.903	rs9388446	chr6:126064920	T/A	cg06289844	chr6:126071538	HEY2	0.38	6.24	0.38	2.1e-9	Brugada syndrome;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg14110147	chr13:28024806	MTIF3	-0.49	-6.6	-0.4	2.77e-10	Neuroticism;
SARC	cis	rs1559088	0.847	rs10423531	chr19:33600140	T/C	cg17764715	chr19:33622953	WDR88	0.5	6.91	0.41	4.61e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs721399	0.553	rs10095072	chr8:18244662	G/T	cg18736775	chr8:18248649	NAT2	-0.59	-6.73	-0.4	1.28e-10	Blood metabolite levels;
SARC	cis	rs9467773	1.000	rs1884948	chr6:26567988	G/A	cg11502198	chr6:26597334	ABT1	0.53	6.46	0.39	6.05e-10	Intelligence (multi-trait analysis);
SARC	cis	rs995000	0.931	rs10889336	chr1:62980410	T/C	cg06896770	chr1:63153194	DOCK7	0.99	14.68	0.69	5.56e-35	Triglyceride levels;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg24291087	chr4:30722781	PCDH7	-0.46	-6.54	-0.39	3.76e-10	Chemerin levels;
SARC	cis	rs1055129	0.655	rs7223416	chr17:73836162	C/G	cg06969265	chr17:73775802	H3F3B	0.43	5.1	0.32	7e-7	White matter hyperintensity burden;
SARC	cis	rs7827545	1.000	rs6995244	chr8:135568959	A/G	cg17885191	chr8:135476712	NA	0.43	4.72	0.3	4.08e-6	Hypertension (SNP x SNP interaction);
SARC	cis	rs2985684	0.841	rs7158577	chr14:50058633	C/T	cg04989706	chr14:50066350	PPIL5	-0.57	-6.29	-0.38	1.6e-9	Carotid intima media thickness;
SARC	cis	rs9612	1.000	rs1058	chr19:44268325	C/G	cg07522664	chr19:44259120	C19orf61	0.5	5.61	0.34	5.83e-8	Exhaled nitric oxide output;
SARC	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg13880726	chr7:1868755	MAD1L1	0.51	6.06	0.37	5.43e-9	Bipolar disorder and schizophrenia;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg01566283	chr6:28109239	ZNF192	-0.47	-6.47	-0.39	5.71e-10	Thyroid stimulating hormone;
SARC	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg11987759	chr7:65425863	GUSB	0.48	6.32	0.38	1.31e-9	Aortic root size;
SARC	cis	rs7119	0.717	rs8032071	chr15:77745762	C/T	cg17802220	chr15:77601643	NA	0.44	5.32	0.33	2.42e-7	Type 2 diabetes;
SARC	cis	rs5167	0.525	rs11083752	chr19:45454363	G/A	cg09555818	chr19:45449301	APOC2	0.55	8.91	0.5	1.5e-16	Blood protein levels;
SARC	cis	rs9896052	0.572	rs4078474	chr17:73489567	C/G	cg04121983	chr17:73511085	CASKIN2	0.42	4.92	0.31	1.64e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs897984	0.520	rs4889622	chr16:30870957	A/G	cg02466173	chr16:30829666	NA	0.41	5.12	0.32	6.39e-7	Dementia with Lewy bodies;
SARC	cis	rs12142240	0.698	rs10158572	chr1:46822440	G/T	cg14993813	chr1:46806288	NSUN4	-0.51	-5.34	-0.33	2.19e-7	Menopause (age at onset);
SARC	cis	rs11190604	1.000	rs11190558	chr10:102209397	C/A	cg07080220	chr10:102295463	HIF1AN	0.78	9.58	0.53	1.56e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs908922	0.676	rs491077	chr1:152519570	C/A	cg09873164	chr1:152488093	CRCT1	0.62	8.04	0.47	4.46e-14	Hair morphology;
SARC	cis	rs2645694	0.626	rs2703120	chr4:77822470	G/A	cg18351406	chr4:77819688	ANKRD56	0.45	6.24	0.38	2.04e-9	Emphysema distribution in smoking;
SARC	cis	rs11809207	0.501	rs2232654	chr1:26496870	A/G	cg23602478	chr1:26503979	CNKSR1	0.28	5.04	0.31	9.21e-7	Height;
SARC	cis	rs67311347	0.713	rs9861194	chr3:40309225	C/T	cg24209194	chr3:40518798	ZNF619	0.54	6.71	0.4	1.44e-10	Renal cell carcinoma;
SARC	cis	rs6840360	1.000	rs1105535	chr4:152605170	A/G	cg22705602	chr4:152727874	NA	-0.38	-6.5	-0.39	4.81e-10	Intelligence (multi-trait analysis);
SARC	cis	rs854765	0.562	rs2955381	chr17:17945500	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-9.75	-0.54	4.63e-19	Total body bone mineral density;
SARC	cis	rs6690583	0.623	rs1371140	chr1:85455362	A/C	cg22153463	chr1:85462885	MCOLN2	0.72	6.96	0.42	3.33e-11	Serum sulfate level;
SARC	cis	rs9303542	0.559	rs12603976	chr17:46617163	C/A	cg04904318	chr17:46607828	HOXB1	-0.45	-4.95	-0.31	1.41e-6	Ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-4.82	-0.3	2.59e-6	Total body bone mineral density;
SARC	trans	rs61931739	0.500	rs56404399	chr12:34543101	A/G	cg13010199	chr12:38710504	ALG10B	0.83	11.73	0.61	2.89e-25	Morning vs. evening chronotype;
SARC	cis	rs765787	0.530	rs4331289	chr15:45515338	C/T	cg25801113	chr15:45476975	SHF	0.28	4.72	0.3	4.06e-6	Uric acid levels;
SARC	cis	rs240764	0.817	rs239239	chr6:101094554	A/G	cg09795085	chr6:101329169	ASCC3	0.44	5.71	0.35	3.39e-8	Neuroticism;
SARC	cis	rs7937682	0.737	rs663763	chr11:111422217	C/T	cg22437258	chr11:111473054	SIK2	0.56	7.34	0.43	3.54e-12	Primary sclerosing cholangitis;
SARC	cis	rs17345786	1.000	rs3804775	chr3:101306507	C/T	cg12386194	chr3:101231763	SENP7	0.74	8.8	0.5	3.16e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2439831	0.867	rs28415933	chr15:43635800	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.08	11.58	0.6	8.71e-25	Lung cancer in ever smokers;
SARC	cis	rs6088590	1.000	rs6120708	chr20:33335526	G/A	cg24642439	chr20:33292090	TP53INP2	0.89	12.73	0.64	1.54e-28	Coronary artery disease;
SARC	cis	rs2153904	0.590	rs823106	chr1:205656453	G/C	cg14893161	chr1:205819251	PM20D1	0.66	5.97	0.36	8.57e-9	Prostate-specific antigen levels;
SARC	cis	rs9398803	0.865	rs9401882	chr6:126755055	A/G	cg19875578	chr6:126661172	C6orf173	0.6	8.07	0.47	3.8e-14	Male-pattern baldness;
SARC	cis	rs7659604	0.540	rs10004284	chr4:122699222	A/T	cg20573242	chr4:122745356	CCNA2	-0.36	-4.72	-0.3	4.05e-6	Type 2 diabetes;
SARC	cis	rs7829975	0.502	rs7820738	chr8:8702607	C/G	cg08975724	chr8:8085496	FLJ10661	-0.47	-5.96	-0.36	9.5e-9	Mood instability;
SARC	cis	rs7917772	0.636	rs4919674	chr10:104522226	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-6.38	-0.39	9.19e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg24466479	chr2:17935221	SMC6;GEN1	-0.51	-6.91	-0.41	4.53e-11	Schizophrenia;
SARC	trans	rs9325144	0.647	rs7957185	chr12:38909710	G/A	cg23762105	chr12:34175262	ALG10	0.48	6.26	0.38	1.83e-9	Morning vs. evening chronotype;
SARC	cis	rs763121	0.853	rs8142098	chr22:39058757	T/G	cg14440974	chr22:39074834	NA	-0.34	-4.89	-0.3	1.9e-6	Menopause (age at onset);
SARC	cis	rs7659604	0.643	rs6838881	chr4:122663616	A/T	cg19748678	chr4:122722346	EXOSC9	0.44	5.0	0.31	1.11e-6	Type 2 diabetes;
SARC	cis	rs72945132	0.678	rs35733235	chr11:70235595	C/T	cg00319359	chr11:70116639	PPFIA1	0.56	5.19	0.32	4.56e-7	Coronary artery disease;
SARC	cis	rs8180040	0.966	rs6792461	chr3:47473168	C/T	cg27129171	chr3:47204927	SETD2	-0.67	-9.58	-0.53	1.56e-18	Colorectal cancer;
SARC	cis	rs2120243	0.572	rs6441129	chr3:157125828	A/G	cg24825693	chr3:157122686	VEPH1	0.45	6.36	0.38	1.04e-9	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg00933542	chr6:150070202	PCMT1	0.3	4.91	0.31	1.69e-6	Testicular germ cell tumor;
SARC	cis	rs1153858	1.000	rs4775907	chr15:45638647	G/A	cg03999130	chr15:45571217	NA	0.39	4.93	0.31	1.58e-6	Homoarginine levels;
SARC	cis	rs7772486	0.727	rs10223508	chr6:146285205	C/T	cg23711669	chr6:146136114	FBXO30	-0.75	-11.49	-0.6	1.73e-24	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2916247	1.000	rs2916248	chr8:93013260	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.58	-6.04	-0.37	5.91e-9	Intelligence (multi-trait analysis);
SARC	cis	rs2075371	0.829	rs35897155	chr7:134002711	G/A	cg00033643	chr7:134001901	SLC35B4	0.46	5.49	0.34	1.07e-7	Mean platelet volume;
SARC	cis	rs2242116	0.796	rs4587	chr3:46963502	T/C	cg02527881	chr3:46936655	PTH1R	-0.38	-5.94	-0.36	1.04e-8	Birth weight;
SARC	cis	rs1057510	1.000	rs1057510	chr12:6683287	C/T	cg19104830	chr12:7342086	PEX5	0.55	5.64	0.35	4.93e-8	Myopia (pathological);
SARC	cis	rs897080	0.515	rs1067366	chr2:44655094	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	6.45	0.39	6.56e-10	Height;
SARC	cis	rs2421770	0.530	rs4756217	chr11:35366733	C/T	cg13971030	chr11:35366721	SLC1A2	-0.34	-5.25	-0.33	3.42e-7	Staphylococcus aureus nasal carriage (persistent);
SARC	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg23758822	chr17:41437982	NA	0.9	11.33	0.6	5.44e-24	Menopause (age at onset);
SARC	cis	rs7932354	0.528	rs2018527	chr11:47175809	A/G	cg03339077	chr11:47165057	C11orf49	0.44	6.04	0.37	6.2e-9	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs9660992	0.573	rs1172159	chr1:205207512	T/C	cg21545522	chr1:205238299	TMCC2	0.39	5.34	0.33	2.22e-7	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg04944784	chr2:26401820	FAM59B	-0.59	-7.7	-0.45	3.84e-13	Gut microbiome composition (summer);
SARC	cis	rs12079745	0.793	rs60011235	chr1:169254727	T/C	cg09363564	chr1:169337483	NME7;BLZF1	-0.78	-4.99	-0.31	1.16e-6	QT interval;
SARC	cis	rs1018836	0.818	rs2285232	chr8:91546162	C/G	cg16814680	chr8:91681699	NA	-0.72	-11.08	-0.59	3.51e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs10911232	0.507	rs10797822	chr1:183017769	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.37	0.56	5.93e-21	Hypertriglyceridemia;
SARC	cis	rs6952808	0.636	rs73048162	chr7:1949328	T/C	cg03354898	chr7:1950403	MAD1L1	-0.38	-5.19	-0.32	4.49e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs7681440	0.583	rs1551980	chr4:90774724	G/A	cg06632027	chr4:90757378	SNCA	-0.47	-5.81	-0.36	2.03e-8	Dementia with Lewy bodies;
SARC	cis	rs7412746	0.658	rs10305714	chr1:150800655	C/T	cg15448220	chr1:150897856	SETDB1	-0.47	-6.2	-0.38	2.51e-9	Melanoma;
SARC	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg05313129	chr8:58192883	C8orf71	-0.48	-5.72	-0.35	3.18e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9392918	0.902	rs12201553	chr6:7719940	A/G	cg23089261	chr6:7723385	NA	0.38	5.18	0.32	4.79e-7	Height;
SARC	cis	rs4780401	0.693	rs8191277	chr16:11764082	A/G	cg01061890	chr16:11836724	TXNDC11	-0.47	-5.97	-0.36	8.62e-9	Rheumatoid arthritis;
SARC	trans	rs56279505	0.690	rs56009681	chr4:100285772	A/T	cg18024358	chr1:3420815	MEGF6	-0.79	-6.28	-0.38	1.61e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs3218477	1.000	rs3218397	chr7:152370193	T/A	cg06618968	chr7:152373420	XRCC2	-0.71	-4.73	-0.3	3.96e-6	Mean platelet volume;
SARC	cis	rs17030434	0.953	rs11099906	chr4:154691690	A/T	cg14289246	chr4:154710475	SFRP2	-0.8	-7.96	-0.46	7.38e-14	Electrocardiographic conduction measures;
SARC	cis	rs9467711	0.606	rs9379873	chr6:26402717	T/C	cg12826209	chr6:26865740	GUSBL1	0.77	4.86	0.3	2.17e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs921968	0.541	rs3770214	chr2:219508988	C/T	cg02176678	chr2:219576539	TTLL4	-0.49	-7.63	-0.45	6.06e-13	Mean corpuscular hemoglobin concentration;
SARC	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg11878867	chr6:150167359	LRP11	-0.34	-4.72	-0.3	4.01e-6	Lung cancer;
SARC	cis	rs9612	1.000	rs1059	chr19:44268348	C/T	cg08581076	chr19:44259116	C19orf61	0.69	8.35	0.48	5.98e-15	Exhaled nitric oxide output;
SARC	cis	rs2033711	0.870	rs4801583	chr19:58918405	A/G	cg00825309	chr19:58991885	ZNF446	-0.55	-7.64	-0.45	5.78e-13	Uric acid clearance;
SARC	trans	rs7819412	0.745	rs2898260	chr8:10939490	G/T	cg08975724	chr8:8085496	FLJ10661	-0.48	-6.41	-0.39	8.12e-10	Triglycerides;
SARC	cis	rs2479724	0.905	rs2251274	chr6:41839438	T/G	cg17623882	chr6:41773611	USP49	-0.46	-5.71	-0.35	3.39e-8	Menarche (age at onset);
SARC	cis	rs10464366	0.746	rs4723821	chr7:39141532	A/G	cg18850127	chr7:39170497	POU6F2	0.44	5.4	0.33	1.64e-7	IgG glycosylation;
SARC	cis	rs4727027	0.704	rs2269972	chr7:148914047	C/T	cg23583168	chr7:148888333	NA	0.81	12.97	0.65	2.56e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs933688	1.000	rs2839728	chr5:90727412	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.02	13.39	0.66	1.04e-30	Smoking behavior;
SARC	cis	rs865483	0.895	rs2107105	chr17:35835080	C/T	cg06561646	chr17:35873369	DUSP14	-0.49	-6.55	-0.39	3.6e-10	Monocyte count;
SARC	cis	rs2464469	0.559	rs8042677	chr15:58202379	C/T	cg12031962	chr15:58353849	ALDH1A2	0.33	4.73	0.3	3.88e-6	Barrett's esophagus  or Esophageal adenocarcinoma;
SARC	cis	rs17376456	0.825	rs17372057	chr5:93071916	C/A	cg21475434	chr5:93447410	FAM172A	0.7	6.06	0.37	5.48e-9	Diabetic retinopathy;
SARC	cis	rs9911578	0.835	rs9788975	chr17:56460800	G/A	cg05425664	chr17:57184151	TRIM37	0.66	8.06	0.47	3.9e-14	Intelligence (multi-trait analysis);
SARC	cis	rs4595586	0.545	rs12815047	chr12:39380901	A/G	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	cis	rs2760061	0.624	rs10442629	chr1:228191070	T/A	cg01200585	chr1:228362443	C1orf69	0.42	5.24	0.32	3.65e-7	Diastolic blood pressure;
SARC	cis	rs9916302	0.851	rs9904919	chr17:37556431	G/C	cg20243544	chr17:37824526	PNMT	-0.57	-6.87	-0.41	5.64e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs1580019	0.568	rs2122633	chr7:32523870	G/T	cg06627557	chr7:32535165	LSM5;AVL9	0.9	14.84	0.7	1.66e-35	Cognitive ability;
SARC	cis	rs9814567	0.752	rs7623567	chr3:134330976	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.51	-6.61	-0.4	2.53e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	trans	rs9951602	0.512	rs7241419	chr18:76640778	C/G	cg02800362	chr5:177631904	HNRNPAB	0.68	8.62	0.49	1.03e-15	Obesity-related traits;
SARC	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg02841227	chr6:26021843	HIST1H4A	0.62	7.52	0.44	1.18e-12	Intelligence (multi-trait analysis);
SARC	cis	rs11711311	0.911	rs34337798	chr3:113396704	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	8.19	0.47	1.67e-14	IgG glycosylation;
SARC	cis	rs826838	1.000	rs6582619	chr12:38729904	A/G	cg26384229	chr12:38710491	ALG10B	0.96	15.62	0.72	4.25e-38	Heart rate;
SARC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.76	-7.97	-0.46	6.85e-14	Platelet count;
SARC	cis	rs8064024	0.681	rs1395602	chr16:4911239	A/C	cg08329684	chr16:4932620	PPL	0.35	5.42	0.33	1.46e-7	Cancer;
SARC	cis	rs3820928	1.000	rs12615988	chr2:227769000	A/G	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.85	-0.36	1.66e-8	Pulmonary function;
SARC	cis	rs9467773	1.000	rs6456734	chr6:26566965	G/T	cg11502198	chr6:26597334	ABT1	0.53	6.46	0.39	6.13e-10	Intelligence (multi-trait analysis);
SARC	trans	rs61931739	0.853	rs7133716	chr12:34041847	G/C	cg26384229	chr12:38710491	ALG10B	-0.58	-7.27	-0.43	5.33e-12	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg21724239	chr8:58056113	NA	0.61	6.43	0.39	7.16e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7560272	0.723	rs7585119	chr2:73724679	A/T	cg20560298	chr2:73613845	ALMS1	-0.52	-7.05	-0.42	1.99e-11	Schizophrenia;
SARC	cis	rs12912251	1.000	rs2132157	chr15:38992547	A/G	cg01338139	chr15:38987640	C15orf53	-0.46	-5.18	-0.32	4.78e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
SARC	cis	rs3784262	0.740	rs2119859	chr15:58254745	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.34	-4.94	-0.31	1.49e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg13271783	chr10:134563150	INPP5A	-0.41	-4.97	-0.31	1.32e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg05897853	chr3:98234845	CLDND1	0.5	7.33	0.43	3.78e-12	Thyroid stimulating hormone;
SARC	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg01570182	chr17:44337453	NA	-0.82	-9.75	-0.54	4.71e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg13395646	chr4:1353034	KIAA1530	-0.56	-6.73	-0.4	1.29e-10	Obesity-related traits;
SARC	cis	rs950169	0.519	rs7237	chr15:85186577	C/T	cg24253500	chr15:84953950	NA	0.36	5.25	0.32	3.5e-7	Schizophrenia;
SARC	cis	rs4774830	0.744	rs62046389	chr15:56307688	T/G	cg24530489	chr15:56299380	NA	-0.84	-4.97	-0.31	1.28e-6	Delta-5 desaturase activity;
SARC	cis	rs6912958	0.781	rs13193380	chr6:88297057	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.43	-0.34	1.42e-7	Monocyte percentage of white cells;
SARC	cis	rs3741404	0.560	rs12362602	chr11:63908660	G/A	cg18225595	chr11:63971243	STIP1	-0.44	-6.82	-0.41	7.69e-11	Platelet count;
SARC	cis	rs2439831	1.000	rs690263	chr15:43704465	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.81	8.46	0.48	2.98e-15	Lung cancer in ever smokers;
SARC	trans	rs61931739	0.534	rs2087128	chr12:34000173	T/C	cg13010199	chr12:38710504	ALG10B	0.66	9.15	0.51	2.97e-17	Morning vs. evening chronotype;
SARC	cis	rs208520	0.802	rs208516	chr6:66946119	T/C	cg07460842	chr6:66804631	NA	-0.92	-10.86	-0.58	1.66e-22	Exhaled nitric oxide output;
SARC	cis	rs4803468	1.000	rs3810175	chr19:41904396	C/T	cg08477640	chr19:41863820	B9D2	-0.48	-6.19	-0.38	2.69e-9	Height;
SARC	cis	rs9660992	0.649	rs72745216	chr1:205261016	G/A	cg07972983	chr1:205091412	RBBP5	0.51	5.95	0.36	9.86e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg19077165	chr18:44547161	KATNAL2	-0.54	-7.52	-0.44	1.15e-12	Personality dimensions;
SARC	cis	rs41271473	0.500	rs4440831	chr1:228887522	C/T	cg00850481	chr1:228891306	NA	0.33	5.2	0.32	4.3e-7	Chronic lymphocytic leukemia;
SARC	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.71	9.35	0.52	7.58e-18	Menarche (age at onset);
SARC	cis	rs854765	0.693	rs9907287	chr17:17774118	C/T	cg16928487	chr17:17741425	SREBF1	0.23	4.88	0.3	1.98e-6	Total body bone mineral density;
SARC	cis	rs7113850	0.541	rs7107940	chr11:24233228	G/A	ch.11.24196551F	chr11:24239977	NA	0.67	5.08	0.32	7.64e-7	Bone fracture in osteoporosis;
SARC	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.85	8.19	0.47	1.71e-14	Platelet count;
SARC	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg08677398	chr8:58056175	NA	0.44	5.24	0.32	3.59e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7927592	0.546	rs599083	chr11:68192346	T/G	cg01657329	chr11:68192670	LRP5	-0.41	-5.5	-0.34	9.88e-8	Total body bone mineral density;
SARC	cis	rs2180341	1.000	rs6910763	chr6:127630925	T/C	cg27446573	chr6:127587934	RNF146	1.02	14.46	0.69	2.89e-34	Breast cancer;
SARC	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg03433033	chr1:76189801	ACADM	0.48	6.1	0.37	4.46e-9	Blood metabolite levels;Acylcarnitine levels;
SARC	trans	rs2727020	0.718	rs1404366	chr11:49415899	T/A	cg15704280	chr7:45808275	SEPT13	-0.79	-10.12	-0.55	3.48e-20	Coronary artery disease;
SARC	cis	rs4911259	0.552	rs13038881	chr20:31468113	T/C	cg13636640	chr20:31349939	DNMT3B	-0.66	-8.96	-0.51	1.1e-16	Inflammatory bowel disease;
SARC	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	14.67	0.69	5.85e-35	Chronic sinus infection;
SARC	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg17971929	chr21:40555470	PSMG1	-0.56	-7.07	-0.42	1.81e-11	Menarche (age at onset);
SARC	cis	rs116095464	1.000	rs62331562	chr5:349298	G/C	cg22496380	chr5:211416	CCDC127	-0.79	-4.81	-0.3	2.75e-6	Breast cancer;
SARC	cis	rs3784262	0.669	rs7171261	chr15:58356855	C/G	cg12031962	chr15:58353849	ALDH1A2	0.34	5.18	0.32	4.85e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs9810089	0.758	rs12492510	chr3:136151631	G/T	cg15507776	chr3:136538369	TMEM22	0.44	4.74	0.3	3.72e-6	Gestational age at birth (child effect);
SARC	cis	rs7481584	0.624	rs449466	chr11:3047603	C/T	cg20651018	chr11:3035856	CARS	0.41	6.08	0.37	4.91e-9	Calcium levels;
SARC	cis	rs7615952	0.512	rs1077621	chr3:125819799	A/G	cg15145296	chr3:125709740	NA	-0.48	-4.73	-0.3	3.92e-6	Blood pressure (smoking interaction);
SARC	cis	rs2115630	0.645	rs4842978	chr15:85197253	T/C	cg17507749	chr15:85114479	UBE2QP1	-0.55	-6.5	-0.39	4.75e-10	P wave terminal force;
SARC	cis	rs4253772	0.744	rs4253760	chr22:46622384	T/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.47	5.16	0.32	5.38e-7	LDL cholesterol;Cholesterol, total;
SARC	cis	rs870825	0.616	rs28620459	chr4:185627132	G/C	cg04058563	chr4:185651563	MLF1IP	0.81	11.25	0.59	9.68e-24	Blood protein levels;
SARC	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg26335602	chr6:28129616	ZNF389	0.52	5.78	0.35	2.41e-8	Depression;
SARC	cis	rs644799	1.000	rs546809	chr11:95579938	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.67	9.01	0.51	7.77e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg00800038	chr16:89945340	TCF25	-0.76	-5.29	-0.33	2.81e-7	Skin colour saturation;
SARC	cis	rs9325144	0.555	rs4882358	chr12:38726640	A/G	cg13010199	chr12:38710504	ALG10B	0.55	7.05	0.42	2.04e-11	Morning vs. evening chronotype;
SARC	cis	rs6448317	0.954	rs7666033	chr4:24925272	A/G	cg21108841	chr4:24914750	CCDC149	-0.51	-5.55	-0.34	7.64e-8	Heschl's gyrus morphology;
SARC	cis	rs1865760	1.000	rs3752421	chr6:25918688	G/A	cg17691542	chr6:26056736	HIST1H1C	0.57	6.96	0.41	3.43e-11	Height;
SARC	cis	rs10463554	0.892	rs158246	chr5:102408849	A/G	cg23492399	chr5:102201601	PAM	-0.51	-5.67	-0.35	4.23e-8	Parkinson's disease;
SARC	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg22903657	chr4:1355424	KIAA1530	-0.36	-4.89	-0.31	1.84e-6	Obesity-related traits;
SARC	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg21724239	chr8:58056113	NA	0.58	6.14	0.37	3.49e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg04267008	chr7:1944627	MAD1L1	-0.52	-6.01	-0.37	7.28e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs12464559	0.522	rs4300824	chr2:152581866	T/C	cg01189475	chr2:152685088	ARL5A	0.66	5.78	0.35	2.44e-8	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs6752107	0.967	rs10210302	chr2:234158839	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.48	6.31	0.38	1.42e-9	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs6088590	0.561	rs11167239	chr20:33140472	G/A	cg24642439	chr20:33292090	TP53INP2	0.65	8.35	0.48	5.97e-15	Coronary artery disease;
SARC	cis	rs1707322	1.000	rs7553924	chr1:46352624	T/C	cg06784218	chr1:46089804	CCDC17	0.35	6.06	0.37	5.3300000000000004e-09	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg20965017	chr5:231967	SDHA	-0.55	-5.26	-0.33	3.23e-7	Breast cancer;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg15780484	chr4:26862189	STIM2	-0.84	-6.88	-0.41	5.52e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7831492	0.564	rs6981979	chr8:41612255	C/T	cg17182837	chr8:41585554	ANK1	-0.36	-4.76	-0.3	3.38e-6	Colorectal cancer;
SARC	cis	rs10504229	0.593	rs58647001	chr8:58025132	G/A	cg11062466	chr8:58055876	NA	0.53	5.35	0.33	2.14e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs477895	1.000	rs11600990	chr11:64082807	C/T	cg04317338	chr11:64019027	PLCB3	0.63	5.15	0.32	5.45e-7	Mean platelet volume;
SARC	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	6.98	0.42	3.08e-11	Platelet count;
SARC	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg25767906	chr1:53392781	SCP2	0.32	4.82	0.3	2.65e-6	Monocyte count;
SARC	cis	rs1707322	0.752	rs6678444	chr1:46229847	A/G	cg06784218	chr1:46089804	CCDC17	0.4	7.02	0.42	2.47e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs10754283	1.000	rs10754283	chr1:90112431	G/T	cg21401794	chr1:90099060	LRRC8C	0.59	8.09	0.47	3.24e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	trans	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.75	10.78	0.58	3.03e-22	Intelligence (multi-trait analysis);
SARC	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg04944784	chr2:26401820	FAM59B	0.49	5.83	0.36	1.85e-8	Gut microbiome composition (summer);
SARC	cis	rs9868809	0.505	rs11706983	chr3:48738678	A/G	cg03060546	chr3:49711283	APEH	-0.5	-4.72	-0.3	4.14e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs6964587	1.000	rs4727266	chr7:91570129	C/T	cg17063962	chr7:91808500	NA	-0.92	-14.58	-0.69	1.19e-34	Breast cancer;
SARC	cis	rs1797081	1.000	rs780634	chr10:16864327	T/G	cg23933602	chr10:16859644	RSU1	0.95	19.32	0.78	2.79e-50	Platelet distribution width;
SARC	cis	rs72781680	1.000	rs56339200	chr2:24188194	C/A	cg08917208	chr2:24149416	ATAD2B	0.79	7.55	0.44	9.78e-13	Lymphocyte counts;
SARC	trans	rs7937682	0.889	rs516263	chr11:111484719	A/C	cg18187862	chr3:45730750	SACM1L	0.55	6.98	0.42	3.04e-11	Primary sclerosing cholangitis;
SARC	cis	rs921968	0.613	rs2303566	chr2:219557738	C/T	cg02176678	chr2:219576539	TTLL4	-0.34	-5.06	-0.31	8.61e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs1552244	0.688	rs113940455	chr3:10014165	A/C	cg24633833	chr3:10029261	TMEM111	0.52	5.02	0.31	1.05e-6	Alzheimer's disease;
SARC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg12419862	chr22:24373484	LOC391322	-0.68	-8.23	-0.47	1.34e-14	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2153535	0.526	rs7748404	chr6:8472500	A/T	cg21535247	chr6:8435926	SLC35B3	0.53	6.72	0.4	1.4e-10	Motion sickness;
SARC	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs17401966	0.931	rs12131441	chr1:10428952	G/A	cg15208524	chr1:10270712	KIF1B	0.5	5.99	0.37	7.88e-9	Hepatocellular carcinoma;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13275176	chr2:97534450	SEMA4C	0.65	8.78	0.5	3.55e-16	Smoking initiation;
SARC	cis	rs3892630	0.757	rs8109823	chr19:33183316	A/G	cg22980127	chr19:33182716	NUDT19	1.06	9.74	0.54	5.16e-19	Red blood cell traits;
SARC	cis	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg08564027	chr20:61660810	NA	0.76	11.8	0.61	1.69e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg21573476	chr21:45109991	RRP1B	-0.56	-8.23	-0.47	1.36e-14	Mean corpuscular volume;
SARC	cis	rs1267303	0.562	rs2476162	chr1:47007324	G/A	cg25110126	chr1:46999211	NA	0.7	7.59	0.45	7.72e-13	Monobrow;
SARC	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs963731	0.649	rs2888585	chr2:39246683	C/T	cg04010122	chr2:39346883	SOS1	-0.89	-5.12	-0.32	6.33e-7	Corticobasal degeneration;
SARC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg26338869	chr17:61819248	STRADA	0.8	10.8	0.58	2.52e-22	Prudent dietary pattern;
SARC	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg11764359	chr7:65958608	NA	0.77	9.41	0.52	5.12e-18	Aortic root size;
SARC	cis	rs4742903	0.904	rs10124553	chr9:106993898	G/A	cg14250997	chr9:106856677	SMC2	0.4	5.17	0.32	5.08e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs722599	0.748	rs55707505	chr14:75362552	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.46	-5.87	-0.36	1.47e-8	IgG glycosylation;
SARC	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-8.65	-0.49	8.29e-16	Chronic sinus infection;
SARC	cis	rs3087591	1.000	rs2952978	chr17:29474744	A/C	cg24425628	chr17:29625626	OMG;NF1	0.53	6.55	0.39	3.57e-10	Hip circumference;
SARC	cis	rs12950390	0.512	rs59396604	chr17:45837777	G/A	cg24803719	chr17:45855879	NA	-0.42	-5.31	-0.33	2.55e-7	IgG glycosylation;
SARC	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg04944784	chr2:26401820	FAM59B	-0.6	-7.95	-0.46	8.14e-14	Gut microbiome composition (summer);
SARC	cis	rs3008870	1.000	rs975451	chr1:67480060	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.91	11.06	0.59	3.94e-23	Lymphocyte percentage of white cells;
SARC	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	8.36	0.48	5.65e-15	Mean platelet volume;
SARC	cis	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg25894440	chr7:65020034	NA	-0.64	-5.05	-0.31	9.07e-7	Diabetic kidney disease;
SARC	cis	rs7666738	0.830	rs10025174	chr4:98914172	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.67	0.49	7.66e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg04277193	chr17:41438351	NA	0.45	4.85	0.3	2.21e-6	Menopause (age at onset);
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg01703355	chr3:152067880	MBNL1	-0.51	-6.38	-0.39	9.62e-10	Alcohol dependence;
SARC	cis	rs3126085	0.935	rs3126056	chr1:152266503	G/A	cg26876637	chr1:152193138	HRNR	-0.46	-5.23	-0.32	3.75e-7	Atopic dermatitis;
SARC	trans	rs1865760	0.929	rs9461224	chr6:25936402	G/T	cg27379773	chr5:180615650	NA	-0.6	-7.34	-0.43	3.53e-12	Height;
SARC	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg01238044	chr22:24384105	GSTT1	0.66	7.18	0.43	9.04e-12	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs7914558	0.933	rs12763665	chr10:104653717	G/A	cg15744005	chr10:104629667	AS3MT	-0.27	-4.89	-0.3	1.91e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs4481887	0.927	rs4523548	chr1:248472399	G/T	cg13385794	chr1:248469461	NA	0.35	5.45	0.34	1.29e-7	Common traits (Other);
SARC	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg08280861	chr8:58055591	NA	0.58	5.63	0.35	5.17e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg24399712	chr22:39784796	NA	-0.44	-5.85	-0.36	1.67e-8	Intelligence (multi-trait analysis);
SARC	cis	rs17376456	0.825	rs6874766	chr5:93213807	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.64	-5.44	-0.34	1.35e-7	Diabetic retinopathy;
SARC	cis	rs7092929	0.883	rs651750	chr10:3577178	A/G	cg14308648	chr10:3568949	NA	0.52	5.22	0.32	3.98e-7	Coronary artery calcification;
SARC	cis	rs7712401	0.562	rs30052	chr5:122305009	A/T	cg19412675	chr5:122181750	SNX24	0.4	5.13	0.32	5.98e-7	Mean platelet volume;
SARC	cis	rs13166103	0.657	rs17766068	chr5:57713579	G/T	cg10487770	chr5:57879443	RAB3C	0.52	5.46	0.34	1.19e-7	Type 2 diabetes (age of onset);
SARC	cis	rs9486719	1.000	rs3906199	chr6:97049899	C/A	cg06623918	chr6:96969491	KIAA0776	-0.79	-8.88	-0.5	1.87e-16	Migraine;Coronary artery disease;
SARC	cis	rs7635838	0.684	rs2594966	chr3:11325276	A/G	cg00170343	chr3:11313890	ATG7	-0.65	-9.05	-0.51	5.87e-17	HDL cholesterol;
SARC	cis	rs3733585	0.648	rs35954357	chr4:9978758	G/C	cg11266682	chr4:10021025	SLC2A9	0.38	6.37	0.39	1.01e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.04	0.37	6.05e-9	Prudent dietary pattern;
SARC	cis	rs1387259	0.759	rs7960122	chr12:48777000	C/T	cg24011408	chr12:48396354	COL2A1	-0.42	-4.81	-0.3	2.76e-6	Obstructive sleep apnea trait (apnea hypopnea index);
SARC	cis	rs6570726	0.935	rs377130	chr6:145836632	C/T	cg05220968	chr6:146057943	EPM2A	-0.29	-4.99	-0.31	1.19e-6	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs7824557	0.701	rs4568582	chr8:11160495	A/T	cg06636001	chr8:8085503	FLJ10661	0.58	7.04	0.42	2.16e-11	Retinal vascular caliber;
SARC	cis	rs6866344	0.570	rs1132336	chr5:178140090	C/T	cg10224037	chr5:178157518	ZNF354A	0.97	13.7	0.67	1.02e-31	Neutrophil percentage of white cells;
SARC	cis	rs193541	0.632	rs6878609	chr5:122095549	C/G	cg19412675	chr5:122181750	SNX24	0.44	5.75	0.35	2.84e-8	Glucose homeostasis traits;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg12749048	chr13:45011471	TSC22D1	-0.45	-6.49	-0.39	4.97e-10	Thyroid stimulating hormone;
SARC	cis	rs4595586	0.655	rs7958206	chr12:39329294	G/A	cg26384229	chr12:38710491	ALG10B	0.46	5.65	0.35	4.71e-8	Morning vs. evening chronotype;
SARC	cis	rs9467773	1.000	rs6922824	chr6:26553815	C/G	cg12292205	chr6:26970375	C6orf41	-0.47	-5.81	-0.36	2.07e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7772486	0.686	rs857879	chr6:145974043	C/A	cg23711669	chr6:146136114	FBXO30	-0.78	-12.56	-0.64	5.68e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2280018	0.538	rs7404526	chr16:15129162	A/G	cg07549590	chr16:15018862	NA	-0.44	-5.76	-0.35	2.7e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.73	6.7	0.4	1.57e-10	Platelet count;
SARC	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.7	-9.24	-0.52	1.62e-17	Intelligence (multi-trait analysis);
SARC	cis	rs7296418	0.663	rs4553407	chr12:123750748	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-5.09	-0.32	7.34e-7	Platelet count;
SARC	cis	rs4953404	0.613	rs1531132	chr2:46892315	A/G	cg09399716	chr2:46890238	NA	-0.23	-4.89	-0.31	1.87e-6	Pulse pressure (alcohol consumption interaction);
SARC	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2072499	0.900	rs2248080	chr1:156195971	T/A	cg24450063	chr1:156163899	SLC25A44	1.09	15.77	0.72	1.28e-38	Testicular germ cell tumor;
SARC	trans	rs1814175	0.645	rs1851845	chr11:49982396	C/T	cg03929089	chr4:120376271	NA	-0.82	-11.88	-0.61	9.2e-26	Height;
SARC	cis	rs17030434	1.000	rs75083896	chr4:154719082	A/G	cg14289246	chr4:154710475	SFRP2	-0.76	-7.12	-0.42	1.31e-11	Electrocardiographic conduction measures;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg22805491	chr14:51172404	NA	-0.79	-6.83	-0.41	7.17e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg22974920	chr21:40686053	BRWD1	0.44	4.78	0.3	3.17e-6	Cognitive function;
SARC	cis	rs72781680	0.821	rs17045981	chr2:24109316	A/G	cg08917208	chr2:24149416	ATAD2B	0.64	6.47	0.39	5.85e-10	Lymphocyte counts;
SARC	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg22484793	chr3:52261325	TLR9	0.29	4.73	0.3	3.85e-6	Electroencephalogram traits;
SARC	cis	rs11574514	1.000	rs62620177	chr16:67860637	C/T	cg01866162	chr16:67596514	CTCF	1.11	6.43	0.39	7.02e-10	Crohn's disease;
SARC	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg00149659	chr3:10157352	C3orf10	0.72	6.62	0.4	2.41e-10	Alzheimer's disease;
SARC	cis	rs9430161	0.611	rs2095920	chr1:11033457	T/A	cg02454025	chr1:11042201	C1orf127	0.87	12.08	0.62	2.04e-26	Ewing sarcoma;
SARC	cis	rs10504229	0.511	rs16921553	chr8:57979314	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-4.86	-0.3	2.12e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs17345786	0.798	rs1609159	chr3:101275902	A/C	cg11279151	chr3:101281821	RG9MTD1	-0.48	-5.52	-0.34	9e-8	Colonoscopy-negative controls vs population controls;
SARC	cis	rs526231	0.543	rs34789	chr5:102460739	A/T	cg23492399	chr5:102201601	PAM	-0.51	-5.55	-0.34	7.77e-8	Primary biliary cholangitis;
SARC	cis	rs5743618	0.516	rs10024216	chr4:38764112	C/T	cg06935464	chr4:38784597	TLR10	0.38	4.84	0.3	2.4e-6	Asthma;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs11676348	0.783	rs13035513	chr2:218960680	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.48	-6.05	-0.37	5.79e-9	Ulcerative colitis;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg26262057	chr11:94227038	MRE11A;ANKRD49	0.54	6.62	0.4	2.51e-10	Breast cancer;
SARC	cis	rs1707322	0.821	rs11211182	chr1:46240170	G/A	cg06784218	chr1:46089804	CCDC17	0.37	6.6	0.4	2.7e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs5167	0.677	rs2238682	chr19:45458593	C/T	cg13119609	chr19:45449297	APOC2	0.39	5.48	0.34	1.11e-7	Blood protein levels;
SARC	cis	rs9399137	0.507	rs7761964	chr6:135314265	T/C	cg22676075	chr6:135203613	NA	0.38	4.84	0.3	2.32e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs77372450	0.636	rs6890471	chr5:157024032	C/T	cg23851860	chr5:157002805	ADAM19	0.5	4.85	0.3	2.27e-6	Bipolar disorder (body mass index interaction);
SARC	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.18	-0.52	2.33e-17	Developmental language disorder (linguistic errors);
SARC	cis	rs4925386	0.840	rs6143024	chr20:60914229	A/G	cg24112000	chr20:60950667	NA	-0.41	-6.34	-0.38	1.15e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs703842	1.000	rs11172342	chr12:58187758	G/T	cg00677455	chr12:58241039	CTDSP2	0.51	6.6	0.4	2.73e-10	Multiple sclerosis;
SARC	cis	rs2342371	0.848	rs4916497	chr3:196198533	T/C	cg15048948	chr3:196158458	UBXN7	-0.49	-5.97	-0.36	8.74e-9	Fat distribution (HIV);
SARC	cis	rs7635838	0.859	rs9869423	chr3:11459156	G/T	cg00170343	chr3:11313890	ATG7	0.64	8.75	0.5	4.47e-16	HDL cholesterol;
SARC	trans	rs360488	0.576	rs16861257	chr2:14296087	T/A	cg13543375	chr1:22470218	WNT4	0.56	6.24	0.38	2.06e-9	Emphysema imaging phenotypes;
SARC	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg11987759	chr7:65425863	GUSB	-0.48	-6.54	-0.39	3.9e-10	Aortic root size;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg05843257	chr22:24951377	SNRPD3;C22orf13	0.5	6.46	0.39	6.13e-10	Breast cancer;
SARC	cis	rs239198	0.578	rs11155708	chr6:101292189	G/A	cg09795085	chr6:101329169	ASCC3	0.46	5.83	0.36	1.87e-8	Menarche (age at onset);
SARC	cis	rs526231	0.578	rs6876278	chr5:102249546	A/G	cg23492399	chr5:102201601	PAM	-0.44	-5.23	-0.32	3.84e-7	Primary biliary cholangitis;
SARC	cis	rs9916302	0.861	rs632202	chr17:37453294	C/A	cg15445000	chr17:37608096	MED1	-0.45	-5.39	-0.33	1.71e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs138249	1.000	rs138244	chr22:50565367	C/T	cg24864161	chr22:50528282	MOV10L1	0.32	5.14	0.32	5.69e-7	Gestational age at birth in labor-initiated deliveries (child effect);
SARC	cis	rs986417	1.000	rs6573318	chr14:61087985	A/G	cg27398547	chr14:60952738	C14orf39	0.88	7.47	0.44	1.6e-12	Gut microbiota (bacterial taxa);
SARC	cis	rs9322817	0.691	rs7753202	chr6:105215289	T/C	cg02098413	chr6:105308735	HACE1	-0.39	-6.13	-0.37	3.8e-9	Thyroid stimulating hormone;
SARC	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs2200578	1.000	rs7566277	chr2:99916242	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.6	5.5	0.34	9.93e-8	IgG glycosylation;
SARC	trans	rs2727020	0.576	rs10839305	chr11:49598733	T/C	cg15704280	chr7:45808275	SEPT13	-0.89	-15.11	-0.7	2.11e-36	Coronary artery disease;
SARC	cis	rs2594989	0.895	rs2606739	chr3:11394611	C/A	cg00170343	chr3:11313890	ATG7	0.58	5.53	0.34	8.4e-8	Circulating chemerin levels;
SARC	cis	rs116095464	0.558	rs56081398	chr5:247318	C/T	cg22857025	chr5:266934	NA	-1.11	-10.56	-0.57	1.45e-21	Breast cancer;
SARC	cis	rs854765	0.583	rs4925125	chr17:17794444	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.42	-5.41	-0.33	1.58e-7	Total body bone mineral density;
SARC	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg20965017	chr5:231967	SDHA	-0.55	-5.26	-0.33	3.23e-7	Breast cancer;
SARC	cis	rs8067545	0.578	rs4925091	chr17:20066988	T/C	cg13482628	chr17:19912719	NA	0.51	6.56	0.39	3.51e-10	Schizophrenia;
SARC	cis	rs2197308	0.643	rs1842597	chr12:37862142	C/G	cg26384229	chr12:38710491	ALG10B	-0.85	-12.31	-0.63	3.78e-27	Morning vs. evening chronotype;
SARC	cis	rs7223966	1.000	rs8064261	chr17:61705212	G/A	cg00588841	chr17:61851480	DDX42;CCDC47	-0.63	-6.95	-0.41	3.57e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs11191205	0.774	rs11191203	chr10:103824920	C/T	cg15320455	chr10:103880129	LDB1	0.82	7.72	0.45	3.36e-13	Intelligence (multi-trait analysis);
SARC	cis	rs2953174	0.786	rs2953145	chr2:241515596	C/G	cg07929629	chr2:241523174	NA	-0.4	-4.78	-0.3	3.08e-6	Bipolar disorder;
SARC	cis	rs17376456	0.542	rs17083380	chr5:93170476	C/G	cg21475434	chr5:93447410	FAM172A	-0.55	-5.7	-0.35	3.62e-8	Diabetic retinopathy;
SARC	cis	rs3845702	1.000	rs3738943	chr2:180846743	G/T	cg01881094	chr2:180872142	CWC22	-0.69	-6.45	-0.39	6.39e-10	Schizophrenia;
SARC	cis	rs6807306	1.000	rs9822958	chr3:167363001	A/T	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.5	4.94	0.31	1.46e-6	Mean platelet volume;
SARC	cis	rs11608355	0.597	rs9943699	chr12:109840876	G/C	cg19025524	chr12:109796872	NA	-0.46	-6.67	-0.4	1.83e-10	Neuroticism;
SARC	trans	rs3942852	0.806	rs4752807	chr11:48128751	T/G	cg15704280	chr7:45808275	SEPT13	-0.58	-6.72	-0.4	1.42e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs80282103	0.764	rs12244052	chr10:1103266	G/A	cg08668510	chr10:1095578	IDI1	0.75	4.89	0.31	1.87e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg16405210	chr4:1374714	KIAA1530	-0.5	-5.79	-0.35	2.29e-8	Obesity-related traits;
SARC	cis	rs6674176	0.561	rs7161	chr1:44438974	A/G	cg13606994	chr1:44402422	ARTN	0.32	5.13	0.32	5.98e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs2180341	0.924	rs6930849	chr6:127630963	A/T	cg27446573	chr6:127587934	RNF146	1.02	14.46	0.69	2.89e-34	Breast cancer;
SARC	cis	rs796364	1.000	rs71424239	chr2:200725473	T/C	cg23649088	chr2:200775458	C2orf69	-0.58	-4.97	-0.31	1.3e-6	Schizophrenia;
SARC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.45	0.56	3.22e-21	Prudent dietary pattern;
SARC	cis	rs9297145	0.678	rs62473007	chr7:98749598	G/C	cg05967295	chr7:98741636	SMURF1	0.76	7.69	0.45	4.09e-13	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
SARC	cis	rs4906332	1.000	rs17617094	chr14:103893428	T/C	cg26031613	chr14:104095156	KLC1	-0.5	-5.84	-0.36	1.72e-8	Coronary artery disease;
SARC	cis	rs9486719	1.000	rs12190397	chr6:97036465	G/A	cg06623918	chr6:96969491	KIAA0776	-0.79	-8.88	-0.5	1.86e-16	Migraine;Coronary artery disease;
SARC	trans	rs1814175	0.669	rs11040473	chr11:49703813	C/T	cg03929089	chr4:120376271	NA	-0.74	-10.96	-0.58	8.45e-23	Height;
SARC	cis	rs9815354	1.000	rs1994157	chr3:41897482	G/A	cg03022575	chr3:42003672	ULK4	0.67	5.73	0.35	3.13e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2652822	0.525	rs3784671	chr15:63569184	C/A	cg02713581	chr15:63449717	RPS27L	0.54	6.27	0.38	1.71e-9	Metabolic traits;
SARC	cis	rs440932	0.887	rs398801	chr8:9031704	A/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-5.48	-0.34	1.08e-7	High light scatter reticulocyte percentage of red cells;
SARC	cis	rs875971	0.545	rs6969224	chr7:65834998	T/G	cg11764359	chr7:65958608	NA	0.68	6.75	0.4	1.16e-10	Aortic root size;
SARC	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	9.56	0.53	1.74e-18	Platelet count;
SARC	cis	rs2228479	0.850	rs17226966	chr16:89825338	A/G	cg26513180	chr16:89883248	FANCA	0.72	4.79	0.3	2.94e-6	Skin colour saturation;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg03925135	chr11:129872748	NCRNA00167;PRDM10	0.49	6.36	0.38	1.03e-9	Lung adenocarcinoma;
SARC	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-8.57	-0.49	1.44e-15	Chronic sinus infection;
SARC	cis	rs9309473	0.950	rs6546858	chr2:73838613	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-5.38	-0.33	1.84e-7	Metabolite levels;
SARC	cis	rs11785693	0.862	rs11778367	chr8:4988398	T/C	cg26367366	chr8:4980734	NA	0.67	6.08	0.37	4.81e-9	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs6580649	0.843	rs3803184	chr12:48398002	G/C	cg05342945	chr12:48394962	COL2A1	-0.53	-5.6	-0.34	5.87e-8	Lung cancer;
SARC	cis	rs9788682	0.747	rs2915695	chr15:78739471	T/C	cg06917634	chr15:78832804	PSMA4	0.52	5.41	0.33	1.55e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs7635838	0.892	rs6442252	chr3:11451416	T/C	cg00170343	chr3:11313890	ATG7	0.62	8.38	0.48	5.1e-15	HDL cholesterol;
SARC	cis	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg25427524	chr10:38739819	LOC399744	-0.52	-8.12	-0.47	2.64e-14	Extrinsic epigenetic age acceleration;
SARC	cis	rs2204008	0.540	rs3908193	chr12:38410907	G/T	cg14851346	chr12:38532713	NA	-0.47	-5.65	-0.35	4.6e-8	Bladder cancer;
SARC	cis	rs7520050	0.966	rs809775	chr1:46538040	A/T	cg24296786	chr1:45957014	TESK2	0.38	4.82	0.3	2.58e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs7617480	0.616	rs9873227	chr3:48773108	G/C	cg07636037	chr3:49044803	WDR6	0.86	9.04	0.51	6.24e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs7084402	0.934	rs1649089	chr10:60289695	T/C	cg07615347	chr10:60278583	BICC1	0.61	8.99	0.51	8.84e-17	Refractive error;
SARC	cis	rs8141529	0.529	rs28458474	chr22:29213034	A/G	cg02153584	chr22:29168773	CCDC117	0.65	6.65	0.4	2.02e-10	Lymphocyte counts;
SARC	cis	rs2721811	0.738	rs722218	chr7:24718710	A/C	cg17569154	chr7:24781545	DFNA5	0.44	6.13	0.37	3.69e-9	Depressive symptoms (multi-trait analysis);
SARC	cis	rs1580019	0.922	rs1466147	chr7:32486262	C/T	cg14728415	chr7:32535168	LSM5;AVL9	0.45	5.43	0.33	1.44e-7	Cognitive ability;
SARC	cis	rs72945132	0.579	rs35077099	chr11:70247970	G/A	cg05964544	chr11:70165517	PPFIA1	-0.62	-6.03	-0.37	6.52e-9	Coronary artery disease;
SARC	cis	rs6429082	0.668	rs291395	chr1:235652049	A/C	cg26050004	chr1:235667680	B3GALNT2	-0.69	-9.53	-0.53	2.21e-18	Adiposity;
SARC	cis	rs1124376	1.000	rs61457790	chr3:20136186	G/A	cg05072819	chr3:20081367	KAT2B	0.52	4.96	0.31	1.36e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs1707322	0.721	rs7520123	chr1:46235219	C/G	cg06784218	chr1:46089804	CCDC17	0.38	6.69	0.4	1.63e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1355223	1.000	rs1355223	chr11:34764479	A/G	cg18508148	chr11:34937573	PDHX;APIP	-0.45	-5.89	-0.36	1.36e-8	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs7923609	1.000	rs10822161	chr10:65118203	G/A	cg01631684	chr10:65280961	REEP3	-0.37	-4.81	-0.3	2.73e-6	Educational attainment;Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs4481887	0.927	rs4534422	chr1:248479482	A/G	cg00666640	chr1:248458726	OR2T12	0.34	5.56	0.34	7.52e-8	Common traits (Other);
SARC	cis	rs2251381	0.750	rs2255055	chr21:30537045	C/T	cg24692254	chr21:30365293	RNF160	0.89	13.61	0.67	1.92e-31	Selective IgA deficiency;
SARC	cis	rs7255436	0.965	rs4044435	chr19:8448177	T/C	cg10174797	chr19:8464628	RAB11B	0.45	6.49	0.39	5e-10	HDL cholesterol;
SARC	cis	rs6570726	0.905	rs375692	chr6:145840368	A/G	cg23711669	chr6:146136114	FBXO30	0.76	11.32	0.6	5.68e-24	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg06873352	chr17:61820015	STRADA	0.53	6.95	0.41	3.74e-11	Prudent dietary pattern;
SARC	cis	rs1691799	0.867	rs1027399	chr12:66760942	G/A	cg16791601	chr12:66731901	HELB	-0.72	-10.86	-0.58	1.72e-22	White blood cell count (basophil);
SARC	cis	rs778371	0.624	rs6733495	chr2:233616709	A/G	cg16596103	chr2:233749413	NGEF	-0.37	-5.56	-0.34	7.22e-8	Schizophrenia;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg05633854	chr12:95466977	NR2C1	0.51	6.79	0.41	8.98e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs941408	0.515	rs1005556	chr19:2778543	G/T	cg00079169	chr19:2811669	THOP1	0.45	4.98	0.31	1.26e-6	Total cholesterol levels;
SARC	trans	rs11098499	0.954	rs12505469	chr4:120249585	C/T	cg25214090	chr10:38739885	LOC399744	0.56	7.19	0.43	8.85e-12	Corneal astigmatism;
SARC	cis	rs2816062	0.747	rs2816049	chr1:18893768	A/G	cg18795169	chr1:18902165	NA	-0.76	-12.0	-0.62	3.71e-26	Urate levels in lean individuals;
SARC	cis	rs1580019	0.522	rs10951340	chr7:32562408	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.61	8.09	0.47	3.2e-14	Cognitive ability;
SARC	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg06212747	chr3:49208901	KLHDC8B	0.65	8.64	0.49	9.19e-16	Parkinson's disease;
SARC	cis	rs28655083	1.000	rs7198870	chr16:77072963	C/T	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.42	-5.97	-0.36	8.68e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7553035	0.764	rs17017668	chr1:211694508	A/G	cg01575408	chr1:211752895	SLC30A1	-0.6	-4.94	-0.31	1.51e-6	Retinopathy in non-diabetics;
SARC	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg20965017	chr5:231967	SDHA	-0.58	-5.52	-0.34	8.82e-8	Breast cancer;
SARC	cis	rs78487399	0.808	rs6708735	chr2:43731354	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-4.84	-0.3	2.37e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs8077889	0.750	rs231541	chr17:41941788	C/G	cg26893861	chr17:41843967	DUSP3	-0.73	-7.18	-0.43	9.05e-12	Triglycerides;
SARC	cis	rs2236918	0.710	rs1776174	chr1:242031839	G/T	cg17736920	chr1:242011382	EXO1	0.64	8.55	0.49	1.69e-15	Menopause (age at onset);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg22562194	chr17:72209580	TTYH2;MGC16275	0.49	6.41	0.39	7.98e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs2729354	1.000	rs2729354	chr11:57355970	A/G	cg02958346	chr11:57425731	CLP1	0.52	5.2	0.32	4.39e-7	Blood protein levels;
SARC	cis	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg06636001	chr8:8085503	FLJ10661	0.61	7.92	0.46	9.41e-14	Mood instability;
SARC	cis	rs77956314	0.515	rs4767490	chr12:117435016	A/G	cg02017074	chr12:117425053	FBXW8	0.55	6.91	0.41	4.58e-11	Subcortical brain region volumes;Hippocampal volume;
SARC	cis	rs6866344	0.601	rs4419608	chr5:178097049	C/T	cg03877680	chr5:178157825	ZNF354A	0.79	8.05	0.47	4.2e-14	Neutrophil percentage of white cells;
SARC	cis	rs4819052	0.679	rs28623526	chr21:46712324	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	6.2	0.38	2.52e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs36715	0.904	rs36701	chr5:127552529	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	8.06	0.47	4.06e-14	Breast cancer;
SARC	cis	rs965469	0.779	rs6051772	chr20:3328654	C/G	cg25506879	chr20:3388711	C20orf194	-0.46	-4.99	-0.31	1.17e-6	IFN-related cytopenia;
SARC	cis	rs1153858	1.000	rs4775909	chr15:45643042	T/C	cg21132104	chr15:45694354	SPATA5L1	0.74	10.2	0.56	1.95e-20	Homoarginine levels;
SARC	cis	rs4595586	0.545	rs12812959	chr12:39371197	T/C	cg13010199	chr12:38710504	ALG10B	0.4	4.75	0.3	3.57e-6	Morning vs. evening chronotype;
SARC	cis	rs72634258	0.503	rs2794666	chr1:7822009	A/G	cg26816564	chr1:7831052	VAMP3	0.55	4.98	0.31	1.26e-6	Inflammatory bowel disease;
SARC	cis	rs36051895	0.632	rs11790841	chr9:5166273	G/C	cg02405213	chr9:5042618	JAK2	-0.55	-5.95	-0.36	9.77e-9	Pediatric autoimmune diseases;
SARC	cis	rs4642101	0.597	rs9865624	chr3:12822786	T/A	cg24848339	chr3:12840334	CAND2	0.33	4.93	0.31	1.59e-6	QRS complex (12-leadsum);
SARC	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg03806693	chr22:41940476	POLR3H	0.9	12.82	0.64	8.04e-29	Vitiligo;
SARC	cis	rs62244186	0.520	rs2372828	chr3:44784949	A/G	cg15687855	chr3:44754131	ZNF502	0.33	4.94	0.31	1.47e-6	Depressive symptoms;
SARC	cis	rs912062	1.000	rs7037561	chr9:832711	C/T	cg01424241	chr9:705143	KANK1	-0.53	-4.75	-0.3	3.6e-6	Obesity-related traits;
SARC	cis	rs41433250	1	rs41433250	chr13:31495835	A/G	cg16374953	chr13:31191680	USPL1	-0.75	-5.34	-0.33	2.26e-7	Influenza A (H1N1) infection;Mild influenza (H1N1) infection;
SARC	cis	rs1355223	0.506	rs12294339	chr11:34860199	C/T	cg11622362	chr11:34938112	PDHX;APIP	0.43	5.51	0.34	9.3e-8	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs734999	0.545	rs6666788	chr1:2567500	A/G	cg20673091	chr1:2541236	MMEL1	-0.32	-4.95	-0.31	1.4e-6	Ulcerative colitis;
SARC	cis	rs7659604	0.728	rs6852923	chr4:122688324	G/A	cg06713675	chr4:122721982	EXOSC9	-0.45	-6.24	-0.38	2.02e-9	Type 2 diabetes;
SARC	cis	rs796364	0.806	rs79333757	chr2:200915716	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-6.61	-0.4	2.63e-10	Schizophrenia;
SARC	cis	rs17666538	1.000	rs61122136	chr8:585027	G/C	cg19660806	chr8:588740	NA	-0.61	-4.82	-0.3	2.62e-6	IgG glycosylation;
SARC	cis	rs7929679	0.521	rs1509667	chr11:34791303	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.36	4.76	0.3	3.47e-6	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
SARC	cis	rs8007846	0.508	rs1256538	chr14:65763026	G/A	cg15999311	chr14:65749247	NA	0.34	5.46	0.34	1.23e-7	Multiple sclerosis--Brain Glutamate Levels;
SARC	cis	rs7772486	0.790	rs2814879	chr6:146201743	T/C	cg05347473	chr6:146136440	FBXO30	0.52	7.44	0.44	1.9e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12824058	0.831	rs4759450	chr12:130812732	G/A	cg24838063	chr12:130822603	PIWIL1	0.63	8.93	0.5	1.34e-16	Menopause (age at onset);
SARC	cis	rs2916247	1.000	rs2920471	chr8:92981874	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.52	-5.51	-0.34	9.65e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7766436	0.540	rs6922087	chr6:22608798	G/A	cg13666174	chr6:22585274	NA	-0.47	-6.49	-0.39	5.19e-10	Coronary artery disease;
SARC	cis	rs9818758	0.607	rs34784192	chr3:49274823	G/T	cg06212747	chr3:49208901	KLHDC8B	-0.71	-6.16	-0.37	3.14e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg05861140	chr6:150128134	PCMT1	-0.39	-4.81	-0.3	2.72e-6	Lung cancer;
SARC	cis	rs7635838	0.892	rs9852530	chr3:11466469	C/T	cg00170343	chr3:11313890	ATG7	0.62	8.4	0.48	4.42e-15	HDL cholesterol;
SARC	trans	rs11250098	0.541	rs6997839	chr8:10766028	T/C	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.75	-0.4	1.16e-10	Morning vs. evening chronotype;
SARC	cis	rs6964587	1.000	rs4265	chr7:91719608	A/G	cg17063962	chr7:91808500	NA	-0.96	-15.84	-0.72	7.74e-39	Breast cancer;
SARC	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg21747090	chr2:27597821	SNX17	-0.54	-7.58	-0.44	8.02e-13	Total body bone mineral density;
SARC	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.73	-7.32	-0.43	3.94e-12	Platelet count;
SARC	cis	rs4595586	0.644	rs10437944	chr12:39308786	A/C	cg26384229	chr12:38710491	ALG10B	0.42	5.18	0.32	4.77e-7	Morning vs. evening chronotype;
SARC	cis	rs644799	1.000	rs514170	chr11:95556696	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.9	14.03	0.68	7.82e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs6500395	0.926	rs7192297	chr16:48670421	G/A	cg04672837	chr16:48644449	N4BP1	0.47	6.24	0.38	2.05e-9	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs870825	0.929	rs55880126	chr4:185591237	T/G	cg04058563	chr4:185651563	MLF1IP	0.85	9.39	0.52	5.68e-18	Blood protein levels;
SARC	cis	rs7103648	0.838	rs11039244	chr11:47466442	G/A	cg10504702	chr11:47789108	FNBP4	0.67	8.63	0.49	9.43e-16	Diastolic blood pressure;Systolic blood pressure;
SARC	trans	rs6964833	1.000	rs2301907	chr7:74114847	T/C	cg07504079	chr7:72649617	NCF1B	-0.59	-6.44	-0.39	6.84e-10	Menarche (age at onset);
SARC	cis	rs9815354	0.812	rs73079360	chr3:41888372	T/A	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs4819052	0.655	rs2330102	chr21:46690968	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.52	6.36	0.38	1.08e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.45	-5.13	-0.32	6.19e-7	Renal function-related traits (BUN);
SARC	cis	rs8114671	0.562	rs6060064	chr20:33406339	C/G	cg24642439	chr20:33292090	TP53INP2	-0.51	-6.5	-0.39	4.94e-10	Height;
SARC	cis	rs6594499	0.872	rs7702774	chr5:110460851	G/T	cg04022379	chr5:110408740	TSLP	0.47	6.02	0.37	6.62e-9	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs3087591	0.659	rs757376	chr17:29717909	A/G	cg24425628	chr17:29625626	OMG;NF1	0.39	4.81	0.3	2.67e-6	Hip circumference;
SARC	cis	rs3796352	1.000	rs11717619	chr3:53003179	A/C	cg15956490	chr3:53032818	SFMBT1	0.7	4.85	0.3	2.25e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs3126085	0.935	rs1353436	chr1:152172658	G/A	cg26876637	chr1:152193138	HRNR	0.47	5.33	0.33	2.33e-7	Atopic dermatitis;
SARC	cis	rs13191362	0.810	rs13200053	chr6:163011443	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.5	0.34	1.01e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg08219700	chr8:58056026	NA	0.66	6.29	0.38	1.58e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2197308	0.765	rs11182900	chr12:37934009	C/T	cg26384229	chr12:38710491	ALG10B	0.9	13.38	0.66	1.18e-30	Morning vs. evening chronotype;
SARC	cis	rs11122272	0.735	rs2486741	chr1:231516450	G/C	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	trans	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	7.04	0.42	2.17e-11	Intelligence (multi-trait analysis);
SARC	cis	rs593982	1.000	rs118030231	chr11:65501905	G/A	cg08755490	chr11:65554678	OVOL1	-0.91	-9.66	-0.53	8.59e-19	Atopic dermatitis;
SARC	cis	rs6545883	0.929	rs2593627	chr2:61618574	T/C	cg15711740	chr2:61764176	XPO1	0.42	5.12	0.32	6.51e-7	Tuberculosis;
SARC	cis	rs17376456	0.825	rs35426871	chr5:93291613	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	5.72	0.35	3.27e-8	Diabetic retinopathy;
SARC	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg22968622	chr17:43663579	NA	0.8	9.85	0.54	2.3e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	trans	rs61931739	0.517	rs9668303	chr12:34366701	C/T	cg13010199	chr12:38710504	ALG10B	0.79	10.75	0.58	3.86e-22	Morning vs. evening chronotype;
SARC	cis	rs60871478	0.898	rs4725241	chr7:796883	C/T	cg05535760	chr7:792225	HEATR2	0.79	8.16	0.47	2.08e-14	Cerebrospinal P-tau181p levels;
SARC	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg16414030	chr3:133502952	NA	0.46	6.22	0.38	2.24e-9	Iron status biomarkers;
SARC	cis	rs16854884	0.837	rs13083224	chr3:143801696	C/T	cg06585982	chr3:143692056	C3orf58	0.58	7.58	0.44	8e-13	Economic and political preferences (feminism/equality);
SARC	cis	rs10876993	0.928	rs1689592	chr12:58057773	C/T	cg18357645	chr12:58087776	OS9	0.49	6.5	0.39	4.81e-10	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs1059312	0.932	rs4760589	chr12:129284382	T/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.48	6.77	0.41	1.03e-10	Systemic lupus erythematosus;
SARC	cis	rs12311304	1.000	rs7358676	chr12:15382293	T/G	cg08258403	chr12:15378311	NA	0.49	7.31	0.43	4.23e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs10979	1.000	rs9403507	chr6:143887821	C/G	cg25407410	chr6:143891975	LOC285740	0.42	4.98	0.31	1.23e-6	Hypospadias;
SARC	cis	rs12479064	0.671	rs62155807	chr2:100076579	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.69	-8.34	-0.48	6.32e-15	Chronic sinus infection;
SARC	cis	rs17376456	0.597	rs10064158	chr5:93095186	C/T	cg21475434	chr5:93447410	FAM172A	0.61	5.95	0.36	9.98e-9	Diabetic retinopathy;
SARC	cis	rs2559856	1.000	rs2695286	chr12:102088507	T/C	cg12924262	chr12:102091054	CHPT1	0.57	7.85	0.46	1.54e-13	Blood protein levels;
SARC	cis	rs950169	0.922	rs62021167	chr15:85118051	T/A	cg17507749	chr15:85114479	UBE2QP1	0.8	9.57	0.53	1.59e-18	Schizophrenia;
SARC	cis	rs2236918	0.710	rs2488470	chr1:242019580	A/G	cg17736920	chr1:242011382	EXO1	0.66	8.94	0.51	1.21e-16	Menopause (age at onset);
SARC	cis	rs7937682	0.564	rs10891277	chr11:111373103	A/G	cg22437258	chr11:111473054	SIK2	-0.4	-4.72	-0.3	4.1e-6	Primary sclerosing cholangitis;
SARC	cis	rs11785400	0.793	rs4736366	chr8:143742413	C/T	cg24634471	chr8:143751801	JRK	0.6	7.6	0.45	7.36e-13	Schizophrenia;
SARC	cis	rs17125944	0.773	rs1952089	chr14:53339777	C/T	cg00686598	chr14:53173677	PSMC6	-0.69	-5.03	-0.31	9.93e-7	Alzheimer's disease (late onset);
SARC	trans	rs2727020	0.514	rs4980444	chr11:49550764	T/A	cg15704280	chr7:45808275	SEPT13	-0.81	-13.14	-0.65	7.3e-30	Coronary artery disease;
SARC	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-5.55	-0.34	7.71e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs12135062	0.901	rs2651928	chr1:3101722	C/T	cg00254258	chr1:3105189	PRDM16	-0.4	-6.89	-0.41	5.14e-11	Migraine;
SARC	cis	rs735539	0.521	rs9552282	chr13:21365721	C/T	cg16922012	chr13:21400325	XPO4	-0.44	-6.22	-0.38	2.24e-9	Dental caries;
SARC	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg22834771	chr12:69754056	YEATS4	-0.47	-6.3	-0.38	1.51e-9	Cerebrospinal fluid biomarker levels;
SARC	cis	rs986417	1.000	rs958504	chr14:60949740	G/A	cg27398547	chr14:60952738	C14orf39	1.02	9.71	0.54	6e-19	Gut microbiota (bacterial taxa);
SARC	cis	rs4243830	0.737	rs4908909	chr1:6599041	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.48	-4.8	-0.3	2.87e-6	Body mass index;
SARC	cis	rs2130392	1.000	rs11132254	chr4:185611592	G/T	cg21366198	chr4:185655624	MLF1IP	-0.39	-4.75	-0.3	3.61e-6	Kawasaki disease;
SARC	cis	rs7223966	1.000	rs9901507	chr17:61765524	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.48	-5.35	-0.33	2.07e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6685188	0.925	rs12752037	chr1:205661614	A/C	cg14159672	chr1:205819179	PM20D1	-0.52	-6.2	-0.38	2.56e-9	White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs7666738	0.753	rs10004827	chr4:99037953	A/C	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9911578	0.704	rs72628393	chr17:56585314	A/T	cg12560992	chr17:57184187	TRIM37	-0.79	-10.29	-0.56	9.95e-21	Intelligence (multi-trait analysis);
SARC	cis	rs7666738	0.830	rs17548431	chr4:98923768	C/G	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9467711	0.591	rs6903228	chr6:25903047	A/G	cg21479132	chr6:26055353	NA	0.74	4.72	0.3	4.08e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.67	9.18	0.52	2.48e-17	Menarche (age at onset);
SARC	cis	rs36051895	0.664	rs2274649	chr9:5090934	A/T	cg02405213	chr9:5042618	JAK2	-0.46	-5.36	-0.33	1.99e-7	Pediatric autoimmune diseases;
SARC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg11494091	chr17:61959527	GH2	0.55	8.26	0.48	1.11e-14	Prudent dietary pattern;
SARC	cis	rs57221529	0.600	rs11750269	chr5:666270	G/A	cg14541582	chr5:601475	NA	-0.42	-5.02	-0.31	1.04e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs497273	0.517	rs580240	chr12:121199903	T/G	cg02403541	chr12:121454288	C12orf43	0.45	5.35	0.33	2.08e-7	Systemic lupus erythematosus;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg17179831	chr6:116645836	DSE	0.46	6.42	0.39	7.72e-10	Thyroid stimulating hormone;
SARC	cis	rs7044106	0.578	rs4837788	chr9:123396801	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.55	4.84	0.3	2.33e-6	Hip circumference adjusted for BMI;
SARC	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs9398803	0.966	rs9388487	chr6:126678268	G/T	cg20229609	chr6:126660872	C6orf173	0.39	5.71	0.35	3.42e-8	Male-pattern baldness;
SARC	cis	rs13191362	1.000	rs4260737	chr6:163137746	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.72	6.11	0.37	4.25e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg12122041	chr4:3234814	HTT	0.5	6.89	0.41	5.15e-11	Schizophrenia;
SARC	trans	rs2018683	0.707	rs10279870	chr7:28968935	A/G	cg19402173	chr7:128379420	CALU	-0.54	-6.96	-0.41	3.38e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs10782582	0.609	rs1159215	chr1:76317869	A/T	cg10523679	chr1:76189770	ACADM	-0.41	-5.28	-0.33	2.97e-7	Daytime sleep phenotypes;
SARC	cis	rs7786877	0.500	rs2272572	chr7:100285888	C/T	cg20848291	chr7:100343083	ZAN	-0.68	-7.4	-0.44	2.42e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs854765	0.547	rs2955372	chr17:17970229	T/C	cg05444541	chr17:17804740	TOM1L2	0.3	4.89	0.31	1.86e-6	Total body bone mineral density;
SARC	cis	rs739401	0.611	rs3782069	chr11:3033275	G/A	cg20651018	chr11:3035856	CARS	-0.44	-6.67	-0.4	1.82e-10	Longevity;
SARC	cis	rs2153535	0.580	rs9505455	chr6:8478622	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	8.24	0.48	1.24e-14	Motion sickness;
SARC	cis	rs8028182	0.636	rs4886716	chr15:75856022	G/C	cg20655648	chr15:75932815	IMP3	0.63	7.32	0.43	3.93e-12	Sudden cardiac arrest;
SARC	cis	rs10927875	0.632	rs4661667	chr1:16162731	C/T	cg21385522	chr1:16154831	NA	-0.89	-13.1	-0.65	9.19e-30	Dilated cardiomyopathy;
SARC	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg24060327	chr5:131705240	SLC22A5	-0.49	-5.88	-0.36	1.43e-8	Acylcarnitine levels;
SARC	cis	rs1008375	1.000	rs3815414	chr4:17606659	A/G	cg16339924	chr4:17578868	LAP3	-0.68	-8.84	-0.5	2.38e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.57	5.08	0.32	7.61e-7	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs3749237	0.615	rs55957735	chr3:49438158	G/A	cg02487422	chr3:49467188	NICN1	0.5	6.51	0.39	4.57e-10	Resting heart rate;
SARC	cis	rs2153535	0.580	rs1119691	chr6:8460452	C/T	cg07606381	chr6:8435919	SLC35B3	0.75	10.61	0.57	1.01e-21	Motion sickness;
SARC	cis	rs11158198	0.599	rs34969541	chr14:58607006	G/A	cg15908186	chr14:58618357	C14orf37	0.4	4.74	0.3	3.7e-6	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs2916247	0.909	rs720444	chr8:93098924	G/T	cg10183463	chr8:93005414	RUNX1T1	0.66	6.9	0.41	4.9e-11	Intelligence (multi-trait analysis);
SARC	cis	rs2273669	0.667	rs10457187	chr6:109336051	G/A	cg05315195	chr6:109294784	ARMC2	-0.63	-5.7	-0.35	3.6e-8	Prostate cancer;
SARC	cis	rs9796	0.870	rs8030306	chr15:41261821	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.41	-5.7	-0.35	3.52e-8	Menopause (age at onset);
SARC	cis	rs12701220	0.572	rs7792825	chr7:1006573	T/C	cg10374962	chr7:1011985	COX19	-0.44	-5.65	-0.35	4.63e-8	Bronchopulmonary dysplasia;
SARC	cis	rs4319547	0.695	rs4758645	chr12:122946487	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.51	-5.87	-0.36	1.47e-8	Body mass index;
SARC	cis	rs1865760	0.929	rs1816546	chr6:25938252	C/T	cg10373733	chr6:25993375	NA	0.4	4.84	0.3	2.39e-6	Height;
SARC	cis	rs11509153	0.672	rs11981005	chr7:12263370	A/G	cg23422036	chr7:12250390	TMEM106B	0.47	6.04	0.37	6.14e-9	Residual cognition;
SARC	cis	rs644799	1.000	rs566204	chr11:95580926	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.89	14.03	0.68	7.94e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs6088590	0.901	rs6087631	chr20:33403509	T/C	cg06115741	chr20:33292138	TP53INP2	0.57	6.9	0.41	4.97e-11	Coronary artery disease;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg08610063	chr20:61569321	C20orf11;DIDO1	0.48	6.44	0.39	6.68e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.86	8.77	0.5	3.73e-16	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs9815354	0.812	rs73073352	chr3:41842184	T/C	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6582630	0.519	rs4436613	chr12:38293653	T/C	cg26384229	chr12:38710491	ALG10B	0.87	12.86	0.64	6.01e-29	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg09517075	chr8:22133004	PIWIL2	0.35	4.84	0.3	2.4e-6	Hypertriglyceridemia;
SARC	trans	rs1865760	0.929	rs9461224	chr6:25936402	G/T	cg18721605	chr18:44676421	HDHD2	-0.55	-6.71	-0.4	1.5e-10	Height;
SARC	cis	rs12142240	0.698	rs77185326	chr1:46818417	T/C	cg00530320	chr1:46809349	NSUN4	0.57	6.92	0.41	4.4e-11	Menopause (age at onset);
SARC	cis	rs12130219	0.500	rs4845737	chr1:152177539	G/A	cg17718321	chr1:152188247	HRNR	-0.33	-4.79	-0.3	2.94e-6	Inflammatory skin disease;
SARC	cis	rs10870270	0.956	rs11146325	chr10:133767529	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.83	-10.17	-0.55	2.47e-20	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg19774624	chr17:42201019	HDAC5	-0.78	-10.94	-0.58	9.59e-23	Total body bone mineral density;
SARC	cis	rs2486288	0.656	rs1719236	chr15:45577783	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.49	-5.71	-0.35	3.41e-8	Glomerular filtration rate;
SARC	cis	rs8067545	0.611	rs2107565	chr17:20088492	C/T	cg13482628	chr17:19912719	NA	-0.55	-7.15	-0.42	1.12e-11	Schizophrenia;
SARC	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg13628971	chr7:2884303	GNA12	0.66	8.08	0.47	3.54e-14	Height;
SARC	cis	rs2624839	0.704	rs13067082	chr3:50221715	A/G	cg19755318	chr3:50243323	SLC38A3	0.29	5.04	0.31	9.48e-7	Intelligence (multi-trait analysis);
SARC	cis	rs908922	0.676	rs568661	chr1:152519787	C/A	cg09873164	chr1:152488093	CRCT1	0.62	8.04	0.47	4.46e-14	Hair morphology;
SARC	cis	rs2013441	1.000	rs2526475	chr17:20136216	T/C	cg13482628	chr17:19912719	NA	-0.48	-6.26	-0.38	1.79e-9	Obesity-related traits;
SARC	cis	rs2276314	0.802	rs4799838	chr18:33597530	T/C	cg19628046	chr18:33552617	C18orf21	0.61	6.29	0.38	1.54e-9	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs7666738	0.822	rs11097599	chr4:98959562	T/A	cg05340658	chr4:99064831	C4orf37	0.66	9.0	0.51	8.07e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg27572855	chr1:25598939	RHD	0.55	9.57	0.53	1.65e-18	Erythrocyte sedimentation rate;
SARC	cis	rs77106637	0.860	rs11603334	chr11:72432985	G/A	cg03713592	chr11:72463424	ARAP1	1.04	10.21	0.56	1.87e-20	Type 2 diabetes;
SARC	cis	rs17376456	0.877	rs35747258	chr5:93310129	C/T	cg25358565	chr5:93447407	FAM172A	1.29	14.58	0.69	1.2e-34	Diabetic retinopathy;
SARC	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg11764359	chr7:65958608	NA	0.73	8.72	0.5	5.25e-16	Aortic root size;
SARC	cis	rs595982	0.702	rs609985	chr19:49370648	A/G	cg03707168	chr19:49379127	PPP1R15A	0.42	5.96	0.36	9.18e-9	Red cell distribution width;
SARC	cis	rs9303280	0.806	rs11078927	chr17:38064405	C/T	cg20243544	chr17:37824526	PNMT	0.44	5.89	0.36	1.33e-8	Self-reported allergy;
SARC	cis	rs941408	1.000	rs941407	chr19:2812153	A/G	cg00079169	chr19:2811669	THOP1	0.45	4.81	0.3	2.72e-6	Total cholesterol levels;
SARC	trans	rs2434529	1.000	rs6865148	chr5:153621015	G/A	cg05016746	chr16:87725309	JPH3	0.55	6.23	0.38	2.13e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7772486	0.790	rs9497431	chr6:146248177	T/C	cg23711669	chr6:146136114	FBXO30	-0.84	-13.4	-0.66	9.4e-31	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg00342743	chr10:76970673	VDAC2	0.48	6.34	0.38	1.16e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs6088590	0.648	rs6059991	chr20:33280836	C/T	cg08999081	chr20:33150536	PIGU	0.41	6.18	0.38	2.83e-9	Coronary artery disease;
SARC	cis	rs9640161	0.830	rs17173702	chr7:150068605	G/A	cg10018233	chr7:150070692	REPIN1	0.7	9.5	0.53	2.67e-18	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs936229	0.749	rs6495126	chr15:75175026	C/T	cg14664628	chr15:75095509	CSK	0.83	10.05	0.55	5.53e-20	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs8038465	0.592	rs1542579	chr15:73935897	A/G	cg15420318	chr15:73925796	NPTN	0.67	7.66	0.45	5.08e-13	Liver enzyme levels (gamma-glutamyl transferase);
SARC	trans	rs561341	1.000	rs497479	chr17:30328605	C/T	cg20587970	chr11:113659929	NA	-1.34	-13.56	-0.66	2.84e-31	Hip circumference adjusted for BMI;
SARC	cis	rs57920188	0.584	rs10915654	chr1:4091419	C/A	cg20703997	chr1:4087676	NA	0.5	5.2	0.32	4.43e-7	Interleukin-17 levels;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg10731022	chr5:139927252	EIF4EBP3;ANKHD1-EIF4EBP3	0.48	6.27	0.38	1.76e-9	Breast cancer;
SARC	cis	rs3749237	0.615	rs55957735	chr3:49438158	G/A	cg07636037	chr3:49044803	WDR6	0.64	8.25	0.48	1.2e-14	Resting heart rate;
SARC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	19.15	0.78	9.78e-50	Prudent dietary pattern;
SARC	cis	rs7568458	0.709	rs56819945	chr2:85755139	C/T	cg23752985	chr2:85803571	VAMP8	0.45	5.69	0.35	3.72e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	trans	rs61931739	0.513	rs10743833	chr12:33897481	C/T	cg13010199	chr12:38710504	ALG10B	0.52	6.48	0.39	5.37e-10	Morning vs. evening chronotype;
SARC	cis	rs2233152	0.520	rs56101381	chr19:41272902	T/C	cg07297178	chr19:42193084	CEACAM7	0.37	4.87	0.3	2.05e-6	Kawasaki disease;
SARC	cis	rs1153858	1.000	rs16942568	chr15:45677390	T/C	cg03999130	chr15:45571217	NA	0.39	4.98	0.31	1.25e-6	Homoarginine levels;
SARC	cis	rs6582630	0.638	rs61931383	chr12:38513845	G/A	cg14851346	chr12:38532713	NA	-0.46	-5.67	-0.35	4.22e-8	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs629535	0.821	rs497398	chr8:70037434	A/T	cg21567404	chr3:27674614	NA	1.04	13.82	0.67	3.98e-32	Dupuytren's disease;
SARC	cis	rs73206853	0.563	rs80044246	chr12:111133535	C/A	cg10860002	chr12:110842031	ANAPC7	0.61	5.19	0.32	4.67e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs9581857	0.556	rs1885990	chr13:28040502	C/T	cg22138327	chr13:27999177	GTF3A	0.55	5.67	0.35	4.25e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	cis	rs11098499	0.954	rs10518328	chr4:120401779	G/A	cg09307838	chr4:120376055	NA	0.91	12.44	0.63	1.44e-27	Corneal astigmatism;
SARC	cis	rs10046574	0.561	rs9656458	chr7:135202300	G/A	cg27474649	chr7:135195673	CNOT4	0.85	7.96	0.46	7.32e-14	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs17600642	0.672	rs17600546	chr10:72457933	T/G	cg19779893	chr10:72451501	ADAMTS14	-0.39	-6.24	-0.38	2.06e-9	Bipolar disorder;
SARC	cis	rs73198271	0.737	rs506960	chr8:8630269	A/C	cg01851573	chr8:8652454	MFHAS1	0.33	4.87	0.3	2.02e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.62	7.52	0.44	1.14e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs12702595	0.875	rs2108783	chr7:7266867	A/C	cg04827551	chr7:7268805	C1GALT1	-0.4	-5.0	-0.31	1.14e-6	Serum dimethylarginine levels (asymmetric/symetric ratio);Symmetrical dimethylarginine levels;
SARC	cis	rs921943	0.957	rs6881725	chr5:78310754	T/C	cg26802063	chr5:78281964	ARSB	0.46	5.0	0.31	1.13e-6	Blood and toenail selenium levels;Blood trace element (Se levels);
SARC	cis	rs2032447	0.530	rs9356996	chr6:26008487	C/A	cg17691542	chr6:26056736	HIST1H1C	0.4	4.92	0.31	1.61e-6	Intelligence (multi-trait analysis);
SARC	cis	rs8114671	0.562	rs2064454	chr20:33496169	C/T	cg24642439	chr20:33292090	TP53INP2	0.49	5.85	0.36	1.68e-8	Height;
SARC	cis	rs634534	0.561	rs14157	chr11:65769780	T/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.84	12.33	0.63	3.18e-27	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs9300255	0.512	rs2851436	chr12:123667354	G/T	cg00376283	chr12:123451042	ABCB9	0.55	6.53	0.39	4.09e-10	Neutrophil percentage of white cells;
SARC	cis	rs9843304	0.868	rs4681516	chr3:149212125	G/C	cg08667024	chr3:149219783	TM4SF4	0.37	5.81	0.36	2.07e-8	Gallstone disease;
SARC	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9581857	0.579	rs9581843	chr13:27980507	T/G	cg01674679	chr13:27998804	GTF3A	-0.61	-4.78	-0.3	3.12e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	cis	rs1448094	0.621	rs10863090	chr12:86282211	C/T	cg00310523	chr12:86230176	RASSF9	0.31	4.79	0.3	3.01e-6	Major depressive disorder;
SARC	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.53	6.07	0.37	5.25e-9	Renal function-related traits (BUN);
SARC	cis	rs524281	0.773	rs2236651	chr11:66001418	C/T	cg14036092	chr11:66035641	RAB1B	-0.59	-6.28	-0.38	1.67e-9	Electroencephalogram traits;
SARC	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.51	5.06	0.31	8.34e-7	Lung function (FEV1/FVC);
SARC	cis	rs11638352	0.661	rs2706491	chr15:44423829	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	-0.76	-5.91	-0.36	1.23e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	cis	rs7586879	0.638	rs10203482	chr2:25136916	T/C	cg04586622	chr2:25135609	ADCY3	0.3	4.94	0.31	1.5e-6	Body mass index;
SARC	cis	rs10193935	0.901	rs10200000	chr2:42442212	A/G	cg27598129	chr2:42591480	NA	-0.35	-4.94	-0.31	1.48e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg26335602	chr6:28129616	ZNF389	0.52	5.88	0.36	1.44e-8	Parkinson's disease;
SARC	cis	rs7918232	1.000	rs6482595	chr10:27380261	A/G	cg14240646	chr10:27532245	ACBD5	0.45	4.81	0.3	2.7e-6	Breast cancer;
SARC	cis	rs2439831	0.850	rs61390361	chr15:44159842	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.93	8.14	0.47	2.39e-14	Lung cancer in ever smokers;
SARC	cis	rs17270561	0.609	rs9348692	chr6:25720812	A/G	cg16482183	chr6:26056742	HIST1H1C	0.43	5.15	0.32	5.5e-7	Iron status biomarkers;
SARC	cis	rs7843479	1.000	rs67385415	chr8:21853733	T/C	cg17168535	chr8:21777572	XPO7	0.65	8.53	0.49	1.85e-15	Mean corpuscular volume;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg27338695	chr8:41435702	AGPAT6	0.49	6.4	0.39	8.53e-10	Tetralogy of Fallot;
SARC	cis	rs2718058	0.630	rs2722363	chr7:37835603	A/G	cg24998770	chr7:37888106	TXNDC3	0.36	5.13	0.32	6.02e-7	Alzheimer's disease (late onset);
SARC	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg17971929	chr21:40555470	PSMG1	-0.57	-7.2	-0.43	8.13e-12	Menarche (age at onset);
SARC	cis	rs7216064	1.000	rs62084246	chr17:65867911	G/C	cg12091567	chr17:66097778	LOC651250	-0.64	-6.45	-0.39	6.56e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs28719689	0.655	rs58892423	chr8:1276014	A/C	cg22761795	chr8:1265118	NA	0.49	4.76	0.3	3.48e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs72781680	0.644	rs72783627	chr2:24315685	A/C	cg08917208	chr2:24149416	ATAD2B	0.59	6.25	0.38	1.99e-9	Lymphocyte counts;
SARC	cis	rs7917772	0.502	rs2296584	chr10:104244323	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	8.29	0.48	9.23e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg09021430	chr5:549028	NA	0.39	5.17	0.32	5.14e-7	Obesity-related traits;
SARC	cis	rs2425143	1.000	rs8116836	chr20:34453362	T/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	5.26	0.33	3.32e-7	Blood protein levels;
SARC	cis	rs79387448	0.638	rs6759588	chr2:103040159	A/G	cg09003973	chr2:102972529	NA	0.71	5.92	0.36	1.15e-8	Gut microbiota (bacterial taxa);
SARC	cis	rs4613509	1	rs4613509	chr3:160728059	T/C	cg04691961	chr3:161091175	C3orf57	-0.57	-7.97	-0.46	7.1e-14	Morning vs. evening chronotype;
SARC	cis	rs911555	0.723	rs12894652	chr14:103926024	A/G	cg24130564	chr14:104152367	KLC1	0.51	6.03	0.37	6.32e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7904368	0.951	rs7905776	chr10:16853609	C/T	cg23933602	chr10:16859644	RSU1	0.59	6.51	0.39	4.66e-10	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	trans	rs61931739	0.534	rs11053010	chr12:34093228	G/A	cg13010199	chr12:38710504	ALG10B	0.77	10.37	0.56	5.83e-21	Morning vs. evening chronotype;
SARC	cis	rs367943	0.966	rs348947	chr5:112822795	C/G	cg12552261	chr5:112820674	MCC	-0.46	-5.27	-0.33	3.05e-7	Type 2 diabetes;
SARC	cis	rs4481887	0.962	rs6686911	chr1:248476969	T/C	cg01631408	chr1:248437212	OR2T33	-0.42	-5.25	-0.33	3.39e-7	Common traits (Other);
SARC	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg11062466	chr8:58055876	NA	0.67	5.84	0.36	1.78e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg22918356	chr10:134496823	INPP5A	-0.53	-6.88	-0.41	5.32e-11	Height;
SARC	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg08219700	chr8:58056026	NA	0.58	6.19	0.38	2.71e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg11644478	chr21:40555479	PSMG1	0.63	7.44	0.44	1.94e-12	Cognitive function;
SARC	cis	rs4988958	0.584	rs7559845	chr2:103046214	T/G	cg03938978	chr2:103052716	IL18RAP	0.32	5.18	0.32	4.72e-7	Asthma (childhood onset);
SARC	cis	rs73198271	0.694	rs73201840	chr8:8647067	G/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-4.97	-0.31	1.3e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg07708937	chr12:57914306	DDIT3	0.5	6.47	0.39	5.57e-10	Myopia (pathological);
SARC	cis	rs2242116	0.932	rs7646906	chr3:46949379	G/A	cg27129171	chr3:47204927	SETD2	0.44	5.6	0.34	6.08e-8	Birth weight;
SARC	cis	rs1448094	0.512	rs12305828	chr12:86249153	C/G	cg02569458	chr12:86230093	RASSF9	0.38	5.39	0.33	1.71e-7	Major depressive disorder;
SARC	cis	rs1707322	0.721	rs28641748	chr1:46212836	A/G	cg06784218	chr1:46089804	CCDC17	0.36	6.22	0.38	2.26e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs3087591	0.960	rs2952984	chr17:29469614	T/C	cg24425628	chr17:29625626	OMG;NF1	0.56	6.97	0.42	3.19e-11	Hip circumference;
SARC	cis	rs80130819	0.748	rs2732477	chr12:48700282	C/T	cg24011408	chr12:48396354	COL2A1	-0.55	-6.11	-0.37	4.18e-9	Prostate cancer;
SARC	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg12463550	chr7:65579703	CRCP	-0.5	-5.55	-0.34	7.9e-8	Aortic root size;
SARC	cis	rs314370	0.855	rs76181418	chr7:100494960	G/T	cg10426581	chr7:100472382	SRRT	0.58	6.13	0.37	3.78e-9	Resting heart rate;
SARC	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg27266027	chr21:40555129	PSMG1	0.51	5.52	0.34	9.21e-8	Cognitive function;
SARC	cis	rs4319547	0.695	rs4758666	chr12:122902840	C/T	cg23029597	chr12:123009494	RSRC2	-0.39	-4.92	-0.31	1.6e-6	Body mass index;
SARC	cis	rs3733346	0.529	rs6842493	chr4:914638	T/C	cg20814179	chr4:940893	TMEM175	0.44	6.27	0.38	1.71e-9	Sjögren's syndrome;
SARC	cis	rs1468333	0.537	rs10479184	chr5:137753917	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.63	7.67	0.45	4.75e-13	Resting heart rate;
SARC	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg03433033	chr1:76189801	ACADM	-0.52	-7.34	-0.43	3.61e-12	Blood metabolite levels;Acylcarnitine levels;
SARC	trans	rs1292048	1	rs1292048	chr17:57955071	A/G	cg15604357	chr1:160386408	VANGL2	0.38	6.55	0.39	3.72e-10	Red cell distribution width;
SARC	cis	rs7264396	0.790	rs6058297	chr20:34271861	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-8.23	-0.47	1.36e-14	Total cholesterol levels;
SARC	cis	rs1355223	0.867	rs1377495	chr11:34682962	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.42	5.14	0.32	5.69e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs7833790	0.700	rs28390260	chr8:82769175	A/T	cg17211192	chr8:82754475	SNX16	0.5	6.24	0.38	2.09e-9	Diastolic blood pressure;
SARC	cis	rs2795502	0.630	rs4948698	chr10:43539459	A/G	cg08461752	chr10:43522343	NA	0.43	4.83	0.3	2.51e-6	Blood protein levels;
SARC	cis	rs763014	0.898	rs8060585	chr16:635794	C/G	cg09263875	chr16:632152	PIGQ	0.5	7.59	0.45	7.5e-13	Height;
SARC	cis	rs992157	1.000	rs2168704	chr2:219142492	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.74	11.31	0.6	6.26e-24	Colorectal cancer;
SARC	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.72	6.23	0.38	2.15e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs6141769	0.569	rs6057617	chr20:31259367	A/G	cg17884169	chr20:31446444	EFCAB8	-0.44	-4.76	-0.3	3.46e-6	Subjective well-being;
SARC	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg06028605	chr16:24865363	SLC5A11	0.36	5.49	0.34	1.05e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7264396	0.832	rs224361	chr20:34061578	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-4.72	-0.3	4.15e-6	Total cholesterol levels;
SARC	cis	rs7944584	1.000	rs7944584	chr11:47336320	A/T	cg20307385	chr11:47447363	PSMC3	0.59	7.05	0.42	1.96e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs7566780	0.516	rs4550668	chr2:16663494	A/T	cg09580478	chr2:16689509	NA	-0.53	-6.66	-0.4	1.91e-10	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs875971	0.545	rs1796217	chr7:66085918	A/G	cg11764359	chr7:65958608	NA	-0.63	-6.17	-0.37	2.99e-9	Aortic root size;
SARC	cis	rs17376456	0.597	rs10064158	chr5:93095186	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.5	5.05	0.31	8.86e-7	Diabetic retinopathy;
SARC	cis	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg18252515	chr7:66147081	NA	1.2	10.67	0.57	6.74e-22	Diabetic kidney disease;
SARC	cis	rs526821	0.595	rs608964	chr11:55339266	G/A	cg04317927	chr11:55418816	OR4S2	0.41	6.08	0.37	5e-9	Pediatric bone mineral density (spine);
SARC	cis	rs523522	0.962	rs670568	chr12:121021206	C/T	cg12219531	chr12:120966889	COQ5	0.82	11.01	0.59	5.52e-23	High light scatter reticulocyte count;
SARC	cis	rs9807989	0.801	rs10176664	chr2:102976172	G/A	cg09003973	chr2:102972529	NA	0.41	5.64	0.35	4.85e-8	Asthma;
SARC	cis	rs798554	1.000	rs798562	chr7:2757938	C/T	cg05793240	chr7:2802953	GNA12	-0.35	-5.15	-0.32	5.52e-7	Height;
SARC	cis	rs1707322	0.752	rs11488313	chr1:46224780	G/C	cg03146154	chr1:46216737	IPP	0.5	5.97	0.36	8.67e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs34172651	0.917	rs6497756	chr16:24798291	G/T	cg00152838	chr16:24741724	TNRC6A	-0.42	-5.22	-0.32	3.97e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2153535	0.580	rs9505446	chr6:8448691	T/C	cg21535247	chr6:8435926	SLC35B3	0.55	6.87	0.41	5.72e-11	Motion sickness;
SARC	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg10876282	chr6:28092338	ZSCAN16	0.47	4.84	0.3	2.34e-6	Parkinson's disease;
SARC	cis	rs1843834	0.539	rs10177898	chr2:225437552	C/T	cg12698349	chr2:225449008	CUL3	0.68	8.92	0.5	1.38e-16	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	5.99	0.37	7.8e-9	Height;
SARC	cis	rs11190604	1.000	rs2489040	chr10:102331298	G/A	cg07080220	chr10:102295463	HIF1AN	0.78	9.51	0.53	2.45e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg25894440	chr7:65020034	NA	-0.73	-5.55	-0.34	7.84e-8	Diabetic kidney disease;
SARC	cis	rs5753618	0.561	rs4820963	chr22:31698166	C/T	cg02404636	chr22:31891804	SFI1	-0.49	-5.26	-0.33	3.21e-7	Colorectal cancer;
SARC	cis	rs11105298	0.891	rs4842654	chr12:89834428	T/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.5	-5.01	-0.31	1.1e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs910316	0.967	rs4903292	chr14:75656245	A/G	cg11812906	chr14:75593930	NEK9	0.82	11.54	0.6	1.18e-24	Height;
SARC	cis	rs3741404	0.672	rs4980524	chr11:63959259	A/C	cg04317338	chr11:64019027	PLCB3	0.43	5.15	0.32	5.55e-7	Platelet count;
SARC	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg16325326	chr1:53192061	ZYG11B	0.9	16.61	0.74	2.1e-41	Monocyte count;
SARC	trans	rs459571	0.883	rs2520096	chr9:136919416	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.65	-7.59	-0.45	7.53e-13	Platelet distribution width;
SARC	cis	rs2795502	0.882	rs2744095	chr10:43337949	A/T	cg20628663	chr10:43360327	NA	-0.47	-6.32	-0.38	1.34e-9	Blood protein levels;
SARC	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg12042659	chr19:58951599	ZNF132	0.41	5.46	0.34	1.23e-7	Uric acid clearance;
SARC	cis	rs4595586	0.545	rs925828	chr12:39364222	A/G	cg26384229	chr12:38710491	ALG10B	0.51	6.25	0.38	1.9e-9	Morning vs. evening chronotype;
SARC	cis	rs6570726	0.599	rs9376951	chr6:145898911	C/T	cg23711669	chr6:146136114	FBXO30	0.8	11.43	0.6	2.61e-24	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2295359	1.000	rs10889661	chr1:67625309	T/A	cg12940439	chr1:67600707	NA	0.43	6.57	0.4	3.18e-10	Psoriasis;
SARC	cis	rs11122272	0.735	rs2749706	chr1:231527170	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.13	-0.55	3.3e-20	Hemoglobin concentration;
SARC	cis	rs6582630	0.502	rs11614397	chr12:38328163	C/T	cg26384229	chr12:38710491	ALG10B	0.86	12.27	0.63	5.08e-27	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7246657	0.943	rs1015849	chr19:37946180	G/A	cg23950597	chr19:37808831	NA	-0.63	-6.04	-0.37	5.94e-9	Coronary artery calcification;
SARC	cis	rs11690935	0.694	rs312921	chr2:172567225	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.98	-15.71	-0.72	2.12e-38	Schizophrenia;
SARC	cis	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg08564027	chr20:61660810	NA	0.76	11.66	0.61	4.65e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs514406	0.505	rs395169	chr1:53174071	G/A	cg16325326	chr1:53192061	ZYG11B	0.94	17.79	0.76	2.67e-45	Monocyte count;
SARC	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg16680214	chr1:154839983	KCNN3	-0.36	-5.62	-0.35	5.36e-8	Prostate cancer;
SARC	cis	rs4595586	0.545	rs61939643	chr12:39378460	G/A	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	cis	rs9640161	0.830	rs13307276	chr7:150061525	T/C	cg21361702	chr7:150065534	REPIN1	0.6	7.02	0.42	2.36e-11	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs2075371	0.897	rs1646743	chr7:134003451	C/A	cg20476274	chr7:133979776	SLC35B4	0.57	7.58	0.44	7.89e-13	Mean platelet volume;
SARC	cis	rs1355223	0.506	rs12294339	chr11:34860199	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.52	-6.59	-0.4	2.92e-10	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg12463550	chr7:65579703	CRCP	0.67	5.06	0.31	8.43e-7	Diabetic kidney disease;
SARC	cis	rs2303745	0.589	rs1965717	chr19:17398559	C/T	cg04248312	chr19:17393744	ANKLE1	-0.58	-7.5	-0.44	1.31e-12	Systemic lupus erythematosus;
SARC	cis	rs829883	0.659	rs12366950	chr12:98947900	T/C	cg25150519	chr12:98850993	NA	-0.6	-7.34	-0.43	3.46e-12	Colorectal adenoma (advanced);
SARC	cis	rs950776	0.518	rs62008174	chr15:78808947	C/T	cg06917634	chr15:78832804	PSMA4	0.87	12.89	0.65	4.59e-29	Sudden cardiac arrest;
SARC	cis	rs7824557	0.527	rs2572446	chr8:11239565	C/T	cg21775007	chr8:11205619	TDH	-0.57	-7.65	-0.45	5.19e-13	Retinal vascular caliber;
SARC	cis	rs950027	0.620	rs1617634	chr15:45615578	A/G	cg21132104	chr15:45694354	SPATA5L1	0.57	7.19	0.43	8.91e-12	Response to fenofibrate (adiponectin levels);
SARC	cis	rs3087591	1.000	rs2952980	chr17:29473353	G/A	cg24425628	chr17:29625626	OMG;NF1	0.53	6.55	0.39	3.57e-10	Hip circumference;
SARC	cis	rs1707322	0.721	rs10890336	chr1:46111056	C/T	cg03146154	chr1:46216737	IPP	0.52	6.32	0.38	1.33e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg04267008	chr7:1944627	MAD1L1	-0.47	-5.25	-0.33	3.35e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs9902453	0.612	rs2617868	chr17:28073247	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.24	-0.43	6.4e-12	Coffee consumption (cups per day);
SARC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.64	-7.96	-0.46	7.32e-14	Longevity;Endometriosis;
SARC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg11905131	chr22:24372483	LOC391322	-0.43	-4.97	-0.31	1.31e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9325144	0.650	rs6582631	chr12:38744135	T/C	cg13010199	chr12:38710504	ALG10B	0.55	7.01	0.42	2.58e-11	Morning vs. evening chronotype;
SARC	cis	rs796364	0.806	rs188102	chr2:200903189	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-6.04	-0.37	5.9e-9	Schizophrenia;
SARC	trans	rs36093844	0.752	rs113529766	chr11:85583401	G/A	cg15359163	chr5:122429178	PRDM6	-0.53	-6.33	-0.38	1.28e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg05025164	chr4:1340916	KIAA1530	-0.84	-11.11	-0.59	2.82e-23	Longevity;
SARC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg09373136	chr17:61933544	TCAM1	-0.45	-6.13	-0.37	3.73e-9	Prudent dietary pattern;
SARC	cis	rs751728	1.000	rs6920075	chr6:33731797	C/T	cg15252951	chr6:33757062	LEMD2	0.59	6.86	0.41	6.13e-11	Crohn's disease;
SARC	cis	rs17023223	0.537	rs12085308	chr1:119677553	T/C	cg05756136	chr1:119680316	WARS2	-0.45	-4.9	-0.31	1.83e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs7617773	0.817	rs6787500	chr3:48299439	T/C	cg11946769	chr3:48343235	NME6	0.66	8.84	0.5	2.42e-16	Coronary artery disease;
SARC	cis	rs7246657	1.000	rs8110011	chr19:37745813	G/T	cg14683738	chr19:37701593	ZNF585B	0.61	5.52	0.34	8.9e-8	Coronary artery calcification;
SARC	cis	rs1483890	0.723	rs900669	chr3:69406802	T/A	cg22125112	chr3:69402811	FRMD4B	0.3	4.99	0.31	1.21e-6	Resting heart rate;
SARC	cis	rs4820539	1.000	rs3827316	chr22:23468538	T/C	cg14186256	chr22:23484241	RTDR1	0.9	14.32	0.68	8.63e-34	Bone mineral density;
SARC	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg11987759	chr7:65425863	GUSB	-0.48	-6.54	-0.39	3.9e-10	Aortic root size;
SARC	cis	rs35306767	0.903	rs13377166	chr10:886259	G/A	cg26597838	chr10:835615	NA	0.82	8.42	0.48	3.87e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.42	0.56	3.95e-21	Prudent dietary pattern;
SARC	cis	rs9815354	0.812	rs17217536	chr3:41923300	A/C	cg03022575	chr3:42003672	ULK4	0.69	5.65	0.35	4.69e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs7811142	1.000	rs6953107	chr7:100095664	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.67	-7.08	-0.42	1.73e-11	Platelet count;
SARC	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg05368731	chr17:41323189	NBR1	0.79	9.57	0.53	1.59e-18	Menopause (age at onset);
SARC	cis	rs7178572	0.568	rs3743478	chr15:77400388	T/C	cg22256960	chr15:77711686	NA	-0.52	-5.55	-0.34	7.69e-8	Type 2 diabetes;
SARC	cis	rs73086581	1.000	rs3746665	chr20:3910406	C/T	cg02187196	chr20:3869020	PANK2	-0.55	-5.51	-0.34	9.28e-8	Response to antidepressants in depression;
SARC	cis	rs10870270	0.956	rs7894	chr10:133769482	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.48	-5.41	-0.33	1.53e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs11122272	0.735	rs910824	chr1:231498773	C/G	cg06096015	chr1:231504339	EGLN1	0.41	6.08	0.37	4.91e-9	Hemoglobin concentration;
SARC	cis	rs7084402	0.905	rs1896244	chr10:60276182	A/G	cg07615347	chr10:60278583	BICC1	-0.59	-8.54	-0.49	1.76e-15	Refractive error;
SARC	cis	rs1669338	0.507	rs4685606	chr3:3177973	T/G	cg16797762	chr3:3221439	CRBN	-0.95	-9.64	-0.53	1.01e-18	White matter integrity;
SARC	cis	rs514406	0.505	rs431427	chr1:53179094	C/A	cg08859206	chr1:53392774	SCP2	-0.35	-5.02	-0.31	1.01e-6	Monocyte count;
SARC	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg05793240	chr7:2802953	GNA12	-0.35	-5.01	-0.31	1.06e-6	Height;
SARC	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg00933542	chr6:150070202	PCMT1	0.31	5.36	0.33	2.04e-7	Lung cancer;
SARC	cis	rs67460515	0.500	rs964533	chr3:160749019	C/A	cg04691961	chr3:161091175	C3orf57	-0.43	-5.22	-0.32	4.02e-7	Parkinson's disease;
SARC	cis	rs17021463	0.902	rs2865352	chr4:95253263	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.45	-6.8	-0.41	8.85e-11	Testicular germ cell tumor;
SARC	cis	rs7000551	0.581	rs4872487	chr8:22256414	C/T	cg12081754	chr8:22256438	SLC39A14	0.85	12.64	0.64	3.03e-28	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs3733585	0.673	rs7376948	chr4:9954708	G/A	cg00071950	chr4:10020882	SLC2A9	-0.37	-5.74	-0.35	2.95e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7944584	0.632	rs749067	chr11:47318157	T/C	cg20307385	chr11:47447363	PSMC3	0.55	6.84	0.41	6.77e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs3092073	0.819	rs3848715	chr20:44564682	G/A	cg27529037	chr20:44575021	PCIF1	-0.33	-5.34	-0.33	2.17e-7	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg11764359	chr7:65958608	NA	-0.72	-8.45	-0.48	3.08e-15	Aortic root size;
SARC	cis	rs9810089	0.835	rs655836	chr3:136097576	T/C	cg15507776	chr3:136538369	TMEM22	0.43	4.76	0.3	3.34e-6	Gestational age at birth (child effect);
SARC	cis	rs896854	0.812	rs12546365	chr8:95911477	T/C	cg13393036	chr8:95962371	TP53INP1	-0.31	-5.35	-0.33	2.08e-7	Type 2 diabetes;
SARC	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg17971929	chr21:40555470	PSMG1	-0.82	-10.25	-0.56	1.38e-20	Cognitive function;
SARC	cis	rs2276314	0.947	rs4799831	chr18:33554775	A/G	cg19628046	chr18:33552617	C18orf21	0.57	6.01	0.37	7.29e-9	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs920590	0.918	rs11777075	chr8:19655666	G/A	cg03894339	chr8:19674705	INTS10	0.54	6.78	0.41	9.8e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs2204008	0.811	rs8189445	chr12:38276295	T/C	cg26384229	chr12:38710491	ALG10B	0.91	13.79	0.67	4.83e-32	Bladder cancer;
SARC	cis	rs2033732	0.706	rs7839360	chr8:85069719	G/T	cg05716166	chr8:85095498	RALYL	0.49	5.84	0.36	1.74e-8	Body mass index;
SARC	cis	rs72945132	0.882	rs59398290	chr11:70134819	G/A	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.78	-0.35	2.39e-8	Coronary artery disease;
SARC	cis	rs7666738	0.830	rs921521	chr4:98838339	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.9	0.5	1.65e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1152591	0.543	rs1152594	chr14:64675044	C/T	cg23250157	chr14:64679961	SYNE2	-0.41	-5.53	-0.34	8.37e-8	Atrial fibrillation;
SARC	cis	rs9309711	0.961	rs11890651	chr2:3482796	T/G	cg10845886	chr2:3471009	TTC15	-0.54	-6.94	-0.41	3.74e-11	Neurofibrillary tangles;
SARC	cis	rs6582630	0.524	rs10785494	chr12:38532431	C/G	cg13010199	chr12:38710504	ALG10B	-0.48	-5.99	-0.37	7.8e-9	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg12379764	chr21:47803548	PCNT	-0.54	-5.61	-0.35	5.64e-8	Testicular germ cell tumor;
SARC	cis	rs3741151	0.686	rs17851510	chr11:73106294	A/C	cg17517138	chr11:73019481	ARHGEF17	0.72	5.71	0.35	3.39e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs909674	0.775	rs4821896	chr22:39833437	T/C	cg05872129	chr22:39784769	NA	-0.43	-5.87	-0.36	1.52e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs2637266	1.000	rs2637266	chr10:78331318	C/T	cg19427642	chr10:78790257	KCNMA1	0.33	5.05	0.31	9.05e-7	Pulmonary function;
SARC	trans	rs11098499	0.954	rs12506546	chr4:120301618	T/C	cg25214090	chr10:38739885	LOC399744	0.57	7.43	0.44	2.01e-12	Corneal astigmatism;
SARC	cis	rs9300255	0.510	rs1727322	chr12:123699520	A/G	cg05973401	chr12:123451056	ABCB9	0.55	5.16	0.32	5.32e-7	Neutrophil percentage of white cells;
SARC	cis	rs6732160	0.588	rs7578991	chr2:73376171	A/G	cg01422370	chr2:73384389	NA	0.38	5.87	0.36	1.52e-8	Intelligence (multi-trait analysis);
SARC	cis	rs73157695	0.963	rs12152043	chr21:47370155	C/T	cg00682050	chr21:47343716	PCBP3	-0.43	-4.83	-0.3	2.51e-6	Myopia;
SARC	cis	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg14343924	chr8:8086146	FLJ10661	0.45	5.46	0.34	1.23e-7	Mood instability;
SARC	cis	rs11711311	1.000	rs2712348	chr3:113460614	C/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	8.48	0.49	2.62e-15	IgG glycosylation;
SARC	cis	rs16976116	0.901	rs7165491	chr15:55500455	A/C	cg17854078	chr15:55489399	RSL24D1	0.61	6.05	0.37	5.85e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs12579753	0.917	rs2401002	chr12:82215870	C/T	cg07988820	chr12:82153109	PPFIA2	-0.49	-5.48	-0.34	1.12e-7	Resting heart rate;
SARC	cis	rs4568518	0.720	rs58338223	chr7:18040129	C/T	cg00911873	chr7:18067463	PRPS1L1	-0.35	-5.12	-0.32	6.52e-7	Measles;
SARC	cis	rs79149102	0.579	rs8039433	chr15:75367367	T/C	cg00629941	chr15:75287862	SCAMP5	-0.62	-4.98	-0.31	1.23e-6	Lung cancer;
SARC	cis	rs3617	0.625	rs11719137	chr3:52876389	G/T	cg18404041	chr3:52824283	ITIH1	0.37	5.36	0.33	1.98e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs2013441	1.000	rs2386429	chr17:20210809	G/A	cg13482628	chr17:19912719	NA	-0.49	-6.16	-0.37	3.13e-9	Obesity-related traits;
SARC	trans	rs9532669	0.963	rs9532662	chr13:41500351	A/C	cg05231509	chr11:108094111	ATM;NPAT	0.48	6.28	0.38	1.66e-9	Cervical cancer;
SARC	cis	rs4727027	0.680	rs6464941	chr7:148826352	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	6.19	0.38	2.71e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs2404602	0.647	rs12898416	chr15:77042292	C/G	cg15268244	chr15:77196840	NA	0.44	5.13	0.32	6.08e-7	Blood metabolite levels;
SARC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg04234412	chr22:24373322	LOC391322	-0.54	-6.29	-0.38	1.59e-9	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs4737010	0.570	rs2111804	chr8:41644266	A/T	cg08923054	chr8:41654455	ANK1	0.67	8.08	0.47	3.42e-14	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
SARC	cis	rs35213789	0.878	rs10487940	chr7:69560422	G/A	cg10619644	chr7:69149951	AUTS2	0.43	5.16	0.32	5.39e-7	Childhood ear infection;
SARC	cis	rs1941023	0.503	rs11230288	chr11:60128968	G/A	cg08716584	chr11:60157161	MS4A7	-0.38	-6.46	-0.39	6.13e-10	Congenital heart disease (maternal effect);
SARC	cis	rs3087591	0.959	rs2051505	chr17:29699859	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.52	-6.32	-0.38	1.32e-9	Hip circumference;
SARC	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg20607798	chr8:58055168	NA	0.6	5.34	0.33	2.19e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2239815	0.515	rs5762829	chr22:29228130	A/G	cg15103426	chr22:29168792	CCDC117	0.61	6.18	0.38	2.8e-9	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
SARC	cis	rs9393692	0.645	rs9467703	chr6:26318903	A/G	cg05868516	chr6:26286170	HIST1H4H	0.45	5.1	0.32	7.04e-7	Educational attainment;
SARC	cis	rs9291683	0.595	rs13145442	chr4:10037261	C/A	cg00071950	chr4:10020882	SLC2A9	0.4	6.29	0.38	1.54e-9	Bone mineral density;
SARC	cis	rs1559088	0.847	rs7254758	chr19:33608047	T/A	cg27124370	chr19:33622961	WDR88	0.42	5.61	0.35	5.64e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs9467773	1.000	rs12526680	chr6:26550954	A/G	cg12292205	chr6:26970375	C6orf41	0.45	5.32	0.33	2.47e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2153535	0.580	rs1120392	chr6:8487053	C/A	cg23788917	chr6:8435910	SLC35B3	0.62	8.09	0.47	3.25e-14	Motion sickness;
SARC	cis	rs17539620	0.624	rs111868524	chr6:154839960	G/C	cg17771515	chr6:154831774	CNKSR3	0.52	4.97	0.31	1.3e-6	Lipoprotein (a) levels;
SARC	cis	rs3733589	0.744	rs3775939	chr4:10025296	C/G	cg16430538	chr4:10459836	ZNF518B	0.61	4.74	0.3	3.79e-6	Renal overload gout;
SARC	cis	rs9303542	0.625	rs7207109	chr17:46607817	C/T	cg04904318	chr17:46607828	HOXB1	-0.46	-5.6	-0.34	5.9e-8	Ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg08219700	chr8:58056026	NA	0.61	6.36	0.38	1.05e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg17490921	chr11:116658887	ZNF259	-0.57	-6.55	-0.39	3.61e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs9910055	0.529	rs183462	chr17:42183376	G/C	cg09913183	chr17:42254507	C17orf65;ASB16	-0.49	-5.84	-0.36	1.73e-8	Total body bone mineral density;
SARC	cis	rs12142240	0.698	rs41293285	chr1:46808426	C/T	cg10495392	chr1:46806563	NSUN4	0.64	6.76	0.4	1.09e-10	Menopause (age at onset);
SARC	cis	rs478304	0.654	rs11227260	chr11:65461158	G/T	cg27068330	chr11:65405492	SIPA1	-0.47	-5.56	-0.34	7.49e-8	Acne (severe);
SARC	cis	rs11225247	0.881	rs7113906	chr11:102253670	C/T	cg11690896	chr11:102217788	BIRC2	0.78	5.55	0.34	7.77e-8	Vein graft stenosis in coronary artery bypass grafting;
SARC	cis	rs2712184	0.683	rs2541403	chr2:217637885	A/G	cg05032264	chr2:217675019	NA	0.47	6.54	0.39	3.91e-10	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
SARC	cis	rs7605378	0.528	rs1704191	chr2:200816393	C/A	cg17644776	chr2:200775616	C2orf69	0.53	6.77	0.41	1.03e-10	Osteoporosis;
SARC	cis	rs78487399	0.614	rs13422551	chr2:43724682	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-4.77	-0.3	3.27e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs854765	0.547	rs28537385	chr17:17902135	G/A	cg04398451	chr17:18023971	MYO15A	-0.47	-6.68	-0.4	1.72e-10	Total body bone mineral density;
SARC	cis	rs7084402	1.000	rs1863665	chr10:60266640	T/C	cg07615347	chr10:60278583	BICC1	-0.58	-8.23	-0.47	1.3e-14	Refractive error;
SARC	cis	rs7777754	0.512	rs11238131	chr7:50538589	T/C	cg18232548	chr7:50535776	DDC	-0.49	-5.68	-0.35	4.09e-8	Response to zileuton treatment in asthma (FEV1 change interaction);
SARC	cis	rs4901847	0.967	rs7492608	chr14:58554401	T/C	cg15908186	chr14:58618357	C14orf37	0.44	4.95	0.31	1.45e-6	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg03060546	chr3:49711283	APEH	0.42	5.31	0.33	2.5e-7	Parkinson's disease;
SARC	cis	rs9457247	0.663	rs2282861	chr6:167440128	C/T	cg07741184	chr6:167504864	NA	0.35	6.99	0.42	2.9e-11	Crohn's disease;
SARC	cis	rs4843747	0.671	rs9921236	chr16:88117015	G/T	cg01573921	chr16:88061006	BANP	-0.47	-5.13	-0.32	6.11e-7	Menopause (age at onset);
SARC	cis	rs523522	0.962	rs1050187	chr12:120902111	A/G	cg12219531	chr12:120966889	COQ5	-0.81	-10.55	-0.57	1.64e-21	High light scatter reticulocyte count;
SARC	cis	rs2439831	0.681	rs540031	chr15:43608855	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.78	8.73	0.5	5.04e-16	Lung cancer in ever smokers;
SARC	cis	rs9916302	0.904	rs12450559	chr17:37694709	G/A	cg20243544	chr17:37824526	PNMT	0.53	6.17	0.37	2.93e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs3857067	0.772	rs10516947	chr4:95110897	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.05	-0.31	8.98e-7	QT interval;
SARC	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg16606324	chr3:10149918	C3orf24	0.47	4.88	0.3	1.92e-6	Alzheimer's disease;
SARC	cis	rs4676380	0.927	rs1583259	chr2:241644934	G/T	cg21930842	chr2:241631663	AQP12A	0.38	5.18	0.32	4.82e-7	Response to metformin (IC50);
SARC	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg02018176	chr4:1364513	KIAA1530	-0.53	-7.69	-0.45	3.99e-13	Longevity;
SARC	cis	rs11098499	0.954	rs3733519	chr4:120423448	A/G	cg24375607	chr4:120327624	NA	0.41	4.86	0.3	2.12e-6	Corneal astigmatism;
SARC	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.56	-5.67	-0.35	4.13e-8	Lung function (FEV1/FVC);
SARC	cis	rs6430585	0.583	rs6728946	chr2:136635343	C/G	cg07169764	chr2:136633963	MCM6	1.13	16.78	0.74	5.87e-42	Corneal structure;
SARC	cis	rs7949030	0.653	rs2516634	chr11:62367186	G/A	cg11742103	chr11:62369870	EML3;MTA2	-0.43	-6.64	-0.4	2.23e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs2290416	0.892	rs77370907	chr8:144664975	G/C	cg10810860	chr8:144639591	GSDMD	-0.71	-4.95	-0.31	1.45e-6	Attention deficit hyperactivity disorder;
SARC	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg11890956	chr21:40555474	PSMG1	-1.04	-15.54	-0.71	7.66e-38	Cognitive function;
SARC	cis	rs9388451	0.874	rs7739566	chr6:126094757	A/T	cg05901451	chr6:126070800	HEY2	-0.67	-9.24	-0.52	1.54e-17	Brugada syndrome;
SARC	cis	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg07636037	chr3:49044803	WDR6	0.5	5.78	0.35	2.36e-8	Resting heart rate;
SARC	cis	rs2073300	0.609	rs8183135	chr20:23384284	C/T	cg16736954	chr20:23401023	NAPB	0.79	4.94	0.31	1.5e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs7208859	0.623	rs7219361	chr17:29080393	G/A	cg13385521	chr17:29058706	SUZ12P	0.83	7.2	0.43	8.4e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs7208859	0.673	rs9895815	chr17:29138033	A/G	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs1949733	0.958	rs3103069	chr4:8509451	T/G	cg11789530	chr4:8429930	ACOX3	-0.82	-11.13	-0.59	2.42e-23	Response to antineoplastic agents;
SARC	cis	rs7980687	0.627	rs1727325	chr12:123698332	G/C	cg00376283	chr12:123451042	ABCB9	0.55	6.53	0.39	4.09e-10	Height;Educational attainment;Head circumference (infant);
SARC	cis	rs4141404	0.923	rs2413046	chr22:31665909	C/A	cg13145458	chr22:31556086	RNF185	0.47	5.05	0.31	8.76e-7	Paclitaxel-induced neuropathy;
SARC	cis	rs9393692	0.572	rs4145878	chr6:26198046	A/T	cg13736514	chr6:26305472	NA	-0.56	-7.3	-0.43	4.48e-12	Educational attainment;
SARC	cis	rs2153535	0.580	rs9393023	chr6:8469994	T/G	cg23788917	chr6:8435910	SLC35B3	0.64	8.39	0.48	4.57e-15	Motion sickness;
SARC	cis	rs9660992	0.710	rs1668867	chr1:205240251	C/T	cg19090574	chr1:205240910	TMCC2	-0.39	-4.9	-0.31	1.77e-6	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg22484793	chr3:52261325	TLR9	0.29	4.8	0.3	2.81e-6	Bipolar disorder;
SARC	cis	rs4595586	0.545	rs17546375	chr12:39407248	C/A	cg26384229	chr12:38710491	ALG10B	0.5	5.77	0.35	2.57e-8	Morning vs. evening chronotype;
SARC	cis	rs2204008	0.782	rs11514339	chr12:38236670	G/A	cg13010199	chr12:38710504	ALG10B	0.81	11.19	0.59	1.51e-23	Bladder cancer;
SARC	cis	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg05084668	chr3:125655381	ALG1L	-0.46	-4.83	-0.3	2.46e-6	Blood pressure (smoking interaction);
SARC	cis	rs8180040	0.966	rs11707895	chr3:47574937	G/A	cg27129171	chr3:47204927	SETD2	-0.69	-9.63	-0.53	1.06e-18	Colorectal cancer;
SARC	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.66	9.14	0.51	3.12e-17	Total body bone mineral density;
SARC	cis	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.41	5.11	0.32	6.75e-7	Eosinophil percentage of white cells;
SARC	cis	rs9916302	0.904	rs11078910	chr17:37671269	G/T	cg20243544	chr17:37824526	PNMT	0.55	6.5	0.39	4.94e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs854765	0.583	rs9912895	chr17:17826020	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.43	-5.54	-0.34	8.19e-8	Total body bone mineral density;
SARC	cis	rs262150	1.000	rs262154	chr7:158773936	G/A	cg19418458	chr7:158789849	NA	-0.46	-5.91	-0.36	1.22e-8	Facial morphology (factor 20);
SARC	cis	rs5753037	0.543	rs140122	chr22:30138908	C/G	cg01021169	chr22:30184971	ASCC2	-0.51	-6.86	-0.41	6.2e-11	Type 1 diabetes;
SARC	cis	rs7428	0.545	rs7572750	chr2:85552186	C/A	cg03728395	chr2:85555865	TGOLN2	-0.48	-6.62	-0.4	2.49e-10	Ear protrusion;
SARC	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-5.61	-0.35	5.58e-8	Bipolar disorder;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg13152082	chr4:100010005	ADH5	0.51	6.55	0.39	3.65e-10	Lung adenocarcinoma;
SARC	cis	rs7089973	0.668	rs61868024	chr10:116637939	A/G	cg03647239	chr10:116582469	FAM160B1	0.41	5.05	0.31	9.02e-7	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg03452623	chr4:187889614	NA	0.79	12.48	0.63	1.02e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs933688	1.000	rs10041402	chr5:90738948	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.04	13.23	0.66	3.43e-30	Smoking behavior;
SARC	trans	rs4332037	0.950	rs56403963	chr7:1946130	C/G	cg11693508	chr17:37793320	STARD3	0.72	6.54	0.39	3.95e-10	Bipolar disorder;
SARC	cis	rs11997175	0.574	rs4446694	chr8:33654978	A/G	ch.8.33884649F	chr8:33765107	NA	0.48	6.45	0.39	6.25e-10	Body mass index;
SARC	cis	rs2243480	0.666	rs1880311	chr7:65276752	G/C	cg18252515	chr7:66147081	NA	1.45	12.54	0.63	6.55e-28	Diabetic kidney disease;
SARC	cis	rs11997175	0.583	rs17780571	chr8:33817821	G/C	ch.8.33884649F	chr8:33765107	NA	0.47	5.98	0.36	8.29e-9	Body mass index;
SARC	cis	rs6088590	0.561	rs6088528	chr20:33156742	G/A	cg24642439	chr20:33292090	TP53INP2	0.66	8.51	0.49	2.12e-15	Coronary artery disease;
SARC	cis	rs634534	0.562	rs642293	chr11:65730217	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.81	11.96	0.62	4.91e-26	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg07167872	chr1:205819463	PM20D1	0.5	6.61	0.4	2.63e-10	Menarche (age at onset);
SARC	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	11.03	0.59	4.93e-23	Alzheimer's disease;
SARC	cis	rs155076	1.000	rs484365	chr13:21845944	G/T	cg25811766	chr13:21894605	NA	-0.51	-5.5	-0.34	9.92e-8	White matter hyperintensity burden;
SARC	cis	rs6815814	0.898	rs5743562	chr4:38806096	T/C	cg02016764	chr4:38805732	TLR1	-0.42	-4.89	-0.31	1.89e-6	Breast cancer;
SARC	cis	rs600231	0.508	rs11227202	chr11:65242717	G/A	cg17120908	chr11:65337727	SSSCA1	-0.45	-5.02	-0.31	1.04e-6	Bone mineral density;
SARC	cis	rs7224737	0.957	rs6503687	chr17:40295397	G/A	cg20291162	chr17:40259547	DHX58	-0.33	-4.85	-0.3	2.24e-6	Fibrinogen levels;
SARC	cis	rs35146811	0.660	rs6465760	chr7:99591418	A/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.39	-4.81	-0.3	2.67e-6	Coronary artery disease;
SARC	cis	rs1865760	0.929	rs9467646	chr6:25957408	A/G	cg18357526	chr6:26021779	HIST1H4A	0.39	4.79	0.3	2.97e-6	Height;
SARC	cis	rs4727027	0.800	rs10952796	chr7:148813138	G/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.48	5.64	0.35	4.84e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs6908034	0.607	rs73376655	chr6:19805664	C/T	cg02682789	chr6:19804855	NA	0.72	5.45	0.34	1.31e-7	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs10911232	0.507	rs10797815	chr1:182996827	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.67	0.57	6.63e-22	Hypertriglyceridemia;
SARC	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg21724239	chr8:58056113	NA	-0.59	-6.3	-0.38	1.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs11711311	0.955	rs9823423	chr3:113419741	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	8.43	0.48	3.7e-15	IgG glycosylation;
SARC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg02353165	chr6:42928485	GNMT	0.66	9.1	0.51	4.26e-17	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs4363385	0.507	rs6587710	chr1:152870716	A/G	cg07796016	chr1:152779584	LCE1C	-0.41	-5.36	-0.33	2.02e-7	Inflammatory skin disease;
SARC	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.89	12.64	0.64	3.1e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs6831352	0.877	rs28987101	chr4:100049253	T/G	cg13256891	chr4:100009986	ADH5	-0.65	-8.11	-0.47	2.83e-14	Alcohol dependence;
SARC	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg04944784	chr2:26401820	FAM59B	0.5	6.49	0.39	5.03e-10	Gut microbiome composition (summer);
SARC	cis	rs2832191	0.703	rs2853827	chr21:30443596	T/C	cg08807101	chr21:30365312	RNF160	0.89	13.61	0.67	1.99e-31	Dental caries;
SARC	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg21747090	chr2:27597821	SNX17	-0.55	-7.64	-0.45	5.63e-13	Total body bone mineral density;
SARC	cis	rs9790314	0.503	rs6441374	chr3:161064540	A/T	cg17135325	chr3:160939158	NMD3	0.64	8.34	0.48	6.64e-15	Morning vs. evening chronotype;
SARC	cis	rs4481887	1.000	rs10888362	chr1:248483975	A/G	cg00666640	chr1:248458726	OR2T12	-0.37	-6.3	-0.38	1.44e-9	Common traits (Other);
SARC	cis	rs826838	0.967	rs826855	chr12:39114888	T/C	cg26384229	chr12:38710491	ALG10B	-0.82	-12.37	-0.63	2.35e-27	Heart rate;
SARC	cis	rs7566780	0.725	rs4832646	chr2:16702399	G/C	cg09580478	chr2:16689509	NA	-0.47	-5.36	-0.33	2.01e-7	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg09699651	chr6:150184138	LRP11	-0.48	-5.68	-0.35	3.9e-8	Lung cancer;
SARC	cis	rs829883	0.867	rs1641640	chr12:98896017	A/G	cg25150519	chr12:98850993	NA	0.71	9.49	0.53	2.82e-18	Colorectal adenoma (advanced);
SARC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.4	4.93	0.31	1.53e-6	Electroencephalogram traits;
SARC	cis	rs1215050	0.765	rs644839	chr4:98716357	C/A	cg05340658	chr4:99064831	C4orf37	0.44	5.85	0.36	1.62e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs72781680	1.000	rs17712391	chr2:24245659	C/T	cg08917208	chr2:24149416	ATAD2B	0.89	8.82	0.5	2.74e-16	Lymphocyte counts;
SARC	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg16405210	chr4:1374714	KIAA1530	-0.48	-5.64	-0.35	4.92e-8	Obesity-related traits;
SARC	cis	rs2303759	0.709	rs8102658	chr19:49828855	C/T	cg22590775	chr19:49891494	CCDC155	0.47	5.23	0.32	3.8e-7	Multiple sclerosis;
SARC	cis	rs7264396	0.790	rs6121020	chr20:34252006	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-8.22	-0.47	1.46e-14	Total cholesterol levels;
SARC	cis	rs7937682	0.575	rs12808601	chr11:111776066	G/A	cg22437258	chr11:111473054	SIK2	-0.49	-5.75	-0.35	2.83e-8	Primary sclerosing cholangitis;
SARC	cis	rs2075371	0.796	rs1643040	chr7:134011703	G/C	cg11752832	chr7:134001865	SLC35B4	0.64	8.44	0.48	3.36e-15	Mean platelet volume;
SARC	cis	rs6977660	0.714	rs13225018	chr7:19816567	C/T	cg05791153	chr7:19748676	TWISTNB	0.56	5.09	0.32	7.33e-7	Thyroid stimulating hormone;
SARC	cis	rs2882877	0.648	rs13007486	chr2:190397484	G/A	cg21926118	chr2:190387206	NA	-0.41	-5.17	-0.32	5.03e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs11098499	0.909	rs10014719	chr4:120320715	G/A	cg09307838	chr4:120376055	NA	0.9	12.37	0.63	2.31e-27	Corneal astigmatism;
SARC	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg17221315	chr6:27791827	HIST1H4J	0.47	5.39	0.33	1.71e-7	Depression;
SARC	cis	rs7647973	0.667	rs4241405	chr3:49642027	C/T	cg07636037	chr3:49044803	WDR6	0.76	6.92	0.41	4.44e-11	Menarche (age at onset);
SARC	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.65	-8.22	-0.47	1.39e-14	Prudent dietary pattern;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg01116966	chr5:133450017	TCF7	0.51	6.72	0.4	1.38e-10	Breast cancer;
SARC	cis	rs2011503	1.000	rs2965201	chr19:19478051	C/T	cg03709012	chr19:19516395	GATAD2A	-0.66	-5.69	-0.35	3.81e-8	Bipolar disorder;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg12183124	chr6:43507374	XPO5	-0.54	-6.75	-0.4	1.15e-10	Height;
SARC	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg17376030	chr22:41985996	PMM1	-0.72	-8.86	-0.5	2.13e-16	Vitiligo;
SARC	cis	rs6540556	0.517	rs11119328	chr1:209885318	C/A	cg05527609	chr1:210001259	C1orf107	-0.52	-4.77	-0.3	3.22e-6	Red blood cell count;
SARC	cis	rs611744	0.604	rs13248461	chr8:109285833	C/T	cg21045802	chr8:109455806	TTC35	0.62	7.84	0.46	1.64e-13	Dupuytren's disease;
SARC	cis	rs1707322	0.717	rs3014249	chr1:46079493	A/G	cg03146154	chr1:46216737	IPP	-0.52	-6.24	-0.38	2e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6772849	0.930	rs1962040	chr3:128324161	G/A	cg01163369	chr3:128370232	RPN1	-0.34	-4.88	-0.3	1.93e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs1865760	0.566	rs2032445	chr6:26044812	T/A	cg10373733	chr6:25993375	NA	0.41	5.06	0.31	8.65e-7	Height;
SARC	cis	rs78545713	1.000	rs77281308	chr6:26250029	C/T	cg00631329	chr6:26305371	NA	-0.74	-6.66	-0.4	2e-10	Iron status biomarkers (total iron binding capacity);
SARC	trans	rs1814175	0.615	rs11040654	chr11:49939485	T/G	cg03929089	chr4:120376271	NA	-0.81	-11.69	-0.61	3.89e-25	Height;
SARC	cis	rs9818758	0.607	rs35673421	chr3:49139406	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.68	-5.69	-0.35	3.71e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs3768617	0.510	rs1547712	chr1:183088013	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.1	0.55	4.11e-20	Fuchs's corneal dystrophy;
SARC	cis	rs1003719	0.699	rs1015549	chr21:38448880	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.67	9.98	0.55	9.34e-20	Eye color traits;
SARC	cis	rs7666738	0.546	rs1456207	chr4:98676911	G/A	cg05340658	chr4:99064831	C4orf37	0.61	7.38	0.44	2.78e-12	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6120849	0.754	rs6119560	chr20:33606977	G/C	cg06115741	chr20:33292138	TP53INP2	0.54	5.16	0.32	5.3e-7	Protein C levels;
SARC	cis	rs3733585	0.699	rs10017674	chr4:9967053	T/C	cg11266682	chr4:10021025	SLC2A9	-0.37	-6.48	-0.39	5.28e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs9911578	0.813	rs8066773	chr17:56601552	A/G	cg05425664	chr17:57184151	TRIM37	-0.66	-7.79	-0.45	2.21e-13	Intelligence (multi-trait analysis);
SARC	cis	rs7824557	0.569	rs7816601	chr8:11205593	T/C	cg21775007	chr8:11205619	TDH	0.67	8.67	0.49	7.48e-16	Retinal vascular caliber;
SARC	cis	rs66573146	0.808	rs55942328	chr4:6990960	T/G	cg00086871	chr4:6988644	TBC1D14	0.86	5.15	0.32	5.57e-7	Granulocyte percentage of myeloid white cells;
SARC	trans	rs9951602	0.512	rs7232551	chr18:76650702	G/A	cg02800362	chr5:177631904	HNRNPAB	0.71	9.0	0.51	8.26e-17	Obesity-related traits;
SARC	trans	rs6600671	1.000	rs1591882	chr1:121183313	G/A	cg00646200	chr1:148855367	NA	0.52	7.26	0.43	5.6e-12	Hip geometry;
SARC	cis	rs1678542	0.679	rs10783834	chr12:57975953	G/C	cg00677455	chr12:58241039	CTDSP2	0.47	5.42	0.33	1.47e-7	Rheumatoid arthritis;
SARC	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg25894440	chr7:65020034	NA	-0.75	-5.67	-0.35	4.13e-8	Diabetic kidney disease;
SARC	cis	rs1008375	1.000	rs7654345	chr4:17691796	A/G	cg16339924	chr4:17578868	LAP3	0.56	7.03	0.42	2.24e-11	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg22535103	chr8:58192502	C8orf71	-0.73	-7.24	-0.43	6.52e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.57	6.75	0.4	1.18e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	12.28	0.63	4.75e-27	Personality dimensions;
SARC	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg19077165	chr18:44547161	KATNAL2	-0.51	-6.95	-0.41	3.57e-11	Personality dimensions;
SARC	cis	rs1215050	0.791	rs13114823	chr4:98671119	G/A	cg05340658	chr4:99064831	C4orf37	-0.44	-5.81	-0.36	2.09e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs1949733	0.848	rs2255501	chr4:8475014	G/A	cg11789530	chr4:8429930	ACOX3	-0.67	-8.19	-0.47	1.77e-14	Response to antineoplastic agents;
SARC	cis	rs56011263	0.687	rs4690188	chr4:703930	G/C	cg20735989	chr4:730612	PCGF3	-0.46	-5.22	-0.32	3.96e-7	White blood cell count;
SARC	cis	rs1348850	0.632	rs10167783	chr2:178519041	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.45	5.13	0.32	6.03e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7647973	1.000	rs7613491	chr3:49508976	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.57	-5.74	-0.35	2.88e-8	Menarche (age at onset);
SARC	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.54	6.97	0.42	3.19e-11	Personality dimensions;
SARC	cis	rs7667	0.960	rs867355	chr1:19699786	A/G	cg15311933	chr1:19638897	PQLC2;AKR7A2	-0.48	-5.47	-0.34	1.15e-7	Crohn's disease and psoriasis;
SARC	cis	rs918629	0.716	rs12055262	chr5:95274632	T/C	cg16656078	chr5:95278638	ELL2	-0.62	-7.54	-0.44	1.03e-12	IgG glycosylation;
SARC	cis	rs957448	0.687	rs10104041	chr8:95571602	G/A	cg26464482	chr8:95565502	KIAA1429	0.43	5.19	0.32	4.63e-7	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs9916302	0.904	rs12450559	chr17:37694709	G/A	cg00129232	chr17:37814104	STARD3	-0.63	-7.73	-0.45	3.25e-13	Glomerular filtration rate (creatinine);
SARC	trans	rs17685	0.816	rs11763076	chr7:75765963	C/T	cg19862616	chr7:65841803	NCRNA00174	0.62	7.72	0.45	3.44e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs8077889	0.619	rs1230399	chr17:41845403	C/T	cg26893861	chr17:41843967	DUSP3	-1.0	-16.15	-0.73	7.13e-40	Triglycerides;
SARC	cis	rs12545109	0.800	rs2670053	chr8:57421998	A/T	cg19413350	chr8:57351067	NA	-0.43	-5.4	-0.33	1.67e-7	Obesity-related traits;
SARC	cis	rs9787249	0.507	rs6660299	chr1:40247106	C/T	cg18217145	chr1:40254695	BMP8B	-0.62	-5.63	-0.35	5.29e-8	Blood protein levels;
SARC	cis	rs7666738	0.830	rs7673880	chr4:99057262	A/G	cg05340658	chr4:99064831	C4orf37	0.63	8.58	0.49	1.31e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1003719	0.737	rs2835587	chr21:38461795	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.65	9.38	0.52	6.15e-18	Eye color traits;
SARC	cis	rs2439831	0.681	rs7168940	chr15:43633334	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	8.5	0.49	2.25e-15	Lung cancer in ever smokers;
SARC	cis	rs1046896	0.594	rs9914570	chr17:80783721	C/T	cg02711726	chr17:80685570	FN3KRP	-0.54	-6.43	-0.39	7.24e-10	Glycated hemoglobin levels;
SARC	cis	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.26	-0.38	1.86e-9	Mood instability;
SARC	cis	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg11266682	chr4:10021025	SLC2A9	0.41	7.29	0.43	4.75e-12	Bone mineral density;
SARC	cis	rs763121	0.962	rs138711	chr22:39139913	C/T	cg21395723	chr22:39101663	GTPBP1	0.47	5.19	0.32	4.59e-7	Menopause (age at onset);
SARC	cis	rs1881797	0.872	rs12404733	chr1:247690417	A/C	cg18198730	chr1:247681584	NA	0.44	4.86	0.3	2.18e-6	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs3784262	0.669	rs4646559	chr15:58354258	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.34	-5.12	-0.32	6.35e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg21280719	chr6:42927975	GNMT	-0.46	-8.13	-0.47	2.47e-14	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs1048238	0.506	rs848194	chr1:16285342	G/A	cg21385522	chr1:16154831	NA	-0.49	-6.08	-0.37	4.75e-9	Systolic blood pressure;
SARC	cis	rs11574514	1.000	rs59343240	chr16:67850529	C/G	cg01866162	chr16:67596514	CTCF	0.79	5.24	0.32	3.51e-7	Crohn's disease;
SARC	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg08859206	chr1:53392774	SCP2	0.39	5.68	0.35	3.99e-8	Monocyte count;
SARC	cis	rs2153535	0.580	rs1889715	chr6:8443475	G/A	cg07606381	chr6:8435919	SLC35B3	0.8	11.46	0.6	2.07e-24	Motion sickness;
SARC	cis	rs7103648	0.669	rs12577383	chr11:47774238	C/T	cg10504702	chr11:47789108	FNBP4	0.77	10.07	0.55	4.85e-20	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs10484885	0.887	rs2273246	chr6:90453263	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.54	-4.89	-0.31	1.88e-6	QRS interval (sulfonylurea treatment interaction);
SARC	trans	rs11098499	0.863	rs3822191	chr4:120428101	A/T	cg25214090	chr10:38739885	LOC399744	0.58	7.14	0.42	1.18e-11	Corneal astigmatism;
SARC	cis	rs9436747	0.641	rs12042884	chr1:66053192	C/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.48	4.94	0.31	1.47e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs2370759	1.000	rs79578760	chr10:32611264	C/A	cg05361325	chr10:32636312	EPC1	-0.76	-6.79	-0.41	9.32e-11	Sexual dysfunction (female);
SARC	cis	rs13256369	1.000	rs13271966	chr8:8575472	T/C	cg18904891	chr8:8559673	CLDN23	0.48	5.53	0.34	8.72e-8	Obesity-related traits;
SARC	cis	rs6834538	0.577	rs10034556	chr4:113449650	T/C	cg05193411	chr4:113558554	LARP7;C4orf21	0.39	4.85	0.3	2.25e-6	Free thyroxine concentration;
SARC	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.72	-7.58	-0.44	8e-13	Platelet count;
SARC	cis	rs459571	0.792	rs55923934	chr9:136888233	C/G	cg01294253	chr9:136912663	BRD3	0.41	5.41	0.33	1.55e-7	Platelet distribution width;
SARC	cis	rs2594989	0.943	rs7646500	chr3:11478000	A/G	cg00170343	chr3:11313890	ATG7	0.6	5.97	0.36	8.81e-9	Circulating chemerin levels;
SARC	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg04267008	chr7:1944627	MAD1L1	-0.6	-6.85	-0.41	6.46e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs3768617	0.811	rs12144261	chr1:183014148	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	8.26	0.48	1.09e-14	Fuchs's corneal dystrophy;
SARC	cis	rs11792861	0.781	rs28361152	chr9:111727529	T/C	cg13535736	chr9:111863775	C9orf5	-0.38	-4.77	-0.3	3.24e-6	Menarche (age at onset);
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg27022615	chr11:70049105	FADD	-0.61	-6.36	-0.38	1.08e-9	Lung cancer in ever smokers;
SARC	cis	rs35213789	0.887	rs624626	chr7:69156535	A/G	cg10619644	chr7:69149951	AUTS2	-0.44	-5.89	-0.36	1.35e-8	Childhood ear infection;
SARC	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg18357526	chr6:26021779	HIST1H4A	0.47	5.89	0.36	1.31e-8	Blood metabolite levels;
SARC	cis	rs3820928	0.934	rs1366756	chr2:227772038	G/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-6.81	-0.41	8.13e-11	Pulmonary function;
SARC	cis	rs12303914	0.762	rs11611333	chr12:10467067	A/G	cg16417563	chr12:10365564	GABARAPL1	0.39	4.74	0.3	3.79e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs854765	0.547	rs2955359	chr17:17946730	T/C	cg05444541	chr17:17804740	TOM1L2	0.3	4.89	0.31	1.85e-6	Total body bone mineral density;
SARC	cis	rs7615952	0.800	rs12489350	chr3:125644116	T/C	cg05084668	chr3:125655381	ALG1L	-0.64	-6.57	-0.4	3.31e-10	Blood pressure (smoking interaction);
SARC	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg23958373	chr8:599963	NA	-0.69	-5.13	-0.32	6.11e-7	IgG glycosylation;
SARC	cis	rs2013441	1.000	rs34644796	chr17:20064128	C/G	cg13482628	chr17:19912719	NA	0.48	6.15	0.37	3.36e-9	Obesity-related traits;
SARC	cis	rs1966248	0.543	rs12206782	chr6:134103192	C/A	cg25632230	chr6:134101081	NA	-0.53	-7.04	-0.42	2.09e-11	Coronary artery disease;
SARC	cis	rs4664308	0.618	rs17830904	chr2:160891688	C/T	cg03641300	chr2:160917029	PLA2R1	0.39	5.04	0.31	9.35e-7	Idiopathic membranous nephropathy;
SARC	cis	rs2153535	0.580	rs7743418	chr6:8438128	A/C	cg23788917	chr6:8435910	SLC35B3	0.65	8.39	0.48	4.61e-15	Motion sickness;
SARC	cis	rs2880765	0.545	rs17553734	chr15:86013059	C/G	cg19183879	chr15:85880815	NA	0.29	4.72	0.3	3.99e-6	Coronary artery disease;
SARC	cis	rs1865760	0.566	rs1539183	chr6:26075051	G/C	cg17691542	chr6:26056736	HIST1H1C	0.52	6.39	0.39	9.04e-10	Height;
SARC	cis	rs9815354	0.767	rs60764195	chr3:41812522	G/C	cg03022575	chr3:42003672	ULK4	0.71	5.89	0.36	1.34e-8	Pulse pressure;Diastolic blood pressure;
SARC	trans	rs1814175	0.645	rs6486022	chr11:49776137	A/G	cg03929089	chr4:120376271	NA	-0.84	-12.3	-0.63	4.13e-27	Height;
SARC	cis	rs2834188	0.737	rs2834179	chr21:34679731	A/G	cg14352951	chr21:34696688	IFNAR1	0.43	5.6	0.34	6.04e-8	Narcolepsy;
SARC	cis	rs9635726	0.638	rs2952155	chr17:37861718	T/C	cg20243544	chr17:37824526	PNMT	0.45	4.96	0.31	1.34e-6	Primary biliary cholangitis;
SARC	cis	rs9393692	0.627	rs1059486	chr6:26200083	A/G	cg05868516	chr6:26286170	HIST1H4H	0.61	8.01	0.46	5.38e-14	Educational attainment;
SARC	cis	rs6815814	0.851	rs17582893	chr4:38886420	G/A	cg06935464	chr4:38784597	TLR10	0.48	4.73	0.3	3.86e-6	Breast cancer;
SARC	cis	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg07777115	chr5:623756	CEP72	-0.61	-5.53	-0.34	8.61e-8	Obesity-related traits;
SARC	cis	rs3770770	0.855	rs62133105	chr2:37243804	T/C	cg14987922	chr2:37194071	STRN	-0.5	-4.9	-0.31	1.78e-6	QRS duration;
SARC	cis	rs751728	0.664	rs747694	chr6:33736490	A/G	cg25922239	chr6:33757077	LEMD2	0.6	7.76	0.45	2.64e-13	Crohn's disease;
SARC	cis	rs4566357	0.576	rs3769644	chr2:227917240	C/G	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.97	-0.36	8.81e-9	Coronary artery disease;
SARC	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg04756594	chr16:24857601	SLC5A11	0.41	5.63	0.35	5.26e-8	Intelligence (multi-trait analysis);
SARC	cis	rs3109167	0.524	rs3801512	chr7:83120677	A/G	cg14519356	chr7:83097669	SEMA3E	0.35	4.72	0.3	4.12e-6	Blood protein levels;
SARC	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg05861140	chr6:150128134	PCMT1	-0.44	-5.72	-0.35	3.18e-8	Lung cancer;
SARC	cis	rs2273669	0.510	rs11757590	chr6:109370003	T/C	cg05315195	chr6:109294784	ARMC2	-0.63	-5.7	-0.35	3.6e-8	Prostate cancer;
SARC	cis	rs9814567	1.000	rs4334685	chr3:134304335	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-6.93	-0.41	4.14e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs35995292	0.500	rs2392606	chr7:38926955	C/A	cg19327137	chr7:38886074	VPS41	0.5	7.3	0.43	4.4e-12	Subjective well-being (multi-trait analysis);
SARC	cis	rs742614	0.533	rs736953	chr20:32415089	G/T	cg06304546	chr20:32448765	NA	-0.57	-7.25	-0.43	5.93e-12	Stearic acid (18:0) levels;
SARC	cis	rs1003719	0.788	rs7277657	chr21:38469523	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.63	9.05	0.51	5.67e-17	Eye color traits;
SARC	cis	rs595982	0.517	rs4801779	chr19:49406651	T/G	cg03707168	chr19:49379127	PPP1R15A	0.44	5.77	0.35	2.49e-8	Red cell distribution width;
SARC	cis	rs8014131	0.652	rs1543389	chr14:85984237	T/C	cg10406690	chr14:85995726	FLRT2	0.4	5.31	0.33	2.6e-7	Menarche (age at onset);
SARC	cis	rs7520050	0.902	rs7514192	chr1:46248977	A/G	cg24296786	chr1:45957014	TESK2	0.42	5.32	0.33	2.45e-7	Red blood cell count;Reticulocyte count;
SARC	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.06	-0.42	1.88e-11	Gut microbiome composition (summer);
SARC	cis	rs2730245	0.569	rs1188955	chr7:158690866	A/G	cg24397884	chr7:158709396	WDR60	0.68	7.97	0.46	6.92e-14	Height;
SARC	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg06634786	chr22:41940651	POLR3H	0.5	6.16	0.37	3.13e-9	Vitiligo;
SARC	cis	rs13095912	1.000	rs6784842	chr3:185342723	C/T	cg11274856	chr3:185301563	NA	0.35	4.84	0.3	2.34e-6	Systolic blood pressure;
SARC	cis	rs8005677	0.926	rs34344888	chr14:23387585	A/G	cg01529538	chr14:23388837	RBM23	0.46	5.72	0.35	3.25e-8	Cognitive ability (multi-trait analysis);
SARC	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg24060327	chr5:131705240	SLC22A5	0.74	8.97	0.51	9.94e-17	Breast cancer;
SARC	cis	rs7772486	0.790	rs9497425	chr6:146234197	G/A	cg23711669	chr6:146136114	FBXO30	-0.75	-11.73	-0.61	2.8e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11997175	0.713	rs6997661	chr8:33638554	A/G	ch.8.33884649F	chr8:33765107	NA	-0.53	-7.02	-0.42	2.44e-11	Body mass index;
SARC	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.67	9.23	0.52	1.75e-17	Menarche (age at onset);
SARC	cis	rs4481887	0.962	rs6663952	chr1:248465682	A/G	cg00666640	chr1:248458726	OR2T12	0.37	6.32	0.38	1.29e-9	Common traits (Other);
SARC	cis	rs1008375	1.000	rs10939746	chr4:17684951	A/G	cg16339924	chr4:17578868	LAP3	-0.63	-8.27	-0.48	1.01e-14	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9868809	0.772	rs73078349	chr3:48688114	G/A	cg12468774	chr3:49236860	CCDC36	0.59	5.16	0.32	5.37e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs2354432	0.556	rs885305	chr1:146786080	G/A	cg25205988	chr1:146714368	CHD1L	-1.05	-7.61	-0.45	6.73e-13	Mitochondrial DNA levels;
SARC	cis	rs17376456	0.825	rs17314074	chr5:93161467	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.69	5.67	0.35	4.15e-8	Diabetic retinopathy;
SARC	cis	rs17376456	0.825	rs17314825	chr5:93234937	A/G	cg25358565	chr5:93447407	FAM172A	1.33	14.69	0.69	5.19e-35	Diabetic retinopathy;
SARC	cis	rs11764590	0.694	rs7797112	chr7:2085165	T/C	cg23043544	chr7:2124092	MAD1L1	-0.34	-4.78	-0.3	3.07e-6	Neuroticism;
SARC	cis	rs7615952	0.736	rs9866347	chr3:125669925	C/T	cg05084668	chr3:125655381	ALG1L	-0.92	-8.48	-0.49	2.68e-15	Blood pressure (smoking interaction);
SARC	trans	rs1994135	0.647	rs11052745	chr12:33695999	G/T	cg13010199	chr12:38710504	ALG10B	0.63	7.41	0.44	2.32e-12	Resting heart rate;
SARC	cis	rs2072499	0.966	rs1137703	chr1:156184458	T/C	cg25208724	chr1:156163844	SLC25A44	0.81	10.42	0.56	3.97e-21	Testicular germ cell tumor;
SARC	cis	rs4689388	0.853	rs1079216	chr4:6282473	T/C	cg14416269	chr4:6271139	WFS1	0.37	5.49	0.34	1.07e-7	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs6910061	0.830	rs58969617	chr6:11110865	C/G	cg27233058	chr6:11094804	LOC221710	0.59	5.38	0.33	1.82e-7	Diabetic kidney disease;
SARC	cis	rs1008375	0.932	rs1008894	chr4:17704667	C/T	cg16339924	chr4:17578868	LAP3	-0.57	-7.34	-0.43	3.6e-12	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg08219700	chr8:58056026	NA	0.52	5.66	0.35	4.52e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg12564285	chr5:131593104	PDLIM4	0.45	6.32	0.38	1.31e-9	Breast cancer;
SARC	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg21724239	chr8:58056113	NA	0.56	6.05	0.37	5.75e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs12311304	0.965	rs7969197	chr12:15362066	G/C	cg08258403	chr12:15378311	NA	0.49	7.63	0.45	6.01e-13	Behavioural disinhibition (generation interaction);
SARC	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg11987759	chr7:65425863	GUSB	-0.55	-7.17	-0.43	9.75e-12	Aortic root size;
SARC	cis	rs6540556	0.769	rs9430017	chr1:209925058	C/T	cg23920097	chr1:209922102	NA	-0.56	-5.66	-0.35	4.48e-8	Red blood cell count;
SARC	cis	rs7681440	0.606	rs356192	chr4:90687927	G/A	cg06632027	chr4:90757378	SNCA	0.42	5.21	0.32	4.22e-7	Dementia with Lewy bodies;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg14150915	chr11:66056828	YIF1A	0.49	6.54	0.39	3.87e-10	Thyroid stimulating hormone;
SARC	cis	rs651907	0.557	rs7651721	chr3:101393583	C/A	cg12386194	chr3:101231763	SENP7	0.5	5.91	0.36	1.22e-8	Colorectal cancer;
SARC	cis	rs9322817	0.691	rs6929352	chr6:105204621	T/C	cg02098413	chr6:105308735	HACE1	-0.39	-6.12	-0.37	3.92e-9	Thyroid stimulating hormone;
SARC	cis	rs11225247	0.881	rs10895292	chr11:102245718	G/C	cg11690896	chr11:102217788	BIRC2	0.78	5.27	0.33	3.1e-7	Vein graft stenosis in coronary artery bypass grafting;
SARC	cis	rs11249608	0.636	rs13361077	chr5:178449174	G/C	cg21905437	chr5:178450457	ZNF879	0.57	7.66	0.45	5.07e-13	Pubertal anthropometrics;
SARC	cis	rs35110281	0.626	rs162389	chr21:44936227	T/C	cg01579765	chr21:45077557	HSF2BP	-0.29	-5.02	-0.31	1.01e-6	Mean corpuscular volume;
SARC	cis	rs1801251	1.000	rs283477	chr2:233649427	A/G	cg25237894	chr2:233734115	C2orf82	0.38	4.83	0.3	2.51e-6	Coronary artery disease;
SARC	cis	rs6570726	0.935	rs376991	chr6:145828073	G/C	cg05220968	chr6:146057943	EPM2A	-0.29	-4.99	-0.31	1.19e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1707322	0.928	rs6681068	chr1:46398382	G/A	cg06784218	chr1:46089804	CCDC17	0.34	5.97	0.36	8.98e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1949733	0.701	rs1880024	chr4:8454639	A/G	cg13073564	chr4:8508604	NA	-0.43	-6.65	-0.4	2.03e-10	Response to antineoplastic agents;
SARC	cis	rs2180341	0.920	rs9401951	chr6:127671632	A/C	cg17762328	chr6:126965162	NA	-0.44	-4.85	-0.3	2.22e-6	Breast cancer;
SARC	cis	rs1669338	0.588	rs62228634	chr3:3184985	A/G	cg16797762	chr3:3221439	CRBN	-0.94	-9.77	-0.54	3.96e-19	White matter integrity;
SARC	cis	rs17376456	0.825	rs1470150	chr5:93138654	C/T	cg21475434	chr5:93447410	FAM172A	-0.7	-6.41	-0.39	8.17e-10	Diabetic retinopathy;
SARC	cis	rs735396	1.000	rs2464195	chr12:121435475	G/A	cg15155738	chr12:121454335	C12orf43	0.5	6.1	0.37	4.47e-9	N-glycan levels;
SARC	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg23172400	chr8:95962367	TP53INP1	-0.28	-4.81	-0.3	2.69e-6	Type 2 diabetes;
SARC	cis	rs9816226	0.618	rs869399	chr3:185826764	C/T	cg00760338	chr3:185826511	ETV5	0.93	13.09	0.65	1.02e-29	Obesity;Body mass index;
SARC	cis	rs2997447	0.802	rs75786059	chr1:26449327	A/G	cg19633962	chr1:26362018	EXTL1	-0.56	-5.06	-0.31	8.59e-7	QRS complex (12-leadsum);
SARC	cis	rs11785693	0.862	rs11786186	chr8:4999059	G/C	cg26367366	chr8:4980734	NA	0.66	6.07	0.37	5.09e-9	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs986417	0.818	rs965455	chr14:60960314	A/C	cg27398547	chr14:60952738	C14orf39	1.02	9.63	0.53	1.06e-18	Gut microbiota (bacterial taxa);
SARC	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.57	-7.45	-0.44	1.76e-12	Mean platelet volume;
SARC	cis	rs56176327	0.600	rs7628207	chr3:49754970	T/C	cg06212747	chr3:49208901	KLHDC8B	0.55	5.52	0.34	9.13e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9322193	0.639	rs4869756	chr6:150207496	G/A	cg11878867	chr6:150167359	LRP11	-0.41	-4.85	-0.3	2.26e-6	Lung cancer;
SARC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg11905131	chr22:24372483	LOC391322	-0.48	-5.28	-0.33	2.99e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg07636037	chr3:49044803	WDR6	0.91	15.45	0.71	1.54e-37	Menarche (age at onset);
SARC	cis	rs950169	1.000	rs35648189	chr15:84740748	T/C	cg24253500	chr15:84953950	NA	0.35	5.04	0.31	9.53e-7	Schizophrenia;
SARC	cis	rs637571	0.522	rs649000	chr11:65742933	T/C	cg26695010	chr11:65641043	EFEMP2	-0.53	-6.72	-0.4	1.37e-10	Eosinophil percentage of white cells;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg25816357	chr12:21670234	GOLT1B	0.46	6.5	0.39	4.85e-10	Thyroid stimulating hormone;
SARC	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg24829409	chr8:58192753	C8orf71	-0.6	-6.23	-0.38	2.13e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs1502172	0.550	rs4894292	chr3:135238987	G/A	cg17077762	chr15:64996104	OAZ2	0.48	6.27	0.38	1.75e-9	Visceral adipose tissue adjusted for BMI;
SARC	cis	rs2952156	0.684	rs1877031	chr17:37814080	G/A	cg07936489	chr17:37558343	FBXL20	-0.43	-5.45	-0.34	1.27e-7	Asthma;
SARC	cis	rs2916247	0.909	rs2083844	chr8:93014149	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.59	-6.26	-0.38	1.81e-9	Intelligence (multi-trait analysis);
SARC	cis	rs4808199	0.895	rs6511036	chr19:19582651	A/G	cg03709012	chr19:19516395	GATAD2A	1.2	13.19	0.65	4.79e-30	Nonalcoholic fatty liver disease;
SARC	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg16479474	chr6:28041457	NA	0.37	5.53	0.34	8.38e-8	Depression;
SARC	cis	rs2980439	0.525	rs2945238	chr8:8170136	A/C	cg08975724	chr8:8085496	FLJ10661	0.54	6.87	0.41	5.92e-11	Neuroticism;
SARC	cis	rs9868809	0.542	rs9873726	chr3:48712367	C/T	cg07636037	chr3:49044803	WDR6	-0.67	-6.14	-0.37	3.57e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg06634786	chr22:41940651	POLR3H	0.51	6.17	0.37	3.07e-9	Vitiligo;
SARC	cis	rs2153535	0.580	rs6900007	chr6:8474035	C/T	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg05872129	chr22:39784769	NA	-0.45	-6.53	-0.39	3.97e-10	Intelligence (multi-trait analysis);
SARC	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg25894440	chr7:65020034	NA	-0.75	-5.67	-0.35	4.23e-8	Diabetic kidney disease;
SARC	cis	rs3796352	1.000	rs2564926	chr3:53094730	G/A	cg15956490	chr3:53032818	SFMBT1	-0.73	-5.45	-0.34	1.27e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs8031584	0.672	rs17227989	chr15:31293774	T/C	cg19680485	chr15:31195859	MTMR15	-0.53	-4.96	-0.31	1.35e-6	Huntington's disease progression;
SARC	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg20203395	chr5:56204925	C5orf35	0.56	5.06	0.31	8.32e-7	Initial pursuit acceleration;
SARC	cis	rs9682041	0.740	rs2111826	chr3:170140846	A/G	cg11886554	chr3:170076028	SKIL	1.11	8.04	0.47	4.4e-14	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs2204008	0.837	rs11168504	chr12:37964922	G/T	cg13010199	chr12:38710504	ALG10B	0.79	11.0	0.58	6.02e-23	Bladder cancer;
SARC	cis	rs5167	0.504	rs4803779	chr19:45456497	T/C	cg10169327	chr19:45448959	APOC2	0.31	5.11	0.32	6.85e-7	Blood protein levels;
SARC	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg04317338	chr11:64019027	PLCB3	0.82	8.73	0.5	5.03e-16	Mean platelet volume;
SARC	cis	rs11581859	0.613	rs36046144	chr1:99189935	C/T	cg20286094	chr1:99190917	SNX7	-0.41	-4.88	-0.3	1.97e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs995000	0.931	rs641540	chr1:62908538	A/G	cg06896770	chr1:63153194	DOCK7	0.89	13.58	0.66	2.52e-31	Triglyceride levels;
SARC	cis	rs10823500	0.830	rs9415007	chr10:71972564	T/C	cg04118878	chr10:71993077	PPA1	0.42	5.15	0.32	5.58e-7	Blood protein levels;
SARC	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg21724239	chr8:58056113	NA	0.43	4.74	0.3	3.66e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs1707322	0.685	rs28617418	chr1:46189526	T/A	cg06784218	chr1:46089804	CCDC17	0.36	6.22	0.38	2.26e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs72945132	0.882	rs6592537	chr11:70172975	C/T	cg05964544	chr11:70165517	PPFIA1	-0.58	-5.57	-0.34	6.99e-8	Coronary artery disease;
SARC	cis	rs9650657	0.572	rs4841465	chr8:10819854	C/T	cg00262122	chr8:11665843	FDFT1	-0.45	-5.46	-0.34	1.22e-7	Neuroticism;
SARC	cis	rs3812831	0.599	rs428636	chr13:114927133	T/C	cg08824895	chr13:115047677	UPF3A	0.51	6.62	0.4	2.47e-10	Schizophrenia;
SARC	cis	rs6448317	0.539	rs13113895	chr4:24932077	T/C	cg21108841	chr4:24914750	CCDC149	-0.59	-7.44	-0.44	1.95e-12	Heschl's gyrus morphology;
SARC	cis	rs1728785	1.000	rs1170431	chr16:68605639	T/C	cg02972257	chr16:68554789	NA	-0.47	-5.56	-0.34	7.2e-8	Ulcerative colitis;
SARC	cis	rs9611565	0.506	rs2024566	chr22:41697338	A/G	cg03806693	chr22:41940476	POLR3H	-0.73	-9.66	-0.53	8.88e-19	Vitiligo;
SARC	cis	rs787274	0.718	rs4979170	chr9:115626918	C/G	cg13803584	chr9:115635662	SNX30	0.88	6.93	0.41	4.11e-11	Age-related hearing impairment (SNP x SNP interaction);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg20278381	chr10:69682560	HERC4	0.55	7.86	0.46	1.4e-13	Thyroid stimulating hormone;
SARC	cis	rs7769051	0.803	rs56148066	chr6:133230115	G/A	cg22852734	chr6:133119734	C6orf192	0.86	7.58	0.44	8.05e-13	Type 2 diabetes nephropathy;
SARC	cis	rs7647973	1.000	rs940045	chr3:49449638	G/A	cg06212747	chr3:49208901	KLHDC8B	0.58	6.07	0.37	5.05e-9	Menarche (age at onset);
SARC	cis	rs644799	0.710	rs56384142	chr11:95502075	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.87	14.28	0.68	1.16e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7927771	1.000	rs34910028	chr11:47758449	T/C	cg05585544	chr11:47624801	NA	-0.37	-4.89	-0.31	1.87e-6	Subjective well-being;
SARC	cis	rs644799	1.000	rs563653	chr11:95561488	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.68	9.17	0.51	2.6e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs3806843	0.676	rs778591	chr5:140025484	G/A	cg16577123	chr5:140027231	NDUFA2;IK	-0.43	-5.04	-0.31	9.15e-7	Depressive symptoms (multi-trait analysis);
SARC	cis	rs72945132	0.882	rs7129843	chr11:70180381	G/A	cg00319359	chr11:70116639	PPFIA1	0.7	6.64	0.4	2.23e-10	Coronary artery disease;
SARC	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg22834771	chr12:69754056	YEATS4	-0.45	-5.99	-0.37	7.75e-9	Blood protein levels;
SARC	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.42	-6.31	-0.38	1.43e-9	Total body bone mineral density;
SARC	cis	rs11122272	0.670	rs2474632	chr1:231484361	C/T	cg06096015	chr1:231504339	EGLN1	0.38	5.7	0.35	3.56e-8	Hemoglobin concentration;
SARC	cis	rs3087591	0.887	rs2905875	chr17:29541339	A/T	cg24425628	chr17:29625626	OMG;NF1	0.49	5.94	0.36	1.04e-8	Hip circumference;
SARC	cis	rs9467773	0.584	rs1021372	chr6:26632444	T/C	cg12292205	chr6:26970375	C6orf41	0.41	5.12	0.32	6.46e-7	Intelligence (multi-trait analysis);
SARC	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg08067268	chr2:26466485	HADHB;HADHA	0.46	5.77	0.35	2.54e-8	Gut microbiome composition (summer);
SARC	cis	rs1707322	1.000	rs11211248	chr1:46476844	A/G	cg03146154	chr1:46216737	IPP	0.47	5.72	0.35	3.29e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs11874712	1.000	rs9962458	chr18:43678625	G/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.52	6.29	0.38	1.59e-9	Migraine - clinic-based;
SARC	cis	rs796364	0.813	rs7565417	chr2:201057491	G/A	cg23649088	chr2:200775458	C2orf69	0.65	7.18	0.43	9.27e-12	Schizophrenia;
SARC	cis	rs11690935	0.851	rs10201430	chr2:172813241	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.77	-10.71	-0.57	4.89e-22	Schizophrenia;
SARC	cis	rs2976388	0.647	rs1048831	chr8:143781858	G/A	cg06565975	chr8:143823917	SLURP1	0.33	5.7	0.35	3.62e-8	Urinary tract infection frequency;
SARC	cis	rs7647973	0.769	rs11130181	chr3:49109919	G/A	cg07636037	chr3:49044803	WDR6	0.86	10.26	0.56	1.24e-20	Menarche (age at onset);
SARC	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-9.15	-0.51	2.85e-17	Alzheimer's disease;
SARC	cis	rs356220	0.632	rs356222	chr4:90643123	A/G	cg06632027	chr4:90757378	SNCA	-0.41	-5.23	-0.32	3.71e-7	Parkinson's disease;
SARC	cis	rs6570726	0.791	rs6902410	chr6:145905261	G/A	cg23711669	chr6:146136114	FBXO30	0.85	14.24	0.68	1.55e-33	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs780096	0.814	rs780093	chr2:27742603	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.31	-5.18	-0.32	4.71e-7	Total body bone mineral density;
SARC	cis	rs9324022	0.929	rs17099617	chr14:101170488	A/G	cg18089426	chr14:101175970	NA	0.55	5.41	0.33	1.54e-7	Plateletcrit;
SARC	cis	rs9487051	0.676	rs6903107	chr6:109597711	A/G	cg01475377	chr6:109611718	NA	-0.35	-5.08	-0.32	7.8e-7	Reticulocyte fraction of red cells;
SARC	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg10523679	chr1:76189770	ACADM	0.47	5.54	0.34	8.25e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9325144	0.625	rs11534879	chr12:38968165	A/G	cg26384229	chr12:38710491	ALG10B	-0.61	-7.99	-0.46	6.02e-14	Morning vs. evening chronotype;
SARC	cis	rs7772486	0.754	rs9373476	chr6:146139741	C/G	cg05347473	chr6:146136440	FBXO30	0.53	7.4	0.44	2.39e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7872515	0.887	rs10992234	chr9:94877836	A/G	cg01248375	chr9:94877805	SPTLC1	0.67	6.02	0.37	6.66e-9	Bipolar disorder and schizophrenia;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg10961240	chr6:64345449	NA	-0.91	-8.07	-0.47	3.64e-14	Autism spectrum disorder or schizophrenia;
SARC	cis	rs4268898	0.662	rs59996104	chr2:24404064	C/T	cg26838691	chr2:24397539	C2orf84	-0.54	-6.27	-0.38	1.75e-9	Asthma;
SARC	cis	rs1023500	0.573	rs8135801	chr22:42475568	A/G	cg04733989	chr22:42467013	NAGA	-0.76	-10.7	-0.57	5.23e-22	Schizophrenia;
SARC	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg22433210	chr17:43662623	NA	0.69	8.18	0.47	1.82e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg25036284	chr2:26402008	FAM59B	-0.46	-5.62	-0.35	5.45e-8	Gut microbiome composition (summer);
SARC	cis	rs7647973	0.710	rs1532204	chr3:49609477	C/G	cg07636037	chr3:49044803	WDR6	0.77	7.01	0.42	2.52e-11	Menarche (age at onset);
SARC	cis	rs2380220	0.541	rs9285413	chr6:96023439	G/A	cg23517279	chr6:96025343	MANEA	0.57	6.3	0.38	1.44e-9	Behavioural disinhibition (generation interaction);
SARC	cis	rs13065560	0.594	rs4234134	chr3:38887970	A/T	cg01426195	chr3:39028469	NA	0.32	4.89	0.31	1.84e-6	Interleukin-18 levels;
SARC	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg27170947	chr2:26402098	FAM59B	0.39	4.98	0.31	1.22e-6	Gut microbiome composition (summer);
SARC	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg22920501	chr2:26401640	FAM59B	-0.51	-6.64	-0.4	2.16e-10	Gut microbiome composition (summer);
SARC	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg24250549	chr1:154909240	PMVK	0.79	11.35	0.6	4.63e-24	Prostate cancer;
SARC	cis	rs473651	0.716	rs548179	chr2:239320505	G/A	cg18131467	chr2:239335373	ASB1	0.88	13.76	0.67	6.06e-32	Multiple system atrophy;
SARC	cis	rs9815354	1.000	rs2128835	chr3:41862873	A/G	cg03022575	chr3:42003672	ULK4	0.57	5.33	0.33	2.34e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs1355223	0.583	rs1549789	chr11:34867947	G/A	cg18508148	chr11:34937573	PDHX;APIP	0.52	6.79	0.41	9.3e-11	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs4722166	0.597	rs1554606	chr7:22768707	T/G	cg26061582	chr7:22766209	IL6	0.51	5.8	0.36	2.17e-8	Lung cancer;
SARC	cis	rs9818758	0.607	rs9862483	chr3:49195441	G/A	cg07636037	chr3:49044803	WDR6	-0.77	-6.78	-0.41	9.75e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg24209194	chr3:40518798	ZNF619	0.64	8.01	0.46	5.33e-14	Renal cell carcinoma;
SARC	cis	rs1348850	0.914	rs4893950	chr2:178304885	T/C	cg23306229	chr2:178417860	TTC30B	0.55	6.37	0.38	1.02e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9814567	0.896	rs58491661	chr3:134355189	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.48	6.09	0.37	4.73e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	trans	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg19760249	chr17:79254595	SLC38A10	0.51	6.73	0.4	1.32e-10	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1790761	0.520	rs12805884	chr11:67387977	G/A	cg23188684	chr11:67383651	NA	-0.43	-5.68	-0.35	3.99e-8	Mean corpuscular volume;
SARC	cis	rs7662987	0.517	rs1154406	chr4:100008494	T/C	cg12011299	chr4:100065546	ADH4	0.32	5.24	0.32	3.6e-7	Smoking initiation;
SARC	cis	rs11785400	1.000	rs10108059	chr8:143750028	G/T	cg10596483	chr8:143751796	JRK	-0.63	-8.36	-0.48	5.76e-15	Schizophrenia;
SARC	cis	rs2404602	0.684	rs1011084	chr15:77007480	C/G	cg15268244	chr15:77196840	NA	0.46	5.31	0.33	2.53e-7	Blood metabolite levels;
SARC	cis	rs1008375	0.897	rs67455495	chr4:17665238	A/T	cg16339924	chr4:17578868	LAP3	-0.62	-7.82	-0.46	1.84e-13	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9457247	0.765	rs4710171	chr6:167430186	A/G	cg07741184	chr6:167504864	NA	0.34	6.46	0.39	6.03e-10	Crohn's disease;
SARC	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg06108461	chr20:60628389	TAF4	0.94	11.3	0.59	6.89e-24	Body mass index;
SARC	trans	rs1994135	0.669	rs2121831	chr12:33697674	G/A	cg13010199	chr12:38710504	ALG10B	0.7	8.49	0.49	2.52e-15	Resting heart rate;
SARC	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg16479474	chr6:28041457	NA	0.36	5.25	0.33	3.43e-7	Depression;
SARC	cis	rs1003719	0.680	rs3737540	chr21:38523266	C/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-8.53	-0.49	1.88e-15	Eye color traits;
SARC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg24503407	chr1:205819492	PM20D1	0.92	15.75	0.72	1.51e-38	Menarche (age at onset);
SARC	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg17971929	chr21:40555470	PSMG1	0.97	13.24	0.66	3.19e-30	Cognitive function;
SARC	cis	rs6539267	0.885	rs12579099	chr12:106765727	A/G	cg00173435	chr12:106696525	TCP11L2	0.56	5.49	0.34	1.07e-7	Tourette syndrome;
SARC	cis	rs34172651	0.876	rs964782	chr16:24811740	T/C	cg00339695	chr16:24857497	SLC5A11	0.31	4.93	0.31	1.6e-6	Intelligence (multi-trait analysis);
SARC	cis	rs3617	0.539	rs4687689	chr3:52948674	A/C	cg18404041	chr3:52824283	ITIH1	0.33	4.74	0.3	3.69e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs7223966	0.921	rs2006123	chr17:61958669	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.46	4.97	0.31	1.32e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg04944784	chr2:26401820	FAM59B	-0.51	-6.18	-0.38	2.82e-9	Gut microbiome composition (summer);
SARC	cis	rs2153535	0.541	rs1414353	chr6:8485642	C/G	cg23788917	chr6:8435910	SLC35B3	0.64	8.4	0.48	4.46e-15	Motion sickness;
SARC	cis	rs6991838	0.584	rs61083799	chr8:66487103	C/T	cg13398993	chr8:66546079	ARMC1	-0.62	-8.36	-0.48	5.88e-15	Intelligence (multi-trait analysis);
SARC	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg17221315	chr6:27791827	HIST1H4J	0.43	4.74	0.3	3.7e-6	Cardiac Troponin-T levels;
SARC	cis	rs4243830	0.850	rs4908558	chr1:6584101	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.76	-7.38	-0.44	2.79e-12	Body mass index;
SARC	cis	rs910316	0.763	rs735452	chr14:75497984	A/G	cg11812906	chr14:75593930	NEK9	-0.79	-11.18	-0.59	1.6e-23	Height;
SARC	cis	rs7927771	0.864	rs2053979	chr11:47439444	A/G	cg05585544	chr11:47624801	NA	-0.36	-4.86	-0.3	2.18e-6	Subjective well-being;
SARC	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg02733842	chr7:1102375	C7orf50	-0.43	-5.52	-0.34	8.92e-8	Bronchopulmonary dysplasia;
SARC	cis	rs2730245	1.000	rs2252502	chr7:158738634	G/C	cg00815399	chr7:158750607	NA	-0.34	-4.73	-0.3	3.96e-6	Height;
SARC	cis	rs5753618	0.583	rs8138596	chr22:31786961	T/A	cg07713946	chr22:31675144	LIMK2	0.35	4.76	0.3	3.46e-6	Colorectal cancer;
SARC	cis	rs7223966	1.000	rs16947014	chr17:61719032	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.29	0.38	1.54e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs72945132	0.882	rs113472486	chr11:70194945	C/G	cg05964544	chr11:70165517	PPFIA1	-0.56	-5.46	-0.34	1.22e-7	Coronary artery disease;
SARC	cis	rs6918586	0.636	rs198817	chr6:26126524	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.44	-5.53	-0.34	8.43e-8	Schizophrenia;
SARC	cis	rs2522056	1.000	rs2706393	chr5:131796067	G/A	cg24060327	chr5:131705240	SLC22A5	0.48	4.76	0.3	3.38e-6	Lymphocyte counts;Fibrinogen;
SARC	cis	rs2153535	0.580	rs2327060	chr6:8447111	G/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.5	0.49	2.33e-15	Motion sickness;
SARC	cis	rs9300255	0.602	rs1106241	chr12:123627016	T/C	cg05973401	chr12:123451056	ABCB9	0.53	5.98	0.36	8.17e-9	Neutrophil percentage of white cells;
SARC	cis	rs6840360	0.967	rs1105534	chr4:152605312	C/A	cg22705602	chr4:152727874	NA	-0.38	-6.53	-0.39	4.08e-10	Intelligence (multi-trait analysis);
SARC	cis	rs607987	0.871	rs10835643	chr11:30294329	T/C	cg06241208	chr11:30344200	C11orf46	0.42	5.03	0.31	9.7e-7	Body mass index;
SARC	cis	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg11935053	chr6:118973021	C6orf204	-0.44	-5.82	-0.36	1.94e-8	Electrocardiographic conduction measures;
SARC	cis	rs3087591	0.887	rs7503395	chr17:29440554	C/T	cg24425628	chr17:29625626	OMG;NF1	0.52	6.47	0.39	5.82e-10	Hip circumference;
SARC	cis	rs12594515	0.935	rs8042519	chr15:45996341	G/C	cg14863074	chr15:45997064	NA	0.34	5.2	0.32	4.31e-7	Waist circumference;Weight;
SARC	cis	rs748404	0.660	rs690446	chr15:43761264	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	5.58	0.34	6.68e-8	Lung cancer;
SARC	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg12311346	chr5:56204834	C5orf35	-0.59	-6.13	-0.37	3.65e-9	Initial pursuit acceleration;
SARC	cis	rs78487399	0.710	rs57381820	chr2:43626668	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-5.03	-0.31	9.83e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs1559088	0.847	rs3786933	chr19:33602881	C/T	cg27124370	chr19:33622961	WDR88	0.43	5.63	0.35	5.15e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs4988958	0.548	rs6543127	chr2:103028301	A/C	cg03938978	chr2:103052716	IL18RAP	0.31	4.96	0.31	1.34e-6	Asthma (childhood onset);
SARC	cis	rs2072499	0.966	rs2842864	chr1:156159217	G/A	cg24450063	chr1:156163899	SLC25A44	1.18	21.59	0.82	1.66e-57	Testicular germ cell tumor;
SARC	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg03185022	chr7:2884158	GNA12	0.45	5.0	0.31	1.13e-6	Height;
SARC	cis	rs8141529	0.509	rs5762853	chr22:29245231	T/G	cg15103426	chr22:29168792	CCDC117	0.57	7.1	0.42	1.48e-11	Lymphocyte counts;
SARC	cis	rs9660992	0.710	rs1768586	chr1:205238275	A/G	cg07972983	chr1:205091412	RBBP5	0.56	6.88	0.41	5.35e-11	Mean corpuscular volume;Mean platelet volume;
SARC	trans	rs11722228	0.522	rs12504600	chr4:10067138	C/A	cg26043149	chr18:55253948	FECH	0.72	8.1	0.47	3.04e-14	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	19.09	0.78	1.48e-49	Prudent dietary pattern;
SARC	cis	rs73635312	0.850	rs17504213	chr10:8949565	T/C	cg24467326	chr10:9646929	NA	0.58	4.95	0.31	1.4e-6	Basal cell carcinoma;
SARC	cis	rs72634258	0.554	rs35307738	chr1:7919839	C/G	cg00042356	chr1:8021962	PARK7	0.66	5.49	0.34	1.03e-7	Inflammatory bowel disease;
SARC	cis	rs9640161	0.742	rs11983355	chr7:150016697	A/C	cg17279839	chr7:150038598	RARRES2	0.45	6.31	0.38	1.37e-9	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs826838	0.559	rs4882276	chr12:38611994	T/C	cg26384229	chr12:38710491	ALG10B	0.6	7.81	0.46	1.9e-13	Heart rate;
SARC	cis	rs73198271	0.920	rs11781542	chr8:8617181	G/T	cg06636001	chr8:8085503	FLJ10661	-0.47	-4.78	-0.3	3.11e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-9.15	-0.51	2.85e-17	Alzheimer's disease;
SARC	cis	rs1044826	0.667	rs295471	chr3:139213922	G/C	cg15131784	chr3:139108705	COPB2	0.4	5.06	0.31	8.66e-7	Obesity-related traits;
SARC	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg11987759	chr7:65425863	GUSB	0.46	6.18	0.38	2.82e-9	Aortic root size;
SARC	cis	rs11581859	0.613	rs9725840	chr1:99204596	G/A	cg20286094	chr1:99190917	SNX7	-0.42	-4.89	-0.31	1.86e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg00684032	chr4:1343700	KIAA1530	-0.37	-5.34	-0.33	2.24e-7	Obesity-related traits;
SARC	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	8.67	0.49	7.35e-16	Mean platelet volume;
SARC	cis	rs7005380	0.531	rs6469860	chr8:120909348	G/A	cg21744203	chr8:120868354	DSCC1	-0.46	-4.83	-0.3	2.42e-6	Interstitial lung disease;
SARC	cis	rs9916302	0.706	rs8067511	chr17:37611352	C/T	cg07936489	chr17:37558343	FBXL20	-0.73	-8.41	-0.48	4.18e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.41	5.16	0.32	5.28e-7	Lymphocyte counts;
SARC	cis	rs796364	1.000	rs281788	chr2:200783705	A/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.73	6.8	0.41	8.64e-11	Schizophrenia;
SARC	cis	rs7149337	0.869	rs10137481	chr14:51694614	C/T	cg23942311	chr14:51606299	NA	0.33	5.99	0.37	8.01e-9	Cancer;
SARC	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg11764359	chr7:65958608	NA	-0.76	-9.24	-0.52	1.55e-17	Aortic root size;
SARC	cis	rs11585357	0.501	rs17458091	chr1:17595925	A/G	cg08277548	chr1:17600880	PADI3	-0.46	-5.0	-0.31	1.15e-6	Hair shape;
SARC	cis	rs113835537	0.529	rs11227503	chr11:66275242	G/C	cg24851651	chr11:66362959	CCS	0.37	4.73	0.3	3.91e-6	Airway imaging phenotypes;
SARC	cis	rs4253772	0.638	rs6007845	chr22:46718417	A/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.76	-7.24	-0.43	6.49e-12	LDL cholesterol;Cholesterol, total;
SARC	cis	rs314370	0.951	rs12667888	chr7:100474289	T/C	cg10426581	chr7:100472382	SRRT	0.62	6.5	0.39	4.7e-10	Resting heart rate;
SARC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg07414643	chr4:187882934	NA	0.52	7.83	0.46	1.66e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6429082	0.608	rs4469707	chr1:235570634	T/C	cg26050004	chr1:235667680	B3GALNT2	-0.6	-7.05	-0.42	2e-11	Adiposity;
SARC	cis	rs2153535	0.547	rs9505475	chr6:8542890	A/G	cg21535247	chr6:8435926	SLC35B3	0.55	6.96	0.41	3.48e-11	Motion sickness;
SARC	cis	rs1215050	0.765	rs1588018	chr4:98756324	G/C	cg05340658	chr4:99064831	C4orf37	0.44	5.81	0.36	2.02e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs9948	0.500	rs62152903	chr2:97570377	T/C	cg26665480	chr2:98280029	ACTR1B	-0.64	-5.46	-0.34	1.19e-7	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg03806693	chr22:41940476	POLR3H	0.9	11.92	0.62	6.71e-26	Vitiligo;
SARC	cis	rs7553864	0.966	rs11161937	chr1:87614510	A/G	cg18153957	chr1:87613403	LOC339524	-0.51	-6.13	-0.37	3.65e-9	Smoking behavior;
SARC	cis	rs9916302	0.904	rs2061342	chr17:37405657	T/G	cg00129232	chr17:37814104	STARD3	-0.6	-7.49	-0.44	1.44e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs11997175	0.583	rs12680811	chr8:33778426	A/C	ch.8.33884649F	chr8:33765107	NA	0.53	7.14	0.42	1.15e-11	Body mass index;
SARC	cis	rs2228479	0.557	rs11648881	chr16:89862434	T/C	cg06558623	chr16:89946397	TCF25	0.94	6.53	0.39	3.99e-10	Skin colour saturation;
SARC	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg27347728	chr4:17578864	LAP3	0.48	6.1	0.37	4.5e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs921968	0.565	rs6436081	chr2:219637884	A/G	cg02176678	chr2:219576539	TTLL4	-0.34	-5.12	-0.32	6.44e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs10464366	0.519	rs6974609	chr7:39219149	C/T	cg18850127	chr7:39170497	POU6F2	0.41	5.2	0.32	4.35e-7	IgG glycosylation;
SARC	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg11987759	chr7:65425863	GUSB	0.46	6.14	0.37	3.57e-9	Aortic root size;
SARC	cis	rs12421382	0.614	rs12799395	chr11:109390862	G/T	cg27471124	chr11:109292789	C11orf87	0.35	4.99	0.31	1.17e-6	Schizophrenia;
SARC	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg11890956	chr21:40555474	PSMG1	1.14	18.82	0.78	1.14e-48	Cognitive function;
SARC	cis	rs3126085	0.935	rs12742573	chr1:152260103	A/C	cg26876637	chr1:152193138	HRNR	-0.51	-5.52	-0.34	8.86e-8	Atopic dermatitis;
SARC	cis	rs11583043	0.708	rs874905	chr1:101539702	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.45	4.8	0.3	2.83e-6	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs1707322	0.686	rs3014239	chr1:46089801	G/A	cg03146154	chr1:46216737	IPP	-0.52	-6.19	-0.38	2.65e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg17971929	chr21:40555470	PSMG1	1.0	14.01	0.68	9.02e-33	Cognitive function;
SARC	cis	rs6665290	0.904	rs3795451	chr1:227181923	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.06	-24.69	-0.85	5.75e-67	Myeloid white cell count;
SARC	cis	rs796364	0.616	rs2689765	chr2:200696352	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.61	4.94	0.31	1.48e-6	Schizophrenia;
SARC	cis	rs11264799	0.520	rs2779159	chr1:157550357	C/T	cg18268488	chr1:157545234	FCRL4	0.32	5.85	0.36	1.68e-8	IgA nephropathy;
SARC	cis	rs3772130	0.583	rs9819530	chr3:121387784	T/G	cg20356878	chr3:121714668	ILDR1	0.39	6.11	0.37	4.15e-9	Cognitive performance;
SARC	cis	rs78545713	0.892	rs76182849	chr6:26257950	C/T	cg00631329	chr6:26305371	NA	-0.78	-7.01	-0.42	2.58e-11	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg08280861	chr8:58055591	NA	0.58	5.63	0.35	5.17e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg11494091	chr17:61959527	GH2	0.53	7.94	0.46	8.67e-14	Prudent dietary pattern;
SARC	cis	rs4642101	0.640	rs3901666	chr3:12824363	G/T	cg05775895	chr3:12838266	CAND2	-0.7	-10.54	-0.57	1.68e-21	QRS complex (12-leadsum);
SARC	cis	rs11122272	0.732	rs999010	chr1:231495316	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-9.61	-0.53	1.22e-18	Hemoglobin concentration;
SARC	cis	rs9398803	0.678	rs9388500	chr6:126876580	C/G	cg20229609	chr6:126660872	C6orf173	0.35	5.07	0.31	8.26e-7	Male-pattern baldness;
SARC	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-8.89	-0.5	1.75e-16	Alzheimer's disease;
SARC	cis	rs11098499	0.954	rs1022145	chr4:120230979	A/G	cg09307838	chr4:120376055	NA	0.9	12.27	0.63	5.12e-27	Corneal astigmatism;
SARC	cis	rs920590	0.758	rs35280191	chr8:19665214	A/C	cg03894339	chr8:19674705	INTS10	0.58	6.95	0.41	3.74e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9467160	0.817	rs12194966	chr6:24437611	G/A	cg16211469	chr6:24423932	MRS2	0.45	5.14	0.32	5.68e-7	Liver enzyme levels;
SARC	cis	rs7223966	0.960	rs2319990	chr17:61705397	T/C	cg26338869	chr17:61819248	STRADA	0.42	4.73	0.3	3.85e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg18876405	chr7:65276391	NA	0.7	8.91	0.5	1.52e-16	Aortic root size;
SARC	cis	rs360798	0.948	rs12617178	chr2:63090065	C/T	cg16915676	chr2:62734870	TMEM17	0.42	5.06	0.31	8.68e-7	Coronary artery disease;
SARC	cis	rs698833	0.926	rs1067342	chr2:44622256	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.72	9.55	0.53	1.92e-18	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs1580019	0.563	rs34319173	chr7:32585904	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.96	16.46	0.73	6.7e-41	Cognitive ability;
SARC	cis	rs11249608	0.548	rs10516150	chr5:178459169	G/C	cg21905437	chr5:178450457	ZNF879	0.56	7.3	0.43	4.45e-12	Pubertal anthropometrics;
SARC	cis	rs644799	1.000	rs10831431	chr11:95510089	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.87	13.82	0.67	4.02e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg07167872	chr1:205819463	PM20D1	0.75	11.56	0.6	9.63e-25	Menarche (age at onset);
SARC	cis	rs72945132	0.882	rs67927691	chr11:70128786	C/A	cg00319359	chr11:70116639	PPFIA1	0.68	6.37	0.39	1.01e-9	Coronary artery disease;
SARC	cis	rs950776	0.745	rs36045869	chr15:78929498	C/T	cg22563815	chr15:78856949	CHRNA5	0.33	5.15	0.32	5.65e-7	Sudden cardiac arrest;
SARC	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg18252515	chr7:66147081	NA	1.35	11.94	0.62	5.84e-26	Diabetic kidney disease;
SARC	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg11987759	chr7:65425863	GUSB	0.46	6.01	0.37	7.26e-9	Aortic root size;
SARC	cis	rs7412746	0.611	rs36008098	chr1:150856806	G/A	cg15448220	chr1:150897856	SETDB1	0.51	6.6	0.4	2.67e-10	Melanoma;
SARC	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg11764359	chr7:65958608	NA	0.66	7.81	0.46	1.93e-13	Aortic root size;
SARC	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg15242686	chr22:24348715	GSTTP1	0.42	5.04	0.31	9.55e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs3106136	0.527	rs2664894	chr4:95153831	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.47	-7.05	-0.42	2.06e-11	Capecitabine sensitivity;
SARC	cis	rs6087990	0.735	rs6087420	chr20:31359391	G/A	cg13636640	chr20:31349939	DNMT3B	0.78	12.28	0.63	4.6e-27	Ulcerative colitis;
SARC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg26338869	chr17:61819248	STRADA	0.81	10.85	0.58	1.8e-22	Prudent dietary pattern;
SARC	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg00684032	chr4:1343700	KIAA1530	0.38	5.52	0.34	9.14e-8	Obesity-related traits;
SARC	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg09455208	chr3:40491958	NA	0.38	5.64	0.35	4.9e-8	Renal cell carcinoma;
SARC	cis	rs9916302	0.706	rs7208252	chr17:37584368	A/G	cg20243544	chr17:37824526	PNMT	0.54	5.61	0.35	5.69e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs5753618	0.583	rs738657	chr22:31841749	T/A	cg02404636	chr22:31891804	SFI1	0.6	7.15	0.42	1.11e-11	Colorectal cancer;
SARC	cis	rs7592578	0.771	rs4258824	chr2:191395027	C/T	cg10560079	chr2:191398806	TMEM194B	-0.74	-8.4	-0.48	4.53e-15	Diastolic blood pressure;
SARC	cis	rs11168351	0.591	rs4258439	chr12:48468652	A/G	cg24011408	chr12:48396354	COL2A1	-0.52	-7.17	-0.42	1.01e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs10876993	0.928	rs1689594	chr12:58057156	T/C	cg18357645	chr12:58087776	OS9	0.49	6.53	0.39	4.11e-10	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs11650494	0.710	rs16948078	chr17:47474800	C/T	cg08112188	chr17:47440006	ZNF652	-0.81	-7.77	-0.45	2.52e-13	Prostate cancer;
SARC	cis	rs7824557	0.628	rs11994376	chr8:11202960	G/A	cg21775007	chr8:11205619	TDH	0.65	8.41	0.48	4.05e-15	Retinal vascular caliber;
SARC	cis	rs1348850	0.874	rs4893822	chr2:178285727	G/T	cg23306229	chr2:178417860	TTC30B	0.51	5.57	0.34	6.84e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs11718455	0.960	rs13065591	chr3:43996585	T/C	cg08738300	chr3:44038990	NA	0.55	6.05	0.37	5.79e-9	Coronary artery disease;
SARC	cis	rs35110281	0.574	rs1836856	chr21:44964638	A/T	cg21573476	chr21:45109991	RRP1B	-0.39	-5.6	-0.34	6.11e-8	Mean corpuscular volume;
SARC	cis	rs761746	0.882	rs5998032	chr22:31928890	T/G	cg15162869	chr22:32027605	PISD	0.36	4.95	0.31	1.39e-6	Intelligence;
SARC	cis	rs9902453	0.791	rs55655651	chr17:28244286	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	6.95	0.41	3.67e-11	Coffee consumption (cups per day);
SARC	cis	rs35110281	0.686	rs162399	chr21:44950020	G/A	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.13	-0.37	3.66e-9	Mean corpuscular volume;
SARC	cis	rs4664304	0.739	rs2162500	chr2:160708645	C/G	cg18514922	chr2:160761262	LY75	0.33	4.77	0.3	3.27e-6	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs6772849	0.896	rs4857859	chr3:128348014	G/T	cg01163369	chr3:128370232	RPN1	-0.33	-4.81	-0.3	2.76e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs2916247	0.908	rs10956823	chr8:93140909	A/C	cg10183463	chr8:93005414	RUNX1T1	-0.58	-6.09	-0.37	4.69e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7666738	0.830	rs1593570	chr4:99017058	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.9	0.5	1.65e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg06618935	chr21:46677482	NA	-0.42	-5.56	-0.34	7.26e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.98	11.82	0.61	1.49e-25	Platelet count;
SARC	cis	rs1355223	0.506	rs11032898	chr11:34870111	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.49	-6.24	-0.38	2.02e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs1570884	0.516	rs9316462	chr13:50176321	A/G	cg08779649	chr13:50194554	NA	0.36	6.27	0.38	1.76e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs3733585	0.781	rs4292328	chr4:9970962	C/T	cg11266682	chr4:10021025	SLC2A9	-0.4	-7.13	-0.42	1.28e-11	Cleft plate (environmental tobacco smoke interaction);
SARC	trans	rs7824557	0.527	rs11785394	chr8:11238029	C/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.62	-0.4	2.46e-10	Retinal vascular caliber;
SARC	cis	rs367943	0.966	rs444322	chr5:112815399	C/T	cg12552261	chr5:112820674	MCC	-0.45	-5.21	-0.32	4.24e-7	Type 2 diabetes;
SARC	cis	rs2832191	1.000	rs2832184	chr21:30483265	C/T	cg08807101	chr21:30365312	RNF160	-0.75	-10.39	-0.56	4.97e-21	Dental caries;
SARC	cis	rs7589342	0.839	rs12997003	chr2:106436413	C/T	cg16077055	chr2:106428750	NCK2	0.34	6.16	0.37	3.18e-9	Addiction;
SARC	cis	rs9814567	1.000	rs6802654	chr3:134217072	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-7.03	-0.42	2.3e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs6963495	0.818	rs73190149	chr7:105152793	C/T	cg13798780	chr7:105162888	PUS7	0.58	5.28	0.33	2.95e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs2439831	0.850	rs544122	chr15:43775732	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	7.36	0.43	3.16e-12	Lung cancer in ever smokers;
SARC	trans	rs9929218	0.529	rs11640736	chr16:68738324	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.8	13.29	0.66	2.19e-30	Colorectal cancer;
SARC	cis	rs921968	0.607	rs2465100	chr2:219551044	A/T	cg02176678	chr2:219576539	TTLL4	-0.33	-4.85	-0.3	2.28e-6	Mean corpuscular hemoglobin concentration;
SARC	trans	rs62103177	0.733	rs62103232	chr18:77635553	G/A	cg05926928	chr17:57297772	GDPD1	1.03	9.32	0.52	9.29e-18	Opioid sensitivity;
SARC	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg24060327	chr5:131705240	SLC22A5	-0.72	-8.77	-0.5	3.82e-16	Breast cancer;
SARC	cis	rs72627123	0.656	rs77660260	chr14:74569573	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.74	5.87	0.36	1.48e-8	Morning vs. evening chronotype;
SARC	cis	rs4664308	0.837	rs56172865	chr2:160967333	C/T	cg03641300	chr2:160917029	PLA2R1	-0.62	-8.32	-0.48	7.61e-15	Idiopathic membranous nephropathy;
SARC	cis	rs10851411	0.697	rs17766258	chr15:42785137	A/G	cg21293051	chr15:42870591	STARD9	-0.48	-4.82	-0.3	2.55e-6	Glucose homeostasis traits;
SARC	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg12463550	chr7:65579703	CRCP	0.69	5.26	0.33	3.2e-7	Diabetic kidney disease;
SARC	cis	rs858239	0.899	rs2268745	chr7:23317600	G/A	cg23682824	chr7:23144976	KLHL7	0.59	7.6	0.45	7.3e-13	Cerebrospinal fluid biomarker levels;
SARC	cis	rs3750965	0.806	rs7107680	chr11:68859894	C/T	cg06818126	chr11:68850279	TPCN2	-0.4	-4.74	-0.3	3.77e-6	Hair color;
SARC	trans	rs12310956	0.515	rs1872745	chr12:33985987	G/A	cg13010199	chr12:38710504	ALG10B	0.65	8.68	0.49	7.12e-16	Morning vs. evening chronotype;
SARC	cis	rs12824058	0.799	rs4759656	chr12:130815804	G/A	cg24838063	chr12:130822603	PIWIL1	0.63	9.06	0.51	5.5e-17	Menopause (age at onset);
SARC	cis	rs12142240	0.698	rs1475390	chr1:46816340	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-5.46	-0.34	1.22e-7	Menopause (age at onset);
SARC	cis	rs73206853	0.841	rs55972509	chr12:110992755	T/C	cg10860002	chr12:110842031	ANAPC7	0.59	5.02	0.31	1.02e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs10911232	0.507	rs4652762	chr1:182993960	T/C	cg13390022	chr1:182993471	LAMC1	0.33	4.97	0.31	1.31e-6	Hypertriglyceridemia;
SARC	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg18876405	chr7:65276391	NA	-0.45	-4.94	-0.31	1.46e-6	Aortic root size;
SARC	cis	rs3087591	0.960	rs2952979	chr17:29474298	T/A	cg24425628	chr17:29625626	OMG;NF1	0.53	6.55	0.39	3.57e-10	Hip circumference;
SARC	cis	rs7296418	0.961	rs1790121	chr12:123604492	G/A	cg16085171	chr12:123569118	PITPNM2	-0.38	-4.87	-0.3	2.04e-6	Platelet count;
SARC	cis	rs6759839	0.698	rs4832634	chr2:16648995	T/C	cg09580478	chr2:16689509	NA	0.48	6.17	0.37	2.98e-9	Mean platelet volume;
SARC	cis	rs9309473	0.950	rs13431529	chr2:73876041	G/C	cg20560298	chr2:73613845	ALMS1	-0.45	-5.59	-0.34	6.21e-8	Metabolite levels;
SARC	cis	rs8114671	0.552	rs2024635	chr20:33422614	G/A	cg24642439	chr20:33292090	TP53INP2	0.55	6.71	0.4	1.45e-10	Height;
SARC	cis	rs995000	0.931	rs624660	chr1:62920388	C/A	cg06896770	chr1:63153194	DOCK7	0.91	13.78	0.67	5.4e-32	Triglyceride levels;
SARC	cis	rs6815814	0.950	rs113465719	chr4:38808045	A/T	cg09316306	chr4:38807337	TLR1	0.5	5.16	0.32	5.23e-7	Breast cancer;
SARC	cis	rs7614311	0.681	rs6776209	chr3:63858633	G/C	cg22134162	chr3:63841271	THOC7	-0.41	-4.76	-0.3	3.35e-6	Lung function (FVC);Lung function (FEV1);
SARC	cis	rs7582720	1.000	rs72926793	chr2:203826396	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs2795502	0.938	rs2744085	chr10:43341976	C/T	cg20628663	chr10:43360327	NA	0.45	6.08	0.37	4.9e-9	Blood protein levels;
SARC	cis	rs2425143	0.547	rs6141583	chr20:34572834	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-5.42	-0.33	1.48e-7	Blood protein levels;
SARC	cis	rs897080	0.515	rs1067404	chr2:44675823	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.55	-5.95	-0.36	9.82e-9	Height;
SARC	cis	rs11718455	0.767	rs6785433	chr3:43964265	A/G	cg08738300	chr3:44038990	NA	0.51	5.52	0.34	9.19e-8	Coronary artery disease;
SARC	cis	rs1278769	0.735	rs12585036	chr13:113535741	C/T	cg01161842	chr13:113518337	ATP11A	0.42	4.94	0.31	1.48e-6	Interstitial lung disease;
SARC	cis	rs1865760	0.865	rs9467645	chr6:25955176	G/C	cg16482183	chr6:26056742	HIST1H1C	0.51	6.55	0.39	3.66e-10	Height;
SARC	cis	rs8031584	1.000	rs1474380	chr15:31269235	T/C	cg14829155	chr15:31115871	NA	-0.44	-5.59	-0.34	6.21e-8	Huntington's disease progression;
SARC	cis	rs11874712	1.000	rs11082509	chr18:43655010	G/A	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.46	5.5	0.34	1.02e-7	Migraine - clinic-based;
SARC	cis	rs6582630	0.519	rs12368889	chr12:38315160	G/A	cg13010199	chr12:38710504	ALG10B	0.78	10.62	0.57	9.89e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs763121	0.853	rs9306329	chr22:39072454	C/T	cg06022373	chr22:39101656	GTPBP1	0.85	10.65	0.57	7.52e-22	Menopause (age at onset);
SARC	cis	rs10162002	0.935	rs9578603	chr13:24040733	C/G	cg00158254	chr13:24040743	NA	0.53	4.92	0.31	1.65e-6	Hypothyroidism;
SARC	cis	rs7833986	1.000	rs13273123	chr8:57100791	C/T	cg26371346	chr8:56986568	SNORD54;RPS20	-0.6	-5.25	-0.33	3.42e-7	Height;
SARC	cis	rs7772486	0.790	rs3923579	chr6:146230232	C/G	cg23711669	chr6:146136114	FBXO30	-0.81	-13.07	-0.65	1.23e-29	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs58785573	0.624	rs337605	chr4:38647753	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.38	4.82	0.3	2.6e-6	Lymphocyte percentage of white cells;
SARC	cis	rs7666738	0.830	rs17558151	chr4:99048699	T/C	cg05340658	chr4:99064831	C4orf37	0.64	8.6	0.49	1.18e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6964587	1.000	rs10234434	chr7:91673308	A/T	cg17063962	chr7:91808500	NA	0.95	16.01	0.72	2e-39	Breast cancer;
SARC	trans	rs13130787	0.638	rs1595511	chr4:94938945	A/G	cg18470593	chr4:15471377	CC2D2A	-0.41	-6.29	-0.38	1.51e-9	Colorectal cancer;
SARC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.65	-6.44	-0.39	6.6e-10	Platelet count;
SARC	cis	rs11608355	0.515	rs56244055	chr12:109936211	G/A	cg05360138	chr12:110035743	NA	0.92	9.39	0.52	5.78e-18	Neuroticism;
SARC	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	12.27	0.63	5.17e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	trans	rs9388451	0.869	rs7764016	chr6:126070789	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.55	-7.02	-0.42	2.36e-11	Brugada syndrome;
SARC	cis	rs4555082	1.000	rs7146012	chr14:105757566	G/A	cg10792982	chr14:105748885	BRF1	0.52	7.7	0.45	3.76e-13	Mean platelet volume;Platelet distribution width;
SARC	cis	rs7000551	0.653	rs4872504	chr8:22326717	A/G	cg12081754	chr8:22256438	SLC39A14	0.57	7.91	0.46	1.03e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs1059312	1.000	rs7135987	chr12:129280117	G/A	cg09035930	chr12:129282057	SLC15A4	0.61	8.74	0.5	4.7e-16	Systemic lupus erythematosus;
SARC	cis	rs453301	0.686	rs3989373	chr8:8911308	G/T	cg11608241	chr8:8085544	FLJ10661	-0.45	-5.71	-0.35	3.5e-8	Joint mobility (Beighton score);
SARC	cis	rs4642101	0.537	rs4997708	chr3:12839603	G/A	cg12400702	chr3:12838781	CAND2	-0.26	-5.06	-0.31	8.47e-7	QRS complex (12-leadsum);
SARC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg11494091	chr17:61959527	GH2	0.54	8.07	0.47	3.81e-14	Prudent dietary pattern;
SARC	cis	rs8064299	0.655	rs2305214	chr17:72768970	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.43	5.1	0.32	6.99e-7	Monocyte count;
SARC	cis	rs7659604	0.935	rs73844280	chr4:122664687	G/A	cg20573242	chr4:122745356	CCNA2	0.44	5.72	0.35	3.18e-8	Type 2 diabetes;
SARC	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg06634786	chr22:41940651	POLR3H	0.54	6.41	0.39	8.14e-10	Vitiligo;
SARC	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	0.78	10.97	0.58	7.71e-23	Total body bone mineral density;
SARC	cis	rs6988636	1.000	rs9987357	chr8:124187620	T/G	cg23067535	chr8:124195133	FAM83A	-0.69	-5.46	-0.34	1.24e-7	Urinary uromodulin levels;
SARC	cis	rs748404	0.631	rs7163288	chr15:43671355	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	5.68	0.35	3.99e-8	Lung cancer;
SARC	cis	rs8013055	0.846	rs10136015	chr14:105973469	A/C	cg19700328	chr14:106028568	NA	-0.6	-8.51	-0.49	2.19e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
SARC	cis	rs9393692	0.905	rs6940237	chr6:26282322	T/C	cg05868516	chr6:26286170	HIST1H4H	0.57	7.67	0.45	4.7e-13	Educational attainment;
SARC	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg15448220	chr1:150897856	SETDB1	0.47	6.22	0.38	2.24e-9	Tonsillectomy;
SARC	cis	rs9916302	0.904	rs585961	chr17:37444036	G/A	cg00129232	chr17:37814104	STARD3	0.59	7.28	0.43	5.23e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg22496380	chr5:211416	CCDC127	-0.86	-9.02	-0.51	6.97e-17	Breast cancer;
SARC	trans	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg20587970	chr11:113659929	NA	-1.33	-13.02	-0.65	1.8e-29	Hip circumference adjusted for BMI;
SARC	cis	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg08975724	chr8:8085496	FLJ10661	0.55	7.42	0.44	2.14e-12	Mood instability;
SARC	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-6.77	-0.41	1.02e-10	Personality dimensions;
SARC	cis	rs7084402	0.565	rs7912792	chr10:60335179	C/T	cg07615347	chr10:60278583	BICC1	0.4	5.35	0.33	2.12e-7	Refractive error;
SARC	cis	rs7428	0.527	rs6547612	chr2:85551184	C/T	cg03728395	chr2:85555865	TGOLN2	-0.47	-6.45	-0.39	6.55e-10	Ear protrusion;
SARC	cis	rs2180341	1.000	rs6937287	chr6:127645719	T/A	cg24812749	chr6:127587940	RNF146	0.98	12.95	0.65	2.92e-29	Breast cancer;
SARC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg23034840	chr1:205782522	SLC41A1	-0.61	-7.87	-0.46	1.34e-13	Menarche (age at onset);
SARC	cis	rs10193935	0.901	rs997288	chr2:42525582	C/G	cg27598129	chr2:42591480	NA	-0.34	-4.72	-0.3	4.03e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs5760092	0.755	rs11090298	chr22:24262061	G/A	cg01238044	chr22:24384105	GSTT1	0.67	7.14	0.42	1.15e-11	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs62244186	0.541	rs3804583	chr3:44884647	G/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.6	7.99	0.46	6.16e-14	Depressive symptoms;
SARC	cis	rs11992162	0.967	rs7461062	chr8:11831948	T/C	cg21775007	chr8:11205619	TDH	0.39	4.78	0.3	3.09e-6	Monocyte count;
SARC	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg03576123	chr11:487126	PTDSS2	-1.15	-11.3	-0.59	6.99e-24	Body mass index;
SARC	cis	rs6088580	0.634	rs9789792	chr20:32957709	G/A	cg08999081	chr20:33150536	PIGU	-0.42	-6.41	-0.39	8.07e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg13939156	chr17:80058883	NA	0.41	6.27	0.38	1.7e-9	Life satisfaction;
SARC	cis	rs4588572	0.686	rs67689570	chr5:77676843	T/C	cg11547950	chr5:77652471	NA	0.41	4.94	0.31	1.48e-6	Triglycerides;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg00844078	chr2:26098817	ASXL2	0.44	6.24	0.38	2.02e-9	Thyroid stimulating hormone;
SARC	cis	rs2204008	0.540	rs1672425	chr12:38122842	G/A	cg14851346	chr12:38532713	NA	-0.45	-5.29	-0.33	2.77e-7	Bladder cancer;
SARC	cis	rs11608355	0.545	rs2302708	chr12:109893726	A/C	cg05360138	chr12:110035743	NA	0.92	9.61	0.53	1.27e-18	Neuroticism;
SARC	cis	rs9300255	0.679	rs4759409	chr12:123719585	G/C	cg00376283	chr12:123451042	ABCB9	0.52	5.98	0.36	8.35e-9	Neutrophil percentage of white cells;
SARC	cis	rs10911232	0.507	rs4369195	chr1:182996291	G/C	cg13390022	chr1:182993471	LAMC1	0.33	5.04	0.31	9.29e-7	Hypertriglyceridemia;
SARC	cis	rs17428076	0.874	rs12619041	chr2:172600716	A/C	cg13550731	chr2:172543902	DYNC1I2	-0.42	-4.72	-0.3	4.02e-6	Myopia;
SARC	cis	rs11718455	0.960	rs4682712	chr3:43997971	T/C	cg21419209	chr3:44054225	NA	-0.43	-5.29	-0.33	2.8e-7	Coronary artery disease;
SARC	cis	rs1322639	0.614	rs9455889	chr6:169566087	A/T	cg04662567	chr6:169592167	NA	-0.51	-5.28	-0.33	2.96e-7	Pulse pressure;
SARC	cis	rs1865760	0.516	rs10807007	chr6:26048931	A/C	cg17691542	chr6:26056736	HIST1H1C	0.5	6.3	0.38	1.47e-9	Height;
SARC	cis	rs57506017	0.585	rs12669919	chr7:12271997	G/A	cg23422036	chr7:12250390	TMEM106B	0.45	5.87	0.36	1.49e-8	Neuroticism;
SARC	cis	rs9325144	0.600	rs7312522	chr12:38730423	A/G	cg13010199	chr12:38710504	ALG10B	0.55	7.07	0.42	1.8e-11	Morning vs. evening chronotype;
SARC	cis	rs3008870	0.755	rs2815366	chr1:67499930	C/T	cg02640540	chr1:67518911	SLC35D1	0.46	5.22	0.32	4.03e-7	Lymphocyte percentage of white cells;
SARC	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.63	7.52	0.44	1.21e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4851254	0.961	rs13022707	chr2:100734946	C/A	cg17356467	chr2:100759845	AFF3	0.29	4.83	0.3	2.46e-6	Intelligence (multi-trait analysis);
SARC	cis	rs4065321	0.522	rs34648856	chr17:38149411	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.39	7.16	0.42	1.02e-11	White blood cell count (basophil);White blood cell count;
SARC	cis	rs2204008	0.806	rs1589382	chr12:38408565	T/A	cg26384229	chr12:38710491	ALG10B	0.83	11.99	0.62	3.98e-26	Bladder cancer;
SARC	cis	rs1153858	1.000	rs66528868	chr15:45668547	A/C	cg03999130	chr15:45571217	NA	0.39	4.98	0.31	1.25e-6	Homoarginine levels;
SARC	cis	rs6582630	0.555	rs2387598	chr12:38510472	G/A	cg13010199	chr12:38710504	ALG10B	-0.71	-9.83	-0.54	2.62e-19	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs11098499	0.754	rs17595608	chr4:120250506	C/T	cg09307838	chr4:120376055	NA	0.83	11.34	0.6	5.05e-24	Corneal astigmatism;
SARC	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg22484793	chr3:52261325	TLR9	0.29	4.77	0.3	3.31e-6	Bipolar disorder;
SARC	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg00990874	chr7:1149470	C7orf50	-0.58	-6.16	-0.37	3.14e-9	Bronchopulmonary dysplasia;
SARC	trans	rs13130787	0.966	rs13105254	chr4:94842776	C/T	cg05263743	chr2:161263709	RBMS1	0.5	6.32	0.38	1.34e-9	Colorectal cancer;
SARC	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg06212747	chr3:49208901	KLHDC8B	0.79	11.58	0.6	8.76e-25	Menarche (age at onset);
SARC	cis	rs9309711	0.689	rs4535075	chr2:3481716	T/C	cg15541040	chr2:3486749	NA	-0.43	-5.76	-0.35	2.6e-8	Neurofibrillary tangles;
SARC	cis	rs9325144	0.600	rs12297194	chr12:38735803	A/G	cg04568710	chr12:38710424	ALG10B	-0.38	-4.72	-0.3	4.08e-6	Morning vs. evening chronotype;
SARC	cis	rs523522	0.962	rs2235218	chr12:120888619	A/C	cg27279351	chr12:120934652	DYNLL1	0.71	8.58	0.49	1.34e-15	High light scatter reticulocyte count;
SARC	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg16606324	chr3:10149918	C3orf24	0.48	5.04	0.31	9.53e-7	Alzheimer's disease;
SARC	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg14784868	chr12:69753453	YEATS4	0.65	9.07	0.51	5.01e-17	Cerebrospinal fluid biomarker levels;
SARC	cis	rs8016982	0.963	rs2099108	chr14:81675420	C/G	cg01989461	chr14:81687754	GTF2A1	0.57	7.17	0.43	9.83e-12	Schizophrenia;
SARC	cis	rs3099143	1.000	rs3110381	chr15:77099665	A/T	cg21673338	chr15:77095150	SCAPER	-0.76	-6.22	-0.38	2.26e-9	Recalcitrant atopic dermatitis;
SARC	cis	rs11105306	1	rs11105306	chr12:89897388	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.52	-5.29	-0.33	2.85e-7	NT-proBNP levels in acute coronary syndrome;
SARC	cis	rs7027203	1.000	rs7864114	chr9:96551954	A/G	cg14598338	chr9:96623480	NA	0.52	6.93	0.41	4.06e-11	DNA methylation (variation);
SARC	cis	rs11098499	0.954	rs28685688	chr4:120420334	T/C	cg24375607	chr4:120327624	NA	0.41	4.86	0.3	2.12e-6	Corneal astigmatism;
SARC	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg04267008	chr7:1944627	MAD1L1	-0.49	-5.66	-0.35	4.49e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs7772486	0.790	rs1133832	chr6:146205604	C/T	cg23711669	chr6:146136114	FBXO30	-0.76	-11.88	-0.61	9.03e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10876993	0.890	rs2619441	chr12:58083015	C/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.39	-4.83	-0.3	2.49e-6	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs7402982	0.625	rs7179841	chr15:99204652	C/T	cg03437748	chr15:99193247	IGF1R	0.63	7.49	0.44	1.43e-12	Birth weight;
SARC	cis	rs11718455	0.921	rs35872933	chr3:44028515	T/G	cg21419209	chr3:44054225	NA	-0.4	-4.79	-0.3	2.99e-6	Coronary artery disease;
SARC	cis	rs6912958	0.500	rs4707352	chr6:87929705	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.75	-10.99	-0.58	6.39e-23	Monocyte percentage of white cells;
SARC	cis	rs6815814	0.950	rs66819621	chr4:38819403	A/G	cg06935464	chr4:38784597	TLR10	0.58	5.73	0.35	3.07e-8	Breast cancer;
SARC	cis	rs9354308	0.838	rs9354305	chr6:66542891	T/C	cg07460842	chr6:66804631	NA	-0.42	-4.85	-0.3	2.27e-6	Metabolite levels;
SARC	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg15595755	chr5:1867978	NA	0.5	6.82	0.41	7.86e-11	Cardiovascular disease risk factors;
SARC	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg24829409	chr8:58192753	C8orf71	-0.57	-5.14	-0.32	5.91e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6570726	0.791	rs9403729	chr6:145907007	C/T	cg23711669	chr6:146136114	FBXO30	0.88	14.74	0.69	3.59e-35	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs981844	0.712	rs62325150	chr4:154728117	T/G	cg14289246	chr4:154710475	SFRP2	0.58	6.64	0.4	2.19e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs11122272	0.735	rs2808580	chr1:231509259	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs7659604	0.728	rs6852923	chr4:122688324	G/A	cg20573242	chr4:122745356	CCNA2	0.5	6.37	0.39	9.81e-10	Type 2 diabetes;
SARC	cis	rs7520050	0.831	rs61783170	chr1:46256329	T/C	cg24296786	chr1:45957014	TESK2	0.39	4.88	0.3	2.01e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs2204008	0.571	rs1117803	chr12:38281007	C/G	cg14851346	chr12:38532713	NA	-0.48	-5.83	-0.36	1.8e-8	Bladder cancer;
SARC	cis	rs765787	0.530	rs4775831	chr15:45534722	A/C	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.67e-7	Uric acid levels;
SARC	cis	rs72627123	0.867	rs73301485	chr14:74468643	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.79	5.97	0.36	8.61e-9	Morning vs. evening chronotype;
SARC	cis	rs898097	0.585	rs9892342	chr17:80893029	C/T	cg20578329	chr17:80767326	TBCD	0.33	4.72	0.3	4.1e-6	Breast cancer;
SARC	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg02725872	chr8:58115012	NA	-0.37	-6.55	-0.39	3.71e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs4423214	0.921	rs11603330	chr11:71153459	C/A	cg05163923	chr11:71159392	DHCR7	0.65	8.67	0.49	7.59e-16	Vitamin D levels;
SARC	cis	rs10911232	0.507	rs10911196	chr1:182995233	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.57	0.57	1.37e-21	Hypertriglyceridemia;
SARC	cis	rs9790314	1.000	rs62279921	chr3:161065441	T/C	cg04691961	chr3:161091175	C3orf57	-0.81	-12.11	-0.62	1.64e-26	Morning vs. evening chronotype;
SARC	cis	rs11190604	1.000	rs2489046	chr10:102346282	A/C	cg14256752	chr10:102295592	HIF1AN	0.41	4.78	0.3	3.15e-6	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg24110177	chr3:50126178	RBM5	0.58	7.91	0.46	1.04e-13	Intelligence (multi-trait analysis);
SARC	trans	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg20587970	chr11:113659929	NA	-0.97	-10.03	-0.55	6.73e-20	Hip circumference adjusted for BMI;
SARC	cis	rs6807306	1.000	rs9818496	chr3:167450310	C/T	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.56	5.48	0.34	1.1e-7	Mean platelet volume;
SARC	cis	rs12142240	0.698	rs10158130	chr1:46822600	T/C	cg00530320	chr1:46809349	NSUN4	0.57	6.79	0.41	9.05e-11	Menopause (age at onset);
SARC	cis	rs3733585	0.673	rs6849729	chr4:9958732	T/C	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.55	-0.34	7.65e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg23422044	chr7:1970798	MAD1L1	-0.45	-4.84	-0.3	2.32e-6	Bipolar disorder;
SARC	cis	rs7512552	0.839	rs486275	chr1:150282784	G/A	cg15654264	chr1:150340011	RPRD2	-0.38	-4.86	-0.3	2.16e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs17030434	0.728	rs16998891	chr4:154646419	T/G	cg14289246	chr4:154710475	SFRP2	-0.66	-6.66	-0.4	1.97e-10	Electrocardiographic conduction measures;
SARC	cis	rs6582630	0.502	rs11182760	chr12:38606273	A/T	cg13010199	chr12:38710504	ALG10B	0.78	10.99	0.58	6.77e-23	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg21775007	chr8:11205619	TDH	-0.41	-5.02	-0.31	1.01e-6	Triglycerides;
SARC	cis	rs1483890	0.642	rs1843050	chr3:69403918	C/T	cg22125112	chr3:69402811	FRMD4B	-0.29	-4.96	-0.31	1.34e-6	Resting heart rate;
SARC	cis	rs76419734	0.558	rs11730082	chr4:106521866	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.67	5.78	0.35	2.34e-8	Post bronchodilator FEV1;
SARC	cis	rs7769051	0.803	rs34334052	chr6:133231829	C/T	cg22852734	chr6:133119734	C6orf192	0.88	7.51	0.44	1.23e-12	Type 2 diabetes nephropathy;
SARC	cis	rs889312	0.961	rs961847	chr5:56041064	C/T	cg14703610	chr5:56206110	C5orf35	0.42	4.96	0.31	1.39e-6	Breast cancer;Breast cancer (early onset);
SARC	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg00149659	chr3:10157352	C3orf10	-1.1	-9.76	-0.54	4.29e-19	Alzheimer's disease;
SARC	cis	rs72945132	0.882	rs2276001	chr11:70181560	T/C	cg05964544	chr11:70165517	PPFIA1	-0.57	-5.52	-0.34	9.07e-8	Coronary artery disease;
SARC	cis	rs6732160	0.932	rs13417029	chr2:73380423	T/G	cg01422370	chr2:73384389	NA	0.3	4.81	0.3	2.74e-6	Intelligence (multi-trait analysis);
SARC	cis	rs1113500	0.897	rs4628530	chr1:108638708	T/G	cg06207961	chr1:108661230	NA	0.44	5.81	0.36	2.02e-8	Growth-regulated protein alpha levels;
SARC	cis	rs910316	1.000	rs175492	chr14:75545220	A/C	cg11812906	chr14:75593930	NEK9	0.81	12.72	0.64	1.65e-28	Height;
SARC	cis	rs11098499	0.865	rs28634456	chr4:120375778	A/G	cg09307838	chr4:120376055	NA	0.89	12.41	0.63	1.71e-27	Corneal astigmatism;
SARC	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg09359103	chr1:154839909	KCNN3	-0.49	-8.19	-0.47	1.68e-14	Prostate cancer;
SARC	cis	rs9894429	0.646	rs8080391	chr17:79566319	A/T	cg18240062	chr17:79603768	NPLOC4	-0.87	-13.6	-0.67	2.06e-31	Eye color traits;
SARC	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.38	-4.78	-0.3	3.08e-6	Lymphocyte counts;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg18126840	chr2:44689831	C2orf34	-0.49	-6.4	-0.39	8.49e-10	Alcohol dependence;
SARC	cis	rs751728	1.000	rs751728	chr6:33764033	C/T	cg15252951	chr6:33757062	LEMD2	0.56	6.58	0.4	3.07e-10	Crohn's disease;
SARC	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg02018176	chr4:1364513	KIAA1530	0.34	5.02	0.31	1.01e-6	Longevity;
SARC	cis	rs7927592	0.673	rs498782	chr11:68275851	A/G	cg01657329	chr11:68192670	LRP5	-0.37	-5.19	-0.32	4.64e-7	Total body bone mineral density;
SARC	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg24209194	chr3:40518798	ZNF619	0.64	7.77	0.45	2.56e-13	Renal cell carcinoma;
SARC	cis	rs9325144	0.534	rs1843866	chr12:38703160	G/T	cg26384229	chr12:38710491	ALG10B	0.59	7.87	0.46	1.33e-13	Morning vs. evening chronotype;
SARC	cis	rs2120243	0.539	rs10936086	chr3:157099859	A/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.38	4.84	0.3	2.38e-6	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs74181299	0.750	rs12472718	chr2:65327620	G/A	cg20592124	chr2:65290738	CEP68	-0.42	-5.87	-0.36	1.49e-8	Pulse pressure;
SARC	cis	rs963731	0.579	rs1377863	chr2:39238854	T/C	cg04010122	chr2:39346883	SOS1	-0.84	-5.27	-0.33	3.06e-7	Corticobasal degeneration;
SARC	cis	rs1448094	0.511	rs17280643	chr12:86210154	C/T	cg00310523	chr12:86230176	RASSF9	-0.3	-4.86	-0.3	2.12e-6	Major depressive disorder;
SARC	cis	rs9527	0.590	rs10786738	chr10:104869451	C/T	cg04362960	chr10:104952993	NT5C2	0.43	4.94	0.31	1.47e-6	Arsenic metabolism;
SARC	cis	rs2425143	1.000	rs4602287	chr20:34368028	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.74	6.35	0.38	1.1e-9	Blood protein levels;
SARC	cis	rs2273669	0.667	rs1424479	chr6:109355790	G/T	cg05315195	chr6:109294784	ARMC2	-0.63	-5.7	-0.35	3.6e-8	Prostate cancer;
SARC	cis	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg18252515	chr7:66147081	NA	-1.38	-12.57	-0.64	5.19e-28	Diabetic kidney disease;
SARC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg06873352	chr17:61820015	STRADA	0.53	6.89	0.41	5.29e-11	Prudent dietary pattern;
SARC	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.22	0.38	2.3e-9	Electroencephalogram traits;
SARC	cis	rs7000551	0.689	rs6993341	chr8:22310933	T/C	cg12081754	chr8:22256438	SLC39A14	0.59	8.34	0.48	6.55e-15	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs367615	0.704	rs7705399	chr5:108850351	G/C	cg17395555	chr5:108820864	NA	0.47	6.77	0.41	1.04e-10	Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs12188164	0.543	rs7728027	chr5:459943	T/C	cg16584290	chr5:462447	EXOC3	0.43	6.61	0.4	2.53e-10	Cystic fibrosis severity;
SARC	cis	rs9733	0.744	rs4970976	chr1:150779524	T/A	cg13175981	chr1:150552382	MCL1	0.61	8.26	0.48	1.12e-14	Tonsillectomy;
SARC	cis	rs201673768	1	rs201673768	chr12:48699606	TGTTTTGTTTTG/T	cg24011408	chr12:48396354	COL2A1	0.5	6.85	0.41	6.37e-11	Platelet count;
SARC	cis	rs2072499	0.966	rs2253677	chr1:156171296	C/G	cg24450063	chr1:156163899	SLC25A44	-1.18	-21.32	-0.81	1.15e-56	Testicular germ cell tumor;
SARC	cis	rs898097	0.845	rs7213006	chr17:80899928	T/C	cg15664640	chr17:80829946	TBCD	0.48	7.63	0.45	5.88e-13	Breast cancer;
SARC	cis	rs11711311	0.955	rs34458493	chr3:113396473	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	7.79	0.45	2.21e-13	IgG glycosylation;
SARC	cis	rs2486288	0.656	rs7166580	chr15:45571209	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.55	-6.87	-0.41	5.78e-11	Glomerular filtration rate;
SARC	cis	rs739401	0.869	rs395188	chr11:3072631	A/G	cg20651018	chr11:3035856	CARS	0.43	6.71	0.4	1.43e-10	Longevity;
SARC	cis	rs10791323	0.536	rs4937842	chr11:133734542	C/G	cg13461336	chr11:133711254	SPATA19	0.29	5.3	0.33	2.71e-7	Childhood ear infection;
SARC	cis	rs6963495	0.818	rs73192125	chr7:105175068	A/C	cg19920283	chr7:105172520	RINT1	0.68	6.0	0.37	7.55e-9	Bipolar disorder (body mass index interaction);
SARC	cis	rs11098499	0.863	rs10030660	chr4:120436704	G/A	cg24375607	chr4:120327624	NA	0.42	4.9	0.31	1.76e-6	Corneal astigmatism;
SARC	cis	rs2834188	1.000	rs2096464	chr21:34686049	G/T	cg04842828	chr21:34696676	IFNAR1	-0.4	-4.72	-0.3	4e-6	Narcolepsy;
SARC	cis	rs3741151	0.773	rs7115055	chr11:73227827	T/C	cg17517138	chr11:73019481	ARHGEF17	0.92	6.86	0.41	6.15e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs986417	1.000	rs8015462	chr14:61046687	G/A	cg27398547	chr14:60952738	C14orf39	0.89	8.5	0.49	2.3e-15	Gut microbiota (bacterial taxa);
SARC	cis	rs4689388	0.926	rs4689391	chr4:6280449	G/A	cg14416269	chr4:6271139	WFS1	0.35	5.47	0.34	1.15e-7	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs10504073	0.584	rs7820270	chr8:49971395	G/T	cg00325661	chr8:49890786	NA	0.52	6.81	0.41	8.45e-11	Blood metabolite ratios;
SARC	cis	rs2239547	0.562	rs2581810	chr3:52960859	C/T	cg22484793	chr3:52261325	TLR9	-0.34	-4.72	-0.3	4.13e-6	Schizophrenia;
SARC	cis	rs9815354	0.680	rs7649989	chr3:41865843	A/C	cg03022575	chr3:42003672	ULK4	0.56	5.29	0.33	2.81e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs1570884	0.516	rs2146144	chr13:50170245	C/T	cg03651054	chr13:50194643	NA	0.32	5.21	0.32	4.22e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	trans	rs9395865	0.520	rs6903708	chr6:53332940	A/G	cg04272052	chr7:99662051	ZNF3;ZSCAN21	0.47	6.24	0.38	2.1e-9	Electroencephalographic traits in alcoholism;
SARC	cis	rs12369635	1.000	rs12369635	chr12:129561356	C/T	cg01909103	chr12:129572610	TMEM132D	-0.71	-6.89	-0.41	5.19e-11	Schizophrenia (inflammation and infection response interaction);
SARC	trans	rs2727020	0.538	rs61885230	chr11:49128958	T/C	cg00717180	chr2:96193071	NA	-0.38	-6.3	-0.38	1.48e-9	Coronary artery disease;
SARC	cis	rs826838	0.616	rs10880738	chr12:38617762	C/T	cg14851346	chr12:38532713	NA	-0.44	-5.32	-0.33	2.39e-7	Heart rate;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg17646610	chr5:121401203	LOX	0.57	8.3	0.48	8.36e-15	Thyroid stimulating hormone;
SARC	cis	rs2153535	0.580	rs1932281	chr6:8473765	A/G	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	cis	rs1348850	0.872	rs13004955	chr2:178398923	A/T	cg23306229	chr2:178417860	TTC30B	-0.51	-5.71	-0.35	3.41e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	13.47	0.66	5.52e-31	Chronic sinus infection;
SARC	cis	rs17030434	1.000	rs75418383	chr4:154719084	A/G	cg14289246	chr4:154710475	SFRP2	-0.76	-7.12	-0.42	1.31e-11	Electrocardiographic conduction measures;
SARC	cis	rs12142240	0.698	rs45517837	chr1:46859225	A/G	cg10495392	chr1:46806563	NSUN4	0.65	6.88	0.41	5.6e-11	Menopause (age at onset);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg27088449	chr22:21272634	CRKL	-0.57	-6.55	-0.39	3.6e-10	Brain volume in infants (cerebrospinal fluid);
SARC	trans	rs7922314	0.557	rs61865713	chr10:64737184	C/T	cg25304107	chr2:177017331	HOXD4	-0.83	-6.46	-0.39	5.88e-10	Cutaneous psoriasis;
SARC	cis	rs7959452	0.535	rs2305641	chr12:69646914	C/T	cg20704777	chr12:70084258	BEST3	-0.31	-4.75	-0.3	3.5e-6	Blood protein levels;
SARC	cis	rs4757645	0.571	rs3781945	chr11:18306272	A/G	cg24872791	chr11:18034920	SERGEF	0.41	5.22	0.32	3.92e-7	Survival in pancreatic cancer;
SARC	cis	rs6831352	0.879	rs2602888	chr4:100041706	C/T	cg13256891	chr4:100009986	ADH5	0.67	8.46	0.48	2.96e-15	Alcohol dependence;
SARC	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9399137	0.507	rs56164974	chr6:135288716	C/T	cg24558204	chr6:135376177	HBS1L	0.62	7.98	0.46	6.83e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs208520	0.690	rs10455595	chr6:66738034	T/C	cg07460842	chr6:66804631	NA	1.04	13.88	0.67	2.45e-32	Exhaled nitric oxide output;
SARC	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg27266027	chr21:40555129	PSMG1	0.51	5.48	0.34	1.1e-7	Cognitive function;
SARC	cis	rs28795989	0.795	rs1878325	chr4:7902838	T/A	cg18538662	chr4:7941764	AFAP1	-0.41	-5.29	-0.33	2.83e-7	Intraocular pressure;
SARC	cis	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg22496380	chr5:211416	CCDC127	-0.88	-9.35	-0.52	7.72e-18	Breast cancer;
SARC	cis	rs9392918	0.934	rs11243202	chr6:7719065	T/C	cg23089261	chr6:7723385	NA	0.37	5.0	0.31	1.15e-6	Height;
SARC	cis	rs6456042	1.000	rs6456042	chr6:166534742	G/T	cg11088901	chr6:166572345	T	0.34	4.84	0.3	2.35e-6	Asthma;
SARC	cis	rs67311347	1.000	rs7612015	chr3:40399974	A/C	cg24209194	chr3:40518798	ZNF619	0.58	7.23	0.43	6.77e-12	Renal cell carcinoma;
SARC	cis	rs735396	1.000	rs2259816	chr12:121435587	A/C	cg25281562	chr12:121454272	C12orf43	-0.51	-6.14	-0.37	3.5e-9	N-glycan levels;
SARC	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg05793240	chr7:2802953	GNA12	-0.36	-5.21	-0.32	4.22e-7	Height;
SARC	cis	rs698813	0.614	rs811494	chr2:44725047	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.55	0.34	7.82e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg08219700	chr8:58056026	NA	0.61	6.36	0.38	1.05e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs950776	0.714	rs660652	chr15:78887832	A/G	cg17108064	chr15:78857060	CHRNA5	-0.3	-5.04	-0.31	9.47e-7	Sudden cardiac arrest;
SARC	cis	rs1348850	0.632	rs13008833	chr2:178514439	G/C	cg22681709	chr2:178499509	PDE11A	-0.42	-5.8	-0.36	2.11e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs36715	1.000	rs40527	chr5:127550252	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	5.84	0.36	1.75e-8	Breast cancer;
SARC	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg07061783	chr6:25882402	NA	-0.42	-5.06	-0.31	8.58e-7	Uric acid levels;
SARC	cis	rs709400	0.628	rs11621510	chr14:103869620	T/C	cg26031613	chr14:104095156	KLC1	0.8	11.43	0.6	2.57e-24	Body mass index;
SARC	cis	rs17376456	0.877	rs9885329	chr5:93380278	G/A	cg25358565	chr5:93447407	FAM172A	1.3	14.36	0.69	6.16e-34	Diabetic retinopathy;
SARC	cis	rs995000	0.839	rs1168028	chr1:62969431	G/A	cg06896770	chr1:63153194	DOCK7	-0.89	-12.99	-0.65	2.12e-29	Triglyceride levels;
SARC	cis	rs79149102	0.579	rs8040961	chr15:75291864	G/A	cg09165964	chr15:75287851	SCAMP5	-0.95	-8.78	-0.5	3.63e-16	Lung cancer;
SARC	cis	rs33912345	0.669	rs1314620	chr14:60877853	A/T	cg27398547	chr14:60952738	C14orf39	-0.39	-4.73	-0.3	3.85e-6	Glaucoma (high intraocular pressure);
SARC	cis	rs2718058	0.589	rs1986618	chr7:37800116	C/G	cg15028436	chr7:37888078	TXNDC3	0.37	4.77	0.3	3.19e-6	Alzheimer's disease (late onset);
SARC	cis	rs57994353	0.600	rs1130640	chr9:139317979	C/T	cg14169450	chr9:139327907	INPP5E	0.45	5.56	0.34	7.44e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg13770153	chr20:60521292	NA	-0.51	-7.02	-0.42	2.39e-11	Body mass index;
SARC	cis	rs765787	0.530	rs12910270	chr15:45512086	G/A	cg21132104	chr15:45694354	SPATA5L1	0.4	4.87	0.3	2.09e-6	Uric acid levels;
SARC	cis	rs9309473	0.687	rs6710659	chr2:73607510	A/G	cg20560298	chr2:73613845	ALMS1	-0.56	-7.16	-0.42	1.03e-11	Metabolite levels;
SARC	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg06636001	chr8:8085503	FLJ10661	0.68	9.04	0.51	6.17e-17	Mood instability;
SARC	cis	rs10876993	0.855	rs1689585	chr12:58080140	A/G	cg18357645	chr12:58087776	OS9	-0.48	-6.31	-0.38	1.37e-9	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs763121	0.853	rs1043441	chr22:39130964	C/T	cg21395723	chr22:39101663	GTPBP1	0.58	6.81	0.41	8.31e-11	Menopause (age at onset);
SARC	cis	rs80130819	0.748	rs1387255	chr12:48648943	C/T	cg05342945	chr12:48394962	COL2A1	-0.56	-5.71	-0.35	3.38e-8	Prostate cancer;
SARC	cis	rs7520050	0.801	rs6703960	chr1:46232723	C/T	cg24296786	chr1:45957014	TESK2	0.43	5.53	0.34	8.71e-8	Red blood cell count;Reticulocyte count;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg14573676	chr9:134954987	MED27	-0.55	-6.67	-0.4	1.89e-10	Fibrinogen levels;
SARC	cis	rs875971	0.964	rs160635	chr7:65528918	T/C	cg18876405	chr7:65276391	NA	0.48	5.96	0.36	9.48e-9	Aortic root size;
SARC	cis	rs2064197	0.564	rs12663319	chr6:9018976	A/T	cg07435756	chr6:8983599	NA	-0.44	-4.79	-0.3	2.95e-6	Glucose homeostasis traits;
SARC	cis	rs17376456	1.000	rs34013242	chr5:93507947	C/T	cg21475434	chr5:93447410	FAM172A	0.92	7.93	0.46	9.34e-14	Diabetic retinopathy;
SARC	cis	rs1348850	0.914	rs7591807	chr2:178252986	A/G	cg23306229	chr2:178417860	TTC30B	0.55	6.34	0.38	1.18e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg11644478	chr21:40555479	PSMG1	1.07	15.38	0.71	2.62e-37	Cognitive function;
SARC	cis	rs911263	0.603	rs2013413	chr14:68805451	C/G	cg18825221	chr14:68749962	RAD51L1	0.42	7.19	0.43	8.6e-12	Primary biliary cholangitis;
SARC	cis	rs17030434	0.834	rs11734251	chr4:154732218	C/T	cg14289246	chr4:154710475	SFRP2	-0.58	-6.51	-0.39	4.46e-10	Electrocardiographic conduction measures;
SARC	cis	rs34172651	0.917	rs1465422	chr16:24772486	C/T	cg06028605	chr16:24865363	SLC5A11	0.27	4.96	0.31	1.34e-6	Intelligence (multi-trait analysis);
SARC	cis	rs17854409	1.000	rs6010770	chr20:61494225	G/T	cg05147244	chr20:61493195	TCFL5	0.82	5.69	0.35	3.71e-8	Obesity-related traits;
SARC	cis	rs2731664	0.721	rs2450333	chr5:176899546	G/A	cg23176889	chr5:176863531	GRK6	-0.59	-8.71	-0.5	5.61e-16	Intelligence (multi-trait analysis);
SARC	cis	rs7786808	0.615	rs1563066	chr7:158194935	A/C	cg01191920	chr7:158217561	PTPRN2	-0.33	-5.62	-0.35	5.41e-8	Obesity-related traits;
SARC	trans	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg06636001	chr8:8085503	FLJ10661	-0.65	-9.12	-0.51	3.61e-17	Neuroticism;
SARC	cis	rs694739	0.541	rs61886926	chr11:64133552	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.66	7.57	0.44	8.82e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs2070488	0.965	rs1984312	chr3:38538466	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.85	-13.14	-0.65	7.26e-30	Electrocardiographic conduction measures;
SARC	cis	rs7043114	0.525	rs6479416	chr9:95053871	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-5.47	-0.34	1.16e-7	Height;
SARC	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg14664628	chr15:75095509	CSK	-0.53	-6.56	-0.39	3.5e-10	Breast cancer;
SARC	cis	rs12681288	0.676	rs2701927	chr8:995886	G/A	cg15309053	chr8:964076	NA	0.46	7.37	0.44	2.87e-12	Schizophrenia;
SARC	cis	rs9787249	0.957	rs41267029	chr1:40214367	A/G	cg24920358	chr1:40204285	PPIE	0.43	5.25	0.33	3.45e-7	Blood protein levels;
SARC	cis	rs4481887	1.000	rs10788781	chr1:248494262	C/T	cg00666640	chr1:248458726	OR2T12	0.4	6.58	0.4	3.1e-10	Common traits (Other);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg04582424	chr1:203764710	ZC3H11A	0.51	6.46	0.39	5.89e-10	Height;
SARC	cis	rs611744	0.967	rs650401	chr8:109196854	C/T	cg21045802	chr8:109455806	TTC35	0.44	5.23	0.32	3.8e-7	Dupuytren's disease;
SARC	cis	rs12472274	0.941	rs2880131	chr2:239089151	A/C	cg17459225	chr2:239074497	NA	0.66	8.45	0.48	3.09e-15	Phospholipid levels (plasma);
SARC	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.51	-4.97	-0.31	1.28e-6	Body mass index;
SARC	trans	rs1814175	0.645	rs866427	chr11:49923853	G/A	cg15704280	chr7:45808275	SEPT13	-0.88	-14.0	-0.68	1.02e-32	Height;
SARC	cis	rs734999	0.505	rs10910108	chr1:2539532	A/G	cg18854424	chr1:2615690	NA	0.32	5.12	0.32	6.25e-7	Ulcerative colitis;
SARC	cis	rs10499694	0.933	rs11575334	chr7:50597301	G/A	cg19499709	chr7:50660583	GRB10	-0.35	-4.77	-0.3	3.28e-6	Body mass index;
SARC	cis	rs9549260	0.569	rs73174811	chr13:41315998	T/G	cg21288729	chr13:41239152	FOXO1	0.54	4.82	0.3	2.64e-6	Red blood cell count;
SARC	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg17376030	chr22:41985996	PMM1	-0.74	-9.4	-0.52	5.48e-18	Vitiligo;
SARC	cis	rs2814982	0.605	rs75152896	chr6:34477793	G/A	cg14254433	chr6:34482411	PACSIN1	-0.51	-4.89	-0.31	1.89e-6	Cholesterol, total;Total cholesterol levels;
SARC	cis	rs2838344	0.776	rs2298561	chr21:45085234	A/G	cg01579765	chr21:45077557	HSF2BP	-0.38	-6.2	-0.38	2.51e-9	Coronary artery disease;
SARC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg09436375	chr6:42928200	GNMT	-0.36	-5.7	-0.35	3.52e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs644799	0.932	rs572015	chr11:95637416	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.67	8.54	0.49	1.8e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs61931739	0.500	rs11053218	chr12:34474792	A/C	cg13010199	chr12:38710504	ALG10B	-0.74	-9.47	-0.53	3.35e-18	Morning vs. evening chronotype;
SARC	cis	rs1008375	1.000	rs1121091	chr4:17676386	A/C	cg27347728	chr4:17578864	LAP3	0.45	5.54	0.34	8.23e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs963731	0.649	rs2168044	chr2:39206386	G/A	cg04010122	chr2:39346883	SOS1	-0.9	-5.09	-0.32	7.27e-7	Corticobasal degeneration;
SARC	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.8	11.98	0.62	4.34e-26	Menarche (age at onset);
SARC	cis	rs6835098	0.924	rs1991727	chr4:174163169	A/G	cg08422745	chr4:174089978	GALNT7	-0.65	-8.63	-0.49	9.55e-16	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg05313129	chr8:58192883	C8orf71	-0.57	-6.36	-0.38	1.04e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9291683	0.546	rs4529049	chr4:10045389	C/T	cg11266682	chr4:10021025	SLC2A9	0.4	6.91	0.41	4.53e-11	Bone mineral density;
SARC	cis	rs739401	0.611	rs7130841	chr11:3043658	A/G	cg25174290	chr11:3078921	CARS	0.59	8.3	0.48	8.25e-15	Longevity;
SARC	cis	rs7681440	0.904	rs2870029	chr4:90772057	G/T	cg06632027	chr4:90757378	SNCA	0.4	5.68	0.35	3.9e-8	Dementia with Lewy bodies;
SARC	trans	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg06437703	chr8:37914619	EIF4EBP1	-0.65	-8.6	-0.49	1.21e-15	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg00409905	chr10:38381863	ZNF37A	-0.58	-8.24	-0.48	1.22e-14	Extrinsic epigenetic age acceleration;
SARC	cis	rs7980687	0.550	rs1727324	chr12:123698603	A/T	cg00376283	chr12:123451042	ABCB9	0.57	5.59	0.34	6.45e-8	Height;Educational attainment;Head circumference (infant);
SARC	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg11890956	chr21:40555474	PSMG1	-0.68	-8.88	-0.5	1.81e-16	Menarche (age at onset);
SARC	cis	rs6500602	0.727	rs11076837	chr16:4569440	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.29	4.77	0.3	3.18e-6	Schizophrenia;
SARC	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg00933542	chr6:150070202	PCMT1	0.31	5.29	0.33	2.86e-7	Lung cancer;
SARC	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.75	7.54	0.44	1.06e-12	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg22535103	chr8:58192502	C8orf71	-0.59	-6.21	-0.38	2.35e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs1814175	0.817	rs6486046	chr11:49997017	T/C	cg15704280	chr7:45808275	SEPT13	-0.97	-18.54	-0.77	9.52e-48	Height;
SARC	cis	rs12477438	0.539	rs720228	chr2:99704547	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	15.29	0.71	5.01e-37	Chronic sinus infection;
SARC	cis	rs832540	0.656	rs832573	chr5:56159578	T/C	cg22800045	chr5:56110881	MAP3K1	0.4	4.88	0.3	1.99e-6	Coronary artery disease;
SARC	cis	rs1008375	0.932	rs4698630	chr4:17614692	C/G	cg27347728	chr4:17578864	LAP3	0.45	5.49	0.34	1.02e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2921073	0.604	rs2979140	chr8:8267202	T/A	cg08975724	chr8:8085496	FLJ10661	0.46	5.32	0.33	2.44e-7	Parkinson's disease;
SARC	cis	rs3087591	1.000	rs7226006	chr17:29650656	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.46	-5.7	-0.35	3.55e-8	Hip circumference;
SARC	cis	rs3772130	0.624	rs56382357	chr3:121452339	T/C	cg20356878	chr3:121714668	ILDR1	0.39	6.06	0.37	5.39e-9	Cognitive performance;
SARC	cis	rs4481887	0.893	rs10888337	chr1:248428227	A/G	cg00666640	chr1:248458726	OR2T12	-0.31	-4.99	-0.31	1.16e-6	Common traits (Other);
SARC	cis	rs8005677	1.000	rs10148215	chr14:23382345	C/T	cg01529538	chr14:23388837	RBM23	0.48	6.01	0.37	7.21e-9	Cognitive ability (multi-trait analysis);
SARC	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg25072359	chr17:41440525	NA	-0.45	-5.27	-0.33	3.1e-7	Menopause (age at onset);
SARC	cis	rs7523050	0.643	rs67091034	chr1:109402567	C/G	cg08274380	chr1:109419600	GPSM2	1.02	7.68	0.45	4.37e-13	Fat distribution (HIV);
SARC	cis	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.83	-0.41	7.46e-11	Neuroticism;
SARC	cis	rs858239	0.600	rs6967419	chr7:23136310	C/T	cg23682824	chr7:23144976	KLHL7	0.7	9.38	0.52	5.93e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg03806693	chr22:41940476	POLR3H	0.87	11.88	0.61	9.02e-26	Vitiligo;
SARC	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg13939156	chr17:80058883	NA	-0.41	-6.33	-0.38	1.27e-9	Life satisfaction;
SARC	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg22968622	chr17:43663579	NA	0.84	10.13	0.55	3.19e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs1034435	0.755	rs6007869	chr22:48894213	A/G	cg05992904	chr22:48892994	FAM19A5	-0.48	-7.08	-0.42	1.73e-11	Late-onset Alzheimer's disease;
SARC	cis	rs9399137	0.507	rs11753673	chr6:135316476	T/C	cg24558204	chr6:135376177	HBS1L	0.61	7.94	0.46	8.39e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs1008375	0.900	rs13144986	chr4:17675019	C/A	cg16339924	chr4:17578868	LAP3	-0.64	-7.98	-0.46	6.57e-14	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1387259	0.929	rs2634666	chr12:48663670	G/T	cg24011408	chr12:48396354	COL2A1	0.46	5.44	0.34	1.32e-7	Obstructive sleep apnea trait (apnea hypopnea index);
SARC	cis	rs9914544	0.545	rs8071783	chr17:18807939	C/G	cg25390199	chr17:18761479	PRPSAP2	0.45	5.86	0.36	1.53e-8	Educational attainment (years of education);
SARC	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.1	21.57	0.82	1.82e-57	Chronic sinus infection;
SARC	cis	rs4073582	0.595	rs555360	chr11:65960061	T/C	cg14036092	chr11:66035641	RAB1B	-0.59	-8.32	-0.48	7.43e-15	Gout;
SARC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg01238044	chr22:24384105	GSTT1	-0.64	-7.91	-0.46	1.06e-13	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs314370	0.621	rs314312	chr7:100422642	G/C	cg10426581	chr7:100472382	SRRT	0.41	5.09	0.32	7.46e-7	Resting heart rate;
SARC	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7264396	0.563	rs2425122	chr20:34328848	C/T	cg01084648	chr20:34329383	RBM39	0.59	5.14	0.32	5.69e-7	Total cholesterol levels;
SARC	cis	rs9814567	0.806	rs7648616	chr3:134318074	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.51	-6.63	-0.4	2.36e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs7615952	0.866	rs6438949	chr3:125650064	G/C	cg05084668	chr3:125655381	ALG1L	-0.68	-6.98	-0.42	3.04e-11	Blood pressure (smoking interaction);
SARC	cis	rs2120243	0.508	rs4435581	chr3:157096217	G/A	cg01018701	chr3:157155998	VEPH1;PTX3	0.39	4.9	0.31	1.78e-6	Hepatocellular carcinoma in hepatitis B infection;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg14991984	chr1:99470129	LPPR5	-0.7	-6.37	-0.39	1.01e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs10504229	0.679	rs16921623	chr8:58039473	G/C	cg20607798	chr8:58055168	NA	0.58	5.24	0.32	3.58e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6500395	0.554	rs2355302	chr16:48738428	C/T	cg04672837	chr16:48644449	N4BP1	0.41	4.72	0.3	4.07e-6	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs6558174	0.965	rs2404655	chr8:22490209	T/C	cg03733263	chr8:22462867	KIAA1967	0.53	6.35	0.38	1.09e-9	Breast cancer;
SARC	cis	rs7726839	0.540	rs61731455	chr5:665295	A/G	cg14541582	chr5:601475	NA	-0.42	-5.06	-0.31	8.69e-7	Obesity-related traits;
SARC	cis	rs1707322	0.717	rs2991988	chr1:46082431	C/A	cg03146154	chr1:46216737	IPP	-0.52	-6.21	-0.38	2.48e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs11165623	0.585	rs55896436	chr1:96994162	G/A	cg10631902	chr5:14652156	NA	-0.42	-6.38	-0.39	9.27e-10	Hip circumference;Waist circumference;
SARC	cis	rs820218	0.886	rs10814	chr17:73616920	A/G	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.57	7.16	0.42	1.06e-11	Rotator cuff tears;
SARC	cis	rs10214930	0.671	rs7799957	chr7:27882260	A/G	cg05786569	chr7:27702416	HIBADH	0.45	4.88	0.3	2e-6	Hypospadias;
SARC	cis	rs1348850	0.574	rs10195917	chr2:178443121	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.47	4.89	0.31	1.85e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs4775413	0.619	rs11857462	chr15:61856011	A/T	cg08099431	chr15:61346347	RORA	-0.4	-4.99	-0.31	1.21e-6	Schizophrenia;
SARC	trans	rs61931739	0.517	rs11053063	chr12:34181011	C/T	cg13010199	chr12:38710504	ALG10B	0.73	9.71	0.54	6.21e-19	Morning vs. evening chronotype;
SARC	cis	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.69	-0.4	1.61e-10	Joint mobility (Beighton score);
SARC	cis	rs412050	0.696	rs56226933	chr22:22339901	C/T	cg17089214	chr22:22089827	YPEL1	0.66	6.11	0.37	4.1e-9	Attention deficit hyperactivity disorder;
SARC	cis	rs6570726	0.935	rs409725	chr6:145840340	G/A	cg05347473	chr6:146136440	FBXO30	0.48	6.42	0.39	7.51e-10	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg12541626	chr19:47217900	PRKD2	-0.48	-6.23	-0.38	2.12e-9	Thyroid cancer;
SARC	cis	rs9487051	0.676	rs7773775	chr6:109600339	T/C	cg01475377	chr6:109611718	NA	-0.35	-5.16	-0.32	5.41e-7	Reticulocyte fraction of red cells;
SARC	cis	rs12142240	0.667	rs45524035	chr1:46862780	C/T	cg10495392	chr1:46806563	NSUN4	0.65	6.93	0.41	4.14e-11	Menopause (age at onset);
SARC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg26338869	chr17:61819248	STRADA	0.82	10.83	0.58	2.09e-22	Prudent dietary pattern;
SARC	cis	rs933688	1.000	rs10058025	chr5:90689052	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.01	12.94	0.65	3.09e-29	Smoking behavior;
SARC	cis	rs939574	1.000	rs939574	chr2:220118531	G/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.56	-5.26	-0.33	3.21e-7	Platelet distribution width;
SARC	cis	rs1395	0.778	rs11693660	chr2:27468856	T/C	cg21747090	chr2:27597821	SNX17	-0.5	-5.95	-0.36	1e-8	Blood metabolite levels;
SARC	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg06028605	chr16:24865363	SLC5A11	0.36	5.59	0.34	6.36e-8	Intelligence (multi-trait analysis);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg15057373	chr2:187600566	FAM171B	0.4	6.31	0.38	1.39e-9	Thyroid stimulating hormone;
SARC	cis	rs908922	0.627	rs11590073	chr1:152500810	C/T	cg09873164	chr1:152488093	CRCT1	0.63	8.0	0.46	5.68e-14	Hair morphology;
SARC	cis	rs5753618	0.509	rs5997912	chr22:31593861	A/G	cg07713946	chr22:31675144	LIMK2	-0.38	-5.29	-0.33	2.76e-7	Colorectal cancer;
SARC	cis	rs4664308	0.935	rs6739867	chr2:160942818	G/A	cg03641300	chr2:160917029	PLA2R1	-0.71	-9.8	-0.54	3.36e-19	Idiopathic membranous nephropathy;
SARC	cis	rs13401104	0.796	rs10929172	chr2:237116600	C/G	cg19324714	chr2:237145437	ASB18	0.56	5.44	0.34	1.36e-7	Educational attainment;
SARC	cis	rs372883	0.563	rs1153293	chr21:30691325	C/T	cg24692254	chr21:30365293	RNF160	0.67	8.74	0.5	4.76e-16	Pancreatic cancer;
SARC	cis	rs7300001	0.510	rs73205064	chr12:110512546	A/G	cg08946844	chr12:110511112	NA	0.63	5.01	0.31	1.07e-6	Headache;
SARC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.33	-4.79	-0.3	2.95e-6	Lymphocyte counts;
SARC	cis	rs4728302	0.583	rs58955798	chr7:133158420	C/T	cg10665199	chr7:133106180	EXOC4	0.4	5.16	0.32	5.21e-7	Intelligence;Intelligence (multi-trait analysis);
SARC	cis	rs1023500	0.596	rs5751209	chr22:42451603	A/G	cg04733989	chr22:42467013	NAGA	0.73	9.89	0.54	1.73e-19	Schizophrenia;
SARC	cis	rs4718428	0.705	rs62465692	chr7:66295745	T/C	cg18252515	chr7:66147081	NA	-0.58	-6.4	-0.39	8.42e-10	Corneal structure;
SARC	cis	rs2204008	0.744	rs11182316	chr12:38499552	G/A	cg13010199	chr12:38710504	ALG10B	0.77	10.44	0.56	3.55e-21	Bladder cancer;
SARC	cis	rs796364	1.000	rs11680723	chr2:200810957	C/G	cg23649088	chr2:200775458	C2orf69	-0.58	-4.91	-0.31	1.71e-6	Schizophrenia;
SARC	cis	rs17345786	0.861	rs11711808	chr3:101235101	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.45	-4.87	-0.3	2.06e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg02733842	chr7:1102375	C7orf50	-0.62	-7.21	-0.43	7.71e-12	Bronchopulmonary dysplasia;
SARC	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg03264133	chr6:25882463	NA	-0.48	-6.26	-0.38	1.81e-9	Blood metabolite levels;
SARC	cis	rs2250402	0.510	rs2898984	chr15:40324075	G/C	cg20255370	chr15:40268687	EIF2AK4	-0.69	-5.73	-0.35	3.07e-8	Corneal curvature;
SARC	cis	rs7937682	0.737	rs518294	chr11:111424716	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.68	-9.78	-0.54	3.87e-19	Primary sclerosing cholangitis;
SARC	cis	rs7681440	0.801	rs1372513	chr4:90790237	G/A	cg01966878	chr4:90757139	SNCA	-0.37	-4.87	-0.3	2.11e-6	Dementia with Lewy bodies;
SARC	cis	rs3768617	0.811	rs12138053	chr1:182979560	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.64	8.73	0.5	4.86e-16	Fuchs's corneal dystrophy;
SARC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg13397359	chr6:42928475	GNMT	0.59	8.07	0.47	3.66e-14	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs11785400	0.701	rs9297967	chr8:143723002	A/C	cg24634471	chr8:143751801	JRK	0.6	7.85	0.46	1.51e-13	Schizophrenia;
SARC	cis	rs6665290	0.935	rs6704144	chr1:227201030	C/G	cg10327440	chr1:227177885	CDC42BPA	-0.91	-15.39	-0.71	2.37e-37	Myeloid white cell count;
SARC	cis	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg07777115	chr5:623756	CEP72	-0.62	-5.56	-0.34	7.5e-8	Obesity-related traits;
SARC	cis	rs4906332	1.000	rs8012127	chr14:103942762	G/A	cg26031613	chr14:104095156	KLC1	-0.49	-5.74	-0.35	2.94e-8	Coronary artery disease;
SARC	cis	rs854765	0.583	rs67253360	chr17:17828973	T/C	cg04398451	chr17:18023971	MYO15A	-0.39	-5.53	-0.34	8.65e-8	Total body bone mineral density;
SARC	cis	rs9611519	0.894	rs4821990	chr22:41438710	A/C	cg17376030	chr22:41985996	PMM1	0.48	5.97	0.36	8.99e-9	Neuroticism;
SARC	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg07701084	chr6:150067640	NUP43	0.42	5.56	0.34	7.3900000000000007e-08	Lung cancer;
SARC	cis	rs1003719	0.715	rs8130643	chr21:38551715	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.25	-0.52	1.49e-17	Eye color traits;
SARC	cis	rs17376456	0.825	rs13164315	chr5:93147421	A/G	cg25358565	chr5:93447407	FAM172A	1.2	12.15	0.62	1.23e-26	Diabetic retinopathy;
SARC	cis	rs933688	1.000	rs10058025	chr5:90689052	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.07	13.53	0.66	3.66e-31	Smoking behavior;
SARC	cis	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg15556689	chr8:8085844	FLJ10661	0.41	5.34	0.33	2.23e-7	Joint mobility (Beighton score);
SARC	cis	rs4919694	0.611	rs7091462	chr10:104948615	C/T	cg04362960	chr10:104952993	NT5C2	0.61	5.58	0.34	6.57e-8	Arsenic metabolism;
SARC	cis	rs4906332	1.000	rs3783400	chr14:103967045	G/A	cg26031613	chr14:104095156	KLC1	-0.49	-5.47	-0.34	1.14e-7	Coronary artery disease;
SARC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg03541381	chr16:790595	NARFL	0.57	6.63	0.4	2.33e-10	Myopia (pathological);
SARC	cis	rs1580019	0.563	rs896137	chr7:32579345	G/T	cg14728415	chr7:32535168	LSM5;AVL9	0.48	5.96	0.36	9.5e-9	Cognitive ability;
SARC	cis	rs7246657	0.891	rs7253114	chr19:37988725	G/A	cg23950597	chr19:37808831	NA	-0.55	-5.38	-0.33	1.77e-7	Coronary artery calcification;
SARC	cis	rs2153535	0.601	rs718504	chr6:8527512	A/G	cg21535247	chr6:8435926	SLC35B3	0.51	6.48	0.39	5.5e-10	Motion sickness;
SARC	trans	rs7824557	0.583	rs2736306	chr8:11239762	A/T	cg06636001	chr8:8085503	FLJ10661	0.61	8.01	0.46	5.64e-14	Retinal vascular caliber;
SARC	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg06618935	chr21:46677482	NA	-0.41	-5.52	-0.34	8.92e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	11.31	0.6	6.28e-24	Alzheimer's disease;
SARC	cis	rs17376456	0.877	rs10061080	chr5:93420559	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.58	5.39	0.33	1.74e-7	Diabetic retinopathy;
SARC	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg09359103	chr1:154839909	KCNN3	-0.38	-5.98	-0.36	8.52e-9	Prostate cancer;
SARC	cis	rs6665290	0.935	rs1929863	chr1:227195728	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.09	-25.43	-0.86	3.74e-69	Myeloid white cell count;
SARC	cis	rs57994353	0.802	rs12002854	chr9:139377499	G/A	cg14169450	chr9:139327907	INPP5E	0.42	5.35	0.33	2.1e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs7772486	0.686	rs9403741	chr6:146030548	G/A	cg23711669	chr6:146136114	FBXO30	-0.79	-12.51	-0.63	8.23e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9640161	0.673	rs11773351	chr7:150030963	T/C	cg21361702	chr7:150065534	REPIN1	0.54	5.25	0.33	3.49e-7	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs3126085	0.935	rs4634913	chr1:152249932	T/C	cg03465714	chr1:152285911	FLG	-0.46	-5.55	-0.34	7.61e-8	Atopic dermatitis;
SARC	cis	rs888194	0.934	rs12314392	chr12:110010866	A/G	cg13986417	chr12:110012484	MVK;MMAB	-0.34	-5.12	-0.32	6.42e-7	Neuroticism;
SARC	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg11987759	chr7:65425863	GUSB	-0.48	-6.14	-0.37	3.61e-9	Aortic root size;
SARC	cis	rs2952156	0.684	rs11658786	chr17:37815899	G/A	cg20243544	chr17:37824526	PNMT	0.62	8.23	0.47	1.32e-14	Asthma;
SARC	cis	rs2412459	0.536	rs7173301	chr15:40269843	C/T	cg22077389	chr15:40226273	EIF2AK4	0.56	4.9	0.31	1.78e-6	Response to haloperidol in psychosis;
SARC	cis	rs921968	0.565	rs6436069	chr2:219597185	T/C	cg02176678	chr2:219576539	TTLL4	-0.34	-5.14	-0.32	5.79e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs10046574	0.831	rs56285116	chr7:135164950	C/T	cg27474649	chr7:135195673	CNOT4	0.87	7.13	0.42	1.27e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs9902453	1.000	rs62070312	chr17:28438877	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	6.66	0.4	1.97e-10	Coffee consumption (cups per day);
SARC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg07167872	chr1:205819463	PM20D1	-0.63	-10.33	-0.56	7.65e-21	Monocyte percentage of white cells;
SARC	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg11987759	chr7:65425863	GUSB	0.58	7.64	0.45	5.63e-13	Aortic root size;
SARC	cis	rs76419734	0.510	rs2544402	chr4:106687733	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	-0.72	-7.48	-0.44	1.53e-12	Post bronchodilator FEV1;
SARC	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.46	-5.77	-0.35	2.51e-8	Lymphocyte counts;
SARC	cis	rs9398803	0.713	rs4621656	chr6:126896168	G/C	cg20229609	chr6:126660872	C6orf173	0.37	5.38	0.33	1.8e-7	Male-pattern baldness;
SARC	cis	rs7582180	0.629	rs11685250	chr2:100955137	C/T	cg14675211	chr2:100938903	LONRF2	0.51	7.5	0.44	1.37e-12	Intelligence (multi-trait analysis);
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg24598330	chr12:95467350	NR2C1	-0.49	-6.53	-0.39	4.05e-10	Neuroticism;
SARC	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg05313129	chr8:58192883	C8orf71	-0.51	-5.87	-0.36	1.46e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs12421382	0.659	rs12420684	chr11:109391788	T/C	cg16359550	chr11:109292809	C11orf87	0.38	5.6	0.34	5.95e-8	Schizophrenia;
SARC	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg13628971	chr7:2884303	GNA12	-0.54	-6.41	-0.39	8.03e-10	Height;
SARC	cis	rs6831352	0.918	rs17218560	chr4:100060794	C/T	cg12011299	chr4:100065546	ADH4	0.33	5.42	0.33	1.51e-7	Alcohol dependence;
SARC	cis	rs7312774	0.618	rs4964195	chr12:107392778	T/C	cg16260113	chr12:107380972	MTERFD3	0.78	6.04	0.37	5.92e-9	Severe influenza A (H1N1) infection;
SARC	cis	rs1018836	0.892	rs4735210	chr8:91549399	G/T	cg16814680	chr8:91681699	NA	-0.71	-11.17	-0.59	1.78e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs3087591	0.762	rs7502029	chr17:29590791	T/A	cg24425628	chr17:29625626	OMG;NF1	0.51	6.18	0.38	2.9e-9	Hip circumference;
SARC	cis	rs2153535	0.580	rs915352	chr6:8442766	G/A	cg21535247	chr6:8435926	SLC35B3	0.56	7.01	0.42	2.6e-11	Motion sickness;
SARC	cis	rs10979	1.000	rs12215667	chr6:143893213	T/C	cg25407410	chr6:143891975	LOC285740	-0.64	-8.72	-0.5	5.26e-16	Hypospadias;
SARC	cis	rs9436747	0.641	rs1938486	chr1:66047125	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.48	4.94	0.31	1.48e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs9457247	1.000	rs422562	chr6:167406318	A/G	cg23791538	chr6:167370224	RNASET2	-0.64	-8.83	-0.5	2.49e-16	Crohn's disease;
SARC	cis	rs4481887	0.927	rs4292985	chr1:248473692	T/A	cg13385794	chr1:248469461	NA	0.35	5.51	0.34	9.64e-8	Common traits (Other);
SARC	cis	rs12586317	0.553	rs78124218	chr14:35570606	G/A	cg16230307	chr14:35515116	FAM177A1	0.91	10.73	0.58	4.26e-22	Psoriasis;
SARC	cis	rs274567	0.501	rs272856	chr5:131687081	G/C	cg04518342	chr5:131593106	PDLIM4	0.42	5.29	0.33	2.88e-7	Blood metabolite levels;
SARC	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg11987759	chr7:65425863	GUSB	-0.47	-6.27	-0.38	1.7e-9	Aortic root size;
SARC	cis	rs4073582	0.595	rs3016319	chr11:65981846	C/T	cg14036092	chr11:66035641	RAB1B	0.61	8.57	0.49	1.43e-15	Gout;
SARC	cis	rs7674212	0.541	rs2615539	chr4:104081106	C/G	cg16532752	chr4:104119610	CENPE	-0.47	-5.87	-0.36	1.47e-8	Type 2 diabetes;
SARC	cis	rs3784262	0.669	rs2414530	chr15:58356362	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.35	-5.21	-0.32	4.12e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs6933660	0.744	rs3800279	chr6:151766162	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.59	7.35	0.43	3.27e-12	Menarche (age at onset);
SARC	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg12463550	chr7:65579703	CRCP	0.48	5.79	0.35	2.23e-8	Aortic root size;
SARC	cis	rs7582720	0.806	rs72926770	chr2:203798585	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.21	0.43	7.78e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs67460515	0.892	rs34896809	chr3:161059804	C/T	cg03342759	chr3:160939853	NMD3	-0.67	-8.73	-0.5	4.99e-16	Parkinson's disease;
SARC	cis	rs10791097	0.694	rs2155750	chr11:130751261	A/C	cg12179176	chr11:130786555	SNX19	0.75	11.27	0.59	8.47e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	trans	rs1865760	0.929	rs9461224	chr6:25936402	G/T	cg24899068	chr19:49999470	RPS11	-0.55	-6.59	-0.4	2.85e-10	Height;
SARC	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg27121462	chr16:89883253	FANCA	-0.68	-10.69	-0.57	5.84e-22	Vitiligo;
SARC	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg07701084	chr6:150067640	NUP43	0.38	4.93	0.31	1.55e-6	Lung cancer;
SARC	cis	rs2276314	1.000	rs9956938	chr18:33567061	A/G	cg19628046	chr18:33552617	C18orf21	0.6	6.43	0.39	7.24e-10	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs11190604	0.673	rs10883498	chr10:102228709	T/A	cg07080220	chr10:102295463	HIF1AN	0.76	9.07	0.51	5.2e-17	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs9818758	0.607	rs35108630	chr3:49088356	T/A	cg07636037	chr3:49044803	WDR6	-0.78	-6.72	-0.4	1.37e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs4319547	0.910	rs6416298	chr12:123002143	C/T	cg23029597	chr12:123009494	RSRC2	-0.44	-5.26	-0.33	3.3e-7	Body mass index;
SARC	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg08280861	chr8:58055591	NA	-0.61	-5.9	-0.36	1.25e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs427394	0.659	rs274693	chr5:6734162	G/A	cg10857441	chr5:6722123	POLS	-0.33	-4.88	-0.3	1.95e-6	Menopause (age at onset);
SARC	cis	rs765787	0.530	rs2413786	chr15:45525394	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.41	-5.1	-0.32	7.12e-7	Uric acid levels;
SARC	cis	rs6696846	0.716	rs6593921	chr1:205062861	A/G	cg21643547	chr1:205240462	TMCC2	-0.57	-7.37	-0.43	3.01e-12	Red blood cell count;
SARC	cis	rs12908161	0.920	rs35758837	chr15:85311382	C/T	cg17507749	chr15:85114479	UBE2QP1	0.54	6.2	0.38	2.61e-9	Schizophrenia;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg14444244	chr2:172270326	METTL8	0.51	7.06	0.42	1.88e-11	Thyroid stimulating hormone;
SARC	cis	rs12545912	0.909	rs11249931	chr8:9475299	T/A	cg21625330	chr8:9911636	MSRA	0.5	4.81	0.3	2.66e-6	Multiple myeloma (hyperdiploidy);
SARC	cis	rs10078	0.571	rs2721028	chr5:443849	A/G	cg07599136	chr5:415885	AHRR	0.64	5.58	0.34	6.62e-8	Fat distribution (HIV);
SARC	cis	rs6582630	0.504	rs4882367	chr12:38330878	A/T	cg13010199	chr12:38710504	ALG10B	-0.51	-6.08	-0.37	4.95e-9	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg03161606	chr19:29218774	NA	0.47	6.75	0.4	1.16e-10	Methadone dose in opioid dependence;
SARC	cis	rs6831352	0.918	rs2602893	chr4:100044095	G/T	cg12011299	chr4:100065546	ADH4	0.34	5.61	0.35	5.65e-8	Alcohol dependence;
SARC	cis	rs1153858	0.723	rs4580098	chr15:45596909	T/A	cg15395560	chr15:45543142	SLC28A2	-0.29	-5.19	-0.32	4.6e-7	Homoarginine levels;
SARC	cis	rs6860806	0.507	rs273901	chr5:131694360	G/T	cg12564285	chr5:131593104	PDLIM4	0.46	6.23	0.38	2.15e-9	Breast cancer;
SARC	cis	rs295137	0.725	rs1729413	chr2:201086663	T/G	cg23649088	chr2:200775458	C2orf69	0.44	5.97	0.36	8.89e-9	Asthma (bronchodilator response);
SARC	cis	rs73206853	0.841	rs4131850	chr12:110812553	G/A	cg10860002	chr12:110842031	ANAPC7	0.63	5.03	0.31	9.95e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	trans	rs11098499	0.955	rs1551	chr4:120158500	T/G	cg25214090	chr10:38739885	LOC399744	0.53	6.9	0.41	4.97e-11	Corneal astigmatism;
SARC	cis	rs4642101	0.824	rs3889515	chr3:12844112	G/C	cg05775895	chr3:12838266	CAND2	0.74	12.05	0.62	2.69e-26	QRS complex (12-leadsum);
SARC	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg18404041	chr3:52824283	ITIH1	-0.44	-6.59	-0.4	2.82e-10	Bipolar disorder;
SARC	cis	rs72781680	0.611	rs2303287	chr2:24302246	A/G	cg06627628	chr2:24431161	ITSN2	0.61	6.43	0.39	7.33e-10	Lymphocyte counts;
SARC	cis	rs9911578	0.839	rs1871751	chr17:57190368	A/G	cg12560992	chr17:57184187	TRIM37	0.82	11.72	0.61	3.1e-25	Intelligence (multi-trait analysis);
SARC	cis	rs36051895	0.632	rs10974969	chr9:5125336	G/A	cg02405213	chr9:5042618	JAK2	-0.42	-4.98	-0.31	1.24e-6	Pediatric autoimmune diseases;
SARC	cis	rs2832191	1.000	rs6516891	chr21:30483070	C/T	cg24692254	chr21:30365293	RNF160	-0.77	-10.73	-0.58	4.22e-22	Dental caries;
SARC	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-8.98	-0.51	9.19e-17	Alzheimer's disease;
SARC	cis	rs1395	0.778	rs4665959	chr2:27443256	C/T	cg21747090	chr2:27597821	SNX17	-0.51	-6.07	-0.37	5.27e-9	Blood metabolite levels;
SARC	cis	rs2153535	1.000	rs11243251	chr6:8368207	G/A	cg23788917	chr6:8435910	SLC35B3	-0.44	-5.36	-0.33	2.04e-7	Motion sickness;
SARC	cis	rs7223966	1.000	rs8077265	chr17:61732727	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.46	-4.98	-0.31	1.24e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs3781913	0.874	rs2035467	chr11:72375142	T/C	cg03713592	chr11:72463424	ARAP1	-0.41	-5.07	-0.32	8.09e-7	Rheumatoid arthritis;
SARC	cis	rs870825	0.655	rs35397385	chr4:185639095	C/T	cg04058563	chr4:185651563	MLF1IP	0.81	11.3	0.6	6.58e-24	Blood protein levels;
SARC	cis	rs1559088	0.847	rs2287680	chr19:33608566	A/G	cg27124370	chr19:33622961	WDR88	-0.42	-5.56	-0.34	7.32e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs356220	0.642	rs2572322	chr4:90634546	G/C	cg06632027	chr4:90757378	SNCA	0.38	4.91	0.31	1.73e-6	Parkinson's disease;
SARC	cis	rs10791323	0.627	rs2723614	chr11:133705871	T/G	cg14349672	chr11:133703707	NA	-0.41	-5.88	-0.36	1.43e-8	Childhood ear infection;
SARC	cis	rs6831352	1.000	rs6532798	chr4:100054827	C/T	cg13256891	chr4:100009986	ADH5	0.65	8.65	0.49	8.37e-16	Alcohol dependence;
SARC	cis	rs2153535	0.542	rs915353	chr6:8440370	A/G	cg07606381	chr6:8435919	SLC35B3	0.78	10.77	0.58	3.25e-22	Motion sickness;
SARC	cis	rs4481887	0.927	rs10888340	chr1:248440381	C/T	cg01631408	chr1:248437212	OR2T33	-0.42	-5.2	-0.32	4.29e-7	Common traits (Other);
SARC	cis	rs2576037	0.763	rs2060418	chr18:44576535	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.5	6.58	0.4	3.02e-10	Personality dimensions;
SARC	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg23758822	chr17:41437982	NA	0.9	11.32	0.6	5.9e-24	Menopause (age at onset);
SARC	cis	rs6570726	0.846	rs453834	chr6:145886261	T/C	cg05347473	chr6:146136440	FBXO30	0.5	6.93	0.41	4.02e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs614226	0.935	rs77955762	chr12:121009948	T/C	cg01236616	chr12:121019343	POP5	-1.24	-16.84	-0.74	3.79e-42	Type 1 diabetes nephropathy;
SARC	cis	rs2073300	0.609	rs6137930	chr20:23376732	G/A	cg16736954	chr20:23401023	NAPB	0.79	4.99	0.31	1.16e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs9517313	0.897	rs4772087	chr13:99115041	A/G	cg07423050	chr13:99094983	FARP1	0.4	5.48	0.34	1.11e-7	Neuroticism;
SARC	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.68	8.62	0.49	1.03e-15	Chronic sinus infection;
SARC	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.34	-5.13	-0.32	6.16e-7	Total body bone mineral density;
SARC	trans	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg20587970	chr11:113659929	NA	-1.38	-13.71	-0.67	8.88e-32	Hip circumference adjusted for BMI;
SARC	cis	rs2658782	0.724	rs1563445	chr11:93246042	A/G	cg15737290	chr11:93063684	CCDC67	0.76	8.4	0.48	4.44e-15	Pulmonary function decline;
SARC	cis	rs9329221	0.651	rs2975648	chr8:10135976	C/T	cg27411982	chr8:10470053	RP1L1	-0.28	-4.81	-0.3	2.66e-6	Neuroticism;
SARC	cis	rs12048904	0.964	rs12027668	chr1:101330984	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.43	5.44	0.34	1.37e-7	Multiple sclerosis;
SARC	cis	rs4727027	0.933	rs12532104	chr7:148864233	A/C	cg23583168	chr7:148888333	NA	-0.74	-11.07	-0.59	3.61e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	trans	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg00938859	chr5:1591904	SDHAP3	0.77	7.42	0.44	2.12e-12	Breast cancer;
SARC	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg25894440	chr7:65020034	NA	-0.72	-5.46	-0.34	1.23e-7	Diabetic kidney disease;
SARC	trans	rs11098499	0.863	rs3822192	chr4:120445720	A/C	cg25214090	chr10:38739885	LOC399744	0.57	7.22	0.43	7.49e-12	Corneal astigmatism;
SARC	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg10130564	chr11:117069849	TAGLN	0.22	5.02	0.31	1.03e-6	Blood protein levels;
SARC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.51	6.71	0.4	1.44e-10	Lymphocyte counts;
SARC	cis	rs2694528	0.686	rs6885703	chr5:59862790	T/C	cg11474532	chr5:59995715	DEPDC1B	0.94	6.5	0.39	4.76e-10	Parkinson's disease;
SARC	cis	rs7103648	1.000	rs7947450	chr11:47429904	G/A	cg10504702	chr11:47789108	FNBP4	0.58	7.59	0.45	7.43e-13	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs2073499	1.000	rs12629572	chr3:50324672	T/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.57	5.13	0.32	5.97e-7	Schizophrenia;
SARC	cis	rs9457247	0.967	rs443570	chr6:167389925	G/A	cg07741184	chr6:167504864	NA	0.29	5.49	0.34	1.04e-7	Crohn's disease;
SARC	cis	rs4595586	0.632	rs1356266	chr12:39403581	A/G	cg26384229	chr12:38710491	ALG10B	-0.42	-5.27	-0.33	3.18e-7	Morning vs. evening chronotype;
SARC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.46	0.57	3.12e-21	Prudent dietary pattern;
SARC	cis	rs9344	0.869	rs2930975	chr11:69451837	C/G	cg09886342	chr11:69490314	ORAOV1	0.38	5.18	0.32	4.9e-7	Immunoglobulin light chain (AL) amyloidosis (kidney involvement);Immunoglobulin light chain (AL) amyloidosis (serum Ig light chain only lambda/kappa based profile);Immunoglobulin light chain (AL) amyloidosis;Immunoglobulin light chain (AL) amyloidosis (heart involvement);Immunoglobulin light chain (AL) amyloidosis (serum Ig light chain only lambda based profile);Immunoglobulin light chain (AL) amyloidosis (serum Ig lambda profile);
SARC	cis	rs2230307	0.572	rs514090	chr1:100563186	C/G	cg24955406	chr1:100503596	HIAT1	0.73	7.18	0.43	9.4e-12	Carotid intima media thickness;
SARC	cis	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg13072238	chr3:49761600	GMPPB	-0.42	-5.43	-0.34	1.4e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6598955	0.670	rs7520517	chr1:26556385	A/C	cg04990556	chr1:26633338	UBXN11	-0.61	-8.42	-0.48	3.96e-15	Obesity-related traits;
SARC	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg07636037	chr3:49044803	WDR6	0.97	16.95	0.74	1.54e-42	Menarche (age at onset);
SARC	cis	rs7586879	0.616	rs13410999	chr2:25097939	T/C	cg04586622	chr2:25135609	ADCY3	0.31	5.34	0.33	2.17e-7	Body mass index;
SARC	cis	rs9486719	0.947	rs6916232	chr6:96985959	A/T	cg06623918	chr6:96969491	KIAA0776	0.77	8.61	0.49	1.12e-15	Migraine;Coronary artery disease;
SARC	cis	rs2011503	0.943	rs4239639	chr19:19435876	G/A	cg03709012	chr19:19516395	GATAD2A	-0.64	-5.73	-0.35	3.11e-8	Bipolar disorder;
SARC	cis	rs6696846	0.765	rs2836	chr1:205111761	G/T	cg21545522	chr1:205238299	TMCC2	-0.35	-5.02	-0.31	1.01e-6	Red blood cell count;
SARC	cis	rs11098499	0.863	rs11731756	chr4:120478696	T/G	cg24375607	chr4:120327624	NA	0.42	4.92	0.31	1.64e-6	Corneal astigmatism;
SARC	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg11644478	chr21:40555479	PSMG1	0.96	11.53	0.6	1.21e-24	Cognitive function;
SARC	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.47	5.44	0.34	1.32e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7618501	0.519	rs3774749	chr3:50207227	C/T	cg24110177	chr3:50126178	RBM5	0.44	5.59	0.34	6.36e-8	Intelligence (multi-trait analysis);
SARC	cis	rs11098499	0.691	rs12510133	chr4:120271344	A/C	cg24375607	chr4:120327624	NA	0.37	4.73	0.3	3.87e-6	Corneal astigmatism;
SARC	cis	rs854765	0.583	rs11078404	chr17:17820487	A/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.43	5.67	0.35	4.17e-8	Total body bone mineral density;
SARC	cis	rs453301	0.624	rs6987558	chr8:8862521	C/G	cg11995313	chr8:8860691	ERI1	-0.49	-6.44	-0.39	6.84e-10	Joint mobility (Beighton score);
SARC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg06873352	chr17:61820015	STRADA	-0.53	-6.96	-0.41	3.47e-11	Prudent dietary pattern;
SARC	cis	rs4974559	0.641	rs28647383	chr4:1312908	G/C	cg02980000	chr4:1222292	CTBP1	0.74	5.55	0.34	7.55e-8	Systolic blood pressure;
SARC	cis	rs7264396	0.563	rs2425119	chr20:34324216	C/A	cg01084648	chr20:34329383	RBM39	0.58	5.03	0.31	9.74e-7	Total cholesterol levels;
SARC	cis	rs3091242	0.933	rs11249251	chr1:25770188	C/G	cg27572855	chr1:25598939	RHD	0.53	9.15	0.51	2.95e-17	Erythrocyte sedimentation rate;
SARC	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg03161606	chr19:29218774	NA	0.47	6.76	0.4	1.09e-10	Methadone dose in opioid dependence;
SARC	cis	rs12477438	0.765	rs6542846	chr2:99563654	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-9.71	-0.54	6.23e-19	Chronic sinus infection;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg03197830	chr15:73371746	NEO1	0.44	6.36	0.38	1.08e-9	Thyroid stimulating hormone;
SARC	cis	rs6540556	0.608	rs4314885	chr1:209902704	G/A	cg23920097	chr1:209922102	NA	-0.5	-5.67	-0.35	4.16e-8	Red blood cell count;
SARC	cis	rs9796	0.870	rs3214068	chr15:41313064	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.42	-5.83	-0.36	1.85e-8	Menopause (age at onset);
SARC	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg02891314	chr5:179741120	GFPT2	-0.51	-6.19	-0.38	2.66e-9	Height;
SARC	cis	rs2075371	0.865	rs2544172	chr7:133931338	T/C	cg20476274	chr7:133979776	SLC35B4	0.58	7.8	0.45	2.08e-13	Mean platelet volume;
SARC	cis	rs4648739	0.613	rs7528894	chr1:1907912	C/T	cg03688085	chr1:1910585	KIAA1751	-0.46	-6.07	-0.37	5.19e-9	Severe influenza A (H1N1) infection;
SARC	trans	rs10209086	0.736	rs1584436	chr2:138298878	A/G	cg14375050	chr4:108848533	NA	0.4	6.24	0.38	2.06e-9	Multiple system atrophy;
SARC	cis	rs4803468	1.000	rs284648	chr19:41926790	T/C	cg14132834	chr19:41945861	ATP5SL	-0.57	-7.45	-0.44	1.85e-12	Height;
SARC	cis	rs7582180	0.715	rs764828	chr2:100908634	A/C	cg14675211	chr2:100938903	LONRF2	0.49	6.78	0.41	9.55e-11	Intelligence (multi-trait analysis);
SARC	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg21829265	chr6:56911139	KIAA1586	0.71	6.55	0.39	3.69e-10	Pancreatic cancer;
SARC	cis	rs739401	0.595	rs2237903	chr11:2967901	C/T	cg05729581	chr11:3078854	CARS	-0.51	-6.57	-0.4	3.27e-10	Longevity;
SARC	cis	rs2463822	1.000	rs2463825	chr11:62094493	G/A	cg06239285	chr11:62104954	ASRGL1	0.9	9.65	0.53	9.5e-19	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg11764359	chr7:65958608	NA	-0.66	-7.91	-0.46	1.04e-13	Aortic root size;
SARC	cis	rs11581859	0.613	rs35232171	chr1:99189039	G/T	cg20286094	chr1:99190917	SNX7	-0.41	-4.88	-0.3	1.97e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs6866344	0.561	rs55974982	chr5:178141421	G/A	cg03877680	chr5:178157825	ZNF354A	1.02	14.39	0.69	5.18e-34	Neutrophil percentage of white cells;
SARC	cis	rs568617	0.953	rs658524	chr11:65647260	A/G	cg00576331	chr11:65640516	EFEMP2	0.47	5.45	0.34	1.27e-7	Crohn's disease;
SARC	cis	rs11605924	0.967	rs6485646	chr11:45865764	G/A	ch.11.939596F	chr11:45881766	CRY2	-0.48	-5.69	-0.35	3.87e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg24209194	chr3:40518798	ZNF619	0.67	8.13	0.47	2.49e-14	Renal cell carcinoma;
SARC	cis	rs778371	0.723	rs2592104	chr2:233645970	G/A	cg16596103	chr2:233749413	NGEF	-0.36	-5.41	-0.33	1.58e-7	Schizophrenia;
SARC	cis	rs12421382	0.659	rs1371331	chr11:109382578	G/A	cg27471124	chr11:109292789	C11orf87	0.37	5.07	0.32	8.1e-7	Schizophrenia;
SARC	trans	rs891088	0.695	rs35296670	chr19:7198004	G/A	cg23582405	chr14:74551333	LIN52;ALDH6A1	0.66	6.43	0.39	7.33e-10	Hip circumference adjusted for BMI;Height;
SARC	cis	rs2439831	0.867	rs16957630	chr15:43642780	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.04	10.9	0.58	1.25e-22	Lung cancer in ever smokers;
SARC	cis	rs240764	0.717	rs183566	chr6:101142605	A/T	cg09795085	chr6:101329169	ASCC3	0.45	5.63	0.35	5.24e-8	Neuroticism;
SARC	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	5.4	0.33	1.66e-7	Personality dimensions;
SARC	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg10560079	chr2:191398806	TMEM194B	0.63	9.08	0.51	4.72e-17	Pulse pressure;
SARC	cis	rs2777491	0.915	rs28583065	chr15:41608470	T/C	cg01768344	chr15:41576519	LOC729082	0.44	4.9	0.31	1.76e-6	Ulcerative colitis;
SARC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg05165339	chr4:1420672	NA	-0.24	-5.28	-0.33	3e-7	Longevity;
SARC	cis	rs9948	0.881	rs7594727	chr2:97489870	A/C	cg01990225	chr2:97406019	LMAN2L	0.65	5.32	0.33	2.45e-7	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs9486715	0.830	rs2255552	chr6:96999643	A/G	cg06623918	chr6:96969491	KIAA0776	-0.91	-13.57	-0.66	2.66e-31	Headache;
SARC	cis	rs9916302	0.847	rs7218670	chr17:37500424	G/A	cg15445000	chr17:37608096	MED1	-0.45	-5.48	-0.34	1.1e-7	Glomerular filtration rate (creatinine);
SARC	trans	rs61931739	0.534	rs12371021	chr12:34062252	T/C	cg26384229	chr12:38710491	ALG10B	0.87	12.36	0.63	2.53e-27	Morning vs. evening chronotype;
SARC	cis	rs10463316	0.894	rs7718085	chr5:150742957	G/C	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.39	-0.33	1.71e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg26354017	chr1:205819088	PM20D1	0.63	6.98	0.42	2.98e-11	Prostate-specific antigen levels;
SARC	cis	rs9325144	0.647	rs4616077	chr12:39092364	T/C	cg13010199	chr12:38710504	ALG10B	-0.52	-6.56	-0.39	3.51e-10	Morning vs. evening chronotype;
SARC	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg16606324	chr3:10149918	C3orf24	0.48	5.04	0.31	9.53e-7	Alzheimer's disease;
SARC	cis	rs6772849	1.000	rs2712378	chr3:128308794	T/C	cg08795948	chr3:128337044	NA	0.37	4.88	0.3	1.96e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs4073054	0.564	rs4564157	chr1:161178155	G/A	cg13853198	chr1:161185092	FCER1G	0.29	4.8	0.3	2.86e-6	Blood metabolite levels;
SARC	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg00339695	chr16:24857497	SLC5A11	-0.42	-6.14	-0.37	3.59e-9	Intelligence (multi-trait analysis);
SARC	cis	rs1215050	0.791	rs2123100	chr4:98803747	T/C	cg05340658	chr4:99064831	C4orf37	0.44	5.85	0.36	1.62e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.43	6.73	0.4	1.32e-10	Schizophrenia;
SARC	cis	rs6963495	0.818	rs73192124	chr7:105171528	C/T	cg19920283	chr7:105172520	RINT1	0.69	5.9	0.36	1.29e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs617219	0.613	rs13182115	chr5:78628411	G/T	cg24856658	chr5:78533917	JMY	0.31	4.84	0.3	2.32e-6	Betaine levels in individuals undergoing cardiac evaluation;
SARC	trans	rs61931739	0.736	rs7314457	chr12:34454301	G/A	cg13010199	chr12:38710504	ALG10B	0.69	9.17	0.51	2.5e-17	Morning vs. evening chronotype;
SARC	cis	rs9921222	0.521	rs78867928	chr16:368986	C/T	cg12437481	chr16:420112	MRPL28	-0.36	-4.99	-0.31	1.21e-6	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs6831352	0.879	rs17218003	chr4:100054723	G/C	cg13256891	chr4:100009986	ADH5	-0.64	-8.0	-0.46	5.7e-14	Alcohol dependence;
SARC	cis	rs910316	0.737	rs398896	chr14:75482827	C/A	cg06637938	chr14:75390232	RPS6KL1	-0.45	-5.91	-0.36	1.22e-8	Height;
SARC	cis	rs11630290	0.592	rs12324668	chr15:64161786	A/T	cg12036633	chr15:63758958	NA	0.47	4.83	0.3	2.47e-6	Iris characteristics;
SARC	cis	rs6540556	0.859	rs1007693	chr1:209931799	C/T	cg23920097	chr1:209922102	NA	-0.6	-6.64	-0.4	2.15e-10	Red blood cell count;
SARC	cis	rs1401999	0.966	rs1533682	chr3:183634879	A/G	cg01324343	chr3:183735012	ABCC5	0.68	14.04	0.68	7.41e-33	Anterior chamber depth;
SARC	cis	rs918629	0.563	rs3777188	chr5:95254502	A/G	cg16656078	chr5:95278638	ELL2	-0.57	-6.67	-0.4	1.81e-10	IgG glycosylation;
SARC	cis	rs6582630	0.555	rs34730221	chr12:38405140	C/T	cg26384229	chr12:38710491	ALG10B	-0.81	-11.73	-0.61	2.77e-25	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.42	-6.45	-0.39	6.22e-10	Total body bone mineral density;
SARC	trans	rs7937682	0.889	rs541198	chr11:111475340	A/G	cg18187862	chr3:45730750	SACM1L	0.55	6.92	0.41	4.43e-11	Primary sclerosing cholangitis;
SARC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg26354017	chr1:205819088	PM20D1	0.85	13.53	0.66	3.52e-31	Menarche (age at onset);
SARC	cis	rs9341808	0.667	rs12209624	chr6:80919133	G/A	cg08355045	chr6:80787529	NA	0.37	5.87	0.36	1.49e-8	Sitting height ratio;
SARC	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg03709012	chr19:19516395	GATAD2A	1.01	17.45	0.75	3.42e-44	Tonsillectomy;
SARC	cis	rs3784262	1.000	rs3204689	chr15:58246802	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.41	-6.16	-0.37	3.16e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs8523	0.779	rs2236212	chr6:10995015	C/G	cg13562911	chr6:11044106	ELOVL2	-0.44	-5.72	-0.35	3.26e-8	Red blood cell fatty acid levels;
SARC	cis	rs644799	0.710	rs10831433	chr11:95519787	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.85	13.37	0.66	1.19e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg08280861	chr8:58055591	NA	0.61	5.78	0.35	2.41e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg01577475	chr2:114033581	PAX8;LOC440839	-0.34	-5.12	-0.32	6.44e-7	Lymphocyte counts;
SARC	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg13395646	chr4:1353034	KIAA1530	0.44	5.26	0.33	3.19e-7	Obesity-related traits;
SARC	cis	rs11697848	1.000	rs77642050	chr20:48517046	G/A	cg17849948	chr20:48532315	SPATA2	0.86	5.17	0.32	4.97e-7	Systemic lupus erythematosus;
SARC	cis	rs8067354	0.645	rs2645492	chr17:57875554	A/G	cg02344993	chr17:57696989	CLTC	-0.63	-6.32	-0.38	1.34e-9	Hemoglobin concentration;
SARC	cis	rs6121246	0.542	rs2376990	chr20:30238744	G/A	cg13852791	chr20:30311386	BCL2L1	0.83	8.87	0.5	2.02e-16	Mean corpuscular hemoglobin;
SARC	cis	rs4727027	0.901	rs6943937	chr7:148869915	A/G	cg23583168	chr7:148888333	NA	-0.72	-10.17	-0.55	2.41e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	trans	rs7070797	0.735	rs17210692	chr10:63525112	G/A	cg06731886	chr7:73284078	NA	-0.51	-6.54	-0.39	3.81e-10	Takotsubo syndrome;
SARC	cis	rs10078	0.571	rs2241597	chr5:480509	A/G	cg26072250	chr5:443457	EXOC3;C5orf55	0.66	5.57	0.34	7.03e-8	Fat distribution (HIV);
SARC	cis	rs883565	0.528	rs9818979	chr3:38963835	C/G	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.44	-5.22	-0.32	3.92e-7	Handedness;
SARC	cis	rs17376456	1.000	rs9968749	chr5:93509559	A/G	cg25358565	chr5:93447407	FAM172A	1.34	14.13	0.68	3.63e-33	Diabetic retinopathy;
SARC	cis	rs796364	0.806	rs34381014	chr2:200916403	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.67	-5.68	-0.35	4.06e-8	Schizophrenia;
SARC	cis	rs17253792	0.732	rs28380739	chr14:56088402	G/A	cg01858014	chr14:56050164	KTN1	-0.67	-5.11	-0.32	6.86e-7	Putamen volume;
SARC	cis	rs72781680	0.665	rs2675356	chr2:24074734	C/T	cg06627628	chr2:24431161	ITSN2	-0.54	-5.63	-0.35	5.2100000000000003e-08	Lymphocyte counts;
SARC	cis	rs12048904	0.595	rs2295280	chr1:101342497	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.62	8.23	0.47	1.33e-14	Multiple sclerosis;
SARC	cis	rs6449957	0.741	rs6882730	chr5:67464205	C/T	cg23036683	chr5:67512108	NA	0.52	5.94	0.36	1.05e-8	Cleft lip with or without cleft palate;
SARC	cis	rs10463554	1.000	rs12656131	chr5:102325878	C/T	cg23492399	chr5:102201601	PAM	0.51	6.34	0.38	1.2e-9	Parkinson's disease;
SARC	cis	rs11122272	0.735	rs2486745	chr1:231505717	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-9.87	-0.54	1.99e-19	Hemoglobin concentration;
SARC	trans	rs1493916	0.905	rs4239383	chr18:31401066	T/C	cg27147174	chr7:100797783	AP1S1	-0.57	-7.25	-0.43	6.2e-12	Life satisfaction;
SARC	cis	rs11718455	0.881	rs17076257	chr3:44006787	C/T	cg08738300	chr3:44038990	NA	0.53	5.92	0.36	1.13e-8	Coronary artery disease;
SARC	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg11062466	chr8:58055876	NA	0.53	5.53	0.34	8.64e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7666738	0.893	rs11729640	chr4:99052699	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9916302	0.904	rs6503503	chr17:37514373	G/A	cg00129232	chr17:37814104	STARD3	0.58	7.24	0.43	6.36e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs9815354	1.000	rs7616844	chr3:41874343	A/G	cg03022575	chr3:42003672	ULK4	0.56	5.29	0.33	2.86e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9457247	1.000	rs394522	chr6:167398071	A/C	cg23791538	chr6:167370224	RNASET2	-0.63	-8.73	-0.5	4.84e-16	Crohn's disease;
SARC	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg24675658	chr1:53192096	ZYG11B	0.67	10.0	0.55	8.27e-20	Monocyte count;
SARC	cis	rs74417235	0.684	rs7723312	chr5:154053249	A/G	cg08754654	chr5:154026448	NA	-0.48	-4.84	-0.3	2.33e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
SARC	cis	rs2046867	0.908	rs11928067	chr3:72796340	T/C	cg25664220	chr3:72788482	NA	-0.29	-4.81	-0.3	2.66e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
SARC	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg05255149	chr17:80675120	FN3KRP	0.43	4.83	0.3	2.52e-6	Glycated hemoglobin levels;
SARC	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg24209194	chr3:40518798	ZNF619	-0.65	-8.21	-0.47	1.56e-14	Renal cell carcinoma;
SARC	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg11987759	chr7:65425863	GUSB	0.6	8.33	0.48	6.96e-15	Corneal structure;
SARC	cis	rs838147	0.537	rs504963	chr19:49208865	G/A	cg07051648	chr19:49177693	NTN5;SEC1	-0.42	-5.39	-0.33	1.68e-7	Dietary macronutrient intake;
SARC	cis	rs4906332	0.840	rs34161327	chr14:103857325	G/A	cg26031613	chr14:104095156	KLC1	-0.54	-6.31	-0.38	1.36e-9	Coronary artery disease;
SARC	cis	rs9399137	0.507	rs10484496	chr6:135299682	T/C	cg24558204	chr6:135376177	HBS1L	0.62	7.98	0.46	6.77e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs67311347	0.544	rs6599088	chr3:40329288	T/C	cg24209194	chr3:40518798	ZNF619	0.5	6.8	0.41	8.92e-11	Renal cell carcinoma;
SARC	cis	rs1008375	1.000	rs10011865	chr4:17645710	G/A	cg16339924	chr4:17578868	LAP3	0.67	8.99	0.51	8.91e-17	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9547692	0.938	rs55639205	chr13:37469994	A/C	cg01493522	chr13:37497338	NA	-0.46	-5.17	-0.32	4.98e-7	Coronary artery disease;
SARC	cis	rs12950390	0.853	rs55745341	chr17:45855778	G/C	cg03474202	chr17:45855739	NA	-0.44	-6.95	-0.41	3.61e-11	IgG glycosylation;
SARC	trans	rs3857536	0.740	rs4710571	chr6:66890250	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.6	-7.14	-0.42	1.19e-11	Blood trace element (Cu levels);
SARC	cis	rs4689388	0.853	rs1079214	chr4:6282157	T/C	cg25554036	chr4:6271136	WFS1	0.42	6.61	0.4	2.65e-10	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs11690935	0.959	rs7572215	chr2:172634228	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.0	-15.73	-0.72	1.83e-38	Schizophrenia;
SARC	cis	rs3126085	0.935	rs6587647	chr1:152192631	C/T	cg26876637	chr1:152193138	HRNR	0.49	5.61	0.35	5.67e-8	Atopic dermatitis;
SARC	cis	rs9911578	1.000	rs172565	chr17:56808996	A/T	cg05425664	chr17:57184151	TRIM37	-0.66	-8.16	-0.47	2.04e-14	Intelligence (multi-trait analysis);
SARC	cis	rs2204008	0.577	rs2623049	chr12:38018831	G/A	cg26384229	chr12:38710491	ALG10B	-0.79	-11.23	-0.59	1.1e-23	Bladder cancer;
SARC	cis	rs995000	0.868	rs1168107	chr1:63161173	A/T	cg06896770	chr1:63153194	DOCK7	-0.85	-12.77	-0.64	1.19e-28	Triglyceride levels;
SARC	cis	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg14343924	chr8:8086146	FLJ10661	0.4	4.88	0.3	1.93e-6	Mood instability;
SARC	cis	rs11190604	1.000	rs11190540	chr10:102202629	A/G	cg07080220	chr10:102295463	HIF1AN	0.79	9.2	0.52	2.08e-17	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg24110177	chr3:50126178	RBM5	-0.62	-8.25	-0.48	1.2e-14	Intelligence (multi-trait analysis);
SARC	trans	rs2388896	1.000	rs1822801	chr10:8955277	A/G	cg14153061	chr9:102669613	STX17	-0.46	-6.3	-0.38	1.51e-9	Tetralogy of Fallot;
SARC	cis	rs1318878	0.565	rs55716164	chr12:15508743	G/A	cg08258403	chr12:15378311	NA	0.48	6.67	0.4	1.87e-10	Intelligence (multi-trait analysis);
SARC	cis	rs2760061	0.598	rs673726	chr1:228120173	T/C	cg02753203	chr1:228287806	NA	-0.54	-7.53	-0.44	1.08e-12	Diastolic blood pressure;
SARC	cis	rs6540556	0.608	rs2064148	chr1:209909385	C/T	cg23920097	chr1:209922102	NA	0.49	5.61	0.34	5.78e-8	Red blood cell count;
SARC	cis	rs2463822	1.000	rs951677	chr11:62107249	G/C	cg06239285	chr11:62104954	ASRGL1	0.85	8.5	0.49	2.25e-15	Chronic obstructive pulmonary disease-related biomarkers;
SARC	trans	rs6815916	1.000	rs11732244	chr4:182554571	T/C	cg13864546	chr1:2310327	MORN1	0.68	6.37	0.39	9.77e-10	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.19	-0.56	2.08e-20	Chronic sinus infection;
SARC	cis	rs12709013	0.646	rs8046154	chr16:58807882	C/T	cg04273148	chr16:57808038	KIFC3	-0.34	-4.83	-0.3	2.51e-6	Blood metabolite ratios;
SARC	cis	rs6582630	0.502	rs1589390	chr12:38416139	C/T	cg14851346	chr12:38532713	NA	-0.46	-5.47	-0.34	1.14e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6964587	0.869	rs10278155	chr7:91532456	T/G	cg17063962	chr7:91808500	NA	-0.91	-14.0	-0.68	9.98e-33	Breast cancer;
SARC	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg23758822	chr17:41437982	NA	0.88	11.24	0.59	1.04e-23	Menopause (age at onset);
SARC	cis	rs7772486	0.790	rs2253880	chr6:146200774	T/C	cg05347473	chr6:146136440	FBXO30	0.52	7.44	0.44	1.9e-12	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs3780486	0.846	rs7865745	chr9:33140976	A/G	cg04842962	chr6:43655489	MRPS18A	-1.1	-20.77	-0.81	6.18e-55	IgG glycosylation;
SARC	cis	rs12824058	0.831	rs12831363	chr12:130814013	C/T	cg24838063	chr12:130822603	PIWIL1	-0.64	-9.12	-0.51	3.65e-17	Menopause (age at onset);
SARC	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	14.0	0.68	9.94e-33	Chronic sinus infection;
SARC	cis	rs7264396	0.790	rs2425097	chr20:34308926	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-8.49	-0.49	2.46e-15	Total cholesterol levels;
SARC	cis	rs911263	0.603	rs12890124	chr14:68781614	A/C	cg18825221	chr14:68749962	RAD51L1	-0.44	-7.61	-0.45	6.97e-13	Primary biliary cholangitis;
SARC	cis	rs3820928	0.845	rs1917126	chr2:227840923	G/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-6.76	-0.4	1.09e-10	Pulmonary function;
SARC	trans	rs61931739	0.824	rs406753	chr12:34117408	A/G	cg26384229	chr12:38710491	ALG10B	0.58	7.88	0.46	1.23e-13	Morning vs. evening chronotype;
SARC	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	11.07	0.59	3.59e-23	Alzheimer's disease;
SARC	cis	rs9291683	0.588	rs3733586	chr4:9997534	C/T	cg00071950	chr4:10020882	SLC2A9	0.39	6.21	0.38	2.38e-9	Bone mineral density;
SARC	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg13175981	chr1:150552382	MCL1	-0.48	-5.91	-0.36	1.23e-8	Tonsillectomy;
SARC	cis	rs10883723	0.668	rs12414407	chr10:104387019	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.58	-7.74	-0.45	3.04e-13	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs9302635	0.678	rs8054585	chr16:72225314	G/A	cg16558253	chr16:72132732	DHX38	-0.54	-6.82	-0.41	7.91e-11	Blood protein levels;
SARC	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg21724239	chr8:58056113	NA	0.56	6.03	0.37	6.24e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg10373733	chr6:25993375	NA	0.4	4.9	0.31	1.8e-6	Height;
SARC	cis	rs8114671	0.805	rs4616	chr20:33590358	C/T	cg08999081	chr20:33150536	PIGU	-0.36	-5.05	-0.31	9e-7	Height;
SARC	cis	rs651907	0.557	rs11712748	chr3:101383562	G/A	cg12386194	chr3:101231763	SENP7	0.5	5.96	0.36	9.5e-9	Colorectal cancer;
SARC	cis	rs2387326	0.671	rs11016103	chr10:129946285	A/G	cg16087940	chr10:129947807	NA	-0.45	-5.68	-0.35	3.91e-8	Select biomarker traits;
SARC	cis	rs9916302	0.808	rs12948906	chr17:37644854	C/T	cg15445000	chr17:37608096	MED1	0.41	4.81	0.3	2.66e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs12347191	0.500	rs1912998	chr9:100621386	T/C	cg13688889	chr9:100608707	NA	-0.48	-5.12	-0.32	6.48e-7	Orofacial clefts;
SARC	cis	rs4481887	0.927	rs6671702	chr1:248482851	G/A	cg01631408	chr1:248437212	OR2T33	-0.39	-4.87	-0.3	2.04e-6	Common traits (Other);
SARC	cis	rs13161115	0.919	rs7736022	chr5:107051983	G/A	cg15160843	chr5:107008084	EFNA5	0.51	4.82	0.3	2.55e-6	Number of children ever born;
SARC	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg26335602	chr6:28129616	ZNF389	0.41	4.95	0.31	1.45e-6	Cardiac Troponin-T levels;
SARC	cis	rs79349575	0.783	rs59270107	chr17:47026185	A/T	cg16584676	chr17:46985605	UBE2Z	0.55	6.58	0.4	3.01e-10	Type 2 diabetes;
SARC	cis	rs7772486	0.754	rs2328707	chr6:146053498	G/A	cg05347473	chr6:146136440	FBXO30	-0.55	-7.65	-0.45	5.17e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4243830	0.850	rs7540913	chr1:6581877	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.86	-8.68	-0.49	7.18e-16	Body mass index;
SARC	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-9.15	-0.51	2.85e-17	Alzheimer's disease;
SARC	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg06713675	chr4:122721982	EXOSC9	-0.52	-7.31	-0.43	4.13e-12	Type 2 diabetes;
SARC	cis	rs13034020	0.522	rs62150970	chr2:61244410	C/G	cg18625361	chr2:61244694	PEX13;PUS10	0.71	6.36	0.38	1.03e-9	Hodgkin's lymphoma;
SARC	cis	rs7617480	0.648	rs6801211	chr3:48774420	C/G	cg06212747	chr3:49208901	KLHDC8B	0.51	5.2	0.32	4.37e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs854765	0.547	rs7209003	chr17:17907393	T/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.64	9.44	0.53	4.01e-18	Total body bone mineral density;
SARC	cis	rs72945132	0.882	rs67927691	chr11:70128786	C/A	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.78	-0.35	2.39e-8	Coronary artery disease;
SARC	cis	rs2952156	0.920	rs14050	chr17:37828072	C/T	cg07936489	chr17:37558343	FBXL20	-0.39	-4.93	-0.31	1.53e-6	Asthma;
SARC	cis	rs6121246	0.559	rs6060599	chr20:30257754	T/G	cg13852791	chr20:30311386	BCL2L1	0.89	11.03	0.59	4.87e-23	Mean corpuscular hemoglobin;
SARC	cis	rs17376456	0.825	rs35496867	chr5:93220400	T/C	cg25358565	chr5:93447407	FAM172A	1.25	13.3	0.66	2.1000000000000002e-30	Diabetic retinopathy;
SARC	cis	rs870825	0.616	rs4444873	chr4:185628406	A/G	cg04058563	chr4:185651563	MLF1IP	0.83	10.93	0.58	1.05e-22	Blood protein levels;
SARC	cis	rs4144743	1.000	rs7224990	chr17:45326878	C/T	cg18085866	chr17:45331354	ITGB3	-0.73	-7.41	-0.44	2.29e-12	Body mass index;
SARC	cis	rs9916302	0.904	rs9894500	chr17:37515735	G/C	cg15445000	chr17:37608096	MED1	-0.46	-5.69	-0.35	3.78e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs9640161	0.789	rs34311995	chr7:150059255	T/C	cg21361702	chr7:150065534	REPIN1	0.59	6.98	0.42	3.1e-11	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg03213289	chr20:61660250	NA	0.46	6.43	0.39	7.22e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs761746	0.960	rs4820979	chr22:31914399	A/G	cg15162869	chr22:32027605	PISD	0.43	5.84	0.36	1.78e-8	Intelligence;
SARC	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg24829409	chr8:58192753	C8orf71	-0.63	-5.96	-0.36	9.37e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10979	0.838	rs12208649	chr6:143893321	G/T	cg25407410	chr6:143891975	LOC285740	-0.64	-8.78	-0.5	3.67e-16	Hypospadias;
SARC	cis	rs3858526	0.959	rs61876224	chr11:5952859	G/A	cg13902645	chr11:5959945	NA	-0.46	-5.3	-0.33	2.62e-7	DNA methylation (variation);
SARC	cis	rs4722166	0.630	rs2091115	chr7:22810166	G/T	cg26061582	chr7:22766209	IL6	0.54	6.35	0.38	1.09e-9	Lung cancer;
SARC	cis	rs1797885	0.546	rs2454421	chr3:12601105	C/T	cg05775895	chr3:12838266	CAND2	0.36	4.82	0.3	2.61e-6	Immature fraction of reticulocytes;
SARC	cis	rs56235845	0.694	rs11748912	chr5:176765395	G/A	cg16006841	chr5:176797999	RGS14	0.52	7.03	0.42	2.25e-11	Hemoglobin concentration;Hematocrit;
SARC	cis	rs6665290	0.835	rs7549586	chr1:227214566	A/G	cg14016676	chr1:227182615	CDC42BPA	0.38	5.45	0.34	1.26e-7	Myeloid white cell count;
SARC	cis	rs10131894	0.611	rs175001	chr14:75436452	A/C	cg11812906	chr14:75593930	NEK9	0.67	8.48	0.49	2.62e-15	Coronary artery disease;
SARC	trans	rs7937682	0.889	rs578022	chr11:111490552	G/T	cg18187862	chr3:45730750	SACM1L	0.55	6.99	0.42	2.93e-11	Primary sclerosing cholangitis;
SARC	cis	rs11190604	1.000	rs11190572	chr10:102232879	A/G	cg07080220	chr10:102295463	HIF1AN	0.76	9.07	0.51	5.2e-17	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs7927771	1.000	rs12787330	chr11:47812311	C/T	cg05585544	chr11:47624801	NA	-0.36	-4.82	-0.3	2.59e-6	Subjective well-being;
SARC	cis	rs1707322	1.000	rs1707338	chr1:46511981	T/G	cg06784218	chr1:46089804	CCDC17	-0.38	-6.82	-0.41	7.8e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs595982	0.527	rs56021835	chr19:49369989	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.65	-7.15	-0.42	1.09e-11	Red cell distribution width;
SARC	cis	rs7089973	0.585	rs7907837	chr10:116610690	G/T	cg03647239	chr10:116582469	FAM160B1	0.55	7.31	0.43	4.17e-12	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg03060546	chr3:49711283	APEH	0.42	5.26	0.33	3.27e-7	Parkinson's disease;
SARC	cis	rs9322817	0.653	rs2400051	chr6:105169478	A/C	cg02098413	chr6:105308735	HACE1	-0.38	-5.96	-0.36	9.31e-9	Thyroid stimulating hormone;
SARC	cis	rs4566357	0.615	rs4350744	chr2:227918146	A/T	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.97	-0.36	8.81e-9	Coronary artery disease;
SARC	cis	rs9611519	0.894	rs9611486	chr22:41458784	C/G	cg17376030	chr22:41985996	PMM1	0.51	6.16	0.37	3.12e-9	Neuroticism;
SARC	cis	rs8078723	0.677	rs11658328	chr17:38149236	T/C	cg17467752	chr17:38218738	THRA	-0.38	-4.89	-0.31	1.88e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs6964587	1.000	rs58965837	chr7:91585258	T/A	cg17063962	chr7:91808500	NA	0.92	14.96	0.7	6.62e-36	Breast cancer;
SARC	cis	rs4972806	0.849	rs2113561	chr2:177030925	G/A	cg14236662	chr2:176988284	HOXD9	0.41	5.84	0.36	1.71e-8	IgG glycosylation;
SARC	cis	rs524281	0.692	rs10896076	chr11:65840668	A/G	cg14036092	chr11:66035641	RAB1B	-0.55	-6.01	-0.37	6.92e-9	Electroencephalogram traits;
SARC	cis	rs2033732	1.000	rs1465809	chr8:85080457	G/A	cg05716166	chr8:85095498	RALYL	0.56	6.45	0.39	6.46e-10	Body mass index;
SARC	cis	rs9828933	0.752	rs73117082	chr3:63947565	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.87	-7.56	-0.44	9.35e-13	Type 2 diabetes;
SARC	cis	rs9457247	0.602	rs9457262	chr6:167473685	A/G	cg07741184	chr6:167504864	NA	0.38	7.32	0.43	3.92e-12	Crohn's disease;
SARC	cis	rs12908161	0.959	rs3748376	chr15:85328352	C/T	cg17507749	chr15:85114479	UBE2QP1	0.54	6.11	0.37	4.18e-9	Schizophrenia;
SARC	cis	rs12348691	0.503	rs3021523	chr9:100616583	T/C	cg13688889	chr9:100608707	NA	-0.47	-5.0	-0.31	1.15e-6	Alopecia areata;
SARC	cis	rs7762018	1.000	rs6941766	chr6:170131653	A/G	cg15038512	chr6:170123185	PHF10	0.51	4.91	0.31	1.73e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg03237412	chr15:44069622	ELL3	0.46	4.73	0.3	3.95e-6	Lung cancer in ever smokers;
SARC	cis	rs1008375	1.000	rs2058339	chr4:17678456	C/T	cg02297831	chr4:17616191	MED28	0.43	5.41	0.33	1.59e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs546131	0.642	rs836950	chr11:34852020	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-4.97	-0.31	1.29e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs7662987	0.517	rs1453873	chr4:100022571	T/C	cg12011299	chr4:100065546	ADH4	0.32	5.26	0.33	3.23e-7	Smoking initiation;
SARC	cis	rs8067545	0.641	rs1479129	chr17:19845769	A/G	cg04132472	chr17:19861366	AKAP10	0.38	5.04	0.31	9.29e-7	Schizophrenia;
SARC	cis	rs2486288	0.656	rs12908818	chr15:45571668	A/G	cg19305227	chr15:45544335	SLC28A2	0.3	5.54	0.34	8.05e-8	Glomerular filtration rate;
SARC	cis	rs3749237	0.595	rs7621003	chr3:49411404	T/C	cg07636037	chr3:49044803	WDR6	0.64	8.25	0.48	1.2e-14	Resting heart rate;
SARC	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg07636037	chr3:49044803	WDR6	0.93	15.3	0.71	4.87e-37	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs7223966	1.000	rs7211213	chr17:61769456	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.57	-6.59	-0.4	2.85e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs77633900	0.614	rs2468113	chr15:76851421	G/C	cg21673338	chr15:77095150	SCAPER	-0.62	-4.74	-0.3	3.67e-6	Non-glioblastoma glioma;Glioma;
SARC	cis	rs2204008	0.660	rs2874343	chr12:38239096	C/T	cg13010199	chr12:38710504	ALG10B	0.81	11.29	0.59	7.4e-24	Bladder cancer;
SARC	cis	rs4642101	0.640	rs12629398	chr3:12826799	A/G	cg05775895	chr3:12838266	CAND2	0.84	15.51	0.71	9.88e-38	QRS complex (12-leadsum);
SARC	cis	rs77372450	0.636	rs13356635	chr5:157014121	A/T	cg23851860	chr5:157002805	ADAM19	0.51	4.91	0.31	1.72e-6	Bipolar disorder (body mass index interaction);
SARC	cis	rs4774830	0.661	rs12443357	chr15:56305980	C/T	cg24530489	chr15:56299380	NA	-0.86	-5.02	-0.31	1.02e-6	Delta-5 desaturase activity;
SARC	cis	rs7408868	1.000	rs7408868	chr19:15285679	G/C	cg14696996	chr19:15285081	NOTCH3	1.0	9.16	0.51	2.71e-17	Pulse pressure;
SARC	cis	rs7824557	0.688	rs2572397	chr8:11176403	G/A	cg21775007	chr8:11205619	TDH	0.55	7.05	0.42	2.01e-11	Retinal vascular caliber;
SARC	cis	rs67311347	0.955	rs73080163	chr3:40533061	G/T	cg24209194	chr3:40518798	ZNF619	0.59	7.47	0.44	1.61e-12	Renal cell carcinoma;
SARC	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.1	-21.61	-0.82	1.37e-57	Chronic sinus infection;
SARC	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg11987759	chr7:65425863	GUSB	0.58	7.61	0.45	6.82e-13	Aortic root size;
SARC	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg03647317	chr4:187891568	NA	-0.35	-4.95	-0.31	1.39e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9818758	0.607	rs9855123	chr3:49229457	C/T	cg03060546	chr3:49711283	APEH	-0.56	-4.86	-0.3	2.17e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg25072359	chr17:41440525	NA	0.52	6.17	0.37	2.95e-9	Menopause (age at onset);
SARC	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg07234876	chr8:600039	NA	0.78	5.81	0.36	2.07e-8	IgG glycosylation;
SARC	cis	rs897080	0.552	rs1067383	chr2:44645911	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	6.36	0.38	1.06e-9	Height;
SARC	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.5	-0.44	1.37e-12	Gut microbiome composition (summer);
SARC	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.45	-5.65	-0.35	4.72e-8	Personality dimensions;
SARC	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg16479474	chr6:28041457	NA	-0.37	-5.21	-0.32	4.25e-7	Depression;
SARC	cis	rs72781680	0.898	rs12614616	chr2:23996501	T/G	cg08917208	chr2:24149416	ATAD2B	0.77	7.29	0.43	4.79e-12	Lymphocyte counts;
SARC	cis	rs765787	0.530	rs13329228	chr15:45533017	C/T	cg24006582	chr15:45444508	DUOX1	-0.56	-7.39	-0.44	2.68e-12	Uric acid levels;
SARC	cis	rs2072499	0.966	rs2842882	chr1:156165342	T/G	cg25208724	chr1:156163844	SLC25A44	0.93	12.69	0.64	2.13e-28	Testicular germ cell tumor;
SARC	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg00933542	chr6:150070202	PCMT1	0.34	5.89	0.36	1.35e-8	Lung cancer;
SARC	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg12463550	chr7:65579703	CRCP	0.5	5.9	0.36	1.27e-8	Aortic root size;
SARC	cis	rs2439831	1.000	rs2245790	chr15:43744457	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	8.64	0.49	8.83e-16	Lung cancer in ever smokers;
SARC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg19665106	chr5:130971021	RAPGEF6	0.55	6.85	0.41	6.49e-11	Myopia (pathological);
SARC	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg13395646	chr4:1353034	KIAA1530	-0.61	-7.17	-0.43	9.72e-12	Obesity-related traits;
SARC	cis	rs11098499	0.743	rs11098501	chr4:120252017	T/G	cg09307838	chr4:120376055	NA	0.81	11.03	0.59	4.84e-23	Corneal astigmatism;
SARC	cis	rs12549025	0.530	rs28656888	chr8:23266209	C/T	cg00472375	chr8:23315376	ENTPD4	0.53	5.96	0.36	9.47e-9	Reticulocyte fraction of red cells;
SARC	cis	rs7666738	0.530	rs2865992	chr4:99067181	A/T	cg05340658	chr4:99064831	C4orf37	0.48	6.49	0.39	5.19e-10	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10870270	1.000	rs7078692	chr10:133775370	T/A	cg17892150	chr10:133769511	PPP2R2D	-0.85	-10.49	-0.57	2.46e-21	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs10046574	0.831	rs10261625	chr7:135173544	C/T	cg27474649	chr7:135195673	CNOT4	0.88	7.14	0.42	1.15e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs1976403	0.633	rs1780324	chr1:21821757	A/G	cg07708622	chr1:21763251	NA	0.31	4.94	0.31	1.52e-6	Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs2414059	0.518	rs2289108	chr15:50782335	G/A	cg05456662	chr15:50716270	USP8	-0.41	-4.96	-0.31	1.33e-6	QT interval;
SARC	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.69	7.17	0.42	1.01e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg12373951	chr3:133503437	NA	0.41	5.88	0.36	1.43e-8	Iron status biomarkers;
SARC	cis	rs514406	0.505	rs6703127	chr1:53180565	C/T	cg16325326	chr1:53192061	ZYG11B	0.95	18.71	0.77	2.59e-48	Monocyte count;
SARC	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg11987759	chr7:65425863	GUSB	0.63	8.38	0.48	4.96e-15	Aortic root size;
SARC	cis	rs9916302	0.904	rs35335692	chr17:37710006	A/G	cg20243544	chr17:37824526	PNMT	0.54	6.25	0.38	1.96e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg08564027	chr20:61660810	NA	0.76	11.8	0.61	1.73e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs6964587	1.000	rs12333563	chr7:91667326	G/A	cg17063962	chr7:91808500	NA	0.93	15.8	0.72	1.07e-38	Breast cancer;
SARC	cis	rs4711350	0.734	rs7739273	chr6:33758065	G/A	cg07979401	chr6:33739406	LEMD2	-0.38	-4.76	-0.3	3.46e-6	Schizophrenia;
SARC	cis	rs526231	0.543	rs246900	chr5:102534629	T/A	cg23492399	chr5:102201601	PAM	-0.51	-5.49	-0.34	1.06e-7	Primary biliary cholangitis;
SARC	cis	rs7727544	0.735	rs272894	chr5:131662460	C/T	cg24060327	chr5:131705240	SLC22A5	-0.68	-8.76	-0.5	4.15e-16	Blood metabolite levels;
SARC	cis	rs992157	0.560	rs4674275	chr2:219097738	G/A	cg00012203	chr2:219082015	ARPC2	-0.73	-10.74	-0.58	3.92e-22	Colorectal cancer;
SARC	cis	rs9388451	0.839	rs4897157	chr6:126102981	A/T	cg05901451	chr6:126070800	HEY2	-0.68	-9.29	-0.52	1.12e-17	Brugada syndrome;
SARC	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg07061783	chr6:25882402	NA	-0.41	-5.01	-0.31	1.05e-6	Intelligence (multi-trait analysis);
SARC	trans	rs208520	0.690	rs12208310	chr6:66730108	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	14.02	0.68	8.69e-33	Exhaled nitric oxide output;
SARC	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg06873352	chr17:61820015	STRADA	0.5	6.49	0.39	5.1e-10	Prudent dietary pattern;
SARC	cis	rs62244186	0.627	rs3935212	chr3:44460954	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.47	5.8	0.36	2.14e-8	Depressive symptoms;
SARC	cis	rs6580649	0.657	rs57863747	chr12:48470425	G/T	cg05342945	chr12:48394962	COL2A1	0.55	5.91	0.36	1.22e-8	Lung cancer;
SARC	cis	rs360798	0.643	rs35387085	chr2:62817544	C/T	cg16915676	chr2:62734870	TMEM17	-0.49	-5.14	-0.32	5.94e-7	Coronary artery disease;
SARC	cis	rs6690583	0.623	rs2028304	chr1:85488030	G/A	cg22153463	chr1:85462885	MCOLN2	-0.68	-6.14	-0.37	3.56e-9	Serum sulfate level;
SARC	cis	rs3812831	0.695	rs7998546	chr13:114939914	C/G	cg06611532	chr13:114900021	NA	0.38	6.06	0.37	5.54e-9	Schizophrenia;
SARC	cis	rs6594499	0.843	rs1993465	chr5:110433098	A/G	cg04022379	chr5:110408740	TSLP	0.46	5.7	0.35	3.55e-8	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs6121246	0.909	rs6089058	chr20:30326338	T/G	cg13852791	chr20:30311386	BCL2L1	0.85	9.18	0.52	2.48e-17	Mean corpuscular hemoglobin;
SARC	cis	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg24110177	chr3:50126178	RBM5	-0.56	-7.44	-0.44	1.96e-12	Intelligence (multi-trait analysis);
SARC	cis	rs7607369	0.536	rs7566656	chr2:219664519	A/G	cg02176678	chr2:219576539	TTLL4	-0.38	-5.81	-0.36	2.03e-8	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs11122272	0.735	rs2355873	chr1:231477442	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-9.57	-0.53	1.62e-18	Hemoglobin concentration;
SARC	cis	rs9359856	0.529	rs1328017	chr6:90297603	T/C	cg13799429	chr6:90582589	CASP8AP2	0.64	4.88	0.3	2e-6	Bipolar disorder;
SARC	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg10374962	chr7:1011985	COX19	0.44	5.12	0.32	6.42e-7	Bronchopulmonary dysplasia;
SARC	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg25894440	chr7:65020034	NA	-0.76	-5.84	-0.36	1.75e-8	Diabetic kidney disease;
SARC	cis	rs9513627	1.000	rs7317330	chr13:100119876	T/G	cg25919922	chr13:100150906	NA	-0.74	-5.45	-0.34	1.26e-7	Obesity-related traits;
SARC	cis	rs11785400	0.793	rs9297969	chr8:143723237	A/G	cg10596483	chr8:143751796	JRK	0.57	7.47	0.44	1.65e-12	Schizophrenia;
SARC	cis	rs4919694	1.000	rs12258551	chr10:104767892	C/G	cg04362960	chr10:104952993	NT5C2	0.61	5.2	0.32	4.44e-7	Arsenic metabolism;
SARC	cis	rs1003719	0.654	rs764175	chr21:38517058	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.33	-0.52	8.73e-18	Eye color traits;
SARC	cis	rs2963155	0.518	rs72801029	chr5:142625806	T/C	cg17617527	chr5:142782415	NR3C1	0.81	5.51	0.34	9.29e-8	Breast cancer;
SARC	cis	rs992157	0.735	rs13430006	chr2:219113089	A/C	cg00012203	chr2:219082015	ARPC2	-0.84	-13.15	-0.65	6.43e-30	Colorectal cancer;
SARC	cis	rs11608355	0.545	rs11613023	chr12:109898047	T/C	cg05360138	chr12:110035743	NA	0.92	9.65	0.53	9.69e-19	Neuroticism;
SARC	cis	rs6570726	0.791	rs9403729	chr6:145907007	C/T	cg05347473	chr6:146136440	FBXO30	0.55	7.6	0.45	7.4e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9303280	0.901	rs2313430	chr17:37929816	T/C	cg20243544	chr17:37824526	PNMT	-0.43	-5.78	-0.35	2.44e-8	Self-reported allergy;
SARC	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg27266027	chr21:40555129	PSMG1	-0.46	-4.96	-0.31	1.38e-6	Cognitive function;
SARC	cis	rs829661	0.532	rs2363073	chr2:30796008	A/C	cg17749961	chr2:30669863	LCLAT1	-0.41	-4.96	-0.31	1.33e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
SARC	cis	rs6484504	0.576	rs169623	chr11:31184157	T/C	cg26647111	chr11:31128758	NA	-0.38	-5.09	-0.32	7.54e-7	Red blood cell count;
SARC	cis	rs9911578	1.000	rs9898626	chr17:56698219	C/G	cg05425664	chr17:57184151	TRIM37	-0.68	-8.49	-0.49	2.48e-15	Intelligence (multi-trait analysis);
SARC	trans	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg00938859	chr5:1591904	SDHAP3	0.79	7.61	0.45	6.69e-13	Breast cancer;
SARC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg26338869	chr17:61819248	STRADA	0.78	10.38	0.56	5.23e-21	Prudent dietary pattern;
SARC	cis	rs10911251	0.546	rs10911260	chr1:183106230	A/C	ch.1.3577855R	chr1:183094577	LAMC1	-0.71	-10.46	-0.57	3.05e-21	Colorectal cancer;
SARC	cis	rs2180341	0.843	rs4895821	chr6:127572761	T/A	cg24812749	chr6:127587940	RNF146	0.95	12.4	0.63	1.86e-27	Breast cancer;
SARC	cis	rs2439831	0.702	rs2467402	chr15:44024490	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.74	-7.5	-0.44	1.37e-12	Lung cancer in ever smokers;
SARC	trans	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	6.97	0.42	3.27e-11	Intelligence (multi-trait analysis);
SARC	cis	rs965469	1.000	rs2236092	chr20:3258188	G/C	cg25506879	chr20:3388711	C20orf194	-0.5	-5.1	-0.32	6.92e-7	IFN-related cytopenia;
SARC	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg26335602	chr6:28129616	ZNF389	0.51	5.56	0.34	7.41e-8	Parkinson's disease;
SARC	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.39	-4.77	-0.3	3.23e-6	Lymphocyte counts;
SARC	cis	rs7429990	0.965	rs9814961	chr3:48017617	A/G	cg11946769	chr3:48343235	NME6	0.47	5.45	0.34	1.28e-7	Educational attainment (years of education);
SARC	cis	rs2839186	0.504	rs11702278	chr21:47936295	T/G	cg12379764	chr21:47803548	PCNT	0.65	8.25	0.48	1.19e-14	Testicular germ cell tumor;
SARC	cis	rs2439831	0.850	rs28524541	chr15:44124831	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.93	8.15	0.47	2.19e-14	Lung cancer in ever smokers;
SARC	cis	rs7520050	0.966	rs1085243	chr1:46544768	C/T	cg24296786	chr1:45957014	TESK2	0.38	4.82	0.3	2.56e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs2239547	0.522	rs2336162	chr3:52951519	C/T	cg18404041	chr3:52824283	ITIH1	0.38	4.78	0.3	3.17e-6	Schizophrenia;
SARC	cis	rs17270561	0.609	rs4712961	chr6:25727334	C/T	cg16482183	chr6:26056742	HIST1H1C	0.43	5.25	0.33	3.49e-7	Iron status biomarkers;
SARC	cis	rs881375	0.715	rs10818482	chr9:123648085	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.5	-6.69	-0.4	1.68e-10	Rheumatoid arthritis;
SARC	trans	rs7824557	0.583	rs2263511	chr8:11233318	A/C	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.4	-0.48	4.51e-15	Retinal vascular caliber;
SARC	cis	rs9916302	0.904	rs602688	chr17:37439496	C/T	cg00129232	chr17:37814104	STARD3	-0.59	-7.35	-0.43	3.34e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs2467099	0.504	rs2666005	chr17:73944596	T/G	cg23806715	chr17:73775811	H3F3B	0.52	5.92	0.36	1.13e-8	Systolic blood pressure;
SARC	cis	rs7772486	0.776	rs2265467	chr6:146218339	T/A	cg23711669	chr6:146136114	FBXO30	0.77	11.79	0.61	1.75e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs644799	0.710	rs10831433	chr11:95519787	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.93	15.51	0.71	9.82e-38	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg21782813	chr7:2030301	MAD1L1	0.44	6.94	0.41	3.88e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs2153535	0.580	rs2184585	chr6:8474168	G/A	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	trans	rs17685	0.712	rs6464994	chr7:75784668	C/T	cg19862616	chr7:65841803	NCRNA00174	0.6	7.38	0.44	2.77e-12	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg04944784	chr2:26401820	FAM59B	0.62	8.05	0.47	4.32e-14	Gut microbiome composition (summer);
SARC	cis	rs4356932	0.967	rs4318674	chr4:76934422	C/G	cg24176760	chr4:76958061	ART3;CXCL11	-0.28	-4.73	-0.3	3.86e-6	Blood protein levels;
SARC	cis	rs3809863	0.602	rs2317677	chr17:45393407	G/A	cg08085267	chr17:45401833	C17orf57	-0.54	-6.7	-0.4	1.57e-10	Glaucoma (primary open-angle);
SARC	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg08859206	chr1:53392774	SCP2	-0.42	-5.94	-0.36	1.02e-8	Monocyte count;
SARC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg10963375	chr1:205815865	PM20D1	0.33	5.03	0.31	9.96e-7	Menarche (age at onset);
SARC	cis	rs7617773	0.817	rs6794644	chr3:48330037	T/C	cg11946769	chr3:48343235	NME6	0.73	9.64	0.53	1.02e-18	Coronary artery disease;
SARC	cis	rs2304069	0.779	rs245080	chr5:149354805	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.62	-6.74	-0.4	1.21e-10	HIV-1 control;
SARC	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.82	11.13	0.59	2.28e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs6088813	0.961	rs2425063	chr20:33924273	C/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.46	5.53	0.34	8.59e-8	Height;
SARC	cis	rs9303401	0.659	rs17822837	chr17:56737838	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.95	10.55	0.57	1.63e-21	Cognitive test performance;
SARC	cis	rs763121	0.853	rs5757196	chr22:39039855	G/C	cg06022373	chr22:39101656	GTPBP1	0.9	11.56	0.6	9.96e-25	Menopause (age at onset);
SARC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg21548813	chr6:291882	DUSP22	-0.64	-8.3	-0.48	8.39e-15	Menopause (age at onset);
SARC	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg00684032	chr4:1343700	KIAA1530	0.38	5.47	0.34	1.15e-7	Obesity-related traits;
SARC	cis	rs7818345	0.967	rs12679671	chr8:19270831	G/T	cg11303988	chr8:19266685	CSGALNACT1	0.41	5.57	0.34	7.06e-8	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs4144743	0.759	rs16969966	chr17:45318452	G/T	cg18085866	chr17:45331354	ITGB3	-0.73	-6.73	-0.4	1.29e-10	Body mass index;
SARC	cis	rs3733585	0.605	rs4697926	chr4:10124567	G/T	cg00071950	chr4:10020882	SLC2A9	0.39	5.86	0.36	1.59e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg15169257	chr19:7099543	NA	-0.51	-6.34	-0.38	1.19e-9	Breast cancer;
SARC	cis	rs9300255	0.602	rs1617434	chr12:123649486	A/G	cg00376283	chr12:123451042	ABCB9	0.59	5.95	0.36	9.67e-9	Neutrophil percentage of white cells;
SARC	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg00684032	chr4:1343700	KIAA1530	0.37	5.37	0.33	1.9e-7	Obesity-related traits;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg01110846	chr16:29937190	KCTD13	-0.49	-6.3	-0.38	1.43e-9	Electrocardiographic conduction measures;
SARC	cis	rs9394169	0.592	rs4304152	chr6:33723290	C/T	cg15676125	chr6:33679581	C6orf125	0.51	6.35	0.38	1.1e-9	Essential tremor;
SARC	cis	rs7843479	1.000	rs10503715	chr8:21850687	G/A	cg17168535	chr8:21777572	XPO7	0.63	8.05	0.47	4.21e-14	Mean corpuscular volume;
SARC	cis	rs6142102	0.961	rs2377957	chr20:32554473	A/G	cg24642439	chr20:33292090	TP53INP2	0.46	4.94	0.31	1.48e-6	Skin pigmentation;
SARC	cis	rs981844	0.712	rs897611	chr4:154755519	T/C	cg14289246	chr4:154710475	SFRP2	-0.47	-5.49	-0.34	1.04e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs6963495	0.818	rs56055535	chr7:105163574	C/A	cg19920283	chr7:105172520	RINT1	0.65	5.48	0.34	1.09e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs11718455	1.000	rs11917515	chr3:44020237	A/G	cg21419209	chr3:44054225	NA	-0.41	-5.04	-0.31	9.47e-7	Coronary artery disease;
SARC	cis	rs67460515	0.892	rs35310734	chr3:160943209	T/G	cg04691961	chr3:161091175	C3orf57	-0.48	-5.94	-0.36	1.04e-8	Parkinson's disease;
SARC	cis	rs6102059	0.503	rs6102032	chr20:39183949	C/T	cg06424997	chr20:39929561	ZHX3	0.37	4.8	0.3	2.86e-6	LDL cholesterol;
SARC	cis	rs9303401	0.659	rs17222621	chr17:56695923	C/T	cg25039879	chr17:56429692	SUPT4H1	0.69	6.55	0.39	3.71e-10	Cognitive test performance;
SARC	cis	rs986417	0.818	rs2057135	chr14:61077022	G/A	cg27398547	chr14:60952738	C14orf39	0.76	7.08	0.42	1.71e-11	Gut microbiota (bacterial taxa);
SARC	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg11764359	chr7:65958608	NA	0.77	9.41	0.52	5.12e-18	Aortic root size;
SARC	cis	rs73635312	0.850	rs17413266	chr10:8952552	C/T	cg24467326	chr10:9646929	NA	0.62	5.1	0.32	6.99e-7	Basal cell carcinoma;
SARC	cis	rs3733585	0.673	rs6843873	chr4:9958788	A/C	cg11266682	chr4:10021025	SLC2A9	-0.35	-6.03	-0.37	6.35e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs78487399	0.808	rs7573500	chr2:43685625	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-4.97	-0.31	1.31e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs7511006	1.000	rs17836662	chr22:50672154	A/G	cg08875078	chr22:50639485	SELO	-0.42	-4.8	-0.3	2.79e-6	Obesity-related traits;
SARC	cis	rs7917772	0.532	rs10748829	chr10:104527244	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-6.39	-0.39	8.73e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs4148883	0.675	rs28762430	chr4:100119257	C/A	cg13256891	chr4:100009986	ADH5	0.56	7.47	0.44	1.6e-12	Alcohol dependence;
SARC	cis	rs7762018	1.000	rs73242927	chr6:170129573	T/A	cg00262263	chr6:170184901	NA	0.39	4.81	0.3	2.66e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs4742903	0.967	rs4743690	chr9:106909577	T/C	cg14250997	chr9:106856677	SMC2	0.47	6.17	0.37	2.95e-9	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg09033563	chr22:24373618	LOC391322	-0.42	-4.92	-0.31	1.62e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9309473	1.000	rs6740223	chr2:73653332	T/C	cg20560298	chr2:73613845	ALMS1	-0.46	-5.64	-0.35	4.8e-8	Metabolite levels;
SARC	cis	rs4561483	0.801	rs33649	chr16:11979608	G/C	cg08843971	chr16:11963173	GSPT1	-0.42	-5.08	-0.32	7.57e-7	Testicular germ cell tumor;
SARC	cis	rs6988636	1.000	rs28537152	chr8:124189071	T/C	cg23067535	chr8:124195133	FAM83A	-0.69	-5.46	-0.34	1.24e-7	Urinary uromodulin levels;
SARC	cis	rs2014572	0.967	rs10421632	chr19:57764770	G/A	cg24459738	chr19:57751996	ZNF805	-0.44	-5.06	-0.31	8.42e-7	Hyperactive-impulsive symptoms;
SARC	cis	rs9868809	0.772	rs9877794	chr3:48718388	G/C	cg06212747	chr3:49208901	KLHDC8B	-0.6	-5.45	-0.34	1.28e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs3768617	0.510	rs4652776	chr1:183091920	G/A	cg13390022	chr1:182993471	LAMC1	0.31	4.73	0.3	3.89e-6	Fuchs's corneal dystrophy;
SARC	trans	rs8020941	0.585	rs80028507	chr14:97500338	T/A	cg05136476	chr3:53190709	NA	-0.64	-6.45	-0.39	6.29e-10	Diabetic kidney disease;
SARC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg11905131	chr22:24372483	LOC391322	-0.43	-4.99	-0.31	1.16e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9381040	0.655	rs6939989	chr6:41020205	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.41	-4.97	-0.31	1.3e-6	Alzheimer's disease (late onset);
SARC	cis	rs4242434	0.927	rs13264187	chr8:22506098	C/T	cg03733263	chr8:22462867	KIAA1967	1.02	17.66	0.76	7.11e-45	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs751728	0.664	rs6929696	chr6:33759290	C/T	cg25922239	chr6:33757077	LEMD2	-0.59	-7.81	-0.46	1.97e-13	Crohn's disease;
SARC	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg23758822	chr17:41437982	NA	-0.86	-10.83	-0.58	2.09e-22	Menopause (age at onset);
SARC	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	5.67	0.35	4.13e-8	Bipolar disorder;
SARC	cis	rs2120019	0.935	rs8042409	chr15:75350433	G/A	cg09165964	chr15:75287851	SCAMP5	-0.92	-13.82	-0.67	3.92e-32	Blood trace element (Zn levels);
SARC	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg00933542	chr6:150070202	PCMT1	0.31	5.05	0.31	8.87e-7	Lung cancer;
SARC	cis	rs820218	0.926	rs820155	chr17:73663778	G/C	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.7	9.58	0.53	1.56e-18	Rotator cuff tears;
SARC	cis	rs920590	0.500	rs7819535	chr8:19689058	A/G	cg01411142	chr8:19674711	INTS10	0.71	6.38	0.39	9.67e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg13206674	chr6:150067644	NUP43	0.46	6.01	0.37	6.92e-9	Lung cancer;
SARC	cis	rs288326	0.561	rs17703779	chr2:183895919	C/T	cg09997497	chr2:183902928	NCKAP1	0.74	5.1	0.32	6.97e-7	Blood protein levels;
SARC	cis	rs854765	0.583	rs9908832	chr17:17871068	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.41	5.03	0.31	9.85e-7	Total body bone mineral density;
SARC	cis	rs554111	0.509	rs495522	chr1:21105994	C/T	cg04902671	chr1:21058625	SH2D5	-0.5	-5.8	-0.36	2.12e-8	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs7208859	0.673	rs11651802	chr17:29159660	T/C	cg13385521	chr17:29058706	SUZ12P	0.86	7.3	0.43	4.51e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9303401	0.659	rs35797125	chr17:56736547	G/A	cg25039879	chr17:56429692	SUPT4H1	0.66	6.1	0.37	4.28e-9	Cognitive test performance;
SARC	cis	rs910316	0.737	rs2098251	chr14:75492696	G/A	cg11812906	chr14:75593930	NEK9	0.77	10.34	0.56	7.35e-21	Height;
SARC	cis	rs7264396	0.790	rs6060539	chr20:34239382	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	5.91	0.36	1.21e-8	Total cholesterol levels;
SARC	cis	rs9818758	0.556	rs116432667	chr3:48947589	C/T	cg07636037	chr3:49044803	WDR6	-0.74	-6.49	-0.39	5.12e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs7617773	0.780	rs6793239	chr3:48351618	G/T	cg11946769	chr3:48343235	NME6	0.76	9.7	0.54	6.55e-19	Coronary artery disease;
SARC	cis	rs6088580	0.524	rs6087616	chr20:33263033	T/C	cg08999081	chr20:33150536	PIGU	-0.35	-5.13	-0.32	6.11e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg18252515	chr7:66147081	NA	-1.26	-11.34	-0.6	5.14e-24	Diabetic kidney disease;
SARC	cis	rs1348850	0.914	rs2364854	chr2:178378452	T/A	cg23306229	chr2:178417860	TTC30B	0.54	6.39	0.39	8.91e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs67460515	0.630	rs7638370	chr3:160921793	G/T	cg04691961	chr3:161091175	C3orf57	-0.4	-4.75	-0.3	3.56e-6	Parkinson's disease;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg01013600	chr19:49141177	DBP;SEC1	-0.57	-6.51	-0.39	4.65e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg05368731	chr17:41323189	NBR1	0.78	9.34	0.52	7.99e-18	Menopause (age at onset);
SARC	cis	rs698833	1.000	rs698834	chr2:44736957	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.65	7.67	0.45	4.64e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg02592271	chr2:27665507	KRTCAP3	-0.43	-6.46	-0.39	6.11e-10	Total body bone mineral density;
SARC	trans	rs1814175	0.566	rs1811673	chr11:49602134	A/G	cg15704280	chr7:45808275	SEPT13	-0.74	-8.64	-0.49	9.12e-16	Height;
SARC	cis	rs2594989	1.000	rs346082	chr3:11329216	C/G	cg00170343	chr3:11313890	ATG7	0.54	5.2	0.32	4.4e-7	Circulating chemerin levels;
SARC	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.66	-0.4	1.91e-10	Total body bone mineral density;
SARC	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9911578	1.000	rs4793950	chr17:56593111	T/C	cg12560992	chr17:57184187	TRIM37	-0.82	-11.0	-0.58	6.29e-23	Intelligence (multi-trait analysis);
SARC	cis	rs12701220	0.503	rs12702024	chr7:1129820	G/C	cg00990874	chr7:1149470	C7orf50	-0.56	-5.52	-0.34	8.83e-8	Bronchopulmonary dysplasia;
SARC	cis	rs9790314	1.000	rs3849524	chr3:161015589	C/T	cg03342759	chr3:160939853	NMD3	-0.57	-7.21	-0.43	7.91e-12	Morning vs. evening chronotype;
SARC	cis	rs282587	0.597	rs1278659	chr13:113386497	G/T	cg02820901	chr13:113351484	ATP11A	-0.49	-4.76	-0.3	3.35e-6	Glycated hemoglobin levels;
SARC	cis	rs2153535	0.541	rs4637688	chr6:8446501	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	8.24	0.48	1.22e-14	Motion sickness;
SARC	cis	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg25833597	chr17:30823145	MYO1D	0.52	4.81	0.3	2.76e-6	Hip circumference adjusted for BMI;
SARC	cis	rs708547	0.581	rs6554400	chr4:57805306	A/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.5	-5.61	-0.34	5.71e-8	Response to bleomycin (chromatid breaks);
SARC	cis	rs6840360	0.571	rs17360371	chr4:152565374	C/T	cg22705602	chr4:152727874	NA	-0.44	-6.84	-0.41	7.02e-11	Intelligence (multi-trait analysis);
SARC	cis	rs16976116	0.803	rs7168737	chr15:55501344	T/C	cg11288833	chr15:55489084	RSL24D1	0.63	6.13	0.37	3.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs11169225	0.724	rs7305290	chr12:50341465	A/G	cg04450003	chr12:50355995	AQP5	0.39	6.14	0.37	3.53e-9	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs11969893	0.850	rs9404055	chr6:101302260	C/T	cg12253828	chr6:101329408	ASCC3	1.16	7.51	0.44	1.24e-12	Economic and political preferences (immigration/crime);
SARC	cis	rs6582630	0.547	rs1589388	chr12:38416025	C/T	cg13010199	chr12:38710504	ALG10B	-0.47	-5.69	-0.35	3.83e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7236492	0.688	rs76247824	chr18:77186287	G/A	cg15644404	chr18:77186268	NFATC1	-0.66	-6.62	-0.4	2.44e-10	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs7937682	0.711	rs4938792	chr11:111420936	T/C	cg09085632	chr11:111637200	PPP2R1B	0.65	9.09	0.51	4.38e-17	Primary sclerosing cholangitis;
SARC	trans	rs35833281	0.953	rs3134698	chr6:55064492	C/T	cg19977494	chr7:128431264	CCDC136	0.71	6.6	0.4	2.7e-10	Morning vs. evening chronotype;
SARC	cis	rs3816788	0.774	rs11784816	chr8:21773500	C/T	cg17168535	chr8:21777572	XPO7	-0.75	-10.06	-0.55	5.28e-20	Lung cancer in ever smokers;
SARC	cis	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg05623727	chr3:50126028	RBM5	-0.37	-5.49	-0.34	1.05e-7	Body mass index;
SARC	cis	rs1215050	0.740	rs783916	chr4:99026264	A/C	cg05340658	chr4:99064831	C4orf37	-0.5	-6.85	-0.41	6.47e-11	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs12824058	0.799	rs4759656	chr12:130815804	G/A	cg26677194	chr12:130822605	PIWIL1	0.55	7.69	0.45	4.13e-13	Menopause (age at onset);
SARC	cis	rs11190604	0.945	rs11190573	chr10:102233172	T/C	cg07080220	chr10:102295463	HIF1AN	0.76	9.07	0.51	5.2e-17	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg26554054	chr8:600488	NA	0.65	5.13	0.32	6.08e-7	IgG glycosylation;
SARC	cis	rs57083693	0.518	rs4764646	chr12:101737886	T/C	cg22051763	chr12:101673672	UTP20	-0.45	-5.41	-0.33	1.55e-7	Alcohol dependence (age at onset);
SARC	cis	rs73206853	0.563	rs73194051	chr12:111204186	T/C	cg10860002	chr12:110842031	ANAPC7	0.58	5.02	0.31	1.01e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs11122272	0.735	rs2066140	chr1:231504311	C/G	cg06096015	chr1:231504339	EGLN1	0.39	5.72	0.35	3.22e-8	Hemoglobin concentration;
SARC	cis	rs7666738	0.753	rs10029372	chr4:98859002	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.59	0.49	1.24e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9457247	0.508	rs6902119	chr6:167505791	T/C	cg07741184	chr6:167504864	NA	0.33	6.14	0.37	3.48e-9	Crohn's disease;
SARC	cis	rs1707322	0.752	rs28719889	chr1:46202283	C/T	cg03146154	chr1:46216737	IPP	0.52	6.3	0.38	1.44e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	10.97	0.58	7.68e-23	Alzheimer's disease;
SARC	cis	rs4479964	0.605	rs6931247	chr6:129961976	C/T	cg27192990	chr6:129479024	LAMA2	0.29	4.86	0.3	2.19e-6	Gut microbiome composition (summer);
SARC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg01516881	chr6:292596	DUSP22	-0.67	-8.45	-0.48	3.25e-15	Menopause (age at onset);
SARC	cis	rs4481887	0.800	rs4278391	chr1:248450495	C/T	cg00666640	chr1:248458726	OR2T12	0.33	5.44	0.34	1.35e-7	Common traits (Other);
SARC	cis	rs6121246	0.559	rs6060919	chr20:30331922	A/T	cg13852791	chr20:30311386	BCL2L1	0.88	10.96	0.58	8.39e-23	Mean corpuscular hemoglobin;
SARC	cis	rs3741151	0.686	rs1002127	chr11:73103835	G/C	cg17517138	chr11:73019481	ARHGEF17	0.69	5.44	0.34	1.37e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs1448094	0.967	rs7312144	chr12:86328256	T/C	cg02569458	chr12:86230093	RASSF9	0.4	5.8	0.36	2.17e-8	Major depressive disorder;
SARC	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg14517863	chr17:44321492	NA	0.42	6.38	0.39	9.33e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9790314	0.521	rs1450522	chr3:161077630	A/G	cg17135325	chr3:160939158	NMD3	0.63	7.9	0.46	1.07e-13	Morning vs. evening chronotype;
SARC	cis	rs66573146	0.831	rs56320732	chr4:6974319	G/A	cg00086871	chr4:6988644	TBC1D14	0.89	5.29	0.33	2.88e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-5.43	-0.33	1.44e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	10.75	0.58	3.72e-22	Platelet count;
SARC	cis	rs7819412	0.715	rs35223712	chr8:11043926	C/T	cg21775007	chr8:11205619	TDH	-0.41	-5.04	-0.31	9.31e-7	Triglycerides;
SARC	cis	rs910316	1.000	rs175436	chr14:75608683	C/G	cg08847533	chr14:75593920	NEK9	-0.87	-13.47	-0.66	5.64e-31	Height;
SARC	cis	rs611744	0.560	rs58605513	chr8:109279122	A/C	cg21045802	chr8:109455806	TTC35	0.61	7.58	0.44	8.25e-13	Dupuytren's disease;
SARC	cis	rs2180341	1.000	rs6569480	chr6:127621748	A/G	cg24812749	chr6:127587940	RNF146	0.96	12.94	0.65	3.21e-29	Breast cancer;
SARC	cis	rs10752881	0.967	rs8179284	chr1:182974707	C/T	cg13390022	chr1:182993471	LAMC1	0.33	5.06	0.31	8.36e-7	Colorectal cancer;
SARC	cis	rs7395581	0.918	rs1052373	chr11:47354787	A/G	cg25783544	chr11:47291846	MADD	-0.5	-5.67	-0.35	4.14e-8	HDL cholesterol;
SARC	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg17971929	chr21:40555470	PSMG1	-0.85	-11.53	-0.6	1.2e-24	Cognitive function;
SARC	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg22535103	chr8:58192502	C8orf71	-0.73	-8.66	-0.49	8.02e-16	Developmental language disorder (linguistic errors);
SARC	cis	rs14978	1.000	rs10235395	chr7:12286050	A/G	cg23422036	chr7:12250390	TMEM106B	0.45	5.45	0.34	1.29e-7	Response to amphetamines;
SARC	cis	rs9359856	0.510	rs78649003	chr6:90454644	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.54	-4.89	-0.31	1.88e-6	Bipolar disorder;
SARC	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg11062466	chr8:58055876	NA	0.7	6.14	0.37	3.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg11843238	chr5:131593191	PDLIM4	0.4	5.11	0.32	6.77e-7	Breast cancer;
SARC	cis	rs9715521	0.677	rs6822690	chr4:59853530	A/G	cg11281224	chr4:60001000	NA	-0.46	-5.9	-0.36	1.29e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs6912958	0.781	rs2207146	chr6:88180641	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.29	-4.99	-0.31	1.21e-6	Monocyte percentage of white cells;
SARC	cis	rs1728785	0.901	rs11642189	chr16:68583990	G/A	cg02972257	chr16:68554789	NA	-0.43	-5.01	-0.31	1.08e-6	Ulcerative colitis;
SARC	cis	rs78487399	0.808	rs7578597	chr2:43732823	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-4.94	-0.31	1.52e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs1153858	1.000	rs7179743	chr15:45638331	G/C	cg21132104	chr15:45694354	SPATA5L1	0.77	10.71	0.57	5.01e-22	Homoarginine levels;
SARC	trans	rs629535	0.814	rs614050	chr8:70065642	G/A	cg21567404	chr3:27674614	NA	1.05	13.61	0.67	2.02e-31	Dupuytren's disease;
SARC	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg15049968	chr18:44337910	ST8SIA5	-0.32	-5.04	-0.31	9.54e-7	Personality dimensions;
SARC	cis	rs6840360	0.571	rs10007653	chr4:152524055	A/G	cg22705602	chr4:152727874	NA	-0.33	-5.18	-0.32	4.7e-7	Intelligence (multi-trait analysis);
SARC	cis	rs72720396	0.789	rs12022460	chr1:91202257	A/G	cg24453699	chr1:91190891	NA	-0.38	-5.03	-0.31	9.68e-7	Morning vs. evening chronotype;Chronotype;
SARC	cis	rs7681440	0.904	rs28777703	chr4:90769924	A/G	cg01966878	chr4:90757139	SNCA	0.38	5.09	0.32	7.22e-7	Dementia with Lewy bodies;
SARC	cis	rs1957429	0.520	rs7144515	chr14:65333725	G/A	cg23373153	chr14:65346875	NA	-0.79	-6.36	-0.38	1.03e-9	Pediatric areal bone mineral density (radius);
SARC	cis	rs7178572	1.000	rs952472	chr15:77776562	A/C	cg22256960	chr15:77711686	NA	-0.56	-6.64	-0.4	2.2e-10	Type 2 diabetes;
SARC	trans	rs61931739	0.513	rs4931760	chr12:33898361	T/C	cg13010199	chr12:38710504	ALG10B	0.57	7.45	0.44	1.83e-12	Morning vs. evening chronotype;
SARC	cis	rs8180040	0.966	rs6787422	chr3:47418509	G/T	cg27129171	chr3:47204927	SETD2	0.66	9.06	0.51	5.37e-17	Colorectal cancer;
SARC	cis	rs9640161	0.673	rs34489187	chr7:150044379	G/A	cg17279839	chr7:150038598	RARRES2	0.41	5.5	0.34	1.01e-7	Blood protein levels;Circulating chemerin levels;
SARC	trans	rs1814175	0.684	rs1827015	chr11:49585241	A/G	cg03929089	chr4:120376271	NA	-0.67	-8.97	-0.51	9.78e-17	Height;
SARC	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg00933542	chr6:150070202	PCMT1	0.31	5.36	0.33	2.04e-7	Lung cancer;
SARC	cis	rs7833986	0.501	rs72653941	chr8:56942247	T/C	cg26371346	chr8:56986568	SNORD54;RPS20	0.74	7.64	0.45	5.66e-13	Height;
SARC	cis	rs5015933	0.801	rs6478703	chr9:128141348	A/G	cg14078157	chr9:128172775	NA	0.33	4.84	0.3	2.33e-6	Body mass index;
SARC	cis	rs950027	0.620	rs1153855	chr15:45660758	C/G	cg26924012	chr15:45694286	SPATA5L1	0.53	6.79	0.41	9.19e-11	Response to fenofibrate (adiponectin levels);
SARC	cis	rs3087591	0.960	rs2905797	chr17:29537458	G/C	cg24425628	chr17:29625626	OMG;NF1	0.54	6.66	0.4	1.99e-10	Hip circumference;
SARC	cis	rs3087591	0.960	rs12940303	chr17:29604862	C/T	cg24425628	chr17:29625626	OMG;NF1	0.55	6.8	0.41	8.91e-11	Hip circumference;
SARC	trans	rs7615952	0.611	rs2947646	chr3:125593602	C/T	cg07211511	chr3:129823064	LOC729375	0.8	7.39	0.44	2.68e-12	Blood pressure (smoking interaction);
SARC	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg06221963	chr1:154839813	KCNN3	-0.53	-8.54	-0.49	1.71e-15	Prostate cancer;
SARC	cis	rs7756236	0.521	rs9470363	chr6:36624713	G/A	cg08179530	chr6:36648295	CDKN1A	0.52	6.41	0.39	8.13e-10	QRS duration;
SARC	cis	rs16944613	0.541	rs13313427	chr15:91090768	G/A	cg26821196	chr15:91095069	CRTC3	0.52	5.36	0.33	2.03e-7	Colorectal cancer;
SARC	cis	rs2882667	0.858	rs11750382	chr5:138456994	A/G	cg04439458	chr5:138467593	SIL1	0.3	5.19	0.32	4.68e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs6540556	0.723	rs11487867	chr1:209892070	G/T	cg23920097	chr1:209922102	NA	-0.55	-5.34	-0.33	2.22e-7	Red blood cell count;
SARC	cis	rs7772486	0.641	rs9390370	chr6:146357569	C/T	cg05347473	chr6:146136440	FBXO30	0.67	9.19	0.52	2.22e-17	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs262150	0.545	rs73167302	chr7:158789762	G/A	cg19418458	chr7:158789849	NA	0.45	4.86	0.3	2.19e-6	Facial morphology (factor 20);
SARC	cis	rs2997447	0.706	rs17184877	chr1:26443908	A/T	cg19633962	chr1:26362018	EXTL1	-0.56	-5.06	-0.31	8.55e-7	QRS complex (12-leadsum);
SARC	cis	rs5769765	0.954	rs5770739	chr22:50268014	C/G	cg03033257	chr22:50311977	ALG12;CRELD2	-0.54	-5.64	-0.35	4.81e-8	Schizophrenia;
SARC	cis	rs9341808	0.718	rs9352806	chr6:80980057	G/T	cg08355045	chr6:80787529	NA	0.35	5.78	0.35	2.34e-8	Sitting height ratio;
SARC	cis	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg08975724	chr8:8085496	FLJ10661	0.51	6.36	0.38	1.04e-9	Mood instability;
SARC	cis	rs1707322	0.928	rs925524	chr1:46496709	A/G	cg03146154	chr1:46216737	IPP	-0.44	-5.17	-0.32	4.99e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs13202913	0.709	rs11965449	chr6:151830598	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	-0.52	-5.17	-0.32	5.05e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs7568458	0.846	rs6738645	chr2:85783128	T/G	cg02493740	chr2:85810744	VAMP5	-0.36	-5.31	-0.33	2.55e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs1318878	0.519	rs16910766	chr12:15497636	G/A	cg08258403	chr12:15378311	NA	0.47	6.67	0.4	1.83e-10	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9388451	0.869	rs7764016	chr6:126070789	T/G	cg05901451	chr6:126070800	HEY2	-0.69	-9.52	-0.53	2.31e-18	Brugada syndrome;
SARC	cis	rs1784581	0.651	rs1784588	chr6:162390027	T/A	cg17173639	chr6:162384350	PARK2	-0.6	-7.76	-0.45	2.69e-13	Itch intensity from mosquito bite;
SARC	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg00450029	chr8:599525	NA	0.61	5.15	0.32	5.61e-7	IgG glycosylation;
SARC	cis	rs9831754	0.906	rs9869812	chr3:78385679	G/A	cg06138941	chr3:78371609	NA	-0.59	-6.92	-0.41	4.22e-11	Calcium levels;
SARC	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg11644478	chr21:40555479	PSMG1	-0.91	-11.79	-0.61	1.87e-25	Cognitive function;
SARC	cis	rs6430585	0.583	rs78364332	chr2:136640101	T/C	cg07169764	chr2:136633963	MCM6	1.12	17.05	0.75	7.47e-43	Corneal structure;
SARC	cis	rs60871478	0.898	rs35928069	chr7:823067	G/C	cg19087971	chr7:751233	PRKAR1B	-0.44	-4.89	-0.31	1.88e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs7647973	0.710	rs12637313	chr3:49645458	A/G	cg06212747	chr3:49208901	KLHDC8B	0.73	6.53	0.39	4.13e-10	Menarche (age at onset);
SARC	cis	rs11881751	0.876	rs34889187	chr19:5018959	G/C	cg04571196	chr19:4910051	UHRF1	0.47	5.12	0.32	6.26e-7	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs4481887	0.962	rs5009868	chr1:248474495	A/G	cg01631408	chr1:248437212	OR2T33	-0.42	-5.27	-0.33	3.09e-7	Common traits (Other);
SARC	cis	rs7894051	1.000	rs11101721	chr10:135190358	C/G	cg26915536	chr10:135191635	PAOX	0.6	4.75	0.3	3.49e-6	Lifespan;
SARC	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.41	-5.1	-0.32	7.08e-7	Lymphocyte counts;
SARC	cis	rs11910985	0.546	rs9977877	chr21:48080493	G/A	cg17243659	chr21:48055224	PRMT2	1.04	5.93	0.36	1.1e-8	Cerebrospinal fluid t-tau:AB1-42 ratio;
SARC	cis	rs6570726	0.935	rs425731	chr6:145834151	A/G	cg05220968	chr6:146057943	EPM2A	-0.29	-4.99	-0.31	1.19e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg11764359	chr7:65958608	NA	0.6	7.18	0.43	9.26e-12	Aortic root size;
SARC	cis	rs4595586	0.655	rs11831499	chr12:39310114	A/T	cg26384229	chr12:38710491	ALG10B	0.41	5.09	0.32	7.23e-7	Morning vs. evening chronotype;
SARC	cis	rs10799590	0.897	rs1436171	chr1:224881828	A/G	cg01808320	chr1:224927238	CNIH3	0.33	4.83	0.3	2.48e-6	Opioid dependence;
SARC	cis	rs17345786	1.000	rs3762729	chr3:101308874	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.45	5.0	0.31	1.11e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg02487422	chr3:49467188	NICN1	-0.39	-4.81	-0.3	2.75e-6	Parkinson's disease;
SARC	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg05872129	chr22:39784769	NA	-0.4	-5.21	-0.32	4.11e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs9840812	0.861	rs645040	chr3:135926622	A/C	cg15507776	chr3:136538369	TMEM22	-0.51	-5.37	-0.33	1.88e-7	Fibrinogen levels;
SARC	cis	rs11098499	0.954	rs10024844	chr4:120311528	A/G	cg09160332	chr4:120329925	NA	-0.33	-4.77	-0.3	3.27e-6	Corneal astigmatism;
SARC	cis	rs12682352	0.602	rs13260419	chr8:8675176	A/G	cg08975724	chr8:8085496	FLJ10661	0.42	5.17	0.32	4.99e-7	Neuroticism;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg01855118	chr6:157007725	NA	0.56	7.38	0.44	2.79e-12	Electrocardiographic conduction measures;
SARC	cis	rs62244186	0.545	rs725866	chr3:44765533	A/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.57	7.37	0.43	3.01e-12	Depressive symptoms;
SARC	cis	rs6963495	0.769	rs73192134	chr7:105189338	T/C	cg19920283	chr7:105172520	RINT1	0.67	5.72	0.35	3.33e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg02891314	chr5:179741120	GFPT2	-0.51	-6.25	-0.38	1.93e-9	Height;
SARC	cis	rs523522	0.962	rs10849753	chr12:120910813	C/T	cg12219531	chr12:120966889	COQ5	0.81	10.4	0.56	4.74e-21	High light scatter reticulocyte count;
SARC	cis	rs7824557	0.564	rs7839307	chr8:11198792	A/G	cg21775007	chr8:11205619	TDH	0.64	8.59	0.49	1.26e-15	Retinal vascular caliber;
SARC	cis	rs4423214	1.000	rs2282620	chr11:71183477	C/T	cg05163923	chr11:71159392	DHCR7	0.68	9.42	0.53	4.51e-18	Vitamin D levels;
SARC	cis	rs4566357	0.615	rs1800517	chr2:227915832	G/A	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.93	-0.36	1.1e-8	Coronary artery disease;
SARC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.12	0.37	3.95e-9	Prudent dietary pattern;
SARC	cis	rs9916302	0.904	rs10491128	chr17:37551988	G/A	cg20243544	chr17:37824526	PNMT	-0.57	-6.87	-0.41	5.88e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs6815814	0.851	rs11466645	chr4:38778203	A/T	cg02016764	chr4:38805732	TLR1	-0.42	-4.72	-0.3	3.98e-6	Breast cancer;
SARC	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg05861140	chr6:150128134	PCMT1	-0.42	-5.36	-0.33	1.96e-7	Lung cancer;
SARC	cis	rs7412746	0.611	rs9661876	chr1:150910911	C/T	cg15448220	chr1:150897856	SETDB1	0.52	6.89	0.41	5.25e-11	Melanoma;
SARC	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg18404041	chr3:52824283	ITIH1	-0.43	-6.58	-0.4	3.15e-10	Bipolar disorder;
SARC	cis	rs1348850	0.651	rs1901824	chr2:178225466	T/C	cg23306229	chr2:178417860	TTC30B	0.41	4.81	0.3	2.71e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg11366901	chr6:160182831	ACAT2	0.61	6.43	0.39	7.17e-10	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs17376456	0.569	rs10476520	chr5:93058290	A/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.56	5.83	0.36	1.83e-8	Diabetic retinopathy;
SARC	cis	rs6088590	0.610	rs6120663	chr20:33081906	A/C	cg08999081	chr20:33150536	PIGU	-0.37	-5.36	-0.33	2.03e-7	Coronary artery disease;
SARC	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg22535103	chr8:58192502	C8orf71	-0.73	-7.24	-0.43	6.52e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs4356932	0.967	rs13128319	chr4:76975206	A/G	cg24176760	chr4:76958061	ART3;CXCL11	0.29	4.88	0.3	1.99e-6	Blood protein levels;
SARC	cis	rs9457247	1.000	rs402749	chr6:167386104	C/T	cg23791538	chr6:167370224	RNASET2	-0.62	-8.66	-0.49	8.17e-16	Crohn's disease;
SARC	cis	rs854765	0.583	rs8078105	chr17:17853782	T/C	cg04398451	chr17:18023971	MYO15A	-0.4	-5.51	-0.34	9.71e-8	Total body bone mineral density;
SARC	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg12292205	chr6:26970375	C6orf41	0.43	5.36	0.33	2.02e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1185460	0.967	rs1786685	chr11:118938957	G/A	cg23280166	chr11:118938394	VPS11	0.81	12.08	0.62	2.1e-26	Coronary artery disease;
SARC	cis	rs9916302	0.808	rs12943928	chr17:37611330	G/A	cg00129232	chr17:37814104	STARD3	-0.63	-7.8	-0.46	2.06e-13	Glomerular filtration rate (creatinine);
SARC	trans	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg20587970	chr11:113659929	NA	-1.31	-13.71	-0.67	9.38e-32	Hip circumference adjusted for BMI;
SARC	cis	rs1008375	0.966	rs10939758	chr4:17698255	C/T	cg16339924	chr4:17578868	LAP3	0.52	6.69	0.4	1.68e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2658782	0.901	rs11601056	chr11:93229161	C/T	cg15737290	chr11:93063684	CCDC67	-0.62	-6.37	-0.39	1e-9	Pulmonary function decline;
SARC	cis	rs7587476	0.505	rs777323	chr2:215738485	A/G	cg04530015	chr2:215796436	ABCA12	0.36	6.04	0.37	6.05e-9	Neuroblastoma;
SARC	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	20.22	0.8	3.44e-53	Chronic sinus infection;
SARC	cis	rs6484504	0.532	rs12788257	chr11:31255045	T/C	cg26647111	chr11:31128758	NA	-0.39	-5.1	-0.32	6.91e-7	Red blood cell count;
SARC	cis	rs936229	0.749	rs6495127	chr15:75194490	C/T	cg14664628	chr15:75095509	CSK	-0.83	-10.11	-0.55	3.8e-20	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs2153535	0.580	rs3938660	chr6:8443335	G/A	cg21535247	chr6:8435926	SLC35B3	0.56	7.01	0.42	2.6e-11	Motion sickness;
SARC	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg10970614	chr2:149510684	EPC2	-0.52	-6.77	-0.41	1.06e-10	Alcohol dependence;
SARC	cis	rs7772486	0.790	rs7753833	chr6:146161432	C/A	cg05347473	chr6:146136440	FBXO30	0.49	6.92	0.41	4.34e-11	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs9951602	0.512	rs12607612	chr18:76651799	G/A	cg02800362	chr5:177631904	HNRNPAB	0.7	8.91	0.5	1.49e-16	Obesity-related traits;
SARC	cis	rs933688	1.000	rs10073657	chr5:90689749	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.94	12.17	0.62	1.03e-26	Smoking behavior;
SARC	cis	rs11098499	0.604	rs34278750	chr4:120571136	G/A	cg09307838	chr4:120376055	NA	0.81	10.7	0.57	5.29e-22	Corneal astigmatism;
SARC	cis	rs6456156	0.586	rs6456149	chr6:167463902	T/C	cg23791538	chr6:167370224	RNASET2	-0.52	-6.79	-0.41	9.49e-11	Primary biliary cholangitis;
SARC	cis	rs11770686	0.513	rs2705825	chr7:75301209	T/C	cg07211516	chr7:75296079	HIP1	-0.46	-5.94	-0.36	1.05e-8	Essential tremor;
SARC	cis	rs709400	0.567	rs11624343	chr14:103859156	T/A	cg26031613	chr14:104095156	KLC1	0.79	11.18	0.59	1.6e-23	Body mass index;
SARC	cis	rs9815354	0.904	rs9848992	chr3:41875297	C/T	cg03022575	chr3:42003672	ULK4	0.62	5.43	0.34	1.39e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg18876405	chr7:65276391	NA	-0.7	-8.85	-0.5	2.18e-16	Aortic root size;
SARC	trans	rs2898290	0.622	rs978803	chr8:11343475	C/T	cg06636001	chr8:8085503	FLJ10661	0.54	7.45	0.44	1.87e-12	Systolic blood pressure;
SARC	cis	rs4917833	0.789	rs10883098	chr10:100218195	C/G	cg19043522	chr10:100227446	HPSE2	0.38	4.72	0.3	4.13e-6	Pediatric bone mineral density (femoral neck);
SARC	cis	rs7833790	0.676	rs7834555	chr8:82697625	A/G	cg06027949	chr8:82754900	SNX16	-0.46	-5.53	-0.34	8.59e-8	Diastolic blood pressure;
SARC	cis	rs4722166	0.630	rs6461667	chr7:22796743	A/G	cg26061582	chr7:22766209	IL6	0.57	6.34	0.38	1.16e-9	Lung cancer;
SARC	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg11987759	chr7:65425863	GUSB	-0.44	-5.79	-0.35	2.29e-8	Calcium levels;
SARC	cis	rs25645	0.771	rs11078936	chr17:38197914	T/C	cg17467752	chr17:38218738	THRA	-0.45	-5.85	-0.36	1.61e-8	Myeloid white cell count;
SARC	cis	rs9815354	1.000	rs1716997	chr3:41924333	A/G	cg03022575	chr3:42003672	ULK4	-0.54	-5.12	-0.32	6.5e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9807989	0.507	rs6543133	chr2:103040177	A/T	cg03938978	chr2:103052716	IL18RAP	0.31	4.99	0.31	1.16e-6	Asthma;
SARC	cis	rs1832871	0.672	rs56115227	chr6:158773884	G/A	cg07165851	chr6:158734300	TULP4	0.53	6.34	0.38	1.16e-9	Height;
SARC	cis	rs7246657	1.000	rs6508710	chr19:37749886	A/G	cg23950597	chr19:37808831	NA	-0.52	-4.93	-0.31	1.54e-6	Coronary artery calcification;
SARC	cis	rs1707322	1.000	rs1588663	chr1:46548825	G/A	cg03146154	chr1:46216737	IPP	-0.48	-5.66	-0.35	4.54e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6570726	0.935	rs12663205	chr6:145818378	G/A	cg23711669	chr6:146136114	FBXO30	0.78	11.91	0.62	7.29e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6061231	0.798	rs2427308	chr20:60969451	C/T	cg22601191	chr20:60968625	CABLES2	0.4	4.87	0.3	2.02e-6	Colorectal cancer;
SARC	cis	rs4319547	0.626	rs11057882	chr12:122875046	A/G	cg23029597	chr12:123009494	RSRC2	-0.43	-5.29	-0.33	2.85e-7	Body mass index;
SARC	cis	rs9303280	0.806	rs12232498	chr17:38040363	T/C	cg20243544	chr17:37824526	PNMT	0.43	5.74	0.35	2.99e-8	Self-reported allergy;
SARC	cis	rs3771570	0.901	rs35256094	chr2:242439938	A/C	cg21155796	chr2:242212141	HDLBP	0.61	5.44	0.34	1.35e-7	Prostate cancer;
SARC	cis	rs7617773	0.780	rs4479622	chr3:48338173	C/T	cg11946769	chr3:48343235	NME6	0.76	9.72	0.54	5.94e-19	Coronary artery disease;
SARC	cis	rs4481887	1.000	rs7517319	chr1:248466408	C/A	cg13385794	chr1:248469461	NA	0.36	5.57	0.34	7.1e-8	Common traits (Other);
SARC	cis	rs73157695	0.963	rs55641372	chr21:47322650	G/A	cg00682050	chr21:47343716	PCBP3	-0.42	-4.82	-0.3	2.61e-6	Myopia;
SARC	cis	rs986417	0.901	rs10483726	chr14:61039476	A/G	cg27398547	chr14:60952738	C14orf39	0.93	9.0	0.51	8.24e-17	Gut microbiota (bacterial taxa);
SARC	cis	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg18252515	chr7:66147081	NA	-1.22	-10.67	-0.57	6.88e-22	Diabetic kidney disease;
SARC	cis	rs4727027	0.866	rs2373437	chr7:148779032	T/C	cg23583168	chr7:148888333	NA	-0.72	-10.18	-0.55	2.24e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs787274	0.764	rs787287	chr9:115534245	T/C	cg13803584	chr9:115635662	SNX30	-0.83	-5.06	-0.31	8.34e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs950169	0.922	rs11630760	chr15:85113337	G/T	cg17507749	chr15:85114479	UBE2QP1	0.79	9.45	0.53	3.89e-18	Schizophrenia;
SARC	cis	rs921968	0.643	rs523396	chr2:219338789	T/G	cg02176678	chr2:219576539	TTLL4	0.36	5.58	0.34	6.83e-8	Mean corpuscular hemoglobin concentration;
SARC	cis	rs7551222	0.752	rs6594016	chr1:204539462	G/A	cg20240347	chr1:204465584	NA	-0.32	-5.62	-0.35	5.46e-8	Schizophrenia;
SARC	cis	rs7937682	0.924	rs489783	chr11:111520522	A/G	cg22437258	chr11:111473054	SIK2	0.74	10.3	0.56	9.9e-21	Primary sclerosing cholangitis;
SARC	cis	rs1448094	0.512	rs12297441	chr12:86233980	C/T	cg02569458	chr12:86230093	RASSF9	0.4	5.58	0.34	6.63e-8	Major depressive disorder;
SARC	trans	rs11250098	0.548	rs7843470	chr8:10784492	C/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.46	-0.39	6.07e-10	Morning vs. evening chronotype;
SARC	cis	rs6963495	0.818	rs73192115	chr7:105169605	T/A	cg19920283	chr7:105172520	RINT1	0.67	5.76	0.35	2.59e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs1451375	0.550	rs2242042	chr7:50529852	T/G	cg14593290	chr7:50529359	DDC	-0.49	-5.05	-0.31	9.05e-7	Malaria;
SARC	cis	rs72781680	0.898	rs72786270	chr2:24059049	G/A	cg06627628	chr2:24431161	ITSN2	-0.66	-6.04	-0.37	5.95e-9	Lymphocyte counts;
SARC	cis	rs11098499	0.754	rs1511025	chr4:120240238	T/C	cg09307838	chr4:120376055	NA	0.81	11.15	0.59	2.11e-23	Corneal astigmatism;
SARC	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg17971929	chr21:40555470	PSMG1	0.99	14.08	0.68	5.62e-33	Cognitive function;
SARC	cis	rs2075671	0.903	rs62483570	chr7:100300649	C/T	cg20848291	chr7:100343083	ZAN	-0.68	-7.52	-0.44	1.19e-12	Other erythrocyte phenotypes;
SARC	cis	rs9486715	0.867	rs6568428	chr6:96903604	A/G	cg18709589	chr6:96969512	KIAA0776	0.54	6.66	0.4	1.95e-10	Headache;
SARC	trans	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg00938859	chr5:1591904	SDHAP3	0.74	7.18	0.43	9.17e-12	Breast cancer;
SARC	cis	rs9399137	0.507	rs4580893	chr6:135297662	G/A	cg24558204	chr6:135376177	HBS1L	0.61	7.97	0.46	7.09e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs9486719	1.000	rs1303852	chr6:96864523	C/T	cg06623918	chr6:96969491	KIAA0776	0.73	8.01	0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs1707322	0.691	rs28495425	chr1:46187320	T/G	cg06784218	chr1:46089804	CCDC17	0.36	6.17	0.37	2.95e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6089584	0.606	rs2296082	chr20:60573983	A/G	cg13770153	chr20:60521292	NA	-0.42	-6.15	-0.37	3.35e-9	Body mass index;
SARC	cis	rs7412746	0.634	rs12562939	chr1:150951452	A/C	cg10589385	chr1:150898437	SETDB1	0.37	4.72	0.3	4.13e-6	Melanoma;
SARC	cis	rs1395	0.778	rs11693001	chr2:27412744	C/T	cg21747090	chr2:27597821	SNX17	-0.48	-5.77	-0.35	2.47e-8	Blood metabolite levels;
SARC	cis	rs4481887	0.962	rs10749653	chr1:248481384	C/G	cg13385794	chr1:248469461	NA	0.36	5.47	0.34	1.18e-7	Common traits (Other);
SARC	cis	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg08975724	chr8:8085496	FLJ10661	0.5	6.34	0.38	1.16e-9	Mood instability;
SARC	cis	rs2070488	0.965	rs7373828	chr3:38524311	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	14.07	0.68	5.86e-33	Electrocardiographic conduction measures;
SARC	trans	rs61931739	0.500	rs7977186	chr12:34431486	C/G	cg13010199	chr12:38710504	ALG10B	0.81	11.39	0.6	3.58e-24	Morning vs. evening chronotype;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg16308174	chr11:70049109	FADD	0.49	6.4	0.39	8.3e-10	Lung adenocarcinoma;
SARC	cis	rs72627509	0.904	rs17081933	chr4:57822869	T/A	cg26694713	chr4:57773883	REST	0.65	6.56	0.39	3.39e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs12142240	0.698	rs6690075	chr1:46819848	G/A	cg14993813	chr1:46806288	NSUN4	-0.52	-5.46	-0.34	1.22e-7	Menopause (age at onset);
SARC	cis	rs7937682	1.000	rs7128353	chr11:111538875	A/G	cg22437258	chr11:111473054	SIK2	0.73	9.84	0.54	2.47e-19	Primary sclerosing cholangitis;
SARC	cis	rs829661	0.532	rs9789517	chr2:30785824	C/G	cg17749961	chr2:30669863	LCLAT1	0.41	5.1	0.32	6.94e-7	Midgestational circulating levels of PBDEs (fetal genetic effect);
SARC	cis	rs7584330	0.744	rs58223447	chr2:238378644	G/C	cg14458575	chr2:238380390	NA	0.59	6.7	0.4	1.54e-10	Prostate cancer;
SARC	cis	rs950776	0.506	rs12915366	chr15:78831753	G/A	cg17108064	chr15:78857060	CHRNA5	0.29	4.9	0.31	1.76e-6	Sudden cardiac arrest;
SARC	cis	rs920590	0.643	rs3855754	chr8:19659499	C/G	cg01411142	chr8:19674711	INTS10	0.4	4.84	0.3	2.42e-6	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs66573146	0.831	rs68111914	chr4:6986677	C/T	cg15105060	chr4:7024189	TBC1D14	-0.69	-4.96	-0.31	1.35e-6	Granulocyte percentage of myeloid white cells;
SARC	cis	rs16976116	0.901	rs1061822	chr15:55496058	A/C	cg11288833	chr15:55489084	RSL24D1	0.63	6.13	0.37	3.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg16405210	chr4:1374714	KIAA1530	0.71	8.7	0.5	6.13e-16	Obesity-related traits;
SARC	cis	rs4742903	0.967	rs4742904	chr9:106856952	C/T	cg14250997	chr9:106856677	SMC2	0.53	7.1	0.42	1.53e-11	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs4319547	0.695	rs11057797	chr12:122860732	G/A	cg23029597	chr12:123009494	RSRC2	0.42	5.26	0.33	3.26e-7	Body mass index;
SARC	cis	rs9392918	0.622	rs9405350	chr6:7704609	G/A	cg23089261	chr6:7723385	NA	0.48	6.3	0.38	1.44e-9	Height;
SARC	cis	rs9640161	0.830	rs7800196	chr7:150061534	C/G	cg21361702	chr7:150065534	REPIN1	0.56	6.64	0.4	2.16e-10	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs9916302	0.904	rs4357971	chr17:37717280	C/T	cg07936489	chr17:37558343	FBXL20	-0.69	-8.91	-0.5	1.45e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs9486719	0.857	rs3798293	chr6:97033370	A/G	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.91	-0.5	1.46e-16	Migraine;Coronary artery disease;
SARC	cis	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg08564027	chr20:61660810	NA	0.76	11.75	0.61	2.46e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs3808502	0.526	rs7823100	chr8:11422491	C/A	cg21775007	chr8:11205619	TDH	-0.46	-5.91	-0.36	1.18e-8	Neuroticism;
SARC	cis	rs11711311	0.955	rs9813630	chr3:113377361	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	7.78	0.45	2.36e-13	IgG glycosylation;
SARC	cis	rs12681288	0.676	rs17740799	chr8:1014327	C/T	cg15309053	chr8:964076	NA	-0.46	-7.69	-0.45	4.06e-13	Schizophrenia;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg27563716	chr4:184365897	CDKN2AIP	0.63	6.45	0.39	6.47e-10	Lung cancer in ever smokers;
SARC	cis	rs1348850	0.872	rs10165785	chr2:178293295	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.63	7.84	0.46	1.63e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2204008	0.837	rs8189467	chr12:38241956	T/C	cg13010199	chr12:38710504	ALG10B	0.78	10.65	0.57	7.82e-22	Bladder cancer;
SARC	cis	rs820218	0.607	rs820168	chr17:73721365	G/C	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.6	6.72	0.4	1.38e-10	Rotator cuff tears;
SARC	cis	rs10927875	0.597	rs61782184	chr1:16150976	G/A	cg21385522	chr1:16154831	NA	-0.92	-13.13	-0.65	7.32e-30	Dilated cardiomyopathy;
SARC	cis	rs4713118	0.513	rs202908	chr6:28011551	C/G	cg26450541	chr6:28235208	ZNF187	0.48	5.01	0.31	1.08e-6	Parkinson's disease;
SARC	cis	rs9790314	0.905	rs7632797	chr3:161002694	C/T	cg04691961	chr3:161091175	C3orf57	0.73	10.64	0.57	8.04e-22	Morning vs. evening chronotype;
SARC	cis	rs9457247	0.765	rs9457252	chr6:167433925	A/G	cg23791538	chr6:167370224	RNASET2	0.53	7.04	0.42	2.13e-11	Crohn's disease;
SARC	cis	rs1550582	0.662	rs6981748	chr8:135501309	A/C	cg17885191	chr8:135476712	NA	-0.75	-7.69	-0.45	4.11e-13	Educational attainment;
SARC	cis	rs7937682	0.921	rs4534611	chr11:111440425	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.83	-12.7	-0.64	1.93e-28	Primary sclerosing cholangitis;
SARC	cis	rs6087990	0.806	rs6088008	chr20:31382860	A/G	cg13636640	chr20:31349939	DNMT3B	0.8	12.69	0.64	2.08e-28	Ulcerative colitis;
SARC	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg06074448	chr4:187884817	NA	-0.39	-5.24	-0.32	3.57e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7208859	0.623	rs9911784	chr17:29124580	A/C	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	8.87	0.5	1.99e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1215050	0.791	rs165250	chr4:98696259	G/A	cg05340658	chr4:99064831	C4orf37	0.43	5.8	0.36	2.11e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs651907	0.557	rs34457525	chr3:101435225	C/T	cg12386194	chr3:101231763	SENP7	0.49	5.78	0.35	2.4e-8	Colorectal cancer;
SARC	cis	rs2180341	0.618	rs12210968	chr6:127596985	A/G	cg27446573	chr6:127587934	RNF146	0.66	8.66	0.49	7.81e-16	Breast cancer;
SARC	cis	rs4332037	0.624	rs11764124	chr7:1891723	C/G	cg12591125	chr7:1885375	MAD1L1	0.47	4.99	0.31	1.18e-6	Bipolar disorder;
SARC	cis	rs3733585	0.781	rs13103690	chr4:9972778	T/G	cg11266682	chr4:10021025	SLC2A9	-0.36	-6.42	-0.39	7.43e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs10504073	0.669	rs341802	chr8:50039313	C/T	cg00325661	chr8:49890786	NA	0.55	7.41	0.44	2.25e-12	Blood metabolite ratios;
SARC	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg26513180	chr16:89883248	FANCA	0.87	15.61	0.72	4.34e-38	Vitiligo;
SARC	cis	rs12893668	0.703	rs4906338	chr14:104050357	A/G	cg26031613	chr14:104095156	KLC1	-0.57	-6.24	-0.38	2.02e-9	Reticulocyte count;
SARC	cis	rs9916302	0.800	rs8081220	chr17:37473157	A/C	cg07936489	chr17:37558343	FBXL20	0.69	9.18	0.52	2.46e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs3857536	0.740	rs9354392	chr6:66894555	G/T	cg07460842	chr6:66804631	NA	-0.61	-7.16	-0.42	1.05e-11	Blood trace element (Cu levels);
SARC	cis	rs4689388	0.853	rs4293850	chr4:6292020	A/C	cg00701064	chr4:6280414	WFS1	0.57	9.1	0.51	4.19e-17	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	trans	rs7395662	0.504	rs1814158	chr11:48437937	C/T	cg15704280	chr7:45808275	SEPT13	-0.48	-6.28	-0.38	1.69e-9	HDL cholesterol;
SARC	cis	rs780096	0.526	rs11682621	chr2:27749669	G/A	cg21747090	chr2:27597821	SNX17	-0.47	-6.35	-0.38	1.13e-9	Total body bone mineral density;
SARC	cis	rs36051895	0.626	rs10283564	chr9:5075628	C/G	cg02405213	chr9:5042618	JAK2	-0.44	-4.97	-0.31	1.29e-6	Pediatric autoimmune diseases;
SARC	cis	rs1448094	0.967	rs7961782	chr12:86326461	T/C	cg02569458	chr12:86230093	RASSF9	0.4	5.8	0.36	2.17e-8	Major depressive disorder;
SARC	trans	rs61931739	0.635	rs4442626	chr12:33912530	C/T	cg26384229	chr12:38710491	ALG10B	0.55	7.13	0.42	1.28e-11	Morning vs. evening chronotype;
SARC	cis	rs208520	0.874	rs208491	chr6:66928459	C/G	cg07460842	chr6:66804631	NA	-1.0	-11.88	-0.61	9.23e-26	Exhaled nitric oxide output;
SARC	cis	rs5769765	0.837	rs8142737	chr22:50291889	T/C	cg03033257	chr22:50311977	ALG12;CRELD2	0.5	5.23	0.32	3.83e-7	Schizophrenia;
SARC	cis	rs6752107	0.791	rs3792106	chr2:234190740	A/G	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.39	5.12	0.32	6.49e-7	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs2732480	0.577	rs2634678	chr12:48735538	C/G	cg21466736	chr12:48725269	NA	-0.33	-5.12	-0.32	6.25e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs1050631	0.564	rs684890	chr18:33744677	T/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.58	7.17	0.42	1.01e-11	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs13082711	0.554	rs4973729	chr3:27390637	G/A	cg02860705	chr3:27208620	NA	0.65	8.19	0.47	1.7e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs708547	0.581	rs13121027	chr4:57813369	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.52	-5.74	-0.35	2.94e-8	Response to bleomycin (chromatid breaks);
SARC	cis	rs6088590	1.000	rs2295354	chr20:33356541	T/C	cg06115741	chr20:33292138	TP53INP2	0.57	6.85	0.41	6.57e-11	Coronary artery disease;
SARC	cis	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg08975724	chr8:8085496	FLJ10661	0.51	6.37	0.39	1.01e-9	Mood instability;
SARC	cis	rs12586317	0.547	rs28395170	chr14:35506988	C/T	cg26967526	chr14:35346199	BAZ1A	-0.59	-6.14	-0.37	3.57e-9	Psoriasis;
SARC	cis	rs780096	1.000	rs780096	chr2:27741072	C/G	cg22903471	chr2:27725779	GCKR	-0.31	-4.83	-0.3	2.52e-6	Total body bone mineral density;
SARC	cis	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg12257692	chr3:49977190	RBM6	-0.27	-4.83	-0.3	2.45e-6	Body mass index;
SARC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg09373136	chr17:61933544	TCAM1	-0.4	-5.55	-0.34	7.78e-8	Prudent dietary pattern;
SARC	cis	rs2153535	0.580	rs1414342	chr6:8462552	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	8.3	0.48	8.23e-15	Motion sickness;
SARC	trans	rs1994135	0.692	rs7958788	chr12:33692179	T/C	cg26384229	chr12:38710491	ALG10B	0.68	8.21	0.47	1.54e-14	Resting heart rate;
SARC	cis	rs6570726	1.000	rs6570699	chr6:145920732	G/A	cg05347473	chr6:146136440	FBXO30	0.48	6.33	0.38	1.26e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs113835537	0.877	rs77239910	chr11:66329639	G/A	cg24851651	chr11:66362959	CCS	0.45	4.82	0.3	2.58e-6	Airway imaging phenotypes;
SARC	cis	rs7582720	1.000	rs72934729	chr2:203737770	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.28	0.43	5.16e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs72627509	0.680	rs79641006	chr4:57847443	T/G	cg26694713	chr4:57773883	REST	0.54	4.92	0.31	1.61e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs1707322	0.682	rs12041197	chr1:46104464	T/C	cg06784218	chr1:46089804	CCDC17	0.36	6.19	0.38	2.64e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs644799	0.542	rs10831416	chr11:95467220	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.49	5.89	0.36	1.35e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg06634786	chr22:41940651	POLR3H	-0.63	-7.58	-0.44	8.31e-13	Vitiligo;
SARC	cis	rs6484504	0.532	rs2774403	chr11:31320530	A/T	cg26647111	chr11:31128758	NA	0.38	4.99	0.31	1.2e-6	Red blood cell count;
SARC	cis	rs9902453	0.967	rs12449783	chr17:28527653	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	6.66	0.4	1.92e-10	Coffee consumption (cups per day);
SARC	cis	rs7666738	0.830	rs11947578	chr4:98930462	T/G	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs921968	0.643	rs522377	chr2:219437476	T/C	cg02176678	chr2:219576539	TTLL4	0.37	5.49	0.34	1.02e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg13114125	chr14:105738426	BRF1	-0.73	-10.99	-0.58	6.64e-23	Mean platelet volume;Platelet distribution width;
SARC	cis	rs751728	0.717	rs2281816	chr6:33772335	A/G	cg15252951	chr6:33757062	LEMD2	0.44	4.77	0.3	3.22e-6	Crohn's disease;
SARC	cis	rs11098499	0.908	rs28559989	chr4:120386627	C/T	cg09307838	chr4:120376055	NA	0.9	12.45	0.63	1.31e-27	Corneal astigmatism;
SARC	cis	rs17270561	0.636	rs1185977	chr6:25829054	A/G	cg16482183	chr6:26056742	HIST1H1C	0.51	6.75	0.4	1.14e-10	Iron status biomarkers;
SARC	cis	rs6831352	1.000	rs6831352	chr4:100063525	T/C	cg12011299	chr4:100065546	ADH4	0.33	5.75	0.35	2.75e-8	Alcohol dependence;
SARC	cis	rs6964587	1.000	rs28410528	chr7:91647390	A/G	cg17063962	chr7:91808500	NA	0.95	16.01	0.72	2.09e-39	Breast cancer;
SARC	cis	rs3796352	1.000	rs11714876	chr3:53101640	C/G	cg27565382	chr3:53032988	SFMBT1	-0.81	-5.86	-0.36	1.59e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2013441	1.000	rs11870147	chr17:20216095	A/G	cg13482628	chr17:19912719	NA	-0.46	-6.03	-0.37	6.38e-9	Obesity-related traits;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg22118250	chr6:27655512	NA	0.49	6.55	0.39	3.74e-10	Chemerin levels;
SARC	cis	rs2276314	0.857	rs16967327	chr18:33587036	C/T	cg19628046	chr18:33552617	C18orf21	0.57	5.91	0.36	1.22e-8	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs3020736	0.500	rs8138678	chr22:42516229	A/G	cg15557168	chr22:42548783	NA	0.36	4.92	0.31	1.67e-6	Autism spectrum disorder or schizophrenia;
SARC	trans	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.64	-6.23	-0.38	2.12e-9	Menarche (age at onset);
SARC	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg04944784	chr2:26401820	FAM59B	-0.47	-5.78	-0.35	2.43e-8	Gut microbiome composition (summer);
SARC	trans	rs1635	0.655	rs73742535	chr6:28302925	G/A	cg08080395	chr15:65488966	CILP	0.66	6.47	0.39	5.71e-10	Schizophrenia;
SARC	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg05185784	chr16:90016020	DEF8	-0.47	-4.99	-0.31	1.2e-6	Skin colour saturation;
SARC	cis	rs11098499	0.874	rs6832670	chr4:120118792	A/G	cg09307838	chr4:120376055	NA	0.82	11.06	0.59	3.96e-23	Corneal astigmatism;
SARC	cis	rs3008870	0.792	rs72673729	chr1:67441673	T/TG	cg08660285	chr1:67390436	MIER1;WDR78	-0.89	-11.03	-0.59	4.76e-23	Lymphocyte percentage of white cells;
SARC	cis	rs2306786	0.558	rs74842310	chr15:59504137	T/C	cg23054309	chr15:59226205	SLTM	0.76	4.86	0.3	2.15e-6	Metabolite levels;
SARC	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6807306	1.000	rs9836028	chr3:167383177	G/C	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.51	5.13	0.32	6.07e-7	Mean platelet volume;
SARC	cis	rs11295209	1	rs11295209	chr4:120480233	TA/T	cg09307838	chr4:120376055	NA	-0.52	-7.07	-0.42	1.76e-11	Plateletcrit;
SARC	cis	rs2204008	0.623	rs1607878	chr12:38376000	A/G	cg13010199	chr12:38710504	ALG10B	0.76	10.16	0.55	2.6e-20	Bladder cancer;
SARC	cis	rs7592578	0.640	rs56127319	chr2:191296429	G/A	cg10560079	chr2:191398806	TMEM194B	-0.71	-8.12	-0.47	2.69e-14	Diastolic blood pressure;
SARC	cis	rs9911578	1.000	rs12602346	chr17:56901713	T/C	cg12560992	chr17:57184187	TRIM37	0.86	12.1	0.62	1.84e-26	Intelligence (multi-trait analysis);
SARC	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg06618935	chr21:46677482	NA	-0.41	-5.37	-0.33	1.92e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	0.87	9.36	0.52	7.24e-18	Alzheimer's disease;
SARC	cis	rs1008375	0.932	rs3846356	chr4:17614176	C/T	cg02297831	chr4:17616191	MED28	0.5	6.4	0.39	8.47e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg08975724	chr8:8085496	FLJ10661	0.49	6.29	0.38	1.57e-9	Retinal vascular caliber;
SARC	cis	rs9790314	0.934	rs461638	chr3:161103166	A/G	cg03342759	chr3:160939853	NMD3	-0.54	-6.68	-0.4	1.75e-10	Morning vs. evening chronotype;
SARC	cis	rs7264396	0.690	rs2425164	chr20:34434916	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-7.1	-0.42	1.48e-11	Total cholesterol levels;
SARC	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg00152838	chr16:24741724	TNRC6A	0.59	5.74	0.35	2.98e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7264396	0.677	rs6060553	chr20:34267386	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.59	5.85	0.36	1.61e-8	Total cholesterol levels;
SARC	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg22535103	chr8:58192502	C8orf71	-0.57	-6.03	-0.37	6.4e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1018836	0.632	rs7017630	chr8:91482604	A/G	cg16814680	chr8:91681699	NA	-0.69	-10.45	-0.56	3.21e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs11719291	0.915	rs9834996	chr3:48754877	G/T	cg07636037	chr3:49044803	WDR6	-0.68	-6.33	-0.38	1.23e-9	Cognitive function;
SARC	cis	rs854765	0.623	rs9893690	chr17:17753846	A/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.38	-4.85	-0.3	2.23e-6	Total body bone mineral density;
SARC	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg00933542	chr6:150070202	PCMT1	0.31	5.36	0.33	2.04e-7	Lung cancer;
SARC	cis	rs2120019	0.938	rs2120020	chr15:75316845	T/C	cg12414181	chr15:75287860	SCAMP5	-0.48	-5.48	-0.34	1.13e-7	Blood trace element (Zn levels);
SARC	cis	rs1267303	0.642	rs3737740	chr1:47000596	G/A	cg25110126	chr1:46999211	NA	0.91	9.84	0.54	2.54e-19	Monobrow;
SARC	trans	rs208520	0.690	rs12202913	chr6:66734198	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	13.86	0.67	2.98e-32	Exhaled nitric oxide output;
SARC	cis	rs787274	0.850	rs7047914	chr9:115620773	A/C	cg13803584	chr9:115635662	SNX30	-0.86	-5.54	-0.34	8.25e-8	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs2043112	0.691	rs10214103	chr5:39077460	A/G	cg04869206	chr5:39074266	RICTOR	0.54	6.78	0.41	9.72e-11	Obesity-related traits;
SARC	cis	rs17376456	0.877	rs17083462	chr5:93462401	T/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.79	0.35	2.3e-8	Diabetic retinopathy;
SARC	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg03806693	chr22:41940476	POLR3H	-0.91	-12.54	-0.63	6.47e-28	Vitiligo;
SARC	cis	rs9581857	0.615	rs9581849	chr13:28005782	G/T	cg01674679	chr13:27998804	GTF3A	-0.68	-5.31	-0.33	2.5e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	cis	rs11574514	1.000	rs77335546	chr16:67868394	C/T	cg01866162	chr16:67596514	CTCF	1.11	6.4	0.39	8.22e-10	Crohn's disease;
SARC	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg11062466	chr8:58055876	NA	0.65	5.98	0.36	8.47e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	10.25	0.56	1.33e-20	Platelet count;
SARC	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg22875332	chr1:76189707	ACADM	-0.46	-5.63	-0.35	5.29e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9325144	0.600	rs12424410	chr12:38758035	A/T	cg26384229	chr12:38710491	ALG10B	-0.6	-7.9	-0.46	1.08e-13	Morning vs. evening chronotype;
SARC	cis	rs664172	1	rs664172	chr15:78862762	G/A	cg06917634	chr15:78832804	PSMA4	-0.51	-5.63	-0.35	5.1e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg18357526	chr6:26021779	HIST1H4A	0.45	5.65	0.35	4.63e-8	Blood metabolite levels;
SARC	cis	rs11209002	1.000	rs10749771	chr1:67573730	A/G	cg02640540	chr1:67518911	SLC35D1	0.47	4.76	0.3	3.42e-6	Crohn's disease;
SARC	cis	rs11785400	1.000	rs10099892	chr8:143734608	C/T	cg10596483	chr8:143751796	JRK	0.65	8.67	0.49	7.24e-16	Schizophrenia;
SARC	cis	rs3781913	0.874	rs12362256	chr11:72368654	C/T	cg03713592	chr11:72463424	ARAP1	-0.48	-5.82	-0.36	1.94e-8	Rheumatoid arthritis;
SARC	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg09699651	chr6:150184138	LRP11	0.39	4.87	0.3	2.04e-6	Lung cancer;
SARC	cis	rs6732160	0.845	rs6718690	chr2:73387162	C/T	cg01422370	chr2:73384389	NA	-0.32	-5.49	-0.34	1.04e-7	Intelligence (multi-trait analysis);
SARC	cis	rs12421382	0.811	rs11602639	chr11:109472829	C/T	cg06719900	chr11:109292894	C11orf87	0.36	4.85	0.3	2.3e-6	Schizophrenia;
SARC	trans	rs1502172	0.550	rs11711492	chr3:135240628	A/T	cg17077762	chr15:64996104	OAZ2	0.48	6.25	0.38	1.98e-9	Visceral adipose tissue adjusted for BMI;
SARC	cis	rs2439831	0.717	rs690170	chr15:43810422	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	6.71	0.4	1.49e-10	Lung cancer in ever smokers;
SARC	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg19671926	chr4:122722719	EXOSC9	-0.54	-5.92	-0.36	1.15e-8	Type 2 diabetes;
SARC	cis	rs6430585	0.583	rs3087343	chr2:136622543	T/G	cg07169764	chr2:136633963	MCM6	1.09	16.65	0.74	1.55e-41	Corneal structure;
SARC	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg09323728	chr8:95962352	TP53INP1	-0.29	-5.05	-0.31	8.88e-7	Type 2 diabetes;
SARC	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg21724239	chr8:58056113	NA	0.71	6.21	0.38	2.46e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7829975	0.564	rs2921057	chr8:8318667	C/T	cg15556689	chr8:8085844	FLJ10661	0.47	6.09	0.37	4.73e-9	Mood instability;
SARC	trans	rs10782582	0.706	rs964024	chr1:76365637	A/C	cg22767735	chr17:19551663	ALDH3A2	-0.48	-6.29	-0.38	1.54e-9	Daytime sleep phenotypes;
SARC	cis	rs870825	0.616	rs28672716	chr4:185647345	G/A	cg04058563	chr4:185651563	MLF1IP	0.8	11.35	0.6	4.56e-24	Blood protein levels;
SARC	cis	rs986417	0.748	rs2179971	chr14:61055466	T/C	cg27398547	chr14:60952738	C14orf39	0.75	7.32	0.43	4.06e-12	Gut microbiota (bacterial taxa);
SARC	cis	rs7246760	0.867	rs61580479	chr19:9782940	G/A	cg16876255	chr19:9731953	ZNF561	0.83	5.11	0.32	6.61e-7	Pursuit maintenance gain;
SARC	cis	rs1044826	0.597	rs6772199	chr3:139178133	C/T	cg15131784	chr3:139108705	COPB2	0.4	5.1	0.32	7.15e-7	Obesity-related traits;
SARC	cis	rs6714710	0.580	rs35564270	chr2:98602165	A/G	cg26665480	chr2:98280029	ACTR1B	0.47	6.24	0.38	2.02e-9	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg07414643	chr4:187882934	NA	0.54	8.01	0.46	5.47e-14	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs61352607	1.000	rs4760355	chr12:57725197	G/A	cg02059047	chr12:57634677	NDUFA4L2	0.43	4.73	0.3	3.91e-6	Triglycerides;
SARC	cis	rs644799	0.965	rs11021317	chr11:95517576	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	15.22	0.71	9.1e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs11711311	0.955	rs12636536	chr3:113474226	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	8.35	0.48	6.19e-15	IgG glycosylation;
SARC	cis	rs17345786	0.861	rs11711808	chr3:101235101	T/C	cg12386194	chr3:101231763	SENP7	0.8	9.65	0.53	9.29e-19	Colonoscopy-negative controls vs population controls;
SARC	trans	rs66573146	1.000	rs56074877	chr4:6990374	C/T	cg07817883	chr1:32538562	TMEM39B	1.25	8.25	0.48	1.19e-14	Granulocyte percentage of myeloid white cells;
SARC	cis	rs78456975	0.943	rs7602369	chr2:1574754	T/C	cg12573674	chr2:1569213	NA	-0.54	-4.92	-0.31	1.62e-6	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs3204270	0.639	rs62080199	chr17:79627906	T/G	cg26965718	chr17:79658957	HGS	-0.62	-5.0	-0.31	1.12e-6	Dental caries;
SARC	cis	rs6456156	0.774	rs2022001	chr6:167529509	C/T	cg07741184	chr6:167504864	NA	-0.29	-5.41	-0.33	1.53e-7	Primary biliary cholangitis;
SARC	trans	rs61931739	0.500	rs34080094	chr12:34547952	G/A	cg13010199	chr12:38710504	ALG10B	0.83	11.73	0.61	2.89e-25	Morning vs. evening chronotype;
SARC	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg08975724	chr8:8085496	FLJ10661	0.66	8.82	0.5	2.82e-16	Neuroticism;
SARC	cis	rs6912958	0.781	rs9444519	chr6:88290398	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.43	-0.34	1.42e-7	Monocyte percentage of white cells;
SARC	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg24399712	chr22:39784796	NA	-0.44	-5.8	-0.36	2.18e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs7223966	1.000	rs8069687	chr17:61883023	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.67	-7.56	-0.44	9.04e-13	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs644799	0.710	rs12272061	chr11:95524067	G/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.62	8.27	0.48	9.95e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs4891159	0.548	rs609487	chr18:74134382	C/G	cg24786174	chr18:74118243	ZNF516	-0.7	-11.89	-0.61	8.53e-26	Longevity;
SARC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg09373136	chr17:61933544	TCAM1	-0.45	-6.15	-0.37	3.36e-9	Prudent dietary pattern;
SARC	cis	rs8017423	0.967	rs55894943	chr14:90714799	A/G	cg20276874	chr14:90721474	PSMC1	-0.35	-4.77	-0.3	3.24e-6	Mortality in heart failure;
SARC	cis	rs34779708	0.966	rs10827491	chr10:35427395	G/A	cg03585969	chr10:35415529	CREM	0.38	4.85	0.3	2.25e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs16866061	1.000	rs11694987	chr2:225397409	C/G	cg12698349	chr2:225449008	CUL3	0.63	8.43	0.48	3.6e-15	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	trans	rs9354308	0.834	rs9354307	chr6:66552953	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.56	-6.63	-0.4	2.36e-10	Metabolite levels;
SARC	cis	rs12586317	0.620	rs7147571	chr14:35530236	T/C	cg05294307	chr14:35346193	BAZ1A	-0.47	-4.76	-0.3	3.33e-6	Psoriasis;
SARC	cis	rs10791323	0.569	rs2282601	chr11:133712594	C/G	cg15485101	chr11:133734466	NA	0.33	5.08	0.32	7.91e-7	Childhood ear infection;
SARC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg09373136	chr17:61933544	TCAM1	-0.45	-6.2	-0.38	2.48e-9	Prudent dietary pattern;
SARC	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg11366901	chr6:160182831	ACAT2	1.0	10.47	0.57	2.79e-21	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs854765	0.583	rs11656840	chr17:17837354	C/T	cg04398451	chr17:18023971	MYO15A	-0.39	-5.56	-0.34	7.34e-8	Total body bone mineral density;
SARC	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg22535103	chr8:58192502	C8orf71	-0.66	-6.2	-0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6840360	0.532	rs4235221	chr4:152511193	C/T	cg22705602	chr4:152727874	NA	-0.43	-6.79	-0.41	9.46e-11	Intelligence (multi-trait analysis);
SARC	cis	rs11676348	0.846	rs3890158	chr2:218990292	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.5	-6.51	-0.39	4.51e-10	Ulcerative colitis;
SARC	cis	rs11764590	0.651	rs12673687	chr7:2081873	C/T	cg23043544	chr7:2124092	MAD1L1	-0.35	-4.87	-0.3	2.09e-6	Neuroticism;
SARC	cis	rs5758659	0.652	rs133305	chr22:42395960	C/T	cg04733989	chr22:42467013	NAGA	0.5	6.74	0.4	1.23e-10	Cognitive function;
SARC	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg04511125	chr2:88470314	THNSL2	0.81	7.27	0.43	5.44e-12	Plasma clusterin levels;
SARC	cis	rs2048656	0.501	rs4510870	chr8:9480416	C/A	cg21625330	chr8:9911636	MSRA	0.53	5.04	0.31	9.54e-7	Schizophrenia;
SARC	trans	rs17685	0.753	rs10233282	chr7:75790081	C/T	cg19862616	chr7:65841803	NCRNA00174	0.64	8.01	0.46	5.5e-14	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg04277193	chr17:41438351	NA	0.46	4.98	0.31	1.25e-6	Menopause (age at onset);
SARC	cis	rs10870270	0.956	rs10430618	chr10:133748996	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.83	-10.76	-0.58	3.57e-22	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs9914544	0.564	rs4334348	chr17:18787004	G/T	cg25390199	chr17:18761479	PRPSAP2	0.46	6.05	0.37	5.66e-9	Educational attainment (years of education);
SARC	cis	rs4642101	0.662	rs57411588	chr3:12820384	C/G	cg24848339	chr3:12840334	CAND2	0.36	5.85	0.36	1.64e-8	QRS complex (12-leadsum);
SARC	cis	rs9527	0.590	rs10509766	chr10:104926334	T/C	cg04362960	chr10:104952993	NT5C2	0.43	5.12	0.32	6.5e-7	Arsenic metabolism;
SARC	cis	rs8017423	0.967	rs4904657	chr14:90721600	A/G	cg20276874	chr14:90721474	PSMC1	-0.38	-5.32	-0.33	2.41e-7	Mortality in heart failure;
SARC	cis	rs17270561	0.609	rs6941933	chr6:25745702	T/C	cg17691542	chr6:26056736	HIST1H1C	0.61	7.36	0.43	3.06e-12	Iron status biomarkers;
SARC	cis	rs796364	0.715	rs78988795	chr2:201095739	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.78	-5.99	-0.37	8.01e-9	Schizophrenia;
SARC	cis	rs910316	0.673	rs2012627	chr14:75443103	C/T	cg06637938	chr14:75390232	RPS6KL1	0.45	5.9	0.36	1.27e-8	Height;
SARC	cis	rs8180040	0.739	rs66539935	chr3:47025327	C/T	cg27129171	chr3:47204927	SETD2	-0.58	-7.7	-0.45	3.97e-13	Colorectal cancer;
SARC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg03395511	chr6:291903	DUSP22	0.54	6.93	0.41	4e-11	Menopause (age at onset);
SARC	cis	rs7130144	0.541	rs28402217	chr11:130459644	C/G	cg26307797	chr11:130446613	NA	-0.7	-5.81	-0.36	2.02e-8	Urate levels in lean individuals;
SARC	cis	rs13144136	0.687	rs11734917	chr4:10660359	C/T	cg10242279	chr4:10666415	CLNK	-0.42	-6.89	-0.41	5.04e-11	Resistance to antihypertensive treatment in hypertension;
SARC	cis	rs9815354	0.638	rs12634670	chr3:41875299	G/C	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2230307	0.536	rs11166385	chr1:100443462	A/G	cg24955406	chr1:100503596	HIAT1	0.7	7.09	0.42	1.59e-11	Carotid intima media thickness;
SARC	cis	rs13082711	0.554	rs13087873	chr3:27392326	C/T	cg02860705	chr3:27208620	NA	0.64	7.94	0.46	8.59e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs1448094	0.842	rs12318815	chr12:86452281	T/C	cg02569458	chr12:86230093	RASSF9	-0.39	-5.82	-0.36	1.95e-8	Major depressive disorder;
SARC	cis	rs9291683	0.588	rs12507330	chr4:10002195	G/A	cg11266682	chr4:10021025	SLC2A9	0.41	7.29	0.43	4.79e-12	Bone mineral density;
SARC	cis	rs73206853	0.686	rs73194039	chr12:111179153	C/T	cg10860002	chr12:110842031	ANAPC7	0.6	5.02	0.31	1.02e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs9815354	0.953	rs6795797	chr3:41862250	A/G	cg03022575	chr3:42003672	ULK4	0.55	5.25	0.33	3.46e-7	Pulse pressure;Diastolic blood pressure;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg27172745	chr16:88105698	BANP	0.52	6.62	0.4	2.45e-10	Schizophrenia;
SARC	cis	rs7566780	0.656	rs1367156	chr2:16678416	A/G	cg09580478	chr2:16689509	NA	0.45	6.1	0.37	4.29e-9	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs11711311	0.869	rs1026364	chr3:113370010	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	7.12	0.42	1.31e-11	IgG glycosylation;
SARC	cis	rs765787	0.530	rs12909987	chr15:45512207	C/T	cg24006582	chr15:45444508	DUOX1	-0.47	-6.16	-0.37	3.11e-9	Uric acid levels;
SARC	cis	rs4243830	0.850	rs12030607	chr1:6601007	T/A	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.57	-5.05	-0.31	9.1e-7	Body mass index;
SARC	cis	rs6088580	0.634	rs6059905	chr20:33126946	T/C	cg24642439	chr20:33292090	TP53INP2	0.67	8.4	0.48	4.49e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg14784868	chr12:69753453	YEATS4	0.63	8.77	0.5	3.78e-16	Cerebrospinal fluid biomarker levels;
SARC	cis	rs10782582	0.593	rs17647178	chr1:76210524	A/G	cg10523679	chr1:76189770	ACADM	-0.44	-5.49	-0.34	1.05e-7	Daytime sleep phenotypes;
SARC	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg06420487	chr17:61919686	SMARCD2	0.49	5.71	0.35	3.46e-8	Height;
SARC	cis	rs13065560	0.594	rs4398365	chr3:38878804	C/G	cg01426195	chr3:39028469	NA	-0.32	-4.89	-0.3	1.9e-6	Interleukin-18 levels;
SARC	cis	rs911263	0.603	rs12881502	chr14:68783791	A/C	cg18825221	chr14:68749962	RAD51L1	0.4	7.09	0.42	1.6e-11	Primary biliary cholangitis;
SARC	cis	rs9457247	0.765	rs10946203	chr6:167446735	A/C	cg07741184	chr6:167504864	NA	0.38	7.44	0.44	1.96e-12	Crohn's disease;
SARC	cis	rs10992471	0.603	rs7045572	chr9:95137964	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.49	-0.34	1.06e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs6690583	0.623	rs12042160	chr1:85504516	A/G	cg22153463	chr1:85462885	MCOLN2	0.74	6.05	0.37	5.67e-9	Serum sulfate level;
SARC	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg04398451	chr17:18023971	MYO15A	0.5	7.03	0.42	2.26e-11	Total body bone mineral density;
SARC	trans	rs2727020	0.533	rs10839195	chr11:48973460	C/T	cg15704280	chr7:45808275	SEPT13	-0.55	-7.45	-0.44	1.8e-12	Coronary artery disease;
SARC	cis	rs9790314	0.638	rs62280303	chr3:160647891	G/A	cg04691961	chr3:161091175	C3orf57	0.62	8.59	0.49	1.27e-15	Morning vs. evening chronotype;
SARC	cis	rs501120	0.929	rs2576355	chr10:44750362	A/G	cg09554077	chr10:44749378	NA	0.46	6.42	0.39	7.38e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg08219700	chr8:58056026	NA	0.61	6.24	0.38	2.05e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6429082	0.902	rs704708	chr1:235620134	T/C	cg26050004	chr1:235667680	B3GALNT2	0.39	4.97	0.31	1.27e-6	Adiposity;
SARC	cis	rs2841233	0.558	rs10145270	chr14:105349891	G/A	cg01147727	chr14:105363015	KIAA0284	-0.33	-5.42	-0.33	1.51e-7	IgG glycosylation;
SARC	trans	rs7937682	0.889	rs3017767	chr11:111508098	A/G	cg18187862	chr3:45730750	SACM1L	0.55	6.96	0.41	3.46e-11	Primary sclerosing cholangitis;
SARC	trans	rs9395865	0.520	rs6903708	chr6:53332940	A/G	cg11949866	chr1:10754891	CASZ1	-0.49	-6.29	-0.38	1.52e-9	Electroencephalographic traits in alcoholism;
SARC	cis	rs826838	0.967	rs826855	chr12:39114888	T/C	cg13010199	chr12:38710504	ALG10B	-0.69	-9.65	-0.53	9.18e-19	Heart rate;
SARC	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg13628971	chr7:2884303	GNA12	-0.65	-7.79	-0.45	2.17e-13	Height;
SARC	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg17971929	chr21:40555470	PSMG1	1.0	13.71	0.67	8.87e-32	Cognitive function;
SARC	cis	rs12579753	0.526	rs73359948	chr12:82322986	A/G	cg07988820	chr12:82153109	PPFIA2	-0.42	-4.79	-0.3	3e-6	Resting heart rate;
SARC	cis	rs712039	0.652	rs67879888	chr17:35795312	A/G	cg16670864	chr17:35848621	DUSP14	0.45	5.03	0.31	9.95e-7	Tuberculosis;
SARC	cis	rs1008375	0.966	rs4698638	chr4:17632988	G/C	cg16339924	chr4:17578868	LAP3	0.66	8.83	0.5	2.57e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs75920871	0.528	rs11216240	chr11:116899248	A/T	cg01368799	chr11:117014884	PAFAH1B2	-0.46	-4.75	-0.3	3.57e-6	Subjective well-being;
SARC	cis	rs9788682	1.000	rs7181447	chr15:78814567	A/G	cg17108064	chr15:78857060	CHRNA5	-0.31	-4.85	-0.3	2.27e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg13206674	chr6:150067644	NUP43	0.47	6.12	0.37	3.99e-9	Lung cancer;
SARC	cis	rs35110281	0.720	rs162380	chr21:44925283	T/C	cg01579765	chr21:45077557	HSF2BP	0.34	5.73	0.35	3.03e-8	Mean corpuscular volume;
SARC	cis	rs7481584	0.926	rs10833024	chr11:3010390	C/T	cg25174290	chr11:3078921	CARS	-0.52	-6.89	-0.41	5.18e-11	Calcium levels;
SARC	cis	rs72781680	0.611	rs2111884	chr2:24289472	A/T	cg08917208	chr2:24149416	ATAD2B	0.61	6.31	0.38	1.42e-9	Lymphocyte counts;
SARC	cis	rs2439831	0.681	rs28594657	chr15:43588888	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.93	0.46	9.28e-14	Lung cancer in ever smokers;
SARC	cis	rs3806933	0.522	rs12515367	chr5:110447853	A/G	cg04022379	chr5:110408740	TSLP	0.72	9.15	0.51	2.96e-17	Eosinophilic esophagitis;
SARC	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	11.84	0.61	1.28e-25	Alzheimer's disease;
SARC	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg08975724	chr8:8085496	FLJ10661	0.66	8.69	0.49	6.42e-16	Systolic blood pressure;
SARC	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg07636037	chr3:49044803	WDR6	0.65	8.57	0.49	1.44e-15	Resting heart rate;
SARC	cis	rs911555	0.504	rs4444269	chr14:104072724	G/C	cg12935359	chr14:103987150	CKB	-0.33	-4.79	-0.3	2.99e-6	Intelligence (multi-trait analysis);
SARC	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg07636037	chr3:49044803	WDR6	1.02	17.85	0.76	1.75e-45	Parkinson's disease;
SARC	cis	rs9457247	1.000	rs430293	chr6:167404958	A/G	cg07741184	chr6:167504864	NA	0.29	5.55	0.34	7.72e-8	Crohn's disease;
SARC	cis	rs6964587	1.000	rs34043009	chr7:91578447	T/C	cg17063962	chr7:91808500	NA	-0.93	-14.95	-0.7	6.9e-36	Breast cancer;
SARC	cis	rs72781680	1.000	rs6751655	chr2:24155478	A/G	cg08917208	chr2:24149416	ATAD2B	0.85	8.04	0.47	4.38e-14	Lymphocyte counts;
SARC	cis	rs4820539	0.966	rs2283803	chr22:23454881	G/A	cg14186256	chr22:23484241	RTDR1	0.84	13.15	0.65	6.47e-30	Bone mineral density;
SARC	cis	rs9916302	0.904	rs8079560	chr17:37497661	C/T	cg15445000	chr17:37608096	MED1	-0.44	-5.39	-0.33	1.71e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs8141529	0.764	rs5752809	chr22:29225500	G/A	cg02153584	chr22:29168773	CCDC117	0.79	11.65	0.61	5e-25	Lymphocyte counts;
SARC	cis	rs1865760	0.566	rs9348706	chr6:26065481	G/C	cg18357526	chr6:26021779	HIST1H4A	0.43	5.41	0.33	1.55e-7	Height;
SARC	cis	rs2153535	0.540	rs9378557	chr6:8517381	T/C	cg21535247	chr6:8435926	SLC35B3	0.57	7.21	0.43	7.67e-12	Motion sickness;
SARC	cis	rs7726839	0.561	rs4957050	chr5:579066	A/C	cg09021430	chr5:549028	NA	-0.48	-6.35	-0.38	1.12e-9	Obesity-related traits;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg11856918	chr8:20054956	ATP6V1B2	0.51	6.81	0.41	8.24e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs9868809	0.656	rs73078362	chr3:48703917	G/C	cg06212747	chr3:49208901	KLHDC8B	-0.68	-4.83	-0.3	2.51e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs73195822	0.614	rs55946973	chr12:111214936	C/T	cg10860002	chr12:110842031	ANAPC7	0.58	5.07	0.31	8.3e-7	Itch intensity from mosquito bite;
SARC	cis	rs7568458	0.837	rs35565292	chr2:85790316	T/A	cg17127132	chr2:85788382	GGCX	0.46	5.94	0.36	1.05e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs1832871	0.711	rs9459924	chr6:158703902	G/A	cg07165851	chr6:158734300	TULP4	0.56	6.76	0.4	1.09e-10	Height;
SARC	cis	rs7700895	0.737	rs3777184	chr5:95262044	G/C	cg16656078	chr5:95278638	ELL2	-0.59	-7.08	-0.42	1.73e-11	IgG glycosylation;
SARC	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.74	-10.24	-0.56	1.46e-20	Total body bone mineral density;
SARC	cis	rs796364	0.951	rs971232	chr2:200792881	C/T	cg23649088	chr2:200775458	C2orf69	0.64	6.06	0.37	5.52e-9	Schizophrenia;
SARC	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg05861140	chr6:150128134	PCMT1	-0.37	-4.78	-0.3	3.18e-6	Lung cancer;
SARC	cis	rs7937682	0.921	rs11213940	chr11:111433927	C/A	cg09085632	chr11:111637200	PPP2R1B	0.83	11.84	0.61	1.28e-25	Primary sclerosing cholangitis;
SARC	cis	rs7625806	0.864	rs13063664	chr3:38108549	T/C	cg15121877	chr3:38081287	DLEC1	0.35	4.76	0.3	3.43e-6	Carotid intima media thickness;
SARC	cis	rs9733	0.519	rs1134067	chr1:150721175	G/T	cg13175981	chr1:150552382	MCL1	-0.47	-5.61	-0.35	5.66e-8	Tonsillectomy;
SARC	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg24675658	chr1:53192096	ZYG11B	0.78	11.17	0.59	1.82e-23	Monocyte count;
SARC	cis	rs1707322	0.752	rs10789467	chr1:46118745	C/G	cg06784218	chr1:46089804	CCDC17	0.36	6.25	0.38	1.93e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6933660	0.646	rs6911456	chr6:151778934	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.72	9.63	0.53	1.06e-18	Menarche (age at onset);
SARC	cis	rs9486715	1.000	rs9486715	chr6:97059769	A/C	cg06623918	chr6:96969491	KIAA0776	-0.84	-11.41	-0.6	3.02e-24	Headache;
SARC	cis	rs11098499	0.909	rs28555550	chr4:120211040	C/G	cg09307838	chr4:120376055	NA	0.84	11.48	0.6	1.76e-24	Corneal astigmatism;
SARC	cis	rs636291	0.517	rs673254	chr1:10550352	C/T	cg17425144	chr1:10567563	PEX14	0.41	6.65	0.4	2.11e-10	Prostate cancer;
SARC	cis	rs1707322	0.865	rs785501	chr1:46579611	C/T	cg03146154	chr1:46216737	IPP	-0.46	-5.44	-0.34	1.34e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg05368731	chr17:41323189	NBR1	0.79	9.57	0.53	1.59e-18	Menopause (age at onset);
SARC	cis	rs3126085	0.935	rs12407553	chr1:152297517	A/G	cg03465714	chr1:152285911	FLG	0.48	5.59	0.34	6.32e-8	Atopic dermatitis;
SARC	cis	rs9398803	0.932	rs9401876	chr6:126669479	C/A	cg19875578	chr6:126661172	C6orf173	0.6	8.17	0.47	1.96e-14	Male-pattern baldness;
SARC	cis	rs2204008	0.570	rs12318341	chr12:38251087	T/C	cg14851346	chr12:38532713	NA	-0.48	-5.83	-0.36	1.8e-8	Bladder cancer;
SARC	cis	rs651907	0.535	rs11711903	chr3:101500748	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	6.11	0.37	4.12e-9	Colorectal cancer;
SARC	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg19729930	chr2:74357872	NA	0.76	11.18	0.59	1.67e-23	Gestational age at birth (maternal effect);
SARC	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg11247378	chr22:39784982	NA	-0.31	-5.13	-0.32	5.98e-7	Intelligence (multi-trait analysis);
SARC	cis	rs3820928	0.605	rs2228555	chr2:227872995	C/T	cg05526886	chr2:227700861	RHBDD1	0.42	5.11	0.32	6.81e-7	Pulmonary function;
SARC	cis	rs6088590	1.000	rs6058111	chr20:33310999	T/C	cg24642439	chr20:33292090	TP53INP2	0.86	12.43	0.63	1.48e-27	Coronary artery disease;
SARC	cis	rs3796352	0.571	rs71301816	chr3:53142071	G/A	cg27565382	chr3:53032988	SFMBT1	0.9	5.85	0.36	1.65e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg18252515	chr7:66147081	NA	-1.14	-9.66	-0.53	8.54e-19	Diabetic kidney disease;
SARC	cis	rs344364	0.511	rs911392	chr16:1947259	A/G	cg26617929	chr16:1858877	NA	-0.71	-6.02	-0.37	6.73e-9	Glomerular filtration rate in chronic kidney disease;
SARC	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg21144161	chr5:423903	AHRR	0.31	4.87	0.3	2.05e-6	Cystic fibrosis severity;
SARC	cis	rs4969178	0.965	rs2292642	chr17:76395430	C/T	cg02836325	chr17:76403955	PGS1	0.33	5.01	0.31	1.07e-6	HDL cholesterol levels;
SARC	cis	rs35110281	0.667	rs7282405	chr21:45123611	C/G	cg01579765	chr21:45077557	HSF2BP	-0.35	-5.51	-0.34	9.31e-8	Mean corpuscular volume;
SARC	cis	rs950027	0.787	rs1153845	chr15:45724729	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.51	-6.11	-0.37	4.24e-9	Response to fenofibrate (adiponectin levels);
SARC	trans	rs393155	0.517	rs330050	chr8:9087679	G/C	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.43	-0.39	6.98e-10	Neuroticism;
SARC	cis	rs854765	0.693	rs9907287	chr17:17774118	C/T	cg05444541	chr17:17804740	TOM1L2	0.3	5.03	0.31	9.8e-7	Total body bone mineral density;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg25818813	chr2:112656629	MERTK	0.49	6.76	0.4	1.13e-10	Tetralogy of Fallot;
SARC	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg01316550	chr5:56110833	MAP3K1	0.53	4.9	0.31	1.8e-6	Initial pursuit acceleration;
SARC	cis	rs17376456	0.569	rs6556839	chr5:93206292	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.49	-4.92	-0.31	1.66e-6	Diabetic retinopathy;
SARC	cis	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg07636037	chr3:49044803	WDR6	0.51	5.84	0.36	1.71e-8	Resting heart rate;
SARC	cis	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg24110177	chr3:50126178	RBM5	0.63	8.44	0.48	3.41e-15	Body mass index;
SARC	cis	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg08975724	chr8:8085496	FLJ10661	0.51	6.38	0.39	9.22e-10	Mood instability;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg05351201	chr14:89029602	ZC3H14	0.54	7.5	0.44	1.3e-12	Tetralogy of Fallot;
SARC	trans	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg21775007	chr8:11205619	TDH	-0.51	-6.43	-0.39	6.98e-10	Joint mobility (Beighton score);
SARC	cis	rs918629	0.679	rs6883880	chr5:95271173	A/T	cg16656078	chr5:95278638	ELL2	-0.67	-7.69	-0.45	4.02e-13	IgG glycosylation;
SARC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg09373136	chr17:61933544	TCAM1	-0.45	-6.16	-0.37	3.18e-9	Prudent dietary pattern;
SARC	cis	rs7786877	0.521	rs4729606	chr7:100321790	T/C	cg20848291	chr7:100343083	ZAN	-0.68	-7.63	-0.45	5.93e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs1185460	0.967	rs1786684	chr11:118938435	G/A	cg01677386	chr11:118938358	VPS11	-0.39	-4.72	-0.3	4.08e-6	Coronary artery disease;
SARC	cis	rs2718058	0.564	rs2709105	chr7:37757216	T/C	cg24998770	chr7:37888106	TXNDC3	-0.31	-4.76	-0.3	3.33e-6	Alzheimer's disease (late onset);
SARC	cis	rs7179456	0.517	rs7167872	chr15:59271375	T/C	cg05156742	chr15:59063176	FAM63B	0.61	7.87	0.46	1.3e-13	Asperger disorder;
SARC	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg07414643	chr4:187882934	NA	-0.47	-7.02	-0.42	2.35e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs5167	0.533	rs11083755	chr19:45490065	C/T	cg10169327	chr19:45448959	APOC2	0.33	4.86	0.3	2.18e-6	Blood protein levels;
SARC	cis	rs12142240	0.698	rs41534051	chr1:46828734	A/G	cg00530320	chr1:46809349	NSUN4	0.6	7.34	0.43	3.59e-12	Menopause (age at onset);
SARC	cis	rs16944613	0.588	rs12438183	chr15:91139244	T/C	cg26821196	chr15:91095069	CRTC3	0.52	5.31	0.33	2.51e-7	Colorectal cancer;
SARC	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg05313129	chr8:58192883	C8orf71	-0.51	-4.94	-0.31	1.49e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs17023223	0.537	rs6662165	chr1:119614071	T/G	cg05756136	chr1:119680316	WARS2	-0.46	-5.31	-0.33	2.58e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs2731664	0.792	rs179809	chr5:176865329	T/G	cg23176889	chr5:176863531	GRK6	-0.56	-8.25	-0.48	1.16e-14	Intelligence (multi-trait analysis);
SARC	trans	rs1853207	1.000	rs79800397	chr10:96714425	C/A	cg02737782	chr1:8014393	NA	-0.89	-6.4	-0.39	8.69e-10	Blood metabolite levels;
SARC	cis	rs73086581	0.945	rs6052219	chr20:3970307	A/G	cg02187196	chr20:3869020	PANK2	0.67	6.46	0.39	6.21e-10	Response to antidepressants in depression;
SARC	cis	rs73206853	0.841	rs73206882	chr12:110840515	G/A	cg10860002	chr12:110842031	ANAPC7	0.62	4.91	0.31	1.72e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg21016266	chr12:122356598	WDR66	0.42	6.49	0.39	5.23e-10	Mean corpuscular volume;
SARC	cis	rs9457247	0.935	rs2757050	chr6:167377165	G/T	cg07741184	chr6:167504864	NA	-0.3	-5.61	-0.35	5.69e-8	Crohn's disease;
SARC	cis	rs208520	0.909	rs9453672	chr6:66991431	A/G	cg07460842	chr6:66804631	NA	0.81	9.32	0.52	9.34e-18	Exhaled nitric oxide output;
SARC	cis	rs651907	0.557	rs17347644	chr3:101547733	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.48	5.41	0.33	1.58e-7	Colorectal cancer;
SARC	cis	rs9796	0.621	rs2928142	chr15:41470449	T/C	cg18705301	chr15:41695430	NDUFAF1	0.56	8.07	0.47	3.82e-14	Menopause (age at onset);
SARC	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	9.06	0.51	5.34e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.46	-5.75	-0.35	2.79e-8	Personality dimensions;
SARC	cis	rs74576663	0.810	rs7331473	chr13:107181265	G/A	cg06534061	chr13:107220663	ARGLU1	0.46	4.73	0.3	3.84e-6	Ankle injury;
SARC	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg10734734	chr19:58859021	A1BG	0.49	5.69	0.35	3.7e-8	Mean platelet volume;
SARC	cis	rs636523	0.561	rs11208008	chr1:63190794	T/G	cg06896770	chr1:63153194	DOCK7	0.72	7.61	0.45	6.8e-13	Lipid traits;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg17855823	chr6:89572705	RNGTT	-0.43	-6.3	-0.38	1.46e-9	Alcohol dependence;
SARC	cis	rs4423214	0.840	rs1792224	chr11:71176141	C/T	cg05163923	chr11:71159392	DHCR7	-0.61	-7.39	-0.44	2.64e-12	Vitamin D levels;
SARC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg11494091	chr17:61959527	GH2	0.54	8.09	0.47	3.28e-14	Prudent dietary pattern;
SARC	cis	rs7412746	0.621	rs72704656	chr1:150828307	A/G	cg10589385	chr1:150898437	SETDB1	0.43	5.66	0.35	4.36e-8	Melanoma;
SARC	cis	rs9300255	0.722	rs12304248	chr12:123810425	C/T	cg00376283	chr12:123451042	ABCB9	-0.47	-4.85	-0.3	2.22e-6	Neutrophil percentage of white cells;
SARC	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg04772025	chr11:68637568	NA	0.49	6.14	0.37	3.49e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs79349575	0.783	rs4793996	chr17:47019597	T/C	cg07967210	chr17:47022446	SNF8	0.38	4.77	0.3	3.2e-6	Type 2 diabetes;
SARC	cis	rs9486719	0.947	rs2499801	chr6:96854594	G/A	cg06623918	chr6:96969491	KIAA0776	0.72	7.47	0.44	1.56e-12	Migraine;Coronary artery disease;
SARC	trans	rs79976124	0.879	rs17511467	chr6:66627293	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	8.0	0.46	5.76e-14	Type 2 diabetes;
SARC	cis	rs2073300	0.609	rs2281434	chr20:23378101	C/A	cg16736954	chr20:23401023	NAPB	0.79	4.99	0.31	1.16e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs7714584	1.000	rs11167526	chr5:150332481	G/A	cg22134413	chr5:150180641	NA	0.86	6.46	0.39	6.16e-10	Crohn's disease;
SARC	cis	rs763121	0.853	rs2267394	chr22:39101633	T/C	cg21395723	chr22:39101663	GTPBP1	0.55	6.56	0.39	3.46e-10	Menopause (age at onset);
SARC	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.39	0.44	2.61e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs73206853	0.563	rs17682444	chr12:111154626	C/T	cg10860002	chr12:110842031	ANAPC7	0.58	4.74	0.3	3.76e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.72	7.44	0.44	1.87e-12	Platelet count;
SARC	cis	rs2228479	0.867	rs62052168	chr16:89947203	G/A	cg12064134	chr16:90016061	DEF8	-0.55	-4.75	-0.3	3.59e-6	Skin colour saturation;
SARC	cis	rs2228479	0.850	rs11648689	chr16:89806732	G/A	cg06558623	chr16:89946397	TCF25	0.91	6.37	0.39	9.81e-10	Skin colour saturation;
SARC	cis	rs918629	0.530	rs2042340	chr5:95235193	T/C	cg16656078	chr5:95278638	ELL2	-0.55	-6.78	-0.41	9.6e-11	IgG glycosylation;
SARC	cis	rs4975616	0.869	rs380286	chr5:1320247	G/A	cg26373071	chr5:1325741	CLPTM1L	0.33	5.38	0.33	1.8e-7	Lung cancer;
SARC	cis	rs4319547	0.688	rs10847242	chr12:123079020	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.5	-6.54	-0.39	3.78e-10	Body mass index;
SARC	cis	rs9398803	0.698	rs1101563	chr6:127049198	T/C	cg19875578	chr6:126661172	C6orf173	-0.64	-8.82	-0.5	2.75e-16	Male-pattern baldness;
SARC	cis	rs11690935	0.959	rs7586207	chr2:172671094	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.97	-15.19	-0.71	1.14e-36	Schizophrenia;
SARC	cis	rs2486288	0.656	rs11629807	chr15:45547037	T/C	cg15395560	chr15:45543142	SLC28A2	0.29	5.59	0.34	6.44e-8	Glomerular filtration rate;
SARC	cis	rs7428	0.527	rs7607284	chr2:85547376	C/G	cg03728395	chr2:85555865	TGOLN2	-0.48	-6.62	-0.4	2.49e-10	Ear protrusion;
SARC	cis	rs3008870	0.755	rs2815360	chr1:67494458	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.62	8.03	0.47	4.73e-14	Lymphocyte percentage of white cells;
SARC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.99	12.16	0.62	1.18e-26	Platelet count;
SARC	cis	rs17826219	0.568	rs9907834	chr17:29154013	G/A	cg13385521	chr17:29058706	SUZ12P	0.85	7.66	0.45	4.88e-13	Body mass index;
SARC	cis	rs17376456	0.877	rs10063045	chr5:93457584	A/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.26	0.33	3.28e-7	Diabetic retinopathy;
SARC	cis	rs3820928	0.967	rs4675113	chr2:227766339	G/A	cg05526886	chr2:227700861	RHBDD1	-0.49	-5.87	-0.36	1.49e-8	Pulmonary function;
SARC	cis	rs7829975	0.539	rs940031	chr8:8546848	C/T	cg06636001	chr8:8085503	FLJ10661	-0.44	-5.25	-0.32	3.5e-7	Mood instability;
SARC	cis	rs7712401	0.546	rs10044921	chr5:122179357	C/G	cg19412675	chr5:122181750	SNX24	0.45	5.81	0.36	1.99e-8	Mean platelet volume;
SARC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.14	0.8	6.21e-53	Prudent dietary pattern;
SARC	cis	rs9325144	0.600	rs10880934	chr12:38730455	C/T	cg13010199	chr12:38710504	ALG10B	-0.54	-6.91	-0.41	4.65e-11	Morning vs. evening chronotype;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg07754938	chr3:48885314	PRKAR2A	0.47	6.25	0.38	1.9e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	trans	rs56279505	0.629	rs17586163	chr4:100274571	T/C	cg21156590	chr1:3420848	MEGF6	-0.83	-6.42	-0.39	7.45e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg11644478	chr21:40555479	PSMG1	1.0	12.14	0.62	1.28e-26	Cognitive function;
SARC	cis	rs992157	0.560	rs1514132	chr2:219084082	C/T	cg00012203	chr2:219082015	ARPC2	-0.73	-10.8	-0.58	2.67e-22	Colorectal cancer;
SARC	cis	rs13343954	0.518	rs7252086	chr19:33534929	T/C	cg27124370	chr19:33622961	WDR88	0.43	5.51	0.34	9.32e-8	Colorectal cancer;
SARC	cis	rs644799	0.544	rs1527450	chr11:95467777	G/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.49	5.88	0.36	1.4e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs1215050	0.791	rs983187	chr4:98816350	A/T	cg05340658	chr4:99064831	C4orf37	0.44	5.86	0.36	1.53e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg00933542	chr6:150070202	PCMT1	0.33	5.77	0.35	2.49e-8	Lung cancer;
SARC	cis	rs1371867	0.875	rs1788173	chr8:101330939	A/G	cg11906718	chr8:101322791	RNF19A	-0.63	-8.37	-0.48	5.26e-15	Atrioventricular conduction;
SARC	cis	rs9300255	0.739	rs2337934	chr12:123745359	A/G	cg05973401	chr12:123451056	ABCB9	0.44	4.78	0.3	3.11e-6	Neutrophil percentage of white cells;
SARC	cis	rs8016982	0.962	rs8007841	chr14:81647878	C/T	cg01989461	chr14:81687754	GTF2A1	-0.56	-7.0	-0.42	2.67e-11	Schizophrenia;
SARC	cis	rs854765	0.583	rs4077198	chr17:17834563	T/C	cg04398451	chr17:18023971	MYO15A	-0.39	-5.56	-0.34	7.34e-8	Total body bone mineral density;
SARC	cis	rs3126085	0.935	rs1390485	chr1:152182168	C/T	cg03465714	chr1:152285911	FLG	0.47	5.6	0.34	5.9e-8	Atopic dermatitis;
SARC	cis	rs10771431	0.597	rs10771412	chr12:9354353	A/C	cg08997352	chr12:9597637	DDX12	-0.55	-7.51	-0.44	1.29e-12	Breast size;
SARC	cis	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg22857025	chr5:266934	NA	-1.06	-11.65	-0.61	5.21e-25	Breast cancer;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg04769218	chr7:99098020	ZNF394	0.48	6.23	0.38	2.13e-9	Height;
SARC	cis	rs7223966	0.921	rs2006123	chr17:61958669	G/T	cg26338869	chr17:61819248	STRADA	0.5	5.64	0.35	5.01e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg08219700	chr8:58056026	NA	0.59	6.27	0.38	1.76e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs11864453	0.786	rs1050362	chr16:72130815	C/A	cg16558253	chr16:72132732	DHX38	-0.59	-9.65	-0.53	9.16e-19	Fibrinogen levels;
SARC	cis	rs916888	0.821	rs199504	chr17:44861003	C/T	cg20120463	chr17:44301886	NA	0.32	5.0	0.31	1.14e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs473651	0.904	rs472247	chr2:239362573	G/A	cg21699342	chr2:239360505	ASB1	0.47	6.81	0.41	8e-11	Multiple system atrophy;
SARC	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg04277193	chr17:41438351	NA	0.45	4.93	0.31	1.59e-6	Menopause (age at onset);
SARC	cis	rs11674184	0.659	rs11679605	chr2:11722468	G/A	cg07314298	chr2:11723111	GREB1	-0.48	-5.84	-0.36	1.77e-8	Endometriosis;
SARC	cis	rs12971120	1.000	rs734559	chr18:72179579	G/A	cg25817165	chr18:72167213	CNDP2	-0.51	-7.56	-0.44	9.11e-13	Refractive error;
SARC	cis	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg08564027	chr20:61660810	NA	0.76	11.54	0.6	1.19e-24	Prostate cancer (SNP x SNP interaction);
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg13182541	chr2:97760610	FAHD2B	0.56	7.64	0.45	5.61e-13	Lung adenocarcinoma;
SARC	cis	rs12079745	0.590	rs75967403	chr1:169173497	T/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.82	-5.16	-0.32	5.16e-7	QT interval;
SARC	cis	rs4713118	0.869	rs6456802	chr6:27698355	A/G	cg17221315	chr6:27791827	HIST1H4J	0.49	5.29	0.33	2.77e-7	Parkinson's disease;
SARC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg06873352	chr17:61820015	STRADA	0.52	6.86	0.41	6.22e-11	Prudent dietary pattern;
SARC	cis	rs6701037	0.967	rs1057302	chr1:175126423	A/G	cg00321850	chr1:175162397	KIAA0040	-0.35	-5.3	-0.33	2.72e-7	Alcohol dependence;
SARC	cis	rs35110281	0.667	rs4819291	chr21:45123139	G/A	cg01579765	chr21:45077557	HSF2BP	-0.37	-5.91	-0.36	1.18e-8	Mean corpuscular volume;
SARC	cis	rs12142240	0.698	rs68191463	chr1:46808695	T/C	cg00530320	chr1:46809349	NSUN4	0.58	7.07	0.42	1.74e-11	Menopause (age at onset);
SARC	cis	rs2204008	0.728	rs12369538	chr12:38443942	C/T	cg26384229	chr12:38710491	ALG10B	0.82	10.95	0.58	9.1e-23	Bladder cancer;
SARC	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg16479474	chr6:28041457	NA	0.35	5.25	0.33	3.38e-7	Parkinson's disease;
SARC	cis	rs9814567	1.000	rs9289475	chr3:134236459	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-7.06	-0.42	1.93e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs4268898	1.000	rs10165445	chr2:24441698	C/T	cg06627628	chr2:24431161	ITSN2	0.59	8.23	0.47	1.32e-14	Asthma;
SARC	cis	rs2991971	0.810	rs781058	chr1:45935056	C/G	cg24296786	chr1:45957014	TESK2	-0.58	-8.07	-0.47	3.78e-14	High light scatter reticulocyte count;
SARC	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	7.38	0.44	2.86e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2718058	0.519	rs2598072	chr7:37875319	A/C	cg24998770	chr7:37888106	TXNDC3	0.46	6.86	0.41	6e-11	Alzheimer's disease (late onset);
SARC	cis	rs6912958	0.754	rs4587143	chr6:88292291	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.47	-0.34	1.18e-7	Monocyte percentage of white cells;
SARC	cis	rs6570726	0.791	rs6570694	chr6:145911204	C/G	cg23711669	chr6:146136114	FBXO30	0.84	14.12	0.68	3.87e-33	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs35110281	0.508	rs2838351	chr21:45110784	A/G	cg04455712	chr21:45112962	RRP1B	0.35	4.88	0.3	1.99e-6	Mean corpuscular volume;
SARC	cis	rs13191362	1.000	rs13193282	chr6:163015442	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.55	5.25	0.33	3.46e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2733201	1.000	rs2733208	chr15:44437692	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.74	5.66	0.35	4.35e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	cis	rs78487399	0.808	rs12105786	chr2:43676433	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-5.01	-0.31	1.08e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs3981351	0.797	rs12414006	chr10:115461485	A/G	cg24846397	chr10:115438155	CASP7	-0.37	-4.79	-0.3	2.97e-6	Obesity-related traits;
SARC	cis	rs838721	0.574	rs11676156	chr2:234259001	G/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.37	4.77	0.3	3.32e-6	Total body bone mineral density;
SARC	cis	rs17376456	0.825	rs6898842	chr5:93213221	T/C	cg25358565	chr5:93447407	FAM172A	1.23	12.44	0.63	1.41e-27	Diabetic retinopathy;
SARC	cis	rs7224737	1.000	rs9912088	chr17:40288278	T/C	cg20291162	chr17:40259547	DHX58	-0.33	-4.79	-0.3	2.95e-6	Fibrinogen levels;
SARC	cis	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg00409905	chr10:38381863	ZNF37A	0.52	7.26	0.43	5.83e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg08280861	chr8:58055591	NA	0.6	5.28	0.33	2.92e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7819412	0.595	rs10503416	chr8:10987553	C/T	cg21775007	chr8:11205619	TDH	0.39	4.86	0.3	2.2e-6	Triglycerides;
SARC	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs11758351	0.660	rs77337633	chr6:26233610	T/C	cg01420254	chr6:26195488	NA	0.55	4.75	0.3	3.49e-6	Gout;Renal underexcretion gout;
SARC	cis	rs9325144	0.625	rs11534879	chr12:38968165	A/G	cg13010199	chr12:38710504	ALG10B	-0.51	-6.51	-0.39	4.62e-10	Morning vs. evening chronotype;
SARC	trans	rs3945119	0.838	rs1335733	chr1:91155690	A/T	cg01730148	chr2:3698421	NA	0.38	6.95	0.41	3.61e-11	Intelligence (multi-trait analysis);
SARC	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.6	5.67	0.35	4.16e-8	Age-related macular degeneration (geographic atrophy);
SARC	trans	rs208520	0.690	rs9345764	chr6:66820597	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-14.08	-0.68	5.46e-33	Exhaled nitric oxide output;
SARC	cis	rs7481584	0.961	rs12797969	chr11:3019216	C/T	cg25174290	chr11:3078921	CARS	-0.5	-6.49	-0.39	5.03e-10	Calcium levels;
SARC	cis	rs7769051	1.000	rs7761365	chr6:133101561	T/A	cg22852734	chr6:133119734	C6orf192	1.13	11.55	0.6	1.1e-24	Type 2 diabetes nephropathy;
SARC	cis	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg25427524	chr10:38739819	LOC399744	-0.57	-8.85	-0.5	2.29e-16	Extrinsic epigenetic age acceleration;
SARC	cis	rs6912958	1.000	rs9294380	chr6:88152667	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.62	-8.72	-0.5	5.41e-16	Monocyte percentage of white cells;
SARC	cis	rs2354432	0.607	rs57078845	chr1:146722222	G/A	cg25205988	chr1:146714368	CHD1L	-1.03	-7.4	-0.44	2.4e-12	Mitochondrial DNA levels;
SARC	cis	rs8017423	0.935	rs59179255	chr14:90691773	A/C	cg20276874	chr14:90721474	PSMC1	-0.34	-4.72	-0.3	4.05e-6	Mortality in heart failure;
SARC	cis	rs3857536	0.776	rs7765531	chr6:66932886	G/A	cg07460842	chr6:66804631	NA	-0.51	-5.75	-0.35	2.79e-8	Blood trace element (Cu levels);
SARC	cis	rs6840360	0.550	rs12651635	chr4:152557786	C/T	cg22705602	chr4:152727874	NA	-0.44	-6.84	-0.41	7.02e-11	Intelligence (multi-trait analysis);
SARC	cis	rs17666538	0.585	rs6559065	chr8:623156	G/C	cg00450029	chr8:599525	NA	0.6	5.1	0.32	7.13e-7	IgG glycosylation;
SARC	cis	rs7684253	0.548	rs62308071	chr4:57716886	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.41	-5.06	-0.31	8.42e-7	Migraine;
SARC	cis	rs4713675	0.565	rs9368773	chr6:33682541	C/A	cg15676125	chr6:33679581	C6orf125	0.52	6.4	0.39	8.3e-10	Plateletcrit;
SARC	cis	rs9290065	0.519	rs1447608	chr3:160682019	G/T	cg03342759	chr3:160939853	NMD3	-0.46	-5.41	-0.33	1.55e-7	Kawasaki disease;
SARC	cis	rs11718455	0.767	rs4682924	chr3:43992760	G/A	cg08738300	chr3:44038990	NA	0.52	5.72	0.35	3.23e-8	Coronary artery disease;
SARC	cis	rs11770686	0.666	rs4731603	chr7:75309874	A/G	cg17787366	chr7:75369077	HIP1	0.4	4.89	0.31	1.87e-6	Essential tremor;
SARC	cis	rs616402	0.527	rs604814	chr1:10567122	G/A	cg07384165	chr1:10488281	NA	-0.4	-5.39	-0.33	1.72e-7	Breast size;
SARC	cis	rs35110281	0.693	rs2838345	chr21:45092715	C/T	cg01579765	chr21:45077557	HSF2BP	-0.33	-5.31	-0.33	2.5e-7	Mean corpuscular volume;
SARC	cis	rs826838	1.000	rs7975243	chr12:38849220	C/T	cg26384229	chr12:38710491	ALG10B	0.93	14.78	0.7	2.62e-35	Heart rate;
SARC	cis	rs7115242	0.800	rs10736487	chr11:116950232	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.64	5.31	0.33	2.53e-7	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
SARC	cis	rs1920116	0.778	rs34194057	chr3:169549551	G/T	cg14222479	chr3:169487675	ARPM1	0.42	4.73	0.3	3.96e-6	Glioma (high-grade);
SARC	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.61	7.4	0.44	2.43e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg18357526	chr6:26021779	HIST1H4A	0.85	11.37	0.6	4.07e-24	Intelligence (multi-trait analysis);
SARC	cis	rs9393777	0.623	rs2093169	chr6:26495099	C/T	cg12826209	chr6:26865740	GUSBL1	0.83	7.62	0.45	6.5e-13	Intelligence (multi-trait analysis);
SARC	cis	rs651907	0.557	rs35850993	chr3:101437433	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	6.46	0.39	6.05e-10	Colorectal cancer;
SARC	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg16325326	chr1:53192061	ZYG11B	0.79	12.46	0.63	1.19e-27	Monocyte count;
SARC	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg22974920	chr21:40686053	BRWD1	0.44	4.77	0.3	3.2e-6	Cognitive function;
SARC	cis	rs11190604	1.000	rs7073586	chr10:102307671	A/G	cg07080220	chr10:102295463	HIF1AN	0.85	9.66	0.53	8.67e-19	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs2180341	0.960	rs6913424	chr6:127707010	A/C	cg24812749	chr6:127587940	RNF146	1.03	13.49	0.66	5.04e-31	Breast cancer;
SARC	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg03060546	chr3:49711283	APEH	0.52	6.83	0.41	7.42e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	trans	rs4295623	0.789	rs12541318	chr8:11594970	G/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.84	-0.41	6.79e-11	Morning vs. evening chronotype;
SARC	cis	rs9916302	0.904	rs2338800	chr17:37498149	C/G	cg15445000	chr17:37608096	MED1	-0.42	-5.09	-0.32	7.21e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs2594989	0.895	rs2606741	chr3:11392426	G/A	cg00170343	chr3:11313890	ATG7	0.6	6.28	0.38	1.65e-9	Circulating chemerin levels;
SARC	cis	rs4148883	0.629	rs10009145	chr4:100047929	G/A	cg13256891	chr4:100009986	ADH5	0.6	8.24	0.47	1.27e-14	Alcohol dependence;
SARC	cis	rs1707322	1.000	rs6671754	chr1:46433990	A/G	cg06784218	chr1:46089804	CCDC17	0.34	5.95	0.36	9.76e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7551222	0.716	rs11240751	chr1:204462050	A/G	cg20240347	chr1:204465584	NA	-0.3	-5.21	-0.32	4.2e-7	Schizophrenia;
SARC	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg22920501	chr2:26401640	FAM59B	0.6	7.86	0.46	1.38e-13	Gut microbiome composition (summer);
SARC	cis	rs8141529	0.732	rs2239815	chr22:29192670	C/T	cg02153584	chr22:29168773	CCDC117	-0.83	-12.75	-0.64	1.38e-28	Lymphocyte counts;
SARC	cis	rs4268898	0.552	rs6754391	chr2:24369019	C/T	cg06627628	chr2:24431161	ITSN2	-0.46	-5.84	-0.36	1.71e-8	Asthma;
SARC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.6	7.82	0.46	1.77e-13	Lymphocyte counts;
SARC	cis	rs2075371	0.966	rs2244690	chr7:133987039	A/G	cg11752832	chr7:134001865	SLC35B4	0.56	7.26	0.43	5.74e-12	Mean platelet volume;
SARC	cis	rs10504229	0.679	rs16921687	chr8:58053514	T/C	cg20607798	chr8:58055168	NA	0.61	5.66	0.35	4.51e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	17.95	0.76	7.94e-46	Prudent dietary pattern;
SARC	trans	rs4076764	0.958	rs6688181	chr1:163384193	C/T	cg18233311	chr5:132362578	ZCCHC10	0.49	6.42	0.39	7.45e-10	Motion sickness;
SARC	cis	rs1371867	0.875	rs1788174	chr8:101330957	C/G	cg11906718	chr8:101322791	RNF19A	-0.71	-8.93	-0.5	1.33e-16	Atrioventricular conduction;
SARC	cis	rs7586879	0.639	rs7567997	chr2:25096952	A/G	cg04586622	chr2:25135609	ADCY3	0.3	4.95	0.31	1.42e-6	Body mass index;
SARC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.58	7.35	0.43	3.26e-12	Prudent dietary pattern;
SARC	cis	rs240764	0.817	rs239229	chr6:101105975	T/C	cg09795085	chr6:101329169	ASCC3	0.44	5.71	0.35	3.39e-8	Neuroticism;
SARC	cis	rs2153535	0.580	rs1932282	chr6:8477330	G/A	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs2635047	0.638	rs2571006	chr18:44718515	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	5.93	0.36	1.06e-8	Educational attainment;
SARC	cis	rs4660306	0.614	rs1765711	chr1:45936285	C/T	cg24296786	chr1:45957014	TESK2	-0.56	-5.58	-0.34	6.68e-8	Homocysteine levels;
SARC	cis	rs950776	0.593	rs588765	chr15:78865425	T/C	cg24631222	chr15:78858424	CHRNA5	0.36	4.74	0.3	3.75e-6	Sudden cardiac arrest;
SARC	cis	rs910316	0.763	rs4556	chr14:75476071	G/C	cg06637938	chr14:75390232	RPS6KL1	0.44	5.75	0.35	2.76e-8	Height;
SARC	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg08280861	chr8:58055591	NA	0.61	5.96	0.36	9.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs3812831	0.695	rs913526	chr13:114928946	G/C	cg06611532	chr13:114900021	NA	0.35	5.72	0.35	3.31e-8	Schizophrenia;
SARC	cis	rs9400467	0.537	rs73530977	chr6:111504819	C/T	cg15721981	chr6:111408429	SLC16A10	0.65	5.46	0.34	1.19e-7	Blood metabolite levels;Amino acid levels;
SARC	cis	rs5022636	0.507	rs2031797	chr1:151278505	A/G	cg13175981	chr1:150552382	MCL1	0.54	5.53	0.34	8.76e-8	Gut microbiota (functional units);
SARC	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg18876405	chr7:65276391	NA	-0.45	-4.98	-0.31	1.23e-6	Aortic root size;
SARC	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.79	-9.3	-0.52	1.04e-17	Alzheimer's disease;
SARC	cis	rs7635838	0.687	rs7625495	chr3:11377918	G/T	cg00170343	chr3:11313890	ATG7	0.64	8.81	0.5	2.97e-16	HDL cholesterol;
SARC	cis	rs9640161	0.742	rs2159236	chr7:150017214	A/G	cg10018233	chr7:150070692	REPIN1	0.71	9.52	0.53	2.35e-18	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs61946325	1.000	rs6491248	chr13:28612457	A/G	cg06137852	chr13:28545283	NA	0.35	4.81	0.3	2.68e-6	Monocyte count;
SARC	cis	rs9902453	0.967	rs7222685	chr17:28496430	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	6.77	0.41	1.07e-10	Coffee consumption (cups per day);
SARC	cis	rs13040088	0.518	rs2427452	chr20:61577275	T/C	cg23096297	chr20:61557774	DIDO1	-0.6	-6.46	-0.39	6.04e-10	Menopause (age at onset);
SARC	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg00149659	chr3:10157352	C3orf10	-0.6	-5.41	-0.33	1.57e-7	Alzheimer's disease;
SARC	cis	rs8078723	0.738	rs3816472	chr17:38142677	A/C	cg17467752	chr17:38218738	THRA	-0.38	-4.91	-0.31	1.69e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs7264396	0.790	rs6058293	chr20:34248891	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-8.22	-0.47	1.46e-14	Total cholesterol levels;
SARC	cis	rs9815354	1.000	rs9856633	chr3:42013850	C/T	cg03022575	chr3:42003672	ULK4	0.56	5.38	0.33	1.77e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs1949733	1.000	rs6858542	chr4:8511547	C/G	cg11789530	chr4:8429930	ACOX3	-0.82	-10.86	-0.58	1.75e-22	Response to antineoplastic agents;
SARC	cis	rs35306767	0.903	rs11815185	chr10:923617	T/A	cg26597838	chr10:835615	NA	0.82	8.5	0.49	2.22e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs875971	0.545	rs10950029	chr7:65634321	A/C	cg11764359	chr7:65958608	NA	0.67	6.76	0.4	1.1e-10	Aortic root size;
SARC	cis	rs6570726	0.818	rs952405	chr6:145925952	T/C	cg05347473	chr6:146136440	FBXO30	0.5	6.86	0.41	6.09e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.64	0.57	8.53e-22	Prudent dietary pattern;
SARC	cis	rs9660992	0.573	rs12140422	chr1:205187981	G/A	cg00857998	chr1:205179979	DSTYK	0.52	6.35	0.38	1.12e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs6582630	0.555	rs11613249	chr12:38519339	T/C	cg13010199	chr12:38710504	ALG10B	0.77	10.66	0.57	7.44e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs986417	1.000	rs2224410	chr14:60970531	T/C	cg27398547	chr14:60952738	C14orf39	1.02	9.43	0.53	4.25e-18	Gut microbiota (bacterial taxa);
SARC	cis	rs5167	0.504	rs4803781	chr19:45459671	C/T	cg20090143	chr19:45452003	APOC2	0.3	4.85	0.3	2.3e-6	Blood protein levels;
SARC	cis	rs9902453	0.845	rs62068583	chr17:28001482	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	7.33	0.43	3.72e-12	Coffee consumption (cups per day);
SARC	cis	rs2882667	0.858	rs11948429	chr5:138458584	G/A	cg04439458	chr5:138467593	SIL1	-0.28	-4.79	-0.3	2.98e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	trans	rs7615952	0.641	rs4490307	chr3:125712676	T/G	cg07211511	chr3:129823064	LOC729375	-0.55	-6.37	-0.39	9.98e-10	Blood pressure (smoking interaction);
SARC	cis	rs651907	0.535	rs61396602	chr3:101509046	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.49	5.72	0.35	3.26e-8	Colorectal cancer;
SARC	cis	rs554111	0.660	rs12042978	chr1:21170811	T/C	cg08890418	chr1:21044141	KIF17	-0.37	-5.19	-0.32	4.61e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs703842	0.928	rs724834	chr12:58180416	G/C	cg00677455	chr12:58241039	CTDSP2	0.5	6.4	0.39	8.35e-10	Multiple sclerosis;
SARC	cis	rs9916302	0.904	rs7210488	chr17:37539819	T/G	cg00129232	chr17:37814104	STARD3	0.6	7.49	0.44	1.39e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg23205692	chr1:25664452	TMEM50A	-0.41	-5.2	-0.32	4.34e-7	Erythrocyte sedimentation rate;
SARC	cis	rs7512552	0.803	rs2454286	chr1:150355538	G/A	cg15654264	chr1:150340011	RPRD2	0.38	4.81	0.3	2.7e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg07967176	chr1:113486135	SLC16A1	-0.51	-6.52	-0.39	4.37e-10	Gut microbiota (bacterial taxa);
SARC	cis	rs9462027	0.606	rs9462024	chr6:34772793	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.99	-0.37	7.89e-9	Systemic lupus erythematosus;
SARC	cis	rs400736	0.800	rs225095	chr1:8102801	T/C	cg25007680	chr1:8021821	PARK7	0.49	6.22	0.38	2.24e-9	Response to antidepressants and depression;
SARC	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-5.55	-0.34	7.58e-8	Bipolar disorder;
SARC	cis	rs12908161	1.000	rs35524990	chr15:85258203	T/C	cg17507749	chr15:85114479	UBE2QP1	0.58	6.68	0.4	1.77e-10	Schizophrenia;
SARC	cis	rs765787	0.530	rs2668751	chr15:45517293	T/C	cg24006582	chr15:45444508	DUOX1	-0.47	-6.24	-0.38	2.08e-9	Uric acid levels;
SARC	cis	rs6450176	0.564	rs34360866	chr5:53332737	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.55	-6.23	-0.38	2.21e-9	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs12142240	0.698	rs1475388	chr1:46816465	G/A	cg00530320	chr1:46809349	NSUN4	0.57	6.92	0.41	4.4e-11	Menopause (age at onset);
SARC	cis	rs11758351	0.660	rs2143345	chr6:26229148	C/T	cg01420254	chr6:26195488	NA	0.61	5.19	0.32	4.5e-7	Gout;Renal underexcretion gout;
SARC	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg02733842	chr7:1102375	C7orf50	-0.62	-7.13	-0.42	1.28e-11	Bronchopulmonary dysplasia;
SARC	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs1256061	0.528	rs10143616	chr14:64740175	G/A	cg23250157	chr14:64679961	SYNE2	0.46	6.51	0.39	4.47e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs10958369	0.871	rs10958370	chr8:54417710	T/A	cg12485204	chr8:54507357	NA	0.4	5.76	0.35	2.67e-8	Response to antineoplastic agents;
SARC	cis	rs72781680	0.716	rs2712079	chr2:24082061	G/A	cg06627628	chr2:24431161	ITSN2	-0.53	-5.61	-0.34	5.82e-8	Lymphocyte counts;
SARC	cis	rs7714584	1.000	rs11739677	chr5:150294883	A/G	cg22134413	chr5:150180641	NA	0.8	6.49	0.39	5.04e-10	Crohn's disease;
SARC	cis	rs734999	0.566	rs4648658	chr1:2560882	G/A	cg20673091	chr1:2541236	MMEL1	-0.32	-5.0	-0.31	1.15e-6	Ulcerative colitis;
SARC	cis	rs6912958	0.781	rs9450732	chr6:88249826	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.52	-7.09	-0.42	1.6e-11	Monocyte percentage of white cells;
SARC	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg16405210	chr4:1374714	KIAA1530	-0.47	-5.64	-0.35	4.97e-8	Obesity-related traits;
SARC	trans	rs208520	0.661	rs207079	chr6:66770462	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-14.44	-0.69	3.46e-34	Exhaled nitric oxide output;
SARC	cis	rs818427	0.681	rs153570	chr5:112299978	T/C	cg07820702	chr5:112228657	REEP5	-0.41	-4.78	-0.3	3.14e-6	Total body bone mineral density;
SARC	cis	rs2011503	0.941	rs80146298	chr19:19426317	C/T	cg03709012	chr19:19516395	GATAD2A	0.63	5.33	0.33	2.33e-7	Bipolar disorder;
SARC	trans	rs637571	0.544	rs617791	chr11:65702523	C/G	cg17712092	chr4:129076599	LARP1B	0.7	9.51	0.53	2.43e-18	Eosinophil percentage of white cells;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg19081843	chr11:68606654	CPT1A	-0.54	-6.8	-0.41	8.91e-11	Breast cancer;
SARC	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg15966229	chr18:44337664	ST8SIA5	-0.37	-4.88	-0.3	1.94e-6	Personality dimensions;
SARC	cis	rs4727027	0.625	rs75129390	chr7:148846775	T/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	5.51	0.34	9.28e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs7729447	0.566	rs3828591	chr5:32713108	G/C	cg16267343	chr5:32710456	NPR3	0.66	8.82	0.5	2.75e-16	Blood pressure;
SARC	cis	rs60871478	1.000	rs4720917	chr7:806998	C/G	cg05535760	chr7:792225	HEATR2	0.78	8.06	0.47	3.86e-14	Cerebrospinal P-tau181p levels;
SARC	cis	rs6912958	0.781	rs9450752	chr6:88300013	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.43	-0.34	1.42e-7	Monocyte percentage of white cells;
SARC	cis	rs6963495	0.818	rs56165465	chr7:105180384	C/T	cg13798780	chr7:105162888	PUS7	0.57	5.32	0.33	2.48e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg00149659	chr3:10157352	C3orf10	0.69	6.4	0.39	8.64e-10	Alzheimer's disease;
SARC	cis	rs6963495	0.818	rs6977748	chr7:105167462	T/G	cg19920283	chr7:105172520	RINT1	0.67	5.7	0.35	3.58e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs9300255	0.679	rs4759409	chr12:123719585	G/C	cg05973401	chr12:123451056	ABCB9	0.47	5.18	0.32	4.77e-7	Neutrophil percentage of white cells;
SARC	cis	rs4423214	0.592	rs11234027	chr11:71234107	G/A	cg05163923	chr11:71159392	DHCR7	-0.51	-5.07	-0.32	7.99e-7	Vitamin D levels;
SARC	cis	rs7178572	0.568	rs11072653	chr15:77693934	C/T	cg22256960	chr15:77711686	NA	-0.51	-5.59	-0.34	6.36e-8	Type 2 diabetes;
SARC	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg18876405	chr7:65276391	NA	-0.46	-5.14	-0.32	5.92e-7	Aortic root size;
SARC	cis	rs6088813	0.857	rs6142378	chr20:33997291	T/A	cg14752227	chr20:34000481	UQCC	-0.37	-4.72	-0.3	4.02e-6	Height;
SARC	cis	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg09021430	chr5:549028	NA	-0.45	-5.8	-0.36	2.1e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs9948	1.000	rs72811627	chr2:97517749	C/A	cg01990225	chr2:97406019	LMAN2L	-0.88	-5.69	-0.35	3.77e-8	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs918629	0.798	rs6894651	chr5:95292267	C/T	cg16656078	chr5:95278638	ELL2	-0.64	-7.69	-0.45	4.21e-13	IgG glycosylation;
SARC	cis	rs2742234	0.504	rs10899780	chr10:43725796	T/C	cg15436174	chr10:43711423	RASGEF1A	0.42	5.05	0.31	9.01e-7	Hirschsprung disease;
SARC	cis	rs2304069	0.601	rs216143	chr5:149444147	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.64	6.77	0.41	1.01e-10	HIV-1 control;
SARC	cis	rs17021463	0.615	rs4626213	chr4:95297241	G/A	cg11021082	chr4:95130006	SMARCAD1	0.36	5.19	0.32	4.62e-7	Testicular germ cell tumor;
SARC	cis	rs2425143	1.000	rs11699793	chr20:34271574	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-5.68	-0.35	3.99e-8	Blood protein levels;
SARC	cis	rs892961	0.777	rs747483	chr17:75412091	C/T	cg05865280	chr17:75406074	SEPT9	0.57	8.47	0.49	2.71e-15	Airflow obstruction;
SARC	cis	rs7511006	0.893	rs5771104	chr22:50651839	C/T	cg16473166	chr22:50639996	SELO	0.47	5.3	0.33	2.71e-7	Obesity-related traits;
SARC	trans	rs17173637	1.000	rs73163600	chr7:150504090	G/C	cg01431114	chr6:166076971	PDE10A	-0.92	-6.31	-0.38	1.37e-9	HDL cholesterol;HDL cholesterol levels;
SARC	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs10791323	0.559	rs10750548	chr11:133729469	A/G	cg15485101	chr11:133734466	NA	0.32	4.97	0.31	1.32e-6	Childhood ear infection;
SARC	cis	rs2153535	0.580	rs2184585	chr6:8474168	G/A	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	cis	rs6570726	0.755	rs2103633	chr6:145894021	C/T	cg23711669	chr6:146136114	FBXO30	0.84	13.98	0.68	1.14e-32	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs76917914	0.954	rs12001675	chr9:100793707	G/A	cg03040243	chr9:100819229	NANS	0.6	6.02	0.37	6.59e-9	Immature fraction of reticulocytes;
SARC	cis	rs708547	0.957	rs2458552	chr4:57773442	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.63	6.8	0.41	8.8e-11	Response to bleomycin (chromatid breaks);
SARC	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.46	5.77	0.35	2.54e-8	Gut microbiome composition (summer);
SARC	cis	rs77633900	0.614	rs203753	chr15:76946195	A/T	cg21673338	chr15:77095150	SCAPER	-0.76	-6.36	-0.38	1.07e-9	Non-glioblastoma glioma;Glioma;
SARC	cis	rs3008870	0.755	rs2815363	chr1:67497221	A/G	cg02640540	chr1:67518911	SLC35D1	-0.46	-5.2	-0.32	4.43e-7	Lymphocyte percentage of white cells;
SARC	cis	rs8031584	0.958	rs7176569	chr15:31244495	G/T	cg19680485	chr15:31195859	MTMR15	0.55	6.52	0.39	4.41e-10	Huntington's disease progression;
SARC	cis	rs7084402	0.967	rs1820542	chr10:60315643	T/C	cg07615347	chr10:60278583	BICC1	0.55	8.07	0.47	3.69e-14	Refractive error;
SARC	trans	rs9354308	0.901	rs2814096	chr6:66566131	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.57	6.71	0.4	1.42e-10	Metabolite levels;
SARC	cis	rs12135062	0.755	rs1553287	chr1:3101277	G/A	cg00254258	chr1:3105189	PRDM16	-0.42	-6.78	-0.41	9.83e-11	Migraine;
SARC	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.51	-5.72	-0.35	3.28e-8	Blood metabolite levels;
SARC	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg18876405	chr7:65276391	NA	0.74	9.42	0.53	4.63e-18	Aortic root size;
SARC	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg04267008	chr7:1944627	MAD1L1	-0.54	-6.21	-0.38	2.38e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs3091242	0.935	rs4233043	chr1:25765483	A/G	cg27572855	chr1:25598939	RHD	0.54	9.3	0.52	1.03e-17	Erythrocyte sedimentation rate;
SARC	cis	rs11785400	0.793	rs4736367	chr8:143742477	G/A	cg10596483	chr8:143751796	JRK	0.55	7.01	0.42	2.59e-11	Schizophrenia;
SARC	cis	rs7092929	0.831	rs667943	chr10:3575417	C/T	cg14308648	chr10:3568949	NA	0.51	5.18	0.32	4.72e-7	Coronary artery calcification;
SARC	trans	rs11098499	0.865	rs28753180	chr4:120405367	A/T	cg25214090	chr10:38739885	LOC399744	0.57	7.29	0.43	4.91e-12	Corneal astigmatism;
SARC	cis	rs67311347	0.544	rs60329764	chr3:40334621	C/T	cg24209194	chr3:40518798	ZNF619	-0.5	-6.96	-0.42	3.37e-11	Renal cell carcinoma;
SARC	cis	rs356220	0.642	rs4437213	chr4:90636629	T/A	cg06632027	chr4:90757378	SNCA	0.39	4.95	0.31	1.42e-6	Parkinson's disease;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg03920172	chr3:170075494	SKIL	-0.51	-6.52	-0.39	4.23e-10	Height;
SARC	cis	rs16854884	1.000	rs2370171	chr3:143765177	C/T	cg06585982	chr3:143692056	C3orf58	0.54	6.61	0.4	2.58e-10	Economic and political preferences (feminism/equality);
SARC	cis	rs12545109	0.800	rs973548	chr8:57416402	C/T	cg09654669	chr8:57350985	NA	-0.39	-5.03	-0.31	9.99e-7	Obesity-related traits;
SARC	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg12923728	chr3:195709715	SDHAP1	-0.69	-8.47	-0.48	2.87e-15	Pancreatic cancer;
SARC	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg11987759	chr7:65425863	GUSB	0.45	6.03	0.37	6.22e-9	Aortic root size;
SARC	cis	rs36051895	0.632	rs12344116	chr9:5142216	G/A	cg02405213	chr9:5042618	JAK2	-0.48	-5.85	-0.36	1.67e-8	Pediatric autoimmune diseases;
SARC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg06873352	chr17:61820015	STRADA	0.52	6.8	0.41	8.54e-11	Prudent dietary pattern;
SARC	cis	rs2289583	0.544	rs6495132	chr15:75255322	C/T	cg10253484	chr15:75165896	SCAMP2	0.48	5.29	0.33	2.87e-7	Systemic lupus erythematosus;
SARC	cis	rs67478160	0.619	rs12437066	chr14:104236844	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.35	-4.83	-0.3	2.46e-6	Schizophrenia;
SARC	cis	rs66486766	1	rs66486766	chr15:84806060	G/A	cg24253500	chr15:84953950	NA	0.37	5.25	0.33	3.38e-7	Bipolar disorder lithium response (categorical) or schizophrenia;
SARC	cis	rs1318878	0.840	rs1599367	chr12:15547680	A/G	cg08258403	chr12:15378311	NA	0.47	6.25	0.38	1.97e-9	Intelligence (multi-trait analysis);
SARC	trans	rs7395662	0.500	rs1605360	chr11:48685714	G/A	cg00717180	chr2:96193071	NA	-0.38	-6.36	-0.38	1.04e-9	HDL cholesterol;
SARC	cis	rs113835537	0.559	rs11227498	chr11:66269714	A/G	cg24851651	chr11:66362959	CCS	0.38	4.81	0.3	2.67e-6	Airway imaging phenotypes;
SARC	cis	rs4742903	0.935	rs1580014	chr9:106933625	A/C	cg14250997	chr9:106856677	SMC2	0.44	5.47	0.34	1.17e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs8044995	0.563	rs1110572	chr16:68396119	A/G	cg05110241	chr16:68378359	PRMT7	-0.55	-5.44	-0.34	1.34e-7	Schizophrenia;
SARC	cis	rs7633857	0.536	rs2889391	chr3:160696186	A/G	cg03342759	chr3:160939853	NMD3	-0.49	-5.98	-0.36	8.5e-9	Educational attainment (years of education);
SARC	cis	rs8016982	0.674	rs11850714	chr14:81662993	C/G	cg01989461	chr14:81687754	GTF2A1	0.76	11.46	0.6	2.06e-24	Schizophrenia;
SARC	cis	rs12042938	0.622	rs58403453	chr1:231813438	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.59	7.56	0.44	9.18e-13	Neuranatomic and neurocognitive phenotypes;
SARC	cis	rs1865760	0.566	rs9379821	chr6:26054268	A/C	cg10373733	chr6:25993375	NA	0.41	5.01	0.31	1.1e-6	Height;
SARC	cis	rs9486715	0.867	rs211159	chr6:97023026	G/A	cg18709589	chr6:96969512	KIAA0776	-0.59	-7.43	-0.44	2.03e-12	Headache;
SARC	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-1.04	-16.02	-0.72	1.89e-39	Height;
SARC	cis	rs17376456	0.877	rs9314095	chr5:93425495	T/C	cg21475434	chr5:93447410	FAM172A	0.86	7.77	0.45	2.57e-13	Diabetic retinopathy;
SARC	trans	rs61931739	0.853	rs10844751	chr12:34099651	T/G	cg13010199	chr12:38710504	ALG10B	-0.55	-7.27	-0.43	5.56e-12	Morning vs. evening chronotype;
SARC	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg06212747	chr3:49208901	KLHDC8B	0.67	8.87	0.5	1.98e-16	Parkinson's disease;
SARC	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg02475777	chr4:1388615	CRIPAK	-0.56	-6.35	-0.38	1.12e-9	Longevity;
SARC	cis	rs2043112	0.691	rs10064513	chr5:39081475	A/G	cg04869206	chr5:39074266	RICTOR	0.46	5.93	0.36	1.08e-8	Obesity-related traits;
SARC	cis	rs6088580	0.601	rs6120668	chr20:33099793	A/G	cg24642439	chr20:33292090	TP53INP2	0.68	8.88	0.5	1.87e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs634534	0.561	rs613924	chr11:65769295	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.41	5.16	0.32	5.18e-7	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.49	7.46	0.44	1.66e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs6540556	0.723	rs12138452	chr1:209886578	T/A	cg05527609	chr1:210001259	C1orf107	-0.54	-4.98	-0.31	1.24e-6	Red blood cell count;
SARC	cis	rs9660992	0.573	rs1172159	chr1:205207512	T/C	cg00857998	chr1:205179979	DSTYK	0.52	6.37	0.39	9.74e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg12310025	chr6:25882481	NA	0.49	6.31	0.38	1.38e-9	Blood metabolite levels;
SARC	cis	rs637571	0.522	rs550435	chr11:65732651	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.58	9.11	0.51	3.78e-17	Eosinophil percentage of white cells;
SARC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg11494091	chr17:61959527	GH2	0.54	8.18	0.47	1.86e-14	Prudent dietary pattern;
SARC	cis	rs2228479	0.702	rs78331410	chr16:89917775	C/T	cg00800038	chr16:89945340	TCF25	-0.82	-5.8	-0.35	2.19e-8	Skin colour saturation;
SARC	cis	rs7084402	0.967	rs1658496	chr10:60279909	G/A	cg07615347	chr10:60278583	BICC1	-0.6	-8.82	-0.5	2.78e-16	Refractive error;
SARC	cis	rs965604	1.000	rs12910910	chr15:78767850	C/T	cg24631222	chr15:78858424	CHRNA5	-0.46	-5.94	-0.36	1.02e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg03351412	chr1:154909251	PMVK	0.63	8.34	0.48	6.44e-15	Prostate cancer;
SARC	cis	rs57994353	0.793	rs12552167	chr9:139322927	C/T	cg13611204	chr9:139324423	INPP5E	-0.29	-5.07	-0.32	7.93e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs936229	0.690	rs2472300	chr15:75033909	A/G	cg14664628	chr15:75095509	CSK	-0.98	-12.45	-0.63	1.31e-27	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs9486715	0.867	rs4839834	chr6:96882109	C/A	cg06623918	chr6:96969491	KIAA0776	0.84	11.84	0.61	1.24e-25	Headache;
SARC	cis	rs12188164	0.543	rs890972	chr5:462465	C/A	cg16584290	chr5:462447	EXOC3	0.43	6.67	0.4	1.81e-10	Cystic fibrosis severity;
SARC	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg18404041	chr3:52824283	ITIH1	-0.43	-6.39	-0.39	9.18e-10	Bipolar disorder;
SARC	cis	rs7586879	0.638	rs13035244	chr2:25134009	T/C	cg04586622	chr2:25135609	ADCY3	0.31	5.1	0.32	6.98e-7	Body mass index;
SARC	cis	rs9858542	0.953	rs6997	chr3:49453834	C/T	cg03060546	chr3:49711283	APEH	-0.56	-6.99	-0.42	2.83e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs8067545	0.512	rs4925071	chr17:19954499	T/C	cg13482628	chr17:19912719	NA	0.43	4.88	0.3	1.99e-6	Schizophrenia;
SARC	cis	rs17376456	1.000	rs34756085	chr5:93556294	A/G	cg25358565	chr5:93447407	FAM172A	1.35	14.06	0.68	6.12e-33	Diabetic retinopathy;
SARC	cis	rs2153535	0.580	rs4960411	chr6:8438231	C/G	cg07606381	chr6:8435919	SLC35B3	0.78	11.09	0.59	3.11e-23	Motion sickness;
SARC	cis	rs422249	0.512	rs99780	chr11:61596633	C/T	cg19610905	chr11:61596333	FADS2	-0.39	-4.76	-0.3	3.4e-6	Trans fatty acid levels;
SARC	cis	rs9868809	0.764	rs2633958	chr3:48635432	A/G	cg07636037	chr3:49044803	WDR6	0.61	4.71	0.3	4.19e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs7772486	0.790	rs9376968	chr6:146180364	T/C	cg23711669	chr6:146136114	FBXO30	0.79	13.1	0.65	9.2e-30	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs72627123	0.867	rs80298117	chr14:74447383	G/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	5.52	0.34	8.92e-8	Morning vs. evening chronotype;
SARC	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg07636037	chr3:49044803	WDR6	1.0	17.66	0.76	6.92e-45	Parkinson's disease;
SARC	cis	rs11676348	0.808	rs12694430	chr2:219015799	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.44	-5.73	-0.35	3.12e-8	Ulcerative colitis;
SARC	cis	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg07777115	chr5:623756	CEP72	-0.56	-4.81	-0.3	2.68e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs11690935	0.959	rs11897196	chr2:172585595	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.99	-15.92	-0.72	4.25e-39	Schizophrenia;
SARC	trans	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg00938859	chr5:1591904	SDHAP3	0.79	7.59	0.45	7.5e-13	Breast cancer;
SARC	cis	rs151234	0.741	rs3194168	chr16:28603012	A/G	cg01378222	chr16:28622494	SULT1A1	-0.49	-5.77	-0.35	2.47e-8	Platelet distribution width;
SARC	cis	rs7086627	0.515	rs10887901	chr10:82210581	G/A	cg00277334	chr10:82204260	NA	-0.56	-9.23	-0.52	1.76e-17	Post bronchodilator FEV1;
SARC	trans	rs61931739	0.926	rs1995966	chr12:34095420	G/A	cg26384229	chr12:38710491	ALG10B	-0.57	-6.86	-0.41	6.13e-11	Morning vs. evening chronotype;
SARC	cis	rs644799	1.000	rs596277	chr11:95566886	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	14.8	0.7	2.24e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs11581859	0.613	rs56054030	chr1:99185477	A/G	cg20286094	chr1:99190917	SNX7	-0.41	-4.88	-0.3	1.97e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs12887734	0.566	rs8548	chr14:104199580	A/C	cg26031613	chr14:104095156	KLC1	-0.55	-6.42	-0.39	7.72e-10	Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	cis	rs7937682	0.663	rs3867466	chr11:111668256	A/C	cg22437258	chr11:111473054	SIK2	-0.5	-5.73	-0.35	3.07e-8	Primary sclerosing cholangitis;
SARC	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.64	-7.66	-0.45	4.92e-13	Gut microbiome composition (summer);
SARC	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	10.47	0.57	2.77e-21	Platelet count;
SARC	trans	rs9951602	0.512	rs9946138	chr18:76654608	A/G	cg02800362	chr5:177631904	HNRNPAB	0.7	8.92	0.5	1.38e-16	Obesity-related traits;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg01623984	chr12:120632437	GCN1L1	0.64	6.52	0.39	4.39e-10	Lung cancer in ever smokers;
SARC	cis	rs2304069	0.507	rs7728264	chr5:149394954	C/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.44	4.94	0.31	1.46e-6	HIV-1 control;
SARC	cis	rs3741404	0.594	rs11231704	chr11:63898182	C/T	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.4	-5.73	-0.35	3.08e-8	Platelet count;
SARC	cis	rs11121022	1.000	rs11121022	chr1:7836659	A/C	cg09696653	chr1:7765353	CAMTA1	0.37	5.03	0.31	9.62e-7	Morning vs. evening chronotype;
SARC	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg13607699	chr17:42295918	UBTF	-0.5	-5.94	-0.36	1.02e-8	Total body bone mineral density;
SARC	cis	rs9790314	0.779	rs1609688	chr3:160877096	T/G	cg03342759	chr3:160939853	NMD3	-0.5	-5.92	-0.36	1.17e-8	Morning vs. evening chronotype;
SARC	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg01017244	chr2:74357527	NA	0.55	6.63	0.4	2.27e-10	Gestational age at birth (maternal effect);
SARC	cis	rs2463822	0.583	rs72919472	chr11:62040655	C/T	cg06239285	chr11:62104954	ASRGL1	-0.86	-8.01	-0.46	5.39e-14	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg09359103	chr1:154839909	KCNN3	-0.49	-8.46	-0.48	3.07e-15	Prostate cancer;
SARC	trans	rs35833281	1.000	rs11751312	chr6:55017019	G/T	cg19977494	chr7:128431264	CCDC136	0.7	6.52	0.39	4.39e-10	Morning vs. evening chronotype;
SARC	cis	rs7927592	0.546	rs638076	chr11:68202580	A/G	cg01657329	chr11:68192670	LRP5	-0.4	-5.43	-0.34	1.39e-7	Total body bone mineral density;
SARC	cis	rs3820928	0.874	rs13393894	chr2:227880543	A/G	cg11843606	chr2:227700838	RHBDD1	-0.57	-7.32	-0.43	3.95e-12	Pulmonary function;
SARC	cis	rs17023223	0.537	rs2794312	chr1:119591046	C/T	cg05756136	chr1:119680316	WARS2	-0.45	-5.44	-0.34	1.35e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs12311304	0.865	rs7132318	chr12:15415874	T/C	cg08258403	chr12:15378311	NA	0.43	6.68	0.4	1.76e-10	Behavioural disinhibition (generation interaction);
SARC	cis	rs7589342	0.745	rs11124066	chr2:106516925	T/A	cg16077055	chr2:106428750	NCK2	0.32	5.73	0.35	3.13e-8	Addiction;
SARC	cis	rs636523	0.561	rs11208010	chr1:63203221	T/C	cg06896770	chr1:63153194	DOCK7	0.72	7.16	0.42	1.03e-11	Lipid traits;
SARC	cis	rs986417	0.818	rs2351173	chr14:61008755	C/T	cg27398547	chr14:60952738	C14orf39	0.96	8.75	0.5	4.38e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs7595412	1.000	rs992603	chr2:199027024	C/T	cg00208931	chr2:198669586	PLCL1	0.75	5.99	0.37	7.75e-9	Hip bone size;
SARC	cis	rs637571	0.528	rs11602769	chr11:65594139	T/C	cg26695010	chr11:65641043	EFEMP2	0.67	9.36	0.52	7.05e-18	Eosinophil percentage of white cells;
SARC	cis	rs6120849	0.707	rs3746444	chr20:33578251	A/G	cg06115741	chr20:33292138	TP53INP2	0.54	5.21	0.32	4.15e-7	Protein C levels;
SARC	cis	rs36051895	0.632	rs10815171	chr9:5172567	G/A	cg02405213	chr9:5042618	JAK2	-0.45	-5.51	-0.34	9.25e-8	Pediatric autoimmune diseases;
SARC	cis	rs2070997	0.607	rs2480372	chr9:133706389	G/A	cg11464064	chr9:133710261	ABL1	0.58	5.24	0.32	3.57e-7	Response to amphetamines;
SARC	cis	rs11096990	0.793	rs9997050	chr4:39302665	A/G	cg09390371	chr4:39460303	LIAS;RPL9	-0.51	-5.03	-0.31	9.87e-7	Cognitive function;
SARC	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg11965913	chr1:205819406	PM20D1	0.42	4.76	0.3	3.39e-6	Parkinson's disease;
SARC	cis	rs2204008	0.614	rs4578492	chr12:38036350	T/C	cg26384229	chr12:38710491	ALG10B	0.89	13.1	0.65	9.74e-30	Bladder cancer;
SARC	cis	rs6450176	0.638	rs11746856	chr5:53291295	A/C	ch.5.1024479R	chr5:53302184	ARL15	-1.06	-12.43	-0.63	1.46e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs10191773	0.589	rs72833410	chr2:113054119	G/A	cg07905836	chr2:113190072	RGPD8;RGPD5	0.91	8.71	0.5	5.53e-16	Yeast infection;
SARC	trans	rs1814175	0.645	rs10128731	chr11:50023554	G/T	cg03929089	chr4:120376271	NA	-0.84	-12.08	-0.62	2.02e-26	Height;
SARC	cis	rs6121246	0.559	rs6087771	chr20:30306724	A/G	cg13852791	chr20:30311386	BCL2L1	0.88	10.91	0.58	1.21e-22	Mean corpuscular hemoglobin;
SARC	cis	rs7264396	1.000	rs224437	chr20:34154371	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-5.4	-0.33	1.63e-7	Total cholesterol levels;
SARC	cis	rs72781680	0.898	rs72786270	chr2:24059049	G/A	cg08917208	chr2:24149416	ATAD2B	0.73	6.5	0.39	4.87e-10	Lymphocyte counts;
SARC	cis	rs9291683	0.530	rs73227883	chr4:9979279	T/C	cg11266682	chr4:10021025	SLC2A9	0.41	7.22	0.43	7.19e-12	Bone mineral density;
SARC	cis	rs7566780	0.772	rs3088224	chr2:16731017	T/C	cg09580478	chr2:16689509	NA	-0.52	-5.64	-0.35	4.89e-8	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs7647973	0.593	rs4855885	chr3:49690199	G/A	cg13072238	chr3:49761600	GMPPB	-0.69	-6.63	-0.4	2.32e-10	Menarche (age at onset);
SARC	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg24209194	chr3:40518798	ZNF619	-0.66	-8.62	-0.49	1.07e-15	Renal cell carcinoma;
SARC	cis	rs1957429	0.614	rs75819890	chr14:65370321	T/G	cg23373153	chr14:65346875	NA	-0.96	-6.07	-0.37	5.27e-9	Pediatric areal bone mineral density (radius);
SARC	cis	rs7178572	0.889	rs11857450	chr15:77802791	C/G	cg22256960	chr15:77711686	NA	0.54	6.27	0.38	1.73e-9	Type 2 diabetes;
SARC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg02018176	chr4:1364513	KIAA1530	0.63	9.57	0.53	1.68e-18	Longevity;
SARC	cis	rs12780845	0.540	rs10904896	chr10:17225826	G/A	cg11116878	chr10:17243438	TRDMT1	0.38	4.8	0.3	2.81e-6	Homocysteine levels;
SARC	cis	rs2073499	0.810	rs78501918	chr3:50369914	A/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.54	5.12	0.32	6.34e-7	Schizophrenia;
SARC	cis	rs6540556	0.723	rs6540550	chr1:209925251	A/G	cg05527609	chr1:210001259	C1orf107	-0.52	-5.25	-0.33	3.45e-7	Red blood cell count;
SARC	cis	rs11734570	0.581	rs4461531	chr4:38603576	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.63	6.96	0.42	3.34e-11	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs34891900	0.507	rs2587084	chr22:18140644	T/G	cg19898043	chr22:18121309	BCL2L13	0.65	7.38	0.44	2.83e-12	Sum neutrophil eosinophil counts;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg12680424	chr13:19239716	NA	-0.59	-6.29	-0.38	1.59e-9	Lung cancer in ever smokers;
SARC	cis	rs11613048	0.897	rs729290	chr12:30334886	C/T	cg12718339	chr12:29936407	TMTC1	-0.35	-4.76	-0.3	3.36e-6	Major depressive disorder;
SARC	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg10374962	chr7:1011985	COX19	-0.46	-5.18	-0.32	4.91e-7	Bronchopulmonary dysplasia;
SARC	cis	rs8067545	0.611	rs2703814	chr17:20117151	T/C	cg13482628	chr17:19912719	NA	-0.55	-7.28	-0.43	5.23e-12	Schizophrenia;
SARC	cis	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg25894440	chr7:65020034	NA	-0.75	-5.64	-0.35	4.85e-8	Diabetic kidney disease;
SARC	cis	rs7615952	0.558	rs7641353	chr3:125339879	T/C	cg21696256	chr3:125484277	NA	-0.36	-5.18	-0.32	4.86e-7	Blood pressure (smoking interaction);
SARC	cis	rs72781680	0.898	rs72796158	chr2:23935727	T/C	cg08917208	chr2:24149416	ATAD2B	0.93	8.58	0.49	1.32e-15	Lymphocyte counts;
SARC	cis	rs7582180	0.764	rs12712075	chr2:100924129	T/C	cg14675211	chr2:100938903	LONRF2	0.51	7.37	0.44	2.87e-12	Intelligence (multi-trait analysis);
SARC	cis	rs11249608	0.548	rs7707587	chr5:178462590	G/C	cg01312482	chr5:178451176	ZNF879	-0.37	-4.74	-0.3	3.69e-6	Pubertal anthropometrics;
SARC	cis	rs11077998	0.967	rs4614761	chr17:80505809	C/T	cg10255544	chr17:80519551	FOXK2	0.48	6.79	0.41	8.97e-11	Reticulocyte fraction of red cells;
SARC	cis	rs2361710	1.000	rs2361710	chr17:78111877	C/T	cg23750729	chr17:78120972	EIF4A3	0.37	4.76	0.3	3.41e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
SARC	cis	rs7762018	1.000	rs6912959	chr6:170126224	G/A	cg13891659	chr6:170190454	C6orf122;C6orf208	0.53	4.92	0.31	1.63e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg22857025	chr5:266934	NA	-1.08	-11.7	-0.61	3.51e-25	Breast cancer;
SARC	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg21659725	chr3:3221576	CRBN	0.53	6.83	0.41	7.25e-11	Intelligence (multi-trait analysis);
SARC	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg25894440	chr7:65020034	NA	-0.73	-5.54	-0.34	8.11e-8	Diabetic kidney disease;
SARC	cis	rs9326248	0.954	rs10790177	chr11:117048417	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.51	5.61	0.35	5.64e-8	Blood protein levels;
SARC	cis	rs2645424	0.635	rs6980952	chr8:11716473	C/G	cg21281001	chr8:11725306	CTSB	-0.44	-5.47	-0.34	1.13e-7	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
SARC	cis	rs4972806	0.849	rs2857541	chr2:177029086	C/T	cg13092806	chr2:177043255	NA	0.39	4.94	0.31	1.51e-6	IgG glycosylation;
SARC	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	cis	rs208520	0.674	rs207103	chr6:66795568	G/T	cg07460842	chr6:66804631	NA	-1.08	-15.02	-0.7	4.17e-36	Exhaled nitric oxide output;
SARC	cis	rs8017423	0.904	rs11623741	chr14:90804474	C/T	cg20276874	chr14:90721474	PSMC1	-0.39	-5.02	-0.31	1.03e-6	Mortality in heart failure;
SARC	cis	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg24375607	chr4:120327624	NA	0.39	4.81	0.3	2.69e-6	Corneal astigmatism;
SARC	cis	rs9814567	0.752	rs9848254	chr3:134330374	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.51	-6.61	-0.4	2.53e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs2075371	0.501	rs1646653	chr7:134024686	A/G	cg00033643	chr7:134001901	SLC35B4	0.47	5.76	0.35	2.67e-8	Mean platelet volume;
SARC	cis	rs11122272	0.735	rs2790891	chr1:231513190	G/A	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs7666738	0.830	rs10028692	chr4:98962585	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg11661375	chr5:17275997	BASP1	0.45	6.24	0.38	2.06e-9	Thyroid stimulating hormone;
SARC	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg18825119	chr6:163149453	PACRG;PARK2	0.39	4.83	0.3	2.51e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs13040088	1.000	rs6090159	chr20:61531351	C/G	cg23096297	chr20:61557774	DIDO1	0.95	10.38	0.56	5.54e-21	Menopause (age at onset);
SARC	trans	rs116095464	0.558	rs10065239	chr5:275288	C/T	cg00938859	chr5:1591904	SDHAP3	0.77	6.32	0.38	1.3e-9	Breast cancer;
SARC	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg10896456	chr17:42255109	ASB16;C17orf65	0.36	5.01	0.31	1.09e-6	Total body bone mineral density;
SARC	cis	rs17001868	0.614	rs5995849	chr22:40777072	C/G	cg07138101	chr22:40742427	ADSL	-0.51	-5.67	-0.35	4.15e-8	Mammographic density (dense area);
SARC	cis	rs9400467	0.506	rs118071464	chr6:111626672	C/T	cg15721981	chr6:111408429	SLC16A10	0.69	5.85	0.36	1.67e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-8.66	-0.49	7.91e-16	Chronic sinus infection;
SARC	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.48	5.92	0.36	1.17e-8	Tonsillectomy;
SARC	cis	rs35160687	0.862	rs13024964	chr2:86511868	G/A	cg10973622	chr2:86423274	IMMT	0.41	5.2	0.32	4.42e-7	Night sleep phenotypes;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg21548032	chr12:104850767	CHST11	0.53	6.63	0.4	2.38e-10	Breast cancer;
SARC	cis	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.75	-0.45	2.91e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs3812831	0.695	rs6560936	chr13:114945972	C/T	cg08824895	chr13:115047677	UPF3A	-0.51	-6.95	-0.41	3.57e-11	Schizophrenia;
SARC	cis	rs4642101	0.824	rs11717013	chr3:12843862	A/C	cg05775895	chr3:12838266	CAND2	0.74	12.05	0.62	2.69e-26	QRS complex (12-leadsum);
SARC	cis	rs6964587	1.000	rs3753108	chr7:91629984	T/G	cg17063962	chr7:91808500	NA	0.96	16.55	0.74	3.24e-41	Breast cancer;
SARC	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg00933542	chr6:150070202	PCMT1	0.31	5.42	0.33	1.47e-7	Lung cancer;
SARC	cis	rs2529049	0.606	rs2721814	chr7:24754509	A/G	cg17569154	chr7:24781545	DFNA5	0.46	6.6	0.4	2.79e-10	Urate levels in obese individuals;
SARC	cis	rs2832077	0.505	rs9305386	chr21:30386751	A/G	cg03476357	chr21:30257390	N6AMT1	0.81	6.47	0.39	5.72e-10	Cognitive test performance;
SARC	cis	rs35955747	0.902	rs140074	chr22:31725634	C/G	cg13145458	chr22:31556086	RNF185	-0.41	-5.22	-0.32	3.93e-7	Neutrophil count;Sum basophil neutrophil counts;
SARC	cis	rs3733585	0.631	rs4697707	chr4:10119787	G/T	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.09	-0.32	7.3e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7818345	0.967	rs6999786	chr8:19277817	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.41	5.57	0.34	7.15e-8	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs10870270	1.000	rs10781564	chr10:133757922	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.84	-10.91	-0.58	1.15e-22	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs765787	0.530	rs3759895	chr15:45543870	G/A	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.51e-10	Uric acid levels;
SARC	cis	rs12311304	0.965	rs7303595	chr12:15359063	T/A	cg08258403	chr12:15378311	NA	0.5	7.55	0.44	9.82e-13	Behavioural disinhibition (generation interaction);
SARC	cis	rs78320035	1.000	rs75852867	chr1:168120868	G/A	cg17113809	chr1:168148080	TIPRL	1.1	6.04	0.37	6.16e-9	Red cell distribution width;
SARC	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg22875332	chr1:76189707	ACADM	0.43	5.43	0.34	1.43e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6570726	0.935	rs449377	chr6:145852437	C/G	cg05220968	chr6:146057943	EPM2A	-0.29	-4.91	-0.31	1.75e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs858239	0.867	rs10250602	chr7:23303701	T/C	cg23682824	chr7:23144976	KLHL7	0.56	6.83	0.41	7.33e-11	Cerebrospinal fluid biomarker levels;
SARC	cis	rs14978	0.959	rs2043538	chr7:12253893	T/C	cg23422036	chr7:12250390	TMEM106B	0.44	5.28	0.33	2.96e-7	Response to amphetamines;
SARC	cis	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg20965017	chr5:231967	SDHA	-0.54	-5.21	-0.32	4.22e-7	Breast cancer;
SARC	cis	rs2221894	0.506	rs79581337	chr8:28950860	T/G	cg07962641	chr8:28805897	HMBOX1	-0.76	-7.7	-0.45	3.95e-13	Obesity-related traits;
SARC	cis	rs15676	1.000	rs10988125	chr9:131572903	A/G	cg00228799	chr9:131580591	ENDOG	0.54	6.66	0.4	1.97e-10	Blood metabolite levels;
SARC	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg16405210	chr4:1374714	KIAA1530	-0.49	-5.75	-0.35	2.77e-8	Obesity-related traits;
SARC	cis	rs26868	0.690	rs26835	chr16:2237549	C/T	cg07587117	chr16:2239488	CASKIN1	0.29	4.83	0.3	2.52e-6	Height;
SARC	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg03650068	chr1:25596491	NA	0.31	4.88	0.3	1.98e-6	Erythrocyte sedimentation rate;
SARC	cis	rs6580649	0.941	rs72644847	chr12:48516093	C/A	cg05342945	chr12:48394962	COL2A1	0.5	5.24	0.32	3.54e-7	Lung cancer;
SARC	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg18370025	chr7:2749541	AMZ1	-0.3	-4.87	-0.3	2.04e-6	Height;
SARC	cis	rs497273	0.530	rs2701185	chr12:121352974	A/G	cg02403541	chr12:121454288	C12orf43	0.46	5.39	0.33	1.73e-7	Systemic lupus erythematosus;
SARC	cis	rs9325144	0.555	rs10748433	chr12:38696352	C/G	cg10518543	chr12:38710700	ALG10B	0.39	4.94	0.31	1.5e-6	Morning vs. evening chronotype;
SARC	cis	rs72781680	0.898	rs17762651	chr2:24115922	A/G	cg06627628	chr2:24431161	ITSN2	-0.66	-6.26	-0.38	1.86e-9	Lymphocyte counts;
SARC	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg23262073	chr20:60523788	NA	-0.58	-8.34	-0.48	6.34e-15	Obesity-related traits;
SARC	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg13939156	chr17:80058883	NA	-0.41	-6.32	-0.38	1.34e-9	Life satisfaction;
SARC	trans	rs12310956	0.532	rs11052948	chr12:33981973	T/C	cg13010199	chr12:38710504	ALG10B	0.75	10.16	0.55	2.58e-20	Morning vs. evening chronotype;
SARC	cis	rs1707322	1.000	rs3922886	chr1:46473902	A/T	cg03146154	chr1:46216737	IPP	0.46	5.54	0.34	8.13e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs12048904	0.512	rs932798	chr1:101249355	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.73	-8.84	-0.5	2.47e-16	Multiple sclerosis;
SARC	cis	rs7552404	0.731	rs10873787	chr1:76367797	G/A	cg22875332	chr1:76189707	ACADM	0.4	4.87	0.3	2.03e-6	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg15595755	chr5:1867978	NA	0.46	6.33	0.38	1.22e-9	Cardiovascular disease risk factors;
SARC	cis	rs8012	0.517	rs8113575	chr19:13030280	G/A	cg11738485	chr19:12877000	HOOK2	0.43	4.76	0.3	3.35e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
SARC	cis	rs950776	0.518	rs12902493	chr15:78819275	C/G	cg24631222	chr15:78858424	CHRNA5	-0.37	-4.72	-0.3	4.16e-6	Sudden cardiac arrest;
SARC	cis	rs13191362	0.872	rs56404230	chr6:163252863	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.62	5.92	0.36	1.17e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.44	-5.79	-0.35	2.25e-8	Longevity;Endometriosis;
SARC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg01238044	chr22:24384105	GSTT1	-0.57	-6.44	-0.39	6.66e-10	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9400467	0.506	rs12207774	chr6:111657576	T/C	cg15721981	chr6:111408429	SLC16A10	0.65	5.65	0.35	4.61e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.75	-0.4	1.13e-10	Total body bone mineral density;
SARC	cis	rs7428	0.545	rs4832163	chr2:85541083	T/C	cg03728395	chr2:85555865	TGOLN2	-0.45	-6.39	-0.39	8.85e-10	Ear protrusion;
SARC	cis	rs9457247	1.000	rs239935	chr6:167411788	G/A	cg07741184	chr6:167504864	NA	0.31	5.75	0.35	2.78e-8	Crohn's disease;
SARC	cis	rs25645	0.830	rs3935281	chr17:38188419	C/T	cg17467752	chr17:38218738	THRA	-0.39	-4.94	-0.31	1.51e-6	Myeloid white cell count;
SARC	cis	rs62229266	0.572	rs4816518	chr21:37453307	C/T	cg12218747	chr21:37451666	NA	-0.39	-5.44	-0.34	1.35e-7	Mitral valve prolapse;
SARC	cis	rs57506017	0.585	rs12668625	chr7:12269817	G/A	cg23422036	chr7:12250390	TMEM106B	0.45	5.87	0.36	1.49e-8	Neuroticism;
SARC	cis	rs9303542	0.559	rs1042822	chr17:46620095	G/T	cg04904318	chr17:46607828	HOXB1	-0.43	-4.78	-0.3	3.08e-6	Ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs651907	0.535	rs13094911	chr3:101519021	T/C	cg12386194	chr3:101231763	SENP7	0.47	5.38	0.33	1.77e-7	Colorectal cancer;
SARC	cis	rs4906332	1.000	rs12896612	chr14:103877868	A/G	cg20474699	chr14:102976161	ANKRD9	0.43	4.77	0.3	3.21e-6	Coronary artery disease;
SARC	cis	rs7666738	0.830	rs7678911	chr4:99057430	C/T	cg05340658	chr4:99064831	C4orf37	0.64	8.69	0.49	6.68e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs8114671	0.562	rs6120746	chr20:33448496	A/G	cg07148914	chr20:33460835	GGT7	0.44	5.4	0.33	1.64e-7	Height;
SARC	cis	rs7590368	0.926	rs12621237	chr2:10957538	T/C	cg25617230	chr2:10952979	PDIA6	0.45	4.89	0.31	1.89e-6	Educational attainment (years of education);
SARC	cis	rs9948	1.000	rs13419073	chr2:97507554	G/C	cg01990225	chr2:97406019	LMAN2L	-0.65	-5.08	-0.32	7.6e-7	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs1448094	0.512	rs6539927	chr12:86244486	T/C	cg02569458	chr12:86230093	RASSF9	0.38	5.42	0.33	1.52e-7	Major depressive disorder;
SARC	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg19077165	chr18:44547161	KATNAL2	-0.5	-6.65	-0.4	2.05e-10	Personality dimensions;
SARC	cis	rs1345301	1.000	rs12470560	chr2:102868840	T/C	cg12451869	chr2:102867685	NA	0.39	5.52	0.34	9.24e-8	Waist circumference;
SARC	cis	rs10851411	0.559	rs56172155	chr15:42882182	C/T	cg21293051	chr15:42870591	STARD9	0.48	4.89	0.3	1.91e-6	Glucose homeostasis traits;
SARC	cis	rs13082711	0.595	rs4973761	chr3:27358620	T/C	cg02860705	chr3:27208620	NA	0.66	7.93	0.46	9.12e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs6500602	0.627	rs1641866	chr16:4593040	A/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.33	5.07	0.32	8.12e-7	Schizophrenia;
SARC	cis	rs4423214	0.959	rs12793224	chr11:71168710	G/A	cg05163923	chr11:71159392	DHCR7	0.66	9.13	0.51	3.43e-17	Vitamin D levels;
SARC	cis	rs17345786	0.602	rs11923273	chr3:101337863	T/C	cg12386194	chr3:101231763	SENP7	0.56	6.82	0.41	7.83e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs11098499	0.909	rs28668716	chr4:120309875	T/C	cg09307838	chr4:120376055	NA	0.91	12.88	0.65	4.9e-29	Corneal astigmatism;
SARC	cis	rs3126085	0.935	rs10888467	chr1:152171707	C/T	cg26876637	chr1:152193138	HRNR	0.47	5.43	0.34	1.39e-7	Atopic dermatitis;
SARC	cis	rs681343	1.000	rs492602	chr19:49206417	A/G	cg21064579	chr19:49206444	FUT2	0.36	5.07	0.32	7.98e-7	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
SARC	cis	rs6964587	1.000	rs7455444	chr7:91639313	C/T	cg17063962	chr7:91808500	NA	0.95	15.97	0.72	2.86e-39	Breast cancer;
SARC	cis	rs9291683	0.530	rs4697698	chr4:9942577	C/T	cg11266682	chr4:10021025	SLC2A9	0.41	7.24	0.43	6.34e-12	Bone mineral density;
SARC	cis	rs3785574	0.705	rs2665856	chr17:61982721	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.59	-6.73	-0.4	1.29e-10	Height;
SARC	cis	rs4713675	0.565	rs6928010	chr6:33676590	T/C	cg15676125	chr6:33679581	C6orf125	0.52	6.36	0.38	1.03e-9	Plateletcrit;
SARC	cis	rs6964587	0.967	rs10953065	chr7:91808915	A/G	cg17063962	chr7:91808500	NA	-0.97	-15.73	-0.72	1.8e-38	Breast cancer;
SARC	trans	rs11098499	0.909	rs28793658	chr4:120307214	A/C	cg25214090	chr10:38739885	LOC399744	0.54	7.08	0.42	1.66e-11	Corneal astigmatism;
SARC	cis	rs6939532	0.597	rs2273558	chr6:26466035	A/C	cg12826209	chr6:26865740	GUSBL1	0.48	5.43	0.34	1.43e-7	Autism spectrum disorder or schizophrenia;
SARC	cis	rs10992471	0.603	rs12341817	chr9:95252152	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.37	-0.33	1.91e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs9303280	0.806	rs2305480	chr17:38062196	G/A	cg00129232	chr17:37814104	STARD3	-0.37	-4.83	-0.3	2.51e-6	Self-reported allergy;
SARC	cis	rs13401104	0.755	rs55787207	chr2:237106584	A/T	cg19324714	chr2:237145437	ASB18	0.59	5.76	0.35	2.59e-8	Educational attainment;
SARC	cis	rs11112613	0.713	rs11112586	chr12:105939816	C/T	cg03607813	chr12:105948248	NA	0.53	6.93	0.41	4.08e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg13206674	chr6:150067644	NUP43	0.46	6.1	0.37	4.29e-9	Lung cancer;
SARC	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.49	7.46	0.44	1.66e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs7647973	0.626	rs1491985	chr3:49739507	G/C	cg13072238	chr3:49761600	GMPPB	-0.61	-6.34	-0.38	1.19e-9	Menarche (age at onset);
SARC	cis	rs7772486	0.713	rs2328704	chr6:146020494	T/C	cg23711669	chr6:146136114	FBXO30	-0.8	-12.48	-0.63	1.01e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs367615	0.704	rs72804385	chr5:108848143	T/C	cg17395555	chr5:108820864	NA	0.47	6.86	0.41	6.08e-11	Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs7843479	0.511	rs4379446	chr8:21777595	C/G	cg17168535	chr8:21777572	XPO7	0.89	13.61	0.67	1.95e-31	Mean corpuscular volume;
SARC	cis	rs8044995	0.501	rs55793998	chr16:68378985	G/T	cg05110241	chr16:68378359	PRMT7	-0.65	-6.3	-0.38	1.44e-9	Schizophrenia;
SARC	trans	rs1200821	0.535	rs1938417	chr10:37687520	A/C	cg25427524	chr10:38739819	LOC399744	0.43	6.61	0.4	2.58e-10	Hemostatic factors and hematological phenotypes;
SARC	cis	rs300774	1.000	rs300781	chr2:110385	G/A	cg06380356	chr2:467891	NA	-0.35	-4.82	-0.3	2.61e-6	Suicide attempts in bipolar disorder;
SARC	cis	rs1865760	1.000	rs7757666	chr6:25902626	T/C	cg10373733	chr6:25993375	NA	0.42	5.05	0.31	8.91e-7	Height;
SARC	cis	rs7666738	0.830	rs4401456	chr4:98959902	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4853036	0.672	rs4853025	chr2:70028904	A/G	cg02498382	chr2:70120550	SNRNP27	-0.36	-4.87	-0.3	2.11e-6	Colorectal or endometrial cancer;
SARC	cis	rs7769051	1.000	rs7769051	chr6:133146796	G/T	cg22852734	chr6:133119734	C6orf192	1.09	10.43	0.56	3.73e-21	Type 2 diabetes nephropathy;
SARC	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg08392591	chr16:89556376	ANKRD11	-0.52	-7.34	-0.43	3.46e-12	Multiple myeloma (IgH translocation);
SARC	cis	rs2439831	1.000	rs690263	chr15:43704465	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.06	11.11	0.59	2.68e-23	Lung cancer in ever smokers;
SARC	cis	rs2153535	0.869	rs11962457	chr6:8375855	A/T	cg21535247	chr6:8435926	SLC35B3	-0.41	-4.8	-0.3	2.9e-6	Motion sickness;
SARC	cis	rs4319547	0.956	rs10744275	chr12:123048618	A/G	cg23029597	chr12:123009494	RSRC2	-0.41	-5.18	-0.32	4.7e-7	Body mass index;
SARC	cis	rs262150	0.851	rs2730249	chr7:158767628	A/G	cg09640425	chr7:158790006	NA	0.37	4.99	0.31	1.18e-6	Facial morphology (factor 20);
SARC	cis	rs6121246	0.542	rs6059761	chr20:30110522	G/C	cg21427119	chr20:30132790	HM13	-0.45	-4.99	-0.31	1.17e-6	Mean corpuscular hemoglobin;
SARC	cis	rs6831352	0.734	rs2602857	chr4:100030318	G/A	cg13256891	chr4:100009986	ADH5	0.59	7.52	0.44	1.18e-12	Alcohol dependence;
SARC	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	8.82	0.5	2.77e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs10779751	0.734	rs6701726	chr1:11126941	C/T	cg08854313	chr1:11322531	MTOR	0.82	11.26	0.59	8.86e-24	Body mass index;
SARC	cis	rs6570726	0.902	rs396681	chr6:145853603	T/C	cg23711669	chr6:146136114	FBXO30	0.78	11.95	0.62	5.64e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7481584	0.581	rs406598	chr11:3076285	G/A	cg05729581	chr11:3078854	CARS	0.54	7.08	0.42	1.66e-11	Calcium levels;
SARC	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg09455208	chr3:40491958	NA	0.39	5.7	0.35	3.63e-8	Renal cell carcinoma;
SARC	cis	rs9894429	1.000	rs7209180	chr17:79581519	C/A	cg18240062	chr17:79603768	NPLOC4	0.71	9.81	0.54	3.03e-19	Eye color traits;
SARC	cis	rs9875589	0.509	rs2731305	chr3:14081342	T/C	cg19554555	chr3:13937349	NA	-0.4	-5.16	-0.32	5.21e-7	Ovarian reserve;
SARC	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg05872129	chr22:39784769	NA	-0.43	-6.02	-0.37	6.81e-9	Intelligence (multi-trait analysis);
SARC	trans	rs7859245	1.000	rs7873626	chr9:138490710	C/T	cg02665744	chr19:50223325	NA	-0.56	-7.14	-0.42	1.16e-11	Response to paliperidone in schizophrenia (negative Marder score);
SARC	cis	rs7659604	1.000	rs34952897	chr4:122664409	C/T	cg19671926	chr4:122722719	EXOSC9	-0.49	-5.95	-0.36	9.84e-9	Type 2 diabetes;
SARC	cis	rs7246657	0.941	rs7259618	chr19:37750719	G/A	cg23950597	chr19:37808831	NA	-0.59	-5.41	-0.33	1.55e-7	Coronary artery calcification;
SARC	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg18876405	chr7:65276391	NA	0.69	8.63	0.49	9.76e-16	Aortic root size;
SARC	cis	rs12540874	0.698	rs13234331	chr7:50560314	G/T	cg18232548	chr7:50535776	DDC	-0.43	-5.09	-0.32	7.44e-7	Systemic sclerosis;
SARC	cis	rs12142240	0.698	rs112068407	chr1:46822291	T/C	cg14993813	chr1:46806288	NSUN4	-0.51	-5.34	-0.33	2.19e-7	Menopause (age at onset);
SARC	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg27286337	chr10:134555280	INPP5A	0.69	8.18	0.47	1.89e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg04511125	chr2:88470314	THNSL2	0.8	7.21	0.43	7.9e-12	Plasma clusterin levels;
SARC	cis	rs11874712	0.965	rs28694780	chr18:43665338	C/T	cg25174615	chr18:43684699	ATP5A1;HAUS1	0.4	4.75	0.3	3.52e-6	Migraine - clinic-based;
SARC	cis	rs2549003	1.000	rs7735073	chr5:131815357	G/A	cg21138405	chr5:131827807	IRF1	0.27	5.44	0.34	1.32e-7	Asthma (sex interaction);
SARC	cis	rs41271473	1.000	rs11578216	chr1:228880098	A/T	cg16512390	chr1:228756714	NA	-0.52	-5.49	-0.34	1.05e-7	Chronic lymphocytic leukemia;
SARC	cis	rs74417235	0.684	rs13185173	chr5:154055081	A/G	cg17344516	chr5:154026930	NA	0.52	5.25	0.33	3.39e-7	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
SARC	cis	rs79349575	0.783	rs56046215	chr17:47008757	A/T	cg16584676	chr17:46985605	UBE2Z	0.54	6.54	0.39	3.79e-10	Type 2 diabetes;
SARC	cis	rs4253772	0.637	rs6008339	chr22:46650846	C/T	cg24881330	chr22:46731750	TRMU	0.62	6.72	0.4	1.41e-10	LDL cholesterol;Cholesterol, total;
SARC	cis	rs826838	1.000	rs11168367	chr12:38913397	T/G	cg26384229	chr12:38710491	ALG10B	0.92	14.25	0.68	1.53e-33	Heart rate;
SARC	cis	rs41271473	1.000	rs41270187	chr1:228878871	T/C	cg16512390	chr1:228756714	NA	0.49	4.95	0.31	1.39e-6	Chronic lymphocytic leukemia;
SARC	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	11.64	0.61	5.7e-25	Alzheimer's disease;
SARC	trans	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg17712092	chr4:129076599	LARP1B	0.7	9.55	0.53	1.89e-18	Eosinophil percentage of white cells;
SARC	cis	rs4761669	0.816	rs4761670	chr12:95199843	A/T	cg21533806	chr12:95267307	NA	0.37	4.76	0.3	3.42e-6	Common carotid intima-media thickness in HIV infection;
SARC	cis	rs9325144	0.600	rs12424410	chr12:38758035	A/T	cg13010199	chr12:38710504	ALG10B	-0.51	-6.47	-0.39	5.79e-10	Morning vs. evening chronotype;
SARC	cis	rs1728785	1.000	rs1728789	chr16:68595776	C/T	cg02972257	chr16:68554789	NA	-0.45	-5.32	-0.33	2.48e-7	Ulcerative colitis;
SARC	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-5.96	-0.36	9.37e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6540556	0.954	rs2076150	chr1:209933540	A/G	cg05527609	chr1:210001259	C1orf107	-0.56	-5.75	-0.35	2.85e-8	Red blood cell count;
SARC	cis	rs7582180	0.606	rs11684004	chr2:100954783	C/T	cg14675211	chr2:100938903	LONRF2	0.51	7.5	0.44	1.37e-12	Intelligence (multi-trait analysis);
SARC	cis	rs4481887	1.000	rs6666690	chr1:248465323	T/C	cg01631408	chr1:248437212	OR2T33	-0.41	-5.25	-0.33	3.35e-7	Common traits (Other);
SARC	cis	rs981844	0.712	rs10014763	chr4:154739140	C/T	cg14289246	chr4:154710475	SFRP2	0.47	5.48	0.34	1.11e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	9.01	0.51	7.59e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg12463550	chr7:65579703	CRCP	-0.51	-5.58	-0.34	6.66e-8	Aortic root size;
SARC	cis	rs9325144	0.534	rs1843887	chr12:38692380	T/C	cg26384229	chr12:38710491	ALG10B	0.59	7.85	0.46	1.51e-13	Morning vs. evening chronotype;
SARC	cis	rs6604026	0.656	rs2774949	chr1:93352553	T/C	cg17283838	chr1:93427260	FAM69A	-0.42	-4.75	-0.3	3.59e-6	Multiple sclerosis;
SARC	cis	rs10949834	0.529	rs150861	chr7:73524901	T/C	cg07137043	chr7:73588983	EIF4H	0.55	4.98	0.31	1.22e-6	Verbal memory performance (residualized delayed recall change);
SARC	cis	rs751728	0.664	rs747694	chr6:33736490	A/G	cg15252951	chr6:33757062	LEMD2	0.41	4.84	0.3	2.33e-6	Crohn's disease;
SARC	cis	rs2816062	0.747	rs2816049	chr1:18893768	A/G	cg10574377	chr1:18908098	NA	0.37	5.34	0.33	2.23e-7	Urate levels in lean individuals;
SARC	cis	rs16944613	0.541	rs6496688	chr15:91090381	G/A	cg26821196	chr15:91095069	CRTC3	0.54	5.63	0.35	5.11e-8	Colorectal cancer;
SARC	cis	rs6908034	0.607	rs12526109	chr6:19820089	C/A	cg02682789	chr6:19804855	NA	0.67	5.36	0.33	2.03e-7	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg11062466	chr8:58055876	NA	0.64	5.98	0.36	8.43e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg19680485	chr15:31195859	MTMR15	-0.57	-6.81	-0.41	8.4e-11	Huntington's disease progression;
SARC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg06873352	chr17:61820015	STRADA	0.52	6.8	0.41	8.54e-11	Prudent dietary pattern;
SARC	cis	rs12369635	0.929	rs3851667	chr12:129550552	G/T	cg01909103	chr12:129572610	TMEM132D	0.59	5.88	0.36	1.4e-8	Schizophrenia (inflammation and infection response interaction);
SARC	cis	rs2354432	0.607	rs55918563	chr1:146718973	G/C	cg25205988	chr1:146714368	CHD1L	-1.04	-7.58	-0.44	8.14e-13	Mitochondrial DNA levels;
SARC	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg20891558	chr2:74357851	NA	0.7	9.26	0.52	1.35e-17	Gestational age at birth (maternal effect);
SARC	trans	rs61931739	0.534	rs1384860	chr12:34045388	T/C	cg13010199	chr12:38710504	ALG10B	0.66	9.05	0.51	5.8e-17	Morning vs. evening chronotype;
SARC	cis	rs7224737	1.000	rs7224737	chr17:40289364	A/G	cg20291162	chr17:40259547	DHX58	0.34	5.2	0.32	4.32e-7	Fibrinogen levels;
SARC	cis	rs2073300	0.609	rs6137907	chr20:23344511	C/T	cg12062639	chr20:23401060	NAPB	1.01	6.97	0.42	3.31e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg02461776	chr11:598696	PHRF1	0.48	5.26	0.33	3.27e-7	Systemic lupus erythematosus;
SARC	cis	rs4243830	0.737	rs7552172	chr1:6612269	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.87	-8.42	-0.48	3.98e-15	Body mass index;
SARC	cis	rs7872515	0.887	rs7029539	chr9:94864322	A/G	cg01248375	chr9:94877805	SPTLC1	0.67	6.02	0.37	6.66e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs910316	1.000	rs12435391	chr14:75601737	A/G	cg11812906	chr14:75593930	NEK9	0.88	13.24	0.66	3.22e-30	Height;
SARC	cis	rs6570726	0.791	rs9322029	chr6:145906683	A/G	cg05347473	chr6:146136440	FBXO30	0.52	7.31	0.43	4.32e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7000551	0.606	rs7844699	chr8:22248920	G/T	cg12081754	chr8:22256438	SLC39A14	-0.83	-12.08	-0.62	2.05e-26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs7255045	0.752	rs55730975	chr19:12973039	G/A	cg21491176	chr19:12958399	MAST1	-0.34	-4.74	-0.3	3.73e-6	Mean corpuscular volume;
SARC	cis	rs2624839	0.704	rs13064381	chr3:50233317	C/T	cg19755318	chr3:50243323	SLC38A3	-0.3	-5.21	-0.32	4.17e-7	Intelligence (multi-trait analysis);
SARC	cis	rs916888	0.610	rs199529	chr17:44837217	A/C	cg03575189	chr17:44344142	NA	0.53	5.3	0.33	2.74e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9790314	0.846	rs9809522	chr3:160983768	G/C	cg03342759	chr3:160939853	NMD3	-0.73	-9.94	-0.55	1.26e-19	Morning vs. evening chronotype;
SARC	cis	rs9902453	0.817	rs2617880	chr17:28106118	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.14	-0.42	1.19e-11	Coffee consumption (cups per day);
SARC	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg04277193	chr17:41438351	NA	0.47	5.1	0.32	7.12e-7	Menopause (age at onset);
SARC	trans	rs208515	0.525	rs10944863	chr6:66676238	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.9	10.58	0.57	1.26e-21	Exhaled nitric oxide levels;
SARC	cis	rs9715521	0.775	rs56957240	chr4:59847774	C/A	cg11281224	chr4:60001000	NA	-0.4	-5.11	-0.32	6.65e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.19	0.8	4.45e-53	Prudent dietary pattern;
SARC	cis	rs2075371	1.000	rs2598285	chr7:133971153	A/T	cg00033643	chr7:134001901	SLC35B4	0.41	5.04	0.31	9.16e-7	Mean platelet volume;
SARC	cis	rs7847628	0.551	rs10818476	chr9:123572038	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.67	9.25	0.52	1.51e-17	Birth weight;
SARC	cis	rs6456156	0.586	rs4710176	chr6:167491639	T/C	cg07741184	chr6:167504864	NA	0.36	6.89	0.41	5.14e-11	Primary biliary cholangitis;
SARC	cis	rs8064299	0.934	rs895692	chr17:72766252	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.48	5.81	0.36	1.99e-8	Monocyte count;
SARC	cis	rs74417235	0.684	rs71590150	chr5:154060512	A/T	cg17344516	chr5:154026930	NA	0.53	5.31	0.33	2.53e-7	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
SARC	cis	rs7219021	0.669	rs35584414	chr17:47022727	C/G	cg16584676	chr17:46985605	UBE2Z	-0.47	-5.19	-0.32	4.6e-7	Schizophrenia or bipolar disorder;
SARC	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.45	-5.61	-0.34	5.7e-8	Tonsillectomy;
SARC	cis	rs709400	0.827	rs2274269	chr14:104029246	G/A	cg26031613	chr14:104095156	KLC1	1.03	20.29	0.8	2.07e-53	Body mass index;
SARC	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg14262678	chr6:151773367	RMND1;C6orf211	-0.71	-9.61	-0.53	1.24e-18	Menarche (age at onset);
SARC	cis	rs35110281	0.720	rs162380	chr21:44925283	T/C	cg21573476	chr21:45109991	RRP1B	0.5	7.37	0.43	2.96e-12	Mean corpuscular volume;
SARC	cis	rs453301	0.686	rs6601280	chr8:8909236	A/T	cg15556689	chr8:8085844	FLJ10661	0.44	5.46	0.34	1.23e-7	Joint mobility (Beighton score);
SARC	cis	rs1318878	0.519	rs56017619	chr12:15503408	A/C	cg08258403	chr12:15378311	NA	0.5	6.98	0.42	3.13e-11	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg08219700	chr8:58056026	NA	0.48	5.01	0.31	1.08e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs4969178	0.896	rs1976704	chr17:76401318	C/T	cg02836325	chr17:76403955	PGS1	0.34	5.21	0.32	4.16e-7	HDL cholesterol levels;
SARC	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.52	-5.25	-0.33	3.4e-7	Lung function (FEV1/FVC);
SARC	cis	rs62432291	0.681	rs420137	chr6:159652931	G/C	cg14500486	chr6:159655392	FNDC1	-0.62	-6.03	-0.37	6.24e-9	Joint mobility (Beighton score);
SARC	cis	rs7666738	0.830	rs28417577	chr4:99053007	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6545883	0.862	rs778141	chr2:61682178	A/G	cg15711740	chr2:61764176	XPO1	-0.43	-5.13	-0.32	6.01e-7	Tuberculosis;
SARC	cis	rs2282802	0.685	rs62385161	chr5:139635747	T/C	cg26211634	chr5:139558579	C5orf32	0.41	5.3	0.33	2.71e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg05896524	chr21:47604654	C21orf56	0.49	6.0	0.37	7.62e-9	Testicular germ cell tumor;
SARC	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg13175981	chr1:150552382	MCL1	-0.54	-6.9	-0.41	4.97e-11	Tonsillectomy;
SARC	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-15.6	-0.71	4.8e-38	Chronic sinus infection;
SARC	cis	rs11792861	0.926	rs3750451	chr9:111822866	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.66	7.54	0.44	1.07e-12	Menarche (age at onset);
SARC	cis	rs554111	0.656	rs10799682	chr1:21424030	G/C	cg08890418	chr1:21044141	KIF17	-0.36	-5.11	-0.32	6.62e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg25157839	chr3:43626312	ANO10	0.5	7.24	0.43	6.65e-12	Thyroid stimulating hormone;
SARC	cis	rs929354	0.739	rs12533082	chr7:157014172	T/A	cg05182265	chr7:156933206	UBE3C	-0.31	-4.79	-0.3	2.93e-6	Body mass index;
SARC	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	5.75	0.35	2.76e-8	Bipolar disorder;
SARC	cis	rs9399137	0.507	rs7768278	chr6:135274957	T/C	cg22676075	chr6:135203613	NA	0.4	5.16	0.32	5.17e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs5753037	0.702	rs140101	chr22:30128380	C/T	cg01021169	chr22:30184971	ASCC2	-0.39	-5.05	-0.31	9.04e-7	Type 1 diabetes;
SARC	cis	rs2295359	1.000	rs11209006	chr1:67619259	T/G	cg11235152	chr1:67600687	NA	0.47	7.07	0.42	1.84e-11	Psoriasis;
SARC	cis	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg03213289	chr20:61660250	NA	0.45	6.16	0.37	3.11e-9	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs16854884	0.837	rs13083068	chr3:143801642	G/T	cg06585982	chr3:143692056	C3orf58	0.58	7.64	0.45	5.7e-13	Economic and political preferences (feminism/equality);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg06437222	chr6:99873228	SFRS18	-0.64	-7.16	-0.42	1.08e-11	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg25894440	chr7:65020034	NA	0.78	5.89	0.36	1.34e-8	Diabetic kidney disease;
SARC	cis	rs7560272	0.723	rs1083923	chr2:73703374	A/G	cg20560298	chr2:73613845	ALMS1	0.54	7.28	0.43	5.19e-12	Schizophrenia;
SARC	cis	rs2011503	1.000	rs80200208	chr19:19554725	C/T	cg15839431	chr19:19639596	YJEFN3	-0.47	-4.74	-0.3	3.78e-6	Bipolar disorder;
SARC	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg26681399	chr22:41777847	TEF	-0.5	-5.53	-0.34	8.77e-8	Vitiligo;
SARC	cis	rs763121	0.651	rs738249	chr22:39037979	T/C	cg06022373	chr22:39101656	GTPBP1	0.89	11.22	0.59	1.25e-23	Menopause (age at onset);
SARC	cis	rs11190604	0.806	rs76835764	chr10:102193612	C/T	cg07080220	chr10:102295463	HIF1AN	0.71	8.15	0.47	2.29e-14	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs9815354	1.000	rs10212536	chr3:41827026	A/G	cg03022575	chr3:42003672	ULK4	0.57	5.51	0.34	9.66e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9859260	0.744	rs557527	chr3:195780709	G/A	cg03462622	chr3:195777018	TFRC	-0.46	-5.3	-0.33	2.63e-7	Mean corpuscular volume;
SARC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg02475777	chr4:1388615	CRIPAK	0.65	7.53	0.44	1.1e-12	Longevity;
SARC	cis	rs79149102	0.579	rs76900720	chr15:75348895	A/T	cg00629941	chr15:75287862	SCAMP5	-0.74	-5.64	-0.35	4.79e-8	Lung cancer;
SARC	cis	rs10876993	0.821	rs1678522	chr12:58049923	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.48	-6.1	-0.37	4.42e-9	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs6088580	0.619	rs1205335	chr20:32927507	C/T	cg08999081	chr20:33150536	PIGU	-0.43	-6.51	-0.39	4.47e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg01238044	chr22:24384105	GSTT1	-0.66	-8.32	-0.48	7.49e-15	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs3820928	0.839	rs13413292	chr2:227893747	G/C	cg11843606	chr2:227700838	RHBDD1	-0.55	-6.84	-0.41	6.88e-11	Pulmonary function;
SARC	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.62	7.52	0.44	1.14e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9285223	1.000	rs4770289	chr13:23126553	G/A	cg08083251	chr13:23309930	NA	-0.46	-4.91	-0.31	1.72e-6	Idiopathic osteonecrosis of the femoral head;
SARC	cis	rs1185460	0.967	rs11217137	chr11:118931030	A/G	cg23280166	chr11:118938394	VPS11	0.74	10.54	0.57	1.76e-21	Coronary artery disease;
SARC	cis	rs876084	0.505	rs7827219	chr8:121130164	G/A	cg06265175	chr8:121136014	COL14A1	0.56	7.24	0.43	6.63e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs950776	0.593	rs555018	chr15:78879242	G/A	cg17108064	chr15:78857060	CHRNA5	-0.31	-5.41	-0.33	1.53e-7	Sudden cardiac arrest;
SARC	cis	rs16976116	0.901	rs8031949	chr15:55492724	A/G	cg17854078	chr15:55489399	RSL24D1	0.63	6.22	0.38	2.3e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs11098499	0.863	rs13140409	chr4:120503460	A/G	cg24375607	chr4:120327624	NA	0.42	4.92	0.31	1.64e-6	Corneal astigmatism;
SARC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	11.32	0.6	5.71e-24	Platelet count;
SARC	cis	rs7940866	0.874	rs7112616	chr11:130805334	T/C	cg12179176	chr11:130786555	SNX19	0.68	9.65	0.53	9.55e-19	Schizophrenia;
SARC	cis	rs6964587	1.000	rs10228334	chr7:91713972	C/T	cg17063962	chr7:91808500	NA	0.94	15.98	0.72	2.68e-39	Breast cancer;
SARC	cis	rs3087591	0.960	rs12943508	chr17:29599954	C/G	cg24425628	chr17:29625626	OMG;NF1	0.53	6.46	0.39	6.2e-10	Hip circumference;
SARC	cis	rs826838	0.967	rs4768330	chr12:39129399	T/C	cg26384229	chr12:38710491	ALG10B	-0.76	-11.59	-0.6	7.97e-25	Heart rate;
SARC	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg15448220	chr1:150897856	SETDB1	0.47	6.22	0.38	2.24e-9	Tonsillectomy;
SARC	cis	rs13401104	0.796	rs1377448	chr2:237119886	C/T	cg19324714	chr2:237145437	ASB18	0.57	5.93	0.36	1.1e-8	Educational attainment;
SARC	cis	rs912057	0.526	rs1294400	chr6:6733421	A/G	cg06612196	chr6:6737390	NA	-0.72	-11.97	-0.62	4.71e-26	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs208520	0.690	rs1580430	chr6:66715162	T/A	cg07460842	chr6:66804631	NA	1.04	14.07	0.68	6e-33	Exhaled nitric oxide output;
SARC	cis	rs3733585	0.673	rs4292333	chr4:9953871	G/A	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.94	-0.36	1.06e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs651907	0.557	rs12629954	chr3:101360623	C/A	cg12386194	chr3:101231763	SENP7	0.5	5.95	0.36	9.98e-9	Colorectal cancer;
SARC	cis	rs10754283	0.967	rs1317864	chr1:90105448	A/G	cg21401794	chr1:90099060	LRRC8C	0.59	8.1	0.47	2.99e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs2425143	1.000	rs6060643	chr20:34449851	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.67	5.43	0.34	1.42e-7	Blood protein levels;
SARC	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg27211696	chr2:191398769	TMEM194B	-0.49	-6.8	-0.41	8.75e-11	Pulse pressure;
SARC	cis	rs6714710	0.580	rs57804205	chr2:98454472	G/A	cg26665480	chr2:98280029	ACTR1B	0.49	6.63	0.4	2.34e-10	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs55823223	0.702	rs3785437	chr17:73906222	G/T	cg14829360	chr17:73884958	NA	-0.66	-6.14	-0.37	3.5e-9	Psoriasis;
SARC	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg11062466	chr8:58055876	NA	0.61	5.75	0.35	2.74e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9807841	0.592	rs10407349	chr19:10758453	G/A	cg17710535	chr19:10819994	QTRT1	0.41	4.88	0.3	1.99e-6	Inflammatory skin disease;
SARC	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg19318889	chr4:1322082	MAEA	0.39	4.83	0.3	2.43e-6	Longevity;
SARC	trans	rs8073060	0.586	rs2523116	chr17:34025460	T/C	cg19694781	chr19:47549865	TMEM160	-0.7	-6.9	-0.41	4.95e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs36051895	0.632	rs111573904	chr9:5169804	A/T	cg02405213	chr9:5042618	JAK2	-0.53	-5.67	-0.35	4.23e-8	Pediatric autoimmune diseases;
SARC	cis	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg24110177	chr3:50126178	RBM5	0.68	9.37	0.52	6.5e-18	Body mass index;
SARC	cis	rs7551222	0.752	rs11240756	chr1:204482594	C/T	cg20240347	chr1:204465584	NA	-0.35	-6.18	-0.38	2.78e-9	Schizophrenia;
SARC	cis	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg18252515	chr7:66147081	NA	-1.34	-11.93	-0.62	6.47e-26	Diabetic kidney disease;
SARC	cis	rs12545109	0.800	rs1467123	chr8:57418870	C/T	cg09654669	chr8:57350985	NA	-0.39	-4.98	-0.31	1.26e-6	Obesity-related traits;
SARC	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs17376456	0.877	rs10060160	chr5:93387879	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.51	0.34	9.53e-8	Diabetic retinopathy;
SARC	cis	rs6860806	0.531	rs270607	chr5:131649186	A/G	cg04518342	chr5:131593106	PDLIM4	0.4	5.29	0.33	2.81e-7	Breast cancer;
SARC	cis	rs7113850	0.541	rs74708033	chr11:24223512	C/T	ch.11.24196551F	chr11:24239977	NA	0.74	5.75	0.35	2.84e-8	Bone fracture in osteoporosis;
SARC	cis	rs896854	0.548	rs574183	chr8:95973816	A/G	cg13393036	chr8:95962371	TP53INP1	0.34	5.23	0.32	3.68e-7	Type 2 diabetes;
SARC	cis	rs9393692	1.000	rs9393692	chr6:26276650	A/G	cg05868516	chr6:26286170	HIST1H4H	0.49	5.85	0.36	1.64e-8	Educational attainment;
SARC	cis	rs6582630	0.513	rs1596446	chr12:38282160	C/T	cg26384229	chr12:38710491	ALG10B	-0.87	-13.08	-0.65	1.08e-29	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs208520	1.000	rs72882086	chr6:66976671	G/A	cg07460842	chr6:66804631	NA	0.88	9.81	0.54	3.15e-19	Exhaled nitric oxide output;
SARC	cis	rs6910061	0.512	rs67794216	chr6:11114209	G/T	cg27233058	chr6:11094804	LOC221710	0.56	5.47	0.34	1.14e-7	Diabetic kidney disease;
SARC	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-5.65	-0.35	4.58e-8	Bipolar disorder;
SARC	cis	rs6545883	0.965	rs2305155	chr2:61729258	A/G	cg15711740	chr2:61764176	XPO1	-0.39	-4.82	-0.3	2.57e-6	Tuberculosis;
SARC	cis	rs858239	0.863	rs274058	chr7:23391509	C/G	cg23682824	chr7:23144976	KLHL7	0.58	7.22	0.43	7.09e-12	Cerebrospinal fluid biomarker levels;
SARC	cis	rs17854409	0.881	rs6011430	chr20:61497014	C/T	cg05147244	chr20:61493195	TCFL5	-0.88	-6.36	-0.38	1.03e-9	Obesity-related traits;
SARC	cis	rs1318878	0.543	rs1117152	chr12:15438032	A/C	cg08258403	chr12:15378311	NA	0.43	6.19	0.38	2.68e-9	Intelligence (multi-trait analysis);
SARC	cis	rs425277	1.000	rs425277	chr1:2069172	C/T	cg21442419	chr1:2182373	SKI	-0.51	-6.39	-0.39	8.91e-10	Height;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg15268184	chr6:170893863	PDCD2	0.64	6.46	0.39	6.06e-10	Lung cancer in ever smokers;
SARC	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.99	11.36	0.6	4.27e-24	Platelet count;
SARC	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg01316550	chr5:56110833	MAP3K1	0.54	4.92	0.31	1.62e-6	Initial pursuit acceleration;
SARC	cis	rs2797160	0.651	rs1268066	chr6:126035041	C/T	cg05901451	chr6:126070800	HEY2	0.43	5.12	0.32	6.34e-7	Endometrial cancer;
SARC	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg12463550	chr7:65579703	CRCP	0.52	5.8	0.36	2.18e-8	Aortic root size;
SARC	cis	rs4481887	0.927	rs11204637	chr1:248492581	G/A	cg01631408	chr1:248437212	OR2T33	-0.39	-4.86	-0.3	2.15e-6	Common traits (Other);
SARC	cis	rs2250402	0.510	rs8031319	chr15:40323692	A/G	cg01081584	chr15:40268610	EIF2AK4	-0.72	-6.16	-0.37	3.21e-9	Corneal curvature;
SARC	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg17971929	chr21:40555470	PSMG1	-0.85	-10.96	-0.58	8.22e-23	Cognitive function;
SARC	cis	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg14541582	chr5:601475	NA	-0.4	-5.03	-0.31	9.91e-7	Obesity-related traits;
SARC	cis	rs76419734	1.000	rs11733150	chr4:106765351	C/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	5.31	0.33	2.52e-7	Post bronchodilator FEV1;
SARC	cis	rs793571	0.590	rs442495	chr15:59022615	T/C	cg05156742	chr15:59063176	FAM63B	0.7	9.64	0.53	1.03e-18	Schizophrenia;
SARC	cis	rs1008375	1.000	rs10027755	chr4:17615954	G/C	cg27347728	chr4:17578864	LAP3	0.46	5.68	0.35	4.06e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg06074448	chr4:187884817	NA	-0.37	-5.14	-0.32	5.9e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9300255	0.544	rs10772995	chr12:123671761	T/C	cg05973401	chr12:123451056	ABCB9	0.52	5.75	0.35	2.83e-8	Neutrophil percentage of white cells;
SARC	cis	rs317689	0.702	rs544696	chr12:69749939	T/C	cg14784868	chr12:69753453	YEATS4	0.49	5.77	0.35	2.55e-8	Response to diuretic therapy;
SARC	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-5.72	-0.35	3.18e-8	Lung cancer;
SARC	cis	rs2387326	0.717	rs10829342	chr10:129944493	C/T	cg16087940	chr10:129947807	NA	-0.45	-5.74	-0.35	2.98e-8	Select biomarker traits;
SARC	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg11843238	chr5:131593191	PDLIM4	0.42	5.22	0.32	4.02e-7	Breast cancer;
SARC	cis	rs9814567	1.000	rs1498718	chr3:134205920	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-7.09	-0.42	1.57e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs1497406	0.744	rs7538216	chr1:16509671	T/C	cg06365898	chr1:16533907	ARHGEF19	0.37	5.09	0.32	7.48e-7	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs13191362	0.810	rs28360533	chr6:162996742	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.57	5.38	0.33	1.85e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs3784262	0.740	rs12910267	chr15:58374603	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.35	-5.03	-0.31	9.75e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg10435706	chr6:150039699	LATS1	0.36	4.8	0.3	2.88e-6	Lung cancer;
SARC	cis	rs6570726	0.967	rs450973	chr6:145863065	C/A	cg23711669	chr6:146136114	FBXO30	0.73	11.08	0.59	3.47e-23	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2153535	0.542	rs4440510	chr6:8471818	C/T	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.85e-22	Motion sickness;
SARC	cis	rs8141529	0.664	rs5762862	chr22:29252732	C/T	cg02153584	chr22:29168773	CCDC117	0.67	8.47	0.49	2.77e-15	Lymphocyte counts;
SARC	trans	rs11098499	1.000	rs13435802	chr4:120177960	A/T	cg25214090	chr10:38739885	LOC399744	-0.5	-6.72	-0.4	1.41e-10	Corneal astigmatism;
SARC	cis	rs412050	0.947	rs239915	chr22:22316631	G/A	cg17089214	chr22:22089827	YPEL1	0.62	5.87	0.36	1.5e-8	Attention deficit hyperactivity disorder;
SARC	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg08677398	chr8:58056175	NA	0.43	5.05	0.31	8.92e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs12922317	0.681	rs2869492	chr16:12071341	T/C	cg02368508	chr16:12060182	TNFRSF17	0.41	6.46	0.39	6.05e-10	Schizophrenia;
SARC	cis	rs7582180	0.764	rs10460478	chr2:100919735	G/A	cg14675211	chr2:100938903	LONRF2	0.53	7.9	0.46	1.1e-13	Intelligence (multi-trait analysis);
SARC	cis	rs12220238	1.000	rs11000930	chr10:75982982	C/G	cg19889307	chr10:75911429	ADK;AP3M1	-0.64	-5.94	-0.36	1.05e-8	Soluble interleukin-2 receptor subunit alpha;
SARC	cis	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg20965017	chr5:231967	SDHA	-0.57	-5.59	-0.34	6.35e-8	Breast cancer;
SARC	cis	rs13191362	1.000	rs4489133	chr6:163137793	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.75	6.38	0.39	9.54e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs10992471	0.729	rs13284038	chr9:95555488	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.62	-0.35	5.53e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs6426558	0.515	rs7543579	chr1:227377699	A/T	cg10327440	chr1:227177885	CDC42BPA	-0.43	-4.91	-0.31	1.73e-6	Neutrophil percentage of white cells;
SARC	cis	rs734999	0.566	rs6424092	chr1:2532899	C/A	cg18854424	chr1:2615690	NA	-0.31	-4.94	-0.31	1.52e-6	Ulcerative colitis;
SARC	cis	rs4727027	0.899	rs11771339	chr7:148854132	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	5.49	0.34	1.07e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs7520050	0.966	rs6656992	chr1:46333068	C/G	cg24296786	chr1:45957014	TESK2	0.39	4.92	0.31	1.63e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.79	10.14	0.55	3e-20	Prudent dietary pattern;
SARC	cis	rs1691799	0.899	rs1168358	chr12:66748664	A/G	cg16791601	chr12:66731901	HELB	-0.74	-11.14	-0.59	2.2e-23	White blood cell count (basophil);
SARC	cis	rs11122272	0.735	rs2486729	chr1:231535584	C/T	cg06096015	chr1:231504339	EGLN1	0.35	5.26	0.33	3.31e-7	Hemoglobin concentration;
SARC	cis	rs892961	0.932	rs9646396	chr17:75416755	G/A	cg05865280	chr17:75406074	SEPT9	0.57	8.09	0.47	3.28e-14	Airflow obstruction;
SARC	cis	rs6964587	1.000	rs10263309	chr7:91645265	A/G	cg17063962	chr7:91808500	NA	0.95	15.99	0.72	2.41e-39	Breast cancer;
SARC	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg11062466	chr8:58055876	NA	0.6	5.71	0.35	3.44e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9640161	0.789	rs28432021	chr7:150046235	G/C	cg21361702	chr7:150065534	REPIN1	0.5	5.56	0.34	7.51e-8	Blood protein levels;Circulating chemerin levels;
SARC	trans	rs11098499	0.820	rs13122709	chr4:120555356	T/A	cg25214090	chr10:38739885	LOC399744	0.51	6.66	0.4	2e-10	Corneal astigmatism;
SARC	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg08493051	chr2:3487164	NA	-0.41	-4.95	-0.31	1.44e-6	Neurofibrillary tangles;
SARC	cis	rs10979	1.000	rs9390113	chr6:143896205	G/A	cg25407410	chr6:143891975	LOC285740	-0.64	-8.78	-0.5	3.67e-16	Hypospadias;
SARC	cis	rs6732160	0.588	rs13403748	chr2:73371475	T/C	cg01422370	chr2:73384389	NA	0.37	5.79	0.35	2.25e-8	Intelligence (multi-trait analysis);
SARC	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.69	9.2	0.52	2.07e-17	Menarche (age at onset);
SARC	cis	rs6728642	1.000	rs113934577	chr2:97888047	G/A	cg26665480	chr2:98280029	ACTR1B	-0.64	-5.07	-0.32	8.2e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs72945132	0.660	rs7121703	chr11:70140296	C/T	cg00319359	chr11:70116639	PPFIA1	0.67	6.08	0.37	4.85e-9	Coronary artery disease;
SARC	cis	rs9916302	0.731	rs11868030	chr17:37650332	A/G	cg07936489	chr17:37558343	FBXL20	-0.69	-8.94	-0.51	1.2e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs6088580	0.634	rs11700221	chr20:32940320	T/C	cg08999081	chr20:33150536	PIGU	-0.43	-6.6	-0.4	2.74e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs3126085	0.935	rs11204951	chr1:152224404	A/G	cg03465714	chr1:152285911	FLG	-0.44	-5.43	-0.34	1.38e-7	Atopic dermatitis;
SARC	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6500637	0.558	rs11076856	chr16:4949815	A/G	cg08329684	chr16:4932620	PPL	-0.39	-6.23	-0.38	2.2e-9	Cancer;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg14093526	chr11:134094620	VPS26B;NCAPD3	0.49	6.36	0.38	1.03e-9	Chemerin levels;
SARC	cis	rs611744	0.967	rs653081	chr8:109230383	G/T	cg21045802	chr8:109455806	TTC35	0.46	5.43	0.34	1.38e-7	Dupuytren's disease;
SARC	cis	rs12971120	0.891	rs3794953	chr18:72180519	C/T	cg26446133	chr18:72167187	CNDP2	-0.48	-6.43	-0.39	7.08e-10	Refractive error;
SARC	cis	rs7296418	0.754	rs1619283	chr12:123717362	A/G	cg00376283	chr12:123451042	ABCB9	0.61	7.44	0.44	1.97e-12	Platelet count;
SARC	cis	rs72945132	0.882	rs1061328	chr11:70185325	C/T	cg00319359	chr11:70116639	PPFIA1	0.7	6.64	0.4	2.23e-10	Coronary artery disease;
SARC	cis	rs2425143	1.000	rs56904633	chr20:34400757	T/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	5.13	0.32	6.08e-7	Blood protein levels;
SARC	cis	rs3820928	0.874	rs4675137	chr2:227883910	G/C	cg05526886	chr2:227700861	RHBDD1	-0.52	-6.37	-0.39	1e-9	Pulmonary function;
SARC	cis	rs10504229	0.679	rs4738574	chr8:58033771	T/C	cg20607798	chr8:58055168	NA	0.57	5.29	0.33	2.84e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg00933542	chr6:150070202	PCMT1	0.32	5.03	0.31	9.77e-7	Lung cancer;
SARC	cis	rs8141529	0.529	rs5762774	chr22:29149796	G/A	cg15103426	chr22:29168792	CCDC117	0.59	5.58	0.34	6.73e-8	Lymphocyte counts;
SARC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.76	9.95	0.55	1.12e-19	Prudent dietary pattern;
SARC	cis	rs7843479	0.601	rs1031882	chr8:21788934	T/G	cg17168535	chr8:21777572	XPO7	0.89	13.55	0.66	3e-31	Mean corpuscular volume;
SARC	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg20607798	chr8:58055168	NA	0.71	5.79	0.35	2.29e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs34779708	0.966	rs10827492	chr10:35429825	A/G	cg03585969	chr10:35415529	CREM	-0.37	-4.78	-0.3	3.04e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs60871478	0.636	rs55663559	chr7:884057	G/A	cg05535760	chr7:792225	HEATR2	-0.7	-6.76	-0.4	1.09e-10	Cerebrospinal P-tau181p levels;
SARC	cis	rs6088580	0.524	rs6088552	chr20:33226491	A/G	cg08999081	chr20:33150536	PIGU	-0.33	-4.89	-0.31	1.85e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs367615	0.552	rs2115511	chr5:108725403	A/T	cg17395555	chr5:108820864	NA	-0.34	-4.91	-0.31	1.72e-6	Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs79149102	0.579	rs12591994	chr15:75320306	A/G	cg17294928	chr15:75287854	SCAMP5	-1.12	-9.31	-0.52	9.88e-18	Lung cancer;
SARC	cis	rs3780378	0.935	rs2149560	chr9:5082106	G/T	cg03508284	chr9:4985524	JAK2	-0.43	-5.17	-0.32	4.93e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
SARC	cis	rs10892173	0.782	rs6421566	chr11:117671398	G/A	cg07621104	chr11:117668040	DSCAML1	0.37	4.78	0.3	3.13e-6	Myopia;
SARC	trans	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg21659725	chr3:3221576	CRBN	0.55	7.21	0.43	7.62e-12	Intelligence (multi-trait analysis);
SARC	cis	rs7674212	0.570	rs2711898	chr4:104063071	C/T	cg16532752	chr4:104119610	CENPE	-0.49	-6.05	-0.37	5.62e-9	Type 2 diabetes;
SARC	cis	rs708547	0.914	rs2412760	chr4:57735192	A/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.57	-5.95	-0.36	9.62e-9	Response to bleomycin (chromatid breaks);
SARC	cis	rs7044106	0.762	rs7024046	chr9:123419178	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	8.62	0.49	1.01e-15	Hip circumference adjusted for BMI;
SARC	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg05332525	chr7:65337924	VKORC1L1	-0.43	-4.81	-0.3	2.73e-6	Calcium levels;
SARC	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg13175981	chr1:150552382	MCL1	-0.47	-5.89	-0.36	1.32e-8	Tonsillectomy;
SARC	cis	rs72781680	0.821	rs113014365	chr2:24159903	C/T	cg06627628	chr2:24431161	ITSN2	-0.57	-5.91	-0.36	1.21e-8	Lymphocyte counts;
SARC	cis	rs4975616	0.804	rs462608	chr5:1336626	T/A	cg06550200	chr5:1325588	CLPTM1L	-0.53	-7.37	-0.43	3.02e-12	Lung cancer;
SARC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg11905131	chr22:24372483	LOC391322	-0.49	-5.77	-0.35	2.48e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs611744	0.523	rs13253581	chr8:109343105	A/G	cg21045802	chr8:109455806	TTC35	0.68	8.66	0.49	8.06e-16	Dupuytren's disease;
SARC	cis	rs9682041	0.932	rs6782252	chr3:170133639	C/T	cg11886554	chr3:170076028	SKIL	1.06	8.84	0.5	2.44e-16	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg03647317	chr4:187891568	NA	-0.34	-4.95	-0.31	1.41e-6	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs8073060	0.544	rs7211724	chr17:33993414	C/G	cg19694781	chr19:47549865	TMEM160	-0.71	-7.27	-0.43	5.26e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs11722228	0.522	rs73212808	chr4:10055439	G/C	cg11266682	chr4:10021025	SLC2A9	0.33	4.79	0.3	3e-6	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs7520050	0.966	rs4660321	chr1:46366760	A/G	cg06784218	chr1:46089804	CCDC17	-0.26	-4.89	-0.31	1.85e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs9393777	0.546	rs9366673	chr6:26893329	C/G	cg12826209	chr6:26865740	GUSBL1	0.95	8.73	0.5	5.09e-16	Intelligence (multi-trait analysis);
SARC	cis	rs1865760	1.000	rs12209482	chr6:25909229	T/G	cg17691542	chr6:26056736	HIST1H1C	0.58	7.18	0.43	9.15e-12	Height;
SARC	cis	rs7666738	0.830	rs1426664	chr4:98988264	A/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2120019	0.938	rs1867150	chr15:75321139	T/C	cg00629941	chr15:75287862	SCAMP5	-0.7	-8.35	-0.48	6.18e-15	Blood trace element (Zn levels);
SARC	cis	rs950169	0.922	rs11630760	chr15:85113337	G/T	cg03959625	chr15:84868606	LOC388152	0.36	4.93	0.31	1.53e-6	Schizophrenia;
SARC	cis	rs17376456	0.877	rs10072592	chr5:93405989	C/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.51	0.34	9.53e-8	Diabetic retinopathy;
SARC	cis	rs57221529	0.766	rs4527146	chr5:555236	A/G	cg09021430	chr5:549028	NA	-0.43	-5.7	-0.35	3.58e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs6121246	0.559	rs6087779	chr20:30370566	T/C	cg13852791	chr20:30311386	BCL2L1	0.89	11.01	0.58	5.74e-23	Mean corpuscular hemoglobin;
SARC	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg11890956	chr21:40555474	PSMG1	1.17	18.87	0.78	7.87e-49	Cognitive function;
SARC	trans	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg07097265	chr17:17727093	SREBF1	-0.5	-6.23	-0.38	2.12e-9	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7614311	0.681	rs2241822	chr3:63965304	A/G	cg22134162	chr3:63841271	THOC7	-0.45	-4.89	-0.3	1.9e-6	Lung function (FVC);Lung function (FEV1);
SARC	cis	rs2594989	0.836	rs347609	chr3:11269999	G/C	cg00170343	chr3:11313890	ATG7	0.65	6.66	0.4	1.96e-10	Circulating chemerin levels;
SARC	cis	rs12922317	0.538	rs442234	chr16:12072161	A/G	cg09319797	chr16:12061715	TNFRSF17	0.35	5.85	0.36	1.67e-8	Schizophrenia;
SARC	cis	rs17376456	0.877	rs12716457	chr5:93397627	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.68	0.35	3.93e-8	Diabetic retinopathy;
SARC	cis	rs864537	0.646	rs1773542	chr1:167432949	T/C	cg09179987	chr1:167433047	CD247	0.44	7.06	0.42	1.92e-11	Celiac disease or Rheumatoid arthritis;Celiac disease;
SARC	cis	rs76419734	1.000	rs10516527	chr4:106734346	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.79	5.34	0.33	2.23e-7	Post bronchodilator FEV1;
SARC	cis	rs10752881	1.000	rs10797812	chr1:182984597	A/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.72	-10.84	-0.58	1.92e-22	Colorectal cancer;
SARC	cis	rs1728785	1.000	rs1170443	chr16:68573295	G/C	cg02972257	chr16:68554789	NA	-0.44	-5.15	-0.32	5.43e-7	Ulcerative colitis;
SARC	cis	rs13082711	0.911	rs77037289	chr3:27512971	C/T	cg02860705	chr3:27208620	NA	0.42	5.44	0.34	1.32e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs9747201	1.000	rs62078307	chr17:80090053	G/T	cg09264619	chr17:80180166	NA	0.48	5.52	0.34	8.94e-8	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.59	7.14	0.42	1.15e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs240764	0.658	rs6909880	chr6:101179354	A/C	cg09795085	chr6:101329169	ASCC3	-0.47	-6.14	-0.37	3.44e-9	Neuroticism;
SARC	cis	rs3741404	0.512	rs4980504	chr11:63873083	G/A	cg04317338	chr11:64019027	PLCB3	-0.41	-4.75	-0.3	3.54e-6	Platelet count;
SARC	cis	rs3136441	1.000	rs4752946	chr11:46896908	C/G	cg25783544	chr11:47291846	MADD	0.59	5.07	0.32	8.19e-7	HDL cholesterol;
SARC	cis	rs6500602	0.826	rs11076830	chr16:4460049	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.33	4.72	0.3	4.09e-6	Schizophrenia;
SARC	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg25036284	chr2:26402008	FAM59B	0.42	4.77	0.3	3.19e-6	Gut microbiome composition (summer);
SARC	cis	rs4073582	1.000	rs524859	chr11:66041079	G/A	cg14036092	chr11:66035641	RAB1B	0.52	6.7	0.4	1.55e-10	Gout;
SARC	cis	rs2273669	0.667	rs12195378	chr6:109284255	A/G	cg05315195	chr6:109294784	ARMC2	-0.57	-5.14	-0.32	5.94e-7	Prostate cancer;
SARC	cis	rs6840360	0.615	rs2120098	chr4:152457180	T/A	cg22705602	chr4:152727874	NA	-0.41	-6.4	-0.39	8.41e-10	Intelligence (multi-trait analysis);
SARC	cis	rs3733585	0.699	rs6449159	chr4:9960498	G/A	cg00071950	chr4:10020882	SLC2A9	-0.37	-5.66	-0.35	4.39e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	8.05	0.47	4.34e-14	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs3126085	0.935	rs11583524	chr1:152161657	T/C	cg26876637	chr1:152193138	HRNR	-0.48	-5.26	-0.33	3.25e-7	Atopic dermatitis;
SARC	cis	rs3820928	0.845	rs2177596	chr2:227890283	A/T	cg11843606	chr2:227700838	RHBDD1	-0.56	-6.96	-0.42	3.36e-11	Pulmonary function;
SARC	cis	rs1153858	1.000	rs10519021	chr15:45631795	G/A	cg26924012	chr15:45694286	SPATA5L1	0.76	10.36	0.56	6.33e-21	Homoarginine levels;
SARC	cis	rs11792861	0.591	rs2282206	chr9:111746267	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.73	9.33	0.52	8.5e-18	Menarche (age at onset);
SARC	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg13699009	chr12:122356056	WDR66	0.62	9.93	0.55	1.28e-19	Mean corpuscular volume;
SARC	cis	rs6430585	0.528	rs309133	chr2:136751842	A/C	cg07169764	chr2:136633963	MCM6	0.93	12.0	0.62	3.86e-26	Corneal structure;
SARC	cis	rs6539267	0.741	rs2279759	chr12:106694988	T/C	cg02476566	chr12:106696527	TCP11L2	0.51	5.24	0.32	3.52e-7	Tourette syndrome;
SARC	cis	rs9611565	0.525	rs9611549	chr22:41705909	C/G	cg17376030	chr22:41985996	PMM1	0.58	7.22	0.43	7.35e-12	Vitiligo;
SARC	cis	rs7772486	0.701	rs7772717	chr6:145954854	T/C	cg05347473	chr6:146136440	FBXO30	0.54	7.62	0.45	6.48e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs909674	0.662	rs2899318	chr22:39837625	A/G	cg24399712	chr22:39784796	NA	-0.4	-5.13	-0.32	6.11e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs4423214	0.592	rs7130829	chr11:71237702	A/T	cg05163923	chr11:71159392	DHCR7	-0.5	-5.01	-0.31	1.06e-6	Vitamin D levels;
SARC	cis	rs6138458	0.585	rs1007881	chr20:25014385	A/G	cg26195577	chr20:24973756	C20orf3	0.7	8.24	0.48	1.22e-14	Blood protein levels;
SARC	cis	rs7412746	0.634	rs2124952	chr1:150923774	T/A	cg13175981	chr1:150552382	MCL1	-0.48	-5.86	-0.36	1.57e-8	Melanoma;
SARC	cis	rs7595412	0.551	rs75402199	chr2:199050088	G/A	cg00208931	chr2:198669586	PLCL1	0.83	4.9	0.31	1.76e-6	Hip bone size;
SARC	cis	rs12142240	0.698	rs17361887	chr1:46834775	A/G	cg14993813	chr1:46806288	NSUN4	-0.5	-5.07	-0.32	7.93e-7	Menopause (age at onset);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg22539706	chr10:24646727	KIAA1217	0.43	6.3	0.38	1.51e-9	Thyroid stimulating hormone;
SARC	cis	rs11792861	0.962	rs3750454	chr9:111801325	C/G	cg13535736	chr9:111863775	C9orf5	0.4	4.97	0.31	1.3e-6	Menarche (age at onset);
SARC	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg05279229	chr7:1896384	MAD1L1	-0.38	-5.23	-0.32	3.86e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs9916302	0.706	rs1054488	chr17:37687968	A/G	cg20243544	chr17:37824526	PNMT	0.52	5.41	0.33	1.56e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs910316	1.000	rs7303	chr14:75520065	T/C	cg23033748	chr14:75592666	NEK9	0.36	4.96	0.31	1.33e-6	Height;
SARC	cis	rs892961	1.000	rs1075457	chr17:75400737	A/G	cg05865280	chr17:75406074	SEPT9	-0.51	-7.39	-0.44	2.67e-12	Airflow obstruction;
SARC	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.51	-5.34	-0.33	2.24e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs7119167	0.950	rs7935204	chr11:73219181	G/A	cg17517138	chr11:73019481	ARHGEF17	0.44	4.74	0.3	3.64e-6	Blood protein levels;
SARC	cis	rs2153535	0.525	rs1335644	chr6:8488041	A/G	cg21535247	chr6:8435926	SLC35B3	0.57	7.26	0.43	5.7e-12	Motion sickness;
SARC	cis	rs13082711	0.516	rs1388785	chr3:27371843	T/C	cg02860705	chr3:27208620	NA	-0.49	-6.69	-0.4	1.68e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs4975616	0.869	rs466502	chr5:1325767	C/T	cg26373071	chr5:1325741	CLPTM1L	-0.31	-5.02	-0.31	1.03e-6	Lung cancer;
SARC	cis	rs11758351	0.587	rs2050950	chr6:26234883	A/G	cg01420254	chr6:26195488	NA	0.55	4.75	0.3	3.49e-6	Gout;Renal underexcretion gout;
SARC	cis	rs67460515	0.892	rs2100238	chr3:161058055	T/A	cg17135325	chr3:160939158	NMD3	0.62	7.94	0.46	8.45e-14	Parkinson's disease;
SARC	trans	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg06437703	chr8:37914619	EIF4EBP1	0.59	7.12	0.42	1.33e-11	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg16049864	chr8:95962084	TP53INP1	-0.52	-8.59	-0.49	1.23e-15	Type 2 diabetes;
SARC	cis	rs9443189	0.570	rs504446	chr6:76326939	T/C	cg01950844	chr6:76311363	SENP6	0.84	8.05	0.47	4.26e-14	Prostate cancer;
SARC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.43	0.56	3.79e-21	Prudent dietary pattern;
SARC	cis	rs11098499	0.754	rs28643450	chr4:120245242	G/A	cg09307838	chr4:120376055	NA	0.81	11.03	0.59	4.84e-23	Corneal astigmatism;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg11482376	chr11:124709245	NA	-0.82	-6.92	-0.41	4.39e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7551222	0.614	rs4951385	chr1:204454165	C/T	cg20240347	chr1:204465584	NA	-0.29	-4.93	-0.31	1.55e-6	Schizophrenia;
SARC	cis	rs2997447	0.739	rs3008224	chr1:26389647	G/A	cg19633962	chr1:26362018	EXTL1	-0.63	-5.14	-0.32	5.7e-7	QRS complex (12-leadsum);
SARC	cis	rs4481887	1.000	rs6671789	chr1:248482931	G/A	cg13385794	chr1:248469461	NA	0.36	5.47	0.34	1.15e-7	Common traits (Other);
SARC	trans	rs9929218	0.861	rs4783667	chr16:68752878	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.64	-8.43	-0.48	3.62e-15	Colorectal cancer;
SARC	cis	rs858239	0.539	rs2178140	chr7:23191625	G/C	cg23682824	chr7:23144976	KLHL7	0.74	9.66	0.53	8.86e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs1865760	0.515	rs2003208	chr6:25940719	G/C	cg17691542	chr6:26056736	HIST1H1C	0.57	7.3	0.43	4.58e-12	Height;
SARC	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg11764359	chr7:65958608	NA	0.83	11.07	0.59	3.72e-23	Aortic root size;
SARC	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg14456004	chr13:21872349	NA	0.48	5.62	0.35	5.54e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs7223966	1.000	rs2665826	chr17:61944924	A/G	cg26338869	chr17:61819248	STRADA	0.51	5.58	0.34	6.67e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg10341310	chr8:66582206	MTFR1	0.54	6.95	0.41	3.67e-11	Schizophrenia;
SARC	cis	rs3087591	0.960	rs2905790	chr17:29476110	A/G	cg24425628	chr17:29625626	OMG;NF1	0.53	6.58	0.4	3.01e-10	Hip circumference;
SARC	cis	rs477692	0.905	rs524545	chr10:131411840	A/C	cg05714579	chr10:131428358	MGMT	-0.61	-8.19	-0.47	1.71e-14	Response to temozolomide;
SARC	cis	rs1568889	1.000	rs34667360	chr11:28055650	T/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	9.61	0.53	1.23e-18	Bipolar disorder;
SARC	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg07153921	chr17:41440717	NA	-0.39	-4.72	-0.3	4.03e-6	Menopause (age at onset);
SARC	cis	rs4356932	1.000	rs6845396	chr4:76951550	G/T	cg24176760	chr4:76958061	ART3;CXCL11	0.3	4.84	0.3	2.33e-6	Blood protein levels;
SARC	cis	rs9381040	0.655	rs9394756	chr6:41016183	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.41	-4.74	-0.3	3.67e-6	Alzheimer's disease (late onset);
SARC	cis	rs644799	1.000	rs516551	chr11:95588626	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.67	8.87	0.5	1.93e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2635047	1.000	rs2684825	chr18:44666415	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.57	7.43	0.44	2.09e-12	Educational attainment;
SARC	cis	rs1215050	0.791	rs968854	chr4:98837863	T/C	cg05340658	chr4:99064831	C4orf37	0.42	5.62	0.35	5.46e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs4746059	0.714	rs11599210	chr10:72457250	A/G	cg18679544	chr10:72432482	ADAMTS14	0.53	7.55	0.44	9.82e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs992157	0.560	rs7605980	chr2:219100869	C/G	cg00012203	chr2:219082015	ARPC2	0.7	10.3	0.56	9.6e-21	Colorectal cancer;
SARC	cis	rs1832871	0.711	rs56043101	chr6:158682277	A/G	cg07165851	chr6:158734300	TULP4	0.55	6.67	0.4	1.8e-10	Height;
SARC	cis	rs910316	0.810	rs77939209	chr14:75670070	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.48	-6.54	-0.39	3.91e-10	Height;
SARC	cis	rs459571	0.834	rs379417	chr9:136890704	G/A	cg01294253	chr9:136912663	BRD3	0.42	5.54	0.34	8.25e-8	Platelet distribution width;
SARC	cis	rs11608355	0.705	rs4766601	chr12:109890080	C/G	cg05360138	chr12:110035743	NA	0.55	5.94	0.36	1.03e-8	Neuroticism;
SARC	cis	rs17666538	1.000	rs59631161	chr8:587808	G/T	cg23958373	chr8:599963	NA	-0.85	-6.73	-0.4	1.3e-10	IgG glycosylation;
SARC	cis	rs6831352	1.000	rs6831352	chr4:100063525	T/C	cg13256891	chr4:100009986	ADH5	0.67	8.84	0.5	2.35e-16	Alcohol dependence;
SARC	cis	rs546131	0.559	rs12803664	chr11:34851929	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-4.79	-0.3	2.93e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs3106136	0.609	rs11097407	chr4:95146135	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.33	-4.73	-0.3	3.91e-6	Capecitabine sensitivity;
SARC	cis	rs11690935	0.959	rs10167419	chr2:172649826	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.99	-16.22	-0.73	4.16e-40	Schizophrenia;
SARC	cis	rs17600642	0.724	rs72814549	chr10:72458913	G/A	cg19779893	chr10:72451501	ADAMTS14	-0.39	-6.16	-0.37	3.22e-9	Bipolar disorder;
SARC	trans	rs6894249	1.000	rs6894249	chr5:131797547	A/G	cg10322510	chr16:12136822	RUNDC2A	-0.53	-7.34	-0.43	3.53e-12	Asthma;
SARC	cis	rs6696846	0.765	rs11576867	chr1:205064676	C/T	cg21643547	chr1:205240462	TMCC2	-0.52	-7.05	-0.42	2e-11	Red blood cell count;
SARC	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg03647317	chr4:187891568	NA	-0.35	-5.13	-0.32	6.17e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3087591	1.000	rs7220268	chr17:29451910	T/C	cg24425628	chr17:29625626	OMG;NF1	0.55	6.98	0.42	3.07e-11	Hip circumference;
SARC	cis	rs2908197	0.866	rs2961048	chr7:75935008	A/T	cg22830091	chr7:75961684	YWHAG	-0.32	-4.73	-0.3	3.9e-6	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs7617480	0.648	rs4974083	chr3:49000626	A/G	cg07636037	chr3:49044803	WDR6	0.88	9.02	0.51	7.03e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs9316337	0.864	rs4769163	chr13:21945868	T/C	cg18095732	chr13:22033692	ZDHHC20	0.38	4.89	0.31	1.88e-6	Schizophrenia;
SARC	cis	rs7582720	1.000	rs72932786	chr2:203698737	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	7.5	0.44	1.36e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs1371867	0.875	rs2439456	chr8:101336874	C/T	cg11906718	chr8:101322791	RNF19A	0.68	8.85	0.5	2.32e-16	Atrioventricular conduction;
SARC	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg09060608	chr5:178986726	RUFY1	-0.33	-4.85	-0.3	2.25e-6	Lung cancer;
SARC	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg13126279	chr21:47581558	C21orf56	0.42	4.89	0.31	1.86e-6	Testicular germ cell tumor;
SARC	cis	rs7005606	1.000	rs3802158	chr8:32404896	C/T	cg14488905	chr8:32406789	NRG1	0.45	6.31	0.38	1.42e-9	Hirschsprung disease;
SARC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg11301795	chr4:187892539	NA	-0.7	-10.35	-0.56	6.76e-21	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7178572	0.568	rs11632966	chr15:77621805	A/C	cg22256960	chr15:77711686	NA	-0.52	-5.75	-0.35	2.72e-8	Type 2 diabetes;
SARC	cis	rs4141404	0.604	rs5753625	chr22:31854846	C/T	cg02404636	chr22:31891804	SFI1	-0.43	-5.34	-0.33	2.2e-7	Paclitaxel-induced neuropathy;
SARC	cis	rs13161895	1.000	rs248318	chr5:179430530	C/T	cg02702477	chr5:179499311	RNF130	0.65	6.46	0.39	5.92e-10	LDL cholesterol;
SARC	cis	rs1865760	0.963	rs1540273	chr6:25924158	T/C	cg17691542	chr6:26056736	HIST1H1C	0.57	6.98	0.42	3.05e-11	Height;
SARC	cis	rs2652834	0.851	rs7170462	chr15:63345622	A/G	cg05507819	chr15:63340323	TPM1	0.6	6.22	0.38	2.24e-9	HDL cholesterol;
SARC	cis	rs17021463	0.673	rs17565759	chr4:95280763	C/T	cg11021082	chr4:95130006	SMARCAD1	0.35	4.74	0.3	3.67e-6	Testicular germ cell tumor;
SARC	cis	rs1865760	0.865	rs9467647	chr6:25957642	A/G	cg18357526	chr6:26021779	HIST1H4A	0.4	4.92	0.31	1.62e-6	Height;
SARC	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg10435706	chr6:150039699	LATS1	0.36	4.81	0.3	2.7e-6	Lung cancer;
SARC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg06873352	chr17:61820015	STRADA	-0.5	-6.47	-0.39	5.66e-10	Prudent dietary pattern;
SARC	cis	rs11077998	0.935	rs9893826	chr17:80511128	C/T	cg10255544	chr17:80519551	FOXK2	0.46	6.91	0.41	4.61e-11	Reticulocyte fraction of red cells;
SARC	cis	rs11723261	0.621	rs7692530	chr4:123445	G/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.4	5.4	0.33	1.61e-7	Immune response to smallpox vaccine (IL-6);
SARC	cis	rs7772486	0.790	rs9403756	chr6:146257761	C/G	cg05347473	chr6:146136440	FBXO30	-0.48	-6.5	-0.39	4.87e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6450176	1.000	rs58369491	chr5:53297295	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.66	-7.64	-0.45	5.69e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs986417	1.000	rs12587609	chr14:60928850	C/G	cg27398547	chr14:60952738	C14orf39	1.02	9.54	0.53	2.06e-18	Gut microbiota (bacterial taxa);
SARC	cis	rs9790314	0.638	rs17236725	chr3:160637935	C/T	cg04691961	chr3:161091175	C3orf57	0.58	8.05	0.47	4.11e-14	Morning vs. evening chronotype;
SARC	cis	rs929354	0.772	rs1002389	chr7:156968323	C/G	cg05182265	chr7:156933206	UBE3C	-0.33	-5.07	-0.32	8.04e-7	Body mass index;
SARC	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg11644478	chr21:40555479	PSMG1	1.02	12.45	0.63	1.28e-27	Cognitive function;
SARC	cis	rs1355223	1.000	rs11607300	chr11:34759319	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.49	-6.16	-0.37	3.16e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs6997458	0.749	rs13270041	chr8:86362963	T/C	cg21346043	chr8:86351067	CA3	-0.34	-4.79	-0.3	3.03e-6	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs79349575	0.783	rs58591767	chr17:47026076	G/A	cg07967210	chr17:47022446	SNF8	0.37	4.71	0.3	4.19e-6	Type 2 diabetes;
SARC	cis	rs9790314	0.846	rs4290817	chr3:160967354	G/A	cg03342759	chr3:160939853	NMD3	-0.73	-9.94	-0.55	1.26e-19	Morning vs. evening chronotype;
SARC	cis	rs8014204	0.804	rs35769520	chr14:75255115	G/A	cg06637938	chr14:75390232	RPS6KL1	0.7	10.09	0.55	4.32e-20	Caffeine consumption;
SARC	cis	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg22857025	chr5:266934	NA	-1.06	-11.66	-0.61	4.84e-25	Breast cancer;
SARC	cis	rs738322	1.000	rs738322	chr22:38569006	A/G	cg25457927	chr22:38595422	NA	-0.28	-5.78	-0.35	2.38e-8	Cutaneous nevi;
SARC	cis	rs116248771	0.549	rs9811858	chr3:158443093	T/C	cg16708174	chr3:158430962	RARRES1	0.49	4.86	0.3	2.14e-6	diarrhoeal disease at age 2;
SARC	cis	rs76917914	0.780	rs2417727	chr9:100846475	T/C	cg03040243	chr9:100819229	NANS	0.68	7.17	0.43	1e-11	Immature fraction of reticulocytes;
SARC	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.08	20.94	0.81	1.8e-55	Chronic sinus infection;
SARC	cis	rs6539267	0.741	rs2279759	chr12:106694988	T/C	cg00173435	chr12:106696525	TCP11L2	0.83	9.84	0.54	2.44e-19	Tourette syndrome;
SARC	cis	rs72627123	0.867	rs113768127	chr14:74467839	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.79	5.97	0.36	8.61e-9	Morning vs. evening chronotype;
SARC	cis	rs6700896	0.931	rs11809906	chr1:66115064	C/T	cg04111102	chr1:66153794	NA	0.35	5.55	0.34	7.6e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs6831352	0.879	rs29001196	chr4:100054116	C/T	cg13256891	chr4:100009986	ADH5	-0.64	-8.0	-0.46	5.7e-14	Alcohol dependence;
SARC	cis	rs7659604	0.702	rs58649165	chr4:122693752	C/A	cg20573242	chr4:122745356	CCNA2	0.52	6.71	0.4	1.48e-10	Type 2 diabetes;
SARC	cis	rs965604	1.000	rs4362358	chr15:78796104	C/T	cg24631222	chr15:78858424	CHRNA5	-0.45	-5.78	-0.35	2.33e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs4481887	1.000	rs4554750	chr1:248496530	C/G	cg13385794	chr1:248469461	NA	0.36	5.34	0.33	2.21e-7	Common traits (Other);
SARC	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg25072359	chr17:41440525	NA	0.51	6.02	0.37	6.83e-9	Menopause (age at onset);
SARC	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg23172400	chr8:95962367	TP53INP1	-0.32	-5.57	-0.34	7.05e-8	Type 2 diabetes;
SARC	cis	rs3540	0.960	rs6496675	chr15:90982756	C/T	cg22089800	chr15:90895588	ZNF774	0.54	6.33	0.38	1.24e-9	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	trans	rs61931739	0.500	rs10844829	chr12:34304916	G/T	cg13010199	chr12:38710504	ALG10B	0.77	10.31	0.56	8.68e-21	Morning vs. evening chronotype;
SARC	cis	rs2120019	0.517	rs872263	chr15:75136444	C/T	cg00629941	chr15:75287862	SCAMP5	-0.63	-5.53	-0.34	8.46e-8	Blood trace element (Zn levels);
SARC	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.38	4.71	0.3	4.2e-6	Tonsillectomy;
SARC	cis	rs11098499	0.710	rs4145952	chr4:120155806	C/A	cg09307838	chr4:120376055	NA	0.76	10.46	0.57	3.07e-21	Corneal astigmatism;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg17510056	chr20:8112972	PLCB1	-0.79	-6.75	-0.4	1.16e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs17209837	1.000	rs45546132	chr7:87086140	C/T	cg00919237	chr7:87102261	ABCB4	-0.5	-5.47	-0.34	1.14e-7	Gallbladder cancer;
SARC	cis	rs12142240	0.698	rs41293273	chr1:46806393	T/C	cg00530320	chr1:46809349	NSUN4	0.55	6.72	0.4	1.35e-10	Menopause (age at onset);
SARC	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg25072359	chr17:41440525	NA	0.48	5.62	0.35	5.43e-8	Menopause (age at onset);
SARC	cis	rs2204008	0.540	rs1283306	chr12:38153778	C/A	cg14851346	chr12:38532713	NA	-0.43	-5.05	-0.31	8.78e-7	Bladder cancer;
SARC	cis	rs2952156	1.000	rs2643194	chr17:37853048	C/T	cg00129232	chr17:37814104	STARD3	-0.68	-8.85	-0.5	2.21e-16	Asthma;
SARC	trans	rs9329221	0.683	rs525726	chr8:9887797	G/C	cg21775007	chr8:11205619	TDH	-0.5	-6.46	-0.39	6.06e-10	Neuroticism;
SARC	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg12463550	chr7:65579703	CRCP	0.5	5.92	0.36	1.14e-8	Aortic root size;
SARC	cis	rs1865760	0.928	rs9295673	chr6:25912094	T/G	cg17691542	chr6:26056736	HIST1H1C	0.58	7.18	0.43	9.15e-12	Height;
SARC	cis	rs6582630	0.599	rs8175936	chr12:38426315	C/G	cg26384229	chr12:38710491	ALG10B	-0.56	-6.98	-0.42	3.13e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs854765	0.594	rs8066560	chr17:17728043	A/G	cg16928487	chr17:17741425	SREBF1	0.23	4.78	0.3	3.09e-6	Total body bone mineral density;
SARC	cis	rs9393692	0.557	rs725575	chr6:26301919	A/T	cg13736514	chr6:26305472	NA	-0.41	-5.01	-0.31	1.06e-6	Educational attainment;
SARC	cis	rs9911578	0.842	rs12450766	chr17:56832965	G/C	cg05425664	chr17:57184151	TRIM37	0.66	7.6	0.45	7.04e-13	Intelligence (multi-trait analysis);
SARC	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg00800038	chr16:89945340	TCF25	-0.76	-5.27	-0.33	3.13e-7	Skin colour saturation;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg00577588	chr22:39916547	ATF4	0.56	6.89	0.41	5.27e-11	Breast cancer;
SARC	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg20607798	chr8:58055168	NA	0.66	5.7	0.35	3.62e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs735539	0.555	rs8001310	chr13:21339700	G/C	cg16922012	chr13:21400325	XPO4	-0.4	-5.47	-0.34	1.15e-7	Dental caries;
SARC	cis	rs4243830	0.737	rs11122091	chr1:6609559	C/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.81	-7.94	-0.46	8.39e-14	Body mass index;
SARC	cis	rs6964587	1.000	rs13224513	chr7:91601465	G/A	cg17063962	chr7:91808500	NA	0.95	15.95	0.72	3.29e-39	Breast cancer;
SARC	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg02951883	chr7:2050386	MAD1L1	-0.37	-4.74	-0.3	3.77e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg03806693	chr22:41940476	POLR3H	0.9	11.92	0.62	6.71e-26	Vitiligo;
SARC	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.8	-11.99	-0.62	4.08e-26	Total body bone mineral density;
SARC	cis	rs4332037	1.000	rs62442899	chr7:1948454	C/T	cg23422044	chr7:1970798	MAD1L1	-0.47	-5.0	-0.31	1.12e-6	Bipolar disorder;
SARC	cis	rs11190604	0.767	rs10883478	chr10:102162852	C/T	cg07080220	chr10:102295463	HIF1AN	0.69	7.57	0.44	8.81e-13	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs12142240	0.698	rs17361805	chr1:46813967	C/T	cg10495392	chr1:46806563	NSUN4	0.64	6.64	0.4	2.17e-10	Menopause (age at onset);
SARC	cis	rs9487051	0.714	rs7774377	chr6:109602443	G/A	cg01475377	chr6:109611718	NA	-0.34	-4.95	-0.31	1.45e-6	Reticulocyte fraction of red cells;
SARC	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg12463550	chr7:65579703	CRCP	-0.69	-5.23	-0.32	3.73e-7	Diabetic kidney disease;
SARC	cis	rs826838	0.935	rs1486357	chr12:39073675	A/G	cg13010199	chr12:38710504	ALG10B	0.77	10.7	0.57	5.25e-22	Heart rate;
SARC	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg11366901	chr6:160182831	ACAT2	0.89	9.02	0.51	6.89e-17	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs875971	0.522	rs9530	chr7:65425894	A/G	cg18876405	chr7:65276391	NA	0.72	9.4	0.52	5.31e-18	Aortic root size;
SARC	trans	rs61931739	0.500	rs7979482	chr12:34542877	C/A	cg26384229	chr12:38710491	ALG10B	0.91	13.78	0.67	5.4e-32	Morning vs. evening chronotype;
SARC	cis	rs2228479	0.850	rs1800355	chr16:89813194	C/T	cg06558623	chr16:89946397	TCF25	0.91	6.4	0.39	8.49e-10	Skin colour saturation;
SARC	cis	rs7681440	0.583	rs2737024	chr4:90721560	A/G	cg06632027	chr4:90757378	SNCA	-0.47	-5.72	-0.35	3.23e-8	Dementia with Lewy bodies;
SARC	cis	rs9914988	0.943	rs9891925	chr17:27104540	A/T	cg20469991	chr17:27169893	C17orf63	-0.5	-5.21	-0.32	4.1e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs910316	1.000	rs10142865	chr14:75555624	G/A	cg08847533	chr14:75593920	NEK9	0.94	16.23	0.73	3.78e-40	Height;
SARC	cis	rs12200560	0.505	rs4839849	chr6:97076673	T/C	cg06623918	chr6:96969491	KIAA0776	0.46	5.29	0.33	2.82e-7	Coronary heart disease;
SARC	cis	rs6930083	0.527	rs9368950	chr6:36627872	T/C	cg00292029	chr6:36703127	NA	0.31	4.71	0.3	4.2e-6	Coronary artery disease;
SARC	cis	rs787274	0.543	rs62576453	chr9:115629921	C/T	cg13803584	chr9:115635662	SNX30	-0.83	-7.03	-0.42	2.25e-11	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs7722600	1.000	rs112579530	chr5:137098810	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.5	4.82	0.3	2.6e-6	Heart rate;
SARC	cis	rs7927592	0.956	rs11228278	chr11:68308530	G/A	cg01657329	chr11:68192670	LRP5	-0.37	-4.73	-0.3	3.87e-6	Total body bone mineral density;
SARC	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg25036284	chr2:26402008	FAM59B	0.46	5.7	0.35	3.59e-8	Gut microbiome composition (summer);
SARC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.81	8.6	0.49	1.18e-15	Platelet count;
SARC	cis	rs4481887	1.000	rs4372295	chr1:248464871	G/T	cg01631408	chr1:248437212	OR2T33	-0.41	-5.28	-0.33	2.94e-7	Common traits (Other);
SARC	cis	rs950169	0.544	rs2036949	chr15:85163605	T/C	cg17507749	chr15:85114479	UBE2QP1	0.61	7.07	0.42	1.8e-11	Schizophrenia;
SARC	cis	rs11687170	0.882	rs11686887	chr2:237057611	T/A	cg19324714	chr2:237145437	ASB18	0.49	4.89	0.31	1.89e-6	Educational attainment;Educational attainment (years of education);
SARC	cis	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg21573476	chr21:45109991	RRP1B	-0.57	-8.5	-0.49	2.25e-15	Mean corpuscular volume;
SARC	cis	rs9911578	0.867	rs4793941	chr17:56472366	G/A	cg05425664	chr17:57184151	TRIM37	0.65	8.06	0.47	3.95e-14	Intelligence (multi-trait analysis);
SARC	cis	rs10089	0.903	rs6862701	chr5:127391249	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	10.19	0.56	2.04e-20	Ileal carcinoids;
SARC	cis	rs9914544	0.545	rs4924940	chr17:18800092	T/C	cg25390199	chr17:18761479	PRPSAP2	0.46	6.04	0.37	5.99e-9	Educational attainment (years of education);
SARC	cis	rs13401104	0.740	rs12465430	chr2:237113578	C/T	cg19324714	chr2:237145437	ASB18	0.57	5.91	0.36	1.22e-8	Educational attainment;
SARC	cis	rs616402	0.527	rs589151	chr1:10567711	C/T	cg17425144	chr1:10567563	PEX14	0.47	7.54	0.44	1.06e-12	Breast size;
SARC	cis	rs459571	0.959	rs2520099	chr9:136918139	T/C	cg13789015	chr9:136890014	NCRNA00094	0.61	8.48	0.49	2.58e-15	Platelet distribution width;
SARC	cis	rs9398803	0.865	rs9375442	chr6:126803137	A/C	cg19875578	chr6:126661172	C6orf173	0.61	8.25	0.48	1.16e-14	Male-pattern baldness;
SARC	cis	rs9316337	0.548	rs9506682	chr13:22024070	T/G	cg21080246	chr13:22033151	ZDHHC20	0.42	4.89	0.31	1.85e-6	Schizophrenia;
SARC	cis	rs12912251	1.000	rs35102843	chr15:38988107	C/A	cg01338139	chr15:38987640	C15orf53	-0.46	-5.42	-0.33	1.52e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
SARC	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.48	-5.48	-0.34	1.12e-7	Huntington's disease progression;
SARC	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg25952890	chr19:58913133	NA	0.36	5.14	0.32	5.8e-7	Uric acid clearance;
SARC	cis	rs748404	0.578	rs2278856	chr15:43631356	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.43	5.41	0.33	1.53e-7	Lung cancer;
SARC	cis	rs4737010	0.630	rs569451	chr8:41623001	G/A	cg08923054	chr8:41654455	ANK1	-0.43	-5.04	-0.31	9.36e-7	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
SARC	cis	rs10875746	0.669	rs11168496	chr12:48650855	G/A	cg26205652	chr12:48591994	NA	0.45	4.96	0.31	1.34e-6	Longevity (90 years and older);
SARC	cis	rs34779708	0.966	rs12765038	chr10:35416513	G/C	cg03585969	chr10:35415529	CREM	0.41	5.1	0.32	7.17e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs7829975	0.511	rs2976906	chr8:8342415	A/T	cg08975724	chr8:8085496	FLJ10661	0.51	6.9	0.41	4.85e-11	Mood instability;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg09318521	chr1:224301995	FBXO28	0.54	6.99	0.42	2.94e-11	Lung adenocarcinoma;
SARC	cis	rs3008870	0.755	rs4655662	chr1:67416432	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.59	7.53	0.44	1.1e-12	Lymphocyte percentage of white cells;
SARC	cis	rs1570884	0.516	rs9316462	chr13:50176321	A/G	cg03651054	chr13:50194643	NA	0.3	4.77	0.3	3.21e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg10591111	chr5:226296	SDHA	-0.52	-4.79	-0.3	2.93e-6	Breast cancer;
SARC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg25418748	chr5:178977236	RUFY1	-0.49	-6.23	-0.38	2.14e-9	Gambling;
SARC	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.48	5.3	0.33	2.67e-7	Renal function-related traits (BUN);
SARC	cis	rs6725041	0.522	rs10164863	chr2:213148179	T/C	cg11217840	chr2:214016358	IKZF2	-0.48	-5.27	-0.33	3.07e-7	QT interval (ambient particulate matter interaction);
SARC	trans	rs61931739	0.500	rs28692887	chr12:34457075	G/A	cg26384229	chr12:38710491	ALG10B	0.92	13.8	0.67	4.45e-32	Morning vs. evening chronotype;
SARC	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg19223190	chr17:80058835	NA	-0.4	-5.56	-0.34	7.43e-8	Life satisfaction;
SARC	cis	rs6831352	0.879	rs2851255	chr4:100042103	C/G	cg13256891	chr4:100009986	ADH5	0.65	8.14	0.47	2.35e-14	Alcohol dependence;
SARC	cis	rs9788682	1.000	rs7181245	chr15:78814389	C/T	cg17108064	chr15:78857060	CHRNA5	-0.31	-4.85	-0.3	2.27e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg12288994	chr5:1860383	NA	0.42	6.79	0.41	9.24e-11	Cardiovascular disease risk factors;
SARC	cis	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg00409905	chr10:38381863	ZNF37A	-0.58	-8.13	-0.47	2.49e-14	Extrinsic epigenetic age acceleration;
SARC	cis	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg20965017	chr5:231967	SDHA	-0.54	-5.18	-0.32	4.87e-7	Breast cancer;
SARC	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg05368731	chr17:41323189	NBR1	0.79	9.75	0.54	4.8e-19	Menopause (age at onset);
SARC	cis	rs356220	0.642	rs356176	chr4:90630801	G/C	cg06632027	chr4:90757378	SNCA	0.41	5.41	0.33	1.57e-7	Parkinson's disease;
SARC	cis	rs9303401	0.659	rs34913878	chr17:56897094	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	11.5	0.6	1.52e-24	Cognitive test performance;
SARC	cis	rs2228479	0.850	rs62056063	chr16:89903680	C/T	cg06558623	chr16:89946397	TCF25	0.93	6.63	0.4	2.29e-10	Skin colour saturation;
SARC	cis	rs6909279	0.678	rs11155795	chr6:151851339	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.47	6.11	0.37	4.1e-9	Bone mineral density;
SARC	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg11987759	chr7:65425863	GUSB	0.57	7.53	0.44	1.14e-12	Aortic root size;
SARC	cis	rs7615952	0.733	rs13314847	chr3:125644788	C/T	cg05084668	chr3:125655381	ALG1L	-0.67	-6.67	-0.4	1.84e-10	Blood pressure (smoking interaction);
SARC	cis	rs11122272	0.735	rs2491405	chr1:231513431	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg03806693	chr22:41940476	POLR3H	0.9	12.15	0.62	1.2e-26	Vitiligo;
SARC	cis	rs9902453	0.904	rs7208579	chr17:28263067	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	6.94	0.41	3.77e-11	Coffee consumption (cups per day);
SARC	trans	rs7615952	0.673	rs9821905	chr3:125620850	A/G	cg07211511	chr3:129823064	LOC729375	0.86	7.74	0.45	2.97e-13	Blood pressure (smoking interaction);
SARC	cis	rs9388451	0.807	rs1269175	chr6:126040435	A/G	cg06289844	chr6:126071538	HEY2	-0.32	-5.23	-0.32	3.74e-7	Brugada syndrome;
SARC	cis	rs4722166	0.695	rs7787893	chr7:22774437	A/G	cg26061582	chr7:22766209	IL6	0.48	5.39	0.33	1.75e-7	Lung cancer;
SARC	cis	rs9381040	0.655	rs4140578	chr6:41041829	A/G	cg02167203	chr6:41068553	NFYA;LOC221442	-0.41	-4.73	-0.3	3.81e-6	Alzheimer's disease (late onset);
SARC	trans	rs1853207	1.000	rs78373114	chr10:96643896	T/A	cg02737782	chr1:8014393	NA	-0.97	-6.42	-0.39	7.44e-10	Blood metabolite levels;
SARC	cis	rs11608355	0.515	rs61941591	chr12:109919965	A/C	cg05360138	chr12:110035743	NA	0.94	9.47	0.53	3.36e-18	Neuroticism;
SARC	cis	rs8017423	0.904	rs11622257	chr14:90715014	C/T	cg20276874	chr14:90721474	PSMC1	0.35	4.73	0.3	3.87e-6	Mortality in heart failure;
SARC	cis	rs2635047	0.615	rs2571005	chr18:44714365	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.46	-5.47	-0.34	1.14e-7	Educational attainment;
SARC	cis	rs9486719	1.000	rs2499816	chr6:96878206	C/T	cg06623918	chr6:96969491	KIAA0776	0.73	8.01	0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs703842	1.000	rs2069502	chr12:58144665	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.75	-10.37	-0.56	5.89e-21	Multiple sclerosis;
SARC	cis	rs4851254	0.660	rs34714421	chr2:100692175	T/C	cg17356467	chr2:100759845	AFF3	0.33	4.91	0.31	1.73e-6	Intelligence (multi-trait analysis);
SARC	trans	rs61931739	0.559	rs4385974	chr12:34313128	G/C	cg13010199	chr12:38710504	ALG10B	0.58	7.45	0.44	1.76e-12	Morning vs. evening chronotype;
SARC	cis	rs7829975	0.509	rs2945269	chr8:8115578	G/C	cg11608241	chr8:8085544	FLJ10661	0.45	5.2	0.32	4.44e-7	Mood instability;
SARC	cis	rs9868809	0.505	rs28567949	chr3:48744560	G/A	cg07636037	chr3:49044803	WDR6	-0.69	-6.55	-0.39	3.7e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	trans	rs8073060	0.586	rs72828038	chr17:33893908	C/A	cg19694781	chr19:47549865	TMEM160	0.64	6.46	0.39	6.2e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs57506017	0.606	rs7797705	chr7:12277773	G/A	cg23422036	chr7:12250390	TMEM106B	0.46	5.97	0.36	8.71e-9	Neuroticism;
SARC	cis	rs240110	0.539	rs6919745	chr6:101338978	T/C	cg09795085	chr6:101329169	ASCC3	0.57	7.81	0.46	1.97e-13	Neuroticism;
SARC	cis	rs8077889	0.672	rs15359	chr17:41843979	C/G	cg26893861	chr17:41843967	DUSP3	-1.04	-17.15	-0.75	3.37e-43	Triglycerides;
SARC	cis	rs6964587	1.000	rs36021614	chr7:91717490	C/G	cg17063962	chr7:91808500	NA	0.96	15.57	0.71	6.19e-38	Breast cancer;
SARC	cis	rs372883	0.935	rs379592	chr21:30706470	A/G	cg24692254	chr21:30365293	RNF160	-0.41	-4.96	-0.31	1.38e-6	Pancreatic cancer;
SARC	cis	rs1483890	1.000	rs900671	chr3:69406527	C/A	cg22125112	chr3:69402811	FRMD4B	0.31	5.18	0.32	4.81e-7	Resting heart rate;
SARC	trans	rs7395662	0.517	rs10838960	chr11:48584741	A/G	cg15704280	chr7:45808275	SEPT13	-0.5	-6.73	-0.4	1.32e-10	HDL cholesterol;
SARC	cis	rs921968	0.541	rs7603816	chr2:219396255	C/T	cg02176678	chr2:219576539	TTLL4	-0.49	-7.57	-0.44	8.67e-13	Mean corpuscular hemoglobin concentration;
SARC	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg06618935	chr21:46677482	NA	-0.41	-5.37	-0.33	1.92e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs3796352	1.000	rs11718834	chr3:52963668	A/C	cg15956490	chr3:53032818	SFMBT1	0.78	5.19	0.32	4.61e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg07157834	chr1:205819609	PM20D1	0.7	11.13	0.59	2.44e-23	Menarche (age at onset);
SARC	cis	rs6864727	1.000	rs217259	chr5:137412963	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.56	6.24	0.38	2e-9	Atrial fibrillation;
SARC	cis	rs72634258	0.945	rs12757968	chr1:8106201	A/G	cg00042356	chr1:8021962	PARK7	0.91	8.42	0.48	3.95e-15	Inflammatory bowel disease;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg16362480	chr16:30077084	ALDOA	0.6	6.3	0.38	1.44e-9	Lung cancer in ever smokers;
SARC	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg15212455	chr7:39170539	POU6F2	0.42	5.34	0.33	2.22e-7	IgG glycosylation;
SARC	cis	rs1983170	0.808	rs2893176	chr1:92017684	A/C	cg25838465	chr1:92012736	NA	0.45	5.49	0.34	1.04e-7	Eosinophil percentage of white cells;
SARC	cis	rs11711311	0.955	rs10934247	chr3:113534941	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	8.56	0.49	1.53e-15	IgG glycosylation;
SARC	cis	rs9902453	0.740	rs1382391	chr17:28111986	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.19	-0.43	8.82e-12	Coffee consumption (cups per day);
SARC	cis	rs1050631	1.000	rs3110564	chr18:33701589	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	-0.42	-5.03	-0.31	9.79e-7	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs7089973	0.604	rs2420065	chr10:116583753	A/G	cg03647239	chr10:116582469	FAM160B1	0.49	6.31	0.38	1.42e-9	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg19723775	chr5:179050963	HNRNPH1	-0.47	-6.26	-0.38	1.86e-9	Lung cancer;
SARC	cis	rs959260	0.614	rs8065441	chr17:73410447	C/G	cg14668889	chr17:73230827	NUP85	-0.49	-4.87	-0.3	2.1e-6	Systemic lupus erythematosus;
SARC	trans	rs3945119	0.805	rs4658169	chr1:91154809	A/C	cg01730148	chr2:3698421	NA	0.34	6.42	0.39	7.7e-10	Intelligence (multi-trait analysis);
SARC	cis	rs11098499	0.754	rs4107728	chr4:120253910	G/A	cg09307838	chr4:120376055	NA	0.81	10.97	0.58	7.4e-23	Corneal astigmatism;
SARC	cis	rs7264396	0.790	rs2295355	chr20:34252654	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	5.91	0.36	1.21e-8	Total cholesterol levels;
SARC	cis	rs644799	0.932	rs10831447	chr11:95663017	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.7	-9.28	-0.52	1.23e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9309711	0.961	rs11692184	chr2:3480710	C/T	cg10845886	chr2:3471009	TTC15	-0.53	-6.86	-0.41	6.25e-11	Neurofibrillary tangles;
SARC	cis	rs7633770	0.643	rs58413466	chr3:46689154	G/T	cg11219411	chr3:46661640	NA	-0.4	-6.17	-0.37	3.05e-9	Coronary artery disease;
SARC	cis	rs4690686	0.500	rs4690431	chr4:177264251	G/A	cg17059388	chr4:177262070	NA	0.36	4.78	0.3	3.09e-6	Essential tremor;
SARC	cis	rs7666738	0.830	rs7672720	chr4:98938760	A/T	cg05340658	chr4:99064831	C4orf37	0.66	8.83	0.5	2.48e-16	Colonoscopy-negative controls vs population controls;
SARC	trans	rs9325144	0.647	rs12231313	chr12:39101929	C/T	cg23762105	chr12:34175262	ALG10	0.49	6.25	0.38	1.96e-9	Morning vs. evening chronotype;
SARC	cis	rs600231	0.708	rs661403	chr11:65242478	A/G	cg17120908	chr11:65337727	SSSCA1	-0.43	-5.51	-0.34	9.24e-8	Bone mineral density;
SARC	cis	rs11203032	0.831	rs10788635	chr10:90927063	A/G	cg16672925	chr10:90967113	CH25H	0.52	5.37	0.33	1.94e-7	Heart failure;
SARC	cis	rs2933343	0.601	rs1680758	chr3:128594897	T/C	cg24203234	chr3:128598194	ACAD9	0.63	8.11	0.47	2.89e-14	IgG glycosylation;
SARC	cis	rs7666738	0.830	rs10012167	chr4:99048579	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4242434	0.672	rs11785031	chr8:22486612	A/G	cg03733263	chr8:22462867	KIAA1967	0.88	13.76	0.67	6.2e-32	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs10465746	0.775	rs4907186	chr1:84340753	G/T	cg10977910	chr1:84465055	TTLL7	0.42	5.09	0.32	7.37e-7	Obesity-related traits;
SARC	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg18404041	chr3:52824283	ITIH1	-0.44	-6.34	-0.38	1.19e-9	Bipolar disorder;
SARC	cis	rs9911578	0.740	rs368243	chr17:56708979	T/C	cg12560992	chr17:57184187	TRIM37	0.62	7.93	0.46	8.9e-14	Intelligence (multi-trait analysis);
SARC	cis	rs8180040	0.800	rs11130126	chr3:47306894	A/G	cg27129171	chr3:47204927	SETD2	-0.72	-9.53	-0.53	2.16e-18	Colorectal cancer;
SARC	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg24209194	chr3:40518798	ZNF619	0.67	8.13	0.47	2.49e-14	Renal cell carcinoma;
SARC	cis	rs11122272	0.766	rs2790871	chr1:231543555	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-9.71	-0.54	6.4e-19	Hemoglobin concentration;
SARC	cis	rs4727027	0.899	rs11768971	chr7:148825826	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	5.35	0.33	2.1e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs12545109	0.800	rs1561224	chr8:57419922	T/C	cg21220214	chr8:57350948	NA	-0.4	-4.84	-0.3	2.37e-6	Obesity-related traits;
SARC	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg08219700	chr8:58056026	NA	0.68	6.06	0.37	5.43e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs898097	0.528	rs2243523	chr17:80680449	G/T	cg15664640	chr17:80829946	TBCD	-0.4	-6.26	-0.38	1.88e-9	Breast cancer;
SARC	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs2153535	0.580	rs969421	chr6:8451949	A/C	cg21535247	chr6:8435926	SLC35B3	0.55	6.84	0.41	6.72e-11	Motion sickness;
SARC	cis	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg06558623	chr16:89946397	TCF25	0.91	6.37	0.38	1.03e-9	Skin colour saturation;
SARC	cis	rs870825	0.929	rs56106324	chr4:185589901	C/A	cg04058563	chr4:185651563	MLF1IP	0.81	9.0	0.51	8.08e-17	Blood protein levels;
SARC	cis	rs5758659	0.935	rs134879	chr22:42664201	A/C	cg15128208	chr22:42549153	NA	-0.34	-4.89	-0.3	1.92e-6	Cognitive function;
SARC	cis	rs9470366	0.545	rs2395655	chr6:36645696	C/T	cg08179530	chr6:36648295	CDKN1A	-0.81	-12.81	-0.64	8.73e-29	QRS duration;
SARC	cis	rs2153535	0.541	rs6908504	chr6:8456778	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	10.66	0.57	7.43e-22	Motion sickness;
SARC	cis	rs2295359	0.824	rs12060309	chr1:67604219	T/C	cg08029281	chr1:67600428	NA	0.38	4.76	0.3	3.33e-6	Psoriasis;
SARC	trans	rs656319	0.629	rs11774276	chr8:10070309	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.63	-0.4	2.27e-10	Myopia (pathological);
SARC	cis	rs2011503	0.843	rs2860494	chr19:19470426	T/C	cg03709012	chr19:19516395	GATAD2A	-0.65	-5.87	-0.36	1.52e-8	Bipolar disorder;
SARC	cis	rs6912958	0.535	rs1753153	chr6:88032834	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.36	6.06	0.37	5.31e-9	Monocyte percentage of white cells;
SARC	cis	rs3820928	0.874	rs10189579	chr2:227864876	A/G	cg11843606	chr2:227700838	RHBDD1	-0.5	-6.12	-0.37	3.84e-9	Pulmonary function;
SARC	cis	rs1008375	0.800	rs10008598	chr4:17607323	T/C	cg16339924	chr4:17578868	LAP3	0.64	8.35	0.48	6.3e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs698833	0.813	rs3768919	chr2:44512971	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.7	8.53	0.49	1.82e-15	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg11062466	chr8:58055876	NA	0.64	5.87	0.36	1.47e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.97	-15.87	-0.72	5.95e-39	Chronic sinus infection;
SARC	cis	rs1865760	0.929	rs9461224	chr6:25936402	G/T	cg10185311	chr6:26124167	HIST1H2AC;HIST1H2BC	-0.53	-6.44	-0.39	6.63e-10	Height;
SARC	cis	rs796364	0.664	rs4673660	chr2:200915395	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.58	5.98	0.36	8.17e-9	Schizophrenia;
SARC	trans	rs8073060	0.586	rs225286	chr17:33930458	G/A	cg19694781	chr19:47549865	TMEM160	-0.64	-6.39	-0.39	8.79e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs9916302	0.904	rs10852933	chr17:37698194	G/T	cg07936489	chr17:37558343	FBXL20	-0.68	-8.81	-0.5	2.97e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs17079247	1.000	rs2130477	chr13:85745985	C/A	ch.13.84760847R	chr13:85862846	NA	-0.56	-4.73	-0.3	3.93e-6	Bipolar disorder (mania);
SARC	cis	rs372883	0.532	rs388707	chr21:30714776	T/C	cg08807101	chr21:30365312	RNF160	-0.47	-5.83	-0.36	1.84e-8	Pancreatic cancer;
SARC	cis	rs10849605	0.867	rs10849602	chr12:1062479	A/G	cg02055889	chr12:1059459	RAD52	0.37	5.17	0.32	5.14e-7	Lung cancer;
SARC	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg11644478	chr21:40555479	PSMG1	1.04	12.94	0.65	3.25e-29	Cognitive function;
SARC	cis	rs9457247	1.000	rs2149091	chr6:167372786	C/T	cg23791538	chr6:167370224	RNASET2	0.63	8.74	0.5	4.74e-16	Crohn's disease;
SARC	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	12.22	0.62	7.4e-27	Chronic sinus infection;
SARC	cis	rs9324022	0.929	rs72698721	chr14:101181189	G/A	cg18089426	chr14:101175970	NA	0.57	5.47	0.34	1.18e-7	Plateletcrit;
SARC	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg08280861	chr8:58055591	NA	0.7	6.02	0.37	6.73e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg16414030	chr3:133502952	NA	-0.39	-5.29	-0.33	2.85e-7	Iron status biomarkers;
SARC	cis	rs7512552	0.809	rs2794679	chr1:150324857	G/A	cg15654264	chr1:150340011	RPRD2	0.38	4.83	0.3	2.49e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs6570726	0.791	rs6912079	chr6:145894949	G/A	cg23711669	chr6:146136114	FBXO30	0.87	14.39	0.69	4.97e-34	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11098499	0.863	rs13140391	chr4:120503437	A/G	cg09307838	chr4:120376055	NA	0.91	12.25	0.63	5.66e-27	Corneal astigmatism;
SARC	cis	rs763121	0.853	rs5757231	chr22:39071658	C/T	cg21395723	chr22:39101663	GTPBP1	-0.55	-6.06	-0.37	5.5e-9	Menopause (age at onset);
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg15611364	chr3:25831423	OXSM;NGLY1	0.49	6.28	0.38	1.68e-9	Lung adenocarcinoma;
SARC	trans	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg17712092	chr4:129076599	LARP1B	0.69	9.37	0.52	6.65e-18	Eosinophil percentage of white cells;
SARC	cis	rs2043112	0.867	rs10069914	chr5:39062689	A/G	cg04869206	chr5:39074266	RICTOR	0.44	5.27	0.33	3.07e-7	Obesity-related traits;
SARC	cis	rs2153535	0.541	rs6923558	chr6:8461467	T/G	cg07606381	chr6:8435919	SLC35B3	0.76	10.71	0.57	4.89e-22	Motion sickness;
SARC	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg18252515	chr7:66147081	NA	0.44	4.88	0.3	1.95e-6	Aortic root size;
SARC	cis	rs6450176	0.904	rs4351101	chr5:53300591	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.68	-7.82	-0.46	1.84e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs2280018	1.000	rs2280017	chr16:15151361	A/G	cg07549590	chr16:15018862	NA	0.37	5.18	0.32	4.81e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs9581943	0.967	rs9581927	chr13:28462645	G/T	cg17352152	chr13:28491409	NA	0.4	5.28	0.33	2.9e-7	Pancreatic cancer;
SARC	cis	rs17270561	0.553	rs6456696	chr6:25741408	A/G	cg16482183	chr6:26056742	HIST1H1C	0.43	5.08	0.32	7.76e-7	Iron status biomarkers;
SARC	cis	rs1865760	0.516	rs9295684	chr6:26069669	T/C	cg02841227	chr6:26021843	HIST1H4A	0.4	4.94	0.31	1.47e-6	Height;
SARC	cis	rs56235845	0.694	rs4976643	chr5:176760227	A/C	cg06060754	chr5:176797920	RGS14	0.45	5.91	0.36	1.21e-8	Hemoglobin concentration;Hematocrit;
SARC	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg07636037	chr3:49044803	WDR6	0.99	17.61	0.76	1.02e-44	Parkinson's disease;
SARC	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg09455208	chr3:40491958	NA	-0.37	-5.53	-0.34	8.71e-8	Renal cell carcinoma;
SARC	cis	rs208520	0.526	rs9294682	chr6:66795159	G/A	cg07460842	chr6:66804631	NA	-1.12	-22.55	-0.83	1.68e-60	Exhaled nitric oxide output;
SARC	cis	rs6690583	0.513	rs7545050	chr1:85552175	A/C	cg22153463	chr1:85462885	MCOLN2	-0.56	-5.55	-0.34	7.74e-8	Serum sulfate level;
SARC	cis	rs9788682	0.747	rs7177514	chr15:78907406	C/G	cg06917634	chr15:78832804	PSMA4	-0.46	-5.27	-0.33	3.04e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs78487399	0.808	rs6544664	chr2:43729108	T/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-4.84	-0.3	2.37e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs920590	0.573	rs12547934	chr8:19680736	T/C	cg03894339	chr8:19674705	INTS10	-0.51	-5.96	-0.36	9.21e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg22903471	chr2:27725779	GCKR	-0.53	-8.35	-0.48	6.22e-15	Total body bone mineral density;
SARC	cis	rs9302635	0.513	rs8061282	chr16:72155938	C/T	cg01557791	chr16:72042693	DHODH	-0.58	-6.46	-0.39	5.93e-10	Blood protein levels;
SARC	cis	rs16854884	0.586	rs7650172	chr3:143729408	G/C	cg06585982	chr3:143692056	C3orf58	0.7	9.83	0.54	2.77e-19	Economic and political preferences (feminism/equality);
SARC	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.43	-5.49	-0.34	1.03e-7	Intelligence (multi-trait analysis);
SARC	cis	rs8180040	0.593	rs4018905	chr3:47138170	A/G	cg27129171	chr3:47204927	SETD2	0.69	9.53	0.53	2.14e-18	Colorectal cancer;
SARC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg22105103	chr4:187893119	NA	0.48	6.44	0.39	6.85e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7762018	0.607	rs80106119	chr6:170048309	T/C	cg19338460	chr6:170058176	WDR27	-0.79	-5.31	-0.33	2.53e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs505401	0.554	rs10401349	chr19:6075713	C/T	cg18109231	chr19:6110877	RFX2	0.72	4.86	0.3	2.19e-6	Mean platelet volume;
SARC	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg18758796	chr5:131593413	PDLIM4	0.37	4.77	0.3	3.25e-6	Acylcarnitine levels;
SARC	cis	rs2227564	0.672	rs10824042	chr10:75645628	C/T	cg16540259	chr10:75572220	NDST2	0.36	5.0	0.31	1.11e-6	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs4268898	0.662	rs9917315	chr2:24431501	C/A	cg06627628	chr2:24431161	ITSN2	-0.84	-10.12	-0.55	3.39e-20	Asthma;
SARC	cis	rs10504073	0.647	rs7817571	chr8:50003218	T/C	cg00325661	chr8:49890786	NA	0.51	6.94	0.41	3.86e-11	Blood metabolite ratios;
SARC	trans	rs1814175	0.645	rs847632	chr11:49926097	C/T	cg03929089	chr4:120376271	NA	-0.82	-11.67	-0.61	4.51e-25	Height;
SARC	cis	rs6424115	0.708	rs13551	chr1:24180962	T/C	cg15997130	chr1:24165203	NA	-0.4	-4.95	-0.31	1.42e-6	Immature fraction of reticulocytes;
SARC	cis	rs10463316	0.817	rs7709507	chr5:150783349	C/T	cg03212797	chr5:150827313	SLC36A1	-0.47	-5.51	-0.34	9.48e-8	Metabolite levels (Pyroglutamine);
SARC	trans	rs2727020	0.523	rs4115783	chr11:49556026	G/A	cg03929089	chr4:120376271	NA	0.7	7.91	0.46	1.01e-13	Coronary artery disease;
SARC	cis	rs72781680	0.800	rs72780112	chr2:23991182	C/T	cg08917208	chr2:24149416	ATAD2B	0.77	7.29	0.43	4.79e-12	Lymphocyte counts;
SARC	cis	rs11583043	0.874	rs6577219	chr1:101415707	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	5.99	0.37	7.88e-9	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs9309473	0.687	rs7576824	chr2:73611281	C/T	cg20560298	chr2:73613845	ALMS1	0.55	6.98	0.42	3.06e-11	Metabolite levels;
SARC	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg16325326	chr1:53192061	ZYG11B	-0.79	-12.07	-0.62	2.22e-26	Monocyte count;
SARC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg01238044	chr22:24384105	GSTT1	-0.57	-6.68	-0.4	1.77e-10	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs10654220	1	rs10654220	chr12:123703422	A/AGTT	cg05973401	chr12:123451056	ABCB9	0.55	5.22	0.32	3.89e-7	Platelet count;
SARC	cis	rs8114671	0.570	rs3761144	chr20:33544075	C/G	cg07148914	chr20:33460835	GGT7	0.41	4.98	0.31	1.23e-6	Height;
SARC	cis	rs2204008	0.811	rs11525004	chr12:38333807	T/A	cg13010199	chr12:38710504	ALG10B	0.79	10.83	0.58	2.12e-22	Bladder cancer;
SARC	cis	rs10911232	0.507	rs3935384	chr1:183028970	C/T	cg13390022	chr1:182993471	LAMC1	0.33	4.95	0.31	1.42e-6	Hypertriglyceridemia;
SARC	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg04277193	chr17:41438351	NA	0.46	4.91	0.31	1.7e-6	Menopause (age at onset);
SARC	cis	rs2304069	0.954	rs9324638	chr5:149400718	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.87	-9.27	-0.52	1.31e-17	HIV-1 control;
SARC	cis	rs6545883	0.894	rs4672436	chr2:61603357	A/C	cg15711740	chr2:61764176	XPO1	0.4	4.73	0.3	3.92e-6	Tuberculosis;
SARC	cis	rs933688	1.000	rs1035477	chr5:90743325	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.0	12.52	0.63	7.66e-28	Smoking behavior;
SARC	cis	rs2075671	0.903	rs11983334	chr7:100302434	C/T	cg03098644	chr7:100410630	EPHB4	0.48	5.26	0.33	3.31e-7	Other erythrocyte phenotypes;
SARC	cis	rs708547	0.836	rs1315005	chr4:57858237	C/G	cg14719990	chr4:57843890	C4orf14;POLR2B	0.41	4.78	0.3	3.11e-6	Response to bleomycin (chromatid breaks);
SARC	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg11987759	chr7:65425863	GUSB	-0.49	-6.38	-0.39	9.5e-10	Aortic root size;
SARC	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg19500275	chr17:80737654	TBCD	0.49	5.96	0.36	9.24e-9	Glycated hemoglobin levels;
SARC	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.1	21.57	0.82	1.82e-57	Chronic sinus infection;
SARC	cis	rs6696846	0.703	rs112653854	chr1:205079251	G/T	cg07972983	chr1:205091412	RBBP5	0.58	7.52	0.44	1.16e-12	Red blood cell count;
SARC	cis	rs6088580	0.524	rs6088569	chr20:33268199	G/A	cg24642439	chr20:33292090	TP53INP2	-0.55	-6.74	-0.4	1.26e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs7429990	0.965	rs11130154	chr3:48069242	C/T	cg11946769	chr3:48343235	NME6	-0.45	-5.24	-0.32	3.64e-7	Educational attainment (years of education);
SARC	cis	rs9611519	0.828	rs28814423	chr22:41452301	G/A	cg17376030	chr22:41985996	PMM1	0.48	5.92	0.36	1.12e-8	Neuroticism;
SARC	cis	rs2153535	0.580	rs5001324	chr6:8451604	A/T	cg21535247	chr6:8435926	SLC35B3	0.55	6.86	0.41	6.15e-11	Motion sickness;
SARC	cis	rs734999	0.549	rs6667564	chr1:2520302	T/C	cg20673091	chr1:2541236	MMEL1	0.33	5.03	0.31	9.63e-7	Ulcerative colitis;
SARC	cis	rs672059	0.934	rs641057	chr1:183156859	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.51	6.93	0.41	4.1e-11	Hypertriglyceridemia;
SARC	cis	rs362272	0.505	rs60208975	chr4:3364530	A/G	cg08741688	chr4:3415352	RGS12	-0.52	-6.6	-0.4	2.8e-10	Serum sulfate level;
SARC	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.41	-6.54	-0.39	3.95e-10	Schizophrenia;
SARC	cis	rs11874712	1.000	rs13381709	chr18:43670988	C/T	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.46	5.5	0.34	1.02e-7	Migraine - clinic-based;
SARC	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg11764359	chr7:65958608	NA	0.65	7.6	0.45	7.08e-13	Aortic root size;
SARC	cis	rs9325144	0.560	rs2387924	chr12:38662883	A/G	cg26384229	chr12:38710491	ALG10B	-0.66	-8.86	-0.5	2.06e-16	Morning vs. evening chronotype;
SARC	cis	rs7264396	0.676	rs6060730	chr20:34558503	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	5.3	0.33	2.71e-7	Total cholesterol levels;
SARC	cis	rs17600642	0.724	rs56287851	chr10:72441401	G/C	cg19779893	chr10:72451501	ADAMTS14	-0.34	-5.1	-0.32	7.14e-7	Bipolar disorder;
SARC	cis	rs9905704	0.647	rs11079367	chr17:57009024	A/G	cg12560992	chr17:57184187	TRIM37	0.4	4.8	0.3	2.88e-6	Testicular germ cell tumor;
SARC	cis	rs644799	0.965	rs549695	chr11:95617788	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	13.71	0.67	9.51e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg11764359	chr7:65958608	NA	-0.72	-8.45	-0.48	3.08e-15	Aortic root size;
SARC	cis	rs9914988	0.725	rs9905510	chr17:27092325	G/A	cg20469991	chr17:27169893	C17orf63	-0.49	-5.09	-0.32	7.41e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs6570726	1.000	rs951143	chr6:145932576	C/T	cg23711669	chr6:146136114	FBXO30	0.75	11.01	0.59	5.54e-23	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg11987759	chr7:65425863	GUSB	-0.49	-6.11	-0.37	4.06e-9	Aortic root size;
SARC	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg20891283	chr12:69753455	YEATS4	0.55	7.5	0.44	1.36e-12	Blood protein levels;
SARC	cis	rs1707322	1.000	rs1612419	chr1:46546945	T/C	cg06784218	chr1:46089804	CCDC17	-0.37	-6.33	-0.38	1.22e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs11792861	0.962	rs3750452	chr9:111801353	T/C	cg13535736	chr9:111863775	C9orf5	-0.41	-5.04	-0.31	9.24e-7	Menarche (age at onset);
SARC	cis	rs4803468	0.967	rs3786553	chr19:41902746	T/G	cg14132834	chr19:41945861	ATP5SL	-0.54	-7.11	-0.42	1.42e-11	Height;
SARC	cis	rs7666738	0.753	rs28463863	chr4:98844444	T/C	cg05340658	chr4:99064831	C4orf37	0.64	8.56	0.49	1.49e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs12142240	0.692	rs7529674	chr1:46818508	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-5.46	-0.34	1.22e-7	Menopause (age at onset);
SARC	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg18252515	chr7:66147081	NA	1.29	11.12	0.59	2.48e-23	Diabetic kidney disease;
SARC	cis	rs3820928	0.874	rs11685983	chr2:227799853	A/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-6.85	-0.41	6.68e-11	Pulmonary function;
SARC	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.82	12.64	0.64	3.01e-28	Personality dimensions;
SARC	cis	rs5762813	0.561	rs5752811	chr22:29225592	C/G	cg15103426	chr22:29168792	CCDC117	-0.61	-5.86	-0.36	1.54e-8	Hematocrit;Hemoglobin concentration;
SARC	trans	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg17712092	chr4:129076599	LARP1B	0.69	9.44	0.53	4.17e-18	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs74181299	0.571	rs6728523	chr2:65282708	G/C	cg20592124	chr2:65290738	CEP68	0.4	5.25	0.33	3.37e-7	Pulse pressure;
SARC	cis	rs34034915	1	rs34034915	chr6:27720703	T/TG	cg17221315	chr6:27791827	HIST1H4J	0.4	4.94	0.31	1.49e-6	Hepatitis A;
SARC	cis	rs2033732	0.826	rs2196618	chr8:85089437	A/G	cg05716166	chr8:85095498	RALYL	0.55	7.07	0.42	1.78e-11	Body mass index;
SARC	cis	rs1729951	0.546	rs361246	chr3:136695667	G/A	cg15507776	chr3:136538369	TMEM22	0.5	5.6	0.34	6.04e-8	Neuroticism;
SARC	cis	rs826838	0.967	rs10875979	chr12:39095149	G/A	cg26384229	chr12:38710491	ALG10B	0.83	12.94	0.65	3.31e-29	Heart rate;
SARC	cis	rs1707322	0.721	rs6429575	chr1:46134216	G/C	cg03146154	chr1:46216737	IPP	0.52	6.32	0.38	1.33e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6963495	0.719	rs73190174	chr7:105161216	T/G	cg13798780	chr7:105162888	PUS7	0.6	5.45	0.34	1.31e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs8031584	0.505	rs2959036	chr15:31219742	T/G	cg19680485	chr15:31195859	MTMR15	0.56	7.11	0.42	1.44e-11	Huntington's disease progression;
SARC	cis	rs4481887	0.741	rs28616194	chr1:248531904	T/A	cg00666640	chr1:248458726	OR2T12	0.36	6.2	0.38	2.58e-9	Common traits (Other);
SARC	cis	rs992157	0.835	rs34353396	chr2:219153982	T/C	cg00012203	chr2:219082015	ARPC2	-0.63	-9.08	-0.51	4.69e-17	Colorectal cancer;
SARC	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg00149659	chr3:10157352	C3orf10	-0.71	-6.66	-0.4	2e-10	Alzheimer's disease;
SARC	cis	rs7587476	0.599	rs61073893	chr2:215744814	C/T	cg04530015	chr2:215796436	ABCA12	-0.36	-5.5	-0.34	9.9e-8	Neuroblastoma;
SARC	cis	rs2197308	0.765	rs7295711	chr12:37903631	C/T	cg26384229	chr12:38710491	ALG10B	0.9	13.3	0.66	2.04e-30	Morning vs. evening chronotype;
SARC	cis	rs244731	0.959	rs6556307	chr5:176641434	C/T	cg16006841	chr5:176797999	RGS14	0.58	6.99	0.42	2.92e-11	Urate levels in lean individuals;
SARC	cis	rs1707322	0.686	rs3014235	chr1:46091512	A/G	cg06784218	chr1:46089804	CCDC17	-0.37	-6.56	-0.4	3.37e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9916302	0.706	rs1877030	chr17:37740161	T/C	cg07936489	chr17:37558343	FBXL20	-0.75	-8.31	-0.48	7.82e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs9457247	1.000	rs422780	chr6:167406209	A/G	cg23791538	chr6:167370224	RNASET2	-0.62	-8.6	-0.49	1.2e-15	Crohn's disease;
SARC	cis	rs2070997	0.607	rs11244143	chr9:133670111	C/T	cg11464064	chr9:133710261	ABL1	-0.58	-5.44	-0.34	1.35e-7	Response to amphetamines;
SARC	cis	rs9479482	0.648	rs912557	chr6:150385977	C/T	cg03788504	chr6:150331562	NA	-0.3	-4.83	-0.3	2.48e-6	Alopecia areata;
SARC	cis	rs12477438	1.000	rs995617	chr2:99857904	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.58	6.07	0.37	5.1e-9	Chronic sinus infection;
SARC	cis	rs12079745	0.590	rs35144581	chr1:169183588	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.78	-5.14	-0.32	5.81e-7	QT interval;
SARC	cis	rs35213789	0.920	rs13228464	chr7:69346385	G/A	cg10619644	chr7:69149951	AUTS2	0.46	5.39	0.33	1.74e-7	Childhood ear infection;
SARC	cis	rs314370	1.000	rs12705089	chr7:100465355	C/T	cg10426581	chr7:100472382	SRRT	0.6	6.31	0.38	1.39e-9	Resting heart rate;
SARC	trans	rs1941687	0.563	rs2032189	chr18:31332200	T/A	cg27147174	chr7:100797783	AP1S1	-0.52	-6.8	-0.41	8.48e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
SARC	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg15595755	chr5:1867978	NA	0.48	6.68	0.4	1.71e-10	Cardiovascular disease risk factors;
SARC	cis	rs7005606	0.935	rs7835688	chr8:32411499	C/G	cg14488905	chr8:32406789	NRG1	0.45	6.25	0.38	1.92e-9	Hirschsprung disease;
SARC	cis	rs7246865	0.510	rs11086051	chr19:17168590	A/G	cg16202187	chr19:17186497	HAUS8;MYO9B	0.41	4.92	0.31	1.62e-6	Reticulocyte fraction of red cells;
SARC	cis	rs7808935	0.914	rs11982766	chr7:27983781	C/T	cg05786569	chr7:27702416	HIBADH	0.54	5.57	0.34	7.08e-8	Prostate cancer;
SARC	cis	rs2439831	1.000	rs471229	chr15:43733994	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.04	10.37	0.56	5.65e-21	Lung cancer in ever smokers;
SARC	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg00149659	chr3:10157352	C3orf10	1.07	9.51	0.53	2.45e-18	Alzheimer's disease;
SARC	cis	rs898097	0.585	rs9892342	chr17:80893029	C/T	cg02711726	chr17:80685570	FN3KRP	-0.38	-5.25	-0.33	3.39e-7	Breast cancer;
SARC	cis	rs6141769	0.542	rs28542091	chr20:31301402	T/C	cg17884169	chr20:31446444	EFCAB8	-0.45	-4.83	-0.3	2.46e-6	Subjective well-being;
SARC	cis	rs1561198	0.523	rs2040349	chr2:85889525	A/C	cg17127132	chr2:85788382	GGCX	0.41	5.05	0.31	9.12e-7	Coronary artery disease;
SARC	cis	rs7959452	0.535	rs2305641	chr12:69646914	C/T	cg22834771	chr12:69754056	YEATS4	-0.43	-5.86	-0.36	1.58e-8	Blood protein levels;
SARC	trans	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg00938859	chr5:1591904	SDHAP3	0.79	7.61	0.45	6.64e-13	Breast cancer;
SARC	cis	rs4800452	0.956	rs4308051	chr18:20735461	T/G	cg13313047	chr18:20735648	CABLES1	-0.46	-4.96	-0.31	1.35e-6	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
SARC	trans	rs2727020	0.688	rs2734002	chr11:49234162	A/G	cg15704280	chr7:45808275	SEPT13	0.82	12.65	0.64	2.92e-28	Coronary artery disease;
SARC	cis	rs9916302	0.706	rs590051	chr17:37446571	T/C	cg20243544	chr17:37824526	PNMT	-0.56	-6.02	-0.37	6.66e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs710216	0.797	rs841855	chr1:43400176	G/A	cg03128534	chr1:43423976	SLC2A1	0.61	5.81	0.36	2.07e-8	Red cell distribution width;
SARC	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg23758822	chr17:41437982	NA	0.86	10.56	0.57	1.52e-21	Menopause (age at onset);
SARC	cis	rs7829975	0.540	rs2976909	chr8:8346690	C/T	cg08975724	chr8:8085496	FLJ10661	-0.46	-5.99	-0.37	7.79e-9	Mood instability;
SARC	cis	rs9916302	0.706	rs4795358	chr17:37573065	A/C	cg07936489	chr17:37558343	FBXL20	-0.77	-9.06	-0.51	5.48e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs11608355	0.545	rs4766603	chr12:109892106	T/C	cg05360138	chr12:110035743	NA	0.92	9.61	0.53	1.27e-18	Neuroticism;
SARC	cis	rs3796352	1.000	rs3097417	chr3:53088601	C/G	cg07884673	chr3:53033167	SFMBT1	-0.68	-4.86	-0.3	2.19e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs11785400	0.928	rs750529	chr8:143744877	G/C	cg10596483	chr8:143751796	JRK	0.64	8.71	0.5	5.74e-16	Schizophrenia;
SARC	cis	rs7264396	0.790	rs6060565	chr20:34285442	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.56	5.76	0.35	2.64e-8	Total cholesterol levels;
SARC	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg12042659	chr19:58951599	ZNF132	0.41	5.44	0.34	1.35e-7	Uric acid clearance;
SARC	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	5.42	0.33	1.46e-7	Bipolar disorder;
SARC	cis	rs9290065	0.519	rs6441346	chr3:160709229	C/T	cg03342759	chr3:160939853	NMD3	-0.49	-6.02	-0.37	6.72e-9	Kawasaki disease;
SARC	cis	rs2832191	0.791	rs28633762	chr21:30500070	C/T	cg08807101	chr21:30365312	RNF160	-0.79	-10.93	-0.58	1.04e-22	Dental caries;
SARC	cis	rs6977660	0.714	rs10231980	chr7:19789383	C/G	cg05791153	chr7:19748676	TWISTNB	0.71	6.37	0.39	9.73e-10	Thyroid stimulating hormone;
SARC	cis	rs10979	1.000	rs9376760	chr6:143886969	C/T	cg25407410	chr6:143891975	LOC285740	-0.6	-7.95	-0.46	8.2e-14	Hypospadias;
SARC	trans	rs3780486	0.846	rs10971419	chr9:33124161	T/C	cg04842962	chr6:43655489	MRPS18A	1.08	19.82	0.79	6.49e-52	IgG glycosylation;
SARC	cis	rs7359276	1	rs7359276	chr15:78892661	C/T	cg24631222	chr15:78858424	CHRNA5	-0.69	-9.43	-0.53	4.19e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs7223966	0.729	rs9902761	chr17:62010627	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	6.3	0.38	1.48e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9733	0.503	rs7556451	chr1:150913142	A/G	cg13175981	chr1:150552382	MCL1	-0.52	-6.43	-0.39	7.28e-10	Tonsillectomy;
SARC	cis	rs910316	0.967	rs4384542	chr14:75658013	A/C	cg23033748	chr14:75592666	NEK9	-0.35	-4.89	-0.3	1.89e-6	Height;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg03269368	chr19:19431604	KIAA0892;SF4	-0.51	-6.38	-0.39	9.56e-10	Schizophrenia;
SARC	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg22168489	chr12:122356033	WDR66	0.65	10.31	0.56	8.64e-21	Mean corpuscular volume;
SARC	cis	rs7084402	0.935	rs10740731	chr10:60348886	G/A	cg07615347	chr10:60278583	BICC1	0.59	8.54	0.49	1.7e-15	Refractive error;
SARC	cis	rs1568889	0.838	rs10835304	chr11:28296529	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.87	14.59	0.69	1.06e-34	Bipolar disorder;
SARC	trans	rs2637266	1.000	rs2637266	chr10:78331318	C/T	cg03689601	chr12:44123569	PUS7L	0.48	7.03	0.42	2.29e-11	Pulmonary function;
SARC	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	8.27	0.48	1.02e-14	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs7264396	0.563	rs11906854	chr20:34383634	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	5.22	0.32	4.01e-7	Total cholesterol levels;
SARC	cis	rs6558174	0.965	rs2009212	chr8:22491496	G/A	cg03733263	chr8:22462867	KIAA1967	0.5	5.84	0.36	1.79e-8	Breast cancer;
SARC	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg08280861	chr8:58055591	NA	0.61	5.96	0.36	9.44e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg14893720	chr7:33149316	RP9	0.5	6.45	0.39	6.45e-10	Lung adenocarcinoma;
SARC	cis	rs10484885	0.793	rs1465954	chr6:90475013	G/A	cg13799429	chr6:90582589	CASP8AP2	0.58	5.14	0.32	5.7e-7	QRS interval (sulfonylurea treatment interaction);
SARC	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg19671926	chr4:122722719	EXOSC9	-0.6	-6.7	-0.4	1.51e-10	Type 2 diabetes;
SARC	cis	rs9296092	0.538	rs9469486	chr6:33516849	G/A	cg13560919	chr6:33536144	NA	-0.51	-6.2	-0.38	2.48e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs735396	0.770	rs1169315	chr12:121443753	T/G	cg15155738	chr12:121454335	C12orf43	0.52	6.57	0.4	3.31e-10	N-glycan levels;
SARC	cis	rs3733585	0.775	rs13124007	chr4:10043931	G/C	cg00071950	chr4:10020882	SLC2A9	0.33	4.98	0.31	1.26e-6	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs1949733	0.816	rs2631746	chr4:8490934	C/T	cg13073564	chr4:8508604	NA	0.35	5.48	0.34	1.1e-7	Response to antineoplastic agents;
SARC	trans	rs7395662	0.500	rs1304199	chr11:48699032	A/G	cg00717180	chr2:96193071	NA	-0.38	-6.36	-0.38	1.04e-9	HDL cholesterol;
SARC	cis	rs2668423	0.502	rs7254913	chr19:1388320	A/G	cg02639931	chr19:1387894	NDUFS7	0.5	9.62	0.53	1.2e-18	Nonalcoholic fatty liver disease;
SARC	cis	rs829880	1.000	rs829880	chr12:98845331	G/T	cg25150519	chr12:98850993	NA	0.7	10.18	0.55	2.28e-20	Colonoscopy-negative controls vs population controls;
SARC	cis	rs3858526	0.959	rs11039699	chr11:5951091	G/A	cg05234568	chr11:5960015	NA	-0.42	-4.99	-0.31	1.2e-6	DNA methylation (variation);
SARC	cis	rs7043114	0.525	rs7864630	chr9:95267560	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.81	-0.36	2.01e-8	Height;
SARC	trans	rs561341	0.629	rs7216107	chr17:30224419	G/A	cg20587970	chr11:113659929	NA	-0.56	-6.59	-0.4	2.89e-10	Hip circumference adjusted for BMI;
SARC	cis	rs7681440	0.583	rs2583989	chr4:90769422	A/G	cg06632027	chr4:90757378	SNCA	-0.45	-5.67	-0.35	4.27e-8	Dementia with Lewy bodies;
SARC	cis	rs13082711	0.554	rs7635958	chr3:27385616	A/C	cg02860705	chr3:27208620	NA	0.65	8.05	0.47	4.16e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg24028161	chr20:5100573	PCNA	-0.51	-6.46	-0.39	5.95e-10	Schizophrenia;
SARC	cis	rs7624766	0.555	rs9814394	chr3:160490977	T/C	cg22637730	chr3:160473554	PPM1L	0.38	4.9	0.31	1.82e-6	Response to methotrexate in rheumatoid arthritis;
SARC	cis	rs10463554	0.963	rs34826	chr5:102441748	T/C	cg23492399	chr5:102201601	PAM	-0.52	-5.72	-0.35	3.2e-8	Parkinson's disease;
SARC	cis	rs56330463	0.967	rs2082395	chr5:148200600	A/G	cg21580376	chr5:148206412	ADRB2	0.37	5.22	0.32	4.04e-7	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Monocyte percentage of white cells;Eosinophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;
SARC	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg09699651	chr6:150184138	LRP11	0.39	4.87	0.3	2.04e-6	Lung cancer;
SARC	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg04518342	chr5:131593106	PDLIM4	0.38	5.27	0.33	3.13e-7	Blood metabolite levels;
SARC	cis	rs2933343	0.700	rs876754	chr3:128627753	T/C	cg25356066	chr3:128598488	ACAD9	0.69	9.27	0.52	1.33e-17	IgG glycosylation;
SARC	cis	rs1468333	0.861	rs10061967	chr5:137467433	T/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.79	10.28	0.56	1.12e-20	Resting heart rate;
SARC	cis	rs883565	0.502	rs7427462	chr3:38963275	G/A	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.43	-5.0	-0.31	1.13e-6	Handedness;
SARC	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.76	-10.09	-0.55	4.4e-20	Chronic sinus infection;
SARC	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	8.82	0.5	2.77e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2289583	0.517	rs2004278	chr15:75264363	C/T	cg14664628	chr15:75095509	CSK	0.49	5.31	0.33	2.62e-7	Systemic lupus erythematosus;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg08889949	chr3:49044473	P4HTM;WDR6	-0.48	-6.34	-0.38	1.16e-9	Electrocardiographic conduction measures;
SARC	cis	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg26116260	chr4:7069785	GRPEL1	0.84	10.28	0.56	1.13e-20	Monocyte percentage of white cells;
SARC	cis	rs554111	0.891	rs659046	chr1:21047725	C/T	cg08890418	chr1:21044141	KIF17	-0.53	-7.47	-0.44	1.57e-12	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs957448	1.000	rs28817653	chr8:95570050	G/A	cg26464482	chr8:95565502	KIAA1429	0.43	4.83	0.3	2.45e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs1800469	1.000	rs2241712	chr19:41869756	C/T	cg08477640	chr19:41863820	B9D2	0.69	9.09	0.51	4.32e-17	Colorectal cancer;
SARC	trans	rs11098499	0.863	rs11947234	chr4:120474859	A/G	cg25214090	chr10:38739885	LOC399744	0.57	7.25	0.43	6.27e-12	Corneal astigmatism;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg13054686	chr1:243418774	SDCCAG8;CEP170	-0.5	-6.25	-0.38	1.9e-9	Schizophrenia;
SARC	cis	rs826838	0.900	rs9739128	chr12:38948960	A/T	cg13010199	chr12:38710504	ALG10B	0.77	10.66	0.57	7.36e-22	Heart rate;
SARC	cis	rs9920	1.000	rs75022895	chr7:116192330	C/T	cg24770985	chr7:116166421	CAV1	0.88	5.2	0.32	4.3e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Immature fraction of reticulocytes;QT interval;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg10083236	chr2:33824519	FAM98A	-0.8	-6.61	-0.4	2.64e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs4660306	0.961	rs2152077	chr1:45986670	G/T	cg24296786	chr1:45957014	TESK2	0.55	6.51	0.39	4.52e-10	Homocysteine levels;
SARC	cis	rs9393777	0.557	rs36034627	chr6:27237363	G/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.37	-4.76	-0.3	3.39e-6	Intelligence (multi-trait analysis);
SARC	cis	rs11638352	0.661	rs2555384	chr15:44420900	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.76	-5.91	-0.36	1.23e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	cis	rs9640161	0.636	rs56190213	chr7:150025720	T/C	cg21361702	chr7:150065534	REPIN1	0.55	5.51	0.34	9.58e-8	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs6500395	1.000	rs1039340	chr16:48574637	A/C	cg04672837	chr16:48644449	N4BP1	0.46	6.0	0.37	7.56e-9	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs6665290	0.901	rs12410103	chr1:227197408	T/C	cg14016676	chr1:227182615	CDC42BPA	0.38	5.55	0.34	7.71e-8	Myeloid white cell count;
SARC	cis	rs6060717	0.698	rs8123175	chr20:34609872	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.51	-5.15	-0.32	5.48e-7	Hip circumference adjusted for BMI;
SARC	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg05863683	chr7:1912471	MAD1L1	0.34	5.01	0.31	1.05e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs2153535	0.580	rs915351	chr6:8442793	C/T	cg21535247	chr6:8435926	SLC35B3	0.56	7.01	0.42	2.6e-11	Motion sickness;
SARC	cis	rs7223966	1.000	rs6504168	chr17:61697469	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	6.91	0.41	4.5e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg18357526	chr6:26021779	HIST1H4A	0.5	5.74	0.35	2.92e-8	Blood metabolite levels;
SARC	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg01276201	chr10:134613136	NA	0.32	5.77	0.35	2.57e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg10792982	chr14:105748885	BRF1	0.5	7.38	0.44	2.82e-12	Mean platelet volume;Platelet distribution width;
SARC	cis	rs1707322	0.929	rs785500	chr1:46593044	C/T	cg06784218	chr1:46089804	CCDC17	-0.36	-6.22	-0.38	2.26e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs721399	0.539	rs12676857	chr8:18266572	T/C	cg18736775	chr8:18248649	NAT2	-0.57	-5.66	-0.35	4.39e-8	Blood metabolite levels;
SARC	cis	rs9462027	0.628	rs9469899	chr6:34793124	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-6.03	-0.37	6.37e-9	Systemic lupus erythematosus;
SARC	cis	rs9513627	0.920	rs7335315	chr13:100121308	G/A	cg25919922	chr13:100150906	NA	-0.69	-5.21	-0.32	4.14e-7	Obesity-related traits;
SARC	trans	rs3942852	0.568	rs4412719	chr11:48101660	T/A	cg15704280	chr7:45808275	SEPT13	-0.66	-8.7	-0.5	6.08e-16	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs356220	0.609	rs356177	chr4:90630675	C/A	cg06632027	chr4:90757378	SNCA	0.42	5.26	0.33	3.25e-7	Parkinson's disease;
SARC	cis	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg24110177	chr3:50126178	RBM5	0.54	7.4	0.44	2.42e-12	Intelligence (multi-trait analysis);
SARC	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg11890956	chr21:40555474	PSMG1	-0.69	-9.11	-0.51	3.92e-17	Menarche (age at onset);
SARC	cis	rs7617773	0.780	rs7632297	chr3:48348163	A/C	cg11946769	chr3:48343235	NME6	0.76	9.7	0.54	6.55e-19	Coronary artery disease;
SARC	trans	rs9395865	0.520	rs6903708	chr6:53332940	A/G	cg13501085	chr19:17326416	USE1	-0.52	-6.57	-0.4	3.34e-10	Electroencephalographic traits in alcoholism;
SARC	cis	rs7005380	0.581	rs9987135	chr8:120936895	A/T	cg21744203	chr8:120868354	DSCC1	0.45	5.29	0.33	2.75e-7	Interstitial lung disease;
SARC	cis	rs6060717	0.536	rs6060683	chr20:34507921	C/T	cg01084648	chr20:34329383	RBM39	0.62	4.73	0.3	3.89e-6	Hip circumference adjusted for BMI;
SARC	trans	rs36093844	0.752	rs17817308	chr11:85593529	G/A	cg15359163	chr5:122429178	PRDM6	-0.53	-6.5	-0.39	4.8e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs3845702	1.000	rs262279	chr2:180869145	G/A	cg01881094	chr2:180872142	CWC22	0.6	5.42	0.33	1.51e-7	Schizophrenia;
SARC	cis	rs9911578	0.967	rs11079354	chr17:56594460	G/A	cg05425664	chr17:57184151	TRIM37	0.65	8.02	0.46	5.23e-14	Intelligence (multi-trait analysis);
SARC	cis	rs7178572	0.568	rs11072643	chr15:77415508	T/A	cg22256960	chr15:77711686	NA	0.48	5.22	0.32	4.05e-7	Type 2 diabetes;
SARC	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg25072359	chr17:41440525	NA	0.51	6.4	0.39	8.61e-10	Menopause (age at onset);
SARC	cis	rs3820928	1.000	rs11692572	chr2:227774503	C/G	cg05526886	chr2:227700861	RHBDD1	-0.5	-6.3	-0.38	1.48e-9	Pulmonary function;
SARC	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg18252515	chr7:66147081	NA	-0.44	-4.75	-0.3	3.5e-6	Aortic root size;
SARC	cis	rs6831352	0.918	rs17217949	chr4:100054312	A/G	cg12011299	chr4:100065546	ADH4	-0.34	-5.74	-0.35	2.95e-8	Alcohol dependence;
SARC	cis	rs17384381	0.953	rs2076699	chr1:85817295	G/A	cg16011679	chr1:85725395	C1orf52	0.65	6.01	0.37	7.09e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6121246	0.529	rs6060174	chr20:30183538	G/A	cg21427119	chr20:30132790	HM13	-0.48	-5.29	-0.33	2.84e-7	Mean corpuscular hemoglobin;
SARC	cis	rs7937682	1.000	rs10789843	chr11:111576158	C/T	cg09085632	chr11:111637200	PPP2R1B	0.98	16.4	0.73	1.02e-40	Primary sclerosing cholangitis;
SARC	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg22496380	chr5:211416	CCDC127	-0.88	-9.35	-0.52	7.72e-18	Breast cancer;
SARC	cis	rs4595586	0.679	rs7312898	chr12:39346833	T/C	cg26384229	chr12:38710491	ALG10B	0.42	5.22	0.32	3.98e-7	Morning vs. evening chronotype;
SARC	cis	rs6062509	0.895	rs6011040	chr20:62337406	C/T	cg27236539	chr20:62289627	RTEL1	-0.48	-5.18	-0.32	4.9e-7	Prostate cancer;
SARC	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg24399712	chr22:39784796	NA	-0.43	-5.69	-0.35	3.8e-8	Intelligence (multi-trait analysis);
SARC	cis	rs1865760	0.566	rs1800702	chr6:26086463	C/G	cg17691542	chr6:26056736	HIST1H1C	0.52	6.41	0.39	8.05e-10	Height;
SARC	cis	rs1318878	0.519	rs11056432	chr12:15497905	C/T	cg08258403	chr12:15378311	NA	0.49	6.94	0.41	3.97e-11	Intelligence (multi-trait analysis);
SARC	cis	rs79387448	0.626	rs80277428	chr2:103080056	G/A	cg09003973	chr2:102972529	NA	0.83	6.56	0.39	3.53e-10	Gut microbiota (bacterial taxa);
SARC	cis	rs62432291	0.614	rs420339	chr6:159657195	G/T	cg14500486	chr6:159655392	FNDC1	-0.64	-6.37	-0.39	9.75e-10	Joint mobility (Beighton score);
SARC	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg14517863	chr17:44321492	NA	-0.32	-4.76	-0.3	3.46e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs10911232	0.507	rs3934579	chr1:183027432	G/A	cg13390022	chr1:182993471	LAMC1	0.35	5.29	0.33	2.8e-7	Hypertriglyceridemia;
SARC	cis	rs7560272	0.723	rs62153184	chr2:73773869	G/C	cg20560298	chr2:73613845	ALMS1	-0.51	-6.73	-0.4	1.27e-10	Schizophrenia;
SARC	trans	rs11634851	0.901	rs2627313	chr15:81006712	C/T	cg04669574	chr12:50297945	FAIM2	0.49	6.38	0.39	9.51e-10	Systolic blood pressure;
SARC	trans	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg08975724	chr8:8085496	FLJ10661	-0.57	-7.42	-0.44	2.17e-12	Triglycerides;
SARC	cis	rs3126085	0.877	rs12116736	chr1:152167062	C/T	cg26876637	chr1:152193138	HRNR	0.48	5.51	0.34	9.32e-8	Atopic dermatitis;
SARC	cis	rs2721811	0.738	rs2521758	chr7:24762292	G/T	cg17569154	chr7:24781545	DFNA5	0.44	6.25	0.38	1.88e-9	Depressive symptoms (multi-trait analysis);
SARC	cis	rs2832077	0.943	rs2832091	chr21:30162855	C/T	cg24692254	chr21:30365293	RNF160	-0.53	-4.81	-0.3	2.69e-6	Cognitive test performance;
SARC	cis	rs546131	0.642	rs473848	chr11:34851977	A/C	cg06937548	chr11:34938143	PDHX;APIP	0.43	5.06	0.31	8.61e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs651907	0.557	rs17411983	chr3:101399126	A/G	cg12386194	chr3:101231763	SENP7	-0.51	-6.18	-0.38	2.92e-9	Colorectal cancer;
SARC	cis	rs826838	1.000	rs826892	chr12:39100790	T/C	cg13010199	chr12:38710504	ALG10B	-0.65	-9.26	-0.52	1.44e-17	Heart rate;
SARC	cis	rs6866344	0.697	rs62392831	chr5:178134365	A/G	cg10224037	chr5:178157518	ZNF354A	1.0	12.5	0.63	8.67e-28	Neutrophil percentage of white cells;
SARC	cis	rs11583043	1.000	rs6700743	chr1:101447384	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	6.01	0.37	7.19e-9	Ulcerative colitis;Inflammatory bowel disease;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg21193977	chr9:139349785	SEC16A	0.46	6.67	0.4	1.79e-10	Schizophrenia;
SARC	cis	rs7584330	0.737	rs10445707	chr2:238368751	A/G	cg11271282	chr2:238384023	NA	0.41	4.8	0.3	2.78e-6	Prostate cancer;
SARC	cis	rs4423214	0.840	rs1790343	chr11:71177207	T/C	cg05163923	chr11:71159392	DHCR7	-0.61	-7.39	-0.44	2.64e-12	Vitamin D levels;
SARC	cis	rs1355223	0.506	rs11032899	chr11:34870234	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.49	-6.22	-0.38	2.28e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs7264396	0.790	rs3787166	chr20:34229072	A/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	5.51	0.34	9.32e-8	Total cholesterol levels;
SARC	cis	rs7927771	0.931	rs4752801	chr11:47907641	A/G	cg20307385	chr11:47447363	PSMC3	-0.47	-5.7	-0.35	3.63e-8	Subjective well-being;
SARC	cis	rs6688613	0.685	rs742048	chr1:166910145	A/C	cg07049167	chr1:166818506	POGK	-0.47	-4.98	-0.31	1.27e-6	Refractive astigmatism;
SARC	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg24324837	chr19:49891574	CCDC155	0.4	4.88	0.3	1.96e-6	Multiple sclerosis;
SARC	cis	rs9948	0.655	rs3731940	chr2:97377883	A/G	cg01990225	chr2:97406019	LMAN2L	0.86	6.8	0.41	8.58e-11	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs1865760	0.663	rs9467656	chr6:25993559	G/A	cg16482183	chr6:26056742	HIST1H1C	0.5	6.7	0.4	1.59e-10	Height;
SARC	cis	rs2404602	0.716	rs17363713	chr15:76746128	G/C	cg22467129	chr15:76604101	ETFA	-0.37	-4.92	-0.31	1.63e-6	Blood metabolite levels;
SARC	cis	rs7582720	0.667	rs114863726	chr2:204158375	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	7.68	0.45	4.37e-13	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs3008870	0.755	rs4655661	chr1:67408828	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.59	7.54	0.44	1.07e-12	Lymphocyte percentage of white cells;
SARC	cis	rs7666738	0.830	rs10001701	chr4:98918871	G/C	cg05340658	chr4:99064831	C4orf37	0.65	8.61	0.49	1.14e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs17001868	0.568	rs17001846	chr22:40744053	A/G	cg07138101	chr22:40742427	ADSL	0.51	5.43	0.34	1.43e-7	Mammographic density (dense area);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg20776722	chr5:130970743	RAPGEF6	-0.81	-6.82	-0.41	7.9e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6840360	0.571	rs17275536	chr4:152498625	C/T	cg22705602	chr4:152727874	NA	-0.41	-6.39	-0.39	8.86e-10	Intelligence (multi-trait analysis);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg25463831	chr14:58766031	FLJ31306;ARID4A	0.61	7.92	0.46	9.79e-14	Breast cancer;
SARC	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg11062466	chr8:58055876	NA	0.66	5.87	0.36	1.52e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs992157	0.767	rs2382822	chr2:219173327	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.65	-9.32	-0.52	9.36e-18	Colorectal cancer;
SARC	cis	rs2463822	0.669	rs72919496	chr11:62052730	T/C	cg06239285	chr11:62104954	ASRGL1	-0.89	-8.27	-0.48	1.03e-14	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg03806693	chr22:41940476	POLR3H	-0.94	-13.2	-0.65	4.31e-30	Vitiligo;
SARC	cis	rs4423214	1.000	rs4944062	chr11:71187294	G/T	cg05163923	chr11:71159392	DHCR7	0.66	9.14	0.51	3.21e-17	Vitamin D levels;
SARC	cis	rs9393692	0.875	rs6939589	chr6:26289203	C/T	cg05868516	chr6:26286170	HIST1H4H	-0.53	-6.99	-0.42	2.89e-11	Educational attainment;
SARC	cis	rs2282802	0.685	rs11748023	chr5:139558584	C/T	cg26211634	chr5:139558579	C5orf32	-0.38	-4.88	-0.3	1.92e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2204008	0.577	rs11520050	chr12:38051839	G/A	cg13010199	chr12:38710504	ALG10B	0.78	10.73	0.57	4.45e-22	Bladder cancer;
SARC	cis	rs2997447	0.601	rs61776577	chr1:26431931	T/C	cg19633962	chr1:26362018	EXTL1	-0.57	-5.05	-0.31	8.95e-7	QRS complex (12-leadsum);
SARC	cis	rs6060960	0.537	rs6089103	chr20:30464919	G/T	cg13852791	chr20:30311386	BCL2L1	0.61	5.74	0.35	2.99e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
SARC	cis	rs7089973	0.584	rs758585	chr10:116582560	C/A	cg03647239	chr10:116582469	FAM160B1	0.54	7.2	0.43	8.18e-12	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg00152838	chr16:24741724	TNRC6A	-0.6	-6.42	-0.39	7.69e-10	Intelligence (multi-trait analysis);
SARC	cis	rs478304	0.654	rs6591185	chr11:65455742	A/G	cg27068330	chr11:65405492	SIPA1	-0.41	-4.77	-0.3	3.25e-6	Acne (severe);
SARC	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg27170947	chr2:26402098	FAM59B	0.37	4.8	0.3	2.79e-6	Gut microbiome composition (summer);
SARC	cis	rs6867032	0.570	rs13166888	chr5:1982966	G/T	cg26168224	chr5:2018326	NA	-0.58	-6.56	-0.4	3.35e-10	Gut microbiome composition (winter);
SARC	cis	rs734999	0.524	rs4648448	chr1:2695687	C/T	cg20673091	chr1:2541236	MMEL1	0.32	4.78	0.3	3.04e-6	Ulcerative colitis;
SARC	cis	rs3733585	0.631	rs7699671	chr4:10125874	C/T	cg00071950	chr4:10020882	SLC2A9	-0.39	-5.91	-0.36	1.22e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7667	1.000	rs10917434	chr1:19707302	C/T	cg15311933	chr1:19638897	PQLC2;AKR7A2	-0.42	-4.85	-0.3	2.21e-6	Crohn's disease and psoriasis;
SARC	cis	rs9517320	0.534	rs3825430	chr13:99129653	C/T	cg07423050	chr13:99094983	FARP1	-0.44	-5.49	-0.34	1.03e-7	Longevity;
SARC	cis	rs12200560	0.505	rs2015196	chr6:97075331	G/C	cg06623918	chr6:96969491	KIAA0776	0.45	5.12	0.32	6.36e-7	Coronary heart disease;
SARC	cis	rs1008375	0.931	rs7672369	chr4:17604825	A/G	cg27347728	chr4:17578864	LAP3	0.46	5.6	0.34	6.12e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9911578	1.000	rs4482353	chr17:56896834	A/G	cg12560992	chr17:57184187	TRIM37	0.87	12.15	0.62	1.19e-26	Intelligence (multi-trait analysis);
SARC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg03647317	chr4:187891568	NA	-0.35	-4.95	-0.31	1.43e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs752092	0.925	rs8032007	chr15:101790817	C/T	cg19997662	chr15:101784653	CHSY1	0.45	5.74	0.35	2.94e-8	Corneal structure;
SARC	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg22920501	chr2:26401640	FAM59B	-0.58	-7.66	-0.45	4.81e-13	Gut microbiome composition (summer);
SARC	trans	rs3734266	0.536	rs35143960	chr6:34761675	A/G	cg08157914	chr7:2646478	IQCE	0.52	6.24	0.38	2.1e-9	Systemic lupus erythematosus;
SARC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg24503407	chr1:205819492	PM20D1	0.81	12.89	0.65	4.82e-29	Menarche (age at onset);
SARC	cis	rs12479064	0.671	rs62155807	chr2:100076579	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.54	-6.14	-0.37	3.52e-9	Chronic sinus infection;
SARC	cis	rs9303401	0.659	rs11079358	chr17:56920949	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	11.58	0.6	8.42e-25	Cognitive test performance;
SARC	cis	rs9420	0.961	rs576859	chr11:57480623	A/C	cg19752551	chr11:57585705	CTNND1	0.39	5.44	0.34	1.34e-7	Schizophrenia;
SARC	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg07701084	chr6:150067640	NUP43	0.44	5.55	0.34	7.66e-8	Lung cancer;
SARC	cis	rs2645694	0.626	rs2645705	chr4:77830434	G/A	cg03477792	chr4:77819574	ANKRD56	0.41	6.1	0.37	4.34e-9	Emphysema distribution in smoking;
SARC	cis	rs2273669	0.915	rs12191613	chr6:109289203	G/A	cg01304950	chr6:109416612	SESN1;C6orf182	0.55	4.84	0.3	2.4e-6	Prostate cancer;
SARC	cis	rs7954584	0.505	rs11043278	chr12:122412145	C/T	cg22618164	chr12:122356400	WDR66	0.42	6.53	0.39	4.17e-10	Mean corpuscular volume;
SARC	cis	rs425277	1.000	rs425277	chr1:2069172	C/T	cg24578937	chr1:2090814	PRKCZ	0.32	6.06	0.37	5.45e-9	Height;
SARC	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg26874164	chr19:58962979	ZNF324B	0.46	6.05	0.37	5.8e-9	Uric acid clearance;
SARC	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg03709012	chr19:19516395	GATAD2A	0.95	14.76	0.7	2.9e-35	Tonsillectomy;
SARC	cis	rs7777754	0.512	rs7785224	chr7:50562361	T/C	cg18232548	chr7:50535776	DDC	-0.49	-5.66	-0.35	4.5e-8	Response to zileuton treatment in asthma (FEV1 change interaction);
SARC	cis	rs1008375	1.000	rs13119927	chr4:17691640	G/A	cg27347728	chr4:17578864	LAP3	-0.47	-5.73	-0.35	3.05e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg13175981	chr1:150552382	MCL1	-0.54	-6.9	-0.41	4.97e-11	Tonsillectomy;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg04657419	chr5:60454782	C5orf43	0.49	6.96	0.41	3.33e-11	Thyroid stimulating hormone;
SARC	cis	rs911555	0.504	rs4444269	chr14:104072724	G/C	cg17925084	chr14:104152323	KLC1	0.39	5.51	0.34	9.32e-8	Intelligence (multi-trait analysis);
SARC	cis	rs5753618	0.504	rs9606848	chr22:31901867	G/A	cg02404636	chr22:31891804	SFI1	0.53	5.91	0.36	1.2e-8	Colorectal cancer;
SARC	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg24675658	chr1:53192096	ZYG11B	0.67	10.01	0.55	7.31e-20	Monocyte count;
SARC	cis	rs2594989	0.943	rs2454500	chr3:11500103	C/T	cg00170343	chr3:11313890	ATG7	0.55	5.35	0.33	2.11e-7	Circulating chemerin levels;
SARC	cis	rs1008375	1.000	rs2315561	chr4:17679695	C/T	cg16339924	chr4:17578868	LAP3	0.64	8.54	0.49	1.7e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs826838	1.000	rs7299124	chr12:39002661	T/C	cg13010199	chr12:38710504	ALG10B	0.77	10.81	0.58	2.52e-22	Heart rate;
SARC	cis	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.5	-7.54	-0.44	1.04e-12	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs35995292	0.534	rs2392607	chr7:38930380	G/A	cg19327137	chr7:38886074	VPS41	0.51	7.73	0.45	3.27e-13	Subjective well-being (multi-trait analysis);
SARC	cis	rs9788682	0.948	rs59683676	chr15:78833453	T/C	cg24631222	chr15:78858424	CHRNA5	0.75	9.65	0.53	9.58e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg13628971	chr7:2884303	GNA12	0.58	6.67	0.4	1.84e-10	Height;
SARC	cis	rs9300255	0.620	rs1716173	chr12:123660721	A/T	cg00376283	chr12:123451042	ABCB9	0.58	6.78	0.41	9.87e-11	Neutrophil percentage of white cells;
SARC	cis	rs7523050	0.643	rs34801874	chr1:109404382	C/T	cg08274380	chr1:109419600	GPSM2	0.99	7.56	0.44	9.38e-13	Fat distribution (HIV);
SARC	cis	rs796364	0.806	rs79333757	chr2:200915716	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.67	-5.68	-0.35	4.06e-8	Schizophrenia;
SARC	cis	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg05084668	chr3:125655381	ALG1L	-0.47	-4.83	-0.3	2.49e-6	Blood pressure (smoking interaction);
SARC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg02725872	chr8:58115012	NA	-0.37	-6.47	-0.39	5.76e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7523050	0.643	rs36052234	chr1:109402943	C/T	cg08274380	chr1:109419600	GPSM2	1.02	7.68	0.45	4.37e-13	Fat distribution (HIV);
SARC	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg26335602	chr6:28129616	ZNF389	0.46	5.29	0.33	2.8e-7	Cardiac Troponin-T levels;
SARC	cis	rs10782582	0.593	rs77733234	chr1:76101655	A/T	cg10523679	chr1:76189770	ACADM	-0.4	-5.04	-0.31	9.43e-7	Daytime sleep phenotypes;
SARC	cis	rs2425143	1.000	rs13038622	chr20:34319343	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-6.02	-0.37	6.75e-9	Blood protein levels;
SARC	cis	rs17376456	0.877	rs13170509	chr5:93378564	T/C	cg25358565	chr5:93447407	FAM172A	1.3	14.36	0.69	6.16e-34	Diabetic retinopathy;
SARC	cis	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg00071950	chr4:10020882	SLC2A9	0.39	6.35	0.38	1.14e-9	Bone mineral density;
SARC	cis	rs1881797	1.000	rs67977965	chr1:247687835	G/A	cg11166453	chr1:247681781	NA	0.46	5.18	0.32	4.74e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg03264133	chr6:25882463	NA	-0.53	-7.07	-0.42	1.83e-11	Intelligence (multi-trait analysis);
SARC	cis	rs73198271	0.710	rs7837843	chr8:8656485	A/G	cg06636001	chr8:8085503	FLJ10661	-0.41	-4.83	-0.3	2.52e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs7666738	0.830	rs9995386	chr4:98907826	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.53	0.49	1.88e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg05623727	chr3:50126028	RBM5	0.36	5.35	0.33	2.05e-7	Body mass index;
SARC	cis	rs57506017	0.585	rs10950394	chr7:12263587	C/T	cg23422036	chr7:12250390	TMEM106B	0.48	6.36	0.38	1.08e-9	Neuroticism;
SARC	cis	rs67460515	0.529	rs6795586	chr3:160897701	A/C	cg04691961	chr3:161091175	C3orf57	-0.47	-5.67	-0.35	4.1e-8	Parkinson's disease;
SARC	cis	rs13392177	0.672	rs4674270	chr2:219053141	G/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.57	-7.28	-0.43	5.13e-12	Pyoderma gangrenosum in inflammatory bowel disease;
SARC	cis	rs9814567	0.806	rs4245904	chr3:134321808	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.51	-6.63	-0.4	2.36e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg03735888	chr19:58951602	ZNF132	0.41	5.37	0.33	1.88e-7	Uric acid clearance;
SARC	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.93	14.82	0.7	1.83e-35	Chronic sinus infection;
SARC	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg06618935	chr21:46677482	NA	-0.36	-4.83	-0.3	2.42e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs503341	0.756	rs480874	chr11:63591965	A/T	cg04362095	chr11:63592001	C11orf84	-0.56	-7.62	-0.45	6.53e-13	Pulse pressure;
SARC	cis	rs854765	0.547	rs2955370	chr17:17966945	C/T	cg05444541	chr17:17804740	TOM1L2	0.3	4.97	0.31	1.3e-6	Total body bone mineral density;
SARC	cis	rs17666538	0.591	rs7818950	chr8:643831	C/T	cg02524346	chr8:600233	NA	0.71	6.02	0.37	6.89e-9	IgG glycosylation;
SARC	cis	rs7561528	0.501	rs1583647	chr2:127885359	A/T	cg12632573	chr2:127783243	NA	0.7	6.3	0.38	1.49e-9	Alzheimer's disease;Alzheimer's disease (late onset);
SARC	trans	rs61931739	0.500	rs12367292	chr12:33998075	T/C	cg13010199	chr12:38710504	ALG10B	0.76	10.28	0.56	1.07e-20	Morning vs. evening chronotype;
SARC	cis	rs4660306	1.000	rs10157597	chr1:45990278	C/A	cg24296786	chr1:45957014	TESK2	0.58	6.79	0.41	9.44e-11	Homocysteine levels;
SARC	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg02931644	chr1:25747376	RHCE	0.46	7.87	0.46	1.35e-13	Erythrocyte sedimentation rate;
SARC	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg06420487	chr17:61919686	SMARCD2	0.43	4.77	0.3	3.22e-6	Height;
SARC	cis	rs2486288	0.656	rs11629807	chr15:45547037	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.5	-6.29	-0.38	1.57e-9	Glomerular filtration rate;
SARC	cis	rs9787249	0.957	rs2274949	chr1:40221067	G/A	cg24920358	chr1:40204285	PPIE	0.43	5.25	0.33	3.43e-7	Blood protein levels;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg12518360	chr11:92931304	SLC36A4	-0.78	-6.48	-0.39	5.28e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1865760	0.929	rs12195653	chr6:25958621	A/G	cg16482183	chr6:26056742	HIST1H1C	0.52	6.7	0.4	1.59e-10	Height;
SARC	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.62	-6.02	-0.37	6.61e-9	Lung function (FEV1/FVC);
SARC	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg07936541	chr2:98206095	ANKRD36B	0.46	6.25	0.38	1.92e-9	Cancer;
SARC	cis	rs1153858	1.000	rs4627277	chr15:45652768	C/A	cg03999130	chr15:45571217	NA	0.39	4.97	0.31	1.27e-6	Homoarginine levels;
SARC	cis	rs3762637	1.000	rs6790051	chr3:122192846	T/C	cg24169773	chr3:122142474	KPNA1	-0.57	-5.85	-0.36	1.67e-8	LDL cholesterol levels;
SARC	cis	rs3126085	0.935	rs1496045	chr1:152184704	C/T	cg26876637	chr1:152193138	HRNR	0.47	5.39	0.33	1.7e-7	Atopic dermatitis;
SARC	cis	rs11785400	0.928	rs2280878	chr8:143722366	G/A	cg24634471	chr8:143751801	JRK	0.64	8.2	0.47	1.58e-14	Schizophrenia;
SARC	trans	rs3780486	0.801	rs6476398	chr9:33119241	C/T	cg04842962	chr6:43655489	MRPS18A	1.08	20.39	0.8	1.03e-53	IgG glycosylation;
SARC	cis	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg12463550	chr7:65579703	CRCP	0.66	5.05	0.31	9.09e-7	Diabetic kidney disease;
SARC	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg00933542	chr6:150070202	PCMT1	0.33	5.74	0.35	2.93e-8	Lung cancer;
SARC	cis	rs35110281	0.667	rs9941787	chr21:45116042	A/G	cg01579765	chr21:45077557	HSF2BP	-0.36	-5.79	-0.35	2.23e-8	Mean corpuscular volume;
SARC	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg00149659	chr3:10157352	C3orf10	0.69	6.9	0.41	4.76e-11	Alzheimer's disease;
SARC	cis	rs6545883	0.894	rs6760075	chr2:61612881	C/A	cg15711740	chr2:61764176	XPO1	0.42	5.12	0.32	6.27e-7	Tuberculosis;
SARC	cis	rs2880765	0.545	rs11631739	chr15:86012578	T/C	cg19183879	chr15:85880815	NA	-0.29	-4.72	-0.3	4.16e-6	Coronary artery disease;
SARC	cis	rs854765	0.547	rs7224047	chr17:17932931	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.42	5.26	0.33	3.22e-7	Total body bone mineral density;
SARC	cis	rs367615	0.661	rs9326775	chr5:108836925	A/T	cg17395555	chr5:108820864	NA	0.49	7.0	0.42	2.7e-11	Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs6426558	0.537	rs648877	chr1:227283614	A/G	cg10327440	chr1:227177885	CDC42BPA	0.42	5.02	0.31	1.02e-6	Neutrophil percentage of white cells;
SARC	cis	rs16986825	0.664	rs5997409	chr22:29222096	T/C	cg02153584	chr22:29168773	CCDC117	0.65	7.11	0.42	1.39e-11	Pancreatic cancer;
SARC	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg06028808	chr11:68637592	NA	0.47	5.78	0.35	2.33e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs2816062	0.861	rs2745312	chr1:18904012	T/A	cg18795169	chr1:18902165	NA	-0.79	-11.94	-0.62	5.74e-26	Urate levels in lean individuals;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg15553911	chr19:54641084	CNOT3	0.51	6.72	0.4	1.42e-10	Thyroid stimulating hormone;
SARC	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg03647317	chr4:187891568	NA	-0.43	-6.12	-0.37	4.02e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs8068544	0.818	rs75771390	chr17:40194054	A/G	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.05	-8.0	-0.46	6e-14	Reticulocyte fraction of red cells;Reticulocyte count;
SARC	cis	rs11264799	0.603	rs12730818	chr1:157575630	T/A	cg18268488	chr1:157545234	FCRL4	0.33	5.62	0.35	5.39e-8	IgA nephropathy;
SARC	cis	rs6570726	0.935	rs424263	chr6:145840073	A/C	cg05220968	chr6:146057943	EPM2A	-0.29	-4.99	-0.31	1.19e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4430311	0.655	rs12141946	chr1:243811634	T/G	cg21452805	chr1:244014465	NA	-0.38	-4.73	-0.3	3.84e-6	Post-traumatic stress disorder (asjusted for relatedness);
SARC	cis	rs787274	1.000	rs813101	chr9:115532907	C/G	cg13803584	chr9:115635662	SNX30	-0.75	-5.78	-0.35	2.44e-8	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg10295955	chr4:187884368	NA	-1.06	-18.56	-0.77	7.79e-48	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg13012494	chr21:47604986	C21orf56	0.47	5.53	0.34	8.64e-8	Testicular germ cell tumor;
SARC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg11494091	chr17:61959527	GH2	0.53	8.09	0.47	3.34e-14	Prudent dietary pattern;
SARC	cis	rs10782582	0.532	rs12132503	chr1:76137762	C/G	cg03433033	chr1:76189801	ACADM	-0.42	-5.42	-0.33	1.46e-7	Daytime sleep phenotypes;
SARC	cis	rs11122272	0.735	rs2739518	chr1:231537633	C/T	cg06096015	chr1:231504339	EGLN1	0.38	5.7	0.35	3.54e-8	Hemoglobin concentration;
SARC	cis	rs11122272	0.735	rs2790892	chr1:231512771	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs1023500	0.505	rs134885	chr22:42673811	C/G	cg04733989	chr22:42467013	NAGA	0.53	6.96	0.41	3.39e-11	Schizophrenia;
SARC	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	12.23	0.63	6.97e-27	Chronic sinus infection;
SARC	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.53	6.66	0.4	2e-10	Personality dimensions;
SARC	cis	rs1580019	0.713	rs2122632	chr7:32524686	A/G	cg07520158	chr7:32535189	LSM5;AVL9	-0.55	-7.04	-0.42	2.13e-11	Cognitive ability;
SARC	cis	rs453301	0.658	rs3855900	chr8:8901921	A/G	cg06636001	chr8:8085503	FLJ10661	-0.64	-8.63	-0.49	9.55e-16	Joint mobility (Beighton score);
SARC	cis	rs6546324	0.625	rs6746394	chr2:67845021	A/C	cg18237512	chr2:67827392	NA	-0.53	-6.33	-0.38	1.22e-9	Endometriosis;
SARC	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg00933542	chr6:150070202	PCMT1	0.31	5.29	0.33	2.83e-7	Lung cancer;
SARC	cis	rs7766436	0.553	rs55936918	chr6:22610269	A/T	cg13666174	chr6:22585274	NA	-0.59	-6.0	-0.37	7.61e-9	Coronary artery disease;
SARC	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg08219700	chr8:58056026	NA	0.67	6.12	0.37	3.99e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg09373136	chr17:61933544	TCAM1	-0.44	-5.8	-0.36	2.13e-8	Prudent dietary pattern;
SARC	cis	rs921968	0.541	rs3755041	chr2:219442499	A/T	cg02176678	chr2:219576539	TTLL4	-0.5	-7.59	-0.45	7.58e-13	Mean corpuscular hemoglobin concentration;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg14290704	chr9:2015039	SMARCA2	-0.77	-6.29	-0.38	1.57e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9916302	0.904	rs9898773	chr17:37532507	C/G	cg00129232	chr17:37814104	STARD3	0.6	7.48	0.44	1.48e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs7223966	1.000	rs11870797	chr17:61804622	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.53	-5.55	-0.34	7.66e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg13880726	chr7:1868755	MAD1L1	0.43	4.99	0.31	1.2e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs12586317	0.620	rs10145433	chr14:35583333	G/A	cg05294307	chr14:35346193	BAZ1A	-0.48	-4.91	-0.31	1.75e-6	Psoriasis;
SARC	cis	rs11792861	0.816	rs3818932	chr9:111664178	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.78	9.49	0.53	2.79e-18	Menarche (age at onset);
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg06717289	chr15:75978121	CSPG4	-0.58	-6.8	-0.41	8.88e-11	Lung cancer in ever smokers;
SARC	cis	rs1691799	0.867	rs1168332	chr12:66761548	C/T	cg16791601	chr12:66731901	HELB	-0.71	-10.78	-0.58	3.09e-22	White blood cell count (basophil);
SARC	cis	rs9487051	1.000	rs7748918	chr6:109613564	A/G	cg01475377	chr6:109611718	NA	-0.37	-5.01	-0.31	1.06e-6	Reticulocyte fraction of red cells;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg18815539	chr4:25162020	SEPSECS	0.53	6.66	0.4	1.96e-10	Breast cancer;
SARC	cis	rs1580019	0.961	rs766660	chr7:32499077	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.74	9.9	0.54	1.68e-19	Cognitive ability;
SARC	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg12463550	chr7:65579703	CRCP	-0.48	-5.5	-0.34	1.02e-7	Aortic root size;
SARC	cis	rs10463554	0.927	rs257308	chr5:102418261	A/C	cg23492399	chr5:102201601	PAM	-0.52	-5.75	-0.35	2.78e-8	Parkinson's disease;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg08174373	chr10:102989254	FLJ41350;LBX1	0.51	6.69	0.4	1.63e-10	Breast cancer;
SARC	cis	rs11122272	0.735	rs973254	chr1:231521149	T/A	cg06096015	chr1:231504339	EGLN1	0.38	5.73	0.35	3.12e-8	Hemoglobin concentration;
SARC	cis	rs10504229	0.679	rs12375445	chr8:58040082	A/G	cg11062466	chr8:58055876	NA	0.53	5.24	0.32	3.52e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg16405210	chr4:1374714	KIAA1530	-0.51	-6.07	-0.37	5.28e-9	Obesity-related traits;
SARC	cis	rs2070677	1.000	rs2515641	chr10:135351362	T/C	cg20169779	chr10:135381914	SYCE1	0.45	5.86	0.36	1.57e-8	Gout;
SARC	cis	rs34245846	0.769	rs12058931	chr1:154825093	C/A	cg24250549	chr1:154909240	PMVK	-0.45	-4.91	-0.31	1.73e-6	Atrial fibrillation;
SARC	cis	rs4423214	0.840	rs1792234	chr11:71182018	T/C	cg05163923	chr11:71159392	DHCR7	-0.6	-7.21	-0.43	7.98e-12	Vitamin D levels;
SARC	cis	rs9397240	0.789	rs12191327	chr6:155588484	T/C	cg07943832	chr6:155568918	TIAM2	-0.61	-5.89	-0.36	1.38e-8	Life satisfaction;
SARC	cis	rs2251381	0.741	rs2735966	chr21:30538174	G/A	cg08807101	chr21:30365312	RNF160	0.78	10.93	0.58	1.03e-22	Selective IgA deficiency;
SARC	trans	rs877282	1.000	rs71491304	chr10:772982	C/T	cg22713356	chr15:30763199	NA	1.04	10.32	0.56	8.5e-21	Uric acid levels;
SARC	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg25427524	chr10:38739819	LOC399744	-0.62	-9.84	-0.54	2.55e-19	Extrinsic epigenetic age acceleration;
SARC	cis	rs853679	1.000	rs853694	chr6:28279100	A/T	cg26450541	chr6:28235208	ZNF187	0.6	5.04	0.31	9.27e-7	Depression;
SARC	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.92	10.24	0.56	1.46e-20	Platelet count;
SARC	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg03351412	chr1:154909251	PMVK	0.65	8.39	0.48	4.69e-15	Prostate cancer;
SARC	cis	rs67478160	0.679	rs7156834	chr14:104211180	G/A	cg08213375	chr14:104286397	PPP1R13B	0.27	4.84	0.3	2.36e-6	Schizophrenia;
SARC	cis	rs3733585	0.699	rs7676733	chr4:9966956	G/A	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.65	-0.35	4.69e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7592578	0.581	rs59109438	chr2:191287683	A/G	cg25963032	chr2:191064776	C2orf88	-0.47	-5.54	-0.34	8.21e-8	Diastolic blood pressure;
SARC	cis	rs16976116	0.901	rs8030981	chr15:55499442	A/G	cg17854078	chr15:55489399	RSL24D1	0.64	6.28	0.38	1.62e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs208515	0.525	rs12204706	chr6:66669930	A/G	cg07460842	chr6:66804631	NA	-0.95	-10.93	-0.58	1.03e-22	Exhaled nitric oxide levels;
SARC	cis	rs6831352	0.918	rs13143133	chr4:100054970	A/G	cg12011299	chr4:100065546	ADH4	-0.34	-5.74	-0.35	2.95e-8	Alcohol dependence;
SARC	cis	rs4268898	1.000	rs1203	chr2:24443330	A/G	cg06627628	chr2:24431161	ITSN2	0.59	8.23	0.47	1.32e-14	Asthma;
SARC	cis	rs2898681	0.642	rs11538878	chr4:53728524	T/C	cg00338735	chr4:53728038	RASL11B	0.38	4.85	0.3	2.26e-6	Optic nerve measurement (cup area);
SARC	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.51	6.23	0.38	2.14e-9	Gut microbiome composition (summer);
SARC	cis	rs9840812	0.559	rs6439640	chr3:136185680	A/G	cg15507776	chr3:136538369	TMEM22	0.65	6.65	0.4	2.02e-10	Fibrinogen levels;
SARC	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg27266027	chr21:40555129	PSMG1	0.51	5.11	0.32	6.77e-7	Cognitive function;
SARC	cis	rs11874712	0.965	rs12954944	chr18:43664115	T/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.46	5.5	0.34	1.02e-7	Migraine - clinic-based;
SARC	cis	rs6834538	1.000	rs6834538	chr4:113544152	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.48	5.66	0.35	4.39e-8	Free thyroxine concentration;
SARC	cis	rs13191362	1.000	rs73035023	chr6:163000927	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.57	5.38	0.33	1.85e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs4595586	0.545	rs11615634	chr12:39364704	A/C	cg13010199	chr12:38710504	ALG10B	0.4	4.74	0.3	3.67e-6	Morning vs. evening chronotype;
SARC	cis	rs9815354	0.812	rs60796012	chr3:41908668	T/C	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs4561483	0.673	rs28279	chr16:11968555	A/C	cg08843971	chr16:11963173	GSPT1	0.43	5.38	0.33	1.84e-7	Testicular germ cell tumor;
SARC	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2361718	0.501	rs8065486	chr17:78138196	A/G	cg23534315	chr17:78082725	GAA	-0.4	-5.11	-0.32	6.71e-7	Yeast infection;
SARC	cis	rs7727544	0.684	rs270602	chr5:131656700	T/C	cg24060327	chr5:131705240	SLC22A5	-0.72	-9.25	-0.52	1.47e-17	Blood metabolite levels;
SARC	cis	rs74181299	0.819	rs2723087	chr2:65298282	T/A	cg20592124	chr2:65290738	CEP68	0.49	7.16	0.42	1.06e-11	Pulse pressure;
SARC	trans	rs1814175	0.765	rs11493326	chr11:50018063	T/C	cg15704280	chr7:45808275	SEPT13	-0.96	-17.83	-0.76	2.02e-45	Height;
SARC	cis	rs3126085	0.935	rs1496045	chr1:152184704	C/T	cg03465714	chr1:152285911	FLG	-0.46	-5.5	-0.34	1e-7	Atopic dermatitis;
SARC	cis	rs55871839	0.559	rs4738736	chr8:59836001	C/T	cg07426533	chr8:59803705	TOX	0.47	5.24	0.32	3.58e-7	Pneumonia;
SARC	cis	rs6815814	0.861	rs1135430	chr4:38789361	T/C	cg06935464	chr4:38784597	TLR10	0.52	5.73	0.35	3.11e-8	Breast cancer;
SARC	cis	rs11155671	0.530	rs9383912	chr6:150206615	T/C	cg00933542	chr6:150070202	PCMT1	0.29	4.91	0.31	1.73e-6	Testicular germ cell tumor;
SARC	cis	rs950880	0.710	rs3771162	chr2:102997174	A/T	cg03938978	chr2:103052716	IL18RAP	-0.34	-4.85	-0.3	2.22e-6	Serum protein levels (sST2);
SARC	cis	rs9398803	0.723	rs1262545	chr6:127074587	C/T	cg19875578	chr6:126661172	C6orf173	-0.62	-8.6	-0.49	1.17e-15	Male-pattern baldness;
SARC	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg05623727	chr3:50126028	RBM5	0.37	5.62	0.35	5.37e-8	Body mass index;
SARC	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs11077998	0.844	rs12185254	chr17:80498972	C/T	cg10255544	chr17:80519551	FOXK2	0.44	6.45	0.39	6.37e-10	Reticulocyte fraction of red cells;
SARC	cis	rs2938670	1	rs2938670	chr15:78740688	T/G	cg18825076	chr15:78729989	IREB2	-0.47	-5.96	-0.36	9.44e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1 in COPD;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs875971	0.660	rs10229345	chr7:65982168	G/C	cg11764359	chr7:65958608	NA	0.7	8.15	0.47	2.21e-14	Aortic root size;
SARC	cis	rs7216064	0.589	rs8072723	chr17:66056970	T/A	cg12091567	chr17:66097778	LOC651250	0.95	12.77	0.64	1.18e-28	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-9.15	-0.51	2.96e-17	Alzheimer's disease;
SARC	cis	rs10465746	0.780	rs1952065	chr1:84464205	T/C	cg10977910	chr1:84465055	TTLL7	0.43	5.28	0.33	2.99e-7	Obesity-related traits;
SARC	cis	rs11583043	0.874	rs11578366	chr1:101396852	T/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.47	5.47	0.34	1.14e-7	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs11098499	0.874	rs12509054	chr4:120115075	A/C	cg09307838	chr4:120376055	NA	0.82	11.06	0.59	3.96e-23	Corneal astigmatism;
SARC	cis	rs3784262	1.000	rs7165247	chr15:58251786	C/T	cg12031962	chr15:58353849	ALDH1A2	0.38	5.64	0.35	4.82e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs710216	0.917	rs710223	chr1:43411038	C/G	cg07803811	chr1:43423981	SLC2A1	0.55	5.45	0.34	1.3e-7	Red cell distribution width;
SARC	cis	rs11190604	1.000	rs1054399	chr10:102312565	C/T	cg07080220	chr10:102295463	HIF1AN	0.82	10.39	0.56	4.98e-21	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs6121246	0.609	rs6060627	chr20:30262159	C/T	cg13852791	chr20:30311386	BCL2L1	0.83	10.09	0.55	4.33e-20	Mean corpuscular hemoglobin;
SARC	cis	rs6964587	1.000	rs926192	chr7:91671853	C/A	cg17063962	chr7:91808500	NA	0.96	16.6	0.74	2.21e-41	Breast cancer;
SARC	cis	rs1904096	0.506	rs6823404	chr4:95197520	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.47	-7.14	-0.42	1.16e-11	Type 2 diabetes;
SARC	cis	rs9788682	0.747	rs2568499	chr15:78722359	T/C	cg24631222	chr15:78858424	CHRNA5	-0.73	-8.66	-0.49	8.13e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg17971929	chr21:40555470	PSMG1	0.99	14.22	0.68	1.85e-33	Cognitive function;
SARC	cis	rs7918232	0.830	rs10764672	chr10:27392541	A/C	cg14442939	chr10:27389572	ANKRD26	-0.74	-7.76	-0.45	2.67e-13	Breast cancer;
SARC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg26354017	chr1:205819088	PM20D1	0.66	9.65	0.53	9.12e-19	Menarche (age at onset);
SARC	cis	rs1476670	0.683	rs2057967	chr1:44515446	T/C	cg09470012	chr1:44509516	NA	0.44	5.65	0.35	4.66e-8	Eotaxin levels;
SARC	cis	rs1882538	0.538	rs9649587	chr7:133104569	A/C	cg10665199	chr7:133106180	EXOC4	0.42	5.35	0.33	2.07e-7	Intelligence (multi-trait analysis);
SARC	cis	rs314370	0.818	rs12705091	chr7:100472380	C/T	cg10426581	chr7:100472382	SRRT	0.66	7.18	0.43	9.15e-12	Resting heart rate;
SARC	cis	rs12681366	0.708	rs2470718	chr8:95359077	C/A	cg26464482	chr8:95565502	KIAA1429	-0.46	-5.85	-0.36	1.68e-8	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs9916302	0.904	rs1619021	chr17:37739274	G/A	cg15445000	chr17:37608096	MED1	0.43	4.88	0.3	1.97e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs2276314	0.857	rs62101393	chr18:33592168	T/C	cg05985134	chr18:33552581	C18orf21	0.69	7.04	0.42	2.09e-11	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs509477	0.718	rs273346	chr18:32603056	G/T	cg23791764	chr18:32556832	MAPRE2	0.42	5.15	0.32	5.43e-7	Cerebrospinal fluid AB1-42 levels;
SARC	cis	rs9914988	0.887	rs12451790	chr17:27112000	C/G	cg20469991	chr17:27169893	C17orf63	-0.5	-5.21	-0.32	4.1e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs17376456	0.877	rs10476599	chr5:93383423	A/G	cg25358565	chr5:93447407	FAM172A	1.3	14.56	0.69	1.43e-34	Diabetic retinopathy;
SARC	cis	rs9457247	0.668	rs2236313	chr6:167360389	C/T	cg07741184	chr6:167504864	NA	0.31	5.89	0.36	1.35e-8	Crohn's disease;
SARC	cis	rs763121	0.853	rs4821816	chr22:39113134	G/A	cg06022373	chr22:39101656	GTPBP1	0.89	12.31	0.63	3.71e-27	Menopause (age at onset);
SARC	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg08859206	chr1:53392774	SCP2	0.41	5.84	0.36	1.77e-8	Monocyte count;
SARC	cis	rs1371867	0.846	rs2439458	chr8:101297984	T/C	cg11906718	chr8:101322791	RNF19A	0.64	8.51	0.49	2.2e-15	Atrioventricular conduction;
SARC	cis	rs72945132	0.882	rs11235967	chr11:70191691	T/C	cg05964544	chr11:70165517	PPFIA1	-0.58	-5.66	-0.35	4.41e-8	Coronary artery disease;
SARC	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.72	-7.58	-0.44	8e-13	Platelet count;
SARC	cis	rs72781680	0.898	rs55657921	chr2:24008091	C/G	cg08917208	chr2:24149416	ATAD2B	0.75	7.09	0.42	1.56e-11	Lymphocyte counts;
SARC	cis	rs9393777	0.623	rs9358947	chr6:26479000	G/A	cg12826209	chr6:26865740	GUSBL1	0.81	7.39	0.44	2.59e-12	Intelligence (multi-trait analysis);
SARC	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	12.37	0.63	2.38e-27	Chronic sinus infection;
SARC	cis	rs7223966	1.000	rs9899491	chr17:61934384	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-5.0	-0.31	1.15e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.8	10.38	0.56	5.49e-21	Prudent dietary pattern;
SARC	cis	rs1153858	1.000	rs1049503	chr15:45653707	T/C	cg26924012	chr15:45694286	SPATA5L1	0.78	11.14	0.59	2.18e-23	Homoarginine levels;
SARC	cis	rs1569175	0.522	rs2347286	chr2:200946393	T/C	cg23649088	chr2:200775458	C2orf69	-0.68	-5.59	-0.34	6.42e-8	Response to treatment for acute lymphoblastic leukemia;
SARC	cis	rs12477438	0.765	rs12470471	chr2:99689141	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.68	9.17	0.51	2.66e-17	Chronic sinus infection;
SARC	cis	rs5758511	0.634	rs1001587	chr22:42670111	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.46	6.83	0.41	7.4e-11	Birth weight;
SARC	cis	rs9457247	1.000	rs413232	chr6:167400972	G/A	cg07741184	chr6:167504864	NA	0.29	5.55	0.34	7.59e-8	Crohn's disease;
SARC	cis	rs11864453	0.963	rs7185215	chr16:72034864	T/C	cg16558253	chr16:72132732	DHX38	-0.48	-7.22	-0.43	7.4e-12	Fibrinogen levels;
SARC	cis	rs6484504	0.532	rs10835756	chr11:31267622	C/T	cg26647111	chr11:31128758	NA	-0.39	-5.05	-0.31	9.01e-7	Red blood cell count;
SARC	cis	rs554111	0.963	rs710312	chr1:21042462	A/G	cg08890418	chr1:21044141	KIF17	0.56	7.66	0.45	4.98e-13	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs13191362	0.507	rs13207363	chr6:163201285	C/G	cg21926612	chr6:163149169	PACRG;PARK2	-0.48	-5.23	-0.32	3.79e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs11719291	0.833	rs13074318	chr3:48816725	C/T	cg01304814	chr3:48885189	PRKAR2A	0.63	5.23	0.32	3.76e-7	Cognitive function;
SARC	cis	rs3796352	1.000	rs13058817	chr3:53024139	C/T	cg27565382	chr3:53032988	SFMBT1	1.04	7.27	0.43	5.28e-12	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs36051895	0.622	rs12686652	chr9:5071942	C/G	cg02405213	chr9:5042618	JAK2	-0.44	-5.08	-0.32	7.75e-7	Pediatric autoimmune diseases;
SARC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg03452623	chr4:187889614	NA	0.79	12.03	0.62	3.04e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg07636037	chr3:49044803	WDR6	0.49	5.67	0.35	4.3e-8	Resting heart rate;
SARC	cis	rs9916302	0.808	rs6503515	chr17:37606433	G/T	cg15445000	chr17:37608096	MED1	0.41	4.91	0.31	1.68e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs6912958	0.559	rs373646	chr6:88056896	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.76	11.62	0.61	6.43e-25	Monocyte percentage of white cells;
SARC	cis	rs11191193	1.000	rs11191193	chr10:103802408	A/G	cg15320455	chr10:103880129	LDB1	0.44	4.8	0.3	2.79e-6	Educational attainment;
SARC	cis	rs12908161	1.000	rs11632465	chr15:85282045	A/T	cg17507749	chr15:85114479	UBE2QP1	0.56	6.49	0.39	5e-10	Schizophrenia;
SARC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg06074448	chr4:187884817	NA	0.43	5.95	0.36	9.81e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs13191362	1.000	rs71567659	chr6:163001736	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.49	0.34	1.04e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs6963495	0.745	rs56239334	chr7:105165351	G/A	cg19920283	chr7:105172520	RINT1	0.66	5.66	0.35	4.47e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs11581859	0.613	rs35806712	chr1:99197872	A/T	cg20286094	chr1:99190917	SNX7	-0.42	-4.99	-0.31	1.2e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs2439831	0.850	rs12440573	chr15:44108997	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.97	8.57	0.49	1.46e-15	Lung cancer in ever smokers;
SARC	cis	rs7568458	0.840	rs2886722	chr2:85742297	C/T	cg17127132	chr2:85788382	GGCX	-0.43	-5.4	-0.33	1.67e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs8016982	0.698	rs8011097	chr14:81702736	T/C	cg01989461	chr14:81687754	GTF2A1	0.72	10.51	0.57	2.16e-21	Schizophrenia;
SARC	cis	rs4911259	0.552	rs6057663	chr20:31463071	G/T	cg13636640	chr20:31349939	DNMT3B	-0.67	-9.22	-0.52	1.84e-17	Inflammatory bowel disease;
SARC	cis	rs7762018	0.607	rs6907814	chr6:170058206	G/A	cg13015042	chr6:170102002	WDR27;C6orf120	0.7	5.06	0.31	8.69e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg22914762	chr4:117220908	MIR1973	-0.45	-6.54	-0.39	3.8e-10	Electrocardiographic conduction measures;
SARC	cis	rs2228479	0.557	rs57071566	chr16:89889327	T/G	cg06558623	chr16:89946397	TCF25	0.91	6.49	0.39	5.16e-10	Skin colour saturation;
SARC	cis	rs6912958	0.559	rs107689	chr6:88069333	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.37	6.55	0.39	3.6e-10	Monocyte percentage of white cells;
SARC	cis	rs4273100	0.688	rs1467028	chr17:19174874	T/C	cg25447019	chr17:19030144	GRAPL	-0.36	-5.42	-0.33	1.52e-7	Schizophrenia;
SARC	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg11987759	chr7:65425863	GUSB	0.47	5.74	0.35	2.93e-8	Aortic root size;
SARC	cis	rs7027203	0.576	rs7865043	chr9:96549004	G/T	cg14598338	chr9:96623480	NA	0.34	4.77	0.3	3.25e-6	DNA methylation (variation);
SARC	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg21724239	chr8:58056113	NA	0.57	6.07	0.37	5.07e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9486719	0.947	rs9398072	chr6:96911304	T/C	cg18709589	chr6:96969512	KIAA0776	0.49	5.18	0.32	4.82e-7	Migraine;Coronary artery disease;
SARC	cis	rs13082711	0.522	rs653076	chr3:27343691	T/C	cg02860705	chr3:27208620	NA	0.43	5.76	0.35	2.68e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs834603	0.611	rs2692540	chr7:47465325	C/G	cg23694490	chr7:47445681	TNS3	-0.33	-5.94	-0.36	1.01e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs12421382	0.659	rs60143378	chr11:109385513	T/C	cg27471124	chr11:109292789	C11orf87	0.38	5.19	0.32	4.65e-7	Schizophrenia;
SARC	cis	rs11677370	0.561	rs4849990	chr2:3819558	A/G	cg17052675	chr2:3827356	NA	-0.42	-4.99	-0.31	1.15e-6	Type 2 diabetes;
SARC	cis	rs1267303	0.710	rs1535739	chr1:46957719	A/C	cg25110126	chr1:46999211	NA	-0.55	-6.44	-0.39	6.73e-10	Monobrow;
SARC	cis	rs12079745	0.793	rs10919156	chr1:169345054	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.9	-5.72	-0.35	3.26e-8	QT interval;
SARC	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg12463550	chr7:65579703	CRCP	-0.7	-5.34	-0.33	2.21e-7	Diabetic kidney disease;
SARC	cis	rs11608355	1.000	rs930356	chr12:109852372	T/C	cg19025524	chr12:109796872	NA	-0.38	-4.92	-0.31	1.62e-6	Neuroticism;
SARC	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg01494348	chr8:144660395	NAPRT1	-0.52	-4.81	-0.3	2.68e-6	Attention deficit hyperactivity disorder;
SARC	cis	rs7582180	0.585	rs6736311	chr2:100950599	C/G	cg14675211	chr2:100938903	LONRF2	0.47	7.0	0.42	2.67e-11	Intelligence (multi-trait analysis);
SARC	cis	rs7937682	0.640	rs587010	chr11:111425658	C/A	cg09085632	chr11:111637200	PPP2R1B	-0.68	-9.78	-0.54	3.87e-19	Primary sclerosing cholangitis;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg06900229	chr17:48556928	RSAD1	0.62	6.37	0.39	9.9e-10	Lung cancer in ever smokers;
SARC	cis	rs10513788	0.665	rs2129824	chr3:181991496	C/T	cg05977900	chr3:182512126	ATP11B	0.47	5.0	0.31	1.14e-6	Cognitive function;
SARC	cis	rs9905704	0.836	rs12952429	chr17:56843070	C/T	cg12560992	chr17:57184187	TRIM37	0.44	5.1	0.32	7.15e-7	Testicular germ cell tumor;
SARC	cis	rs282587	0.569	rs409896	chr13:113400338	G/T	cg02820901	chr13:113351484	ATP11A	-0.51	-4.91	-0.31	1.71e-6	Glycated hemoglobin levels;
SARC	cis	rs73206853	0.841	rs73191825	chr12:110942205	T/C	cg10860002	chr12:110842031	ANAPC7	0.62	4.83	0.3	2.52e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs3771570	0.901	rs73008106	chr2:242422446	C/T	cg21155796	chr2:242212141	HDLBP	0.55	5.31	0.33	2.61e-7	Prostate cancer;
SARC	trans	rs17685	0.633	rs3801471	chr7:75696188	T/G	cg19862616	chr7:65841803	NCRNA00174	0.64	8.02	0.47	5.29e-14	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs9788682	0.747	rs2568490	chr15:78738370	T/C	cg24631222	chr15:78858424	CHRNA5	-0.75	-9.28	-0.52	1.25e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs4713118	0.513	rs149958	chr6:28013617	A/C	cg16479474	chr6:28041457	NA	0.33	4.95	0.31	1.43e-6	Parkinson's disease;
SARC	cis	rs637571	0.780	rs677029	chr11:65683531	A/G	cg26695010	chr11:65641043	EFEMP2	-0.55	-7.08	-0.42	1.69e-11	Eosinophil percentage of white cells;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg24717964	chr20:61477008	DPH3B;TCFL5	-0.49	-6.31	-0.38	1.36e-9	Electrocardiographic conduction measures;
SARC	trans	rs9650657	0.801	rs2409663	chr8:10643233	G/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.5	-0.39	4.87e-10	Neuroticism;
SARC	cis	rs7843479	1.000	rs1032094	chr8:21820479	A/T	cg17168535	chr8:21777572	XPO7	0.61	7.83	0.46	1.69e-13	Mean corpuscular volume;
SARC	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	9.26	0.52	1.39e-17	Platelet count;
SARC	cis	rs941408	1.000	rs1640273	chr19:2803227	C/T	cg06609049	chr19:2785107	THOP1	0.77	9.93	0.55	1.33e-19	Total cholesterol levels;
SARC	cis	rs7615952	0.605	rs11708269	chr3:125332150	C/T	cg05084668	chr3:125655381	ALG1L	-0.64	-5.04	-0.31	9.53e-7	Blood pressure (smoking interaction);
SARC	cis	rs6088580	0.634	rs6088488	chr20:32992631	T/C	cg24642439	chr20:33292090	TP53INP2	-0.68	-8.73	-0.5	4.96e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs7833986	0.501	rs2719255	chr8:57036658	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.74	7.59	0.45	7.75e-13	Height;
SARC	trans	rs10519937	0.935	rs111615826	chr5:126740501	A/G	cg26526953	chr19:1921199	SCAMP4	0.6	6.26	0.38	1.79e-9	IgG glycosylation;
SARC	cis	rs7927771	0.864	rs3781626	chr11:47442893	A/T	cg20307385	chr11:47447363	PSMC3	-0.58	-7.41	-0.44	2.31e-12	Subjective well-being;
SARC	cis	rs2153535	0.580	rs1932275	chr6:8442333	T/A	cg21535247	chr6:8435926	SLC35B3	0.56	6.91	0.41	4.54e-11	Motion sickness;
SARC	cis	rs9818758	0.556	rs9814987	chr3:49207849	T/C	cg00383909	chr3:49044727	WDR6	0.67	6.05	0.37	5.78e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	trans	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.52	6.73	0.4	1.3100000000000001e-10	Intelligence (multi-trait analysis);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg14220272	chr21:38445791	PIGP;TTC3	0.53	6.79	0.41	9.03e-11	Breast cancer;
SARC	cis	rs1051424	0.642	rs115869798	chr17:57892829	T/A	cg02344993	chr17:57696989	CLTC	0.66	6.83	0.41	7.52e-11	Obesity-related traits;
SARC	cis	rs7568458	0.905	rs10187424	chr2:85794297	T/C	cg17127132	chr2:85788382	GGCX	0.43	5.61	0.34	5.73e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs13191362	0.935	rs35378894	chr6:163123933	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.4	5.1	0.32	7.09e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs17376456	0.825	rs17372649	chr5:93126096	C/G	cg21475434	chr5:93447410	FAM172A	0.71	6.04	0.37	6.13e-9	Diabetic retinopathy;
SARC	cis	rs2153535	0.601	rs6906170	chr6:8543128	T/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.64	0.49	9.03e-16	Motion sickness;
SARC	cis	rs11190604	1.000	rs76683169	chr10:102358397	A/T	cg07080220	chr10:102295463	HIF1AN	0.77	8.89	0.5	1.66e-16	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs2760061	0.583	rs708113	chr1:228192753	T/A	cg02753203	chr1:228287806	NA	0.79	11.67	0.61	4.33e-25	Diastolic blood pressure;
SARC	cis	rs10463554	0.892	rs158408	chr5:102407374	G/A	cg23492399	chr5:102201601	PAM	-0.43	-4.81	-0.3	2.77e-6	Parkinson's disease;
SARC	cis	rs965469	1.000	rs2236118	chr20:3302058	C/T	cg25506879	chr20:3388711	C20orf194	-0.49	-4.87	-0.3	2.04e-6	IFN-related cytopenia;
SARC	cis	rs950027	1.000	rs950027	chr15:45801035	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.49	-5.84	-0.36	1.76e-8	Response to fenofibrate (adiponectin levels);
SARC	cis	rs10754283	0.756	rs17441836	chr1:90135433	C/T	cg21401794	chr1:90099060	LRRC8C	0.5	6.39	0.39	9.1e-10	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs9916302	0.904	rs8065963	chr17:37681332	C/T	cg00129232	chr17:37814104	STARD3	-0.64	-7.78	-0.45	2.37e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs7917772	0.582	rs10786685	chr10:104323103	C/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.44	5.57	0.34	6.88e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs730775	0.505	rs325001	chr6:44270936	A/G	cg21130236	chr6:44246755	TMEM151B	0.24	4.73	0.3	3.85e-6	Monocyte percentage of white cells;Monocyte count;
SARC	trans	rs9650657	0.871	rs7814142	chr8:10637552	G/A	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.51	-0.39	4.56e-10	Neuroticism;
SARC	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9660992	0.573	rs1172139	chr1:205213962	G/A	cg21545522	chr1:205238299	TMCC2	0.39	5.34	0.33	2.17e-7	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs7561273	0.609	rs10197527	chr2:24352398	A/C	cg07265300	chr2:24346000	PFN4;LOC375190	-0.42	-4.72	-0.3	4.01e-6	Quantitative traits;
SARC	cis	rs72781680	0.898	rs7589440	chr2:24038595	G/A	cg08917208	chr2:24149416	ATAD2B	0.78	7.32	0.43	3.96e-12	Lymphocyte counts;
SARC	cis	rs7818688	0.654	rs75680386	chr8:95986148	A/G	cg13393036	chr8:95962371	TP53INP1	0.43	5.11	0.32	6.78e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs6442522	0.550	rs4036833	chr3:15406428	G/C	cg16303742	chr3:15540471	COLQ	0.36	5.55	0.34	7.65e-8	Uric acid levels;
SARC	cis	rs748404	0.631	rs560191	chr15:43767774	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	5.58	0.34	6.68e-8	Lung cancer;
SARC	cis	rs4253772	0.513	rs9306512	chr22:46716603	T/C	cg24881330	chr22:46731750	TRMU	0.81	8.29	0.48	8.95e-15	LDL cholesterol;Cholesterol, total;
SARC	cis	rs929596	0.606	rs10178992	chr2:234657877	T/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.35	-5.06	-0.31	8.63e-7	Total bilirubin levels in HIV-1 infection;
SARC	cis	rs79149102	0.579	rs6495138	chr15:75304692	A/G	cg17294928	chr15:75287854	SCAMP5	-1.01	-9.29	-0.52	1.13e-17	Lung cancer;
SARC	cis	rs2268241	0.938	rs2268242	chr21:34781104	C/T	cg14850771	chr21:34775459	IFNGR2	0.97	9.33	0.52	8.64e-18	Obesity-related traits;
SARC	cis	rs17376456	0.877	rs12153788	chr5:93405437	A/G	cg25358565	chr5:93447407	FAM172A	1.3	14.56	0.69	1.43e-34	Diabetic retinopathy;
SARC	cis	rs9811216	1.000	rs1997392	chr3:169509652	A/G	cg14222479	chr3:169487675	ARPM1	-0.43	-5.15	-0.32	5.41e-7	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs1215050	0.791	rs9993992	chr4:98810851	C/G	cg05340658	chr4:99064831	C4orf37	0.44	5.87	0.36	1.48e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs769267	0.501	rs2965187	chr19:19522970	T/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	5.33	0.33	2.37e-7	Tonsillectomy;
SARC	cis	rs9399137	0.507	rs4289677	chr6:135275485	A/G	cg24558204	chr6:135376177	HBS1L	0.61	7.99	0.46	6.08e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs950169	0.922	rs11639244	chr15:84832650	G/A	cg17507749	chr15:85114479	UBE2QP1	0.76	8.7	0.49	6.27e-16	Schizophrenia;
SARC	cis	rs12421382	0.576	rs116158609	chr11:109389358	T/A	cg27471124	chr11:109292789	C11orf87	0.36	5.18	0.32	4.89e-7	Schizophrenia;
SARC	cis	rs858239	0.541	rs4624924	chr7:23168843	A/C	cg23682824	chr7:23144976	KLHL7	0.74	9.84	0.54	2.51e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9790314	0.750	rs6765270	chr3:160899974	A/G	cg04691961	chr3:161091175	C3orf57	-0.66	-8.87	-0.5	1.98e-16	Morning vs. evening chronotype;
SARC	cis	rs1215050	0.765	rs181521	chr4:98745728	A/C	cg05340658	chr4:99064831	C4orf37	0.44	5.85	0.36	1.62e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs9916302	0.706	rs4332770	chr17:37704712	T/C	cg07936489	chr17:37558343	FBXL20	-0.74	-8.58	-0.49	1.37e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg13866156	chr1:1669148	SLC35E2	-0.63	-9.57	-0.53	1.59e-18	Body mass index;
SARC	cis	rs3820928	0.874	rs2228557	chr2:227872182	G/A	cg05526886	chr2:227700861	RHBDD1	-0.49	-5.82	-0.36	1.89e-8	Pulmonary function;
SARC	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.68	7.17	0.43	9.96e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg09359103	chr1:154839909	KCNN3	-0.41	-6.82	-0.41	7.55e-11	Prostate cancer;
SARC	cis	rs703842	0.892	rs1021469	chr12:58208164	C/T	cg00677455	chr12:58241039	CTDSP2	0.54	7.35	0.43	3.28e-12	Multiple sclerosis;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg09786701	chr20:2539517	TMC2	0.43	6.25	0.38	1.91e-9	Chemerin levels;
SARC	cis	rs793571	0.669	rs714696	chr15:58962987	C/G	cg05156742	chr15:59063176	FAM63B	0.68	8.58	0.49	1.34e-15	Schizophrenia;
SARC	cis	rs36051895	0.632	rs10974983	chr9:5149657	G/T	cg02405213	chr9:5042618	JAK2	-0.43	-4.95	-0.31	1.39e-6	Pediatric autoimmune diseases;
SARC	cis	rs4727027	0.631	rs62507511	chr7:148796080	C/A	cg23583168	chr7:148888333	NA	-0.74	-10.2	-0.56	1.93e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs9303401	0.614	rs34550282	chr17:57092788	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.98	9.98	0.55	9.2e-20	Cognitive test performance;
SARC	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg05896524	chr21:47604654	C21orf56	0.42	5.04	0.31	9.35e-7	Testicular germ cell tumor;
SARC	cis	rs240764	0.853	rs1875400	chr6:101020968	T/C	cg09795085	chr6:101329169	ASCC3	-0.45	-5.95	-0.36	9.52e-9	Neuroticism;
SARC	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg11764359	chr7:65958608	NA	0.83	11.12	0.59	2.49e-23	Aortic root size;
SARC	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg07701084	chr6:150067640	NUP43	0.44	5.72	0.35	3.19e-8	Lung cancer;
SARC	cis	rs1707322	1.000	rs11211237	chr1:46447329	G/C	cg06784218	chr1:46089804	CCDC17	0.34	5.95	0.36	9.76e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs12048904	0.595	rs10493937	chr1:101342650	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.55	-7.38	-0.44	2.73e-12	Multiple sclerosis;
SARC	cis	rs300703	0.576	rs3791216	chr2:237142	C/A	cg21211680	chr2:198530	NA	0.52	5.21	0.32	4.11e-7	Blood protein levels;
SARC	cis	rs1144333	0.655	rs76794487	chr1:76384055	G/A	cg03433033	chr1:76189801	ACADM	0.64	5.23	0.32	3.73e-7	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-8.27	-0.48	1.05e-14	Chronic sinus infection;
SARC	cis	rs1957429	0.808	rs7149922	chr14:65334541	C/T	cg23373153	chr14:65346875	NA	0.96	10.11	0.55	3.79e-20	Pediatric areal bone mineral density (radius);
SARC	cis	rs7666738	0.830	rs4699594	chr4:98980775	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs3741404	0.560	rs17699798	chr11:63898806	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.65	-8.33	-0.48	6.79e-15	Platelet count;
SARC	cis	rs11785400	0.793	rs7000765	chr8:143722457	G/A	cg24634471	chr8:143751801	JRK	0.61	7.79	0.45	2.15e-13	Schizophrenia;
SARC	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg00149659	chr3:10157352	C3orf10	1.07	9.51	0.53	2.45e-18	Alzheimer's disease;
SARC	cis	rs7587476	0.906	rs2070096	chr2:215645545	C/G	cg04530015	chr2:215796436	ABCA12	-0.4	-6.08	-0.37	4.89e-9	Neuroblastoma;
SARC	cis	rs2439831	0.867	rs3101443	chr15:43912372	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	8.38	0.48	5.18e-15	Lung cancer in ever smokers;
SARC	cis	rs7520050	0.966	rs12049588	chr1:46472422	G/A	cg24296786	chr1:45957014	TESK2	0.39	4.92	0.31	1.62e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs9916302	0.851	rs677888	chr17:37461018	T/G	cg00129232	chr17:37814104	STARD3	0.62	7.27	0.43	5.37e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	21.26	0.81	1.8e-56	Prudent dietary pattern;
SARC	cis	rs739401	0.595	rs6578304	chr11:2998279	A/G	cg05729581	chr11:3078854	CARS	0.52	6.8	0.41	8.65e-11	Longevity;
SARC	cis	rs7216064	1.000	rs7216064	chr17:65898809	G/A	cg12091567	chr17:66097778	LOC651250	-0.7	-7.28	-0.43	4.96e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs721399	1.000	rs1495745	chr8:18262723	T/G	cg18736775	chr8:18248649	NAT2	0.39	4.95	0.31	1.43e-6	Blood metabolite levels;
SARC	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg02733842	chr7:1102375	C7orf50	-0.41	-4.93	-0.31	1.59e-6	Bronchopulmonary dysplasia;
SARC	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.35	-0.43	3.34e-12	Gut microbiome composition (summer);
SARC	cis	rs2227564	0.794	rs2688620	chr10:75684532	A/G	cg16540259	chr10:75572220	NDST2	0.36	4.96	0.31	1.38e-6	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs4660306	1.000	rs2356561	chr1:45980862	T/G	cg24296786	chr1:45957014	TESK2	0.57	6.84	0.41	6.92e-11	Homocysteine levels;
SARC	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg22535103	chr8:58192502	C8orf71	-0.57	-5.88	-0.36	1.45e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg18876405	chr7:65276391	NA	0.72	9.42	0.53	4.52e-18	Aortic root size;
SARC	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg11890956	chr21:40555474	PSMG1	-0.71	-9.27	-0.52	1.32e-17	Menarche (age at onset);
SARC	cis	rs9815354	0.812	rs73071239	chr3:41992610	C/A	cg03022575	chr3:42003672	ULK4	0.72	6.26	0.38	1.79e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs3784262	0.967	rs11630835	chr15:58269462	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.37	-5.46	-0.34	1.2e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs924607	0.898	rs1697990	chr5:626278	A/G	cg09021430	chr5:549028	NA	0.31	5.98	0.36	8.36e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs2292864	0.764	rs2292867	chr17:45357489	C/T	cg18085866	chr17:45331354	ITGB3	-0.68	-6.18	-0.38	2.89e-9	Left atrial antero-posterior diameter;
SARC	cis	rs2227564	0.729	rs2688617	chr10:75646147	A/T	cg16540259	chr10:75572220	NDST2	0.36	5.0	0.31	1.11e-6	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs17376456	0.825	rs17372725	chr5:93135588	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.7	6.46	0.39	6.08e-10	Diabetic retinopathy;
SARC	cis	rs986417	0.901	rs1007152	chr14:60999493	C/T	cg27398547	chr14:60952738	C14orf39	0.96	8.88	0.5	1.87e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs6088590	0.648	rs6058105	chr20:33271719	C/T	cg24642439	chr20:33292090	TP53INP2	0.75	10.04	0.55	6.19e-20	Coronary artery disease;
SARC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.76	-7.91	-0.46	1.01e-13	Platelet count;
SARC	cis	rs13191362	1.000	rs13190742	chr6:163008758	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.56	5.35	0.33	2.07e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs6088580	0.634	rs4911152	chr20:32955024	T/C	cg24642439	chr20:33292090	TP53INP2	-0.64	-8.33	-0.48	7.15e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs12451471	0.637	rs7567	chr17:78093549	G/T	cg24585782	chr17:78113791	EIF4A3	-0.54	-5.88	-0.36	1.41e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
SARC	cis	rs7633770	0.841	rs11130100	chr3:46679198	A/T	cg11219411	chr3:46661640	NA	-0.46	-7.76	-0.45	2.66e-13	Coronary artery disease;
SARC	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg13175981	chr1:150552382	MCL1	-0.53	-6.81	-0.41	8.15e-11	Tonsillectomy;
SARC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg26338869	chr17:61819248	STRADA	0.8	10.72	0.57	4.8e-22	Prudent dietary pattern;
SARC	cis	rs7250872	0.647	rs2304612	chr19:1817866	A/G	cg18850929	chr19:1828978	REXO1	-0.46	-5.94	-0.36	1.05e-8	Bipolar disorder;
SARC	cis	rs7666738	0.830	rs13149779	chr4:99010145	G/T	cg05340658	chr4:99064831	C4orf37	0.65	8.85	0.5	2.27e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.5	5.65	0.35	4.61e-8	Renal function-related traits (BUN);
SARC	cis	rs1983170	0.808	rs12080863	chr1:92018721	T/C	cg25838465	chr1:92012736	NA	0.44	5.38	0.33	1.82e-7	Eosinophil percentage of white cells;
SARC	cis	rs9346455	0.892	rs9364152	chr6:72007417	C/T	cg27238071	chr6:71998145	OGFRL1	0.59	5.0	0.31	1.12e-6	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
SARC	cis	rs6570726	0.935	rs414646	chr6:145831685	T/C	cg05347473	chr6:146136440	FBXO30	0.48	6.42	0.39	7.51e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2288073	0.965	rs36101491	chr2:24387532	C/T	cg06627628	chr2:24431161	ITSN2	-0.7	-8.36	-0.48	5.78e-15	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs950776	0.518	rs12915428	chr15:78823368	G/A	cg22563815	chr15:78856949	CHRNA5	0.41	6.82	0.41	7.56e-11	Sudden cardiac arrest;
SARC	cis	rs9467711	0.591	rs13195279	chr6:25919431	T/A	cg21479132	chr6:26055353	NA	0.77	4.84	0.3	2.35e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs818427	0.896	rs351770	chr5:112199199	C/A	cg07820702	chr5:112228657	REEP5	0.54	6.3	0.38	1.46e-9	Total body bone mineral density;
SARC	cis	rs1008375	0.866	rs2109518	chr4:17572162	G/A	cg27347728	chr4:17578864	LAP3	0.45	5.48	0.34	1.1e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6964587	0.626	rs9008	chr7:91502407	C/G	cg17063962	chr7:91808500	NA	-0.77	-11.24	-0.59	1.05e-23	Breast cancer;
SARC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg01238044	chr22:24384105	GSTT1	-0.54	-6.11	-0.37	4.06e-9	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2153535	0.580	rs6597325	chr6:8461053	A/C	cg07606381	chr6:8435919	SLC35B3	0.75	10.69	0.57	5.96e-22	Motion sickness;
SARC	cis	rs4780401	0.933	rs1579258	chr16:11824903	C/G	cg01061890	chr16:11836724	TXNDC11	-0.51	-6.58	-0.4	3.16e-10	Rheumatoid arthritis;
SARC	cis	rs2797160	0.651	rs6569437	chr6:126034540	T/G	cg06289844	chr6:126071538	HEY2	-0.32	-5.05	-0.31	9.11e-7	Endometrial cancer;
SARC	cis	rs950776	0.684	rs11637635	chr15:78877150	A/G	cg06917634	chr15:78832804	PSMA4	-0.78	-10.66	-0.57	7.08e-22	Sudden cardiac arrest;
SARC	cis	rs78545713	0.892	rs11751286	chr6:26241361	C/G	cg13736514	chr6:26305472	NA	-0.61	-5.14	-0.32	5.89e-7	Iron status biomarkers (total iron binding capacity);
SARC	trans	rs12460587	0.587	rs10415150	chr19:52604625	C/G	cg19274401	chr19:33878161	PEPD	-0.43	-6.36	-0.38	1.03e-9	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
SARC	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg06713675	chr4:122721982	EXOSC9	-0.49	-6.83	-0.41	7.35e-11	Type 2 diabetes;
SARC	cis	rs7666738	0.512	rs1648536	chr4:99019881	G/T	cg05340658	chr4:99064831	C4orf37	-0.48	-6.56	-0.39	3.46e-10	Colonoscopy-negative controls vs population controls;
SARC	cis	rs965469	0.857	rs6037523	chr20:3249463	A/T	cg25506879	chr20:3388711	C20orf194	-0.47	-4.95	-0.31	1.4e-6	IFN-related cytopenia;
SARC	cis	rs6831352	0.837	rs2924583	chr4:100044640	T/C	cg13256891	chr4:100009986	ADH5	0.66	8.38	0.48	4.94e-15	Alcohol dependence;
SARC	cis	rs6121246	0.954	rs6121245	chr20:30432060	G/A	cg13852791	chr20:30311386	BCL2L1	0.8	8.54	0.49	1.79e-15	Mean corpuscular hemoglobin;
SARC	cis	rs10752881	0.935	rs10797834	chr1:183048749	T/G	cg13390022	chr1:182993471	LAMC1	0.33	5.03	0.31	9.72e-7	Colorectal cancer;
SARC	cis	rs6570726	0.935	rs386823	chr6:145841365	C/T	cg05347473	chr6:146136440	FBXO30	0.48	6.42	0.39	7.51e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1318878	0.565	rs12317475	chr12:15468046	T/C	cg08258403	chr12:15378311	NA	0.51	7.05	0.42	2.01e-11	Intelligence (multi-trait analysis);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg20875397	chr2:146310448	NA	0.46	6.63	0.4	2.37e-10	Thyroid stimulating hormone;
SARC	trans	rs1814175	0.650	rs6486000	chr11:49659090	T/A	cg03929089	chr4:120376271	NA	-0.78	-10.75	-0.58	3.68e-22	Height;
SARC	trans	rs11165623	0.765	rs11807955	chr1:96891623	C/T	cg10631902	chr5:14652156	NA	-0.48	-7.69	-0.45	4.03e-13	Hip circumference;Waist circumference;
SARC	cis	rs561341	0.941	rs550213	chr17:30317518	C/G	cg00745463	chr17:30367425	LRRC37B	-0.62	-4.94	-0.31	1.47e-6	Hip circumference adjusted for BMI;
SARC	cis	rs7336332	0.569	rs7988412	chr13:28000282	C/T	cg01674679	chr13:27998804	GTF3A	-0.53	-5.23	-0.32	3.74e-7	Weight;
SARC	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg22496380	chr5:211416	CCDC127	-0.88	-9.27	-0.52	1.3e-17	Breast cancer;
SARC	cis	rs2732480	0.557	rs2732454	chr12:48719677	T/C	cg21466736	chr12:48725269	NA	-0.31	-4.83	-0.3	2.45e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs611744	0.967	rs684904	chr8:109199417	G/A	cg21045802	chr8:109455806	TTC35	0.44	5.23	0.32	3.81e-7	Dupuytren's disease;
SARC	cis	rs72772090	0.634	rs12186366	chr5:96088850	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.62	-5.17	-0.32	5.12e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg05861140	chr6:150128134	PCMT1	-0.4	-5.27	-0.33	3.04e-7	Lung cancer;
SARC	cis	rs7786808	0.712	rs2335167	chr7:158213948	A/C	cg01191920	chr7:158217561	PTPRN2	-0.34	-6.01	-0.37	7.26e-9	Obesity-related traits;
SARC	cis	rs7666738	0.830	rs10011009	chr4:98981749	G/A	cg05340658	chr4:99064831	C4orf37	0.64	8.6	0.49	1.18e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs8058578	0.832	rs7500719	chr16:30840877	C/T	cg02466173	chr16:30829666	NA	-0.46	-6.15	-0.37	3.42e-9	Multiple myeloma;
SARC	cis	rs818427	1.000	rs712664	chr5:112223601	A/C	cg07820702	chr5:112228657	REEP5	-0.43	-4.72	-0.3	4e-6	Total body bone mineral density;
SARC	cis	rs1878931	0.507	rs11648783	chr16:3406626	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.56	5.94	0.36	1.05e-8	Body mass index (adult);
SARC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.41	0.52	4.87e-18	Prudent dietary pattern;
SARC	cis	rs7020830	0.898	rs13290794	chr9:37183628	C/T	cg14294708	chr9:37120828	ZCCHC7	1.13	19.87	0.79	4.55e-52	Schizophrenia;
SARC	cis	rs79149102	0.579	rs28394281	chr15:75326754	C/G	cg00629941	chr15:75287862	SCAMP5	-0.72	-5.53	-0.34	8.53e-8	Lung cancer;
SARC	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	12.05	0.62	2.53e-26	Chronic sinus infection;
SARC	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg05165339	chr4:1420672	NA	-0.22	-4.94	-0.31	1.51e-6	Longevity;
SARC	cis	rs131805	1.000	rs3091397	chr22:50957520	C/T	cg12969734	chr22:50962224	SCO2	0.43	5.03	0.31	9.9e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs7044106	0.762	rs4142158	chr9:123410819	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	8.61	0.49	1.09e-15	Hip circumference adjusted for BMI;
SARC	cis	rs9815354	0.812	rs17215883	chr3:41841873	C/T	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs12474201	0.572	rs7596521	chr2:46918665	A/G	cg06386533	chr2:46925753	SOCS5	0.47	5.47	0.34	1.14e-7	Height;
SARC	cis	rs2730245	0.563	rs2709857	chr7:158685257	T/C	cg14689365	chr7:158441557	NCAPG2	0.4	4.78	0.3	3.16e-6	Height;
SARC	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg12463550	chr7:65579703	CRCP	-0.52	-5.56	-0.34	7.34e-8	Aortic root size;
SARC	cis	rs7666738	1.000	rs13116475	chr4:99054843	C/T	cg05340658	chr4:99064831	C4orf37	-0.58	-7.18	-0.43	9.31e-12	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10883723	0.810	rs10883728	chr10:104269301	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-8.3	-0.48	8.3e-15	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs2976388	0.647	rs2585154	chr8:143783485	C/T	cg06565975	chr8:143823917	SLURP1	0.3	5.31	0.33	2.53e-7	Urinary tract infection frequency;
SARC	cis	rs1568889	1.000	rs12790932	chr11:28046189	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	10.22	0.56	1.65e-20	Bipolar disorder;
SARC	cis	rs7582720	1.000	rs72928605	chr2:203832120	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	6.93	0.41	4.15e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs17600642	0.950	rs78001063	chr10:72465321	A/G	cg19779893	chr10:72451501	ADAMTS14	-0.47	-6.96	-0.41	3.52e-11	Bipolar disorder;
SARC	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg03264133	chr6:25882463	NA	0.53	7.02	0.42	2.34e-11	Blood metabolite levels;
SARC	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg25894440	chr7:65020034	NA	-0.72	-5.44	-0.34	1.35e-7	Diabetic kidney disease;
SARC	cis	rs34779708	0.966	rs6481941	chr10:35440141	G/A	cg03585969	chr10:35415529	CREM	0.38	4.81	0.3	2.73e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs763121	0.819	rs3747173	chr22:39069045	A/G	cg06022373	chr22:39101656	GTPBP1	0.86	10.88	0.58	1.41e-22	Menopause (age at onset);
SARC	cis	rs1003719	0.688	rs2835660	chr21:38568882	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-8.88	-0.5	1.88e-16	Eye color traits;
SARC	cis	rs62244186	0.711	rs6778410	chr3:44743993	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.47	5.81	0.36	2.03e-8	Depressive symptoms;
SARC	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs3106136	0.872	rs2059606	chr4:95255278	C/T	cg11021082	chr4:95130006	SMARCAD1	0.42	6.65	0.4	2.03e-10	Capecitabine sensitivity;
SARC	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg24209194	chr3:40518798	ZNF619	0.66	8.11	0.47	2.97e-14	Renal cell carcinoma;
SARC	cis	rs10779751	0.690	rs743577	chr1:11119135	G/A	cg08854313	chr1:11322531	MTOR	0.86	11.93	0.62	6.4e-26	Body mass index;
SARC	cis	rs9457247	0.935	rs9348211	chr6:167375173	G/C	cg23791538	chr6:167370224	RNASET2	0.62	8.55	0.49	1.63e-15	Crohn's disease;
SARC	cis	rs12956009	0.583	rs12965907	chr18:44888455	C/G	cg15049968	chr18:44337910	ST8SIA5	-0.31	-4.72	-0.3	4.11e-6	Educational attainment (years of education);
SARC	cis	rs546131	0.642	rs579926	chr11:34853155	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.43	5.06	0.31	8.61e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs240764	0.555	rs11967951	chr6:101231905	G/A	cg09795085	chr6:101329169	ASCC3	0.45	5.66	0.35	4.42e-8	Neuroticism;
SARC	cis	rs17331151	0.573	rs2276818	chr3:52864635	A/G	cg04865290	chr3:52927548	TMEM110	-0.6	-5.93	-0.36	1.11e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs1355223	0.902	rs10501134	chr11:34749137	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-5.65	-0.35	4.73e-8	Systemic lupus erythematosus and Systemic sclerosis;
SARC	trans	rs561341	0.739	rs8070554	chr17:30216868	A/T	cg20587970	chr11:113659929	NA	0.71	7.11	0.42	1.4e-11	Hip circumference adjusted for BMI;
SARC	cis	rs78487399	0.808	rs79271345	chr2:43746094	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.58	-4.78	-0.3	3.14e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg11235426	chr6:292522	DUSP22	0.62	7.99	0.46	6.08e-14	Menopause (age at onset);
SARC	cis	rs208520	0.802	rs4710314	chr6:66883656	G/A	cg07460842	chr6:66804631	NA	-1.06	-13.6	-0.67	2.2e-31	Exhaled nitric oxide output;
SARC	cis	rs12681366	0.663	rs1561648	chr8:95474437	C/T	cg13257157	chr8:95487014	RAD54B	0.39	4.92	0.31	1.65e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg24549020	chr5:56110836	MAP3K1	0.81	8.4	0.48	4.37e-15	Initial pursuit acceleration;
SARC	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg11764359	chr7:65958608	NA	-0.54	-6.19	-0.38	2.72e-9	Aortic root size;
SARC	cis	rs17376456	0.597	rs6869110	chr5:93355531	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.49	-5.34	-0.33	2.2e-7	Diabetic retinopathy;
SARC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg07308232	chr7:1071921	C7orf50	-0.49	-5.72	-0.35	3.32e-8	Longevity;Endometriosis;
SARC	cis	rs703842	0.963	rs923829	chr12:58174306	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.78	11.47	0.6	1.98e-24	Multiple sclerosis;
SARC	cis	rs10489202	1.000	rs718885	chr1:167954659	A/G	cg24449463	chr1:168025552	DCAF6	-0.64	-7.1	-0.42	1.5e-11	Schizophrenia;
SARC	cis	rs7659604	0.702	rs6815790	chr4:122695385	A/C	cg19671926	chr4:122722719	EXOSC9	-0.5	-5.75	-0.35	2.77e-8	Type 2 diabetes;
SARC	cis	rs832540	0.656	rs6862118	chr5:56106474	G/A	cg22800045	chr5:56110881	MAP3K1	0.41	5.02	0.31	1.02e-6	Coronary artery disease;
SARC	cis	rs72781680	0.848	rs6748727	chr2:24041058	G/A	cg06627628	chr2:24431161	ITSN2	-0.67	-6.31	-0.38	1.39e-9	Lymphocyte counts;
SARC	cis	rs9473924	0.542	rs2857506	chr6:50800308	C/T	cg14470998	chr6:50812995	TFAP2B	0.68	6.19	0.38	2.64e-9	Body mass index;
SARC	cis	rs763121	0.889	rs9607557	chr22:39040279	G/A	cg06022373	chr22:39101656	GTPBP1	0.85	11.21	0.59	1.34e-23	Menopause (age at onset);
SARC	cis	rs9359856	0.564	rs72915903	chr6:90420190	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.58	-4.73	-0.3	3.81e-6	Bipolar disorder;
SARC	cis	rs11874712	1.000	rs8089150	chr18:43674300	A/G	cg25174615	chr18:43684699	ATP5A1;HAUS1	0.4	4.77	0.3	3.31e-6	Migraine - clinic-based;
SARC	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg20203395	chr5:56204925	C5orf35	0.6	5.26	0.33	3.26e-7	Initial pursuit acceleration;
SARC	trans	rs634534	0.562	rs661335	chr11:65754061	G/A	cg17712092	chr4:129076599	LARP1B	0.68	9.19	0.52	2.21e-17	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs3812049	0.826	rs34576922	chr5:127364103	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.88	-9.81	-0.54	3.13e-19	Lymphocyte counts;Red cell distribution width;
SARC	cis	rs6456156	0.711	rs1855025	chr6:167537594	A/G	cg07741184	chr6:167504864	NA	-0.3	-5.71	-0.35	3.49e-8	Primary biliary cholangitis;
SARC	cis	rs6580649	0.941	rs72644842	chr12:48448274	A/G	cg05342945	chr12:48394962	COL2A1	0.56	6.03	0.37	6.35e-9	Lung cancer;
SARC	cis	rs7091068	0.536	rs6583901	chr10:95409998	C/T	cg20715218	chr10:95462985	C10orf4	-0.55	-6.84	-0.41	6.75e-11	Urinary tract infection frequency;
SARC	cis	rs6500602	1.000	rs6500602	chr16:4497451	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.37	6.11	0.37	4.2e-9	Schizophrenia;
SARC	trans	rs7824557	0.602	rs10096194	chr8:11207672	C/G	cg06636001	chr8:8085503	FLJ10661	0.51	6.24	0.38	2.08e-9	Retinal vascular caliber;
SARC	cis	rs8114671	0.836	rs6120778	chr20:33565169	T/C	cg24642439	chr20:33292090	TP53INP2	0.49	5.62	0.35	5.43e-8	Height;
SARC	cis	rs11252926	0.537	rs6560836	chr10:444997	C/T	cg08603382	chr10:743973	NA	0.38	4.9	0.31	1.83e-6	Psychosis in Alzheimer's disease;
SARC	cis	rs2239547	0.522	rs6792578	chr3:53004604	G/A	cg11645453	chr3:52864694	ITIH4	0.35	5.49	0.34	1.05e-7	Schizophrenia;
SARC	cis	rs2730245	0.527	rs924910	chr7:158672272	C/T	cg24397884	chr7:158709396	WDR60	1.17	10.57	0.57	1.39e-21	Height;
SARC	cis	rs8070128	0.583	rs7406982	chr17:17942613	C/T	cg04398451	chr17:18023971	MYO15A	-0.47	-6.58	-0.4	2.99e-10	Total body bone mineral density;
SARC	cis	rs7727544	0.735	rs274559	chr5:131720070	A/G	cg24060327	chr5:131705240	SLC22A5	0.67	8.67	0.49	7.48e-16	Blood metabolite levels;
SARC	cis	rs11711311	1.000	rs9827682	chr3:113450251	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	8.48	0.49	2.62e-15	IgG glycosylation;
SARC	cis	rs607987	0.871	rs4923629	chr11:30295232	C/T	cg06241208	chr11:30344200	C11orf46	0.42	5.03	0.31	9.7e-7	Body mass index;
SARC	cis	rs757081	0.667	rs12577418	chr11:17101554	C/G	cg15432903	chr11:17409602	KCNJ11	-0.37	-4.74	-0.3	3.7e-6	Systolic blood pressure;
SARC	cis	rs9916302	0.904	rs12452509	chr17:37574722	G/A	cg15445000	chr17:37608096	MED1	0.42	5.02	0.31	1.02e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs6963495	0.818	rs711430	chr7:105167969	A/G	cg19920283	chr7:105172520	RINT1	0.67	6.51	0.39	4.49e-10	Bipolar disorder (body mass index interaction);
SARC	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg24633833	chr3:10029261	TMEM111	0.52	5.25	0.33	3.43e-7	Alzheimer's disease;
SARC	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg05313129	chr8:58192883	C8orf71	-0.57	-6.42	-0.39	7.72e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6429082	0.818	rs291381	chr1:235641924	A/G	cg26050004	chr1:235667680	B3GALNT2	0.67	8.33	0.48	6.82e-15	Adiposity;
SARC	cis	rs7247513	0.639	rs12984441	chr19:12760287	A/C	cg06417478	chr19:12876846	HOOK2	0.39	4.86	0.3	2.14e-6	Bipolar disorder;
SARC	cis	rs7300001	0.596	rs11064924	chr12:110510301	G/T	cg08946844	chr12:110511112	NA	0.63	5.02	0.31	1.03e-6	Headache;
SARC	cis	rs2439831	0.867	rs28729853	chr15:43673680	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	8.28	0.48	9.93e-15	Lung cancer in ever smokers;
SARC	cis	rs8067354	0.645	rs2173119	chr17:57859705	C/T	cg13753209	chr17:57696993	CLTC	0.62	6.25	0.38	1.98e-9	Hemoglobin concentration;
SARC	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7216064	0.531	rs6504573	chr17:66015963	C/T	cg12091567	chr17:66097778	LOC651250	-0.75	-8.83	-0.5	2.61e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs6964587	1.000	rs2237568	chr7:91622676	G/A	cg17063962	chr7:91808500	NA	0.95	15.95	0.72	3.15e-39	Breast cancer;
SARC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.97	12.03	0.62	3.02e-26	Platelet count;
SARC	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg09517075	chr8:22133004	PIWIL2	0.34	4.72	0.3	4.12e-6	Hypertriglyceridemia;
SARC	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg08280861	chr8:58055591	NA	0.56	4.81	0.3	2.66e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs8072100	0.790	rs3760371	chr17:45695914	T/C	cg08085267	chr17:45401833	C17orf57	0.42	4.99	0.31	1.17e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs8064024	0.604	rs1049212	chr16:4932929	A/G	cg08329684	chr16:4932620	PPL	-0.43	-6.82	-0.41	7.85e-11	Cancer;
SARC	trans	rs2018683	0.691	rs4722881	chr7:29001560	A/G	cg19402173	chr7:128379420	CALU	0.6	7.63	0.45	5.88e-13	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs4720575	1.000	rs917108	chr7:47088047	A/G	cg00036614	chr7:47093842	NA	-0.43	-6.06	-0.37	5.56e-9	Angiotensin-converting enzyme inhibitor intolerance;
SARC	cis	rs2120019	0.567	rs12385940	chr15:75168162	C/T	cg00629941	chr15:75287862	SCAMP5	-0.59	-5.47	-0.34	1.14e-7	Blood trace element (Zn levels);
SARC	cis	rs13256369	1.000	rs10103769	chr8:8573036	G/T	cg18904891	chr8:8559673	CLDN23	0.5	5.77	0.35	2.49e-8	Obesity-related traits;
SARC	cis	rs3820928	0.874	rs4675134	chr2:227843489	C/T	cg11843606	chr2:227700838	RHBDD1	-0.57	-7.25	-0.43	6.13e-12	Pulmonary function;
SARC	cis	rs12421382	0.659	rs57978015	chr11:109385473	T/C	cg27471124	chr11:109292789	C11orf87	0.38	5.19	0.32	4.65e-7	Schizophrenia;
SARC	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg17221315	chr6:27791827	HIST1H4J	-0.5	-5.18	-0.32	4.76e-7	Parkinson's disease;
SARC	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg20119798	chr7:94954144	PON1	-0.37	-4.9	-0.31	1.79e-6	Paraoxonase activity;
SARC	cis	rs787274	1.000	rs10124260	chr9:115559341	T/C	cg13803584	chr9:115635662	SNX30	-0.83	-5.01	-0.31	1.08e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs11098499	0.863	rs1010740	chr4:120463409	C/T	cg24375607	chr4:120327624	NA	-0.42	-4.97	-0.31	1.32e-6	Corneal astigmatism;
SARC	cis	rs1348850	0.668	rs13034886	chr2:178493301	G/T	cg23306229	chr2:178417860	TTC30B	0.63	6.82	0.41	7.8e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7179456	0.545	rs2250583	chr15:59050382	C/T	cg05156742	chr15:59063176	FAM63B	-0.68	-8.84	-0.5	2.42e-16	Asperger disorder;
SARC	cis	rs2239815	0.515	rs6005917	chr22:29233486	A/G	cg02153584	chr22:29168773	CCDC117	0.66	7.56	0.44	9e-13	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
SARC	cis	rs6963495	0.818	rs1355614	chr7:105179176	A/G	cg13798780	chr7:105162888	PUS7	0.48	4.9	0.31	1.77e-6	Bipolar disorder (body mass index interaction);
SARC	cis	rs3768617	1.000	rs3820697	chr1:183100226	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.58	7.82	0.46	1.8e-13	Fuchs's corneal dystrophy;
SARC	cis	rs2075671	0.903	rs11520986	chr7:100276994	A/G	cg03098644	chr7:100410630	EPHB4	0.45	4.91	0.31	1.75e-6	Other erythrocyte phenotypes;
SARC	cis	rs16937	0.618	rs6659069	chr1:205182031	A/G	cg21643547	chr1:205240462	TMCC2	-0.41	-5.04	-0.31	9.2e-7	Schizophrenia;
SARC	cis	rs735539	0.521	rs716480	chr13:21418094	T/G	cg16922012	chr13:21400325	XPO4	-0.44	-5.99	-0.37	7.71e-9	Dental caries;
SARC	cis	rs9733	0.715	rs7534124	chr1:150739073	C/T	cg13175981	chr1:150552382	MCL1	0.61	8.2	0.47	1.66e-14	Tonsillectomy;
SARC	cis	rs9513627	1.000	rs7321269	chr13:100126271	C/T	cg25919922	chr13:100150906	NA	-0.66	-5.0	-0.31	1.14e-6	Obesity-related traits;
SARC	cis	rs2153535	0.580	rs5001322	chr6:8451608	A/G	cg23788917	chr6:8435910	SLC35B3	0.64	8.54	0.49	1.8e-15	Motion sickness;
SARC	cis	rs11155671	0.530	rs7757984	chr6:150208651	A/G	cg09699651	chr6:150184138	LRP11	0.51	6.56	0.39	3.53e-10	Testicular germ cell tumor;
SARC	cis	rs7264396	0.676	rs6058383	chr20:34556005	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-6.92	-0.41	4.41e-11	Total cholesterol levels;
SARC	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg05872129	chr22:39784769	NA	-0.38	-5.4	-0.33	1.68e-7	Intelligence (multi-trait analysis);
SARC	cis	rs5758511	0.680	rs5758651	chr22:42609148	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.46	6.97	0.42	3.2e-11	Birth weight;
SARC	cis	rs7296418	0.699	rs11057219	chr12:123750073	T/C	cg05973401	chr12:123451056	ABCB9	0.48	5.55	0.34	7.8e-8	Platelet count;
SARC	cis	rs8031584	0.578	rs1088473	chr15:31139298	A/G	cg14298792	chr15:30685198	CHRFAM7A	0.48	5.48	0.34	1.12e-7	Huntington's disease progression;
SARC	cis	rs2933343	0.951	rs789217	chr3:128593201	C/T	cg25356066	chr3:128598488	ACAD9	0.58	6.78	0.41	9.73e-11	IgG glycosylation;
SARC	trans	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg00938859	chr5:1591904	SDHAP3	0.74	7.18	0.43	9.17e-12	Breast cancer;
SARC	cis	rs6580649	0.941	rs1635529	chr12:48395102	T/G	cg24011408	chr12:48396354	COL2A1	0.61	6.78	0.41	9.84e-11	Lung cancer;
SARC	cis	rs920590	0.684	rs59259846	chr8:19669468	C/G	cg17834443	chr8:19674713	INTS10	0.63	7.46	0.44	1.73e-12	Acute lymphoblastic leukemia (childhood);
SARC	trans	rs61931739	0.500	rs7306435	chr12:34482933	A/G	cg13010199	chr12:38710504	ALG10B	-0.82	-11.58	-0.6	8.59e-25	Morning vs. evening chronotype;
SARC	cis	rs7833790	0.929	rs28464834	chr8:82797356	A/T	cg27398817	chr8:82754497	SNX16	0.5	5.61	0.35	5.68e-8	Diastolic blood pressure;
SARC	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg18252515	chr7:66147081	NA	-1.3	-11.5	-0.6	1.59e-24	Diabetic kidney disease;
SARC	cis	rs523522	0.962	rs7471	chr12:120941215	T/C	cg12219531	chr12:120966889	COQ5	0.83	11.18	0.59	1.61e-23	High light scatter reticulocyte count;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg11754259	chr11:130184488	ZBTB44	-0.85	-7.4	-0.44	2.5e-12	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7829975	0.511	rs2948286	chr8:8130160	A/G	cg15556689	chr8:8085844	FLJ10661	0.57	7.3	0.43	4.62e-12	Mood instability;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg21393986	chr3:196159244	UBXN7	-0.79	-6.47	-0.39	5.76e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs501120	1.000	rs1746048	chr10:44775824	A/G	cg09554077	chr10:44749378	NA	-0.37	-4.84	-0.3	2.39e-6	Coronary artery disease;Coronary heart disease;
SARC	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg02931644	chr1:25747376	RHCE	-0.47	-8.0	-0.46	5.84e-14	Erythrocyte sedimentation rate;
SARC	cis	rs965604	1.000	rs965604	chr15:78789223	G/A	cg24631222	chr15:78858424	CHRNA5	-0.45	-5.85	-0.36	1.65e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs3126085	0.935	rs3120659	chr1:152293202	A/G	cg03465714	chr1:152285911	FLG	0.48	5.57	0.34	6.86e-8	Atopic dermatitis;
SARC	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg08280861	chr8:58055591	NA	-0.66	-5.69	-0.35	3.8e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs8067545	0.685	rs4479309	chr17:19971583	C/T	cg13482628	chr17:19912719	NA	0.54	7.14	0.42	1.17e-11	Schizophrenia;
SARC	cis	rs477692	0.673	rs579325	chr10:131363688	C/T	cg05714579	chr10:131428358	MGMT	0.56	7.31	0.43	4.2e-12	Response to temozolomide;
SARC	cis	rs72781680	1.000	rs11553491	chr2:24225901	G/C	cg08917208	chr2:24149416	ATAD2B	0.85	8.26	0.48	1.06e-14	Lymphocyte counts;
SARC	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.45	5.06	0.31	8.38e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs12711979	0.509	rs10195596	chr2:3824222	T/G	cg17052675	chr2:3827356	NA	-0.52	-7.58	-0.44	8e-13	Itch intensity from mosquito bite adjusted by bite size;
SARC	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg05313129	chr8:58192883	C8orf71	-0.51	-4.85	-0.3	2.27e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs9831754	0.704	rs1512492	chr3:78471190	A/C	cg06138941	chr3:78371609	NA	-0.56	-6.75	-0.4	1.19e-10	Calcium levels;
SARC	cis	rs11122272	0.735	rs2749706	chr1:231527170	C/A	cg06096015	chr1:231504339	EGLN1	0.39	5.83	0.36	1.88e-8	Hemoglobin concentration;
SARC	cis	rs79149102	0.579	rs12593476	chr15:75282092	A/C	cg00629941	chr15:75287862	SCAMP5	-0.7	-5.4	-0.33	1.61e-7	Lung cancer;
SARC	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg07636037	chr3:49044803	WDR6	1.01	17.77	0.76	3.21e-45	Parkinson's disease;
SARC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.42	5.18	0.32	4.73e-7	Bipolar disorder;
SARC	cis	rs2070997	0.667	rs13295907	chr9:133718242	G/T	cg11464064	chr9:133710261	ABL1	0.62	5.99	0.37	7.99e-9	Response to amphetamines;
SARC	cis	rs7264396	0.623	rs2425127	chr20:34332037	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	5.32	0.33	2.49e-7	Total cholesterol levels;
SARC	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg18876405	chr7:65276391	NA	-0.46	-5.04	-0.31	9.38e-7	Aortic root size;
SARC	cis	rs508618	0.666	rs480902	chr1:231531627	C/T	cg06096015	chr1:231504339	EGLN1	-0.38	-4.84	-0.3	2.35e-6	Red blood cell count;
SARC	cis	rs1355223	0.583	rs2915238	chr11:34884405	C/A	cg11058730	chr11:34937778	PDHX;APIP	0.8	11.59	0.6	7.94e-25	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs9790314	1.000	rs459697	chr3:161093420	G/A	cg04691961	chr3:161091175	C3orf57	-0.81	-12.0	-0.62	3.87e-26	Morning vs. evening chronotype;
SARC	cis	rs929354	0.742	rs10251112	chr7:156963524	A/G	cg05182265	chr7:156933206	UBE3C	-0.34	-5.17	-0.32	5.16e-7	Body mass index;
SARC	cis	rs12142240	0.698	rs1984490	chr1:46858734	C/T	cg00530320	chr1:46809349	NSUN4	-0.57	-6.9	-0.41	4.96e-11	Menopause (age at onset);
SARC	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg01276201	chr10:134613136	NA	0.31	5.34	0.33	2.25e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs9398803	0.713	rs9375447	chr6:126874091	A/G	cg19875578	chr6:126661172	C6orf173	0.65	8.99	0.51	8.82e-17	Male-pattern baldness;
SARC	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg25427524	chr10:38739819	LOC399744	-0.63	-10.05	-0.55	5.66e-20	Extrinsic epigenetic age acceleration;
SARC	cis	rs10504229	0.679	rs72649131	chr8:58054288	G/T	cg08219700	chr8:58056026	NA	0.6	6.05	0.37	5.66e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs12421382	0.636	rs1439519	chr11:109378438	A/G	cg27471124	chr11:109292789	C11orf87	0.36	5.04	0.31	9.21e-7	Schizophrenia;
SARC	cis	rs10504229	0.679	rs4737454	chr8:58033965	A/T	cg08219700	chr8:58056026	NA	0.6	6.12	0.37	3.98e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7772486	0.534	rs34541797	chr6:146205304	A/G	cg23711669	chr6:146136114	FBXO30	0.85	12.23	0.63	6.79e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7043114	0.544	rs7852510	chr9:95316359	T/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.5	-6.2	-0.38	2.54e-9	Height;
SARC	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.44	5.44	0.34	1.37e-7	Tonsillectomy;
SARC	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg11598736	chr3:195384522	SDHAP2	0.61	6.62	0.4	2.41e-10	Lung disease severity in cystic fibrosis;
SARC	cis	rs57920188	0.584	rs12080516	chr1:4089613	C/T	cg20703997	chr1:4087676	NA	0.52	5.77	0.35	2.47e-8	Interleukin-17 levels;
SARC	cis	rs1468333	1.000	rs2967782	chr5:137529682	C/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.83	11.96	0.62	5.17e-26	Resting heart rate;
SARC	cis	rs763121	0.853	rs4821810	chr22:39072098	C/G	cg06022373	chr22:39101656	GTPBP1	0.91	12.78	0.64	1.05e-28	Menopause (age at onset);
SARC	cis	rs76419734	0.510	rs2193856	chr4:106742958	A/C	cg24545054	chr4:106630052	GSTCD;INTS12	-0.76	-7.73	-0.45	3.25e-13	Post bronchodilator FEV1;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg05393777	chr14:45369479	C14orf28	0.53	6.92	0.41	4.21e-11	Thyroid stimulating hormone;
SARC	cis	rs28374715	0.578	rs7169543	chr15:41620405	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.17	-19.16	-0.78	8.85e-50	Ulcerative colitis;
SARC	trans	rs4883201	0.561	rs1805725	chr12:9097933	C/A	cg24352934	chr17:1053717	ABR	0.57	6.58	0.4	3.15e-10	Cholesterol, total;Total cholesterol levels;
SARC	cis	rs7246657	0.765	rs10402455	chr19:37728707	G/A	cg14683738	chr19:37701593	ZNF585B	0.59	4.92	0.31	1.66e-6	Coronary artery calcification;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg18046087	chr11:66035276	KLC2;RAB1B	0.5	6.24	0.38	2.04e-9	Breast cancer;
SARC	cis	rs854765	0.583	rs7207043	chr17:17819188	A/G	cg05444541	chr17:17804740	TOM1L2	-0.3	-4.98	-0.31	1.21e-6	Total body bone mineral density;
SARC	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg11317459	chr13:21872234	NA	0.45	5.19	0.32	4.57e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs1355223	0.872	rs1258466	chr11:34730066	T/A	cg18508148	chr11:34937573	PDHX;APIP	-0.38	-4.82	-0.3	2.64e-6	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs123509	0.874	rs339683	chr3:42788511	G/T	cg12982090	chr3:42733453	KBTBD5	0.53	6.44	0.39	6.81e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg25072359	chr17:41440525	NA	0.53	6.28	0.38	1.61e-9	Menopause (age at onset);
SARC	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg04756594	chr16:24857601	SLC5A11	0.42	5.77	0.35	2.55e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2075371	1.000	rs7486	chr7:133975183	A/G	cg11752832	chr7:134001865	SLC35B4	0.57	7.45	0.44	1.81e-12	Mean platelet volume;
SARC	cis	rs73198271	1.000	rs11775476	chr8:8607869	T/C	cg06636001	chr8:8085503	FLJ10661	-0.48	-4.72	-0.3	4.04e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg05623727	chr3:50126028	RBM5	0.33	4.91	0.31	1.69e-6	Intelligence (multi-trait analysis);
SARC	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg25036284	chr2:26402008	FAM59B	0.46	5.7	0.35	3.59e-8	Gut microbiome composition (summer);
SARC	cis	rs72945132	0.882	rs7123602	chr11:70181489	C/T	cg00319359	chr11:70116639	PPFIA1	0.7	6.63	0.4	2.36e-10	Coronary artery disease;
SARC	cis	rs854765	0.547	rs4365348	chr17:17912548	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.45	5.82	0.36	1.9e-8	Total body bone mineral density;
SARC	trans	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-10.55	-0.57	1.63e-21	Intelligence (multi-trait analysis);
SARC	cis	rs240764	0.817	rs12207086	chr6:101150463	G/A	cg09795085	chr6:101329169	ASCC3	-0.47	-6.09	-0.37	4.74e-9	Neuroticism;
SARC	cis	rs9291683	0.530	rs13115193	chr4:9982191	C/T	cg11266682	chr4:10021025	SLC2A9	0.39	7.02	0.42	2.35e-11	Bone mineral density;
SARC	cis	rs2999052	1.000	rs2811476	chr3:127898501	A/C	cg19755928	chr3:128723491	CCDC48	0.39	4.79	0.3	2.93e-6	Hypospadias;
SARC	cis	rs2075371	0.611	rs62462979	chr7:134019379	G/T	cg11752832	chr7:134001865	SLC35B4	0.52	6.54	0.39	3.84e-10	Mean platelet volume;
SARC	cis	rs6141769	0.518	rs6057620	chr20:31265165	A/G	cg17884169	chr20:31446444	EFCAB8	-0.46	-4.86	-0.3	2.16e-6	Subjective well-being;
SARC	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg26119090	chr2:26468346	HADHA;HADHB	0.94	13.09	0.65	1.01e-29	Gut microbiome composition (summer);
SARC	cis	rs7615952	0.673	rs9841194	chr3:125635739	C/T	cg05084668	chr3:125655381	ALG1L	-0.92	-8.62	-0.49	1.04e-15	Blood pressure (smoking interaction);
SARC	cis	rs9807989	0.811	rs11689730	chr2:102969984	C/A	cg09003973	chr2:102972529	NA	0.41	5.57	0.34	7.03e-8	Asthma;
SARC	trans	rs7927370	1.000	rs61894225	chr11:55344928	A/C	cg07162727	chr16:4848039	ROGDI	0.84	6.28	0.38	1.67e-9	Systemic lupus erythematosus;
SARC	cis	rs8028182	0.636	rs4462560	chr15:75647964	G/C	cg20655648	chr15:75932815	IMP3	-0.65	-7.57	-0.44	8.47e-13	Sudden cardiac arrest;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg18022606	chr11:64944740	NA	0.52	6.87	0.41	5.92e-11	Breast cancer;
SARC	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg11890956	chr21:40555474	PSMG1	-0.68	-9.01	-0.51	7.44e-17	Menarche (age at onset);
SARC	cis	rs6963495	0.818	rs116845562	chr7:105217038	T/C	cg19920283	chr7:105172520	RINT1	0.67	5.72	0.35	3.33e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg15448220	chr1:150897856	SETDB1	0.46	6.02	0.37	6.66e-9	Tonsillectomy;
SARC	cis	rs765787	0.530	rs12913123	chr15:45516425	C/T	cg24006582	chr15:45444508	DUOX1	0.44	5.49	0.34	1.04e-7	Uric acid levels;
SARC	cis	rs7666738	0.830	rs28416660	chr4:98899525	C/G	cg05340658	chr4:99064831	C4orf37	0.64	8.46	0.48	3.06e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6582630	0.519	rs11181998	chr12:38439970	C/A	cg13010199	chr12:38710504	ALG10B	0.75	10.24	0.56	1.42e-20	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg03709012	chr19:19516395	GATAD2A	1.01	17.45	0.75	3.42e-44	Tonsillectomy;
SARC	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg21016266	chr12:122356598	WDR66	0.31	4.74	0.3	3.65e-6	Mean corpuscular volume;
SARC	trans	rs1814175	0.702	rs4881644	chr11:49786367	C/T	cg15704280	chr7:45808275	SEPT13	-0.96	-17.96	-0.76	7.69e-46	Height;
SARC	cis	rs10644111	1	rs10644111	chr7:91652178	A/AAAC	cg17063962	chr7:91808500	NA	0.96	16.55	0.74	3.39e-41	Breast cancer;
SARC	cis	rs7633857	0.532	rs9873705	chr3:160768818	A/T	cg03342759	chr3:160939853	NMD3	-0.58	-7.19	-0.43	8.93e-12	Educational attainment (years of education);
SARC	cis	rs113835537	0.559	rs74933537	chr11:66274958	A/C	cg24851651	chr11:66362959	CCS	0.38	4.89	0.3	1.91e-6	Airway imaging phenotypes;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00146096	chr11:22647309	FANCF	-0.5	-6.28	-0.38	1.6e-9	Smoking initiation;
SARC	cis	rs713477	1.000	rs7148481	chr14:55909267	G/A	cg13175173	chr14:55914753	NA	-0.3	-4.75	-0.3	3.63e-6	Pediatric bone mineral content (femoral neck);
SARC	cis	rs6704768	0.545	rs5004510	chr2:233679275	A/C	cg16596103	chr2:233749413	NGEF	0.33	4.96	0.31	1.37e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs943466	1.000	rs943462	chr6:33769578	G/A	cg04676172	chr6:33757040	LEMD2	0.47	4.86	0.3	2.18e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
SARC	cis	rs2486288	0.656	rs8024620	chr15:45574329	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.55	-6.86	-0.41	5.98e-11	Glomerular filtration rate;
SARC	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg25072359	chr17:41440525	NA	0.48	5.55	0.34	7.82e-8	Menopause (age at onset);
SARC	cis	rs1322639	0.657	rs12203887	chr6:169572252	C/T	cg03254818	chr6:169586852	NA	0.72	7.21	0.43	7.81e-12	Pulse pressure;
SARC	cis	rs10463554	0.963	rs10463555	chr5:102319037	A/C	cg23492399	chr5:102201601	PAM	-0.49	-6.11	-0.37	4.07e-9	Parkinson's disease;
SARC	cis	rs796364	0.951	rs59695400	chr2:201021325	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.51	-5.06	-0.31	8.7e-7	Schizophrenia;
SARC	cis	rs73206853	0.841	rs56065235	chr12:111016287	C/T	cg10860002	chr12:110842031	ANAPC7	0.63	5.16	0.32	5.39e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg11764359	chr7:65958608	NA	-0.55	-6.44	-0.39	6.9e-10	Aortic root size;
SARC	cis	rs6484504	0.512	rs2774402	chr11:31312897	G/C	cg26647111	chr11:31128758	NA	0.39	5.0	0.31	1.1e-6	Red blood cell count;
SARC	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-9.16	-0.51	2.76e-17	Alzheimer's disease;
SARC	cis	rs7659604	0.502	rs13108419	chr4:122687238	A/G	cg19671926	chr4:122722719	EXOSC9	0.64	8.13	0.47	2.51e-14	Type 2 diabetes;
SARC	cis	rs1784581	0.674	rs1789989	chr6:162408138	C/T	cg17173639	chr6:162384350	PARK2	0.52	6.81	0.41	8.31e-11	Itch intensity from mosquito bite;
SARC	cis	rs854765	0.693	rs4924823	chr17:17764502	A/G	cg05444541	chr17:17804740	TOM1L2	0.31	5.16	0.32	5.27e-7	Total body bone mineral density;
SARC	cis	rs16976116	0.901	rs62020114	chr15:55501116	T/C	cg17854078	chr15:55489399	RSL24D1	0.66	6.53	0.39	4.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs11764590	0.694	rs6972969	chr7:2099331	A/G	cg21782813	chr7:2030301	MAD1L1	-0.32	-4.9	-0.31	1.76e-6	Neuroticism;
SARC	cis	rs2153535	0.505	rs1737583	chr6:8536812	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	8.3	0.48	8.69e-15	Motion sickness;
SARC	cis	rs11690935	0.921	rs3770445	chr2:172708919	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.97	-14.66	-0.69	6.56e-35	Schizophrenia;
SARC	cis	rs7223966	1.000	rs11658175	chr17:61923838	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.46	4.89	0.31	1.88e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7296418	0.663	rs11057276	chr12:123820397	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.36	4.9	0.31	1.79e-6	Platelet count;
SARC	cis	rs1008375	0.898	rs4698620	chr4:17587361	C/T	cg02297831	chr4:17616191	MED28	0.49	6.22	0.38	2.31e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs883565	0.569	rs7637036	chr3:38997778	C/T	cg26331595	chr3:39149181	GORASP1;TTC21A	0.44	5.12	0.32	6.25e-7	Handedness;
SARC	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg06138931	chr13:21896616	NA	0.47	6.46	0.39	6.07e-10	White matter hyperintensity burden;
SARC	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg18252515	chr7:66147081	NA	-0.47	-5.09	-0.32	7.32e-7	Aortic root size;
SARC	cis	rs17401966	0.838	rs4529713	chr1:10307295	A/G	cg15208524	chr1:10270712	KIF1B	0.45	5.32	0.33	2.46e-7	Hepatocellular carcinoma;
SARC	cis	rs11574514	0.661	rs9925393	chr16:67780829	C/T	cg01866162	chr16:67596514	CTCF	0.77	5.03	0.31	9.81e-7	Crohn's disease;
SARC	cis	rs35110281	0.744	rs230644	chr21:44917183	C/T	cg21573476	chr21:45109991	RRP1B	0.45	6.56	0.39	3.44e-10	Mean corpuscular volume;
SARC	cis	rs739401	0.572	rs389128	chr11:3083873	G/T	cg08508325	chr11:3079039	CARS	-0.29	-7.04	-0.42	2.09e-11	Longevity;
SARC	cis	rs2916247	0.788	rs7004846	chr8:93127056	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.51	-5.48	-0.34	1.08e-7	Intelligence (multi-trait analysis);
SARC	cis	rs4253772	0.550	rs6008600	chr22:46704676	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.62	5.12	0.32	6.49e-7	LDL cholesterol;Cholesterol, total;
SARC	cis	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg05623727	chr3:50126028	RBM5	-0.37	-5.49	-0.34	1.05e-7	Body mass index;
SARC	cis	rs9640161	0.830	rs17173682	chr7:150059602	A/G	cg17279839	chr7:150038598	RARRES2	0.35	5.13	0.32	6.04e-7	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs6570726	0.791	rs4896820	chr6:145894957	T/C	cg05347473	chr6:146136440	FBXO30	0.51	7.09	0.42	1.56e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs17376456	1.000	rs56046246	chr5:93531545	T/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.61	5.23	0.32	3.75e-7	Diabetic retinopathy;
SARC	cis	rs9420	0.961	rs12146541	chr11:57508678	G/C	cg23127183	chr11:57508653	C11orf31	-0.57	-6.63	-0.4	2.25e-10	Schizophrenia;
SARC	cis	rs11770686	0.902	rs2023891	chr7:75322549	G/T	cg17787366	chr7:75369077	HIP1	-0.43	-5.33	-0.33	2.32e-7	Essential tremor;
SARC	cis	rs6504663	0.596	rs7208018	chr17:48557863	C/T	cg03611598	chr17:48586076	MYCBPAP	-0.51	-5.76	-0.35	2.65e-8	Visceral fat;
SARC	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg09455208	chr3:40491958	NA	-0.39	-5.56	-0.34	7.22e-8	Renal cell carcinoma;
SARC	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg08280861	chr8:58055591	NA	0.59	5.22	0.32	4.02e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9902453	0.904	rs4567782	chr17:28268800	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	6.94	0.41	3.77e-11	Coffee consumption (cups per day);
SARC	cis	rs10463554	0.963	rs1595553	chr5:102378868	A/C	cg23492399	chr5:102201601	PAM	-0.51	-5.65	-0.35	4.78e-8	Parkinson's disease;
SARC	cis	rs1003719	0.708	rs3787788	chr21:38502804	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-9.12	-0.51	3.5e-17	Eye color traits;
SARC	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	11.31	0.6	6.28e-24	Alzheimer's disease;
SARC	cis	rs929354	1.000	rs8101	chr7:157061474	A/G	cg05182265	chr7:156933206	UBE3C	0.31	4.74	0.3	3.66e-6	Body mass index;
SARC	cis	rs4295623	0.531	rs2898295	chr8:11595969	C/T	cg00262122	chr8:11665843	FDFT1	-0.41	-4.92	-0.31	1.61e-6	Morning vs. evening chronotype;
SARC	cis	rs918629	0.724	rs10515232	chr5:95310985	A/G	cg16656078	chr5:95278638	ELL2	0.69	7.67	0.45	4.78e-13	IgG glycosylation;
SARC	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg24675658	chr1:53192096	ZYG11B	0.78	11.25	0.59	9.77e-24	Monocyte count;
SARC	cis	rs13191362	0.872	rs73020362	chr6:163005737	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.57	5.38	0.33	1.85e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg24549020	chr5:56110836	MAP3K1	0.81	8.51	0.49	2.11e-15	Initial pursuit acceleration;
SARC	cis	rs11098499	0.954	rs6849171	chr4:120409549	G/A	cg09307838	chr4:120376055	NA	0.94	13.24	0.66	3.2e-30	Corneal astigmatism;
SARC	cis	rs9916302	0.904	rs2338800	chr17:37498149	C/G	cg07936489	chr17:37558343	FBXL20	0.69	9.17	0.52	2.51e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs10464366	0.746	rs34792397	chr7:39146331	G/A	cg18850127	chr7:39170497	POU6F2	0.43	5.43	0.34	1.39e-7	IgG glycosylation;
SARC	cis	rs9788682	1.000	rs61204066	chr15:78815298	G/A	cg17108064	chr15:78857060	CHRNA5	-0.3	-4.72	-0.3	4.15e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs1865760	1.000	rs6910174	chr6:25904414	C/T	cg17691542	chr6:26056736	HIST1H1C	0.57	7.05	0.42	1.98e-11	Height;
SARC	cis	rs734999	0.549	rs2764840	chr1:2529437	C/T	cg18854424	chr1:2615690	NA	-0.32	-5.11	-0.32	6.76e-7	Ulcerative colitis;
SARC	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg12042659	chr19:58951599	ZNF132	0.43	5.62	0.35	5.47e-8	Uric acid clearance;
SARC	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg13175981	chr1:150552382	MCL1	-0.48	-5.93	-0.36	1.09e-8	Tonsillectomy;
SARC	cis	rs9911578	0.967	rs3826353	chr17:57075299	C/T	cg12560992	chr17:57184187	TRIM37	0.86	12.14	0.62	1.33e-26	Intelligence (multi-trait analysis);
SARC	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	20.77	0.81	6.22e-55	Chronic sinus infection;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg00475194	chr2:190690877	PMS1	0.46	6.4	0.39	8.45e-10	Thyroid stimulating hormone;
SARC	cis	rs4141404	0.757	rs5749272	chr22:31830351	C/T	cg00478049	chr22:31556069	RNF185	0.38	5.0	0.31	1.14e-6	Paclitaxel-induced neuropathy;
SARC	cis	rs10504229	0.679	rs16921687	chr8:58053514	T/C	cg08219700	chr8:58056026	NA	0.59	5.98	0.36	8.5e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2882667	0.858	rs6882112	chr5:138413735	C/T	cg04439458	chr5:138467593	SIL1	0.28	4.85	0.3	2.28e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs7647973	0.667	rs6446286	chr3:49681704	A/G	cg13072238	chr3:49761600	GMPPB	-0.58	-5.82	-0.36	1.9e-8	Menarche (age at onset);
SARC	cis	rs9303280	0.773	rs4795397	chr17:38023745	A/G	cg20243544	chr17:37824526	PNMT	0.43	5.65	0.35	4.6e-8	Self-reported allergy;
SARC	cis	rs911555	0.692	rs7145753	chr14:103866100	G/A	cg12935359	chr14:103987150	CKB	0.4	5.49	0.34	1.06e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7551222	0.749	rs11240764	chr1:204569376	A/G	cg20240347	chr1:204465584	NA	-0.29	-5.18	-0.32	4.91e-7	Schizophrenia;
SARC	cis	rs10089	0.953	rs7713860	chr5:127428789	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.85	10.44	0.56	3.42e-21	Ileal carcinoids;
SARC	cis	rs7949030	0.596	rs11231138	chr11:62316195	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.4	5.84	0.36	1.74e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs2075371	1.000	rs2598292	chr7:133988584	C/G	cg20476274	chr7:133979776	SLC35B4	0.62	8.41	0.48	4.18e-15	Mean platelet volume;
SARC	cis	rs7666738	0.546	rs34159897	chr4:98787367	T/C	cg05340658	chr4:99064831	C4orf37	0.59	7.17	0.43	9.77e-12	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6700896	0.931	rs4420065	chr1:66161461	T/C	cg04111102	chr1:66153794	NA	-0.35	-5.32	-0.33	2.48e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg24675658	chr1:53192096	ZYG11B	0.57	8.08	0.47	3.54e-14	Monocyte count;
SARC	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg08280861	chr8:58055591	NA	0.61	5.81	0.36	2.02e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2997447	0.761	rs2802312	chr1:26430822	T/C	cg19633962	chr1:26362018	EXTL1	-0.6	-5.23	-0.32	3.73e-7	QRS complex (12-leadsum);
SARC	cis	rs4481887	0.927	rs9651176	chr1:248447343	A/G	cg01631408	chr1:248437212	OR2T33	-0.45	-5.74	-0.35	2.89e-8	Common traits (Other);
SARC	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg12311346	chr5:56204834	C5orf35	-0.57	-5.82	-0.36	1.96e-8	Initial pursuit acceleration;
SARC	cis	rs6582630	0.537	rs12823925	chr12:38409323	C/T	cg26384229	chr12:38710491	ALG10B	0.83	11.99	0.62	3.98e-26	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.58	7.71	0.45	3.71e-13	Lymphocyte counts;
SARC	cis	rs6964587	1.000	rs6465347	chr7:91693837	A/G	cg17063962	chr7:91808500	NA	0.96	16.21	0.73	4.33e-40	Breast cancer;
SARC	trans	rs9354308	0.899	rs2814153	chr6:66557611	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.56	6.44	0.39	6.89e-10	Metabolite levels;
SARC	cis	rs1865760	0.566	rs1971509	chr6:26085777	T/C	cg10373733	chr6:25993375	NA	0.45	5.43	0.34	1.4e-7	Height;
SARC	cis	rs80282103	0.867	rs11819178	chr10:1098417	A/G	cg08668510	chr10:1095578	IDI1	0.72	4.76	0.3	3.37e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs7223966	1.000	rs112143304	chr17:61822401	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	7.09	0.42	1.55e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg05332525	chr7:65337924	VKORC1L1	0.43	4.86	0.3	2.15e-6	Calcium levels;
SARC	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg03033257	chr22:50311977	ALG12;CRELD2	0.58	5.79	0.35	2.3e-8	Schizophrenia;
SARC	cis	rs761746	0.739	rs5753691	chr22:31952045	A/G	cg15162869	chr22:32027605	PISD	-0.44	-5.53	-0.34	8.45e-8	Intelligence;
SARC	cis	rs4742903	0.509	rs10991163	chr9:106967120	T/C	cg14250997	chr9:106856677	SMC2	0.39	4.8	0.3	2.77e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs2075371	1.000	rs1862047	chr7:133978078	G/C	cg11752832	chr7:134001865	SLC35B4	0.57	7.45	0.44	1.81e-12	Mean platelet volume;
SARC	cis	rs473651	0.935	rs559579	chr2:239339501	G/C	cg00800569	chr2:239229395	TRAF3IP1	0.64	6.84	0.41	6.89e-11	Multiple system atrophy;
SARC	cis	rs9815354	0.812	rs57162396	chr3:41896031	G/A	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2421770	0.530	rs7945809	chr11:35369253	G/A	cg13971030	chr11:35366721	SLC1A2	-0.33	-5.07	-0.32	8.23e-7	Staphylococcus aureus nasal carriage (persistent);
SARC	trans	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg06437703	chr8:37914619	EIF4EBP1	-0.56	-6.64	-0.4	2.14e-10	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs73086581	1.000	rs73088421	chr20:3997871	A/G	cg02187196	chr20:3869020	PANK2	0.59	5.57	0.34	6.97e-8	Response to antidepressants in depression;
SARC	cis	rs7929679	0.602	rs10501135	chr11:34811180	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.37	4.84	0.3	2.41e-6	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
SARC	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg09877947	chr5:131593287	PDLIM4	0.42	5.01	0.31	1.09e-6	Blood metabolite levels;
SARC	cis	rs765787	0.530	rs12915804	chr15:45512562	T/C	cg24006582	chr15:45444508	DUOX1	0.43	5.5	0.34	9.82e-8	Uric acid levels;
SARC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	20.44	0.8	7e-54	Prudent dietary pattern;
SARC	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg07701084	chr6:150067640	NUP43	0.4	5.37	0.33	1.91e-7	Lung cancer;
SARC	cis	rs1008375	1.000	rs1860596	chr4:17660082	C/T	cg27347728	chr4:17578864	LAP3	0.48	5.99	0.37	7.94e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg03647317	chr4:187891568	NA	-0.36	-5.14	-0.32	5.74e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs897080	0.758	rs936038	chr2:44759732	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.4	-4.72	-0.3	4.06e-6	Height;
SARC	cis	rs5753618	0.509	rs4820951	chr22:31586248	G/A	cg02404636	chr22:31891804	SFI1	-0.48	-5.05	-0.31	8.88e-7	Colorectal cancer;
SARC	cis	rs10876993	0.890	rs774891	chr12:58068571	G/A	cg18357645	chr12:58087776	OS9	0.47	6.1	0.37	4.34e-9	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs6570726	0.935	rs391524	chr6:145823844	A/G	cg05220968	chr6:146057943	EPM2A	-0.29	-4.99	-0.31	1.19e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7659604	1.000	rs7689722	chr4:122665955	T/C	cg20573242	chr4:122745356	CCNA2	0.44	5.74	0.35	3e-8	Type 2 diabetes;
SARC	cis	rs899997	0.906	rs6495317	chr15:78991716	A/C	cg04896959	chr15:78267971	NA	-0.46	-5.39	-0.33	1.68e-7	Coronary artery disease or large artery stroke;
SARC	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-9.07	-0.51	5.04e-17	Alzheimer's disease;
SARC	cis	rs4742903	0.904	rs10991167	chr9:106974382	C/T	cg14250997	chr9:106856677	SMC2	-0.42	-5.3	-0.33	2.72e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs228769	0.792	rs454192	chr17:42171206	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	-0.51	-5.28	-0.33	2.91e-7	Bone mineral density (hip);Bone mineral density (spine);
SARC	cis	rs72781680	0.800	rs72790306	chr2:24111311	T/G	cg08917208	chr2:24149416	ATAD2B	0.95	9.54	0.53	2.03e-18	Lymphocyte counts;
SARC	cis	rs2502731	1.000	rs2502731	chr9:130976557	A/G	cg13642260	chr9:130955380	CIZ1	-0.53	-7.86	-0.46	1.4e-13	Attention deficit hyperactivity disorder;
SARC	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs36051895	0.623	rs2381215	chr9:5262607	C/T	cg02405213	chr9:5042618	JAK2	-0.43	-4.99	-0.31	1.2e-6	Pediatric autoimmune diseases;
SARC	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg14159672	chr1:205819179	PM20D1	-0.51	-5.74	-0.35	2.91e-8	White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs77633900	0.614	rs1443110	chr15:76928322	C/T	cg21673338	chr15:77095150	SCAPER	0.61	5.14	0.32	5.74e-7	Non-glioblastoma glioma;Glioma;
SARC	cis	rs72781680	1.000	rs17763442	chr2:24255991	C/T	cg06627628	chr2:24431161	ITSN2	-0.7	-6.47	-0.39	5.6e-10	Lymphocyte counts;
SARC	cis	rs7011049	1.000	rs11997774	chr8:53833370	T/A	cg26025543	chr8:53854495	NA	0.61	5.59	0.34	6.42e-8	Systolic blood pressure;
SARC	cis	rs920590	0.758	rs2898491	chr8:19661883	C/T	cg01411142	chr8:19674711	INTS10	0.48	5.55	0.34	7.86e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs13256369	0.901	rs12679831	chr8:8566411	T/G	cg17143192	chr8:8559678	CLDN23	0.54	6.16	0.37	3.24e-9	Obesity-related traits;
SARC	cis	rs4901847	0.562	rs3829765	chr14:58605790	G/A	cg15908186	chr14:58618357	C14orf37	0.58	7.43	0.44	2.1e-12	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg02711726	chr17:80685570	FN3KRP	-0.54	-6.61	-0.4	2.58e-10	Glycated hemoglobin levels;
SARC	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	12.64	0.64	3.01e-28	Platelet count;
SARC	cis	rs4565302	1.000	rs62397044	chr6:38386685	T/C	cg26053840	chr6:38644662	GLO1	-0.49	-4.92	-0.31	1.6e-6	Mammographic density;
SARC	cis	rs11583043	0.918	rs11582211	chr1:101416871	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.47	5.67	0.35	4.26e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs314370	0.570	rs314314	chr7:100423841	C/T	cg10426581	chr7:100472382	SRRT	0.42	5.34	0.33	2.22e-7	Resting heart rate;
SARC	cis	rs73206853	0.609	rs61582364	chr12:110967847	T/G	cg10860002	chr12:110842031	ANAPC7	0.6	5.0	0.31	1.1e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs9296092	0.517	rs56069946	chr6:33511136	G/A	cg13560919	chr6:33536144	NA	-0.44	-4.84	-0.3	2.39e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs870825	0.550	rs59051283	chr4:185646476	C/T	cg04058563	chr4:185651563	MLF1IP	0.8	11.35	0.6	4.56e-24	Blood protein levels;
SARC	cis	rs4481887	0.597	rs4504921	chr1:248582011	T/C	cg00666640	chr1:248458726	OR2T12	0.3	4.87	0.3	2.04e-6	Common traits (Other);
SARC	cis	rs10754283	0.905	rs7519969	chr1:90108721	G/C	cg21401794	chr1:90099060	LRRC8C	0.59	8.09	0.47	3.24e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs1670533	0.872	rs6854793	chr4:1055768	T/C	cg27284194	chr4:1044797	NA	0.47	4.96	0.31	1.37e-6	Recombination rate (females);
SARC	cis	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg15556689	chr8:8085844	FLJ10661	0.57	7.31	0.43	4.2e-12	Mood instability;
SARC	cis	rs4689388	0.856	rs10016157	chr4:6294414	T/C	cg14416269	chr4:6271139	WFS1	0.32	4.92	0.31	1.61e-6	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs2153535	0.580	rs4960421	chr6:8459292	C/T	cg07606381	chr6:8435919	SLC35B3	0.75	10.66	0.57	7.43e-22	Motion sickness;
SARC	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg15049968	chr18:44337910	ST8SIA5	-0.33	-5.2	-0.32	4.33e-7	Personality dimensions;
SARC	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.99	11.73	0.61	2.89e-25	Platelet count;
SARC	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.65	-7.82	-0.46	1.78e-13	Gut microbiome composition (summer);
SARC	cis	rs11098499	0.954	rs66506550	chr4:120371445	T/A	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	cis	rs17376456	0.877	rs10060462	chr5:93455073	C/T	cg21475434	chr5:93447410	FAM172A	0.86	7.71	0.45	3.65e-13	Diabetic retinopathy;
SARC	cis	rs6582630	0.599	rs11181807	chr12:38403763	G/A	cg13010199	chr12:38710504	ALG10B	-0.48	-5.81	-0.36	2.05e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg22920501	chr2:26401640	FAM59B	-0.55	-6.98	-0.42	2.99e-11	Gut microbiome composition (summer);
SARC	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg06108461	chr20:60628389	TAF4	-0.89	-11.84	-0.61	1.21e-25	Body mass index;
SARC	cis	rs9916302	0.904	rs11655531	chr17:37697959	T/C	cg00129232	chr17:37814104	STARD3	-0.65	-7.95	-0.46	8.02e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs798554	0.731	rs2283779	chr7:2815140	G/A	cg04166393	chr7:2884313	GNA12	0.41	4.97	0.31	1.32e-6	Height;
SARC	cis	rs11792861	0.816	rs2275637	chr9:111696043	C/G	cg13535736	chr9:111863775	C9orf5	-0.39	-4.87	-0.3	2.01e-6	Menarche (age at onset);
SARC	cis	rs2502731	0.539	rs3003615	chr9:130997892	C/T	cg13642260	chr9:130955380	CIZ1	0.4	5.48	0.34	1.1e-7	Attention deficit hyperactivity disorder;
SARC	cis	rs3820928	0.967	rs16822905	chr2:227770727	G/C	cg11843606	chr2:227700838	RHBDD1	-0.56	-6.95	-0.41	3.65e-11	Pulmonary function;
SARC	cis	rs10911251	0.546	rs12034436	chr1:183114797	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.67	9.7	0.54	6.82e-19	Colorectal cancer;
SARC	cis	rs2204008	0.665	rs11495668	chr12:38221018	C/T	cg13010199	chr12:38710504	ALG10B	0.77	10.51	0.57	2.11e-21	Bladder cancer;
SARC	cis	rs4969178	0.896	rs1976704	chr17:76401318	C/T	cg20026190	chr17:76395443	PGS1	0.4	5.37	0.33	1.86e-7	HDL cholesterol levels;
SARC	cis	rs9303401	0.659	rs12946852	chr17:57013337	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.05	11.76	0.61	2.3e-25	Cognitive test performance;
SARC	cis	rs4481887	0.830	rs9662041	chr1:248484701	A/T	cg13385794	chr1:248469461	NA	0.33	4.99	0.31	1.18e-6	Common traits (Other);
SARC	cis	rs74417235	0.684	rs13186731	chr5:154056002	C/T	cg17344516	chr5:154026930	NA	0.52	5.25	0.33	3.39e-7	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
SARC	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg11062466	chr8:58055876	NA	0.61	5.75	0.35	2.74e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1790761	0.520	rs1551884	chr11:67399601	C/G	cg00290607	chr11:67383545	NA	-0.45	-5.7	-0.35	3.52e-8	Mean corpuscular volume;
SARC	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg17971929	chr21:40555470	PSMG1	0.98	13.83	0.67	3.76e-32	Cognitive function;
SARC	cis	rs651907	0.557	rs13099674	chr3:101489629	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	6.48	0.39	5.37e-10	Colorectal cancer;
SARC	trans	rs3808502	0.549	rs4841564	chr8:11425809	T/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-6.52	-0.39	4.23e-10	Neuroticism;
SARC	cis	rs2404602	0.716	rs284895	chr15:76751225	C/G	cg22467129	chr15:76604101	ETFA	0.35	4.73	0.3	3.92e-6	Blood metabolite levels;
SARC	cis	rs9786986	0.609	rs12401387	chr1:235701314	C/T	cg08848088	chr1:235714526	GNG4	0.53	5.5	0.34	9.93e-8	Body mass index;
SARC	cis	rs7666738	0.830	rs13101352	chr4:98957544	C/T	cg05340658	chr4:99064831	C4orf37	0.66	9.0	0.51	8.07e-17	Colonoscopy-negative controls vs population controls;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg07617175	chr5:99871683	FAM174A	-0.78	-6.61	-0.4	2.53e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs67311347	1.000	rs66841330	chr3:40531123	G/A	cg09455208	chr3:40491958	NA	0.34	5.0	0.31	1.12e-6	Renal cell carcinoma;
SARC	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg08677398	chr8:58056175	NA	0.43	5.18	0.32	4.74e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9916302	0.861	rs10491129	chr17:37461643	T/G	cg15445000	chr17:37608096	MED1	-0.45	-5.4	-0.33	1.64e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs854765	0.583	rs4414547	chr17:17859052	G/T	cg04398451	chr17:18023971	MYO15A	-0.4	-5.51	-0.34	9.71e-8	Total body bone mineral density;
SARC	cis	rs6088813	1.000	rs6087703	chr20:33996433	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	-0.45	-5.39	-0.33	1.75e-7	Height;
SARC	cis	rs6604026	0.698	rs10874744	chr1:93306317	G/A	cg17283838	chr1:93427260	FAM69A	-0.42	-4.96	-0.31	1.35e-6	Multiple sclerosis;
SARC	cis	rs634534	0.562	rs642293	chr11:65730217	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.43	-5.39	-0.33	1.7e-7	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs981844	0.775	rs62323975	chr4:154737617	A/G	cg14289246	chr4:154710475	SFRP2	0.57	6.15	0.37	3.35e-9	Response to statins (LDL cholesterol change);
SARC	cis	rs3771570	1.000	rs73004382	chr2:242382192	C/T	cg21155796	chr2:242212141	HDLBP	0.7	6.35	0.38	1.09e-9	Prostate cancer;
SARC	cis	rs9811216	1.000	rs6793295	chr3:169518455	T/C	cg14222479	chr3:169487675	ARPM1	0.43	5.27	0.33	3.04e-7	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs1832871	0.672	rs9456289	chr6:158740347	G/A	cg07165851	chr6:158734300	TULP4	0.58	6.77	0.41	1.05e-10	Height;
SARC	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg06634786	chr22:41940651	POLR3H	-0.43	-5.06	-0.31	8.66e-7	Vitiligo;
SARC	cis	rs66573146	1.000	rs66519732	chr4:6990569	C/G	cg00086871	chr4:6988644	TBC1D14	0.94	5.11	0.32	6.57e-7	Granulocyte percentage of myeloid white cells;
SARC	trans	rs12310956	0.532	rs35366144	chr12:33992000	C/G	cg13010199	chr12:38710504	ALG10B	0.75	10.2	0.56	1.97e-20	Morning vs. evening chronotype;
SARC	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg11644478	chr21:40555479	PSMG1	-1.02	-13.99	-0.68	1.05e-32	Cognitive function;
SARC	cis	rs3126085	0.935	rs2184953	chr1:152280782	A/G	cg03465714	chr1:152285911	FLG	0.45	5.34	0.33	2.16e-7	Atopic dermatitis;
SARC	cis	rs9790314	0.560	rs4856701	chr3:161044106	G/T	cg03342759	chr3:160939853	NMD3	-0.53	-6.64	-0.4	2.19e-10	Morning vs. evening chronotype;
SARC	cis	rs6893807	1.000	rs1422191	chr5:87949158	G/A	cg09002922	chr5:87956389	LOC645323	-0.41	-4.78	-0.3	3.15e-6	Body mass index;
SARC	cis	rs11690935	0.632	rs12991740	chr2:172885996	C/T	cg13550731	chr2:172543902	DYNC1I2	0.68	9.39	0.52	5.84e-18	Schizophrenia;
SARC	trans	rs61931739	0.500	rs7979769	chr12:34509522	C/T	cg26384229	chr12:38710491	ALG10B	0.91	13.63	0.67	1.63e-31	Morning vs. evening chronotype;
SARC	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg04317338	chr11:64019027	PLCB3	0.6	7.11	0.42	1.44e-11	Platelet count;
SARC	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg07414643	chr4:187882934	NA	0.47	7.2	0.43	8.24e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2834188	0.924	rs2007849	chr21:34681116	G/A	cg15382669	chr21:34697036	IFNAR1	0.42	4.84	0.3	2.33e-6	Narcolepsy;
SARC	cis	rs2239547	0.522	rs9844736	chr3:52931971	T/G	cg18404041	chr3:52824283	ITIH1	0.44	5.49	0.34	1.03e-7	Schizophrenia;
SARC	cis	rs7998202	0.667	rs282568	chr13:113371938	A/G	cg02820901	chr13:113351484	ATP11A	0.49	4.75	0.3	3.54e-6	Glycated hemoglobin levels;
SARC	cis	rs8028182	0.666	rs4886708	chr15:75762608	C/T	cg20655648	chr15:75932815	IMP3	0.64	7.55	0.44	9.97e-13	Sudden cardiac arrest;
SARC	cis	rs11098499	0.909	rs71614422	chr4:120359340	G/A	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	cis	rs7178909	0.902	rs3853638	chr15:90443140	C/T	cg19708238	chr15:90437601	AP3S2	-0.62	-8.25	-0.48	1.17e-14	Common traits (Other);
SARC	cis	rs854765	0.693	rs8080061	chr17:17776389	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.64	-9.42	-0.53	4.48e-18	Total body bone mineral density;
SARC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg06074448	chr4:187884817	NA	-0.38	-5.09	-0.32	7.53e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs113835537	0.529	rs11227510	chr11:66281220	T/C	cg24851651	chr11:66362959	CCS	0.37	4.76	0.3	3.36e-6	Airway imaging phenotypes;
SARC	cis	rs992157	0.798	rs1017698	chr2:219170525	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.62	-8.85	-0.5	2.17e-16	Colorectal cancer;
SARC	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg11764359	chr7:65958608	NA	-0.87	-12.4	-0.63	1.84e-27	Aortic root size;
SARC	cis	rs2119480	0.762	rs418935	chr13:111309267	C/G	cg07595035	chr13:111291582	CARKD	-0.36	-4.87	-0.3	2.02e-6	Diastolic blood pressure;
SARC	cis	rs2075371	0.835	rs1646724	chr7:134001875	T/G	cg00033643	chr7:134001901	SLC35B4	0.53	6.6	0.4	2.7e-10	Mean platelet volume;
SARC	cis	rs9393692	0.905	rs9379838	chr6:26277133	C/T	cg00631329	chr6:26305371	NA	-0.58	-8.36	-0.48	5.54e-15	Educational attainment;
SARC	cis	rs7617773	0.963	rs12495221	chr3:48179178	C/T	cg11946769	chr3:48343235	NME6	-0.5	-5.98	-0.36	8.41e-9	Coronary artery disease;
SARC	cis	rs6696846	0.749	rs61822566	chr1:205078660	T/C	cg21643547	chr1:205240462	TMCC2	-0.54	-6.89	-0.41	5.02e-11	Red blood cell count;
SARC	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg24829409	chr8:58192753	C8orf71	-0.68	-6.28	-0.38	1.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs763121	0.853	rs3747174	chr22:39069181	T/C	cg14440974	chr22:39074834	NA	-0.33	-4.8	-0.3	2.84e-6	Menopause (age at onset);
SARC	cis	rs36051895	0.664	rs3780377	chr9:5110899	T/C	cg02405213	chr9:5042618	JAK2	-0.43	-4.86	-0.3	2.19e-6	Pediatric autoimmune diseases;
SARC	cis	rs739401	0.611	rs7130841	chr11:3043658	A/G	cg20651018	chr11:3035856	CARS	-0.46	-7.16	-0.42	1.06e-11	Longevity;
SARC	trans	rs2727020	0.729	rs2299650	chr11:49174007	A/C	cg15704280	chr7:45808275	SEPT13	-0.77	-11.64	-0.61	5.63e-25	Coronary artery disease;
SARC	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg11764359	chr7:65958608	NA	0.79	10.1	0.55	4.02e-20	Aortic root size;
SARC	cis	rs9303542	0.625	rs62065846	chr17:46592858	G/A	cg04904318	chr17:46607828	HOXB1	-0.43	-4.86	-0.3	2.21e-6	Ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg17971929	chr21:40555470	PSMG1	-0.86	-11.47	-0.6	1.98e-24	Cognitive function;
SARC	cis	rs11585357	0.895	rs72633806	chr1:17617943	A/G	cg08277548	chr1:17600880	PADI3	-0.48	-5.43	-0.33	1.45e-7	Hair shape;
SARC	cis	rs17030434	0.822	rs4696492	chr4:154679981	T/A	cg14289246	chr4:154710475	SFRP2	0.63	6.8	0.41	8.76e-11	Electrocardiographic conduction measures;
SARC	cis	rs6089584	1.000	rs6089581	chr20:60562394	G/A	cg23262073	chr20:60523788	NA	-0.44	-6.42	-0.39	7.39e-10	Body mass index;
SARC	trans	rs61931739	0.534	rs11052957	chr12:33995354	G/A	cg13010199	chr12:38710504	ALG10B	0.65	8.89	0.5	1.72e-16	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg08677398	chr8:58056175	NA	-0.44	-5.21	-0.32	4.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs4144743	0.759	rs1009312	chr17:45332140	G/A	cg18085866	chr17:45331354	ITGB3	-0.72	-7.29	-0.43	4.8e-12	Body mass index;
SARC	cis	rs6831352	0.691	rs2602887	chr4:100041473	A/G	cg13256891	chr4:100009986	ADH5	0.64	7.94	0.46	8.31e-14	Alcohol dependence;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg21907156	chr5:79703652	ZFYVE16	-0.9	-7.62	-0.45	6.17e-13	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9309473	0.653	rs6718843	chr2:73852505	C/A	cg20560298	chr2:73613845	ALMS1	-0.45	-5.48	-0.34	1.11e-7	Metabolite levels;
SARC	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg24829409	chr8:58192753	C8orf71	-0.62	-6.41	-0.39	8.1e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9398803	0.687	rs6911485	chr6:126975115	A/G	cg19875578	chr6:126661172	C6orf173	0.63	8.7	0.5	5.9e-16	Male-pattern baldness;
SARC	cis	rs2380220	0.872	rs2613528	chr6:95939437	C/G	cg04719120	chr6:96025338	MANEA	-0.62	-5.79	-0.35	2.26e-8	Behavioural disinhibition (generation interaction);
SARC	cis	rs10892173	0.566	rs10892175	chr11:117674355	G/A	cg21014159	chr11:117668035	DSCAML1	0.43	5.7	0.35	3.58e-8	Myopia;
SARC	cis	rs7223966	1.000	rs9891018	chr17:61827856	A/G	cg26338869	chr17:61819248	STRADA	0.44	4.74	0.3	3.72e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs61931739	0.534	rs11052974	chr12:34029877	T/G	cg26384229	chr12:38710491	ALG10B	0.86	12.5	0.63	9.09e-28	Morning vs. evening chronotype;
SARC	cis	rs6831352	0.729	rs4699718	chr4:100067791	G/A	cg12011299	chr4:100065546	ADH4	-0.32	-5.09	-0.32	7.33e-7	Alcohol dependence;
SARC	cis	rs9818758	0.607	rs80170003	chr3:48951640	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.7	-5.88	-0.36	1.39e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs7592578	0.825	rs12477369	chr2:191455624	G/T	cg10560079	chr2:191398806	TMEM194B	0.77	8.62	0.49	1.05e-15	Diastolic blood pressure;
SARC	cis	rs820218	0.926	rs864234	chr17:73663313	C/A	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.71	9.64	0.53	1.01e-18	Rotator cuff tears;
SARC	cis	rs79149102	0.579	rs76518150	chr15:75292721	C/G	cg00629941	chr15:75287862	SCAMP5	-0.67	-5.11	-0.32	6.66e-7	Lung cancer;
SARC	cis	rs240764	0.548	rs12206838	chr6:101180128	G/A	cg09795085	chr6:101329169	ASCC3	-0.49	-6.42	-0.39	7.54e-10	Neuroticism;
SARC	cis	rs17270561	0.609	rs1165181	chr6:25825390	T/A	cg17691542	chr6:26056736	HIST1H1C	0.49	6.29	0.38	1.58e-9	Iron status biomarkers;
SARC	cis	rs9818758	0.607	rs61729488	chr3:49067904	T/C	cg01304814	chr3:48885189	PRKAR2A	0.65	5.25	0.33	3.46e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs4919087	0.810	rs10786321	chr10:99026112	T/C	cg25902810	chr10:99078978	FRAT1	0.46	5.65	0.35	4.61e-8	Monocyte count;
SARC	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg03735888	chr19:58951602	ZNF132	0.41	5.22	0.32	3.94e-7	Uric acid clearance;
SARC	cis	rs9291683	0.546	rs13110307	chr4:10044364	T/C	cg00071950	chr4:10020882	SLC2A9	0.33	4.98	0.31	1.26e-6	Bone mineral density;
SARC	cis	rs412050	0.696	rs17821818	chr22:22334962	C/T	cg17089214	chr22:22089827	YPEL1	0.77	5.28	0.33	2.89e-7	Attention deficit hyperactivity disorder;
SARC	cis	rs2562456	0.874	rs2562417	chr19:21711202	T/C	cg00806126	chr19:22604979	ZNF98	0.49	5.03	0.31	9.61e-7	Pain;
SARC	cis	rs818427	0.964	rs465454	chr5:112230331	A/G	cg07820702	chr5:112228657	REEP5	-0.45	-4.94	-0.31	1.46e-6	Total body bone mineral density;
SARC	cis	rs76419734	0.850	rs76817161	chr4:106751135	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	5.33	0.33	2.37e-7	Post bronchodilator FEV1;
SARC	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg11764359	chr7:65958608	NA	0.76	8.78	0.5	3.62e-16	Aortic root size;
SARC	cis	rs883565	0.655	rs6599000	chr3:39061512	A/G	cg01426195	chr3:39028469	NA	-0.36	-5.26	-0.33	3.29e-7	Handedness;
SARC	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg14298792	chr15:30685198	CHRFAM7A	-0.53	-5.73	-0.35	3.03e-8	Huntington's disease progression;
SARC	cis	rs3818285	0.679	rs2475275	chr10:111633979	C/T	cg00817464	chr10:111662876	XPNPEP1	0.5	7.84	0.46	1.5700000000000001e-13	Superior crus of antihelix expression;
SARC	cis	rs17376456	0.569	rs10050364	chr5:93064127	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.56	5.85	0.36	1.67e-8	Diabetic retinopathy;
SARC	cis	rs523522	0.962	rs655530	chr12:121022275	T/C	cg27279351	chr12:120934652	DYNLL1	0.71	8.75	0.5	4.4e-16	High light scatter reticulocyte count;
SARC	cis	rs10875746	0.807	rs12297004	chr12:48453820	A/G	cg26205652	chr12:48591994	NA	0.55	5.96	0.36	9.4e-9	Longevity (90 years and older);
SARC	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg06634786	chr22:41940651	POLR3H	-0.55	-6.45	-0.39	6.42e-10	Vitiligo;
SARC	cis	rs11122272	0.735	rs2572248	chr1:231514942	A/G	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs1707322	0.964	rs785499	chr1:46592420	G/A	cg06784218	chr1:46089804	CCDC17	-0.36	-6.06	-0.37	5.34e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7621025	0.505	rs34281413	chr3:136461860	C/T	cg15507776	chr3:136538369	TMEM22	-0.97	-8.3	-0.48	8.24e-15	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
SARC	cis	rs910316	0.967	rs12890371	chr14:75593839	T/C	cg08847533	chr14:75593920	NEK9	0.92	15.73	0.72	1.77e-38	Height;
SARC	cis	rs1003719	0.715	rs8128387	chr21:38556787	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.29	-0.52	1.11e-17	Eye color traits;
SARC	cis	rs9291683	0.507	rs3796837	chr4:10011321	C/G	cg00071950	chr4:10020882	SLC2A9	0.33	5.03	0.31	9.76e-7	Bone mineral density;
SARC	cis	rs2249694	0.620	rs9419079	chr10:135326985	G/A	cg20169779	chr10:135381914	SYCE1	0.41	5.56	0.34	7.21e-8	Obesity-related traits;
SARC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg20607798	chr8:58055168	NA	0.67	5.45	0.34	1.3e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-8.93	-0.5	1.31e-16	Alzheimer's disease;
SARC	cis	rs62432291	0.681	rs436277	chr6:159634142	G/A	cg14500486	chr6:159655392	FNDC1	0.6	5.98	0.36	8.31e-9	Joint mobility (Beighton score);
SARC	cis	rs6701037	0.748	rs11585368	chr1:175135448	G/A	cg00321850	chr1:175162397	KIAA0040	-0.31	-4.76	-0.3	3.36e-6	Alcohol dependence;
SARC	cis	rs897984	0.553	rs2335013	chr16:30877346	T/G	cg02466173	chr16:30829666	NA	0.4	4.97	0.31	1.27e-6	Dementia with Lewy bodies;
SARC	cis	rs7659604	0.502	rs13106764	chr4:122699630	C/G	cg19748678	chr4:122722346	EXOSC9	-0.43	-5.46	-0.34	1.21e-7	Type 2 diabetes;
SARC	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg24690094	chr11:67383802	NA	0.36	5.35	0.33	2.13e-7	Mean corpuscular volume;
SARC	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg15448220	chr1:150897856	SETDB1	0.47	6.22	0.38	2.24e-9	Tonsillectomy;
SARC	cis	rs7666738	0.830	rs6833312	chr4:98951356	A/T	cg05340658	chr4:99064831	C4orf37	0.66	8.98	0.51	9.36e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs72627123	0.867	rs8015927	chr14:74465756	A/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	-0.81	-6.23	-0.38	2.2e-9	Morning vs. evening chronotype;
SARC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg06873352	chr17:61820015	STRADA	0.53	6.88	0.41	5.32e-11	Prudent dietary pattern;
SARC	cis	rs4906332	1.000	rs78316803	chr14:103942863	A/G	cg26031613	chr14:104095156	KLC1	-0.49	-5.74	-0.35	2.94e-8	Coronary artery disease;
SARC	cis	rs6456156	0.586	rs13208636	chr6:167461965	T/G	cg23791538	chr6:167370224	RNASET2	-0.52	-6.79	-0.41	9.49e-11	Primary biliary cholangitis;
SARC	cis	rs1865760	0.566	rs1971509	chr6:26085777	T/C	cg18357526	chr6:26021779	HIST1H4A	0.41	4.98	0.31	1.23e-6	Height;
SARC	cis	rs7945705	0.738	rs11042067	chr11:8815453	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.38	-5.27	-0.33	3.15e-7	Hemoglobin concentration;
SARC	cis	rs477692	0.655	rs7906680	chr10:131442671	C/G	cg05714579	chr10:131428358	MGMT	-0.59	-7.54	-0.44	1.02e-12	Response to temozolomide;
SARC	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg07701084	chr6:150067640	NUP43	0.41	5.48	0.34	1.11e-7	Lung cancer;
SARC	cis	rs11190604	1.000	rs12354411	chr10:102294537	G/A	cg07080220	chr10:102295463	HIF1AN	0.81	9.96	0.55	1.07e-19	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs17345786	0.511	rs13061565	chr3:101392270	T/C	cg12386194	chr3:101231763	SENP7	0.49	5.85	0.36	1.61e-8	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg06558623	chr16:89946397	TCF25	0.88	6.17	0.37	3e-9	Skin colour saturation;
SARC	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg00933542	chr6:150070202	PCMT1	0.31	5.34	0.33	2.24e-7	Lung cancer;
SARC	cis	rs8028182	0.636	rs12909863	chr15:75825822	G/C	cg20655648	chr15:75932815	IMP3	0.61	7.17	0.43	9.98e-12	Sudden cardiac arrest;
SARC	cis	rs2933343	0.953	rs2933344	chr3:128658715	A/G	cg24203234	chr3:128598194	ACAD9	0.55	6.2	0.38	2.6e-9	IgG glycosylation;
SARC	cis	rs7223966	0.921	rs6504186	chr17:61863932	G/A	cg26338869	chr17:61819248	STRADA	0.45	4.93	0.31	1.59e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs9545047	0.584	rs12871015	chr13:79907699	A/G	cg20462845	chr19:3572957	HMG20B	-0.47	-6.29	-0.38	1.53e-9	Schizophrenia;
SARC	trans	rs9354308	0.771	rs2814100	chr6:66528107	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.57	6.57	0.4	3.21e-10	Metabolite levels;
SARC	cis	rs3540	0.533	rs11633692	chr15:91056043	G/A	cg22089800	chr15:90895588	ZNF774	-0.6	-7.47	-0.44	1.56e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs9875589	0.957	rs13077668	chr3:13929756	A/G	cg19554555	chr3:13937349	NA	-0.56	-7.4	-0.44	2.52e-12	Ovarian reserve;
SARC	trans	rs629535	0.767	rs72654070	chr8:70079369	G/A	cg21567404	chr3:27674614	NA	-1.06	-13.84	-0.67	3.53e-32	Dupuytren's disease;
SARC	cis	rs57920188	0.640	rs4311852	chr1:4085353	C/A	cg20703997	chr1:4087676	NA	0.58	6.1	0.37	4.36e-9	Interleukin-17 levels;
SARC	cis	rs9300255	0.510	rs1727323	chr12:123698790	T/C	cg00376283	chr12:123451042	ABCB9	0.55	6.53	0.39	4.09e-10	Neutrophil percentage of white cells;
SARC	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs8180040	0.726	rs4682844	chr3:46982737	T/C	cg27129171	chr3:47204927	SETD2	-0.69	-9.77	-0.54	4.17e-19	Colorectal cancer;
SARC	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg11987759	chr7:65425863	GUSB	-0.49	-6.21	-0.38	2.46e-9	Aortic root size;
SARC	cis	rs6991838	0.765	rs4424306	chr8:66530909	G/C	cg13398993	chr8:66546079	ARMC1	0.42	5.33	0.33	2.26e-7	Intelligence (multi-trait analysis);
SARC	cis	rs79149102	0.737	rs16973172	chr15:75156944	G/A	cg17294928	chr15:75287854	SCAMP5	-0.94	-5.54	-0.34	8.05e-8	Lung cancer;
SARC	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg06108461	chr20:60628389	TAF4	-0.92	-12.69	-0.64	2.14e-28	Body mass index;
SARC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg14893161	chr1:205819251	PM20D1	0.93	15.84	0.72	7.57e-39	Menarche (age at onset);
SARC	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	10.7	0.57	5.58e-22	Platelet count;
SARC	cis	rs888194	0.568	rs10850137	chr12:109874794	C/G	cg05360138	chr12:110035743	NA	0.47	5.62	0.35	5.34e-8	Neuroticism;
SARC	cis	rs12458462	0.892	rs12456692	chr18:77482189	C/T	cg23301140	chr18:77439876	CTDP1	0.62	7.98	0.46	6.52e-14	Monocyte count;
SARC	cis	rs9325144	0.671	rs7485963	chr12:38768254	C/G	cg26384229	chr12:38710491	ALG10B	-0.59	-7.74	-0.45	2.92e-13	Morning vs. evening chronotype;
SARC	cis	rs9815354	0.812	rs4299460	chr3:41952445	A/C	cg03022575	chr3:42003672	ULK4	0.7	5.7	0.35	3.66e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs13191362	1.000	rs34138336	chr6:163144929	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.75	6.38	0.39	9.54e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2652822	0.509	rs8468	chr15:63434110	C/T	cg02713581	chr15:63449717	RPS27L	0.51	5.74	0.35	2.98e-8	Metabolic traits;
SARC	cis	rs7474896	0.537	rs2749589	chr10:38266870	C/T	cg00409905	chr10:38381863	ZNF37A	0.42	4.81	0.3	2.77e-6	Obesity (extreme);
SARC	cis	rs9457247	1.000	rs439237	chr6:167391392	A/G	cg07741184	chr6:167504864	NA	0.29	5.49	0.34	1.04e-7	Crohn's disease;
SARC	trans	rs10506458	1.000	rs17763435	chr12:63416511	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	0.76	6.81	0.41	8.13e-11	Hemostatic factors and hematological phenotypes;
SARC	cis	rs1949733	1.000	rs3103071	chr4:8508579	C/G	cg11789530	chr4:8429930	ACOX3	-0.84	-11.42	-0.6	2.87e-24	Response to antineoplastic agents;
SARC	trans	rs11098499	0.863	rs3822194	chr4:120471648	A/G	cg25214090	chr10:38739885	LOC399744	0.57	7.25	0.43	6.27e-12	Corneal astigmatism;
SARC	cis	rs853679	1.000	rs2799077	chr6:28234597	C/T	cg26450541	chr6:28235208	ZNF187	0.59	4.74	0.3	3.65e-6	Depression;
SARC	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.54	0.44	1.06e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4742903	0.935	rs10991168	chr9:106974902	C/T	cg14250997	chr9:106856677	SMC2	0.44	5.51	0.34	9.51e-8	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs4481887	0.927	rs4916121	chr1:248432003	C/T	cg01631408	chr1:248437212	OR2T33	-0.46	-5.7	-0.35	3.65e-8	Common traits (Other);
SARC	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg02788857	chr8:22132959	PIWIL2	0.35	4.96	0.31	1.35e-6	Hypertriglyceridemia;
SARC	cis	rs7818345	0.967	rs10107416	chr8:19286253	A/G	cg11303988	chr8:19266685	CSGALNACT1	-0.38	-5.06	-0.31	8.39e-7	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs2562456	0.920	rs2650784	chr19:21666597	T/C	cg03331224	chr19:21860916	NA	0.29	4.78	0.3	3.08e-6	Pain;
SARC	cis	rs7551222	0.752	rs6681905	chr1:204535789	T/G	cg20240347	chr1:204465584	NA	-0.32	-5.64	-0.35	4.93e-8	Schizophrenia;
SARC	cis	rs2204008	0.744	rs2222344	chr12:38406832	T/G	cg26384229	chr12:38710491	ALG10B	0.84	12.16	0.62	1.14e-26	Bladder cancer;
SARC	cis	rs7539542	0.556	rs6662413	chr1:202888496	C/T	cg08940984	chr1:202857613	RABIF	-0.35	-4.74	-0.3	3.69e-6	Mean platelet volume;
SARC	cis	rs12142240	0.698	rs17361915	chr1:46847321	C/T	cg00530320	chr1:46809349	NSUN4	0.57	7.0	0.42	2.74e-11	Menopause (age at onset);
SARC	cis	rs611744	0.967	rs673854	chr8:109191838	G/A	cg21045802	chr8:109455806	TTC35	0.43	5.05	0.31	8.79e-7	Dupuytren's disease;
SARC	cis	rs72945132	0.882	rs17160762	chr11:70134766	A/G	cg05964544	chr11:70165517	PPFIA1	0.55	5.48	0.34	1.08e-7	Coronary artery disease;
SARC	cis	rs7264396	0.563	rs2425081	chr20:34299733	C/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	5.69	0.35	3.71e-8	Total cholesterol levels;
SARC	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg21724239	chr8:58056113	NA	0.47	4.85	0.3	2.3e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs1691799	0.867	rs2172881	chr12:66766039	C/G	cg16791601	chr12:66731901	HELB	-0.7	-10.22	-0.56	1.67e-20	White blood cell count (basophil);
SARC	cis	rs6088580	0.609	rs6059845	chr20:33036500	G/A	cg08999081	chr20:33150536	PIGU	0.42	6.47	0.39	5.77e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs7084402	0.935	rs893370	chr10:60360834	A/T	cg07615347	chr10:60278583	BICC1	0.61	8.83	0.5	2.57e-16	Refractive error;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg12708852	chr17:29421804	NF1	0.62	6.4	0.39	8.51e-10	Lung cancer in ever smokers;
SARC	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7587476	0.599	rs61073893	chr2:215744814	C/T	cg04004882	chr2:215674386	BARD1	0.56	6.02	0.37	6.59e-9	Neuroblastoma;
SARC	cis	rs60752752	0.777	rs11205282	chr1:153365310	T/C	cg26882115	chr1:153603048	S100A1;S100A13	-0.6	-4.72	-0.3	4.11e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs2180341	1.000	rs9375499	chr6:127618072	T/C	cg24812749	chr6:127587940	RNF146	0.97	12.89	0.65	4.63e-29	Breast cancer;
SARC	cis	rs41278232	0.557	rs817349	chr20:62609766	C/T	cg24354818	chr20:62328094	TNFRSF6B	0.35	4.96	0.31	1.34e-6	Tonsillectomy;
SARC	cis	rs7647973	0.710	rs6446284	chr3:49616997	A/G	cg03060546	chr3:49711283	APEH	0.72	6.71	0.4	1.44e-10	Menarche (age at onset);
SARC	cis	rs76419734	1.000	rs72671811	chr4:106615603	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.82	5.06	0.31	8.65e-7	Post bronchodilator FEV1;
SARC	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg26335602	chr6:28129616	ZNF389	0.51	5.56	0.34	7.41e-8	Parkinson's disease;
SARC	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg00933542	chr6:150070202	PCMT1	0.33	5.63	0.35	5.13e-8	Lung cancer;
SARC	cis	rs9303401	0.659	rs12935851	chr17:56600244	C/A	cg25039879	chr17:56429692	SUPT4H1	0.66	6.16	0.37	3.19e-9	Cognitive test performance;
SARC	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg05368731	chr17:41323189	NBR1	0.8	9.71	0.54	6.3e-19	Menopause (age at onset);
SARC	cis	rs798554	0.616	rs1636251	chr7:2884720	T/C	cg13628971	chr7:2884303	GNA12	0.47	5.75	0.35	2.72e-8	Height;
SARC	cis	rs2276314	0.512	rs7234973	chr18:33450336	A/G	cg05985134	chr18:33552581	C18orf21	0.41	4.8	0.3	2.79e-6	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs4481887	0.893	rs4576683	chr1:248472390	T/C	cg00666640	chr1:248458726	OR2T12	0.34	5.7	0.35	3.65e-8	Common traits (Other);
SARC	cis	rs798554	0.679	rs7807978	chr7:2814635	C/T	cg04166393	chr7:2884313	GNA12	0.4	5.06	0.31	8.66e-7	Height;
SARC	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-5.45	-0.34	1.28e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs1784581	0.721	rs9365356	chr6:162414789	A/G	cg17173639	chr6:162384350	PARK2	0.64	8.7	0.5	6.24e-16	Itch intensity from mosquito bite;
SARC	trans	rs17685	0.672	rs56343450	chr7:75796235	C/T	cg19862616	chr7:65841803	NCRNA00174	0.64	8.01	0.46	5.5e-14	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg23172400	chr8:95962367	TP53INP1	-0.31	-5.3	-0.33	2.64e-7	Type 2 diabetes;
SARC	cis	rs4763879	0.778	rs7977940	chr12:9838916	C/G	cg27502298	chr12:9555721	NA	0.5	5.51	0.34	9.48e-8	Type 1 diabetes;
SARC	cis	rs9790314	0.663	rs13098884	chr3:160687386	A/G	cg04691961	chr3:161091175	C3orf57	0.59	8.07	0.47	3.63e-14	Morning vs. evening chronotype;
SARC	cis	rs3820928	0.874	rs10933165	chr2:227883648	C/G	cg11843606	chr2:227700838	RHBDD1	0.54	6.57	0.4	3.18e-10	Pulmonary function;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg18023558	chr4:10118459	WDR1	0.46	6.27	0.38	1.76e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs2882877	0.648	rs11694976	chr2:190377894	C/T	cg21926118	chr2:190387206	NA	-0.41	-5.04	-0.31	9.52e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs7666738	0.830	rs4699592	chr4:98974202	A/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2594989	0.733	rs2616538	chr3:11581076	G/T	cg00170343	chr3:11313890	ATG7	0.56	6.37	0.39	9.91e-10	Circulating chemerin levels;
SARC	cis	rs7568458	0.709	rs2043675	chr2:85769975	C/T	cg02493740	chr2:85810744	VAMP5	0.42	5.28	0.33	3.02e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs12148488	0.966	rs12899062	chr15:75347641	A/C	cg09165964	chr15:75287851	SCAMP5	-0.49	-6.51	-0.39	4.55e-10	Caffeine consumption;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg27475076	chr20:30458103	TTLL9;DUSP15	-0.76	-6.47	-0.39	5.86e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg13939156	chr17:80058883	NA	-0.4	-6.27	-0.38	1.77e-9	Life satisfaction;
SARC	cis	rs7223966	0.960	rs11659013	chr17:61869559	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.5	-5.18	-0.32	4.77e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.39	-4.83	-0.3	2.51e-6	Blood metabolite levels;
SARC	cis	rs4803468	0.967	rs3786553	chr19:41902746	T/G	cg09537434	chr19:41945824	ATP5SL	-0.94	-16.33	-0.73	1.77e-40	Height;
SARC	trans	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg00938859	chr5:1591904	SDHAP3	0.77	7.42	0.44	2.12e-12	Breast cancer;
SARC	trans	rs17685	0.623	rs7782808	chr7:75768645	C/T	cg19862616	chr7:65841803	NCRNA00174	0.62	7.72	0.45	3.44e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg13770153	chr20:60521292	NA	-0.45	-6.31	-0.38	1.39e-9	Body mass index;
SARC	cis	rs7624766	0.743	rs1403048	chr3:160477897	C/A	cg22637730	chr3:160473554	PPM1L	0.43	5.64	0.35	4.89e-8	Response to methotrexate in rheumatoid arthritis;
SARC	cis	rs2251381	0.523	rs2832306	chr21:30754468	C/T	cg24692254	chr21:30365293	RNF160	-0.5	-6.25	-0.38	1.89e-9	Selective IgA deficiency;
SARC	cis	rs950776	0.714	rs660652	chr15:78887832	A/G	cg22563815	chr15:78856949	CHRNA5	-0.34	-5.4	-0.33	1.63e-7	Sudden cardiac arrest;
SARC	cis	rs9814567	1.000	rs6804770	chr3:134230234	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-7.02	-0.42	2.38e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs910316	1.000	rs4899544	chr14:75546556	C/T	cg23033748	chr14:75592666	NEK9	0.37	5.19	0.32	4.6e-7	Height;
SARC	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg16325326	chr1:53192061	ZYG11B	0.77	12.07	0.62	2.27e-26	Monocyte count;
SARC	cis	rs5995756	0.712	rs713733	chr22:39997170	G/A	cg10455938	chr22:40058150	CACNA1I	-0.5	-6.43	-0.39	7.08e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs826838	0.967	rs1684413	chr12:39128704	G/A	cg26384229	chr12:38710491	ALG10B	-0.76	-11.59	-0.6	7.97e-25	Heart rate;
SARC	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.58	-0.4	3.05e-10	Total body bone mineral density;
SARC	cis	rs733592	1.000	rs1859440	chr12:48427329	T/C	cg21466736	chr12:48725269	NA	0.3	5.18	0.32	4.9e-7	Plateletcrit;
SARC	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	5.96	0.36	9.28e-9	Tonsillectomy;
SARC	cis	rs10875746	0.951	rs61918826	chr12:48543978	T/C	cg27446233	chr12:48516484	PFKM	-0.46	-5.24	-0.32	3.59e-7	Longevity (90 years and older);
SARC	cis	rs79149102	0.579	rs8034149	chr15:75311842	G/C	cg00629941	chr15:75287862	SCAMP5	-0.7	-5.39	-0.33	1.72e-7	Lung cancer;
SARC	cis	rs2197308	0.728	rs7304305	chr12:37932990	T/C	cg26384229	chr12:38710491	ALG10B	-0.79	-11.38	-0.6	3.64e-24	Morning vs. evening chronotype;
SARC	cis	rs9341808	0.644	rs76102095	chr6:80942026	G/C	cg08355045	chr6:80787529	NA	-0.35	-5.72	-0.35	3.27e-8	Sitting height ratio;
SARC	cis	rs1355223	0.506	rs1509659	chr11:34865133	A/G	cg11622362	chr11:34938112	PDHX;APIP	0.46	6.04	0.37	5.98e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs11785693	0.866	rs11782170	chr8:4976942	A/G	cg26367366	chr8:4980734	NA	-0.61	-5.63	-0.35	5.19e-8	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs72781680	1.000	rs6710426	chr2:24159288	A/G	cg06627628	chr2:24431161	ITSN2	-0.69	-6.48	-0.39	5.36e-10	Lymphocyte counts;
SARC	cis	rs2075371	0.611	rs34573600	chr7:134018937	C/T	cg11752832	chr7:134001865	SLC35B4	0.5	6.22	0.38	2.3e-9	Mean platelet volume;
SARC	trans	rs66573146	1.000	rs67067921	chr4:6984341	A/T	cg07817883	chr1:32538562	TMEM39B	1.52	9.1	0.51	4.22e-17	Granulocyte percentage of myeloid white cells;
SARC	cis	rs11578119	0.933	rs4423075	chr1:170477349	T/C	cg09767346	chr1:170501363	GORAB	0.4	4.73	0.3	3.91e-6	Male-pattern baldness;
SARC	cis	rs6580649	0.769	rs60629297	chr12:48438290	T/A	cg24011408	chr12:48396354	COL2A1	-0.46	-5.04	-0.31	9.18e-7	Lung cancer;
SARC	trans	rs4295623	0.507	rs2256241	chr8:11494657	C/T	cg08975724	chr8:8085496	FLJ10661	-0.48	-6.33	-0.38	1.23e-9	Morning vs. evening chronotype;
SARC	cis	rs2522056	1.000	rs1003533	chr5:131755651	C/T	cg24060327	chr5:131705240	SLC22A5	0.64	6.54	0.39	3.96e-10	Lymphocyte counts;Fibrinogen;
SARC	cis	rs7729447	0.566	rs3792765	chr5:32713836	A/G	cg16267343	chr5:32710456	NPR3	0.61	7.9	0.46	1.13e-13	Blood pressure;
SARC	cis	rs12478296	1.000	rs56323081	chr2:243040807	A/G	cg06360820	chr2:242988706	NA	-0.61	-4.82	-0.3	2.57e-6	Obesity-related traits;
SARC	cis	rs2073300	0.609	rs6132615	chr20:23413200	T/C	cg12062639	chr20:23401060	NAPB	0.95	6.01	0.37	7.21e-9	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs17270561	0.636	rs6456698	chr6:25741664	A/C	cg16482183	chr6:26056742	HIST1H1C	0.43	5.08	0.32	7.76e-7	Iron status biomarkers;
SARC	cis	rs35306767	0.903	rs11253462	chr10:889323	T/G	cg26597838	chr10:835615	NA	0.78	8.53	0.49	1.89e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs2013441	1.000	rs17759959	chr17:20024095	A/G	cg13482628	chr17:19912719	NA	0.47	6.13	0.37	3.66e-9	Obesity-related traits;
SARC	cis	rs9398803	0.965	rs4895807	chr6:126686513	C/G	cg20229609	chr6:126660872	C6orf173	0.41	6.02	0.37	6.81e-9	Male-pattern baldness;
SARC	cis	rs10088262	0.629	rs12549683	chr8:124798276	G/C	cg20713898	chr8:124780851	FAM91A1	-0.64	-7.14	-0.42	1.17e-11	Pancreatic cancer;
SARC	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/A	cg11502198	chr6:26597334	ABT1	0.59	7.43	0.44	2e-12	Intelligence (multi-trait analysis);
SARC	cis	rs865483	0.929	rs853225	chr17:35791505	A/C	cg06561646	chr17:35873369	DUSP14	-0.48	-6.22	-0.38	2.24e-9	Monocyte count;
SARC	cis	rs7937682	0.587	rs611607	chr11:111349765	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.54	-6.65	-0.4	2.01e-10	Primary sclerosing cholangitis;
SARC	cis	rs7553864	1.000	rs4514217	chr1:87614094	G/A	cg18153957	chr1:87613403	LOC339524	-0.47	-5.55	-0.34	7.8e-8	Smoking behavior;
SARC	cis	rs17376456	0.825	rs10054790	chr5:93272520	A/G	cg21475434	chr5:93447410	FAM172A	0.85	7.51	0.44	1.22e-12	Diabetic retinopathy;
SARC	cis	rs7635838	0.819	rs4684781	chr3:11516299	G/A	cg00170343	chr3:11313890	ATG7	0.62	8.75	0.5	4.31e-16	HDL cholesterol;
SARC	cis	rs72781680	0.821	rs72796401	chr2:24180078	T/A	cg06627628	chr2:24431161	ITSN2	-0.57	-6.05	-0.37	5.69e-9	Lymphocyte counts;
SARC	cis	rs12142240	0.738	rs67545510	chr1:46806242	G/T	cg10495392	chr1:46806563	NSUN4	0.64	6.84	0.41	6.77e-11	Menopause (age at onset);
SARC	cis	rs7589342	0.801	rs13031068	chr2:106455021	A/G	cg16077055	chr2:106428750	NCK2	0.4	7.5	0.44	1.31e-12	Addiction;
SARC	cis	rs12594515	1.000	rs8032835	chr15:45997897	C/G	cg14863074	chr15:45997064	NA	0.34	5.2	0.32	4.34e-7	Waist circumference;Weight;
SARC	cis	rs4144743	0.941	rs7222617	chr17:45324080	G/T	cg18085866	chr17:45331354	ITGB3	-0.71	-7.35	-0.43	3.36e-12	Body mass index;
SARC	cis	rs11098499	0.738	rs34965784	chr4:120361586	G/C	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs2327429	0.858	rs17062991	chr6:134193910	G/A	cg25632230	chr6:134101081	NA	-0.46	-5.5	-0.34	9.97e-8	Coronary artery disease;
SARC	cis	rs6733011	0.542	rs6542860	chr2:99679376	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.41	-4.94	-0.31	1.51e-6	Bipolar disorder;
SARC	cis	rs76419734	1.000	rs11732650	chr4:106754231	G/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	5.31	0.33	2.52e-7	Post bronchodilator FEV1;
SARC	cis	rs6963495	0.818	rs73190187	chr7:105164401	A/T	cg13798780	chr7:105162888	PUS7	0.6	5.45	0.34	1.31e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs6815814	0.851	rs17582921	chr4:38892649	T/C	cg06935464	chr4:38784597	TLR10	0.5	4.8	0.3	2.88e-6	Breast cancer;
SARC	cis	rs9787249	0.957	rs6670841	chr1:40220284	C/G	cg02773041	chr1:40204384	PPIE	0.51	6.34	0.38	1.18e-9	Blood protein levels;
SARC	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg16339924	chr4:17578868	LAP3	0.66	8.88	0.5	1.81e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs3617	0.522	rs6773650	chr3:52897095	A/T	cg18404041	chr3:52824283	ITIH1	-0.35	-5.21	-0.32	4.16e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.49	0.39	5.06e-10	Electroencephalogram traits;
SARC	cis	rs4660306	1.000	rs882803	chr1:45976147	G/A	cg24296786	chr1:45957014	TESK2	0.56	6.63	0.4	2.3e-10	Homocysteine levels;
SARC	cis	rs11098499	0.739	rs10031033	chr4:120151452	C/T	cg09307838	chr4:120376055	NA	0.74	9.82	0.54	2.88e-19	Corneal astigmatism;
SARC	cis	rs2439831	0.867	rs935901	chr15:43651256	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	7.88	0.46	1.25e-13	Lung cancer in ever smokers;
SARC	cis	rs524281	0.817	rs10896092	chr11:65958046	A/C	cg14036092	chr11:66035641	RAB1B	-0.5	-5.36	-0.33	1.99e-7	Electroencephalogram traits;
SARC	cis	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg15556689	chr8:8085844	FLJ10661	0.58	7.46	0.44	1.67e-12	Mood instability;
SARC	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg13939156	chr17:80058883	NA	0.41	6.36	0.38	1.06e-9	Life satisfaction;
SARC	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg22496380	chr5:211416	CCDC127	-0.84	-8.6	-0.49	1.19e-15	Breast cancer;
SARC	cis	rs1865760	0.588	rs9467658	chr6:26010881	T/G	cg17691542	chr6:26056736	HIST1H1C	0.51	6.54	0.39	3.77e-10	Height;
SARC	cis	rs9902453	1.000	rs7221743	chr17:28407876	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.53	-6.93	-0.41	4.11e-11	Coffee consumption (cups per day);
SARC	cis	rs9457247	0.663	rs2237277	chr6:167442107	G/A	cg23791538	chr6:167370224	RNASET2	-0.52	-7.03	-0.42	2.23e-11	Crohn's disease;
SARC	trans	rs8073060	0.586	rs2011897	chr17:34054408	A/T	cg19694781	chr19:47549865	TMEM160	0.65	6.69	0.4	1.62e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs6866344	0.697	rs6873150	chr5:178125704	G/A	cg10224037	chr5:178157518	ZNF354A	1.0	12.26	0.63	5.35e-27	Neutrophil percentage of white cells;
SARC	cis	rs2933343	0.909	rs1683817	chr3:128651536	G/A	cg25356066	chr3:128598488	ACAD9	0.59	6.65	0.4	2.07e-10	IgG glycosylation;
SARC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg07157834	chr1:205819609	PM20D1	0.71	10.72	0.57	4.53e-22	Menarche (age at onset);
SARC	cis	rs13077101	0.927	rs386748	chr3:120511574	T/G	cg24332942	chr3:120408071	RABL3	-0.38	-4.77	-0.3	3.18e-6	Obesity-related traits;
SARC	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg05863683	chr7:1912471	MAD1L1	0.32	4.84	0.3	2.41e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs3892630	0.878	rs66788054	chr19:33190146	G/T	cg22980127	chr19:33182716	NUDT19	1.06	9.77	0.54	4.14e-19	Red blood cell traits;
SARC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg16132339	chr22:24313637	DDTL;DDT	0.4	5.45	0.34	1.29e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	trans	rs17221829	0.733	rs11018668	chr11:89356178	C/T	cg10132809	chr7:71198544	NA	-0.46	-6.31	-0.38	1.36e-9	Anxiety in major depressive disorder;
SARC	cis	rs17253792	0.822	rs10137885	chr14:56173590	A/G	cg01858014	chr14:56050164	KTN1	-0.63	-5.07	-0.32	8.05e-7	Putamen volume;
SARC	cis	rs6540556	0.723	rs11119336	chr1:209930585	G/C	cg05527609	chr1:210001259	C1orf107	-0.68	-6.43	-0.39	6.96e-10	Red blood cell count;
SARC	cis	rs3859192	0.561	rs9916158	chr17:38182229	G/T	cg17467752	chr17:38218738	THRA	-0.37	-4.73	-0.3	3.91e-6	White blood cell count;
SARC	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.51	-6.44	-0.39	6.91e-10	Bipolar disorder;
SARC	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg05861140	chr6:150128134	PCMT1	-0.42	-5.0	-0.31	1.15e-6	Lung cancer;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg12436713	chr12:76479005	NAP1L1	0.81	6.7	0.4	1.51e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs4780401	0.609	rs8063099	chr16:11806714	T/G	cg01061890	chr16:11836724	TXNDC11	-0.61	-8.7	-0.5	6.01e-16	Rheumatoid arthritis;
SARC	cis	rs72781680	0.821	rs12616257	chr2:24135034	A/G	cg06627628	chr2:24431161	ITSN2	-0.58	-6.2	-0.38	2.52e-9	Lymphocyte counts;
SARC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.43	0.56	3.79e-21	Prudent dietary pattern;
SARC	cis	rs763121	0.853	rs6001173	chr22:39015302	A/G	cg06022373	chr22:39101656	GTPBP1	0.88	11.7	0.61	3.46e-25	Menopause (age at onset);
SARC	cis	rs1270639	0.778	rs2952650	chr7:157450939	C/T	cg13357408	chr7:157437802	PTPRN2	0.48	4.8	0.3	2.86e-6	Colorectal cancer;
SARC	cis	rs634534	0.563	rs470192	chr11:65724291	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.4	5.06	0.31	8.61e-7	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs240764	0.658	rs7451736	chr6:101189901	C/T	cg09795085	chr6:101329169	ASCC3	-0.49	-6.42	-0.39	7.54e-10	Neuroticism;
SARC	cis	rs41264869	0.689	rs61822621	chr1:205101554	G/A	cg21643547	chr1:205240462	TMCC2	0.44	4.78	0.3	3.12e-6	Blood protein levels;
SARC	cis	rs933688	0.532	rs868557	chr5:90550379	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.44	-4.94	-0.31	1.5e-6	Smoking behavior;
SARC	cis	rs36051895	0.659	rs7862042	chr9:5268139	G/A	cg02405213	chr9:5042618	JAK2	-0.44	-5.16	-0.32	5.38e-7	Pediatric autoimmune diseases;
SARC	cis	rs910316	0.967	rs4903293	chr14:75656568	A/G	cg11812906	chr14:75593930	NEK9	-0.81	-11.63	-0.61	6.14e-25	Height;
SARC	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg04234412	chr22:24373322	LOC391322	-0.52	-6.37	-0.38	1.02e-9	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs11105298	0.891	rs10858902	chr12:89927789	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.55	-5.54	-0.34	8.05e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs1865760	1.000	rs2071297	chr6:25924513	C/G	cg10373733	chr6:25993375	NA	-0.42	-4.98	-0.31	1.26e-6	Height;
SARC	cis	rs4763879	0.778	rs11052497	chr12:9849275	C/T	cg27502298	chr12:9555721	NA	0.45	4.9	0.31	1.81e-6	Type 1 diabetes;
SARC	cis	rs735539	0.521	rs9550672	chr13:21428380	G/T	cg16922012	chr13:21400325	XPO4	-0.44	-6.08	-0.37	4.98e-9	Dental caries;
SARC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.12	-20.66	-0.8	1.34e-54	Prudent dietary pattern;
SARC	trans	rs1865760	0.929	rs9461224	chr6:25936402	G/T	cg05735009	chr7:39606071	C7orf36	-0.55	-6.61	-0.4	2.61e-10	Height;
SARC	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg00933542	chr6:150070202	PCMT1	0.31	4.83	0.3	2.51e-6	Lung cancer;
SARC	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg16606324	chr3:10149918	C3orf24	0.5	4.86	0.3	2.14e-6	Alzheimer's disease;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20511056	chr1:54519321	C1orf83;TMEM59	-0.55	-6.66	-0.4	1.9e-10	Fibrinogen levels;
SARC	cis	rs1865760	0.516	rs9393684	chr6:26075531	G/C	cg18357526	chr6:26021779	HIST1H4A	0.42	5.31	0.33	2.52e-7	Height;
SARC	cis	rs2439831	0.850	rs28696802	chr15:44140395	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	8.02	0.47	5.04e-14	Lung cancer in ever smokers;
SARC	cis	rs7762018	0.607	rs77004024	chr6:170063437	G/A	cg13015042	chr6:170102002	WDR27;C6orf120	0.73	4.99	0.31	1.2e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs35110281	0.776	rs1073522	chr21:45009219	T/A	cg21573476	chr21:45109991	RRP1B	-0.52	-7.56	-0.44	9.03e-13	Mean corpuscular volume;
SARC	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg15049968	chr18:44337910	ST8SIA5	-0.33	-5.16	-0.32	5.31e-7	Personality dimensions;
SARC	cis	rs11585357	0.793	rs11587669	chr1:17616259	C/T	cg08277548	chr1:17600880	PADI3	-0.46	-5.18	-0.32	4.9e-7	Hair shape;
SARC	cis	rs11641365	1.000	rs11641365	chr16:88773893	A/G	cg00034003	chr16:88779146	CTU2	0.46	6.38	0.39	9.2e-10	Autism spectrum disorder-related traits;
SARC	cis	rs3762637	1.000	rs7609972	chr3:122199426	T/G	cg24169773	chr3:122142474	KPNA1	-0.57	-5.85	-0.36	1.67e-8	LDL cholesterol levels;
SARC	cis	rs2197308	0.565	rs12809769	chr12:37909968	C/T	cg13010199	chr12:38710504	ALG10B	0.8	11.02	0.59	5.3e-23	Morning vs. evening chronotype;
SARC	trans	rs11098499	0.863	rs3775843	chr4:120427844	T/C	cg25214090	chr10:38739885	LOC399744	0.59	7.32	0.43	3.92e-12	Corneal astigmatism;
SARC	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg24250549	chr1:154909240	PMVK	0.83	12.34	0.63	2.91e-27	Prostate cancer;
SARC	cis	rs1153858	1.000	rs2467863	chr15:45641880	G/A	cg03999130	chr15:45571217	NA	0.39	4.96	0.31	1.37e-6	Homoarginine levels;
SARC	cis	rs2486288	0.656	rs11632724	chr15:45550791	G/A	cg15395560	chr15:45543142	SLC28A2	0.29	5.63	0.35	5.17e-8	Glomerular filtration rate;
SARC	cis	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg05623727	chr3:50126028	RBM5	-0.34	-5.27	-0.33	3.18e-7	Intelligence (multi-trait analysis);
SARC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg07157834	chr1:205819609	PM20D1	-0.68	-10.74	-0.58	4e-22	Menarche (age at onset);
SARC	cis	rs6545883	0.895	rs2177961	chr2:61560264	T/C	cg15711740	chr2:61764176	XPO1	0.4	4.84	0.3	2.33e-6	Tuberculosis;
SARC	cis	rs916888	0.821	rs199504	chr17:44861003	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.64	-6.88	-0.41	5.39e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs1008375	0.863	rs2058336	chr4:17608299	T/C	cg16339924	chr4:17578868	LAP3	0.67	8.86	0.5	2.05e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs3771570	1.000	rs62193210	chr2:242323616	G/A	cg21155796	chr2:242212141	HDLBP	0.67	6.04	0.37	5.91e-9	Prostate cancer;
SARC	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg06618935	chr21:46677482	NA	-0.41	-5.36	-0.33	2.03e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg04248312	chr19:17393744	ANKLE1	-0.61	-8.04	-0.47	4.39e-14	Systemic lupus erythematosus;
SARC	cis	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg18252515	chr7:66147081	NA	-1.38	-12.57	-0.64	5.19e-28	Diabetic kidney disease;
SARC	cis	rs9549367	0.865	rs9549366	chr13:113907644	G/A	cg18105134	chr13:113819100	PROZ	-0.36	-5.48	-0.34	1.11e-7	Platelet distribution width;
SARC	cis	rs9303280	0.901	rs869402	chr17:38068043	C/T	cg20243544	chr17:37824526	PNMT	0.4	5.2	0.32	4.36e-7	Self-reported allergy;
SARC	cis	rs112591243	0.685	rs117450955	chr21:47990916	T/A	cg10657630	chr21:48055338	PRMT2	0.86	5.41	0.33	1.57e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs7615952	0.512	rs34085484	chr3:125544186	T/C	cg05084668	chr3:125655381	ALG1L	-0.49	-5.17	-0.32	5.02e-7	Blood pressure (smoking interaction);
SARC	cis	rs7178909	0.872	rs7174330	chr15:90434579	C/T	cg19708238	chr15:90437601	AP3S2	-0.6	-7.82	-0.46	1.84e-13	Common traits (Other);
SARC	cis	rs9300255	0.544	rs1790130	chr12:123701270	A/C	cg00376283	chr12:123451042	ABCB9	0.55	6.53	0.39	4.09e-10	Neutrophil percentage of white cells;
SARC	cis	rs2120243	0.565	rs13087207	chr3:157099638	G/A	cg01018701	chr3:157155998	VEPH1;PTX3	0.38	4.84	0.3	2.38e-6	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg16325326	chr1:53192061	ZYG11B	-0.94	-18.17	-0.77	1.57e-46	Monocyte count;
SARC	cis	rs6089584	1.000	rs6089583	chr20:60563624	G/A	cg23262073	chr20:60523788	NA	-0.44	-6.42	-0.39	7.39e-10	Body mass index;
SARC	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg12292205	chr6:26970375	C6orf41	-0.56	-6.17	-0.37	2.96e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg04944784	chr2:26401820	FAM59B	0.6	7.95	0.46	8.14e-14	Gut microbiome composition (summer);
SARC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-4.93	-0.31	1.59e-6	Total body bone mineral density;
SARC	cis	rs10463554	0.927	rs34795	chr5:102424420	C/T	cg23492399	chr5:102201601	PAM	-0.54	-5.89	-0.36	1.31e-8	Parkinson's disease;
SARC	cis	rs3768617	0.510	rs3768622	chr1:183090011	G/A	cg13390022	chr1:182993471	LAMC1	0.32	4.76	0.3	3.44e-6	Fuchs's corneal dystrophy;
SARC	cis	rs9393692	0.557	rs12660432	chr6:26317384	C/T	cg13736514	chr6:26305472	NA	-0.4	-4.96	-0.31	1.35e-6	Educational attainment;
SARC	cis	rs3758785	0.512	rs534137	chr11:94072986	G/C	cg13023536	chr11:94226537	MRE11A;ANKRD49	-0.47	-5.95	-0.36	9.81e-9	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
SARC	cis	rs11625487	0.957	rs10145540	chr14:77957354	C/T	cg16049707	chr14:77965284	ISM2	-0.62	-7.84	-0.46	1.65e-13	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
SARC	cis	rs12497850	1.000	rs4858831	chr3:48735558	C/T	cg06212747	chr3:49208901	KLHDC8B	0.63	8.51	0.49	2.08e-15	Parkinson's disease;
SARC	cis	rs9309473	0.797	rs6723247	chr2:73846749	A/G	cg20560298	chr2:73613845	ALMS1	-0.44	-5.31	-0.33	2.57e-7	Metabolite levels;
SARC	cis	rs67460515	0.892	rs35310734	chr3:160943209	T/G	cg03342759	chr3:160939853	NMD3	-0.7	-8.98	-0.51	9.61e-17	Parkinson's disease;
SARC	cis	rs7084402	0.565	rs11006187	chr10:60333383	A/G	cg07615347	chr10:60278583	BICC1	-0.4	-5.49	-0.34	1.03e-7	Refractive error;
SARC	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg21226059	chr5:178986404	RUFY1	0.36	5.12	0.32	6.44e-7	Lung cancer;
SARC	cis	rs1318878	0.840	rs1599368	chr12:15547632	A/C	cg08258403	chr12:15378311	NA	0.46	6.15	0.37	3.34e-9	Intelligence (multi-trait analysis);
SARC	cis	rs3741151	0.686	rs73546735	chr11:73256797	C/T	cg17517138	chr11:73019481	ARHGEF17	0.93	6.88	0.41	5.4e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg08280861	chr8:58055591	NA	0.57	5.14	0.32	5.73e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg07414643	chr4:187882934	NA	-0.48	-6.86	-0.41	6.06e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9682041	1.000	rs57508070	chr3:170074374	C/A	cg11886554	chr3:170076028	SKIL	1.06	8.37	0.48	5.49e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs7568458	0.837	rs3731827	chr2:85806068	T/C	cg23752985	chr2:85803571	VAMP8	0.35	5.15	0.32	5.62e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs2115630	0.967	rs11073731	chr15:85355113	C/A	cg17507749	chr15:85114479	UBE2QP1	-0.47	-5.73	-0.35	3.04e-8	P wave terminal force;
SARC	cis	rs7555523	1.000	rs7555523	chr1:165718979	C/A	cg19769164	chr1:165738335	TMCO1	0.59	4.92	0.31	1.63e-6	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	cis	rs8141529	0.600	rs16986838	chr22:29312578	C/T	cg15103426	chr22:29168792	CCDC117	0.61	6.22	0.38	2.32e-9	Lymphocyte counts;
SARC	cis	rs2073499	1.000	rs2071803	chr3:50407344	G/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.52	4.85	0.3	2.27e-6	Schizophrenia;
SARC	cis	rs6750720	0.503	rs10202379	chr2:100596865	A/G	cg22139774	chr2:100720529	AFF3	-0.3	-4.91	-0.31	1.75e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.68	9.26	0.52	1.44e-17	Lymphocyte counts;
SARC	cis	rs651907	0.535	rs13065944	chr3:101473088	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	6.39	0.39	8.85e-10	Colorectal cancer;
SARC	cis	rs554111	0.660	rs658851	chr1:21079425	T/C	cg08890418	chr1:21044141	KIF17	0.45	6.32	0.38	1.34e-9	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs9612	1.000	rs16976747	chr19:44238152	G/A	cg07522664	chr19:44259120	C19orf61	0.47	5.51	0.34	9.56e-8	Exhaled nitric oxide output;
SARC	cis	rs6450176	0.625	rs3822499	chr5:53289459	C/G	ch.5.1024479R	chr5:53302184	ARL15	-0.85	-9.98	-0.55	9.3e-20	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs6088580	0.608	rs2105109	chr20:32971932	A/G	cg24642439	chr20:33292090	TP53INP2	-0.68	-8.73	-0.5	4.96e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	12.14	0.62	1.32e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg20965017	chr5:231967	SDHA	-0.56	-5.3	-0.33	2.71e-7	Breast cancer;
SARC	cis	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg12463550	chr7:65579703	CRCP	0.68	5.24	0.32	3.61e-7	Diabetic kidney disease;
SARC	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg00933542	chr6:150070202	PCMT1	0.3	5.14	0.32	5.77e-7	Lung cancer;
SARC	cis	rs12545912	0.909	rs6987698	chr8:9484694	T/C	cg21625330	chr8:9911636	MSRA	0.53	5.03	0.31	9.73e-7	Multiple myeloma (hyperdiploidy);
SARC	trans	rs1814175	0.519	rs10839291	chr11:49514321	G/A	cg03929089	chr4:120376271	NA	0.7	7.86	0.46	1.46e-13	Height;
SARC	cis	rs910316	0.967	rs8013444	chr14:75661981	A/G	cg08847533	chr14:75593920	NEK9	-0.86	-13.47	-0.66	5.83e-31	Height;
SARC	cis	rs4372836	0.729	rs10198789	chr2:28968811	C/T	cg09522027	chr2:28974177	PPP1CB	0.35	4.73	0.3	3.86e-6	Body mass index;
SARC	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-6.53	-0.39	4.04e-10	Bipolar disorder;
SARC	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.73	-7.32	-0.43	3.94e-12	Platelet count;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg16108253	chr15:34659687	LPCAT4	0.51	6.69	0.4	1.6e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg21782813	chr7:2030301	MAD1L1	0.42	6.61	0.4	2.66e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg18876405	chr7:65276391	NA	-0.48	-5.69	-0.35	3.85e-8	Aortic root size;
SARC	cis	rs1448094	0.935	rs11117108	chr12:86322310	T/A	cg02569458	chr12:86230093	RASSF9	0.4	5.8	0.36	2.17e-8	Major depressive disorder;
SARC	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg25427524	chr10:38739819	LOC399744	-0.61	-9.92	-0.54	1.41e-19	Extrinsic epigenetic age acceleration;
SARC	cis	rs6088580	0.634	rs6579165	chr20:32994715	A/G	cg08999081	chr20:33150536	PIGU	-0.44	-6.65	-0.4	2.07e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs7552404	0.924	rs1303169	chr1:76195041	T/C	cg03433033	chr1:76189801	ACADM	0.48	7.08	0.42	1.73e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg11141652	chr22:24348549	GSTTP1	-0.44	-5.05	-0.31	8.92e-7	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs733592	0.723	rs10875766	chr12:48593580	G/C	cg24011408	chr12:48396354	COL2A1	0.44	5.91	0.36	1.23e-8	Plateletcrit;
SARC	cis	rs1468333	1.000	rs10479179	chr5:137564115	A/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.81	10.96	0.58	7.9399999999999994e-23	Resting heart rate;
SARC	cis	rs1152591	0.669	rs2978381	chr14:64766652	T/C	cg23250157	chr14:64679961	SYNE2	0.44	6.35	0.38	1.11e-9	Atrial fibrillation;
SARC	cis	rs2439831	0.867	rs12443102	chr15:43932103	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.78	7.38	0.44	2.84e-12	Lung cancer in ever smokers;
SARC	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg18252515	chr7:66147081	NA	-0.47	-5.09	-0.32	7.32e-7	Aortic root size;
SARC	cis	rs910316	0.687	rs11627442	chr14:75669649	A/G	cg11812906	chr14:75593930	NEK9	-0.71	-9.58	-0.53	1.53e-18	Height;
SARC	cis	rs1728785	1.000	rs1645927	chr16:68589300	T/G	cg02972257	chr16:68554789	NA	-0.45	-5.32	-0.33	2.48e-7	Ulcerative colitis;
SARC	cis	rs2303759	0.709	rs3760667	chr19:49814832	C/T	cg24324837	chr19:49891574	CCDC155	0.4	4.82	0.3	2.6e-6	Multiple sclerosis;
SARC	cis	rs66887589	0.775	rs6843229	chr4:120424087	T/C	cg09307838	chr4:120376055	NA	0.54	7.39	0.44	2.59e-12	Diastolic blood pressure;
SARC	cis	rs829883	1.000	rs829883	chr12:98879606	G/A	cg25150519	chr12:98850993	NA	0.7	9.48	0.53	3.07e-18	Colorectal adenoma (advanced);
SARC	cis	rs1109861	0.663	rs658469	chr10:11221366	C/T	cg03813164	chr10:11059725	CUGBP2	-0.35	-4.83	-0.3	2.44e-6	Urinary albumin-to-creatinine ratio;
SARC	trans	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg20587970	chr11:113659929	NA	-0.98	-10.31	-0.56	8.79e-21	Hip circumference adjusted for BMI;
SARC	cis	rs11638352	1.000	rs2733204	chr15:44417012	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.77	-5.84	-0.36	1.78e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	cis	rs2380220	1.000	rs9400318	chr6:95972381	T/A	cg04719120	chr6:96025338	MANEA	0.65	6.72	0.4	1.39e-10	Behavioural disinhibition (generation interaction);
SARC	cis	rs6580649	1.000	rs6580649	chr12:48410517	A/G	cg05342945	chr12:48394962	COL2A1	-0.53	-5.74	-0.35	2.88e-8	Lung cancer;
SARC	cis	rs6088813	0.961	rs981818	chr20:33924130	C/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.46	5.53	0.34	8.59e-8	Height;
SARC	cis	rs4555082	0.834	rs2816607	chr14:105718385	A/T	cg13114125	chr14:105738426	BRF1	-0.8	-11.52	-0.6	1.33e-24	Mean platelet volume;Platelet distribution width;
SARC	cis	rs2652822	0.530	rs1017545	chr15:63553994	A/G	cg02713581	chr15:63449717	RPS27L	0.53	5.9	0.36	1.26e-8	Metabolic traits;
SARC	cis	rs3768617	0.510	rs10797838	chr1:183077020	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.74	11.21	0.59	1.28e-23	Fuchs's corneal dystrophy;
SARC	cis	rs2594989	0.887	rs4684071	chr3:11443084	C/G	cg00170343	chr3:11313890	ATG7	0.6	5.6	0.34	5.92e-8	Circulating chemerin levels;
SARC	cis	rs3796352	0.527	rs11716506	chr3:52944328	C/T	cg04865290	chr3:52927548	TMEM110	-0.58	-5.31	-0.33	2.61e-7	Immune reponse to smallpox (secreted IL-2);
SARC	trans	rs561341	0.941	rs550213	chr17:30317518	C/G	cg20587970	chr11:113659929	NA	-1.25	-12.69	-0.64	2.11e-28	Hip circumference adjusted for BMI;
SARC	cis	rs10927875	0.894	rs34957618	chr1:16320499	G/C	cg21385522	chr1:16154831	NA	-0.7	-9.09	-0.51	4.39e-17	Dilated cardiomyopathy;
SARC	cis	rs7647973	0.731	rs9831648	chr3:49214303	G/T	cg07636037	chr3:49044803	WDR6	0.88	9.51	0.53	2.44e-18	Menarche (age at onset);
SARC	cis	rs60871478	0.853	rs62432864	chr7:808405	T/G	cg05535760	chr7:792225	HEATR2	0.77	7.85	0.46	1.52e-13	Cerebrospinal P-tau181p levels;
SARC	cis	rs2112347	0.502	rs34339	chr5:74931333	G/T	cg06933384	chr5:74808293	COL4A3BP;POLK	-0.58	-5.56	-0.34	7.22e-8	Body mass index (joint analysis main effects and smoking interaction);Waist circumference;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Hip circumference;Body mass index;Body mass index in physically active individuals;Obesity;
SARC	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg02725872	chr8:58115012	NA	-0.34	-5.46	-0.34	1.19e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs12458462	0.892	rs2242174	chr18:77458037	T/C	cg23301140	chr18:77439876	CTDP1	0.6	7.78	0.45	2.36e-13	Monocyte count;
SARC	cis	rs796364	0.616	rs2689765	chr2:200696352	T/C	cg23649088	chr2:200775458	C2orf69	0.55	4.73	0.3	3.85e-6	Schizophrenia;
SARC	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg04772025	chr11:68637568	NA	0.5	6.23	0.38	2.16e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs13256369	0.851	rs13266562	chr8:8564065	T/C	cg17143192	chr8:8559678	CLDN23	0.53	5.87	0.36	1.46e-8	Obesity-related traits;
SARC	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	7.76	0.45	2.65e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg16405210	chr4:1374714	KIAA1530	-0.43	-4.81	-0.3	2.68e-6	Obesity-related traits;
SARC	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.39	-4.97	-0.31	1.28e-6	Lymphocyte counts;
SARC	trans	rs1814175	0.817	rs1621090	chr11:49895868	C/A	cg03929089	chr4:120376271	NA	-0.9	-14.56	-0.69	1.39e-34	Height;
SARC	cis	rs6818397	1.000	rs6818397	chr4:3434885	A/C	cg08741688	chr4:3415352	RGS12	0.39	5.4	0.33	1.61e-7	LDL cholesterol levels;Total cholesterol levels;
SARC	cis	rs11719291	0.833	rs11709246	chr3:48859498	G/A	cg07636037	chr3:49044803	WDR6	-0.73	-6.45	-0.39	6.39e-10	Cognitive function;
SARC	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.7	5.17	0.32	4.95e-7	Initial pursuit acceleration;
SARC	cis	rs7772486	0.790	rs2253307	chr6:146196181	T/G	cg05347473	chr6:146136440	FBXO30	0.55	7.71	0.45	3.72e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2033732	0.706	rs10958211	chr8:85074884	G/C	cg05716166	chr8:85095498	RALYL	0.47	5.64	0.35	4.83e-8	Body mass index;
SARC	cis	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg03060546	chr3:49711283	APEH	0.61	6.44	0.39	6.83e-10	Menarche (age at onset);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg13104508	chr6:157527531	ARID1B	-0.76	-6.4	-0.39	8.31e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs524281	0.861	rs10896077	chr11:65851733	C/G	cg14036092	chr11:66035641	RAB1B	-0.5	-5.25	-0.33	3.49e-7	Electroencephalogram traits;
SARC	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg00684032	chr4:1343700	KIAA1530	0.37	5.32	0.33	2.49e-7	Obesity-related traits;
SARC	cis	rs4713118	0.869	rs9393851	chr6:27699581	A/T	cg17221315	chr6:27791827	HIST1H4J	0.49	5.29	0.33	2.77e-7	Parkinson's disease;
SARC	cis	rs6088580	0.634	rs6141465	chr20:32967314	T/C	cg08999081	chr20:33150536	PIGU	-0.42	-6.49	-0.39	4.98e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs9400467	0.537	rs12196955	chr6:111442937	A/G	cg15721981	chr6:111408429	SLC16A10	0.65	5.76	0.35	2.59e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs6450176	0.909	rs1541681	chr5:53304620	G/T	ch.5.1024479R	chr5:53302184	ARL15	-0.68	-7.85	-0.46	1.49e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg20965017	chr5:231967	SDHA	-0.55	-5.27	-0.33	3.04e-7	Breast cancer;
SARC	cis	rs10197940	0.638	rs2288193	chr2:152348842	T/A	cg19508488	chr2:152266495	RIF1	0.51	5.57	0.34	6.84e-8	Lung cancer;
SARC	cis	rs78487399	0.808	rs28700209	chr2:43667465	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-5.69	-0.35	3.78e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs6542838	0.611	rs1976766	chr2:99522754	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-6.29	-0.38	1.56e-9	Fear of minor pain;
SARC	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg21226059	chr5:178986404	RUFY1	0.36	4.92	0.31	1.64e-6	Lung cancer;
SARC	cis	rs17345786	0.628	rs11718446	chr3:101552553	C/T	cg12386194	chr3:101231763	SENP7	0.61	6.93	0.41	4.14e-11	Colonoscopy-negative controls vs population controls;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg11704435	chr12:133281175	PXMP2	0.5	6.48	0.39	5.44e-10	Schizophrenia;
SARC	cis	rs4253772	0.591	rs9627324	chr22:46656511	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.64	7.09	0.42	1.61e-11	LDL cholesterol;Cholesterol, total;
SARC	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg17691542	chr6:26056736	HIST1H1C	0.43	5.04	0.31	9.47e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.6	8.01	0.46	5.34e-14	Menarche (age at onset);
SARC	cis	rs9815354	0.812	rs73069213	chr3:41940590	G/A	cg03022575	chr3:42003672	ULK4	0.7	5.7	0.35	3.66e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs4803468	0.967	rs1077856	chr19:41885221	T/C	cg08477640	chr19:41863820	B9D2	0.46	6.01	0.37	7.09e-9	Height;
SARC	cis	rs6840360	0.550	rs62327349	chr4:152627230	G/C	cg22705602	chr4:152727874	NA	-0.45	-6.99	-0.42	2.86e-11	Intelligence (multi-trait analysis);
SARC	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg12923728	chr3:195709715	SDHAP1	-0.69	-8.57	-0.49	1.49e-15	Pancreatic cancer;
SARC	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg14926445	chr8:58193284	C8orf71	-0.41	-4.89	-0.31	1.86e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs7674212	0.556	rs6533039	chr4:103859538	A/G	cg16532752	chr4:104119610	CENPE	-0.41	-4.77	-0.3	3.18e-6	Type 2 diabetes;
SARC	cis	rs9814567	0.929	rs13316205	chr3:134223563	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-7.03	-0.42	2.3e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs7769051	0.522	rs7761207	chr6:133110430	G/A	cg22852734	chr6:133119734	C6orf192	1.18	7.85	0.46	1.49e-13	Type 2 diabetes nephropathy;
SARC	cis	rs7772486	0.790	rs9376970	chr6:146241472	A/C	cg23711669	chr6:146136114	FBXO30	-0.82	-13.25	-0.66	3.16e-30	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs738322	0.870	rs2277844	chr22:38577515	G/A	cg25457927	chr22:38595422	NA	0.3	6.47	0.39	5.74e-10	Cutaneous nevi;
SARC	cis	rs1348850	0.914	rs7573763	chr2:178249808	C/T	cg23306229	chr2:178417860	TTC30B	0.55	6.38	0.39	9.48e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs10504229	0.679	rs73681882	chr8:58030038	A/G	cg08219700	chr8:58056026	NA	0.62	6.28	0.38	1.64e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs61931739	0.500	rs11053217	chr12:34470036	A/C	cg26384229	chr12:38710491	ALG10B	0.84	12.41	0.63	1.79e-27	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg08677398	chr8:58056175	NA	0.44	5.27	0.33	3.14e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs870825	0.860	rs72689284	chr4:185596680	A/G	cg04058563	chr4:185651563	MLF1IP	0.79	9.72	0.54	5.82e-19	Blood protein levels;
SARC	cis	rs9814567	0.712	rs9838889	chr3:134332311	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.51	-6.61	-0.4	2.53e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs7044106	0.537	rs4434680	chr9:123489688	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	5.55	0.34	7.83e-8	Hip circumference adjusted for BMI;
SARC	cis	rs412050	0.501	rs2876980	chr22:22106535	C/T	cg17089214	chr22:22089827	YPEL1	-0.79	-6.9	-0.41	4.89e-11	Attention deficit hyperactivity disorder;
SARC	cis	rs10463554	0.963	rs34777	chr5:102452258	C/T	cg23492399	chr5:102201601	PAM	-0.5	-5.54	-0.34	8.31e-8	Parkinson's disease;
SARC	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg11890956	chr21:40555474	PSMG1	1.03	15.17	0.7	1.29e-36	Cognitive function;
SARC	cis	rs3126085	0.935	rs11583524	chr1:152161657	T/C	cg09127314	chr1:152161683	NA	-0.43	-4.74	-0.3	3.76e-6	Atopic dermatitis;
SARC	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg05861140	chr6:150128134	PCMT1	-0.37	-4.77	-0.3	3.24e-6	Lung cancer;
SARC	cis	rs2070677	0.932	rs2987786	chr10:135365303	C/T	cg20169779	chr10:135381914	SYCE1	-0.43	-5.37	-0.33	1.9e-7	Gout;
SARC	cis	rs787274	0.850	rs4979176	chr9:115641181	A/G	cg13803584	chr9:115635662	SNX30	0.8	5.95	0.36	9.85e-9	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs3784262	0.631	rs4646566	chr15:58348173	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.34	-5.04	-0.31	9.49e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	trans	rs9388451	0.839	rs980014	chr6:126068001	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.57	-7.34	-0.43	3.6e-12	Brugada syndrome;
SARC	cis	rs1113500	0.814	rs893983	chr1:108630338	C/T	cg06207961	chr1:108661230	NA	-0.37	-4.88	-0.3	1.94e-6	Growth-regulated protein alpha levels;
SARC	cis	rs3768617	0.510	rs12061219	chr1:183101471	G/A	cg13390022	chr1:182993471	LAMC1	0.31	4.79	0.3	3.01e-6	Fuchs's corneal dystrophy;
SARC	cis	rs9814567	1.000	rs1814336	chr3:134200823	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-7.06	-0.42	1.85e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs1355223	0.902	rs1361645	chr11:34746385	G/C	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-5.28	-0.33	2.93e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs2832191	0.740	rs2832177	chr21:30478353	G/A	cg24692254	chr21:30365293	RNF160	-1.05	-18.71	-0.77	2.63e-48	Dental caries;
SARC	trans	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg21659725	chr3:3221576	CRBN	-0.53	-6.84	-0.41	6.93e-11	Intelligence (multi-trait analysis);
SARC	cis	rs6502050	0.626	rs11868521	chr17:80100195	T/G	cg13939156	chr17:80058883	NA	0.37	5.72	0.35	3.23e-8	Life satisfaction;
SARC	cis	rs12477438	0.501	rs11123770	chr2:99825102	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.96	15.89	0.72	5.3e-39	Chronic sinus infection;
SARC	trans	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg00938859	chr5:1591904	SDHAP3	0.79	7.66	0.45	5.1e-13	Breast cancer;
SARC	cis	rs4642101	0.534	rs13316229	chr3:12807371	C/T	cg05775895	chr3:12838266	CAND2	0.54	7.6	0.45	6.98e-13	QRS complex (12-leadsum);
SARC	cis	rs9462027	0.606	rs6906129	chr6:34801160	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-6.12	-0.37	3.99e-9	Systemic lupus erythematosus;
SARC	cis	rs8077889	0.645	rs1230396	chr17:41843029	A/C	cg26893861	chr17:41843967	DUSP3	-1.04	-17.15	-0.75	3.37e-43	Triglycerides;
SARC	cis	rs7520050	0.807	rs28844317	chr1:46209207	T/C	cg24296786	chr1:45957014	TESK2	-0.44	-5.68	-0.35	4.09e-8	Red blood cell count;Reticulocyte count;
SARC	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg05313129	chr8:58192883	C8orf71	-0.45	-5.54	-0.34	7.95e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1153858	1.000	rs12593370	chr15:45617417	C/T	cg03999130	chr15:45571217	NA	0.4	5.07	0.32	8.23e-7	Homoarginine levels;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg08207256	chr19:10828848	DNM2;MIR638	-0.51	-6.32	-0.38	1.3e-9	Schizophrenia;
SARC	cis	rs9894429	1.000	rs4074915	chr17:79579230	G/A	cg18240062	chr17:79603768	NPLOC4	-0.71	-9.64	-0.53	1.03e-18	Eye color traits;
SARC	cis	rs6570726	0.791	rs9376953	chr6:145912226	G/T	cg23711669	chr6:146136114	FBXO30	0.88	14.58	0.69	1.2e-34	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg21755457	chr12:54020320	ATF7	-0.51	-6.3	-0.38	1.44e-9	Breast cancer;
SARC	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg10253484	chr15:75165896	SCAMP2	-0.39	-4.74	-0.3	3.74e-6	Breast cancer;
SARC	cis	rs4742903	0.935	rs1507513	chr9:106973857	A/G	cg14250997	chr9:106856677	SMC2	0.43	5.47	0.34	1.14e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg20102877	chr2:27665638	KRTCAP3	0.38	5.4	0.33	1.63e-7	Total body bone mineral density;
SARC	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.97	14.05	0.68	6.85e-33	Gut microbiome composition (summer);
SARC	cis	rs6807306	1.000	rs9844216	chr3:167430441	G/A	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.54	5.24	0.32	3.53e-7	Mean platelet volume;
SARC	cis	rs5167	0.586	rs4803774	chr19:45450872	A/G	cg20090143	chr19:45452003	APOC2	0.31	4.93	0.31	1.55e-6	Blood protein levels;
SARC	cis	rs826838	1.000	rs11183160	chr12:38676702	T/C	cg13010199	chr12:38710504	ALG10B	0.82	11.84	0.61	1.27e-25	Heart rate;
SARC	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg07636037	chr3:49044803	WDR6	0.99	17.59	0.76	1.22e-44	Parkinson's disease;
SARC	cis	rs7552404	0.924	rs1146574	chr1:76202671	A/G	cg22875332	chr1:76189707	ACADM	0.4	5.72	0.35	3.18e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg13108194	chr13:111367256	ING1	-0.71	-5.07	-0.32	8.24e-7	Obesity-related traits;
SARC	cis	rs870825	0.549	rs28579266	chr4:185627262	T/C	cg04058563	chr4:185651563	MLF1IP	0.81	11.25	0.59	9.68e-24	Blood protein levels;
SARC	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-10.49	-0.57	2.44e-21	Chronic sinus infection;
SARC	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg11644478	chr21:40555479	PSMG1	1.03	14.49	0.69	2.39e-34	Cognitive function;
SARC	cis	rs1395	0.961	rs4665963	chr2:27528692	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.34	-4.9	-0.31	1.77e-6	Blood metabolite levels;
SARC	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg23172400	chr8:95962367	TP53INP1	-0.31	-5.38	-0.33	1.83e-7	Type 2 diabetes;
SARC	cis	rs112158604	1	rs112158604	chr1:150696792	TCTTCTGCAG/T	cg13175981	chr1:150552382	MCL1	0.64	8.81	0.5	2.83e-16	Lymphocyte counts;
SARC	cis	rs1873147	1.000	rs4774470	chr15:63312119	G/A	cg05507819	chr15:63340323	TPM1	-0.47	-5.13	-0.32	6.15e-7	Orofacial clefts;
SARC	cis	rs6598163	0.517	rs11246827	chr12:132296423	G/A	cg15284433	chr12:132323321	MMP17	-0.37	-4.75	-0.3	3.6e-6	Migraine;
SARC	cis	rs10936602	0.520	rs28525288	chr3:169554872	A/G	cg27020690	chr3:169482358	NA	0.39	4.97	0.31	1.28e-6	Renal cell carcinoma;
SARC	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.68	9.08	0.51	4.82e-17	Menarche (age at onset);
SARC	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg21782813	chr7:2030301	MAD1L1	0.39	6.14	0.37	3.59e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg25739689	chr13:111141839	COL4A2	0.67	5.14	0.32	5.82e-7	Obesity-related traits;
SARC	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1348850	0.793	rs13020788	chr2:178480714	C/A	cg22681709	chr2:178499509	PDE11A	-0.4	-5.29	-0.33	2.84e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg09658576	chr7:139477957	TBXAS1;HIPK2	0.78	6.69	0.4	1.66e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs8014131	0.639	rs1543388	chr14:85984195	G/A	cg10406690	chr14:85995726	FLRT2	0.4	5.08	0.32	7.57e-7	Menarche (age at onset);
SARC	cis	rs4481887	1.000	rs4372295	chr1:248464871	G/T	cg13385794	chr1:248469461	NA	0.33	5.12	0.32	6.46e-7	Common traits (Other);
SARC	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg09323728	chr8:95962352	TP53INP1	-0.32	-5.47	-0.34	1.18e-7	Type 2 diabetes;
SARC	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg11987759	chr7:65425863	GUSB	0.49	6.06	0.37	5.48e-9	Aortic root size;
SARC	cis	rs9341808	0.718	rs9352803	chr6:80864667	G/T	cg08355045	chr6:80787529	NA	0.34	5.44	0.34	1.31e-7	Sitting height ratio;
SARC	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	11.16	0.59	1.94e-23	Alzheimer's disease;
SARC	cis	rs2486288	0.656	rs12904150	chr15:45547605	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.5	-6.29	-0.38	1.57e-9	Glomerular filtration rate;
SARC	cis	rs10876993	0.890	rs774887	chr12:58034835	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.47	-5.87	-0.36	1.49e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs73086581	1.000	rs73086549	chr20:3954662	C/A	cg02187196	chr20:3869020	PANK2	0.67	6.4	0.39	8.3e-10	Response to antidepressants in depression;
SARC	cis	rs10876993	0.928	rs1689595	chr12:58056763	C/T	cg18357645	chr12:58087776	OS9	0.49	6.53	0.39	4.11e-10	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg08219700	chr8:58056026	NA	0.57	5.52	0.34	9.12e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6430585	0.528	rs309151	chr2:136661150	C/T	cg07169764	chr2:136633963	MCM6	1.02	13.4	0.66	9.47e-31	Corneal structure;
SARC	cis	rs1448094	0.549	rs57614821	chr12:86235361	A/C	cg00310523	chr12:86230176	RASSF9	0.33	5.3	0.33	2.62e-7	Major depressive disorder;
SARC	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg27347728	chr4:17578864	LAP3	0.48	6.1	0.37	4.5e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg07636037	chr3:49044803	WDR6	0.98	17.1	0.75	4.92e-43	Parkinson's disease;
SARC	cis	rs820218	0.728	rs820152	chr17:73616088	T/C	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.5	6.21	0.38	2.38e-9	Rotator cuff tears;
SARC	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg10523679	chr1:76189770	ACADM	0.51	6.81	0.41	8.23e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6429082	0.755	rs291371	chr1:235693105	C/G	cg26050004	chr1:235667680	B3GALNT2	0.64	8.54	0.49	1.75e-15	Adiposity;
SARC	cis	rs2153535	0.580	rs2327064	chr6:8454052	C/T	cg07606381	chr6:8435919	SLC35B3	0.75	10.24	0.56	1.44e-20	Motion sickness;
SARC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg09373136	chr17:61933544	TCAM1	-0.44	-6.07	-0.37	5.25e-9	Prudent dietary pattern;
SARC	trans	rs1994135	0.654	rs1447872	chr12:33718343	C/A	cg26384229	chr12:38710491	ALG10B	0.85	10.48	0.57	2.72e-21	Resting heart rate;
SARC	cis	rs10791097	0.694	rs1893017	chr11:130756253	C/T	cg12179176	chr11:130786555	SNX19	0.76	11.43	0.6	2.59e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs372883	0.600	rs2832294	chr21:30739671	A/C	cg08807101	chr21:30365312	RNF160	0.59	7.45	0.44	1.81e-12	Pancreatic cancer;
SARC	cis	rs524281	0.773	rs10791862	chr11:66013664	T/C	cg14036092	chr11:66035641	RAB1B	-0.59	-6.28	-0.38	1.67e-9	Electroencephalogram traits;
SARC	cis	rs7666738	0.830	rs13136930	chr4:98937933	A/T	cg05340658	chr4:99064831	C4orf37	0.67	9.07	0.51	5.22e-17	Colonoscopy-negative controls vs population controls;
SARC	trans	rs6964833	1.000	rs36044436	chr7:74089819	G/C	cg07504079	chr7:72649617	NCF1B	-0.61	-6.53	-0.39	4.12e-10	Menarche (age at onset);
SARC	cis	rs1153858	1.000	rs7167900	chr15:45639471	A/G	cg21132104	chr15:45694354	SPATA5L1	0.77	10.71	0.57	5.01e-22	Homoarginine levels;
SARC	cis	rs4466137	0.909	rs4466136	chr5:82985576	T/G	cg16102102	chr5:83017553	HAPLN1	-0.76	-9.76	-0.54	4.4e-19	Prostate cancer;
SARC	cis	rs3820928	0.560	rs12620324	chr2:227950021	C/T	cg11843606	chr2:227700838	RHBDD1	-0.48	-5.39	-0.33	1.69e-7	Pulmonary function;
SARC	cis	rs4423214	1.000	rs12785878	chr11:71167449	G/T	cg24826892	chr11:71159390	DHCR7	0.45	5.56	0.34	7.47e-8	Vitamin D levels;
SARC	cis	rs1348850	0.567	rs3770011	chr2:178537890	C/T	cg22681709	chr2:178499509	PDE11A	-0.36	-5.14	-0.32	5.89e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1003719	0.715	rs2835647	chr21:38546773	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.48	-0.53	3.11e-18	Eye color traits;
SARC	cis	rs12979813	1.000	rs8101802	chr19:11336182	G/C	cg00586551	chr19:11347513	LOC55908;DOCK6	0.43	5.09	0.32	7.29e-7	HDL cholesterol;
SARC	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	6.98	0.42	3.08e-11	Platelet count;
SARC	cis	rs1669338	0.507	rs4685609	chr3:3202279	T/C	cg16797762	chr3:3221439	CRBN	-0.94	-9.67	-0.54	8.3e-19	White matter integrity;
SARC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.58	-0.4	3.11e-10	Total body bone mineral density;
SARC	cis	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg08975724	chr8:8085496	FLJ10661	0.51	6.61	0.4	2.58e-10	Mood instability;
SARC	cis	rs546131	0.614	rs12791769	chr11:34834268	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-4.83	-0.3	2.52e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs7635838	0.617	rs346084	chr3:11281159	C/T	cg00170343	chr3:11313890	ATG7	0.74	9.83	0.54	2.6e-19	HDL cholesterol;
SARC	cis	rs9443189	1.000	rs1280044	chr6:76522602	A/G	cg01950844	chr6:76311363	SENP6	-0.75	-6.48	-0.39	5.46e-10	Prostate cancer;
SARC	cis	rs11630290	0.592	rs12324556	chr15:64160951	G/A	cg12036633	chr15:63758958	NA	0.48	4.94	0.31	1.52e-6	Iris characteristics;
SARC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg17178900	chr1:205818956	PM20D1	0.75	11.58	0.6	8.42e-25	Menarche (age at onset);
SARC	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg13206674	chr6:150067644	NUP43	0.46	6.1	0.37	4.29e-9	Lung cancer;
SARC	cis	rs7592578	0.581	rs59109438	chr2:191287683	A/G	cg27211696	chr2:191398769	TMEM194B	-0.48	-5.2	-0.32	4.39e-7	Diastolic blood pressure;
SARC	cis	rs4727027	0.933	rs6464940	chr7:148826309	G/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.47	5.7	0.35	3.52e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs7681440	0.904	rs28403500	chr4:90769729	T/G	cg06632027	chr4:90757378	SNCA	0.39	5.66	0.35	4.49e-8	Dementia with Lewy bodies;
SARC	cis	rs10754283	0.967	rs10922680	chr1:90101326	C/T	cg21401794	chr1:90099060	LRRC8C	-0.59	-8.21	-0.47	1.48e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg02725872	chr8:58115012	NA	-0.36	-6.12	-0.37	3.91e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9916302	0.904	rs4357971	chr17:37717280	C/T	cg20243544	chr17:37824526	PNMT	0.54	6.33	0.38	1.28e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs9787249	0.957	rs12086750	chr1:40210468	G/C	cg02773041	chr1:40204384	PPIE	0.53	6.47	0.39	5.79e-10	Blood protein levels;
SARC	cis	rs7666738	0.830	rs10022331	chr4:98960392	C/A	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs8067545	0.750	rs7208635	chr17:19990990	T/C	cg13482628	chr17:19912719	NA	0.53	7.07	0.42	1.78e-11	Schizophrenia;
SARC	cis	rs6484504	0.600	rs972714	chr11:31358875	T/G	cg02090638	chr11:31391270	DNAJC24;DCDC1	0.39	5.0	0.31	1.15e-6	Red blood cell count;
SARC	cis	rs921968	0.612	rs496908	chr2:219357742	A/T	cg02176678	chr2:219576539	TTLL4	0.41	6.37	0.39	9.97e-10	Mean corpuscular hemoglobin concentration;
SARC	cis	rs5758659	0.652	rs133340	chr22:42417687	A/T	cg04733989	chr22:42467013	NAGA	-0.53	-6.97	-0.42	3.23e-11	Cognitive function;
SARC	cis	rs11098499	0.954	rs11940028	chr4:120411907	T/C	cg24375607	chr4:120327624	NA	0.41	4.86	0.3	2.12e-6	Corneal astigmatism;
SARC	cis	rs2075371	1.000	rs1862051	chr7:133981021	G/A	cg11752832	chr7:134001865	SLC35B4	0.56	7.28	0.43	5.13e-12	Mean platelet volume;
SARC	cis	rs7223966	0.961	rs35844156	chr17:61837568	G/A	cg00588841	chr17:61851480	DDX42;CCDC47	-0.67	-7.22	-0.43	7.19e-12	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs4820539	0.902	rs9612237	chr22:23472954	T/C	cg14186256	chr22:23484241	RTDR1	0.88	14.42	0.69	3.9e-34	Bone mineral density;
SARC	cis	rs10140922	0.931	rs4982262	chr14:35822193	C/T	cg26967526	chr14:35346199	BAZ1A	-0.4	-5.04	-0.31	9.47e-7	Hip circumference adjusted for BMI;
SARC	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg12042659	chr19:58951599	ZNF132	0.41	5.46	0.34	1.23e-7	Uric acid clearance;
SARC	cis	rs2204008	0.548	rs2320740	chr12:38166421	G/A	cg26384229	chr12:38710491	ALG10B	0.89	13.09	0.65	1.03e-29	Bladder cancer;
SARC	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg06108461	chr20:60628389	TAF4	-0.9	-12.11	-0.62	1.64e-26	Body mass index;
SARC	cis	rs3092073	0.624	rs3848719	chr20:44596545	G/A	cg17986701	chr20:44574422	PCIF1	0.36	5.04	0.31	9.55e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg12257692	chr3:49977190	RBM6	-0.28	-4.91	-0.31	1.7e-6	Body mass index;
SARC	cis	rs7582180	0.629	rs6716636	chr2:100940067	C/G	cg14675211	chr2:100938903	LONRF2	0.51	7.68	0.45	4.44e-13	Intelligence (multi-trait analysis);
SARC	cis	rs2228479	0.850	rs17226973	chr16:89825248	T/C	cg26513180	chr16:89883248	FANCA	0.72	4.79	0.3	2.99e-6	Skin colour saturation;
SARC	cis	rs7103648	0.838	rs2293576	chr11:47434986	A/G	cg20307385	chr11:47447363	PSMC3	-0.8	-12.08	-0.62	2.07e-26	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs11997175	0.546	rs10808337	chr8:33583850	T/C	ch.8.33884649F	chr8:33765107	NA	0.48	6.03	0.37	6.22e-9	Body mass index;
SARC	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.62	-6.73	-0.4	1.29e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs826838	0.868	rs12322306	chr12:39130021	A/G	cg26384229	chr12:38710491	ALG10B	-0.76	-11.59	-0.6	7.97e-25	Heart rate;
SARC	cis	rs57221529	0.825	rs72703051	chr5:582997	G/A	cg09021430	chr5:549028	NA	-0.44	-5.2	-0.32	4.33e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs6733011	0.508	rs6542843	chr2:99533729	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-6.08	-0.37	4.77e-9	Bipolar disorder;
SARC	cis	rs787274	0.850	rs7873289	chr9:115638386	G/A	cg13803584	chr9:115635662	SNX30	-0.88	-6.09	-0.37	4.52e-9	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs7662987	0.517	rs1311617	chr4:100012425	T/G	cg13256891	chr4:100009986	ADH5	0.66	8.33	0.48	7.17e-15	Smoking initiation;
SARC	cis	rs4713675	0.565	rs4711343	chr6:33714548	G/A	cg15676125	chr6:33679581	C6orf125	0.58	7.14	0.42	1.15e-11	Plateletcrit;
SARC	cis	rs2718058	0.601	rs2709104	chr7:37762810	A/G	cg15028436	chr7:37888078	TXNDC3	-0.35	-4.91	-0.31	1.73e-6	Alzheimer's disease (late onset);
SARC	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.62	-6.73	-0.4	1.29e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7727544	0.735	rs2631370	chr5:131703776	T/C	cg24060327	chr5:131705240	SLC22A5	0.68	8.64	0.49	8.86e-16	Blood metabolite levels;
SARC	cis	rs80130819	0.688	rs2634672	chr12:48649640	G/A	cg05342945	chr12:48394962	COL2A1	-0.53	-5.69	-0.35	3.7e-8	Prostate cancer;
SARC	cis	rs7084402	0.967	rs1658440	chr10:60323933	T/A	cg07615347	chr10:60278583	BICC1	0.6	8.78	0.5	3.68e-16	Refractive error;
SARC	cis	rs11997175	0.625	rs11777333	chr8:33596470	C/A	ch.8.33884649F	chr8:33765107	NA	0.48	6.05	0.37	5.66e-9	Body mass index;
SARC	cis	rs73206853	0.841	rs17792048	chr12:110866543	C/A	cg10860002	chr12:110842031	ANAPC7	0.61	4.85	0.3	2.22e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs12973672	1.000	rs10421768	chr19:35772899	A/G	cg12095397	chr19:35769544	USF2	0.37	4.83	0.3	2.43e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg26335602	chr6:28129616	ZNF389	0.53	5.88	0.36	1.43e-8	Depression;
SARC	cis	rs35160687	0.829	rs13017143	chr2:86466549	C/T	cg10973622	chr2:86423274	IMMT	-0.39	-5.0	-0.31	1.14e-6	Night sleep phenotypes;
SARC	trans	rs1814175	0.645	rs1608632	chr11:49967148	C/T	cg03929089	chr4:120376271	NA	-0.82	-11.87	-0.61	1.01e-25	Height;
SARC	trans	rs2727020	1.000	rs2727020	chr11:49111407	C/G	cg15704280	chr7:45808275	SEPT13	0.74	9.71	0.54	6.23e-19	Coronary artery disease;
SARC	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg22875332	chr1:76189707	ACADM	0.41	5.77	0.35	2.47e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg11987759	chr7:65425863	GUSB	-0.5	-6.47	-0.39	5.83e-10	Aortic root size;
SARC	cis	rs1878931	0.501	rs9635547	chr16:3416664	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.74	9.1	0.51	4.19e-17	Body mass index (adult);
SARC	cis	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg00745463	chr17:30367425	LRRC37B	-0.69	-5.28	-0.33	2.96e-7	Hip circumference adjusted for BMI;
SARC	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg11764359	chr7:65958608	NA	-0.83	-11.09	-0.59	3.2e-23	Aortic root size;
SARC	cis	rs9303542	0.559	rs2326012	chr17:46618581	C/T	cg04904318	chr17:46607828	HOXB1	-0.45	-5.03	-0.31	9.89e-7	Ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs7851660	0.527	rs7859751	chr9:100575888	C/T	cg13688889	chr9:100608707	NA	-0.46	-5.4	-0.33	1.62e-7	Strep throat;
SARC	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.29	-0.43	4.84e-12	Gut microbiome composition (summer);
SARC	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg11766577	chr21:47581405	C21orf56	-0.49	-5.87	-0.36	1.5e-8	Testicular germ cell tumor;
SARC	cis	rs2070488	0.965	rs2126534	chr3:38445165	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	14.46	0.69	3.06e-34	Electrocardiographic conduction measures;
SARC	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg11890956	chr21:40555474	PSMG1	1.17	19.37	0.79	1.93e-50	Cognitive function;
SARC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg20607798	chr8:58055168	NA	0.58	5.55	0.34	7.69e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg12564285	chr5:131593104	PDLIM4	-0.33	-4.93	-0.31	1.55e-6	Breast cancer;
SARC	cis	rs7945705	0.905	rs7947631	chr11:8844909	A/G	cg14711859	chr11:8959438	ASCL3	0.34	5.24	0.32	3.59e-7	Hemoglobin concentration;
SARC	cis	rs9300255	0.566	rs1716169	chr12:123716930	A/T	cg00376283	chr12:123451042	ABCB9	0.52	4.96	0.31	1.36e-6	Neutrophil percentage of white cells;
SARC	cis	rs13161895	1.000	rs6873994	chr5:179436696	T/G	cg06664874	chr5:179499304	RNF130	-0.49	-4.78	-0.3	3.14e-6	LDL cholesterol;
SARC	cis	rs3741404	0.672	rs4980524	chr11:63959259	A/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	9.78	0.54	3.86e-19	Platelet count;
SARC	cis	rs262150	0.574	rs2730273	chr7:158797754	A/C	cg09640425	chr7:158790006	NA	-0.39	-5.39	-0.33	1.69e-7	Facial morphology (factor 20);
SARC	cis	rs13191362	1.000	rs35593345	chr6:163174981	G/C	cg21926612	chr6:163149169	PACRG;PARK2	0.75	6.37	0.39	9.91e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs10931896	0.531	rs296801	chr2:201142812	C/T	cg17644776	chr2:200775616	C2orf69	0.42	5.68	0.35	3.96e-8	Systolic blood pressure;
SARC	cis	rs4969178	0.965	rs938350	chr17:76399552	C/T	cg20026190	chr17:76395443	PGS1	0.39	5.3	0.33	2.75e-7	HDL cholesterol levels;
SARC	cis	rs2011503	1.000	rs754256	chr19:19578591	A/G	cg03709012	chr19:19516395	GATAD2A	-0.64	-5.51	-0.34	9.58e-8	Bipolar disorder;
SARC	cis	rs4372836	0.729	rs12714241	chr2:28969413	T/C	cg09522027	chr2:28974177	PPP1CB	0.35	4.72	0.3	3.99e-6	Body mass index;
SARC	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg11764359	chr7:65958608	NA	0.8	10.0	0.55	8.09e-20	Aortic root size;
SARC	cis	rs9309473	1.000	rs13398956	chr2:73720258	C/A	cg20560298	chr2:73613845	ALMS1	-0.53	-6.31	-0.38	1.36e-9	Metabolite levels;
SARC	cis	rs4792901	0.959	rs12603797	chr17:41630813	A/G	cg22562494	chr17:41607896	ETV4	-0.34	-5.4	-0.33	1.68e-7	Dupuytren's disease;
SARC	cis	rs2153535	0.526	rs1796689	chr6:8536433	A/C	cg07606381	chr6:8435919	SLC35B3	0.75	10.53	0.57	1.88e-21	Motion sickness;
SARC	cis	rs2832191	0.646	rs2832214	chr21:30517127	C/T	cg08807101	chr21:30365312	RNF160	-0.7	-8.42	-0.48	3.76e-15	Dental caries;
SARC	trans	rs61931739	0.534	rs1852222	chr12:34008665	C/A	cg26384229	chr12:38710491	ALG10B	0.75	10.64	0.57	8.46e-22	Morning vs. evening chronotype;
SARC	cis	rs60871478	1.000	rs62432242	chr7:797715	G/A	cg19087971	chr7:751233	PRKAR1B	-0.43	-4.97	-0.31	1.28e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs4148883	0.504	rs28720150	chr4:100132790	T/G	cg12011299	chr4:100065546	ADH4	-0.33	-5.77	-0.35	2.49e-8	Alcohol dependence;
SARC	cis	rs796364	0.806	rs6435040	chr2:200861161	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.71	6.07	0.37	5.18e-9	Schizophrenia;
SARC	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg22535103	chr8:58192502	C8orf71	-0.6	-6.15	-0.37	3.42e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2882667	0.858	rs66839813	chr5:138442322	A/T	cg04439458	chr5:138467593	SIL1	-0.28	-4.9	-0.31	1.76e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs62064224	0.533	rs11657826	chr17:30790386	T/A	cg25809561	chr17:30822961	MYO1D	0.35	5.04	0.31	9.33e-7	Schizophrenia;
SARC	cis	rs4727027	0.870	rs11525060	chr7:148801091	G/A	cg23583168	chr7:148888333	NA	-0.72	-10.01	-0.55	7.48e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs1003719	0.843	rs1003721	chr21:38492657	T/G	cg10648535	chr21:38446584	PIGP;TTC3	0.58	7.71	0.45	3.55e-13	Eye color traits;
SARC	trans	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg21659725	chr3:3221576	CRBN	0.53	6.83	0.41	7.24e-11	Intelligence (multi-trait analysis);
SARC	trans	rs61931739	0.517	rs10844815	chr12:34245150	G/A	cg13010199	chr12:38710504	ALG10B	0.74	10.06	0.55	5.14e-20	Morning vs. evening chronotype;
SARC	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.8	-12.15	-0.62	1.27e-26	Personality dimensions;
SARC	cis	rs3126085	0.935	rs12760382	chr1:152260287	G/T	cg26876637	chr1:152193138	HRNR	-0.49	-5.61	-0.35	5.65e-8	Atopic dermatitis;
SARC	cis	rs7044106	0.762	rs12003646	chr9:123470621	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	5.88	0.36	1.43e-8	Hip circumference adjusted for BMI;
SARC	cis	rs8114671	0.740	rs3761141	chr20:33737824	A/C	cg24642439	chr20:33292090	TP53INP2	0.46	5.37	0.33	1.93e-7	Height;
SARC	cis	rs2243480	0.706	rs6460257	chr7:65196780	C/T	cg18252515	chr7:66147081	NA	-0.96	-9.04	-0.51	6.28e-17	Diabetic kidney disease;
SARC	cis	rs936229	0.668	rs67411922	chr15:75187612	A/G	cg10253484	chr15:75165896	SCAMP2	-0.55	-6.02	-0.37	6.71e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs17270561	0.639	rs9356989	chr6:25781950	A/G	cg17691542	chr6:26056736	HIST1H1C	0.6	7.4	0.44	2.48e-12	Iron status biomarkers;
SARC	cis	rs12477438	0.822	rs6727170	chr2:99588042	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-8.52	-0.49	2.06e-15	Chronic sinus infection;
SARC	cis	rs7614311	0.681	rs10510903	chr3:63970192	C/G	cg22134162	chr3:63841271	THOC7	-0.44	-4.82	-0.3	2.65e-6	Lung function (FVC);Lung function (FEV1);
SARC	cis	rs11098499	0.954	rs6857105	chr4:120222298	C/G	cg09160332	chr4:120329925	NA	-0.34	-4.82	-0.3	2.58e-6	Corneal astigmatism;
SARC	cis	rs524281	0.861	rs3953856	chr11:65965908	T/A	cg14036092	chr11:66035641	RAB1B	-0.47	-4.88	-0.3	1.96e-6	Electroencephalogram traits;
SARC	cis	rs765787	0.530	rs11854294	chr15:45527996	A/G	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.51e-10	Uric acid levels;
SARC	cis	rs910316	1.000	rs10149880	chr14:75633008	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.51	-6.84	-0.41	6.72e-11	Height;
SARC	cis	rs4727027	0.901	rs6944781	chr7:148829566	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.47	5.7	0.35	3.52e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg04772025	chr11:68637568	NA	0.48	5.94	0.36	1.03e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg27266027	chr21:40555129	PSMG1	0.5	5.52	0.34	9.07e-8	Cognitive function;
SARC	cis	rs2013441	0.613	rs4925082	chr17:19994673	C/T	cg13482628	chr17:19912719	NA	-0.38	-4.86	-0.3	2.11e-6	Obesity-related traits;
SARC	cis	rs9435341	0.896	rs1623927	chr1:107596120	T/C	cg09367891	chr1:107599246	PRMT6	-0.75	-9.09	-0.51	4.47e-17	Facial morphology (factor 21, depth of nasal alae);
SARC	cis	rs6060717	0.610	rs6060755	chr20:34606915	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-4.73	-0.3	3.93e-6	Hip circumference adjusted for BMI;
SARC	cis	rs239198	0.602	rs11755579	chr6:101322469	A/C	cg09795085	chr6:101329169	ASCC3	0.47	6.03	0.37	6.32e-9	Menarche (age at onset);
SARC	cis	rs2963155	0.518	rs712189	chr5:142631258	C/T	cg17617527	chr5:142782415	NR3C1	0.81	5.67	0.35	4.31e-8	Breast cancer;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg01036173	chr9:5437898	C9orf46	-0.74	-6.25	-0.38	1.95e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs10504229	0.679	rs16921606	chr8:58034477	A/C	cg11062466	chr8:58055876	NA	0.49	4.94	0.31	1.5e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs7223966	1.000	rs11871767	chr17:61698723	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	6.69	0.4	1.64e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6860806	0.507	rs200837	chr5:131699958	G/A	cg24060327	chr5:131705240	SLC22A5	-0.71	-8.46	-0.48	2.92e-15	Breast cancer;
SARC	cis	rs992157	0.798	rs4996257	chr2:219162836	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.62	8.63	0.49	9.72e-16	Colorectal cancer;
SARC	cis	rs9457247	1.000	rs2769347	chr6:167371737	T/A	cg07741184	chr6:167504864	NA	-0.3	-5.6	-0.34	5.89e-8	Crohn's disease;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg08889949	chr3:49044473	P4HTM;WDR6	-0.76	-6.24	-0.38	2.02e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg03185022	chr7:2884158	GNA12	0.45	5.02	0.31	1.03e-6	Height;
SARC	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg24549020	chr5:56110836	MAP3K1	0.53	5.83	0.36	1.82e-8	Initial pursuit acceleration;
SARC	cis	rs950776	0.616	rs3743077	chr15:78894896	C/T	cg17108064	chr15:78857060	CHRNA5	0.32	5.43	0.33	1.44e-7	Sudden cardiac arrest;
SARC	cis	rs67311347	0.544	rs2887965	chr3:40334154	A/G	cg09455208	chr3:40491958	NA	-0.32	-5.27	-0.33	3.04e-7	Renal cell carcinoma;
SARC	cis	rs763121	0.925	rs5750654	chr22:39051428	T/C	cg21395723	chr22:39101663	GTPBP1	0.54	6.27	0.38	1.7e-9	Menopause (age at onset);
SARC	cis	rs2180341	0.513	rs12196828	chr6:127696864	C/T	cg24812749	chr6:127587940	RNF146	0.55	6.61	0.4	2.54e-10	Breast cancer;
SARC	cis	rs6964587	0.843	rs56075286	chr7:91731518	G/A	cg17063962	chr7:91808500	NA	0.96	16.47	0.73	6.03e-41	Breast cancer;
SARC	cis	rs2576037	0.796	rs2571020	chr18:44584189	A/T	cg19077165	chr18:44547161	KATNAL2	0.45	6.22	0.38	2.25e-9	Personality dimensions;
SARC	cis	rs957448	1.000	rs60655325	chr8:95564834	G/T	cg26464482	chr8:95565502	KIAA1429	0.43	4.83	0.3	2.45e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs9814567	1.000	rs13087875	chr3:134261123	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	7.08	0.42	1.73e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg11062466	chr8:58055876	NA	0.66	6.12	0.37	3.97e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6545883	0.859	rs62149714	chr2:61603869	T/G	cg15711740	chr2:61764176	XPO1	0.4	4.73	0.3	3.92e-6	Tuberculosis;
SARC	trans	rs8002861	0.935	rs4101376	chr13:44469835	C/T	cg17145862	chr1:211918768	LPGAT1	-0.57	-9.52	-0.53	2.32e-18	Leprosy;
SARC	cis	rs2834188	1.000	rs1018742	chr21:34686381	A/G	cg14352951	chr21:34696688	IFNAR1	0.45	5.49	0.34	1.05e-7	Narcolepsy;
SARC	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	cis	rs6545883	0.560	rs11677775	chr2:61503110	T/C	cg10580144	chr2:61372316	C2orf74	-0.4	-5.42	-0.33	1.47e-7	Tuberculosis;
SARC	cis	rs10512697	0.803	rs11747645	chr5:3576820	A/G	cg19473799	chr5:3511975	NA	0.67	5.12	0.32	6.47e-7	Immune response to smallpox vaccine (IL-6);
SARC	cis	rs3768617	0.966	rs10797850	chr1:183094802	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.57	7.65	0.45	5.26e-13	Fuchs's corneal dystrophy;
SARC	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg11764359	chr7:65958608	NA	-0.88	-12.78	-0.64	1.04e-28	Aortic root size;
SARC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg09373136	chr17:61933544	TCAM1	-0.44	-6.04	-0.37	6.05e-9	Prudent dietary pattern;
SARC	cis	rs10078	0.515	rs890984	chr5:479540	A/G	cg24955955	chr5:415729	AHRR	0.72	6.59	0.4	2.83e-10	Fat distribution (HIV);
SARC	cis	rs2235649	0.798	rs4100646	chr16:1850446	C/T	cg03715980	chr16:1756201	MAPK8IP3	0.43	4.86	0.3	2.15e-6	Blood metabolite levels;
SARC	cis	rs9303401	0.659	rs35928756	chr17:56702652	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	12.09	0.62	2e-26	Cognitive test performance;
SARC	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg05368731	chr17:41323189	NBR1	0.79	9.68	0.54	7.38e-19	Menopause (age at onset);
SARC	cis	rs12579753	0.956	rs35278765	chr12:82173126	T/C	cg07988820	chr12:82153109	PPFIA2	-0.6	-6.91	-0.41	4.54e-11	Resting heart rate;
SARC	cis	rs4481887	0.708	rs6587463	chr1:248544452	G/C	cg13385794	chr1:248469461	NA	0.34	5.55	0.34	7.62e-8	Common traits (Other);
SARC	cis	rs11718455	0.960	rs11929518	chr3:44016874	A/G	cg08738300	chr3:44038990	NA	0.54	5.85	0.36	1.63e-8	Coronary artery disease;
SARC	cis	rs16976116	0.851	rs28699327	chr15:55500335	A/G	cg11288833	chr15:55489084	RSL24D1	0.63	6.13	0.37	3.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2836633	1.000	rs2836634	chr21:40068230	T/A	cg12884169	chr21:40033163	ERG	0.46	8.0	0.46	5.74e-14	Coronary artery disease;
SARC	cis	rs9303401	0.538	rs8078280	chr17:56473132	A/G	cg25039879	chr17:56429692	SUPT4H1	0.62	5.56	0.34	7.52e-8	Cognitive test performance;
SARC	trans	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg11693508	chr17:37793320	STARD3	0.76	7.14	0.42	1.21e-11	Bipolar disorder;
SARC	cis	rs11574514	1.000	rs8054034	chr16:67773652	C/A	cg01866162	chr16:67596514	CTCF	0.75	4.89	0.31	1.86e-6	Crohn's disease;
SARC	cis	rs1707322	1.000	rs7532204	chr1:46485075	C/G	cg03146154	chr1:46216737	IPP	-0.46	-5.59	-0.34	6.36e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg24549020	chr5:56110836	MAP3K1	-0.65	-5.81	-0.36	1.99e-8	Initial pursuit acceleration;
SARC	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.62	-8.74	-0.5	4.6e-16	Total body bone mineral density;
SARC	cis	rs3733585	0.637	rs6850684	chr4:9964380	G/T	cg11266682	chr4:10021025	SLC2A9	-0.37	-6.31	-0.38	1.4e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs5753618	0.561	rs4820963	chr22:31698166	C/T	cg07713946	chr22:31675144	LIMK2	-0.38	-5.3	-0.33	2.7e-7	Colorectal cancer;
SARC	cis	rs8014204	0.870	rs3742790	chr14:75308758	C/T	cg17347104	chr14:75034677	LTBP2	0.44	5.53	0.34	8.47e-8	Caffeine consumption;
SARC	cis	rs2439831	0.867	rs12443102	chr15:43932103	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	8.16	0.47	2.15e-14	Lung cancer in ever smokers;
SARC	cis	rs7666738	0.830	rs3857217	chr4:99034347	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg22834771	chr12:69754056	YEATS4	-0.44	-5.74	-0.35	2.95e-8	Blood protein levels;
SARC	cis	rs17125944	0.505	rs118053951	chr14:53259829	G/A	cg00686598	chr14:53173677	PSMC6	1.27	8.86	0.5	2.11e-16	Alzheimer's disease (late onset);
SARC	cis	rs4711350	1.000	rs2395447	chr6:33743174	T/C	cg18005901	chr6:33739558	LEMD2	-0.45	-4.9	-0.31	1.76e-6	Schizophrenia;
SARC	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg05368731	chr17:41323189	NBR1	0.79	9.57	0.53	1.62e-18	Menopause (age at onset);
SARC	cis	rs4835937	0.645	rs4836348	chr5:127278773	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.58	4.91	0.31	1.68e-6	Cancer;
SARC	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg25894440	chr7:65020034	NA	0.78	5.89	0.36	1.34e-8	Diabetic kidney disease;
SARC	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg26839252	chr6:160211577	TCP1;MRPL18	0.57	5.08	0.32	7.61e-7	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs6545883	0.929	rs778154	chr2:61646631	T/C	cg15711740	chr2:61764176	XPO1	0.4	4.89	0.3	1.9e-6	Tuberculosis;
SARC	cis	rs34375054	0.687	rs4559740	chr12:125632996	G/A	cg25124228	chr12:125621409	AACS	-0.56	-5.83	-0.36	1.85e-8	Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs672059	0.966	rs492228	chr1:183156476	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.51	6.93	0.41	4.1e-11	Hypertriglyceridemia;
SARC	cis	rs9296092	0.538	rs9461887	chr6:33526827	C/T	cg13560919	chr6:33536144	NA	-0.51	-6.03	-0.37	6.47e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs8141529	0.732	rs2347447	chr22:29179739	C/A	cg02153584	chr22:29168773	CCDC117	0.82	12.64	0.64	3.06e-28	Lymphocyte counts;
SARC	cis	rs4805272	0.512	rs7245724	chr19:29341679	C/T	cg12756686	chr19:29218302	NA	0.51	5.53	0.34	8.45e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs4243830	0.850	rs4908915	chr1:6601607	T/C	cg04093404	chr1:6614507	TAS1R1;NOL9	0.55	4.84	0.3	2.38e-6	Body mass index;
SARC	cis	rs1790761	0.692	rs1269981	chr11:67334959	G/A	cg24690094	chr11:67383802	NA	0.37	5.45	0.34	1.25e-7	Mean corpuscular volume;
SARC	cis	rs7927592	0.913	rs3740631	chr11:68341722	T/G	cg01657329	chr11:68192670	LRP5	-0.43	-5.11	-0.32	6.59e-7	Total body bone mineral density;
SARC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg07414643	chr4:187882934	NA	0.5	7.5	0.44	1.34e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.61	0.53	1.27e-18	Prudent dietary pattern;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg07439679	chr10:70137262	RUFY2	0.56	7.73	0.45	3.21e-13	Thyroid stimulating hormone;
SARC	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg07701084	chr6:150067640	NUP43	0.38	4.95	0.31	1.43e-6	Lung cancer;
SARC	cis	rs672059	1.000	rs483783	chr1:183162152	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.51	7.02	0.42	2.39e-11	Hypertriglyceridemia;
SARC	cis	rs9549260	0.753	rs9532562	chr13:41153585	A/G	cg21288729	chr13:41239152	FOXO1	0.61	6.17	0.37	3.02e-9	Red blood cell count;
SARC	cis	rs7327064	1.000	rs7331697	chr13:36763345	G/A	cg13455704	chr13:36871754	C13orf38	-0.52	-5.72	-0.35	3.22e-8	Economic and political preferences;
SARC	cis	rs7312933	0.528	rs10880238	chr12:42489613	A/G	cg17420585	chr12:42539391	GXYLT1	-0.44	-6.82	-0.41	7.62e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	trans	rs2018683	0.707	rs1021690	chr7:28974488	A/G	cg19402173	chr7:128379420	CALU	-0.5	-6.43	-0.39	7.13e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs3762637	0.941	rs75344200	chr3:122073421	C/T	cg24169773	chr3:122142474	KPNA1	-0.53	-5.13	-0.32	5.96e-7	LDL cholesterol levels;
SARC	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg12463550	chr7:65579703	CRCP	0.69	5.26	0.33	3.2e-7	Diabetic kidney disease;
SARC	cis	rs2486288	0.656	rs1706768	chr15:45569443	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.57	-7.13	-0.42	1.26e-11	Glomerular filtration rate;
SARC	cis	rs7644634	0.634	rs1443106	chr3:105422146	C/A	cg23051926	chr3:105466016	CBLB	0.44	5.52	0.34	9.08e-8	Itch intensity from mosquito bite;
SARC	cis	rs1153858	1.000	rs3809472	chr15:45694318	G/T	cg26924012	chr15:45694286	SPATA5L1	0.78	10.68	0.57	6.18e-22	Homoarginine levels;
SARC	cis	rs6456156	1.000	rs6911766	chr6:167523170	T/G	cg07741184	chr6:167504864	NA	-0.31	-5.66	-0.35	4.36e-8	Primary biliary cholangitis;
SARC	cis	rs757081	0.637	rs34941502	chr11:17155432	G/A	cg15432903	chr11:17409602	KCNJ11	-0.37	-4.79	-0.3	2.97e-6	Systolic blood pressure;
SARC	cis	rs888194	0.934	rs3742015	chr12:110017125	T/C	cg13986417	chr12:110012484	MVK;MMAB	-0.33	-5.01	-0.31	1.06e-6	Neuroticism;
SARC	cis	rs17376456	0.877	rs12109629	chr5:93359702	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.76	0.35	2.64e-8	Diabetic retinopathy;
SARC	cis	rs6809651	0.524	rs1356292	chr3:185824903	C/T	cg00760338	chr3:185826511	ETV5	0.87	10.92	0.58	1.07e-22	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
SARC	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.49	-6.12	-0.37	3.97e-9	Lymphocyte counts;
SARC	cis	rs1878931	0.624	rs37810	chr16:3451881	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.7	-7.86	-0.46	1.38e-13	Body mass index (adult);
SARC	cis	rs76419734	1.000	rs79412014	chr4:106755444	T/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.77	5.19	0.32	4.53e-7	Post bronchodilator FEV1;
SARC	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.24	-0.47	1.27e-14	Chronic sinus infection;
SARC	cis	rs6570726	0.905	rs430248	chr6:145874104	A/G	cg05220968	chr6:146057943	EPM2A	-0.3	-5.09	-0.32	7.23e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7766436	0.885	rs13198323	chr6:22577065	C/T	cg13666174	chr6:22585274	NA	-0.58	-7.21	-0.43	7.72e-12	Coronary artery disease;
SARC	cis	rs17826219	0.500	rs57005940	chr17:29066329	C/G	cg13385521	chr17:29058706	SUZ12P	0.84	7.31	0.43	4.29e-12	Body mass index;
SARC	cis	rs13191362	1.000	rs73035021	chr6:163000716	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.49	0.34	1.04e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs35110281	0.659	rs2236667	chr21:45112939	A/G	cg04455712	chr21:45112962	RRP1B	0.34	4.87	0.3	2.07e-6	Mean corpuscular volume;
SARC	cis	rs11758351	0.778	rs41266801	chr6:26197493	C/A	cg01420254	chr6:26195488	NA	0.55	4.76	0.3	3.32e-6	Gout;Renal underexcretion gout;
SARC	cis	rs9787249	0.957	rs41267029	chr1:40214367	A/G	cg02773041	chr1:40204384	PPIE	0.53	6.46	0.39	6.11e-10	Blood protein levels;
SARC	cis	rs7223966	1.000	rs11657081	chr17:61792339	C/T	cg00588841	chr17:61851480	DDX42;CCDC47	-0.63	-7.17	-0.43	9.77e-12	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1971762	0.527	rs4019971	chr12:53978715	A/G	cg06632207	chr12:54070931	ATP5G2	0.57	7.69	0.45	4.14e-13	Height;
SARC	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg16325326	chr1:53192061	ZYG11B	0.82	12.98	0.65	2.42e-29	Monocyte count;
SARC	cis	rs4481887	1.000	rs4360555	chr1:248468591	G/T	cg01631408	chr1:248437212	OR2T33	-0.42	-5.3	-0.33	2.68e-7	Common traits (Other);
SARC	cis	rs986417	0.892	rs8016349	chr14:60798366	A/G	cg27398547	chr14:60952738	C14orf39	-0.96	-8.29	-0.48	9.11e-15	Gut microbiota (bacterial taxa);
SARC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg27564656	chr1:36023414	NCDN;KIAA0319L	-0.63	-7.05	-0.42	1.99e-11	Plasma amyloid beta peptide concentrations (ABx-40);
SARC	cis	rs2115630	0.936	rs11073663	chr15:85260268	A/G	cg12501888	chr15:85177176	SCAND2	-0.46	-5.61	-0.34	5.84e-8	P wave terminal force;
SARC	cis	rs4450798	0.512	rs114314619	chr3:13772831	G/A	cg25224369	chr3:12918528	NA	0.39	4.76	0.3	3.35e-6	Bipolar disorder with mood-incongruent psychosis;
SARC	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg11062466	chr8:58055876	NA	0.52	5.42	0.33	1.51e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg05368731	chr17:41323189	NBR1	0.8	9.84	0.54	2.52e-19	Menopause (age at onset);
SARC	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	11.03	0.59	4.93e-23	Alzheimer's disease;
SARC	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.49	6.21	0.38	2.46e-9	Personality dimensions;
SARC	cis	rs3845702	0.800	rs6744281	chr2:180844382	G/A	cg01881094	chr2:180872142	CWC22	-1.12	-9.3	-0.52	1.07e-17	Schizophrenia;
SARC	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg22168489	chr12:122356033	WDR66	-0.64	-9.93	-0.55	1.36e-19	Mean corpuscular volume;
SARC	cis	rs920590	0.641	rs2035889	chr8:19634087	T/A	cg03894339	chr8:19674705	INTS10	0.54	6.0	0.37	7.55e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs11718455	0.920	rs4682927	chr3:44033299	C/A	cg21419209	chr3:44054225	NA	-0.39	-4.73	-0.3	3.83e-6	Coronary artery disease;
SARC	cis	rs501120	0.706	rs1657346	chr10:44777560	G/C	cg09554077	chr10:44749378	NA	0.46	4.76	0.3	3.46e-6	Coronary artery disease;Coronary heart disease;
SARC	cis	rs921968	0.541	rs17572485	chr2:219296545	C/T	cg02176678	chr2:219576539	TTLL4	-0.41	-6.26	-0.38	1.8e-9	Mean corpuscular hemoglobin concentration;
SARC	cis	rs1784581	0.588	rs1789986	chr6:162409978	C/T	cg17173639	chr6:162384350	PARK2	-0.51	-6.43	-0.39	7.27e-10	Itch intensity from mosquito bite;
SARC	cis	rs7264396	0.790	rs6058294	chr20:34259396	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-7.88	-0.46	1.27e-13	Total cholesterol levels;
SARC	cis	rs910316	0.699	rs175039	chr14:75468950	G/C	cg08847533	chr14:75593920	NEK9	-0.82	-11.57	-0.6	8.93e-25	Height;
SARC	cis	rs921968	0.541	rs496674	chr2:219432569	G/A	cg02176678	chr2:219576539	TTLL4	0.47	7.13	0.42	1.28e-11	Mean corpuscular hemoglobin concentration;
SARC	cis	rs1050631	0.564	rs1785934	chr18:33718326	A/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.59	7.17	0.43	9.66e-12	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg02187348	chr16:89574699	SPG7	0.65	9.61	0.53	1.26e-18	Multiple myeloma (IgH translocation);
SARC	cis	rs7772486	0.754	rs9399567	chr6:146147295	C/T	cg23711669	chr6:146136114	FBXO30	0.87	14.92	0.7	8.83e-36	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg03709012	chr19:19516395	GATAD2A	-0.96	-15.46	-0.71	1.41e-37	Tonsillectomy;
SARC	cis	rs3768617	0.510	rs12091137	chr1:183075732	A/G	cg13390022	chr1:182993471	LAMC1	0.32	4.78	0.3	3.1e-6	Fuchs's corneal dystrophy;
SARC	cis	rs9894429	0.789	rs35887231	chr17:79587126	G/A	cg18240062	chr17:79603768	NPLOC4	0.88	13.72	0.67	8.78e-32	Eye color traits;
SARC	cis	rs12971120	1.000	rs734559	chr18:72179579	G/A	cg26446133	chr18:72167187	CNDP2	-0.47	-6.94	-0.41	3.86e-11	Refractive error;
SARC	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg16405210	chr4:1374714	KIAA1530	0.71	8.77	0.5	3.81e-16	Obesity-related traits;
SARC	cis	rs3126085	0.935	rs1496051	chr1:152164923	G/A	cg03465714	chr1:152285911	FLG	-0.47	-5.56	-0.34	7.45e-8	Atopic dermatitis;
SARC	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg22875332	chr1:76189707	ACADM	0.48	6.72	0.4	1.4e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7223966	0.960	rs2319990	chr17:61705397	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	6.75	0.4	1.15e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6598955	0.543	rs60433268	chr1:26548055	A/C	cg04990556	chr1:26633338	UBXN11	0.75	7.65	0.45	5.2e-13	Obesity-related traits;
SARC	trans	rs9325144	0.647	rs35138700	chr12:38804474	C/T	cg23762105	chr12:34175262	ALG10	0.49	6.4	0.39	8.67e-10	Morning vs. evening chronotype;
SARC	cis	rs28655083	0.828	rs7190227	chr16:77119568	T/C	cg01504555	chr16:77246968	SYCE1L	0.41	5.12	0.32	6.51e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6912958	0.754	rs2268994	chr6:88185386	A/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.51	-6.82	-0.41	7.6e-11	Monocyte percentage of white cells;
SARC	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg13206674	chr6:150067644	NUP43	0.48	6.45	0.39	6.29e-10	Lung cancer;
SARC	cis	rs12145833	1.000	rs2802727	chr1:243483326	C/T	cg02356786	chr1:243265016	LOC731275	-0.55	-4.76	-0.3	3.41e-6	Obesity (early onset extreme);
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg20618750	chr5:149380010	HMGXB3;TIGD6	-0.48	-6.36	-0.38	1.07e-9	Electrocardiographic conduction measures;
SARC	cis	rs6582630	0.502	rs12815350	chr12:38439921	A/T	cg13010199	chr12:38710504	ALG10B	0.73	9.29	0.52	1.17e-17	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg11366901	chr6:160182831	ACAT2	0.91	9.18	0.52	2.38e-17	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs2273669	0.667	rs78383792	chr6:109312498	A/G	cg05315195	chr6:109294784	ARMC2	-0.59	-5.45	-0.34	1.28e-7	Prostate cancer;
SARC	cis	rs4851254	0.626	rs13001783	chr2:100689652	A/T	cg17356467	chr2:100759845	AFF3	0.32	4.83	0.3	2.45e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9916302	0.652	rs9903269	chr17:37742383	A/T	cg00129232	chr17:37814104	STARD3	-0.66	-7.08	-0.42	1.67e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs7712401	0.715	rs1062350	chr5:122358506	G/A	cg19412675	chr5:122181750	SNX24	-0.42	-5.3	-0.33	2.65e-7	Mean platelet volume;
SARC	cis	rs11676348	0.967	rs4674258	chr2:218990586	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.48	-6.43	-0.39	7.32e-10	Ulcerative colitis;
SARC	cis	rs6500395	1.000	rs9938633	chr16:48682093	G/C	cg04672837	chr16:48644449	N4BP1	0.46	6.28	0.38	1.65e-9	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg14343924	chr8:8086146	FLJ10661	0.38	4.73	0.3	3.96e-6	Mood instability;
SARC	cis	rs314370	0.570	rs314324	chr7:100433794	C/T	cg10426581	chr7:100472382	SRRT	0.44	5.65	0.35	4.7e-8	Resting heart rate;
SARC	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg06634786	chr22:41940651	POLR3H	0.57	6.43	0.39	7.14e-10	Vitiligo;
SARC	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg06634786	chr22:41940651	POLR3H	0.54	6.45	0.39	6.4e-10	Vitiligo;
SARC	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.85	10.07	0.55	4.81e-20	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg03264133	chr6:25882463	NA	-0.55	-7.08	-0.42	1.65e-11	Intelligence (multi-trait analysis);
SARC	cis	rs7727544	0.684	rs274561	chr5:131719228	A/C	cg07395648	chr5:131743802	NA	-0.4	-4.74	-0.3	3.64e-6	Blood metabolite levels;
SARC	cis	rs1865760	0.865	rs9467645	chr6:25955176	G/C	cg17691542	chr6:26056736	HIST1H1C	0.58	7.29	0.43	4.93e-12	Height;
SARC	cis	rs950169	0.541	rs10795	chr15:85177297	G/A	cg17507749	chr15:85114479	UBE2QP1	0.58	6.77	0.41	1.03e-10	Schizophrenia;
SARC	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg13628971	chr7:2884303	GNA12	0.67	7.73	0.45	3.22e-13	Height;
SARC	cis	rs1336900	0.544	rs10888386	chr1:150611957	A/G	cg13175981	chr1:150552382	MCL1	0.52	6.35	0.38	1.1e-9	Blood protein levels;
SARC	cis	rs12594515	0.967	rs11070465	chr15:45984899	A/G	cg14863074	chr15:45997064	NA	0.34	5.18	0.32	4.74e-7	Waist circumference;Weight;
SARC	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg07648498	chr16:89883185	FANCA	0.39	5.22	0.32	3.91e-7	Vitiligo;
SARC	cis	rs73001065	0.818	rs73004966	chr19:19716558	C/T	cg03709012	chr19:19516395	GATAD2A	0.84	5.79	0.35	2.22e-8	LDL cholesterol;
SARC	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg18876405	chr7:65276391	NA	0.47	5.76	0.35	2.62e-8	Aortic root size;
SARC	cis	rs2479724	1.000	rs1536703	chr6:41852755	C/T	cg17623882	chr6:41773611	USP49	-0.47	-6.16	-0.37	3.21e-9	Menarche (age at onset);
SARC	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.68	7.29	0.43	4.76e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs4319547	0.915	rs1473553	chr12:122985057	G/T	cg05707623	chr12:122985044	ZCCHC8	-0.67	-7.88	-0.46	1.24e-13	Body mass index;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg18672986	chr19:35521772	SCN1B	0.48	6.27	0.38	1.74e-9	Lung adenocarcinoma;
SARC	trans	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg21665057	chr3:196295764	WDR53;FBXO45	-0.74	-10.81	-0.58	2.44e-22	Blood protein levels;
SARC	cis	rs400736	0.894	rs225092	chr1:8036075	G/C	cg25007680	chr1:8021821	PARK7	0.53	6.83	0.41	7.17e-11	Response to antidepressants and depression;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg24688926	chr19:6737877	GPR108	0.52	6.23	0.38	2.13e-9	Blood pressure;
SARC	cis	rs593982	1.000	rs56257941	chr11:65505641	C/T	cg08755490	chr11:65554678	OVOL1	-0.91	-9.66	-0.53	8.59e-19	Atopic dermatitis;
SARC	cis	rs2415984	0.541	rs12433740	chr14:46933240	G/T	cg14871534	chr14:47121158	RPL10L	0.38	5.22	0.32	3.94e-7	Number of children ever born;
SARC	cis	rs6546550	0.901	rs6750488	chr2:70146125	C/T	cg02498382	chr2:70120550	SNRNP27	-0.32	-5.22	-0.32	3.9e-7	Prevalent atrial fibrillation;
SARC	cis	rs4919087	0.561	rs793522	chr10:99022614	T/G	cg25902810	chr10:99078978	FRAT1	-0.55	-5.82	-0.36	1.9e-8	Monocyte count;
SARC	cis	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg11266682	chr4:10021025	SLC2A9	0.41	7.29	0.43	4.75e-12	Bone mineral density;
SARC	cis	rs7666738	0.830	rs13328005	chr4:99055480	T/C	cg05340658	chr4:99064831	C4orf37	0.63	8.53	0.49	1.93e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg13206674	chr6:150067644	NUP43	0.41	5.37	0.33	1.95e-7	Lung cancer;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg11368438	chr3:142751654	SR140	-0.51	-6.31	-0.38	1.4e-9	Alcohol dependence;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg15135638	chr3:183947356	VWA5B2	0.48	6.44	0.39	6.92e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs6580649	0.825	rs4760611	chr12:48421449	A/G	cg05342945	chr12:48394962	COL2A1	-0.57	-6.19	-0.38	2.63e-9	Lung cancer;
SARC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg14893161	chr1:205819251	PM20D1	-0.83	-13.84	-0.67	3.44e-32	Monocyte percentage of white cells;
SARC	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg04277193	chr17:41438351	NA	0.44	4.73	0.3	3.83e-6	Menopause (age at onset);
SARC	cis	rs1801251	1.000	rs13008942	chr2:233594875	G/A	cg25237894	chr2:233734115	C2orf82	0.38	4.96	0.31	1.36e-6	Coronary artery disease;
SARC	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg06634786	chr22:41940651	POLR3H	-0.57	-6.89	-0.41	5.09e-11	Vitiligo;
SARC	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg12463550	chr7:65579703	CRCP	0.67	5.06	0.31	8.43e-7	Diabetic kidney disease;
SARC	cis	rs3008870	1.000	rs2985824	chr1:67410171	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.89	-11.33	-0.6	5.47e-24	Lymphocyte percentage of white cells;
SARC	cis	rs9790314	0.747	rs1599386	chr3:160856314	C/T	cg04691961	chr3:161091175	C3orf57	0.66	9.04	0.51	6.34e-17	Morning vs. evening chronotype;
SARC	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg12463550	chr7:65579703	CRCP	-0.71	-5.42	-0.33	1.47e-7	Diabetic kidney disease;
SARC	cis	rs501120	1.000	rs687175	chr10:44751910	C/T	cg09554077	chr10:44749378	NA	-0.44	-6.09	-0.37	4.6e-9	Coronary artery disease;Coronary heart disease;
SARC	cis	rs9457247	0.967	rs447042	chr6:167405435	C/T	cg07741184	chr6:167504864	NA	0.29	5.55	0.34	7.72e-8	Crohn's disease;
SARC	cis	rs4888262	0.604	rs12935075	chr16:74676033	A/T	ch.16.1684049R	chr16:74565916	GLG1	0.37	4.78	0.3	3.05e-6	Testicular germ cell tumor;
SARC	cis	rs17401966	0.898	rs12117635	chr1:10317445	C/T	cg15208524	chr1:10270712	KIF1B	0.45	5.29	0.33	2.84e-7	Hepatocellular carcinoma;
SARC	cis	rs7959452	0.535	rs7135092	chr12:69658330	T/C	cg22834771	chr12:69754056	YEATS4	-0.41	-5.41	-0.33	1.55e-7	Blood protein levels;
SARC	cis	rs2439831	0.867	rs45585139	chr15:43700427	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.71	6.19	0.38	2.62e-9	Lung cancer in ever smokers;
SARC	trans	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.51	6.45	0.39	6.35e-10	Intelligence (multi-trait analysis);
SARC	cis	rs1008375	1.000	rs9291659	chr4:17662360	A/C	cg27347728	chr4:17578864	LAP3	0.45	5.56	0.34	7.29e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs372883	0.624	rs1153286	chr21:30684383	A/G	cg08807101	chr21:30365312	RNF160	-0.58	-7.47	-0.44	1.62e-12	Pancreatic cancer;
SARC	cis	rs73086581	0.838	rs41398349	chr20:4024439	C/T	cg02187196	chr20:3869020	PANK2	-0.5	-4.95	-0.31	1.44e-6	Response to antidepressants in depression;
SARC	cis	rs853679	1.000	rs853685	chr6:28288785	C/T	cg26450541	chr6:28235208	ZNF187	0.62	5.19	0.32	4.64e-7	Depression;
SARC	cis	rs6570726	0.935	rs372378	chr6:145816227	A/G	cg05220968	chr6:146057943	EPM2A	-0.29	-4.83	-0.3	2.44e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3733585	0.598	rs28677023	chr4:9958326	C/A	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.55	-0.34	7.65e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs756699	0.643	rs244657	chr5:133448850	A/G	cg20442289	chr5:133305704	C5orf15	0.53	5.54	0.34	8.12e-8	Multiple sclerosis;
SARC	cis	rs13082711	0.911	rs77685358	chr3:27519158	C/T	cg02860705	chr3:27208620	NA	0.46	5.78	0.35	2.43e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs3784262	0.669	rs12912093	chr15:58332583	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.35	-5.15	-0.32	5.43e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs2066819	0.901	rs1274490	chr12:56649601	A/G	cg26734620	chr12:56694298	CS	-0.83	-6.2	-0.38	2.6e-9	Psoriasis vulgaris;
SARC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.51	5.93	0.36	1.11e-8	Prudent dietary pattern;
SARC	cis	rs703842	1.000	rs10877019	chr12:58172929	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.76	-10.57	-0.57	1.35e-21	Multiple sclerosis;
SARC	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg22800045	chr5:56110881	MAP3K1	0.73	7.74	0.45	2.98e-13	Initial pursuit acceleration;
SARC	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.76	7.39	0.44	2.69e-12	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs2120243	0.501	rs1456107	chr3:157119520	A/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.39	4.94	0.31	1.48e-6	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs2070488	0.662	rs6599202	chr3:38480651	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.63	8.33	0.48	6.75e-15	Electrocardiographic conduction measures;
SARC	cis	rs6089584	0.528	rs4925335	chr20:60627034	G/A	cg06108461	chr20:60628389	TAF4	-0.72	-9.38	-0.52	5.95e-18	Body mass index;
SARC	cis	rs911555	0.723	rs4906320	chr14:103876925	T/C	cg12935359	chr14:103987150	CKB	0.39	5.35	0.33	2.09e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg18252515	chr7:66147081	NA	-1.31	-11.71	-0.61	3.25e-25	Diabetic kidney disease;
SARC	cis	rs3870371	0.911	rs11785053	chr8:122702041	G/T	cg21781600	chr8:122651575	HAS2;HAS2AS	0.48	5.45	0.34	1.3e-7	Periodontal disease-related phenotypes;
SARC	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.46	-5.68	-0.35	3.99e-8	Intelligence (multi-trait analysis);
SARC	cis	rs950776	0.593	rs555018	chr15:78879242	G/A	cg24631222	chr15:78858424	CHRNA5	0.37	4.77	0.3	3.21e-6	Sudden cardiac arrest;
SARC	cis	rs2916247	1.000	rs1899666	chr8:93006087	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.65	-6.62	-0.4	2.51e-10	Intelligence (multi-trait analysis);
SARC	cis	rs2153535	0.580	rs2184586	chr6:8474182	A/G	cg07606381	chr6:8435919	SLC35B3	0.76	10.76	0.58	3.55e-22	Motion sickness;
SARC	cis	rs9457247	0.756	rs1811123	chr6:167403443	T/C	cg23791538	chr6:167370224	RNASET2	-0.64	-8.84	-0.5	2.43e-16	Crohn's disease;
SARC	trans	rs61931739	0.500	rs11052990	chr12:34058647	T/A	cg26384229	chr12:38710491	ALG10B	0.86	12.43	0.63	1.55e-27	Morning vs. evening chronotype;
SARC	cis	rs1865760	0.663	rs9379815	chr6:25980116	T/A	cg16482183	chr6:26056742	HIST1H1C	0.49	6.55	0.39	3.59e-10	Height;
SARC	cis	rs9457247	0.565	rs12178491	chr6:167512474	C/T	cg07741184	chr6:167504864	NA	0.37	7.05	0.42	2e-11	Crohn's disease;
SARC	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg13206674	chr6:150067644	NUP43	0.41	5.31	0.33	2.51e-7	Lung cancer;
SARC	cis	rs4820294	1.000	rs739139	chr22:38067011	C/G	cg21798802	chr22:38057573	PDXP	0.38	5.81	0.36	2.02e-8	Fat distribution (HIV);
SARC	cis	rs881375	0.967	rs1860824	chr9:123659339	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.42	4.99	0.31	1.16e-6	Rheumatoid arthritis;
SARC	cis	rs2153535	0.580	rs6918391	chr6:8461178	A/C	cg21535247	chr6:8435926	SLC35B3	0.53	6.7	0.4	1.58e-10	Motion sickness;
SARC	cis	rs7552404	0.924	rs2275378	chr1:76198436	T/C	cg03433033	chr1:76189801	ACADM	0.51	7.52	0.44	1.16e-12	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs34172651	0.797	rs12920941	chr16:24830866	T/A	cg04756594	chr16:24857601	SLC5A11	0.34	5.49	0.34	1.05e-7	Intelligence (multi-trait analysis);
SARC	cis	rs73206853	0.841	rs56306150	chr12:110716775	A/T	cg10860002	chr12:110842031	ANAPC7	0.63	5.1	0.32	6.94e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs17376456	0.935	rs13156002	chr5:93508931	G/A	cg25358565	chr5:93447407	FAM172A	1.34	14.13	0.68	3.63e-33	Diabetic retinopathy;
SARC	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg03650068	chr1:25596491	NA	0.32	4.98	0.31	1.23e-6	Erythrocyte sedimentation rate;
SARC	trans	rs9329221	0.527	rs6989657	chr8:10330873	C/G	cg06636001	chr8:8085503	FLJ10661	0.59	8.54	0.49	1.81e-15	Neuroticism;
SARC	cis	rs6904897	0.563	rs4896117	chr6:135229400	T/C	cg22676075	chr6:135203613	NA	-0.66	-9.87	-0.54	1.95e-19	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs2295359	0.892	rs12029362	chr1:67624231	G/A	cg11235152	chr1:67600687	NA	0.52	7.17	0.42	1.01e-11	Psoriasis;
SARC	cis	rs208520	0.690	rs10944872	chr6:66708239	T/G	cg07460842	chr6:66804631	NA	1.06	14.64	0.69	7.47e-35	Exhaled nitric oxide output;
SARC	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg00031303	chr3:195681400	NA	0.48	5.56	0.34	7.54e-8	Pancreatic cancer;
SARC	cis	rs11785693	0.865	rs7815144	chr8:4970788	G/T	cg26367366	chr8:4980734	NA	-0.64	-6.03	-0.37	6.33e-9	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs4319547	0.915	rs11058402	chr12:122981053	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.67	-7.88	-0.46	1.24e-13	Body mass index;
SARC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg15242686	chr22:24348715	GSTTP1	0.43	5.29	0.33	2.83e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1865760	0.865	rs9393678	chr6:25945819	C/T	cg17691542	chr6:26056736	HIST1H1C	0.58	7.3	0.43	4.62e-12	Height;
SARC	cis	rs6504663	0.558	rs11871603	chr17:48559037	T/G	cg03168497	chr17:48586147	MYCBPAP	0.52	5.7	0.35	3.65e-8	Visceral fat;
SARC	cis	rs2011503	0.943	rs1529745	chr19:19517325	C/G	cg15839431	chr19:19639596	YJEFN3	-0.49	-4.79	-0.3	2.92e-6	Bipolar disorder;
SARC	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg07343612	chr16:622815	PIGQ	-0.61	-8.49	-0.49	2.39e-15	Height;
SARC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg06074448	chr4:187884817	NA	-0.37	-5.07	-0.32	8.2e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2228479	0.702	rs17233441	chr16:89817998	C/G	cg26513180	chr16:89883248	FANCA	0.72	4.79	0.3	2.99e-6	Skin colour saturation;
SARC	cis	rs7644634	0.531	rs7624530	chr3:105398093	G/A	cg23051926	chr3:105466016	CBLB	0.47	5.4	0.33	1.68e-7	Itch intensity from mosquito bite;
SARC	cis	rs2933343	0.951	rs789251	chr3:128576770	G/A	cg24203234	chr3:128598194	ACAD9	0.55	6.08	0.37	4.81e-9	IgG glycosylation;
SARC	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg02475777	chr4:1388615	CRIPAK	0.67	7.77	0.45	2.53e-13	Longevity;
SARC	cis	rs34172651	0.917	rs200529	chr16:24758502	T/C	cg06028605	chr16:24865363	SLC5A11	-0.28	-5.1	-0.32	7.14e-7	Intelligence (multi-trait analysis);
SARC	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg22004693	chr7:99632812	ZKSCAN1	-0.5	-5.14	-0.32	5.88e-7	Lung function (FEV1/FVC);
SARC	cis	rs761746	0.881	rs12484606	chr22:31937476	C/T	cg15162869	chr22:32027605	PISD	0.35	4.79	0.3	2.97e-6	Intelligence;
SARC	cis	rs155076	0.711	rs4770131	chr13:21897468	A/G	cg06138931	chr13:21896616	NA	0.5	6.61	0.4	2.66e-10	White matter hyperintensity burden;
SARC	cis	rs554111	0.637	rs529162	chr1:21063311	T/A	cg04902671	chr1:21058625	SH2D5	-0.5	-5.93	-0.36	1.06e-8	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs870825	0.616	rs41278579	chr4:185622402	A/G	cg04058563	chr4:185651563	MLF1IP	0.84	11.44	0.6	2.36e-24	Blood protein levels;
SARC	trans	rs9354308	0.903	rs9360158	chr6:66558164	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.55	-6.61	-0.4	2.63e-10	Metabolite levels;
SARC	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg09455208	chr3:40491958	NA	0.39	5.57	0.34	6.86e-8	Renal cell carcinoma;
SARC	trans	rs9650657	0.801	rs718741	chr8:10614384	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.48	-0.39	5.4e-10	Neuroticism;
SARC	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg00339695	chr16:24857497	SLC5A11	0.41	5.78	0.35	2.38e-8	Intelligence (multi-trait analysis);
SARC	cis	rs6570726	0.935	rs430561	chr6:145813140	C/T	cg23711669	chr6:146136114	FBXO30	0.82	12.78	0.64	1.08e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs908922	0.651	rs1572534	chr1:152509689	G/A	cg09873164	chr1:152488093	CRCT1	0.66	8.83	0.5	2.54e-16	Hair morphology;
SARC	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg21782813	chr7:2030301	MAD1L1	0.4	6.49	0.39	5.14e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs17125944	0.686	rs12884504	chr14:53360494	G/A	cg00686598	chr14:53173677	PSMC6	-0.63	-4.87	-0.3	2.06e-6	Alzheimer's disease (late onset);
SARC	cis	rs2295359	0.824	rs11209003	chr1:67601132	G/T	cg11235152	chr1:67600687	NA	0.54	7.22	0.43	7.15e-12	Psoriasis;
SARC	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg03452623	chr4:187889614	NA	0.81	12.69	0.64	2.18e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg10792982	chr14:105748885	BRF1	-0.53	-8.11	-0.47	2.81e-14	Mean platelet volume;Platelet distribution width;
SARC	cis	rs2439831	0.541	rs12440854	chr15:43610672	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	7.58	0.44	8.3e-13	Lung cancer in ever smokers;
SARC	cis	rs7412746	0.503	rs72704639	chr1:150798335	A/C	cg10589385	chr1:150898437	SETDB1	0.4	5.38	0.33	1.79e-7	Melanoma;
SARC	cis	rs9467773	0.869	rs1796521	chr6:26421392	T/C	cg11502198	chr6:26597334	ABT1	-0.49	-5.85	-0.36	1.69e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2908197	0.713	rs2961038	chr7:75952070	G/C	cg07849177	chr7:76178544	LOC100133091	-0.43	-5.0	-0.31	1.14e-6	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg06221963	chr1:154839813	KCNN3	-0.51	-8.34	-0.48	6.64e-15	Prostate cancer;
SARC	cis	rs9470366	0.883	rs12199346	chr6:36641546	C/A	cg08179530	chr6:36648295	CDKN1A	0.57	6.1	0.37	4.44e-9	QRS duration;
SARC	cis	rs2011013	1.000	rs56278218	chr15:84626694	A/T	cg17507749	chr15:85114479	UBE2QP1	-0.46	-4.8	-0.3	2.78e-6	Sitting height ratio;
SARC	cis	rs854765	0.547	rs7212167	chr17:17913504	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.44	5.7	0.35	3.57e-8	Total body bone mineral density;
SARC	cis	rs72627509	0.556	rs4412049	chr4:57727962	G/A	cg26694713	chr4:57773883	REST	0.66	5.93	0.36	1.11e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs8141529	0.529	rs5762780	chr22:29151760	G/A	cg15103426	chr22:29168792	CCDC117	0.58	5.66	0.35	4.42e-8	Lymphocyte counts;
SARC	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg06420487	chr17:61919686	SMARCD2	0.43	4.79	0.3	2.93e-6	Height;
SARC	cis	rs2797160	0.651	rs1268093	chr6:126029235	C/T	cg06289844	chr6:126071538	HEY2	-0.31	-4.79	-0.3	2.95e-6	Endometrial cancer;
SARC	cis	rs2197308	0.606	rs2218397	chr12:38278307	C/T	cg14851346	chr12:38532713	NA	-0.46	-5.46	-0.34	1.24e-7	Morning vs. evening chronotype;
SARC	cis	rs7617773	0.743	rs11715876	chr3:48377922	G/A	cg11946769	chr3:48343235	NME6	0.77	9.66	0.53	8.6e-19	Coronary artery disease;
SARC	cis	rs9916302	0.851	rs11078904	chr17:37650569	G/A	cg20243544	chr17:37824526	PNMT	0.55	6.53	0.39	4.05e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs713477	1.000	rs7149622	chr14:55909402	T/C	cg13175173	chr14:55914753	NA	-0.3	-4.75	-0.3	3.63e-6	Pediatric bone mineral content (femoral neck);
SARC	cis	rs599083	0.744	rs603129	chr11:68186669	A/T	cg24974729	chr11:67764320	UNC93B1	-0.32	-4.79	-0.3	2.94e-6	Bone mineral density (spine);
SARC	cis	rs709400	0.663	rs1028613	chr14:103888324	G/A	cg12935359	chr14:103987150	CKB	-0.4	-5.88	-0.36	1.4e-8	Body mass index;
SARC	cis	rs9660992	0.573	rs1172147	chr1:205225457	G/A	cg00857998	chr1:205179979	DSTYK	0.51	6.44	0.39	6.62e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs2075371	0.933	rs1901214	chr7:133945108	C/T	cg20476274	chr7:133979776	SLC35B4	-0.59	-7.88	-0.46	1.29e-13	Mean platelet volume;
SARC	cis	rs6570726	0.935	rs391820	chr6:145821284	C/T	cg23711669	chr6:146136114	FBXO30	0.76	11.37	0.6	3.96e-24	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs61931739	0.500	rs11053268	chr12:34545121	T/C	cg26384229	chr12:38710491	ALG10B	0.85	12.63	0.64	3.4e-28	Morning vs. evening chronotype;
SARC	cis	rs798554	0.610	rs2251491	chr7:2852835	T/C	cg04166393	chr7:2884313	GNA12	0.45	5.5	0.34	1.01e-7	Height;
SARC	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs17600642	0.855	rs72814565	chr10:72474758	G/C	cg19779893	chr10:72451501	ADAMTS14	-0.44	-6.65	-0.4	2.11e-10	Bipolar disorder;
SARC	cis	rs17666538	1.000	rs17666538	chr8:566207	T/C	cg19660806	chr8:588740	NA	-0.64	-4.84	-0.3	2.42e-6	IgG glycosylation;
SARC	cis	rs34779708	0.931	rs34954932	chr10:35410807	G/T	cg03585969	chr10:35415529	CREM	0.42	5.36	0.33	1.97e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs2380220	0.606	rs9488080	chr6:96006973	A/G	cg15832292	chr6:96025679	MANEA	0.54	5.93	0.36	1.08e-8	Behavioural disinhibition (generation interaction);
SARC	cis	rs4761669	0.958	rs7134873	chr12:95193389	C/T	cg21533806	chr12:95267307	NA	0.38	4.79	0.3	3.03e-6	Common carotid intima-media thickness in HIV infection;
SARC	cis	rs6545883	0.929	rs7563678	chr2:61741811	C/T	cg15711740	chr2:61764176	XPO1	0.44	5.36	0.33	1.97e-7	Tuberculosis;
SARC	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg14517863	chr17:44321492	NA	0.4	6.01	0.37	7.2e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9285223	1.000	rs73154259	chr13:23127021	A/G	cg18959621	chr13:23310464	NA	0.39	4.73	0.3	3.9e-6	Idiopathic osteonecrosis of the femoral head;
SARC	cis	rs6121246	0.567	rs6060262	chr20:30193071	A/C	cg21427119	chr20:30132790	HM13	-0.45	-4.98	-0.31	1.23e-6	Mean corpuscular hemoglobin;
SARC	cis	rs2204008	0.715	rs11525003	chr12:38332359	G/A	cg13010199	chr12:38710504	ALG10B	0.79	10.83	0.58	2.12e-22	Bladder cancer;
SARC	cis	rs17345786	1.000	rs17345786	chr3:101318318	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.49	-5.55	-0.34	7.7e-8	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg03351412	chr1:154909251	PMVK	0.64	8.17	0.47	2e-14	Prostate cancer;
SARC	cis	rs9470366	0.509	rs4713996	chr6:36629714	C/T	cg08179530	chr6:36648295	CDKN1A	-0.65	-8.73	-0.5	4.88e-16	QRS duration;
SARC	trans	rs7395662	0.553	rs4882155	chr11:48705801	T/C	cg15704280	chr7:45808275	SEPT13	-0.53	-7.19	-0.43	8.66e-12	HDL cholesterol;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg16011480	chr10:97667594	C10orf131	-0.52	-6.27	-0.38	1.72e-9	Fibrinogen levels;
SARC	cis	rs4713118	0.513	rs149942	chr6:28001610	T/C	cg26450541	chr6:28235208	ZNF187	0.46	4.86	0.3	2.14e-6	Parkinson's disease;
SARC	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg24549020	chr5:56110836	MAP3K1	-0.51	-5.58	-0.34	6.82e-8	Initial pursuit acceleration;
SARC	cis	rs7647973	0.626	rs1078341	chr3:49685592	A/G	cg06212747	chr3:49208901	KLHDC8B	0.55	5.5	0.34	9.82e-8	Menarche (age at onset);
SARC	cis	rs10128251	0.625	rs9424204	chr10:5726376	C/G	cg09072322	chr10:5726702	C10orf18	0.45	5.24	0.32	3.64e-7	Childhood ear infection;
SARC	cis	rs6840360	0.593	rs1877186	chr4:152692418	C/G	cg22705602	chr4:152727874	NA	-0.5	-8.77	-0.5	3.77e-16	Intelligence (multi-trait analysis);
SARC	cis	rs17539620	0.624	rs871069	chr6:154837578	A/C	cg20019720	chr6:154832845	CNKSR3	0.41	4.84	0.3	2.39e-6	Lipoprotein (a) levels;
SARC	cis	rs34172651	0.876	rs7186893	chr16:24806420	G/T	cg04756594	chr16:24857601	SLC5A11	0.38	5.9	0.36	1.29e-8	Intelligence (multi-trait analysis);
SARC	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg18225595	chr11:63971243	STIP1	0.57	8.43	0.48	3.59e-15	Platelet count;
SARC	cis	rs9381107	1.000	rs9381212	chr6:9476532	C/T	cg14735645	chr6:9486422	NA	-0.45	-4.74	-0.3	3.65e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs2832077	0.506	rs2832081	chr21:30152992	A/C	cg24692254	chr21:30365293	RNF160	0.55	6.01	0.37	7e-9	Cognitive test performance;
SARC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.56	6.52	0.39	4.39e-10	Prudent dietary pattern;
SARC	cis	rs11711311	1.000	rs9826465	chr3:113432254	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	8.29	0.48	8.87e-15	IgG glycosylation;
SARC	cis	rs787274	0.867	rs2798316	chr9:115462552	T/C	cg13803584	chr9:115635662	SNX30	0.69	5.58	0.34	6.64e-8	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs2921073	0.509	rs2976931	chr8:8257317	C/A	cg15556689	chr8:8085844	FLJ10661	0.52	6.04	0.37	6.09e-9	Parkinson's disease;
SARC	cis	rs9790314	0.586	rs11713185	chr3:161111357	C/G	cg17135325	chr3:160939158	NMD3	0.53	6.56	0.39	3.43e-10	Morning vs. evening chronotype;
SARC	cis	rs763121	0.853	rs3761454	chr22:39066820	C/T	cg06022373	chr22:39101656	GTPBP1	0.86	10.71	0.57	4.88e-22	Menopause (age at onset);
SARC	cis	rs7568458	0.905	rs10198569	chr2:85794415	C/T	cg02493740	chr2:85810744	VAMP5	0.35	4.87	0.3	2.08e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.98	-16.17	-0.73	6.02e-40	Chronic sinus infection;
SARC	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9581857	0.685	rs10467687	chr13:28036516	G/A	cg01674679	chr13:27998804	GTF3A	-0.61	-4.76	-0.3	3.44e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	cis	rs12142240	0.628	rs56126529	chr1:46808860	C/T	cg10495392	chr1:46806563	NSUN4	0.64	6.76	0.4	1.09e-10	Menopause (age at onset);
SARC	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg09455208	chr3:40491958	NA	0.39	5.63	0.35	5.17e-8	Renal cell carcinoma;
SARC	cis	rs9457247	1.000	rs2149085	chr6:167371110	T/C	cg23791538	chr6:167370224	RNASET2	0.63	8.74	0.5	4.61e-16	Crohn's disease;
SARC	cis	rs3020736	0.500	rs2413669	chr22:42507748	A/C	cg04733989	chr22:42467013	NAGA	-0.76	-10.57	-0.57	1.4e-21	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2952156	0.959	rs1495101	chr17:37832103	C/A	cg00129232	chr17:37814104	STARD3	-0.69	-9.54	-0.53	2.01e-18	Asthma;
SARC	cis	rs2439831	0.850	rs9944216	chr15:44160773	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.9	-8.06	-0.47	4.04e-14	Lung cancer in ever smokers;
SARC	trans	rs61931739	0.500	rs7979240	chr12:34509026	C/T	cg13010199	chr12:38710504	ALG10B	0.81	11.3	0.59	6.82e-24	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg08280861	chr8:58055591	NA	0.61	5.96	0.36	9.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6782228	0.606	rs2712417	chr3:128345179	A/G	cg08795948	chr3:128337044	NA	0.36	4.92	0.31	1.62e-6	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
SARC	cis	rs7113850	0.541	rs76874215	chr11:24235158	G/A	ch.11.24196551F	chr11:24239977	NA	0.72	5.44	0.34	1.36e-7	Bone fracture in osteoporosis;
SARC	cis	rs780094	0.585	rs7586601	chr2:27584666	A/G	cg21747090	chr2:27597821	SNX17	-0.48	-6.31	-0.38	1.42e-9	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs6733011	0.628	rs1983352	chr2:99454227	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.39	-4.95	-0.31	1.41e-6	Bipolar disorder;
SARC	cis	rs854765	0.647	rs7406744	chr17:17981938	C/G	cg05444541	chr17:17804740	TOM1L2	-0.32	-5.33	-0.33	2.29e-7	Total body bone mineral density;
SARC	cis	rs7772486	0.681	rs9390343	chr6:146010527	A/T	cg23711669	chr6:146136114	FBXO30	-0.8	-12.55	-0.64	6.04e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7927771	0.524	rs12286721	chr11:47701528	G/T	cg20307385	chr11:47447363	PSMC3	-0.51	-7.05	-0.42	2e-11	Subjective well-being;
SARC	cis	rs883565	0.612	rs784512	chr3:39165110	G/T	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.44	-5.12	-0.32	6.37e-7	Handedness;
SARC	cis	rs11997175	0.550	rs10954943	chr8:33815972	A/G	ch.8.33884649F	chr8:33765107	NA	0.46	5.92	0.36	1.12e-8	Body mass index;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg10663503	chr17:8126298	C17orf44	0.53	6.23	0.38	2.15e-9	Fibrinogen levels;
SARC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg21280719	chr6:42927975	GNMT	-0.47	-8.15	-0.47	2.17e-14	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs6088590	0.523	rs6058084	chr20:33183804	C/T	cg24642439	chr20:33292090	TP53INP2	0.66	8.51	0.49	2.17e-15	Coronary artery disease;
SARC	cis	rs2075371	1.000	rs1421484	chr7:133979795	T/C	cg20476274	chr7:133979776	SLC35B4	0.6	8.31	0.48	8.14e-15	Mean platelet volume;
SARC	cis	rs6690583	0.562	rs6688354	chr1:85520854	A/G	cg22153463	chr1:85462885	MCOLN2	0.66	4.83	0.3	2.53e-6	Serum sulfate level;
SARC	cis	rs9309473	0.607	rs12478346	chr2:73584360	C/T	cg20560298	chr2:73613845	ALMS1	-0.53	-6.35	-0.38	1.1e-9	Metabolite levels;
SARC	cis	rs12142240	0.698	rs112068407	chr1:46822291	T/C	cg10495392	chr1:46806563	NSUN4	0.65	6.8	0.41	8.89e-11	Menopause (age at onset);
SARC	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg01448562	chr3:133502909	NA	-0.47	-7.23	-0.43	7.06e-12	Iron status biomarkers;
SARC	cis	rs2230307	0.536	rs473759	chr1:100557282	C/G	cg24955406	chr1:100503596	HIAT1	0.68	6.62	0.4	2.41e-10	Carotid intima media thickness;
SARC	cis	rs651907	0.557	rs62284199	chr3:101478531	T/G	cg12386194	chr3:101231763	SENP7	0.49	5.79	0.35	2.28e-8	Colorectal cancer;
SARC	cis	rs6582630	0.519	rs7294292	chr12:38349540	C/T	cg26384229	chr12:38710491	ALG10B	0.87	12.69	0.64	2.17e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs920590	0.643	rs13280085	chr8:19669959	G/T	cg17834443	chr8:19674713	INTS10	-0.49	-6.16	-0.37	3.22e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9443189	0.813	rs2842561	chr6:76434273	A/C	cg01950844	chr6:76311363	SENP6	-0.69	-6.25	-0.38	1.89e-9	Prostate cancer;
SARC	cis	rs6120849	0.663	rs11698868	chr20:33549946	C/T	cg24642439	chr20:33292090	TP53INP2	0.59	5.85	0.36	1.64e-8	Protein C levels;
SARC	cis	rs17376456	0.597	rs6869110	chr5:93355531	G/A	cg21475434	chr5:93447410	FAM172A	-0.61	-6.46	-0.39	6e-10	Diabetic retinopathy;
SARC	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.43	-6.28	-0.38	1.61e-9	Total body bone mineral density;
SARC	cis	rs7216064	0.734	rs12942774	chr17:65967562	A/G	cg12091567	chr17:66097778	LOC651250	0.51	5.81	0.36	2.09e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs7089973	0.604	rs11196947	chr10:116601372	G/A	cg08188268	chr10:116634841	FAM160B1	0.28	4.77	0.3	3.18e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs9325144	0.600	rs12227663	chr12:38734922	C/T	cg13010199	chr12:38710504	ALG10B	-0.52	-6.64	-0.4	2.22e-10	Morning vs. evening chronotype;
SARC	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg07685180	chr8:600429	NA	0.83	6.25	0.38	1.99e-9	IgG glycosylation;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg27161463	chr11:118123074	MPZL3	0.51	6.84	0.41	6.83e-11	Chemerin levels;
SARC	cis	rs2952156	0.920	rs732083	chr17:37834367	G/A	cg20243544	chr17:37824526	PNMT	0.54	7.06	0.42	1.87e-11	Asthma;
SARC	cis	rs6570726	0.791	rs1509213	chr6:145783360	G/A	cg23711669	chr6:146136114	FBXO30	-0.86	-14.23	-0.68	1.69e-33	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs12554020	0.786	rs76703294	chr9:96256166	G/A	cg26442883	chr16:49686662	ZNF423	0.56	6.24	0.38	2.1e-9	Schizophrenia;
SARC	cis	rs2439831	0.618	rs8023508	chr15:44176103	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.78	-7.44	-0.44	1.89e-12	Lung cancer in ever smokers;
SARC	cis	rs6493487	0.512	rs71471522	chr15:51153797	G/A	cg02338191	chr15:51200825	AP4E1	0.52	4.98	0.31	1.25e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg06212747	chr3:49208901	KLHDC8B	0.7	9.44	0.53	3.9e-18	Parkinson's disease;
SARC	trans	rs61931739	0.500	rs11053271	chr12:34545407	C/A	cg26384229	chr12:38710491	ALG10B	0.91	13.78	0.67	5.4e-32	Morning vs. evening chronotype;
SARC	cis	rs854765	0.562	rs2955381	chr17:17945500	G/C	cg04398451	chr17:18023971	MYO15A	0.47	6.55	0.39	3.55e-10	Total body bone mineral density;
SARC	cis	rs2760061	0.598	rs658238	chr1:228121291	A/G	cg02753203	chr1:228287806	NA	-0.54	-7.53	-0.44	1.08e-12	Diastolic blood pressure;
SARC	cis	rs74417235	0.684	rs13179754	chr5:154059845	C/T	cg08893839	chr5:154027129	NA	0.49	4.72	0.3	4.01e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
SARC	cis	rs79149102	0.579	rs7342591	chr15:75306863	C/T	cg09165964	chr15:75287851	SCAMP5	0.87	8.37	0.48	5.5e-15	Lung cancer;
SARC	cis	rs66573146	0.831	rs68111914	chr4:6986677	C/T	cg00086871	chr4:6988644	TBC1D14	0.9	5.39	0.33	1.72e-7	Granulocyte percentage of myeloid white cells;
SARC	trans	rs6964833	1.000	rs4717906	chr7:74086247	G/A	cg07504079	chr7:72649617	NCF1B	-0.58	-6.26	-0.38	1.79e-9	Menarche (age at onset);
SARC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.64	0.53	1.01e-18	Prudent dietary pattern;
SARC	cis	rs11122272	0.735	rs2808603	chr1:231537738	T/C	cg06096015	chr1:231504339	EGLN1	0.39	5.73	0.35	3.13e-8	Hemoglobin concentration;
SARC	cis	rs8114671	0.662	rs6088664	chr20:33551100	G/A	cg24642439	chr20:33292090	TP53INP2	0.44	5.33	0.33	2.35e-7	Height;
SARC	cis	rs7208859	0.623	rs11650973	chr17:29214045	G/A	cg13385521	chr17:29058706	SUZ12P	0.86	7.34	0.43	3.54e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs7927771	1.000	rs10838747	chr11:47716324	G/C	cg05585544	chr11:47624801	NA	-0.38	-5.02	-0.31	1.05e-6	Subjective well-being;
SARC	cis	rs36051895	0.623	rs57707737	chr9:5062844	A/T	cg02405213	chr9:5042618	JAK2	-0.45	-5.03	-0.31	9.91e-7	Pediatric autoimmune diseases;
SARC	cis	rs3008870	1.000	rs3008848	chr1:67379284	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.93	11.27	0.59	8.55e-24	Lymphocyte percentage of white cells;
SARC	cis	rs244731	0.959	rs918459	chr5:176669030	C/T	cg06060754	chr5:176797920	RGS14	-0.42	-5.04	-0.31	9.22e-7	Urate levels in lean individuals;
SARC	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg11644478	chr21:40555479	PSMG1	-0.58	-7.14	-0.42	1.19e-11	Menarche (age at onset);
SARC	cis	rs2013441	1.000	rs2058971	chr17:20219508	T/A	cg13482628	chr17:19912719	NA	-0.48	-6.22	-0.38	2.29e-9	Obesity-related traits;
SARC	cis	rs12682352	0.602	rs28399241	chr8:8663215	C/T	cg08975724	chr8:8085496	FLJ10661	0.41	5.12	0.32	6.36e-7	Neuroticism;
SARC	cis	rs34779708	0.931	rs11010077	chr10:35328088	C/T	cg03585969	chr10:35415529	CREM	-0.4	-5.06	-0.31	8.33e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs3091242	0.728	rs706845	chr1:25730713	G/A	cg27572855	chr1:25598939	RHD	0.56	9.63	0.53	1.09e-18	Erythrocyte sedimentation rate;
SARC	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg14582100	chr15:45693742	SPATA5L1	-0.35	-4.91	-0.31	1.75e-6	Homoarginine levels;
SARC	cis	rs9420	0.961	rs11604325	chr11:57497011	C/A	cg19752551	chr11:57585705	CTNND1	-0.5	-6.79	-0.41	9.24e-11	Schizophrenia;
SARC	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg22903471	chr2:27725779	GCKR	-0.52	-8.29	-0.48	8.93e-15	Total body bone mineral density;
SARC	cis	rs9309473	1.000	rs10496191	chr2:73673798	C/T	cg20560298	chr2:73613845	ALMS1	-0.49	-5.89	-0.36	1.37e-8	Metabolite levels;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg14077078	chr5:64965832	SGTB	0.44	6.33	0.38	1.25e-9	Thyroid stimulating hormone;
SARC	cis	rs75064307	0.834	rs4855562	chr3:108116835	C/T	cg03329597	chr3:108125523	MYH15	0.47	4.87	0.3	2.04e-6	Intelligence (multi-trait analysis);
SARC	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg12463550	chr7:65579703	CRCP	0.5	5.9	0.36	1.27e-8	Aortic root size;
SARC	cis	rs6496044	0.526	rs4291869	chr15:86054523	G/A	cg10818794	chr15:86012489	AKAP13	-0.37	-4.72	-0.3	4.03e-6	Interstitial lung disease;
SARC	cis	rs11155671	0.530	rs4869763	chr6:150211684	T/C	cg09699651	chr6:150184138	LRP11	0.52	6.59	0.4	2.86e-10	Testicular germ cell tumor;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg08292080	chr16:56398010	AMFR	0.49	6.75	0.4	1.18e-10	Schizophrenia;
SARC	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg14820908	chr5:178986412	RUFY1	-0.35	-4.97	-0.31	1.32e-6	Lung cancer;
SARC	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg22834771	chr12:69754056	YEATS4	-0.44	-5.78	-0.35	2.43e-8	Blood protein levels;
SARC	cis	rs826838	1.000	rs11183941	chr12:38851692	G/C	cg26384229	chr12:38710491	ALG10B	0.93	14.91	0.7	9.31e-36	Heart rate;
SARC	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.95	14.46	0.69	3.03e-34	Chronic sinus infection;
SARC	cis	rs9467773	1.000	rs1535277	chr6:26567802	G/T	cg11502198	chr6:26597334	ABT1	0.53	6.46	0.39	6.05e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg24110177	chr3:50126178	RBM5	-0.54	-7.1	-0.42	1.51e-11	Intelligence (multi-trait analysis);
SARC	cis	rs7647973	1.000	rs8897	chr3:49460407	A/G	cg06212747	chr3:49208901	KLHDC8B	0.52	5.8	0.36	2.14e-8	Menarche (age at onset);
SARC	cis	rs11098499	0.865	rs28845498	chr4:120405186	G/A	cg09307838	chr4:120376055	NA	0.93	12.78	0.64	1.08e-28	Corneal astigmatism;
SARC	cis	rs17021463	0.966	rs7657789	chr4:95178589	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.48	-7.26	-0.43	5.65e-12	Testicular germ cell tumor;
SARC	cis	rs9894429	0.646	rs6565612	chr17:79602820	C/T	cg10661904	chr17:79619235	PDE6G	0.44	6.18	0.38	2.84e-9	Eye color traits;
SARC	cis	rs2486288	0.656	rs1719232	chr15:45572072	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.54	-6.66	-0.4	2e-10	Glomerular filtration rate;
SARC	cis	rs2718058	0.564	rs1450176	chr7:37756528	T/C	cg15028436	chr7:37888078	TXNDC3	-0.38	-5.36	-0.33	2.03e-7	Alzheimer's disease (late onset);
SARC	cis	rs56011263	0.687	rs4690186	chr4:703607	G/A	cg17689763	chr4:710664	PCGF3	-0.67	-9.36	-0.52	6.99e-18	White blood cell count;
SARC	cis	rs9443189	0.813	rs2842556	chr6:76447204	T/C	cg01950844	chr6:76311363	SENP6	-0.71	-6.61	-0.4	2.57e-10	Prostate cancer;
SARC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg05025164	chr4:1340916	KIAA1530	0.88	11.67	0.61	4.51e-25	Longevity;
SARC	cis	rs2749592	0.918	rs11011388	chr10:38155210	C/T	cg00409905	chr10:38381863	ZNF37A	0.54	5.94	0.36	1.02e-8	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs1003719	0.715	rs2835646	chr21:38546574	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.48	-0.53	3.11e-18	Eye color traits;
SARC	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg00933542	chr6:150070202	PCMT1	0.31	5.29	0.33	2.83e-7	Lung cancer;
SARC	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg12463550	chr7:65579703	CRCP	-0.49	-5.34	-0.33	2.21e-7	Aortic root size;
SARC	cis	rs2916247	1.000	rs2920464	chr8:92987753	C/T	cg10183463	chr8:93005414	RUNX1T1	0.56	5.2	0.32	4.39e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7524258	0.934	rs6689453	chr1:7288384	C/T	cg07173049	chr1:7289937	CAMTA1	0.33	6.4	0.39	8.56e-10	Tourette's syndrome or obsessive-compulsive disorder;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg01934787	chr3:37152029	LRRFIP2	0.51	7.26	0.43	5.73e-12	Thyroid stimulating hormone;
SARC	cis	rs2380220	0.872	rs115871915	chr6:95934180	T/C	cg23517279	chr6:96025343	MANEA	-0.54	-5.39	-0.33	1.76e-7	Behavioural disinhibition (generation interaction);
SARC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg11494091	chr17:61959527	GH2	0.54	8.17	0.47	1.95e-14	Prudent dietary pattern;
SARC	cis	rs1568889	0.941	rs35357280	chr11:28322745	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	8.72	0.5	5.19e-16	Bipolar disorder;
SARC	cis	rs9815354	1.000	rs6599170	chr3:41772718	C/G	cg03022575	chr3:42003672	ULK4	0.56	5.33	0.33	2.26e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg26924012	chr15:45694286	SPATA5L1	0.77	10.99	0.58	6.8e-23	Metabolite levels (small molecules and protein measures);
SARC	trans	rs7819412	0.749	rs11991118	chr8:10939273	A/C	cg15556689	chr8:8085844	FLJ10661	0.49	6.6	0.4	2.81e-10	Triglycerides;
SARC	cis	rs1559088	0.576	rs4805852	chr19:33609441	C/T	cg17764715	chr19:33622953	WDR88	0.61	8.36	0.48	5.55e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs7824557	0.564	rs2736304	chr8:11236964	C/T	cg21775007	chr8:11205619	TDH	-0.64	-8.49	-0.49	2.41e-15	Retinal vascular caliber;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg26832062	chr1:54303852	TMEM48	0.55	6.84	0.41	6.94e-11	Breast cancer;
SARC	cis	rs16976116	0.901	rs2899582	chr15:55491734	T/C	cg11288833	chr15:55489084	RSL24D1	0.63	6.09	0.37	4.66e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4761669	0.724	rs4297523	chr12:95190846	G/T	cg21533806	chr12:95267307	NA	0.37	4.72	0.3	4.08e-6	Common carotid intima-media thickness in HIV infection;
SARC	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg24209194	chr3:40518798	ZNF619	0.7	8.3	0.48	8.63e-15	Renal cell carcinoma;
SARC	cis	rs9443189	0.570	rs7755068	chr6:76405700	A/G	cg01950844	chr6:76311363	SENP6	0.86	8.18	0.47	1.82e-14	Prostate cancer;
SARC	cis	rs3796352	1.000	rs35720014	chr3:52982110	A/C	cg27565382	chr3:53032988	SFMBT1	0.94	6.27	0.38	1.72e-9	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg09323728	chr8:95962352	TP53INP1	-0.29	-4.95	-0.31	1.41e-6	Type 2 diabetes;
SARC	cis	rs7582180	0.606	rs4851299	chr2:100954191	C/A	cg14675211	chr2:100938903	LONRF2	0.51	7.63	0.45	5.86e-13	Intelligence (multi-trait analysis);
SARC	cis	rs1362404	0.648	rs7186604	chr16:51971253	C/G	cg10063805	chr16:52002298	NA	0.34	4.73	0.3	3.9e-6	Gut microbiota (bacterial taxa);
SARC	cis	rs3741151	0.686	rs11828904	chr11:73139116	T/C	cg17517138	chr11:73019481	ARHGEF17	0.66	5.48	0.34	1.08e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs4654899	0.897	rs6679753	chr1:21066634	G/C	cg04902671	chr1:21058625	SH2D5	-0.4	-4.76	-0.3	3.38e-6	Superior frontal gyrus grey matter volume;
SARC	cis	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg24110177	chr3:50126178	RBM5	-0.59	-7.46	-0.44	1.67e-12	Intelligence (multi-trait analysis);
SARC	cis	rs2529049	0.606	rs2529086	chr7:24728564	T/C	cg17569154	chr7:24781545	DFNA5	0.46	6.53	0.39	4.11e-10	Urate levels in obese individuals;
SARC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.12	0.37	3.96e-9	Prudent dietary pattern;
SARC	cis	rs992157	0.798	rs7587220	chr2:219160864	C/A	cg00012203	chr2:219082015	ARPC2	-0.65	-9.27	-0.52	1.3e-17	Colorectal cancer;
SARC	cis	rs6542838	0.702	rs4851167	chr2:99496303	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.4	-5.08	-0.32	7.78e-7	Fear of minor pain;
SARC	cis	rs6141769	0.569	rs6057621	chr20:31265297	A/G	cg17884169	chr20:31446444	EFCAB8	-0.48	-4.96	-0.31	1.36e-6	Subjective well-being;
SARC	trans	rs62103177	0.564	rs11874805	chr18:77697110	T/C	cg05926928	chr17:57297772	GDPD1	0.79	7.33	0.43	3.8e-12	Opioid sensitivity;
SARC	cis	rs6988636	1.000	rs7002332	chr8:124185442	G/C	cg23067535	chr8:124195133	FAM83A	-0.64	-5.3	-0.33	2.72e-7	Urinary uromodulin levels;
SARC	cis	rs2228479	0.702	rs12600047	chr16:89831630	G/A	cg06558623	chr16:89946397	TCF25	0.91	5.99	0.37	7.81e-9	Skin colour saturation;
SARC	cis	rs4975616	0.686	rs37008	chr5:1351538	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.41	-5.65	-0.35	4.57e-8	Lung cancer;
SARC	cis	rs1451375	0.617	rs745043	chr7:50543955	T/G	cg14593290	chr7:50529359	DDC	-0.46	-4.97	-0.31	1.28e-6	Malaria;
SARC	cis	rs986417	0.901	rs10150982	chr14:60987006	T/G	cg27398547	chr14:60952738	C14orf39	0.96	8.88	0.5	1.87e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs57920188	0.584	rs12128330	chr1:4092926	G/A	cg20703997	chr1:4087676	NA	0.51	5.39	0.33	1.69e-7	Interleukin-17 levels;
SARC	cis	rs8062405	0.824	rs62034319	chr16:28532188	T/G	cg08761264	chr16:28874980	SH2B1	-0.42	-4.78	-0.3	3.11e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs4919694	0.572	rs4917995	chr10:104845443	A/T	cg04362960	chr10:104952993	NT5C2	-0.61	-5.76	-0.35	2.63e-8	Arsenic metabolism;
SARC	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.75	11.09	0.59	3.1e-23	Menarche (age at onset);
SARC	cis	rs765787	0.530	rs12915804	chr15:45512562	T/C	cg21132104	chr15:45694354	SPATA5L1	0.4	4.87	0.3	2.09e-6	Uric acid levels;
SARC	cis	rs561341	0.714	rs473535	chr17:30312365	A/G	cg00745463	chr17:30367425	LRRC37B	-0.65	-5.11	-0.32	6.71e-7	Hip circumference adjusted for BMI;
SARC	cis	rs7084402	0.534	rs7911971	chr10:60305160	G/A	cg07615347	chr10:60278583	BICC1	-0.38	-5.08	-0.32	7.9e-7	Refractive error;
SARC	cis	rs6088580	0.601	rs6120668	chr20:33099793	A/G	cg08999081	chr20:33150536	PIGU	0.45	6.91	0.41	4.59e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs9303401	0.614	rs68100606	chr17:56500898	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.02	10.65	0.57	7.64e-22	Cognitive test performance;
SARC	cis	rs1322639	0.614	rs6937001	chr6:169565086	C/T	cg03254818	chr6:169586852	NA	-0.76	-7.69	-0.45	4.18e-13	Pulse pressure;
SARC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.42	0.53	4.71e-18	Prudent dietary pattern;
SARC	cis	rs763121	0.819	rs4560233	chr22:38982442	A/T	cg21395723	chr22:39101663	GTPBP1	0.55	6.01	0.37	7.16e-9	Menopause (age at onset);
SARC	trans	rs1814175	0.645	rs847630	chr11:49926360	C/T	cg15704280	chr7:45808275	SEPT13	-0.88	-14.0	-0.68	1.02e-32	Height;
SARC	cis	rs6570726	0.935	rs446242	chr6:145843866	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.55	0.39	3.64e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs910316	0.737	rs175071	chr14:75498177	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.55	-7.65	-0.45	5.37e-13	Height;
SARC	cis	rs1044826	1.000	rs1586863	chr3:139138242	C/G	cg15131784	chr3:139108705	COPB2	0.45	5.28	0.33	2.95e-7	Obesity-related traits;
SARC	cis	rs56235845	0.694	rs4976643	chr5:176760227	A/C	cg17509989	chr5:176798049	RGS14	0.57	7.75	0.45	2.86e-13	Hemoglobin concentration;Hematocrit;
SARC	cis	rs7666738	0.830	rs6817645	chr4:99016054	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7811528	0.591	rs11770552	chr7:2709471	C/T	cg11411865	chr7:2701802	TTYH3	0.59	5.49	0.34	1.05e-7	Schizophrenia;
SARC	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg12016809	chr21:47604291	C21orf56	-0.46	-5.64	-0.35	4.78e-8	Testicular germ cell tumor;
SARC	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg03575189	chr17:44344142	NA	-0.53	-5.2	-0.32	4.37e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg09249081	chr2:24521631	ITSN2	0.54	7.63	0.45	5.98e-13	Thyroid stimulating hormone;
SARC	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg22168489	chr12:122356033	WDR66	0.67	10.13	0.55	3.24e-20	Mean corpuscular volume;
SARC	cis	rs36051895	0.632	rs7036536	chr9:5181610	T/C	cg02405213	chr9:5042618	JAK2	-0.42	-4.84	-0.3	2.42e-6	Pediatric autoimmune diseases;
SARC	cis	rs427394	0.659	rs274678	chr5:6752385	A/G	cg10857441	chr5:6722123	POLS	0.32	4.75	0.3	3.48e-6	Menopause (age at onset);
SARC	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg17376030	chr22:41985996	PMM1	0.64	7.79	0.45	2.15e-13	Vitiligo;
SARC	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg08280861	chr8:58055591	NA	0.6	5.83	0.36	1.8e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs854765	0.616	rs8076747	chr17:17853595	C/T	cg04398451	chr17:18023971	MYO15A	-0.43	-6.04	-0.37	6.08e-9	Total body bone mineral density;
SARC	cis	rs7208859	0.623	rs2035494	chr17:29130393	T/G	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg10523679	chr1:76189770	ACADM	0.48	5.56	0.34	7.31e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs11638352	1.000	rs2615288	chr15:44415886	T/A	cg27015174	chr15:43622946	ADAL;LCMT2	-0.77	-5.84	-0.36	1.78e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	cis	rs2243480	0.522	rs431168	chr7:65511604	G/T	cg18252515	chr7:66147081	NA	-1.0	-6.24	-0.38	2.07e-9	Diabetic kidney disease;
SARC	cis	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg05623727	chr3:50126028	RBM5	-0.33	-5.07	-0.32	8.07e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7786877	0.508	rs11765509	chr7:100310990	T/G	cg03098644	chr7:100410630	EPHB4	0.47	5.24	0.32	3.64e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs67311347	1.000	rs4128740	chr3:40519532	C/A	cg24209194	chr3:40518798	ZNF619	0.63	7.58	0.44	8.32e-13	Renal cell carcinoma;
SARC	cis	rs9322817	0.691	rs6907016	chr6:105211360	G/A	cg02098413	chr6:105308735	HACE1	-0.38	-6.0	-0.37	7.35e-9	Thyroid stimulating hormone;
SARC	cis	rs362296	0.698	rs362266	chr4:3259632	C/G	cg06533319	chr4:3265114	C4orf44	0.39	6.08	0.37	4.89e-9	Parental longevity (mother's age at death);
SARC	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.46	-5.77	-0.35	2.54e-8	Gut microbiome composition (summer);
SARC	cis	rs6565180	0.791	rs4247355	chr16:30392099	A/G	cg17640201	chr16:30407289	ZNF48	0.95	14.84	0.7	1.62e-35	Tonsillectomy;
SARC	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg05025164	chr4:1340916	KIAA1530	0.63	7.85	0.46	1.47e-13	Longevity;
SARC	cis	rs9296092	0.538	rs78061112	chr6:33526587	T/G	cg13560919	chr6:33536144	NA	-0.52	-6.41	-0.39	8.07e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg14893161	chr1:205819251	PM20D1	0.46	5.31	0.33	2.52e-7	Parkinson's disease;
SARC	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg11062466	chr8:58055876	NA	0.56	5.69	0.35	3.79e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.32	-4.8	-0.3	2.9e-6	Menopause (age at onset);
SARC	cis	rs1152591	0.524	rs1255990	chr14:64661523	A/G	cg23250157	chr14:64679961	SYNE2	-0.44	-6.14	-0.37	3.58e-9	Atrial fibrillation;
SARC	cis	rs11711311	1.000	rs921741	chr3:113444051	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	8.14	0.47	2.31e-14	IgG glycosylation;
SARC	cis	rs7945705	0.837	rs10769966	chr11:8847041	C/A	cg21881798	chr11:8931708	C11orf17;ST5	0.38	5.06	0.31	8.62e-7	Hemoglobin concentration;
SARC	cis	rs7949030	0.626	rs61296092	chr11:62320838	T/C	cg11742103	chr11:62369870	EML3;MTA2	0.43	6.28	0.38	1.6e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs7927771	0.832	rs55677087	chr11:47397714	C/G	cg20307385	chr11:47447363	PSMC3	-0.57	-7.07	-0.42	1.77e-11	Subjective well-being;
SARC	cis	rs897080	0.515	rs1067321	chr2:44631312	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	6.49	0.39	5.2e-10	Height;
SARC	cis	rs7615952	0.546	rs2976733	chr3:125414138	T/C	cg21696256	chr3:125484277	NA	-0.36	-5.12	-0.32	6.27e-7	Blood pressure (smoking interaction);
SARC	cis	rs6493487	0.512	rs35114758	chr15:51371419	C/G	cg02338191	chr15:51200825	AP4E1	0.54	4.94	0.31	1.48e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs7772486	0.790	rs2247429	chr6:146217769	T/C	cg05347473	chr6:146136440	FBXO30	0.49	6.63	0.4	2.33e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9902453	0.726	rs4795523	chr17:28176314	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	7.25	0.43	5.96e-12	Coffee consumption (cups per day);
SARC	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg09323728	chr8:95962352	TP53INP1	-0.29	-4.96	-0.31	1.34e-6	Type 2 diabetes;
SARC	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.89	12.64	0.64	3.1e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	6.0	0.37	7.37e-9	Prudent dietary pattern;
SARC	cis	rs6540556	0.769	rs17389198	chr1:209922058	G/A	cg05527609	chr1:210001259	C1orf107	-0.61	-5.77	-0.35	2.46e-8	Red blood cell count;
SARC	trans	rs61931739	0.591	rs4931764	chr12:33979423	A/G	cg26384229	chr12:38710491	ALG10B	0.61	7.91	0.46	1.01e-13	Morning vs. evening chronotype;
SARC	cis	rs2180341	1.000	rs2057223	chr6:127637374	T/C	cg17762328	chr6:126965162	NA	-0.47	-5.32	-0.33	2.46e-7	Breast cancer;
SARC	cis	rs27434	0.529	rs34757	chr5:96152588	T/C	cg16492584	chr5:96139282	ERAP1	-0.56	-7.15	-0.42	1.12e-11	Ankylosing spondylitis;
SARC	cis	rs3808502	0.526	rs7823101	chr8:11422492	C/G	cg21775007	chr8:11205619	TDH	-0.46	-5.91	-0.36	1.18e-8	Neuroticism;
SARC	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg17221315	chr6:27791827	HIST1H4J	0.47	5.28	0.33	2.97e-7	Depression;
SARC	cis	rs7786808	0.741	rs4909222	chr7:158228095	C/T	cg01191920	chr7:158217561	PTPRN2	0.43	8.14	0.47	2.41e-14	Obesity-related traits;
SARC	cis	rs2816062	0.813	rs6698315	chr1:18895806	A/G	cg10574377	chr1:18908098	NA	0.35	5.02	0.31	1.02e-6	Urate levels in lean individuals;
SARC	cis	rs9905704	0.846	rs302861	chr17:56697040	G/C	cg12560992	chr17:57184187	TRIM37	0.42	4.87	0.3	2.03e-6	Testicular germ cell tumor;
SARC	cis	rs1008375	0.966	rs10006317	chr4:17702525	A/G	cg27347728	chr4:17578864	LAP3	0.46	5.78	0.35	2.4e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2230307	0.536	rs629340	chr1:100538621	A/T	cg24955406	chr1:100503596	HIAT1	0.68	6.62	0.4	2.41e-10	Carotid intima media thickness;
SARC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.63	-0.4	2.28e-10	Total body bone mineral density;
SARC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg26354017	chr1:205819088	PM20D1	0.85	13.71	0.67	9.14e-32	Menarche (age at onset);
SARC	cis	rs11608355	0.545	rs12823587	chr12:109896390	A/G	cg05360138	chr12:110035743	NA	0.92	9.61	0.53	1.27e-18	Neuroticism;
SARC	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg08048268	chr3:133502702	NA	-0.43	-5.75	-0.35	2.86e-8	Iron status biomarkers;
SARC	cis	rs3820928	0.934	rs60141402	chr2:227761445	A/C	cg11843606	chr2:227700838	RHBDD1	-0.52	-6.53	-0.39	4.09e-10	Pulmonary function;
SARC	cis	rs752010	0.806	rs10890148	chr1:42091517	T/C	cg06885757	chr1:42089581	HIVEP3	0.4	6.2	0.38	2.59e-9	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg09021430	chr5:549028	NA	-0.41	-5.48	-0.34	1.08e-7	Obesity-related traits;
SARC	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg11764359	chr7:65958608	NA	0.8	10.13	0.55	3.27e-20	Aortic root size;
SARC	cis	rs2180341	1.000	rs2144742	chr6:127595786	C/A	cg24812749	chr6:127587940	RNF146	0.96	12.68	0.64	2.3e-28	Breast cancer;
SARC	trans	rs61931739	0.500	rs7977194	chr12:34408459	G/A	cg26384229	chr12:38710491	ALG10B	0.92	13.89	0.67	2.39e-32	Morning vs. evening chronotype;
SARC	cis	rs2075371	0.966	rs2544224	chr7:133995832	A/G	cg11752832	chr7:134001865	SLC35B4	0.56	7.1	0.42	1.47e-11	Mean platelet volume;
SARC	cis	rs546131	0.642	rs1594426	chr11:34833459	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-4.83	-0.3	2.52e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs2013441	0.965	rs8071665	chr17:20209943	T/C	cg13482628	chr17:19912719	NA	-0.49	-6.33	-0.38	1.23e-9	Obesity-related traits;
SARC	cis	rs7568458	0.709	rs2592551	chr2:85780131	G/A	cg23752985	chr2:85803571	VAMP8	0.45	5.75	0.35	2.78e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs73198271	0.694	rs115037021	chr8:8647080	A/C	cg06636001	chr8:8085503	FLJ10661	-0.46	-4.97	-0.31	1.3e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs9916302	0.706	rs9906612	chr17:37547631	A/C	cg20243544	chr17:37824526	PNMT	-0.55	-5.77	-0.35	2.46e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.54	6.15	0.37	3.35e-9	Prudent dietary pattern;
SARC	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg07414643	chr4:187882934	NA	0.42	6.24	0.38	2.09e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9325144	0.647	rs12830095	chr12:38864199	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-7.13	-0.42	1.25e-11	Morning vs. evening chronotype;
SARC	cis	rs910316	1.000	rs876403	chr14:75602834	A/T	cg23033748	chr14:75592666	NEK9	0.37	5.25	0.33	3.37e-7	Height;
SARC	cis	rs705471	0.578	rs11251954	chr10:3628517	A/G	cg14308648	chr10:3568949	NA	-0.55	-6.95	-0.41	3.7e-11	Capecitabine sensitivity;
SARC	cis	rs11122272	0.735	rs2474625	chr1:231519331	A/G	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs17253792	0.822	rs10145687	chr14:56124384	T/C	cg01858014	chr14:56050164	KTN1	-0.7	-5.91	-0.36	1.2e-8	Putamen volume;
SARC	cis	rs9811216	0.876	rs11711621	chr3:169524016	C/T	cg14222479	chr3:169487675	ARPM1	0.44	5.09	0.32	7.53e-7	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs6495122	0.501	rs7167261	chr15:75343807	T/C	cg09165964	chr15:75287851	SCAMP5	-0.49	-6.48	-0.39	5.27e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	trans	rs61931739	0.500	rs28624237	chr12:34457171	G/T	cg26384229	chr12:38710491	ALG10B	0.92	13.8	0.67	4.45e-32	Morning vs. evening chronotype;
SARC	cis	rs897080	0.518	rs1067330	chr2:44627822	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.62	7.48	0.44	1.52e-12	Height;
SARC	cis	rs2115630	0.645	rs3825877	chr15:85174631	G/A	cg17507749	chr15:85114479	UBE2QP1	-0.52	-6.25	-0.38	1.91e-9	P wave terminal force;
SARC	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs910316	1.000	rs7147118	chr14:75610170	G/C	cg08847533	chr14:75593920	NEK9	0.91	15.61	0.71	4.59e-38	Height;
SARC	cis	rs7296418	0.630	rs11608305	chr12:123791165	C/G	cg00376283	chr12:123451042	ABCB9	0.56	6.85	0.41	6.7e-11	Platelet count;
SARC	cis	rs507506	0.771	rs929229	chr17:7105399	C/T	cg14438174	chr17:7137923	DVL2	0.42	5.42	0.33	1.46e-7	Adiponectin levels;
SARC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg23034840	chr1:205782522	SLC41A1	0.45	5.69	0.35	3.83e-8	Menarche (age at onset);
SARC	cis	rs11971779	0.648	rs6947309	chr7:139035830	C/T	cg23387468	chr7:139079360	LUC7L2	0.33	4.74	0.3	3.68e-6	Diisocyanate-induced asthma;
SARC	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg05313129	chr8:58192883	C8orf71	-0.52	-5.96	-0.36	9.41e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10465746	0.714	rs12141272	chr1:84434517	C/T	cg10977910	chr1:84465055	TTLL7	0.45	5.55	0.34	7.94e-8	Obesity-related traits;
SARC	cis	rs10046574	0.764	rs10269360	chr7:135147425	A/C	cg27474649	chr7:135195673	CNOT4	0.89	7.27	0.43	5.3e-12	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs10463316	0.962	rs61647401	chr5:150743076	T/C	cg03212797	chr5:150827313	SLC36A1	-0.44	-5.18	-0.32	4.69e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs317865	0.737	rs28483204	chr4:16205098	A/G	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.62	4.8	0.3	2.78e-6	Kidney disease (early stage) in type 1 diabetes;
SARC	cis	rs11718455	0.960	rs35666538	chr3:44004826	A/G	cg08738300	chr3:44038990	NA	0.54	5.94	0.36	1.01e-8	Coronary artery disease;
SARC	cis	rs262150	0.842	rs2657398	chr7:158784911	T/C	cg19418458	chr7:158789849	NA	-0.49	-6.73	-0.4	1.33e-10	Facial morphology (factor 20);
SARC	cis	rs9796	0.840	rs1009913	chr15:41331050	C/T	cg18705301	chr15:41695430	NDUFAF1	0.41	5.73	0.35	3.08e-8	Menopause (age at onset);
SARC	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg27266027	chr21:40555129	PSMG1	0.51	5.54	0.34	8.25e-8	Cognitive function;
SARC	cis	rs7811142	1.000	rs6972167	chr7:100080013	G/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.7	7.01	0.42	2.5e-11	Platelet count;
SARC	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-15.45	-0.71	1.52e-37	Chronic sinus infection;
SARC	cis	rs9916302	0.653	rs11657058	chr17:37699378	T/G	cg00129232	chr17:37814104	STARD3	-0.57	-6.07	-0.37	5.26e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg24250549	chr1:154909240	PMVK	0.62	8.13	0.47	2.48e-14	Prostate cancer;
SARC	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.66	-7.94	-0.46	8.73e-14	Gut microbiome composition (summer);
SARC	cis	rs6752107	0.901	rs11687982	chr2:234149039	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.46	6.19	0.38	2.66e-9	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs7833986	0.501	rs72653957	chr8:56990048	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.73	7.37	0.43	2.98e-12	Height;
SARC	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg10523679	chr1:76189770	ACADM	0.54	6.93	0.41	4.14e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs1348850	0.574	rs11889488	chr2:178426793	A/G	cg23306229	chr2:178417860	TTC30B	-0.81	-7.89	-0.46	1.16e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs10463554	0.927	rs158250	chr5:102406779	G/C	cg23492399	chr5:102201601	PAM	-0.45	-4.99	-0.31	1.21e-6	Parkinson's disease;
SARC	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg03351412	chr1:154909251	PMVK	0.63	8.12	0.47	2.72e-14	Prostate cancer;
SARC	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg18404041	chr3:52824283	ITIH1	-0.44	-6.7	-0.4	1.58e-10	Bipolar disorder;
SARC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg20102877	chr2:27665638	KRTCAP3	-0.36	-5.09	-0.32	7.24e-7	Total body bone mineral density;
SARC	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	5.96	0.36	9.28e-9	Tonsillectomy;
SARC	cis	rs9467773	1.000	rs6910899	chr6:26524339	A/G	cg11502198	chr6:26597334	ABT1	0.47	5.93	0.36	1.1e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg21017887	chr14:105400489	NA	0.53	7.5	0.44	1.3e-12	Rheumatoid arthritis;
SARC	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg18252515	chr7:66147081	NA	-0.58	-6.24	-0.38	2.01e-9	Aortic root size;
SARC	cis	rs7772486	0.686	rs4895684	chr6:146114023	A/C	cg05347473	chr6:146136440	FBXO30	-0.51	-7.16	-0.42	1.03e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3540	0.553	rs12592611	chr15:91004093	C/T	cg22089800	chr15:90895588	ZNF774	0.67	8.56	0.49	1.51e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs12477438	1.000	rs12053372	chr2:99810055	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-8.49	-0.49	2.5e-15	Chronic sinus infection;
SARC	cis	rs11252926	0.831	rs816570	chr10:680475	C/T	cg08603382	chr10:743973	NA	-0.53	-6.83	-0.41	7.3e-11	Psychosis in Alzheimer's disease;
SARC	cis	rs11676348	0.935	rs4674250	chr2:218977531	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.47	-6.31	-0.38	1.4e-9	Ulcerative colitis;
SARC	cis	rs7772486	0.727	rs10223508	chr6:146285205	C/T	cg05347473	chr6:146136440	FBXO30	-0.45	-6.03	-0.37	6.22e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3809863	0.602	rs6504833	chr17:45396087	A/G	cg08085267	chr17:45401833	C17orf57	-0.51	-6.16	-0.37	3.15e-9	Glaucoma (primary open-angle);
SARC	cis	rs7197653	0.667	rs7190070	chr16:68353983	C/T	cg09835421	chr16:68378352	PRMT7	-0.64	-5.61	-0.34	5.85e-8	Magnesium levels;
SARC	cis	rs9814567	0.806	rs4535271	chr3:134321669	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.51	-6.63	-0.4	2.36e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg07636037	chr3:49044803	WDR6	0.99	17.25	0.75	1.59e-43	Parkinson's disease;
SARC	cis	rs4561483	0.864	rs190461	chr16:12005745	A/G	cg08843971	chr16:11963173	GSPT1	-0.43	-4.86	-0.3	2.12e-6	Testicular germ cell tumor;
SARC	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg04317338	chr11:64019027	PLCB3	0.62	7.34	0.43	3.6e-12	Platelet count;
SARC	cis	rs1322639	0.614	rs6925950	chr6:169563958	A/G	cg03254818	chr6:169586852	NA	0.7	6.78	0.41	9.91e-11	Pulse pressure;
SARC	cis	rs35160687	0.814	rs6547673	chr2:86528938	A/G	cg10973622	chr2:86423274	IMMT	0.41	5.56	0.34	7.18e-8	Night sleep phenotypes;
SARC	cis	rs2295359	1.000	rs4655524	chr1:67629469	G/A	cg11235152	chr1:67600687	NA	0.46	6.96	0.41	3.49e-11	Psoriasis;
SARC	cis	rs7681440	0.835	rs7656954	chr4:90784670	G/A	cg02192967	chr4:90758406	SNCA	0.38	5.32	0.33	2.44e-7	Dementia with Lewy bodies;
SARC	cis	rs10046574	0.561	rs10215176	chr7:135198589	A/G	cg27474649	chr7:135195673	CNOT4	0.85	7.92	0.46	9.66e-14	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs7647973	1.000	rs7648995	chr3:49438803	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.56	-5.75	-0.35	2.8e-8	Menarche (age at onset);
SARC	cis	rs4481887	0.708	rs6688853	chr1:248548006	G/A	cg13385794	chr1:248469461	NA	0.32	5.23	0.32	3.78e-7	Common traits (Other);
SARC	cis	rs344364	0.511	rs12596510	chr16:1949480	G/A	cg26617929	chr16:1858877	NA	-0.71	-6.06	-0.37	5.5e-9	Glomerular filtration rate in chronic kidney disease;
SARC	trans	rs9354308	1.000	rs9360161	chr6:66565457	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.55	6.66	0.4	1.91e-10	Metabolite levels;
SARC	trans	rs2727020	0.681	rs1976901	chr11:49378697	T/C	cg15704280	chr7:45808275	SEPT13	-0.82	-13.3	-0.66	2.06e-30	Coronary artery disease;
SARC	cis	rs2273669	0.667	rs4509156	chr6:109308952	A/C	cg05315195	chr6:109294784	ARMC2	0.59	5.47	0.34	1.18e-7	Prostate cancer;
SARC	cis	rs6942407	0.696	rs4400318	chr7:86860524	A/C	cg02420886	chr7:86849541	C7orf23	0.6	5.31	0.33	2.59e-7	Food allergy;
SARC	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg13175981	chr1:150552382	MCL1	-0.53	-6.77	-0.41	1.06e-10	Tonsillectomy;
SARC	cis	rs8068544	0.818	rs8079958	chr17:40155467	C/T	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.06	-8.41	-0.48	4.15e-15	Reticulocyte fraction of red cells;Reticulocyte count;
SARC	cis	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg22857025	chr5:266934	NA	-1.04	-11.12	-0.59	2.6e-23	Breast cancer;
SARC	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2404602	0.647	rs12439141	chr15:77095423	T/C	cg15268244	chr15:77196840	NA	0.43	5.03	0.31	9.79e-7	Blood metabolite levels;
SARC	cis	rs6087990	0.899	rs1003521	chr20:31366598	T/C	cg13636640	chr20:31349939	DNMT3B	0.8	12.66	0.64	2.7e-28	Ulcerative colitis;
SARC	cis	rs34172651	0.606	rs7194189	chr16:24703484	G/T	cg06028605	chr16:24865363	SLC5A11	-0.33	-4.83	-0.3	2.43e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	12.07	0.62	2.21e-26	Platelet count;
SARC	cis	rs921968	0.541	rs7583449	chr2:219403022	A/C	cg02176678	chr2:219576539	TTLL4	-0.53	-8.14	-0.47	2.34e-14	Mean corpuscular hemoglobin concentration;
SARC	cis	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg11266682	chr4:10021025	SLC2A9	0.41	7.29	0.43	4.75e-12	Bone mineral density;
SARC	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg18252515	chr7:66147081	NA	0.48	5.12	0.32	6.34e-7	Aortic root size;
SARC	cis	rs13401104	0.633	rs35055104	chr2:237108884	C/T	cg19324714	chr2:237145437	ASB18	0.58	5.74	0.35	2.94e-8	Educational attainment;
SARC	cis	rs9303401	0.538	rs8078280	chr17:56473132	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.0	10.41	0.56	4.3e-21	Cognitive test performance;
SARC	cis	rs11809207	0.523	rs2186232	chr1:26502676	T/A	cg00300879	chr1:26503847	CNKSR1	0.32	4.9	0.31	1.76e-6	Height;
SARC	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg15352829	chr14:105391018	PLD4	-0.32	-5.89	-0.36	1.32e-8	Rheumatoid arthritis;
SARC	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg04518342	chr5:131593106	PDLIM4	-0.44	-5.58	-0.34	6.77e-8	Breast cancer;
SARC	cis	rs12956009	0.559	rs1893787	chr18:44856030	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.57	7.36	0.43	3.14e-12	Educational attainment (years of education);
SARC	cis	rs4423214	1.000	rs1044482	chr11:71155171	C/T	cg05163923	chr11:71159392	DHCR7	0.67	9.19	0.52	2.2e-17	Vitamin D levels;
SARC	cis	rs459571	1.000	rs456207	chr9:136911140	G/A	cg01294253	chr9:136912663	BRD3	0.39	5.13	0.32	6.07e-7	Platelet distribution width;
SARC	cis	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg15145296	chr3:125709740	NA	-0.49	-4.95	-0.31	1.45e-6	Blood pressure (smoking interaction);
SARC	cis	rs10463554	0.963	rs3776857	chr5:102358160	A/G	cg23492399	chr5:102201601	PAM	-0.47	-5.16	-0.32	5.2e-7	Parkinson's disease;
SARC	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg05872129	chr22:39784769	NA	0.38	5.29	0.33	2.77e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs34779708	0.966	rs17499247	chr10:35426755	A/G	cg03585969	chr10:35415529	CREM	0.38	4.85	0.3	2.25e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs526231	0.543	rs34767	chr5:102489511	A/C	cg23492399	chr5:102201601	PAM	-0.51	-5.76	-0.35	2.67e-8	Primary biliary cholangitis;
SARC	cis	rs651907	0.557	rs34624546	chr3:101374226	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	6.12	0.37	4.03e-9	Colorectal cancer;
SARC	cis	rs1483890	0.723	rs34184121	chr3:69411426	A/T	cg22125112	chr3:69402811	FRMD4B	0.29	4.78	0.3	3.12e-6	Resting heart rate;
SARC	cis	rs7523050	0.730	rs12726126	chr1:109436128	A/G	cg08274380	chr1:109419600	GPSM2	1.1	8.68	0.49	6.9e-16	Fat distribution (HIV);
SARC	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg06221963	chr1:154839813	KCNN3	-0.5	-8.12	-0.47	2.69e-14	Prostate cancer;
SARC	cis	rs10754283	0.934	rs10754284	chr1:90113702	A/C	cg21401794	chr1:90099060	LRRC8C	0.59	8.09	0.47	3.24e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs72945132	0.882	rs11235739	chr11:70132780	C/T	cg00319359	chr11:70116639	PPFIA1	0.65	6.07	0.37	5.24e-9	Coronary artery disease;
SARC	cis	rs644799	0.932	rs480079	chr11:95643777	A/T	cg25478527	chr11:95522999	CEP57;FAM76B	-0.64	-8.33	-0.48	7.07e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs6772849	0.930	rs12630379	chr3:128370204	G/C	cg01163369	chr3:128370232	RPN1	-0.34	-4.96	-0.31	1.34e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs2120243	0.539	rs722484	chr3:157100627	C/T	cg24825693	chr3:157122686	VEPH1	-0.45	-6.27	-0.38	1.74e-9	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs2658782	0.901	rs2605611	chr11:93229319	T/G	cg15737290	chr11:93063684	CCDC67	0.64	6.74	0.4	1.24e-10	Pulmonary function decline;
SARC	cis	rs11997175	0.558	rs9792124	chr8:33797689	A/C	ch.8.33884649F	chr8:33765107	NA	0.43	5.28	0.33	2.99e-7	Body mass index;
SARC	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.72	8.43	0.48	3.55e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg05335107	chr2:109400084	RANBP2	-0.53	-6.29	-0.38	1.53e-9	Alcohol dependence;
SARC	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg08280861	chr8:58055591	NA	0.54	4.75	0.3	3.48e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs2075371	0.829	rs11770764	chr7:134003308	T/C	cg11752832	chr7:134001865	SLC35B4	0.55	6.82	0.41	7.87e-11	Mean platelet volume;
SARC	cis	rs9916302	0.653	rs11654954	chr17:37745979	C/T	cg00129232	chr17:37814104	STARD3	0.67	7.31	0.43	4.28e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs6088580	0.634	rs6120666	chr20:33090718	A/G	cg08999081	chr20:33150536	PIGU	0.45	6.91	0.41	4.59e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg06873352	chr17:61820015	STRADA	0.53	6.86	0.41	6.23e-11	Prudent dietary pattern;
SARC	cis	rs7216064	1.000	rs62084240	chr17:65859233	C/A	cg12091567	chr17:66097778	LOC651250	-0.67	-6.52	-0.39	4.2e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs2479724	0.935	rs2025951	chr6:41827193	C/T	cg17623882	chr6:41773611	USP49	0.47	5.94	0.36	1.06e-8	Menarche (age at onset);
SARC	cis	rs705471	0.966	rs10904060	chr10:3654200	C/T	cg14308648	chr10:3568949	NA	-0.56	-6.89	-0.41	5.05e-11	Capecitabine sensitivity;
SARC	cis	rs9815354	1.000	rs73069392	chr3:41787009	C/T	cg03022575	chr3:42003672	ULK4	0.64	5.93	0.36	1.11e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6598955	0.670	rs7522905	chr1:26609259	C/T	cg04990556	chr1:26633338	UBXN11	-0.59	-8.06	-0.47	3.93e-14	Obesity-related traits;
SARC	cis	rs2832191	0.716	rs1984012	chr21:30392472	T/C	cg24692254	chr21:30365293	RNF160	1.02	18.55	0.77	8.73e-48	Dental caries;
SARC	cis	rs7647973	1.000	rs7647973	chr3:49510931	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.57	-5.74	-0.35	2.88e-8	Menarche (age at onset);
SARC	cis	rs2594989	1.000	rs2594993	chr3:11360744	C/T	cg00170343	chr3:11313890	ATG7	0.54	5.22	0.32	4.05e-7	Circulating chemerin levels;
SARC	cis	rs986417	1.000	rs10149915	chr14:60943110	G/A	cg27398547	chr14:60952738	C14orf39	1.03	9.89	0.54	1.74e-19	Gut microbiota (bacterial taxa);
SARC	cis	rs10206020	0.885	rs6720923	chr2:1574197	T/C	cg26248373	chr2:1572462	NA	-0.6	-8.42	-0.48	3.76e-15	IgG glycosylation;
SARC	cis	rs9467773	0.549	rs9467805	chr6:26583366	C/T	cg12292205	chr6:26970375	C6orf41	0.42	5.21	0.32	4.23e-7	Intelligence (multi-trait analysis);
SARC	cis	rs4742903	1.000	rs10761010	chr9:106858788	G/A	cg14250997	chr9:106856677	SMC2	0.52	6.88	0.41	5.35e-11	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs3126085	0.935	rs4845426	chr1:152195359	A/G	cg03465714	chr1:152285911	FLG	-0.45	-5.6	-0.34	6.01e-8	Atopic dermatitis;
SARC	cis	rs2204008	0.837	rs2127955	chr12:37969194	A/G	cg13010199	chr12:38710504	ALG10B	0.67	9.01	0.51	7.82e-17	Bladder cancer;
SARC	trans	rs12660691	0.786	rs10872346	chr6:130012053	C/T	cg06036239	chr1:59234929	NA	-0.67	-6.41	-0.39	8.05e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
SARC	cis	rs1153858	1.000	rs10519022	chr15:45663684	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.79	-11.11	-0.59	2.7e-23	Homoarginine levels;
SARC	cis	rs780094	0.585	rs7586601	chr2:27584666	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.42	-6.89	-0.41	5.25e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs9527	0.615	rs10883811	chr10:104727279	A/G	cg04362960	chr10:104952993	NT5C2	0.42	4.98	0.31	1.23e-6	Arsenic metabolism;
SARC	cis	rs3771570	1.000	rs1056801	chr2:242292307	T/C	cg21155796	chr2:242212141	HDLBP	0.68	6.09	0.37	4.67e-9	Prostate cancer;
SARC	cis	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg20965017	chr5:231967	SDHA	-0.57	-5.57	-0.34	7.12e-8	Breast cancer;
SARC	cis	rs4975709	0.569	rs931509	chr5:1858821	A/T	cg15595755	chr5:1867978	NA	0.49	6.56	0.39	3.46e-10	Cardiovascular disease risk factors;
SARC	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg11764359	chr7:65958608	NA	-0.53	-6.07	-0.37	5.11e-9	Aortic root size;
SARC	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg04944784	chr2:26401820	FAM59B	-0.47	-5.78	-0.35	2.34e-8	Gut microbiome composition (summer);
SARC	cis	rs9910055	0.530	rs2269907	chr17:42294215	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	0.46	6.14	0.37	3.44e-9	Total body bone mineral density;
SARC	cis	rs8180040	0.900	rs4858894	chr3:47484953	C/G	cg27129171	chr3:47204927	SETD2	0.67	9.32	0.52	9.19e-18	Colorectal cancer;
SARC	cis	rs4423214	1.000	rs2276361	chr11:71169648	A/G	cg24826892	chr11:71159390	DHCR7	0.49	6.26	0.38	1.79e-9	Vitamin D levels;
SARC	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-5.58	-0.34	6.54e-8	Electroencephalogram traits;
SARC	cis	rs6484504	0.576	rs286649	chr11:31230468	C/T	cg26647111	chr11:31128758	NA	-0.4	-5.19	-0.32	4.56e-7	Red blood cell count;
SARC	cis	rs12579753	0.956	rs7965168	chr12:82184467	C/A	cg07988820	chr12:82153109	PPFIA2	-0.57	-6.77	-0.41	1.03e-10	Resting heart rate;
SARC	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.74	8.5	0.49	2.3e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs459571	0.839	rs2519831	chr9:136886257	T/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.6	-6.81	-0.41	8.21e-11	Platelet distribution width;
SARC	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg27572855	chr1:25598939	RHD	0.55	9.43	0.53	4.28e-18	Erythrocyte sedimentation rate;
SARC	cis	rs4555082	0.834	rs2735825	chr14:105710900	G/A	cg13114125	chr14:105738426	BRF1	-0.81	-12.07	-0.62	2.19e-26	Mean platelet volume;Platelet distribution width;
SARC	cis	rs1018836	0.828	rs2105968	chr8:91591825	A/G	cg16814680	chr8:91681699	NA	-0.76	-12.04	-0.62	2.72e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.43	0.39	7.27e-10	Height;
SARC	trans	rs1459104	0.571	rs10459012	chr11:55091574	C/A	cg15704280	chr7:45808275	SEPT13	0.56	6.31	0.38	1.39e-9	Body mass index;
SARC	cis	rs1448094	0.872	rs7300073	chr12:86393513	A/C	cg02569458	chr12:86230093	RASSF9	0.38	5.62	0.35	5.33e-8	Major depressive disorder;
SARC	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg14581129	chr12:53358946	NA	-0.41	-5.36	-0.33	2.02e-7	Cancer (pleiotropy);
SARC	cis	rs13191362	0.935	rs35049401	chr6:162968464	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.53	4.81	0.3	2.74e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg20573242	chr4:122745356	CCNA2	0.58	7.58	0.44	8.38e-13	Type 2 diabetes;
SARC	cis	rs1865760	0.566	rs1539183	chr6:26075051	G/C	cg10373733	chr6:25993375	NA	0.44	5.41	0.33	1.57e-7	Height;
SARC	cis	rs7937682	0.575	rs11604704	chr11:111764396	G/A	cg22437258	chr11:111473054	SIK2	-0.48	-5.51	-0.34	9.43e-8	Primary sclerosing cholangitis;
SARC	cis	rs8114671	0.562	rs8116657	chr20:33476474	C/G	cg24642439	chr20:33292090	TP53INP2	0.47	5.67	0.35	4.18e-8	Height;
SARC	cis	rs66887589	0.934	rs56843000	chr4:120516597	T/C	cg09307838	chr4:120376055	NA	-0.52	-7.01	-0.42	2.48e-11	Diastolic blood pressure;
SARC	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg27266027	chr21:40555129	PSMG1	0.48	5.24	0.32	3.61e-7	Cognitive function;
SARC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.44	-5.61	-0.35	5.6e-8	Longevity;Endometriosis;
SARC	cis	rs9611565	0.879	rs2235845	chr22:41729294	T/G	cg03806693	chr22:41940476	POLR3H	-0.68	-9.44	-0.53	3.99e-18	Vitiligo;
SARC	cis	rs2120019	1.000	rs34237279	chr15:75361121	A/G	cg00629941	chr15:75287862	SCAMP5	-0.61	-7.16	-0.42	1.03e-11	Blood trace element (Zn levels);
SARC	trans	rs10448080	0.879	rs240946	chr8:28568905	A/G	cg26258108	chr2:232329189	NCL	0.47	6.32	0.38	1.3e-9	Height;
SARC	cis	rs12545109	0.800	rs1467123	chr8:57418870	C/T	cg21220214	chr8:57350948	NA	-0.4	-4.84	-0.3	2.37e-6	Obesity-related traits;
SARC	trans	rs2727020	0.675	rs1684258	chr11:49340020	G/A	cg03929089	chr4:120376271	NA	0.67	7.28	0.43	5.02e-12	Coronary artery disease;
SARC	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg13939156	chr17:80058883	NA	-0.43	-6.57	-0.4	3.29e-10	Life satisfaction;
SARC	cis	rs1971762	0.545	rs6580949	chr12:53924293	T/C	cg06632207	chr12:54070931	ATP5G2	0.56	7.73	0.45	3.24e-13	Height;
SARC	cis	rs9916302	0.808	rs6503515	chr17:37606433	G/T	cg20243544	chr17:37824526	PNMT	0.56	6.73	0.4	1.32e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs1784581	0.588	rs9295178	chr6:162419226	T/A	cg17173639	chr6:162384350	PARK2	0.51	6.49	0.39	5.19e-10	Itch intensity from mosquito bite;
SARC	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg07701084	chr6:150067640	NUP43	0.41	5.37	0.33	1.94e-7	Lung cancer;
SARC	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg05368731	chr17:41323189	NBR1	0.71	8.57	0.49	1.47e-15	Menopause (age at onset);
SARC	cis	rs820218	0.886	rs820147	chr17:73615644	C/T	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.58	7.39	0.44	2.54e-12	Rotator cuff tears;
SARC	cis	rs787274	1.000	rs787291	chr9:115507904	A/T	cg13803584	chr9:115635662	SNX30	0.83	4.87	0.3	2.03e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs3218477	1.000	rs75534275	chr7:152334694	C/T	cg06618968	chr7:152373420	XRCC2	-0.77	-4.91	-0.31	1.74e-6	Mean platelet volume;
SARC	cis	rs698833	0.828	rs3738984	chr2:44531484	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.63	-8.42	-0.48	3.78e-15	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs17253792	0.822	rs10151664	chr14:56029533	A/G	cg01858014	chr14:56050164	KTN1	-0.69	-5.34	-0.33	2.18e-7	Putamen volume;
SARC	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg05896524	chr21:47604654	C21orf56	0.42	5.04	0.31	9.35e-7	Testicular germ cell tumor;
SARC	cis	rs6500602	0.963	rs7201012	chr16:4480682	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.36	5.91	0.36	1.23e-8	Schizophrenia;
SARC	cis	rs6582630	0.502	rs2387603	chr12:38353389	A/C	cg26384229	chr12:38710491	ALG10B	0.87	12.85	0.64	6.2e-29	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2153535	0.580	rs9378551	chr6:8463744	A/G	cg07606381	chr6:8435919	SLC35B3	0.76	10.78	0.58	3.09e-22	Motion sickness;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg13457403	chr21:44313401	NDUFV3	0.51	6.3	0.38	1.51e-9	Height;
SARC	cis	rs734999	0.588	rs6668149	chr1:2558308	A/C	cg20673091	chr1:2541236	MMEL1	-0.32	-4.98	-0.31	1.23e-6	Ulcerative colitis;
SARC	cis	rs1008375	0.897	rs3733577	chr4:17649233	T/G	cg16339924	chr4:17578868	LAP3	0.64	8.49	0.49	2.48e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2204008	0.660	rs2320745	chr12:38239101	T/C	cg26384229	chr12:38710491	ALG10B	0.9	12.92	0.65	3.68e-29	Bladder cancer;
SARC	cis	rs1865760	0.566	rs3752419	chr6:26027433	C/T	cg18357526	chr6:26021779	HIST1H4A	0.45	5.5	0.34	1.01e-7	Height;
SARC	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg04944784	chr2:26401820	FAM59B	0.59	7.88	0.46	1.25e-13	Gut microbiome composition (summer);
SARC	cis	rs4253772	0.637	rs3087501	chr22:46647909	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.63	6.74	0.4	1.23e-10	LDL cholesterol;Cholesterol, total;
SARC	cis	rs2882667	0.858	rs13174479	chr5:138444170	G/A	cg04439458	chr5:138467593	SIL1	-0.29	-4.94	-0.31	1.49e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg24101359	chr6:42928495	GNMT	-0.43	-5.98	-0.36	8.37e-9	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs71636778	0.543	rs17162330	chr1:27236212	A/G	cg12203394	chr1:27248618	NUDC	0.55	4.79	0.3	2.92e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs6121246	0.567	rs7266471	chr20:30220599	T/A	cg13852791	chr20:30311386	BCL2L1	0.65	5.66	0.35	4.48e-8	Mean corpuscular hemoglobin;
SARC	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.75	7.86	0.46	1.42e-13	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg00149659	chr3:10157352	C3orf10	0.81	7.87	0.46	1.36e-13	Alzheimer's disease;
SARC	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	9.07	0.51	5e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs763121	0.853	rs2072796	chr22:39064230	A/G	cg21395723	chr22:39101663	GTPBP1	0.55	6.14	0.37	3.52e-9	Menopause (age at onset);
SARC	cis	rs7769051	0.522	rs6934190	chr6:133116664	G/A	cg22852734	chr6:133119734	C6orf192	1.25	7.92	0.46	9.87e-14	Type 2 diabetes nephropathy;
SARC	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg11764359	chr7:65958608	NA	-0.79	-9.77	-0.54	4.17e-19	Aortic root size;
SARC	cis	rs854765	0.654	rs11078400	chr17:17757728	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.66	-9.79	-0.54	3.47e-19	Total body bone mineral density;
SARC	cis	rs6060717	0.536	rs6058356	chr20:34491530	A/G	cg01084648	chr20:34329383	RBM39	0.65	4.82	0.3	2.56e-6	Hip circumference adjusted for BMI;
SARC	cis	rs7647973	0.710	rs6446284	chr3:49616997	A/G	cg07636037	chr3:49044803	WDR6	0.77	7.01	0.42	2.52e-11	Menarche (age at onset);
SARC	cis	rs1707322	0.685	rs6690926	chr1:46134978	T/C	cg03146154	chr1:46216737	IPP	0.52	6.32	0.38	1.33e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7927771	0.864	rs2293580	chr11:47440283	T/A	cg20307385	chr11:47447363	PSMC3	0.6	7.61	0.45	6.72e-13	Subjective well-being;
SARC	cis	rs9316337	0.520	rs8001135	chr13:22015251	C/A	cg18095732	chr13:22033692	ZDHHC20	0.39	4.75	0.3	3.63e-6	Schizophrenia;
SARC	cis	rs2486288	0.656	rs2461705	chr15:45570241	A/G	cg19305227	chr15:45544335	SLC28A2	0.31	5.72	0.35	3.33e-8	Glomerular filtration rate;
SARC	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg13939156	chr17:80058883	NA	0.4	6.22	0.38	2.23e-9	Life satisfaction;
SARC	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-7.83	-0.46	1.71e-13	Alzheimer's disease;
SARC	cis	rs9291683	0.530	rs17246501	chr4:9985710	A/C	cg00071950	chr4:10020882	SLC2A9	0.43	6.78	0.41	9.93e-11	Bone mineral density;
SARC	cis	rs1023500	0.529	rs133375	chr22:42466509	C/G	cg04733989	chr22:42467013	NAGA	0.76	10.59	0.57	1.16e-21	Schizophrenia;
SARC	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg15049968	chr18:44337910	ST8SIA5	-0.33	-5.29	-0.33	2.83e-7	Personality dimensions;
SARC	cis	rs3733585	0.699	rs7694997	chr4:9947811	A/G	cg00071950	chr4:10020882	SLC2A9	-0.39	-6.12	-0.37	3.83e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs9443189	0.615	rs6453829	chr6:76268509	C/T	cg01950844	chr6:76311363	SENP6	0.87	7.79	0.45	2.23e-13	Prostate cancer;
SARC	cis	rs7769051	0.614	rs6912936	chr6:133102664	A/G	cg22852734	chr6:133119734	C6orf192	1.13	11.48	0.6	1.85e-24	Type 2 diabetes nephropathy;
SARC	cis	rs3127447	0.836	rs2670115	chr10:79335095	A/C	cg26615853	chr10:79347104	KCNMA1	-0.32	-4.77	-0.3	3.21e-6	Educational attainment;
SARC	cis	rs9325144	0.581	rs2653758	chr12:38946233	G/T	cg13010199	chr12:38710504	ALG10B	-0.61	-7.98	-0.46	6.68e-14	Morning vs. evening chronotype;
SARC	cis	rs17376456	0.877	rs13153245	chr5:93374891	G/A	cg25358565	chr5:93447407	FAM172A	1.3	14.78	0.7	2.47e-35	Diabetic retinopathy;
SARC	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg05793240	chr7:2802953	GNA12	0.35	5.03	0.31	9.98e-7	Height;
SARC	cis	rs7772486	0.720	rs4896844	chr6:146075224	T/C	cg23711669	chr6:146136114	FBXO30	-0.92	-16.53	-0.73	3.75e-41	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7818345	0.967	rs4554480	chr8:19284072	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.42	5.61	0.34	5.84e-8	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs10463316	0.894	rs869196	chr5:150746287	G/T	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.43	-0.34	1.41e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs11098499	0.562	rs58583086	chr4:120556362	A/G	cg09307838	chr4:120376055	NA	-0.72	-10.09	-0.55	4.28e-20	Corneal astigmatism;
SARC	cis	rs66573146	0.831	rs73088564	chr4:6984553	G/C	cg00086871	chr4:6988644	TBC1D14	0.89	5.29	0.33	2.88e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs7772486	0.654	rs6906402	chr6:146089307	C/G	cg05347473	chr6:146136440	FBXO30	-0.55	-7.7	-0.45	3.97e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs17376456	0.696	rs6860390	chr5:93494731	G/T	cg25358565	chr5:93447407	FAM172A	-0.89	-10.11	-0.55	3.65e-20	Diabetic retinopathy;
SARC	cis	rs34311866	0.808	rs11248059	chr4:960331	C/G	cg07828340	chr4:882639	GAK	0.73	5.77	0.35	2.53e-8	Parkinson's disease;
SARC	cis	rs7246657	0.882	rs4803539	chr19:37897522	A/C	cg23950597	chr19:37808831	NA	-0.56	-5.68	-0.35	3.9e-8	Coronary artery calcification;
SARC	cis	rs561341	0.609	rs7209493	chr17:30197323	A/G	cg13647721	chr17:30228624	UTP6	-0.63	-6.24	-0.38	2.03e-9	Hip circumference adjusted for BMI;
SARC	cis	rs2933343	1.000	rs876755	chr3:128627933	C/T	cg24203234	chr3:128598194	ACAD9	0.56	6.27	0.38	1.75e-9	IgG glycosylation;
SARC	cis	rs1865760	1.000	rs3799372	chr6:25922311	A/G	cg10373733	chr6:25993375	NA	0.42	5.02	0.31	1.04e-6	Height;
SARC	cis	rs8014204	0.544	rs2286913	chr14:75386576	G/A	cg08847533	chr14:75593920	NEK9	0.5	5.79	0.35	2.21e-8	Caffeine consumption;
SARC	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg17971929	chr21:40555470	PSMG1	0.98	13.58	0.66	2.48e-31	Cognitive function;
SARC	cis	rs7103648	0.669	rs7114011	chr11:47811309	A/C	cg20307385	chr11:47447363	PSMC3	0.76	10.39	0.56	5.12e-21	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg16325326	chr1:53192061	ZYG11B	0.78	12.02	0.62	3.14e-26	Monocyte count;
SARC	cis	rs3767633	0.858	rs7532448	chr1:161862745	C/T	cg09175582	chr1:161736000	ATF6	0.68	5.88	0.36	1.38e-8	IgG glycosylation;
SARC	cis	rs7029536	0.551	rs11791288	chr9:130173224	T/C	cg09445097	chr9:130186736	ZNF79	0.53	4.99	0.31	1.2e-6	Metabolite levels (HVA);
SARC	cis	rs2204008	0.774	rs4534658	chr12:38246783	G/A	cg13010199	chr12:38710504	ALG10B	0.8	11.25	0.59	9.69e-24	Bladder cancer;
SARC	cis	rs4853036	0.723	rs35690619	chr2:70053619	A/T	cg02498382	chr2:70120550	SNRNP27	-0.44	-5.25	-0.33	3.39e-7	Colorectal or endometrial cancer;
SARC	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg07167872	chr1:205819463	PM20D1	0.48	5.55	0.34	7.89e-8	Prostate-specific antigen levels;
SARC	cis	rs4713118	0.824	rs13211701	chr6:27750079	T/C	cg17221315	chr6:27791827	HIST1H4J	0.47	5.1	0.32	6.97e-7	Parkinson's disease;
SARC	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg00933542	chr6:150070202	PCMT1	0.31	5.29	0.33	2.83e-7	Lung cancer;
SARC	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.59e-6	Parkinson's disease;
SARC	cis	rs6495122	0.699	rs2168518	chr15:75081078	G/A	cg14664628	chr15:75095509	CSK	-0.8	-10.52	-0.57	1.99e-21	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.52	5.99	0.37	7.81e-9	Renal function-related traits (BUN);
SARC	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg07636037	chr3:49044803	WDR6	1.0	17.64	0.76	8.38e-45	Parkinson's disease;
SARC	cis	rs8016982	0.674	rs6574631	chr14:81675772	C/T	cg01989461	chr14:81687754	GTF2A1	0.73	11.15	0.59	1.98e-23	Schizophrenia;
SARC	cis	rs7465272	0.500	rs7463655	chr8:143731034	G/C	cg10596483	chr8:143751796	JRK	0.57	7.39	0.44	2.61e-12	Bipolar disorder and schizophrenia;
SARC	cis	rs2050392	0.624	rs303447	chr10:30728464	T/C	cg25182066	chr10:30743637	MAP3K8	0.43	5.8	0.36	2.17e-8	Inflammatory bowel disease;
SARC	cis	rs11249608	0.636	rs13359572	chr5:178449276	T/C	cg21905437	chr5:178450457	ZNF879	0.57	7.66	0.45	5.07e-13	Pubertal anthropometrics;
SARC	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg05861140	chr6:150128134	PCMT1	-0.42	-5.44	-0.34	1.32e-7	Lung cancer;
SARC	cis	rs11992162	0.597	rs6996342	chr8:11784541	C/T	cg02127589	chr8:12458309	NA	-0.32	-4.78	-0.3	3.13e-6	Monocyte count;
SARC	cis	rs3008870	1.000	rs1137656	chr1:67451602	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.89	-11.03	-0.59	4.76e-23	Lymphocyte percentage of white cells;
SARC	cis	rs1448094	0.511	rs7967183	chr12:86216845	T/G	cg02569458	chr12:86230093	RASSF9	0.42	5.83	0.36	1.87e-8	Major depressive disorder;
SARC	cis	rs2645424	0.519	rs17154027	chr8:11713852	C/T	cg21281001	chr8:11725306	CTSB	-0.41	-5.04	-0.31	9.17e-7	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
SARC	cis	rs1707322	0.752	rs10430105	chr1:46138876	G/A	cg03146154	chr1:46216737	IPP	0.52	6.25	0.38	1.92e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs11039571	0.588	rs10734564	chr11:48160429	A/G	cg15704280	chr7:45808275	SEPT13	-0.63	-6.43	-0.39	7.02e-10	D-dimer levels;
SARC	cis	rs1153858	1.000	rs1820518	chr15:45694579	C/T	cg21132104	chr15:45694354	SPATA5L1	0.78	10.56	0.57	1.54e-21	Homoarginine levels;
SARC	cis	rs7932354	0.528	rs10838660	chr11:47152273	C/T	cg03339077	chr11:47165057	C11orf49	-0.47	-6.37	-0.39	1.01e-9	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs13082711	0.954	rs34348584	chr3:27532704	T/C	cg02860705	chr3:27208620	NA	0.47	5.75	0.35	2.79e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg21724239	chr8:58056113	NA	0.6	6.37	0.38	1.03e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1008375	1.000	rs28545485	chr4:17645376	C/T	cg16339924	chr4:17578868	LAP3	0.67	8.99	0.51	8.91e-17	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg20607798	chr8:58055168	NA	0.58	5.57	0.34	6.9e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7937682	0.960	rs480293	chr11:111469132	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.93	-14.06	-0.68	6.32e-33	Primary sclerosing cholangitis;
SARC	cis	rs3126085	0.935	rs11204947	chr1:152218257	G/T	cg26876637	chr1:152193138	HRNR	-0.5	-5.63	-0.35	5.07e-8	Atopic dermatitis;
SARC	cis	rs950169	0.922	rs11635505	chr15:85097034	A/C	cg17507749	chr15:85114479	UBE2QP1	-0.77	-9.37	-0.52	6.65e-18	Schizophrenia;
SARC	cis	rs2834188	0.883	rs16997869	chr21:34696867	C/T	cg04842828	chr21:34696676	IFNAR1	-0.4	-4.75	-0.3	3.58e-6	Narcolepsy;
SARC	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	11.64	0.61	5.7e-25	Alzheimer's disease;
SARC	cis	rs6582630	0.555	rs11610015	chr12:38508856	A/G	cg26384229	chr12:38710491	ALG10B	0.84	12.25	0.63	5.65e-27	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2976388	0.609	rs2717603	chr8:143803193	T/C	cg06565975	chr8:143823917	SLURP1	0.28	4.73	0.3	3.92e-6	Urinary tract infection frequency;
SARC	cis	rs57506017	0.585	rs6460901	chr7:12255434	C/T	cg23422036	chr7:12250390	TMEM106B	0.5	6.68	0.4	1.72e-10	Neuroticism;
SARC	cis	rs2836974	0.583	rs2776306	chr21:40713754	A/G	cg17971929	chr21:40555470	PSMG1	0.62	8.04	0.47	4.42e-14	Cognitive function;
SARC	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.9	9.19	0.52	2.28e-17	Platelet count;
SARC	cis	rs2073300	0.609	rs74809795	chr20:23372383	A/C	cg16736954	chr20:23401023	NAPB	0.79	4.99	0.31	1.16e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg16325326	chr1:53192061	ZYG11B	0.91	16.75	0.74	7.26e-42	Monocyte count;
SARC	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	13.51	0.66	4.16e-31	Chronic sinus infection;
SARC	cis	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg14019146	chr3:50243930	SLC38A3	-0.33	-5.08	-0.32	7.77e-7	Intelligence (multi-trait analysis);
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg14422660	chr6:105628044	POPDC3	0.51	6.24	0.38	2.05e-9	Blood pressure;
SARC	cis	rs73206853	0.764	rs56273026	chr12:110901691	A/C	cg10860002	chr12:110842031	ANAPC7	0.64	5.11	0.32	6.75e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs1982346	0.850	rs2193855	chr4:106750022	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	-0.76	-5.25	-0.32	3.5e-7	Lung function (FEV1);
SARC	cis	rs11098499	0.954	rs10518331	chr4:120323595	C/T	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg06005911	chr10:22622123	NA	0.42	6.73	0.4	1.34e-10	Thyroid stimulating hormone;
SARC	trans	rs629535	0.821	rs650267	chr8:70029160	C/T	cg21567404	chr3:27674614	NA	1.05	14.23	0.68	1.78e-33	Dupuytren's disease;
SARC	cis	rs7208859	0.623	rs77009951	chr17:29080650	T/C	cg13385521	chr17:29058706	SUZ12P	0.88	7.75	0.45	2.9e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs3771570	0.901	rs3815262	chr2:242352582	A/T	cg21155796	chr2:242212141	HDLBP	0.56	5.45	0.34	1.28e-7	Prostate cancer;
SARC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.54	7.0	0.42	2.64e-11	Lymphocyte counts;
SARC	cis	rs2075371	1.000	rs2244694	chr7:133987093	C/T	cg11752832	chr7:134001865	SLC35B4	0.56	7.26	0.43	5.74e-12	Mean platelet volume;
SARC	cis	rs16854884	0.632	rs35716467	chr3:143684993	C/A	cg06585982	chr3:143692056	C3orf58	0.67	9.02	0.51	7.28e-17	Economic and political preferences (feminism/equality);
SARC	cis	rs7772486	0.686	rs9403739	chr6:146015357	A/G	cg05347473	chr6:146136440	FBXO30	-0.52	-7.21	-0.43	7.81e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs67366981	1.000	rs8006732	chr14:77713070	T/G	cg06779847	chr14:77687015	TMEM63C	-0.44	-4.82	-0.3	2.53e-6	Obsessive-compulsive symptoms;
SARC	cis	rs807669	0.807	rs807431	chr22:19242361	G/A	cg02655711	chr22:19163373	SLC25A1	0.4	5.58	0.34	6.82e-8	Metabolite levels;
SARC	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg06028808	chr11:68637592	NA	0.41	5.16	0.32	5.19e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg08677398	chr8:58056175	NA	0.43	5.05	0.31	8.92e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs644799	0.965	rs10831430	chr11:95509638	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.68	9.38	0.52	6.06e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7408868	0.908	rs757474	chr19:15273624	T/C	cg14696996	chr19:15285081	NOTCH3	1.06	8.68	0.49	6.85e-16	Pulse pressure;
SARC	cis	rs950776	0.695	rs1878399	chr15:78912003	G/C	cg22563815	chr15:78856949	CHRNA5	-0.38	-6.43	-0.39	7.17e-10	Sudden cardiac arrest;
SARC	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg19660806	chr8:588740	NA	0.53	4.84	0.3	2.41e-6	IgG glycosylation;
SARC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg07167872	chr1:205819463	PM20D1	0.75	11.75	0.61	2.35e-25	Menarche (age at onset);
SARC	trans	rs6076960	0.629	rs6054008	chr20:6212370	C/T	cg21095983	chr6:86352623	SYNCRIP	0.43	6.29	0.38	1.54e-9	Smooth-surface caries;
SARC	cis	rs2576037	0.796	rs2571018	chr18:44585344	T/A	cg15049968	chr18:44337910	ST8SIA5	0.33	5.3	0.33	2.63e-7	Personality dimensions;
SARC	cis	rs778371	1.000	rs709937	chr2:233744021	A/G	cg16596103	chr2:233749413	NGEF	-0.38	-5.64	-0.35	4.81e-8	Schizophrenia;
SARC	cis	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg25427524	chr10:38739819	LOC399744	0.48	7.37	0.43	2.91e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg20607798	chr8:58055168	NA	0.56	5.27	0.33	3.12e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6831352	0.819	rs1154401	chr4:100009738	G/C	cg12011299	chr4:100065546	ADH4	0.27	4.89	0.31	1.88e-6	Alcohol dependence;
SARC	cis	rs6578185	0.810	rs3935445	chr8:142452618	C/A	cg07762003	chr8:142452454	FLJ43860	-0.31	-5.36	-0.33	2.01e-7	Endometriosis;
SARC	cis	rs112591243	0.685	rs2839366	chr21:48026443	A/T	cg10657630	chr21:48055338	PRMT2	-0.82	-5.7	-0.35	3.59e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs79149102	0.579	rs3812943	chr15:75312715	C/G	cg09165964	chr15:75287851	SCAMP5	-1.03	-8.62	-0.49	1.05e-15	Lung cancer;
SARC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg05552183	chr6:42928497	GNMT	0.63	8.91	0.5	1.45e-16	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs910316	0.737	rs175055	chr14:75488946	T/G	cg23033748	chr14:75592666	NEK9	-0.36	-4.73	-0.3	3.85e-6	Height;
SARC	cis	rs7666738	0.830	rs2865990	chr4:99067399	C/A	cg05340658	chr4:99064831	C4orf37	0.65	8.7	0.5	6.15e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7772486	0.720	rs702320	chr6:146006654	G/A	cg23711669	chr6:146136114	FBXO30	-0.87	-14.73	-0.69	3.63e-35	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg07636037	chr3:49044803	WDR6	1.0	17.51	0.75	2.22e-44	Parkinson's disease;
SARC	cis	rs9815354	0.812	rs55682201	chr3:41848497	A/G	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs796364	1.000	rs281759	chr2:200787719	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.74	6.62	0.4	2.41e-10	Schizophrenia;
SARC	cis	rs644799	0.648	rs1016031	chr11:95473365	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.58	-7.14	-0.42	1.18e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg22903471	chr2:27725779	GCKR	-0.51	-7.68	-0.45	4.26e-13	Total body bone mineral density;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg26962342	chr5:153418526	MFAP3;FAM114A2	0.53	6.74	0.4	1.22e-10	Gallstone disease;
SARC	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg22968622	chr17:43663579	NA	-1.13	-15.28	-0.71	5.37e-37	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7412746	0.611	rs72704679	chr1:150897477	C/T	cg10589385	chr1:150898437	SETDB1	0.4	5.31	0.33	2.54e-7	Melanoma;
SARC	cis	rs8044995	0.563	rs3743743	chr16:68397775	C/T	cg05110241	chr16:68378359	PRMT7	-0.69	-6.74	-0.4	1.24e-10	Schizophrenia;
SARC	cis	rs12477438	0.765	rs13406288	chr2:99589585	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-9.88	-0.54	1.92e-19	Chronic sinus infection;
SARC	cis	rs2286885	1.000	rs2286885	chr9:129246487	A/C	cg14319473	chr9:129242481	FAM125B	0.38	4.83	0.3	2.47e-6	Intraocular pressure;
SARC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg04267008	chr7:1944627	MAD1L1	0.47	5.41	0.33	1.59e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs503341	0.756	rs10897450	chr11:63593219	G/C	cg04362095	chr11:63592001	C11orf84	-0.57	-7.81	-0.46	1.91e-13	Pulse pressure;
SARC	cis	rs6866344	0.697	rs17184302	chr5:178127676	C/T	cg10224037	chr5:178157518	ZNF354A	0.99	11.95	0.62	5.67e-26	Neutrophil percentage of white cells;
SARC	cis	rs3126085	0.935	rs11204976	chr1:152273777	C/T	cg26876637	chr1:152193138	HRNR	-0.49	-5.26	-0.33	3.23e-7	Atopic dermatitis;
SARC	cis	rs9462027	0.606	rs3777752	chr6:34772212	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.92	-0.36	1.16e-8	Systemic lupus erythematosus;
SARC	cis	rs1966248	0.543	rs1414668	chr6:134108060	C/T	cg25632230	chr6:134101081	NA	0.51	6.66	0.4	2e-10	Coronary artery disease;
SARC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg03647317	chr4:187891568	NA	0.39	5.51	0.34	9.3e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg22875332	chr1:76189707	ACADM	0.5	6.98	0.42	3.07e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs1153858	1.000	rs7163720	chr15:45639374	G/A	cg03999130	chr15:45571217	NA	0.39	4.93	0.31	1.58e-6	Homoarginine levels;
SARC	trans	rs61931739	0.500	rs34418276	chr12:34535976	C/T	cg13010199	chr12:38710504	ALG10B	0.85	12.01	0.62	3.39e-26	Morning vs. evening chronotype;
SARC	cis	rs12042938	0.600	rs1094655	chr1:231774362	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.53	7.31	0.43	4.31e-12	Neuranatomic and neurocognitive phenotypes;
SARC	cis	rs7223966	1.000	rs8067064	chr17:61825984	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.52	-5.31	-0.33	2.51e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs7824557	0.564	rs2572395	chr8:11235360	A/C	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.7	-0.5	6e-16	Retinal vascular caliber;
SARC	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg25894440	chr7:65020034	NA	-0.73	-5.48	-0.34	1.09e-7	Diabetic kidney disease;
SARC	trans	rs61931739	0.500	rs11053185	chr12:34428857	A/G	cg13010199	chr12:38710504	ALG10B	0.75	10.68	0.57	6.18e-22	Morning vs. evening chronotype;
SARC	cis	rs9300255	0.510	rs1790133	chr12:123698518	T/G	cg05973401	chr12:123451056	ABCB9	0.52	5.94	0.36	1.01e-8	Neutrophil percentage of white cells;
SARC	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg27266027	chr21:40555129	PSMG1	-0.5	-5.45	-0.34	1.25e-7	Cognitive function;
SARC	cis	rs11651753	0.561	rs11654010	chr17:45960865	C/T	cg02219949	chr17:45927392	SP6	-0.35	-4.83	-0.3	2.49e-6	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	cis	rs561341	1.000	rs7210970	chr17:30262169	G/A	cg13647721	chr17:30228624	UTP6	0.57	4.96	0.31	1.36e-6	Hip circumference adjusted for BMI;
SARC	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.56	5.11	0.32	6.63e-7	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs6570726	0.935	rs416987	chr6:145847005	G/C	cg05347473	chr6:146136440	FBXO30	0.49	6.55	0.39	3.56e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg22875332	chr1:76189707	ACADM	0.48	6.56	0.39	3.45e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs4970988	0.527	rs12067556	chr1:150614535	G/A	cg13175981	chr1:150552382	MCL1	-0.53	-6.26	-0.38	1.84e-9	Urate levels;
SARC	cis	rs1408799	0.720	rs13284445	chr9:12724267	C/T	cg05274944	chr9:12693694	TYRP1	0.35	5.2	0.32	4.28e-7	Eye color;Blue vs. green eyes;
SARC	cis	rs11190604	1.000	rs3793706	chr10:102269085	A/C	cg07080220	chr10:102295463	HIF1AN	-0.79	-9.63	-0.53	1.07e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs17376456	0.825	rs10072232	chr5:93398890	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.86	0.36	1.59e-8	Diabetic retinopathy;
SARC	cis	rs2425143	0.822	rs6060677	chr20:34499368	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.61	-4.8	-0.3	2.88e-6	Blood protein levels;
SARC	cis	rs3008870	0.755	rs12562761	chr1:67396739	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.6	7.74	0.45	2.92e-13	Lymphocyte percentage of white cells;
SARC	cis	rs6121246	0.529	rs6060210	chr20:30187681	C/T	cg21427119	chr20:30132790	HM13	-0.48	-5.29	-0.33	2.84e-7	Mean corpuscular hemoglobin;
SARC	cis	rs600231	0.706	rs11227221	chr11:65319265	T/C	cg17120908	chr11:65337727	SSSCA1	0.49	6.09	0.37	4.68e-9	Bone mineral density;
SARC	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg00149659	chr3:10157352	C3orf10	0.72	6.74	0.4	1.22e-10	Alzheimer's disease;
SARC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg03647317	chr4:187891568	NA	-0.36	-5.04	-0.31	9.55e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg22920501	chr2:26401640	FAM59B	0.55	6.74	0.4	1.2e-10	Gut microbiome composition (summer);
SARC	cis	rs10927875	0.526	rs35340817	chr1:16178917	T/C	cg21385522	chr1:16154831	NA	-0.86	-9.67	-0.54	8.28e-19	Dilated cardiomyopathy;
SARC	cis	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg14541582	chr5:601475	NA	-0.38	-4.91	-0.31	1.75e-6	Obesity-related traits;
SARC	cis	rs981844	1.000	rs2405431	chr4:154656396	A/G	cg14289246	chr4:154710475	SFRP2	0.58	6.66	0.4	1.92e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs11718455	0.960	rs1852036	chr3:44003862	C/T	cg21419209	chr3:44054225	NA	-0.41	-5.02	-0.31	1.02e-6	Coronary artery disease;
SARC	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg23205692	chr1:25664452	TMEM50A	0.42	5.18	0.32	4.88e-7	Erythrocyte sedimentation rate;
SARC	cis	rs1707322	0.721	rs10890341	chr1:46147240	C/A	cg03146154	chr1:46216737	IPP	0.52	6.23	0.38	2.11e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs631288	0.793	rs6681716	chr1:146707824	A/C	cg25205988	chr1:146714368	CHD1L	0.85	6.15	0.37	3.42e-9	PR interval in Tripanosoma cruzi seropositivity;
SARC	trans	rs9329221	0.682	rs6982308	chr8:10193772	C/G	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.76	-0.4	1.11e-10	Neuroticism;
SARC	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg16325326	chr1:53192061	ZYG11B	0.85	13.31	0.66	1.94e-30	Monocyte count;
SARC	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.23e-9	Life satisfaction;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg23981150	chr1:161111090	NA	0.51	6.34	0.38	1.18e-9	Breast cancer;
SARC	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg08677398	chr8:58056175	NA	0.44	5.25	0.33	3.38e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1707322	1.000	rs9793167	chr1:46446800	G/A	cg06784218	chr1:46089804	CCDC17	0.34	5.95	0.36	9.76e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4423214	0.959	rs11606611	chr11:71164046	C/G	cg24826892	chr11:71159390	DHCR7	0.44	5.3	0.33	2.74e-7	Vitamin D levels;
SARC	cis	rs2204008	0.683	rs12370288	chr12:38127740	G/A	cg13010199	chr12:38710504	ALG10B	0.77	10.48	0.57	2.58e-21	Bladder cancer;
SARC	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.48	0.44	1.5e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7208859	0.673	rs9907197	chr17:29018263	C/T	cg13385521	chr17:29058706	SUZ12P	0.9	7.79	0.45	2.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs2425143	1.000	rs4504072	chr20:34448773	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-5.96	-0.36	9.2e-9	Blood protein levels;
SARC	cis	rs4148883	0.689	rs1154415	chr4:99999033	T/C	cg13256891	chr4:100009986	ADH5	0.62	8.38	0.48	5e-15	Alcohol dependence;
SARC	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg07701084	chr6:150067640	NUP43	-0.39	-5.09	-0.32	7.28e-7	Lung cancer;
SARC	cis	rs9457247	0.730	rs9459841	chr6:167431949	G/A	cg07741184	chr6:167504864	NA	0.34	6.78	0.41	9.85e-11	Crohn's disease;
SARC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.8	10.38	0.56	5.49e-21	Prudent dietary pattern;
SARC	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg20102877	chr2:27665638	KRTCAP3	-0.37	-5.08	-0.32	7.64e-7	Total body bone mineral density;
SARC	cis	rs10085978	0.604	rs11167128	chr8:143225883	A/G	cg10913563	chr8:143808814	C8orf55	-0.37	-4.86	-0.3	2.11e-6	Mosquito bite size;
SARC	cis	rs2070677	0.935	rs4582924	chr10:135409033	T/G	cg20169779	chr10:135381914	SYCE1	-0.54	-6.6	-0.4	2.79e-10	Gout;
SARC	cis	rs1348850	0.574	rs4893834	chr2:178442288	C/T	cg23306229	chr2:178417860	TTC30B	-0.73	-7.12	-0.42	1.3e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1728785	1.000	rs4783656	chr16:68580722	C/T	cg02972257	chr16:68554789	NA	-0.43	-5.01	-0.31	1.08e-6	Ulcerative colitis;
SARC	cis	rs7617480	0.587	rs9311431	chr3:48848787	T/A	cg07636037	chr3:49044803	WDR6	0.88	8.96	0.51	1.1e-16	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs7336332	0.598	rs7669	chr13:28009851	C/T	cg01674679	chr13:27998804	GTF3A	-0.55	-4.73	-0.3	3.89e-6	Weight;
SARC	cis	rs870825	0.929	rs72689260	chr4:185590656	G/T	cg04058563	chr4:185651563	MLF1IP	0.79	8.8	0.5	3.22e-16	Blood protein levels;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg09610133	chr19:42772831	NA	-0.49	-6.42	-0.39	7.53e-10	Neuroticism;
SARC	cis	rs9341808	0.644	rs62408577	chr6:80942024	T/A	cg08355045	chr6:80787529	NA	-0.35	-5.72	-0.35	3.27e-8	Sitting height ratio;
SARC	cis	rs9916302	0.861	rs593480	chr17:37453780	A/C	cg15445000	chr17:37608096	MED1	-0.45	-5.39	-0.33	1.71e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs10916814	0.632	rs6691041	chr1:20898650	A/G	cg24502330	chr1:20914028	CDA	-0.3	-5.27	-0.33	3.16e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg18876405	chr7:65276391	NA	0.41	4.79	0.3	2.98e-6	Aortic root size;
SARC	cis	rs6484504	0.532	rs11031342	chr11:31309818	G/A	cg02090638	chr11:31391270	DNAJC24;DCDC1	-0.42	-5.31	-0.33	2.51e-7	Red blood cell count;
SARC	trans	rs1814175	0.817	rs7946556	chr11:49944874	G/A	cg03929089	chr4:120376271	NA	-0.89	-14.41	-0.69	4.28e-34	Height;
SARC	cis	rs4919087	0.683	rs1687372	chr10:98978185	A/T	cg25902810	chr10:99078978	FRAT1	-0.56	-6.29	-0.38	1.6e-9	Monocyte count;
SARC	cis	rs1185460	0.967	rs1784460	chr11:118938371	A/T	cg01677386	chr11:118938358	VPS11	0.42	5.21	0.32	4.2e-7	Coronary artery disease;
SARC	cis	rs11098499	0.863	rs1480939	chr4:120456927	T/C	cg24375607	chr4:120327624	NA	0.42	4.9	0.31	1.76e-6	Corneal astigmatism;
SARC	cis	rs11252926	0.800	rs2209625	chr10:747115	A/C	cg08603382	chr10:743973	NA	-0.51	-6.22	-0.38	2.29e-9	Psychosis in Alzheimer's disease;
SARC	cis	rs7829975	0.840	rs555617	chr8:8592845	C/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-5.16	-0.32	5.17e-7	Mood instability;
SARC	cis	rs763121	0.853	rs5757193	chr22:39034867	A/G	cg21395723	chr22:39101663	GTPBP1	-0.57	-6.25	-0.38	1.94e-9	Menopause (age at onset);
SARC	trans	rs9388451	0.626	rs1739384	chr6:126099246	C/A	cg05039488	chr6:79577232	IRAK1BP1	-0.59	-7.62	-0.45	6.2800000000000005e-13	Brugada syndrome;
SARC	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg22618164	chr12:122356400	WDR66	0.4	6.01	0.37	6.93e-9	Mean corpuscular volume;
SARC	cis	rs12311304	1.000	rs12580168	chr12:15387773	T/C	cg08258403	chr12:15378311	NA	0.48	7.24	0.43	6.45e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.44	-5.48	-0.34	1.11e-7	Personality dimensions;
SARC	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg07234876	chr8:600039	NA	1.02	7.49	0.44	1.43e-12	IgG glycosylation;
SARC	cis	rs992157	0.560	rs12992937	chr2:219087072	A/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.59	-7.9	-0.46	1.12e-13	Colorectal cancer;
SARC	cis	rs3888647	0.561	rs4758617	chr11:2995185	T/A	cg20651018	chr11:3035856	CARS	-0.45	-7.13	-0.42	1.27e-11	Type 2 diabetes;
SARC	cis	rs35955747	0.777	rs5997895	chr22:31566173	T/G	cg02404636	chr22:31891804	SFI1	-0.4	-4.99	-0.31	1.2e-6	Neutrophil count;Sum basophil neutrophil counts;
SARC	cis	rs4268898	0.679	rs2551181	chr2:24437548	C/T	cg26838691	chr2:24397539	C2orf84	0.44	5.26	0.33	3.32e-7	Asthma;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg13538257	chr6:153324006	MTRF1L	0.52	6.7	0.4	1.53e-10	Gallstone disease;
SARC	cis	rs17376456	0.877	rs10044066	chr5:93437580	T/C	cg25358565	chr5:93447407	FAM172A	1.31	15.17	0.7	1.33e-36	Diabetic retinopathy;
SARC	cis	rs921968	0.565	rs4674329	chr2:219595507	A/G	cg02176678	chr2:219576539	TTLL4	-0.34	-5.14	-0.32	5.73e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs7395581	0.918	rs3781622	chr11:47348702	T/C	cg25783544	chr11:47291846	MADD	0.49	5.49	0.34	1.06e-7	HDL cholesterol;
SARC	cis	rs7927771	0.697	rs11039307	chr11:47611152	C/T	cg05585544	chr11:47624801	NA	-0.33	-4.77	-0.3	3.29e-6	Subjective well-being;
SARC	cis	rs3857067	0.806	rs7676797	chr4:95099194	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.32	-4.83	-0.3	2.42e-6	QT interval;
SARC	cis	rs911263	0.603	rs7150988	chr14:68793704	C/T	cg18825221	chr14:68749962	RAD51L1	0.41	7.38	0.44	2.8e-12	Primary biliary cholangitis;
SARC	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg03517284	chr6:25882590	NA	-0.44	-5.82	-0.36	1.89e-8	Intelligence (multi-trait analysis);
SARC	cis	rs12681366	0.663	rs2919660	chr8:95470697	C/A	cg13257157	chr8:95487014	RAD54B	0.39	4.92	0.31	1.65e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs7191439	0.728	rs4238687	chr16:88788903	T/G	cg27087555	chr16:88793112	FAM38A	-1.15	-8.85	-0.5	2.17e-16	Plateletcrit;
SARC	cis	rs9473924	0.542	rs35546156	chr6:50829785	C/T	cg14470998	chr6:50812995	TFAP2B	0.72	6.47	0.39	5.64e-10	Body mass index;
SARC	cis	rs910316	0.673	rs2012627	chr14:75443103	C/T	cg08847533	chr14:75593920	NEK9	0.89	13.55	0.66	3.15e-31	Height;
SARC	cis	rs11249608	0.548	rs2047354	chr5:178455247	T/C	cg21905437	chr5:178450457	ZNF879	0.59	8.22	0.47	1.45e-14	Pubertal anthropometrics;
SARC	cis	rs2153535	0.580	rs9392223	chr6:8468650	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	6.51	0.39	4.49e-10	Motion sickness;
SARC	cis	rs2624839	0.602	rs2526398	chr3:50187596	G/C	cg14019146	chr3:50243930	SLC38A3	-0.33	-5.3	-0.33	2.73e-7	Intelligence (multi-trait analysis);
SARC	trans	rs1814175	0.817	rs10769617	chr11:49810421	G/A	cg15704280	chr7:45808275	SEPT13	-0.97	-17.96	-0.76	7.46e-46	Height;
SARC	cis	rs10490913	0.806	rs7923757	chr10:120163406	G/T	cg23160142	chr10:120154512	NA	0.35	5.14	0.32	5.87e-7	Cancer;
SARC	cis	rs2304069	0.954	rs2276983	chr5:149424966	C/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.58	5.68	0.35	4.01e-8	HIV-1 control;
SARC	cis	rs9815354	1.000	rs13087719	chr3:41951576	C/T	cg03022575	chr3:42003672	ULK4	-0.55	-5.21	-0.32	4.11e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs3087591	1.000	rs4541129	chr17:29442878	T/C	cg24425628	chr17:29625626	OMG;NF1	0.56	7.13	0.42	1.25e-11	Hip circumference;
SARC	cis	rs2153535	0.580	rs9406164	chr6:8470048	C/T	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs3858526	0.874	rs10838879	chr11:5950169	C/T	cg05234568	chr11:5960015	NA	-0.42	-4.99	-0.31	1.2e-6	DNA methylation (variation);
SARC	cis	rs780094	0.606	rs6729709	chr2:27583156	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.42	-6.89	-0.41	5.25e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs3820928	0.874	rs10177995	chr2:227781600	T/C	cg11843606	chr2:227700838	RHBDD1	-0.56	-7.15	-0.42	1.13e-11	Pulmonary function;
SARC	cis	rs7587476	0.784	rs36086595	chr2:215680293	A/G	cg04530015	chr2:215796436	ABCA12	-0.41	-6.76	-0.4	1.11e-10	Neuroblastoma;
SARC	cis	rs9640161	0.830	rs12703061	chr7:150062545	T/C	cg21361702	chr7:150065534	REPIN1	0.59	7.02	0.42	2.41e-11	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg24110177	chr3:50126178	RBM5	0.61	8.14	0.47	2.45e-14	Body mass index;
SARC	cis	rs7633770	0.841	rs6774048	chr3:46702202	C/G	cg11219411	chr3:46661640	NA	0.47	7.94	0.46	8.66e-14	Coronary artery disease;
SARC	cis	rs9788682	0.747	rs28480606	chr15:78762313	A/G	cg24631222	chr15:78858424	CHRNA5	0.74	9.03	0.51	6.53e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs453301	0.605	rs7843024	chr8:8799976	G/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-6.94	-0.41	3.77e-11	Joint mobility (Beighton score);
SARC	cis	rs9747201	1.000	rs4347682	chr17:80175591	A/G	cg09264619	chr17:80180166	NA	-0.53	-5.88	-0.36	1.39e-8	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs611744	0.870	rs635941	chr8:109235457	G/A	cg21045802	chr8:109455806	TTC35	0.5	6.09	0.37	4.56e-9	Dupuytren's disease;
SARC	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg06634786	chr22:41940651	POLR3H	-0.55	-6.64	-0.4	2.16e-10	Vitiligo;
SARC	cis	rs208520	0.661	rs7766144	chr6:66827795	C/T	cg07460842	chr6:66804631	NA	-1.06	-14.03	-0.68	8.04e-33	Exhaled nitric oxide output;
SARC	cis	rs72945132	0.825	rs2298411	chr11:70206046	G/A	cg05964544	chr11:70165517	PPFIA1	-0.57	-5.55	-0.34	7.57e-8	Coronary artery disease;
SARC	cis	rs73206853	0.764	rs7311376	chr12:110605559	C/T	cg10860002	chr12:110842031	ANAPC7	0.66	5.39	0.33	1.72e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg04166393	chr7:2884313	GNA12	-0.64	-7.72	-0.45	3.45e-13	Height;
SARC	cis	rs12545109	0.800	rs1553969	chr8:57420187	A/G	cg21220214	chr8:57350948	NA	-0.4	-4.84	-0.3	2.37e-6	Obesity-related traits;
SARC	cis	rs6860806	0.507	rs272854	chr5:131688017	C/T	cg12564285	chr5:131593104	PDLIM4	0.44	5.94	0.36	1.04e-8	Breast cancer;
SARC	cis	rs2239815	0.515	rs5752810	chr22:29225523	G/A	cg02153584	chr22:29168773	CCDC117	0.66	7.23	0.43	6.98e-12	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
SARC	cis	rs9457247	0.508	rs6902119	chr6:167505791	T/C	cg23791538	chr6:167370224	RNASET2	-0.4	-4.97	-0.31	1.32e-6	Crohn's disease;
SARC	cis	rs6867032	1.000	rs4398675	chr5:2015816	G/A	cg26168224	chr5:2018326	NA	0.92	14.86	0.7	1.4e-35	Gut microbiome composition (winter);
SARC	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg17691542	chr6:26056736	HIST1H1C	0.54	6.84	0.41	6.72e-11	Height;
SARC	cis	rs2153535	0.580	rs6941670	chr6:8446346	G/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.6	0.49	1.19e-15	Motion sickness;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg05382772	chr11:65686513	DRAP1;C11orf68	-0.8	-6.57	-0.4	3.3e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs10916814	0.588	rs10799640	chr1:20896411	T/C	cg24502330	chr1:20914028	CDA	-0.29	-5.12	-0.32	6.44e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs1707322	0.964	rs785496	chr1:46588006	T/C	cg06784218	chr1:46089804	CCDC17	-0.35	-6.01	-0.37	7.21e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs62064224	0.738	rs2344972	chr17:30633671	G/C	cg18200150	chr17:30822561	MYO1D	0.36	5.43	0.33	1.45e-7	Schizophrenia;
SARC	cis	rs9457247	0.663	rs6456143	chr6:167415440	C/A	cg23791538	chr6:167370224	RNASET2	-0.51	-6.92	-0.41	4.33e-11	Crohn's disease;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg08739755	chr2:172815385	HAT1	0.53	7.57	0.44	8.46e-13	Thyroid stimulating hormone;
SARC	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg03999130	chr15:45571217	NA	0.39	5.01	0.31	1.09e-6	Homoarginine levels;
SARC	cis	rs3780378	1.000	rs1328918	chr9:5107394	A/G	cg02405213	chr9:5042618	JAK2	-0.42	-5.09	-0.32	7.23e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
SARC	cis	rs4481887	0.927	rs6587444	chr1:248438452	C/T	cg00666640	chr1:248458726	OR2T12	-0.34	-5.0	-0.31	1.14e-6	Common traits (Other);
SARC	cis	rs1865760	0.827	rs9461227	chr6:25960815	C/T	cg18357526	chr6:26021779	HIST1H4A	0.39	4.8	0.3	2.86e-6	Height;
SARC	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.51	6.49	0.39	5.13e-10	Personality dimensions;
SARC	cis	rs2576037	0.796	rs2576041	chr18:44580919	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.5	6.61	0.4	2.67e-10	Personality dimensions;
SARC	cis	rs7084402	0.967	rs1649039	chr10:60330041	C/T	cg07615347	chr10:60278583	BICC1	0.59	8.61	0.49	1.1e-15	Refractive error;
SARC	cis	rs2439831	0.867	rs2245176	chr15:43750762	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.05	10.98	0.58	7.25e-23	Lung cancer in ever smokers;
SARC	cis	rs2153535	0.601	rs9406160	chr6:8464907	A/C	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	cis	rs9291683	0.546	rs10939672	chr4:10052136	A/G	cg00071950	chr4:10020882	SLC2A9	0.33	5.03	0.31	9.62e-7	Bone mineral density;
SARC	cis	rs12142240	0.698	rs17361936	chr1:46862893	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-5.56	-0.34	7.46e-8	Menopause (age at onset);
SARC	trans	rs13325613	0.667	rs13060713	chr3:46272709	A/C	cg12387106	chr12:133178249	NA	0.87	6.47	0.39	5.82e-10	Monocyte count;
SARC	cis	rs7953249	0.656	rs1732391	chr12:121392341	C/T	cg02403541	chr12:121454288	C12orf43	-0.73	-9.66	-0.53	8.66e-19	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg18252515	chr7:66147081	NA	-0.5	-5.36	-0.33	2.02e-7	Aortic root size;
SARC	cis	rs12142240	0.730	rs56030283	chr1:46823093	C/G	cg14993813	chr1:46806288	NSUN4	-0.51	-5.34	-0.33	2.19e-7	Menopause (age at onset);
SARC	cis	rs473651	0.935	rs10170056	chr2:239339291	G/C	cg00800569	chr2:239229395	TRAF3IP1	0.64	6.84	0.41	6.89e-11	Multiple system atrophy;
SARC	cis	rs6963495	0.818	rs1721498	chr7:105178819	A/C	cg19920283	chr7:105172520	RINT1	-0.74	-7.68	-0.45	4.43e-13	Bipolar disorder (body mass index interaction);
SARC	trans	rs561341	0.689	rs578635	chr17:30289897	A/C	cg20587970	chr11:113659929	NA	-0.74	-8.1	-0.47	2.98e-14	Hip circumference adjusted for BMI;
SARC	trans	rs11098499	0.818	rs7688802	chr4:120451668	G/A	cg25214090	chr10:38739885	LOC399744	0.57	7.35	0.43	3.31e-12	Corneal astigmatism;
SARC	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg13699009	chr12:122356056	WDR66	0.6	9.17	0.52	2.53e-17	Mean corpuscular volume;
SARC	cis	rs9303401	0.659	rs17822807	chr17:56687190	A/C	cg25039879	chr17:56429692	SUPT4H1	0.71	6.69	0.4	1.62e-10	Cognitive test performance;
SARC	cis	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg08045932	chr20:61659980	NA	0.49	6.67	0.4	1.84e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs9398803	0.723	rs853981	chr6:127045460	C/T	cg20229609	chr6:126660872	C6orf173	-0.34	-4.85	-0.3	2.29e-6	Male-pattern baldness;
SARC	cis	rs1468333	0.964	rs2350306	chr5:137512178	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	-0.78	-11.03	-0.59	5.06e-23	Resting heart rate;
SARC	cis	rs7364180	0.582	rs139568	chr22:42210985	C/T	cg03806693	chr22:41940476	POLR3H	0.6	8.35	0.48	6.05e-15	Alzheimer's disease biomarkers;
SARC	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg11987759	chr7:65425863	GUSB	-0.48	-6.54	-0.39	3.9e-10	Aortic root size;
SARC	cis	rs10752881	0.935	rs10911197	chr1:182995399	T/C	cg13390022	chr1:182993471	LAMC1	0.33	4.97	0.31	1.29e-6	Colorectal cancer;
SARC	cis	rs9905704	0.647	rs10221208	chr17:57047885	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.4	-4.96	-0.31	1.34e-6	Testicular germ cell tumor;
SARC	cis	rs17533156	0.525	rs77932036	chr17:75207586	T/G	cg11416367	chr17:75137675	SEC14L1	0.82	8.97	0.51	1.02e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg06212747	chr3:49208901	KLHDC8B	0.51	6.45	0.39	6.22e-10	Resting heart rate;
SARC	cis	rs3818285	0.556	rs941864	chr10:111656948	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.53	-7.4	-0.44	2.5e-12	Superior crus of antihelix expression;
SARC	cis	rs599083	0.530	rs583545	chr11:68178635	T/C	cg01657329	chr11:68192670	LRP5	0.47	6.36	0.38	1.07e-9	Bone mineral density (spine);
SARC	cis	rs9398803	0.723	rs853982	chr6:127046121	C/T	cg19875578	chr6:126661172	C6orf173	-0.61	-8.33	-0.48	6.93e-15	Male-pattern baldness;
SARC	cis	rs7208859	0.623	rs55811708	chr17:29104731	G/T	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs2908197	0.806	rs2961047	chr7:75935056	A/G	cg22830091	chr7:75961684	YWHAG	-0.33	-4.99	-0.31	1.2e-6	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs34779708	0.931	rs10508815	chr10:35332621	A/C	cg03585969	chr10:35415529	CREM	0.38	4.81	0.3	2.67e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg07701084	chr6:150067640	NUP43	0.42	5.54	0.34	8.02e-8	Lung cancer;
SARC	cis	rs7937682	0.889	rs484013	chr11:111495779	G/A	cg22437258	chr11:111473054	SIK2	0.74	10.3	0.56	9.79e-21	Primary sclerosing cholangitis;
SARC	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg17971929	chr21:40555470	PSMG1	0.98	13.58	0.66	2.56e-31	Cognitive function;
SARC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg26338869	chr17:61819248	STRADA	0.81	10.78	0.58	3.09e-22	Prudent dietary pattern;
SARC	cis	rs10463554	0.963	rs62364874	chr5:102392179	T/C	cg23492399	chr5:102201601	PAM	-0.52	-5.73	-0.35	3.13e-8	Parkinson's disease;
SARC	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg19223190	chr17:80058835	NA	0.45	6.35	0.38	1.13e-9	Life satisfaction;
SARC	cis	rs9303401	0.614	rs34058624	chr17:57118121	T/C	cg25039879	chr17:56429692	SUPT4H1	0.56	5.0	0.31	1.11e-6	Cognitive test performance;
SARC	cis	rs10911628	0.892	rs10489697	chr1:184667731	C/T	cg12222949	chr1:184005360	GLT25D2	-0.45	-4.81	-0.3	2.72e-6	Systemic lupus erythematosus;
SARC	cis	rs861020	0.606	rs629224	chr1:210005071	C/T	cg05527609	chr1:210001259	C1orf107	0.77	9.81	0.54	3.1400000000000002e-19	Orofacial clefts;
SARC	cis	rs7520050	0.931	rs6686134	chr1:46378268	A/G	cg06784218	chr1:46089804	CCDC17	-0.26	-4.79	-0.3	2.97e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg04166393	chr7:2884313	GNA12	0.65	7.32	0.43	4.08e-12	Height;
SARC	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg11301795	chr4:187892539	NA	-0.7	-10.69	-0.57	5.92e-22	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6831352	0.819	rs1230158	chr4:99990186	T/C	cg12011299	chr4:100065546	ADH4	0.3	5.42	0.33	1.5e-7	Alcohol dependence;
SARC	cis	rs2011503	1.000	rs17684164	chr19:19626769	C/T	cg03709012	chr19:19516395	GATAD2A	0.6	5.29	0.33	2.8e-7	Bipolar disorder;
SARC	cis	rs2204008	0.840	rs3892363	chr12:38479487	G/A	cg13010199	chr12:38710504	ALG10B	0.75	10.21	0.56	1.79e-20	Bladder cancer;
SARC	cis	rs6142102	0.961	rs6120487	chr20:32622608	A/G	cg24642439	chr20:33292090	TP53INP2	0.45	4.9	0.31	1.8e-6	Skin pigmentation;
SARC	cis	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg15556689	chr8:8085844	FLJ10661	0.43	5.31	0.33	2.51e-7	Mood instability;
SARC	cis	rs7412746	0.611	rs2271076	chr1:150916657	C/T	cg15448220	chr1:150897856	SETDB1	0.52	6.89	0.41	5.25e-11	Melanoma;
SARC	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg16680214	chr1:154839983	KCNN3	-0.32	-4.78	-0.3	3.08e-6	Prostate cancer;
SARC	cis	rs2732480	0.500	rs2450989	chr12:48653408	A/G	cg24011408	chr12:48396354	COL2A1	-0.46	-5.35	-0.33	2.1e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs67460515	0.500	rs9822435	chr3:160748068	A/T	cg17135325	chr3:160939158	NMD3	0.5	5.91	0.36	1.23e-8	Parkinson's disease;
SARC	cis	rs73206853	0.609	rs7306167	chr12:110892449	A/G	cg10860002	chr12:110842031	ANAPC7	0.64	5.11	0.32	6.75e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg04317338	chr11:64019027	PLCB3	0.57	6.76	0.41	1.07e-10	Platelet count;
SARC	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg24642844	chr7:1081250	C7orf50	-0.49	-5.17	-0.32	5e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs28655083	1.000	rs1875582	chr16:77063147	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	0.41	5.25	0.33	3.4e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs992157	0.700	rs10165153	chr2:219159629	T/C	cg00012203	chr2:219082015	ARPC2	0.65	9.23	0.52	1.74e-17	Colorectal cancer;
SARC	cis	rs240764	0.764	rs12208241	chr6:100933472	T/C	cg09795085	chr6:101329169	ASCC3	-0.41	-5.19	-0.32	4.68e-7	Neuroticism;
SARC	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs4948523	0.530	rs67362351	chr10:60306548	C/A	cg07615347	chr10:60278583	BICC1	-0.38	-5.08	-0.32	7.9e-7	Myopia;
SARC	cis	rs5753618	0.539	rs5997933	chr22:31672752	A/C	cg00478049	chr22:31556069	RNF185	0.44	4.78	0.3	3.16e-6	Colorectal cancer;
SARC	cis	rs910316	1.000	rs2268617	chr14:75608728	G/A	cg08847533	chr14:75593920	NEK9	0.93	15.39	0.71	2.33e-37	Height;
SARC	cis	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.63	-0.45	5.88e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs6545883	0.895	rs2256617	chr2:61679924	A/G	cg15711740	chr2:61764176	XPO1	-0.41	-4.89	-0.3	1.92e-6	Tuberculosis;
SARC	cis	rs7824557	0.545	rs34482136	chr8:11227885	C/T	cg21775007	chr8:11205619	TDH	-0.64	-8.52	-0.49	1.96e-15	Retinal vascular caliber;
SARC	cis	rs4805272	0.512	rs4805278	chr19:29336664	C/T	cg12756686	chr19:29218302	NA	0.51	5.53	0.34	8.45e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg11644478	chr21:40555479	PSMG1	1.02	14.53	0.69	1.73e-34	Cognitive function;
SARC	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.83	8.3	0.48	8.42e-15	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs4820539	1.000	rs5751589	chr22:23475762	A/G	cg14186256	chr22:23484241	RTDR1	-0.87	-13.61	-0.67	2.03e-31	Bone mineral density;
SARC	cis	rs9309473	0.607	rs6720094	chr2:73588076	A/G	cg20560298	chr2:73613845	ALMS1	-0.55	-7.13	-0.42	1.25e-11	Metabolite levels;
SARC	cis	rs9290065	0.519	rs6441345	chr3:160696867	C/T	cg04691961	chr3:161091175	C3orf57	-0.48	-6.26	-0.38	1.81e-9	Kawasaki disease;
SARC	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg02725872	chr8:58115012	NA	-0.37	-6.55	-0.39	3.71e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg12463550	chr7:65579703	CRCP	0.51	5.44	0.34	1.32e-7	Aortic root size;
SARC	trans	rs3942852	0.806	rs11039515	chr11:48119474	A/G	cg15704280	chr7:45808275	SEPT13	0.58	6.77	0.41	1.02e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.62	7.44	0.44	1.87e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1476670	0.710	rs751442	chr1:44509551	A/C	cg09470012	chr1:44509516	NA	0.44	5.64	0.35	5.02e-8	Eotaxin levels;
SARC	cis	rs7829975	0.510	rs2979160	chr8:8307666	A/G	cg08975724	chr8:8085496	FLJ10661	0.62	8.03	0.47	4.79e-14	Mood instability;
SARC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg26338869	chr17:61819248	STRADA	0.76	9.97	0.55	9.85e-20	Prudent dietary pattern;
SARC	cis	rs17253792	0.822	rs74720318	chr14:56099828	G/T	cg01858014	chr14:56050164	KTN1	-0.66	-4.94	-0.31	1.51e-6	Putamen volume;
SARC	cis	rs7247513	0.759	rs73002392	chr19:12768391	G/A	cg23899408	chr19:12877188	HOOK2	0.44	5.55	0.34	7.76e-8	Bipolar disorder;
SARC	trans	rs3808502	0.585	rs4549730	chr8:11239078	T/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.76	-0.45	2.68e-13	Neuroticism;
SARC	cis	rs9326248	0.727	rs4938347	chr11:117021759	T/A	cg01368799	chr11:117014884	PAFAH1B2	0.59	5.89	0.36	1.36e-8	Blood protein levels;
SARC	cis	rs896854	0.812	rs12546365	chr8:95911477	T/C	cg16049864	chr8:95962084	TP53INP1	-0.46	-7.67	-0.45	4.7e-13	Type 2 diabetes;
SARC	cis	rs8017423	0.967	rs7147809	chr14:90715025	A/G	cg20276874	chr14:90721474	PSMC1	-0.36	-4.99	-0.31	1.19e-6	Mortality in heart failure;
SARC	cis	rs7264396	0.563	rs6058302	chr20:34290037	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	5.69	0.35	3.71e-8	Total cholesterol levels;
SARC	cis	rs7512552	0.839	rs12040949	chr1:150447462	C/T	cg15654264	chr1:150340011	RPRD2	0.38	4.83	0.3	2.46e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	trans	rs3780486	0.846	rs12554995	chr9:33132044	A/G	cg04842962	chr6:43655489	MRPS18A	1.1	20.63	0.8	1.68e-54	IgG glycosylation;
SARC	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg19748678	chr4:122722346	EXOSC9	0.75	9.5	0.53	2.59e-18	Type 2 diabetes;
SARC	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg24549020	chr5:56110836	MAP3K1	0.81	8.4	0.48	4.37e-15	Initial pursuit acceleration;
SARC	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg05368731	chr17:41323189	NBR1	0.8	9.59	0.53	1.43e-18	Menopause (age at onset);
SARC	cis	rs1008375	1.000	rs2215450	chr4:17675394	T/G	cg16339924	chr4:17578868	LAP3	0.62	8.24	0.47	1.26e-14	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg04944784	chr2:26401820	FAM59B	-0.51	-6.99	-0.42	2.79e-11	Gut microbiome composition (summer);
SARC	trans	rs4699154	0.668	rs6820799	chr4:106011099	G/A	cg26219070	chr12:92433263	NA	-0.53	-6.63	-0.4	2.31e-10	Mean platelet volume;Platelet count;
SARC	trans	rs3780486	0.846	rs6476402	chr9:33148552	G/A	cg04842962	chr6:43655489	MRPS18A	1.01	17.17	0.75	3.03e-43	IgG glycosylation;
SARC	cis	rs12579753	0.789	rs1343933	chr12:82123301	A/C	cg07988820	chr12:82153109	PPFIA2	-0.61	-7.2	-0.43	8.38e-12	Resting heart rate;
SARC	cis	rs78487399	0.710	rs7572923	chr2:43685109	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-4.97	-0.31	1.31e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs7662987	0.517	rs2602866	chr4:100034997	A/G	cg13256891	chr4:100009986	ADH5	0.68	8.58	0.49	1.31e-15	Smoking initiation;
SARC	cis	rs6570726	0.905	rs406799	chr6:145821837	G/C	cg05220968	chr6:146057943	EPM2A	-0.29	-4.83	-0.3	2.44e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6693567	0.545	rs6699093	chr1:150440451	A/G	cg09579323	chr1:150459698	TARS2	-0.44	-5.63	-0.35	5.05e-8	Migraine;
SARC	cis	rs7408868	1.000	rs7250232	chr19:15277199	C/T	cg14696996	chr19:15285081	NOTCH3	1.07	8.74	0.5	4.73e-16	Pulse pressure;
SARC	cis	rs2645694	0.626	rs904050	chr4:77826089	T/G	cg06046430	chr4:77819534	ANKRD56	0.53	7.56	0.44	8.97e-13	Emphysema distribution in smoking;
SARC	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg06697600	chr4:7070879	GRPEL1	-0.36	-4.73	-0.3	3.91e-6	Monocyte percentage of white cells;
SARC	cis	rs796364	0.951	rs7586320	chr2:201068209	C/G	cg23649088	chr2:200775458	C2orf69	0.66	7.27	0.43	5.43e-12	Schizophrenia;
SARC	cis	rs10875746	0.669	rs61940962	chr12:48595477	A/C	cg26205652	chr12:48591994	NA	0.46	4.9	0.31	1.76e-6	Longevity (90 years and older);
SARC	cis	rs412050	1.000	rs239919	chr22:22313128	C/T	cg17089214	chr22:22089827	YPEL1	0.57	5.43	0.34	1.4e-7	Attention deficit hyperactivity disorder;
SARC	cis	rs74181299	0.571	rs7559813	chr2:65278023	A/G	cg20592124	chr2:65290738	CEP68	-0.4	-5.3	-0.33	2.62e-7	Pulse pressure;
SARC	cis	rs478304	0.654	rs1074155	chr11:65458197	C/T	cg27068330	chr11:65405492	SIPA1	0.44	5.13	0.32	6.16e-7	Acne (severe);
SARC	trans	rs7819412	0.505	rs17726209	chr8:11022185	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	7.22	0.43	7.4e-12	Triglycerides;
SARC	cis	rs950027	0.620	rs2486274	chr15:45666228	G/T	cg15395560	chr15:45543142	SLC28A2	-0.27	-5.28	-0.33	3e-7	Response to fenofibrate (adiponectin levels);
SARC	cis	rs9372253	0.678	rs9487392	chr6:110708626	C/T	cg19196401	chr6:110721138	DDO	0.39	5.2	0.32	4.43e-7	Platelet distribution width;
SARC	cis	rs6542838	0.609	rs13028500	chr2:99528296	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.55	-7.27	-0.43	5.52e-12	Fear of minor pain;
SARC	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg02574844	chr11:5959923	NA	-0.36	-5.09	-0.32	7.45e-7	DNA methylation (variation);
SARC	cis	rs3862260	0.509	rs3795662	chr1:120165135	G/T	cg16322792	chr1:120165303	ZNF697	0.29	6.09	0.37	4.51e-9	Systemic lupus erythematosus;
SARC	cis	rs12586317	0.620	rs10145433	chr14:35583333	G/A	cg16230307	chr14:35515116	FAM177A1	0.93	10.94	0.58	9.35e-23	Psoriasis;
SARC	cis	rs79349575	0.756	rs2643361	chr17:46977462	T/G	cg16584676	chr17:46985605	UBE2Z	0.54	6.58	0.4	3.1e-10	Type 2 diabetes;
SARC	cis	rs1153858	0.723	rs1719238	chr15:45594766	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.74	-9.47	-0.53	3.27e-18	Homoarginine levels;
SARC	cis	rs55894533	0.597	rs2645408	chr8:11746358	A/G	cg21281001	chr8:11725306	CTSB	0.46	5.6	0.34	5.92e-8	Leprosy;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg17739026	chr1:27114420	PIGV	0.55	7.47	0.44	1.6e-12	Tetralogy of Fallot;
SARC	cis	rs12541335	0.639	rs68063696	chr8:22153236	A/G	cg02463440	chr8:22132932	PIWIL2	0.46	6.42	0.39	7.37e-10	Hypertriglyceridemia;
SARC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.08	0.37	4.83e-9	Prudent dietary pattern;
SARC	cis	rs2120019	1.000	rs12901243	chr15:75374233	C/T	cg09165964	chr15:75287851	SCAMP5	-0.87	-13.08	-0.65	1.1e-29	Blood trace element (Zn levels);
SARC	cis	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg25427524	chr10:38739819	LOC399744	-0.53	-8.24	-0.47	1.27e-14	Extrinsic epigenetic age acceleration;
SARC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.97	10.66	0.57	7.33e-22	Platelet count;
SARC	cis	rs11608355	0.960	rs11066526	chr12:109854476	G/C	cg05360138	chr12:110035743	NA	0.43	4.78	0.3	3.04e-6	Neuroticism;
SARC	cis	rs7647973	0.593	rs59684465	chr3:49874246	C/T	cg03060546	chr3:49711283	APEH	-0.65	-6.91	-0.41	4.67e-11	Menarche (age at onset);
SARC	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1707322	1.000	rs4660895	chr1:46329739	C/T	cg06784218	chr1:46089804	CCDC17	0.33	5.78	0.35	2.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1559088	0.947	rs7259879	chr19:33549462	T/C	cg17764715	chr19:33622953	WDR88	0.48	6.27	0.38	1.75e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs1034435	0.755	rs5768679	chr22:48892847	T/G	cg05992904	chr22:48892994	FAM19A5	-0.48	-7.04	-0.42	2.14e-11	Late-onset Alzheimer's disease;
SARC	cis	rs10752881	1.000	rs10797802	chr1:182973158	A/T	cg13390022	chr1:182993471	LAMC1	-0.33	-4.9	-0.31	1.79e-6	Colorectal cancer;
SARC	cis	rs3733585	0.699	rs28610447	chr4:9971517	T/C	cg11266682	chr4:10021025	SLC2A9	-0.38	-6.39	-0.39	9.06e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs9309473	0.519	rs2421574	chr2:73908767	C/G	cg20560298	chr2:73613845	ALMS1	0.46	6.24	0.38	2.1e-9	Metabolite levels;
SARC	cis	rs12200560	0.505	rs211165	chr6:97068520	A/T	cg06623918	chr6:96969491	KIAA0776	0.46	5.18	0.32	4.79e-7	Coronary heart disease;
SARC	trans	rs10209086	0.736	rs1584436	chr2:138298878	A/G	cg09325174	chr14:50154983	POLE2	0.48	6.37	0.39	1.01e-9	Multiple system atrophy;
SARC	cis	rs73206853	0.764	rs55913108	chr12:110816507	T/C	cg10860002	chr12:110842031	ANAPC7	0.64	5.15	0.32	5.49e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs12586317	0.620	rs10145433	chr14:35583333	G/A	cg26967526	chr14:35346199	BAZ1A	-0.64	-6.93	-0.41	4.19e-11	Psoriasis;
SARC	cis	rs950169	0.887	rs3860265	chr15:84945185	C/T	cg17507749	chr15:85114479	UBE2QP1	0.78	9.49	0.53	2.84e-18	Schizophrenia;
SARC	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg21442419	chr1:2182373	SKI	0.48	6.24	0.38	2.03e-9	Height;
SARC	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg22683308	chr4:1340831	KIAA1530	0.49	5.61	0.35	5.61e-8	Longevity;
SARC	cis	rs36051895	0.623	rs3780382	chr9:5232299	G/A	cg02405213	chr9:5042618	JAK2	-0.42	-5.05	-0.31	8.86e-7	Pediatric autoimmune diseases;
SARC	cis	rs10089	1.000	rs1864922	chr5:127420700	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.83	9.89	0.54	1.7e-19	Ileal carcinoids;
SARC	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg05368731	chr17:41323189	NBR1	0.78	9.39	0.52	5.62e-18	Menopause (age at onset);
SARC	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg04756594	chr16:24857601	SLC5A11	-0.46	-6.23	-0.38	2.13e-9	Intelligence (multi-trait analysis);
SARC	cis	rs9430161	0.611	rs35033941	chr1:11034382	C/T	cg02454025	chr1:11042201	C1orf127	0.87	12.08	0.62	2.04e-26	Ewing sarcoma;
SARC	trans	rs34421088	0.560	rs2245357	chr8:11399484	A/T	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.59	-0.4	2.96e-10	Neuroticism;
SARC	cis	rs796364	0.806	rs35200468	chr2:201110368	G/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.79	-6.36	-0.38	1.03e-9	Schizophrenia;
SARC	cis	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg00800038	chr16:89945340	TCF25	-0.74	-5.1	-0.32	7.08e-7	Skin colour saturation;
SARC	cis	rs11122272	0.525	rs61835222	chr1:231537917	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-9.74	-0.54	4.85e-19	Hemoglobin concentration;
SARC	cis	rs11770686	0.659	rs2705838	chr7:75297037	G/C	cg07211516	chr7:75296079	HIP1	-0.35	-4.79	-0.3	2.98e-6	Essential tremor;
SARC	cis	rs10197940	0.624	rs10497082	chr2:152355258	T/C	cg19508488	chr2:152266495	RIF1	0.51	5.55	0.34	7.75e-8	Lung cancer;
SARC	cis	rs17401966	1.000	rs17401924	chr1:10384439	A/G	cg15208524	chr1:10270712	KIF1B	0.6	6.7	0.4	1.54e-10	Hepatocellular carcinoma;
SARC	cis	rs13166103	0.571	rs963615	chr5:57755936	C/T	cg10487770	chr5:57879443	RAB3C	0.47	5.17	0.32	5.04e-7	Type 2 diabetes (age of onset);
SARC	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg18876405	chr7:65276391	NA	0.45	5.06	0.31	8.47e-7	Aortic root size;
SARC	cis	rs6087990	0.965	rs2424899	chr20:31343543	A/C	cg13636640	chr20:31349939	DNMT3B	0.8	12.74	0.64	1.5e-28	Ulcerative colitis;
SARC	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg09699651	chr6:150184138	LRP11	0.5	6.43	0.39	7.1e-10	Testicular germ cell tumor;
SARC	cis	rs950776	0.518	rs3813572	chr15:78832588	T/C	cg22563815	chr15:78856949	CHRNA5	0.41	6.82	0.41	7.56e-11	Sudden cardiac arrest;
SARC	cis	rs2380220	0.574	rs7766765	chr6:95997362	G/A	cg15832292	chr6:96025679	MANEA	0.5	5.53	0.34	8.74e-8	Behavioural disinhibition (generation interaction);
SARC	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg27572855	chr1:25598939	RHD	0.54	9.03	0.51	6.46e-17	Erythrocyte sedimentation rate;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg11193896	chr8:17100916	CNOT7	0.46	6.6	0.4	2.79e-10	Thyroid stimulating hormone;
SARC	cis	rs3762637	0.882	rs56074178	chr3:122180011	C/G	cg24169773	chr3:122142474	KPNA1	-0.56	-5.73	-0.35	3.07e-8	LDL cholesterol levels;
SARC	cis	rs3741151	0.881	rs7951174	chr11:73093135	G/C	cg17517138	chr11:73019481	ARHGEF17	0.84	6.18	0.38	2.77e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs4969178	0.930	rs7208596	chr17:76396528	C/G	cg02836325	chr17:76403955	PGS1	0.33	5.01	0.31	1.07e-6	HDL cholesterol levels;
SARC	trans	rs1814175	0.817	rs1851860	chr11:49861310	A/C	cg15704280	chr7:45808275	SEPT13	-0.95	-18.05	-0.76	3.88e-46	Height;
SARC	cis	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg07777115	chr5:623756	CEP72	-0.62	-5.54	-0.34	8.01e-8	Obesity-related traits;
SARC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.71	9.71	0.54	6.34e-19	Lymphocyte counts;
SARC	cis	rs67311347	0.955	rs73078170	chr3:40483947	C/T	cg01475735	chr3:40494733	NA	-0.51	-5.47	-0.34	1.13e-7	Renal cell carcinoma;
SARC	cis	rs17376456	0.825	rs10038831	chr5:93124115	C/T	cg25358565	chr5:93447407	FAM172A	1.17	12.03	0.62	3.11e-26	Diabetic retinopathy;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg16901991	chr2:24272451	FKBP1B	0.51	6.39	0.39	8.71e-10	Breast cancer;
SARC	trans	rs877282	0.853	rs12779017	chr10:763619	T/C	cg22713356	chr15:30763199	NA	1.04	10.13	0.55	3.18e-20	Uric acid levels;
SARC	cis	rs4742903	0.967	rs6479215	chr9:106885243	A/G	cg14250997	chr9:106856677	SMC2	-0.53	-7.13	-0.42	1.22e-11	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg21644426	chr2:191273491	MFSD6	0.53	7.15	0.42	1.1e-11	Pulse pressure;
SARC	cis	rs9303280	0.936	rs907091	chr17:37921742	A/G	cg20243544	chr17:37824526	PNMT	0.52	7.06	0.42	1.92e-11	Self-reported allergy;
SARC	cis	rs1468333	1.000	rs2057831	chr5:137535133	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.82	11.81	0.61	1.54e-25	Resting heart rate;
SARC	cis	rs9815354	0.951	rs1717018	chr3:41913617	G/A	cg03022575	chr3:42003672	ULK4	0.55	5.27	0.33	3.16e-7	Pulse pressure;Diastolic blood pressure;
SARC	trans	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg17830980	chr10:43048298	ZNF37B	-0.51	-6.71	-0.4	1.5e-10	Extrinsic epigenetic age acceleration;
SARC	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg16325326	chr1:53192061	ZYG11B	-0.8	-12.46	-0.63	1.23e-27	Monocyte count;
SARC	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg11764359	chr7:65958608	NA	0.69	8.12	0.47	2.65e-14	Aortic root size;
SARC	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg16325326	chr1:53192061	ZYG11B	0.73	10.85	0.58	1.77e-22	Monocyte count;
SARC	cis	rs7552404	0.924	rs12136754	chr1:76230232	C/A	cg03433033	chr1:76189801	ACADM	0.52	7.41	0.44	2.29e-12	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6546550	0.935	rs7563062	chr2:70050725	G/A	cg02498382	chr2:70120550	SNRNP27	-0.43	-7.38	-0.44	2.81e-12	Prevalent atrial fibrillation;
SARC	trans	rs10506458	0.915	rs2013050	chr12:63394310	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.74	-6.26	-0.38	1.81e-9	Hemostatic factors and hematological phenotypes;
SARC	cis	rs7044106	0.762	rs12003646	chr9:123470621	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	9.26	0.52	1.38e-17	Hip circumference adjusted for BMI;
SARC	trans	rs931812	0.895	rs965625	chr8:101909749	T/C	cg20993868	chr7:22813445	NA	0.48	6.56	0.39	3.48e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs3768617	0.510	rs10797844	chr1:183082067	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.8e-21	Fuchs's corneal dystrophy;
SARC	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg12463550	chr7:65579703	CRCP	0.48	5.55	0.34	7.83e-8	Aortic root size;
SARC	cis	rs6545883	0.826	rs2694651	chr2:61588642	T/C	cg15711740	chr2:61764176	XPO1	0.4	4.79	0.3	3.01e-6	Tuberculosis;
SARC	cis	rs9843304	0.624	rs13061914	chr3:149202132	A/C	cg08667024	chr3:149219783	TM4SF4	-0.4	-5.91	-0.36	1.21e-8	Gallstone disease;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23731901	chr1:167906689	BRP44;DCAF6	-0.49	-6.46	-0.39	6.16e-10	Smoking initiation;
SARC	cis	rs9858542	1.000	rs9836291	chr3:49697459	G/A	cg03060546	chr3:49711283	APEH	-0.65	-7.98	-0.46	6.76e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs2276314	0.857	rs28540805	chr18:33641975	T/G	cg19628046	chr18:33552617	C18orf21	0.55	5.61	0.35	5.69e-8	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs3087591	0.919	rs2952983	chr17:29470288	G/C	cg24425628	chr17:29625626	OMG;NF1	0.57	7.14	0.42	1.18e-11	Hip circumference;
SARC	cis	rs12912251	0.591	rs4924291	chr15:39000484	A/C	cg10631289	chr15:39006617	NA	0.41	4.85	0.3	2.26e-6	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
SARC	cis	rs4273100	0.646	rs2296981	chr17:19213335	C/G	cg25447019	chr17:19030144	GRAPL	0.37	5.66	0.35	4.33e-8	Schizophrenia;
SARC	cis	rs79149102	0.579	rs73438569	chr15:75354486	T/A	cg09165964	chr15:75287851	SCAMP5	-1.08	-9.39	-0.52	5.51e-18	Lung cancer;
SARC	cis	rs546131	0.642	rs11605381	chr11:34847193	T/A	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-4.77	-0.3	3.23e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs10927875	0.662	rs848309	chr1:16308447	T/C	cg21385522	chr1:16154831	NA	0.52	6.4	0.39	8.48e-10	Dilated cardiomyopathy;
SARC	cis	rs7208859	0.673	rs9889755	chr17:29234505	A/G	cg14067834	chr17:29058358	SUZ12P	-0.52	-4.83	-0.3	2.44e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs1008375	0.966	rs6449330	chr4:17703949	C/T	cg27347728	chr4:17578864	LAP3	-0.47	-5.91	-0.36	1.18e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs473651	0.935	rs558924	chr2:239339511	A/G	cg00800569	chr2:239229395	TRAF3IP1	0.64	6.84	0.41	6.89e-11	Multiple system atrophy;
SARC	cis	rs721399	0.539	rs57180587	chr8:18269581	A/T	cg18736775	chr8:18248649	NAT2	-0.56	-5.42	-0.33	1.51e-7	Blood metabolite levels;
SARC	trans	rs66573146	0.803	rs59742225	chr4:6969942	C/T	cg07817883	chr1:32538562	TMEM39B	1.44	9.01	0.51	7.49e-17	Granulocyte percentage of myeloid white cells;
SARC	cis	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg13647721	chr17:30228624	UTP6	-0.69	-5.88	-0.36	1.4e-8	Hip circumference adjusted for BMI;
SARC	cis	rs2531992	0.563	rs2531988	chr16:4028417	T/G	cg05927578	chr16:4029543	ADCY9	0.49	6.05	0.37	5.85e-9	Waist circumference;
SARC	cis	rs73198271	0.740	rs1039912	chr8:8648229	C/T	cg08975724	chr8:8085496	FLJ10661	-0.45	-4.91	-0.31	1.75e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs748404	0.650	rs556851	chr15:43571219	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.44	5.48	0.34	1.08e-7	Lung cancer;
SARC	cis	rs672059	1.000	rs522372	chr1:183157449	C/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.51	-6.97	-0.42	3.32e-11	Hypertriglyceridemia;
SARC	cis	rs2072499	0.833	rs2251636	chr1:156202809	G/C	cg25208724	chr1:156163844	SLC25A44	0.82	10.2	0.56	1.8899999999999998e-20	Testicular germ cell tumor;
SARC	cis	rs910316	0.934	rs4903278	chr14:75535019	C/A	cg08847533	chr14:75593920	NEK9	0.89	14.54	0.69	1.56e-34	Height;
SARC	cis	rs9436747	0.748	rs1782754	chr1:65993348	G/A	cg04111102	chr1:66153794	NA	-0.4	-4.78	-0.3	3.07e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs76419734	1.000	rs11731386	chr4:106600338	A/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.76	4.89	0.31	1.87e-6	Post bronchodilator FEV1;
SARC	cis	rs2952156	0.920	rs907090	chr17:37833632	T/C	cg00129232	chr17:37814104	STARD3	-0.7	-10.11	-0.55	3.81e-20	Asthma;
SARC	cis	rs9325144	0.602	rs10785590	chr12:38694145	C/T	cg13010199	chr12:38710504	ALG10B	0.56	7.33	0.43	3.73e-12	Morning vs. evening chronotype;
SARC	cis	rs473651	0.935	rs540636	chr2:239358341	T/C	cg21699342	chr2:239360505	ASB1	0.52	7.6	0.45	7.21e-13	Multiple system atrophy;
SARC	cis	rs57506017	0.585	rs6460899	chr7:12253050	A/C	cg23422036	chr7:12250390	TMEM106B	0.5	6.8	0.41	8.53e-11	Neuroticism;
SARC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.13	0.37	3.78e-9	Prudent dietary pattern;
SARC	cis	rs9796	0.870	rs2306083	chr15:41347658	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.4	-5.47	-0.34	1.13e-7	Menopause (age at onset);
SARC	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.48	-6.04	-0.37	6.07e-9	Lymphocyte counts;
SARC	cis	rs6500602	0.647	rs4785967	chr16:4523208	G/A	cg08645402	chr16:4508243	NA	0.48	6.46	0.39	5.97e-10	Schizophrenia;
SARC	cis	rs3540	0.960	rs60825716	chr15:90958053	G/A	cg22089800	chr15:90895588	ZNF774	0.48	5.15	0.32	5.45e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs7659604	0.502	rs10013916	chr4:122702179	T/G	cg19748678	chr4:122722346	EXOSC9	-0.43	-5.38	-0.33	1.83e-7	Type 2 diabetes;
SARC	cis	rs7098414	0.511	rs7899513	chr10:82150559	G/A	cg00277334	chr10:82204260	NA	-0.36	-5.17	-0.32	4.99e-7	Post bronchodilator FEV1;
SARC	cis	rs10782582	0.593	rs4646960	chr1:76211103	C/A	cg03433033	chr1:76189801	ACADM	-0.42	-5.43	-0.33	1.44e-7	Daytime sleep phenotypes;
SARC	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.45	-5.58	-0.34	6.74e-8	Tonsillectomy;
SARC	cis	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.51	-0.44	1.26e-12	Mood instability;
SARC	cis	rs11249608	0.548	rs11960161	chr5:178453837	A/G	cg21905437	chr5:178450457	ZNF879	0.59	8.22	0.47	1.45e-14	Pubertal anthropometrics;
SARC	cis	rs2635047	0.512	rs9962436	chr18:44599109	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.55	7.27	0.43	5.46e-12	Educational attainment;
SARC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.65	0.53	9.21e-19	Prudent dietary pattern;
SARC	cis	rs476633	0.691	rs11858115	chr15:41542591	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.56	-7.97	-0.46	7.14e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs2239547	0.563	rs4302374	chr3:52905802	T/C	cg18404041	chr3:52824283	ITIH1	-0.39	-4.73	-0.3	3.94e-6	Schizophrenia;
SARC	cis	rs7223966	1.000	rs72848797	chr17:61934664	G/A	cg26338869	chr17:61819248	STRADA	0.53	5.51	0.34	9.68e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs921968	0.521	rs56923478	chr2:219638539	A/G	cg02176678	chr2:219576539	TTLL4	-0.33	-5.03	-0.31	9.92e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs3733585	0.699	rs6449174	chr4:9966422	C/T	cg11266682	chr4:10021025	SLC2A9	-0.38	-6.56	-0.39	3.46e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs10781543	0.839	rs10870071	chr9:139382184	T/C	cg14169450	chr9:139327907	INPP5E	0.45	6.48	0.39	5.52e-10	Monocyte percentage of white cells;
SARC	cis	rs2933343	0.729	rs1683816	chr3:128651195	G/T	cg25356066	chr3:128598488	ACAD9	-0.71	-9.33	-0.52	8.6e-18	IgG glycosylation;
SARC	cis	rs2095921	1	rs2095921	chr1:11033322	C/G	cg27631724	chr1:11040367	C1orf127	0.33	4.71	0.3	4.2e-6	Male-pattern baldness;
SARC	cis	rs9462027	0.628	rs10947521	chr6:34689377	G/T	cg07306190	chr6:34760872	UHRF1BP1	0.42	5.91	0.36	1.19e-8	Systemic lupus erythematosus;
SARC	cis	rs3820928	0.804	rs4144327	chr2:227790262	C/T	cg11843606	chr2:227700838	RHBDD1	-0.56	-7.12	-0.42	1.33e-11	Pulmonary function;
SARC	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg08280861	chr8:58055591	NA	0.69	5.78	0.35	2.33e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9611519	0.603	rs9607764	chr22:41411804	G/C	cg06634786	chr22:41940651	POLR3H	-0.38	-4.96	-0.31	1.34e-6	Neuroticism;
SARC	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg08222618	chr4:941054	TMEM175	0.42	5.57	0.34	7.12e-8	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
SARC	cis	rs858239	0.600	rs2003555	chr7:23122915	C/T	cg23682824	chr7:23144976	KLHL7	0.7	9.38	0.52	5.93e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs6964587	1.000	rs10243241	chr7:91705696	A/G	cg17063962	chr7:91808500	NA	0.96	16.16	0.73	6.46e-40	Breast cancer;
SARC	cis	rs9814567	1.000	rs9832785	chr3:134213070	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.09	-0.42	1.64e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs17376456	0.877	rs13165147	chr5:93422214	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.89	0.36	1.36e-8	Diabetic retinopathy;
SARC	cis	rs6570726	0.935	rs369214	chr6:145856709	G/A	cg05220968	chr6:146057943	EPM2A	-0.3	-5.08	-0.32	7.76e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs8067354	0.645	rs2665400	chr17:57880201	G/A	cg02344993	chr17:57696989	CLTC	0.67	7.01	0.42	2.54e-11	Hemoglobin concentration;
SARC	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.0	-16.69	-0.74	1.14e-41	Chronic sinus infection;
SARC	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg23758822	chr17:41437982	NA	0.88	12.1	0.62	1.8e-26	Menopause (age at onset);
SARC	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg16606324	chr3:10149918	C3orf24	0.48	4.75	0.3	3.56e-6	Alzheimer's disease;
SARC	cis	rs7818688	0.697	rs11783985	chr8:95979886	A/G	cg13393036	chr8:95962371	TP53INP1	0.4	4.85	0.3	2.27e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg22857025	chr5:266934	NA	-1.04	-11.5	-0.6	1.59e-24	Breast cancer;
SARC	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg09359103	chr1:154839909	KCNN3	0.44	7.22	0.43	7.36e-12	Prostate cancer;
SARC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg26338869	chr17:61819248	STRADA	-0.79	-10.59	-0.57	1.22e-21	Prudent dietary pattern;
SARC	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg06618935	chr21:46677482	NA	-0.39	-5.23	-0.32	3.81e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9761603	0.812	rs9307773	chr4:138415539	A/G	cg12033966	chr4:138453416	PCDH18	0.56	7.23	0.43	6.72e-12	Diastolic blood pressure;
SARC	cis	rs7769051	0.522	rs73550455	chr6:133096633	A/G	cg22852734	chr6:133119734	C6orf192	1.18	7.59	0.45	7.56e-13	Type 2 diabetes nephropathy;
SARC	cis	rs1729951	0.514	rs75977	chr3:136700549	C/A	cg15507776	chr3:136538369	TMEM22	0.47	5.12	0.32	6.41e-7	Neuroticism;
SARC	cis	rs8031584	0.541	rs2955797	chr15:31210981	A/G	cg19680485	chr15:31195859	MTMR15	0.57	7.43	0.44	2.05e-12	Huntington's disease progression;
SARC	cis	rs7264396	0.635	rs6060703	chr20:34529906	T/C	cg12579300	chr20:34535607	PHF20	-0.42	-4.93	-0.31	1.58e-6	Total cholesterol levels;
SARC	cis	rs2204008	0.744	rs11514073	chr12:38399553	A/C	cg13010199	chr12:38710504	ALG10B	0.8	10.56	0.57	1.43e-21	Bladder cancer;
SARC	cis	rs1865721	0.771	rs7228890	chr18:73137492	C/A	cg26385618	chr18:73139727	C18orf62	-0.41	-5.65	-0.35	4.75e-8	Intelligence;
SARC	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg27572855	chr1:25598939	RHD	0.54	9.34	0.52	7.91e-18	Erythrocyte sedimentation rate;
SARC	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg24549020	chr5:56110836	MAP3K1	0.81	8.4	0.48	4.37e-15	Initial pursuit acceleration;
SARC	cis	rs7084402	0.935	rs10763553	chr10:60274049	C/A	cg07615347	chr10:60278583	BICC1	-0.58	-8.37	-0.48	5.19e-15	Refractive error;
SARC	trans	rs7937682	0.883	rs1789358	chr11:111474116	G/A	cg18187862	chr3:45730750	SACM1L	0.52	6.48	0.39	5.44e-10	Primary sclerosing cholangitis;
SARC	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.42	-6.42	-0.39	7.6e-10	Total body bone mineral density;
SARC	cis	rs7327064	0.879	rs1328650	chr13:36712330	G/T	cg13455704	chr13:36871754	C13orf38	-0.5	-5.03	-0.31	9.74e-7	Economic and political preferences;
SARC	cis	rs9818758	0.607	rs73082362	chr3:49113729	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.63	-4.76	-0.3	3.37e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs5769765	1.000	rs910800	chr22:50278642	C/T	cg03033257	chr22:50311977	ALG12;CRELD2	-0.54	-5.64	-0.35	4.81e-8	Schizophrenia;
SARC	cis	rs9324022	0.929	rs9635298	chr14:101172542	C/T	cg18089426	chr14:101175970	NA	0.54	4.95	0.31	1.41e-6	Plateletcrit;
SARC	cis	rs4865169	0.871	rs9918067	chr4:57870544	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.42	-5.06	-0.31	8.49e-7	Breast cancer;
SARC	cis	rs12950390	0.853	rs12451815	chr17:45855956	A/G	cg03474202	chr17:45855739	NA	-0.44	-6.7	-0.4	1.51e-10	IgG glycosylation;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg11072887	chr6:37322624	RNF8	-0.61	-6.98	-0.42	3.04e-11	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs2282802	0.685	rs6869910	chr5:139629450	T/C	cg26211634	chr5:139558579	C5orf32	0.4	5.12	0.32	6.48e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6732160	0.845	rs13413175	chr2:73389916	T/C	cg01422370	chr2:73384389	NA	0.32	5.41	0.33	1.54e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2820315	0.540	rs10920259	chr1:201797696	C/T	cg11586189	chr1:201857591	SHISA4	-0.35	-5.56	-0.34	7.38e-8	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
SARC	cis	rs1976403	0.633	rs1697422	chr1:21821897	T/C	cg07708622	chr1:21763251	NA	0.33	5.13	0.32	5.99e-7	Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs1008375	1.000	rs62295634	chr4:17685346	C/A	cg27347728	chr4:17578864	LAP3	0.45	5.57	0.34	7.05e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs554111	0.613	rs6699704	chr1:21241432	G/C	cg04902671	chr1:21058625	SH2D5	0.43	5.32	0.33	2.48e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	11.83	0.61	1.3e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs2562456	0.917	rs6511253	chr19:21678798	A/G	cg00806126	chr19:22604979	ZNF98	0.47	4.91	0.31	1.72e-6	Pain;
SARC	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	11.33	0.6	5.32e-24	Platelet count;
SARC	cis	rs12311304	1.000	rs12307681	chr12:15402932	C/T	cg08258403	chr12:15378311	NA	0.49	7.39	0.44	2.53e-12	Behavioural disinhibition (generation interaction);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg10013169	chr6:5997028	NA	-0.59	-6.58	-0.4	3.02e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs3204955	1.000	rs6673301	chr1:116241211	A/G	cg20810993	chr1:116250018	CASQ2	-0.48	-5.24	-0.32	3.53e-7	Itch intensity from mosquito bite adjusted by bite size;
SARC	cis	rs765787	0.530	rs2413786	chr15:45525394	C/A	cg24006582	chr15:45444508	DUOX1	-0.49	-6.5	-0.39	4.93e-10	Uric acid levels;
SARC	cis	rs12142240	0.698	rs66575205	chr1:46814092	T/G	cg14993813	chr1:46806288	NSUN4	-0.52	-5.46	-0.34	1.22e-7	Menopause (age at onset);
SARC	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg11878867	chr6:150167359	LRP11	-0.36	-4.85	-0.3	2.23e-6	Lung cancer;
SARC	cis	rs9457247	0.602	rs2239827	chr6:167490945	G/A	cg23791538	chr6:167370224	RNASET2	-0.54	-6.91	-0.41	4.58e-11	Crohn's disease;
SARC	cis	rs1468333	1.000	rs217263	chr5:137480666	G/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.79	10.34	0.56	7.36e-21	Resting heart rate;
SARC	cis	rs67311347	0.544	rs35112505	chr3:40337075	A/G	cg24209194	chr3:40518798	ZNF619	0.49	6.6	0.4	2.72e-10	Renal cell carcinoma;
SARC	cis	rs7824557	0.564	rs2043508	chr8:11227406	G/A	cg12395012	chr8:11607386	GATA4	0.3	5.0	0.31	1.15e-6	Retinal vascular caliber;
SARC	cis	rs2153535	0.580	rs7763190	chr6:8484197	G/A	cg07606381	chr6:8435919	SLC35B3	0.78	11.07	0.59	3.71e-23	Motion sickness;
SARC	cis	rs1790761	0.520	rs4930461	chr11:67394895	A/G	cg00864171	chr11:67383662	NA	0.45	5.9	0.36	1.26e-8	Mean corpuscular volume;
SARC	cis	rs7555523	0.887	rs4269750	chr1:165711510	C/T	cg19769164	chr1:165738335	TMCO1	0.59	4.91	0.31	1.7e-6	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	cis	rs870825	0.860	rs60523653	chr4:185604676	T/C	cg04058563	chr4:185651563	MLF1IP	0.76	9.26	0.52	1.4e-17	Blood protein levels;
SARC	cis	rs9611519	0.929	rs9611469	chr22:41433319	T/C	cg03806693	chr22:41940476	POLR3H	-0.61	-7.54	-0.44	1.03e-12	Neuroticism;
SARC	cis	rs7772486	0.686	rs702314	chr6:146003510	G/A	cg05347473	chr6:146136440	FBXO30	-0.51	-7.07	-0.42	1.81e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4423214	0.879	rs1792281	chr11:71135496	G/A	cg05163923	chr11:71159392	DHCR7	-0.54	-6.22	-0.38	2.28e-9	Vitamin D levels;
SARC	cis	rs356220	0.642	rs356174	chr4:90630901	G/T	cg06632027	chr4:90757378	SNCA	0.41	5.41	0.33	1.57e-7	Parkinson's disease;
SARC	cis	rs1401999	0.690	rs3805112	chr3:183645662	C/T	cg01324343	chr3:183735012	ABCC5	0.59	10.57	0.57	1.38e-21	Anterior chamber depth;
SARC	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg01341218	chr17:43662625	NA	-0.81	-9.36	-0.52	7.04e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs918629	0.601	rs889302	chr5:95264652	A/C	cg16656078	chr5:95278638	ELL2	-0.54	-6.79	-0.41	9.4e-11	IgG glycosylation;
SARC	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	6.24	0.38	2.09e-9	Platelet count;
SARC	cis	rs7552404	0.696	rs1417405	chr1:76457797	T/C	cg22875332	chr1:76189707	ACADM	0.43	4.99	0.31	1.17e-6	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.62	-6.73	-0.4	1.29e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs933688	0.532	rs2367292	chr5:90556785	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.46	-5.17	-0.32	5.09e-7	Smoking behavior;
SARC	cis	rs3796352	1.000	rs13078971	chr3:53103645	G/C	cg12962167	chr3:53033115	SFMBT1	0.77	5.01	0.31	1.06e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs9581943	0.967	rs4424773	chr13:28470544	C/G	cg16302790	chr13:28498334	PDX1	0.55	8.32	0.48	7.52e-15	Pancreatic cancer;
SARC	cis	rs7681440	0.606	rs2737008	chr4:90747183	G/A	cg06632027	chr4:90757378	SNCA	-0.43	-5.32	-0.33	2.4e-7	Dementia with Lewy bodies;
SARC	cis	rs6484504	0.600	rs366758	chr11:31222499	A/C	cg26647111	chr11:31128758	NA	-0.39	-5.1	-0.32	7.11e-7	Red blood cell count;
SARC	cis	rs17270561	0.609	rs4712963	chr6:25740502	C/T	cg17691542	chr6:26056736	HIST1H1C	0.6	7.24	0.43	6.49e-12	Iron status biomarkers;
SARC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg04267008	chr7:1944627	MAD1L1	-0.59	-6.88	-0.41	5.59e-11	Bipolar disorder and schizophrenia;
SARC	trans	rs208520	0.690	rs207118	chr6:66788948	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.06	-14.41	-0.69	4.36e-34	Exhaled nitric oxide output;
SARC	cis	rs9309473	0.500	rs6757996	chr2:73772251	G/A	cg20560298	chr2:73613845	ALMS1	-0.53	-7.1	-0.42	1.46e-11	Metabolite levels;
SARC	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg00933542	chr6:150070202	PCMT1	0.33	5.71	0.35	3.36e-8	Lung cancer;
SARC	cis	rs240764	0.853	rs12206945	chr6:101018032	C/T	cg09795085	chr6:101329169	ASCC3	0.44	5.79	0.35	2.21e-8	Neuroticism;
SARC	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg18758796	chr5:131593413	PDLIM4	0.38	4.93	0.31	1.55e-6	Acylcarnitine levels;
SARC	cis	rs7772486	0.754	rs702304	chr6:145990797	A/G	cg23711669	chr6:146136114	FBXO30	-0.87	-14.26	-0.68	1.42e-33	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12997796	0.556	rs34353387	chr2:86974834	A/C	cg25203885	chr2:87302643	LOC285074	-0.61	-5.14	-0.32	5.79e-7	Schizophrenia;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg21824413	chr3:23987438	NR1D2	-0.79	-6.46	-0.39	5.89e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg07701084	chr6:150067640	NUP43	0.41	5.4	0.33	1.62e-7	Lung cancer;
SARC	cis	rs7084402	0.967	rs1649045	chr10:60327047	T/C	cg07615347	chr10:60278583	BICC1	0.57	8.39	0.48	4.75e-15	Refractive error;
SARC	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg12463550	chr7:65579703	CRCP	0.48	5.79	0.35	2.23e-8	Aortic root size;
SARC	cis	rs3087591	0.960	rs11870097	chr17:29448097	C/T	cg24425628	chr17:29625626	OMG;NF1	0.55	6.92	0.41	4.27e-11	Hip circumference;
SARC	cis	rs11690935	1.000	rs11678984	chr2:172535848	T/G	cg13550731	chr2:172543902	DYNC1I2	0.99	15.4	0.71	2.28e-37	Schizophrenia;
SARC	trans	rs9949291	0.565	rs1581426	chr18:61375519	C/T	cg02720697	chr19:3359204	NFIC	0.5	6.49	0.39	5.08e-10	Eosinophil percentage of white cells;
SARC	trans	rs7824557	0.628	rs6988922	chr8:11194911	A/G	cg06636001	chr8:8085503	FLJ10661	0.52	6.32	0.38	1.3e-9	Retinal vascular caliber;
SARC	cis	rs9359856	0.510	rs74437492	chr6:90338728	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.61	-5.39	-0.33	1.69e-7	Bipolar disorder;
SARC	cis	rs3791556	0.504	rs1001285	chr2:240107814	A/G	cg03475776	chr2:240114298	HDAC4	0.3	4.98	0.31	1.27e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	trans	rs8073060	0.586	rs225298	chr17:33923946	T/G	cg19694781	chr19:47549865	TMEM160	-0.65	-6.58	-0.4	3.05e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg24675658	chr1:53192096	ZYG11B	0.64	9.04	0.51	6.1e-17	Monocyte count;
SARC	cis	rs9486719	1.000	rs10872018	chr6:97026429	G/A	cg06623918	chr6:96969491	KIAA0776	-0.79	-8.83	-0.5	2.51e-16	Migraine;Coronary artery disease;
SARC	cis	rs3771570	1.000	rs6752050	chr2:242228780	T/C	cg21155796	chr2:242212141	HDLBP	0.66	5.62	0.35	5.57e-8	Prostate cancer;
SARC	cis	rs35110281	0.540	rs55840436	chr21:45118541	G/T	cg04455712	chr21:45112962	RRP1B	0.34	4.8	0.3	2.77e-6	Mean corpuscular volume;
SARC	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg17221315	chr6:27791827	HIST1H4J	0.49	5.0	0.31	1.15e-6	Parkinson's disease;
SARC	cis	rs9325144	0.560	rs10506125	chr12:39120287	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.15	0.51	2.94e-17	Morning vs. evening chronotype;
SARC	cis	rs911555	0.692	rs7146215	chr14:103915908	A/G	cg12935359	chr14:103987150	CKB	0.4	5.44	0.34	1.38e-7	Intelligence (multi-trait analysis);
SARC	trans	rs9858542	0.953	rs11926781	chr3:49603289	C/T	cg21659725	chr3:3221576	CRBN	-0.55	-6.38	-0.39	9.23e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg11247378	chr22:39784982	NA	-0.32	-5.19	-0.32	4.59e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs7819412	0.715	rs2409727	chr8:11043236	C/T	cg21775007	chr8:11205619	TDH	-0.42	-5.06	-0.31	8.41e-7	Triglycerides;
SARC	cis	rs73086581	1.000	rs73086512	chr20:3922772	C/A	cg02187196	chr20:3869020	PANK2	0.66	6.38	0.39	9.69e-10	Response to antidepressants in depression;
SARC	cis	rs4150161	0.656	rs2288026	chr16:84220344	C/G	cg10106505	chr16:84220380	TAF1C	0.71	5.81	0.36	2.01e-8	Systolic blood pressure response to hydrochlorothiazide in hypertension;
SARC	cis	rs2652834	0.519	rs4075584	chr15:63340292	C/T	cg05507819	chr15:63340323	TPM1	0.91	10.0	0.55	7.94e-20	HDL cholesterol;
SARC	cis	rs1468333	0.567	rs10080108	chr5:137655242	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.66	8.04	0.47	4.63e-14	Resting heart rate;
SARC	cis	rs67460515	0.892	rs13073147	chr3:161045237	T/C	cg03342759	chr3:160939853	NMD3	-0.68	-8.66	-0.49	8.12e-16	Parkinson's disease;
SARC	cis	rs72945132	1.000	rs72945132	chr11:70113901	G/C	cg00319359	chr11:70116639	PPFIA1	0.69	6.23	0.38	2.19e-9	Coronary artery disease;
SARC	cis	rs12479064	0.724	rs3792150	chr2:100041849	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.55	-6.5	-0.39	4.77e-10	Chronic sinus infection;
SARC	cis	rs34783982	0.881	rs12437678	chr15:89497084	C/T	cg26213453	chr15:89455860	MFGE8	0.29	5.14	0.32	5.81e-7	Squamous cell lung carcinoma;
SARC	cis	rs1267303	0.675	rs1267308	chr1:46987718	A/G	cg25110126	chr1:46999211	NA	-0.74	-8.35	-0.48	5.96e-15	Monobrow;
SARC	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg11941060	chr3:133502564	NA	-0.33	-4.76	-0.3	3.37e-6	Iron status biomarkers;
SARC	cis	rs3540	0.533	rs937793	chr15:91053583	A/G	cg22089800	chr15:90895588	ZNF774	-0.52	-6.26	-0.38	1.81e-9	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs6582630	0.576	rs2387837	chr12:38403164	G/T	cg14851346	chr12:38532713	NA	-0.48	-5.83	-0.36	1.82e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs11190604	1.000	rs7080356	chr10:102266735	A/C	cg07080220	chr10:102295463	HIF1AN	0.79	9.68	0.54	7.56e-19	Palmitoleic acid (16:1n-7) levels;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg06716613	chr4:39640782	C4orf34	0.53	6.86	0.41	6.23e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs11645898	0.935	rs72787091	chr16:72190184	C/T	cg14768367	chr16:72042858	DHODH	-0.65	-5.76	-0.35	2.69e-8	Blood protein levels;
SARC	cis	rs668210	0.793	rs1786172	chr11:65770658	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.7	7.5	0.44	1.37e-12	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9326248	1.000	rs4938354	chr11:117051165	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.48	5.12	0.32	6.45e-7	Blood protein levels;
SARC	cis	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg05623727	chr3:50126028	RBM5	-0.32	-4.91	-0.31	1.74e-6	Intelligence (multi-trait analysis);
SARC	trans	rs61931739	0.890	rs1705748	chr12:34133171	A/G	cg13010199	chr12:38710504	ALG10B	0.56	7.62	0.45	6.2800000000000005e-13	Morning vs. evening chronotype;
SARC	cis	rs4660306	0.744	rs11211114	chr1:45926243	G/C	cg24296786	chr1:45957014	TESK2	-0.56	-5.53	-0.34	8.72e-8	Homocysteine levels;
SARC	cis	rs7296418	0.961	rs7957096	chr12:123544878	A/G	cg05973401	chr12:123451056	ABCB9	0.55	6.53	0.39	4.17e-10	Platelet count;
SARC	cis	rs7772486	0.720	rs9403757	chr6:146261271	C/T	cg23711669	chr6:146136114	FBXO30	-0.8	-12.47	-0.63	1.13e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9457247	0.967	rs2149083	chr6:167370971	G/C	cg23791538	chr6:167370224	RNASET2	0.63	8.61	0.49	1.13e-15	Crohn's disease;
SARC	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg27170947	chr2:26402098	FAM59B	-0.37	-4.8	-0.3	2.79e-6	Gut microbiome composition (summer);
SARC	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg21782813	chr7:2030301	MAD1L1	0.37	5.53	0.34	8.69e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs763121	0.925	rs1043312	chr22:39131727	T/G	cg06022373	chr22:39101656	GTPBP1	0.75	9.84	0.54	2.57e-19	Menopause (age at onset);
SARC	cis	rs7819412	0.521	rs2409720	chr8:11037903	A/C	cg12395012	chr8:11607386	GATA4	0.29	5.1	0.32	7.09e-7	Triglycerides;
SARC	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg13126279	chr21:47581558	C21orf56	-0.49	-5.92	-0.36	1.14e-8	Testicular germ cell tumor;
SARC	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg05313129	chr8:58192883	C8orf71	-0.57	-6.56	-0.39	3.42e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg01448562	chr3:133502909	NA	-0.56	-8.65	-0.49	8.48e-16	Iron status biomarkers;
SARC	cis	rs7296418	0.738	rs1568428	chr12:123738876	A/G	cg00376283	chr12:123451042	ABCB9	-0.58	-7.29	-0.43	4.68e-12	Platelet count;
SARC	cis	rs17023223	0.537	rs12065809	chr1:119724535	A/T	cg05756136	chr1:119680316	WARS2	-0.49	-5.62	-0.35	5.47e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs9788721	0.902	rs951266	chr15:78878541	C/T	cg06917634	chr15:78832804	PSMA4	-0.49	-5.28	-0.33	2.95e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg21724239	chr8:58056113	NA	0.64	6.5	0.39	4.82e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6570726	0.902	rs4895678	chr6:145935510	C/T	cg23711669	chr6:146136114	FBXO30	0.75	10.99	0.58	6.67e-23	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4969178	0.930	rs12601079	chr17:76400329	G/A	cg20026190	chr17:76395443	PGS1	0.4	5.35	0.33	2.05e-7	HDL cholesterol levels;
SARC	cis	rs11874712	0.966	rs9962380	chr18:43678706	C/T	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.46	5.48	0.34	1.08e-7	Migraine - clinic-based;
SARC	cis	rs9894429	0.789	rs8074989	chr17:79598728	G/C	cg18240062	chr17:79603768	NPLOC4	0.88	13.71	0.67	9.24e-32	Eye color traits;
SARC	cis	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg19500275	chr17:80737654	TBCD	0.43	5.15	0.32	5.65e-7	Glycated hemoglobin levels;
SARC	cis	rs9916302	0.706	rs9891892	chr17:37479856	A/C	cg00129232	chr17:37814104	STARD3	0.53	5.7	0.35	3.69e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs3766606	0.505	rs72633047	chr1:7935440	G/A	cg05338066	chr1:7812865	CAMTA1	0.55	4.99	0.31	1.16e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs4713675	0.584	rs4713667	chr6:33680016	G/C	cg15676125	chr6:33679581	C6orf125	0.53	6.41	0.39	8.06e-10	Plateletcrit;
SARC	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg11062466	chr8:58055876	NA	0.61	5.75	0.35	2.74e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs17270561	0.609	rs1937132	chr6:25757017	A/G	cg17691542	chr6:26056736	HIST1H1C	0.6	7.28	0.43	5.11e-12	Iron status biomarkers;
SARC	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg20007245	chr22:24372913	LOC391322	0.65	7.44	0.44	1.91e-12	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs11785693	0.862	rs13281354	chr8:4987756	G/T	cg26367366	chr8:4980734	NA	0.72	6.42	0.39	7.56e-10	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.59e-6	Depression;
SARC	cis	rs9399135	0.527	rs61738492	chr6:135282771	G/A	cg24558204	chr6:135376177	HBS1L	0.62	8.32	0.48	7.52e-15	Red blood cell count;
SARC	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.09	12.8	0.64	9e-29	Platelet count;
SARC	cis	rs7408868	1.000	rs10422818	chr19:15285272	A/G	cg14696996	chr19:15285081	NOTCH3	0.98	8.66	0.49	7.92e-16	Pulse pressure;
SARC	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg08859206	chr1:53392774	SCP2	0.43	6.27	0.38	1.7e-9	Monocyte count;
SARC	cis	rs4727027	0.933	rs12540094	chr7:148847178	A/G	cg23583168	chr7:148888333	NA	0.76	11.48	0.6	1.77e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs7589342	0.831	rs10169998	chr2:106452253	A/G	cg16077055	chr2:106428750	NCK2	0.4	7.33	0.43	3.79e-12	Addiction;
SARC	cis	rs787274	0.718	rs4979173	chr9:115627699	A/C	cg13803584	chr9:115635662	SNX30	-0.91	-7.23	-0.43	6.97e-12	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs12579753	1.000	rs7966755	chr12:82221604	A/G	cg07988820	chr12:82153109	PPFIA2	-0.53	-6.2	-0.38	2.51e-9	Resting heart rate;
SARC	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg24642844	chr7:1081250	C7orf50	-0.52	-5.66	-0.35	4.39e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs7829975	0.510	rs2979160	chr8:8307666	A/G	cg15556689	chr8:8085844	FLJ10661	0.59	7.6	0.45	7.32e-13	Mood instability;
SARC	cis	rs2204008	0.618	rs8186932	chr12:38338386	G/A	cg14851346	chr12:38532713	NA	-0.48	-5.7	-0.35	3.64e-8	Bladder cancer;
SARC	cis	rs13144136	0.687	rs4235336	chr4:10663850	C/T	cg10242279	chr4:10666415	CLNK	-0.43	-6.99	-0.42	2.83e-11	Resistance to antihypertensive treatment in hypertension;
SARC	cis	rs2153535	0.580	rs1932285	chr6:8477719	T/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.24	0.48	1.23e-14	Motion sickness;
SARC	cis	rs2153535	0.580	rs1034272	chr6:8469335	G/C	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs2055729	0.507	rs814424	chr8:9942924	C/T	cg21625330	chr8:9911636	MSRA	0.76	7.62	0.45	6.18e-13	Multiple myeloma (hyperdiploidy);
SARC	cis	rs7681440	0.538	rs2737015	chr4:90745283	T/C	cg06632027	chr4:90757378	SNCA	-0.44	-5.48	-0.34	1.1e-7	Dementia with Lewy bodies;
SARC	cis	rs3820928	0.709	rs2894627	chr2:227910171	A/G	cg05526886	chr2:227700861	RHBDD1	-0.44	-4.89	-0.31	1.87e-6	Pulmonary function;
SARC	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg11644478	chr21:40555479	PSMG1	-0.89	-11.32	-0.6	5.88e-24	Cognitive function;
SARC	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg27541892	chr1:1571801	CDK11B	0.4	5.55	0.34	7.88e-8	Body mass index;
SARC	cis	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg09021430	chr5:549028	NA	-0.44	-5.69	-0.35	3.85e-8	Obesity-related traits;
SARC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.81	-10.22	-0.56	1.7e-20	Prudent dietary pattern;
SARC	cis	rs2289583	0.503	rs12050494	chr15:75260896	G/A	cg14664628	chr15:75095509	CSK	0.49	5.31	0.33	2.62e-7	Systemic lupus erythematosus;
SARC	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg26335602	chr6:28129616	ZNF389	0.48	5.5	0.34	9.97e-8	Parkinson's disease;
SARC	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg03517284	chr6:25882590	NA	-0.5	-6.5	-0.39	4.78e-10	Intelligence (multi-trait analysis);
SARC	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.69	9.44	0.53	4.09e-18	Menarche (age at onset);
SARC	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg16434002	chr17:42200994	HDAC5	-0.43	-5.4	-0.33	1.63e-7	Total body bone mineral density;
SARC	cis	rs826838	0.935	rs1160162	chr12:38959795	G/A	cg26384229	chr12:38710491	ALG10B	0.92	14.29	0.68	1.05e-33	Heart rate;
SARC	cis	rs10463316	0.894	rs6579860	chr5:150752338	G/A	cg03212797	chr5:150827313	SLC36A1	-0.53	-6.34	-0.38	1.16e-9	Metabolite levels (Pyroglutamine);
SARC	cis	rs787274	0.867	rs10739374	chr9:115602703	G/C	cg13803584	chr9:115635662	SNX30	-0.83	-5.06	-0.31	8.34e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg22496380	chr5:211416	CCDC127	-0.88	-9.59	-0.53	1.47e-18	Breast cancer;
SARC	cis	rs2153535	0.580	rs9405390	chr6:8466209	T/G	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	cis	rs9948	1.000	rs62152790	chr2:97478579	G/A	cg01990225	chr2:97406019	LMAN2L	-0.93	-6.52	-0.39	4.26e-10	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs473651	0.904	rs551859	chr2:239371836	T/C	cg18131467	chr2:239335373	ASB1	0.92	14.77	0.7	2.73e-35	Multiple system atrophy;
SARC	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg23939001	chr4:940644	TMEM175	0.4	5.3	0.33	2.7e-7	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
SARC	cis	rs240764	0.853	rs11155498	chr6:101019551	G/C	cg09795085	chr6:101329169	ASCC3	-0.45	-5.95	-0.36	9.78e-9	Neuroticism;
SARC	cis	rs76419734	1.000	rs72671828	chr4:106624800	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.82	5.06	0.31	8.65e-7	Post bronchodilator FEV1;
SARC	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg07414643	chr4:187882934	NA	-0.46	-6.73	-0.4	1.27e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg13206674	chr6:150067644	NUP43	0.46	6.1	0.37	4.29e-9	Lung cancer;
SARC	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	17.63	0.76	9e-45	Height;
SARC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg14784868	chr12:69753453	YEATS4	0.51	6.77	0.41	1.01e-10	Blood protein levels;
SARC	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg04166393	chr7:2884313	GNA12	0.67	7.97	0.46	6.95e-14	Height;
SARC	cis	rs9394841	0.585	rs9381096	chr6:41821137	C/T	cg08135965	chr6:41755394	TOMM6	0.62	6.19	0.38	2.64e-9	Mean corpuscular hemoglobin;Red cell distribution width;
SARC	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg07343612	chr16:622815	PIGQ	-0.61	-8.49	-0.49	2.39e-15	Height;
SARC	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg24209194	chr3:40518798	ZNF619	0.66	8.02	0.47	5.15e-14	Renal cell carcinoma;
SARC	cis	rs6459788	0.692	rs10807645	chr7:157258979	T/C	cg06271696	chr7:157225062	NA	0.36	5.54	0.34	8.07e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs7592578	0.825	rs12477369	chr2:191455624	G/T	cg27211696	chr2:191398769	TMEM194B	0.51	5.3	0.33	2.67e-7	Diastolic blood pressure;
SARC	cis	rs883565	0.569	rs704959	chr3:39180263	G/A	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.44	-5.11	-0.32	6.56e-7	Handedness;
SARC	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg09455208	chr3:40491958	NA	0.39	5.85	0.36	1.66e-8	Renal cell carcinoma;
SARC	cis	rs4975616	0.869	rs466502	chr5:1325767	C/T	cg06550200	chr5:1325588	CLPTM1L	0.56	8.24	0.48	1.22e-14	Lung cancer;
SARC	trans	rs9650657	0.504	rs10109167	chr8:11033525	C/T	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.65	-0.45	5.39e-13	Neuroticism;
SARC	cis	rs4073582	0.595	rs801741	chr11:65917084	A/G	cg14036092	chr11:66035641	RAB1B	0.62	8.53	0.49	1.93e-15	Gout;
SARC	cis	rs11250098	0.547	rs2409764	chr8:11281273	C/T	cg21775007	chr8:11205619	TDH	0.41	5.2	0.32	4.36e-7	Morning vs. evening chronotype;
SARC	cis	rs8180040	0.647	rs57756484	chr3:47239333	A/G	cg27129171	chr3:47204927	SETD2	-0.69	-9.4	-0.52	5.33e-18	Colorectal cancer;
SARC	cis	rs6088580	0.634	rs1205336	chr20:32926336	G/A	cg08999081	chr20:33150536	PIGU	-0.43	-6.7	-0.4	1.53e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs7659604	1.000	rs6823488	chr4:122664819	A/G	cg19748678	chr4:122722346	EXOSC9	0.41	5.1	0.32	6.99e-7	Type 2 diabetes;
SARC	cis	rs6977660	0.507	rs72591448	chr7:19775298	C/T	cg07541023	chr7:19748670	TWISTNB	0.92	8.02	0.47	5.06e-14	Thyroid stimulating hormone;
SARC	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg11859384	chr17:80120422	CCDC57	-0.39	-4.73	-0.3	3.91e-6	Life satisfaction;
SARC	trans	rs6600671	1.000	rs4844380	chr1:121193620	A/T	cg00646200	chr1:148855367	NA	0.51	7.1	0.42	1.53e-11	Hip geometry;
SARC	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg24399712	chr22:39784796	NA	-0.45	-6.03	-0.37	6.31e-9	Intelligence (multi-trait analysis);
SARC	cis	rs9322817	0.691	rs2486135	chr6:105282263	C/T	cg02098413	chr6:105308735	HACE1	0.38	5.91	0.36	1.18e-8	Thyroid stimulating hormone;
SARC	cis	rs1707322	0.717	rs2253862	chr1:46081960	C/T	cg03146154	chr1:46216737	IPP	-0.52	-6.21	-0.38	2.48e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs10876993	0.821	rs1678522	chr12:58049923	G/A	cg18357645	chr12:58087776	OS9	0.46	5.92	0.36	1.13e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg12310025	chr6:25882481	NA	0.43	5.43	0.34	1.43e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6430585	0.528	rs12474975	chr2:136702118	A/T	cg07169764	chr2:136633963	MCM6	1.02	13.66	0.67	1.37e-31	Corneal structure;
SARC	cis	rs7614311	0.681	rs73117042	chr3:63896543	T/C	cg22134162	chr3:63841271	THOC7	-0.46	-4.95	-0.31	1.44e-6	Lung function (FVC);Lung function (FEV1);
SARC	cis	rs11644362	1.000	rs3843707	chr16:12996788	G/A	cg06890432	chr16:12997467	SHISA9	-0.49	-6.37	-0.38	1.01e-9	Positive affect;Subjective well-being;
SARC	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg00933542	chr6:150070202	PCMT1	0.31	5.07	0.32	8.05e-7	Lung cancer;
SARC	cis	rs6772849	0.930	rs7639400	chr3:128323356	T/C	cg08795948	chr3:128337044	NA	0.56	7.92	0.46	9.76e-14	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs9473924	0.580	rs68118663	chr6:50815367	C/T	cg14470998	chr6:50812995	TFAP2B	0.66	6.0	0.37	7.55e-9	Body mass index;
SARC	trans	rs1814175	0.588	rs1794144	chr11:49918233	A/G	cg15704280	chr7:45808275	SEPT13	-0.88	-14.0	-0.68	1.02e-32	Height;
SARC	cis	rs6840360	0.967	rs6535812	chr4:152599374	C/A	cg22705602	chr4:152727874	NA	-0.38	-6.54	-0.39	3.91e-10	Intelligence (multi-trait analysis);
SARC	cis	rs1728785	1.000	rs6499181	chr16:68593002	A/T	cg02972257	chr16:68554789	NA	-0.45	-5.32	-0.33	2.48e-7	Ulcerative colitis;
SARC	trans	rs6600671	1.000	rs2319969	chr1:121207335	A/G	cg00646200	chr1:148855367	NA	0.56	7.73	0.45	3.24e-13	Hip geometry;
SARC	cis	rs2732480	0.500	rs7966829	chr12:48615603	G/T	cg24011408	chr12:48396354	COL2A1	0.43	4.79	0.3	2.99e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs9393692	0.645	rs766406	chr6:26319588	G/T	cg05868516	chr6:26286170	HIST1H4H	0.52	5.95	0.36	9.97e-9	Educational attainment;
SARC	cis	rs6496044	0.568	rs11636764	chr15:86079751	G/A	cg10818794	chr15:86012489	AKAP13	-0.39	-4.86	-0.3	2.18e-6	Interstitial lung disease;
SARC	cis	rs992157	0.735	rs13393821	chr2:219076742	C/G	cg20019365	chr2:219134978	PNKD;AAMP	0.66	9.33	0.52	8.48e-18	Colorectal cancer;
SARC	cis	rs79349575	0.783	rs2112617	chr17:46977125	G/A	cg07967210	chr17:47022446	SNF8	0.37	4.75	0.3	3.52e-6	Type 2 diabetes;
SARC	cis	rs4668356	0.803	rs2059723	chr2:171831197	G/T	cg13882835	chr2:172017928	TLK1	0.64	5.62	0.35	5.33e-8	Cognitive performance;
SARC	cis	rs9916302	0.904	rs7208274	chr17:37513796	C/T	cg15445000	chr17:37608096	MED1	-0.44	-5.39	-0.33	1.71e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg13988995	chr13:111340350	CARS2	0.71	5.61	0.34	5.83e-8	Obesity-related traits;
SARC	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg06808227	chr14:105710500	BRF1	-0.55	-7.48	-0.44	1.47e-12	Mean platelet volume;Platelet distribution width;
SARC	cis	rs10484885	0.648	rs2777848	chr6:90535993	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.68	-7.23	-0.43	7.06e-12	QRS interval (sulfonylurea treatment interaction);
SARC	cis	rs896854	0.517	rs2013597	chr8:95951807	G/A	cg16049864	chr8:95962084	TP53INP1	-0.34	-5.01	-0.31	1.09e-6	Type 2 diabetes;
SARC	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg06634786	chr22:41940651	POLR3H	0.5	6.12	0.37	3.99e-9	Vitiligo;
SARC	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg12463550	chr7:65579703	CRCP	0.5	5.9	0.36	1.27e-8	Aortic root size;
SARC	cis	rs7605378	0.528	rs281791	chr2:200850402	A/G	cg17644776	chr2:200775616	C2orf69	-0.57	-7.31	-0.43	4.22e-12	Osteoporosis;
SARC	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg16145915	chr7:1198662	ZFAND2A	-0.34	-4.89	-0.31	1.86e-6	Longevity;Endometriosis;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg21173440	chr5:55008212	SLC38A9	-0.55	-6.66	-0.4	1.94e-10	Fibrinogen levels;
SARC	cis	rs1059312	0.966	rs35907548	chr12:129282180	T/C	cg09035930	chr12:129282057	SLC15A4	0.62	8.93	0.5	1.32e-16	Systemic lupus erythematosus;
SARC	cis	rs617791	0.530	rs55947178	chr11:65754230	G/A	cg26695010	chr11:65641043	EFEMP2	0.58	7.13	0.42	1.25e-11	Breast cancer;
SARC	cis	rs6963495	0.719	rs73190174	chr7:105161216	T/G	cg19920283	chr7:105172520	RINT1	0.65	5.48	0.34	1.09e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs2115630	1.000	rs6496452	chr15:85372645	A/T	cg12501888	chr15:85177176	SCAND2	-0.43	-5.35	-0.33	2.14e-7	P wave terminal force;
SARC	cis	rs11098499	0.691	rs2136911	chr4:120265859	G/A	cg09307838	chr4:120376055	NA	0.75	10.42	0.56	4.08e-21	Corneal astigmatism;
SARC	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	0.82	8.56	0.49	1.51e-15	Alzheimer's disease;
SARC	cis	rs1707322	0.682	rs28490344	chr1:46197948	C/T	cg03146154	chr1:46216737	IPP	0.53	6.37	0.39	1.01e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg12463550	chr7:65579703	CRCP	0.52	5.81	0.36	2.06e-8	Aortic root size;
SARC	cis	rs10875746	0.625	rs2898065	chr12:48644619	C/A	cg26205652	chr12:48591994	NA	0.46	4.97	0.31	1.31e-6	Longevity (90 years and older);
SARC	cis	rs4595586	0.525	rs7972595	chr12:39338000	G/A	cg26384229	chr12:38710491	ALG10B	0.54	6.3	0.38	1.44e-9	Morning vs. evening chronotype;
SARC	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg09439093	chr6:4135575	PECI	-0.52	-6.77	-0.41	1.04e-10	Parental extreme longevity (95 years and older);
SARC	cis	rs637571	0.522	rs556643	chr11:65733289	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.44	-5.56	-0.34	7.55e-8	Eosinophil percentage of white cells;
SARC	cis	rs4242434	0.597	rs876714	chr8:22482799	A/G	cg03733263	chr8:22462867	KIAA1967	0.86	13.76	0.67	6.42e-32	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs6964587	0.626	rs6951795	chr7:91543764	T/C	cg17063962	chr7:91808500	NA	-0.77	-11.34	-0.6	5.07e-24	Breast cancer;
SARC	cis	rs60843830	0.633	rs1078763	chr2:113763	A/G	cg12623918	chr2:306882	NA	-0.35	-6.22	-0.38	2.28e-9	Spherical equivalent (joint analysis main effects and education interaction);
SARC	cis	rs2153535	0.580	rs2327057	chr6:8443319	G/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.39	0.48	4.61e-15	Motion sickness;
SARC	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg19223190	chr17:80058835	NA	-0.43	-6.02	-0.37	6.57e-9	Life satisfaction;
SARC	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg17376030	chr22:41985996	PMM1	0.76	9.36	0.52	7.05e-18	Vitiligo;
SARC	cis	rs11997175	0.625	rs7018213	chr8:33625770	T/C	ch.8.33884649F	chr8:33765107	NA	0.52	6.61	0.4	2.57e-10	Body mass index;
SARC	cis	rs6963495	0.818	rs55794529	chr7:105165747	T/C	cg19920283	chr7:105172520	RINT1	0.66	5.62	0.35	5.45e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.61	7.4	0.44	2.43e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1348850	0.514	rs4893974	chr2:178497026	A/G	cg23306229	chr2:178417860	TTC30B	0.57	5.55	0.34	7.73e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg11766577	chr21:47581405	C21orf56	0.41	4.97	0.31	1.29e-6	Testicular germ cell tumor;
SARC	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.29	0.38	1.55e-9	Bipolar disorder;
SARC	cis	rs11583043	0.874	rs6577222	chr1:101420502	C/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.48	5.88	0.36	1.38e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs7551222	0.681	rs10900595	chr1:204511602	C/A	cg20240347	chr1:204465584	NA	-0.3	-5.17	-0.32	5.16e-7	Schizophrenia;
SARC	trans	rs61931739	0.635	rs1486883	chr12:33908740	C/T	cg26384229	chr12:38710491	ALG10B	0.57	7.36	0.43	3.11e-12	Morning vs. evening chronotype;
SARC	trans	rs1814175	0.645	rs1851844	chr11:50021773	T/C	cg15704280	chr7:45808275	SEPT13	-0.9	-14.33	-0.68	7.84e-34	Height;
SARC	trans	rs629535	0.665	rs2433331	chr8:70041943	T/C	cg21567404	chr3:27674614	NA	1.04	13.87	0.67	2.73e-32	Dupuytren's disease;
SARC	cis	rs804280	0.525	rs17153755	chr8:11611500	C/G	cg12395012	chr8:11607386	GATA4	-0.3	-4.96	-0.31	1.33e-6	Myopia (pathological);
SARC	cis	rs453301	0.506	rs686189	chr8:8623637	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.81	-0.41	8.38e-11	Joint mobility (Beighton score);
SARC	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg04287289	chr16:89883240	FANCA	-0.62	-8.57	-0.49	1.48e-15	Vitiligo;
SARC	cis	rs4718428	0.705	rs13231140	chr7:66361618	C/G	cg12165864	chr7:66369176	NA	-0.46	-5.17	-0.32	5.1e-7	Corneal structure;
SARC	cis	rs7833986	1.000	rs72654002	chr8:57095939	C/T	cg26371346	chr8:56986568	SNORD54;RPS20	0.6	5.33	0.33	2.36e-7	Height;
SARC	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg18357526	chr6:26021779	HIST1H4A	0.46	5.85	0.36	1.64e-8	Blood metabolite levels;
SARC	cis	rs1707322	0.752	rs28545085	chr1:46201950	G/A	cg06784218	chr1:46089804	CCDC17	0.36	6.29	0.38	1.55e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs73001065	0.901	rs10401969	chr19:19407718	A/G	cg03709012	chr19:19516395	GATAD2A	0.88	5.48	0.34	1.12e-7	LDL cholesterol;
SARC	cis	rs6448317	0.539	rs11931422	chr4:24936925	T/C	cg21108841	chr4:24914750	CCDC149	-0.59	-7.22	-0.43	7.53e-12	Heschl's gyrus morphology;
SARC	cis	rs4253772	0.550	rs6008598	chr22:46704243	C/T	cg24881330	chr22:46731750	TRMU	0.68	5.74	0.35	2.96e-8	LDL cholesterol;Cholesterol, total;
SARC	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	10.08	0.55	4.63e-20	Platelet count;
SARC	cis	rs965604	1.000	rs1062980	chr15:78792527	T/C	cg24631222	chr15:78858424	CHRNA5	0.49	6.2	0.38	2.55e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs11190604	1.000	rs7079756	chr10:102302105	G/A	cg07080220	chr10:102295463	HIF1AN	0.82	9.59	0.53	1.44e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs6429082	0.846	rs2270538	chr1:235602404	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.65	-8.45	-0.48	3.22e-15	Adiposity;
SARC	cis	rs8180040	1.000	rs807931	chr3:47389317	C/T	cg27129171	chr3:47204927	SETD2	0.69	9.76	0.54	4.4e-19	Colorectal cancer;
SARC	cis	rs11711311	1.000	rs9828449	chr3:113518602	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	8.69	0.49	6.43e-16	IgG glycosylation;
SARC	cis	rs10463316	0.894	rs954339	chr5:150752161	C/A	cg03212797	chr5:150827313	SLC36A1	-0.46	-5.47	-0.34	1.16e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs9916302	0.904	rs2061342	chr17:37405657	T/G	cg07936489	chr17:37558343	FBXL20	-0.66	-8.73	-0.5	4.85e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs708547	0.874	rs1630798	chr4:57883558	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.68	8.04	0.47	4.65e-14	Response to bleomycin (chromatid breaks);
SARC	cis	rs732765	1.000	rs3742785	chr14:75373034	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.45	-5.25	-0.33	3.45e-7	Non-small cell lung cancer;
SARC	cis	rs2075371	1.000	rs2598294	chr7:133991690	C/T	cg20476274	chr7:133979776	SLC35B4	0.62	8.41	0.48	4.18e-15	Mean platelet volume;
SARC	trans	rs8081395	0.741	rs1292056	chr17:57959047	C/T	cg15604357	chr1:160386408	VANGL2	0.38	6.55	0.39	3.72e-10	White blood cell count;
SARC	cis	rs11651000	0.947	rs11657376	chr17:45835984	A/T	cg24803719	chr17:45855879	NA	-0.42	-5.31	-0.33	2.55e-7	IgG glycosylation;
SARC	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg12288994	chr5:1860383	NA	0.39	6.43	0.39	7e-10	Cardiovascular disease risk factors;
SARC	cis	rs28829049	0.731	rs7537573	chr1:19373605	C/T	cg13387374	chr1:19411106	UBR4	0.41	4.91	0.31	1.73e-6	QRS duration in Tripanosoma cruzi seropositivity;
SARC	cis	rs1662342	0.800	rs60336569	chr18:3279687	T/C	cg14211874	chr18:3262499	MYL12B	-0.69	-5.53	-0.34	8.41e-8	QRS duration;
SARC	cis	rs920590	0.684	rs7461774	chr8:19666645	G/A	cg17834443	chr8:19674713	INTS10	0.63	7.51	0.44	1.27e-12	Acute lymphoblastic leukemia (childhood);
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg20646490	chr19:45971291	FOSB	0.49	6.3	0.38	1.46e-9	Electrocardiographic conduction measures;
SARC	cis	rs72949976	0.584	rs12471432	chr2:214022893	A/T	cg08319019	chr2:214017104	IKZF2	0.48	6.52	0.39	4.34e-10	Lung cancer;Squamous cell lung carcinoma;
SARC	cis	rs12142240	0.698	rs17357621	chr1:46807697	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-5.45	-0.34	1.28e-7	Menopause (age at onset);
SARC	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg13206674	chr6:150067644	NUP43	0.41	5.37	0.33	1.95e-7	Lung cancer;
SARC	cis	rs2239547	0.521	rs9682464	chr3:52888485	C/T	cg18404041	chr3:52824283	ITIH1	-0.41	-5.07	-0.32	7.92e-7	Schizophrenia;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg23012288	chr2:132250142	FAM128A;LOC150776	0.56	6.37	0.39	1e-9	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg13939156	chr17:80058883	NA	0.36	5.68	0.35	3.95e-8	Life satisfaction;
SARC	cis	rs72772090	0.539	rs111886458	chr5:96125047	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.6	-4.78	-0.3	3.1e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg09508770	chr1:107684255	NTNG1	-0.79	-6.86	-0.41	6.04e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs910316	0.875	rs12588099	chr14:75594462	A/T	cg08847533	chr14:75593920	NEK9	0.91	15.37	0.71	2.83e-37	Height;
SARC	cis	rs9612	1.000	rs7246677	chr19:44248625	G/A	cg07522664	chr19:44259120	C19orf61	0.47	5.43	0.34	1.4e-7	Exhaled nitric oxide output;
SARC	cis	rs11166927	0.594	rs7828992	chr8:140826670	A/G	cg16909799	chr8:140841666	TRAPPC9	-0.41	-5.51	-0.34	9.71e-8	Pediatric non-alcoholic fatty liver disease activity score;
SARC	cis	rs35110281	0.774	rs2838327	chr21:45018566	A/C	cg21573476	chr21:45109991	RRP1B	-0.49	-7.35	-0.43	3.33e-12	Mean corpuscular volume;
SARC	cis	rs16976116	0.704	rs7183895	chr15:55513712	G/A	cg17854078	chr15:55489399	RSL24D1	0.55	5.61	0.34	5.72e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs73635312	0.850	rs74623270	chr10:8995292	G/A	cg24467326	chr10:9646929	NA	0.6	5.13	0.32	6.05e-7	Basal cell carcinoma;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg11430659	chr2:201374471	KCTD18	-0.59	-6.56	-0.39	3.35e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg26335602	chr6:28129616	ZNF389	0.53	5.91	0.36	1.2e-8	Depression;
SARC	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg16434002	chr17:42200994	HDAC5	-0.43	-5.42	-0.33	1.52e-7	Total body bone mineral density;
SARC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.63	-6.82	-0.41	7.62e-11	Platelet count;
SARC	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg05234568	chr11:5960015	NA	0.38	5.32	0.33	2.45e-7	DNA methylation (variation);
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg18370979	chr5:93411837	FAM172A	-0.55	-6.67	-0.4	1.82e-10	Alcohol dependence;
SARC	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg19500275	chr17:80737654	TBCD	0.42	4.82	0.3	2.6e-6	Glycated hemoglobin levels;
SARC	cis	rs11098499	0.954	rs12508504	chr4:120410607	A/C	cg09160332	chr4:120329925	NA	-0.33	-4.78	-0.3	3.16e-6	Corneal astigmatism;
SARC	cis	rs9479482	0.967	rs763574	chr6:150349415	G/C	cg03788504	chr6:150331562	NA	-0.33	-5.45	-0.34	1.29e-7	Alopecia areata;
SARC	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg06808227	chr14:105710500	BRF1	-0.52	-6.62	-0.4	2.46e-10	Mean platelet volume;Platelet distribution width;
SARC	cis	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg14019146	chr3:50243930	SLC38A3	-0.32	-5.0	-0.31	1.13e-6	Intelligence (multi-trait analysis);
SARC	cis	rs10752881	1.000	rs8179282	chr1:182974598	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.76	0.58	3.38e-22	Colorectal cancer;
SARC	cis	rs7712401	0.601	rs246285	chr5:122244968	C/G	cg19412675	chr5:122181750	SNX24	-0.38	-4.86	-0.3	2.16e-6	Mean platelet volume;
SARC	trans	rs9325144	0.555	rs4882358	chr12:38726640	A/G	cg23762105	chr12:34175262	ALG10	-0.55	-7.18	-0.43	9.03e-12	Morning vs. evening chronotype;
SARC	trans	rs1814175	0.817	rs2866863	chr11:49953242	C/T	cg03929089	chr4:120376271	NA	-0.89	-14.59	-0.69	1.1e-34	Height;
SARC	cis	rs7659604	1.000	rs35901586	chr4:122664757	T/A	cg20573242	chr4:122745356	CCNA2	0.44	5.82	0.36	1.99e-8	Type 2 diabetes;
SARC	cis	rs7937682	0.632	rs7128862	chr11:111755435	C/T	cg22437258	chr11:111473054	SIK2	-0.47	-5.4	-0.33	1.61e-7	Primary sclerosing cholangitis;
SARC	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	11.63	0.61	5.84e-25	Alzheimer's disease;
SARC	cis	rs2080454	0.895	rs2908875	chr16:49089422	C/T	cg07494500	chr16:49889639	NA	-0.39	-4.83	-0.3	2.43e-6	Body mass index;
SARC	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg04944784	chr2:26401820	FAM59B	-0.48	-6.04	-0.37	6.05e-9	Gut microbiome composition (summer);
SARC	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-5.55	-0.34	7.71e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs4819052	0.679	rs8132135	chr21:46694782	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	6.51	0.39	4.47e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs3820928	0.874	rs1917123	chr2:227889783	T/G	cg05526886	chr2:227700861	RHBDD1	-0.47	-5.42	-0.33	1.52e-7	Pulmonary function;
SARC	cis	rs8180040	0.620	rs9845728	chr3:47103376	C/T	cg27129171	chr3:47204927	SETD2	0.7	9.56	0.53	1.79e-18	Colorectal cancer;
SARC	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg00825309	chr19:58991885	ZNF446	0.58	8.15	0.47	2.23e-14	Uric acid clearance;
SARC	trans	rs61931739	0.534	rs11053049	chr12:34164537	T/C	cg26384229	chr12:38710491	ALG10B	0.85	12.35	0.63	2.69e-27	Morning vs. evening chronotype;
SARC	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg05863683	chr7:1912471	MAD1L1	0.34	5.09	0.32	7.21e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs6598955	1.000	rs10902728	chr1:26598281	T/C	cg04990556	chr1:26633338	UBXN11	0.65	7.92	0.46	9.96e-14	Obesity-related traits;
SARC	cis	rs10927875	0.632	rs6699394	chr1:16145143	C/A	cg07117364	chr1:16154769	NA	-0.45	-5.35	-0.33	2.1e-7	Dilated cardiomyopathy;
SARC	trans	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg21659725	chr3:3221576	CRBN	0.52	6.71	0.4	1.46e-10	Intelligence (multi-trait analysis);
SARC	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg05444541	chr17:17804740	TOM1L2	0.31	5.09	0.32	7.55e-7	Total body bone mineral density;
SARC	cis	rs3857067	0.806	rs4693001	chr4:95115097	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.05	-0.31	8.98e-7	QT interval;
SARC	cis	rs12421382	0.881	rs1808843	chr11:109389471	A/G	cg16359550	chr11:109292809	C11orf87	0.44	6.25	0.38	1.93e-9	Schizophrenia;
SARC	cis	rs9860428	0.565	rs7646439	chr3:112580237	T/C	cg17974142	chr3:113464438	ATP6V1A;NAA50	-0.38	-4.76	-0.3	3.43e-6	Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);Rheumatoid arthritis;
SARC	cis	rs8114671	0.562	rs2223881	chr20:33506463	A/C	cg07148914	chr20:33460835	GGT7	0.44	5.39	0.33	1.69e-7	Height;
SARC	cis	rs12347191	0.500	rs907578	chr9:100622883	A/G	cg13688889	chr9:100608707	NA	-0.48	-5.01	-0.31	1.08e-6	Orofacial clefts;
SARC	cis	rs1707322	1.000	rs6682683	chr1:46342337	A/G	cg03146154	chr1:46216737	IPP	0.48	5.74	0.35	2.92e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg15145296	chr3:125709740	NA	-0.48	-4.86	-0.3	2.19e-6	Blood pressure (smoking interaction);
SARC	cis	rs16976116	0.951	rs12385963	chr15:55482851	A/G	cg17854078	chr15:55489399	RSL24D1	0.66	6.52	0.39	4.27e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4820539	1.000	rs885963	chr22:23460939	G/T	cg14186256	chr22:23484241	RTDR1	0.89	14.17	0.68	2.83e-33	Bone mineral density;
SARC	trans	rs9650657	0.737	rs2116095	chr8:10635297	T/C	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.34	-0.38	1.16e-9	Neuroticism;
SARC	cis	rs3126085	0.935	rs1496050	chr1:152163549	T/C	cg09127314	chr1:152161683	NA	0.42	4.79	0.3	3.03e-6	Atopic dermatitis;
SARC	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg05793240	chr7:2802953	GNA12	-0.36	-5.23	-0.32	3.8e-7	Height;
SARC	cis	rs11997175	0.646	rs4733180	chr8:33700520	C/T	ch.8.33884649F	chr8:33765107	NA	0.63	8.6	0.49	1.21e-15	Body mass index;
SARC	cis	rs950027	0.549	rs1719250	chr15:45609773	A/G	cg21132104	chr15:45694354	SPATA5L1	0.57	7.32	0.43	3.94e-12	Response to fenofibrate (adiponectin levels);
SARC	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg15052019	chr19:19431593	KIAA0892;SF4	-0.38	-4.71	-0.3	4.2e-6	Tonsillectomy;
SARC	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg18876405	chr7:65276391	NA	-0.46	-5.51	-0.34	9.4e-8	Aortic root size;
SARC	cis	rs7312774	0.618	rs4964518	chr12:107466217	C/T	cg16260113	chr12:107380972	MTERFD3	0.82	6.27	0.38	1.69e-9	Severe influenza A (H1N1) infection;
SARC	cis	rs9393692	0.620	rs9393697	chr6:26293841	C/T	cg13736514	chr6:26305472	NA	-0.4	-4.86	-0.3	2.15e-6	Educational attainment;
SARC	cis	rs13314892	0.728	rs62251025	chr3:69862189	A/G	cg17445875	chr3:69859618	MITF	-0.49	-5.1	-0.32	6.98e-7	QRS complex (12-leadsum);
SARC	cis	rs7772486	0.743	rs9390344	chr6:146012755	C/G	cg05347473	chr6:146136440	FBXO30	-0.51	-6.89	-0.41	5.28e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7786877	0.680	rs28584500	chr7:100216341	G/A	cg20848291	chr7:100343083	ZAN	-0.63	-5.84	-0.36	1.75e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs6088580	0.524	rs2889855	chr20:33276853	A/G	cg24642439	chr20:33292090	TP53INP2	-0.53	-6.56	-0.39	3.5e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs72781680	0.898	rs72788214	chr2:24087621	A/C	cg06627628	chr2:24431161	ITSN2	-0.65	-6.37	-0.39	9.72e-10	Lymphocyte counts;
SARC	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg04317338	chr11:64019027	PLCB3	0.81	8.77	0.5	3.82e-16	Mean platelet volume;
SARC	cis	rs10162002	1.000	rs17078796	chr13:24043830	A/G	cg00158254	chr13:24040743	NA	-0.55	-5.53	-0.34	8.63e-8	Hypothyroidism;
SARC	cis	rs554111	0.574	rs4060971	chr1:21506930	C/T	cg08890418	chr1:21044141	KIF17	0.36	5.03	0.31	9.77e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg25894440	chr7:65020034	NA	-0.73	-5.54	-0.34	8.11e-8	Diabetic kidney disease;
SARC	cis	rs748404	0.586	rs2584700	chr15:43685332	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	5.57	0.34	6.83e-8	Lung cancer;
SARC	cis	rs5167	0.534	rs56803710	chr19:45481884	C/T	cg09555818	chr19:45449301	APOC2	0.39	5.17	0.32	5.11e-7	Blood protein levels;
SARC	cis	rs763121	0.819	rs5750658	chr22:39060917	C/T	cg14440974	chr22:39074834	NA	-0.34	-4.89	-0.3	1.9e-6	Menopause (age at onset);
SARC	cis	rs2153535	0.580	rs6929206	chr6:8447961	A/G	cg21535247	chr6:8435926	SLC35B3	0.56	6.93	0.41	4.07e-11	Motion sickness;
SARC	cis	rs7914558	1.000	rs6584540	chr10:104927634	A/G	cg04362960	chr10:104952993	NT5C2	0.43	5.19	0.32	4.51e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	trans	rs1478897	0.804	rs9329246	chr8:11392880	A/G	cg08975724	chr8:8085496	FLJ10661	0.51	6.59	0.4	2.84e-10	Systemic lupus erythematosus;
SARC	cis	rs12079745	1.000	rs11810815	chr1:169329790	T/C	cg09363564	chr1:169337483	NME7;BLZF1	-0.96	-5.76	-0.35	2.64e-8	QT interval;
SARC	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.98	11.32	0.6	5.83e-24	Platelet count;
SARC	cis	rs10779751	0.734	rs7533211	chr1:11132965	G/C	cg08854313	chr1:11322531	MTOR	0.85	11.94	0.62	6.12e-26	Body mass index;
SARC	cis	rs10463554	1.000	rs12659870	chr5:102336571	T/C	cg23492399	chr5:102201601	PAM	-0.47	-5.46	-0.34	1.2e-7	Parkinson's disease;
SARC	cis	rs12682352	0.579	rs7006589	chr8:8668486	A/G	cg08975724	chr8:8085496	FLJ10661	0.45	5.64	0.35	4.94e-8	Neuroticism;
SARC	cis	rs2153535	0.560	rs9379214	chr6:8480870	T/C	cg07606381	chr6:8435919	SLC35B3	0.79	11.16	0.59	1.88e-23	Motion sickness;
SARC	cis	rs9916302	0.904	rs1077715	chr17:37683548	A/T	cg00129232	chr17:37814104	STARD3	-0.65	-8.0	-0.46	5.76e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs7565124	0.909	rs6747473	chr2:20252008	C/G	cg23821541	chr2:20251993	LAPTM4A	0.49	4.74	0.3	3.73e-6	Major depressive disorder;
SARC	cis	rs950776	0.518	rs12910100	chr15:78822667	C/T	cg06917634	chr15:78832804	PSMA4	0.91	14.24	0.68	1.6e-33	Sudden cardiac arrest;
SARC	trans	rs523340	0.605	rs3780512	chr9:111654395	C/T	cg15396299	chr8:123793789	ZHX2	-0.81	-6.24	-0.38	2e-9	Information processing speed;
SARC	cis	rs2290159	1.000	rs2290159	chr3:12628920	G/C	cg23032965	chr3:12705835	RAF1	0.73	7.69	0.45	4.15e-13	Cholesterol, total;
SARC	cis	rs2153535	0.601	rs718504	chr6:8527512	A/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.19	0.47	1.75e-14	Motion sickness;
SARC	cis	rs561341	0.941	rs2428341	chr17:30317295	C/T	cg00745463	chr17:30367425	LRRC37B	-0.56	-4.75	-0.3	3.61e-6	Hip circumference adjusted for BMI;
SARC	cis	rs932287	0.505	rs2742536	chr11:8909816	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.46	-6.55	-0.39	3.57e-10	Colonoscopy-negative controls vs population controls;
SARC	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg16479474	chr6:28041457	NA	0.37	5.47	0.34	1.17e-7	Depression;
SARC	trans	rs7824557	0.527	rs2572376	chr8:11237756	C/A	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.44	-0.39	6.68e-10	Retinal vascular caliber;
SARC	cis	rs7555523	0.887	rs10800155	chr1:165723770	A/G	cg24409356	chr1:165738333	TMCO1	0.74	6.29	0.38	1.56e-9	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg17221315	chr6:27791827	HIST1H4J	0.48	5.02	0.31	1.03e-6	Parkinson's disease;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg15123010	chr7:79134707	NA	0.48	6.38	0.39	9.56e-10	Thyroid stimulating hormone;
SARC	trans	rs1853207	1.000	rs78609324	chr10:96603745	T/C	cg02737782	chr1:8014393	NA	-0.95	-6.37	-0.39	1.01e-9	Blood metabolite levels;
SARC	cis	rs3857536	0.813	rs7757118	chr6:66946661	T/C	cg07460842	chr6:66804631	NA	-0.45	-5.19	-0.32	4.5e-7	Blood trace element (Cu levels);
SARC	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.75	7.36	0.43	3.08e-12	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.48	5.56	0.34	7.48e-8	Renal function-related traits (BUN);
SARC	trans	rs1814175	0.645	rs10839448	chr11:49938930	G/A	cg03929089	chr4:120376271	NA	-0.82	-11.67	-0.61	4.51e-25	Height;
SARC	cis	rs3020736	0.500	rs11090076	chr22:42514190	T/C	cg04733989	chr22:42467013	NAGA	-0.76	-10.6	-0.57	1.15e-21	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg07701084	chr6:150067640	NUP43	0.43	5.5	0.34	9.92e-8	Lung cancer;
SARC	cis	rs72781680	0.611	rs72783605	chr2:24287864	A/G	cg06627628	chr2:24431161	ITSN2	-0.57	-6.02	-0.37	6.7e-9	Lymphocyte counts;
SARC	cis	rs965469	1.000	rs2236098	chr20:3267133	A/G	cg25506879	chr20:3388711	C20orf194	-0.47	-4.76	-0.3	3.42e-6	IFN-related cytopenia;
SARC	cis	rs6121246	0.529	rs7261354	chr20:30202414	T/C	cg13852791	chr20:30311386	BCL2L1	0.64	5.62	0.35	5.35e-8	Mean corpuscular hemoglobin;
SARC	cis	rs365132	0.875	rs2962844	chr5:176333748	G/T	cg16309518	chr5:176445507	NA	-0.45	-5.89	-0.36	1.33e-8	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs7246657	0.943	rs4801803	chr19:37966923	A/G	cg18154014	chr19:37997991	ZNF793	-0.43	-4.72	-0.3	4.13e-6	Coronary artery calcification;
SARC	cis	rs986417	0.748	rs1955691	chr14:61004128	G/A	cg27398547	chr14:60952738	C14orf39	0.96	8.75	0.5	4.38e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs10911232	0.507	rs4652763	chr1:182994084	A/G	cg13390022	chr1:182993471	LAMC1	0.33	4.97	0.31	1.31e-6	Hypertriglyceridemia;
SARC	cis	rs4926611	0.698	rs35227000	chr1:54060016	G/C	cg08927728	chr1:54059983	GLIS1	0.3	5.02	0.31	1.03e-6	Hand grip strength;
SARC	cis	rs7084402	0.934	rs1658428	chr10:60330917	T/C	cg07615347	chr10:60278583	BICC1	0.57	8.42	0.48	3.91e-15	Refractive error;
SARC	cis	rs651907	0.514	rs12636046	chr3:101434448	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	6.19	0.38	2.71e-9	Colorectal cancer;
SARC	cis	rs67133203	0.632	rs829022	chr12:51374748	G/T	cg13576200	chr12:52111417	SCN8A	0.33	4.91	0.31	1.71e-6	Urinary tract infection frequency;
SARC	cis	rs6815814	0.950	rs5743593	chr4:38802913	A/G	cg02016764	chr4:38805732	TLR1	-0.4	-4.82	-0.3	2.64e-6	Breast cancer;
SARC	cis	rs7766436	0.767	rs13215709	chr6:22604121	A/G	cg13666174	chr6:22585274	NA	-0.51	-7.07	-0.42	1.8e-11	Coronary artery disease;
SARC	cis	rs7914558	0.966	rs10748837	chr10:104880236	T/C	cg04362960	chr10:104952993	NT5C2	0.43	5.22	0.32	4.04e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs55871839	0.684	rs13271523	chr8:59806664	T/C	cg07426533	chr8:59803705	TOX	-0.45	-5.97	-0.36	8.58e-9	Pneumonia;
SARC	cis	rs11785693	0.862	rs11786595	chr8:5001621	T/G	cg26367366	chr8:4980734	NA	0.6	5.4	0.33	1.64e-7	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs2072499	0.966	rs2842857	chr1:156168736	T/C	cg25208724	chr1:156163844	SLC25A44	0.93	12.89	0.65	4.85e-29	Testicular germ cell tumor;
SARC	cis	rs981844	0.890	rs62325113	chr4:154692555	A/G	cg14289246	chr4:154710475	SFRP2	0.64	7.11	0.42	1.4e-11	Response to statins (LDL cholesterol change);
SARC	cis	rs7584330	0.780	rs12474519	chr2:238377012	G/A	cg14458575	chr2:238380390	NA	0.42	5.12	0.32	6.27e-7	Prostate cancer;
SARC	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg04234412	chr22:24373322	LOC391322	-0.72	-9.99	-0.55	8.85e-20	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.0	-17.61	-0.76	1.08e-44	Chronic sinus infection;
SARC	cis	rs2180341	0.618	rs11154398	chr6:127654281	C/A	cg27446573	chr6:127587934	RNF146	0.68	8.87	0.5	1.93e-16	Breast cancer;
SARC	cis	rs35213789	0.762	rs627981	chr7:69163761	A/G	cg10619644	chr7:69149951	AUTS2	-0.36	-4.95	-0.31	1.44e-6	Childhood ear infection;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg26647219	chr3:149376215	WWTR1	0.51	6.33	0.38	1.27e-9	Breast cancer;
SARC	cis	rs11785400	0.793	rs4567014	chr8:143737690	G/C	cg10596483	chr8:143751796	JRK	0.55	7.01	0.42	2.59e-11	Schizophrenia;
SARC	cis	rs2120243	0.533	rs1500921	chr3:157055427	C/T	cg24825693	chr3:157122686	VEPH1	-0.4	-5.65	-0.35	4.71e-8	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs910316	0.737	rs175055	chr14:75488946	T/G	cg08847533	chr14:75593920	NEK9	-0.82	-11.68	-0.61	4.18e-25	Height;
SARC	cis	rs2153535	0.580	rs1119691	chr6:8460452	C/T	cg21535247	chr6:8435926	SLC35B3	0.52	6.51	0.39	4.55e-10	Motion sickness;
SARC	cis	rs3126085	0.935	rs11204981	chr1:152298212	C/T	cg03465714	chr1:152285911	FLG	0.48	5.57	0.34	6.9e-8	Atopic dermatitis;
SARC	cis	rs9807989	0.507	rs7584093	chr2:102997721	C/T	cg03938978	chr2:103052716	IL18RAP	0.32	5.12	0.32	6.26e-7	Asthma;
SARC	trans	rs62103177	0.733	rs62096747	chr18:77619568	A/G	cg05926928	chr17:57297772	GDPD1	1.08	9.29	0.52	1.12e-17	Opioid sensitivity;
SARC	cis	rs4555082	0.834	rs2816631	chr14:105739477	G/A	cg10792982	chr14:105748885	BRF1	0.54	8.03	0.47	4.87e-14	Mean platelet volume;Platelet distribution width;
SARC	cis	rs9300255	0.679	rs10772998	chr12:123721177	T/G	cg05973401	chr12:123451056	ABCB9	0.47	5.18	0.32	4.77e-7	Neutrophil percentage of white cells;
SARC	cis	rs4819052	0.679	rs2838859	chr21:46684517	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.61	7.66	0.45	5.07e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs36051895	0.659	rs62541540	chr9:5040080	A/G	cg02405213	chr9:5042618	JAK2	-0.54	-6.0	-0.37	7.57e-9	Pediatric autoimmune diseases;
SARC	cis	rs7520050	0.778	rs3014216	chr1:46035760	A/T	cg24296786	chr1:45957014	TESK2	-0.47	-6.03	-0.37	6.52e-9	Red blood cell count;Reticulocyte count;
SARC	cis	rs9814567	0.896	rs4245907	chr3:134347876	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.5	-6.4	-0.39	8.24e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10465746	0.570	rs1886769	chr1:84471134	C/A	cg04407776	chr1:84465009	TTLL7	-0.4	-4.74	-0.3	3.69e-6	Obesity-related traits;
SARC	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg04518342	chr5:131593106	PDLIM4	0.37	5.19	0.32	4.58e-7	Breast cancer;
SARC	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg18404041	chr3:52824283	ITIH1	-0.44	-6.66	-0.4	1.97e-10	Bipolar disorder;
SARC	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg24209194	chr3:40518798	ZNF619	0.67	8.39	0.48	4.77e-15	Renal cell carcinoma;
SARC	cis	rs7772486	0.790	rs4435956	chr6:146232403	G/C	cg23711669	chr6:146136114	FBXO30	-0.79	-12.49	-0.63	9.48e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9583531	0.509	rs12184676	chr13:111396484	A/G	cg15841412	chr13:111365552	ING1	-0.57	-5.19	-0.32	4.58e-7	Coronary artery disease;
SARC	cis	rs2531992	0.858	rs2230742	chr16:4016676	C/T	cg05927578	chr16:4029543	ADCY9	-0.42	-4.98	-0.31	1.27e-6	Waist circumference;
SARC	cis	rs7949030	0.596	rs11231138	chr11:62316195	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.52	7.72	0.45	3.37e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	trans	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg21659725	chr3:3221576	CRBN	0.52	6.72	0.4	1.39e-10	Intelligence (multi-trait analysis);
SARC	cis	rs72781680	1.000	rs72798418	chr2:24188922	A/G	cg08917208	chr2:24149416	ATAD2B	0.79	7.55	0.44	9.78e-13	Lymphocyte counts;
SARC	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg02725872	chr8:58115012	NA	-0.37	-6.55	-0.39	3.71e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs965469	0.779	rs6051693	chr20:3244449	T/G	cg25506879	chr20:3388711	C20orf194	-0.47	-4.94	-0.31	1.49e-6	IFN-related cytopenia;
SARC	cis	rs10791097	0.690	rs12284487	chr11:130729705	T/C	cg12179176	chr11:130786555	SNX19	0.65	9.14	0.51	3.26e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs67478160	0.634	rs1955660	chr14:104229985	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.35	-4.88	-0.3	1.97e-6	Schizophrenia;
SARC	cis	rs1003719	0.591	rs1053984	chr21:38574018	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.56	-7.65	-0.45	5.18e-13	Eye color traits;
SARC	trans	rs11722228	0.549	rs73212863	chr4:10104173	C/T	cg26043149	chr18:55253948	FECH	0.7	8.09	0.47	3.38e-14	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs3761847	0.593	rs10985140	chr9:123822837	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.41	5.13	0.32	6e-7	Rheumatoid arthritis;
SARC	cis	rs2153535	0.580	rs4365970	chr6:8453813	C/T	cg21535247	chr6:8435926	SLC35B3	-0.56	-6.96	-0.41	3.42e-11	Motion sickness;
SARC	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg11766577	chr21:47581405	C21orf56	0.43	5.03	0.31	9.88e-7	Testicular germ cell tumor;
SARC	cis	rs7644634	0.661	rs2083758	chr3:105478162	A/G	cg23051926	chr3:105466016	CBLB	0.46	5.71	0.35	3.39e-8	Itch intensity from mosquito bite;
SARC	cis	rs7020830	0.898	rs7846747	chr9:37167539	A/C	cg14294708	chr9:37120828	ZCCHC7	1.12	20.73	0.81	8.56e-55	Schizophrenia;
SARC	cis	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg07777115	chr5:623756	CEP72	-0.62	-5.57	-0.34	6.94e-8	Obesity-related traits;
SARC	cis	rs2153535	0.580	rs3938660	chr6:8443335	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg08219700	chr8:58056026	NA	0.58	6.19	0.38	2.71e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9788682	0.948	rs34664138	chr15:78831624	T/G	cg06917634	chr15:78832804	PSMA4	-0.58	-6.52	-0.39	4.36e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs611744	0.967	rs673015	chr8:109191669	C/T	cg21045802	chr8:109455806	TTC35	0.49	6.08	0.37	4.81e-9	Dupuytren's disease;
SARC	cis	rs1318878	0.565	rs11056449	chr12:15512617	C/T	cg08258403	chr12:15378311	NA	0.48	6.67	0.4	1.87e-10	Intelligence (multi-trait analysis);
SARC	cis	rs9677476	0.657	rs13418346	chr2:232132374	A/G	cg23338755	chr2:231921595	PSMD1	-0.4	-5.06	-0.31	8.38e-7	Food antigen IgG levels;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg14339287	chr19:14640339	TECR;MIR639	0.48	6.43	0.39	7.04e-10	Tetralogy of Fallot;
SARC	cis	rs2361718	0.631	rs12601637	chr17:78142455	T/C	cg06718696	chr17:78121285	EIF4A3	0.42	4.73	0.3	3.96e-6	Yeast infection;
SARC	cis	rs7395581	0.959	rs59663860	chr11:47276350	G/C	cg25783544	chr11:47291846	MADD	0.48	5.02	0.31	1.02e-6	HDL cholesterol;
SARC	cis	rs13191362	0.872	rs13194619	chr6:163203657	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.64	5.64	0.35	4.94e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-5.45	-0.34	1.28e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg08219700	chr8:58056026	NA	0.6	5.71	0.35	3.49e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6912958	0.703	rs9359748	chr6:88095500	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.76	11.56	0.6	9.79e-25	Monocyte percentage of white cells;
SARC	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg21442419	chr1:2182373	SKI	-0.4	-5.09	-0.32	7.39e-7	Height;
SARC	cis	rs73206853	0.841	rs73191834	chr12:110963841	T/G	cg10860002	chr12:110842031	ANAPC7	0.6	4.86	0.3	2.19e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs4727027	0.933	rs7788925	chr7:148831621	A/G	cg23583168	chr7:148888333	NA	-0.74	-11.01	-0.59	5.64e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs12754538	0.850	rs7545384	chr1:8580960	C/A	cg13785123	chr1:8931135	ENO1	-0.46	-5.15	-0.32	5.48e-7	Subjective well-being;
SARC	cis	rs7647973	1.000	rs3870341	chr3:49584745	A/G	cg06212747	chr3:49208901	KLHDC8B	0.58	6.05	0.37	5.83e-9	Menarche (age at onset);
SARC	cis	rs7959452	0.530	rs12811632	chr12:69755003	G/A	cg22834771	chr12:69754056	YEATS4	-0.45	-5.94	-0.36	1.01e-8	Blood protein levels;
SARC	cis	rs80282103	0.571	rs56183119	chr10:1068370	C/T	cg08668510	chr10:1095578	IDI1	0.83	5.88	0.36	1.38e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg20007245	chr22:24372913	LOC391322	-0.82	-11.59	-0.6	8.1e-25	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6484504	0.576	rs11031324	chr11:31250299	T/C	cg26647111	chr11:31128758	NA	-0.4	-5.15	-0.32	5.56e-7	Red blood cell count;
SARC	cis	rs2276314	0.857	rs28379448	chr18:33604364	C/A	cg19628046	chr18:33552617	C18orf21	0.62	6.36	0.38	1.03e-9	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs240764	0.817	rs151573	chr6:101086333	T/C	cg09795085	chr6:101329169	ASCC3	0.46	6.01	0.37	6.98e-9	Neuroticism;
SARC	cis	rs4253772	0.550	rs9615951	chr22:46728056	C/A	cg23346237	chr22:46685655	TTC38	0.39	4.8	0.3	2.79e-6	LDL cholesterol;Cholesterol, total;
SARC	cis	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg07636037	chr3:49044803	WDR6	0.63	8.36	0.48	5.59e-15	Resting heart rate;
SARC	cis	rs76917914	0.820	rs55978131	chr9:100813404	G/A	cg03040243	chr9:100819229	NANS	0.72	7.89	0.46	1.21e-13	Immature fraction of reticulocytes;
SARC	cis	rs17376456	0.877	rs10213956	chr5:93460839	C/T	cg21475434	chr5:93447410	FAM172A	0.86	7.77	0.45	2.57e-13	Diabetic retinopathy;
SARC	cis	rs10140922	0.966	rs10135277	chr14:35823231	A/G	cg26967526	chr14:35346199	BAZ1A	0.4	5.02	0.31	1.04e-6	Hip circumference adjusted for BMI;
SARC	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg13699009	chr12:122356056	WDR66	0.69	11.51	0.6	1.42e-24	Mean corpuscular volume;
SARC	cis	rs7412746	0.587	rs11204722	chr1:150730184	A/C	cg10589385	chr1:150898437	SETDB1	-0.41	-5.44	-0.34	1.32e-7	Melanoma;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg23773983	chr6:16761891	ATXN1	-0.5	-6.49	-0.39	5.08e-10	Electrocardiographic conduction measures;
SARC	cis	rs9868809	0.772	rs9841602	chr3:48713570	A/G	cg12468774	chr3:49236860	CCDC36	0.47	5.08	0.32	7.83e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	trans	rs6815916	1.000	rs62339530	chr4:182554779	A/G	cg13864546	chr1:2310327	MORN1	0.68	6.36	0.38	1.05e-9	Venous thromboembolism (SNP x SNP interaction);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg09058860	chr1:173837788	SNORD74;ZBTB37;GAS5	-0.46	-6.32	-0.38	1.34e-9	Chemerin levels;
SARC	cis	rs12367572	0.965	rs10785539	chr12:45233023	G/C	cg04608330	chr12:45269318	NELL2	-0.51	-6.41	-0.39	7.97e-10	Gut microbiome composition (summer);
SARC	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.39	0.44	2.66e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs698833	0.548	rs6544760	chr2:44553014	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.7	7.89	0.46	1.16e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg18876405	chr7:65276391	NA	0.68	8.2	0.47	1.59e-14	Aortic root size;
SARC	cis	rs2486288	0.656	rs11637920	chr15:45550905	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.45	-5.57	-0.34	7.07e-8	Glomerular filtration rate;
SARC	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg09699651	chr6:150184138	LRP11	0.51	6.28	0.38	1.68e-9	Testicular germ cell tumor;
SARC	cis	rs4713118	0.824	rs2179095	chr6:27750858	A/G	cg17221315	chr6:27791827	HIST1H4J	-0.46	-4.94	-0.31	1.46e-6	Parkinson's disease;
SARC	cis	rs7568458	0.870	rs1058588	chr2:85808871	A/G	cg02493740	chr2:85810744	VAMP5	0.34	5.01	0.31	1.1e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs10875746	0.669	rs9634261	chr12:48686871	A/G	cg26205652	chr12:48591994	NA	0.47	5.07	0.31	8.29e-7	Longevity (90 years and older);
SARC	cis	rs1267303	0.642	rs11588450	chr1:47000996	C/T	cg25110126	chr1:46999211	NA	-0.87	-9.7	-0.54	6.65e-19	Monobrow;
SARC	cis	rs858239	0.601	rs2141307	chr7:23191424	G/C	cg23682824	chr7:23144976	KLHL7	0.67	8.49	0.49	2.46e-15	Cerebrospinal fluid biomarker levels;
SARC	trans	rs1814175	0.669	rs12364577	chr11:49707361	A/C	cg03929089	chr4:120376271	NA	-0.73	-10.67	-0.57	6.8e-22	Height;
SARC	cis	rs7772486	0.701	rs11155438	chr6:145950112	C/G	cg23711669	chr6:146136114	FBXO30	0.88	15.07	0.7	2.69e-36	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12142240	0.698	rs1057533	chr1:46815836	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-5.39	-0.33	1.77e-7	Menopause (age at onset);
SARC	cis	rs1215050	0.791	rs11729826	chr4:98657190	G/T	cg05340658	chr4:99064831	C4orf37	-0.43	-5.67	-0.35	4.27e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs8141529	0.748	rs5762881	chr22:29289346	C/A	cg15103426	chr22:29168792	CCDC117	0.66	8.64	0.49	9.17e-16	Lymphocyte counts;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg15997635	chr19:6737431	GPR108	0.47	6.28	0.38	1.67e-9	Schizophrenia;
SARC	cis	rs6582630	0.638	rs12425379	chr12:38523705	G/A	cg14851346	chr12:38532713	NA	-0.47	-5.83	-0.36	1.82e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7246657	0.891	rs7257495	chr19:37823876	C/G	cg14683738	chr19:37701593	ZNF585B	0.51	4.94	0.31	1.52e-6	Coronary artery calcification;
SARC	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg16405210	chr4:1374714	KIAA1530	-0.51	-5.98	-0.36	8.24e-9	Obesity-related traits;
SARC	cis	rs16937	0.711	rs10751431	chr1:205128059	C/T	cg00857998	chr1:205179979	DSTYK	0.4	4.79	0.3	2.97e-6	Schizophrenia;
SARC	cis	rs1707322	0.963	rs11211229	chr1:46400517	A/C	cg03146154	chr1:46216737	IPP	0.46	5.53	0.34	8.66e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg08219700	chr8:58056026	NA	0.68	6.44	0.39	6.92e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6088590	0.561	rs6059926	chr20:33164804	C/T	cg08999081	chr20:33150536	PIGU	0.44	6.78	0.41	9.96e-11	Coronary artery disease;
SARC	cis	rs35110281	0.837	rs2838341	chr21:45076443	A/G	cg01579765	chr21:45077557	HSF2BP	-0.32	-5.43	-0.33	1.44e-7	Mean corpuscular volume;
SARC	cis	rs7772486	0.597	rs6912351	chr6:146264071	T/C	cg05347473	chr6:146136440	FBXO30	-0.73	-9.92	-0.54	1.43e-19	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10942707	chr12:75905227	KRR1	-0.54	-7.08	-0.42	1.72e-11	Smoking initiation;
SARC	cis	rs7223966	1.000	rs55674647	chr17:61794195	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.52	-5.33	-0.33	2.33e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9303401	0.659	rs12150264	chr17:56939927	G/A	cg25039879	chr17:56429692	SUPT4H1	0.62	5.77	0.35	2.46e-8	Cognitive test performance;
SARC	cis	rs1062177	0.855	rs62395861	chr5:151269270	A/G	cg00977110	chr5:151150581	G3BP1	0.51	4.98	0.31	1.22e-6	Preschool internalizing problems;
SARC	cis	rs9303401	0.573	rs35104446	chr17:57180234	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.98	10.26	0.56	1.25e-20	Cognitive test performance;
SARC	cis	rs908922	0.651	rs1988805	chr1:152531495	T/G	cg09873164	chr1:152488093	CRCT1	0.61	7.84	0.46	1.6e-13	Hair morphology;
SARC	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg13880726	chr7:1868755	MAD1L1	0.51	6.07	0.37	5.26e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs2191566	0.576	rs431509	chr19:44496070	A/G	cg20607764	chr19:44506953	ZNF230	0.43	4.9	0.31	1.83e-6	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9815354	1.000	rs9840532	chr3:41885697	A/G	cg03022575	chr3:42003672	ULK4	0.57	5.4	0.33	1.61e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs11623869	0.711	rs2403173	chr14:103909289	T/C	cg12935359	chr14:103987150	CKB	-0.41	-5.96	-0.36	9.33e-9	Bone mineral density;
SARC	cis	rs11902236	0.660	rs2116014	chr2:10110357	T/C	cg02698806	chr2:10522874	HPCAL1	0.3	4.72	0.3	4.09e-6	Prostate cancer;
SARC	trans	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg27034413	chr4:24586189	DHX15	0.45	6.27	0.38	1.71e-9	Immature fraction of reticulocytes;
SARC	cis	rs60871478	0.898	rs4725241	chr7:796883	C/T	cg19087971	chr7:751233	PRKAR1B	-0.44	-5.0	-0.31	1.11e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs1559088	0.842	rs12977993	chr19:33580453	T/A	cg27124370	chr19:33622961	WDR88	0.43	5.65	0.35	4.58e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	trans	rs1945213	0.694	rs34537090	chr11:55843285	G/C	cg15704280	chr7:45808275	SEPT13	0.64	6.76	0.4	1.11e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg22834771	chr12:69754056	YEATS4	-0.48	-6.33	-0.38	1.25e-9	Cerebrospinal fluid biomarker levels;
SARC	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs72781680	0.898	rs72786279	chr2:24063266	C/T	cg08917208	chr2:24149416	ATAD2B	0.78	7.43	0.44	2.09e-12	Lymphocyte counts;
SARC	cis	rs7647973	0.771	rs9865051	chr3:49166069	C/T	cg07636037	chr3:49044803	WDR6	0.81	8.64	0.49	9.35e-16	Menarche (age at onset);
SARC	cis	rs7103648	0.695	rs10838726	chr11:47568344	C/G	cg20307385	chr11:47447363	PSMC3	0.78	11.2	0.59	1.37e-23	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs4141404	0.757	rs5749272	chr22:31830351	C/T	cg02404636	chr22:31891804	SFI1	-0.5	-6.57	-0.4	3.22e-10	Paclitaxel-induced neuropathy;
SARC	cis	rs854765	0.547	rs4072739	chr17:17884660	G/A	cg04398451	chr17:18023971	MYO15A	-0.45	-6.22	-0.38	2.33e-9	Total body bone mineral density;
SARC	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg11644478	chr21:40555479	PSMG1	1.02	14.32	0.68	8.73e-34	Cognitive function;
SARC	cis	rs6088590	1.000	rs2236270	chr20:33523155	G/T	cg24642439	chr20:33292090	TP53INP2	0.78	10.52	0.57	1.91e-21	Coronary artery disease;
SARC	cis	rs1003719	0.788	rs4817845	chr21:38447132	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.67	9.98	0.55	9.49e-20	Eye color traits;
SARC	trans	rs11098499	0.863	rs6833334	chr4:120504227	C/T	cg25214090	chr10:38739885	LOC399744	0.57	7.25	0.43	6.27e-12	Corneal astigmatism;
SARC	cis	rs9435341	0.965	rs1762485	chr1:107625056	C/T	cg09367891	chr1:107599246	PRMT6	-0.73	-8.81	-0.5	2.86e-16	Facial morphology (factor 21, depth of nasal alae);
SARC	cis	rs3812831	0.695	rs423237	chr13:114930955	C/T	cg08824895	chr13:115047677	UPF3A	0.51	6.61	0.4	2.6200000000000003e-10	Schizophrenia;
SARC	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg11987759	chr7:65425863	GUSB	-0.5	-5.97	-0.36	8.76e-9	Aortic root size;
SARC	cis	rs6911965	0.606	rs59061545	chr6:24487993	C/T	cg20631270	chr6:24437470	GPLD1	0.51	4.82	0.3	2.59e-6	Hematological and biochemical traits;
SARC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg08677398	chr8:58056175	NA	0.44	5.27	0.33	3.14e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6912958	0.525	rs59322	chr6:88020521	C/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.77	11.1	0.59	3.01e-23	Monocyte percentage of white cells;
SARC	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-7.91	-0.46	1.01e-13	Chronic sinus infection;
SARC	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.27	-4.87	-0.3	2.02e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg23758822	chr17:41437982	NA	0.85	10.11	0.55	3.67e-20	Menopause (age at onset);
SARC	cis	rs9811216	0.917	rs3796145	chr3:169524862	A/C	cg14222479	chr3:169487675	ARPM1	0.44	5.09	0.32	7.53e-7	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg00149659	chr3:10157352	C3orf10	0.96	7.8	0.46	2.03e-13	Alzheimer's disease;
SARC	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-9.0	-0.51	8.32e-17	Alzheimer's disease;
SARC	cis	rs1865760	0.566	rs10807006	chr6:26048752	C/A	cg16482183	chr6:26056742	HIST1H1C	0.49	6.29	0.38	1.6e-9	Height;
SARC	cis	rs992157	0.710	rs56364928	chr2:219059058	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.64	8.94	0.51	1.22e-16	Colorectal cancer;
SARC	cis	rs3087591	0.708	rs3815154	chr17:29654974	G/A	cg24425628	chr17:29625626	OMG;NF1	0.42	5.39	0.33	1.74e-7	Hip circumference;
SARC	cis	rs9815354	0.951	rs9837273	chr3:41813104	T/C	cg03022575	chr3:42003672	ULK4	0.6	5.76	0.35	2.69e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.64	9.28	0.52	1.19e-17	Total body bone mineral density;
SARC	cis	rs7188697	0.646	rs7184114	chr16:58585369	C/A	cg21335942	chr16:58549945	SETD6	-0.44	-5.65	-0.35	4.66e-8	QT interval;
SARC	cis	rs898097	0.845	rs7213006	chr17:80899928	T/C	cg15369054	chr17:80825471	TBCD	-0.54	-8.24	-0.48	1.25e-14	Breast cancer;
SARC	cis	rs9902453	0.817	rs55974138	chr17:28215546	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	7.03	0.42	2.22e-11	Coffee consumption (cups per day);
SARC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg12419862	chr22:24373484	LOC391322	-0.9	-14.03	-0.68	8.04e-33	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs12142240	0.698	rs66516678	chr1:46810112	G/T	cg10495392	chr1:46806563	NSUN4	0.64	6.76	0.4	1.09e-10	Menopause (age at onset);
SARC	cis	rs72781680	1.000	rs12616250	chr2:24211550	T/C	cg08917208	chr2:24149416	ATAD2B	0.78	7.62	0.45	6.31e-13	Lymphocyte counts;
SARC	cis	rs6732160	0.564	rs7605716	chr2:73376250	G/A	cg01422370	chr2:73384389	NA	0.38	5.87	0.36	1.52e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7020830	0.858	rs13293465	chr9:37127678	C/T	cg14294708	chr9:37120828	ZCCHC7	1.16	20.66	0.8	1.37e-54	Schizophrenia;
SARC	cis	rs9815354	0.812	rs73077359	chr3:41850016	G/A	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg09373136	chr17:61933544	TCAM1	0.44	5.91	0.36	1.23e-8	Prudent dietary pattern;
SARC	cis	rs7084402	0.934	rs1649067	chr10:60305240	T/C	cg07615347	chr10:60278583	BICC1	0.59	8.61	0.49	1.12e-15	Refractive error;
SARC	cis	rs477692	0.569	rs10764887	chr10:131321719	A/T	cg16159175	chr10:131325350	MGMT	0.34	4.9	0.31	1.83e-6	Response to temozolomide;
SARC	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg18252515	chr7:66147081	NA	-1.3	-11.5	-0.6	1.59e-24	Diabetic kidney disease;
SARC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	20.33	0.8	1.57e-53	Prudent dietary pattern;
SARC	cis	rs11997175	0.655	rs7833512	chr8:33662884	C/T	ch.8.33884649F	chr8:33765107	NA	0.46	6.04	0.37	6e-9	Body mass index;
SARC	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg05863683	chr7:1912471	MAD1L1	0.38	5.69	0.35	3.73e-8	Bipolar disorder and schizophrenia;
SARC	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg12527284	chr5:75013342	C5orf37	-0.5	-6.35	-0.38	1.09e-9	Parental extreme longevity (95 years and older);
SARC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg23131131	chr22:24373011	LOC391322	-0.48	-5.13	-0.32	6.06e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6964587	0.934	rs6973792	chr7:91749798	C/A	cg17063962	chr7:91808500	NA	0.95	15.41	0.71	2.05e-37	Breast cancer;
SARC	cis	rs6674176	0.660	rs6680421	chr1:44408969	A/C	cg13606994	chr1:44402422	ARTN	0.34	5.49	0.34	1.05e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg16606324	chr3:10149918	C3orf24	0.48	5.04	0.31	9.53e-7	Alzheimer's disease;
SARC	cis	rs10992471	0.756	rs11792342	chr9:95143668	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-6.69	-0.4	1.67e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.98	-15.84	-0.72	7.78e-39	Chronic sinus infection;
SARC	cis	rs67311347	0.876	rs13068097	chr3:40504424	T/A	cg01475735	chr3:40494733	NA	0.5	5.75	0.35	2.79e-8	Renal cell carcinoma;
SARC	cis	rs644799	1.000	rs586238	chr11:95560371	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.68	8.98	0.51	9.2e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs11155671	0.530	rs7764376	chr6:150210344	A/G	cg09699651	chr6:150184138	LRP11	0.52	6.59	0.4	2.86e-10	Testicular germ cell tumor;
SARC	cis	rs7246657	0.550	rs10411176	chr19:37686953	G/T	cg23950597	chr19:37808831	NA	-0.56	-4.74	-0.3	3.79e-6	Coronary artery calcification;
SARC	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg18876405	chr7:65276391	NA	-0.51	-6.19	-0.38	2.74e-9	Aortic root size;
SARC	cis	rs3820928	0.874	rs4675130	chr2:227827740	G/T	cg11843606	chr2:227700838	RHBDD1	-0.55	-6.85	-0.41	6.37e-11	Pulmonary function;
SARC	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg17971929	chr21:40555470	PSMG1	-0.86	-11.06	-0.59	4e-23	Cognitive function;
SARC	trans	rs11098499	0.697	rs4373140	chr4:120307698	A/G	cg25214090	chr10:38739885	LOC399744	0.55	7.14	0.42	1.15e-11	Corneal astigmatism;
SARC	cis	rs950776	0.518	rs1979907	chr15:78842239	T/C	cg06917634	chr15:78832804	PSMA4	-0.9	-13.95	-0.67	1.44e-32	Sudden cardiac arrest;
SARC	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg02725872	chr8:58115012	NA	-0.34	-5.38	-0.33	1.78e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs11509153	0.648	rs1019306	chr7:12251826	C/T	cg23422036	chr7:12250390	TMEM106B	0.48	6.21	0.38	2.36e-9	Residual cognition;
SARC	cis	rs9818758	0.607	rs67060340	chr3:48915321	C/T	cg01304814	chr3:48885189	PRKAR2A	0.62	5.12	0.32	6.46e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs9457247	0.668	rs2236313	chr6:167360389	C/T	cg23791538	chr6:167370224	RNASET2	-0.41	-5.34	-0.33	2.18e-7	Crohn's disease;
SARC	cis	rs2444240	1.000	rs494965	chr11:120053650	C/T	cg16945685	chr11:120038821	NA	-0.27	-5.05	-0.31	8.76e-7	Corneal curvature;
SARC	cis	rs1949733	0.523	rs16842557	chr4:8543985	C/T	cg11789530	chr4:8429930	ACOX3	-0.7	-7.82	-0.46	1.81e-13	Response to antineoplastic agents;
SARC	cis	rs826838	0.967	rs826858	chr12:39116731	A/G	cg26384229	chr12:38710491	ALG10B	-0.82	-12.46	-0.63	1.18e-27	Heart rate;
SARC	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg03452623	chr4:187889614	NA	-0.76	-12.04	-0.62	2.75e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs981844	0.712	rs55656103	chr4:154757478	T/C	cg14289246	chr4:154710475	SFRP2	0.58	6.62	0.4	2.45e-10	Response to statins (LDL cholesterol change);
SARC	trans	rs61931739	0.926	rs13377754	chr12:34051765	T/C	cg13010199	chr12:38710504	ALG10B	-0.53	-6.44	-0.39	6.76e-10	Morning vs. evening chronotype;
SARC	cis	rs875971	0.545	rs316328	chr7:65608838	A/G	cg11764359	chr7:65958608	NA	-0.62	-6.7	-0.4	1.53e-10	Aortic root size;
SARC	cis	rs9399135	0.967	rs4896119	chr6:135293391	C/T	cg24558204	chr6:135376177	HBS1L	0.45	6.07	0.37	5.16e-9	Red blood cell count;
SARC	cis	rs7223966	1.000	rs11079509	chr17:61762148	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.49	-4.9	-0.31	1.82e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs3824344	0.531	rs7870336	chr9:37007769	C/G	cg14294708	chr9:37120828	ZCCHC7	-0.42	-4.92	-0.31	1.62e-6	Intelligence;
SARC	cis	rs6732160	0.932	rs6546802	chr2:73379564	G/A	cg01422370	chr2:73384389	NA	0.3	4.81	0.3	2.74e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2832077	0.527	rs59730679	chr21:30226244	T/C	cg03476357	chr21:30257390	N6AMT1	-0.56	-6.24	-0.38	2.03e-9	Cognitive test performance;
SARC	cis	rs72634258	0.554	rs34305100	chr1:7913029	A/G	cg05338066	chr1:7812865	CAMTA1	0.56	4.9	0.31	1.82e-6	Inflammatory bowel disease;
SARC	cis	rs17376456	0.877	rs13169675	chr5:93331284	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.62	5.58	0.34	6.55e-8	Diabetic retinopathy;
SARC	cis	rs796364	0.664	rs4673660	chr2:200915395	C/T	cg23649088	chr2:200775458	C2orf69	0.63	6.89	0.41	5.09e-11	Schizophrenia;
SARC	cis	rs2180341	0.920	rs9401951	chr6:127671632	A/C	cg27446573	chr6:127587934	RNF146	1.05	14.53	0.69	1.75e-34	Breast cancer;
SARC	cis	rs7561528	0.501	rs55828408	chr2:127885624	T/A	cg12632573	chr2:127783243	NA	0.7	6.3	0.38	1.49e-9	Alzheimer's disease;Alzheimer's disease (late onset);
SARC	cis	rs9902453	1.000	rs7222308	chr17:28277041	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	6.86	0.41	6.29e-11	Coffee consumption (cups per day);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg02977761	chr19:42901279	NA	0.53	6.97	0.42	3.23e-11	Chemerin levels;
SARC	cis	rs9341808	0.718	rs2322631	chr6:80843956	A/C	cg08355045	chr6:80787529	NA	0.34	5.5	0.34	9.77e-8	Sitting height ratio;
SARC	cis	rs7098414	0.511	rs10749592	chr10:82150891	C/T	cg00277334	chr10:82204260	NA	-0.35	-5.1	-0.32	7.09e-7	Post bronchodilator FEV1;
SARC	cis	rs910316	1.000	rs10143132	chr14:75525850	G/A	cg11812906	chr14:75593930	NEK9	0.9	13.91	0.67	2.06e-32	Height;
SARC	cis	rs4555082	0.872	rs7153832	chr14:105730563	G/T	cg06808227	chr14:105710500	BRF1	-0.48	-6.18	-0.38	2.89e-9	Mean platelet volume;Platelet distribution width;
SARC	cis	rs651907	0.557	rs3806653	chr3:101396972	T/C	cg12386194	chr3:101231763	SENP7	0.5	6.02	0.37	6.66e-9	Colorectal cancer;
SARC	cis	rs3796352	0.892	rs11718388	chr3:53076415	G/A	cg12962167	chr3:53033115	SFMBT1	0.72	5.0	0.31	1.14e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs7937682	0.710	rs674230	chr11:111437887	A/G	cg22437258	chr11:111473054	SIK2	0.7	9.18	0.52	2.34e-17	Primary sclerosing cholangitis;
SARC	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg21171335	chr12:122356390	WDR66	0.41	6.41	0.39	8e-10	Mean corpuscular volume;
SARC	cis	rs78487399	0.808	rs7586101	chr2:43669851	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.58	5.13	0.32	6.04e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg22974920	chr21:40686053	BRWD1	0.44	4.78	0.3	3.17e-6	Cognitive function;
SARC	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg02725872	chr8:58115012	NA	-0.27	-4.87	-0.3	2.09e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs7662987	0.517	rs2602866	chr4:100034997	A/G	cg12011299	chr4:100065546	ADH4	0.33	5.53	0.34	8.55e-8	Smoking initiation;
SARC	cis	rs2439831	0.867	rs3213991	chr15:43670280	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.08	11.58	0.6	8.71e-25	Lung cancer in ever smokers;
SARC	trans	rs61931739	0.517	rs1844525	chr12:34103183	T/A	cg13010199	chr12:38710504	ALG10B	0.77	10.37	0.56	5.83e-21	Morning vs. evening chronotype;
SARC	cis	rs2749592	0.550	rs9733309	chr10:37882405	G/A	cg25427524	chr10:38739819	LOC399744	0.45	6.65	0.4	2.1e-10	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs79149102	0.649	rs1531163	chr15:75113083	A/G	cg09165964	chr15:75287851	SCAMP5	-0.86	-5.73	-0.35	3.05e-8	Lung cancer;
SARC	cis	rs796364	1.000	rs281771	chr2:200812202	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-6.92	-0.41	4.22e-11	Schizophrenia;
SARC	cis	rs965469	1.000	rs6051723	chr20:3278512	C/A	cg25506879	chr20:3388711	C20orf194	-0.5	-5.04	-0.31	9.37e-7	IFN-related cytopenia;
SARC	cis	rs2650000	0.798	rs2701175	chr12:121391671	C/A	cg15155738	chr12:121454335	C12orf43	-0.45	-5.44	-0.34	1.32e-7	Metabolic traits;LDL cholesterol;
SARC	cis	rs2228479	0.702	rs12599561	chr16:89894358	C/G	cg00800038	chr16:89945340	TCF25	-0.82	-5.8	-0.36	2.19e-8	Skin colour saturation;
SARC	cis	rs2120243	0.539	rs6441127	chr3:157095507	T/C	cg24825693	chr3:157122686	VEPH1	-0.46	-6.19	-0.38	2.74e-9	Hepatocellular carcinoma in hepatitis B infection;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg25136961	chr6:71122946	FAM135A	-0.6	-6.99	-0.42	2.87e-11	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs12908161	1.000	rs35960805	chr15:85343980	T/G	cg17507749	chr15:85114479	UBE2QP1	0.54	6.28	0.38	1.68e-9	Schizophrenia;
SARC	cis	rs10760123	1	rs10760123	chr9:123650534	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.43	5.11	0.32	6.75e-7	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs796364	0.806	rs10445791	chr2:201078307	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-5.91	-0.36	1.21e-8	Schizophrenia;
SARC	cis	rs2730245	0.636	rs2657382	chr7:158650941	G/A	cg24397884	chr7:158709396	WDR60	0.74	8.6	0.49	1.15e-15	Height;
SARC	cis	rs10911232	0.507	rs4266836	chr1:183029070	T/G	cg13390022	chr1:182993471	LAMC1	0.33	4.99	0.31	1.17e-6	Hypertriglyceridemia;
SARC	cis	rs1865760	0.534	rs72834629	chr6:26023032	C/T	cg10373733	chr6:25993375	NA	0.48	5.29	0.33	2.84e-7	Height;
SARC	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg05368731	chr17:41323189	NBR1	0.72	8.77	0.5	3.72e-16	Menopause (age at onset);
SARC	cis	rs918629	0.530	rs3777192	chr5:95246867	G/A	cg16656078	chr5:95278638	ELL2	-0.58	-7.04	-0.42	2.17e-11	IgG glycosylation;
SARC	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg12310025	chr6:25882481	NA	-0.43	-5.44	-0.34	1.36e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9911578	0.967	rs11656413	chr17:57082013	A/C	cg05425664	chr17:57184151	TRIM37	0.67	8.76	0.5	4.1e-16	Intelligence (multi-trait analysis);
SARC	cis	rs6964587	0.773	rs12536421	chr7:92008220	A/G	cg17063962	chr7:91808500	NA	0.88	12.4	0.63	1.83e-27	Breast cancer;
SARC	cis	rs8044868	0.530	rs2288000	chr16:72058881	A/G	cg16558253	chr16:72132732	DHX38	-0.41	-6.11	-0.37	4.2e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
SARC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg07167872	chr1:205819463	PM20D1	0.75	11.49	0.6	1.7e-24	Menarche (age at onset);
SARC	cis	rs9902453	0.817	rs62068625	chr17:28176581	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	7.31	0.43	4.31e-12	Coffee consumption (cups per day);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg20762182	chr15:69727293	KIF23	-0.54	-6.94	-0.41	3.84e-11	Height;
SARC	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4713118	0.699	rs573179	chr6:27849676	C/A	cg17221315	chr6:27791827	HIST1H4J	0.51	5.13	0.32	5.97e-7	Parkinson's disease;
SARC	cis	rs77633900	0.614	rs2930681	chr15:76995150	G/A	cg21673338	chr15:77095150	SCAPER	-0.6	-5.05	-0.31	8.79e-7	Non-glioblastoma glioma;Glioma;
SARC	cis	rs9341808	0.935	rs1535825	chr6:80938586	C/T	cg08355045	chr6:80787529	NA	-0.33	-5.48	-0.34	1.12e-7	Sitting height ratio;
SARC	cis	rs4819052	1.000	rs2297284	chr21:46705345	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.77	8.95	0.51	1.12e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7766436	0.767	rs6456498	chr6:22603610	A/G	cg13666174	chr6:22585274	NA	0.51	7.13	0.42	1.28e-11	Coronary artery disease;
SARC	cis	rs9899728	0.539	rs56267297	chr17:73046996	T/C	cg27626185	chr17:73056755	KCTD2	-0.95	-7.32	-0.43	3.95e-12	Alzheimer's disease or small vessel stroke;
SARC	cis	rs524281	0.861	rs11227415	chr11:65885459	C/T	cg14036092	chr11:66035641	RAB1B	0.48	5.04	0.31	9.52e-7	Electroencephalogram traits;
SARC	cis	rs7552404	0.924	rs2153126	chr1:76199345	C/G	cg22875332	chr1:76189707	ACADM	0.46	6.69	0.4	1.64e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs13390159	0.714	rs115794429	chr2:237155261	T/C	cg19324714	chr2:237145437	ASB18	0.5	4.9	0.31	1.78e-6	Response to statin therapy;
SARC	cis	rs2933343	0.700	rs789233	chr3:128603150	G/T	cg25356066	chr3:128598488	ACAD9	0.7	9.51	0.53	2.51e-18	IgG glycosylation;
SARC	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg02725872	chr8:58115012	NA	-0.37	-6.54	-0.39	3.94e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs17253792	0.822	rs80085988	chr14:56096173	A/G	cg01858014	chr14:56050164	KTN1	-0.68	-5.37	-0.33	1.86e-7	Putamen volume;
SARC	cis	rs2290720	0.930	rs11110742	chr12:101692559	G/A	cg22051763	chr12:101673672	UTP20	-0.44	-5.35	-0.33	2.08e-7	Brain structure (hippocampal volume);
SARC	cis	rs7552404	0.924	rs1251075	chr1:76190569	C/G	cg03433033	chr1:76189801	ACADM	0.49	7.24	0.43	6.65e-12	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs73206853	0.534	rs73205059	chr12:110509947	G/A	cg08946844	chr12:110511112	NA	0.63	5.02	0.31	1.03e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs11581859	0.613	rs6703336	chr1:99197600	G/A	cg20286094	chr1:99190917	SNX7	-0.42	-4.93	-0.31	1.55e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs9300255	0.620	rs1727311	chr12:123660716	T/G	cg05973401	chr12:123451056	ABCB9	0.55	5.26	0.33	3.28e-7	Neutrophil percentage of white cells;
SARC	cis	rs1215050	0.791	rs6532702	chr4:98766641	C/T	cg05340658	chr4:99064831	C4orf37	0.47	6.16	0.37	3.09e-9	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg16132339	chr22:24313637	DDTL;DDT	0.39	5.32	0.33	2.44e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9807841	0.617	rs892087	chr19:10794793	C/T	cg17710535	chr19:10819994	QTRT1	0.42	4.91	0.31	1.71e-6	Inflammatory skin disease;
SARC	cis	rs1707322	0.686	rs2230658	chr1:46078854	A/G	cg03146154	chr1:46216737	IPP	-0.52	-6.29	-0.38	1.54e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7312933	0.558	rs7305397	chr12:42850058	T/C	cg19980929	chr12:42632907	YAF2	0.48	6.79	0.41	9.24e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs748404	0.631	rs6493084	chr15:43647627	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.39	4.8	0.3	2.89e-6	Lung cancer;
SARC	cis	rs12142240	0.698	rs4372193	chr1:46853233	G/T	cg00530320	chr1:46809349	NSUN4	0.57	7.0	0.42	2.74e-11	Menopause (age at onset);
SARC	cis	rs9467773	0.620	rs9467810	chr6:26608261	A/C	cg12292205	chr6:26970375	C6orf41	0.43	5.26	0.33	3.22e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2120019	1.000	rs12324912	chr15:75361006	G/A	cg12414181	chr15:75287860	SCAMP5	-0.43	-4.9	-0.31	1.78e-6	Blood trace element (Zn levels);
SARC	cis	rs1691799	0.831	rs6581678	chr12:66776656	A/G	cg16791601	chr12:66731901	HELB	-0.69	-10.38	-0.56	5.22e-21	White blood cell count (basophil);
SARC	cis	rs9300255	0.602	rs2851450	chr12:123703501	C/T	cg05973401	chr12:123451056	ABCB9	0.52	5.89	0.36	1.34e-8	Neutrophil percentage of white cells;
SARC	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg04317338	chr11:64019027	PLCB3	0.55	6.48	0.39	5.28e-10	Platelet count;
SARC	cis	rs78487399	0.710	rs76215753	chr2:43597142	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-4.81	-0.3	2.72e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg03806693	chr22:41940476	POLR3H	0.89	11.95	0.62	5.29e-26	Vitiligo;
SARC	cis	rs11792861	0.962	rs72607162	chr9:111793719	T/C	cg13535736	chr9:111863775	C9orf5	-0.41	-5.05	-0.31	9.02e-7	Menarche (age at onset);
SARC	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg18252515	chr7:66147081	NA	-1.29	-11.32	-0.6	5.72e-24	Diabetic kidney disease;
SARC	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg11062466	chr8:58055876	NA	0.61	5.75	0.35	2.74e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs11250098	0.574	rs4240672	chr8:10767917	G/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.59	-0.4	2.86e-10	Morning vs. evening chronotype;
SARC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.03	12.46	0.63	1.18e-27	Platelet count;
SARC	cis	rs765787	0.530	rs12442533	chr15:45529631	G/C	cg24006582	chr15:45444508	DUOX1	0.45	5.62	0.35	5.53e-8	Uric acid levels;
SARC	cis	rs4727027	0.901	rs1137432	chr7:148801658	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	5.81	0.36	2e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs2777491	0.957	rs2015781	chr15:41648967	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.75	-11.17	-0.59	1.7e-23	Ulcerative colitis;
SARC	cis	rs7296418	0.699	rs11608297	chr12:123826642	T/C	cg00376283	chr12:123451042	ABCB9	0.57	6.99	0.42	2.88e-11	Platelet count;
SARC	cis	rs1046896	0.607	rs12449739	chr17:80683420	G/A	cg02711726	chr17:80685570	FN3KRP	-0.62	-7.66	-0.45	5.07e-13	Glycated hemoglobin levels;
SARC	cis	rs6693567	0.545	rs4970922	chr1:150458094	C/A	cg09579323	chr1:150459698	TARS2	0.43	5.51	0.34	9.7e-8	Migraine;
SARC	cis	rs6570726	0.846	rs7762536	chr6:145923145	T/C	cg23711669	chr6:146136114	FBXO30	0.79	12.58	0.64	5e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg02475777	chr4:1388615	CRIPAK	0.65	7.43	0.44	2.07e-12	Longevity;
SARC	cis	rs2070997	0.548	rs11244145	chr9:133674088	A/G	cg11464064	chr9:133710261	ABL1	0.63	5.96	0.36	9.17e-9	Response to amphetamines;
SARC	cis	rs4889855	0.530	rs4889872	chr17:78621306	G/A	cg17956530	chr17:78667699	RPTOR	0.46	5.18	0.32	4.76e-7	Fractional excretion of uric acid;
SARC	cis	rs73206853	0.841	rs7961345	chr12:111081598	C/T	cg08946844	chr12:110511112	NA	0.56	4.78	0.3	3.05e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs2290159	0.800	rs73132351	chr3:12688284	A/G	cg23032965	chr3:12705835	RAF1	0.76	8.18	0.47	1.78e-14	Cholesterol, total;
SARC	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg00933542	chr6:150070202	PCMT1	0.31	5.27	0.33	3.05e-7	Lung cancer;
SARC	cis	rs4423214	1.000	rs4423214	chr11:71173254	C/T	cg05163923	chr11:71159392	DHCR7	0.67	9.5	0.53	2.71e-18	Vitamin D levels;
SARC	cis	rs9815354	0.953	rs1717003	chr3:41937000	C/T	cg03022575	chr3:42003672	ULK4	-0.56	-5.45	-0.34	1.28e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs67478160	0.643	rs7156697	chr14:104211136	G/A	cg26031613	chr14:104095156	KLC1	-0.4	-4.78	-0.3	3.12e-6	Schizophrenia;
SARC	cis	rs17401966	1.000	rs2229687	chr1:10473196	C/T	cg15208524	chr1:10270712	KIF1B	0.43	4.96	0.31	1.39e-6	Hepatocellular carcinoma;
SARC	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg24549020	chr5:56110836	MAP3K1	0.7	7.17	0.42	1.01e-11	Initial pursuit acceleration;
SARC	cis	rs9911578	0.741	rs2611776	chr17:56819636	G/T	cg12560992	chr17:57184187	TRIM37	0.88	12.21	0.62	7.58e-27	Intelligence (multi-trait analysis);
SARC	cis	rs796364	0.806	rs11679658	chr2:200923081	A/G	cg23649088	chr2:200775458	C2orf69	-0.62	-5.5	-0.34	9.78e-8	Schizophrenia;
SARC	cis	rs7326068	0.610	rs2596150	chr13:21317048	C/T	cg16922012	chr13:21400325	XPO4	-0.45	-6.32	-0.38	1.29e-9	Schizophrenia, bipolar disorder and depression (combined);
SARC	cis	rs2028299	0.920	rs11638138	chr15:90428755	A/G	cg19708238	chr15:90437601	AP3S2	-0.46	-5.17	-0.32	5.07e-7	Type 2 diabetes;
SARC	cis	rs897080	0.515	rs698767	chr2:44576417	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.66	7.65	0.45	5.28e-13	Height;
SARC	cis	rs453301	0.652	rs2043129	chr8:8825504	C/G	cg08975724	chr8:8085496	FLJ10661	0.48	5.83	0.36	1.87e-8	Joint mobility (Beighton score);
SARC	cis	rs7772486	0.754	rs9373475	chr6:146126419	C/T	cg23711669	chr6:146136114	FBXO30	0.91	16.06	0.72	1.46e-39	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7582720	1.000	rs114899426	chr2:203771652	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.31	0.43	4.24e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs74781061	0.722	rs77102700	chr15:74896941	G/A	cg09165964	chr15:75287851	SCAMP5	-0.58	-4.8	-0.3	2.83e-6	Endometriosis;
SARC	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg20203395	chr5:56204925	C5orf35	0.6	5.38	0.33	1.82e-7	Initial pursuit acceleration;
SARC	cis	rs854765	0.547	rs2955380	chr17:17944349	A/G	cg05444541	chr17:17804740	TOM1L2	0.3	4.89	0.31	1.85e-6	Total body bone mineral density;
SARC	cis	rs16976116	0.901	rs113679855	chr15:55502428	C/T	cg17854078	chr15:55489399	RSL24D1	0.67	6.56	0.39	3.51e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs17384381	1.000	rs36110608	chr1:85852936	A/C	cg16011679	chr1:85725395	C1orf52	0.64	5.93	0.36	1.06e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9868809	0.505	rs28793701	chr3:48762683	C/G	cg07636037	chr3:49044803	WDR6	-0.71	-6.55	-0.39	3.59e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg13939156	chr17:80058883	NA	-0.41	-6.37	-0.39	1e-9	Life satisfaction;
SARC	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg08742575	chr21:47604166	C21orf56	0.39	4.81	0.3	2.67e-6	Testicular germ cell tumor;
SARC	cis	rs9611519	0.929	rs4820423	chr22:41430338	A/T	cg17376030	chr22:41985996	PMM1	0.5	6.05	0.37	5.85e-9	Neuroticism;
SARC	cis	rs796364	0.806	rs79897806	chr2:201073968	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-5.91	-0.36	1.21e-8	Schizophrenia;
SARC	cis	rs8028182	0.636	rs11637586	chr15:75791112	G/C	cg20655648	chr15:75932815	IMP3	0.64	7.3	0.43	4.38e-12	Sudden cardiac arrest;
SARC	cis	rs721399	0.719	rs4646254	chr8:18262059	A/G	cg18736775	chr8:18248649	NAT2	-0.62	-6.84	-0.41	6.9e-11	Blood metabolite levels;
SARC	cis	rs7223966	1.000	rs11658740	chr17:61751069	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.51	-5.36	-0.33	2e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6685188	0.920	rs6593964	chr1:205662337	G/T	cg14159672	chr1:205819179	PM20D1	0.49	5.46	0.34	1.23e-7	White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs2933343	0.729	rs1680786	chr3:128644840	T/C	cg24203234	chr3:128598194	ACAD9	0.64	8.08	0.47	3.49e-14	IgG glycosylation;
SARC	cis	rs9916302	0.706	rs28482878	chr17:37497100	A/G	cg07936489	chr17:37558343	FBXL20	0.76	9.22	0.52	1.85e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs67460515	0.563	rs6441362	chr3:160877613	G/A	cg03342759	chr3:160939853	NMD3	-0.63	-7.84	-0.46	1.65e-13	Parkinson's disease;
SARC	cis	rs4727027	0.835	rs6959224	chr7:148784495	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.47	5.45	0.34	1.26e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg13206674	chr6:150067644	NUP43	0.45	5.98	0.36	8.25e-9	Lung cancer;
SARC	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	11.31	0.6	6.28e-24	Alzheimer's disease;
SARC	cis	rs11997175	0.549	rs4349945	chr8:33654323	T/C	ch.8.33884649F	chr8:33765107	NA	0.48	6.45	0.39	6.25e-10	Body mass index;
SARC	trans	rs11039798	0.588	rs12284168	chr11:48555627	C/T	cg15704280	chr7:45808275	SEPT13	0.64	6.63	0.4	2.35e-10	Axial length;
SARC	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg18876405	chr7:65276391	NA	-0.7	-8.81	-0.5	3e-16	Aortic root size;
SARC	cis	rs11785400	1.000	rs3735999	chr8:143746069	T/C	cg10596483	chr8:143751796	JRK	0.64	8.5	0.49	2.36e-15	Schizophrenia;
SARC	cis	rs11122272	0.735	rs2572249	chr1:231514829	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-9.79	-0.54	3.66e-19	Hemoglobin concentration;
SARC	cis	rs7772486	0.875	rs1331645	chr6:146398407	C/G	cg23711669	chr6:146136114	FBXO30	0.75	11.56	0.6	1.02e-24	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9457247	0.602	rs13204839	chr6:167471119	G/A	cg07741184	chr6:167504864	NA	0.38	7.32	0.43	3.92e-12	Crohn's disease;
SARC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg26354017	chr1:205819088	PM20D1	0.73	11.19	0.59	1.56e-23	Monocyte percentage of white cells;
SARC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg03487637	chr11:45940039	PEX16	0.48	6.41	0.39	7.95e-10	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg24633833	chr3:10029261	TMEM111	0.52	5.0	0.31	1.13e-6	Alzheimer's disease;
SARC	cis	rs6582630	0.679	rs7301806	chr12:38596667	G/A	cg13010199	chr12:38710504	ALG10B	0.52	6.58	0.4	3.09e-10	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs4713118	0.955	rs9380012	chr6:27684654	A/G	cg17221315	chr6:27791827	HIST1H4J	0.49	4.97	0.31	1.3e-6	Parkinson's disease;
SARC	cis	rs6060717	0.536	rs6060704	chr20:34530270	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-5.73	-0.35	3.1e-8	Hip circumference adjusted for BMI;
SARC	cis	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-9.15	-0.51	2.98e-17	Joint mobility (Beighton score);
SARC	cis	rs796364	0.756	rs2949006	chr2:200715388	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.81	7.11	0.42	1.4e-11	Schizophrenia;
SARC	cis	rs4664308	0.618	rs62175488	chr2:160892758	T/C	cg03641300	chr2:160917029	PLA2R1	-0.39	-5.05	-0.31	8.93e-7	Idiopathic membranous nephropathy;
SARC	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg03433033	chr1:76189801	ACADM	0.53	7.72	0.45	3.49e-13	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg24633833	chr3:10029261	TMEM111	0.52	5.21	0.32	4.13e-7	Alzheimer's disease;
SARC	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg05861140	chr6:150128134	PCMT1	-0.41	-5.34	-0.33	2.19e-7	Lung cancer;
SARC	cis	rs2279817	0.818	rs34304724	chr1:17994850	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.54	-4.87	-0.3	2.02e-6	Neuroticism;
SARC	cis	rs1023500	0.573	rs133370	chr22:42465260	T/C	cg04733989	chr22:42467013	NAGA	0.76	10.8	0.58	2.61e-22	Schizophrenia;
SARC	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg01475735	chr3:40494733	NA	-0.47	-5.22	-0.32	3.95e-7	Renal cell carcinoma;
SARC	cis	rs9807989	0.571	rs10208293	chr2:102966310	G/A	cg09003973	chr2:102972529	NA	0.46	5.75	0.35	2.76e-8	Asthma;
SARC	cis	rs1729951	0.546	rs835634	chr3:136676303	C/T	cg15507776	chr3:136538369	TMEM22	0.52	5.79	0.35	2.25e-8	Neuroticism;
SARC	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg26752003	chr8:145688521	CYHR1	0.53	6.87	0.41	5.67e-11	Age at first birth;
SARC	trans	rs6981523	0.553	rs2409730	chr8:11060638	C/A	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.4	-0.39	8.59e-10	Neuroticism;
SARC	cis	rs14978	1.000	rs10236369	chr7:12280838	A/G	cg23422036	chr7:12250390	TMEM106B	0.44	5.28	0.33	3e-7	Response to amphetamines;
SARC	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.51	-6.46	-0.39	5.88e-10	Lymphocyte counts;
SARC	cis	rs1801251	0.963	rs35362030	chr2:233612845	A/G	cg25237894	chr2:233734115	C2orf82	0.38	5.03	0.31	9.71e-7	Coronary artery disease;
SARC	cis	rs2952156	0.920	rs1018246	chr17:37835240	C/T	cg07936489	chr17:37558343	FBXL20	-0.41	-5.29	-0.33	2.84e-7	Asthma;
SARC	cis	rs3126085	0.935	rs4511111	chr1:152211624	C/G	cg26876637	chr1:152193138	HRNR	-0.51	-5.22	-0.32	3.95e-7	Atopic dermatitis;
SARC	cis	rs7216064	0.953	rs9890629	chr17:65871559	G/A	cg12091567	chr17:66097778	LOC651250	-0.7	-7.66	-0.45	4.94e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg18252515	chr7:66147081	NA	-1.42	-13.08	-0.65	1.15e-29	Diabetic kidney disease;
SARC	cis	rs6911965	0.641	rs7766241	chr6:24485357	G/A	cg20631270	chr6:24437470	GPLD1	0.51	4.82	0.3	2.59e-6	Hematological and biochemical traits;
SARC	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg05861140	chr6:150128134	PCMT1	-0.39	-5.0	-0.31	1.15e-6	Lung cancer;
SARC	cis	rs780094	0.585	rs7586601	chr2:27584666	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.41	-6.15	-0.37	3.31e-9	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg07414643	chr4:187882934	NA	-0.48	-6.97	-0.42	3.26e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg24110177	chr3:50126178	RBM5	-0.54	-7.17	-0.43	9.79e-12	Intelligence (multi-trait analysis);
SARC	cis	rs910316	0.935	rs3742771	chr14:75599647	A/G	cg06637938	chr14:75390232	RPS6KL1	0.48	6.64	0.4	2.13e-10	Height;
SARC	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg11878867	chr6:150167359	LRP11	-0.34	-4.71	-0.3	4.17e-6	Lung cancer;
SARC	cis	rs12545109	0.800	rs1467124	chr8:57418862	T/G	cg19413350	chr8:57351067	NA	-0.43	-5.4	-0.33	1.67e-7	Obesity-related traits;
SARC	cis	rs76419734	0.850	rs112292976	chr4:106779785	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.77	5.19	0.32	4.53e-7	Post bronchodilator FEV1;
SARC	cis	rs7598759	0.527	rs7571691	chr2:232369401	C/T	cg19187155	chr2:232395269	NMUR1	0.81	13.01	0.65	1.82e-29	Noise-induced hearing loss;
SARC	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg24209194	chr3:40518798	ZNF619	0.58	7.11	0.42	1.42e-11	Renal cell carcinoma;
SARC	cis	rs2576037	0.566	rs2437854	chr18:44557613	T/C	cg19077165	chr18:44547161	KATNAL2	0.56	7.65	0.45	5.21e-13	Personality dimensions;
SARC	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg24642844	chr7:1081250	C7orf50	-0.58	-5.86	-0.36	1.56e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs644799	1.000	rs546809	chr11:95579938	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.89	13.97	0.68	1.24e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs4819052	0.655	rs2330102	chr21:46690968	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	6.51	0.39	4.47e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs3008870	0.755	rs2815362	chr1:67496803	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.6	7.71	0.45	3.55e-13	Lymphocyte percentage of white cells;
SARC	cis	rs7666738	0.791	rs10856934	chr4:99010844	A/G	cg05340658	chr4:99064831	C4orf37	-0.69	-9.13	-0.51	3.27e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6062302	0.522	rs3787112	chr20:62222411	G/A	cg16989086	chr20:62203971	PRIC285	0.46	4.74	0.3	3.73e-6	Glioblastoma;
SARC	cis	rs72781680	0.611	rs72781692	chr2:24263319	T/G	cg08917208	chr2:24149416	ATAD2B	0.66	6.39	0.39	8.72e-10	Lymphocyte counts;
SARC	cis	rs9807841	0.617	rs2229383	chr19:10794630	G/T	cg17710535	chr19:10819994	QTRT1	0.42	5.03	0.31	9.63e-7	Inflammatory skin disease;
SARC	cis	rs1609391	0.543	rs2117009	chr3:136633571	A/T	cg15507776	chr3:136538369	TMEM22	-0.82	-11.54	-0.6	1.13e-24	Neuroticism;
SARC	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg27266027	chr21:40555129	PSMG1	-0.4	-4.77	-0.3	3.3e-6	Menarche (age at onset);
SARC	cis	rs2115630	0.936	rs11073663	chr15:85260268	A/G	cg17507749	chr15:85114479	UBE2QP1	-0.46	-5.59	-0.34	6.2e-8	P wave terminal force;
SARC	cis	rs7223966	1.000	rs8073373	chr17:61703320	T/C	cg26338869	chr17:61819248	STRADA	0.44	5.09	0.32	7.26e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	7.72	0.45	3.42e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs477692	0.604	rs1008982	chr10:131445731	T/C	cg05714579	chr10:131428358	MGMT	-0.62	-8.21	-0.47	1.52e-14	Response to temozolomide;
SARC	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg11843238	chr5:131593191	PDLIM4	0.42	5.29	0.33	2.75e-7	Blood metabolite levels;
SARC	cis	rs151234	0.741	rs10521145	chr16:28596884	A/G	cg01378222	chr16:28622494	SULT1A1	0.45	5.58	0.34	6.6e-8	Platelet distribution width;
SARC	cis	rs9790314	0.663	rs4557202	chr3:160820524	G/C	cg04691961	chr3:161091175	C3orf57	-0.55	-7.19	-0.43	8.54e-12	Morning vs. evening chronotype;
SARC	cis	rs1371867	0.846	rs1660326	chr8:101290447	G/A	cg11906718	chr8:101322791	RNF19A	0.7	8.97	0.51	1.03e-16	Atrioventricular conduction;
SARC	cis	rs9902453	1.000	rs9906340	chr17:28398977	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-6.98	-0.42	3e-11	Coffee consumption (cups per day);
SARC	cis	rs17270561	0.636	rs1575535	chr6:25809909	C/T	cg16482183	chr6:26056742	HIST1H1C	0.4	4.96	0.31	1.37e-6	Iron status biomarkers;
SARC	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.67	9.23	0.52	1.75e-17	Menarche (age at onset);
SARC	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	13.68	0.67	1.13e-31	Chronic sinus infection;
SARC	cis	rs9303401	0.659	rs35539277	chr17:56853833	G/A	cg25039879	chr17:56429692	SUPT4H1	0.71	6.49	0.39	5.1e-10	Cognitive test performance;
SARC	cis	rs9309473	1.000	rs7598419	chr2:73798223	A/G	cg20560298	chr2:73613845	ALMS1	-0.48	-5.68	-0.35	4.09e-8	Metabolite levels;
SARC	cis	rs2180341	0.889	rs9321074	chr6:127618019	G/A	cg24812749	chr6:127587940	RNF146	0.97	12.89	0.65	4.63e-29	Breast cancer;
SARC	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg06634786	chr22:41940651	POLR3H	-0.56	-6.52	-0.39	4.42e-10	Vitiligo;
SARC	trans	rs66573146	0.831	rs73088564	chr4:6984553	G/C	cg07817883	chr1:32538562	TMEM39B	1.32	8.67	0.49	7.41e-16	Granulocyte percentage of myeloid white cells;
SARC	cis	rs820218	0.770	rs820153	chr17:73616239	C/G	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.62	8.3	0.48	8.63e-15	Rotator cuff tears;
SARC	cis	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg25427524	chr10:38739819	LOC399744	-0.62	-9.95	-0.55	1.16e-19	Extrinsic epigenetic age acceleration;
SARC	cis	rs2486288	0.656	rs8039352	chr15:45551790	A/G	cg15395560	chr15:45543142	SLC28A2	0.31	6.04	0.37	6.09e-9	Glomerular filtration rate;
SARC	cis	rs6484504	0.576	rs158146	chr11:31210433	G/A	cg02090638	chr11:31391270	DNAJC24;DCDC1	-0.37	-4.8	-0.3	2.84e-6	Red blood cell count;
SARC	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg00684032	chr4:1343700	KIAA1530	-0.36	-5.37	-0.33	1.9e-7	Obesity-related traits;
SARC	cis	rs7927592	0.956	rs7102273	chr11:68385579	T/C	cg01657329	chr11:68192670	LRP5	-0.41	-5.08	-0.32	7.68e-7	Total body bone mineral density;
SARC	cis	rs10088262	0.540	rs6988602	chr8:124788502	C/T	cg15047889	chr8:124780837	FAM91A1	0.69	7.1	0.42	1.52e-11	Pancreatic cancer;
SARC	cis	rs881375	0.678	rs7021049	chr9:123683982	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.53	7.15	0.42	1.09e-11	Rheumatoid arthritis;
SARC	cis	rs1691799	0.867	rs1168333	chr12:66761377	G/A	cg16791601	chr12:66731901	HELB	-0.72	-10.89	-0.58	1.33e-22	White blood cell count (basophil);
SARC	cis	rs1669338	1.000	rs1669338	chr3:3199635	A/C	cg16797762	chr3:3221439	CRBN	0.85	9.39	0.52	5.61e-18	White matter integrity;
SARC	cis	rs7927771	0.832	rs11605672	chr11:47413733	A/G	cg20307385	chr11:47447363	PSMC3	-0.56	-6.9	-0.41	4.99e-11	Subjective well-being;
SARC	cis	rs11098499	0.564	rs11098507	chr4:120288286	G/A	cg09307838	chr4:120376055	NA	0.83	11.84	0.61	1.21e-25	Corneal astigmatism;
SARC	cis	rs7552404	0.731	rs1770887	chr1:76401812	A/G	cg03433033	chr1:76189801	ACADM	-0.44	-5.29	-0.33	2.88e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg17971929	chr21:40555470	PSMG1	0.98	13.77	0.67	5.73e-32	Cognitive function;
SARC	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg23221052	chr5:179740743	GFPT2	-0.52	-6.61	-0.4	2.55e-10	Height;
SARC	cis	rs61409971	0.961	rs10131290	chr14:93015479	A/C	cg04718702	chr14:93020195	RIN3	-0.37	-4.88	-0.3	1.96e-6	Lymphocyte percentage of white cells;
SARC	cis	rs12545109	0.800	rs970838	chr8:57414806	A/G	cg19413350	chr8:57351067	NA	-0.43	-5.32	-0.33	2.38e-7	Obesity-related traits;
SARC	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg04546413	chr19:29218101	NA	0.63	8.52	0.49	2.01e-15	Methadone dose in opioid dependence;
SARC	cis	rs7429990	0.965	rs1013431	chr3:48029118	A/C	cg11946769	chr3:48343235	NME6	-0.45	-5.34	-0.33	2.17e-7	Educational attainment (years of education);
SARC	cis	rs9638182	1.000	rs11974409	chr7:72989390	A/G	cg07467649	chr7:72856462	BAZ1B	0.47	5.01	0.31	1.07e-6	Triglycerides;
SARC	cis	rs17270561	0.636	rs7754814	chr6:25745243	A/T	cg17691542	chr6:26056736	HIST1H1C	0.61	7.36	0.43	3.06e-12	Iron status biomarkers;
SARC	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg22535103	chr8:58192502	C8orf71	-0.61	-6.5	-0.39	4.93e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs981844	0.712	rs1037648	chr4:154737877	T/C	cg14289246	chr4:154710475	SFRP2	-0.45	-5.17	-0.32	5.14e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs4808199	0.948	rs2074300	chr19:19380996	G/T	cg03709012	chr19:19516395	GATAD2A	1.1	10.57	0.57	1.38e-21	Nonalcoholic fatty liver disease;
SARC	cis	rs1401999	0.714	rs7646621	chr3:183640865	A/C	cg01324343	chr3:183735012	ABCC5	-0.57	-10.37	-0.56	5.9e-21	Anterior chamber depth;
SARC	cis	rs12497850	0.644	rs11928552	chr3:48739883	T/C	cg07636037	chr3:49044803	WDR6	0.88	13.77	0.67	5.7e-32	Parkinson's disease;
SARC	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg18876405	chr7:65276391	NA	0.69	8.46	0.48	3e-15	Aortic root size;
SARC	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg11987759	chr7:65425863	GUSB	-0.48	-6.54	-0.39	3.9e-10	Aortic root size;
SARC	cis	rs9457247	1.000	rs430097	chr6:167405073	A/G	cg23791538	chr6:167370224	RNASET2	-0.63	-8.74	-0.5	4.69e-16	Crohn's disease;
SARC	cis	rs7178572	0.568	rs7166927	chr15:77673459	A/G	cg22256960	chr15:77711686	NA	0.5	5.55	0.34	7.7e-8	Type 2 diabetes;
SARC	cis	rs9788721	0.900	rs4243084	chr15:78911672	G/C	cg06917634	chr15:78832804	PSMA4	-0.55	-6.1	-0.37	4.35e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs35849525	0.814	rs7635601	chr3:50044006	A/T	cg24110177	chr3:50126178	RBM5	-0.52	-5.67	-0.35	4.22e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9911578	1.000	rs4636974	chr17:56965373	C/G	cg12560992	chr17:57184187	TRIM37	0.86	11.75	0.61	2.37e-25	Intelligence (multi-trait analysis);
SARC	cis	rs11758351	0.866	rs2069018	chr6:26205718	T/C	cg23601095	chr6:26197514	HIST1H3D	0.55	4.86	0.3	2.19e-6	Gout;Renal underexcretion gout;
SARC	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.54e-6	Depression;
SARC	cis	rs17270561	0.609	rs9393655	chr6:25711338	A/G	cg16482183	chr6:26056742	HIST1H1C	0.42	5.05	0.31	9.05e-7	Iron status biomarkers;
SARC	cis	rs9796	0.870	rs2927061	chr15:41302219	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.4	-5.54	-0.34	8.34e-8	Menopause (age at onset);
SARC	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg08109568	chr15:31115862	NA	0.53	6.81	0.41	8.4e-11	Huntington's disease progression;
SARC	cis	rs13418410	0.539	rs11677468	chr2:33839053	T/C	cg04131969	chr2:33951647	MYADML	-0.66	-9.74	-0.54	4.95e-19	Non-response to antidepressants and depression;
SARC	cis	rs13191362	1.000	rs68045643	chr6:163029709	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.54	5.29	0.33	2.82e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs7940866	0.770	rs10750456	chr11:130819634	A/G	cg12179176	chr11:130786555	SNX19	0.67	9.5	0.53	2.61e-18	Schizophrenia;
SARC	cis	rs2885056	0.783	rs73007347	chr19:10650649	C/T	cg06529468	chr19:10676722	KRI1	-0.49	-5.15	-0.32	5.63e-7	Red cell distribution width;
SARC	cis	rs2997447	0.761	rs56299762	chr1:26441638	G/A	cg19633962	chr1:26362018	EXTL1	-0.56	-5.06	-0.31	8.55e-7	QRS complex (12-leadsum);
SARC	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg11764359	chr7:65958608	NA	-0.83	-11.09	-0.59	3.13e-23	Aortic root size;
SARC	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg04944784	chr2:26401820	FAM59B	-0.48	-5.99	-0.37	7.95e-9	Gut microbiome composition (summer);
SARC	trans	rs561341	0.505	rs548298	chr17:30297494	C/A	cg20587970	chr11:113659929	NA	-1.26	-12.41	-0.63	1.72e-27	Hip circumference adjusted for BMI;
SARC	cis	rs7546668	0.640	rs3766161	chr1:15809036	G/A	cg18192808	chr1:15853278	DNAJC16	0.43	4.96	0.31	1.39e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs7772486	0.790	rs2265919	chr6:146221753	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.62	0.4	2.39e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs17270561	0.583	rs7765833	chr6:25712433	C/A	cg16482183	chr6:26056742	HIST1H1C	0.41	5.09	0.32	7.21e-7	Iron status biomarkers;
SARC	trans	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg20587970	chr11:113659929	NA	-1.33	-13.84	-0.67	3.43e-32	Hip circumference adjusted for BMI;
SARC	cis	rs6060717	0.610	rs2590964	chr20:34613376	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-4.88	-0.3	1.96e-6	Hip circumference adjusted for BMI;
SARC	cis	rs2011503	0.882	rs751857	chr19:19602873	G/T	cg03709012	chr19:19516395	GATAD2A	0.61	5.36	0.33	1.95e-7	Bipolar disorder;
SARC	cis	rs1707322	0.826	rs10890349	chr1:46249955	T/C	cg03146154	chr1:46216737	IPP	0.51	6.28	0.38	1.68e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs593982	0.920	rs1151501	chr11:65484883	A/G	cg08755490	chr11:65554678	OVOL1	0.88	8.07	0.47	3.63e-14	Atopic dermatitis;
SARC	cis	rs9303401	0.659	rs12940212	chr17:56674474	T/C	cg25039879	chr17:56429692	SUPT4H1	0.69	6.25	0.38	1.89e-9	Cognitive test performance;
SARC	cis	rs12997796	0.556	rs13004867	chr2:86982504	C/G	cg25203885	chr2:87302643	LOC285074	-0.61	-5.14	-0.32	5.79e-7	Schizophrenia;
SARC	cis	rs7666738	0.830	rs1876192	chr4:98727555	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.54	0.49	1.74e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10504229	0.679	rs2218271	chr8:58052446	T/A	cg21724239	chr8:58056113	NA	0.58	5.84	0.36	1.71e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs12824058	0.831	rs11060825	chr12:130807905	A/G	cg26677194	chr12:130822605	PIWIL1	0.53	7.21	0.43	7.73e-12	Menopause (age at onset);
SARC	cis	rs6540556	0.954	rs654984	chr1:209937382	C/T	cg23920097	chr1:209922102	NA	0.45	5.19	0.32	4.55e-7	Red blood cell count;
SARC	cis	rs8008758	0.963	rs10132271	chr14:101688874	C/T	cg26224664	chr14:101693935	NA	-0.4	-6.48	-0.39	5.42e-10	Body mass index (alcohol intake interaction);
SARC	trans	rs36093844	0.848	rs2084079	chr11:85590436	C/A	cg27065003	chr5:122429449	PRDM6	-0.49	-6.24	-0.38	2.06e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs4819052	0.679	rs28623526	chr21:46712324	T/C	cg06618935	chr21:46677482	NA	-0.36	-4.75	-0.3	3.51e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9309473	0.950	rs6546860	chr2:73844249	G/A	cg07208825	chr2:73871855	ALMS1P	0.33	4.97	0.31	1.32e-6	Metabolite levels;
SARC	cis	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg05623727	chr3:50126028	RBM5	-0.36	-5.19	-0.32	4.67e-7	Intelligence (multi-trait analysis);
SARC	cis	rs4689388	0.926	rs9998519	chr4:6292909	C/T	cg14416269	chr4:6271139	WFS1	0.33	5.05	0.31	8.77e-7	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg10381488	chr15:45694016	SPATA5L1	0.39	4.73	0.3	3.83e-6	Homoarginine levels;
SARC	cis	rs208520	0.754	rs851593	chr6:66875783	C/T	cg07460842	chr6:66804631	NA	1.14	15.28	0.71	5.59e-37	Exhaled nitric oxide output;
SARC	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg00149659	chr3:10157352	C3orf10	0.78	7.3	0.43	4.52e-12	Alzheimer's disease;
SARC	cis	rs7667	0.881	rs12031691	chr1:19750909	G/T	cg15311933	chr1:19638897	PQLC2;AKR7A2	-0.44	-5.24	-0.32	3.54e-7	Crohn's disease and psoriasis;
SARC	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg12373951	chr3:133503437	NA	0.35	5.05	0.31	8.9e-7	Iron status biomarkers;
SARC	cis	rs7666738	0.606	rs4577589	chr4:99087858	A/G	cg05340658	chr4:99064831	C4orf37	0.47	5.96	0.36	9.43e-9	Colonoscopy-negative controls vs population controls;
SARC	cis	rs944802	0.684	rs10811665	chr9:22146604	T/C	cg00491127	chr9:22154101	NA	-0.52	-5.82	-0.36	1.98e-8	White blood cell count;
SARC	cis	rs9398803	0.723	rs853968	chr6:127071753	C/T	cg20229609	chr6:126660872	C6orf173	-0.34	-4.79	-0.3	3.02e-6	Male-pattern baldness;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg27347579	chr5:43446499	C5orf28	0.45	6.41	0.39	8.1e-10	Thyroid stimulating hormone;
SARC	cis	rs17826219	0.789	rs4794873	chr17:28748352	C/T	cg13385521	chr17:29058706	SUZ12P	0.58	5.17	0.32	5.13e-7	Body mass index;
SARC	cis	rs11098499	0.863	rs3733525	chr4:120447048	A/G	cg09307838	chr4:120376055	NA	0.91	12.31	0.63	3.63e-27	Corneal astigmatism;
SARC	trans	rs3780486	0.757	rs10758189	chr9:33125804	A/G	cg20290983	chr6:43655470	MRPS18A	1.13	22.53	0.83	1.98e-60	IgG glycosylation;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg22395299	chr21:47706029	MCM3AP;C21orf57	-0.5	-6.25	-0.38	1.97e-9	Schizophrenia;
SARC	cis	rs6539267	0.748	rs1921953	chr12:106721012	C/T	cg00173435	chr12:106696525	TCP11L2	0.82	9.36	0.52	6.83e-18	Tourette syndrome;
SARC	cis	rs7312933	0.558	rs1051453	chr12:42852217	C/T	cg19980929	chr12:42632907	YAF2	0.49	7.07	0.42	1.83e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs6540556	0.723	rs1000282	chr1:209894785	T/C	cg23920097	chr1:209922102	NA	-0.5	-5.05	-0.31	9.05e-7	Red blood cell count;
SARC	cis	rs11871801	0.517	rs10454087	chr17:40735641	C/T	cg20126647	chr17:40714003	COASY	0.5	5.57	0.34	7.04e-8	Crohn's disease;
SARC	cis	rs1345301	0.552	rs67880537	chr2:102864106	A/G	cg12451869	chr2:102867685	NA	0.42	5.72	0.35	3.26e-8	Waist circumference;
SARC	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	15.02	0.7	4.1e-36	Chronic sinus infection;
SARC	trans	rs11098499	0.604	rs17051352	chr4:120581427	G/A	cg25214090	chr10:38739885	LOC399744	0.51	6.53	0.39	4.06e-10	Corneal astigmatism;
SARC	cis	rs1348850	0.632	rs12616288	chr2:178503813	G/T	cg22681709	chr2:178499509	PDE11A	-0.42	-5.7	-0.35	3.61e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs11687170	0.882	rs34046099	chr2:237062296	A/C	cg19324714	chr2:237145437	ASB18	0.47	4.73	0.3	3.82e-6	Educational attainment;Educational attainment (years of education);
SARC	cis	rs12142240	0.698	rs3991877	chr1:46853749	C/A	cg00530320	chr1:46809349	NSUN4	0.57	7.0	0.42	2.74e-11	Menopause (age at onset);
SARC	cis	rs7681440	0.904	rs12331318	chr4:90770255	A/G	cg06632027	chr4:90757378	SNCA	0.38	5.44	0.34	1.33e-7	Dementia with Lewy bodies;
SARC	cis	rs12545912	0.909	rs12335063	chr8:9470316	T/A	cg21625330	chr8:9911636	MSRA	-0.49	-4.75	-0.3	3.56e-6	Multiple myeloma (hyperdiploidy);
SARC	cis	rs1215050	0.527	rs1214998	chr4:99042878	T/G	cg05340658	chr4:99064831	C4orf37	0.5	6.86	0.41	6.1e-11	Waist-to-hip ratio adjusted for body mass index;
SARC	trans	rs62103177	0.810	rs62103188	chr18:77627661	G/A	cg05926928	chr17:57297772	GDPD1	1.09	9.19	0.52	2.24e-17	Opioid sensitivity;
SARC	cis	rs4561483	0.799	rs33635	chr16:11991944	C/T	cg08843971	chr16:11963173	GSPT1	-0.42	-4.73	-0.3	3.91e-6	Testicular germ cell tumor;
SARC	cis	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg24110177	chr3:50126178	RBM5	-0.55	-7.24	-0.43	6.58e-12	Intelligence (multi-trait analysis);
SARC	cis	rs910316	1.000	rs13099	chr14:75599155	G/A	cg11812906	chr14:75593930	NEK9	-0.84	-12.37	-0.63	2.36e-27	Height;
SARC	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg18305652	chr10:134549665	INPP5A	0.34	5.26	0.33	3.23e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs7647973	0.593	rs28535523	chr3:49848414	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.59	-5.94	-0.36	1.01e-8	Menarche (age at onset);
SARC	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.72	8.47	0.49	2.82e-15	Height;
SARC	cis	rs3733585	0.673	rs9994937	chr4:9964799	G/T	cg11266682	chr4:10021025	SLC2A9	-0.36	-6.22	-0.38	2.24e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.44	4.96	0.31	1.38e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg16900910	chr15:72789182	ARIH1	0.47	6.57	0.4	3.28e-10	Thyroid stimulating hormone;
SARC	cis	rs7927592	0.913	rs67005337	chr11:68307758	A/C	cg01657329	chr11:68192670	LRP5	-0.39	-4.72	-0.3	4.1e-6	Total body bone mineral density;
SARC	cis	rs7617773	0.817	rs936427	chr3:48301074	A/G	cg11946769	chr3:48343235	NME6	-0.71	-9.03	-0.51	6.52e-17	Coronary artery disease;
SARC	cis	rs10911251	0.546	rs2027081	chr1:183074576	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.68	9.93	0.55	1.31e-19	Colorectal cancer;
SARC	cis	rs763121	0.853	rs2072794	chr22:39150543	G/T	cg21395723	chr22:39101663	GTPBP1	0.55	6.27	0.38	1.75e-9	Menopause (age at onset);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg05415724	chr2:113033170	ZC3H6	0.51	6.27	0.38	1.71e-9	Height;
SARC	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg17221315	chr6:27791827	HIST1H4J	0.49	5.09	0.32	7.39e-7	Parkinson's disease;
SARC	cis	rs9392918	0.600	rs6597281	chr6:7699361	C/A	cg23089261	chr6:7723385	NA	0.53	6.76	0.4	1.11e-10	Height;
SARC	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg18252515	chr7:66147081	NA	0.45	4.88	0.3	1.98e-6	Aortic root size;
SARC	trans	rs8030605	0.516	rs12440142	chr15:56537518	G/A	cg13518625	chr8:29522838	NA	-0.57	-6.26	-0.38	1.79e-9	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs11122272	0.735	rs973252	chr1:231520802	A/G	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs10876993	0.890	rs1678516	chr12:58047458	G/A	cg18357645	chr12:58087776	OS9	0.46	6.05	0.37	5.87e-9	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs2242194	0.816	rs11264296	chr1:154994750	T/C	cg03351412	chr1:154909251	PMVK	0.46	5.59	0.34	6.24e-8	Schizophrenia;
SARC	cis	rs8180040	0.653	rs6808742	chr3:47051512	G/A	cg27129171	chr3:47204927	SETD2	0.66	9.04	0.51	6.35e-17	Colorectal cancer;
SARC	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg22535103	chr8:58192502	C8orf71	-0.59	-6.06	-0.37	5.57e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs796364	0.951	rs10931888	chr2:201022952	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.57	-5.15	-0.32	5.47e-7	Schizophrenia;
SARC	cis	rs6484504	0.625	rs7112412	chr11:31370271	T/C	cg02090638	chr11:31391270	DNAJC24;DCDC1	0.41	5.21	0.32	4.19e-7	Red blood cell count;
SARC	cis	rs2228479	0.850	rs2238532	chr16:89863672	T/C	cg06558623	chr16:89946397	TCF25	0.94	6.53	0.39	3.99e-10	Skin colour saturation;
SARC	cis	rs9868809	0.505	rs13434258	chr3:48738491	T/C	cg03060546	chr3:49711283	APEH	-0.51	-4.75	-0.3	3.52e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs13314892	0.728	rs62252232	chr3:69889257	A/T	cg17445875	chr3:69859618	MITF	-0.48	-4.95	-0.31	1.45e-6	QRS complex (12-leadsum);
SARC	cis	rs787274	1.000	rs787298	chr9:115542206	C/T	cg13803584	chr9:115635662	SNX30	-0.79	-6.14	-0.37	3.47e-9	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs7520050	0.966	rs7550746	chr1:46351719	T/A	cg06784218	chr1:46089804	CCDC17	-0.26	-4.83	-0.3	2.5e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs11764590	0.694	rs4721359	chr7:2104951	A/G	cg21782813	chr7:2030301	MAD1L1	-0.34	-5.25	-0.33	3.38e-7	Neuroticism;
SARC	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg02463440	chr8:22132932	PIWIL2	-0.46	-6.53	-0.39	3.97e-10	Hypertriglyceridemia;
SARC	cis	rs67366981	0.925	rs66846709	chr14:77692812	G/A	cg06779847	chr14:77687015	TMEM63C	-0.54	-6.25	-0.38	1.94e-9	Obsessive-compulsive symptoms;
SARC	cis	rs11792861	0.781	rs28361106	chr9:111762385	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.73	8.54	0.49	1.78e-15	Menarche (age at onset);
SARC	cis	rs1949733	0.666	rs3103070	chr4:8508825	A/G	cg13073564	chr4:8508604	NA	0.43	6.96	0.41	3.41e-11	Response to antineoplastic agents;
SARC	cis	rs2522056	1.000	rs11242113	chr5:131777234	G/A	cg24060327	chr5:131705240	SLC22A5	0.56	5.85	0.36	1.63e-8	Lymphocyte counts;Fibrinogen;
SARC	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg11764359	chr7:65958608	NA	0.65	7.59	0.45	7.45e-13	Aortic root size;
SARC	trans	rs11098499	0.865	rs9994730	chr4:120381564	A/C	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	cis	rs6570726	0.791	rs422099	chr6:145806936	C/T	cg05347473	chr6:146136440	FBXO30	0.53	7.27	0.43	5.3e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4423214	0.592	rs10898234	chr11:71236684	A/G	cg05163923	chr11:71159392	DHCR7	-0.5	-5.01	-0.31	1.06e-6	Vitamin D levels;
SARC	cis	rs55871839	0.533	rs1015794	chr8:59838228	C/T	cg07426533	chr8:59803705	TOX	0.47	5.29	0.33	2.79e-7	Pneumonia;
SARC	cis	rs2439831	0.681	rs526450	chr15:43599325	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.04	12.07	0.62	2.28e-26	Lung cancer in ever smokers;
SARC	cis	rs11105298	0.891	rs10858900	chr12:89925081	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-5.48	-0.34	1.09e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs9902453	0.838	rs9646438	chr17:28209091	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	7.05	0.42	2.07e-11	Coffee consumption (cups per day);
SARC	cis	rs2120243	0.539	rs10936086	chr3:157099859	A/C	cg24825693	chr3:157122686	VEPH1	-0.45	-6.27	-0.38	1.74e-9	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs757647	0.503	rs10038448	chr5:137515781	C/G	cg27119451	chr5:137514611	BRD8;KIF20A	-0.52	-5.3	-0.33	2.66e-7	Menarche (age at onset);
SARC	cis	rs7223966	1.000	rs11658329	chr17:61763031	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.56	-6.61	-0.4	2.6e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9303401	0.614	rs28651036	chr17:57080471	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.0	10.61	0.57	1.02e-21	Cognitive test performance;
SARC	cis	rs10089	1.000	rs6595800	chr5:127411647	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	10.09	0.55	4.38e-20	Ileal carcinoids;
SARC	cis	rs6704644	0.651	rs7597465	chr2:234328182	G/C	cg27060346	chr2:234359958	DGKD	-0.73	-5.46	-0.34	1.19e-7	Bilirubin levels;
SARC	cis	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg22857025	chr5:266934	NA	-1.05	-11.9	-0.61	7.87e-26	Breast cancer;
SARC	cis	rs11249608	0.548	rs7704565	chr5:178473923	G/C	cg01312482	chr5:178451176	ZNF879	-0.42	-5.38	-0.33	1.78e-7	Pubertal anthropometrics;
SARC	cis	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg03213289	chr20:61660250	NA	0.46	6.43	0.39	7.22e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs35110281	0.659	rs11909064	chr21:45092095	G/C	cg21573476	chr21:45109991	RRP1B	-0.61	-8.65	-0.49	8.75e-16	Mean corpuscular volume;
SARC	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg17294928	chr15:75287854	SCAMP5	0.57	7.28	0.43	5.1e-12	Breast cancer;
SARC	cis	rs1448094	0.872	rs10863147	chr12:86408441	G/C	cg02569458	chr12:86230093	RASSF9	0.38	5.63	0.35	5.04e-8	Major depressive disorder;
SARC	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg14403583	chr14:105418241	AHNAK2	-0.58	-7.63	-0.45	5.95e-13	Rheumatoid arthritis;
SARC	trans	rs2727020	0.894	rs1880438	chr11:49370698	A/G	cg03929089	chr4:120376271	NA	-0.72	-9.06	-0.51	5.54e-17	Coronary artery disease;
SARC	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg19077165	chr18:44547161	KATNAL2	-0.52	-7.29	-0.43	4.74e-12	Personality dimensions;
SARC	cis	rs9633740	0.947	rs7096909	chr10:82284512	A/T	cg01528321	chr10:82214614	TSPAN14	-0.93	-10.85	-0.58	1.84e-22	Post bronchodilator FEV1;
SARC	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg13206674	chr6:150067644	NUP43	0.43	5.63	0.35	5.03e-8	Lung cancer;
SARC	cis	rs6426558	0.515	rs7521110	chr1:227384459	T/A	cg10327440	chr1:227177885	CDC42BPA	-0.43	-5.03	-0.31	9.59e-7	Neutrophil percentage of white cells;
SARC	cis	rs5758659	0.652	rs4822084	chr22:42435868	A/G	cg04733989	chr22:42467013	NAGA	-0.55	-6.99	-0.42	2.92e-11	Cognitive function;
SARC	trans	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.5	-0.39	4.71e-10	Triglycerides;
SARC	cis	rs3862260	0.509	rs10923879	chr1:120163831	A/G	cg16322792	chr1:120165303	ZNF697	0.29	6.09	0.37	4.51e-9	Systemic lupus erythematosus;
SARC	cis	rs13427251	0.903	rs6746402	chr2:100150443	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.48	-6.03	-0.37	6.24e-9	Chronic sinus infection;
SARC	cis	rs76917914	0.775	rs7867404	chr9:100810918	T/C	cg03040243	chr9:100819229	NANS	0.74	7.81	0.46	1.96e-13	Immature fraction of reticulocytes;
SARC	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg03934478	chr11:495069	RNH1	0.54	5.0	0.31	1.15e-6	Body mass index;
SARC	cis	rs7208859	0.623	rs8068645	chr17:29104342	T/A	cg13385521	chr17:29058706	SUZ12P	0.89	7.77	0.45	2.53e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9858542	0.953	rs6766581	chr3:49539401	T/C	cg03060546	chr3:49711283	APEH	-0.58	-7.13	-0.42	1.28e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.26	0.38	1.8e-9	Height;
SARC	cis	rs4423214	0.879	rs1790330	chr11:71147825	C/T	cg05163923	chr11:71159392	DHCR7	-0.6	-7.02	-0.42	2.38e-11	Vitamin D levels;
SARC	cis	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11166252	chr7:17338258	AHR	-0.44	-5.27	-0.33	3.08e-7	Fibrinogen levels;
SARC	cis	rs735396	1.000	rs1169310	chr12:121439433	G/A	cg25281562	chr12:121454272	C12orf43	0.5	6.06	0.37	5.55e-9	N-glycan levels;
SARC	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg15049968	chr18:44337910	ST8SIA5	0.36	5.69	0.35	3.82e-8	Personality dimensions;
SARC	cis	rs7953249	1.000	rs7953249	chr12:121403724	A/G	cg25281562	chr12:121454272	C12orf43	0.39	4.79	0.3	2.96e-6	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs12291225	0.679	rs11023172	chr11:14295367	C/G	cg19336497	chr11:14380999	RRAS2	-0.4	-6.77	-0.41	1.02e-10	Sense of smell;
SARC	cis	rs4268898	1.000	rs6746005	chr2:24434345	G/A	cg06627628	chr2:24431161	ITSN2	0.6	8.32	0.48	7.27e-15	Asthma;
SARC	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg11764359	chr7:65958608	NA	0.88	12.58	0.64	4.89e-28	Aortic root size;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg11219407	chr1:154531432	UBE2Q1	0.51	6.33	0.38	1.23e-9	Fibrinogen levels;
SARC	cis	rs6752107	1.000	rs2241878	chr2:234183718	T/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.46	6.06	0.37	5.45e-9	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs7586879	0.520	rs6718511	chr2:25122324	A/G	cg04586622	chr2:25135609	ADCY3	0.32	5.49	0.34	1.04e-7	Body mass index;
SARC	cis	rs739401	0.611	rs2239900	chr11:3030992	C/T	cg08508325	chr11:3079039	CARS	-0.34	-8.31	-0.48	7.74e-15	Longevity;
SARC	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.75	-8.2	-0.47	1.59e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs17539620	0.624	rs62432743	chr6:154836214	T/G	cg20019720	chr6:154832845	CNKSR3	0.41	4.84	0.3	2.39e-6	Lipoprotein (a) levels;
SARC	cis	rs78545713	1.000	rs11753610	chr6:26251601	C/T	cg00631329	chr6:26305371	NA	0.64	6.08	0.37	4.92e-9	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg13206674	chr6:150067644	NUP43	0.47	5.77	0.35	2.5e-8	Lung cancer;
SARC	cis	rs12545109	0.800	rs973548	chr8:57416402	C/T	cg19413350	chr8:57351067	NA	-0.42	-5.25	-0.33	3.38e-7	Obesity-related traits;
SARC	cis	rs72949976	0.584	rs13001511	chr2:214025262	G/A	cg08319019	chr2:214017104	IKZF2	0.48	6.48	0.39	5.44e-10	Lung cancer;Squamous cell lung carcinoma;
SARC	cis	rs2153535	0.580	rs1932280	chr6:8473654	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	8.42	0.48	3.95e-15	Motion sickness;
SARC	cis	rs7615952	0.575	rs35949599	chr3:125544202	G/A	cg05084668	chr3:125655381	ALG1L	-0.49	-5.17	-0.32	5.02e-7	Blood pressure (smoking interaction);
SARC	cis	rs6964587	0.740	rs2020360	chr7:91439506	G/C	cg17063962	chr7:91808500	NA	0.84	11.78	0.61	2.02e-25	Breast cancer;
SARC	cis	rs7089973	0.534	rs61869275	chr10:116749600	G/A	cg08188268	chr10:116634841	FAM160B1	0.4	5.17	0.32	5.02e-7	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs9905704	0.846	rs11079356	chr17:56864242	C/A	cg12560992	chr17:57184187	TRIM37	0.45	5.24	0.32	3.56e-7	Testicular germ cell tumor;
SARC	cis	rs703842	1.000	rs703842	chr12:58162739	C/T	cg00677455	chr12:58241039	CTDSP2	-0.49	-6.54	-0.39	3.89e-10	Multiple sclerosis;
SARC	cis	rs2153535	0.580	rs2327053	chr6:8443127	A/G	cg21535247	chr6:8435926	SLC35B3	0.61	7.68	0.45	4.34e-13	Motion sickness;
SARC	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg00149659	chr3:10157352	C3orf10	1.1	10.05	0.55	5.5e-20	Alzheimer's disease;
SARC	cis	rs782590	0.935	rs10460508	chr2:55882565	A/C	cg18811423	chr2:55921094	PNPT1	0.71	10.82	0.58	2.21e-22	Metabolic syndrome;
SARC	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg24846343	chr22:24311635	DDTL	-0.41	-4.86	-0.3	2.14e-6	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.8	10.35	0.56	6.69e-21	Prudent dietary pattern;
SARC	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg05368731	chr17:41323189	NBR1	0.7	8.65	0.49	8.51e-16	Menopause (age at onset);
SARC	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg08859206	chr1:53392774	SCP2	-0.41	-5.92	-0.36	1.14e-8	Monocyte count;
SARC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.65	0.53	9.21e-19	Prudent dietary pattern;
SARC	cis	rs9324022	0.929	rs12888043	chr14:101170436	A/G	cg18089426	chr14:101175970	NA	-0.51	-4.75	-0.3	3.59e-6	Plateletcrit;
SARC	cis	rs3796352	0.667	rs34860124	chr3:52857778	T/A	cg15956490	chr3:53032818	SFMBT1	0.72	4.78	0.3	3.15e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs13401104	0.716	rs12463651	chr2:237128272	A/G	cg19324714	chr2:237145437	ASB18	0.61	5.88	0.36	1.43e-8	Educational attainment;
SARC	trans	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.8	-0.41	8.74e-11	Neuroticism;
SARC	cis	rs4853036	0.951	rs61422548	chr2:70110249	G/T	cg02498382	chr2:70120550	SNRNP27	-0.37	-4.83	-0.3	2.42e-6	Colorectal or endometrial cancer;
SARC	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg13206674	chr6:150067644	NUP43	0.42	5.45	0.34	1.26e-7	Lung cancer;
SARC	cis	rs12142240	0.698	rs6695043	chr1:46844530	A/G	cg00530320	chr1:46809349	NSUN4	-0.57	-6.92	-0.41	4.26e-11	Menopause (age at onset);
SARC	cis	rs9905704	0.801	rs302847	chr17:56687481	C/T	cg12560992	chr17:57184187	TRIM37	0.42	4.87	0.3	2.03e-6	Testicular germ cell tumor;
SARC	cis	rs595982	0.726	rs607356	chr19:49371241	T/C	cg03707168	chr19:49379127	PPP1R15A	0.4	5.2	0.32	4.38e-7	Red cell distribution width;
SARC	cis	rs17209837	0.915	rs17149660	chr7:87089524	T/C	cg00919237	chr7:87102261	ABCB4	-0.5	-5.47	-0.34	1.14e-7	Gallbladder cancer;
SARC	cis	rs6840360	0.593	rs6857073	chr4:152689274	A/G	cg22705602	chr4:152727874	NA	0.49	8.34	0.48	6.37e-15	Intelligence (multi-trait analysis);
SARC	cis	rs17376456	0.597	rs1031423	chr5:93276883	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.45	-5.01	-0.31	1.1e-6	Diabetic retinopathy;
SARC	cis	rs9462027	0.606	rs7756009	chr6:34715395	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.4	-5.7	-0.35	3.67e-8	Systemic lupus erythematosus;
SARC	cis	rs986417	1.000	rs1254254	chr14:60831146	G/A	cg27398547	chr14:60952738	C14orf39	-1.0	-8.64	-0.49	9.19e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs2404602	0.536	rs11072599	chr15:76774508	T/C	cg22467129	chr15:76604101	ETFA	-0.37	-4.82	-0.3	2.64e-6	Blood metabolite levels;
SARC	cis	rs7219021	0.739	rs1973404	chr17:46967892	G/T	cg16584676	chr17:46985605	UBE2Z	-0.49	-5.69	-0.35	3.72e-8	Schizophrenia or bipolar disorder;
SARC	cis	rs7607369	0.648	rs7559629	chr2:219657013	A/T	cg02176678	chr2:219576539	TTLL4	-0.51	-8.24	-0.47	1.27e-14	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs9790314	0.521	rs60625846	chr3:161084525	G/T	cg04691961	chr3:161091175	C3orf57	-0.58	-7.67	-0.45	4.63e-13	Morning vs. evening chronotype;
SARC	cis	rs4986172	0.655	rs1044977	chr17:43227214	T/C	cg27395066	chr17:43221220	ACBD4	0.39	5.09	0.32	7.43e-7	Height;
SARC	cis	rs3092073	0.624	rs11906879	chr20:44591324	C/T	cg00981651	chr20:44574847	PCIF1	-0.29	-4.74	-0.3	3.64e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2204008	0.806	rs7305409	chr12:38349133	G/A	cg26384229	chr12:38710491	ALG10B	0.91	13.46	0.66	6.11e-31	Bladder cancer;
SARC	cis	rs17376456	0.877	rs10035340	chr5:93490465	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.61	5.12	0.32	6.49e-7	Diabetic retinopathy;
SARC	cis	rs7539542	0.516	rs10920530	chr1:202902754	A/G	cg08940984	chr1:202857613	RABIF	0.36	4.71	0.3	4.18e-6	Mean platelet volume;
SARC	cis	rs6963495	0.818	rs73190167	chr7:105160418	A/G	cg13798780	chr7:105162888	PUS7	0.6	5.45	0.34	1.31e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs10927875	0.501	rs9660676	chr1:16279041	C/T	cg21385522	chr1:16154831	NA	-0.86	-9.36	-0.52	6.79e-18	Dilated cardiomyopathy;
SARC	cis	rs7084402	0.967	rs1658490	chr10:60281616	G/A	cg07615347	chr10:60278583	BICC1	-0.6	-8.82	-0.5	2.71e-16	Refractive error;
SARC	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.68	6.58	0.4	3.13e-10	Platelet count;
SARC	cis	rs9911578	1.000	rs302840	chr17:56673079	C/G	cg05425664	chr17:57184151	TRIM37	-0.66	-8.29	-0.48	8.87e-15	Intelligence (multi-trait analysis);
SARC	cis	rs2070997	0.607	rs11244140	chr9:133663058	T/C	cg11464064	chr9:133710261	ABL1	0.53	5.04	0.31	9.3e-7	Response to amphetamines;
SARC	cis	rs11874712	1.000	rs1800636	chr18:43670420	C/T	cg25174615	chr18:43684699	ATP5A1;HAUS1	0.4	4.75	0.3	3.52e-6	Migraine - clinic-based;
SARC	cis	rs2841277	0.741	rs9672139	chr14:105408182	T/G	cg15352829	chr14:105391018	PLD4	-0.36	-6.75	-0.4	1.16e-10	Rheumatoid arthritis;
SARC	cis	rs79149102	0.579	rs78434425	chr15:75304754	C/T	cg09165964	chr15:75287851	SCAMP5	-1.11	-9.13	-0.51	3.27e-17	Lung cancer;
SARC	cis	rs9905704	0.846	rs2567894	chr17:56794115	G/A	cg12560992	chr17:57184187	TRIM37	0.43	4.93	0.31	1.58e-6	Testicular germ cell tumor;
SARC	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg03517284	chr6:25882590	NA	-0.39	-5.16	-0.32	5.38e-7	Intelligence (multi-trait analysis);
SARC	cis	rs986417	0.748	rs10142401	chr14:61039403	A/G	cg27398547	chr14:60952738	C14orf39	0.77	8.0	0.46	5.7e-14	Gut microbiota (bacterial taxa);
SARC	cis	rs12980942	0.872	rs12985339	chr19:41801756	A/T	cg25627403	chr19:41769009	HNRNPUL1	-0.62	-4.98	-0.31	1.24e-6	Coronary artery disease;
SARC	cis	rs3617	0.625	rs2071042	chr3:52864584	A/G	cg04865290	chr3:52927548	TMEM110	-0.34	-5.0	-0.31	1.14e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs9788721	0.836	rs17405217	chr15:78731149	C/T	cg06917634	chr15:78832804	PSMA4	-0.55	-5.9	-0.36	1.28e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs3126085	0.825	rs11204933	chr1:152172185	C/T	cg26876637	chr1:152193138	HRNR	0.48	5.51	0.34	9.32e-8	Atopic dermatitis;
SARC	cis	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg06558623	chr16:89946397	TCF25	0.93	6.44	0.39	6.63e-10	Skin colour saturation;
SARC	cis	rs453301	0.719	rs34004903	chr8:8892604	C/T	cg08975724	chr8:8085496	FLJ10661	-0.48	-6.2	-0.38	2.51e-9	Joint mobility (Beighton score);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg07391610	chr1:211432754	RCOR3	-0.85	-7.34	-0.43	3.53e-12	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2732480	0.557	rs2732484	chr12:48737245	A/C	cg21466736	chr12:48725269	NA	-0.34	-5.31	-0.33	2.54e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs2952156	0.920	rs1476278	chr17:37836243	C/T	cg00129232	chr17:37814104	STARD3	-0.72	-10.21	-0.56	1.81e-20	Asthma;
SARC	cis	rs2361718	0.522	rs11867921	chr17:78121170	G/T	cg27427491	chr17:78079615	GAA	-0.35	-4.96	-0.31	1.39e-6	Yeast infection;
SARC	cis	rs765787	0.530	rs4238377	chr15:45541981	A/G	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.51e-10	Uric acid levels;
SARC	cis	rs7312774	0.618	rs4964513	chr12:107375758	T/C	cg16260113	chr12:107380972	MTERFD3	1.2	9.08	0.51	4.89e-17	Severe influenza A (H1N1) infection;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg16411160	chr2:61645778	SNORA70B;USP34	0.45	6.29	0.38	1.54e-9	Thyroid stimulating hormone;
SARC	cis	rs73206853	0.841	rs56887341	chr12:110947185	T/C	cg10860002	chr12:110842031	ANAPC7	0.59	4.76	0.3	3.44e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs12421382	0.778	rs12804063	chr11:109495509	C/T	cg15948088	chr11:109293068	C11orf87	-0.4	-5.08	-0.32	7.67e-7	Schizophrenia;
SARC	cis	rs2051211	1.000	rs17037804	chr3:38559215	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.63	-7.22	-0.43	7.16e-12	QRS duration;
SARC	cis	rs7666738	0.791	rs34790496	chr4:98930516	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.73	0.5	5.01e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg18402987	chr7:1209562	NA	0.56	4.78	0.3	3.17e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs9987353	0.589	rs1053036	chr8:9060077	A/G	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.21	-0.47	1.55e-14	Recombination measurement;
SARC	cis	rs9527	0.615	rs11191485	chr10:104729816	G/C	cg04362960	chr10:104952993	NT5C2	0.42	4.97	0.31	1.3e-6	Arsenic metabolism;
SARC	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg25036284	chr2:26402008	FAM59B	0.49	5.97	0.36	8.85e-9	Gut microbiome composition (summer);
SARC	cis	rs8114671	0.662	rs6088664	chr20:33551100	G/A	cg07148914	chr20:33460835	GGT7	0.41	4.95	0.31	1.45e-6	Height;
SARC	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg08677398	chr8:58056175	NA	0.44	5.25	0.33	3.38e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1865760	0.929	rs9358896	chr6:25943197	C/A	cg16482183	chr6:26056742	HIST1H1C	0.52	6.64	0.4	2.17e-10	Height;
SARC	cis	rs3733585	0.605	rs4235354	chr4:10122942	C/A	cg11266682	chr4:10021025	SLC2A9	-0.38	-6.14	-0.37	3.6e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs5753037	0.653	rs140131	chr22:30151716	A/G	cg01021169	chr22:30184971	ASCC2	-0.45	-6.31	-0.38	1.38e-9	Type 1 diabetes;
SARC	cis	rs523522	0.962	rs4767905	chr12:120930835	C/T	cg12219531	chr12:120966889	COQ5	0.83	11.18	0.59	1.61e-23	High light scatter reticulocyte count;
SARC	cis	rs10911232	0.507	rs6660111	chr1:183014289	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.26	0.56	1.32e-20	Hypertriglyceridemia;
SARC	cis	rs748404	0.697	rs471122	chr15:43558574	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.39	-4.94	-0.31	1.46e-6	Lung cancer;
SARC	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg03650068	chr1:25596491	NA	-0.31	-4.71	-0.3	4.19e-6	Plateletcrit;Mean corpuscular volume;
SARC	cis	rs2997447	0.846	rs61775425	chr1:26405634	A/T	cg19633962	chr1:26362018	EXTL1	-0.62	-5.62	-0.35	5.36e-8	QRS complex (12-leadsum);
SARC	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg05793240	chr7:2802953	GNA12	-0.37	-5.38	-0.33	1.81e-7	Height;
SARC	cis	rs607987	0.871	rs4923631	chr11:30301868	T/C	cg06241208	chr11:30344200	C11orf46	0.42	5.03	0.31	9.7e-7	Body mass index;
SARC	cis	rs760805	1.000	rs4649037	chr1:25258301	G/T	cg22509179	chr1:25234806	RUNX3	-0.5	-6.97	-0.42	3.32e-11	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs7106204	0.800	rs7120940	chr11:24236485	C/A	ch.11.24196551F	chr11:24239977	NA	0.58	5.85	0.36	1.69e-8	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs554111	0.656	rs10799682	chr1:21424030	G/C	cg04902671	chr1:21058625	SH2D5	0.43	5.31	0.33	2.57e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs9467773	1.000	rs9467783	chr6:26542894	C/T	cg11502198	chr6:26597334	ABT1	0.43	5.31	0.33	2.51e-7	Intelligence (multi-trait analysis);
SARC	cis	rs918629	0.567	rs4642392	chr5:95255379	A/G	cg16656078	chr5:95278638	ELL2	0.52	6.55	0.39	3.62e-10	IgG glycosylation;
SARC	cis	rs6580649	0.941	rs17122612	chr12:48459488	C/G	cg24011408	chr12:48396354	COL2A1	-0.47	-5.09	-0.32	7.28e-7	Lung cancer;
SARC	cis	rs2236918	0.965	rs2488472	chr1:242019919	T/C	cg17736920	chr1:242011382	EXO1	0.78	11.01	0.58	5.8e-23	Menopause (age at onset);
SARC	cis	rs11690462	0.926	rs11689086	chr2:26549127	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.42	5.4	0.33	1.63e-7	Coronary artery disease;
SARC	cis	rs6570726	1.000	rs444564	chr6:145859795	G/C	cg05220968	chr6:146057943	EPM2A	-0.29	-4.91	-0.31	1.73e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2242116	0.796	rs9852082	chr3:46972377	T/C	cg02527881	chr3:46936655	PTH1R	-0.37	-5.68	-0.35	4.02e-8	Birth weight;
SARC	cis	rs7927592	0.913	rs6591344	chr11:68360873	G/A	cg01657329	chr11:68192670	LRP5	-0.43	-5.11	-0.32	6.59e-7	Total body bone mineral density;
SARC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.46	-7.19	-0.43	8.74e-12	Longevity;Endometriosis;
SARC	cis	rs3087591	1.000	rs2905877	chr17:29543269	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.47	-5.6	-0.34	5.9e-8	Hip circumference;
SARC	cis	rs17376456	0.825	rs13182631	chr5:93115701	A/G	cg21475434	chr5:93447410	FAM172A	0.72	6.25	0.38	1.92e-9	Diabetic retinopathy;
SARC	cis	rs12135062	0.851	rs2651925	chr1:3101863	C/G	cg00254258	chr1:3105189	PRDM16	0.41	6.89	0.41	5.19e-11	Migraine;
SARC	cis	rs10992471	0.729	rs6479418	chr9:95064762	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-6.67	-0.4	1.84e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs5167	0.583	rs7252480	chr19:45458925	C/T	cg13119609	chr19:45449297	APOC2	0.39	5.48	0.34	1.11e-7	Blood protein levels;
SARC	cis	rs2404602	0.735	rs2468130	chr15:76796496	T/C	cg15268244	chr15:77196840	NA	0.42	5.09	0.32	7.4e-7	Blood metabolite levels;
SARC	cis	rs3808502	0.525	rs13280813	chr8:11425105	G/T	cg21775007	chr8:11205619	TDH	-0.47	-6.23	-0.38	2.21e-9	Neuroticism;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg00311921	chr22:19119464	TSSK2;DGCR14	-0.78	-6.99	-0.42	2.93e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg15448220	chr1:150897856	SETDB1	0.48	6.38	0.39	9.29e-10	Tonsillectomy;
SARC	trans	rs9929218	0.508	rs1559366	chr16:68799611	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.77	11.96	0.62	5.26e-26	Colorectal cancer;
SARC	cis	rs11048434	0.626	rs1805736	chr12:9084931	A/G	cg26114124	chr12:9217669	LOC144571	-0.23	-4.74	-0.3	3.66e-6	Sjögren's syndrome;
SARC	cis	rs2011503	0.941	rs2010506	chr19:19387356	C/T	cg03709012	chr19:19516395	GATAD2A	0.61	5.25	0.33	3.38e-7	Bipolar disorder;
SARC	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg13866156	chr1:1669148	SLC35E2	-0.62	-9.23	-0.52	1.66e-17	Body mass index;
SARC	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg11644478	chr21:40555479	PSMG1	-0.56	-6.95	-0.41	3.69e-11	Menarche (age at onset);
SARC	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg21724239	chr8:58056113	NA	0.55	5.8	0.36	2.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg16049864	chr8:95962084	TP53INP1	-0.46	-7.3	-0.43	4.44e-12	Type 2 diabetes;
SARC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg06873352	chr17:61820015	STRADA	0.53	6.9	0.41	4.95e-11	Prudent dietary pattern;
SARC	cis	rs5758659	0.714	rs5758574	chr22:42481400	G/C	cg04733989	chr22:42467013	NAGA	-0.49	-6.11	-0.37	4.24e-9	Cognitive function;
SARC	cis	rs1153858	1.000	rs4627277	chr15:45652768	C/A	cg21132104	chr15:45694354	SPATA5L1	0.77	10.99	0.58	6.68e-23	Homoarginine levels;
SARC	cis	rs7927592	0.913	rs7118897	chr11:68360680	G/A	cg20283391	chr11:68216788	NA	-0.44	-4.73	-0.3	3.88e-6	Total body bone mineral density;
SARC	cis	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg22496380	chr5:211416	CCDC127	-0.88	-9.28	-0.52	1.21e-17	Breast cancer;
SARC	cis	rs7044106	0.791	rs2416798	chr9:123480603	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	5.9	0.36	1.3e-8	Hip circumference adjusted for BMI;
SARC	cis	rs2011503	1.000	rs1560687	chr19:19562902	G/A	cg03709012	chr19:19516395	GATAD2A	0.64	5.69	0.35	3.77e-8	Bipolar disorder;
SARC	cis	rs67311347	0.544	rs9877105	chr3:40333366	T/C	cg24209194	chr3:40518798	ZNF619	0.5	6.72	0.4	1.35e-10	Renal cell carcinoma;
SARC	cis	rs9420	0.816	rs674094	chr11:57665336	A/C	cg19752551	chr11:57585705	CTNND1	0.49	6.2	0.38	2.6e-9	Schizophrenia;
SARC	cis	rs9920506	0.536	rs11636605	chr15:78928878	A/G	cg24631222	chr15:78858424	CHRNA5	-0.51	-5.88	-0.36	1.38e-8	Post bronchodilator FEV1;
SARC	cis	rs1448094	0.556	rs11611968	chr12:86168022	G/A	cg02569458	chr12:86230093	RASSF9	0.37	5.03	0.31	9.77e-7	Major depressive disorder;
SARC	cis	rs11690935	0.851	rs7573003	chr2:172741415	T/A	cg13550731	chr2:172543902	DYNC1I2	-0.93	-13.57	-0.66	2.73e-31	Schizophrenia;
SARC	cis	rs7512552	0.839	rs11577843	chr1:150398258	A/G	cg15654264	chr1:150340011	RPRD2	0.39	5.03	0.31	9.63e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs1983891	0.908	rs2148342	chr6:41519522	G/A	cg15051332	chr6:41514432	FOXP4	0.57	6.28	0.38	1.66e-9	Prostate cancer;
SARC	cis	rs9398803	0.687	rs853987	chr6:127024775	A/G	cg19875578	chr6:126661172	C6orf173	-0.64	-8.87	-0.5	1.94e-16	Male-pattern baldness;
SARC	cis	rs6918586	0.658	rs198830	chr6:26118246	T/A	cg18357526	chr6:26021779	HIST1H4A	-0.45	-5.75	-0.35	2.76e-8	Schizophrenia;
SARC	cis	rs2304069	0.826	rs2244195	chr5:149403528	C/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.9	9.99	0.55	8.71e-20	HIV-1 control;
SARC	cis	rs9815354	1.000	rs2371627	chr3:41839219	A/G	cg03022575	chr3:42003672	ULK4	0.58	5.58	0.34	6.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs559928	0.606	rs1011219	chr11:63973396	A/G	cg02228329	chr11:64053129	BAD;GPR137	-0.65	-5.25	-0.33	3.43e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs10911232	0.507	rs6672306	chr1:183058898	C/T	cg13390022	chr1:182993471	LAMC1	0.33	5.07	0.32	8.14e-7	Hypertriglyceridemia;
SARC	cis	rs12079745	0.793	rs11805562	chr1:169292916	A/C	cg09363564	chr1:169337483	NME7;BLZF1	-0.87	-5.22	-0.32	3.93e-7	QT interval;
SARC	cis	rs2635047	0.967	rs3816125	chr18:44601611	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.61	-7.98	-0.46	6.77e-14	Educational attainment;
SARC	cis	rs10875746	1.000	rs10875746	chr12:48518264	A/C	cg26205652	chr12:48591994	NA	0.43	5.09	0.32	7.43e-7	Longevity (90 years and older);
SARC	cis	rs754466	0.580	rs17516020	chr10:79538734	C/T	cg17075019	chr10:79541650	NA	-0.77	-9.68	-0.54	7.62e-19	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg08280861	chr8:58055591	NA	0.7	5.73	0.35	3.1e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs36051895	0.664	rs11788834	chr9:5092466	G/A	cg02405213	chr9:5042618	JAK2	-0.47	-5.59	-0.34	6.31e-8	Pediatric autoimmune diseases;
SARC	cis	rs155076	0.938	rs261375	chr13:21871882	A/G	cg14456004	chr13:21872349	NA	1.1	13.09	0.65	1.01e-29	White matter hyperintensity burden;
SARC	cis	rs67311347	0.955	rs1129200	chr3:40532257	T/C	cg09455208	chr3:40491958	NA	0.32	4.91	0.31	1.7e-6	Renal cell carcinoma;
SARC	cis	rs6815814	0.950	rs5743560	chr4:38806200	G/T	cg06935464	chr4:38784597	TLR10	0.63	6.31	0.38	1.41e-9	Breast cancer;
SARC	cis	rs4689592	0.523	rs4256224	chr4:7074583	T/C	cg26116260	chr4:7069785	GRPEL1	0.9	10.97	0.58	7.79e-23	Monocyte percentage of white cells;
SARC	cis	rs2882667	0.858	rs11959803	chr5:138451315	G/A	cg04439458	chr5:138467593	SIL1	-0.28	-4.79	-0.3	3.02e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs3204955	1.000	rs12126394	chr1:116241559	A/C	cg20810993	chr1:116250018	CASQ2	-0.48	-5.22	-0.32	3.99e-7	Itch intensity from mosquito bite adjusted by bite size;
SARC	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg22535103	chr8:58192502	C8orf71	-0.59	-6.21	-0.38	2.37e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	9.8	0.54	3.29e-19	Platelet count;
SARC	cis	rs6815814	0.950	rs5743563	chr4:38806019	A/G	cg09316306	chr4:38807337	TLR1	0.5	5.16	0.32	5.35e-7	Breast cancer;
SARC	cis	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg08564027	chr20:61660810	NA	0.78	11.75	0.61	2.44e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs7520050	0.933	rs6656022	chr1:46394315	A/G	cg06784218	chr1:46089804	CCDC17	-0.26	-4.75	-0.3	3.57e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs7917772	0.636	rs7069489	chr10:104525371	A/G	ch.10.2196322F	chr10:104248062	ACTR1A	0.47	5.47	0.34	1.16e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs2599510	0.783	rs62136349	chr2:32827504	G/A	cg02381751	chr2:32503542	YIPF4	0.43	5.05	0.31	8.83e-7	Interleukin-18 levels;
SARC	cis	rs12421382	0.778	rs12804063	chr11:109495509	C/T	cg16359550	chr11:109292809	C11orf87	-0.38	-5.12	-0.32	6.32e-7	Schizophrenia;
SARC	cis	rs1008375	0.646	rs13103430	chr4:17567355	A/C	cg27347728	chr4:17578864	LAP3	-0.47	-5.48	-0.34	1.1e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9815354	0.812	rs73071242	chr3:41993011	T/C	cg03022575	chr3:42003672	ULK4	0.72	6.26	0.38	1.79e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg19671926	chr4:122722719	EXOSC9	-0.57	-6.43	-0.39	7.22e-10	Type 2 diabetes;
SARC	cis	rs6088590	1.000	rs6087623	chr20:33317662	C/G	cg06115741	chr20:33292138	TP53INP2	0.57	6.91	0.41	4.71e-11	Coronary artery disease;
SARC	cis	rs757081	0.667	rs12577525	chr11:17260116	G/A	cg15432903	chr11:17409602	KCNJ11	-0.37	-4.79	-0.3	3.01e-6	Systolic blood pressure;
SARC	cis	rs4595586	0.545	rs1303886	chr12:39366876	G/A	cg26384229	chr12:38710491	ALG10B	0.51	6.25	0.38	1.9e-9	Morning vs. evening chronotype;
SARC	cis	rs7523050	0.643	rs34096625	chr1:109401101	G/A	cg08274380	chr1:109419600	GPSM2	1.05	7.99	0.46	6.39e-14	Fat distribution (HIV);
SARC	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg02018176	chr4:1364513	KIAA1530	0.33	4.89	0.31	1.84e-6	Longevity;
SARC	cis	rs2327429	0.541	rs12193973	chr6:134151297	A/G	cg25632230	chr6:134101081	NA	0.43	5.39	0.33	1.71e-7	Coronary artery disease;
SARC	cis	rs8067354	0.645	rs7215180	chr17:57822354	A/G	cg02344993	chr17:57696989	CLTC	0.65	6.69	0.4	1.61e-10	Hemoglobin concentration;
SARC	cis	rs6456042	1.000	rs3099293	chr6:166530658	A/C	cg11088901	chr6:166572345	T	-0.35	-5.1	-0.32	7.02e-7	Asthma;
SARC	cis	rs9399137	0.507	rs11758774	chr6:135383789	T/G	cg22676075	chr6:135203613	NA	0.4	4.88	0.3	2e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs9354308	0.933	rs2022856	chr6:66568235	G/T	cg07460842	chr6:66804631	NA	0.49	5.59	0.34	6.34e-8	Metabolite levels;
SARC	cis	rs6121246	0.567	rs6060295	chr20:30198473	C/T	cg13852791	chr20:30311386	BCL2L1	0.68	5.91	0.36	1.2e-8	Mean corpuscular hemoglobin;
SARC	cis	rs6545883	0.965	rs2305156	chr2:61729268	T/C	cg15711740	chr2:61764176	XPO1	-0.43	-5.3	-0.33	2.68e-7	Tuberculosis;
SARC	cis	rs826838	1.000	rs10875991	chr12:39108886	G/C	cg13010199	chr12:38710504	ALG10B	0.76	10.53	0.57	1.91e-21	Heart rate;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg22885975	chr20:55926578	RAE1	0.5	6.33	0.38	1.25e-9	Schizophrenia;
SARC	cis	rs7264396	0.563	rs59064961	chr20:34307950	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	5.69	0.35	3.71e-8	Total cholesterol levels;
SARC	cis	rs509477	0.662	rs273343	chr18:32604173	G/C	cg23791764	chr18:32556832	MAPRE2	0.43	5.26	0.33	3.26e-7	Cerebrospinal fluid AB1-42 levels;
SARC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.39	0.56	4.87e-21	Prudent dietary pattern;
SARC	cis	rs778371	0.915	rs938569	chr2:233759695	C/G	cg16596103	chr2:233749413	NGEF	-0.35	-4.78	-0.3	3.13e-6	Schizophrenia;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg16533245	chr17:10612342	C17orf48	0.48	6.41	0.39	7.92e-10	Thyroid stimulating hormone;
SARC	cis	rs16854884	0.586	rs7611326	chr3:143736374	C/T	cg06585982	chr3:143692056	C3orf58	0.7	9.66	0.53	8.81e-19	Economic and political preferences (feminism/equality);
SARC	cis	rs72901758	0.768	rs11659046	chr17:76245718	G/A	cg23302638	chr17:76210176	BIRC5	0.46	4.76	0.3	3.4e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
SARC	cis	rs9291683	0.566	rs13144709	chr4:10044182	C/T	cg11266682	chr4:10021025	SLC2A9	0.4	6.91	0.41	4.53e-11	Bone mineral density;
SARC	cis	rs4481887	0.893	rs9651175	chr1:248446888	G/T	cg13385794	chr1:248469461	NA	0.34	5.13	0.32	6.09e-7	Common traits (Other);
SARC	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg23958373	chr8:599963	NA	0.7	5.94	0.36	1.01e-8	IgG glycosylation;
SARC	trans	rs208520	0.661	rs1100950	chr6:66827285	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-13.6	-0.67	2.17e-31	Exhaled nitric oxide output;
SARC	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg16606324	chr3:10149918	C3orf24	0.47	4.77	0.3	3.25e-6	Alzheimer's disease;
SARC	cis	rs7027203	1.000	rs7027203	chr9:96562563	A/C	cg14598338	chr9:96623480	NA	0.52	6.97	0.42	3.25e-11	DNA methylation (variation);
SARC	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg08859206	chr1:53392774	SCP2	-0.35	-5.23	-0.32	3.8e-7	Monocyte count;
SARC	cis	rs1008375	0.966	rs28441502	chr4:17598384	G/A	cg27347728	chr4:17578864	LAP3	0.46	5.45	0.34	1.27e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs921968	0.565	rs7603709	chr2:219642601	C/T	cg02176678	chr2:219576539	TTLL4	-0.32	-4.91	-0.31	1.7e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs10992471	0.627	rs4744138	chr9:95291909	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.44	-5.01	-0.31	1.06e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.48	7.48	0.44	1.52e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs6840258	1.000	rs10516788	chr4:87960857	A/G	cg11209507	chr4:87813803	C4orf36	0.44	4.73	0.3	3.82e-6	Mean corpuscular volume;Basophil percentage of granulocytes;
SARC	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.63	7.82	0.46	1.81e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg10295955	chr4:187884368	NA	-1.05	-17.56	-0.75	1.58e-44	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3008870	0.959	rs56707923	chr1:67388016	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.93	11.49	0.6	1.62e-24	Lymphocyte percentage of white cells;
SARC	cis	rs10782582	0.593	rs74090712	chr1:76189098	A/G	cg03433033	chr1:76189801	ACADM	-0.41	-5.35	-0.33	2.07e-7	Daytime sleep phenotypes;
SARC	cis	rs8141529	0.748	rs9620841	chr22:29290981	C/T	cg02153584	chr22:29168773	CCDC117	0.77	11.31	0.6	6.33e-24	Lymphocyte counts;
SARC	cis	rs834603	0.965	rs700755	chr7:47445641	A/G	cg23694490	chr7:47445681	TNS3	-0.41	-7.58	-0.44	8.15e-13	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg11987759	chr7:65425863	GUSB	0.58	7.79	0.45	2.22e-13	Aortic root size;
SARC	cis	rs921968	0.613	rs2710250	chr2:219543277	A/G	cg02176678	chr2:219576539	TTLL4	-0.35	-5.06	-0.31	8.59e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs10504229	0.593	rs2317990	chr8:58024168	G/T	cg08219700	chr8:58056026	NA	0.66	6.49	0.39	5.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	8.67	0.49	7.35e-16	Mean platelet volume;
SARC	cis	rs9911578	0.967	rs7214892	chr17:57065401	G/A	cg05425664	chr17:57184151	TRIM37	-0.64	-7.94	-0.46	8.46e-14	Intelligence (multi-trait analysis);
SARC	cis	rs17270561	0.636	rs6923367	chr6:25745852	A/T	cg17691542	chr6:26056736	HIST1H1C	0.61	7.36	0.43	3.06e-12	Iron status biomarkers;
SARC	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg04944784	chr2:26401820	FAM59B	-0.51	-6.49	-0.39	5.22e-10	Gut microbiome composition (summer);
SARC	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.61e-6	Depression;
SARC	cis	rs4589502	1.000	rs75502100	chr15:67131417	T/C	cg12317470	chr15:67143691	NA	0.65	4.77	0.3	3.22e-6	Lung cancer (smoking interaction);
SARC	trans	rs1814175	0.935	rs28586931	chr11:49693872	G/A	cg15704280	chr7:45808275	SEPT13	-0.94	-16.94	-0.74	1.71e-42	Height;
SARC	cis	rs7617773	0.780	rs11706277	chr3:48360433	A/G	cg11946769	chr3:48343235	NME6	0.78	9.57	0.53	1.64e-18	Coronary artery disease;
SARC	cis	rs920590	0.643	rs3855754	chr8:19659499	C/G	cg17834443	chr8:19674713	INTS10	0.48	5.94	0.36	1.03e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg15448220	chr1:150897856	SETDB1	0.47	6.19	0.38	2.7e-9	Tonsillectomy;
SARC	cis	rs17376456	1.000	rs67150649	chr5:93292377	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	5.79	0.35	2.23e-8	Diabetic retinopathy;
SARC	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg18252515	chr7:66147081	NA	-1.33	-11.96	-0.62	5.03e-26	Diabetic kidney disease;
SARC	cis	rs778371	0.723	rs12999865	chr2:233627250	T/C	cg20388707	chr2:233749442	NGEF	-0.34	-4.99	-0.31	1.16e-6	Schizophrenia;
SARC	cis	rs10028773	0.546	rs13117947	chr4:120257060	A/G	cg09307838	chr4:120376055	NA	0.52	7.0	0.42	2.66e-11	Educational attainment;
SARC	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg03575189	chr17:44344142	NA	0.61	5.97	0.36	8.61e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg05368731	chr17:41323189	NBR1	0.7	8.4	0.48	4.43e-15	Menopause (age at onset);
SARC	cis	rs2976388	0.556	rs10956985	chr8:143818750	C/A	cg06565975	chr8:143823917	SLURP1	-0.31	-4.76	-0.3	3.45e-6	Urinary tract infection frequency;
SARC	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.06	0.37	5.52e-9	Height;
SARC	cis	rs17376456	0.825	rs12716453	chr5:93271697	T/C	cg25358565	chr5:93447407	FAM172A	1.29	14.23	0.68	1.68e-33	Diabetic retinopathy;
SARC	cis	rs36051895	0.632	rs12684720	chr9:5150800	T/C	cg02405213	chr9:5042618	JAK2	-0.47	-5.62	-0.35	5.56e-8	Pediatric autoimmune diseases;
SARC	cis	rs1881797	1.000	rs1881796	chr1:247688931	G/A	cg11166453	chr1:247681781	NA	0.46	5.07	0.31	8.29e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs933688	0.532	rs13164949	chr5:90538489	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.51	-5.72	-0.35	3.2e-8	Smoking behavior;
SARC	cis	rs9300255	0.602	rs884548	chr12:123634122	A/G	cg00376283	chr12:123451042	ABCB9	0.57	6.67	0.4	1.81e-10	Neutrophil percentage of white cells;
SARC	cis	rs2273669	0.667	rs12215381	chr6:109363217	C/T	cg05315195	chr6:109294784	ARMC2	-0.63	-5.7	-0.35	3.6e-8	Prostate cancer;
SARC	cis	rs5769765	0.908	rs138864	chr22:50204712	G/A	cg03033257	chr22:50311977	ALG12;CRELD2	0.53	5.23	0.32	3.84e-7	Schizophrenia;
SARC	cis	rs7223966	1.000	rs9912904	chr17:61763534	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	6.59	0.4	2.94e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9911578	1.000	rs2531734	chr17:56550804	T/C	cg05425664	chr17:57184151	TRIM37	0.66	8.06	0.47	4.04e-14	Intelligence (multi-trait analysis);
SARC	cis	rs3857536	0.874	rs9354389	chr6:66885791	A/G	cg07460842	chr6:66804631	NA	-0.46	-5.35	-0.33	2.11e-7	Blood trace element (Cu levels);
SARC	cis	rs11971779	0.680	rs1862879	chr7:139019951	A/G	cg23387468	chr7:139079360	LUC7L2	0.33	4.8	0.3	2.82e-6	Diisocyanate-induced asthma;
SARC	cis	rs41264869	0.657	rs7530217	chr1:205109019	T/A	cg21643547	chr1:205240462	TMCC2	0.46	5.05	0.31	8.82e-7	Blood protein levels;
SARC	cis	rs3820928	1.000	rs3731593	chr2:227773924	A/G	cg05526886	chr2:227700861	RHBDD1	-0.5	-6.21	-0.38	2.45e-9	Pulmonary function;
SARC	cis	rs9322817	0.583	rs10782363	chr6:105149713	C/G	cg02098413	chr6:105308735	HACE1	0.38	5.91	0.36	1.21e-8	Thyroid stimulating hormone;
SARC	cis	rs1562975	0.609	rs12505944	chr4:109411822	G/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.45	5.81	0.36	2.08e-8	Height;
SARC	cis	rs7086627	0.515	rs7088877	chr10:82208860	C/G	cg00277334	chr10:82204260	NA	-0.57	-9.46	-0.53	3.6e-18	Post bronchodilator FEV1;
SARC	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg09455208	chr3:40491958	NA	0.38	5.51	0.34	9.28e-8	Renal cell carcinoma;
SARC	cis	rs3820928	0.874	rs10194663	chr2:227875369	T/A	cg11843606	chr2:227700838	RHBDD1	-0.52	-6.42	-0.39	7.55e-10	Pulmonary function;
SARC	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg17971929	chr21:40555470	PSMG1	0.99	13.74	0.67	7.45e-32	Cognitive function;
SARC	cis	rs60871478	0.636	rs10245785	chr7:894422	T/C	cg05535760	chr7:792225	HEATR2	-0.73	-6.9	-0.41	4.97e-11	Cerebrospinal P-tau181p levels;
SARC	cis	rs9611519	0.579	rs8136274	chr22:41415311	T/C	cg06634786	chr22:41940651	POLR3H	-0.38	-4.9	-0.31	1.8e-6	Neuroticism;
SARC	cis	rs6570726	0.791	rs6912079	chr6:145894949	G/A	cg05347473	chr6:146136440	FBXO30	0.54	7.43	0.44	2e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs116095464	1.000	rs2015774	chr5:312958	G/T	cg22857025	chr5:266934	NA	-1.04	-8.6	-0.49	1.21e-15	Breast cancer;
SARC	cis	rs9393692	0.840	rs9358915	chr6:26277268	G/A	cg13736514	chr6:26305472	NA	-0.6	-8.38	-0.48	5.15e-15	Educational attainment;
SARC	cis	rs4805272	0.512	rs7245724	chr19:29341679	C/T	cg04546413	chr19:29218101	NA	0.46	5.17	0.32	5.12e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs10979	1.000	rs9376756	chr6:143886125	C/T	cg25407410	chr6:143891975	LOC285740	-0.47	-6.1	-0.37	4.3e-9	Hypospadias;
SARC	cis	rs67460515	0.563	rs1599375	chr3:160897771	C/T	cg17135325	chr3:160939158	NMD3	-0.69	-8.98	-0.51	9.28e-17	Parkinson's disease;
SARC	cis	rs3008870	0.785	rs10889651	chr1:67463513	A/T	cg02640540	chr1:67518911	SLC35D1	-0.45	-5.12	-0.32	6.43e-7	Lymphocyte percentage of white cells;
SARC	cis	rs921968	0.541	rs4674314	chr2:219423520	A/G	cg02176678	chr2:219576539	TTLL4	-0.45	-6.77	-0.41	1.01e-10	Mean corpuscular hemoglobin concentration;
SARC	cis	rs193541	0.555	rs2438151	chr5:122199197	A/G	cg19412675	chr5:122181750	SNX24	0.5	6.61	0.4	2.6e-10	Glucose homeostasis traits;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg02773889	chr13:42615649	NA	-0.66	-7.55	-0.44	9.88e-13	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg25427524	chr10:38739819	LOC399744	-0.59	-9.16	-0.51	2.73e-17	Extrinsic epigenetic age acceleration;
SARC	cis	rs2153535	0.541	rs945304	chr6:8442892	A/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.62	0.49	1.02e-15	Motion sickness;
SARC	cis	rs4901847	1.000	rs12884702	chr14:58555329	A/T	cg15908186	chr14:58618357	C14orf37	0.43	5.04	0.31	9.46e-7	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg06028605	chr16:24865363	SLC5A11	-0.36	-5.71	-0.35	3.37e-8	Intelligence (multi-trait analysis);
SARC	cis	rs76878669	0.606	rs1785639	chr11:66100430	G/A	cg14036092	chr11:66035641	RAB1B	0.43	5.19	0.32	4.51e-7	Educational attainment (years of education);
SARC	cis	rs796364	0.951	rs281793	chr2:200847990	G/A	cg23649088	chr2:200775458	C2orf69	0.61	5.81	0.36	2.09e-8	Schizophrenia;
SARC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg11203670	chr7:100026453	MEPCE;ZCWPW1	0.54	5.65	0.35	4.67e-8	Platelet count;
SARC	trans	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg21775007	chr8:11205619	TDH	-0.5	-6.41	-0.39	7.8e-10	Neuroticism;
SARC	cis	rs2115630	0.905	rs1975277	chr15:85329558	C/T	cg12501888	chr15:85177176	SCAND2	-0.47	-5.7	-0.35	3.58e-8	P wave terminal force;
SARC	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg07389463	chr12:132296394	NA	0.36	5.82	0.36	1.96e-8	Migraine;
SARC	cis	rs834603	0.575	rs834606	chr7:47450632	A/G	cg23694490	chr7:47445681	TNS3	-0.34	-6.13	-0.37	3.65e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs80130819	0.748	rs10747531	chr12:48632280	A/G	cg05342945	chr12:48394962	COL2A1	-0.51	-5.45	-0.34	1.3e-7	Prostate cancer;
SARC	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg24549020	chr5:56110836	MAP3K1	0.81	8.35	0.48	6.22e-15	Initial pursuit acceleration;
SARC	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg18252515	chr7:66147081	NA	0.45	4.85	0.3	2.27e-6	Aortic root size;
SARC	cis	rs796364	0.951	rs7586320	chr2:201068209	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.53	5.25	0.33	3.49e-7	Schizophrenia;
SARC	cis	rs9916302	0.851	rs4794810	chr17:37603774	T/C	cg20243544	chr17:37824526	PNMT	0.57	6.95	0.41	3.65e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg07274523	chr3:49395745	GPX1	0.49	5.46	0.34	1.21e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs9309473	0.848	rs9750915	chr2:73811880	T/C	cg20560298	chr2:73613845	ALMS1	-0.48	-5.89	-0.36	1.32e-8	Metabolite levels;
SARC	cis	rs6088590	1.000	rs6087632	chr20:33407704	A/C	cg06115741	chr20:33292138	TP53INP2	0.54	6.51	0.39	4.68e-10	Coronary artery disease;
SARC	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg22535103	chr8:58192502	C8orf71	-0.7	-6.25	-0.38	1.95e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs11731606	0.508	rs7677981	chr4:95299736	C/T	cg00507259	chr4:95128692	SMARCAD1	0.54	5.31	0.33	2.59e-7	Mean platelet volume;
SARC	cis	rs2766692	0.810	rs7151517	chr14:100767044	C/G	cg14866419	chr14:100704911	YY1	-0.48	-5.45	-0.34	1.25e-7	Electroencephalographic traits in alcoholism;
SARC	cis	rs7223966	1.000	rs8078862	chr17:61854068	C/T	cg26338869	chr17:61819248	STRADA	0.45	4.85	0.3	2.23e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7635838	0.751	rs9850938	chr3:11587471	T/G	cg00170343	chr3:11313890	ATG7	-0.62	-8.65	-0.49	8.68e-16	HDL cholesterol;
SARC	cis	rs1059312	0.808	rs4760533	chr12:129297651	A/G	cg23521905	chr12:129298690	SLC15A4;MGC16384	-0.52	-7.68	-0.45	4.51e-13	Systemic lupus erythematosus;
SARC	cis	rs6782228	0.606	rs2253144	chr3:128329920	C/T	cg08795948	chr3:128337044	NA	-0.37	-5.08	-0.32	7.65e-7	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
SARC	cis	rs7592578	0.771	rs4439990	chr2:191398353	A/C	cg27211696	chr2:191398769	TMEM194B	-0.54	-5.54	-0.34	8.02e-8	Diastolic blood pressure;
SARC	cis	rs7617773	0.743	rs13081633	chr3:48357281	A/G	cg11946769	chr3:48343235	NME6	0.76	9.7	0.54	6.55e-19	Coronary artery disease;
SARC	cis	rs6088580	0.543	rs13042351	chr20:33238573	G/A	cg24642439	chr20:33292090	TP53INP2	-0.54	-6.65	-0.4	2.08e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs13178130	0.515	rs329304	chr5:133897829	A/G	cg26284174	chr5:133860141	NA	0.42	4.81	0.3	2.71e-6	Menarche (age at onset);
SARC	cis	rs2295359	1.000	rs736197	chr1:67607135	G/T	cg12940439	chr1:67600707	NA	0.44	6.83	0.41	7.47e-11	Psoriasis;
SARC	cis	rs6088590	1.000	rs6119512	chr20:33306904	T/C	cg08999081	chr20:33150536	PIGU	0.34	4.91	0.31	1.75e-6	Coronary artery disease;
SARC	cis	rs7246657	0.943	rs10413602	chr19:37891492	T/C	cg23950597	chr19:37808831	NA	-0.62	-6.05	-0.37	5.66e-9	Coronary artery calcification;
SARC	trans	rs7070797	0.735	rs7076398	chr10:63533663	T/A	cg06731886	chr7:73284078	NA	-0.51	-6.5	-0.39	4.86e-10	Takotsubo syndrome;
SARC	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg23758822	chr17:41437982	NA	0.9	11.51	0.6	1.45e-24	Menopause (age at onset);
SARC	cis	rs9457247	0.663	rs2301436	chr6:167437988	C/T	cg23791538	chr6:167370224	RNASET2	-0.5	-6.56	-0.39	3.44e-10	Crohn's disease;
SARC	cis	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.41	-5.12	-0.32	6.31e-7	Eosinophil percentage of white cells;
SARC	cis	rs35110281	0.641	rs4818858	chr21:45083097	C/T	cg21573476	chr21:45109991	RRP1B	0.56	7.7	0.45	3.87e-13	Mean corpuscular volume;
SARC	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg00149659	chr3:10157352	C3orf10	-0.74	-7.18	-0.43	9.48e-12	Alzheimer's disease;
SARC	cis	rs12971120	1.000	rs2278162	chr18:72175814	A/G	cg25817165	chr18:72167213	CNDP2	-0.5	-7.42	-0.44	2.12e-12	Refractive error;
SARC	cis	rs1580019	0.713	rs2122632	chr7:32524686	A/G	cg14728415	chr7:32535168	LSM5;AVL9	-0.48	-5.98	-0.36	8.23e-9	Cognitive ability;
SARC	cis	rs4803468	0.967	rs3213860	chr19:41920211	T/C	cg14132834	chr19:41945861	ATP5SL	-0.55	-7.19	-0.43	8.79e-12	Height;
SARC	cis	rs9467773	0.620	rs9461276	chr6:26595168	T/C	cg11502198	chr6:26597334	ABT1	0.66	8.87	0.5	1.97e-16	Intelligence (multi-trait analysis);
SARC	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg12463550	chr7:65579703	CRCP	0.48	5.79	0.35	2.23e-8	Aortic root size;
SARC	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.14	0.37	3.5e-9	Bipolar disorder;
SARC	cis	rs2075371	0.863	rs1646638	chr7:134008706	T/C	cg00033643	chr7:134001901	SLC35B4	0.52	6.53	0.39	4.06e-10	Mean platelet volume;
SARC	cis	rs7020830	0.522	rs10814509	chr9:37111057	A/G	cg14294708	chr9:37120828	ZCCHC7	0.85	12.0	0.62	3.82e-26	Schizophrenia;
SARC	cis	rs921968	0.643	rs589967	chr2:219445165	T/C	cg02176678	chr2:219576539	TTLL4	0.35	5.34	0.33	2.2e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg07701084	chr6:150067640	NUP43	0.42	5.32	0.33	2.46e-7	Lung cancer;
SARC	cis	rs76419734	1.000	rs28488297	chr4:106767226	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.73	5.35	0.33	2.06e-7	Post bronchodilator FEV1;
SARC	cis	rs10911232	0.507	rs61081633	chr1:182995608	A/G	cg13390022	chr1:182993471	LAMC1	0.33	4.97	0.31	1.29e-6	Hypertriglyceridemia;
SARC	cis	rs10870270	0.830	rs11146269	chr10:133761820	G/A	cg26149184	chr10:133730230	NA	0.46	5.09	0.32	7.26e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs3008870	0.755	rs2755254	chr1:67470855	C/T	cg02640540	chr1:67518911	SLC35D1	0.45	5.21	0.32	4.09e-7	Lymphocyte percentage of white cells;
SARC	cis	rs7551222	0.752	rs4951389	chr1:204475834	G/T	cg20240347	chr1:204465584	NA	-0.35	-6.41	-0.39	8.06e-10	Schizophrenia;
SARC	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg06074448	chr4:187884817	NA	-0.41	-5.45	-0.34	1.3e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs34779708	0.742	rs35912711	chr10:35312996	T/C	cg03585969	chr10:35415529	CREM	0.39	4.82	0.3	2.55e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs910316	1.000	rs11159117	chr14:75584867	C/T	cg08847533	chr14:75593920	NEK9	0.94	15.81	0.72	9.24e-39	Height;
SARC	cis	rs8113308	0.752	rs8113758	chr19:52493307	C/T	cg25782003	chr19:52490127	ZNF350	0.72	6.02	0.37	6.65e-9	Survival in endocrine treated breast cancer (estrogen-receptor positive);
SARC	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg16479474	chr6:28041457	NA	0.36	5.27	0.33	3.04e-7	Depression;
SARC	cis	rs17023223	0.581	rs12064109	chr1:119642296	T/C	cg05756136	chr1:119680316	WARS2	-0.45	-4.88	-0.3	2e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs11583043	0.874	rs6577222	chr1:101420502	C/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.48	6.03	0.37	6.33e-9	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs3796352	1.000	rs34943350	chr3:53012888	C/T	cg07884673	chr3:53033167	SFMBT1	0.83	5.17	0.32	5.01e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs11630290	1.000	rs72750981	chr15:63983737	A/T	cg12036633	chr15:63758958	NA	-0.57	-5.45	-0.34	1.26e-7	Iris characteristics;
SARC	trans	rs11098499	0.863	rs6853998	chr4:120475860	C/A	cg25214090	chr10:38739885	LOC399744	0.57	7.25	0.43	6.27e-12	Corneal astigmatism;
SARC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg12000995	chr2:27665139	KRTCAP3	-0.3	-4.77	-0.3	3.24e-6	Total body bone mineral density;
SARC	cis	rs2404602	0.647	rs2404600	chr15:77173557	C/T	cg15268244	chr15:77196840	NA	0.45	5.18	0.32	4.76e-7	Blood metabolite levels;
SARC	cis	rs7666738	0.830	rs4699331	chr4:99059816	T/C	cg05340658	chr4:99064831	C4orf37	0.64	8.66	0.49	7.7e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs73206853	0.764	rs73194012	chr12:111100627	T/C	cg10860002	chr12:110842031	ANAPC7	0.57	4.87	0.3	2.07e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg06723301	chr22:21213449	SNAP29;PI4KA	0.63	6.45	0.39	6.54e-10	Lung cancer in ever smokers;
SARC	cis	rs1707322	1.000	rs785504	chr1:46595696	C/T	cg06784218	chr1:46089804	CCDC17	-0.36	-6.24	-0.38	2.03e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7937682	0.889	rs490199	chr11:111487890	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.87	-13.3	-0.66	2.02e-30	Primary sclerosing cholangitis;
SARC	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg06212747	chr3:49208901	KLHDC8B	0.74	10.39	0.56	5.04e-21	Menarche (age at onset);
SARC	cis	rs7291412	0.540	rs9627391	chr22:46447097	C/T	cg13269407	chr22:46450107	C22orf26;LOC150381	0.36	4.94	0.31	1.51e-6	Dupuytren's disease;Subjective well-being;
SARC	cis	rs5744897	0.581	rs35235926	chr12:133304126	G/A	cg16945633	chr12:133170342	NA	0.58	5.84	0.36	1.77e-8	Urate levels in overweight individuals;
SARC	cis	rs3733585	0.699	rs6823361	chr4:9963127	A/G	cg11266682	chr4:10021025	SLC2A9	-0.34	-5.85	-0.36	1.62e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs4713675	0.584	rs6917140	chr6:33678394	C/G	cg15676125	chr6:33679581	C6orf125	0.54	6.59	0.4	2.96e-10	Plateletcrit;
SARC	cis	rs12048904	0.512	rs932798	chr1:101249355	G/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.55	-6.1	-0.37	4.33e-9	Multiple sclerosis;
SARC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg23131131	chr22:24373011	LOC391322	-0.43	-4.98	-0.31	1.25e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg09699651	chr6:150184138	LRP11	0.45	5.54	0.34	8.23e-8	Lung cancer;
SARC	cis	rs6088580	0.609	rs945674	chr20:32964247	G/C	cg08999081	chr20:33150536	PIGU	-0.44	-6.65	-0.4	2.07e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs9291683	0.566	rs13144709	chr4:10044182	C/T	cg00071950	chr4:10020882	SLC2A9	0.33	4.98	0.31	1.26e-6	Bone mineral density;
SARC	cis	rs9810089	0.676	rs526574	chr3:136103349	A/G	cg15507776	chr3:136538369	TMEM22	0.45	5.0	0.31	1.12e-6	Gestational age at birth (child effect);
SARC	cis	rs763121	0.752	rs5757222	chr22:39060473	C/T	cg14440974	chr22:39074834	NA	-0.34	-4.89	-0.3	1.9e-6	Menopause (age at onset);
SARC	cis	rs12586317	0.547	rs112138868	chr14:35444385	C/T	cg16230307	chr14:35515116	FAM177A1	1.02	11.72	0.61	3.08e-25	Psoriasis;
SARC	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg05861140	chr6:150128134	PCMT1	-0.41	-5.28	-0.33	2.98e-7	Lung cancer;
SARC	cis	rs7681440	0.904	rs7680761	chr4:90763510	A/T	cg06632027	chr4:90757378	SNCA	0.41	5.88	0.36	1.38e-8	Dementia with Lewy bodies;
SARC	cis	rs17253792	0.822	rs9972178	chr14:56073480	A/G	cg01858014	chr14:56050164	KTN1	-0.71	-5.63	-0.35	5.25e-8	Putamen volume;
SARC	cis	rs1401999	0.836	rs34571027	chr3:183726644	T/C	cg01324343	chr3:183735012	ABCC5	0.64	12.67	0.64	2.41e-28	Anterior chamber depth;
SARC	cis	rs372883	0.648	rs1153291	chr21:30689070	G/T	cg08807101	chr21:30365312	RNF160	-0.48	-5.92	-0.36	1.15e-8	Pancreatic cancer;
SARC	cis	rs4742903	0.967	rs7048372	chr9:106859738	T/C	cg21169611	chr9:106856078	SMC2	0.4	4.94	0.31	1.48e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs11731606	0.508	rs6827755	chr4:95309170	C/T	cg00507259	chr4:95128692	SMARCAD1	0.48	4.72	0.3	4.07e-6	Mean platelet volume;
SARC	cis	rs8044868	0.530	rs2287998	chr16:72059269	C/T	cg16558253	chr16:72132732	DHX38	0.4	5.97	0.36	8.91e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
SARC	cis	rs9436747	0.748	rs1185692	chr1:66000659	C/G	cg14976592	chr1:65886160	LEPROT;LEPR	-0.53	-5.19	-0.32	4.49e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs11098499	0.865	rs11098513	chr4:120316075	A/G	cg09307838	chr4:120376055	NA	0.92	12.95	0.65	2.93e-29	Corneal astigmatism;
SARC	trans	rs7937682	1.000	rs505372	chr11:111507189	A/C	cg18187862	chr3:45730750	SACM1L	0.56	6.96	0.41	3.35e-11	Primary sclerosing cholangitis;
SARC	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg16479474	chr6:28041457	NA	0.33	5.1	0.32	6.88e-7	Cardiac Troponin-T levels;
SARC	cis	rs9341808	0.667	rs583426	chr6:80946687	G/A	cg08355045	chr6:80787529	NA	-0.36	-5.9	-0.36	1.26e-8	Sitting height ratio;
SARC	cis	rs1355223	0.583	rs1553757	chr11:34867089	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.75	10.91	0.58	1.2e-22	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs13392177	0.660	rs12988046	chr2:219073804	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.57	-7.34	-0.43	3.5e-12	Pyoderma gangrenosum in inflammatory bowel disease;
SARC	cis	rs6871536	1.000	rs7449456	chr5:131953427	C/T	cg11797159	chr5:131991491	NA	0.38	4.98	0.31	1.22e-6	Asthma (childhood onset);
SARC	trans	rs1814175	0.935	rs7925863	chr11:49615802	C/A	cg15704280	chr7:45808275	SEPT13	-0.91	-15.94	-0.72	3.59e-39	Height;
SARC	cis	rs7186128	0.503	rs35128250	chr16:16926779	A/C	cg05297692	chr16:16228264	ABCC1	-0.37	-4.88	-0.3	2e-6	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs965469	0.779	rs6139092	chr20:3334651	T/C	cg25506879	chr20:3388711	C20orf194	-0.47	-5.24	-0.32	3.66e-7	IFN-related cytopenia;
SARC	cis	rs4595586	1.000	rs4768388	chr12:39223924	G/A	cg26384229	chr12:38710491	ALG10B	-0.4	-4.86	-0.3	2.18e-6	Morning vs. evening chronotype;
SARC	cis	rs10492096	1.000	rs12427239	chr12:6590626	C/T	cg13857086	chr12:6580257	VAMP1	0.7	6.99	0.42	2.84e-11	Hip geometry;
SARC	cis	rs12153160	1.000	rs12520732	chr5:152955877	A/G	cg16532600	chr5:153857824	HAND1	0.51	4.8	0.3	2.85e-6	Middle childhood and early adolescence aggressive behavior;
SARC	cis	rs4727027	0.933	rs1058059	chr7:148879134	A/T	cg23583168	chr7:148888333	NA	-0.73	-10.62	-0.57	9.81e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs425277	1.000	rs436045	chr1:2071556	A/G	cg24578937	chr1:2090814	PRKCZ	-0.32	-6.02	-0.37	6.78e-9	Height;
SARC	cis	rs921968	0.643	rs3770218	chr2:219525335	C/T	cg02176678	chr2:219576539	TTLL4	0.36	5.35	0.33	2.09e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs950169	1.000	rs79318564	chr15:84786150	G/A	cg17507749	chr15:85114479	UBE2QP1	0.76	9.19	0.52	2.21e-17	Schizophrenia;
SARC	cis	rs8084125	0.832	rs884472	chr18:74946087	A/G	cg05528293	chr18:74961138	GALR1	0.52	5.8	0.36	2.16e-8	Obesity-related traits;
SARC	cis	rs17666538	1.000	rs73177066	chr8:585750	C/T	cg07234876	chr8:600039	NA	-1.0	-7.44	-0.44	1.88e-12	IgG glycosylation;
SARC	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg18305652	chr10:134549665	INPP5A	0.35	5.15	0.32	5.65e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs910316	0.763	rs4556	chr14:75476071	G/C	cg11812906	chr14:75593930	NEK9	0.8	11.04	0.59	4.69e-23	Height;
SARC	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg16479474	chr6:28041457	NA	0.34	5.19	0.32	4.68e-7	Cardiac Troponin-T levels;
SARC	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.46	-5.77	-0.35	2.48e-8	Lymphocyte counts;
SARC	cis	rs8180040	0.701	rs13066214	chr3:47033937	C/T	cg27129171	chr3:47204927	SETD2	0.65	9.08	0.51	4.73e-17	Colorectal cancer;
SARC	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg17376030	chr22:41985996	PMM1	-0.76	-9.34	-0.52	8.25e-18	Vitiligo;
SARC	cis	rs986417	0.901	rs1955687	chr14:60988606	A/G	cg27398547	chr14:60952738	C14orf39	1.0	9.54	0.53	1.95e-18	Gut microbiota (bacterial taxa);
SARC	cis	rs2549003	1.000	rs7701588	chr5:131819970	T/C	cg21138405	chr5:131827807	IRF1	0.27	5.33	0.33	2.26e-7	Asthma (sex interaction);
SARC	cis	rs7681440	0.606	rs2737009	chr4:90746836	A/G	cg06632027	chr4:90757378	SNCA	-0.43	-5.32	-0.33	2.4e-7	Dementia with Lewy bodies;
SARC	cis	rs2624839	0.704	rs2624833	chr3:50212512	G/T	cg24110177	chr3:50126178	RBM5	-0.56	-6.88	-0.41	5.43e-11	Intelligence (multi-trait analysis);
SARC	cis	rs9868809	0.505	rs11719291	chr3:48735706	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.58	-5.3	-0.33	2.69e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs3768617	0.565	rs10752898	chr1:183077896	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.67	9.6	0.53	1.37e-18	Fuchs's corneal dystrophy;
SARC	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg11890956	chr21:40555474	PSMG1	-0.7	-8.98	-0.51	9.11e-17	Menarche (age at onset);
SARC	cis	rs1044826	1.000	rs9818691	chr3:139113199	C/T	cg15131784	chr3:139108705	COPB2	0.45	5.16	0.32	5.22e-7	Obesity-related traits;
SARC	cis	rs9487051	0.676	rs9398196	chr6:109601554	A/G	cg01475377	chr6:109611718	NA	-0.36	-5.26	-0.33	3.22e-7	Reticulocyte fraction of red cells;
SARC	cis	rs7847628	0.550	rs12343516	chr9:123603469	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.94	14.96	0.7	6.69e-36	Birth weight;
SARC	cis	rs76917914	0.537	rs3780471	chr9:100847551	G/T	cg03040243	chr9:100819229	NANS	0.52	5.78	0.35	2.42e-8	Immature fraction of reticulocytes;
SARC	cis	rs7103648	0.695	rs12223593	chr11:47789082	T/G	cg20307385	chr11:47447363	PSMC3	0.76	10.21	0.56	1.77e-20	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs7250872	0.647	rs2304613	chr19:1817943	G/C	cg18850929	chr19:1828978	REXO1	0.46	5.78	0.35	2.38e-8	Bipolar disorder;
SARC	cis	rs10870270	1.000	rs10159943	chr10:133744744	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.46	-5.44	-0.34	1.33e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs1545257	0.537	rs4581852	chr2:24638256	C/A	cg06627628	chr2:24431161	ITSN2	-0.55	-6.97	-0.42	3.18e-11	Sjögren's syndrome;
SARC	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg03264133	chr6:25882463	NA	-0.37	-5.02	-0.31	1.02e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7084402	1.000	rs6481402	chr10:60268977	T/C	cg07615347	chr10:60278583	BICC1	-0.58	-8.47	-0.49	2.83e-15	Refractive error;
SARC	cis	rs13631	0.965	rs7853589	chr9:140003844	A/G	cg14289826	chr9:140003911	NA	-0.31	-4.75	-0.3	3.54e-6	Cerebrospinal fluid biomarker levels;
SARC	cis	rs11098499	1.000	rs11726229	chr4:120211580	C/T	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.69e-6	Corneal astigmatism;
SARC	cis	rs11785693	0.862	rs62491171	chr8:4987177	G/A	cg26367366	chr8:4980734	NA	0.7	6.35	0.38	1.11e-9	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs2806561	0.765	rs679591	chr1:23499916	T/C	cg12483005	chr1:23474871	LUZP1	0.41	5.46	0.34	1.23e-7	Height;
SARC	cis	rs3820928	0.874	rs56324594	chr2:227868854	C/T	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.66	-0.35	4.32e-8	Pulmonary function;
SARC	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg02725872	chr8:58115012	NA	-0.37	-6.55	-0.39	3.71e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1580019	0.961	rs1610143	chr7:32498331	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.73	9.78	0.54	3.93e-19	Cognitive ability;
SARC	cis	rs7662987	0.517	rs3018047	chr4:100014510	C/T	cg12011299	chr4:100065546	ADH4	-0.32	-5.43	-0.34	1.39e-7	Smoking initiation;
SARC	cis	rs1434579	0.572	rs926052	chr19:44952236	A/T	cg15540054	chr19:45004280	ZNF180	0.39	4.8	0.3	2.88e-6	Tuberculosis;
SARC	cis	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg05084668	chr3:125655381	ALG1L	-0.5	-5.33	-0.33	2.36e-7	Blood pressure (smoking interaction);
SARC	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg18876405	chr7:65276391	NA	0.71	9.3	0.52	1.06e-17	Aortic root size;
SARC	cis	rs3018066	0.518	rs7697673	chr4:107296620	G/T	cg09646026	chr4:107269030	AIMP1	-0.45	-4.9	-0.31	1.82e-6	Cancer;
SARC	cis	rs526231	0.543	rs27698	chr5:102526175	C/T	cg23492399	chr5:102201601	PAM	0.5	5.41	0.33	1.54e-7	Primary biliary cholangitis;
SARC	cis	rs6782228	0.606	rs10048945	chr3:128409680	C/T	cg16766828	chr3:128327626	NA	-0.32	-4.78	-0.3	3.11e-6	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
SARC	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg18404041	chr3:52824283	ITIH1	-0.44	-6.5	-0.39	4.94e-10	Bipolar disorder;
SARC	cis	rs36051895	0.664	rs7847141	chr9:5097171	A/T	cg02405213	chr9:5042618	JAK2	-0.45	-5.6	-0.34	6.1e-8	Pediatric autoimmune diseases;
SARC	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg11764359	chr7:65958608	NA	-0.78	-9.67	-0.54	8.24e-19	Aortic root size;
SARC	cis	rs2997447	0.846	rs61775422	chr1:26395898	C/T	cg19633962	chr1:26362018	EXTL1	-0.67	-5.47	-0.34	1.18e-7	QRS complex (12-leadsum);
SARC	cis	rs721399	1.000	rs11780610	chr8:18259876	C/T	cg18736775	chr8:18248649	NAT2	0.42	5.56	0.34	7.49e-8	Blood metabolite levels;
SARC	cis	rs7568458	0.846	rs6547621	chr2:85774676	G/A	cg02493740	chr2:85810744	VAMP5	-0.36	-5.3	-0.33	2.66e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	trans	rs1478897	0.898	rs2248932	chr8:11391650	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.67	-0.4	1.81e-10	Systemic lupus erythematosus;
SARC	cis	rs6063312	0.667	rs9679994	chr20:47281853	T/C	cg18078177	chr20:47281410	PREX1	0.58	7.24	0.43	6.63e-12	Tonometry;
SARC	cis	rs2760061	0.626	rs596675	chr1:228117892	G/A	cg02753203	chr1:228287806	NA	-0.54	-7.39	-0.44	2.55e-12	Diastolic blood pressure;
SARC	cis	rs67311347	1.000	rs6599102	chr3:40468406	G/A	cg24209194	chr3:40518798	ZNF619	0.62	8.13	0.47	2.47e-14	Renal cell carcinoma;
SARC	cis	rs910316	1.000	rs175425	chr14:75626131	T/C	cg11812906	chr14:75593930	NEK9	-0.82	-11.68	-0.61	4.09e-25	Height;
SARC	cis	rs4727027	0.870	rs1568945	chr7:148874112	T/G	cg23583168	chr7:148888333	NA	-0.73	-10.33	-0.56	7.92e-21	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs2408955	0.521	rs1476607	chr12:48524804	A/G	cg24011408	chr12:48396354	COL2A1	-0.43	-5.25	-0.32	3.5e-7	Glycated hemoglobin levels;
SARC	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg07701084	chr6:150067640	NUP43	0.41	5.44	0.34	1.32e-7	Lung cancer;
SARC	cis	rs9905704	0.846	rs35082135	chr17:56939694	A/G	cg12560992	chr17:57184187	TRIM37	0.47	5.57	0.34	7.12e-8	Testicular germ cell tumor;
SARC	cis	rs7465272	1.000	rs7835613	chr8:143682428	C/T	cg10596483	chr8:143751796	JRK	0.57	6.14	0.37	3.55e-9	Bipolar disorder and schizophrenia;
SARC	trans	rs36093844	0.800	rs78356210	chr11:85581267	G/A	cg27065003	chr5:122429449	PRDM6	-0.56	-6.57	-0.4	3.21e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	trans	rs3780486	0.846	rs10124479	chr9:33136233	T/G	cg20290983	chr6:43655470	MRPS18A	1.14	21.94	0.82	1.32e-58	IgG glycosylation;
SARC	cis	rs2273669	0.667	rs114481082	chr6:109280932	G/A	cg05315195	chr6:109294784	ARMC2	-0.59	-5.25	-0.33	3.42e-7	Prostate cancer;
SARC	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.93	-15.23	-0.71	8.29e-37	Chronic sinus infection;
SARC	cis	rs9309473	0.950	rs6546860	chr2:73844249	G/A	cg20560298	chr2:73613845	ALMS1	-0.44	-5.3	-0.33	2.66e-7	Metabolite levels;
SARC	cis	rs7914558	0.966	rs1890185	chr10:104748718	A/G	cg04362960	chr10:104952993	NT5C2	0.42	5.09	0.32	7.37e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs7937682	0.883	rs566647	chr11:111466607	A/G	cg22437258	chr11:111473054	SIK2	-0.82	-11.0	-0.58	6.07e-23	Primary sclerosing cholangitis;
SARC	cis	rs3126085	0.935	rs4595369	chr1:152248193	G/A	cg03465714	chr1:152285911	FLG	-0.46	-5.55	-0.34	7.61e-8	Atopic dermatitis;
SARC	cis	rs2120243	0.572	rs3816528	chr3:157127290	C/T	cg24825693	chr3:157122686	VEPH1	0.49	6.83	0.41	7.27e-11	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs73198271	0.632	rs57687880	chr8:8602910	C/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-5.71	-0.35	3.43e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs2387326	0.717	rs10829334	chr10:129943402	C/T	cg16087940	chr10:129947807	NA	-0.45	-5.56	-0.34	7.21e-8	Select biomarker traits;
SARC	cis	rs6087990	0.584	rs6058897	chr20:31398105	G/T	cg13636640	chr20:31349939	DNMT3B	-0.67	-9.97	-0.55	9.68e-20	Ulcerative colitis;
SARC	trans	rs925098	0.577	rs961014	chr4:18010384	A/G	cg08521178	chr6:170491202	NA	0.41	6.28	0.38	1.62e-9	Birth weight;Height;
SARC	cis	rs9399137	0.507	rs10484496	chr6:135299682	T/C	cg22676075	chr6:135203613	NA	0.38	4.8	0.3	2.83e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs2153535	0.542	rs6912740	chr6:8439959	A/G	cg21535247	chr6:8435926	SLC35B3	0.56	7.01	0.42	2.6e-11	Motion sickness;
SARC	cis	rs3091242	0.967	rs3093614	chr1:25677844	T/A	cg02931644	chr1:25747376	RHCE	-0.48	-8.06	-0.47	3.88e-14	Erythrocyte sedimentation rate;
SARC	cis	rs708547	0.836	rs1315005	chr4:57858237	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.74	9.81	0.54	3.1e-19	Response to bleomycin (chromatid breaks);
SARC	cis	rs12579753	0.956	rs11115038	chr12:82214660	T/G	cg07988820	chr12:82153109	PPFIA2	-0.56	-6.23	-0.38	2.12e-9	Resting heart rate;
SARC	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.38	-4.78	-0.3	3.08e-6	Lymphocyte counts;
SARC	cis	rs9914988	0.565	rs66811679	chr17:27296421	C/G	cg10538030	chr17:27276405	PHF12	-0.63	-5.1	-0.32	6.91e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg07701084	chr6:150067640	NUP43	0.41	5.39	0.33	1.71e-7	Lung cancer;
SARC	cis	rs3126085	0.935	rs4845733	chr1:152162568	T/C	cg03465714	chr1:152285911	FLG	-0.47	-5.61	-0.35	5.61e-8	Atopic dermatitis;
SARC	cis	rs921968	0.509	rs832813	chr2:219354569	T/C	cg02176678	chr2:219576539	TTLL4	0.41	6.2	0.38	2.56e-9	Mean corpuscular hemoglobin concentration;
SARC	cis	rs3106136	1.000	rs3106136	chr4:95153349	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.39	-6.06	-0.37	5.56e-9	Capecitabine sensitivity;
SARC	cis	rs7178572	1.000	rs12910361	chr15:77782335	A/G	cg22256960	chr15:77711686	NA	-0.56	-6.59	-0.4	2.99e-10	Type 2 diabetes;
SARC	cis	rs9910055	0.529	rs228746	chr17:42173752	T/C	cg19774624	chr17:42201019	HDAC5	0.55	6.54	0.39	3.8e-10	Total body bone mineral density;
SARC	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg15052019	chr19:19431593	KIAA0892;SF4	-0.4	-4.83	-0.3	2.51e-6	Tonsillectomy;
SARC	cis	rs611744	0.669	rs13251024	chr8:109258333	T/C	cg21045802	chr8:109455806	TTC35	0.6	7.65	0.45	5.26e-13	Dupuytren's disease;
SARC	trans	rs17685	0.753	rs4732595	chr7:75755139	A/G	cg19862616	chr7:65841803	NCRNA00174	0.6	7.33	0.43	3.79e-12	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs12079745	0.793	rs11806445	chr1:169219029	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.79	-5.17	-0.32	5.05e-7	QT interval;
SARC	cis	rs6062302	0.548	rs4809310	chr20:62228745	G/A	cg09650180	chr20:62225654	GMEB2	-0.47	-5.69	-0.35	3.72e-8	Glioblastoma;
SARC	cis	rs3540	0.554	rs12900987	chr15:91071776	T/C	cg22089800	chr15:90895588	ZNF774	-0.6	-7.47	-0.44	1.6e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	trans	rs1814175	0.817	rs10839465	chr11:49981554	C/A	cg15704280	chr7:45808275	SEPT13	-0.98	-18.59	-0.77	6.51e-48	Height;
SARC	cis	rs6545883	1.000	rs6545883	chr2:61772257	A/G	cg15711740	chr2:61764176	XPO1	-0.41	-4.96	-0.31	1.33e-6	Tuberculosis;
SARC	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg18876405	chr7:65276391	NA	-0.69	-8.87	-0.5	1.92e-16	Aortic root size;
SARC	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg05025164	chr4:1340916	KIAA1530	0.57	7.22	0.43	7.41e-12	Longevity;
SARC	cis	rs6450176	1.000	rs3776716	chr5:53298923	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.67	-7.8	-0.46	2.06e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg14517863	chr17:44321492	NA	-0.32	-4.75	-0.3	3.53e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9329289	0.610	rs10903783	chr10:2540623	C/T	cg15501526	chr10:2543763	NA	0.38	5.97	0.36	8.63e-9	Age-related hearing impairment;
SARC	cis	rs4722166	0.630	rs13311155	chr7:22789789	A/C	cg26061582	chr7:22766209	IL6	0.54	6.05	0.37	5.76e-9	Lung cancer;
SARC	cis	rs7582720	1.000	rs72934763	chr2:203758396	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.31	0.43	4.24e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs17023223	0.537	rs12072768	chr1:119593918	A/G	cg05756136	chr1:119680316	WARS2	-0.44	-5.28	-0.33	2.91e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg19346786	chr7:2764209	NA	-0.33	-4.84	-0.3	2.41e-6	Height;
SARC	cis	rs1003719	0.788	rs2835575	chr21:38455936	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.65	9.46	0.53	3.43e-18	Eye color traits;
SARC	cis	rs3087591	1.000	rs3087591	chr17:29630970	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.57	-7.07	-0.42	1.76e-11	Hip circumference;
SARC	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg16405210	chr4:1374714	KIAA1530	-0.51	-5.98	-0.36	8.24e-9	Obesity-related traits;
SARC	cis	rs1023500	0.505	rs134878	chr22:42663874	A/G	cg04733989	chr22:42467013	NAGA	0.55	6.98	0.42	2.97e-11	Schizophrenia;
SARC	cis	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg22857025	chr5:266934	NA	-1.06	-11.8	-0.61	1.74e-25	Breast cancer;
SARC	cis	rs910316	0.763	rs175036	chr14:75464295	C/T	cg23033748	chr14:75592666	NEK9	-0.38	-5.25	-0.33	3.43e-7	Height;
SARC	cis	rs8036030	0.604	rs11856835	chr15:74716174	G/A	cg10253484	chr15:75165896	SCAMP2	-0.49	-5.94	-0.36	1.05e-8	Airflow obstruction;
SARC	cis	rs9790314	0.902	rs9863590	chr3:161116445	T/C	cg04691961	chr3:161091175	C3orf57	-0.78	-11.64	-0.61	5.42e-25	Morning vs. evening chronotype;
SARC	cis	rs818427	0.964	rs456313	chr5:112224952	G/C	cg07820702	chr5:112228657	REEP5	-0.46	-5.14	-0.32	5.73e-7	Total body bone mineral density;
SARC	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg21747090	chr2:27597821	SNX17	-0.58	-8.08	-0.47	3.45e-14	Total body bone mineral density;
SARC	cis	rs941408	0.515	rs1736188	chr19:2782368	A/G	cg06609049	chr19:2785107	THOP1	0.97	14.58	0.69	1.17e-34	Total cholesterol levels;
SARC	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg24549020	chr5:56110836	MAP3K1	-0.47	-5.21	-0.32	4.2e-7	Initial pursuit acceleration;
SARC	trans	rs6479527	0.806	rs1316814	chr9:96742718	A/G	cg18791779	chr6:166689411	NA	-0.55	-6.47	-0.39	5.68e-10	Esophageal adenocarcinoma;
SARC	cis	rs7772486	0.719	rs7753770	chr6:146066161	G/A	cg05347473	chr6:146136440	FBXO30	-0.55	-7.74	-0.45	2.92e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9948	1.000	rs6753987	chr2:97521820	C/T	cg01990225	chr2:97406019	LMAN2L	-0.79	-5.61	-0.35	5.65e-8	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs17401966	1.000	rs4846208	chr1:10313839	T/C	cg15208524	chr1:10270712	KIF1B	0.58	6.52	0.39	4.26e-10	Hepatocellular carcinoma;
SARC	cis	rs2777491	0.540	rs7164684	chr15:41705008	G/T	cg18705301	chr15:41695430	NDUFAF1	-1.16	-18.05	-0.76	3.86e-46	Ulcerative colitis;
SARC	cis	rs10504229	0.679	rs7840100	chr8:58036662	T/G	cg08280861	chr8:58055591	NA	0.52	4.92	0.31	1.62e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg11995313	chr8:8860691	ERI1	-0.38	-4.88	-0.3	1.97e-6	Joint mobility (Beighton score);
SARC	cis	rs7186908	0.761	rs34714490	chr16:72177099	G/T	cg16558253	chr16:72132732	DHX38	-0.55	-6.53	-0.39	4.13e-10	Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs9916302	0.904	rs10852933	chr17:37698194	G/T	cg00129232	chr17:37814104	STARD3	-0.63	-7.73	-0.45	3.25e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg09699651	chr6:150184138	LRP11	0.39	4.87	0.3	2.04e-6	Lung cancer;
SARC	cis	rs4319547	0.774	rs7959238	chr12:123131498	A/T	cg05707623	chr12:122985044	ZCCHC8	-0.55	-6.29	-0.38	1.59e-9	Body mass index;
SARC	cis	rs546131	0.642	rs2956073	chr11:34842883	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.43	4.93	0.31	1.55e-6	Lung disease severity in cystic fibrosis;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg21344215	chr2:27851972	GPN1;CCDC121	0.49	6.56	0.39	3.36e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs9814567	0.806	rs11927539	chr3:134319448	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.49	-6.41	-0.39	7.94e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs1707322	0.752	rs12047629	chr1:46162802	G/A	cg06784218	chr1:46089804	CCDC17	0.36	6.24	0.38	2.03e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9916302	0.821	rs412430	chr17:37737094	C/G	cg00129232	chr17:37814104	STARD3	-0.66	-7.89	-0.46	1.15e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.93	12.61	0.64	3.98e-28	Platelet count;
SARC	cis	rs2421770	0.530	rs3901811	chr11:35365675	C/T	cg13971030	chr11:35366721	SLC1A2	-0.33	-4.99	-0.31	1.18e-6	Staphylococcus aureus nasal carriage (persistent);
SARC	cis	rs9858542	0.953	rs9824092	chr3:49674147	C/G	cg07274523	chr3:49395745	GPX1	0.49	5.61	0.35	5.68e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs4481887	0.604	rs4430368	chr1:248411573	A/G	cg00666640	chr1:248458726	OR2T12	0.32	4.8	0.3	2.79e-6	Common traits (Other);
SARC	trans	rs1814175	0.645	rs28454367	chr11:50045708	G/A	cg15704280	chr7:45808275	SEPT13	-0.89	-14.15	-0.68	3.23e-33	Height;
SARC	cis	rs9815354	0.767	rs73069245	chr3:41951452	G/A	cg03022575	chr3:42003672	ULK4	0.7	5.7	0.35	3.66e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg27541892	chr1:1571801	CDK11B	0.4	5.48	0.34	1.12e-7	Body mass index;
SARC	cis	rs6540556	0.723	rs10863785	chr1:209908876	C/T	cg23920097	chr1:209922102	NA	0.48	5.15	0.32	5.57e-7	Red blood cell count;
SARC	cis	rs2011503	1.000	rs17684164	chr19:19626769	C/T	cg15839431	chr19:19639596	YJEFN3	-0.48	-4.77	-0.3	3.32e-6	Bipolar disorder;
SARC	cis	rs11992186	0.597	rs11781841	chr8:8595263	T/A	cg06636001	chr8:8085503	FLJ10661	-0.46	-5.67	-0.35	4.24e-8	Neuroticism;
SARC	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg06212747	chr3:49208901	KLHDC8B	0.66	8.79	0.5	3.35e-16	Parkinson's disease;
SARC	cis	rs910316	0.737	rs2098251	chr14:75492696	G/A	cg08847533	chr14:75593920	NEK9	0.82	11.75	0.61	2.39e-25	Height;
SARC	cis	rs1669338	0.588	rs62228620	chr3:3184913	C/T	cg16797762	chr3:3221439	CRBN	-0.93	-9.66	-0.53	9.01e-19	White matter integrity;
SARC	cis	rs7044106	0.762	rs7357638	chr9:123389204	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	8.56	0.49	1.55e-15	Hip circumference adjusted for BMI;
SARC	cis	rs7772486	0.790	rs6570724	chr6:146151283	T/C	cg23711669	chr6:146136114	FBXO30	0.8	13.21	0.65	4.21e-30	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6999452	1.000	rs2941655	chr8:106366330	T/G	cg12032713	chr8:106369363	ZFPM2	-0.31	-5.0	-0.31	1.13e-6	Gut microbiome composition (summer);
SARC	cis	rs10791097	0.720	rs6590518	chr11:130733530	C/T	cg09137382	chr11:130731461	NA	0.34	5.37	0.33	1.87e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	trans	rs3734266	0.702	rs35081279	chr6:34744776	G/C	cg08157914	chr7:2646478	IQCE	0.52	6.24	0.38	2.1e-9	Systemic lupus erythematosus;
SARC	cis	rs216026	0.689	rs4765701	chr12:2770891	C/T	cg19945202	chr12:2788847	CACNA1C	0.61	7.62	0.45	6.5e-13	Fractional exhaled nitric oxide (childhood);
SARC	cis	rs6088580	0.634	rs6058041	chr20:33018008	A/G	cg24642439	chr20:33292090	TP53INP2	0.65	8.47	0.49	2.7e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs1707322	1.000	rs1768800	chr1:46549188	A/G	cg06784218	chr1:46089804	CCDC17	-0.36	-6.21	-0.38	2.44e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg09455208	chr3:40491958	NA	0.39	5.68	0.35	4.09e-8	Renal cell carcinoma;
SARC	cis	rs3820928	1.000	rs11692572	chr2:227774503	C/G	cg11843606	chr2:227700838	RHBDD1	-0.57	-7.52	-0.44	1.2e-12	Pulmonary function;
SARC	cis	rs826838	1.000	rs1095575	chr12:39110284	C/G	cg26384229	chr12:38710491	ALG10B	-0.79	-12.11	-0.62	1.6e-26	Heart rate;
SARC	cis	rs748404	0.578	rs4547312	chr15:43632138	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.55	6.71	0.4	1.5e-10	Lung cancer;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg11599612	chr6:151187337	MTHFD1L	-0.76	-6.27	-0.38	1.75e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7474896	0.583	rs11011346	chr10:38009483	C/T	cg25427524	chr10:38739819	LOC399744	-0.49	-5.61	-0.35	5.63e-8	Obesity (extreme);
SARC	cis	rs826838	0.874	rs10880943	chr12:38734317	C/T	cg26384229	chr12:38710491	ALG10B	0.96	15.61	0.71	4.59e-38	Heart rate;
SARC	cis	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg22857025	chr5:266934	NA	-1.04	-11.62	-0.61	6.46e-25	Breast cancer;
SARC	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg13175981	chr1:150552382	MCL1	-0.54	-6.9	-0.41	4.97e-11	Tonsillectomy;
SARC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.04	0.37	6.05e-9	Prudent dietary pattern;
SARC	cis	rs3796352	1.000	rs13074524	chr3:52974184	A/G	cg15956490	chr3:53032818	SFMBT1	0.79	5.18	0.32	4.85e-7	Immune reponse to smallpox (secreted IL-2);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg24675879	chr17:28444056	MIR423;CCDC55	-0.62	-7.11	-0.42	1.39e-11	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs920590	0.758	rs1817836	chr8:19664852	T/C	cg03894339	chr8:19674705	INTS10	0.56	6.68	0.4	1.71e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs2832191	0.716	rs7284006	chr21:30475186	T/A	cg08807101	chr21:30365312	RNF160	0.92	14.32	0.68	8.53e-34	Dental caries;
SARC	cis	rs3008870	0.755	rs12562761	chr1:67396739	C/T	cg02640540	chr1:67518911	SLC35D1	0.44	5.01	0.31	1.1e-6	Lymphocyte percentage of white cells;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg13793178	chr1:26232731	STMN1	0.49	6.93	0.41	4.2e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs9462027	0.585	rs1201873	chr6:34550657	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-6.26	-0.38	1.79e-9	Systemic lupus erythematosus;
SARC	cis	rs13202913	0.609	rs13205308	chr6:151753440	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.6	4.94	0.31	1.51e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs6582630	0.519	rs10880194	chr12:38302836	G/A	cg13010199	chr12:38710504	ALG10B	0.78	10.82	0.58	2.18e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg21747090	chr2:27597821	SNX17	-0.55	-7.68	-0.45	4.44e-13	Total body bone mineral density;
SARC	cis	rs10875746	0.669	rs10431526	chr12:48690143	A/G	cg26205652	chr12:48591994	NA	0.49	5.21	0.32	4.23e-7	Longevity (90 years and older);
SARC	cis	rs698813	0.674	rs6544751	chr2:44495845	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	6.22	0.38	2.27e-9	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs1707322	0.752	rs3811436	chr1:46125880	T/C	cg06784218	chr1:46089804	CCDC17	0.36	6.25	0.38	1.97e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6439153	0.967	rs61480393	chr3:128699759	T/C	cg25356066	chr3:128598488	ACAD9	0.47	5.53	0.34	8.74e-8	Pneumococcal bacteremia;
SARC	cis	rs2304069	0.545	rs1864998	chr5:149389465	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.59	6.94	0.41	3.86e-11	HIV-1 control;
SARC	cis	rs2963155	0.590	rs258757	chr5:142620736	A/G	cg17617527	chr5:142782415	NR3C1	-0.63	-4.73	-0.3	3.85e-6	Breast cancer;
SARC	cis	rs651907	0.557	rs11710533	chr3:101351472	G/A	cg12386194	chr3:101231763	SENP7	0.5	5.97	0.36	8.73e-9	Colorectal cancer;
SARC	cis	rs7666738	0.830	rs4699595	chr4:99012827	A/G	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6963495	0.769	rs117986187	chr7:105167311	G/A	cg13798780	chr7:105162888	PUS7	0.6	5.56	0.34	7.22e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs1559088	0.625	rs10411739	chr19:33616327	T/C	cg17764715	chr19:33622953	WDR88	0.62	8.41	0.48	4.23e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs57920188	0.584	rs57277002	chr1:4092054	T/G	cg20703997	chr1:4087676	NA	0.48	5.1	0.32	7.05e-7	Interleukin-17 levels;
SARC	cis	rs10823500	0.777	rs7919014	chr10:71944577	T/C	cg04118878	chr10:71993077	PPA1	0.52	5.67	0.35	4.22e-8	Blood protein levels;
SARC	cis	rs11718455	0.960	rs34019365	chr3:44004735	G/A	cg08738300	chr3:44038990	NA	0.53	5.9	0.36	1.3e-8	Coronary artery disease;
SARC	cis	rs950776	0.518	rs2292117	chr15:78834689	C/T	cg06917634	chr15:78832804	PSMA4	0.91	14.04	0.68	7.65e-33	Sudden cardiac arrest;
SARC	cis	rs459571	0.959	rs2520100	chr9:136918137	A/T	cg01294253	chr9:136912663	BRD3	0.44	5.79	0.35	2.2e-8	Platelet distribution width;
SARC	cis	rs2832191	0.791	rs2065270	chr21:30485420	T/C	cg08807101	chr21:30365312	RNF160	-0.84	-11.82	-0.61	1.44e-25	Dental caries;
SARC	cis	rs36051895	0.626	rs10815149	chr9:5063701	T/C	cg02405213	chr9:5042618	JAK2	-0.49	-5.78	-0.35	2.33e-8	Pediatric autoimmune diseases;
SARC	cis	rs11204677	1	rs11204677	chr1:150574695	C/G	cg18016565	chr1:150552671	MCL1	-0.39	-5.29	-0.33	2.81e-7	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs11098499	0.821	rs3775852	chr4:120454556	A/G	cg09307838	chr4:120376055	NA	0.91	12.31	0.63	3.63e-27	Corneal astigmatism;
SARC	cis	rs11583043	1.000	rs6660290	chr1:101483512	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.49	-5.44	-0.34	1.32e-7	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs8051517	1.000	rs71395853	chr16:68395522	C/T	cg01866162	chr16:67596514	CTCF	1.1	6.2	0.38	2.57e-9	Blood protein levels;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg04407811	chr5:179160270	MAML1	-0.8	-6.69	-0.4	1.62e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2070488	0.775	rs2070489	chr3:38519424	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.78	11.86	0.61	1.11e-25	Electrocardiographic conduction measures;
SARC	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg22800045	chr5:56110881	MAP3K1	0.74	7.76	0.45	2.64e-13	Initial pursuit acceleration;
SARC	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg03806693	chr22:41940476	POLR3H	-0.93	-12.85	-0.64	6.45e-29	Vitiligo;
SARC	cis	rs911555	0.692	rs7140647	chr14:103893465	A/G	cg24130564	chr14:104152367	KLC1	0.49	5.72	0.35	3.33e-8	Intelligence (multi-trait analysis);
SARC	cis	rs78487399	0.803	rs75275342	chr2:43762885	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-5.11	-0.32	6.6e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.5	-0.44	1.37e-12	Gut microbiome composition (summer);
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg03503288	chr13:20660277	ZMYM2	-0.58	-7.28	-0.43	4.95e-12	Alcohol dependence;
SARC	cis	rs798554	0.567	rs1182194	chr7:2868824	C/G	cg13628971	chr7:2884303	GNA12	0.42	4.99	0.31	1.18e-6	Height;
SARC	cis	rs7412746	0.611	rs11204747	chr1:150927152	A/G	cg13175981	chr1:150552382	MCL1	0.53	6.47	0.39	5.83e-10	Melanoma;
SARC	cis	rs8141529	0.748	rs2064261	chr22:29287730	C/T	cg15103426	chr22:29168792	CCDC117	0.64	8.34	0.48	6.61e-15	Lymphocyte counts;
SARC	cis	rs2273669	0.667	rs76747161	chr6:109305456	G/A	cg05315195	chr6:109294784	ARMC2	-0.57	-5.24	-0.32	3.62e-7	Prostate cancer;
SARC	cis	rs60871478	1.000	rs35488064	chr7:812722	G/C	cg05535760	chr7:792225	HEATR2	0.77	7.89	0.46	1.15e-13	Cerebrospinal P-tau181p levels;
SARC	cis	rs72781680	1.000	rs72781649	chr2:24210864	A/G	cg08917208	chr2:24149416	ATAD2B	0.78	7.62	0.45	6.31e-13	Lymphocyte counts;
SARC	cis	rs1113500	0.933	rs11185261	chr1:108638703	G/A	cg06207961	chr1:108661230	NA	0.44	5.81	0.36	2.02e-8	Growth-regulated protein alpha levels;
SARC	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg12648201	chr2:27665141	KRTCAP3	0.36	5.35	0.33	2.13e-7	Total body bone mineral density;
SARC	cis	rs908922	0.676	rs1538083	chr1:152517116	A/G	cg09873164	chr1:152488093	CRCT1	0.64	8.56	0.49	1.58e-15	Hair morphology;
SARC	cis	rs9790314	1.000	rs336585	chr3:161081670	A/G	cg04691961	chr3:161091175	C3orf57	-0.81	-11.85	-0.61	1.13e-25	Morning vs. evening chronotype;
SARC	cis	rs73206853	0.841	rs61663407	chr12:111055128	A/G	cg08946844	chr12:110511112	NA	0.56	4.72	0.3	4.05e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs4243830	0.850	rs1010584	chr1:6579843	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.78	-7.6	-0.45	7.28e-13	Body mass index;
SARC	cis	rs559928	0.553	rs508326	chr11:64176029	C/T	cg05555928	chr11:63887634	MACROD1	0.35	4.9	0.31	1.81e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg08564027	chr20:61660810	NA	0.76	11.8	0.61	1.69e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg18252515	chr7:66147081	NA	1.35	12.11	0.62	1.7e-26	Diabetic kidney disease;
SARC	cis	rs12956009	0.583	rs11082575	chr18:44905068	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.61	-7.58	-0.44	8.16e-13	Educational attainment (years of education);
SARC	cis	rs2644899	0.715	rs2607415	chr19:41262687	C/G	cg24958765	chr19:41283667	RAB4B	-0.58	-6.83	-0.41	7.3e-11	Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs9902453	1.000	rs7212497	chr17:28335949	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.52	-6.74	-0.4	1.21e-10	Coffee consumption (cups per day);
SARC	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg22903657	chr4:1355424	KIAA1530	-0.43	-5.83	-0.36	1.8e-8	Obesity-related traits;
SARC	cis	rs7512552	0.839	rs1103115	chr1:150332304	G/A	cg15654264	chr1:150340011	RPRD2	0.38	4.83	0.3	2.49e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs9916302	0.706	rs7208252	chr17:37584368	A/G	cg15445000	chr17:37608096	MED1	0.46	4.89	0.3	1.91e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg12292205	chr6:26970375	C6orf41	-0.56	-6.17	-0.37	2.96e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6570726	0.902	rs406979	chr6:145838983	G/T	cg23711669	chr6:146136114	FBXO30	0.78	11.84	0.61	1.21e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.06	16.0	0.72	2.18e-39	Height;
SARC	cis	rs898097	0.812	rs56274787	chr17:80862682	C/T	cg15369054	chr17:80825471	TBCD	0.57	7.87	0.46	1.34e-13	Breast cancer;
SARC	cis	rs6061231	0.740	rs11698650	chr20:60958374	A/T	cg22633769	chr20:60982531	CABLES2	0.43	4.78	0.3	3.06e-6	Colorectal cancer;
SARC	cis	rs11690935	0.921	rs4668414	chr2:172704291	A/C	cg13550731	chr2:172543902	DYNC1I2	-0.98	-14.77	-0.7	2.83e-35	Schizophrenia;
SARC	cis	rs8067354	0.645	rs2645486	chr17:57885901	T/A	cg02344993	chr17:57696989	CLTC	0.65	6.69	0.4	1.66e-10	Hemoglobin concentration;
SARC	cis	rs2200578	1.000	rs60025964	chr2:99880577	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.67	6.59	0.4	2.92e-10	IgG glycosylation;
SARC	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg10373733	chr6:25993375	NA	0.4	4.9	0.31	1.8e-6	Height;
SARC	cis	rs854765	0.506	rs7210400	chr17:17949957	C/T	cg04398451	chr17:18023971	MYO15A	0.46	6.67	0.4	1.82e-10	Total body bone mineral density;
SARC	trans	rs9325144	0.600	rs12297194	chr12:38735803	A/G	cg23762105	chr12:34175262	ALG10	0.53	6.95	0.41	3.61e-11	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg21724239	chr8:58056113	NA	0.61	5.93	0.36	1.1e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg25072359	chr17:41440525	NA	0.51	6.13	0.37	3.66e-9	Menopause (age at onset);
SARC	cis	rs17376456	0.825	rs13357713	chr5:93145423	T/C	cg25358565	chr5:93447407	FAM172A	1.2	12.15	0.62	1.23e-26	Diabetic retinopathy;
SARC	cis	rs9815354	0.812	rs73081383	chr3:41920614	A/G	cg03022575	chr3:42003672	ULK4	0.69	5.65	0.35	4.69e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs240764	0.817	rs239238	chr6:101094880	G/T	cg09795085	chr6:101329169	ASCC3	0.46	5.96	0.36	9.39e-9	Neuroticism;
SARC	cis	rs4319547	1.000	rs1392236	chr12:123074890	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.66	-7.98	-0.46	6.73e-14	Body mass index;
SARC	cis	rs1580019	0.921	rs1580023	chr7:32497881	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.43	5.04	0.31	9.3e-7	Cognitive ability;
SARC	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg04511125	chr2:88470314	THNSL2	0.8	7.19	0.43	8.91e-12	Plasma clusterin levels;
SARC	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg00149659	chr3:10157352	C3orf10	1.1	9.77	0.54	3.94e-19	Alzheimer's disease;
SARC	cis	rs2559856	1.000	rs10860771	chr12:102087242	A/G	cg12924262	chr12:102091054	CHPT1	0.56	7.7	0.45	3.94e-13	Blood protein levels;
SARC	cis	rs7587476	0.862	rs13001462	chr2:215678346	G/A	cg04530015	chr2:215796436	ABCA12	-0.41	-6.8	-0.41	8.62e-11	Neuroblastoma;
SARC	cis	rs228437	0.913	rs73554512	chr6:134941513	G/A	cg24504307	chr6:134963096	NA	-0.52	-5.94	-0.36	1.02e-8	Melanoma;
SARC	cis	rs16858210	0.607	rs953419	chr3:183585883	C/T	cg25686905	chr3:183603175	PARL	0.43	4.89	0.31	1.85e-6	Menopause (age at onset);
SARC	cis	rs523522	0.962	rs7488320	chr12:120981630	G/T	cg27279351	chr12:120934652	DYNLL1	0.72	8.89	0.5	1.75e-16	High light scatter reticulocyte count;
SARC	cis	rs10046574	0.831	rs10278289	chr7:135089662	A/G	cg27474649	chr7:135195673	CNOT4	0.83	6.82	0.41	7.94e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg07701084	chr6:150067640	NUP43	0.43	5.31	0.33	2.56e-7	Lung cancer;
SARC	cis	rs2486288	0.656	rs11637364	chr15:45579238	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.49	-5.91	-0.36	1.18e-8	Glomerular filtration rate;
SARC	cis	rs9660992	0.512	rs12123773	chr1:205122420	C/G	cg07972983	chr1:205091412	RBBP5	0.56	7.34	0.43	3.54e-12	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs2370759	1.000	rs75984055	chr10:32591276	T/C	cg01819863	chr10:32635814	EPC1	0.99	9.87	0.54	2.03e-19	Sexual dysfunction (female);
SARC	cis	rs2425143	1.000	rs6058325	chr20:34388806	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	5.15	0.32	5.6e-7	Blood protein levels;
SARC	cis	rs9788721	0.836	rs2656065	chr15:78750549	G/A	cg06917634	chr15:78832804	PSMA4	-0.49	-5.24	-0.32	3.53e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs911555	0.723	rs7149767	chr14:103863545	G/A	cg12935359	chr14:103987150	CKB	0.39	5.35	0.33	2.07e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6088590	0.930	rs6087618	chr20:33288407	C/T	cg08999081	chr20:33150536	PIGU	0.34	5.0	0.31	1.11e-6	Coronary artery disease;
SARC	cis	rs35849525	1.000	rs35849525	chr3:50067350	T/C	cg24110177	chr3:50126178	RBM5	-0.49	-5.39	-0.33	1.7e-7	Intelligence (multi-trait analysis);
SARC	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg06212747	chr3:49208901	KLHDC8B	0.65	8.64	0.49	9.19e-16	Parkinson's disease;
SARC	cis	rs2651899	0.902	rs1624023	chr1:3079337	C/T	cg22674798	chr1:3096360	PRDM16	0.25	5.23	0.32	3.75e-7	Migraine;
SARC	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	11.57	0.6	9.53e-25	Platelet count;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg06596743	chr16:77228577	MON1B	-0.46	-6.28	-0.38	1.69e-9	Height;
SARC	cis	rs6582630	0.519	rs7294300	chr12:38277359	C/A	cg13010199	chr12:38710504	ALG10B	0.81	11.31	0.6	6.33e-24	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs910316	1.000	rs175492	chr14:75545220	A/C	cg23033748	chr14:75592666	NEK9	0.33	4.78	0.3	3.07e-6	Height;
SARC	cis	rs4718428	0.705	rs4717331	chr7:66378886	C/T	cg18252515	chr7:66147081	NA	-0.56	-6.12	-0.37	3.97e-9	Corneal structure;
SARC	cis	rs4481887	0.893	rs10736379	chr1:248455876	A/T	cg13385794	chr1:248469461	NA	0.32	4.92	0.31	1.67e-6	Common traits (Other);
SARC	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg09699651	chr6:150184138	LRP11	0.42	5.14	0.32	5.9e-7	Lung cancer;
SARC	cis	rs12477438	1.000	rs17760953	chr2:99859863	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-6.59	-0.4	2.86e-10	Chronic sinus infection;
SARC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg05552183	chr6:42928497	GNMT	0.57	7.76	0.45	2.71e-13	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.46	5.26	0.33	3.27e-7	Renal function-related traits (BUN);
SARC	cis	rs11097912	0.632	rs11097929	chr4:107264000	G/T	cg09646026	chr4:107269030	AIMP1	-0.44	-4.72	-0.3	4.12e-6	Airflow obstruction;
SARC	cis	rs9467773	1.000	rs6925895	chr6:26572165	G/T	cg12292205	chr6:26970375	C6orf41	0.45	5.43	0.33	1.45e-7	Intelligence (multi-trait analysis);
SARC	cis	rs16866061	0.515	rs11695326	chr2:225415134	A/G	cg12698349	chr2:225449008	CUL3	0.86	15.95	0.72	3.4e-39	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg05313129	chr8:58192883	C8orf71	-0.51	-5.85	-0.36	1.63e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10737909	0.510	rs12025158	chr1:15539259	A/G	cg21012057	chr1:15538911	TMEM51	0.39	5.42	0.33	1.47e-7	Migraine;
SARC	cis	rs7927771	0.725	rs11570094	chr11:47359706	A/C	cg20307385	chr11:47447363	PSMC3	0.46	5.08	0.32	7.89e-7	Subjective well-being;
SARC	cis	rs2072499	0.778	rs41265025	chr1:156163906	C/T	cg25208724	chr1:156163844	SLC25A44	0.87	9.89	0.54	1.74e-19	Testicular germ cell tumor;
SARC	cis	rs228437	0.802	rs228449	chr6:134903629	A/G	cg24504307	chr6:134963096	NA	0.44	5.0	0.31	1.13e-6	Melanoma;
SARC	cis	rs826838	0.935	rs11169547	chr12:39185625	C/A	cg13010199	chr12:38710504	ALG10B	0.74	9.8	0.54	3.32e-19	Heart rate;
SARC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	10.11	0.55	3.59e-20	Platelet count;
SARC	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg26874164	chr19:58962979	ZNF324B	-0.53	-6.95	-0.41	3.71e-11	Uric acid clearance;
SARC	cis	rs17376456	0.597	rs7708175	chr5:93381182	A/G	cg21475434	chr5:93447410	FAM172A	-0.6	-6.35	-0.38	1.11e-9	Diabetic retinopathy;
SARC	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg11062466	chr8:58055876	NA	0.51	5.07	0.32	8.09e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9790314	0.601	rs1450519	chr3:161094930	A/G	cg03342759	chr3:160939853	NMD3	-0.53	-6.74	-0.4	1.21e-10	Morning vs. evening chronotype;
SARC	cis	rs9549260	0.564	rs4943805	chr13:41270080	A/G	cg21288729	chr13:41239152	FOXO1	0.44	5.06	0.31	8.36e-7	Red blood cell count;
SARC	cis	rs10752881	0.967	rs8179284	chr1:182974707	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.76	0.58	3.38e-22	Colorectal cancer;
SARC	cis	rs1113500	0.933	rs10785833	chr1:108639082	A/G	cg06207961	chr1:108661230	NA	0.44	5.92	0.36	1.13e-8	Growth-regulated protein alpha levels;
SARC	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg11987759	chr7:65425863	GUSB	-0.49	-5.8	-0.36	2.17e-8	Aortic root size;
SARC	cis	rs7617773	0.780	rs35778847	chr3:48346985	G/T	cg11946769	chr3:48343235	NME6	0.76	9.7	0.54	6.55e-19	Coronary artery disease;
SARC	cis	rs55823223	0.564	rs4572466	chr17:73846314	A/C	cg06969265	chr17:73775802	H3F3B	0.48	5.25	0.33	3.38e-7	Psoriasis;
SARC	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.72	-7.51	-0.44	1.22e-12	Platelet count;
SARC	cis	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg22496380	chr5:211416	CCDC127	-0.88	-9.12	-0.51	3.7e-17	Breast cancer;
SARC	cis	rs4595586	0.545	rs12819186	chr12:39356912	C/T	cg26384229	chr12:38710491	ALG10B	0.51	6.22	0.38	2.25e-9	Morning vs. evening chronotype;
SARC	cis	rs2952156	0.920	rs11078919	chr17:37835755	T/C	cg20243544	chr17:37824526	PNMT	0.56	7.49	0.44	1.45e-12	Asthma;
SARC	cis	rs17376456	0.825	rs28645862	chr5:93233128	G/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.66	0.35	4.4e-8	Diabetic retinopathy;
SARC	cis	rs11098499	0.954	rs7687843	chr4:120421211	C/T	cg24375607	chr4:120327624	NA	0.41	4.86	0.3	2.12e-6	Corneal astigmatism;
SARC	cis	rs5769765	1.000	rs34774661	chr22:50267508	C/G	cg03033257	chr22:50311977	ALG12;CRELD2	-0.54	-5.64	-0.35	4.81e-8	Schizophrenia;
SARC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg06873352	chr17:61820015	STRADA	-0.55	-7.25	-0.43	5.98e-12	Prudent dietary pattern;
SARC	cis	rs12682352	0.652	rs1567398	chr8:8726804	A/C	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.16	-0.37	3.11e-9	Neuroticism;
SARC	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg16405210	chr4:1374714	KIAA1530	-0.53	-6.49	-0.39	5.13e-10	Longevity;
SARC	cis	rs5769765	0.955	rs8138687	chr22:50291869	A/G	cg03033257	chr22:50311977	ALG12;CRELD2	0.52	5.33	0.33	2.28e-7	Schizophrenia;
SARC	cis	rs826838	0.868	rs864324	chr12:39122853	A/G	cg26384229	chr12:38710491	ALG10B	0.69	9.77	0.54	4.03e-19	Heart rate;
SARC	cis	rs9916302	0.706	rs582176	chr17:37453999	T/C	cg20243544	chr17:37824526	PNMT	-0.56	-6.02	-0.37	6.66e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs7940866	0.903	rs11222421	chr11:130872351	A/T	cg12179176	chr11:130786555	SNX19	0.64	8.56	0.49	1.51e-15	Schizophrenia;
SARC	cis	rs10088262	0.629	rs7827665	chr8:124804190	G/A	cg15047889	chr8:124780837	FAM91A1	-0.65	-7.22	-0.43	7.24e-12	Pancreatic cancer;
SARC	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg21782813	chr7:2030301	MAD1L1	-0.32	-4.97	-0.31	1.31e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs12950390	0.853	rs59513807	chr17:45867925	G/A	cg03474202	chr17:45855739	NA	-0.42	-6.61	-0.4	2.65e-10	IgG glycosylation;
SARC	cis	rs7824557	0.564	rs6601584	chr8:11232343	C/G	cg12395012	chr8:11607386	GATA4	0.3	4.93	0.31	1.58e-6	Retinal vascular caliber;
SARC	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg16606324	chr3:10149918	C3orf24	0.49	4.8	0.3	2.87e-6	Alzheimer's disease;
SARC	cis	rs3106136	0.872	rs10033662	chr4:95239462	G/A	cg11021082	chr4:95130006	SMARCAD1	0.38	5.75	0.35	2.73e-8	Capecitabine sensitivity;
SARC	cis	rs798554	0.704	rs798531	chr7:2770067	G/C	cg13628971	chr7:2884303	GNA12	0.47	5.73	0.35	3.09e-8	Height;
SARC	cis	rs2276314	0.857	rs62101394	chr18:33592299	C/T	cg05985134	chr18:33552581	C18orf21	0.69	7.04	0.42	2.09e-11	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs17376456	0.877	rs28637444	chr5:93495548	C/T	cg21475434	chr5:93447410	FAM172A	0.89	7.4	0.44	2.4e-12	Diabetic retinopathy;
SARC	cis	rs1008375	0.966	rs7666888	chr4:17695722	C/T	cg16339924	chr4:17578868	LAP3	0.52	6.59	0.4	2.89e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg26554054	chr8:600488	NA	0.61	5.1	0.32	7.09e-7	IgG glycosylation;
SARC	cis	rs9916302	0.904	rs9898170	chr17:37510092	T/C	cg00129232	chr17:37814104	STARD3	0.58	7.24	0.43	6.36e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs7824557	0.564	rs2572394	chr8:11235393	A/G	cg21775007	chr8:11205619	TDH	-0.65	-8.62	-0.49	1.05e-15	Retinal vascular caliber;
SARC	cis	rs9341808	0.718	rs2874829	chr6:80856097	A/G	cg08355045	chr6:80787529	NA	0.35	5.58	0.34	6.55e-8	Sitting height ratio;
SARC	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg06634786	chr22:41940651	POLR3H	0.5	5.75	0.35	2.73e-8	Vitiligo;
SARC	cis	rs9916302	0.851	rs12947620	chr17:37605364	T/C	cg20243544	chr17:37824526	PNMT	0.56	6.73	0.4	1.32e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs9309473	0.583	rs6709853	chr2:73576065	T/A	cg20560298	chr2:73613845	ALMS1	-0.54	-6.84	-0.41	7.09e-11	Metabolite levels;
SARC	trans	rs61931739	0.500	rs11053261	chr12:34530810	C/T	cg13010199	chr12:38710504	ALG10B	0.83	11.73	0.61	2.89e-25	Morning vs. evening chronotype;
SARC	cis	rs2115630	1.000	rs2879828	chr15:85361977	G/T	cg12501888	chr15:85177176	SCAND2	-0.47	-5.86	-0.36	1.58e-8	P wave terminal force;
SARC	cis	rs13095912	1.000	rs1823238	chr3:185341970	G/A	cg11274856	chr3:185301563	NA	0.35	4.9	0.31	1.82e-6	Systolic blood pressure;
SARC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg18765753	chr7:1198926	ZFAND2A	-0.34	-5.29	-0.33	2.86e-7	Longevity;Endometriosis;
SARC	trans	rs877282	0.945	rs71489301	chr10:770191	A/G	cg22713356	chr15:30763199	NA	1.03	9.96	0.55	1.07e-19	Uric acid levels;
SARC	cis	rs546131	0.642	rs508062	chr11:34843820	C/G	cg11058730	chr11:34937778	PDHX;APIP	0.44	5.09	0.32	7.3e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs35110281	0.782	rs2051407	chr21:45079245	T/C	cg04455712	chr21:45112962	RRP1B	0.35	4.98	0.31	1.24e-6	Mean corpuscular volume;
SARC	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg27266027	chr21:40555129	PSMG1	0.51	5.5	0.34	9.96e-8	Cognitive function;
SARC	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.35	-0.43	3.34e-12	Gut microbiome composition (summer);
SARC	cis	rs6121246	0.512	rs45443696	chr20:30311396	A/C	cg13852791	chr20:30311386	BCL2L1	0.88	10.96	0.58	8.39e-23	Mean corpuscular hemoglobin;
SARC	cis	rs36051895	0.553	rs16922773	chr9:5197436	T/G	cg02405213	chr9:5042618	JAK2	-0.42	-4.74	-0.3	3.67e-6	Pediatric autoimmune diseases;
SARC	cis	rs17270561	0.609	rs9393659	chr6:25731358	T/C	cg17691542	chr6:26056736	HIST1H1C	0.57	7.04	0.42	2.14e-11	Iron status biomarkers;
SARC	cis	rs2439831	1.000	rs690436	chr15:43761205	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.08	11.37	0.6	3.94e-24	Lung cancer in ever smokers;
SARC	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg11987759	chr7:65425863	GUSB	-0.48	-5.87	-0.36	1.51e-8	Aortic root size;
SARC	cis	rs818427	0.927	rs7213	chr5:112203564	T/A	cg07820702	chr5:112228657	REEP5	0.52	5.91	0.36	1.2e-8	Total body bone mineral density;
SARC	cis	rs9487051	1.000	rs6568571	chr6:109613252	A/T	cg01475377	chr6:109611718	NA	-0.41	-5.54	-0.34	8.01e-8	Reticulocyte fraction of red cells;
SARC	cis	rs12971120	0.891	rs11151960	chr18:72177232	G/A	cg25817165	chr18:72167213	CNDP2	-0.5	-6.78	-0.41	9.71e-11	Refractive error;
SARC	cis	rs55986470	0.763	rs2280034	chr2:239438298	C/T	cg21699342	chr2:239360505	ASB1	-0.46	-4.89	-0.31	1.85e-6	Chronotype;
SARC	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg03060546	chr3:49711283	APEH	0.44	5.61	0.34	5.8e-8	Parkinson's disease;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg16102063	chr8:22298240	PPP3CC	0.48	6.35	0.38	1.1e-9	Chemerin levels;
SARC	cis	rs4972806	0.849	rs2071581	chr2:177026148	G/T	cg14236662	chr2:176988284	HOXD9	0.41	5.78	0.35	2.37e-8	IgG glycosylation;
SARC	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-6.47	-0.39	5.84e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7246865	0.510	rs6512161	chr19:17171582	A/G	cg16202187	chr19:17186497	HAUS8;MYO9B	0.39	4.77	0.3	3.2e-6	Reticulocyte fraction of red cells;
SARC	cis	rs7729447	0.813	rs7715279	chr5:32689875	T/A	cg16267343	chr5:32710456	NPR3	0.63	8.3	0.48	8.49e-15	Blood pressure;
SARC	cis	rs2439831	0.867	rs2412780	chr15:43655794	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	8.32	0.48	7.2e-15	Lung cancer in ever smokers;
SARC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg04234412	chr22:24373322	LOC391322	0.64	8.41	0.48	4.1e-15	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs72781680	1.000	rs7594510	chr2:24173377	A/G	cg08917208	chr2:24149416	ATAD2B	0.79	7.54	0.44	1.05e-12	Lymphocyte counts;
SARC	cis	rs17376456	0.569	rs896729	chr5:93222178	A/G	cg25358565	chr5:93447407	FAM172A	-0.92	-10.54	-0.57	1.66e-21	Diabetic retinopathy;
SARC	cis	rs6840360	1.000	rs4696283	chr4:152580516	A/G	cg22705602	chr4:152727874	NA	-0.37	-6.32	-0.38	1.33e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7599312	0.534	rs6751692	chr2:213408120	C/T	cg16329650	chr2:213403929	ERBB4	0.69	10.27	0.56	1.16e-20	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg12751644	chr20:60527061	NA	0.44	5.69	0.35	3.78e-8	Obesity-related traits;
SARC	cis	rs2073300	0.609	rs6137931	chr20:23376875	G/C	cg16736954	chr20:23401023	NAPB	0.79	4.99	0.31	1.16e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs13191362	1.000	rs13220181	chr6:163004401	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.56	5.41	0.33	1.53e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg20007245	chr22:24372913	LOC391322	-0.65	-7.92	-0.46	9.8e-14	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg13393036	chr8:95962371	TP53INP1	-0.37	-6.17	-0.37	2.92e-9	Type 2 diabetes;
SARC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg26338869	chr17:61819248	STRADA	0.81	10.95	0.58	8.96e-23	Prudent dietary pattern;
SARC	cis	rs9814567	0.929	rs9815297	chr3:134215052	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-7.09	-0.42	1.56e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs7833790	0.929	rs28464834	chr8:82797356	A/T	cg17211192	chr8:82754475	SNX16	0.56	6.19	0.38	2.76e-9	Diastolic blood pressure;
SARC	cis	rs3091242	0.967	rs3091240	chr1:25676935	G/T	cg23205692	chr1:25664452	TMEM50A	0.44	5.33	0.33	2.27e-7	Erythrocyte sedimentation rate;
SARC	cis	rs8114671	0.562	rs6088635	chr20:33466501	A/G	cg07148914	chr20:33460835	GGT7	0.46	5.66	0.35	4.36e-8	Height;
SARC	cis	rs4727027	0.866	rs7778766	chr7:148806729	A/G	cg23583168	chr7:148888333	NA	-0.74	-10.37	-0.56	5.62e-21	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs2228479	0.850	rs45567439	chr16:89814604	G/A	cg00800038	chr16:89945340	TCF25	-0.74	-5.17	-0.32	5.14e-7	Skin colour saturation;
SARC	cis	rs2204008	0.683	rs12370288	chr12:38127740	G/A	cg26384229	chr12:38710491	ALG10B	0.88	12.67	0.64	2.49e-28	Bladder cancer;
SARC	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg05313129	chr8:58192883	C8orf71	-0.57	-6.29	-0.38	1.54e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1784581	0.802	rs7768986	chr6:162427890	G/C	cg17173639	chr6:162384350	PARK2	0.65	8.89	0.5	1.66e-16	Itch intensity from mosquito bite;
SARC	cis	rs9815354	1.000	rs9873207	chr3:41884750	C/T	cg03022575	chr3:42003672	ULK4	0.62	5.43	0.34	1.39e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-4.92	-0.31	1.61e-6	Total body bone mineral density;
SARC	cis	rs9549260	0.753	rs9532578	chr13:41236407	G/A	cg21288729	chr13:41239152	FOXO1	0.63	6.29	0.38	1.55e-9	Red blood cell count;
SARC	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg05313129	chr8:58192883	C8orf71	-0.62	-6.34	-0.38	1.18e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs11264799	0.603	rs12755544	chr1:157553017	C/T	cg18268488	chr1:157545234	FCRL4	0.33	5.61	0.35	5.62e-8	IgA nephropathy;
SARC	cis	rs3768617	0.811	rs10911233	chr1:183052585	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	8.19	0.47	1.72e-14	Fuchs's corneal dystrophy;
SARC	cis	rs7644634	0.576	rs9860539	chr3:105392150	A/C	cg23051926	chr3:105466016	CBLB	0.47	5.4	0.33	1.68e-7	Itch intensity from mosquito bite;
SARC	cis	rs6728642	0.519	rs72811651	chr2:97572229	G/C	cg26665480	chr2:98280029	ACTR1B	-0.64	-5.46	-0.34	1.19e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs9916302	0.706	rs4516267	chr17:37471482	G/T	cg20243544	chr17:37824526	PNMT	-0.56	-6.02	-0.37	6.66e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs16976116	0.619	rs11071173	chr15:55467558	C/G	cg17854078	chr15:55489399	RSL24D1	-0.6	-5.19	-0.32	4.57e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs798554	0.634	rs1182180	chr7:2873279	G/T	cg13628971	chr7:2884303	GNA12	0.41	5.01	0.31	1.07e-6	Height;
SARC	cis	rs13401104	0.796	rs72620808	chr2:237114372	G/A	cg19324714	chr2:237145437	ASB18	0.57	5.91	0.36	1.22e-8	Educational attainment;
SARC	cis	rs79976124	0.837	rs10944858	chr6:66646039	G/A	cg07460842	chr6:66804631	NA	0.62	6.73	0.4	1.27e-10	Type 2 diabetes;
SARC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg09373136	chr17:61933544	TCAM1	0.5	6.75	0.4	1.13e-10	Prudent dietary pattern;
SARC	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg02725872	chr8:58115012	NA	-0.34	-5.37	-0.33	1.91e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6912958	0.684	rs6931069	chr6:88367082	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-6.31	-0.38	1.41e-9	Monocyte percentage of white cells;
SARC	trans	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.75	-10.78	-0.58	3.03e-22	Intelligence (multi-trait analysis);
SARC	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg11843238	chr5:131593191	PDLIM4	-0.4	-5.0	-0.31	1.1e-6	Breast cancer;
SARC	cis	rs4242434	0.672	rs3758041	chr8:22486987	A/G	cg03733263	chr8:22462867	KIAA1967	0.88	13.76	0.67	6.2e-32	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs2033711	0.811	rs9304814	chr19:58951811	C/A	cg13877915	chr19:58951672	ZNF132	0.63	9.05	0.51	5.78e-17	Uric acid clearance;
SARC	cis	rs2273669	0.667	rs12205053	chr6:109338110	T/C	cg05315195	chr6:109294784	ARMC2	-0.63	-5.7	-0.35	3.6e-8	Prostate cancer;
SARC	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	12.56	0.64	5.61e-28	Platelet count;
SARC	cis	rs6429082	0.755	rs291372	chr1:235694106	G/C	cg26050004	chr1:235667680	B3GALNT2	0.65	8.48	0.49	2.63e-15	Adiposity;
SARC	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg12667521	chr19:29218732	NA	0.4	5.3	0.33	2.7e-7	Methadone dose in opioid dependence;
SARC	cis	rs4689388	0.890	rs4689398	chr4:6302199	C/T	cg25554036	chr4:6271136	WFS1	0.37	6.04	0.37	6.13e-9	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs4727027	0.933	rs4725800	chr7:148862516	C/G	cg23583168	chr7:148888333	NA	-0.72	-10.14	-0.55	3.01e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs2303759	0.709	rs8102658	chr19:49828855	C/T	cg24324837	chr19:49891574	CCDC155	0.4	4.78	0.3	3.15e-6	Multiple sclerosis;
SARC	trans	rs9325144	0.600	rs10785615	chr12:38733627	G/C	cg23762105	chr12:34175262	ALG10	-0.54	-7.14	-0.42	1.19e-11	Morning vs. evening chronotype;
SARC	cis	rs11098499	0.821	rs28665282	chr4:120384186	C/T	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs35213789	0.791	rs210593	chr7:69244312	A/G	cg10619644	chr7:69149951	AUTS2	0.35	4.77	0.3	3.26e-6	Childhood ear infection;
SARC	cis	rs4555082	0.834	rs28846738	chr14:105745781	A/G	cg10792982	chr14:105748885	BRF1	0.5	7.65	0.45	5.39e-13	Mean platelet volume;Platelet distribution width;
SARC	cis	rs4128725	1.000	rs12035635	chr1:159349251	C/T	cg25076881	chr1:159409836	OR10J1	0.4	4.78	0.3	3.04e-6	Select biomarker traits;
SARC	cis	rs9611519	0.894	rs9623320	chr22:41478482	G/A	cg03806693	chr22:41940476	POLR3H	-0.61	-7.42	-0.44	2.23e-12	Neuroticism;
SARC	cis	rs950169	0.887	rs12903946	chr15:84954430	T/C	cg24253500	chr15:84953950	NA	0.36	5.21	0.32	4.19e-7	Schizophrenia;
SARC	cis	rs6831352	0.959	rs6532796	chr4:100042242	C/T	cg12011299	chr4:100065546	ADH4	-0.35	-6.11	-0.37	4.16e-9	Alcohol dependence;
SARC	cis	rs137603	0.966	rs470079	chr22:39708333	T/C	cg01093212	chr22:39715156	SNORD43;RPL3	-0.43	-5.19	-0.32	4.65e-7	Primary biliary cholangitis;
SARC	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.67	-8.58	-0.49	1.37e-15	Intelligence (multi-trait analysis);
SARC	cis	rs6963495	0.818	rs73192122	chr7:105171471	G/A	cg13798780	chr7:105162888	PUS7	0.61	5.59	0.34	6.32e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs9399135	0.967	rs13191501	chr6:135366880	T/C	cg22676075	chr6:135203613	NA	0.34	4.75	0.3	3.59e-6	Red blood cell count;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg21583160	chr1:48938137	SPATA6	0.49	6.27	0.38	1.77e-9	Schizophrenia;
SARC	cis	rs778371	0.676	rs17164	chr2:233593499	C/T	cg16596103	chr2:233749413	NGEF	-0.32	-4.83	-0.3	2.44e-6	Schizophrenia;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg19956889	chr10:11650681	USP6NL	0.45	6.51	0.39	4.51e-10	Thyroid stimulating hormone;
SARC	cis	rs12079745	0.793	rs12063056	chr1:169264107	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.81	-5.21	-0.32	4.14e-7	QT interval;
SARC	cis	rs826838	1.000	rs826891	chr12:39100824	A/G	cg26384229	chr12:38710491	ALG10B	-0.77	-12.0	-0.62	3.9e-26	Heart rate;
SARC	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-8.35	-0.48	6.2e-15	Alzheimer's disease;
SARC	cis	rs7223966	1.000	rs7209435	chr17:61712964	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.59	-6.72	-0.4	1.41e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7726839	0.555	rs7720419	chr5:589343	A/T	cg23206463	chr5:561769	NA	-0.44	-6.31	-0.38	1.43e-9	Obesity-related traits;
SARC	trans	rs61931739	0.534	rs1912773	chr12:34097401	T/C	cg26384229	chr12:38710491	ALG10B	0.87	12.44	0.63	1.37e-27	Morning vs. evening chronotype;
SARC	cis	rs96067	0.805	rs7522400	chr1:36613380	A/G	cg24686825	chr1:36642396	MAP7D1	-0.57	-6.79	-0.41	9.44e-11	Corneal structure;
SARC	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.43	0.39	7.26e-10	Height;
SARC	trans	rs1814175	0.817	rs10839397	chr11:49857074	C/T	cg03929089	chr4:120376271	NA	-0.9	-15.01	-0.7	4.47e-36	Height;
SARC	cis	rs9399135	0.967	rs34546690	chr6:135369709	T/C	cg24558204	chr6:135376177	HBS1L	0.46	6.22	0.38	2.22e-9	Red blood cell count;
SARC	cis	rs10504229	0.679	rs78941440	chr8:58052095	A/G	cg08219700	chr8:58056026	NA	0.59	5.93	0.36	1.06e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs611744	0.647	rs1448150	chr8:109276161	T/C	cg21045802	chr8:109455806	TTC35	0.61	7.54	0.44	1.06e-12	Dupuytren's disease;
SARC	cis	rs10504229	0.679	rs16921687	chr8:58053514	T/C	cg21724239	chr8:58056113	NA	0.58	5.9	0.36	1.27e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2933343	0.818	rs6764681	chr3:128568380	G/C	cg25356066	chr3:128598488	ACAD9	-0.58	-6.46	-0.39	6.19e-10	IgG glycosylation;
SARC	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg12064134	chr16:90016061	DEF8	-0.57	-4.76	-0.3	3.38e-6	Skin colour saturation;
SARC	cis	rs7560272	0.538	rs4852976	chr2:73936322	T/C	cg20560298	chr2:73613845	ALMS1	0.45	5.92	0.36	1.15e-8	Schizophrenia;
SARC	cis	rs2273669	0.667	rs12214121	chr6:109322554	A/G	cg05315195	chr6:109294784	ARMC2	0.56	5.22	0.32	3.98e-7	Prostate cancer;
SARC	cis	rs11122272	0.735	rs2486736	chr1:231521478	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.68	10.13	0.55	3.22e-20	Hemoglobin concentration;
SARC	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg04277193	chr17:41438351	NA	0.45	4.86	0.3	2.15e-6	Menopause (age at onset);
SARC	trans	rs1941687	0.505	rs8091920	chr18:31303557	C/G	cg27147174	chr7:100797783	AP1S1	-0.53	-6.87	-0.41	5.94e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
SARC	cis	rs1865760	1.000	rs56118523	chr6:25908975	A/G	cg17691542	chr6:26056736	HIST1H1C	0.58	7.18	0.43	9.15e-12	Height;
SARC	cis	rs2153535	0.580	rs6910742	chr6:8448328	G/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.42	0.6	2.9e-24	Motion sickness;
SARC	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg08859206	chr1:53392774	SCP2	0.39	5.53	0.34	8.44e-8	Monocyte count;
SARC	cis	rs116095464	0.558	rs9312978	chr5:221930	C/G	cg22496380	chr5:211416	CCDC127	-0.89	-7.97	-0.46	7.24e-14	Breast cancer;
SARC	cis	rs10904908	0.931	rs7903137	chr10:17259567	C/T	cg01003015	chr10:17271136	VIM	-0.43	-5.24	-0.32	3.6e-7	Total cholesterol levels;Cholesterol, total;
SARC	cis	rs7592578	0.771	rs75579212	chr2:191376575	C/T	cg27211696	chr2:191398769	TMEM194B	-0.55	-5.77	-0.35	2.5e-8	Diastolic blood pressure;
SARC	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg11764359	chr7:65958608	NA	-0.67	-7.96	-0.46	7.7e-14	Aortic root size;
SARC	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg24549020	chr5:56110836	MAP3K1	0.81	8.57	0.49	1.46e-15	Initial pursuit acceleration;
SARC	cis	rs4727027	0.833	rs2107846	chr7:148832774	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	5.38	0.33	1.82e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs4646312	0.555	rs8185002	chr22:19933048	G/T	cg07194846	chr22:19930177	COMT;TXNRD2	-0.49	-6.4	-0.39	8.47e-10	Schizophrenia;
SARC	cis	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg12463550	chr7:65579703	CRCP	0.68	5.24	0.32	3.61e-7	Diabetic kidney disease;
SARC	cis	rs6439153	0.967	rs9821769	chr3:128726266	T/C	cg25356066	chr3:128598488	ACAD9	0.46	5.43	0.34	1.42e-7	Pneumococcal bacteremia;
SARC	cis	rs2455799	0.519	rs2062821	chr3:15697644	A/T	cg16303742	chr3:15540471	COLQ	-0.36	-5.24	-0.32	3.52e-7	Mean platelet volume;
SARC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg11494091	chr17:61959527	GH2	0.55	8.24	0.48	1.24e-14	Prudent dietary pattern;
SARC	cis	rs10463554	0.963	rs13340364	chr5:102339110	G/A	cg23492399	chr5:102201601	PAM	-0.47	-5.32	-0.33	2.43e-7	Parkinson's disease;
SARC	cis	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg20965017	chr5:231967	SDHA	-0.55	-5.32	-0.33	2.41e-7	Breast cancer;
SARC	cis	rs76419734	1.000	rs72673803	chr4:106696756	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.8	5.36	0.33	2.02e-7	Post bronchodilator FEV1;
SARC	cis	rs7829975	0.684	rs488904	chr8:8587571	T/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.34	-0.48	6.37e-15	Mood instability;
SARC	cis	rs818427	0.964	rs864682	chr5:112220556	C/T	cg07820702	chr5:112228657	REEP5	-0.45	-5.07	-0.32	8e-7	Total body bone mineral density;
SARC	cis	rs2228479	0.557	rs57071566	chr16:89889327	T/G	cg00800038	chr16:89945340	TCF25	-0.82	-5.79	-0.35	2.31e-8	Skin colour saturation;
SARC	cis	rs6089584	0.586	rs1079755	chr20:60615262	G/A	cg13770153	chr20:60521292	NA	-0.4	-5.74	-0.35	2.88e-8	Body mass index;
SARC	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg15052019	chr19:19431593	KIAA0892;SF4	0.39	4.78	0.3	3.06e-6	Tonsillectomy;
SARC	cis	rs898097	0.690	rs12452304	chr17:80811659	G/A	cg20578329	chr17:80767326	TBCD	-0.49	-6.63	-0.4	2.34e-10	Breast cancer;
SARC	cis	rs644799	0.562	rs1254989	chr11:95508121	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.82	12.05	0.62	2.65e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7223966	0.960	rs7212379	chr17:61706122	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.51	-5.51	-0.34	9.28e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9948	0.655	rs62156210	chr2:97393736	A/T	cg01990225	chr2:97406019	LMAN2L	-0.95	-6.43	-0.39	7.25e-10	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs2228479	0.718	rs62054253	chr16:89896932	T/C	cg06558623	chr16:89946397	TCF25	0.91	6.5	0.39	4.78e-10	Skin colour saturation;
SARC	trans	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg00938859	chr5:1591904	SDHAP3	0.79	7.6	0.45	7.02e-13	Breast cancer;
SARC	cis	rs35110281	0.633	rs4819292	chr21:45125223	A/G	cg04455712	chr21:45112962	RRP1B	0.34	4.72	0.3	4.13e-6	Mean corpuscular volume;
SARC	cis	rs6580649	0.943	rs1990029	chr12:48407987	C/T	cg05342945	chr12:48394962	COL2A1	-0.56	-5.69	-0.35	3.74e-8	Lung cancer;
SARC	trans	rs66573146	1.000	rs66712119	chr4:6965428	A/T	cg07817883	chr1:32538562	TMEM39B	1.45	9.08	0.51	4.59e-17	Granulocyte percentage of myeloid white cells;
SARC	cis	rs2797685	0.945	rs1773138	chr1:7891797	C/T	cg00864860	chr1:7907996	UTS2	-0.37	-5.23	-0.32	3.74e-7	Crohn's disease;
SARC	cis	rs9660992	0.710	rs4951184	chr1:205240659	A/T	cg21643547	chr1:205240462	TMCC2	-0.63	-8.66	-0.49	7.74e-16	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs17001868	0.568	rs9611312	chr22:40734790	T/C	cg07138101	chr22:40742427	ADSL	0.54	5.94	0.36	1.01e-8	Mammographic density (dense area);
SARC	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg11644478	chr21:40555479	PSMG1	1.04	14.54	0.69	1.63e-34	Cognitive function;
SARC	cis	rs7255436	0.965	rs12981318	chr19:8451430	G/A	cg10174797	chr19:8464628	RAB11B	0.45	6.44	0.39	6.84e-10	HDL cholesterol;
SARC	cis	rs595982	0.527	rs17272673	chr19:49362992	C/A	cg15549821	chr19:49342101	PLEKHA4	-0.67	-7.32	-0.43	4e-12	Red cell distribution width;
SARC	cis	rs1050631	0.563	rs685042	chr18:33743998	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.55	6.47	0.39	5.82e-10	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs999943	0.774	rs12205634	chr6:33611667	C/G	cg14003231	chr6:33640908	ITPR3	0.61	9.81	0.54	3.03e-19	Obesity (extreme);
SARC	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg13395646	chr4:1353034	KIAA1530	-0.47	-5.66	-0.35	4.42e-8	Obesity-related traits;
SARC	cis	rs2594989	0.733	rs9882513	chr3:11558377	T/C	cg00170343	chr3:11313890	ATG7	-0.57	-6.44	-0.39	6.8e-10	Circulating chemerin levels;
SARC	cis	rs920590	0.876	rs3907478	chr8:19657753	G/T	cg01411142	chr8:19674711	INTS10	0.43	5.19	0.32	4.48e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg06420487	chr17:61919686	SMARCD2	0.44	4.87	0.3	2.01e-6	Height;
SARC	cis	rs9325144	0.560	rs11183090	chr12:38662293	G/C	cg26384229	chr12:38710491	ALG10B	-0.66	-8.86	-0.5	2.06e-16	Morning vs. evening chronotype;
SARC	cis	rs1153858	1.000	rs3759899	chr15:45655903	T/C	cg03999130	chr15:45571217	NA	0.39	5.06	0.31	8.55e-7	Homoarginine levels;
SARC	cis	rs2180341	1.000	rs2180341	chr6:127600630	C/T	cg17762328	chr6:126965162	NA	-0.46	-5.16	-0.32	5.2e-7	Breast cancer;
SARC	cis	rs7937682	0.575	rs34695265	chr11:111719128	T/C	cg09085632	chr11:111637200	PPP2R1B	0.78	10.54	0.57	1.76e-21	Primary sclerosing cholangitis;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg10227393	chr19:3721525	NA	0.52	6.83	0.41	7.53e-11	Chemerin levels;
SARC	cis	rs67311347	1.000	rs2305521	chr3:40429183	A/G	cg24209194	chr3:40518798	ZNF619	0.59	7.37	0.43	3.02e-12	Renal cell carcinoma;
SARC	cis	rs74417235	0.673	rs6873342	chr5:154051835	A/G	cg17344516	chr5:154026930	NA	-0.58	-5.75	-0.35	2.77e-8	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
SARC	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg11644478	chr21:40555479	PSMG1	-0.58	-7.06	-0.42	1.9e-11	Menarche (age at onset);
SARC	cis	rs77633900	0.614	rs2629021	chr15:76974083	C/T	cg21673338	chr15:77095150	SCAPER	-0.6	-5.05	-0.31	8.79e-7	Non-glioblastoma glioma;Glioma;
SARC	cis	rs2120243	0.539	rs9857875	chr3:157078897	C/T	cg24825693	chr3:157122686	VEPH1	-0.45	-6.04	-0.37	6.03e-9	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.77	9.35	0.52	7.54e-18	Prudent dietary pattern;
SARC	cis	rs16854884	0.710	rs1530479	chr3:143819653	C/T	cg06585982	chr3:143692056	C3orf58	0.46	6.27	0.38	1.76e-9	Economic and political preferences (feminism/equality);
SARC	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg21724239	chr8:58056113	NA	0.58	5.75	0.35	2.75e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9916302	0.904	rs4511574	chr17:37532916	A/G	cg07936489	chr17:37558343	FBXL20	-0.74	-9.55	-0.53	1.88e-18	Glomerular filtration rate (creatinine);
SARC	cis	rs933688	1.000	rs332529	chr5:90789470	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	11.87	0.61	1.03e-25	Smoking behavior;
SARC	cis	rs2153535	0.580	rs6597330	chr6:8492076	T/C	cg21535247	chr6:8435926	SLC35B3	0.57	7.26	0.43	5.7e-12	Motion sickness;
SARC	cis	rs748404	0.697	rs513970	chr15:43579566	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.43	5.25	0.33	3.37e-7	Lung cancer;
SARC	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.73	-7.58	-0.44	7.9e-13	Platelet count;
SARC	cis	rs1348850	0.831	rs1345139	chr2:178449791	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.64	7.85	0.46	1.5e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	trans	rs7824557	0.564	rs2736295	chr8:11234780	C/G	cg06636001	chr8:8085503	FLJ10661	0.63	8.5	0.49	2.28e-15	Retinal vascular caliber;
SARC	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.92	13.83	0.67	3.74e-32	Chronic sinus infection;
SARC	cis	rs3768617	0.510	rs7518957	chr1:183093028	A/T	cg13390022	chr1:182993471	LAMC1	-0.3	-4.73	-0.3	3.96e-6	Fuchs's corneal dystrophy;
SARC	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg18876405	chr7:65276391	NA	0.48	5.82	0.36	1.9e-8	Calcium levels;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg06476034	chr17:6915753	RNASEK	-0.52	-6.6	-0.4	2.75e-10	Schizophrenia;
SARC	cis	rs11687170	0.882	rs73131628	chr2:237060570	C/T	cg19324714	chr2:237145437	ASB18	0.49	4.89	0.31	1.89e-6	Educational attainment;Educational attainment (years of education);
SARC	cis	rs2273669	0.667	rs75671532	chr6:109341298	A/G	cg05315195	chr6:109294784	ARMC2	-0.63	-5.7	-0.35	3.6e-8	Prostate cancer;
SARC	cis	rs17376456	0.696	rs6860390	chr5:93494731	G/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.5	-5.31	-0.33	2.51e-7	Diabetic retinopathy;
SARC	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg14893161	chr1:205819251	PM20D1	0.47	5.22	0.32	4.01e-7	Parkinson's disease;
SARC	cis	rs7772486	0.754	rs9390356	chr6:146118983	A/T	cg05347473	chr6:146136440	FBXO30	-0.56	-7.75	-0.45	2.78e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7568458	0.870	rs6733913	chr2:85757379	T/C	cg02493740	chr2:85810744	VAMP5	-0.34	-5.03	-0.31	9.83e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs7772486	0.790	rs1832362	chr6:146179955	C/T	cg05347473	chr6:146136440	FBXO30	0.51	7.3	0.43	4.63e-12	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs7937682	0.889	rs567859	chr11:111486738	A/G	cg18187862	chr3:45730750	SACM1L	0.55	6.99	0.42	2.93e-11	Primary sclerosing cholangitis;
SARC	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg00933542	chr6:150070202	PCMT1	0.32	5.34	0.33	2.23e-7	Lung cancer;
SARC	cis	rs796364	0.625	rs13035260	chr2:201132377	A/G	cg23649088	chr2:200775458	C2orf69	-0.69	-6.98	-0.42	3.02e-11	Schizophrenia;
SARC	cis	rs11153147	0.655	rs117298489	chr6:109432996	T/G	cg05315195	chr6:109294784	ARMC2	-0.6	-5.02	-0.31	1.01e-6	Mean corpuscular volume;
SARC	cis	rs644799	0.710	rs473852	chr11:95568757	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.92	15.7	0.72	2.18e-38	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg22968622	chr17:43663579	NA	1.14	15.46	0.71	1.35e-37	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs12995491	0.902	rs6737641	chr2:88529471	A/T	cg04511125	chr2:88470314	THNSL2	-0.38	-5.71	-0.35	3.43e-8	Response to metformin (IC50);
SARC	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg03735888	chr19:58951602	ZNF132	-0.43	-5.59	-0.34	6.17e-8	Uric acid clearance;
SARC	cis	rs2286885	1.000	rs10819171	chr9:129253074	G/A	cg14319473	chr9:129242481	FAM125B	0.38	4.75	0.3	3.54e-6	Intraocular pressure;
SARC	cis	rs9911578	0.967	rs8082544	chr17:57185807	C/T	cg05425664	chr17:57184151	TRIM37	0.64	8.01	0.46	5.34e-14	Intelligence (multi-trait analysis);
SARC	cis	rs35213789	0.762	rs610930	chr7:69189726	A/G	cg10619644	chr7:69149951	AUTS2	-0.36	-4.95	-0.31	1.44e-6	Childhood ear infection;
SARC	cis	rs12079745	0.793	rs12097260	chr1:169317195	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.98	-5.75	-0.35	2.79e-8	QT interval;
SARC	cis	rs2594989	0.943	rs2454499	chr3:11500531	T/C	cg00170343	chr3:11313890	ATG7	0.55	5.35	0.33	2.11e-7	Circulating chemerin levels;
SARC	cis	rs2153535	0.580	rs7453115	chr6:8447261	A/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.75	0.5	4.47e-16	Motion sickness;
SARC	cis	rs6582630	0.519	rs8189623	chr12:38351436	G/A	cg26384229	chr12:38710491	ALG10B	0.87	12.69	0.64	2.17e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs34172651	0.917	rs35283675	chr16:24820393	A/G	cg04756594	chr16:24857601	SLC5A11	0.37	5.72	0.35	3.22e-8	Intelligence (multi-trait analysis);
SARC	cis	rs995000	0.931	rs10157265	chr1:63093617	C/T	cg06896770	chr1:63153194	DOCK7	0.89	13.36	0.66	1.34e-30	Triglyceride levels;
SARC	cis	rs6700896	0.931	rs2211651	chr1:66156021	G/T	cg04111102	chr1:66153794	NA	0.37	5.62	0.35	5.35e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs13191362	0.935	rs66923841	chr6:163177317	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.73	6.21	0.38	2.44e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs7727544	0.735	rs274568	chr5:131713578	C/T	cg07395648	chr5:131743802	NA	0.41	4.82	0.3	2.57e-6	Blood metabolite levels;
SARC	cis	rs1448094	0.791	rs11117122	chr12:86337749	A/C	cg02569458	chr12:86230093	RASSF9	0.44	6.26	0.38	1.86e-9	Major depressive disorder;
SARC	cis	rs2153535	0.580	rs1335633	chr6:8448800	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	8.38	0.48	5.16e-15	Motion sickness;
SARC	cis	rs9788682	1.000	rs12438181	chr15:78812098	G/A	cg24631222	chr15:78858424	CHRNA5	0.75	9.74	0.54	4.88e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs7777484	0.500	rs2533885	chr7:2835655	C/T	cg18446336	chr7:2847575	GNA12	-0.32	-4.74	-0.3	3.68e-6	Height;
SARC	cis	rs2421770	0.530	rs4755396	chr11:35370624	G/A	cg13971030	chr11:35366721	SLC1A2	-0.34	-5.28	-0.33	2.97e-7	Staphylococcus aureus nasal carriage (persistent);
SARC	cis	rs35160687	0.901	rs35281683	chr2:86526372	T/C	cg10973622	chr2:86423274	IMMT	0.38	4.89	0.31	1.86e-6	Night sleep phenotypes;
SARC	cis	rs6493487	0.547	rs2414053	chr15:51129924	T/C	cg02338191	chr15:51200825	AP4E1	0.49	4.8	0.3	2.82e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs2153535	0.580	rs1932282	chr6:8477330	G/A	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg14829155	chr15:31115871	NA	0.48	6.22	0.38	2.27e-9	Huntington's disease progression;
SARC	cis	rs3008870	1.000	rs2815352	chr1:67482104	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.91	11.06	0.59	3.94e-23	Lymphocyte percentage of white cells;
SARC	cis	rs11583043	0.575	rs12727971	chr1:101589175	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.45	4.98	0.31	1.24e-6	Ulcerative colitis;Inflammatory bowel disease;
SARC	trans	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg20587970	chr11:113659929	NA	-0.94	-9.39	-0.52	5.88e-18	Hip circumference adjusted for BMI;
SARC	cis	rs7647973	0.710	rs6797299	chr3:49609794	G/T	cg07636037	chr3:49044803	WDR6	0.77	7.01	0.42	2.52e-11	Menarche (age at onset);
SARC	cis	rs12142240	0.698	rs6684274	chr1:46810842	A/G	cg10495392	chr1:46806563	NSUN4	-0.64	-7.04	-0.42	2.19e-11	Menopause (age at onset);
SARC	cis	rs10875746	0.669	rs11168508	chr12:48683511	G/C	cg26205652	chr12:48591994	NA	0.47	5.11	0.32	6.83e-7	Longevity (90 years and older);
SARC	cis	rs1005277	0.638	rs1005278	chr10:38218748	G/A	cg25427524	chr10:38739819	LOC399744	0.45	6.6	0.4	2.69e-10	Extrinsic epigenetic age acceleration;
SARC	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg03060546	chr3:49711283	APEH	0.48	6.4	0.39	8.48e-10	Menarche (age at onset);
SARC	cis	rs9790314	1.000	rs6794601	chr3:160946769	C/T	cg04691961	chr3:161091175	C3orf57	-0.75	-10.82	-0.58	2.33e-22	Morning vs. evening chronotype;
SARC	cis	rs4555082	0.794	rs2735829	chr14:105708472	C/T	cg13114125	chr14:105738426	BRF1	-0.81	-12.05	-0.62	2.55e-26	Mean platelet volume;Platelet distribution width;
SARC	cis	rs11098499	0.697	rs28655325	chr4:120372999	A/G	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	cis	rs6598955	0.724	rs7547520	chr1:26592310	C/T	cg04990556	chr1:26633338	UBXN11	-0.58	-7.97	-0.46	7.06e-14	Obesity-related traits;
SARC	cis	rs7216064	1.000	rs8079754	chr17:65887896	A/G	cg12091567	chr17:66097778	LOC651250	-0.62	-6.43	-0.39	7.2e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs910316	0.967	rs2010678	chr14:75567178	C/T	cg23033748	chr14:75592666	NEK9	0.37	5.27	0.33	3.12e-7	Height;
SARC	cis	rs12600053	0.687	rs11149686	chr16:84847247	A/G	cg09249803	chr16:84846936	NA	0.35	4.94	0.31	1.51e-6	Asthma (childhood onset);
SARC	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg16325326	chr1:53192061	ZYG11B	-0.91	-16.18	-0.73	5.59e-40	Monocyte count;
SARC	cis	rs302972	0.826	rs303010	chr6:25082105	C/T	cg11028769	chr6:25138951	CMAH	-0.66	-4.84	-0.3	2.39e-6	Creatinine levels in ischemic stroke;
SARC	cis	rs3126085	0.935	rs12409762	chr1:152175398	G/A	cg26876637	chr1:152193138	HRNR	-0.48	-5.47	-0.34	1.14e-7	Atopic dermatitis;
SARC	cis	rs3820928	0.775	rs10179756	chr2:227897076	A/G	cg11843606	chr2:227700838	RHBDD1	-0.55	-6.84	-0.41	6.88e-11	Pulmonary function;
SARC	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg24642844	chr7:1081250	C7orf50	-0.6	-6.11	-0.37	4.06e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs2153535	0.541	rs9328477	chr6:8519109	T/C	cg21535247	chr6:8435926	SLC35B3	0.58	7.25	0.43	6.2e-12	Motion sickness;
SARC	cis	rs208520	0.690	rs207091	chr6:66799847	G/T	cg07460842	chr6:66804631	NA	-1.08	-14.98	-0.7	5.37e-36	Exhaled nitric oxide output;
SARC	cis	rs6840360	0.593	rs4696286	chr4:152606547	G/A	cg22705602	chr4:152727874	NA	-0.49	-8.39	-0.48	4.81e-15	Intelligence (multi-trait analysis);
SARC	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg04944784	chr2:26401820	FAM59B	-0.49	-6.25	-0.38	1.89e-9	Gut microbiome composition (summer);
SARC	cis	rs826838	0.872	rs826878	chr12:39088837	A/T	cg26384229	chr12:38710491	ALG10B	-0.75	-11.16	-0.59	1.94e-23	Heart rate;
SARC	cis	rs79149102	0.579	rs9673012	chr15:75293737	C/T	cg00629941	chr15:75287862	SCAMP5	-0.64	-5.11	-0.32	6.76e-7	Lung cancer;
SARC	cis	rs9875589	0.509	rs11927267	chr3:14073992	T/G	cg19554555	chr3:13937349	NA	-0.41	-5.4	-0.33	1.64e-7	Ovarian reserve;
SARC	cis	rs7223966	1.000	rs7220892	chr17:61908316	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.5	-5.13	-0.32	6.19e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs854765	0.583	rs4414547	chr17:17859052	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	9.85	0.54	2.34e-19	Total body bone mineral density;
SARC	cis	rs2180341	0.883	rs9388568	chr6:127690694	C/A	cg27446573	chr6:127587934	RNF146	1.06	14.81	0.7	2.04e-35	Breast cancer;
SARC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.53	6.69	0.4	1.64e-10	Lymphocyte counts;
SARC	cis	rs2153535	0.580	rs9406172	chr6:8515464	T/A	cg21535247	chr6:8435926	SLC35B3	0.58	7.25	0.43	6.2e-12	Motion sickness;
SARC	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg26335602	chr6:28129616	ZNF389	0.52	5.69	0.35	3.74e-8	Depression;
SARC	cis	rs244293	0.760	rs12945393	chr17:53045243	G/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.4	-4.74	-0.3	3.74e-6	Menarche (age at onset);
SARC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.42	-6.42	-0.39	7.6e-10	Total body bone mineral density;
SARC	cis	rs8067545	0.750	rs4924803	chr17:19991806	C/T	cg13482628	chr17:19912719	NA	0.56	7.43	0.44	2.11e-12	Schizophrenia;
SARC	cis	rs72781680	1.000	rs72781671	chr2:24231123	A/G	cg06627628	chr2:24431161	ITSN2	-0.73	-6.9	-0.41	4.77e-11	Lymphocyte counts;
SARC	cis	rs9325144	0.647	rs12424190	chr12:39111206	A/T	cg26384229	chr12:38710491	ALG10B	-0.62	-7.65	-0.45	5.15e-13	Morning vs. evening chronotype;
SARC	cis	rs7247513	0.658	rs4804728	chr19:12752928	G/A	cg01871581	chr19:12707946	ZNF490	-0.74	-9.65	-0.53	9.25e-19	Bipolar disorder;
SARC	cis	rs2153535	0.580	rs1115078	chr6:8449638	G/A	cg07606381	chr6:8435919	SLC35B3	0.77	11.07	0.59	3.77e-23	Motion sickness;
SARC	cis	rs9325144	0.555	rs11183215	chr12:38693127	G/A	cg13010199	chr12:38710504	ALG10B	-0.57	-7.42	-0.44	2.21e-12	Morning vs. evening chronotype;
SARC	cis	rs11864453	0.647	rs10492813	chr16:72122463	A/G	cg16558253	chr16:72132732	DHX38	0.5	8.13	0.47	2.46e-14	Fibrinogen levels;
SARC	trans	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg08975724	chr8:8085496	FLJ10661	0.49	6.26	0.38	1.82e-9	Retinal vascular caliber;
SARC	cis	rs2288912	0.838	rs2239375	chr19:45459851	T/C	cg13119609	chr19:45449297	APOC2	0.51	8.84	0.5	2.32e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs1942	1.000	rs1942	chr15:41774423	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.39	-5.33	-0.33	2.28e-7	Eosinophil percentage of granulocytes;
SARC	cis	rs6545883	0.929	rs3732170	chr2:61749716	C/T	cg15711740	chr2:61764176	XPO1	-0.43	-5.39	-0.33	1.72e-7	Tuberculosis;
SARC	cis	rs826838	0.935	rs11169511	chr12:39175802	T/C	cg13010199	chr12:38710504	ALG10B	0.74	9.86	0.54	2.23e-19	Heart rate;
SARC	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg12311346	chr5:56204834	C5orf35	-0.65	-6.45	-0.39	6.38e-10	Type 2 diabetes;
SARC	cis	rs3820928	0.874	rs55959848	chr2:227805426	C/A	cg05526886	chr2:227700861	RHBDD1	-0.54	-6.64	-0.4	2.19e-10	Pulmonary function;
SARC	cis	rs2652822	0.525	rs11634159	chr15:63507422	C/T	cg02713581	chr15:63449717	RPS27L	0.53	6.4	0.39	8.36e-10	Metabolic traits;
SARC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg11965913	chr1:205819406	PM20D1	0.89	14.61	0.69	9.5e-35	Menarche (age at onset);
SARC	cis	rs7914558	0.966	rs1971589	chr10:104744406	A/G	cg04362960	chr10:104952993	NT5C2	0.41	5.01	0.31	1.07e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs372883	0.507	rs8132992	chr21:30750561	T/C	cg08807101	chr21:30365312	RNF160	0.53	6.62	0.4	2.43e-10	Pancreatic cancer;
SARC	cis	rs113835537	0.866	rs59320108	chr11:66365996	A/T	cg24851651	chr11:66362959	CCS	0.46	4.87	0.3	2.04e-6	Airway imaging phenotypes;
SARC	cis	rs17376456	0.877	rs10514380	chr5:93409370	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	6.12	0.37	3.99e-9	Diabetic retinopathy;
SARC	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.66	-6.89	-0.41	5.03e-11	Platelet count;
SARC	cis	rs2624839	0.704	rs1046956	chr3:50222926	T/A	cg14019146	chr3:50243930	SLC38A3	0.43	6.92	0.41	4.32e-11	Intelligence (multi-trait analysis);
SARC	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg11644478	chr21:40555479	PSMG1	-0.59	-7.31	-0.43	4.33e-12	Menarche (age at onset);
SARC	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg02018176	chr4:1364513	KIAA1530	0.41	6.3	0.38	1.51e-9	Longevity;
SARC	cis	rs6582630	0.615	rs10880642	chr12:38554152	A/G	cg26384229	chr12:38710491	ALG10B	-0.57	-7.35	-0.43	3.35e-12	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg07092213	chr7:1199455	ZFAND2A	-0.4	-5.05	-0.31	8.82e-7	Longevity;Endometriosis;
SARC	cis	rs921968	0.541	rs6717433	chr2:219375711	G/C	cg02176678	chr2:219576539	TTLL4	-0.52	-8.03	-0.47	4.85e-14	Mean corpuscular hemoglobin concentration;
SARC	cis	rs703842	1.000	rs3782130	chr12:58161898	G/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.79	11.63	0.61	5.91e-25	Multiple sclerosis;
SARC	cis	rs9398803	0.651	rs9388509	chr6:126989977	G/A	cg19875578	chr6:126661172	C6orf173	0.62	8.6	0.49	1.15e-15	Male-pattern baldness;
SARC	cis	rs7572733	0.555	rs10202569	chr2:198934726	C/G	cg00792783	chr2:198669748	PLCL1	0.43	4.85	0.3	2.25e-6	Dermatomyositis;
SARC	cis	rs6591182	0.967	rs11227229	chr11:65354150	C/T	cg27068330	chr11:65405492	SIPA1	-0.41	-5.05	-0.31	9.08e-7	Non-alcoholic fatty liver disease histology (lobular);
SARC	cis	rs992157	0.697	rs13384682	chr2:219069137	G/A	cg00012203	chr2:219082015	ARPC2	0.84	13.95	0.67	1.51e-32	Colorectal cancer;
SARC	cis	rs9948	0.655	rs62152771	chr2:97447121	C/G	cg01990225	chr2:97406019	LMAN2L	-0.96	-6.75	-0.4	1.15e-10	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg14893161	chr1:205819251	PM20D1	-0.55	-6.01	-0.37	6.95e-9	White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs3741151	0.773	rs17244602	chr11:73219907	A/G	cg10635786	chr11:73019496	ARHGEF17	-0.65	-5.16	-0.32	5.3e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs561341	0.663	rs72821936	chr17:30224068	C/G	cg12000587	chr17:30186630	C17orf79	-0.34	-5.17	-0.32	5.11e-7	Hip circumference adjusted for BMI;
SARC	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg18252515	chr7:66147081	NA	-1.35	-12.01	-0.62	3.48e-26	Diabetic kidney disease;
SARC	cis	rs910316	1.000	rs2300601	chr14:75639571	A/G	cg11812906	chr14:75593930	NEK9	0.9	12.48	0.63	1.05e-27	Height;
SARC	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg02841227	chr6:26021843	HIST1H4A	0.64	7.71	0.45	3.59e-13	Intelligence (multi-trait analysis);
SARC	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg01341218	chr17:43662625	NA	0.7	7.93	0.46	9.19e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs4900538	0.963	rs1190553	chr14:102915331	G/T	cg18135206	chr14:102964638	TECPR2	-0.69	-9.34	-0.52	8.17e-18	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	19.09	0.78	1.48e-49	Prudent dietary pattern;
SARC	cis	rs734999	0.545	rs12730932	chr1:2559589	T/G	cg20673091	chr1:2541236	MMEL1	-0.32	-4.98	-0.31	1.23e-6	Ulcerative colitis;
SARC	cis	rs57920188	0.640	rs4478781	chr1:4086827	C/T	cg20703997	chr1:4087676	NA	0.51	5.14	0.32	5.74e-7	Interleukin-17 levels;
SARC	cis	rs2645424	0.635	rs62495697	chr8:11709007	G/A	cg21281001	chr8:11725306	CTSB	0.52	6.42	0.39	7.41e-10	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
SARC	cis	rs11585357	0.895	rs112208664	chr1:17632010	G/A	cg08277548	chr1:17600880	PADI3	-0.43	-5.12	-0.32	6.47e-7	Hair shape;
SARC	cis	rs6061231	0.740	rs11698650	chr20:60958374	A/T	cg23531748	chr20:60969906	CABLES2	0.45	5.41	0.33	1.56e-7	Colorectal cancer;
SARC	cis	rs2735413	0.918	rs7190752	chr16:78077430	T/C	cg04733911	chr16:78082701	NA	-0.31	-5.61	-0.34	5.78e-8	Systolic blood pressure (alcohol consumption interaction);
SARC	trans	rs61931739	0.635	rs10743836	chr12:33961680	C/T	cg26384229	chr12:38710491	ALG10B	0.57	7.37	0.43	2.93e-12	Morning vs. evening chronotype;
SARC	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg05863683	chr7:1912471	MAD1L1	0.34	5.21	0.32	4.18e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg11764359	chr7:65958608	NA	-0.75	-8.74	-0.5	4.7e-16	Aortic root size;
SARC	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	12.61	0.64	3.88e-28	Platelet count;
SARC	cis	rs6120849	0.754	rs17319032	chr20:33643296	T/C	cg24642439	chr20:33292090	TP53INP2	0.57	5.48	0.34	1.1e-7	Protein C levels;
SARC	cis	rs765787	0.530	rs1631533	chr15:45518628	C/T	cg24006582	chr15:45444508	DUOX1	-0.5	-6.57	-0.4	3.24e-10	Uric acid levels;
SARC	cis	rs2857078	0.654	rs4793083	chr17:42312973	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.44	-5.9	-0.36	1.27e-8	Red cell distribution width;Reticulocyte count;
SARC	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg25894440	chr7:65020034	NA	0.78	5.89	0.36	1.34e-8	Diabetic kidney disease;
SARC	cis	rs1983170	0.808	rs10874787	chr1:92017749	A/G	cg25838465	chr1:92012736	NA	-0.45	-5.47	-0.34	1.17e-7	Eosinophil percentage of white cells;
SARC	cis	rs58653258	1.000	rs72752290	chr1:234999438	G/A	cg14037484	chr1:235490207	ARID4B	-0.77	-5.58	-0.34	6.69e-8	Granulocyte percentage of myeloid white cells;
SARC	cis	rs11764590	0.694	rs7801349	chr7:2085553	T/C	cg21782813	chr7:2030301	MAD1L1	-0.31	-4.83	-0.3	2.48e-6	Neuroticism;
SARC	cis	rs6988636	1.000	rs60827294	chr8:124187842	T/C	cg23067535	chr8:124195133	FAM83A	-0.69	-5.46	-0.34	1.24e-7	Urinary uromodulin levels;
SARC	cis	rs897984	0.553	rs2125293	chr16:30863875	T/C	cg02466173	chr16:30829666	NA	0.43	5.48	0.34	1.12e-7	Dementia with Lewy bodies;
SARC	cis	rs7582180	0.606	rs10174145	chr2:100932488	T/C	cg14675211	chr2:100938903	LONRF2	0.49	7.22	0.43	7.35e-12	Intelligence (multi-trait analysis);
SARC	cis	rs501120	0.925	rs1746050	chr10:44777188	C/A	cg09554077	chr10:44749378	NA	0.51	6.67	0.4	1.8e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs16976116	0.803	rs28590021	chr15:55490993	C/T	cg11288833	chr15:55489084	RSL24D1	0.63	6.09	0.37	4.66e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs713587	0.967	rs6749422	chr2:25150011	C/G	cg01884057	chr2:25150051	NA	0.3	4.87	0.3	2.08e-6	Body mass index in non-asthmatics;
SARC	cis	rs7614311	0.639	rs111234932	chr3:63842449	C/T	cg22134162	chr3:63841271	THOC7	-0.48	-5.07	-0.32	8.21e-7	Lung function (FVC);Lung function (FEV1);
SARC	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg11062466	chr8:58055876	NA	0.53	5.48	0.34	1.12e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs561341	0.739	rs1978116	chr17:30220978	A/C	cg12000587	chr17:30186630	C17orf79	-0.35	-4.76	-0.3	3.34e-6	Hip circumference adjusted for BMI;
SARC	cis	rs72781680	1.000	rs72781680	chr2:24238928	C/T	cg06627628	chr2:24431161	ITSN2	-0.74	-7.11	-0.42	1.39e-11	Lymphocyte counts;
SARC	cis	rs7089973	0.604	rs7919649	chr10:116609576	T/C	cg03647239	chr10:116582469	FAM160B1	0.51	6.5	0.39	4.81e-10	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs28655083	0.843	rs1502433	chr16:77087101	C/T	cg01753188	chr16:77233325	SYCE1L;MON1B	0.4	6.03	0.37	6.48e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg11764359	chr7:65958608	NA	-0.66	-7.79	-0.45	2.25e-13	Aortic root size;
SARC	cis	rs477692	0.699	rs557311	chr10:131389484	A/G	cg14263093	chr10:131365266	MGMT	0.35	5.03	0.31	9.81e-7	Response to temozolomide;
SARC	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg19223190	chr17:80058835	NA	-0.38	-5.38	-0.33	1.77e-7	Life satisfaction;
SARC	cis	rs7017697	0.569	rs10092840	chr8:19672040	G/T	cg17834443	chr8:19674713	INTS10	-0.41	-5.21	-0.32	4.19e-7	Breast cancer;
SARC	cis	rs950776	0.720	rs11633223	chr15:78935476	T/C	cg22563815	chr15:78856949	CHRNA5	0.31	4.91	0.31	1.7e-6	Sudden cardiac arrest;
SARC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg05064044	chr6:292385	DUSP22	-0.58	-7.44	-0.44	1.91e-12	Menopause (age at onset);
SARC	cis	rs7223966	1.000	rs16947042	chr17:61766457	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.45	5.03	0.31	9.75e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9348739	1	rs9348739	chr6:26923099	G/C	cg12826209	chr6:26865740	GUSBL1	0.86	5.83	0.36	1.85e-8	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9911578	0.741	rs2611776	chr17:56819636	G/T	cg05425664	chr17:57184151	TRIM37	-0.66	-8.15	-0.47	2.24e-14	Intelligence (multi-trait analysis);
SARC	cis	rs77669868	0.866	rs2735195	chr11:114051192	A/G	cg01914181	chr11:114070210	ZBTB16	-0.41	-5.19	-0.32	4.62e-7	Monocyte percentage of white cells;
SARC	cis	rs198851	0.915	rs72834630	chr6:26025186	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.39	-4.87	-0.3	2.02e-6	Red cell distribution width;High light scatter reticulocyte percentage of red cells;Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs796364	0.806	rs79725795	chr2:201083534	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-6.09	-0.37	4.55e-9	Schizophrenia;
SARC	cis	rs4128725	1.000	rs12142553	chr1:159341672	T/C	cg25076881	chr1:159409836	OR10J1	0.4	4.78	0.3	3.04e-6	Select biomarker traits;
SARC	cis	rs11025559	0.773	rs10833334	chr11:20498640	T/C	cg19653624	chr11:20408972	PRMT3	-0.58	-6.32	-0.38	1.34e-9	Pursuit maintenance gain;
SARC	cis	rs9916302	0.851	rs2338795	chr17:37399364	T/G	cg07936489	chr17:37558343	FBXL20	-0.68	-8.97	-0.51	1.02e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs6843082	0.531	rs10032150	chr4:111646618	A/G	cg25750389	chr4:111544016	PITX2	0.38	5.01	0.31	1.06e-6	Stroke (ischemic);Incident atrial fibrillation;Atrial fibrillation;
SARC	cis	rs17376456	1.000	rs56046246	chr5:93531545	T/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.14	0.32	5.94e-7	Diabetic retinopathy;
SARC	cis	rs79149102	0.649	rs28431073	chr15:75107637	A/C	cg09165964	chr15:75287851	SCAMP5	-0.9	-5.36	-0.33	2e-7	Lung cancer;
SARC	cis	rs9916302	0.706	rs1877030	chr17:37740161	T/C	cg20243544	chr17:37824526	PNMT	0.52	5.17	0.32	4.95e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs77106637	1.000	rs11605166	chr11:72669777	T/C	cg03713592	chr11:72463424	ARAP1	0.87	7.76	0.45	2.69e-13	Type 2 diabetes;
SARC	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-9.98	-0.55	9.05e-20	Chronic sinus infection;
SARC	cis	rs7819412	0.749	rs11991118	chr8:10939273	A/C	cg21775007	chr8:11205619	TDH	0.4	5.12	0.32	6.49e-7	Triglycerides;
SARC	cis	rs3008870	1.000	rs12044278	chr1:67460977	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.89	-11.03	-0.59	4.76e-23	Lymphocyte percentage of white cells;
SARC	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg03806693	chr22:41940476	POLR3H	-0.95	-12.88	-0.64	5.15e-29	Vitiligo;
SARC	cis	rs8114671	0.562	rs6087642	chr20:33468306	T/C	cg24642439	chr20:33292090	TP53INP2	0.49	6.08	0.37	4.84e-9	Height;
SARC	cis	rs4268898	0.722	rs11680491	chr2:24416292	T/A	cg06627628	chr2:24431161	ITSN2	0.53	7.11	0.42	1.45e-11	Asthma;
SARC	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg24633833	chr3:10029261	TMEM111	0.52	5.25	0.33	3.43e-7	Alzheimer's disease;
SARC	cis	rs9325144	0.556	rs34565156	chr12:39028239	G/A	cg13010199	chr12:38710504	ALG10B	-0.53	-6.67	-0.4	1.81e-10	Morning vs. evening chronotype;
SARC	cis	rs739401	0.611	rs10833048	chr11:3020040	A/G	cg20651018	chr11:3035856	CARS	-0.44	-6.75	-0.4	1.15e-10	Longevity;
SARC	cis	rs911555	0.723	rs4906324	chr14:103923099	A/G	cg12935359	chr14:103987150	CKB	0.39	5.33	0.33	2.27e-7	Intelligence (multi-trait analysis);
SARC	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	8.67	0.49	7.45e-16	Mean platelet volume;
SARC	cis	rs8067354	0.645	rs72838857	chr17:57836767	A/G	cg13753209	chr17:57696993	CLTC	0.63	6.35	0.38	1.09e-9	Hemoglobin concentration;
SARC	cis	rs7769051	0.522	rs7775241	chr6:133109022	T/C	cg07930552	chr6:133119739	C6orf192	0.93	5.75	0.35	2.77e-8	Type 2 diabetes nephropathy;
SARC	cis	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg22857025	chr5:266934	NA	-1.06	-11.8	-0.61	1.74e-25	Breast cancer;
SARC	cis	rs911555	0.723	rs4906320	chr14:103876925	T/C	cg24130564	chr14:104152367	KLC1	0.47	5.43	0.33	1.44e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6045173	0.524	rs6075279	chr20:18027258	A/T	ch.20.378824F	chr20:17967508	C20orf72	0.41	5.01	0.31	1.09e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs4699052	1.000	rs4699055	chr4:104154500	T/C	cg16532752	chr4:104119610	CENPE	-0.44	-5.22	-0.32	3.99e-7	Testicular germ cell tumor;
SARC	trans	rs10100465	0.596	rs218009	chr8:118716275	A/G	cg17257676	chr22:29137984	CHEK2;HSCB	0.61	6.28	0.38	1.63e-9	Leprosy;
SARC	cis	rs7429990	0.864	rs6777081	chr3:48155569	T/C	cg11946769	chr3:48343235	NME6	-0.49	-5.49	-0.34	1.04e-7	Educational attainment (years of education);
SARC	cis	rs6860806	0.507	rs270608	chr5:131648406	C/T	cg04518342	chr5:131593106	PDLIM4	0.43	5.38	0.33	1.79e-7	Breast cancer;
SARC	cis	rs7727544	0.684	rs2631363	chr5:131707095	A/G	cg24060327	chr5:131705240	SLC22A5	0.7	8.97	0.51	1.03e-16	Blood metabolite levels;
SARC	cis	rs6570726	0.935	rs413916	chr6:145831400	T/C	cg05220968	chr6:146057943	EPM2A	-0.29	-4.82	-0.3	2.57e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs35213789	0.768	rs11974201	chr7:69334991	C/T	cg10619644	chr7:69149951	AUTS2	0.39	4.83	0.3	2.49e-6	Childhood ear infection;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg11599612	chr6:151187337	MTHFD1L	-0.51	-6.72	-0.4	1.4e-10	Electrocardiographic conduction measures;
SARC	cis	rs6942407	0.592	rs10085726	chr7:86851397	T/A	cg02420886	chr7:86849541	C7orf23	0.71	6.17	0.37	2.99e-9	Food allergy;
SARC	cis	rs6977660	0.652	rs10274428	chr7:19850592	C/T	cg07541023	chr7:19748670	TWISTNB	0.55	4.94	0.31	1.49e-6	Thyroid stimulating hormone;
SARC	cis	rs10046574	0.561	rs10226494	chr7:135214412	C/G	cg27474649	chr7:135195673	CNOT4	0.78	7.44	0.44	1.95e-12	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg21017887	chr14:105400489	NA	0.5	7.03	0.42	2.33e-11	Rheumatoid arthritis;
SARC	cis	rs950169	0.580	rs1061737	chr15:85183790	G/C	cg17507749	chr15:85114479	UBE2QP1	0.58	6.77	0.41	1.03e-10	Schizophrenia;
SARC	cis	rs9303401	0.659	rs12946397	chr17:56769979	C/T	cg25039879	chr17:56429692	SUPT4H1	0.68	6.4	0.39	8.57e-10	Cognitive test performance;
SARC	cis	rs75920871	0.528	rs7941428	chr11:116903384	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.46	-4.74	-0.3	3.71e-6	Subjective well-being;
SARC	cis	rs6665290	0.904	rs11586604	chr1:227183865	G/T	cg14016676	chr1:227182615	CDC42BPA	0.34	4.95	0.31	1.44e-6	Myeloid white cell count;
SARC	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg22974920	chr21:40686053	BRWD1	0.47	5.16	0.32	5.18e-7	Cognitive function;
SARC	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg12463550	chr7:65579703	CRCP	-0.47	-5.16	-0.32	5.3e-7	Aortic root size;
SARC	cis	rs7084402	0.934	rs1579394	chr10:60294625	T/A	cg07615347	chr10:60278583	BICC1	0.6	8.91	0.5	1.45e-16	Refractive error;
SARC	cis	rs6582630	0.572	rs1969363	chr12:38514872	A/G	cg14851346	chr12:38532713	NA	0.41	4.9	0.31	1.81e-6	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9916302	0.904	rs8066704	chr17:37477218	C/T	cg20243544	chr17:37824526	PNMT	-0.53	-6.35	-0.38	1.1e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs9303542	0.559	rs62066693	chr17:46617530	G/C	cg04904318	chr17:46607828	HOXB1	-0.45	-4.95	-0.31	1.41e-6	Ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs1448094	0.802	rs11117146	chr12:86382870	C/T	cg02569458	chr12:86230093	RASSF9	-0.41	-6.09	-0.37	4.65e-9	Major depressive disorder;
SARC	cis	rs7712401	0.601	rs30067	chr5:122293668	A/T	cg19412675	chr5:122181750	SNX24	0.4	5.13	0.32	5.98e-7	Mean platelet volume;
SARC	cis	rs80130819	0.748	rs901962	chr12:48741219	A/T	cg05342945	chr12:48394962	COL2A1	-0.49	-5.28	-0.33	2.89e-7	Prostate cancer;
SARC	cis	rs7589342	0.899	rs11885225	chr2:106486548	T/C	cg16077055	chr2:106428750	NCK2	0.35	6.26	0.38	1.78e-9	Addiction;
SARC	cis	rs1153858	0.943	rs28605551	chr15:45641720	C/T	cg21132104	chr15:45694354	SPATA5L1	0.78	10.82	0.58	2.33e-22	Homoarginine levels;
SARC	trans	rs7615952	0.688	rs17334074	chr3:125540460	A/G	cg07211511	chr3:129823064	LOC729375	0.65	7.54	0.44	1.05e-12	Blood pressure (smoking interaction);
SARC	cis	rs765787	0.530	rs11636404	chr15:45535861	C/G	cg25801113	chr15:45476975	SHF	0.3	4.92	0.31	1.62e-6	Uric acid levels;
SARC	cis	rs5750854	0.503	rs5750861	chr22:40026141	C/A	cg10455938	chr22:40058150	CACNA1I	0.46	5.55	0.34	7.91e-8	Intelligence (multi-trait analysis);
SARC	cis	rs62344088	1.000	rs6872393	chr5:155854	A/G	cg20965017	chr5:231967	SDHA	0.8	5.03	0.31	9.74e-7	Asthma (childhood onset);
SARC	cis	rs7044106	0.762	rs1867254	chr9:123429078	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	8.57	0.49	1.46e-15	Hip circumference adjusted for BMI;
SARC	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg22800045	chr5:56110881	MAP3K1	0.73	7.56	0.44	9.49e-13	Initial pursuit acceleration;
SARC	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg11987759	chr7:65425863	GUSB	-0.48	-6.54	-0.39	3.9e-10	Aortic root size;
SARC	cis	rs910316	0.737	rs175510	chr14:75524839	G/A	cg23033748	chr14:75592666	NEK9	-0.38	-5.22	-0.32	3.87e-7	Height;
SARC	cis	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg11266682	chr4:10021025	SLC2A9	0.41	7.34	0.43	3.52e-12	Bone mineral density;
SARC	cis	rs4969178	0.965	rs11653305	chr17:76386918	T/C	cg02836325	chr17:76403955	PGS1	0.32	4.86	0.3	2.13e-6	HDL cholesterol levels;
SARC	cis	rs12474201	0.928	rs13429704	chr2:46960329	G/T	cg06386533	chr2:46925753	SOCS5	0.82	12.06	0.62	2.49e-26	Height;
SARC	cis	rs356220	0.642	rs6825421	chr4:90634806	T/A	cg06632027	chr4:90757378	SNCA	0.39	5.0	0.31	1.13e-6	Parkinson's disease;
SARC	cis	rs7592578	0.771	rs4258824	chr2:191395027	C/T	cg27211696	chr2:191398769	TMEM194B	-0.5	-5.36	-0.33	1.98e-7	Diastolic blood pressure;
SARC	cis	rs6912958	0.559	rs173333	chr6:88047754	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.34	5.92	0.36	1.17e-8	Monocyte percentage of white cells;
SARC	cis	rs6910061	0.750	rs6456870	chr6:11115486	C/T	cg27233058	chr6:11094804	LOC221710	0.58	5.32	0.33	2.41e-7	Diabetic kidney disease;
SARC	cis	rs6674176	0.628	rs3791116	chr1:44414156	T/A	cg13606994	chr1:44402422	ARTN	-0.33	-5.36	-0.33	1.96e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg19748678	chr4:122722346	EXOSC9	0.65	7.82	0.46	1.85e-13	Type 2 diabetes;
SARC	cis	rs950169	0.887	rs62029593	chr15:84955180	A/G	cg17507749	chr15:85114479	UBE2QP1	0.77	9.42	0.53	4.67e-18	Schizophrenia;
SARC	cis	rs1920116	0.778	rs34237331	chr3:169551870	C/A	cg08193579	chr3:169529701	LRRC34	0.4	4.74	0.3	3.75e-6	Glioma (high-grade);
SARC	cis	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg22857025	chr5:266934	NA	-1.06	-11.63	-0.61	5.91e-25	Breast cancer;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg23727087	chr12:133300001	NA	0.48	7.08	0.42	1.67e-11	Schizophrenia;
SARC	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg18876405	chr7:65276391	NA	0.71	9.27	0.52	1.28e-17	Calcium levels;
SARC	cis	rs61925898	1	rs61925898	chr12:66779537	A/G	cg16791601	chr12:66731901	HELB	-0.68	-10.04	-0.55	6.18e-20	Basophil percentage of granulocytes;Basophil percentage of white cells;
SARC	cis	rs7727544	0.684	rs272869	chr5:131677997	A/G	cg07395648	chr5:131743802	NA	-0.43	-5.04	-0.31	9.34e-7	Blood metabolite levels;
SARC	trans	rs13240504	0.557	rs10265534	chr7:126174539	C/T	cg12155036	chr3:194015171	NA	-0.56	-6.44	-0.39	6.58e-10	Anti-saccade response;
SARC	cis	rs7553864	0.574	rs6576867	chr1:87615796	A/T	cg17420885	chr1:87600446	LOC339524	-0.35	-4.93	-0.31	1.58e-6	Smoking behavior;
SARC	cis	rs4566357	0.521	rs78411533	chr2:227910807	G/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.87	-0.36	1.51e-8	Coronary artery disease;
SARC	cis	rs198851	0.920	rs7752351	chr6:25990842	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.37	-4.73	-0.3	3.87e-6	Red cell distribution width;High light scatter reticulocyte percentage of red cells;Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs10791323	0.569	rs1944734	chr11:133720077	G/A	cg15485101	chr11:133734466	NA	0.35	5.38	0.33	1.82e-7	Childhood ear infection;
SARC	cis	rs9790314	0.560	rs4856701	chr3:161044106	G/T	cg17135325	chr3:160939158	NMD3	0.56	7.14	0.42	1.15e-11	Morning vs. evening chronotype;
SARC	cis	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg22496380	chr5:211416	CCDC127	-0.88	-9.35	-0.52	7.72e-18	Breast cancer;
SARC	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg23262073	chr20:60523788	NA	0.44	6.09	0.37	4.58e-9	Body mass index;
SARC	cis	rs1881797	0.932	rs2387038	chr1:247674919	G/A	cg18198730	chr1:247681584	NA	0.5	5.24	0.32	3.63e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs2197308	0.740	rs1842595	chr12:37906223	G/A	cg13010199	chr12:38710504	ALG10B	-0.68	-9.06	-0.51	5.6e-17	Morning vs. evening chronotype;
SARC	cis	rs7264396	0.635	rs6119672	chr20:34479767	A/G	cg12579300	chr20:34535607	PHF20	-0.41	-4.83	-0.3	2.45e-6	Total cholesterol levels;
SARC	cis	rs3126085	0.935	rs6587666	chr1:152296863	C/T	cg26876637	chr1:152193138	HRNR	-0.5	-5.61	-0.34	5.74e-8	Atopic dermatitis;
SARC	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg23758822	chr17:41437982	NA	0.9	11.47	0.6	1.98e-24	Menopause (age at onset);
SARC	cis	rs9512730	0.527	rs11619784	chr13:27999643	A/G	cg08193333	chr13:27998609	GTF3A	0.44	4.98	0.31	1.26e-6	Schizophrenia;
SARC	trans	rs17685	0.725	rs6467993	chr7:75719350	G/A	cg19862616	chr7:65841803	NCRNA00174	0.61	7.41	0.44	2.28e-12	Coffee consumption;Coffee consumption (cups per day);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg07908574	chr1:8396933	SLC45A1	-0.77	-6.46	-0.39	6.21e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7084402	0.967	rs2577393	chr10:60286159	C/T	cg07615347	chr10:60278583	BICC1	0.6	8.82	0.5	2.75e-16	Refractive error;
SARC	cis	rs11583043	0.957	rs6577223	chr1:101499750	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.49	5.54	0.34	8.1e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg24829409	chr8:58192753	C8orf71	-0.55	-6.17	-0.37	2.94e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs2347867	0.771	rs4371852	chr6:152242900	T/G	cg12042060	chr8:4846849	CSMD1	-0.4	-6.26	-0.38	1.83e-9	Age at first birth;
SARC	cis	rs72792276	1.000	rs72792276	chr5:127364126	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.7	5.81	0.36	2.04e-8	Red cell distribution width;
SARC	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg19774624	chr17:42201019	HDAC5	0.79	11.43	0.6	2.69e-24	Total body bone mineral density;
SARC	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg21724239	chr8:58056113	NA	-0.59	-5.66	-0.35	4.48e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs478304	0.637	rs11227255	chr11:65454044	C/T	cg27068330	chr11:65405492	SIPA1	-0.41	-4.84	-0.3	2.32e-6	Acne (severe);
SARC	cis	rs1969363	0.509	rs8189633	chr12:38065155	C/G	cg13010199	chr12:38710504	ALG10B	0.78	10.73	0.57	4.45e-22	Morning vs. evening chronotype;
SARC	cis	rs736408	0.500	rs2878762	chr3:52919002	T/C	cg22484793	chr3:52261325	TLR9	0.34	4.77	0.3	3.26e-6	Bipolar disorder;
SARC	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.75	10.18	0.55	2.31e-20	Personality dimensions;
SARC	cis	rs763121	0.888	rs2235229	chr22:39124912	A/G	cg06022373	chr22:39101656	GTPBP1	0.69	9.13	0.51	3.48e-17	Menopause (age at onset);
SARC	cis	rs7624766	0.714	rs1378660	chr3:160535871	T/C	cg22637730	chr3:160473554	PPM1L	0.42	5.5	0.34	9.92e-8	Response to methotrexate in rheumatoid arthritis;
SARC	cis	rs41271473	0.526	rs12353961	chr1:228738252	G/C	cg16512390	chr1:228756714	NA	0.62	5.58	0.34	6.73e-8	Chronic lymphocytic leukemia;
SARC	trans	rs208520	0.690	rs12204512	chr6:66710486	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	14.02	0.68	8.85e-33	Exhaled nitric oxide output;
SARC	cis	rs6442522	0.768	rs3821638	chr3:15511044	A/G	cg16303742	chr3:15540471	COLQ	0.34	4.96	0.31	1.39e-6	Uric acid levels;
SARC	trans	rs11098499	0.697	rs10020027	chr4:120381879	G/C	cg25214090	chr10:38739885	LOC399744	0.54	7.11	0.42	1.38e-11	Corneal astigmatism;
SARC	cis	rs2180341	1.000	rs4897207	chr6:127605898	C/T	cg27446573	chr6:127587934	RNF146	1.01	14.22	0.68	1.88e-33	Breast cancer;
SARC	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7945705	0.967	rs10840141	chr11:8902218	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.4	5.55	0.34	7.79e-8	Hemoglobin concentration;
SARC	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg11764359	chr7:65958608	NA	0.78	9.86	0.54	2.14e-19	Aortic root size;
SARC	cis	rs9309473	0.660	rs62151564	chr2:73615449	A/G	cg20560298	chr2:73613845	ALMS1	-0.5	-5.06	-0.31	8.32e-7	Metabolite levels;
SARC	cis	rs1468333	1.000	rs423258	chr5:137475787	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.78	10.39	0.56	4.95e-21	Resting heart rate;
SARC	cis	rs6062302	0.522	rs6090475	chr20:62245397	C/A	cg09650180	chr20:62225654	GMEB2	-0.45	-5.55	-0.34	7.75e-8	Glioblastoma;
SARC	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg11987759	chr7:65425863	GUSB	0.47	5.68	0.35	4.01e-8	Aortic root size;
SARC	cis	rs2273669	0.667	rs9688496	chr6:109364825	G/T	cg05315195	chr6:109294784	ARMC2	-0.63	-5.7	-0.35	3.6e-8	Prostate cancer;
SARC	cis	rs11792861	0.888	rs57314245	chr9:111813832	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.68	8.04	0.47	4.39e-14	Menarche (age at onset);
SARC	cis	rs11838776	0.522	rs7318424	chr13:111021623	C/G	cg06243866	chr13:111019493	COL4A2	0.61	9.3	0.52	1.09e-17	Coronary artery disease;
SARC	cis	rs698833	0.547	rs1067355	chr2:44663152	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.54	-5.9	-0.36	1.28e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs7027203	0.828	rs10761288	chr9:96609363	C/T	cg14598338	chr9:96623480	NA	-0.54	-7.84	-0.46	1.65e-13	DNA methylation (variation);
SARC	cis	rs74181299	0.684	rs60136636	chr2:65338422	G/A	cg20592124	chr2:65290738	CEP68	-0.41	-5.75	-0.35	2.78e-8	Pulse pressure;
SARC	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.39	-4.83	-0.3	2.5e-6	Lymphocyte counts;
SARC	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg13206674	chr6:150067644	NUP43	0.43	5.62	0.35	5.57e-8	Lung cancer;
SARC	cis	rs7824557	0.628	rs11782706	chr8:11186215	A/C	cg21775007	chr8:11205619	TDH	0.65	8.32	0.48	7.44e-15	Retinal vascular caliber;
SARC	cis	rs16854884	0.802	rs6783329	chr3:143798454	T/G	cg06585982	chr3:143692056	C3orf58	0.6	7.89	0.46	1.14e-13	Economic and political preferences (feminism/equality);
SARC	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg04277193	chr17:41438351	NA	-0.47	-5.1	-0.32	6.99e-7	Menopause (age at onset);
SARC	cis	rs2303759	0.918	rs10405465	chr19:49869298	C/T	cg22590775	chr19:49891494	CCDC155	0.48	5.53	0.34	8.71e-8	Multiple sclerosis;
SARC	trans	rs1814175	0.669	rs10839315	chr11:49654406	G/A	cg15704280	chr7:45808275	SEPT13	-0.79	-12.32	-0.63	3.54e-27	Height;
SARC	cis	rs17600642	0.694	rs17600433	chr10:72445227	A/G	cg19779893	chr10:72451501	ADAMTS14	0.35	5.76	0.35	2.71e-8	Bipolar disorder;
SARC	cis	rs10752881	1.000	rs6701400	chr1:182977197	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.76	0.58	3.38e-22	Colorectal cancer;
SARC	cis	rs3812831	0.654	rs9314900	chr13:114937618	A/C	cg15896084	chr13:114927664	NA	0.38	5.04	0.31	9.16e-7	Schizophrenia;
SARC	trans	rs827625	0.712	rs1838477	chr10:8969850	T/A	cg13445358	chr12:53661749	ESPL1	0.53	6.4	0.39	8.24e-10	Response to metformin (IC50);
SARC	cis	rs67478160	0.654	rs1997913	chr14:104213960	C/T	cg08213375	chr14:104286397	PPP1R13B	0.26	4.73	0.3	3.93e-6	Schizophrenia;
SARC	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg23758822	chr17:41437982	NA	0.89	11.4	0.6	3.2e-24	Menopause (age at onset);
SARC	cis	rs12532878	0.652	rs11768465	chr7:100198386	C/T	cg20848291	chr7:100343083	ZAN	-0.46	-4.77	-0.3	3.25e-6	Mean corpuscular hemoglobin;
SARC	cis	rs11874712	1.000	rs8088881	chr18:43664970	T/C	cg25174615	chr18:43684699	ATP5A1;HAUS1	0.4	4.75	0.3	3.52e-6	Migraine - clinic-based;
SARC	cis	rs10781543	0.748	rs68002978	chr9:139325641	C/T	cg14169450	chr9:139327907	INPP5E	0.43	5.71	0.35	3.47e-8	Monocyte percentage of white cells;
SARC	cis	rs910316	1.000	rs2268617	chr14:75608728	G/A	cg11812906	chr14:75593930	NEK9	0.88	13.39	0.66	1.08e-30	Height;
SARC	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg17294928	chr15:75287854	SCAMP5	0.49	6.11	0.37	4.11e-9	Breast cancer;
SARC	cis	rs7246865	0.510	rs3816549	chr19:17173937	G/A	cg16202187	chr19:17186497	HAUS8;MYO9B	0.39	4.78	0.3	3.17e-6	Reticulocyte fraction of red cells;
SARC	trans	rs61931739	0.500	rs11053248	chr12:34518011	G/A	cg13010199	chr12:38710504	ALG10B	0.82	11.58	0.6	8.37e-25	Morning vs. evening chronotype;
SARC	cis	rs7223966	1.000	rs9903897	chr17:61716705	T/A	cg26338869	chr17:61819248	STRADA	0.43	4.88	0.3	1.97e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg19723775	chr5:179050963	HNRNPH1	0.57	7.59	0.45	7.59e-13	Lung cancer;
SARC	cis	rs35110281	0.811	rs9980185	chr21:45057905	A/G	cg01579765	chr21:45077557	HSF2BP	-0.39	-6.69	-0.4	1.63e-10	Mean corpuscular volume;
SARC	cis	rs5769765	1.000	rs5769760	chr22:50259696	A/G	cg03033257	chr22:50311977	ALG12;CRELD2	-0.54	-5.64	-0.35	4.81e-8	Schizophrenia;
SARC	cis	rs79149102	0.579	rs6495140	chr15:75306041	T/C	cg17294928	chr15:75287854	SCAMP5	-1.01	-9.29	-0.52	1.13e-17	Lung cancer;
SARC	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg18876405	chr7:65276391	NA	0.71	8.86	0.5	2.03e-16	Aortic root size;
SARC	cis	rs9300255	0.537	rs2682429	chr12:123642955	C/G	cg05973401	chr12:123451056	ABCB9	0.53	6.13	0.37	3.64e-9	Neutrophil percentage of white cells;
SARC	cis	rs9291683	0.632	rs10939669	chr4:10045827	A/G	cg00071950	chr4:10020882	SLC2A9	0.39	6.29	0.38	1.52e-9	Bone mineral density;
SARC	cis	rs2070997	0.607	rs72765060	chr9:133712404	T/C	cg11464064	chr9:133710261	ABL1	0.64	5.79	0.35	2.23e-8	Response to amphetamines;
SARC	cis	rs9359856	0.510	rs6454775	chr6:90465000	A/T	cg13799429	chr6:90582589	CASP8AP2	0.53	4.78	0.3	3.14e-6	Bipolar disorder;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg18879160	chr19:12175540	ZNF844	0.65	6.73	0.4	1.29e-10	Lung cancer in ever smokers;
SARC	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg07061783	chr6:25882402	NA	-0.42	-4.84	-0.3	2.34e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg24846343	chr22:24311635	DDTL	0.5	6.87	0.41	5.69e-11	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg12463550	chr7:65579703	CRCP	0.68	5.24	0.32	3.61e-7	Diabetic kidney disease;
SARC	cis	rs6582630	0.555	rs2197308	chr12:38281261	A/G	cg13010199	chr12:38710504	ALG10B	-0.53	-6.63	-0.4	2.35e-10	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs4481887	0.962	rs6663952	chr1:248465682	A/G	cg01631408	chr1:248437212	OR2T33	-0.44	-5.62	-0.35	5.3e-8	Common traits (Other);
SARC	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.97e-8	Aortic root size;
SARC	cis	rs1881797	0.872	rs12408686	chr1:247691141	C/T	cg05639522	chr1:247681581	NA	0.44	4.78	0.3	3.04e-6	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs3204955	0.802	rs11580293	chr1:116246752	C/T	cg20810993	chr1:116250018	CASQ2	-0.5	-5.03	-0.31	9.86e-7	Itch intensity from mosquito bite adjusted by bite size;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg20793623	chr3:41236272	NA	0.43	6.48	0.39	5.46e-10	Thyroid stimulating hormone;
SARC	trans	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg21659725	chr3:3221576	CRBN	-0.8	-12.22	-0.62	7.09e-27	Intelligence (multi-trait analysis);
SARC	cis	rs8028182	0.636	rs10152155	chr15:75701554	A/T	cg20655648	chr15:75932815	IMP3	0.65	7.67	0.45	4.75e-13	Sudden cardiac arrest;
SARC	trans	rs1957429	0.520	rs72625641	chr14:65335761	C/T	cg10286983	chr6:24494717	ALDH5A1	-0.75	-6.61	-0.4	2.52e-10	Pediatric areal bone mineral density (radius);
SARC	cis	rs7312933	0.558	rs4768411	chr12:42855390	A/G	cg19980929	chr12:42632907	YAF2	-0.46	-6.81	-0.41	8.04e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg11987759	chr7:65425863	GUSB	0.48	5.92	0.36	1.15e-8	Aortic root size;
SARC	cis	rs4642101	0.765	rs9871991	chr3:12827525	C/A	cg05775895	chr3:12838266	CAND2	0.76	12.26	0.63	5.21e-27	QRS complex (12-leadsum);
SARC	cis	rs721399	0.553	rs13282367	chr8:18244986	T/G	cg18736775	chr8:18248649	NAT2	-0.68	-7.37	-0.43	2.93e-12	Blood metabolite levels;
SARC	cis	rs4642101	0.765	rs3901665	chr3:12824610	C/A	cg12400702	chr3:12838781	CAND2	-0.26	-5.27	-0.33	3.08e-7	QRS complex (12-leadsum);
SARC	cis	rs7937682	1.000	rs11213980	chr11:111562692	A/T	cg09085632	chr11:111637200	PPP2R1B	0.97	16.41	0.73	9.41e-41	Primary sclerosing cholangitis;
SARC	cis	rs4268898	1.000	rs10195436	chr2:24436112	C/T	cg26838691	chr2:24397539	C2orf84	0.38	5.14	0.32	5.75e-7	Asthma;
SARC	cis	rs7312774	0.618	rs2888892	chr12:107328071	C/T	cg16260113	chr12:107380972	MTERFD3	1.01	7.8	0.46	2.02e-13	Severe influenza A (H1N1) infection;
SARC	cis	rs7927771	0.965	rs1064608	chr11:47640429	G/C	cg20307385	chr11:47447363	PSMC3	-0.54	-6.55	-0.39	3.64e-10	Subjective well-being;
SARC	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg23221052	chr5:179740743	GFPT2	-0.53	-6.65	-0.4	2.09e-10	Height;
SARC	cis	rs858239	0.932	rs858272	chr7:23276785	A/G	cg23682824	chr7:23144976	KLHL7	0.63	7.92	0.46	9.81e-14	Cerebrospinal fluid biomarker levels;
SARC	cis	rs3820928	0.934	rs60141402	chr2:227761445	A/C	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.83	-0.36	1.82e-8	Pulmonary function;
SARC	trans	rs9888736	0.501	rs938043	chr15:47909513	A/G	cg01357263	chr12:122459509	BCL7A	-0.52	-6.5	-0.39	4.82e-10	Body mass index;
SARC	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg19223190	chr17:80058835	NA	0.48	6.71	0.4	1.43e-10	Life satisfaction;
SARC	cis	rs9467603	0.800	rs4236040	chr6:25761209	T/C	cg21479132	chr6:26055353	NA	-0.75	-4.81	-0.3	2.66e-6	Intelligence (multi-trait analysis);
SARC	cis	rs12155623	0.592	rs12682003	chr8:49865454	G/T	cg06076277	chr8:49783056	NA	0.3	5.08	0.32	7.61e-7	Sudden cardiac arrest;
SARC	cis	rs6582630	0.638	rs1829584	chr12:38526299	G/T	cg26384229	chr12:38710491	ALG10B	-0.59	-7.58	-0.44	8.36e-13	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg08280861	chr8:58055591	NA	0.63	6.03	0.37	6.21e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6912958	0.781	rs3918467	chr6:88180388	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.29	-4.81	-0.3	2.72e-6	Monocyte percentage of white cells;
SARC	cis	rs9399135	0.935	rs987690	chr6:135350379	A/G	cg24558204	chr6:135376177	HBS1L	0.45	6.07	0.37	5.25e-9	Red blood cell count;
SARC	cis	rs9911578	0.867	rs72628394	chr17:57121313	C/T	cg12560992	chr17:57184187	TRIM37	-0.8	-10.97	-0.58	7.82e-23	Intelligence (multi-trait analysis);
SARC	cis	rs2832077	0.506	rs2832081	chr21:30152992	A/C	cg08807101	chr21:30365312	RNF160	0.51	5.59	0.34	6.21e-8	Cognitive test performance;
SARC	cis	rs11122272	0.677	rs2808615	chr1:231550171	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.67	9.91	0.54	1.54e-19	Hemoglobin concentration;
SARC	cis	rs17376456	0.877	rs9314095	chr5:93425495	T/C	cg25358565	chr5:93447407	FAM172A	1.32	14.94	0.7	7.42e-36	Diabetic retinopathy;
SARC	cis	rs4319547	1.000	rs6489157	chr12:123101673	C/G	cg23029597	chr12:123009494	RSRC2	0.42	5.46	0.34	1.25e-7	Body mass index;
SARC	cis	rs9612	1.000	rs28446957	chr19:44246600	T/A	cg07522664	chr19:44259120	C19orf61	0.49	5.55	0.34	7.65e-8	Exhaled nitric oxide output;
SARC	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg24209194	chr3:40518798	ZNF619	0.67	8.2	0.47	1.66e-14	Renal cell carcinoma;
SARC	cis	rs12579753	0.913	rs17749243	chr12:82178079	A/C	cg07988820	chr12:82153109	PPFIA2	-0.59	-6.91	-0.41	4.68e-11	Resting heart rate;
SARC	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.95	-15.39	-0.71	2.45e-37	Chronic sinus infection;
SARC	cis	rs13082711	0.911	rs11709954	chr3:27421427	C/T	cg02860705	chr3:27208620	NA	0.51	6.42	0.39	7.54e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs910316	0.967	rs2268619	chr14:75640354	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.54	-7.01	-0.42	2.56e-11	Height;
SARC	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.43	0.44	2.1e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs3008870	0.920	rs3008860	chr1:67391003	G/C	cg08660285	chr1:67390436	MIER1;WDR78	0.93	11.48	0.6	1.77e-24	Lymphocyte percentage of white cells;
SARC	cis	rs11718455	0.883	rs6795366	chr3:44005735	C/T	cg08738300	chr3:44038990	NA	0.5	5.52	0.34	9.13e-8	Coronary artery disease;
SARC	cis	rs7829975	0.846	rs7005216	chr8:8547110	C/G	cg06636001	chr8:8085503	FLJ10661	-0.64	-8.4	-0.48	4.35e-15	Mood instability;
SARC	cis	rs79349575	0.783	rs11079844	chr17:47028334	G/A	cg07967210	chr17:47022446	SNF8	0.37	4.71	0.3	4.19e-6	Type 2 diabetes;
SARC	cis	rs1448094	0.506	rs61930640	chr12:86173333	T/C	cg02569458	chr12:86230093	RASSF9	0.38	4.99	0.31	1.19e-6	Major depressive disorder;
SARC	cis	rs2204008	0.715	rs11514282	chr12:38169056	G/T	cg26384229	chr12:38710491	ALG10B	0.88	12.94	0.65	3.26e-29	Bladder cancer;
SARC	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg08677398	chr8:58056175	NA	0.44	5.26	0.33	3.24e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9896052	0.591	rs11077790	chr17:73464718	G/A	cg04121983	chr17:73511085	CASKIN2	0.41	5.44	0.34	1.33e-7	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs7824557	0.564	rs2572379	chr8:11237480	A/G	cg21775007	chr8:11205619	TDH	-0.63	-8.39	-0.48	4.56e-15	Retinal vascular caliber;
SARC	cis	rs9486715	0.867	rs9480700	chr6:96965056	A/G	cg06623918	chr6:96969491	KIAA0776	0.88	12.63	0.64	3.28e-28	Headache;
SARC	cis	rs9420	0.961	rs12804972	chr11:57463767	T/C	cg23127183	chr11:57508653	C11orf31	-0.56	-6.36	-0.38	1.08e-9	Schizophrenia;
SARC	cis	rs6963495	0.818	rs73190156	chr7:105153567	C/T	cg19920283	chr7:105172520	RINT1	0.65	5.53	0.34	8.62e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs1878931	0.615	rs6501171	chr16:3402610	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.87	12.67	0.64	2.46e-28	Body mass index (adult);
SARC	cis	rs12824058	0.831	rs4759451	chr12:130812739	G/A	cg23887609	chr12:130822674	PIWIL1	0.37	5.15	0.32	5.52e-7	Menopause (age at onset);
SARC	cis	rs7647973	0.626	rs35129566	chr3:49866584	T/G	cg06212747	chr3:49208901	KLHDC8B	-0.59	-5.94	-0.36	1.01e-8	Menarche (age at onset);
SARC	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg00339695	chr16:24857497	SLC5A11	0.41	5.81	0.36	2.03e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9815354	0.812	rs73828283	chr3:41835099	T/C	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9916302	0.706	rs2302073	chr17:37457342	A/G	cg15445000	chr17:37608096	MED1	-0.45	-4.92	-0.31	1.62e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-8.91	-0.5	1.49e-16	Alzheimer's disease;
SARC	cis	rs1707322	0.691	rs28495425	chr1:46187320	T/G	cg03146154	chr1:46216737	IPP	0.53	6.35	0.38	1.12e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6088590	0.523	rs6059913	chr20:33143288	G/A	cg24642439	chr20:33292090	TP53INP2	0.65	8.36	0.48	5.83e-15	Coronary artery disease;
SARC	cis	rs10489202	1.000	rs12407660	chr1:167954363	C/T	cg24449463	chr1:168025552	DCAF6	-0.64	-7.1	-0.42	1.5e-11	Schizophrenia;
SARC	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.62	7.72	0.45	3.39e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg26335602	chr6:28129616	ZNF389	0.48	5.5	0.34	9.97e-8	Parkinson's disease;
SARC	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	8.82	0.5	2.77e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs656319	0.513	rs34990153	chr8:9996389	A/G	cg21775007	chr8:11205619	TDH	-0.5	-6.42	-0.39	7.42e-10	Myopia (pathological);
SARC	cis	rs6598955	0.666	rs12759434	chr1:26607123	C/T	cg04990556	chr1:26633338	UBXN11	-0.58	-8.02	-0.46	5.24e-14	Obesity-related traits;
SARC	cis	rs13161895	0.938	rs594202	chr5:179417335	C/T	cg02702477	chr5:179499311	RNF130	0.62	5.91	0.36	1.22e-8	LDL cholesterol;
SARC	cis	rs3733589	1.000	rs3775942	chr4:10020307	G/A	cg16430538	chr4:10459836	ZNF518B	0.62	4.97	0.31	1.27e-6	Renal overload gout;
SARC	cis	rs78487399	0.808	rs6732766	chr2:43712785	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-5.28	-0.33	2.99e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg11890956	chr21:40555474	PSMG1	1.17	18.92	0.78	5.47e-49	Cognitive function;
SARC	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	8.93	0.51	1.29e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1468333	1.000	rs2906128	chr5:137550054	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.79	10.66	0.57	7.25e-22	Resting heart rate;
SARC	cis	rs2836950	0.545	rs2836922	chr21:40516308	C/T	cg11644478	chr21:40555479	PSMG1	-0.56	-6.6	-0.4	2.81e-10	Menarche (age at onset);
SARC	cis	rs12142240	0.698	rs66575205	chr1:46814092	T/G	cg10495392	chr1:46806563	NSUN4	0.65	6.83	0.41	7.25e-11	Menopause (age at onset);
SARC	cis	rs1348850	0.914	rs11893448	chr2:178280013	T/C	cg23306229	chr2:178417860	TTC30B	0.52	6.03	0.37	6.44e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg05313129	chr8:58192883	C8orf71	-0.62	-6.34	-0.38	1.18e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs798554	0.610	rs1182209	chr7:2808595	C/T	cg04166393	chr7:2884313	GNA12	0.4	4.9	0.31	1.83e-6	Height;
SARC	cis	rs1051424	0.642	rs115869798	chr17:57892829	T/A	cg13753209	chr17:57696993	CLTC	0.67	7.24	0.43	6.66e-12	Obesity-related traits;
SARC	cis	rs78320035	1.000	rs74882027	chr1:168164273	G/A	cg17113809	chr1:168148080	TIPRL	1.26	6.78	0.41	9.78e-11	Red cell distribution width;
SARC	cis	rs708547	1.000	rs708547	chr4:57821309	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.65	6.92	0.41	4.4e-11	Response to bleomycin (chromatid breaks);
SARC	cis	rs765787	0.530	rs4775844	chr15:45542048	T/C	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.81e-6	Uric acid levels;
SARC	cis	rs6545883	0.894	rs10177303	chr2:61594459	G/A	cg15711740	chr2:61764176	XPO1	0.4	4.77	0.3	3.29e-6	Tuberculosis;
SARC	cis	rs1691799	0.899	rs1168328	chr12:66729250	T/C	cg16791601	chr12:66731901	HELB	-0.72	-11.07	-0.59	3.63e-23	White blood cell count (basophil);
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg23614605	chr14:35761327	PSMA6	0.5	6.61	0.4	2.63e-10	Lung adenocarcinoma;
SARC	cis	rs505401	0.554	rs11879374	chr19:6088681	T/G	cg18109231	chr19:6110877	RFX2	0.68	4.77	0.3	3.18e-6	Mean platelet volume;
SARC	cis	rs9467773	0.620	rs2504566	chr6:26660488	G/C	cg12292205	chr6:26970375	C6orf41	0.4	4.9	0.31	1.77e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg27266027	chr21:40555129	PSMG1	-0.53	-6.01	-0.37	6.97e-9	Cognitive function;
SARC	cis	rs7429990	0.965	rs5016900	chr3:47822877	G/C	cg11946769	chr3:48343235	NME6	0.69	6.86	0.41	6.28e-11	Educational attainment (years of education);
SARC	cis	rs1707322	0.721	rs28817701	chr1:46186050	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.17	0.37	2.95e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6831352	0.879	rs4699716	chr4:100066125	G/A	cg13256891	chr4:100009986	ADH5	-0.65	-7.8	-0.45	2.07e-13	Alcohol dependence;
SARC	cis	rs6500602	0.702	rs6500605	chr16:4502410	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.37	6.25	0.38	1.97e-9	Schizophrenia;
SARC	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg00149659	chr3:10157352	C3orf10	0.78	7.3	0.43	4.52e-12	Alzheimer's disease;
SARC	cis	rs79349575	0.715	rs1058018	chr17:47000251	C/T	cg16584676	chr17:46985605	UBE2Z	0.52	6.43	0.39	7.13e-10	Type 2 diabetes;
SARC	cis	rs11697848	0.867	rs117436392	chr20:48531814	G/A	cg17849948	chr20:48532315	SPATA2	0.87	5.2	0.32	4.3e-7	Systemic lupus erythematosus;
SARC	cis	rs10799445	0.550	rs7512348	chr1:227740272	C/T	cg26340147	chr1:227730820	NA	0.33	4.72	0.3	4.05e-6	Height;
SARC	cis	rs7027203	0.964	rs7854075	chr9:96571211	G/A	cg14598338	chr9:96623480	NA	0.54	7.08	0.42	1.7e-11	DNA methylation (variation);
SARC	cis	rs9902453	1.000	rs9902453	chr17:28349095	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.54	-7.09	-0.42	1.59e-11	Coffee consumption (cups per day);
SARC	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.99	11.64	0.61	5.6e-25	Platelet count;
SARC	cis	rs17270561	0.666	rs17320090	chr6:25720215	C/G	cg17691542	chr6:26056736	HIST1H1C	0.59	7.21	0.43	7.66e-12	Iron status biomarkers;
SARC	cis	rs7927592	0.913	rs7107622	chr11:68374183	T/C	cg01657329	chr11:68192670	LRP5	-0.4	-4.92	-0.31	1.64e-6	Total body bone mineral density;
SARC	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg03185022	chr7:2884158	GNA12	0.47	5.4	0.33	1.63e-7	Height;
SARC	cis	rs7582720	0.943	rs72926799	chr2:203828192	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs13161895	1.000	rs4235504	chr5:179453680	T/C	cg06664874	chr5:179499304	RNF130	0.5	4.8	0.3	2.89e-6	LDL cholesterol;
SARC	cis	rs10916814	0.632	rs1890003	chr1:20899101	T/C	cg24502330	chr1:20914028	CDA	-0.3	-5.27	-0.33	3.16e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs10489202	0.865	rs744168	chr1:168094079	G/T	cg24449463	chr1:168025552	DCAF6	-0.5	-5.19	-0.32	4.54e-7	Schizophrenia;
SARC	cis	rs3815700	1.000	rs8104328	chr19:33094371	G/A	cg02997394	chr19:33096574	ANKRD27	0.8	8.23	0.47	1.36e-14	Eosinophilic esophagitis;
SARC	cis	rs7647973	0.588	rs9883000	chr3:49667691	A/G	cg13072238	chr3:49761600	GMPPB	-0.49	-4.95	-0.31	1.44e-6	Menarche (age at onset);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg00914777	chr14:93651123	MOAP1;C14orf109	0.48	6.63	0.4	2.37e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs7662987	0.517	rs2851263	chr4:100030354	A/G	cg12011299	chr4:100065546	ADH4	0.33	5.57	0.34	6.86e-8	Smoking initiation;
SARC	cis	rs826838	0.874	rs11183816	chr12:38834656	T/G	cg13010199	chr12:38710504	ALG10B	0.78	11.14	0.59	2.27e-23	Heart rate;
SARC	cis	rs12479064	0.724	rs112900993	chr2:99948805	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.68	-8.44	-0.48	3.44e-15	Chronic sinus infection;
SARC	cis	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg15556689	chr8:8085844	FLJ10661	0.43	5.26	0.33	3.19e-7	Mood instability;
SARC	cis	rs6088580	0.634	rs1890000	chr20:32968312	G/T	cg24642439	chr20:33292090	TP53INP2	-0.65	-8.53	-0.49	1.85e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg25894440	chr7:65020034	NA	-0.74	-5.64	-0.35	4.95e-8	Diabetic kidney disease;
SARC	cis	rs9443189	0.570	rs523465	chr6:76330434	G/C	cg01950844	chr6:76311363	SENP6	0.84	8.05	0.47	4.26e-14	Prostate cancer;
SARC	cis	rs114858855	1.000	rs9480969	chr6:109839117	A/G	cg26835506	chr6:109038353	NA	-0.63	-5.17	-0.32	5.02e-7	Plasma trimethylamine N-oxide levels;
SARC	cis	rs950169	0.922	rs12912934	chr15:85114447	C/T	cg24253500	chr15:84953950	NA	0.37	5.27	0.33	3.13e-7	Schizophrenia;
SARC	cis	rs8077889	1.000	rs17742905	chr17:41891143	C/A	cg26893861	chr17:41843967	DUSP3	0.94	11.67	0.61	4.31e-25	Triglycerides;
SARC	cis	rs116095464	0.558	rs73029475	chr5:206969	T/C	cg22857025	chr5:266934	NA	-1.13	-10.64	-0.57	8.44e-22	Breast cancer;
SARC	cis	rs748404	0.697	rs493177	chr15:43543258	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.48	6.23	0.38	2.13e-9	Lung cancer;
SARC	cis	rs2070488	1.000	rs17733640	chr3:38446742	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	14.45	0.69	3.18e-34	Electrocardiographic conduction measures;
SARC	cis	rs17376456	0.597	rs7733142	chr5:93322795	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.48	-5.33	-0.33	2.33e-7	Diabetic retinopathy;
SARC	cis	rs12142240	0.698	rs10158130	chr1:46822600	T/C	cg14993813	chr1:46806288	NSUN4	-0.51	-5.34	-0.33	2.19e-7	Menopause (age at onset);
SARC	cis	rs7566780	0.594	rs1346749	chr2:16635775	A/G	cg09580478	chr2:16689509	NA	-0.44	-5.84	-0.36	1.78e-8	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs854765	0.583	rs28428991	chr17:17827649	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	9.75	0.54	4.62e-19	Total body bone mineral density;
SARC	cis	rs7726839	0.540	rs74553517	chr5:665671	C/T	cg09021430	chr5:549028	NA	-0.4	-4.95	-0.31	1.41e-6	Obesity-related traits;
SARC	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg10150615	chr22:24372951	LOC391322	-0.42	-4.97	-0.31	1.31e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	trans	rs1814175	0.653	rs10839480	chr11:50034556	C/T	cg03929089	chr4:120376271	NA	-0.89	-14.57	-0.69	1.31e-34	Height;
SARC	cis	rs9309473	0.950	rs6546858	chr2:73838613	G/A	cg07208825	chr2:73871855	ALMS1P	0.35	5.16	0.32	5.28e-7	Metabolite levels;
SARC	cis	rs796364	0.806	rs11688194	chr2:200916239	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.67	-5.68	-0.35	4.06e-8	Schizophrenia;
SARC	cis	rs6540556	0.723	rs9430012	chr1:209900615	G/C	cg05527609	chr1:210001259	C1orf107	-0.62	-5.76	-0.35	2.65e-8	Red blood cell count;
SARC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg03647317	chr4:187891568	NA	-0.34	-4.81	-0.3	2.76e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs854765	0.583	rs8065970	chr17:17858771	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	9.85	0.54	2.34e-19	Total body bone mineral density;
SARC	cis	rs10089	1.000	rs72794392	chr5:127490061	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	9.19	0.52	2.21e-17	Ileal carcinoids;
SARC	cis	rs6598955	0.543	rs12122527	chr1:26549748	C/T	cg04990556	chr1:26633338	UBXN11	0.73	7.55	0.44	1e-12	Obesity-related traits;
SARC	cis	rs72781680	0.846	rs72780108	chr2:23986780	G/A	cg06627628	chr2:24431161	ITSN2	-0.67	-6.35	-0.38	1.14e-9	Lymphocyte counts;
SARC	trans	rs11039798	0.557	rs683180	chr11:48463949	A/G	cg15704280	chr7:45808275	SEPT13	-0.64	-6.78	-0.41	9.68e-11	Axial length;
SARC	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg11987759	chr7:65425863	GUSB	-0.6	-7.96	-0.46	7.64e-14	Aortic root size;
SARC	cis	rs4619890	0.528	rs28437157	chr4:7874435	C/A	cg18538662	chr4:7941764	AFAP1	-0.38	-4.9	-0.31	1.82e-6	Glaucoma (primary open-angle);
SARC	cis	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg08975724	chr8:8085496	FLJ10661	0.45	5.53	0.34	8.71e-8	Mood instability;
SARC	cis	rs2153535	0.580	rs6597335	chr6:8527714	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	6.53	0.39	4.11e-10	Motion sickness;
SARC	cis	rs2295359	0.892	rs72676058	chr1:67627681	C/A	cg11235152	chr1:67600687	NA	0.51	7.0	0.42	2.75e-11	Psoriasis;
SARC	cis	rs2204008	0.777	rs11179774	chr12:38219559	A/C	cg13010199	chr12:38710504	ALG10B	0.77	10.51	0.57	2.11e-21	Bladder cancer;
SARC	cis	rs372883	0.648	rs1003772	chr21:30736145	A/T	cg08807101	chr21:30365312	RNF160	0.6	7.54	0.44	1.05e-12	Pancreatic cancer;
SARC	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg09323728	chr8:95962352	TP53INP1	-0.3	-5.09	-0.32	7.46e-7	Type 2 diabetes;
SARC	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg18252515	chr7:66147081	NA	-1.34	-11.85	-0.61	1.13e-25	Diabetic kidney disease;
SARC	cis	rs16976116	0.619	rs4774750	chr15:55466155	G/A	cg11288833	chr15:55489084	RSL24D1	-0.62	-5.28	-0.33	3.02e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs12142240	0.698	rs17357676	chr1:46812444	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-5.48	-0.34	1.12e-7	Menopause (age at onset);
SARC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg11905131	chr22:24372483	LOC391322	0.53	6.26	0.38	1.79e-9	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6456156	0.565	rs6456153	chr6:167472167	T/C	cg07741184	chr6:167504864	NA	0.36	7.09	0.42	1.62e-11	Primary biliary cholangitis;
SARC	cis	rs7582180	0.564	rs2309795	chr2:100954290	G/A	cg14675211	chr2:100938903	LONRF2	0.48	7.13	0.42	1.25e-11	Intelligence (multi-trait analysis);
SARC	trans	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg00938859	chr5:1591904	SDHAP3	0.69	6.36	0.38	1.03e-9	Breast cancer;
SARC	cis	rs1707322	0.717	rs2991989	chr1:46082965	C/T	cg03146154	chr1:46216737	IPP	-0.52	-6.21	-0.38	2.48e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs957448	1.000	rs957447	chr8:95541223	C/A	cg26464482	chr8:95565502	KIAA1429	0.43	4.83	0.3	2.45e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs28374715	0.617	rs28626792	chr15:41562218	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.7	-9.53	-0.53	2.19e-18	Ulcerative colitis;
SARC	cis	rs751728	0.689	rs3763257	chr6:33773696	T/A	cg25922239	chr6:33757077	LEMD2	0.64	7.5	0.44	1.3e-12	Crohn's disease;
SARC	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg13206674	chr6:150067644	NUP43	0.45	5.79	0.35	2.22e-8	Lung cancer;
SARC	cis	rs35995292	0.500	rs1019065	chr7:38939775	C/T	cg19327137	chr7:38886074	VPS41	0.52	7.69	0.45	4.22e-13	Subjective well-being (multi-trait analysis);
SARC	cis	rs9467773	1.000	rs6456734	chr6:26566965	G/T	cg12292205	chr6:26970375	C6orf41	0.45	5.42	0.33	1.46e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7681440	0.606	rs2583970	chr4:90746610	G/A	cg06632027	chr4:90757378	SNCA	-0.44	-5.43	-0.34	1.39e-7	Dementia with Lewy bodies;
SARC	cis	rs6964587	0.967	rs6974827	chr7:91772945	C/T	cg17063962	chr7:91808500	NA	0.98	17.35	0.75	7.27e-44	Breast cancer;
SARC	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg24060327	chr5:131705240	SLC22A5	-0.5	-6.11	-0.37	4.13e-9	Blood metabolite levels;
SARC	cis	rs9902453	0.726	rs3110494	chr17:27976597	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	6.96	0.41	3.44e-11	Coffee consumption (cups per day);
SARC	trans	rs1994135	0.647	rs1351681	chr12:33698724	G/A	cg13010199	chr12:38710504	ALG10B	0.74	8.79	0.5	3.32e-16	Resting heart rate;
SARC	cis	rs7662987	0.517	rs2851260	chr4:100033574	C/T	cg13256891	chr4:100009986	ADH5	0.68	8.58	0.49	1.31e-15	Smoking initiation;
SARC	cis	rs7937682	0.921	rs688354	chr11:111438762	A/G	cg22437258	chr11:111473054	SIK2	0.68	8.95	0.51	1.15e-16	Primary sclerosing cholangitis;
SARC	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg05368731	chr17:41323189	NBR1	0.8	9.65	0.53	9.38e-19	Menopause (age at onset);
SARC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg22903471	chr2:27725779	GCKR	-0.52	-8.13	-0.47	2.53e-14	Total body bone mineral density;
SARC	cis	rs7264396	0.635	rs6058351	chr20:34486093	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-7.52	-0.44	1.15e-12	Total cholesterol levels;
SARC	cis	rs1048238	0.818	rs945421	chr1:16345393	T/C	cg21385522	chr1:16154831	NA	0.5	6.0	0.37	7.66e-9	Systolic blood pressure;
SARC	cis	rs9843304	0.568	rs13062027	chr3:149212679	G/C	cg08667024	chr3:149219783	TM4SF4	-0.35	-5.03	-0.31	9.86e-7	Gallstone disease;
SARC	trans	rs61931739	0.500	rs11053189	chr12:34433455	G/A	cg13010199	chr12:38710504	ALG10B	0.81	11.39	0.6	3.58e-24	Morning vs. evening chronotype;
SARC	cis	rs8060686	0.545	rs75229939	chr16:68164949	G/A	cg27539214	chr16:67997921	SLC12A4	-0.54	-5.03	-0.31	9.6e-7	HDL cholesterol;Metabolic syndrome;
SARC	trans	rs1973993	0.717	rs55650017	chr1:96952142	G/A	cg10631902	chr5:14652156	NA	-0.43	-7.01	-0.42	2.57e-11	Weight;
SARC	cis	rs826838	0.967	rs11169142	chr12:39085773	A/T	cg13010199	chr12:38710504	ALG10B	-0.67	-9.68	-0.54	7.59e-19	Heart rate;
SARC	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2120243	0.539	rs12629552	chr3:157086630	T/A	cg01018701	chr3:157155998	VEPH1;PTX3	0.4	4.94	0.31	1.48e-6	Hepatocellular carcinoma in hepatitis B infection;
SARC	trans	rs1814175	0.817	rs7950856	chr11:49976394	C/T	cg03929089	chr4:120376271	NA	-0.88	-14.05	-0.68	6.62e-33	Height;
SARC	cis	rs9790314	1.000	rs9846756	chr3:160983809	A/C	cg03342759	chr3:160939853	NMD3	-0.6	-7.58	-0.44	8.23e-13	Morning vs. evening chronotype;
SARC	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.1	23.97	0.84	8.05e-65	Chronic sinus infection;
SARC	cis	rs7762018	0.607	rs6907814	chr6:170058206	G/A	cg14662283	chr6:170068385	WDR27	-0.64	-4.74	-0.3	3.71e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs4276643	0.805	rs2685413	chr8:27810577	T/G	cg26001764	chr8:28560637	EXTL3	0.3	4.78	0.3	3.11e-6	Low vWF levels;
SARC	cis	rs992157	0.560	rs10932763	chr2:219085863	G/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.59	-7.9	-0.46	1.12e-13	Colorectal cancer;
SARC	cis	rs644799	0.511	rs12791736	chr11:95475399	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.75	9.96	0.55	1.08e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs6964587	0.655	rs6965864	chr7:91595596	A/G	cg17063962	chr7:91808500	NA	0.83	12.53	0.63	7.25e-28	Breast cancer;
SARC	cis	rs9303280	0.806	rs11870965	chr17:38030205	T/A	cg20243544	chr17:37824526	PNMT	0.43	5.65	0.35	4.74e-8	Self-reported allergy;
SARC	cis	rs8180040	0.739	rs12488225	chr3:47235107	G/A	cg02527881	chr3:46936655	PTH1R	-0.31	-4.79	-0.3	3.01e-6	Colorectal cancer;
SARC	cis	rs10416265	0.527	rs11084699	chr19:33538393	A/T	cg17764715	chr19:33622953	WDR88	0.58	7.88	0.46	1.28e-13	Bone properties (heel);
SARC	cis	rs2197308	0.606	rs12314897	chr12:38392293	C/T	cg26384229	chr12:38710491	ALG10B	-0.57	-7.06	-0.42	1.93e-11	Morning vs. evening chronotype;
SARC	cis	rs2180341	1.000	rs6569486	chr6:127708424	A/C	cg24812749	chr6:127587940	RNF146	1.03	13.28	0.66	2.34e-30	Breast cancer;
SARC	cis	rs6815814	0.851	rs10023850	chr4:38763693	G/A	cg06935464	chr4:38784597	TLR10	0.54	4.85	0.3	2.29e-6	Breast cancer;
SARC	cis	rs6570726	0.791	rs952406	chr6:145925616	C/A	cg05347473	chr6:146136440	FBXO30	0.48	6.6	0.4	2.76e-10	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs629535	0.767	rs72654073	chr8:70081231	G/A	cg21567404	chr3:27674614	NA	-1.05	-13.65	-0.67	1.47e-31	Dupuytren's disease;
SARC	cis	rs2075671	0.903	rs62483570	chr7:100300649	C/T	cg03098644	chr7:100410630	EPHB4	0.46	5.06	0.31	8.43e-7	Other erythrocyte phenotypes;
SARC	cis	rs55823223	0.564	rs58363746	chr17:73850819	C/T	cg23806715	chr17:73775811	H3F3B	0.46	4.9	0.31	1.77e-6	Psoriasis;
SARC	cis	rs10227331	0.846	rs12673606	chr7:157297518	C/G	cg04156418	chr7:157293606	NA	0.44	7.2	0.43	8.21e-12	Inattentive symptoms;
SARC	cis	rs67460515	0.563	rs13085336	chr3:160880599	G/A	cg03342759	chr3:160939853	NMD3	-0.64	-7.87	-0.46	1.32e-13	Parkinson's disease;
SARC	cis	rs16866061	1.000	rs72974219	chr2:225423784	G/C	cg12698349	chr2:225449008	CUL3	0.72	10.55	0.57	1.6e-21	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	cis	rs3762637	0.941	rs28679619	chr3:122100349	C/A	cg24169773	chr3:122142474	KPNA1	-0.56	-5.52	-0.34	9.04e-8	LDL cholesterol levels;
SARC	cis	rs12188164	0.965	rs11739543	chr5:443676	G/A	cg21144161	chr5:423903	AHRR	0.31	4.84	0.3	2.39e-6	Cystic fibrosis severity;
SARC	cis	rs793571	0.614	rs347117	chr15:59000957	C/T	cg05156742	chr15:59063176	FAM63B	0.69	9.37	0.52	6.52e-18	Schizophrenia;
SARC	cis	rs2011503	0.891	rs2965190	chr19:19451591	A/G	cg03709012	chr19:19516395	GATAD2A	-0.64	-5.78	-0.35	2.38e-8	Bipolar disorder;
SARC	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg06558623	chr16:89946397	TCF25	0.91	6.17	0.37	3.02e-9	Skin colour saturation;
SARC	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg21724239	chr8:58056113	NA	0.69	6.35	0.38	1.11e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs765787	0.530	rs4444275	chr15:45535347	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.67e-7	Uric acid levels;
SARC	cis	rs2645694	0.532	rs2645706	chr4:77829606	A/C	cg06046430	chr4:77819534	ANKRD56	0.52	7.38	0.44	2.8e-12	Emphysema distribution in smoking;
SARC	trans	rs9329221	0.537	rs6983332	chr8:9977918	A/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.95	-0.46	8.16e-14	Neuroticism;
SARC	cis	rs710216	0.917	rs710223	chr1:43411038	C/G	cg22176566	chr1:43424700	SLC2A1	0.55	5.38	0.33	1.79e-7	Red cell distribution width;
SARC	cis	rs2933343	0.621	rs789242	chr3:128585707	T/C	cg24203234	chr3:128598194	ACAD9	0.64	8.08	0.47	3.42e-14	IgG glycosylation;
SARC	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg04277193	chr17:41438351	NA	0.44	4.73	0.3	3.83e-6	Menopause (age at onset);
SARC	trans	rs17221829	0.733	rs11018668	chr11:89356178	C/T	cg07020846	chr15:70390363	TLE3	0.48	6.58	0.4	3.05e-10	Anxiety in major depressive disorder;
SARC	cis	rs7927592	0.956	rs10896334	chr11:68281494	C/T	cg01657329	chr11:68192670	LRP5	-0.39	-4.91	-0.31	1.69e-6	Total body bone mineral density;
SARC	cis	rs10870270	0.956	rs11146325	chr10:133767529	A/G	cg26149184	chr10:133730230	NA	0.46	5.03	0.31	9.68e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg18876405	chr7:65276391	NA	0.69	9.06	0.51	5.62e-17	Aortic root size;
SARC	cis	rs6570726	0.791	rs12208812	chr6:145900924	T/G	cg23711669	chr6:146136114	FBXO30	0.89	14.72	0.69	3.93e-35	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10911232	0.524	rs10911229	chr1:183050368	C/G	cg13390022	chr1:182993471	LAMC1	0.33	5.06	0.31	8.41e-7	Hypertriglyceridemia;
SARC	cis	rs950169	0.800	rs34302901	chr15:85110943	C/G	cg24253500	chr15:84953950	NA	0.37	5.26	0.33	3.21e-7	Schizophrenia;
SARC	cis	rs2380220	1.000	rs2380222	chr6:95975395	C/T	cg07718321	chr6:96025334	MANEA	0.5	5.14	0.32	5.74e-7	Behavioural disinhibition (generation interaction);
SARC	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg21724239	chr8:58056113	NA	0.6	6.31	0.38	1.43e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs826838	1.000	rs11168367	chr12:38913397	T/G	cg13010199	chr12:38710504	ALG10B	0.77	10.73	0.58	4.26e-22	Heart rate;
SARC	cis	rs10791097	0.694	rs7125622	chr11:130743388	T/C	cg09137382	chr11:130731461	NA	0.31	4.79	0.3	3.01e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs981844	0.712	rs4616729	chr4:154746900	T/G	cg14289246	chr4:154710475	SFRP2	-0.45	-5.36	-0.33	1.96e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs910187	0.605	rs6122559	chr20:45810617	T/G	cg27589058	chr20:45804311	EYA2	-0.32	-5.03	-0.31	9.95e-7	Migraine;
SARC	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg25894440	chr7:65020034	NA	-0.75	-5.67	-0.35	4.13e-8	Diabetic kidney disease;
SARC	cis	rs6993270	0.779	rs111486708	chr8:120929694	G/C	cg21659575	chr8:120844832	TAF2	0.51	4.9	0.31	1.83e-6	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs2055729	0.591	rs17150950	chr8:9881009	T/C	cg21625330	chr8:9911636	MSRA	-0.45	-5.1	-0.32	6.98e-7	Multiple myeloma (hyperdiploidy);
SARC	cis	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg00745463	chr17:30367425	LRRC37B	-0.63	-5.02	-0.31	1.05e-6	Hip circumference adjusted for BMI;
SARC	cis	rs6570726	1.000	rs373778	chr6:145873252	C/T	cg23711669	chr6:146136114	FBXO30	0.74	11.05	0.59	4.11e-23	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg00938859	chr5:1591904	SDHAP3	0.76	7.1	0.42	1.53e-11	Breast cancer;
SARC	trans	rs1853207	1.000	rs74996264	chr10:96713995	A/G	cg02737782	chr1:8014393	NA	-0.89	-6.4	-0.39	8.69e-10	Blood metabolite levels;
SARC	cis	rs7312933	0.558	rs11181483	chr12:42798384	G/C	cg19980929	chr12:42632907	YAF2	0.5	7.17	0.42	1.02e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.5	-0.44	1.34e-12	Gut microbiome composition (summer);
SARC	cis	rs3018712	0.532	rs2510399	chr11:68421458	A/G	cg01657329	chr11:68192670	LRP5	0.56	5.13	0.32	6.2e-7	Total body bone mineral density;
SARC	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	10.38	0.56	5.26e-21	Alzheimer's disease;
SARC	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg00933542	chr6:150070202	PCMT1	0.31	5.37	0.33	1.9e-7	Lung cancer;
SARC	cis	rs9611519	1.000	rs5758267	chr22:41619350	A/T	cg03806693	chr22:41940476	POLR3H	0.49	5.82	0.36	1.91e-8	Neuroticism;
SARC	cis	rs2549003	1.000	rs2549009	chr5:131826765	T/C	cg21138405	chr5:131827807	IRF1	-0.27	-5.21	-0.32	4.22e-7	Asthma (sex interaction);
SARC	cis	rs10411936	0.608	rs7259642	chr19:16601926	C/A	cg10248733	chr19:16607483	C19orf44;CALR3	0.58	6.98	0.42	3.1e-11	White blood cell count;Multiple sclerosis;
SARC	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg21442419	chr1:2182373	SKI	0.42	5.28	0.33	2.98e-7	Height;
SARC	cis	rs9987353	0.544	rs2929469	chr8:9062656	T/G	cg08975724	chr8:8085496	FLJ10661	0.4	4.82	0.3	2.63e-6	Recombination measurement;
SARC	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg22857025	chr5:266934	NA	-1.06	-11.8	-0.61	1.74e-25	Breast cancer;
SARC	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg05368731	chr17:41323189	NBR1	0.8	9.52	0.53	2.4e-18	Menopause (age at onset);
SARC	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg07701084	chr6:150067640	NUP43	0.41	5.26	0.33	3.28e-7	Lung cancer;
SARC	cis	rs67460515	1.000	rs67460515	chr3:161068566	T/C	cg04691961	chr3:161091175	C3orf57	-0.51	-6.39	-0.39	8.82e-10	Parkinson's disease;
SARC	cis	rs79349575	0.783	rs4793998	chr17:47019899	C/T	cg16584676	chr17:46985605	UBE2Z	0.55	6.66	0.4	1.91e-10	Type 2 diabetes;
SARC	cis	rs2836974	0.545	rs3167757	chr21:40714478	C/T	cg17971929	chr21:40555470	PSMG1	0.63	8.14	0.47	2.44e-14	Cognitive function;
SARC	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg21747090	chr2:27597821	SNX17	-0.55	-7.62	-0.45	6.44e-13	Total body bone mineral density;
SARC	cis	rs7246657	0.943	rs28402338	chr19:37833923	G/A	cg23950597	chr19:37808831	NA	-0.6	-5.85	-0.36	1.67e-8	Coronary artery calcification;
SARC	cis	rs7474896	0.583	rs1735621	chr10:38167723	G/T	cg00409905	chr10:38381863	ZNF37A	0.46	5.03	0.31	9.79e-7	Obesity (extreme);
SARC	cis	rs7000551	0.659	rs2280521	chr8:22271995	G/T	cg12081754	chr8:22256438	SLC39A14	-0.41	-5.0	-0.31	1.12e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg24829409	chr8:58192753	C8orf71	-0.64	-6.18	-0.38	2.77e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs710216	0.623	rs841858	chr1:43399167	G/T	cg07803811	chr1:43423981	SLC2A1	0.52	4.86	0.3	2.12e-6	Red cell distribution width;
SARC	cis	rs76419734	1.000	rs72673823	chr4:106719973	G/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.75	4.95	0.31	1.43e-6	Post bronchodilator FEV1;
SARC	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	12.62	0.64	3.53e-28	Chronic sinus infection;
SARC	cis	rs72634258	0.503	rs697675	chr1:7838113	A/C	cg05338066	chr1:7812865	CAMTA1	0.67	5.74	0.35	2.86e-8	Inflammatory bowel disease;
SARC	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg08859206	chr1:53392774	SCP2	0.42	6.05	0.37	5.78e-9	Monocyte count;
SARC	cis	rs765787	0.530	rs1648286	chr15:45517386	G/C	cg21132104	chr15:45694354	SPATA5L1	-0.4	-4.86	-0.3	2.19e-6	Uric acid levels;
SARC	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.97	-15.77	-0.72	1.3e-38	Chronic sinus infection;
SARC	cis	rs7551222	0.752	rs12130686	chr1:204554057	G/C	cg20240347	chr1:204465584	NA	-0.28	-4.99	-0.31	1.2e-6	Schizophrenia;
SARC	cis	rs2153535	0.504	rs9405393	chr6:8467432	G/T	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	cis	rs11098499	0.866	rs12513310	chr4:120288039	T/A	cg09307838	chr4:120376055	NA	0.83	11.82	0.61	1.46e-25	Corneal astigmatism;
SARC	cis	rs9393692	0.557	rs62394764	chr6:26305503	T/C	cg13736514	chr6:26305472	NA	-0.4	-4.96	-0.31	1.35e-6	Educational attainment;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg12344600	chr6:89769123	NA	-0.78	-6.4	-0.39	8.28e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7223966	0.921	rs2006123	chr17:61958669	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.45	-4.74	-0.3	3.69e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg24060327	chr5:131705240	SLC22A5	-0.5	-5.98	-0.36	8.28e-9	Acylcarnitine levels;
SARC	cis	rs4792901	0.759	rs3179927	chr17:41601911	A/G	cg22562494	chr17:41607896	ETV4	-0.3	-4.8	-0.3	2.85e-6	Dupuytren's disease;
SARC	cis	rs3857536	0.817	rs35371029	chr6:66900350	T/C	cg07460842	chr6:66804631	NA	-0.44	-5.26	-0.33	3.22e-7	Blood trace element (Cu levels);
SARC	cis	rs6088590	1.000	rs6088590	chr20:33313566	T/C	cg06115741	chr20:33292138	TP53INP2	0.56	6.81	0.41	8.18e-11	Coronary artery disease;
SARC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg24101359	chr6:42928495	GNMT	0.47	6.27	0.38	1.75e-9	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs10931896	0.531	rs295118	chr2:201144004	C/T	cg17644776	chr2:200775616	C2orf69	0.44	5.95	0.36	9.87e-9	Systolic blood pressure;
SARC	cis	rs36051895	0.659	rs10974935	chr9:5050307	C/T	cg02405213	chr9:5042618	JAK2	-0.48	-5.53	-0.34	8.36e-8	Pediatric autoimmune diseases;
SARC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg09373136	chr17:61933544	TCAM1	-0.45	-6.11	-0.37	4.26e-9	Prudent dietary pattern;
SARC	cis	rs11122272	0.735	rs11122280	chr1:231519816	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-9.53	-0.53	2.22e-18	Hemoglobin concentration;
SARC	cis	rs7296418	0.630	rs28419092	chr12:123812629	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-5.03	-0.31	9.74e-7	Platelet count;
SARC	cis	rs362272	0.524	rs2857982	chr4:3358665	G/A	cg08741688	chr4:3415352	RGS12	-0.51	-6.35	-0.38	1.09e-9	Serum sulfate level;
SARC	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg11987759	chr7:65425863	GUSB	0.45	5.98	0.36	8.46e-9	Aortic root size;
SARC	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.72	7.46	0.44	1.67e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs986417	0.748	rs12436632	chr14:61034416	T/C	cg27398547	chr14:60952738	C14orf39	0.76	7.76	0.45	2.57e-13	Gut microbiota (bacterial taxa);
SARC	cis	rs1983170	0.736	rs12127718	chr1:91997490	A/T	cg25838465	chr1:92012736	NA	0.53	5.46	0.34	1.22e-7	Eosinophil percentage of white cells;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19383656	chr1:114355263	RSBN1	-0.52	-6.84	-0.41	7.06e-11	Smoking initiation;
SARC	cis	rs644799	1.000	rs509720	chr11:95562771	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.9	14.03	0.68	7.82e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg17971929	chr21:40555470	PSMG1	0.99	14.22	0.68	1.86e-33	Cognitive function;
SARC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg23034840	chr1:205782522	SLC41A1	0.61	7.54	0.44	1.03e-12	Menarche (age at onset);
SARC	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg18252515	chr7:66147081	NA	0.42	4.76	0.3	3.45e-6	Aortic root size;
SARC	cis	rs6831352	0.918	rs4699713	chr4:100060513	C/T	cg13256891	chr4:100009986	ADH5	-0.65	-8.0	-0.46	5.94e-14	Alcohol dependence;
SARC	trans	rs9650657	0.836	rs1073913	chr8:10611708	A/C	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.86	-0.41	6.13e-11	Neuroticism;
SARC	cis	rs2204008	0.837	rs11181857	chr12:38413255	C/G	cg13010199	chr12:38710504	ALG10B	0.74	9.99	0.55	8.42e-20	Bladder cancer;
SARC	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg13206674	chr6:150067644	NUP43	0.41	5.37	0.33	1.95e-7	Lung cancer;
SARC	cis	rs76419734	1.000	rs17036120	chr4:106621508	G/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.82	5.06	0.31	8.65e-7	Post bronchodilator FEV1;
SARC	cis	rs9875589	0.915	rs13097822	chr3:13969396	T/A	cg19554555	chr3:13937349	NA	0.54	6.81	0.41	8.28e-11	Ovarian reserve;
SARC	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg20607798	chr8:58055168	NA	0.53	5.01	0.31	1.09e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg25833597	chr17:30823145	MYO1D	-0.51	-5.06	-0.31	8.64e-7	Hip circumference adjusted for BMI;
SARC	cis	rs12579753	0.879	rs1986537	chr12:82156475	G/C	cg07988820	chr12:82153109	PPFIA2	-0.59	-7.09	-0.42	1.6e-11	Resting heart rate;
SARC	cis	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg00071950	chr4:10020882	SLC2A9	0.39	6.35	0.38	1.14e-9	Bone mineral density;
SARC	cis	rs9290065	0.519	rs6763532	chr3:160701816	G/A	cg17135325	chr3:160939158	NMD3	0.4	4.73	0.3	3.91e-6	Kawasaki disease;
SARC	cis	rs7914558	1.000	rs943038	chr10:104826261	T/C	cg04362960	chr10:104952993	NT5C2	0.42	5.12	0.32	6.3e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.41	0.44	2.36e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg11644478	chr21:40555479	PSMG1	-0.87	-11.34	-0.6	4.98e-24	Cognitive function;
SARC	cis	rs240764	0.567	rs12528607	chr6:101260131	A/G	cg09795085	chr6:101329169	ASCC3	0.44	5.5	0.34	1.02e-7	Neuroticism;
SARC	cis	rs2066819	1.000	rs1274493	chr12:56682371	C/T	cg26734620	chr12:56694298	CS	-0.86	-6.37	-0.39	1.01e-9	Psoriasis vulgaris;
SARC	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.4	-5.0	-0.31	1.14e-6	Menarche (age at onset);
SARC	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg15049968	chr18:44337910	ST8SIA5	-0.33	-5.3	-0.33	2.65e-7	Personality dimensions;
SARC	trans	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg13542817	chr10:104154499	NFKB2	-0.7	-6.56	-0.39	3.39e-10	Cutaneous psoriasis;
SARC	cis	rs908922	0.676	rs477621	chr1:152486252	T/C	cg09873164	chr1:152488093	CRCT1	0.63	8.3	0.48	8.3e-15	Hair morphology;
SARC	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg22920501	chr2:26401640	FAM59B	0.56	7.63	0.45	6e-13	Gut microbiome composition (summer);
SARC	cis	rs7772486	0.790	rs2254257	chr6:146203724	C/T	cg23711669	chr6:146136114	FBXO30	0.81	13.09	0.65	1.04e-29	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs12270115	0.611	rs10160626	chr11:79499407	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.66	-6.32	-0.38	1.3e-9	Preschool internalizing problems;
SARC	cis	rs3008870	0.727	rs2755270	chr1:67474503	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.59	7.6	0.45	7e-13	Lymphocyte percentage of white cells;
SARC	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg24209194	chr3:40518798	ZNF619	-0.65	-8.08	-0.47	3.47e-14	Renal cell carcinoma;
SARC	cis	rs35110281	0.626	rs162367	chr21:44934857	A/G	cg21573476	chr21:45109991	RRP1B	-0.43	-6.15	-0.37	3.26e-9	Mean corpuscular volume;
SARC	trans	rs629535	0.590	rs62513427	chr8:70138891	A/T	cg21567404	chr3:27674614	NA	-0.94	-10.24	-0.56	1.44e-20	Dupuytren's disease;
SARC	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg00149659	chr3:10157352	C3orf10	0.69	6.44	0.39	6.6e-10	Alzheimer's disease;
SARC	cis	rs3796352	1.000	rs35849389	chr3:53005235	A/G	cg12962167	chr3:53033115	SFMBT1	0.73	4.8	0.3	2.82e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs8014204	0.762	rs8016389	chr14:75287554	T/C	cg06637938	chr14:75390232	RPS6KL1	0.54	7.55	0.44	9.56e-13	Caffeine consumption;
SARC	cis	rs12142240	0.698	rs68112720	chr1:46813888	T/C	cg10495392	chr1:46806563	NSUN4	0.65	6.83	0.41	7.25e-11	Menopause (age at onset);
SARC	cis	rs17376456	0.877	rs10050465	chr5:93349963	C/A	cg21475434	chr5:93447410	FAM172A	0.85	7.56	0.44	9.43e-13	Diabetic retinopathy;
SARC	cis	rs6582630	0.555	rs1969362	chr12:38514843	C/T	cg26384229	chr12:38710491	ALG10B	0.87	12.74	0.64	1.46e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1318878	0.565	rs11056440	chr12:15501355	C/A	cg08258403	chr12:15378311	NA	0.51	7.08	0.42	1.68e-11	Intelligence (multi-trait analysis);
SARC	cis	rs1003719	0.715	rs9974494	chr21:38566566	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.3	-0.52	1.05e-17	Eye color traits;
SARC	cis	rs734999	0.545	rs10910111	chr1:2542653	A/G	cg20673091	chr1:2541236	MMEL1	0.33	4.94	0.31	1.48e-6	Ulcerative colitis;
SARC	cis	rs11249608	0.789	rs1969025	chr5:178425192	A/G	cg21905437	chr5:178450457	ZNF879	0.47	6.37	0.38	1.02e-9	Pubertal anthropometrics;
SARC	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg24250549	chr1:154909240	PMVK	0.82	11.88	0.61	9.15e-26	Prostate cancer;
SARC	cis	rs981844	1.000	rs2606332	chr4:154655372	G/A	cg14289246	chr4:154710475	SFRP2	0.59	6.72	0.4	1.37e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs950776	0.518	rs12906846	chr15:78825295	G/A	cg17108064	chr15:78857060	CHRNA5	0.29	4.93	0.31	1.56e-6	Sudden cardiac arrest;
SARC	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg05368731	chr17:41323189	NBR1	0.79	9.57	0.53	1.62e-18	Menopause (age at onset);
SARC	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1707322	0.752	rs8179402	chr1:46142466	C/A	cg03146154	chr1:46216737	IPP	0.52	6.32	0.38	1.33e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg18876405	chr7:65276391	NA	0.7	8.7	0.5	6.12e-16	Aortic root size;
SARC	cis	rs6807306	1.000	rs6807030	chr3:167349530	C/T	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.53	5.36	0.33	2e-7	Mean platelet volume;
SARC	cis	rs9309473	1.000	rs10193972	chr2:73717656	A/G	cg07208825	chr2:73871855	ALMS1P	0.33	4.77	0.3	3.27e-6	Metabolite levels;
SARC	cis	rs7914558	0.966	rs7908280	chr10:104816947	C/G	cg04362960	chr10:104952993	NT5C2	0.42	5.11	0.32	6.59e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs9527	0.590	rs11191572	chr10:104893137	A/G	cg04362960	chr10:104952993	NT5C2	0.44	5.15	0.32	5.58e-7	Arsenic metabolism;
SARC	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg06618935	chr21:46677482	NA	-0.42	-5.63	-0.35	5.12e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg25894440	chr7:65020034	NA	0.79	5.96	0.36	9.49e-9	Diabetic kidney disease;
SARC	cis	rs7914558	0.966	rs7085598	chr10:104650128	T/C	cg04362960	chr10:104952993	NT5C2	0.41	4.95	0.31	1.42e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg20085812	chr3:39149038	GORASP1;TTC21A	0.48	6.25	0.38	1.91e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1467026	0.563	rs58674721	chr3:12811233	G/A	cg05775895	chr3:12838266	CAND2	0.61	8.96	0.51	1.05e-16	P wave duration;
SARC	cis	rs7914558	1.000	rs10786733	chr10:104794947	G/A	cg04362960	chr10:104952993	NT5C2	0.42	5.14	0.32	5.7e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg08355456	chr11:67383691	NA	0.45	6.08	0.37	4.92e-9	Mean corpuscular volume;
SARC	cis	rs710216	0.957	rs2886876	chr1:43432741	A/G	cg07803811	chr1:43423981	SLC2A1	-0.51	-5.15	-0.32	5.54e-7	Red cell distribution width;
SARC	cis	rs16854884	0.657	rs6783089	chr3:143738034	T/C	cg06585982	chr3:143692056	C3orf58	0.67	9.14	0.51	3.13e-17	Economic and political preferences (feminism/equality);
SARC	cis	rs9790314	0.747	rs4616689	chr3:160856269	A/G	cg04691961	chr3:161091175	C3orf57	-0.69	-9.6	-0.53	1.33e-18	Morning vs. evening chronotype;
SARC	cis	rs9911578	1.000	rs1057068	chr17:56598439	T/C	cg12560992	chr17:57184187	TRIM37	-0.79	-10.44	-0.56	3.45e-21	Intelligence (multi-trait analysis);
SARC	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg01316550	chr5:56110833	MAP3K1	0.52	4.82	0.3	2.54e-6	Initial pursuit acceleration;
SARC	cis	rs13166103	0.657	rs719427	chr5:57711041	A/G	cg10487770	chr5:57879443	RAB3C	-0.54	-5.57	-0.34	6.95e-8	Type 2 diabetes (age of onset);
SARC	cis	rs6121246	0.909	rs6060679	chr20:30270772	C/G	cg13852791	chr20:30311386	BCL2L1	-0.85	-9.18	-0.52	2.48e-17	Mean corpuscular hemoglobin;
SARC	cis	rs1881797	1.000	rs68059491	chr1:247683070	C/T	cg18198730	chr1:247681584	NA	0.51	5.41	0.33	1.57e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs6582630	0.519	rs11514056	chr12:38284001	G/T	cg26384229	chr12:38710491	ALG10B	0.89	13.06	0.65	1.31e-29	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs61931739	0.534	rs10506120	chr12:34235603	G/A	cg26384229	chr12:38710491	ALG10B	0.84	12.06	0.62	2.41e-26	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.593	rs7000752	chr8:58026980	C/G	cg11062466	chr8:58055876	NA	0.55	5.45	0.34	1.27e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs920590	0.796	rs11778257	chr8:19634598	A/T	cg03894339	chr8:19674705	INTS10	0.57	6.94	0.41	3.82e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs73206853	0.841	rs4131852	chr12:110812657	C/G	cg10860002	chr12:110842031	ANAPC7	0.63	5.03	0.31	9.95e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg23034840	chr1:205782522	SLC41A1	0.62	7.95	0.46	8.08e-14	Menarche (age at onset);
SARC	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg05368731	chr17:41323189	NBR1	0.8	9.59	0.53	1.43e-18	Menopause (age at onset);
SARC	cis	rs6088813	0.885	rs224331	chr20:34022387	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.47	5.53	0.34	8.77e-8	Height;
SARC	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg22903657	chr4:1355424	KIAA1530	-0.41	-5.64	-0.35	4.99e-8	Obesity-related traits;
SARC	cis	rs921968	0.541	rs6720403	chr2:219294258	A/C	cg02176678	chr2:219576539	TTLL4	-0.4	-5.97	-0.36	8.72e-9	Mean corpuscular hemoglobin concentration;
SARC	cis	rs6704644	0.651	rs11694406	chr2:234331810	G/A	cg27060346	chr2:234359958	DGKD	-0.67	-5.01	-0.31	1.08e-6	Bilirubin levels;
SARC	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg09455208	chr3:40491958	NA	0.38	5.51	0.34	9.28e-8	Renal cell carcinoma;
SARC	cis	rs2235642	0.717	rs9937922	chr16:1658154	C/G	cg03715980	chr16:1756201	MAPK8IP3	0.41	5.04	0.31	9.43e-7	Coronary artery disease;
SARC	cis	rs6665290	0.836	rs12593	chr1:227172290	A/G	cg14016676	chr1:227182615	CDC42BPA	-0.34	-4.82	-0.3	2.59e-6	Myeloid white cell count;
SARC	cis	rs57083693	0.518	rs6538982	chr12:101708103	T/C	cg22051763	chr12:101673672	UTP20	-0.44	-5.26	-0.33	3.19e-7	Alcohol dependence (age at onset);
SARC	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg05872129	chr22:39784769	NA	-0.4	-5.55	-0.34	7.66e-8	Intelligence (multi-trait analysis);
SARC	cis	rs778371	0.522	rs10205801	chr2:233597196	G/A	cg20388707	chr2:233749442	NGEF	-0.35	-5.45	-0.34	1.3e-7	Schizophrenia;
SARC	cis	rs11971779	0.527	rs4379397	chr7:139043385	G/A	cg23387468	chr7:139079360	LUC7L2	0.33	4.71	0.3	4.2e-6	Diisocyanate-induced asthma;
SARC	cis	rs2370759	1.000	rs11594459	chr10:32561858	A/C	cg05361325	chr10:32636312	EPC1	-0.75	-6.57	-0.4	3.28e-10	Sexual dysfunction (female);
SARC	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg11764359	chr7:65958608	NA	-0.78	-9.41	-0.52	4.86e-18	Aortic root size;
SARC	cis	rs2522056	0.932	rs1012793	chr5:131781345	G/C	cg24060327	chr5:131705240	SLC22A5	0.56	5.85	0.36	1.63e-8	Lymphocyte counts;Fibrinogen;
SARC	cis	rs9916302	0.706	rs9899069	chr17:37540772	A/G	cg07936489	chr17:37558343	FBXL20	0.78	9.36	0.52	6.81e-18	Glomerular filtration rate (creatinine);
SARC	cis	rs10752881	1.000	rs4420053	chr1:182976133	A/C	cg13390022	chr1:182993471	LAMC1	0.33	5.06	0.31	8.36e-7	Colorectal cancer;
SARC	cis	rs9303401	0.632	rs7502541	chr17:57241019	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.62	7.35	0.43	3.24e-12	Cognitive test performance;
SARC	cis	rs8032315	1.000	rs8032315	chr15:91418297	A/T	cg05469396	chr15:91419421	FURIN	-0.36	-4.98	-0.31	1.25e-6	Autism spectrum disorder or schizophrenia;
SARC	trans	rs6981523	0.553	rs11783045	chr8:11056175	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.52	-0.39	4.25e-10	Neuroticism;
SARC	cis	rs2361718	0.967	rs12942941	chr17:78103013	C/T	cg06718696	chr17:78121285	EIF4A3	0.48	5.51	0.34	9.55e-8	Yeast infection;
SARC	cis	rs11608355	0.618	rs11066368	chr12:109790342	C/T	cg05360138	chr12:110035743	NA	0.4	4.89	0.31	1.84e-6	Neuroticism;
SARC	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs992157	0.965	rs62182826	chr2:219148723	C/A	cg00012203	chr2:219082015	ARPC2	0.73	11.21	0.59	1.34e-23	Colorectal cancer;
SARC	cis	rs995000	0.931	rs1627591	chr1:62989807	C/T	cg06896770	chr1:63153194	DOCK7	-0.88	-12.57	-0.64	5.16e-28	Triglyceride levels;
SARC	cis	rs758129	0.722	rs208826	chr15:89926799	G/A	cg03745604	chr15:89905304	NA	0.38	5.12	0.32	6.29e-7	Schizophrenia;
SARC	cis	rs881375	0.967	rs2109896	chr9:123683106	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.42	5.0	0.31	1.15e-6	Rheumatoid arthritis;
SARC	cis	rs1387259	0.899	rs7307566	chr12:48604682	A/G	cg24011408	chr12:48396354	COL2A1	0.46	5.45	0.34	1.3e-7	Obstructive sleep apnea trait (apnea hypopnea index);
SARC	cis	rs7660520	0.557	rs76004373	chr4:183731011	C/G	cg04181038	chr4:183730758	NA	0.56	5.85	0.36	1.66e-8	Pediatric autoimmune diseases;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg06852250	chr1:171750693	METTL13	0.5	6.63	0.4	2.25e-10	Chemerin levels;
SARC	cis	rs918629	0.798	rs2546199	chr5:95282091	A/C	cg16656078	chr5:95278638	ELL2	-0.63	-7.74	-0.45	3.09e-13	IgG glycosylation;
SARC	cis	rs2280018	0.526	rs2966129	chr16:15152927	A/C	cg07549590	chr16:15018862	NA	0.57	7.5	0.44	1.36e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs10791323	0.572	rs4412766	chr11:133742811	A/C	cg06766960	chr11:133703094	NA	-0.3	-4.77	-0.3	3.25e-6	Childhood ear infection;
SARC	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg20965017	chr5:231967	SDHA	-0.56	-5.3	-0.33	2.71e-7	Breast cancer;
SARC	cis	rs9818758	0.607	rs9837625	chr3:49215966	C/T	cg00383909	chr3:49044727	WDR6	0.7	6.03	0.37	6.31e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs7617773	0.780	rs7645425	chr3:48362369	A/T	cg11946769	chr3:48343235	NME6	0.77	9.81	0.54	2.97e-19	Coronary artery disease;
SARC	cis	rs6714710	0.603	rs2305143	chr2:98413781	C/T	cg26665480	chr2:98280029	ACTR1B	0.51	6.84	0.41	6.93e-11	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs12579753	1.000	rs10862372	chr12:82249804	C/T	cg07988820	chr12:82153109	PPFIA2	-0.56	-6.64	-0.4	2.13e-10	Resting heart rate;
SARC	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg11764359	chr7:65958608	NA	0.66	7.85	0.46	1.53e-13	Aortic root size;
SARC	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.42	-6.3	-0.38	1.49e-9	Total body bone mineral density;
SARC	cis	rs240764	0.853	rs12190903	chr6:100983505	C/T	cg09795085	chr6:101329169	ASCC3	-0.48	-6.32	-0.38	1.35e-9	Neuroticism;
SARC	cis	rs2652822	0.935	rs2292038	chr15:63449680	C/G	cg02713581	chr15:63449717	RPS27L	-0.76	-10.14	-0.55	3e-20	Metabolic traits;
SARC	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg06618935	chr21:46677482	NA	-0.39	-5.14	-0.32	5.72e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7712401	0.601	rs173480	chr5:122254131	C/A	cg19412675	chr5:122181750	SNX24	0.41	5.24	0.32	3.56e-7	Mean platelet volume;
SARC	cis	rs2213920	0.516	rs6415818	chr9:118210588	A/G	cg13918206	chr9:118159781	DEC1	0.81	6.49	0.39	4.99e-10	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs3820928	1.000	rs11686072	chr2:227777493	A/T	cg05526886	chr2:227700861	RHBDD1	-0.5	-6.14	-0.37	3.52e-9	Pulmonary function;
SARC	cis	rs1569175	0.522	rs10221945	chr2:200875847	T/C	cg23649088	chr2:200775458	C2orf69	-0.66	-5.56	-0.34	7.24e-8	Response to treatment for acute lymphoblastic leukemia;
SARC	cis	rs11792861	0.816	rs7021366	chr9:111727670	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.74	8.97	0.51	9.68e-17	Menarche (age at onset);
SARC	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg17971929	chr21:40555470	PSMG1	1.0	14.03	0.68	7.72e-33	Cognitive function;
SARC	cis	rs995000	0.965	rs10789113	chr1:63015199	A/T	cg06896770	chr1:63153194	DOCK7	0.99	15.28	0.71	5.69e-37	Triglyceride levels;
SARC	cis	rs1568889	1.000	rs7112860	chr11:28151609	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.73	9.63	0.53	1.08e-18	Bipolar disorder;
SARC	cis	rs6864727	0.963	rs13358047	chr5:137403095	T/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.56	6.24	0.38	2e-9	Atrial fibrillation;
SARC	cis	rs17376456	0.877	rs28418572	chr5:93144161	A/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.71	6.32	0.38	1.33e-9	Diabetic retinopathy;
SARC	cis	rs963731	0.649	rs1454223	chr2:39224351	G/T	cg04010122	chr2:39346883	SOS1	-1.09	-6.07	-0.37	5.14e-9	Corticobasal degeneration;
SARC	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg18252515	chr7:66147081	NA	-1.3	-11.62	-0.61	6.33e-25	Diabetic kidney disease;
SARC	cis	rs2120019	1.000	rs8036197	chr15:75370232	T/C	cg17294928	chr15:75287854	SCAMP5	-0.9	-13.28	-0.66	2.39e-30	Blood trace element (Zn levels);
SARC	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg24250549	chr1:154909240	PMVK	0.83	11.95	0.62	5.56e-26	Prostate cancer;
SARC	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	12.62	0.64	3.53e-28	Chronic sinus infection;
SARC	cis	rs1008375	0.932	rs10009933	chr4:17670107	A/C	cg16339924	chr4:17578868	LAP3	0.64	8.33	0.48	6.95e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1949733	0.656	rs2688224	chr4:8404700	C/G	cg13073564	chr4:8508604	NA	-0.43	-6.61	-0.4	2.57e-10	Response to antineoplastic agents;
SARC	cis	rs66887589	0.616	rs7659403	chr4:120207254	T/A	cg09307838	chr4:120376055	NA	0.61	8.08	0.47	3.59e-14	Diastolic blood pressure;
SARC	cis	rs7582720	1.000	rs72934715	chr2:203713280	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	7.55	0.44	9.63e-13	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs6087990	0.735	rs1040554	chr20:31380073	C/T	cg13636640	chr20:31349939	DNMT3B	0.81	12.95	0.65	2.91e-29	Ulcerative colitis;
SARC	cis	rs2153535	0.580	rs6597332	chr6:8504748	C/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.06	0.59	3.84e-23	Motion sickness;
SARC	cis	rs228437	1.000	rs9376050	chr6:134910136	A/G	cg24504307	chr6:134963096	NA	0.51	5.87	0.36	1.46e-8	Melanoma;
SARC	cis	rs2153535	0.563	rs6942177	chr6:8534460	A/G	cg07606381	chr6:8435919	SLC35B3	-0.73	-10.29	-0.56	1.02e-20	Motion sickness;
SARC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg20007245	chr22:24372913	LOC391322	0.78	10.89	0.58	1.39e-22	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg09165964	chr15:75287851	SCAMP5	0.58	7.86	0.46	1.38e-13	Breast cancer;
SARC	cis	rs7412746	0.658	rs2275235	chr1:150730279	A/G	cg10589385	chr1:150898437	SETDB1	0.39	5.06	0.31	8.49e-7	Melanoma;
SARC	cis	rs2013441	0.965	rs9896221	chr17:20180337	G/A	cg13482628	chr17:19912719	NA	-0.47	-6.17	-0.37	2.92e-9	Obesity-related traits;
SARC	cis	rs11098499	0.865	rs4001305	chr4:120359236	G/T	cg09307838	chr4:120376055	NA	0.92	13.13	0.65	7.35e-30	Corneal astigmatism;
SARC	cis	rs73086581	1.000	rs6037708	chr20:3961253	C/G	cg02187196	chr20:3869020	PANK2	0.65	6.53	0.39	4.01e-10	Response to antidepressants in depression;
SARC	cis	rs11621710	0.898	rs10147080	chr14:35596092	C/A	cg16230307	chr14:35515116	FAM177A1	0.5	6.36	0.38	1.04e-9	Granulocyte percentage of myeloid white cells;
SARC	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg07701084	chr6:150067640	NUP43	0.39	4.74	0.3	3.64e-6	Lung cancer;
SARC	cis	rs8523	0.838	rs17675322	chr6:11059185	T/A	cg13562911	chr6:11044106	ELOVL2	0.48	6.37	0.39	9.74e-10	Red blood cell fatty acid levels;
SARC	cis	rs6142102	0.886	rs6059583	chr20:32532114	T/G	cg24642439	chr20:33292090	TP53INP2	0.45	4.82	0.3	2.61e-6	Skin pigmentation;
SARC	cis	rs7712401	0.541	rs6867714	chr5:122382059	T/G	cg19412675	chr5:122181750	SNX24	0.47	6.04	0.37	6.16e-9	Mean platelet volume;
SARC	cis	rs1348850	0.837	rs4243388	chr2:178284604	T/G	cg23306229	chr2:178417860	TTC30B	0.52	6.03	0.37	6.44e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs35213789	0.853	rs10237870	chr7:69268010	G/T	cg10619644	chr7:69149951	AUTS2	0.36	4.73	0.3	3.83e-6	Childhood ear infection;
SARC	cis	rs6977660	0.507	rs72591449	chr7:19775443	T/C	cg05791153	chr7:19748676	TWISTNB	0.9	7.53	0.44	1.1e-12	Thyroid stimulating hormone;
SARC	cis	rs9910055	0.530	rs2269907	chr17:42294215	G/A	cg13607699	chr17:42295918	UBTF	0.85	13.59	0.67	2.25e-31	Total body bone mineral density;
SARC	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg06108461	chr20:60628389	TAF4	-0.98	-13.19	-0.65	4.72e-30	Body mass index;
SARC	cis	rs6696846	1.000	rs6696846	chr1:205041952	C/T	cg21643547	chr1:205240462	TMCC2	-0.51	-6.82	-0.41	7.74e-11	Red blood cell count;
SARC	cis	rs459571	0.959	rs2520099	chr9:136918139	T/C	cg01294253	chr9:136912663	BRD3	0.42	5.45	0.34	1.26e-7	Platelet distribution width;
SARC	cis	rs7824557	0.872	rs6601577	chr8:11102682	C/G	cg21775007	chr8:11205619	TDH	0.4	4.94	0.31	1.49e-6	Retinal vascular caliber;
SARC	cis	rs896854	0.516	rs12679044	chr8:95891356	C/A	cg16049864	chr8:95962084	TP53INP1	-0.4	-6.61	-0.4	2.66e-10	Type 2 diabetes;
SARC	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg04772025	chr11:68637568	NA	0.55	6.96	0.42	3.37e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7937682	0.883	rs549143	chr11:111463779	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.93	-14.06	-0.68	6.32e-33	Primary sclerosing cholangitis;
SARC	cis	rs1153858	1.000	rs67744121	chr15:45677237	C/G	cg26924012	chr15:45694286	SPATA5L1	0.79	11.28	0.59	7.91e-24	Homoarginine levels;
SARC	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg18876405	chr7:65276391	NA	-0.72	-9.0	-0.51	8.24e-17	Aortic root size;
SARC	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg03264133	chr6:25882463	NA	0.38	5.03	0.31	9.81e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9858542	0.953	rs4625	chr3:49572140	A/G	cg07274523	chr3:49395745	GPX1	0.51	6.0	0.37	7.32e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs4742903	0.967	rs10820610	chr9:106907819	G/A	cg14250997	chr9:106856677	SMC2	0.47	6.12	0.37	3.93e-9	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg12591125	chr7:1885375	MAD1L1	0.5	5.26	0.33	3.25e-7	Bipolar disorder;
SARC	cis	rs950776	0.593	rs6495306	chr15:78865893	C/T	cg24631222	chr15:78858424	CHRNA5	0.37	4.82	0.3	2.62e-6	Sudden cardiac arrest;
SARC	cis	rs4481887	1.000	rs4554750	chr1:248496530	C/G	cg00666640	chr1:248458726	OR2T12	0.4	6.54	0.39	3.85e-10	Common traits (Other);
SARC	trans	rs61931739	0.635	rs1405025	chr12:33908491	C/T	cg13010199	chr12:38710504	ALG10B	0.51	6.45	0.39	6.22e-10	Morning vs. evening chronotype;
SARC	cis	rs3126085	0.935	rs74129461	chr1:152285099	C/T	cg09127314	chr1:152161683	NA	-0.44	-4.75	-0.3	3.59e-6	Atopic dermatitis;
SARC	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.59	5.37	0.33	1.93e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2506889	0.553	rs11580264	chr1:10605796	C/A	cg07384165	chr1:10488281	NA	-0.42	-5.5	-0.34	1.02e-7	Breast cancer;
SARC	cis	rs314370	0.904	rs314373	chr7:100456595	G/A	cg10426581	chr7:100472382	SRRT	0.6	6.25	0.38	1.94e-9	Resting heart rate;
SARC	cis	rs9443189	0.813	rs2647410	chr6:76433825	A/G	cg01950844	chr6:76311363	SENP6	-0.71	-6.54	-0.39	3.79e-10	Prostate cancer;
SARC	cis	rs6484504	0.625	rs1535741	chr11:31375072	T/C	cg19308365	chr11:31391254	DNAJC24;DCDC1	0.38	4.74	0.3	3.65e-6	Red blood cell count;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg11201772	chr17:62915060	LRRC37A3	0.54	6.99	0.42	2.84e-11	Lung adenocarcinoma;
SARC	cis	rs2228479	0.850	rs62056068	chr16:89909737	C/T	cg12064134	chr16:90016061	DEF8	-0.56	-4.83	-0.3	2.47e-6	Skin colour saturation;
SARC	trans	rs9354308	0.933	rs2814131	chr6:66562051	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.57	6.71	0.4	1.42e-10	Metabolite levels;
SARC	cis	rs6142102	0.659	rs6057945	chr20:32517180	A/T	cg24642439	chr20:33292090	TP53INP2	0.45	4.78	0.3	3.13e-6	Skin pigmentation;
SARC	cis	rs6570726	0.935	rs446242	chr6:145843866	A/G	cg05220968	chr6:146057943	EPM2A	-0.3	-5.07	-0.31	8.29e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6088590	0.735	rs2273684	chr20:33529766	G/T	cg24642439	chr20:33292090	TP53INP2	-0.58	-7.52	-0.44	1.17e-12	Coronary artery disease;
SARC	cis	rs2832191	0.935	rs67287920	chr21:30523519	C/A	cg24692254	chr21:30365293	RNF160	-0.79	-11.08	-0.59	3.49e-23	Dental caries;
SARC	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg05025164	chr4:1340916	KIAA1530	0.46	5.44	0.34	1.36e-7	Obesity-related traits;
SARC	cis	rs7615952	0.546	rs2922197	chr3:125322032	G/A	cg21696256	chr3:125484277	NA	-0.4	-4.76	-0.3	3.34e-6	Blood pressure (smoking interaction);
SARC	cis	rs9818758	0.556	rs9880309	chr3:49304329	G/C	cg06212747	chr3:49208901	KLHDC8B	-0.7	-5.94	-0.36	1.05e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs6456156	0.586	rs720325	chr6:167467349	G/T	cg23791538	chr6:167370224	RNASET2	-0.49	-6.34	-0.38	1.15e-9	Primary biliary cholangitis;
SARC	cis	rs4906332	1.000	rs55930273	chr14:103960298	G/A	cg26031613	chr14:104095156	KLC1	-0.49	-5.76	-0.35	2.64e-8	Coronary artery disease;
SARC	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg20607798	chr8:58055168	NA	0.72	5.95	0.36	9.65e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9815354	1.000	rs56207540	chr3:41976627	G/C	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg23172400	chr8:95962367	TP53INP1	-0.35	-5.98	-0.36	8.43e-9	Type 2 diabetes;
SARC	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg19077165	chr18:44547161	KATNAL2	-0.5	-6.87	-0.41	5.65e-11	Personality dimensions;
SARC	cis	rs10927875	0.722	rs6660685	chr1:16346988	A/G	cg21385522	chr1:16154831	NA	0.71	9.1	0.51	4.19e-17	Dilated cardiomyopathy;
SARC	cis	rs2180341	0.597	rs3798859	chr6:127663116	C/T	cg27446573	chr6:127587934	RNF146	0.68	8.84	0.5	2.4e-16	Breast cancer;
SARC	cis	rs7714584	1.000	rs10065172	chr5:150227998	C/T	cg22134413	chr5:150180641	NA	0.78	6.54	0.39	3.82e-10	Crohn's disease;
SARC	cis	rs17384381	0.953	rs12122816	chr1:85792384	C/T	cg16011679	chr1:85725395	C1orf52	0.64	5.64	0.35	4.94e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs523522	0.962	rs10849753	chr12:120910813	C/T	cg27279351	chr12:120934652	DYNLL1	0.7	8.44	0.48	3.44e-15	High light scatter reticulocyte count;
SARC	cis	rs9916302	0.706	rs667239	chr17:37442241	A/G	cg00129232	chr17:37814104	STARD3	0.53	5.74	0.35	2.91e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs1322639	0.571	rs13204417	chr6:169575355	G/A	cg03254818	chr6:169586852	NA	-0.39	-5.0	-0.31	1.14e-6	Pulse pressure;
SARC	cis	rs2213920	0.516	rs2188042	chr9:118159740	C/T	cg13918206	chr9:118159781	DEC1	-0.86	-7.13	-0.42	1.25e-11	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg04166393	chr7:2884313	GNA12	0.48	5.72	0.35	3.19e-8	Height;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg19440553	chr5:93486848	C5orf36	0.46	6.34	0.38	1.21e-9	Thyroid stimulating hormone;
SARC	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg05036130	chr6:150231994	NA	0.32	5.64	0.35	4.87e-8	Testicular germ cell tumor;
SARC	cis	rs6665290	0.901	rs3795453	chr1:227205331	A/G	cg14016676	chr1:227182615	CDC42BPA	0.37	5.44	0.34	1.34e-7	Myeloid white cell count;
SARC	cis	rs17270561	0.609	rs12529272	chr6:25731342	A/G	cg16482183	chr6:26056742	HIST1H1C	0.43	5.25	0.33	3.47e-7	Iron status biomarkers;
SARC	trans	rs61931739	0.529	rs1525900	chr12:33976652	T/G	cg13010199	chr12:38710504	ALG10B	0.56	7.14	0.42	1.2e-11	Morning vs. evening chronotype;
SARC	cis	rs477692	0.569	rs10764885	chr10:131310207	G/A	cg05714579	chr10:131428358	MGMT	0.56	7.69	0.45	4.09e-13	Response to temozolomide;
SARC	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg07636037	chr3:49044803	WDR6	1.04	18.84	0.78	1.01e-48	Parkinson's disease;
SARC	cis	rs950169	0.920	rs2135551	chr15:84707851	A/G	cg24253500	chr15:84953950	NA	0.35	5.08	0.32	7.66e-7	Schizophrenia;
SARC	cis	rs7246657	0.765	rs7247259	chr19:37851090	T/C	cg14683738	chr19:37701593	ZNF585B	0.51	4.99	0.31	1.16e-6	Coronary artery calcification;
SARC	cis	rs9479482	1.000	rs11155697	chr6:150357423	C/T	cg03788504	chr6:150331562	NA	-0.32	-5.25	-0.33	3.41e-7	Alopecia areata;
SARC	cis	rs742614	0.533	rs2092737	chr20:32428135	A/C	cg06304546	chr20:32448765	NA	-0.56	-7.25	-0.43	6.08e-12	Stearic acid (18:0) levels;
SARC	cis	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.86	13.03	0.65	1.6800000000000001e-29	Eosinophil percentage of white cells;
SARC	cis	rs2070997	0.607	rs3847190	chr9:133715590	C/T	cg11464064	chr9:133710261	ABL1	0.62	6.01	0.37	7.23e-9	Response to amphetamines;
SARC	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	16.94	0.74	1.71e-42	Height;
SARC	cis	rs1215050	0.791	rs2123099	chr4:98803456	A/G	cg05340658	chr4:99064831	C4orf37	0.44	5.85	0.36	1.62e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs616402	0.527	rs2274985	chr1:10573867	G/A	cg17425144	chr1:10567563	PEX14	0.45	7.31	0.43	4.3e-12	Breast size;
SARC	cis	rs6456156	0.586	rs12527827	chr6:167469271	C/T	cg23791538	chr6:167370224	RNASET2	-0.52	-6.81	-0.41	8.22e-11	Primary biliary cholangitis;
SARC	cis	rs3768617	0.510	rs12061219	chr1:183101471	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.66e-21	Fuchs's corneal dystrophy;
SARC	cis	rs7429990	0.932	rs4293721	chr3:48045137	C/A	cg11946769	chr3:48343235	NME6	-0.45	-5.24	-0.32	3.64e-7	Educational attainment (years of education);
SARC	cis	rs1707322	0.717	rs11211161	chr1:46148138	A/C	cg03146154	chr1:46216737	IPP	0.52	6.31	0.38	1.39e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9815354	1.000	rs9842305	chr3:41998412	G/A	cg03022575	chr3:42003672	ULK4	-0.59	-5.67	-0.35	4.22e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs651907	0.535	rs36060163	chr3:101360963	C/T	cg12386194	chr3:101231763	SENP7	0.5	5.92	0.36	1.14e-8	Colorectal cancer;
SARC	cis	rs6088580	0.634	rs3736762	chr20:33037336	C/T	cg24642439	chr20:33292090	TP53INP2	0.68	8.78	0.5	3.54e-16	Glomerular filtration rate (creatinine);
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg02895278	chr8:26195897	PPP2R2A	-0.52	-6.36	-0.38	1.07e-9	Alcohol dependence;
SARC	trans	rs11098499	0.580	rs12509234	chr4:120319434	T/C	cg25214090	chr10:38739885	LOC399744	0.57	7.46	0.44	1.7e-12	Corneal astigmatism;
SARC	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg09672200	chr7:1117916	C7orf50	-0.39	-4.73	-0.3	3.95e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs7589342	0.839	rs11895235	chr2:106432355	C/G	cg14210321	chr2:106509881	NCK2	-0.42	-4.79	-0.3	2.98e-6	Addiction;
SARC	cis	rs17376456	0.877	rs13169675	chr5:93331284	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.31	0.33	2.51e-7	Diabetic retinopathy;
SARC	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg06074448	chr4:187884817	NA	-0.41	-5.44	-0.34	1.38e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-6.49	-0.39	5.23e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs123509	0.687	rs73075301	chr3:42832650	C/T	cg12982090	chr3:42733453	KBTBD5	-0.53	-5.95	-0.36	9.96e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2933343	0.553	rs35076317	chr3:128715535	T/C	cg25356066	chr3:128598488	ACAD9	0.61	7.5	0.44	1.33e-12	IgG glycosylation;
SARC	cis	rs7027203	0.790	rs10123836	chr9:96584109	G/T	cg14598338	chr9:96623480	NA	-0.55	-7.97	-0.46	7.07e-14	DNA methylation (variation);
SARC	cis	rs7666738	0.830	rs10470894	chr4:99039107	G/A	cg05340658	chr4:99064831	C4orf37	0.62	8.39	0.48	4.6e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs240764	0.645	rs240152	chr6:101067489	G/C	cg09795085	chr6:101329169	ASCC3	0.43	5.25	0.33	3.43e-7	Neuroticism;
SARC	cis	rs2153535	0.580	rs6421948	chr6:8531020	T/C	cg07606381	chr6:8435919	SLC35B3	0.76	10.92	0.58	1.12e-22	Motion sickness;
SARC	cis	rs12579753	0.917	rs7313521	chr12:82205656	G/A	cg07988820	chr12:82153109	PPFIA2	-0.52	-6.11	-0.37	4.18e-9	Resting heart rate;
SARC	cis	rs2153535	0.580	rs6597327	chr6:8482157	G/A	cg07606381	chr6:8435919	SLC35B3	0.78	11.13	0.59	2.44e-23	Motion sickness;
SARC	cis	rs4927850	0.794	rs2019472	chr3:195735371	T/C	cg12923728	chr3:195709715	SDHAP1	-0.7	-7.79	-0.45	2.25e-13	Pancreatic cancer;
SARC	cis	rs10504229	0.679	rs72649131	chr8:58054288	G/T	cg21724239	chr8:58056113	NA	0.59	5.97	0.36	9e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs61931739	0.817	rs1705771	chr12:34174950	C/G	cg13010199	chr12:38710504	ALG10B	0.58	7.8	0.46	2.02e-13	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg11062466	chr8:58055876	NA	0.53	5.53	0.34	8.39e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1865760	1.000	rs3752421	chr6:25918688	G/A	cg16482183	chr6:26056742	HIST1H1C	0.5	6.24	0.38	2.01e-9	Height;
SARC	trans	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg06636001	chr8:8085503	FLJ10661	0.58	7.8	0.46	2.02e-13	Retinal vascular caliber;
SARC	cis	rs6840258	0.660	rs55816619	chr4:87959805	G/A	cg11209507	chr4:87813803	C4orf36	0.49	4.98	0.31	1.21e-6	Mean corpuscular volume;Basophil percentage of granulocytes;
SARC	cis	rs7726839	0.526	rs11960159	chr5:568685	C/T	cg07777115	chr5:623756	CEP72	-0.53	-5.17	-0.32	4.99e-7	Obesity-related traits;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg27572068	chr3:25728371	NA	-0.53	-6.68	-0.4	1.69e-10	Height;
SARC	cis	rs2342371	0.848	rs12632592	chr3:196219365	G/A	cg15048948	chr3:196158458	UBXN7	0.55	6.81	0.41	8.25e-11	Fat distribution (HIV);
SARC	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg02187348	chr16:89574699	SPG7	-0.66	-9.74	-0.54	4.86e-19	Multiple myeloma (IgH translocation);
SARC	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg07636037	chr3:49044803	WDR6	1.01	17.97	0.76	6.89e-46	Parkinson's disease;
SARC	cis	rs7208859	0.673	rs11658344	chr17:29207745	G/T	cg13385521	chr17:29058706	SUZ12P	0.86	7.34	0.43	3.54e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs854765	0.583	rs11869536	chr17:17826528	T/A	cg05444541	chr17:17804740	TOM1L2	-0.29	-4.98	-0.31	1.22e-6	Total body bone mineral density;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg10245697	chr20:3869582	PANK2	0.48	6.35	0.38	1.11e-9	Chemerin levels;
SARC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg22903471	chr2:27725779	GCKR	-0.49	-7.42	-0.44	2.21e-12	Total body bone mineral density;
SARC	cis	rs2070997	0.607	rs2855190	chr9:133708361	C/T	cg11464064	chr9:133710261	ABL1	-0.57	-5.52	-0.34	9.18e-8	Response to amphetamines;
SARC	cis	rs34330	0.562	rs10492235	chr12:12851339	T/G	cg09462578	chr12:12878428	APOLD1	-0.6	-5.77	-0.35	2.51e-8	Systemic lupus erythematosus;
SARC	cis	rs2732480	0.577	rs2634678	chr12:48735538	C/G	cg24011408	chr12:48396354	COL2A1	0.43	5.07	0.32	8.19e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs9640161	0.830	rs3735165	chr7:150068371	T/C	cg10018233	chr7:150070692	REPIN1	0.71	12.11	0.62	1.72e-26	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs509477	0.962	rs562412	chr18:32576305	T/C	cg23791764	chr18:32556832	MAPRE2	-0.56	-6.75	-0.4	1.15e-10	Cerebrospinal fluid AB1-42 levels;
SARC	cis	rs10791097	0.677	rs11222359	chr11:130730648	A/G	cg09137382	chr11:130731461	NA	0.33	5.15	0.32	5.48e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs10411936	0.750	rs8112401	chr19:16593012	C/T	cg10248733	chr19:16607483	C19orf44;CALR3	0.57	6.92	0.41	4.36e-11	White blood cell count;Multiple sclerosis;
SARC	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg18252515	chr7:66147081	NA	0.52	5.67	0.35	4.2e-8	Aortic root size;
SARC	cis	rs7615952	0.576	rs17523380	chr3:125802874	C/T	cg04553112	chr3:125709451	NA	-0.48	-5.02	-0.31	1.01e-6	Blood pressure (smoking interaction);
SARC	cis	rs72781680	0.611	rs72783619	chr2:24311607	G/A	cg08917208	chr2:24149416	ATAD2B	0.62	6.41	0.39	8.14e-10	Lymphocyte counts;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15888699	chr11:57298252	TIMM10	-0.52	-6.29	-0.38	1.53e-9	Fibrinogen levels;
SARC	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg12463550	chr7:65579703	CRCP	0.48	5.79	0.35	2.23e-8	Aortic root size;
SARC	cis	rs796364	0.806	rs4673634	chr2:200863349	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.71	6.07	0.37	5.18e-9	Schizophrenia;
SARC	cis	rs6815814	0.950	rs5743795	chr4:38832495	C/T	cg06935464	chr4:38784597	TLR10	0.51	4.91	0.31	1.73e-6	Breast cancer;
SARC	cis	rs4780401	0.609	rs55934118	chr16:11820003	G/C	cg01061890	chr16:11836724	TXNDC11	-0.62	-8.85	-0.5	2.2e-16	Rheumatoid arthritis;
SARC	cis	rs62432291	0.681	rs388001	chr6:159658459	C/T	cg14500486	chr6:159655392	FNDC1	-0.64	-6.37	-0.39	9.75e-10	Joint mobility (Beighton score);
SARC	cis	rs6835098	1.000	rs9990666	chr4:174083150	G/T	cg08422745	chr4:174089978	GALNT7	-0.75	-10.19	-0.56	2.1e-20	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.34	-4.81	-0.3	2.65e-6	Longevity;Endometriosis;
SARC	cis	rs11098499	0.913	rs10010696	chr4:120164303	T/C	cg09307838	chr4:120376055	NA	0.85	11.62	0.61	6.53e-25	Corneal astigmatism;
SARC	trans	rs6600671	0.967	rs12069545	chr1:121172203	A/G	cg00646200	chr1:148855367	NA	0.49	6.87	0.41	5.92e-11	Hip geometry;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg00841985	chr3:15901302	ANKRD28	0.5	6.5	0.39	4.92e-10	Lung adenocarcinoma;
SARC	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg21724239	chr8:58056113	NA	0.69	5.98	0.36	8.45e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs78456975	1.000	rs13400784	chr2:1564473	T/A	cg26248373	chr2:1572462	NA	-0.58	-6.03	-0.37	6.32e-9	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs2153535	0.580	rs6900007	chr6:8474035	C/T	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	cis	rs782590	0.774	rs2627773	chr2:55900459	A/G	cg18811423	chr2:55921094	PNPT1	0.7	10.64	0.57	8.12e-22	Metabolic syndrome;
SARC	cis	rs9660992	0.700	rs1172125	chr1:205258442	A/T	cg21545522	chr1:205238299	TMCC2	0.4	5.67	0.35	4.18e-8	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.66	0.35	4.44e-8	Bipolar disorder;
SARC	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg01448562	chr3:133502909	NA	-0.5	-7.68	-0.45	4.39e-13	Iron status biomarkers;
SARC	cis	rs2273669	0.915	rs1080945	chr6:109304694	A/G	cg01304950	chr6:109416612	SESN1;C6orf182	0.55	4.91	0.31	1.75e-6	Prostate cancer;
SARC	cis	rs9916302	0.718	rs10445306	chr17:37591422	A/G	cg00129232	chr17:37814104	STARD3	-0.63	-7.66	-0.45	5.09e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs6963495	0.745	rs55906043	chr7:105165367	T/G	cg19920283	chr7:105172520	RINT1	0.66	5.66	0.35	4.47e-8	Bipolar disorder (body mass index interaction);
SARC	trans	rs17685	0.712	rs1639620	chr7:75704090	A/G	cg19862616	chr7:65841803	NCRNA00174	0.63	7.77	0.45	2.42e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs6540556	0.634	rs11485195	chr1:209891738	T/C	cg23920097	chr1:209922102	NA	-0.51	-5.21	-0.32	4.18e-7	Red blood cell count;
SARC	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg05793240	chr7:2802953	GNA12	-0.37	-5.3	-0.33	2.64e-7	Height;
SARC	cis	rs13191362	1.000	rs7769686	chr6:163199467	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.65	5.77	0.35	2.51e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs926392	0.533	rs6129162	chr20:37683195	G/A	cg16355469	chr20:37678765	NA	0.78	10.02	0.55	7.21e-20	Dialysis-related mortality;
SARC	cis	rs9914988	0.613	rs4794842	chr17:27290751	G/T	cg10538030	chr17:27276405	PHF12	-0.62	-5.03	-0.31	1e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs72627509	0.951	rs17087335	chr4:57838583	G/T	cg26694713	chr4:57773883	REST	0.7	6.96	0.42	3.33e-11	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-4.79	-0.3	2.97e-6	Total body bone mineral density;
SARC	cis	rs4742903	0.870	rs10991172	chr9:106976151	C/T	cg14250997	chr9:106856677	SMC2	0.4	5.02	0.31	1.02e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	trans	rs34421088	0.548	rs2618443	chr8:11384556	A/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.43	-0.39	7.24e-10	Neuroticism;
SARC	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-8.39	-0.48	4.81e-15	Chronic sinus infection;
SARC	cis	rs3768617	0.510	rs2224933	chr1:183095765	A/G	cg13390022	chr1:182993471	LAMC1	0.31	4.79	0.3	3.01e-6	Fuchs's corneal dystrophy;
SARC	cis	rs35306767	0.903	rs11816064	chr10:931176	A/C	cg26597838	chr10:835615	NA	0.82	8.5	0.49	2.22e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs787274	1.000	rs7868830	chr9:115577125	G/A	cg13803584	chr9:115635662	SNX30	-0.76	-5.73	-0.35	3.1e-8	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs9796	0.870	rs7169375	chr15:41311046	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.38	-5.24	-0.32	3.52e-7	Menopause (age at onset);
SARC	cis	rs9486715	0.867	rs9480700	chr6:96965056	A/G	cg18709589	chr6:96969512	KIAA0776	0.61	7.52	0.44	1.16e-12	Headache;
SARC	trans	rs7824557	0.564	rs2736293	chr8:11234613	T/A	cg15556689	chr8:8085844	FLJ10661	-0.55	-6.96	-0.41	3.44e-11	Retinal vascular caliber;
SARC	cis	rs7592578	0.723	rs4371384	chr2:191430741	A/G	cg25963032	chr2:191064776	C2orf88	0.44	4.81	0.3	2.72e-6	Diastolic blood pressure;
SARC	cis	rs11997175	0.655	rs72630923	chr8:33662404	C/A	ch.8.33884649F	chr8:33765107	NA	0.47	6.16	0.37	3.15e-9	Body mass index;
SARC	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.92	13.88	0.67	2.57e-32	Chronic sinus infection;
SARC	cis	rs2153535	0.584	rs9502723	chr6:8541504	G/A	cg23788917	chr6:8435910	SLC35B3	0.62	8.22	0.47	1.4e-14	Motion sickness;
SARC	cis	rs10782582	0.569	rs74090722	chr1:76197262	A/G	cg10523679	chr1:76189770	ACADM	-0.44	-5.49	-0.34	1.02e-7	Daytime sleep phenotypes;
SARC	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg18225595	chr11:63971243	STIP1	0.57	8.43	0.48	3.59e-15	Platelet count;
SARC	cis	rs9894429	0.646	rs12603868	chr17:79618834	G/C	cg10661904	chr17:79619235	PDE6G	-0.47	-6.61	-0.4	2.57e-10	Eye color traits;
SARC	cis	rs28655083	0.912	rs2171097	chr16:77085037	C/G	cg01504555	chr16:77246968	SYCE1L	-0.38	-4.87	-0.3	2.06e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg11247378	chr22:39784982	NA	-0.33	-5.35	-0.33	2.15e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg24633833	chr3:10029261	TMEM111	0.53	5.31	0.33	2.51e-7	Alzheimer's disease;
SARC	cis	rs3106136	0.527	rs4235050	chr4:95157156	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.47	-7.05	-0.42	2.06e-11	Capecitabine sensitivity;
SARC	trans	rs3780486	0.581	rs1137642	chr9:33118904	A/G	cg04842962	chr6:43655489	MRPS18A	0.89	13.05	0.65	1.37e-29	IgG glycosylation;
SARC	cis	rs1003719	0.715	rs2835675	chr21:38582815	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-8.81	-0.5	3.01e-16	Eye color traits;
SARC	cis	rs9733	0.687	rs12410050	chr1:150857141	A/G	cg15448220	chr1:150897856	SETDB1	-0.39	-5.18	-0.32	4.87e-7	Tonsillectomy;
SARC	cis	rs9486715	0.867	rs1127175	chr6:96999725	C/T	cg18709589	chr6:96969512	KIAA0776	-0.52	-6.28	-0.38	1.65e-9	Headache;
SARC	cis	rs3796352	1.000	rs13072395	chr3:52980573	T/C	cg12962167	chr3:53033115	SFMBT1	0.85	5.4	0.33	1.61e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs943466	1.000	rs943461	chr6:33769409	C/G	cg04676172	chr6:33757040	LEMD2	0.46	4.78	0.3	3.17e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
SARC	trans	rs1814175	0.715	rs11040586	chr11:49858432	T/A	cg03929089	chr4:120376271	NA	-0.9	-15.01	-0.7	4.47e-36	Height;
SARC	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg08219700	chr8:58056026	NA	0.49	5.09	0.32	7.43e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2576037	0.796	rs2571030	chr18:44573854	G/A	cg15049968	chr18:44337910	ST8SIA5	0.34	5.62	0.35	5.37e-8	Personality dimensions;
SARC	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	10.75	0.58	3.72e-22	Platelet count;
SARC	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg06618935	chr21:46677482	NA	-0.42	-5.62	-0.35	5.29e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4073582	0.516	rs1151539	chr11:66031660	C/T	cg14036092	chr11:66035641	RAB1B	0.62	8.92	0.5	1.41e-16	Gout;
SARC	cis	rs35146811	0.771	rs1060544	chr7:99613476	C/T	cg22004693	chr7:99632812	ZKSCAN1	-0.45	-4.95	-0.31	1.43e-6	Coronary artery disease;
SARC	cis	rs10504229	0.593	rs80174614	chr8:58024631	G/A	cg22535103	chr8:58192502	C8orf71	-0.6	-5.76	-0.35	2.61e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs34783982	0.881	rs34031857	chr15:89500560	G/A	cg26213453	chr15:89455860	MFGE8	0.27	4.72	0.3	4.01e-6	Squamous cell lung carcinoma;
SARC	cis	rs9300255	0.544	rs1790123	chr12:123659542	C/T	cg05973401	chr12:123451056	ABCB9	0.54	5.18	0.32	4.8e-7	Neutrophil percentage of white cells;
SARC	cis	rs9682041	0.932	rs7631221	chr3:170069893	A/G	cg11886554	chr3:170076028	SKIL	0.69	6.3	0.38	1.45e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs7831492	0.564	rs60792897	chr8:41609623	C/T	cg17182837	chr8:41585554	ANK1	-0.39	-5.07	-0.32	8.2e-7	Colorectal cancer;
SARC	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg05861140	chr6:150128134	PCMT1	-0.44	-5.72	-0.35	3.18e-8	Lung cancer;
SARC	trans	rs66573146	0.656	rs66905212	chr4:6949508	G/C	cg07817883	chr1:32538562	TMEM39B	1.12	8.18	0.47	1.86e-14	Granulocyte percentage of myeloid white cells;
SARC	cis	rs3784262	0.904	rs4646620	chr15:58258241	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.38	-5.71	-0.35	3.44e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs6831352	0.837	rs2924583	chr4:100044640	T/C	cg12011299	chr4:100065546	ADH4	0.34	5.68	0.35	4e-8	Alcohol dependence;
SARC	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg10589385	chr1:150898437	SETDB1	0.37	5.12	0.32	6.54e-7	Tonsillectomy;
SARC	cis	rs2295359	1.000	rs11209007	chr1:67619345	C/G	cg08029281	chr1:67600428	NA	0.36	5.01	0.31	1.1e-6	Psoriasis;
SARC	cis	rs4423214	0.879	rs1630498	chr11:71150785	A/C	cg05163923	chr11:71159392	DHCR7	-0.6	-7.04	-0.42	2.08e-11	Vitamin D levels;
SARC	cis	rs7264396	0.790	rs1040695	chr20:34244829	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	5.89	0.36	1.36e-8	Total cholesterol levels;
SARC	cis	rs7589728	0.748	rs35051888	chr2:88482258	G/A	cg04511125	chr2:88470314	THNSL2	0.65	5.89	0.36	1.37e-8	Plasma clusterin levels;
SARC	cis	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg14541582	chr5:601475	NA	-0.39	-4.91	-0.31	1.71e-6	Obesity-related traits;
SARC	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg11764359	chr7:65958608	NA	0.88	12.58	0.64	4.89e-28	Aortic root size;
SARC	cis	rs950776	0.518	rs12910978	chr15:78810017	A/G	cg06917634	chr15:78832804	PSMA4	0.87	12.84	0.64	6.7e-29	Sudden cardiac arrest;
SARC	cis	rs9911578	0.835	rs9904993	chr17:56468569	G/T	cg12560992	chr17:57184187	TRIM37	-0.74	-9.47	-0.53	3.34e-18	Intelligence (multi-trait analysis);
SARC	cis	rs7106204	0.534	rs113519220	chr11:24251432	T/C	ch.11.24196551F	chr11:24239977	NA	0.64	4.78	0.3	3.11e-6	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg18252515	chr7:66147081	NA	0.6	6.57	0.4	3.3e-10	Aortic root size;
SARC	cis	rs476633	0.691	rs28409265	chr15:41539404	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.55	-7.66	-0.45	5.02e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs2204008	0.774	rs7305085	chr12:38263511	C/T	cg26384229	chr12:38710491	ALG10B	0.91	13.64	0.67	1.61e-31	Bladder cancer;
SARC	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg13939156	chr17:80058883	NA	-0.41	-6.27	-0.38	1.7e-9	Life satisfaction;
SARC	cis	rs12973672	1.000	rs2280747	chr19:35770064	C/T	cg12095397	chr19:35769544	USF2	0.38	4.79	0.3	2.9e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg22862634	chr11:62369728	EML3;MTA2	0.46	6.15	0.37	3.43e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg22920501	chr2:26401640	FAM59B	-0.61	-8.2	-0.47	1.62e-14	Gut microbiome composition (summer);
SARC	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg16479474	chr6:28041457	NA	0.37	5.53	0.34	8.38e-8	Depression;
SARC	cis	rs3092073	0.624	rs13040315	chr20:44585793	A/G	cg27529037	chr20:44575021	PCIF1	0.36	5.75	0.35	2.72e-8	Intelligence (multi-trait analysis);
SARC	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg13939156	chr17:80058883	NA	0.36	5.62	0.35	5.52e-8	Life satisfaction;
SARC	cis	rs1467026	0.691	rs9985266	chr3:12803162	C/T	cg05775895	chr3:12838266	CAND2	-0.6	-8.56	-0.49	1.59e-15	P wave duration;
SARC	cis	rs8053891	0.805	rs12149869	chr16:71995946	T/C	cg16558253	chr16:72132732	DHX38	-0.42	-5.36	-0.33	1.99e-7	Coronary artery disease;
SARC	cis	rs3768617	0.510	rs2296290	chr1:183079412	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.8e-21	Fuchs's corneal dystrophy;
SARC	cis	rs916888	0.610	rs199529	chr17:44837217	A/C	cg14517863	chr17:44321492	NA	0.33	5.08	0.32	7.92e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs11722228	0.549	rs3796818	chr4:10097976	C/T	cg11266682	chr4:10021025	SLC2A9	0.33	4.72	0.3	4e-6	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs57994353	0.897	rs72775778	chr9:139381128	G/A	cg14169450	chr9:139327907	INPP5E	0.41	5.19	0.32	4.61e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs7174348	1	rs7174348	chr15:78792439	G/A	cg24631222	chr15:78858424	CHRNA5	0.74	9.03	0.51	6.82e-17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
SARC	cis	rs2997447	0.761	rs74384164	chr1:26430379	C/T	cg19633962	chr1:26362018	EXTL1	-0.64	-5.32	-0.33	2.49e-7	QRS complex (12-leadsum);
SARC	cis	rs4481887	0.927	rs12731721	chr1:248474210	G/A	cg13385794	chr1:248469461	NA	0.35	5.45	0.34	1.29e-7	Common traits (Other);
SARC	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg11890956	chr21:40555474	PSMG1	-0.7	-9.34	-0.52	7.91e-18	Menarche (age at onset);
SARC	cis	rs870825	0.616	rs6552802	chr4:185620751	C/G	cg04058563	chr4:185651563	MLF1IP	0.82	11.42	0.6	2.8e-24	Blood protein levels;
SARC	cis	rs2200578	1.000	rs2200578	chr2:99876244	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.56	5.31	0.33	2.5e-7	IgG glycosylation;
SARC	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg03709012	chr19:19516395	GATAD2A	1.01	17.45	0.75	3.42e-44	Tonsillectomy;
SARC	cis	rs992157	0.735	rs12990082	chr2:219102332	C/T	cg00012203	chr2:219082015	ARPC2	0.86	13.92	0.67	1.79e-32	Colorectal cancer;
SARC	cis	rs11098499	0.863	rs6858592	chr4:120458692	G/A	cg09307838	chr4:120376055	NA	0.93	12.94	0.65	3.31e-29	Corneal astigmatism;
SARC	cis	rs2841277	0.771	rs2819469	chr14:105394859	G/A	cg21017887	chr14:105400489	NA	-0.55	-7.61	-0.45	6.56e-13	Rheumatoid arthritis;
SARC	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg24675658	chr1:53192096	ZYG11B	-0.56	-7.7	-0.45	3.93e-13	Monocyte count;
SARC	cis	rs1005277	0.522	rs289647	chr10:37968278	A/G	cg00409905	chr10:38381863	ZNF37A	-0.52	-7.17	-0.43	9.75e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs58804349	0.605	rs72779330	chr10:43522315	C/G	cg08461752	chr10:43522343	NA	-0.47	-4.93	-0.31	1.54e-6	Pediatric bone mineral content (radius);
SARC	cis	rs709400	0.663	rs11628213	chr14:103952453	A/C	cg26031613	chr14:104095156	KLC1	0.83	12.13	0.62	1.39e-26	Body mass index;
SARC	cis	rs7223966	1.000	rs8075521	chr17:61804954	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	6.88	0.41	5.45e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs12579753	1.000	rs7963577	chr12:82174115	T/C	cg07988820	chr12:82153109	PPFIA2	-0.58	-6.76	-0.41	1.09e-10	Resting heart rate;
SARC	cis	rs9916302	0.851	rs11078904	chr17:37650569	G/A	cg07936489	chr17:37558343	FBXL20	-0.69	-8.94	-0.51	1.2e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs7914558	1.000	rs3740387	chr10:104849468	G/A	cg04362960	chr10:104952993	NT5C2	0.39	4.73	0.3	3.86e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs1865760	0.516	rs9295684	chr6:26069669	T/C	cg10373733	chr6:25993375	NA	0.39	4.81	0.3	2.69e-6	Height;
SARC	cis	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg12463550	chr7:65579703	CRCP	0.68	5.21	0.32	4.1e-7	Diabetic kidney disease;
SARC	cis	rs611744	0.967	rs653633	chr8:109196151	T/G	cg21045802	chr8:109455806	TTC35	0.44	5.3	0.33	2.63e-7	Dupuytren's disease;
SARC	cis	rs2115630	0.755	rs7169629	chr15:85191274	C/G	cg12501888	chr15:85177176	SCAND2	0.48	5.98	0.36	8.17e-9	P wave terminal force;
SARC	cis	rs34330	0.562	rs7486387	chr12:12866911	G/A	cg09462578	chr12:12878428	APOLD1	-0.56	-5.45	-0.34	1.25e-7	Systemic lupus erythematosus;
SARC	cis	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg22857025	chr5:266934	NA	-1.05	-11.9	-0.61	7.87e-26	Breast cancer;
SARC	cis	rs908922	0.676	rs4845441	chr1:152485421	C/T	cg09873164	chr1:152488093	CRCT1	0.65	8.27	0.48	1.03e-14	Hair morphology;
SARC	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg16325326	chr1:53192061	ZYG11B	0.77	12.31	0.63	3.7e-27	Monocyte count;
SARC	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg16405210	chr4:1374714	KIAA1530	-0.51	-5.95	-0.36	1e-8	Obesity-related traits;
SARC	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg25894440	chr7:65020034	NA	0.45	5.04	0.31	9.38e-7	Calcium levels;
SARC	cis	rs798554	1.000	rs798563	chr7:2757867	A/C	cg05793240	chr7:2802953	GNA12	-0.36	-5.19	-0.32	4.51e-7	Height;
SARC	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-6.37	-0.38	1.02e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs12079745	0.590	rs12095526	chr1:169401827	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.81	-5.31	-0.33	2.62e-7	QT interval;
SARC	cis	rs6665290	0.935	rs6693535	chr1:227197685	G/A	cg14016676	chr1:227182615	CDC42BPA	0.38	5.55	0.34	7.71e-8	Myeloid white cell count;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg09419297	chr15:77712428	HMG20A	-0.87	-7.52	-0.44	1.15e-12	Autism spectrum disorder or schizophrenia;
SARC	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg19723775	chr5:179050963	HNRNPH1	-0.48	-6.32	-0.38	1.33e-9	Lung cancer;
SARC	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg17376030	chr22:41985996	PMM1	0.75	9.34	0.52	7.81e-18	Vitiligo;
SARC	cis	rs4973397	0.509	rs10191571	chr2:232279975	C/A	cg09339159	chr2:232260559	B3GNT7	0.45	5.35	0.33	2.1e-7	Anti-saccade response;
SARC	cis	rs6840360	0.726	rs6816292	chr4:152730543	C/T	cg22705602	chr4:152727874	NA	0.36	6.0	0.37	7.42e-9	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg18876405	chr7:65276391	NA	-0.47	-5.27	-0.33	3.15e-7	Aortic root size;
SARC	cis	rs3733585	0.660	rs13122290	chr4:9933832	A/G	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.29	-0.43	4.71e-12	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7555523	1.000	rs7555523	chr1:165718979	C/A	cg24409356	chr1:165738333	TMCO1	0.8	6.69	0.4	1.65e-10	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	cis	rs3815700	0.688	rs259252	chr19:33149991	G/C	cg02997394	chr19:33096574	ANKRD27	0.68	5.17	0.32	5.05e-7	Eosinophilic esophagitis;
SARC	cis	rs748404	0.697	rs574065	chr15:43550655	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.53	-6.29	-0.38	1.51e-9	Lung cancer;
SARC	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg25072359	chr17:41440525	NA	0.51	6.13	0.37	3.72e-9	Menopause (age at onset);
SARC	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg11764359	chr7:65958608	NA	-0.86	-12.18	-0.62	9.99e-27	Aortic root size;
SARC	cis	rs6121246	0.738	rs2376996	chr20:30316667	T/A	cg13852791	chr20:30311386	BCL2L1	0.85	9.18	0.52	2.48e-17	Mean corpuscular hemoglobin;
SARC	cis	rs244731	0.959	rs7724098	chr5:176659570	G/A	cg16006841	chr5:176797999	RGS14	-0.57	-6.81	-0.41	8.34e-11	Urate levels in lean individuals;
SARC	cis	rs733592	0.507	rs56129148	chr12:48485530	T/C	cg24011408	chr12:48396354	COL2A1	-0.51	-7.12	-0.42	1.31e-11	Plateletcrit;
SARC	cis	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg13647721	chr17:30228624	UTP6	-0.72	-5.95	-0.36	9.7e-9	Hip circumference adjusted for BMI;
SARC	trans	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.21	-0.43	7.82e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs9487051	0.676	rs7753697	chr6:109593292	A/G	cg01475377	chr6:109611718	NA	-0.35	-5.08	-0.32	7.66e-7	Reticulocyte fraction of red cells;
SARC	cis	rs6964587	1.000	rs12666179	chr7:91574110	T/C	cg17063962	chr7:91808500	NA	-0.93	-14.92	-0.7	8.86e-36	Breast cancer;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg25214684	chr1:39457099	AKIRIN1	0.46	6.29	0.38	1.56e-9	Tetralogy of Fallot;
SARC	cis	rs4974559	0.501	rs1250093	chr4:1240911	G/A	cg02980000	chr4:1222292	CTBP1	-0.79	-6.39	-0.39	9.01e-10	Systolic blood pressure;
SARC	cis	rs607987	0.802	rs2786257	chr11:30340725	G/A	cg06241208	chr11:30344200	C11orf46	-0.39	-4.77	-0.3	3.27e-6	Body mass index;
SARC	cis	rs3126085	1.000	rs11588170	chr1:152286032	C/T	cg26876637	chr1:152193138	HRNR	-0.51	-5.23	-0.32	3.81e-7	Atopic dermatitis;
SARC	cis	rs7582720	0.943	rs72926800	chr2:203829225	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg08219700	chr8:58056026	NA	0.62	6.56	0.4	3.37e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg13206674	chr6:150067644	NUP43	0.4	5.19	0.32	4.62e-7	Lung cancer;
SARC	cis	rs10979	1.000	rs9390107	chr6:143892721	A/T	cg25407410	chr6:143891975	LOC285740	-0.64	-8.67	-0.49	7.47e-16	Hypospadias;
SARC	cis	rs1182180	0.538	rs4722006	chr7:2765723	A/G	cg04166393	chr7:2884313	GNA12	0.37	4.82	0.3	2.54e-6	Platelet count;
SARC	cis	rs2289583	0.503	rs113742359	chr15:75261643	A/G	cg14664628	chr15:75095509	CSK	0.47	5.08	0.32	7.88e-7	Systemic lupus erythematosus;
SARC	cis	rs950169	0.840	rs12905223	chr15:85114268	T/C	cg24253500	chr15:84953950	NA	0.37	5.28	0.33	2.98e-7	Schizophrenia;
SARC	cis	rs2505675	0.961	rs2450300	chr6:2322454	C/T	cg16550324	chr6:2245327	GMDS	0.41	5.06	0.31	8.64e-7	Tuberculosis;
SARC	cis	rs9611519	0.894	rs8136923	chr22:41470522	G/A	cg17376030	chr22:41985996	PMM1	0.5	6.18	0.38	2.77e-9	Neuroticism;
SARC	cis	rs9324022	0.858	rs1004573	chr14:101178235	G/C	cg18089426	chr14:101175970	NA	0.58	5.56	0.34	7.46e-8	Plateletcrit;
SARC	cis	rs763121	0.819	rs6001205	chr22:39100264	T/A	cg21395723	chr22:39101663	GTPBP1	0.52	5.79	0.35	2.25e-8	Menopause (age at onset);
SARC	cis	rs9790314	1.000	rs975323	chr3:161021322	A/G	cg03342759	chr3:160939853	NMD3	-0.59	-7.36	-0.43	3.23e-12	Morning vs. evening chronotype;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg21490179	chr3:40494492	NA	0.56	7.56	0.44	9.18e-13	Lung adenocarcinoma;
SARC	cis	rs5753618	0.583	rs2273251	chr22:31843567	G/C	cg02404636	chr22:31891804	SFI1	0.49	5.19	0.32	4.5e-7	Colorectal cancer;
SARC	cis	rs9513627	0.915	rs9585070	chr13:100118843	G/C	cg25919922	chr13:100150906	NA	-0.75	-5.5	-0.34	1.01e-7	Obesity-related traits;
SARC	cis	rs57994353	0.793	rs33982662	chr9:139324737	C/A	cg14169450	chr9:139327907	INPP5E	0.43	5.56	0.34	7.52e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs8141529	0.529	rs2236141	chr22:29137870	C/T	cg02153584	chr22:29168773	CCDC117	0.63	6.28	0.38	1.65e-9	Lymphocyte counts;
SARC	cis	rs425277	0.917	rs78395918	chr1:2045876	G/A	cg21442419	chr1:2182373	SKI	-0.48	-5.8	-0.36	2.09e-8	Height;
SARC	cis	rs4268898	0.722	rs6723257	chr2:24391129	A/G	cg26838691	chr2:24397539	C2orf84	0.43	5.77	0.35	2.57e-8	Asthma;
SARC	cis	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg05623727	chr3:50126028	RBM5	-0.34	-5.19	-0.32	4.52e-7	Intelligence (multi-trait analysis);
SARC	cis	rs11098499	0.863	rs2306457	chr4:120472839	T/A	cg24375607	chr4:120327624	NA	0.41	4.78	0.3	3.14e-6	Corneal astigmatism;
SARC	cis	rs7626444	0.625	rs1486358	chr3:196485590	T/C	cg12930392	chr3:196481615	PAK2	0.25	4.9	0.31	1.79e-6	Monocyte count;
SARC	cis	rs9513593	1.000	rs7331894	chr13:99852952	C/T	cg21788972	chr13:99853209	UBAC2	0.53	5.15	0.32	5.54e-7	Psoriasis;
SARC	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg11644478	chr21:40555479	PSMG1	1.03	14.57	0.69	1.33e-34	Cognitive function;
SARC	cis	rs10860964	0.746	rs10860952	chr12:103576018	G/A	cg11784990	chr12:103218665	NA	-0.31	-4.77	-0.3	3.2e-6	Schizophrenia;
SARC	cis	rs738321	0.794	rs6001026	chr22:38545363	C/T	cg25457927	chr22:38595422	NA	-0.26	-4.79	-0.3	3.02e-6	Breast cancer;
SARC	cis	rs193541	0.632	rs1903260	chr5:122135188	T/C	cg19412675	chr5:122181750	SNX24	0.5	6.56	0.4	3.35e-10	Glucose homeostasis traits;
SARC	cis	rs9682041	1.000	rs15709	chr3:170110529	T/A	cg11886554	chr3:170076028	SKIL	1.04	8.45	0.48	3.27e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg27572855	chr1:25598939	RHD	-0.55	-9.23	-0.52	1.77e-17	Plateletcrit;Mean corpuscular volume;
SARC	cis	rs7312933	0.567	rs11181399	chr12:42666412	G/A	cg19980929	chr12:42632907	YAF2	0.46	6.62	0.4	2.49e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg11766577	chr21:47581405	C21orf56	-0.41	-4.97	-0.31	1.29e-6	Testicular germ cell tumor;
SARC	cis	rs9790314	0.967	rs463928	chr3:161087734	A/T	cg04691961	chr3:161091175	C3orf57	-0.83	-13.29	-0.66	2.28e-30	Morning vs. evening chronotype;
SARC	cis	rs950776	0.616	rs6495307	chr15:78890321	C/T	cg24631222	chr15:78858424	CHRNA5	-0.36	-4.75	-0.3	3.58e-6	Sudden cardiac arrest;
SARC	cis	rs7264396	0.790	rs3787164	chr20:34228866	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.56	5.76	0.35	2.64e-8	Total cholesterol levels;
SARC	cis	rs36051895	0.664	rs10121077	chr9:5098411	G/A	cg02405213	chr9:5042618	JAK2	-0.45	-5.55	-0.34	7.79e-8	Pediatric autoimmune diseases;
SARC	cis	rs2043112	0.867	rs6878291	chr5:39030707	G/A	cg04869206	chr5:39074266	RICTOR	0.47	5.65	0.35	4.69e-8	Obesity-related traits;
SARC	cis	rs6604026	0.656	rs7542608	chr1:93401194	A/G	cg17283838	chr1:93427260	FAM69A	0.41	4.77	0.3	3.25e-6	Multiple sclerosis;
SARC	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg11890956	chr21:40555474	PSMG1	1.17	19.68	0.79	1.83e-51	Cognitive function;
SARC	cis	rs4974559	0.947	rs58750335	chr4:1364764	G/A	cg02980000	chr4:1222292	CTBP1	0.65	4.76	0.3	3.34e-6	Systolic blood pressure;
SARC	cis	rs533123	0.591	rs525672	chr1:29141967	A/G	cg08366446	chr1:29138936	OPRD1	0.79	5.24	0.32	3.61e-7	Schizophrenia;
SARC	cis	rs3087591	0.919	rs2072131	chr17:29559588	G/C	cg24425628	chr17:29625626	OMG;NF1	-0.48	-5.87	-0.36	1.46e-8	Hip circumference;
SARC	cis	rs10464366	0.544	rs12668821	chr7:39167846	T/A	cg15212455	chr7:39170539	POU6F2	0.39	4.96	0.31	1.34e-6	IgG glycosylation;
SARC	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-5.96	-0.36	9.37e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7824557	0.872	rs2572417	chr8:11111462	A/T	cg21775007	chr8:11205619	TDH	-0.48	-6.09	-0.37	4.52e-9	Retinal vascular caliber;
SARC	cis	rs2180341	0.618	rs11154396	chr6:127638911	C/T	cg27446573	chr6:127587934	RNF146	0.68	8.82	0.5	2.74e-16	Breast cancer;
SARC	cis	rs875971	0.825	rs59466412	chr7:65565358	A/G	cg18876405	chr7:65276391	NA	-0.46	-5.18	-0.32	4.7e-7	Aortic root size;
SARC	cis	rs17376456	0.877	rs12716457	chr5:93397627	T/C	cg21475434	chr5:93447410	FAM172A	0.85	7.56	0.44	9.4e-13	Diabetic retinopathy;
SARC	cis	rs35213789	0.760	rs36070993	chr7:69019890	A/C	cg10619644	chr7:69149951	AUTS2	0.39	5.12	0.32	6.42e-7	Childhood ear infection;
SARC	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg22920501	chr2:26401640	FAM59B	0.44	5.49	0.34	1.03e-7	Gut microbiome composition (summer);
SARC	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	13.86	0.67	2.88e-32	Chronic sinus infection;
SARC	cis	rs7666738	0.830	rs6532721	chr4:99048015	G/A	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs898097	0.812	rs55794221	chr17:80849003	G/A	cg20578329	chr17:80767326	TBCD	-0.51	-6.81	-0.41	8.26e-11	Breast cancer;
SARC	cis	rs10979	0.597	rs9496687	chr6:143908815	A/G	cg25407410	chr6:143891975	LOC285740	-0.52	-5.86	-0.36	1.54e-8	Hypospadias;
SARC	cis	rs2180341	0.855	rs9385422	chr6:127716457	C/T	cg27446573	chr6:127587934	RNF146	0.77	10.14	0.55	2.92e-20	Breast cancer;
SARC	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg09263875	chr16:632152	PIGQ	0.55	8.52	0.49	1.98e-15	Height;
SARC	cis	rs735396	0.595	rs2258287	chr12:121454313	G/T	cg02403541	chr12:121454288	C12orf43	0.87	14.12	0.68	4e-33	N-glycan levels;
SARC	cis	rs559928	0.606	rs60394481	chr11:63909035	G/A	cg05555928	chr11:63887634	MACROD1	-0.51	-4.85	-0.3	2.26e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg15541040	chr2:3486749	NA	-0.43	-5.77	-0.35	2.47e-8	Neurofibrillary tangles;
SARC	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg19346786	chr7:2764209	NA	-0.36	-5.37	-0.33	1.89e-7	Height;
SARC	cis	rs4803468	0.934	rs11880674	chr19:41889423	A/T	cg08477640	chr19:41863820	B9D2	0.44	5.66	0.35	4.39e-8	Height;
SARC	cis	rs7555523	0.887	rs2790053	chr1:165737704	C/G	cg24409356	chr1:165738333	TMCO1	0.8	6.87	0.41	5.83e-11	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	cis	rs9916302	0.904	rs8079303	chr17:37530755	G/C	cg00129232	chr17:37814104	STARD3	0.6	7.43	0.44	2.06e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs9987353	0.519	rs13276350	chr8:9063157	T/C	cg08975724	chr8:8085496	FLJ10661	-0.4	-4.73	-0.3	3.91e-6	Recombination measurement;
SARC	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.78	-8.32	-0.48	7.3e-15	Alzheimer's disease;
SARC	cis	rs10840133	1	rs10840133	chr11:8846369	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.38	5.05	0.31	9.01e-7	Reticulocyte fraction of red cells;
SARC	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg24060327	chr5:131705240	SLC22A5	0.48	5.76	0.35	2.58e-8	Acylcarnitine levels;
SARC	cis	rs1023500	0.551	rs2854837	chr22:42458481	G/A	cg04733989	chr22:42467013	NAGA	0.72	9.64	0.53	1.01e-18	Schizophrenia;
SARC	cis	rs2153535	0.580	rs9393016	chr6:8458573	T/A	cg21535247	chr6:8435926	SLC35B3	0.52	6.55	0.39	3.66e-10	Motion sickness;
SARC	cis	rs752010	0.806	rs943375	chr1:42092152	A/G	cg06885757	chr1:42089581	HIVEP3	0.41	6.21	0.38	2.44e-9	Lupus nephritis in systemic lupus erythematosus;
SARC	trans	rs1814175	0.935	rs1827017	chr11:49632592	C/G	cg15704280	chr7:45808275	SEPT13	-0.91	-16.05	-0.72	1.56e-39	Height;
SARC	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg27266027	chr21:40555129	PSMG1	-0.49	-5.44	-0.34	1.33e-7	Cognitive function;
SARC	cis	rs13191362	1.000	rs13220048	chr6:163004325	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.57	5.38	0.33	1.85e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg26338869	chr17:61819248	STRADA	0.79	10.59	0.57	1.19e-21	Prudent dietary pattern;
SARC	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.48	5.86	0.36	1.55e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs2197308	0.692	rs67352173	chr12:37906912	A/T	cg26384229	chr12:38710491	ALG10B	0.88	12.62	0.64	3.66e-28	Morning vs. evening chronotype;
SARC	cis	rs10464366	0.544	rs4355688	chr7:39158402	C/T	cg18850127	chr7:39170497	POU6F2	0.41	5.45	0.34	1.28e-7	IgG glycosylation;
SARC	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg05896524	chr21:47604654	C21orf56	0.55	6.82	0.41	7.66e-11	Testicular germ cell tumor;
SARC	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg13206674	chr6:150067644	NUP43	0.41	5.06	0.31	8.63e-7	Lung cancer;
SARC	cis	rs453301	0.652	rs2043129	chr8:8825504	C/G	cg15556689	chr8:8085844	FLJ10661	0.5	6.03	0.37	6.4e-9	Joint mobility (Beighton score);
SARC	cis	rs7264396	0.635	rs6060660	chr20:34476649	T/C	cg12579300	chr20:34535607	PHF20	-0.42	-4.92	-0.31	1.63e-6	Total cholesterol levels;
SARC	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.46	5.77	0.35	2.54e-8	Gut microbiome composition (summer);
SARC	cis	rs6963495	0.818	rs116457537	chr7:105152072	A/G	cg19920283	chr7:105172520	RINT1	0.63	5.3	0.33	2.75e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs2832077	0.943	rs2832100	chr21:30175628	A/C	cg24692254	chr21:30365293	RNF160	-0.52	-4.99	-0.31	1.2e-6	Cognitive test performance;
SARC	cis	rs7808935	0.628	rs62451116	chr7:27938980	A/G	cg05786569	chr7:27702416	HIBADH	0.74	8.0	0.46	5.77e-14	Prostate cancer;
SARC	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg12756686	chr19:29218302	NA	0.69	8.93	0.51	1.28e-16	Methadone dose in opioid dependence;
SARC	cis	rs4713118	0.786	rs200502	chr6:27788062	C/T	cg17221315	chr6:27791827	HIST1H4J	0.55	5.96	0.36	9.09e-9	Parkinson's disease;
SARC	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg11764359	chr7:65958608	NA	0.88	12.59	0.64	4.36e-28	Aortic root size;
SARC	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg25072359	chr17:41440525	NA	0.51	6.08	0.37	4.92e-9	Menopause (age at onset);
SARC	cis	rs7666738	0.761	rs1456210	chr4:98645932	T/G	cg05340658	chr4:99064831	C4orf37	0.63	8.08	0.47	3.52e-14	Colonoscopy-negative controls vs population controls;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24341556	chr1:110881868	RBM15	-0.51	-6.35	-0.38	1.14e-9	Smoking initiation;
SARC	cis	rs7552404	0.924	rs2153126	chr1:76199345	C/G	cg10523679	chr1:76189770	ACADM	0.51	7.07	0.42	1.75e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs4742903	0.935	rs10116938	chr9:106977255	T/G	cg14250997	chr9:106856677	SMC2	0.4	5.02	0.31	1.02e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg11905131	chr22:24372483	LOC391322	0.43	4.99	0.31	1.17e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7208859	0.673	rs75142521	chr17:29240537	G/A	cg13385521	chr17:29058706	SUZ12P	0.89	7.09	0.42	1.63e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs763121	0.853	rs2281020	chr22:39064406	A/G	cg21395723	chr22:39101663	GTPBP1	0.54	6.03	0.37	6.24e-9	Menopause (age at onset);
SARC	cis	rs73001065	0.636	rs8182472	chr19:19539891	A/G	cg03709012	chr19:19516395	GATAD2A	1.0	7.45	0.44	1.87e-12	LDL cholesterol;
SARC	cis	rs892961	0.836	rs8071497	chr17:75414358	T/C	cg05865280	chr17:75406074	SEPT9	0.56	8.25	0.48	1.14e-14	Airflow obstruction;
SARC	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg09359103	chr1:154839909	KCNN3	0.44	7.48	0.44	1.5e-12	Prostate cancer;
SARC	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg05313129	chr8:58192883	C8orf71	-0.48	-5.72	-0.35	3.18e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg18404041	chr3:52824283	ITIH1	-0.43	-6.57	-0.4	3.33e-10	Bipolar disorder;
SARC	cis	rs721399	1.000	rs11787313	chr8:18260026	G/C	cg18736775	chr8:18248649	NAT2	0.43	5.7	0.35	3.57e-8	Blood metabolite levels;
SARC	cis	rs79149102	0.579	rs2304904	chr15:75315975	G/A	cg17294928	chr15:75287854	SCAMP5	-1.12	-9.16	-0.51	2.78e-17	Lung cancer;
SARC	cis	rs55871839	0.619	rs6471756	chr8:59802159	A/G	cg07426533	chr8:59803705	TOX	-0.43	-5.7	-0.35	3.55e-8	Pneumonia;
SARC	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg05872129	chr22:39784769	NA	-0.41	-5.54	-0.34	8.28e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.43	0.39	7.26e-10	Height;
SARC	cis	rs67311347	1.000	rs4973878	chr3:40407565	C/T	cg09455208	chr3:40491958	NA	0.4	6.31	0.38	1.36e-9	Renal cell carcinoma;
SARC	cis	rs2235642	0.750	rs2859310	chr16:1656765	C/T	cg03715980	chr16:1756201	MAPK8IP3	-0.39	-4.81	-0.3	2.74e-6	Coronary artery disease;
SARC	cis	rs634534	0.591	rs688862	chr11:65733393	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.69	9.5	0.53	2.65e-18	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg11987759	chr7:65425863	GUSB	-0.51	-6.69	-0.4	1.68e-10	Aortic root size;
SARC	cis	rs5167	0.504	rs4803779	chr19:45456497	T/C	cg13119609	chr19:45449297	APOC2	0.5	8.44	0.48	3.42e-15	Blood protein levels;
SARC	cis	rs7772486	0.534	rs34541797	chr6:146205304	A/G	cg05347473	chr6:146136440	FBXO30	0.72	9.95	0.55	1.18e-19	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1728785	1.000	rs7196104	chr16:68579746	C/A	cg02972257	chr16:68554789	NA	-0.43	-5.01	-0.31	1.08e-6	Ulcerative colitis;
SARC	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg13939156	chr17:80058883	NA	0.4	6.25	0.38	1.92e-9	Life satisfaction;
SARC	trans	rs116095464	0.558	rs10055993	chr5:264296	A/C	cg00938859	chr5:1591904	SDHAP3	0.76	6.24	0.38	2.07e-9	Breast cancer;
SARC	cis	rs7582720	1.000	rs72934556	chr2:203990789	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.34	0.43	3.6e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs4141404	0.851	rs5997893	chr22:31556103	A/G	cg13145458	chr22:31556086	RNF185	0.53	6.49	0.39	5.11e-10	Paclitaxel-induced neuropathy;
SARC	cis	rs10870270	0.956	rs7894	chr10:133769482	G/C	cg26149184	chr10:133730230	NA	0.46	5.05	0.31	9e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs9420	0.961	rs79260745	chr11:57612960	T/C	cg23127183	chr11:57508653	C11orf31	-0.58	-6.76	-0.4	1.09e-10	Schizophrenia;
SARC	cis	rs34172651	0.917	rs11642302	chr16:24770856	G/A	cg00339695	chr16:24857497	SLC5A11	0.28	4.74	0.3	3.77e-6	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg12463550	chr7:65579703	CRCP	-0.49	-5.28	-0.33	2.93e-7	Aortic root size;
SARC	cis	rs7666738	0.830	rs4699577	chr4:98846513	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.77	0.5	3.87e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg06212747	chr3:49208901	KLHDC8B	0.7	9.51	0.53	2.48e-18	Parkinson's disease;
SARC	cis	rs2115536	0.640	rs934134	chr15:80168218	T/C	cg00225070	chr15:80189496	MTHFS	0.52	6.72	0.4	1.34e-10	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
SARC	cis	rs10782582	0.593	rs4638068	chr1:76161663	G/A	cg03433033	chr1:76189801	ACADM	-0.42	-5.43	-0.33	1.44e-7	Daytime sleep phenotypes;
SARC	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg11764359	chr7:65958608	NA	0.56	6.55	0.39	3.64e-10	Aortic root size;
SARC	cis	rs763121	0.744	rs5757140	chr22:38957013	T/C	cg14440974	chr22:39074834	NA	-0.32	-4.73	-0.3	3.95e-6	Menopause (age at onset);
SARC	cis	rs7223966	0.960	rs2319990	chr17:61705397	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.44	5.03	0.31	9.86e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs861020	0.710	rs7516902	chr1:210022179	A/G	cg23166289	chr1:210001082	C1orf107	0.51	5.4	0.33	1.62e-7	Orofacial clefts;
SARC	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg22920501	chr2:26401640	FAM59B	0.57	7.06	0.42	1.93e-11	Gut microbiome composition (summer);
SARC	cis	rs2242116	0.796	rs4683297	chr3:46973673	T/C	cg02527881	chr3:46936655	PTH1R	0.37	5.73	0.35	3.15e-8	Birth weight;
SARC	cis	rs921968	0.510	rs591573	chr2:219478193	C/T	cg02176678	chr2:219576539	TTLL4	0.46	6.88	0.41	5.57e-11	Mean corpuscular hemoglobin concentration;
SARC	cis	rs7659604	0.502	rs13104233	chr4:122672473	T/C	cg19671926	chr4:122722719	EXOSC9	0.54	6.88	0.41	5.46e-11	Type 2 diabetes;
SARC	cis	rs477692	0.673	rs556253	chr10:131355781	G/A	cg05714579	chr10:131428358	MGMT	0.55	7.11	0.42	1.42e-11	Response to temozolomide;
SARC	cis	rs2180341	0.814	rs7768435	chr6:127737038	A/C	cg24812749	chr6:127587940	RNF146	0.78	9.92	0.55	1.39e-19	Breast cancer;
SARC	cis	rs3733585	0.657	rs62286568	chr4:10124889	C/T	cg00071950	chr4:10020882	SLC2A9	-0.38	-5.41	-0.33	1.58e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg14343924	chr8:8086146	FLJ10661	0.4	4.91	0.31	1.73e-6	Mood instability;
SARC	cis	rs2562456	0.833	rs2562487	chr19:21651382	C/T	cg00806126	chr19:22604979	ZNF98	-0.46	-4.8	-0.3	2.88e-6	Pain;
SARC	cis	rs8077889	0.871	rs17675370	chr17:41900030	T/C	cg26893861	chr17:41843967	DUSP3	0.92	11.34	0.6	4.92e-24	Triglycerides;
SARC	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg11764359	chr7:65958608	NA	0.65	7.59	0.45	7.45e-13	Aortic root size;
SARC	cis	rs1707322	1.000	rs946524	chr1:46487560	A/G	cg03146154	chr1:46216737	IPP	-0.46	-5.59	-0.34	6.36e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg17497419	chr2:24346215	PFN4;LOC375190	-0.54	-6.77	-0.41	1.05e-10	Schizophrenia;
SARC	cis	rs55823223	0.564	rs9894009	chr17:73850414	C/T	cg10935138	chr17:73851978	WBP2	0.47	5.29	0.33	2.76e-7	Psoriasis;
SARC	cis	rs875971	0.545	rs10950036	chr7:65818228	G/T	cg11764359	chr7:65958608	NA	0.65	6.4	0.39	8.35e-10	Aortic root size;
SARC	cis	rs933688	0.532	rs13164949	chr5:90538489	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.47	-5.47	-0.34	1.15e-7	Smoking behavior;
SARC	cis	rs9902453	0.765	rs2127001	chr17:28098219	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.11	-0.42	1.42e-11	Coffee consumption (cups per day);
SARC	cis	rs4148883	0.645	rs1154404	chr4:100009004	A/T	cg12011299	chr4:100065546	ADH4	0.37	6.76	0.4	1.12e-10	Alcohol dependence;
SARC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg25703541	chr22:24373054	LOC391322	-0.84	-12.36	-0.63	2.6e-27	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs3219474	0.505	rs487174	chr1:46009536	C/T	cg24296786	chr1:45957014	TESK2	-0.63	-4.72	-0.3	4.06e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs8014204	0.935	rs3742786	chr14:75373011	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.74	-11.02	-0.59	5.32e-23	Caffeine consumption;
SARC	cis	rs6964587	0.934	rs12531561	chr7:91707780	A/G	cg17063962	chr7:91808500	NA	0.96	16.21	0.73	4.6e-40	Breast cancer;
SARC	cis	rs11785400	0.793	rs4371985	chr8:143737279	C/T	cg10596483	chr8:143751796	JRK	0.52	6.51	0.39	4.61e-10	Schizophrenia;
SARC	cis	rs708547	1.000	rs10003229	chr4:57809598	A/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.61	-6.5	-0.39	4.77e-10	Response to bleomycin (chromatid breaks);
SARC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg11494091	chr17:61959527	GH2	0.55	8.29	0.48	9.05e-15	Prudent dietary pattern;
SARC	cis	rs6089584	0.546	rs6089308	chr20:60583529	C/T	cg13770153	chr20:60521292	NA	-0.42	-6.24	-0.38	2.07e-9	Body mass index;
SARC	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg21724239	chr8:58056113	NA	0.6	6.27	0.38	1.72e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg18252515	chr7:66147081	NA	-1.43	-12.98	-0.65	2.35e-29	Gout;
SARC	cis	rs4689388	0.856	rs1046314	chr4:6303955	A/G	cg00701064	chr4:6280414	WFS1	-0.57	-9.37	-0.52	6.38e-18	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg19680485	chr15:31195859	MTMR15	-0.59	-6.74	-0.4	1.25e-10	Huntington's disease progression;
SARC	trans	rs1814175	0.511	rs61905634	chr11:49819736	G/A	cg15704280	chr7:45808275	SEPT13	-0.97	-17.66	-0.76	7.4e-45	Height;
SARC	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg09323728	chr8:95962352	TP53INP1	-0.29	-4.91	-0.31	1.72e-6	Type 2 diabetes;
SARC	cis	rs4780401	0.933	rs4584833	chr16:11798758	C/T	cg01061890	chr16:11836724	TXNDC11	-0.5	-6.49	-0.39	5.19e-10	Rheumatoid arthritis;
SARC	cis	rs9462027	0.628	rs10947531	chr6:34765118	A/C	cg07306190	chr6:34760872	UHRF1BP1	0.41	5.84	0.36	1.76e-8	Systemic lupus erythematosus;
SARC	cis	rs981844	0.848	rs72731652	chr4:154641123	A/T	cg14289246	chr4:154710475	SFRP2	0.49	5.38	0.33	1.81e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	-0.9	-10.6	-0.57	1.13e-21	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg17221315	chr6:27791827	HIST1H4J	0.47	4.81	0.3	2.76e-6	Depression;
SARC	cis	rs16976116	0.851	rs11855907	chr15:55494634	A/C	cg17854078	chr15:55489399	RSL24D1	0.66	6.53	0.39	4.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs11630290	0.592	rs12232336	chr15:64153357	T/C	cg12036633	chr15:63758958	NA	0.47	4.9	0.31	1.77e-6	Iris characteristics;
SARC	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg16479474	chr6:28041457	NA	0.37	5.35	0.33	2.08e-7	Parkinson's disease;
SARC	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg03806693	chr22:41940476	POLR3H	0.91	11.59	0.6	8.02e-25	Vitiligo;
SARC	cis	rs9790314	1.000	rs7647327	chr3:161016421	T/C	cg03342759	chr3:160939853	NMD3	-0.59	-7.41	-0.44	2.34e-12	Morning vs. evening chronotype;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg20021244	chr5:139944115	APBB3;SLC35A4	0.52	6.49	0.39	5.12e-10	Breast cancer;
SARC	cis	rs9747201	1.000	rs56051385	chr17:80126712	T/C	cg17462356	chr17:80056334	FASN	0.47	5.39	0.33	1.71e-7	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.55	7.1	0.42	1.5e-11	Personality dimensions;
SARC	cis	rs17666538	0.636	rs62486234	chr8:589157	G/T	cg07234876	chr8:600039	NA	-0.64	-5.56	-0.34	7.27e-8	IgG glycosylation;
SARC	cis	rs6665290	0.935	rs1929862	chr1:227199718	G/A	cg14016676	chr1:227182615	CDC42BPA	0.36	5.28	0.33	2.92e-7	Myeloid white cell count;
SARC	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg12463550	chr7:65579703	CRCP	0.65	5.04	0.31	9.53e-7	Diabetic kidney disease;
SARC	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg03433033	chr1:76189801	ACADM	0.57	8.0	0.46	5.87e-14	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs113835537	0.935	rs57043177	chr11:66423147	A/G	cg24851651	chr11:66362959	CCS	0.48	5.17	0.32	5.15e-7	Airway imaging phenotypes;
SARC	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-5.61	-0.35	5.58e-8	Bipolar disorder;
SARC	cis	rs7659604	0.521	rs4833773	chr4:122689245	C/T	cg19671926	chr4:122722719	EXOSC9	0.66	8.64	0.49	9.06e-16	Type 2 diabetes;
SARC	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg11890956	chr21:40555474	PSMG1	1.18	19.81	0.79	6.98e-52	Cognitive function;
SARC	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg22105103	chr4:187893119	NA	-0.47	-6.43	-0.39	6.96e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11723261	0.582	rs11732336	chr4:140512	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.36	4.72	0.3	4.03e-6	Immune response to smallpox vaccine (IL-6);
SARC	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9296092	0.517	rs76361685	chr6:33536458	G/C	cg13560919	chr6:33536144	NA	-0.54	-6.3	-0.38	1.43e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs796364	0.715	rs77089299	chr2:201116853	A/G	cg23649088	chr2:200775458	C2orf69	-0.63	-4.75	-0.3	3.52e-6	Schizophrenia;
SARC	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg22105103	chr4:187893119	NA	0.5	6.47	0.39	5.84e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs765787	0.530	rs4775834	chr15:45537511	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.67e-7	Uric acid levels;
SARC	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg18876405	chr7:65276391	NA	-0.46	-5.44	-0.34	1.35e-7	Aortic root size;
SARC	cis	rs4481887	0.893	rs11204632	chr1:248479532	G/A	cg13385794	chr1:248469461	NA	0.34	5.09	0.32	7.38e-7	Common traits (Other);
SARC	cis	rs3741404	0.609	rs592271	chr11:63872029	G/T	cg04317338	chr11:64019027	PLCB3	0.48	5.52	0.34	9.17e-8	Platelet count;
SARC	cis	rs7647973	1.000	rs9860055	chr3:49506900	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.56	-5.94	-0.36	1.03e-8	Menarche (age at onset);
SARC	cis	rs4714291	1.000	rs6917453	chr6:39992386	A/G	cg09256477	chr6:40556568	LRFN2	0.28	4.92	0.31	1.63e-6	Strep throat;
SARC	cis	rs6594499	0.872	rs10038177	chr5:110436450	C/T	cg04022379	chr5:110408740	TSLP	0.45	5.62	0.35	5.39e-8	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs9393692	0.902	rs6456711	chr6:26302572	A/C	cg05868516	chr6:26286170	HIST1H4H	0.53	6.61	0.4	2.6200000000000003e-10	Educational attainment;
SARC	cis	rs1559088	0.600	rs7255229	chr19:33562807	A/G	cg17764715	chr19:33622953	WDR88	0.58	7.88	0.46	1.26e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg06138931	chr13:21896616	NA	0.34	4.94	0.31	1.49e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs55794721	0.509	rs12027110	chr1:25775682	A/T	cg02931644	chr1:25747376	RHCE	0.43	6.98	0.42	3.11e-11	Plateletcrit;Mean corpuscular volume;
SARC	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg01316550	chr5:56110833	MAP3K1	0.54	4.95	0.31	1.39e-6	Initial pursuit acceleration;
SARC	cis	rs9911578	1.000	rs1971659	chr17:57004787	A/G	cg12560992	chr17:57184187	TRIM37	0.85	11.7	0.61	3.63e-25	Intelligence (multi-trait analysis);
SARC	cis	rs995000	0.899	rs10889337	chr1:62980607	G/A	cg06896770	chr1:63153194	DOCK7	0.93	13.69	0.67	1.09e-31	Triglyceride levels;
SARC	cis	rs7586879	0.616	rs916485	chr2:25082273	T/C	cg04586622	chr2:25135609	ADCY3	0.32	5.31	0.33	2.58e-7	Body mass index;
SARC	cis	rs11170631	0.504	rs10128880	chr12:53927783	T/C	cg06632207	chr12:54070931	ATP5G2	0.56	7.77	0.45	2.44e-13	Height;
SARC	cis	rs2439831	0.850	rs8023458	chr15:44080939	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	7.7	0.45	3.96e-13	Lung cancer in ever smokers;
SARC	cis	rs765787	0.530	rs1706837	chr15:45519036	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.43	-5.28	-0.33	2.99e-7	Uric acid levels;
SARC	trans	rs61931739	0.500	rs2389269	chr12:34034179	C/T	cg26384229	chr12:38710491	ALG10B	0.86	12.44	0.63	1.4e-27	Morning vs. evening chronotype;
SARC	cis	rs2439831	0.850	rs11856795	chr15:44160582	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.93	8.14	0.47	2.39e-14	Lung cancer in ever smokers;
SARC	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg04267008	chr7:1944627	MAD1L1	-0.51	-5.8	-0.36	2.12e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs4601821	1.000	rs6589375	chr11:113255111	C/A	cg14159747	chr11:113255604	NA	0.37	4.85	0.3	2.24e-6	Alcoholic chronic pancreatitis;
SARC	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.95	-13.96	-0.67	1.32e-32	Gut microbiome composition (summer);
SARC	cis	rs4555082	0.830	rs3803319	chr14:105752458	G/A	cg06808227	chr14:105710500	BRF1	-0.51	-6.45	-0.39	6.3e-10	Mean platelet volume;Platelet distribution width;
SARC	cis	rs28655083	1.000	rs8059347	chr16:77068259	C/T	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.46	-6.47	-0.39	5.68e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg26818010	chr10:134567672	INPP5A	-0.65	-6.92	-0.41	4.21e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg18135555	chr8:22132992	PIWIL2	0.36	5.25	0.33	3.35e-7	Hypertriglyceridemia;
SARC	cis	rs4234284	0.556	rs7650549	chr3:126968288	C/T	cg27326032	chr3:127006922	NA	-0.52	-6.0	-0.37	7.58e-9	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
SARC	cis	rs7681440	0.835	rs7668531	chr4:90791819	G/T	cg02192967	chr4:90758406	SNCA	0.37	5.14	0.32	5.79e-7	Dementia with Lewy bodies;
SARC	cis	rs13191362	0.872	rs36069443	chr6:163248701	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.63	6.04	0.37	6e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs9309473	0.950	rs6546854	chr2:73834034	A/G	cg20560298	chr2:73613845	ALMS1	-0.49	-5.85	-0.36	1.64e-8	Metabolite levels;
SARC	cis	rs9486719	1.000	rs2263192	chr6:96873037	C/G	cg06623918	chr6:96969491	KIAA0776	0.73	8.01	0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs9581943	0.967	rs9579128	chr13:28481938	A/G	cg16302790	chr13:28498334	PDX1	0.54	8.07	0.47	3.8e-14	Pancreatic cancer;
SARC	cis	rs3812831	0.654	rs367312	chr13:114930195	G/A	cg22348356	chr13:114891224	RASA3	0.36	5.13	0.32	6.02e-7	Schizophrenia;
SARC	cis	rs10779751	0.770	rs1148480	chr1:11172006	A/G	cg08854313	chr1:11322531	MTOR	0.9	13.37	0.66	1.24e-30	Body mass index;
SARC	cis	rs4927850	1.000	rs4927848	chr3:195738406	A/G	cg12696929	chr3:195401817	SDHAP2	0.39	5.09	0.32	7.38e-7	Pancreatic cancer;
SARC	cis	rs920590	0.721	rs67989257	chr8:19660278	G/A	cg17834443	chr8:19674713	INTS10	0.58	6.97	0.42	3.2e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs7829975	0.508	rs1594437	chr8:8825875	T/C	cg11608241	chr8:8085544	FLJ10661	0.42	4.89	0.31	1.84e-6	Mood instability;
SARC	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg08048268	chr3:133502702	NA	-0.43	-5.86	-0.36	1.54e-8	Iron status biomarkers;
SARC	cis	rs34172651	0.917	rs200533	chr16:24754771	C/T	cg00339695	chr16:24857497	SLC5A11	-0.29	-4.9	-0.31	1.77e-6	Intelligence (multi-trait analysis);
SARC	cis	rs8028182	0.636	rs4564532	chr15:75706296	C/G	cg20655648	chr15:75932815	IMP3	0.63	7.52	0.44	1.2e-12	Sudden cardiac arrest;
SARC	cis	rs738322	0.935	rs133014	chr22:38571087	T/G	cg25457927	chr22:38595422	NA	-0.29	-5.95	-0.36	9.77e-9	Cutaneous nevi;
SARC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg06873352	chr17:61820015	STRADA	-0.47	-6.16	-0.37	3.14e-9	Prudent dietary pattern;
SARC	cis	rs644799	1.000	rs596277	chr11:95566886	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.66	8.88	0.5	1.8e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2760061	0.626	rs594916	chr1:228133544	C/A	cg02753203	chr1:228287806	NA	-0.54	-7.49	-0.44	1.4e-12	Diastolic blood pressure;
SARC	cis	rs7786877	0.723	rs10487157	chr7:100214487	C/G	cg16850897	chr7:100343110	ZAN	-0.58	-5.71	-0.35	3.35e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg26063862	chr1:21023254	KIF17	-0.47	-6.43	-0.39	7.23e-10	Neuroticism;
SARC	cis	rs1538970	0.816	rs11211123	chr1:45957609	G/A	cg05343316	chr1:45956843	TESK2	0.82	8.79	0.5	3.28e-16	Platelet count;
SARC	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg21724239	chr8:58056113	NA	0.58	6.14	0.37	3.49e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4851254	0.961	rs6713524	chr2:100747357	A/G	cg17356467	chr2:100759845	AFF3	0.3	5.08	0.32	7.68e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2204008	0.805	rs11514348	chr12:38243427	T/C	cg26384229	chr12:38710491	ALG10B	0.91	13.64	0.67	1.61e-31	Bladder cancer;
SARC	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg17376030	chr22:41985996	PMM1	-0.69	-8.72	-0.5	5.23e-16	Vitiligo;
SARC	cis	rs2180341	0.618	rs12199451	chr6:127597780	C/G	cg24812749	chr6:127587940	RNF146	0.52	6.11	0.37	4.2e-9	Breast cancer;
SARC	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg23172400	chr8:95962367	TP53INP1	-0.31	-5.36	-0.33	2.02e-7	Type 2 diabetes;
SARC	cis	rs3126085	0.877	rs1552996	chr1:152171104	C/A	cg03465714	chr1:152285911	FLG	-0.47	-5.56	-0.34	7.45e-8	Atopic dermatitis;
SARC	cis	rs9790314	0.690	rs1599389	chr3:160836006	G/A	cg04691961	chr3:161091175	C3orf57	-0.56	-7.35	-0.43	3.29e-12	Morning vs. evening chronotype;
SARC	cis	rs1062177	1.000	rs2915887	chr5:151205504	C/T	cg00977110	chr5:151150581	G3BP1	0.57	5.67	0.35	4.17e-8	Preschool internalizing problems;
SARC	cis	rs2227631	0.505	rs6955537	chr7:100759727	A/G	cg18465962	chr7:100767262	NA	-0.58	-7.79	-0.45	2.23e-13	Plasminogen activator inhibitor type 1 levels (PAI-1);
SARC	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg00684032	chr4:1343700	KIAA1530	0.37	5.34	0.33	2.23e-7	Obesity-related traits;
SARC	cis	rs7666738	0.830	rs7691433	chr4:98968118	A/T	cg05340658	chr4:99064831	C4orf37	0.66	8.61	0.49	1.1e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs910316	1.000	rs7147118	chr14:75610170	G/C	cg23033748	chr14:75592666	NEK9	0.38	5.43	0.33	1.44e-7	Height;
SARC	cis	rs9916302	0.718	rs7219909	chr17:37706243	C/T	cg15445000	chr17:37608096	MED1	0.42	4.91	0.31	1.68e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs738322	0.967	rs4385	chr22:38573229	T/C	cg25457927	chr22:38595422	NA	-0.29	-5.96	-0.36	9.03e-9	Cutaneous nevi;
SARC	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg15595755	chr5:1867978	NA	0.44	6.25	0.38	1.88e-9	Cardiovascular disease risk factors;
SARC	cis	rs739401	0.572	rs389285	chr11:3062673	G/A	cg05729581	chr11:3078854	CARS	-0.48	-6.25	-0.38	1.94e-9	Longevity;
SARC	cis	rs8114671	0.586	rs6087634	chr20:33413809	G/A	cg07148914	chr20:33460835	GGT7	0.42	5.02	0.31	1.02e-6	Height;
SARC	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg03354898	chr7:1950403	MAD1L1	-0.35	-4.72	-0.3	4.1e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs7223966	0.961	rs35844156	chr17:61837568	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.52	-5.38	-0.33	1.83e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6545883	0.860	rs6545847	chr2:61445333	C/T	cg15711740	chr2:61764176	XPO1	0.4	4.85	0.3	2.28e-6	Tuberculosis;
SARC	cis	rs6594499	0.542	rs7722241	chr5:110460747	T/A	cg04022379	chr5:110408740	TSLP	0.58	7.83	0.46	1.69e-13	Allergic disease (asthma, hay fever or eczema);
SARC	trans	rs1814175	0.791	rs1722023	chr11:49908136	G/C	cg15704280	chr7:45808275	SEPT13	-0.98	-18.28	-0.77	6.55e-47	Height;
SARC	cis	rs631288	0.557	rs2354434	chr1:146679428	A/G	cg25205988	chr1:146714368	CHD1L	1.08	6.4	0.39	8.34e-10	PR interval in Tripanosoma cruzi seropositivity;
SARC	cis	rs6568686	0.627	rs174374	chr6:111906055	A/G	cg15721981	chr6:111408429	SLC16A10	0.59	5.31	0.33	2.62e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-7.83	-0.46	1.71e-13	Alzheimer's disease;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg23935746	chr5:68463041	CCNB1	0.56	6.89	0.41	5.11e-11	Blood pressure;
SARC	cis	rs6570726	0.599	rs9403725	chr6:145897622	A/T	cg23711669	chr6:146136114	FBXO30	-0.73	-9.38	-0.52	6e-18	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6700896	0.897	rs11208701	chr1:66134698	C/T	cg04111102	chr1:66153794	NA	0.36	5.66	0.35	4.49e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs7917772	0.636	rs7897384	chr10:104529042	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-6.35	-0.38	1.1e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg24675658	chr1:53192096	ZYG11B	-0.56	-7.7	-0.45	3.92e-13	Monocyte count;
SARC	cis	rs9796	0.649	rs8035828	chr15:41467287	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.55	-7.73	-0.45	3.19e-13	Menopause (age at onset);
SARC	cis	rs4243830	0.850	rs4908904	chr1:6580250	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.79	8.19	0.47	1.77e-14	Body mass index;
SARC	cis	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg15556689	chr8:8085844	FLJ10661	0.62	7.81	0.46	1.96e-13	Systolic blood pressure;
SARC	cis	rs933688	1.000	rs1895448	chr5:90743854	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.99	12.79	0.64	1e-28	Smoking behavior;
SARC	cis	rs10131894	0.611	rs175000	chr14:75436367	T/C	cg08847533	chr14:75593920	NEK9	-0.76	-10.48	-0.57	2.57e-21	Coronary artery disease;
SARC	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg03351412	chr1:154909251	PMVK	0.62	7.85	0.46	1.49e-13	Prostate cancer;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg14705778	chr4:174254825	HMGB2	0.51	6.85	0.41	6.51e-11	Chemerin levels;
SARC	cis	rs9329289	0.550	rs11251294	chr10:2562328	C/T	cg15501526	chr10:2543763	NA	-0.47	-6.84	-0.41	6.9e-11	Age-related hearing impairment;
SARC	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg08859206	chr1:53392774	SCP2	0.48	6.6	0.4	2.68e-10	Monocyte count;
SARC	cis	rs698833	0.886	rs698802	chr2:44697624	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.67	8.27	0.48	1.03e-14	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs9303401	0.659	rs12940212	chr17:56674474	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.08	11.47	0.6	2e-24	Cognitive test performance;
SARC	cis	rs7223966	1.000	rs6504167	chr17:61693194	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-5.95	-0.36	9.67e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2197308	0.765	rs11182964	chr12:37935052	C/T	cg26384229	chr12:38710491	ALG10B	0.9	13.38	0.66	1.18e-30	Morning vs. evening chronotype;
SARC	cis	rs2011503	1.000	rs11670761	chr19:19649327	G/C	cg03709012	chr19:19516395	GATAD2A	0.6	5.29	0.33	2.8e-7	Bipolar disorder;
SARC	cis	rs9467711	0.591	rs28360595	chr6:26030044	A/G	cg21479132	chr6:26055353	NA	0.87	5.8	0.36	2.11e-8	Autism spectrum disorder or schizophrenia;
SARC	cis	rs765787	0.530	rs12904331	chr15:45518293	C/T	cg24006582	chr15:45444508	DUOX1	0.43	5.32	0.33	2.45e-7	Uric acid levels;
SARC	trans	rs61931739	0.500	rs1601628	chr12:34047375	A/C	cg13010199	chr12:38710504	ALG10B	0.67	9.1	0.51	4.09e-17	Morning vs. evening chronotype;
SARC	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg11764359	chr7:65958608	NA	-0.78	-9.57	-0.53	1.69e-18	Aortic root size;
SARC	trans	rs2396442	1.000	rs2256819	chr6:45418402	A/G	cg01345517	chr12:16064533	DERA	-0.57	-6.35	-0.38	1.15e-9	Left ventricle wall thickness;
SARC	cis	rs11249608	0.548	rs6875622	chr5:178451397	C/T	cg21905437	chr5:178450457	ZNF879	0.58	7.92	0.46	9.53e-14	Pubertal anthropometrics;
SARC	cis	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg08045932	chr20:61659980	NA	0.5	6.75	0.4	1.17e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs644799	0.648	rs1255182	chr11:95472391	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.71	9.93	0.55	1.31e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg09373136	chr17:61933544	TCAM1	-0.44	-6.11	-0.37	4.1e-9	Prudent dietary pattern;
SARC	cis	rs7539409	0.651	rs7521788	chr1:84309320	G/T	cg10977910	chr1:84465055	TTLL7	0.63	6.01	0.37	7.13e-9	Alzheimer's disease;
SARC	cis	rs9815354	1.000	rs9852303	chr3:41759525	C/T	cg03022575	chr3:42003672	ULK4	0.55	5.23	0.32	3.75e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs12421382	0.659	rs1371332	chr11:109381687	A/T	cg16359550	chr11:109292809	C11orf87	0.35	4.99	0.31	1.16e-6	Schizophrenia;
SARC	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg00684032	chr4:1343700	KIAA1530	0.36	5.37	0.33	1.94e-7	Obesity-related traits;
SARC	cis	rs12586317	0.582	rs731906	chr14:35604543	C/T	cg26967526	chr14:35346199	BAZ1A	-0.59	-6.02	-0.37	6.59e-9	Psoriasis;
SARC	cis	rs651907	0.557	rs3864012	chr3:101397623	T/C	cg12386194	chr3:101231763	SENP7	0.5	6.13	0.37	3.76e-9	Colorectal cancer;
SARC	cis	rs7607369	0.782	rs514799	chr2:219411203	A/G	cg02176678	chr2:219576539	TTLL4	0.47	7.16	0.42	1.06e-11	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs4595586	0.545	rs11615638	chr12:39364766	A/C	cg13010199	chr12:38710504	ALG10B	0.4	4.75	0.3	3.57e-6	Morning vs. evening chronotype;
SARC	cis	rs7011049	1.000	rs78200075	chr8:53845907	G/A	cg26025543	chr8:53854495	NA	0.6	5.39	0.33	1.73e-7	Systolic blood pressure;
SARC	cis	rs6988636	1.000	rs57322232	chr8:124193532	A/G	cg23067535	chr8:124195133	FAM83A	-0.71	-5.75	-0.35	2.83e-8	Urinary uromodulin levels;
SARC	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg13206674	chr6:150067644	NUP43	0.43	5.61	0.34	5.83e-8	Lung cancer;
SARC	cis	rs4568518	0.903	rs6957876	chr7:18040264	A/G	cg00911873	chr7:18067463	PRPS1L1	0.35	5.12	0.32	6.44e-7	Measles;
SARC	cis	rs2228479	0.850	rs62054224	chr16:89892071	C/T	cg06558623	chr16:89946397	TCF25	0.93	6.63	0.4	2.29e-10	Skin colour saturation;
SARC	cis	rs11585357	0.895	rs72633808	chr1:17618665	A/G	cg08277548	chr1:17600880	PADI3	-0.46	-5.31	-0.33	2.55e-7	Hair shape;
SARC	trans	rs1493916	0.655	rs4534926	chr18:31349072	G/C	cg27147174	chr7:100797783	AP1S1	-0.57	-7.03	-0.42	2.24e-11	Life satisfaction;
SARC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg11494091	chr17:61959527	GH2	0.53	7.94	0.46	8.67e-14	Prudent dietary pattern;
SARC	cis	rs2153535	0.580	rs9505455	chr6:8478622	A/G	cg07606381	chr6:8435919	SLC35B3	0.78	11.13	0.59	2.44e-23	Motion sickness;
SARC	cis	rs10752881	1.000	rs12133714	chr1:182988252	A/G	cg13390022	chr1:182993471	LAMC1	0.35	5.24	0.32	3.63e-7	Colorectal cancer;
SARC	cis	rs943466	1.000	rs11753083	chr6:33761111	C/G	cg04676172	chr6:33757040	LEMD2	0.45	4.77	0.3	3.21e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
SARC	cis	rs12701220	0.503	rs13222294	chr7:1172969	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.37	-4.8	-0.3	2.78e-6	Bronchopulmonary dysplasia;
SARC	cis	rs7772486	0.790	rs2243665	chr6:146208120	A/C	cg05347473	chr6:146136440	FBXO30	0.49	6.47	0.39	5.7e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs763121	0.853	rs5757231	chr22:39071658	C/T	cg14440974	chr22:39074834	NA	0.33	4.83	0.3	2.53e-6	Menopause (age at onset);
SARC	cis	rs7644634	0.559	rs9288815	chr3:105425910	G/T	cg23051926	chr3:105466016	CBLB	0.47	5.33	0.33	2.26e-7	Itch intensity from mosquito bite;
SARC	cis	rs11509153	0.687	rs6974465	chr7:12253178	T/C	cg23422036	chr7:12250390	TMEM106B	0.48	6.22	0.38	2.22e-9	Residual cognition;
SARC	cis	rs10911232	0.507	rs10797829	chr1:183033228	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.72	-10.86	-0.58	1.72e-22	Hypertriglyceridemia;
SARC	cis	rs6060717	0.536	rs17431878	chr20:34502107	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	5.14	0.32	5.79e-7	Hip circumference adjusted for BMI;
SARC	cis	rs12893668	0.645	rs35229468	chr14:104052057	C/T	cg26031613	chr14:104095156	KLC1	-0.58	-6.48	-0.39	5.3e-10	Reticulocyte count;
SARC	cis	rs4803468	0.967	rs11670583	chr19:41920440	A/T	cg14132834	chr19:41945861	ATP5SL	-0.55	-7.19	-0.43	8.79e-12	Height;
SARC	cis	rs3793683	0.965	rs3829131	chr10:134564627	A/G	cg27286337	chr10:134555280	INPP5A	-0.88	-14.77	-0.7	2.7900000000000003e-35	Migraine;
SARC	cis	rs11785693	0.862	rs73183606	chr8:4986999	C/T	cg26367366	chr8:4980734	NA	0.72	6.42	0.39	7.56e-10	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs9325144	0.541	rs7303395	chr12:38664124	C/T	cg26384229	chr12:38710491	ALG10B	-0.63	-8.12	-0.47	2.64e-14	Morning vs. evening chronotype;
SARC	cis	rs11122272	0.733	rs2749700	chr1:231522734	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-9.6	-0.53	1.31e-18	Hemoglobin concentration;
SARC	cis	rs3857067	0.806	rs34396894	chr4:95097600	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.08	-0.32	7.8e-7	QT interval;
SARC	cis	rs11190604	1.000	rs7070776	chr10:102264672	A/G	cg14256752	chr10:102295592	HIF1AN	0.42	4.77	0.3	3.2e-6	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	10.04	0.55	6.12e-20	Platelet count;
SARC	cis	rs938554	0.744	rs6449137	chr4:9932479	A/T	cg25986240	chr4:9926439	SLC2A9	0.3	4.9	0.31	1.76e-6	Blood metabolite levels;
SARC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg02725872	chr8:58115012	NA	-0.37	-6.55	-0.39	3.71e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1707322	1.000	rs10890372	chr1:46391020	T/G	cg06784218	chr1:46089804	CCDC17	0.34	5.97	0.36	8.8e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs35110281	0.616	rs2236666	chr21:45109856	T/C	cg04455712	chr21:45112962	RRP1B	0.35	4.93	0.31	1.55e-6	Mean corpuscular volume;
SARC	cis	rs7927771	0.826	rs2293578	chr11:47437403	C/T	cg05585544	chr11:47624801	NA	-0.37	-4.95	-0.31	1.43e-6	Subjective well-being;
SARC	cis	rs7666738	0.830	rs28867087	chr4:98880349	T/A	cg05340658	chr4:99064831	C4orf37	0.65	8.72	0.5	5.23e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7084402	0.902	rs1649016	chr10:60288540	T/A	cg07615347	chr10:60278583	BICC1	0.6	8.86	0.5	2.16e-16	Refractive error;
SARC	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg16405210	chr4:1374714	KIAA1530	-0.51	-6.1	-0.37	4.41e-9	Obesity-related traits;
SARC	cis	rs12586317	0.883	rs4982254	chr14:35755737	C/T	cg26967526	chr14:35346199	BAZ1A	-0.51	-5.34	-0.33	2.19e-7	Psoriasis;
SARC	cis	rs8141529	0.702	rs5762870	chr22:29261159	C/T	cg15103426	chr22:29168792	CCDC117	0.68	8.95	0.51	1.18e-16	Lymphocyte counts;
SARC	cis	rs2120243	0.539	rs6441128	chr3:157121258	A/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.43	5.49	0.34	1.05e-7	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg21724239	chr8:58056113	NA	0.6	6.34	0.38	1.17e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7223966	1.000	rs7220821	chr17:61704147	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.56	-6.52	-0.39	4.4e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs3857536	0.904	rs9345778	chr6:66899971	G/T	cg07460842	chr6:66804631	NA	-0.44	-5.26	-0.33	3.22e-7	Blood trace element (Cu levels);
SARC	cis	rs12540874	0.698	rs3823674	chr7:50571996	C/T	cg18232548	chr7:50535776	DDC	-0.4	-4.78	-0.3	3.13e-6	Systemic sclerosis;
SARC	cis	rs10754283	0.967	rs4658307	chr1:90117586	G/T	cg21401794	chr1:90099060	LRRC8C	0.58	8.04	0.47	4.55e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs4595586	0.525	rs12812749	chr12:39363254	C/T	cg26384229	chr12:38710491	ALG10B	0.52	6.22	0.38	2.28e-9	Morning vs. evening chronotype;
SARC	cis	rs7520050	0.933	rs12045165	chr1:46256022	C/A	cg24296786	chr1:45957014	TESK2	0.38	4.8	0.3	2.86e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs820218	0.728	rs820148	chr17:73615887	A/G	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.51	6.34	0.38	1.2e-9	Rotator cuff tears;
SARC	trans	rs12310956	0.532	rs2171534	chr12:33838998	C/T	cg26384229	chr12:38710491	ALG10B	0.66	8.53	0.49	1.82e-15	Morning vs. evening chronotype;
SARC	cis	rs7216064	0.700	rs4791295	chr17:65997317	G/A	cg12091567	chr17:66097778	LOC651250	-0.81	-8.73	-0.5	5.05e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs9303401	0.659	rs62083410	chr17:56964386	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	11.27	0.59	8.61e-24	Cognitive test performance;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg22291694	chr6:162294486	PARK2	-0.53	-6.27	-0.38	1.73e-9	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs9911578	0.904	rs7209253	chr17:56908987	C/T	cg05425664	chr17:57184151	TRIM37	-0.64	-7.98	-0.46	6.52e-14	Intelligence (multi-trait analysis);
SARC	cis	rs950880	0.710	rs2080289	chr2:102995020	G/A	cg03938978	chr2:103052716	IL18RAP	-0.34	-4.85	-0.3	2.22e-6	Serum protein levels (sST2);
SARC	cis	rs7843479	0.601	rs4872207	chr8:21842751	C/G	cg17168535	chr8:21777572	XPO7	-0.86	-13.13	-0.65	7.5e-30	Mean corpuscular volume;
SARC	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg15541040	chr2:3486749	NA	-0.44	-5.66	-0.35	4.41e-8	Neurofibrillary tangles;
SARC	cis	rs875971	0.825	rs59466412	chr7:65565358	A/G	cg12463550	chr7:65579703	CRCP	-0.48	-5.26	-0.33	3.28e-7	Aortic root size;
SARC	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg22433210	chr17:43662623	NA	0.99	11.61	0.61	7.1e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs34172651	0.917	rs8049667	chr16:24773524	G/A	cg06028605	chr16:24865363	SLC5A11	0.27	4.74	0.3	3.66e-6	Intelligence (multi-trait analysis);
SARC	cis	rs13256369	1.000	rs10110591	chr8:8576608	G/T	cg18904891	chr8:8559673	CLDN23	-0.5	-5.95	-0.36	9.66e-9	Obesity-related traits;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg10536398	chr20:56935483	RAB22A	0.45	6.25	0.38	1.92e-9	Thyroid stimulating hormone;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg06296570	chr7:130792605	FLJ43663	0.51	6.37	0.39	9.97e-10	Breast cancer;
SARC	cis	rs963731	0.649	rs1869513	chr2:39205315	A/G	cg04010122	chr2:39346883	SOS1	-0.79	-4.91	-0.31	1.75e-6	Corticobasal degeneration;
SARC	cis	rs17376456	0.877	rs9314099	chr5:93447375	T/C	cg21475434	chr5:93447410	FAM172A	0.88	8.11	0.47	2.81e-14	Diabetic retinopathy;
SARC	cis	rs2439831	0.850	rs8042868	chr15:43939642	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	7.97	0.46	7.08e-14	Lung cancer in ever smokers;
SARC	cis	rs6570726	0.764	rs366673	chr6:145814628	T/A	cg05347473	chr6:146136440	FBXO30	0.53	7.35	0.43	3.43e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs35213789	0.762	rs645245	chr7:69162183	A/G	cg10619644	chr7:69149951	AUTS2	-0.36	-4.95	-0.31	1.44e-6	Childhood ear infection;
SARC	cis	rs6867032	0.834	rs4526149	chr5:1990166	G/A	cg26168224	chr5:2018326	NA	-0.65	-8.32	-0.48	7.46e-15	Gut microbiome composition (winter);
SARC	cis	rs3931020	0.688	rs452242	chr1:75225625	G/T	cg10128416	chr1:75198403	TYW3;CRYZ	-0.48	-4.99	-0.31	1.16e-6	Resistin levels;
SARC	cis	rs6570726	0.967	rs450973	chr6:145863065	C/A	cg05347473	chr6:146136440	FBXO30	0.48	6.59	0.4	2.88e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg15145296	chr3:125709740	NA	-0.5	-4.96	-0.31	1.36e-6	Blood pressure (smoking interaction);
SARC	cis	rs7786808	0.544	rs6971888	chr7:158193835	G/A	cg01191920	chr7:158217561	PTPRN2	0.35	5.99	0.37	7.97e-9	Obesity-related traits;
SARC	cis	rs6582630	0.599	rs8175936	chr12:38426315	C/G	cg13010199	chr12:38710504	ALG10B	-0.47	-5.75	-0.35	2.81e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs763121	0.853	rs4820345	chr22:39091151	T/C	cg06022373	chr22:39101656	GTPBP1	0.83	10.15	0.55	2.84e-20	Menopause (age at onset);
SARC	cis	rs73086581	1.000	rs73084594	chr20:3916380	T/G	cg02187196	chr20:3869020	PANK2	0.64	6.17	0.37	3.07e-9	Response to antidepressants in depression;
SARC	cis	rs888194	0.690	rs9593	chr12:109994870	A/T	cg13986417	chr12:110012484	MVK;MMAB	-0.32	-4.84	-0.3	2.4e-6	Neuroticism;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg19285119	chr11:105948212	KBTBD3;AASDHPPT	-0.77	-6.35	-0.38	1.14e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs4253772	0.591	rs6008538	chr22:46685963	G/A	cg24881330	chr22:46731750	TRMU	0.73	7.73	0.45	3.11e-13	LDL cholesterol;Cholesterol, total;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg01936090	chr1:179923733	CEP350	-0.62	-7.13	-0.42	1.27e-11	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs10207060	1.000	rs10207060	chr2:240687289	A/C	cg20333904	chr2:240724165	NA	-0.27	-5.15	-0.32	5.51e-7	Obesity-related traits;
SARC	cis	rs2327429	0.827	rs7752775	chr6:134172346	C/G	cg25632230	chr6:134101081	NA	0.46	5.73	0.35	3.11e-8	Coronary artery disease;
SARC	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg04944784	chr2:26401820	FAM59B	-0.5	-6.37	-0.39	1.01e-9	Gut microbiome composition (summer);
SARC	cis	rs113835537	0.529	rs57634456	chr11:66250838	A/C	cg24851651	chr11:66362959	CCS	0.38	4.76	0.3	3.4e-6	Airway imaging phenotypes;
SARC	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.35	4.81	0.3	2.73e-6	Personality dimensions;
SARC	cis	rs6570726	0.967	rs418662	chr6:145848832	A/C	cg23711669	chr6:146136114	FBXO30	0.74	11.2	0.59	1.38e-23	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6912958	0.712	rs4498321	chr6:88339251	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-6.46	-0.39	6.16e-10	Monocyte percentage of white cells;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg08625590	chr10:20104948	PLXDC2	0.48	6.39	0.39	9.11e-10	Chemerin levels;
SARC	cis	rs2635047	0.530	rs4986228	chr18:44595259	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.46	-5.64	-0.35	5.01e-8	Educational attainment;
SARC	cis	rs4481887	0.741	rs6681758	chr1:248540413	T/A	cg00666640	chr1:248458726	OR2T12	0.34	5.96	0.36	9.33e-9	Common traits (Other);
SARC	cis	rs7666738	0.830	rs3907020	chr4:99038583	T/C	cg05340658	chr4:99064831	C4orf37	0.64	8.6	0.49	1.18e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg03999130	chr15:45571217	NA	0.39	5.09	0.32	7.55e-7	Homoarginine levels;
SARC	cis	rs2814982	0.543	rs75776386	chr6:34465215	G/A	cg14254433	chr6:34482411	PACSIN1	-0.5	-4.74	-0.3	3.75e-6	Cholesterol, total;Total cholesterol levels;
SARC	cis	rs6840360	0.615	rs4696267	chr4:152464500	A/G	cg22705602	chr4:152727874	NA	-0.4	-6.25	-0.38	1.92e-9	Intelligence (multi-trait analysis);
SARC	cis	rs35110281	0.782	rs1454651	chr21:45012476	A/G	cg21573476	chr21:45109991	RRP1B	-0.53	-7.57	-0.44	8.84e-13	Mean corpuscular volume;
SARC	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg19346786	chr7:2764209	NA	0.33	5.0	0.31	1.13e-6	Height;
SARC	cis	rs6088590	1.000	rs6087626	chr20:33347328	C/T	cg24642439	chr20:33292090	TP53INP2	0.88	12.45	0.63	1.26e-27	Coronary artery disease;
SARC	cis	rs6570726	0.791	rs6913727	chr6:145899826	A/G	cg05347473	chr6:146136440	FBXO30	0.51	7.2	0.43	8.39e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2735413	0.881	rs12923218	chr16:78080274	C/G	cg04733911	chr16:78082701	NA	-0.3	-5.47	-0.34	1.14e-7	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg24110177	chr3:50126178	RBM5	-0.4	-5.06	-0.31	8.7e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg07701084	chr6:150067640	NUP43	0.41	5.4	0.33	1.62e-7	Lung cancer;
SARC	cis	rs7833986	1.000	rs34516759	chr8:57097138	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.6	5.33	0.33	2.36e-7	Height;
SARC	cis	rs1046896	1.000	rs28485881	chr17:80690014	G/A	cg02711726	chr17:80685570	FN3KRP	-0.65	-7.8	-0.45	2.13e-13	Glycated hemoglobin levels;
SARC	cis	rs7020830	0.898	rs997318	chr9:37364094	C/T	cg14294708	chr9:37120828	ZCCHC7	1.12	20.17	0.8	5.13e-53	Schizophrenia;
SARC	cis	rs11581859	0.613	rs12738955	chr1:99199457	G/A	cg20286094	chr1:99190917	SNX7	-0.42	-4.93	-0.31	1.55e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs412050	0.744	rs238781	chr22:22341871	C/T	cg17089214	chr22:22089827	YPEL1	0.63	5.87	0.36	1.51e-8	Attention deficit hyperactivity disorder;
SARC	cis	rs6466055	0.777	rs10277120	chr7:104834417	A/T	cg04380332	chr7:105027541	SRPK2	0.4	4.81	0.3	2.7e-6	Schizophrenia;
SARC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg25721501	chr19:984170	WDR18	-0.56	-6.27	-0.38	1.75e-9	Hepatitis;
SARC	cis	rs854765	0.547	rs2955359	chr17:17946730	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-9.75	-0.54	4.63e-19	Total body bone mineral density;
SARC	cis	rs4595586	0.525	rs7970652	chr12:39374873	T/C	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	cis	rs10911232	0.524	rs10737238	chr1:183025303	A/G	cg13390022	chr1:182993471	LAMC1	0.36	5.4	0.33	1.66e-7	Hypertriglyceridemia;
SARC	cis	rs7223966	1.000	rs8067431	chr17:61817048	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.49	-4.95	-0.31	1.44e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs10791097	0.694	rs2155752	chr11:130755998	C/T	cg12179176	chr11:130786555	SNX19	0.76	11.43	0.6	2.59e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs6540556	0.768	rs6692012	chr1:209935490	A/G	cg05527609	chr1:210001259	C1orf107	-0.57	-5.86	-0.36	1.59e-8	Red blood cell count;
SARC	cis	rs7624766	0.555	rs6794047	chr3:160523531	T/C	cg22637730	chr3:160473554	PPM1L	0.37	4.76	0.3	3.37e-6	Response to methotrexate in rheumatoid arthritis;
SARC	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg19077165	chr18:44547161	KATNAL2	0.53	7.35	0.43	3.3e-12	Personality dimensions;
SARC	cis	rs453301	0.658	rs3855900	chr8:8901921	A/G	cg11995313	chr8:8860691	ERI1	0.47	5.98	0.36	8.26e-9	Joint mobility (Beighton score);
SARC	cis	rs60843830	0.662	rs6721594	chr2:305203	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	-0.49	-6.91	-0.41	4.51e-11	Spherical equivalent (joint analysis main effects and education interaction);
SARC	cis	rs9911578	1.000	rs654778	chr17:56736473	A/C	cg05425664	chr17:57184151	TRIM37	-0.66	-8.22	-0.47	1.44e-14	Intelligence (multi-trait analysis);
SARC	cis	rs2354432	1.000	rs11239944	chr1:146691015	C/T	cg25205988	chr1:146714368	CHD1L	0.99	11.53	0.6	1.26e-24	Mitochondrial DNA levels;
SARC	cis	rs10752881	1.000	rs6424879	chr1:182986592	T/C	cg13390022	chr1:182993471	LAMC1	0.35	5.24	0.32	3.63e-7	Colorectal cancer;
SARC	cis	rs9457247	0.534	rs9355610	chr6:167383075	G/A	cg23791538	chr6:167370224	RNASET2	0.65	9.27	0.52	1.34e-17	Crohn's disease;
SARC	cis	rs10504073	0.626	rs6472220	chr8:50008477	C/A	cg00325661	chr8:49890786	NA	0.5	6.82	0.41	7.66e-11	Blood metabolite ratios;
SARC	cis	rs5769765	0.955	rs2319465	chr22:50265784	A/C	cg03033257	chr22:50311977	ALG12;CRELD2	-0.54	-5.64	-0.35	4.81e-8	Schizophrenia;
SARC	cis	rs8017423	0.935	rs11628952	chr14:90734953	T/C	cg20276874	chr14:90721474	PSMC1	0.35	4.83	0.3	2.49e-6	Mortality in heart failure;
SARC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg06873352	chr17:61820015	STRADA	0.52	6.76	0.4	1.1e-10	Prudent dietary pattern;
SARC	cis	rs288326	0.561	rs74942055	chr2:183793653	A/G	cg09997497	chr2:183902928	NCKAP1	0.75	5.13	0.32	6.18e-7	Blood protein levels;
SARC	cis	rs644799	0.932	rs523934	chr11:95641775	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	13.62	0.67	1.77e-31	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg24549020	chr5:56110836	MAP3K1	0.81	8.29	0.48	9.03e-15	Initial pursuit acceleration;
SARC	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg26354017	chr1:205819088	PM20D1	0.46	5.89	0.36	1.36e-8	Menarche (age at onset);
SARC	cis	rs4689388	0.926	rs11732178	chr4:6292643	G/C	cg14416269	chr4:6271139	WFS1	0.35	5.49	0.34	1.07e-7	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs2072499	0.966	rs2842864	chr1:156159217	G/A	cg25208724	chr1:156163844	SLC25A44	0.92	12.68	0.64	2.29e-28	Testicular germ cell tumor;
SARC	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg06634786	chr22:41940651	POLR3H	-0.59	-7.03	-0.42	2.22e-11	Vitiligo;
SARC	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg22683308	chr4:1340831	KIAA1530	0.46	5.54	0.34	8.34e-8	Longevity;
SARC	cis	rs1153858	1.000	rs3809472	chr15:45694318	G/T	cg15395560	chr15:45543142	SLC28A2	-0.27	-4.91	-0.31	1.74e-6	Homoarginine levels;
SARC	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg22535103	chr8:58192502	C8orf71	-0.7	-8.15	-0.47	2.21e-14	Developmental language disorder (linguistic errors);
SARC	cis	rs4742903	0.935	rs17237053	chr9:106946359	C/T	cg14250997	chr9:106856677	SMC2	-0.38	-4.74	-0.3	3.74e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs7246657	0.525	rs10405238	chr19:37488055	T/G	cg14683738	chr19:37701593	ZNF585B	0.55	4.86	0.3	2.13e-6	Coronary artery calcification;
SARC	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg22535103	chr8:58192502	C8orf71	-0.68	-6.28	-0.38	1.65e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2486288	0.656	rs12440356	chr15:45567529	T/C	cg21132104	chr15:45694354	SPATA5L1	0.58	7.36	0.43	3.17e-12	Glomerular filtration rate;
SARC	cis	rs6570726	0.818	rs9399555	chr6:145877554	T/C	cg23711669	chr6:146136114	FBXO30	0.77	12.3	0.63	3.91e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6733011	0.502	rs6542847	chr2:99573471	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.56	-7.12	-0.42	1.34e-11	Bipolar disorder;
SARC	cis	rs7772486	0.624	rs6930154	chr6:146025662	C/T	cg05347473	chr6:146136440	FBXO30	-0.5	-6.89	-0.41	5.07e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12142240	0.698	rs17361950	chr1:46864150	C/T	cg00530320	chr1:46809349	NSUN4	0.58	6.83	0.41	7.29e-11	Menopause (age at onset);
SARC	cis	rs66887589	0.870	rs2389875	chr4:120557014	G/T	cg09307838	chr4:120376055	NA	-0.54	-7.33	-0.43	3.67e-12	Diastolic blood pressure;
SARC	cis	rs1267303	0.636	rs1267310	chr1:46987307	A/T	cg25110126	chr1:46999211	NA	-0.69	-7.64	-0.45	5.57e-13	Monobrow;
SARC	cis	rs1008375	0.900	rs10019460	chr4:17686337	T/C	cg02297831	chr4:17616191	MED28	-0.42	-5.11	-0.32	6.7e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg20607798	chr8:58055168	NA	0.6	5.33	0.33	2.27e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9296092	0.500	rs9461885	chr6:33521069	G/T	cg13560919	chr6:33536144	NA	-0.5	-6.31	-0.38	1.38e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs9486719	1.000	rs12207570	chr6:96987884	A/C	cg18709589	chr6:96969512	KIAA0776	-0.52	-5.26	-0.33	3.32e-7	Migraine;Coronary artery disease;
SARC	cis	rs6582630	0.555	rs7294313	chr12:38323603	G/A	cg13010199	chr12:38710504	ALG10B	-0.5	-6.0	-0.37	7.39e-9	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1008375	0.900	rs7658447	chr4:17579415	T/C	cg16339924	chr4:17578868	LAP3	0.7	9.07	0.51	4.93e-17	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4851254	1.000	rs4851254	chr2:100762937	C/G	cg04109781	chr2:100722022	AFF3	0.33	4.73	0.3	3.92e-6	Intelligence (multi-trait analysis);
SARC	cis	rs734999	0.545	rs10797436	chr1:2538349	G/A	cg18854424	chr1:2615690	NA	0.32	5.04	0.31	9.14e-7	Ulcerative colitis;
SARC	cis	rs273218	0.671	rs27877	chr5:53387784	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.59	5.48	0.34	1.08e-7	Migraine;
SARC	cis	rs4689388	0.926	rs12508672	chr4:6287965	G/A	cg00701064	chr4:6280414	WFS1	0.55	8.63	0.49	9.96e-16	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs155076	1.000	rs261423	chr13:21852331	A/C	cg14456004	chr13:21872349	NA	-0.99	-12.67	-0.64	2.44e-28	White matter hyperintensity burden;
SARC	cis	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg05623727	chr3:50126028	RBM5	0.33	4.91	0.31	1.69e-6	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg18876405	chr7:65276391	NA	-0.47	-5.58	-0.34	6.51e-8	Aortic root size;
SARC	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	9.07	0.51	5e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-9.15	-0.51	2.85e-17	Alzheimer's disease;
SARC	cis	rs9486715	0.790	rs2971602	chr6:97022468	C/T	cg18709589	chr6:96969512	KIAA0776	-0.59	-7.44	-0.44	1.88e-12	Headache;
SARC	cis	rs9300255	0.596	rs11057207	chr12:123730891	T/G	cg05973401	chr12:123451056	ABCB9	0.52	5.89	0.36	1.37e-8	Neutrophil percentage of white cells;
SARC	cis	rs4975616	0.869	rs370348	chr5:1331219	A/G	cg26373071	chr5:1325741	CLPTM1L	0.3	4.94	0.31	1.48e-6	Lung cancer;
SARC	cis	rs11098499	0.690	rs34818745	chr4:120257055	T/C	cg09307838	chr4:120376055	NA	0.89	12.16	0.62	1.14e-26	Corneal astigmatism;
SARC	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg19223190	chr17:80058835	NA	0.46	6.44	0.39	6.67e-10	Life satisfaction;
SARC	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg07701084	chr6:150067640	NUP43	0.41	5.38	0.33	1.84e-7	Lung cancer;
SARC	cis	rs875971	0.545	rs35459055	chr7:65944386	G/A	cg11764359	chr7:65958608	NA	0.65	6.38	0.39	9.28e-10	Aortic root size;
SARC	cis	rs7614311	1.000	rs2637983	chr3:63821632	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	0.48	5.06	0.31	8.53e-7	Lung function (FVC);Lung function (FEV1);
SARC	cis	rs4481887	1.000	rs6666690	chr1:248465323	T/C	cg13385794	chr1:248469461	NA	0.35	5.34	0.33	2.17e-7	Common traits (Other);
SARC	cis	rs79839061	0.610	rs2279181	chr4:882643	A/G	cg07828340	chr4:882639	GAK	-0.78	-6.45	-0.39	6.41e-10	Intelligence (multi-trait analysis);
SARC	cis	rs1707322	1.000	rs7539800	chr1:46262129	C/G	cg06784218	chr1:46089804	CCDC17	-0.37	-6.63	-0.4	2.35e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2075371	0.863	rs12672691	chr7:133954431	C/T	cg20476274	chr7:133979776	SLC35B4	0.57	7.41	0.44	2.28e-12	Mean platelet volume;
SARC	trans	rs7534824	0.860	rs6674749	chr1:101620239	A/C	cg18795461	chr1:36591112	NA	0.62	6.43	0.39	7.09e-10	Refractive astigmatism;
SARC	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	9.42	0.53	4.58e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg20090690	chr10:134436459	INPP5A	0.43	4.86	0.3	2.12e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg22824265	chr14:39901331	FBXO33	0.54	6.81	0.41	8.28e-11	Breast cancer;
SARC	cis	rs7520050	0.966	rs12144263	chr1:46352446	G/A	cg06784218	chr1:46089804	CCDC17	-0.26	-4.83	-0.3	2.5e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs757978	1.000	rs73116394	chr2:242367915	A/G	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.81	-6.97	-0.42	3.16e-11	Chronic lymphocytic leukemia;
SARC	cis	rs453301	0.686	rs11787026	chr8:8902371	A/T	cg15556689	chr8:8085844	FLJ10661	0.53	6.91	0.41	4.52e-11	Joint mobility (Beighton score);
SARC	cis	rs9467773	1.000	rs6925703	chr6:26521589	G/A	cg12292205	chr6:26970375	C6orf41	0.44	5.46	0.34	1.24e-7	Intelligence (multi-trait analysis);
SARC	cis	rs734999	0.505	rs4648659	chr1:2560903	T/G	cg00980319	chr1:2560884	MMEL1	0.34	4.9	0.31	1.83e-6	Ulcerative colitis;
SARC	cis	rs9914988	0.943	rs11651867	chr17:27147248	T/G	cg20469991	chr17:27169893	C17orf63	-0.52	-5.39	-0.33	1.74e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs3008870	0.583	rs2815369	chr1:67500894	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.83	9.1	0.51	4.11e-17	Lymphocyte percentage of white cells;
SARC	cis	rs7617773	0.779	rs3731487	chr3:48229624	C/T	cg11946769	chr3:48343235	NME6	0.72	9.33	0.52	8.8e-18	Coronary artery disease;
SARC	cis	rs6840360	0.571	rs11944139	chr4:152505291	T/C	cg22705602	chr4:152727874	NA	-0.44	-6.75	-0.4	1.13e-10	Intelligence (multi-trait analysis);
SARC	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.76	9.44	0.53	4.04e-18	Height;
SARC	cis	rs2070433	0.660	rs11701034	chr21:47793235	A/G	cg12379764	chr21:47803548	PCNT	0.6	5.12	0.32	6.5e-7	Lymphocyte counts;
SARC	cis	rs1008375	0.966	rs4515155	chr4:17696477	G/T	cg27347728	chr4:17578864	LAP3	0.44	5.67	0.35	4.14e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6061231	0.724	rs1570027	chr20:60968596	A/G	cg24112000	chr20:60950667	NA	-0.36	-5.14	-0.32	5.68e-7	Colorectal cancer;
SARC	cis	rs9916302	0.904	rs4795384	chr17:37716771	C/G	cg20243544	chr17:37824526	PNMT	0.58	6.89	0.41	5.29e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.68	0.57	6.45e-22	Prudent dietary pattern;
SARC	cis	rs76419734	1.000	rs11735527	chr4:106679692	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.76	5.11	0.32	6.56e-7	Post bronchodilator FEV1;
SARC	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg22920501	chr2:26401640	FAM59B	0.48	6.14	0.37	3.57e-9	Gut microbiome composition (summer);
SARC	cis	rs2463822	0.920	rs7924998	chr11:62073980	C/G	cg06239285	chr11:62104954	ASRGL1	-0.91	-8.31	-0.48	7.74e-15	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg15049968	chr18:44337910	ST8SIA5	-0.34	-5.45	-0.34	1.3e-7	Personality dimensions;
SARC	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg12419862	chr22:24373484	LOC391322	0.74	8.44	0.48	3.4e-15	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs3768617	0.510	rs2296300	chr1:183099701	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.66e-21	Fuchs's corneal dystrophy;
SARC	cis	rs1941023	0.606	rs7926219	chr11:60180335	C/T	cg08716584	chr11:60157161	MS4A7	-0.32	-5.14	-0.32	5.89e-7	Congenital heart disease (maternal effect);
SARC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.06	18.0	0.76	5.36e-46	Prudent dietary pattern;
SARC	cis	rs6831352	0.842	rs1230156	chr4:99989626	C/T	cg12011299	chr4:100065546	ADH4	0.34	5.82	0.36	1.92e-8	Alcohol dependence;
SARC	cis	rs9899728	0.539	rs11077772	chr17:73035698	C/T	cg27626185	chr17:73056755	KCTD2	-0.97	-7.37	-0.43	2.96e-12	Alzheimer's disease or small vessel stroke;
SARC	trans	rs1814175	0.817	rs1988416	chr11:49932324	G/A	cg03929089	chr4:120376271	NA	-0.88	-13.88	-0.67	2.51e-32	Height;
SARC	cis	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg05623727	chr3:50126028	RBM5	-0.34	-5.25	-0.33	3.37e-7	Intelligence (multi-trait analysis);
SARC	cis	rs3768617	0.706	rs11588675	chr1:182988052	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.67	9.46	0.53	3.6e-18	Fuchs's corneal dystrophy;
SARC	cis	rs2976388	0.647	rs13272904	chr8:143782614	T/C	cg06565975	chr8:143823917	SLURP1	0.3	5.12	0.32	6.5e-7	Urinary tract infection frequency;
SARC	cis	rs11785400	0.793	rs2976400	chr8:143743611	G/A	cg24634471	chr8:143751801	JRK	0.59	7.54	0.44	1.02e-12	Schizophrenia;
SARC	cis	rs6424115	0.830	rs3123554	chr1:24196401	C/T	cg15997130	chr1:24165203	NA	-0.45	-6.05	-0.37	5.63e-9	Immature fraction of reticulocytes;
SARC	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg04277193	chr17:41438351	NA	0.45	4.9	0.31	1.8e-6	Menopause (age at onset);
SARC	cis	rs6582630	0.503	rs4882293	chr12:38388200	G/C	cg26384229	chr12:38710491	ALG10B	-0.57	-7.11	-0.42	1.43e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.73	7.01	0.42	2.53e-11	Platelet count;
SARC	trans	rs9354308	0.770	rs2802048	chr6:66525044	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.55	6.4	0.39	8.56e-10	Metabolite levels;
SARC	cis	rs9398803	0.865	rs9398805	chr6:126726295	C/T	cg20229609	chr6:126660872	C6orf173	0.4	5.85	0.36	1.68e-8	Male-pattern baldness;
SARC	cis	rs9796	0.700	rs2305656	chr15:41279519	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.52	-7.0	-0.42	2.66e-11	Menopause (age at onset);
SARC	cis	rs7927771	0.965	rs1064608	chr11:47640429	G/C	cg05585544	chr11:47624801	NA	-0.4	-5.31	-0.33	2.59e-7	Subjective well-being;
SARC	cis	rs9611565	0.921	rs5751080	chr22:41736267	A/G	cg03806693	chr22:41940476	POLR3H	-0.69	-9.52	-0.53	2.32e-18	Vitiligo;
SARC	cis	rs1215050	0.740	rs783936	chr4:98928628	G/T	cg05340658	chr4:99064831	C4orf37	-0.48	-6.42	-0.39	7.44e-10	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs6580649	0.941	rs1018973	chr12:48441692	C/G	cg05342945	chr12:48394962	COL2A1	-0.56	-6.15	-0.37	3.28e-9	Lung cancer;
SARC	cis	rs6963495	0.745	rs818620	chr7:105172685	G/C	cg13798780	chr7:105162888	PUS7	0.48	4.79	0.3	2.98e-6	Bipolar disorder (body mass index interaction);
SARC	cis	rs9303401	0.538	rs3785493	chr17:56472119	G/T	cg25039879	chr17:56429692	SUPT4H1	-0.67	-5.9	-0.36	1.26e-8	Cognitive test performance;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg20685431	chr4:186347356	UFSP2	0.5	6.24	0.38	2.01e-9	Breast cancer;
SARC	trans	rs7824557	0.592	rs920044	chr8:11224313	C/T	cg06636001	chr8:8085503	FLJ10661	0.59	7.69	0.45	4.22e-13	Retinal vascular caliber;
SARC	cis	rs965469	0.619	rs6037565	chr20:3330308	T/C	cg25506879	chr20:3388711	C20orf194	-0.46	-4.99	-0.31	1.17e-6	IFN-related cytopenia;
SARC	cis	rs11122272	0.603	rs2998427	chr1:231528112	A/G	cg06096015	chr1:231504339	EGLN1	0.39	5.82	0.36	1.97e-8	Hemoglobin concentration;
SARC	cis	rs4642101	0.765	rs1985428	chr3:12829315	A/G	cg12400702	chr3:12838781	CAND2	0.25	5.02	0.31	1.03e-6	QRS complex (12-leadsum);
SARC	cis	rs2303745	0.589	rs1864116	chr19:17393015	C/T	cg04248312	chr19:17393744	ANKLE1	-0.61	-8.03	-0.47	4.94e-14	Systemic lupus erythematosus;
SARC	cis	rs13256369	0.865	rs13277708	chr8:8573936	T/C	cg18904891	chr8:8559673	CLDN23	0.4	4.72	0.3	3.99e-6	Obesity-related traits;
SARC	cis	rs10865397	0.506	rs13414160	chr2:73383261	C/A	cg01422370	chr2:73384389	NA	0.37	6.13	0.37	3.66e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7568458	0.684	rs1048739	chr2:85764968	T/G	cg02493740	chr2:85810744	VAMP5	-0.41	-5.16	-0.32	5.4e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs854765	0.547	rs9896837	chr17:17924868	A/G	cg05444541	chr17:17804740	TOM1L2	-0.31	-5.04	-0.31	9.56e-7	Total body bone mineral density;
SARC	cis	rs6580649	0.941	rs1968071	chr12:48489357	A/G	cg24011408	chr12:48396354	COL2A1	-0.47	-5.34	-0.33	2.16e-7	Lung cancer;
SARC	cis	rs71636778	0.631	rs1883660	chr1:27191411	A/T	cg04852280	chr1:26496234	ZNF593	0.53	4.8	0.3	2.84e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs2645694	0.533	rs2703125	chr4:77819900	T/C	cg03477792	chr4:77819574	ANKRD56	0.5	7.36	0.43	3.09e-12	Emphysema distribution in smoking;
SARC	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg00149659	chr3:10157352	C3orf10	0.66	6.6	0.4	2.82e-10	Alzheimer's disease;
SARC	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg03709012	chr19:19516395	GATAD2A	-0.96	-14.96	-0.7	6.36e-36	Tonsillectomy;
SARC	cis	rs950027	0.620	rs1145084	chr15:45675440	G/A	cg26924012	chr15:45694286	SPATA5L1	0.53	6.79	0.41	9.23e-11	Response to fenofibrate (adiponectin levels);
SARC	cis	rs72781680	0.898	rs72786276	chr2:24062566	G/A	cg06627628	chr2:24431161	ITSN2	-0.71	-6.65	-0.4	2.04e-10	Lymphocyte counts;
SARC	cis	rs10782582	0.609	rs5745331	chr1:76273313	A/G	cg10523679	chr1:76189770	ACADM	-0.4	-4.86	-0.3	2.19e-6	Daytime sleep phenotypes;
SARC	cis	rs9815354	0.812	rs56290987	chr3:42004882	T/C	cg03022575	chr3:42003672	ULK4	0.68	5.89	0.36	1.34e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs7592578	0.771	rs62181034	chr2:191354963	C/A	cg10560079	chr2:191398806	TMEM194B	-0.79	-8.95	-0.51	1.15e-16	Diastolic blood pressure;
SARC	cis	rs4727027	0.866	rs2373437	chr7:148779032	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	5.95	0.36	9.81e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs526231	0.543	rs40092	chr5:102424213	A/G	cg23492399	chr5:102201601	PAM	-0.52	-5.63	-0.35	5.04e-8	Primary biliary cholangitis;
SARC	cis	rs13161895	1.000	rs34674199	chr5:179473900	G/A	cg02702477	chr5:179499311	RNF130	0.65	6.2	0.38	2.5e-9	LDL cholesterol;
SARC	cis	rs690037	0.641	rs538525	chr3:16376279	A/G	cg23474789	chr3:16306055	DPH3;OXNAD1	0.51	5.85	0.36	1.65e-8	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);
SARC	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	8.97	0.51	1.03e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs57994353	0.897	rs36101132	chr9:139367566	G/A	cg13611204	chr9:139324423	INPP5E	-0.28	-4.89	-0.3	1.91e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs3008870	0.959	rs2815353	chr1:67483372	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.91	11.06	0.59	3.94e-23	Lymphocyte percentage of white cells;
SARC	cis	rs193541	0.632	rs430069	chr5:122263351	G/A	cg19412675	chr5:122181750	SNX24	0.51	6.48	0.39	5.3e-10	Glucose homeostasis traits;
SARC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.51	5.77	0.35	2.55e-8	Prudent dietary pattern;
SARC	cis	rs58653258	0.881	rs72752285	chr1:234991559	C/T	cg14037484	chr1:235490207	ARID4B	-0.65	-4.79	-0.3	3e-6	Granulocyte percentage of myeloid white cells;
SARC	cis	rs73206853	0.764	rs57033697	chr12:110550992	G/A	cg10860002	chr12:110842031	ANAPC7	0.65	5.28	0.33	2.93e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs7520050	0.807	rs4353138	chr1:46219803	C/T	cg24296786	chr1:45957014	TESK2	0.42	5.23	0.32	3.77e-7	Red blood cell count;Reticulocyte count;
SARC	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg00684032	chr4:1343700	KIAA1530	0.39	5.52	0.34	8.95e-8	Obesity-related traits;
SARC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg20607798	chr8:58055168	NA	0.73	6.15	0.37	3.38e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs12357919	0.542	rs3740471	chr10:105363289	T/C	cg00126946	chr10:105363258	SH3PXD2A	0.5	7.21	0.43	7.59e-12	White matter hyperintensity burden;
SARC	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg00990874	chr7:1149470	C7orf50	-0.55	-6.01	-0.37	7e-9	Bronchopulmonary dysplasia;
SARC	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-5.96	-0.36	9.37e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg12311346	chr5:56204834	C5orf35	-0.57	-6.1	-0.37	4.48e-9	Initial pursuit acceleration;
SARC	cis	rs17376456	0.877	rs17374627	chr5:93296306	C/T	cg21475434	chr5:93447410	FAM172A	0.86	7.8	0.46	2.06e-13	Diabetic retinopathy;
SARC	cis	rs6912958	0.712	rs9444525	chr6:88324142	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-5.64	-0.35	4.9e-8	Monocyte percentage of white cells;
SARC	cis	rs6597981	0.592	rs10902218	chr11:743813	C/T	cg21775979	chr11:780331	NA	0.33	4.78	0.3	3.11e-6	Breast cancer;
SARC	cis	rs826838	1.000	rs826851	chr12:39112639	A/G	cg26384229	chr12:38710491	ALG10B	-0.8	-12.03	-0.62	3.06e-26	Heart rate;
SARC	cis	rs11585357	0.842	rs72633804	chr1:17617024	T/C	cg08277548	chr1:17600880	PADI3	-0.47	-5.3	-0.33	2.71e-7	Hair shape;
SARC	cis	rs2836633	0.929	rs11702165	chr21:40035313	C/T	cg12884169	chr21:40033163	ERG	0.48	8.84	0.5	2.32e-16	Coronary artery disease;
SARC	cis	rs9329289	0.851	rs61835719	chr10:2543390	A/G	cg15501526	chr10:2543763	NA	0.53	8.27	0.48	1.03e-14	Age-related hearing impairment;
SARC	cis	rs11722228	1.000	rs6823877	chr4:9921931	T/C	cg25986240	chr4:9926439	SLC2A9	0.3	5.14	0.32	5.94e-7	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs9399135	0.967	rs1041481	chr6:135335063	G/A	cg24558204	chr6:135376177	HBS1L	0.45	6.03	0.37	6.24e-9	Red blood cell count;
SARC	cis	rs11190604	1.000	rs3793771	chr10:102222957	C/G	cg07080220	chr10:102295463	HIF1AN	0.74	9.16	0.51	2.83e-17	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs9547692	1.000	rs9547692	chr13:37473243	A/C	cg01493522	chr13:37497338	NA	-0.46	-5.08	-0.32	7.88e-7	Coronary artery disease;
SARC	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg27266027	chr21:40555129	PSMG1	0.47	5.07	0.32	7.96e-7	Cognitive function;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg02827371	chr10:32735380	CCDC7	0.52	6.51	0.39	4.52e-10	Gallstone disease;
SARC	trans	rs9329221	0.537	rs13254175	chr8:9978772	C/T	cg06636001	chr8:8085503	FLJ10661	0.52	7.26	0.43	5.79e-12	Neuroticism;
SARC	cis	rs72720396	0.789	rs10922910	chr1:91199862	G/T	cg13456504	chr1:91191583	NA	0.34	5.07	0.31	8.29e-7	Morning vs. evening chronotype;Chronotype;
SARC	cis	rs4268898	0.662	rs2303296	chr2:24432839	A/G	cg06627628	chr2:24431161	ITSN2	-0.84	-10.12	-0.55	3.39e-20	Asthma;
SARC	cis	rs739401	1.000	rs739401	chr11:3036324	C/T	cg20651018	chr11:3035856	CARS	0.45	6.89	0.41	5.28e-11	Longevity;
SARC	cis	rs6991838	0.584	rs7814841	chr8:66541563	A/G	cg13398993	chr8:66546079	ARMC1	0.62	8.19	0.47	1.72e-14	Intelligence (multi-trait analysis);
SARC	cis	rs11098499	0.863	rs58452170	chr4:120459674	A/T	cg09160332	chr4:120329925	NA	-0.35	-4.77	-0.3	3.19e-6	Corneal astigmatism;
SARC	cis	rs10791323	0.633	rs2171006	chr11:133728323	T/C	cg15485101	chr11:133734466	NA	0.32	5.24	0.32	3.55e-7	Childhood ear infection;
SARC	cis	rs10752881	1.000	rs10911190	chr1:182979080	C/T	cg13390022	chr1:182993471	LAMC1	0.33	5.06	0.31	8.36e-7	Colorectal cancer;
SARC	cis	rs739401	0.967	rs451041	chr11:3060725	C/T	cg05729581	chr11:3078854	CARS	-0.42	-5.44	-0.34	1.37e-7	Longevity;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg06722069	chr3:113822382	NA	0.49	6.41	0.39	8.07e-10	Schizophrenia;
SARC	cis	rs2656056	1	rs2656056	chr15:78722519	T/C	cg24631222	chr15:78858424	CHRNA5	-0.73	-8.66	-0.49	8.13e-16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
SARC	cis	rs6580649	0.941	rs4760614	chr12:48427884	A/G	cg24011408	chr12:48396354	COL2A1	-0.47	-5.15	-0.32	5.45e-7	Lung cancer;
SARC	cis	rs5769765	1.000	rs8138941	chr22:50290678	G/A	cg03033257	chr22:50311977	ALG12;CRELD2	0.52	5.33	0.33	2.28e-7	Schizophrenia;
SARC	cis	rs3892630	0.878	rs7246451	chr19:33209614	C/G	cg22980127	chr19:33182716	NUDT19	1.02	8.82	0.5	2.78e-16	Red blood cell traits;
SARC	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg24675658	chr1:53192096	ZYG11B	-0.59	-8.25	-0.48	1.15e-14	Monocyte count;
SARC	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg08219700	chr8:58056026	NA	0.6	5.71	0.35	3.49e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg22834771	chr12:69754056	YEATS4	-0.44	-5.78	-0.35	2.42e-8	Blood protein levels;
SARC	cis	rs1904096	0.506	rs28701470	chr4:95167088	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.47	-6.81	-0.41	8.11e-11	Type 2 diabetes;
SARC	cis	rs733592	0.894	rs886589	chr12:48477197	C/T	cg21466736	chr12:48725269	NA	0.32	5.38	0.33	1.83e-7	Plateletcrit;
SARC	cis	rs2832191	0.967	rs3787660	chr21:30520907	C/T	cg24692254	chr21:30365293	RNF160	0.77	10.66	0.57	7.28e-22	Dental caries;
SARC	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg19592336	chr6:28129416	ZNF389	-0.5	-5.13	-0.32	6.21e-7	Depression;
SARC	cis	rs2075371	0.796	rs1646644	chr7:134011817	A/T	cg11752832	chr7:134001865	SLC35B4	0.64	8.44	0.48	3.34e-15	Mean platelet volume;
SARC	cis	rs6500602	0.702	rs11076834	chr16:4549583	C/G	cg08645402	chr16:4508243	NA	0.37	4.99	0.31	1.2e-6	Schizophrenia;
SARC	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg19678392	chr7:94953810	PON1	0.41	5.98	0.36	8.52e-9	Paraoxonase activity;
SARC	cis	rs9951602	0.607	rs3017651	chr18:76668622	T/C	cg00806245	chr18:76673096	NA	-0.44	-6.24	-0.38	2.08e-9	Obesity-related traits;
SARC	cis	rs7666738	0.753	rs13111199	chr4:98953705	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg23758822	chr17:41437982	NA	0.86	10.56	0.57	1.52e-21	Menopause (age at onset);
SARC	cis	rs7246760	0.867	rs12462694	chr19:9778032	C/T	cg16876255	chr19:9731953	ZNF561	0.83	5.09	0.32	7.49e-7	Pursuit maintenance gain;
SARC	cis	rs6456156	0.565	rs12529238	chr6:167465576	G/A	cg07741184	chr6:167504864	NA	0.35	6.83	0.41	7.46e-11	Primary biliary cholangitis;
SARC	cis	rs6696846	0.765	rs61822567	chr1:205078725	T/C	cg21643547	chr1:205240462	TMCC2	-0.56	-7.6	-0.45	7.34e-13	Red blood cell count;
SARC	cis	rs6912958	0.559	rs446851	chr6:88043640	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.73	10.78	0.58	3.06e-22	Monocyte percentage of white cells;
SARC	cis	rs888194	0.725	rs2241210	chr12:109950144	A/G	cg13986417	chr12:110012484	MVK;MMAB	-0.31	-4.77	-0.3	3.19e-6	Neuroticism;
SARC	cis	rs7847628	0.566	rs10739575	chr9:123606101	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.52	-4.97	-0.31	1.28e-6	Birth weight;
SARC	cis	rs2153535	0.580	rs1932282	chr6:8477330	G/A	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	cis	rs7762018	1.000	rs6459657	chr6:170136454	A/G	cg13891659	chr6:170190454	C6orf122;C6orf208	0.54	4.77	0.3	3.29e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs66887589	0.807	rs9799664	chr4:120326678	C/T	cg09307838	chr4:120376055	NA	0.54	7.39	0.44	2.63e-12	Diastolic blood pressure;
SARC	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg03576123	chr11:487126	PTDSS2	-1.15	-11.85	-0.61	1.13e-25	Body mass index;
SARC	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg21747090	chr2:27597821	SNX17	-0.54	-7.37	-0.43	2.98e-12	Menopause (age at onset);
SARC	cis	rs4699052	0.963	rs6533066	chr4:104163607	C/G	cg16532752	chr4:104119610	CENPE	-0.44	-5.19	-0.32	4.62e-7	Testicular germ cell tumor;
SARC	cis	rs870825	0.616	rs57316663	chr4:185630011	T/C	cg04058563	chr4:185651563	MLF1IP	0.81	11.25	0.59	9.68e-24	Blood protein levels;
SARC	cis	rs9611519	1.000	rs2273085	chr22:41615376	C/T	cg03806693	chr22:41940476	POLR3H	-0.53	-6.53	-0.39	4.1e-10	Neuroticism;
SARC	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg15847926	chr7:2749597	AMZ1	-0.29	-4.77	-0.3	3.18e-6	Height;
SARC	cis	rs10982256	0.774	rs12551529	chr9:117256896	A/G	cg15903421	chr9:117267460	DFNB31	0.38	4.95	0.31	1.4e-6	Bipolar disorder;
SARC	cis	rs1865760	0.566	rs9467672	chr6:26083904	C/T	cg10373733	chr6:25993375	NA	0.45	5.43	0.34	1.4e-7	Height;
SARC	cis	rs1318878	0.519	rs11056448	chr12:15512137	A/T	cg08258403	chr12:15378311	NA	0.51	6.94	0.41	3.84e-11	Intelligence (multi-trait analysis);
SARC	cis	rs17428076	0.793	rs72881938	chr2:172628752	C/G	cg13550731	chr2:172543902	DYNC1I2	0.44	4.85	0.3	2.22e-6	Myopia;
SARC	cis	rs3858526	0.920	rs10742832	chr11:5926020	C/G	cg02574844	chr11:5959923	NA	-0.42	-5.12	-0.32	6.44e-7	DNA methylation (variation);
SARC	trans	rs2018683	0.711	rs1874977	chr7:28968083	A/G	cg19402173	chr7:128379420	CALU	-0.59	-7.61	-0.45	6.72e-13	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs344364	0.511	rs1742468	chr16:1950243	C/G	cg26617929	chr16:1858877	NA	-0.71	-6.06	-0.37	5.5e-9	Glomerular filtration rate in chronic kidney disease;
SARC	cis	rs10463554	0.963	rs6596530	chr5:102371440	C/G	cg23492399	chr5:102201601	PAM	-0.47	-5.17	-0.32	5.04e-7	Parkinson's disease;
SARC	cis	rs713477	1.000	rs12888361	chr14:55906187	A/G	cg13175173	chr14:55914753	NA	-0.31	-4.8	-0.3	2.85e-6	Pediatric bone mineral content (femoral neck);
SARC	cis	rs41271473	0.526	rs2182202	chr1:228733959	G/C	cg16512390	chr1:228756714	NA	0.62	5.58	0.34	6.73e-8	Chronic lymphocytic leukemia;
SARC	cis	rs4805272	0.626	rs12608533	chr19:29331405	C/G	cg12756686	chr19:29218302	NA	0.53	6.32	0.38	1.3e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs1008375	1.000	rs2058339	chr4:17678456	C/T	cg16339924	chr4:17578868	LAP3	0.64	8.46	0.48	3.04e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6963495	0.818	rs73190186	chr7:105164368	G/C	cg19920283	chr7:105172520	RINT1	0.65	5.48	0.34	1.09e-7	Bipolar disorder (body mass index interaction);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg17831680	chr6:142468432	VTA1	-0.49	-6.53	-0.39	4.19e-10	Chemerin levels;
SARC	cis	rs2594989	0.831	rs7651790	chr3:11572610	C/T	cg00170343	chr3:11313890	ATG7	-0.57	-5.84	-0.36	1.75e-8	Circulating chemerin levels;
SARC	cis	rs9398803	0.865	rs9388494	chr6:126776094	G/T	cg20229609	chr6:126660872	C6orf173	0.4	5.81	0.36	2.09e-8	Male-pattern baldness;
SARC	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg09455208	chr3:40491958	NA	0.4	5.97	0.36	8.89e-9	Renal cell carcinoma;
SARC	trans	rs904095	0.583	rs1789921	chr4:100269202	G/A	cg01588345	chr2:120023921	NA	0.43	6.28	0.38	1.62e-9	Alcohol dependence;
SARC	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg22433210	chr17:43662623	NA	-0.72	-8.5	-0.49	2.35e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	trans	rs3942852	0.759	rs905475	chr11:48149755	C/T	cg15704280	chr7:45808275	SEPT13	-0.57	-6.61	-0.4	2.55e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs4689388	0.853	rs6817447	chr4:6286847	G/T	cg25554036	chr4:6271136	WFS1	0.42	6.82	0.41	7.83e-11	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.74	10.04	0.55	6.13e-20	Menarche (age at onset);
SARC	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg25365034	chr2:23785230	KLHL29	-0.51	-6.7	-0.4	1.54e-10	Migraine with aura;
SARC	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs17401966	0.838	rs61775885	chr1:10281445	T/C	cg15208524	chr1:10270712	KIF1B	0.47	5.59	0.34	6.49e-8	Hepatocellular carcinoma;
SARC	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg19729930	chr2:74357872	NA	0.76	11.18	0.59	1.67e-23	Gestational age at birth (maternal effect);
SARC	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg08859206	chr1:53392774	SCP2	-0.39	-5.59	-0.34	6.49e-8	Monocyte count;
SARC	trans	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg21659725	chr3:3221576	CRBN	0.78	11.74	0.61	2.69e-25	Intelligence (multi-trait analysis);
SARC	cis	rs7027203	0.828	rs10761288	chr9:96609363	C/T	cg13679303	chr9:96623674	NA	-0.34	-4.89	-0.31	1.84e-6	DNA methylation (variation);
SARC	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg19223190	chr17:80058835	NA	-0.43	-6.02	-0.37	6.57e-9	Life satisfaction;
SARC	cis	rs920590	0.758	rs7012358	chr8:19662498	C/T	cg03894339	chr8:19674705	INTS10	0.54	6.32	0.38	1.31e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs6484504	0.576	rs208072	chr11:31141288	A/G	cg26647111	chr11:31128758	NA	0.39	5.09	0.32	7.43e-7	Red blood cell count;
SARC	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg09699651	chr6:150184138	LRP11	0.56	7.24	0.43	6.43e-12	Testicular germ cell tumor;
SARC	cis	rs72781680	0.716	rs6731314	chr2:24048338	C/T	cg08917208	chr2:24149416	ATAD2B	-0.6	-6.09	-0.37	4.64e-9	Lymphocyte counts;
SARC	cis	rs9733	0.593	rs10888384	chr1:150574256	C/T	cg17724175	chr1:150552817	MCL1	-0.4	-5.06	-0.31	8.4e-7	Tonsillectomy;
SARC	cis	rs79349575	0.715	rs4793997	chr17:47019672	C/A	cg07967210	chr17:47022446	SNF8	0.38	4.77	0.3	3.2e-6	Type 2 diabetes;
SARC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg26338869	chr17:61819248	STRADA	0.77	10.23	0.56	1.53e-20	Prudent dietary pattern;
SARC	cis	rs9354308	0.868	rs9363458	chr6:66552798	T/C	cg07460842	chr6:66804631	NA	-0.42	-4.84	-0.3	2.36e-6	Metabolite levels;
SARC	cis	rs524281	0.861	rs10896086	chr11:65914764	T/A	cg14036092	chr11:66035641	RAB1B	-0.5	-5.11	-0.32	6.72e-7	Electroencephalogram traits;
SARC	trans	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg06636001	chr8:8085503	FLJ10661	0.63	8.59	0.49	1.26e-15	Retinal vascular caliber;
SARC	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg26335602	chr6:28129616	ZNF389	0.53	5.95	0.36	9.59e-9	Depression;
SARC	trans	rs877282	0.891	rs11253355	chr10:768367	C/G	cg22713356	chr15:30763199	NA	1.03	10.34	0.56	6.99e-21	Uric acid levels;
SARC	cis	rs6910061	0.789	rs9461490	chr6:11119471	G/A	cg27233058	chr6:11094804	LOC221710	0.58	5.31	0.33	2.52e-7	Diabetic kidney disease;
SARC	cis	rs7084402	0.935	rs4948524	chr10:60351224	C/A	cg07615347	chr10:60278583	BICC1	0.59	8.54	0.49	1.71e-15	Refractive error;
SARC	cis	rs9398803	0.687	rs1340952	chr6:126951510	C/T	cg20229609	chr6:126660872	C6orf173	0.37	5.28	0.33	2.99e-7	Male-pattern baldness;
SARC	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg18252515	chr7:66147081	NA	-0.47	-5.08	-0.32	7.88e-7	Aortic root size;
SARC	cis	rs2016266	0.784	rs10747666	chr12:53716836	G/A	cg26875137	chr12:53738046	NA	0.38	5.27	0.33	3.08e-7	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs7178572	0.568	rs12905951	chr15:77649431	G/A	cg22256960	chr15:77711686	NA	-0.52	-5.76	-0.35	2.69e-8	Type 2 diabetes;
SARC	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg06108461	chr20:60628389	TAF4	-0.88	-10.85	-0.58	1.85e-22	Body mass index;
SARC	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg17376030	chr22:41985996	PMM1	0.76	9.52	0.53	2.3e-18	Vitiligo;
SARC	trans	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg10573763	chr19:19030094	COPE;DDX49	-0.69	-6.49	-0.39	5.22e-10	Cutaneous psoriasis;
SARC	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg26818010	chr10:134567672	INPP5A	-0.62	-6.49	-0.39	5.08e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs2486288	0.656	rs11632920	chr15:45551264	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.47	-5.72	-0.35	3.21e-8	Glomerular filtration rate;
SARC	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg17279839	chr7:150038598	RARRES2	-0.51	-7.61	-0.45	6.6e-13	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs6665290	0.901	rs61834005	chr1:227202789	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.06	-23.13	-0.83	2.86e-62	Myeloid white cell count;
SARC	trans	rs9329221	0.905	rs10283145	chr8:10241411	C/T	cg08975724	chr8:8085496	FLJ10661	-0.58	-7.3	-0.43	4.54e-12	Neuroticism;
SARC	cis	rs3733585	0.673	rs4580649	chr4:9948461	G/A	cg00071950	chr4:10020882	SLC2A9	-0.39	-5.98	-0.36	8.35e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs6502050	0.712	rs8077079	chr17:80059011	C/T	cg19223190	chr17:80058835	NA	-0.47	-6.68	-0.4	1.76e-10	Life satisfaction;
SARC	cis	rs2075371	0.966	rs722657	chr7:133994956	T/C	cg00033643	chr7:134001901	SLC35B4	0.42	5.06	0.31	8.41e-7	Mean platelet volume;
SARC	cis	rs9886651	0.935	rs4524749	chr8:128805447	G/A	cg24514600	chr8:128805414	PVT1	-0.41	-5.34	-0.33	2.22e-7	Epithelial ovarian cancer;Serous invasive ovarian cancer;
SARC	cis	rs78545713	1.000	rs3734534	chr6:26240649	A/G	cg00631329	chr6:26305371	NA	0.7	6.14	0.37	3.62e-9	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs16866061	1.000	rs16866061	chr2:225439844	A/G	cg12698349	chr2:225449008	CUL3	0.75	10.59	0.57	1.17e-21	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	cis	rs4969178	0.965	rs11077364	chr17:76400337	C/A	cg02836325	chr17:76403955	PGS1	0.34	5.21	0.32	4.2e-7	HDL cholesterol levels;
SARC	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg07507251	chr3:52567010	NT5DC2	0.33	5.26	0.33	3.27e-7	Hemoglobin concentration;
SARC	cis	rs7223966	1.000	rs6504182	chr17:61823672	T/C	cg00588841	chr17:61851480	DDX42;CCDC47	-0.61	-7.04	-0.42	2.1e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs10490913	0.806	rs10787823	chr10:120164509	C/T	cg23160142	chr10:120154512	NA	0.36	5.4	0.33	1.66e-7	Cancer;
SARC	cis	rs11702148	0.552	rs6517178	chr21:34888621	C/T	cg14850771	chr21:34775459	IFNGR2	-0.37	-4.75	-0.3	3.56e-6	Mean corpuscular hemoglobin;
SARC	cis	rs7044106	0.762	rs1886337	chr9:123443776	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	5.44	0.34	1.32e-7	Hip circumference adjusted for BMI;
SARC	cis	rs9948	0.786	rs62152774	chr2:97448377	A/G	cg01990225	chr2:97406019	LMAN2L	-0.96	-6.95	-0.41	3.73e-11	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg27541892	chr1:1571801	CDK11B	0.4	5.51	0.34	9.66e-8	Body mass index;
SARC	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg11764359	chr7:65958608	NA	0.86	12.33	0.63	3.29e-27	Aortic root size;
SARC	cis	rs7523050	0.643	rs67567504	chr1:109402580	C/A	cg08274380	chr1:109419600	GPSM2	1.02	7.68	0.45	4.37e-13	Fat distribution (HIV);
SARC	cis	rs9660992	0.573	rs12144980	chr1:205185104	C/T	cg21545522	chr1:205238299	TMCC2	0.42	5.86	0.36	1.58e-8	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs752010	0.645	rs1109254	chr1:42091770	T/C	cg06885757	chr1:42089581	HIVEP3	0.53	7.55	0.44	1e-12	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs7043114	0.525	rs1133908	chr9:95068046	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.49	-0.34	1.04e-7	Height;
SARC	cis	rs9303280	0.836	rs11557467	chr17:38028634	G/T	cg20243544	chr17:37824526	PNMT	0.42	5.58	0.34	6.64e-8	Self-reported allergy;
SARC	cis	rs1113500	0.897	rs2336127	chr1:108640870	G/A	cg06207961	chr1:108661230	NA	0.45	6.05	0.37	5.71e-9	Growth-regulated protein alpha levels;
SARC	cis	rs9462027	0.628	rs1125341	chr6:34786305	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-6.04	-0.37	5.95e-9	Systemic lupus erythematosus;
SARC	cis	rs8031584	0.541	rs2955777	chr15:31219788	A/C	cg19680485	chr15:31195859	MTMR15	0.56	7.11	0.42	1.44e-11	Huntington's disease progression;
SARC	cis	rs4243830	0.850	rs10779790	chr1:6608435	A/G	cg04093404	chr1:6614507	TAS1R1;NOL9	0.61	5.16	0.32	5.37e-7	Body mass index;
SARC	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	11.99	0.62	4.13e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9790314	0.582	rs13071909	chr3:160604864	A/G	cg04691961	chr3:161091175	C3orf57	0.55	7.47	0.44	1.6e-12	Morning vs. evening chronotype;
SARC	cis	rs9303401	0.538	rs10515155	chr17:56481944	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.06	11.03	0.59	5.07e-23	Cognitive test performance;
SARC	cis	rs2396545	0.680	rs35467761	chr11:571568	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.46	-5.06	-0.31	8.44e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg20965017	chr5:231967	SDHA	-0.55	-5.26	-0.33	3.23e-7	Breast cancer;
SARC	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.47	5.44	0.34	1.33e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9467773	0.595	rs2451736	chr6:26620544	G/A	cg12292205	chr6:26970375	C6orf41	0.4	5.04	0.31	9.34e-7	Intelligence (multi-trait analysis);
SARC	cis	rs12579753	1.000	rs12366580	chr12:82222784	G/A	cg07988820	chr12:82153109	PPFIA2	-0.53	-6.1	-0.37	4.27e-9	Resting heart rate;
SARC	cis	rs62432291	0.681	rs450538	chr6:159659523	A/G	cg14500486	chr6:159655392	FNDC1	-0.64	-6.37	-0.39	9.75e-10	Joint mobility (Beighton score);
SARC	cis	rs270601	0.909	rs2569265	chr5:131704519	T/C	cg11843238	chr5:131593191	PDLIM4	-0.4	-4.96	-0.31	1.36e-6	Acylcarnitine levels;
SARC	cis	rs2180341	0.960	rs7753913	chr6:127671296	A/G	cg17762328	chr6:126965162	NA	-0.44	-4.85	-0.3	2.22e-6	Breast cancer;
SARC	cis	rs6831352	0.877	rs29001183	chr4:100056539	C/T	cg12011299	chr4:100065546	ADH4	-0.34	-5.74	-0.35	2.95e-8	Alcohol dependence;
SARC	cis	rs7264396	0.563	rs17092980	chr20:34289005	T/C	cg01084648	chr20:34329383	RBM39	0.56	4.93	0.31	1.57e-6	Total cholesterol levels;
SARC	cis	rs922107	0.738	rs12729983	chr1:90046593	A/G	cg15422784	chr1:90023713	LRRC8B	-0.32	-4.72	-0.3	4.11e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
SARC	cis	rs12791968	1.000	rs11038240	chr11:45002878	A/G	cg11846598	chr11:44996168	LOC221122	0.37	5.76	0.35	2.64e-8	Inhibitory control;
SARC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.6	7.69	0.45	4.01e-13	Lymphocyte counts;
SARC	cis	rs8180040	0.726	rs2061197	chr3:47001350	C/T	cg27129171	chr3:47204927	SETD2	-0.68	-9.3	-0.52	1.05e-17	Colorectal cancer;
SARC	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg12923728	chr3:195709715	SDHAP1	-0.71	-8.82	-0.5	2.82e-16	Pancreatic cancer;
SARC	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg09699651	chr6:150184138	LRP11	0.39	4.87	0.3	2.04e-6	Lung cancer;
SARC	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg04944784	chr2:26401820	FAM59B	-0.47	-5.77	-0.35	2.47e-8	Gut microbiome composition (summer);
SARC	cis	rs9611519	0.894	rs13053242	chr22:41459486	G/A	cg17376030	chr22:41985996	PMM1	0.52	6.26	0.38	1.84e-9	Neuroticism;
SARC	cis	rs7829975	0.511	rs2976906	chr8:8342415	A/T	cg15556689	chr8:8085844	FLJ10661	0.4	5.24	0.32	3.64e-7	Mood instability;
SARC	cis	rs11112613	0.713	rs10507192	chr12:105948247	A/G	cg03607813	chr12:105948248	NA	0.57	7.99	0.46	6.05e-14	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs57994353	0.897	rs12551527	chr9:139358425	C/G	cg13611204	chr9:139324423	INPP5E	-0.28	-4.85	-0.3	2.26e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs11770686	0.902	rs7803077	chr7:75323206	T/C	cg17787366	chr7:75369077	HIP1	0.44	5.47	0.34	1.17e-7	Essential tremor;
SARC	cis	rs2089162	1	rs2089162	chr15:78739763	A/G	cg06917634	chr15:78832804	PSMA4	-0.54	-5.73	-0.35	3.07e-8	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs7264396	0.790	rs2425096	chr20:34308588	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	5.96	0.36	9.48e-9	Total cholesterol levels;
SARC	cis	rs739401	0.611	rs7109088	chr11:3027485	G/T	cg25174290	chr11:3078921	CARS	0.56	7.83	0.46	1.67e-13	Longevity;
SARC	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg00339695	chr16:24857497	SLC5A11	0.42	6.13	0.37	3.71e-9	Intelligence (multi-trait analysis);
SARC	cis	rs12971120	0.891	rs2303463	chr18:72168608	G/A	cg25817165	chr18:72167213	CNDP2	-0.53	-7.59	-0.45	7.66e-13	Refractive error;
SARC	cis	rs2594989	0.733	rs6777022	chr3:11577636	G/A	cg00170343	chr3:11313890	ATG7	-0.56	-6.14	-0.37	3.51e-9	Circulating chemerin levels;
SARC	cis	rs13223928	0.621	rs4722440	chr7:3155901	C/T	cg19214707	chr7:3157722	NA	0.33	4.72	0.3	4.03e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
SARC	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg22875332	chr1:76189707	ACADM	0.48	6.61	0.4	2.65e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6088590	0.930	rs6120723	chr20:33364655	C/T	cg24642439	chr20:33292090	TP53INP2	0.87	12.25	0.63	5.88e-27	Coronary artery disease;
SARC	cis	rs7520050	0.966	rs7556436	chr1:46363880	C/T	cg24296786	chr1:45957014	TESK2	-0.38	-4.92	-0.31	1.66e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs11644362	0.966	rs11645507	chr16:12992570	C/A	cg06890432	chr16:12997467	SHISA9	-0.51	-6.64	-0.4	2.15e-10	Positive affect;Subjective well-being;
SARC	cis	rs17270561	0.609	rs4711094	chr6:25706174	T/A	cg16482183	chr6:26056742	HIST1H1C	0.42	5.14	0.32	5.85e-7	Iron status biomarkers;
SARC	cis	rs2153535	0.580	rs9328488	chr6:8529411	G/C	cg07606381	chr6:8435919	SLC35B3	0.74	10.59	0.57	1.15e-21	Motion sickness;
SARC	cis	rs3768617	0.510	rs6424888	chr1:183085696	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.67	-9.93	-0.55	1.36e-19	Fuchs's corneal dystrophy;
SARC	cis	rs12142240	0.698	rs72677599	chr1:46834251	G/A	cg00530320	chr1:46809349	NSUN4	0.58	7.07	0.42	1.78e-11	Menopause (age at onset);
SARC	cis	rs911555	0.576	rs8015723	chr14:103895909	A/G	cg24130564	chr14:104152367	KLC1	0.44	4.81	0.3	2.77e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7927771	0.826	rs7925389	chr11:47466790	A/T	cg20307385	chr11:47447363	PSMC3	-0.6	-7.64	-0.45	5.58e-13	Subjective well-being;
SARC	cis	rs67460515	0.531	rs13060601	chr3:160823159	G/A	cg17135325	chr3:160939158	NMD3	0.65	7.81	0.46	1.95e-13	Parkinson's disease;
SARC	cis	rs2180341	0.513	rs12196828	chr6:127696864	C/T	cg27446573	chr6:127587934	RNF146	0.63	7.96	0.46	7.36e-14	Breast cancer;
SARC	cis	rs4891159	0.527	rs34956524	chr18:74130480	A/G	cg24786174	chr18:74118243	ZNF516	0.72	12.17	0.62	1.09e-26	Longevity;
SARC	cis	rs9344	0.837	rs1385874	chr11:69451580	G/A	cg26123414	chr11:69490316	ORAOV1	-0.37	-4.91	-0.31	1.68e-6	Immunoglobulin light chain (AL) amyloidosis (kidney involvement);Immunoglobulin light chain (AL) amyloidosis (serum Ig light chain only lambda/kappa based profile);Immunoglobulin light chain (AL) amyloidosis;Immunoglobulin light chain (AL) amyloidosis (heart involvement);Immunoglobulin light chain (AL) amyloidosis (serum Ig light chain only lambda based profile);Immunoglobulin light chain (AL) amyloidosis (serum Ig lambda profile);
SARC	cis	rs1355223	0.902	rs1773910	chr11:34741253	G/A	cg18508148	chr11:34937573	PDHX;APIP	-0.38	-4.83	-0.3	2.46e-6	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg13699009	chr12:122356056	WDR66	0.59	9.59	0.53	1.46e-18	Mean corpuscular volume;
SARC	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg19500275	chr17:80737654	TBCD	-0.5	-6.05	-0.37	5.77e-9	Glycated hemoglobin levels;
SARC	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-8.03	-0.47	4.67e-14	Chronic sinus infection;
SARC	cis	rs2070488	0.861	rs1858740	chr3:38438372	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	13.3	0.66	2.04e-30	Electrocardiographic conduction measures;
SARC	cis	rs9788682	1.000	rs12441354	chr15:78821016	G/A	cg24631222	chr15:78858424	CHRNA5	0.74	10.15	0.55	2.76e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs12079745	0.590	rs76722603	chr1:169321442	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.98	-5.75	-0.35	2.79e-8	QT interval;
SARC	cis	rs780096	0.814	rs780093	chr2:27742603	T/C	cg11618577	chr2:27665543	KRTCAP3	-0.32	-5.18	-0.32	4.73e-7	Total body bone mineral density;
SARC	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.58	5.48	0.34	1.1e-7	Age-related macular degeneration (geographic atrophy);
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg12089543	chr22:46646381	C22orf40	0.48	6.39	0.39	8.94e-10	Schizophrenia;
SARC	cis	rs9788682	0.747	rs2568485	chr15:78752114	C/T	cg06917634	chr15:78832804	PSMA4	0.51	5.3	0.33	2.63e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	trans	rs61931739	0.534	rs11052974	chr12:34029877	T/G	cg13010199	chr12:38710504	ALG10B	0.76	10.36	0.56	6.16e-21	Morning vs. evening chronotype;
SARC	cis	rs7617773	0.780	rs13090538	chr3:48370769	A/C	cg11946769	chr3:48343235	NME6	0.79	10.19	0.56	2.06e-20	Coronary artery disease;
SARC	trans	rs1814175	0.645	rs10742953	chr11:49807491	C/G	cg15704280	chr7:45808275	SEPT13	0.83	12.43	0.63	1.46e-27	Height;
SARC	cis	rs2239547	0.522	rs7652131	chr3:52997154	C/T	cg11645453	chr3:52864694	ITIH4	0.34	5.4	0.33	1.65e-7	Schizophrenia;
SARC	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg16414030	chr3:133502952	NA	-0.36	-4.76	-0.3	3.39e-6	Iron status biomarkers;
SARC	cis	rs1355223	0.506	rs7130678	chr11:34869181	A/G	cg18508148	chr11:34937573	PDHX;APIP	-0.39	-4.89	-0.31	1.88e-6	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs1008375	0.966	rs2191504	chr4:17675592	C/G	cg02297831	chr4:17616191	MED28	0.43	5.47	0.34	1.16e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1468333	0.894	rs435570	chr5:137468635	T/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.78	10.34	0.56	7.46e-21	Resting heart rate;
SARC	cis	rs7712401	0.601	rs2164773	chr5:122338917	T/C	cg19412675	chr5:122181750	SNX24	-0.42	-5.38	-0.33	1.84e-7	Mean platelet volume;
SARC	cis	rs11249608	0.548	rs2132671	chr5:178457434	A/G	cg21905437	chr5:178450457	ZNF879	-0.58	-8.2	-0.47	1.6e-14	Pubertal anthropometrics;
SARC	cis	rs9393692	0.577	rs9358914	chr6:26262063	G/T	cg13736514	chr6:26305472	NA	-0.41	-4.78	-0.3	3.13e-6	Educational attainment;
SARC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg06873352	chr17:61820015	STRADA	0.54	7.1	0.42	1.49e-11	Prudent dietary pattern;
SARC	cis	rs2153535	0.580	rs9393022	chr6:8466588	T/C	cg21535247	chr6:8435926	SLC35B3	0.54	6.79	0.41	9.19e-11	Motion sickness;
SARC	cis	rs965469	1.000	rs1040727	chr20:3264292	G/A	cg25506879	chr20:3388711	C20orf194	-0.5	-5.11	-0.32	6.73e-7	IFN-related cytopenia;
SARC	cis	rs6964587	0.692	rs10271430	chr7:91710466	G/C	cg17063962	chr7:91808500	NA	0.81	12.19	0.62	9.35e-27	Breast cancer;
SARC	cis	rs7208859	0.673	rs11652409	chr17:29182707	T/A	cg13385521	chr17:29058706	SUZ12P	0.86	7.34	0.43	3.54e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs2732480	0.500	rs1552550	chr12:48643351	C/A	cg24011408	chr12:48396354	COL2A1	0.46	5.35	0.33	2.08e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs9326248	0.954	rs521171	chr11:117064693	C/G	cg10130564	chr11:117069849	TAGLN	0.24	5.3	0.33	2.74e-7	Blood protein levels;
SARC	cis	rs10489202	0.683	rs202260	chr1:167956167	G/T	cg24449463	chr1:168025552	DCAF6	-0.64	-8.51	-0.49	2.18e-15	Schizophrenia;
SARC	cis	rs11098499	0.820	rs6829903	chr4:120506884	C/T	cg24375607	chr4:120327624	NA	0.42	4.92	0.31	1.64e-6	Corneal astigmatism;
SARC	cis	rs13191362	0.507	rs2803051	chr6:163034979	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.43	-4.81	-0.3	2.75e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg01475735	chr3:40494733	NA	-0.45	-4.97	-0.31	1.32e-6	Renal cell carcinoma;
SARC	cis	rs2425143	1.000	rs6060578	chr20:34305445	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	5.22	0.32	4e-7	Blood protein levels;
SARC	cis	rs7772486	0.754	rs9497434	chr6:146260753	C/T	cg23711669	chr6:146136114	FBXO30	-0.81	-12.94	-0.65	3.15e-29	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs362272	0.545	rs3135145	chr4:3299504	T/C	cg06533319	chr4:3265114	C4orf44	-0.33	-5.17	-0.32	5.13e-7	Serum sulfate level;
SARC	cis	rs10860964	0.746	rs11111484	chr12:103578127	G/A	cg11784990	chr12:103218665	NA	-0.31	-4.85	-0.3	2.26e-6	Schizophrenia;
SARC	cis	rs5753618	0.583	rs8141150	chr22:31800336	C/T	cg07713946	chr22:31675144	LIMK2	0.36	4.92	0.31	1.63e-6	Colorectal cancer;
SARC	cis	rs798554	0.655	rs798492	chr7:2799184	C/T	cg04166393	chr7:2884313	GNA12	-0.41	-5.02	-0.31	1.04e-6	Height;
SARC	cis	rs55883249	1.000	rs62119429	chr2:9743585	G/C	cg23886495	chr2:9695866	ADAM17	0.66	6.73	0.4	1.33e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs10782582	0.609	rs5745410	chr1:76314356	C/A	cg03433033	chr1:76189801	ACADM	-0.39	-4.99	-0.31	1.16e-6	Daytime sleep phenotypes;
SARC	cis	rs826838	0.651	rs12367384	chr12:38618460	G/T	cg13010199	chr12:38710504	ALG10B	0.7	9.21	0.52	2.01e-17	Heart rate;
SARC	cis	rs9921222	0.502	rs28461430	chr16:369562	G/A	cg12437481	chr16:420112	MRPL28	-0.36	-4.99	-0.31	1.17e-6	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.6	-6.31	-0.38	1.42e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs9309473	1.000	rs6755241	chr2:73641364	C/T	cg20560298	chr2:73613845	ALMS1	-0.48	-5.96	-0.36	9.16e-9	Metabolite levels;
SARC	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg26335602	chr6:28129616	ZNF389	0.52	5.65	0.35	4.72e-8	Depression;
SARC	cis	rs17666538	0.792	rs58523286	chr8:675683	C/T	cg02524346	chr8:600233	NA	-0.9	-5.67	-0.35	4.29e-8	IgG glycosylation;
SARC	cis	rs854765	0.547	rs9913277	chr17:17919749	G/T	cg04398451	chr17:18023971	MYO15A	-0.45	-6.48	-0.39	5.43e-10	Total body bone mineral density;
SARC	cis	rs826838	0.804	rs6580755	chr12:39159190	C/T	cg13010199	chr12:38710504	ALG10B	0.75	10.2	0.56	1.91e-20	Heart rate;
SARC	cis	rs17270561	0.609	rs1165208	chr6:25803904	G/A	cg16482183	chr6:26056742	HIST1H1C	0.48	6.14	0.37	3.54e-9	Iron status biomarkers;
SARC	cis	rs921968	0.541	rs7574429	chr2:219498759	T/G	cg02176678	chr2:219576539	TTLL4	0.5	7.61	0.45	6.66e-13	Mean corpuscular hemoglobin concentration;
SARC	cis	rs10782582	0.593	rs74968421	chr1:76233496	T/C	cg03433033	chr1:76189801	ACADM	-0.42	-5.29	-0.33	2.77e-7	Daytime sleep phenotypes;
SARC	cis	rs6815814	0.950	rs5743580	chr4:38804405	C/T	cg06935464	chr4:38784597	TLR10	0.63	6.31	0.38	1.41e-9	Breast cancer;
SARC	cis	rs2916247	1.000	rs11779617	chr8:93034215	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.58	-5.83	-0.36	1.84e-8	Intelligence (multi-trait analysis);
SARC	cis	rs6542838	0.641	rs6760065	chr2:99486318	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-5.54	-0.34	8.12e-8	Fear of minor pain;
SARC	cis	rs698833	0.527	rs12470423	chr2:44765199	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.4	5.11	0.32	6.85e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	trans	rs2727020	0.894	rs10839265	chr11:49369733	C/T	cg15704280	chr7:45808275	SEPT13	-0.74	-9.67	-0.54	8.17e-19	Coronary artery disease;
SARC	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg20607798	chr8:58055168	NA	0.57	4.86	0.3	2.2e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs4481887	0.893	rs10888349	chr1:248448625	T/C	cg01631408	chr1:248437212	OR2T33	-0.44	-5.58	-0.34	6.81e-8	Common traits (Other);
SARC	cis	rs35110281	0.720	rs162372	chr21:44928863	C/T	cg21573476	chr21:45109991	RRP1B	0.5	7.23	0.43	6.88e-12	Mean corpuscular volume;
SARC	cis	rs9902453	0.704	rs2628179	chr17:28071796	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.24	-0.43	6.45e-12	Coffee consumption (cups per day);
SARC	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg08219700	chr8:58056026	NA	-0.55	-5.15	-0.32	5.55e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs561341	0.700	rs6505266	chr17:30225813	G/A	cg12000587	chr17:30186630	C17orf79	-0.33	-5.12	-0.32	6.45e-7	Hip circumference adjusted for BMI;
SARC	cis	rs2624839	0.704	rs11919418	chr3:50233215	T/G	cg24110177	chr3:50126178	RBM5	-0.55	-7.0	-0.42	2.76e-11	Intelligence (multi-trait analysis);
SARC	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg03354898	chr7:1950403	MAD1L1	-0.36	-4.86	-0.3	2.12e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg16405210	chr4:1374714	KIAA1530	-0.5	-5.86	-0.36	1.61e-8	Obesity-related traits;
SARC	cis	rs4076764	1.000	rs6683181	chr1:163417077	C/T	cg06092702	chr1:163392909	NA	-0.3	-4.85	-0.3	2.27e-6	Motion sickness;
SARC	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg08219700	chr8:58056026	NA	0.63	6.0	0.37	7.62e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs748404	0.631	rs6493086	chr15:43655394	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.4	4.83	0.3	2.5e-6	Lung cancer;
SARC	cis	rs66573146	0.831	rs56300156	chr4:6990813	G/C	cg15105060	chr4:7024189	TBC1D14	-0.66	-4.75	-0.3	3.49e-6	Granulocyte percentage of myeloid white cells;
SARC	cis	rs4927850	1.000	rs4927848	chr3:195738406	A/G	cg01181863	chr3:195395398	SDHAP2	-0.63	-7.27	-0.43	5.39e-12	Pancreatic cancer;
SARC	cis	rs11122272	0.735	rs2749709	chr1:231530476	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-9.93	-0.55	1.35e-19	Hemoglobin concentration;
SARC	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg15595755	chr5:1867978	NA	0.49	6.8	0.41	8.62e-11	Cardiovascular disease risk factors;
SARC	cis	rs9807989	0.507	rs10203558	chr2:103027640	T/C	cg03938978	chr2:103052716	IL18RAP	0.31	5.04	0.31	9.37e-7	Asthma;
SARC	cis	rs7617773	0.780	rs3197223	chr3:48335857	C/T	cg11946769	chr3:48343235	NME6	0.76	9.72	0.54	5.65e-19	Coronary artery disease;
SARC	cis	rs2288073	0.965	rs10173949	chr2:24410256	A/C	cg26838691	chr2:24397539	C2orf84	-0.55	-6.84	-0.41	6.85e-11	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg06212747	chr3:49208901	KLHDC8B	0.65	8.6	0.49	1.2e-15	Parkinson's disease;
SARC	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	11.31	0.6	6.28e-24	Alzheimer's disease;
SARC	cis	rs8067354	0.609	rs1292066	chr17:57932314	T/A	cg13753209	chr17:57696993	CLTC	0.62	6.59	0.4	2.98e-10	Hemoglobin concentration;
SARC	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg06221963	chr1:154839813	KCNN3	-0.52	-8.26	-0.48	1.11e-14	Prostate cancer;
SARC	cis	rs208520	1.000	rs12199876	chr6:66989469	A/G	cg07460842	chr6:66804631	NA	0.9	10.36	0.56	6.24e-21	Exhaled nitric oxide output;
SARC	cis	rs10911232	0.507	rs35782443	chr1:183051502	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.35	0.56	6.82e-21	Hypertriglyceridemia;
SARC	cis	rs4144743	1.000	rs72823474	chr17:45321776	G/C	cg18085866	chr17:45331354	ITGB3	-0.73	-7.4	-0.44	2.42e-12	Body mass index;
SARC	cis	rs12142240	0.698	rs67941619	chr1:46838219	A/G	cg00530320	chr1:46809349	NSUN4	0.57	7.0	0.42	2.74e-11	Menopause (age at onset);
SARC	cis	rs1059312	0.808	rs4760533	chr12:129297651	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.45	5.53	0.34	8.74e-8	Systemic lupus erythematosus;
SARC	cis	rs6674176	0.561	rs4660263	chr1:44421433	A/C	cg12908607	chr1:44402522	ARTN	-0.38	-6.55	-0.39	3.64e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs5167	0.504	rs8100120	chr19:45466058	T/C	cg10169327	chr19:45448959	APOC2	0.33	5.63	0.35	5.08e-8	Blood protein levels;
SARC	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg19671926	chr4:122722719	EXOSC9	-0.55	-6.03	-0.37	6.38e-9	Type 2 diabetes;
SARC	trans	rs12310956	0.532	rs7967627	chr12:33974669	G/T	cg13010199	chr12:38710504	ALG10B	0.65	8.66	0.49	7.86e-16	Morning vs. evening chronotype;
SARC	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg05872129	chr22:39784769	NA	0.46	6.41	0.39	7.91e-10	Intelligence (multi-trait analysis);
SARC	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg12373951	chr3:133503437	NA	0.36	5.29	0.33	2.88e-7	Iron status biomarkers;
SARC	cis	rs2228479	0.850	rs17233455	chr16:89816407	A/G	cg26513180	chr16:89883248	FANCA	0.72	4.79	0.3	2.99e-6	Skin colour saturation;
SARC	cis	rs7917772	0.629	rs1475646	chr10:104522564	G/T	ch.10.2196322F	chr10:104248062	ACTR1A	-0.46	-5.4	-0.33	1.61e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs10982256	0.789	rs2296262	chr9:117265406	C/T	cg21159778	chr9:117266918	DFNB31	0.39	5.37	0.33	1.91e-7	Bipolar disorder;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg09611962	chr16:30886742	NA	0.49	6.63	0.4	2.29e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs1949733	0.523	rs16842560	chr4:8544238	G/A	cg05004818	chr4:8539015	NA	0.38	4.83	0.3	2.45e-6	Response to antineoplastic agents;
SARC	cis	rs7561528	0.501	rs60572885	chr2:127891116	T/C	cg12632573	chr2:127783243	NA	0.65	5.55	0.34	7.91e-8	Alzheimer's disease;Alzheimer's disease (late onset);
SARC	cis	rs7043114	0.525	rs8067	chr9:95218829	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.75	-0.35	2.72e-8	Height;
SARC	cis	rs1050631	0.564	rs1785905	chr18:33713287	T/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.59	7.17	0.43	9.66e-12	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg00149659	chr3:10157352	C3orf10	0.69	6.9	0.41	4.76e-11	Alzheimer's disease;
SARC	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg19223190	chr17:80058835	NA	0.44	6.19	0.38	2.67e-9	Life satisfaction;
SARC	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg13395646	chr4:1353034	KIAA1530	-0.57	-6.81	-0.41	7.99e-11	Obesity-related traits;
SARC	cis	rs9436747	0.626	rs7513047	chr1:65950340	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.38	4.93	0.31	1.58e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs1008375	1.000	rs7661631	chr4:17679751	T/C	cg16339924	chr4:17578868	LAP3	-0.66	-8.61	-0.49	1.09e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs3126085	1.000	rs72696963	chr1:152181189	T/C	cg26876637	chr1:152193138	HRNR	-0.51	-5.35	-0.33	2.15e-7	Atopic dermatitis;
SARC	cis	rs13082711	0.871	rs13061912	chr3:27495586	A/G	cg02860705	chr3:27208620	NA	0.46	5.89	0.36	1.33e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg06074448	chr4:187884817	NA	-0.36	-4.85	-0.3	2.25e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs644799	0.710	rs3017756	chr11:95537358	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	13.53	0.66	3.66e-31	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs55962025	0.842	rs2269477	chr4:3184464	G/T	cg06533319	chr4:3265114	C4orf44	0.34	5.03	0.31	9.77e-7	Parental longevity (mother's age at death);
SARC	cis	rs9660992	0.649	rs12128229	chr1:205268014	C/A	cg07972983	chr1:205091412	RBBP5	0.51	5.97	0.36	8.74e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs56104184	0.779	rs17272666	chr19:49356294	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.89	-8.46	-0.48	3.03e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg22974920	chr21:40686053	BRWD1	0.43	4.77	0.3	3.31e-6	Cognitive function;
SARC	cis	rs240764	0.554	rs6570970	chr6:101233082	C/A	cg09795085	chr6:101329169	ASCC3	0.45	5.66	0.35	4.42e-8	Neuroticism;
SARC	cis	rs3858526	0.920	rs11511938	chr11:5928793	A/G	cg13902645	chr11:5959945	NA	-0.45	-5.23	-0.32	3.7e-7	DNA methylation (variation);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg10717722	chr10:124134020	PLEKHA1	0.47	6.36	0.38	1.06e-9	Chemerin levels;
SARC	cis	rs11190604	1.000	rs2495741	chr10:102331795	A/G	cg14256752	chr10:102295592	HIF1AN	0.42	4.76	0.3	3.38e-6	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg27494647	chr7:150038898	RARRES2	-0.36	-4.96	-0.31	1.34e-6	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs12421382	0.881	rs1808843	chr11:109389471	A/G	cg06719900	chr11:109292894	C11orf87	0.35	4.79	0.3	3.03e-6	Schizophrenia;
SARC	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.33	-4.93	-0.31	1.54e-6	Total body bone mineral density;
SARC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg26338869	chr17:61819248	STRADA	0.8	10.83	0.58	2.15e-22	Prudent dietary pattern;
SARC	cis	rs7592578	0.766	rs62181052	chr2:191387858	A/G	cg10560079	chr2:191398806	TMEM194B	-0.79	-8.23	-0.47	1.36e-14	Diastolic blood pressure;
SARC	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg13206674	chr6:150067644	NUP43	0.4	4.84	0.3	2.32e-6	Lung cancer;
SARC	cis	rs72781680	0.611	rs72781696	chr2:24267014	C/T	cg06627628	chr2:24431161	ITSN2	-0.61	-6.04	-0.37	6.18e-9	Lymphocyte counts;
SARC	cis	rs9810089	0.802	rs73222302	chr3:136098085	A/G	cg15507776	chr3:136538369	TMEM22	0.45	4.97	0.31	1.33e-6	Gestational age at birth (child effect);
SARC	cis	rs9325144	0.560	rs1825802	chr12:38650341	C/T	cg13010199	chr12:38710504	ALG10B	-0.57	-7.44	-0.44	1.87e-12	Morning vs. evening chronotype;
SARC	cis	rs2806561	0.704	rs7532266	chr1:23551623	A/C	cg12483005	chr1:23474871	LUZP1	-0.46	-5.87	-0.36	1.46e-8	Height;
SARC	trans	rs208520	0.742	rs208454	chr6:66907783	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.93	-10.74	-0.58	4.13e-22	Exhaled nitric oxide output;
SARC	cis	rs6484504	0.600	rs2761593	chr11:31326752	G/T	cg19308365	chr11:31391254	DNAJC24;DCDC1	0.39	4.82	0.3	2.59e-6	Red blood cell count;
SARC	cis	rs9467773	0.620	rs2494694	chr6:26619328	A/T	cg12292205	chr6:26970375	C6orf41	0.4	5.04	0.31	9.34e-7	Intelligence (multi-trait analysis);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg23576258	chr2:39999331	THUMPD2	0.48	6.6	0.4	2.7e-10	Thyroid stimulating hormone;
SARC	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg19077165	chr18:44547161	KATNAL2	-0.52	-7.15	-0.42	1.09e-11	Personality dimensions;
SARC	cis	rs7089973	0.872	rs7909657	chr10:116629096	C/G	cg08188268	chr10:116634841	FAM160B1	0.37	5.89	0.36	1.33e-8	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs7937682	0.593	rs1944121	chr11:111347223	T/C	cg09085632	chr11:111637200	PPP2R1B	0.43	4.94	0.31	1.48e-6	Primary sclerosing cholangitis;
SARC	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg13206674	chr6:150067644	NUP43	0.53	6.84	0.41	6.85e-11	Lung cancer;
SARC	cis	rs6087990	0.735	rs2065576	chr20:31389009	C/T	cg13636640	chr20:31349939	DNMT3B	0.77	12.01	0.62	3.49e-26	Ulcerative colitis;
SARC	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg04756594	chr16:24857601	SLC5A11	-0.45	-6.0	-0.37	7.61e-9	Intelligence (multi-trait analysis);
SARC	cis	rs950776	0.714	rs472054	chr15:78887994	A/G	cg22563815	chr15:78856949	CHRNA5	-0.34	-5.41	-0.33	1.53e-7	Sudden cardiac arrest;
SARC	cis	rs8041863	1.000	rs7176941	chr15:89350967	C/T	cg00506935	chr15:89169262	AEN	-0.32	-4.73	-0.3	3.81e-6	Height;
SARC	cis	rs9398803	0.687	rs1417572	chr6:126958727	T/C	cg19875578	chr6:126661172	C6orf173	0.61	8.32	0.48	7.54e-15	Male-pattern baldness;
SARC	cis	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg05623727	chr3:50126028	RBM5	-0.35	-5.21	-0.32	4.11e-7	Body mass index;
SARC	cis	rs72627509	0.951	rs6554401	chr4:57825336	C/G	cg26694713	chr4:57773883	REST	0.65	6.57	0.4	3.31e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg09323728	chr8:95962352	TP53INP1	-0.29	-4.79	-0.3	2.95e-6	Type 2 diabetes;
SARC	cis	rs2180341	0.920	rs1073931	chr6:127681762	A/T	cg17762328	chr6:126965162	NA	-0.43	-4.75	-0.3	3.62e-6	Breast cancer;
SARC	cis	rs2712184	0.756	rs2712182	chr2:217647525	T/C	cg05032264	chr2:217675019	NA	-0.53	-6.99	-0.42	2.86e-11	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
SARC	cis	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-5.49	-0.34	1.04e-7	Neuroticism;
SARC	cis	rs8084125	0.832	rs62105182	chr18:74951407	T/C	cg26065057	chr18:74961000	GALR1	0.47	4.89	0.31	1.89e-6	Obesity-related traits;
SARC	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg26681399	chr22:41777847	TEF	-0.43	-4.81	-0.3	2.68e-6	Vitiligo;
SARC	cis	rs1448094	0.512	rs7970842	chr12:86243258	C/T	cg02569458	chr12:86230093	RASSF9	0.39	5.46	0.34	1.2e-7	Major depressive disorder;
SARC	cis	rs6058796	1.000	rs6141779	chr20:31259366	C/T	cg13636640	chr20:31349939	DNMT3B	0.56	4.94	0.31	1.48e-6	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs9948	0.521	rs62156206	chr2:97357108	G/A	cg01990225	chr2:97406019	LMAN2L	-0.98	-7.47	-0.44	1.56e-12	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs7412746	0.658	rs12410394	chr1:150860186	G/A	cg13175981	chr1:150552382	MCL1	-0.49	-5.9	-0.36	1.29e-8	Melanoma;
SARC	cis	rs9818758	0.607	rs55873331	chr3:49597055	C/T	cg00383909	chr3:49044727	WDR6	0.78	6.53	0.39	4.12e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs11112613	0.713	rs60865625	chr12:105940256	A/C	cg03607813	chr12:105948248	NA	0.55	7.33	0.43	3.76e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg06074448	chr4:187884817	NA	-0.38	-5.19	-0.32	4.58e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6089584	0.606	rs2273989	chr20:60579138	G/A	cg23262073	chr20:60523788	NA	-0.36	-5.38	-0.33	1.82e-7	Body mass index;
SARC	cis	rs2933343	0.903	rs2638846	chr3:128587163	A/T	cg24203234	chr3:128598194	ACAD9	0.53	5.93	0.36	1.09e-8	IgG glycosylation;
SARC	cis	rs858239	0.537	rs6942981	chr7:23231548	C/T	cg23682824	chr7:23144976	KLHL7	0.67	8.49	0.49	2.5e-15	Cerebrospinal fluid biomarker levels;
SARC	cis	rs7714584	0.826	rs34005003	chr5:150225199	C/T	cg22134413	chr5:150180641	NA	0.78	6.56	0.39	3.42e-10	Crohn's disease;
SARC	cis	rs11098499	0.722	rs1814814	chr4:120258124	C/G	cg24375607	chr4:120327624	NA	0.4	5.01	0.31	1.08e-6	Corneal astigmatism;
SARC	cis	rs4689388	0.926	rs10012946	chr4:6293350	C/T	cg00701064	chr4:6280414	WFS1	-0.56	-8.78	-0.5	3.55e-16	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.76	9.12	0.51	3.57e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs11997175	0.766	rs6995220	chr8:33708919	C/A	ch.8.33884649F	chr8:33765107	NA	0.57	7.77	0.45	2.53e-13	Body mass index;
SARC	cis	rs10870270	0.830	rs10781571	chr10:133774316	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.48	-5.35	-0.33	2.13e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs9911578	0.967	rs12603238	chr17:57130785	C/T	cg20303301	chr17:57937339	TUBD1	0.34	4.86	0.3	2.19e-6	Intelligence (multi-trait analysis);
SARC	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg16479474	chr6:28041457	NA	0.37	5.49	0.34	1.04e-7	Depression;
SARC	cis	rs2290159	0.800	rs28462331	chr3:12660466	G/C	cg23032965	chr3:12705835	RAF1	0.73	7.89	0.46	1.18e-13	Cholesterol, total;
SARC	cis	rs10992471	0.528	rs3739606	chr9:95237222	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.42	-4.72	-0.3	4.12e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs6570726	0.935	rs451349	chr6:145820894	A/G	cg23711669	chr6:146136114	FBXO30	0.78	11.91	0.62	7.29e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg05861140	chr6:150128134	PCMT1	-0.41	-5.36	-0.33	1.95e-7	Lung cancer;
SARC	cis	rs17666538	1.000	rs59631161	chr8:587808	G/T	cg07685180	chr8:600429	NA	-0.73	-5.89	-0.36	1.37e-8	IgG glycosylation;
SARC	trans	rs11098499	0.657	rs9996569	chr4:120299004	G/C	cg25214090	chr10:38739885	LOC399744	0.55	7.14	0.42	1.15e-11	Corneal astigmatism;
SARC	cis	rs2832191	0.626	rs2254796	chr21:30341891	A/G	cg08807101	chr21:30365312	RNF160	-0.87	-13.5	-0.66	4.38e-31	Dental caries;
SARC	cis	rs6665290	0.669	rs7552783	chr1:227174145	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.01	-20.33	-0.8	1.55e-53	Myeloid white cell count;
SARC	cis	rs546131	0.642	rs2915186	chr11:34851183	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.42	4.91	0.31	1.69e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs6728642	0.808	rs114192053	chr2:97871906	G/A	cg26665480	chr2:98280029	ACTR1B	-0.64	-5.07	-0.32	8.2e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs8031584	0.958	rs11629793	chr15:31238423	G/A	cg14298792	chr15:30685198	CHRFAM7A	-0.45	-4.93	-0.31	1.57e-6	Huntington's disease progression;
SARC	cis	rs6582630	0.576	rs2387836	chr12:38560070	A/G	cg04568710	chr12:38710424	ALG10B	0.46	5.51	0.34	9.42e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg07701084	chr6:150067640	NUP43	0.41	5.43	0.34	1.38e-7	Lung cancer;
SARC	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg02725872	chr8:58115012	NA	-0.33	-5.25	-0.33	3.45e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs9329221	0.905	rs10283145	chr8:10241411	C/T	cg06636001	chr8:8085503	FLJ10661	-0.69	-9.17	-0.51	2.65e-17	Neuroticism;
SARC	cis	rs3812049	0.737	rs790155	chr5:127498380	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.83	9.1	0.51	4.08e-17	Lymphocyte counts;Red cell distribution width;
SARC	cis	rs11190604	1.000	rs11190604	chr10:102302457	A/G	cg07080220	chr10:102295463	HIF1AN	0.82	9.29	0.52	1.14e-17	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs4906332	1.000	rs2065017	chr14:103879579	T/C	cg26031613	chr14:104095156	KLC1	-0.48	-5.64	-0.35	5.02e-8	Coronary artery disease;
SARC	trans	rs9325144	0.534	rs1973293	chr12:38679575	C/T	cg23762105	chr12:34175262	ALG10	-0.52	-6.98	-0.42	3.03e-11	Morning vs. evening chronotype;
SARC	cis	rs2952156	0.920	rs2934951	chr17:37833328	A/G	cg20243544	chr17:37824526	PNMT	0.54	7.21	0.43	7.62e-12	Asthma;
SARC	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg11644478	chr21:40555479	PSMG1	-0.89	-11.4	-0.6	3.15e-24	Cognitive function;
SARC	cis	rs7772486	0.597	rs9386136	chr6:146158300	A/T	cg23711669	chr6:146136114	FBXO30	0.83	12.2	0.62	8.2e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6582630	0.502	rs10880450	chr12:38440294	G/C	cg13010199	chr12:38710504	ALG10B	0.73	9.31	0.52	9.67e-18	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2842992	0.747	rs4709378	chr6:160227435	G/C	cg11366901	chr6:160182831	ACAT2	1.01	9.67	0.54	7.99e-19	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg18252515	chr7:66147081	NA	-1.33	-11.84	-0.61	1.22e-25	Diabetic kidney disease;
SARC	cis	rs9818758	0.607	rs113186424	chr3:49272726	T/C	cg01304814	chr3:48885189	PRKAR2A	0.61	5.07	0.32	8.11e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs11997175	0.603	rs7462153	chr8:33814607	C/T	ch.8.33884649F	chr8:33765107	NA	0.44	5.59	0.34	6.24e-8	Body mass index;
SARC	cis	rs9435341	0.762	rs3861909	chr1:107544176	A/G	cg09367891	chr1:107599246	PRMT6	-0.68	-8.2	-0.47	1.63e-14	Facial morphology (factor 21, depth of nasal alae);
SARC	cis	rs10513788	0.855	rs17289828	chr3:182060941	C/T	cg05977900	chr3:182512126	ATP11B	0.47	4.83	0.3	2.47e-6	Cognitive function;
SARC	cis	rs1451375	0.617	rs11772714	chr7:50542843	G/A	cg14593290	chr7:50529359	DDC	-0.46	-4.98	-0.31	1.25e-6	Malaria;
SARC	trans	rs7824557	0.510	rs2736297	chr8:11234885	C/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.02	-0.42	2.36e-11	Retinal vascular caliber;
SARC	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg24549020	chr5:56110836	MAP3K1	0.44	5.07	0.32	8.11e-7	Coronary artery disease;
SARC	cis	rs854765	0.547	rs2955378	chr17:17930253	G/A	cg05444541	chr17:17804740	TOM1L2	-0.3	-4.86	-0.3	2.16e-6	Total body bone mineral density;
SARC	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg18252515	chr7:66147081	NA	-0.44	-4.8	-0.3	2.78e-6	Aortic root size;
SARC	cis	rs3087591	0.810	rs2269856	chr17:29482701	C/T	cg24425628	chr17:29625626	OMG;NF1	0.56	6.88	0.41	5.46e-11	Hip circumference;
SARC	cis	rs7635838	0.892	rs66974661	chr3:11482729	A/G	cg00170343	chr3:11313890	ATG7	0.64	8.76	0.5	3.99e-16	HDL cholesterol;
SARC	cis	rs344364	0.511	rs1742462	chr16:1946062	A/C	cg26617929	chr16:1858877	NA	-0.71	-6.06	-0.37	5.5e-9	Glomerular filtration rate in chronic kidney disease;
SARC	cis	rs5753618	0.561	rs2283879	chr22:31638448	G/A	cg02404636	chr22:31891804	SFI1	-0.47	-4.99	-0.31	1.19e-6	Colorectal cancer;
SARC	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg18357526	chr6:26021779	HIST1H4A	0.46	5.72	0.35	3.18e-8	Blood metabolite levels;
SARC	cis	rs6831352	0.879	rs56272995	chr4:100060882	A/G	cg13256891	chr4:100009986	ADH5	-0.65	-8.0	-0.46	5.94e-14	Alcohol dependence;
SARC	cis	rs6696846	0.716	rs6593921	chr1:205062861	A/G	cg00857998	chr1:205179979	DSTYK	0.44	5.3	0.33	2.68e-7	Red blood cell count;
SARC	cis	rs6540556	0.608	rs2282738	chr1:209882015	C/T	cg05527609	chr1:210001259	C1orf107	-0.47	-4.75	-0.3	3.58e-6	Red blood cell count;
SARC	cis	rs372883	0.564	rs766928	chr21:30753606	A/G	cg08807101	chr21:30365312	RNF160	0.57	7.17	0.43	9.9e-12	Pancreatic cancer;
SARC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.62	-6.59	-0.4	2.82e-10	Platelet count;
SARC	cis	rs734999	0.588	rs6668149	chr1:2558308	A/C	cg18854424	chr1:2615690	NA	-0.31	-4.91	-0.31	1.73e-6	Ulcerative colitis;
SARC	cis	rs7296418	0.738	rs10846489	chr12:123743927	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.39	5.19	0.32	4.64e-7	Platelet count;
SARC	cis	rs2354432	0.599	rs4950423	chr1:146854539	T/C	cg25205988	chr1:146714368	CHD1L	0.95	7.02	0.42	2.35e-11	Mitochondrial DNA levels;
SARC	cis	rs6991838	0.556	rs7846527	chr8:66498757	A/G	cg13398993	chr8:66546079	ARMC1	-0.62	-8.31	-0.48	7.89e-15	Intelligence (multi-trait analysis);
SARC	cis	rs59918340	0.728	rs10875467	chr8:142233396	A/C	cg16341495	chr8:142228727	SLC45A4	0.36	5.22	0.32	3.99e-7	Immature fraction of reticulocytes;
SARC	cis	rs193541	0.632	rs7735618	chr5:122176245	C/G	cg19412675	chr5:122181750	SNX24	0.49	6.45	0.39	6.45e-10	Glucose homeostasis traits;
SARC	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.62	-6.33	-0.38	1.24e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg19901468	chr14:105411992	AHNAK2	-0.73	-10.79	-0.58	2.78e-22	Rheumatoid arthritis;
SARC	cis	rs11190604	1.000	rs11816840	chr10:102309220	G/C	cg07080220	chr10:102295463	HIF1AN	0.82	10.39	0.56	4.98e-21	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs6918586	0.681	rs198831	chr6:26116996	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.46	-5.8	-0.36	2.16e-8	Schizophrenia;
SARC	cis	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg25894440	chr7:65020034	NA	-0.74	-5.55	-0.34	7.85e-8	Diabetic kidney disease;
SARC	cis	rs9291683	0.618	rs13137343	chr4:10043028	C/A	cg11266682	chr4:10021025	SLC2A9	0.4	7.27	0.43	5.35e-12	Bone mineral density;
SARC	cis	rs1153858	1.000	rs60476496	chr15:45713801	C/T	cg21132104	chr15:45694354	SPATA5L1	0.78	10.53	0.57	1.86e-21	Homoarginine levels;
SARC	trans	rs17221829	0.733	rs11018668	chr11:89356178	C/T	cg14218513	chr9:123639924	PHF19	0.46	6.31	0.38	1.42e-9	Anxiety in major depressive disorder;
SARC	cis	rs7894051	1.000	rs11101721	chr10:135190358	C/G	cg03826430	chr10:135192749	PAOX	-0.88	-6.1	-0.37	4.48e-9	Lifespan;
SARC	cis	rs10088262	0.629	rs7015861	chr8:124795613	C/T	cg02993010	chr8:124780839	FAM91A1	-0.76	-9.12	-0.51	3.7e-17	Pancreatic cancer;
SARC	cis	rs12950390	0.820	rs58391889	chr17:45865959	A/G	cg24803719	chr17:45855879	NA	-0.47	-7.71	-0.45	3.56e-13	IgG glycosylation;
SARC	cis	rs12190007	0.547	rs3006178	chr6:169823936	G/A	cg15038512	chr6:170123185	PHF10	-0.49	-6.69	-0.4	1.6e-10	Obesity-related traits;
SARC	cis	rs9527	0.545	rs7095304	chr10:104954795	G/A	cg04362960	chr10:104952993	NT5C2	0.43	5.06	0.31	8.57e-7	Arsenic metabolism;
SARC	cis	rs2213920	0.679	rs4979534	chr9:118211159	T/C	cg13918206	chr9:118159781	DEC1	0.8	6.38	0.39	9.55e-10	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs11640734	0.609	rs11647746	chr16:89806343	C/A	cg06558623	chr16:89946397	TCF25	0.75	5.85	0.36	1.67e-8	Interleukin-17 levels;
SARC	cis	rs1949733	1.000	rs1880023	chr4:8480831	C/T	cg11789530	chr4:8429930	ACOX3	-0.82	-11.21	-0.59	1.34e-23	Response to antineoplastic agents;
SARC	cis	rs7772486	0.686	rs1292337	chr6:145967807	A/G	cg23711669	chr6:146136114	FBXO30	-0.78	-12.56	-0.64	5.68e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9322817	0.902	rs963949	chr6:105174273	A/G	cg02098413	chr6:105308735	HACE1	-0.34	-4.75	-0.3	3.49e-6	Thyroid stimulating hormone;
SARC	cis	rs2276314	0.857	rs4799408	chr18:33588982	C/T	cg05985134	chr18:33552581	C18orf21	-0.71	-7.53	-0.44	1.1e-12	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs6840360	0.571	rs718800	chr4:152549307	A/T	cg22705602	chr4:152727874	NA	0.4	5.74	0.35	2.93e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2467099	1.000	rs2467099	chr17:73949045	C/T	cg23806715	chr17:73775811	H3F3B	0.55	5.47	0.34	1.18e-7	Systolic blood pressure;
SARC	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg03576123	chr11:487126	PTDSS2	-1.16	-11.48	-0.6	1.74e-24	Body mass index;
SARC	trans	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.07	-0.42	1.81e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg03351412	chr1:154909251	PMVK	0.62	7.81	0.46	1.98e-13	Prostate cancer;
SARC	cis	rs2599510	0.811	rs2710625	chr2:32822957	G/A	cg02381751	chr2:32503542	YIPF4	0.47	5.79	0.35	2.24e-8	Interleukin-18 levels;
SARC	cis	rs2354432	0.607	rs6689243	chr1:146710559	A/T	cg25205988	chr1:146714368	CHD1L	-1.04	-7.47	-0.44	1.58e-12	Mitochondrial DNA levels;
SARC	cis	rs9462027	0.561	rs2235568	chr6:34570094	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-6.17	-0.37	3.07e-9	Systemic lupus erythematosus;
SARC	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg11764359	chr7:65958608	NA	-0.53	-6.13	-0.37	3.78e-9	Aortic root size;
SARC	cis	rs9303401	0.527	rs7224468	chr17:56749943	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	11.88	0.61	9.47e-26	Cognitive test performance;
SARC	cis	rs7084402	0.967	rs2170779	chr10:60277249	G/A	cg07615347	chr10:60278583	BICC1	-0.6	-8.82	-0.5	2.78e-16	Refractive error;
SARC	cis	rs6732160	0.706	rs1430348	chr2:73367058	C/T	cg01422370	chr2:73384389	NA	0.32	5.27	0.33	3.09e-7	Intelligence (multi-trait analysis);
SARC	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg26554054	chr8:600488	NA	0.64	5.17	0.32	4.95e-7	IgG glycosylation;
SARC	cis	rs11651000	0.895	rs79065115	chr17:45855929	C/G	cg24803719	chr17:45855879	NA	-0.43	-5.18	-0.32	4.9e-7	IgG glycosylation;
SARC	cis	rs7829975	0.582	rs6983150	chr8:8792426	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.75	-0.4	1.18e-10	Mood instability;
SARC	cis	rs10193935	0.901	rs3755304	chr2:42589921	A/G	cg27598129	chr2:42591480	NA	0.34	4.9	0.31	1.81e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2239547	0.522	rs2336669	chr3:52994138	C/T	cg07507251	chr3:52567010	NT5DC2	-0.38	-4.96	-0.31	1.33e-6	Schizophrenia;
SARC	cis	rs916888	0.531	rs183211	chr17:44788310	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.54	6.33	0.38	1.25e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs3741151	1.000	rs76764824	chr11:73073580	C/T	cg17517138	chr11:73019481	ARHGEF17	0.99	7.01	0.42	2.57e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg24110177	chr3:50126178	RBM5	-0.59	-7.48	-0.44	1.55e-12	Intelligence (multi-trait analysis);
SARC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg17291435	chr2:106015527	FHL2	-0.59	-6.53	-0.39	3.97e-10	Hepatitis;
SARC	cis	rs7223966	1.000	rs13380863	chr17:61780793	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.46	4.8	0.3	2.78e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg11028091	chr15:72522207	PKM2	-0.75	-6.38	-0.39	9.36e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6964587	1.000	rs6979085	chr7:91673623	C/T	cg17063962	chr7:91808500	NA	0.93	15.8	0.72	1.07e-38	Breast cancer;
SARC	cis	rs6429082	0.702	rs2131922	chr1:235705001	G/T	cg26050004	chr1:235667680	B3GALNT2	-0.44	-4.81	-0.3	2.67e-6	Adiposity;
SARC	cis	rs2273669	0.667	rs12215344	chr6:109329641	A/C	cg05315195	chr6:109294784	ARMC2	-0.64	-5.7	-0.35	3.68e-8	Prostate cancer;
SARC	cis	rs950169	1.000	rs12916348	chr15:84765527	C/T	cg17507749	chr15:85114479	UBE2QP1	0.75	9.16	0.51	2.77e-17	Schizophrenia;
SARC	cis	rs10504229	0.679	rs4738574	chr8:58033771	T/C	cg21724239	chr8:58056113	NA	0.6	6.2	0.38	2.51e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9715521	0.935	rs72634625	chr4:59836434	T/A	cg11281224	chr4:60001000	NA	-0.39	-4.97	-0.31	1.31e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9457247	1.000	rs365189	chr6:167384545	G/A	cg07741184	chr6:167504864	NA	0.3	5.61	0.35	5.69e-8	Crohn's disease;
SARC	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg04546413	chr19:29218101	NA	0.63	8.54	0.49	1.71e-15	Methadone dose in opioid dependence;
SARC	cis	rs17270561	0.609	rs4712960	chr6:25727265	C/T	cg17691542	chr6:26056736	HIST1H1C	0.58	7.09	0.42	1.59e-11	Iron status biomarkers;
SARC	cis	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg11266682	chr4:10021025	SLC2A9	0.41	7.29	0.43	4.75e-12	Bone mineral density;
SARC	cis	rs11098499	0.909	rs2127821	chr4:120394535	T/C	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs9640161	0.789	rs34311995	chr7:150059255	T/C	cg10018233	chr7:150070692	REPIN1	0.71	10.46	0.57	2.97e-21	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs66887589	0.616	rs11098497	chr4:120187068	C/T	cg09307838	chr4:120376055	NA	0.61	8.08	0.47	3.59e-14	Diastolic blood pressure;
SARC	cis	rs449789	0.857	rs687314	chr6:159716262	G/C	cg14500486	chr6:159655392	FNDC1	-0.44	-5.02	-0.31	1.01e-6	Pulse pressure;
SARC	cis	rs12554020	0.892	rs75625893	chr9:96367288	A/G	cg21184699	chr9:96277131	FAM120A	-0.5	-4.73	-0.3	3.97e-6	Schizophrenia;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg04872475	chr1:11159259	EXOSC10	0.51	6.81	0.41	8.36e-11	Lung adenocarcinoma;
SARC	cis	rs11608355	0.597	rs12579285	chr12:109832712	T/C	cg05360138	chr12:110035743	NA	0.38	4.72	0.3	4.13e-6	Neuroticism;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg19423197	chr3:113465120	ATP6V1A;NAA50	0.53	7.12	0.42	1.3e-11	Tetralogy of Fallot;
SARC	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg16479474	chr6:28041457	NA	0.35	5.26	0.33	3.28e-7	Parkinson's disease;
SARC	cis	rs832540	1.000	rs252914	chr5:56198150	A/C	cg14703610	chr5:56206110	C5orf35	0.55	6.96	0.42	3.35e-11	Coronary artery disease;
SARC	cis	rs6546550	0.904	rs3771537	chr2:70038792	A/C	cg02498382	chr2:70120550	SNRNP27	-0.39	-6.35	-0.38	1.14e-9	Prevalent atrial fibrillation;
SARC	cis	rs546131	0.928	rs546521	chr11:34824773	G/C	cg06937548	chr11:34938143	PDHX;APIP	0.48	6.14	0.37	3.59e-9	Lung disease severity in cystic fibrosis;
SARC	cis	rs2486288	0.656	rs11854325	chr15:45548959	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.45	-5.55	-0.34	7.66e-8	Glomerular filtration rate;
SARC	cis	rs6570726	0.791	rs1280275	chr6:145892402	C/T	cg23711669	chr6:146136114	FBXO30	0.83	13.59	0.66	2.33e-31	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg06028808	chr11:68637592	NA	0.48	6.23	0.38	2.15e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7615952	0.599	rs7631268	chr3:125755664	T/A	cg15145296	chr3:125709740	NA	-0.49	-4.82	-0.3	2.64e-6	Blood pressure (smoking interaction);
SARC	cis	rs9902453	0.845	rs7209622	chr17:28256807	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	7.09	0.42	1.55e-11	Coffee consumption (cups per day);
SARC	cis	rs1044826	0.619	rs57357132	chr3:139118358	A/T	cg15131784	chr3:139108705	COPB2	-0.4	-5.15	-0.32	5.62e-7	Obesity-related traits;
SARC	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg10435706	chr6:150039699	LATS1	0.36	4.8	0.3	2.88e-6	Lung cancer;
SARC	cis	rs9341808	0.718	rs2143887	chr6:80917287	T/C	cg08355045	chr6:80787529	NA	0.33	5.31	0.33	2.55e-7	Sitting height ratio;
SARC	cis	rs5753618	0.504	rs8138525	chr22:32011929	T/C	cg07713946	chr22:31675144	LIMK2	-0.36	-4.97	-0.31	1.32e-6	Colorectal cancer;
SARC	cis	rs6496667	0.533	rs2074583	chr15:91009192	T/C	cg22089800	chr15:90895588	ZNF774	0.44	5.05	0.31	8.78e-7	Rheumatoid arthritis;
SARC	cis	rs703842	1.000	rs11172349	chr12:58212528	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.78	11.27	0.59	8.54e-24	Multiple sclerosis;
SARC	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.66	6.3	0.38	1.45e-9	Platelet count;
SARC	cis	rs41278232	0.557	rs817343	chr20:62607160	C/T	cg24354818	chr20:62328094	TNFRSF6B	0.35	4.93	0.31	1.54e-6	Tonsillectomy;
SARC	cis	rs2594989	0.887	rs2454513	chr3:11549596	C/T	cg00170343	chr3:11313890	ATG7	0.57	5.6	0.34	6e-8	Circulating chemerin levels;
SARC	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg11987759	chr7:65425863	GUSB	-0.47	-6.27	-0.38	1.7e-9	Aortic root size;
SARC	cis	rs12079745	0.793	rs10919098	chr1:169189422	T/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.88	-5.6	-0.34	5.96e-8	QT interval;
SARC	cis	rs4319547	0.585	rs7952868	chr12:122846949	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.57	-6.46	-0.39	6.02e-10	Body mass index;
SARC	cis	rs10484885	0.680	rs72921943	chr6:90581542	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.72	-7.7	-0.45	3.95e-13	QRS interval (sulfonylurea treatment interaction);
SARC	cis	rs8180040	0.764	rs12629262	chr3:47196580	C/T	cg02527881	chr3:46936655	PTH1R	-0.32	-4.97	-0.31	1.28e-6	Colorectal cancer;
SARC	cis	rs6908034	0.660	rs76322282	chr6:19801660	G/A	cg02682789	chr6:19804855	NA	0.72	5.23	0.32	3.82e-7	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs7247513	0.964	rs12979795	chr19:12717847	C/T	cg01871581	chr19:12707946	ZNF490	0.84	12.16	0.62	1.18e-26	Bipolar disorder;
SARC	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg22920501	chr2:26401640	FAM59B	0.54	6.76	0.4	1.12e-10	Gut microbiome composition (summer);
SARC	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg16405210	chr4:1374714	KIAA1530	-0.45	-5.19	-0.32	4.68e-7	Obesity-related traits;
SARC	cis	rs17608059	1.000	rs17608059	chr17:13910549	C/T	cg11395062	chr17:14139857	CDRT15	0.51	7.35	0.43	3.27e-12	Temperament;
SARC	cis	rs2013441	1.000	rs2526464	chr17:20075052	A/G	cg13482628	chr17:19912719	NA	-0.48	-6.15	-0.37	3.36e-9	Obesity-related traits;
SARC	cis	rs6964587	0.935	rs9770444	chr7:91783162	T/G	cg17063962	chr7:91808500	NA	0.98	17.34	0.75	7.95e-44	Breast cancer;
SARC	cis	rs11098499	0.863	rs1552095	chr4:120460306	A/G	cg24375607	chr4:120327624	NA	0.42	4.97	0.31	1.28e-6	Corneal astigmatism;
SARC	cis	rs7617480	0.585	rs7373072	chr3:48960017	T/A	cg07636037	chr3:49044803	WDR6	0.93	10.92	0.58	1.07e-22	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs1691799	0.899	rs1168295	chr12:66734151	G/C	cg16791601	chr12:66731901	HELB	-0.72	-10.74	-0.58	3.91e-22	White blood cell count (basophil);
SARC	cis	rs7412746	0.658	rs59024312	chr1:150909005	T/G	cg10589385	chr1:150898437	SETDB1	0.42	5.64	0.35	4.91e-8	Melanoma;
SARC	cis	rs35110281	0.777	rs7276215	chr21:44990697	A/G	cg21573476	chr21:45109991	RRP1B	-0.52	-7.58	-0.44	8.16e-13	Mean corpuscular volume;
SARC	cis	rs2382817	0.580	rs6756265	chr2:219095554	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.59	-7.89	-0.46	1.14e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg14665389	chr10:114710815	TCF7L2	0.43	5.3	0.33	2.64e-7	Breast cancer;
SARC	cis	rs11190604	1.000	rs11190613	chr10:102313997	C/T	cg07510080	chr10:102295549	HIF1AN	-0.43	-4.74	-0.3	3.7e-6	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-6.79	-0.41	9.33e-11	Personality dimensions;
SARC	cis	rs7666738	0.830	rs13122054	chr4:98972974	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.81	0.5	3.02e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4742903	0.509	rs12377116	chr9:106959243	A/G	cg14250997	chr9:106856677	SMC2	0.39	4.87	0.3	2.03e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs9341808	0.718	rs4437429	chr6:80828592	A/G	cg08355045	chr6:80787529	NA	0.34	5.41	0.33	1.59e-7	Sitting height ratio;
SARC	cis	rs7666738	0.830	rs62318503	chr4:98935479	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg22433210	chr17:43662623	NA	1.04	12.66	0.64	2.67e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs12956009	0.583	rs12965907	chr18:44888455	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	7.64	0.45	5.6e-13	Educational attainment (years of education);
SARC	cis	rs698833	0.886	rs2053454	chr2:44550290	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.69	8.96	0.51	1.09e-16	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs9341808	0.754	rs9294173	chr6:80991630	T/A	cg08355045	chr6:80787529	NA	0.35	5.68	0.35	4.05e-8	Sitting height ratio;
SARC	cis	rs12142240	0.667	rs66990604	chr1:46822073	G/A	cg00530320	chr1:46809349	NSUN4	0.57	6.79	0.41	9.05e-11	Menopause (age at onset);
SARC	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg17221315	chr6:27791827	HIST1H4J	0.48	5.2	0.32	4.26e-7	Parkinson's disease;
SARC	cis	rs6815814	0.768	rs2013740	chr4:38891737	A/G	cg06935464	chr4:38784597	TLR10	0.45	4.98	0.31	1.26e-6	Breast cancer;
SARC	trans	rs9650657	0.589	rs12542037	chr8:10758496	G/A	cg06636001	chr8:8085503	FLJ10661	0.57	7.42	0.44	2.2e-12	Neuroticism;
SARC	cis	rs27434	0.583	rs34760	chr5:96153491	T/C	cg16492584	chr5:96139282	ERAP1	-0.56	-6.96	-0.42	3.35e-11	Ankylosing spondylitis;
SARC	cis	rs12586317	0.576	rs12586302	chr14:35691074	G/C	cg16230307	chr14:35515116	FAM177A1	0.44	5.3	0.33	2.66e-7	Psoriasis;
SARC	cis	rs2439831	0.850	rs28513374	chr15:44125495	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	7.56	0.44	9.11e-13	Lung cancer in ever smokers;
SARC	cis	rs9300255	0.510	rs1727322	chr12:123699520	A/G	cg00376283	chr12:123451042	ABCB9	0.57	5.59	0.34	6.45e-8	Neutrophil percentage of white cells;
SARC	cis	rs35110281	0.641	rs9978858	chr21:45085552	A/G	cg01579765	chr21:45077557	HSF2BP	-0.4	-6.22	-0.38	2.28e-9	Mean corpuscular volume;
SARC	cis	rs2718058	0.519	rs2598072	chr7:37875319	A/C	cg15028436	chr7:37888078	TXNDC3	0.47	6.14	0.37	3.57e-9	Alzheimer's disease (late onset);
SARC	cis	rs7587476	0.784	rs17424051	chr2:215688992	G/C	cg04530015	chr2:215796436	ABCA12	-0.41	-6.7	-0.4	1.56e-10	Neuroblastoma;
SARC	cis	rs9325144	0.555	rs1973292	chr12:38679626	T/C	cg26384229	chr12:38710491	ALG10B	0.6	8.03	0.47	4.66e-14	Morning vs. evening chronotype;
SARC	cis	rs9916302	0.904	rs602282	chr17:37433021	C/T	cg07936489	chr17:37558343	FBXL20	-0.69	-9.22	-0.52	1.82e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs13166103	0.657	rs34415498	chr5:57698428	G/A	cg10487770	chr5:57879443	RAB3C	0.52	5.54	0.34	8.05e-8	Type 2 diabetes (age of onset);
SARC	cis	rs7714584	1.000	rs12656600	chr5:150311872	A/G	cg22134413	chr5:150180641	NA	0.81	6.82	0.41	7.88e-11	Crohn's disease;
SARC	cis	rs6088590	1.000	rs6119524	chr20:33373813	C/T	cg24642439	chr20:33292090	TP53INP2	0.88	12.36	0.63	2.45e-27	Coronary artery disease;
SARC	cis	rs698833	0.892	rs786408	chr2:44733156	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.65	8.46	0.48	3.04e-15	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs898097	1.000	rs898097	chr17:80904310	C/T	cg15664640	chr17:80829946	TBCD	0.51	8.12	0.47	2.73e-14	Breast cancer;
SARC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.58	7.56	0.44	9.28e-13	Lymphocyte counts;
SARC	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg01341218	chr17:43662625	NA	-0.69	-8.09	-0.47	3.35e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs36051895	0.695	rs7851556	chr9:5022807	C/T	cg02405213	chr9:5042618	JAK2	-0.52	-5.98	-0.36	8.39e-9	Pediatric autoimmune diseases;
SARC	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	17.66	0.76	7.16e-45	Height;
SARC	cis	rs67311347	1.000	rs951560	chr3:40463471	A/G	cg24209194	chr3:40518798	ZNF619	0.63	8.18	0.47	1.82e-14	Renal cell carcinoma;
SARC	cis	rs9875589	0.957	rs6778297	chr3:13932143	C/T	cg19554555	chr3:13937349	NA	0.51	6.63	0.4	2.29e-10	Ovarian reserve;
SARC	cis	rs7481584	0.581	rs105686	chr11:3062467	G/A	cg25174290	chr11:3078921	CARS	-0.57	-8.04	-0.47	4.52e-14	Calcium levels;
SARC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg11905131	chr22:24372483	LOC391322	-0.5	-5.9	-0.36	1.31e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9325144	0.647	rs61937754	chr12:39060543	T/C	cg13010199	chr12:38710504	ALG10B	-0.54	-6.88	-0.41	5.36e-11	Morning vs. evening chronotype;
SARC	cis	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg08045932	chr20:61659980	NA	0.5	6.84	0.41	6.72e-11	Prostate cancer (SNP x SNP interaction);
SARC	trans	rs208520	0.690	rs12192710	chr6:66718137	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	14.0	0.68	1.01e-32	Exhaled nitric oxide output;
SARC	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg07343612	chr16:622815	PIGQ	-0.6	-8.42	-0.48	3.76e-15	Height;
SARC	cis	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg14343924	chr8:8086146	FLJ10661	0.41	4.92	0.31	1.6e-6	Mood instability;
SARC	cis	rs9916302	0.904	rs4795384	chr17:37716771	C/G	cg15445000	chr17:37608096	MED1	0.44	5.27	0.33	3.15e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs9303401	0.614	rs12947982	chr17:57140301	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.98	10.0	0.55	7.88e-20	Cognitive test performance;
SARC	cis	rs2180341	0.961	rs9375501	chr6:127652539	C/T	cg24812749	chr6:127587940	RNF146	0.98	13.14	0.65	7.1e-30	Breast cancer;
SARC	cis	rs12908161	0.959	rs61074241	chr15:85333396	C/T	cg17507749	chr15:85114479	UBE2QP1	0.52	5.64	0.35	4.79e-8	Schizophrenia;
SARC	cis	rs986417	1.000	rs1033733	chr14:60932438	G/T	cg27398547	chr14:60952738	C14orf39	1.01	9.11	0.51	3.86e-17	Gut microbiota (bacterial taxa);
SARC	cis	rs933688	0.583	rs10036206	chr5:90609178	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.65	5.88	0.36	1.38e-8	Smoking behavior;
SARC	cis	rs9790314	0.502	rs2404342	chr3:161092562	C/T	cg03342759	chr3:160939853	NMD3	-0.63	-7.88	-0.46	1.25e-13	Morning vs. evening chronotype;
SARC	cis	rs6582630	0.519	rs4294627	chr12:38293982	C/T	cg26384229	chr12:38710491	ALG10B	0.87	12.86	0.64	6.01e-29	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg00149659	chr3:10157352	C3orf10	-0.79	-6.89	-0.41	5.02e-11	Alzheimer's disease;
SARC	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.593	rs16921589	chr8:58024387	C/A	cg20607798	chr8:58055168	NA	0.62	5.51	0.34	9.38e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7589342	0.899	rs10185551	chr2:106492201	A/C	cg14210321	chr2:106509881	NCK2	-0.5	-5.82	-0.36	1.89e-8	Addiction;
SARC	cis	rs3806933	0.522	rs13179305	chr5:110444474	G/A	cg04022379	chr5:110408740	TSLP	0.7	8.83	0.5	2.53e-16	Eosinophilic esophagitis;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg02677328	chr6:52267982	PAQR8	-0.54	-6.4	-0.39	8.59e-10	Alcohol dependence;
SARC	cis	rs611744	0.870	rs423940	chr8:109093578	C/T	cg21045802	chr8:109455806	TTC35	0.42	4.97	0.31	1.29e-6	Dupuytren's disease;
SARC	cis	rs7607369	0.536	rs11892469	chr2:219669488	A/T	cg02176678	chr2:219576539	TTLL4	-0.38	-5.67	-0.35	4.2e-8	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg27121462	chr16:89883253	FANCA	0.7	10.69	0.57	5.98e-22	Vitiligo;
SARC	cis	rs7595412	1.000	rs12468657	chr2:199077927	C/T	cg00208931	chr2:198669586	PLCL1	-0.62	-5.09	-0.32	7.23e-7	Hip bone size;
SARC	cis	rs6604026	0.656	rs2255717	chr1:93368500	G/T	cg17283838	chr1:93427260	FAM69A	-0.43	-4.91	-0.31	1.68e-6	Multiple sclerosis;
SARC	cis	rs11098499	0.754	rs66900435	chr4:120249425	C/A	cg09307838	chr4:120376055	NA	0.82	11.19	0.59	1.49e-23	Corneal astigmatism;
SARC	cis	rs9303280	0.806	rs4795395	chr17:37962987	T/A	cg19468946	chr17:37922297	IKZF3	-0.31	-5.23	-0.32	3.81e-7	Self-reported allergy;
SARC	cis	rs9581857	0.685	rs9319369	chr13:28042323	A/T	cg01674679	chr13:27998804	GTF3A	-0.63	-4.73	-0.3	3.86e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	cis	rs9911578	0.967	rs11079368	chr17:57086473	C/T	cg12560992	chr17:57184187	TRIM37	-0.87	-12.54	-0.63	6.44e-28	Intelligence (multi-trait analysis);
SARC	cis	rs910316	0.967	rs12890371	chr14:75593839	T/C	cg11812906	chr14:75593930	NEK9	0.87	13.87	0.67	2.61e-32	Height;
SARC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.59	7.72	0.45	3.36e-13	Lymphocyte counts;
SARC	cis	rs6964587	0.626	rs12704631	chr7:91523525	T/C	cg17063962	chr7:91808500	NA	-0.78	-11.47	-0.6	1.95e-24	Breast cancer;
SARC	cis	rs4927850	0.829	rs6768483	chr3:195745963	C/G	cg01181863	chr3:195395398	SDHAP2	-0.81	-9.14	-0.51	3.26e-17	Pancreatic cancer;
SARC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg22105103	chr4:187893119	NA	0.5	6.86	0.41	6.16e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg13770153	chr20:60521292	NA	-0.45	-6.31	-0.38	1.39e-9	Body mass index;
SARC	cis	rs3733585	0.673	rs4459990	chr4:9954005	T/C	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.39	-0.33	1.76e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7644634	0.624	rs17202230	chr3:105373929	T/C	cg23051926	chr3:105466016	CBLB	0.47	5.8	0.36	2.15e-8	Itch intensity from mosquito bite;
SARC	cis	rs17030434	0.654	rs10021631	chr4:154646675	A/G	cg14289246	chr4:154710475	SFRP2	-0.54	-5.59	-0.34	6.26e-8	Electrocardiographic conduction measures;
SARC	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg09359103	chr1:154839909	KCNN3	-0.48	-8.12	-0.47	2.73e-14	Prostate cancer;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg16284739	chr13:53226399	SUGT1	0.49	6.29	0.38	1.53e-9	Lung adenocarcinoma;
SARC	cis	rs757978	1.000	rs757978	chr2:242371101	C/T	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.81	-7.05	-0.42	1.97e-11	Chronic lymphocytic leukemia;
SARC	cis	rs17376456	0.825	rs10053405	chr5:93275403	A/G	cg21475434	chr5:93447410	FAM172A	-0.9	-7.42	-0.44	2.11e-12	Diabetic retinopathy;
SARC	cis	rs6570726	0.791	rs13202312	chr6:145913093	T/G	cg23711669	chr6:146136114	FBXO30	0.88	14.58	0.69	1.2e-34	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.44	5.51	0.34	9.37e-8	Tonsillectomy;
SARC	cis	rs2011503	1.000	rs4808970	chr19:19651140	A/G	cg15839431	chr19:19639596	YJEFN3	-0.48	-4.77	-0.3	3.32e-6	Bipolar disorder;
SARC	cis	rs10754283	0.967	rs10754285	chr1:90116587	A/G	cg21401794	chr1:90099060	LRRC8C	0.6	7.94	0.46	8.44e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs34783982	0.881	rs34286613	chr15:89496283	G/C	cg26213453	chr15:89455860	MFGE8	0.28	4.96	0.31	1.37e-6	Squamous cell lung carcinoma;
SARC	cis	rs9291683	0.546	rs12504565	chr4:10045145	G/A	cg11266682	chr4:10021025	SLC2A9	0.4	6.91	0.41	4.53e-11	Bone mineral density;
SARC	cis	rs76878669	0.561	rs11823140	chr11:66098322	G/T	cg14036092	chr11:66035641	RAB1B	-0.43	-5.13	-0.32	6e-7	Educational attainment (years of education);
SARC	cis	rs72945132	0.882	rs67822447	chr11:70230972	G/T	cg00319359	chr11:70116639	PPFIA1	0.68	6.46	0.39	6.04e-10	Coronary artery disease;
SARC	cis	rs72781680	0.611	rs72797818	chr2:24351107	G/A	cg08917208	chr2:24149416	ATAD2B	0.61	6.11	0.37	4.15e-9	Lymphocyte counts;
SARC	cis	rs8177179	0.565	rs4355280	chr3:133468425	A/G	cg01448562	chr3:133502909	NA	-0.48	-7.12	-0.42	1.33e-11	Iron status biomarkers (transferrin levels);
SARC	cis	rs912057	0.841	rs1294423	chr6:6743795	C/T	cg06612196	chr6:6737390	NA	0.64	9.32	0.52	9.03e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs9916302	0.904	rs11078910	chr17:37671269	G/T	cg00129232	chr17:37814104	STARD3	-0.65	-7.93	-0.46	8.82e-14	Glomerular filtration rate (creatinine);
SARC	trans	rs7937682	0.889	rs521155	chr11:111492563	G/A	cg18187862	chr3:45730750	SACM1L	0.55	6.99	0.42	2.93e-11	Primary sclerosing cholangitis;
SARC	cis	rs6062302	0.548	rs6089940	chr20:62252695	C/T	cg09650180	chr20:62225654	GMEB2	-0.45	-5.55	-0.34	7.75e-8	Glioblastoma;
SARC	cis	rs933688	0.509	rs2941895	chr5:90520510	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.45	-5.12	-0.32	6.27e-7	Smoking behavior;
SARC	cis	rs698833	0.828	rs6705951	chr2:44534012	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.63	8.08	0.47	3.43e-14	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs3859192	0.599	rs2270401	chr17:38176256	A/T	cg17344932	chr17:38183730	MED24;SNORD124	0.4	7.35	0.43	3.33e-12	White blood cell count;
SARC	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg22105103	chr4:187893119	NA	0.5	6.84	0.41	7.11e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg07157834	chr1:205819609	PM20D1	0.41	4.96	0.31	1.38e-6	Parkinson's disease;
SARC	cis	rs4902562	1.000	rs4902562	chr14:68731458	C/T	cg18825221	chr14:68749962	RAD51L1	0.37	6.55	0.39	3.63e-10	Systemic lupus erythematosus;
SARC	cis	rs593982	0.764	rs55796623	chr11:65411714	G/A	cg08755490	chr11:65554678	OVOL1	-0.91	-7.68	-0.45	4.25e-13	Atopic dermatitis;
SARC	cis	rs7667	0.959	rs12561981	chr1:19731281	G/A	cg15311933	chr1:19638897	PQLC2;AKR7A2	-0.45	-5.39	-0.33	1.68e-7	Crohn's disease and psoriasis;
SARC	trans	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-7.07	-0.42	1.83e-11	Intelligence (multi-trait analysis);
SARC	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg12311346	chr5:56204834	C5orf35	-0.57	-5.82	-0.36	1.96e-8	Initial pursuit acceleration;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg10069470	chr5:102594905	C5orf30	0.49	6.46	0.39	6.05e-10	Tetralogy of Fallot;
SARC	cis	rs950027	0.620	rs35861938	chr15:45637343	T/C	cg15395560	chr15:45543142	SLC28A2	-0.27	-5.17	-0.32	5.14e-7	Response to fenofibrate (adiponectin levels);
SARC	cis	rs7103648	0.838	rs2293576	chr11:47434986	A/G	cg10504702	chr11:47789108	FNBP4	-0.63	-8.21	-0.47	1.48e-14	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs6546324	1.000	rs6546324	chr2:67856490	A/C	cg18237512	chr2:67827392	NA	-0.43	-5.52	-0.34	8.79e-8	Endometriosis;
SARC	cis	rs11969893	0.649	rs1321204	chr6:101468591	A/G	cg12253828	chr6:101329408	ASCC3	0.65	4.94	0.31	1.47e-6	Economic and political preferences (immigration/crime);
SARC	cis	rs601338	1	rs601338	chr19:49206674	G/A	cg21064579	chr19:49206444	FUT2	0.35	4.91	0.31	1.74e-6	Number of common colds;Blood metabolite levels;Blood metabolite ratios;
SARC	cis	rs7336332	0.598	rs76790205	chr13:28002885	C/T	cg01674679	chr13:27998804	GTF3A	-0.57	-5.3	-0.33	2.66e-7	Weight;
SARC	cis	rs1957429	0.901	rs1951491	chr14:65346950	G/A	cg23373153	chr14:65346875	NA	1.07	11.42	0.6	2.73e-24	Pediatric areal bone mineral density (radius);
SARC	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	8.4	0.48	4.36e-15	Mean platelet volume;
SARC	cis	rs72781680	0.611	rs2111884	chr2:24289472	A/T	cg06627628	chr2:24431161	ITSN2	-0.57	-6.02	-0.37	6.7e-9	Lymphocyte counts;
SARC	cis	rs16976116	0.901	rs9920220	chr15:55503982	T/C	cg11288833	chr15:55489084	RSL24D1	0.6	5.77	0.35	2.46e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1395	0.710	rs11682913	chr2:27473649	G/A	cg21747090	chr2:27597821	SNX17	-0.49	-5.86	-0.36	1.59e-8	Blood metabolite levels;
SARC	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg18876405	chr7:65276391	NA	0.47	5.72	0.35	3.3e-8	Aortic root size;
SARC	cis	rs17376456	0.877	rs13170509	chr5:93378564	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.51	0.34	9.53e-8	Diabetic retinopathy;
SARC	cis	rs7264396	0.790	rs2425096	chr20:34308588	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-8.36	-0.48	5.7e-15	Total cholesterol levels;
SARC	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg11941060	chr3:133502564	NA	0.34	4.86	0.3	2.11e-6	Iron status biomarkers;
SARC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.13	0.37	3.73e-9	Prudent dietary pattern;
SARC	trans	rs208520	0.690	rs207107	chr6:66794385	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.06	-14.41	-0.69	4.36e-34	Exhaled nitric oxide output;
SARC	cis	rs9902453	0.765	rs6505143	chr17:28150585	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	6.97	0.42	3.31e-11	Coffee consumption (cups per day);
SARC	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg16049864	chr8:95962084	TP53INP1	-0.53	-8.7	-0.5	6.22e-16	Type 2 diabetes;
SARC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg04234412	chr22:24373322	LOC391322	-0.65	-8.52	-0.49	2.04e-15	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7208859	0.623	rs11658022	chr17:29085359	A/T	cg13385521	chr17:29058706	SUZ12P	0.85	7.06	0.42	1.85e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs7474896	0.583	rs11011341	chr10:37998500	G/A	cg00409905	chr10:38381863	ZNF37A	-0.45	-4.85	-0.3	2.21e-6	Obesity (extreme);
SARC	cis	rs453301	0.686	rs6748	chr8:8890802	C/T	cg11995313	chr8:8860691	ERI1	0.43	5.46	0.34	1.2e-7	Joint mobility (Beighton score);
SARC	cis	rs2997447	0.846	rs12071062	chr1:26412199	T/G	cg19633962	chr1:26362018	EXTL1	-0.6	-5.74	-0.35	2.92e-8	QRS complex (12-leadsum);
SARC	cis	rs1949733	1.000	rs2631758	chr4:8495304	G/A	cg13073564	chr4:8508604	NA	0.47	7.74	0.45	2.94e-13	Response to antineoplastic agents;
SARC	cis	rs72781680	1.000	rs11125372	chr2:24257582	A/T	cg08917208	chr2:24149416	ATAD2B	-0.81	-7.84	-0.46	1.63e-13	Lymphocyte counts;
SARC	cis	rs28374715	0.662	rs522063	chr15:41476209	A/G	cg18705301	chr15:41695430	NDUFAF1	0.94	13.93	0.67	1.71e-32	Ulcerative colitis;
SARC	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-6.42	-0.39	7.53e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2885056	0.783	rs73007347	chr19:10650649	C/T	cg04833646	chr19:10679720	CDKN2D	0.91	10.94	0.58	9.72e-23	Red cell distribution width;
SARC	cis	rs6088590	0.965	rs6088620	chr20:33412022	A/G	cg06115741	chr20:33292138	TP53INP2	0.54	6.51	0.39	4.68e-10	Coronary artery disease;
SARC	cis	rs67460515	0.926	rs13062740	chr3:161024208	G/A	cg17135325	chr3:160939158	NMD3	0.62	7.82	0.46	1.85e-13	Parkinson's disease;
SARC	cis	rs3815700	0.844	rs444089	chr19:33106991	G/C	cg24916020	chr19:33096688	ANKRD27	0.57	5.37	0.33	1.88e-7	Eosinophilic esophagitis;
SARC	cis	rs11264799	0.603	rs12118837	chr1:157561302	G/A	cg18268488	chr1:157545234	FCRL4	0.33	5.62	0.35	5.39e-8	IgA nephropathy;
SARC	trans	rs2018683	0.707	rs2391717	chr7:28971162	G/C	cg19402173	chr7:128379420	CALU	-0.53	-6.95	-0.41	3.6e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs7103648	0.932	rs7104036	chr11:47462140	A/G	cg10504702	chr11:47789108	FNBP4	0.6	7.82	0.46	1.84e-13	Diastolic blood pressure;Systolic blood pressure;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg25192419	chr8:25042348	DOCK5	0.49	6.5	0.39	4.89e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs2075371	0.829	rs1993058	chr7:133930361	G/A	cg11752832	chr7:134001865	SLC35B4	0.5	6.11	0.37	4.17e-9	Mean platelet volume;
SARC	cis	rs10463554	0.927	rs468844	chr5:102423576	A/G	cg23492399	chr5:102201601	PAM	-0.54	-5.89	-0.36	1.31e-8	Parkinson's disease;
SARC	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg15352829	chr14:105391018	PLD4	-0.33	-6.34	-0.38	1.19e-9	Rheumatoid arthritis;
SARC	cis	rs4481887	0.927	rs4244173	chr1:248466899	G/C	cg00666640	chr1:248458726	OR2T12	0.37	6.11	0.37	4.23e-9	Common traits (Other);
SARC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg11494091	chr17:61959527	GH2	0.53	8.02	0.47	5.12e-14	Prudent dietary pattern;
SARC	cis	rs7666738	0.830	rs28619044	chr4:98789814	G/C	cg05340658	chr4:99064831	C4orf37	0.65	8.54	0.49	1.74e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg03213289	chr20:61660250	NA	0.45	6.08	0.37	4.87e-9	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs6133127	0.529	rs297755	chr20:4501875	G/A	cg14606382	chr20:4573199	NA	0.49	5.27	0.33	3.16e-7	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
SARC	cis	rs1005277	0.683	rs7923868	chr10:37989766	T/C	cg00409905	chr10:38381863	ZNF37A	-0.49	-6.73	-0.4	1.29e-10	Extrinsic epigenetic age acceleration;
SARC	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg18252515	chr7:66147081	NA	0.45	4.85	0.3	2.27e-6	Aortic root size;
SARC	cis	rs459571	0.839	rs2519831	chr9:136886257	T/A	cg01294253	chr9:136912663	BRD3	0.4	5.16	0.32	5.25e-7	Platelet distribution width;
SARC	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg07308232	chr7:1071921	C7orf50	-0.46	-5.89	-0.36	1.33e-8	Longevity;Endometriosis;
SARC	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.47	-0.39	5.69e-10	Mood instability;
SARC	cis	rs4975616	0.839	rs2447853	chr5:1333077	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.55	-7.53	-0.44	1.12e-12	Lung cancer;
SARC	cis	rs617791	0.508	rs2276132	chr11:65770545	G/A	cg09462587	chr11:65769444	EIF1AD;BANF1	0.41	4.84	0.3	2.4e-6	Breast cancer;
SARC	cis	rs9611565	0.802	rs9611577	chr22:41793090	T/G	cg03806693	chr22:41940476	POLR3H	-0.85	-12.04	-0.62	2.9e-26	Vitiligo;
SARC	cis	rs10189230	0.967	rs13026659	chr2:222353014	C/T	cg14652038	chr2:222343519	EPHA4	0.46	6.23	0.38	2.2e-9	Urate levels in lean individuals;
SARC	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg15049968	chr18:44337910	ST8SIA5	0.33	5.16	0.32	5.4e-7	Personality dimensions;
SARC	cis	rs6570726	0.935	rs384806	chr6:145814889	C/G	cg23711669	chr6:146136114	FBXO30	0.78	11.91	0.62	7.29e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.6	7.58	0.44	8.09e-13	Lymphocyte counts;
SARC	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.42	4.97	0.31	1.33e-6	Bipolar disorder;
SARC	cis	rs7929679	0.551	rs10836303	chr11:34792702	T/C	cg06937548	chr11:34938143	PDHX;APIP	0.36	4.76	0.3	3.47e-6	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
SARC	trans	rs561341	0.700	rs79272796	chr17:30226974	T/C	cg20587970	chr11:113659929	NA	-0.6	-6.85	-0.41	6.57e-11	Hip circumference adjusted for BMI;
SARC	cis	rs7818688	0.697	rs35032356	chr8:95977484	G/T	cg13393036	chr8:95962371	TP53INP1	0.4	4.85	0.3	2.27e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg03213289	chr20:61660250	NA	0.46	6.43	0.39	7.22e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.03	0.37	6.27e-9	Prudent dietary pattern;
SARC	cis	rs10078	0.571	rs2241597	chr5:480509	A/G	cg24955955	chr5:415729	AHRR	0.72	6.64	0.4	2.16e-10	Fat distribution (HIV);
SARC	cis	rs11716531	0.512	rs7612312	chr3:27230230	C/A	cg02860705	chr3:27208620	NA	0.52	7.29	0.43	4.74e-12	Diastolic blood pressure;
SARC	cis	rs60871478	0.636	rs6976929	chr7:901382	C/T	cg05535760	chr7:792225	HEATR2	-0.76	-7.25	-0.43	6.11e-12	Cerebrospinal P-tau181p levels;
SARC	cis	rs7937682	0.575	rs12808601	chr11:111776066	G/A	cg09085632	chr11:111637200	PPP2R1B	0.77	10.46	0.57	3.09e-21	Primary sclerosing cholangitis;
SARC	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg24209194	chr3:40518798	ZNF619	0.66	8.14	0.47	2.44e-14	Renal cell carcinoma;
SARC	cis	rs1318878	0.543	rs10466855	chr12:15455927	G/A	cg08258403	chr12:15378311	NA	0.46	6.66	0.4	1.9e-10	Intelligence (multi-trait analysis);
SARC	cis	rs6582630	0.555	rs11181053	chr12:38271364	T/C	cg26384229	chr12:38710491	ALG10B	-0.63	-8.02	-0.46	5.27e-14	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs12681366	0.537	rs2919664	chr8:95468713	A/G	cg13257157	chr8:95487014	RAD54B	0.4	4.76	0.3	3.41e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg07636037	chr3:49044803	WDR6	0.99	17.31	0.75	1.02e-43	Parkinson's disease;
SARC	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg12463550	chr7:65579703	CRCP	-0.49	-5.24	-0.32	3.63e-7	Aortic root size;
SARC	cis	rs17376456	0.825	rs10078941	chr5:93279029	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	6.11	0.37	4.09e-9	Diabetic retinopathy;
SARC	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg09165964	chr15:75287851	SCAMP5	-0.51	-6.92	-0.41	4.3e-11	Breast cancer;
SARC	cis	rs11997175	0.603	rs7001603	chr8:33680978	T/G	ch.8.33884649F	chr8:33765107	NA	0.61	8.17	0.47	1.98e-14	Body mass index;
SARC	cis	rs9303401	0.659	rs66514313	chr17:56714057	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	12.63	0.64	3.28e-28	Cognitive test performance;
SARC	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.5	-6.22	-0.38	2.27e-9	Lymphocyte counts;
SARC	cis	rs4819052	0.788	rs9978857	chr21:46705155	T/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.66	7.8	0.46	2.07e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs208520	1.000	rs12194996	chr6:66973366	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.76	8.48	0.49	2.58e-15	Exhaled nitric oxide output;
SARC	cis	rs11711311	0.747	rs7638378	chr3:113343630	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	7.34	0.43	3.53e-12	IgG glycosylation;
SARC	cis	rs2522056	0.808	rs2706373	chr5:131804256	C/T	cg24060327	chr5:131705240	SLC22A5	0.48	4.76	0.3	3.47e-6	Lymphocyte counts;Fibrinogen;
SARC	cis	rs995000	0.899	rs11207976	chr1:62976751	G/A	cg06896770	chr1:63153194	DOCK7	0.92	13.58	0.66	2.46e-31	Triglyceride levels;
SARC	cis	rs72781680	0.898	rs72796166	chr2:23939311	G/C	cg08917208	chr2:24149416	ATAD2B	0.92	8.77	0.5	3.93e-16	Lymphocyte counts;
SARC	cis	rs4595586	0.545	rs12809435	chr12:39404341	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-6.57	-0.4	3.17e-10	Morning vs. evening chronotype;
SARC	cis	rs7937682	0.575	rs7124696	chr11:111747297	A/G	cg09085632	chr11:111637200	PPP2R1B	0.77	10.19	0.56	2.06e-20	Primary sclerosing cholangitis;
SARC	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg02951883	chr7:2050386	MAD1L1	-0.38	-4.74	-0.3	3.67e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs9916302	0.706	rs1874226	chr17:37729031	C/T	cg20243544	chr17:37824526	PNMT	-0.56	-5.87	-0.36	1.5e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs3820928	0.874	rs2276593	chr2:227898434	A/G	cg11843606	chr2:227700838	RHBDD1	0.51	5.99	0.37	7.71e-9	Pulmonary function;
SARC	cis	rs35213789	0.853	rs2533434	chr7:69129079	T/G	cg10619644	chr7:69149951	AUTS2	-0.44	-5.89	-0.36	1.35e-8	Childhood ear infection;
SARC	cis	rs2985684	0.947	rs1952013	chr14:50087357	C/G	cg04989706	chr14:50066350	PPIL5	-0.54	-5.65	-0.35	4.76e-8	Carotid intima media thickness;
SARC	cis	rs11874712	1.000	rs1800639	chr18:43671240	G/T	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.48	5.99	0.37	8.01e-9	Migraine - clinic-based;
SARC	cis	rs9790314	0.601	rs1450519	chr3:161094930	A/G	cg17135325	chr3:160939158	NMD3	0.44	5.55	0.34	7.67e-8	Morning vs. evening chronotype;
SARC	cis	rs10791097	0.694	rs7942621	chr11:130751308	C/G	cg12179176	chr11:130786555	SNX19	0.75	11.1	0.59	2.9e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg22433210	chr17:43662623	NA	1.03	12.67	0.64	2.48e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs1395	0.710	rs1992291	chr2:27504312	A/G	cg21747090	chr2:27597821	SNX17	-0.5	-6.07	-0.37	5.07e-9	Blood metabolite levels;
SARC	cis	rs9325144	0.555	rs1843867	chr12:38703855	A/G	cg26384229	chr12:38710491	ALG10B	-0.59	-7.75	-0.45	2.88e-13	Morning vs. evening chronotype;
SARC	cis	rs739401	0.595	rs2237903	chr11:2967901	C/T	cg25174290	chr11:3078921	CARS	0.59	8.27	0.48	1.01e-14	Longevity;
SARC	cis	rs9911578	1.000	rs302840	chr17:56673079	C/G	cg12560992	chr17:57184187	TRIM37	0.82	11.2	0.59	1.36e-23	Intelligence (multi-trait analysis);
SARC	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg25894440	chr7:65020034	NA	0.45	5.04	0.31	9.55e-7	Calcium levels;
SARC	cis	rs240764	0.644	rs4329121	chr6:101087507	G/C	cg09795085	chr6:101329169	ASCC3	0.38	4.83	0.3	2.49e-6	Neuroticism;
SARC	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg18876405	chr7:65276391	NA	0.44	5.19	0.32	4.54e-7	Aortic root size;
SARC	cis	rs11039131	0.929	rs1685404	chr11:47243665	C/G	cg20307385	chr11:47447363	PSMC3	-0.42	-4.85	-0.3	2.3e-6	Schizophrenia;
SARC	cis	rs1401999	1.000	rs2176824	chr3:183654029	C/G	cg01324343	chr3:183735012	ABCC5	0.67	13.66	0.67	1.33e-31	Anterior chamber depth;
SARC	cis	rs4423214	0.840	rs1792235	chr11:71181473	C/T	cg05163923	chr11:71159392	DHCR7	-0.6	-7.29	-0.43	4.65e-12	Vitamin D levels;
SARC	cis	rs965469	1.000	rs965469	chr20:3381549	T/C	cg25506879	chr20:3388711	C20orf194	-0.56	-5.74	-0.35	3e-8	IFN-related cytopenia;
SARC	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.75	10.82	0.58	2.3e-22	Personality dimensions;
SARC	cis	rs9815354	0.857	rs9852020	chr3:41830206	G/A	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2075371	0.966	rs1646676	chr7:133999267	G/A	cg20476274	chr7:133979776	SLC35B4	0.63	8.51	0.49	2.17e-15	Mean platelet volume;
SARC	cis	rs9660992	0.649	rs12128229	chr1:205268014	C/A	cg21643547	chr1:205240462	TMCC2	-0.59	-7.35	-0.43	3.31e-12	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs1865760	1.000	rs6905887	chr6:25912103	T/C	cg17691542	chr6:26056736	HIST1H1C	0.58	7.16	0.42	1.03e-11	Height;
SARC	cis	rs7246657	0.941	rs7256130	chr19:37933981	T/C	cg23950597	chr19:37808831	NA	-0.57	-5.67	-0.35	4.24e-8	Coronary artery calcification;
SARC	cis	rs6964587	1.000	rs13245393	chr7:91641928	A/G	cg17063962	chr7:91808500	NA	0.93	15.73	0.72	1.7e-38	Breast cancer;
SARC	cis	rs7811142	1.000	rs6953107	chr7:100095664	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	10.28	0.56	1.14e-20	Platelet count;
SARC	cis	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg05084668	chr3:125655381	ALG1L	-0.48	-4.87	-0.3	2.02e-6	Blood pressure (smoking interaction);
SARC	cis	rs5753618	0.561	rs2283881	chr22:31638932	G/A	cg13145458	chr22:31556086	RNF185	0.48	5.13	0.32	5.98e-7	Colorectal cancer;
SARC	cis	rs7914558	0.933	rs2066323	chr10:104871361	A/G	cg04362960	chr10:104952993	NT5C2	0.43	5.22	0.32	3.89e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9291683	0.552	rs17187075	chr4:9990328	G/C	cg11266682	chr4:10021025	SLC2A9	0.44	7.81	0.46	1.94e-13	Bone mineral density;
SARC	cis	rs7130144	0.541	rs1921572	chr11:130461520	A/G	cg26307797	chr11:130446613	NA	-0.68	-5.72	-0.35	3.31e-8	Urate levels in lean individuals;
SARC	cis	rs7647973	1.000	rs7644148	chr3:49545241	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.56	-5.94	-0.36	1.03e-8	Menarche (age at onset);
SARC	cis	rs6484504	0.553	rs7113880	chr11:31279557	A/G	cg26647111	chr11:31128758	NA	-0.39	-5.07	-0.32	8.23e-7	Red blood cell count;
SARC	cis	rs13390159	0.941	rs1377449	chr2:237155847	T/C	cg19324714	chr2:237145437	ASB18	0.5	4.95	0.31	1.41e-6	Response to statin therapy;
SARC	cis	rs6120849	0.754	rs11167253	chr20:33614449	T/C	cg06115741	chr20:33292138	TP53INP2	0.54	5.16	0.32	5.3e-7	Protein C levels;
SARC	cis	rs7223966	0.655	rs9906882	chr17:61634382	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.48	-5.04	-0.31	9.33e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs644799	1.000	rs10831431	chr11:95510089	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.68	9.44	0.53	3.97e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg16414030	chr3:133502952	NA	0.4	5.45	0.34	1.3e-7	Iron status biomarkers;
SARC	cis	rs425277	1.000	rs262665	chr1:2083173	A/G	cg24578937	chr1:2090814	PRKCZ	0.31	5.93	0.36	1.06e-8	Height;
SARC	cis	rs9815354	0.680	rs10510730	chr3:41849013	C/G	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs8017423	0.933	rs7150378	chr14:90724566	G/A	cg20276874	chr14:90721474	PSMC1	-0.39	-5.49	-0.34	1.06e-7	Mortality in heart failure;
SARC	cis	rs9457247	0.871	rs1811121	chr6:167403539	T/C	cg23791538	chr6:167370224	RNASET2	-0.63	-8.73	-0.5	4.9e-16	Crohn's disease;
SARC	cis	rs2562456	0.917	rs11085463	chr19:21751302	G/T	cg00806126	chr19:22604979	ZNF98	-0.46	-4.86	-0.3	2.2e-6	Pain;
SARC	cis	rs2933343	0.951	rs796862	chr3:128593040	G/A	cg25356066	chr3:128598488	ACAD9	0.6	6.91	0.41	4.64e-11	IgG glycosylation;
SARC	cis	rs9790314	0.586	rs67077657	chr3:161138521	A/G	cg03342759	chr3:160939853	NMD3	-0.58	-7.07	-0.42	1.83e-11	Morning vs. evening chronotype;
SARC	cis	rs6582630	0.502	rs1607867	chr12:38385463	C/T	cg26384229	chr12:38710491	ALG10B	0.87	12.69	0.64	2.17e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs56235845	0.694	rs11749830	chr5:176766547	G/A	cg16006841	chr5:176797999	RGS14	0.55	7.28	0.43	5.23e-12	Hemoglobin concentration;Hematocrit;
SARC	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg20607798	chr8:58055168	NA	0.57	4.86	0.3	2.2e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs875971	0.520	rs12666485	chr7:65625122	T/C	cg11764359	chr7:65958608	NA	0.67	6.65	0.4	2.03e-10	Aortic root size;
SARC	cis	rs699371	0.557	rs2286412	chr14:74969167	C/T	cg16374328	chr14:74960395	NPC2;ISCA2	0.41	4.93	0.31	1.6e-6	Height;
SARC	cis	rs6495122	0.699	rs12905199	chr15:75070196	A/G	cg14664628	chr15:75095509	CSK	-0.79	-10.44	-0.56	3.43e-21	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	cis	rs453301	0.686	rs4840389	chr8:8884503	G/C	cg11608241	chr8:8085544	FLJ10661	-0.44	-5.65	-0.35	4.74e-8	Joint mobility (Beighton score);
SARC	cis	rs870825	0.616	rs9715644	chr4:185632965	C/T	cg04058563	chr4:185651563	MLF1IP	0.83	11.16	0.59	1.91e-23	Blood protein levels;
SARC	cis	rs4689388	0.727	rs1801213	chr4:6293696	C/G	cg00701064	chr4:6280414	WFS1	0.51	7.31	0.43	4.36e-12	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	trans	rs1502172	0.550	rs12497466	chr3:135241656	C/T	cg17077762	chr15:64996104	OAZ2	0.48	6.24	0.38	2e-9	Visceral adipose tissue adjusted for BMI;
SARC	cis	rs12347191	0.500	rs973473	chr9:100620730	T/G	cg13688889	chr9:100608707	NA	-0.48	-5.07	-0.32	8.16e-7	Orofacial clefts;
SARC	cis	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg22496380	chr5:211416	CCDC127	-0.88	-9.28	-0.52	1.21e-17	Breast cancer;
SARC	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg03264133	chr6:25882463	NA	-0.51	-6.62	-0.4	2.39e-10	Intelligence (multi-trait analysis);
SARC	cis	rs67478160	0.643	rs7156697	chr14:104211136	G/A	cg08213375	chr14:104286397	PPP1R13B	0.27	4.84	0.3	2.36e-6	Schizophrenia;
SARC	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg20965017	chr5:231967	SDHA	-0.58	-5.76	-0.35	2.6e-8	Breast cancer;
SARC	cis	rs6430585	0.583	rs2839740	chr2:136648883	G/T	cg07169764	chr2:136633963	MCM6	1.09	13.96	0.67	1.38e-32	Corneal structure;
SARC	cis	rs7044106	0.762	rs1158553	chr9:123400974	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	8.58	0.49	1.32e-15	Hip circumference adjusted for BMI;
SARC	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg07636037	chr3:49044803	WDR6	1.03	18.67	0.77	3.59e-48	Parkinson's disease;
SARC	cis	rs722599	0.651	rs7159354	chr14:75253847	A/G	cg06637938	chr14:75390232	RPS6KL1	0.39	4.93	0.31	1.54e-6	IgG glycosylation;
SARC	cis	rs6066835	0.702	rs6095229	chr20:47283774	C/T	cg18078177	chr20:47281410	PREX1	0.78	4.81	0.3	2.7e-6	Multiple myeloma;
SARC	cis	rs28386778	0.703	rs2286565	chr17:62010232	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.88	-12.41	-0.63	1.71e-27	Prudent dietary pattern;
SARC	cis	rs3106136	0.843	rs1344612	chr4:95265228	G/A	cg11021082	chr4:95130006	SMARCAD1	0.35	5.29	0.33	2.82e-7	Capecitabine sensitivity;
SARC	cis	rs57994353	0.897	rs3812594	chr9:139368953	G/A	cg14169450	chr9:139327907	INPP5E	0.4	5.05	0.31	8.82e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs4888262	0.545	rs4243108	chr16:74692453	A/G	ch.16.1684049R	chr16:74565916	GLG1	-0.4	-5.15	-0.32	5.61e-7	Testicular germ cell tumor;
SARC	cis	rs728616	0.614	rs1998374	chr10:81702722	T/C	cg05935833	chr10:81318306	SFTPA2	-0.42	-5.01	-0.31	1.07e-6	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.52	5.91	0.36	1.23e-8	Renal function-related traits (BUN);
SARC	cis	rs7615952	0.512	rs1077621	chr3:125819799	A/G	cg05084668	chr3:125655381	ALG1L	-0.47	-4.83	-0.3	2.49e-6	Blood pressure (smoking interaction);
SARC	trans	rs8073060	0.586	rs7212488	chr17:33993476	A/T	cg19694781	chr19:47549865	TMEM160	-0.71	-7.27	-0.43	5.26e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs5753618	0.583	rs5753631	chr22:31863022	A/C	cg07713946	chr22:31675144	LIMK2	0.35	4.87	0.3	2.05e-6	Colorectal cancer;
SARC	cis	rs1707322	0.682	rs28490344	chr1:46197948	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.22	0.38	2.26e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs56114371	0.530	rs9348774	chr6:27688930	C/T	cg17221315	chr6:27791827	HIST1H4J	0.51	4.78	0.3	3.13e-6	Breast cancer;
SARC	trans	rs1814175	0.817	rs1794162	chr11:49899506	A/C	cg15704280	chr7:45808275	SEPT13	-0.98	-18.29	-0.77	5.97e-47	Height;
SARC	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg20607798	chr8:58055168	NA	0.58	5.02	0.31	1.04e-6	Developmental language disorder (linguistic errors);
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg08887425	chr11:110300464	FDX1	-0.63	-6.62	-0.4	2.39e-10	Lung cancer in ever smokers;
SARC	cis	rs17270561	0.609	rs9393658	chr6:25730438	C/T	cg16482183	chr6:26056742	HIST1H1C	0.43	5.25	0.33	3.49e-7	Iron status biomarkers;
SARC	cis	rs4253772	0.591	rs6007726	chr22:46650858	A/C	cg24881330	chr22:46731750	TRMU	0.62	6.72	0.4	1.41e-10	LDL cholesterol;Cholesterol, total;
SARC	cis	rs1008375	0.932	rs4698627	chr4:17605959	T/C	cg16339924	chr4:17578868	LAP3	0.67	8.83	0.5	2.6e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4356932	1.000	rs7674409	chr4:76958334	C/G	cg18402991	chr4:76958054	ART3;CXCL11	0.29	4.74	0.3	3.78e-6	Blood protein levels;
SARC	cis	rs8067545	0.641	rs203450	chr17:19823070	C/T	cg13482628	chr17:19912719	NA	0.52	6.63	0.4	2.36e-10	Schizophrenia;
SARC	cis	rs9660992	0.573	rs7368327	chr1:205214792	C/T	cg21545522	chr1:205238299	TMCC2	0.39	5.34	0.33	2.17e-7	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs10876993	0.728	rs1082503	chr12:58036717	G/A	cg18357645	chr12:58087776	OS9	0.46	6.01	0.37	6.94e-9	Celiac disease or Rheumatoid arthritis;
SARC	trans	rs877282	1.000	rs10904552	chr10:774326	A/G	cg22713356	chr15:30763199	NA	0.98	10.12	0.55	3.53e-20	Uric acid levels;
SARC	trans	rs61931739	0.517	rs10844802	chr12:34231001	C/A	cg26384229	chr12:38710491	ALG10B	0.84	12.03	0.62	3.02e-26	Morning vs. evening chronotype;
SARC	cis	rs2204008	0.658	rs12371956	chr12:38298010	A/T	cg26384229	chr12:38710491	ALG10B	0.85	12.48	0.63	1.01e-27	Bladder cancer;
SARC	cis	rs12681288	0.676	rs7459467	chr8:999359	C/T	cg15309053	chr8:964076	NA	0.44	7.05	0.42	1.99e-11	Schizophrenia;
SARC	cis	rs2952156	0.883	rs8077172	chr17:37834977	G/T	cg20243544	chr17:37824526	PNMT	0.56	7.44	0.44	1.94e-12	Asthma;
SARC	cis	rs6696846	0.749	rs6692170	chr1:205074019	G/A	cg21643547	chr1:205240462	TMCC2	-0.54	-6.93	-0.41	4.06e-11	Red blood cell count;
SARC	cis	rs1153858	1.000	rs66939267	chr15:45676902	T/A	cg03999130	chr15:45571217	NA	0.39	4.98	0.31	1.25e-6	Homoarginine levels;
SARC	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg12288994	chr5:1860383	NA	0.39	6.27	0.38	1.71e-9	Cardiovascular disease risk factors;
SARC	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg04277193	chr17:41438351	NA	0.44	4.73	0.3	3.83e-6	Menopause (age at onset);
SARC	cis	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg06636001	chr8:8085503	FLJ10661	0.7	10.26	0.56	1.31e-20	Mood instability;
SARC	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg05368731	chr17:41323189	NBR1	0.7	8.74	0.5	4.76e-16	Menopause (age at onset);
SARC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.7	0.54	6.52e-19	Prudent dietary pattern;
SARC	cis	rs11785693	0.862	rs6995565	chr8:4990461	C/T	cg26367366	chr8:4980734	NA	-0.59	-4.99	-0.31	1.18e-6	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs7429990	0.931	rs62262084	chr3:47653822	C/T	cg11946769	chr3:48343235	NME6	0.67	6.88	0.41	5.51e-11	Educational attainment (years of education);
SARC	cis	rs2327429	0.827	rs1535616	chr6:134171132	C/T	cg25632230	chr6:134101081	NA	-0.46	-5.59	-0.34	6.34e-8	Coronary artery disease;
SARC	cis	rs4660261	0.526	rs3011228	chr1:44325995	A/G	cg13606994	chr1:44402422	ARTN	-0.29	-4.77	-0.3	3.3e-6	Intelligence (multi-trait analysis);
SARC	cis	rs400736	1.000	rs400736	chr1:8078309	T/C	cg25007680	chr1:8021821	PARK7	0.48	6.31	0.38	1.42e-9	Response to antidepressants and depression;
SARC	cis	rs2559856	1.000	rs2559855	chr12:102090080	A/G	cg12924262	chr12:102091054	CHPT1	-0.54	-6.96	-0.42	3.37e-11	Blood protein levels;
SARC	cis	rs3857067	0.806	rs1876918	chr4:95099424	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.35	-5.13	-0.32	6.01e-7	QT interval;
SARC	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg13206674	chr6:150067644	NUP43	0.41	4.91	0.31	1.71e-6	Lung cancer;
SARC	cis	rs11583043	1.000	rs12567858	chr1:101517688	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.47	5.43	0.33	1.44e-7	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs2276314	0.857	rs28435069	chr18:33628475	A/G	cg05985134	chr18:33552581	C18orf21	0.7	7.44	0.44	1.98e-12	Endometriosis;Drug-induced torsades de pointes;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg25195416	chr21:46696626	POFUT2	-0.51	-6.33	-0.38	1.27e-9	Height;
SARC	cis	rs748404	0.631	rs6493083	chr15:43637985	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.55	6.32	0.38	1.33e-9	Lung cancer;
SARC	cis	rs2963155	0.518	rs10482614	chr5:142782402	C/T	cg17617527	chr5:142782415	NR3C1	0.78	6.27	0.38	1.77e-9	Breast cancer;
SARC	cis	rs981844	0.712	rs1563461	chr4:154751913	C/T	cg14289246	chr4:154710475	SFRP2	-0.45	-5.36	-0.33	1.96e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs4319547	0.737	rs7964138	chr12:122950375	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.56	-6.61	-0.4	2.53e-10	Body mass index;
SARC	trans	rs61931739	0.534	rs11053047	chr12:34161084	C/T	cg13010199	chr12:38710504	ALG10B	0.72	9.7	0.54	6.57e-19	Morning vs. evening chronotype;
SARC	cis	rs1008375	0.966	rs6449313	chr4:17588320	A/G	cg16339924	chr4:17578868	LAP3	0.71	9.58	0.53	1.53e-18	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs13256369	0.851	rs13254997	chr8:8563753	G/C	cg17143192	chr8:8559678	CLDN23	0.52	5.83	0.36	1.82e-8	Obesity-related traits;
SARC	cis	rs2191566	0.960	rs8105571	chr19:44510341	C/T	cg20607764	chr19:44506953	ZNF230	-0.47	-5.43	-0.34	1.41e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs959260	1.000	rs4789188	chr17:73397871	A/C	cg14668889	chr17:73230827	NUP85	-0.44	-4.92	-0.31	1.6e-6	Systemic lupus erythematosus;
SARC	cis	rs9858542	0.953	rs7648841	chr3:49416825	G/A	cg07274523	chr3:49395745	GPX1	0.53	6.25	0.38	1.94e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs7223966	0.921	rs67018565	chr17:61928055	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.47	4.98	0.31	1.22e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2832191	1.000	rs9984793	chr21:30486471	T/C	cg24692254	chr21:30365293	RNF160	-0.77	-10.73	-0.58	4.22e-22	Dental caries;
SARC	cis	rs2463822	1.000	rs1406384	chr11:62083530	A/G	cg06239285	chr11:62104954	ASRGL1	-0.83	-9.03	-0.51	6.5e-17	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs2777491	0.789	rs316617	chr15:41795900	C/T	cg18705301	chr15:41695430	NDUFAF1	0.69	10.04	0.55	6.26e-20	Ulcerative colitis;
SARC	cis	rs7113850	0.541	rs77868378	chr11:24233684	C/T	ch.11.24196551F	chr11:24239977	NA	0.75	5.46	0.34	1.25e-7	Bone fracture in osteoporosis;
SARC	cis	rs2594989	0.943	rs346068	chr3:11302933	A/G	cg00170343	chr3:11313890	ATG7	0.57	5.17	0.32	5.12e-7	Circulating chemerin levels;
SARC	cis	rs365132	0.875	rs3923879	chr5:176355312	C/T	cg16309518	chr5:176445507	NA	-0.48	-6.24	-0.38	2.01e-9	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs12594515	1.000	rs8043291	chr15:45996247	T/A	cg14863074	chr15:45997064	NA	0.34	5.18	0.32	4.79e-7	Waist circumference;Weight;
SARC	cis	rs1865721	0.771	rs8093397	chr18:73136217	C/G	cg26385618	chr18:73139727	C18orf62	-0.4	-5.53	-0.34	8.56e-8	Intelligence;
SARC	cis	rs4555082	0.957	rs8022526	chr14:105756485	A/G	cg10792982	chr14:105748885	BRF1	0.49	7.32	0.43	3.93e-12	Mean platelet volume;Platelet distribution width;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg27400655	chr3:52739685	GLT8D1;SPCS1	-0.56	-6.77	-0.41	1.04e-10	Fibrinogen levels;
SARC	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg22974920	chr21:40686053	BRWD1	-0.44	-4.94	-0.31	1.47e-6	Cognitive function;
SARC	cis	rs7914558	1.000	rs10883837	chr10:104896486	G/A	cg04362960	chr10:104952993	NT5C2	0.42	5.03	0.31	9.64e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs9790314	0.663	rs778653	chr3:160716041	G/T	cg04691961	chr3:161091175	C3orf57	-0.58	-8.07	-0.47	3.71e-14	Morning vs. evening chronotype;
SARC	cis	rs9788682	1.000	rs7181245	chr15:78814389	C/T	cg24631222	chr15:78858424	CHRNA5	0.72	9.67	0.54	8.32e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs76419734	0.850	rs72671861	chr4:106648865	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.84	5.56	0.34	7.44e-8	Post bronchodilator FEV1;
SARC	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg21442419	chr1:2182373	SKI	0.38	5.06	0.31	8.7e-7	Height;
SARC	cis	rs7659604	0.502	rs28522256	chr4:122709266	C/T	cg19748678	chr4:122722346	EXOSC9	-0.41	-5.02	-0.31	1e-6	Type 2 diabetes;
SARC	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.48	-0.39	5.4e-10	Total body bone mineral density;
SARC	cis	rs910316	0.763	rs175435	chr14:75612025	A/G	cg11812906	chr14:75593930	NEK9	0.78	10.91	0.58	1.21e-22	Height;
SARC	cis	rs1008375	0.931	rs2315558	chr4:17674558	C/A	cg16339924	chr4:17578868	LAP3	0.62	8.24	0.47	1.26e-14	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7546668	0.640	rs3766160	chr1:15808872	G/A	cg18192808	chr1:15853278	DNAJC16	0.45	5.13	0.32	6.14e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs7635838	0.718	rs2249051	chr3:11403234	G/A	cg00170343	chr3:11313890	ATG7	0.63	8.78	0.5	3.53e-16	HDL cholesterol;
SARC	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg07636037	chr3:49044803	WDR6	0.99	17.31	0.75	1.02e-43	Parkinson's disease;
SARC	cis	rs477692	0.699	rs471390	chr10:131382825	A/G	cg14263093	chr10:131365266	MGMT	-0.36	-5.07	-0.32	8.17e-7	Response to temozolomide;
SARC	trans	rs61931739	0.500	rs11053167	chr12:34387092	A/C	cg26384229	chr12:38710491	ALG10B	0.91	13.8	0.67	4.51e-32	Morning vs. evening chronotype;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg21687300	chr1:52284363	NRD1	0.48	7.29	0.43	4.75e-12	Thyroid stimulating hormone;
SARC	cis	rs7223966	1.000	rs8078462	chr17:61857937	T/G	cg00588841	chr17:61851480	DDX42;CCDC47	-0.69	-7.44	-0.44	1.93e-12	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs546131	0.614	rs473885	chr11:34851961	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.43	5.06	0.31	8.61e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs62064224	0.702	rs2302277	chr17:30791509	C/G	cg09324608	chr17:30823087	MYO1D	0.34	5.07	0.32	8.1e-7	Schizophrenia;
SARC	cis	rs67311347	0.911	rs6775936	chr3:40377399	T/G	cg24209194	chr3:40518798	ZNF619	0.58	7.35	0.43	3.24e-12	Renal cell carcinoma;
SARC	cis	rs2832077	0.527	rs2142375	chr21:30223742	G/A	cg03476357	chr21:30257390	N6AMT1	-0.55	-6.17	-0.37	3.07e-9	Cognitive test performance;
SARC	trans	rs2727020	0.553	rs4980447	chr11:49591662	T/C	cg03929089	chr4:120376271	NA	-0.68	-7.47	-0.44	1.57e-12	Coronary artery disease;
SARC	cis	rs4689388	0.890	rs13130845	chr4:6297646	A/C	cg14416269	chr4:6271139	WFS1	0.31	4.79	0.3	2.95e-6	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	trans	rs747334	0.846	rs7897603	chr10:92708759	C/G	cg25937148	chr3:43147320	C3orf39	-0.47	-6.45	-0.39	6.43e-10	Fibroblast growth factor basic levels;
SARC	cis	rs8067545	0.611	rs7212500	chr17:20045658	A/G	cg13482628	chr17:19912719	NA	0.56	7.43	0.44	2.02e-12	Schizophrenia;
SARC	cis	rs8523	0.586	rs1225744	chr6:10954540	A/G	cg13562911	chr6:11044106	ELOVL2	0.43	5.81	0.36	1.99e-8	Red blood cell fatty acid levels;
SARC	cis	rs4481887	0.927	rs10788779	chr1:248481661	C/G	cg13385794	chr1:248469461	NA	0.34	5.22	0.32	4e-7	Common traits (Other);
SARC	cis	rs8084125	0.832	rs62105182	chr18:74951407	T/C	cg05528293	chr18:74961138	GALR1	0.51	5.79	0.35	2.23e-8	Obesity-related traits;
SARC	cis	rs55728055	0.661	rs1018488	chr22:31992376	A/G	cg01338084	chr22:32026380	PISD	1.08	6.32	0.38	1.3e-9	Age-related hearing impairment;
SARC	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg07636037	chr3:49044803	WDR6	1.02	18.37	0.77	3.4e-47	Parkinson's disease;
SARC	cis	rs7236492	0.688	rs77069608	chr18:77186319	C/T	cg15644404	chr18:77186268	NFATC1	-0.66	-6.62	-0.4	2.44e-10	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs17376456	0.825	rs10038828	chr5:93124056	C/T	cg21475434	chr5:93447410	FAM172A	0.71	6.04	0.37	6.13e-9	Diabetic retinopathy;
SARC	cis	rs2729385	1.000	rs2729385	chr11:57262993	C/T	cg02958346	chr11:57425731	CLP1	0.48	5.36	0.33	2e-7	Interleukin-18 levels;
SARC	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg24642844	chr7:1081250	C7orf50	-0.58	-5.86	-0.36	1.56e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.61	7.4	0.44	2.43e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9611519	0.590	rs4821980	chr22:41415479	C/G	cg17376030	chr22:41985996	PMM1	0.39	4.85	0.3	2.29e-6	Neuroticism;
SARC	cis	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg22496380	chr5:211416	CCDC127	-0.88	-9.35	-0.52	7.72e-18	Breast cancer;
SARC	cis	rs5769765	1.000	rs1033665	chr22:50252127	A/G	cg03033257	chr22:50311977	ALG12;CRELD2	0.53	5.64	0.35	5.02e-8	Schizophrenia;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg21135616	chr2:240294246	HDAC4	-0.42	-6.39	-0.39	8.81e-10	Chemerin levels;
SARC	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.46	-7.09	-0.42	1.58e-11	Longevity;Endometriosis;
SARC	cis	rs7089973	0.604	rs7095816	chr10:116585109	T/C	cg03647239	chr10:116582469	FAM160B1	0.54	7.21	0.43	7.94e-12	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs9486719	0.857	rs11751075	chr6:97065751	G/A	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.51	-0.34	9.35e-8	Migraine;Coronary artery disease;
SARC	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg19761014	chr17:28927070	LRRC37B2	-0.6	-5.15	-0.32	5.48e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs2549003	1.000	rs2548997	chr5:131835395	C/T	cg21138405	chr5:131827807	IRF1	-0.25	-5.13	-0.32	5.99e-7	Asthma (sex interaction);
SARC	cis	rs651907	0.557	rs11710533	chr3:101351472	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	6.18	0.38	2.78e-9	Colorectal cancer;
SARC	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg13012494	chr21:47604986	C21orf56	-0.47	-5.08	-0.32	7.83e-7	Testicular germ cell tumor;
SARC	trans	rs561341	0.941	rs2470236	chr17:30304940	G/C	cg20587970	chr11:113659929	NA	-1.25	-12.78	-0.64	1.07e-28	Hip circumference adjusted for BMI;
SARC	cis	rs2425143	1.000	rs12481228	chr20:34218673	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-5.83	-0.36	1.88e-8	Blood protein levels;
SARC	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg21724239	chr8:58056113	NA	0.57	6.15	0.37	3.36e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2011503	0.941	rs55765017	chr19:19368264	G/A	cg03709012	chr19:19516395	GATAD2A	0.64	5.57	0.34	7.18e-8	Bipolar disorder;
SARC	cis	rs10489202	0.954	rs12403023	chr1:168086999	A/G	cg24449463	chr1:168025552	DCAF6	-0.55	-6.3	-0.38	1.45e-9	Schizophrenia;
SARC	trans	rs3942852	0.568	rs10769313	chr11:48097466	A/G	cg03929089	chr4:120376271	NA	-0.56	-6.84	-0.41	7.02e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs7772486	0.764	rs2265471	chr6:146220250	G/A	cg05347473	chr6:146136440	FBXO30	0.48	6.49	0.39	5.14e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs950880	0.710	rs11465633	chr2:102997733	G/T	cg03938978	chr2:103052716	IL18RAP	-0.34	-4.85	-0.3	2.22e-6	Serum protein levels (sST2);
SARC	cis	rs10779751	0.734	rs2748877	chr1:11129437	T/C	cg08854313	chr1:11322531	MTOR	0.83	11.49	0.6	1.66e-24	Body mass index;
SARC	cis	rs7666738	0.830	rs11726604	chr4:99000969	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	8.14	0.47	2.43e-14	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs73036520	0.846	rs17356664	chr19:45740771	C/T	cg01416317	chr19:45737208	EXOC3L2	0.36	5.36	0.33	2.03e-7	Monocyte percentage of white cells;
SARC	cis	rs11630290	0.592	rs1017531	chr15:64158650	G/A	cg12036633	chr15:63758958	NA	0.49	5.27	0.33	3.16e-7	Iris characteristics;
SARC	cis	rs9858542	0.953	rs9878943	chr3:49434654	G/A	cg07274523	chr3:49395745	GPX1	0.55	6.4	0.39	8.26e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg10523679	chr1:76189770	ACADM	0.45	5.59	0.34	6.47e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs734999	0.545	rs7364820	chr1:2556709	G/A	cg18854424	chr1:2615690	NA	0.31	4.91	0.31	1.73e-6	Ulcerative colitis;
SARC	cis	rs11785400	0.793	rs9297972	chr8:143723660	C/T	cg24634471	chr8:143751801	JRK	0.6	7.74	0.45	2.98e-13	Schizophrenia;
SARC	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg25072359	chr17:41440525	NA	0.48	5.59	0.34	6.49e-8	Menopause (age at onset);
SARC	cis	rs735396	1.000	rs735396	chr12:121438844	T/C	cg25281562	chr12:121454272	C12orf43	0.5	6.06	0.37	5.55e-9	N-glycan levels;
SARC	cis	rs995000	0.965	rs7520810	chr1:63095711	C/T	cg06896770	chr1:63153194	DOCK7	0.9	13.31	0.66	1.97e-30	Triglyceride levels;
SARC	cis	rs11613048	0.897	rs6487883	chr12:30321589	C/T	cg12718339	chr12:29936407	TMTC1	-0.36	-5.0	-0.31	1.11e-6	Major depressive disorder;
SARC	cis	rs6456156	0.586	rs12528689	chr6:167461746	A/G	cg07741184	chr6:167504864	NA	0.35	6.83	0.41	7.46e-11	Primary biliary cholangitis;
SARC	cis	rs1966248	0.543	rs4895994	chr6:134120826	G/A	cg25632230	chr6:134101081	NA	-0.53	-7.04	-0.42	2.15e-11	Coronary artery disease;
SARC	cis	rs8028182	0.636	rs4243034	chr15:75750969	G/A	cg20655648	chr15:75932815	IMP3	0.64	7.62	0.45	6.19e-13	Sudden cardiac arrest;
SARC	cis	rs986417	1.000	rs1956555	chr14:60968804	A/G	cg27398547	chr14:60952738	C14orf39	1.02	9.63	0.53	1.06e-18	Gut microbiota (bacterial taxa);
SARC	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	-0.75	-7.34	-0.43	3.52e-12	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs1215050	0.791	rs7688192	chr4:98900798	G/T	cg05340658	chr4:99064831	C4orf37	-0.44	-5.93	-0.36	1.11e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs9467773	1.000	rs3736782	chr6:26505403	C/A	cg12292205	chr6:26970375	C6orf41	0.43	5.24	0.32	3.66e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg23758822	chr17:41437982	NA	0.9	11.45	0.6	2.28e-24	Menopause (age at onset);
SARC	cis	rs1448094	0.556	rs17345522	chr12:86169929	T/C	cg00310523	chr12:86230176	RASSF9	0.33	5.01	0.31	1.07e-6	Major depressive disorder;
SARC	cis	rs826838	1.000	rs10880785	chr12:38655405	T/G	cg26384229	chr12:38710491	ALG10B	0.93	14.73	0.69	3.88e-35	Heart rate;
SARC	cis	rs1050631	0.960	rs1789516	chr18:33691688	T/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.43	5.23	0.32	3.77e-7	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs26232	0.521	rs11958562	chr5:102363061	C/T	cg23492399	chr5:102201601	PAM	-0.47	-5.2	-0.32	4.29e-7	Rheumatoid arthritis;
SARC	cis	rs826838	0.616	rs10880751	chr12:38627485	C/T	cg13010199	chr12:38710504	ALG10B	0.5	6.25	0.38	1.94e-9	Heart rate;
SARC	cis	rs7223966	0.921	rs7225092	chr17:61864005	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.47	4.95	0.31	1.4e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2120019	1.000	rs7173833	chr15:75369618	C/T	cg00629941	chr15:75287862	SCAMP5	-0.54	-6.41	-0.39	8.07e-10	Blood trace element (Zn levels);
SARC	cis	rs2652834	1.000	rs36116701	chr15:63397494	T/C	cg05507819	chr15:63340323	TPM1	0.54	5.36	0.33	2e-7	HDL cholesterol;
SARC	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg00933542	chr6:150070202	PCMT1	0.33	5.36	0.33	1.98e-7	Lung cancer;
SARC	cis	rs9527	0.590	rs11191578	chr10:104902337	A/T	cg04362960	chr10:104952993	NT5C2	0.44	5.18	0.32	4.78e-7	Arsenic metabolism;
SARC	cis	rs6964587	0.967	rs9656003	chr7:91766322	A/C	cg17063962	chr7:91808500	NA	0.97	16.98	0.74	1.23e-42	Breast cancer;
SARC	cis	rs1059312	1.000	rs1059312	chr12:129278864	A/G	cg09035930	chr12:129282057	SLC15A4	-0.56	-7.94	-0.46	8.76e-14	Systemic lupus erythematosus;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11207300	chr12:95867190	METAP2	0.51	6.43	0.39	7.22e-10	Smoking initiation;
SARC	cis	rs1355223	0.902	rs7129089	chr11:34699699	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-5.7	-0.35	3.54e-8	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs6683419	0.604	rs11590110	chr1:19848723	T/C	cg12094543	chr1:19923282	C1orf151	0.6	6.55	0.39	3.58e-10	Serum thyroid-stimulating hormone levels;
SARC	cis	rs2421770	0.532	rs7130967	chr11:35374008	A/G	cg13971030	chr11:35366721	SLC1A2	-0.34	-4.71	-0.3	4.17e-6	Staphylococcus aureus nasal carriage (persistent);
SARC	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg12463550	chr7:65579703	CRCP	0.69	5.24	0.32	3.54e-7	Diabetic kidney disease;
SARC	cis	rs10425738	0.536	rs10426903	chr19:41417719	T/C	cg17435250	chr19:41386441	CYP2A7	-0.37	-5.31	-0.33	2.52e-7	nicotine metabolite ratio in current smokers;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
SARC	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg16049864	chr8:95962084	TP53INP1	-0.51	-8.35	-0.48	6.04e-15	Type 2 diabetes;
SARC	cis	rs7662987	0.517	rs2602877	chr4:100039847	T/A	cg12011299	chr4:100065546	ADH4	0.33	5.47	0.34	1.13e-7	Smoking initiation;
SARC	cis	rs2153535	0.580	rs4960423	chr6:8477210	C/T	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	trans	rs6981523	0.500	rs4412337	chr8:11072020	C/T	cg06636001	chr8:8085503	FLJ10661	0.52	6.67	0.4	1.89e-10	Neuroticism;
SARC	cis	rs898097	1.000	rs898098	chr17:80904564	G/A	cg20578329	chr17:80767326	TBCD	0.46	6.36	0.38	1.03e-9	Breast cancer;
SARC	cis	rs4819052	0.679	rs4819053	chr21:46711357	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.58	-7.19	-0.43	9e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg10295955	chr4:187884368	NA	-1.08	-19.47	-0.79	9.08e-51	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6089584	0.566	rs6061401	chr20:60607482	G/A	cg06108461	chr20:60628389	TAF4	-0.71	-9.3	-0.52	1.09e-17	Body mass index;
SARC	cis	rs4243830	0.850	rs908273	chr1:6588604	G/A	cg04093404	chr1:6614507	TAS1R1;NOL9	0.59	5.27	0.33	3.18e-7	Body mass index;
SARC	trans	rs2727020	0.553	rs7479975	chr11:49581964	C/G	cg03929089	chr4:120376271	NA	-0.74	-10.75	-0.58	3.82e-22	Coronary artery disease;
SARC	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	11.2	0.59	1.44e-23	Alzheimer's disease;
SARC	cis	rs9875589	0.915	rs9835402	chr3:13954396	A/G	cg19554555	chr3:13937349	NA	0.51	6.63	0.4	2.37e-10	Ovarian reserve;
SARC	cis	rs4808199	0.947	rs7250658	chr19:19571100	A/G	cg03709012	chr19:19516395	GATAD2A	1.2	13.19	0.65	4.79e-30	Nonalcoholic fatty liver disease;
SARC	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg22535103	chr8:58192502	C8orf71	-0.65	-6.02	-0.37	6.62e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs3857536	0.904	rs9294684	chr6:66897589	A/C	cg07460842	chr6:66804631	NA	0.45	5.34	0.33	2.19e-7	Blood trace element (Cu levels);
SARC	cis	rs12893597	0.541	rs12589755	chr14:76841939	A/C	cg20290672	chr14:76816747	NA	-0.38	-4.82	-0.3	2.64e-6	Maximal oxygen uptake response;
SARC	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg03709012	chr19:19516395	GATAD2A	-0.95	-15.25	-0.71	7.23e-37	Tonsillectomy;
SARC	cis	rs2153535	0.580	rs9406167	chr6:8502852	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	7.31	0.43	4.22e-12	Motion sickness;
SARC	cis	rs8103278	1.000	rs9807819	chr19:46239598	C/T	cg11657440	chr19:46296263	DMWD	-0.73	-9.05	-0.51	5.95e-17	Coronary artery disease;
SARC	cis	rs911263	0.603	rs10141370	chr14:68776170	G/A	cg18825221	chr14:68749962	RAD51L1	0.43	7.78	0.45	2.31e-13	Primary biliary cholangitis;
SARC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg10963375	chr1:205815865	PM20D1	0.33	5.0	0.31	1.13e-6	Menarche (age at onset);
SARC	cis	rs9640161	0.711	rs55881542	chr7:150025734	G/A	cg21361702	chr7:150065534	REPIN1	0.5	5.06	0.31	8.55e-7	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs6540556	0.723	rs12034758	chr1:209920545	G/A	cg23920097	chr1:209922102	NA	-0.6	-6.14	-0.37	3.54e-9	Red blood cell count;
SARC	cis	rs2075371	0.637	rs13245165	chr7:133951492	A/T	cg20476274	chr7:133979776	SLC35B4	0.57	7.41	0.44	2.28e-12	Mean platelet volume;
SARC	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg13175981	chr1:150552382	MCL1	-0.54	-6.84	-0.41	6.75e-11	Tonsillectomy;
SARC	cis	rs6693567	0.565	rs3125808	chr1:150314272	T/C	cg09579323	chr1:150459698	TARS2	0.42	5.31	0.33	2.56e-7	Migraine;
SARC	cis	rs654950	0.934	rs641974	chr1:42002137	G/A	cg06885757	chr1:42089581	HIVEP3	-0.41	-5.93	-0.36	1.11e-8	Airway imaging phenotypes;
SARC	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-9.17	-0.51	2.59e-17	Alzheimer's disease;
SARC	cis	rs1843834	0.505	rs940317	chr2:225358118	C/T	cg22455342	chr2:225449267	CUL3	0.64	8.01	0.46	5.44e-14	IgE levels in asthmatics (D.p. specific);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg20230856	chr3:176769657	TBL1XR1	0.45	6.72	0.4	1.37e-10	Thyroid stimulating hormone;
SARC	cis	rs9902453	1.000	rs9890205	chr17:28382704	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.53	-6.96	-0.41	3.47e-11	Coffee consumption (cups per day);
SARC	cis	rs79349575	0.783	rs4794000	chr17:47022755	C/G	cg16584676	chr17:46985605	UBE2Z	0.55	6.66	0.4	1.91e-10	Type 2 diabetes;
SARC	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg03351412	chr1:154909251	PMVK	0.6	7.26	0.43	5.87e-12	Prostate cancer;
SARC	trans	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg06437703	chr8:37914619	EIF4EBP1	-0.53	-6.37	-0.39	9.94e-10	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg03433033	chr1:76189801	ACADM	0.55	7.71	0.45	3.52e-13	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6570726	0.791	rs370654	chr6:145879005	C/G	cg05347473	chr6:146136440	FBXO30	0.54	7.54	0.44	1.05e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1348850	0.598	rs12616259	chr2:178503803	C/T	cg22681709	chr2:178499509	PDE11A	-0.41	-5.53	-0.34	8.53e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9796	0.870	rs10851402	chr15:41263438	C/T	cg18705301	chr15:41695430	NDUFAF1	0.41	5.54	0.34	8.15e-8	Menopause (age at onset);
SARC	cis	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg07777115	chr5:623756	CEP72	-0.56	-4.83	-0.3	2.49e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg05340658	chr4:99064831	C4orf37	0.57	7.16	0.42	1.02e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9818758	0.607	rs3923475	chr3:49055788	G/T	cg00383909	chr3:49044727	WDR6	0.77	6.71	0.4	1.47e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg08859206	chr1:53392774	SCP2	-0.38	-5.44	-0.34	1.36e-7	Monocyte count;
SARC	cis	rs12701220	0.504	rs12702092	chr7:1145868	G/A	cg01324507	chr7:1177794	C7orf50	0.51	4.73	0.3	3.88e-6	Bronchopulmonary dysplasia;
SARC	cis	rs6088813	1.000	rs2248393	chr20:33926103	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.45	5.37	0.33	1.93e-7	Height;
SARC	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg09699651	chr6:150184138	LRP11	0.39	4.86	0.3	2.17e-6	Lung cancer;
SARC	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg09359103	chr1:154839909	KCNN3	-0.46	-7.73	-0.45	3.23e-13	Prostate cancer;
SARC	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg19223190	chr17:80058835	NA	0.45	6.3	0.38	1.43e-9	Life satisfaction;
SARC	cis	rs55883249	0.957	rs16867083	chr2:9767441	C/T	cg23886495	chr2:9695866	ADAM17	-0.65	-6.89	-0.41	5.2e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg22920501	chr2:26401640	FAM59B	0.59	7.57	0.44	8.77e-13	Gut microbiome composition (summer);
SARC	cis	rs7044106	0.762	rs10818471	chr9:123394045	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	5.01	0.31	1.05e-6	Hip circumference adjusted for BMI;
SARC	cis	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg24110177	chr3:50126178	RBM5	0.58	7.91	0.46	1.04e-13	Intelligence (multi-trait analysis);
SARC	cis	rs11122272	0.735	rs2808611	chr1:231548480	A/G	cg06096015	chr1:231504339	EGLN1	-0.38	-5.61	-0.35	5.68e-8	Hemoglobin concentration;
SARC	cis	rs9549260	0.755	rs7338669	chr13:41200091	C/T	cg21288729	chr13:41239152	FOXO1	-0.64	-8.74	-0.5	4.67e-16	Red blood cell count;
SARC	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg03060546	chr3:49711283	APEH	0.48	6.31	0.38	1.37e-9	Menarche (age at onset);
SARC	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg08048268	chr3:133502702	NA	0.42	5.67	0.35	4.1e-8	Iron status biomarkers;
SARC	cis	rs8060686	0.516	rs255052	chr16:68024995	C/T	cg27539214	chr16:67997921	SLC12A4	-0.58	-5.28	-0.33	3.02e-7	HDL cholesterol;Metabolic syndrome;
SARC	cis	rs3126085	0.935	rs74127901	chr1:152195579	G/A	cg26876637	chr1:152193138	HRNR	-0.49	-5.43	-0.34	1.41e-7	Atopic dermatitis;
SARC	cis	rs765787	0.530	rs12917187	chr15:45538297	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.67e-7	Uric acid levels;
SARC	cis	rs76917914	0.538	rs4743164	chr9:100864249	C/T	cg03040243	chr9:100819229	NANS	0.53	5.75	0.35	2.82e-8	Immature fraction of reticulocytes;
SARC	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg11764359	chr7:65958608	NA	0.79	9.88	0.54	1.93e-19	Aortic root size;
SARC	cis	rs1707322	1.000	rs7519181	chr1:46387829	G/C	cg06784218	chr1:46089804	CCDC17	0.34	5.97	0.36	8.8e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg20607798	chr8:58055168	NA	0.66	5.2	0.32	4.28e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2180341	0.574	rs13192350	chr6:127677762	G/T	cg24812749	chr6:127587940	RNF146	0.59	7.18	0.43	9.48e-12	Breast cancer;
SARC	cis	rs9300255	0.544	rs1716175	chr12:123658388	A/T	cg05973401	chr12:123451056	ABCB9	0.53	5.95	0.36	9.6e-9	Neutrophil percentage of white cells;
SARC	cis	rs931812	0.829	rs13266662	chr8:101916156	C/T	cg07585502	chr8:101912084	NA	-0.38	-4.8	-0.3	2.81e-6	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg16325326	chr1:53192061	ZYG11B	0.93	17.39	0.75	5.69e-44	Monocyte count;
SARC	cis	rs208520	0.526	rs9351542	chr6:66788571	A/G	cg07460842	chr6:66804631	NA	-1.12	-22.84	-0.83	2.24e-61	Exhaled nitric oxide output;
SARC	cis	rs910316	0.763	rs12588981	chr14:75460561	A/G	cg06637938	chr14:75390232	RPS6KL1	0.46	6.06	0.37	5.29e-9	Height;
SARC	cis	rs950776	0.593	rs680244	chr15:78871288	T/C	cg22563815	chr15:78856949	CHRNA5	-0.38	-6.44	-0.39	6.68e-10	Sudden cardiac arrest;
SARC	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs8014204	0.773	rs2241275	chr14:75251440	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.72	-10.48	-0.57	2.55e-21	Caffeine consumption;
SARC	cis	rs9733	0.650	rs6698495	chr1:150564476	T/C	cg13175981	chr1:150552382	MCL1	0.69	9.46	0.53	3.64e-18	Tonsillectomy;
SARC	cis	rs28829049	0.597	rs2296107	chr1:19476649	C/G	cg13387374	chr1:19411106	UBR4	0.44	5.28	0.33	2.99e-7	QRS duration in Tripanosoma cruzi seropositivity;
SARC	cis	rs6815814	0.950	rs66922907	chr4:38812537	A/G	cg09316306	chr4:38807337	TLR1	0.46	4.71	0.3	4.18e-6	Breast cancer;
SARC	cis	rs9616064	0.740	rs6520049	chr22:46996309	C/T	cg05621596	chr22:47072043	GRAMD4	-0.45	-6.12	-0.37	3.99e-9	Urate levels in obese individuals;
SARC	cis	rs35146811	0.771	rs6465762	chr7:99620554	G/A	cg22004693	chr7:99632812	ZKSCAN1	-0.45	-4.95	-0.31	1.43e-6	Coronary artery disease;
SARC	cis	rs2576037	0.901	rs2576036	chr18:44587102	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	10.28	0.56	1.14e-20	Personality dimensions;
SARC	trans	rs4295623	0.553	rs11250163	chr8:11596437	G/T	cg06636001	chr8:8085503	FLJ10661	0.58	7.37	0.43	2.91e-12	Morning vs. evening chronotype;
SARC	cis	rs651907	0.557	rs11720745	chr3:101441690	G/A	cg12386194	chr3:101231763	SENP7	0.48	5.74	0.35	2.96e-8	Colorectal cancer;
SARC	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg26681399	chr22:41777847	TEF	-0.46	-4.96	-0.31	1.35e-6	Vitiligo;
SARC	cis	rs2486288	0.656	rs12911186	chr15:45551423	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.51	-6.44	-0.39	6.68e-10	Glomerular filtration rate;
SARC	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg17221315	chr6:27791827	HIST1H4J	0.45	4.85	0.3	2.28e-6	Cardiac Troponin-T levels;
SARC	cis	rs853679	0.585	rs201000	chr6:27809159	C/T	cg17221315	chr6:27791827	HIST1H4J	0.56	5.15	0.32	5.56e-7	Depression;
SARC	cis	rs7769051	1.000	rs9493454	chr6:133144629	G/T	cg07930552	chr6:133119739	C6orf192	-0.89	-8.32	-0.48	7.49e-15	Type 2 diabetes nephropathy;
SARC	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg06212747	chr3:49208901	KLHDC8B	0.65	8.64	0.49	9.19e-16	Parkinson's disease;
SARC	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg00409905	chr10:38381863	ZNF37A	-0.49	-6.74	-0.4	1.22e-10	Extrinsic epigenetic age acceleration;
SARC	cis	rs1062177	0.855	rs1346489	chr5:151266534	C/T	cg00977110	chr5:151150581	G3BP1	0.51	5.46	0.34	1.24e-7	Preschool internalizing problems;
SARC	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg11644478	chr21:40555479	PSMG1	1.02	14.32	0.68	8.73e-34	Cognitive function;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg01934787	chr3:37152029	LRRFIP2	-0.59	-7.69	-0.45	4.17e-13	Alcohol dependence;
SARC	cis	rs72634258	0.945	rs2294889	chr1:8075934	A/G	cg00042356	chr1:8021962	PARK7	0.75	7.05	0.42	2.07e-11	Inflammatory bowel disease;
SARC	cis	rs3862260	0.509	rs3795663	chr1:120165187	G/A	cg16322792	chr1:120165303	ZNF697	0.29	6.09	0.37	4.51e-9	Systemic lupus erythematosus;
SARC	cis	rs7635838	0.859	rs6784883	chr3:11444453	G/A	cg00170343	chr3:11313890	ATG7	0.61	8.1	0.47	3.04e-14	HDL cholesterol;
SARC	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg06634786	chr22:41940651	POLR3H	-0.57	-6.77	-0.41	1.05e-10	Vitiligo;
SARC	cis	rs4481887	1.000	rs4430369	chr1:248464330	A/G	cg01631408	chr1:248437212	OR2T33	-0.43	-5.52	-0.34	8.86e-8	Common traits (Other);
SARC	cis	rs3858526	0.959	rs11039699	chr11:5951091	G/A	cg13902645	chr11:5959945	NA	-0.46	-5.3	-0.33	2.62e-7	DNA methylation (variation);
SARC	cis	rs12579753	0.597	rs2244802	chr12:82153749	C/G	cg07988820	chr12:82153109	PPFIA2	0.55	6.93	0.41	4.03e-11	Resting heart rate;
SARC	cis	rs2204008	0.747	rs11514040	chr12:38201040	G/A	cg26384229	chr12:38710491	ALG10B	0.88	12.94	0.65	3.26e-29	Bladder cancer;
SARC	cis	rs829883	0.646	rs249836	chr12:98878342	T/C	cg25150519	chr12:98850993	NA	0.42	5.39	0.33	1.68e-7	Colorectal adenoma (advanced);
SARC	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	8.13	0.47	2.59e-14	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs1055129	0.682	rs7217432	chr17:73834604	A/G	cg14829360	chr17:73884958	NA	-0.45	-6.15	-0.37	3.36e-9	White matter hyperintensity burden;
SARC	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.85	8.46	0.48	2.98e-15	Platelet count;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg26396707	chr1:161129261	USP21	0.77	6.51	0.39	4.49e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-7.83	-0.46	1.71e-13	Alzheimer's disease;
SARC	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg13126279	chr21:47581558	C21orf56	-0.45	-5.39	-0.33	1.73e-7	Testicular germ cell tumor;
SARC	cis	rs36051895	0.664	rs3780372	chr9:5097544	C/T	cg02405213	chr9:5042618	JAK2	-0.45	-5.53	-0.34	8.78e-8	Pediatric autoimmune diseases;
SARC	cis	rs611744	0.901	rs599357	chr8:109194160	T/C	cg21045802	chr8:109455806	TTC35	0.44	5.3	0.33	2.63e-7	Dupuytren's disease;
SARC	cis	rs1153858	1.000	rs9788780	chr15:45685487	T/A	cg21132104	chr15:45694354	SPATA5L1	0.78	10.56	0.57	1.54e-21	Homoarginine levels;
SARC	cis	rs6831352	0.918	rs2602893	chr4:100044095	G/T	cg13256891	chr4:100009986	ADH5	0.67	8.36	0.48	5.85e-15	Alcohol dependence;
SARC	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg05234568	chr11:5960015	NA	-0.39	-5.29	-0.33	2.83e-7	DNA methylation (variation);
SARC	cis	rs2857078	0.720	rs9901595	chr17:42305699	G/A	cg13607699	chr17:42295918	UBTF	0.86	13.55	0.66	3.21e-31	Red cell distribution width;Reticulocyte count;
SARC	cis	rs9303401	0.659	rs12946397	chr17:56769979	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	12.31	0.63	3.57e-27	Cognitive test performance;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg09025725	chr1:43124093	PPIH	0.66	6.72	0.4	1.36e-10	Lung cancer in ever smokers;
SARC	cis	rs1113500	0.862	rs11185264	chr1:108640506	T/C	cg06207961	chr1:108661230	NA	0.45	6.0	0.37	7.6e-9	Growth-regulated protein alpha levels;
SARC	cis	rs858239	0.570	rs10271613	chr7:23162586	G/A	cg23682824	chr7:23144976	KLHL7	0.74	10.17	0.55	2.37e-20	Cerebrospinal fluid biomarker levels;
SARC	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg16479474	chr6:28041457	NA	0.34	5.19	0.32	4.68e-7	Cardiac Troponin-T levels;
SARC	cis	rs9815354	1.000	rs17063584	chr3:41861463	A/G	cg03022575	chr3:42003672	ULK4	0.57	5.37	0.33	1.9e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg08280861	chr8:58055591	NA	0.6	5.68	0.35	3.99e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg13239297	chr3:50192725	SEMA3F	0.47	6.25	0.38	1.98e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg01475735	chr3:40494733	NA	0.49	5.64	0.35	4.78e-8	Renal cell carcinoma;
SARC	cis	rs7623687	1.000	rs7623687	chr3:49448566	A/C	cg19401529	chr3:49056140	DALRD3	0.63	5.47	0.34	1.17e-7	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
SARC	cis	rs826838	0.935	rs10875816	chr12:38955014	C/A	cg13010199	chr12:38710504	ALG10B	0.77	10.68	0.57	6.4e-22	Heart rate;
SARC	cis	rs2486288	0.656	rs8039153	chr15:45579813	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.5	-6.01	-0.37	7.21e-9	Glomerular filtration rate;
SARC	cis	rs6815814	0.950	rs5743565	chr4:38805983	T/C	cg09316306	chr4:38807337	TLR1	0.5	5.16	0.32	5.35e-7	Breast cancer;
SARC	cis	rs10504229	0.679	rs60869047	chr8:58053221	G/A	cg21724239	chr8:58056113	NA	0.57	5.84	0.36	1.76e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg20463403	chr6:36168142	BRPF3	0.54	6.41	0.39	8.01e-10	Blood pressure;
SARC	cis	rs2839627	0.598	rs56098337	chr21:44271365	G/T	cg03543861	chr21:44258195	NA	0.45	4.85	0.3	2.3e-6	Information processing speed;
SARC	cis	rs3749237	0.555	rs2117939	chr3:49415179	C/A	cg03060546	chr3:49711283	APEH	0.74	10.67	0.57	6.93e-22	Resting heart rate;
SARC	cis	rs9398803	0.686	rs3861458	chr6:126912162	G/A	cg19875578	chr6:126661172	C6orf173	0.63	8.7	0.5	5.9e-16	Male-pattern baldness;
SARC	cis	rs770189	0.910	rs700594	chr5:88101142	A/G	cg18498987	chr5:88179539	MEF2C	0.38	4.85	0.3	2.25e-6	Tonometry;
SARC	cis	rs9467773	1.000	rs9393731	chr6:26529374	C/T	cg12292205	chr6:26970375	C6orf41	0.44	5.37	0.33	1.87e-7	Intelligence (multi-trait analysis);
SARC	cis	rs721399	0.539	rs2898476	chr8:18266924	G/A	cg18736775	chr8:18248649	NAT2	-0.57	-5.52	-0.34	9.04e-8	Blood metabolite levels;
SARC	cis	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg15145296	chr3:125709740	NA	-0.49	-4.74	-0.3	3.66e-6	Blood pressure (smoking interaction);
SARC	trans	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg06830555	chr3:18486241	NA	-0.45	-6.32	-0.38	1.33e-9	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2651899	0.872	rs207199	chr1:3076857	T/G	cg22674798	chr1:3096360	PRDM16	0.26	5.37	0.33	1.93e-7	Migraine;
SARC	trans	rs2727020	0.521	rs11039902	chr11:48679467	A/G	cg00717180	chr2:96193071	NA	-0.38	-6.36	-0.38	1.04e-9	Coronary artery disease;
SARC	cis	rs7267979	0.789	rs6050472	chr20:25219852	A/G	cg13962466	chr20:25176127	ENTPD6	0.43	5.41	0.33	1.59e-7	Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs10463316	0.780	rs6894899	chr5:150775913	C/T	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.37	-0.33	1.86e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg24110177	chr3:50126178	RBM5	0.54	7.22	0.43	7.31e-12	Intelligence (multi-trait analysis);
SARC	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	10.56	0.57	1.5e-21	Alzheimer's disease;
SARC	cis	rs2011503	1.000	rs76790018	chr19:19652157	G/A	cg15839431	chr19:19639596	YJEFN3	-0.48	-4.77	-0.3	3.32e-6	Bipolar disorder;
SARC	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg22535103	chr8:58192502	C8orf71	-0.7	-6.25	-0.38	1.95e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1707322	0.826	rs10890349	chr1:46249955	T/C	cg06784218	chr1:46089804	CCDC17	0.36	6.39	0.39	8.93e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs72781680	0.898	rs72786288	chr2:24075416	G/T	cg06627628	chr2:24431161	ITSN2	-0.67	-6.45	-0.39	6.22e-10	Lymphocyte counts;
SARC	cis	rs9300255	0.602	rs1626899	chr12:123708063	A/G	cg00376283	chr12:123451042	ABCB9	0.53	6.21	0.38	2.45e-9	Neutrophil percentage of white cells;
SARC	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg17971929	chr21:40555470	PSMG1	-0.59	-7.36	-0.43	3.16e-12	Menarche (age at onset);
SARC	cis	rs9303542	0.559	rs1042818	chr17:46620111	T/C	cg04904318	chr17:46607828	HOXB1	-0.44	-4.88	-0.3	1.93e-6	Ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg18876405	chr7:65276391	NA	-0.49	-5.53	-0.34	8.47e-8	Aortic root size;
SARC	trans	rs4834272	0.580	rs9884299	chr4:113302950	A/G	cg04861380	chr7:150497663	TMEM176B;TMEM176A	-0.48	-6.91	-0.41	4.5e-11	Body mass index;
SARC	cis	rs9896052	0.608	rs9797247	chr17:73445814	C/T	cg27037648	chr17:73511087	CASKIN2	0.4	4.86	0.3	2.2e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs9807989	0.839	rs1974675	chr2:102986375	G/A	cg09003973	chr2:102972529	NA	0.41	5.52	0.34	8.96e-8	Asthma;
SARC	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg21442419	chr1:2182373	SKI	-0.48	-6.29	-0.38	1.53e-9	Height;
SARC	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg11644478	chr21:40555479	PSMG1	-0.88	-10.77	-0.58	3.26e-22	Cognitive function;
SARC	trans	rs7819412	0.654	rs34741518	chr8:10776860	A/C	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.25	-0.38	1.97e-9	Triglycerides;
SARC	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg16325326	chr1:53192061	ZYG11B	0.73	10.75	0.58	3.76e-22	Monocyte count;
SARC	cis	rs112790992	1	rs112790992	chr14:105758217	A/C	cg13114125	chr14:105738426	BRF1	-0.74	-10.85	-0.58	1.83e-22	Platelet count;
SARC	cis	rs2200578	0.786	rs62158261	chr2:99563210	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.53	4.72	0.3	3.99e-6	IgG glycosylation;
SARC	cis	rs13191362	0.573	rs9365499	chr6:163271833	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.43	5.03	0.31	9.93e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs9457247	1.000	rs439553	chr6:167391212	A/G	cg07741184	chr6:167504864	NA	0.3	5.76	0.35	2.69e-8	Crohn's disease;
SARC	cis	rs7250872	0.647	rs12976128	chr19:1817113	A/C	cg18850929	chr19:1828978	REXO1	0.45	5.68	0.35	3.94e-8	Bipolar disorder;
SARC	cis	rs9309473	0.615	rs62151562	chr2:73603540	T/G	cg20560298	chr2:73613845	ALMS1	-0.58	-5.64	-0.35	4.83e-8	Metabolite levels;
SARC	cis	rs7408868	0.563	rs10423702	chr19:15300069	T/C	cg14696996	chr19:15285081	NOTCH3	0.79	7.28	0.43	5.05e-12	Pulse pressure;
SARC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	6.0	0.37	7.37e-9	Prudent dietary pattern;
SARC	trans	rs2727020	0.523	rs7948958	chr11:49506749	G/A	cg15704280	chr7:45808275	SEPT13	0.71	8.13	0.47	2.51e-14	Coronary artery disease;
SARC	cis	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg05084668	chr3:125655381	ALG1L	-0.5	-5.29	-0.33	2.79e-7	Blood pressure (smoking interaction);
SARC	cis	rs6815814	0.851	rs73235002	chr4:38769018	A/G	cg06935464	chr4:38784597	TLR10	0.58	5.28	0.33	2.99e-7	Breast cancer;
SARC	cis	rs1691799	0.799	rs10784525	chr12:66772766	G/A	cg16791601	chr12:66731901	HELB	-0.71	-10.48	-0.57	2.7e-21	White blood cell count (basophil);
SARC	cis	rs933688	1.000	rs6865495	chr5:90746424	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.02	13.18	0.65	5.03e-30	Smoking behavior;
SARC	cis	rs1790761	0.658	rs684928	chr11:67329742	G/A	cg24690094	chr11:67383802	NA	0.37	5.45	0.34	1.25e-7	Mean corpuscular volume;
SARC	cis	rs883565	0.569	rs784511	chr3:39165548	A/G	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.44	-5.12	-0.32	6.37e-7	Handedness;
SARC	cis	rs55871839	0.640	rs4738734	chr8:59814330	A/T	cg07426533	chr8:59803705	TOX	-0.43	-5.77	-0.35	2.51e-8	Pneumonia;
SARC	cis	rs2425143	0.730	rs6058354	chr20:34491110	C/A	cg01084648	chr20:34329383	RBM39	0.62	4.75	0.3	3.62e-6	Blood protein levels;
SARC	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg09455208	chr3:40491958	NA	-0.36	-5.52	-0.34	8.85e-8	Renal cell carcinoma;
SARC	cis	rs992157	0.710	rs6752254	chr2:219058743	C/T	cg00012203	chr2:219082015	ARPC2	0.81	13.24	0.66	3.22e-30	Colorectal cancer;
SARC	cis	rs6088590	0.542	rs6059956	chr20:33220070	A/G	cg08999081	chr20:33150536	PIGU	0.46	7.04	0.42	2.16e-11	Coronary artery disease;
SARC	trans	rs11098499	0.865	rs4001305	chr4:120359236	G/T	cg25214090	chr10:38739885	LOC399744	0.54	7.11	0.42	1.38e-11	Corneal astigmatism;
SARC	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg04518342	chr5:131593106	PDLIM4	-0.45	-5.61	-0.34	5.86e-8	Blood metabolite levels;
SARC	cis	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg18252515	chr7:66147081	NA	-1.27	-11.31	-0.6	6.26e-24	Diabetic kidney disease;
SARC	cis	rs12586317	0.547	rs10130773	chr14:35445299	G/A	cg16230307	chr14:35515116	FAM177A1	1.02	11.72	0.61	3.08e-25	Psoriasis;
SARC	cis	rs13161895	1.000	rs27012	chr5:179402211	A/C	cg02702477	chr5:179499311	RNF130	0.61	5.76	0.35	2.6e-8	LDL cholesterol;
SARC	cis	rs992157	0.643	rs10191283	chr2:219056755	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.65	8.94	0.51	1.19e-16	Colorectal cancer;
SARC	cis	rs9393692	0.645	rs6939048	chr6:26327953	G/A	cg00631329	chr6:26305371	NA	-0.64	-8.36	-0.48	5.57e-15	Educational attainment;
SARC	cis	rs2153535	0.580	rs2152347	chr6:8474281	A/G	cg21535247	chr6:8435926	SLC35B3	0.54	6.79	0.41	9.19e-11	Motion sickness;
SARC	cis	rs7607369	0.648	rs17470271	chr2:219651995	A/T	cg02176678	chr2:219576539	TTLL4	0.51	8.38	0.48	5.14e-15	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg03264133	chr6:25882463	NA	0.37	4.82	0.3	2.58e-6	Intelligence (multi-trait analysis);
SARC	cis	rs1865760	0.566	rs2051544	chr6:26071093	C/T	cg18357526	chr6:26021779	HIST1H4A	0.42	5.15	0.32	5.61e-7	Height;
SARC	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg21747090	chr2:27597821	SNX17	-0.54	-7.33	-0.43	3.72e-12	Total body bone mineral density;
SARC	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg12463550	chr7:65579703	CRCP	-0.47	-5.41	-0.33	1.54e-7	Aortic root size;
SARC	cis	rs2153535	0.580	rs9379216	chr6:8481235	G/A	cg21535247	chr6:8435926	SLC35B3	0.55	6.97	0.42	3.17e-11	Motion sickness;
SARC	cis	rs2228479	0.867	rs12919804	chr16:89945369	G/A	cg06558623	chr16:89946397	TCF25	0.98	8.13	0.47	2.6e-14	Skin colour saturation;
SARC	cis	rs12709013	0.636	rs1646279	chr16:58784139	T/G	cg04273148	chr16:57808038	KIFC3	0.32	4.77	0.3	3.24e-6	Blood metabolite ratios;
SARC	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	10.08	0.55	4.63e-20	Platelet count;
SARC	trans	rs11098499	0.954	rs9685777	chr4:120365965	C/A	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	cis	rs12464483	0.524	rs1901906	chr2:30884576	A/G	cg17749961	chr2:30669863	LCLAT1	-0.55	-5.68	-0.35	3.97e-8	Pre-treatment pain in head and neck squamous cell carcinoma;
SARC	cis	rs9381040	0.610	rs6919961	chr6:41020361	T/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.4	-4.72	-0.3	4.06e-6	Alzheimer's disease (late onset);
SARC	cis	rs6500602	0.627	rs3848372	chr16:4587875	C/A	cg09269891	chr16:3843415	CREBBP	-0.43	-5.03	-0.31	9.77e-7	Schizophrenia;
SARC	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	5.38	0.33	1.79e-7	Bipolar disorder;
SARC	cis	rs797680	0.930	rs1474927	chr1:93570368	C/T	cg01538778	chr1:93646459	TMED5;CCDC18	0.42	4.9	0.31	1.8e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
SARC	cis	rs34375054	0.553	rs12580221	chr12:125621066	T/C	cg25124228	chr12:125621409	AACS	-0.65	-8.32	-0.48	7.43e-15	Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs9916302	0.904	rs4794814	chr17:37696852	G/A	cg07936489	chr17:37558343	FBXL20	-0.68	-8.78	-0.5	3.5e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs453301	0.686	rs2409120	chr8:8882571	G/C	cg11608241	chr8:8085544	FLJ10661	-0.44	-5.68	-0.35	4.02e-8	Joint mobility (Beighton score);
SARC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.6	7.69	0.45	4.03e-13	Lymphocyte counts;
SARC	cis	rs7772486	0.790	rs6917482	chr6:146243581	C/T	cg23711669	chr6:146136114	FBXO30	-0.8	-12.46	-0.63	1.2100000000000001e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7843479	0.965	rs17616085	chr8:21857267	C/T	cg17168535	chr8:21777572	XPO7	0.66	8.44	0.48	3.42e-15	Mean corpuscular volume;
SARC	cis	rs9309473	1.000	rs11901272	chr2:73720444	A/G	cg07208825	chr2:73871855	ALMS1P	0.33	4.76	0.3	3.36e-6	Metabolite levels;
SARC	cis	rs11785400	1.000	rs13265663	chr8:143732255	A/C	cg24634471	chr8:143751801	JRK	0.67	8.94	0.51	1.24e-16	Schizophrenia;
SARC	cis	rs7937682	0.564	rs9633937	chr11:111372799	C/T	cg22437258	chr11:111473054	SIK2	-0.41	-4.82	-0.3	2.58e-6	Primary sclerosing cholangitis;
SARC	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.53	8.15	0.47	2.22e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs6540556	0.723	rs10863785	chr1:209908876	C/T	cg05527609	chr1:210001259	C1orf107	0.58	5.72	0.35	3.24e-8	Red blood cell count;
SARC	cis	rs3768617	0.510	rs3765522	chr1:183077618	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.8e-21	Fuchs's corneal dystrophy;
SARC	cis	rs12497850	1.000	rs6788650	chr3:48749543	T/C	cg06212747	chr3:49208901	KLHDC8B	0.65	8.83	0.5	2.6e-16	Parkinson's disease;
SARC	cis	rs17376456	0.825	rs13156202	chr5:93157721	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.73	-6.76	-0.41	1.08e-10	Diabetic retinopathy;
SARC	cis	rs9660992	0.624	rs72745217	chr1:205261482	C/G	cg21545522	chr1:205238299	TMCC2	0.46	6.07	0.37	5.05e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs2425143	1.000	rs6060642	chr20:34449840	G/T	cg01084648	chr20:34329383	RBM39	0.64	4.95	0.31	1.44e-6	Blood protein levels;
SARC	cis	rs10411936	0.626	rs8113060	chr19:16596795	G/C	cg10248733	chr19:16607483	C19orf44;CALR3	0.62	7.48	0.44	1.52e-12	White blood cell count;Multiple sclerosis;
SARC	cis	rs854765	0.506	rs7210400	chr17:17949957	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.64	-9.39	-0.52	5.69e-18	Total body bone mineral density;
SARC	trans	rs7937682	1.000	rs10502147	chr11:111569931	G/A	cg18187862	chr3:45730750	SACM1L	-0.55	-6.9	-0.41	4.84e-11	Primary sclerosing cholangitis;
SARC	trans	rs11098499	0.863	rs13149407	chr4:120437825	A/G	cg25214090	chr10:38739885	LOC399744	0.57	7.35	0.43	3.31e-12	Corneal astigmatism;
SARC	cis	rs600231	0.665	rs2105608	chr11:65228618	T/A	cg17120908	chr11:65337727	SSSCA1	-0.39	-5.03	-0.31	9.6e-7	Bone mineral density;
SARC	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg05896524	chr21:47604654	C21orf56	0.42	5.04	0.31	9.35e-7	Testicular germ cell tumor;
SARC	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg07061783	chr6:25882402	NA	0.43	5.25	0.33	3.38e-7	Intelligence (multi-trait analysis);
SARC	cis	rs4423214	1.000	rs11606612	chr11:71164047	C/A	cg05163923	chr11:71159392	DHCR7	0.65	8.66	0.49	8.18e-16	Vitamin D levels;
SARC	cis	rs370915	0.542	rs1000060	chr4:187839499	G/A	cg19519643	chr4:187840862	NA	-0.55	-7.71	-0.45	3.72e-13	Gout;
SARC	cis	rs5753618	0.583	rs2899164	chr22:31790289	G/A	cg07713946	chr22:31675144	LIMK2	0.35	4.85	0.3	2.22e-6	Colorectal cancer;
SARC	cis	rs995000	0.965	rs10889353	chr1:63118196	A/C	cg06896770	chr1:63153194	DOCK7	0.96	14.73	0.69	3.85e-35	Triglyceride levels;
SARC	cis	rs793571	0.522	rs11071398	chr15:59120077	A/G	cg05156742	chr15:59063176	FAM63B	0.83	12.7	0.64	2.01e-28	Schizophrenia;
SARC	cis	rs3824867	0.920	rs7107853	chr11:47453518	T/C	cg20307385	chr11:47447363	PSMC3	-0.48	-5.3	-0.33	2.72e-7	Mean corpuscular hemoglobin;
SARC	cis	rs6429082	0.875	rs4659524	chr1:235583354	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.41	-5.28	-0.33	2.92e-7	Adiposity;
SARC	cis	rs13166103	0.723	rs13159762	chr5:57748556	T/C	cg10487770	chr5:57879443	RAB3C	0.52	5.5	0.34	9.92e-8	Type 2 diabetes (age of onset);
SARC	cis	rs453301	0.658	rs9329175	chr8:8866661	C/T	cg11995313	chr8:8860691	ERI1	0.47	5.93	0.36	1.07e-8	Joint mobility (Beighton score);
SARC	cis	rs6456156	0.565	rs2181058	chr6:167465330	A/T	cg07741184	chr6:167504864	NA	0.35	6.83	0.41	7.46e-11	Primary biliary cholangitis;
SARC	cis	rs6580649	0.941	rs3742074	chr12:48457385	C/T	cg24011408	chr12:48396354	COL2A1	-0.48	-5.31	-0.33	2.56e-7	Lung cancer;
SARC	cis	rs6088580	0.608	rs1205342	chr20:32921842	C/T	cg24642439	chr20:33292090	TP53INP2	-0.67	-8.52	-0.49	1.97e-15	Glomerular filtration rate (creatinine);
SARC	trans	rs11098499	0.954	rs12499324	chr4:120393786	C/T	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	cis	rs9457247	0.902	rs34560498	chr6:167395862	A/G	cg23791538	chr6:167370224	RNASET2	-0.63	-8.73	-0.5	4.9e-16	Crohn's disease;
SARC	cis	rs9796	0.870	rs12910027	chr15:41283817	A/T	cg18705301	chr15:41695430	NDUFAF1	0.42	5.71	0.35	3.44e-8	Menopause (age at onset);
SARC	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg00933542	chr6:150070202	PCMT1	0.33	5.5	0.34	9.79e-8	Lung cancer;
SARC	cis	rs6429082	1.000	rs2055127	chr1:235598973	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.45	-5.86	-0.36	1.6e-8	Adiposity;
SARC	cis	rs1298908	0.639	rs2236568	chr10:82035923	C/A	cg01528321	chr10:82214614	TSPAN14	0.36	4.72	0.3	4.13e-6	Diabetic kidney disease;
SARC	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.97	-15.37	-0.71	2.85e-37	Chronic sinus infection;
SARC	trans	rs629535	0.773	rs489206	chr8:70064883	T/C	cg21567404	chr3:27674614	NA	1.06	13.5	0.66	4.52e-31	Dupuytren's disease;
SARC	cis	rs17270561	0.609	rs1937127	chr6:25769872	G/T	cg17691542	chr6:26056736	HIST1H1C	-0.59	-6.96	-0.41	3.38e-11	Iron status biomarkers;
SARC	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg22535103	chr8:58192502	C8orf71	0.7	7.16	0.42	1.03e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs7178572	0.568	rs4886515	chr15:77686886	G/A	cg22256960	chr15:77711686	NA	-0.51	-5.59	-0.34	6.36e-8	Type 2 diabetes;
SARC	cis	rs11097912	0.603	rs7678229	chr4:107021950	C/T	cg09646026	chr4:107269030	AIMP1	-0.45	-4.74	-0.3	3.74e-6	Airflow obstruction;
SARC	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg04277193	chr17:41438351	NA	0.46	4.98	0.31	1.23e-6	Menopause (age at onset);
SARC	cis	rs2204008	0.775	rs12369238	chr12:38176051	A/G	cg26384229	chr12:38710491	ALG10B	0.87	12.39	0.63	2.07e-27	Bladder cancer;
SARC	cis	rs137699	0.959	rs5757631	chr22:39755953	T/C	cg24399712	chr22:39784796	NA	-0.33	-4.89	-0.3	1.9e-6	IgG glycosylation;
SARC	cis	rs2652822	0.967	rs1472631	chr15:63423739	A/G	cg02713581	chr15:63449717	RPS27L	0.72	9.68	0.54	7.55e-19	Metabolic traits;
SARC	cis	rs10504229	0.679	rs10504217	chr8:58037522	A/G	cg22535103	chr8:58192502	C8orf71	-0.53	-5.46	-0.34	1.24e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1215050	0.791	rs1727278	chr4:98853576	A/G	cg05340658	chr4:99064831	C4orf37	-0.44	-5.89	-0.36	1.37e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs10992471	0.676	rs13286566	chr9:95473178	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.42	-4.89	-0.31	1.88e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs4975616	0.843	rs4975615	chr5:1315343	C/T	cg07493874	chr5:1342172	CLPTM1L	0.47	6.46	0.39	6.19e-10	Lung cancer;
SARC	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg22968622	chr17:43663579	NA	0.79	10.02	0.55	7.26e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs2859741	0.546	rs10489413	chr1:37513906	C/T	cg09363841	chr1:37513479	NA	-0.28	-5.01	-0.31	1.09e-6	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
SARC	cis	rs7044106	0.762	rs1867254	chr9:123429078	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	4.94	0.31	1.47e-6	Hip circumference adjusted for BMI;
SARC	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	11.64	0.61	5.7e-25	Alzheimer's disease;
SARC	cis	rs1707322	0.752	rs61784798	chr1:46173481	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.24	0.38	2.03e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg03060546	chr3:49711283	APEH	-0.5	-6.74	-0.4	1.22e-10	Menarche (age at onset);
SARC	trans	rs61931739	0.534	rs10844732	chr12:34037104	A/C	cg26384229	chr12:38710491	ALG10B	0.85	12.34	0.63	2.98e-27	Morning vs. evening chronotype;
SARC	cis	rs2153535	0.580	rs9406174	chr6:8516764	T/C	cg21535247	chr6:8435926	SLC35B3	0.58	7.25	0.43	6.2e-12	Motion sickness;
SARC	cis	rs5753618	0.561	rs2073857	chr22:31658281	A/G	cg13145458	chr22:31556086	RNF185	0.47	5.05	0.31	8.76e-7	Colorectal cancer;
SARC	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.73	8.68	0.49	6.93e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg11987759	chr7:65425863	GUSB	-0.58	-7.96	-0.46	7.3e-14	Calcium levels;
SARC	cis	rs3923518	1.000	rs4527319	chr3:38880142	A/G	cg15678707	chr3:39149194	GORASP1;TTC21A	0.46	4.85	0.3	2.26e-6	Migraine;
SARC	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg11890956	chr21:40555474	PSMG1	-0.68	-9.01	-0.51	7.5e-17	Menarche (age at onset);
SARC	cis	rs2153535	0.580	rs9505454	chr6:8478532	T/G	cg21535247	chr6:8435926	SLC35B3	0.58	7.33	0.43	3.7e-12	Motion sickness;
SARC	cis	rs7833986	1.000	rs34404111	chr8:57099190	T/C	cg26371346	chr8:56986568	SNORD54;RPS20	0.6	5.33	0.33	2.36e-7	Height;
SARC	cis	rs67311347	0.544	rs9864664	chr3:40336226	T/C	cg24209194	chr3:40518798	ZNF619	0.49	6.6	0.4	2.72e-10	Renal cell carcinoma;
SARC	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg26116260	chr4:7069785	GRPEL1	0.93	11.58	0.6	8.69e-25	Monocyte percentage of white cells;
SARC	cis	rs6752107	0.967	rs3792111	chr2:234179690	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.49	6.44	0.39	6.59e-10	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg24110177	chr3:50126178	RBM5	0.38	4.87	0.3	2.11e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9902453	0.817	rs880749	chr17:28059970	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.23	-0.43	7.04e-12	Coffee consumption (cups per day);
SARC	cis	rs698833	0.892	rs698797	chr2:44689905	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.72	9.45	0.53	3.76e-18	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg13944838	chr5:179740914	GFPT2	-0.59	-7.43	-0.44	1.99e-12	Height;
SARC	cis	rs11648796	0.757	rs6600231	chr16:766485	A/G	cg00908189	chr16:619842	PIGQ	-0.55	-6.15	-0.37	3.25e-9	Height;
SARC	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg18252515	chr7:66147081	NA	0.6	6.57	0.4	3.3e-10	Aortic root size;
SARC	cis	rs2115630	0.846	rs8024538	chr15:85368419	A/T	cg17507749	chr15:85114479	UBE2QP1	-0.55	-6.46	-0.39	6.21e-10	P wave terminal force;
SARC	cis	rs208520	1.000	rs12195505	chr6:66986279	T/A	cg07460842	chr6:66804631	NA	0.9	10.32	0.56	8.16e-21	Exhaled nitric oxide output;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg01448931	chr10:69685877	HERC4	0.46	6.42	0.39	7.42e-10	Thyroid stimulating hormone;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg01148728	chr11:117198424	CEP164	-0.6	-6.9	-0.41	4.84e-11	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs1008375	0.900	rs4698625	chr4:17599500	G/T	cg27347728	chr4:17578864	LAP3	0.47	5.62	0.35	5.52e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7927771	0.864	rs11600581	chr11:47448497	T/C	cg20307385	chr11:47447363	PSMC3	-0.6	-7.56	-0.44	9.48e-13	Subjective well-being;
SARC	cis	rs13195786	0.512	rs13201214	chr6:10162200	C/G	cg22367191	chr6:10425648	NA	0.66	4.9	0.31	1.79e-6	Calcium levels;
SARC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.76	9.52	0.53	2.33e-18	Prudent dietary pattern;
SARC	cis	rs3762637	1.000	rs9858558	chr3:122139742	G/A	cg24169773	chr3:122142474	KPNA1	-0.56	-5.64	-0.35	4.87e-8	LDL cholesterol levels;
SARC	cis	rs9660992	0.649	rs72745216	chr1:205261016	G/A	cg00857998	chr1:205179979	DSTYK	0.43	4.99	0.31	1.2e-6	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg06618935	chr21:46677482	NA	-0.39	-5.09	-0.32	7.41e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4917300	0.650	rs4917218	chr8:143072470	G/A	cg06573787	chr8:143070187	NA	0.37	5.53	0.34	8.42e-8	Amyotrophic lateral sclerosis;
SARC	cis	rs6570726	0.967	rs403584	chr6:145807010	G/A	cg05347473	chr6:146136440	FBXO30	0.46	6.31	0.38	1.37e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3784262	1.000	rs4369598	chr15:58318603	G/T	cg12031962	chr15:58353849	ALDH1A2	-0.38	-5.75	-0.35	2.77e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs5762813	0.561	rs34298044	chr22:29164855	G/C	cg15103426	chr22:29168792	CCDC117	0.62	5.99	0.37	7.93e-9	Hematocrit;Hemoglobin concentration;
SARC	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg27266027	chr21:40555129	PSMG1	0.51	5.52	0.34	9.21e-8	Cognitive function;
SARC	cis	rs9807989	0.507	rs4851579	chr2:103028984	G/A	cg03938978	chr2:103052716	IL18RAP	0.31	4.96	0.31	1.34e-6	Asthma;
SARC	cis	rs999943	0.846	rs999942	chr6:33624902	G/C	cg14003231	chr6:33640908	ITPR3	0.52	8.8	0.5	3.18e-16	Obesity (extreme);
SARC	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg22484793	chr3:52261325	TLR9	0.29	4.77	0.3	3.31e-6	Bipolar disorder;
SARC	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg22496380	chr5:211416	CCDC127	-0.84	-8.6	-0.49	1.19e-15	Breast cancer;
SARC	cis	rs7264396	0.635	rs6060685	chr20:34512023	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	5.27	0.33	3.09e-7	Total cholesterol levels;
SARC	cis	rs7666738	0.830	rs3911282	chr4:99037602	T/A	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2286885	1.000	rs7851961	chr9:129249140	G/A	cg14319473	chr9:129242481	FAM125B	0.38	4.86	0.3	2.16e-6	Intraocular pressure;
SARC	cis	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg18252515	chr7:66147081	NA	-1.25	-10.99	-0.58	6.44e-23	Diabetic kidney disease;
SARC	cis	rs7582180	0.614	rs4850931	chr2:101005145	C/T	cg14675211	chr2:100938903	LONRF2	0.55	8.25	0.48	1.19e-14	Intelligence (multi-trait analysis);
SARC	cis	rs4819052	0.788	rs13049700	chr21:46701909	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	6.81	0.41	8.16e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4648845	0.777	rs2477686	chr1:2392648	C/G	cg11214544	chr1:2391121	NA	-0.4	-7.07	-0.42	1.76e-11	Schizophrenia;
SARC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg21280719	chr6:42927975	GNMT	-0.46	-7.86	-0.46	1.41e-13	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg08975724	chr8:8085496	FLJ10661	0.4	5.21	0.32	4.11e-7	Joint mobility (Beighton score);
SARC	cis	rs2576037	0.796	rs2576038	chr18:44582200	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.49	6.44	0.39	6.77e-10	Personality dimensions;
SARC	cis	rs7659604	0.605	rs1396080	chr4:122740454	T/G	cg19748678	chr4:122722346	EXOSC9	0.66	8.0	0.46	5.88e-14	Type 2 diabetes;
SARC	cis	rs57506017	0.585	rs1019307	chr7:12251790	C/G	cg23422036	chr7:12250390	TMEM106B	-0.5	-6.61	-0.4	2.61e-10	Neuroticism;
SARC	cis	rs9747201	1.000	rs12943668	chr17:80109930	C/T	cg09264619	chr17:80180166	NA	0.49	5.76	0.35	2.64e-8	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs12477438	0.677	rs12475034	chr2:99699464	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.91	-11.52	-0.6	1.33e-24	Chronic sinus infection;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg18174089	chr10:49609776	MAPK8	0.49	7.38	0.44	2.76e-12	Thyroid stimulating hormone;
SARC	cis	rs3820928	0.904	rs2217359	chr2:227759892	C/T	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.73	-0.35	3.08e-8	Pulmonary function;
SARC	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg00450029	chr8:599525	NA	0.72	5.56	0.34	7.3e-8	IgG glycosylation;
SARC	cis	rs12497850	1.000	rs1352420	chr3:48757291	A/G	cg06212747	chr3:49208901	KLHDC8B	0.67	8.92	0.5	1.37e-16	Parkinson's disease;
SARC	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg04518342	chr5:131593106	PDLIM4	0.42	5.36	0.33	1.99e-7	Acylcarnitine levels;
SARC	cis	rs703842	1.000	rs11172333	chr12:58170335	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.78	11.39	0.6	3.38e-24	Multiple sclerosis;
SARC	cis	rs637571	0.726	rs669371	chr11:65674153	G/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.38	-4.88	-0.3	1.97e-6	Eosinophil percentage of white cells;
SARC	cis	rs708547	0.647	rs1626594	chr4:57878254	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.57	7.18	0.43	9.05e-12	Response to bleomycin (chromatid breaks);
SARC	cis	rs709400	0.628	rs11621510	chr14:103869620	T/C	cg12935359	chr14:103987150	CKB	-0.39	-5.72	-0.35	3.21e-8	Body mass index;
SARC	trans	rs7824557	0.767	rs2164273	chr8:11168499	A/G	cg06636001	chr8:8085503	FLJ10661	0.58	7.02	0.42	2.38e-11	Retinal vascular caliber;
SARC	cis	rs12545109	0.765	rs2055985	chr8:57410821	T/A	cg21220214	chr8:57350948	NA	-0.4	-4.72	-0.3	4.12e-6	Obesity-related traits;
SARC	cis	rs9399135	0.967	rs6923827	chr6:135335382	C/T	cg24558204	chr6:135376177	HBS1L	0.44	5.94	0.36	1.04e-8	Red blood cell count;
SARC	cis	rs2153535	0.580	rs969422	chr6:8451780	A/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.49	1.52e-15	Motion sickness;
SARC	cis	rs6570726	0.791	rs9403734	chr6:145931459	C/G	cg05347473	chr6:146136440	FBXO30	0.54	7.46	0.44	1.67e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	0.679	rs11783557	chr8:58030644	A/G	cg08280861	chr8:58055591	NA	0.57	5.28	0.33	3.01e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.47	-5.89	-0.36	1.31e-8	Tonsillectomy;
SARC	cis	rs2228479	0.850	rs17227064	chr16:89816314	A/G	cg26513180	chr16:89883248	FANCA	0.72	4.79	0.3	2.99e-6	Skin colour saturation;
SARC	cis	rs950776	0.684	rs11637635	chr15:78877150	A/G	cg22563815	chr15:78856949	CHRNA5	-0.34	-5.36	-0.33	1.97e-7	Sudden cardiac arrest;
SARC	trans	rs1910358	0.554	rs10057796	chr5:23759746	C/T	cg04283218	chr14:90421238	TDP1;C14orf143	0.57	6.85	0.41	6.37e-11	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs722599	0.748	rs17093914	chr14:75363641	A/G	cg08847533	chr14:75593920	NEK9	0.45	5.14	0.32	5.8e-7	IgG glycosylation;
SARC	cis	rs929354	0.772	rs6954050	chr7:156978554	A/G	cg05182265	chr7:156933206	UBE3C	-0.33	-5.02	-0.31	1.03e-6	Body mass index;
SARC	cis	rs9457247	1.000	rs1819333	chr6:167373547	G/T	cg07741184	chr6:167504864	NA	0.29	5.48	0.34	1.11e-7	Crohn's disease;
SARC	cis	rs6582630	0.519	rs8189609	chr12:38281408	A/G	cg26384229	chr12:38710491	ALG10B	0.91	13.64	0.67	1.61e-31	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg16486109	chr11:613632	IRF7	0.47	6.16	0.37	3.18e-9	Systemic lupus erythematosus;
SARC	cis	rs35110281	0.777	rs7276215	chr21:44990697	A/G	cg01579765	chr21:45077557	HSF2BP	-0.35	-5.89	-0.36	1.37e-8	Mean corpuscular volume;
SARC	cis	rs1348850	0.872	rs7559521	chr2:178452328	A/G	cg23306229	chr2:178417860	TTC30B	-0.51	-5.83	-0.36	1.8e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2282802	0.685	rs13177186	chr5:139640476	A/G	cg26211634	chr5:139558579	C5orf32	0.41	5.28	0.33	2.98e-7	Intelligence (multi-trait analysis);
SARC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg09373136	chr17:61933544	TCAM1	-0.44	-6.09	-0.37	4.59e-9	Prudent dietary pattern;
SARC	cis	rs10791323	0.660	rs10791332	chr11:133732150	A/G	cg13461336	chr11:133711254	SPATA19	-0.27	-5.03	-0.31	9.85e-7	Childhood ear infection;
SARC	cis	rs1008375	0.966	rs28750296	chr4:17685826	A/T	cg27347728	chr4:17578864	LAP3	0.45	5.54	0.34	8.14e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4242434	0.672	rs10110443	chr8:22484296	C/G	cg03733263	chr8:22462867	KIAA1967	0.87	13.76	0.67	6.26e-32	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg11987759	chr7:65425863	GUSB	-0.58	-7.96	-0.46	7.3e-14	Calcium levels;
SARC	cis	rs1355223	0.902	rs7102625	chr11:34739717	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.43	5.27	0.33	3.05e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs9948	1.000	rs62152834	chr2:97504863	C/G	cg01990225	chr2:97406019	LMAN2L	-0.64	-5.06	-0.31	8.4e-7	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.48	0.53	3.05e-18	Prudent dietary pattern;
SARC	cis	rs4711350	1.000	rs4711350	chr6:33741716	A/G	cg18005901	chr6:33739558	LEMD2	-0.46	-5.0	-0.31	1.13e-6	Schizophrenia;
SARC	cis	rs539096	0.500	rs2527776	chr1:44345292	G/A	cg12908607	chr1:44402522	ARTN	-0.31	-5.58	-0.34	6.5e-8	Intelligence (multi-trait analysis);
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg24512778	chr2:152684544	ARL5A	-0.5	-6.64	-0.4	2.18e-10	Schizophrenia;
SARC	trans	rs8073060	0.586	rs4796104	chr17:34046832	T/C	cg19694781	chr19:47549865	TMEM160	0.72	6.95	0.41	3.67e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs3096299	0.606	rs8052103	chr16:89541243	A/T	cg08609400	chr16:89586677	SPG7	0.5	5.89	0.36	1.36e-8	Multiple myeloma (IgH translocation);
SARC	cis	rs6860806	0.507	rs2631372	chr5:131703578	C/G	cg12564285	chr5:131593104	PDLIM4	0.43	5.36	0.33	2.04e-7	Breast cancer;
SARC	cis	rs12022452	0.591	rs11208315	chr1:40985402	G/C	cg25568243	chr1:40974465	DEM1	0.53	4.85	0.3	2.26e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs9309711	0.922	rs13431788	chr2:3482912	G/A	cg10845886	chr2:3471009	TTC15	-0.6	-7.56	-0.44	9.11e-13	Neurofibrillary tangles;
SARC	cis	rs651907	0.557	rs11711079	chr3:101386918	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	6.43	0.39	6.98e-10	Colorectal cancer;
SARC	cis	rs2463822	0.583	rs7129536	chr11:62030829	C/T	cg06239285	chr11:62104954	ASRGL1	-0.85	-7.57	-0.44	8.41e-13	Chronic obstructive pulmonary disease-related biomarkers;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg05614176	chr13:113242512	TUBGCP3	0.51	6.76	0.4	1.12e-10	Tetralogy of Fallot;
SARC	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg20891283	chr12:69753455	YEATS4	0.55	7.42	0.44	2.14e-12	Blood protein levels;
SARC	cis	rs9611519	0.929	rs9611465	chr22:41426139	G/A	cg17376030	chr22:41985996	PMM1	0.5	5.96	0.36	9.12e-9	Neuroticism;
SARC	cis	rs4273100	0.688	rs12938803	chr17:19204432	A/C	cg25447019	chr17:19030144	GRAPL	0.36	5.66	0.35	4.54e-8	Schizophrenia;
SARC	cis	rs6952808	0.609	rs34967784	chr7:1949507	T/G	cg05863683	chr7:1912471	MAD1L1	0.37	5.69	0.35	3.83e-8	Bipolar disorder and schizophrenia;
SARC	trans	rs9395865	0.520	rs6903708	chr6:53332940	A/G	cg12635606	chr4:99849853	EIF4E	-0.56	-7.0	-0.42	2.67e-11	Electroencephalographic traits in alcoholism;
SARC	cis	rs3796352	1.000	rs71301808	chr3:53085577	C/G	cg07884673	chr3:53033167	SFMBT1	0.85	5.65	0.35	4.7e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs59918340	0.728	rs2304279	chr8:142229891	A/G	cg16341495	chr8:142228727	SLC45A4	-0.36	-5.15	-0.32	5.57e-7	Immature fraction of reticulocytes;
SARC	cis	rs957448	1.000	rs72674852	chr8:95548751	C/T	cg26464482	chr8:95565502	KIAA1429	0.43	4.83	0.3	2.45e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs7208859	0.573	rs60724269	chr17:29113273	G/T	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9470366	0.772	rs9918353	chr6:36622677	A/C	cg08179530	chr6:36648295	CDKN1A	0.56	6.12	0.37	3.83e-9	QRS duration;
SARC	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.12	24.2	0.85	1.59e-65	Chronic sinus infection;
SARC	cis	rs2239547	0.522	rs6445550	chr3:52983434	G/A	cg11645453	chr3:52864694	ITIH4	0.34	5.3	0.33	2.7e-7	Schizophrenia;
SARC	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.79	12.06	0.62	2.37e-26	Personality dimensions;
SARC	trans	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg21659725	chr3:3221576	CRBN	-0.81	-12.44	-0.63	1.38e-27	Intelligence (multi-trait analysis);
SARC	cis	rs9911578	1.000	rs437732	chr17:56675861	A/C	cg05425664	chr17:57184151	TRIM37	-0.69	-8.6	-0.49	1.16e-15	Intelligence (multi-trait analysis);
SARC	cis	rs2522056	1.000	rs2522054	chr5:131799526	G/T	cg24060327	chr5:131705240	SLC22A5	0.49	4.91	0.31	1.75e-6	Lymphocyte counts;Fibrinogen;
SARC	cis	rs7552404	0.731	rs5745491	chr1:76350159	T/G	cg10523679	chr1:76189770	ACADM	-0.43	-5.23	-0.32	3.76e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs12142240	0.698	rs1053627	chr1:46827728	A/C	cg14993813	chr1:46806288	NSUN4	-0.51	-5.34	-0.33	2.19e-7	Menopause (age at onset);
SARC	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	-0.44	-5.26	-0.33	3.31e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9300255	0.722	rs28458312	chr12:123863265	G/T	cg00376283	chr12:123451042	ABCB9	-0.48	-5.02	-0.31	1.03e-6	Neutrophil percentage of white cells;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg20842997	chr4:39529386	UGDH	0.6	8.45	0.48	3.22e-15	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs12541335	0.579	rs59283125	chr8:22212311	G/A	cg18135555	chr8:22132992	PIWIL2	0.38	5.59	0.34	6.42e-8	Hypertriglyceridemia;
SARC	cis	rs7818345	0.967	rs13255946	chr8:19275354	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.42	5.7	0.35	3.66e-8	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs2361718	0.564	rs2304844	chr17:78084507	G/C	cg23534315	chr17:78082725	GAA	0.47	5.88	0.36	1.41e-8	Yeast infection;
SARC	cis	rs2304069	0.526	rs6863283	chr5:149402448	C/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.6	7.16	0.42	1.05e-11	HIV-1 control;
SARC	cis	rs1707322	0.686	rs3014251	chr1:46077428	G/C	cg06784218	chr1:46089804	CCDC17	-0.38	-6.65	-0.4	2.09e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg12698349	chr2:225449008	CUL3	-0.64	-8.12	-0.47	2.66e-14	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs35213789	0.536	rs9791609	chr7:69035611	C/G	cg10619644	chr7:69149951	AUTS2	-0.35	-4.96	-0.31	1.37e-6	Childhood ear infection;
SARC	cis	rs2075371	0.897	rs12667905	chr7:134000812	A/C	cg11752832	chr7:134001865	SLC35B4	0.51	6.29	0.38	1.52e-9	Mean platelet volume;
SARC	cis	rs2361710	0.704	rs12937349	chr17:78120320	G/C	cg06718696	chr17:78121285	EIF4A3	0.39	4.76	0.3	3.33e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
SARC	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg21724239	chr8:58056113	NA	0.6	6.31	0.38	1.43e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7666738	0.716	rs1426660	chr4:98876792	T/A	cg05340658	chr4:99064831	C4orf37	0.65	8.59	0.49	1.24e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs17030434	0.906	rs4696491	chr4:154679865	T/C	cg14289246	chr4:154710475	SFRP2	0.62	6.42	0.39	7.45e-10	Electrocardiographic conduction measures;
SARC	cis	rs6570726	0.905	rs430248	chr6:145874104	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.56	0.39	3.48e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9398803	0.713	rs1490385	chr6:126875521	C/T	cg19875578	chr6:126661172	C6orf173	0.62	8.62	0.49	1.02e-15	Male-pattern baldness;
SARC	cis	rs2732480	0.557	rs923397	chr12:48720392	G/A	cg24011408	chr12:48396354	COL2A1	0.4	4.74	0.3	3.68e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs6831352	0.918	rs6813415	chr4:100048509	T/C	cg12011299	chr4:100065546	ADH4	-0.34	-5.66	-0.35	4.44e-8	Alcohol dependence;
SARC	cis	rs3796352	1.000	rs35737577	chr3:53002557	G/C	cg15956490	chr3:53032818	SFMBT1	0.75	4.98	0.31	1.24e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs11098499	0.644	rs10012252	chr4:120559139	T/C	cg09307838	chr4:120376055	NA	0.76	10.34	0.56	7.43e-21	Corneal astigmatism;
SARC	trans	rs11098499	0.909	rs10026736	chr4:120384322	G/C	cg25214090	chr10:38739885	LOC399744	0.56	7.22	0.43	7.14e-12	Corneal astigmatism;
SARC	cis	rs7824557	0.564	rs6601584	chr8:11232343	C/G	cg21775007	chr8:11205619	TDH	-0.65	-8.64	-0.49	9.2e-16	Retinal vascular caliber;
SARC	cis	rs4588572	0.643	rs10043027	chr5:77792707	T/C	cg11547950	chr5:77652471	NA	-0.41	-5.11	-0.32	6.67e-7	Triglycerides;
SARC	cis	rs4141404	0.757	rs5749272	chr22:31830351	C/T	cg13145458	chr22:31556086	RNF185	0.43	5.55	0.34	7.64e-8	Paclitaxel-induced neuropathy;
SARC	cis	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg26850624	chr5:429559	AHRR	-0.31	-4.77	-0.3	3.21e-6	Cystic fibrosis severity;
SARC	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg02725872	chr8:58115012	NA	0.33	5.26	0.33	3.2e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs193541	0.632	rs30036	chr5:122278260	A/G	cg19412675	chr5:122181750	SNX24	0.47	6.03	0.37	6.32e-9	Glucose homeostasis traits;
SARC	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg22484793	chr3:52261325	TLR9	0.29	4.77	0.3	3.31e-6	Bipolar disorder;
SARC	cis	rs5758511	0.680	rs56111723	chr22:42664883	T/A	cg00645731	chr22:42541494	CYP2D7P1	0.44	6.52	0.39	4.33e-10	Birth weight;
SARC	cis	rs9682041	0.597	rs62295834	chr3:170075701	G/A	cg11886554	chr3:170076028	SKIL	0.66	6.33	0.38	1.25e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs5769765	1.000	rs8184990	chr22:50273174	A/G	cg03033257	chr22:50311977	ALG12;CRELD2	-0.54	-5.64	-0.35	4.81e-8	Schizophrenia;
SARC	cis	rs3126085	1.000	rs11485508	chr1:152253167	T/G	cg03465714	chr1:152285911	FLG	-0.46	-5.55	-0.34	7.61e-8	Atopic dermatitis;
SARC	cis	rs10461617	0.535	rs7709874	chr5:56047451	C/T	cg24549020	chr5:56110836	MAP3K1	0.68	7.54	0.44	1.05e-12	Type 2 diabetes;
SARC	cis	rs13082711	0.522	rs480646	chr3:27327143	C/T	cg02860705	chr3:27208620	NA	0.45	5.96	0.36	9.1e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs67478160	0.584	rs2295148	chr14:104195610	T/C	cg26031613	chr14:104095156	KLC1	-0.42	-5.36	-0.33	2.03e-7	Schizophrenia;
SARC	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg24531977	chr5:56204891	C5orf35	-0.57	-5.98	-0.36	8.41e-9	Initial pursuit acceleration;
SARC	cis	rs4938330	0.552	rs3882895	chr11:117090545	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.52	-5.51	-0.34	9.61e-8	Blood protein levels;
SARC	cis	rs6582630	0.555	rs7965311	chr12:38513307	G/A	cg13010199	chr12:38710504	ALG10B	-0.7	-9.7	-0.54	6.42e-19	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs965469	1.000	rs6037547	chr20:3299228	C/A	cg25506879	chr20:3388711	C20orf194	-0.52	-5.25	-0.33	3.39e-7	IFN-related cytopenia;
SARC	cis	rs17600642	0.715	rs55924079	chr10:72466016	G/C	cg19779893	chr10:72451501	ADAMTS14	-0.47	-7.0	-0.42	2.73e-11	Bipolar disorder;
SARC	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg19671926	chr4:122722719	EXOSC9	-0.6	-6.7	-0.4	1.51e-10	Type 2 diabetes;
SARC	cis	rs10489202	1.000	rs12404574	chr1:167961235	C/T	cg17859187	chr1:168147929	TIPRL	-0.45	-4.79	-0.3	3.01e-6	Schizophrenia;
SARC	cis	rs826838	0.967	rs1684411	chr12:39128494	C/T	cg26384229	chr12:38710491	ALG10B	-0.75	-11.21	-0.59	1.27e-23	Heart rate;
SARC	cis	rs1976403	0.659	rs10799700	chr1:21820968	G/C	cg00786952	chr1:21763130	NA	0.35	5.84	0.36	1.72e-8	Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs6456042	1.000	rs3127415	chr6:166537088	C/T	cg11088901	chr6:166572345	T	-0.33	-4.79	-0.3	2.97e-6	Asthma;
SARC	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg12463550	chr7:65579703	CRCP	-0.48	-5.25	-0.33	3.44e-7	Aortic root size;
SARC	cis	rs2072499	0.750	rs72708291	chr1:156177285	A/T	cg25208724	chr1:156163844	SLC25A44	0.78	8.7	0.5	6.21e-16	Testicular germ cell tumor;
SARC	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg15448220	chr1:150897856	SETDB1	0.47	6.25	0.38	1.94e-9	Tonsillectomy;
SARC	cis	rs1865760	0.929	rs2876693	chr6:25954434	C/G	cg10373733	chr6:25993375	NA	0.4	4.78	0.3	3.04e-6	Height;
SARC	cis	rs2732480	0.577	rs2732479	chr12:48736260	A/C	cg24011408	chr12:48396354	COL2A1	0.43	5.07	0.32	8.23e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs6963495	0.818	rs6944787	chr7:105147309	C/T	cg13798780	chr7:105162888	PUS7	0.61	5.75	0.35	2.79e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs11711311	0.955	rs34048496	chr3:113414121	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	8.12	0.47	2.7e-14	IgG glycosylation;
SARC	cis	rs7223966	0.960	rs2854222	chr17:61939015	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.52	-5.75	-0.35	2.82e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-9.19	-0.52	2.22e-17	Alzheimer's disease;
SARC	cis	rs9858542	0.903	rs9875617	chr3:49634696	G/A	cg07274523	chr3:49395745	GPX1	0.51	5.9	0.36	1.28e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs1048238	0.506	rs848210	chr1:16259813	A/G	cg21385522	chr1:16154831	NA	-0.44	-5.25	-0.32	3.5e-7	Systolic blood pressure;
SARC	cis	rs896854	0.552	rs2515236	chr8:95934907	A/G	cg16049864	chr8:95962084	TP53INP1	0.42	6.12	0.37	3.97e-9	Type 2 diabetes;
SARC	cis	rs9467773	0.584	rs1021372	chr6:26632444	T/C	cg11502198	chr6:26597334	ABT1	0.63	8.63	0.49	9.91e-16	Intelligence (multi-trait analysis);
SARC	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg27347728	chr4:17578864	LAP3	0.47	6.0	0.37	7.39e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs61931739	0.534	rs12372721	chr12:34175301	C/T	cg13010199	chr12:38710504	ALG10B	0.72	9.61	0.53	1.27e-18	Morning vs. evening chronotype;
SARC	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg22168489	chr12:122356033	WDR66	0.64	9.93	0.55	1.3e-19	Mean corpuscular volume;
SARC	cis	rs58785573	0.504	rs11947292	chr4:38634749	A/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.41	5.4	0.33	1.61e-7	Lymphocyte percentage of white cells;
SARC	cis	rs3936840	0.548	rs1190545	chr14:102904179	G/C	cg18135206	chr14:102964638	TECPR2	-0.42	-4.86	-0.3	2.2e-6	Plateletcrit;
SARC	cis	rs854765	0.547	rs9897761	chr17:17912011	A/T	cg04398451	chr17:18023971	MYO15A	-0.44	-6.29	-0.38	1.53e-9	Total body bone mineral density;
SARC	cis	rs2073300	0.609	rs6137937	chr20:23385419	G/A	cg16736954	chr20:23401023	NAPB	0.79	4.94	0.31	1.5e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs9325144	0.555	rs6582607	chr12:38717678	T/C	cg13010199	chr12:38710504	ALG10B	-0.55	-7.03	-0.42	2.26e-11	Morning vs. evening chronotype;
SARC	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg19223190	chr17:80058835	NA	-0.43	-6.02	-0.37	6.61e-9	Life satisfaction;
SARC	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg13395646	chr4:1353034	KIAA1530	-0.53	-6.33	-0.38	1.23e-9	Obesity-related traits;
SARC	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs3741151	0.773	rs73544720	chr11:73173496	A/G	cg17517138	chr11:73019481	ARHGEF17	0.92	6.84	0.41	6.98e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg03487200	chr16:24580235	RBBP6	-0.51	-6.36	-0.38	1.03e-9	Body mass index;
SARC	cis	rs4148883	0.689	rs2602861	chr4:100030896	C/T	cg12011299	chr4:100065546	ADH4	0.36	6.71	0.4	1.47e-10	Alcohol dependence;
SARC	cis	rs9811216	1.000	rs7625734	chr3:169508915	A/G	cg14222479	chr3:169487675	ARPM1	0.42	5.22	0.32	3.99e-7	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs7005606	0.967	rs9642727	chr8:32414032	A/C	cg14488905	chr8:32406789	NRG1	0.46	6.54	0.39	3.9e-10	Hirschsprung disease;
SARC	cis	rs12893668	0.703	rs729438	chr14:104092789	A/G	cg26031613	chr14:104095156	KLC1	0.47	5.49	0.34	1.05e-7	Reticulocyte count;
SARC	cis	rs10782582	0.609	rs10873797	chr1:76377191	G/T	cg03433033	chr1:76189801	ACADM	-0.39	-4.93	-0.31	1.59e-6	Daytime sleep phenotypes;
SARC	cis	rs1552244	0.882	rs9812006	chr3:10022658	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-9.12	-0.51	3.7e-17	Alzheimer's disease;
SARC	trans	rs3734266	0.639	rs11967912	chr6:34757853	A/C	cg08157914	chr7:2646478	IQCE	0.52	6.24	0.38	2.1e-9	Systemic lupus erythematosus;
SARC	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	-0.75	-5.9	-0.36	1.27e-8	Initial pursuit acceleration;
SARC	cis	rs1801251	1.000	rs12474040	chr2:233615345	T/G	cg25237894	chr2:233734115	C2orf82	0.38	5.03	0.31	9.71e-7	Coronary artery disease;
SARC	cis	rs501120	1.000	rs915083	chr10:44755406	T/G	cg09554077	chr10:44749378	NA	0.48	6.67	0.4	1.85e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs911555	0.723	rs6575982	chr14:103862681	G/A	cg12935359	chr14:103987150	CKB	0.39	5.33	0.33	2.33e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg11366901	chr6:160182831	ACAT2	1.01	10.38	0.56	5.4e-21	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs644799	1.000	rs586238	chr11:95560371	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.9	13.62	0.67	1.88e-31	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs870825	0.616	rs10022834	chr4:185649431	A/G	cg04058563	chr4:185651563	MLF1IP	0.8	11.35	0.6	4.56e-24	Blood protein levels;
SARC	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-8.98	-0.51	9.19e-17	Alzheimer's disease;
SARC	cis	rs8044995	0.563	rs57434514	chr16:68402649	G/A	cg05110241	chr16:68378359	PRMT7	-0.69	-6.69	-0.4	1.64e-10	Schizophrenia;
SARC	cis	rs2549003	0.674	rs960757	chr5:131826310	G/A	cg21138405	chr5:131827807	IRF1	0.28	5.33	0.33	2.37e-7	Asthma (sex interaction);
SARC	cis	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg03060546	chr3:49711283	APEH	0.65	8.08	0.47	3.52e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs4718428	0.705	rs68168107	chr7:66255238	G/A	cg18876405	chr7:65276391	NA	0.46	5.13	0.32	6.06e-7	Corneal structure;
SARC	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg04944784	chr2:26401820	FAM59B	0.59	7.88	0.46	1.25e-13	Gut microbiome composition (summer);
SARC	cis	rs11122272	0.766	rs2739511	chr1:231526490	G/C	cg06096015	chr1:231504339	EGLN1	0.38	5.73	0.35	3.12e-8	Hemoglobin concentration;
SARC	trans	rs9329221	0.510	rs4841282	chr8:9975604	C/A	cg06636001	chr8:8085503	FLJ10661	0.56	7.56	0.44	9.32e-13	Neuroticism;
SARC	cis	rs7666738	0.830	rs11727612	chr4:99001662	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9303401	0.659	rs62083436	chr17:57031742	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.05	11.76	0.61	2.3e-25	Cognitive test performance;
SARC	cis	rs7929679	0.521	rs10768094	chr11:34792189	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.36	4.76	0.3	3.47e-6	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
SARC	cis	rs7829975	0.572	rs7005000	chr8:8796602	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.25	-0.43	6.22e-12	Mood instability;
SARC	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg10591111	chr5:226296	SDHA	-0.55	-4.97	-0.31	1.31e-6	Breast cancer;
SARC	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg04166393	chr7:2884313	GNA12	0.48	5.47	0.34	1.14e-7	Height;
SARC	cis	rs4588572	0.643	rs10474554	chr5:77799158	C/T	cg11547950	chr5:77652471	NA	-0.38	-4.75	-0.3	3.51e-6	Triglycerides;
SARC	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg09699651	chr6:150184138	LRP11	0.39	4.87	0.3	2.04e-6	Lung cancer;
SARC	trans	rs61931739	0.513	rs7956626	chr12:33901640	C/T	cg26384229	chr12:38710491	ALG10B	0.62	8.25	0.48	1.14e-14	Morning vs. evening chronotype;
SARC	cis	rs4481887	1.000	rs4916128	chr1:248466706	G/A	cg00666640	chr1:248458726	OR2T12	0.37	6.3	0.38	1.43e-9	Common traits (Other);
SARC	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg00149659	chr3:10157352	C3orf10	0.64	6.01	0.37	7.21e-9	Alzheimer's disease;
SARC	cis	rs7615952	0.641	rs4490307	chr3:125712676	T/G	cg05084668	chr3:125655381	ALG1L	-0.5	-5.66	-0.35	4.4e-8	Blood pressure (smoking interaction);
SARC	trans	rs877282	0.853	rs11596346	chr10:756673	A/T	cg22713356	chr15:30763199	NA	0.99	9.88	0.54	1.92e-19	Uric acid levels;
SARC	cis	rs7772486	0.754	rs857881	chr6:145970793	C/A	cg23711669	chr6:146136114	FBXO30	-0.88	-15.08	-0.7	2.57e-36	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs897984	0.553	rs2125293	chr16:30863875	T/C	cg00531865	chr16:30841666	NA	0.46	4.94	0.31	1.51e-6	Dementia with Lewy bodies;
SARC	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg03709012	chr19:19516395	GATAD2A	1.02	17.81	0.76	2.23e-45	Tonsillectomy;
SARC	cis	rs9513627	1.000	rs7996624	chr13:100127541	G/T	cg25919922	chr13:100150906	NA	-0.65	-4.91	-0.31	1.73e-6	Obesity-related traits;
SARC	cis	rs2153904	0.590	rs823106	chr1:205656453	G/C	cg07167872	chr1:205819463	PM20D1	0.57	5.3	0.33	2.71e-7	Prostate-specific antigen levels;
SARC	cis	rs6580649	0.783	rs1635526	chr12:48396785	C/T	cg05342945	chr12:48394962	COL2A1	-0.55	-5.66	-0.35	4.33e-8	Lung cancer;
SARC	cis	rs9831754	1.000	rs9855903	chr3:78347988	C/A	cg06138941	chr3:78371609	NA	-0.58	-6.68	-0.4	1.7e-10	Calcium levels;
SARC	trans	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg00262122	chr8:11665843	FDFT1	-0.51	-6.51	-0.39	4.5e-10	Neuroticism;
SARC	cis	rs9611565	0.592	rs9611612	chr22:41961189	T/C	cg03806693	chr22:41940476	POLR3H	-0.85	-11.18	-0.59	1.66e-23	Vitiligo;
SARC	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.32	0.38	1.32e-9	Bipolar disorder;
SARC	cis	rs7659604	1.000	rs7659943	chr4:122665560	C/T	cg19671926	chr4:122722719	EXOSC9	-0.51	-5.97	-0.36	8.68e-9	Type 2 diabetes;
SARC	cis	rs17376456	0.569	rs2045021	chr5:93224222	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.49	-5.15	-0.32	5.43e-7	Diabetic retinopathy;
SARC	cis	rs1419980	0.586	rs10845548	chr12:7777657	T/A	cg10578777	chr12:7781093	NA	-0.52	-5.63	-0.35	5.15e-8	HDL cholesterol levels;
SARC	cis	rs412050	0.547	rs78907487	chr22:22151939	A/C	cg17089214	chr22:22089827	YPEL1	0.78	6.87	0.41	5.78e-11	Attention deficit hyperactivity disorder;
SARC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg24503407	chr1:205819492	PM20D1	0.92	16.22	0.73	4.03e-40	Menarche (age at onset);
SARC	cis	rs7762018	0.607	rs75438963	chr6:170047695	G/A	cg19338460	chr6:170058176	WDR27	-0.79	-5.31	-0.33	2.53e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs4268898	0.722	rs10445893	chr2:24407128	A/G	cg26838691	chr2:24397539	C2orf84	0.42	5.74	0.35	2.96e-8	Asthma;
SARC	cis	rs4243830	0.850	rs12410405	chr1:6581283	C/G	cg05709478	chr1:6581295	PLEKHG5	0.46	4.83	0.3	2.42e-6	Body mass index;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg21217024	chr11:105481406	GRIA4	-0.83	-7.12	-0.42	1.35e-11	Autism spectrum disorder or schizophrenia;
SARC	trans	rs7830939	0.586	rs10108359	chr8:9327086	C/G	cg06636001	chr8:8085503	FLJ10661	0.51	6.42	0.39	7.71e-10	Neuroticism;
SARC	cis	rs9462027	0.628	rs7771778	chr6:34660324	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.42	6.01	0.37	6.96e-9	Systemic lupus erythematosus;
SARC	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg13628971	chr7:2884303	GNA12	0.58	6.87	0.41	5.66e-11	Height;
SARC	cis	rs12681288	0.823	rs4735974	chr8:1000218	T/G	cg15309053	chr8:964076	NA	0.41	6.97	0.42	3.3e-11	Schizophrenia;
SARC	cis	rs28374715	0.681	rs7162231	chr15:41591859	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.13	-19.09	-0.78	1.48e-49	Ulcerative colitis;
SARC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	10.46	0.57	2.97e-21	Platelet count;
SARC	trans	rs2727020	0.615	rs4980435	chr11:49591576	G/A	cg15704280	chr7:45808275	SEPT13	-0.88	-15.16	-0.7	1.41e-36	Coronary artery disease;
SARC	cis	rs2976388	0.609	rs2572909	chr8:143806464	C/G	cg06565975	chr8:143823917	SLURP1	0.28	4.73	0.3	3.92e-6	Urinary tract infection frequency;
SARC	cis	rs13006833	0.668	rs291447	chr2:191177005	A/C	cg25963032	chr2:191064776	C2orf88	0.38	5.38	0.33	1.79e-7	Urinary metabolites;
SARC	cis	rs5417	0.662	rs12601936	chr17:7172609	A/G	cg14438174	chr17:7137923	DVL2	-0.51	-6.82	-0.41	7.73e-11	Diastolic blood pressure;
SARC	cis	rs8016982	0.657	rs8021125	chr14:81704787	C/T	cg01989461	chr14:81687754	GTF2A1	-0.73	-10.81	-0.58	2.52e-22	Schizophrenia;
SARC	cis	rs66887589	0.616	rs11732621	chr4:120212883	A/C	cg09307838	chr4:120376055	NA	0.63	8.5	0.49	2.29e-15	Diastolic blood pressure;
SARC	cis	rs9916302	0.904	rs679995	chr17:37441679	A/T	cg15445000	chr17:37608096	MED1	-0.46	-5.59	-0.34	6.39e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs9916302	0.851	rs612209	chr17:37442713	G/C	cg15445000	chr17:37608096	MED1	-0.42	-5.16	-0.32	5.18e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs9322193	0.566	rs4869768	chr6:150245203	A/G	cg11878867	chr6:150167359	LRP11	0.4	5.02	0.31	1.02e-6	Lung cancer;
SARC	cis	rs7772486	0.686	rs9399565	chr6:146081906	G/T	cg05347473	chr6:146136440	FBXO30	-0.51	-7.14	-0.42	1.15e-11	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs7819412	0.654	rs34741518	chr8:10776860	A/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.36	-0.43	3.09e-12	Triglycerides;
SARC	cis	rs9341808	0.600	rs2505930	chr6:80837058	A/G	cg08355045	chr6:80787529	NA	0.36	5.38	0.33	1.83e-7	Sitting height ratio;
SARC	cis	rs2370759	0.945	rs10508773	chr10:32575444	C/T	cg01819863	chr10:32635814	EPC1	1.01	9.89	0.54	1.71e-19	Sexual dysfunction (female);
SARC	cis	rs17270561	0.609	rs9358883	chr6:25755515	A/G	cg17691542	chr6:26056736	HIST1H1C	0.6	7.28	0.43	5.11e-12	Iron status biomarkers;
SARC	cis	rs778371	0.874	rs1083522	chr2:233745521	C/T	cg16596103	chr2:233749413	NGEF	0.36	5.26	0.33	3.19e-7	Schizophrenia;
SARC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg04267008	chr7:1944627	MAD1L1	-0.49	-5.44	-0.34	1.33e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs7829975	0.846	rs1879957	chr8:8544808	T/C	cg15556689	chr8:8085844	FLJ10661	-0.47	-5.81	-0.36	2.03e-8	Mood instability;
SARC	cis	rs7208859	0.573	rs55661352	chr17:29045628	A/G	cg13385521	chr17:29058706	SUZ12P	0.86	7.24	0.43	6.48e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs4141404	0.748	rs2232170	chr22:31537122	A/G	cg07713946	chr22:31675144	LIMK2	-0.4	-5.22	-0.32	4.05e-7	Paclitaxel-induced neuropathy;
SARC	cis	rs2213920	0.619	rs4979528	chr9:118194902	G/A	cg13918206	chr9:118159781	DEC1	0.79	6.26	0.38	1.82e-9	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs4588572	0.643	rs7701154	chr5:77716621	G/A	cg11547950	chr5:77652471	NA	-0.42	-5.13	-0.32	6.16e-7	Triglycerides;
SARC	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg11764359	chr7:65958608	NA	-0.87	-12.29	-0.63	4.37e-27	Aortic root size;
SARC	cis	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg24110177	chr3:50126178	RBM5	0.4	5.06	0.31	8.7e-7	Intelligence (multi-trait analysis);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg21205276	chr9:95056231	IARS;SNORA84	-0.8	-6.76	-0.4	1.07e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg18357526	chr6:26021779	HIST1H4A	0.9	12.04	0.62	2.88e-26	Intelligence (multi-trait analysis);
SARC	cis	rs9831754	0.906	rs2314196	chr3:78411050	C/T	cg06138941	chr3:78371609	NA	-0.52	-6.3	-0.38	1.47e-9	Calcium levels;
SARC	cis	rs1468333	0.667	rs2240332	chr5:137767893	C/G	cg27119451	chr5:137514611	BRD8;KIF20A	-0.67	-7.86	-0.46	1.4e-13	Resting heart rate;
SARC	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg07701084	chr6:150067640	NUP43	0.41	5.39	0.33	1.75e-7	Lung cancer;
SARC	cis	rs611744	0.604	rs6469170	chr8:109305277	T/C	cg21045802	chr8:109455806	TTC35	0.68	8.69	0.49	6.69e-16	Dupuytren's disease;
SARC	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg11987759	chr7:65425863	GUSB	-0.47	-6.27	-0.38	1.7e-9	Aortic root size;
SARC	trans	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.58	-6.94	-0.41	3.93e-11	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs72653721	0.938	rs72653722	chr6:10976212	A/C	cg13562911	chr6:11044106	ELOVL2	0.57	5.94	0.36	1.01e-8	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	cis	rs4319547	0.585	rs7953007	chr12:122816977	A/C	cg23029597	chr12:123009494	RSRC2	-0.4	-5.03	-0.31	9.93e-7	Body mass index;
SARC	cis	rs76917914	0.954	rs7855432	chr9:100760113	G/T	cg03040243	chr9:100819229	NANS	0.59	6.17	0.37	2.93e-9	Immature fraction of reticulocytes;
SARC	cis	rs7246657	0.525	rs1667359	chr19:37486172	G/A	cg23950597	chr19:37808831	NA	-0.56	-5.16	-0.32	5.31e-7	Coronary artery calcification;
SARC	cis	rs7762018	0.607	rs75964125	chr6:170054290	T/A	cg13015042	chr6:170102002	WDR27;C6orf120	0.66	4.75	0.3	3.56e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs2153535	0.580	rs6926759	chr6:8456176	G/A	cg23788917	chr6:8435910	SLC35B3	0.64	8.39	0.48	4.75e-15	Motion sickness;
SARC	cis	rs3767633	0.925	rs10753666	chr1:161861147	C/G	cg09175582	chr1:161736000	ATF6	0.65	5.5	0.34	9.86e-8	IgG glycosylation;
SARC	cis	rs1904096	0.506	rs2865350	chr4:95212813	A/T	cg11021082	chr4:95130006	SMARCAD1	0.46	6.37	0.39	9.77e-10	Type 2 diabetes;
SARC	cis	rs7681440	0.606	rs2583982	chr4:90753244	T/C	cg06632027	chr4:90757378	SNCA	-0.42	-5.25	-0.33	3.35e-7	Dementia with Lewy bodies;
SARC	cis	rs2242116	1.000	rs1138518	chr3:46944274	T/C	cg02527881	chr3:46936655	PTH1R	-0.42	-6.65	-0.4	2.09e-10	Birth weight;
SARC	trans	rs7615952	0.733	rs13314847	chr3:125644788	C/T	cg07211511	chr3:129823064	LOC729375	-0.97	-10.83	-0.58	2.17e-22	Blood pressure (smoking interaction);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg08492202	chr8:42911315	FNTA	-0.79	-6.55	-0.39	3.67e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.67	0.54	7.99e-19	Prudent dietary pattern;
SARC	cis	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg24110177	chr3:50126178	RBM5	-0.54	-7.17	-0.43	1e-11	Intelligence (multi-trait analysis);
SARC	cis	rs9814567	0.752	rs4955542	chr3:134328740	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.54	-7.0	-0.42	2.73e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	5.34	0.33	2.17e-7	Tonsillectomy;
SARC	cis	rs9467773	0.967	rs1056347	chr6:26527524	G/C	cg11502198	chr6:26597334	ABT1	0.47	5.93	0.36	1.1e-8	Intelligence (multi-trait analysis);
SARC	cis	rs73198271	0.531	rs11985640	chr8:8652504	C/T	cg01851573	chr8:8652454	MFHAS1	0.39	4.81	0.3	2.69e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs2976388	0.647	rs2244163	chr8:143784500	T/G	cg06565975	chr8:143823917	SLURP1	0.3	5.31	0.33	2.55e-7	Urinary tract infection frequency;
SARC	cis	rs6500395	0.962	rs9921741	chr16:48589896	G/A	cg04672837	chr16:48644449	N4BP1	0.42	5.59	0.34	6.31e-8	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs2070677	0.935	rs11101880	chr10:135412888	T/C	cg20169779	chr10:135381914	SYCE1	-0.51	-6.07	-0.37	5.16e-9	Gout;
SARC	cis	rs4253772	0.591	rs6008361	chr22:46652372	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.65	-7.09	-0.42	1.55e-11	LDL cholesterol;Cholesterol, total;
SARC	cis	rs72627123	0.867	rs11848920	chr14:74476866	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.75	5.74	0.35	2.89e-8	Morning vs. evening chronotype;
SARC	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg11890956	chr21:40555474	PSMG1	1.16	19.13	0.78	1.1e-49	Cognitive function;
SARC	cis	rs7089973	0.604	rs10885620	chr10:116630048	A/T	cg03647239	chr10:116582469	FAM160B1	0.53	7.01	0.42	2.57e-11	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs11190604	1.000	rs4919469	chr10:102298855	C/A	cg07080220	chr10:102295463	HIF1AN	0.8	9.44	0.53	3.91e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs7647973	0.710	rs11130208	chr3:49615624	G/T	cg07636037	chr3:49044803	WDR6	0.77	7.01	0.42	2.52e-11	Menarche (age at onset);
SARC	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg20090690	chr10:134436459	INPP5A	0.49	4.92	0.31	1.64e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs8141529	0.732	rs5752798	chr22:29181868	A/G	cg15103426	chr22:29168792	CCDC117	0.69	9.21	0.52	1.94e-17	Lymphocyte counts;
SARC	cis	rs2075371	0.932	rs2241332	chr7:133969439	A/G	cg11752832	chr7:134001865	SLC35B4	0.5	6.25	0.38	1.89e-9	Mean platelet volume;
SARC	cis	rs11098499	0.913	rs13126596	chr4:120140729	A/G	cg09307838	chr4:120376055	NA	0.82	11.05	0.59	4.35e-23	Corneal astigmatism;
SARC	cis	rs7647973	0.593	rs62262730	chr3:49808274	T/G	cg03060546	chr3:49711283	APEH	-0.58	-5.75	-0.35	2.79e-8	Menarche (age at onset);
SARC	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg11987759	chr7:65425863	GUSB	-0.58	-7.94	-0.46	8.33e-14	Calcium levels;
SARC	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg05863683	chr7:1912471	MAD1L1	0.37	5.65	0.35	4.55e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs17253792	0.822	rs113350960	chr14:56087713	G/A	cg01858014	chr14:56050164	KTN1	-0.67	-5.11	-0.32	6.86e-7	Putamen volume;
SARC	cis	rs9916302	0.768	rs11078900	chr17:37614641	C/T	cg00129232	chr17:37814104	STARD3	-0.66	-8.02	-0.47	5.2e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs8053891	0.756	rs28629271	chr16:72003732	C/T	cg16558253	chr16:72132732	DHX38	-0.39	-4.91	-0.31	1.72e-6	Coronary artery disease;
SARC	cis	rs7633770	0.805	rs11710264	chr3:46661579	T/C	cg11219411	chr3:46661640	NA	0.5	8.6	0.49	1.16e-15	Coronary artery disease;
SARC	cis	rs2153535	0.580	rs5001322	chr6:8451608	A/G	cg21535247	chr6:8435926	SLC35B3	0.55	6.86	0.41	6.15e-11	Motion sickness;
SARC	cis	rs2228479	0.618	rs72477006	chr16:89950299	G/C	cg06558623	chr16:89946397	TCF25	0.97	7.97	0.46	7.11e-14	Skin colour saturation;
SARC	cis	rs60752752	0.852	rs11583949	chr1:153355322	A/G	cg26882115	chr1:153603048	S100A1;S100A13	-0.66	-4.94	-0.31	1.46e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs9399137	0.529	rs7739722	chr6:135282225	T/C	cg22676075	chr6:135203613	NA	0.41	5.27	0.33	3.15e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs7520050	0.966	rs785491	chr1:46583418	G/A	cg06784218	chr1:46089804	CCDC17	-0.26	-4.74	-0.3	3.77e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs787274	0.867	rs786978	chr9:115460239	A/G	cg13803584	chr9:115635662	SNX30	-0.78	-6.05	-0.37	5.58e-9	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs7000551	0.751	rs2469768	chr8:22381362	G/A	cg12081754	chr8:22256438	SLC39A14	0.57	8.01	0.46	5.33e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs7614311	0.689	rs56329572	chr3:63846672	G/A	cg22134162	chr3:63841271	THOC7	-0.48	-5.07	-0.32	8.21e-7	Lung function (FVC);Lung function (FEV1);
SARC	cis	rs8031584	1.000	rs11634216	chr15:31288670	G/A	cg08109568	chr15:31115862	NA	-0.42	-4.8	-0.3	2.9e-6	Huntington's disease progression;
SARC	cis	rs818427	1.000	rs712668	chr5:112197637	T/G	cg07820702	chr5:112228657	REEP5	0.45	5.05	0.31	8.85e-7	Total body bone mineral density;
SARC	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg11861562	chr11:117069780	TAGLN	0.21	4.73	0.3	3.88e-6	Blood protein levels;
SARC	cis	rs1023500	0.596	rs133369	chr22:42463814	C/T	cg04733989	chr22:42467013	NAGA	0.76	10.64	0.57	8.04e-22	Schizophrenia;
SARC	cis	rs9309473	1.000	rs56154726	chr2:73721767	C/T	cg20560298	chr2:73613845	ALMS1	-0.53	-6.31	-0.38	1.36e-9	Metabolite levels;
SARC	cis	rs55883249	1.000	rs62119392	chr2:9714033	G/C	cg23886495	chr2:9695866	ADAM17	0.68	6.75	0.4	1.13e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg21724239	chr8:58056113	NA	0.68	6.47	0.39	5.62e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7772486	0.754	rs2064185	chr6:146066814	G/A	cg05347473	chr6:146136440	FBXO30	-0.56	-7.8	-0.46	2e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.95	14.57	0.69	1.26e-34	Chronic sinus infection;
SARC	cis	rs1865760	0.566	rs4529296	chr6:26083135	C/G	cg16482183	chr6:26056742	HIST1H1C	0.47	5.91	0.36	1.22e-8	Height;
SARC	cis	rs2230307	0.572	rs17122001	chr1:100628311	A/T	cg24955406	chr1:100503596	HIAT1	0.63	6.26	0.38	1.82e-9	Carotid intima media thickness;
SARC	cis	rs4727443	1.000	rs4727443	chr7:99593346	C/A	cg22004693	chr7:99632812	ZKSCAN1	0.62	7.96	0.46	7.54e-14	Interstitial lung disease;
SARC	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg08742575	chr21:47604166	C21orf56	0.39	4.97	0.31	1.3e-6	Testicular germ cell tumor;
SARC	cis	rs9325144	0.647	rs61930266	chr12:38922048	A/G	cg13010199	chr12:38710504	ALG10B	-0.48	-5.98	-0.36	8.23e-9	Morning vs. evening chronotype;
SARC	cis	rs8067545	0.611	rs1373146	chr17:20206675	G/A	cg13482628	chr17:19912719	NA	-0.58	-7.72	-0.45	3.32e-13	Schizophrenia;
SARC	cis	rs6835098	0.500	rs13112928	chr4:174158132	A/G	cg08422745	chr4:174089978	GALNT7	0.5	6.55	0.39	3.58e-10	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs35110281	0.667	rs4819287	chr21:45120147	A/G	cg01579765	chr21:45077557	HSF2BP	-0.36	-5.71	-0.35	3.38e-8	Mean corpuscular volume;
SARC	cis	rs9733	0.650	rs3738485	chr1:150552392	C/G	cg18016565	chr1:150552671	MCL1	-0.4	-5.48	-0.34	1.13e-7	Tonsillectomy;
SARC	cis	rs4808199	0.793	rs12459676	chr19:19425141	A/T	cg03709012	chr19:19516395	GATAD2A	1.13	10.86	0.58	1.73e-22	Nonalcoholic fatty liver disease;
SARC	cis	rs1448094	0.549	rs10863085	chr12:86236328	G/A	cg02569458	chr12:86230093	RASSF9	0.39	5.48	0.34	1.11e-7	Major depressive disorder;
SARC	cis	rs6840360	0.571	rs2407069	chr4:152533201	G/A	cg22705602	chr4:152727874	NA	-0.41	-6.43	-0.39	7.24e-10	Intelligence (multi-trait analysis);
SARC	cis	rs4253772	0.530	rs6008774	chr22:46755298	C/G	cg24881330	chr22:46731750	TRMU	0.8	7.66	0.45	5.03e-13	LDL cholesterol;Cholesterol, total;
SARC	cis	rs736408	0.812	rs2071507	chr3:52826707	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.39	0.33	1.69e-7	Bipolar disorder;
SARC	cis	rs7647973	0.710	rs11130207	chr3:49611666	T/G	cg13072238	chr3:49761600	GMPPB	-0.61	-5.33	-0.33	2.34e-7	Menarche (age at onset);
SARC	cis	rs7659604	0.689	rs59131059	chr4:122666357	C/T	cg19671926	chr4:122722719	EXOSC9	-0.51	-6.24	-0.38	2.04e-9	Type 2 diabetes;
SARC	cis	rs477692	0.967	rs519690	chr10:131424033	G/A	cg05714579	chr10:131428358	MGMT	0.55	7.13	0.42	1.23e-11	Response to temozolomide;
SARC	cis	rs1153858	1.000	rs1980288	chr15:45620612	T/C	cg15395560	chr15:45543142	SLC28A2	-0.26	-4.74	-0.3	3.78e-6	Homoarginine levels;
SARC	cis	rs72634258	0.945	rs225132	chr1:8095500	A/C	cg00042356	chr1:8021962	PARK7	0.64	6.3	0.38	1.51e-9	Inflammatory bowel disease;
SARC	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.49	-5.34	-0.33	2.18e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs1559088	0.947	rs7259879	chr19:33549462	T/C	cg27124370	chr19:33622961	WDR88	0.42	5.31	0.33	2.62e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg11062466	chr8:58055876	NA	0.56	5.67	0.35	4.19e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2204008	0.540	rs3908193	chr12:38410907	G/T	cg13010199	chr12:38710504	ALG10B	-0.47	-5.7	-0.35	3.66e-8	Bladder cancer;
SARC	cis	rs9768139	0.733	rs921617	chr7:158118198	A/G	cg25566285	chr7:158114605	PTPRN2	0.31	5.19	0.32	4.66e-7	Calcium levels;
SARC	cis	rs2153535	0.580	rs1932283	chr6:8477661	C/T	cg07606381	chr6:8435919	SLC35B3	0.77	11.1	0.59	2.86e-23	Motion sickness;
SARC	cis	rs9457247	1.000	rs422694	chr6:167406074	G/T	cg07741184	chr6:167504864	NA	0.29	5.55	0.34	7.72e-8	Crohn's disease;
SARC	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg08280861	chr8:58055591	NA	0.57	5.1	0.32	6.94e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs61931739	0.500	rs7489132	chr12:34539712	C/T	cg26384229	chr12:38710491	ALG10B	0.91	13.78	0.67	5.4e-32	Morning vs. evening chronotype;
SARC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.68	9.21	0.52	1.96e-17	Lymphocyte counts;
SARC	cis	rs559928	0.606	rs11600628	chr11:63976027	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.67	4.98	0.31	1.23e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs5753618	0.555	rs9609302	chr22:31895987	A/C	cg02404636	chr22:31891804	SFI1	0.5	5.19	0.32	4.63e-7	Colorectal cancer;
SARC	cis	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg05623727	chr3:50126028	RBM5	0.33	4.99	0.31	1.21e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9291683	0.546	rs13139055	chr4:10038924	G/T	cg11266682	chr4:10021025	SLC2A9	0.4	6.87	0.41	5.73e-11	Bone mineral density;
SARC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg24846343	chr22:24311635	DDTL	0.52	7.58	0.44	8.19e-13	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1448094	0.621	rs10863091	chr12:86282240	T/C	cg02569458	chr12:86230093	RASSF9	0.4	5.46	0.34	1.22e-7	Major depressive disorder;
SARC	cis	rs9815354	0.812	rs74947509	chr3:42006323	T/C	cg03022575	chr3:42003672	ULK4	0.65	5.61	0.34	5.72e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs509477	0.718	rs273357	chr18:32597237	G/T	cg23791764	chr18:32556832	MAPRE2	0.42	5.22	0.32	3.94e-7	Cerebrospinal fluid AB1-42 levels;
SARC	cis	rs3813567	0.759	rs12595350	chr15:78953464	G/A	cg04896959	chr15:78267971	NA	-0.53	-5.26	-0.33	3.22e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg09863175	chr15:57618660	NA	0.52	6.58	0.4	3.03e-10	Breast cancer;
SARC	cis	rs12477438	1.000	rs12053372	chr2:99810055	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.92	-11.79	-0.61	1.82e-25	Chronic sinus infection;
SARC	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg22618164	chr12:122356400	WDR66	-0.37	-5.89	-0.36	1.35e-8	Mean corpuscular volume;
SARC	cis	rs524281	0.861	rs10896094	chr11:65959206	C/T	cg14036092	chr11:66035641	RAB1B	-0.5	-5.37	-0.33	1.89e-7	Electroencephalogram traits;
SARC	cis	rs858239	0.536	rs6961109	chr7:23252413	C/T	cg23682824	chr7:23144976	KLHL7	0.62	7.88	0.46	1.21e-13	Cerebrospinal fluid biomarker levels;
SARC	cis	rs13401104	0.796	rs12472312	chr2:237113030	G/A	cg19324714	chr2:237145437	ASB18	0.58	6.05	0.37	5.77e-9	Educational attainment;
SARC	cis	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg07777115	chr5:623756	CEP72	-0.62	-5.56	-0.34	7.5e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs7647973	0.626	rs4855849	chr3:49653378	A/G	cg06212747	chr3:49208901	KLHDC8B	0.59	5.82	0.36	1.94e-8	Menarche (age at onset);
SARC	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg05535760	chr7:792225	HEATR2	0.83	8.23	0.47	1.36e-14	Cerebrospinal P-tau181p levels;
SARC	cis	rs7011049	1.000	rs11985687	chr8:53832602	G/A	cg26025543	chr8:53854495	NA	0.61	5.55	0.34	7.75e-8	Systolic blood pressure;
SARC	cis	rs453301	0.658	rs13271797	chr8:8885954	G/A	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.41	-0.39	8.06e-10	Joint mobility (Beighton score);
SARC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg19077165	chr18:44547161	KATNAL2	0.57	7.93	0.46	9.12e-14	Personality dimensions;
SARC	cis	rs1062177	1.000	rs2016409	chr5:151126324	G/T	cg00977110	chr5:151150581	G3BP1	-0.6	-5.94	-0.36	1.01e-8	Preschool internalizing problems;
SARC	cis	rs7772486	0.701	rs2244308	chr6:146213706	C/T	cg23711669	chr6:146136114	FBXO30	0.76	11.9	0.61	7.75e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6840360	0.571	rs55808836	chr4:152554991	C/T	cg22705602	chr4:152727874	NA	-0.44	-6.81	-0.41	8.1e-11	Intelligence (multi-trait analysis);
SARC	cis	rs2153535	0.526	rs9406179	chr6:8538224	G/A	cg21535247	chr6:8435926	SLC35B3	0.55	6.82	0.41	7.81e-11	Motion sickness;
SARC	cis	rs4805272	0.539	rs1075733	chr19:29324460	C/T	cg14983838	chr19:29218262	NA	0.63	7.25	0.43	6.06e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs10927875	0.632	rs4661666	chr1:16162471	C/A	cg07117364	chr1:16154769	NA	-0.44	-5.23	-0.32	3.7e-7	Dilated cardiomyopathy;
SARC	cis	rs826838	0.838	rs11183646	chr12:38799846	A/T	cg13010199	chr12:38710504	ALG10B	0.79	11.26	0.59	8.77e-24	Heart rate;
SARC	cis	rs8038465	0.874	rs11574497	chr15:74004557	A/T	cg15420318	chr15:73925796	NPTN	0.42	4.77	0.3	3.29e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs925228	0.504	rs7568272	chr2:24313785	T/C	cg01493198	chr2:24299560	SF3B14	0.82	4.9	0.31	1.78e-6	Reticulocyte fraction of red cells;Reticulocyte count;
SARC	cis	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg09021430	chr5:549028	NA	-0.43	-5.57	-0.34	6.83e-8	Obesity-related traits;
SARC	cis	rs1005277	0.522	rs289648	chr10:37971837	T/C	cg00409905	chr10:38381863	ZNF37A	-0.51	-6.94	-0.41	3.78e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs9303401	0.646	rs8067682	chr17:57219391	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.65	8.06	0.47	4.05e-14	Cognitive test performance;
SARC	cis	rs703842	1.000	rs10431505	chr12:58178589	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.78	11.47	0.6	1.98e-24	Multiple sclerosis;
SARC	cis	rs9916302	0.851	rs7220650	chr17:37487168	A/G	cg15445000	chr17:37608096	MED1	-0.44	-5.32	-0.33	2.43e-7	Glomerular filtration rate (creatinine);
SARC	trans	rs9650657	0.683	rs7830431	chr8:10700317	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.95	-0.41	3.53e-11	Neuroticism;
SARC	cis	rs7824557	0.602	rs7833966	chr8:11206220	C/G	cg21775007	chr8:11205619	TDH	0.67	8.67	0.49	7.42e-16	Retinal vascular caliber;
SARC	cis	rs6594499	0.872	rs10060003	chr5:110449357	A/G	cg04022379	chr5:110408740	TSLP	0.48	6.08	0.37	4.89e-9	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs2303745	0.544	rs6512181	chr19:17399213	T/G	cg22549504	chr19:17448937	GTPBP3	0.52	5.23	0.32	3.77e-7	Systemic lupus erythematosus;
SARC	cis	rs17376456	1.000	rs34756085	chr5:93556294	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.61	5.23	0.32	3.75e-7	Diabetic retinopathy;
SARC	cis	rs9420	0.961	rs12804972	chr11:57463767	T/C	cg19752551	chr11:57585705	CTNND1	-0.5	-6.74	-0.4	1.24e-10	Schizophrenia;
SARC	cis	rs7760949	0.963	rs1330117	chr6:13920926	C/T	cg27413430	chr6:13925136	RNF182	0.41	4.93	0.31	1.53e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg11764359	chr7:65958608	NA	0.88	12.58	0.64	4.89e-28	Aortic root size;
SARC	cis	rs1185460	0.546	rs17075	chr11:118959331	A/G	cg23280166	chr11:118938394	VPS11	-0.47	-6.02	-0.37	6.71e-9	Coronary artery disease;
SARC	cis	rs5760092	0.755	rs11090298	chr22:24262061	G/A	cg15242686	chr22:24348715	GSTTP1	-0.48	-5.45	-0.34	1.27e-7	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg11608241	chr8:8085544	FLJ10661	-0.44	-5.4	-0.33	1.66e-7	Schizophrenia;
SARC	cis	rs11122272	0.735	rs10489611	chr1:231517854	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs72945132	0.823	rs12292240	chr11:70152612	T/C	cg05964544	chr11:70165517	PPFIA1	-0.61	-5.87	-0.36	1.5e-8	Coronary artery disease;
SARC	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg11366901	chr6:160182831	ACAT2	1.02	10.79	0.58	2.78e-22	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs4925386	0.681	rs2427296	chr20:60927475	G/A	cg24112000	chr20:60950667	NA	-0.36	-5.26	-0.33	3.26e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs9896052	0.535	rs35615150	chr17:73433560	G/A	cg27037648	chr17:73511087	CASKIN2	0.4	4.81	0.3	2.65e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-7.84	-0.46	1.64e-13	Chronic sinus infection;
SARC	cis	rs7829975	0.774	rs1703982	chr8:8598388	A/T	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.42	-0.39	7.76e-10	Mood instability;
SARC	cis	rs13256369	1.000	rs4841016	chr8:8572561	C/T	cg17143192	chr8:8559678	CLDN23	0.54	6.14	0.37	3.46e-9	Obesity-related traits;
SARC	cis	rs3768617	0.510	rs1413390	chr1:183096634	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.82e-21	Fuchs's corneal dystrophy;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg05671791	chr16:89574615	SPG7	0.47	6.44	0.39	6.75e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs6690583	0.573	rs61768854	chr1:85460021	T/C	cg22488158	chr1:85528044	WDR63	0.62	5.16	0.32	5.16e-7	Serum sulfate level;
SARC	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-7.74	-0.45	3.07e-13	Chronic sinus infection;
SARC	cis	rs854765	0.693	rs35451946	chr17:17764061	C/G	cg16928487	chr17:17741425	SREBF1	0.22	4.71	0.3	4.17e-6	Total body bone mineral density;
SARC	cis	rs1580019	0.813	rs2044839	chr7:32500805	A/C	cg07520158	chr7:32535189	LSM5;AVL9	0.42	4.91	0.31	1.72e-6	Cognitive ability;
SARC	cis	rs644148	0.836	rs2686777	chr19:45000386	T/C	cg15540054	chr19:45004280	ZNF180	-0.44	-5.03	-0.31	9.64e-7	Personality dimensions;
SARC	cis	rs5753618	0.504	rs9606847	chr22:31901789	G/C	cg07713946	chr22:31675144	LIMK2	0.37	5.19	0.32	4.56e-7	Colorectal cancer;
SARC	cis	rs1008375	0.932	rs6449321	chr4:17644472	A/G	cg16339924	chr4:17578868	LAP3	0.65	8.6	0.49	1.22e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1865760	0.566	rs1800702	chr6:26086463	C/G	cg18357526	chr6:26021779	HIST1H4A	0.41	4.98	0.31	1.23e-6	Height;
SARC	cis	rs9316337	0.611	rs9285163	chr13:21926900	C/T	cg18095732	chr13:22033692	ZDHHC20	0.43	5.68	0.35	4.09e-8	Schizophrenia;
SARC	trans	rs3780486	1.000	rs3780480	chr9:33163486	G/T	cg04842962	chr6:43655489	MRPS18A	0.96	13.28	0.66	2.39e-30	IgG glycosylation;
SARC	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg08219700	chr8:58056026	NA	0.69	6.54	0.39	3.96e-10	Developmental language disorder (linguistic errors);
SARC	trans	rs12554020	0.786	rs75576302	chr9:96255222	G/C	cg26442883	chr16:49686662	ZNF423	0.56	6.24	0.38	2.1e-9	Schizophrenia;
SARC	cis	rs6540556	0.608	rs7532324	chr1:209918090	C/T	cg05527609	chr1:210001259	C1orf107	-0.51	-5.08	-0.32	7.88e-7	Red blood cell count;
SARC	cis	rs28785552	0.897	rs34244888	chr19:53242228	T/A	cg10871876	chr19:53194124	ZNF83	0.38	4.74	0.3	3.8e-6	Response to paliperidone in schizophrenia (PANSS score);
SARC	cis	rs12134245	0.874	rs17501937	chr1:92021705	C/T	cg25838465	chr1:92012736	NA	0.55	7.68	0.45	4.5e-13	Breast cancer;
SARC	cis	rs9916302	0.851	rs4794810	chr17:37603774	T/C	cg07936489	chr17:37558343	FBXL20	-0.66	-8.68	-0.49	7.1e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs739401	0.611	rs494427	chr11:3048140	A/G	cg25174290	chr11:3078921	CARS	0.57	8.08	0.47	3.54e-14	Longevity;
SARC	cis	rs9303401	0.659	rs36109237	chr17:56653834	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.09	12.25	0.63	5.64e-27	Cognitive test performance;
SARC	cis	rs1401999	0.628	rs1520195	chr3:183736882	G/A	cg01324343	chr3:183735012	ABCC5	0.57	10.8	0.58	2.62e-22	Anterior chamber depth;
SARC	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg21724239	chr8:58056113	NA	0.61	5.84	0.36	1.71e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7819412	0.740	rs28633434	chr8:11053922	G/A	cg03403963	chr8:11986501	LOC392196;FAM66D	-0.34	-4.86	-0.3	2.19e-6	Triglycerides;
SARC	cis	rs7618501	0.966	rs2246832	chr3:49881134	A/T	cg05623727	chr3:50126028	RBM5	0.33	4.98	0.31	1.23e-6	Intelligence (multi-trait analysis);
SARC	cis	rs858239	0.601	rs15775	chr7:23164701	C/T	cg23682824	chr7:23144976	KLHL7	0.74	10.16	0.55	2.52e-20	Cerebrospinal fluid biomarker levels;
SARC	cis	rs1865760	0.865	rs4478388	chr6:25953633	A/G	cg18357526	chr6:26021779	HIST1H4A	0.4	4.87	0.3	2.03e-6	Height;
SARC	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg06212747	chr3:49208901	KLHDC8B	0.63	8.35	0.48	5.93e-15	Parkinson's disease;
SARC	cis	rs7833790	0.632	rs6415653	chr8:82702536	A/G	cg06027949	chr8:82754900	SNX16	-0.47	-5.61	-0.35	5.58e-8	Diastolic blood pressure;
SARC	cis	rs7584330	0.737	rs7568588	chr2:238364342	G/T	cg14458575	chr2:238380390	NA	0.46	5.65	0.35	4.71e-8	Prostate cancer;
SARC	cis	rs989128	0.600	rs9913677	chr17:48628581	T/A	cg20467136	chr17:48638190	CACNA1G	0.47	5.45	0.34	1.25e-7	Type 2 diabetes;
SARC	cis	rs473651	0.904	rs10929275	chr2:239323169	A/G	cg18131467	chr2:239335373	ASB1	0.95	15.77	0.72	1.29e-38	Multiple system atrophy;
SARC	cis	rs10504073	0.584	rs56134839	chr8:49918899	C/T	cg00325661	chr8:49890786	NA	0.52	6.9	0.41	4.88e-11	Blood metabolite ratios;
SARC	cis	rs262150	0.502	rs73167295	chr7:158782949	T/A	cg19418458	chr7:158789849	NA	0.44	4.86	0.3	2.13e-6	Facial morphology (factor 20);
SARC	cis	rs13314892	0.692	rs57317066	chr3:69861072	G/A	cg17445875	chr3:69859618	MITF	-0.49	-5.1	-0.32	6.98e-7	QRS complex (12-leadsum);
SARC	cis	rs8072100	0.713	rs9899859	chr17:45513049	A/G	cg08085267	chr17:45401833	C17orf57	-0.43	-5.03	-0.31	9.66e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs9300255	0.596	rs10732573	chr12:123743883	G/C	cg05973401	chr12:123451056	ABCB9	0.48	5.24	0.32	3.53e-7	Neutrophil percentage of white cells;
SARC	cis	rs7582720	1.000	rs115396314	chr2:203721314	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.76	7.4	0.44	2.38e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs4737010	0.536	rs6474365	chr8:41662940	G/T	cg17182837	chr8:41585554	ANK1	-0.48	-5.17	-0.32	4.96e-7	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
SARC	cis	rs644799	0.672	rs11021307	chr11:95501407	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.94	16.24	0.73	3.62e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs61931739	1.000	rs11052967	chr12:34020030	T/G	cg26384229	chr12:38710491	ALG10B	-0.57	-7.13	-0.42	1.23e-11	Morning vs. evening chronotype;
SARC	cis	rs7566780	0.656	rs10164502	chr2:16660586	A/T	cg09580478	chr2:16689509	NA	-0.48	-6.63	-0.4	2.29e-10	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs7589342	0.894	rs6736932	chr2:106444854	A/G	cg14210321	chr2:106509881	NCK2	-0.45	-5.31	-0.33	2.54e-7	Addiction;
SARC	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg04518342	chr5:131593106	PDLIM4	-0.45	-5.61	-0.34	5.86e-8	Blood metabolite levels;
SARC	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg00152838	chr16:24741724	TNRC6A	-0.6	-6.42	-0.39	7.69e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs523522	0.923	rs3916065	chr12:120934624	A/C	cg27279351	chr12:120934652	DYNLL1	0.72	8.91	0.5	1.5e-16	High light scatter reticulocyte count;
SARC	trans	rs61931739	0.534	rs10844840	chr12:34364517	C/T	cg13010199	chr12:38710504	ALG10B	0.79	10.85	0.58	1.88e-22	Morning vs. evening chronotype;
SARC	cis	rs3784262	0.692	rs3784256	chr15:58263046	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.33	-4.87	-0.3	2.04e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs7766436	0.614	rs11753682	chr6:22566908	C/T	cg13666174	chr6:22585274	NA	-0.56	-5.86	-0.36	1.59e-8	Coronary artery disease;
SARC	cis	rs911263	0.603	rs11626138	chr14:68786993	A/G	cg18825221	chr14:68749962	RAD51L1	0.4	7.09	0.42	1.6e-11	Primary biliary cholangitis;
SARC	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg11764359	chr7:65958608	NA	0.86	12.33	0.63	3.29e-27	Aortic root size;
SARC	cis	rs1729951	0.575	rs2163896	chr3:136691177	G/A	cg15507776	chr3:136538369	TMEM22	0.5	5.6	0.34	6.04e-8	Neuroticism;
SARC	cis	rs4233802	1.000	rs11888189	chr2:151151382	A/G	cg25300694	chr2:151184358	NA	0.82	5.0	0.31	1.14e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	trans	rs11976180	0.517	rs6949375	chr7:143773851	T/G	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.64	-6.5	-0.39	4.9e-10	Obesity-related traits;
SARC	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	11.81	0.61	1.59e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs739401	0.572	rs410820	chr11:3080102	G/A	cg08508325	chr11:3079039	CARS	-0.3	-7.14	-0.42	1.19e-11	Longevity;
SARC	cis	rs10504073	0.584	rs74457150	chr8:49890753	C/G	cg00325661	chr8:49890786	NA	0.51	6.73	0.4	1.28e-10	Blood metabolite ratios;
SARC	cis	rs2043112	0.964	rs10461998	chr5:38984797	T/C	cg04869206	chr5:39074266	RICTOR	0.52	6.26	0.38	1.83e-9	Obesity-related traits;
SARC	trans	rs17780086	0.529	rs7406406	chr17:30220153	T/G	cg20587970	chr11:113659929	NA	-0.57	-6.63	-0.4	2.36e-10	Height;
SARC	cis	rs62064224	0.791	rs11654833	chr17:30667728	C/T	cg25809561	chr17:30822961	MYO1D	0.34	5.04	0.31	9.15e-7	Schizophrenia;
SARC	cis	rs9322817	0.691	rs2499663	chr6:105300570	A/G	cg02098413	chr6:105308735	HACE1	-0.39	-5.95	-0.36	9.83e-9	Thyroid stimulating hormone;
SARC	cis	rs9309473	0.519	rs35421685	chr2:73910138	T/C	cg20560298	chr2:73613845	ALMS1	0.47	6.39	0.39	8.85e-10	Metabolite levels;
SARC	cis	rs2276314	0.857	rs28375959	chr18:33601534	T/G	cg05985134	chr18:33552581	C18orf21	0.66	6.75	0.4	1.14e-10	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg16325326	chr1:53192061	ZYG11B	0.81	12.75	0.64	1.31e-28	Monocyte count;
SARC	cis	rs4595586	0.967	rs11169807	chr12:39244161	A/G	cg26384229	chr12:38710491	ALG10B	0.39	4.8	0.3	2.86e-6	Morning vs. evening chronotype;
SARC	cis	rs3820928	0.869	rs2396436	chr2:227795464	G/A	cg11843606	chr2:227700838	RHBDD1	-0.56	-7.12	-0.42	1.33e-11	Pulmonary function;
SARC	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.76	7.39	0.44	2.69e-12	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs7582180	0.629	rs12621892	chr2:100947124	G/C	cg14675211	chr2:100938903	LONRF2	0.51	7.66	0.45	4.82e-13	Intelligence (multi-trait analysis);
SARC	cis	rs6840360	0.554	rs10222838	chr4:152690099	T/C	cg22705602	chr4:152727874	NA	-0.5	-8.96	-0.51	1.1e-16	Intelligence (multi-trait analysis);
SARC	cis	rs2204008	0.641	rs2387810	chr12:38368875	G/T	cg26384229	chr12:38710491	ALG10B	0.87	12.65	0.64	2.85e-28	Bladder cancer;
SARC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg10862848	chr6:42927986	GNMT	-0.45	-7.4	-0.44	2.41e-12	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	6.98	0.42	3.08e-11	Platelet count;
SARC	cis	rs7524258	0.903	rs4908608	chr1:7292772	T/C	cg07173049	chr1:7289937	CAMTA1	0.41	7.97	0.46	7.07e-14	Tourette's syndrome or obsessive-compulsive disorder;
SARC	cis	rs9788682	1.000	rs61204066	chr15:78815298	G/A	cg24631222	chr15:78858424	CHRNA5	0.77	10.62	0.57	9.87e-22	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6089584	0.627	rs13045575	chr20:60565596	G/A	cg23262073	chr20:60523788	NA	-0.38	-5.9	-0.36	1.27e-8	Body mass index;
SARC	cis	rs6963495	0.745	rs56239334	chr7:105165351	G/A	cg13798780	chr7:105162888	PUS7	0.61	5.61	0.34	5.84e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs734999	0.505	rs4073286	chr1:2539901	A/C	cg18854424	chr1:2615690	NA	0.33	5.16	0.32	5.34e-7	Ulcerative colitis;
SARC	cis	rs6568686	0.627	rs174381	chr6:111913479	C/T	cg15721981	chr6:111408429	SLC16A10	0.58	5.01	0.31	1.08e-6	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs698833	0.961	rs1223162	chr2:44737704	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.65	7.52	0.44	1.16e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs9302635	0.513	rs7198572	chr16:72183220	G/A	cg16558253	chr16:72132732	DHX38	-0.54	-6.44	-0.39	6.9e-10	Blood protein levels;
SARC	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg05368731	chr17:41323189	NBR1	0.8	9.59	0.53	1.43e-18	Menopause (age at onset);
SARC	cis	rs7681440	0.583	rs2737034	chr4:90777464	C/G	cg06632027	chr4:90757378	SNCA	-0.47	-5.81	-0.36	2.03e-8	Dementia with Lewy bodies;
SARC	cis	rs7123876	0.587	rs55765314	chr11:72360935	C/A	cg03713592	chr11:72463424	ARAP1	0.57	5.11	0.32	6.58e-7	Body mass index;
SARC	cis	rs4423214	1.000	rs2852853	chr11:71150217	C/T	cg24826892	chr11:71159390	DHCR7	0.44	5.46	0.34	1.21e-7	Vitamin D levels;
SARC	cis	rs17125944	0.686	rs11621275	chr14:53363316	C/G	cg00686598	chr14:53173677	PSMC6	-0.68	-5.09	-0.32	7.44e-7	Alzheimer's disease (late onset);
SARC	cis	rs7904368	0.754	rs7076779	chr10:16852667	C/T	cg23933602	chr10:16859644	RSU1	0.55	5.59	0.34	6.43e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg22105103	chr4:187893119	NA	0.5	6.47	0.39	5.84e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs854765	0.575	rs7207821	chr17:17891781	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.42	5.22	0.32	4.03e-7	Total body bone mineral density;
SARC	cis	rs10088262	0.629	rs7828192	chr8:124804669	C/T	cg15047889	chr8:124780837	FAM91A1	-0.65	-7.25	-0.43	6.14e-12	Pancreatic cancer;
SARC	cis	rs9858542	0.953	rs71324979	chr3:49619651	T/C	cg07274523	chr3:49395745	GPX1	0.51	5.9	0.36	1.28e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs8192478	0.793	rs8192477	chr15:78910463	G/C	cg24631222	chr15:78858424	CHRNA5	0.56	7.03	0.42	2.29e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs288326	0.561	rs17265894	chr2:183858168	A/G	cg09997497	chr2:183902928	NCKAP1	0.72	5.05	0.31	8.72e-7	Blood protein levels;
SARC	cis	rs7833790	0.654	rs6415652	chr8:82702257	G/A	cg06027949	chr8:82754900	SNX16	-0.47	-5.61	-0.35	5.58e-8	Diastolic blood pressure;
SARC	cis	rs7662987	0.517	rs2602876	chr4:100039535	A/T	cg13256891	chr4:100009986	ADH5	0.68	8.74	0.5	4.79e-16	Smoking initiation;
SARC	cis	rs9682041	0.627	rs11917188	chr3:170088607	C/T	cg11886554	chr3:170076028	SKIL	0.62	6.1	0.37	4.34e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs2070997	0.607	rs2987902	chr9:133710246	A/T	cg11464064	chr9:133710261	ABL1	0.64	5.86	0.36	1.53e-8	Response to amphetamines;
SARC	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg13699009	chr12:122356056	WDR66	0.69	11.5	0.6	1.53e-24	Mean corpuscular volume;
SARC	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg16606324	chr3:10149918	C3orf24	-0.49	-5.01	-0.31	1.05e-6	Alzheimer's disease;
SARC	cis	rs12950390	0.893	rs12325760	chr17:45840886	C/T	cg03474202	chr17:45855739	NA	-0.46	-7.26	-0.43	5.71e-12	IgG glycosylation;
SARC	cis	rs1008375	1.000	rs11722037	chr4:17683811	G/A	cg27347728	chr4:17578864	LAP3	0.44	5.5	0.34	9.74e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2153535	0.580	rs1335637	chr6:8465101	A/G	cg23788917	chr6:8435910	SLC35B3	0.64	8.39	0.48	4.57e-15	Motion sickness;
SARC	cis	rs7769051	0.711	rs9493437	chr6:133088405	A/T	cg07930552	chr6:133119739	C6orf192	0.87	7.69	0.45	4.08e-13	Type 2 diabetes nephropathy;
SARC	cis	rs7208859	0.623	rs12103508	chr17:29086781	T/G	cg13385521	chr17:29058706	SUZ12P	0.9	7.81	0.46	1.96e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs1153858	1.000	rs11858495	chr15:45637662	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.73	-9.73	-0.54	5.36e-19	Homoarginine levels;
SARC	cis	rs4792901	0.759	rs9915640	chr17:41603882	T/C	cg22562494	chr17:41607896	ETV4	-0.31	-4.88	-0.3	1.99e-6	Dupuytren's disease;
SARC	cis	rs703842	0.642	rs10876994	chr12:58064737	A/C	cg00677455	chr12:58241039	CTDSP2	0.53	5.89	0.36	1.33e-8	Multiple sclerosis;
SARC	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg11987759	chr7:65425863	GUSB	0.49	5.98	0.36	8.43e-9	Aortic root size;
SARC	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.4	-6.07	-0.37	5.06e-9	Total body bone mineral density;
SARC	cis	rs12048904	0.964	rs17123467	chr1:101331760	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.4	4.91	0.31	1.7e-6	Multiple sclerosis;
SARC	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg00149659	chr3:10157352	C3orf10	0.66	6.6	0.4	2.82e-10	Alzheimer's disease;
SARC	cis	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg08045932	chr20:61659980	NA	0.5	6.84	0.41	7.06e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs56104184	0.830	rs17206679	chr19:49342237	C/G	cg15549821	chr19:49342101	PLEKHA4	-0.93	-9.74	-0.54	4.87e-19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs9911578	0.839	rs7208505	chr17:57187729	C/T	cg12560992	chr17:57184187	TRIM37	0.82	12.02	0.62	3.24e-26	Intelligence (multi-trait analysis);
SARC	cis	rs6088590	0.735	rs6088618	chr20:33409350	G/A	cg08999081	chr20:33150536	PIGU	0.36	5.25	0.33	3.46e-7	Coronary artery disease;
SARC	cis	rs721399	0.553	rs59416053	chr8:18240800	G/C	cg18736775	chr8:18248649	NAT2	-0.67	-7.33	-0.43	3.79e-12	Blood metabolite levels;
SARC	cis	rs34172651	0.917	rs1075987	chr16:24794957	G/A	cg00152838	chr16:24741724	TNRC6A	-0.42	-5.17	-0.32	5e-7	Intelligence (multi-trait analysis);
SARC	cis	rs732765	1.000	rs13391	chr14:75370123	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.45	-5.26	-0.33	3.31e-7	Non-small cell lung cancer;
SARC	cis	rs965604	0.965	rs13180	chr15:78789488	C/T	cg24631222	chr15:78858424	CHRNA5	-0.44	-5.75	-0.35	2.72e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs1983170	1.000	rs1983170	chr1:91986482	G/A	cg25838465	chr1:92012736	NA	0.53	5.78	0.35	2.39e-8	Eosinophil percentage of white cells;
SARC	cis	rs888194	0.690	rs888192	chr12:109995097	C/T	cg13986417	chr12:110012484	MVK;MMAB	0.32	4.98	0.31	1.23e-6	Neuroticism;
SARC	cis	rs2985684	0.948	rs11623263	chr14:50083295	A/G	cg04989706	chr14:50066350	PPIL5	-0.56	-6.02	-0.37	6.65e-9	Carotid intima media thickness;
SARC	cis	rs1059312	0.966	rs7135968	chr12:129280066	G/A	cg09035930	chr12:129282057	SLC15A4	0.61	8.74	0.5	4.7e-16	Systemic lupus erythematosus;
SARC	cis	rs1044826	0.642	rs432387	chr3:139231853	T/G	cg15131784	chr3:139108705	COPB2	-0.4	-5.06	-0.31	8.52e-7	Obesity-related traits;
SARC	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.35	4.81	0.3	2.73e-6	Personality dimensions;
SARC	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg20607798	chr8:58055168	NA	0.63	5.85	0.36	1.62e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4917300	0.606	rs4917277	chr8:143095525	C/G	cg06573787	chr8:143070187	NA	-0.38	-5.3	-0.33	2.74e-7	Amyotrophic lateral sclerosis;
SARC	cis	rs8141529	0.664	rs5762862	chr22:29252732	C/T	cg15103426	chr22:29168792	CCDC117	0.58	6.82	0.41	7.64e-11	Lymphocyte counts;
SARC	cis	rs10040989	0.510	rs77085797	chr5:137776297	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.71	4.73	0.3	3.95e-6	QT interval;
SARC	cis	rs9291683	0.526	rs7695555	chr4:10001656	T/C	cg00071950	chr4:10020882	SLC2A9	0.37	5.67	0.35	4.15e-8	Bone mineral density;
SARC	cis	rs7727544	0.684	rs274560	chr5:131719450	T/C	cg07395648	chr5:131743802	NA	0.4	4.72	0.3	4.07e-6	Blood metabolite levels;
SARC	cis	rs908922	0.676	rs7531317	chr1:152528439	A/C	cg09873164	chr1:152488093	CRCT1	0.58	7.5	0.44	1.3e-12	Hair morphology;
SARC	cis	rs2898681	0.614	rs962416	chr4:53695657	G/T	cg00338735	chr4:53728038	RASL11B	-0.38	-4.73	-0.3	3.96e-6	Optic nerve measurement (cup area);
SARC	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg22875332	chr1:76189707	ACADM	0.5	6.98	0.42	3.07e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6088580	0.524	rs6088560	chr20:33228549	T/C	cg08999081	chr20:33150536	PIGU	-0.35	-5.12	-0.32	6.32e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs3213545	0.700	rs10849829	chr12:121470256	A/G	cg25281562	chr12:121454272	C12orf43	-0.5	-6.36	-0.38	1.05e-9	Subjective well-being;Cardiovascular disease risk factors;
SARC	cis	rs4803468	1.000	rs878083	chr19:41897688	G/A	cg09537434	chr19:41945824	ATP5SL	-0.92	-15.7	-0.72	2.19e-38	Height;
SARC	cis	rs2594989	0.670	rs9845397	chr3:11470263	C/T	cg00170343	chr3:11313890	ATG7	0.6	5.39	0.33	1.74e-7	Circulating chemerin levels;
SARC	cis	rs7568458	0.709	rs762684	chr2:85782023	G/A	cg23752985	chr2:85803571	VAMP8	0.45	5.75	0.35	2.78e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs1018836	0.663	rs2205152	chr8:91483618	C/T	cg16814680	chr8:91681699	NA	0.73	10.89	0.58	1.39e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs9911578	0.967	rs7502208	chr17:57165097	G/A	cg20303301	chr17:57937339	TUBD1	-0.34	-4.93	-0.31	1.55e-6	Intelligence (multi-trait analysis);
SARC	cis	rs995000	0.965	rs10889332	chr1:62950858	A/G	cg06896770	chr1:63153194	DOCK7	-0.94	-14.76	-0.7	2.95e-35	Triglyceride levels;
SARC	cis	rs7408868	1.000	rs2074617	chr19:15276055	C/G	cg14696996	chr19:15285081	NOTCH3	1.05	8.52	0.49	1.95e-15	Pulse pressure;
SARC	cis	rs12682352	0.602	rs13260419	chr8:8675176	A/G	cg15556689	chr8:8085844	FLJ10661	0.39	4.73	0.3	3.94e-6	Neuroticism;
SARC	cis	rs7223966	1.000	rs8068603	chr17:61755211	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.48	-5.35	-0.33	2.07e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs854765	0.583	rs10048206	chr17:17866897	A/G	cg04398451	chr17:18023971	MYO15A	-0.4	-5.51	-0.34	9.71e-8	Total body bone mineral density;
SARC	cis	rs765787	0.530	rs4774550	chr15:45542312	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.22	-0.32	4.05e-7	Uric acid levels;
SARC	cis	rs751728	1.000	rs6925273	chr6:33732448	A/G	cg15252951	chr6:33757062	LEMD2	0.59	6.8	0.41	8.72e-11	Crohn's disease;
SARC	cis	rs3820928	0.874	rs3752896	chr2:227886925	C/T	cg05526886	chr2:227700861	RHBDD1	-0.47	-5.46	-0.34	1.2e-7	Pulmonary function;
SARC	cis	rs17030434	0.784	rs6835640	chr4:154650494	C/T	cg14289246	chr4:154710475	SFRP2	-0.51	-5.76	-0.35	2.61e-8	Electrocardiographic conduction measures;
SARC	cis	rs721399	0.524	rs7005648	chr8:18278208	T/A	cg18736775	chr8:18248649	NAT2	0.55	5.56	0.34	7.34e-8	Blood metabolite levels;
SARC	trans	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg23339449	chr15:99191944	IGF1R	0.46	6.46	0.39	6.03e-10	Immature fraction of reticulocytes;
SARC	cis	rs4803468	1.000	rs2241710	chr19:41912092	G/C	cg14132834	chr19:41945861	ATP5SL	-0.56	-7.32	-0.43	4.06e-12	Height;
SARC	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg18404041	chr3:52824283	ITIH1	-0.34	-5.19	-0.32	4.62e-7	Electroencephalogram traits;
SARC	cis	rs9788682	1.000	rs61204066	chr15:78815298	G/A	cg06917634	chr15:78832804	PSMA4	-0.57	-6.47	-0.39	5.85e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs7833790	0.700	rs7834483	chr8:82704828	A/G	cg17211192	chr8:82754475	SNX16	-0.5	-5.93	-0.36	1.09e-8	Diastolic blood pressure;
SARC	cis	rs992157	0.835	rs13005100	chr2:219151767	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.69	-10.04	-0.55	6.05e-20	Colorectal cancer;
SARC	trans	rs629535	0.814	rs62513378	chr8:70095788	G/C	cg21567404	chr3:27674614	NA	-1.07	-13.9	-0.67	2.14e-32	Dupuytren's disease;
SARC	cis	rs9733	0.635	rs486836	chr1:150875967	A/T	cg15448220	chr1:150897856	SETDB1	-0.41	-5.49	-0.34	1.04e-7	Tonsillectomy;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg07981864	chr11:93862257	PANX1	0.49	6.31	0.38	1.38e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs1062177	0.724	rs2964590	chr5:151118146	C/G	cg00977110	chr5:151150581	G3BP1	-0.54	-5.4	-0.33	1.61e-7	Preschool internalizing problems;
SARC	cis	rs7296418	0.636	rs11057261	chr12:123797567	T/C	cg05973401	chr12:123451056	ABCB9	0.48	5.56	0.34	7.53e-8	Platelet count;
SARC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg02353165	chr6:42928485	GNMT	0.63	8.54	0.49	1.74e-15	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs12682352	0.602	rs6988939	chr8:8666916	C/T	cg08975724	chr8:8085496	FLJ10661	0.42	5.15	0.32	5.61e-7	Neuroticism;
SARC	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg13206674	chr6:150067644	NUP43	0.43	5.64	0.35	5e-8	Lung cancer;
SARC	cis	rs818427	1.000	rs514763	chr5:112215156	C/T	cg07820702	chr5:112228657	REEP5	-0.52	-5.9	-0.36	1.27e-8	Total body bone mineral density;
SARC	cis	rs7824557	0.527	rs4634600	chr8:11239017	T/A	cg21775007	chr8:11205619	TDH	-0.58	-7.71	-0.45	3.68e-13	Retinal vascular caliber;
SARC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg15242686	chr22:24348715	GSTTP1	0.41	5.2	0.32	4.46e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2191566	0.845	rs7258517	chr19:44535999	G/T	cg20607764	chr19:44506953	ZNF230	-0.45	-5.01	-0.31	1.07e-6	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs12709013	0.636	rs1646278	chr16:58783988	C/G	cg04273148	chr16:57808038	KIFC3	0.32	4.72	0.3	4.08e-6	Blood metabolite ratios;
SARC	cis	rs9517313	0.565	rs9556978	chr13:99234648	G/A	cg07423050	chr13:99094983	FARP1	-0.39	-5.04	-0.31	9.19e-7	Neuroticism;
SARC	cis	rs709400	0.930	rs57447494	chr14:104034569	G/A	cg24130564	chr14:104152367	KLC1	-0.38	-4.83	-0.3	2.53e-6	Body mass index;
SARC	cis	rs751728	1.000	rs6925273	chr6:33732448	A/G	cg25922239	chr6:33757077	LEMD2	0.79	10.43	0.56	3.78e-21	Crohn's disease;
SARC	cis	rs78487399	0.808	rs17030925	chr2:43713808	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.03	-0.31	9.75e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	ch.2.4215183F	chr2:211401919	CPS1	-0.48	-6.56	-0.39	3.54e-10	Tetralogy of Fallot;
SARC	cis	rs7223966	1.000	rs9908044	chr17:61747032	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.73	0.4	1.32e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs11605924	0.792	rs10838524	chr11:45870177	A/G	ch.11.939596F	chr11:45881766	CRY2	-0.48	-5.9	-0.36	1.29e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg18404041	chr3:52824283	ITIH1	-0.44	-6.73	-0.4	1.34e-10	Bipolar disorder;
SARC	cis	rs12930096	1.000	rs67188060	chr16:11679517	A/G	cg07439791	chr16:11680400	LITAF	0.57	5.79	0.35	2.24e-8	QT interval;
SARC	cis	rs7931462	0.655	rs6483208	chr11:92705844	A/C	cg24261808	chr11:93474459	C11orf54;TAF1D	0.67	5.11	0.32	6.76e-7	DNA methylation (parent-of-origin);
SARC	cis	rs3126085	0.877	rs1969019	chr1:152211502	A/C	cg26876637	chr1:152193138	HRNR	0.46	5.37	0.33	1.88e-7	Atopic dermatitis;
SARC	cis	rs2732480	0.577	rs2450994	chr12:48721832	G/A	cg21466736	chr12:48725269	NA	-0.31	-4.76	-0.3	3.33e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs73198271	0.562	rs17698256	chr8:8659613	C/T	cg01851573	chr8:8652454	MFHAS1	0.46	5.68	0.35	3.94e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs2153535	0.541	rs6938688	chr6:8521629	G/T	cg23788917	chr6:8435910	SLC35B3	0.64	8.66	0.49	7.75e-16	Motion sickness;
SARC	cis	rs6502050	0.799	rs6502088	chr17:80169484	C/T	cg19223190	chr17:80058835	NA	0.47	6.34	0.38	1.19e-9	Life satisfaction;
SARC	cis	rs644799	1.000	rs474252	chr11:95619292	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.9	13.27	0.66	2.6e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs17345786	1.000	rs3804778	chr3:101294572	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.45	5.03	0.31	9.74e-7	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg27266027	chr21:40555129	PSMG1	0.49	5.25	0.33	3.4e-7	Cognitive function;
SARC	cis	rs7011049	1.000	rs72640865	chr8:53842471	C/T	cg26025543	chr8:53854495	NA	0.6	5.39	0.33	1.73e-7	Systolic blood pressure;
SARC	cis	rs17253792	0.822	rs28754619	chr14:56088394	G/A	cg01858014	chr14:56050164	KTN1	-0.67	-5.11	-0.32	6.86e-7	Putamen volume;
SARC	cis	rs10754283	0.967	rs10801760	chr1:90113824	G/A	cg21401794	chr1:90099060	LRRC8C	0.59	8.09	0.47	3.24e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs4319547	0.508	rs10846826	chr12:122894987	C/T	cg23029597	chr12:123009494	RSRC2	-0.42	-5.21	-0.32	4.18e-7	Body mass index;
SARC	cis	rs2760061	0.598	rs2796056	chr1:228122901	G/A	cg02753203	chr1:228287806	NA	-0.55	-7.51	-0.44	1.25e-12	Diastolic blood pressure;
SARC	cis	rs6121246	0.529	rs6060291	chr20:30198043	T/G	cg21427119	chr20:30132790	HM13	-0.48	-5.29	-0.33	2.84e-7	Mean corpuscular hemoglobin;
SARC	cis	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg18252515	chr7:66147081	NA	-1.34	-12.05	-0.62	2.51e-26	Diabetic kidney disease;
SARC	cis	rs13191362	0.872	rs13213421	chr6:163203805	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.63	5.64	0.35	4.95e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.95	10.3	0.56	9.29e-21	Platelet count;
SARC	cis	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg06636001	chr8:8085503	FLJ10661	0.7	9.52	0.53	2.35e-18	Neuroticism;
SARC	cis	rs6807306	1.000	rs6771578	chr3:167448546	T/C	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.51	4.83	0.3	2.44e-6	Mean platelet volume;
SARC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg27588902	chr6:42928151	GNMT	-0.37	-5.68	-0.35	4.03e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs7395581	0.959	rs2013867	chr11:47260272	A/G	cg25783544	chr11:47291846	MADD	0.49	5.33	0.33	2.36e-7	HDL cholesterol;
SARC	cis	rs11785400	0.793	rs4736362	chr8:143741381	G/A	cg10596483	chr8:143751796	JRK	0.55	7.01	0.42	2.59e-11	Schizophrenia;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg11917415	chr6:71135081	FAM135A	0.46	6.32	0.38	1.32e-9	Thyroid stimulating hormone;
SARC	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg12463550	chr7:65579703	CRCP	-0.49	-5.42	-0.33	1.47e-7	Aortic root size;
SARC	cis	rs858239	0.601	rs73272053	chr7:23155525	A/G	cg23682824	chr7:23144976	KLHL7	0.66	8.55	0.49	1.68e-15	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg13206674	chr6:150067644	NUP43	0.46	6.06	0.37	5.43e-9	Lung cancer;
SARC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg12648201	chr2:27665141	KRTCAP3	-0.32	-4.78	-0.3	3.05e-6	Total body bone mineral density;
SARC	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.78	-0.5	3.56e-16	Alzheimer's disease;
SARC	cis	rs2204008	0.720	rs11180923	chr12:38255172	A/T	cg13010199	chr12:38710504	ALG10B	0.81	11.31	0.6	6.15e-24	Bladder cancer;
SARC	cis	rs7578035	0.742	rs6733011	chr2:99465502	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-4.98	-0.31	1.24e-6	Bipolar disorder;
SARC	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.64	-8.93	-0.5	1.35e-16	Total body bone mineral density;
SARC	cis	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg14343924	chr8:8086146	FLJ10661	0.41	4.75	0.3	3.59e-6	Systolic blood pressure;
SARC	cis	rs6815814	0.950	rs3924112	chr4:38795810	C/T	cg09316306	chr4:38807337	TLR1	0.5	5.14	0.32	5.87e-7	Breast cancer;
SARC	cis	rs4722166	0.695	rs35779989	chr7:22800314	A/C	cg26061582	chr7:22766209	IL6	0.47	5.43	0.34	1.4e-7	Lung cancer;
SARC	cis	rs7208859	0.623	rs9914242	chr17:29216245	G/T	cg13385521	chr17:29058706	SUZ12P	0.89	7.35	0.43	3.23e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs826838	0.809	rs11169666	chr12:39211300	T/C	cg13010199	chr12:38710504	ALG10B	0.74	9.69	0.54	7.24e-19	Heart rate;
SARC	trans	rs12554020	0.786	rs78865387	chr9:96264109	A/C	cg26442883	chr16:49686662	ZNF423	0.56	6.24	0.38	2.1e-9	Schizophrenia;
SARC	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg11878867	chr6:150167359	LRP11	-0.34	-4.85	-0.3	2.29e-6	Lung cancer;
SARC	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg11644478	chr21:40555479	PSMG1	-0.6	-7.52	-0.44	1.16e-12	Menarche (age at onset);
SARC	cis	rs2933343	0.729	rs1683780	chr3:128640239	C/T	cg25356066	chr3:128598488	ACAD9	0.73	9.5	0.53	2.69e-18	IgG glycosylation;
SARC	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	7.67	0.45	4.58e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs17739167	0.550	rs11070354	chr15:42233211	C/T	cg20935245	chr15:42234343	EHD4	0.46	6.01	0.37	7e-9	Monocyte count;
SARC	cis	rs9818758	0.607	rs4855860	chr3:49526044	A/T	cg00383909	chr3:49044727	WDR6	-0.72	-5.18	-0.32	4.76e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg11062466	chr8:58055876	NA	0.54	5.53	0.34	8.37e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs262150	0.837	rs2657404	chr7:158783155	C/T	cg04111992	chr7:158790115	NA	-0.38	-5.1	-0.32	7.15e-7	Facial morphology (factor 20);
SARC	cis	rs2153535	0.580	rs2327050	chr6:8440630	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	8.27	0.48	1.05e-14	Motion sickness;
SARC	trans	rs1814175	0.645	rs1851849	chr11:50012164	G/A	cg03929089	chr4:120376271	NA	-0.84	-12.14	-0.62	1.33e-26	Height;
SARC	cis	rs73206853	0.841	rs7961345	chr12:111081598	C/T	cg10860002	chr12:110842031	ANAPC7	0.62	5.07	0.32	8.09e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg16606324	chr3:10149918	C3orf24	0.48	5.04	0.31	9.53e-7	Alzheimer's disease;
SARC	cis	rs796364	1.000	rs281763	chr2:200794870	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.78	7.15	0.42	1.12e-11	Schizophrenia;
SARC	cis	rs7599312	0.517	rs10192988	chr2:213407782	T/G	cg16329650	chr2:213403929	ERBB4	0.71	10.59	0.57	1.19e-21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg07308232	chr7:1071921	C7orf50	-0.55	-6.89	-0.41	5.25e-11	Longevity;Endometriosis;
SARC	cis	rs4253772	0.591	rs6007740	chr22:46654323	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.63	-7.04	-0.42	2.12e-11	LDL cholesterol;Cholesterol, total;
SARC	cis	rs1800469	1.000	rs2241712	chr19:41869756	C/T	cg09537434	chr19:41945824	ATP5SL	-0.6	-7.38	-0.44	2.72e-12	Colorectal cancer;
SARC	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg17158414	chr2:27665306	KRTCAP3	0.38	6.4	0.39	8.57e-10	Total body bone mineral density;
SARC	trans	rs2055729	0.614	rs17150693	chr8:9741652	C/G	cg06636001	chr8:8085503	FLJ10661	0.57	6.25	0.38	1.91e-9	Multiple myeloma (hyperdiploidy);
SARC	cis	rs1920116	0.778	rs34194057	chr3:169549551	G/T	cg08193579	chr3:169529701	LRRC34	0.42	4.99	0.31	1.18e-6	Glioma (high-grade);
SARC	cis	rs3762637	0.943	rs10439995	chr3:122189160	C/A	cg24169773	chr3:122142474	KPNA1	-0.55	-5.55	-0.34	7.73e-8	LDL cholesterol levels;
SARC	cis	rs12950390	0.512	rs72831681	chr17:45847174	C/G	cg24803719	chr17:45855879	NA	-0.42	-5.29	-0.33	2.8e-7	IgG glycosylation;
SARC	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg22590775	chr19:49891494	CCDC155	0.5	5.69	0.35	3.79e-8	Multiple sclerosis;
SARC	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg03941709	chr7:87505496	SLC25A40;DBF4	-0.49	-6.35	-0.38	1.12e-9	Thyroid cancer;
SARC	cis	rs6732160	0.588	rs2043101	chr2:73374050	A/G	cg01422370	chr2:73384389	NA	0.37	5.82	0.36	1.97e-8	Intelligence (multi-trait analysis);
SARC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg05025164	chr4:1340916	KIAA1530	0.88	10.91	0.58	1.2e-22	Longevity;
SARC	cis	rs4243830	0.850	rs12760251	chr1:6601336	C/T	cg04093404	chr1:6614507	TAS1R1;NOL9	0.55	4.88	0.3	1.97e-6	Body mass index;
SARC	cis	rs611744	0.967	rs475865	chr8:109235858	G/C	cg21045802	chr8:109455806	TTC35	0.45	5.39	0.33	1.69e-7	Dupuytren's disease;
SARC	cis	rs5015933	0.801	rs4837016	chr9:128141809	A/G	cg14078157	chr9:128172775	NA	0.32	4.72	0.3	3.99e-6	Body mass index;
SARC	cis	rs7246657	0.943	rs34603719	chr19:37794528	T/G	cg23950597	chr19:37808831	NA	-0.57	-5.07	-0.31	8.28e-7	Coronary artery calcification;
SARC	cis	rs9393692	0.645	rs4145910	chr6:26313305	T/C	cg05868516	chr6:26286170	HIST1H4H	0.48	5.56	0.34	7.31e-8	Educational attainment;
SARC	cis	rs11122272	0.735	rs2808611	chr1:231548480	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.69	10.2	0.56	1.98e-20	Hemoglobin concentration;
SARC	cis	rs9309711	0.560	rs6548164	chr2:3472665	C/T	cg15541040	chr2:3486749	NA	0.44	6.01	0.37	7.12e-9	Neurofibrillary tangles;
SARC	cis	rs9329221	0.527	rs6989657	chr8:10330873	C/G	cg21775007	chr8:11205619	TDH	0.37	4.96	0.31	1.36e-6	Neuroticism;
SARC	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg05863683	chr7:1912471	MAD1L1	0.36	5.5	0.34	1.02e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg18252515	chr7:66147081	NA	-1.34	-12.05	-0.62	2.51e-26	Diabetic kidney disease;
SARC	cis	rs17826219	0.568	rs9903854	chr17:29153998	C/T	cg13385521	chr17:29058706	SUZ12P	0.85	7.66	0.45	4.88e-13	Body mass index;
SARC	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg05185784	chr16:90016020	DEF8	-0.45	-4.76	-0.3	3.32e-6	Skin colour saturation;
SARC	cis	rs858239	0.602	rs6953996	chr7:23175946	A/G	cg23682824	chr7:23144976	KLHL7	0.68	8.58	0.49	1.39e-15	Cerebrospinal fluid biomarker levels;
SARC	cis	rs7412746	0.658	rs897815	chr1:150879101	C/T	cg10589385	chr1:150898437	SETDB1	-0.43	-5.74	-0.35	2.91e-8	Melanoma;
SARC	cis	rs7264396	0.563	rs6060580	chr20:34310512	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-7.17	-0.43	9.99e-12	Total cholesterol levels;
SARC	cis	rs72634258	0.554	rs68024107	chr1:7914066	G/C	cg00042356	chr1:8021962	PARK7	0.6	5.03	0.31	9.83e-7	Inflammatory bowel disease;
SARC	cis	rs9436747	0.626	rs11590603	chr1:65951897	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	-0.38	-4.86	-0.3	2.19e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	trans	rs61931739	0.534	rs2220547	chr12:34106255	G/A	cg26384229	chr12:38710491	ALG10B	0.87	12.43	0.63	1.5e-27	Morning vs. evening chronotype;
SARC	cis	rs7429990	0.965	rs7651237	chr3:48105528	A/G	cg11946769	chr3:48343235	NME6	-0.6	-6.55	-0.39	3.74e-10	Educational attainment (years of education);
SARC	cis	rs16976116	0.901	rs73409851	chr15:55502516	G/A	cg11288833	chr15:55489084	RSL24D1	0.63	6.13	0.37	3.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs17125944	0.656	rs74825460	chr14:53390015	C/T	cg00686598	chr14:53173677	PSMC6	0.89	5.91	0.36	1.18e-8	Alzheimer's disease (late onset);
SARC	cis	rs11122272	0.735	rs1416916	chr1:231533027	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.28	-0.56	1.11e-20	Hemoglobin concentration;
SARC	cis	rs11630290	0.806	rs72752906	chr15:64093465	G/T	cg12036633	chr15:63758958	NA	-0.53	-5.27	-0.33	3.15e-7	Iris characteristics;
SARC	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	12.91	0.65	3.97e-29	Chronic sinus infection;
SARC	cis	rs1873147	1.000	rs12443285	chr15:63313596	C/T	cg05507819	chr15:63340323	TPM1	-0.45	-4.89	-0.31	1.84e-6	Orofacial clefts;
SARC	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg08742575	chr21:47604166	C21orf56	-0.48	-6.06	-0.37	5.4e-9	Testicular germ cell tumor;
SARC	cis	rs3540	0.960	rs1505936	chr15:91010776	T/C	cg22089800	chr15:90895588	ZNF774	0.51	5.83	0.36	1.84e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs13256369	1.000	rs13282915	chr8:8570891	T/G	cg17143192	chr8:8559678	CLDN23	0.53	6.27	0.38	1.74e-9	Obesity-related traits;
SARC	cis	rs9341808	0.714	rs4256394	chr6:80882142	C/T	cg08355045	chr6:80787529	NA	0.34	5.38	0.33	1.78e-7	Sitting height ratio;
SARC	cis	rs6674176	0.597	rs4031031	chr1:44393533	C/T	cg12908607	chr1:44402522	ARTN	-0.37	-6.45	-0.39	6.5e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs17376456	0.877	rs7728736	chr5:93404277	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.76	0.35	2.64e-8	Diabetic retinopathy;
SARC	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg13628971	chr7:2884303	GNA12	0.55	6.55	0.39	3.65e-10	Height;
SARC	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.77	-8.03	-0.47	4.84e-14	Alzheimer's disease;
SARC	trans	rs208520	0.954	rs1468153	chr6:67009054	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.77	7.87	0.46	1.33e-13	Exhaled nitric oxide output;
SARC	cis	rs10489202	0.657	rs3767479	chr1:168069840	C/A	cg24449463	chr1:168025552	DCAF6	-0.58	-7.4	-0.44	2.52e-12	Schizophrenia;
SARC	cis	rs6674176	0.597	rs3762422	chr1:44400532	T/A	cg12908607	chr1:44402522	ARTN	-0.39	-6.91	-0.41	4.69e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs60871478	0.636	rs4719520	chr7:875216	C/G	cg05535760	chr7:792225	HEATR2	-0.7	-6.92	-0.41	4.4e-11	Cerebrospinal P-tau181p levels;
SARC	cis	rs2124969	0.562	rs6750639	chr2:161066862	T/C	cg03641300	chr2:160917029	PLA2R1	-0.43	-5.72	-0.35	3.3e-8	Waist circumference adjusted for body mass index;
SARC	cis	rs709400	0.628	rs1951392	chr14:103853367	T/G	cg26031613	chr14:104095156	KLC1	0.82	11.82	0.61	1.47e-25	Body mass index;
SARC	cis	rs72634258	0.796	rs10746475	chr1:8168261	T/A	cg00042356	chr1:8021962	PARK7	-0.63	-5.98	-0.36	8.53e-9	Inflammatory bowel disease;
SARC	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	11.03	0.59	4.93e-23	Alzheimer's disease;
SARC	cis	rs1451375	0.617	rs10267323	chr7:50591424	A/G	cg18232548	chr7:50535776	DDC	0.48	4.77	0.3	3.25e-6	Malaria;
SARC	cis	rs617791	0.508	rs747526	chr11:65776071	C/A	cg26695010	chr11:65641043	EFEMP2	0.57	6.98	0.42	3.06e-11	Breast cancer;
SARC	cis	rs2180341	0.960	rs7766942	chr6:127691323	G/T	cg24812749	chr6:127587940	RNF146	1.02	13.46	0.66	6.06e-31	Breast cancer;
SARC	cis	rs1728785	0.901	rs1103286	chr16:68578625	C/T	cg02972257	chr16:68554789	NA	-0.43	-5.01	-0.31	1.08e-6	Ulcerative colitis;
SARC	cis	rs10936602	0.539	rs28688695	chr3:169554781	A/G	cg27020690	chr3:169482358	NA	0.39	4.97	0.31	1.28e-6	Renal cell carcinoma;
SARC	cis	rs896543	0.702	rs12692190	chr2:237496190	C/T	cg25295825	chr2:237489920	CXCR7	0.49	5.95	0.36	9.62e-9	Alcohol dependence (age at onset);
SARC	cis	rs4727027	0.901	rs4727019	chr7:148822266	A/G	cg23583168	chr7:148888333	NA	-0.74	-10.55	-0.57	1.56e-21	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs2832191	1.000	rs8131214	chr21:30483386	T/G	cg08807101	chr21:30365312	RNF160	-0.75	-10.39	-0.56	4.97e-21	Dental caries;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg14557232	chr4:1368966	KIAA1530	0.48	6.36	0.38	1.08e-9	Schizophrenia;
SARC	cis	rs2180341	0.960	rs7745944	chr6:127709574	A/G	cg27446573	chr6:127587934	RNF146	1.06	14.33	0.68	8.19e-34	Breast cancer;
SARC	cis	rs9894429	1.000	rs3935543	chr17:79579874	T/C	cg18240062	chr17:79603768	NPLOC4	0.71	9.81	0.54	3.03e-19	Eye color traits;
SARC	cis	rs7264396	0.635	rs6060696	chr20:34522060	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-7.5	-0.44	1.37e-12	Total cholesterol levels;
SARC	cis	rs6088580	0.634	rs6141465	chr20:32967314	T/C	cg24642439	chr20:33292090	TP53INP2	-0.66	-8.58	-0.49	1.36e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	12.74	0.64	1.44e-28	Platelet count;
SARC	cis	rs672059	1.000	rs1760624	chr1:183158552	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.52	7.16	0.42	1.04e-11	Hypertriglyceridemia;
SARC	cis	rs6665290	0.904	rs10916075	chr1:227184074	G/A	cg14016676	chr1:227182615	CDC42BPA	0.36	5.09	0.32	7.4e-7	Myeloid white cell count;
SARC	cis	rs3087591	0.664	rs2525565	chr17:29666588	T/C	cg24425628	chr17:29625626	OMG;NF1	0.41	5.3	0.33	2.66e-7	Hip circumference;
SARC	trans	rs7937682	0.855	rs539553	chr11:111477333	C/T	cg18187862	chr3:45730750	SACM1L	0.56	6.99	0.42	2.79e-11	Primary sclerosing cholangitis;
SARC	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg04013166	chr16:89971882	TCF25	-0.48	-5.23	-0.32	3.84e-7	Skin colour saturation;
SARC	trans	rs2727020	0.615	rs10128582	chr11:49447424	C/T	cg15704280	chr7:45808275	SEPT13	-0.86	-13.84	-0.67	3.46e-32	Coronary artery disease;
SARC	cis	rs9303401	0.646	rs9892425	chr17:57241938	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.57	6.99	0.42	2.85e-11	Cognitive test performance;
SARC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg02353165	chr6:42928485	GNMT	0.7	10.04	0.55	6.04e-20	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs6570726	0.755	rs451699	chr6:145830594	C/G	cg05347473	chr6:146136440	FBXO30	0.53	7.29	0.43	4.79e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs698833	0.509	rs6715202	chr2:44516282	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.68	7.42	0.44	2.13e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg18608025	chr4:898531	GAK	-0.51	-6.37	-0.39	9.86e-10	Gut microbiota (bacterial taxa);
SARC	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg11764359	chr7:65958608	NA	0.77	8.92	0.5	1.45e-16	Aortic root size;
SARC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	9.11	0.51	3.9e-17	Prudent dietary pattern;
SARC	cis	rs6831352	0.879	rs7672728	chr4:100055173	A/G	cg12011299	chr4:100065546	ADH4	-0.34	-5.74	-0.35	2.95e-8	Alcohol dependence;
SARC	cis	rs1728785	1.000	rs1728801	chr16:68571457	A/C	cg02972257	chr16:68554789	NA	-0.44	-5.15	-0.32	5.43e-7	Ulcerative colitis;
SARC	cis	rs35110281	0.807	rs2838328	chr21:45023234	G/C	cg01579765	chr21:45077557	HSF2BP	-0.33	-5.68	-0.35	3.94e-8	Mean corpuscular volume;
SARC	cis	rs959260	0.557	rs12943902	chr17:73400627	G/C	cg14668889	chr17:73230827	NUP85	-0.45	-5.05	-0.31	8.8e-7	Systemic lupus erythematosus;
SARC	cis	rs7223966	1.000	rs55868506	chr17:61851686	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	7.12	0.42	1.35e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs13256369	1.000	rs873063	chr8:8572447	A/G	cg18904891	chr8:8559673	CLDN23	0.5	5.81	0.36	2e-8	Obesity-related traits;
SARC	cis	rs796364	0.806	rs1106400	chr2:201004089	T/C	cg23649088	chr2:200775458	C2orf69	-0.64	-6.49	-0.39	5.01e-10	Schizophrenia;
SARC	cis	rs4481887	1.000	rs4244179	chr1:248470984	T/A	cg13385794	chr1:248469461	NA	0.36	5.48	0.34	1.09e-7	Common traits (Other);
SARC	cis	rs12887734	0.546	rs12886637	chr14:104222892	A/G	cg26031613	chr14:104095156	KLC1	0.48	5.51	0.34	9.45e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	cis	rs5750830	0.594	rs9611166	chr22:39775268	T/C	cg05872129	chr22:39784769	NA	-0.46	-6.67	-0.4	1.81e-10	Intelligence (multi-trait analysis);
SARC	cis	rs8064299	0.655	rs895691	chr17:72766300	G/T	cg25054828	chr17:72772726	NAT9;TMEM104	0.42	4.84	0.3	2.38e-6	Monocyte count;
SARC	cis	rs636291	0.500	rs655271	chr1:10536635	G/A	cg07384165	chr1:10488281	NA	-0.47	-6.58	-0.4	3.12e-10	Prostate cancer;
SARC	cis	rs3858526	0.796	rs9645652	chr11:5944264	C/T	cg02574844	chr11:5959923	NA	-0.42	-5.17	-0.32	5.15e-7	DNA methylation (variation);
SARC	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg09699651	chr6:150184138	LRP11	0.39	4.86	0.3	2.19e-6	Lung cancer;
SARC	cis	rs7246657	0.943	rs6508711	chr19:37815134	G/T	cg23950597	chr19:37808831	NA	-0.54	-5.46	-0.34	1.24e-7	Coronary artery calcification;
SARC	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg09455208	chr3:40491958	NA	0.41	6.29	0.38	1.53e-9	Renal cell carcinoma;
SARC	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs9818758	0.607	rs11706189	chr3:49210833	C/A	cg07636037	chr3:49044803	WDR6	-0.75	-6.75	-0.4	1.16e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg07157834	chr1:205819609	PM20D1	0.5	6.88	0.41	5.45e-11	Menarche (age at onset);
SARC	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg10207240	chr12:122356781	WDR66	0.3	4.88	0.3	2.01e-6	Mean corpuscular volume;
SARC	cis	rs875622	0.556	rs4808047	chr19:16527834	T/C	cg10248733	chr19:16607483	C19orf44;CALR3	-0.65	-6.81	-0.41	8.15e-11	White matter integrity;Neutrophil percentage of white cells;
SARC	cis	rs11608355	1.000	rs3742020	chr12:109883254	T/C	cg19025524	chr12:109796872	NA	-0.39	-5.13	-0.32	6.14e-7	Neuroticism;
SARC	cis	rs1559088	0.847	rs8100392	chr19:33605933	T/C	cg17764715	chr19:33622953	WDR88	0.49	6.66	0.4	1.99e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg06074448	chr4:187884817	NA	-0.43	-5.91	-0.36	1.22e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg00409905	chr10:38381863	ZNF37A	-0.53	-7.3	-0.43	4.56e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs4443100	0.874	rs6003483	chr22:23379625	T/C	cg14186256	chr22:23484241	RTDR1	0.48	4.99	0.31	1.19e-6	Serum parathyroid hormone levels;
SARC	cis	rs453301	0.652	rs2043129	chr8:8825504	C/G	cg11608241	chr8:8085544	FLJ10661	0.42	4.89	0.31	1.84e-6	Joint mobility (Beighton score);
SARC	cis	rs1728785	1.000	rs8058145	chr16:68584090	G/A	cg02972257	chr16:68554789	NA	-0.43	-5.01	-0.31	1.08e-6	Ulcerative colitis;
SARC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.37	0.52	6.44e-18	Prudent dietary pattern;
SARC	cis	rs2404602	0.679	rs12899871	chr15:76757347	T/C	cg22467129	chr15:76604101	ETFA	-0.36	-4.75	-0.3	3.52e-6	Blood metabolite levels;
SARC	cis	rs17741873	0.836	rs4745723	chr10:75603338	T/C	cg07699608	chr10:75541558	CHCHD1	0.49	4.84	0.3	2.35e-6	Paclitaxel disposition in epithelial ovarian cancer;
SARC	cis	rs1401999	0.714	rs13066518	chr3:183635498	T/A	cg01324343	chr3:183735012	ABCC5	0.58	10.7	0.57	5.48e-22	Anterior chamber depth;
SARC	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg15448220	chr1:150897856	SETDB1	0.48	6.29	0.38	1.55e-9	Melanoma;
SARC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg11905131	chr22:24372483	LOC391322	-0.51	-6.0	-0.37	7.41e-9	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7412746	0.658	rs4970987	chr1:150949682	T/C	cg10589385	chr1:150898437	SETDB1	0.37	4.78	0.3	3.07e-6	Melanoma;
SARC	cis	rs7264396	0.623	rs6060504	chr20:34197619	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-7.09	-0.42	1.58e-11	Total cholesterol levels;
SARC	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-6.59	-0.4	2.84e-10	Personality dimensions;
SARC	cis	rs1949733	0.554	rs4259044	chr4:8536188	A/G	cg13073564	chr4:8508604	NA	0.42	6.96	0.41	3.48e-11	Response to antineoplastic agents;
SARC	cis	rs9513627	1.000	rs7338761	chr13:100119731	A/G	cg25919922	chr13:100150906	NA	-0.75	-5.5	-0.34	9.72e-8	Obesity-related traits;
SARC	cis	rs9300255	0.679	rs10772998	chr12:123721177	T/G	cg00376283	chr12:123451042	ABCB9	0.52	5.98	0.36	8.35e-9	Neutrophil percentage of white cells;
SARC	trans	rs61931739	0.534	rs1490113	chr12:34132394	A/G	cg26384229	chr12:38710491	ALG10B	0.87	12.6	0.64	4.2e-28	Morning vs. evening chronotype;
SARC	cis	rs6442522	0.867	rs12637268	chr3:15500248	T/C	cg16303742	chr3:15540471	COLQ	0.34	4.92	0.31	1.6e-6	Uric acid levels;
SARC	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg08280861	chr8:58055591	NA	0.56	5.22	0.32	4.01e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	5.35	0.33	2.05e-7	Tonsillectomy;
SARC	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg13939156	chr17:80058883	NA	-0.45	-6.97	-0.42	3.26e-11	Life satisfaction;
SARC	cis	rs5758659	1.000	rs5758659	chr22:42622003	C/T	cg15557168	chr22:42548783	NA	-0.34	-4.74	-0.3	3.76e-6	Cognitive function;
SARC	cis	rs11122272	0.735	rs2437148	chr1:231513979	A/G	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs10782582	0.593	rs12132750	chr1:76136222	A/G	cg03433033	chr1:76189801	ACADM	-0.43	-5.45	-0.34	1.25e-7	Daytime sleep phenotypes;
SARC	trans	rs11098499	0.954	rs6834796	chr4:120414693	A/C	cg25214090	chr10:38739885	LOC399744	0.58	7.47	0.44	1.63e-12	Corneal astigmatism;
SARC	cis	rs11785400	0.793	rs34875149	chr8:143736131	G/A	cg24634471	chr8:143751801	JRK	0.58	7.46	0.44	1.71e-12	Schizophrenia;
SARC	cis	rs654950	0.934	rs654220	chr1:42002556	A/T	cg06885757	chr1:42089581	HIVEP3	-0.41	-5.93	-0.36	1.11e-8	Airway imaging phenotypes;
SARC	cis	rs4253772	0.591	rs6007727	chr22:46650959	G/A	cg24881330	chr22:46731750	TRMU	0.62	6.72	0.4	1.41e-10	LDL cholesterol;Cholesterol, total;
SARC	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg05313129	chr8:58192883	C8orf71	-0.62	-6.35	-0.38	1.11e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.593	rs113184543	chr8:58042950	A/G	cg08280861	chr8:58055591	NA	0.55	5.06	0.31	8.42e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9325144	0.647	rs1386018	chr12:39104360	C/T	cg13010199	chr12:38710504	ALG10B	-0.52	-6.47	-0.39	5.68e-10	Morning vs. evening chronotype;
SARC	trans	rs7819412	0.521	rs9329238	chr8:11033737	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.78	-0.41	9.62e-11	Triglycerides;
SARC	cis	rs3749237	0.555	rs2117939	chr3:49415179	C/A	cg02487422	chr3:49467188	NICN1	0.48	6.39	0.39	8.9e-10	Resting heart rate;
SARC	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg18876405	chr7:65276391	NA	-0.43	-4.72	-0.3	4.07e-6	Aortic root size;
SARC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	6.0	0.37	7.37e-9	Prudent dietary pattern;
SARC	cis	rs6690583	0.573	rs7547317	chr1:85456961	T/G	cg22488158	chr1:85528044	WDR63	0.62	5.16	0.32	5.16e-7	Serum sulfate level;
SARC	cis	rs4713118	0.662	rs469228	chr6:27970704	A/G	cg26335602	chr6:28129616	ZNF389	0.48	5.22	0.32	4.01e-7	Parkinson's disease;
SARC	cis	rs916888	0.610	rs199452	chr17:44801340	C/T	cg01570182	chr17:44337453	NA	0.6	7.36	0.43	3.23e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg23758822	chr17:41437982	NA	0.85	10.86	0.58	1.71e-22	Menopause (age at onset);
SARC	cis	rs6908034	0.607	rs78774173	chr6:19820686	T/C	cg02682789	chr6:19804855	NA	0.67	5.36	0.33	2.03e-7	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs11190604	0.767	rs10509743	chr10:102190406	C/T	cg07080220	chr10:102295463	HIF1AN	0.72	8.28	0.48	9.7e-15	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs7582180	0.591	rs1030902	chr2:101007178	T/G	cg14675211	chr2:100938903	LONRF2	0.52	7.7	0.45	3.9e-13	Intelligence (multi-trait analysis);
SARC	cis	rs11264799	0.603	rs11799853	chr1:157557957	T/C	cg18268488	chr1:157545234	FCRL4	0.31	5.35	0.33	2.07e-7	IgA nephropathy;
SARC	cis	rs7044106	0.762	rs4142158	chr9:123410819	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	4.97	0.31	1.33e-6	Hip circumference adjusted for BMI;
SARC	trans	rs3780486	0.846	rs7036812	chr9:33143822	T/C	cg04842962	chr6:43655489	MRPS18A	1.05	18.5	0.77	1.22e-47	IgG glycosylation;
SARC	cis	rs3126085	1.000	rs114304428	chr1:152254010	T/C	cg26876637	chr1:152193138	HRNR	-0.5	-5.14	-0.32	5.95e-7	Atopic dermatitis;
SARC	cis	rs9916302	0.706	rs6503504	chr17:37514412	A/G	cg00129232	chr17:37814104	STARD3	0.53	5.69	0.35	3.85e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs17270561	0.609	rs7754296	chr6:25744878	A/G	cg17691542	chr6:26056736	HIST1H1C	0.55	6.68	0.4	1.71e-10	Iron status biomarkers;
SARC	cis	rs2153535	0.580	rs7341383	chr6:8470634	A/C	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs6121246	0.909	rs6060644	chr20:30265652	G/A	cg13852791	chr20:30311386	BCL2L1	0.86	9.16	0.51	2.76e-17	Mean corpuscular hemoglobin;
SARC	cis	rs17666538	0.585	rs6559063	chr8:623051	C/T	cg02524346	chr8:600233	NA	0.62	4.76	0.3	3.38e-6	IgG glycosylation;
SARC	cis	rs9790314	0.905	rs7633186	chr3:161003124	A/G	cg04691961	chr3:161091175	C3orf57	-0.75	-10.75	-0.58	3.7e-22	Morning vs. evening chronotype;
SARC	cis	rs7666738	0.830	rs13144564	chr4:98939276	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg11644478	chr21:40555479	PSMG1	1.06	15.39	0.71	2.39e-37	Cognitive function;
SARC	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg15049968	chr18:44337910	ST8SIA5	-0.35	-5.63	-0.35	5.06e-8	Personality dimensions;
SARC	cis	rs17666538	0.792	rs115204727	chr8:676639	G/A	cg07234876	chr8:600039	NA	-0.96	-6.01	-0.37	7.22e-9	IgG glycosylation;
SARC	cis	rs17533156	0.612	rs12603478	chr17:75128651	A/G	cg18815765	chr17:75136729	SEC14L1	0.52	5.06	0.31	8.44e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs7264396	0.635	rs6058378	chr20:34546658	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-7.1	-0.42	1.54e-11	Total cholesterol levels;
SARC	trans	rs11165623	0.792	rs12123543	chr1:96964549	T/C	cg10631902	chr5:14652156	NA	-0.46	-7.47	-0.44	1.63e-12	Hip circumference;Waist circumference;
SARC	cis	rs763121	0.819	rs5757160	chr22:38989646	T/C	cg21395723	chr22:39101663	GTPBP1	0.58	6.81	0.41	8.44e-11	Menopause (age at onset);
SARC	cis	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg25894440	chr7:65020034	NA	0.52	4.8	0.3	2.79e-6	Aortic root size;
SARC	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg16680214	chr1:154839983	KCNN3	-0.36	-5.72	-0.35	3.2e-8	Prostate cancer;
SARC	cis	rs11997175	0.624	rs7465686	chr8:33718321	G/A	ch.8.33884649F	chr8:33765107	NA	0.56	7.24	0.43	6.38e-12	Body mass index;
SARC	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg08564027	chr20:61660810	NA	0.76	11.8	0.61	1.69e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs6942407	0.512	rs1859124	chr7:86747876	C/T	cg02420886	chr7:86849541	C7orf23	-0.74	-6.19	-0.38	2.76e-9	Food allergy;
SARC	cis	rs9457247	0.765	rs12212247	chr6:167413539	T/C	cg23791538	chr6:167370224	RNASET2	-0.53	-6.91	-0.41	4.59e-11	Crohn's disease;
SARC	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg09359103	chr1:154839909	KCNN3	-0.39	-6.09	-0.37	4.73e-9	Prostate cancer;
SARC	cis	rs6495122	0.662	rs12898997	chr15:75090349	C/T	cg14664628	chr15:75095509	CSK	-0.8	-10.53	-0.57	1.88e-21	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	cis	rs9398803	0.661	rs1262543	chr6:127032499	G/A	cg19875578	chr6:126661172	C6orf173	-0.62	-8.5	-0.49	2.23e-15	Male-pattern baldness;
SARC	cis	rs950169	0.881	rs34117475	chr15:85108443	T/C	cg17507749	chr15:85114479	UBE2QP1	0.79	9.59	0.53	1.43e-18	Schizophrenia;
SARC	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg24549020	chr5:56110836	MAP3K1	0.81	8.29	0.48	9.03e-15	Initial pursuit acceleration;
SARC	cis	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg09021430	chr5:549028	NA	-0.43	-5.51	-0.34	9.68e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg16680214	chr1:154839983	KCNN3	0.32	5.11	0.32	6.85e-7	Prostate cancer;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg09699751	chr2:232320598	NCL;SNORA75	0.45	6.26	0.38	1.84e-9	Thyroid stimulating hormone;
SARC	cis	rs9660992	0.649	rs12128254	chr1:205268097	C/T	cg00857998	chr1:205179979	DSTYK	0.43	4.93	0.31	1.54e-6	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs7179456	0.700	rs3985721	chr15:59258606	T/C	cg05156742	chr15:59063176	FAM63B	0.57	7.35	0.43	3.33e-12	Asperger disorder;
SARC	cis	rs2658782	0.756	rs2658777	chr11:93148423	C/T	cg15737290	chr11:93063684	CCDC67	0.7	7.53	0.44	1.11e-12	Pulmonary function decline;
SARC	cis	rs193541	0.632	rs154504	chr5:122204086	A/T	cg19412675	chr5:122181750	SNX24	0.51	6.85	0.41	6.43e-11	Glucose homeostasis traits;
SARC	cis	rs365302	0.672	rs396364	chr6:159611151	C/T	cg14500486	chr6:159655392	FNDC1	0.38	4.75	0.3	3.57e-6	Coronary heart disease;
SARC	cis	rs35213789	0.878	rs12669794	chr7:69564376	T/C	cg10619644	chr7:69149951	AUTS2	0.41	5.06	0.31	8.65e-7	Childhood ear infection;
SARC	cis	rs6964587	0.967	rs6970743	chr7:91744311	C/G	cg17063962	chr7:91808500	NA	0.95	15.89	0.72	5.16e-39	Breast cancer;
SARC	trans	rs3929778	1.000	rs13045192	chr20:6463017	G/A	cg00270625	chr22:51017019	CPT1B;CHKB-CPT1B	0.61	6.82	0.41	7.94e-11	QRS complex (Cornell);
SARC	cis	rs5753618	0.561	rs4820043	chr22:31647094	A/G	cg02404636	chr22:31891804	SFI1	-0.46	-4.88	-0.3	1.94e-6	Colorectal cancer;
SARC	cis	rs2273669	0.915	rs6941125	chr6:109287209	T/A	cg01304950	chr6:109416612	SESN1;C6orf182	0.54	4.8	0.3	2.87e-6	Prostate cancer;
SARC	cis	rs6831352	0.879	rs67311928	chr4:100048999	A/G	cg13256891	chr4:100009986	ADH5	-0.66	-8.28	-0.48	9.71e-15	Alcohol dependence;
SARC	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.49	5.56	0.34	7.5e-8	Renal function-related traits (BUN);
SARC	cis	rs2180341	1.000	rs7776136	chr6:127638348	A/T	cg24812749	chr6:127587940	RNF146	0.99	13.31	0.66	1.91e-30	Breast cancer;
SARC	cis	rs7589342	0.536	rs7562892	chr2:106396212	C/T	cg16077055	chr2:106428750	NCK2	0.31	6.1	0.37	4.38e-9	Addiction;
SARC	cis	rs1568889	1.000	rs9783281	chr11:28033786	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.76	10.27	0.56	1.23e-20	Bipolar disorder;
SARC	cis	rs9325144	0.600	rs1817648	chr12:38733424	C/T	cg10518543	chr12:38710700	ALG10B	-0.39	-4.83	-0.3	2.47e-6	Morning vs. evening chronotype;
SARC	cis	rs11809180	0.546	rs12059132	chr1:169401824	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.79	-5.14	-0.32	5.9e-7	Electrocardiographic traits;
SARC	cis	rs7819412	0.715	rs2409727	chr8:11043236	C/T	cg12395012	chr8:11607386	GATA4	0.33	5.49	0.34	1.02e-7	Triglycerides;
SARC	cis	rs9436747	0.641	rs12028951	chr1:66053081	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	-0.54	-5.69	-0.35	3.75e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs3762637	0.943	rs72960447	chr3:122235105	G/A	cg24169773	chr3:122142474	KPNA1	-0.58	-5.86	-0.36	1.57e-8	LDL cholesterol levels;
SARC	cis	rs7714584	1.000	rs59531858	chr5:150247063	T/G	cg22134413	chr5:150180641	NA	0.93	7.27	0.43	5.4e-12	Crohn's disease;
SARC	cis	rs7223966	1.000	rs56383601	chr17:61929968	A/C	cg00588841	chr17:61851480	DDX42;CCDC47	-0.61	-6.29	-0.38	1.55e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg22875332	chr1:76189707	ACADM	0.43	5.43	0.34	1.43e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs113835537	0.597	rs10896129	chr11:66338300	T/C	cg24851651	chr11:66362959	CCS	0.41	5.28	0.33	2.93e-7	Airway imaging phenotypes;
SARC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.55	-9.59	-0.53	1.39e-18	Longevity;Endometriosis;
SARC	cis	rs9398803	0.706	rs9388502	chr6:126909389	G/A	cg20229609	chr6:126660872	C6orf173	0.35	5.07	0.31	8.26e-7	Male-pattern baldness;
SARC	cis	rs3857536	0.813	rs7771569	chr6:66946717	C/T	cg07460842	chr6:66804631	NA	-0.45	-5.19	-0.32	4.5e-7	Blood trace element (Cu levels);
SARC	cis	rs9430161	0.598	rs34350247	chr1:11034460	A/G	cg02454025	chr1:11042201	C1orf127	0.87	12.31	0.63	3.73e-27	Ewing sarcoma;
SARC	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg05368731	chr17:41323189	NBR1	0.8	9.59	0.53	1.43e-18	Menopause (age at onset);
SARC	cis	rs2115630	1.000	rs1030863	chr15:85282635	C/T	cg12501888	chr15:85177176	SCAND2	-0.47	-5.63	-0.35	5.2e-8	P wave terminal force;
SARC	cis	rs698833	0.852	rs2241870	chr2:44549204	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.69	8.92	0.5	1.38e-16	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs9916302	0.904	rs6503506	chr17:37524653	C/A	cg20243544	chr17:37824526	PNMT	-0.55	-6.61	-0.4	2.58e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs710865	1.000	rs710865	chr1:19568972	A/G	cg13387374	chr1:19411106	UBR4	0.47	6.02	0.37	6.84e-9	Brain structure;
SARC	cis	rs6665290	0.935	rs1929863	chr1:227195728	C/T	cg14016676	chr1:227182615	CDC42BPA	0.39	5.59	0.34	6.27e-8	Myeloid white cell count;
SARC	cis	rs1801251	1.000	rs6714245	chr2:233580505	T/C	cg25237894	chr2:233734115	C2orf82	0.36	4.73	0.3	3.88e-6	Coronary artery disease;
SARC	cis	rs1008375	0.932	rs4698628	chr4:17608620	A/G	cg27347728	chr4:17578864	LAP3	0.45	5.52	0.34	8.94e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2153535	0.580	rs1832101	chr6:8460177	A/G	cg21535247	chr6:8435926	SLC35B3	0.52	6.51	0.39	4.55e-10	Motion sickness;
SARC	cis	rs9768139	0.935	rs6953748	chr7:158121184	G/A	cg25566285	chr7:158114605	PTPRN2	-0.31	-5.37	-0.33	1.91e-7	Calcium levels;
SARC	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg22974920	chr21:40686053	BRWD1	-0.45	-5.02	-0.31	1.04e-6	Cognitive function;
SARC	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg18252515	chr7:66147081	NA	0.48	5.14	0.32	5.72e-7	Aortic root size;
SARC	cis	rs883565	0.543	rs35628459	chr3:39174437	T/A	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.46	-5.37	-0.33	1.86e-7	Handedness;
SARC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg26338869	chr17:61819248	STRADA	0.81	10.89	0.58	1.38e-22	Prudent dietary pattern;
SARC	cis	rs8067545	0.750	rs4924804	chr17:19991839	C/T	cg13482628	chr17:19912719	NA	0.55	7.28	0.43	5.24e-12	Schizophrenia;
SARC	cis	rs11098499	0.954	rs3733520	chr4:120423480	C/G	cg09160332	chr4:120329925	NA	-0.36	-5.04	-0.31	9.36e-7	Corneal astigmatism;
SARC	cis	rs9916302	0.706	rs594794	chr17:37453485	T/C	cg15445000	chr17:37608096	MED1	-0.45	-4.92	-0.31	1.62e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg24829409	chr8:58192753	C8orf71	-0.6	-6.23	-0.38	2.13e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7044106	0.762	rs966397	chr9:123453312	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	5.44	0.34	1.32e-7	Hip circumference adjusted for BMI;
SARC	cis	rs9326248	0.520	rs236919	chr11:117095361	A/G	cg20270762	chr11:117014891	PAFAH1B2	0.42	5.08	0.32	7.67e-7	Blood protein levels;
SARC	cis	rs11690935	0.959	rs10207085	chr2:172585885	T/G	cg13550731	chr2:172543902	DYNC1I2	-0.99	-15.92	-0.72	4.25e-39	Schizophrenia;
SARC	cis	rs11581859	0.613	rs9728363	chr1:99233980	T/A	cg20286094	chr1:99190917	SNX7	-0.43	-5.08	-0.32	7.68e-7	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs11155671	0.530	rs6935829	chr6:150217811	C/T	cg00933542	chr6:150070202	PCMT1	0.3	5.07	0.32	8.25e-7	Testicular germ cell tumor;
SARC	cis	rs77372450	0.636	rs11949232	chr5:157011001	A/T	cg23851860	chr5:157002805	ADAM19	0.51	4.91	0.31	1.72e-6	Bipolar disorder (body mass index interaction);
SARC	cis	rs2197308	0.631	rs4882308	chr12:38446252	G/C	cg14851346	chr12:38532713	NA	-0.47	-5.76	-0.35	2.6e-8	Morning vs. evening chronotype;
SARC	cis	rs6997458	0.742	rs3758077	chr8:86375503	C/A	cg21346043	chr8:86351067	CA3	-0.34	-4.74	-0.3	3.8e-6	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs6901004	0.803	rs354531	chr6:111548933	C/T	cg15721981	chr6:111408429	SLC16A10	-0.4	-4.8	-0.3	2.8e-6	Blood metabolite levels;
SARC	cis	rs7666738	0.753	rs7657644	chr4:99057734	T/A	cg05340658	chr4:99064831	C4orf37	0.64	8.69	0.49	6.68e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9815354	0.812	rs73071307	chr3:41798699	T/C	cg03022575	chr3:42003672	ULK4	0.72	5.99	0.37	7.83e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6570726	0.935	rs428659	chr6:145827039	T/C	cg23711669	chr6:146136114	FBXO30	0.78	11.86	0.61	1.04e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2017305	0.834	rs12266901	chr10:70783522	T/C	cg01024728	chr10:70782572	NA	0.62	5.18	0.32	4.74e-7	Depression (quantitative trait);
SARC	cis	rs4808199	1.000	rs60003758	chr19:19557353	A/G	cg03709012	chr19:19516395	GATAD2A	1.18	13.34	0.66	1.52e-30	Nonalcoholic fatty liver disease;
SARC	cis	rs9896052	0.614	rs11077791	chr17:73474629	T/G	cg04121983	chr17:73511085	CASKIN2	0.43	4.94	0.31	1.48e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs2237234	1.000	rs2237234	chr6:26391394	G/A	cg12826209	chr6:26865740	GUSBL1	0.5	5.08	0.32	7.59e-7	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7833790	0.724	rs72603871	chr8:82754460	C/G	cg17211192	chr8:82754475	SNX16	0.5	6.24	0.38	2.09e-9	Diastolic blood pressure;
SARC	cis	rs709400	0.663	rs3783402	chr14:103967929	C/G	cg26031613	chr14:104095156	KLC1	0.82	11.75	0.61	2.46e-25	Body mass index;
SARC	cis	rs2952156	0.920	rs907090	chr17:37833632	T/C	cg07936489	chr17:37558343	FBXL20	-0.4	-5.28	-0.33	2.89e-7	Asthma;
SARC	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.48	5.69	0.35	3.75e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs6570726	0.935	rs368848	chr6:145855281	A/T	cg05347473	chr6:146136440	FBXO30	0.49	6.62	0.4	2.41e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg06212747	chr3:49208901	KLHDC8B	0.51	6.48	0.39	5.37e-10	Resting heart rate;
SARC	cis	rs3793683	0.928	rs10781585	chr10:134553369	C/A	cg27286337	chr10:134555280	INPP5A	-0.87	-15.03	-0.7	3.77e-36	Migraine;
SARC	cis	rs2016266	0.964	rs1110720	chr12:53682326	G/A	cg26875137	chr12:53738046	NA	0.37	5.06	0.31	8.64e-7	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs10504229	0.724	rs72649117	chr8:58037639	A/G	cg22535103	chr8:58192502	C8orf71	-0.53	-5.46	-0.34	1.24e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg25894440	chr7:65020034	NA	-0.73	-5.54	-0.34	8.32e-8	Diabetic kidney disease;
SARC	cis	rs2290402	0.536	rs2279175	chr4:852013	G/A	cg00846425	chr4:957561	DGKQ	-0.42	-4.86	-0.3	2.12e-6	Type 2 diabetes;
SARC	cis	rs11122272	0.735	rs2355872	chr1:231478489	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-9.67	-0.54	8.12e-19	Hemoglobin concentration;
SARC	cis	rs6570726	0.755	rs2092296	chr6:145893684	A/C	cg05347473	chr6:146136440	FBXO30	0.51	7.17	0.43	9.59e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1044826	1.000	rs13085888	chr3:139164874	C/T	cg15131784	chr3:139108705	COPB2	-0.47	-5.5	-0.34	1.01e-7	Obesity-related traits;
SARC	cis	rs12956009	0.518	rs10164267	chr18:44820032	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.39	4.91	0.31	1.72e-6	Educational attainment (years of education);
SARC	cis	rs7617773	0.817	rs9311421	chr3:48293078	G/A	cg11946769	chr3:48343235	NME6	0.66	8.76	0.5	4.04e-16	Coronary artery disease;
SARC	cis	rs2075371	0.501	rs1643051	chr7:134025372	A/G	cg20476274	chr7:133979776	SLC35B4	-0.4	-5.05	-0.31	9.1e-7	Mean platelet volume;
SARC	cis	rs11864453	0.762	rs6416742	chr16:72149061	C/T	cg16558253	chr16:72132732	DHX38	-0.6	-9.3	-0.52	1.09e-17	Fibrinogen levels;
SARC	cis	rs41271473	1.000	rs4641285	chr1:228878663	G/A	cg16512390	chr1:228756714	NA	0.49	4.92	0.31	1.66e-6	Chronic lymphocytic leukemia;
SARC	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg18252515	chr7:66147081	NA	1.35	12.11	0.62	1.7e-26	Diabetic kidney disease;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg17412964	chr13:31040351	HMGB1	-0.47	-6.29	-0.38	1.53e-9	Neuroticism;
SARC	cis	rs7615952	0.558	rs17334039	chr3:125540308	A/G	cg05084668	chr3:125655381	ALG1L	-0.5	-5.3	-0.33	2.68e-7	Blood pressure (smoking interaction);
SARC	trans	rs1493916	0.807	rs10775455	chr18:31310761	A/C	cg27147174	chr7:100797783	AP1S1	-0.54	-7.47	-0.44	1.64e-12	Life satisfaction;
SARC	cis	rs11792861	0.926	rs17729523	chr9:111773317	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.7	8.15	0.47	2.25e-14	Menarche (age at onset);
SARC	cis	rs2439831	0.850	rs28413881	chr15:44174099	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.81	7.48	0.44	1.46e-12	Lung cancer in ever smokers;
SARC	cis	rs2295359	0.824	rs12060309	chr1:67604219	T/C	cg03340356	chr1:67600835	NA	0.38	4.86	0.3	2.2e-6	Psoriasis;
SARC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.62	-0.4	2.4e-10	Total body bone mineral density;
SARC	cis	rs1218582	0.741	rs705094	chr1:154917314	G/A	cg03351412	chr1:154909251	PMVK	0.6	7.63	0.45	5.94e-13	Prostate cancer;
SARC	cis	rs2292864	0.764	rs72825627	chr17:45386289	C/G	cg18085866	chr17:45331354	ITGB3	-0.7	-5.22	-0.32	3.94e-7	Left atrial antero-posterior diameter;
SARC	cis	rs4555082	0.915	rs2816632	chr14:105741355	C/T	cg13114125	chr14:105738426	BRF1	0.75	11.51	0.6	1.41e-24	Mean platelet volume;Platelet distribution width;
SARC	cis	rs2204008	0.542	rs34770471	chr12:38009613	C/T	cg26384229	chr12:38710491	ALG10B	0.89	13.14	0.65	6.99e-30	Bladder cancer;
SARC	cis	rs7568458	0.870	rs6719046	chr2:85757371	G/A	cg02493740	chr2:85810744	VAMP5	-0.34	-5.03	-0.31	9.83e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs2011503	1.000	rs11670687	chr19:19621752	A/G	cg03709012	chr19:19516395	GATAD2A	0.6	5.29	0.33	2.8e-7	Bipolar disorder;
SARC	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg16325326	chr1:53192061	ZYG11B	0.72	10.43	0.56	3.78e-21	Monocyte count;
SARC	trans	rs9650657	0.530	rs6982381	chr8:10952500	A/T	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.68	-0.49	6.94e-16	Neuroticism;
SARC	cis	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg07777115	chr5:623756	CEP72	-0.57	-5.09	-0.32	7.38e-7	Obesity-related traits;
SARC	cis	rs6582630	0.638	rs12425531	chr12:38550387	A/G	cg14851346	chr12:38532713	NA	-0.44	-5.29	-0.33	2.8e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs17270561	0.609	rs7746502	chr6:25718762	T/A	cg17691542	chr6:26056736	HIST1H1C	-0.54	-6.79	-0.41	9.15e-11	Iron status biomarkers;
SARC	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg16325326	chr1:53192061	ZYG11B	0.8	12.12	0.62	1.6e-26	Monocyte count;
SARC	cis	rs2153535	0.580	rs1119690	chr6:8460660	G/A	cg23788917	chr6:8435910	SLC35B3	0.62	8.14	0.47	2.37e-14	Motion sickness;
SARC	cis	rs2013441	1.000	rs2703782	chr17:20144799	A/G	cg13482628	chr17:19912719	NA	-0.48	-6.34	-0.38	1.18e-9	Obesity-related traits;
SARC	cis	rs2777491	1.000	rs7177641	chr15:41743426	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.8	-12.11	-0.62	1.69e-26	Ulcerative colitis;
SARC	cis	rs4919694	0.572	rs12243903	chr10:104906992	T/C	cg04362960	chr10:104952993	NT5C2	0.58	5.29	0.33	2.79e-7	Arsenic metabolism;
SARC	cis	rs9436747	0.748	rs1171270	chr1:65997841	G/A	cg04111102	chr1:66153794	NA	-0.4	-4.88	-0.3	1.98e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs2404602	0.735	rs2461871	chr15:76822418	C/G	cg15268244	chr15:77196840	NA	0.41	5.1	0.32	6.89e-7	Blood metabolite levels;
SARC	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg11890956	chr21:40555474	PSMG1	1.18	19.88	0.79	4.44e-52	Cognitive function;
SARC	cis	rs6570726	0.935	rs382910	chr6:145865941	G/A	cg05220968	chr6:146057943	EPM2A	-0.29	-4.9	-0.31	1.82e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs611744	0.905	rs640950	chr8:109157819	T/A	cg21045802	chr8:109455806	TTC35	0.44	5.22	0.32	3.94e-7	Dupuytren's disease;
SARC	cis	rs208520	0.909	rs9345809	chr6:67017543	T/C	cg07460842	chr6:66804631	NA	0.84	8.59	0.49	1.29e-15	Exhaled nitric oxide output;
SARC	cis	rs793571	0.590	rs618684	chr15:59115922	A/G	cg05156742	chr15:59063176	FAM63B	0.75	10.29	0.56	1.03e-20	Schizophrenia;
SARC	cis	rs9875589	0.509	rs4684174	chr3:14048375	C/T	cg19554555	chr3:13937349	NA	-0.4	-5.14	-0.32	5.95e-7	Ovarian reserve;
SARC	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg22168489	chr12:122356033	WDR66	0.61	9.65	0.53	9.65e-19	Mean corpuscular volume;
SARC	cis	rs2635047	0.624	rs2289036	chr18:44595809	A/T	cg19077165	chr18:44547161	KATNAL2	0.4	5.2	0.32	4.46e-7	Educational attainment;
SARC	cis	rs854765	0.551	rs8070748	chr17:17859421	A/G	cg04398451	chr17:18023971	MYO15A	-0.4	-5.51	-0.34	9.71e-8	Total body bone mineral density;
SARC	cis	rs12148488	0.816	rs11854975	chr15:75363876	C/T	cg17294928	chr15:75287854	SCAMP5	0.5	6.27	0.38	1.74e-9	Caffeine consumption;
SARC	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg16405210	chr4:1374714	KIAA1530	-0.58	-7.13	-0.42	1.24e-11	Obesity-related traits;
SARC	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg14784868	chr12:69753453	YEATS4	0.51	6.77	0.41	1.04e-10	Blood protein levels;
SARC	cis	rs7103648	0.864	rs10769264	chr11:47423340	C/T	cg10504702	chr11:47789108	FNBP4	0.58	7.64	0.45	5.51e-13	Diastolic blood pressure;Systolic blood pressure;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg14230542	chr1:110577941	FAM40A	-0.55	-6.27	-0.38	1.7e-9	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs66573146	0.831	rs67702333	chr4:6983040	C/G	cg15105060	chr4:7024189	TBC1D14	-0.69	-4.92	-0.31	1.63e-6	Granulocyte percentage of myeloid white cells;
SARC	cis	rs62344088	0.590	rs61710713	chr5:181499	G/A	cg20965017	chr5:231967	SDHA	-0.85	-5.7	-0.35	3.56e-8	Asthma (childhood onset);
SARC	cis	rs79349575	0.777	rs28517720	chr17:46976756	C/G	cg16584676	chr17:46985605	UBE2Z	0.54	6.57	0.4	3.17e-10	Type 2 diabetes;
SARC	cis	rs13095912	1.000	rs13095912	chr3:185302098	G/A	cg11274856	chr3:185301563	NA	0.35	4.83	0.3	2.51e-6	Systolic blood pressure;
SARC	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg09699651	chr6:150184138	LRP11	0.5	6.07	0.37	5.16e-9	Lung cancer;
SARC	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg11843238	chr5:131593191	PDLIM4	0.42	5.7	0.35	3.55e-8	Acylcarnitine levels;
SARC	cis	rs501120	1.000	rs620356	chr10:44761073	A/C	cg09554077	chr10:44749378	NA	0.48	6.45	0.39	6.48e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.47	-6.18	-0.38	2.89e-9	Gut microbiome composition (summer);
SARC	cis	rs698833	0.886	rs2241871	chr2:44548613	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.68	8.77	0.5	3.87e-16	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs1348850	0.914	rs4893957	chr2:178380409	A/G	cg23306229	chr2:178417860	TTC30B	0.55	6.29	0.38	1.55e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2288912	0.838	rs7251503	chr19:45455715	C/G	cg20090143	chr19:45452003	APOC2	0.31	4.99	0.31	1.18e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs17376456	0.569	rs11135394	chr5:93187135	C/T	cg21475434	chr5:93447410	FAM172A	-0.56	-5.8	-0.36	2.1e-8	Diabetic retinopathy;
SARC	cis	rs2120243	0.539	rs12638732	chr3:157113871	T/C	cg24825693	chr3:157122686	VEPH1	-0.46	-6.41	-0.39	8.16e-10	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs4566357	1.000	rs1917129	chr2:227927951	A/T	cg11843606	chr2:227700838	RHBDD1	-0.38	-4.87	-0.3	2.11e-6	Coronary artery disease;
SARC	cis	rs2075371	1.000	rs2058976	chr7:133981379	G/T	cg11752832	chr7:134001865	SLC35B4	0.57	7.45	0.44	1.78e-12	Mean platelet volume;
SARC	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg16325326	chr1:53192061	ZYG11B	0.8	12.39	0.63	2.1e-27	Monocyte count;
SARC	cis	rs3126085	0.935	rs4845429	chr1:152225376	G/C	cg03465714	chr1:152285911	FLG	-0.45	-5.47	-0.34	1.15e-7	Atopic dermatitis;
SARC	cis	rs3812831	0.695	rs8000778	chr13:114944310	T/C	cg06611532	chr13:114900021	NA	0.36	6.21	0.38	2.42e-9	Schizophrenia;
SARC	cis	rs2529049	0.606	rs2721779	chr7:24729082	A/G	cg17569154	chr7:24781545	DFNA5	0.46	6.53	0.39	4.11e-10	Urate levels in obese individuals;
SARC	trans	rs7815944	1.000	rs11786998	chr8:129458698	T/A	cg17342469	chr22:46473074	NA	0.68	6.44	0.39	6.88e-10	Atopic dermatitis;
SARC	cis	rs7633857	0.536	rs1447609	chr3:160696311	A/G	cg03342759	chr3:160939853	NMD3	-0.47	-5.67	-0.35	4.11e-8	Educational attainment (years of education);
SARC	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg27541892	chr1:1571801	CDK11B	0.41	5.6	0.34	5.95e-8	Body mass index;
SARC	cis	rs9916302	0.851	rs11078907	chr17:37662954	C/T	cg15445000	chr17:37608096	MED1	0.4	4.75	0.3	3.6e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg13770153	chr20:60521292	NA	-0.52	-7.36	-0.43	3.05e-12	Body mass index;
SARC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg26338869	chr17:61819248	STRADA	-0.69	-9.11	-0.51	3.94e-17	Prudent dietary pattern;
SARC	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.51	6.04	0.37	5.91e-9	Calcium levels;
SARC	trans	rs10506458	1.000	rs11174759	chr12:63444363	A/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.76	-6.85	-0.41	6.41e-11	Hemostatic factors and hematological phenotypes;
SARC	cis	rs6088590	0.707	rs67159833	chr20:33488079	T/C	cg24642439	chr20:33292090	TP53INP2	0.73	8.82	0.5	2.65e-16	Coronary artery disease;
SARC	cis	rs35213789	0.887	rs981291	chr7:69071656	G/A	cg10619644	chr7:69149951	AUTS2	-0.44	-5.73	-0.35	3.08e-8	Childhood ear infection;
SARC	trans	rs1814175	0.587	rs7937757	chr11:49978342	G/A	cg15704280	chr7:45808275	SEPT13	-0.89	-14.17	-0.68	2.8e-33	Height;
SARC	cis	rs6570726	0.791	rs621382	chr6:145799144	T/C	cg05347473	chr6:146136440	FBXO30	0.51	7.03	0.42	2.28e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg11987759	chr7:65425863	GUSB	-0.47	-6.23	-0.38	2.17e-9	Aortic root size;
SARC	cis	rs6558174	0.930	rs1038311	chr8:22489247	T/C	cg03733263	chr8:22462867	KIAA1967	0.54	6.35	0.38	1.1e-9	Breast cancer;
SARC	cis	rs2073300	0.609	rs17757442	chr20:23421101	A/G	cg16736954	chr20:23401023	NAPB	-0.77	-4.79	-0.3	3.02e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs910316	0.763	rs12588981	chr14:75460561	A/G	cg11812906	chr14:75593930	NEK9	0.8	11.01	0.58	5.76e-23	Height;
SARC	cis	rs17539620	0.624	rs12665520	chr6:154835273	C/T	cg17771515	chr6:154831774	CNKSR3	0.54	5.15	0.32	5.51e-7	Lipoprotein (a) levels;
SARC	cis	rs7937682	0.602	rs4936804	chr11:111743851	A/C	cg22437258	chr11:111473054	SIK2	-0.48	-5.53	-0.34	8.7e-8	Primary sclerosing cholangitis;
SARC	cis	rs963731	0.649	rs1454221	chr2:39215672	C/T	cg04010122	chr2:39346883	SOS1	-1.06	-6.29	-0.38	1.58e-9	Corticobasal degeneration;
SARC	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg12756686	chr19:29218302	NA	0.71	9.39	0.52	5.83e-18	Methadone dose in opioid dependence;
SARC	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg13126279	chr21:47581558	C21orf56	-0.42	-5.17	-0.32	5.07e-7	Testicular germ cell tumor;
SARC	cis	rs11581859	0.613	rs12057921	chr1:99199446	T/C	cg20286094	chr1:99190917	SNX7	-0.42	-4.99	-0.31	1.2e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	trans	rs17685	0.784	rs1637043	chr7:75699099	G/A	cg19862616	chr7:65841803	NCRNA00174	0.63	7.83	0.46	1.68e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs9875589	0.509	rs2168718	chr3:14084157	A/G	cg19554555	chr3:13937349	NA	-0.4	-5.18	-0.32	4.83e-7	Ovarian reserve;
SARC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.79	-10.32	-0.56	8.26e-21	Prudent dietary pattern;
SARC	cis	rs7824557	0.564	rs6601584	chr8:11232343	C/G	cg00262122	chr8:11665843	FDFT1	-0.39	-4.72	-0.3	4.11e-6	Retinal vascular caliber;
SARC	cis	rs2859741	0.546	rs3934329	chr1:37504523	C/T	cg09363841	chr1:37513479	NA	-0.3	-5.15	-0.32	5.6e-7	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
SARC	cis	rs62244186	0.545	rs9284880	chr3:44759389	C/T	cg15687855	chr3:44754131	ZNF502	-0.32	-4.76	-0.3	3.36e-6	Depressive symptoms;
SARC	cis	rs9818758	0.607	rs67831908	chr3:49313513	T/G	cg07636037	chr3:49044803	WDR6	-0.75	-6.54	-0.39	3.94e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs7020830	0.898	rs495863	chr9:37346955	T/C	cg14294708	chr9:37120828	ZCCHC7	1.11	20.0	0.79	1.78e-52	Schizophrenia;
SARC	cis	rs611744	0.625	rs4735055	chr8:109286642	G/A	cg21045802	chr8:109455806	TTC35	0.67	8.53	0.49	1.9e-15	Dupuytren's disease;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg24731597	chr1:95392380	CNN3	0.48	6.35	0.38	1.1e-9	Chemerin levels;
SARC	cis	rs1008375	0.932	rs6449315	chr4:17590219	A/G	cg27347728	chr4:17578864	LAP3	0.53	6.49	0.39	4.99e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9393777	0.513	rs9379905	chr6:26630990	G/A	cg12826209	chr6:26865740	GUSBL1	0.63	5.69	0.35	3.84e-8	Intelligence (multi-trait analysis);
SARC	cis	rs5753618	0.561	rs2040533	chr22:31679110	G/C	cg13145458	chr22:31556086	RNF185	0.47	5.07	0.32	8.12e-7	Colorectal cancer;
SARC	cis	rs2033732	1.000	rs2033732	chr8:85079709	T/C	cg05716166	chr8:85095498	RALYL	0.56	6.57	0.4	3.26e-10	Body mass index;
SARC	cis	rs1983170	0.736	rs11589162	chr1:91974743	C/G	cg25838465	chr1:92012736	NA	0.57	5.64	0.35	4.93e-8	Eosinophil percentage of white cells;
SARC	cis	rs981844	0.775	rs17299519	chr4:154762123	C/T	cg14289246	chr4:154710475	SFRP2	0.61	6.97	0.42	3.21e-11	Response to statins (LDL cholesterol change);
SARC	cis	rs4268898	0.662	rs72793208	chr2:24510284	C/T	cg26838691	chr2:24397539	C2orf84	-0.48	-5.55	-0.34	7.73e-8	Asthma;
SARC	cis	rs5167	0.504	rs7248162	chr19:45454686	T/C	cg09555818	chr19:45449301	APOC2	0.55	8.91	0.5	1.5e-16	Blood protein levels;
SARC	cis	rs2463822	1.000	rs115395195	chr11:62100353	G/A	cg06239285	chr11:62104954	ASRGL1	-0.87	-8.4	-0.48	4.41e-15	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs16944613	0.636	rs6416552	chr15:91132111	T/C	cg26821196	chr15:91095069	CRTC3	0.55	5.89	0.36	1.36e-8	Colorectal cancer;
SARC	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg03264133	chr6:25882463	NA	-0.35	-4.79	-0.3	2.94e-6	Blood metabolite levels;
SARC	cis	rs7819412	0.521	rs2409720	chr8:11037903	A/C	cg21775007	chr8:11205619	TDH	-0.44	-5.71	-0.35	3.43e-8	Triglycerides;
SARC	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg24060327	chr5:131705240	SLC22A5	-0.43	-5.21	-0.32	4.2e-7	Blood metabolite levels;
SARC	cis	rs11252926	0.545	rs11252693	chr10:532139	A/G	cg08603382	chr10:743973	NA	0.36	4.76	0.3	3.39e-6	Psychosis in Alzheimer's disease;
SARC	cis	rs6570726	0.935	rs906774	chr6:145813770	T/C	cg05220968	chr6:146057943	EPM2A	-0.29	-4.83	-0.3	2.44e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10463316	0.817	rs1318783	chr5:150814807	T/G	cg03212797	chr5:150827313	SLC36A1	-0.46	-5.47	-0.34	1.18e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs10982256	0.817	rs2297814	chr9:117267172	G/A	cg21159778	chr9:117266918	DFNB31	0.39	5.51	0.34	9.57e-8	Bipolar disorder;
SARC	cis	rs12458130	0.892	rs539715	chr18:8667407	A/G	cg25899954	chr18:8660164	NA	-0.67	-6.01	-0.37	6.98e-9	Inflammatory skin disease;
SARC	cis	rs4727027	0.933	rs4727028	chr7:148874666	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.44	-5.57	-0.34	7e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs7762018	1.000	rs6912959	chr6:170126224	G/A	cg00262263	chr6:170184901	NA	0.39	4.75	0.3	3.51e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	trans	rs57046232	0.502	rs17794544	chr20:6460319	A/T	cg27502912	chr22:51017001	CPT1B;CHKB-CPT1B	0.6	6.28	0.38	1.6e-9	Colorectal cancer;
SARC	cis	rs67460515	0.563	rs9876142	chr3:160780968	A/G	cg17135325	chr3:160939158	NMD3	-0.56	-6.32	-0.38	1.31e-9	Parkinson's disease;
SARC	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg05025164	chr4:1340916	KIAA1530	-0.46	-5.34	-0.33	2.22e-7	Obesity-related traits;
SARC	cis	rs35110281	0.776	rs2838338	chr21:45075582	T/C	cg01579765	chr21:45077557	HSF2BP	-0.37	-6.34	-0.38	1.2e-9	Mean corpuscular volume;
SARC	trans	rs17221829	0.733	rs11018668	chr11:89356178	C/T	cg19803735	chr11:111807800	DIXDC1	-0.48	-6.46	-0.39	5.99e-10	Anxiety in major depressive disorder;
SARC	cis	rs7264396	0.635	rs6060703	chr20:34529906	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.52	5.27	0.33	3.18e-7	Total cholesterol levels;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg22424536	chr5:175792478	ARL10	-0.5	-6.31	-0.38	1.38e-9	Height;
SARC	cis	rs3768617	0.510	rs2296292	chr1:183086757	A/C	cg13390022	chr1:182993471	LAMC1	0.32	4.83	0.3	2.44e-6	Fuchs's corneal dystrophy;
SARC	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg12564285	chr5:131593104	PDLIM4	0.37	5.37	0.33	1.92e-7	Blood metabolite levels;
SARC	cis	rs4974559	0.594	rs11946384	chr4:1313566	T/C	cg02980000	chr4:1222292	CTBP1	0.61	5.79	0.35	2.3e-8	Systolic blood pressure;
SARC	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg24531977	chr5:56204891	C5orf35	-0.54	-5.45	-0.34	1.26e-7	Initial pursuit acceleration;
SARC	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg20607798	chr8:58055168	NA	0.57	5.53	0.34	8.58e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2070997	0.607	rs2314342	chr9:133707362	A/G	cg11464064	chr9:133710261	ABL1	0.59	5.25	0.33	3.4e-7	Response to amphetamines;
SARC	cis	rs1832871	0.711	rs9459946	chr6:158707957	T/C	cg07165851	chr6:158734300	TULP4	0.54	6.56	0.39	3.5e-10	Height;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg16754766	chr12:42877927	PRICKLE1	0.83	7.0	0.42	2.79e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1008375	0.966	rs3775924	chr4:17585984	T/C	cg16339924	chr4:17578868	LAP3	0.69	9.17	0.51	2.59e-17	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs17030434	1.000	rs12646124	chr4:154718084	G/T	cg14289246	chr4:154710475	SFRP2	-0.77	-7.02	-0.42	2.39e-11	Electrocardiographic conduction measures;
SARC	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg19223190	chr17:80058835	NA	0.44	6.19	0.38	2.67e-9	Life satisfaction;
SARC	cis	rs7909074	0.831	rs2065466	chr10:45384047	T/C	cg04218760	chr10:45406644	TMEM72	-0.26	-5.07	-0.32	8.11e-7	Mean corpuscular volume;
SARC	cis	rs17270561	0.609	rs1892255	chr6:25750354	G/A	cg17691542	chr6:26056736	HIST1H1C	0.59	7.2	0.43	8.15e-12	Iron status biomarkers;
SARC	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg24549020	chr5:56110836	MAP3K1	0.53	5.92	0.36	1.14e-8	Initial pursuit acceleration;
SARC	cis	rs11578119	0.933	rs1888173	chr1:170530657	A/G	cg09767346	chr1:170501363	GORAB	0.45	5.35	0.33	2.13e-7	Male-pattern baldness;
SARC	cis	rs910316	0.935	rs3742771	chr14:75599647	A/G	cg08847533	chr14:75593920	NEK9	0.91	15.06	0.7	2.95e-36	Height;
SARC	cis	rs3733585	0.638	rs7377625	chr4:9953099	T/C	cg11266682	chr4:10021025	SLC2A9	-0.35	-6.02	-0.37	6.77e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs8078723	0.802	rs9303283	chr17:38192633	A/G	cg17467752	chr17:38218738	THRA	0.67	9.67	0.54	8.22e-19	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.55	6.09	0.37	4.62e-9	Prudent dietary pattern;
SARC	trans	rs116095464	0.558	rs6879656	chr5:264428	T/C	cg00938859	chr5:1591904	SDHAP3	0.77	6.73	0.4	1.27e-10	Breast cancer;
SARC	cis	rs208520	0.690	rs207114	chr6:66791703	C/T	cg07460842	chr6:66804631	NA	-1.1	-14.94	-0.7	7.43e-36	Exhaled nitric oxide output;
SARC	cis	rs734999	0.545	rs28532547	chr1:2561286	T/G	cg00980319	chr1:2560884	MMEL1	0.34	4.9	0.31	1.83e-6	Ulcerative colitis;
SARC	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg19223190	chr17:80058835	NA	0.48	6.57	0.4	3.24e-10	Life satisfaction;
SARC	trans	rs11165623	0.740	rs11165638	chr1:96921357	C/A	cg10631902	chr5:14652156	NA	-0.48	-7.83	-0.46	1.7e-13	Hip circumference;Waist circumference;
SARC	cis	rs2481665	0.772	rs6681153	chr1:62536469	T/C	cg18591186	chr1:62594603	INADL	-0.5	-6.92	-0.41	4.28e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs3796352	1.000	rs71301809	chr3:53090312	C/T	cg27565382	chr3:53032988	SFMBT1	0.98	6.93	0.41	4.19e-11	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	12.62	0.64	3.67e-28	Platelet count;
SARC	cis	rs6088580	0.634	rs6087577	chr20:32955423	C/T	cg08999081	chr20:33150536	PIGU	0.41	6.29	0.38	1.59e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs2387326	0.717	rs12254442	chr10:129945793	C/T	cg16087940	chr10:129947807	NA	-0.45	-5.79	-0.35	2.31e-8	Select biomarker traits;
SARC	cis	rs950776	0.593	rs601079	chr15:78869579	T/A	cg06917634	chr15:78832804	PSMA4	-0.84	-12.6	-0.64	4.24e-28	Sudden cardiac arrest;
SARC	cis	rs6500602	0.702	rs3789038	chr16:4546586	C/G	cg08645402	chr16:4508243	NA	-0.4	-5.47	-0.34	1.13e-7	Schizophrenia;
SARC	cis	rs6834538	0.928	rs10434015	chr4:113401363	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.47	5.71	0.35	3.35e-8	Free thyroxine concentration;
SARC	cis	rs9790314	0.715	rs7622047	chr3:160770505	G/A	cg04691961	chr3:161091175	C3orf57	-0.6	-8.18	-0.47	1.82e-14	Morning vs. evening chronotype;
SARC	cis	rs3106136	0.807	rs7657805	chr4:95273659	C/T	cg11021082	chr4:95130006	SMARCAD1	0.35	5.43	0.34	1.38e-7	Capecitabine sensitivity;
SARC	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4253772	0.591	rs10854854	chr22:46684706	C/G	cg24881330	chr22:46731750	TRMU	0.65	4.93	0.31	1.53e-6	LDL cholesterol;Cholesterol, total;
SARC	cis	rs10752881	0.875	rs10752894	chr1:183050610	A/G	cg13390022	chr1:182993471	LAMC1	0.33	5.06	0.31	8.41e-7	Colorectal cancer;
SARC	cis	rs5167	0.525	rs10402642	chr19:45453878	G/A	cg13119609	chr19:45449297	APOC2	0.5	8.44	0.48	3.4e-15	Blood protein levels;
SARC	cis	rs9325144	0.671	rs7306605	chr12:38730471	C/T	cg26384229	chr12:38710491	ALG10B	0.61	8.08	0.47	3.41e-14	Morning vs. evening chronotype;
SARC	cis	rs11722228	0.964	rs10939614	chr4:9926613	T/C	cg00071950	chr4:10020882	SLC2A9	-0.32	-4.82	-0.3	2.64e-6	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs920590	0.758	rs1826420	chr8:19664878	G/T	cg03894339	chr8:19674705	INTS10	0.56	6.72	0.4	1.4e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.56	6.44	0.39	6.62e-10	Prudent dietary pattern;
SARC	cis	rs4253772	0.591	rs6008365	chr22:46652929	G/A	cg24881330	chr22:46731750	TRMU	0.62	6.86	0.41	6.14e-11	LDL cholesterol;Cholesterol, total;
SARC	cis	rs6466055	0.692	rs4727621	chr7:105028370	T/C	cg04380332	chr7:105027541	SRPK2	-0.41	-4.75	-0.3	3.61e-6	Schizophrenia;
SARC	cis	rs1401999	1.000	rs10937158	chr3:183708439	T/C	cg01324343	chr3:183735012	ABCC5	0.66	13.24	0.66	3.19e-30	Anterior chamber depth;
SARC	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg27266027	chr21:40555129	PSMG1	-0.5	-5.5	-0.34	9.74e-8	Cognitive function;
SARC	cis	rs240764	0.853	rs4461738	chr6:100977940	T/C	cg09795085	chr6:101329169	ASCC3	-0.46	-6.04	-0.37	5.97e-9	Neuroticism;
SARC	cis	rs7617773	0.694	rs13099560	chr3:48204768	C/T	cg11946769	chr3:48343235	NME6	-0.64	-8.51	-0.49	2.08e-15	Coronary artery disease;
SARC	cis	rs2816062	0.813	rs2816040	chr1:18889536	C/T	cg10574377	chr1:18908098	NA	-0.37	-5.3	-0.33	2.64e-7	Urate levels in lean individuals;
SARC	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.85	12.84	0.64	6.58e-29	Chronic sinus infection;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg04749066	chr2:192746843	NA	0.55	7.01	0.42	2.57e-11	Breast cancer;
SARC	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.5	-5.81	-0.36	2.07e-8	Blood metabolite levels;
SARC	cis	rs16921914	0.565	rs286650	chr11:31230207	T/C	cg02090638	chr11:31391270	DNAJC24;DCDC1	-0.4	-5.01	-0.31	1.08e-6	Bone mineral density (spine);
SARC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.7	9.17	0.52	2.54e-17	Lymphocyte counts;
SARC	cis	rs832540	0.629	rs3309	chr5:56092779	A/T	cg24549020	chr5:56110836	MAP3K1	-0.48	-5.5	-0.34	9.99e-8	Coronary artery disease;
SARC	cis	rs854765	0.663	rs16960744	chr17:17755259	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.6	-8.81	-0.5	2.86e-16	Total body bone mineral density;
SARC	cis	rs1345301	0.587	rs10186746	chr2:102866377	G/A	cg12451869	chr2:102867685	NA	0.43	5.93	0.36	1.07e-8	Waist circumference;
SARC	cis	rs35306767	0.903	rs11815185	chr10:923617	T/A	cg20503657	chr10:835505	NA	0.88	8.48	0.49	2.64e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs4555082	0.874	rs28625632	chr14:105748849	G/T	cg10792982	chr14:105748885	BRF1	0.55	8.22	0.47	1.45e-14	Mean platelet volume;Platelet distribution width;
SARC	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.7	6.58	0.4	3.05e-10	Platelet count;
SARC	cis	rs7223966	0.960	rs113155878	chr17:61706560	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.51	-5.27	-0.33	3.12e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2228479	0.572	rs62054252	chr16:89896834	G/A	cg12064134	chr16:90016061	DEF8	-0.56	-4.9	-0.31	1.77e-6	Skin colour saturation;
SARC	cis	rs965469	1.000	rs6037560	chr20:3323055	T/C	cg25506879	chr20:3388711	C20orf194	-0.52	-5.34	-0.33	2.23e-7	IFN-related cytopenia;
SARC	cis	rs7927771	1.000	rs10838748	chr11:47716381	T/G	cg20307385	chr11:47447363	PSMC3	-0.49	-5.95	-0.36	9.6e-9	Subjective well-being;
SARC	cis	rs6087990	0.965	rs6058869	chr20:31348750	C/T	cg13636640	chr20:31349939	DNMT3B	0.8	12.83	0.64	7.31e-29	Ulcerative colitis;
SARC	cis	rs79839061	0.666	rs62297063	chr4:869708	G/A	cg07828340	chr4:882639	GAK	0.77	5.87	0.36	1.52e-8	Intelligence (multi-trait analysis);
SARC	cis	rs748404	0.631	rs11070399	chr15:43646347	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	5.78	0.35	2.37e-8	Lung cancer;
SARC	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg11987759	chr7:65425863	GUSB	-0.62	-8.24	-0.48	1.25e-14	Aortic root size;
SARC	cis	rs829883	0.659	rs12366275	chr12:98920276	G/C	cg25150519	chr12:98850993	NA	-0.64	-7.8	-0.46	2.01e-13	Colorectal adenoma (advanced);
SARC	cis	rs1904096	0.506	rs10028613	chr4:95223698	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.46	-6.46	-0.39	5.92e-10	Type 2 diabetes;
SARC	cis	rs2153904	0.793	rs1891091	chr1:205661418	A/G	cg23034840	chr1:205782522	SLC41A1	0.67	5.74	0.35	2.96e-8	Prostate-specific antigen levels;
SARC	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg26850624	chr5:429559	AHRR	-0.31	-4.77	-0.3	3.21e-6	Cystic fibrosis severity;
SARC	cis	rs754466	0.580	rs10824571	chr10:79531931	G/A	cg17075019	chr10:79541650	NA	-0.84	-13.0	-0.65	2.07e-29	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2425143	1.000	rs56052651	chr20:34344084	C/T	cg01084648	chr20:34329383	RBM39	0.63	5.02	0.31	1.03e-6	Blood protein levels;
SARC	cis	rs17600642	0.855	rs2024464	chr10:72467944	A/G	cg19779893	chr10:72451501	ADAMTS14	-0.47	-7.16	-0.42	1.04e-11	Bipolar disorder;
SARC	cis	rs7027203	0.576	rs7862149	chr9:96546778	A/G	cg14598338	chr9:96623480	NA	0.34	4.76	0.3	3.42e-6	DNA methylation (variation);
SARC	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg01475735	chr3:40494733	NA	0.47	5.09	0.32	7.32e-7	Renal cell carcinoma;
SARC	cis	rs1182196	0.533	rs2527521	chr7:2904928	A/G	cg13628971	chr7:2884303	GNA12	-0.39	-5.11	-0.32	6.76e-7	Plateletcrit;
SARC	cis	rs8031584	0.918	rs34095794	chr15:31269691	C/T	cg19680485	chr15:31195859	MTMR15	-0.51	-5.95	-0.36	9.62e-9	Huntington's disease progression;
SARC	cis	rs7106204	0.514	rs2068454	chr11:24256166	C/G	ch.11.24196551F	chr11:24239977	NA	-0.65	-7.04	-0.42	2.18e-11	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs6489785	0.525	rs558275	chr12:121196891	A/G	cg02403541	chr12:121454288	C12orf43	0.44	5.02	0.31	1.02e-6	Longevity;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg11494091	chr17:61959527	GH2	0.53	7.86	0.46	1.4e-13	Prudent dietary pattern;
SARC	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg11764359	chr7:65958608	NA	-0.72	-8.42	-0.48	3.77e-15	Aortic root size;
SARC	cis	rs1943345	0.556	rs523414	chr11:82910666	C/G	cg07047830	chr11:82868014	PCF11	0.47	6.0	0.37	7.56e-9	Obesity-related traits;
SARC	cis	rs6598955	0.543	rs6699798	chr1:26556442	G/T	cg04990556	chr1:26633338	UBXN11	0.76	7.81	0.46	1.92e-13	Obesity-related traits;
SARC	cis	rs11711311	0.712	rs6795099	chr3:113338782	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.5	6.17	0.37	3.04e-9	IgG glycosylation;
SARC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg14893161	chr1:205819251	PM20D1	-0.92	-14.05	-0.68	6.62e-33	Menarche (age at onset);
SARC	cis	rs7666738	0.830	rs12233741	chr4:98950296	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10754283	0.934	rs1934043	chr1:90106645	C/T	cg21401794	chr1:90099060	LRRC8C	0.59	8.1	0.47	2.99e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs12048904	0.505	rs11166511	chr1:101240686	G/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.7	-8.34	-0.48	6.63e-15	Multiple sclerosis;
SARC	cis	rs4427176	0.769	rs6601341	chr8:9506176	C/T	cg21625330	chr8:9911636	MSRA	0.59	5.08	0.32	7.78e-7	Mosquito bite size;
SARC	cis	rs9788721	0.836	rs11858836	chr15:78783277	G/A	cg18825076	chr15:78729989	IREB2	-0.53	-6.28	-0.38	1.67e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs208520	0.526	rs9363522	chr6:66816642	C/T	cg07460842	chr6:66804631	NA	-1.12	-22.45	-0.83	3.48e-60	Exhaled nitric oxide output;
SARC	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.41	-6.32	-0.38	1.28e-9	Total body bone mineral density;
SARC	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.49	5.95	0.36	9.64e-9	Gut microbiome composition (summer);
SARC	cis	rs2841277	0.741	rs9672139	chr14:105408182	T/G	cg21017887	chr14:105400489	NA	0.53	7.3	0.43	4.45e-12	Rheumatoid arthritis;
SARC	cis	rs72945132	0.882	rs7950916	chr11:70210001	T/C	cg00319359	chr11:70116639	PPFIA1	0.67	6.21	0.38	2.36e-9	Coronary artery disease;
SARC	trans	rs931812	0.895	rs4734016	chr8:101910071	C/T	cg20993868	chr7:22813445	NA	0.48	6.31	0.38	1.39e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs2718058	0.589	rs10258880	chr7:37793033	C/T	cg24998770	chr7:37888106	TXNDC3	-0.31	-4.71	-0.3	4.18e-6	Alzheimer's disease (late onset);
SARC	cis	rs79149102	0.649	rs2305667	chr15:75144543	G/A	cg09165964	chr15:75287851	SCAMP5	-1.14	-7.0	-0.42	2.72e-11	Lung cancer;
SARC	cis	rs3020736	0.500	rs6002623	chr22:42513761	G/A	cg15557168	chr22:42548783	NA	0.36	4.92	0.31	1.62e-6	Autism spectrum disorder or schizophrenia;
SARC	trans	rs61931739	0.500	rs11053201	chr12:34453903	T/A	cg13010199	chr12:38710504	ALG10B	0.81	11.29	0.59	7.09e-24	Morning vs. evening chronotype;
SARC	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg03213289	chr20:61660250	NA	0.46	6.43	0.39	7.22e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs6840360	1.000	rs3749563	chr4:152596508	T/C	cg22705602	chr4:152727874	NA	-0.36	-6.14	-0.37	3.6e-9	Intelligence (multi-trait analysis);
SARC	cis	rs6860806	0.531	rs274556	chr5:131722075	A/G	cg11843238	chr5:131593191	PDLIM4	-0.4	-4.96	-0.31	1.33e-6	Breast cancer;
SARC	cis	rs7714584	1.000	rs931058	chr5:150333698	A/T	cg22134413	chr5:150180641	NA	0.85	6.5	0.39	4.84e-10	Crohn's disease;
SARC	cis	rs9682041	0.627	rs6786374	chr3:170105233	A/G	cg11886554	chr3:170076028	SKIL	-0.62	-6.18	-0.38	2.86e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs4481887	0.893	rs4512685	chr1:248446246	C/T	cg13385794	chr1:248469461	NA	0.34	5.13	0.32	6.09e-7	Common traits (Other);
SARC	cis	rs7818688	0.697	rs74553842	chr8:95984392	C/T	cg13393036	chr8:95962371	TP53INP1	0.4	4.84	0.3	2.34e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs10752881	1.000	rs10752886	chr1:182987248	A/G	cg13390022	chr1:182993471	LAMC1	0.35	5.24	0.32	3.63e-7	Colorectal cancer;
SARC	cis	rs2228479	0.850	rs62054257	chr16:89900195	G/A	cg00800038	chr16:89945340	TCF25	-0.82	-5.77	-0.35	2.46e-8	Skin colour saturation;
SARC	cis	rs6991838	0.584	rs7841652	chr8:66518627	T/G	cg13398993	chr8:66546079	ARMC1	-0.62	-8.19	-0.47	1.72e-14	Intelligence (multi-trait analysis);
SARC	trans	rs10506458	1.000	rs12580997	chr12:63433420	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.73	-6.79	-0.41	9.13e-11	Hemostatic factors and hematological phenotypes;
SARC	cis	rs761746	0.920	rs5753662	chr22:31901432	G/A	cg15823100	chr22:32027580	PISD	0.35	5.04	0.31	9.46e-7	Intelligence;
SARC	cis	rs67460515	0.892	rs34771618	chr3:161059795	A/C	cg17135325	chr3:160939158	NMD3	0.63	8.16	0.47	2.08e-14	Parkinson's disease;
SARC	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.51	6.03	0.37	6.23e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7264396	0.563	rs6058302	chr20:34290037	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-7.17	-0.43	9.99e-12	Total cholesterol levels;
SARC	cis	rs6977660	0.714	rs12666488	chr7:19788403	G/A	cg05791153	chr7:19748676	TWISTNB	0.73	6.43	0.39	7.21e-10	Thyroid stimulating hormone;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg09155575	chr17:38084037	ORMDL3	-0.64	-7.23	-0.43	6.73e-12	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs875971	1.000	rs1183245	chr7:65541185	C/T	cg11764359	chr7:65958608	NA	-0.85	-11.95	-0.62	5.53e-26	Aortic root size;
SARC	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg22307029	chr19:49891270	CCDC155	0.62	7.41	0.44	2.33e-12	Multiple sclerosis;
SARC	cis	rs1670533	1.000	rs935970	chr4:1045323	C/G	cg27284194	chr4:1044797	NA	-0.46	-5.09	-0.32	7.49e-7	Recombination rate (females);
SARC	cis	rs2304069	0.909	rs30831	chr5:149359053	C/T	cg12661370	chr5:149340060	SLC26A2	-0.55	-5.28	-0.33	2.94e-7	HIV-1 control;
SARC	cis	rs7786877	0.500	rs2272572	chr7:100285888	C/T	cg16850897	chr7:100343110	ZAN	-0.65	-6.87	-0.41	5.67e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs981844	0.857	rs62325141	chr4:154716407	A/G	cg14289246	chr4:154710475	SFRP2	0.66	7.04	0.42	2.15e-11	Response to statins (LDL cholesterol change);
SARC	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.8	7.85	0.46	1.48e-13	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs11168351	0.833	rs6580652	chr12:48447105	C/A	cg24011408	chr12:48396354	COL2A1	-0.41	-4.92	-0.31	1.64e-6	Bipolar disorder and schizophrenia;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg14163061	chr2:44223239	LRPPRC	-0.51	-6.59	-0.4	2.97e-10	Schizophrenia;
SARC	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg11890956	chr21:40555474	PSMG1	1.18	20.03	0.8	1.43e-52	Cognitive function;
SARC	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg04166393	chr7:2884313	GNA12	-0.53	-6.24	-0.38	2.02e-9	Height;
SARC	cis	rs35110281	0.626	rs162388	chr21:44936032	G/A	cg21573476	chr21:45109991	RRP1B	-0.45	-6.67	-0.4	1.79e-10	Mean corpuscular volume;
SARC	trans	rs8073060	0.586	rs6505486	chr17:33996776	G/A	cg19694781	chr19:47549865	TMEM160	-0.71	-7.06	-0.42	1.85e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs829883	0.932	rs249840	chr12:98871993	T/C	cg25150519	chr12:98850993	NA	0.69	9.36	0.52	6.96e-18	Colorectal adenoma (advanced);
SARC	cis	rs6753739	0.784	rs437512	chr2:219926168	T/C	cg24212621	chr2:219920517	IHH	0.36	4.86	0.3	2.17e-6	Height;
SARC	cis	rs7937890	0.732	rs7946902	chr11:14273308	C/T	cg02886208	chr11:14281011	SPON1	0.43	5.75	0.35	2.76e-8	Mitochondrial DNA levels;
SARC	cis	rs6121246	0.865	rs6058421	chr20:30295013	G/C	cg13852791	chr20:30311386	BCL2L1	0.86	9.16	0.51	2.76e-17	Mean corpuscular hemoglobin;
SARC	trans	rs7824557	0.527	rs4631425	chr8:11239054	C/T	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.76	-0.45	2.68e-13	Retinal vascular caliber;
SARC	cis	rs11792861	0.816	rs113624314	chr9:111689953	G/A	cg13535736	chr9:111863775	C9orf5	-0.38	-4.78	-0.3	3.12e-6	Menarche (age at onset);
SARC	cis	rs1318878	0.565	rs11056439	chr12:15500183	G/A	cg08258403	chr12:15378311	NA	0.51	7.08	0.42	1.68e-11	Intelligence (multi-trait analysis);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg23391324	chr15:73344290	NEO1	-0.81	-6.9	-0.41	4.83e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7772486	0.790	rs9497424	chr6:146225271	C/A	cg05347473	chr6:146136440	FBXO30	-0.47	-6.43	-0.39	7.28e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10876993	0.784	rs10083154	chr12:58020933	G/A	cg18357645	chr12:58087776	OS9	-0.42	-5.26	-0.33	3.26e-7	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg09699651	chr6:150184138	LRP11	0.49	5.93	0.36	1.06e-8	Lung cancer;
SARC	cis	rs924607	0.966	rs1709554	chr5:637443	A/G	cg09021430	chr5:549028	NA	-0.34	-6.44	-0.39	6.82e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs1395	0.922	rs13404327	chr2:27519153	G/T	cg21747090	chr2:27597821	SNX17	-0.45	-5.41	-0.33	1.54e-7	Blood metabolite levels;
SARC	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.44	5.51	0.34	9.56e-8	Electroencephalogram traits;
SARC	cis	rs2228479	0.850	rs9282681	chr16:89805914	T/C	cg06558623	chr16:89946397	TCF25	0.9	6.24	0.38	2.06e-9	Skin colour saturation;
SARC	cis	rs7647973	1.000	rs11130189	chr3:49347357	C/A	cg06212747	chr3:49208901	KLHDC8B	0.53	5.71	0.35	3.36e-8	Menarche (age at onset);
SARC	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg13628971	chr7:2884303	GNA12	0.5	5.88	0.36	1.41e-8	Height;
SARC	cis	rs16854884	1.000	rs62269906	chr3:143808812	A/G	cg06585982	chr3:143692056	C3orf58	0.52	6.14	0.37	3.49e-9	Economic and political preferences (feminism/equality);
SARC	cis	rs17270561	0.609	rs4711098	chr6:25734339	C/T	cg16482183	chr6:26056742	HIST1H1C	0.43	5.22	0.32	3.92e-7	Iron status biomarkers;
SARC	cis	rs734999	0.545	rs6684865	chr1:2546229	A/G	cg18854424	chr1:2615690	NA	-0.34	-5.3	-0.33	2.67e-7	Ulcerative colitis;
SARC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.16	0.81	3.73e-56	Prudent dietary pattern;
SARC	cis	rs3858526	0.883	rs11039686	chr11:5948725	T/C	cg02574844	chr11:5959923	NA	-0.43	-5.29	-0.33	2.83e-7	DNA methylation (variation);
SARC	cis	rs10078	0.571	rs890977	chr5:476910	T/C	cg24955955	chr5:415729	AHRR	0.73	6.46	0.39	6.17e-10	Fat distribution (HIV);
SARC	cis	rs870825	0.929	rs72689255	chr4:185590141	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	9.42	0.53	4.75e-18	Blood protein levels;
SARC	cis	rs477692	0.603	rs10829602	chr10:131326790	G/A	cg14263093	chr10:131365266	MGMT	0.42	5.98	0.36	8.16e-9	Response to temozolomide;
SARC	cis	rs9790314	1.000	rs9870059	chr3:161017240	T/C	cg04691961	chr3:161091175	C3orf57	-0.79	-11.51	-0.6	1.41e-24	Morning vs. evening chronotype;
SARC	cis	rs11122272	0.735	rs2572248	chr1:231514942	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs829883	0.664	rs829864	chr12:98850195	C/T	cg25150519	chr12:98850993	NA	0.84	13.52	0.66	4.05e-31	Colorectal adenoma (advanced);
SARC	cis	rs1057510	0.929	rs10849492	chr12:6720795	A/G	cg19104830	chr12:7342086	PEX5	0.49	4.78	0.3	3.09e-6	Myopia (pathological);
SARC	cis	rs4727027	0.901	rs11760293	chr7:148811725	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	5.37	0.33	1.86e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs712039	0.583	rs853223	chr17:35791149	T/C	cg16670864	chr17:35848621	DUSP14	0.48	5.25	0.33	3.44e-7	Tuberculosis;
SARC	cis	rs2011503	1.000	rs2965178	chr19:19482911	T/G	cg03709012	chr19:19516395	GATAD2A	-0.63	-5.66	-0.35	4.5e-8	Bipolar disorder;
SARC	cis	rs11864453	1.000	rs7201491	chr16:72034312	G/A	cg16558253	chr16:72132732	DHX38	-0.48	-7.22	-0.43	7.4e-12	Fibrinogen levels;
SARC	cis	rs11785400	1.000	rs754957	chr8:143746416	A/G	cg24634471	chr8:143751801	JRK	0.67	8.88	0.5	1.79e-16	Schizophrenia;
SARC	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg10435706	chr6:150039699	LATS1	0.36	4.8	0.3	2.88e-6	Lung cancer;
SARC	cis	rs7914558	0.966	rs3977751	chr10:104920232	A/G	cg04362960	chr10:104952993	NT5C2	0.42	4.99	0.31	1.16e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs17376456	0.825	rs12153021	chr5:93073913	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.72	6.53	0.39	3.99e-10	Diabetic retinopathy;
SARC	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg06618935	chr21:46677482	NA	-0.39	-5.14	-0.32	5.72e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs5769765	0.908	rs138867	chr22:50207703	A/G	cg03033257	chr22:50311977	ALG12;CRELD2	-0.51	-5.11	-0.32	6.68e-7	Schizophrenia;
SARC	cis	rs6545883	1.000	rs778763	chr2:61785639	C/G	cg15711740	chr2:61764176	XPO1	-0.44	-5.38	-0.33	1.81e-7	Tuberculosis;
SARC	cis	rs116095464	0.614	rs10059220	chr5:242813	C/T	cg22857025	chr5:266934	NA	-1.1	-10.4	-0.56	4.82e-21	Breast cancer;
SARC	cis	rs9894429	0.869	rs9748184	chr17:79596280	A/G	cg10661904	chr17:79619235	PDE6G	-0.34	-4.76	-0.3	3.45e-6	Eye color traits;
SARC	cis	rs9640161	0.742	rs2108853	chr7:150017589	A/C	cg17279839	chr7:150038598	RARRES2	0.46	6.56	0.4	3.35e-10	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs7953249	0.656	rs1732391	chr12:121392341	C/T	cg25281562	chr12:121454272	C12orf43	-0.46	-5.44	-0.34	1.37e-7	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs6570726	0.935	rs386344	chr6:145855622	A/G	cg23711669	chr6:146136114	FBXO30	0.76	11.32	0.6	6.01e-24	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3008870	1.000	rs2985817	chr1:67398607	G/C	cg08660285	chr1:67390436	MIER1;WDR78	0.91	11.38	0.6	3.78e-24	Lymphocyte percentage of white cells;
SARC	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg18404041	chr3:52824283	ITIH1	-0.44	-6.66	-0.4	1.97e-10	Bipolar disorder;
SARC	cis	rs13392177	0.660	rs62185964	chr2:219073745	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.57	-7.33	-0.43	3.7e-12	Pyoderma gangrenosum in inflammatory bowel disease;
SARC	cis	rs8072100	0.688	rs7221224	chr17:45419061	T/G	cg08085267	chr17:45401833	C17orf57	0.43	5.01	0.31	1.06e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs601339	0.877	rs2649991	chr12:123179461	A/G	cg18578876	chr12:123200353	GPR109B	0.43	4.84	0.3	2.35e-6	Adiponectin levels;
SARC	cis	rs6963495	0.818	rs818619	chr7:105172505	A/T	cg19920283	chr7:105172520	RINT1	0.68	6.61	0.4	2.55e-10	Bipolar disorder (body mass index interaction);
SARC	cis	rs1707322	1.000	rs785486	chr1:46575148	G/C	cg03146154	chr1:46216737	IPP	-0.46	-5.44	-0.34	1.34e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7726839	0.540	rs28364691	chr5:664084	G/A	cg14541582	chr5:601475	NA	-0.4	-4.86	-0.3	2.17e-6	Obesity-related traits;
SARC	trans	rs10838798	0.504	rs11039634	chr11:48297843	A/G	cg15704280	chr7:45808275	SEPT13	-0.48	-6.64	-0.4	2.2e-10	Height;
SARC	cis	rs6456156	0.603	rs2345754	chr6:167484361	T/C	cg23791538	chr6:167370224	RNASET2	-0.53	-6.99	-0.42	2.86e-11	Primary biliary cholangitis;
SARC	cis	rs965469	1.000	rs6051722	chr20:3274435	A/G	cg25506879	chr20:3388711	C20orf194	-0.5	-5.04	-0.31	9.42e-7	IFN-related cytopenia;
SARC	cis	rs11690935	1.000	rs12053003	chr2:172537350	A/C	cg13550731	chr2:172543902	DYNC1I2	0.99	15.24	0.71	7.5e-37	Schizophrenia;
SARC	cis	rs7828089	1.000	rs34542820	chr8:22264079	C/T	cg12081754	chr8:22256438	SLC39A14	0.44	5.78	0.35	2.43e-8	Verbal declarative memory;
SARC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg11494091	chr17:61959527	GH2	0.54	7.89	0.46	1.16e-13	Prudent dietary pattern;
SARC	cis	rs7617773	0.851	rs13068288	chr3:48331751	A/T	cg11946769	chr3:48343235	NME6	0.7	8.5	0.49	2.29e-15	Coronary artery disease;
SARC	trans	rs7615952	0.575	rs35949599	chr3:125544202	G/A	cg07211511	chr3:129823064	LOC729375	-0.75	-8.65	-0.49	8.6e-16	Blood pressure (smoking interaction);
SARC	cis	rs6912958	0.754	rs4707374	chr6:88255438	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.52	-7.04	-0.42	2.08e-11	Monocyte percentage of white cells;
SARC	cis	rs2762353	0.524	rs9467596	chr6:25783022	A/G	cg17691542	chr6:26056736	HIST1H1C	-0.41	-5.07	-0.32	7.96e-7	Blood metabolite levels;
SARC	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg09323728	chr8:95962352	TP53INP1	-0.33	-5.41	-0.33	1.59e-7	Type 2 diabetes;
SARC	cis	rs2180341	0.920	rs1073931	chr6:127681762	A/T	cg27446573	chr6:127587934	RNF146	1.06	14.63	0.69	8.13e-35	Breast cancer;
SARC	cis	rs9916302	0.706	rs1874226	chr17:37729031	C/T	cg00129232	chr17:37814104	STARD3	0.58	6.22	0.38	2.24e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.97e-8	Aortic root size;
SARC	cis	rs7592578	0.766	rs12472081	chr2:191398545	G/A	cg27211696	chr2:191398769	TMEM194B	-0.51	-5.16	-0.32	5.26e-7	Diastolic blood pressure;
SARC	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2273669	0.667	rs7759680	chr6:109310649	C/T	cg01304950	chr6:109416612	SESN1;C6orf182	0.55	4.89	0.3	1.9e-6	Prostate cancer;
SARC	cis	rs3815700	0.841	rs10410895	chr19:33093655	T/G	cg02997394	chr19:33096574	ANKRD27	0.8	8.23	0.47	1.36e-14	Eosinophilic esophagitis;
SARC	cis	rs6952808	0.858	rs12671113	chr7:1965255	G/A	cg05863683	chr7:1912471	MAD1L1	0.35	5.21	0.32	4.22e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs3126085	0.935	rs4634913	chr1:152249932	T/C	cg26876637	chr1:152193138	HRNR	0.46	5.29	0.33	2.86e-7	Atopic dermatitis;
SARC	cis	rs2153535	0.541	rs1414347	chr6:8471831	T/C	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.85e-22	Motion sickness;
SARC	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg00339695	chr16:24857497	SLC5A11	-0.43	-5.69	-0.35	3.79e-8	Intelligence (multi-trait analysis);
SARC	cis	rs876084	0.505	rs9969405	chr8:121107146	A/G	cg06265175	chr8:121136014	COL14A1	0.58	7.56	0.44	9.46e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs36051895	0.632	rs10974984	chr9:5150427	T/C	cg02405213	chr9:5042618	JAK2	-0.45	-5.39	-0.33	1.76e-7	Pediatric autoimmune diseases;
SARC	cis	rs9457247	1.000	rs415842	chr6:167406681	G/A	cg07741184	chr6:167504864	NA	0.29	5.6	0.34	5.95e-8	Crohn's disease;
SARC	cis	rs6912958	0.712	rs4707383	chr6:88330602	T/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.54	-0.34	8.34e-8	Monocyte percentage of white cells;
SARC	cis	rs1790761	0.692	rs611663	chr11:67312221	C/T	cg24690094	chr11:67383802	NA	0.33	4.92	0.31	1.67e-6	Mean corpuscular volume;
SARC	cis	rs17384381	0.861	rs35240561	chr1:85775217	C/G	cg16011679	chr1:85725395	C1orf52	0.72	6.24	0.38	2.07e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3096299	0.582	rs12935119	chr16:89542874	A/T	cg08392591	chr16:89556376	ANKRD11	0.45	6.1	0.37	4.48e-9	Multiple myeloma (IgH translocation);
SARC	cis	rs9486719	1.000	rs3798296	chr6:97052286	G/A	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.42	-0.48	3.9e-15	Migraine;Coronary artery disease;
SARC	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg16479474	chr6:28041457	NA	0.36	5.27	0.33	3.04e-7	Depression;
SARC	cis	rs9325144	0.560	rs10876005	chr12:39126149	C/G	cg26384229	chr12:38710491	ALG10B	-0.59	-8.04	-0.47	4.48e-14	Morning vs. evening chronotype;
SARC	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg12311346	chr5:56204834	C5orf35	0.59	6.27	0.38	1.76e-9	Initial pursuit acceleration;
SARC	cis	rs738322	1.000	rs4381	chr22:38570791	T/C	cg25457927	chr22:38595422	NA	-0.29	-5.95	-0.36	9.77e-9	Cutaneous nevi;
SARC	cis	rs1865760	0.625	rs9393681	chr6:26008260	A/G	cg10373733	chr6:25993375	NA	0.42	5.37	0.33	1.89e-7	Height;
SARC	trans	rs208520	0.690	rs1776365	chr6:66834474	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-13.86	-0.67	2.96e-32	Exhaled nitric oxide output;
SARC	cis	rs763121	0.853	rs2072796	chr22:39064230	A/G	cg06022373	chr22:39101656	GTPBP1	0.87	10.97	0.58	7.86e-23	Menopause (age at onset);
SARC	cis	rs4148883	0.645	rs2851264	chr4:100029715	C/T	cg12011299	chr4:100065546	ADH4	0.36	6.69	0.4	1.64e-10	Alcohol dependence;
SARC	cis	rs4975709	0.569	rs931509	chr5:1858821	A/T	cg14773178	chr5:1868261	NA	0.36	5.53	0.34	8.61e-8	Cardiovascular disease risk factors;
SARC	cis	rs748404	0.660	rs2439846	chr15:43740970	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.49	5.57	0.34	7e-8	Lung cancer;
SARC	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg08677398	chr8:58056175	NA	0.41	4.96	0.31	1.38e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs5417	0.689	rs55868524	chr17:7170665	G/A	cg13768953	chr17:7114967	DLG4	0.32	5.18	0.32	4.86e-7	Diastolic blood pressure;
SARC	cis	rs2153904	0.793	rs12118655	chr1:205663478	A/G	cg24503407	chr1:205819492	PM20D1	-0.58	-4.96	-0.31	1.35e-6	Prostate-specific antigen levels;
SARC	cis	rs9916302	0.821	rs1966915	chr17:37425262	A/C	cg00129232	chr17:37814104	STARD3	-0.59	-7.39	-0.44	2.69e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs17376456	0.825	rs28610997	chr5:93248374	T/C	cg25358565	chr5:93447407	FAM172A	1.3	14.36	0.69	6.63e-34	Diabetic retinopathy;
SARC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg23109134	chr10:7830051	ATP5C1;KIN	-0.5	-6.41	-0.39	8.17e-10	HDL cholesterol;
SARC	cis	rs7264396	0.563	rs2425100	chr20:34310115	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-7.17	-0.43	9.99e-12	Total cholesterol levels;
SARC	cis	rs1059312	1.000	rs2291350	chr12:129283711	G/A	cg09035930	chr12:129282057	SLC15A4	0.62	8.96	0.51	1.05e-16	Systemic lupus erythematosus;
SARC	cis	rs1707322	0.721	rs11211181	chr1:46236800	C/T	cg06784218	chr1:46089804	CCDC17	0.38	6.67	0.4	1.81e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7772486	0.719	rs702307	chr6:145993454	C/G	cg05347473	chr6:146136440	FBXO30	-0.54	-7.56	-0.44	9.17e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2479724	0.870	rs3747753	chr6:41753380	G/T	cg17623882	chr6:41773611	USP49	0.45	5.71	0.35	3.34e-8	Menarche (age at onset);
SARC	cis	rs6088580	0.524	rs6087612	chr20:33230822	T/G	cg24642439	chr20:33292090	TP53INP2	-0.54	-6.73	-0.4	1.3e-10	Glomerular filtration rate (creatinine);
SARC	trans	rs453301	0.571	rs330048	chr8:9087278	A/C	cg06636001	chr8:8085503	FLJ10661	-0.69	-9.42	-0.53	4.56e-18	Joint mobility (Beighton score);
SARC	cis	rs11214589	0.651	rs11214595	chr11:113259658	G/T	cg14159747	chr11:113255604	NA	0.37	5.2	0.32	4.46e-7	Neuroticism;
SARC	cis	rs2180341	1.000	rs9401950	chr6:127655485	C/T	cg17762328	chr6:126965162	NA	-0.45	-5.11	-0.32	6.78e-7	Breast cancer;
SARC	cis	rs6570726	0.935	rs906774	chr6:145813770	T/C	cg05347473	chr6:146136440	FBXO30	0.49	6.48	0.39	5.27e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg21782813	chr7:2030301	MAD1L1	0.39	6.19	0.38	2.63e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs910316	0.687	rs175059	chr14:75490667	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.52	-7.08	-0.42	1.73e-11	Height;
SARC	cis	rs6088813	1.000	rs6142359	chr20:33960450	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	-0.43	-5.24	-0.32	3.67e-7	Height;
SARC	cis	rs35110281	0.743	rs230640	chr21:44914815	A/T	cg01579765	chr21:45077557	HSF2BP	0.32	5.5	0.34	1.02e-7	Mean corpuscular volume;
SARC	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg19077165	chr18:44547161	KATNAL2	0.55	7.55	0.44	9.53e-13	Personality dimensions;
SARC	cis	rs6088590	0.707	rs67159833	chr20:33488079	T/C	cg06115741	chr20:33292138	TP53INP2	0.5	5.55	0.34	7.82e-8	Coronary artery disease;
SARC	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg21782813	chr7:2030301	MAD1L1	0.31	4.77	0.3	3.29e-6	Schizophrenia;
SARC	trans	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg21659725	chr3:3221576	CRBN	-0.53	-6.84	-0.41	6.71e-11	Intelligence (multi-trait analysis);
SARC	cis	rs9815354	1.000	rs7648578	chr3:41858731	C/T	cg03022575	chr3:42003672	ULK4	0.58	5.45	0.34	1.27e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs798554	0.610	rs2527696	chr7:2858315	T/C	cg04166393	chr7:2884313	GNA12	0.45	5.49	0.34	1.03e-7	Height;
SARC	trans	rs61931739	0.534	rs11053072	chr12:34202399	A/C	cg26384229	chr12:38710491	ALG10B	0.84	12.1	0.62	1.76e-26	Morning vs. evening chronotype;
SARC	cis	rs8014204	0.748	rs12889277	chr14:75229376	A/T	cg06637938	chr14:75390232	RPS6KL1	0.76	11.26	0.59	9.11e-24	Caffeine consumption;
SARC	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg02018176	chr4:1364513	KIAA1530	0.39	5.72	0.35	3.27e-8	Longevity;
SARC	trans	rs9329221	0.655	rs656319	chr8:9814411	A/G	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.44	-0.39	6.68e-10	Neuroticism;
SARC	cis	rs2916247	0.954	rs13252280	chr8:93088151	C/T	cg10183463	chr8:93005414	RUNX1T1	0.68	7.28	0.43	5.06e-12	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg12463550	chr7:65579703	CRCP	-0.5	-5.57	-0.34	6.84e-8	Aortic root size;
SARC	cis	rs765787	0.530	rs12903149	chr15:45539076	G/A	cg24006582	chr15:45444508	DUOX1	0.46	5.76	0.35	2.63e-8	Uric acid levels;
SARC	cis	rs9768139	0.708	rs896780	chr7:158113972	C/T	cg25566285	chr7:158114605	PTPRN2	0.34	5.85	0.36	1.66e-8	Calcium levels;
SARC	cis	rs13006833	0.739	rs291470	chr2:191189558	T/A	cg25963032	chr2:191064776	C2orf88	0.36	5.02	0.31	1.04e-6	Urinary metabolites;
SARC	trans	rs36093844	0.800	rs112468922	chr11:85576694	A/G	cg27065003	chr5:122429449	PRDM6	-0.52	-6.31	-0.38	1.37e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs7647973	0.626	rs6809879	chr3:49834571	A/G	cg13072238	chr3:49761600	GMPPB	0.62	5.92	0.36	1.14e-8	Menarche (age at onset);
SARC	cis	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg09021430	chr5:549028	NA	-0.45	-5.69	-0.35	3.74e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs7084402	0.967	rs1658480	chr10:60289374	C/G	cg07615347	chr10:60278583	BICC1	0.6	8.84	0.5	2.34e-16	Refractive error;
SARC	cis	rs7223966	1.000	rs11542436	chr17:61778689	A/C	cg26338869	chr17:61819248	STRADA	0.45	4.92	0.31	1.66e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs77741769	0.700	rs7980311	chr12:121355860	C/T	cg02403541	chr12:121454288	C12orf43	0.47	5.18	0.32	4.69e-7	Mean corpuscular volume;
SARC	cis	rs7223966	0.960	rs11659013	chr17:61869559	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.45	4.82	0.3	2.6e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs3768617	0.528	rs6686682	chr1:183080539	A/G	cg13390022	chr1:182993471	LAMC1	0.32	4.88	0.3	1.95e-6	Fuchs's corneal dystrophy;
SARC	cis	rs7208859	0.623	rs1054400	chr17:29109954	A/G	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs8077889	0.750	rs76557360	chr17:41936842	G/A	cg26893861	chr17:41843967	DUSP3	0.75	7.18	0.43	9.48e-12	Triglycerides;
SARC	cis	rs1865760	1.000	rs2071301	chr6:25914263	G/T	cg18357526	chr6:26021779	HIST1H4A	0.4	4.72	0.3	4e-6	Height;
SARC	cis	rs7223966	1.000	rs9899788	chr17:61756384	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.73	0.4	1.32e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6831352	0.505	rs11722561	chr4:100088737	T/A	cg13256891	chr4:100009986	ADH5	0.48	6.25	0.38	1.99e-9	Alcohol dependence;
SARC	cis	rs6456156	0.583	rs7748224	chr6:167456860	C/T	cg23791538	chr6:167370224	RNASET2	-0.51	-6.73	-0.4	1.28e-10	Primary biliary cholangitis;
SARC	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg14403583	chr14:105418241	AHNAK2	-0.58	-7.61	-0.45	6.95e-13	Rheumatoid arthritis;
SARC	cis	rs4803468	1.000	rs284650	chr19:41927129	A/G	cg09537434	chr19:41945824	ATP5SL	-0.98	-17.28	-0.75	1.27e-43	Height;
SARC	cis	rs858239	0.600	rs4628176	chr7:23142566	C/T	cg23682824	chr7:23144976	KLHL7	0.67	8.81	0.5	2.99e-16	Cerebrospinal fluid biomarker levels;
SARC	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg11843238	chr5:131593191	PDLIM4	-0.42	-5.14	-0.32	5.92e-7	Blood metabolite levels;
SARC	cis	rs9858542	0.953	rs9841110	chr3:49492481	C/G	cg03060546	chr3:49711283	APEH	-0.58	-7.13	-0.42	1.28e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs763121	0.889	rs2267390	chr22:38889657	C/T	cg21395723	chr22:39101663	GTPBP1	0.62	7.13	0.42	1.25e-11	Menopause (age at onset);
SARC	trans	rs35833281	1.000	rs3122163	chr6:55056368	C/T	cg19977494	chr7:128431264	CCDC136	0.71	6.57	0.4	3.25e-10	Morning vs. evening chronotype;
SARC	trans	rs9951602	0.512	rs56009939	chr18:76644497	T/G	cg02800362	chr5:177631904	HNRNPAB	0.68	8.61	0.49	1.13e-15	Obesity-related traits;
SARC	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg21171335	chr12:122356390	WDR66	-0.4	-6.47	-0.39	5.74e-10	Mean corpuscular volume;
SARC	cis	rs7927771	0.864	rs2868459	chr11:47454972	C/G	cg05585544	chr11:47624801	NA	-0.35	-4.72	-0.3	4e-6	Subjective well-being;
SARC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.67	0.54	8.17e-19	Prudent dietary pattern;
SARC	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg13395646	chr4:1353034	KIAA1530	-0.53	-6.33	-0.38	1.23e-9	Obesity-related traits;
SARC	cis	rs3771570	0.901	rs9052	chr2:242434809	G/T	cg21155796	chr2:242212141	HDLBP	0.48	4.73	0.3	3.89e-6	Prostate cancer;
SARC	cis	rs9303280	0.901	rs2305479	chr17:38062217	C/T	cg20243544	chr17:37824526	PNMT	0.44	6.0	0.37	7.6e-9	Self-reported allergy;
SARC	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg08859206	chr1:53392774	SCP2	0.39	5.61	0.35	5.69e-8	Monocyte count;
SARC	cis	rs7077164	1.000	rs1227764	chr10:71583223	G/A	cg20696214	chr10:71583771	COL13A1	-0.37	-5.0	-0.31	1.14e-6	Non-alcoholic fatty liver disease histology (lobular);
SARC	cis	rs3091242	1.000	rs646867	chr1:25709258	A/C	cg23205692	chr1:25664452	TMEM50A	0.42	5.06	0.31	8.63e-7	Erythrocyte sedimentation rate;
SARC	cis	rs7264396	0.790	rs6060582	chr20:34313297	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.75	8.49	0.49	2.46e-15	Total cholesterol levels;
SARC	cis	rs7130144	0.541	rs7936388	chr11:130462511	T/C	cg26307797	chr11:130446613	NA	-0.68	-5.72	-0.35	3.31e-8	Urate levels in lean individuals;
SARC	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg06618935	chr21:46677482	NA	-0.41	-5.39	-0.33	1.72e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7727544	0.606	rs200838	chr5:131710399	A/C	cg24060327	chr5:131705240	SLC22A5	0.41	4.94	0.31	1.5e-6	Blood metabolite levels;
SARC	cis	rs6964587	0.773	rs13236026	chr7:91885873	A/G	cg17063962	chr7:91808500	NA	0.92	12.82	0.64	8.07e-29	Breast cancer;
SARC	cis	rs9303401	0.704	rs7359501	chr17:56641200	C/T	cg05425664	chr17:57184151	TRIM37	-0.42	-5.07	-0.32	7.94e-7	Cognitive test performance;
SARC	cis	rs7481584	0.517	rs80872	chr11:3049984	G/T	cg25174290	chr11:3078921	CARS	-0.6	-8.35	-0.48	6.26e-15	Calcium levels;
SARC	cis	rs765787	0.530	rs4775835	chr15:45537553	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.67e-7	Uric acid levels;
SARC	cis	rs7617773	0.817	rs3731534	chr3:48211777	C/T	cg11946769	chr3:48343235	NME6	0.71	9.28	0.52	1.25e-17	Coronary artery disease;
SARC	cis	rs1018836	0.632	rs7017295	chr8:91482356	C/T	cg16814680	chr8:91681699	NA	0.68	10.29	0.56	9.97e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs6714710	0.603	rs12988571	chr2:98405695	C/T	cg26665480	chr2:98280029	ACTR1B	0.47	6.34	0.38	1.17e-9	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs9470366	0.816	rs4331968	chr6:36623243	A/T	cg08179530	chr6:36648295	CDKN1A	0.54	5.97	0.36	8.85e-9	QRS duration;
SARC	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg16606324	chr3:10149918	C3orf24	0.52	5.07	0.32	8.05e-7	Alzheimer's disease;
SARC	cis	rs11098499	0.644	rs28787668	chr4:120554687	G/A	cg09307838	chr4:120376055	NA	0.76	10.31	0.56	8.82e-21	Corneal astigmatism;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg05279707	chr20:49547986	ADNP	0.52	6.6	0.4	2.8e-10	Breast cancer;
SARC	cis	rs2425143	1.000	rs2425078	chr20:34298163	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	5.24	0.32	3.65e-7	Blood protein levels;
SARC	cis	rs10849893	0.576	rs7296507	chr12:121847135	A/G	cg01154721	chr12:121881891	KDM2B	-0.37	-5.31	-0.33	2.54e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs4319547	0.661	rs10773172	chr12:122939655	G/A	cg23029597	chr12:123009494	RSRC2	-0.38	-4.84	-0.3	2.42e-6	Body mass index;
SARC	cis	rs9858542	0.953	rs9858280	chr3:49597737	T/C	cg03060546	chr3:49711283	APEH	-0.61	-7.78	-0.45	2.3e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs10493773	0.775	rs12739713	chr1:86150378	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.54	-8.31	-0.48	7.78e-15	Urate levels in overweight individuals;
SARC	cis	rs9303280	0.754	rs3816470	chr17:37985801	A/G	cg20243544	chr17:37824526	PNMT	0.4	5.24	0.32	3.53e-7	Self-reported allergy;
SARC	cis	rs1536827	0.688	rs2031922	chr10:135340093	T/C	cg22671611	chr10:135291010	NA	-0.61	-5.16	-0.32	5.24e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs7520050	0.966	rs785481	chr1:46554518	G/A	cg24296786	chr1:45957014	TESK2	0.38	4.82	0.3	2.56e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs1538970	0.739	rs4660863	chr1:45955868	T/C	cg05343316	chr1:45956843	TESK2	0.82	8.79	0.5	3.28e-16	Platelet count;
SARC	cis	rs6582630	0.516	rs8186746	chr12:38347638	G/T	cg14851346	chr12:38532713	NA	-0.47	-5.61	-0.34	5.75e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6912958	0.559	rs445434	chr6:88041849	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.75	11.0	0.58	5.91e-23	Monocyte percentage of white cells;
SARC	cis	rs3820928	0.874	rs67513858	chr2:227804819	A/C	cg11843606	chr2:227700838	RHBDD1	-0.56	-7.12	-0.42	1.33e-11	Pulmonary function;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg26910092	chr2:216300599	FN1	-0.47	-6.34	-0.38	1.21e-9	Neuroticism;
SARC	cis	rs9828933	0.516	rs704371	chr3:63867528	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	0.79	8.48	0.49	2.62e-15	Type 2 diabetes;
SARC	cis	rs748404	0.697	rs531910	chr15:43560607	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.41	5.13	0.32	6.02e-7	Lung cancer;
SARC	cis	rs1008375	1.000	rs6849704	chr4:17652031	G/C	cg27347728	chr4:17578864	LAP3	0.47	5.88	0.36	1.42e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs35213789	0.887	rs6974004	chr7:69215184	T/G	cg10619644	chr7:69149951	AUTS2	-0.44	-5.85	-0.36	1.67e-8	Childhood ear infection;
SARC	cis	rs1144333	0.510	rs12408897	chr1:76448102	T/C	cg03433033	chr1:76189801	ACADM	0.61	4.9	0.31	1.77e-6	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg11489262	chr17:43973426	MAPT;LOC100128977;LOC100130148	0.47	4.95	0.31	1.41e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs10089	1.000	rs2409109	chr5:127461471	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	10.26	0.56	1.31e-20	Ileal carcinoids;
SARC	cis	rs17666538	0.792	rs1979174	chr8:592274	C/A	cg02524346	chr8:600233	NA	0.81	6.63	0.4	2.38e-10	IgG glycosylation;
SARC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	10.64	0.57	8.51e-22	Platelet count;
SARC	cis	rs1059312	1.000	rs9738216	chr12:129281788	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.48	-5.88	-0.36	1.42e-8	Systemic lupus erythematosus;
SARC	cis	rs9398803	0.713	rs9401888	chr6:126877523	A/G	cg19875578	chr6:126661172	C6orf173	0.6	8.14	0.47	2.45e-14	Male-pattern baldness;
SARC	cis	rs9788721	0.934	rs16969968	chr15:78882925	G/A	cg18825076	chr15:78729989	IREB2	-0.45	-5.15	-0.32	5.46e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs2288073	0.896	rs13404513	chr2:24410780	G/A	cg26838691	chr2:24397539	C2orf84	-0.55	-6.84	-0.41	6.85e-11	Venous thromboembolism (SNP x SNP interaction);
SARC	trans	rs61931739	0.500	rs10844845	chr12:34381117	C/T	cg13010199	chr12:38710504	ALG10B	0.74	10.5	0.57	2.31e-21	Morning vs. evening chronotype;
SARC	cis	rs2295359	0.824	rs4655679	chr1:67599657	A/G	cg11235152	chr1:67600687	NA	-0.54	-7.45	-0.44	1.82e-12	Psoriasis;
SARC	cis	rs17376456	0.877	rs13170509	chr5:93378564	T/C	cg21475434	chr5:93447410	FAM172A	0.85	7.5	0.44	1.34e-12	Diabetic retinopathy;
SARC	cis	rs12142240	0.667	rs12062	chr1:46830447	G/T	cg10495392	chr1:46806563	NSUN4	-0.65	-6.93	-0.41	4.13e-11	Menopause (age at onset);
SARC	cis	rs17376456	0.542	rs10070350	chr5:93103753	C/G	cg25358565	chr5:93447407	FAM172A	0.93	10.45	0.56	3.24e-21	Diabetic retinopathy;
SARC	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg17376030	chr22:41985996	PMM1	0.73	9.09	0.51	4.3e-17	Vitiligo;
SARC	cis	rs7584330	0.737	rs7584314	chr2:238361089	C/T	cg11271282	chr2:238384023	NA	0.44	5.04	0.31	9.36e-7	Prostate cancer;
SARC	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg25405998	chr7:65216604	CCT6P1	0.52	6.16	0.37	3.15e-9	Calcium levels;
SARC	cis	rs12754538	0.595	rs12025126	chr1:8759554	C/T	cg13785123	chr1:8931135	ENO1	0.46	5.84	0.36	1.7e-8	Subjective well-being;
SARC	trans	rs34421088	0.560	rs2248315	chr8:11397086	T/A	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.64	-0.4	2.14e-10	Neuroticism;
SARC	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg23758822	chr17:41437982	NA	0.92	11.73	0.61	2.75e-25	Menopause (age at onset);
SARC	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg04518342	chr5:131593106	PDLIM4	-0.43	-5.5	-0.34	1.02e-7	Breast cancer;
SARC	cis	rs11864453	0.713	rs8051882	chr16:72142072	A/G	cg16558253	chr16:72132732	DHX38	0.53	8.36	0.48	5.8e-15	Fibrinogen levels;
SARC	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg13206674	chr6:150067644	NUP43	0.46	6.1	0.37	4.29e-9	Lung cancer;
SARC	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg17971929	chr21:40555470	PSMG1	-0.59	-7.44	-0.44	1.89e-12	Menarche (age at onset);
SARC	cis	rs2425143	1.000	rs7273815	chr20:34232415	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-5.55	-0.34	7.91e-8	Blood protein levels;
SARC	cis	rs2061333	0.557	rs8105860	chr19:44606928	A/G	cg18700516	chr19:44507157	ZNF230	-0.57	-5.44	-0.34	1.32e-7	Alzheimer's disease;
SARC	cis	rs7772486	0.686	rs1045820	chr6:145947080	C/T	cg05347473	chr6:146136440	FBXO30	0.51	7.11	0.42	1.4e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7246657	0.525	rs10405238	chr19:37488055	T/G	cg23950597	chr19:37808831	NA	-0.56	-5.11	-0.32	6.68e-7	Coronary artery calcification;
SARC	cis	rs365132	0.875	rs353491	chr5:176432947	C/G	cg16309518	chr5:176445507	NA	-0.49	-6.28	-0.38	1.64e-9	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs1044826	1.000	rs13092935	chr3:139175464	C/T	cg15131784	chr3:139108705	COPB2	0.45	5.19	0.32	4.65e-7	Obesity-related traits;
SARC	cis	rs875971	0.867	rs13227219	chr7:65844062	T/A	cg11764359	chr7:65958608	NA	0.88	12.52	0.63	7.87e-28	Aortic root size;
SARC	trans	rs1973993	0.745	rs9437743	chr1:96961723	C/T	cg10631902	chr5:14652156	NA	0.42	6.78	0.41	9.69e-11	Weight;
SARC	cis	rs7216064	1.000	rs55896768	chr17:65913358	T/C	cg12091567	chr17:66097778	LOC651250	-0.75	-8.29	-0.48	9.02e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs9987353	0.522	rs2929466	chr8:9063899	G/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-5.71	-0.35	3.41e-8	Recombination measurement;
SARC	cis	rs1580019	0.520	rs13228793	chr7:32711465	C/T	cg07520158	chr7:32535189	LSM5;AVL9	0.56	6.45	0.39	6.44e-10	Cognitive ability;
SARC	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg11494091	chr17:61959527	GH2	0.54	8.0	0.46	5.95e-14	Prudent dietary pattern;
SARC	cis	rs9303401	0.527	rs12946522	chr17:56768103	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	11.29	0.59	7.29e-24	Cognitive test performance;
SARC	cis	rs9325144	0.555	rs4882284	chr12:38710459	C/T	cg10518543	chr12:38710700	ALG10B	-0.4	-5.13	-0.32	6.2e-7	Morning vs. evening chronotype;
SARC	cis	rs4074493	0.963	rs4074492	chr1:231172439	G/A	cg22172038	chr1:231176991	FAM89A	0.34	4.99	0.31	1.2e-6	Carotid plaque burden (smoking interaction);
SARC	cis	rs3126085	0.935	rs12063165	chr1:152176357	C/T	cg09127314	chr1:152161683	NA	0.42	4.76	0.3	3.44e-6	Atopic dermatitis;
SARC	cis	rs4595586	0.545	rs11615700	chr12:39365104	A/G	cg13010199	chr12:38710504	ALG10B	0.4	4.75	0.3	3.57e-6	Morning vs. evening chronotype;
SARC	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg00149659	chr3:10157352	C3orf10	0.73	7.09	0.42	1.61e-11	Alzheimer's disease;
SARC	cis	rs9894429	0.816	rs7406040	chr17:79597583	A/C	cg18240062	chr17:79603768	NPLOC4	0.88	13.71	0.67	9.24e-32	Eye color traits;
SARC	cis	rs11190604	1.000	rs11190555	chr10:102209160	A/G	cg07080220	chr10:102295463	HIF1AN	0.78	9.58	0.53	1.56e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs754466	0.580	rs10824576	chr10:79566040	G/C	cg17075019	chr10:79541650	NA	-0.82	-12.65	-0.64	2.95e-28	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1057510	0.790	rs16932801	chr12:6720382	A/G	cg19104830	chr12:7342086	PEX5	-0.55	-4.88	-0.3	1.93e-6	Myopia (pathological);
SARC	cis	rs7772486	0.790	rs9497427	chr6:146238302	T/A	cg05347473	chr6:146136440	FBXO30	-0.46	-6.31	-0.38	1.43e-9	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg23305229	chr14:50999536	MAP4K5;ATL1	-0.51	-6.46	-0.39	5.94e-10	Thyroid cancer;
SARC	cis	rs9325144	0.581	rs2730929	chr12:38942739	T/C	cg13010199	chr12:38710504	ALG10B	-0.61	-8.16	-0.47	2.12e-14	Morning vs. evening chronotype;
SARC	cis	rs1055129	0.560	rs9891076	chr17:73911715	C/T	cg06969265	chr17:73775802	H3F3B	0.46	5.53	0.34	8.43e-8	White matter hyperintensity burden;
SARC	cis	rs11718455	0.960	rs35277738	chr3:44006732	T/C	cg08738300	chr3:44038990	NA	0.53	5.97	0.36	8.89e-9	Coronary artery disease;
SARC	cis	rs9788721	0.934	rs16969968	chr15:78882925	G/A	cg06917634	chr15:78832804	PSMA4	-0.58	-6.0	-0.37	7.33e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg17221315	chr6:27791827	HIST1H4J	0.46	4.8	0.3	2.89e-6	Depression;
SARC	cis	rs9467773	0.620	rs9467810	chr6:26608261	A/C	cg11502198	chr6:26597334	ABT1	0.65	8.77	0.5	3.84e-16	Intelligence (multi-trait analysis);
SARC	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg03806693	chr22:41940476	POLR3H	0.92	12.55	0.64	5.95e-28	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs9487051	0.676	rs9386788	chr6:109600523	C/T	cg01475377	chr6:109611718	NA	0.36	5.37	0.33	1.94e-7	Reticulocyte fraction of red cells;
SARC	cis	rs1113500	0.836	rs2801220	chr1:108584649	A/G	cg06207961	chr1:108661230	NA	-0.4	-5.07	-0.32	8.14e-7	Growth-regulated protein alpha levels;
SARC	cis	rs8114671	0.586	rs734111	chr20:33533736	A/C	cg24642439	chr20:33292090	TP53INP2	0.48	5.65	0.35	4.68e-8	Height;
SARC	cis	rs7223966	1.000	rs7216798	chr17:61740963	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.45	5.03	0.31	9.75e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg24549020	chr5:56110836	MAP3K1	-0.44	-5.08	-0.32	7.7300000000000005e-07	Coronary artery disease;
SARC	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg19223190	chr17:80058835	NA	-0.43	-5.88	-0.36	1.45e-8	Life satisfaction;
SARC	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.43	0.39	7.26e-10	Height;
SARC	cis	rs7666738	0.719	rs35184673	chr4:99050945	T/C	cg05340658	chr4:99064831	C4orf37	0.51	5.62	0.35	5.56e-8	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7264396	0.790	rs6058283	chr20:34216276	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.56	5.58	0.34	6.67e-8	Total cholesterol levels;
SARC	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg00409905	chr10:38381863	ZNF37A	-0.49	-6.74	-0.4	1.22e-10	Extrinsic epigenetic age acceleration;
SARC	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg11764359	chr7:65958608	NA	-0.78	-9.49	-0.53	2.76e-18	Aortic root size;
SARC	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg19223190	chr17:80058835	NA	-0.4	-5.56	-0.34	7.43e-8	Life satisfaction;
SARC	cis	rs3809566	1.000	rs4775612	chr15:63332157	T/C	cg05507819	chr15:63340323	TPM1	0.53	5.96	0.36	9.21e-9	Platelet count;
SARC	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg06221963	chr1:154839813	KCNN3	-0.45	-6.96	-0.41	3.42e-11	Prostate cancer;
SARC	trans	rs11098499	0.863	rs7669520	chr4:120515278	T/C	cg25214090	chr10:38739885	LOC399744	0.57	7.32	0.43	4.06e-12	Corneal astigmatism;
SARC	cis	rs2594989	0.887	rs9850117	chr3:11571991	C/T	cg00170343	chr3:11313890	ATG7	-0.6	-5.83	-0.36	1.84e-8	Circulating chemerin levels;
SARC	cis	rs939574	1.000	rs11689596	chr2:220093423	T/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.56	-5.34	-0.33	2.26e-7	Platelet distribution width;
SARC	cis	rs9527	0.615	rs12248123	chr10:104735366	A/G	cg04362960	chr10:104952993	NT5C2	0.43	5.02	0.31	1.01e-6	Arsenic metabolism;
SARC	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs986417	0.818	rs767602	chr14:61098624	G/T	cg27398547	chr14:60952738	C14orf39	0.72	6.69	0.4	1.68e-10	Gut microbiota (bacterial taxa);
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg21157707	chr9:139908753	ABCA2	0.45	6.38	0.39	9.26e-10	Schizophrenia;
SARC	cis	rs3733585	0.605	rs4697710	chr4:10122649	T/C	cg11266682	chr4:10021025	SLC2A9	-0.39	-6.34	-0.38	1.2e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs1401999	1.000	rs7620350	chr3:183710053	A/T	cg01324343	chr3:183735012	ABCC5	0.66	13.24	0.66	3.19e-30	Anterior chamber depth;
SARC	cis	rs9611519	1.000	rs9611510	chr22:41569124	T/C	cg03806693	chr22:41940476	POLR3H	-0.59	-7.16	-0.42	1.05e-11	Neuroticism;
SARC	cis	rs6565189	1.000	rs6565189	chr16:30507265	A/C	cg17640201	chr16:30407289	ZNF48	0.51	5.4	0.33	1.64e-7	Tonsillectomy;
SARC	cis	rs6430585	0.528	rs309119	chr2:136710372	T/C	cg07169764	chr2:136633963	MCM6	0.91	11.84	0.61	1.29e-25	Corneal structure;
SARC	cis	rs861020	1.000	rs630984	chr1:209982293	C/T	cg05527609	chr1:210001259	C1orf107	0.9	10.15	0.55	2.74e-20	Orofacial clefts;
SARC	cis	rs6088580	0.634	rs6120669	chr20:33105028	T/C	cg24642439	chr20:33292090	TP53INP2	0.66	8.35	0.48	6.21e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs7264396	0.563	rs6060592	chr20:34352414	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	5.35	0.33	2.08e-7	Total cholesterol levels;
SARC	cis	rs7522061	0.546	rs10908585	chr1:157642481	T/A	cg18268488	chr1:157545234	FCRL4	0.26	4.79	0.3	2.9e-6	Blood protein levels;
SARC	cis	rs3760982	0.585	rs8109478	chr19:44298256	C/T	cg11993925	chr19:44307056	LYPD5	0.31	4.82	0.3	2.63e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
SARC	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg12463550	chr7:65579703	CRCP	-0.45	-4.92	-0.31	1.63e-6	Aortic root size;
SARC	cis	rs11718455	0.881	rs17076257	chr3:44006787	C/T	cg21419209	chr3:44054225	NA	-0.43	-5.2	-0.32	4.32e-7	Coronary artery disease;
SARC	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg10435706	chr6:150039699	LATS1	0.36	4.8	0.3	2.88e-6	Lung cancer;
SARC	cis	rs1055129	0.537	rs10852766	chr17:73951864	T/C	cg06969265	chr17:73775802	H3F3B	-0.41	-4.78	-0.3	3.1e-6	White matter hyperintensity burden;
SARC	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg02931644	chr1:25747376	RHCE	0.46	7.78	0.45	2.28e-13	Erythrocyte sedimentation rate;
SARC	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.48	0.39	5.37e-10	Bipolar disorder;
SARC	cis	rs4481887	0.962	rs12037921	chr1:248454167	T/G	cg01631408	chr1:248437212	OR2T33	-0.41	-5.21	-0.32	4.07e-7	Common traits (Other);
SARC	cis	rs13256369	0.802	rs13280101	chr8:8562773	G/A	cg17143192	chr8:8559678	CLDN23	0.52	5.84	0.36	1.77e-8	Obesity-related traits;
SARC	cis	rs1865760	0.532	rs9295687	chr6:26082710	T/C	cg18357526	chr6:26021779	HIST1H4A	0.41	4.98	0.31	1.23e-6	Height;
SARC	cis	rs10791097	0.694	rs4436551	chr11:130755739	A/G	cg12179176	chr11:130786555	SNX19	-0.74	-11.14	-0.59	2.13e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg08280861	chr8:58055591	NA	0.61	5.94	0.36	1.01e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10911232	0.507	rs11582514	chr1:182992161	T/C	cg13390022	chr1:182993471	LAMC1	0.34	5.2	0.32	4.33e-7	Hypertriglyceridemia;
SARC	cis	rs3892630	0.588	rs8106748	chr19:33282797	G/A	cg22980127	chr19:33182716	NUDT19	1.1	11.8	0.61	1.69e-25	Red blood cell traits;
SARC	cis	rs8072100	0.676	rs7221345	chr17:45405144	G/A	cg08085267	chr17:45401833	C17orf57	-0.54	-6.59	-0.4	2.85e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg07148880	chr1:200992788	KIF21B	0.48	6.46	0.39	6.17e-10	Breast cancer;
SARC	cis	rs10782582	0.586	rs1856791	chr1:76308942	C/T	cg10523679	chr1:76189770	ACADM	-0.43	-5.27	-0.33	3.06e-7	Daytime sleep phenotypes;
SARC	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg18252515	chr7:66147081	NA	0.48	5.14	0.32	5.88e-7	Aortic root size;
SARC	cis	rs7666738	0.830	rs1813642	chr4:98852225	G/A	cg05340658	chr4:99064831	C4orf37	0.66	8.78	0.5	3.5e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1697139	0.583	rs11960733	chr5:66538715	C/T	cg11553311	chr5:66541588	NA	0.31	4.96	0.31	1.36e-6	Breast cancer;
SARC	cis	rs7617480	0.648	rs6796790	chr3:48780317	G/A	cg06212747	chr3:49208901	KLHDC8B	0.51	5.2	0.32	4.37e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs35110281	0.715	rs969060	chr21:45080852	T/G	cg21573476	chr21:45109991	RRP1B	-0.57	-8.27	-0.48	1.05e-14	Mean corpuscular volume;
SARC	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg09699651	chr6:150184138	LRP11	0.39	4.84	0.3	2.41e-6	Lung cancer;
SARC	cis	rs2425143	0.908	rs6060605	chr20:34378132	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-6.01	-0.37	7.08e-9	Blood protein levels;
SARC	cis	rs1003719	0.680	rs3992	chr21:38505969	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-9.13	-0.51	3.35e-17	Eye color traits;
SARC	cis	rs10911232	0.507	rs10797816	chr1:182998486	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.52	0.57	2.05e-21	Hypertriglyceridemia;
SARC	trans	rs3780486	0.846	rs7873903	chr9:33142728	G/A	cg04842962	chr6:43655489	MRPS18A	1.08	18.85	0.78	9.23e-49	IgG glycosylation;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg03749393	chr13:31191824	USPL1	0.53	6.38	0.39	9.36e-10	Blood pressure;
SARC	trans	rs1814175	0.669	rs11040455	chr11:49669829	G/C	cg03929089	chr4:120376271	NA	-0.71	-10.02	-0.55	6.9e-20	Height;
SARC	cis	rs12421382	0.507	rs10890995	chr11:109327622	A/G	cg11473876	chr11:109292803	C11orf87	-0.42	-5.62	-0.35	5.47e-8	Schizophrenia;
SARC	cis	rs4974559	0.739	rs6845586	chr4:1323070	G/A	cg02980000	chr4:1222292	CTBP1	0.65	4.98	0.31	1.23e-6	Systolic blood pressure;
SARC	cis	rs4253772	0.591	rs6520010	chr22:46721223	G/A	cg24881330	chr22:46731750	TRMU	0.84	8.7	0.5	6.12e-16	LDL cholesterol;Cholesterol, total;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg03409937	chr12:110236627	TRPV4	0.5	6.39	0.39	8.98e-10	Schizophrenia;
SARC	cis	rs501120	1.000	rs501120	chr10:44753867	T/C	cg09554077	chr10:44749378	NA	0.48	6.67	0.4	1.85e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs765787	0.530	rs12913123	chr15:45516425	C/T	cg26924012	chr15:45694286	SPATA5L1	0.41	4.89	0.31	1.86e-6	Uric acid levels;
SARC	cis	rs7523050	0.643	rs12752417	chr1:109400639	A/C	cg08274380	chr1:109419600	GPSM2	-1.15	-8.25	-0.48	1.14e-14	Fat distribution (HIV);
SARC	cis	rs2153535	0.541	rs7774752	chr6:8468978	C/T	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	cis	rs7546668	0.640	rs4661634	chr1:15808289	C/T	cg21858823	chr1:15850916	CASP9	0.48	5.87	0.36	1.46e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs4713118	0.628	rs9295740	chr6:27689502	G/A	cg17221315	chr6:27791827	HIST1H4J	0.51	4.81	0.3	2.7e-6	Parkinson's disease;
SARC	trans	rs7824557	0.564	rs2736294	chr8:11234626	T/C	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.72	-0.5	5.4e-16	Retinal vascular caliber;
SARC	cis	rs9354308	0.868	rs6923994	chr6:66555665	C/T	cg07460842	chr6:66804631	NA	-0.45	-5.19	-0.32	4.55e-7	Metabolite levels;
SARC	trans	rs1853207	1.000	rs75280500	chr10:96582914	G/A	cg02737782	chr1:8014393	NA	-0.95	-6.37	-0.39	1.01e-9	Blood metabolite levels;
SARC	cis	rs7959452	0.570	rs10878964	chr12:69720691	T/G	cg14784868	chr12:69753453	YEATS4	0.42	5.5	0.34	9.98e-8	Blood protein levels;
SARC	cis	rs2070997	0.607	rs4504690	chr9:133663764	A/G	cg11464064	chr9:133710261	ABL1	0.62	5.91	0.36	1.18e-8	Response to amphetamines;
SARC	cis	rs459571	1.000	rs467387	chr9:136907005	G/A	cg13789015	chr9:136890014	NCRNA00094	0.64	8.81	0.5	2.91e-16	Platelet distribution width;
SARC	cis	rs9399135	0.967	rs6569990	chr6:135365818	C/T	cg24558204	chr6:135376177	HBS1L	0.46	6.18	0.38	2.88e-9	Red blood cell count;
SARC	cis	rs2228479	0.850	rs3785279	chr16:89824562	G/C	cg00800038	chr16:89945340	TCF25	-0.74	-5.14	-0.32	5.75e-7	Skin colour saturation;
SARC	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg11644478	chr21:40555479	PSMG1	0.87	11.2	0.59	1.41e-23	Cognitive function;
SARC	trans	rs7615952	0.932	rs6438948	chr3:125650045	A/T	cg07211511	chr3:129823064	LOC729375	0.93	10.8	0.58	2.58e-22	Blood pressure (smoking interaction);
SARC	cis	rs2180341	1.000	rs6904520	chr6:127629802	T/C	cg24812749	chr6:127587940	RNF146	0.97	12.89	0.65	4.63e-29	Breast cancer;
SARC	cis	rs6963495	0.818	rs117907809	chr7:105168472	C/A	cg13798780	chr7:105162888	PUS7	0.58	5.31	0.33	2.59e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg11764359	chr7:65958608	NA	0.62	4.94	0.31	1.47e-6	Diabetic kidney disease;
SARC	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.43	5.06	0.31	8.34e-7	Gut microbiome composition (summer);
SARC	cis	rs9467773	0.583	rs2498380	chr6:26643996	C/G	cg11502198	chr6:26597334	ABT1	-0.6	-8.0	-0.46	5.81e-14	Intelligence (multi-trait analysis);
SARC	cis	rs6690583	0.623	rs1371141	chr1:85455372	C/A	cg22153463	chr1:85462885	MCOLN2	0.72	6.96	0.42	3.33e-11	Serum sulfate level;
SARC	cis	rs6570726	0.791	rs440477	chr6:145854188	C/T	cg05347473	chr6:146136440	FBXO30	0.54	7.45	0.44	1.82e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12311304	0.871	rs9787983	chr12:15412898	A/G	cg08258403	chr12:15378311	NA	0.43	6.68	0.4	1.76e-10	Behavioural disinhibition (generation interaction);
SARC	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg08677398	chr8:58056175	NA	0.43	5.09	0.32	7.42e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs782590	0.935	rs782568	chr2:55881538	T/C	cg18811423	chr2:55921094	PNPT1	0.69	10.5	0.57	2.3e-21	Metabolic syndrome;
SARC	cis	rs708547	0.957	rs781667	chr4:57798469	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.61	6.35	0.38	1.11e-9	Response to bleomycin (chromatid breaks);
SARC	cis	rs28374715	0.617	rs16971733	chr15:41562030	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.7	-9.53	-0.53	2.19e-18	Ulcerative colitis;
SARC	cis	rs9467773	1.000	rs4713006	chr6:26519872	A/G	cg12292205	chr6:26970375	C6orf41	0.44	5.46	0.34	1.24e-7	Intelligence (multi-trait analysis);
SARC	trans	rs7615952	0.932	rs13086087	chr3:125646281	A/C	cg07211511	chr3:129823064	LOC729375	-0.96	-10.68	-0.57	6.26e-22	Blood pressure (smoking interaction);
SARC	cis	rs607987	0.871	rs1222220	chr11:30343925	C/A	cg06241208	chr11:30344200	C11orf46	-0.39	-4.86	-0.3	2.17e-6	Body mass index;
SARC	cis	rs9291683	0.588	rs35099040	chr4:10018839	T/C	cg11266682	chr4:10021025	SLC2A9	0.41	7.37	0.43	2.9e-12	Bone mineral density;
SARC	cis	rs17376456	0.877	rs9314100	chr5:93447394	T/C	cg25358565	chr5:93447407	FAM172A	1.32	14.75	0.69	3.21e-35	Diabetic retinopathy;
SARC	cis	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg06636001	chr8:8085503	FLJ10661	0.7	9.61	0.53	1.24e-18	Mood instability;
SARC	cis	rs2075371	1.000	rs447266	chr7:133989543	A/G	cg20476274	chr7:133979776	SLC35B4	0.6	8.07	0.47	3.65e-14	Mean platelet volume;
SARC	cis	rs9341808	0.628	rs9294172	chr6:80918561	G/A	cg08355045	chr6:80787529	NA	0.37	5.85	0.36	1.66e-8	Sitting height ratio;
SARC	cis	rs2180341	1.000	rs3798852	chr6:127636733	A/G	cg17762328	chr6:126965162	NA	-0.46	-5.23	-0.32	3.84e-7	Breast cancer;
SARC	cis	rs2180341	0.920	rs1073931	chr6:127681762	A/T	cg24812749	chr6:127587940	RNF146	1.01	13.21	0.65	4.24e-30	Breast cancer;
SARC	cis	rs924607	0.931	rs1709556	chr5:637058	A/G	cg09021430	chr5:549028	NA	-0.33	-6.16	-0.37	3.18e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	trans	rs9329221	0.683	rs4598253	chr8:9890304	A/T	cg21775007	chr8:11205619	TDH	-0.49	-6.4	-0.39	8.53e-10	Neuroticism;
SARC	cis	rs11581859	0.613	rs6678214	chr1:99184272	T/C	cg20286094	chr1:99190917	SNX7	-0.42	-4.99	-0.31	1.2e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs1401999	1.000	rs4148571	chr3:183720576	A/C	cg01324343	chr3:183735012	ABCC5	0.66	13.3	0.66	2.02e-30	Anterior chamber depth;
SARC	cis	rs1008375	0.931	rs1860592	chr4:17577028	C/G	cg16339924	chr4:17578868	LAP3	0.69	9.17	0.51	2.59e-17	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs3820928	0.874	rs10176882	chr2:227896432	A/T	cg11843606	chr2:227700838	RHBDD1	-0.49	-5.81	-0.36	2.06e-8	Pulmonary function;
SARC	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg22535103	chr8:58192502	C8orf71	-0.69	-8.14	-0.47	2.39e-14	Developmental language disorder (linguistic errors);
SARC	cis	rs10484885	0.877	rs17735389	chr6:90323139	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.55	-4.72	-0.3	4.14e-6	QRS interval (sulfonylurea treatment interaction);
SARC	cis	rs7027203	1.000	rs7854820	chr9:96526027	A/G	cg14598338	chr9:96623480	NA	0.5	6.75	0.4	1.19e-10	DNA methylation (variation);
SARC	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg05368731	chr17:41323189	NBR1	0.78	9.53	0.53	2.2e-18	Menopause (age at onset);
SARC	cis	rs8067545	0.611	rs8078716	chr17:20044291	G/A	cg13482628	chr17:19912719	NA	0.52	6.81	0.41	8.45e-11	Schizophrenia;
SARC	cis	rs6484504	0.532	rs10835757	chr11:31281902	C/T	cg02090638	chr11:31391270	DNAJC24;DCDC1	-0.46	-5.83	-0.36	1.83e-8	Red blood cell count;
SARC	cis	rs72781680	0.848	rs72780199	chr2:24016269	A/C	cg08917208	chr2:24149416	ATAD2B	0.75	7.09	0.42	1.56e-11	Lymphocyte counts;
SARC	cis	rs8114671	0.585	rs2236271	chr20:33523840	G/T	cg07148914	chr20:33460835	GGT7	-0.45	-5.41	-0.33	1.6e-7	Height;
SARC	cis	rs62344088	0.590	rs61710713	chr5:181499	G/A	cg22857025	chr5:266934	NA	-0.84	-5.45	-0.34	1.27e-7	Asthma (childhood onset);
SARC	cis	rs12586317	0.547	rs2383693	chr14:35500205	A/C	cg16230307	chr14:35515116	FAM177A1	1.02	11.85	0.61	1.18e-25	Psoriasis;
SARC	cis	rs7246657	0.525	rs10401417	chr19:37467540	C/T	cg23950597	chr19:37808831	NA	-0.56	-5.08	-0.32	7.72e-7	Coronary artery calcification;
SARC	cis	rs3858526	0.833	rs4758184	chr11:5926719	A/G	cg13902645	chr11:5959945	NA	-0.44	-5.03	-0.31	9.72e-7	DNA methylation (variation);
SARC	cis	rs2295359	0.892	rs10789224	chr1:67605134	C/T	cg12940439	chr1:67600707	NA	-0.48	-7.02	-0.42	2.4e-11	Psoriasis;
SARC	cis	rs9858542	0.953	rs10640	chr3:49454277	G/A	cg03060546	chr3:49711283	APEH	-0.59	-7.32	-0.43	3.91e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs6598955	0.724	rs3924934	chr1:26644079	A/G	cg04990556	chr1:26633338	UBXN11	-0.61	-8.23	-0.47	1.36e-14	Obesity-related traits;
SARC	cis	rs2832077	0.527	rs2832116	chr21:30228368	C/A	cg08807101	chr21:30365312	RNF160	-0.56	-6.3	-0.38	1.45e-9	Cognitive test performance;
SARC	cis	rs12681366	0.537	rs2919656	chr8:95473034	C/T	cg13257157	chr8:95487014	RAD54B	0.4	4.81	0.3	2.67e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs4280164	0.551	rs8008406	chr14:24811159	C/T	cg16194253	chr14:24768981	DHRS1;C14orf21	0.56	6.09	0.37	4.54e-9	Parent of origin effect on language impairment (paternal);
SARC	cis	rs4128725	0.925	rs75431404	chr1:159414685	C/G	cg25076881	chr1:159409836	OR10J1	0.4	4.8	0.3	2.84e-6	Select biomarker traits;
SARC	cis	rs79976124	0.879	rs77185357	chr6:66629070	G/A	cg07460842	chr6:66804631	NA	0.64	6.96	0.41	3.39e-11	Type 2 diabetes;
SARC	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	8.35	0.48	6.15e-15	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs3126085	0.877	rs2338431	chr1:152169305	A/G	cg26876637	chr1:152193138	HRNR	0.48	5.47	0.34	1.14e-7	Atopic dermatitis;
SARC	cis	rs155076	1.000	rs564685	chr13:21846879	A/G	cg11317459	chr13:21872234	NA	-0.98	-12.36	-0.63	2.52e-27	White matter hyperintensity burden;
SARC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg11026874	chr17:30368766	LRRC37B	0.6	6.75	0.4	1.19e-10	Hepatitis;
SARC	cis	rs3126085	0.935	rs11584427	chr1:152299788	A/G	cg03465714	chr1:152285911	FLG	0.44	4.71	0.3	4.18e-6	Atopic dermatitis;
SARC	cis	rs17253792	0.822	rs78386830	chr14:56069224	G/A	cg01858014	chr14:56050164	KTN1	-0.67	-5.16	-0.32	5.38e-7	Putamen volume;
SARC	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg16339924	chr4:17578868	LAP3	0.66	8.76	0.5	4e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1008375	0.835	rs9760627	chr4:17651508	C/T	cg27347728	chr4:17578864	LAP3	0.46	5.67	0.35	4.1e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs2727020	0.521	rs7131163	chr11:49574774	C/T	cg15704280	chr7:45808275	SEPT13	-0.72	-8.25	-0.48	1.2e-14	Coronary artery disease;
SARC	cis	rs501120	1.000	rs622956	chr10:44755183	A/G	cg09554077	chr10:44749378	NA	0.48	6.67	0.4	1.85e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs11583043	1.000	rs35445887	chr1:101523639	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.47	5.21	0.32	4.23e-7	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs1865760	1.000	rs2071298	chr6:25914901	G/A	cg16482183	chr6:26056742	HIST1H1C	0.5	6.15	0.37	3.38e-9	Height;
SARC	cis	rs6831352	0.918	rs1126672	chr4:100047812	G/A	cg13256891	chr4:100009986	ADH5	-0.66	-8.28	-0.48	9.71e-15	Alcohol dependence;
SARC	cis	rs240764	0.658	rs9390679	chr6:101216102	C/T	cg09795085	chr6:101329169	ASCC3	-0.44	-5.64	-0.35	4.87e-8	Neuroticism;
SARC	cis	rs7818688	0.654	rs11783262	chr8:95979816	A/G	cg13393036	chr8:95962371	TP53INP1	0.4	4.85	0.3	2.27e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.96	9.82	0.54	2.78e-19	Platelet count;
SARC	cis	rs1569175	0.655	rs281792	chr2:200850378	C/T	cg23649088	chr2:200775458	C2orf69	-0.74	-4.75	-0.3	3.53e-6	Response to treatment for acute lymphoblastic leukemia;
SARC	cis	rs11644362	0.903	rs2014726	chr16:12992849	T/C	cg06890432	chr16:12997467	SHISA9	-0.54	-7.16	-0.42	1.04e-11	Positive affect;Subjective well-being;
SARC	cis	rs1107366	1.000	rs9874508	chr3:125902417	A/G	cg01346077	chr3:125931526	NA	-0.34	-4.82	-0.3	2.54e-6	Metabolite levels;
SARC	cis	rs6450176	1.000	rs6886510	chr5:53303127	A/G	ch.5.1024479R	chr5:53302184	ARL15	0.66	7.86	0.46	1.39e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg10658240	chr2:181925401	UBE2E3	0.51	6.75	0.4	1.18e-10	Thyroid stimulating hormone;
SARC	trans	rs7815944	0.661	rs11780606	chr8:129355112	G/A	cg17342469	chr22:46473074	NA	0.72	6.83	0.41	7.2e-11	Atopic dermatitis;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg04436397	chr3:180630790	FXR1	0.6	7.59	0.45	7.8e-13	Breast cancer;
SARC	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg18252515	chr7:66147081	NA	0.44	4.75	0.3	3.5e-6	Aortic root size;
SARC	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg16325326	chr1:53192061	ZYG11B	0.95	18.16	0.77	1.68e-46	Monocyte count;
SARC	cis	rs826838	1.000	rs826838	chr12:39106731	C/T	cg26384229	chr12:38710491	ALG10B	-0.79	-12.13	-0.62	1.45e-26	Heart rate;
SARC	cis	rs4481887	1.000	rs6681423	chr1:248482834	C/A	cg13385794	chr1:248469461	NA	0.36	5.47	0.34	1.15e-7	Common traits (Other);
SARC	cis	rs898097	0.812	rs56405605	chr17:80843663	T/C	cg20578329	chr17:80767326	TBCD	-0.51	-6.74	-0.4	1.25e-10	Breast cancer;
SARC	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.74	8.74	0.5	4.58e-16	Height;
SARC	cis	rs3087591	1.000	rs8082020	chr17:29694795	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.49	-5.93	-0.36	1.07e-8	Hip circumference;
SARC	cis	rs13191362	1.000	rs13206253	chr6:163166902	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.59	5.38	0.33	1.84e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs12754538	0.687	rs10864363	chr1:8767311	G/T	cg13785123	chr1:8931135	ENO1	0.42	4.95	0.31	1.44e-6	Subjective well-being;
SARC	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg25036284	chr2:26402008	FAM59B	0.43	5.42	0.33	1.52e-7	Gut microbiome composition (summer);
SARC	cis	rs3820928	0.605	rs6748311	chr2:227792530	T/A	cg05526886	chr2:227700861	RHBDD1	-0.48	-6.03	-0.37	6.52e-9	Pulmonary function;
SARC	cis	rs6450176	1.000	rs3776715	chr5:53299095	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.67	-7.78	-0.45	2.32e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs2073300	0.609	rs56094936	chr20:23401586	G/A	cg16736954	chr20:23401023	NAPB	0.77	4.76	0.3	3.39e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs2576037	0.899	rs2571034	chr18:44578565	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.52	6.68	0.4	1.7e-10	Personality dimensions;
SARC	cis	rs73001065	0.901	rs739846	chr19:19419071	G/A	cg03709012	chr19:19516395	GATAD2A	0.97	5.49	0.34	1.04e-7	LDL cholesterol;
SARC	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg25072359	chr17:41440525	NA	0.54	6.34	0.38	1.15e-9	Menopause (age at onset);
SARC	cis	rs765787	0.530	rs12915027	chr15:45512626	G/A	cg24006582	chr15:45444508	DUOX1	0.45	5.77	0.35	2.53e-8	Uric acid levels;
SARC	cis	rs8180040	0.902	rs73081205	chr3:47517670	A/C	cg27129171	chr3:47204927	SETD2	-0.68	-9.56	-0.53	1.8e-18	Colorectal cancer;
SARC	cis	rs453301	0.686	rs4840389	chr8:8884503	G/C	cg11995313	chr8:8860691	ERI1	0.4	5.18	0.32	4.75e-7	Joint mobility (Beighton score);
SARC	cis	rs7216064	1.000	rs62084238	chr17:65856573	T/A	cg12091567	chr17:66097778	LOC651250	-0.64	-6.37	-0.39	1.01e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs4689388	0.889	rs10026334	chr4:6294607	G/A	cg14416269	chr4:6271139	WFS1	0.32	4.92	0.31	1.61e-6	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs908922	0.676	rs7530609	chr1:152526812	C/A	cg09873164	chr1:152488093	CRCT1	0.61	7.89	0.46	1.18e-13	Hair morphology;
SARC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.8	10.38	0.56	5.49e-21	Prudent dietary pattern;
SARC	cis	rs634534	0.622	rs624273	chr11:65712413	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.46	5.88	0.36	1.42e-8	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs2414059	0.548	rs3098177	chr15:50783777	A/G	cg05456662	chr15:50716270	USP8	-0.39	-4.92	-0.31	1.65e-6	QT interval;
SARC	cis	rs79149102	0.579	rs7166105	chr15:75343942	A/G	cg09165964	chr15:75287851	SCAMP5	0.95	9.01	0.51	7.52e-17	Lung cancer;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg12616926	chr2:161350516	RBMS1	-0.47	-6.3	-0.38	1.46e-9	Thyroid stimulating hormone;
SARC	cis	rs3947	0.855	rs1293327	chr8:11694986	G/A	cg09768257	chr8:11628346	NEIL2	-0.36	-4.75	-0.3	3.53e-6	Blood protein levels;
SARC	cis	rs6840360	1.000	rs6839074	chr4:152603357	A/G	cg22705602	chr4:152727874	NA	0.39	6.76	0.4	1.11e-10	Intelligence (multi-trait analysis);
SARC	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg10876282	chr6:28092338	ZSCAN16	0.49	4.87	0.3	2.11e-6	Parkinson's disease;
SARC	cis	rs2404602	0.647	rs11072628	chr15:77107761	C/A	cg15268244	chr15:77196840	NA	0.43	5.01	0.31	1.07e-6	Blood metabolite levels;
SARC	cis	rs5753037	0.702	rs140100	chr22:30128240	C/T	cg01021169	chr22:30184971	ASCC2	-0.39	-5.22	-0.32	3.95e-7	Type 1 diabetes;
SARC	cis	rs7044106	0.762	rs10760115	chr9:123476952	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	5.94	0.36	1.01e-8	Hip circumference adjusted for BMI;
SARC	cis	rs9486715	0.867	rs9373907	chr6:96981189	G/A	cg18709589	chr6:96969512	KIAA0776	0.62	7.79	0.45	2.18e-13	Headache;
SARC	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg21724239	chr8:58056113	NA	0.75	6.75	0.4	1.14e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7481584	0.624	rs511990	chr11:3052936	A/G	cg20651018	chr11:3035856	CARS	0.41	6.13	0.37	3.73e-9	Calcium levels;
SARC	cis	rs2635047	0.638	rs2668760	chr18:44682891	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.51	6.72	0.4	1.35e-10	Educational attainment;
SARC	cis	rs1008375	1.000	rs6849704	chr4:17652031	G/C	cg02297831	chr4:17616191	MED28	0.49	6.31	0.38	1.39e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg19223190	chr17:80058835	NA	0.46	6.41	0.39	8.01e-10	Life satisfaction;
SARC	cis	rs7474896	0.559	rs1779075	chr10:38167530	C/G	cg25427524	chr10:38739819	LOC399744	0.52	6.46	0.39	6.05e-10	Obesity (extreme);
SARC	cis	rs2952156	0.883	rs1495100	chr17:37832279	C/T	cg20243544	chr17:37824526	PNMT	0.53	6.86	0.41	6.05e-11	Asthma;
SARC	cis	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg25427524	chr10:38739819	LOC399744	0.57	9.08	0.51	4.6e-17	Extrinsic epigenetic age acceleration;
SARC	cis	rs6835098	1.000	rs10027708	chr4:174083116	T/C	cg08422745	chr4:174089978	GALNT7	-0.75	-10.19	-0.56	2.1e-20	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs1468333	0.667	rs4835784	chr5:137730794	T/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.71	8.34	0.48	6.38e-15	Resting heart rate;
SARC	cis	rs9875589	0.957	rs66716710	chr3:13938728	A/G	cg19554555	chr3:13937349	NA	0.51	6.58	0.4	3.16e-10	Ovarian reserve;
SARC	cis	rs7624766	0.743	rs9883862	chr3:160527265	C/A	cg22637730	chr3:160473554	PPM1L	0.43	5.58	0.34	6.58e-8	Response to methotrexate in rheumatoid arthritis;
SARC	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg23758822	chr17:41437982	NA	-0.91	-11.72	-0.61	3.14e-25	Menopause (age at onset);
SARC	cis	rs7662987	0.517	rs1154406	chr4:100008494	T/C	cg13256891	chr4:100009986	ADH5	0.66	8.33	0.48	7.17e-15	Smoking initiation;
SARC	cis	rs17270561	0.636	rs77343532	chr6:25828828	G/A	cg17691542	chr6:26056736	HIST1H1C	0.57	7.34	0.43	3.57e-12	Iron status biomarkers;
SARC	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg10435706	chr6:150039699	LATS1	-0.36	-4.79	-0.3	2.93e-6	Lung cancer;
SARC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.8	10.61	0.57	1.04e-21	Prudent dietary pattern;
SARC	cis	rs9467773	1.000	rs3736781	chr6:26505362	G/A	cg11502198	chr6:26597334	ABT1	0.48	5.98	0.36	8.37e-9	Intelligence (multi-trait analysis);
SARC	cis	rs58235267	0.591	rs2162014	chr2:63345507	C/A	cg17519650	chr2:63277830	OTX1	0.4	4.96	0.31	1.34e-6	Prostate-specific antigen levels (conditioned on lead SNPs);
SARC	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg24549020	chr5:56110836	MAP3K1	0.81	8.46	0.48	3.01e-15	Initial pursuit acceleration;
SARC	cis	rs17125944	0.615	rs1886785	chr14:53312106	A/C	cg00686598	chr14:53173677	PSMC6	-0.63	-4.88	-0.3	2e-6	Alzheimer's disease (late onset);
SARC	cis	rs617791	0.569	rs11227370	chr11:65747693	C/T	cg26695010	chr11:65641043	EFEMP2	0.58	7.12	0.42	1.34e-11	Breast cancer;
SARC	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg11890956	chr21:40555474	PSMG1	1.17	16.7	0.74	1.04e-41	Cognitive function;
SARC	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg00933542	chr6:150070202	PCMT1	0.31	5.27	0.33	3.07e-7	Lung cancer;
SARC	cis	rs1832871	0.672	rs13437296	chr6:158762819	A/C	cg07165851	chr6:158734300	TULP4	0.58	6.78	0.41	9.7e-11	Height;
SARC	cis	rs6121246	0.511	rs879982	chr20:30398510	A/G	cg13852791	chr20:30311386	BCL2L1	0.87	10.91	0.58	1.14e-22	Mean corpuscular hemoglobin;
SARC	cis	rs13256369	0.851	rs13267036	chr8:8566685	G/A	cg17143192	chr8:8559678	CLDN23	0.53	6.0	0.37	7.38e-9	Obesity-related traits;
SARC	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg23758822	chr17:41437982	NA	0.95	12.85	0.64	6.21e-29	Menopause (age at onset);
SARC	cis	rs1707322	1.000	rs2458400	chr1:46530798	C/T	cg03146154	chr1:46216737	IPP	-0.48	-5.63	-0.35	5.16e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg22126032	chr7:116166529	CAV1	-0.62	-7.21	-0.43	7.78e-12	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs2463822	0.583	rs7104825	chr11:62026833	C/T	cg06239285	chr11:62104954	ASRGL1	-0.82	-7.56	-0.44	9.29e-13	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs8114671	0.527	rs6088650	chr20:33514465	C/T	cg07148914	chr20:33460835	GGT7	-0.42	-5.09	-0.32	7.27e-7	Height;
SARC	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg20607798	chr8:58055168	NA	0.52	4.9	0.31	1.76e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs6840360	1.000	rs7671651	chr4:152597202	C/G	cg22705602	chr4:152727874	NA	-0.36	-6.14	-0.37	3.6e-9	Intelligence (multi-trait analysis);
SARC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg26354017	chr1:205819088	PM20D1	0.84	12.63	0.64	3.42e-28	Menarche (age at onset);
SARC	trans	rs10155879	0.837	rs2536262	chr7:85895157	G/A	cg15416352	chr17:2300911	MNT	0.51	6.28	0.38	1.61e-9	Interleukin-4 levels;
SARC	cis	rs73206853	0.544	rs55752061	chr12:111126096	G/C	cg10860002	chr12:110842031	ANAPC7	0.63	5.32	0.33	2.49e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg11203670	chr7:100026453	MEPCE;ZCWPW1	0.52	4.88	0.3	1.95e-6	Platelet count;
SARC	cis	rs4555082	0.915	rs66527719	chr14:105750523	C/G	cg13114125	chr14:105738426	BRF1	-0.8	-12.08	-0.62	2.14e-26	Mean platelet volume;Platelet distribution width;
SARC	cis	rs17253792	0.822	rs10142757	chr14:56074211	C/A	cg01858014	chr14:56050164	KTN1	-0.69	-5.36	-0.33	2.02e-7	Putamen volume;
SARC	cis	rs7681440	0.606	rs1442146	chr4:90748646	C/G	cg06632027	chr4:90757378	SNCA	-0.42	-5.25	-0.33	3.41e-7	Dementia with Lewy bodies;
SARC	cis	rs2228479	0.702	rs62053702	chr16:89860688	G/T	cg00800038	chr16:89945340	TCF25	-0.8	-5.6	-0.34	6.15e-8	Skin colour saturation;
SARC	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg09323728	chr8:95962352	TP53INP1	-0.29	-4.91	-0.31	1.72e-6	Type 2 diabetes;
SARC	cis	rs2439831	0.867	rs689616	chr15:43761901	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	8.35	0.48	6.17e-15	Lung cancer in ever smokers;
SARC	cis	rs3796352	1.000	rs11718538	chr3:52975987	C/G	cg15956490	chr3:53032818	SFMBT1	0.79	5.18	0.32	4.85e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs929354	0.685	rs7807856	chr7:156934498	T/C	cg05182265	chr7:156933206	UBE3C	-0.34	-5.19	-0.32	4.49e-7	Body mass index;
SARC	cis	rs826838	0.935	rs1160162	chr12:38959795	G/A	cg13010199	chr12:38710504	ALG10B	0.77	10.61	0.57	1.01e-21	Heart rate;
SARC	cis	rs7312933	0.558	rs11181502	chr12:42823833	A/G	cg19980929	chr12:42632907	YAF2	0.47	6.63	0.4	2.27e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs412000	0.560	rs4793583	chr17:56451407	A/C	cg12560992	chr17:57184187	TRIM37	-0.76	-9.5	-0.53	2.63e-18	Primary tooth development (time to first tooth eruption);
SARC	cis	rs950776	0.518	rs12594391	chr15:78816240	A/G	cg06917634	chr15:78832804	PSMA4	0.9	13.8	0.67	4.79e-32	Sudden cardiac arrest;
SARC	cis	rs3126085	0.935	rs11204952	chr1:152227321	G/A	cg26876637	chr1:152193138	HRNR	0.45	5.2	0.32	4.35e-7	Atopic dermatitis;
SARC	cis	rs12311304	1.000	rs11056412	chr12:15406943	T/C	cg08258403	chr12:15378311	NA	0.47	7.13	0.42	1.23e-11	Behavioural disinhibition (generation interaction);
SARC	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg19680485	chr15:31195859	MTMR15	-0.58	-6.88	-0.41	5.42e-11	Huntington's disease progression;
SARC	cis	rs3733585	0.673	rs4467564	chr4:9953472	G/T	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.39	-0.33	1.76e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs9325144	0.555	rs4882358	chr12:38726640	A/G	cg26384229	chr12:38710491	ALG10B	0.6	7.86	0.46	1.39e-13	Morning vs. evening chronotype;
SARC	cis	rs796364	0.806	rs11688168	chr2:200916004	G/A	cg23649088	chr2:200775458	C2orf69	-0.6	-5.29	-0.33	2.77e-7	Schizophrenia;
SARC	cis	rs7000551	0.675	rs2443503	chr8:22381850	A/G	cg12081754	chr8:22256438	SLC39A14	0.56	7.75	0.45	2.81e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs2834188	1.000	rs2834188	chr21:34689253	A/G	cg14352951	chr21:34696688	IFNAR1	0.46	5.56	0.34	7.2e-8	Narcolepsy;
SARC	cis	rs9341808	0.690	rs2505932	chr6:80839252	G/T	cg08355045	chr6:80787529	NA	0.35	5.68	0.35	3.98e-8	Sitting height ratio;
SARC	cis	rs11997175	0.670	rs34985841	chr8:33661889	C/A	ch.8.33884649F	chr8:33765107	NA	0.49	6.6	0.4	2.67e-10	Body mass index;
SARC	cis	rs501120	1.000	rs671765	chr10:44752976	A/G	cg09554077	chr10:44749378	NA	0.52	7.14	0.42	1.15e-11	Coronary artery disease;Coronary heart disease;
SARC	cis	rs2816062	0.786	rs2745317	chr1:18896552	G/A	cg18795169	chr1:18902165	NA	-0.79	-12.77	-0.64	1.18e-28	Urate levels in lean individuals;
SARC	cis	rs9399135	0.660	rs9389248	chr6:135282656	T/C	cg24558204	chr6:135376177	HBS1L	0.47	6.24	0.38	2e-9	Red blood cell count;
SARC	cis	rs881375	0.967	rs7875829	chr9:123660398	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.41	4.95	0.31	1.4e-6	Rheumatoid arthritis;
SARC	cis	rs7662987	0.517	rs1377689	chr4:100021787	A/G	cg13256891	chr4:100009986	ADH5	0.66	8.13	0.47	2.55e-14	Smoking initiation;
SARC	cis	rs9840812	0.953	rs34330586	chr3:135800409	A/T	cg15507776	chr3:136538369	TMEM22	-0.46	-4.83	-0.3	2.52e-6	Fibrinogen levels;
SARC	cis	rs2594989	0.616	rs6442255	chr3:11474492	A/G	cg00170343	chr3:11313890	ATG7	0.58	5.61	0.35	5.67e-8	Circulating chemerin levels;
SARC	cis	rs4243830	0.649	rs11579888	chr1:6609896	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.87	-8.42	-0.48	3.98e-15	Body mass index;
SARC	cis	rs2694528	0.609	rs1379112	chr5:59995742	C/A	cg11474532	chr5:59995715	DEPDC1B	0.94	6.61	0.4	2.64e-10	Parkinson's disease;
SARC	cis	rs4713118	0.911	rs9461406	chr6:27719764	C/T	cg17221315	chr6:27791827	HIST1H4J	-0.51	-5.35	-0.33	2.05e-7	Parkinson's disease;
SARC	cis	rs7246657	0.943	rs10420722	chr19:37973774	C/G	cg23950597	chr19:37808831	NA	-0.61	-5.71	-0.35	3.44e-8	Coronary artery calcification;
SARC	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.41	-6.22	-0.38	2.33e-9	Total body bone mineral density;
SARC	cis	rs4803468	0.967	rs4802116	chr19:41905540	C/T	cg08477640	chr19:41863820	B9D2	0.48	6.27	0.38	1.77e-9	Height;
SARC	cis	rs9470366	0.816	rs1321310	chr6:36623124	C/T	cg08179530	chr6:36648295	CDKN1A	-0.52	-5.74	-0.35	2.93e-8	QRS duration;
SARC	cis	rs208520	1.000	rs12212063	chr6:66985148	C/A	cg07460842	chr6:66804631	NA	0.8	9.33	0.52	8.5e-18	Exhaled nitric oxide output;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg25495311	chr6:116454307	NT5DC1	0.46	6.35	0.38	1.15e-9	Thyroid stimulating hormone;
SARC	cis	rs509477	1.000	rs7236052	chr18:32574540	A/G	cg23791764	chr18:32556832	MAPRE2	-0.56	-6.55	-0.39	3.64e-10	Cerebrospinal fluid AB1-42 levels;
SARC	cis	rs9660992	0.512	rs12123773	chr1:205122420	C/G	cg21545522	chr1:205238299	TMCC2	0.35	4.95	0.31	1.42e-6	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs854765	0.583	rs8070128	chr17:17804725	C/T	cg05444541	chr17:17804740	TOM1L2	0.3	5.21	0.32	4.07e-7	Total body bone mineral density;
SARC	cis	rs12541335	0.536	rs4266653	chr8:22169087	A/G	cg02788857	chr8:22132959	PIWIL2	0.37	5.3	0.33	2.67e-7	Hypertriglyceridemia;
SARC	cis	rs208515	0.556	rs12214562	chr6:66681011	T/A	cg07460842	chr6:66804631	NA	0.96	11.01	0.59	5.47e-23	Exhaled nitric oxide levels;
SARC	cis	rs7666738	0.830	rs4699574	chr4:98725544	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.54	0.49	1.74e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs79149102	0.737	rs74450883	chr15:75193432	A/G	cg09165964	chr15:75287851	SCAMP5	-1.12	-7.21	-0.43	7.58e-12	Lung cancer;
SARC	cis	rs1003719	0.713	rs7277150	chr21:38490006	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.95	0.51	1.17e-16	Eye color traits;
SARC	cis	rs10870270	1.000	rs4880263	chr10:133787629	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.82	-9.73	-0.54	5.44e-19	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg02475777	chr4:1388615	CRIPAK	0.61	7.18	0.43	9.48e-12	Longevity;
SARC	cis	rs3815700	1.000	rs8104328	chr19:33094371	G/A	cg24916020	chr19:33096688	ANKRD27	0.56	5.41	0.33	1.59e-7	Eosinophilic esophagitis;
SARC	cis	rs2486288	0.587	rs12899942	chr15:45547280	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.5	-6.29	-0.38	1.57e-9	Glomerular filtration rate;
SARC	trans	rs7824557	0.836	rs2736378	chr8:11119760	G/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-6.84	-0.41	6.98e-11	Retinal vascular caliber;
SARC	cis	rs17270561	0.609	rs4711101	chr6:25741970	A/G	cg17691542	chr6:26056736	HIST1H1C	0.61	7.36	0.43	3.06e-12	Iron status biomarkers;
SARC	cis	rs16986825	0.599	rs34751572	chr22:29170138	C/G	cg15103426	chr22:29168792	CCDC117	0.62	5.98	0.36	8.48e-9	Pancreatic cancer;
SARC	cis	rs8044995	0.563	rs61746794	chr16:68387457	C/T	cg05110241	chr16:68378359	PRMT7	-0.7	-6.78	-0.41	9.58e-11	Schizophrenia;
SARC	cis	rs7904368	0.707	rs12253979	chr10:16853415	T/C	cg14835575	chr10:16859367	RSU1	0.77	7.61	0.45	6.82e-13	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs2115536	1.000	rs11637477	chr15:80193295	C/T	cg00225070	chr15:80189496	MTHFS	0.66	9.0	0.51	8.05e-17	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
SARC	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg27266027	chr21:40555129	PSMG1	-0.5	-5.59	-0.34	6.37e-8	Cognitive function;
SARC	cis	rs898097	0.812	rs8065641	chr17:80820259	A/G	cg15664640	chr17:80829946	TBCD	-0.54	-8.38	-0.48	5.19e-15	Breast cancer;
SARC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.96	10.21	0.56	1.81e-20	Platelet count;
SARC	cis	rs870825	0.698	rs28412823	chr4:185638829	T/C	cg04058563	chr4:185651563	MLF1IP	0.81	11.26	0.59	9.09e-24	Blood protein levels;
SARC	cis	rs7712401	0.601	rs35858098	chr5:122334365	A/G	cg19412675	chr5:122181750	SNX24	-0.43	-5.43	-0.34	1.41e-7	Mean platelet volume;
SARC	cis	rs7520050	0.966	rs7556615	chr1:46461369	G/A	cg24296786	chr1:45957014	TESK2	0.38	4.87	0.3	2.04e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs2635047	0.967	rs9960264	chr18:44606996	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.65	8.61	0.49	1.11e-15	Educational attainment;
SARC	cis	rs1865760	0.865	rs9467650	chr6:25958235	A/G	cg10373733	chr6:25993375	NA	0.4	4.8	0.3	2.82e-6	Height;
SARC	cis	rs910316	0.935	rs3742771	chr14:75599647	A/G	cg23033748	chr14:75592666	NEK9	0.37	5.21	0.32	4.06e-7	Height;
SARC	cis	rs9427116	0.502	rs12125166	chr1:154582129	A/G	cg04143106	chr1:153963266	RPS27	-0.41	-4.91	-0.31	1.74e-6	Blood protein levels;
SARC	cis	rs526231	0.543	rs158400	chr5:102413332	T/C	cg23492399	chr5:102201601	PAM	-0.51	-5.52	-0.34	8.81e-8	Primary biliary cholangitis;
SARC	trans	rs208520	1.000	rs12189683	chr6:66977716	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.83	-9.3	-0.52	1.06e-17	Exhaled nitric oxide output;
SARC	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg21724239	chr8:58056113	NA	0.6	6.31	0.38	1.43e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg26354017	chr1:205819088	PM20D1	-0.46	-5.83	-0.36	1.86e-8	Menarche (age at onset);
SARC	cis	rs1707322	1.000	rs4390216	chr1:46266456	C/T	cg06784218	chr1:46089804	CCDC17	0.33	5.76	0.35	2.66e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs910316	1.000	rs175436	chr14:75608683	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.49	-6.79	-0.41	9.19e-11	Height;
SARC	cis	rs3733585	0.699	rs6844316	chr4:9958977	A/G	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.55	-0.34	7.65e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs3825932	0.701	rs1036937	chr15:79237180	C/A	cg25744700	chr15:79237217	CTSH	0.37	4.98	0.31	1.24e-6	Type 1 diabetes;
SARC	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg25894440	chr7:65020034	NA	-0.71	-5.4	-0.33	1.62e-7	Diabetic kidney disease;
SARC	cis	rs10979	1.000	rs9403504	chr6:143885430	G/A	cg25407410	chr6:143891975	LOC285740	-0.6	-7.87	-0.46	1.31e-13	Hypospadias;
SARC	cis	rs8067354	0.645	rs72840522	chr17:57829992	G/A	cg13753209	chr17:57696993	CLTC	0.67	7.24	0.43	6.46e-12	Hemoglobin concentration;
SARC	cis	rs7223966	1.000	rs8069687	chr17:61883023	C/T	cg26338869	chr17:61819248	STRADA	-0.47	-5.01	-0.31	1.09e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg14159672	chr1:205819179	PM20D1	0.97	18.51	0.77	1.17e-47	Menarche (age at onset);
SARC	cis	rs3126085	0.935	rs12027807	chr1:152253726	C/G	cg03465714	chr1:152285911	FLG	-0.46	-5.55	-0.34	7.61e-8	Atopic dermatitis;
SARC	cis	rs858239	0.614	rs10229956	chr7:23402936	C/G	cg23682824	chr7:23144976	KLHL7	-0.45	-5.6	-0.34	5.91e-8	Cerebrospinal fluid biomarker levels;
SARC	cis	rs4957048	0.891	rs11960196	chr5:568857	C/A	cg07777115	chr5:623756	CEP72	-0.56	-5.16	-0.32	5.32e-7	Ulcerative colitis;
SARC	cis	rs2204008	0.594	rs11531211	chr12:37998007	T/G	cg13010199	chr12:38710504	ALG10B	-0.65	-8.7	-0.5	6.06e-16	Bladder cancer;
SARC	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg21782813	chr7:2030301	MAD1L1	0.39	6.07	0.37	5.07e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs12579753	0.917	rs7138533	chr12:82187885	C/G	cg07988820	chr12:82153109	PPFIA2	-0.52	-6.14	-0.37	3.55e-9	Resting heart rate;
SARC	cis	rs8180040	0.620	rs11715121	chr3:47072621	T/A	cg27129171	chr3:47204927	SETD2	-0.7	-9.5	-0.53	2.59e-18	Colorectal cancer;
SARC	cis	rs5167	0.601	rs892131	chr19:45496996	C/T	cg09555818	chr19:45449301	APOC2	0.39	5.2	0.32	4.38e-7	Blood protein levels;
SARC	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg04277193	chr17:41438351	NA	0.44	4.75	0.3	3.63e-6	Menopause (age at onset);
SARC	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg02931644	chr1:25747376	RHCE	0.47	7.97	0.46	6.87e-14	Erythrocyte sedimentation rate;
SARC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.8	10.38	0.56	5.49e-21	Prudent dietary pattern;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg08090396	chr3:52805200	NEK4	0.5	6.45	0.39	6.57e-10	Breast cancer;
SARC	cis	rs2180341	0.814	rs6940933	chr6:127732740	C/G	cg24812749	chr6:127587940	RNF146	0.78	9.75	0.54	4.84e-19	Breast cancer;
SARC	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg19346786	chr7:2764209	NA	-0.42	-6.31	-0.38	1.36e-9	Height;
SARC	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg11890956	chr21:40555474	PSMG1	1.18	16.91	0.74	2.18e-42	Cognitive function;
SARC	cis	rs7914558	0.966	rs2297786	chr10:104679978	C/T	cg04362960	chr10:104952993	NT5C2	0.41	4.9	0.31	1.78e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs2576037	0.796	rs2571032	chr18:44578250	T/A	cg15049968	chr18:44337910	ST8SIA5	0.33	5.43	0.34	1.39e-7	Personality dimensions;
SARC	cis	rs918629	0.761	rs10073752	chr5:95279233	A/C	cg16656078	chr5:95278638	ELL2	-0.69	-8.14	-0.47	2.38e-14	IgG glycosylation;
SARC	cis	rs17270561	0.609	rs9356984	chr6:25725481	C/T	cg16482183	chr6:26056742	HIST1H1C	-0.4	-4.78	-0.3	3.12e-6	Iron status biomarkers;
SARC	cis	rs739401	0.527	rs423236	chr11:3065916	C/T	cg05729581	chr11:3078854	CARS	-0.48	-6.21	-0.38	2.43e-9	Longevity;
SARC	cis	rs8180040	0.620	rs6768722	chr3:47079112	G/A	cg27129171	chr3:47204927	SETD2	0.7	9.5	0.53	2.59e-18	Colorectal cancer;
SARC	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.59	-7.06	-0.42	1.9e-11	Gut microbiome composition (summer);
SARC	cis	rs5022636	0.507	rs2800953	chr1:151338570	A/G	cg13175981	chr1:150552382	MCL1	-0.53	-5.72	-0.35	3.18e-8	Gut microbiota (functional units);
SARC	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.77	11.01	0.59	5.64e-23	Personality dimensions;
SARC	cis	rs12900463	0.813	rs187316	chr15:85405995	T/C	cg24253500	chr15:84953950	NA	0.35	4.79	0.3	2.98e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);
SARC	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg11062466	chr8:58055876	NA	0.63	5.84	0.36	1.77e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2439831	1.000	rs2245790	chr15:43744457	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	10.76	0.58	3.42e-22	Lung cancer in ever smokers;
SARC	cis	rs738322	0.935	rs75387	chr22:38572057	C/T	cg25457927	chr22:38595422	NA	-0.29	-5.95	-0.36	9.7e-9	Cutaneous nevi;
SARC	cis	rs4481887	0.888	rs12042602	chr1:248482053	C/T	cg13385794	chr1:248469461	NA	0.33	5.09	0.32	7.48e-7	Common traits (Other);
SARC	cis	rs9303542	0.694	rs9906950	chr17:46577167	A/G	cg04904318	chr17:46607828	HOXB1	0.4	4.98	0.31	1.22e-6	Ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs4332037	0.539	rs34571717	chr7:2106855	T/C	cg23043544	chr7:2124092	MAD1L1	-0.35	-4.82	-0.3	2.58e-6	Bipolar disorder;
SARC	cis	rs5753618	0.509	rs2413033	chr22:31574213	A/G	cg07713946	chr22:31675144	LIMK2	-0.39	-5.58	-0.34	6.74e-8	Colorectal cancer;
SARC	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg12463550	chr7:65579703	CRCP	0.55	5.86	0.36	1.54e-8	Aortic root size;
SARC	cis	rs4660306	0.672	rs532639	chr1:46024481	T/C	cg24296786	chr1:45957014	TESK2	0.42	4.89	0.31	1.86e-6	Homocysteine levels;
SARC	cis	rs7945705	0.747	rs2742480	chr11:8993130	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-7.04	-0.42	2.16e-11	Hemoglobin concentration;
SARC	cis	rs7666738	0.830	rs2865980	chr4:99027422	T/G	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9457247	0.934	rs2345571	chr6:167403400	T/G	cg23791538	chr6:167370224	RNASET2	-0.63	-8.73	-0.5	4.84e-16	Crohn's disease;
SARC	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg06634786	chr22:41940651	POLR3H	-0.57	-6.73	-0.4	1.29e-10	Vitiligo;
SARC	cis	rs2073499	1.000	rs2071803	chr3:50407344	G/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.64	4.89	0.31	1.89e-6	Schizophrenia;
SARC	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg18404041	chr3:52824283	ITIH1	-0.38	-5.61	-0.35	5.58e-8	Bipolar disorder;
SARC	cis	rs986417	1.000	rs12147690	chr14:60924009	A/G	cg27398547	chr14:60952738	C14orf39	1.02	9.54	0.53	2.06e-18	Gut microbiota (bacterial taxa);
SARC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.7	9.48	0.53	3.03e-18	Lymphocyte counts;
SARC	cis	rs1865760	0.786	rs1436308	chr6:25939567	T/G	cg17691542	chr6:26056736	HIST1H1C	0.61	7.76	0.45	2.73e-13	Height;
SARC	cis	rs9325144	0.681	rs7957376	chr12:39096518	C/T	cg26384229	chr12:38710491	ALG10B	0.68	6.99	0.42	2.94e-11	Morning vs. evening chronotype;
SARC	cis	rs7589342	0.839	rs10192144	chr2:106439854	A/G	cg16077055	chr2:106428750	NCK2	0.33	5.96	0.36	9.24e-9	Addiction;
SARC	cis	rs3820928	0.967	rs720501	chr2:227778445	C/T	cg11843606	chr2:227700838	RHBDD1	-0.53	-6.61	-0.4	2.67e-10	Pulmonary function;
SARC	cis	rs8180040	0.620	rs4683322	chr3:47093189	T/C	cg27129171	chr3:47204927	SETD2	0.69	9.48	0.53	3.01e-18	Colorectal cancer;
SARC	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg08677398	chr8:58056175	NA	0.44	5.24	0.32	3.59e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6963495	0.818	rs56177071	chr7:105165648	C/T	cg13798780	chr7:105162888	PUS7	0.6	5.56	0.34	7.22e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs7582180	0.663	rs930374	chr2:100962700	A/G	cg14675211	chr2:100938903	LONRF2	0.51	7.64	0.45	5.61e-13	Intelligence (multi-trait analysis);
SARC	cis	rs9916302	0.706	rs582176	chr17:37453999	T/C	cg07936489	chr17:37558343	FBXL20	0.75	8.92	0.5	1.37e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg13939156	chr17:80058883	NA	0.4	6.22	0.38	2.23e-9	Life satisfaction;
SARC	cis	rs2180341	0.576	rs2057224	chr6:127624414	C/G	cg24812749	chr6:127587940	RNF146	0.6	7.45	0.44	1.8e-12	Breast cancer;
SARC	cis	rs2180341	0.782	rs6912196	chr6:127722732	C/G	cg24812749	chr6:127587940	RNF146	0.77	10.24	0.56	1.47e-20	Breast cancer;
SARC	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg11987759	chr7:65425863	GUSB	-0.46	-5.88	-0.36	1.42e-8	Aortic root size;
SARC	cis	rs11770686	0.766	rs13222599	chr7:75335041	A/G	cg17787366	chr7:75369077	HIP1	0.43	5.39	0.33	1.75e-7	Essential tremor;
SARC	cis	rs6582630	0.622	rs11182004	chr12:38441254	G/A	cg13010199	chr12:38710504	ALG10B	-0.46	-5.63	-0.35	5.19e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9733	0.818	rs11204695	chr1:150657011	T/G	cg13175981	chr1:150552382	MCL1	0.65	8.99	0.51	8.45e-17	Tonsillectomy;
SARC	cis	rs17376456	0.825	rs28705226	chr5:93233135	T/C	cg25358565	chr5:93447407	FAM172A	1.28	14.23	0.68	1.75e-33	Diabetic retinopathy;
SARC	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg04944784	chr2:26401820	FAM59B	0.51	6.33	0.38	1.25e-9	Gut microbiome composition (summer);
SARC	cis	rs2404602	0.716	rs17460201	chr15:76673627	C/T	cg26408565	chr15:76604113	ETFA	0.38	5.07	0.32	8.17e-7	Blood metabolite levels;
SARC	cis	rs6502050	0.787	rs7222326	chr17:80057272	T/C	cg13939156	chr17:80058883	NA	0.39	6.24	0.38	2.1e-9	Life satisfaction;
SARC	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg19671926	chr4:122722719	EXOSC9	-0.55	-6.26	-0.38	1.84e-9	Type 2 diabetes;
SARC	cis	rs3768617	0.811	rs4285667	chr1:182970225	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.63	8.63	0.49	9.67e-16	Fuchs's corneal dystrophy;
SARC	cis	rs9815354	0.812	rs73069208	chr3:41939198	C/T	cg03022575	chr3:42003672	ULK4	0.7	5.7	0.35	3.66e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs4595586	0.545	rs11610886	chr12:39390613	C/G	cg26384229	chr12:38710491	ALG10B	0.5	6.12	0.37	3.98e-9	Morning vs. evening chronotype;
SARC	cis	rs2228479	0.850	rs12597296	chr16:89822331	C/T	cg26513180	chr16:89883248	FANCA	0.72	4.79	0.3	2.99e-6	Skin colour saturation;
SARC	cis	rs7772486	0.566	rs735536	chr6:146036832	A/C	cg23711669	chr6:146136114	FBXO30	-0.8	-12.71	-0.64	1.82e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs965469	1.000	rs2236107	chr20:3285821	C/T	cg25506879	chr20:3388711	C20orf194	-0.49	-5.31	-0.33	2.52e-7	IFN-related cytopenia;
SARC	cis	rs1707322	0.964	rs10890358	chr1:46319025	T/A	cg03146154	chr1:46216737	IPP	0.47	5.67	0.35	4.31e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6952808	0.636	rs73048162	chr7:1949328	T/C	cg21782813	chr7:2030301	MAD1L1	0.37	5.77	0.35	2.52e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg18252515	chr7:66147081	NA	-1.29	-11.29	-0.59	7.43e-24	Diabetic kidney disease;
SARC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg02592271	chr2:27665507	KRTCAP3	0.43	6.77	0.41	1.01e-10	Total body bone mineral density;
SARC	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg07636037	chr3:49044803	WDR6	1.01	17.82	0.76	2.13e-45	Parkinson's disease;
SARC	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	7.88	0.46	1.28e-13	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg02725872	chr8:58115012	NA	-0.36	-6.37	-0.39	1.01e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	15.58	0.71	5.4e-38	Chronic sinus infection;
SARC	cis	rs9868809	0.772	rs9809222	chr3:48714411	C/T	cg03060546	chr3:49711283	APEH	-0.55	-5.12	-0.32	6.27e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs7524258	0.868	rs4243825	chr1:7308264	T/C	cg07173049	chr1:7289937	CAMTA1	0.38	7.24	0.43	6.54e-12	Tourette's syndrome or obsessive-compulsive disorder;
SARC	cis	rs9359856	0.564	rs34766278	chr6:90397132	G/C	cg13799429	chr6:90582589	CASP8AP2	-0.58	-4.73	-0.3	3.81e-6	Bipolar disorder;
SARC	cis	rs9392918	0.622	rs9328438	chr6:7699382	T/G	cg23089261	chr6:7723385	NA	0.53	6.76	0.4	1.11e-10	Height;
SARC	cis	rs6120849	0.754	rs6120828	chr20:33674460	A/G	cg06115741	chr20:33292138	TP53INP2	0.52	4.91	0.31	1.7e-6	Protein C levels;
SARC	trans	rs61931739	0.890	rs1849160	chr12:34140191	A/G	cg26384229	chr12:38710491	ALG10B	0.6	7.92	0.46	9.43e-14	Morning vs. evening chronotype;
SARC	cis	rs7584330	0.554	rs7582964	chr2:238385766	C/T	cg08992911	chr2:238395768	MLPH	-0.54	-4.77	-0.3	3.23e-6	Prostate cancer;
SARC	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg16680214	chr1:154839983	KCNN3	-0.36	-5.62	-0.35	5.36e-8	Prostate cancer;
SARC	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg13385521	chr17:29058706	SUZ12P	0.74	6.88	0.41	5.53e-11	Body mass index;
SARC	cis	rs1008375	1.000	rs4698651	chr4:17694223	A/G	cg02297831	chr4:17616191	MED28	0.39	4.8	0.3	2.78e-6	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6089584	0.526	rs6061965	chr20:60607858	A/C	cg06108461	chr20:60628389	TAF4	-0.67	-8.63	-0.49	9.7e-16	Body mass index;
SARC	cis	rs6988636	1.000	rs58177772	chr8:124188067	T/C	cg23067535	chr8:124195133	FAM83A	-0.69	-5.46	-0.34	1.24e-7	Urinary uromodulin levels;
SARC	cis	rs875971	0.597	rs11763224	chr7:65983615	G/T	cg11764359	chr7:65958608	NA	0.65	6.41	0.39	7.78e-10	Aortic root size;
SARC	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg13628971	chr7:2884303	GNA12	-0.67	-8.11	-0.47	2.92e-14	Height;
SARC	cis	rs10779751	0.770	rs2275527	chr1:11190646	A/G	cg08854313	chr1:11322531	MTOR	0.74	9.4	0.52	5.2e-18	Body mass index;
SARC	cis	rs477692	0.544	rs7923750	chr10:131446895	G/C	cg05714579	chr10:131428358	MGMT	-0.66	-8.69	-0.49	6.74e-16	Response to temozolomide;
SARC	cis	rs763121	0.853	rs4821816	chr22:39113134	G/A	cg21395723	chr22:39101663	GTPBP1	0.56	6.82	0.41	7.89e-11	Menopause (age at onset);
SARC	cis	rs9788682	0.633	rs2656070	chr15:78730252	A/G	cg24631222	chr15:78858424	CHRNA5	-0.73	-8.81	-0.5	2.9e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg24209194	chr3:40518798	ZNF619	0.66	8.16	0.47	2.08e-14	Renal cell carcinoma;
SARC	trans	rs61931739	0.782	rs451940	chr12:34196005	T/C	cg13010199	chr12:38710504	ALG10B	0.58	7.68	0.45	4.49e-13	Morning vs. evening chronotype;
SARC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.35	5.32	0.33	2.42e-7	Electroencephalogram traits;
SARC	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg24633833	chr3:10029261	TMEM111	0.53	5.48	0.34	1.13e-7	Alzheimer's disease;
SARC	cis	rs7927592	0.956	rs7113287	chr11:68372186	A/T	cg01657329	chr11:68192670	LRP5	-0.39	-4.88	-0.3	1.99e-6	Total body bone mineral density;
SARC	cis	rs644799	1.000	rs586498	chr11:95537828	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.7	9.55	0.53	1.87e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9486719	1.000	rs11757063	chr6:96884886	C/T	cg06623918	chr6:96969491	KIAA0776	-0.76	-8.43	-0.48	3.56e-15	Migraine;Coronary artery disease;
SARC	cis	rs3126085	0.935	rs10888466	chr1:152166223	A/C	cg26876637	chr1:152193138	HRNR	-0.5	-5.72	-0.35	3.24e-8	Atopic dermatitis;
SARC	cis	rs703842	1.000	rs1599932	chr12:58177943	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.78	11.25	0.59	9.62e-24	Multiple sclerosis;
SARC	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg11211951	chr8:145729740	GPT	-0.51	-7.64	-0.45	5.65e-13	Age at first birth;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg06333435	chr8:22102724	POLR3D;MIR320A	-0.55	-6.94	-0.41	3.96e-11	Gallstone disease;
SARC	cis	rs523522	0.926	rs10849766	chr12:121025894	G/A	cg12219531	chr12:120966889	COQ5	0.82	10.7	0.57	5.52e-22	High light scatter reticulocyte count;
SARC	cis	rs78456975	1.000	rs13414537	chr2:1556330	C/T	cg01028140	chr2:1542097	TPO	-0.54	-5.53	-0.34	8.54e-8	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs2153535	0.601	rs9502719	chr6:8541032	A/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.57	0.49	1.42e-15	Motion sickness;
SARC	cis	rs1044826	0.957	rs12494556	chr3:139223719	T/C	cg15131784	chr3:139108705	COPB2	0.47	5.32	0.33	2.4e-7	Obesity-related traits;
SARC	cis	rs2645694	0.533	rs2645680	chr4:77820956	T/C	cg18351406	chr4:77819688	ANKRD56	0.45	6.31	0.38	1.37e-9	Emphysema distribution in smoking;
SARC	cis	rs7772486	0.622	rs1292333	chr6:145982344	C/T	cg23711669	chr6:146136114	FBXO30	-0.79	-12.68	-0.64	2.33e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11792861	0.926	rs72607166	chr9:111821530	A/C	cg13535736	chr9:111863775	C9orf5	-0.41	-5.05	-0.31	8.85e-7	Menarche (age at onset);
SARC	cis	rs7582180	0.614	rs4340543	chr2:101005511	G/A	cg14675211	chr2:100938903	LONRF2	0.53	8.03	0.47	4.86e-14	Intelligence (multi-trait analysis);
SARC	cis	rs4727027	0.727	rs3801980	chr7:148878620	T/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	5.77	0.35	2.49e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs72781680	0.898	rs72780125	chr2:24000145	T/C	cg08917208	chr2:24149416	ATAD2B	0.93	8.88	0.5	1.86e-16	Lymphocyte counts;
SARC	cis	rs708547	0.836	rs1625691	chr4:57845740	T/C	cg14719990	chr4:57843890	C4orf14;POLR2B	0.44	5.14	0.32	5.75e-7	Response to bleomycin (chromatid breaks);
SARC	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg02592271	chr2:27665507	KRTCAP3	-0.41	-6.24	-0.38	2.06e-9	Total body bone mineral density;
SARC	cis	rs10782582	0.545	rs111927462	chr1:76195422	A/G	cg10523679	chr1:76189770	ACADM	-0.45	-5.38	-0.33	1.77e-7	Daytime sleep phenotypes;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg19873842	chr12:26204575	RASSF8	0.49	6.81	0.41	8.31e-11	Thyroid stimulating hormone;
SARC	cis	rs7264396	0.563	rs2425137	chr20:34345396	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-6.03	-0.37	6.36e-9	Total cholesterol levels;
SARC	cis	rs9858542	0.951	rs1800668	chr3:49395757	G/A	cg03060546	chr3:49711283	APEH	-0.58	-7.24	-0.43	6.34e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs9902453	0.765	rs2169810	chr17:28167941	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	7.05	0.42	1.96e-11	Coffee consumption (cups per day);
SARC	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg06558623	chr16:89946397	TCF25	0.85	7.28	0.43	5.23e-12	Skin colour saturation;
SARC	trans	rs7815944	1.000	rs76344458	chr8:129396016	C/T	cg17342469	chr22:46473074	NA	0.71	6.7	0.4	1.58e-10	Atopic dermatitis;
SARC	cis	rs7681440	0.606	rs2736998	chr4:90754336	A/C	cg06632027	chr4:90757378	SNCA	0.44	5.64	0.35	4.79e-8	Dementia with Lewy bodies;
SARC	cis	rs7617773	0.707	rs13061269	chr3:48373343	C/T	cg11946769	chr3:48343235	NME6	0.76	9.57	0.53	1.61e-18	Coronary artery disease;
SARC	cis	rs11249608	0.548	rs62393076	chr5:178450646	C/G	cg21905437	chr5:178450457	ZNF879	0.59	8.04	0.47	4.41e-14	Pubertal anthropometrics;
SARC	cis	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg25894440	chr7:65020034	NA	-0.77	-5.95	-0.36	9.84e-9	Diabetic kidney disease;
SARC	cis	rs73198271	0.562	rs113730597	chr8:8651573	G/A	cg01851573	chr8:8652454	MFHAS1	0.39	4.72	0.3	3.99e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs6442522	0.505	rs1105497	chr3:15406900	A/G	cg16303742	chr3:15540471	COLQ	0.36	5.56	0.34	7.33e-8	Uric acid levels;
SARC	cis	rs7980687	0.678	rs7132277	chr12:123593382	C/T	cg00376283	chr12:123451042	ABCB9	-0.54	-5.04	-0.31	9.49e-7	Height;Educational attainment;Head circumference (infant);
SARC	cis	rs910316	0.763	rs175490	chr14:75545685	A/G	cg11812906	chr14:75593930	NEK9	0.79	11.15	0.59	2.1e-23	Height;
SARC	cis	rs6831352	0.918	rs2602895	chr4:100045840	C/T	cg12011299	chr4:100065546	ADH4	0.34	5.64	0.35	4.82e-8	Alcohol dependence;
SARC	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg15352829	chr14:105391018	PLD4	-0.33	-6.34	-0.38	1.19e-9	Rheumatoid arthritis;
SARC	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg19729930	chr2:74357872	NA	0.7	10.49	0.57	2.41e-21	Gestational age at birth (maternal effect);
SARC	cis	rs10911251	0.528	rs10911248	chr1:183080564	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.8e-21	Colorectal cancer;
SARC	trans	rs11039798	0.623	rs6485879	chr11:48587984	G/T	cg15704280	chr7:45808275	SEPT13	0.63	6.46	0.39	5.9e-10	Axial length;
SARC	trans	rs3942852	0.568	rs10838800	chr11:48094879	C/T	cg03929089	chr4:120376271	NA	-0.56	-6.87	-0.41	5.73e-11	Acute lymphoblastic leukemia (childhood);
SARC	trans	rs637571	0.522	rs679581	chr11:65746653	A/G	cg17712092	chr4:129076599	LARP1B	0.71	9.54	0.53	2.05e-18	Eosinophil percentage of white cells;
SARC	cis	rs3857536	0.740	rs6455080	chr6:66887413	T/A	cg07460842	chr6:66804631	NA	-0.61	-7.22	-0.43	7.11e-12	Blood trace element (Cu levels);
SARC	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg12419862	chr22:24373484	LOC391322	-0.67	-8.49	-0.49	2.4e-15	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2439831	0.867	rs8039638	chr15:43634405	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.08	11.58	0.6	8.71e-25	Lung cancer in ever smokers;
SARC	cis	rs72634258	0.554	rs34305100	chr1:7913029	A/G	cg00042356	chr1:8021962	PARK7	0.65	5.37	0.33	1.86e-7	Inflammatory bowel disease;
SARC	cis	rs9948	0.655	rs61742095	chr2:97366088	T/C	cg01990225	chr2:97406019	LMAN2L	-0.98	-7.44	-0.44	1.87e-12	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs7633770	0.786	rs9845998	chr3:46683710	G/A	cg11219411	chr3:46661640	NA	0.43	7.06	0.42	1.85e-11	Coronary artery disease;
SARC	cis	rs2153535	0.580	rs7341382	chr6:8470549	A/G	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg24549020	chr5:56110836	MAP3K1	0.45	5.25	0.33	3.49e-7	Coronary artery disease;
SARC	trans	rs7147624	0.608	rs4902413	chr14:66187091	T/C	cg12158889	chr2:84663044	SUCLG1	-0.43	-6.28	-0.38	1.63e-9	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs709400	0.633	rs1951391	chr14:103898313	T/C	cg12935359	chr14:103987150	CKB	-0.41	-5.98	-0.36	8.35e-9	Body mass index;
SARC	cis	rs818427	0.896	rs460832	chr5:112225148	G/A	cg07820702	chr5:112228657	REEP5	-0.46	-5.23	-0.32	3.82e-7	Total body bone mineral density;
SARC	cis	rs10276381	0.786	rs73089302	chr7:28187134	G/A	cg23620719	chr7:28220237	JAZF1	0.71	5.89	0.36	1.31e-8	Crohn's disease;
SARC	cis	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg05623727	chr3:50126028	RBM5	0.33	5.1	0.32	6.9e-7	Intelligence (multi-trait analysis);
SARC	trans	rs1814175	0.715	rs1722007	chr11:49897319	T/C	cg15704280	chr7:45808275	SEPT13	-0.95	-17.47	-0.75	3.1e-44	Height;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg03390569	chr2:54013802	LOC100302652;ASB3;ERLEC1	-0.6	-6.64	-0.4	2.24e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs1153858	1.000	rs12441971	chr15:45671957	A/T	cg03999130	chr15:45571217	NA	0.39	4.98	0.31	1.25e-6	Homoarginine levels;
SARC	cis	rs2380220	0.872	rs115871915	chr6:95934180	T/C	cg04719120	chr6:96025338	MANEA	-0.64	-6.4	-0.39	8.45e-10	Behavioural disinhibition (generation interaction);
SARC	cis	rs9790314	0.663	rs4679924	chr3:160661862	T/C	cg04691961	chr3:161091175	C3orf57	0.6	8.35	0.48	6.15e-15	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs8114671	0.562	rs6087653	chr20:33522054	T/C	cg07148914	chr20:33460835	GGT7	0.42	5.04	0.31	9.19e-7	Height;
SARC	cis	rs7940866	0.740	rs7131121	chr11:130806424	A/G	cg12179176	chr11:130786555	SNX19	0.66	9.34	0.52	8.17e-18	Schizophrenia;
SARC	cis	rs72945132	0.562	rs7951959	chr11:70234272	A/G	cg05964544	chr11:70165517	PPFIA1	-0.66	-6.64	-0.4	2.14e-10	Coronary artery disease;
SARC	cis	rs10489202	1.000	rs7538251	chr1:168001752	C/G	cg24449463	chr1:168025552	DCAF6	-0.64	-6.99	-0.42	2.89e-11	Schizophrenia;
SARC	cis	rs9902453	0.808	rs76039587	chr17:28233760	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	6.95	0.41	3.67e-11	Coffee consumption (cups per day);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg11422541	chr12:49182586	ADCY6	0.5	6.35	0.38	1.14e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg00745463	chr17:30367425	LRRC37B	-0.68	-5.23	-0.32	3.82e-7	Hip circumference adjusted for BMI;
SARC	cis	rs2153535	0.546	rs1335640	chr6:8485325	A/C	cg07606381	chr6:8435919	SLC35B3	0.78	11.07	0.59	3.71e-23	Motion sickness;
SARC	cis	rs3820928	0.618	rs2141828	chr2:227922470	T/C	cg05526886	chr2:227700861	RHBDD1	-0.47	-5.1	-0.32	7.19e-7	Pulmonary function;
SARC	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg12463550	chr7:65579703	CRCP	-0.5	-5.55	-0.34	7.57e-8	Aortic root size;
SARC	cis	rs1538970	0.962	rs9429072	chr1:45810091	C/T	cg05343316	chr1:45956843	TESK2	-0.68	-8.26	-0.48	1.09e-14	Platelet count;
SARC	cis	rs3820928	0.775	rs10179756	chr2:227897076	A/G	cg05526886	chr2:227700861	RHBDD1	-0.5	-5.98	-0.36	8.26e-9	Pulmonary function;
SARC	cis	rs986417	0.901	rs1010052	chr14:61003071	G/A	cg27398547	chr14:60952738	C14orf39	0.99	9.41	0.52	4.88e-18	Gut microbiota (bacterial taxa);
SARC	cis	rs4595586	0.545	rs12820138	chr12:39357049	A/G	cg26384229	chr12:38710491	ALG10B	0.51	6.25	0.38	1.9e-9	Morning vs. evening chronotype;
SARC	cis	rs7084402	0.967	rs7921207	chr10:60270235	G/T	cg07615347	chr10:60278583	BICC1	-0.58	-8.47	-0.49	2.84e-15	Refractive error;
SARC	cis	rs12950390	0.853	rs8071192	chr17:45856141	A/G	cg03474202	chr17:45855739	NA	-0.43	-6.82	-0.41	7.95e-11	IgG glycosylation;
SARC	cis	rs9796	0.621	rs537244	chr15:41469313	G/T	cg18705301	chr15:41695430	NDUFAF1	0.56	8.07	0.47	3.82e-14	Menopause (age at onset);
SARC	cis	rs875971	0.545	rs6460281	chr7:65681115	A/C	cg11764359	chr7:65958608	NA	0.66	6.45	0.39	6.55e-10	Aortic root size;
SARC	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg17376030	chr22:41985996	PMM1	0.77	9.46	0.53	3.4e-18	Vitiligo;
SARC	cis	rs9790314	0.723	rs1026572	chr3:160887654	A/G	cg03342759	chr3:160939853	NMD3	-0.56	-6.91	-0.41	4.65e-11	Morning vs. evening chronotype;
SARC	cis	rs921968	0.565	rs6436086	chr2:219640125	T/C	cg02176678	chr2:219576539	TTLL4	-0.33	-5.03	-0.31	9.92e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs7086627	0.515	rs10887901	chr10:82210581	G/A	cg01528321	chr10:82214614	TSPAN14	0.58	8.5	0.49	2.27e-15	Post bronchodilator FEV1;
SARC	cis	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg20965017	chr5:231967	SDHA	-0.54	-5.15	-0.32	5.44e-7	Breast cancer;
SARC	cis	rs710216	0.912	rs11537640	chr1:43424519	T/G	cg03128534	chr1:43423976	SLC2A1	0.66	6.68	0.4	1.75e-10	Red cell distribution width;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg01353139	chr8:124170018	NA	0.76	6.41	0.39	8.06e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2486288	0.656	rs7166580	chr15:45571209	C/G	cg19305227	chr15:45544335	SLC28A2	0.31	5.78	0.35	2.39e-8	Glomerular filtration rate;
SARC	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg13628971	chr7:2884303	GNA12	0.66	7.93	0.46	9.22e-14	Height;
SARC	cis	rs7833790	0.963	rs10958046	chr8:82729210	A/G	cg17211192	chr8:82754475	SNX16	-0.59	-6.45	-0.39	6.36e-10	Diastolic blood pressure;
SARC	cis	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg03060546	chr3:49711283	APEH	0.61	7.47	0.44	1.58e-12	Resting heart rate;
SARC	cis	rs11168187	0.843	rs7306556	chr12:48119997	C/G	cg12761788	chr12:48120090	P11	0.38	5.01	0.31	1.1e-6	Vertical cup-disc ratio;
SARC	cis	rs721399	0.752	rs4921913	chr8:18272377	C/T	cg18736775	chr8:18248649	NAT2	0.42	5.2	0.32	4.44e-7	Blood metabolite levels;
SARC	cis	rs2718058	0.630	rs2718045	chr7:37795438	C/G	cg15028436	chr7:37888078	TXNDC3	-0.38	-5.13	-0.32	5.99e-7	Alzheimer's disease (late onset);
SARC	cis	rs1008375	1.000	rs4698651	chr4:17694223	A/G	cg16339924	chr4:17578868	LAP3	0.56	7.0	0.42	2.67e-11	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7524258	0.867	rs916392	chr1:7271930	T/C	cg07173049	chr1:7289937	CAMTA1	0.39	7.55	0.44	9.81e-13	Tourette's syndrome or obsessive-compulsive disorder;
SARC	cis	rs7717697	0.797	rs10076654	chr5:82742901	A/G	cg19814134	chr5:82768288	VCAN	0.42	4.98	0.31	1.26e-6	Vertical cup-disc ratio;
SARC	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg05890377	chr2:74357713	NA	0.45	5.14	0.32	5.8e-7	Gestational age at birth (maternal effect);
SARC	cis	rs9814567	1.000	rs6772896	chr3:134203347	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-7.06	-0.42	1.85e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs3126085	0.867	rs11204948	chr1:152218473	A/G	cg26876637	chr1:152193138	HRNR	0.5	5.53	0.34	8.69e-8	Atopic dermatitis;
SARC	cis	rs4727027	0.870	rs62507512	chr7:148799338	C/T	cg23583168	chr7:148888333	NA	-0.74	-10.4	-0.56	4.66e-21	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs778371	0.697	rs2344611	chr2:233581937	A/G	cg20388707	chr2:233749442	NGEF	-0.35	-5.06	-0.31	8.64e-7	Schizophrenia;
SARC	cis	rs6867032	0.958	rs9312970	chr5:2002415	C/A	cg26168224	chr5:2018326	NA	-0.78	-10.74	-0.58	4.11e-22	Gut microbiome composition (winter);
SARC	cis	rs1387259	0.931	rs11168474	chr12:48621384	A/C	cg24011408	chr12:48396354	COL2A1	0.46	5.36	0.33	1.99e-7	Obstructive sleep apnea trait (apnea hypopnea index);
SARC	cis	rs2295359	1.000	rs11465754	chr1:67631431	A/G	cg08029281	chr1:67600428	NA	0.36	5.1	0.32	7.05e-7	Psoriasis;
SARC	cis	rs2304069	0.545	rs9686746	chr5:149399968	G/A	cg12661370	chr5:149340060	SLC26A2	0.55	6.46	0.39	5.99e-10	HIV-1 control;
SARC	cis	rs9828933	0.766	rs704372	chr3:63867453	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	0.72	7.08	0.42	1.73e-11	Type 2 diabetes;
SARC	cis	rs2645694	0.626	rs2703151	chr4:77834095	A/G	cg03477792	chr4:77819574	ANKRD56	0.4	5.74	0.35	2.97e-8	Emphysema distribution in smoking;
SARC	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg18252515	chr7:66147081	NA	-0.53	-5.69	-0.35	3.86e-8	Aortic root size;
SARC	cis	rs854765	0.583	rs8070128	chr17:17804725	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.41	-5.5	-0.34	9.96e-8	Total body bone mineral density;
SARC	cis	rs17376456	0.778	rs72786662	chr5:93137630	C/T	cg21475434	chr5:93447410	FAM172A	0.72	6.28	0.38	1.62e-9	Diabetic retinopathy;
SARC	cis	rs9303542	0.694	rs8071207	chr17:46584016	T/C	cg04904318	chr17:46607828	HOXB1	0.4	4.98	0.31	1.22e-6	Ovarian cancer;Epithelial ovarian cancer;
SARC	trans	rs7927370	1.000	rs76463468	chr11:55327996	G/T	cg07162727	chr16:4848039	ROGDI	0.87	6.39	0.39	9e-10	Systemic lupus erythematosus;
SARC	cis	rs2354432	0.607	rs7537279	chr1:146673642	A/G	cg25205988	chr1:146714368	CHD1L	1.04	8.94	0.51	1.2e-16	Mitochondrial DNA levels;
SARC	cis	rs7561149	0.714	rs10190741	chr2:179687872	C/T	cg17765952	chr2:179737173	CCDC141	-0.35	-4.91	-0.31	1.72e-6	QT interval;
SARC	cis	rs17666538	0.792	rs58523286	chr8:675683	C/T	cg07234876	chr8:600039	NA	-0.96	-6.01	-0.37	7.22e-9	IgG glycosylation;
SARC	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.73	10.05	0.55	5.71e-20	Personality dimensions;
SARC	cis	rs9715521	0.677	rs17493148	chr4:59861895	T/C	cg11281224	chr4:60001000	NA	-0.51	-6.34	-0.38	1.16e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.87	11.99	0.62	3.96e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs137603	0.901	rs137612	chr22:39698010	A/G	cg01093212	chr22:39715156	SNORD43;RPL3	-0.44	-5.24	-0.32	3.51e-7	Primary biliary cholangitis;
SARC	cis	rs12950390	0.820	rs58391889	chr17:45865959	A/G	cg03474202	chr17:45855739	NA	-0.44	-6.9	-0.41	4.99e-11	IgG glycosylation;
SARC	cis	rs9916302	0.904	rs587343	chr17:37440603	C/T	cg20243544	chr17:37824526	PNMT	-0.59	-7.45	-0.44	1.86e-12	Glomerular filtration rate (creatinine);
SARC	trans	rs61931739	0.500	rs6488209	chr12:34319309	A/G	cg26384229	chr12:38710491	ALG10B	0.74	10.27	0.56	1.22e-20	Morning vs. evening chronotype;
SARC	cis	rs56330463	0.934	rs2082382	chr5:148200553	G/A	cg21580376	chr5:148206412	ADRB2	0.41	5.34	0.33	2.16e-7	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Monocyte percentage of white cells;Eosinophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;
SARC	cis	rs7582180	0.627	rs6749018	chr2:101001859	G/T	cg14675211	chr2:100938903	LONRF2	0.52	7.44	0.44	1.93e-12	Intelligence (multi-trait analysis);
SARC	cis	rs751728	1.000	rs755496	chr6:33734376	C/G	cg25922239	chr6:33757077	LEMD2	0.8	10.55	0.57	1.62e-21	Crohn's disease;
SARC	cis	rs698833	0.852	rs2582918	chr2:44582275	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.76	9.86	0.54	2.2e-19	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs356220	0.632	rs356205	chr4:90657186	C/T	cg06632027	chr4:90757378	SNCA	0.4	5.05	0.31	8.73e-7	Parkinson's disease;
SARC	cis	rs151234	0.741	rs11647881	chr16:28606173	C/A	cg01378222	chr16:28622494	SULT1A1	-0.44	-4.86	-0.3	2.14e-6	Platelet distribution width;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg19467586	chr17:45266599	CDC27	-0.79	-6.9	-0.41	4.96e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1707322	0.717	rs2253862	chr1:46081960	C/T	cg06784218	chr1:46089804	CCDC17	-0.39	-6.88	-0.41	5.34e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs5757673	1	rs5757673	chr22:39837920	T/C	cg11247378	chr22:39784982	NA	-0.31	-4.76	-0.3	3.47e-6	Post bronchodilator FEV1;
SARC	cis	rs7412746	0.611	rs2864873	chr1:150814174	A/G	cg13175981	chr1:150552382	MCL1	-0.55	-6.9	-0.41	4.88e-11	Melanoma;
SARC	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg12311346	chr5:56204834	C5orf35	-0.54	-5.58	-0.34	6.53e-8	Initial pursuit acceleration;
SARC	cis	rs861020	0.630	rs628445	chr1:210004953	C/T	cg05527609	chr1:210001259	C1orf107	0.78	10.12	0.55	3.37e-20	Orofacial clefts;
SARC	cis	rs11098499	0.863	rs2306456	chr4:120472422	C/G	cg09307838	chr4:120376055	NA	0.91	12.25	0.63	5.66e-27	Corneal astigmatism;
SARC	cis	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg15145296	chr3:125709740	NA	-0.51	-4.95	-0.31	1.44e-6	Blood pressure (smoking interaction);
SARC	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	8.29	0.48	8.95e-15	Mean platelet volume;
SARC	cis	rs763121	0.819	rs5757169	chr22:39003495	G/A	cg06022373	chr22:39101656	GTPBP1	0.9	11.97	0.62	4.83e-26	Menopause (age at onset);
SARC	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg27266027	chr21:40555129	PSMG1	0.49	5.4	0.33	1.62e-7	Cognitive function;
SARC	cis	rs9341808	0.621	rs2322627	chr6:80806341	T/A	cg08355045	chr6:80787529	NA	0.38	6.08	0.37	4.99e-9	Sitting height ratio;
SARC	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg11764359	chr7:65958608	NA	-0.59	-7.02	-0.42	2.38e-11	Calcium levels;
SARC	cis	rs1059312	1.000	rs3825180	chr12:129279242	A/G	cg09035930	chr12:129282057	SLC15A4	-0.54	-7.55	-0.44	9.94e-13	Systemic lupus erythematosus;
SARC	cis	rs1008375	0.966	rs11737844	chr4:17697421	A/C	cg16339924	chr4:17578868	LAP3	0.52	6.67	0.4	1.8e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9397240	0.789	rs9397799	chr6:155595698	G/T	cg07943832	chr6:155568918	TIAM2	-0.61	-5.86	-0.36	1.56e-8	Life satisfaction;
SARC	cis	rs9467773	1.000	rs10484442	chr6:26555879	A/G	cg11502198	chr6:26597334	ABT1	0.48	5.83	0.36	1.8e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2235642	0.533	rs2667679	chr16:1654946	G/A	cg09065629	chr16:1709722	CRAMP1L	0.39	5.0	0.31	1.15e-6	Coronary artery disease;
SARC	cis	rs9790314	0.639	rs6769642	chr3:160763469	C/A	cg04691961	chr3:161091175	C3orf57	-0.61	-8.2	-0.47	1.61e-14	Morning vs. evening chronotype;
SARC	cis	rs16976116	1.000	rs16976116	chr15:55480467	T/C	cg17854078	chr15:55489399	RSL24D1	0.62	6.24	0.38	2.03e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs3815700	0.614	rs259255	chr19:33151765	T/C	cg02997394	chr19:33096574	ANKRD27	0.68	5.15	0.32	5.5e-7	Eosinophilic esophagitis;
SARC	cis	rs554111	0.656	rs12021529	chr1:21306161	C/T	cg04902671	chr1:21058625	SH2D5	-0.44	-5.46	-0.34	1.23e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs875971	0.545	rs10950025	chr7:65623933	G/A	cg11764359	chr7:65958608	NA	0.67	6.65	0.4	2.03e-10	Aortic root size;
SARC	cis	rs4820539	0.933	rs2267004	chr22:23459863	G/A	cg14186256	chr22:23484241	RTDR1	0.84	13.15	0.65	6.55e-30	Bone mineral density;
SARC	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	16.12	0.73	8.93e-40	Chronic sinus infection;
SARC	cis	rs59918340	0.764	rs4961258	chr8:142232878	A/G	cg16341495	chr8:142228727	SLC45A4	0.34	4.78	0.3	3.09e-6	Immature fraction of reticulocytes;
SARC	cis	rs5769765	1.000	rs5770742	chr22:50270309	T/C	cg03033257	chr22:50311977	ALG12;CRELD2	-0.54	-5.64	-0.35	4.81e-8	Schizophrenia;
SARC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg14159672	chr1:205819179	PM20D1	0.94	17.88	0.76	1.36e-45	Menarche (age at onset);
SARC	cis	rs7566780	0.693	rs725456	chr2:16661088	A/G	cg09580478	chr2:16689509	NA	0.49	5.75	0.35	2.74e-8	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs796364	0.806	rs112305133	chr2:201010380	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.53	-4.87	-0.3	2.08e-6	Schizophrenia;
SARC	cis	rs67311347	1.000	rs977652	chr3:40479169	A/G	cg09455208	chr3:40491958	NA	0.41	6.57	0.4	3.34e-10	Renal cell carcinoma;
SARC	cis	rs921968	0.565	rs3755045	chr2:219609162	T/G	cg02176678	chr2:219576539	TTLL4	-0.32	-4.94	-0.31	1.48e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg03351412	chr1:154909251	PMVK	0.65	8.34	0.48	6.47e-15	Prostate cancer;
SARC	cis	rs9303280	0.901	rs8067378	chr17:38051348	A/G	cg20243544	chr17:37824526	PNMT	0.45	6.09	0.37	4.62e-9	Self-reported allergy;
SARC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg09373136	chr17:61933544	TCAM1	-0.44	-6.04	-0.37	6.05e-9	Prudent dietary pattern;
SARC	cis	rs2797160	1.000	rs1739376	chr6:126012084	C/G	cg05901451	chr6:126070800	HEY2	0.52	6.62	0.4	2.42e-10	Endometrial cancer;
SARC	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg03650068	chr1:25596491	NA	0.35	5.44	0.34	1.36e-7	Erythrocyte sedimentation rate;
SARC	cis	rs986417	0.901	rs7157458	chr14:60999852	C/T	cg27398547	chr14:60952738	C14orf39	1.02	9.81	0.54	3.15e-19	Gut microbiota (bacterial taxa);
SARC	cis	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg19761014	chr17:28927070	LRRC37B2	0.54	4.8	0.3	2.87e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs933688	1.000	rs4382199	chr5:90744228	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.0	12.52	0.63	7.66e-28	Smoking behavior;
SARC	cis	rs10870270	1.000	rs10870270	chr10:133754334	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.48	-5.61	-0.34	5.71e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs7246657	0.943	rs8109038	chr19:38015709	A/G	cg23950597	chr19:37808831	NA	0.56	5.47	0.34	1.18e-7	Coronary artery calcification;
SARC	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2361718	0.933	rs8066452	chr17:78104080	A/G	cg27427491	chr17:78079615	GAA	-0.32	-5.39	-0.33	1.71e-7	Yeast infection;
SARC	cis	rs3087591	0.960	rs1801052	chr17:29508775	C/T	cg24425628	chr17:29625626	OMG;NF1	0.49	6.02	0.37	6.69e-9	Hip circumference;
SARC	cis	rs1318878	0.565	rs7304487	chr12:15477683	T/C	cg08258403	chr12:15378311	NA	0.46	6.58	0.4	3.13e-10	Intelligence (multi-trait analysis);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg13448378	chr8:103250761	RRM2B	0.77	6.27	0.38	1.76e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9807989	0.507	rs4851571	chr2:103019000	C/T	cg03938978	chr2:103052716	IL18RAP	0.31	5.02	0.31	1.04e-6	Asthma;
SARC	cis	rs7617773	0.817	rs9830016	chr3:48282494	A/G	cg11946769	chr3:48343235	NME6	0.7	9.27	0.52	1.27e-17	Coronary artery disease;
SARC	cis	rs634534	0.622	rs593525	chr11:65727799	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.56	8.62	0.49	1.07e-15	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg09323728	chr8:95962352	TP53INP1	-0.33	-5.47	-0.34	1.16e-7	Type 2 diabetes;
SARC	trans	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-10.59	-0.57	1.18e-21	Intelligence (multi-trait analysis);
SARC	cis	rs240764	0.746	rs240153	chr6:101067135	A/C	cg09795085	chr6:101329169	ASCC3	0.45	5.66	0.35	4.49e-8	Neuroticism;
SARC	cis	rs1865760	1.000	rs9393675	chr6:25930116	G/A	cg17691542	chr6:26056736	HIST1H1C	0.58	7.08	0.42	1.7e-11	Height;
SARC	cis	rs6672530	0.518	rs6683151	chr1:227811514	C/T	cg26340147	chr1:227730820	NA	-0.35	-4.96	-0.31	1.38e-6	Hip circumference adjusted for BMI;
SARC	cis	rs9323205	0.723	rs55980461	chr14:51737434	G/A	cg23942311	chr14:51606299	NA	-0.35	-4.77	-0.3	3.26e-6	Cancer;
SARC	cis	rs1105228	0.592	rs12525198	chr6:165667564	C/T	cg20535254	chr6:165714960	C6orf118	0.34	4.8	0.3	2.82e-6	Number of pregnancies;Number of children;
SARC	cis	rs28655083	1.000	rs1875582	chr16:77063147	A/G	cg01504555	chr16:77246968	SYCE1L	0.43	5.05	0.31	8.72e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg16414030	chr3:133502952	NA	-0.38	-4.97	-0.31	1.32e-6	Iron status biomarkers;
SARC	cis	rs7223966	1.000	rs6504167	chr17:61693194	G/C	cg00588841	chr17:61851480	DDX42;CCDC47	-0.63	-6.88	-0.41	5.44e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs995000	0.965	rs10789112	chr1:62957758	T/C	cg06896770	chr1:63153194	DOCK7	0.97	14.57	0.69	1.29e-34	Triglyceride levels;
SARC	cis	rs9457247	0.756	rs2345572	chr6:167403441	A/T	cg23791538	chr6:167370224	RNASET2	-0.63	-8.65	-0.49	8.55e-16	Crohn's disease;
SARC	cis	rs7772486	0.641	rs960385	chr6:146371074	G/A	cg23711669	chr6:146136114	FBXO30	0.73	10.15	0.55	2.77e-20	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12044355	0.896	rs11122324	chr1:231859181	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.47	6.23	0.38	2.18e-9	Alzheimer's disease;
SARC	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg24633833	chr3:10029261	TMEM111	0.52	5.25	0.33	3.43e-7	Alzheimer's disease;
SARC	cis	rs9303401	0.580	rs2013166	chr17:56637630	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.09	12.25	0.63	5.64e-27	Cognitive test performance;
SARC	cis	rs662064	0.852	rs1411402	chr1:10579545	G/T	cg01551238	chr1:11548576	PTCHD2	-0.36	-4.74	-0.3	3.7e-6	Asthma;
SARC	cis	rs79149102	0.579	rs3816261	chr15:75336173	T/A	cg00629941	chr15:75287862	SCAMP5	-0.79	-5.8	-0.36	2.13e-8	Lung cancer;
SARC	cis	rs651907	0.557	rs12629658	chr3:101356535	A/G	cg12386194	chr3:101231763	SENP7	0.5	5.95	0.36	9.98e-9	Colorectal cancer;
SARC	cis	rs10078	0.510	rs2278248	chr5:469570	G/T	cg08916839	chr5:415575	AHRR	0.74	7.35	0.43	3.34e-12	Fat distribution (HIV);
SARC	cis	rs1580019	0.563	rs34201720	chr7:32568935	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.97	17.78	0.76	2.87e-45	Cognitive ability;
SARC	cis	rs12079745	0.590	rs2280257	chr1:169352787	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.81	-5.32	-0.33	2.42e-7	QT interval;
SARC	cis	rs2153904	0.590	rs823106	chr1:205656453	G/C	cg17178900	chr1:205818956	PM20D1	0.57	5.27	0.33	3.08e-7	Prostate-specific antigen levels;
SARC	cis	rs28669119	0.778	rs770525	chr5:88123550	A/T	cg18498987	chr5:88179539	MEF2C	-0.53	-5.35	-0.33	2.14e-7	Schizophrenia;
SARC	cis	rs870825	0.616	rs61653735	chr4:185630025	G/A	cg04058563	chr4:185651563	MLF1IP	0.81	11.04	0.59	4.53e-23	Blood protein levels;
SARC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg09373136	chr17:61933544	TCAM1	-0.45	-6.2	-0.38	2.48e-9	Prudent dietary pattern;
SARC	cis	rs1707322	1.000	rs4074225	chr1:46392364	G/C	cg03146154	chr1:46216737	IPP	0.5	6.07	0.37	5.13e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7582180	0.764	rs12615466	chr2:100924065	C/A	cg14675211	chr2:100938903	LONRF2	0.54	7.84	0.46	1.61e-13	Intelligence (multi-trait analysis);
SARC	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg21442419	chr1:2182373	SKI	-0.39	-5.06	-0.31	8.44e-7	Height;
SARC	cis	rs11574514	1.000	rs79576279	chr16:67958239	C/T	cg01866162	chr16:67596514	CTCF	1.1	6.61	0.4	2.65e-10	Crohn's disease;
SARC	cis	rs6988636	0.901	rs16898076	chr8:124187721	T/C	cg23067535	chr8:124195133	FAM83A	-0.69	-5.46	-0.34	1.24e-7	Urinary uromodulin levels;
SARC	cis	rs9296095	1.000	rs5745582	chr6:33546498	C/T	cg14003231	chr6:33640908	ITPR3	0.36	5.71	0.35	3.41e-8	Platelet count;
SARC	cis	rs478304	0.651	rs11600918	chr11:65511965	A/G	cg26695010	chr11:65641043	EFEMP2	0.4	4.97	0.31	1.31e-6	Acne (severe);
SARC	cis	rs4742903	0.935	rs6479228	chr9:106980912	G/A	cg14250997	chr9:106856677	SMC2	0.39	4.85	0.3	2.28e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs6430585	0.528	rs111682961	chr2:136653848	C/T	cg07169764	chr2:136633963	MCM6	1.07	13.63	0.67	1.71e-31	Corneal structure;
SARC	cis	rs6069325	0.529	rs6069323	chr20:54139209	C/G	cg06877860	chr20:55043471	C20orf43	-0.5	-4.78	-0.3	3.16e-6	Motion sickness;
SARC	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg11987759	chr7:65425863	GUSB	0.5	6.49	0.39	5.09e-10	Aortic root size;
SARC	cis	rs1865760	1.000	rs2071297	chr6:25924513	C/G	cg16482183	chr6:26056742	HIST1H1C	-0.48	-5.96	-0.36	9.23e-9	Height;
SARC	cis	rs8051517	0.661	rs34530665	chr16:68395828	G/C	cg01866162	chr16:67596514	CTCF	1.17	6.53	0.39	4.19e-10	Blood protein levels;
SARC	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg08280861	chr8:58055591	NA	0.6	5.71	0.35	3.4e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs3784262	0.740	rs1372369	chr15:58294381	T/G	cg12031962	chr15:58353849	ALDH1A2	-0.34	-5.04	-0.31	9.42e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg14893161	chr1:205819251	PM20D1	0.52	6.75	0.4	1.15e-10	Menarche (age at onset);
SARC	cis	rs941408	0.963	rs2537855	chr19:2806574	A/G	cg06609049	chr19:2785107	THOP1	0.85	10.76	0.58	3.37e-22	Total cholesterol levels;
SARC	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg16325326	chr1:53192061	ZYG11B	-0.9	-15.44	-0.71	1.65e-37	Monocyte count;
SARC	cis	rs4906332	0.966	rs2065016	chr14:103879656	T/A	cg26031613	chr14:104095156	KLC1	-0.51	-5.96	-0.36	9.05e-9	Coronary artery disease;
SARC	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg16680214	chr1:154839983	KCNN3	-0.36	-5.64	-0.35	4.97e-8	Prostate cancer;
SARC	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg05861140	chr6:150128134	PCMT1	-0.39	-4.72	-0.3	4.07e-6	Lung cancer;
SARC	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg27266027	chr21:40555129	PSMG1	0.5	5.45	0.34	1.26e-7	Cognitive function;
SARC	cis	rs4148883	0.645	rs2851264	chr4:100029715	C/T	cg13256891	chr4:100009986	ADH5	0.63	8.65	0.49	8.27e-16	Alcohol dependence;
SARC	cis	rs6088813	0.885	rs6142353	chr20:33942685	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	-0.46	-5.51	-0.34	9.28e-8	Height;
SARC	cis	rs3813567	0.759	rs12595350	chr15:78953464	G/A	cg24631222	chr15:78858424	CHRNA5	0.52	4.95	0.31	1.46e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
SARC	cis	rs4800452	0.871	rs9961220	chr18:20733201	G/T	cg13313047	chr18:20735648	CABLES1	-0.47	-5.13	-0.32	6.02e-7	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
SARC	trans	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg00938859	chr5:1591904	SDHAP3	0.79	7.66	0.45	5.1e-13	Breast cancer;
SARC	cis	rs2228479	0.850	rs62056061	chr16:89901767	G/A	cg06558623	chr16:89946397	TCF25	0.93	6.63	0.4	2.29e-10	Skin colour saturation;
SARC	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg14773178	chr5:1868261	NA	0.33	5.17	0.32	5.12e-7	Cardiovascular disease risk factors;
SARC	cis	rs4988958	0.565	rs1035125	chr2:103033839	C/A	cg03938978	chr2:103052716	IL18RAP	0.31	4.96	0.31	1.34e-6	Asthma (childhood onset);
SARC	cis	rs9467711	0.606	rs9379897	chr6:26601526	T/C	cg12826209	chr6:26865740	GUSBL1	0.72	4.85	0.3	2.22e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs72653721	1.000	rs2295599	chr6:10961454	C/A	cg13562911	chr6:11044106	ELOVL2	0.58	6.11	0.37	4.14e-9	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg02711726	chr17:80685570	FN3KRP	-0.54	-6.51	-0.39	4.55e-10	Glycated hemoglobin levels;
SARC	cis	rs1953600	0.870	rs2788296	chr10:81937889	G/A	cg00277334	chr10:82204260	NA	0.37	5.39	0.33	1.74e-7	Sarcoidosis;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg08231577	chr1:117077088	CD58	-0.47	-6.39	-0.39	8.83e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs433852	1.000	rs433852	chr19:49117104	C/T	cg06530960	chr19:49140787	SEC1;DBP	-0.62	-6.99	-0.42	2.89e-11	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg01181863	chr3:195395398	SDHAP2	-0.74	-8.39	-0.48	4.67e-15	Pancreatic cancer;
SARC	cis	rs7296418	0.961	rs1790121	chr12:123604492	G/A	cg00376283	chr12:123451042	ABCB9	0.67	8.66	0.49	8.16e-16	Platelet count;
SARC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.8	10.38	0.56	5.49e-21	Prudent dietary pattern;
SARC	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg21782813	chr7:2030301	MAD1L1	0.41	6.57	0.4	3.31e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs8023845	1.000	rs62019997	chr15:40443476	T/C	cg20259534	chr15:40453036	BUB1B	0.76	8.08	0.47	3.58e-14	Chronic lymphocytic leukemia;
SARC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg11965913	chr1:205819406	PM20D1	0.87	13.65	0.67	1.46e-31	Menarche (age at onset);
SARC	cis	rs3087591	0.879	rs4795591	chr17:29612410	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.55	-6.73	-0.4	1.3e-10	Hip circumference;
SARC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg18481137	chr3:71631744	FOXP1	-0.57	-6.34	-0.38	1.2e-9	Hepatitis;
SARC	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg23131131	chr22:24373011	LOC391322	-0.48	-5.32	-0.33	2.42e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7223966	1.000	rs7216798	chr17:61740963	G/A	cg26338869	chr17:61819248	STRADA	0.44	5.14	0.32	5.82e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg01181863	chr3:195395398	SDHAP2	-0.63	-7.64	-0.45	5.73e-13	Pancreatic cancer;
SARC	cis	rs10870270	1.000	rs4880246	chr10:133764064	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.49	-5.59	-0.34	6.28e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg15847926	chr7:2749597	AMZ1	-0.3	-4.95	-0.31	1.4e-6	Height;
SARC	cis	rs11098499	0.865	rs3956464	chr4:120256764	T/C	cg09307838	chr4:120376055	NA	0.81	11.03	0.59	4.84e-23	Corneal astigmatism;
SARC	cis	rs2439831	0.717	rs9806227	chr15:43680115	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.06	11.44	0.6	2.43e-24	Lung cancer in ever smokers;
SARC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.46	0.57	3.1e-21	Prudent dietary pattern;
SARC	cis	rs477895	0.568	rs12418035	chr11:63871558	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	8.66	0.49	8.1e-16	Mean platelet volume;
SARC	cis	rs7772486	0.686	rs702305	chr6:145973840	A/G	cg05220968	chr6:146057943	EPM2A	0.28	4.88	0.3	1.93e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2816062	0.710	rs2816052	chr1:18895536	T/C	cg18795169	chr1:18902165	NA	-0.78	-12.27	-0.63	4.82e-27	Urate levels in lean individuals;
SARC	cis	rs9486719	1.000	rs3798296	chr6:97052286	G/A	cg18709589	chr6:96969512	KIAA0776	-0.48	-4.83	-0.3	2.44e-6	Migraine;Coronary artery disease;
SARC	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg22974920	chr21:40686053	BRWD1	0.46	4.97	0.31	1.28e-6	Cognitive function;
SARC	cis	rs4481887	0.861	rs10788776	chr1:248479177	T/C	cg01631408	chr1:248437212	OR2T33	-0.38	-4.81	-0.3	2.73e-6	Common traits (Other);
SARC	cis	rs17376456	0.877	rs7702521	chr5:93484579	G/T	cg21475434	chr5:93447410	FAM172A	0.9	7.57	0.44	8.64e-13	Diabetic retinopathy;
SARC	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg25072359	chr17:41440525	NA	0.51	6.13	0.37	3.66e-9	Menopause (age at onset);
SARC	cis	rs7833986	0.501	rs72653990	chr8:57037115	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.74	7.59	0.45	7.75e-13	Height;
SARC	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg06634786	chr22:41940651	POLR3H	-0.58	-6.95	-0.41	3.74e-11	Vitiligo;
SARC	cis	rs2832077	0.527	rs2776210	chr21:30268558	A/G	cg24692254	chr21:30365293	RNF160	0.73	8.59	0.49	1.25e-15	Cognitive test performance;
SARC	cis	rs7260598	0.539	rs116746751	chr19:24064218	A/G	cg27517351	chr19:23941871	ZNF681	0.54	4.73	0.3	3.86e-6	Response to taxane treatment (placlitaxel);
SARC	cis	rs11235843	1.000	rs2272248	chr11:73371942	A/C	cg18195628	chr11:73498948	MRPL48	0.67	4.86	0.3	2.13e-6	Hand grip strength;
SARC	cis	rs7197653	0.748	rs61460037	chr16:68336125	A/C	cg05110241	chr16:68378359	PRMT7	-0.69	-6.18	-0.38	2.88e-9	Magnesium levels;
SARC	cis	rs7726839	0.526	rs55647623	chr5:567747	T/C	cg07777115	chr5:623756	CEP72	-0.55	-5.03	-0.31	9.81e-7	Obesity-related traits;
SARC	cis	rs17608059	1.000	rs17608059	chr17:13910549	C/T	cg27005118	chr17:13972210	COX10	-0.33	-4.77	-0.3	3.23e-6	Temperament;
SARC	cis	rs8044995	0.568	rs55675218	chr16:68323647	G/C	cg09835421	chr16:68378352	PRMT7	-0.64	-5.32	-0.33	2.38e-7	Schizophrenia;
SARC	cis	rs1008375	0.931	rs3796814	chr4:17602033	G/C	cg16339924	chr4:17578868	LAP3	0.66	8.7	0.5	5.98e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7833986	0.501	rs72653953	chr8:56970795	C/T	cg26371346	chr8:56986568	SNORD54;RPS20	0.74	7.41	0.44	2.36e-12	Height;
SARC	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg05863683	chr7:1912471	MAD1L1	0.37	5.52	0.34	9e-8	Bipolar disorder and schizophrenia;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg23654174	chr1:47779667	STIL	0.54	7.04	0.42	2.12e-11	Lung adenocarcinoma;
SARC	cis	rs262150	0.567	rs2527177	chr7:158804737	T/C	cg09640425	chr7:158790006	NA	-0.39	-5.73	-0.35	3.11e-8	Facial morphology (factor 20);
SARC	cis	rs10046574	0.561	rs17481974	chr7:135195701	A/G	cg27474649	chr7:135195673	CNOT4	0.85	7.92	0.46	9.66e-14	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs67311347	1.000	rs2168111	chr3:40395325	T/G	cg24209194	chr3:40518798	ZNF619	0.58	7.21	0.43	7.61e-12	Renal cell carcinoma;
SARC	cis	rs561341	1.000	rs55962687	chr17:30260369	C/T	cg00745463	chr17:30367425	LRRC37B	-0.62	-4.78	-0.3	3.05e-6	Hip circumference adjusted for BMI;
SARC	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg13939156	chr17:80058883	NA	-0.42	-6.48	-0.39	5.51e-10	Life satisfaction;
SARC	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg01475735	chr3:40494733	NA	-0.48	-5.25	-0.33	3.4e-7	Renal cell carcinoma;
SARC	cis	rs6061231	0.505	rs13037253	chr20:60928724	G/A	cg24112000	chr20:60950667	NA	-0.36	-5.29	-0.33	2.78e-7	Colorectal cancer;
SARC	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg16405210	chr4:1374714	KIAA1530	-0.52	-6.5	-0.39	4.73e-10	Obesity-related traits;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg11728900	chr10:13203459	MCM10	-0.56	-6.31	-0.38	1.39e-9	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs2116941	0.523	rs17000211	chr19:10369086	C/T	cg01850179	chr19:10340795	S1PR2	0.56	6.91	0.41	4.53e-11	Pulse pressure;
SARC	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg18252515	chr7:66147081	NA	-1.29	-11.2	-0.59	1.41e-23	Diabetic kidney disease;
SARC	cis	rs9902453	0.740	rs2617867	chr17:28049399	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.53	-6.97	-0.42	3.23e-11	Coffee consumption (cups per day);
SARC	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg13264159	chr8:625131	ERICH1	-0.79	-5.29	-0.33	2.88e-7	IgG glycosylation;
SARC	cis	rs9443189	0.615	rs602873	chr6:76323818	T/A	cg01950844	chr6:76311363	SENP6	0.84	8.05	0.47	4.26e-14	Prostate cancer;
SARC	cis	rs2505675	0.563	rs163074	chr6:2215622	A/G	cg16550324	chr6:2245327	GMDS	0.47	5.59	0.34	6.45e-8	Tuberculosis;
SARC	cis	rs17608059	0.518	rs4792436	chr17:13972307	T/A	cg11395062	chr17:14139857	CDRT15	-0.49	-6.73	-0.4	1.3e-10	Temperament;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg05709402	chr10:34661208	PARD3	0.45	6.29	0.38	1.52e-9	Thyroid stimulating hormone;
SARC	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg22683308	chr4:1340831	KIAA1530	0.44	5.37	0.33	1.92e-7	Longevity;
SARC	cis	rs965469	1.000	rs6139117	chr20:3387785	C/T	cg25506879	chr20:3388711	C20orf194	-0.55	-5.6	-0.34	5.87e-8	IFN-related cytopenia;
SARC	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg19223190	chr17:80058835	NA	-0.42	-5.73	-0.35	3.09e-8	Life satisfaction;
SARC	cis	rs7264396	0.635	rs7263302	chr20:34545858	T/C	cg12579300	chr20:34535607	PHF20	-0.43	-5.01	-0.31	1.06e-6	Total cholesterol levels;
SARC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.34	-5.09	-0.32	7.42e-7	Lymphocyte counts;
SARC	cis	rs1144333	0.655	rs76975224	chr1:76470793	T/C	cg03433033	chr1:76189801	ACADM	0.64	5.22	0.32	3.95e-7	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg13628971	chr7:2884303	GNA12	0.67	8.3	0.48	8.72e-15	Height;
SARC	cis	rs459482	0.504	rs469483	chr21:42818515	C/T	cg14166395	chr21:42792516	MX1	-0.42	-4.77	-0.3	3.26e-6	IgG glycosylation;
SARC	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg22484793	chr3:52261325	TLR9	0.29	4.73	0.3	3.83e-6	Bipolar disorder;
SARC	cis	rs2997447	0.761	rs61776575	chr1:26429844	G/A	cg19633962	chr1:26362018	EXTL1	-0.64	-5.29	-0.33	2.77e-7	QRS complex (12-leadsum);
SARC	cis	rs2180341	1.000	rs6910763	chr6:127630925	T/C	cg24812749	chr6:127587940	RNF146	0.97	12.89	0.65	4.63e-29	Breast cancer;
SARC	cis	rs17666538	1.000	rs57255985	chr8:574131	C/T	cg07685180	chr8:600429	NA	-0.78	-5.74	-0.35	2.89e-8	IgG glycosylation;
SARC	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.57	7.51	0.44	1.24e-12	Menarche (age at onset);
SARC	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg26039829	chr8:22132926	PIWIL2	0.46	6.61	0.4	2.58e-10	Hypertriglyceridemia;
SARC	cis	rs6815814	0.851	rs4274855	chr4:38777471	C/T	cg09316306	chr4:38807337	TLR1	0.52	5.23	0.32	3.81e-7	Breast cancer;
SARC	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg16606324	chr3:10149918	C3orf24	0.48	4.76	0.3	3.46e-6	Alzheimer's disease;
SARC	cis	rs2997457	0.515	rs3120157	chr1:26278141	T/C	cg24596570	chr1:26146463	FAM54B;LOC646471	0.5	4.72	0.3	4.03e-6	Facial morphology (factor 16);
SARC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg14159672	chr1:205819179	PM20D1	0.86	13.99	0.68	1.05e-32	Menarche (age at onset);
SARC	cis	rs10911232	0.507	rs7515822	chr1:183037803	A/G	cg13390022	chr1:182993471	LAMC1	0.34	5.08	0.32	7.69e-7	Hypertriglyceridemia;
SARC	cis	rs739401	0.566	rs7931504	chr11:3026712	C/T	cg20651018	chr11:3035856	CARS	-0.43	-6.46	-0.39	6.21e-10	Longevity;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg26022992	chr1:145507616	RBM8A	0.47	6.27	0.38	1.77e-9	Chemerin levels;
SARC	cis	rs747650	0.504	rs7935346	chr11:47008379	A/G	cg03339077	chr11:47165057	C11orf49	-0.37	-4.81	-0.3	2.74e-6	Acne (severe);
SARC	cis	rs698833	0.538	rs1067396	chr2:44637738	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.61	7.37	0.43	3.01e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs10883723	0.810	rs2281879	chr10:104268877	C/G	ch.10.2196322F	chr10:104248062	ACTR1A	0.57	7.95	0.46	7.99e-14	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs9815354	1.000	rs1716669	chr3:41908681	A/G	cg03022575	chr3:42003672	ULK4	0.55	5.27	0.33	3.16e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs15676	0.783	rs10819442	chr9:131564750	C/G	cg00228799	chr9:131580591	ENDOG	-0.56	-7.09	-0.42	1.59e-11	Blood metabolite levels;
SARC	trans	rs61931739	0.534	rs6488189	chr12:33995865	C/T	cg26384229	chr12:38710491	ALG10B	0.86	12.3	0.63	3.92e-27	Morning vs. evening chronotype;
SARC	cis	rs4819052	0.620	rs421619	chr21:46546115	C/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.58	6.07	0.37	5.21e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs11098499	0.599	rs3864142	chr4:120266191	A/T	cg09307838	chr4:120376055	NA	0.75	10.42	0.56	4.08e-21	Corneal astigmatism;
SARC	cis	rs992157	0.775	rs7559428	chr2:219150238	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.7	-10.27	-0.56	1.22e-20	Colorectal cancer;
SARC	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg23262073	chr20:60523788	NA	-0.39	-5.63	-0.35	5.17e-8	Body mass index;
SARC	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs644799	1.000	rs3177463	chr11:95502128	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	15.67	0.72	2.83e-38	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2425143	0.730	rs6058354	chr20:34491110	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-5.64	-0.35	5.01e-8	Blood protein levels;
SARC	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg18404041	chr3:52824283	ITIH1	-0.44	-6.59	-0.4	2.82e-10	Bipolar disorder;
SARC	cis	rs6062302	0.522	rs2297428	chr20:62221766	C/T	cg09650180	chr20:62225654	GMEB2	-0.48	-5.99	-0.37	7.74e-9	Glioblastoma;
SARC	cis	rs4319547	0.876	rs10846978	chr12:122964708	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.67	-7.88	-0.46	1.24e-13	Body mass index;
SARC	cis	rs1448094	0.817	rs10863122	chr12:86346047	T/C	cg02569458	chr12:86230093	RASSF9	0.42	6.04	0.37	6.16e-9	Major depressive disorder;
SARC	cis	rs12142240	0.667	rs12062	chr1:46830447	G/T	cg00530320	chr1:46809349	NSUN4	-0.57	-7.01	-0.42	2.55e-11	Menopause (age at onset);
SARC	trans	rs11098499	0.954	rs12510138	chr4:120423935	C/G	cg25214090	chr10:38739885	LOC399744	0.57	7.47	0.44	1.6e-12	Corneal astigmatism;
SARC	cis	rs950776	0.616	rs6495307	chr15:78890321	C/T	cg06917634	chr15:78832804	PSMA4	0.78	11.49	0.6	1.65e-24	Sudden cardiac arrest;
SARC	cis	rs9322817	0.583	rs9391227	chr6:105158634	T/A	cg02098413	chr6:105308735	HACE1	-0.38	-5.84	-0.36	1.71e-8	Thyroid stimulating hormone;
SARC	trans	rs1549733	0.515	rs6714760	chr2:218439027	C/A	cg19642148	chr3:47844666	DHX30	0.71	6.61	0.4	2.56e-10	Optic disc area;
SARC	cis	rs11105298	0.891	rs10858864	chr12:89846230	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.49	-4.93	-0.31	1.57e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs9796	0.870	rs3101436	chr15:41287689	A/G	cg18705301	chr15:41695430	NDUFAF1	0.41	5.73	0.35	3.06e-8	Menopause (age at onset);
SARC	cis	rs4727027	0.933	rs1468369	chr7:148839840	G/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	5.58	0.34	6.5e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs2816062	0.786	rs2745316	chr1:18896830	G/A	cg18795169	chr1:18902165	NA	-0.79	-12.91	-0.65	4.02e-29	Urate levels in lean individuals;
SARC	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg25036284	chr2:26402008	FAM59B	0.46	5.7	0.35	3.59e-8	Gut microbiome composition (summer);
SARC	cis	rs17376456	0.825	rs17372649	chr5:93126096	C/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.7	6.35	0.38	1.1e-9	Diabetic retinopathy;
SARC	trans	rs7815944	1.000	rs16902895	chr8:129425593	A/G	cg17342469	chr22:46473074	NA	0.71	6.7	0.4	1.58e-10	Atopic dermatitis;
SARC	cis	rs9303542	0.625	rs7222242	chr17:46565486	C/A	cg04904318	chr17:46607828	HOXB1	-0.47	-5.45	-0.34	1.29e-7	Ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs9399137	0.507	rs4896129	chr6:135349845	C/T	cg22676075	chr6:135203613	NA	0.39	4.97	0.31	1.29e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs12586317	0.514	rs74590021	chr14:35490113	T/G	cg16230307	chr14:35515116	FAM177A1	1.02	11.85	0.61	1.18e-25	Psoriasis;
SARC	cis	rs36051895	0.593	rs12682970	chr9:5168137	C/T	cg02405213	chr9:5042618	JAK2	-0.52	-5.89	-0.36	1.37e-8	Pediatric autoimmune diseases;
SARC	cis	rs5753618	0.504	rs9609297	chr22:31893731	G/T	cg02404636	chr22:31891804	SFI1	0.56	5.49	0.34	1.07e-7	Colorectal cancer;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg09055355	chr8:130951979	FAM49B	0.63	6.51	0.39	4.69e-10	Lung cancer in ever smokers;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg26797661	chr1:151138516	LYSMD1;SCNM1	0.47	6.28	0.38	1.66e-9	Chemerin levels;
SARC	cis	rs4763879	0.739	rs2114871	chr12:9829438	A/T	cg27502298	chr12:9555721	NA	0.46	5.05	0.31	8.72e-7	Type 1 diabetes;
SARC	cis	rs1865760	0.566	rs4529296	chr6:26083135	C/G	cg18357526	chr6:26021779	HIST1H4A	0.41	4.98	0.31	1.23e-6	Height;
SARC	cis	rs4268898	0.552	rs12621083	chr2:24367540	C/T	cg26838691	chr2:24397539	C2orf84	0.38	5.05	0.31	9.11e-7	Asthma;
SARC	cis	rs362296	0.698	rs3095073	chr4:3263138	C/T	cg06533319	chr4:3265114	C4orf44	0.35	5.87	0.36	1.52e-8	Parental longevity (mother's age at death);
SARC	cis	rs1008375	0.966	rs4235389	chr4:17696280	A/G	cg16339924	chr4:17578868	LAP3	0.5	6.34	0.38	1.2e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1707322	0.752	rs10430105	chr1:46138876	G/A	cg06784218	chr1:46089804	CCDC17	0.36	6.25	0.38	1.97e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1046896	0.520	rs9895409	chr17:80902719	C/T	cg03160526	chr17:80928410	B3GNTL1	0.35	4.83	0.3	2.53e-6	Glycated hemoglobin levels;
SARC	cis	rs2013441	1.000	rs11654025	chr17:20198160	A/T	cg13482628	chr17:19912719	NA	-0.52	-6.82	-0.41	7.98e-11	Obesity-related traits;
SARC	cis	rs3733585	0.673	rs6843873	chr4:9958788	A/C	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.55	-0.34	7.65e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg06618935	chr21:46677482	NA	-0.38	-5.19	-0.32	4.52e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7710178	0.878	rs446261	chr5:156072820	A/T	cg26439139	chr5:155924786	SGCD	-0.51	-5.49	-0.34	1.06e-7	Airway responsiveness in chronic obstructive pulmonary disease;
SARC	cis	rs3762637	1.000	rs9833415	chr3:122159840	G/A	cg24169773	chr3:122142474	KPNA1	-0.56	-5.73	-0.35	3.07e-8	LDL cholesterol levels;
SARC	cis	rs7598759	0.712	rs6727510	chr2:232332016	T/C	cg19187155	chr2:232395269	NMUR1	0.6	8.52	0.49	2e-15	Noise-induced hearing loss;
SARC	cis	rs9467773	0.967	rs1535276	chr6:26520941	T/C	cg11502198	chr6:26597334	ABT1	0.47	5.93	0.36	1.1e-8	Intelligence (multi-trait analysis);
SARC	cis	rs12079745	0.623	rs12091844	chr1:169433273	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.85	-5.18	-0.32	4.88e-7	QT interval;
SARC	cis	rs7644634	0.661	rs2305037	chr3:105422844	C/T	cg23051926	chr3:105466016	CBLB	-0.42	-5.38	-0.33	1.82e-7	Itch intensity from mosquito bite;
SARC	cis	rs6499129	0.558	rs28711261	chr16:67617186	A/G	cg01866162	chr16:67596514	CTCF	0.54	4.73	0.3	3.92e-6	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg03188948	chr7:1209495	NA	0.42	5.51	0.34	9.56e-8	Longevity;Endometriosis;
SARC	cis	rs155076	0.938	rs261375	chr13:21871882	A/G	cg25811766	chr13:21894605	NA	0.58	5.75	0.35	2.85e-8	White matter hyperintensity burden;
SARC	cis	rs9473924	0.542	rs9463665	chr6:50928520	G/T	cg14470998	chr6:50812995	TFAP2B	0.7	6.37	0.39	1.01e-9	Body mass index;
SARC	trans	rs827625	0.853	rs1444784	chr10:8985952	G/A	cg13445358	chr12:53661749	ESPL1	-0.54	-6.42	-0.39	7.39e-10	Response to metformin (IC50);
SARC	cis	rs6582630	0.622	rs11182005	chr12:38441292	G/A	cg14851346	chr12:38532713	NA	-0.47	-5.76	-0.35	2.6e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg12311346	chr5:56204834	C5orf35	-0.73	-7.14	-0.42	1.16e-11	Initial pursuit acceleration;
SARC	cis	rs113835537	0.529	rs4930379	chr11:66255674	G/A	cg24851651	chr11:66362959	CCS	0.38	4.79	0.3	2.98e-6	Airway imaging phenotypes;
SARC	cis	rs826838	0.967	rs1486345	chr12:39131677	G/A	cg26384229	chr12:38710491	ALG10B	-0.77	-11.58	-0.6	8.49e-25	Heart rate;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg15504467	chr11:108093238	ATM;NPAT	0.48	6.27	0.38	1.77e-9	Lung adenocarcinoma;
SARC	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg08280861	chr8:58055591	NA	0.62	5.86	0.36	1.56e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg26338869	chr17:61819248	STRADA	-0.7	-9.04	-0.51	6.18e-17	Prudent dietary pattern;
SARC	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg09359103	chr1:154839909	KCNN3	-0.43	-6.84	-0.41	6.88e-11	Prostate cancer;
SARC	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg11644478	chr21:40555479	PSMG1	1.02	14.16	0.68	2.93e-33	Cognitive function;
SARC	cis	rs7624766	0.743	rs959960	chr3:160469056	T/C	cg22637730	chr3:160473554	PPM1L	0.45	5.95	0.36	9.76e-9	Response to methotrexate in rheumatoid arthritis;
SARC	cis	rs35213789	0.800	rs12698846	chr7:69552392	G/A	cg10619644	chr7:69149951	AUTS2	0.42	5.13	0.32	5.97e-7	Childhood ear infection;
SARC	cis	rs7113850	0.551	rs4365050	chr11:24245730	G/A	ch.11.24196551F	chr11:24239977	NA	0.74	5.42	0.33	1.51e-7	Bone fracture in osteoporosis;
SARC	cis	rs2976388	0.647	rs2572906	chr8:143798269	G/A	cg06565975	chr8:143823917	SLURP1	0.31	5.32	0.33	2.47e-7	Urinary tract infection frequency;
SARC	cis	rs2276314	0.857	rs62101393	chr18:33592168	T/C	cg19628046	chr18:33552617	C18orf21	0.58	5.87	0.36	1.51e-8	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs7605378	0.688	rs769961	chr2:200712141	C/A	cg23649088	chr2:200775458	C2orf69	0.72	9.36	0.52	6.92e-18	Osteoporosis;
SARC	cis	rs3008870	0.916	rs2025608	chr1:67422550	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.92	11.37	0.6	3.93e-24	Lymphocyte percentage of white cells;
SARC	cis	rs11098499	0.866	rs7677068	chr4:120291704	C/T	cg09307838	chr4:120376055	NA	0.83	11.82	0.61	1.46e-25	Corneal astigmatism;
SARC	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg26513180	chr16:89883248	FANCA	-0.68	-9.52	-0.53	2.37e-18	Vitiligo;
SARC	cis	rs9392918	0.967	rs9405351	chr6:7712582	A/G	cg23089261	chr6:7723385	NA	0.39	5.1	0.32	7.04e-7	Height;
SARC	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg08219700	chr8:58056026	NA	0.6	5.71	0.35	3.49e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9815354	0.812	rs12108049	chr3:41958161	A/G	cg03022575	chr3:42003672	ULK4	0.7	5.8	0.36	2.16e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg21724239	chr8:58056113	NA	0.69	6.34	0.38	1.16e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2594989	0.836	rs347607	chr3:11268021	A/C	cg00170343	chr3:11313890	ATG7	-0.67	-7.08	-0.42	1.65e-11	Circulating chemerin levels;
SARC	cis	rs8017423	0.605	rs3742673	chr14:90735707	C/T	cg14092571	chr14:90743983	NA	-0.37	-5.36	-0.33	1.99e-7	Mortality in heart failure;
SARC	cis	rs941408	1.000	rs1076447	chr19:2792128	C/G	cg00079169	chr19:2811669	THOP1	0.5	5.45	0.34	1.31e-7	Total cholesterol levels;
SARC	cis	rs17376456	0.877	rs56373208	chr5:93491276	C/A	cg21475434	chr5:93447410	FAM172A	0.89	7.4	0.44	2.4e-12	Diabetic retinopathy;
SARC	cis	rs920590	0.523	rs4464983	chr8:19680979	C/T	cg01411142	chr8:19674711	INTS10	-0.45	-5.37	-0.33	1.92e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs5758659	1.000	rs5758660	chr22:42623718	C/A	cg15128208	chr22:42549153	NA	-0.37	-5.37	-0.33	1.89e-7	Cognitive function;
SARC	cis	rs1569175	1.000	rs281777	chr2:200839613	T/C	cg23649088	chr2:200775458	C2orf69	-0.85	-5.74	-0.35	2.87e-8	Response to treatment for acute lymphoblastic leukemia;
SARC	cis	rs5995756	0.736	rs8140185	chr22:40010806	A/G	cg10455938	chr22:40058150	CACNA1I	0.48	6.13	0.37	3.74e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs28655083	0.956	rs11863953	chr16:77065710	G/A	cg01504555	chr16:77246968	SYCE1L	-0.39	-4.92	-0.31	1.66e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9398803	0.865	rs2130603	chr6:126826819	A/C	cg20229609	chr6:126660872	C6orf173	0.41	5.94	0.36	1.03e-8	Male-pattern baldness;
SARC	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.09	0.37	4.57e-9	Height;
SARC	cis	rs2718058	0.606	rs2598077	chr7:37870427	G/C	cg24998770	chr7:37888106	TXNDC3	0.4	5.93	0.36	1.11e-8	Alzheimer's disease (late onset);
SARC	cis	rs1008375	1.000	rs114490726	chr4:17680898	T/C	cg02297831	chr4:17616191	MED28	0.44	5.5	0.34	1.01e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2075371	0.501	rs1643043	chr7:134013902	C/T	cg20476274	chr7:133979776	SLC35B4	0.46	5.77	0.35	2.53e-8	Mean platelet volume;
SARC	cis	rs2380220	0.606	rs4559095	chr6:95994154	A/C	cg04719120	chr6:96025338	MANEA	0.53	6.03	0.37	6.38e-9	Behavioural disinhibition (generation interaction);
SARC	cis	rs7666738	0.830	rs34313689	chr4:99013689	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7833790	0.724	rs6473311	chr8:82726682	G/A	cg06027949	chr8:82754900	SNX16	-0.49	-6.21	-0.38	2.39e-9	Diastolic blood pressure;
SARC	cis	rs35306767	0.953	rs1539174	chr10:974870	C/G	cg20503657	chr10:835505	NA	0.63	6.66	0.4	1.9e-10	Eosinophil percentage of granulocytes;
SARC	cis	rs6912958	0.781	rs985764	chr6:88215206	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.52	-6.91	-0.41	4.49e-11	Monocyte percentage of white cells;
SARC	cis	rs9815354	0.903	rs7373694	chr3:42012719	G/A	cg03022575	chr3:42003672	ULK4	-0.56	-5.38	-0.33	1.81e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs5758659	0.652	rs133358	chr22:42442539	A/T	cg04733989	chr22:42467013	NAGA	0.55	7.28	0.43	4.99e-12	Cognitive function;
SARC	cis	rs10754283	0.901	rs10922684	chr1:90117934	T/C	cg21401794	chr1:90099060	LRRC8C	0.59	8.25	0.48	1.2e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs4748857	0.891	rs4748858	chr10:23599920	G/A	cg12804278	chr10:23633326	C10orf67	0.4	4.78	0.3	3.13e-6	Systemic lupus erythematosus;
SARC	cis	rs9916302	0.904	rs4795356	chr17:37535631	C/T	cg07936489	chr17:37558343	FBXL20	0.7	9.29	0.52	1.12e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs9325144	0.555	rs4550281	chr12:38689937	A/G	cg13010199	chr12:38710504	ALG10B	0.56	7.33	0.43	3.73e-12	Morning vs. evening chronotype;
SARC	cis	rs6141769	0.542	rs6119932	chr20:31263802	G/T	cg17884169	chr20:31446444	EFCAB8	-0.43	-4.74	-0.3	3.72e-6	Subjective well-being;
SARC	cis	rs8180040	0.764	rs6794193	chr3:47114904	T/C	cg27129171	chr3:47204927	SETD2	0.67	9.27	0.52	1.3e-17	Colorectal cancer;
SARC	cis	rs7927771	0.832	rs10838704	chr11:47424717	T/C	cg20307385	chr11:47447363	PSMC3	-0.59	-7.4	-0.44	2.53e-12	Subjective well-being;
SARC	cis	rs2204008	0.521	rs7311188	chr12:38542813	C/G	cg26384229	chr12:38710491	ALG10B	-0.57	-7.24	-0.43	6.66e-12	Bladder cancer;
SARC	cis	rs2549003	1.000	rs7734334	chr5:131815004	C/A	cg21138405	chr5:131827807	IRF1	0.28	5.49	0.34	1.04e-7	Asthma (sex interaction);
SARC	cis	rs533123	0.816	rs569356	chr1:29136686	A/G	cg08366446	chr1:29138936	OPRD1	-0.85	-6.84	-0.41	6.93e-11	Schizophrenia;
SARC	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg15242686	chr22:24348715	GSTTP1	-0.48	-5.45	-0.34	1.27e-7	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs2070433	0.500	rs2070435	chr21:47961711	C/T	cg12379764	chr21:47803548	PCNT	0.55	5.98	0.36	8.23e-9	Lymphocyte counts;
SARC	cis	rs7084402	0.967	rs1649036	chr10:60331878	C/A	cg07615347	chr10:60278583	BICC1	0.57	8.42	0.48	3.91e-15	Refractive error;
SARC	cis	rs12421382	0.636	rs34802147	chr11:109380008	C/T	cg27471124	chr11:109292789	C11orf87	0.34	4.87	0.3	2.03e-6	Schizophrenia;
SARC	cis	rs138544659	1	rs138544659	chr15:78900701	T/G	cg06917634	chr15:78832804	PSMA4	-0.55	-5.87	-0.36	1.47e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs6840360	0.615	rs12647616	chr4:152607662	G/A	cg22705602	chr4:152727874	NA	-0.49	-8.47	-0.49	2.76e-15	Intelligence (multi-trait analysis);
SARC	cis	rs2806561	0.577	rs488438	chr1:23498999	T/A	cg12483005	chr1:23474871	LUZP1	0.43	5.54	0.34	8.12e-8	Height;
SARC	cis	rs911555	0.511	rs8007489	chr14:104054572	A/G	cg12935359	chr14:103987150	CKB	0.37	5.58	0.34	6.59e-8	Intelligence (multi-trait analysis);
SARC	cis	rs10876993	0.784	rs1871417	chr12:58018979	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.47	5.93	0.36	1.06e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs4319547	0.915	rs10773208	chr12:122970156	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.67	-7.88	-0.46	1.24e-13	Body mass index;
SARC	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.28	-0.52	1.19e-17	Developmental language disorder (linguistic errors);
SARC	cis	rs11578119	0.933	rs12140770	chr1:170449235	T/A	cg09767346	chr1:170501363	GORAB	0.44	5.15	0.32	5.49e-7	Male-pattern baldness;
SARC	cis	rs7208859	0.725	rs9891656	chr17:29243355	A/T	cg13385521	chr17:29058706	SUZ12P	0.79	7.04	0.42	2.08e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg19774624	chr17:42201019	HDAC5	-0.85	-13.4	-0.66	9.39e-31	Total body bone mineral density;
SARC	cis	rs6120849	0.754	rs6120790	chr20:33599090	A/T	cg24642439	chr20:33292090	TP53INP2	0.57	5.46	0.34	1.22e-7	Protein C levels;
SARC	trans	rs9951602	0.512	rs4799245	chr18:76653397	T/C	cg02800362	chr5:177631904	HNRNPAB	0.7	8.91	0.5	1.49e-16	Obesity-related traits;
SARC	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg03033257	chr22:50311977	ALG12;CRELD2	0.61	5.8	0.36	2.1e-8	Schizophrenia;
SARC	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.06	17.7	0.76	5.38e-45	Height;
SARC	cis	rs4917833	0.510	rs754586	chr10:100224362	A/G	cg19043522	chr10:100227446	HPSE2	0.44	5.69	0.35	3.8e-8	Pediatric bone mineral density (femoral neck);
SARC	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg18357526	chr6:26021779	HIST1H4A	0.57	6.58	0.4	3.01e-10	Uric acid levels;
SARC	cis	rs4642101	0.824	rs3889514	chr3:12844072	T/C	cg05775895	chr3:12838266	CAND2	0.74	12.05	0.62	2.69e-26	QRS complex (12-leadsum);
SARC	cis	rs9790314	0.638	rs6764019	chr3:160638851	A/C	cg04691961	chr3:161091175	C3orf57	0.61	8.31	0.48	7.68e-15	Morning vs. evening chronotype;
SARC	cis	rs7113850	0.541	rs7935630	chr11:24222206	A/C	ch.11.24196551F	chr11:24239977	NA	0.74	5.75	0.35	2.84e-8	Bone fracture in osteoporosis;
SARC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg18402987	chr7:1209562	NA	0.43	5.7	0.35	3.6e-8	Longevity;Endometriosis;
SARC	cis	rs453301	0.538	rs7830804	chr8:8970762	G/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.2	-0.38	2.5e-9	Joint mobility (Beighton score);
SARC	cis	rs9303401	0.659	rs34878689	chr17:56694330	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.08	11.8	0.61	1.72e-25	Cognitive test performance;
SARC	cis	rs6484504	0.600	rs10835763	chr11:31345574	G/A	cg02090638	chr11:31391270	DNAJC24;DCDC1	0.41	5.1	0.32	6.95e-7	Red blood cell count;
SARC	cis	rs3087591	0.683	rs10512434	chr17:29639590	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.41	-5.41	-0.33	1.57e-7	Hip circumference;
SARC	cis	rs11509153	0.542	rs4721056	chr7:12251262	T/G	cg23422036	chr7:12250390	TMEM106B	0.5	6.36	0.38	1.06e-9	Residual cognition;
SARC	cis	rs4803468	0.967	rs892044	chr19:41903671	A/G	cg09537434	chr19:41945824	ATP5SL	-0.93	-15.79	-0.72	1.15e-38	Height;
SARC	cis	rs4660306	0.614	rs12032658	chr1:45923851	C/G	cg24296786	chr1:45957014	TESK2	-0.54	-5.22	-0.32	3.97e-7	Homocysteine levels;
SARC	cis	rs798766	0.514	rs798750	chr4:1717171	G/A	cg01305441	chr4:1723418	TMEM129;TACC3	-0.38	-4.74	-0.3	3.79e-6	Bladder cancer;Urinary bladder cancer;
SARC	cis	rs6912958	0.712	rs6454640	chr6:88370352	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.47	6.16	0.37	3.23e-9	Monocyte percentage of white cells;
SARC	cis	rs5758659	1.000	rs134873	chr22:42657566	T/G	cg15128208	chr22:42549153	NA	-0.35	-5.15	-0.32	5.55e-7	Cognitive function;
SARC	cis	rs9611519	0.780	rs9611542	chr22:41677317	C/T	cg03806693	chr22:41940476	POLR3H	-0.73	-9.56	-0.53	1.71e-18	Neuroticism;
SARC	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg09060608	chr5:178986726	RUFY1	-0.35	-5.11	-0.32	6.82e-7	Lung cancer;
SARC	cis	rs861020	0.771	rs661849	chr1:210001233	C/T	cg23166289	chr1:210001082	C1orf107	0.51	5.59	0.34	6.24e-8	Orofacial clefts;
SARC	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg11987759	chr7:65425863	GUSB	-0.58	-7.64	-0.45	5.63e-13	Aortic root size;
SARC	cis	rs763121	0.853	rs7289855	chr22:39042221	G/T	cg06022373	chr22:39101656	GTPBP1	0.92	11.84	0.61	1.22e-25	Menopause (age at onset);
SARC	cis	rs1865760	0.865	rs9467651	chr6:25958257	C/G	cg18357526	chr6:26021779	HIST1H4A	0.4	4.93	0.31	1.57e-6	Height;
SARC	cis	rs57677839	1	rs57677839	chr11:17028189	G/A	cg15378786	chr11:17036137	PLEKHA7	0.81	12.76	0.64	1.25e-28	Coronary artery disease;
SARC	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg06028808	chr11:68637592	NA	0.45	5.86	0.36	1.54e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs710216	0.957	rs3738514	chr1:43426591	A/G	cg22176566	chr1:43424700	SLC2A1	-0.49	-4.89	-0.31	1.84e-6	Red cell distribution width;
SARC	cis	rs11155671	0.530	rs9371215	chr6:150194298	C/T	cg09217309	chr6:150244204	RAET1G	0.41	5.12	0.32	6.38e-7	Testicular germ cell tumor;
SARC	cis	rs7326068	0.595	rs2762988	chr13:21370780	T/A	cg16922012	chr13:21400325	XPO4	-0.44	-6.13	-0.37	3.76e-9	Schizophrenia, bipolar disorder and depression (combined);
SARC	trans	rs208520	1.000	rs208523	chr6:66954195	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.82	-8.98	-0.51	9.32e-17	Exhaled nitric oxide output;
SARC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg12648201	chr2:27665141	KRTCAP3	0.33	5.07	0.31	8.29e-7	Total body bone mineral density;
SARC	cis	rs559928	0.556	rs734762	chr11:63912189	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	5.26	0.33	3.29e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs4072980	0.545	rs11210870	chr1:38449910	T/C	cg12658694	chr1:38397304	INPP5B	-0.82	-8.99	-0.51	8.94e-17	Coronary artery disease;
SARC	cis	rs12079745	0.590	rs12061080	chr1:169332848	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.96	-5.76	-0.35	2.64e-8	QT interval;
SARC	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg13395646	chr4:1353034	KIAA1530	-0.46	-5.42	-0.33	1.51e-7	Obesity-related traits;
SARC	cis	rs10463554	0.892	rs1561404	chr5:102299351	G/C	cg23492399	chr5:102201601	PAM	-0.46	-5.55	-0.34	7.89e-8	Parkinson's disease;
SARC	cis	rs76419734	1.000	rs72673853	chr4:106756877	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	5.31	0.33	2.52e-7	Post bronchodilator FEV1;
SARC	cis	rs6912958	1.000	rs13214153	chr6:88153983	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.62	-8.71	-0.5	5.53e-16	Monocyte percentage of white cells;
SARC	cis	rs7044106	0.500	rs56725168	chr9:123492576	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	9.92	0.54	1.43e-19	Hip circumference adjusted for BMI;
SARC	trans	rs2898290	0.622	rs7822109	chr8:11349147	T/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.48	-0.44	1.52e-12	Systolic blood pressure;
SARC	cis	rs9905704	0.846	rs28363318	chr17:56798207	T/C	cg12560992	chr17:57184187	TRIM37	0.43	4.93	0.31	1.58e-6	Testicular germ cell tumor;
SARC	cis	rs6665290	0.901	rs7535826	chr1:227213968	A/C	cg14016676	chr1:227182615	CDC42BPA	-0.33	-4.74	-0.3	3.65e-6	Myeloid white cell count;
SARC	cis	rs11676348	0.808	rs4674267	chr2:219046437	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.42	-5.35	-0.33	2.14e-7	Ulcerative colitis;
SARC	cis	rs4555082	1.000	rs7149013	chr14:105759840	T/C	cg13114125	chr14:105738426	BRF1	-0.73	-10.31	-0.56	8.7e-21	Mean platelet volume;Platelet distribution width;
SARC	cis	rs4481887	0.927	rs4244173	chr1:248466899	G/C	cg01631408	chr1:248437212	OR2T33	-0.43	-5.53	-0.34	8.5e-8	Common traits (Other);
SARC	cis	rs2204008	0.774	rs7304438	chr12:38361146	T/G	cg13010199	chr12:38710504	ALG10B	0.78	10.77	0.58	3.24e-22	Bladder cancer;
SARC	cis	rs748404	0.697	rs473016	chr15:43558823	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.53	6.37	0.39	9.92e-10	Lung cancer;
SARC	cis	rs765787	0.530	rs12910270	chr15:45512086	G/A	cg26924012	chr15:45694286	SPATA5L1	0.43	5.36	0.33	1.98e-7	Uric acid levels;
SARC	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg05861140	chr6:150128134	PCMT1	-0.41	-5.34	-0.33	2.19e-7	Lung cancer;
SARC	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-7.92	-0.46	9.73e-14	Chronic sinus infection;
SARC	cis	rs950776	0.616	rs495090	chr15:78870003	A/G	cg06917634	chr15:78832804	PSMA4	-0.76	-10.29	-0.56	1.02e-20	Sudden cardiac arrest;
SARC	cis	rs6089584	0.546	rs6061980	chr20:60618877	G/A	cg13770153	chr20:60521292	NA	-0.37	-5.37	-0.33	1.89e-7	Body mass index;
SARC	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg11366901	chr6:160182831	ACAT2	0.97	9.82	0.54	2.82e-19	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs3106136	0.967	rs12499309	chr4:95171284	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.4	-6.18	-0.38	2.91e-9	Capecitabine sensitivity;
SARC	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg08859206	chr1:53392774	SCP2	0.36	5.22	0.32	3.96e-7	Monocyte count;
SARC	cis	rs17125944	0.615	rs2357944	chr14:53305573	T/G	cg00686598	chr14:53173677	PSMC6	-0.76	-5.65	-0.35	4.64e-8	Alzheimer's disease (late onset);
SARC	cis	rs6732160	0.588	rs1430345	chr2:73370682	A/G	cg01422370	chr2:73384389	NA	0.37	5.76	0.35	2.67e-8	Intelligence (multi-trait analysis);
SARC	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg03352830	chr11:487213	PTDSS2	-0.54	-5.08	-0.32	7.7300000000000005e-07	Body mass index;
SARC	cis	rs7017697	1.000	rs6980875	chr8:19685948	C/T	cg03894339	chr8:19674705	INTS10	-0.42	-5.15	-0.32	5.45e-7	Breast cancer;
SARC	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg03806693	chr22:41940476	POLR3H	0.88	11.67	0.61	4.34e-25	Crohn's disease;Inflammatory bowel disease;
SARC	trans	rs9427116	0.502	rs12125166	chr1:154582129	A/G	cg00006032	chr14:66974439	GPHN	-0.47	-6.23	-0.38	2.12e-9	Blood protein levels;
SARC	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.5	-6.04	-0.37	6.16e-9	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg11764359	chr7:65958608	NA	-0.78	-9.49	-0.53	2.76e-18	Aortic root size;
SARC	cis	rs8077889	0.672	rs3785810	chr17:41850689	C/G	cg26893861	chr17:41843967	DUSP3	0.99	15.54	0.71	7.68e-38	Triglycerides;
SARC	cis	rs17376456	0.877	rs10514380	chr5:93409370	C/T	cg21475434	chr5:93447410	FAM172A	0.87	7.91	0.46	1.06e-13	Diabetic retinopathy;
SARC	cis	rs6964587	1.000	rs6956596	chr7:91750107	T/G	cg17063962	chr7:91808500	NA	0.95	15.35	0.71	3.17e-37	Breast cancer;
SARC	cis	rs6728642	1.000	rs113863815	chr2:97657813	A/G	cg26665480	chr2:98280029	ACTR1B	-0.6	-4.84	-0.3	2.39e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg18252515	chr7:66147081	NA	0.46	5.05	0.31	8.81e-7	Aortic root size;
SARC	cis	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg03060546	chr3:49711283	APEH	-0.67	-8.37	-0.48	5.47e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs2980439	0.557	rs2976876	chr8:8318850	T/C	cg06636001	chr8:8085503	FLJ10661	0.68	9.19	0.52	2.22e-17	Neuroticism;
SARC	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg06558623	chr16:89946397	TCF25	0.71	5.97	0.36	8.69e-9	Skin colour saturation;
SARC	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg11764359	chr7:65958608	NA	-0.74	-8.88	-0.5	1.84e-16	Aortic root size;
SARC	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg03433033	chr1:76189801	ACADM	-0.43	-5.64	-0.35	4.81e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs908922	0.676	rs1970283	chr1:152495619	G/C	cg09873164	chr1:152488093	CRCT1	0.66	8.61	0.49	1.1e-15	Hair morphology;
SARC	cis	rs6500395	1.000	rs7201196	chr16:48674030	C/T	cg04672837	chr16:48644449	N4BP1	0.47	6.24	0.38	2.05e-9	Response to tocilizumab in rheumatoid arthritis;
SARC	trans	rs453301	0.624	rs330060	chr8:9090902	A/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.7	-0.4	1.52e-10	Joint mobility (Beighton score);
SARC	cis	rs9815354	1.000	rs1716651	chr3:41975099	A/T	cg03022575	chr3:42003672	ULK4	-0.55	-5.26	-0.33	3.22e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs7432375	0.610	rs4420814	chr3:136513282	T/C	cg15507776	chr3:136538369	TMEM22	0.62	7.69	0.45	4.05e-13	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	cis	rs10911251	0.528	rs10911248	chr1:183080564	G/A	cg13390022	chr1:182993471	LAMC1	0.32	4.88	0.3	1.95e-6	Colorectal cancer;
SARC	cis	rs9768139	0.935	rs10155946	chr7:158122116	C/T	cg25566285	chr7:158114605	PTPRN2	-0.33	-5.62	-0.35	5.32e-8	Calcium levels;
SARC	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg18876405	chr7:65276391	NA	-0.43	-5.28	-0.33	3.02e-7	Aortic root size;
SARC	cis	rs9436747	0.641	rs4655680	chr1:66041469	G/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.48	5.21	0.32	4.24e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg21724239	chr8:58056113	NA	0.6	5.85	0.36	1.64e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg25025879	chr12:53359317	NA	-0.5	-5.95	-0.36	9.82e-9	Cancer (pleiotropy);
SARC	cis	rs2529049	0.537	rs2721787	chr7:24670875	A/C	cg17569154	chr7:24781545	DFNA5	0.5	7.13	0.42	1.22e-11	Urate levels in obese individuals;
SARC	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg01238044	chr22:24384105	GSTT1	-0.45	-5.04	-0.31	9.4e-7	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs13082711	0.554	rs34066402	chr3:27387987	G/A	cg02860705	chr3:27208620	NA	0.65	8.1	0.47	3.12e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg15057440	chr2:74685383	WBP1	0.58	7.0	0.42	2.78e-11	Blood pressure;
SARC	trans	rs10435719	0.753	rs9694940	chr8:11789858	G/C	cg06636001	chr8:8085503	FLJ10661	0.5	6.3	0.38	1.48e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
SARC	cis	rs11098499	0.908	rs7695996	chr4:120322033	C/T	cg24375607	chr4:120327624	NA	0.4	4.75	0.3	3.5e-6	Corneal astigmatism;
SARC	trans	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg06636001	chr8:8085503	FLJ10661	-0.72	-10.09	-0.55	4.24e-20	Triglycerides;
SARC	cis	rs503734	0.502	rs513154	chr3:100953212	T/G	cg27318481	chr3:100970896	IMPG2	-0.47	-5.48	-0.34	1.12e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs7089973	0.872	rs17092542	chr10:116630289	G/A	cg08188268	chr10:116634841	FAM160B1	0.35	5.64	0.35	4.96e-8	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs4555082	0.718	rs75139030	chr14:105710853	A/AG	cg06808227	chr14:105710500	BRF1	-0.51	-6.51	-0.39	4.46e-10	Mean platelet volume;Platelet distribution width;
SARC	cis	rs7647973	0.696	rs7100	chr3:49053219	A/G	cg07636037	chr3:49044803	WDR6	0.85	9.13	0.51	3.31e-17	Menarche (age at onset);
SARC	cis	rs9911578	0.967	rs302843	chr17:56727986	C/T	cg12560992	chr17:57184187	TRIM37	0.83	11.32	0.6	5.91e-24	Intelligence (multi-trait analysis);
SARC	cis	rs9398803	0.713	rs6921183	chr6:126869029	A/T	cg19875578	chr6:126661172	C6orf173	0.65	8.99	0.51	8.82e-17	Male-pattern baldness;
SARC	cis	rs854765	0.583	rs8070722	chr17:17813562	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.43	5.58	0.34	6.79e-8	Total body bone mineral density;
SARC	cis	rs1707322	1.000	rs10890355	chr1:46317348	G/A	cg06784218	chr1:46089804	CCDC17	0.33	5.77	0.35	2.45e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs11574514	1.000	rs8051653	chr16:67848515	T/C	cg01866162	chr16:67596514	CTCF	0.79	5.24	0.32	3.51e-7	Crohn's disease;
SARC	cis	rs950169	0.919	rs12915589	chr15:84734464	T/C	cg17507749	chr15:85114479	UBE2QP1	0.76	9.12	0.51	3.56e-17	Schizophrenia;
SARC	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-6.31	-0.38	1.37e-9	Personality dimensions;
SARC	cis	rs7223966	0.921	rs3020612	chr17:61960878	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	7.13	0.42	1.25e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7103648	0.695	rs6485758	chr11:47530024	G/A	cg20307385	chr11:47447363	PSMC3	0.78	11.17	0.59	1.81e-23	Diastolic blood pressure;Systolic blood pressure;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg22586474	chr7:931148	C7orf20	0.54	7.01	0.42	2.52e-11	Schizophrenia;
SARC	cis	rs9790314	0.967	rs339101	chr3:161064193	A/T	cg04691961	chr3:161091175	C3orf57	-0.8	-12.06	-0.62	2.35e-26	Morning vs. evening chronotype;
SARC	cis	rs7089973	0.604	rs11196936	chr10:116588630	C/T	cg03647239	chr10:116582469	FAM160B1	0.49	6.3	0.38	1.48e-9	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs36051895	0.632	rs7032616	chr9:5180996	T/C	cg02405213	chr9:5042618	JAK2	-0.42	-4.86	-0.3	2.13e-6	Pediatric autoimmune diseases;
SARC	cis	rs1420338	0.967	rs10272282	chr7:34172073	C/T	cg01275685	chr7:34179230	BMPER	-0.4	-4.89	-0.31	1.87e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg23830780	chr10:37106964	NA	0.41	6.34	0.38	1.18e-9	Thyroid stimulating hormone;
SARC	cis	rs27434	0.583	rs34764	chr5:96155229	A/G	cg16492584	chr5:96139282	ERAP1	-0.56	-6.97	-0.42	3.17e-11	Ankylosing spondylitis;
SARC	cis	rs4253772	0.513	rs6008612	chr22:46707907	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.74	7.54	0.44	1.05e-12	LDL cholesterol;Cholesterol, total;
SARC	cis	rs9303401	0.614	rs8081058	chr17:57160513	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.97	10.17	0.55	2.42e-20	Cognitive test performance;
SARC	cis	rs189798	0.826	rs330903	chr8:8990645	G/A	cg06636001	chr8:8085503	FLJ10661	-0.42	-4.97	-0.31	1.33e-6	Myopia (pathological);
SARC	cis	rs6060717	0.536	rs11699899	chr20:34525646	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-5.73	-0.35	3.1e-8	Hip circumference adjusted for BMI;
SARC	cis	rs7959452	0.605	rs12819406	chr12:69696400	G/T	cg20891283	chr12:69753455	YEATS4	0.41	5.42	0.33	1.48e-7	Blood protein levels;
SARC	cis	rs3858526	0.959	rs1840179	chr11:5949148	A/G	cg02574844	chr11:5959923	NA	-0.42	-5.14	-0.32	5.77e-7	DNA methylation (variation);
SARC	trans	rs9329221	0.620	rs6601427	chr8:10156025	A/G	cg06636001	chr8:8085503	FLJ10661	-0.64	-9.11	-0.51	3.89e-17	Neuroticism;
SARC	cis	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg00409905	chr10:38381863	ZNF37A	-0.55	-8.07	-0.47	3.75e-14	Extrinsic epigenetic age acceleration;
SARC	cis	rs6696846	0.791	rs7520752	chr1:205054114	C/T	cg21643547	chr1:205240462	TMCC2	0.57	7.86	0.46	1.38e-13	Red blood cell count;
SARC	cis	rs9303401	0.659	rs12948133	chr17:56673602	T/C	cg25039879	chr17:56429692	SUPT4H1	0.67	6.17	0.37	2.93e-9	Cognitive test performance;
SARC	cis	rs7264396	0.790	rs6060539	chr20:34239382	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-8.22	-0.47	1.46e-14	Total cholesterol levels;
SARC	cis	rs270601	0.913	rs273899	chr5:131695178	G/A	cg24060327	chr5:131705240	SLC22A5	-0.71	-8.46	-0.48	2.92e-15	Acylcarnitine levels;
SARC	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg11644478	chr21:40555479	PSMG1	-0.89	-11.46	-0.6	2.09e-24	Cognitive function;
SARC	cis	rs7927592	0.513	rs3853616	chr11:68198252	A/G	cg01657329	chr11:68192670	LRP5	-0.42	-5.72	-0.35	3.18e-8	Total body bone mineral density;
SARC	cis	rs4780401	0.609	rs9924522	chr16:11816852	C/A	cg01061890	chr16:11836724	TXNDC11	-0.62	-8.73	-0.5	4.86e-16	Rheumatoid arthritis;
SARC	cis	rs7264396	0.561	rs2064725	chr20:34569142	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-5.57	-0.34	7.09e-8	Total cholesterol levels;
SARC	cis	rs611744	0.506	rs4735054	chr8:109261780	A/C	cg21045802	chr8:109455806	TTC35	-0.61	-7.9	-0.46	1.07e-13	Dupuytren's disease;
SARC	trans	rs10519937	1.000	rs11959505	chr5:126726288	A/T	cg26526953	chr19:1921199	SCAMP4	0.64	6.44	0.39	6.64e-10	IgG glycosylation;
SARC	cis	rs1023500	0.596	rs133352	chr22:42434022	C/A	cg04733989	chr22:42467013	NAGA	0.73	10.21	0.56	1.86e-20	Schizophrenia;
SARC	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg06221963	chr1:154839813	KCNN3	-0.53	-8.65	-0.49	8.4e-16	Prostate cancer;
SARC	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4481887	0.927	rs4523548	chr1:248472399	G/T	cg01631408	chr1:248437212	OR2T33	-0.39	-5.06	-0.31	8.56e-7	Common traits (Other);
SARC	trans	rs208515	0.556	rs12206707	chr6:66697182	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.99	11.49	0.6	1.62e-24	Exhaled nitric oxide levels;
SARC	cis	rs138880	0.580	rs28562884	chr22:50312869	T/C	cg03033257	chr22:50311977	ALG12;CRELD2	0.66	5.01	0.31	1.06e-6	Schizophrenia;
SARC	cis	rs6840360	0.593	rs4696107	chr4:152606823	G/A	cg22705602	chr4:152727874	NA	-0.49	-8.46	-0.48	2.88e-15	Intelligence (multi-trait analysis);
SARC	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg09455208	chr3:40491958	NA	0.4	5.81	0.36	2.01e-8	Renal cell carcinoma;
SARC	cis	rs7937682	0.855	rs490897	chr11:111487914	A/G	cg22437258	chr11:111473054	SIK2	0.75	10.19	0.56	2.17e-20	Primary sclerosing cholangitis;
SARC	cis	rs709400	0.663	rs2273703	chr14:103918029	C/G	cg12935359	chr14:103987150	CKB	-0.39	-5.81	-0.36	2e-8	Body mass index;
SARC	cis	rs2153535	0.580	rs2184584	chr6:8468407	T/C	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg11890956	chr21:40555474	PSMG1	1.13	18.53	0.77	9.93e-48	Cognitive function;
SARC	cis	rs11809207	0.523	rs7087	chr1:26496651	T/C	cg23602478	chr1:26503979	CNKSR1	0.28	5.04	0.31	9.15e-7	Height;
SARC	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg27170947	chr2:26402098	FAM59B	0.39	4.98	0.31	1.22e-6	Gut microbiome composition (summer);
SARC	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg11764359	chr7:65958608	NA	-0.72	-8.42	-0.48	3.77e-15	Aortic root size;
SARC	cis	rs8067354	0.645	rs11079389	chr17:57887952	G/A	cg13753209	chr17:57696993	CLTC	0.61	6.28	0.38	1.68e-9	Hemoglobin concentration;
SARC	cis	rs2251381	0.808	rs7364112	chr21:30548968	C/A	cg24692254	chr21:30365293	RNF160	0.85	12.26	0.63	5.24e-27	Selective IgA deficiency;
SARC	cis	rs25645	0.830	rs3935281	chr17:38188419	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.39	7.17	0.42	1.01e-11	Myeloid white cell count;
SARC	cis	rs16976116	0.901	rs28526269	chr15:55499190	A/G	cg11288833	chr15:55489084	RSL24D1	0.63	6.13	0.37	3.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9843304	0.507	rs56242998	chr3:149214480	G/A	cg08667024	chr3:149219783	TM4SF4	0.47	7.15	0.42	1.1e-11	Gallstone disease;
SARC	cis	rs644799	0.965	rs502521	chr11:95533557	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	9.34	0.52	8.01e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7786808	0.712	rs2335167	chr7:158213948	A/C	cg09998033	chr7:158218633	PTPRN2	-0.34	-5.17	-0.32	4.93e-7	Obesity-related traits;
SARC	cis	rs17376456	0.825	rs13361613	chr5:93272176	C/T	cg21475434	chr5:93447410	FAM172A	0.86	7.72	0.45	3.37e-13	Diabetic retinopathy;
SARC	cis	rs2594989	0.733	rs6779007	chr3:11583254	C/T	cg00170343	chr3:11313890	ATG7	-0.59	-6.43	-0.39	7.34e-10	Circulating chemerin levels;
SARC	cis	rs9818758	0.607	rs56306491	chr3:49314960	G/A	cg01304814	chr3:48885189	PRKAR2A	0.68	5.51	0.34	9.37e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs7412746	0.611	rs1889741	chr1:150869045	T/C	cg15448220	chr1:150897856	SETDB1	0.52	6.87	0.41	5.67e-11	Melanoma;
SARC	cis	rs5753618	0.519	rs5997939	chr22:31677130	C/G	cg07713946	chr22:31675144	LIMK2	-0.38	-5.32	-0.33	2.44e-7	Colorectal cancer;
SARC	cis	rs2153535	0.580	rs7341382	chr6:8470549	A/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs11098499	0.954	rs10518331	chr4:120323595	C/T	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs9309473	1.000	rs7598396	chr2:73652628	A/G	cg20560298	chr2:73613845	ALMS1	-0.48	-5.89	-0.36	1.35e-8	Metabolite levels;
SARC	cis	rs733592	0.524	rs10875744	chr12:48498440	G/C	cg24011408	chr12:48396354	COL2A1	0.51	7.16	0.42	1.04e-11	Plateletcrit;
SARC	cis	rs1949733	0.543	rs62287446	chr4:8535988	G/A	cg11789530	chr4:8429930	ACOX3	-0.48	-5.6	-0.34	5.9e-8	Response to antineoplastic agents;
SARC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	18.99	0.78	3.24e-49	Prudent dietary pattern;
SARC	cis	rs2948294	0.545	rs11776397	chr8:8115161	C/T	cg06636001	chr8:8085503	FLJ10661	0.63	7.51	0.44	1.26e-12	Red cell distribution width;
SARC	cis	rs858239	0.699	rs955187	chr7:23194605	A/G	cg23682824	chr7:23144976	KLHL7	-0.65	-8.39	-0.48	4.57e-15	Cerebrospinal fluid biomarker levels;
SARC	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg12696929	chr3:195401817	SDHAP2	0.4	5.27	0.33	3.03e-7	Pancreatic cancer;
SARC	cis	rs10779751	0.770	rs6674994	chr1:11239515	T/C	cg08854313	chr1:11322531	MTOR	0.87	12.8	0.64	9.47e-29	Body mass index;
SARC	cis	rs6701037	1.000	rs6702010	chr1:175123858	C/A	cg00321850	chr1:175162397	KIAA0040	-0.34	-5.02	-0.31	1.03e-6	Alcohol dependence;
SARC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg21747090	chr2:27597821	SNX17	-0.55	-7.68	-0.45	4.44e-13	Total body bone mineral density;
SARC	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg11764359	chr7:65958608	NA	0.79	9.88	0.54	1.93e-19	Aortic root size;
SARC	cis	rs9291683	0.546	rs13110307	chr4:10044364	T/C	cg11266682	chr4:10021025	SLC2A9	0.4	6.91	0.41	4.53e-11	Bone mineral density;
SARC	cis	rs7584330	0.784	rs6724766	chr2:238413600	A/G	cg11271282	chr2:238384023	NA	0.43	4.79	0.3	3.02e-6	Prostate cancer;
SARC	cis	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg18252515	chr7:66147081	NA	-1.22	-10.1	-0.55	3.89e-20	Diabetic kidney disease;
SARC	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1395	0.885	rs7575245	chr2:27527321	G/A	cg21747090	chr2:27597821	SNX17	-0.46	-5.45	-0.34	1.28e-7	Blood metabolite levels;
SARC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.19	0.8	4.45e-53	Prudent dietary pattern;
SARC	cis	rs2153535	0.505	rs1737583	chr6:8536812	G/A	cg21535247	chr6:8435926	SLC35B3	0.55	6.81	0.41	8.01e-11	Motion sickness;
SARC	cis	rs17376456	1.000	rs17376456	chr5:93557702	C/T	cg21475434	chr5:93447410	FAM172A	-0.89	-7.69	-0.45	4.2e-13	Diabetic retinopathy;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg23197559	chr2:232573080	PTMA	0.54	7.19	0.43	8.83e-12	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs936229	0.798	rs1869959	chr15:75147332	A/C	cg10253484	chr15:75165896	SCAMP2	-0.46	-4.89	-0.3	1.91e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg24675658	chr1:53192096	ZYG11B	0.66	9.47	0.53	3.3e-18	Monocyte count;
SARC	cis	rs9467773	1.000	rs9467778	chr6:26534743	T/C	cg11502198	chr6:26597334	ABT1	0.46	5.53	0.34	8.38e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7762018	0.556	rs78233989	chr6:170102041	C/G	cg19338460	chr6:170058176	WDR27	-0.76	-5.36	-0.33	2.02e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs473651	0.935	rs515412	chr2:239345394	A/T	cg18131467	chr2:239335373	ASB1	0.92	14.98	0.7	5.69e-36	Multiple system atrophy;
SARC	cis	rs10489525	0.599	rs34710929	chr1:115606608	G/A	cg01522456	chr1:115632236	TSPAN2	0.46	5.45	0.34	1.29e-7	Autism;
SARC	cis	rs2153535	0.580	rs9328479	chr6:8519646	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	8.21	0.47	1.56e-14	Motion sickness;
SARC	cis	rs7208859	0.673	rs11658435	chr17:29228561	A/G	cg13385521	chr17:29058706	SUZ12P	0.85	7.23	0.43	7.08e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs2153535	0.580	rs1932283	chr6:8477661	C/T	cg23788917	chr6:8435910	SLC35B3	0.64	8.6	0.49	1.2e-15	Motion sickness;
SARC	cis	rs6665290	0.935	rs12403236	chr1:227196502	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.08	-23.94	-0.84	9.53e-65	Myeloid white cell count;
SARC	cis	rs11190604	1.000	rs2298074	chr10:102247526	G/C	cg07080220	chr10:102295463	HIF1AN	0.74	8.43	0.48	3.51e-15	Palmitoleic acid (16:1n-7) levels;
SARC	trans	rs17780086	0.527	rs17182651	chr17:30547537	G/A	cg20587970	chr11:113659929	NA	-1.29	-10.23	-0.56	1.55e-20	Height;
SARC	cis	rs2288912	0.838	rs2239375	chr19:45459851	T/C	cg10169327	chr19:45448959	APOC2	0.32	5.33	0.33	2.3e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs10754283	0.967	rs10737708	chr1:90119804	A/G	cg21401794	chr1:90099060	LRRC8C	0.6	8.45	0.48	3.16e-15	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs11785400	0.793	rs1056012	chr8:143740167	A/G	cg10596483	chr8:143751796	JRK	0.55	7.01	0.42	2.59e-11	Schizophrenia;
SARC	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg22920501	chr2:26401640	FAM59B	-0.55	-7.26	-0.43	5.77e-12	Gut microbiome composition (summer);
SARC	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg21782813	chr7:2030301	MAD1L1	0.3	4.95	0.31	1.39e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs77372450	0.551	rs60235007	chr5:157069349	G/C	cg05585991	chr5:157099197	C5orf52	0.55	5.63	0.35	5.26e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	18.99	0.78	3.24e-49	Prudent dietary pattern;
SARC	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg27266027	chr21:40555129	PSMG1	0.51	5.59	0.34	6.36e-8	Cognitive function;
SARC	cis	rs7681440	0.775	rs6848181	chr4:90807252	T/C	cg02192967	chr4:90758406	SNCA	0.35	4.88	0.3	1.95e-6	Dementia with Lewy bodies;
SARC	cis	rs7223966	1.000	rs7220892	chr17:61908316	G/A	cg26338869	chr17:61819248	STRADA	0.48	5.13	0.32	6.17e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1957429	0.901	rs1467570	chr14:65347858	A/G	cg23373153	chr14:65346875	NA	1.07	11.5	0.6	1.53e-24	Pediatric areal bone mineral density (radius);
SARC	cis	rs7914558	0.966	rs10883805	chr10:104708251	T/C	cg04362960	chr10:104952993	NT5C2	0.41	5.0	0.31	1.15e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs8180040	0.726	rs7628747	chr3:47001990	A/T	cg27129171	chr3:47204927	SETD2	0.64	8.85	0.5	2.25e-16	Colorectal cancer;
SARC	cis	rs696281	0.861	rs10258341	chr7:16723533	A/G	cg22204915	chr7:17582718	NA	0.4	4.73	0.3	3.83e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;
SARC	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg20607798	chr8:58055168	NA	0.61	5.39	0.33	1.74e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7537052	0.669	rs2296263	chr1:36641729	C/T	cg24686825	chr1:36642396	MAP7D1	-0.65	-8.51	-0.49	2.18e-15	Schizophrenia;
SARC	cis	rs2279817	1.000	rs2354290	chr1:18019861	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.45	4.88	0.3	1.93e-6	Neuroticism;
SARC	cis	rs787274	1.000	rs1418409	chr9:115573707	T/C	cg13803584	chr9:115635662	SNX30	-0.83	-4.96	-0.31	1.33e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs7904368	0.659	rs3740169	chr10:16873547	C/T	cg23933602	chr10:16859644	RSU1	0.66	7.89	0.46	1.15e-13	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg00409905	chr10:38381863	ZNF37A	-0.55	-7.96	-0.46	7.61e-14	Extrinsic epigenetic age acceleration;
SARC	cis	rs7644634	0.649	rs2284993	chr3:105405280	A/G	cg23051926	chr3:105466016	CBLB	0.47	5.81	0.36	2.06e-8	Itch intensity from mosquito bite;
SARC	cis	rs709400	0.894	rs10143293	chr14:104063014	G/A	cg26031613	chr14:104095156	KLC1	1.04	20.39	0.8	9.77e-54	Body mass index;
SARC	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg17971929	chr21:40555470	PSMG1	0.98	13.78	0.67	5.39e-32	Cognitive function;
SARC	cis	rs7103648	0.630	rs7120548	chr11:47662932	A/G	cg20307385	chr11:47447363	PSMC3	0.78	11.44	0.6	2.46e-24	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs7681440	0.583	rs2737023	chr4:90739505	T/C	cg06632027	chr4:90757378	SNCA	-0.42	-5.23	-0.32	3.81e-7	Dementia with Lewy bodies;
SARC	cis	rs9399135	0.935	rs2150680	chr6:135347131	G/C	cg24558204	chr6:135376177	HBS1L	0.45	6.07	0.37	5.25e-9	Red blood cell count;
SARC	cis	rs10421328	0.821	rs10423311	chr19:19757262	C/G	cg03709012	chr19:19516395	GATAD2A	0.56	5.97	0.36	8.75e-9	Parental longevity (combined parental age at death);
SARC	cis	rs941764	0.862	rs8021298	chr14:91840153	G/A	cg10511902	chr14:91842949	CCDC88C	0.29	4.72	0.3	4.15e-6	Breast cancer;
SARC	cis	rs1008375	0.966	rs7666888	chr4:17695722	C/T	cg27347728	chr4:17578864	LAP3	0.45	5.72	0.35	3.28e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs5417	0.662	rs8067500	chr17:7172631	A/G	cg14438174	chr17:7137923	DVL2	0.58	7.59	0.45	7.62e-13	Diastolic blood pressure;
SARC	cis	rs1580019	0.885	rs1610141	chr7:32498435	C/T	cg14728415	chr7:32535168	LSM5;AVL9	0.42	4.99	0.31	1.16e-6	Cognitive ability;
SARC	cis	rs6815814	0.950	rs5743566	chr4:38805942	G/C	cg09316306	chr4:38807337	TLR1	0.5	5.16	0.32	5.23e-7	Breast cancer;
SARC	cis	rs7223966	1.000	rs6504170	chr17:61709168	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-6.05	-0.37	5.65e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9828933	0.766	rs3774725	chr3:63974258	T/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.9	-8.13	-0.47	2.53e-14	Type 2 diabetes;
SARC	cis	rs2652822	0.935	rs12594313	chr15:63436662	A/G	cg02713581	chr15:63449717	RPS27L	0.72	9.76	0.54	4.46e-19	Metabolic traits;
SARC	cis	rs60871478	0.679	rs62432240	chr7:794813	A/G	cg05535760	chr7:792225	HEATR2	0.84	7.79	0.45	2.26e-13	Cerebrospinal P-tau181p levels;
SARC	cis	rs7412746	0.552	rs4970980	chr1:150864992	A/C	cg10589385	chr1:150898437	SETDB1	0.4	5.38	0.33	1.8e-7	Melanoma;
SARC	cis	rs9400467	0.537	rs12202411	chr6:111488518	G/A	cg15721981	chr6:111408429	SLC16A10	0.68	5.85	0.36	1.63e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs35110281	0.744	rs162398	chr21:44949285	T/C	cg01579765	chr21:45077557	HSF2BP	-0.32	-5.6	-0.34	6.02e-8	Mean corpuscular volume;
SARC	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg18364779	chr6:26104403	HIST1H4C	0.43	5.14	0.32	5.92e-7	Intelligence (multi-trait analysis);
SARC	cis	rs11581859	0.613	rs11166091	chr1:99198061	C/T	cg20286094	chr1:99190917	SNX7	-0.42	-4.99	-0.31	1.2e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs651907	0.557	rs34376498	chr3:101480156	C/T	cg12386194	chr3:101231763	SENP7	0.49	5.79	0.35	2.28e-8	Colorectal cancer;
SARC	cis	rs79149102	0.649	rs12594158	chr15:75109953	C/T	cg09165964	chr15:75287851	SCAMP5	-0.99	-5.92	-0.36	1.15e-8	Lung cancer;
SARC	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg12463550	chr7:65579703	CRCP	-0.48	-5.36	-0.33	2.04e-7	Aortic root size;
SARC	cis	rs9896933	0.623	rs77166830	chr17:80833525	T/C	cg15664640	chr17:80829946	TBCD	-0.49	-5.61	-0.35	5.57e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
SARC	cis	rs6752107	1.000	rs2241880	chr2:234183368	A/G	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.45	6.17	0.37	3.02e-9	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs9814567	1.000	rs4572812	chr3:134291177	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	7.01	0.42	2.54e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs8044995	0.501	rs73613952	chr16:68352808	G/C	cg05110241	chr16:68378359	PRMT7	-0.67	-6.08	-0.37	4.81e-9	Schizophrenia;
SARC	cis	rs8180040	0.764	rs4682852	chr3:47177772	C/T	cg27129171	chr3:47204927	SETD2	0.68	9.71	0.54	6.16e-19	Colorectal cancer;
SARC	trans	rs6964833	1.000	rs6967152	chr7:74099317	C/T	cg07504079	chr7:72649617	NCF1B	-0.61	-6.59	-0.4	2.83e-10	Menarche (age at onset);
SARC	cis	rs7635838	0.596	rs443503	chr3:11261912	A/T	cg00170343	chr3:11313890	ATG7	-0.6	-7.48	-0.44	1.49e-12	HDL cholesterol;
SARC	cis	rs11651000	0.654	rs12451801	chr17:45820975	T/C	cg03474202	chr17:45855739	NA	-0.38	-5.5	-0.34	9.98e-8	IgG glycosylation;
SARC	cis	rs7647973	0.626	rs62260723	chr3:49872124	T/C	cg07636037	chr3:49044803	WDR6	-0.63	-6.43	-0.39	7.01e-10	Menarche (age at onset);
SARC	cis	rs6570726	0.738	rs7746330	chr6:145899257	A/C	cg05347473	chr6:146136440	FBXO30	0.55	7.51	0.44	1.24e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs910316	1.000	rs10143132	chr14:75525850	G/A	cg08847533	chr14:75593920	NEK9	0.96	16.08	0.73	1.2e-39	Height;
SARC	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.69	8.61	0.49	1.07e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9840812	0.769	rs3755636	chr3:135968828	G/C	cg15507776	chr3:136538369	TMEM22	0.5	5.32	0.33	2.46e-7	Fibrinogen levels;
SARC	trans	rs6582630	0.533	rs4103689	chr12:38702980	A/C	cg23762105	chr12:34175262	ALG10	-0.54	-7.22	-0.43	7.2e-12	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs829883	0.622	rs4762498	chr12:98964737	A/G	cg25150519	chr12:98850993	NA	-0.62	-7.5	-0.44	1.33e-12	Colorectal adenoma (advanced);
SARC	trans	rs9650657	0.538	rs11250093	chr8:10798828	C/T	cg06636001	chr8:8085503	FLJ10661	0.52	6.69	0.4	1.66e-10	Neuroticism;
SARC	cis	rs6426558	0.537	rs7512409	chr1:227484038	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.44	-5.24	-0.32	3.63e-7	Neutrophil percentage of white cells;
SARC	cis	rs854765	0.583	rs9912895	chr17:17826020	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-9.9	-0.54	1.61e-19	Total body bone mineral density;
SARC	cis	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg13124370	chr4:22517059	GPR125	0.48	5.58	0.34	6.62e-8	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs7520050	0.966	rs10789487	chr1:46420221	G/A	cg24296786	chr1:45957014	TESK2	0.38	4.87	0.3	2.02e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg02725872	chr8:58115012	NA	-0.33	-5.33	-0.33	2.33e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg22920501	chr2:26401640	FAM59B	0.61	8.22	0.47	1.39e-14	Gut microbiome composition (summer);
SARC	cis	rs2777491	1.000	rs7168177	chr15:41715585	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.82	-12.12	-0.62	1.55e-26	Ulcerative colitis;
SARC	cis	rs6540556	0.723	rs9430014	chr1:209905372	A/C	cg23920097	chr1:209922102	NA	-0.52	-5.31	-0.33	2.59e-7	Red blood cell count;
SARC	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg03709012	chr19:19516395	GATAD2A	0.95	14.79	0.7	2.38e-35	Tonsillectomy;
SARC	cis	rs11690935	0.959	rs12692970	chr2:172594197	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.99	-15.89	-0.72	5.28e-39	Schizophrenia;
SARC	cis	rs1005277	0.522	rs289643	chr10:37941494	T/G	cg25427524	chr10:38739819	LOC399744	-0.49	-7.09	-0.42	1.57e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs546131	0.642	rs34999475	chr11:34829848	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-5.05	-0.31	8.72e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs7429990	0.965	rs800762	chr3:47905570	G/C	cg11946769	chr3:48343235	NME6	0.45	5.16	0.32	5.26e-7	Educational attainment (years of education);
SARC	cis	rs9818758	0.545	rs55921200	chr3:49189316	T/C	cg00383909	chr3:49044727	WDR6	0.8	6.46	0.39	6.09e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg00933542	chr6:150070202	PCMT1	0.3	4.91	0.31	1.73e-6	Testicular germ cell tumor;
SARC	cis	rs7772486	0.686	rs857880	chr6:145971115	T/C	cg05347473	chr6:146136440	FBXO30	-0.54	-7.4	-0.44	2.47e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7666738	0.716	rs11721453	chr4:99045485	G/T	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2204008	0.837	rs11514225	chr12:38076270	G/A	cg13010199	chr12:38710504	ALG10B	0.78	10.67	0.57	6.53e-22	Bladder cancer;
SARC	cis	rs2439831	0.681	rs1549523	chr15:43624189	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.09	12.69	0.64	2.16e-28	Lung cancer in ever smokers;
SARC	cis	rs137603	0.623	rs470075	chr22:39686806	G/A	cg01093212	chr22:39715156	SNORD43;RPL3	-0.47	-5.43	-0.34	1.42e-7	Primary biliary cholangitis;
SARC	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.5e-10	Life satisfaction;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg02067788	chr5:132387589	HSPA4	0.5	6.67	0.4	1.82e-10	Chemerin levels;
SARC	cis	rs6496667	0.533	rs886491	chr15:90993215	G/A	cg22089800	chr15:90895588	ZNF774	0.43	4.92	0.31	1.65e-6	Rheumatoid arthritis;
SARC	trans	rs1814175	0.817	rs10769617	chr11:49810421	G/A	cg03929089	chr4:120376271	NA	-0.9	-14.66	-0.69	6.51e-35	Height;
SARC	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.44	-5.59	-0.34	6.49e-8	Blood metabolite levels;
SARC	cis	rs735396	0.595	rs1169279	chr12:121455873	C/T	cg02403541	chr12:121454288	C12orf43	0.9	14.41	0.69	4.41e-34	N-glycan levels;
SARC	cis	rs6060717	0.536	rs11699899	chr20:34525646	G/C	cg01084648	chr20:34329383	RBM39	0.62	4.72	0.3	4.09e-6	Hip circumference adjusted for BMI;
SARC	cis	rs10078	0.559	rs2671891	chr5:456386	A/G	cg08916839	chr5:415575	AHRR	0.82	7.76	0.45	2.67e-13	Fat distribution (HIV);
SARC	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg24829409	chr8:58192753	C8orf71	-0.55	-4.92	-0.31	1.61e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-5.51	-0.34	9.44e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg02725872	chr8:58115012	NA	-0.37	-6.63	-0.4	2.3e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg16479474	chr6:28041457	NA	0.34	5.29	0.33	2.81e-7	Cardiac Troponin-T levels;
SARC	cis	rs6456156	0.586	rs1358883	chr6:167467433	C/G	cg07741184	chr6:167504864	NA	-0.36	-6.96	-0.42	3.37e-11	Primary biliary cholangitis;
SARC	cis	rs7027203	0.828	rs3957506	chr9:96588133	C/T	cg14598338	chr9:96623480	NA	-0.55	-7.94	-0.46	8.42e-14	DNA methylation (variation);
SARC	cis	rs2013441	0.931	rs12937827	chr17:20033202	G/C	cg13482628	chr17:19912719	NA	0.47	6.13	0.37	3.67e-9	Obesity-related traits;
SARC	cis	rs6138458	0.828	rs6132785	chr20:24993414	T/C	cg26195577	chr20:24973756	C20orf3	0.76	8.8	0.5	3.22e-16	Blood protein levels;
SARC	cis	rs7717697	0.797	rs12152797	chr5:82751307	A/C	cg19814134	chr5:82768288	VCAN	0.44	5.15	0.32	5.61e-7	Vertical cup-disc ratio;
SARC	cis	rs4555082	0.718	rs75139030	chr14:105710853	A/AG	cg10792982	chr14:105748885	BRF1	0.55	8.22	0.47	1.46e-14	Mean platelet volume;Platelet distribution width;
SARC	cis	rs7937682	0.575	rs1940391	chr11:111776891	G/A	cg09085632	chr11:111637200	PPP2R1B	0.77	10.46	0.57	3.09e-21	Primary sclerosing cholangitis;
SARC	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.7	6.78	0.41	9.97e-11	Platelet count;
SARC	cis	rs12079745	0.623	rs2275300	chr1:169337515	G/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.92	-5.9	-0.36	1.29e-8	QT interval;
SARC	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg12463550	chr7:65579703	CRCP	0.48	5.24	0.32	3.65e-7	Aortic root size;
SARC	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg12311346	chr5:56204834	C5orf35	-0.58	-6.01	-0.37	7.24e-9	Initial pursuit acceleration;
SARC	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg27266027	chr21:40555129	PSMG1	0.47	5.1	0.32	7.1e-7	Cognitive function;
SARC	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg19660806	chr8:588740	NA	0.53	4.84	0.3	2.41e-6	IgG glycosylation;
SARC	cis	rs73206853	0.698	rs59574270	chr12:111112098	A/C	cg10860002	chr12:110842031	ANAPC7	0.58	4.95	0.31	1.41e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs826838	0.935	rs11169511	chr12:39175802	T/C	cg26384229	chr12:38710491	ALG10B	0.88	12.78	0.64	1.09e-28	Heart rate;
SARC	cis	rs4969178	0.965	rs3817295	chr17:76394526	T/A	cg20026190	chr17:76395443	PGS1	0.39	5.3	0.33	2.71e-7	HDL cholesterol levels;
SARC	cis	rs870825	0.655	rs35764203	chr4:185639078	C/A	cg04058563	chr4:185651563	MLF1IP	0.81	11.3	0.6	6.58e-24	Blood protein levels;
SARC	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg06221963	chr1:154839813	KCNN3	-0.49	-7.84	-0.46	1.64e-13	Prostate cancer;
SARC	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.37	0.39	9.97e-10	Bipolar disorder;
SARC	cis	rs7949030	0.653	rs2849030	chr11:62366986	G/A	cg11742103	chr11:62369870	EML3;MTA2	-0.42	-6.5	-0.39	4.89e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg25427524	chr10:38739819	LOC399744	-0.57	-8.93	-0.5	1.33e-16	Extrinsic epigenetic age acceleration;
SARC	cis	rs8141529	0.748	rs132533	chr22:29299571	A/G	cg15103426	chr22:29168792	CCDC117	-0.64	-8.18	-0.47	1.89e-14	Lymphocyte counts;
SARC	cis	rs10992471	0.528	rs1924243	chr9:95224847	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.42	-4.72	-0.3	4.12e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg13206674	chr6:150067644	NUP43	0.44	5.74	0.35	2.86e-8	Lung cancer;
SARC	cis	rs4073582	0.894	rs801733	chr11:65934549	A/C	cg14036092	chr11:66035641	RAB1B	0.52	6.32	0.38	1.31e-9	Gout;
SARC	cis	rs5753618	0.561	rs9609254	chr22:31705942	G/A	cg07713946	chr22:31675144	LIMK2	0.37	5.17	0.32	5.08e-7	Colorectal cancer;
SARC	cis	rs7953249	0.564	rs1183910	chr12:121420807	G/A	cg25281562	chr12:121454272	C12orf43	0.51	6.06	0.37	5.29e-9	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs3931020	0.688	rs405445	chr1:75221150	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	-0.46	-4.89	-0.31	1.87e-6	Resistin levels;
SARC	cis	rs9611519	0.639	rs7289989	chr22:41476799	A/C	cg03806693	chr22:41940476	POLR3H	-0.53	-6.9	-0.41	4.86e-11	Neuroticism;
SARC	cis	rs2439831	0.850	rs11070408	chr15:44034788	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	7.55	0.44	1.01e-12	Lung cancer in ever smokers;
SARC	cis	rs9296092	0.538	rs62407565	chr6:33535739	A/G	cg13560919	chr6:33536144	NA	-0.56	-6.81	-0.41	8.33e-11	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg26597838	chr10:835615	NA	1.02	10.3	0.56	9.35e-21	Eosinophil percentage of granulocytes;
SARC	cis	rs950027	0.584	rs1145086	chr15:45654327	A/G	cg21132104	chr15:45694354	SPATA5L1	0.55	7.09	0.42	1.59e-11	Response to fenofibrate (adiponectin levels);
SARC	cis	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg22857025	chr5:266934	NA	-1.06	-11.69	-0.61	3.74e-25	Breast cancer;
SARC	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.85	12.26	0.63	5.5e-27	Chronic sinus infection;
SARC	cis	rs7647973	0.626	rs1352889	chr3:49652148	T/C	cg06212747	chr3:49208901	KLHDC8B	0.58	5.8	0.36	2.18e-8	Menarche (age at onset);
SARC	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	5.9	0.36	1.26e-8	Bipolar disorder;
SARC	cis	rs9916302	0.861	rs8081033	chr17:37506650	A/G	cg07936489	chr17:37558343	FBXL20	0.68	9.16	0.51	2.78e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs17253792	0.822	rs10083493	chr14:56045411	C/T	cg01858014	chr14:56050164	KTN1	-0.69	-5.25	-0.33	3.42e-7	Putamen volume;
SARC	cis	rs6867032	0.958	rs4505990	chr5:2015811	A/G	cg26168224	chr5:2018326	NA	0.92	14.86	0.7	1.4e-35	Gut microbiome composition (winter);
SARC	cis	rs5758659	0.904	rs5758653	chr22:42613485	G/T	cg15128208	chr22:42549153	NA	-0.37	-5.27	-0.33	3.13e-7	Cognitive function;
SARC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg23131131	chr22:24373011	LOC391322	-0.48	-5.27	-0.33	3.11e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9309711	0.922	rs13385119	chr2:3484521	G/A	cg10845886	chr2:3471009	TTC15	-0.6	-7.56	-0.44	9.11e-13	Neurofibrillary tangles;
SARC	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg11890956	chr21:40555474	PSMG1	-1.06	-16.24	-0.73	3.55e-40	Cognitive function;
SARC	cis	rs9325144	0.505	rs10785560	chr12:38636622	C/T	cg26384229	chr12:38710491	ALG10B	0.77	10.73	0.58	4.36e-22	Morning vs. evening chronotype;
SARC	trans	rs1853207	1.000	rs117317596	chr10:96573396	C/G	cg02737782	chr1:8014393	NA	-0.99	-6.59	-0.4	2.82e-10	Blood metabolite levels;
SARC	cis	rs2239547	0.657	rs6445538	chr3:52874288	T/C	cg11645453	chr3:52864694	ITIH4	0.31	4.74	0.3	3.67e-6	Schizophrenia;
SARC	cis	rs2197308	0.626	rs6581156	chr12:37858731	C/A	cg26384229	chr12:38710491	ALG10B	-0.83	-12.2	-0.62	8.45e-27	Morning vs. evening chronotype;
SARC	cis	rs2425143	1.000	rs2295356	chr20:34252856	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.13	0.32	6.04e-7	Blood protein levels;
SARC	cis	rs6121246	0.528	rs6060252	chr20:30191084	A/G	cg13852791	chr20:30311386	BCL2L1	0.68	5.91	0.36	1.2e-8	Mean corpuscular hemoglobin;
SARC	cis	rs372883	0.613	rs1153289	chr21:30686212	G/T	cg24692254	chr21:30365293	RNF160	-0.64	-8.24	-0.47	1.26e-14	Pancreatic cancer;
SARC	cis	rs9457247	1.000	rs408918	chr6:167399282	G/T	cg07741184	chr6:167504864	NA	0.27	5.09	0.32	7.28e-7	Crohn's disease;
SARC	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6062302	0.549	rs4809586	chr20:62249402	C/T	cg09650180	chr20:62225654	GMEB2	-0.45	-5.55	-0.34	7.75e-8	Glioblastoma;
SARC	cis	rs2729354	0.779	rs2454663	chr11:57358083	T/C	cg17237962	chr11:57479805	MED19;TMX2	0.46	4.75	0.3	3.53e-6	Blood protein levels;
SARC	cis	rs2153535	0.584	rs9502723	chr6:8541504	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	6.49	0.39	4.98e-10	Motion sickness;
SARC	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg07414643	chr4:187882934	NA	0.35	4.82	0.3	2.55e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs921968	0.541	rs12987171	chr2:219327030	G/C	cg02176678	chr2:219576539	TTLL4	0.47	7.22	0.43	7.15e-12	Mean corpuscular hemoglobin concentration;
SARC	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg25894440	chr7:65020034	NA	0.79	5.96	0.36	9.49e-9	Diabetic kidney disease;
SARC	cis	rs637571	0.522	rs566590	chr11:65754062	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.45	-5.58	-0.34	6.51e-8	Eosinophil percentage of white cells;
SARC	cis	rs9300255	0.620	rs1716173	chr12:123660721	A/T	cg05973401	chr12:123451056	ABCB9	0.53	5.97	0.36	8.72e-9	Neutrophil percentage of white cells;
SARC	cis	rs9457247	0.967	rs2769346	chr6:167370999	A/G	cg23791538	chr6:167370224	RNASET2	0.63	8.74	0.5	4.71e-16	Crohn's disease;
SARC	cis	rs8077889	0.956	rs4793026	chr17:41850508	A/G	cg26893861	chr17:41843967	DUSP3	0.79	9.34	0.52	8.27e-18	Triglycerides;
SARC	cis	rs67311347	0.822	rs11709089	chr3:40351484	C/T	cg24209194	chr3:40518798	ZNF619	0.56	6.99	0.42	2.9e-11	Renal cell carcinoma;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg13268919	chr11:842945	TSPAN4;POLR2L	-0.96	-8.2	-0.47	1.58e-14	Autism spectrum disorder or schizophrenia;
SARC	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.59	4.9	0.31	1.77e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	trans	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-10.55	-0.57	1.63e-21	Intelligence (multi-trait analysis);
SARC	cis	rs11155671	0.530	rs9397420	chr6:150206781	C/T	cg05036130	chr6:150231994	NA	-0.3	-5.21	-0.32	4.11e-7	Testicular germ cell tumor;
SARC	cis	rs4689388	0.793	rs4689393	chr4:6287241	T/C	cg14416269	chr4:6271139	WFS1	0.35	5.35	0.33	2.08e-7	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs4642101	0.535	rs55692304	chr3:12840057	C/T	cg24848339	chr3:12840334	CAND2	0.39	6.15	0.37	3.33e-9	QRS complex (12-leadsum);
SARC	cis	rs2153535	0.580	rs9379222	chr6:8514788	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	8.28	0.48	9.37e-15	Motion sickness;
SARC	cis	rs9314323	0.535	rs1055479	chr8:26240646	A/G	cg11498726	chr8:26250323	BNIP3L	-0.51	-6.83	-0.41	7.36e-11	Red cell distribution width;
SARC	cis	rs11719291	0.831	rs11715177	chr3:48763894	G/A	cg03060546	chr3:49711283	APEH	-0.53	-4.83	-0.3	2.53e-6	Cognitive function;
SARC	cis	rs9788682	0.694	rs3825845	chr15:78910258	C/T	cg06917634	chr15:78832804	PSMA4	-0.45	-4.91	-0.31	1.73e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs10089	1.000	rs10057122	chr5:127512063	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	8.91	0.5	1.54e-16	Ileal carcinoids;
SARC	cis	rs35306767	0.903	rs10508208	chr10:910983	C/T	cg20503657	chr10:835505	NA	0.78	7.63	0.45	5.99e-13	Eosinophil percentage of granulocytes;
SARC	cis	rs6546324	0.580	rs2861684	chr2:67837380	T/C	cg18237512	chr2:67827392	NA	-0.46	-5.6	-0.34	5.95e-8	Endometriosis;
SARC	cis	rs2070997	0.607	rs2261468	chr9:133708873	T/C	cg11464064	chr9:133710261	ABL1	0.65	6.05	0.37	5.84e-9	Response to amphetamines;
SARC	cis	rs16866061	1.000	rs72974238	chr2:225432470	C/A	cg12698349	chr2:225449008	CUL3	0.73	10.62	0.57	9.93e-22	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg21144161	chr5:423903	AHRR	0.31	4.84	0.3	2.39e-6	Cystic fibrosis severity;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg12747167	chr1:70715648	SFRS11	0.46	6.24	0.38	2e-9	Thyroid stimulating hormone;
SARC	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg11764359	chr7:65958608	NA	-0.67	-7.93	-0.46	8.84e-14	Aortic root size;
SARC	cis	rs748404	0.631	rs12905772	chr15:43648444	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	5.83	0.36	1.79e-8	Lung cancer;
SARC	cis	rs10789491	1.000	rs2083485	chr1:47170091	G/C	cg15501359	chr1:47185051	KIAA0494	0.76	8.14	0.47	2.36e-14	Response to hepatitis C treatment;
SARC	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg04166393	chr7:2884313	GNA12	0.49	5.71	0.35	3.36e-8	Height;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg01434783	chr4:124319883	SPRY1	0.54	6.97	0.42	3.14e-11	Breast cancer;
SARC	cis	rs2836974	0.545	rs3167757	chr21:40714478	C/T	cg11890956	chr21:40555474	PSMG1	0.73	9.84	0.54	2.51e-19	Cognitive function;
SARC	cis	rs12477438	0.765	rs13390672	chr2:99589829	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-8.16	-0.47	2.11e-14	Chronic sinus infection;
SARC	cis	rs738322	0.967	rs133013	chr22:38570912	C/T	cg25457927	chr22:38595422	NA	-0.29	-5.95	-0.36	9.77e-9	Cutaneous nevi;
SARC	cis	rs9858542	0.953	rs7623659	chr3:49414791	C/T	cg07274523	chr3:49395745	GPX1	0.53	6.26	0.38	1.8e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs3771395	1.000	rs3771397	chr2:71132948	A/G	cg21294935	chr2:71128538	VAX2	0.65	5.41	0.33	1.55e-7	Corneal astigmatism;
SARC	cis	rs9790314	0.503	rs6441374	chr3:161064540	A/T	cg04691961	chr3:161091175	C3orf57	-0.55	-7.1	-0.42	1.47e-11	Morning vs. evening chronotype;
SARC	cis	rs13161895	1.000	rs6873994	chr5:179436696	T/G	cg04265672	chr5:179402240	RNF130	0.52	5.15	0.32	5.48e-7	LDL cholesterol;
SARC	cis	rs4319547	0.698	rs4039670	chr12:122822655	A/G	cg23029597	chr12:123009494	RSRC2	-0.41	-5.23	-0.32	3.8e-7	Body mass index;
SARC	cis	rs7412746	0.622	rs72704654	chr1:150826410	G/A	cg10589385	chr1:150898437	SETDB1	0.42	5.61	0.34	5.7e-8	Melanoma;
SARC	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.31	-4.79	-0.3	3e-6	Total body bone mineral density;
SARC	cis	rs3812831	0.635	rs6560937	chr13:114945991	C/G	cg08824895	chr13:115047677	UPF3A	0.53	7.2	0.43	8.47e-12	Schizophrenia;
SARC	cis	rs11785693	0.862	rs62491169	chr8:4986425	C/A	cg26367366	chr8:4980734	NA	0.74	6.63	0.4	2.28e-10	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs858239	0.600	rs7799422	chr7:23128413	G/A	cg23682824	chr7:23144976	KLHL7	0.7	9.38	0.52	5.93e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs1865760	0.865	rs9393677	chr6:25945815	G/A	cg16482183	chr6:26056742	HIST1H1C	0.51	6.49	0.39	4.98e-10	Height;
SARC	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg11764359	chr7:65958608	NA	0.65	7.59	0.45	7.45e-13	Aortic root size;
SARC	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg22857025	chr5:266934	NA	-1.06	-11.8	-0.61	1.74e-25	Breast cancer;
SARC	cis	rs11098499	0.954	rs11098526	chr4:120390359	C/T	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs1008375	1.000	rs28693609	chr4:17645233	C/T	cg27347728	chr4:17578864	LAP3	0.48	5.95	0.36	9.58e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg05896524	chr21:47604654	C21orf56	0.53	6.5	0.39	4.96e-10	Testicular germ cell tumor;
SARC	cis	rs747650	0.892	rs7937101	chr11:47226488	A/G	cg03339077	chr11:47165057	C11orf49	-0.46	-6.47	-0.39	5.57e-10	Acne (severe);
SARC	trans	rs61931739	0.534	rs1490109	chr12:34064077	T/C	cg26384229	chr12:38710491	ALG10B	0.73	10.12	0.55	3.46e-20	Morning vs. evening chronotype;
SARC	cis	rs8014204	0.566	rs7145575	chr14:75145528	T/A	cg17347104	chr14:75034677	LTBP2	-0.48	-6.33	-0.38	1.25e-9	Caffeine consumption;
SARC	cis	rs9326248	0.581	rs10790167	chr11:116800943	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.61	7.69	0.45	4.04e-13	Blood protein levels;
SARC	cis	rs7429990	0.932	rs12493348	chr3:48143538	A/T	cg11946769	chr3:48343235	NME6	-0.46	-5.42	-0.33	1.46e-7	Educational attainment (years of education);
SARC	cis	rs2916247	1.000	rs4734170	chr8:93051254	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.58	-6.15	-0.37	3.4e-9	Intelligence (multi-trait analysis);
SARC	cis	rs9733	0.650	rs11204684	chr1:150608894	A/G	cg17724175	chr1:150552817	MCL1	-0.38	-4.92	-0.31	1.66e-6	Tonsillectomy;
SARC	cis	rs36051895	0.623	rs6476956	chr9:5261238	A/G	cg02405213	chr9:5042618	JAK2	-0.42	-5.04	-0.31	9.47e-7	Pediatric autoimmune diseases;
SARC	cis	rs2011503	1.000	rs2965201	chr19:19478051	C/T	cg15839431	chr19:19639596	YJEFN3	0.51	4.98	0.31	1.24e-6	Bipolar disorder;
SARC	cis	rs2153535	0.580	rs9393023	chr6:8469994	T/G	cg07606381	chr6:8435919	SLC35B3	0.77	10.83	0.58	2.14e-22	Motion sickness;
SARC	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg11366901	chr6:160182831	ACAT2	1.03	10.87	0.58	1.54e-22	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs11098499	0.779	rs28495013	chr4:120375831	A/C	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	cis	rs9914544	0.545	rs9912568	chr17:18792719	G/A	cg25390199	chr17:18761479	PRPSAP2	0.46	6.05	0.37	5.66e-9	Educational attainment (years of education);
SARC	cis	rs2933343	0.951	rs7648327	chr3:128570708	A/G	cg25356066	chr3:128598488	ACAD9	0.56	6.32	0.38	1.3e-9	IgG glycosylation;
SARC	cis	rs8031584	0.918	rs34693097	chr15:31253984	A/G	cg14829155	chr15:31115871	NA	-0.43	-5.44	-0.34	1.32e-7	Huntington's disease progression;
SARC	cis	rs1018697	0.518	rs2250301	chr10:104548393	G/A	cg04362960	chr10:104952993	NT5C2	-0.54	-5.58	-0.34	6.57e-8	Colorectal adenoma (advanced);
SARC	cis	rs561341	0.883	rs72821942	chr17:30234460	C/T	cg13647721	chr17:30228624	UTP6	0.65	5.37	0.33	1.89e-7	Hip circumference adjusted for BMI;
SARC	cis	rs2075371	0.933	rs1868784	chr7:133945932	A/G	cg11752832	chr7:134001865	SLC35B4	0.53	6.75	0.4	1.17e-10	Mean platelet volume;
SARC	cis	rs34779708	0.966	rs2045918	chr10:35418517	T/G	cg03585969	chr10:35415529	CREM	0.39	4.73	0.3	3.86e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs1483890	0.723	rs13077078	chr3:69411402	C/A	cg22125112	chr3:69402811	FRMD4B	0.29	4.78	0.3	3.12e-6	Resting heart rate;
SARC	cis	rs1729951	0.575	rs361243	chr3:136697786	C/T	cg15507776	chr3:136538369	TMEM22	0.49	5.39	0.33	1.69e-7	Neuroticism;
SARC	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.72	10.32	0.56	8.38e-21	Menarche (age at onset);
SARC	cis	rs7666738	0.800	rs13106995	chr4:99028790	A/T	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg13628971	chr7:2884303	GNA12	0.56	6.67	0.4	1.79e-10	Height;
SARC	cis	rs7551222	0.752	rs10793765	chr1:204549375	A/G	cg20240347	chr1:204465584	NA	-0.33	-5.88	-0.36	1.4e-8	Schizophrenia;
SARC	cis	rs6088580	0.608	rs2105109	chr20:32971932	A/G	cg08999081	chr20:33150536	PIGU	-0.44	-6.65	-0.4	2.07e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg00933542	chr6:150070202	PCMT1	0.31	5.3	0.33	2.72e-7	Lung cancer;
SARC	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg23758822	chr17:41437982	NA	0.87	10.68	0.57	6.32e-22	Menopause (age at onset);
SARC	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg13939156	chr17:80058883	NA	0.4	6.25	0.38	1.92e-9	Life satisfaction;
SARC	cis	rs55883249	0.957	rs17362839	chr2:9754439	T/C	cg23886495	chr2:9695866	ADAM17	0.69	7.0	0.42	2.72e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs55871839	0.684	rs7829715	chr8:59803836	C/T	cg07426533	chr8:59803705	TOX	0.38	5.14	0.32	5.69e-7	Pneumonia;
SARC	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.96	11.67	0.61	4.4e-25	Platelet count;
SARC	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg27266027	chr21:40555129	PSMG1	-0.45	-4.88	-0.3	1.93e-6	Cognitive function;
SARC	cis	rs2153535	0.542	rs9378553	chr6:8472632	T/C	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	cis	rs9828933	0.938	rs2578011	chr3:64004819	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.72	-6.84	-0.41	7.01e-11	Type 2 diabetes;
SARC	cis	rs16866061	0.855	rs11687736	chr2:225405122	A/T	cg12698349	chr2:225449008	CUL3	0.72	10.54	0.57	1.73e-21	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg26116260	chr4:7069785	GRPEL1	0.92	11.77	0.61	2.09e-25	Monocyte percentage of white cells;
SARC	cis	rs4566357	0.615	rs2396445	chr2:227917726	C/G	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.58	-0.34	6.55e-8	Coronary artery disease;
SARC	cis	rs10992471	0.603	rs1980848	chr9:95248571	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.47	5.37	0.33	1.91e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs9300255	0.506	rs11057251	chr12:123791227	A/G	cg05973401	chr12:123451056	ABCB9	-0.5	-5.73	-0.35	3.12e-8	Neutrophil percentage of white cells;
SARC	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg18876405	chr7:65276391	NA	-0.46	-5.18	-0.32	4.74e-7	Aortic root size;
SARC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg03452623	chr4:187889614	NA	-0.75	-11.5	-0.6	1.58e-24	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1345301	0.935	rs11691721	chr2:102876679	G/A	cg12451869	chr2:102867685	NA	0.38	5.39	0.33	1.75e-7	Waist circumference;
SARC	cis	rs6424115	0.760	rs2999566	chr1:24051124	A/G	cg15997130	chr1:24165203	NA	0.38	4.79	0.3	2.95e-6	Immature fraction of reticulocytes;
SARC	cis	rs3857536	0.679	rs7740850	chr6:66981033	G/A	cg07460842	chr6:66804631	NA	-0.42	-4.76	-0.3	3.35e-6	Blood trace element (Cu levels);
SARC	cis	rs36051895	0.695	rs10974921	chr9:5024427	T/A	cg02405213	chr9:5042618	JAK2	-0.51	-5.43	-0.34	1.4e-7	Pediatric autoimmune diseases;
SARC	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.44	6.57	0.4	3.3e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs7084402	0.967	rs1649081	chr10:60292444	G/A	cg07615347	chr10:60278583	BICC1	0.61	8.99	0.51	8.94e-17	Refractive error;
SARC	cis	rs2729354	0.953	rs2848625	chr11:57330650	G/C	cg02958346	chr11:57425731	CLP1	0.5	4.97	0.31	1.3e-6	Blood protein levels;
SARC	cis	rs208520	0.837	rs208489	chr6:66927584	G/A	cg07460842	chr6:66804631	NA	-1.0	-11.88	-0.61	9.23e-26	Exhaled nitric oxide output;
SARC	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	7.26	0.43	5.86e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs3784262	0.742	rs28379349	chr15:58202494	A/G	cg12031962	chr15:58353849	ALDH1A2	0.39	5.62	0.35	5.36e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg11494091	chr17:61959527	GH2	0.52	7.57	0.44	8.53e-13	Prudent dietary pattern;
SARC	cis	rs74417235	0.639	rs2396994	chr5:154052750	A/T	cg08893839	chr5:154027129	NA	-0.51	-4.73	-0.3	3.94e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
SARC	cis	rs10911232	0.507	rs10911212	chr1:183024469	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.09	0.55	4.29e-20	Hypertriglyceridemia;
SARC	cis	rs13082711	0.911	rs997680	chr3:27443638	G/A	cg02860705	chr3:27208620	NA	0.45	6.03	0.37	6.45e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs6901004	0.805	rs354532	chr6:111548813	C/T	cg15721981	chr6:111408429	SLC16A10	-0.41	-4.95	-0.31	1.39e-6	Blood metabolite levels;
SARC	cis	rs782590	0.967	rs4290693	chr2:55799991	C/G	cg18811423	chr2:55921094	PNPT1	0.7	10.05	0.55	5.83e-20	Metabolic syndrome;
SARC	cis	rs9911578	1.000	rs9901181	chr17:56964271	C/T	cg05425664	chr17:57184151	TRIM37	-0.65	-7.95	-0.46	8.09e-14	Intelligence (multi-trait analysis);
SARC	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-4.76	-0.3	3.38e-6	Total body bone mineral density;
SARC	cis	rs9611519	0.894	rs4821998	chr22:41468273	C/G	cg17376030	chr22:41985996	PMM1	0.52	6.38	0.39	9.61e-10	Neuroticism;
SARC	cis	rs6062302	0.522	rs3787107	chr20:62230576	G/A	cg09650180	chr20:62225654	GMEB2	-0.47	-5.69	-0.35	3.72e-8	Glioblastoma;
SARC	cis	rs765787	0.530	rs11636395	chr15:45535684	G/C	cg24006582	chr15:45444508	DUOX1	-0.54	-7.09	-0.42	1.62e-11	Uric acid levels;
SARC	cis	rs7870753	0.838	rs7039472	chr9:99245574	C/T	cg25260653	chr9:99212216	HABP4	0.51	4.77	0.3	3.21e-6	Height;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg27413820	chr17:17701697	RAI1	-0.41	-6.28	-0.38	1.6e-9	Chemerin levels;
SARC	cis	rs1707322	1.000	rs11211232	chr1:46411146	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.38	0.39	9.69e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs78487399	0.710	rs72879276	chr2:43627101	T/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-5.03	-0.31	9.83e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs16978956	0.779	rs2424169	chr20:18327445	C/T	cg12587960	chr20:18033564	OVOL2	-0.28	-4.78	-0.3	3.08e-6	Body mass index;
SARC	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg11843238	chr5:131593191	PDLIM4	-0.41	-5.04	-0.31	9.23e-7	Breast cancer;
SARC	cis	rs10982256	0.875	rs10759710	chr9:117252598	C/T	cg15903421	chr9:117267460	DFNB31	-0.36	-4.73	-0.3	3.91e-6	Bipolar disorder;
SARC	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg18876405	chr7:65276391	NA	0.69	9.05	0.51	5.93e-17	Calcium levels;
SARC	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.77	7.62	0.45	6.49e-13	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg17971929	chr21:40555470	PSMG1	0.98	13.64	0.67	1.62e-31	Cognitive function;
SARC	cis	rs4253772	0.637	rs8139035	chr22:46651367	A/G	cg24881330	chr22:46731750	TRMU	0.62	6.72	0.4	1.41e-10	LDL cholesterol;Cholesterol, total;
SARC	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg02297831	chr4:17616191	MED28	0.51	6.63	0.4	2.36e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10779751	1.000	rs7549109	chr1:11278813	C/G	cg08854313	chr1:11322531	MTOR	-0.89	-13.72	-0.67	8.67e-32	Body mass index;
SARC	cis	rs9807989	0.507	rs10208196	chr2:102996345	G/A	cg03938978	chr2:103052716	IL18RAP	0.32	5.17	0.32	5.14e-7	Asthma;
SARC	trans	rs747334	0.846	rs7897603	chr10:92708759	C/G	cg07746351	chr16:89466392	ANKRD11	-0.51	-7.07	-0.42	1.83e-11	Fibroblast growth factor basic levels;
SARC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.8	10.5	0.57	2.27e-21	Prudent dietary pattern;
SARC	cis	rs12479064	0.724	rs4851203	chr2:99986932	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.56	-6.55	-0.39	3.56e-10	Chronic sinus infection;
SARC	cis	rs9916302	0.904	rs2338800	chr17:37498149	C/G	cg00129232	chr17:37814104	STARD3	0.6	7.33	0.43	3.75e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs908922	0.582	rs1856121	chr1:152512169	A/T	cg09873164	chr1:152488093	CRCT1	0.66	8.77	0.5	3.71e-16	Hair morphology;
SARC	cis	rs3796352	1.000	rs13072457	chr3:53102389	G/A	cg12962167	chr3:53033115	SFMBT1	0.78	5.03	0.31	9.65e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg00409905	chr10:38381863	ZNF37A	0.55	7.89	0.46	1.14e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs7587476	0.906	rs2070096	chr2:215645545	C/G	cg11970703	chr2:215861251	ABCA12	-0.39	-5.77	-0.35	2.46e-8	Neuroblastoma;
SARC	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg11890956	chr21:40555474	PSMG1	1.17	19.38	0.79	1.78e-50	Cognitive function;
SARC	cis	rs1050631	0.564	rs1785929	chr18:33725165	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.58	7.17	0.42	1.01e-11	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs35110281	0.712	rs167930	chr21:44946625	G/A	cg21573476	chr21:45109991	RRP1B	-0.44	-6.49	-0.39	5.2e-10	Mean corpuscular volume;
SARC	cis	rs6087990	0.735	rs6057647	chr20:31381690	A/T	cg13636640	chr20:31349939	DNMT3B	0.8	12.78	0.64	1.07e-28	Ulcerative colitis;
SARC	cis	rs2832191	0.740	rs2853830	chr21:30416824	A/G	cg08807101	chr21:30365312	RNF160	0.87	12.92	0.65	3.67e-29	Dental caries;
SARC	cis	rs4481887	0.893	rs7538645	chr1:248478137	C/T	cg00666640	chr1:248458726	OR2T12	0.33	5.54	0.34	7.95e-8	Common traits (Other);
SARC	cis	rs7592578	0.639	rs13417431	chr2:191293055	A/G	cg25963032	chr2:191064776	C2orf88	-0.47	-5.62	-0.35	5.35e-8	Diastolic blood pressure;
SARC	cis	rs3091242	1.000	rs3091242	chr1:25674785	C/T	cg02931644	chr1:25747376	RHCE	0.48	8.0	0.46	5.98e-14	Erythrocyte sedimentation rate;
SARC	trans	rs12967884	0.892	rs60335038	chr18:76558850	G/A	cg10946435	chr1:154843044	KCNN3	0.57	6.36	0.38	1.06e-9	Subcutaneous adipose tissue;
SARC	cis	rs7568458	0.870	rs2366639	chr2:85809955	A/G	cg23752985	chr2:85803571	VAMP8	0.34	4.92	0.31	1.66e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg17178900	chr1:205818956	PM20D1	0.4	5.18	0.32	4.83e-7	Menarche (age at onset);
SARC	cis	rs9467773	0.620	rs2504599	chr6:26641060	C/T	cg11502198	chr6:26597334	ABT1	0.63	8.48	0.49	2.6e-15	Intelligence (multi-trait analysis);
SARC	cis	rs2075371	0.829	rs9641970	chr7:134004887	C/A	cg11752832	chr7:134001865	SLC35B4	0.55	6.82	0.41	7.87e-11	Mean platelet volume;
SARC	cis	rs9291683	0.527	rs11727087	chr4:10096020	A/G	cg00071950	chr4:10020882	SLC2A9	0.39	5.99	0.37	8.07e-9	Bone mineral density;
SARC	cis	rs270601	0.909	rs2569265	chr5:131704519	T/C	cg24060327	chr5:131705240	SLC22A5	0.71	8.53	0.49	1.9e-15	Acylcarnitine levels;
SARC	cis	rs7666738	0.830	rs7698771	chr4:98986479	T/G	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1318878	0.806	rs66716825	chr12:15554246	G/C	cg08258403	chr12:15378311	NA	0.47	6.39	0.39	9e-10	Intelligence (multi-trait analysis);
SARC	cis	rs1448094	0.527	rs1900700	chr12:86232166	C/T	cg02569458	chr12:86230093	RASSF9	0.38	5.27	0.33	3.15e-7	Major depressive disorder;
SARC	cis	rs6568686	0.786	rs7776286	chr6:111810216	A/G	cg15721981	chr6:111408429	SLC16A10	-0.6	-4.85	-0.3	2.22e-6	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs2976388	0.524	rs7012804	chr8:143844650	A/G	cg06565975	chr8:143823917	SLURP1	0.28	4.79	0.3	2.96e-6	Urinary tract infection frequency;
SARC	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg24531977	chr5:56204891	C5orf35	0.6	5.77	0.35	2.57e-8	Initial pursuit acceleration;
SARC	cis	rs10872587	0.657	rs11155459	chr6:146578751	A/G	cg23711669	chr6:146136114	FBXO30	-0.75	-7.87	-0.46	1.35e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs36051895	0.632	rs12337481	chr9:5134599	T/G	cg02405213	chr9:5042618	JAK2	-0.47	-5.78	-0.35	2.42e-8	Pediatric autoimmune diseases;
SARC	cis	rs999943	0.846	rs9357162	chr6:33613344	G/A	cg14003231	chr6:33640908	ITPR3	0.56	9.34	0.52	8.15e-18	Obesity (extreme);
SARC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg11987759	chr7:65425863	GUSB	-0.44	-5.77	-0.35	2.49e-8	Calcium levels;
SARC	cis	rs9790314	1.000	rs7638668	chr3:161047283	G/A	cg04691961	chr3:161091175	C3orf57	-0.79	-11.9	-0.61	7.81e-26	Morning vs. evening chronotype;
SARC	cis	rs2153904	0.590	rs823106	chr1:205656453	G/C	cg14159672	chr1:205819179	PM20D1	0.58	5.23	0.32	3.7e-7	Prostate-specific antigen levels;
SARC	cis	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg25894440	chr7:65020034	NA	-0.77	-5.9	-0.36	1.24e-8	Diabetic kidney disease;
SARC	cis	rs7772486	0.743	rs62433835	chr6:146032688	C/G	cg05347473	chr6:146136440	FBXO30	-0.49	-6.55	-0.39	3.64e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs35110281	0.743	rs230640	chr21:44914815	A/T	cg21573476	chr21:45109991	RRP1B	0.44	6.27	0.38	1.74e-9	Mean corpuscular volume;
SARC	cis	rs12044355	0.929	rs6667123	chr1:231851991	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.53	7.08	0.42	1.68e-11	Alzheimer's disease;
SARC	trans	rs877282	0.945	rs877280	chr10:771599	C/T	cg22713356	chr15:30763199	NA	1.05	10.14	0.55	3.04e-20	Uric acid levels;
SARC	cis	rs12451471	0.559	rs34746710	chr17:78079224	G/A	cg06718696	chr17:78121285	EIF4A3	0.87	9.94	0.55	1.26e-19	Plateletcrit;Mean corpuscular hemoglobin concentration;
SARC	cis	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg00745463	chr17:30367425	LRRC37B	-0.67	-5.32	-0.33	2.4e-7	Hip circumference adjusted for BMI;
SARC	cis	rs9894429	0.869	rs9748184	chr17:79596280	A/G	cg18240062	chr17:79603768	NPLOC4	0.74	10.13	0.55	3.28e-20	Eye color traits;
SARC	cis	rs78487399	0.808	rs111783562	chr2:43759381	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-4.81	-0.3	2.67e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg06618935	chr21:46677482	NA	-0.4	-5.3	-0.33	2.72e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs7819412	0.505	rs17782554	chr8:11022106	C/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.37	-0.43	3.04e-12	Triglycerides;
SARC	cis	rs2180341	0.782	rs6924274	chr6:127721556	T/A	cg27446573	chr6:127587934	RNF146	0.74	10.18	0.55	2.2e-20	Breast cancer;
SARC	cis	rs1865760	0.786	rs2164487	chr6:25950800	A/C	cg17691542	chr6:26056736	HIST1H1C	0.58	7.33	0.43	3.67e-12	Height;
SARC	cis	rs6991838	0.778	rs13261559	chr8:66462043	G/A	cg13398993	chr8:66546079	ARMC1	0.42	5.22	0.32	4.03e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2652822	0.507	rs7176597	chr15:63494482	G/A	cg02713581	chr15:63449717	RPS27L	0.47	5.2	0.32	4.3e-7	Metabolic traits;
SARC	cis	rs11676348	0.774	rs57545959	chr2:219047718	A/G	cg00012203	chr2:219082015	ARPC2	0.44	5.74	0.35	2.98e-8	Ulcerative colitis;
SARC	cis	rs6815814	0.950	rs114719937	chr4:38808585	G/C	cg06935464	chr4:38784597	TLR10	0.63	6.31	0.38	1.41e-9	Breast cancer;
SARC	cis	rs6661961	0.686	rs4845766	chr1:152391282	G/T	cg20671415	chr1:152976275	SPRR3	-0.24	-4.71	-0.3	4.17e-6	Atopic dermatitis;
SARC	cis	rs4243830	0.850	rs10779787	chr1:6599755	C/G	cg05709478	chr1:6581295	PLEKHG5	-0.48	-4.8	-0.3	2.87e-6	Body mass index;
SARC	cis	rs4803468	1.000	rs3213861	chr19:41919944	A/C	cg08477640	chr19:41863820	B9D2	0.45	5.68	0.35	3.94e-8	Height;
SARC	cis	rs2425143	0.908	rs73275433	chr20:34187552	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.54	-4.93	-0.31	1.59e-6	Blood protein levels;
SARC	cis	rs7223966	1.000	rs8064261	chr17:61705212	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.53	-5.58	-0.34	6.77e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg07701084	chr6:150067640	NUP43	0.4	5.36	0.33	2.04e-7	Lung cancer;
SARC	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	5.69	0.35	3.71e-8	Bipolar disorder;
SARC	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg13939156	chr17:80058883	NA	-0.45	-6.97	-0.42	3.17e-11	Life satisfaction;
SARC	cis	rs7833986	1.000	rs36103212	chr8:57101475	G/T	cg26371346	chr8:56986568	SNORD54;RPS20	0.6	5.33	0.33	2.36e-7	Height;
SARC	cis	rs7103648	0.966	rs874896	chr11:47418953	C/G	cg20307385	chr11:47447363	PSMC3	0.86	14.01	0.68	9.6e-33	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg06212747	chr3:49208901	KLHDC8B	0.64	8.59	0.49	1.3e-15	Parkinson's disease;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg14580081	chr19:45873861	ERCC2	0.49	6.34	0.38	1.21e-9	Height;
SARC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg06873352	chr17:61820015	STRADA	0.51	6.53	0.39	4.01e-10	Prudent dietary pattern;
SARC	cis	rs7927771	0.826	rs2293578	chr11:47437403	C/T	cg20307385	chr11:47447363	PSMC3	-0.58	-7.26	-0.43	5.62e-12	Subjective well-being;
SARC	cis	rs8180040	0.653	rs6808742	chr3:47051512	G/A	cg02527881	chr3:46936655	PTH1R	-0.31	-4.74	-0.3	3.65e-6	Colorectal cancer;
SARC	cis	rs6121246	0.559	rs6119728	chr20:30413121	G/A	cg13852791	chr20:30311386	BCL2L1	0.81	10.14	0.55	3.06e-20	Mean corpuscular hemoglobin;
SARC	cis	rs2952156	0.959	rs2941503	chr17:37828745	A/G	cg00129232	chr17:37814104	STARD3	-0.69	-9.44	-0.53	3.9e-18	Asthma;
SARC	cis	rs10979	1.000	rs13197332	chr6:143888095	T/A	cg25407410	chr6:143891975	LOC285740	-0.64	-8.74	-0.5	4.55e-16	Hypospadias;
SARC	trans	rs61931739	0.553	rs68124042	chr12:34064431	C/A	cg13010199	chr12:38710504	ALG10B	0.77	10.36	0.56	6.42e-21	Morning vs. evening chronotype;
SARC	cis	rs10876993	0.890	rs12302351	chr12:58062590	T/C	cg18357645	chr12:58087776	OS9	0.44	5.81	0.36	2.01e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.58	0.34	6.8e-8	Bipolar disorder;
SARC	cis	rs13191362	1.000	rs13190742	chr6:163008758	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.5	0.34	1.01e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs10875746	0.903	rs725454	chr12:48502100	A/G	cg26205652	chr12:48591994	NA	0.56	6.19	0.38	2.62e-9	Longevity (90 years and older);
SARC	cis	rs7246657	0.943	rs10406177	chr19:37907947	G/A	cg23950597	chr19:37808831	NA	-0.57	-5.67	-0.35	4.24e-8	Coronary artery calcification;
SARC	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7582720	1.000	rs72932784	chr2:203698470	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	7.5	0.44	1.36e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg15242686	chr22:24348715	GSTTP1	0.41	5.36	0.33	2.01e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs112591243	0.685	rs117443865	chr21:47959731	C/G	cg10657630	chr21:48055338	PRMT2	0.77	4.87	0.3	2.07e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs4268898	0.662	rs58971404	chr2:24403753	G/A	cg06627628	chr2:24431161	ITSN2	-0.8	-9.59	-0.53	1.46e-18	Asthma;
SARC	cis	rs11098499	0.644	rs7693919	chr4:120540571	G/A	cg09307838	chr4:120376055	NA	0.77	10.48	0.57	2.73e-21	Corneal astigmatism;
SARC	cis	rs4900538	0.963	rs2273905	chr14:102974999	T/C	cg18135206	chr14:102964638	TECPR2	0.68	8.93	0.5	1.3e-16	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs2404618	0.593	rs7815979	chr8:1484887	A/G	cg13402656	chr8:1511478	DLGAP2	-0.56	-8.06	-0.47	3.88e-14	Lung cancer;
SARC	cis	rs17001868	0.568	rs9611325	chr22:40782490	G/A	cg07138101	chr22:40742427	ADSL	0.57	6.19	0.38	2.7e-9	Mammographic density (dense area);
SARC	cis	rs644799	1.000	rs7749	chr11:95565789	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	14.88	0.7	1.16e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs908922	0.676	rs539393	chr1:152518896	C/T	cg09873164	chr1:152488093	CRCT1	0.62	8.04	0.47	4.46e-14	Hair morphology;
SARC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg23034840	chr1:205782522	SLC41A1	0.6	7.45	0.44	1.86e-12	Menarche (age at onset);
SARC	cis	rs4588572	0.643	rs1864172	chr5:77690945	T/C	cg11547950	chr5:77652471	NA	0.4	4.89	0.31	1.88e-6	Triglycerides;
SARC	cis	rs735396	0.770	rs1169315	chr12:121443753	T/G	cg25281562	chr12:121454272	C12orf43	0.57	7.15	0.42	1.1e-11	N-glycan levels;
SARC	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg12463550	chr7:65579703	CRCP	0.48	5.79	0.35	2.23e-8	Aortic root size;
SARC	cis	rs7208859	0.573	rs28779471	chr17:29084369	T/C	cg13385521	chr17:29058706	SUZ12P	0.89	7.89	0.46	1.18e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs17599629	0.502	rs2055975	chr1:150618632	G/T	cg15448220	chr1:150897856	SETDB1	-0.4	-4.98	-0.31	1.23e-6	Prostate cancer;
SARC	cis	rs2239547	0.563	rs4302374	chr3:52905802	T/C	cg11645453	chr3:52864694	ITIH4	0.32	4.77	0.3	3.22e-6	Schizophrenia;
SARC	cis	rs2235642	0.653	rs7197288	chr16:1654753	C/A	cg09065629	chr16:1709722	CRAMP1L	0.38	5.29	0.33	2.88e-7	Coronary artery disease;
SARC	cis	rs4689388	0.853	rs13108780	chr4:6294630	A/G	cg00701064	chr4:6280414	WFS1	0.54	8.58	0.49	1.38e-15	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs1008375	1.000	rs10009541	chr4:17682218	C/T	cg27347728	chr4:17578864	LAP3	-0.51	-6.22	-0.38	2.28e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10493773	0.609	rs2389972	chr1:86190666	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.61	-10.04	-0.55	6.15e-20	Urate levels in overweight individuals;
SARC	cis	rs28374715	0.578	rs8036026	chr15:41630499	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.17	-19.16	-0.78	8.85e-50	Ulcerative colitis;
SARC	cis	rs910316	1.000	rs7303	chr14:75520065	T/C	cg06637938	chr14:75390232	RPS6KL1	0.57	8.13	0.47	2.57e-14	Height;
SARC	cis	rs6696846	0.791	rs10158848	chr1:205061192	C/T	cg07972983	chr1:205091412	RBBP5	0.57	7.36	0.43	3.18e-12	Red blood cell count;
SARC	cis	rs2594989	0.943	rs2442785	chr3:11521828	C/T	cg00170343	chr3:11313890	ATG7	0.52	5.18	0.32	4.69e-7	Circulating chemerin levels;
SARC	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg03452623	chr4:187889614	NA	-0.76	-11.83	-0.61	1.32e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2230307	0.536	rs7518943	chr1:100463422	G/T	cg24955406	chr1:100503596	HIAT1	0.75	7.65	0.45	5.34e-13	Carotid intima media thickness;
SARC	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg18876405	chr7:65276391	NA	-0.47	-5.76	-0.35	2.59e-8	Aortic root size;
SARC	cis	rs3820928	1.000	rs1835158	chr2:227763993	C/A	cg11843606	chr2:227700838	RHBDD1	-0.52	-6.53	-0.39	4.09e-10	Pulmonary function;
SARC	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg07701084	chr6:150067640	NUP43	0.41	5.42	0.33	1.5e-7	Lung cancer;
SARC	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg12310025	chr6:25882481	NA	-0.45	-5.62	-0.35	5.56e-8	Intelligence (multi-trait analysis);
SARC	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg21747090	chr2:27597821	SNX17	-0.54	-7.51	-0.44	1.26e-12	Menopause (age at onset);
SARC	cis	rs9911578	1.000	rs12938772	chr17:56776320	T/C	cg05425664	chr17:57184151	TRIM37	-0.67	-8.25	-0.48	1.17e-14	Intelligence (multi-trait analysis);
SARC	cis	rs7395581	1.000	rs830085	chr11:47251199	G/A	cg25783544	chr11:47291846	MADD	-0.47	-5.14	-0.32	5.8e-7	HDL cholesterol;
SARC	cis	rs7667	0.959	rs1566531	chr1:19727896	G/A	cg15311933	chr1:19638897	PQLC2;AKR7A2	-0.44	-5.05	-0.31	8.91e-7	Crohn's disease and psoriasis;
SARC	cis	rs17401966	0.931	rs11584023	chr1:10302596	A/G	cg15208524	chr1:10270712	KIF1B	0.5	5.97	0.36	8.97e-9	Hepatocellular carcinoma;
SARC	cis	rs3962382	1	rs3962382	chr1:68165693	A/C	cg10178795	chr1:68298432	GNG12	-0.57	-6.3	-0.38	1.43e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	trans	rs3808502	0.526	rs7823100	chr8:11422491	C/A	cg06636001	chr8:8085503	FLJ10661	-0.65	-9.02	-0.51	7.33e-17	Neuroticism;
SARC	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	10.91	0.58	1.14e-22	Alzheimer's disease;
SARC	cis	rs7264396	0.563	rs2425116	chr20:34323553	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-7.01	-0.42	2.5e-11	Total cholesterol levels;
SARC	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg11764359	chr7:65958608	NA	-0.78	-9.48	-0.53	3e-18	Aortic root size;
SARC	cis	rs4268898	0.662	rs2891380	chr2:24525830	G/A	cg26838691	chr2:24397539	C2orf84	-0.49	-5.67	-0.35	4.3e-8	Asthma;
SARC	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6831352	0.918	rs7689753	chr4:100055575	A/G	cg12011299	chr4:100065546	ADH4	-0.34	-5.74	-0.35	2.95e-8	Alcohol dependence;
SARC	cis	rs9399135	0.869	rs9402675	chr6:135325794	C/G	cg24558204	chr6:135376177	HBS1L	0.45	6.12	0.37	4e-9	Red blood cell count;
SARC	cis	rs7792596	1.000	rs6465411	chr7:94003260	T/C	cg20814616	chr7:94014465	NA	-0.43	-5.3	-0.33	2.65e-7	Intelligence;
SARC	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.5	5.44	0.34	1.34e-7	Renal function-related traits (BUN);
SARC	cis	rs10504229	0.679	rs73681882	chr8:58030038	A/G	cg11062466	chr8:58055876	NA	0.54	5.22	0.32	3.88e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1318878	0.793	rs984561	chr12:15547275	A/C	cg08258403	chr12:15378311	NA	0.46	6.15	0.37	3.34e-9	Intelligence (multi-trait analysis);
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg01771876	chr2:11886613	LPIN1	-0.61	-6.26	-0.38	1.8e-9	Lung cancer in ever smokers;
SARC	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg05313129	chr8:58192883	C8orf71	-0.52	-5.96	-0.36	9.41e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs11098499	0.863	rs58452170	chr4:120459674	A/T	cg09307838	chr4:120376055	NA	0.93	12.66	0.64	2.64e-28	Corneal astigmatism;
SARC	cis	rs943466	0.955	rs11757524	chr6:33766212	A/G	cg04676172	chr6:33757040	LEMD2	0.46	4.85	0.3	2.27e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
SARC	cis	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg07777115	chr5:623756	CEP72	-0.56	-4.9	-0.31	1.77e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs2361718	0.500	rs12451697	chr17:78100690	T/A	cg23534315	chr17:78082725	GAA	0.41	5.21	0.32	4.08e-7	Yeast infection;
SARC	cis	rs17666538	0.710	rs1703941	chr8:658447	G/A	cg02524346	chr8:600233	NA	0.73	5.5	0.34	1.01e-7	IgG glycosylation;
SARC	cis	rs2180341	0.924	rs9285459	chr6:127631113	T/C	cg17762328	chr6:126965162	NA	-0.46	-5.24	-0.32	3.55e-7	Breast cancer;
SARC	cis	rs2952156	0.684	rs1877031	chr17:37814080	G/A	cg20243544	chr17:37824526	PNMT	0.62	8.23	0.47	1.32e-14	Asthma;
SARC	cis	rs17401966	0.931	rs12409754	chr1:10457540	T/C	cg15208524	chr1:10270712	KIF1B	0.44	5.02	0.31	1.01e-6	Hepatocellular carcinoma;
SARC	cis	rs8180040	0.654	rs13078131	chr3:47204939	G/T	cg27129171	chr3:47204927	SETD2	0.67	9.52	0.53	2.28e-18	Colorectal cancer;
SARC	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg11247378	chr22:39784982	NA	-0.31	-5.01	-0.31	1.09e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2916247	1.000	rs7002565	chr8:93057196	A/C	cg10183463	chr8:93005414	RUNX1T1	-0.57	-6.04	-0.37	6.18e-9	Intelligence (multi-trait analysis);
SARC	cis	rs910316	0.967	rs175502	chr14:75533679	A/G	cg11812906	chr14:75593930	NEK9	-0.85	-12.69	-0.64	2.06e-28	Height;
SARC	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg00149659	chr3:10157352	C3orf10	0.78	7.26	0.43	5.61e-12	Alzheimer's disease;
SARC	cis	rs16976116	0.803	rs28590021	chr15:55490993	C/T	cg17854078	chr15:55489399	RSL24D1	0.66	6.46	0.39	6.14e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs61931739	0.500	rs7311284	chr12:34478477	C/G	cg26384229	chr12:38710491	ALG10B	0.91	13.67	0.67	1.28e-31	Morning vs. evening chronotype;
SARC	cis	rs2832077	0.506	rs2832088	chr21:30158620	G/A	cg24692254	chr21:30365293	RNF160	-0.55	-6.02	-0.37	6.68e-9	Cognitive test performance;
SARC	cis	rs78545713	0.502	rs3823157	chr6:26272039	A/G	cg12826209	chr6:26865740	GUSBL1	-0.52	-4.83	-0.3	2.46e-6	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs60871478	0.545	rs35400476	chr7:795686	A/G	cg05535760	chr7:792225	HEATR2	0.75	7.8	0.45	2.1e-13	Cerebrospinal P-tau181p levels;
SARC	cis	rs11608355	0.545	rs11066737	chr12:109904792	A/G	cg05360138	chr12:110035743	NA	-0.96	-9.97	-0.55	9.78e-20	Neuroticism;
SARC	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg12463550	chr7:65579703	CRCP	-0.46	-5.13	-0.32	5.99e-7	Aortic root size;
SARC	cis	rs2549003	1.000	rs13170412	chr5:131823519	A/G	cg21138405	chr5:131827807	IRF1	0.27	5.26	0.33	3.26e-7	Asthma (sex interaction);
SARC	cis	rs1048238	0.506	rs848195	chr1:16286522	A/G	cg21385522	chr1:16154831	NA	-0.51	-6.37	-0.39	9.75e-10	Systolic blood pressure;
SARC	trans	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg00578252	chr1:36916159	OSCP1	-0.66	-6.39	-0.39	9.14e-10	Cutaneous psoriasis;
SARC	cis	rs11785693	0.862	rs17350978	chr8:4983418	G/C	cg26367366	chr8:4980734	NA	0.68	6.08	0.37	4.98e-9	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs3923518	1.000	rs13080116	chr3:38907223	T/C	cg26331595	chr3:39149181	GORASP1;TTC21A	0.46	4.92	0.31	1.63e-6	Migraine;
SARC	cis	rs9325144	0.671	rs12818797	chr12:39019409	A/G	cg13010199	chr12:38710504	ALG10B	-0.54	-6.89	-0.41	5.31e-11	Morning vs. evening chronotype;
SARC	cis	rs7106204	0.764	rs57490470	chr11:24234370	A/G	ch.11.24196551F	chr11:24239977	NA	0.67	5.07	0.32	7.95e-7	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs10754283	0.967	rs6663363	chr1:90116854	A/G	cg21401794	chr1:90099060	LRRC8C	0.58	7.95	0.46	8.04e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs9611519	1.000	rs2057070	chr22:41564287	T/C	cg17376030	chr22:41985996	PMM1	0.45	5.02	0.31	1.03e-6	Neuroticism;
SARC	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-4.91	-0.31	1.71e-6	Total body bone mineral density;
SARC	cis	rs11227306	0.902	rs625652	chr11:65641931	T/A	cg26695010	chr11:65641043	EFEMP2	0.58	7.55	0.44	9.68e-13	DNA methylation (variation);
SARC	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg03806693	chr22:41940476	POLR3H	0.87	11.46	0.6	2.15e-24	Vitiligo;
SARC	cis	rs2228479	0.702	rs62052710	chr16:89854893	C/T	cg06558623	chr16:89946397	TCF25	0.93	6.44	0.39	6.63e-10	Skin colour saturation;
SARC	cis	rs862034	0.509	rs7149930	chr14:74954059	C/T	cg16374328	chr14:74960395	NPC2;ISCA2	0.43	5.35	0.33	2.09e-7	Height;
SARC	cis	rs617791	0.508	rs1047464	chr11:65769456	A/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.6	7.47	0.44	1.57e-12	Breast cancer;
SARC	trans	rs11781622	0.945	rs7016551	chr8:24370878	A/G	cg17078393	chr1:32717002	LCK	0.43	6.47	0.39	5.8e-10	White matter integrity;
SARC	cis	rs981844	1.000	rs2251639	chr4:154656410	T/C	cg14289246	chr4:154710475	SFRP2	0.58	6.66	0.4	1.92e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs4713118	0.540	rs469227	chr6:27970705	A/C	cg16479474	chr6:28041457	NA	0.35	5.03	0.31	9.78e-7	Parkinson's disease;
SARC	cis	rs7223966	0.961	rs112709843	chr17:61836936	T/A	cg26338869	chr17:61819248	STRADA	0.48	5.28	0.33	3e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs546131	0.600	rs502857	chr11:34854662	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.45	5.15	0.32	5.53e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs67460515	1.000	rs67460515	chr3:161068566	T/C	cg17135325	chr3:160939158	NMD3	0.61	7.55	0.44	9.64e-13	Parkinson's disease;
SARC	cis	rs17270561	0.609	rs9379789	chr6:25745579	A/G	cg16482183	chr6:26056742	HIST1H1C	0.43	5.08	0.32	7.76e-7	Iron status biomarkers;
SARC	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg24690094	chr11:67383802	NA	0.55	8.59	0.49	1.29e-15	Mean corpuscular volume;
SARC	trans	rs7824557	0.544	rs1865521	chr8:11231249	T/C	cg06636001	chr8:8085503	FLJ10661	0.59	7.63	0.45	5.85e-13	Retinal vascular caliber;
SARC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg03452623	chr4:187889614	NA	-0.76	-12.09	-0.62	1.86e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4865169	1.000	rs4865169	chr4:57879792	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.42	-5.06	-0.31	8.62e-7	Breast cancer;
SARC	cis	rs1023500	0.505	rs134874	chr22:42661144	A/G	cg15557168	chr22:42548783	NA	-0.38	-5.34	-0.33	2.18e-7	Schizophrenia;
SARC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	6.08	0.37	5e-9	Prudent dietary pattern;
SARC	cis	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.84	12.36	0.63	2.64e-27	Eosinophil percentage of white cells;
SARC	cis	rs1371867	0.817	rs1788208	chr8:101312515	T/C	cg11906718	chr8:101322791	RNF19A	0.71	9.02	0.51	7.17e-17	Atrioventricular conduction;
SARC	cis	rs16854884	0.837	rs13062793	chr3:143808387	A/G	cg06585982	chr3:143692056	C3orf58	0.57	7.22	0.43	7.13e-12	Economic and political preferences (feminism/equality);
SARC	cis	rs6910061	0.957	rs6916541	chr6:11095258	C/A	cg27233058	chr6:11094804	LOC221710	0.57	5.5	0.34	1.02e-7	Diabetic kidney disease;
SARC	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg06028808	chr11:68637592	NA	0.49	6.26	0.38	1.79e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs1215050	0.740	rs1084777	chr4:99017542	C/T	cg05340658	chr4:99064831	C4orf37	-0.48	-6.47	-0.39	5.69e-10	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs848	0.500	rs72797378	chr5:131986925	A/T	cg11797159	chr5:131991491	NA	0.42	5.41	0.33	1.57e-7	Alopecia areata;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs8038465	0.615	rs11072430	chr15:73981701	A/G	cg15420318	chr15:73925796	NPTN	-0.52	-6.23	-0.38	2.21e-9	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2075371	1.000	rs2544221	chr7:133993014	G/C	cg11752832	chr7:134001865	SLC35B4	0.58	7.5	0.44	1.34e-12	Mean platelet volume;
SARC	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg20102877	chr2:27665638	KRTCAP3	-0.39	-5.41	-0.33	1.54e-7	Total body bone mineral density;
SARC	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg05368731	chr17:41323189	NBR1	0.7	8.45	0.48	3.28e-15	Menopause (age at onset);
SARC	cis	rs12594515	1.000	rs6493168	chr15:45986811	A/C	cg14863074	chr15:45997064	NA	0.34	5.24	0.32	3.57e-7	Waist circumference;Weight;
SARC	cis	rs870825	0.721	rs72703528	chr4:185607311	A/G	cg04058563	chr4:185651563	MLF1IP	0.85	10.21	0.56	1.83e-20	Blood protein levels;
SARC	cis	rs1865760	0.865	rs9467647	chr6:25957642	A/G	cg17691542	chr6:26056736	HIST1H1C	0.58	7.36	0.43	3.13e-12	Height;
SARC	cis	rs838721	0.574	rs34332006	chr2:234257452	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.39	4.94	0.31	1.49e-6	Total body bone mineral density;
SARC	cis	rs4742903	0.935	rs9775540	chr9:106977722	A/G	cg14250997	chr9:106856677	SMC2	0.4	4.98	0.31	1.22e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg25072359	chr17:41440525	NA	0.53	6.28	0.38	1.61e-9	Menopause (age at onset);
SARC	cis	rs10504229	0.679	rs12679920	chr8:58051710	G/T	cg22535103	chr8:58192502	C8orf71	-0.57	-5.71	-0.35	3.46e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6582630	0.519	rs12582285	chr12:38298753	C/T	cg13010199	chr12:38710504	ALG10B	0.77	10.59	0.57	1.16e-21	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.31	-4.76	-0.3	3.39e-6	Menopause (age at onset);
SARC	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg16606324	chr3:10149918	C3orf24	0.48	4.75	0.3	3.56e-6	Alzheimer's disease;
SARC	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.44	6.57	0.4	3.3e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs7582720	1.000	rs72934749	chr2:203746816	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.31	0.43	4.24e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs12681288	0.862	rs2004701	chr8:1022287	A/G	cg15309053	chr8:964076	NA	0.41	6.93	0.41	4.11e-11	Schizophrenia;
SARC	cis	rs9296092	0.517	rs7775914	chr6:33518110	T/C	cg13560919	chr6:33536144	NA	-0.51	-6.21	-0.38	2.37e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg03452623	chr4:187889614	NA	-0.79	-12.37	-0.63	2.34e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7615952	0.736	rs13063122	chr3:125643860	G/A	cg05084668	chr3:125655381	ALG1L	-0.63	-6.44	-0.39	6.7e-10	Blood pressure (smoking interaction);
SARC	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg00339695	chr16:24857497	SLC5A11	0.42	5.67	0.35	4.18e-8	Intelligence (multi-trait analysis);
SARC	cis	rs6439153	0.743	rs71331685	chr3:128711425	T/A	cg25356066	chr3:128598488	ACAD9	0.47	5.66	0.35	4.5e-8	Pneumococcal bacteremia;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg16257254	chr2:152685072	ARL5A	0.5	6.26	0.38	1.84e-9	Lung adenocarcinoma;
SARC	cis	rs9911578	1.000	rs9807057	chr17:56889952	A/C	cg05425664	chr17:57184151	TRIM37	-0.64	-7.94	-0.46	8.68e-14	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg11764359	chr7:65958608	NA	-0.75	-9.33	-0.52	8.74e-18	Aortic root size;
SARC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.38	-5.61	-0.34	5.83e-8	Longevity;Endometriosis;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg12456090	chr18:23670518	SS18	0.51	6.53	0.39	4.05e-10	Breast cancer;
SARC	trans	rs17221829	0.733	rs11018668	chr11:89356178	C/T	cg14951488	chr10:95256188	CEP55	-0.47	-6.28	-0.38	1.65e-9	Anxiety in major depressive disorder;
SARC	cis	rs2228479	0.850	rs62054638	chr16:89821131	G/C	cg06558623	chr16:89946397	TCF25	0.88	6.21	0.38	2.39e-9	Skin colour saturation;
SARC	cis	rs5750854	0.530	rs5750863	chr22:40026948	A/T	cg10455938	chr22:40058150	CACNA1I	0.43	5.07	0.32	8.21e-7	Intelligence (multi-trait analysis);
SARC	trans	rs7922314	0.571	rs61865710	chr10:64735714	T/C	cg25304107	chr2:177017331	HOXD4	-0.84	-6.49	-0.39	5.21e-10	Cutaneous psoriasis;
SARC	cis	rs2404618	0.624	rs7012381	chr8:1475357	C/T	cg13402656	chr8:1511478	DLGAP2	-0.59	-8.7	-0.5	6.1e-16	Lung cancer;
SARC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg01171360	chr6:293285	DUSP22	-0.54	-6.83	-0.41	7.14e-11	Menopause (age at onset);
SARC	cis	rs16933812	0.500	rs883967	chr9:36993788	T/C	cg14294708	chr9:37120828	ZCCHC7	-0.46	-5.19	-0.32	4.52e-7	Obesity-related traits;
SARC	cis	rs9814567	0.964	rs9815894	chr3:134282796	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.04	-0.42	2.19e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs546131	0.614	rs473885	chr11:34851961	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.42	4.83	0.3	2.49e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg24846343	chr22:24311635	DDTL	0.53	7.54	0.44	1.04e-12	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7103648	0.695	rs12577643	chr11:47467172	A/T	cg20307385	chr11:47447363	PSMC3	0.82	11.79	0.61	1.75e-25	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs7223966	0.961	rs112709843	chr17:61836936	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.56	-6.14	-0.37	3.62e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2865116	0.747	rs9791418	chr7:68966777	T/C	cg10619644	chr7:69149951	AUTS2	0.34	4.72	0.3	4.02e-6	Positive affect;
SARC	cis	rs3824867	0.920	rs7948705	chr11:47447955	C/G	cg20307385	chr11:47447363	PSMC3	-0.47	-5.12	-0.32	6.25e-7	Mean corpuscular hemoglobin;
SARC	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.99	11.36	0.6	4.27e-24	Platelet count;
SARC	cis	rs7662987	0.517	rs2851277	chr4:100022910	G/T	cg13256891	chr4:100009986	ADH5	0.66	8.12	0.47	2.64e-14	Smoking initiation;
SARC	cis	rs9388451	1.000	rs9388451	chr6:126090377	A/G	cg05901451	chr6:126070800	HEY2	-0.67	-9.33	-0.52	8.58e-18	Brugada syndrome;
SARC	cis	rs34779708	0.931	rs55724039	chr10:35465397	A/G	cg03585969	chr10:35415529	CREM	0.39	4.88	0.3	1.93e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs561341	0.843	rs879945	chr17:30242796	G/A	cg13647721	chr17:30228624	UTP6	0.69	6.4	0.39	8.49e-10	Hip circumference adjusted for BMI;
SARC	cis	rs13191362	1.000	rs13207239	chr6:163008772	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.5	0.34	1.01e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg09373136	chr17:61933544	TCAM1	-0.45	-6.22	-0.38	2.33e-9	Prudent dietary pattern;
SARC	cis	rs9486715	0.867	rs9373887	chr6:96957004	C/T	cg06623918	chr6:96969491	KIAA0776	0.89	12.91	0.65	3.96e-29	Headache;
SARC	cis	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg08564027	chr20:61660810	NA	0.76	11.8	0.61	1.69e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs12079745	0.590	rs3766092	chr1:169273400	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.91	-5.55	-0.34	7.82e-8	QT interval;
SARC	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg03433033	chr1:76189801	ACADM	0.52	6.94	0.41	3.93e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg00149659	chr3:10157352	C3orf10	0.64	6.07	0.37	5.22e-9	Alzheimer's disease;
SARC	cis	rs2153535	0.580	rs2327051	chr6:8441150	A/G	cg23788917	chr6:8435910	SLC35B3	-0.63	-7.93	-0.46	8.86e-14	Motion sickness;
SARC	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg14517863	chr17:44321492	NA	0.33	4.88	0.3	2.01e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg02633286	chr7:137687037	CREB3L2	-0.48	-6.26	-0.38	1.86e-9	Thyroid cancer;
SARC	cis	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg15428835	chr7:75027521	TRIM73;TRIM74	-0.3	-5.04	-0.31	9.51e-7	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg01448562	chr3:133502909	NA	-0.44	-6.4	-0.39	8.39e-10	Iron status biomarkers;
SARC	cis	rs907683	0.635	rs11691617	chr2:220295167	C/T	cg15015639	chr2:220282977	DES	0.34	5.37	0.33	1.94e-7	Resting heart rate;
SARC	cis	rs6700896	0.931	rs1938490	chr1:66132800	T/A	cg04111102	chr1:66153794	NA	0.36	5.66	0.35	4.49e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs5769765	1.000	rs2295408	chr22:50261051	A/G	cg03033257	chr22:50311977	ALG12;CRELD2	-0.53	-5.5	-0.34	9.76e-8	Schizophrenia;
SARC	cis	rs7044106	0.762	rs1547268	chr9:123408688	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	8.61	0.49	1.09e-15	Hip circumference adjusted for BMI;
SARC	cis	rs2230307	0.536	rs2784173	chr1:100639752	A/G	cg24955406	chr1:100503596	HIAT1	-0.65	-6.32	-0.38	1.3e-9	Carotid intima media thickness;
SARC	cis	rs10791323	0.569	rs10750541	chr11:133713189	A/C	cg14349672	chr11:133703707	NA	0.37	5.2	0.32	4.36e-7	Childhood ear infection;
SARC	cis	rs875971	1.000	rs1183245	chr7:65541185	C/T	cg11987759	chr7:65425863	GUSB	0.43	5.69	0.35	3.81e-8	Aortic root size;
SARC	cis	rs4481887	1.000	rs4430369	chr1:248464330	A/G	cg13385794	chr1:248469461	NA	0.34	5.24	0.32	3.68e-7	Common traits (Other);
SARC	cis	rs67311347	0.956	rs13066971	chr3:40462510	A/T	cg09455208	chr3:40491958	NA	-0.41	-6.55	-0.39	3.57e-10	Renal cell carcinoma;
SARC	cis	rs995000	0.931	rs11207997	chr1:63061906	C/T	cg06896770	chr1:63153194	DOCK7	0.93	13.9	0.67	2.11e-32	Triglyceride levels;
SARC	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg12564285	chr5:131593104	PDLIM4	-0.37	-5.38	-0.33	1.82e-7	Acylcarnitine levels;
SARC	cis	rs1950500	0.545	rs1950501	chr14:24806800	C/G	cg22990158	chr14:24802150	ADCY4	-0.34	-5.83	-0.36	1.85e-8	Height;
SARC	cis	rs703842	1.000	rs10877012	chr12:58162085	G/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.79	11.51	0.6	1.4e-24	Multiple sclerosis;
SARC	cis	rs9303401	0.659	rs17822735	chr17:56620167	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	11.81	0.61	1.61e-25	Cognitive test performance;
SARC	cis	rs2120243	0.539	rs988587	chr3:157054271	A/C	cg24825693	chr3:157122686	VEPH1	-0.5	-6.65	-0.4	2.1e-10	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs473651	0.935	rs558924	chr2:239339511	A/G	cg21699342	chr2:239360505	ASB1	0.49	5.95	0.36	9.57e-9	Multiple system atrophy;
SARC	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	8.71	0.5	5.56e-16	Alzheimer's disease;
SARC	cis	rs611744	0.647	rs587340	chr8:109246032	C/A	cg21045802	chr8:109455806	TTC35	0.6	7.54	0.44	1.02e-12	Dupuytren's disease;
SARC	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg04267008	chr7:1944627	MAD1L1	-0.57	-6.34	-0.38	1.21e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs796364	0.570	rs4673491	chr2:200669108	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.56	4.73	0.3	3.89e-6	Schizophrenia;
SARC	cis	rs7605378	0.528	rs812760	chr2:200724372	C/T	cg23649088	chr2:200775458	C2orf69	0.76	10.49	0.57	2.38e-21	Osteoporosis;
SARC	cis	rs7940866	0.801	rs10894288	chr11:130808679	T/C	cg12179176	chr11:130786555	SNX19	0.66	9.35	0.52	7.69e-18	Schizophrenia;
SARC	cis	rs11098499	0.754	rs1980026	chr4:120251643	C/A	cg09307838	chr4:120376055	NA	0.81	11.03	0.59	4.84e-23	Corneal astigmatism;
SARC	trans	rs17685	0.725	rs2302436	chr7:75676988	A/T	cg19862616	chr7:65841803	NCRNA00174	-0.6	-7.57	-0.44	8.55e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs798554	0.567	rs2527695	chr7:2858267	T/G	cg13628971	chr7:2884303	GNA12	0.48	5.99	0.37	7.87e-9	Height;
SARC	cis	rs2916247	1.000	rs72671424	chr8:93056264	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.57	-5.86	-0.36	1.54e-8	Intelligence (multi-trait analysis);
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg14286274	chr1:211555998	C1orf97	0.47	6.27	0.38	1.7e-9	Schizophrenia;
SARC	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg07507251	chr3:52567010	NT5DC2	0.3	4.72	0.3	3.98e-6	Electroencephalogram traits;
SARC	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg08677398	chr8:58056175	NA	0.43	5.05	0.31	8.92e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs116095464	0.850	rs6896163	chr5:303686	A/G	cg22857025	chr5:266934	NA	-1.1	-8.5	-0.49	2.34e-15	Breast cancer;
SARC	cis	rs6963495	0.818	rs55922564	chr7:105155890	G/A	cg19920283	chr7:105172520	RINT1	0.65	5.48	0.34	1.09e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs721399	1.000	rs4646248	chr8:18260355	C/T	cg18736775	chr8:18248649	NAT2	0.43	5.57	0.34	6.89e-8	Blood metabolite levels;
SARC	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	5.42	0.33	1.47e-7	Bipolar disorder;
SARC	cis	rs4148883	0.675	rs34511427	chr4:100105405	G/T	cg12011299	chr4:100065546	ADH4	0.36	6.77	0.41	1.03e-10	Alcohol dependence;
SARC	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	11.03	0.59	4.93e-23	Alzheimer's disease;
SARC	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg03806693	chr22:41940476	POLR3H	0.88	12.27	0.63	5.13e-27	Vitiligo;
SARC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg01171360	chr6:293285	DUSP22	-0.54	-6.86	-0.41	6.26e-11	Menopause (age at onset);
SARC	cis	rs7246657	0.943	rs13345116	chr19:37847098	A/T	cg14683738	chr19:37701593	ZNF585B	0.51	4.99	0.31	1.16e-6	Coronary artery calcification;
SARC	cis	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg05623727	chr3:50126028	RBM5	0.35	5.11	0.32	6.72e-7	Body mass index;
SARC	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg07701084	chr6:150067640	NUP43	0.38	4.95	0.31	1.43e-6	Lung cancer;
SARC	cis	rs477692	0.905	rs563859	chr10:131417586	T/C	cg05714579	chr10:131428358	MGMT	0.59	7.99	0.46	6.2e-14	Response to temozolomide;
SARC	cis	rs9513627	1.000	rs73556165	chr13:100120317	C/T	cg25919922	chr13:100150906	NA	-0.7	-5.29	-0.33	2.86e-7	Obesity-related traits;
SARC	cis	rs963731	0.649	rs297150	chr2:39326164	C/T	cg04010122	chr2:39346883	SOS1	-1.02	-6.05	-0.37	5.77e-9	Corticobasal degeneration;
SARC	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg24642844	chr7:1081250	C7orf50	-0.57	-5.99	-0.37	7.74e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs2230307	0.536	rs561119	chr1:100603891	G/A	cg24955406	chr1:100503596	HIAT1	-0.67	-6.64	-0.4	2.19e-10	Carotid intima media thickness;
SARC	cis	rs9300255	0.543	rs520088	chr12:123522150	C/G	cg00376283	chr12:123451042	ABCB9	0.53	5.89	0.36	1.32e-8	Neutrophil percentage of white cells;
SARC	cis	rs644799	0.542	rs10831417	chr11:95467262	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	-0.66	-8.46	-0.48	2.89e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs4865169	0.934	rs3796531	chr4:57850846	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	0.4	4.85	0.3	2.24e-6	Breast cancer;
SARC	cis	rs7312774	0.618	rs12316286	chr12:107343020	C/A	cg16260113	chr12:107380972	MTERFD3	0.93	7.65	0.45	5.22e-13	Severe influenza A (H1N1) infection;
SARC	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg16606324	chr3:10149918	C3orf24	0.49	4.86	0.3	2.13e-6	Alzheimer's disease;
SARC	cis	rs9486715	0.867	rs7451950	chr6:96879974	T/C	cg06623918	chr6:96969491	KIAA0776	0.88	12.7	0.64	1.95e-28	Headache;
SARC	cis	rs77372450	0.636	rs6556090	chr5:157001183	A/C	cg23851860	chr5:157002805	ADAM19	0.51	4.85	0.3	2.24e-6	Bipolar disorder (body mass index interaction);
SARC	cis	rs950169	0.881	rs4842852	chr15:84941961	A/G	cg17507749	chr15:85114479	UBE2QP1	0.79	9.66	0.53	8.73e-19	Schizophrenia;
SARC	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg13206674	chr6:150067644	NUP43	0.47	5.95	0.36	9.68e-9	Lung cancer;
SARC	cis	rs4481887	0.861	rs4497248	chr1:248450525	T/C	cg00666640	chr1:248458726	OR2T12	0.33	5.39	0.33	1.69e-7	Common traits (Other);
SARC	cis	rs9296092	0.517	rs9461877	chr6:33516667	C/T	cg13560919	chr6:33536144	NA	-0.5	-5.91	-0.36	1.22e-8	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	trans	rs6600671	1.000	rs11249351	chr1:121171942	G/A	cg00646200	chr1:148855367	NA	0.49	6.86	0.41	6.26e-11	Hip geometry;
SARC	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg05313129	chr8:58192883	C8orf71	-0.58	-6.37	-0.39	9.85e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg04944784	chr2:26401820	FAM59B	-0.59	-7.51	-0.44	1.28e-12	Gut microbiome composition (summer);
SARC	cis	rs67460515	0.563	rs13071892	chr3:160817877	A/C	cg17135325	chr3:160939158	NMD3	0.64	7.79	0.45	2.22e-13	Parkinson's disease;
SARC	cis	rs2153535	0.601	rs9505451	chr6:8469950	C/T	cg07606381	chr6:8435919	SLC35B3	0.77	10.83	0.58	2.14e-22	Motion sickness;
SARC	cis	rs1882538	0.512	rs13241734	chr7:133122742	C/G	cg10665199	chr7:133106180	EXOC4	0.42	5.22	0.32	3.98e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg23758822	chr17:41437982	NA	0.9	12.59	0.64	4.36e-28	Menopause (age at onset);
SARC	cis	rs9902453	0.904	rs7212292	chr17:28409264	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.57	-7.44	-0.44	1.91e-12	Coffee consumption (cups per day);
SARC	cis	rs3784262	0.669	rs4646602	chr15:58294757	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.35	-5.25	-0.33	3.45e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs28374715	0.578	rs72739630	chr15:41631064	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.16	-17.91	-0.76	1.08e-45	Ulcerative colitis;
SARC	cis	rs9660180	0.620	rs34298494	chr1:1663402	A/C	cg27541892	chr1:1571801	CDK11B	-0.66	-8.66	-0.49	7.85e-16	Body mass index;
SARC	cis	rs372883	0.554	rs10154065	chr21:30749480	G/C	cg08807101	chr21:30365312	RNF160	0.53	6.76	0.4	1.11e-10	Pancreatic cancer;
SARC	cis	rs7617773	0.817	rs34225441	chr3:48308891	T/A	cg11946769	chr3:48343235	NME6	0.7	8.99	0.51	8.78e-17	Coronary artery disease;
SARC	cis	rs55883249	1.000	rs55883249	chr2:9741535	C/A	cg23886495	chr2:9695866	ADAM17	0.66	6.73	0.4	1.33e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg00800038	chr16:89945340	TCF25	-0.76	-5.12	-0.32	6.35e-7	Skin colour saturation;
SARC	cis	rs9329221	0.905	rs13254263	chr8:10255181	A/G	cg21775007	chr8:11205619	TDH	-0.42	-5.07	-0.32	8.23e-7	Neuroticism;
SARC	cis	rs6484504	0.576	rs208093	chr11:31184400	C/T	cg14844989	chr11:31128820	NA	0.34	4.9	0.31	1.81e-6	Red blood cell count;
SARC	trans	rs11976180	0.569	rs12703565	chr7:143754401	C/T	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.62	-6.28	-0.38	1.62e-9	Obesity-related traits;
SARC	trans	rs3780486	0.505	rs10217267	chr9:33146528	T/C	cg04842962	chr6:43655489	MRPS18A	0.83	11.36	0.6	4.46e-24	IgG glycosylation;
SARC	cis	rs2455601	0.608	rs10840137	chr11:8890079	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.39	-4.84	-0.3	2.36e-6	Schizophrenia;
SARC	trans	rs1814175	0.566	rs1811673	chr11:49602134	A/G	cg03929089	chr4:120376271	NA	-0.74	-8.33	-0.48	6.85e-15	Height;
SARC	cis	rs9814567	1.000	rs6801596	chr3:134252114	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.1	-0.42	1.49e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg09373136	chr17:61933544	TCAM1	-0.45	-6.14	-0.37	3.58e-9	Prudent dietary pattern;
SARC	cis	rs2916247	0.954	rs990132	chr8:93106039	A/G	cg10183463	chr8:93005414	RUNX1T1	0.66	6.95	0.41	3.7e-11	Intelligence (multi-trait analysis);
SARC	cis	rs7216064	0.953	rs11871285	chr17:65840809	G/T	cg12091567	chr17:66097778	LOC651250	-0.69	-6.99	-0.42	2.89e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs34779708	0.931	rs4934704	chr10:35332164	C/T	cg03585969	chr10:35415529	CREM	0.39	4.97	0.31	1.31e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg22800045	chr5:56110881	MAP3K1	0.75	8.0	0.46	5.94e-14	Initial pursuit acceleration;
SARC	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg27286337	chr10:134555280	INPP5A	0.63	7.24	0.43	6.46e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs3820928	0.874	rs13383070	chr2:227904939	C/T	cg11843606	chr2:227700838	RHBDD1	-0.51	-6.4	-0.39	8.66e-10	Pulmonary function;
SARC	cis	rs2153535	0.580	rs9406169	chr6:8509470	A/T	cg21535247	chr6:8435926	SLC35B3	0.55	7.09	0.42	1.63e-11	Motion sickness;
SARC	cis	rs72945132	0.882	rs72947078	chr11:70197542	G/T	cg05964544	chr11:70165517	PPFIA1	-0.57	-5.36	-0.33	2.04e-7	Coronary artery disease;
SARC	cis	rs9650657	0.615	rs11996727	chr8:10691489	C/T	cg21775007	chr8:11205619	TDH	-0.39	-4.86	-0.3	2.15e-6	Neuroticism;
SARC	cis	rs7647973	0.710	rs6446285	chr3:49626306	G/A	cg03060546	chr3:49711283	APEH	0.68	5.77	0.35	2.51e-8	Menarche (age at onset);
SARC	cis	rs611744	0.967	rs859788	chr8:109227570	A/G	cg21045802	chr8:109455806	TTC35	0.44	5.26	0.33	3.18e-7	Dupuytren's disease;
SARC	cis	rs7551222	0.752	rs12125533	chr1:204529302	A/C	cg20240347	chr1:204465584	NA	-0.32	-5.64	-0.35	4.99e-8	Schizophrenia;
SARC	cis	rs920590	0.758	rs7012358	chr8:19662498	C/T	cg01411142	chr8:19674711	INTS10	0.48	5.55	0.34	7.86e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs2072499	1.000	rs2241107	chr1:156182710	C/T	cg25208724	chr1:156163844	SLC25A44	-0.81	-10.55	-0.57	1.6e-21	Testicular germ cell tumor;
SARC	cis	rs9436747	0.605	rs11587159	chr1:65987205	C/G	cg14976592	chr1:65886160	LEPROT;LEPR	-0.43	-5.65	-0.35	4.7e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg09373136	chr17:61933544	TCAM1	-0.45	-6.14	-0.37	3.58e-9	Prudent dietary pattern;
SARC	cis	rs1200821	0.529	rs2475206	chr10:37802532	A/G	cg00409905	chr10:38381863	ZNF37A	0.45	6.16	0.37	3.16e-9	Hemostatic factors and hematological phenotypes;
SARC	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg20607798	chr8:58055168	NA	0.6	5.33	0.33	2.29e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg11704751	chr12:63329118	PPM1H	-0.65	-6.3	-0.38	1.5e-9	Cutaneous psoriasis;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg12294506	chr8:6565850	AGPAT5	0.54	6.79	0.41	8.97e-11	Breast cancer;
SARC	cis	rs12682352	0.715	rs332039	chr8:8723651	C/G	cg06636001	chr8:8085503	FLJ10661	0.53	6.89	0.41	5.2e-11	Neuroticism;
SARC	cis	rs13390159	0.714	rs111699014	chr2:237155259	G/A	cg19324714	chr2:237145437	ASB18	0.5	4.9	0.31	1.78e-6	Response to statin therapy;
SARC	cis	rs8067545	0.641	rs203458	chr17:19816898	A/C	cg13482628	chr17:19912719	NA	0.53	6.68	0.4	1.75e-10	Schizophrenia;
SARC	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg24209194	chr3:40518798	ZNF619	-0.66	-8.45	-0.48	3.17e-15	Renal cell carcinoma;
SARC	cis	rs73001065	0.591	rs2285626	chr19:19467545	C/T	cg03709012	chr19:19516395	GATAD2A	1.04	8.31	0.48	8.18e-15	LDL cholesterol;
SARC	cis	rs644799	1.000	rs527899	chr11:95529242	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.7	9.55	0.53	1.87e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg01341218	chr17:43662625	NA	0.97	11.19	0.59	1.57e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7833986	0.501	rs2953897	chr8:56980569	C/T	cg26371346	chr8:56986568	SNORD54;RPS20	0.72	7.24	0.43	6.48e-12	Height;
SARC	cis	rs9911578	1.000	rs1472288	chr17:56910720	G/A	cg05425664	chr17:57184151	TRIM37	-0.64	-7.98	-0.46	6.52e-14	Intelligence (multi-trait analysis);
SARC	cis	rs8067545	0.641	rs175922	chr17:19825579	T/C	cg04132472	chr17:19861366	AKAP10	0.38	4.97	0.31	1.27e-6	Schizophrenia;
SARC	cis	rs7818345	0.737	rs17407149	chr8:19274848	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.38	4.82	0.3	2.59e-6	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.42	-7.19	-0.43	8.65e-12	Total body bone mineral density;
SARC	cis	rs9916302	0.861	rs4795376	chr17:37669043	T/C	cg00129232	chr17:37814104	STARD3	-0.65	-8.01	-0.46	5.61e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs9814567	1.000	rs9828815	chr3:134265749	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.1	-0.42	1.49e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs9420	0.961	rs11570190	chr11:57560452	A/C	cg19752551	chr11:57585705	CTNND1	-0.52	-7.17	-0.42	1.01e-11	Schizophrenia;
SARC	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg00933542	chr6:150070202	PCMT1	0.31	5.31	0.33	2.6e-7	Lung cancer;
SARC	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg03806693	chr22:41940476	POLR3H	0.88	11.67	0.61	4.34e-25	Vitiligo;
SARC	cis	rs1707322	1.000	rs1768818	chr1:46514286	G/C	cg06784218	chr1:46089804	CCDC17	-0.38	-6.82	-0.41	7.8e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7027203	0.828	rs10761287	chr9:96609150	A/G	cg13679303	chr9:96623674	NA	-0.35	-5.0	-0.31	1.14e-6	DNA methylation (variation);
SARC	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.89	-13.58	-0.66	2.52e-31	Chronic sinus infection;
SARC	cis	rs9910055	0.529	rs850851	chr17:42177674	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.43	-5.09	-0.32	7.38e-7	Total body bone mineral density;
SARC	cis	rs865483	0.895	rs1016678	chr17:35874192	A/G	cg06561646	chr17:35873369	DUSP14	-0.54	-7.02	-0.42	2.34e-11	Monocyte count;
SARC	cis	rs875971	0.545	rs1638735	chr7:66095738	C/T	cg11764359	chr7:65958608	NA	0.67	6.55	0.39	3.62e-10	Aortic root size;
SARC	trans	rs61931739	0.591	rs1608907	chr12:33945435	A/G	cg26384229	chr12:38710491	ALG10B	0.56	7.22	0.43	7.29e-12	Morning vs. evening chronotype;
SARC	cis	rs6963495	0.649	rs1706888	chr7:105149176	A/G	cg19920283	chr7:105172520	RINT1	0.57	5.88	0.36	1.43e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs11098499	0.644	rs34835603	chr4:120553428	C/T	cg09307838	chr4:120376055	NA	0.76	10.28	0.56	1.08e-20	Corneal astigmatism;
SARC	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.76	-10.15	-0.55	2.81e-20	Chronic sinus infection;
SARC	cis	rs881375	0.967	rs2109895	chr9:123677827	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	4.77	0.3	3.2e-6	Rheumatoid arthritis;
SARC	cis	rs4660306	0.848	rs1088099	chr1:45946654	T/C	cg24296786	chr1:45957014	TESK2	-0.58	-6.64	-0.4	2.15e-10	Homocysteine levels;
SARC	cis	rs12367572	0.796	rs7979141	chr12:45282630	A/T	cg04608330	chr12:45269318	NELL2	-0.47	-5.87	-0.36	1.45e-8	Gut microbiome composition (summer);
SARC	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg06028605	chr16:24865363	SLC5A11	-0.39	-6.05	-0.37	5.62e-9	Intelligence (multi-trait analysis);
SARC	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg13880726	chr7:1868755	MAD1L1	0.5	6.06	0.37	5.45e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs651907	0.557	rs7612283	chr3:101434919	C/T	cg12386194	chr3:101231763	SENP7	0.49	5.78	0.35	2.4e-8	Colorectal cancer;
SARC	cis	rs2645694	0.603	rs2703123	chr4:77821154	C/T	cg03477792	chr4:77819574	ANKRD56	0.5	7.5	0.44	1.35e-12	Emphysema distribution in smoking;
SARC	cis	rs7824557	0.564	rs12547100	chr8:11242632	G/A	cg21775007	chr8:11205619	TDH	-0.64	-8.39	-0.48	4.65e-15	Retinal vascular caliber;
SARC	cis	rs3749237	0.964	rs10865959	chr3:49891002	G/C	cg03060546	chr3:49711283	APEH	0.55	6.3	0.38	1.47e-9	Resting heart rate;
SARC	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg02841227	chr6:26021843	HIST1H4A	0.53	6.47	0.39	5.67e-10	Intelligence (multi-trait analysis);
SARC	cis	rs16937	0.711	rs12142514	chr1:205122529	A/G	cg00857998	chr1:205179979	DSTYK	0.4	4.89	0.3	1.9e-6	Schizophrenia;
SARC	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg18252515	chr7:66147081	NA	-1.33	-11.96	-0.62	5.03e-26	Diabetic kidney disease;
SARC	cis	rs3812049	0.693	rs9327468	chr5:127441861	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.88	9.6	0.53	1.34e-18	Lymphocyte counts;Red cell distribution width;
SARC	cis	rs9486719	1.000	rs2971603	chr6:97035418	C/T	cg06623918	chr6:96969491	KIAA0776	-0.77	-9.37	-0.52	6.76e-18	Migraine;Coronary artery disease;
SARC	cis	rs7044106	0.791	rs10984998	chr9:123481516	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	6.11	0.37	4.14e-9	Hip circumference adjusted for BMI;
SARC	cis	rs7615952	0.800	rs35390120	chr3:125599809	G/A	cg05084668	chr3:125655381	ALG1L	-0.78	-7.64	-0.45	5.74e-13	Blood pressure (smoking interaction);
SARC	cis	rs12950390	0.853	rs11655112	chr17:45856563	T/C	cg03474202	chr17:45855739	NA	-0.43	-6.74	-0.4	1.22e-10	IgG glycosylation;
SARC	cis	rs2013441	1.000	rs1373147	chr17:20206645	T/A	cg13482628	chr17:19912719	NA	-0.49	-6.33	-0.38	1.23e-9	Obesity-related traits;
SARC	cis	rs11583043	1.000	rs7535068	chr1:101490329	T/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.49	5.8	0.36	2.12e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg09517075	chr8:22133004	PIWIL2	0.36	4.86	0.3	2.13e-6	Hypertriglyceridemia;
SARC	cis	rs11997175	0.574	rs4733456	chr8:33656359	C/T	ch.8.33884649F	chr8:33765107	NA	0.46	6.09	0.37	4.5e-9	Body mass index;
SARC	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg16405210	chr4:1374714	KIAA1530	-0.49	-6.17	-0.37	3.05e-9	Longevity;
SARC	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg18404041	chr3:52824283	ITIH1	-0.44	-6.59	-0.4	2.89e-10	Bipolar disorder;
SARC	cis	rs4853012	0.887	rs6737314	chr2:74339586	A/G	cg05890377	chr2:74357713	NA	0.6	7.24	0.43	6.46e-12	Gestational age at birth (maternal effect);
SARC	cis	rs926938	0.584	rs869990	chr1:115379614	A/G	cg12756093	chr1:115239321	AMPD1	-0.36	-4.75	-0.3	3.59e-6	Autism;
SARC	cis	rs10779751	1.000	rs2253213	chr1:11265785	A/G	cg08854313	chr1:11322531	MTOR	0.78	10.71	0.57	4.85e-22	Body mass index;
SARC	cis	rs10958369	0.836	rs2376145	chr8:54399343	G/C	cg12485204	chr8:54507357	NA	0.35	5.14	0.32	5.81e-7	Response to antineoplastic agents;
SARC	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	10.04	0.55	5.9e-20	Alzheimer's disease;
SARC	cis	rs4975616	0.869	rs380286	chr5:1320247	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.54	-7.4	-0.44	2.48e-12	Lung cancer;
SARC	cis	rs7084402	0.967	rs1658478	chr10:60289551	C/T	cg07615347	chr10:60278583	BICC1	0.61	8.99	0.51	8.84e-17	Refractive error;
SARC	cis	rs9487051	0.836	rs9487036	chr6:109607449	C/T	cg01475377	chr6:109611718	NA	-0.41	-5.96	-0.36	9.28e-9	Reticulocyte fraction of red cells;
SARC	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg06138931	chr13:21896616	NA	0.46	6.44	0.39	6.77e-10	White matter hyperintensity burden;
SARC	cis	rs1699337	0.505	rs167466	chr3:12281103	C/T	cg04748988	chr3:12329223	PPARG	0.38	5.09	0.32	7.45e-7	Cholesterol, total;
SARC	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.74	6.7	0.4	1.57e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2839627	0.513	rs7282879	chr21:44286525	C/T	cg03543861	chr21:44258195	NA	0.46	4.98	0.31	1.23e-6	Information processing speed;
SARC	cis	rs9486719	1.000	rs12210146	chr6:96903962	A/G	cg18709589	chr6:96969512	KIAA0776	0.51	5.07	0.32	8.26e-7	Migraine;Coronary artery disease;
SARC	cis	rs244731	0.959	rs6556307	chr5:176641434	C/T	cg17509989	chr5:176798049	RGS14	0.69	8.73	0.5	5e-16	Urate levels in lean individuals;
SARC	cis	rs2797160	0.684	rs1832937	chr6:125985934	A/G	cg05901451	chr6:126070800	HEY2	0.38	4.87	0.3	2.02e-6	Endometrial cancer;
SARC	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg12463550	chr7:65579703	CRCP	0.54	5.69	0.35	3.85e-8	Aortic root size;
SARC	cis	rs2204008	0.694	rs10880262	chr12:38328696	C/T	cg13010199	chr12:38710504	ALG10B	0.68	8.64	0.49	9.02e-16	Bladder cancer;
SARC	cis	rs1008375	1.000	rs1008374	chr4:17683219	G/A	cg02297831	chr4:17616191	MED28	0.44	5.52	0.34	8.9e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9325144	0.647	rs61931899	chr12:38892422	A/G	cg13010199	chr12:38710504	ALG10B	-0.45	-5.66	-0.35	4.53e-8	Morning vs. evening chronotype;
SARC	cis	rs2439831	0.850	rs7174208	chr15:44052682	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	7.55	0.44	1.01e-12	Lung cancer in ever smokers;
SARC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.14	0.8	6.21e-53	Prudent dietary pattern;
SARC	cis	rs56104184	0.830	rs17272645	chr19:49342366	C/G	cg15549821	chr19:49342101	PLEKHA4	0.89	11.03	0.59	4.92e-23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs2070997	0.756	rs10901292	chr9:133723594	A/G	cg03924115	chr9:133768966	QRFP	0.53	4.95	0.31	1.4e-6	Response to amphetamines;
SARC	cis	rs2290159	0.848	rs6771385	chr3:12639419	A/G	cg23032965	chr3:12705835	RAF1	0.67	7.15	0.42	1.09e-11	Cholesterol, total;
SARC	cis	rs4481887	0.830	rs6686474	chr1:248477116	A/C	cg00666640	chr1:248458726	OR2T12	0.33	5.54	0.34	7.95e-8	Common traits (Other);
SARC	cis	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg00409905	chr10:38381863	ZNF37A	0.55	7.93	0.46	9.01e-14	Extrinsic epigenetic age acceleration;
SARC	cis	rs6088590	0.561	rs764597	chr20:33161225	C/T	cg24642439	chr20:33292090	TP53INP2	0.66	8.45	0.48	3.09e-15	Coronary artery disease;
SARC	cis	rs7523050	0.643	rs12725689	chr1:109405151	T/C	cg08274380	chr1:109419600	GPSM2	1.04	7.81	0.46	1.96e-13	Fat distribution (HIV);
SARC	cis	rs7624766	0.555	rs2049215	chr3:160512424	C/A	cg22637730	chr3:160473554	PPM1L	0.38	4.85	0.3	2.24e-6	Response to methotrexate in rheumatoid arthritis;
SARC	cis	rs1421811	0.606	rs62369523	chr5:32713365	T/G	cg16267343	chr5:32710456	NPR3	0.89	11.56	0.6	9.82e-25	Blood pressure;
SARC	cis	rs60871478	0.947	rs62432239	chr7:794576	C/T	cg19087971	chr7:751233	PRKAR1B	-0.43	-4.95	-0.31	1.45e-6	Cerebrospinal P-tau181p levels;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	ch.1.46653973R	chr1:46881386	NA	0.53	7.01	0.42	2.58e-11	Breast cancer;
SARC	cis	rs6693567	0.565	rs1694379	chr1:150292417	C/A	cg09579323	chr1:150459698	TARS2	0.44	5.49	0.34	1.04e-7	Migraine;
SARC	cis	rs17345786	1.000	rs997739	chr3:101313940	A/G	cg12386194	chr3:101231763	SENP7	0.72	8.64	0.49	9.18e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10504073	0.626	rs9298106	chr8:50007508	T/G	cg00325661	chr8:49890786	NA	0.51	6.9	0.41	4.89e-11	Blood metabolite ratios;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg27199523	chr6:139094722	CCDC28A	-0.77	-6.33	-0.38	1.23e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg02353165	chr6:42928485	GNMT	0.61	8.41	0.48	4.18e-15	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs9902453	0.967	rs8082175	chr17:28430303	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	6.71	0.4	1.5e-10	Coffee consumption (cups per day);
SARC	cis	rs2204008	0.744	rs67889662	chr12:38327042	T/A	cg26384229	chr12:38710491	ALG10B	0.9	12.95	0.65	2.89e-29	Bladder cancer;
SARC	cis	rs11122272	0.735	rs2790883	chr1:231532726	A/G	cg06096015	chr1:231504339	EGLN1	0.38	5.7	0.35	3.65e-8	Hemoglobin concentration;
SARC	cis	rs9916302	0.706	rs649180	chr17:37464959	A/C	cg15445000	chr17:37608096	MED1	-0.45	-4.76	-0.3	3.42e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg26338869	chr17:61819248	STRADA	0.79	10.63	0.57	8.77e-22	Prudent dietary pattern;
SARC	cis	rs116095464	0.558	rs113796397	chr5:246503	A/G	cg22496380	chr5:211416	CCDC127	-0.87	-8.99	-0.51	8.93e-17	Breast cancer;
SARC	cis	rs3733585	0.648	rs28513781	chr4:9959334	G/C	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.55	-0.34	7.65e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs3126085	0.877	rs7535536	chr1:152193544	A/G	cg09127314	chr1:152161683	NA	0.41	4.81	0.3	2.72e-6	Atopic dermatitis;
SARC	cis	rs2153535	0.580	rs7742794	chr6:8459723	C/A	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.04e-14	Motion sickness;
SARC	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg03735888	chr19:58951602	ZNF132	0.42	5.56	0.34	7.54e-8	Uric acid clearance;
SARC	cis	rs12134245	0.747	rs35654098	chr1:92001452	T/A	cg25838465	chr1:92012736	NA	-0.69	-9.93	-0.55	1.29e-19	Breast cancer;
SARC	cis	rs7296418	0.922	rs1790134	chr12:123697898	T/C	cg00376283	chr12:123451042	ABCB9	0.62	7.58	0.44	8.26e-13	Platelet count;
SARC	cis	rs57083693	0.500	rs11110751	chr12:101718142	T/C	cg22051763	chr12:101673672	UTP20	-0.44	-5.21	-0.32	4.11e-7	Alcohol dependence (age at onset);
SARC	cis	rs4800452	0.956	rs4239436	chr18:20731930	A/G	cg13313047	chr18:20735648	CABLES1	-0.47	-5.13	-0.32	6.02e-7	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
SARC	cis	rs9790314	0.871	rs336561	chr3:161125305	C/T	cg03342759	chr3:160939853	NMD3	-0.57	-6.98	-0.42	3.05e-11	Morning vs. evening chronotype;
SARC	cis	rs8014204	0.762	rs973879	chr14:75297727	T/C	cg06637938	chr14:75390232	RPS6KL1	0.55	7.9	0.46	1.11e-13	Caffeine consumption;
SARC	cis	rs9902453	0.817	rs2628170	chr17:28056612	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.53	-7.0	-0.42	2.73e-11	Coffee consumption (cups per day);
SARC	cis	rs936229	0.861	rs7162232	chr15:75115895	G/A	cg14664628	chr15:75095509	CSK	-1.05	-15.38	-0.71	2.56e-37	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg11890956	chr21:40555474	PSMG1	-0.68	-8.81	-0.5	2.98e-16	Menarche (age at onset);
SARC	cis	rs2408955	0.501	rs8716	chr12:48539482	T/G	cg24011408	chr12:48396354	COL2A1	0.43	5.23	0.32	3.68e-7	Glycated hemoglobin levels;
SARC	trans	rs2727020	0.656	rs7925524	chr11:49437542	G/A	cg03929089	chr4:120376271	NA	-0.73	-9.1	-0.51	4.05e-17	Coronary artery disease;
SARC	cis	rs1371867	0.810	rs3020182	chr8:101233008	T/C	cg11906718	chr8:101322791	RNF19A	-0.66	-8.44	-0.48	3.33e-15	Atrioventricular conduction;
SARC	cis	rs9486719	0.843	rs976357	chr6:96849679	C/T	cg06623918	chr6:96969491	KIAA0776	0.74	7.29	0.43	4.77e-12	Migraine;Coronary artery disease;
SARC	cis	rs6580649	0.941	rs7959755	chr12:48446318	T/A	cg05342945	chr12:48394962	COL2A1	0.56	6.03	0.37	6.35e-9	Lung cancer;
SARC	cis	rs3020736	0.500	rs6002601	chr22:42489058	A/T	cg04733989	chr22:42467013	NAGA	-0.76	-10.7	-0.57	5.23e-22	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2204008	0.616	rs1607852	chr12:38398125	G/A	cg13010199	chr12:38710504	ALG10B	0.79	10.53	0.57	1.87e-21	Bladder cancer;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg21595039	chr6:166721644	PRR18	0.46	6.35	0.38	1.1e-9	Tetralogy of Fallot;
SARC	cis	rs7552404	0.656	rs11161792	chr1:76336746	C/T	cg03433033	chr1:76189801	ACADM	0.48	5.89	0.36	1.35e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7647973	0.588	rs4855848	chr3:49653457	C/T	cg06212747	chr3:49208901	KLHDC8B	0.59	5.82	0.36	1.94e-8	Menarche (age at onset);
SARC	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg20965017	chr5:231967	SDHA	-0.55	-5.26	-0.33	3.23e-7	Breast cancer;
SARC	cis	rs2180341	0.960	rs9401953	chr6:127687574	G/A	cg27446573	chr6:127587934	RNF146	1.06	14.81	0.7	2.04e-35	Breast cancer;
SARC	cis	rs4664308	0.810	rs59019419	chr2:161061287	G/A	cg03641300	chr2:160917029	PLA2R1	-0.63	-8.09	-0.47	3.22e-14	Idiopathic membranous nephropathy;
SARC	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-4.98	-0.31	1.22e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs1322639	0.697	rs12661910	chr6:169584388	A/G	cg03254818	chr6:169586852	NA	0.66	6.81	0.41	8.25e-11	Pulse pressure;
SARC	cis	rs6866344	0.569	rs56070635	chr5:178150169	A/C	cg10224037	chr5:178157518	ZNF354A	1.0	12.69	0.64	2.08e-28	Neutrophil percentage of white cells;
SARC	cis	rs3818285	0.655	rs588160	chr10:111641538	C/T	cg00817464	chr10:111662876	XPNPEP1	0.52	8.22	0.47	1.4e-14	Superior crus of antihelix expression;
SARC	cis	rs7481584	0.624	rs440130	chr11:3051476	A/G	cg05729581	chr11:3078854	CARS	0.57	7.4	0.44	2.45e-12	Calcium levels;
SARC	cis	rs6087990	0.806	rs1474738	chr20:31380309	G/A	cg13636640	chr20:31349939	DNMT3B	0.8	12.7	0.64	2.01e-28	Ulcerative colitis;
SARC	cis	rs9291683	1.000	rs9291683	chr4:10324160	C/T	cg11266682	chr4:10021025	SLC2A9	0.31	5.71	0.35	3.43e-8	Bone mineral density;
SARC	trans	rs57994514	0.524	rs10504471	chr8:71189128	T/C	cg04828133	chr7:155259845	NA	-0.98	-6.67	-0.4	1.83e-10	Intelligence (multi-trait analysis);
SARC	cis	rs62244186	0.659	rs1806579	chr3:44509281	T/C	cg15225532	chr3:44803084	KIF15;KIAA1143	0.46	5.75	0.35	2.84e-8	Depressive symptoms;
SARC	cis	rs7647973	0.710	rs9869120	chr3:49624065	T/C	cg07636037	chr3:49044803	WDR6	0.77	7.01	0.42	2.52e-11	Menarche (age at onset);
SARC	cis	rs11587400	0.572	rs2268697	chr1:115227493	A/G	cg12756093	chr1:115239321	AMPD1	0.39	4.93	0.31	1.54e-6	Autism;
SARC	cis	rs6121246	0.697	rs6087716	chr20:30229040	C/T	cg13852791	chr20:30311386	BCL2L1	0.8	8.64	0.49	9.21e-16	Mean corpuscular hemoglobin;
SARC	cis	rs1348850	0.793	rs13020788	chr2:178480714	C/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.52	5.89	0.36	1.33e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs17079247	0.908	rs12855915	chr13:85739065	T/C	ch.13.84760847R	chr13:85862846	NA	-0.56	-4.72	-0.3	4.11e-6	Bipolar disorder (mania);
SARC	cis	rs57506017	0.565	rs12699333	chr7:12269804	C/T	cg23422036	chr7:12250390	TMEM106B	0.45	5.87	0.36	1.49e-8	Neuroticism;
SARC	trans	rs7824557	0.583	rs2263512	chr8:11233419	T/G	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.4	-0.48	4.4e-15	Retinal vascular caliber;
SARC	cis	rs854765	0.583	rs11869536	chr17:17826528	T/A	cg04398451	chr17:18023971	MYO15A	-0.39	-5.48	-0.34	1.12e-7	Total body bone mineral density;
SARC	cis	rs11098499	0.863	rs6835635	chr4:120458867	A/G	cg24375607	chr4:120327624	NA	0.43	5.08	0.32	7.56e-7	Corneal astigmatism;
SARC	cis	rs910316	1.000	rs12435391	chr14:75601737	A/G	cg06637938	chr14:75390232	RPS6KL1	0.49	6.66	0.4	2e-10	Height;
SARC	cis	rs1707322	0.721	rs10749856	chr1:46164846	A/T	cg06784218	chr1:46089804	CCDC17	0.36	6.17	0.37	2.95e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs826838	1.000	rs1095575	chr12:39110284	C/G	cg13010199	chr12:38710504	ALG10B	-0.67	-9.48	-0.53	3.1e-18	Heart rate;
SARC	cis	rs11240408	1	rs11240408	chr1:205264536	A/T	cg21643547	chr1:205240462	TMCC2	0.63	8.18	0.47	1.87e-14	Platelet count;
SARC	cis	rs2486288	0.656	rs1706770	chr15:45575062	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.56	-6.92	-0.41	4.4e-11	Glomerular filtration rate;
SARC	cis	rs7103648	0.864	rs10742802	chr11:47432725	T/G	cg10504702	chr11:47789108	FNBP4	0.58	7.58	0.44	8.01e-13	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs4595586	0.545	rs7307303	chr12:39368976	A/G	cg26384229	chr12:38710491	ALG10B	0.51	6.25	0.38	1.9e-9	Morning vs. evening chronotype;
SARC	cis	rs72945132	0.714	rs66542029	chr11:70196302	A/T	cg00319359	chr11:70116639	PPFIA1	0.67	6.17	0.37	3.01e-9	Coronary artery disease;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg26820641	chr20:30326728	TPX2	-0.64	-7.27	-0.43	5.25e-12	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg14159672	chr1:205819179	PM20D1	0.86	14.62	0.69	8.7e-35	Menarche (age at onset);
SARC	cis	rs9902453	0.845	rs72823935	chr17:28008595	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	7.26	0.43	5.89e-12	Coffee consumption (cups per day);
SARC	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs8114671	0.836	rs2425006	chr20:33571228	T/G	cg24642439	chr20:33292090	TP53INP2	-0.48	-5.56	-0.34	7.22e-8	Height;
SARC	cis	rs921968	0.565	rs7562426	chr2:219605118	G/A	cg02176678	chr2:219576539	TTLL4	-0.33	-5.02	-0.31	1.05e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs1034435	0.755	rs5767171	chr22:48891881	A/G	cg05992904	chr22:48892994	FAM19A5	-0.44	-6.41	-0.39	7.88e-10	Late-onset Alzheimer's disease;
SARC	cis	rs1559088	0.847	rs6510348	chr19:33601946	G/A	cg27124370	chr19:33622961	WDR88	0.43	5.69	0.35	3.82e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs7666738	0.830	rs17027198	chr4:98991085	G/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg08859206	chr1:53392774	SCP2	0.38	5.43	0.34	1.38e-7	Monocyte count;
SARC	cis	rs9309473	0.500	rs6546862	chr2:73860348	G/A	cg20560298	chr2:73613845	ALMS1	0.5	6.9	0.41	5e-11	Metabolite levels;
SARC	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg15921436	chr17:44337874	NA	0.49	4.81	0.3	2.77e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg23637372	chr6:100016255	CCNC	0.51	6.54	0.39	3.93e-10	Height;
SARC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.22	0.81	2.28e-56	Prudent dietary pattern;
SARC	cis	rs1699337	0.896	rs2938388	chr3:12437978	A/G	cg04748988	chr3:12329223	PPARG	0.4	4.96	0.31	1.38e-6	Cholesterol, total;
SARC	cis	rs911555	0.755	rs4143998	chr14:103955247	T/C	cg24130564	chr14:104152367	KLC1	-0.5	-5.94	-0.36	1.01e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9896052	0.649	rs6501798	chr17:73444647	C/T	cg04121983	chr17:73511085	CASKIN2	0.43	5.12	0.32	6.43e-7	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	10.71	0.57	5.08e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9341808	0.727	rs1324120	chr6:80976125	G/C	cg08355045	chr6:80787529	NA	0.35	5.6	0.34	6.12e-8	Sitting height ratio;
SARC	cis	rs17376456	0.877	rs35747258	chr5:93310129	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.8	0.35	2.2e-8	Diabetic retinopathy;
SARC	cis	rs6484504	0.625	rs4922859	chr11:31382517	A/G	cg26647111	chr11:31128758	NA	0.37	4.81	0.3	2.65e-6	Red blood cell count;
SARC	cis	rs7940866	0.903	rs1433980	chr11:130870956	A/G	cg12179176	chr11:130786555	SNX19	0.56	7.74	0.45	3.01e-13	Schizophrenia;
SARC	cis	rs1707322	0.686	rs2230659	chr1:46078884	C/T	cg06784218	chr1:46089804	CCDC17	-0.38	-6.66	-0.4	1.92e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6908034	0.882	rs6456259	chr6:19761718	A/G	cg02682789	chr6:19804855	NA	0.55	5.24	0.32	3.57e-7	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs7005380	0.581	rs2326432	chr8:120932912	A/G	cg21744203	chr8:120868354	DSCC1	-0.46	-5.34	-0.33	2.22e-7	Interstitial lung disease;
SARC	cis	rs9814567	1.000	rs62271514	chr3:134298554	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	6.89	0.41	5.31e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs77372450	0.636	rs10066519	chr5:157017429	A/G	cg23851860	chr5:157002805	ADAM19	0.5	4.83	0.3	2.5e-6	Bipolar disorder (body mass index interaction);
SARC	trans	rs8073060	0.544	rs225244	chr17:33946581	A/G	cg19694781	chr19:47549865	TMEM160	0.65	6.63	0.4	2.36e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg11843238	chr5:131593191	PDLIM4	0.42	5.7	0.35	3.55e-8	Acylcarnitine levels;
SARC	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg22920501	chr2:26401640	FAM59B	-0.57	-7.45	-0.44	1.82e-12	Gut microbiome composition (summer);
SARC	cis	rs4319547	0.695	rs6488958	chr12:122880704	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.54	-6.13	-0.37	3.7e-9	Body mass index;
SARC	cis	rs9291683	0.595	rs13145442	chr4:10037261	C/A	cg11266682	chr4:10021025	SLC2A9	0.4	7.09	0.42	1.58e-11	Bone mineral density;
SARC	cis	rs7592578	0.771	rs12052514	chr2:191378170	C/T	cg25963032	chr2:191064776	C2orf88	-0.48	-5.27	-0.33	3.04e-7	Diastolic blood pressure;
SARC	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg13395646	chr4:1353034	KIAA1530	0.42	4.96	0.31	1.38e-6	Obesity-related traits;
SARC	cis	rs10504073	0.584	rs60449482	chr8:49974865	G/A	cg00325661	chr8:49890786	NA	0.52	6.91	0.41	4.54e-11	Blood metabolite ratios;
SARC	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg23758822	chr17:41437982	NA	0.89	11.31	0.6	6.35e-24	Menopause (age at onset);
SARC	cis	rs7927771	0.965	rs35184771	chr11:47475189	G/T	cg20307385	chr11:47447363	PSMC3	-0.53	-6.56	-0.4	3.36e-10	Subjective well-being;
SARC	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg01181863	chr3:195395398	SDHAP2	-0.57	-6.51	-0.39	4.68e-10	Pancreatic cancer;
SARC	cis	rs8141529	0.732	rs2269577	chr22:29196757	G/C	cg15103426	chr22:29168792	CCDC117	0.68	9.22	0.52	1.87e-17	Lymphocyte counts;
SARC	cis	rs12421382	0.690	rs2716049	chr11:109609889	A/C	cg11473876	chr11:109292803	C11orf87	0.4	5.39	0.33	1.73e-7	Schizophrenia;
SARC	cis	rs10504073	0.584	rs10957356	chr8:49980634	G/A	cg00325661	chr8:49890786	NA	0.52	6.9	0.41	4.76e-11	Blood metabolite ratios;
SARC	cis	rs765787	0.530	rs2413784	chr15:45530516	A/C	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.81e-6	Uric acid levels;
SARC	cis	rs270601	0.837	rs367805	chr5:131701279	T/C	cg04518342	chr5:131593106	PDLIM4	0.4	5.23	0.32	3.86e-7	Acylcarnitine levels;
SARC	cis	rs910316	0.763	rs175057	chr14:75489632	C/T	cg11812906	chr14:75593930	NEK9	-0.73	-9.44	-0.53	4.04e-18	Height;
SARC	cis	rs72781680	1.000	rs72796351	chr2:24158425	T/C	cg08917208	chr2:24149416	ATAD2B	0.77	7.19	0.43	8.94e-12	Lymphocyte counts;
SARC	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg18876405	chr7:65276391	NA	-0.44	-5.44	-0.34	1.33e-7	Aortic root size;
SARC	cis	rs798554	0.524	rs2283784	chr7:2855337	T/C	cg04166393	chr7:2884313	GNA12	0.44	5.47	0.34	1.14e-7	Height;
SARC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg15785580	chr16:31119650	BCKDK	0.51	6.39	0.39	8.81e-10	Myopia (pathological);
SARC	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg18252515	chr7:66147081	NA	-1.25	-10.99	-0.58	6.44e-23	Diabetic kidney disease;
SARC	cis	rs734999	0.588	rs3748818	chr1:2525660	G/A	cg00980319	chr1:2560884	MMEL1	-0.35	-5.01	-0.31	1.08e-6	Ulcerative colitis;
SARC	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg10523679	chr1:76189770	ACADM	-0.44	-5.25	-0.32	3.5e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-9.87	-0.54	1.98e-19	Chronic sinus infection;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg09441736	chr7:101849549	CUX1	0.52	6.46	0.39	6.12e-10	Blood pressure;
SARC	cis	rs250677	0.687	rs171636	chr5:148434545	G/A	cg12140854	chr5:148520817	ABLIM3	-0.41	-4.83	-0.3	2.51e-6	Breast cancer;
SARC	cis	rs17001868	0.568	rs909669	chr22:40742417	C/T	cg07138101	chr22:40742427	ADSL	0.55	6.03	0.37	6.49e-9	Mammographic density (dense area);
SARC	cis	rs796364	0.789	rs176008	chr2:200814720	A/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.78	7.07	0.42	1.8e-11	Schizophrenia;
SARC	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg26335602	chr6:28129616	ZNF389	0.53	5.95	0.36	9.59e-9	Depression;
SARC	cis	rs9309473	0.632	rs7599076	chr2:73585519	G/T	cg20560298	chr2:73613845	ALMS1	-0.57	-7.34	-0.43	3.56e-12	Metabolite levels;
SARC	cis	rs4713118	0.568	rs9468213	chr6:27706180	G/A	cg17221315	chr6:27791827	HIST1H4J	0.39	4.84	0.3	2.37e-6	Parkinson's disease;
SARC	trans	rs9929218	0.911	rs4783685	chr16:68834107	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.5	-6.26	-0.38	1.86e-9	Colorectal cancer;
SARC	cis	rs17057640	1.000	rs17057640	chr6:130019354	A/G	cg08633085	chr6:130031345	ARHGAP18	-0.67	-5.52	-0.34	8.92e-8	Cognitive function;
SARC	trans	rs9650657	0.515	rs7820860	chr8:10950396	C/G	cg08975724	chr8:8085496	FLJ10661	-0.59	-7.66	-0.45	5.03e-13	Neuroticism;
SARC	trans	rs66573146	1.000	rs73088528	chr4:6967747	G/C	cg07817883	chr1:32538562	TMEM39B	1.45	9.08	0.51	4.59e-17	Granulocyte percentage of myeloid white cells;
SARC	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg00149659	chr3:10157352	C3orf10	0.69	6.38	0.39	9.6e-10	Alzheimer's disease;
SARC	cis	rs1707322	0.752	rs12062535	chr1:46222880	G/A	cg03146154	chr1:46216737	IPP	0.51	6.14	0.37	3.45e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6138458	1.000	rs227651	chr20:24929834	A/G	cg26195577	chr20:24973756	C20orf3	0.89	9.55	0.53	1.89e-18	Blood protein levels;
SARC	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg16606324	chr3:10149918	C3orf24	0.49	4.82	0.3	2.56e-6	Alzheimer's disease;
SARC	cis	rs17376456	0.825	rs72786702	chr5:93254656	A/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.67	6.14	0.37	3.48e-9	Diabetic retinopathy;
SARC	cis	rs7681440	0.904	rs6816469	chr4:90772885	G/C	cg06632027	chr4:90757378	SNCA	0.4	5.67	0.35	4.21e-8	Dementia with Lewy bodies;
SARC	cis	rs9660992	0.573	rs1172147	chr1:205225457	G/A	cg21643547	chr1:205240462	TMCC2	-0.55	-7.24	-0.43	6.66e-12	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs7560272	0.538	rs17434655	chr2:73923089	C/T	cg20560298	chr2:73613845	ALMS1	-0.43	-5.51	-0.34	9.48e-8	Schizophrenia;
SARC	cis	rs11235843	0.778	rs4944861	chr11:73430505	G/T	cg18195628	chr11:73498948	MRPL48	0.65	4.99	0.31	1.2e-6	Hand grip strength;
SARC	cis	rs1153858	1.000	rs12593370	chr15:45617417	C/T	cg21132104	chr15:45694354	SPATA5L1	0.81	11.31	0.6	6.21e-24	Homoarginine levels;
SARC	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg20607798	chr8:58055168	NA	0.63	5.63	0.35	5.15e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs11098499	0.954	rs10034623	chr4:120397829	G/A	cg09307838	chr4:120376055	NA	0.91	12.91	0.65	3.89e-29	Corneal astigmatism;
SARC	cis	rs8031584	0.560	rs7171208	chr15:31198929	A/G	cg14829155	chr15:31115871	NA	0.4	5.39	0.33	1.68e-7	Huntington's disease progression;
SARC	cis	rs2952156	0.876	rs903504	chr17:37829570	C/G	cg07936489	chr17:37558343	FBXL20	-0.43	-5.62	-0.35	5.49e-8	Asthma;
SARC	cis	rs9467773	1.000	rs9467778	chr6:26534743	T/C	cg12292205	chr6:26970375	C6orf41	0.45	5.43	0.34	1.41e-7	Intelligence (multi-trait analysis);
SARC	cis	rs73206853	0.563	rs7968913	chr12:111138558	C/T	cg10860002	chr12:110842031	ANAPC7	0.62	5.23	0.32	3.75e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg11890956	chr21:40555474	PSMG1	-0.69	-9.09	-0.51	4.33e-17	Menarche (age at onset);
SARC	cis	rs8077889	0.956	rs6503476	chr17:41850163	C/T	cg26893861	chr17:41843967	DUSP3	0.87	10.16	0.55	2.59e-20	Triglycerides;
SARC	cis	rs3820928	0.967	rs720501	chr2:227778445	C/T	cg05526886	chr2:227700861	RHBDD1	-0.52	-6.23	-0.38	2.12e-9	Pulmonary function;
SARC	cis	rs11874712	0.965	rs8083998	chr18:43673144	A/C	cg25174615	chr18:43684699	ATP5A1;HAUS1	0.4	4.77	0.3	3.31e-6	Migraine - clinic-based;
SARC	cis	rs7130144	0.534	rs74855511	chr11:130460751	G/A	cg26307797	chr11:130446613	NA	-0.7	-5.78	-0.35	2.33e-8	Urate levels in lean individuals;
SARC	cis	rs17401966	0.838	rs10864449	chr1:10296922	A/T	cg15208524	chr1:10270712	KIF1B	0.47	5.42	0.33	1.5e-7	Hepatocellular carcinoma;
SARC	cis	rs7000551	0.725	rs2248987	chr8:22399002	C/G	cg12081754	chr8:22256438	SLC39A14	0.58	7.96	0.46	7.35e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg18252515	chr7:66147081	NA	-1.34	-12.05	-0.62	2.51e-26	Diabetic kidney disease;
SARC	cis	rs6088590	0.603	rs6579186	chr20:33282198	G/C	cg08999081	chr20:33150536	PIGU	0.41	6.24	0.38	2.02e-9	Coronary artery disease;
SARC	cis	rs3784262	0.739	rs1550574	chr15:58213368	G/T	cg12031962	chr15:58353849	ALDH1A2	-0.39	-5.76	-0.35	2.67e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs35213789	0.734	rs649200	chr7:69178209	G/A	cg10619644	chr7:69149951	AUTS2	-0.35	-4.78	-0.3	3.16e-6	Childhood ear infection;
SARC	cis	rs3093024	0.595	rs4458654	chr6:167476068	A/C	cg23791538	chr6:167370224	RNASET2	-0.53	-7.01	-0.42	2.51e-11	Rheumatoid arthritis;
SARC	cis	rs1371867	0.875	rs1660344	chr8:101324659	A/G	cg11906718	chr8:101322791	RNF19A	0.71	9.12	0.51	3.68e-17	Atrioventricular conduction;
SARC	cis	rs2276314	1.000	rs1540042	chr18:33555236	C/T	cg05985134	chr18:33552581	C18orf21	0.7	7.6	0.45	7.23e-13	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs67311347	0.577	rs11129870	chr3:40260406	G/A	cg24209194	chr3:40518798	ZNF619	0.46	5.51	0.34	9.62e-8	Renal cell carcinoma;
SARC	cis	rs12893668	0.645	rs12889403	chr14:104034746	C/T	cg26031613	chr14:104095156	KLC1	-0.51	-5.42	-0.33	1.48e-7	Reticulocyte count;
SARC	cis	rs7546668	1.000	rs6429746	chr1:15815579	A/G	cg18192808	chr1:15853278	DNAJC16	-0.44	-5.37	-0.33	1.9e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs7246657	0.943	rs1035479	chr19:37893300	G/T	cg23950597	chr19:37808831	NA	0.57	5.81	0.36	2.05e-8	Coronary artery calcification;
SARC	cis	rs1707322	1.000	rs4660336	chr1:46487976	T/C	cg06784218	chr1:46089804	CCDC17	-0.34	-6.0	-0.37	7.61e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2439831	0.681	rs2278858	chr15:43632755	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.05	9.86	0.54	2.2e-19	Lung cancer in ever smokers;
SARC	cis	rs7624766	0.967	rs12497406	chr3:160429243	T/G	cg22637730	chr3:160473554	PPM1L	0.38	4.96	0.31	1.34e-6	Response to methotrexate in rheumatoid arthritis;
SARC	cis	rs35306767	0.903	rs11253494	chr10:937047	C/T	cg20503657	chr10:835505	NA	0.78	7.5	0.44	1.3e-12	Eosinophil percentage of granulocytes;
SARC	cis	rs11583043	0.575	rs7528842	chr1:101583663	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.46	-5.01	-0.31	1.08e-6	Ulcerative colitis;Inflammatory bowel disease;
SARC	trans	rs9329221	0.736	rs2001337	chr8:10251154	G/A	cg06636001	chr8:8085503	FLJ10661	0.59	7.14	0.42	1.17e-11	Neuroticism;
SARC	cis	rs7666738	0.830	rs4699590	chr4:98974030	A/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6696846	0.703	rs112653854	chr1:205079251	G/T	cg21545522	chr1:205238299	TMCC2	0.34	4.76	0.3	3.35e-6	Red blood cell count;
SARC	trans	rs36093844	0.752	rs77497327	chr11:85586941	G/A	cg15359163	chr5:122429178	PRDM6	-0.54	-6.44	-0.39	6.72e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs12291225	0.877	rs11023160	chr11:14264225	T/A	cg19336497	chr11:14380999	RRAS2	-0.34	-5.36	-0.33	1.99e-7	Sense of smell;
SARC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg11235426	chr6:292522	DUSP22	-0.61	-7.78	-0.45	2.42e-13	Menopause (age at onset);
SARC	cis	rs9420	0.925	rs10896636	chr11:57448032	C/G	cg23127183	chr11:57508653	C11orf31	-0.56	-6.36	-0.38	1.05e-9	Schizophrenia;
SARC	cis	rs7617480	0.648	rs4858800	chr3:48755820	A/G	cg07636037	chr3:49044803	WDR6	0.78	8.35	0.48	6.26e-15	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs1023500	0.573	rs133370	chr22:42465260	T/C	cg15557168	chr22:42548783	NA	-0.35	-4.86	-0.3	2.19e-6	Schizophrenia;
SARC	cis	rs1707322	0.721	rs12037803	chr1:46156492	A/G	cg03146154	chr1:46216737	IPP	0.53	6.35	0.38	1.12e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4713118	0.539	rs200967	chr6:27862127	A/G	cg17221315	chr6:27791827	HIST1H4J	0.43	4.8	0.3	2.89e-6	Parkinson's disease;
SARC	cis	rs981844	0.775	rs17371261	chr4:154738479	G/T	cg14289246	chr4:154710475	SFRP2	-0.58	-6.36	-0.38	1.04e-9	Response to statins (LDL cholesterol change);
SARC	cis	rs12079745	0.793	rs12071224	chr1:169191945	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.8	-5.35	-0.33	2.06e-7	QT interval;
SARC	cis	rs2522056	1.000	rs2522047	chr5:131795882	G/T	cg24060327	chr5:131705240	SLC22A5	0.48	4.76	0.3	3.38e-6	Lymphocyte counts;Fibrinogen;
SARC	cis	rs17270561	0.609	rs9379785	chr6:25726213	G/A	cg16482183	chr6:26056742	HIST1H1C	0.43	5.25	0.33	3.49e-7	Iron status biomarkers;
SARC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	5.98	0.36	8.19e-9	Prudent dietary pattern;
SARC	cis	rs1003719	0.762	rs11701556	chr21:38455153	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.65	9.46	0.53	3.43e-18	Eye color traits;
SARC	trans	rs1814175	0.616	rs847641	chr11:49919261	T/C	cg03929089	chr4:120376271	NA	-0.81	-11.69	-0.61	3.89e-25	Height;
SARC	cis	rs6540556	0.769	rs6540553	chr1:209929044	C/G	cg05527609	chr1:210001259	C1orf107	-0.55	-5.53	-0.34	8.54e-8	Red blood cell count;
SARC	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.27	-4.92	-0.31	1.61e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs754466	0.606	rs12356375	chr10:79594514	C/A	cg17075019	chr10:79541650	NA	-0.82	-13.08	-0.65	1.15e-29	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1559088	0.744	rs12972060	chr19:33537096	C/T	cg27124370	chr19:33622961	WDR88	-0.39	-4.9	-0.31	1.79e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs546131	0.600	rs525202	chr11:34821948	A/C	cg06937548	chr11:34938143	PDHX;APIP	0.41	4.82	0.3	2.55e-6	Lung disease severity in cystic fibrosis;
SARC	trans	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg00938859	chr5:1591904	SDHAP3	0.78	7.47	0.44	1.56e-12	Breast cancer;
SARC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg11203670	chr7:100026453	MEPCE;ZCWPW1	0.49	4.83	0.3	2.48e-6	Platelet count;
SARC	cis	rs2050392	0.624	rs303444	chr10:30729347	C/T	cg25182066	chr10:30743637	MAP3K8	0.43	5.8	0.36	2.17e-8	Inflammatory bowel disease;
SARC	cis	rs9354308	0.866	rs2814092	chr6:66547346	C/G	cg07460842	chr6:66804631	NA	0.48	5.48	0.34	1.12e-7	Metabolite levels;
SARC	cis	rs17376456	0.597	rs7728825	chr5:93384594	T/C	cg25358565	chr5:93447407	FAM172A	-0.85	-9.98	-0.55	9.16e-20	Diabetic retinopathy;
SARC	cis	rs7666738	0.830	rs11721726	chr4:98996314	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9868809	0.505	rs28657585	chr3:48736216	A/T	cg00383909	chr3:49044727	WDR6	0.63	5.93	0.36	1.07e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs2302729	0.625	rs12228313	chr12:2831297	C/T	cg19945202	chr12:2788847	CACNA1C	0.54	5.27	0.33	3.1e-7	Sleep quality;
SARC	cis	rs12477438	0.765	rs28648058	chr2:99696417	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-7.6	-0.45	7.03e-13	Chronic sinus infection;
SARC	cis	rs9581857	0.579	rs75326986	chr13:27997758	C/T	cg01674679	chr13:27998804	GTF3A	-0.6	-4.97	-0.31	1.31e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg06618935	chr21:46677482	NA	-0.41	-5.37	-0.33	1.92e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs12421382	1.000	rs12421382	chr11:109378071	C/T	cg27471124	chr11:109292789	C11orf87	0.5	6.61	0.4	2.59e-10	Schizophrenia;
SARC	cis	rs6540556	0.954	rs7536882	chr1:209936673	C/G	cg23920097	chr1:209922102	NA	-0.62	-6.95	-0.41	3.56e-11	Red blood cell count;
SARC	cis	rs1468333	1.000	rs3777113	chr5:137493897	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.79	11.18	0.59	1.67e-23	Resting heart rate;
SARC	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.79	-10.9	-0.58	1.3e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg00449899	chr8:53626436	RB1CC1	-0.6	-6.83	-0.41	7.11e-11	Brain volume in infants (cerebrospinal fluid);
SARC	trans	rs11039798	0.588	rs6485857	chr11:48556511	C/A	cg15704280	chr7:45808275	SEPT13	0.65	6.66	0.4	1.9e-10	Axial length;
SARC	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg11987759	chr7:65425863	GUSB	-0.6	-7.95	-0.46	7.8500000000000006e-14	Aortic root size;
SARC	cis	rs79349575	0.783	rs832410	chr17:46972865	C/T	cg07967210	chr17:47022446	SNF8	0.38	4.78	0.3	3.07e-6	Type 2 diabetes;
SARC	cis	rs7824557	0.933	rs6601576	chr8:11100275	A/T	cg21775007	chr8:11205619	TDH	-0.47	-5.51	-0.34	9.34e-8	Retinal vascular caliber;
SARC	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg11764359	chr7:65958608	NA	-0.66	-7.84	-0.46	1.62e-13	Aortic root size;
SARC	cis	rs6500395	1.000	rs9922734	chr16:48603192	A/G	cg04672837	chr16:48644449	N4BP1	-0.47	-6.3	-0.38	1.51e-9	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs13161895	1.000	rs35592104	chr5:179447661	A/T	cg04265672	chr5:179402240	RNF130	-0.5	-4.92	-0.31	1.61e-6	LDL cholesterol;
SARC	cis	rs834603	0.546	rs1704969	chr7:47467787	A/G	cg23694490	chr7:47445681	TNS3	-0.32	-5.89	-0.36	1.36e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg18252515	chr7:66147081	NA	-0.51	-5.79	-0.35	2.3e-8	Aortic root size;
SARC	cis	rs7666738	0.570	rs1869351	chr4:99077286	T/C	cg05340658	chr4:99064831	C4orf37	0.47	5.95	0.36	9.8e-9	Colonoscopy-negative controls vs population controls;
SARC	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg18876405	chr7:65276391	NA	-0.73	-9.53	-0.53	2.2e-18	Aortic root size;
SARC	cis	rs9788721	0.836	rs2568494	chr15:78740964	G/A	cg18825076	chr15:78729989	IREB2	-0.48	-6.03	-0.37	6.46e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs926392	0.896	rs4812357	chr20:37683071	C/T	cg16355469	chr20:37678765	NA	-0.57	-7.24	-0.43	6.32e-12	Dialysis-related mortality;
SARC	cis	rs2228479	0.850	rs17227064	chr16:89816314	A/G	cg00800038	chr16:89945340	TCF25	-0.74	-5.14	-0.32	5.75e-7	Skin colour saturation;
SARC	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg13880726	chr7:1868755	MAD1L1	0.53	6.21	0.38	2.35e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg00149659	chr3:10157352	C3orf10	1.07	9.97	0.55	1e-19	Alzheimer's disease;
SARC	cis	rs4843747	0.749	rs12102841	chr16:88072574	C/G	cg01573921	chr16:88061006	BANP	0.52	5.5	0.34	9.8e-8	Menopause (age at onset);
SARC	cis	rs13161895	0.941	rs12519642	chr5:179438626	T/G	cg06664874	chr5:179499304	RNF130	-0.49	-4.78	-0.3	3.14e-6	LDL cholesterol;
SARC	cis	rs7647973	0.710	rs11130208	chr3:49615624	G/T	cg03060546	chr3:49711283	APEH	0.72	6.71	0.4	1.44e-10	Menarche (age at onset);
SARC	cis	rs6088580	0.524	rs6142210	chr20:33223012	C/T	cg07148914	chr20:33460835	GGT7	-0.4	-4.87	-0.3	2.09e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs5753618	0.539	rs8135344	chr22:31671932	G/T	cg07713946	chr22:31675144	LIMK2	-0.37	-5.24	-0.32	3.63e-7	Colorectal cancer;
SARC	cis	rs6582630	0.548	rs8189608	chr12:38327775	T/G	cg14851346	chr12:38532713	NA	-0.45	-5.25	-0.33	3.42e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9916302	0.706	rs9893735	chr17:37469858	A/C	cg00129232	chr17:37814104	STARD3	0.54	5.76	0.35	2.7e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs4988958	0.527	rs6756161	chr2:103048417	C/A	cg03938978	chr2:103052716	IL18RAP	0.32	5.18	0.32	4.72e-7	Asthma (childhood onset);
SARC	cis	rs735396	0.627	rs2264778	chr12:121450354	C/A	cg04422896	chr12:121454269	C12orf43	0.46	5.99	0.37	8.09e-9	N-glycan levels;
SARC	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg05793240	chr7:2802953	GNA12	-0.35	-5.08	-0.32	7.6e-7	Height;
SARC	cis	rs12586317	0.534	rs28384418	chr14:35452126	C/A	cg16230307	chr14:35515116	FAM177A1	0.77	9.58	0.53	1.52e-18	Psoriasis;
SARC	cis	rs7824557	0.701	rs2060465	chr8:11162609	T/C	cg21775007	chr8:11205619	TDH	0.52	6.27	0.38	1.77e-9	Retinal vascular caliber;
SARC	cis	rs3768617	0.510	rs10752899	chr1:183081241	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.13	0.55	3.12e-20	Fuchs's corneal dystrophy;
SARC	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg24549020	chr5:56110836	MAP3K1	-0.52	-5.77	-0.35	2.5e-8	Initial pursuit acceleration;
SARC	cis	rs4268898	0.662	rs12052954	chr2:24425620	C/T	cg06627628	chr2:24431161	ITSN2	0.79	9.95	0.55	1.19e-19	Asthma;
SARC	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.6	-6.31	-0.38	1.42e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.38	5.35	0.33	2.14e-7	Total body bone mineral density;
SARC	cis	rs812925	0.512	rs1177309	chr2:61385248	A/G	cg10580144	chr2:61372316	C2orf74	0.37	4.86	0.3	2.17e-6	Immature fraction of reticulocytes;
SARC	cis	rs57506017	0.585	rs1468804	chr7:12275508	A/G	cg23422036	chr7:12250390	TMEM106B	0.46	5.87	0.36	1.47e-8	Neuroticism;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg11653675	chr2:46811648	RHOQ;PIGF	-0.51	-6.52	-0.39	4.23e-10	Alcohol dependence;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg05433637	chr1:1510598	SSU72	0.49	6.39	0.39	8.92e-10	Lung adenocarcinoma;
SARC	cis	rs514406	0.505	rs269289	chr1:53167151	A/C	cg16325326	chr1:53192061	ZYG11B	0.9	16.67	0.74	1.3e-41	Monocyte count;
SARC	cis	rs2075371	1.000	rs2598292	chr7:133988584	C/G	cg11752832	chr7:134001865	SLC35B4	0.57	7.43	0.44	1.99e-12	Mean platelet volume;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg05765466	chr1:45957060	TESK2	-0.57	-6.47	-0.39	5.65e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg00149659	chr3:10157352	C3orf10	0.7	6.58	0.4	3.15e-10	Alzheimer's disease;
SARC	trans	rs7937682	0.889	rs551825	chr11:111480116	C/G	cg18187862	chr3:45730750	SACM1L	0.55	6.97	0.42	3.29e-11	Primary sclerosing cholangitis;
SARC	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg26681399	chr22:41777847	TEF	-0.45	-4.86	-0.3	2.14e-6	Vitiligo;
SARC	cis	rs6840360	1.000	rs4696109	chr4:152668785	A/C	cg22705602	chr4:152727874	NA	-0.37	-6.51	-0.39	4.54e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg10523679	chr1:76189770	ACADM	-0.42	-5.74	-0.35	2.9e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2303745	0.589	rs6512179	chr19:17399105	T/C	cg10664184	chr19:17420304	DDA1	0.48	4.91	0.31	1.73e-6	Systemic lupus erythematosus;
SARC	cis	rs7617773	0.817	rs9819094	chr3:48319558	C/T	cg11946769	chr3:48343235	NME6	0.69	9.02	0.51	7.05e-17	Coronary artery disease;
SARC	cis	rs861020	0.606	rs4844903	chr1:210006267	C/T	cg05527609	chr1:210001259	C1orf107	0.78	10.12	0.55	3.37e-20	Orofacial clefts;
SARC	cis	rs7786808	0.741	rs35059736	chr7:158224692	C/T	cg01191920	chr7:158217561	PTPRN2	-0.43	-8.02	-0.47	4.99e-14	Obesity-related traits;
SARC	cis	rs10927875	0.830	rs1763610	chr1:16335527	C/G	cg21385522	chr1:16154831	NA	-0.67	-8.61	-0.49	1.14e-15	Dilated cardiomyopathy;
SARC	cis	rs9831754	0.906	rs7611939	chr3:78392751	A/C	cg06138941	chr3:78371609	NA	-0.59	-6.97	-0.42	3.31e-11	Calcium levels;
SARC	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg11301795	chr4:187892539	NA	-0.72	-10.68	-0.57	6.21e-22	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg10267162	chr2:97001818	NCAPH	0.76	6.31	0.38	1.41e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs5753618	0.561	rs2078803	chr22:31652852	G/A	cg13145458	chr22:31556086	RNF185	0.47	5.06	0.31	8.33e-7	Colorectal cancer;
SARC	cis	rs616402	0.564	rs602601	chr1:10567058	C/T	cg07384165	chr1:10488281	NA	-0.4	-5.39	-0.33	1.72e-7	Breast size;
SARC	cis	rs2832191	0.935	rs67287920	chr21:30523519	C/A	cg08807101	chr21:30365312	RNF160	-0.74	-10.15	-0.55	2.76e-20	Dental caries;
SARC	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg10435706	chr6:150039699	LATS1	0.37	4.87	0.3	2.04e-6	Lung cancer;
SARC	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg00152838	chr16:24741724	TNRC6A	-0.6	-6.43	-0.39	7.21e-10	Intelligence (multi-trait analysis);
SARC	cis	rs12421382	0.659	rs1371330	chr11:109382692	G/T	cg27471124	chr11:109292789	C11orf87	0.37	5.07	0.32	8.1e-7	Schizophrenia;
SARC	cis	rs9467773	1.000	rs1056667	chr6:26510564	T/C	cg12292205	chr6:26970375	C6orf41	0.43	5.24	0.32	3.66e-7	Intelligence (multi-trait analysis);
SARC	cis	rs10754283	0.967	rs10801761	chr1:90115269	C/T	cg21401794	chr1:90099060	LRRC8C	0.59	8.07	0.47	3.77e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs644799	0.625	rs1255177	chr11:95471495	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.67	8.97	0.51	9.75e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs3771570	0.786	rs62186378	chr2:242211554	G/A	cg21155796	chr2:242212141	HDLBP	0.71	6.21	0.38	2.45e-9	Prostate cancer;
SARC	cis	rs4481887	1.000	rs10888356	chr1:248465044	C/T	cg00666640	chr1:248458726	OR2T12	-0.33	-5.44	-0.34	1.33e-7	Common traits (Other);
SARC	cis	rs11687170	0.816	rs11691030	chr2:237058068	G/A	cg19324714	chr2:237145437	ASB18	0.49	4.89	0.31	1.89e-6	Educational attainment;Educational attainment (years of education);
SARC	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg05861140	chr6:150128134	PCMT1	-0.42	-5.44	-0.34	1.32e-7	Lung cancer;
SARC	cis	rs17376456	0.877	rs35075119	chr5:93385457	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	6.12	0.37	3.99e-9	Diabetic retinopathy;
SARC	cis	rs2011503	1.000	rs55927782	chr19:19642032	T/C	cg15839431	chr19:19639596	YJEFN3	-0.49	-4.81	-0.3	2.73e-6	Bipolar disorder;
SARC	cis	rs72781680	0.715	rs72796332	chr2:24142060	G/A	cg06627628	chr2:24431161	ITSN2	-0.56	-5.86	-0.36	1.56e-8	Lymphocyte counts;
SARC	cis	rs644799	1.000	rs543530	chr11:95545170	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	15.35	0.71	3.21e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7520050	0.807	rs28378621	chr1:46189554	T/C	cg06784218	chr1:46089804	CCDC17	0.26	4.79	0.3	2.98e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg11494091	chr17:61959527	GH2	0.54	8.07	0.47	3.81e-14	Prudent dietary pattern;
SARC	cis	rs1008375	0.800	rs35463363	chr4:17613423	G/T	cg27347728	chr4:17578864	LAP3	0.47	5.82	0.36	1.99e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7255045	0.788	rs1124820	chr19:12957114	G/A	cg21491176	chr19:12958399	MAST1	-0.35	-4.8	-0.3	2.87e-6	Mean corpuscular volume;
SARC	cis	rs708547	0.647	rs1403233	chr4:57885053	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.53	-6.62	-0.4	2.49e-10	Response to bleomycin (chromatid breaks);
SARC	cis	rs9916302	0.904	rs650106	chr17:37451559	A/G	cg07936489	chr17:37558343	FBXL20	0.68	9.06	0.51	5.39e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs2645694	0.533	rs2703125	chr4:77819900	T/C	cg06046430	chr4:77819534	ANKRD56	0.53	7.52	0.44	1.16e-12	Emphysema distribution in smoking;
SARC	cis	rs796364	0.951	rs12613687	chr2:200999256	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.62	-5.83	-0.36	1.8e-8	Schizophrenia;
SARC	cis	rs7674212	0.541	rs2251322	chr4:104079424	C/T	cg16532752	chr4:104119610	CENPE	-0.48	-6.04	-0.37	6.16e-9	Type 2 diabetes;
SARC	cis	rs2180341	0.538	rs11556354	chr6:127664661	G/A	cg27446573	chr6:127587934	RNF146	0.56	6.95	0.41	3.65e-11	Breast cancer;
SARC	cis	rs1318878	0.547	rs56364377	chr12:15523959	T/G	cg08258403	chr12:15378311	NA	0.5	6.84	0.41	6.85e-11	Intelligence (multi-trait analysis);
SARC	cis	rs778371	0.697	rs2344613	chr2:233603065	C/G	cg16596103	chr2:233749413	NGEF	-0.36	-5.44	-0.34	1.35e-7	Schizophrenia;
SARC	cis	rs883565	0.569	rs7638329	chr3:39020408	T/C	cg26331595	chr3:39149181	GORASP1;TTC21A	0.45	5.36	0.33	2.01e-7	Handedness;
SARC	cis	rs367943	1.000	rs348930	chr5:112814763	T/C	cg12552261	chr5:112820674	MCC	-0.45	-5.19	-0.32	4.65e-7	Type 2 diabetes;
SARC	cis	rs10911251	0.546	rs1051473	chr1:183114146	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.68	9.84	0.54	2.43e-19	Colorectal cancer;
SARC	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg03060546	chr3:49711283	APEH	0.4	5.03	0.31	9.85e-7	Parkinson's disease;
SARC	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg08219700	chr8:58056026	NA	0.59	6.37	0.39	9.79e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6582630	0.519	rs8186992	chr12:38325848	C/T	cg13010199	chr12:38710504	ALG10B	0.77	10.42	0.56	4.19e-21	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs897984	0.683	rs9932572	chr16:30841642	A/G	cg00531865	chr16:30841666	NA	-0.51	-6.01	-0.37	6.99e-9	Dementia with Lewy bodies;
SARC	cis	rs11098499	0.954	rs13107475	chr4:120393011	A/T	cg09307838	chr4:120376055	NA	0.92	13.13	0.65	7.35e-30	Corneal astigmatism;
SARC	cis	rs2916247	0.954	rs7013145	chr8:93170892	T/A	cg10183463	chr8:93005414	RUNX1T1	0.46	4.94	0.31	1.51e-6	Intelligence (multi-trait analysis);
SARC	cis	rs651907	0.512	rs771324	chr3:101610365	T/A	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.44	-4.88	-0.3	1.95e-6	Colorectal cancer;
SARC	cis	rs12479064	0.724	rs28369945	chr2:100080928	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-5.89	-0.36	1.31e-8	Chronic sinus infection;
SARC	cis	rs11098499	0.865	rs1112817	chr4:120297800	T/C	cg09307838	chr4:120376055	NA	0.91	12.88	0.65	4.9e-29	Corneal astigmatism;
SARC	cis	rs10416265	0.503	rs1981818	chr19:33615122	C/T	cg27124370	chr19:33622961	WDR88	-0.54	-7.06	-0.42	1.84e-11	Bone properties (heel);
SARC	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg11494091	chr17:61959527	GH2	0.35	4.76	0.3	3.42e-6	Height;
SARC	cis	rs911555	0.723	rs2273701	chr14:103923225	G/T	cg12935359	chr14:103987150	CKB	0.39	5.33	0.33	2.27e-7	Intelligence (multi-trait analysis);
SARC	cis	rs854765	0.663	rs16960744	chr17:17755259	A/G	cg16928487	chr17:17741425	SREBF1	0.24	5.13	0.32	6.12e-7	Total body bone mineral density;
SARC	cis	rs10189230	0.967	rs11692482	chr2:222352405	C/T	cg14652038	chr2:222343519	EPHA4	0.42	5.69	0.35	3.73e-8	Urate levels in lean individuals;
SARC	cis	rs907683	0.570	rs2666104	chr2:220281010	C/T	cg15015639	chr2:220282977	DES	-0.4	-5.46	-0.34	1.23e-7	Resting heart rate;
SARC	cis	rs72781680	0.800	rs6718635	chr2:24066183	A/C	cg06627628	chr2:24431161	ITSN2	-0.71	-6.61	-0.4	2.54e-10	Lymphocyte counts;
SARC	cis	rs8028182	0.583	rs4886722	chr15:75921636	C/A	cg20655648	chr15:75932815	IMP3	0.66	7.94	0.46	8.28e-14	Sudden cardiac arrest;
SARC	cis	rs858239	0.508	rs10242104	chr7:23220450	C/T	cg23682824	chr7:23144976	KLHL7	0.67	8.55	0.49	1.63e-15	Cerebrospinal fluid biomarker levels;
SARC	cis	rs4642101	0.793	rs12714880	chr3:12832101	G/A	cg24848339	chr3:12840334	CAND2	0.33	5.07	0.32	8.23e-7	QRS complex (12-leadsum);
SARC	cis	rs2295359	0.643	rs1569922	chr1:67664963	C/T	cg11235152	chr1:67600687	NA	0.37	5.46	0.34	1.24e-7	Psoriasis;
SARC	cis	rs1468333	1.000	rs2967784	chr5:137539239	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.8	10.76	0.58	3.54e-22	Resting heart rate;
SARC	cis	rs16976116	0.619	rs7172575	chr15:55462544	T/C	cg17854078	chr15:55489399	RSL24D1	-0.65	-5.71	-0.35	3.43e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs365132	1.000	rs365132	chr5:176378574	G/T	cg16309518	chr5:176445507	NA	-0.47	-6.17	-0.37	2.99e-9	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs9815354	0.951	rs1617271	chr3:41914000	G/T	cg03022575	chr3:42003672	ULK4	0.55	5.27	0.33	3.16e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6570726	0.935	rs407721	chr6:145871354	A/C	cg05347473	chr6:146136440	FBXO30	0.49	6.57	0.4	3.23e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs5758511	0.680	rs5758682	chr22:42645202	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.46	6.9	0.41	4.87e-11	Birth weight;
SARC	cis	rs12142240	0.698	rs66516678	chr1:46810112	G/T	cg00530320	chr1:46809349	NSUN4	0.58	7.07	0.42	1.74e-11	Menopause (age at onset);
SARC	cis	rs644148	0.902	rs12982159	chr19:44964300	C/T	cg15540054	chr19:45004280	ZNF180	-0.47	-5.8	-0.36	2.18e-8	Personality dimensions;
SARC	cis	rs73086581	0.786	rs6037705	chr20:3952830	G/C	cg02187196	chr20:3869020	PANK2	0.65	6.53	0.39	4.01e-10	Response to antidepressants in depression;
SARC	cis	rs2908197	0.843	rs2961040	chr7:75946763	A/C	cg22830091	chr7:75961684	YWHAG	-0.33	-4.9	-0.31	1.78e-6	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs10752881	0.905	rs12132262	chr1:182989949	T/A	cg13390022	chr1:182993471	LAMC1	0.34	5.23	0.32	3.82e-7	Colorectal cancer;
SARC	cis	rs11690935	0.632	rs6723259	chr2:172622527	A/C	cg13550731	chr2:172543902	DYNC1I2	0.66	9.48	0.53	3.02e-18	Schizophrenia;
SARC	cis	rs7044106	0.791	rs10984995	chr9:123479210	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	9.95	0.55	1.13e-19	Hip circumference adjusted for BMI;
SARC	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg19774624	chr17:42201019	HDAC5	-0.89	-14.26	-0.68	1.33e-33	Total body bone mineral density;
SARC	cis	rs2120243	0.539	rs4640512	chr3:157120066	C/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.39	5.07	0.32	8.2e-7	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg00031303	chr3:195681400	NA	0.5	5.76	0.35	2.67e-8	Pancreatic cancer;
SARC	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	9.59	0.53	1.45e-18	Platelet count;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg05745464	chr10:120514788	C10orf46	0.48	6.41	0.39	7.89e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs4803468	0.967	rs1077856	chr19:41885221	T/C	cg09537434	chr19:41945824	ATP5SL	-0.93	-16.06	-0.72	1.36e-39	Height;
SARC	cis	rs7084402	0.967	rs1658477	chr10:60289607	A/G	cg07615347	chr10:60278583	BICC1	0.61	8.99	0.51	8.84e-17	Refractive error;
SARC	cis	rs11098499	0.863	rs9997631	chr4:120469995	C/G	cg09307838	chr4:120376055	NA	0.91	12.58	0.64	4.84e-28	Corneal astigmatism;
SARC	trans	rs11165623	0.792	rs1931180	chr1:96914049	C/T	cg10631902	chr5:14652156	NA	-0.48	-7.82	-0.46	1.83e-13	Hip circumference;Waist circumference;
SARC	cis	rs1153858	1.000	rs12439274	chr15:45636667	A/G	cg21132104	chr15:45694354	SPATA5L1	0.78	11.05	0.59	4.21e-23	Homoarginine levels;
SARC	cis	rs6871536	1.000	rs12653750	chr5:131971902	C/T	cg11797159	chr5:131991491	NA	0.39	5.05	0.31	8.78e-7	Asthma (childhood onset);
SARC	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg03806693	chr22:41940476	POLR3H	-1.0	-14.01	-0.68	8.95e-33	Vitiligo;
SARC	cis	rs208520	0.608	rs3846803	chr6:66805743	C/A	cg07460842	chr6:66804631	NA	-1.08	-15.01	-0.7	4.51e-36	Exhaled nitric oxide output;
SARC	cis	rs2153535	0.580	rs9378556	chr6:8514695	A/G	cg21535247	chr6:8435926	SLC35B3	0.57	7.21	0.43	7.67e-12	Motion sickness;
SARC	cis	rs9902453	1.000	rs12600993	chr17:28291222	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	6.83	0.41	7.23e-11	Coffee consumption (cups per day);
SARC	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg19901468	chr14:105411992	AHNAK2	-0.73	-10.79	-0.58	2.78e-22	Rheumatoid arthritis;
SARC	cis	rs3540	0.960	rs2238329	chr15:91028401	G/A	cg22089800	chr15:90895588	ZNF774	0.5	5.78	0.35	2.32e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs8077889	0.703	rs231534	chr17:41945564	C/T	cg26893861	chr17:41843967	DUSP3	-0.69	-6.87	-0.41	5.92e-11	Triglycerides;
SARC	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg05279229	chr7:1896384	MAD1L1	-0.38	-5.18	-0.32	4.69e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs1003719	0.646	rs2835672	chr21:38581234	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.18	-0.52	2.43e-17	Eye color traits;
SARC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg03647317	chr4:187891568	NA	-0.35	-5.01	-0.31	1.09e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs13191362	1.000	rs35126854	chr6:163012443	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.56	5.49	0.34	1.06e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2380220	0.935	rs7748857	chr6:96001887	A/G	cg23517279	chr6:96025343	MANEA	0.47	5.08	0.32	7.58e-7	Behavioural disinhibition (generation interaction);
SARC	cis	rs11838776	0.522	rs7318424	chr13:111021623	C/G	cg05272587	chr13:111038400	COL4A2	0.35	5.39	0.33	1.7e-7	Coronary artery disease;
SARC	cis	rs72627123	0.867	rs58102735	chr14:74467531	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.79	5.97	0.36	8.61e-9	Morning vs. evening chronotype;
SARC	cis	rs36051895	0.659	rs10974944	chr9:5070831	C/G	cg02405213	chr9:5042618	JAK2	-0.5	-5.71	-0.35	3.34e-8	Pediatric autoimmune diseases;
SARC	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg09720205	chr16:57508738	DOK4	-0.48	-6.32	-0.38	1.29e-9	Migraine with aura;
SARC	cis	rs977987	0.835	rs8046109	chr16:75360096	A/G	cg03315344	chr16:75512273	CHST6	0.34	5.78	0.35	2.33e-8	Dupuytren's disease;
SARC	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.46	-5.82	-0.36	1.94e-8	Intelligence (multi-trait analysis);
SARC	cis	rs17376456	0.825	rs10214278	chr5:93237679	C/T	cg21475434	chr5:93447410	FAM172A	-0.72	-6.44	-0.39	6.7e-10	Diabetic retinopathy;
SARC	cis	rs2153535	0.580	rs7741403	chr6:8530578	C/T	cg07606381	chr6:8435919	SLC35B3	-0.71	-10.05	-0.55	5.54e-20	Motion sickness;
SARC	cis	rs910316	0.763	rs175450	chr14:75590340	G/A	cg08847533	chr14:75593920	NEK9	-0.79	-11.59	-0.6	7.88e-25	Height;
SARC	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-15.27	-0.71	6.09e-37	Chronic sinus infection;
SARC	cis	rs67311347	0.577	rs1880763	chr3:40283255	C/T	cg24209194	chr3:40518798	ZNF619	-0.42	-5.08	-0.32	7.67e-7	Renal cell carcinoma;
SARC	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg21016266	chr12:122356598	WDR66	0.31	4.89	0.3	1.89e-6	Mean corpuscular volume;
SARC	cis	rs778371	1.000	rs778370	chr2:233743363	C/T	cg16596103	chr2:233749413	NGEF	0.36	5.18	0.32	4.69e-7	Schizophrenia;
SARC	cis	rs12291225	0.535	rs11023203	chr11:14409815	G/A	cg19336497	chr11:14380999	RRAS2	-0.33	-5.76	-0.35	2.65e-8	Sense of smell;
SARC	cis	rs523522	0.962	rs10744752	chr12:120900554	T/G	cg12219531	chr12:120966889	COQ5	0.81	10.52	0.57	1.98e-21	High light scatter reticulocyte count;
SARC	cis	rs9457247	0.935	rs2757046	chr6:167374353	C/T	cg23791538	chr6:167370224	RNASET2	0.63	8.74	0.5	4.81e-16	Crohn's disease;
SARC	cis	rs9815354	0.638	rs73069277	chr3:41967521	C/T	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs4924590	0.531	rs12913835	chr15:42227869	C/T	cg20935245	chr15:42234343	EHD4	0.5	6.35	0.38	1.11e-9	Lymphocyte percentage of white cells;Sum basophil neutrophil counts;Granulocyte count;
SARC	trans	rs61931739	0.500	rs6488224	chr12:34537205	T/C	cg13010199	chr12:38710504	ALG10B	0.78	11.07	0.59	3.68e-23	Morning vs. evening chronotype;
SARC	cis	rs995000	0.839	rs1168010	chr1:62943979	G/A	cg06896770	chr1:63153194	DOCK7	-0.9	-13.43	-0.66	7.67e-31	Triglyceride levels;
SARC	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg21782813	chr7:2030301	MAD1L1	0.35	5.58	0.34	6.74e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs13095912	1.000	rs13100034	chr3:185318804	G/A	cg11274856	chr3:185301563	NA	0.35	4.83	0.3	2.52e-6	Systolic blood pressure;
SARC	cis	rs1003719	0.762	rs4399800	chr21:38489478	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.63	8.95	0.51	1.17e-16	Eye color traits;
SARC	cis	rs6570726	0.791	rs6918814	chr6:145906028	G/A	cg23711669	chr6:146136114	FBXO30	0.8	13.02	0.65	1.72e-29	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg20795500	chr2:174970644	OLA1	-0.56	-6.85	-0.41	6.49e-11	Alcohol dependence;
SARC	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg17971929	chr21:40555470	PSMG1	0.99	13.58	0.66	2.57e-31	Cognitive function;
SARC	trans	rs35833281	0.951	rs28385614	chr6:55032063	C/T	cg19977494	chr7:128431264	CCDC136	-0.71	-6.62	-0.4	2.43e-10	Morning vs. evening chronotype;
SARC	trans	rs11098499	0.909	rs9994810	chr4:120381590	A/G	cg25214090	chr10:38739885	LOC399744	0.54	7.11	0.42	1.38e-11	Corneal astigmatism;
SARC	cis	rs9513627	0.915	rs73556173	chr13:100121766	C/T	cg25919922	chr13:100150906	NA	-0.7	-5.26	-0.33	3.26e-7	Obesity-related traits;
SARC	cis	rs60871478	1.000	rs62432860	chr7:807522	G/C	cg05535760	chr7:792225	HEATR2	0.78	8.06	0.47	3.86e-14	Cerebrospinal P-tau181p levels;
SARC	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg22618164	chr12:122356400	WDR66	0.41	6.66	0.4	1.9e-10	Mean corpuscular volume;
SARC	cis	rs7927771	0.756	rs10742803	chr11:47439938	A/G	cg20307385	chr11:47447363	PSMC3	0.6	7.61	0.45	6.72e-13	Subjective well-being;
SARC	cis	rs13191362	1.000	rs35017019	chr6:162982581	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.57	5.5	0.34	9.84e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs1395	0.778	rs62128747	chr2:27412605	T/C	cg21747090	chr2:27597821	SNX17	-0.48	-5.77	-0.35	2.47e-8	Blood metabolite levels;
SARC	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-9.01	-0.51	7.82e-17	Alzheimer's disease;
SARC	cis	rs7264396	0.635	rs6058378	chr20:34546658	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	4.92	0.31	1.67e-6	Total cholesterol levels;
SARC	cis	rs9916302	0.706	rs9899069	chr17:37540772	A/G	cg00129232	chr17:37814104	STARD3	0.54	5.79	0.35	2.23e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs1865760	0.865	rs9467652	chr6:25959127	A/G	cg17691542	chr6:26056736	HIST1H1C	0.58	7.36	0.43	3.14e-12	Height;
SARC	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg24531977	chr5:56204891	C5orf35	-0.56	-5.92	-0.36	1.16e-8	Initial pursuit acceleration;
SARC	cis	rs9399135	0.967	rs2297338	chr6:135375762	G/A	cg24558204	chr6:135376177	HBS1L	0.46	6.24	0.38	2.09e-9	Red blood cell count;
SARC	trans	rs61931739	0.817	rs1705754	chr12:34145569	A/G	cg13010199	chr12:38710504	ALG10B	0.56	7.44	0.44	1.9e-12	Morning vs. evening chronotype;
SARC	cis	rs7223966	1.000	rs15637	chr17:61772050	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.73	0.4	1.32e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6582630	0.537	rs1949611	chr12:38373092	C/T	cg26384229	chr12:38710491	ALG10B	-0.83	-12.14	-0.62	1.37e-26	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs7824557	0.778	rs6601572	chr8:11093337	C/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.25	-0.38	1.89e-9	Retinal vascular caliber;
SARC	cis	rs9354308	0.677	rs9363462	chr6:66557612	A/T	cg07460842	chr6:66804631	NA	-0.45	-5.13	-0.32	6.24e-7	Metabolite levels;
SARC	cis	rs6912958	0.754	rs6918909	chr6:88247251	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.51	-6.89	-0.41	5.29e-11	Monocyte percentage of white cells;
SARC	cis	rs9581943	0.901	rs9554188	chr13:28462132	G/A	cg25299895	chr13:28498091	PDX1	0.38	5.13	0.32	6.03e-7	Pancreatic cancer;
SARC	cis	rs617791	0.530	rs7934543	chr11:65752508	G/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.57	6.91	0.41	4.47e-11	Breast cancer;
SARC	cis	rs4642101	0.737	rs9877165	chr3:12828497	C/T	cg12400702	chr3:12838781	CAND2	-0.26	-5.29	-0.33	2.78e-7	QRS complex (12-leadsum);
SARC	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg25036284	chr2:26402008	FAM59B	-0.45	-5.54	-0.34	8.35e-8	Gut microbiome composition (summer);
SARC	cis	rs9309473	1.000	rs7582606	chr2:73813945	A/G	cg20560298	chr2:73613845	ALMS1	-0.48	-5.83	-0.36	1.85e-8	Metabolite levels;
SARC	cis	rs9325144	0.624	rs10506126	chr12:39123244	G/A	cg26384229	chr12:38710491	ALG10B	-0.57	-7.35	-0.43	3.35e-12	Morning vs. evening chronotype;
SARC	cis	rs9807989	0.507	rs6758936	chr2:102991369	A/G	cg03938978	chr2:103052716	IL18RAP	-0.32	-5.19	-0.32	4.56e-7	Asthma;
SARC	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg18252515	chr7:66147081	NA	-0.53	-5.7	-0.35	3.64e-8	Aortic root size;
SARC	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg18876405	chr7:65276391	NA	0.47	5.45	0.34	1.27e-7	Aortic root size;
SARC	cis	rs2304069	0.644	rs216131	chr5:149431223	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.56	5.39	0.33	1.75e-7	HIV-1 control;
SARC	cis	rs2278491	0.557	rs4876680	chr8:117777914	C/G	cg23513447	chr8:117778558	UTP23	-0.47	-5.16	-0.32	5.28e-7	Body mass index;
SARC	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg11987759	chr7:65425863	GUSB	0.62	8.25	0.48	1.21e-14	Aortic root size;
SARC	cis	rs11190604	1.000	rs11190602	chr10:102297256	T/C	cg07080220	chr10:102295463	HIF1AN	0.8	9.44	0.53	3.91e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg18305652	chr10:134549665	INPP5A	0.36	5.1	0.32	7.09e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs200895692	1	rs200895692	chr1:43421956	CGCCTGTAATCCCAG/C	cg03128534	chr1:43423976	SLC2A1	0.54	5.11	0.32	6.78e-7	Monocyte count;
SARC	cis	rs9896052	0.534	rs8065160	chr17:73441090	A/G	cg04121983	chr17:73511085	CASKIN2	-0.45	-5.28	-0.33	2.93e-7	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg14893161	chr1:205819251	PM20D1	0.64	8.52	0.49	2.06e-15	Menarche (age at onset);
SARC	cis	rs12421382	0.507	rs10890995	chr11:109327622	A/G	cg16359550	chr11:109292809	C11orf87	-0.41	-5.78	-0.35	2.42e-8	Schizophrenia;
SARC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	5.98	0.36	8.46e-9	Prudent dietary pattern;
SARC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg21747090	chr2:27597821	SNX17	-0.55	-7.68	-0.45	4.44e-13	Total body bone mineral density;
SARC	cis	rs4077341	1.000	rs4077341	chr8:22962348	G/T	cg03596993	chr8:23386458	SLC25A37	-0.41	-4.99	-0.31	1.16e-6	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
SARC	cis	rs950776	0.518	rs12916483	chr15:78832397	G/A	cg06917634	chr15:78832804	PSMA4	0.91	14.19	0.68	2.3e-33	Sudden cardiac arrest;
SARC	cis	rs7647973	0.925	rs9834003	chr3:49216472	T/C	cg07636037	chr3:49044803	WDR6	0.8	9.19	0.52	2.19e-17	Menarche (age at onset);
SARC	cis	rs13191362	0.688	rs73025321	chr6:162974896	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.57	4.87	0.3	2.06e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2730245	0.505	rs1188956	chr7:158690576	G/A	cg17136484	chr7:158649327	WDR60	0.43	4.93	0.31	1.54e-6	Height;
SARC	trans	rs4814920	0.756	rs1543472	chr20:19848027	C/T	cg01137401	chr3:147107349	ZIC4	0.51	6.26	0.38	1.81e-9	Bipolar disorder (body mass index interaction);
SARC	cis	rs1707322	1.000	rs4660334	chr1:46462126	A/C	cg03146154	chr1:46216737	IPP	0.45	5.32	0.33	2.4e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg26335602	chr6:28129616	ZNF389	0.52	5.84	0.36	1.75e-8	Depression;
SARC	cis	rs910316	0.967	rs10246	chr14:75544470	T/A	cg08847533	chr14:75593920	NEK9	0.94	15.68	0.72	2.68e-38	Height;
SARC	cis	rs526821	0.595	rs504661	chr11:55312683	A/G	cg04317927	chr11:55418816	OR4S2	0.39	5.74	0.35	2.93e-8	Pediatric bone mineral density (spine);
SARC	cis	rs27434	0.583	rs193482	chr5:96157846	A/G	cg16492584	chr5:96139282	ERAP1	-0.57	-7.11	-0.42	1.4e-11	Ankylosing spondylitis;
SARC	cis	rs13006833	0.694	rs291448	chr2:191177216	T/C	cg25963032	chr2:191064776	C2orf88	0.36	4.99	0.31	1.16e-6	Urinary metabolites;
SARC	cis	rs72627509	0.904	rs7687767	chr4:57824932	C/T	cg26694713	chr4:57773883	REST	-0.64	-6.64	-0.4	2.15e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs17253792	0.732	rs79014965	chr14:56117551	T/G	cg01858014	chr14:56050164	KTN1	-0.66	-5.09	-0.32	7.27e-7	Putamen volume;
SARC	trans	rs208520	0.754	rs1100989	chr6:66880532	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.09	-14.31	-0.68	9.05e-34	Exhaled nitric oxide output;
SARC	cis	rs290268	0.838	rs1319677	chr9:93565999	A/G	cg02608019	chr9:93564028	SYK	0.35	5.1	0.32	7.02e-7	Platelet count;
SARC	cis	rs963731	0.649	rs6704656	chr2:39210398	A/T	cg04010122	chr2:39346883	SOS1	0.89	4.9	0.31	1.82e-6	Corticobasal degeneration;
SARC	cis	rs9457247	0.663	rs9295384	chr6:167448113	T/A	cg23791538	chr6:167370224	RNASET2	-0.53	-7.06	-0.42	1.89e-11	Crohn's disease;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg25655799	chr10:79397930	KCNMA1	-0.51	-6.62	-0.4	2.47e-10	Electrocardiographic conduction measures;
SARC	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg20887711	chr4:1340912	KIAA1530	0.42	5.05	0.31	9.01e-7	Longevity;
SARC	cis	rs6834538	1.000	rs2351761	chr4:113447911	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.46	5.49	0.34	1.06e-7	Free thyroxine concentration;
SARC	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	16.12	0.73	8.93e-40	Chronic sinus infection;
SARC	cis	rs854765	0.583	rs66531105	chr17:17809001	C/T	cg05444541	chr17:17804740	TOM1L2	-0.3	-5.12	-0.32	6.26e-7	Total body bone mineral density;
SARC	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg00933542	chr6:150070202	PCMT1	0.31	5.36	0.33	2.04e-7	Lung cancer;
SARC	trans	rs3749237	1.000	rs1317140	chr3:49878652	G/A	cg21659725	chr3:3221576	CRBN	0.57	6.33	0.38	1.28e-9	Resting heart rate;
SARC	cis	rs10992471	0.756	rs7043152	chr9:95138499	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-6.69	-0.4	1.67e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg15921436	chr17:44337874	NA	0.53	5.36	0.33	2.02e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.99	11.36	0.6	4.27e-24	Platelet count;
SARC	cis	rs2916247	0.954	rs991871	chr8:93164505	T/A	cg10183463	chr8:93005414	RUNX1T1	0.46	4.88	0.3	1.99e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9916302	0.706	rs7208487	chr17:37543449	T/G	cg00129232	chr17:37814104	STARD3	0.54	5.79	0.35	2.23e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs11719291	0.915	rs9834996	chr3:48754877	G/T	cg06212747	chr3:49208901	KLHDC8B	-0.58	-5.24	-0.32	3.6e-7	Cognitive function;
SARC	cis	rs2243480	1.000	rs316315	chr7:65591205	C/T	cg12463550	chr7:65579703	CRCP	-0.55	-5.16	-0.32	5.31e-7	Diabetic kidney disease;
SARC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.79	-10.22	-0.56	1.68e-20	Prudent dietary pattern;
SARC	cis	rs9325144	0.555	rs4882284	chr12:38710459	C/T	cg04568710	chr12:38710424	ALG10B	-0.4	-5.08	-0.32	7.85e-7	Morning vs. evening chronotype;
SARC	cis	rs2115630	0.967	rs8028490	chr15:85277888	G/A	cg17507749	chr15:85114479	UBE2QP1	-0.47	-5.61	-0.35	5.68e-8	P wave terminal force;
SARC	cis	rs7086627	0.515	rs10887899	chr10:82210214	G/A	cg00277334	chr10:82204260	NA	-0.57	-9.34	-0.52	7.79e-18	Post bronchodilator FEV1;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg20919844	chr3:50388170	TUSC4;CYB561D2	0.5	6.57	0.4	3.26e-10	Chemerin levels;
SARC	cis	rs6908034	0.660	rs111231540	chr6:19802226	A/C	cg02682789	chr6:19804855	NA	0.71	5.1	0.32	7.14e-7	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	22.86	0.83	1.85e-61	Chronic sinus infection;
SARC	cis	rs9462027	0.630	rs2744943	chr6:34643179	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-6.02	-0.37	6.85e-9	Systemic lupus erythematosus;
SARC	cis	rs2882877	0.661	rs35623329	chr2:190443445	T/C	cg10752008	chr2:190445175	SLC40A1	0.44	5.19	0.32	4.58e-7	Mean corpuscular hemoglobin concentration;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg18570997	chr7:129710291	KLHDC10	-0.51	-6.77	-0.41	1.04e-10	Neuroticism;
SARC	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-5.0	-0.31	1.12e-6	Total body bone mineral density;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg20619563	chr6:84621458	CYB5R4	0.5	7.11	0.42	1.42e-11	Tetralogy of Fallot;
SARC	cis	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg25894440	chr7:65020034	NA	-0.67	-5.88	-0.36	1.39e-8	Diabetic kidney disease;
SARC	cis	rs703842	1.000	rs3825079	chr12:58203354	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.78	11.16	0.59	1.87e-23	Multiple sclerosis;
SARC	cis	rs6500602	0.679	rs736685	chr16:4508606	T/C	cg08645402	chr16:4508243	NA	0.47	6.25	0.38	1.99e-9	Schizophrenia;
SARC	cis	rs208520	1.000	rs208520	chr6:66952828	G/T	cg07460842	chr6:66804631	NA	-0.79	-8.8	-0.5	3.1e-16	Exhaled nitric oxide output;
SARC	cis	rs7647973	0.626	rs7649428	chr3:49868876	A/T	cg06212747	chr3:49208901	KLHDC8B	-0.6	-5.92	-0.36	1.13e-8	Menarche (age at onset);
SARC	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg15966229	chr18:44337664	ST8SIA5	-0.37	-4.81	-0.3	2.68e-6	Personality dimensions;
SARC	cis	rs7618501	0.966	rs2246832	chr3:49881134	A/T	cg13072238	chr3:49761600	GMPPB	0.47	6.05	0.37	5.74e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7762018	0.607	rs78941587	chr6:170061157	G/C	cg14662283	chr6:170068385	WDR27	-0.66	-4.74	-0.3	3.7e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs7523050	0.643	rs35885176	chr1:109401868	G/A	cg08274380	chr1:109419600	GPSM2	1.03	7.67	0.45	4.7e-13	Fat distribution (HIV);
SARC	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg11764359	chr7:65958608	NA	-0.72	-8.42	-0.48	3.77e-15	Aortic root size;
SARC	cis	rs7843479	0.965	rs17581910	chr8:21799626	A/G	cg17168535	chr8:21777572	XPO7	0.63	8.06	0.47	3.85e-14	Mean corpuscular volume;
SARC	cis	rs3008870	1.000	rs2985794	chr1:67425311	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.92	11.37	0.6	3.93e-24	Lymphocyte percentage of white cells;
SARC	cis	rs2832191	0.692	rs2245734	chr21:30359965	C/T	cg08807101	chr21:30365312	RNF160	0.9	14.31	0.68	9.14e-34	Dental caries;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg00939558	chr1:154301037	ATP8B2	0.48	6.51	0.39	4.44e-10	Thyroid stimulating hormone;
SARC	cis	rs6088580	0.634	rs6088478	chr20:32971719	T/C	cg24642439	chr20:33292090	TP53INP2	-0.65	-8.43	-0.48	3.57e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg04999588	chr10:65390179	NA	-0.52	-4.81	-0.3	2.73e-6	Cutaneous psoriasis;
SARC	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1348850	0.914	rs1348849	chr2:178358072	C/T	cg23306229	chr2:178417860	TTC30B	0.57	6.67	0.4	1.8e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs6815814	0.950	rs56408159	chr4:38812116	T/A	cg02016764	chr4:38805732	TLR1	-0.41	-4.86	-0.3	2.18e-6	Breast cancer;
SARC	cis	rs854765	0.547	rs9896837	chr17:17924868	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.4	4.88	0.3	1.94e-6	Total body bone mineral density;
SARC	cis	rs72945132	1.000	rs7938912	chr11:70114885	C/T	cg00319359	chr11:70116639	PPFIA1	0.72	6.75	0.4	1.14e-10	Coronary artery disease;
SARC	cis	rs2204008	0.837	rs12370891	chr12:37984531	A/G	cg13010199	chr12:38710504	ALG10B	0.78	10.71	0.57	5.11e-22	Bladder cancer;
SARC	cis	rs3737883	1.000	rs7538696	chr1:203034309	G/A	cg03900565	chr1:203031815	PPFIA4	0.34	5.33	0.33	2.36e-7	Early onset atrial fibrillation;
SARC	cis	rs4972806	0.814	rs1446575	chr2:177047801	A/C	cg14236662	chr2:176988284	HOXD9	0.34	4.79	0.3	2.93e-6	IgG glycosylation;
SARC	cis	rs9640161	0.742	rs2159236	chr7:150017214	A/G	cg21361702	chr7:150065534	REPIN1	0.47	4.93	0.31	1.54e-6	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs3126085	0.935	rs11204947	chr1:152218257	G/T	cg03465714	chr1:152285911	FLG	0.49	5.78	0.35	2.41e-8	Atopic dermatitis;
SARC	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg11843238	chr5:131593191	PDLIM4	0.39	4.9	0.31	1.76e-6	Breast cancer;
SARC	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg06028808	chr11:68637592	NA	0.47	5.79	0.35	2.23e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg12419862	chr22:24373484	LOC391322	-0.73	-9.2	-0.52	2.06e-17	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6772849	1.000	rs66910450	chr3:128303893	C/T	cg08795948	chr3:128337044	NA	0.38	4.98	0.31	1.27e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs10992471	0.603	rs10992342	chr9:95212068	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.25	-0.33	3.41e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs3126085	0.935	rs7531094	chr1:152176850	A/G	cg03465714	chr1:152285911	FLG	-0.47	-5.62	-0.35	5.47e-8	Atopic dermatitis;
SARC	cis	rs9894429	0.646	rs8080391	chr17:79566319	A/T	cg21984481	chr17:79567631	NPLOC4	0.35	4.83	0.3	2.53e-6	Eye color traits;
SARC	cis	rs11792861	0.591	rs4978763	chr9:111728067	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.78	9.93	0.55	1.29e-19	Menarche (age at onset);
SARC	cis	rs9309473	0.948	rs11884776	chr2:73746923	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-5.74	-0.35	2.95e-8	Metabolite levels;
SARC	cis	rs2439831	1.000	rs2584726	chr15:43715382	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.09	11.42	0.6	2.73e-24	Lung cancer in ever smokers;
SARC	cis	rs6570726	0.935	rs407721	chr6:145871354	A/C	cg23711669	chr6:146136114	FBXO30	0.78	11.99	0.62	4.06e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7937682	0.737	rs663763	chr11:111422217	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.68	-9.78	-0.54	3.87e-19	Primary sclerosing cholangitis;
SARC	cis	rs73206853	0.841	rs16940933	chr12:111102574	C/A	cg10860002	chr12:110842031	ANAPC7	0.57	4.78	0.3	3.06e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs898097	0.812	rs8065641	chr17:80820259	A/G	cg20578329	chr17:80767326	TBCD	-0.47	-6.5	-0.39	4.92e-10	Breast cancer;
SARC	cis	rs9916302	0.706	rs9909304	chr17:37500508	G/T	cg00129232	chr17:37814104	STARD3	0.53	5.69	0.35	3.85e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs698813	0.851	rs786420	chr2:44719893	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.44	0.34	1.37e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs1957429	0.614	rs73279823	chr14:65351315	A/G	cg23373153	chr14:65346875	NA	-1.01	-7.74	-0.45	3.04e-13	Pediatric areal bone mineral density (radius);
SARC	cis	rs12155623	0.504	rs10808736	chr8:49873039	C/A	cg22283653	chr8:49824208	NA	0.41	6.1	0.37	4.42e-9	Sudden cardiac arrest;
SARC	cis	rs2425143	0.908	rs6060632	chr20:34422601	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-6.33	-0.38	1.22e-9	Blood protein levels;
SARC	cis	rs858239	0.600	rs7785842	chr7:23141706	T/A	cg23682824	chr7:23144976	KLHL7	0.69	9.39	0.52	5.65e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs6088580	0.634	rs6059779	chr20:32950325	C/T	cg24642439	chr20:33292090	TP53INP2	-0.67	-8.62	-0.49	1.02e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.68	-8.96	-0.51	1.05e-16	Total body bone mineral density;
SARC	cis	rs4925386	0.840	rs8124907	chr20:60913127	A/G	cg24112000	chr20:60950667	NA	-0.4	-6.14	-0.37	3.61e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs546131	0.928	rs550313	chr11:34830919	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.48	5.99	0.37	7.73e-9	Lung disease severity in cystic fibrosis;
SARC	trans	rs7131987	0.903	rs1035604	chr12:29393102	G/A	cg03755522	chr8:41585237	ANK1	0.45	6.25	0.38	1.97e-9	QT interval;
SARC	cis	rs1348850	0.632	rs4470372	chr2:178505857	G/A	cg22681709	chr2:178499509	PDE11A	-0.42	-5.73	-0.35	3.11e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9420	0.784	rs12798206	chr11:57668479	T/G	cg23127183	chr11:57508653	C11orf31	-0.54	-5.39	-0.33	1.72e-7	Schizophrenia;
SARC	cis	rs7769051	0.522	rs6934190	chr6:133116664	G/A	cg07930552	chr6:133119739	C6orf192	1.01	5.99	0.37	7.7e-9	Type 2 diabetes nephropathy;
SARC	cis	rs4443100	0.535	rs13055979	chr22:23474085	C/T	cg14186256	chr22:23484241	RTDR1	0.51	5.55	0.34	7.75e-8	Serum parathyroid hormone levels;
SARC	cis	rs7772486	0.875	rs10872583	chr6:146396699	G/T	cg23711669	chr6:146136114	FBXO30	-0.78	-12.46	-0.63	1.19e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11190604	0.767	rs4919458	chr10:102177728	G/A	cg07080220	chr10:102295463	HIF1AN	-0.7	-8.5	-0.49	2.36e-15	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs2153535	0.526	rs7748404	chr6:8472500	A/T	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.04e-14	Motion sickness;
SARC	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg16325326	chr1:53192061	ZYG11B	-0.8	-12.8	-0.64	9.58e-29	Monocyte count;
SARC	cis	rs4642101	0.686	rs9822382	chr3:12828828	T/G	cg05775895	chr3:12838266	CAND2	0.75	12.1	0.62	1.78e-26	QRS complex (12-leadsum);
SARC	cis	rs1008375	0.902	rs12503164	chr4:17656107	C/T	cg16339924	chr4:17578868	LAP3	0.66	8.83	0.5	2.57e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg17221315	chr6:27791827	HIST1H4J	0.46	4.79	0.3	2.99e-6	Depression;
SARC	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg12463550	chr7:65579703	CRCP	0.48	5.23	0.32	3.76e-7	Aortic root size;
SARC	cis	rs25645	0.744	rs66826786	chr17:38206092	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.38	6.91	0.41	4.56e-11	Myeloid white cell count;
SARC	cis	rs3771570	1.000	rs1984598	chr2:242284824	G/A	cg21155796	chr2:242212141	HDLBP	0.58	5.45	0.34	1.25e-7	Prostate cancer;
SARC	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	9.58	0.53	1.54e-18	Platelet count;
SARC	cis	rs10191773	0.589	rs72831638	chr2:112949212	C/G	cg07905836	chr2:113190072	RGPD8;RGPD5	0.96	8.02	0.47	5.17e-14	Yeast infection;
SARC	cis	rs11578119	0.902	rs12138138	chr1:170420921	C/T	cg09767346	chr1:170501363	GORAB	0.44	5.23	0.32	3.78e-7	Male-pattern baldness;
SARC	cis	rs9300255	0.602	rs1790126	chr12:123683563	C/T	cg05973401	chr12:123451056	ABCB9	0.52	5.89	0.36	1.34e-8	Neutrophil percentage of white cells;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg19768357	chr5:77072009	TBCA	0.5	6.79	0.41	9.37e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs9527	0.590	rs12414232	chr10:104914491	A/T	cg04362960	chr10:104952993	NT5C2	0.45	5.22	0.32	3.93e-7	Arsenic metabolism;
SARC	cis	rs35160687	0.814	rs1863063	chr2:86518249	A/C	cg10973622	chr2:86423274	IMMT	0.41	5.52	0.34	8.97e-8	Night sleep phenotypes;
SARC	cis	rs208520	0.690	rs851467	chr6:66802721	A/G	cg07460842	chr6:66804631	NA	-1.08	-14.98	-0.7	5.37e-36	Exhaled nitric oxide output;
SARC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg06074448	chr4:187884817	NA	-0.38	-5.18	-0.32	4.69e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg24060327	chr5:131705240	SLC22A5	-0.71	-8.69	-0.49	6.4e-16	Breast cancer;
SARC	cis	rs1559088	0.600	rs6510344	chr19:33583942	C/A	cg17764715	chr19:33622953	WDR88	0.57	7.97	0.46	7.22e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs9393692	0.645	rs766407	chr6:26319534	T/C	cg05868516	chr6:26286170	HIST1H4H	0.48	5.56	0.34	7.31e-8	Educational attainment;
SARC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg20007245	chr22:24372913	LOC391322	-0.69	-8.41	-0.48	4.16e-15	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1580019	0.665	rs34147895	chr7:32531796	G/C	cg07520158	chr7:32535189	LSM5;AVL9	0.59	7.41	0.44	2.3e-12	Cognitive ability;
SARC	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg11764359	chr7:65958608	NA	-0.67	-7.95	-0.46	7.87e-14	Aortic root size;
SARC	cis	rs9816226	1.000	rs73052033	chr3:185828465	T/C	cg00760338	chr3:185826511	ETV5	-0.89	-9.58	-0.53	1.55e-18	Obesity;Body mass index;
SARC	cis	rs12780845	0.505	rs11254394	chr10:17183072	G/A	cg11116878	chr10:17243438	TRDMT1	0.4	4.88	0.3	1.99e-6	Homocysteine levels;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg22505778	chr3:113822317	NA	-0.81	-6.78	-0.41	9.97e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2197308	0.692	rs7488528	chr12:37912971	G/A	cg13010199	chr12:38710504	ALG10B	0.79	10.89	0.58	1.33e-22	Morning vs. evening chronotype;
SARC	cis	rs4243830	0.571	rs60256927	chr1:6614747	G/A	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.66	-5.3	-0.33	2.64e-7	Body mass index;
SARC	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.97	-15.87	-0.72	5.95e-39	Chronic sinus infection;
SARC	cis	rs9389248	0.690	rs6569982	chr6:135256495	C/G	cg22676075	chr6:135203613	NA	0.4	5.3	0.33	2.66e-7	High light scatter reticulocyte percentage of red cells;
SARC	cis	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg18252515	chr7:66147081	NA	-1.41	-12.63	-0.64	3.24e-28	Gout;
SARC	cis	rs3815700	0.764	rs259234	chr19:33121729	A/C	cg02997394	chr19:33096574	ANKRD27	-0.61	-4.93	-0.31	1.59e-6	Eosinophilic esophagitis;
SARC	cis	rs9479482	0.935	rs9479507	chr6:150366514	T/G	cg03788504	chr6:150331562	NA	-0.33	-5.35	-0.33	2.06e-7	Alopecia areata;
SARC	cis	rs8017423	0.935	rs716122	chr14:90792313	A/C	cg20276874	chr14:90721474	PSMC1	0.38	5.01	0.31	1.07e-6	Mortality in heart failure;
SARC	cis	rs7833790	1.000	rs7833384	chr8:82730915	T/C	cg27398817	chr8:82754497	SNX16	-0.5	-5.54	-0.34	8.19e-8	Diastolic blood pressure;
SARC	cis	rs11098499	0.863	rs36040693	chr4:120477616	A/G	cg09307838	chr4:120376055	NA	0.91	12.25	0.63	5.66e-27	Corneal astigmatism;
SARC	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg05025164	chr4:1340916	KIAA1530	0.61	7.62	0.45	6.43e-13	Longevity;
SARC	cis	rs1256061	0.654	rs1256040	chr14:64738394	G/A	cg23250157	chr14:64679961	SYNE2	0.46	6.45	0.39	6.38e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg24549020	chr5:56110836	MAP3K1	0.81	8.4	0.48	4.37e-15	Initial pursuit acceleration;
SARC	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg27541892	chr1:1571801	CDK11B	0.41	5.65	0.35	4.59e-8	Body mass index;
SARC	cis	rs7100689	0.725	rs2185425	chr10:82139941	T/C	cg01528321	chr10:82214614	TSPAN14	0.81	11.35	0.6	4.56e-24	Post bronchodilator FEV1;
SARC	cis	rs7178572	0.568	rs8030074	chr15:77654232	C/T	cg22256960	chr15:77711686	NA	-0.52	-5.73	-0.35	3.07e-8	Type 2 diabetes;
SARC	cis	rs4253772	0.592	rs1807600	chr22:46644640	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.5	5.24	0.32	3.55e-7	LDL cholesterol;Cholesterol, total;
SARC	cis	rs1570884	0.556	rs2146146	chr13:50170368	C/T	cg08779649	chr13:50194554	NA	0.37	6.4	0.39	8.38e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg21782813	chr7:2030301	MAD1L1	-0.33	-5.06	-0.31	8.67e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs2486288	0.656	rs11631021	chr15:45556829	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.5	-6.42	-0.39	7.53e-10	Glomerular filtration rate;
SARC	cis	rs611744	0.967	rs689256	chr8:109186398	T/A	cg21045802	chr8:109455806	TTC35	0.44	5.3	0.33	2.64e-7	Dupuytren's disease;
SARC	cis	rs35110281	0.600	rs11089092	chr21:45120994	A/C	cg04455712	chr21:45112962	RRP1B	0.34	4.8	0.3	2.79e-6	Mean corpuscular volume;
SARC	trans	rs11098499	0.954	rs28429722	chr4:120300093	G/A	cg25214090	chr10:38739885	LOC399744	0.55	7.14	0.42	1.15e-11	Corneal astigmatism;
SARC	cis	rs929354	0.707	rs1182445	chr7:157024428	C/G	cg05182265	chr7:156933206	UBE3C	0.32	4.82	0.3	2.59e-6	Body mass index;
SARC	cis	rs2370759	1.000	rs11597888	chr10:32635834	G/A	cg05361325	chr10:32636312	EPC1	-0.76	-6.75	-0.4	1.15e-10	Sexual dysfunction (female);
SARC	cis	rs11098499	0.743	rs10003567	chr4:120241674	C/T	cg09307838	chr4:120376055	NA	0.81	11.15	0.59	2.11e-23	Corneal astigmatism;
SARC	trans	rs10929925	0.522	rs10929929	chr2:6161125	C/T	cg25116709	chr5:122426797	PRDM6	-0.42	-6.31	-0.38	1.42e-9	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
SARC	cis	rs7607369	0.718	rs6727147	chr2:219639024	G/A	cg02176678	chr2:219576539	TTLL4	-0.33	-5.03	-0.31	9.92e-7	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.44	-5.36	-0.33	1.97e-7	Lymphocyte counts;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg25097514	chr2:219157373	TMBIM1;PNKD	-0.52	-6.44	-0.39	6.65e-10	Height;
SARC	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg18252515	chr7:66147081	NA	-1.34	-11.86	-0.61	1.09e-25	Diabetic kidney disease;
SARC	cis	rs17854409	1.000	rs6011427	chr20:61496680	C/T	cg05147244	chr20:61493195	TCFL5	0.82	5.75	0.35	2.84e-8	Obesity-related traits;
SARC	cis	rs9914988	0.943	rs4795457	chr17:27087929	C/T	cg20469991	chr17:27169893	C17orf63	-0.53	-5.62	-0.35	5.46e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs28795989	0.896	rs7687431	chr4:7889492	T/C	cg18538662	chr4:7941764	AFAP1	-0.37	-4.75	-0.3	3.62e-6	Intraocular pressure;
SARC	cis	rs12915189	0.756	rs6496693	chr15:91119125	G/A	cg26821196	chr15:91095069	CRTC3	0.47	5.36	0.33	2.03e-7	Information processing speed;
SARC	cis	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg24110177	chr3:50126178	RBM5	-0.62	-8.1	-0.47	3.15e-14	Body mass index;
SARC	cis	rs17539620	0.624	rs871068	chr6:154837514	C/A	cg17771515	chr6:154831774	CNKSR3	0.53	5.07	0.32	8.2e-7	Lipoprotein (a) levels;
SARC	cis	rs7592578	0.771	rs12052514	chr2:191378170	C/T	cg10560079	chr2:191398806	TMEM194B	-0.78	-8.66	-0.49	8.14e-16	Diastolic blood pressure;
SARC	cis	rs9948	0.786	rs62156227	chr2:97417942	C/A	cg01990225	chr2:97406019	LMAN2L	-0.97	-6.96	-0.42	3.35e-11	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs7927592	0.913	rs55883802	chr11:68278829	G/A	cg01657329	chr11:68192670	LRP5	-0.41	-5.01	-0.31	1.08e-6	Total body bone mineral density;
SARC	cis	rs769267	0.598	rs8108705	chr19:19675367	G/T	cg03709012	chr19:19516395	GATAD2A	-0.76	-10.0	-0.55	8.1e-20	Tonsillectomy;
SARC	cis	rs10791097	0.667	rs1893019	chr11:130756664	C/G	cg12179176	chr11:130786555	SNX19	0.76	11.42	0.6	2.81e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs8067545	0.611	rs733794	chr17:20157957	T/C	cg13482628	chr17:19912719	NA	-0.57	-7.54	-0.44	1.02e-12	Schizophrenia;
SARC	cis	rs7084402	0.934	rs1658426	chr10:60331542	A/T	cg07615347	chr10:60278583	BICC1	0.57	8.41	0.48	4.23e-15	Refractive error;
SARC	cis	rs858239	0.600	rs28646184	chr7:23139595	T/C	cg23682824	chr7:23144976	KLHL7	0.7	9.63	0.53	1.09e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg03060546	chr3:49711283	APEH	-0.67	-8.37	-0.48	5.47e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs4969178	0.965	rs12450500	chr17:76395750	C/T	cg02836325	chr17:76403955	PGS1	0.33	5.01	0.31	1.07e-6	HDL cholesterol levels;
SARC	cis	rs2075371	0.734	rs13225086	chr7:134011411	C/T	cg11752832	chr7:134001865	SLC35B4	0.57	7.14	0.42	1.16e-11	Mean platelet volume;
SARC	cis	rs7914558	0.966	rs746293	chr10:104897254	G/T	cg04362960	chr10:104952993	NT5C2	0.42	5.03	0.31	9.64e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs9325144	0.600	rs1817648	chr12:38733424	C/T	cg26384229	chr12:38710491	ALG10B	-0.57	-7.44	-0.44	1.95e-12	Morning vs. evening chronotype;
SARC	cis	rs79149102	0.579	rs58645417	chr15:75325858	T/G	cg09165964	chr15:75287851	SCAMP5	-1.02	-8.98	-0.51	9.6e-17	Lung cancer;
SARC	cis	rs116095464	0.558	rs9312956	chr5:201812	T/C	cg22496380	chr5:211416	CCDC127	-0.91	-8.14	-0.47	2.41e-14	Breast cancer;
SARC	cis	rs2075371	0.501	rs1643057	chr7:134027521	A/G	cg20476274	chr7:133979776	SLC35B4	0.4	5.09	0.32	7.28e-7	Mean platelet volume;
SARC	cis	rs17095355	1.000	rs7068482	chr10:111729503	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.43	-4.83	-0.3	2.46e-6	Biliary atresia;
SARC	cis	rs4568518	0.869	rs12699942	chr7:18037685	C/T	cg00911873	chr7:18067463	PRPS1L1	-0.33	-4.72	-0.3	4.04e-6	Measles;
SARC	cis	rs921968	0.541	rs72965126	chr2:219330189	C/T	cg02176678	chr2:219576539	TTLL4	-0.5	-7.61	-0.45	6.69e-13	Mean corpuscular hemoglobin concentration;
SARC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.43	-6.58	-0.4	3.16e-10	Total body bone mineral density;
SARC	cis	rs11098499	0.955	rs11931312	chr4:120159023	T/C	cg24375607	chr4:120327624	NA	0.39	4.72	0.3	4.14e-6	Corneal astigmatism;
SARC	cis	rs9768139	0.708	rs11769028	chr7:158113881	G/A	cg25566285	chr7:158114605	PTPRN2	0.34	5.85	0.36	1.66e-8	Calcium levels;
SARC	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg06212747	chr3:49208901	KLHDC8B	0.51	6.48	0.39	5.37e-10	Resting heart rate;
SARC	cis	rs2832191	0.791	rs2832196	chr21:30497412	G/A	cg24692254	chr21:30365293	RNF160	-0.84	-11.9	-0.61	8.06e-26	Dental caries;
SARC	cis	rs1348850	0.519	rs4144275	chr2:178523368	C/T	cg22681709	chr2:178499509	PDE11A	-0.34	-4.8	-0.3	2.87e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs13144136	0.687	rs11737643	chr4:10658199	T/A	cg10242279	chr4:10666415	CLNK	-0.43	-7.09	-0.42	1.56e-11	Resistance to antihypertensive treatment in hypertension;
SARC	cis	rs1865760	0.532	rs1061482	chr6:26086699	G/T	cg10373733	chr6:25993375	NA	0.46	5.58	0.34	6.74e-8	Height;
SARC	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg26116260	chr4:7069785	GRPEL1	0.94	11.68	0.61	3.98e-25	Monocyte percentage of white cells;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14074924	chr1:1167315	SDF4;B3GALT6	0.54	6.66	0.4	1.9e-10	Smoking initiation;
SARC	cis	rs6582630	0.555	rs7305352	chr12:38473800	T/C	cg13010199	chr12:38710504	ALG10B	0.77	10.35	0.56	6.77e-21	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs921968	0.541	rs526897	chr2:219433597	C/T	cg02176678	chr2:219576539	TTLL4	0.49	7.29	0.43	4.67e-12	Mean corpuscular hemoglobin concentration;
SARC	cis	rs8031584	0.918	rs34693097	chr15:31253984	A/G	cg08109568	chr15:31115862	NA	-0.47	-5.84	-0.36	1.73e-8	Huntington's disease progression;
SARC	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.46	6.1	0.37	4.46e-9	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs17376456	1.000	rs13154249	chr5:93550508	C/T	cg21475434	chr5:93447410	FAM172A	0.95	8.25	0.48	1.16e-14	Diabetic retinopathy;
SARC	cis	rs651907	0.557	rs2318090	chr3:101474933	A/G	cg12386194	chr3:101231763	SENP7	0.48	5.68	0.35	3.93e-8	Colorectal cancer;
SARC	cis	rs3820928	1.000	rs10204368	chr2:227774244	G/C	cg05526886	chr2:227700861	RHBDD1	-0.5	-6.11	-0.37	4.08e-9	Pulmonary function;
SARC	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg12648201	chr2:27665141	KRTCAP3	-0.32	-4.84	-0.3	2.36e-6	Total body bone mineral density;
SARC	cis	rs503734	0.521	rs546105	chr3:100967920	A/G	cg27318481	chr3:100970896	IMPG2	-0.43	-4.96	-0.31	1.39e-6	Inflammatory bowel disease;Crohn's disease;
SARC	trans	rs2727020	0.575	rs10769587	chr11:49549849	C/G	cg15704280	chr7:45808275	SEPT13	-0.81	-13.14	-0.65	7.3e-30	Coronary artery disease;
SARC	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg20102877	chr2:27665638	KRTCAP3	-0.33	-4.73	-0.3	3.92e-6	Total body bone mineral density;
SARC	trans	rs1994135	0.715	rs10844625	chr12:33693006	C/T	cg13010199	chr12:38710504	ALG10B	0.61	7.21	0.43	7.86e-12	Resting heart rate;
SARC	cis	rs72781680	0.611	rs4149373	chr2:24300023	C/T	cg06627628	chr2:24431161	ITSN2	-0.57	-5.92	-0.36	1.13e-8	Lymphocyte counts;
SARC	cis	rs7246657	0.638	rs7246461	chr19:38196581	C/G	cg23950597	chr19:37808831	NA	0.49	4.74	0.3	3.75e-6	Coronary artery calcification;
SARC	cis	rs9875589	0.509	rs11718142	chr3:14018793	G/T	cg19554555	chr3:13937349	NA	-0.41	-5.4	-0.33	1.64e-7	Ovarian reserve;
SARC	cis	rs4646312	0.588	rs9332332	chr22:19935071	G/A	cg07194846	chr22:19930177	COMT;TXNRD2	0.5	6.27	0.38	1.72e-9	Schizophrenia;
SARC	cis	rs7666738	0.791	rs1896156	chr4:99020882	C/G	cg05340658	chr4:99064831	C4orf37	0.66	9.04	0.51	6.35e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1153858	1.000	rs28679834	chr15:45616206	C/T	cg26924012	chr15:45694286	SPATA5L1	0.76	10.26	0.56	1.24e-20	Homoarginine levels;
SARC	cis	rs56235845	0.694	rs11738681	chr5:176761535	A/G	cg06060754	chr5:176797920	RGS14	0.44	5.82	0.36	1.96e-8	Hemoglobin concentration;Hematocrit;
SARC	cis	rs4774830	0.744	rs17819312	chr15:56297427	G/A	cg24530489	chr15:56299380	NA	-0.93	-4.87	-0.3	2.1e-6	Delta-5 desaturase activity;
SARC	cis	rs854765	0.583	rs4925126	chr17:17798633	C/T	cg04398451	chr17:18023971	MYO15A	-0.41	-5.77	-0.35	2.5e-8	Total body bone mineral density;
SARC	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg16414030	chr3:133502952	NA	-0.46	-6.12	-0.37	3.98e-9	Iron status biomarkers;
SARC	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg19223190	chr17:80058835	NA	0.43	6.05	0.37	5.72e-9	Life satisfaction;
SARC	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg09455208	chr3:40491958	NA	-0.37	-5.66	-0.35	4.41e-8	Renal cell carcinoma;
SARC	cis	rs7772486	0.641	rs9390370	chr6:146357569	C/T	cg23711669	chr6:146136114	FBXO30	0.74	10.17	0.55	2.43e-20	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11190604	0.767	rs74869390	chr10:102189385	A/G	cg07080220	chr10:102295463	HIF1AN	0.72	8.28	0.48	9.7e-15	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs3733585	0.746	rs4318650	chr4:10016868	T/C	cg00071950	chr4:10020882	SLC2A9	0.32	4.88	0.3	1.93e-6	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg17178900	chr1:205818956	PM20D1	0.39	5.05	0.31	8.96e-7	Menarche (age at onset);
SARC	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg11062466	chr8:58055876	NA	0.61	5.75	0.35	2.74e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7512552	0.646	rs1694367	chr1:150329469	T/A	cg15654264	chr1:150340011	RPRD2	0.38	4.83	0.3	2.49e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs7589728	0.844	rs2363010	chr2:88496399	G/C	cg04511125	chr2:88470314	THNSL2	0.77	6.69	0.4	1.61e-10	Plasma clusterin levels;
SARC	cis	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.04	-0.37	6.14e-9	Joint mobility (Beighton score);
SARC	cis	rs193541	0.545	rs12518979	chr5:122181787	G/T	cg19412675	chr5:122181750	SNX24	-0.5	-6.64	-0.4	2.16e-10	Glucose homeostasis traits;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg27395288	chr20:31407532	MAPRE1	-0.52	-6.84	-0.41	6.94e-11	Thyroid stimulating hormone;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg00465337	chr10:15145341	RPP38	0.49	6.28	0.38	1.64e-9	Breast cancer;
SARC	cis	rs11719291	0.915	rs11557629	chr3:48732223	G/A	cg00383909	chr3:49044727	WDR6	0.63	5.84	0.36	1.71e-8	Cognitive function;
SARC	cis	rs6570726	1.000	rs374464	chr6:145846679	A/C	cg05347473	chr6:146136440	FBXO30	0.49	6.52	0.39	4.27e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg09021430	chr5:549028	NA	-0.45	-5.72	-0.35	3.18e-8	Lung disease severity in cystic fibrosis;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg16752778	chr1:77685229	PIGK	-0.51	-7.37	-0.43	2.93e-12	Neuroticism;
SARC	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg08219700	chr8:58056026	NA	0.49	5.02	0.31	1.01e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs67460515	0.892	rs13059340	chr3:161062631	T/C	cg17135325	chr3:160939158	NMD3	0.63	8.05	0.47	4.19e-14	Parkinson's disease;
SARC	cis	rs11718455	0.960	rs11917885	chr3:44008013	A/G	cg08738300	chr3:44038990	NA	-0.54	-6.07	-0.37	5.26e-9	Coronary artery disease;
SARC	cis	rs2153535	0.580	rs9406163	chr6:8466642	C/T	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs748404	0.560	rs1869258	chr15:43803621	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.41	4.75	0.3	3.56e-6	Lung cancer;
SARC	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg05872129	chr22:39784769	NA	-0.45	-6.53	-0.39	4.1e-10	Intelligence (multi-trait analysis);
SARC	cis	rs17376456	0.932	rs3940842	chr5:93534858	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.61	5.23	0.32	3.75e-7	Diabetic retinopathy;
SARC	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg18252515	chr7:66147081	NA	0.51	5.77	0.35	2.55e-8	Aortic root size;
SARC	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg09359103	chr1:154839909	KCNN3	-0.46	-7.63	-0.45	5.84e-13	Prostate cancer;
SARC	cis	rs10876993	0.855	rs1689601	chr12:58049557	G/A	cg18357645	chr12:58087776	OS9	0.47	6.11	0.37	4.09e-9	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs9650657	0.812	rs10089615	chr8:10634132	C/T	cg21775007	chr8:11205619	TDH	-0.38	-4.79	-0.3	3.01e-6	Neuroticism;
SARC	cis	rs12908161	0.959	rs11637728	chr15:85203392	A/T	cg17507749	chr15:85114479	UBE2QP1	0.59	6.75	0.4	1.16e-10	Schizophrenia;
SARC	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg22804935	chr4:926322	TMEM175;GAK	-0.51	-6.54	-0.39	3.93e-10	Thyroid cancer;
SARC	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	7.3	0.43	4.53e-12	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs1865760	0.593	rs2097273	chr6:25941310	A/C	cg17691542	chr6:26056736	HIST1H1C	0.56	7.1	0.42	1.51e-11	Height;
SARC	cis	rs3126085	0.935	rs10888471	chr1:152200849	G/T	cg03465714	chr1:152285911	FLG	0.41	5.38	0.33	1.78e-7	Atopic dermatitis;
SARC	cis	rs2228479	0.850	rs17233497	chr16:89815152	G/A	cg06558623	chr16:89946397	TCF25	0.9	6.1	0.37	4.39e-9	Skin colour saturation;
SARC	cis	rs8078723	1.000	rs4795416	chr17:38158133	C/T	cg17467752	chr17:38218738	THRA	0.46	5.89	0.36	1.31e-8	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs9788721	0.630	rs77681598	chr15:78906103	C/A	cg06917634	chr15:78832804	PSMA4	-0.79	-11.58	-0.6	8.55e-25	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs7219021	0.518	rs6504584	chr17:46941419	G/T	cg07967210	chr17:47022446	SNF8	-0.41	-5.36	-0.33	1.97e-7	Schizophrenia or bipolar disorder;
SARC	cis	rs9650315	0.530	rs68005065	chr8:57090308	C/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.49	4.77	0.3	3.31e-6	Height;
SARC	trans	rs61931739	0.534	rs10844816	chr12:34248533	C/A	cg26384229	chr12:38710491	ALG10B	0.83	12.05	0.62	2.56e-26	Morning vs. evening chronotype;
SARC	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg15049968	chr18:44337910	ST8SIA5	-0.35	-5.48	-0.34	1.11e-7	Personality dimensions;
SARC	cis	rs7219021	0.811	rs3959442	chr17:46894377	A/C	cg16584676	chr17:46985605	UBE2Z	-0.41	-4.72	-0.3	4.1e-6	Schizophrenia or bipolar disorder;
SARC	cis	rs4268898	0.552	rs12621083	chr2:24367540	C/T	cg06627628	chr2:24431161	ITSN2	0.48	6.22	0.38	2.29e-9	Asthma;
SARC	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg03709012	chr19:19516395	GATAD2A	1.0	17.34	0.75	7.93e-44	Tonsillectomy;
SARC	cis	rs4072980	0.524	rs28442147	chr1:38395410	T/A	cg12658694	chr1:38397304	INPP5B	0.72	8.28	0.48	9.45e-15	Coronary artery disease;
SARC	cis	rs1707322	1.000	rs785519	chr1:46568562	C/T	cg03146154	chr1:46216737	IPP	-0.48	-5.8	-0.36	2.13e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs35213789	0.920	rs2159679	chr7:69314965	A/G	cg10619644	chr7:69149951	AUTS2	0.46	5.54	0.34	8.09e-8	Childhood ear infection;
SARC	cis	rs240764	0.817	rs239249	chr6:101087081	G/A	cg09795085	chr6:101329169	ASCC3	0.46	6.01	0.37	6.98e-9	Neuroticism;
SARC	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg20607798	chr8:58055168	NA	0.57	5.33	0.33	2.27e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10911232	0.507	rs10797820	chr1:183011366	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.44	0.56	3.45e-21	Hypertriglyceridemia;
SARC	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg00149659	chr3:10157352	C3orf10	0.68	6.38	0.39	9.46e-10	Alzheimer's disease;
SARC	cis	rs10089	1.000	rs72794401	chr5:127517626	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	8.74	0.5	4.54e-16	Ileal carcinoids;
SARC	cis	rs7412746	0.658	rs6677420	chr1:150946490	G/A	cg10589385	chr1:150898437	SETDB1	0.41	5.3	0.33	2.71e-7	Melanoma;
SARC	trans	rs61931739	0.534	rs11052983	chr12:34045787	C/A	cg26384229	chr12:38710491	ALG10B	0.75	10.68	0.57	6.46e-22	Morning vs. evening chronotype;
SARC	cis	rs2963155	0.518	rs2918419	chr5:142722353	T/C	cg17617527	chr5:142782415	NR3C1	0.83	6.13	0.37	3.75e-9	Breast cancer;
SARC	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	11.4	0.6	3.24e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs1468333	0.667	rs6886388	chr5:137733423	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.71	8.34	0.48	6.38e-15	Resting heart rate;
SARC	cis	rs1800469	1.000	rs1549933	chr19:41871142	A/G	cg09537434	chr19:41945824	ATP5SL	-0.6	-7.38	-0.44	2.72e-12	Colorectal cancer;
SARC	cis	rs6714710	0.603	rs13034929	chr2:98402772	G/C	cg26665480	chr2:98280029	ACTR1B	0.54	7.2	0.43	8.21e-12	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs9467773	0.967	rs6941022	chr6:26553531	T/C	cg12292205	chr6:26970375	C6orf41	0.46	5.51	0.34	9.65e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9435341	0.965	rs55909997	chr1:107581039	G/A	cg09367891	chr1:107599246	PRMT6	0.75	9.41	0.52	5.12e-18	Facial morphology (factor 21, depth of nasal alae);
SARC	cis	rs11077998	0.840	rs9910991	chr17:80481193	G/A	cg10255544	chr17:80519551	FOXK2	0.44	6.24	0.38	2.07e-9	Reticulocyte fraction of red cells;
SARC	cis	rs6456156	0.586	rs12213683	chr6:167460718	G/A	cg07741184	chr6:167504864	NA	0.35	6.83	0.41	7.46e-11	Primary biliary cholangitis;
SARC	cis	rs6991838	0.584	rs7835313	chr8:66546126	C/G	cg13398993	chr8:66546079	ARMC1	0.62	8.19	0.47	1.72e-14	Intelligence (multi-trait analysis);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg06509661	chr1:234614745	TARBP1	0.55	7.71	0.45	3.71e-13	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs3126085	0.935	rs12730241	chr1:152274016	G/A	cg03465714	chr1:152285911	FLG	0.5	5.73	0.35	3.04e-8	Atopic dermatitis;
SARC	cis	rs12579753	0.917	rs6539580	chr12:82184765	T/C	cg07988820	chr12:82153109	PPFIA2	-0.52	-6.21	-0.38	2.35e-9	Resting heart rate;
SARC	cis	rs41278232	0.557	rs817341	chr20:62606765	C/T	cg24354818	chr20:62328094	TNFRSF6B	0.35	4.83	0.3	2.43e-6	Tonsillectomy;
SARC	cis	rs59918340	0.728	rs59172574	chr8:142231945	C/G	cg16341495	chr8:142228727	SLC45A4	-0.36	-5.11	-0.32	6.78e-7	Immature fraction of reticulocytes;
SARC	cis	rs2439831	0.850	rs558656	chr15:43723514	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.09	11.37	0.6	4.12e-24	Lung cancer in ever smokers;
SARC	cis	rs7520050	0.966	rs1085243	chr1:46544768	C/T	cg06784218	chr1:46089804	CCDC17	-0.26	-4.82	-0.3	2.57e-6	Red blood cell count;Reticulocyte count;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg24333206	chr3:140660642	SLC25A36	0.54	6.93	0.41	4.05e-11	Breast cancer;
SARC	cis	rs6133127	0.640	rs11696522	chr20:4475946	T/C	cg14606382	chr20:4573199	NA	-0.49	-5.17	-0.32	5.04e-7	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
SARC	trans	rs61931739	0.500	rs7963282	chr12:34535255	A/C	cg13010199	chr12:38710504	ALG10B	0.78	11.07	0.59	3.68e-23	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg02725872	chr8:58115012	NA	-0.36	-6.09	-0.37	4.51e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg07507251	chr3:52567010	NT5DC2	0.31	4.85	0.3	2.25e-6	Electroencephalogram traits;
SARC	cis	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg22496380	chr5:211416	CCDC127	-0.88	-9.55	-0.53	1.95e-18	Breast cancer;
SARC	cis	rs826838	0.904	rs10876086	chr12:39188208	C/A	cg13010199	chr12:38710504	ALG10B	0.74	9.8	0.54	3.32e-19	Heart rate;
SARC	cis	rs6565180	0.632	rs8050812	chr16:30385837	C/T	cg17640201	chr16:30407289	ZNF48	-0.92	-12.03	-0.62	2.97e-26	Tonsillectomy;
SARC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	11.15	0.59	2.1e-23	Platelet count;
SARC	cis	rs78487399	0.710	rs7561114	chr2:43701951	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-5.13	-0.32	6.24e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs72945132	0.882	rs3900797	chr11:70186614	C/T	cg00319359	chr11:70116639	PPFIA1	0.7	6.56	0.39	3.47e-10	Coronary artery disease;
SARC	cis	rs2075371	1.000	rs2058976	chr7:133981379	G/T	cg20476274	chr7:133979776	SLC35B4	0.62	8.49	0.49	2.48e-15	Mean platelet volume;
SARC	cis	rs561341	1.000	rs501957	chr17:30314504	C/T	cg00745463	chr17:30367425	LRRC37B	-0.69	-5.34	-0.33	2.21e-7	Hip circumference adjusted for BMI;
SARC	cis	rs13082711	0.522	rs586229	chr3:27354520	A/G	cg02860705	chr3:27208620	NA	0.44	5.87	0.36	1.47e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs11718455	1.000	rs1524885	chr3:44031847	G/A	cg08738300	chr3:44038990	NA	0.51	5.63	0.35	5.13e-8	Coronary artery disease;
SARC	cis	rs1707322	0.789	rs7540578	chr1:46252144	C/T	cg03146154	chr1:46216737	IPP	0.52	6.52	0.39	4.35e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2732480	0.577	rs2634691	chr12:48708259	G/T	cg24011408	chr12:48396354	COL2A1	0.43	4.97	0.31	1.29e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs1707322	0.647	rs6686944	chr1:46156308	G/T	cg03146154	chr1:46216737	IPP	0.53	6.32	0.38	1.28e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs3733585	0.699	rs6834893	chr4:9959123	C/T	cg11266682	chr4:10021025	SLC2A9	-0.35	-6.03	-0.37	6.35e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs9398803	0.687	rs3905044	chr6:126972883	A/G	cg20229609	chr6:126660872	C6orf173	0.37	5.39	0.33	1.74e-7	Male-pattern baldness;
SARC	cis	rs8141529	0.644	rs5752795	chr22:29178820	T/C	cg02153584	chr22:29168773	CCDC117	0.82	12.64	0.64	3.06e-28	Lymphocyte counts;
SARC	cis	rs12438659	1	rs12438659	chr15:78824924	G/A	cg06917634	chr15:78832804	PSMA4	-0.59	-6.63	-0.4	2.26e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs1355223	0.902	rs11603774	chr11:34732891	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.27	-0.33	3.16e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.48	-6.01	-0.37	7.23e-9	Lymphocyte counts;
SARC	cis	rs9420	0.961	rs71484461	chr11:57488890	G/A	cg23127183	chr11:57508653	C11orf31	-0.55	-6.28	-0.38	1.61e-9	Schizophrenia;
SARC	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg06028808	chr11:68637592	NA	0.46	5.95	0.36	9.94e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7208859	0.623	rs73263788	chr17:29216490	T/C	cg13385521	chr17:29058706	SUZ12P	0.85	7.23	0.43	7.08e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs2380220	0.872	rs67846436	chr6:95951521	G/T	cg04719120	chr6:96025338	MANEA	-0.64	-6.4	-0.39	8.45e-10	Behavioural disinhibition (generation interaction);
SARC	cis	rs2439831	0.867	rs2447208	chr15:43933895	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.93	8.32	0.48	7.38e-15	Lung cancer in ever smokers;
SARC	cis	rs11690935	0.610	rs3770458	chr2:172651287	C/T	cg13550731	chr2:172543902	DYNC1I2	0.66	9.6	0.53	1.32e-18	Schizophrenia;
SARC	cis	rs2033732	0.613	rs10101678	chr8:85060063	G/T	cg05716166	chr8:85095498	RALYL	0.47	5.59	0.34	6.28e-8	Body mass index;
SARC	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg27266027	chr21:40555129	PSMG1	-0.47	-5.2	-0.32	4.38e-7	Cognitive function;
SARC	cis	rs76419734	0.850	rs17331332	chr4:106808107	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	-0.81	-5.22	-0.32	3.9e-7	Post bronchodilator FEV1;
SARC	cis	rs7917772	0.636	rs2249845	chr10:104512095	A/G	ch.10.2196322F	chr10:104248062	ACTR1A	-0.49	-5.61	-0.34	5.83e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg08564027	chr20:61660810	NA	0.76	11.8	0.61	1.69e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs858239	0.600	rs6461692	chr7:23139695	G/C	cg23682824	chr7:23144976	KLHL7	0.7	9.27	0.52	1.34e-17	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9457247	0.967	rs388406	chr6:167409562	A/G	cg07741184	chr6:167504864	NA	0.3	5.59	0.34	6.38e-8	Crohn's disease;
SARC	cis	rs4423214	0.840	rs1792231	chr11:71182681	G/A	cg05163923	chr11:71159392	DHCR7	-0.6	-7.21	-0.43	7.58e-12	Vitamin D levels;
SARC	cis	rs17376456	0.569	rs11135397	chr5:93214975	G/T	cg21475434	chr5:93447410	FAM172A	0.62	6.24	0.38	2.08e-9	Diabetic retinopathy;
SARC	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg13206674	chr6:150067644	NUP43	0.48	6.17	0.38	2.92e-9	Lung cancer;
SARC	cis	rs6582630	0.519	rs12578283	chr12:38325349	A/T	cg26384229	chr12:38710491	ALG10B	0.87	12.46	0.63	1.19e-27	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg00933542	chr6:150070202	PCMT1	0.31	5.25	0.33	3.38e-7	Lung cancer;
SARC	cis	rs77956314	0.515	rs4767473	chr12:117365506	C/T	cg16111737	chr12:117408163	FBXW8	-0.48	-6.27	-0.38	1.69e-9	Subcortical brain region volumes;Hippocampal volume;
SARC	cis	rs2933343	0.700	rs1680778	chr3:128614185	A/C	cg25356066	chr3:128598488	ACAD9	0.73	9.66	0.53	8.57e-19	IgG glycosylation;
SARC	cis	rs7909074	1.000	rs4948926	chr10:45392604	G/C	cg04218760	chr10:45406644	TMEM72	-0.24	-4.8	-0.3	2.81e-6	Mean corpuscular volume;
SARC	cis	rs2354432	0.607	rs11239980	chr1:146782698	G/A	cg25205988	chr1:146714368	CHD1L	-1.02	-7.73	-0.45	3.15e-13	Mitochondrial DNA levels;
SARC	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg00933542	chr6:150070202	PCMT1	0.29	4.98	0.31	1.24e-6	Lung cancer;
SARC	cis	rs11155671	0.530	rs7763849	chr6:150206380	C/T	cg09699651	chr6:150184138	LRP11	0.48	6.17	0.37	3.02e-9	Testicular germ cell tumor;
SARC	cis	rs57244997	1.000	rs73026551	chr6:162393642	A/C	cg17173639	chr6:162384350	PARK2	-0.65	-6.17	-0.37	2.94e-9	Mosquito bite size;
SARC	cis	rs644799	0.540	rs10831422	chr11:95478968	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.72	9.34	0.52	8.18e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9660992	0.573	rs12125276	chr1:205199440	C/T	cg07972983	chr1:205091412	RBBP5	0.57	7.02	0.42	2.35e-11	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs2290402	0.536	rs56223707	chr4:881896	C/T	cg00846425	chr4:957561	DGKQ	-0.44	-4.93	-0.31	1.59e-6	Type 2 diabetes;
SARC	cis	rs561341	0.843	rs879944	chr17:30242803	A/G	cg13647721	chr17:30228624	UTP6	0.66	6.1	0.37	4.29e-9	Hip circumference adjusted for BMI;
SARC	cis	rs7011049	1.000	rs72640848	chr8:53836225	A/G	cg26025543	chr8:53854495	NA	0.6	5.46	0.34	1.2e-7	Systolic blood pressure;
SARC	cis	rs9796	0.689	rs8032195	chr15:41448790	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.46	-6.23	-0.38	2.1e-9	Menopause (age at onset);
SARC	cis	rs35272691	1	rs35272691	chr17:38157841	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.39	7.15	0.42	1.14e-11	White blood cell count (neutrophil);
SARC	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg15242686	chr22:24348715	GSTTP1	0.45	5.57	0.34	6.86e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs477692	0.699	rs528549	chr10:131381574	A/G	cg05714579	chr10:131428358	MGMT	0.56	7.29	0.43	4.67e-12	Response to temozolomide;
SARC	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg04944784	chr2:26401820	FAM59B	0.6	7.95	0.46	8.14e-14	Gut microbiome composition (summer);
SARC	cis	rs950027	0.620	rs1426932	chr15:45687256	T/C	cg21132104	chr15:45694354	SPATA5L1	0.54	6.72	0.4	1.41e-10	Response to fenofibrate (adiponectin levels);
SARC	cis	rs644148	0.933	rs565819	chr19:44967714	A/G	cg15540054	chr19:45004280	ZNF180	0.47	5.7	0.35	3.58e-8	Personality dimensions;
SARC	cis	rs2073300	0.609	rs17757228	chr20:23351288	A/T	cg16736954	chr20:23401023	NAPB	0.81	5.0	0.31	1.11e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs2531992	0.800	rs1045476	chr16:4015313	A/G	cg08098950	chr16:4033226	ADCY9	-0.32	-5.14	-0.32	5.89e-7	Waist circumference;
SARC	cis	rs992157	0.643	rs10191283	chr2:219056755	G/A	cg00012203	chr2:219082015	ARPC2	0.83	13.3	0.66	2.1000000000000002e-30	Colorectal cancer;
SARC	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg10589385	chr1:150898437	SETDB1	0.41	5.45	0.34	1.29e-7	Melanoma;
SARC	cis	rs28374715	0.532	rs316604	chr15:41775221	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.15	-18.43	-0.77	2.07e-47	Ulcerative colitis;
SARC	cis	rs35160687	0.640	rs13015186	chr2:86485578	A/G	cg10973622	chr2:86423274	IMMT	0.4	5.02	0.31	1.03e-6	Night sleep phenotypes;
SARC	cis	rs2228479	0.850	rs57267516	chr16:89903552	G/A	cg00800038	chr16:89945340	TCF25	-0.8	-5.68	-0.35	4.07e-8	Skin colour saturation;
SARC	cis	rs826838	0.616	rs10880754	chr12:38628154	C/T	cg13010199	chr12:38710504	ALG10B	-0.52	-6.43	-0.39	7.18e-10	Heart rate;
SARC	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.63	4.86	0.3	2.18e-6	Initial pursuit acceleration;
SARC	cis	rs826838	0.585	rs4363678	chr12:38624514	G/A	cg26384229	chr12:38710491	ALG10B	0.6	7.76	0.45	2.59e-13	Heart rate;
SARC	cis	rs3859192	0.577	rs2227333	chr17:38174167	C/G	cg17467752	chr17:38218738	THRA	-0.38	-4.73	-0.3	3.92e-6	White blood cell count;
SARC	cis	rs7336332	0.598	rs1885988	chr13:28010262	C/T	cg01674679	chr13:27998804	GTF3A	0.55	5.24	0.32	3.59e-7	Weight;
SARC	cis	rs9300255	0.722	rs12298826	chr12:123829028	A/G	cg00376283	chr12:123451042	ABCB9	-0.45	-4.75	-0.3	3.5e-6	Neutrophil percentage of white cells;
SARC	cis	rs796364	0.951	rs11897245	chr2:201063644	A/G	cg23649088	chr2:200775458	C2orf69	0.66	7.37	0.43	2.94e-12	Schizophrenia;
SARC	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg22974920	chr21:40686053	BRWD1	0.46	5.12	0.32	6.32e-7	Cognitive function;
SARC	cis	rs7959452	0.640	rs12370042	chr12:69692420	C/G	cg20891283	chr12:69753455	YEATS4	0.41	5.52	0.34	9e-8	Blood protein levels;
SARC	cis	rs6772849	0.930	rs1962040	chr3:128324161	G/A	cg08795948	chr3:128337044	NA	0.55	7.7	0.45	3.89e-13	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg05368731	chr17:41323189	NBR1	0.78	9.51	0.53	2.46e-18	Menopause (age at onset);
SARC	cis	rs7647973	0.554	rs13096480	chr3:49658084	A/G	cg03060546	chr3:49711283	APEH	0.67	7.1	0.42	1.54e-11	Menarche (age at onset);
SARC	cis	rs9788721	1.000	rs931794	chr15:78826180	G/A	cg18825076	chr15:78729989	IREB2	0.42	5.15	0.32	5.44e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs41271473	0.526	rs12136157	chr1:228703236	T/C	cg16512390	chr1:228756714	NA	0.64	5.91	0.36	1.2e-8	Chronic lymphocytic leukemia;
SARC	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.95	13.96	0.67	1.32e-32	Gut microbiome composition (summer);
SARC	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.08	22.74	0.83	4.39e-61	Chronic sinus infection;
SARC	cis	rs2153535	0.580	rs7766852	chr6:8472417	C/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.61	0.49	1.13e-15	Motion sickness;
SARC	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg19223190	chr17:80058835	NA	0.44	6.12	0.37	3.88e-9	Life satisfaction;
SARC	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg11941060	chr3:133502564	NA	-0.41	-5.81	-0.36	2.08e-8	Iron status biomarkers;
SARC	cis	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg02711726	chr17:80685570	FN3KRP	-0.56	-6.93	-0.41	4.18e-11	Glycated hemoglobin levels;
SARC	trans	rs17685	0.625	rs1639630	chr7:75730499	T/C	cg19862616	chr7:65841803	NCRNA00174	0.63	7.77	0.45	2.42e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs6088590	1.000	rs6119516	chr20:33328024	C/T	cg06115741	chr20:33292138	TP53INP2	0.54	6.56	0.39	3.41e-10	Coronary artery disease;
SARC	cis	rs13343954	0.518	rs2216594	chr19:33533258	G/A	cg27124370	chr19:33622961	WDR88	0.43	5.5	0.34	1.02e-7	Colorectal cancer;
SARC	cis	rs28829049	0.566	rs59681755	chr1:19528985	G/A	cg13387374	chr1:19411106	UBR4	0.43	5.06	0.31	8.61e-7	QRS duration in Tripanosoma cruzi seropositivity;
SARC	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg27266027	chr21:40555129	PSMG1	0.47	4.81	0.3	2.68e-6	Cognitive function;
SARC	cis	rs72653721	0.689	rs4435941	chr6:11061518	C/T	cg13562911	chr6:11044106	ELOVL2	0.54	6.09	0.37	4.62e-9	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg05313129	chr8:58192883	C8orf71	-0.5	-5.94	-0.36	1.03e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6964587	0.773	rs59242586	chr7:91918145	A/G	cg17063962	chr7:91808500	NA	0.92	12.91	0.65	3.91e-29	Breast cancer;
SARC	cis	rs17854409	0.803	rs1048109	chr20:61472120	G/A	cg05147244	chr20:61493195	TCFL5	0.94	6.03	0.37	6.42e-9	Obesity-related traits;
SARC	cis	rs9916302	0.680	rs2271308	chr17:37817482	T/C	cg07936489	chr17:37558343	FBXL20	-0.43	-5.52	-0.34	9.17e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs2075371	0.965	rs1862049	chr7:133978344	A/T	cg20476274	chr7:133979776	SLC35B4	0.6	8.18	0.47	1.8e-14	Mean platelet volume;
SARC	cis	rs7264396	0.513	rs3787169	chr20:34419884	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.4	-0.39	8.57e-10	Total cholesterol levels;
SARC	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg16680214	chr1:154839983	KCNN3	-0.36	-5.64	-0.35	4.97e-8	Prostate cancer;
SARC	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.8	-11.76	-0.61	2.25e-25	Total body bone mineral density;
SARC	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg06618935	chr21:46677482	NA	-0.39	-5.14	-0.32	5.72e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs738322	0.934	rs84473	chr22:38557326	T/C	cg25457927	chr22:38595422	NA	-0.25	-5.21	-0.32	4.23e-7	Cutaneous nevi;
SARC	cis	rs3749237	0.595	rs17595772	chr3:49409704	G/A	cg03060546	chr3:49711283	APEH	0.75	10.72	0.57	4.68e-22	Resting heart rate;
SARC	cis	rs10876993	0.928	rs1689586	chr12:58079586	A/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.4	-5.04	-0.31	9.41e-7	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs9611519	0.780	rs5751071	chr22:41656332	G/A	cg17376030	chr22:41985996	PMM1	0.52	6.69	0.4	1.63e-10	Neuroticism;
SARC	trans	rs9951602	0.512	rs4799249	chr18:76654370	A/G	cg02800362	chr5:177631904	HNRNPAB	0.7	8.92	0.5	1.4e-16	Obesity-related traits;
SARC	cis	rs7566780	0.758	rs4632345	chr2:16702654	A/G	cg09580478	chr2:16689509	NA	-0.42	-5.7	-0.35	3.55e-8	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	trans	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.23	-0.38	2.13e-9	Neuroticism;
SARC	cis	rs735539	0.521	rs2818990	chr13:21388724	A/G	cg16922012	chr13:21400325	XPO4	0.45	6.63	0.4	2.28e-10	Dental caries;
SARC	cis	rs7937682	0.883	rs517982	chr11:111462687	T/C	cg22437258	chr11:111473054	SIK2	0.76	9.86	0.54	2.22e-19	Primary sclerosing cholangitis;
SARC	cis	rs9393692	1.000	rs2393593	chr6:26285683	T/C	cg05868516	chr6:26286170	HIST1H4H	0.49	5.83	0.36	1.79e-8	Educational attainment;
SARC	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg03709012	chr19:19516395	GATAD2A	1.05	18.1	0.76	2.49e-46	Tonsillectomy;
SARC	cis	rs6964587	0.626	rs4729011	chr7:91515419	G/A	cg17063962	chr7:91808500	NA	-0.78	-11.54	-0.6	1.13e-24	Breast cancer;
SARC	trans	rs561341	1.000	rs506766	chr17:30289659	T/C	cg20587970	chr11:113659929	NA	-1.33	-12.92	-0.65	3.69e-29	Hip circumference adjusted for BMI;
SARC	cis	rs7011049	0.915	rs78887309	chr8:53860016	A/C	cg26025543	chr8:53854495	NA	0.61	5.37	0.33	1.87e-7	Systolic blood pressure;
SARC	cis	rs8177253	0.696	rs4459901	chr3:133465699	T/C	cg01448562	chr3:133502909	NA	-0.43	-6.35	-0.38	1.12e-9	Iron status biomarkers;
SARC	cis	rs2115630	0.691	rs2292462	chr15:85200754	G/T	cg12501888	chr15:85177176	SCAND2	-0.5	-6.06	-0.37	5.52e-9	P wave terminal force;
SARC	cis	rs3096299	0.582	rs12935119	chr16:89542874	A/T	cg02034447	chr16:89574710	SPG7	0.43	5.59	0.34	6.34e-8	Multiple myeloma (IgH translocation);
SARC	cis	rs16976116	0.901	rs28589384	chr15:55494366	A/G	cg17854078	chr15:55489399	RSL24D1	0.66	6.53	0.39	4.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs3923518	1.000	rs11928473	chr3:38897271	T/C	cg26331595	chr3:39149181	GORASP1;TTC21A	0.46	4.81	0.3	2.72e-6	Migraine;
SARC	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg02524346	chr8:600233	NA	-0.64	-5.72	-0.35	3.23e-8	IgG glycosylation;
SARC	cis	rs4642101	0.639	rs9870433	chr3:12853566	T/C	cg12400702	chr3:12838781	CAND2	-0.25	-4.89	-0.31	1.88e-6	QRS complex (12-leadsum);
SARC	cis	rs3764563	1.000	rs4239612	chr19:15727442	A/G	cg20725493	chr19:15740067	CYP4F8	-0.67	-4.95	-0.31	1.4e-6	Inflammatory biomarkers;
SARC	cis	rs2280018	0.526	rs2966129	chr16:15152927	A/C	cg27102117	chr16:15229624	NA	-0.5	-6.05	-0.37	5.59e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs11112613	1.000	rs11112613	chr12:106003786	A/G	cg03607813	chr12:105948248	NA	0.55	6.46	0.39	5.93e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs2120019	1.000	rs7168680	chr15:75369212	G/A	cg17294928	chr15:75287854	SCAMP5	-0.9	-13.28	-0.66	2.39e-30	Blood trace element (Zn levels);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg07617175	chr5:99871683	FAM174A	-0.5	-6.26	-0.38	1.79e-9	Height;
SARC	cis	rs9290065	0.519	rs956447	chr3:160668917	G/C	cg04691961	chr3:161091175	C3orf57	-0.51	-6.31	-0.38	1.38e-9	Kawasaki disease;
SARC	cis	rs136211	0.577	rs9610498	chr22:36777739	C/T	cg16924664	chr22:36878180	TXN2	0.44	5.61	0.35	5.63e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs28795989	0.896	rs7655918	chr4:7889301	A/G	cg18538662	chr4:7941764	AFAP1	-0.37	-4.73	-0.3	3.9e-6	Intraocular pressure;
SARC	cis	rs61989804	0.826	rs56231407	chr14:65706761	C/T	cg15999311	chr14:65749247	NA	0.51	4.85	0.3	2.25e-6	Midgestational circulating levels of PCBs (fetal genetic effect);
SARC	cis	rs668210	0.793	rs622779	chr11:65744247	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.52	-4.99	-0.31	1.18e-6	Cerebrospinal fluid biomarker levels;
SARC	cis	rs3126085	1.000	rs3126092	chr1:152307955	T/A	cg26876637	chr1:152193138	HRNR	-0.45	-4.87	-0.3	2.07e-6	Atopic dermatitis;
SARC	cis	rs6938	0.618	rs12912839	chr15:75221245	C/T	cg14664628	chr15:75095509	CSK	-0.42	-5.08	-0.32	7.59e-7	Breast cancer;
SARC	cis	rs13191362	1.000	rs35017019	chr6:162982581	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.56	5.44	0.34	1.34e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg16405210	chr4:1374714	KIAA1530	-0.46	-5.49	-0.34	1.04e-7	Obesity-related traits;
SARC	cis	rs1007738	0.542	rs10838664	chr11:47203904	G/A	cg03339077	chr11:47165057	C11orf49	0.41	5.0	0.31	1.14e-6	Bone mineral density (hip);
SARC	cis	rs7568458	0.870	rs1972297	chr2:85808573	T/C	cg02493740	chr2:85810744	VAMP5	-0.35	-5.13	-0.32	6.03e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs10463554	0.963	rs257318	chr5:102445470	C/T	cg23492399	chr5:102201601	PAM	-0.47	-5.19	-0.32	4.6e-7	Parkinson's disease;
SARC	cis	rs651907	0.557	rs13081846	chr3:101383321	T/C	cg12386194	chr3:101231763	SENP7	0.49	5.85	0.36	1.61e-8	Colorectal cancer;
SARC	trans	rs561341	0.505	rs41291021	chr17:30410689	C/A	cg20587970	chr11:113659929	NA	-1.35	-11.07	-0.59	3.75e-23	Hip circumference adjusted for BMI;
SARC	cis	rs2228479	0.850	rs62054257	chr16:89900195	G/A	cg12064134	chr16:90016061	DEF8	-0.56	-4.79	-0.3	2.91e-6	Skin colour saturation;
SARC	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg19748678	chr4:122722346	EXOSC9	0.74	9.78	0.54	3.78e-19	Type 2 diabetes;
SARC	cis	rs524281	0.731	rs11227439	chr11:66025679	G/A	cg14036092	chr11:66035641	RAB1B	-0.57	-5.77	-0.35	2.53e-8	Electroencephalogram traits;
SARC	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg16339924	chr4:17578868	LAP3	0.66	8.88	0.5	1.81e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs61931739	0.500	rs10772154	chr12:34373271	A/C	cg26384229	chr12:38710491	ALG10B	0.83	12.43	0.63	1.53e-27	Morning vs. evening chronotype;
SARC	cis	rs739401	0.611	rs7109088	chr11:3027485	G/T	cg20651018	chr11:3035856	CARS	-0.46	-7.16	-0.42	1.02e-11	Longevity;
SARC	cis	rs6963495	0.745	rs73190179	chr7:105162812	C/A	cg19920283	chr7:105172520	RINT1	0.65	5.48	0.34	1.09e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs2073300	0.609	rs3746737	chr20:23424638	C/T	cg16736954	chr20:23401023	NAPB	0.77	4.81	0.3	2.76e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs61935443	0.832	rs10859778	chr12:95268010	C/G	cg21533806	chr12:95267307	NA	0.72	8.54	0.49	1.76e-15	Schizophrenia;
SARC	trans	rs2727020	0.553	rs61904166	chr11:49581461	T/C	cg15704280	chr7:45808275	SEPT13	-0.83	-13.69	-0.67	1.06e-31	Coronary artery disease;
SARC	cis	rs7178572	0.849	rs1005752	chr15:77818128	C/A	cg22256960	chr15:77711686	NA	-0.52	-5.82	-0.36	1.92e-8	Type 2 diabetes;
SARC	cis	rs11690935	0.788	rs6715929	chr2:172877507	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.7	-9.54	-0.53	2.08e-18	Schizophrenia;
SARC	cis	rs36051895	0.658	rs11999928	chr9:5006743	T/G	cg02405213	chr9:5042618	JAK2	-0.55	-6.38	-0.39	9.26e-10	Pediatric autoimmune diseases;
SARC	cis	rs240764	0.645	rs239208	chr6:101139285	G/A	cg09795085	chr6:101329169	ASCC3	0.44	5.53	0.34	8.72e-8	Neuroticism;
SARC	cis	rs13256369	0.851	rs13271698	chr8:8567539	C/A	cg18904891	chr8:8559673	CLDN23	0.48	5.54	0.34	8.31e-8	Obesity-related traits;
SARC	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.46	-5.83	-0.36	1.83e-8	Personality dimensions;
SARC	cis	rs13191362	1.000	rs68144677	chr6:163149024	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.43	5.3	0.33	2.71e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg08219700	chr8:58056026	NA	0.61	6.36	0.38	1.05e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg01448562	chr3:133502909	NA	-0.44	-6.48	-0.39	5.48e-10	Iron status biomarkers;
SARC	cis	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg08975724	chr8:8085496	FLJ10661	-0.44	-5.44	-0.34	1.38e-7	Mood instability;
SARC	cis	rs6964587	1.000	rs2188155	chr7:91599825	A/C	cg17063962	chr7:91808500	NA	0.93	15.52	0.71	8.63e-38	Breast cancer;
SARC	cis	rs72945132	0.882	rs72947012	chr11:70149472	G/A	cg00319359	chr11:70116639	PPFIA1	0.68	6.19	0.38	2.66e-9	Coronary artery disease;
SARC	cis	rs7208859	0.673	rs11655623	chr17:29162173	T/C	cg13385521	chr17:29058706	SUZ12P	0.86	7.3	0.43	4.51e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs1003719	0.715	rs2835642	chr21:38539066	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.48	-0.53	3.11e-18	Eye color traits;
SARC	cis	rs3020736	0.500	rs6002605	chr22:42494335	A/G	cg15557168	chr22:42548783	NA	0.35	4.81	0.3	2.67e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs4481887	0.927	rs4279879	chr1:248486475	A/G	cg00666640	chr1:248458726	OR2T12	0.35	5.75	0.35	2.83e-8	Common traits (Other);
SARC	cis	rs6840360	0.809	rs6847303	chr4:152730221	G/A	cg22705602	chr4:152727874	NA	0.39	6.83	0.41	7.37e-11	Intelligence (multi-trait analysis);
SARC	cis	rs9368481	0.594	rs2636425	chr6:26799460	A/G	cg12292205	chr6:26970375	C6orf41	0.52	6.06	0.37	5.31e-9	Autism spectrum disorder or schizophrenia;
SARC	trans	rs6911965	0.935	rs114687023	chr6:24468652	A/G	cg03607907	chr16:20083459	GPR139	0.58	6.33	0.38	1.23e-9	Hematological and biochemical traits;
SARC	cis	rs17376456	0.877	rs12153506	chr5:93360953	T/G	cg25358565	chr5:93447407	FAM172A	1.3	14.78	0.7	2.47e-35	Diabetic retinopathy;
SARC	cis	rs9948	1.000	rs12172	chr2:97500852	C/G	cg01990225	chr2:97406019	LMAN2L	-0.9	-6.26	-0.38	1.81e-9	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs1008375	1.000	rs56974987	chr4:17627856	G/A	cg02297831	chr4:17616191	MED28	0.48	6.04	0.37	6.13e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs78545713	0.502	rs3823157	chr6:26272039	A/G	cg05868516	chr6:26286170	HIST1H4H	0.5	4.81	0.3	2.65e-6	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs17331151	0.541	rs4687676	chr3:52890418	C/T	cg04865290	chr3:52927548	TMEM110	0.56	5.54	0.34	8.02e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs826838	0.967	rs11183022	chr12:38652519	G/A	cg26384229	chr12:38710491	ALG10B	0.93	14.73	0.69	3.88e-35	Heart rate;
SARC	cis	rs10463316	0.608	rs7700423	chr5:150769155	C/T	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.32	-0.33	2.42e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs875971	0.545	rs4441996	chr7:65588220	T/C	cg11764359	chr7:65958608	NA	-0.64	-6.52	-0.39	4.26e-10	Aortic root size;
SARC	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg18252515	chr7:66147081	NA	-0.63	-6.7	-0.4	1.55e-10	Aortic root size;
SARC	cis	rs5753618	0.509	rs5749224	chr22:31558549	C/T	cg02404636	chr22:31891804	SFI1	-0.51	-5.76	-0.35	2.7e-8	Colorectal cancer;
SARC	cis	rs877282	0.583	rs10904566	chr10:821662	C/G	cg15764593	chr10:829463	NA	-0.44	-4.8	-0.3	2.78e-6	Uric acid levels;
SARC	cis	rs17023223	0.537	rs12064033	chr1:119709558	G/A	cg05756136	chr1:119680316	WARS2	-0.49	-5.62	-0.35	5.47e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg01546424	chr6:149721457	MAP3K7IP2;SUMO4	-0.52	-6.48	-0.39	5.35e-10	Gallstone disease;
SARC	cis	rs9359856	0.564	rs56396054	chr6:90360406	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.63	-4.95	-0.31	1.41e-6	Bipolar disorder;
SARC	cis	rs2933343	0.729	rs789230	chr3:128602558	G/A	cg25356066	chr3:128598488	ACAD9	0.73	9.65	0.53	9.44e-19	IgG glycosylation;
SARC	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg11764359	chr7:65958608	NA	-0.74	-8.66	-0.49	8.01e-16	Aortic root size;
SARC	trans	rs12310956	0.532	rs7306007	chr12:33975209	C/G	cg13010199	chr12:38710504	ALG10B	0.65	8.66	0.49	7.86e-16	Morning vs. evening chronotype;
SARC	cis	rs898097	0.625	rs7406464	chr17:80891460	A/G	cg20578329	chr17:80767326	TBCD	-0.34	-4.98	-0.31	1.22e-6	Breast cancer;
SARC	cis	rs344364	0.511	rs2982452	chr16:1949511	G/A	cg26617929	chr16:1858877	NA	-0.71	-6.06	-0.37	5.5e-9	Glomerular filtration rate in chronic kidney disease;
SARC	cis	rs1707322	0.682	rs10890335	chr1:46100394	G/C	cg03146154	chr1:46216737	IPP	0.51	6.11	0.37	4.04e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs459571	0.959	rs408307	chr9:136892523	A/G	cg01294253	chr9:136912663	BRD3	-0.49	-6.56	-0.4	3.37e-10	Platelet distribution width;
SARC	cis	rs6840360	0.571	rs4696101	chr4:152528513	A/G	cg22705602	chr4:152727874	NA	-0.43	-6.69	-0.4	1.65e-10	Intelligence (multi-trait analysis);
SARC	cis	rs3126085	0.935	rs55942250	chr1:152251914	G/A	cg03465714	chr1:152285911	FLG	0.5	5.75	0.35	2.79e-8	Atopic dermatitis;
SARC	cis	rs2439831	0.850	rs28891769	chr15:44072860	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	7.74	0.45	3.01e-13	Lung cancer in ever smokers;
SARC	cis	rs9916302	0.851	rs12936996	chr17:37665554	A/G	cg07936489	chr17:37558343	FBXL20	0.69	8.99	0.51	8.75e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg17376030	chr22:41985996	PMM1	0.77	9.51	0.53	2.44e-18	Vitiligo;
SARC	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg08219700	chr8:58056026	NA	-0.6	-5.64	-0.35	4.98e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6963495	0.745	rs68153235	chr7:105184832	A/C	cg19920283	chr7:105172520	RINT1	0.72	7.15	0.42	1.13e-11	Bipolar disorder (body mass index interaction);
SARC	cis	rs73086581	1.000	rs73086581	chr20:3977325	T/C	cg02187196	chr20:3869020	PANK2	0.6	5.53	0.34	8.5e-8	Response to antidepressants in depression;
SARC	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg03709012	chr19:19516395	GATAD2A	1.01	17.32	0.75	9.53e-44	Tonsillectomy;
SARC	cis	rs7587476	0.736	rs62202002	chr2:215690600	T/C	cg11970703	chr2:215861251	ABCA12	-0.31	-4.75	-0.3	3.63e-6	Neuroblastoma;
SARC	cis	rs9916302	0.904	rs34363096	chr17:37594294	G/A	cg07936489	chr17:37558343	FBXL20	-0.7	-9.25	-0.52	1.5e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs12142240	0.698	rs58162700	chr1:46816659	T/A	cg00530320	chr1:46809349	NSUN4	0.57	6.92	0.41	4.4e-11	Menopause (age at onset);
SARC	cis	rs425277	0.916	rs414777	chr1:2101687	G/A	cg21442419	chr1:2182373	SKI	-0.52	-6.64	-0.4	2.19e-10	Height;
SARC	cis	rs6674176	0.561	rs4660263	chr1:44421433	A/C	cg13606994	chr1:44402422	ARTN	-0.33	-5.27	-0.33	3.16e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg18402987	chr7:1209562	NA	0.42	5.45	0.34	1.26e-7	Longevity;Endometriosis;
SARC	trans	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg21659725	chr3:3221576	CRBN	-0.79	-11.96	-0.62	5.19e-26	Intelligence (multi-trait analysis);
SARC	cis	rs9733	0.744	rs3754211	chr1:150951857	G/A	cg15448220	chr1:150897856	SETDB1	0.41	5.46	0.34	1.19e-7	Tonsillectomy;
SARC	cis	rs908922	0.676	rs4240883	chr1:152526260	C/T	cg09873164	chr1:152488093	CRCT1	0.6	7.89	0.46	1.16e-13	Hair morphology;
SARC	cis	rs9911578	1.000	rs9911578	chr17:56953147	C/T	cg12560992	chr17:57184187	TRIM37	0.86	11.82	0.61	1.41e-25	Intelligence (multi-trait analysis);
SARC	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg24642844	chr7:1081250	C7orf50	-0.52	-5.84	-0.36	1.78e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs2011503	1.000	rs1560687	chr19:19562902	G/A	cg15839431	chr19:19639596	YJEFN3	-0.47	-4.74	-0.3	3.78e-6	Bipolar disorder;
SARC	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg22535103	chr8:58192502	C8orf71	-0.73	-7.24	-0.43	6.52e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs7412746	0.611	rs66847267	chr1:150875173	C/A	cg10589385	chr1:150898437	SETDB1	0.4	5.38	0.33	1.8e-7	Melanoma;
SARC	cis	rs1008375	0.900	rs4698622	chr4:17589557	C/T	cg27347728	chr4:17578864	LAP3	0.51	6.23	0.38	2.14e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs853679	0.599	rs149949	chr6:28011516	T/C	cg19592336	chr6:28129416	ZNF389	0.66	5.0	0.31	1.11e-6	Depression;
SARC	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-8.66	-0.49	7.91e-16	Chronic sinus infection;
SARC	cis	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg13072238	chr3:49761600	GMPPB	-0.43	-5.57	-0.34	6.88e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7681440	0.606	rs2737006	chr4:90749686	A/G	cg06632027	chr4:90757378	SNCA	-0.42	-5.25	-0.33	3.41e-7	Dementia with Lewy bodies;
SARC	cis	rs995000	0.931	rs10889347	chr1:63075826	G/A	cg06896770	chr1:63153194	DOCK7	0.89	13.21	0.65	4.23e-30	Triglyceride levels;
SARC	cis	rs2832191	0.671	rs73346699	chr21:30515529	C/T	cg08807101	chr21:30365312	RNF160	-0.7	-8.49	-0.49	2.41e-15	Dental caries;
SARC	cis	rs12912251	0.591	rs3102119	chr15:39003601	C/T	cg01338139	chr15:38987640	C15orf53	-0.55	-5.07	-0.32	8.06e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
SARC	cis	rs2153535	0.546	rs9378559	chr6:8539058	A/T	cg07606381	chr6:8435919	SLC35B3	0.76	10.67	0.57	6.88e-22	Motion sickness;
SARC	cis	rs9886651	0.869	rs11779374	chr8:128792310	G/A	cg24514600	chr8:128805414	PVT1	-0.39	-5.07	-0.32	8.21e-7	Epithelial ovarian cancer;Serous invasive ovarian cancer;
SARC	cis	rs1003719	0.715	rs2835657	chr21:38565064	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-8.92	-0.5	1.36e-16	Eye color traits;
SARC	cis	rs751728	0.648	rs6922275	chr6:33749739	G/A	cg25922239	chr6:33757077	LEMD2	0.58	7.6	0.45	7.1e-13	Crohn's disease;
SARC	cis	rs2486288	0.656	rs2413772	chr15:45549862	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.45	-5.66	-0.35	4.39e-8	Glomerular filtration rate;
SARC	cis	rs2130392	0.926	rs10428357	chr4:185636217	T/A	cg04058563	chr4:185651563	MLF1IP	0.39	5.62	0.35	5.45e-8	Kawasaki disease;
SARC	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg11644478	chr21:40555479	PSMG1	1.03	14.35	0.69	6.72e-34	Cognitive function;
SARC	cis	rs735396	1.000	rs2259852	chr12:121434833	G/A	cg15155738	chr12:121454335	C12orf43	0.5	6.1	0.37	4.47e-9	N-glycan levels;
SARC	cis	rs7927771	1.000	rs4752857	chr11:47655752	C/T	cg05585544	chr11:47624801	NA	-0.38	-5.14	-0.32	5.92e-7	Subjective well-being;
SARC	cis	rs6912958	0.781	rs2268993	chr6:88184111	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.51	-6.82	-0.41	7.6e-11	Monocyte percentage of white cells;
SARC	cis	rs17270561	0.636	rs9393656	chr6:25722059	A/C	cg17691542	chr6:26056736	HIST1H1C	0.59	7.27	0.43	5.48e-12	Iron status biomarkers;
SARC	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg20607798	chr8:58055168	NA	-0.57	-5.52	-0.34	8.94e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg18876405	chr7:65276391	NA	-0.46	-5.51	-0.34	9.31e-8	Aortic root size;
SARC	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg22683308	chr4:1340831	KIAA1530	0.45	5.5	0.34	9.89e-8	Longevity;
SARC	cis	rs10905065	1.000	rs7913067	chr10:5787305	C/T	cg09072322	chr10:5726702	C10orf18	-0.44	-5.53	-0.34	8.61e-8	Menopause (age at onset);
SARC	cis	rs17376456	0.825	rs10054903	chr5:93281491	C/A	cg25358565	chr5:93447407	FAM172A	1.29	14.27	0.68	1.27e-33	Diabetic retinopathy;
SARC	cis	rs12134245	0.776	rs13447526	chr1:91983174	A/G	cg25838465	chr1:92012736	NA	0.62	8.64	0.49	9.22e-16	Breast cancer;
SARC	cis	rs7651190	1	rs7651190	chr3:41765955	A/G	cg03022575	chr3:42003672	ULK4	0.57	5.36	0.33	2.01e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);
SARC	cis	rs826838	0.802	rs10785619	chr12:38742897	T/A	cg13010199	chr12:38710504	ALG10B	0.71	9.75	0.54	4.59e-19	Heart rate;
SARC	cis	rs10088262	0.527	rs3911939	chr8:124793744	T/G	cg20713898	chr8:124780851	FAM91A1	-0.66	-6.95	-0.41	3.72e-11	Pancreatic cancer;
SARC	cis	rs6735179	0.609	rs13405140	chr2:1759020	C/T	cg08534653	chr2:1747700	PXDN	0.39	4.76	0.3	3.43e-6	Response to antipsychotic treatment;
SARC	cis	rs854765	0.583	rs4257260	chr17:17857003	A/G	cg04398451	chr17:18023971	MYO15A	-0.4	-5.51	-0.34	9.71e-8	Total body bone mineral density;
SARC	cis	rs7772486	0.790	rs9403750	chr6:146167762	G/A	cg23711669	chr6:146136114	FBXO30	0.8	13.15	0.65	6.42e-30	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs13006833	0.739	rs291472	chr2:191190605	A/G	cg25963032	chr2:191064776	C2orf88	0.34	4.79	0.3	2.94e-6	Urinary metabolites;
SARC	cis	rs2153535	0.560	rs2210798	chr6:8481522	C/T	cg21535247	chr6:8435926	SLC35B3	0.55	6.97	0.42	3.17e-11	Motion sickness;
SARC	cis	rs921968	0.541	rs3731867	chr2:219472734	G/A	cg02176678	chr2:219576539	TTLL4	-0.53	-7.9	-0.46	1.1e-13	Mean corpuscular hemoglobin concentration;
SARC	cis	rs7264396	0.690	rs2425157	chr20:34419083	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-7.15	-0.42	1.14e-11	Total cholesterol levels;
SARC	cis	rs13191362	0.872	rs13196631	chr6:163001588	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.49	0.34	1.04e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	trans	rs925098	0.597	rs13130622	chr4:17923314	C/T	cg08521178	chr6:170491202	NA	0.43	6.63	0.4	2.32e-10	Birth weight;Height;
SARC	cis	rs7843479	0.965	rs733544	chr8:21835628	A/G	cg17168535	chr8:21777572	XPO7	0.62	7.92	0.46	9.95e-14	Mean corpuscular volume;
SARC	cis	rs526231	0.543	rs34787	chr5:102458903	G/C	cg23492399	chr5:102201601	PAM	-0.51	-5.55	-0.34	7.77e-8	Primary biliary cholangitis;
SARC	cis	rs72781680	1.000	rs56068891	chr2:24230633	A/G	cg08917208	chr2:24149416	ATAD2B	0.94	9.2	0.52	2.17e-17	Lymphocyte counts;
SARC	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg22903657	chr4:1355424	KIAA1530	-0.36	-4.9	-0.31	1.82e-6	Obesity-related traits;
SARC	cis	rs7219021	0.705	rs962273	chr17:46978353	T/C	cg16584676	chr17:46985605	UBE2Z	0.5	5.93	0.36	1.1e-8	Schizophrenia or bipolar disorder;
SARC	cis	rs10911232	0.507	rs7547953	chr1:183031641	T/G	cg13390022	chr1:182993471	LAMC1	0.34	5.18	0.32	4.69e-7	Hypertriglyceridemia;
SARC	cis	rs9457247	1.000	rs1794693	chr6:167405670	T/C	cg23791538	chr6:167370224	RNASET2	-0.63	-8.74	-0.5	4.69e-16	Crohn's disease;
SARC	cis	rs9325144	0.600	rs7312522	chr12:38730423	A/G	cg26384229	chr12:38710491	ALG10B	0.6	7.88	0.46	1.25e-13	Morning vs. evening chronotype;
SARC	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg17376030	chr22:41985996	PMM1	-0.75	-9.28	-0.52	1.24e-17	Vitiligo;
SARC	cis	rs3741151	0.686	rs7112924	chr11:73106408	C/T	cg17517138	chr11:73019481	ARHGEF17	0.72	5.82	0.36	1.94e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs2120243	0.539	rs4680358	chr3:157069275	A/G	cg24825693	chr3:157122686	VEPH1	-0.46	-6.24	-0.38	2.03e-9	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs2882877	0.648	rs11680808	chr2:190376493	A/G	cg21926118	chr2:190387206	NA	-0.4	-5.02	-0.31	1.02e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs1371867	0.846	rs1788196	chr8:101290088	C/T	cg11906718	chr8:101322791	RNF19A	0.65	8.53	0.49	1.92e-15	Atrioventricular conduction;
SARC	cis	rs9393692	0.905	rs9379843	chr6:26289435	A/G	cg13736514	chr6:26305472	NA	-0.62	-8.61	-0.49	1.12e-15	Educational attainment;
SARC	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg18252515	chr7:66147081	NA	1.29	11.21	0.59	1.32e-23	Diabetic kidney disease;
SARC	cis	rs9646954	0.542	rs11674830	chr2:101024735	A/G	cg14675211	chr2:100938903	LONRF2	0.53	7.81	0.46	1.95e-13	Intelligence (multi-trait analysis);
SARC	cis	rs9303280	0.936	rs12950209	chr17:38049102	T/C	cg20243544	chr17:37824526	PNMT	0.43	5.76	0.35	2.61e-8	Self-reported allergy;
SARC	cis	rs72792276	1.000	rs72794361	chr5:127435188	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	6.19	0.38	2.7e-9	Red cell distribution width;
SARC	cis	rs448720	0.811	rs2458506	chr15:68182610	G/A	cg05925327	chr15:68127851	NA	-0.34	-4.93	-0.31	1.58e-6	Cognitive performance;
SARC	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg11764359	chr7:65958608	NA	-0.78	-9.67	-0.54	8.24e-19	Aortic root size;
SARC	cis	rs3087591	0.708	rs67065748	chr17:29605631	T/A	cg24425628	chr17:29625626	OMG;NF1	0.55	6.73	0.4	1.3e-10	Hip circumference;
SARC	cis	rs854765	0.583	rs8065416	chr17:17851162	C/T	cg04398451	chr17:18023971	MYO15A	-0.4	-5.51	-0.34	9.71e-8	Total body bone mineral density;
SARC	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg09699651	chr6:150184138	LRP11	0.39	4.86	0.3	2.19e-6	Lung cancer;
SARC	cis	rs12421382	0.614	rs12420249	chr11:109390254	T/G	cg27471124	chr11:109292789	C11orf87	0.35	5.05	0.31	9.02e-7	Schizophrenia;
SARC	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg21782813	chr7:2030301	MAD1L1	0.4	5.98	0.36	8.22e-9	Schizophrenia, schizoaffective disorder or bipolar disorder;
SARC	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.43	-0.56	3.88e-21	Chronic sinus infection;
SARC	cis	rs2153535	0.580	rs6421949	chr6:8531769	G/A	cg07606381	chr6:8435919	SLC35B3	0.76	10.92	0.58	1.12e-22	Motion sickness;
SARC	cis	rs4253772	0.701	rs9627280	chr22:46643964	T/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.49	5.25	0.33	3.47e-7	LDL cholesterol;Cholesterol, total;
SARC	cis	rs1983891	0.742	rs9369295	chr6:41564026	G/C	cg15051332	chr6:41514432	FOXP4	0.51	5.4	0.33	1.63e-7	Prostate cancer;
SARC	cis	rs7681440	0.583	rs2583965	chr4:90740103	G/T	cg06632027	chr4:90757378	SNCA	-0.42	-5.23	-0.32	3.81e-7	Dementia with Lewy bodies;
SARC	trans	rs66573146	0.831	rs11546450	chr4:7032180	G/A	cg07817883	chr1:32538562	TMEM39B	1.26	8.0	0.46	5.96e-14	Granulocyte percentage of myeloid white cells;
SARC	cis	rs11025559	0.716	rs1596376	chr11:20454229	T/C	cg04101203	chr11:20408940	PRMT3	-0.53	-5.87	-0.36	1.49e-8	Pursuit maintenance gain;
SARC	cis	rs9814567	1.000	rs9854299	chr3:134206728	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-7.02	-0.42	2.34e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs9815354	0.812	rs73071203	chr3:41977464	A/C	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	trans	rs9325144	0.555	rs10748433	chr12:38696352	C/G	cg23762105	chr12:34175262	ALG10	-0.53	-7.07	-0.42	1.81e-11	Morning vs. evening chronotype;
SARC	cis	rs9309473	0.528	rs79799178	chr2:73791235	A/G	cg20560298	chr2:73613845	ALMS1	-0.5	-5.0	-0.31	1.14e-6	Metabolite levels;
SARC	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg02018176	chr4:1364513	KIAA1530	0.61	9.01	0.51	7.88e-17	Longevity;
SARC	cis	rs12142240	0.698	rs67200518	chr1:46835777	T/C	cg10495392	chr1:46806563	NSUN4	0.65	6.88	0.41	5.6e-11	Menopause (age at onset);
SARC	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg00933542	chr6:150070202	PCMT1	0.33	5.53	0.34	8.5e-8	Lung cancer;
SARC	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg08048268	chr3:133502702	NA	-0.43	-5.74	-0.35	2.97e-8	Iron status biomarkers;
SARC	cis	rs10958369	0.934	rs11781325	chr8:54412679	A/G	cg12485204	chr8:54507357	NA	0.35	5.24	0.32	3.55e-7	Response to antineoplastic agents;
SARC	cis	rs881375	0.900	rs1930786	chr9:123691469	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	5.34	0.33	2.25e-7	Rheumatoid arthritis;
SARC	cis	rs262150	1.000	rs262154	chr7:158773936	G/A	cg04111992	chr7:158790115	NA	-0.37	-4.73	-0.3	3.82e-6	Facial morphology (factor 20);
SARC	cis	rs7819412	0.715	rs35223712	chr8:11043926	C/T	cg03403963	chr8:11986501	LOC392196;FAM66D	-0.36	-5.16	-0.32	5.23e-7	Triglycerides;
SARC	cis	rs751728	0.626	rs6457741	chr6:33756026	C/T	cg25922239	chr6:33757077	LEMD2	0.58	7.64	0.45	5.71e-13	Crohn's disease;
SARC	cis	rs6088580	0.634	rs4142007	chr20:32990050	G/T	cg24642439	chr20:33292090	TP53INP2	-0.66	-8.58	-0.49	1.36e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs13191362	1.000	rs13209728	chr6:162997533	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.57	5.51	0.34	9.61e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs17209837	0.920	rs17149652	chr7:87087187	G/T	cg00919237	chr7:87102261	ABCB4	-0.5	-5.47	-0.34	1.14e-7	Gallbladder cancer;
SARC	cis	rs12701220	0.689	rs12701824	chr7:1102364	G/A	cg02733842	chr7:1102375	C7orf50	-0.67	-7.73	-0.45	3.25e-13	Bronchopulmonary dysplasia;
SARC	cis	rs1256061	0.654	rs1256033	chr14:64745399	A/G	cg23250157	chr14:64679961	SYNE2	0.46	6.44	0.39	6.82e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs911263	0.603	rs12880842	chr14:68764254	A/G	cg18825221	chr14:68749962	RAD51L1	0.44	7.96	0.46	7.54e-14	Primary biliary cholangitis;
SARC	cis	rs870825	0.616	rs2090589	chr4:185647731	A/G	cg04058563	chr4:185651563	MLF1IP	0.8	11.35	0.6	4.56e-24	Blood protein levels;
SARC	trans	rs7819412	0.715	rs35223712	chr8:11043926	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.73	-0.4	1.33e-10	Triglycerides;
SARC	cis	rs9303401	0.659	rs35082010	chr17:56936867	A/G	cg25039879	chr17:56429692	SUPT4H1	0.62	5.77	0.35	2.46e-8	Cognitive test performance;
SARC	cis	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg18252515	chr7:66147081	NA	-1.33	-11.96	-0.62	5.03e-26	Diabetic kidney disease;
SARC	cis	rs12497850	1.000	rs4858831	chr3:48735558	C/T	cg07636037	chr3:49044803	WDR6	0.89	14.54	0.69	1.55e-34	Parkinson's disease;
SARC	cis	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg14541582	chr5:601475	NA	-0.4	-4.93	-0.31	1.54e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg23696834	chr6:42928345	GNMT	-0.32	-4.75	-0.3	3.57e-6	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs8044868	0.530	rs2288002	chr16:72057282	A/G	cg16558253	chr16:72132732	DHX38	-0.41	-6.09	-0.37	4.59e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
SARC	cis	rs2304069	0.913	rs9324637	chr5:149390947	T/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.89	9.27	0.52	1.32e-17	HIV-1 control;
SARC	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg08109568	chr15:31115862	NA	-0.52	-6.71	-0.4	1.46e-10	Huntington's disease progression;
SARC	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg12373951	chr3:133503437	NA	0.43	6.1	0.37	4.48e-9	Iron status biomarkers;
SARC	cis	rs526231	0.543	rs26523	chr5:102456254	C/T	cg23492399	chr5:102201601	PAM	-0.52	-5.62	-0.35	5.5e-8	Primary biliary cholangitis;
SARC	cis	rs73206853	0.764	rs7966591	chr12:110644045	G/A	cg10860002	chr12:110842031	ANAPC7	0.65	5.25	0.33	3.39e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg08677398	chr8:58056175	NA	0.44	5.25	0.33	3.38e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2239547	0.657	rs13072536	chr3:52861211	A/T	cg18404041	chr3:52824283	ITIH1	-0.42	-5.01	-0.31	1.05e-6	Schizophrenia;
SARC	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg17971929	chr21:40555470	PSMG1	0.85	11.03	0.59	4.92e-23	Cognitive function;
SARC	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg25072359	chr17:41440525	NA	0.51	6.07	0.37	5.28e-9	Menopause (age at onset);
SARC	cis	rs4742903	0.967	rs4743689	chr9:106909300	G/A	cg14250997	chr9:106856677	SMC2	0.47	6.17	0.37	3e-9	High-grade serous ovarian cancer;Breast cancer;
SARC	trans	rs61931739	0.929	rs7955240	chr12:34066388	G/A	cg26384229	chr12:38710491	ALG10B	-0.53	-7.12	-0.42	1.31e-11	Morning vs. evening chronotype;
SARC	cis	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg00409905	chr10:38381863	ZNF37A	-0.55	-7.88	-0.46	1.26e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs9457247	0.765	rs9459838	chr6:167426599	C/G	cg07741184	chr6:167504864	NA	0.34	6.53	0.39	4.1e-10	Crohn's disease;
SARC	cis	rs67133203	0.606	rs12820559	chr12:51565619	T/C	cg15029631	chr12:52078762	SCN8A	-0.42	-4.93	-0.31	1.59e-6	Urinary tract infection frequency;
SARC	trans	rs61931739	0.534	rs10844828	chr12:34303109	C/T	cg26384229	chr12:38710491	ALG10B	0.75	10.5	0.57	2.35e-21	Morning vs. evening chronotype;
SARC	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg24209194	chr3:40518798	ZNF619	-0.65	-8.28	-0.48	9.51e-15	Renal cell carcinoma;
SARC	trans	rs1814175	0.817	rs1818890	chr11:49856882	T/C	cg15704280	chr7:45808275	SEPT13	-0.96	-18.1	-0.76	2.52e-46	Height;
SARC	cis	rs8103278	0.507	rs16939	chr19:46276056	C/A	cg11657440	chr19:46296263	DMWD	0.8	10.54	0.57	1.7e-21	Coronary artery disease;
SARC	cis	rs12824058	0.831	rs4759450	chr12:130812732	G/A	cg26677194	chr12:130822605	PIWIL1	0.54	7.41	0.44	2.25e-12	Menopause (age at onset);
SARC	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg16339924	chr4:17578868	LAP3	0.66	8.76	0.5	4e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg20607798	chr8:58055168	NA	0.66	5.7	0.35	3.62e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10782582	0.593	rs11589276	chr1:76105545	G/A	cg03433033	chr1:76189801	ACADM	-0.4	-5.26	-0.33	3.34e-7	Daytime sleep phenotypes;
SARC	cis	rs2425143	0.730	rs6579259	chr20:34462550	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	5.16	0.32	5.29e-7	Blood protein levels;
SARC	cis	rs9815354	1.000	rs939558	chr3:41976040	C/A	cg03022575	chr3:42003672	ULK4	-0.55	-5.26	-0.33	3.22e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg24209194	chr3:40518798	ZNF619	0.66	8.02	0.47	5.15e-14	Renal cell carcinoma;
SARC	cis	rs17376456	0.877	rs10213956	chr5:93460839	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.89	0.36	1.36e-8	Diabetic retinopathy;
SARC	cis	rs921968	0.541	rs3770213	chr2:219508372	A/T	cg02176678	chr2:219576539	TTLL4	-0.52	-8.02	-0.46	5.26e-14	Mean corpuscular hemoglobin concentration;
SARC	cis	rs123509	0.913	rs339661	chr3:42753904	G/A	cg12982090	chr3:42733453	KBTBD5	0.53	6.53	0.39	4.13e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	trans	rs61931739	0.500	rs1601628	chr12:34047375	A/C	cg26384229	chr12:38710491	ALG10B	0.75	10.68	0.57	6.46e-22	Morning vs. evening chronotype;
SARC	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.5	0.39	4.96e-10	Bipolar disorder;
SARC	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg12463550	chr7:65579703	CRCP	0.5	5.9	0.36	1.27e-8	Aortic root size;
SARC	cis	rs11190604	1.000	rs2489050	chr10:102350898	T/A	cg07080220	chr10:102295463	HIF1AN	0.77	8.04	0.47	4.66e-14	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs9398803	0.713	rs3861455	chr6:126897969	A/C	cg19875578	chr6:126661172	C6orf173	0.63	8.7	0.5	5.9e-16	Male-pattern baldness;
SARC	cis	rs34172651	0.537	rs8049014	chr16:24698903	A/G	cg00152838	chr16:24741724	TNRC6A	-0.49	-4.98	-0.31	1.24e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2204008	0.538	rs61931093	chr12:38242911	C/T	cg13010199	chr12:38710504	ALG10B	-0.52	-6.44	-0.39	6.73e-10	Bladder cancer;
SARC	cis	rs35110281	0.744	rs162396	chr21:44947807	T/C	cg01579765	chr21:45077557	HSF2BP	-0.32	-5.6	-0.34	6.02e-8	Mean corpuscular volume;
SARC	cis	rs9354308	0.899	rs1938059	chr6:66539291	G/A	cg07460842	chr6:66804631	NA	0.48	5.49	0.34	1.03e-7	Metabolite levels;
SARC	cis	rs7833790	0.685	rs13255262	chr8:82728024	T/G	cg27398817	chr8:82754497	SNX16	-0.44	-5.58	-0.34	6.8e-8	Diastolic blood pressure;
SARC	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg10935138	chr17:73851978	WBP2	0.52	5.48	0.34	1.12e-7	Psoriasis;
SARC	cis	rs360798	0.512	rs2215870	chr2:63132342	C/G	cg17519650	chr2:63277830	OTX1	0.41	5.09	0.32	7.22e-7	Coronary artery disease;
SARC	cis	rs1008375	0.966	rs6825133	chr4:17577776	C/T	cg27347728	chr4:17578864	LAP3	0.49	6.06	0.37	5.46e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2153535	0.580	rs1577467	chr6:8444241	G/A	cg21535247	chr6:8435926	SLC35B3	0.56	7.01	0.42	2.6e-11	Motion sickness;
SARC	cis	rs709400	1.000	rs2403205	chr14:104143385	C/T	cg26031613	chr14:104095156	KLC1	0.97	17.59	0.76	1.24e-44	Body mass index;
SARC	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg13395646	chr4:1353034	KIAA1530	-0.55	-6.58	-0.4	3.03e-10	Obesity-related traits;
SARC	cis	rs2594989	0.790	rs2443712	chr3:11538063	A/G	cg00170343	chr3:11313890	ATG7	0.51	5.68	0.35	4.05e-8	Circulating chemerin levels;
SARC	cis	rs13191362	0.808	rs13217502	chr6:163231414	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.38	5.38	0.33	1.78e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs7216064	1.000	rs62085993	chr17:65923152	T/C	cg12091567	chr17:66097778	LOC651250	-0.7	-7.28	-0.43	4.96e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs4742903	0.904	rs10123189	chr9:107000640	A/G	cg14250997	chr9:106856677	SMC2	0.39	4.91	0.31	1.7e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs9435341	0.965	rs2335104	chr1:107583641	A/T	cg09367891	chr1:107599246	PRMT6	0.66	8.5	0.49	2.3e-15	Facial morphology (factor 21, depth of nasal alae);
SARC	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg08219700	chr8:58056026	NA	0.74	6.82	0.41	7.6e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg08219700	chr8:58056026	NA	0.62	6.3	0.38	1.44e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs1493916	0.967	rs34341086	chr18:31400141	C/T	cg27147174	chr7:100797783	AP1S1	-0.57	-7.06	-0.42	1.85e-11	Life satisfaction;
SARC	cis	rs921968	0.565	rs6757772	chr2:219618497	T/G	cg02176678	chr2:219576539	TTLL4	-0.32	-4.88	-0.3	1.93e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs208520	0.690	rs851465	chr6:66840293	G/A	cg07460842	chr6:66804631	NA	-1.04	-14.38	-0.69	5.61e-34	Exhaled nitric oxide output;
SARC	cis	rs7712401	0.601	rs28892	chr5:122283826	A/G	cg19412675	chr5:122181750	SNX24	-0.41	-5.17	-0.32	5.01e-7	Mean platelet volume;
SARC	cis	rs992157	1.000	rs13429408	chr2:219142860	C/A	cg00012203	chr2:219082015	ARPC2	0.73	11.25	0.59	9.74e-24	Colorectal cancer;
SARC	cis	rs2180341	0.960	rs9398840	chr6:127669744	G/A	cg24812749	chr6:127587940	RNF146	1.01	13.21	0.65	4.13e-30	Breast cancer;
SARC	cis	rs7582180	0.614	rs10193204	chr2:101004540	A/G	cg14675211	chr2:100938903	LONRF2	-0.51	-7.5	-0.44	1.32e-12	Intelligence (multi-trait analysis);
SARC	cis	rs7092929	0.941	rs611726	chr10:3572073	T/C	cg14308648	chr10:3568949	NA	0.5	5.0	0.31	1.11e-6	Coronary artery calcification;
SARC	cis	rs10463316	0.862	rs11747047	chr5:150777953	C/T	cg03212797	chr5:150827313	SLC36A1	-0.51	-6.1	-0.37	4.43e-9	Metabolite levels (Pyroglutamine);
SARC	cis	rs1865760	0.566	rs2032443	chr6:26046802	A/G	cg16482183	chr6:26056742	HIST1H1C	0.49	6.31	0.38	1.41e-9	Height;
SARC	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg23172400	chr8:95962367	TP53INP1	-0.31	-5.38	-0.33	1.83e-7	Type 2 diabetes;
SARC	cis	rs2425143	0.818	rs7272684	chr20:34424692	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-6.33	-0.38	1.22e-9	Blood protein levels;
SARC	cis	rs918629	0.530	rs1423269	chr5:95255724	A/G	cg16656078	chr5:95278638	ELL2	-0.58	-7.15	-0.42	1.1e-11	IgG glycosylation;
SARC	cis	rs9309473	1.000	rs9309473	chr2:73743982	A/G	cg20560298	chr2:73613845	ALMS1	-0.53	-6.41	-0.39	7.83e-10	Metabolite levels;
SARC	cis	rs6089584	0.924	rs6142906	chr20:60552554	G/C	cg23262073	chr20:60523788	NA	-0.41	-5.85	-0.36	1.61e-8	Body mass index;
SARC	cis	rs7597155	0.566	rs4852944	chr2:69950772	C/G	cg02498382	chr2:70120550	SNRNP27	-0.33	-5.27	-0.33	3.08e-7	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs9660992	0.674	rs17345837	chr1:205263122	C/T	cg07972983	chr1:205091412	RBBP5	0.5	5.9	0.36	1.26e-8	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs921968	0.643	rs4674321	chr2:219511368	G/A	cg02176678	chr2:219576539	TTLL4	0.43	6.71	0.4	1.47e-10	Mean corpuscular hemoglobin concentration;
SARC	cis	rs1568889	0.838	rs11030265	chr11:28296168	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.87	14.78	0.7	2.63e-35	Bipolar disorder;
SARC	cis	rs7412746	0.611	rs10888395	chr1:150762171	C/T	cg13175981	chr1:150552382	MCL1	-0.54	-6.59	-0.4	2.9e-10	Melanoma;
SARC	cis	rs526231	0.543	rs183752	chr5:102507812	T/C	cg23492399	chr5:102201601	PAM	-0.53	-5.63	-0.35	5.27e-8	Primary biliary cholangitis;
SARC	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg21132104	chr15:45694354	SPATA5L1	0.77	10.98	0.58	6.87e-23	Homoarginine levels;
SARC	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.71	9.35	0.52	7.44e-18	Chronic sinus infection;
SARC	cis	rs16933812	0.510	rs7026469	chr9:36991227	A/G	cg14294708	chr9:37120828	ZCCHC7	-0.43	-4.81	-0.3	2.7e-6	Obesity-related traits;
SARC	cis	rs2013441	1.000	rs34089239	chr17:20057959	G/T	cg13482628	chr17:19912719	NA	0.48	6.15	0.37	3.36e-9	Obesity-related traits;
SARC	cis	rs7772486	0.686	rs2142983	chr6:146069701	G/C	cg23711669	chr6:146136114	FBXO30	-0.8	-12.99	-0.65	2.26e-29	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3749237	0.595	rs2878298	chr3:49406080	T/C	cg07636037	chr3:49044803	WDR6	0.63	8.1	0.47	3.09e-14	Resting heart rate;
SARC	cis	rs11098499	0.532	rs4833624	chr4:120585497	C/T	cg09307838	chr4:120376055	NA	0.78	11.03	0.59	4.91e-23	Corneal astigmatism;
SARC	cis	rs763121	0.853	rs5757234	chr22:39072686	C/T	cg06022373	chr22:39101656	GTPBP1	0.9	12.54	0.63	6.72e-28	Menopause (age at onset);
SARC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg07414643	chr4:187882934	NA	0.5	7.49	0.44	1.45e-12	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg25087958	chr5:34915621	RAD1;BRIX1	0.6	7.85	0.46	1.53e-13	Breast cancer;
SARC	cis	rs11098499	0.566	rs7664440	chr4:120578540	A/G	cg09307838	chr4:120376055	NA	0.82	10.74	0.58	3.93e-22	Corneal astigmatism;
SARC	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.98	-16.11	-0.73	9.49e-40	Chronic sinus infection;
SARC	trans	rs7824557	0.606	rs1435277	chr8:11196970	C/T	cg06636001	chr8:8085503	FLJ10661	0.62	8.13	0.47	2.54e-14	Retinal vascular caliber;
SARC	cis	rs9611519	0.565	rs8135524	chr22:41436442	T/C	cg17376030	chr22:41985996	PMM1	0.43	5.44	0.34	1.36e-7	Neuroticism;
SARC	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.59e-6	Parkinson's disease;
SARC	cis	rs13191362	1.000	rs73035025	chr6:163000988	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.57	5.38	0.33	1.85e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg25427524	chr10:38739819	LOC399744	-0.61	-9.92	-0.55	1.38e-19	Extrinsic epigenetic age acceleration;
SARC	cis	rs7833790	0.724	rs6473311	chr8:82726682	G/A	cg27398817	chr8:82754497	SNX16	-0.44	-5.58	-0.34	6.51e-8	Diastolic blood pressure;
SARC	cis	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg15556689	chr8:8085844	FLJ10661	0.41	5.19	0.32	4.53e-7	Neuroticism;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg17846497	chr17:78290901	RNF213	-0.76	-6.31	-0.38	1.39e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.53	-5.24	-0.32	3.62e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs743757	1.000	rs743857	chr3:50493550	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.51	4.85	0.3	2.29e-6	Diastolic blood pressure;
SARC	cis	rs1003719	0.715	rs8126941	chr21:38551542	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.6	-8.67	-0.49	7.25e-16	Eye color traits;
SARC	cis	rs7607369	0.536	rs13033409	chr2:219666509	T/G	cg02176678	chr2:219576539	TTLL4	-0.4	-6.16	-0.37	3.12e-9	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg22920501	chr2:26401640	FAM59B	-0.56	-7.4	-0.44	2.5e-12	Gut microbiome composition (summer);
SARC	cis	rs4646312	0.555	rs8140265	chr22:19921641	G/A	cg07194846	chr22:19930177	COMT;TXNRD2	0.51	6.62	0.4	2.41e-10	Schizophrenia;
SARC	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.63e-10	Life satisfaction;
SARC	cis	rs1964356	0.967	rs2953802	chr8:8851881	G/A	cg15556689	chr8:8085844	FLJ10661	0.41	4.91	0.31	1.71e-6	Mean corpuscular volume;
SARC	cis	rs7223966	1.000	rs8074771	chr17:61735865	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-5.95	-0.36	9.56e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs698833	0.828	rs6745281	chr2:44534472	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.65	8.56	0.49	1.54e-15	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs17270561	0.609	rs4711095	chr6:25726774	A/C	cg16482183	chr6:26056742	HIST1H1C	0.43	5.25	0.33	3.49e-7	Iron status biomarkers;
SARC	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg24209194	chr3:40518798	ZNF619	0.58	7.14	0.42	1.16e-11	Renal cell carcinoma;
SARC	cis	rs2191566	0.576	rs436790	chr19:44491927	A/G	cg20607764	chr19:44506953	ZNF230	-0.43	-4.86	-0.3	2.12e-6	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9815354	1.000	rs9869440	chr3:41763155	G/C	cg03022575	chr3:42003672	ULK4	0.57	5.34	0.33	2.2e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg18357526	chr6:26021779	HIST1H4A	0.88	11.71	0.61	3.22e-25	Intelligence (multi-trait analysis);
SARC	cis	rs427394	0.735	rs416689	chr5:6740855	C/T	cg10857441	chr5:6722123	POLS	-0.34	-5.09	-0.32	7.35e-7	Menopause (age at onset);
SARC	cis	rs1008375	0.966	rs6832962	chr4:17652133	T/C	cg16339924	chr4:17578868	LAP3	0.66	8.65	0.49	8.66e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg12463550	chr7:65579703	CRCP	-0.5	-5.59	-0.34	6.32e-8	Aortic root size;
SARC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg02951883	chr7:2050386	MAD1L1	0.53	6.99	0.42	2.87e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs67311347	1.000	rs7642906	chr3:40492633	G/A	cg24209194	chr3:40518798	ZNF619	-0.65	-8.65	-0.49	8.24e-16	Renal cell carcinoma;
SARC	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg17328964	chr8:145687451	CYHR1	0.39	5.13	0.32	6e-7	Age at first birth;
SARC	cis	rs4803468	1.000	rs2241708	chr19:41912270	C/T	cg08477640	chr19:41863820	B9D2	0.41	5.18	0.32	4.7e-7	Height;
SARC	cis	rs9858213	1	rs9858213	chr3:49731861	G/T	cg03060546	chr3:49711283	APEH	-0.65	-8.04	-0.47	4.49e-14	Educational attainment;
SARC	cis	rs1570884	0.516	rs9526580	chr13:50164023	C/G	cg08779649	chr13:50194554	NA	-0.38	-6.61	-0.4	2.66e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	trans	rs7824557	0.527	rs4634600	chr8:11239017	T/A	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.76	-0.45	2.68e-13	Retinal vascular caliber;
SARC	cis	rs11098499	0.505	rs75122014	chr4:120362426	G/C	cg09307838	chr4:120376055	NA	0.89	12.16	0.62	1.13e-26	Corneal astigmatism;
SARC	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg11062466	chr8:58055876	NA	0.52	4.95	0.31	1.44e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs548181	0.668	rs540555	chr11:125486848	T/C	cg03464685	chr11:125439445	EI24	1.02	9.92	0.55	1.39e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs3126085	0.877	rs4456098	chr1:152176034	C/T	cg09127314	chr1:152161683	NA	0.42	4.77	0.3	3.32e-6	Atopic dermatitis;
SARC	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg21724239	chr8:58056113	NA	0.58	6.21	0.38	2.4e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs36715	1.000	rs2617621	chr5:127546266	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	7.19	0.43	8.57e-12	Breast cancer;
SARC	cis	rs6840360	0.533	rs1397683	chr4:152715916	T/C	cg22705602	chr4:152727874	NA	0.47	8.08	0.47	3.39e-14	Intelligence (multi-trait analysis);
SARC	cis	rs9467711	0.722	rs35825164	chr6:26117404	T/C	cg21479132	chr6:26055353	NA	0.97	6.77	0.41	1.06e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg23758822	chr17:41437982	NA	0.88	11.19	0.59	1.55e-23	Menopause (age at onset);
SARC	cis	rs290268	0.838	rs290993	chr9:93559572	G/A	cg02608019	chr9:93564028	SYK	0.35	5.12	0.32	6.27e-7	Platelet count;
SARC	cis	rs7772486	0.764	rs9399569	chr6:146242942	C/T	cg05347473	chr6:146136440	FBXO30	-0.46	-6.34	-0.38	1.21e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.39	0.56	4.87e-21	Prudent dietary pattern;
SARC	cis	rs2933343	0.729	rs1680785	chr3:128644816	C/T	cg24203234	chr3:128598194	ACAD9	0.64	8.08	0.47	3.49e-14	IgG glycosylation;
SARC	cis	rs9303401	0.614	rs17175663	chr17:57108437	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	10.42	0.56	4.09e-21	Cognitive test performance;
SARC	cis	rs7714584	1.000	rs76433514	chr5:150306532	C/G	cg22134413	chr5:150180641	NA	0.8	6.49	0.39	5.04e-10	Crohn's disease;
SARC	cis	rs4642101	0.597	rs12638595	chr3:12819281	T/C	cg24848339	chr3:12840334	CAND2	0.37	5.97	0.36	8.93e-9	QRS complex (12-leadsum);
SARC	cis	rs593982	0.719	rs555903	chr11:65466911	G/A	cg08755490	chr11:65554678	OVOL1	-0.77	-7.47	-0.44	1.59e-12	Atopic dermatitis;
SARC	cis	rs11583043	1.000	rs17123612	chr1:101476814	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.49	5.88	0.36	1.42e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs76419734	0.557	rs11730365	chr4:106782447	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.86	5.96	0.36	9.17e-9	Post bronchodilator FEV1;
SARC	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg22920501	chr2:26401640	FAM59B	0.61	8.19	0.47	1.71e-14	Gut microbiome composition (summer);
SARC	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg22920501	chr2:26401640	FAM59B	-0.55	-7.28	-0.43	5.2e-12	Gut microbiome composition (summer);
SARC	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg08859206	chr1:53392774	SCP2	-0.33	-4.71	-0.3	4.17e-6	Monocyte count;
SARC	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg11764359	chr7:65958608	NA	-0.66	-7.88	-0.46	1.24e-13	Aortic root size;
SARC	cis	rs1941023	0.503	rs4939350	chr11:60136243	C/G	cg08716584	chr11:60157161	MS4A7	-0.4	-6.71	-0.4	1.49e-10	Congenital heart disease (maternal effect);
SARC	cis	rs9354308	0.764	rs1938073	chr6:66583387	C/G	cg07460842	chr6:66804631	NA	0.41	4.73	0.3	3.85e-6	Metabolite levels;
SARC	cis	rs858239	0.899	rs2268747	chr7:23313462	A/G	cg23682824	chr7:23144976	KLHL7	0.57	7.08	0.42	1.65e-11	Cerebrospinal fluid biomarker levels;
SARC	trans	rs9329221	0.662	rs13254942	chr8:10257678	C/T	cg06636001	chr8:8085503	FLJ10661	-0.6	-7.37	-0.43	2.87e-12	Neuroticism;
SARC	trans	rs61931739	0.500	rs11053185	chr12:34428857	A/G	cg26384229	chr12:38710491	ALG10B	0.83	12.64	0.64	3.16e-28	Morning vs. evening chronotype;
SARC	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg11366901	chr6:160182831	ACAT2	1.04	10.86	0.58	1.7e-22	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs9858542	0.953	rs9814873	chr3:49454112	A/G	cg03060546	chr3:49711283	APEH	-0.59	-7.34	-0.43	3.59e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs2439831	0.867	rs16957627	chr15:43642657	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.04	10.9	0.58	1.25e-22	Lung cancer in ever smokers;
SARC	cis	rs6545883	0.929	rs778155	chr2:61647901	A/G	cg15711740	chr2:61764176	XPO1	0.41	4.96	0.31	1.34e-6	Tuberculosis;
SARC	cis	rs703842	1.000	rs10877013	chr12:58165085	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.78	11.47	0.6	1.92e-24	Multiple sclerosis;
SARC	cis	rs2832077	0.527	rs11088095	chr21:30223188	A/T	cg24692254	chr21:30365293	RNF160	-0.65	-7.62	-0.45	6.52e-13	Cognitive test performance;
SARC	cis	rs2629540	0.924	rs2629541	chr10:126425866	G/A	cg08799069	chr10:126477246	METTL10	0.65	6.42	0.39	7.59e-10	Cocaine dependence;
SARC	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.76	-7.78	-0.45	2.41e-13	Platelet count;
SARC	cis	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg13647721	chr17:30228624	UTP6	0.61	5.38	0.33	1.84e-7	Hip circumference adjusted for BMI;
SARC	cis	rs7727544	0.636	rs2631365	chr5:131705949	T/C	cg24060327	chr5:131705240	SLC22A5	0.66	8.47	0.49	2.72e-15	Blood metabolite levels;
SARC	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg03576123	chr11:487126	PTDSS2	1.15	10.89	0.58	1.33e-22	Body mass index;
SARC	cis	rs2380220	0.872	rs4546494	chr6:95990626	A/C	cg04719120	chr6:96025338	MANEA	0.63	6.86	0.41	6.11e-11	Behavioural disinhibition (generation interaction);
SARC	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.97e-8	Aortic root size;
SARC	cis	rs8114671	0.562	rs6120757	chr20:33488771	C/T	cg07148914	chr20:33460835	GGT7	0.45	5.49	0.34	1.07e-7	Height;
SARC	cis	rs10782582	0.593	rs11163904	chr1:76121208	A/G	cg10523679	chr1:76189770	ACADM	0.39	4.98	0.31	1.27e-6	Daytime sleep phenotypes;
SARC	cis	rs5769765	0.908	rs4824109	chr22:50271460	T/C	cg03033257	chr22:50311977	ALG12;CRELD2	-0.54	-5.64	-0.35	4.81e-8	Schizophrenia;
SARC	trans	rs8073060	0.586	rs2523114	chr17:34023762	G/A	cg19694781	chr19:47549865	TMEM160	-0.7	-6.8	-0.41	8.59e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg06697600	chr4:7070879	GRPEL1	-0.4	-5.04	-0.31	9.32e-7	Monocyte percentage of white cells;
SARC	cis	rs2273669	0.915	rs6928200	chr6:109294164	A/C	cg05315195	chr6:109294784	ARMC2	-0.48	-4.78	-0.3	3.15e-6	Prostate cancer;
SARC	cis	rs11677370	0.561	rs12986995	chr2:3826965	G/A	cg17052675	chr2:3827356	NA	-0.54	-6.43	-0.39	7.04e-10	Type 2 diabetes;
SARC	cis	rs2242116	0.796	rs4683297	chr3:46973673	T/C	cg27129171	chr3:47204927	SETD2	-0.62	-8.12	-0.47	2.75e-14	Birth weight;
SARC	cis	rs6860806	0.507	rs270614	chr5:131640813	G/A	cg04518342	chr5:131593106	PDLIM4	0.43	5.44	0.34	1.32e-7	Breast cancer;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg04996728	chr19:51021677	LRRC4B	0.44	6.36	0.38	1.06e-9	Schizophrenia;
SARC	trans	rs2637266	0.745	rs2583039	chr10:78440187	A/G	cg01907658	chr5:132299243	AFF4	-0.46	-6.23	-0.38	2.12e-9	Pulmonary function;
SARC	cis	rs7044106	0.537	rs10818474	chr9:123489964	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.72	8.3	0.48	8.51e-15	Hip circumference adjusted for BMI;
SARC	cis	rs6991838	0.806	rs35284121	chr8:66463465	A/G	cg13398993	chr8:66546079	ARMC1	0.4	4.99	0.31	1.2e-6	Intelligence (multi-trait analysis);
SARC	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.53	-6.7	-0.4	1.56e-10	Resting heart rate;
SARC	cis	rs2933343	0.679	rs789221	chr3:128591625	A/G	cg25356066	chr3:128598488	ACAD9	0.71	9.39	0.52	5.79e-18	IgG glycosylation;
SARC	cis	rs7587476	1.000	rs3768707	chr2:215645135	C/T	cg04004882	chr2:215674386	BARD1	0.56	6.41	0.39	7.9e-10	Neuroblastoma;
SARC	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg11644478	chr21:40555479	PSMG1	-0.9	-11.48	-0.6	1.77e-24	Cognitive function;
SARC	cis	rs67311347	0.955	rs6764102	chr3:40378153	C/G	cg09455208	chr3:40491958	NA	0.39	6.12	0.37	3.93e-9	Renal cell carcinoma;
SARC	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg24503407	chr1:205819492	PM20D1	0.44	5.16	0.32	5.29e-7	Parkinson's disease;
SARC	trans	rs12097821	0.666	rs4480389	chr1:107130373	C/T	cg24684357	chr21:43188367	RIPK4	0.64	6.38	0.39	9.7e-10	Non-obstructive azoospermia;
SARC	cis	rs35110281	0.693	rs2838345	chr21:45092715	C/T	cg21573476	chr21:45109991	RRP1B	-0.59	-8.58	-0.49	1.31e-15	Mean corpuscular volume;
SARC	cis	rs11143230	1.000	rs11143230	chr9:74887703	G/T	cg07476130	chr9:74525250	C9orf85;FAM108B1	0.53	5.86	0.36	1.56e-8	Suicidal ideation;
SARC	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg13877915	chr19:58951672	ZNF132	0.66	9.91	0.54	1.49e-19	Uric acid clearance;
SARC	trans	rs9329221	0.736	rs2001338	chr8:10251217	A/G	cg06636001	chr8:8085503	FLJ10661	0.58	7.04	0.42	2.09e-11	Neuroticism;
SARC	cis	rs2953145	0.545	rs2975751	chr2:241521135	G/A	cg07929629	chr2:241523174	NA	0.38	4.8	0.3	2.87e-6	Bipolar disorder;
SARC	cis	rs2200578	1.000	rs72954221	chr2:99899445	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.63	5.99	0.37	7.89e-9	IgG glycosylation;
SARC	cis	rs7772486	0.754	rs857881	chr6:145970793	C/A	cg05347473	chr6:146136440	FBXO30	-0.55	-7.7	-0.45	3.9e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs57506017	0.540	rs1435527	chr7:12262571	C/T	cg23422036	chr7:12250390	TMEM106B	0.49	6.41	0.39	8.02e-10	Neuroticism;
SARC	cis	rs9290065	0.519	rs1530636	chr3:160697442	A/G	cg03342759	chr3:160939853	NMD3	0.48	5.78	0.35	2.35e-8	Kawasaki disease;
SARC	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.59	7.2	0.43	8.05e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7560272	0.538	rs11126415	chr2:73936500	C/T	cg20560298	chr2:73613845	ALMS1	0.42	5.51	0.34	9.54e-8	Schizophrenia;
SARC	cis	rs6580649	0.941	rs4589362	chr12:48478664	T/C	cg24011408	chr12:48396354	COL2A1	-0.48	-5.36	-0.33	2.04e-7	Lung cancer;
SARC	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg18876405	chr7:65276391	NA	0.46	5.25	0.33	3.41e-7	Aortic root size;
SARC	cis	rs79149102	0.579	rs7172065	chr15:75321910	C/T	cg17294928	chr15:75287854	SCAMP5	-1.09	-8.36	-0.48	5.71e-15	Lung cancer;
SARC	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg10591111	chr5:226296	SDHA	-0.52	-4.86	-0.3	2.16e-6	Breast cancer;
SARC	cis	rs3008870	1.000	rs1925412	chr1:67405057	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.9	11.08	0.59	3.48e-23	Lymphocyte percentage of white cells;
SARC	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg13206674	chr6:150067644	NUP43	0.41	5.36	0.33	1.98e-7	Lung cancer;
SARC	cis	rs10992471	0.603	rs13301537	chr9:95229047	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.25	-0.33	3.37e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs7937682	0.632	rs10891294	chr11:111699224	C/T	cg22437258	chr11:111473054	SIK2	-0.49	-5.62	-0.35	5.54e-8	Primary sclerosing cholangitis;
SARC	cis	rs7296418	0.961	rs7957096	chr12:123544878	A/G	cg00376283	chr12:123451042	ABCB9	0.64	8.1	0.47	3.07e-14	Platelet count;
SARC	cis	rs6121246	0.567	rs2889488	chr20:30185758	G/A	cg21427119	chr20:30132790	HM13	-0.45	-4.98	-0.31	1.23e-6	Mean corpuscular hemoglobin;
SARC	cis	rs96067	0.805	rs2296268	chr1:36603165	G/A	cg24686825	chr1:36642396	MAP7D1	-0.43	-4.83	-0.3	2.43e-6	Corneal structure;
SARC	cis	rs2635047	0.837	rs2571009	chr18:44650279	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.56	7.73	0.45	3.13e-13	Educational attainment;
SARC	cis	rs6504663	1.000	rs6504661	chr17:48580126	A/T	cg00901687	chr17:48585270	MYCBPAP	-0.5	-6.6	-0.4	2.74e-10	Visceral fat;
SARC	cis	rs72634258	0.842	rs7545745	chr1:8165667	T/A	cg00042356	chr1:8021962	PARK7	-0.61	-5.83	-0.36	1.79e-8	Inflammatory bowel disease;
SARC	cis	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg12463550	chr7:65579703	CRCP	0.68	5.24	0.32	3.61e-7	Diabetic kidney disease;
SARC	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg04166393	chr7:2884313	GNA12	0.68	8.21	0.47	1.48e-14	Height;
SARC	cis	rs3857536	0.611	rs6927407	chr6:66870010	T/C	cg07460842	chr6:66804631	NA	-0.71	-8.71	-0.5	5.87e-16	Blood trace element (Cu levels);
SARC	cis	rs526231	0.543	rs246915	chr5:102558044	G/A	cg23492399	chr5:102201601	PAM	-0.56	-5.99	-0.37	7.77e-9	Primary biliary cholangitis;
SARC	cis	rs6088580	0.634	rs2378133	chr20:32919505	C/G	cg08999081	chr20:33150536	PIGU	-0.45	-6.78	-0.41	9.73e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs6977660	0.652	rs10486362	chr7:19755224	A/G	cg07541023	chr7:19748670	TWISTNB	-0.92	-7.85	-0.46	1.47e-13	Thyroid stimulating hormone;
SARC	cis	rs2288073	0.619	rs6713263	chr2:24375463	A/G	cg26838691	chr2:24397539	C2orf84	-0.43	-5.84	-0.36	1.71e-8	Venous thromboembolism (SNP x SNP interaction);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg12141611	chr14:91581030	C14orf159	0.74	6.46	0.39	5.92e-10	Autism spectrum disorder or schizophrenia;
SARC	trans	rs61931739	0.500	rs11053282	chr12:34561151	T/C	cg26384229	chr12:38710491	ALG10B	0.91	13.72	0.67	8.65e-32	Morning vs. evening chronotype;
SARC	cis	rs9660992	0.710	rs1151787	chr1:205254238	G/A	cg21643547	chr1:205240462	TMCC2	-0.61	-7.9	-0.46	1.08e-13	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs9818758	0.607	rs35283189	chr3:49113668	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.69	-5.82	-0.36	1.98e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg00908189	chr16:619842	PIGQ	0.86	12.71	0.64	1.84e-28	Height;
SARC	cis	rs208520	0.955	rs9345808	chr6:67008262	C/T	cg07460842	chr6:66804631	NA	0.72	7.99	0.46	6.18e-14	Exhaled nitric oxide output;
SARC	cis	rs11098499	0.863	rs3822195	chr4:120471660	C/T	cg24375607	chr4:120327624	NA	0.42	4.92	0.31	1.64e-6	Corneal astigmatism;
SARC	cis	rs1348850	0.651	rs4893936	chr2:178240676	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	7.78	0.45	2.29e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs10254118	0.757	rs7788086	chr7:133135206	C/T	cg10665199	chr7:133106180	EXOC4	0.4	4.89	0.31	1.87e-6	Intelligence (multi-trait analysis);
SARC	cis	rs73635312	0.850	rs74725049	chr10:8966312	T/C	cg24467326	chr10:9646929	NA	0.61	5.08	0.32	7.78e-7	Basal cell carcinoma;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg02951695	chr10:134400351	INPP5A	-0.5	-6.27	-0.38	1.72e-9	Height;
SARC	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg14784868	chr12:69753453	YEATS4	0.65	9.07	0.51	5.01e-17	Cerebrospinal fluid biomarker levels;
SARC	cis	rs16976116	0.803	rs28530662	chr15:55498836	A/G	cg11288833	chr15:55489084	RSL24D1	0.62	6.02	0.37	6.78e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6582630	0.519	rs8186881	chr12:38310285	A/G	cg26384229	chr12:38710491	ALG10B	0.87	12.74	0.64	1.45e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs72843506	1.000	rs10459969	chr17:19935901	T/C	cg13482628	chr17:19912719	NA	0.61	5.46	0.34	1.23e-7	Schizophrenia;
SARC	cis	rs6835098	1.000	rs4695826	chr4:174089426	T/G	cg08422745	chr4:174089978	GALNT7	-0.77	-10.37	-0.56	5.62e-21	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.68	6.6	0.4	2.67e-10	Platelet count;
SARC	cis	rs9393692	0.875	rs6939589	chr6:26289203	C/T	cg13736514	chr6:26305472	NA	0.62	8.72	0.5	5.51e-16	Educational attainment;
SARC	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs712039	0.652	rs829161	chr17:35763863	C/T	cg16670864	chr17:35848621	DUSP14	-0.49	-5.49	-0.34	1.05e-7	Tuberculosis;
SARC	cis	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg13147721	chr7:65941812	NA	-0.52	-4.79	-0.3	3.03e-6	Diabetic kidney disease;
SARC	cis	rs2180341	0.781	rs6913350	chr6:127570560	C/T	cg27446573	chr6:127587934	RNF146	0.9	12.4	0.63	1.84e-27	Breast cancer;
SARC	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg23958373	chr8:599963	NA	0.74	5.65	0.35	4.69e-8	IgG glycosylation;
SARC	cis	rs9790314	0.846	rs4856714	chr3:160961824	T/C	cg04691961	chr3:161091175	C3orf57	-0.64	-8.7	-0.5	5.91e-16	Morning vs. evening chronotype;
SARC	cis	rs611744	0.550	rs1448154	chr8:109281053	T/C	cg21045802	chr8:109455806	TTC35	0.62	7.72	0.45	3.38e-13	Dupuytren's disease;
SARC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	6.02	0.37	6.81e-9	Prudent dietary pattern;
SARC	cis	rs7582720	0.943	rs72932556	chr2:203845996	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs611744	0.837	rs422847	chr8:109103274	C/T	cg21045802	chr8:109455806	TTC35	-0.44	-5.24	-0.32	3.61e-7	Dupuytren's disease;
SARC	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg26335602	chr6:28129616	ZNF389	0.52	5.88	0.36	1.44e-8	Parkinson's disease;
SARC	cis	rs13082711	0.911	rs34307140	chr3:27467875	A/C	cg02860705	chr3:27208620	NA	0.45	5.87	0.36	1.51e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs7264396	0.563	rs78084033	chr20:34219990	A/C	cg01084648	chr20:34329383	RBM39	0.64	5.14	0.32	5.91e-7	Total cholesterol levels;
SARC	cis	rs751728	1.000	rs9394166	chr6:33751122	G/C	cg15252951	chr6:33757062	LEMD2	0.59	6.98	0.42	3.11e-11	Crohn's disease;
SARC	cis	rs9969804	0.502	rs9299400	chr9:94939981	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.42	-5.0	-0.31	1.13e-6	Height;
SARC	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg11764359	chr7:65958608	NA	0.53	6.2	0.38	2.57e-9	Aortic root size;
SARC	cis	rs8070463	0.520	rs11652969	chr17:45817367	G/A	cg24803719	chr17:45855879	NA	-0.42	-7.05	-0.42	1.97e-11	Multiple sclerosis;Ankylosing spondylitis;
SARC	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg06618935	chr21:46677482	NA	-0.43	-5.18	-0.32	4.84e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6964587	1.000	rs2888851	chr7:91648341	G/A	cg17063962	chr7:91808500	NA	0.95	16.01	0.72	2.09e-39	Breast cancer;
SARC	cis	rs1691799	0.867	rs1168297	chr12:66735644	T/C	cg16791601	chr12:66731901	HELB	-0.71	-10.66	-0.57	7.26e-22	White blood cell count (basophil);
SARC	cis	rs7639513	0.545	rs12714874	chr3:12719928	C/T	cg23032965	chr3:12705835	RAF1	0.69	7.6	0.45	7.27e-13	Itch intensity from mosquito bite;
SARC	cis	rs2921036	0.529	rs2979192	chr8:8338147	C/T	cg15556689	chr8:8085844	FLJ10661	0.42	4.83	0.3	2.43e-6	Neuroticism;
SARC	cis	rs72634258	0.503	rs71637401	chr1:7837012	G/A	cg05338066	chr1:7812865	CAMTA1	0.66	5.45	0.34	1.3e-7	Inflammatory bowel disease;
SARC	cis	rs9430161	0.611	rs72644043	chr1:11033051	T/A	cg02454025	chr1:11042201	C1orf127	0.87	12.08	0.62	2.04e-26	Ewing sarcoma;
SARC	cis	rs9747201	0.926	rs34153075	chr17:80135728	C/A	cg17462356	chr17:80056334	FASN	0.48	5.49	0.34	1.06e-7	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg21747090	chr2:27597821	SNX17	-0.55	-7.68	-0.45	4.38e-13	Total body bone mineral density;
SARC	cis	rs11785400	0.793	rs11543967	chr8:143739435	A/G	cg24634471	chr8:143751801	JRK	-0.59	-7.32	-0.43	3.94e-12	Schizophrenia;
SARC	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg04772025	chr11:68637568	NA	0.51	6.15	0.37	3.34e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs80130819	0.748	rs2732478	chr12:48699537	G/A	cg24011408	chr12:48396354	COL2A1	0.52	5.89	0.36	1.33e-8	Prostate cancer;
SARC	trans	rs10085978	0.604	rs11167127	chr8:143225736	C/T	cg12891252	chr10:43902500	HNRNPF	0.52	6.34	0.38	1.19e-9	Mosquito bite size;
SARC	cis	rs34779708	0.966	rs35777088	chr10:35409048	T/C	cg03585969	chr10:35415529	CREM	0.42	5.17	0.32	5.03e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs9902453	0.933	rs9303628	chr17:28527228	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	6.72	0.4	1.35e-10	Coffee consumption (cups per day);
SARC	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg04277193	chr17:41438351	NA	-0.45	-4.92	-0.31	1.63e-6	Menopause (age at onset);
SARC	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg09165964	chr15:75287851	SCAMP5	0.6	8.08	0.47	3.58e-14	Breast cancer;
SARC	cis	rs62064224	0.818	rs11080180	chr17:30682998	G/A	cg18200150	chr17:30822561	MYO1D	0.43	6.81	0.41	8.37e-11	Schizophrenia;
SARC	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg27286337	chr10:134555280	INPP5A	0.71	8.17	0.47	2.02e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs7264396	0.563	rs2425111	chr20:34319765	A/C	cg01084648	chr20:34329383	RBM39	0.58	5.03	0.31	9.74e-7	Total cholesterol levels;
SARC	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.85	11.17	0.59	1.76e-23	Platelet count;
SARC	trans	rs9329221	0.650	rs657913	chr8:9882575	G/T	cg06636001	chr8:8085503	FLJ10661	-0.67	-9.57	-0.53	1.66e-18	Neuroticism;
SARC	cis	rs10911232	0.524	rs4487994	chr1:182982173	T/A	cg13390022	chr1:182993471	LAMC1	0.34	5.17	0.32	5.11e-7	Hypertriglyceridemia;
SARC	cis	rs950169	0.881	rs62029596	chr15:84955434	A/G	cg24253500	chr15:84953950	NA	0.36	5.21	0.32	4.19e-7	Schizophrenia;
SARC	cis	rs7615952	0.932	rs13086087	chr3:125646281	A/C	cg05084668	chr3:125655381	ALG1L	-0.67	-6.63	-0.4	2.32e-10	Blood pressure (smoking interaction);
SARC	cis	rs4742903	0.509	rs10991107	chr9:106860969	T/C	cg14250997	chr9:106856677	SMC2	0.49	6.15	0.37	3.34e-9	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs854765	0.663	rs12941550	chr17:17753828	C/A	cg05444541	chr17:17804740	TOM1L2	0.3	5.11	0.32	6.83e-7	Total body bone mineral density;
SARC	cis	rs6696846	0.765	rs61822568	chr1:205081166	C/G	cg21643547	chr1:205240462	TMCC2	-0.58	-7.73	-0.45	3.12e-13	Red blood cell count;
SARC	cis	rs1348850	0.914	rs9789582	chr2:178330173	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.71	9.14	0.51	3.06e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9916302	0.904	rs801419	chr17:37466327	A/G	cg15445000	chr17:37608096	MED1	-0.46	-5.65	-0.35	4.66e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs67460515	0.506	rs935497	chr3:160600563	A/G	cg03342759	chr3:160939853	NMD3	-0.53	-5.7	-0.35	3.64e-8	Parkinson's disease;
SARC	cis	rs9916302	0.851	rs11078907	chr17:37662954	C/T	cg07936489	chr17:37558343	FBXL20	-0.69	-8.94	-0.51	1.2e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs6500602	0.702	rs3789038	chr16:4546586	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.28	-4.95	-0.31	1.43e-6	Schizophrenia;
SARC	cis	rs10140922	0.966	rs10132397	chr14:35822447	G/T	cg26967526	chr14:35346199	BAZ1A	-0.39	-4.9	-0.31	1.82e-6	Hip circumference adjusted for BMI;
SARC	cis	rs947211	0.898	rs1772153	chr1:205745782	C/T	cg11965913	chr1:205819406	PM20D1	-0.45	-5.11	-0.32	6.73e-7	Parkinson's disease;
SARC	cis	rs34375054	0.735	rs34961756	chr12:125628598	C/T	cg25124228	chr12:125621409	AACS	-0.52	-6.59	-0.4	2.9e-10	Post bronchodilator FEV1/FVC ratio;
SARC	trans	rs7819412	0.745	rs6601569	chr8:11073578	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.8	-0.41	8.85e-11	Triglycerides;
SARC	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.96	13.9	0.67	2.19e-32	Height;
SARC	cis	rs9818758	0.607	rs56004653	chr3:49072228	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.64	-4.99	-0.31	1.2e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs2120019	1.000	rs7162900	chr15:75368017	T/C	cg00629941	chr15:75287862	SCAMP5	-0.6	-7.22	-0.43	7.22e-12	Blood trace element (Zn levels);
SARC	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg00149659	chr3:10157352	C3orf10	0.64	5.91	0.36	1.22e-8	Alzheimer's disease;
SARC	cis	rs12142240	0.698	rs1057533	chr1:46815836	C/T	cg10495392	chr1:46806563	NSUN4	0.65	6.77	0.41	1.03e-10	Menopause (age at onset);
SARC	cis	rs2074585	0.802	rs2589940	chr15:90931363	C/T	cg22089800	chr15:90895588	ZNF774	0.76	9.77	0.54	3.95e-19	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs12134245	0.776	rs13447526	chr1:91983174	A/G	cg02896835	chr1:92012615	NA	0.48	6.41	0.39	8e-10	Breast cancer;
SARC	cis	rs7178909	0.902	rs2043881	chr15:90439960	G/A	cg19708238	chr15:90437601	AP3S2	0.63	8.52	0.49	2.01e-15	Common traits (Other);
SARC	cis	rs4588572	0.643	rs10063742	chr5:77759362	A/G	cg11547950	chr5:77652471	NA	-0.41	-5.03	-0.31	9.75e-7	Triglycerides;
SARC	cis	rs8067545	0.578	rs4925087	chr17:20024582	A/C	cg13482628	chr17:19912719	NA	0.52	6.83	0.41	7.47e-11	Schizophrenia;
SARC	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg11764359	chr7:65958608	NA	-0.63	-7.46	-0.44	1.66e-12	Aortic root size;
SARC	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg14582100	chr15:45693742	SPATA5L1	0.35	4.91	0.31	1.69e-6	Homoarginine levels;
SARC	cis	rs6714710	0.603	rs10432626	chr2:98561153	C/A	cg26665480	chr2:98280029	ACTR1B	0.49	6.48	0.39	5.33e-10	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg22496380	chr5:211416	CCDC127	-0.88	-9.28	-0.52	1.21e-17	Breast cancer;
SARC	cis	rs76419734	1.000	rs72671837	chr4:106635902	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.84	5.56	0.34	7.44e-8	Post bronchodilator FEV1;
SARC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg26338869	chr17:61819248	STRADA	0.79	10.07	0.55	4.93e-20	Prudent dietary pattern;
SARC	cis	rs10992471	0.603	rs4743873	chr9:95270781	C/T	cg13798575	chr9:95087839	CENPP;NOL8	0.45	5.14	0.32	5.79e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg22105103	chr4:187893119	NA	0.5	6.83	0.41	7.49e-11	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs10838798	0.504	rs11039673	chr11:48335156	G/A	cg15704280	chr7:45808275	SEPT13	-0.48	-6.57	-0.4	3.21e-10	Height;
SARC	cis	rs12291225	0.546	rs12291662	chr11:14342949	T/C	cg19336497	chr11:14380999	RRAS2	-0.44	-7.73	-0.45	3.24e-13	Sense of smell;
SARC	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg22857025	chr5:266934	NA	-1.06	-11.8	-0.61	1.74e-25	Breast cancer;
SARC	cis	rs7824557	0.578	rs2060458	chr8:11212811	C/A	cg21775007	chr8:11205619	TDH	0.73	9.67	0.54	8.24e-19	Retinal vascular caliber;
SARC	cis	rs4481887	0.861	rs4295906	chr1:248429861	C/T	cg01631408	chr1:248437212	OR2T33	-0.43	-5.34	-0.33	2.25e-7	Common traits (Other);
SARC	cis	rs739401	0.611	rs401707	chr11:3050965	T/C	cg08508325	chr11:3079039	CARS	-0.32	-7.7	-0.45	3.81e-13	Longevity;
SARC	cis	rs3820928	0.874	rs13393894	chr2:227880543	A/G	cg05526886	chr2:227700861	RHBDD1	-0.52	-6.37	-0.39	1e-9	Pulmonary function;
SARC	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg24531977	chr5:56204891	C5orf35	0.52	5.21	0.32	4.2e-7	Initial pursuit acceleration;
SARC	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg03185022	chr7:2884158	GNA12	0.44	4.73	0.3	3.91e-6	Height;
SARC	cis	rs2273669	0.915	rs10872028	chr6:109313728	A/G	cg05315195	chr6:109294784	ARMC2	0.47	4.74	0.3	3.71e-6	Prostate cancer;
SARC	cis	rs938554	0.744	rs13129697	chr4:9926967	T/G	cg25986240	chr4:9926439	SLC2A9	0.3	4.75	0.3	3.53e-6	Blood metabolite levels;
SARC	cis	rs7264396	0.943	rs224431	chr20:34153599	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-5.37	-0.33	1.88e-7	Total cholesterol levels;
SARC	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg14517863	chr17:44321492	NA	0.41	6.18	0.38	2.91e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs10463554	0.892	rs66505956	chr5:102279557	C/T	cg23492399	chr5:102201601	PAM	-0.47	-5.5	-0.34	9.91e-8	Parkinson's disease;
SARC	cis	rs10463316	0.894	rs3905511	chr5:150768204	G/A	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.27	-0.33	3.06e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs1153858	0.887	rs7164139	chr15:45670851	G/A	cg26924012	chr15:45694286	SPATA5L1	0.79	11.28	0.59	7.91e-24	Homoarginine levels;
SARC	cis	rs9341808	0.667	rs7746917	chr6:80931503	T/C	cg08355045	chr6:80787529	NA	0.38	5.97	0.36	8.83e-9	Sitting height ratio;
SARC	cis	rs6582630	0.537	rs1949610	chr12:38387838	C/T	cg13010199	chr12:38710504	ALG10B	0.78	10.77	0.58	3.24e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs17270561	0.609	rs12203927	chr6:25732690	A/G	cg17691542	chr6:26056736	HIST1H1C	0.58	7.09	0.42	1.59e-11	Iron status biomarkers;
SARC	cis	rs67460515	0.563	rs6772723	chr3:160895074	C/G	cg03342759	chr3:160939853	NMD3	-0.6	-7.4	-0.44	2.49e-12	Parkinson's disease;
SARC	cis	rs2228479	1.000	rs12596492	chr16:89957169	T/G	cg00800038	chr16:89945340	TCF25	-0.75	-5.23	-0.32	3.82e-7	Skin colour saturation;
SARC	cis	rs7618501	0.966	rs13085679	chr3:49869631	G/A	cg13072238	chr3:49761600	GMPPB	0.47	6.07	0.37	5.14e-9	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg18876405	chr7:65276391	NA	-0.72	-9.19	-0.52	2.26e-17	Aortic root size;
SARC	cis	rs10504073	0.647	rs2292399	chr8:49987230	A/G	cg00325661	chr8:49890786	NA	0.55	7.29	0.43	4.87e-12	Blood metabolite ratios;
SARC	cis	rs6674176	0.628	rs2301993	chr1:44426025	G/A	cg13606994	chr1:44402422	ARTN	-0.33	-5.34	-0.33	2.24e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs9457247	0.935	rs1187530	chr6:167376812	C/T	cg07741184	chr6:167504864	NA	-0.3	-5.61	-0.35	5.69e-8	Crohn's disease;
SARC	cis	rs3820928	1.000	rs2163041	chr2:227772480	T/C	cg05526886	chr2:227700861	RHBDD1	-0.5	-6.11	-0.37	4.08e-9	Pulmonary function;
SARC	cis	rs4664308	1.000	rs6759836	chr2:160912802	C/T	cg03641300	chr2:160917029	PLA2R1	-0.68	-9.19	-0.52	2.29e-17	Idiopathic membranous nephropathy;
SARC	cis	rs9916302	0.706	rs9909304	chr17:37500508	G/T	cg15445000	chr17:37608096	MED1	-0.46	-5.04	-0.31	9.46e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs77106637	0.789	rs76550717	chr11:72428172	A/G	cg03713592	chr11:72463424	ARAP1	1.06	10.03	0.55	6.36e-20	Type 2 diabetes;
SARC	cis	rs12950390	0.548	rs7215477	chr17:45858117	A/C	cg24803719	chr17:45855879	NA	-0.47	-7.82	-0.46	1.79e-13	IgG glycosylation;
SARC	cis	rs4727027	0.736	rs12704084	chr7:148915050	C/G	cg23583168	chr7:148888333	NA	-0.8	-12.22	-0.62	7.41e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs7932354	0.554	rs6485721	chr11:47040854	A/G	cg03339077	chr11:47165057	C11orf49	-0.39	-5.27	-0.33	3.06e-7	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs12142240	0.698	rs7548675	chr1:46809321	C/G	cg10495392	chr1:46806563	NSUN4	0.64	6.76	0.4	1.09e-10	Menopause (age at onset);
SARC	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.59	-7.01	-0.42	2.61e-11	Gut microbiome composition (summer);
SARC	cis	rs36051895	0.664	rs10115172	chr9:5098549	C/T	cg02405213	chr9:5042618	JAK2	-0.47	-5.62	-0.35	5.52e-8	Pediatric autoimmune diseases;
SARC	cis	rs2070488	0.965	rs3762788	chr3:38493852	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	14.64	0.69	7.76e-35	Electrocardiographic conduction measures;
SARC	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg18876405	chr7:65276391	NA	-0.72	-9.54	-0.53	2.08e-18	Aortic root size;
SARC	cis	rs1018836	0.668	rs9297857	chr8:91480964	A/C	cg16814680	chr8:91681699	NA	-0.69	-10.47	-0.57	2.87e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	trans	rs7144584	1.000	rs7144584	chr14:64275812	A/G	cg02382666	chr7:134463454	CALD1	-0.58	-6.76	-0.4	1.07e-10	Pulmonary function decline;
SARC	cis	rs2816062	0.786	rs735946	chr1:18901323	T/C	cg18795169	chr1:18902165	NA	-0.82	-12.95	-0.65	2.95e-29	Urate levels in lean individuals;
SARC	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg25894440	chr7:65020034	NA	-0.77	-5.95	-0.36	9.84e-9	Diabetic kidney disease;
SARC	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg22618164	chr12:122356400	WDR66	-0.42	-6.84	-0.41	6.87e-11	Mean corpuscular volume;
SARC	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg06212747	chr3:49208901	KLHDC8B	0.79	11.58	0.6	8.76e-25	Menarche (age at onset);
SARC	cis	rs2013441	1.000	rs2703780	chr17:20143672	A/G	cg13482628	chr17:19912719	NA	-0.47	-6.2	-0.38	2.57e-9	Obesity-related traits;
SARC	cis	rs2012796	0.743	rs8020575	chr14:81859521	G/A	cg02996355	chr14:81879375	NA	0.51	5.7	0.35	3.7e-8	Night sleep phenotypes;
SARC	cis	rs9790314	0.613	rs1447619	chr3:160616077	A/T	cg04691961	chr3:161091175	C3orf57	0.52	7.07	0.42	1.79e-11	Morning vs. evening chronotype;
SARC	cis	rs2304069	0.837	rs10041451	chr5:149385197	A/C	cg12661370	chr5:149340060	SLC26A2	0.59	5.64	0.35	4.83e-8	HIV-1 control;
SARC	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg13939156	chr17:80058883	NA	-0.42	-6.48	-0.39	5.51e-10	Life satisfaction;
SARC	cis	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg12463550	chr7:65579703	CRCP	0.68	5.09	0.32	7.53e-7	Gout;
SARC	cis	rs3126085	0.935	rs11204951	chr1:152224404	A/G	cg26876637	chr1:152193138	HRNR	0.46	5.41	0.33	1.57e-7	Atopic dermatitis;
SARC	cis	rs7710178	0.761	rs157339	chr5:156132278	A/G	cg26439139	chr5:155924786	SGCD	-0.46	-4.89	-0.31	1.84e-6	Airway responsiveness in chronic obstructive pulmonary disease;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg09410845	chr2:203241870	BMPR2	0.52	6.33	0.38	1.26e-9	Fibrinogen levels;
SARC	cis	rs7264396	0.635	rs6060696	chr20:34522060	C/T	cg12579300	chr20:34535607	PHF20	-0.42	-4.93	-0.31	1.58e-6	Total cholesterol levels;
SARC	cis	rs3820928	0.839	rs12470666	chr2:227876525	G/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-5.85	-0.36	1.65e-8	Pulmonary function;
SARC	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg20887711	chr4:1340912	KIAA1530	0.49	5.95	0.36	9.82e-9	Longevity;
SARC	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg13126279	chr21:47581558	C21orf56	0.42	5.15	0.32	5.63e-7	Testicular germ cell tumor;
SARC	cis	rs3758785	0.537	rs565367	chr11:94070642	C/G	cg13023536	chr11:94226537	MRE11A;ANKRD49	-0.42	-5.2	-0.32	4.31e-7	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
SARC	cis	rs881375	0.967	rs7034653	chr9:123687372	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.44	5.26	0.33	3.21e-7	Rheumatoid arthritis;
SARC	cis	rs1153858	1.000	rs3809472	chr15:45694318	G/T	cg21132104	chr15:45694354	SPATA5L1	0.78	10.56	0.57	1.54e-21	Homoarginine levels;
SARC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg27588902	chr6:42928151	GNMT	-0.37	-5.62	-0.35	5.33e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs4713118	0.868	rs10484401	chr6:27746590	A/T	cg26335602	chr6:28129616	ZNF389	-0.48	-4.8	-0.3	2.82e-6	Parkinson's disease;
SARC	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.69	9.19	0.52	2.21e-17	Menarche (age at onset);
SARC	cis	rs703842	1.000	rs10877013	chr12:58165085	C/T	cg00677455	chr12:58241039	CTDSP2	0.51	6.81	0.41	8.29e-11	Multiple sclerosis;
SARC	cis	rs10752881	1.000	rs4420053	chr1:182976133	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.76	0.58	3.38e-22	Colorectal cancer;
SARC	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg12923728	chr3:195709715	SDHAP1	-0.69	-8.63	-0.49	9.95e-16	Pancreatic cancer;
SARC	cis	rs453301	0.686	rs6748	chr8:8890802	C/T	cg06636001	chr8:8085503	FLJ10661	-0.61	-8.2	-0.47	1.64e-14	Joint mobility (Beighton score);
SARC	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg06634786	chr22:41940651	POLR3H	0.51	6.09	0.37	4.6e-9	Vitiligo;
SARC	cis	rs17376456	0.877	rs17083460	chr5:93462354	A/G	cg25358565	chr5:93447407	FAM172A	1.31	15.17	0.7	1.33e-36	Diabetic retinopathy;
SARC	cis	rs748404	0.660	rs689767	chr15:43722077	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	5.75	0.35	2.76e-8	Lung cancer;
SARC	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg24675658	chr1:53192096	ZYG11B	0.6	8.35	0.48	6.02e-15	Monocyte count;
SARC	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-8.03	-0.47	4.67e-14	Chronic sinus infection;
SARC	cis	rs6582630	0.598	rs12823134	chr12:38514347	T/A	cg13010199	chr12:38710504	ALG10B	-0.5	-6.19	-0.38	2.63e-9	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs72949976	0.511	rs11903721	chr2:214016752	G/C	cg08319019	chr2:214017104	IKZF2	-0.54	-7.48	-0.44	1.46e-12	Lung cancer;Squamous cell lung carcinoma;
SARC	cis	rs698833	0.780	rs11124986	chr2:44508835	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	6.66	0.4	2e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg11890956	chr21:40555474	PSMG1	0.73	9.23	0.52	1.68e-17	Cognitive function;
SARC	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.1	21.57	0.82	1.82e-57	Chronic sinus infection;
SARC	cis	rs7617773	0.780	rs34630841	chr3:48343261	G/A	cg11946769	chr3:48343235	NME6	0.76	9.7	0.54	6.55e-19	Coronary artery disease;
SARC	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg20891558	chr2:74357851	NA	-0.65	-9.06	-0.51	5.42e-17	Gestational age at birth (maternal effect);
SARC	cis	rs6598955	0.724	rs12757113	chr1:26597144	C/T	cg04990556	chr1:26633338	UBXN11	-0.58	-7.77	-0.45	2.44e-13	Obesity-related traits;
SARC	cis	rs7552404	0.731	rs7523573	chr1:76372020	G/T	cg22875332	chr1:76189707	ACADM	0.4	4.74	0.3	3.75e-6	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.58	-6.34	-0.38	1.19e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs2985684	0.802	rs10150823	chr14:50051751	C/T	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.45	4.93	0.31	1.57e-6	Carotid intima media thickness;
SARC	cis	rs10911251	0.508	rs729672	chr1:183109236	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.68	9.79	0.54	3.44e-19	Colorectal cancer;
SARC	cis	rs9400467	0.537	rs111262375	chr6:111418816	C/G	cg15721981	chr6:111408429	SLC16A10	0.71	6.05	0.37	5.7e-9	Blood metabolite levels;Amino acid levels;
SARC	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg26335602	chr6:28129616	ZNF389	0.52	5.88	0.36	1.44e-8	Depression;
SARC	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg07157834	chr1:205819609	PM20D1	0.42	5.74	0.35	2.96e-8	Menarche (age at onset);
SARC	cis	rs6920965	0.507	rs12203025	chr6:126192034	C/T	cg05901451	chr6:126070800	HEY2	-0.48	-5.83	-0.36	1.8e-8	High light scatter reticulocyte count;
SARC	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg13206674	chr6:150067644	NUP43	0.41	5.36	0.33	1.98e-7	Lung cancer;
SARC	cis	rs56235845	0.694	rs11748912	chr5:176765395	G/A	cg17509989	chr5:176798049	RGS14	0.57	7.8	0.45	2.09e-13	Hemoglobin concentration;Hematocrit;
SARC	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg11062466	chr8:58055876	NA	0.64	5.4	0.33	1.66e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2370759	0.945	rs10508773	chr10:32575444	C/T	cg18270830	chr10:32634957	EPC1	0.65	5.77	0.35	2.46e-8	Sexual dysfunction (female);
SARC	cis	rs933688	0.938	rs10063683	chr5:90714595	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.08	13.76	0.67	6.36e-32	Smoking behavior;
SARC	cis	rs6540556	0.859	rs1007693	chr1:209931799	C/T	cg05527609	chr1:210001259	C1orf107	-0.64	-6.42	-0.39	7.71e-10	Red blood cell count;
SARC	cis	rs7512552	0.768	rs7517441	chr1:150283643	A/T	cg15654264	chr1:150340011	RPRD2	-0.38	-4.86	-0.3	2.16e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg12463550	chr7:65579703	CRCP	-0.49	-5.42	-0.33	1.47e-7	Aortic root size;
SARC	cis	rs7561528	0.501	rs56193035	chr2:127891207	C/G	cg12632573	chr2:127783243	NA	0.66	5.98	0.37	8.11e-9	Alzheimer's disease;Alzheimer's disease (late onset);
SARC	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg18876405	chr7:65276391	NA	-0.72	-9.18	-0.52	2.4e-17	Aortic root size;
SARC	cis	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.84	12.7	0.64	2.02e-28	Eosinophil percentage of white cells;
SARC	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg19223190	chr17:80058835	NA	0.46	6.43	0.39	7.11e-10	Life satisfaction;
SARC	cis	rs1707322	1.000	rs785507	chr1:46541558	C/T	cg03146154	chr1:46216737	IPP	-0.48	-5.55	-0.34	7.65e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs36093844	0.800	rs76663264	chr11:85578455	C/G	cg15359163	chr5:122429178	PRDM6	-0.53	-6.38	-0.39	9.19e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs75920871	0.528	rs11600552	chr11:116900947	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.46	-4.75	-0.3	3.57e-6	Subjective well-being;
SARC	cis	rs898097	0.845	rs7213006	chr17:80899928	T/C	cg20578329	chr17:80767326	TBCD	0.43	6.09	0.37	4.61e-9	Breast cancer;
SARC	cis	rs1371867	0.875	rs1788184	chr8:101335106	A/G	cg11906718	chr8:101322791	RNF19A	0.66	8.65	0.49	8.33e-16	Atrioventricular conduction;
SARC	cis	rs2153535	0.601	rs1855765	chr6:8444325	C/T	cg07606381	chr6:8435919	SLC35B3	0.78	11.09	0.59	3.11e-23	Motion sickness;
SARC	cis	rs3091242	0.933	rs932372	chr1:25755014	G/A	cg27572855	chr1:25598939	RHD	0.52	8.75	0.5	4.24e-16	Erythrocyte sedimentation rate;
SARC	cis	rs7264396	0.563	rs3827029	chr20:34332784	G/T	cg01084648	chr20:34329383	RBM39	-0.55	-4.98	-0.31	1.24e-6	Total cholesterol levels;
SARC	cis	rs9457247	1.000	rs397713	chr6:167386714	G/A	cg07741184	chr6:167504864	NA	0.29	5.49	0.34	1.04e-7	Crohn's disease;
SARC	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	8.4	0.48	4.48e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1355223	0.902	rs12800220	chr11:34701617	A/G	cg18508148	chr11:34937573	PDHX;APIP	-0.41	-5.28	-0.33	2.9e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs9581943	0.933	rs61652270	chr13:28461726	C/T	cg25299895	chr13:28498091	PDX1	0.38	5.13	0.32	6.03e-7	Pancreatic cancer;
SARC	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg16325326	chr1:53192061	ZYG11B	-0.83	-13.0	-0.65	2.09e-29	Monocyte count;
SARC	cis	rs7666738	0.830	rs28852677	chr4:99039509	T/G	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg05861140	chr6:150128134	PCMT1	-0.41	-5.17	-0.32	5.01e-7	Lung cancer;
SARC	cis	rs9398803	0.830	rs1415671	chr6:126759587	T/G	cg19875578	chr6:126661172	C6orf173	0.62	8.51	0.49	2.21e-15	Male-pattern baldness;
SARC	cis	rs6089584	1.000	rs6142910	chr20:60562181	C/A	cg23262073	chr20:60523788	NA	-0.44	-6.42	-0.39	7.39e-10	Body mass index;
SARC	cis	rs36051895	0.632	rs62541959	chr9:5175687	G/C	cg02405213	chr9:5042618	JAK2	-0.45	-5.11	-0.32	6.66e-7	Pediatric autoimmune diseases;
SARC	cis	rs9790314	0.637	rs7628880	chr3:160743217	C/A	cg04691961	chr3:161091175	C3orf57	-0.58	-7.98	-0.46	6.53e-14	Morning vs. evening chronotype;
SARC	cis	rs244731	1.000	rs244730	chr5:176539212	A/G	cg16006841	chr5:176797999	RGS14	-0.53	-6.6	-0.4	2.81e-10	Urate levels in lean individuals;
SARC	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg03709012	chr19:19516395	GATAD2A	1.0	17.04	0.74	8.22e-43	Tonsillectomy;
SARC	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1707322	0.721	rs10890333	chr1:46100322	T/C	cg06784218	chr1:46089804	CCDC17	0.36	6.18	0.38	2.9e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs3096299	0.586	rs4572400	chr16:89533516	T/A	cg08392591	chr16:89556376	ANKRD11	0.58	8.1	0.47	3.03e-14	Multiple myeloma (IgH translocation);
SARC	cis	rs17345786	0.906	rs55710435	chr3:101180330	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.45	-4.73	-0.3	3.97e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs80130819	0.748	rs987986	chr12:48645427	C/G	cg24011408	chr12:48396354	COL2A1	0.52	5.9	0.36	1.25e-8	Prostate cancer;
SARC	cis	rs288326	0.561	rs75466155	chr2:183706804	T/G	cg09997497	chr2:183902928	NCKAP1	0.72	4.99	0.31	1.21e-6	Blood protein levels;
SARC	cis	rs9650657	0.530	rs6982381	chr8:10952500	A/T	cg21775007	chr8:11205619	TDH	-0.46	-5.79	-0.35	2.29e-8	Neuroticism;
SARC	cis	rs2153535	0.540	rs9378557	chr6:8517381	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	8.21	0.47	1.56e-14	Motion sickness;
SARC	cis	rs765787	0.530	rs55771002	chr15:45541566	T/C	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.81e-6	Uric acid levels;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg06688411	chr11:65153958	FRMD8	0.5	6.4	0.39	8.61e-10	Lung adenocarcinoma;
SARC	cis	rs7644634	0.559	rs1867190	chr3:105474535	C/T	cg23051926	chr3:105466016	CBLB	0.49	5.57	0.34	6.93e-8	Itch intensity from mosquito bite;
SARC	cis	rs748404	0.660	rs690012	chr15:43719755	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	5.75	0.35	2.76e-8	Lung cancer;
SARC	trans	rs13325613	0.915	rs71327041	chr3:46267582	C/T	cg12387106	chr12:133178249	NA	0.84	6.57	0.4	3.25e-10	Monocyte count;
SARC	cis	rs2075371	0.966	rs2544224	chr7:133995832	A/G	cg00033643	chr7:134001901	SLC35B4	0.42	5.06	0.31	8.41e-7	Mean platelet volume;
SARC	cis	rs9790314	0.779	rs1599374	chr3:160891727	G/A	cg04691961	chr3:161091175	C3orf57	-0.7	-9.48	-0.53	3.08e-18	Morning vs. evening chronotype;
SARC	cis	rs240764	0.817	rs6922219	chr6:101153907	G/C	cg09795085	chr6:101329169	ASCC3	-0.45	-5.89	-0.36	1.32e-8	Neuroticism;
SARC	cis	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg24110177	chr3:50126178	RBM5	0.4	5.06	0.31	8.7e-7	Intelligence (multi-trait analysis);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg10237911	chr5:72861638	UTP15;ANKRA2	-0.48	-6.46	-0.39	6.01e-10	Chemerin levels;
SARC	cis	rs13191362	0.507	rs2849534	chr6:163144657	T/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.44	-4.8	-0.3	2.84e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs1707322	1.000	rs12097761	chr1:46291162	T/C	cg06784218	chr1:46089804	CCDC17	0.35	6.1	0.37	4.41e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg22800045	chr5:56110881	MAP3K1	0.63	6.79	0.41	9.24e-11	Initial pursuit acceleration;
SARC	cis	rs4144743	0.759	rs16941731	chr17:45317022	C/T	cg18085866	chr17:45331354	ITGB3	0.73	6.38	0.39	9.24e-10	Body mass index;
SARC	cis	rs1348850	0.914	rs10497503	chr2:178371739	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.63	8.0	0.46	5.73e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7582720	1.000	rs79642273	chr2:203830851	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs4595586	0.545	rs12816776	chr12:39375817	A/G	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	cis	rs8067545	0.611	rs2013443	chr17:20023109	G/C	cg13482628	chr17:19912719	NA	0.56	7.23	0.43	6.97e-12	Schizophrenia;
SARC	trans	rs11098499	0.909	rs28668716	chr4:120309875	T/C	cg25214090	chr10:38739885	LOC399744	0.55	7.14	0.42	1.15e-11	Corneal astigmatism;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12336574	chr1:193090803	CDC73	-0.51	-6.46	-0.39	6.08e-10	Smoking initiation;
SARC	cis	rs2120019	0.567	rs8029351	chr15:75177237	A/C	cg17294928	chr15:75287854	SCAMP5	-0.88	-9.27	-0.52	1.33e-17	Blood trace element (Zn levels);
SARC	cis	rs698833	0.663	rs1223222	chr2:44756361	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	6.57	0.4	3.23e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs6087990	0.842	rs6119279	chr20:31330612	A/G	cg13636640	chr20:31349939	DNMT3B	0.79	12.57	0.64	5.17e-28	Ulcerative colitis;
SARC	cis	rs6060717	0.536	rs8125393	chr20:34496162	G/T	cg01084648	chr20:34329383	RBM39	0.62	4.75	0.3	3.62e-6	Hip circumference adjusted for BMI;
SARC	trans	rs17685	0.784	rs1613890	chr7:75735037	T/C	cg19862616	chr7:65841803	NCRNA00174	0.63	7.77	0.45	2.42e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs11722228	1.000	rs4697695	chr4:9915850	C/T	cg25986240	chr4:9926439	SLC2A9	-0.29	-4.9	-0.31	1.83e-6	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg11494091	chr17:61959527	GH2	0.53	7.86	0.46	1.4e-13	Prudent dietary pattern;
SARC	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg12463550	chr7:65579703	CRCP	-0.71	-5.37	-0.33	1.9e-7	Diabetic kidney disease;
SARC	cis	rs943466	0.513	rs943467	chr6:33731811	A/T	cg25922239	chr6:33757077	LEMD2	0.43	5.37	0.33	1.95e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
SARC	cis	rs10752881	0.967	rs8179361	chr1:182974572	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.76	0.58	3.38e-22	Colorectal cancer;
SARC	cis	rs7043114	0.525	rs10116241	chr9:95240546	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-5.44	-0.34	1.36e-7	Height;
SARC	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg24324837	chr19:49891574	CCDC155	0.47	5.82	0.36	1.91e-8	Multiple sclerosis;
SARC	cis	rs9807841	0.592	rs2043304	chr19:10772112	T/C	cg17710535	chr19:10819994	QTRT1	0.44	5.15	0.32	5.42e-7	Inflammatory skin disease;
SARC	cis	rs2089162	1	rs2089162	chr15:78739763	A/G	cg18825076	chr15:78729989	IREB2	-0.55	-6.62	-0.4	2.49e-10	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	8.51	0.49	2.13e-15	Mean platelet volume;
SARC	cis	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg21573476	chr21:45109991	RRP1B	-0.56	-8.38	-0.48	5.03e-15	Mean corpuscular volume;
SARC	cis	rs9457247	1.000	rs404222	chr6:167402150	G/A	cg23791538	chr6:167370224	RNASET2	-0.62	-8.55	-0.49	1.65e-15	Crohn's disease;
SARC	cis	rs711830	1.000	rs2113559	chr2:177031099	A/G	cg13092806	chr2:177043255	NA	0.64	6.32	0.38	1.3e-9	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
SARC	cis	rs1348850	0.914	rs12612857	chr2:178467144	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	6.89	0.41	5.1e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs155076	1.000	rs484365	chr13:21845944	G/T	cg14456004	chr13:21872349	NA	-1.0	-12.77	-0.64	1.13e-28	White matter hyperintensity burden;
SARC	cis	rs76917914	0.820	rs7046514	chr9:100815088	C/T	cg03040243	chr9:100819229	NANS	0.74	8.06	0.47	4.02e-14	Immature fraction of reticulocytes;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg01302165	chr20:35492437	C20orf117	0.52	6.96	0.41	3.38e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs174551	1	rs174551	chr11:61573684	T/C	cg19610905	chr11:61596333	FADS2	-0.4	-4.79	-0.3	3.03e-6	LDL cholesterol;
SARC	cis	rs4919087	0.748	rs1687369	chr10:98976923	G/A	cg25902810	chr10:99078978	FRAT1	-0.55	-6.09	-0.37	4.54e-9	Monocyte count;
SARC	cis	rs7666738	0.830	rs13137859	chr4:99050319	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	trans	rs3942852	0.806	rs10838805	chr11:48118993	A/C	cg15704280	chr7:45808275	SEPT13	-0.59	-6.8	-0.41	8.89e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs6450176	0.625	rs3776726	chr5:53290052	T/A	ch.5.1024479R	chr5:53302184	ARL15	-0.85	-9.95	-0.55	1.14e-19	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs7223966	0.921	rs11655493	chr17:61733052	C/T	cg00588841	chr17:61851480	DDX42;CCDC47	-0.61	-6.56	-0.39	3.4e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg12463550	chr7:65579703	CRCP	-0.45	-5.04	-0.31	9.24e-7	Aortic root size;
SARC	cis	rs3126085	1.000	rs11485508	chr1:152253167	T/G	cg26876637	chr1:152193138	HRNR	0.46	5.29	0.33	2.86e-7	Atopic dermatitis;
SARC	cis	rs12421382	1.000	rs12421382	chr11:109378071	C/T	cg16359550	chr11:109292809	C11orf87	0.42	5.83	0.36	1.87e-8	Schizophrenia;
SARC	cis	rs1008375	1.000	rs4698198	chr4:17656536	G/A	cg16339924	chr4:17578868	LAP3	0.66	8.83	0.5	2.57e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg11905131	chr22:24372483	LOC391322	-0.49	-5.62	-0.35	5.31e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg16339924	chr4:17578868	LAP3	0.63	8.28	0.48	9.43e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg11062466	chr8:58055876	NA	0.64	5.98	0.36	8.43e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs3820928	0.692	rs2396434	chr2:227775223	G/T	cg11843606	chr2:227700838	RHBDD1	-0.56	-7.73	-0.45	3.26e-13	Pulmonary function;
SARC	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg04267008	chr7:1944627	MAD1L1	-0.53	-6.09	-0.37	4.68e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs1580019	0.587	rs7805311	chr7:32558302	A/G	cg07520158	chr7:32535189	LSM5;AVL9	-0.59	-7.55	-0.44	9.66e-13	Cognitive ability;
SARC	cis	rs920590	0.684	rs59565447	chr8:19668430	A/T	cg03894339	chr8:19674705	INTS10	0.63	7.24	0.43	6.42e-12	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	9.92	0.54	1.45e-19	Platelet count;
SARC	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg04277193	chr17:41438351	NA	0.45	4.8	0.3	2.85e-6	Menopause (age at onset);
SARC	cis	rs524281	0.773	rs2155201	chr11:65992344	T/C	cg14036092	chr11:66035641	RAB1B	-0.59	-6.24	-0.38	2.1e-9	Electroencephalogram traits;
SARC	trans	rs561341	1.000	rs560132	chr17:30320019	C/T	cg20587970	chr11:113659929	NA	-1.35	-13.75	-0.67	6.99e-32	Hip circumference adjusted for BMI;
SARC	cis	rs6964587	1.000	rs7785095	chr7:91640773	A/T	cg17063962	chr7:91808500	NA	-0.92	-15.14	-0.7	1.68e-36	Breast cancer;
SARC	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg20607798	chr8:58055168	NA	0.63	7.35	0.43	3.3e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs34172651	0.917	rs1465422	chr16:24772486	C/T	cg00339695	chr16:24857497	SLC5A11	0.29	4.81	0.3	2.73e-6	Intelligence (multi-trait analysis);
SARC	cis	rs734999	0.967	rs6671426	chr1:2504234	C/A	cg18854424	chr1:2615690	NA	0.3	4.87	0.3	2.02e-6	Ulcerative colitis;
SARC	cis	rs72781680	0.611	rs72783625	chr2:24315540	C/T	cg08917208	chr2:24149416	ATAD2B	0.6	6.32	0.38	1.32e-9	Lymphocyte counts;
SARC	cis	rs9660992	0.674	rs12122105	chr1:205256818	C/T	cg07972983	chr1:205091412	RBBP5	0.52	6.18	0.38	2.77e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg18876405	chr7:65276391	NA	-0.45	-5.31	-0.33	2.51e-7	Aortic root size;
SARC	cis	rs897984	0.683	rs12447534	chr16:30804257	C/T	cg02466173	chr16:30829666	NA	0.5	7.2	0.43	8.07e-12	Dementia with Lewy bodies;
SARC	cis	rs2011503	1.000	rs4808962	chr19:19579557	A/G	cg15839431	chr19:19639596	YJEFN3	-0.47	-4.73	-0.3	3.84e-6	Bipolar disorder;
SARC	cis	rs356220	0.656	rs356218	chr4:90637010	A/G	cg06632027	chr4:90757378	SNCA	0.41	5.47	0.34	1.15e-7	Parkinson's disease;
SARC	cis	rs11098499	0.754	rs1546503	chr4:120241167	T/C	cg09307838	chr4:120376055	NA	0.81	11.15	0.59	2.11e-23	Corneal astigmatism;
SARC	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6087990	1.000	rs2424901	chr20:31344512	A/G	cg13636640	chr20:31349939	DNMT3B	0.81	12.8	0.64	9.27e-29	Ulcerative colitis;
SARC	cis	rs2070488	0.636	rs2284817	chr3:38510388	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.63	8.11	0.47	2.82e-14	Electrocardiographic conduction measures;
SARC	cis	rs7044106	0.708	rs959558	chr9:123368911	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	5.49	0.34	1.03e-7	Hip circumference adjusted for BMI;
SARC	trans	rs9929218	0.954	rs7186333	chr16:68815838	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.49	-6.35	-0.38	1.1e-9	Colorectal cancer;
SARC	cis	rs1348850	0.768	rs57681892	chr2:178357645	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.64	8.24	0.48	1.24e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs72949976	1.000	rs62186568	chr2:214033955	G/A	cg08319019	chr2:214017104	IKZF2	-0.5	-6.73	-0.4	1.29e-10	Lung cancer;Squamous cell lung carcinoma;
SARC	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg13880726	chr7:1868755	MAD1L1	0.47	5.56	0.34	7.25e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	5.38	0.33	1.86e-7	Personality dimensions;
SARC	cis	rs1559088	0.948	rs7247748	chr19:33594023	T/C	cg27124370	chr19:33622961	WDR88	0.44	5.87	0.36	1.5e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg13939156	chr17:80058883	NA	0.4	6.25	0.38	1.92e-9	Life satisfaction;
SARC	cis	rs57504626	1	rs57504626	chr19:19720399	C/T	cg03709012	chr19:19516395	GATAD2A	0.84	5.87	0.36	1.48e-8	Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
SARC	cis	rs8523	0.901	rs1238273	chr6:10968904	A/G	cg13562911	chr6:11044106	ELOVL2	0.44	5.72	0.35	3.31e-8	Red blood cell fatty acid levels;
SARC	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg24675658	chr1:53192096	ZYG11B	-0.67	-9.96	-0.55	1.09e-19	Monocyte count;
SARC	cis	rs57994353	0.598	rs72775768	chr9:139324574	C/T	cg13611204	chr9:139324423	INPP5E	-0.29	-4.96	-0.31	1.36e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs6580649	0.883	rs7967762	chr12:48420214	C/T	cg24011408	chr12:48396354	COL2A1	-0.48	-5.47	-0.34	1.19e-7	Lung cancer;
SARC	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.79	5.81	0.36	2.09e-8	Initial pursuit acceleration;
SARC	cis	rs1348850	0.645	rs10181259	chr2:178428256	C/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.54	5.83	0.36	1.81e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1348850	0.537	rs3770010	chr2:178537796	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.43	5.02	0.31	1.02e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs6582630	0.519	rs8189461	chr12:38374870	G/T	cg26384229	chr12:38710491	ALG10B	0.87	12.69	0.64	2.17e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs67460515	0.926	rs66508859	chr3:160946351	C/T	cg04691961	chr3:161091175	C3orf57	-0.47	-5.82	-0.36	1.89e-8	Parkinson's disease;
SARC	cis	rs2387326	1.000	rs10764751	chr10:129926420	A/C	cg16087940	chr10:129947807	NA	-0.51	-6.42	-0.39	7.51e-10	Select biomarker traits;
SARC	cis	rs8067354	0.872	rs2645466	chr17:57853214	A/C	cg02344993	chr17:57696989	CLTC	0.42	4.8	0.3	2.85e-6	Hemoglobin concentration;
SARC	cis	rs3754214	0.857	rs9126	chr1:150259400	A/C	cg09579323	chr1:150459698	TARS2	-0.4	-5.01	-0.31	1.06e-6	Cerebrospinal fluid biomarker levels;
SARC	cis	rs4595586	0.545	rs2388177	chr12:39364403	T/C	cg26384229	chr12:38710491	ALG10B	0.51	6.25	0.38	1.9e-9	Morning vs. evening chronotype;
SARC	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg00933542	chr6:150070202	PCMT1	0.36	6.08	0.37	4.96e-9	Lung cancer;
SARC	cis	rs2239547	0.522	rs2336669	chr3:52994138	C/T	cg11645453	chr3:52864694	ITIH4	-0.33	-5.28	-0.33	2.9e-7	Schizophrenia;
SARC	cis	rs4642101	0.694	rs12631514	chr3:12838293	G/C	cg05775895	chr3:12838266	CAND2	0.82	14.69	0.69	5.26e-35	QRS complex (12-leadsum);
SARC	cis	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg05084668	chr3:125655381	ALG1L	-0.49	-5.22	-0.32	4.02e-7	Blood pressure (smoking interaction);
SARC	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg12373951	chr3:133503437	NA	0.36	5.26	0.33	3.27e-7	Iron status biomarkers;
SARC	cis	rs3771570	1.000	rs62193221	chr2:242354632	T/C	cg21155796	chr2:242212141	HDLBP	0.7	6.26	0.38	1.8e-9	Prostate cancer;
SARC	cis	rs138249	1.000	rs138249	chr22:50569790	C/T	cg24864161	chr22:50528282	MOV10L1	0.31	4.99	0.31	1.21e-6	Gestational age at birth in labor-initiated deliveries (child effect);
SARC	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.19	-0.56	2.08e-20	Chronic sinus infection;
SARC	cis	rs17331151	0.573	rs4687556	chr3:52890475	T/C	cg04865290	chr3:52927548	TMEM110	0.58	5.91	0.36	1.19e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2425143	1.000	rs4602287	chr20:34368028	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.64	-5.23	-0.32	3.83e-7	Blood protein levels;
SARC	cis	rs10911251	0.528	rs2093982	chr1:183094191	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.82e-21	Colorectal cancer;
SARC	cis	rs7762018	1.000	rs6904601	chr6:170131905	T/G	cg15038512	chr6:170123185	PHF10	0.51	4.91	0.31	1.73e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs9660992	0.710	rs1180721	chr1:205232696	T/C	cg00857998	chr1:205179979	DSTYK	0.51	6.25	0.38	1.96e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs1008375	1.000	rs4698634	chr4:17630192	A/C	cg02297831	chr4:17616191	MED28	-0.51	-6.31	-0.38	1.36e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7224737	1.000	rs8070446	chr17:40285879	G/A	cg20291162	chr17:40259547	DHX58	-0.33	-4.87	-0.3	2.08e-6	Fibrinogen levels;
SARC	cis	rs17539620	0.624	rs62432740	chr6:154836054	C/T	cg17771515	chr6:154831774	CNKSR3	0.53	5.07	0.32	8.2e-7	Lipoprotein (a) levels;
SARC	cis	rs12711979	0.509	rs13000873	chr2:3823705	T/C	cg17052675	chr2:3827356	NA	-0.52	-7.56	-0.44	9.02e-13	Itch intensity from mosquito bite adjusted by bite size;
SARC	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg13206674	chr6:150067644	NUP43	0.46	6.1	0.37	4.29e-9	Lung cancer;
SARC	cis	rs459482	0.504	rs363882	chr21:42818273	C/T	cg14166395	chr21:42792516	MX1	-0.42	-4.86	-0.3	2.18e-6	IgG glycosylation;
SARC	cis	rs12142240	0.698	rs6697123	chr1:46811310	A/C	cg14993813	chr1:46806288	NSUN4	-0.52	-5.48	-0.34	1.12e-7	Menopause (age at onset);
SARC	cis	rs2836974	0.897	rs2776308	chr21:40715175	A/G	cg11890956	chr21:40555474	PSMG1	1.08	16.37	0.73	1.3e-40	Cognitive function;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg27402766	chr3:100468242	ABI3BP	0.5	6.71	0.4	1.49e-10	Thyroid stimulating hormone;
SARC	cis	rs7027203	0.828	rs10761287	chr9:96609150	A/G	cg14598338	chr9:96623480	NA	-0.54	-7.64	-0.45	5.77e-13	DNA methylation (variation);
SARC	cis	rs10932679	0.532	rs2024488	chr2:217662968	G/A	cg05032264	chr2:217675019	NA	-0.5	-5.81	-0.36	1.99e-8	Pulse pressure;
SARC	cis	rs9815354	0.812	rs60659106	chr3:41949569	G/C	cg03022575	chr3:42003672	ULK4	0.7	5.7	0.35	3.66e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs35213789	0.534	rs6944645	chr7:69016081	T/C	cg10619644	chr7:69149951	AUTS2	0.35	5.0	0.31	1.11e-6	Childhood ear infection;
SARC	cis	rs7584330	0.868	rs6760842	chr2:238398165	C/T	cg21707521	chr2:238875814	UBE2F	-0.4	-5.66	-0.35	4.48e-8	Prostate cancer;
SARC	cis	rs1635	0.826	rs115041649	chr6:28274653	G/C	cg15743358	chr6:28303923	ZNF323	-0.75	-4.84	-0.3	2.32e-6	Schizophrenia;
SARC	cis	rs889312	0.500	rs11960484	chr5:56109154	C/T	cg14703610	chr5:56206110	C5orf35	-0.48	-5.91	-0.36	1.23e-8	Breast cancer;Breast cancer (early onset);
SARC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg17178900	chr1:205818956	PM20D1	0.67	9.88	0.54	1.85e-19	Menarche (age at onset);
SARC	trans	rs61931739	0.534	rs11053049	chr12:34164537	T/C	cg13010199	chr12:38710504	ALG10B	0.73	9.84	0.54	2.42e-19	Morning vs. evening chronotype;
SARC	cis	rs6484504	0.532	rs1475558	chr11:31263428	A/G	cg02090638	chr11:31391270	DNAJC24;DCDC1	-0.42	-5.04	-0.31	9.32e-7	Red blood cell count;
SARC	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-10.5	-0.57	2.32e-21	Chronic sinus infection;
SARC	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.36	4.82	0.3	2.56e-6	Total body bone mineral density;
SARC	cis	rs7937682	0.921	rs12806479	chr11:111443192	G/C	cg22437258	chr11:111473054	SIK2	-0.66	-8.29	-0.48	9.04e-15	Primary sclerosing cholangitis;
SARC	cis	rs6952808	0.858	rs12671113	chr7:1965255	G/A	cg04267008	chr7:1944627	MAD1L1	-0.64	-7.58	-0.44	8.07e-13	Bipolar disorder and schizophrenia;
SARC	cis	rs208520	1.000	rs9453663	chr6:66976077	A/G	cg07460842	chr6:66804631	NA	0.79	8.89	0.5	1.68e-16	Exhaled nitric oxide output;
SARC	cis	rs55823223	0.618	rs11867339	chr17:73862093	A/G	cg08125733	chr17:73851984	WBP2	0.66	7.07	0.42	1.82e-11	Psoriasis;
SARC	cis	rs11809207	0.523	rs2783628	chr1:26501827	A/C	cg00300879	chr1:26503847	CNKSR1	0.31	4.78	0.3	3.07e-6	Height;
SARC	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg20120463	chr17:44301886	NA	0.32	5.03	0.31	9.89e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg00149659	chr3:10157352	C3orf10	0.69	6.44	0.39	6.6e-10	Alzheimer's disease;
SARC	cis	rs1468333	0.929	rs2107682	chr5:137543135	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.8	10.6	0.57	1.13e-21	Resting heart rate;
SARC	cis	rs3857536	0.741	rs2097679	chr6:66937994	T/C	cg07460842	chr6:66804631	NA	-0.51	-5.83	-0.36	1.86e-8	Blood trace element (Cu levels);
SARC	cis	rs4481887	0.821	rs7515408	chr1:248425738	C/T	cg13385794	chr1:248469461	NA	0.32	4.77	0.3	3.21e-6	Common traits (Other);
SARC	cis	rs10791323	0.660	rs10791330	chr11:133727535	C/T	cg13461336	chr11:133711254	SPATA19	-0.28	-5.04	-0.31	9.34e-7	Childhood ear infection;
SARC	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg11764359	chr7:65958608	NA	-0.81	-10.54	-0.57	1.73e-21	Aortic root size;
SARC	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg03433033	chr1:76189801	ACADM	0.55	7.75	0.45	2.76e-13	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs854765	0.724	rs62072049	chr17:17906520	T/C	cg04398451	chr17:18023971	MYO15A	-0.43	-6.31	-0.38	1.42e-9	Total body bone mineral density;
SARC	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg11062466	chr8:58055876	NA	0.52	5.4	0.33	1.64e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs3812111	0.510	rs1569824	chr6:116590802	T/A	cg18828861	chr6:116576566	TSPYL4	0.33	4.85	0.3	2.21e-6	Age-related macular degeneration;
SARC	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.82	12.26	0.63	5.4e-27	Personality dimensions;
SARC	cis	rs10046574	0.831	rs7780028	chr7:135092556	A/G	cg27474649	chr7:135195673	CNOT4	0.88	7.16	0.42	1.02e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs2658782	0.951	rs72972357	chr11:93118840	T/C	cg15737290	chr11:93063684	CCDC67	-0.73	-7.34	-0.43	3.55e-12	Pulmonary function decline;
SARC	cis	rs11098499	0.954	rs11935596	chr4:120412457	G/C	cg09307838	chr4:120376055	NA	0.93	12.73	0.64	1.6e-28	Corneal astigmatism;
SARC	cis	rs1865760	1.000	rs7770139	chr6:25925823	A/G	cg10373733	chr6:25993375	NA	0.42	5.02	0.31	1.03e-6	Height;
SARC	cis	rs78545713	0.649	rs11753717	chr6:26220202	G/C	cg00631329	chr6:26305371	NA	-0.71	-5.14	-0.32	5.85e-7	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg10591111	chr5:226296	SDHA	-0.56	-5.08	-0.32	7.89e-7	Breast cancer;
SARC	cis	rs7589342	0.862	rs10469862	chr2:106509907	C/T	cg14210321	chr2:106509881	NCK2	-0.5	-5.88	-0.36	1.38e-8	Addiction;
SARC	cis	rs8058578	1.000	rs67456513	chr16:30714828	A/T	cg00531865	chr16:30841666	NA	-0.51	-5.79	-0.35	2.24e-8	Multiple myeloma;
SARC	cis	rs6570726	0.935	rs387965	chr6:145869366	A/G	cg23711669	chr6:146136114	FBXO30	0.74	10.95	0.58	8.9e-23	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4280164	0.945	rs2224122	chr14:24783414	G/C	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.54	-5.12	-0.32	6.45e-7	Parent of origin effect on language impairment (paternal);
SARC	cis	rs6430585	0.583	rs4988163	chr2:136628121	G/T	cg07169764	chr2:136633963	MCM6	1.06	15.44	0.71	1.65e-37	Corneal structure;
SARC	cis	rs7937682	0.889	rs12360825	chr11:111528786	A/T	cg22437258	chr11:111473054	SIK2	0.74	10.14	0.55	3.05e-20	Primary sclerosing cholangitis;
SARC	cis	rs10911232	0.524	rs10911209	chr1:183013988	T/G	cg13390022	chr1:182993471	LAMC1	0.36	5.42	0.33	1.48e-7	Hypertriglyceridemia;
SARC	cis	rs425277	0.917	rs262656	chr1:2088754	A/C	cg21442419	chr1:2182373	SKI	-0.53	-6.71	-0.4	1.44e-10	Height;
SARC	cis	rs897984	0.683	rs8046001	chr16:30833321	C/T	cg02466173	chr16:30829666	NA	-0.54	-7.84	-0.46	1.56e-13	Dementia with Lewy bodies;
SARC	cis	rs10861342	0.892	rs11112366	chr12:105486108	G/A	cg23923672	chr12:105501055	KIAA1033	0.73	5.3	0.33	2.74e-7	IgG glycosylation;
SARC	cis	rs9296092	0.538	rs9469488	chr6:33517117	G/T	cg13560919	chr6:33536144	NA	-0.5	-5.91	-0.36	1.22e-8	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg12564285	chr5:131593104	PDLIM4	-0.48	-6.37	-0.39	1e-9	Breast cancer;
SARC	cis	rs9398803	0.687	rs4629707	chr6:126937890	T/C	cg19875578	chr6:126661172	C6orf173	0.6	8.22	0.47	1.39e-14	Male-pattern baldness;
SARC	cis	rs9487051	0.676	rs6568567	chr6:109596993	A/G	cg01475377	chr6:109611718	NA	-0.35	-5.08	-0.32	7.8e-7	Reticulocyte fraction of red cells;
SARC	cis	rs7020830	0.898	rs2790063	chr9:37287405	G/A	cg14294708	chr9:37120828	ZCCHC7	1.1	19.74	0.79	1.26e-51	Schizophrenia;
SARC	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg17376030	chr22:41985996	PMM1	-0.73	-9.01	-0.51	7.45e-17	Vitiligo;
SARC	cis	rs721399	0.539	rs10089958	chr8:18269343	A/G	cg18736775	chr8:18248649	NAT2	-0.56	-5.42	-0.33	1.51e-7	Blood metabolite levels;
SARC	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg12311346	chr5:56204834	C5orf35	0.42	4.81	0.3	2.66e-6	Type 2 diabetes;
SARC	cis	rs9815354	0.767	rs6805140	chr3:41995791	A/G	cg03022575	chr3:42003672	ULK4	0.68	5.97	0.36	8.59e-9	Pulse pressure;Diastolic blood pressure;
SARC	trans	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg04267164	chr19:49402096	TULP2	-0.48	-6.86	-0.41	6.18e-11	Immature fraction of reticulocytes;
SARC	cis	rs7681440	0.606	rs990087	chr4:90755177	A/C	cg06632027	chr4:90757378	SNCA	-0.44	-5.44	-0.34	1.32e-7	Dementia with Lewy bodies;
SARC	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg17221315	chr6:27791827	HIST1H4J	0.51	5.13	0.32	5.96e-7	Parkinson's disease;
SARC	cis	rs11731606	0.712	rs17378658	chr4:95390157	A/G	cg20625393	chr4:95128694	SMARCAD1	-0.51	-5.12	-0.32	6.33e-7	Mean platelet volume;
SARC	cis	rs3815700	1.000	rs8101356	chr19:33093402	C/T	cg02997394	chr19:33096574	ANKRD27	0.8	8.23	0.47	1.36e-14	Eosinophilic esophagitis;
SARC	cis	rs9902453	1.000	rs4075623	chr17:28386526	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.53	-6.96	-0.41	3.52e-11	Coffee consumption (cups per day);
SARC	cis	rs2652822	0.710	rs56208666	chr15:63451858	T/G	cg02713581	chr15:63449717	RPS27L	0.69	8.63	0.49	9.58e-16	Metabolic traits;
SARC	cis	rs6831352	0.918	rs29001203	chr4:100053091	A/G	cg12011299	chr4:100065546	ADH4	-0.35	-5.87	-0.36	1.48e-8	Alcohol dependence;
SARC	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg18135555	chr8:22132992	PIWIL2	0.39	5.87	0.36	1.49e-8	Hypertriglyceridemia;
SARC	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg25072359	chr17:41440525	NA	0.48	5.62	0.35	5.43e-8	Menopause (age at onset);
SARC	cis	rs7220711	1.000	rs12602349	chr17:41792236	T/C	cg26893861	chr17:41843967	DUSP3	0.41	5.24	0.32	3.61e-7	Bone mineral density (spine);Bone mineral density (hip);
SARC	cis	rs1983891	0.742	rs4711677	chr6:41555862	G/A	cg15051332	chr6:41514432	FOXP4	0.48	5.06	0.31	8.51e-7	Prostate cancer;
SARC	cis	rs6005807	0.543	rs6005866	chr22:29162940	A/G	cg02153584	chr22:29168773	CCDC117	0.66	5.17	0.32	5.08e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
SARC	cis	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg03060546	chr3:49711283	APEH	0.68	7.25	0.43	5.97e-12	Menarche (age at onset);
SARC	cis	rs1699337	0.538	rs66615477	chr3:12298314	G/T	cg04748988	chr3:12329223	PPARG	-0.43	-5.71	-0.35	3.43e-8	Cholesterol, total;
SARC	cis	rs7615952	0.546	rs11717632	chr3:125321130	G/C	cg05084668	chr3:125655381	ALG1L	-0.55	-4.89	-0.31	1.88e-6	Blood pressure (smoking interaction);
SARC	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg11764359	chr7:65958608	NA	0.77	9.41	0.52	5.12e-18	Aortic root size;
SARC	cis	rs6546550	0.901	rs6729760	chr2:70161032	C/T	cg02498382	chr2:70120550	SNRNP27	-0.34	-5.76	-0.35	2.67e-8	Prevalent atrial fibrillation;
SARC	cis	rs11190604	0.767	rs11190513	chr10:102165238	A/G	cg07080220	chr10:102295463	HIF1AN	0.73	7.84	0.46	1.61e-13	Palmitoleic acid (16:1n-7) levels;
SARC	trans	rs8073060	0.660	rs34184070	chr17:34003810	A/G	cg19694781	chr19:47549865	TMEM160	-0.7	-6.92	-0.41	4.32e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg16132339	chr22:24313637	DDTL;DDT	-0.42	-5.33	-0.33	2.32e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-8.76	-0.5	4.18e-16	Alzheimer's disease;
SARC	cis	rs7223966	1.000	rs8067431	chr17:61817048	T/C	cg00588841	chr17:61851480	DDX42;CCDC47	-0.67	-7.22	-0.43	7.19e-12	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg01448562	chr3:133502909	NA	-0.59	-9.06	-0.51	5.6e-17	Iron status biomarkers;
SARC	cis	rs4481887	0.741	rs1361413	chr1:248529521	C/G	cg13385794	chr1:248469461	NA	-0.35	-5.71	-0.35	3.37e-8	Common traits (Other);
SARC	cis	rs57502260	0.764	rs3867143	chr11:68223074	A/G	cg01657329	chr11:68192670	LRP5	-0.49	-4.81	-0.3	2.75e-6	Total body bone mineral density (age 45-60);
SARC	cis	rs3617	0.652	rs60332615	chr3:52867595	C/A	cg18404041	chr3:52824283	ITIH1	0.37	5.37	0.33	1.9e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs34172651	0.917	rs8043962	chr16:24781372	A/G	cg00152838	chr16:24741724	TNRC6A	-0.42	-5.31	-0.33	2.5e-7	Intelligence (multi-trait analysis);
SARC	trans	rs61931739	0.817	rs10743841	chr12:34252870	T/C	cg13010199	chr12:38710504	ALG10B	0.53	6.99	0.42	2.82e-11	Morning vs. evening chronotype;
SARC	cis	rs13256369	1.000	rs4841017	chr8:8577093	A/G	cg17143192	chr8:8559678	CLDN23	0.52	6.08	0.37	4.84e-9	Obesity-related traits;
SARC	cis	rs1008375	0.966	rs2191504	chr4:17675592	C/G	cg27347728	chr4:17578864	LAP3	0.45	5.54	0.34	8.23e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs761746	0.921	rs761747	chr22:32001835	C/A	cg15823100	chr22:32027580	PISD	-0.34	-5.07	-0.32	8.22e-7	Intelligence;
SARC	cis	rs3796352	1.000	rs11710707	chr3:52975916	A/G	cg07884673	chr3:53033167	SFMBT1	0.8	4.95	0.31	1.43e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg22857025	chr5:266934	NA	-1.06	-11.62	-0.61	6.2e-25	Breast cancer;
SARC	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg16414030	chr3:133502952	NA	-0.4	-5.44	-0.34	1.32e-7	Iron status biomarkers;
SARC	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg11890956	chr21:40555474	PSMG1	1.18	19.47	0.79	8.8e-51	Cognitive function;
SARC	trans	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-10.55	-0.57	1.63e-21	Intelligence (multi-trait analysis);
SARC	cis	rs870825	0.616	rs4610378	chr4:185624220	C/T	cg04058563	chr4:185651563	MLF1IP	-0.84	-11.62	-0.61	6.27e-25	Blood protein levels;
SARC	cis	rs1801251	1.000	rs283475	chr2:233654381	A/C	cg25237894	chr2:233734115	C2orf82	-0.35	-4.72	-0.3	4.05e-6	Coronary artery disease;
SARC	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg18252515	chr7:66147081	NA	-0.54	-5.98	-0.36	8.53e-9	Aortic root size;
SARC	cis	rs2120243	0.647	rs9289983	chr3:157146005	G/A	cg01018701	chr3:157155998	VEPH1;PTX3	0.5	6.41	0.39	7.96e-10	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg17376030	chr22:41985996	PMM1	0.6	7.28	0.43	5.2e-12	Vitiligo;
SARC	trans	rs208515	0.525	rs12193560	chr6:66690457	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.99	11.54	0.6	1.13e-24	Exhaled nitric oxide levels;
SARC	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg11301795	chr4:187892539	NA	-0.76	-12.12	-0.62	1.53e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs35110281	0.633	rs4818860	chr21:45119617	C/T	cg21573476	chr21:45109991	RRP1B	-0.6	-8.97	-0.51	1e-16	Mean corpuscular volume;
SARC	cis	rs9457247	0.663	rs9457258	chr6:167444254	T/C	cg23791538	chr6:167370224	RNASET2	-0.52	-7.03	-0.42	2.23e-11	Crohn's disease;
SARC	cis	rs62244186	0.659	rs9819766	chr3:44520980	G/C	cg15225532	chr3:44803084	KIF15;KIAA1143	0.47	5.82	0.36	1.97e-8	Depressive symptoms;
SARC	cis	rs765787	0.530	rs12592055	chr15:45514477	C/T	cg26924012	chr15:45694286	SPATA5L1	0.42	5.08	0.32	7.84e-7	Uric acid levels;
SARC	cis	rs9291683	0.588	rs17247314	chr4:10004743	C/G	cg00071950	chr4:10020882	SLC2A9	0.39	6.22	0.38	2.27e-9	Bone mineral density;
SARC	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg08048268	chr3:133502702	NA	-0.49	-6.56	-0.39	3.4e-10	Iron status biomarkers;
SARC	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.03	15.82	0.72	9.16e-39	Height;
SARC	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg11987759	chr7:65425863	GUSB	-0.6	-8.01	-0.46	5.62e-14	Aortic root size;
SARC	cis	rs721399	0.568	rs34987019	chr8:18274443	T/C	cg18736775	chr8:18248649	NAT2	-0.52	-5.59	-0.34	6.39e-8	Blood metabolite levels;
SARC	cis	rs6582630	0.537	rs66855609	chr12:38299029	T/C	cg13010199	chr12:38710504	ALG10B	0.76	10.22	0.56	1.75e-20	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg08280861	chr8:58055591	NA	0.6	5.28	0.33	2.92e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg02725872	chr8:58115012	NA	-0.37	-6.55	-0.39	3.71e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9291683	0.588	rs4697705	chr4:10108127	G/A	cg11266682	chr4:10021025	SLC2A9	-0.48	-8.77	-0.5	3.92e-16	Bone mineral density;
SARC	cis	rs7327064	0.960	rs9546567	chr13:36742906	C/T	cg13455704	chr13:36871754	C13orf38	-0.49	-5.51	-0.34	9.41e-8	Economic and political preferences;
SARC	cis	rs1949733	0.816	rs2631746	chr4:8490934	C/T	cg11789530	chr4:8429930	ACOX3	-0.68	-8.7	-0.5	5.94e-16	Response to antineoplastic agents;
SARC	cis	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg12064134	chr16:90016061	DEF8	-0.59	-5.06	-0.31	8.56e-7	Skin colour saturation;
SARC	cis	rs9790314	1.000	rs9872514	chr3:161042833	T/C	cg04691961	chr3:161091175	C3orf57	-0.76	-11.17	-0.59	1.82e-23	Morning vs. evening chronotype;
SARC	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg00933542	chr6:150070202	PCMT1	0.31	5.29	0.33	2.83e-7	Lung cancer;
SARC	cis	rs1707322	0.686	rs2275085	chr1:46085852	C/T	cg03146154	chr1:46216737	IPP	-0.52	-6.32	-0.38	1.29e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs61931739	0.500	rs11053223	chr12:34481947	T/A	cg13010199	chr12:38710504	ALG10B	0.82	11.49	0.6	1.62e-24	Morning vs. evening chronotype;
SARC	cis	rs11718455	0.960	rs35869565	chr3:44002394	G/C	cg21419209	chr3:44054225	NA	-0.42	-5.04	-0.31	9.45e-7	Coronary artery disease;
SARC	cis	rs3820928	0.874	rs12467261	chr2:227888838	T/C	cg11843606	chr2:227700838	RHBDD1	-0.56	-7.0	-0.42	2.75e-11	Pulmonary function;
SARC	cis	rs9309473	0.539	rs7574268	chr2:73904872	C/T	cg20560298	chr2:73613845	ALMS1	0.51	6.99	0.42	2.85e-11	Metabolite levels;
SARC	cis	rs17376456	1.000	rs34854140	chr5:93538169	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.21	0.32	4.18e-7	Diabetic retinopathy;
SARC	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg22105103	chr4:187893119	NA	-0.5	-6.77	-0.41	1.04e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4853036	0.951	rs6710444	chr2:70120632	G/A	cg02498382	chr2:70120550	SNRNP27	-0.4	-5.76	-0.35	2.65e-8	Colorectal or endometrial cancer;
SARC	cis	rs2075371	1.000	rs1862050	chr7:133980999	T/C	cg11752832	chr7:134001865	SLC35B4	0.57	7.45	0.44	1.77e-12	Mean platelet volume;
SARC	cis	rs4561483	0.801	rs33620	chr16:12008546	C/G	cg08843971	chr16:11963173	GSPT1	-0.41	-4.93	-0.31	1.54e-6	Testicular germ cell tumor;
SARC	cis	rs524281	0.692	rs10791845	chr11:65834340	C/G	cg14036092	chr11:66035641	RAB1B	0.57	6.59	0.4	2.91e-10	Electroencephalogram traits;
SARC	cis	rs79349575	0.783	rs62078372	chr17:47028989	T/C	cg07967210	chr17:47022446	SNF8	0.37	4.71	0.3	4.19e-6	Type 2 diabetes;
SARC	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg25952890	chr19:58913133	NA	0.35	4.95	0.31	1.44e-6	Uric acid clearance;
SARC	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg02018176	chr4:1364513	KIAA1530	0.33	4.96	0.31	1.34e-6	Longevity;
SARC	cis	rs1153858	0.621	rs1719237	chr15:45579822	G/A	cg19305227	chr15:45544335	SLC28A2	-0.28	-4.92	-0.31	1.67e-6	Homoarginine levels;
SARC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg21782813	chr7:2030301	MAD1L1	0.44	7.0	0.42	2.76e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs3741404	0.620	rs2236647	chr11:63964605	A/G	cg05555928	chr11:63887634	MACROD1	0.32	4.95	0.31	1.43e-6	Platelet count;
SARC	cis	rs11252926	0.931	rs12358336	chr10:566981	A/T	cg08603382	chr10:743973	NA	-0.55	-6.92	-0.41	4.31e-11	Psychosis in Alzheimer's disease;
SARC	cis	rs921968	0.643	rs500317	chr2:219432953	G/C	cg02176678	chr2:219576539	TTLL4	0.36	5.52	0.34	9.16e-8	Mean corpuscular hemoglobin concentration;
SARC	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg07153921	chr17:41440717	NA	-0.39	-4.81	-0.3	2.73e-6	Menopause (age at onset);
SARC	cis	rs11931598	0.509	rs13140943	chr4:6977109	A/G	cg02705895	chr4:6642252	MRFAP1	-0.4	-4.82	-0.3	2.64e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs8072100	1.000	rs4794048	chr17:45763073	A/C	cg08085267	chr17:45401833	C17orf57	-0.43	-4.95	-0.31	1.44e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs11574514	1.000	rs77055954	chr16:68246428	C/T	cg01866162	chr16:67596514	CTCF	1.07	6.09	0.37	4.7e-9	Crohn's disease;
SARC	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg17971929	chr21:40555470	PSMG1	-0.86	-11.37	-0.6	4.14e-24	Cognitive function;
SARC	cis	rs1799949	0.602	rs8176199	chr17:41230524	T/G	cg25072359	chr17:41440525	NA	0.51	5.17	0.32	5.06e-7	Menopause (age at onset);
SARC	cis	rs6500395	1.000	rs34844432	chr16:48682418	C/T	cg04672837	chr16:48644449	N4BP1	0.46	6.28	0.38	1.65e-9	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs910316	0.737	rs175072	chr14:75502827	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.55	-7.59	-0.45	7.67e-13	Height;
SARC	cis	rs1448094	0.817	rs10863108	chr12:86328249	C/T	cg02569458	chr12:86230093	RASSF9	0.41	5.83	0.36	1.88e-8	Major depressive disorder;
SARC	cis	rs7615952	0.512	rs2979334	chr3:125358824	G/A	cg21696256	chr3:125484277	NA	-0.35	-5.05	-0.31	8.97e-7	Blood pressure (smoking interaction);
SARC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg14159672	chr1:205819179	PM20D1	-0.69	-11.34	-0.6	5.1e-24	Monocyte percentage of white cells;
SARC	cis	rs11697848	1.000	rs55713402	chr20:48529477	A/C	cg17849948	chr20:48532315	SPATA2	0.87	5.2	0.32	4.3e-7	Systemic lupus erythematosus;
SARC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg09373136	chr17:61933544	TCAM1	-0.45	-6.17	-0.37	2.98e-9	Prudent dietary pattern;
SARC	cis	rs2204008	0.729	rs2892365	chr12:38446760	G/C	cg13010199	chr12:38710504	ALG10B	-0.69	-9.46	-0.53	3.49e-18	Bladder cancer;
SARC	cis	rs72615157	0.539	rs12673441	chr7:99670328	A/T	cg22004693	chr7:99632812	ZKSCAN1	0.73	8.93	0.5	1.34e-16	Lung function (FEV1/FVC);
SARC	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg18252515	chr7:66147081	NA	0.59	6.34	0.38	1.17e-9	Aortic root size;
SARC	cis	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg25894440	chr7:65020034	NA	-0.76	-5.71	-0.35	3.37e-8	Diabetic kidney disease;
SARC	cis	rs986417	1.000	rs1254298	chr14:60883842	C/T	cg27398547	chr14:60952738	C14orf39	-1.02	-8.79	-0.5	3.41e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs4718428	0.705	rs68168107	chr7:66255238	G/A	cg18252515	chr7:66147081	NA	-0.56	-6.14	-0.37	3.61e-9	Corneal structure;
SARC	cis	rs6578185	0.810	rs7816220	chr8:142453585	T/C	cg07762003	chr8:142452454	FLJ43860	-0.33	-5.71	-0.35	3.44e-8	Endometriosis;
SARC	cis	rs9325144	0.560	rs11182930	chr12:38633693	A/T	cg26384229	chr12:38710491	ALG10B	-0.62	-7.98	-0.46	6.51e-14	Morning vs. evening chronotype;
SARC	cis	rs9290065	0.538	rs6809206	chr3:160755708	G/A	cg03342759	chr3:160939853	NMD3	-0.56	-6.93	-0.41	4.12e-11	Kawasaki disease;
SARC	cis	rs11098499	0.954	rs10005644	chr4:120298477	T/C	cg09307838	chr4:120376055	NA	0.91	12.88	0.65	4.9e-29	Corneal astigmatism;
SARC	cis	rs9291683	0.509	rs10939671	chr4:10050815	T/C	cg00071950	chr4:10020882	SLC2A9	0.34	5.31	0.33	2.51e-7	Bone mineral density;
SARC	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-8.89	-0.5	1.75e-16	Alzheimer's disease;
SARC	cis	rs4906332	1.000	rs2065018	chr14:103879187	C/T	cg26031613	chr14:104095156	KLC1	0.48	5.63	0.35	5.29e-8	Coronary artery disease;
SARC	cis	rs12594515	1.000	rs7173144	chr15:45991196	A/G	cg14863074	chr15:45997064	NA	0.34	5.24	0.32	3.57e-7	Waist circumference;Weight;
SARC	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg08280861	chr8:58055591	NA	0.67	5.25	0.33	3.4e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg22252469	chr13:33702794	STARD13	0.45	6.34	0.38	1.18e-9	Thyroid stimulating hormone;
SARC	cis	rs16976116	0.704	rs7183603	chr15:55513718	C/A	cg17854078	chr15:55489399	RSL24D1	0.55	5.61	0.34	5.72e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6598955	0.724	rs12096059	chr1:26596709	G/A	cg04990556	chr1:26633338	UBXN11	-0.59	-8.11	-0.47	2.94e-14	Obesity-related traits;
SARC	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg27286337	chr10:134555280	INPP5A	0.69	7.93	0.46	9.21e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs425277	1.000	rs262647	chr1:2095699	C/T	cg21442419	chr1:2182373	SKI	-0.52	-6.59	-0.4	2.92e-10	Height;
SARC	cis	rs10465746	0.725	rs4907188	chr1:84361608	C/T	cg10977910	chr1:84465055	TTLL7	0.41	5.07	0.31	8.26e-7	Obesity-related traits;
SARC	cis	rs9549260	0.592	rs9315783	chr13:41289164	T/C	cg21288729	chr13:41239152	FOXO1	0.44	5.21	0.32	4.22e-7	Red blood cell count;
SARC	cis	rs9810089	0.903	rs10935185	chr3:136290529	C/G	cg15507776	chr3:136538369	TMEM22	0.44	4.75	0.3	3.63e-6	Gestational age at birth (child effect);
SARC	trans	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg17830980	chr10:43048298	ZNF37B	-0.52	-6.74	-0.4	1.23e-10	Extrinsic epigenetic age acceleration;
SARC	cis	rs2948294	0.588	rs4840913	chr8:8116906	A/C	cg06636001	chr8:8085503	FLJ10661	0.57	6.62	0.4	2.46e-10	Red cell distribution width;
SARC	cis	rs73086581	0.741	rs17212649	chr20:3853093	A/G	cg02187196	chr20:3869020	PANK2	0.64	5.64	0.35	4.79e-8	Response to antidepressants in depression;
SARC	cis	rs3733585	0.673	rs4627861	chr4:9954238	T/G	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.39	-0.33	1.76e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-8.16	-0.47	2.11e-14	Chronic sinus infection;
SARC	cis	rs3768617	0.510	rs7518957	chr1:183093028	A/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.67	-10.2	-0.56	1.98e-20	Fuchs's corneal dystrophy;
SARC	cis	rs11758351	0.866	rs77205516	chr6:26205356	T/A	cg23601095	chr6:26197514	HIST1H3D	0.55	4.86	0.3	2.19e-6	Gout;Renal underexcretion gout;
SARC	cis	rs4689388	0.926	rs4689394	chr4:6291003	C/G	cg14416269	chr4:6271139	WFS1	-0.33	-5.0	-0.31	1.11e-6	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs875971	0.545	rs67775320	chr7:65658779	T/C	cg11764359	chr7:65958608	NA	0.67	6.66	0.4	1.92e-10	Aortic root size;
SARC	cis	rs6867913	1.000	rs12519447	chr5:141457161	G/A	cg26513854	chr5:141295517	NA	0.35	5.14	0.32	5.74e-7	Asthma;
SARC	cis	rs1878931	0.501	rs37800	chr16:3423648	T/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.74	-9.29	-0.52	1.11e-17	Body mass index (adult);
SARC	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.45	4.98	0.31	1.24e-6	Renal function-related traits (BUN);
SARC	cis	rs459571	1.000	rs467387	chr9:136907005	G/A	cg01294253	chr9:136912663	BRD3	0.45	5.73	0.35	3.08e-8	Platelet distribution width;
SARC	cis	rs832540	0.898	rs252888	chr5:56227326	T/A	cg14703610	chr5:56206110	C5orf35	0.48	5.78	0.35	2.36e-8	Coronary artery disease;
SARC	cis	rs7829975	0.871	rs7829826	chr8:8578120	T/A	cg15556689	chr8:8085844	FLJ10661	-0.44	-5.13	-0.32	6.15e-7	Mood instability;
SARC	cis	rs9457247	0.765	rs12212247	chr6:167413539	T/C	cg07741184	chr6:167504864	NA	0.34	6.51	0.39	4.6e-10	Crohn's disease;
SARC	cis	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg25427524	chr10:38739819	LOC399744	-0.53	-8.32	-0.48	7.33e-15	Extrinsic epigenetic age acceleration;
SARC	cis	rs57561814	0.510	rs2066992	chr7:22768249	G/T	cg01770232	chr7:22766155	IL6	0.68	5.89	0.36	1.38e-8	Tonsillectomy;
SARC	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg08219700	chr8:58056026	NA	0.6	5.71	0.35	3.49e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg12463550	chr7:65579703	CRCP	0.52	5.81	0.36	2.06e-8	Aortic root size;
SARC	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg10589385	chr1:150898437	SETDB1	0.38	5.03	0.31	9.83e-7	Melanoma;
SARC	cis	rs6665290	0.904	rs2297416	chr1:227172935	C/G	cg14016676	chr1:227182615	CDC42BPA	0.34	5.01	0.31	1.06e-6	Myeloid white cell count;
SARC	cis	rs6840360	0.571	rs6811676	chr4:152562726	T/C	cg22705602	chr4:152727874	NA	-0.43	-6.69	-0.4	1.66e-10	Intelligence (multi-trait analysis);
SARC	cis	rs72627123	0.656	rs765720	chr14:74541326	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.74	5.78	0.35	2.33e-8	Morning vs. evening chronotype;
SARC	cis	rs7914558	0.966	rs10748839	chr10:104953547	A/G	cg04362960	chr10:104952993	NT5C2	0.4	4.78	0.3	3.07e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs4660261	0.526	rs2040950	chr1:44315113	G/C	cg12908607	chr1:44402522	ARTN	-0.33	-5.78	-0.35	2.44e-8	Intelligence (multi-trait analysis);
SARC	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	9.12	0.51	3.65e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs818427	0.929	rs469663	chr5:112231829	A/G	cg07820702	chr5:112228657	REEP5	-0.5	-5.62	-0.35	5.46e-8	Total body bone mineral density;
SARC	cis	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg22496380	chr5:211416	CCDC127	-0.87	-9.24	-0.52	1.63e-17	Breast cancer;
SARC	cis	rs3768617	0.624	rs34105373	chr1:183098387	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.58	7.82	0.46	1.8e-13	Fuchs's corneal dystrophy;
SARC	cis	rs6815814	0.950	rs114719937	chr4:38808585	G/C	cg02016764	chr4:38805732	TLR1	-0.42	-4.89	-0.31	1.89e-6	Breast cancer;
SARC	cis	rs9462027	0.628	rs7741437	chr6:34737553	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.84	-0.36	1.71e-8	Systemic lupus erythematosus;
SARC	cis	rs4906332	1.000	rs2065015	chr14:103904061	G/T	cg26031613	chr14:104095156	KLC1	0.51	5.98	0.36	8.51e-9	Coronary artery disease;
SARC	cis	rs6772849	0.662	rs12494372	chr3:128401693	A/C	cg08795948	chr3:128337044	NA	0.54	7.04	0.42	2.09e-11	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs2729354	1.000	rs2729355	chr11:57353983	T/G	cg02958346	chr11:57425731	CLP1	0.52	5.25	0.33	3.47e-7	Blood protein levels;
SARC	cis	rs7296418	0.961	rs10848428	chr12:123572495	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.42	-5.74	-0.35	2.91e-8	Platelet count;
SARC	cis	rs7633857	0.512	rs10936215	chr3:160652271	A/G	cg04691961	chr3:161091175	C3orf57	-0.46	-5.77	-0.35	2.57e-8	Educational attainment (years of education);
SARC	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg10523679	chr1:76189770	ACADM	0.52	6.86	0.41	6.1e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs10513788	0.665	rs1352346	chr3:181993919	A/C	cg05977900	chr3:182512126	ATP11B	0.47	4.97	0.31	1.3e-6	Cognitive function;
SARC	cis	rs34891900	0.507	rs2008085	chr22:18204316	T/G	cg19898043	chr22:18121309	BCL2L13	0.65	7.31	0.43	4.31e-12	Sum neutrophil eosinophil counts;
SARC	cis	rs1008375	0.932	rs6857678	chr4:17696964	A/T	cg27347728	chr4:17578864	LAP3	0.44	5.67	0.35	4.13e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs12586317	0.586	rs74243590	chr14:35513246	G/A	cg16230307	chr14:35515116	FAM177A1	1.03	11.98	0.62	4.42e-26	Psoriasis;
SARC	cis	rs4889855	0.556	rs56873925	chr17:78536611	C/T	cg17956530	chr17:78667699	RPTOR	0.42	4.75	0.3	3.51e-6	Fractional excretion of uric acid;
SARC	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg01448562	chr3:133502909	NA	-0.45	-6.58	-0.4	3.06e-10	Iron status biomarkers;
SARC	cis	rs8180040	0.966	rs11130137	chr3:47578838	C/T	cg27129171	chr3:47204927	SETD2	0.65	9.23	0.52	1.66e-17	Colorectal cancer;
SARC	cis	rs7595412	1.000	rs1808850	chr2:198978661	A/G	cg00208931	chr2:198669586	PLCL1	-0.79	-6.1	-0.37	4.28e-9	Hip bone size;
SARC	cis	rs2228479	0.850	rs11644526	chr16:89898660	C/T	cg06558623	chr16:89946397	TCF25	0.93	6.63	0.4	2.29e-10	Skin colour saturation;
SARC	cis	rs4819052	0.679	rs2255761	chr21:46683622	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.61	7.7	0.45	3.98e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs644799	1.000	rs543530	chr11:95545170	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.7	9.55	0.53	1.87e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs1712517	0.844	rs1163074	chr10:105021762	C/T	cg05636881	chr10:105038444	INA	0.33	4.83	0.3	2.48e-6	Migraine;
SARC	trans	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.74	-10.81	-0.58	2.44e-22	Intelligence (multi-trait analysis);
SARC	cis	rs1450679	0.891	rs1411103	chr9:106854958	C/T	cg21169611	chr9:106856078	SMC2	0.56	4.88	0.3	1.98e-6	Response to cytadine analogues (cytosine arabinoside);
SARC	cis	rs722599	0.748	rs7145173	chr14:75351647	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.41	-5.17	-0.32	5.13e-7	IgG glycosylation;
SARC	cis	rs9362426	1.000	rs9362426	chr6:88089874	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.41	5.14	0.32	5.74e-7	Depressive episodes in bipolar disorder;
SARC	cis	rs2239547	0.563	rs4687560	chr3:52898121	T/G	cg22484793	chr3:52261325	TLR9	0.37	4.9	0.31	1.76e-6	Schizophrenia;
SARC	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg15847926	chr7:2749597	AMZ1	-0.3	-4.86	-0.3	2.14e-6	Height;
SARC	cis	rs651907	0.557	rs34947019	chr3:101532235	C/T	cg12386194	chr3:101231763	SENP7	0.47	5.28	0.33	2.9e-7	Colorectal cancer;
SARC	cis	rs7208859	0.725	rs9915802	chr17:29173058	T/C	cg13385521	chr17:29058706	SUZ12P	0.77	6.89	0.41	5.31e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs7465272	1.000	rs35900184	chr8:143693411	C/T	cg01509843	chr8:143695822	ARC	0.45	4.83	0.3	2.45e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg22920501	chr2:26401640	FAM59B	0.56	7.23	0.43	6.74e-12	Gut microbiome composition (summer);
SARC	cis	rs2948294	0.524	rs13270062	chr8:8112650	C/A	cg08975724	chr8:8085496	FLJ10661	0.54	6.43	0.39	7.2e-10	Red cell distribution width;
SARC	cis	rs7666738	0.830	rs921523	chr4:98841659	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.8	0.5	3.11e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs539096	0.500	rs2367804	chr1:44314266	C/T	cg12908607	chr1:44402522	ARTN	-0.32	-5.65	-0.35	4.75e-8	Intelligence (multi-trait analysis);
SARC	cis	rs6546550	0.935	rs6747542	chr2:70106832	T/C	cg02498382	chr2:70120550	SNRNP27	-0.36	-5.99	-0.37	7.73e-9	Prevalent atrial fibrillation;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg26073427	chr3:149689325	PFN2	0.51	6.3	0.38	1.48e-9	Breast cancer;
SARC	trans	rs4295623	0.504	rs11250160	chr8:11592717	G/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.44	-0.39	6.63e-10	Morning vs. evening chronotype;
SARC	cis	rs950776	0.518	rs11630349	chr15:78824608	C/T	cg06917634	chr15:78832804	PSMA4	0.91	14.24	0.68	1.6e-33	Sudden cardiac arrest;
SARC	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	-0.39	-4.75	-0.3	3.58e-6	Tonsillectomy;
SARC	cis	rs7223966	1.000	rs13380863	chr17:61780793	G/A	cg00588841	chr17:61851480	DDX42;CCDC47	-0.66	-7.17	-0.43	1e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg16479474	chr6:28041457	NA	0.37	5.51	0.34	9.41e-8	Depression;
SARC	cis	rs79149102	0.522	rs4887158	chr15:74847814	G/A	cg09165964	chr15:75287851	SCAMP5	-0.65	-5.02	-0.31	1.04e-6	Lung cancer;
SARC	cis	rs11122272	0.766	rs2024879	chr1:231528638	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.14	-0.55	2.98e-20	Hemoglobin concentration;
SARC	cis	rs9549260	0.755	rs8001443	chr13:41216646	C/T	cg21288729	chr13:41239152	FOXO1	-0.73	-10.02	-0.55	7.13e-20	Red blood cell count;
SARC	cis	rs11112613	0.775	rs7959699	chr12:105959848	C/A	cg03607813	chr12:105948248	NA	0.51	7.07	0.42	1.83e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs1345301	0.518	rs2110661	chr2:102863221	C/T	cg12451869	chr2:102867685	NA	0.41	5.67	0.35	4.25e-8	Waist circumference;
SARC	trans	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg07211511	chr3:129823064	LOC729375	-0.57	-6.27	-0.38	1.74e-9	Blood pressure (smoking interaction);
SARC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.45	0.56	3.24e-21	Prudent dietary pattern;
SARC	cis	rs9467711	0.591	rs13203673	chr6:25979122	T/C	cg21479132	chr6:26055353	NA	0.82	4.85	0.3	2.27e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs10463554	0.892	rs10434791	chr5:102389472	C/G	cg23492399	chr5:102201601	PAM	-0.51	-5.65	-0.35	4.78e-8	Parkinson's disease;
SARC	cis	rs2204008	0.743	rs11182052	chr12:38450421	T/C	cg26384229	chr12:38710491	ALG10B	0.84	12.17	0.62	1.09e-26	Bladder cancer;
SARC	cis	rs2204008	0.641	rs66876045	chr12:38205713	G/A	cg26384229	chr12:38710491	ALG10B	0.89	13.09	0.65	1.03e-29	Bladder cancer;
SARC	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg27266027	chr21:40555129	PSMG1	0.53	5.84	0.36	1.76e-8	Cognitive function;
SARC	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.47	5.2	0.32	4.35e-7	Renal function-related traits (BUN);
SARC	cis	rs2486288	0.656	rs2271438	chr15:45557468	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.49	-6.21	-0.38	2.45e-9	Glomerular filtration rate;
SARC	cis	rs9467773	0.595	rs2172007	chr6:26639777	A/C	cg11502198	chr6:26597334	ABT1	0.6	7.75	0.45	2.75e-13	Intelligence (multi-trait analysis);
SARC	cis	rs9291683	0.527	rs3822241	chr4:10094931	G/A	cg11266682	chr4:10021025	SLC2A9	-0.47	-8.19	-0.47	1.68e-14	Bone mineral density;
SARC	cis	rs6570726	0.935	rs454370	chr6:145846729	T/G	cg05347473	chr6:146136440	FBXO30	0.49	6.55	0.39	3.56e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7772486	0.754	rs4896841	chr6:146041522	T/C	cg05347473	chr6:146136440	FBXO30	-0.54	-7.46	-0.44	1.71e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.33	-5.01	-0.31	1.1e-6	Total body bone mineral density;
SARC	cis	rs2243480	0.522	rs12698511	chr7:65474919	G/T	cg18252515	chr7:66147081	NA	-1.02	-6.48	-0.39	5.55e-10	Diabetic kidney disease;
SARC	cis	rs9859260	0.744	rs406271	chr3:195776976	T/C	cg03462622	chr3:195777018	TFRC	-0.47	-5.41	-0.33	1.53e-7	Mean corpuscular volume;
SARC	cis	rs1707322	0.752	rs11211168	chr1:46163647	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.31	0.38	1.38e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4742903	0.904	rs971969	chr9:106929798	A/C	cg14250997	chr9:106856677	SMC2	0.44	5.47	0.34	1.17e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs16866061	0.962	rs16825685	chr2:225434256	C/G	cg12698349	chr2:225449008	CUL3	0.73	11.03	0.59	4.76e-23	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg09323728	chr8:95962352	TP53INP1	-0.33	-5.63	-0.35	5.05e-8	Type 2 diabetes;
SARC	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg21782813	chr7:2030301	MAD1L1	0.44	6.89	0.41	5.22e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs6570726	0.935	rs454614	chr6:145832633	C/T	cg05220968	chr6:146057943	EPM2A	-0.29	-4.99	-0.31	1.19e-6	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg22433210	chr17:43662623	NA	-0.72	-8.5	-0.49	2.35e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs17125944	0.506	rs7160285	chr14:53311400	A/C	cg00686598	chr14:53173677	PSMC6	-0.63	-4.88	-0.3	2e-6	Alzheimer's disease (late onset);
SARC	cis	rs523522	0.962	rs4767903	chr12:120930046	G/A	cg27279351	chr12:120934652	DYNLL1	0.71	8.85	0.5	2.22e-16	High light scatter reticulocyte count;
SARC	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg09517075	chr8:22133004	PIWIL2	0.35	4.84	0.3	2.34e-6	Hypertriglyceridemia;
SARC	cis	rs7666738	0.830	rs1111541	chr4:99033860	A/G	cg05340658	chr4:99064831	C4orf37	-0.62	-8.02	-0.47	5.19e-14	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1401999	0.807	rs9869029	chr3:183735286	C/G	cg01324343	chr3:183735012	ABCC5	0.66	13.19	0.65	4.79e-30	Anterior chamber depth;
SARC	cis	rs11792861	0.926	rs1333344	chr9:111776224	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.68	7.9	0.46	1.08e-13	Menarche (age at onset);
SARC	cis	rs10193935	0.901	rs12619348	chr2:42625586	C/T	cg27598129	chr2:42591480	NA	-0.38	-5.28	-0.33	3.01e-7	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2120019	0.938	rs8036573	chr15:75308690	C/T	cg00629941	chr15:75287862	SCAMP5	-0.7	-8.12	-0.47	2.63e-14	Blood trace element (Zn levels);
SARC	cis	rs10876993	0.821	rs1629032	chr12:58038686	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.46	-5.92	-0.36	1.16e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs262150	0.788	rs2657408	chr7:158782275	A/G	cg09640425	chr7:158790006	NA	-0.39	-5.38	-0.33	1.82e-7	Facial morphology (factor 20);
SARC	cis	rs921968	0.541	rs7601872	chr2:219319885	C/G	cg02176678	chr2:219576539	TTLL4	-0.49	-7.38	-0.44	2.83e-12	Mean corpuscular hemoglobin concentration;
SARC	cis	rs2153535	0.563	rs1737586	chr6:8535897	C/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.51	0.49	2.16e-15	Motion sickness;
SARC	trans	rs634534	0.622	rs501353	chr11:65739549	T/G	cg17712092	chr4:129076599	LARP1B	0.61	7.75	0.45	2.92e-13	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs2952156	0.876	rs903504	chr17:37829570	C/G	cg20243544	chr17:37824526	PNMT	0.55	7.17	0.43	1e-11	Asthma;
SARC	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg24633833	chr3:10029261	TMEM111	0.52	5.25	0.33	3.43e-7	Alzheimer's disease;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg25551661	chr18:11851326	GNAL;CHMP1B	0.87	7.44	0.44	1.92e-12	Autism spectrum disorder or schizophrenia;
SARC	cis	rs11581859	0.613	rs12402587	chr1:99205528	G/C	cg20286094	chr1:99190917	SNX7	-0.42	-4.89	-0.31	1.86e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs7959452	0.640	rs4761233	chr12:69722880	T/C	cg14784868	chr12:69753453	YEATS4	0.41	5.35	0.33	2.08e-7	Blood protein levels;
SARC	cis	rs858239	0.670	rs3807452	chr7:23162081	C/T	cg23682824	chr7:23144976	KLHL7	-0.65	-8.19	-0.47	1.67e-14	Cerebrospinal fluid biomarker levels;
SARC	cis	rs7113850	0.541	rs7927067	chr11:24232604	G/A	ch.11.24196551F	chr11:24239977	NA	0.73	5.37	0.33	1.91e-7	Bone fracture in osteoporosis;
SARC	cis	rs7647973	0.710	rs11130207	chr3:49611666	T/G	cg07636037	chr3:49044803	WDR6	0.77	7.01	0.42	2.52e-11	Menarche (age at onset);
SARC	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.33	-5.15	-0.32	5.42e-7	Total body bone mineral density;
SARC	cis	rs899997	0.862	rs8043123	chr15:78973393	C/T	cg04896959	chr15:78267971	NA	-0.44	-5.44	-0.34	1.32e-7	Coronary artery disease or large artery stroke;
SARC	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg16479474	chr6:28041457	NA	0.38	5.46	0.34	1.19e-7	Depression;
SARC	cis	rs6089584	1.000	rs3787425	chr20:60559256	C/T	cg06108461	chr20:60628389	TAF4	-0.91	-11.96	-0.62	5.27e-26	Body mass index;
SARC	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg02018176	chr4:1364513	KIAA1530	0.39	5.68	0.35	3.99e-8	Obesity-related traits;
SARC	cis	rs2204008	0.905	rs7294297	chr12:38442573	T/C	cg13010199	chr12:38710504	ALG10B	0.72	9.15	0.51	3.01e-17	Bladder cancer;
SARC	cis	rs3733585	0.664	rs17245436	chr4:9958169	A/G	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.36	-0.33	1.96e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs72781680	0.898	rs72796171	chr2:23942667	G/C	cg06627628	chr2:24431161	ITSN2	-0.66	-6.25	-0.38	1.94e-9	Lymphocyte counts;
SARC	cis	rs910316	0.935	rs175448	chr14:75591071	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.52	-7.4	-0.44	2.44e-12	Height;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg18732869	chr19:6739680	TRIP10	-0.52	-6.52	-0.39	4.44e-10	Schizophrenia;
SARC	cis	rs6430585	0.583	rs7581814	chr2:136641593	C/G	cg07169764	chr2:136633963	MCM6	-1.08	-16.19	-0.73	5.2e-40	Corneal structure;
SARC	cis	rs10911251	0.528	rs4652777	chr1:183091992	T/G	cg13390022	chr1:182993471	LAMC1	0.31	4.73	0.3	3.89e-6	Colorectal cancer;
SARC	cis	rs854765	0.547	rs2955378	chr17:17930253	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.66	9.63	0.53	1.05e-18	Total body bone mineral density;
SARC	trans	rs61931739	0.635	rs10743837	chr12:33982162	A/G	cg13010199	chr12:38710504	ALG10B	0.55	6.96	0.41	3.37e-11	Morning vs. evening chronotype;
SARC	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg14893161	chr1:205819251	PM20D1	0.47	5.27	0.33	3.08e-7	Parkinson's disease;
SARC	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.4	6.03	0.37	6.47e-9	Schizophrenia;
SARC	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg23758822	chr17:41437982	NA	0.88	11.32	0.6	6.01e-24	Menopause (age at onset);
SARC	cis	rs2439831	1.000	rs9920763	chr15:43760508	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.91	7.96	0.46	7.38e-14	Lung cancer in ever smokers;
SARC	cis	rs9325144	0.581	rs6582564	chr12:38671282	G/A	cg26384229	chr12:38710491	ALG10B	-0.66	-8.8	-0.5	3.11e-16	Morning vs. evening chronotype;
SARC	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg05025164	chr4:1340916	KIAA1530	0.84	11.13	0.59	2.44e-23	Longevity;
SARC	cis	rs2075371	1.000	rs2544211	chr7:133973230	A/G	cg20476274	chr7:133979776	SLC35B4	0.63	8.73	0.5	5.06e-16	Mean platelet volume;
SARC	cis	rs4253772	0.550	rs6008601	chr22:46705326	C/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.61	5.1	0.32	6.93e-7	LDL cholesterol;Cholesterol, total;
SARC	cis	rs4805272	0.539	rs1422212	chr19:29330191	T/A	cg04546413	chr19:29218101	NA	0.53	6.12	0.37	3.96e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs7223966	1.000	rs11657306	chr17:61704822	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.77	0.41	1.06e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg21755440	chr3:20227801	SGOL1	0.51	6.33	0.38	1.23e-9	Breast cancer;
SARC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg10862848	chr6:42927986	GNMT	-0.36	-5.75	-0.35	2.72e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs9309473	1.000	rs1114380	chr2:73804708	A/G	cg20560298	chr2:73613845	ALMS1	-0.47	-5.79	-0.35	2.28e-8	Metabolite levels;
SARC	cis	rs4566357	0.557	rs2272201	chr2:227912551	T/A	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.86	-0.36	1.61e-8	Coronary artery disease;
SARC	cis	rs6570726	0.935	rs380883	chr6:145822992	A/G	cg05347473	chr6:146136440	FBXO30	0.45	5.85	0.36	1.69e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs748404	0.578	rs576557	chr15:43597737	T/C	cg08831455	chr15:43942014	CATSPER2	-0.42	-4.91	-0.31	1.72e-6	Lung cancer;
SARC	cis	rs7264396	0.635	rs6058355	chr20:34491343	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-7.65	-0.45	5.39e-13	Total cholesterol levels;
SARC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg09373136	chr17:61933544	TCAM1	-0.44	-6.09	-0.37	4.59e-9	Prudent dietary pattern;
SARC	cis	rs10504229	0.679	rs16921623	chr8:58039473	G/C	cg08280861	chr8:58055591	NA	0.55	4.96	0.31	1.35e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs9467773	1.000	rs9467774	chr6:26505036	C/A	cg11502198	chr6:26597334	ABT1	0.48	5.98	0.36	8.37e-9	Intelligence (multi-trait analysis);
SARC	cis	rs74181299	0.571	rs2302647	chr2:65283174	G/A	cg20592124	chr2:65290738	CEP68	0.4	5.25	0.33	3.37e-7	Pulse pressure;
SARC	cis	rs6088580	0.524	rs6087612	chr20:33230822	T/G	cg07148914	chr20:33460835	GGT7	-0.4	-4.86	-0.3	2.19e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs2204008	0.774	rs8189620	chr12:38241621	A/G	cg13010199	chr12:38710504	ALG10B	0.81	11.32	0.6	5.79e-24	Bladder cancer;
SARC	cis	rs356220	0.632	rs356202	chr4:90666291	G/A	cg06632027	chr4:90757378	SNCA	0.4	5.02	0.31	1.05e-6	Parkinson's disease;
SARC	cis	rs2032447	0.613	rs6456708	chr6:26032847	G/C	cg10373733	chr6:25993375	NA	0.4	4.93	0.31	1.53e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9443189	0.813	rs2133191	chr6:76440761	C/T	cg01950844	chr6:76311363	SENP6	-0.72	-6.72	-0.4	1.42e-10	Prostate cancer;
SARC	cis	rs78487399	0.808	rs75135247	chr2:43699399	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-5.01	-0.31	1.07e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg03060546	chr3:49711283	APEH	0.42	5.23	0.32	3.84e-7	Parkinson's disease;
SARC	cis	rs9325144	0.647	rs7487395	chr12:38865660	C/A	cg26384229	chr12:38710491	ALG10B	-0.55	-7.11	-0.42	1.45e-11	Morning vs. evening chronotype;
SARC	cis	rs3106136	0.934	rs34145031	chr4:95167123	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.39	-6.03	-0.37	6.38e-9	Capecitabine sensitivity;
SARC	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg12463550	chr7:65579703	CRCP	0.7	5.33	0.33	2.28e-7	Diabetic kidney disease;
SARC	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg20965017	chr5:231967	SDHA	-0.58	-5.52	-0.34	8.82e-8	Breast cancer;
SARC	cis	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg25427524	chr10:38739819	LOC399744	-0.57	-9.02	-0.51	7.3e-17	Extrinsic epigenetic age acceleration;
SARC	cis	rs2120243	0.592	rs28638274	chr3:157124479	C/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.44	5.54	0.34	8.01e-8	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs2290402	0.536	rs12509561	chr4:850701	C/T	cg00846425	chr4:957561	DGKQ	-0.42	-4.86	-0.3	2.12e-6	Type 2 diabetes;
SARC	cis	rs7772486	0.790	rs2254283	chr6:146204289	T/C	cg05347473	chr6:146136440	FBXO30	0.49	6.75	0.4	1.18e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2016266	1.000	rs10783573	chr12:53728369	G/A	cg26875137	chr12:53738046	NA	0.38	5.33	0.33	2.37e-7	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg15448220	chr1:150897856	SETDB1	0.47	6.25	0.38	1.94e-9	Tonsillectomy;
SARC	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg19761014	chr17:28927070	LRRC37B2	0.55	4.95	0.31	1.41e-6	Body mass index;
SARC	cis	rs9290065	0.519	rs6808386	chr3:160673263	A/T	cg03342759	chr3:160939853	NMD3	-0.48	-5.67	-0.35	4.21e-8	Kawasaki disease;
SARC	cis	rs6504663	0.596	rs7208018	chr17:48557863	C/T	cg22571038	chr17:48585470	MYCBPAP	-0.46	-5.31	-0.33	2.6e-7	Visceral fat;
SARC	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg11764359	chr7:65958608	NA	-0.84	-12.12	-0.62	1.49e-26	Aortic root size;
SARC	cis	rs7264396	0.836	rs6058276	chr20:34187728	T/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.48	4.88	0.3	1.96e-6	Total cholesterol levels;
SARC	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	10.12	0.55	3.42e-20	Platelet count;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg00437443	chr6:11094621	LOC221710	0.54	6.79	0.41	9.17e-11	Breast cancer;
SARC	cis	rs9652490	1.000	rs13313467	chr15:77966168	A/C	cg10633664	chr15:78485063	ACSBG1	0.25	4.76	0.3	3.4e-6	Essential tremor;
SARC	cis	rs734999	0.588	rs60520190	chr1:2533706	G/A	cg20673091	chr1:2541236	MMEL1	0.33	5.19	0.32	4.53e-7	Ulcerative colitis;
SARC	cis	rs1865760	0.566	rs9295686	chr6:26081983	G/C	cg16482183	chr6:26056742	HIST1H1C	0.47	5.91	0.36	1.22e-8	Height;
SARC	cis	rs6088590	0.965	rs910869	chr20:33292777	C/T	cg24642439	chr20:33292090	TP53INP2	0.89	12.95	0.65	3.04e-29	Coronary artery disease;
SARC	cis	rs13256369	1.000	rs12547721	chr8:8570671	C/T	cg17143192	chr8:8559678	CLDN23	0.54	6.29	0.38	1.58e-9	Obesity-related traits;
SARC	cis	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg24110177	chr3:50126178	RBM5	-0.4	-5.06	-0.31	8.7e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2976388	0.609	rs2244152	chr8:143784885	C/A	cg06565975	chr8:143823917	SLURP1	0.32	5.53	0.34	8.54e-8	Urinary tract infection frequency;
SARC	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg24250549	chr1:154909240	PMVK	0.8	11.6	0.61	7.42e-25	Prostate cancer;
SARC	cis	rs35110281	0.807	rs4818850	chr21:45028071	T/G	cg21573476	chr21:45109991	RRP1B	-0.5	-7.44	-0.44	1.94e-12	Mean corpuscular volume;
SARC	cis	rs7833790	0.926	rs72686467	chr8:82758929	T/G	cg27398817	chr8:82754497	SNX16	0.52	5.64	0.35	5e-8	Diastolic blood pressure;
SARC	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg22105103	chr4:187893119	NA	0.5	6.87	0.41	5.84e-11	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs56279505	0.690	rs62307324	chr4:100282591	C/G	cg18024358	chr1:3420815	MEGF6	-0.82	-6.42	-0.39	7.63e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1580019	0.587	rs6951955	chr7:32548761	A/T	cg06627557	chr7:32535165	LSM5;AVL9	0.97	17.34	0.75	8e-44	Cognitive ability;
SARC	cis	rs2361710	0.669	rs12940486	chr17:78118569	T/C	cg23534315	chr17:78082725	GAA	0.33	5.03	0.31	9.71e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
SARC	cis	rs7084402	0.935	rs10763558	chr10:60341934	A/C	cg07615347	chr10:60278583	BICC1	-0.54	-7.41	-0.44	2.36e-12	Refractive error;
SARC	cis	rs8031584	0.560	rs1056118	chr15:31203786	G/A	cg19680485	chr15:31195859	MTMR15	0.59	7.59	0.45	7.54e-13	Huntington's disease progression;
SARC	cis	rs7223966	1.000	rs9901507	chr17:61765524	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.73	0.4	1.32e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg01475735	chr3:40494733	NA	-0.47	-5.25	-0.33	3.46e-7	Renal cell carcinoma;
SARC	cis	rs1057510	0.790	rs12322604	chr12:6717645	A/G	cg12392916	chr12:6772545	ING4	0.52	4.73	0.3	3.95e-6	Myopia (pathological);
SARC	cis	rs2764208	0.599	rs9368828	chr6:34661449	A/T	cg07306190	chr6:34760872	UHRF1BP1	0.43	6.17	0.37	3.04e-9	Systemic lupus erythematosus;
SARC	cis	rs6500602	0.702	rs6500605	chr16:4502410	C/T	cg08645402	chr16:4508243	NA	0.45	5.94	0.36	1.02e-8	Schizophrenia;
SARC	cis	rs16976116	0.901	rs1061823	chr15:55496043	T/A	cg11288833	chr15:55489084	RSL24D1	0.63	6.13	0.37	3.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7223966	1.000	rs56383601	chr17:61929968	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-4.76	-0.3	3.33e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs911555	0.504	rs8021368	chr14:104074810	G/A	cg12935359	chr14:103987150	CKB	-0.33	-4.79	-0.3	2.99e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.78	11.75	0.61	2.4e-25	Total body bone mineral density;
SARC	cis	rs2273669	0.915	rs1887414	chr6:109292736	C/T	cg01304950	chr6:109416612	SESN1;C6orf182	-0.6	-5.59	-0.34	6.47e-8	Prostate cancer;
SARC	cis	rs9325144	0.505	rs901635	chr12:38646572	A/C	cg13010199	chr12:38710504	ALG10B	-0.66	-8.72	-0.5	5.46e-16	Morning vs. evening chronotype;
SARC	cis	rs9549260	0.753	rs10507486	chr13:41186501	A/G	cg21288729	chr13:41239152	FOXO1	-0.57	-6.12	-0.37	4.02e-9	Red blood cell count;
SARC	cis	rs3845702	0.736	rs6722147	chr2:180829704	G/A	cg01881094	chr2:180872142	CWC22	-1.12	-9.33	-0.52	8.56e-18	Schizophrenia;
SARC	trans	rs1814175	0.645	rs11040661	chr11:49952146	G/T	cg03929089	chr4:120376271	NA	-0.82	-11.67	-0.61	4.51e-25	Height;
SARC	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg04166393	chr7:2884313	GNA12	0.51	6.0	0.37	7.38e-9	Height;
SARC	cis	rs9381040	0.655	rs2294695	chr6:41036770	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.47	-5.02	-0.31	1.01e-6	Alzheimer's disease (late onset);
SARC	cis	rs6121246	0.529	rs6060171	chr20:30183269	C/T	cg13852791	chr20:30311386	BCL2L1	0.68	5.9	0.36	1.27e-8	Mean corpuscular hemoglobin;
SARC	cis	rs7412746	0.611	rs752376	chr1:150941381	C/T	cg10589385	chr1:150898437	SETDB1	0.38	5.02	0.31	1.03e-6	Melanoma;
SARC	cis	rs2011503	0.714	rs113980591	chr19:19565357	G/A	cg03709012	chr19:19516395	GATAD2A	0.61	5.26	0.33	3.34e-7	Bipolar disorder;
SARC	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg12648201	chr2:27665141	KRTCAP3	0.33	4.98	0.31	1.21e-6	Total body bone mineral density;
SARC	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg08677398	chr8:58056175	NA	0.44	5.25	0.33	3.38e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs798554	0.610	rs2527696	chr7:2858315	T/C	cg13628971	chr7:2884303	GNA12	0.48	5.99	0.37	7.87e-9	Height;
SARC	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg12042659	chr19:58951599	ZNF132	0.43	5.72	0.35	3.19e-8	Uric acid clearance;
SARC	cis	rs2028299	0.959	rs12912009	chr15:90429148	G/A	cg19708238	chr15:90437601	AP3S2	0.46	5.26	0.33	3.34e-7	Type 2 diabetes;
SARC	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg04518342	chr5:131593106	PDLIM4	0.44	5.66	0.35	4.37e-8	Breast cancer;
SARC	cis	rs9457247	0.624	rs2239826	chr6:167504880	T/C	cg07741184	chr6:167504864	NA	0.4	7.68	0.45	4.46e-13	Crohn's disease;
SARC	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg21782813	chr7:2030301	MAD1L1	0.36	5.66	0.35	4.33e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.46	-5.03	-0.31	9.95e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs9815354	0.953	rs1717007	chr3:41942199	T/C	cg03022575	chr3:42003672	ULK4	-0.55	-5.21	-0.32	4.11e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2012796	0.665	rs72703728	chr14:81834523	G/A	cg02996355	chr14:81879375	NA	0.51	5.62	0.35	5.42e-8	Night sleep phenotypes;
SARC	cis	rs748404	0.650	rs518234	chr15:43573421	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.43	5.24	0.32	3.53e-7	Lung cancer;
SARC	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg18357526	chr6:26021779	HIST1H4A	0.6	7.31	0.43	4.22e-12	Intelligence (multi-trait analysis);
SARC	cis	rs17376456	0.809	rs13177800	chr5:93307350	T/C	cg25358565	chr5:93447407	FAM172A	1.29	14.36	0.69	6.28e-34	Diabetic retinopathy;
SARC	cis	rs6582630	0.584	rs12832156	chr12:38419435	C/T	cg13010199	chr12:38710504	ALG10B	-0.49	-5.93	-0.36	1.11e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg00149659	chr3:10157352	C3orf10	0.68	6.38	0.39	9.46e-10	Alzheimer's disease;
SARC	cis	rs9527	0.569	rs10786730	chr10:104724200	G/A	cg04362960	chr10:104952993	NT5C2	0.42	4.95	0.31	1.44e-6	Arsenic metabolism;
SARC	cis	rs1003719	0.614	rs1053808	chr21:38525356	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-8.09	-0.47	3.25e-14	Eye color traits;
SARC	cis	rs561341	1.000	rs483301	chr17:30293398	G/T	cg00745463	chr17:30367425	LRRC37B	-0.69	-5.28	-0.33	2.96e-7	Hip circumference adjusted for BMI;
SARC	cis	rs546131	0.642	rs11600239	chr11:34821699	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-4.92	-0.31	1.67e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs35110281	0.748	rs2838322	chr21:44998615	G/C	cg21573476	chr21:45109991	RRP1B	-0.52	-7.68	-0.45	4.39e-13	Mean corpuscular volume;
SARC	cis	rs73195822	0.614	rs55680931	chr12:111218297	A/T	cg10860002	chr12:110842031	ANAPC7	0.67	5.11	0.32	6.85e-7	Itch intensity from mosquito bite;
SARC	cis	rs8072100	0.790	rs11079783	chr17:45686016	C/T	cg08085267	chr17:45401833	C17orf57	0.4	4.79	0.3	2.96e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg18230493	chr5:56204884	C5orf35	0.59	5.41	0.33	1.58e-7	Initial pursuit acceleration;
SARC	cis	rs2948294	0.524	rs13270062	chr8:8112650	C/A	cg06636001	chr8:8085503	FLJ10661	0.66	8.09	0.47	3.28e-14	Red cell distribution width;
SARC	cis	rs10463316	0.894	rs13357969	chr5:150751557	A/G	cg03212797	chr5:150827313	SLC36A1	-0.53	-6.56	-0.39	3.42e-10	Metabolite levels (Pyroglutamine);
SARC	cis	rs17001868	0.568	rs9611318	chr22:40739414	C/G	cg07138101	chr22:40742427	ADSL	0.54	5.94	0.36	1.01e-8	Mammographic density (dense area);
SARC	cis	rs4748857	0.947	rs10828426	chr10:23602901	C/T	cg12804278	chr10:23633326	C10orf67	0.4	4.88	0.3	1.94e-6	Systemic lupus erythematosus;
SARC	cis	rs11658309	1	rs11658309	chr17:17762247	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.64	-9.44	-0.53	4.07e-18	Strep throat;
SARC	cis	rs8042680	0.522	rs12595616	chr15:91563513	C/T	cg08919649	chr15:91565780	VPS33B	-0.42	-5.29	-0.33	2.88e-7	Type 2 diabetes;
SARC	cis	rs2276314	1.000	rs1540042	chr18:33555236	C/T	cg19628046	chr18:33552617	C18orf21	0.56	5.92	0.36	1.12e-8	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs297755	0.675	rs297764	chr20:4485927	G/A	cg14606382	chr20:4573199	NA	0.5	5.97	0.36	8.66e-9	Current cigarettes per day in chronic obstructive pulmonary disease;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg23069120	chr6:71559905	SMAP1	0.48	6.48	0.39	5.55e-10	Thyroid stimulating hormone;
SARC	cis	rs908922	0.676	rs10788842	chr1:152514588	A/T	cg09873164	chr1:152488093	CRCT1	0.64	8.6	0.49	1.16e-15	Hair morphology;
SARC	cis	rs240764	0.853	rs1875401	chr6:101023588	G/A	cg09795085	chr6:101329169	ASCC3	-0.45	-5.95	-0.36	9.52e-9	Neuroticism;
SARC	trans	rs61931739	0.534	rs73103090	chr12:34098801	C/T	cg26384229	chr12:38710491	ALG10B	0.86	12.32	0.63	3.52e-27	Morning vs. evening chronotype;
SARC	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg23758822	chr17:41437982	NA	0.86	11.11	0.59	2.71e-23	Menopause (age at onset);
SARC	cis	rs3087591	0.922	rs2905799	chr17:29536901	G/A	cg24425628	chr17:29625626	OMG;NF1	0.48	5.8	0.36	2.11e-8	Hip circumference;
SARC	cis	rs2933343	0.649	rs789214	chr3:128594995	A/G	cg24203234	chr3:128598194	ACAD9	0.63	8.11	0.47	2.89e-14	IgG glycosylation;
SARC	cis	rs1018836	0.595	rs2223010	chr8:91480068	A/G	cg16814680	chr8:91681699	NA	-0.7	-10.48	-0.57	2.68e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs2303759	0.709	rs10411679	chr19:49826480	A/T	cg22590775	chr19:49891494	CCDC155	0.48	5.31	0.33	2.6e-7	Multiple sclerosis;
SARC	cis	rs2635047	0.542	rs2684814	chr18:44754103	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.38	-4.82	-0.3	2.54e-6	Educational attainment;
SARC	cis	rs7615952	0.543	rs4645102	chr3:125424441	A/G	cg21696256	chr3:125484277	NA	-0.36	-5.12	-0.32	6.27e-7	Blood pressure (smoking interaction);
SARC	cis	rs6831352	1.000	rs10017466	chr4:100055800	C/T	cg13256891	chr4:100009986	ADH5	0.64	8.74	0.5	4.72e-16	Alcohol dependence;
SARC	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg18252515	chr7:66147081	NA	-1.32	-11.83	-0.61	1.38e-25	Diabetic kidney disease;
SARC	cis	rs6540556	0.608	rs2282738	chr1:209882015	C/T	cg23920097	chr1:209922102	NA	-0.43	-4.74	-0.3	3.74e-6	Red blood cell count;
SARC	cis	rs2011503	1.000	rs1036215	chr19:19657198	C/T	cg15839431	chr19:19639596	YJEFN3	-0.5	-4.9	-0.31	1.78e-6	Bipolar disorder;
SARC	cis	rs4642101	0.618	rs7612317	chr3:12820558	C/T	cg24848339	chr3:12840334	CAND2	0.36	5.85	0.36	1.64e-8	QRS complex (12-leadsum);
SARC	cis	rs765787	0.530	rs1648286	chr15:45517386	G/C	cg26924012	chr15:45694286	SPATA5L1	-0.44	-5.43	-0.34	1.42e-7	Uric acid levels;
SARC	cis	rs4841097	0.806	rs6992247	chr8:8948469	G/T	cg15556689	chr8:8085844	FLJ10661	0.39	4.82	0.3	2.55e-6	Platelet distribution width;
SARC	cis	rs7555523	0.887	rs4657476	chr1:165732661	A/G	cg24409356	chr1:165738333	TMCO1	-0.8	-6.56	-0.39	3.47e-10	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	cis	rs8180040	0.966	rs6790763	chr3:47572585	C/A	cg27129171	chr3:47204927	SETD2	0.67	9.11	0.51	3.8e-17	Colorectal cancer;
SARC	cis	rs796364	0.951	rs6722092	chr2:201059371	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.5	5.0	0.31	1.11e-6	Schizophrenia;
SARC	cis	rs9899728	0.764	rs7219493	chr17:73044188	T/C	cg27626185	chr17:73056755	KCTD2	-0.62	-5.18	-0.32	4.79e-7	Alzheimer's disease or small vessel stroke;
SARC	cis	rs13191362	1.000	rs34697913	chr6:163000187	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.57	5.38	0.33	1.85e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs9462027	0.628	rs9469886	chr6:34758824	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.92	-0.36	1.13e-8	Systemic lupus erythematosus;
SARC	cis	rs2153535	0.580	rs969421	chr6:8451949	A/C	cg07606381	chr6:8435919	SLC35B3	0.78	11.13	0.59	2.34e-23	Motion sickness;
SARC	cis	rs13191362	0.872	rs36069443	chr6:163248701	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.37	5.22	0.32	3.87e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs4481887	1.000	rs4589143	chr1:248470446	A/G	cg13385794	chr1:248469461	NA	0.36	5.48	0.34	1.09e-7	Common traits (Other);
SARC	cis	rs6709815	0.841	rs6740004	chr2:219663153	G/A	cg02176678	chr2:219576539	TTLL4	-0.4	-6.11	-0.37	4.25e-9	Reticulocyte count;High light scatter reticulocyte count;
SARC	cis	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg06636001	chr8:8085503	FLJ10661	-0.67	-8.45	-0.48	3.11e-15	Mood instability;
SARC	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg18404041	chr3:52824283	ITIH1	-0.43	-6.46	-0.39	6.04e-10	Bipolar disorder;
SARC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg07308232	chr7:1071921	C7orf50	-0.48	-5.76	-0.35	2.71e-8	Longevity;Endometriosis;
SARC	trans	rs10506458	0.915	rs12426017	chr12:63396272	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.74	-6.26	-0.38	1.81e-9	Hemostatic factors and hematological phenotypes;
SARC	cis	rs12142240	0.731	rs12385693	chr1:46818921	A/C	cg10495392	chr1:46806563	NSUN4	0.64	6.81	0.41	8.02e-11	Menopause (age at onset);
SARC	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg18876405	chr7:65276391	NA	-0.44	-4.87	-0.3	2.02e-6	Aortic root size;
SARC	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg03264133	chr6:25882463	NA	-0.52	-6.62	-0.4	2.41e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7625806	0.795	rs9756569	chr3:38106851	T/C	cg15121877	chr3:38081287	DLEC1	0.35	4.74	0.3	3.73e-6	Carotid intima media thickness;
SARC	cis	rs7264396	0.790	rs2425125	chr20:34330954	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.74	8.38	0.48	4.97e-15	Total cholesterol levels;
SARC	cis	rs79149102	0.579	rs3910748	chr15:75318652	A/G	cg17294928	chr15:75287854	SCAMP5	-1.08	-9.43	-0.53	4.22e-18	Lung cancer;
SARC	cis	rs5753037	0.640	rs131260	chr22:30132964	A/C	cg01021169	chr22:30184971	ASCC2	-0.46	-6.45	-0.39	6.31e-10	Type 1 diabetes;
SARC	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	10.4	0.56	4.82e-21	Platelet count;
SARC	cis	rs67460515	0.500	rs9832109	chr3:160723364	T/C	cg04691961	chr3:161091175	C3orf57	-0.44	-5.4	-0.33	1.6e-7	Parkinson's disease;
SARC	cis	rs6580649	1.000	rs7305954	chr12:48403530	C/T	cg24011408	chr12:48396354	COL2A1	0.55	6.34	0.38	1.2e-9	Lung cancer;
SARC	cis	rs3136516	1.000	rs3136516	chr11:46760756	G/A	cg03339077	chr11:47165057	C11orf49	-0.33	-4.77	-0.3	3.21e-6	Venous thromboembolism;
SARC	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg11890956	chr21:40555474	PSMG1	1.17	19.37	0.79	1.93e-50	Cognitive function;
SARC	cis	rs4481887	0.861	rs4497248	chr1:248450525	T/C	cg01631408	chr1:248437212	OR2T33	-0.42	-5.37	-0.33	1.87e-7	Common traits (Other);
SARC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg17178900	chr1:205818956	PM20D1	0.65	9.32	0.52	9.19e-18	Menarche (age at onset);
SARC	cis	rs11651000	0.894	rs66490177	chr17:45817723	T/C	cg24803719	chr17:45855879	NA	-0.37	-4.82	-0.3	2.65e-6	IgG glycosylation;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg08054244	chr14:88789549	KCNK10	-0.5	-6.44	-0.39	6.88e-10	Height;
SARC	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg12310025	chr6:25882481	NA	-0.46	-5.78	-0.35	2.4e-8	Intelligence (multi-trait analysis);
SARC	cis	rs4253772	0.513	rs6008700	chr22:46722560	C/T	cg24881330	chr22:46731750	TRMU	0.82	8.54	0.49	1.72e-15	LDL cholesterol;Cholesterol, total;
SARC	cis	rs3093024	0.595	rs4458654	chr6:167476068	A/C	cg07741184	chr6:167504864	NA	0.38	7.32	0.43	3.92e-12	Rheumatoid arthritis;
SARC	cis	rs73086581	1.000	rs17286768	chr20:3924569	A/G	cg02187196	chr20:3869020	PANK2	0.67	6.38	0.39	9.48e-10	Response to antidepressants in depression;
SARC	cis	rs12044355	0.892	rs1538974	chr1:231828596	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.6	-7.89	-0.46	1.17e-13	Alzheimer's disease;
SARC	cis	rs1468333	0.592	rs13185930	chr5:137577513	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.75	8.11	0.47	2.83e-14	Resting heart rate;
SARC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg12419862	chr22:24373484	LOC391322	-0.72	-9.21	-0.52	2e-17	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2439831	1.000	rs527921	chr15:43770416	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.79	-7.9	-0.46	1.11e-13	Lung cancer in ever smokers;
SARC	cis	rs34779708	0.931	rs67976880	chr10:35372261	G/C	cg03585969	chr10:35415529	CREM	0.39	4.86	0.3	2.17e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs412050	0.696	rs76843711	chr22:22262093	C/A	cg17089214	chr22:22089827	YPEL1	0.61	5.25	0.33	3.46e-7	Attention deficit hyperactivity disorder;
SARC	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg01341218	chr17:43662625	NA	-0.85	-9.63	-0.53	1.11e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg00933542	chr6:150070202	PCMT1	0.3	4.99	0.31	1.16e-6	Testicular germ cell tumor;
SARC	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2952156	0.920	rs2934953	chr17:37832315	T/A	cg00129232	chr17:37814104	STARD3	-0.69	-9.54	-0.53	2.01e-18	Asthma;
SARC	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg24829409	chr8:58192753	C8orf71	-0.59	-5.1	-0.32	7.19e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2380220	0.872	rs4546494	chr6:95990626	A/C	cg07718321	chr6:96025334	MANEA	0.48	5.14	0.32	5.89e-7	Behavioural disinhibition (generation interaction);
SARC	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg08219700	chr8:58056026	NA	0.61	6.35	0.38	1.13e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1113500	0.933	rs11185256	chr1:108633957	C/T	cg06207961	chr1:108661230	NA	0.45	5.92	0.36	1.12e-8	Growth-regulated protein alpha levels;
SARC	cis	rs614226	0.938	rs7972244	chr12:120994872	A/G	cg01236616	chr12:121019343	POP5	1.26	18.96	0.78	4.17e-49	Type 1 diabetes nephropathy;
SARC	cis	rs950169	0.959	rs12902070	chr15:84793558	T/C	cg17507749	chr15:85114479	UBE2QP1	0.76	9.16	0.51	2.68e-17	Schizophrenia;
SARC	cis	rs3857067	0.806	rs10008044	chr4:95092850	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.34	-4.97	-0.31	1.27e-6	QT interval;
SARC	cis	rs9790314	0.669	rs7630768	chr3:160864879	T/A	cg03342759	chr3:160939853	NMD3	-0.56	-7.15	-0.42	1.14e-11	Morning vs. evening chronotype;
SARC	cis	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg14541582	chr5:601475	NA	-0.4	-4.8	-0.3	2.89e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs72781680	1.000	rs72796328	chr2:24141343	A/G	cg06627628	chr2:24431161	ITSN2	-0.74	-6.78	-0.41	9.84e-11	Lymphocyte counts;
SARC	cis	rs5753037	0.543	rs131268	chr22:30147938	C/G	cg01021169	chr22:30184971	ASCC2	-0.5	-6.77	-0.41	1.05e-10	Type 1 diabetes;
SARC	cis	rs1062177	0.855	rs919262	chr5:151266084	C/T	cg00977110	chr5:151150581	G3BP1	-0.54	-5.75	-0.35	2.74e-8	Preschool internalizing problems;
SARC	cis	rs7255436	0.894	rs10413136	chr19:8452879	T/C	cg10174797	chr19:8464628	RAB11B	0.44	6.28	0.38	1.63e-9	HDL cholesterol;
SARC	cis	rs854765	0.547	rs12150369	chr17:17911014	G/A	cg04398451	chr17:18023971	MYO15A	-0.44	-6.29	-0.38	1.53e-9	Total body bone mineral density;
SARC	cis	rs6988636	1.000	rs58189203	chr8:124184739	G/T	cg23067535	chr8:124195133	FAM83A	-0.65	-4.97	-0.31	1.29e-6	Urinary uromodulin levels;
SARC	cis	rs13082711	0.911	rs6797389	chr3:27502070	G/T	cg02860705	chr3:27208620	NA	0.48	6.02	0.37	6.8e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs17600642	0.672	rs72814544	chr10:72454923	G/A	cg19779893	chr10:72451501	ADAMTS14	-0.4	-6.19	-0.38	2.67e-9	Bipolar disorder;
SARC	cis	rs2486288	0.656	rs9921025	chr15:45546602	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.5	-6.25	-0.38	1.9e-9	Glomerular filtration rate;
SARC	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.96	12.97	0.65	2.62e-29	Platelet count;
SARC	cis	rs888194	0.738	rs7956536	chr12:109980516	A/G	cg13986417	chr12:110012484	MVK;MMAB	0.32	4.8	0.3	2.85e-6	Neuroticism;
SARC	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg01017244	chr2:74357527	NA	0.6	7.29	0.43	4.66e-12	Gestational age at birth (maternal effect);
SARC	cis	rs6901004	0.803	rs4947107	chr6:111442505	C/T	cg15721981	chr6:111408429	SLC16A10	-0.47	-5.66	-0.35	4.37e-8	Blood metabolite levels;
SARC	cis	rs6088580	0.584	rs2378203	chr20:32993846	A/T	cg08999081	chr20:33150536	PIGU	-0.44	-6.49	-0.39	5.11e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs1711745	0.702	rs2995805	chr9:115454618	T/C	cg13803584	chr9:115635662	SNX30	0.73	5.69	0.35	3.83e-8	Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
SARC	cis	rs9341808	0.586	rs3805869	chr6:81045917	T/C	cg08355045	chr6:80787529	NA	0.31	4.73	0.3	3.97e-6	Sitting height ratio;
SARC	cis	rs1018836	0.608	rs7843149	chr8:91474961	C/T	cg16814680	chr8:91681699	NA	-0.65	-9.33	-0.52	8.89e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs79349575	0.756	rs2291726	chr17:47039254	T/C	cg16584676	chr17:46985605	UBE2Z	-0.48	-5.62	-0.35	5.46e-8	Type 2 diabetes;
SARC	cis	rs644799	0.965	rs10831425	chr11:95500628	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	15.44	0.71	1.68e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	8.12	0.47	2.68e-14	Alzheimer's disease;
SARC	cis	rs11785400	0.793	rs13255558	chr8:143748080	C/T	cg10596483	chr8:143751796	JRK	0.54	6.82	0.41	7.87e-11	Schizophrenia;
SARC	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg23262073	chr20:60523788	NA	0.58	8.38	0.48	5e-15	Obesity-related traits;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg11116035	chr5:78807149	HOMER1	0.5	7.4	0.44	2.5e-12	Thyroid stimulating hormone;
SARC	cis	rs58688157	0.883	rs7936397	chr11:577534	G/A	cg16486109	chr11:613632	IRF7	0.41	5.57	0.34	6.83e-8	Systemic lupus erythematosus;
SARC	cis	rs829883	0.659	rs11109521	chr12:98930809	C/A	cg25150519	chr12:98850993	NA	-0.59	-7.3	-0.43	4.42e-12	Colorectal adenoma (advanced);
SARC	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg24675658	chr1:53192096	ZYG11B	0.75	10.64	0.57	8.58e-22	Monocyte count;
SARC	cis	rs981844	1.000	rs55792703	chr4:154668278	C/A	cg14289246	chr4:154710475	SFRP2	0.57	6.43	0.39	7.08e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs7566780	1.000	rs4832652	chr2:16725395	A/T	cg09580478	chr2:16689509	NA	0.35	4.81	0.3	2.7e-6	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	trans	rs7937682	0.855	rs539693	chr11:111477387	A/G	cg18187862	chr3:45730750	SACM1L	0.55	6.92	0.41	4.43e-11	Primary sclerosing cholangitis;
SARC	cis	rs12477438	0.871	rs62156364	chr2:99695097	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.91	-11.71	-0.61	3.23e-25	Chronic sinus infection;
SARC	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg13939156	chr17:80058883	NA	-0.42	-6.48	-0.39	5.51e-10	Life satisfaction;
SARC	cis	rs3126085	0.935	rs11204943	chr1:152203906	A/C	cg03465714	chr1:152285911	FLG	-0.44	-5.3	-0.33	2.67e-7	Atopic dermatitis;
SARC	cis	rs9359856	0.510	rs17293240	chr6:90396370	C/T	cg13799429	chr6:90582589	CASP8AP2	0.53	5.02	0.31	1.01e-6	Bipolar disorder;
SARC	cis	rs6120849	0.754	rs6088678	chr20:33607551	A/G	cg24642439	chr20:33292090	TP53INP2	-0.55	-5.25	-0.33	3.48e-7	Protein C levels;
SARC	cis	rs60871478	0.579	rs56109762	chr7:925967	G/A	cg05535760	chr7:792225	HEATR2	-0.78	-7.1	-0.42	1.52e-11	Cerebrospinal P-tau181p levels;
SARC	cis	rs2180341	1.000	rs6903878	chr6:127638600	C/G	cg27446573	chr6:127587934	RNF146	1.03	14.54	0.69	1.56e-34	Breast cancer;
SARC	cis	rs11651000	0.947	rs11657376	chr17:45835984	A/T	cg03474202	chr17:45855739	NA	-0.42	-5.12	-0.32	6.27e-7	IgG glycosylation;
SARC	trans	rs3857536	0.740	rs9342532	chr6:66886297	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.6	-7.1	-0.42	1.48e-11	Blood trace element (Cu levels);
SARC	cis	rs35213789	0.762	rs210591	chr7:69247003	C/T	cg10619644	chr7:69149951	AUTS2	0.35	4.78	0.3	3.14e-6	Childhood ear infection;
SARC	cis	rs11718455	0.960	rs17076254	chr3:44000361	C/T	cg08738300	chr3:44038990	NA	0.54	6.14	0.37	3.6e-9	Coronary artery disease;
SARC	cis	rs950027	0.620	rs2467862	chr15:45643843	T/G	cg26924012	chr15:45694286	SPATA5L1	0.52	6.64	0.4	2.16e-10	Response to fenofibrate (adiponectin levels);
SARC	trans	rs17221829	0.733	rs11018668	chr11:89356178	C/T	cg13397649	chr18:12376968	AFG3L2	-0.48	-6.46	-0.39	6.13e-10	Anxiety in major depressive disorder;
SARC	cis	rs9354308	0.770	rs2802048	chr6:66525044	C/G	cg07460842	chr6:66804631	NA	0.49	5.54	0.34	7.96e-8	Metabolite levels;
SARC	cis	rs9549367	0.713	rs4907599	chr13:113861441	C/T	cg18105134	chr13:113819100	PROZ	0.42	6.37	0.39	9.95e-10	Platelet distribution width;
SARC	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg11764359	chr7:65958608	NA	0.86	12.33	0.63	3.29e-27	Aortic root size;
SARC	cis	rs12478296	0.685	rs12473450	chr2:242991746	C/T	cg06360820	chr2:242988706	NA	-0.58	-6.04	-0.37	6.03e-9	Obesity-related traits;
SARC	cis	rs6424115	1.000	rs58035855	chr1:24165248	G/C	cg15997130	chr1:24165203	NA	-0.49	-6.59	-0.4	2.84e-10	Immature fraction of reticulocytes;
SARC	cis	rs981844	0.712	rs1037650	chr4:154737657	G/A	cg14289246	chr4:154710475	SFRP2	-0.44	-5.1	-0.32	7.03e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs9467711	0.651	rs16891334	chr6:26124303	T/C	cg21479132	chr6:26055353	NA	0.93	6.78	0.41	1e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs17270561	0.609	rs2000351	chr6:25759783	T/C	cg17691542	chr6:26056736	HIST1H1C	0.57	7.0	0.42	2.78e-11	Iron status biomarkers;
SARC	cis	rs5753618	0.555	rs5749291	chr22:31907523	C/G	cg02404636	chr22:31891804	SFI1	0.53	5.91	0.36	1.2e-8	Colorectal cancer;
SARC	cis	rs7633857	0.512	rs13098529	chr3:160657053	A/G	cg04691961	chr3:161091175	C3orf57	-0.47	-5.78	-0.35	2.34e-8	Educational attainment (years of education);
SARC	cis	rs6991838	0.550	rs4737750	chr8:66550959	G/C	cg13398993	chr8:66546079	ARMC1	0.62	8.17	0.47	1.92e-14	Intelligence (multi-trait analysis);
SARC	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg06212747	chr3:49208901	KLHDC8B	0.68	9.01	0.51	7.56e-17	Parkinson's disease;
SARC	cis	rs11608355	0.508	rs11066411	chr12:109804194	A/G	cg19025524	chr12:109796872	NA	-0.41	-5.04	-0.31	9.25e-7	Neuroticism;
SARC	cis	rs11098499	0.754	rs7672594	chr4:120248543	A/C	cg09307838	chr4:120376055	NA	0.81	11.03	0.59	4.84e-23	Corneal astigmatism;
SARC	cis	rs6088580	0.524	rs6088565	chr20:33254986	A/C	cg07148914	chr20:33460835	GGT7	-0.43	-5.15	-0.32	5.63e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg16479474	chr6:28041457	NA	0.36	5.24	0.32	3.65e-7	Parkinson's disease;
SARC	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg04267008	chr7:1944627	MAD1L1	-0.5	-5.79	-0.35	2.24e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs765787	0.530	rs28526629	chr15:45540462	C/T	cg24006582	chr15:45444508	DUOX1	-0.56	-7.39	-0.44	2.68e-12	Uric acid levels;
SARC	cis	rs1401999	0.510	rs12634398	chr3:183708405	A/G	cg01324343	chr3:183735012	ABCC5	0.49	8.39	0.48	4.68e-15	Anterior chamber depth;
SARC	cis	rs17125944	0.686	rs4450307	chr14:53334783	G/A	cg00686598	chr14:53173677	PSMC6	-0.67	-4.88	-0.3	1.99e-6	Alzheimer's disease (late onset);
SARC	cis	rs12042938	0.935	rs1094653	chr1:231794794	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.59	8.29	0.48	9.03e-15	Neuranatomic and neurocognitive phenotypes;
SARC	cis	rs1904096	0.506	rs13435702	chr4:95167751	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.47	-7.12	-0.42	1.35e-11	Type 2 diabetes;
SARC	cis	rs8060686	0.920	rs16942887	chr16:67928042	G/A	cg27539214	chr16:67997921	SLC12A4	-0.54	-5.11	-0.32	6.76e-7	HDL cholesterol;Metabolic syndrome;
SARC	cis	rs5753618	0.583	rs2273251	chr22:31843567	G/C	cg07713946	chr22:31675144	LIMK2	0.37	5.07	0.32	8.11e-7	Colorectal cancer;
SARC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg21782813	chr7:2030301	MAD1L1	-0.47	-7.52	-0.44	1.15e-12	Bipolar disorder and schizophrenia;
SARC	cis	rs9948	1.000	rs6576986	chr2:97508320	G/C	cg01990225	chr2:97406019	LMAN2L	-0.64	-5.06	-0.31	8.4e-7	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs861020	0.606	rs629224	chr1:210005071	C/T	cg23166289	chr1:210001082	C1orf107	0.39	4.73	0.3	3.97e-6	Orofacial clefts;
SARC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.35	0.52	7.64e-18	Prudent dietary pattern;
SARC	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg13939156	chr17:80058883	NA	-0.42	-6.42	-0.39	7.66e-10	Life satisfaction;
SARC	cis	rs10870270	0.957	rs7074604	chr10:133740373	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.45	-5.37	-0.33	1.93e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs10174077	0.687	rs4664491	chr2:152479986	C/T	cg19508488	chr2:152266495	RIF1	0.48	5.18	0.32	4.84e-7	Squamous cell lung carcinoma;
SARC	cis	rs9399135	0.967	rs1854865	chr6:135360300	C/G	cg22676075	chr6:135203613	NA	0.35	4.88	0.3	1.96e-6	Red blood cell count;
SARC	cis	rs1401999	1.000	rs6800217	chr3:183685893	T/C	cg01324343	chr3:183735012	ABCC5	0.67	13.43	0.66	7.75e-31	Anterior chamber depth;
SARC	cis	rs2239547	0.522	rs6770957	chr3:52995416	T/C	cg07507251	chr3:52567010	NT5DC2	0.39	5.09	0.32	7.42e-7	Schizophrenia;
SARC	cis	rs5417	0.662	rs12601936	chr17:7172609	A/G	cg25256661	chr17:7137939	DVL2	-0.68	-10.18	-0.55	2.29e-20	Diastolic blood pressure;
SARC	cis	rs7756236	0.521	rs9462209	chr6:36628042	T/G	cg08179530	chr6:36648295	CDKN1A	0.51	6.26	0.38	1.86e-9	QRS duration;
SARC	cis	rs477692	0.673	rs511361	chr10:131365052	C/T	cg05714579	chr10:131428358	MGMT	0.56	7.23	0.43	7.02e-12	Response to temozolomide;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg04985097	chr5:74807689	COL4A3BP;POLK	-0.81	-6.95	-0.41	3.58e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.36	6.02	0.37	6.85e-9	Schizophrenia;
SARC	cis	rs1153858	0.943	rs4774580	chr15:45652086	G/A	cg26924012	chr15:45694286	SPATA5L1	0.77	11.01	0.58	5.85e-23	Homoarginine levels;
SARC	cis	rs7726839	0.561	rs4957049	chr5:579080	C/A	cg07777115	chr5:623756	CEP72	-0.61	-5.53	-0.34	8.61e-8	Obesity-related traits;
SARC	cis	rs11098499	0.657	rs4463052	chr4:120313258	T/C	cg09307838	chr4:120376055	NA	0.91	12.88	0.65	4.9e-29	Corneal astigmatism;
SARC	cis	rs6598955	0.724	rs4659420	chr1:26614333	G/A	cg04990556	chr1:26633338	UBXN11	-0.59	-8.11	-0.47	2.84e-14	Obesity-related traits;
SARC	cis	rs35995292	0.553	rs2392605	chr7:38924670	T/C	cg19327137	chr7:38886074	VPS41	0.51	7.64	0.45	5.55e-13	Subjective well-being (multi-trait analysis);
SARC	cis	rs1003719	0.715	rs2156077	chr21:38539357	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.65	-9.6	-0.53	1.3e-18	Eye color traits;
SARC	cis	rs1008375	0.966	rs1476836	chr4:17585014	G/C	cg02297831	chr4:17616191	MED28	0.49	6.22	0.38	2.31e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7005606	1.000	rs2439302	chr8:32432369	C/G	cg14488905	chr8:32406789	NRG1	0.44	6.28	0.38	1.64e-9	Hirschsprung disease;
SARC	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg24209194	chr3:40518798	ZNF619	0.66	8.11	0.47	2.86e-14	Renal cell carcinoma;
SARC	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg08280861	chr8:58055591	NA	0.58	4.89	0.31	1.89e-6	Developmental language disorder (linguistic errors);
SARC	trans	rs11098499	0.913	rs35271032	chr4:120156659	C/T	cg25214090	chr10:38739885	LOC399744	0.54	6.95	0.41	3.66e-11	Corneal astigmatism;
SARC	cis	rs7740797	0.875	rs3800006	chr6:155099371	A/G	cg02865717	chr6:155053990	RBM16	0.34	4.89	0.3	1.92e-6	Colorectal or endometrial cancer;
SARC	cis	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg03060546	chr3:49711283	APEH	0.75	11.17	0.59	1.7e-23	Resting heart rate;
SARC	cis	rs644799	1.000	rs527899	chr11:95529242	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	14.15	0.68	3.08e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg11764359	chr7:65958608	NA	0.59	7.09	0.42	1.56e-11	Calcium levels;
SARC	cis	rs7247513	0.639	rs12984441	chr19:12760287	A/C	cg11738485	chr19:12877000	HOOK2	0.41	4.79	0.3	2.92e-6	Bipolar disorder;
SARC	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg25811766	chr13:21894605	NA	0.7	8.29	0.48	8.88e-15	White matter hyperintensity burden;
SARC	cis	rs7666738	0.830	rs6532719	chr4:99043691	A/G	cg05340658	chr4:99064831	C4orf37	0.64	8.67	0.49	7.6e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs3796352	0.764	rs11714902	chr3:53101544	G/C	cg12962167	chr3:53033115	SFMBT1	0.77	5.23	0.32	3.86e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg05861140	chr6:150128134	PCMT1	-0.41	-5.15	-0.32	5.56e-7	Lung cancer;
SARC	cis	rs7412746	0.611	rs10788794	chr1:150728676	T/C	cg13175981	chr1:150552382	MCL1	-0.52	-6.38	-0.39	9.28e-10	Melanoma;
SARC	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs5758511	0.680	rs17002902	chr22:42625509	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.46	6.9	0.41	4.87e-11	Birth weight;
SARC	cis	rs739401	0.611	rs572373	chr11:3055361	T/C	cg08508325	chr11:3079039	CARS	-0.32	-8.03	-0.47	4.75e-14	Longevity;
SARC	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg24531977	chr5:56204891	C5orf35	-0.56	-5.88	-0.36	1.43e-8	Initial pursuit acceleration;
SARC	cis	rs17253792	0.822	rs28831725	chr14:56087569	C/T	cg01858014	chr14:56050164	KTN1	-0.67	-5.11	-0.32	6.86e-7	Putamen volume;
SARC	cis	rs57506017	0.585	rs11509153	chr7:12263800	G/A	cg23422036	chr7:12250390	TMEM106B	0.48	6.26	0.38	1.86e-9	Neuroticism;
SARC	cis	rs3784262	0.669	rs4646592	chr15:58302557	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.34	-5.21	-0.32	4.21e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs929843	1	rs929843	chr16:70045748	A/C	cg09409435	chr16:70099608	PDXDC2	0.86	9.8	0.54	3.41e-19	Menarche (age at onset);
SARC	cis	rs13090388	1	rs13090388	chr3:49391082	C/T	cg07274523	chr3:49395745	GPX1	0.54	6.35	0.38	1.12e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);
SARC	cis	rs7552404	0.961	rs211710	chr1:76109038	G/A	cg10523679	chr1:76189770	ACADM	-0.51	-6.51	-0.39	4.45e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs929354	0.557	rs62491947	chr7:156960813	G/A	cg05182265	chr7:156933206	UBE3C	-0.33	-5.08	-0.32	7.67e-7	Body mass index;
SARC	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg26335602	chr6:28129616	ZNF389	-0.47	-5.64	-0.35	4.94e-8	Depression;
SARC	trans	rs2727020	0.521	rs7126835	chr11:49594658	T/C	cg15704280	chr7:45808275	SEPT13	-0.71	-8.05	-0.47	4.35e-14	Coronary artery disease;
SARC	cis	rs7520050	0.931	rs11211224	chr1:46384388	G/A	cg06784218	chr1:46089804	CCDC17	-0.26	-4.75	-0.3	3.57e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs9916302	0.904	rs8077104	chr17:37530510	A/G	cg20243544	chr17:37824526	PNMT	-0.55	-6.63	-0.4	2.36e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs10189230	0.967	rs12993766	chr2:222350321	C/T	cg14652038	chr2:222343519	EPHA4	0.44	5.85	0.36	1.65e-8	Urate levels in lean individuals;
SARC	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.39	4.75	0.3	3.55e-6	Tonsillectomy;
SARC	cis	rs6912958	0.559	rs1201409	chr6:88055264	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.75	11.49	0.6	1.68e-24	Monocyte percentage of white cells;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg17109273	chr14:24712029	TINF2	0.51	6.52	0.39	4.39e-10	Lung adenocarcinoma;
SARC	cis	rs1008375	0.864	rs4698196	chr4:17574735	T/C	cg27347728	chr4:17578864	LAP3	0.5	5.99	0.37	8.03e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9325144	0.555	rs12424003	chr12:38688140	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-8.24	-0.48	1.23e-14	Morning vs. evening chronotype;
SARC	cis	rs72945132	1.000	rs56913804	chr11:70114673	G/A	cg05964544	chr11:70165517	PPFIA1	-0.54	-5.26	-0.33	3.31e-7	Coronary artery disease;
SARC	cis	rs9354308	0.899	rs2802058	chr6:66550787	T/G	cg07460842	chr6:66804631	NA	0.48	5.48	0.34	1.12e-7	Metabolite levels;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg03562565	chr10:20108524	PLXDC2	-0.48	-6.71	-0.4	1.5e-10	Thyroid stimulating hormone;
SARC	cis	rs8141529	0.719	rs9625619	chr22:29272328	T/A	cg02153584	chr22:29168773	CCDC117	0.77	11.34	0.6	5.12e-24	Lymphocyte counts;
SARC	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg08280861	chr8:58055591	NA	0.6	5.71	0.35	3.4e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7927771	1.000	rs35624992	chr11:47615798	G/C	cg05585544	chr11:47624801	NA	-0.36	-4.85	-0.3	2.27e-6	Subjective well-being;
SARC	cis	rs11612508	0.660	rs918115	chr12:12616403	C/T	cg12403778	chr12:11804115	ETV6	-0.38	-5.24	-0.32	3.59e-7	Inflammatory bowel disease;
SARC	cis	rs4642101	0.640	rs3901666	chr3:12824363	G/T	cg24848339	chr3:12840334	CAND2	-0.38	-5.69	-0.35	3.83e-8	QRS complex (12-leadsum);
SARC	cis	rs4280164	0.578	rs17184689	chr14:24794440	A/C	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.58	-6.39	-0.39	8.97e-10	Parent of origin effect on language impairment (paternal);
SARC	cis	rs826838	0.967	rs1719858	chr12:39124505	C/T	cg13010199	chr12:38710504	ALG10B	-0.64	-8.96	-0.51	1.06e-16	Heart rate;
SARC	cis	rs7312774	0.618	rs7953088	chr12:107334539	G/C	cg16260113	chr12:107380972	MTERFD3	0.86	7.11	0.42	1.39e-11	Severe influenza A (H1N1) infection;
SARC	cis	rs9896052	0.572	rs4078474	chr17:73489567	C/G	cg27037648	chr17:73511087	CASKIN2	0.4	4.79	0.3	2.97e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs9905704	0.624	rs11652761	chr17:56986095	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.41	-5.01	-0.31	1.1e-6	Testicular germ cell tumor;
SARC	cis	rs7582720	1.000	rs6722332	chr2:203745327	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.31	0.43	4.24e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs13191362	1.000	rs35583420	chr6:163214327	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.47	5.95	0.36	9.66e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs9457247	1.000	rs376574	chr6:167389956	A/T	cg07741184	chr6:167504864	NA	0.29	5.49	0.34	1.04e-7	Crohn's disease;
SARC	cis	rs9916302	0.904	rs13341996	chr17:37536862	C/T	cg15445000	chr17:37608096	MED1	-0.42	-5.08	-0.32	7.81e-7	Glomerular filtration rate (creatinine);
SARC	trans	rs12310956	0.532	rs10772114	chr12:33853970	G/A	cg26384229	chr12:38710491	ALG10B	0.59	7.55	0.44	9.82e-13	Morning vs. evening chronotype;
SARC	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg18370025	chr7:2749541	AMZ1	-0.3	-4.86	-0.3	2.17e-6	Height;
SARC	cis	rs1568889	0.838	rs4572130	chr11:28371794	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	13.55	0.66	3.12e-31	Bipolar disorder;
SARC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg04234412	chr22:24373322	LOC391322	-0.45	-5.2	-0.32	4.43e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7647973	0.593	rs1799844	chr3:49847642	G/A	cg07636037	chr3:49044803	WDR6	-0.61	-5.76	-0.35	2.61e-8	Menarche (age at onset);
SARC	cis	rs9467773	0.620	rs2451711	chr6:26663110	A/G	cg11502198	chr6:26597334	ABT1	0.63	8.48	0.49	2.58e-15	Intelligence (multi-trait analysis);
SARC	cis	rs13202913	0.639	rs9397407	chr6:151748995	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.59	4.97	0.31	1.32e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs9790314	1.000	rs336591	chr3:161078080	A/G	cg04691961	chr3:161091175	C3orf57	-0.81	-12.41	-0.63	1.74e-27	Morning vs. evening chronotype;
SARC	cis	rs2213920	0.619	rs2188047	chr9:118256660	G/C	cg13918206	chr9:118159781	DEC1	0.83	6.48	0.39	5.45e-10	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg11987759	chr7:65425863	GUSB	-0.47	-6.27	-0.38	1.7e-9	Aortic root size;
SARC	cis	rs2011503	1.000	rs75582668	chr19:19569023	C/T	cg15839431	chr19:19639596	YJEFN3	-0.47	-4.74	-0.3	3.78e-6	Bipolar disorder;
SARC	cis	rs7659604	0.967	rs34949254	chr4:122664344	G/A	cg19671926	chr4:122722719	EXOSC9	-0.49	-6.02	-0.37	6.71e-9	Type 2 diabetes;
SARC	cis	rs13191362	0.810	rs35509380	chr6:163053028	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.61	5.28	0.33	2.91e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs6594499	0.872	rs2112541	chr5:110449346	T/C	cg04022379	chr5:110408740	TSLP	0.48	6.08	0.37	4.89e-9	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs7681440	0.654	rs356199	chr4:90682327	G/A	cg06632027	chr4:90757378	SNCA	0.42	5.16	0.32	5.31e-7	Dementia with Lewy bodies;
SARC	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg11644478	chr21:40555479	PSMG1	1.06	15.22	0.71	9e-37	Cognitive function;
SARC	cis	rs155076	1.000	rs261407	chr13:21855213	C/A	cg25811766	chr13:21894605	NA	-0.52	-5.53	-0.34	8.74e-8	White matter hyperintensity burden;
SARC	cis	rs7666738	0.830	rs2865989	chr4:99067532	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.71	0.5	5.54e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs787274	0.543	rs4978509	chr9:115635641	C/G	cg13803584	chr9:115635662	SNX30	-0.87	-7.35	-0.43	3.3e-12	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs601339	1.000	rs601339	chr12:123174743	A/G	cg18578876	chr12:123200353	GPR109B	0.43	4.91	0.31	1.68e-6	Adiponectin levels;
SARC	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg12463550	chr7:65579703	CRCP	0.67	5.15	0.32	5.59e-7	Diabetic kidney disease;
SARC	cis	rs2712184	0.660	rs10164732	chr2:217645669	A/T	cg05032264	chr2:217675019	NA	0.52	7.01	0.42	2.56e-11	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
SARC	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg23958373	chr8:599963	NA	0.96	7.49	0.44	1.44e-12	IgG glycosylation;
SARC	cis	rs2180341	1.000	rs9375499	chr6:127618072	T/C	cg17762328	chr6:126965162	NA	-0.46	-5.24	-0.32	3.55e-7	Breast cancer;
SARC	cis	rs8013055	0.796	rs28662250	chr14:105996341	C/G	cg19700328	chr14:106028568	NA	-0.6	-8.02	-0.47	5.03e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
SARC	cis	rs1801251	1.000	rs6717841	chr2:233590255	C/T	cg25237894	chr2:233734115	C2orf82	0.39	5.03	0.31	9.83e-7	Coronary artery disease;
SARC	cis	rs9291683	0.609	rs12507050	chr4:10007305	G/T	cg00071950	chr4:10020882	SLC2A9	0.39	6.24	0.38	2.03e-9	Bone mineral density;
SARC	cis	rs7000551	0.751	rs2449338	chr8:22369232	A/G	cg12081754	chr8:22256438	SLC39A14	0.56	7.73	0.45	3.2e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs2153535	0.580	rs4639392	chr6:8446547	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	8.4	0.48	4.51e-15	Motion sickness;
SARC	cis	rs2290402	0.536	rs4690336	chr4:867242	A/G	cg00846425	chr4:957561	DGKQ	0.41	4.77	0.3	3.2e-6	Type 2 diabetes;
SARC	cis	rs1448094	0.872	rs7311150	chr12:86435989	A/T	cg02569458	chr12:86230093	RASSF9	0.37	5.46	0.34	1.23e-7	Major depressive disorder;
SARC	cis	rs10779751	0.770	rs12041740	chr1:11236524	G/A	cg08854313	chr1:11322531	MTOR	0.87	12.8	0.64	9.47e-29	Body mass index;
SARC	cis	rs427394	0.632	rs377137	chr5:6740468	T/G	cg10857441	chr5:6722123	POLS	-0.34	-4.91	-0.31	1.68e-6	Menopause (age at onset);
SARC	cis	rs1559088	0.895	rs13345542	chr19:33586739	G/C	cg17764715	chr19:33622953	WDR88	0.49	6.72	0.4	1.4e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs2718058	0.630	rs2722228	chr7:37859818	G/A	cg24998770	chr7:37888106	TXNDC3	0.35	5.08	0.32	7.79e-7	Alzheimer's disease (late onset);
SARC	cis	rs8141529	0.753	rs5752813	chr22:29226570	T/G	cg15103426	chr22:29168792	CCDC117	0.69	9.18	0.52	2.4e-17	Lymphocyte counts;
SARC	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.41	-5.55	-0.34	7.6e-8	Personality dimensions;
SARC	cis	rs981844	0.961	rs62325084	chr4:154662603	C/T	cg14289246	chr4:154710475	SFRP2	0.59	6.74	0.4	1.25e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs1395	0.922	rs11898114	chr2:27515527	C/T	cg21747090	chr2:27597821	SNX17	-0.44	-5.36	-0.33	2.02e-7	Blood metabolite levels;
SARC	cis	rs6546550	0.901	rs34586537	chr2:70163316	G/T	cg02498382	chr2:70120550	SNRNP27	0.34	5.4	0.33	1.68e-7	Prevalent atrial fibrillation;
SARC	cis	rs17376456	1.000	rs17376456	chr5:93557702	C/T	cg25358565	chr5:93447407	FAM172A	-1.33	-14.0	-0.68	1.01e-32	Diabetic retinopathy;
SARC	cis	rs6594499	0.500	rs12514810	chr5:110455357	T/A	cg04022379	chr5:110408740	TSLP	0.7	9.16	0.51	2.8e-17	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg20607798	chr8:58055168	NA	0.57	5.53	0.34	8.58e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg11062466	chr8:58055876	NA	0.53	5.48	0.34	1.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9788682	0.792	rs35031105	chr15:78772806	C/T	cg06917634	chr15:78832804	PSMA4	-0.53	-5.51	-0.34	9.53e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs7568458	0.846	rs7605975	chr2:85772548	C/T	cg17127132	chr2:85788382	GGCX	0.48	6.53	0.39	3.98e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs72945132	1.000	rs56913804	chr11:70114673	G/A	cg00319359	chr11:70116639	PPFIA1	0.72	6.75	0.4	1.14e-10	Coronary artery disease;
SARC	cis	rs8014204	0.550	rs7152906	chr14:75125540	T/C	cg06637938	chr14:75390232	RPS6KL1	0.61	8.83	0.5	2.6e-16	Caffeine consumption;
SARC	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	6.01	0.37	7.25e-9	Height;
SARC	cis	rs554111	0.656	rs17450586	chr1:21254593	T/G	cg04902671	chr1:21058625	SH2D5	0.43	5.33	0.33	2.29e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.09	12.48	0.63	1.03e-27	Platelet count;
SARC	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg02725872	chr8:58115012	NA	-0.37	-6.52	-0.39	4.21e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1707322	0.827	rs12125508	chr1:46246010	A/G	cg03146154	chr1:46216737	IPP	0.5	6.23	0.38	2.17e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg11890956	chr21:40555474	PSMG1	-0.7	-9.2	-0.52	2.12e-17	Menarche (age at onset);
SARC	cis	rs9322193	0.516	rs1999632	chr6:150187873	C/T	cg09699651	chr6:150184138	LRP11	0.48	4.96	0.31	1.34e-6	Lung cancer;
SARC	cis	rs10782582	0.609	rs1001160	chr1:76358591	A/C	cg03433033	chr1:76189801	ACADM	-0.39	-5.1	-0.32	7.07e-7	Daytime sleep phenotypes;
SARC	cis	rs11690935	0.959	rs2674484	chr2:172574612	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.99	-15.94	-0.72	3.4e-39	Schizophrenia;
SARC	trans	rs56279505	0.629	rs3910713	chr4:100258648	T/G	cg21156590	chr1:3420848	MEGF6	-0.83	-6.43	-0.39	7.07e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg09754991	chr13:107220236	ARGLU1	-0.48	-6.3	-0.38	1.43e-9	Electrocardiographic conduction measures;
SARC	cis	rs1562975	0.722	rs56011514	chr4:109456614	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.46	5.46	0.34	1.25e-7	Height;
SARC	cis	rs17376456	0.825	rs13165400	chr5:93091427	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.72	6.53	0.39	3.99e-10	Diabetic retinopathy;
SARC	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg19223190	chr17:80058835	NA	0.44	6.0	0.37	7.33e-9	Life satisfaction;
SARC	cis	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg26594101	chr16:53165934	CHD9	-0.41	-5.61	-0.35	5.68e-8	Tetralogy of Fallot;
SARC	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg21724239	chr8:58056113	NA	0.47	4.85	0.3	2.26e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	9.75	0.54	4.61e-19	Platelet count;
SARC	cis	rs4689388	0.853	rs13114527	chr4:6294655	T/G	cg00701064	chr4:6280414	WFS1	0.54	8.58	0.49	1.38e-15	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs13191362	1.000	rs13207239	chr6:163008772	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.56	5.35	0.33	2.07e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs9309473	0.583	rs6546822	chr2:73575098	G/A	cg20560298	chr2:73613845	ALMS1	-0.54	-6.84	-0.41	7.09e-11	Metabolite levels;
SARC	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg16606324	chr3:10149918	C3orf24	0.51	4.95	0.31	1.39e-6	Alzheimer's disease;
SARC	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg12016809	chr21:47604291	C21orf56	0.47	5.54	0.34	8.35e-8	Testicular germ cell tumor;
SARC	cis	rs2629540	0.924	rs1545910	chr10:126428145	G/C	cg08799069	chr10:126477246	METTL10	-0.68	-7.03	-0.42	2.33e-11	Cocaine dependence;
SARC	cis	rs8114671	0.562	rs1801310	chr20:33517014	A/G	cg24642439	chr20:33292090	TP53INP2	0.46	5.56	0.34	7.46e-8	Height;
SARC	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg11952622	chr19:58962976	ZNF324B	0.58	7.58	0.44	7.96e-13	Uric acid clearance;
SARC	cis	rs853679	0.760	rs11967137	chr6:28199764	A/G	cg26335602	chr6:28129616	ZNF389	0.51	5.04	0.31	9.56e-7	Depression;
SARC	cis	rs9325144	0.555	rs4882284	chr12:38710459	C/T	cg13010199	chr12:38710504	ALG10B	-0.57	-7.57	-0.44	8.55e-13	Morning vs. evening chronotype;
SARC	cis	rs262150	0.842	rs2657398	chr7:158784911	T/C	cg04111992	chr7:158790115	NA	-0.37	-4.9	-0.31	1.79e-6	Facial morphology (factor 20);
SARC	cis	rs2976388	0.609	rs2585144	chr8:143800269	A/T	cg06565975	chr8:143823917	SLURP1	0.28	4.73	0.3	3.97e-6	Urinary tract infection frequency;
SARC	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg27398817	chr8:82754497	SNX16	0.44	5.53	0.34	8.49e-8	Diastolic blood pressure;
SARC	cis	rs3784262	0.740	rs1441829	chr15:58289739	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.34	-4.89	-0.31	1.88e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg13395646	chr4:1353034	KIAA1530	-0.51	-6.12	-0.37	3.98e-9	Obesity-related traits;
SARC	cis	rs765787	0.530	rs2433229	chr15:45515235	C/A	cg25801113	chr15:45476975	SHF	0.28	4.72	0.3	4.06e-6	Uric acid levels;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg09783738	chr11:109964017	ZC3H12C	0.49	6.42	0.39	7.61e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg16405210	chr4:1374714	KIAA1530	-0.49	-5.69	-0.35	3.78e-8	Obesity-related traits;
SARC	cis	rs11719291	0.833	rs11709246	chr3:48859498	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.63	-5.4	-0.33	1.67e-7	Cognitive function;
SARC	cis	rs7296418	0.619	rs7139321	chr12:123719528	T/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-5.03	-0.31	9.66e-7	Platelet count;
SARC	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg19223190	chr17:80058835	NA	0.44	6.16	0.37	3.17e-9	Life satisfaction;
SARC	cis	rs6120849	1.000	rs6120849	chr20:33730387	C/T	cg24642439	chr20:33292090	TP53INP2	0.52	5.25	0.33	3.4e-7	Protein C levels;
SARC	cis	rs2841277	0.712	rs2841280	chr14:105393556	G/C	cg14403583	chr14:105418241	AHNAK2	0.62	8.03	0.47	4.89e-14	Rheumatoid arthritis;
SARC	cis	rs6964587	1.000	rs13231578	chr7:91663266	C/T	cg17063962	chr7:91808500	NA	0.93	15.59	0.71	5.12e-38	Breast cancer;
SARC	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg03264133	chr6:25882463	NA	-0.5	-6.47	-0.39	5.77e-10	Blood metabolite levels;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg03410407	chr10:39023676	NA	-0.49	-6.24	-0.38	2.02e-9	Height;
SARC	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg13114125	chr14:105738426	BRF1	-0.81	-11.72	-0.61	3.03e-25	Mean platelet volume;Platelet distribution width;
SARC	cis	rs950776	0.518	rs12914694	chr15:78814444	G/A	cg17108064	chr15:78857060	CHRNA5	0.28	4.78	0.3	3.07e-6	Sudden cardiac arrest;
SARC	cis	rs950027	0.620	rs1145076	chr15:45684508	G/T	cg26924012	chr15:45694286	SPATA5L1	0.54	6.99	0.42	2.94e-11	Response to fenofibrate (adiponectin levels);
SARC	trans	rs3808502	0.526	rs7822958	chr8:11422442	C/A	cg08975724	chr8:8085496	FLJ10661	-0.48	-6.29	-0.38	1.59e-9	Neuroticism;
SARC	trans	rs2727020	0.530	rs7113153	chr11:49457957	G/A	cg03929089	chr4:120376271	NA	-0.69	-7.57	-0.44	8.63e-13	Coronary artery disease;
SARC	cis	rs13418410	0.539	rs35866672	chr2:33842174	G/A	cg04131969	chr2:33951647	MYADML	-0.65	-9.39	-0.52	5.65e-18	Non-response to antidepressants and depression;
SARC	cis	rs116300850	0.757	rs60436694	chr5:76861305	A/C	cg02017109	chr5:76788595	WDR41	0.45	4.92	0.31	1.65e-6	Alzheimer disease and age of onset;
SARC	cis	rs6484504	0.652	rs494464	chr11:31386150	C/T	cg02090638	chr11:31391270	DNAJC24;DCDC1	0.39	4.89	0.31	1.88e-6	Red blood cell count;
SARC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg11494091	chr17:61959527	GH2	0.53	7.97	0.46	7.23e-14	Prudent dietary pattern;
SARC	cis	rs636523	0.561	rs12130333	chr1:63191777	A/G	cg06896770	chr1:63153194	DOCK7	-0.69	-7.26	-0.43	5.71e-12	Lipid traits;
SARC	cis	rs2624839	0.602	rs2526390	chr3:50192760	C/T	cg19755318	chr3:50243323	SLC38A3	-0.31	-5.32	-0.33	2.41e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7084402	1.000	rs11006169	chr10:60269326	T/A	cg07615347	chr10:60278583	BICC1	-0.58	-8.47	-0.49	2.84e-15	Refractive error;
SARC	cis	rs7220711	0.967	rs2342314	chr17:41786389	T/G	cg26893861	chr17:41843967	DUSP3	0.4	5.12	0.32	6.43e-7	Bone mineral density (spine);Bone mineral density (hip);
SARC	cis	rs4819052	0.679	rs2255761	chr21:46683622	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	6.61	0.4	2.65e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg03433033	chr1:76189801	ACADM	0.54	7.64	0.45	5.6e-13	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs11122272	0.706	rs2749710	chr1:231535112	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.66	9.67	0.54	8.26e-19	Hemoglobin concentration;
SARC	cis	rs910187	0.678	rs6124964	chr20:45812536	T/G	cg27589058	chr20:45804311	EYA2	-0.32	-4.99	-0.31	1.19e-6	Migraine;
SARC	cis	rs16976116	0.572	rs28704633	chr15:55446541	T/G	cg17854078	chr15:55489399	RSL24D1	0.64	5.65	0.35	4.69e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6912958	0.781	rs7742965	chr6:88278196	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.43	-0.34	1.42e-7	Monocyte percentage of white cells;
SARC	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg13206674	chr6:150067644	NUP43	0.55	6.74	0.4	1.22e-10	Lung cancer;
SARC	cis	rs282587	0.569	rs378491	chr13:113398408	C/A	cg02820901	chr13:113351484	ATP11A	-0.48	-4.81	-0.3	2.7e-6	Glycated hemoglobin levels;
SARC	cis	rs2295359	0.892	rs17375018	chr1:67655147	A/G	cg11235152	chr1:67600687	NA	-0.49	-7.1	-0.42	1.47e-11	Psoriasis;
SARC	cis	rs3540	0.960	rs8030722	chr15:90974920	G/A	cg22089800	chr15:90895588	ZNF774	0.51	5.72	0.35	3.23e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs7223966	1.000	rs9895920	chr17:61852719	T/C	cg26338869	chr17:61819248	STRADA	0.45	5.03	0.31	9.9e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs524281	0.773	rs10750781	chr11:66037270	A/G	cg14036092	chr11:66035641	RAB1B	-0.59	-6.01	-0.37	7.02e-9	Electroencephalogram traits;
SARC	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg24531977	chr5:56204891	C5orf35	-0.53	-5.34	-0.33	2.22e-7	Initial pursuit acceleration;
SARC	cis	rs372883	0.600	rs1153277	chr21:30666867	A/T	cg08807101	chr21:30365312	RNF160	-0.59	-7.4	-0.44	2.42e-12	Pancreatic cancer;
SARC	cis	rs7819412	0.645	rs10156356	chr8:11046209	T/C	cg21775007	chr8:11205619	TDH	-0.49	-6.35	-0.38	1.09e-9	Triglycerides;
SARC	cis	rs7666738	0.791	rs11097601	chr4:98960103	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg20891283	chr12:69753455	YEATS4	0.68	9.8	0.54	3.26e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs1476587	0.527	rs1859126	chr7:86752134	C/A	cg02420886	chr7:86849541	C7orf23	0.6	5.44	0.34	1.32e-7	Brachial circumference;
SARC	cis	rs2013441	1.000	rs2703785	chr17:20152418	C/T	cg13482628	chr17:19912719	NA	-0.47	-6.2	-0.38	2.57e-9	Obesity-related traits;
SARC	cis	rs62244186	0.748	rs2888410	chr3:44655476	A/C	cg15225532	chr3:44803084	KIF15;KIAA1143	0.44	5.56	0.34	7.42e-8	Depressive symptoms;
SARC	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg12311346	chr5:56204834	C5orf35	0.74	7.25	0.43	5.95e-12	Initial pursuit acceleration;
SARC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.8	0.58	2.71e-22	Prudent dietary pattern;
SARC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg22903471	chr2:27725779	GCKR	-0.48	-7.23	-0.43	6.88e-12	Total body bone mineral density;
SARC	trans	rs8073060	0.505	rs225276	chr17:33973034	T/C	cg19694781	chr19:47549865	TMEM160	-0.68	-6.86	-0.41	6.05e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs4794202	0.618	rs11079799	chr17:45956073	A/G	cg23391107	chr17:45924227	SP6	0.47	5.17	0.32	5.14e-7	Alzheimer's disease (cognitive decline);
SARC	cis	rs9790314	0.875	rs163327	chr3:161062724	A/G	cg04691961	chr3:161091175	C3orf57	-0.72	-10.27	-0.56	1.19e-20	Morning vs. evening chronotype;
SARC	cis	rs4727443	0.769	rs12672695	chr7:99580426	C/A	cg22004693	chr7:99632812	ZKSCAN1	0.67	8.97	0.51	1.03e-16	Interstitial lung disease;
SARC	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg02462569	chr6:150064036	NUP43	-0.4	-5.23	-0.32	3.77e-7	Lung cancer;
SARC	cis	rs7223966	1.000	rs6504169	chr17:61709145	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.53	-5.58	-0.34	6.72e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7998202	0.667	rs914016	chr13:113355057	A/C	cg02820901	chr13:113351484	ATP11A	0.56	5.06	0.31	8.58e-7	Glycated hemoglobin levels;
SARC	cis	rs7635838	0.617	rs346076	chr3:11292682	A/G	cg00170343	chr3:11313890	ATG7	-0.76	-10.58	-0.57	1.32e-21	HDL cholesterol;
SARC	cis	rs922107	0.713	rs6680212	chr1:90045922	C/T	cg15422784	chr1:90023713	LRRC8B	-0.32	-4.72	-0.3	4.11e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
SARC	cis	rs2153535	0.580	rs4960412	chr6:8438261	G/C	cg21535247	chr6:8435926	SLC35B3	0.56	7.01	0.42	2.6e-11	Motion sickness;
SARC	cis	rs200986	1	rs200986	chr6:27824766	G/C	cg20933634	chr6:27740509	NA	0.39	4.78	0.3	3.13e-6	Autism spectrum disorder or schizophrenia;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg03784614	chr12:32259462	BICD1	0.51	6.72	0.4	1.42e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs751728	1.000	rs3806108	chr6:33767579	C/G	cg25922239	chr6:33757077	LEMD2	0.78	10.02	0.55	6.88e-20	Crohn's disease;
SARC	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg16680214	chr1:154839983	KCNN3	-0.32	-5.03	-0.31	9.73e-7	Prostate cancer;
SARC	cis	rs17376456	0.696	rs6860390	chr5:93494731	G/T	cg21475434	chr5:93447410	FAM172A	-0.65	-6.61	-0.4	2.57e-10	Diabetic retinopathy;
SARC	cis	rs77633900	0.614	rs2469244	chr15:76884127	G/A	cg21673338	chr15:77095150	SCAPER	-0.75	-6.16	-0.37	3.1e-9	Non-glioblastoma glioma;Glioma;
SARC	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg11764359	chr7:65958608	NA	-0.78	-9.49	-0.53	2.76e-18	Aortic root size;
SARC	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.51	0.34	9.64e-8	Bipolar disorder;
SARC	trans	rs56279505	0.629	rs35189763	chr4:100261252	C/A	cg18024358	chr1:3420815	MEGF6	-0.84	-6.43	-0.39	7.04e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg11890956	chr21:40555474	PSMG1	1.16	19.35	0.79	2.15e-50	Cognitive function;
SARC	cis	rs6665290	0.669	rs3795446	chr1:227180981	C/T	cg14016676	chr1:227182615	CDC42BPA	-0.34	-4.84	-0.3	2.39e-6	Myeloid white cell count;
SARC	cis	rs4889855	0.556	rs9911795	chr17:78626115	T/C	cg17956530	chr17:78667699	RPTOR	-0.48	-5.47	-0.34	1.13e-7	Fractional excretion of uric acid;
SARC	cis	rs1348850	0.958	rs1545364	chr2:178462882	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.63	7.7	0.45	3.82e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9612	1.000	rs2277745	chr19:44259077	C/T	cg08581076	chr19:44259116	C19orf61	0.71	8.89	0.5	1.7e-16	Exhaled nitric oxide output;
SARC	cis	rs9660992	0.573	rs12144980	chr1:205185104	C/T	cg07972983	chr1:205091412	RBBP5	0.57	7.09	0.42	1.56e-11	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs7474896	0.515	rs2738203	chr10:38277596	G/A	cg25427524	chr10:38739819	LOC399744	0.47	5.28	0.33	2.98e-7	Obesity (extreme);
SARC	cis	rs1113500	0.933	rs3893034	chr1:108632178	G/A	cg06207961	chr1:108661230	NA	0.44	5.82	0.36	1.93e-8	Growth-regulated protein alpha levels;
SARC	cis	rs2479724	0.846	rs2488338	chr6:41808351	A/G	cg17623882	chr6:41773611	USP49	-0.44	-5.52	-0.34	9.03e-8	Menarche (age at onset);
SARC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg26338869	chr17:61819248	STRADA	-0.73	-9.83	-0.54	2.61e-19	Prudent dietary pattern;
SARC	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg07701084	chr6:150067640	NUP43	0.42	5.51	0.34	9.26e-8	Lung cancer;
SARC	cis	rs3768617	0.510	rs4651140	chr1:183096952	G/T	cg13390022	chr1:182993471	LAMC1	0.31	4.79	0.3	3.01e-6	Fuchs's corneal dystrophy;
SARC	cis	rs9815354	0.556	rs60966614	chr3:42005166	A/G	cg03022575	chr3:42003672	ULK4	0.68	5.89	0.36	1.34e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg08045932	chr20:61659980	NA	0.5	6.84	0.41	7.06e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs7635838	0.590	rs2256773	chr3:11386329	C/G	cg00170343	chr3:11313890	ATG7	0.62	8.69	0.49	6.51e-16	HDL cholesterol;
SARC	cis	rs55883249	1.000	rs10495573	chr2:9712160	T/G	cg23886495	chr2:9695866	ADAM17	0.68	6.75	0.4	1.13e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs12586317	0.620	rs76293361	chr14:35570889	G/A	cg16230307	chr14:35515116	FAM177A1	0.92	10.85	0.58	1.78e-22	Psoriasis;
SARC	cis	rs933688	0.941	rs6452954	chr5:90735692	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.01	13.41	0.66	9.21e-31	Smoking behavior;
SARC	cis	rs9547692	1.000	rs493248	chr13:37473386	C/T	cg01493522	chr13:37497338	NA	-0.46	-5.28	-0.33	2.89e-7	Coronary artery disease;
SARC	cis	rs644799	0.540	rs10831419	chr11:95478037	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.72	9.34	0.52	8.18e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs1348850	0.567	rs880898	chr2:178532470	C/T	cg22681709	chr2:178499509	PDE11A	-0.37	-5.21	-0.32	4.08e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9527	0.590	rs1541213	chr10:104885330	A/G	cg04362960	chr10:104952993	NT5C2	0.44	5.15	0.32	5.58e-7	Arsenic metabolism;
SARC	cis	rs1580019	0.922	rs34545272	chr7:32460630	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.79	11.46	0.6	2.01e-24	Cognitive ability;
SARC	cis	rs854765	0.618	rs8066982	chr17:17851377	T/C	cg05444541	chr17:17804740	TOM1L2	-0.29	-4.82	-0.3	2.56e-6	Total body bone mineral density;
SARC	cis	rs611744	0.967	rs603889	chr8:109224232	C/T	cg21045802	chr8:109455806	TTC35	0.46	5.43	0.34	1.38e-7	Dupuytren's disease;
SARC	cis	rs7927771	0.832	rs10769262	chr11:47411581	G/A	cg20307385	chr11:47447363	PSMC3	0.58	7.37	0.43	2.98e-12	Subjective well-being;
SARC	cis	rs1215050	0.740	rs783938	chr4:99010336	A/T	cg05340658	chr4:99064831	C4orf37	-0.46	-6.26	-0.38	1.84e-9	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg22800045	chr5:56110881	MAP3K1	-0.68	-6.37	-0.39	9.84e-10	Initial pursuit acceleration;
SARC	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg11494091	chr17:61959527	GH2	0.35	4.77	0.3	3.29e-6	Height;
SARC	cis	rs1153858	1.000	rs12439274	chr15:45636667	A/G	cg26924012	chr15:45694286	SPATA5L1	0.74	10.3	0.56	9.83e-21	Homoarginine levels;
SARC	cis	rs6493487	0.512	rs35655196	chr15:51321908	A/G	cg02338191	chr15:51200825	AP4E1	0.53	4.83	0.3	2.44e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs7223966	1.000	rs9908044	chr17:61747032	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.45	5.03	0.31	9.75e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs4689388	0.926	rs4234730	chr4:6296343	A/G	cg00701064	chr4:6280414	WFS1	0.51	7.82	0.46	1.8e-13	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs17253792	0.822	rs78922774	chr14:56115302	T/A	cg01858014	chr14:56050164	KTN1	-0.64	-4.75	-0.3	3.57e-6	Putamen volume;
SARC	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg00149659	chr3:10157352	C3orf10	1.1	9.97	0.55	9.7e-20	Alzheimer's disease;
SARC	trans	rs2727020	0.553	rs11040400	chr11:49518296	C/A	cg03929089	chr4:120376271	NA	-0.75	-10.97	-0.58	7.44e-23	Coronary artery disease;
SARC	cis	rs67311347	1.000	rs28491638	chr3:40496263	T/C	cg01475735	chr3:40494733	NA	-0.46	-5.16	-0.32	5.33e-7	Renal cell carcinoma;
SARC	cis	rs7772486	0.727	rs10447449	chr6:146138707	A/G	cg23711669	chr6:146136114	FBXO30	0.82	13.83	0.67	3.68e-32	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg15242686	chr22:24348715	GSTTP1	-0.47	-5.37	-0.33	1.93e-7	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs6088813	1.000	rs6142373	chr20:33983314	T/A	cg23207816	chr20:34252616	CPNE1;RBM12	-0.43	-5.24	-0.32	3.67e-7	Height;
SARC	cis	rs7005380	0.581	rs9649949	chr8:120913575	G/A	cg21744203	chr8:120868354	DSCC1	-0.48	-5.59	-0.34	6.28e-8	Interstitial lung disease;
SARC	cis	rs12893668	0.542	rs12884809	chr14:104095320	G/A	cg26031613	chr14:104095156	KLC1	-0.56	-6.43	-0.39	7.08e-10	Reticulocyte count;
SARC	cis	rs17345786	0.511	rs1138818	chr3:101399583	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	6.69	0.4	1.6e-10	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-8.89	-0.5	1.75e-16	Alzheimer's disease;
SARC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.42	-6.44	-0.39	6.6e-10	Total body bone mineral density;
SARC	cis	rs9325144	0.560	rs2387924	chr12:38662883	A/G	cg13010199	chr12:38710504	ALG10B	-0.57	-7.44	-0.44	1.87e-12	Morning vs. evening chronotype;
SARC	cis	rs17376456	0.877	rs28418572	chr5:93144161	A/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.71	6.48	0.39	5.38e-10	Diabetic retinopathy;
SARC	cis	rs2228479	0.850	rs34033205	chr16:89922959	G/T	cg06558623	chr16:89946397	TCF25	0.93	6.61	0.4	2.59e-10	Skin colour saturation;
SARC	cis	rs910316	1.000	rs9805979	chr14:75566209	G/A	cg06637938	chr14:75390232	RPS6KL1	0.54	7.69	0.45	4.04e-13	Height;
SARC	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg09033563	chr22:24373618	LOC391322	-0.59	-7.59	-0.45	7.85e-13	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9640161	0.830	rs3735165	chr7:150068371	T/C	cg21361702	chr7:150065534	REPIN1	0.52	6.67	0.4	1.8e-10	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs73206853	0.764	rs7314552	chr12:110618890	C/T	cg10860002	chr12:110842031	ANAPC7	0.64	5.27	0.33	3.06e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs2997447	0.846	rs3008417	chr1:26403470	G/A	cg19633962	chr1:26362018	EXTL1	-0.59	-5.35	-0.33	2.08e-7	QRS complex (12-leadsum);
SARC	cis	rs66887589	0.720	rs2036858	chr4:120249237	A/C	cg09307838	chr4:120376055	NA	0.56	7.45	0.44	1.77e-12	Diastolic blood pressure;
SARC	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg00933542	chr6:150070202	PCMT1	0.31	5.36	0.33	2.04e-7	Lung cancer;
SARC	cis	rs2635047	0.811	rs12956009	chr18:44768024	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	6.61	0.4	2.64e-10	Educational attainment;
SARC	cis	rs9916302	0.904	rs11078910	chr17:37671269	G/T	cg07936489	chr17:37558343	FBXL20	-0.69	-8.9	-0.5	1.63e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs950027	0.620	rs2467862	chr15:45643843	T/G	cg21132104	chr15:45694354	SPATA5L1	0.56	7.07	0.42	1.84e-11	Response to fenofibrate (adiponectin levels);
SARC	cis	rs6696846	0.749	rs7553876	chr1:205079915	A/G	cg21545522	chr1:205238299	TMCC2	0.38	5.13	0.32	6.03e-7	Red blood cell count;
SARC	cis	rs10493773	1.000	rs12754358	chr1:86248431	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.49	-7.08	-0.42	1.7e-11	Urate levels in overweight individuals;
SARC	cis	rs1707322	1.000	rs10890359	chr1:46336635	A/G	cg06784218	chr1:46089804	CCDC17	0.33	5.78	0.35	2.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs11792861	0.781	rs2151426	chr9:111743797	A/C	cg13535736	chr9:111863775	C9orf5	-0.39	-4.72	-0.3	4.08e-6	Menarche (age at onset);
SARC	cis	rs9660992	0.573	rs4400674	chr1:205218425	A/C	cg07972983	chr1:205091412	RBBP5	-0.55	-7.03	-0.42	2.29e-11	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs1215050	0.740	rs783941	chr4:99008235	T/C	cg05340658	chr4:99064831	C4orf37	-0.47	-6.43	-0.39	7.03e-10	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs1949733	0.628	rs2688231	chr4:8490981	G/A	cg13073564	chr4:8508604	NA	-0.46	-7.48	-0.44	1.47e-12	Response to antineoplastic agents;
SARC	cis	rs12477438	1.000	rs73963398	chr2:99887025	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-6.76	-0.4	1.09e-10	Chronic sinus infection;
SARC	cis	rs13191362	1.000	rs36007635	chr6:163009335	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.56	5.35	0.33	2.07e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs13191362	0.938	rs13208970	chr6:163006368	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.56	5.41	0.33	1.53e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs10927875	0.619	rs2102664	chr1:16130169	A/G	cg21385522	chr1:16154831	NA	-0.61	-8.17	-0.47	1.9e-14	Dilated cardiomyopathy;
SARC	cis	rs8180040	0.932	rs62248599	chr3:47516728	G/A	cg27129171	chr3:47204927	SETD2	-0.69	-9.67	-0.54	8.31e-19	Colorectal cancer;
SARC	cis	rs9462027	0.628	rs9462023	chr6:34769410	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.92	-0.36	1.16e-8	Systemic lupus erythematosus;
SARC	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg13206674	chr6:150067644	NUP43	0.46	6.07	0.37	5.05e-9	Lung cancer;
SARC	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg22800045	chr5:56110881	MAP3K1	0.74	7.83	0.46	1.74e-13	Initial pursuit acceleration;
SARC	cis	rs60871478	0.898	rs62432225	chr7:789433	G/A	cg09839136	chr7:766187	HEATR2;PRKAR1B	0.56	4.78	0.3	3.1e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs11214589	0.651	rs17600713	chr11:113259947	C/T	cg14159747	chr11:113255604	NA	0.37	5.32	0.33	2.46e-7	Neuroticism;
SARC	cis	rs453301	0.522	rs2929309	chr8:9083771	C/A	cg15556689	chr8:8085844	FLJ10661	-0.45	-5.5	-0.34	1e-7	Joint mobility (Beighton score);
SARC	cis	rs12249377	0.519	rs10881838	chr10:92590233	A/G	cg14313238	chr10:92632228	RPP30	0.43	5.14	0.32	5.91e-7	White matter microstructure (global fractional anisotropy);
SARC	cis	rs1865760	0.929	rs9461224	chr6:25936402	G/T	cg16218610	chr6:26124417	HIST1H2AC;HIST1H2BC	-0.42	-4.87	-0.3	2.08e-6	Height;
SARC	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg03161606	chr19:29218774	NA	0.47	6.76	0.4	1.09e-10	Methadone dose in opioid dependence;
SARC	cis	rs9611519	0.780	rs5751072	chr22:41656509	C/T	cg17376030	chr22:41985996	PMM1	0.52	6.6	0.4	2.7e-10	Neuroticism;
SARC	cis	rs10782582	0.569	rs1770892	chr1:76389359	T/C	cg03433033	chr1:76189801	ACADM	-0.41	-5.26	-0.33	3.27e-7	Daytime sleep phenotypes;
SARC	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.48	-6.01	-0.37	7.23e-9	Lymphocyte counts;
SARC	cis	rs7395581	0.798	rs10769252	chr11:47343955	A/G	cg25783544	chr11:47291846	MADD	0.48	5.32	0.33	2.41e-7	HDL cholesterol;
SARC	cis	rs11150038	0.826	rs9934062	chr16:78087287	C/T	cg04733911	chr16:78082701	NA	0.44	4.83	0.3	2.52e-6	Colorectal or endometrial cancer;
SARC	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg24209194	chr3:40518798	ZNF619	0.65	7.91	0.46	1.03e-13	Renal cell carcinoma;
SARC	cis	rs9913156	0.515	rs11658808	chr17:4577112	C/T	cg00122941	chr17:4613640	ARRB2	-0.56	-7.01	-0.42	2.49e-11	Lymphocyte counts;
SARC	cis	rs35110281	0.840	rs7276633	chr21:45078800	C/T	cg21573476	chr21:45109991	RRP1B	-0.5	-7.12	-0.42	1.36e-11	Mean corpuscular volume;
SARC	cis	rs11651000	0.857	rs56172120	chr17:45824904	G/A	cg24803719	chr17:45855879	NA	-0.52	-7.65	-0.45	5.26e-13	IgG glycosylation;
SARC	cis	rs8072100	0.754	rs8081717	chr17:45653921	T/A	cg08085267	chr17:45401833	C17orf57	0.41	4.79	0.3	3e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	trans	rs1814175	0.645	rs1722000	chr11:49917928	A/C	cg03929089	chr4:120376271	NA	-0.81	-11.69	-0.61	3.89e-25	Height;
SARC	cis	rs9291683	0.546	rs7442336	chr4:10045783	G/A	cg11266682	chr4:10021025	SLC2A9	0.4	6.91	0.41	4.53e-11	Bone mineral density;
SARC	cis	rs12311304	0.965	rs7965695	chr12:15368644	G/A	cg08258403	chr12:15378311	NA	0.46	7.25	0.43	6.02e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs360798	0.598	rs2129508	chr2:62860131	G/A	cg16915676	chr2:62734870	TMEM17	0.45	5.53	0.34	8.55e-8	Coronary artery disease;
SARC	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg12463550	chr7:65579703	CRCP	0.48	5.79	0.35	2.23e-8	Aortic root size;
SARC	cis	rs2777491	0.915	rs16971767	chr15:41623308	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.74	-10.99	-0.58	6.61e-23	Ulcerative colitis;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg02624558	chr1:202777611	KDM5B	0.49	6.39	0.39	8.98e-10	Chemerin levels;
SARC	cis	rs10463316	0.894	rs6579866	chr5:150762524	A/G	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.28	-0.33	2.89e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	14.0	0.68	9.94e-33	Chronic sinus infection;
SARC	cis	rs4690686	0.500	rs17062801	chr4:177262381	G/A	cg17059388	chr4:177262070	NA	0.37	4.84	0.3	2.33e-6	Essential tremor;
SARC	cis	rs412050	0.502	rs75034650	chr22:22177949	C/T	cg17089214	chr22:22089827	YPEL1	0.77	6.59	0.4	2.84e-10	Attention deficit hyperactivity disorder;
SARC	cis	rs854765	0.583	rs7214002	chr17:17852104	G/C	cg05444541	chr17:17804740	TOM1L2	-0.31	-5.04	-0.31	9.18e-7	Total body bone mineral density;
SARC	cis	rs9640161	0.830	rs17173681	chr7:150059414	A/G	cg10018233	chr7:150070692	REPIN1	-0.7	-10.31	-0.56	8.76e-21	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg13206674	chr6:150067644	NUP43	0.41	5.28	0.33	2.94e-7	Lung cancer;
SARC	cis	rs1018836	0.575	rs17635255	chr8:91518135	A/T	cg16814680	chr8:91681699	NA	-0.68	-8.29	-0.48	8.83e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs7582720	1.000	rs114110842	chr2:203823400	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg05863683	chr7:1912471	MAD1L1	0.34	4.98	0.31	1.25e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs1881797	1.000	rs12081895	chr1:247686666	C/G	cg18198730	chr1:247681584	NA	0.48	5.29	0.33	2.85e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs617791	0.678	rs551659	chr11:65749645	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.42	-5.15	-0.32	5.62e-7	Breast cancer;
SARC	cis	rs950169	0.919	rs17300292	chr15:84762568	G/C	cg17507749	chr15:85114479	UBE2QP1	0.75	9.12	0.51	3.59e-17	Schizophrenia;
SARC	cis	rs995000	0.929	rs636523	chr1:62920008	A/G	cg06896770	chr1:63153194	DOCK7	0.97	14.97	0.7	5.76e-36	Triglyceride levels;
SARC	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg23262073	chr20:60523788	NA	-0.45	-6.56	-0.39	3.46e-10	Body mass index;
SARC	cis	rs7772486	0.641	rs2253757	chr6:146199686	C/T	cg05347473	chr6:146136440	FBXO30	0.71	9.95	0.55	1.16e-19	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2046867	0.818	rs62249861	chr3:72867779	A/G	cg25664220	chr3:72788482	NA	-0.29	-4.77	-0.3	3.27e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
SARC	cis	rs12754538	0.660	rs7517686	chr1:8642487	T/G	cg13785123	chr1:8931135	ENO1	-0.44	-4.88	-0.3	2e-6	Subjective well-being;
SARC	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg01341218	chr17:43662625	NA	0.69	8.27	0.48	1.05e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7666738	0.861	rs28821920	chr4:98962743	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg21724239	chr8:58056113	NA	0.55	5.8	0.36	2.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg09699651	chr6:150184138	LRP11	0.46	5.48	0.34	1.08e-7	Lung cancer;
SARC	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg11644478	chr21:40555479	PSMG1	-0.88	-11.28	-0.59	7.68e-24	Cognitive function;
SARC	cis	rs644799	0.603	rs1255180	chr11:95472134	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.54	6.75	0.4	1.2e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9304742	0.962	rs12150933	chr19:53455221	A/G	cg24044776	chr19:53454761	ZNF816A	-0.4	-5.6	-0.34	6.09e-8	Psoriasis;
SARC	cis	rs1707322	1.000	rs1707338	chr1:46511981	T/G	cg03146154	chr1:46216737	IPP	-0.47	-5.65	-0.35	4.59e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs1814175	0.669	rs12364577	chr11:49707361	A/C	cg15704280	chr7:45808275	SEPT13	-0.8	-12.95	-0.65	2.91e-29	Height;
SARC	cis	rs2635047	0.638	rs2571002	chr18:44665052	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	6.57	0.4	3.26e-10	Educational attainment;
SARC	cis	rs644799	1.000	rs632388	chr11:95563775	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.9	14.03	0.68	7.82e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs4561483	0.831	rs33621	chr16:12008513	G/A	cg08843971	chr16:11963173	GSPT1	-0.43	-4.79	-0.3	2.91e-6	Testicular germ cell tumor;
SARC	cis	rs3796352	1.000	rs34340609	chr3:53077276	A/G	cg27565382	chr3:53032988	SFMBT1	0.59	4.72	0.3	4.15e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs6570726	0.791	rs398408	chr6:145801020	G/A	cg05347473	chr6:146136440	FBXO30	0.51	7.03	0.42	2.31e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg00409905	chr10:38381863	ZNF37A	-0.53	-7.51	-0.44	1.25e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg21724239	chr8:58056113	NA	0.61	6.07	0.37	5.21e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6964587	0.967	rs6465353	chr7:91779971	G/T	cg17063962	chr7:91808500	NA	-0.97	-16.98	-0.74	1.29e-42	Breast cancer;
SARC	cis	rs854765	0.547	rs9912096	chr17:17896673	A/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.44	5.74	0.35	2.96e-8	Total body bone mineral density;
SARC	cis	rs11785693	0.817	rs62491199	chr8:4997878	G/A	cg26367366	chr8:4980734	NA	0.7	6.17	0.37	2.95e-9	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs12594515	1.000	rs56220882	chr15:45997075	C/G	cg14863074	chr15:45997064	NA	0.34	5.18	0.32	4.79e-7	Waist circumference;Weight;
SARC	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg00933542	chr6:150070202	PCMT1	0.31	5.25	0.33	3.38e-7	Lung cancer;
SARC	cis	rs798554	0.591	rs757791	chr7:2867296	A/G	cg13628971	chr7:2884303	GNA12	0.45	5.31	0.33	2.6e-7	Height;
SARC	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg11494091	chr17:61959527	GH2	0.37	5.18	0.32	4.88e-7	Height;
SARC	cis	rs72945132	0.882	rs2276001	chr11:70181560	T/C	cg00319359	chr11:70116639	PPFIA1	0.71	6.65	0.4	2.06e-10	Coronary artery disease;
SARC	cis	rs9486719	0.857	rs2983897	chr6:97033780	C/T	cg18709589	chr6:96969512	KIAA0776	-0.44	-4.88	-0.3	1.93e-6	Migraine;Coronary artery disease;
SARC	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg13175981	chr1:150552382	MCL1	-0.54	-6.82	-0.41	7.54e-11	Tonsillectomy;
SARC	cis	rs9814567	1.000	rs9289478	chr3:134268619	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.13	-0.42	1.24e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs12142240	0.698	rs932816	chr1:46859749	G/A	cg14993813	chr1:46806288	NSUN4	-0.52	-5.56	-0.34	7.46e-8	Menopause (age at onset);
SARC	cis	rs7100689	0.599	rs6585968	chr10:82139807	T/C	cg01528321	chr10:82214614	TSPAN14	0.74	10.19	0.56	2.13e-20	Post bronchodilator FEV1;
SARC	cis	rs7937682	0.883	rs490492	chr11:111465150	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.93	-14.06	-0.68	6.32e-33	Primary sclerosing cholangitis;
SARC	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg18252515	chr7:66147081	NA	-1.35	-12.11	-0.62	1.7e-26	Diabetic kidney disease;
SARC	cis	rs4642101	0.765	rs9871991	chr3:12827525	C/A	cg24848339	chr3:12840334	CAND2	0.32	4.92	0.31	1.63e-6	QRS complex (12-leadsum);
SARC	cis	rs10504229	0.636	rs114725691	chr8:58054292	C/T	cg22535103	chr8:58192502	C8orf71	-0.59	-5.97	-0.36	8.89e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs943466	0.956	rs11758463	chr6:33762625	A/G	cg04676172	chr6:33757040	LEMD2	0.47	4.98	0.31	1.24e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
SARC	cis	rs959260	0.614	rs930297	chr17:73404537	C/T	cg14668889	chr17:73230827	NUP85	-0.51	-5.11	-0.32	6.56e-7	Systemic lupus erythematosus;
SARC	cis	rs9768139	0.935	rs7800718	chr7:158121878	G/A	cg25566285	chr7:158114605	PTPRN2	-0.33	-5.62	-0.35	5.3e-8	Calcium levels;
SARC	cis	rs4423214	1.000	rs12278461	chr11:71182185	C/T	cg05163923	chr11:71159392	DHCR7	0.67	9.36	0.52	7.22e-18	Vitamin D levels;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg18663768	chr10:103546545	MGEA5	0.47	6.23	0.38	2.13e-9	Thyroid stimulating hormone;
SARC	cis	rs6120849	0.754	rs6120813	chr20:33642112	T/C	cg06115741	chr20:33292138	TP53INP2	0.54	5.16	0.32	5.3e-7	Protein C levels;
SARC	cis	rs3126085	0.935	rs877776	chr1:152178018	C/G	cg26876637	chr1:152193138	HRNR	0.5	6.03	0.37	6.31e-9	Atopic dermatitis;
SARC	cis	rs66716358	0.744	rs1869480	chr11:44319657	C/G	cg16977035	chr11:44330474	ALX4	-0.28	-5.19	-0.32	4.47e-7	Monobrow;
SARC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg20102877	chr2:27665638	KRTCAP3	-0.37	-5.25	-0.33	3.44e-7	Total body bone mineral density;
SARC	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg04166393	chr7:2884313	GNA12	0.55	6.45	0.39	6.52e-10	Height;
SARC	cis	rs36051895	0.589	rs7874785	chr9:5196695	C/T	cg02405213	chr9:5042618	JAK2	0.51	5.94	0.36	1.03e-8	Pediatric autoimmune diseases;
SARC	cis	rs710216	0.917	rs2297977	chr1:43415288	G/T	cg07803811	chr1:43423981	SLC2A1	0.53	5.38	0.33	1.81e-7	Red cell distribution width;
SARC	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.7	-7.23	-0.43	6.97e-12	Platelet count;
SARC	cis	rs921968	0.541	rs2241527	chr2:219537224	A/G	cg02176678	chr2:219576539	TTLL4	0.55	8.04	0.47	4.56e-14	Mean corpuscular hemoglobin concentration;
SARC	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg05861140	chr6:150128134	PCMT1	-0.39	-5.06	-0.31	8.44e-7	Lung cancer;
SARC	cis	rs4566357	0.576	rs6750845	chr2:227911037	T/G	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.87	-0.36	1.51e-8	Coronary artery disease;
SARC	cis	rs995000	0.868	rs1168017	chr1:63002551	A/G	cg06896770	chr1:63153194	DOCK7	-0.9	-13.49	-0.66	5.08e-31	Triglyceride levels;
SARC	cis	rs208520	0.770	rs2224422	chr6:66883993	G/A	cg07460842	chr6:66804631	NA	-1.06	-13.61	-0.67	1.99e-31	Exhaled nitric oxide output;
SARC	cis	rs9388451	0.626	rs3799712	chr6:126075103	A/G	cg06289844	chr6:126071538	HEY2	0.36	5.64	0.35	4.95e-8	Brugada syndrome;
SARC	cis	rs2191566	0.821	rs59756444	chr19:44513656	C/G	cg20607764	chr19:44506953	ZNF230	-0.44	-5.03	-0.31	9.87e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg15242686	chr22:24348715	GSTTP1	0.4	5.17	0.32	5.15e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg08564027	chr20:61660810	NA	0.76	11.8	0.61	1.69e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg11301795	chr4:187892539	NA	-0.69	-10.22	-0.56	1.69e-20	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.42	5.23	0.32	3.74e-7	Tonsillectomy;
SARC	cis	rs826838	1.000	rs4575342	chr12:38663831	G/A	cg13010199	chr12:38710504	ALG10B	0.82	11.85	0.61	1.17e-25	Heart rate;
SARC	cis	rs6089584	1.000	rs6089584	chr20:60564086	G/C	cg13770153	chr20:60521292	NA	-0.55	-7.78	-0.45	2.39e-13	Body mass index;
SARC	cis	rs721399	0.927	rs1495747	chr8:18262861	T/C	cg18736775	chr8:18248649	NAT2	0.4	5.14	0.32	5.78e-7	Blood metabolite levels;
SARC	cis	rs7712401	0.601	rs438196	chr5:122263063	T/G	cg19412675	chr5:122181750	SNX24	0.41	5.24	0.32	3.56e-7	Mean platelet volume;
SARC	cis	rs79149102	0.579	rs8033125	chr15:75374970	G/C	cg17294928	chr15:75287854	SCAMP5	-0.91	-8.33	-0.48	6.76e-15	Lung cancer;
SARC	cis	rs3109167	0.524	rs2713192	chr7:83125010	C/T	cg14519356	chr7:83097669	SEMA3E	0.35	4.72	0.3	4.12e-6	Blood protein levels;
SARC	cis	rs526231	0.511	rs3756582	chr5:102339552	G/C	cg23492399	chr5:102201601	PAM	-0.51	-5.77	-0.35	2.47e-8	Primary biliary cholangitis;
SARC	cis	rs644799	1.000	rs693597	chr11:95589629	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	14.6	0.69	1.05e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs11718455	0.921	rs1404482	chr3:43997282	A/G	cg21419209	chr3:44054225	NA	-0.43	-5.28	-0.33	2.94e-7	Coronary artery disease;
SARC	cis	rs875971	0.545	rs1547529	chr7:65723846	T/C	cg11764359	chr7:65958608	NA	0.66	6.62	0.4	2.48e-10	Aortic root size;
SARC	cis	rs7712401	0.601	rs185009	chr5:122273767	A/G	cg19412675	chr5:122181750	SNX24	0.4	5.09	0.32	7.55e-7	Mean platelet volume;
SARC	cis	rs854765	0.583	rs8065970	chr17:17858771	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.43	5.52	0.34	9.04e-8	Total body bone mineral density;
SARC	cis	rs6120849	0.802	rs6087681	chr20:33752896	G/C	cg24642439	chr20:33292090	TP53INP2	0.49	4.82	0.3	2.57e-6	Protein C levels;
SARC	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.39	0.44	2.66e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg07308232	chr7:1071921	C7orf50	0.66	8.32	0.48	7.45e-15	Longevity;Endometriosis;
SARC	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg08645402	chr16:4508243	NA	0.42	4.9	0.31	1.81e-6	Schizophrenia;
SARC	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg14983838	chr19:29218262	NA	0.77	10.53	0.57	1.83e-21	Methadone dose in opioid dependence;
SARC	cis	rs61935443	0.501	rs7961115	chr12:95203139	C/T	cg21533806	chr12:95267307	NA	-0.38	-4.92	-0.31	1.6e-6	Schizophrenia;
SARC	cis	rs1152591	0.505	rs1152601	chr14:64667337	T/C	cg23250157	chr14:64679961	SYNE2	0.43	5.97	0.36	8.71e-9	Atrial fibrillation;
SARC	cis	rs17401966	0.838	rs55676616	chr1:10290126	T/C	cg15208524	chr1:10270712	KIF1B	0.48	5.58	0.34	6.77e-8	Hepatocellular carcinoma;
SARC	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.5	-6.32	-0.38	1.29e-9	Lymphocyte counts;
SARC	cis	rs1355223	0.833	rs286885	chr11:34687346	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.39	5.08	0.32	7.59e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg18252515	chr7:66147081	NA	-1.3	-11.62	-0.61	6.33e-25	Diabetic kidney disease;
SARC	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg04277193	chr17:41438351	NA	0.45	4.89	0.31	1.84e-6	Menopause (age at onset);
SARC	cis	rs9341808	0.559	rs7762895	chr6:81061431	C/T	cg08355045	chr6:80787529	NA	0.32	4.96	0.31	1.38e-6	Sitting height ratio;
SARC	cis	rs17401966	0.898	rs6670208	chr1:10252667	C/T	cg15208524	chr1:10270712	KIF1B	0.46	5.37	0.33	1.88e-7	Hepatocellular carcinoma;
SARC	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg11987759	chr7:65425863	GUSB	-0.47	-6.27	-0.38	1.7e-9	Aortic root size;
SARC	cis	rs870825	0.655	rs72703561	chr4:185630890	T/C	cg04058563	chr4:185651563	MLF1IP	0.82	11.01	0.58	5.81e-23	Blood protein levels;
SARC	cis	rs55871839	0.559	rs7834158	chr8:59843813	C/A	cg07426533	chr8:59803705	TOX	0.49	5.69	0.35	3.76e-8	Pneumonia;
SARC	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg13770153	chr20:60521292	NA	-0.52	-7.4	-0.44	2.47e-12	Body mass index;
SARC	cis	rs17023223	0.537	rs2645302	chr1:119590398	A/C	cg05756136	chr1:119680316	WARS2	-0.44	-5.29	-0.33	2.77e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg11890956	chr21:40555474	PSMG1	1.17	19.56	0.79	4.75e-51	Cognitive function;
SARC	cis	rs2228479	0.764	rs11641201	chr16:89983276	T/C	cg26513180	chr16:89883248	FANCA	0.58	4.79	0.3	3e-6	Skin colour saturation;
SARC	cis	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.63	-0.45	5.88e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-5.48	-0.34	1.12e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg27266027	chr21:40555129	PSMG1	0.51	5.57	0.34	6.84e-8	Cognitive function;
SARC	cis	rs6964587	1.000	rs415	chr7:91580490	A/G	cg17063962	chr7:91808500	NA	-0.94	-15.25	-0.71	6.82e-37	Breast cancer;
SARC	cis	rs11785400	0.963	rs4579507	chr8:143733663	C/G	cg24634471	chr8:143751801	JRK	0.67	9.05	0.51	5.93e-17	Schizophrenia;
SARC	cis	rs7615952	0.611	rs2947646	chr3:125593602	C/T	cg05084668	chr3:125655381	ALG1L	0.88	8.23	0.47	1.3e-14	Blood pressure (smoking interaction);
SARC	cis	rs2230307	0.536	rs6677998	chr1:100461046	G/A	cg24955406	chr1:100503596	HIAT1	0.71	7.03	0.42	2.28e-11	Carotid intima media thickness;
SARC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg21724239	chr8:58056113	NA	0.7	9.34	0.52	7.77e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs9858542	0.537	rs4410472	chr3:49329090	A/T	cg00383909	chr3:49044727	WDR6	0.54	5.6	0.34	6.03e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg08859206	chr1:53392774	SCP2	0.39	5.65	0.35	4.74e-8	Monocyte count;
SARC	cis	rs8060686	0.545	rs12600062	chr16:68287544	C/A	cg27539214	chr16:67997921	SLC12A4	-0.61	-5.72	-0.35	3.29e-8	HDL cholesterol;Metabolic syndrome;
SARC	cis	rs7927771	0.524	rs7118747	chr11:47889545	C/T	cg20307385	chr11:47447363	PSMC3	-0.48	-6.49	-0.39	5.23e-10	Subjective well-being;
SARC	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg27286337	chr10:134555280	INPP5A	0.67	8.28	0.48	9.94e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs865483	0.895	rs853234	chr17:35843050	A/G	cg06561646	chr17:35873369	DUSP14	0.48	6.42	0.39	7.4e-10	Monocyte count;
SARC	cis	rs7568458	0.870	rs1562323	chr2:85809711	T/C	cg23752985	chr2:85803571	VAMP8	0.34	5.09	0.32	7.41e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs4268898	0.697	rs10445892	chr2:24406958	T/C	cg06627628	chr2:24431161	ITSN2	0.54	7.3	0.43	4.42e-12	Asthma;
SARC	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg03354898	chr7:1950403	MAD1L1	-0.36	-4.87	-0.3	2.03e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg18252515	chr7:66147081	NA	-1.3	-11.5	-0.6	1.59e-24	Diabetic kidney disease;
SARC	cis	rs4478037	0.642	rs77202692	chr3:33115776	A/C	cg19404215	chr3:33155277	CRTAP	0.74	6.15	0.37	3.26e-9	Major depressive disorder;
SARC	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg26119090	chr2:26468346	HADHA;HADHB	0.95	13.96	0.67	1.32e-32	Gut microbiome composition (summer);
SARC	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg24209194	chr3:40518798	ZNF619	0.66	8.16	0.47	2.08e-14	Renal cell carcinoma;
SARC	cis	rs929596	0.728	rs6744284	chr2:234625297	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.32	-4.72	-0.3	4.07e-6	Total bilirubin levels in HIV-1 infection;
SARC	cis	rs13401104	0.796	rs1073463	chr2:237118096	G/A	cg19324714	chr2:237145437	ASB18	0.57	5.66	0.35	4.32e-8	Educational attainment;
SARC	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg20607798	chr8:58055168	NA	0.58	5.57	0.34	6.9e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg24110177	chr3:50126178	RBM5	0.58	7.91	0.46	1.04e-13	Intelligence (multi-trait analysis);
SARC	cis	rs16937	0.662	rs10900464	chr1:205157100	T/C	cg21643547	chr1:205240462	TMCC2	-0.4	-4.91	-0.31	1.71e-6	Schizophrenia;
SARC	cis	rs700651	0.789	rs882954	chr2:198907444	A/G	cg00792783	chr2:198669748	PLCL1	0.43	4.82	0.3	2.6e-6	Intracranial aneurysm;
SARC	cis	rs10911232	0.507	rs4652766	chr1:182994336	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.57	0.57	1.37e-21	Hypertriglyceridemia;
SARC	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg07636037	chr3:49044803	WDR6	0.99	17.48	0.75	2.73e-44	Parkinson's disease;
SARC	cis	rs1318878	0.565	rs12312525	chr12:15496651	A/G	cg08258403	chr12:15378311	NA	0.48	6.68	0.4	1.69e-10	Intelligence (multi-trait analysis);
SARC	cis	rs3733585	0.673	rs6836706	chr4:9964251	T/A	cg11266682	chr4:10021025	SLC2A9	-0.35	-6.03	-0.37	6.35e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg05623727	chr3:50126028	RBM5	-0.35	-5.46	-0.34	1.2e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9359856	0.636	rs6454767	chr6:90317335	G/A	cg13799429	chr6:90582589	CASP8AP2	0.56	5.08	0.32	7.71e-7	Bipolar disorder;
SARC	cis	rs950169	0.959	rs12911210	chr15:84792083	A/C	cg24253500	chr15:84953950	NA	0.36	5.43	0.34	1.4e-7	Schizophrenia;
SARC	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg11987759	chr7:65425863	GUSB	0.58	7.61	0.45	6.82e-13	Aortic root size;
SARC	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg24060327	chr5:131705240	SLC22A5	-0.71	-8.69	-0.49	6.56e-16	Acylcarnitine levels;
SARC	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg21442419	chr1:2182373	SKI	-0.46	-5.98	-0.36	8.47e-9	Height;
SARC	cis	rs7959452	0.605	rs12819406	chr12:69696400	G/T	cg22834771	chr12:69754056	YEATS4	-0.41	-5.49	-0.34	1.06e-7	Blood protein levels;
SARC	trans	rs7615952	0.512	rs34085484	chr3:125544186	T/C	cg07211511	chr3:129823064	LOC729375	-0.75	-8.65	-0.49	8.6e-16	Blood pressure (smoking interaction);
SARC	cis	rs11758351	0.925	rs78932312	chr6:26194869	A/G	cg01420254	chr6:26195488	NA	0.55	4.8	0.3	2.79e-6	Gout;Renal underexcretion gout;
SARC	cis	rs7712401	0.791	rs10059964	chr5:122118293	A/G	cg19412675	chr5:122181750	SNX24	0.38	5.0	0.31	1.14e-6	Mean platelet volume;
SARC	cis	rs5753618	0.509	rs5749229	chr22:31587218	T/C	cg02404636	chr22:31891804	SFI1	-0.48	-5.05	-0.31	8.88e-7	Colorectal cancer;
SARC	cis	rs6964587	1.000	rs10245095	chr7:91710845	A/G	cg17063962	chr7:91808500	NA	0.97	16.79	0.74	5.2e-42	Breast cancer;
SARC	cis	rs6582630	0.599	rs1851114	chr12:38424671	C/T	cg14851346	chr12:38532713	NA	-0.46	-5.59	-0.34	6.43e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-7.47	-0.44	1.58e-12	Alzheimer's disease;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg05051316	chr19:10946973	TMED1	-0.52	-6.59	-0.4	2.89e-10	Schizophrenia;
SARC	cis	rs13401104	0.796	rs719544	chr2:237118282	A/C	cg19324714	chr2:237145437	ASB18	0.57	5.66	0.35	4.32e-8	Educational attainment;
SARC	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg13206674	chr6:150067644	NUP43	0.41	5.33	0.33	2.29e-7	Lung cancer;
SARC	cis	rs826838	0.967	rs2069211	chr12:39128892	C/T	cg13010199	chr12:38710504	ALG10B	-0.63	-8.88	-0.5	1.87e-16	Heart rate;
SARC	cis	rs7659604	0.502	rs4315813	chr4:122674866	G/A	cg19671926	chr4:122722719	EXOSC9	0.55	6.99	0.42	2.87e-11	Type 2 diabetes;
SARC	cis	rs2985684	1.000	rs3007030	chr14:50086563	C/T	cg23336454	chr14:50234671	KLHDC2	-0.46	-4.96	-0.31	1.34e-6	Carotid intima media thickness;
SARC	cis	rs262150	0.714	rs2657397	chr7:158785095	C/T	cg09640425	chr7:158790006	NA	-0.36	-4.9	-0.31	1.76e-6	Facial morphology (factor 20);
SARC	cis	rs11690935	0.959	rs2292815	chr2:172586651	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.99	-15.5	-0.71	1.02e-37	Schizophrenia;
SARC	cis	rs17376456	0.569	rs7729807	chr5:93104089	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.5	5.09	0.32	7.22e-7	Diabetic retinopathy;
SARC	cis	rs1198872	0.563	rs2008967	chr2:10964293	A/G	cg15705551	chr2:10952987	PDIA6	0.47	5.98	0.36	8.18e-9	Cardiac Troponin-T levels;
SARC	cis	rs11122272	0.735	rs2749705	chr1:231526696	C/T	cg06096015	chr1:231504339	EGLN1	0.4	5.99	0.37	7.74e-9	Hemoglobin concentration;
SARC	cis	rs853679	0.723	rs9366718	chr6:28205502	A/T	cg17221315	chr6:27791827	HIST1H4J	0.51	4.74	0.3	3.69e-6	Depression;
SARC	trans	rs73158705	0.720	rs6943656	chr7:136639436	C/T	cg24291203	chr8:100025000	VPS13B	-0.73	-6.25	-0.38	1.94e-9	Resting heart rate;
SARC	cis	rs7247513	0.964	rs1007352	chr19:12722545	G/C	cg01871581	chr19:12707946	ZNF490	-0.89	-12.7	-0.64	2.04e-28	Bipolar disorder;
SARC	cis	rs858239	0.831	rs7796541	chr7:23389073	G/T	cg23682824	chr7:23144976	KLHL7	0.5	6.33	0.38	1.23e-9	Cerebrospinal fluid biomarker levels;
SARC	cis	rs2908197	0.737	rs6465097	chr7:75972914	T/C	cg24580635	chr7:76178542	LOC100133091	-0.42	-4.87	-0.3	2.08e-6	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs1580019	0.844	rs1037322	chr7:32501857	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.79	10.96	0.58	8.21e-23	Cognitive ability;
SARC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.68	0.57	6.45e-22	Prudent dietary pattern;
SARC	cis	rs2834188	0.737	rs2834179	chr21:34679731	A/G	cg15382669	chr21:34697036	IFNAR1	0.4	4.87	0.3	2.06e-6	Narcolepsy;
SARC	cis	rs2153535	0.541	rs9379207	chr6:8458186	C/T	cg07606381	chr6:8435919	SLC35B3	0.75	10.66	0.57	7.43e-22	Motion sickness;
SARC	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg12311346	chr5:56204834	C5orf35	-0.4	-4.92	-0.31	1.66e-6	Coronary artery disease;
SARC	cis	rs8031584	1.000	rs890159	chr15:31291634	G/A	cg19680485	chr15:31195859	MTMR15	-0.55	-5.73	-0.35	3.03e-8	Huntington's disease progression;
SARC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg06873352	chr17:61820015	STRADA	0.53	6.88	0.41	5.32e-11	Prudent dietary pattern;
SARC	cis	rs7605378	1.000	rs7605378	chr2:200676926	A/C	cg23649088	chr2:200775458	C2orf69	0.51	5.86	0.36	1.56e-8	Osteoporosis;
SARC	cis	rs10752881	0.967	rs10911186	chr1:182972542	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.72	10.86	0.58	1.6400000000000001e-22	Colorectal cancer;
SARC	cis	rs11098499	0.908	rs28499576	chr4:120386677	G/A	cg09160332	chr4:120329925	NA	-0.33	-4.72	-0.3	4.09e-6	Corneal astigmatism;
SARC	cis	rs3126085	0.935	rs4845421	chr1:152173259	G/T	cg26876637	chr1:152193138	HRNR	0.48	5.51	0.34	9.32e-8	Atopic dermatitis;
SARC	cis	rs6690583	0.697	rs2012369	chr1:85520845	T/C	cg22153463	chr1:85462885	MCOLN2	-0.62	-6.44	-0.39	6.8e-10	Serum sulfate level;
SARC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.64	0.57	8.23e-22	Prudent dietary pattern;
SARC	cis	rs72781680	0.848	rs55725028	chr2:23966447	A/G	cg06627628	chr2:24431161	ITSN2	-0.66	-6.1	-0.37	4.31e-9	Lymphocyte counts;
SARC	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg16479474	chr6:28041457	NA	0.33	5.01	0.31	1.09e-6	Cardiac Troponin-T levels;
SARC	cis	rs6700896	0.931	rs10789192	chr1:66125770	G/A	cg04111102	chr1:66153794	NA	0.36	5.66	0.35	4.49e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg01316550	chr5:56110833	MAP3K1	0.53	4.94	0.31	1.52e-6	Initial pursuit acceleration;
SARC	cis	rs7829975	0.633	rs2979181	chr8:8323088	A/T	cg15556689	chr8:8085844	FLJ10661	0.47	6.09	0.37	4.69e-9	Mood instability;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg27328408	chr15:75615005	NA	-0.48	-6.34	-0.38	1.2e-9	Height;
SARC	cis	rs9457247	0.508	rs9457268	chr6:167503639	A/T	cg07741184	chr6:167504864	NA	0.33	6.14	0.37	3.48e-9	Crohn's disease;
SARC	cis	rs986417	1.000	rs1951114	chr14:60922005	C/G	cg27398547	chr14:60952738	C14orf39	-1.02	-9.54	-0.53	2.06e-18	Gut microbiota (bacterial taxa);
SARC	cis	rs9987353	0.589	rs1053036	chr8:9060077	A/G	cg11608241	chr8:8085544	FLJ10661	-0.4	-4.84	-0.3	2.37e-6	Recombination measurement;
SARC	cis	rs713477	1.000	rs2185036	chr14:55907710	A/G	cg13175173	chr14:55914753	NA	-0.3	-4.74	-0.3	3.69e-6	Pediatric bone mineral content (femoral neck);
SARC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg23034840	chr1:205782522	SLC41A1	0.61	7.95	0.46	8.15e-14	Menarche (age at onset);
SARC	cis	rs2439831	0.867	rs935901	chr15:43651256	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.11	9.62	0.53	1.17e-18	Lung cancer in ever smokers;
SARC	cis	rs1707322	1.000	rs11211217	chr1:46348229	C/G	cg06784218	chr1:46089804	CCDC17	0.35	6.09	0.37	4.55e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs3857536	0.813	rs2188589	chr6:66939570	C/T	cg07460842	chr6:66804631	NA	-0.51	-5.83	-0.36	1.86e-8	Blood trace element (Cu levels);
SARC	cis	rs6952808	0.931	rs12537430	chr7:1868761	A/G	cg04267008	chr7:1944627	MAD1L1	0.49	5.54	0.34	8.24e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg11644478	chr21:40555479	PSMG1	-0.87	-11.41	-0.6	3.07e-24	Cognitive function;
SARC	cis	rs899997	0.773	rs11072783	chr15:78965966	G/A	cg04896959	chr15:78267971	NA	0.45	4.88	0.3	1.98e-6	Coronary artery disease or large artery stroke;
SARC	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.58	5.46	0.34	1.2e-7	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs7011049	1.000	rs4521776	chr8:53838833	G/C	cg26025543	chr8:53854495	NA	0.6	5.43	0.34	1.42e-7	Systolic blood pressure;
SARC	cis	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg09021430	chr5:549028	NA	-0.44	-5.69	-0.35	3.85e-8	Obesity-related traits;
SARC	cis	rs10779751	0.727	rs4845852	chr1:11233559	C/T	cg08854313	chr1:11322531	MTOR	0.87	12.8	0.64	9.47e-29	Body mass index;
SARC	cis	rs2290402	0.572	rs3736087	chr4:876318	C/T	cg00846425	chr4:957561	DGKQ	-0.46	-5.23	-0.32	3.84e-7	Type 2 diabetes;
SARC	cis	rs2153535	0.580	rs969422	chr6:8451780	A/T	cg21535247	chr6:8435926	SLC35B3	0.55	6.84	0.41	6.72e-11	Motion sickness;
SARC	cis	rs1957429	0.808	rs6573580	chr14:65331766	C/G	cg23373153	chr14:65346875	NA	0.91	9.55	0.53	1.94e-18	Pediatric areal bone mineral density (radius);
SARC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg06074448	chr4:187884817	NA	-0.38	-5.07	-0.32	8.06e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.06	0.81	7.38e-56	Prudent dietary pattern;
SARC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg16132339	chr22:24313637	DDTL;DDT	0.38	5.11	0.32	6.77e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs11122272	0.735	rs2355872	chr1:231478489	A/T	cg06096015	chr1:231504339	EGLN1	0.38	5.75	0.35	2.84e-8	Hemoglobin concentration;
SARC	trans	rs17685	0.753	rs10085567	chr7:75734206	A/C	cg19862616	chr7:65841803	NCRNA00174	0.61	7.41	0.44	2.24e-12	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs10791323	0.572	rs4412766	chr11:133742811	A/C	cg13461336	chr11:133711254	SPATA19	-0.28	-5.02	-0.31	1.02e-6	Childhood ear infection;
SARC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg26338869	chr17:61819248	STRADA	-0.8	-10.69	-0.57	5.68e-22	Prudent dietary pattern;
SARC	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg06634786	chr22:41940651	POLR3H	0.54	6.62	0.4	2.4e-10	Vitiligo;
SARC	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-6.49	-0.39	5.23e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg26924012	chr15:45694286	SPATA5L1	0.77	10.99	0.58	6.8e-23	Homoarginine levels;
SARC	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg18252515	chr7:66147081	NA	0.58	6.27	0.38	1.7e-9	Aortic root size;
SARC	cis	rs2952156	0.920	rs2934956	chr17:37830447	T/A	cg20243544	chr17:37824526	PNMT	0.55	7.18	0.43	9.23e-12	Asthma;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg10963209	chr7:148844378	ZNF398	0.49	6.24	0.38	2.08e-9	Breast cancer;
SARC	cis	rs9921192	0.967	rs3747571	chr16:4323983	A/G	cg00021532	chr16:4324280	TFAP4	0.8	12.25	0.63	5.84e-27	Prostate-specific antigen levels;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg13675469	chr1:174992539	MRPS14	0.78	6.51	0.39	4.69e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs459571	0.959	rs2073818	chr9:136918662	C/A	cg01294253	chr9:136912663	BRD3	0.44	5.79	0.35	2.2e-8	Platelet distribution width;
SARC	cis	rs67460515	0.892	rs7647374	chr3:160975576	T/A	cg04691961	chr3:161091175	C3orf57	-0.47	-5.82	-0.36	1.89e-8	Parkinson's disease;
SARC	cis	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg14541582	chr5:601475	NA	-0.41	-5.12	-0.32	6.26e-7	Obesity-related traits;
SARC	cis	rs654950	0.806	rs7550496	chr1:42043834	G/A	cg06885757	chr1:42089581	HIVEP3	0.39	5.64	0.35	5e-8	Airway imaging phenotypes;
SARC	cis	rs1691799	0.867	rs1168309	chr12:66726439	A/G	cg16791601	chr12:66731901	HELB	0.73	10.93	0.58	1e-22	White blood cell count (basophil);
SARC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg07157834	chr1:205819609	PM20D1	0.63	9.93	0.55	1.34e-19	Monocyte percentage of white cells;
SARC	cis	rs722599	0.847	rs2058919	chr14:75310812	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.52	-7.1	-0.42	1.52e-11	IgG glycosylation;
SARC	cis	rs5753618	0.561	rs2073857	chr22:31658281	A/G	cg02404636	chr22:31891804	SFI1	-0.49	-5.24	-0.32	3.53e-7	Colorectal cancer;
SARC	cis	rs7937682	0.632	rs11214028	chr11:111761149	T/C	cg22437258	chr11:111473054	SIK2	-0.48	-5.43	-0.34	1.38e-7	Primary sclerosing cholangitis;
SARC	cis	rs7681440	0.583	rs2736988	chr4:90776345	C/T	cg06632027	chr4:90757378	SNCA	-0.46	-5.73	-0.35	3.04e-8	Dementia with Lewy bodies;
SARC	cis	rs2250402	0.510	rs2291621	chr15:40324837	C/T	cg20255370	chr15:40268687	EIF2AK4	-0.66	-5.57	-0.34	7.04e-8	Corneal curvature;
SARC	cis	rs11785400	0.762	rs7460801	chr8:143730972	C/A	cg10596483	chr8:143751796	JRK	0.57	7.39	0.44	2.61e-12	Schizophrenia;
SARC	cis	rs2213920	0.619	rs7870511	chr9:118196904	A/G	cg13918206	chr9:118159781	DEC1	0.82	6.54	0.39	3.77e-10	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg18404041	chr3:52824283	ITIH1	-0.36	-5.37	-0.33	1.94e-7	Electroencephalogram traits;
SARC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg07414643	chr4:187882934	NA	0.44	6.65	0.4	2.01e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2070488	0.804	rs13092164	chr3:38458533	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	12.36	0.63	2.53e-27	Electrocardiographic conduction measures;
SARC	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg26335602	chr6:28129616	ZNF389	0.53	5.88	0.36	1.43e-8	Parkinson's disease;
SARC	cis	rs832540	0.519	rs10940518	chr5:56270794	C/T	cg14703610	chr5:56206110	C5orf35	0.46	5.44	0.34	1.32e-7	Coronary artery disease;
SARC	cis	rs72781680	0.678	rs56145919	chr2:24088489	A/G	cg06627628	chr2:24431161	ITSN2	-0.54	-5.81	-0.36	2.01e-8	Lymphocyte counts;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg27548245	chr12:1803843	ADIPOR2	0.45	6.33	0.38	1.27e-9	Thyroid stimulating hormone;
SARC	cis	rs7529073	0.545	rs340884	chr1:214145389	T/C	cg24083324	chr1:214162604	PROX1	0.41	5.71	0.35	3.38e-8	Schizophrenia;
SARC	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.48	-5.82	-0.36	1.92e-8	Gut microbiome composition (summer);
SARC	cis	rs16937	0.662	rs11588199	chr1:205164580	C/T	cg21643547	chr1:205240462	TMCC2	-0.4	-4.91	-0.31	1.71e-6	Schizophrenia;
SARC	cis	rs4969178	0.930	rs12452576	chr17:76386037	A/C	cg20026190	chr17:76395443	PGS1	0.41	5.36	0.33	1.97e-7	HDL cholesterol levels;
SARC	cis	rs11098499	0.954	rs17009122	chr4:120362403	G/A	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	cis	rs7959452	0.640	rs4274230	chr12:69700772	T/G	cg20891283	chr12:69753455	YEATS4	0.41	5.42	0.33	1.48e-7	Blood protein levels;
SARC	cis	rs2011503	1.000	rs78176666	chr19:19636702	T/C	cg15839431	chr19:19639596	YJEFN3	-0.48	-4.77	-0.3	3.32e-6	Bipolar disorder;
SARC	cis	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg24110177	chr3:50126178	RBM5	0.54	7.43	0.44	2.09e-12	Intelligence (multi-trait analysis);
SARC	cis	rs1059312	1.000	rs9738216	chr12:129281788	C/T	cg09035930	chr12:129282057	SLC15A4	0.63	9.17	0.51	2.63e-17	Systemic lupus erythematosus;
SARC	cis	rs1215050	0.904	rs1727285	chr4:98978821	G/A	cg05340658	chr4:99064831	C4orf37	-0.42	-5.39	-0.33	1.72e-7	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs9916302	0.706	rs594794	chr17:37453485	T/C	cg20243544	chr17:37824526	PNMT	-0.56	-6.02	-0.37	6.66e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs9325144	0.560	rs13377717	chr12:38639474	T/A	cg26384229	chr12:38710491	ALG10B	-0.65	-8.79	-0.5	3.4e-16	Morning vs. evening chronotype;
SARC	cis	rs6570726	0.967	rs450973	chr6:145863065	C/A	cg05220968	chr6:146057943	EPM2A	-0.28	-4.87	-0.3	2.1e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg08048268	chr3:133502702	NA	-0.49	-6.47	-0.39	5.84e-10	Iron status biomarkers;
SARC	cis	rs6594499	0.872	rs6865932	chr5:110436852	G/C	cg04022379	chr5:110408740	TSLP	0.45	5.62	0.35	5.39e-8	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs13082711	0.954	rs34772035	chr3:27468872	C/G	cg02860705	chr3:27208620	NA	0.48	6.09	0.37	4.52e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg17376030	chr22:41985996	PMM1	0.69	8.39	0.48	4.57e-15	Vitiligo;
SARC	cis	rs7638909	0.512	rs11720166	chr3:38599812	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.41	-4.81	-0.3	2.68e-6	Electrocardiographic conduction measures;
SARC	cis	rs6484504	0.576	rs286649	chr11:31230468	C/T	cg02090638	chr11:31391270	DNAJC24;DCDC1	-0.39	-4.95	-0.31	1.43e-6	Red blood cell count;
SARC	cis	rs6570726	0.967	rs441364	chr6:145853662	G/C	cg05347473	chr6:146136440	FBXO30	0.47	6.3	0.38	1.47e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6495122	0.501	rs7167261	chr15:75343807	T/C	cg17294928	chr15:75287854	SCAMP5	-0.51	-6.56	-0.4	3.37e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	cis	rs1904096	0.506	rs4693381	chr4:95206855	A/T	cg11021082	chr4:95130006	SMARCAD1	0.46	6.83	0.41	7.44e-11	Type 2 diabetes;
SARC	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg25894440	chr7:65020034	NA	-0.72	-5.46	-0.34	1.2e-7	Diabetic kidney disease;
SARC	cis	rs1395	0.961	rs4665965	chr2:27536380	C/T	cg21747090	chr2:27597821	SNX17	0.46	5.6	0.34	5.88e-8	Blood metabolite levels;
SARC	cis	rs7681440	0.560	rs986610	chr4:90751655	T/C	cg06632027	chr4:90757378	SNCA	-0.42	-5.25	-0.33	3.35e-7	Dementia with Lewy bodies;
SARC	cis	rs6568686	0.627	rs12207557	chr6:111767459	C/T	cg15721981	chr6:111408429	SLC16A10	0.65	5.67	0.35	4.31e-8	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs55962025	0.846	rs363064	chr4:3141410	C/T	cg06533319	chr4:3265114	C4orf44	0.33	4.9	0.31	1.76e-6	Parental longevity (mother's age at death);
SARC	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg02018176	chr4:1364513	KIAA1530	0.34	4.85	0.3	2.24e-6	Obesity-related traits;
SARC	cis	rs854765	0.583	rs62064158	chr17:17826935	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	9.82	0.54	2.79e-19	Total body bone mineral density;
SARC	cis	rs3733585	0.673	rs9994937	chr4:9964799	G/T	cg00071950	chr4:10020882	SLC2A9	-0.37	-5.74	-0.35	2.89e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs4938330	0.512	rs4938327	chr11:116906728	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-5.14	-0.32	5.79e-7	Blood protein levels;
SARC	cis	rs3126085	0.867	rs11204948	chr1:152218473	A/G	cg03465714	chr1:152285911	FLG	-0.51	-5.87	-0.36	1.49e-8	Atopic dermatitis;
SARC	cis	rs644799	1.000	rs505220	chr11:95563228	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	14.89	0.7	1.07e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs6991838	0.557	rs57419568	chr8:66510868	G/A	cg13398993	chr8:66546079	ARMC1	-0.62	-8.37	-0.48	5.33e-15	Intelligence (multi-trait analysis);
SARC	cis	rs16976116	0.901	rs11852763	chr15:55494606	T/C	cg11288833	chr15:55489084	RSL24D1	0.62	6.02	0.37	6.78e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs12142240	0.698	rs72885198	chr1:46812888	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-5.45	-0.34	1.3e-7	Menopause (age at onset);
SARC	cis	rs7818688	0.591	rs10098025	chr8:95989583	T/A	cg13393036	chr8:95962371	TP53INP1	0.39	4.77	0.3	3.24e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs611744	0.647	rs702808	chr8:109252554	T/C	cg21045802	chr8:109455806	TTC35	0.6	7.65	0.45	5.26e-13	Dupuytren's disease;
SARC	cis	rs9916302	0.904	rs7216086	chr17:37709422	G/A	cg00129232	chr17:37814104	STARD3	-0.64	-7.98	-0.46	6.72e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs11581859	0.587	rs9729811	chr1:99206773	C/T	cg20286094	chr1:99190917	SNX7	-0.41	-4.81	-0.3	2.75e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4253772	0.513	rs6008700	chr22:46722560	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.77	7.74	0.45	3.02e-13	LDL cholesterol;Cholesterol, total;
SARC	cis	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg05623727	chr3:50126028	RBM5	-0.34	-5.19	-0.32	4.52e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1387259	0.758	rs2634670	chr12:48771877	G/A	cg24011408	chr12:48396354	COL2A1	0.43	5.18	0.32	4.7e-7	Obstructive sleep apnea trait (apnea hypopnea index);
SARC	cis	rs9467773	1.000	rs6930120	chr6:26555484	A/G	cg11502198	chr6:26597334	ABT1	0.5	6.09	0.37	4.53e-9	Intelligence (multi-trait analysis);
SARC	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg16049864	chr8:95962084	TP53INP1	-0.47	-7.69	-0.45	4.13e-13	Type 2 diabetes;
SARC	cis	rs17548007	0.597	rs2373913	chr12:103362556	C/T	cg27569040	chr12:103351855	ASCL1	0.53	4.75	0.3	3.59e-6	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
SARC	cis	rs61935443	0.501	rs10777621	chr12:95194120	T/A	cg21533806	chr12:95267307	NA	0.38	4.79	0.3	3.03e-6	Schizophrenia;
SARC	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg05863683	chr7:1912471	MAD1L1	0.37	5.65	0.35	4.55e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg15448220	chr1:150897856	SETDB1	-0.46	-6.09	-0.37	4.7e-9	Tonsillectomy;
SARC	cis	rs7178572	0.524	rs2175941	chr15:77584498	T/C	cg22256960	chr15:77711686	NA	-0.51	-5.54	-0.34	8.14e-8	Type 2 diabetes;
SARC	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg18305652	chr10:134549665	INPP5A	0.33	5.09	0.32	7.27e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg18876405	chr7:65276391	NA	-0.44	-4.87	-0.3	2.02e-6	Aortic root size;
SARC	cis	rs11718455	0.767	rs11708363	chr3:43966585	G/A	cg08738300	chr3:44038990	NA	0.52	5.68	0.35	4.09e-8	Coronary artery disease;
SARC	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg22535103	chr8:58192502	C8orf71	-0.6	-6.33	-0.38	1.24e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs72781680	0.846	rs55707417	chr2:24029928	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	8.76	0.5	4.07e-16	Lymphocyte counts;
SARC	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg18404041	chr3:52824283	ITIH1	-0.42	-6.29	-0.38	1.56e-9	Bipolar disorder;
SARC	cis	rs898097	0.690	rs12452304	chr17:80811659	G/A	cg15369054	chr17:80825471	TBCD	0.54	7.82	0.46	1.77e-13	Breast cancer;
SARC	trans	rs4332037	0.552	rs11773627	chr7:2002733	A/G	cg11693508	chr17:37793320	STARD3	0.63	6.38	0.39	9.22e-10	Bipolar disorder;
SARC	cis	rs2235544	0.565	rs677481	chr1:54468837	A/C	cg10336722	chr1:54665764	CYB5RL;MRPL37	-0.38	-4.74	-0.3	3.66e-6	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
SARC	cis	rs80130819	0.636	rs2732470	chr12:48664757	T/G	cg24011408	chr12:48396354	COL2A1	0.53	6.01	0.37	6.93e-9	Prostate cancer;
SARC	cis	rs4774830	0.744	rs73420376	chr15:56283648	T/C	cg24530489	chr15:56299380	NA	-0.85	-5.52	-0.34	9.24e-8	Delta-5 desaturase activity;
SARC	cis	rs1008375	0.932	rs6449317	chr4:17631253	T/C	cg02297831	chr4:17616191	MED28	0.47	5.95	0.36	9.7e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg06636001	chr8:8085503	FLJ10661	0.68	9.72	0.54	5.62e-19	Neuroticism;
SARC	cis	rs12079745	0.793	rs11802239	chr1:169128802	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.9	-6.01	-0.37	6.98e-9	QT interval;
SARC	cis	rs9393692	1.000	rs9393692	chr6:26276650	A/G	cg13736514	chr6:26305472	NA	-0.67	-8.83	-0.5	2.57e-16	Educational attainment;
SARC	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.93	12.61	0.64	3.98e-28	Platelet count;
SARC	cis	rs1983891	0.826	rs4714476	chr6:41513740	T/C	cg15051332	chr6:41514432	FOXP4	0.54	5.76	0.35	2.59e-8	Prostate cancer;
SARC	cis	rs56313388	0.793	rs9937815	chr16:56330832	C/T	cg02433656	chr16:56322654	GNAO1	-0.37	-5.52	-0.34	9.03e-8	Pulse pressure;
SARC	cis	rs8114671	0.836	rs62213676	chr20:33612676	T/A	cg08999081	chr20:33150536	PIGU	-0.34	-4.9	-0.31	1.79e-6	Height;
SARC	cis	rs9807989	0.507	rs1592458	chr2:103031749	A/T	cg03938978	chr2:103052716	IL18RAP	0.31	4.96	0.31	1.34e-6	Asthma;
SARC	cis	rs7264396	0.622	rs3787165	chr20:34228946	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	5.91	0.36	1.19e-8	Total cholesterol levels;
SARC	cis	rs10463316	0.817	rs1508772	chr5:150816561	A/C	cg03212797	chr5:150827313	SLC36A1	-0.46	-5.36	-0.33	1.96e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs10927875	0.578	rs10927859	chr1:16141862	C/T	cg21385522	chr1:16154831	NA	-0.92	-13.08	-0.65	1.12e-29	Dilated cardiomyopathy;
SARC	cis	rs9796	0.866	rs1678750	chr15:41410705	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.43	-5.88	-0.36	1.4e-8	Menopause (age at onset);
SARC	cis	rs9309473	0.583	rs6705203	chr2:73574600	T/C	cg20560298	chr2:73613845	ALMS1	-0.57	-7.13	-0.42	1.26e-11	Metabolite levels;
SARC	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg06212747	chr3:49208901	KLHDC8B	0.68	8.97	0.51	1e-16	Parkinson's disease;
SARC	cis	rs763121	0.853	rs3788545	chr22:39065172	A/G	cg06022373	chr22:39101656	GTPBP1	0.86	10.51	0.57	2.11e-21	Menopause (age at onset);
SARC	cis	rs2304069	0.913	rs3812009	chr5:149380159	G/C	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.69	6.65	0.4	2.07e-10	HIV-1 control;
SARC	cis	rs4481887	0.888	rs4525076	chr1:248456876	T/G	cg00666640	chr1:248458726	OR2T12	0.35	5.73	0.35	3.14e-8	Common traits (Other);
SARC	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg06558623	chr16:89946397	TCF25	-0.79	-6.73	-0.4	1.34e-10	Skin colour saturation;
SARC	cis	rs2304069	0.954	rs10045945	chr5:149419297	C/T	cg12661370	chr5:149340060	SLC26A2	0.6	5.83	0.36	1.8e-8	HIV-1 control;
SARC	cis	rs1707322	0.827	rs10890347	chr1:46242332	A/T	cg06784218	chr1:46089804	CCDC17	-0.36	-6.58	-0.4	3.05e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs12824058	0.831	rs4759658	chr12:130815872	C/T	cg26677194	chr12:130822605	PIWIL1	0.55	7.69	0.45	4.13e-13	Menopause (age at onset);
SARC	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.68	8.36	0.48	5.72e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs12956009	0.583	rs35970525	chr18:44882625	C/T	cg15049968	chr18:44337910	ST8SIA5	-0.31	-4.72	-0.3	4.11e-6	Educational attainment (years of education);
SARC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.56	-6.35	-0.38	1.11e-9	Longevity;Endometriosis;
SARC	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg03351412	chr1:154909251	PMVK	0.61	7.78	0.45	2.39e-13	Prostate cancer;
SARC	cis	rs7553864	0.966	rs1886635	chr1:87614950	G/A	cg18153957	chr1:87613403	LOC339524	-0.47	-5.55	-0.34	7.77e-8	Smoking behavior;
SARC	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg12756686	chr19:29218302	NA	0.68	8.99	0.51	8.47e-17	Methadone dose in opioid dependence;
SARC	cis	rs3796352	1.000	rs11713206	chr3:52999243	A/G	cg12962167	chr3:53033115	SFMBT1	0.79	4.92	0.31	1.64e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs17125944	0.686	rs912861	chr14:53333290	C/G	cg00686598	chr14:53173677	PSMC6	-0.68	-5.53	-0.34	8.48e-8	Alzheimer's disease (late onset);
SARC	cis	rs2635047	0.713	rs17723389	chr18:44762307	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	6.43	0.39	7.08e-10	Educational attainment;
SARC	cis	rs1008375	0.933	rs6449324	chr4:17694880	G/C	cg02297831	chr4:17616191	MED28	0.39	4.88	0.3	1.99e-6	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs11098499	0.954	rs12507964	chr4:120413061	T/A	cg24375607	chr4:120327624	NA	0.41	4.86	0.3	2.12e-6	Corneal astigmatism;
SARC	cis	rs9868809	0.542	rs9873726	chr3:48712367	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.55	-4.89	-0.3	1.91e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.69	7.54	0.44	1.07e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs820218	0.847	rs820145	chr17:73613975	G/A	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.59	7.51	0.44	1.23e-12	Rotator cuff tears;
SARC	cis	rs35110281	0.594	rs230641	chr21:44915441	T/C	cg21573476	chr21:45109991	RRP1B	0.44	6.39	0.39	8.89e-10	Mean corpuscular volume;
SARC	cis	rs7178572	0.524	rs7163503	chr15:77493505	C/A	cg22256960	chr15:77711686	NA	-0.5	-5.53	-0.34	8.67e-8	Type 2 diabetes;
SARC	cis	rs55823223	0.648	rs11867560	chr17:73857206	A/G	cg14829360	chr17:73884958	NA	-0.62	-7.94	-0.46	8.27e-14	Psoriasis;
SARC	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg04944784	chr2:26401820	FAM59B	0.62	7.62	0.45	6.44e-13	Gut microbiome composition (summer);
SARC	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg22496380	chr5:211416	CCDC127	-0.88	-9.35	-0.52	7.72e-18	Breast cancer;
SARC	cis	rs10927875	0.722	rs1763605	chr1:16338925	T/G	cg21385522	chr1:16154831	NA	0.71	9.12	0.51	3.56e-17	Dilated cardiomyopathy;
SARC	cis	rs933688	0.938	rs12110065	chr5:90718474	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.03	13.38	0.66	1.15e-30	Smoking behavior;
SARC	cis	rs9894429	1.000	rs7503679	chr17:79583843	G/C	cg18240062	chr17:79603768	NPLOC4	0.71	9.81	0.54	3.03e-19	Eye color traits;
SARC	cis	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.84	12.37	0.63	2.31e-27	Eosinophil percentage of white cells;
SARC	cis	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg05623727	chr3:50126028	RBM5	-0.34	-5.29	-0.33	2.76e-7	Intelligence (multi-trait analysis);
SARC	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.47	5.2	0.32	4.35e-7	Renal function-related traits (BUN);
SARC	cis	rs6693567	0.565	rs6685252	chr1:150259945	T/A	cg09579323	chr1:150459698	TARS2	-0.4	-5.02	-0.31	1.04e-6	Migraine;
SARC	cis	rs17376456	1.000	rs13181660	chr5:93533658	A/G	cg25358565	chr5:93447407	FAM172A	1.34	14.63	0.69	8.08e-35	Diabetic retinopathy;
SARC	cis	rs13082711	0.520	rs2724494	chr3:27563920	C/A	cg02860705	chr3:27208620	NA	0.38	4.91	0.31	1.73e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.23e-9	Life satisfaction;
SARC	cis	rs9920	0.585	rs2024210	chr7:116153011	C/T	cg24770985	chr7:116166421	CAV1	0.86	5.66	0.35	4.53e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Immature fraction of reticulocytes;QT interval;
SARC	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg00800038	chr16:89945340	TCF25	-0.64	-5.35	-0.33	2.12e-7	Skin colour saturation;
SARC	cis	rs9457247	0.967	rs376097	chr6:167410878	A/G	cg23791538	chr6:167370224	RNASET2	-0.6	-8.22	-0.47	1.39e-14	Crohn's disease;
SARC	cis	rs796364	0.589	rs6743217	chr2:201134914	G/A	cg23649088	chr2:200775458	C2orf69	-0.64	-6.58	-0.4	3.04e-10	Schizophrenia;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg03157633	chr12:13154475	HTR7P;HEBP1	0.47	6.24	0.38	2.04e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs1691799	0.867	rs1168344	chr12:66758213	G/A	cg16791601	chr12:66731901	HELB	-0.72	-10.83	-0.58	2.06e-22	White blood cell count (basophil);
SARC	trans	rs7824557	0.545	rs2572450	chr8:11229638	C/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.08	-0.42	1.66e-11	Retinal vascular caliber;
SARC	cis	rs9682041	0.688	rs7621787	chr3:170146862	T/A	cg11886554	chr3:170076028	SKIL	1.07	7.94	0.46	8.63e-14	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg05368731	chr17:41323189	NBR1	0.68	8.49	0.49	2.41e-15	Menopause (age at onset);
SARC	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg11764359	chr7:65958608	NA	0.88	12.58	0.64	4.89e-28	Aortic root size;
SARC	cis	rs1034435	0.723	rs713946	chr22:48891376	T/C	cg05992904	chr22:48892994	FAM19A5	-0.44	-6.45	-0.39	6.54e-10	Late-onset Alzheimer's disease;
SARC	cis	rs6912958	0.712	rs7746465	chr6:88348996	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-6.46	-0.39	6.16e-10	Monocyte percentage of white cells;
SARC	cis	rs3106136	0.678	rs12646487	chr4:95279907	T/A	cg11021082	chr4:95130006	SMARCAD1	0.34	5.06	0.31	8.65e-7	Capecitabine sensitivity;
SARC	cis	rs78487399	0.808	rs6544666	chr2:43732234	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-4.84	-0.3	2.37e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.51	-6.58	-0.4	3.11e-10	Lymphocyte counts;
SARC	cis	rs611744	0.647	rs633901	chr8:109242981	G/T	cg21045802	chr8:109455806	TTC35	0.6	7.67	0.45	4.79e-13	Dupuytren's disease;
SARC	cis	rs7666738	0.830	rs6840766	chr4:99016260	C/G	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6570726	0.935	rs371744	chr6:145841024	C/T	cg23711669	chr6:146136114	FBXO30	0.78	11.84	0.61	1.21e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg24110177	chr3:50126178	RBM5	-0.54	-7.17	-0.43	1e-11	Intelligence (multi-trait analysis);
SARC	cis	rs568617	1.000	rs693824	chr11:65654783	A/G	cg26695010	chr11:65641043	EFEMP2	-0.49	-5.75	-0.35	2.82e-8	Crohn's disease;
SARC	cis	rs7481584	1.000	rs12804412	chr11:3020782	G/A	cg05729581	chr11:3078854	CARS	0.47	5.78	0.35	2.42e-8	Calcium levels;
SARC	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg13939156	chr17:80058883	NA	-0.4	-6.23	-0.38	2.21e-9	Life satisfaction;
SARC	cis	rs17376456	0.825	rs10075217	chr5:93176774	C/G	cg21475434	chr5:93447410	FAM172A	0.8	6.54	0.39	3.9e-10	Diabetic retinopathy;
SARC	cis	rs7560272	0.538	rs2001436	chr2:73928965	A/T	cg20560298	chr2:73613845	ALMS1	0.47	6.2	0.38	2.54e-9	Schizophrenia;
SARC	cis	rs2075371	1.000	rs2544221	chr7:133993014	G/C	cg20476274	chr7:133979776	SLC35B4	0.61	8.11	0.47	2.9e-14	Mean platelet volume;
SARC	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg10845886	chr2:3471009	TTC15	-0.36	-4.86	-0.3	2.12e-6	Neurofibrillary tangles;
SARC	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg22920501	chr2:26401640	FAM59B	-0.61	-8.19	-0.47	1.71e-14	Gut microbiome composition (summer);
SARC	cis	rs1348850	0.574	rs11889488	chr2:178426793	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.63	-5.93	-0.36	1.06e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.34	-5.01	-0.31	1.07e-6	Longevity;Endometriosis;
SARC	cis	rs34172651	0.917	rs12923476	chr16:24798079	G/A	cg06028605	chr16:24865363	SLC5A11	0.29	4.9	0.31	1.77e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7659604	0.702	rs58649165	chr4:122693752	C/A	cg06713675	chr4:122721982	EXOSC9	-0.5	-7.01	-0.42	2.58e-11	Type 2 diabetes;
SARC	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg13206674	chr6:150067644	NUP43	0.46	6.1	0.37	4.29e-9	Lung cancer;
SARC	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg00149659	chr3:10157352	C3orf10	1.09	10.0	0.55	7.87e-20	Alzheimer's disease;
SARC	cis	rs9309473	1.000	rs6546835	chr2:73664715	G/A	cg20560298	chr2:73613845	ALMS1	-0.5	-5.96	-0.36	9.12e-9	Metabolite levels;
SARC	trans	rs7980799	0.711	rs12319055	chr12:33626509	C/T	cg13010199	chr12:38710504	ALG10B	-0.53	-6.3	-0.38	1.46e-9	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs9393777	0.588	rs3799380	chr6:26467182	C/T	cg12826209	chr6:26865740	GUSBL1	-0.78	-8.17	-0.47	1.97e-14	Intelligence (multi-trait analysis);
SARC	cis	rs854765	0.547	rs2955359	chr17:17946730	T/C	cg04398451	chr17:18023971	MYO15A	0.47	6.55	0.39	3.55e-10	Total body bone mineral density;
SARC	cis	rs11809207	0.523	rs7087	chr1:26496651	T/C	cg00300879	chr1:26503847	CNKSR1	0.31	4.86	0.3	2.16e-6	Height;
SARC	cis	rs453301	0.631	rs28572014	chr8:8793607	C/T	cg15556689	chr8:8085844	FLJ10661	-0.41	-5.0	-0.31	1.1e-6	Joint mobility (Beighton score);
SARC	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg12000995	chr2:27665139	KRTCAP3	-0.31	-4.86	-0.3	2.17e-6	Total body bone mineral density;
SARC	cis	rs2933343	0.729	rs813732	chr3:128619357	C/T	cg24203234	chr3:128598194	ACAD9	0.63	7.75	0.45	2.9e-13	IgG glycosylation;
SARC	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	10.67	0.57	6.63e-22	Alzheimer's disease;
SARC	cis	rs6500395	1.000	rs9930199	chr16:48571263	A/G	cg04672837	chr16:48644449	N4BP1	0.48	6.37	0.39	9.8e-10	Response to tocilizumab in rheumatoid arthritis;
SARC	trans	rs3780486	0.505	rs10117038	chr9:33122626	T/C	cg20290983	chr6:43655470	MRPS18A	0.93	14.13	0.68	3.68e-33	IgG glycosylation;
SARC	trans	rs1814175	0.754	rs28663627	chr11:50048829	C/T	cg03929089	chr4:120376271	NA	-0.86	-13.62	-0.67	1.81e-31	Height;
SARC	cis	rs2306786	0.558	rs61753957	chr15:59500117	T/C	cg23054309	chr15:59226205	SLTM	0.76	5.0	0.31	1.14e-6	Metabolite levels;
SARC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg20102877	chr2:27665638	KRTCAP3	-0.37	-5.23	-0.32	3.71e-7	Total body bone mineral density;
SARC	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg03351412	chr1:154909251	PMVK	0.62	7.91	0.46	1.03e-13	Prostate cancer;
SARC	cis	rs7208859	0.623	rs383436	chr17:28959179	A/G	cg13385521	chr17:29058706	SUZ12P	0.85	6.08	0.37	4.86e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.33	-4.96	-0.31	1.34e-6	Longevity;Endometriosis;
SARC	cis	rs2153535	0.542	rs915354	chr6:8440357	T/C	cg23788917	chr6:8435910	SLC35B3	0.65	8.25	0.48	1.19e-14	Motion sickness;
SARC	cis	rs7474896	0.583	rs11011347	chr10:38019264	G/A	cg00409905	chr10:38381863	ZNF37A	-0.46	-4.89	-0.31	1.87e-6	Obesity (extreme);
SARC	cis	rs6815814	0.768	rs6835514	chr4:38894380	C/T	cg06935464	chr4:38784597	TLR10	-0.43	-4.83	-0.3	2.52e-6	Breast cancer;
SARC	cis	rs72945132	0.882	rs12278741	chr11:70135742	A/G	cg00319359	chr11:70116639	PPFIA1	0.68	6.37	0.39	1.01e-9	Coronary artery disease;
SARC	cis	rs6088813	1.000	rs6088821	chr20:33987576	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	-0.45	-5.39	-0.33	1.71e-7	Height;
SARC	cis	rs7264396	0.790	rs6058290	chr20:34247702	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	5.89	0.36	1.36e-8	Total cholesterol levels;
SARC	cis	rs6831352	0.918	rs17817958	chr4:100061245	A/C	cg12011299	chr4:100065546	ADH4	0.32	4.78	0.3	3.16e-6	Alcohol dependence;
SARC	cis	rs17741873	0.779	rs10509346	chr10:75596014	A/G	cg07699608	chr10:75541558	CHCHD1	-0.51	-5.8	-0.36	2.18e-8	Paclitaxel disposition in epithelial ovarian cancer;
SARC	cis	rs7729447	0.566	rs1421811	chr5:32714270	C/G	cg16267343	chr5:32710456	NPR3	0.61	7.9	0.46	1.13e-13	Blood pressure;
SARC	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg11987759	chr7:65425863	GUSB	0.47	5.87	0.36	1.52e-8	Aortic root size;
SARC	cis	rs10892173	0.846	rs12790243	chr11:117678543	C/T	cg21014159	chr11:117668035	DSCAML1	0.34	4.75	0.3	3.59e-6	Myopia;
SARC	cis	rs11098499	0.954	rs59394118	chr4:120295551	A/G	cg09160332	chr4:120329925	NA	-0.33	-4.72	-0.3	4.16e-6	Corneal astigmatism;
SARC	cis	rs9894429	0.671	rs6565616	chr17:79612161	C/T	cg18240062	chr17:79603768	NPLOC4	0.58	7.06	0.42	1.86e-11	Eye color traits;
SARC	cis	rs1729951	0.546	rs12054408	chr3:136677645	T/C	cg15507776	chr3:136538369	TMEM22	0.51	5.73	0.35	3.12e-8	Neuroticism;
SARC	cis	rs911555	0.755	rs7148567	chr14:103882234	C/T	cg24130564	chr14:104152367	KLC1	-0.5	-5.8	-0.36	2.12e-8	Intelligence (multi-trait analysis);
SARC	cis	rs611744	0.573	rs674580	chr8:109251690	C/G	cg21045802	chr8:109455806	TTC35	0.63	8.42	0.48	3.81e-15	Dupuytren's disease;
SARC	cis	rs6570726	1.000	rs1935615	chr6:145921117	G/T	cg05220968	chr6:146057943	EPM2A	-0.3	-5.09	-0.32	7.26e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1153858	1.000	rs7164602	chr15:45671325	A/G	cg21132104	chr15:45694354	SPATA5L1	0.78	11.01	0.59	5.55e-23	Homoarginine levels;
SARC	cis	rs9660992	0.674	rs56198325	chr1:205265450	G/A	cg00857998	chr1:205179979	DSTYK	0.42	4.91	0.31	1.69e-6	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.45	0.53	3.79e-18	Prudent dietary pattern;
SARC	cis	rs7635838	0.617	rs184700	chr3:11293061	A/G	cg00170343	chr3:11313890	ATG7	0.7	9.28	0.52	1.19e-17	HDL cholesterol;
SARC	cis	rs1707322	0.627	rs3014213	chr1:46045522	T/C	cg03146154	chr1:46216737	IPP	-0.51	-6.07	-0.37	5.12e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs708547	0.578	rs781665	chr4:57831461	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.49	6.0	0.37	7.63e-9	Response to bleomycin (chromatid breaks);
SARC	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg06420487	chr17:61919686	SMARCD2	-0.47	-5.21	-0.32	4.15e-7	Height;
SARC	cis	rs34172651	0.917	rs12923476	chr16:24798079	G/A	cg04756594	chr16:24857601	SLC5A11	0.38	5.96	0.36	9.34e-9	Intelligence (multi-trait analysis);
SARC	cis	rs1062177	0.951	rs2915876	chr5:151150745	C/A	cg00977110	chr5:151150581	G3BP1	0.62	6.15	0.37	3.25e-9	Preschool internalizing problems;
SARC	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg07701084	chr6:150067640	NUP43	-0.43	-5.63	-0.35	5.26e-8	Lung cancer;
SARC	cis	rs834603	0.518	rs834605	chr7:47450456	T/C	cg23694490	chr7:47445681	TNS3	-0.34	-6.05	-0.37	5.69e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	trans	rs61931739	0.817	rs10772143	chr12:34230651	T/G	cg26384229	chr12:38710491	ALG10B	0.61	8.04	0.47	4.56e-14	Morning vs. evening chronotype;
SARC	cis	rs9902453	0.904	rs4375718	chr17:28363642	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.18	-0.43	9.42e-12	Coffee consumption (cups per day);
SARC	cis	rs7659604	0.689	rs59131059	chr4:122666357	C/T	cg20573242	chr4:122745356	CCNA2	0.44	5.66	0.35	4.33e-8	Type 2 diabetes;
SARC	cis	rs9527	0.590	rs10883834	chr10:104881402	T/C	cg04362960	chr10:104952993	NT5C2	0.43	4.94	0.31	1.47e-6	Arsenic metabolism;
SARC	cis	rs6005807	0.543	rs2294431	chr22:29177200	C/T	cg02153584	chr22:29168773	CCDC117	0.66	5.13	0.32	6.2e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
SARC	cis	rs4481887	1.000	rs4589143	chr1:248470446	A/G	cg00666640	chr1:248458726	OR2T12	0.37	6.23	0.38	2.17e-9	Common traits (Other);
SARC	cis	rs7937682	0.587	rs571594	chr11:111359334	A/G	cg22437258	chr11:111473054	SIK2	-0.49	-5.8	-0.35	2.2e-8	Primary sclerosing cholangitis;
SARC	cis	rs920590	0.837	rs4398935	chr8:19649487	T/C	cg03894339	chr8:19674705	INTS10	0.46	5.64	0.35	4.95e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs4713118	0.588	rs200994	chr6:27813813	A/C	cg17221315	chr6:27791827	HIST1H4J	-0.54	-5.89	-0.36	1.34e-8	Parkinson's disease;
SARC	cis	rs9300255	0.698	rs4759416	chr12:123746357	C/G	cg05973401	chr12:123451056	ABCB9	0.45	4.91	0.31	1.75e-6	Neutrophil percentage of white cells;
SARC	cis	rs17253792	0.749	rs79713967	chr14:56124186	T/C	cg01858014	chr14:56050164	KTN1	-0.67	-5.19	-0.32	4.67e-7	Putamen volume;
SARC	cis	rs4268898	0.896	rs2702042	chr2:24546542	C/T	cg26838691	chr2:24397539	C2orf84	-0.36	-4.92	-0.31	1.66e-6	Asthma;
SARC	cis	rs910316	1.000	rs11623413	chr14:75588824	C/T	cg23033748	chr14:75592666	NEK9	-0.36	-5.04	-0.31	9.2e-7	Height;
SARC	cis	rs818427	0.635	rs2229992	chr5:112162854	C/T	cg07820702	chr5:112228657	REEP5	-0.46	-5.19	-0.32	4.57e-7	Total body bone mineral density;
SARC	cis	rs1008375	0.932	rs9283698	chr4:17662471	T/C	cg02297831	chr4:17616191	MED28	0.44	5.45	0.34	1.27e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7223966	1.000	rs2854219	chr17:61942682	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	7.54	0.44	1.03e-12	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7937682	0.924	rs501089	chr11:111502479	G/T	cg09085632	chr11:111637200	PPP2R1B	0.88	12.88	0.64	4.98e-29	Primary sclerosing cholangitis;
SARC	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg24531977	chr5:56204891	C5orf35	-0.53	-5.34	-0.33	2.25e-7	Type 2 diabetes;
SARC	cis	rs1873147	1.000	rs4775601	chr15:63311980	C/T	cg05507819	chr15:63340323	TPM1	0.47	5.19	0.32	4.65e-7	Orofacial clefts;
SARC	cis	rs854765	0.547	rs2955384	chr17:17939573	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.4	4.9	0.31	1.83e-6	Total body bone mineral density;
SARC	cis	rs9814567	1.000	rs7433991	chr3:134312292	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-6.93	-0.41	4.14e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs12681288	0.676	rs6983981	chr8:1016011	A/C	cg15309053	chr8:964076	NA	0.45	7.25	0.43	5.92e-12	Schizophrenia;
SARC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg06873352	chr17:61820015	STRADA	0.52	6.8	0.41	8.81e-11	Prudent dietary pattern;
SARC	cis	rs2629540	0.781	rs2293064	chr10:126396511	C/G	cg08799069	chr10:126477246	METTL10	0.59	6.02	0.37	6.87e-9	Cocaine dependence;
SARC	cis	rs778371	0.647	rs974321	chr2:233638351	G/A	cg16596103	chr2:233749413	NGEF	-0.35	-5.21	-0.32	4.09e-7	Schizophrenia;
SARC	cis	rs7654585	1.000	rs7654585	chr4:25942751	A/G	cg10409131	chr4:25915609	C4orf52	0.52	6.55	0.39	3.67e-10	Obesity-related traits;
SARC	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg18876405	chr7:65276391	NA	-0.72	-9.0	-0.51	8.24e-17	Aortic root size;
SARC	cis	rs67311347	0.544	rs67533651	chr3:40338367	T/A	cg09455208	chr3:40491958	NA	0.3	4.92	0.31	1.66e-6	Renal cell carcinoma;
SARC	cis	rs290268	0.874	rs772407	chr9:93560850	A/C	cg02608019	chr9:93564028	SYK	0.34	4.99	0.31	1.18e-6	Platelet count;
SARC	cis	rs1448094	0.534	rs11613070	chr12:86167544	T/A	cg00310523	chr12:86230176	RASSF9	0.32	4.96	0.31	1.38e-6	Major depressive disorder;
SARC	cis	rs943466	1.000	rs11755593	chr6:33740325	G/C	cg04676172	chr6:33757040	LEMD2	0.49	5.04	0.31	9.51e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
SARC	cis	rs36051895	0.623	rs3780383	chr9:5232409	G/C	cg02405213	chr9:5042618	JAK2	-0.44	-4.87	-0.3	2.07e-6	Pediatric autoimmune diseases;
SARC	trans	rs11098499	0.954	rs59394118	chr4:120295551	A/G	cg25214090	chr10:38739885	LOC399744	0.55	7.14	0.42	1.18e-11	Corneal astigmatism;
SARC	cis	rs734999	0.545	rs7364820	chr1:2556709	G/A	cg00980319	chr1:2560884	MMEL1	-0.34	-4.9	-0.31	1.83e-6	Ulcerative colitis;
SARC	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg18758796	chr5:131593413	PDLIM4	0.37	4.77	0.3	3.25e-6	Acylcarnitine levels;
SARC	cis	rs9392918	0.690	rs9505259	chr6:7685746	T/C	cg23089261	chr6:7723385	NA	0.37	4.87	0.3	2.03e-6	Height;
SARC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg11494091	chr17:61959527	GH2	0.55	8.08	0.47	3.4e-14	Prudent dietary pattern;
SARC	cis	rs644799	0.544	rs1150360	chr11:95512060	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	6.24	0.38	2.08e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2439831	1.000	rs101094	chr15:43787322	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.05	10.85	0.58	1.78e-22	Lung cancer in ever smokers;
SARC	cis	rs7666738	0.962	rs4699596	chr4:99012924	C/T	cg05340658	chr4:99064831	C4orf37	0.58	7.27	0.43	5.54e-12	Colonoscopy-negative controls vs population controls;
SARC	cis	rs3796352	1.000	rs11718752	chr3:53130745	T/C	cg15956490	chr3:53032818	SFMBT1	0.69	4.77	0.3	3.31e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs7186908	0.793	rs7191623	chr16:72212044	G/A	cg16558253	chr16:72132732	DHX38	-0.5	-6.04	-0.37	6.06e-9	Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg05863683	chr7:1912471	MAD1L1	0.35	5.27	0.33	3.14e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs10880689	1	rs10880689	chr12:37930102	A/G	cg13010199	chr12:38710504	ALG10B	0.76	10.14	0.55	2.95e-20	Resting heart rate;
SARC	cis	rs3820928	0.874	rs1917122	chr2:227835681	C/T	cg05526886	chr2:227700861	RHBDD1	-0.56	-6.78	-0.41	9.69e-11	Pulmonary function;
SARC	cis	rs6912958	0.559	rs242270	chr6:88062190	C/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.28	-4.73	-0.3	3.9e-6	Monocyte percentage of white cells;
SARC	cis	rs35213789	0.803	rs12698813	chr7:69362702	T/C	cg10619644	chr7:69149951	AUTS2	0.39	4.8	0.3	2.82e-6	Childhood ear infection;
SARC	cis	rs6088580	0.634	rs2378134	chr20:32938085	C/T	cg08999081	chr20:33150536	PIGU	-0.43	-6.57	-0.4	3.32e-10	Glomerular filtration rate (creatinine);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg13706365	chr10:11504219	USP6NL	0.51	6.8	0.41	8.91e-11	Thyroid stimulating hormone;
SARC	cis	rs11155671	0.530	rs9383912	chr6:150206615	T/C	cg09699651	chr6:150184138	LRP11	0.51	6.55	0.39	3.7e-10	Testicular germ cell tumor;
SARC	cis	rs6582630	0.555	rs10880611	chr12:38509316	C/G	cg26384229	chr12:38710491	ALG10B	0.85	12.35	0.63	2.74e-27	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs8031584	0.578	rs1088473	chr15:31139298	A/G	cg14829155	chr15:31115871	NA	0.49	6.29	0.38	1.59e-9	Huntington's disease progression;
SARC	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg05313129	chr8:58192883	C8orf71	-0.49	-4.74	-0.3	3.69e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs11711311	1.000	rs7645473	chr3:113516187	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	8.41	0.48	4.12e-15	IgG glycosylation;
SARC	cis	rs7959452	0.868	rs12812860	chr12:69746671	T/C	cg20891283	chr12:69753455	YEATS4	0.45	5.98	0.36	8.35e-9	Blood protein levels;
SARC	cis	rs13314892	0.734	rs75308677	chr3:69854691	C/G	cg17445875	chr3:69859618	MITF	-0.58	-5.7	-0.35	3.56e-8	QRS complex (12-leadsum);
SARC	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4253772	0.591	rs73886791	chr22:46687212	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.72	7.51	0.44	1.28e-12	LDL cholesterol;Cholesterol, total;
SARC	cis	rs4919087	0.561	rs10082521	chr10:99070526	A/T	cg25902810	chr10:99078978	FRAT1	-0.59	-6.22	-0.38	2.29e-9	Monocyte count;
SARC	trans	rs2727020	0.701	rs7949044	chr11:49597334	C/T	cg03929089	chr4:120376271	NA	-0.76	-9.96	-0.55	1.1e-19	Coronary artery disease;
SARC	cis	rs6598955	0.543	rs3795687	chr1:26560745	G/A	cg04990556	chr1:26633338	UBXN11	0.74	7.9	0.46	1.08e-13	Obesity-related traits;
SARC	cis	rs10782582	0.593	rs11578480	chr1:76208989	T/G	cg03433033	chr1:76189801	ACADM	-0.42	-5.47	-0.34	1.15e-7	Daytime sleep phenotypes;
SARC	cis	rs425277	1.000	rs809912	chr1:2078385	C/T	cg21442419	chr1:2182373	SKI	-0.52	-6.68	-0.4	1.76e-10	Height;
SARC	cis	rs7772486	0.686	rs9497395	chr6:146013592	A/G	cg05347473	chr6:146136440	FBXO30	-0.51	-7.1	-0.42	1.49e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7829975	0.510	rs2979160	chr8:8307666	A/G	cg11608241	chr8:8085544	FLJ10661	0.45	5.48	0.34	1.07e-7	Mood instability;
SARC	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg26119090	chr2:26468346	HADHA;HADHB	0.7	8.08	0.47	3.4e-14	Gut microbiome composition (summer);
SARC	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg15448220	chr1:150897856	SETDB1	0.45	5.95	0.36	9.54e-9	Tonsillectomy;
SARC	cis	rs1419980	0.673	rs12146828	chr12:7739341	C/G	cg10578777	chr12:7781093	NA	-0.55	-5.9	-0.36	1.3e-8	HDL cholesterol levels;
SARC	trans	rs9388451	0.874	rs7739566	chr6:126094757	A/T	cg05039488	chr6:79577232	IRAK1BP1	-0.57	-7.44	-0.44	1.89e-12	Brugada syndrome;
SARC	cis	rs2204008	0.694	rs10880262	chr12:38328696	C/T	cg14851346	chr12:38532713	NA	0.45	5.32	0.33	2.47e-7	Bladder cancer;
SARC	cis	rs78320035	1.000	rs77626995	chr1:168110070	A/T	cg17113809	chr1:168148080	TIPRL	1.15	6.69	0.4	1.61e-10	Red cell distribution width;
SARC	cis	rs4423214	0.879	rs1790353	chr11:71136730	C/T	cg05163923	chr11:71159392	DHCR7	-0.59	-6.85	-0.41	6.51e-11	Vitamin D levels;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg09592456	chr22:19780308	GNB1L	0.49	6.42	0.39	7.7e-10	Breast cancer;
SARC	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg02725872	chr8:58115012	NA	-0.37	-6.55	-0.39	3.71e-10	Developmental language disorder (linguistic errors);
SARC	trans	rs641862	1	rs641862	chr13:110790232	C/T	cg04283000	chr13:113472466	ATP11A	0.9	6.7	0.4	1.59e-10	Obesity-related traits;
SARC	cis	rs60871478	1.000	rs4719314	chr7:822523	A/G	cg05535760	chr7:792225	HEATR2	0.71	7.24	0.43	6.64e-12	Cerebrospinal P-tau181p levels;
SARC	cis	rs950027	0.549	rs12909409	chr15:45608582	T/G	cg26924012	chr15:45694286	SPATA5L1	-0.48	-5.84	-0.36	1.77e-8	Response to fenofibrate (adiponectin levels);
SARC	cis	rs1355223	0.583	rs2941057	chr11:34882220	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.79	11.52	0.6	1.37e-24	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg03060546	chr3:49711283	APEH	0.59	7.42	0.44	2.22e-12	Resting heart rate;
SARC	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-7.83	-0.46	1.68e-13	Alzheimer's disease;
SARC	cis	rs6866344	0.570	rs4266420	chr5:178137161	C/G	cg03877680	chr5:178157825	ZNF354A	1.01	14.09	0.68	5.13e-33	Neutrophil percentage of white cells;
SARC	cis	rs2760061	0.583	rs708118	chr1:228201801	A/G	cg01200585	chr1:228362443	C1orf69	-0.42	-5.36	-0.33	1.95e-7	Diastolic blood pressure;
SARC	cis	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg00745463	chr17:30367425	LRRC37B	-0.58	-4.98	-0.31	1.22e-6	Hip circumference adjusted for BMI;
SARC	cis	rs4423214	0.559	rs10898228	chr11:71228358	A/T	cg05163923	chr11:71159392	DHCR7	-0.5	-5.03	-0.31	9.97e-7	Vitamin D levels;
SARC	cis	rs16854884	0.606	rs60676654	chr3:143734937	A/G	cg06585982	chr3:143692056	C3orf58	0.67	9.14	0.51	3.13e-17	Economic and political preferences (feminism/equality);
SARC	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg04267008	chr7:1944627	MAD1L1	-0.58	-6.58	-0.4	3.14e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs7666738	0.830	rs9998803	chr4:99002519	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs76419734	0.510	rs28450989	chr4:106630007	G/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.79	9.53	0.53	2.15e-18	Post bronchodilator FEV1;
SARC	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.78	-8.17	-0.47	2e-14	Alzheimer's disease;
SARC	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg11764359	chr7:65958608	NA	-0.62	-7.38	-0.44	2.86e-12	Aortic root size;
SARC	cis	rs873946	0.689	rs2803993	chr10:134550606	T/C	cg01276201	chr10:134613136	NA	0.28	4.93	0.31	1.55e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs910316	0.967	rs1071989	chr14:75564659	G/T	cg23033748	chr14:75592666	NEK9	0.37	5.19	0.32	4.58e-7	Height;
SARC	cis	rs11098499	0.754	rs11724409	chr4:120252361	A/G	cg09307838	chr4:120376055	NA	0.81	11.03	0.59	4.84e-23	Corneal astigmatism;
SARC	cis	rs9457247	1.000	rs448060	chr6:167382622	A/G	cg23791538	chr6:167370224	RNASET2	-0.63	-8.74	-0.5	4.81e-16	Crohn's disease;
SARC	cis	rs9346455	0.614	rs58732838	chr6:72000496	C/T	cg27238071	chr6:71998145	OGFRL1	0.57	4.86	0.3	2.18e-6	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
SARC	cis	rs17376456	0.877	rs10050465	chr5:93349963	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.64	0.35	4.86e-8	Diabetic retinopathy;
SARC	cis	rs9790314	0.686	rs2306061	chr3:160787502	C/T	cg04691961	chr3:161091175	C3orf57	-0.59	-8.03	-0.47	4.72e-14	Morning vs. evening chronotype;
SARC	cis	rs4268898	0.552	rs35331966	chr2:24367828	C/T	cg06627628	chr2:24431161	ITSN2	0.48	6.22	0.38	2.29e-9	Asthma;
SARC	cis	rs11112613	0.713	rs12321309	chr12:105943263	T/G	cg03607813	chr12:105948248	NA	0.55	7.27	0.43	5.52e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs17270561	0.609	rs1165211	chr6:25800922	T/C	cg16482183	chr6:26056742	HIST1H1C	0.48	6.17	0.37	2.97e-9	Iron status biomarkers;
SARC	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg11764359	chr7:65958608	NA	-0.8	-10.37	-0.56	5.77e-21	Aortic root size;
SARC	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg03264133	chr6:25882463	NA	-0.62	-8.2	-0.47	1.58e-14	Intelligence (multi-trait analysis);
SARC	cis	rs763121	0.853	rs1065201	chr22:39069510	T/C	cg21395723	chr22:39101663	GTPBP1	0.54	6.14	0.37	3.53e-9	Menopause (age at onset);
SARC	cis	rs7113850	0.541	rs7131336	chr11:24219418	C/T	ch.11.24196551F	chr11:24239977	NA	0.69	6.43	0.39	7.1e-10	Bone fracture in osteoporosis;
SARC	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg23982607	chr1:1823379	GNB1	-0.64	-10.77	-0.58	3.37e-22	Body mass index;
SARC	cis	rs7192750	0.617	rs9929256	chr16:72040032	A/C	cg14768367	chr16:72042858	DHODH	0.77	5.99	0.37	8.01e-9	LDL cholesterol levels;Total cholesterol levels;
SARC	cis	rs12579753	0.879	rs11115009	chr12:82165409	G/T	cg07988820	chr12:82153109	PPFIA2	0.58	6.93	0.41	3.98e-11	Resting heart rate;
SARC	cis	rs11025559	0.716	rs1596376	chr11:20454229	T/C	cg19653624	chr11:20408972	PRMT3	-0.55	-6.16	-0.37	3.18e-9	Pursuit maintenance gain;
SARC	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg20607798	chr8:58055168	NA	0.57	5.57	0.34	7.15e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs12579753	0.879	rs12579544	chr12:82164043	A/C	cg07988820	chr12:82153109	PPFIA2	-0.61	-7.25	-0.43	6.11e-12	Resting heart rate;
SARC	cis	rs1707322	0.964	rs785499	chr1:46592420	G/A	cg03146154	chr1:46216737	IPP	-0.48	-5.61	-0.34	5.79e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg13770153	chr20:60521292	NA	-0.53	-7.08	-0.42	1.67e-11	Body mass index;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg01305483	chr7:935436	C7orf20	-0.46	-6.34	-0.38	1.18e-9	Chemerin levels;
SARC	cis	rs854765	0.520	rs9899355	chr17:17898243	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.66	9.4	0.52	5.46e-18	Total body bone mineral density;
SARC	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.48	5.91	0.36	1.21e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg08109568	chr15:31115862	NA	-0.42	-5.21	-0.32	4.14e-7	Huntington's disease progression;
SARC	cis	rs12432203	1.000	rs4566067	chr14:51729487	A/G	cg23715682	chr14:50863043	CDKL1	0.63	5.27	0.33	3.09e-7	Cancer;
SARC	cis	rs8014204	0.839	rs6574197	chr14:75331487	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.74	-10.77	-0.58	3.27e-22	Caffeine consumption;
SARC	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg04944784	chr2:26401820	FAM59B	-0.48	-5.99	-0.37	7.95e-9	Gut microbiome composition (summer);
SARC	cis	rs7740797	0.875	rs9322480	chr6:155128332	G/C	cg02865717	chr6:155053990	RBM16	-0.34	-4.94	-0.31	1.49e-6	Colorectal or endometrial cancer;
SARC	cis	rs2573652	1.000	rs2581359	chr15:100513707	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.36	-4.76	-0.3	3.34e-6	Height;
SARC	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg24399712	chr22:39784796	NA	-0.43	-5.24	-0.32	3.55e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6540556	0.954	rs3753606	chr1:209937212	C/T	cg05527609	chr1:210001259	C1orf107	0.52	5.72	0.35	3.27e-8	Red blood cell count;
SARC	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg18404041	chr3:52824283	ITIH1	-0.4	-6.0	-0.37	7.68e-9	Electroencephalogram traits;
SARC	cis	rs950027	0.596	rs2467853	chr15:45698793	T/G	cg26924012	chr15:45694286	SPATA5L1	0.51	6.42	0.39	7.54e-10	Response to fenofibrate (adiponectin levels);
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg21047528	chr22:42915898	RRP7A	0.51	6.52	0.39	4.28e-10	Lung adenocarcinoma;
SARC	cis	rs1707322	0.928	rs61785614	chr1:46446047	A/G	cg03146154	chr1:46216737	IPP	0.45	5.41	0.33	1.57e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs916888	0.610	rs199536	chr17:44820425	T/C	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.57	-6.62	-0.4	2.51e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs10504073	0.669	rs818560	chr8:50035417	C/T	cg00325661	chr8:49890786	NA	0.54	7.38	0.44	2.7e-12	Blood metabolite ratios;
SARC	cis	rs6871536	1.000	rs62383710	chr5:131900597	G/A	cg11797159	chr5:131991491	NA	0.38	4.91	0.31	1.67e-6	Asthma (childhood onset);
SARC	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg16049864	chr8:95962084	TP53INP1	-0.47	-7.69	-0.45	4.03e-13	Type 2 diabetes;
SARC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg04234412	chr22:24373322	LOC391322	-0.56	-6.6	-0.4	2.68e-10	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7647973	1.000	rs2312462	chr3:49601255	A/G	cg07636037	chr3:49044803	WDR6	0.69	7.9	0.46	1.13e-13	Menarche (age at onset);
SARC	cis	rs9916302	0.706	rs4516267	chr17:37471482	G/T	cg00129232	chr17:37814104	STARD3	0.54	5.76	0.35	2.7e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs1545257	0.505	rs67786999	chr2:24637160	T/G	cg06627628	chr2:24431161	ITSN2	-0.56	-7.08	-0.42	1.64e-11	Sjögren's syndrome;
SARC	cis	rs3768617	0.510	rs4651142	chr1:183097386	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.2	0.56	1.95e-20	Fuchs's corneal dystrophy;
SARC	cis	rs150641967	1	rs150641967	chr19:19370340	TGACA/T	cg03709012	chr19:19516395	GATAD2A	0.93	4.8	0.3	2.85e-6	Triglyceride levels;Very low density lipoprotein cholesterol levels;Low density lipoprotein cholesterol;Total cholesterol levels;
SARC	cis	rs5753618	0.583	rs2273249	chr22:31836486	T/C	cg02404636	chr22:31891804	SFI1	0.49	5.33	0.33	2.3e-7	Colorectal cancer;
SARC	cis	rs751728	0.931	rs2296746	chr6:33744711	C/T	cg15252951	chr6:33757062	LEMD2	0.6	7.07	0.42	1.82e-11	Crohn's disease;
SARC	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg18357526	chr6:26021779	HIST1H4A	-0.43	-5.26	-0.33	3.22e-7	Blood metabolite levels;
SARC	cis	rs9467773	0.583	rs1021373	chr6:26632457	G/A	cg12292205	chr6:26970375	C6orf41	0.41	5.12	0.32	6.46e-7	Intelligence (multi-trait analysis);
SARC	trans	rs7584330	0.868	rs6760842	chr2:238398165	C/T	cg13125884	chr15:71408291	CT62	0.45	6.55	0.39	3.58e-10	Prostate cancer;
SARC	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg05872129	chr22:39784769	NA	-0.41	-5.8	-0.36	2.1e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7103648	1.000	rs10838709	chr11:47447346	C/T	cg20307385	chr11:47447363	PSMC3	0.87	14.32	0.68	8.55e-34	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs13191362	0.935	rs67673890	chr6:163107647	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.39	4.83	0.3	2.49e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs12479064	0.724	rs112900993	chr2:99948805	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.56	-6.46	-0.39	6.06e-10	Chronic sinus infection;
SARC	cis	rs12048904	0.595	rs10493937	chr1:101342650	A/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.53	-6.7	-0.4	1.56e-10	Multiple sclerosis;
SARC	cis	rs17376456	0.825	rs13156202	chr5:93157721	C/T	cg25358565	chr5:93447407	FAM172A	-1.21	-12.46	-0.63	1.19e-27	Diabetic retinopathy;
SARC	cis	rs6582630	0.554	rs8189625	chr12:38401177	C/T	cg26384229	chr12:38710491	ALG10B	-0.57	-7.04	-0.42	2.19e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs459571	0.959	rs2810491	chr9:136923331	C/T	cg01294253	chr9:136912663	BRD3	-0.39	-5.04	-0.31	9.43e-7	Platelet distribution width;
SARC	cis	rs7481584	0.624	rs12417389	chr11:3035304	G/C	cg25174290	chr11:3078921	CARS	-0.58	-8.02	-0.47	5.19e-14	Calcium levels;
SARC	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.46	5.39	0.33	1.69e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9303401	0.659	rs34275691	chr17:56736640	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.09	12.1	0.62	1.73e-26	Cognitive test performance;
SARC	cis	rs13191362	0.810	rs66921603	chr6:162996982	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.49	0.34	1.04e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg06577658	chr19:46296270	DMWD	0.44	5.12	0.32	6.28e-7	Coronary artery disease;
SARC	cis	rs2303759	0.709	rs10414921	chr19:49823047	C/T	cg22307029	chr19:49891270	CCDC155	0.6	6.77	0.41	1.05e-10	Multiple sclerosis;
SARC	cis	rs60871478	1.000	rs34086011	chr7:805430	C/T	cg19087971	chr7:751233	PRKAR1B	-0.43	-4.9	-0.31	1.77e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg01570182	chr17:44337453	NA	0.8	9.22	0.52	1.77e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs6058796	1.000	rs6141772	chr20:31246662	A/C	cg13636640	chr20:31349939	DNMT3B	0.55	4.85	0.3	2.26e-6	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg03060546	chr3:49711283	APEH	0.42	5.23	0.32	3.86e-7	Parkinson's disease;
SARC	cis	rs72634258	0.891	rs404381	chr1:8080745	C/T	cg00042356	chr1:8021962	PARK7	0.6	5.91	0.36	1.21e-8	Inflammatory bowel disease;
SARC	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg12667521	chr19:29218732	NA	0.39	5.26	0.33	3.27e-7	Methadone dose in opioid dependence;
SARC	cis	rs6696846	0.740	rs17344537	chr1:205091427	T/G	cg21643547	chr1:205240462	TMCC2	-0.59	-7.94	-0.46	8.31e-14	Red blood cell count;
SARC	trans	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg20587970	chr11:113659929	NA	-1.31	-13.87	-0.67	2.62e-32	Hip circumference adjusted for BMI;
SARC	cis	rs12586317	0.511	rs113770696	chr14:35444383	C/T	cg16230307	chr14:35515116	FAM177A1	1.02	11.72	0.61	3.08e-25	Psoriasis;
SARC	cis	rs6815814	0.950	rs9306967	chr4:38807911	G/C	cg06935464	chr4:38784597	TLR10	0.52	5.78	0.35	2.41e-8	Breast cancer;
SARC	cis	rs4555082	0.874	rs78923231	chr14:105754033	C/T	cg10792982	chr14:105748885	BRF1	0.54	8.01	0.46	5.62e-14	Mean platelet volume;Platelet distribution width;
SARC	cis	rs963731	0.649	rs78510010	chr2:39348662	T/C	cg04010122	chr2:39346883	SOS1	1.11	6.38	0.39	9.36e-10	Corticobasal degeneration;
SARC	cis	rs7647973	0.588	rs4855848	chr3:49653457	C/T	cg07636037	chr3:49044803	WDR6	0.63	6.42	0.39	7.57e-10	Menarche (age at onset);
SARC	cis	rs2204008	0.776	rs8186824	chr12:38316537	A/C	cg26384229	chr12:38710491	ALG10B	0.85	12.23	0.63	6.69e-27	Bladder cancer;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg04828493	chr13:111328783	CARS2	0.54	4.73	0.3	3.95e-6	Obesity-related traits;
SARC	cis	rs9747201	0.926	rs7222764	chr17:80062698	G/A	cg09264619	chr17:80180166	NA	0.47	5.34	0.33	2.23e-7	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs1691799	0.899	rs1168293	chr12:66733904	G/A	cg16791601	chr12:66731901	HELB	-0.72	-10.72	-0.57	4.65e-22	White blood cell count (basophil);
SARC	cis	rs78456975	0.943	rs13391932	chr2:1577679	T/C	cg12573674	chr2:1569213	NA	-0.57	-5.17	-0.32	4.92e-7	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs4481887	0.927	rs12042598	chr1:248482016	C/T	cg00666640	chr1:248458726	OR2T12	0.35	5.63	0.35	5.09e-8	Common traits (Other);
SARC	cis	rs27434	0.583	rs151908	chr5:96156494	A/G	cg16492584	chr5:96139282	ERAP1	-0.57	-7.1	-0.42	1.49e-11	Ankylosing spondylitis;
SARC	cis	rs911555	0.755	rs9671414	chr14:103967299	C/T	cg26031613	chr14:104095156	KLC1	-0.43	-4.9	-0.31	1.78e-6	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg08219700	chr8:58056026	NA	0.67	6.12	0.37	3.99e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs17376456	0.825	rs13156202	chr5:93157721	C/T	cg21475434	chr5:93447410	FAM172A	-0.79	-6.8	-0.41	8.82e-11	Diabetic retinopathy;
SARC	cis	rs9916302	0.904	rs8081338	chr17:37406139	C/T	cg20243544	chr17:37824526	PNMT	0.54	6.47	0.39	5.79e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs7474896	0.559	rs1735641	chr10:38184852	C/A	cg25427524	chr10:38739819	LOC399744	0.53	6.3	0.38	1.48e-9	Obesity (extreme);
SARC	cis	rs5769765	0.862	rs138857	chr22:50199589	C/T	cg03033257	chr22:50311977	ALG12;CRELD2	0.51	4.89	0.31	1.84e-6	Schizophrenia;
SARC	cis	rs30380	0.632	rs26496	chr5:96137882	A/G	cg16492584	chr5:96139282	ERAP1	-0.48	-5.5	-0.34	1.02e-7	Cerebrospinal fluid biomarker levels;
SARC	cis	rs4803468	1.000	rs4803465	chr19:41918158	A/G	cg14132834	chr19:41945861	ATP5SL	0.53	7.28	0.43	5.24e-12	Height;
SARC	cis	rs6964587	0.626	rs6972945	chr7:91549576	C/G	cg17063962	chr7:91808500	NA	-0.76	-10.87	-0.58	1.61e-22	Breast cancer;
SARC	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg18252515	chr7:66147081	NA	0.43	4.8	0.3	2.86e-6	Aortic root size;
SARC	cis	rs10463316	0.817	rs10052992	chr5:150788602	C/T	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.39	-0.33	1.74e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs2963155	0.518	rs865482	chr5:142640317	C/A	cg17617527	chr5:142782415	NR3C1	0.86	6.06	0.37	5.31e-9	Breast cancer;
SARC	trans	rs3857536	0.544	rs208453	chr6:66906841	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.71	-8.13	-0.47	2.6e-14	Blood trace element (Cu levels);
SARC	cis	rs3857536	0.813	rs6455091	chr6:66949127	C/G	cg07460842	chr6:66804631	NA	-0.45	-5.19	-0.32	4.5e-7	Blood trace element (Cu levels);
SARC	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg00149659	chr3:10157352	C3orf10	0.69	6.9	0.41	4.76e-11	Alzheimer's disease;
SARC	cis	rs17376456	0.825	rs13171131	chr5:93223028	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.61	5.49	0.34	1.05e-7	Diabetic retinopathy;
SARC	cis	rs6121246	0.567	rs6058203	chr20:30198979	C/T	cg21427119	chr20:30132790	HM13	-0.48	-5.29	-0.33	2.84e-7	Mean corpuscular hemoglobin;
SARC	cis	rs743757	0.816	rs6792502	chr3:50531201	C/A	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.57	5.19	0.32	4.54e-7	Diastolic blood pressure;
SARC	cis	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg13072238	chr3:49761600	GMPPB	-0.42	-5.43	-0.34	1.4e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7666738	0.830	rs2865978	chr4:99017946	G/T	cg05340658	chr4:99064831	C4orf37	0.66	9.04	0.51	6.35e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10911232	0.507	rs4575047	chr1:182976028	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.76	0.58	3.38e-22	Hypertriglyceridemia;
SARC	cis	rs8014131	0.615	rs1543387	chr14:85984180	G/A	cg10406690	chr14:85995726	FLRT2	0.4	5.08	0.32	7.57e-7	Menarche (age at onset);
SARC	cis	rs6582630	0.555	rs1906260	chr12:38601013	T/G	cg13010199	chr12:38710504	ALG10B	0.8	11.21	0.59	1.3e-23	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2204008	0.729	rs114133083	chr12:38182923	G/C	cg13010199	chr12:38710504	ALG10B	-0.61	-7.73	-0.45	3.17e-13	Bladder cancer;
SARC	cis	rs1878931	0.520	rs12447807	chr16:3413896	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.97	16.6	0.74	2.2e-41	Body mass index (adult);
SARC	cis	rs6060717	0.528	rs73905955	chr20:34332938	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.68	5.65	0.35	4.66e-8	Hip circumference adjusted for BMI;
SARC	cis	rs8062405	0.824	rs28772958	chr16:28535305	A/G	cg08761264	chr16:28874980	SH2B1	-0.42	-4.76	-0.3	3.33e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs8078723	0.714	rs3785550	chr17:38149727	C/T	cg17467752	chr17:38218738	THRA	-0.38	-4.89	-0.31	1.88e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs7772486	0.686	rs2092263	chr6:146029687	G/A	cg23711669	chr6:146136114	FBXO30	-0.8	-12.61	-0.64	3.8e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs67311347	1.000	rs7631893	chr3:40440869	C/T	cg09455208	chr3:40491958	NA	0.4	6.23	0.38	2.19e-9	Renal cell carcinoma;
SARC	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.85	12.39	0.63	2.02e-27	Chronic sinus infection;
SARC	cis	rs793571	0.590	rs474875	chr15:59086703	A/C	cg05156742	chr15:59063176	FAM63B	0.75	10.76	0.58	3.43e-22	Schizophrenia;
SARC	cis	rs4443100	0.670	rs9612225	chr22:23406619	G/A	cg14186256	chr22:23484241	RTDR1	0.57	5.78	0.35	2.36e-8	Serum parathyroid hormone levels;
SARC	cis	rs9581857	0.556	rs9581861	chr13:28039991	C/T	cg01674679	chr13:27998804	GTF3A	-0.6	-5.9	-0.36	1.27e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	cis	rs7617773	0.539	rs6779517	chr3:48384388	C/T	cg11946769	chr3:48343235	NME6	0.53	6.66	0.4	1.98e-10	Coronary artery disease;
SARC	cis	rs6570726	0.559	rs11754523	chr6:145727951	A/G	cg23711669	chr6:146136114	FBXO30	-0.63	-8.14	-0.47	2.39e-14	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs72781680	0.898	rs7563564	chr2:23993404	T/C	cg06627628	chr2:24431161	ITSN2	-0.67	-6.35	-0.38	1.14e-9	Lymphocyte counts;
SARC	cis	rs9790314	0.586	rs73021449	chr3:161128941	G/A	cg04691961	chr3:161091175	C3orf57	-0.49	-6.06	-0.37	5.29e-9	Morning vs. evening chronotype;
SARC	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg07701084	chr6:150067640	NUP43	0.41	5.42	0.33	1.5e-7	Lung cancer;
SARC	cis	rs2439831	0.681	rs825740	chr15:43592408	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.05	11.82	0.61	1.4e-25	Lung cancer in ever smokers;
SARC	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg14893161	chr1:205819251	PM20D1	0.47	5.46	0.34	1.2e-7	Parkinson's disease;
SARC	cis	rs56104184	0.830	rs73061622	chr19:49358111	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.94	-8.43	-0.48	3.66e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg20891558	chr2:74357851	NA	0.69	9.54	0.53	1.97e-18	Gestational age at birth (maternal effect);
SARC	cis	rs2075371	1.000	rs2244700	chr7:133987374	A/G	cg20476274	chr7:133979776	SLC35B4	0.6	8.07	0.47	3.78e-14	Mean platelet volume;
SARC	cis	rs2120243	0.539	rs12486427	chr3:157113276	A/C	cg24825693	chr3:157122686	VEPH1	-0.46	-6.42	-0.39	7.47e-10	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs546131	0.600	rs525202	chr11:34821948	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.44	5.0	0.31	1.15e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs651907	0.557	rs34947019	chr3:101532235	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	5.74	0.35	2.98e-8	Colorectal cancer;
SARC	cis	rs921968	0.541	rs488767	chr2:219466860	G/T	cg02176678	chr2:219576539	TTLL4	0.46	6.8	0.41	8.55e-11	Mean corpuscular hemoglobin concentration;
SARC	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg24060327	chr5:131705240	SLC22A5	-0.72	-8.75	-0.5	4.31e-16	Acylcarnitine levels;
SARC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg09033563	chr22:24373618	LOC391322	-0.52	-6.42	-0.39	7.48e-10	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs240764	0.658	rs12210255	chr6:101187540	G/C	cg09795085	chr6:101329169	ASCC3	-0.49	-6.48	-0.39	5.39e-10	Neuroticism;
SARC	cis	rs9611565	0.569	rs6002328	chr22:41710034	T/C	cg03806693	chr22:41940476	POLR3H	-0.7	-9.19	-0.52	2.25e-17	Vitiligo;
SARC	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg05368731	chr17:41323189	NBR1	0.8	9.59	0.53	1.43e-18	Menopause (age at onset);
SARC	cis	rs2235642	0.928	rs1057610	chr16:1605537	T/C	cg26528668	chr16:1614120	IFT140	0.37	4.8	0.3	2.9e-6	Coronary artery disease;
SARC	cis	rs76419734	1.000	rs74917833	chr4:106643161	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.84	5.42	0.33	1.51e-7	Post bronchodilator FEV1;
SARC	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg16414030	chr3:133502952	NA	-0.4	-5.44	-0.34	1.36e-7	Iron status biomarkers;
SARC	cis	rs12586317	0.547	rs28577270	chr14:35498443	G/A	cg16230307	chr14:35515116	FAM177A1	1.02	11.85	0.61	1.18e-25	Psoriasis;
SARC	cis	rs7959452	0.640	rs11177599	chr12:69721970	G/A	cg22834771	chr12:69754056	YEATS4	-0.4	-5.27	-0.33	3.16e-7	Blood protein levels;
SARC	cis	rs7833790	0.963	rs1451997	chr8:82774053	A/T	cg17211192	chr8:82754475	SNX16	0.57	6.19	0.38	2.65e-9	Diastolic blood pressure;
SARC	cis	rs1062177	0.855	rs919263	chr5:151265853	A/G	cg00977110	chr5:151150581	G3BP1	0.56	5.89	0.36	1.32e-8	Preschool internalizing problems;
SARC	cis	rs6121246	0.821	rs6058448	chr20:30332396	C/T	cg13852791	chr20:30311386	BCL2L1	0.85	9.18	0.52	2.48e-17	Mean corpuscular hemoglobin;
SARC	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg06713675	chr4:122721982	EXOSC9	-0.51	-6.65	-0.4	2.12e-10	Type 2 diabetes;
SARC	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg00152838	chr16:24741724	TNRC6A	-0.59	-6.01	-0.37	7.23e-9	Intelligence (multi-trait analysis);
SARC	cis	rs11105298	0.891	rs12369195	chr12:89934972	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-5.43	-0.34	1.43e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs6893807	0.943	rs13166120	chr5:87948883	G/A	cg09002922	chr5:87956389	LOC645323	-0.43	-4.84	-0.3	2.36e-6	Body mass index;
SARC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg09373136	chr17:61933544	TCAM1	-0.4	-5.71	-0.35	3.37e-8	Prudent dietary pattern;
SARC	cis	rs526231	0.543	rs72785717	chr5:102333105	C/T	cg23492399	chr5:102201601	PAM	-0.5	-5.6	-0.34	5.9e-8	Primary biliary cholangitis;
SARC	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs3768617	0.510	rs7529465	chr1:183096880	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.82e-21	Fuchs's corneal dystrophy;
SARC	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg02733842	chr7:1102375	C7orf50	-0.41	-5.06	-0.31	8.66e-7	Bronchopulmonary dysplasia;
SARC	cis	rs6121246	0.738	rs6121242	chr20:30410877	T/C	cg13852791	chr20:30311386	BCL2L1	0.85	9.24	0.52	1.64e-17	Mean corpuscular hemoglobin;
SARC	cis	rs17401966	0.838	rs8019	chr1:10366487	T/G	cg15208524	chr1:10270712	KIF1B	0.48	5.56	0.34	7.51e-8	Hepatocellular carcinoma;
SARC	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg12373951	chr3:133503437	NA	0.37	5.3	0.33	2.68e-7	Iron status biomarkers;
SARC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	18.96	0.78	4.17e-49	Prudent dietary pattern;
SARC	cis	rs6580649	0.941	rs1859441	chr12:48423233	C/T	cg05342945	chr12:48394962	COL2A1	0.58	5.97	0.36	8.75e-9	Lung cancer;
SARC	cis	rs9916302	0.904	rs4795355	chr17:37427382	C/T	cg00129232	chr17:37814104	STARD3	-0.59	-7.37	-0.43	2.9e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs2273669	0.588	rs2145767	chr6:109296185	C/T	cg05315195	chr6:109294784	ARMC2	-0.59	-5.22	-0.32	4.01e-7	Prostate cancer;
SARC	cis	rs7726839	0.540	rs11738281	chr5:662547	T/C	cg07777115	chr5:623756	CEP72	-0.57	-5.04	-0.31	9.55e-7	Obesity-related traits;
SARC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg04234412	chr22:24373322	LOC391322	-0.52	-6.1	-0.37	4.44e-9	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7223966	1.000	rs8075422	chr17:61804686	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.47	-5.11	-0.32	6.78e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs12754538	0.850	rs17385519	chr1:8527520	C/T	cg13785123	chr1:8931135	ENO1	-0.44	-4.86	-0.3	2.16e-6	Subjective well-being;
SARC	cis	rs79839061	0.610	rs62297062	chr4:869698	C/T	cg07828340	chr4:882639	GAK	0.77	5.87	0.36	1.52e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7712401	0.715	rs6862366	chr5:122360158	G/C	cg19412675	chr5:122181750	SNX24	-0.42	-5.33	-0.33	2.33e-7	Mean platelet volume;
SARC	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg13206674	chr6:150067644	NUP43	0.43	5.61	0.34	5.83e-8	Lung cancer;
SARC	cis	rs1545257	0.505	rs958352	chr2:24634240	A/G	cg06627628	chr2:24431161	ITSN2	-0.56	-7.2	-0.43	8.28e-12	Sjögren's syndrome;
SARC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.11	-20.45	-0.8	6.59e-54	Prudent dietary pattern;
SARC	cis	rs2120243	0.539	rs12486427	chr3:157113276	A/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.39	5.07	0.32	8.25e-7	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs12950390	0.853	rs10445375	chr17:45864314	C/T	cg03474202	chr17:45855739	NA	0.42	6.73	0.4	1.33e-10	IgG glycosylation;
SARC	cis	rs4819052	0.766	rs4819035	chr21:46645715	A/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.58	6.22	0.38	2.31e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs5769765	0.526	rs5770722	chr22:50253220	G/C	cg03033257	chr22:50311977	ALG12;CRELD2	-0.54	-4.75	-0.3	3.58e-6	Schizophrenia;
SARC	cis	rs782590	0.818	rs2627782	chr2:55825352	A/G	cg18811423	chr2:55921094	PNPT1	0.56	7.97	0.46	6.83e-14	Metabolic syndrome;
SARC	cis	rs4805272	0.512	rs11879141	chr19:29320335	G/A	cg12756686	chr19:29218302	NA	0.59	6.59	0.4	2.85e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg17971929	chr21:40555470	PSMG1	-0.97	-13.52	-0.66	3.82e-31	Cognitive function;
SARC	cis	rs7560272	0.538	rs3980695	chr2:73939552	A/G	cg20560298	chr2:73613845	ALMS1	0.43	5.74	0.35	2.91e-8	Schizophrenia;
SARC	cis	rs798554	1.000	rs798563	chr7:2757867	A/C	cg04166393	chr7:2884313	GNA12	0.59	7.1	0.42	1.49e-11	Height;
SARC	cis	rs12142240	0.698	rs72677600	chr1:46834449	G/A	cg00530320	chr1:46809349	NSUN4	0.58	6.91	0.41	4.52e-11	Menopause (age at onset);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg20677521	chr2:32191527	MEMO1	0.45	6.35	0.38	1.12e-9	Thyroid stimulating hormone;
SARC	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg11843238	chr5:131593191	PDLIM4	0.41	5.13	0.32	6.04e-7	Breast cancer;
SARC	cis	rs9790314	0.905	rs6774276	chr3:160941318	C/T	cg03342759	chr3:160939853	NMD3	-0.62	-7.92	-0.46	9.63e-14	Morning vs. evening chronotype;
SARC	cis	rs11191270	0.554	rs10444022	chr10:104084889	A/G	cg15320455	chr10:103880129	LDB1	1.04	9.1	0.51	4.05e-17	Intelligence (multi-trait analysis);
SARC	cis	rs4332037	0.624	rs56256289	chr7:1892529	C/T	cg12591125	chr7:1885375	MAD1L1	0.47	5.04	0.31	9.4e-7	Bipolar disorder;
SARC	cis	rs2836950	0.772	rs62222988	chr21:40569508	T/C	cg11644478	chr21:40555479	PSMG1	-0.41	-4.76	-0.3	3.34e-6	Menarche (age at onset);
SARC	cis	rs748404	0.676	rs4401024	chr15:43650335	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.39	4.8	0.3	2.89e-6	Lung cancer;
SARC	cis	rs11583043	0.708	rs36023027	chr1:101575205	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.44	4.81	0.3	2.66e-6	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs2777491	0.915	rs7180418	chr15:41629502	A/C	cg01768344	chr15:41576519	LOC729082	0.45	4.97	0.31	1.31e-6	Ulcerative colitis;
SARC	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg14820908	chr5:178986412	RUFY1	0.36	5.25	0.33	3.42e-7	Lung cancer;
SARC	cis	rs742614	0.533	rs2103804	chr20:32425403	A/G	cg06304546	chr20:32448765	NA	0.55	7.14	0.42	1.17e-11	Stearic acid (18:0) levels;
SARC	trans	rs3780486	0.846	rs6476399	chr9:33123013	A/G	cg20290983	chr6:43655470	MRPS18A	1.14	23.61	0.84	9.56e-64	IgG glycosylation;
SARC	cis	rs892961	0.932	rs11658267	chr17:75411884	C/T	cg05865280	chr17:75406074	SEPT9	-0.55	-8.32	-0.48	7.49e-15	Airflow obstruction;
SARC	cis	rs763121	0.853	rs5750662	chr22:39072472	G/A	cg21395723	chr22:39101663	GTPBP1	0.54	6.04	0.37	6.17e-9	Menopause (age at onset);
SARC	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg07308232	chr7:1071921	C7orf50	-0.48	-5.98	-0.36	8.15e-9	Longevity;Endometriosis;
SARC	cis	rs2243480	1.000	rs160643	chr7:65558222	C/T	cg25894440	chr7:65020034	NA	-0.75	-5.83	-0.36	1.83e-8	Diabetic kidney disease;
SARC	cis	rs834603	0.575	rs2665775	chr7:47465387	C/T	cg23694490	chr7:47445681	TNS3	-0.33	-5.89	-0.36	1.34e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs6963495	0.818	rs818619	chr7:105172505	A/T	cg13798780	chr7:105162888	PUS7	0.48	4.79	0.3	2.98e-6	Bipolar disorder (body mass index interaction);
SARC	cis	rs11098499	0.863	rs7669520	chr4:120515278	T/C	cg24375607	chr4:120327624	NA	0.41	4.86	0.3	2.17e-6	Corneal astigmatism;
SARC	cis	rs17376456	0.809	rs13177800	chr5:93307350	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.59	5.28	0.33	2.98e-7	Diabetic retinopathy;
SARC	cis	rs7904368	0.806	rs7087360	chr10:16872337	C/A	cg23933602	chr10:16859644	RSU1	0.56	5.64	0.35	4.86e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs2011503	0.882	rs4808958	chr19:19571752	G/A	cg15839431	chr19:19639596	YJEFN3	-0.49	-4.82	-0.3	2.6e-6	Bipolar disorder;
SARC	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg03351412	chr1:154909251	PMVK	0.62	7.74	0.45	3.06e-13	Prostate cancer;
SARC	cis	rs7626444	0.625	rs2686593	chr3:196477401	G/A	cg12930392	chr3:196481615	PAK2	0.26	5.14	0.32	5.89e-7	Monocyte count;
SARC	cis	rs7089973	0.604	rs8181444	chr10:116588981	C/T	cg08188268	chr10:116634841	FAM160B1	0.28	4.77	0.3	3.18e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.95	-15.47	-0.71	1.34e-37	Chronic sinus infection;
SARC	cis	rs34779708	0.897	rs35784065	chr10:35353574	C/T	cg03585969	chr10:35415529	CREM	0.38	4.85	0.3	2.27e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs1678542	1.000	rs1678542	chr12:57968715	C/G	cg00677455	chr12:58241039	CTDSP2	-0.37	-4.94	-0.31	1.51e-6	Rheumatoid arthritis;
SARC	cis	rs11608355	0.515	rs2287184	chr12:109970251	T/C	cg05360138	chr12:110035743	NA	0.9	9.41	0.52	4.84e-18	Neuroticism;
SARC	cis	rs7208859	0.673	rs55658077	chr17:29156519	A/G	cg13385521	chr17:29058706	SUZ12P	0.87	7.83	0.46	1.76e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg27170947	chr2:26402098	FAM59B	-0.36	-4.73	-0.3	3.92e-6	Gut microbiome composition (summer);
SARC	cis	rs72945132	0.882	rs4261311	chr11:70132902	C/T	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.78	-0.35	2.39e-8	Coronary artery disease;
SARC	cis	rs2070488	1.000	rs1002675	chr3:38445226	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	13.94	0.67	1.59e-32	Electrocardiographic conduction measures;
SARC	cis	rs13161895	1.000	rs1102191	chr5:179416210	C/T	cg02702477	chr5:179499311	RNF130	0.63	5.92	0.36	1.15e-8	LDL cholesterol;
SARC	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg23248424	chr5:179741104	GFPT2	-0.49	-5.95	-0.36	9.85e-9	Height;
SARC	cis	rs1144333	0.655	rs1146649	chr1:76268803	A/G	cg03433033	chr1:76189801	ACADM	-0.58	-4.75	-0.3	3.54e-6	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs3768617	0.510	rs6424889	chr1:183091796	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.1	0.55	4.11e-20	Fuchs's corneal dystrophy;
SARC	cis	rs9487051	0.714	rs6902892	chr6:109627601	G/T	cg01475377	chr6:109611718	NA	-0.37	-5.36	-0.33	2.02e-7	Reticulocyte fraction of red cells;
SARC	cis	rs11122272	0.735	rs2491412	chr1:231535880	A/T	cg06096015	chr1:231504339	EGLN1	0.36	5.42	0.33	1.51e-7	Hemoglobin concentration;
SARC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.96	10.21	0.56	1.81e-20	Platelet count;
SARC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg26338869	chr17:61819248	STRADA	0.79	10.45	0.56	3.32e-21	Prudent dietary pattern;
SARC	cis	rs6570726	0.846	rs397311	chr6:145806701	C/T	cg23711669	chr6:146136114	FBXO30	-0.8	-12.86	-0.64	6.04e-29	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10992471	0.603	rs7033979	chr9:95223980	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.34	-0.33	2.25e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs3771570	1.000	rs73002147	chr2:242302934	T/C	cg21155796	chr2:242212141	HDLBP	0.68	6.1	0.37	4.3e-9	Prostate cancer;
SARC	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg14664628	chr15:75095509	CSK	-0.42	-5.07	-0.32	7.94e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	cis	rs698813	0.763	rs698764	chr2:44573658	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.66	7.71	0.45	3.74e-13	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs4243830	0.850	rs12760251	chr1:6601336	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.88	-9.05	-0.51	5.81e-17	Body mass index;
SARC	cis	rs9399135	0.507	rs2072825	chr6:135253451	A/G	cg24558204	chr6:135376177	HBS1L	-0.53	-6.59	-0.4	2.86e-10	Red blood cell count;
SARC	cis	rs7011049	1.000	rs72643588	chr8:53849335	C/T	cg26025543	chr8:53854495	NA	0.6	5.39	0.33	1.73e-7	Systolic blood pressure;
SARC	cis	rs10504073	0.647	rs62507245	chr8:50006939	A/T	cg00325661	chr8:49890786	NA	0.55	7.4	0.44	2.49e-12	Blood metabolite ratios;
SARC	cis	rs3892630	0.500	rs6510301	chr19:33359791	A/T	cg22980127	chr19:33182716	NUDT19	0.53	5.21	0.32	4.26e-7	Red blood cell traits;
SARC	cis	rs921968	0.648	rs538483	chr2:219458656	T/C	cg02176678	chr2:219576539	TTLL4	0.35	5.34	0.33	2.2e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg18252515	chr7:66147081	NA	-1.3	-11.45	-0.6	2.31e-24	Diabetic kidney disease;
SARC	cis	rs10870270	0.956	rs4880405	chr10:133787021	G/A	cg26149184	chr10:133730230	NA	0.49	5.12	0.32	6.37e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs12887734	0.524	rs12588797	chr14:104300020	C/T	cg26031613	chr14:104095156	KLC1	0.44	5.14	0.32	5.78e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	cis	rs6582630	0.537	rs6582500	chr12:38534206	G/A	cg26384229	chr12:38710491	ALG10B	0.88	13.1	0.65	9.25e-30	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2230307	0.831	rs558270	chr1:100499285	G/C	cg24955406	chr1:100503596	HIAT1	0.67	5.5	0.34	9.76e-8	Carotid intima media thickness;
SARC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg11494091	chr17:61959527	GH2	0.54	8.07	0.47	3.81e-14	Prudent dietary pattern;
SARC	cis	rs72792276	0.818	rs57249773	chr5:127463166	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	6.19	0.38	2.7e-9	Red cell distribution width;
SARC	cis	rs9486719	0.843	rs2499792	chr6:96846264	A/C	cg06623918	chr6:96969491	KIAA0776	0.75	7.39	0.44	2.65e-12	Migraine;Coronary artery disease;
SARC	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg11987759	chr7:65425863	GUSB	-0.48	-5.87	-0.36	1.51e-8	Aortic root size;
SARC	cis	rs72781680	0.898	rs111460347	chr2:24018833	G/A	cg08917208	chr2:24149416	ATAD2B	0.76	7.11	0.42	1.4e-11	Lymphocyte counts;
SARC	cis	rs9486715	1.000	rs6905568	chr6:97066382	T/C	cg06623918	chr6:96969491	KIAA0776	-0.81	-11.12	-0.59	2.56e-23	Headache;
SARC	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg22974920	chr21:40686053	BRWD1	-0.44	-4.75	-0.3	3.56e-6	Cognitive function;
SARC	cis	rs6545883	0.929	rs778140	chr2:61682976	C/T	cg15711740	chr2:61764176	XPO1	-0.43	-5.13	-0.32	6.01e-7	Tuberculosis;
SARC	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg21724239	chr8:58056113	NA	0.6	6.37	0.38	1.03e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg05861140	chr6:150128134	PCMT1	-0.38	-4.85	-0.3	2.22e-6	Lung cancer;
SARC	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg12463550	chr7:65579703	CRCP	0.5	5.93	0.36	1.09e-8	Aortic root size;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg11801651	chr14:74551261	LIN52;ALDH6A1	0.51	6.83	0.41	7.15e-11	Chemerin levels;
SARC	cis	rs72634258	0.945	rs441597	chr1:8080895	A/G	cg00042356	chr1:8021962	PARK7	0.62	5.88	0.36	1.45e-8	Inflammatory bowel disease;
SARC	cis	rs2576037	0.899	rs2571034	chr18:44578565	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.65	-9.06	-0.51	5.33e-17	Personality dimensions;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg01149132	chr14:68141218	VTI1B	0.46	6.48	0.39	5.46e-10	Chemerin levels;
SARC	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	-0.93	-11.59	-0.6	7.8e-25	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs3808502	0.549	rs4841564	chr8:11425809	T/G	cg21775007	chr8:11205619	TDH	-0.46	-6.19	-0.38	2.7e-9	Neuroticism;
SARC	cis	rs6456156	0.586	rs12525855	chr6:167480013	T/G	cg07741184	chr6:167504864	NA	0.37	7.09	0.42	1.6e-11	Primary biliary cholangitis;
SARC	cis	rs240764	0.631	rs6932158	chr6:101246010	T/C	cg09795085	chr6:101329169	ASCC3	-0.45	-5.85	-0.36	1.64e-8	Neuroticism;
SARC	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg08219700	chr8:58056026	NA	0.6	7.58	0.44	8.06e-13	Developmental language disorder (linguistic errors);
SARC	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg27121462	chr16:89883253	FANCA	0.67	10.72	0.57	4.78e-22	Vitiligo;
SARC	cis	rs7551222	0.752	rs4252694	chr1:204499056	A/G	cg20240347	chr1:204465584	NA	-0.34	-6.04	-0.37	5.97e-9	Schizophrenia;
SARC	cis	rs2242194	0.816	rs11264296	chr1:154994750	T/C	cg06221963	chr1:154839813	KCNN3	-0.4	-6.08	-0.37	4.9e-9	Schizophrenia;
SARC	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg03264133	chr6:25882463	NA	-0.51	-6.43	-0.39	7.31e-10	Intelligence (multi-trait analysis);
SARC	cis	rs11098499	0.954	rs12506546	chr4:120301618	T/C	cg09307838	chr4:120376055	NA	0.89	12.27	0.63	4.85e-27	Corneal astigmatism;
SARC	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg08677398	chr8:58056175	NA	0.44	5.24	0.32	3.59e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg05863683	chr7:1912471	MAD1L1	0.32	4.71	0.3	4.18e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs4595586	0.545	rs12816546	chr12:39398913	C/T	cg26384229	chr12:38710491	ALG10B	0.49	5.81	0.36	2.01e-8	Morning vs. evening chronotype;
SARC	cis	rs12148488	0.966	rs12899062	chr15:75347641	A/C	cg17294928	chr15:75287854	SCAMP5	-0.49	-6.38	-0.39	9.36e-10	Caffeine consumption;
SARC	cis	rs9326248	0.581	rs10892063	chr11:116896155	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.68	8.53	0.49	1.91e-15	Blood protein levels;
SARC	trans	rs3780486	0.846	rs10813948	chr9:33121570	G/A	cg20290983	chr6:43655470	MRPS18A	1.15	23.73	0.84	4.12e-64	IgG glycosylation;
SARC	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs11098499	0.909	rs28884220	chr4:120307211	A/G	cg09307838	chr4:120376055	NA	0.91	12.95	0.65	2.99e-29	Corneal astigmatism;
SARC	cis	rs2204008	0.837	rs1589395	chr12:38420405	C/T	cg26384229	chr12:38710491	ALG10B	0.84	12.04	0.62	2.79e-26	Bladder cancer;
SARC	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg11644478	chr21:40555479	PSMG1	-1.05	-14.55	-0.69	1.53e-34	Cognitive function;
SARC	cis	rs7756236	0.521	rs6907793	chr6:36625206	A/G	cg08179530	chr6:36648295	CDKN1A	0.53	6.45	0.39	6.33e-10	QRS duration;
SARC	cis	rs16954776	1	rs16954776	chr13:98700617	C/T	cg17579214	chr13:98085375	RAP2A	-0.79	-4.91	-0.31	1.72e-6	Smooth-surface caries;
SARC	cis	rs933688	1.000	rs12655973	chr5:90736537	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.99	12.66	0.64	2.74e-28	Smoking behavior;
SARC	trans	rs61931739	0.517	rs12816252	chr12:34067693	G/A	cg26384229	chr12:38710491	ALG10B	0.87	12.36	0.63	2.53e-27	Morning vs. evening chronotype;
SARC	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg05863683	chr7:1912471	MAD1L1	0.31	4.73	0.3	3.85e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs854765	0.547	rs6502633	chr17:17941037	G/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.42	5.24	0.32	3.6e-7	Total body bone mineral density;
SARC	cis	rs9611519	0.964	rs4820428	chr22:41537589	C/T	cg17376030	chr22:41985996	PMM1	-0.46	-5.26	-0.33	3.29e-7	Neuroticism;
SARC	cis	rs2120019	0.505	rs77456790	chr15:75330095	G/T	cg00629941	chr15:75287862	SCAMP5	-0.76	-5.33	-0.33	2.32e-7	Blood trace element (Zn levels);
SARC	trans	rs61931739	0.500	rs10844864	chr12:34532468	A/G	cg26384229	chr12:38710491	ALG10B	0.85	12.63	0.64	3.4e-28	Morning vs. evening chronotype;
SARC	cis	rs921968	0.565	rs6436082	chr2:219639430	A/G	cg02176678	chr2:219576539	TTLL4	-0.33	-5.03	-0.31	9.92e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs7772486	0.754	rs4360151	chr6:146255079	A/C	cg05347473	chr6:146136440	FBXO30	-0.46	-6.3	-0.38	1.46e-9	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg03912614	chr20:33734751	EDEM2	0.5	6.45	0.39	6.3e-10	Breast cancer;
SARC	cis	rs240764	0.658	rs6570922	chr6:101177262	C/T	cg09795085	chr6:101329169	ASCC3	-0.52	-6.86	-0.41	6.23e-11	Neuroticism;
SARC	cis	rs11112613	0.713	rs2374502	chr12:105938939	T/C	cg03607813	chr12:105948248	NA	0.53	7.05	0.42	2.03e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs6088590	0.523	rs6088536	chr20:33189106	T/C	cg08999081	chr20:33150536	PIGU	0.45	6.82	0.41	7.77e-11	Coronary artery disease;
SARC	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg17971929	chr21:40555470	PSMG1	0.98	13.6	0.67	2.19e-31	Cognitive function;
SARC	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg15049968	chr18:44337910	ST8SIA5	-0.32	-4.98	-0.31	1.26e-6	Personality dimensions;
SARC	cis	rs6570726	1.000	rs1935617	chr6:145943326	C/T	cg05220968	chr6:146057943	EPM2A	-0.3	-5.07	-0.32	7.95e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1348850	0.598	rs1405717	chr2:178500101	G/T	cg23306229	chr2:178417860	TTC30B	0.52	5.88	0.36	1.41e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg16325326	chr1:53192061	ZYG11B	-0.91	-15.6	-0.71	4.61e-38	Monocyte count;
SARC	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	11.64	0.61	5.7e-25	Alzheimer's disease;
SARC	cis	rs7568458	0.905	rs10172544	chr2:85788270	C/A	cg17127132	chr2:85788382	GGCX	0.41	5.24	0.32	3.62e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs1728785	1.000	rs1364109	chr16:68595505	T/C	cg02972257	chr16:68554789	NA	-0.45	-5.32	-0.33	2.48e-7	Ulcerative colitis;
SARC	cis	rs10754283	0.967	rs7519971	chr1:90108743	G/A	cg21401794	chr1:90099060	LRRC8C	0.59	8.09	0.47	3.24e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs858239	1.000	rs199347	chr7:23293746	A/G	cg23682824	chr7:23144976	KLHL7	0.62	7.64	0.45	5.68e-13	Cerebrospinal fluid biomarker levels;
SARC	cis	rs5753618	0.561	rs13054220	chr22:31704492	A/G	cg13145458	chr22:31556086	RNF185	-0.47	-4.97	-0.31	1.3e-6	Colorectal cancer;
SARC	cis	rs9381040	0.626	rs2272986	chr6:41037778	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.48	-5.51	-0.34	9.45e-8	Alzheimer's disease (late onset);
SARC	cis	rs3820928	0.845	rs7570869	chr2:227878818	A/C	cg05526886	chr2:227700861	RHBDD1	-0.51	-6.12	-0.37	3.85e-9	Pulmonary function;
SARC	cis	rs4820539	1.000	rs756631	chr22:23463183	A/G	cg14186256	chr22:23484241	RTDR1	0.89	14.2	0.68	2.26e-33	Bone mineral density;
SARC	cis	rs7084402	0.565	rs10826200	chr10:60333847	T/C	cg07615347	chr10:60278583	BICC1	0.36	4.81	0.3	2.71e-6	Refractive error;
SARC	cis	rs3126085	0.935	rs34188926	chr1:152293481	A/C	cg26876637	chr1:152193138	HRNR	-0.5	-5.58	-0.34	6.59e-8	Atopic dermatitis;
SARC	cis	rs240764	0.711	rs240148	chr6:101076767	C/T	cg09795085	chr6:101329169	ASCC3	0.45	5.66	0.35	4.47e-8	Neuroticism;
SARC	cis	rs796364	0.951	rs12613687	chr2:200999256	C/T	cg23649088	chr2:200775458	C2orf69	-0.59	-5.78	-0.35	2.43e-8	Schizophrenia;
SARC	cis	rs10916814	0.632	rs7524492	chr1:20902750	G/A	cg24502330	chr1:20914028	CDA	-0.28	-4.83	-0.3	2.52e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs6570726	0.791	rs446362	chr6:145878716	G/T	cg05347473	chr6:146136440	FBXO30	0.54	7.57	0.44	8.62e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg13206674	chr6:150067644	NUP43	0.44	5.72	0.35	3.23e-8	Lung cancer;
SARC	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg22903471	chr2:27725779	GCKR	-0.49	-7.36	-0.43	3.22e-12	Total body bone mineral density;
SARC	cis	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg09021430	chr5:549028	NA	-0.43	-5.56	-0.34	7.26e-8	Obesity-related traits;
SARC	cis	rs2599510	0.811	rs62136345	chr2:32807223	G/T	cg02381751	chr2:32503542	YIPF4	0.46	5.62	0.35	5.53e-8	Interleukin-18 levels;
SARC	cis	rs4808199	0.894	rs9304960	chr19:19465529	G/A	cg03709012	chr19:19516395	GATAD2A	1.13	11.33	0.6	5.5e-24	Nonalcoholic fatty liver disease;
SARC	cis	rs854765	0.724	rs62072049	chr17:17906520	T/C	cg16928487	chr17:17741425	SREBF1	-0.23	-4.81	-0.3	2.66e-6	Total body bone mineral density;
SARC	cis	rs7666738	0.546	rs1863602	chr4:98909304	T/C	cg05340658	chr4:99064831	C4orf37	0.59	7.24	0.43	6.6e-12	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2197308	0.659	rs11181327	chr12:37903171	C/T	cg13010199	chr12:38710504	ALG10B	-0.68	-9.06	-0.51	5.6e-17	Morning vs. evening chronotype;
SARC	cis	rs2200578	1.000	rs60025964	chr2:99880577	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.56	5.35	0.33	2.07e-7	IgG glycosylation;
SARC	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg01475735	chr3:40494733	NA	-0.46	-5.21	-0.32	4.13e-7	Renal cell carcinoma;
SARC	cis	rs2933343	1.000	rs2630252	chr3:128624772	T/C	cg25356066	chr3:128598488	ACAD9	0.59	6.6	0.4	2.79e-10	IgG glycosylation;
SARC	cis	rs17209837	1.000	rs45554032	chr7:87078547	G/T	cg00919237	chr7:87102261	ABCB4	-0.44	-4.76	-0.3	3.42e-6	Gallbladder cancer;
SARC	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.49	5.84	0.36	1.74e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs11718455	0.920	rs13084408	chr3:44008967	G/A	cg21419209	chr3:44054225	NA	-0.41	-4.99	-0.31	1.16e-6	Coronary artery disease;
SARC	cis	rs3820928	0.839	rs58580037	chr2:227876274	G/T	cg05526886	chr2:227700861	RHBDD1	-0.5	-5.99	-0.37	8.01e-9	Pulmonary function;
SARC	cis	rs7772486	0.806	rs2247317	chr6:146217570	C/T	cg23711669	chr6:146136114	FBXO30	0.76	11.76	0.61	2.22e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	7.35	0.43	3.35e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs61931739	0.500	rs11615231	chr12:34413330	T/C	cg26384229	chr12:38710491	ALG10B	0.92	13.84	0.67	3.3e-32	Morning vs. evening chronotype;
SARC	cis	rs7772486	0.686	rs857880	chr6:145971115	T/C	cg05220968	chr6:146057943	EPM2A	0.28	4.82	0.3	2.6e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs36051895	0.586	rs12342421	chr9:5065750	G/C	cg02405213	chr9:5042618	JAK2	-0.48	-5.41	-0.33	1.58e-7	Pediatric autoimmune diseases;
SARC	cis	rs10046574	0.831	rs111522774	chr7:135135327	C/A	cg27474649	chr7:135195673	CNOT4	0.88	7.17	0.43	9.89e-12	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs5167	0.505	rs7257468	chr19:45453144	C/T	cg13119609	chr19:45449297	APOC2	0.5	8.43	0.48	3.6e-15	Blood protein levels;
SARC	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg05332525	chr7:65337924	VKORC1L1	0.43	4.85	0.3	2.28e-6	Calcium levels;
SARC	trans	rs11098499	0.863	rs1552092	chr4:120488496	C/T	cg25214090	chr10:38739885	LOC399744	0.57	7.25	0.43	6.27e-12	Corneal astigmatism;
SARC	cis	rs4742903	0.527	rs10991147	chr9:106951059	T/C	cg14250997	chr9:106856677	SMC2	0.39	4.85	0.3	2.3e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs2251381	0.750	rs2251186	chr21:30528880	G/A	cg08807101	chr21:30365312	RNF160	0.77	10.34	0.56	6.99e-21	Selective IgA deficiency;
SARC	cis	rs9389248	0.690	rs2064101	chr6:135250530	G/A	cg24558204	chr6:135376177	HBS1L	-0.52	-6.31	-0.38	1.39e-9	High light scatter reticulocyte percentage of red cells;
SARC	cis	rs17376456	0.877	rs10073039	chr5:93467709	A/G	cg21475434	chr5:93447410	FAM172A	0.86	7.77	0.45	2.57e-13	Diabetic retinopathy;
SARC	cis	rs2204008	0.640	rs11520199	chr12:38211026	T/C	cg13010199	chr12:38710504	ALG10B	0.78	10.64	0.57	8.61e-22	Bladder cancer;
SARC	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg11987759	chr7:65425863	GUSB	0.57	7.53	0.44	1.14e-12	Aortic root size;
SARC	cis	rs6964587	1.000	rs7800582	chr7:91701346	G/A	cg17063962	chr7:91808500	NA	0.96	16.21	0.73	4.33e-40	Breast cancer;
SARC	cis	rs7264396	0.690	rs2425172	chr20:34443893	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-7.07	-0.42	1.76e-11	Total cholesterol levels;
SARC	cis	rs7633770	0.841	rs11709936	chr3:46680483	C/G	cg11219411	chr3:46661640	NA	0.47	8.03	0.47	4.87e-14	Coronary artery disease;
SARC	trans	rs9325144	0.560	rs11183189	chr12:38683770	T/A	cg23762105	chr12:34175262	ALG10	-0.53	-6.86	-0.41	6e-11	Morning vs. evening chronotype;
SARC	trans	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg06437703	chr8:37914619	EIF4EBP1	-0.59	-7.14	-0.42	1.21e-11	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs3771570	0.901	rs73006381	chr2:242406654	G/C	cg21155796	chr2:242212141	HDLBP	0.64	5.98	0.36	8.5e-9	Prostate cancer;
SARC	cis	rs1865760	0.566	rs9358904	chr6:26068566	C/T	cg16482183	chr6:26056742	HIST1H1C	0.47	5.91	0.36	1.23e-8	Height;
SARC	trans	rs2055729	0.645	rs12544019	chr8:9742578	T/C	cg06636001	chr8:8085503	FLJ10661	0.58	6.42	0.39	7.57e-10	Multiple myeloma (hyperdiploidy);
SARC	cis	rs2153535	0.580	rs9406171	chr6:8515362	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	8.21	0.47	1.56e-14	Motion sickness;
SARC	trans	rs1814175	0.645	rs28549248	chr11:50042740	C/T	cg15704280	chr7:45808275	SEPT13	-0.89	-14.15	-0.68	3.23e-33	Height;
SARC	trans	rs1814175	0.817	rs1319547	chr11:49916705	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-18.24	-0.77	8.77e-47	Height;
SARC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg09436375	chr6:42928200	GNMT	-0.36	-5.56	-0.34	7.26e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg11301795	chr4:187892539	NA	-0.7	-10.45	-0.56	3.32e-21	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg24829409	chr8:58192753	C8orf71	-0.62	-6.42	-0.39	7.57e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6089584	0.566	rs7274240	chr20:60622004	C/T	cg06108461	chr20:60628389	TAF4	-0.7	-9.32	-0.52	8.96e-18	Body mass index;
SARC	cis	rs16948098	1	rs16948098	chr15:44219607	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	6.06	0.37	5.44e-9	Serum albumin level;
SARC	cis	rs6911965	0.641	rs77980283	chr6:24485813	C/T	cg20631270	chr6:24437470	GPLD1	0.51	4.82	0.3	2.59e-6	Hematological and biochemical traits;
SARC	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg00745463	chr17:30367425	LRRC37B	-0.63	-5.03	-0.31	9.84e-7	Hip circumference adjusted for BMI;
SARC	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg12310025	chr6:25882481	NA	-0.52	-6.61	-0.4	2.54e-10	Intelligence (multi-trait analysis);
SARC	cis	rs10089	1.000	rs10061367	chr5:127449021	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	10.32	0.56	8.06e-21	Ileal carcinoids;
SARC	cis	rs35213789	0.878	rs7790084	chr7:69565340	G/A	cg10619644	chr7:69149951	AUTS2	0.41	5.07	0.32	8.07e-7	Childhood ear infection;
SARC	cis	rs4974559	1.000	rs4974559	chr4:1380848	C/T	cg02980000	chr4:1222292	CTBP1	-0.55	-5.95	-0.36	9.95e-9	Systolic blood pressure;
SARC	cis	rs8114671	0.804	rs3803936	chr20:33632775	T/C	cg24642439	chr20:33292090	TP53INP2	-0.5	-5.87	-0.36	1.48e-8	Height;
SARC	cis	rs17270561	0.609	rs1179086	chr6:25791745	A/T	cg17691542	chr6:26056736	HIST1H1C	0.45	5.49	0.34	1.05e-7	Iron status biomarkers;
SARC	cis	rs12142240	0.738	rs67545510	chr1:46806242	G/T	cg14993813	chr1:46806288	NSUN4	-0.53	-5.62	-0.35	5.53e-8	Menopause (age at onset);
SARC	cis	rs73206853	0.841	rs17619763	chr12:110645829	C/T	cg10860002	chr12:110842031	ANAPC7	0.65	5.13	0.32	5.97e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg08219700	chr8:58056026	NA	0.62	6.52	0.39	4.28e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs4975616	0.804	rs381949	chr5:1322468	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.52	-7.41	-0.44	2.25e-12	Lung cancer;
SARC	cis	rs8141529	0.764	rs5752812	chr22:29225603	T/A	cg15103426	chr22:29168792	CCDC117	0.67	8.75	0.5	4.51e-16	Lymphocyte counts;
SARC	cis	rs7044106	0.708	rs920745	chr9:123429943	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	5.44	0.34	1.32e-7	Hip circumference adjusted for BMI;
SARC	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg00149659	chr3:10157352	C3orf10	0.69	6.44	0.39	6.6e-10	Alzheimer's disease;
SARC	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	6.41	0.39	8.11e-10	Platelet count;
SARC	cis	rs2304069	1.000	rs10072275	chr5:149401596	T/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.89	9.76	0.54	4.33e-19	HIV-1 control;
SARC	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg22903471	chr2:27725779	GCKR	-0.43	-6.37	-0.39	1.01e-9	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs17666538	1.000	rs57896286	chr8:571479	T/C	cg19660806	chr8:588740	NA	-0.63	-4.87	-0.3	2.07e-6	IgG glycosylation;
SARC	cis	rs9815354	1.000	rs6768128	chr3:41865080	G/A	cg03022575	chr3:42003672	ULK4	0.57	5.32	0.33	2.38e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6910061	0.830	rs7762961	chr6:11109669	A/G	cg27233058	chr6:11094804	LOC221710	-0.6	-5.58	-0.34	6.72e-8	Diabetic kidney disease;
SARC	cis	rs7089973	0.604	rs11819372	chr10:116594934	A/G	cg03647239	chr10:116582469	FAM160B1	0.56	7.35	0.43	3.25e-12	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs9486719	0.843	rs3849198	chr6:97036539	C/A	cg06623918	chr6:96969491	KIAA0776	-0.79	-8.88	-0.5	1.86e-16	Migraine;Coronary artery disease;
SARC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg11203670	chr7:100026453	MEPCE;ZCWPW1	0.54	5.26	0.33	3.24e-7	Platelet count;
SARC	cis	rs6665290	0.901	rs61834005	chr1:227202789	C/T	cg14016676	chr1:227182615	CDC42BPA	0.37	5.31	0.33	2.54e-7	Myeloid white cell count;
SARC	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg16479474	chr6:28041457	NA	-0.38	-5.69	-0.35	3.78e-8	Depression;
SARC	cis	rs72945132	0.660	rs67433166	chr11:70121604	T/A	cg00319359	chr11:70116639	PPFIA1	0.68	6.37	0.39	1.01e-9	Coronary artery disease;
SARC	cis	rs11608355	0.545	rs918107	chr12:109904198	C/T	cg05360138	chr12:110035743	NA	-0.94	-9.48	-0.53	3.14e-18	Neuroticism;
SARC	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg26818010	chr10:134567672	INPP5A	-0.52	-5.73	-0.35	3.14e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs33912345	0.695	rs1254301	chr14:60885149	T/C	cg27398547	chr14:60952738	C14orf39	-0.39	-4.78	-0.3	3.09e-6	Glaucoma (high intraocular pressure);
SARC	cis	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg05084668	chr3:125655381	ALG1L	-0.49	-5.49	-0.34	1.03e-7	Blood pressure (smoking interaction);
SARC	cis	rs735539	0.555	rs2762990	chr13:21371427	T/C	cg16922012	chr13:21400325	XPO4	-0.39	-5.47	-0.34	1.18e-7	Dental caries;
SARC	cis	rs7474896	0.583	rs1735621	chr10:38167723	G/T	cg25427524	chr10:38739819	LOC399744	0.51	6.3	0.38	1.48e-9	Obesity (extreme);
SARC	cis	rs56011263	0.687	rs4690188	chr4:703930	G/C	cg05835009	chr4:710272	PCGF3	0.57	6.67	0.4	1.89e-10	White blood cell count;
SARC	cis	rs12190007	0.508	rs9406321	chr6:169726841	A/T	cg16388071	chr6:169726476	NA	0.58	7.97	0.46	6.83e-14	Obesity-related traits;
SARC	cis	rs78456975	1.000	rs10177095	chr2:1570976	C/A	cg12573674	chr2:1569213	NA	-0.54	-4.91	-0.31	1.71e-6	Placebo response in major depressive disorder (% change in symptom score);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg07372659	chr6:20866952	CDKAL1	0.47	6.29	0.38	1.57e-9	Thyroid stimulating hormone;
SARC	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg06420487	chr17:61919686	SMARCD2	0.48	5.48	0.34	1.1e-7	Height;
SARC	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg06420487	chr17:61919686	SMARCD2	0.44	4.86	0.3	2.2e-6	Height;
SARC	cis	rs7481584	0.624	rs412842	chr11:3047448	A/G	cg25174290	chr11:3078921	CARS	-0.59	-8.27	-0.48	1.02e-14	Calcium levels;
SARC	cis	rs6570726	0.935	rs365658	chr6:145844588	C/T	cg05347473	chr6:146136440	FBXO30	0.48	6.47	0.39	5.7e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7113850	0.541	rs7118538	chr11:24223615	C/T	ch.11.24196551F	chr11:24239977	NA	0.74	5.75	0.35	2.84e-8	Bone fracture in osteoporosis;
SARC	cis	rs1185460	0.967	rs4454730	chr11:118937444	G/A	cg01677386	chr11:118938358	VPS11	-0.4	-4.89	-0.31	1.85e-6	Coronary artery disease;
SARC	cis	rs9611519	1.000	rs5758268	chr22:41622419	A/T	cg03806693	chr22:41940476	POLR3H	-0.56	-6.84	-0.41	6.82e-11	Neuroticism;
SARC	cis	rs10751667	0.600	rs10902264	chr11:1003523	G/A	cg20946044	chr11:1010712	AP2A2	-0.35	-4.99	-0.31	1.16e-6	Alzheimer's disease (late onset);
SARC	cis	rs861020	0.630	rs655713	chr1:210006438	C/T	cg23166289	chr1:210001082	C1orf107	0.39	4.74	0.3	3.66e-6	Orofacial clefts;
SARC	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg22535103	chr8:58192502	C8orf71	-0.81	-9.35	-0.52	7.44e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs55883249	1.000	rs11692112	chr2:9723732	G/T	cg23886495	chr2:9695866	ADAM17	0.69	6.98	0.42	3.12e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs1966248	0.543	rs6909803	chr6:134111198	C/T	cg25632230	chr6:134101081	NA	-0.52	-7.07	-0.42	1.82e-11	Coronary artery disease;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg18141365	chr7:33169015	BBS9	-0.87	-7.23	-0.43	6.86e-12	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6665290	0.935	rs1929864	chr1:227195500	T/G	cg14016676	chr1:227182615	CDC42BPA	0.38	5.55	0.34	7.68e-8	Myeloid white cell count;
SARC	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg19223190	chr17:80058835	NA	0.44	6.19	0.38	2.67e-9	Life satisfaction;
SARC	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg11062466	chr8:58055876	NA	0.56	5.67	0.35	4.19e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg05236768	chr16:3532912	NAT15	-0.48	-6.59	-0.4	2.94e-10	Electrocardiographic conduction measures;
SARC	trans	rs75804782	0.641	rs57080728	chr2:239350487	T/C	cg01134436	chr17:81009848	B3GNTL1	0.86	6.23	0.38	2.11e-9	Morning vs. evening chronotype;Chronotype;
SARC	cis	rs7246865	0.510	rs34833670	chr19:17172983	T/C	cg16202187	chr19:17186497	HAUS8;MYO9B	0.39	4.77	0.3	3.2e-6	Reticulocyte fraction of red cells;
SARC	cis	rs4588572	0.643	rs13359053	chr5:77690224	T/C	cg11547950	chr5:77652471	NA	0.4	4.89	0.31	1.88e-6	Triglycerides;
SARC	cis	rs9916302	0.706	rs2338799	chr17:37513941	G/A	cg15445000	chr17:37608096	MED1	-0.47	-5.08	-0.32	7.63e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs7589342	0.628	rs62152201	chr2:106411664	C/T	cg16077055	chr2:106428750	NCK2	0.32	5.42	0.33	1.5e-7	Addiction;
SARC	cis	rs2295359	0.963	rs12030867	chr1:67627620	T/C	cg08029281	chr1:67600428	NA	0.36	4.94	0.31	1.52e-6	Psoriasis;
SARC	cis	rs6089584	0.586	rs4925216	chr20:60599923	G/A	cg23262073	chr20:60523788	NA	-0.36	-5.43	-0.33	1.44e-7	Body mass index;
SARC	cis	rs9815354	0.812	rs11129935	chr3:41985203	A/C	cg03022575	chr3:42003672	ULK4	0.72	6.26	0.38	1.79e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2806561	0.704	rs856510	chr1:23524407	A/C	cg12483005	chr1:23474871	LUZP1	0.47	6.11	0.37	4.05e-9	Height;
SARC	cis	rs2153535	0.542	rs9505465	chr6:8510846	C/T	cg07606381	chr6:8435919	SLC35B3	0.79	11.05	0.59	4.27e-23	Motion sickness;
SARC	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.43	-5.4	-0.33	1.65e-7	Lymphocyte counts;
SARC	trans	rs1994135	0.692	rs1579909	chr12:33694780	T/C	cg26384229	chr12:38710491	ALG10B	0.69	8.33	0.48	6.93e-15	Resting heart rate;
SARC	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	10.47	0.57	2.77e-21	Platelet count;
SARC	cis	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg06212747	chr3:49208901	KLHDC8B	0.58	5.74	0.35	2.88e-8	Menarche (age at onset);
SARC	cis	rs742614	0.533	rs6120395	chr20:32451693	A/G	cg06304546	chr20:32448765	NA	-0.54	-6.99	-0.42	2.95e-11	Stearic acid (18:0) levels;
SARC	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs2777491	0.957	rs8027626	chr15:41711514	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.81	-11.71	-0.61	3.25e-25	Ulcerative colitis;
SARC	cis	rs7586879	0.828	rs10195271	chr2:25108650	A/C	cg04586622	chr2:25135609	ADCY3	-0.3	-5.01	-0.31	1.09e-6	Body mass index;
SARC	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg09455208	chr3:40491958	NA	0.39	5.67	0.35	4.15e-8	Renal cell carcinoma;
SARC	trans	rs7824557	0.751	rs2099456	chr8:11127001	A/C	cg06636001	chr8:8085503	FLJ10661	0.54	6.61	0.4	2.63e-10	Retinal vascular caliber;
SARC	cis	rs7681440	0.904	rs17192189	chr4:90774928	A/C	cg02192967	chr4:90758406	SNCA	-0.34	-4.78	-0.3	3.15e-6	Dementia with Lewy bodies;
SARC	trans	rs2727020	0.658	rs4980440	chr11:49386017	C/T	cg15704280	chr7:45808275	SEPT13	-0.85	-13.78	-0.67	5.21e-32	Coronary artery disease;
SARC	cis	rs35213789	0.878	rs12698843	chr7:69545755	C/A	cg10619644	chr7:69149951	AUTS2	0.42	5.13	0.32	5.97e-7	Childhood ear infection;
SARC	cis	rs1707322	1.000	rs785480	chr1:46492164	C/G	cg06784218	chr1:46089804	CCDC17	0.34	5.84	0.36	1.78e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7647973	0.626	rs9835157	chr3:49797769	G/A	cg13072238	chr3:49761600	GMPPB	0.6	6.16	0.37	3.16e-9	Menarche (age at onset);
SARC	cis	rs6714710	0.535	rs3192177	chr2:98354511	G/A	cg26665480	chr2:98280029	ACTR1B	0.53	6.78	0.41	9.72e-11	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs6714710	0.603	rs2278700	chr2:98427382	T/C	cg26665480	chr2:98280029	ACTR1B	0.51	6.84	0.41	6.93e-11	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs2228479	0.850	rs45524643	chr16:89815824	G/A	cg00800038	chr16:89945340	TCF25	-0.74	-5.14	-0.32	5.75e-7	Skin colour saturation;
SARC	cis	rs2486288	0.656	rs11629858	chr15:45547114	T/C	cg15395560	chr15:45543142	SLC28A2	0.28	5.44	0.34	1.37e-7	Glomerular filtration rate;
SARC	cis	rs3768617	0.510	rs10797842	chr1:183081867	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.25	0.56	1.35e-20	Fuchs's corneal dystrophy;
SARC	cis	rs9549260	0.755	rs7985364	chr13:41179580	C/G	cg21288729	chr13:41239152	FOXO1	0.6	7.8	0.45	2.09e-13	Red blood cell count;
SARC	cis	rs617791	0.678	rs551659	chr11:65749645	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.55	8.4	0.48	4.44e-15	Breast cancer;
SARC	cis	rs365132	0.875	rs2456178	chr5:176413570	C/G	cg16309518	chr5:176445507	NA	-0.47	-6.07	-0.37	5.09e-9	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs3126085	0.935	rs4845736	chr1:152175551	G/A	cg03465714	chr1:152285911	FLG	-0.47	-5.56	-0.34	7.45e-8	Atopic dermatitis;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg23381224	chr10:89311690	MINPP1	0.49	6.57	0.4	3.23e-10	Thyroid stimulating hormone;
SARC	cis	rs7274811	0.652	rs293732	chr20:31975090	G/A	cg21523528	chr20:32077966	CBFA2T2	-0.41	-4.82	-0.3	2.58e-6	Height;
SARC	cis	rs826838	0.684	rs12367400	chr12:38618673	G/T	cg13010199	chr12:38710504	ALG10B	0.8	11.21	0.59	1.3e-23	Heart rate;
SARC	cis	rs1003719	0.680	rs2154537	chr21:38502012	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-8.86	-0.5	2.06e-16	Eye color traits;
SARC	cis	rs6952808	0.635	rs6952727	chr7:1947958	A/G	cg21782813	chr7:2030301	MAD1L1	0.36	5.63	0.35	5.22e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs2836974	0.565	rs34304022	chr21:40579619	G/A	cg11644478	chr21:40555479	PSMG1	0.79	6.79	0.41	9.38e-11	Cognitive function;
SARC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg11494091	chr17:61959527	GH2	0.55	8.29	0.48	9.13e-15	Prudent dietary pattern;
SARC	cis	rs9394841	0.692	rs2395795	chr6:41802354	G/A	cg08135965	chr6:41755394	TOMM6	0.61	6.45	0.39	6.49e-10	Mean corpuscular hemoglobin;Red cell distribution width;
SARC	cis	rs2832077	0.527	rs9981922	chr21:30212718	A/G	cg03476357	chr21:30257390	N6AMT1	-0.53	-6.07	-0.37	5.12e-9	Cognitive test performance;
SARC	cis	rs2594989	0.778	rs6764721	chr3:11470639	A/T	cg00170343	chr3:11313890	ATG7	0.59	5.5	0.34	9.88e-8	Circulating chemerin levels;
SARC	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg15448220	chr1:150897856	SETDB1	-0.45	-5.99	-0.37	7.9e-9	Tonsillectomy;
SARC	cis	rs17401966	0.931	rs17034821	chr1:10414645	A/G	cg15208524	chr1:10270712	KIF1B	0.51	6.09	0.37	4.56e-9	Hepatocellular carcinoma;
SARC	trans	rs6044112	0.784	rs6075067	chr20:16515824	T/C	cg09086761	chr11:62369541	MTA2	-0.74	-6.51	-0.39	4.66e-10	Response to taxane treatment (docetaxel);
SARC	cis	rs9790314	0.586	rs16832279	chr3:161120483	C/T	cg17135325	chr3:160939158	NMD3	0.53	6.55	0.39	3.73e-10	Morning vs. evening chronotype;
SARC	cis	rs995000	0.868	rs1168113	chr1:63156098	T/C	cg06896770	chr1:63153194	DOCK7	-0.87	-13.53	-0.66	3.69e-31	Triglyceride levels;
SARC	cis	rs6570726	0.935	rs429306	chr6:145827016	T/C	cg23711669	chr6:146136114	FBXO30	0.78	11.86	0.61	1.04e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1949733	0.958	rs2631731	chr4:8429817	A/G	cg11789530	chr4:8429930	ACOX3	0.9	12.11	0.62	1.63e-26	Response to antineoplastic agents;
SARC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg20887711	chr4:1340912	KIAA1530	0.81	10.23	0.56	1.61e-20	Longevity;
SARC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg20102877	chr2:27665638	KRTCAP3	-0.37	-5.25	-0.33	3.44e-7	Total body bone mineral density;
SARC	cis	rs3733585	0.699	rs7658170	chr4:9966593	C/T	cg00071950	chr4:10020882	SLC2A9	0.38	5.71	0.35	3.36e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg26119090	chr2:26468346	HADHA;HADHB	0.96	12.81	0.64	8.25e-29	Gut microbiome composition (summer);
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg17303299	chr12:7023527	ENO2	-0.66	-6.79	-0.41	9.27e-11	Lung cancer in ever smokers;
SARC	cis	rs4481887	1.000	rs10888362	chr1:248483975	A/G	cg01631408	chr1:248437212	OR2T33	0.4	5.14	0.32	5.91e-7	Common traits (Other);
SARC	cis	rs7474896	0.616	rs2474561	chr10:38373544	C/T	cg00409905	chr10:38381863	ZNF37A	-0.52	-5.09	-0.32	7.27e-7	Obesity (extreme);
SARC	cis	rs524281	0.861	rs10791856	chr11:65964650	T/C	cg14036092	chr11:66035641	RAB1B	-0.49	-5.32	-0.33	2.47e-7	Electroencephalogram traits;
SARC	cis	rs1707322	1.000	rs10890365	chr1:46359348	C/T	cg06784218	chr1:46089804	CCDC17	0.35	6.18	0.38	2.84e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg03060546	chr3:49711283	APEH	0.49	6.38	0.39	9.65e-10	Menarche (age at onset);
SARC	cis	rs526231	0.543	rs257303	chr5:102416727	A/G	cg23492399	chr5:102201601	PAM	-0.51	-5.52	-0.34	8.81e-8	Primary biliary cholangitis;
SARC	cis	rs12200560	0.505	rs211178	chr6:97074094	T/A	cg06623918	chr6:96969491	KIAA0776	0.45	5.11	0.32	6.85e-7	Coronary heart disease;
SARC	cis	rs12579753	0.871	rs1922540	chr12:82197496	A/G	cg07988820	chr12:82153109	PPFIA2	-0.57	-6.6	-0.4	2.67e-10	Resting heart rate;
SARC	cis	rs6570726	0.791	rs9376945	chr6:145828080	T/A	cg05347473	chr6:146136440	FBXO30	0.53	7.29	0.43	4.79e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs66887589	0.616	rs6843509	chr4:120220196	G/A	cg09307838	chr4:120376055	NA	0.62	8.15	0.47	2.28e-14	Diastolic blood pressure;
SARC	trans	rs1814175	0.645	rs28478790	chr11:50054322	C/A	cg03929089	chr4:120376271	NA	-0.83	-11.84	-0.61	1.24e-25	Height;
SARC	cis	rs34172651	0.917	rs12599173	chr16:24823619	T/C	cg04756594	chr16:24857601	SLC5A11	0.32	5.13	0.32	6.05e-7	Intelligence (multi-trait analysis);
SARC	cis	rs3126085	0.935	rs3126056	chr1:152266503	G/A	cg03465714	chr1:152285911	FLG	0.46	5.54	0.34	8.11e-8	Atopic dermatitis;
SARC	cis	rs9291683	0.595	rs11722930	chr4:10035454	G/A	cg11266682	chr4:10021025	SLC2A9	0.4	7.09	0.42	1.55e-11	Bone mineral density;
SARC	cis	rs703842	0.739	rs701008	chr12:58117645	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.54	7.05	0.42	2.01e-11	Multiple sclerosis;
SARC	cis	rs6733011	0.628	rs981602	chr2:99464275	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.39	-4.86	-0.3	2.12e-6	Bipolar disorder;
SARC	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg13699009	chr12:122356056	WDR66	0.6	9.95	0.55	1.15e-19	Mean corpuscular volume;
SARC	cis	rs4481887	1.000	rs10736378	chr1:248455769	T/G	cg13385794	chr1:248469461	NA	0.32	4.92	0.31	1.67e-6	Common traits (Other);
SARC	cis	rs9818758	0.607	rs73074866	chr3:49626666	C/T	cg00383909	chr3:49044727	WDR6	0.78	6.53	0.39	4.12e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs11644362	1.000	rs4505301	chr16:12989467	A/G	cg06890432	chr16:12997467	SHISA9	-0.55	-7.34	-0.43	3.46e-12	Positive affect;Subjective well-being;
SARC	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg15049968	chr18:44337910	ST8SIA5	-0.35	-5.65	-0.35	4.75e-8	Personality dimensions;
SARC	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.54	0.34	8.31e-8	Bipolar disorder;
SARC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg09373136	chr17:61933544	TCAM1	-0.45	-6.22	-0.38	2.33e-9	Prudent dietary pattern;
SARC	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg18404041	chr3:52824283	ITIH1	-0.38	-5.72	-0.35	3.23e-8	Electroencephalogram traits;
SARC	cis	rs9419702	0.568	rs11156445	chr10:133542301	T/C	cg04492858	chr10:133558786	NA	0.32	5.14	0.32	5.8e-7	Survival in rectal cancer;
SARC	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg20273122	chr11:68671309	IGHMBP2;MRPL21	-0.44	-5.16	-0.32	5.38e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs73198271	0.765	rs534103	chr8:8634069	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.35	-0.38	1.13e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg06108461	chr20:60628389	TAF4	-0.88	-10.91	-0.58	1.18e-22	Body mass index;
SARC	cis	rs765787	0.530	rs4238376	chr15:45541887	T/C	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.81e-6	Uric acid levels;
SARC	trans	rs1814175	0.654	rs7482446	chr11:49779020	A/G	cg15704280	chr7:45808275	SEPT13	-0.98	-18.12	-0.76	2.24e-46	Height;
SARC	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-9.68	-0.54	7.76e-19	Chronic sinus infection;
SARC	cis	rs2576037	0.899	rs2576035	chr18:44587654	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.67	-9.42	-0.53	4.61e-18	Personality dimensions;
SARC	cis	rs7264396	0.623	rs2425123	chr20:34329547	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.59	5.44	0.34	1.35e-7	Total cholesterol levels;
SARC	trans	rs208520	0.690	rs12197578	chr6:66725905	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	14.02	0.68	8.69e-33	Exhaled nitric oxide output;
SARC	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg08048268	chr3:133502702	NA	-0.46	-6.18	-0.38	2.79e-9	Iron status biomarkers;
SARC	cis	rs11203032	0.831	rs11203023	chr10:90954240	T/C	cg16672925	chr10:90967113	CH25H	0.54	6.04	0.37	5.9e-9	Heart failure;
SARC	cis	rs6088580	0.634	rs6142159	chr20:32993035	G/A	cg08999081	chr20:33150536	PIGU	-0.42	-6.49	-0.39	4.98e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg22535103	chr8:58192502	C8orf71	-0.66	-5.68	-0.35	4.07e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7312933	0.933	rs4534650	chr12:42444222	A/G	cg19980929	chr12:42632907	YAF2	0.34	4.81	0.3	2.76e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.83	8.42	0.48	3.96e-15	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs708547	0.647	rs1277308	chr4:57897864	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.58	7.14	0.42	1.15e-11	Response to bleomycin (chromatid breaks);
SARC	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg27266027	chr21:40555129	PSMG1	0.51	5.57	0.34	6.84e-8	Cognitive function;
SARC	cis	rs282587	0.569	rs399569	chr13:113398464	A/T	cg02820901	chr13:113351484	ATP11A	-0.5	-4.92	-0.31	1.65e-6	Glycated hemoglobin levels;
SARC	cis	rs9814567	0.793	rs55940445	chr3:134306064	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	6.94	0.41	3.77e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs4144743	1.000	rs2037150	chr17:45328718	G/A	cg18085866	chr17:45331354	ITGB3	-0.73	-7.41	-0.44	2.29e-12	Body mass index;
SARC	cis	rs4906332	1.000	rs11625172	chr14:103944912	G/A	cg26031613	chr14:104095156	KLC1	-0.49	-5.74	-0.35	2.94e-8	Coronary artery disease;
SARC	cis	rs8014204	0.804	rs35641442	chr14:75207263	G/A	cg06637938	chr14:75390232	RPS6KL1	0.73	10.85	0.58	1.8e-22	Caffeine consumption;
SARC	cis	rs6060717	0.536	rs6060683	chr20:34507921	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-5.72	-0.35	3.27e-8	Hip circumference adjusted for BMI;
SARC	cis	rs17376456	1.000	rs35184505	chr5:93561535	A/G	cg25358565	chr5:93447407	FAM172A	1.31	14.48	0.69	2.46e-34	Diabetic retinopathy;
SARC	cis	rs2880765	0.566	rs12911430	chr15:86011264	A/T	cg19183879	chr15:85880815	NA	-0.29	-4.72	-0.3	4.16e-6	Coronary artery disease;
SARC	cis	rs8077889	0.917	rs72836545	chr17:41892602	A/G	cg26893861	chr17:41843967	DUSP3	0.92	11.51	0.6	1.43e-24	Triglycerides;
SARC	cis	rs2075371	0.966	rs722657	chr7:133994956	T/C	cg20476274	chr7:133979776	SLC35B4	0.63	8.51	0.49	2.17e-15	Mean platelet volume;
SARC	cis	rs6752107	1.000	rs6738490	chr2:234161583	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.46	5.93	0.36	1.06e-8	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs6060960	0.537	rs6087787	chr20:30452089	G/A	cg13852791	chr20:30311386	BCL2L1	0.64	5.44	0.34	1.35e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
SARC	cis	rs228437	1.000	rs6934385	chr6:134916471	A/G	cg24504307	chr6:134963096	NA	0.56	6.14	0.37	3.51e-9	Melanoma;
SARC	cis	rs6429082	0.667	rs10802800	chr1:235706283	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.59	-6.32	-0.38	1.29e-9	Adiposity;
SARC	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg18876405	chr7:65276391	NA	-0.69	-8.31	-0.48	8.12e-15	Aortic root size;
SARC	cis	rs16854884	0.657	rs6766685	chr3:143736916	C/T	cg06585982	chr3:143692056	C3orf58	0.67	9.14	0.51	3.13e-17	Economic and political preferences (feminism/equality);
SARC	cis	rs3857536	0.834	rs4710573	chr6:66890366	C/A	cg07460842	chr6:66804631	NA	-0.44	-5.22	-0.32	3.92e-7	Blood trace element (Cu levels);
SARC	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg17971929	chr21:40555470	PSMG1	-0.88	-11.28	-0.59	7.77e-24	Cognitive function;
SARC	cis	rs34172651	0.917	rs200532	chr16:24756148	C/T	cg00152838	chr16:24741724	TNRC6A	0.41	5.09	0.32	7.35e-7	Intelligence (multi-trait analysis);
SARC	cis	rs3741798	1.000	rs78807762	chr12:12484136	G/A	cg08615371	chr12:12503544	MANSC1	0.81	5.99	0.37	7.93e-9	Cerebrospinal fluid biomarker levels;
SARC	cis	rs2073300	0.609	rs6132606	chr20:23367453	G/A	cg12062639	chr20:23401060	NAPB	0.95	6.5	0.39	4.74e-10	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs9513627	0.915	rs4324006	chr13:100122545	A/G	cg25919922	chr13:100150906	NA	-0.69	-5.17	-0.32	4.94e-7	Obesity-related traits;
SARC	cis	rs2288912	0.807	rs7251501	chr19:45455706	C/T	cg10169327	chr19:45448959	APOC2	0.31	5.11	0.32	6.85e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs9916302	0.821	rs12938268	chr17:37572139	G/A	cg15445000	chr17:37608096	MED1	0.44	5.34	0.33	2.23e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs7246657	0.943	rs2291004	chr19:37997952	C/A	cg23950597	chr19:37808831	NA	-0.56	-5.34	-0.33	2.2e-7	Coronary artery calcification;
SARC	cis	rs1008375	0.900	rs7658447	chr4:17579415	T/C	cg02297831	chr4:17616191	MED28	0.46	5.64	0.35	4.89e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs3008870	1.000	rs17497828	chr1:67452322	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.89	-10.55	-0.57	1.63e-21	Lymphocyte percentage of white cells;
SARC	cis	rs13191362	1.000	rs35103567	chr6:163183400	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.73	6.21	0.38	2.44e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs9388451	0.626	rs1343115	chr6:126069817	C/G	cg05901451	chr6:126070800	HEY2	-0.52	-6.45	-0.39	6.31e-10	Brugada syndrome;
SARC	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg24675658	chr1:53192096	ZYG11B	0.59	8.28	0.48	9.42e-15	Monocyte count;
SARC	cis	rs7647973	1.000	rs62259944	chr3:49430883	G/A	cg07636037	chr3:49044803	WDR6	-0.71	-7.09	-0.42	1.59e-11	Menarche (age at onset);
SARC	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg13393036	chr8:95962371	TP53INP1	-0.34	-5.63	-0.35	5.15e-8	Type 2 diabetes;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg15003695	chr4:39978799	PDS5A	-0.53	-7.02	-0.42	2.42e-11	Neuroticism;
SARC	cis	rs72781680	0.898	rs6712175	chr2:24023431	T/G	cg08917208	chr2:24149416	ATAD2B	0.76	7.11	0.42	1.4e-11	Lymphocyte counts;
SARC	cis	rs1865721	0.771	rs724764	chr18:73139742	C/T	cg26385618	chr18:73139727	C18orf62	-0.42	-5.98	-0.36	8.44e-9	Intelligence;
SARC	cis	rs2354432	0.891	rs2165743	chr1:146690319	C/T	cg25205988	chr1:146714368	CHD1L	1.06	11.09	0.59	3.12e-23	Mitochondrial DNA levels;
SARC	cis	rs11122272	0.735	rs2790884	chr1:231531932	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.08	-0.55	4.68e-20	Hemoglobin concentration;
SARC	cis	rs6714710	0.580	rs11680018	chr2:98479581	C/A	cg26665480	chr2:98280029	ACTR1B	0.49	6.72	0.4	1.38e-10	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs6446731	0.614	rs6446727	chr4:3274488	T/A	cg06533319	chr4:3265114	C4orf44	-0.32	-5.18	-0.32	4.88e-7	Mean platelet volume;
SARC	cis	rs3733585	0.673	rs4495037	chr4:9954050	C/G	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.39	-0.33	1.76e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs3762637	0.941	rs7653592	chr3:122218371	G/A	cg24169773	chr3:122142474	KPNA1	-0.56	-5.66	-0.35	4.42e-8	LDL cholesterol levels;
SARC	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg11987759	chr7:65425863	GUSB	0.48	5.94	0.36	1.06e-8	Aortic root size;
SARC	cis	rs3892630	0.588	rs2287881	chr19:33333155	A/G	cg22980127	chr19:33182716	NUDT19	-0.92	-9.83	-0.54	2.7e-19	Red blood cell traits;
SARC	cis	rs12545109	0.765	rs2438063	chr8:57384360	A/G	cg19413350	chr8:57351067	NA	0.44	4.89	0.3	1.91e-6	Obesity-related traits;
SARC	cis	rs113601626	1	rs113601626	chr2:24239189	T/TCCTGGC	cg08917208	chr2:24149416	ATAD2B	0.92	9.07	0.51	4.92e-17	Lymphocyte percentage of white cells;
SARC	cis	rs748404	0.697	rs492743	chr15:43560945	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.41	5.13	0.32	6.02e-7	Lung cancer;
SARC	cis	rs637571	0.546	rs10791827	chr11:65596546	C/A	cg26695010	chr11:65641043	EFEMP2	0.68	9.51	0.53	2.56e-18	Eosinophil percentage of white cells;
SARC	trans	rs208520	0.955	rs17644076	chr6:67004973	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.81	-9.04	-0.51	6.06e-17	Exhaled nitric oxide output;
SARC	cis	rs2380220	0.935	rs7748857	chr6:96001887	A/G	cg04719120	chr6:96025338	MANEA	0.58	6.35	0.38	1.11e-9	Behavioural disinhibition (generation interaction);
SARC	cis	rs7264396	0.635	rs6060719	chr20:34546013	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-7.1	-0.42	1.54e-11	Total cholesterol levels;
SARC	cis	rs1707322	0.656	rs9429172	chr1:46092476	C/G	cg03146154	chr1:46216737	IPP	-0.51	-6.1	-0.37	4.4e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs17376456	0.825	rs10052662	chr5:93271385	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	5.77	0.35	2.56e-8	Diabetic retinopathy;
SARC	cis	rs7786808	0.608	rs9692003	chr7:158204696	G/A	cg01191920	chr7:158217561	PTPRN2	0.36	6.11	0.37	4.23e-9	Obesity-related traits;
SARC	cis	rs9323205	0.871	rs2999393	chr14:51655167	G/T	cg23942311	chr14:51606299	NA	0.35	5.58	0.34	6.79e-8	Cancer;
SARC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg26338869	chr17:61819248	STRADA	0.8	10.64	0.57	8.58e-22	Prudent dietary pattern;
SARC	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg02725872	chr8:58115012	NA	-0.34	-5.46	-0.34	1.19e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg01017244	chr2:74357527	NA	0.58	7.33	0.43	3.76e-12	Gestational age at birth (maternal effect);
SARC	cis	rs11240408	1	rs11240408	chr1:205264536	A/T	cg21545522	chr1:205238299	TMCC2	-0.44	-5.93	-0.36	1.09e-8	Platelet count;
SARC	cis	rs5753618	0.509	rs5997902	chr22:31583007	A/G	cg02404636	chr22:31891804	SFI1	-0.48	-5.18	-0.32	4.83e-7	Colorectal cancer;
SARC	cis	rs6964587	0.869	rs10276682	chr7:91486070	G/A	cg17063962	chr7:91808500	NA	-0.89	-13.51	-0.66	4.14e-31	Breast cancer;
SARC	cis	rs2718058	0.606	rs2598077	chr7:37870427	G/C	cg15028436	chr7:37888078	TXNDC3	0.39	4.94	0.31	1.49e-6	Alzheimer's disease (late onset);
SARC	cis	rs4722166	0.695	rs4722177	chr7:22798531	T/C	cg26061582	chr7:22766209	IL6	0.47	5.44	0.34	1.35e-7	Lung cancer;
SARC	cis	rs561341	0.714	rs7218466	chr17:30263314	A/G	cg13647721	chr17:30228624	UTP6	0.57	4.96	0.31	1.36e-6	Hip circumference adjusted for BMI;
SARC	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg07061783	chr6:25882402	NA	-0.41	-4.81	-0.3	2.73e-6	Intelligence (multi-trait analysis);
SARC	cis	rs1395	0.710	rs72817533	chr2:27482612	A/G	cg21747090	chr2:27597821	SNX17	-0.49	-5.91	-0.36	1.2e-8	Blood metabolite levels;
SARC	cis	rs10908458	0.808	rs11264322	chr1:155087933	G/A	cg27045062	chr1:155054711	EFNA3	0.35	4.79	0.3	2.96e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs17376456	0.877	rs28633397	chr5:93447048	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.79	0.35	2.3e-8	Diabetic retinopathy;
SARC	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg16606324	chr3:10149918	C3orf24	0.48	4.75	0.3	3.56e-6	Alzheimer's disease;
SARC	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.78	5.72	0.35	3.26e-8	Initial pursuit acceleration;
SARC	cis	rs1707322	0.752	rs6678444	chr1:46229847	A/G	cg03146154	chr1:46216737	IPP	0.5	5.9	0.36	1.29e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9911578	1.000	rs7207693	chr17:57016525	C/T	cg12560992	chr17:57184187	TRIM37	0.85	11.7	0.61	3.63e-25	Intelligence (multi-trait analysis);
SARC	cis	rs6582630	0.502	rs10880092	chr12:38262965	A/T	cg26384229	chr12:38710491	ALG10B	0.91	13.64	0.67	1.61e-31	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs4660261	0.526	rs810680	chr1:44347856	C/T	cg12908607	chr1:44402522	ARTN	-0.32	-5.68	-0.35	3.92e-8	Intelligence (multi-trait analysis);
SARC	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg16405210	chr4:1374714	KIAA1530	-0.56	-6.74	-0.4	1.25e-10	Obesity-related traits;
SARC	cis	rs763121	0.853	rs9610986	chr22:39025277	T/C	cg06022373	chr22:39101656	GTPBP1	0.88	11.17	0.59	1.82e-23	Menopause (age at onset);
SARC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg11494091	chr17:61959527	GH2	0.54	8.18	0.47	1.79e-14	Prudent dietary pattern;
SARC	cis	rs2153535	0.580	rs2152348	chr6:8474301	C/A	cg21535247	chr6:8435926	SLC35B3	0.56	7.09	0.42	1.55e-11	Motion sickness;
SARC	cis	rs11098499	0.954	rs2306455	chr4:120421969	G/A	cg09307838	chr4:120376055	NA	0.93	12.73	0.64	1.6e-28	Corneal astigmatism;
SARC	cis	rs7264396	0.561	rs6060741	chr20:34571484	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.56	5.21	0.32	4.22e-7	Total cholesterol levels;
SARC	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.43	5.2	0.32	4.3e-7	Electroencephalogram traits;
SARC	cis	rs6088813	0.961	rs6060369	chr20:33907161	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.43	5.25	0.33	3.44e-7	Height;
SARC	cis	rs6489785	0.501	rs551125	chr12:121203427	C/T	cg02403541	chr12:121454288	C12orf43	0.43	4.93	0.31	1.59e-6	Longevity;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg07777115	chr5:623756	CEP72	-0.57	-5.09	-0.32	7.38e-7	Obesity-related traits;
SARC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg06873352	chr17:61820015	STRADA	0.52	6.76	0.4	1.1e-10	Prudent dietary pattern;
SARC	cis	rs2153535	0.521	rs6939827	chr6:8461360	C/G	cg07606381	chr6:8435919	SLC35B3	0.77	11.07	0.59	3.68e-23	Motion sickness;
SARC	cis	rs986417	1.000	rs2351176	chr14:61073731	A/T	cg27398547	chr14:60952738	C14orf39	0.88	7.64	0.45	5.68e-13	Gut microbiota (bacterial taxa);
SARC	cis	rs7208859	0.623	rs9914499	chr17:29107588	G/A	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs2933343	0.761	rs789225	chr3:128600229	G/A	cg25356066	chr3:128598488	ACAD9	0.71	9.53	0.53	2.1e-18	IgG glycosylation;
SARC	cis	rs897080	0.515	rs1067334	chr2:44626633	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.7	0.4	1.59e-10	Height;
SARC	cis	rs6580649	0.941	rs1018973	chr12:48441692	C/G	cg24011408	chr12:48396354	COL2A1	0.48	5.41	0.33	1.58e-7	Lung cancer;
SARC	cis	rs782590	0.935	rs62165197	chr2:55801812	C/T	cg18811423	chr2:55921094	PNPT1	0.68	10.53	0.57	1.78e-21	Metabolic syndrome;
SARC	cis	rs7084402	0.967	rs1346302	chr10:60267137	G/A	cg07615347	chr10:60278583	BICC1	-0.57	-8.25	-0.48	1.14e-14	Refractive error;
SARC	cis	rs2425143	1.000	rs6060643	chr20:34449851	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-5.96	-0.36	9.2e-9	Blood protein levels;
SARC	cis	rs66887589	0.616	rs10032299	chr4:120206419	C/T	cg09307838	chr4:120376055	NA	0.62	8.26	0.48	1.07e-14	Diastolic blood pressure;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg15950665	chr7:35077767	DPY19L1	0.49	6.29	0.38	1.6e-9	Thyroid stimulating hormone;
SARC	cis	rs2180341	0.961	rs3798857	chr6:127659473	A/T	cg24812749	chr6:127587940	RNF146	0.98	13.14	0.65	7.1e-30	Breast cancer;
SARC	cis	rs10479542	0.683	rs7380706	chr5:178961872	C/T	cg19723775	chr5:179050963	HNRNPH1	0.41	5.19	0.32	4.5e-7	Lung cancer;
SARC	cis	rs1957429	0.520	rs72625637	chr14:65307705	G/A	cg23373153	chr14:65346875	NA	-0.69	-5.15	-0.32	5.6e-7	Pediatric areal bone mineral density (radius);
SARC	cis	rs2204008	0.688	rs12824232	chr12:38175901	G/A	cg13010199	chr12:38710504	ALG10B	0.78	10.64	0.57	8.61e-22	Bladder cancer;
SARC	cis	rs36051895	0.589	rs7038763	chr9:5076399	T/C	cg02405213	chr9:5042618	JAK2	-0.43	-5.19	-0.32	4.59e-7	Pediatric autoimmune diseases;
SARC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg06896619	chr17:61851486	DDX42;CCDC47	-0.43	-4.83	-0.3	2.44e-6	Prudent dietary pattern;
SARC	cis	rs722599	0.599	rs3825708	chr14:75200697	C/T	cg06637938	chr14:75390232	RPS6KL1	0.41	5.13	0.32	6.01e-7	IgG glycosylation;
SARC	cis	rs1322639	1.000	rs1322639	chr6:169587103	G/A	cg04662567	chr6:169592167	NA	0.5	6.51	0.39	4.62e-10	Pulse pressure;
SARC	cis	rs12022452	0.556	rs11208298	chr1:40978878	A/G	cg25568243	chr1:40974465	DEM1	0.52	4.78	0.3	3.07e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs11719291	0.504	rs71324924	chr3:48865444	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.63	-5.4	-0.33	1.67e-7	Cognitive function;
SARC	cis	rs7607369	0.648	rs7559490	chr2:219656867	A/T	cg02176678	chr2:219576539	TTLL4	-0.51	-8.24	-0.47	1.27e-14	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs9815354	0.767	rs73081335	chr3:41895177	A/G	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg26335602	chr6:28129616	ZNF389	0.53	5.88	0.36	1.43e-8	Depression;
SARC	cis	rs11225247	0.881	rs12279056	chr11:102257584	T/A	cg11690896	chr11:102217788	BIRC2	0.77	5.37	0.33	1.93e-7	Vein graft stenosis in coronary artery bypass grafting;
SARC	cis	rs910316	0.591	rs7157158	chr14:75457238	A/G	cg08847533	chr14:75593920	NEK9	0.89	13.56	0.66	2.82e-31	Height;
SARC	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg13939156	chr17:80058883	NA	-0.42	-6.48	-0.39	5.51e-10	Life satisfaction;
SARC	cis	rs13191362	1.000	rs35383933	chr6:163002869	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.49	0.34	1.04e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs76917914	0.820	rs3739670	chr9:100819192	C/T	cg03040243	chr9:100819229	NANS	0.72	7.9	0.46	1.13e-13	Immature fraction of reticulocytes;
SARC	cis	rs6060717	0.654	rs6060686	chr20:34512606	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-7.29	-0.43	4.75e-12	Hip circumference adjusted for BMI;
SARC	cis	rs228769	1.000	rs12937692	chr17:42256430	G/A	cg19774624	chr17:42201019	HDAC5	-0.77	-9.75	-0.54	4.63e-19	Bone mineral density (hip);Bone mineral density (spine);
SARC	cis	rs16912285	0.786	rs76326641	chr11:24253072	G/A	ch.11.24196551F	chr11:24239977	NA	0.73	6.26	0.38	1.84e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs11676348	0.935	rs4674250	chr2:218977531	G/A	cg00012203	chr2:219082015	ARPC2	-0.45	-6.01	-0.37	7.19e-9	Ulcerative colitis;
SARC	cis	rs6696846	0.936	rs1042831	chr1:205043250	G/C	cg00857998	chr1:205179979	DSTYK	0.39	4.92	0.31	1.61e-6	Red blood cell count;
SARC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.19	0.8	4.45e-53	Prudent dietary pattern;
SARC	cis	rs9747201	1.000	rs4506966	chr17:80175421	T/C	cg09264619	chr17:80180166	NA	-0.53	-5.88	-0.36	1.39e-8	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs929354	0.772	rs6459737	chr7:156975136	G/A	cg05182265	chr7:156933206	UBE3C	-0.33	-5.02	-0.31	1.03e-6	Body mass index;
SARC	trans	rs7824557	0.564	rs2736302	chr8:11236419	T/C	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.72	-0.5	5.49e-16	Retinal vascular caliber;
SARC	cis	rs10876993	0.928	rs1678540	chr12:58065002	A/G	cg18357645	chr12:58087776	OS9	0.46	5.98	0.36	8.51e-9	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs9818758	0.607	rs56306491	chr3:49314960	G/A	cg07636037	chr3:49044803	WDR6	-0.78	-6.69	-0.4	1.61e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	trans	rs1493916	1.000	rs4393645	chr18:31394407	C/T	cg27147174	chr7:100797783	AP1S1	-0.59	-7.67	-0.45	4.76e-13	Life satisfaction;
SARC	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg24633833	chr3:10029261	TMEM111	0.52	5.25	0.33	3.43e-7	Alzheimer's disease;
SARC	cis	rs12142240	0.698	rs66911505	chr1:46823298	A/G	cg00530320	chr1:46809349	NSUN4	0.57	6.79	0.41	9.05e-11	Menopause (age at onset);
SARC	cis	rs7772486	0.790	rs3924498	chr6:146233338	A/T	cg05347473	chr6:146136440	FBXO30	-0.48	-6.56	-0.39	3.5e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9916302	0.861	rs11078896	chr17:37415544	C/T	cg20243544	chr17:37824526	PNMT	0.56	6.87	0.41	5.74e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs5758659	0.652	rs133326	chr22:42406885	G/A	cg04733989	chr22:42467013	NAGA	0.52	6.96	0.41	3.38e-11	Cognitive function;
SARC	cis	rs2832077	0.527	rs9981922	chr21:30212718	A/G	cg08807101	chr21:30365312	RNF160	-0.54	-6.31	-0.38	1.41e-9	Cognitive test performance;
SARC	cis	rs616402	0.527	rs11121581	chr1:10577740	A/G	cg17425144	chr1:10567563	PEX14	0.45	7.26	0.43	5.66e-12	Breast size;
SARC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.34	-5.06	-0.31	8.5e-7	Total body bone mineral density;
SARC	cis	rs7647973	0.626	rs1352889	chr3:49652148	T/C	cg13072238	chr3:49761600	GMPPB	-0.62	-6.18	-0.38	2.9e-9	Menarche (age at onset);
SARC	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg24060327	chr5:131705240	SLC22A5	-0.5	-5.98	-0.36	8.28e-9	Acylcarnitine levels;
SARC	cis	rs6430585	0.528	rs6743537	chr2:136702601	C/T	cg07169764	chr2:136633963	MCM6	0.94	12.17	0.62	1.02e-26	Corneal structure;
SARC	cis	rs798554	1.000	rs798563	chr7:2757867	A/C	cg19346786	chr7:2764209	NA	-0.4	-5.94	-0.36	1.04e-8	Height;
SARC	trans	rs10109025	0.701	rs10101292	chr8:10856474	T/C	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.96	-0.41	3.49e-11	Joint mobility (Beighton score);
SARC	cis	rs910316	1.000	rs12590452	chr14:75548756	T/C	cg11812906	chr14:75593930	NEK9	0.89	14.1	0.68	4.66e-33	Height;
SARC	cis	rs4953404	0.613	rs897532	chr2:46893225	G/A	cg09399716	chr2:46890238	NA	-0.24	-4.94	-0.31	1.51e-6	Pulse pressure (alcohol consumption interaction);
SARC	cis	rs17001868	0.568	rs9611329	chr22:40792038	G/T	cg07138101	chr22:40742427	ADSL	0.54	6.02	0.37	6.89e-9	Mammographic density (dense area);
SARC	cis	rs9715521	0.867	rs4860465	chr4:59832537	G/T	cg11281224	chr4:60001000	NA	-0.39	-5.02	-0.31	1.01e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg04234412	chr22:24373322	LOC391322	-0.57	-7.22	-0.43	7.4e-12	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg05861140	chr6:150128134	PCMT1	-0.37	-4.79	-0.3	2.92e-6	Lung cancer;
SARC	cis	rs2795502	0.882	rs2744093	chr10:43339243	A/G	cg20628663	chr10:43360327	NA	-0.47	-6.32	-0.38	1.33e-9	Blood protein levels;
SARC	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg05896524	chr21:47604654	C21orf56	0.42	5.04	0.31	9.35e-7	Testicular germ cell tumor;
SARC	cis	rs748404	0.697	rs555001	chr15:43545728	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.53	6.27	0.38	1.78e-9	Lung cancer;
SARC	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg11764359	chr7:65958608	NA	-0.65	-7.72	-0.45	3.48e-13	Aortic root size;
SARC	cis	rs995000	0.931	rs6675401	chr1:63073975	C/T	cg06896770	chr1:63153194	DOCK7	0.89	13.21	0.65	4.23e-30	Triglyceride levels;
SARC	cis	rs72945132	0.823	rs12292240	chr11:70152612	T/C	cg00319359	chr11:70116639	PPFIA1	0.67	6.08	0.37	4.85e-9	Coronary artery disease;
SARC	cis	rs1878931	0.696	rs35984213	chr16:3451030	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	1.01	18.97	0.78	3.82e-49	Body mass index (adult);
SARC	cis	rs7824557	0.564	rs12550129	chr8:11233917	C/T	cg21775007	chr8:11205619	TDH	-0.65	-8.63	-0.49	9.45e-16	Retinal vascular caliber;
SARC	cis	rs765787	0.530	rs4544188	chr15:45535393	C/A	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.81e-6	Uric acid levels;
SARC	cis	rs155076	0.938	rs536209	chr13:21847714	C/T	cg06138931	chr13:21896616	NA	-0.39	-5.08	-0.32	7.88e-7	White matter hyperintensity burden;
SARC	cis	rs1318878	0.565	rs1600334	chr12:15459404	T/C	cg08258403	chr12:15378311	NA	0.49	6.85	0.41	6.49e-11	Intelligence (multi-trait analysis);
SARC	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg12064134	chr16:90016061	DEF8	-0.57	-4.78	-0.3	3.14e-6	Skin colour saturation;
SARC	cis	rs9858542	0.537	rs34514189	chr3:49373045	A/G	cg00383909	chr3:49044727	WDR6	0.51	5.11	0.32	6.76e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs11608355	1.000	rs9669684	chr12:109860644	C/T	cg19025524	chr12:109796872	NA	-0.4	-5.06	-0.31	8.4e-7	Neuroticism;
SARC	cis	rs2066819	0.818	rs773652	chr12:56674766	G/A	cg26316697	chr12:56727976	PAN2	-0.9	-6.37	-0.39	9.89e-10	Psoriasis vulgaris;
SARC	cis	rs114858855	1.000	rs927127	chr6:110010672	G/A	cg26835506	chr6:109038353	NA	-0.59	-4.82	-0.3	2.58e-6	Plasma trimethylamine N-oxide levels;
SARC	cis	rs644799	1.000	rs593665	chr11:95574302	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	14.8	0.7	2.24e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg22683308	chr4:1340831	KIAA1530	0.46	5.53	0.34	8.53e-8	Longevity;
SARC	cis	rs910187	0.605	rs2281367	chr20:45808960	T/C	cg27589058	chr20:45804311	EYA2	-0.3	-4.96	-0.31	1.36e-6	Migraine;
SARC	cis	rs2731664	0.792	rs2544809	chr5:176885499	T/C	cg23176889	chr5:176863531	GRK6	-0.55	-8.14	-0.47	2.43e-14	Intelligence (multi-trait analysis);
SARC	cis	rs524281	0.861	rs7931544	chr11:65917034	C/T	cg14036092	chr11:66035641	RAB1B	-0.51	-5.41	-0.33	1.55e-7	Electroencephalogram traits;
SARC	cis	rs10782582	0.564	rs17647711	chr1:76241710	C/G	cg10523679	chr1:76189770	ACADM	-0.43	-5.07	-0.32	7.94e-7	Daytime sleep phenotypes;
SARC	trans	rs1945213	0.659	rs2086558	chr11:55844453	T/G	cg15704280	chr7:45808275	SEPT13	0.66	6.87	0.41	5.94e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs77956314	0.901	rs118117321	chr12:117414790	C/G	cg16111737	chr12:117408163	FBXW8	0.6	5.22	0.32	3.92e-7	Subcortical brain region volumes;Hippocampal volume;
SARC	cis	rs9457247	0.967	rs2769355	chr6:167380493	G/A	cg07741184	chr6:167504864	NA	-0.29	-5.5	-0.34	1.02e-7	Crohn's disease;
SARC	cis	rs3126085	0.696	rs41266112	chr1:152185762	C/G	cg03465714	chr1:152285911	FLG	-0.47	-5.6	-0.34	5.91e-8	Atopic dermatitis;
SARC	cis	rs79349575	0.681	rs56080003	chr17:47019049	A/T	cg07967210	chr17:47022446	SNF8	0.38	4.77	0.3	3.2e-6	Type 2 diabetes;
SARC	trans	rs208520	0.690	rs6932475	chr6:66863155	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-13.93	-0.67	1.73e-32	Exhaled nitric oxide output;
SARC	cis	rs9815354	1.000	rs1717011	chr3:41980199	T/C	cg03022575	chr3:42003672	ULK4	-0.55	-5.27	-0.33	3.16e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg24642844	chr7:1081250	C7orf50	-0.59	-6.23	-0.38	2.22e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs9911578	0.967	rs9907940	chr17:56663842	A/G	cg05425664	chr17:57184151	TRIM37	-0.66	-8.25	-0.48	1.16e-14	Intelligence (multi-trait analysis);
SARC	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	12.24	0.63	6.48e-27	Chronic sinus infection;
SARC	cis	rs67460515	0.892	rs4856756	chr3:160999414	G/A	cg17135325	chr3:160939158	NMD3	0.61	7.72	0.45	3.44e-13	Parkinson's disease;
SARC	cis	rs208520	0.874	rs208518	chr6:66948501	C/G	cg07460842	chr6:66804631	NA	0.94	11.26	0.59	9.32e-24	Exhaled nitric oxide output;
SARC	cis	rs67478160	0.634	rs2295140	chr14:104216293	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.35	-4.84	-0.3	2.39e-6	Schizophrenia;
SARC	cis	rs11945232	1.000	rs6854710	chr4:88334640	A/G	cg23841344	chr4:88312519	HSD17B11	-0.59	-7.48	-0.44	1.51e-12	Intelligence (multi-trait analysis);
SARC	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg25072359	chr17:41440525	NA	0.5	5.94	0.36	1.04e-8	Menopause (age at onset);
SARC	cis	rs2253017	0.767	rs4770070	chr13:21330776	G/A	cg16922012	chr13:21400325	XPO4	-0.42	-5.57	-0.34	7.08e-8	PR segment;
SARC	cis	rs35110281	0.667	rs4818859	chr21:45117120	G/A	cg01579765	chr21:45077557	HSF2BP	-0.35	-5.55	-0.34	7.6e-8	Mean corpuscular volume;
SARC	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg08645402	chr16:4508243	NA	0.45	5.4	0.33	1.68e-7	Schizophrenia;
SARC	cis	rs12048904	0.595	rs2295280	chr1:101342497	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.56	7.57	0.44	8.91e-13	Multiple sclerosis;
SARC	cis	rs7408868	1.000	rs757475	chr19:15273749	C/T	cg14696996	chr19:15285081	NOTCH3	1.06	8.68	0.49	6.85e-16	Pulse pressure;
SARC	cis	rs950776	0.518	rs8053	chr15:78841220	T/C	cg17108064	chr15:78857060	CHRNA5	-0.29	-4.81	-0.3	2.73e-6	Sudden cardiac arrest;
SARC	cis	rs28374715	0.532	rs28584379	chr15:41670408	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.17	-18.76	-0.78	1.76e-48	Ulcerative colitis;
SARC	cis	rs17376456	0.825	rs17314825	chr5:93234937	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.61	0.35	5.58e-8	Diabetic retinopathy;
SARC	trans	rs208520	0.507	rs3903670	chr6:66812183	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-21.5	-0.82	3.05e-57	Exhaled nitric oxide output;
SARC	cis	rs1219407	0.655	rs1219392	chr11:121764234	A/G	cg05724965	chr11:122753715	C11orf63	-0.58	-4.73	-0.3	3.96e-6	Mood disorder in prion disease;
SARC	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg11987759	chr7:65425863	GUSB	-0.5	-6.19	-0.38	2.62e-9	Aortic root size;
SARC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg24846343	chr22:24311635	DDTL	0.54	7.38	0.44	2.81e-12	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg11890956	chr21:40555474	PSMG1	1.18	20.06	0.8	1.13e-52	Cognitive function;
SARC	cis	rs11997175	0.704	rs11775534	chr8:33695232	G/A	ch.8.33884649F	chr8:33765107	NA	0.57	7.72	0.45	3.31e-13	Body mass index;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg09662605	chr5:143550023	YIPF5;KCTD16	0.5	6.58	0.4	3.15e-10	Chemerin levels;
SARC	cis	rs7592578	0.599	rs62180992	chr2:191285732	A/G	cg27211696	chr2:191398769	TMEM194B	-0.45	-4.75	-0.3	3.55e-6	Diastolic blood pressure;
SARC	cis	rs3617	0.625	rs11922961	chr3:52868610	T/C	cg04865290	chr3:52927548	TMEM110	0.34	4.93	0.31	1.57e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs2361710	0.668	rs4889830	chr17:78114528	G/A	cg20811857	chr17:78079795	GAA	-0.32	-5.19	-0.32	4.49e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
SARC	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg26116260	chr4:7069785	GRPEL1	0.95	11.81	0.61	1.51e-25	Monocyte percentage of white cells;
SARC	cis	rs748404	0.578	rs507178	chr15:43610135	A/G	cg08831455	chr15:43942014	CATSPER2	-0.4	-4.74	-0.3	3.79e-6	Lung cancer;
SARC	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg03264133	chr6:25882463	NA	0.52	6.78	0.41	9.7e-11	Blood metabolite levels;
SARC	cis	rs9916302	0.629	rs9972882	chr17:37807698	A/C	cg20243544	chr17:37824526	PNMT	0.55	6.66	0.4	1.98e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs17270561	0.636	rs7453371	chr6:25719256	A/G	cg16482183	chr6:26056742	HIST1H1C	0.43	5.11	0.32	6.67e-7	Iron status biomarkers;
SARC	cis	rs6920965	0.507	rs7754833	chr6:126190894	A/G	cg05901451	chr6:126070800	HEY2	-0.48	-5.83	-0.36	1.8e-8	High light scatter reticulocyte count;
SARC	cis	rs1018836	0.923	rs13259842	chr8:91550819	A/G	cg16814680	chr8:91681699	NA	-0.77	-12.46	-0.63	1.22e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs35213789	0.878	rs6951909	chr7:69509686	C/T	cg10619644	chr7:69149951	AUTS2	0.41	5.09	0.32	7.26e-7	Childhood ear infection;
SARC	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg11987759	chr7:65425863	GUSB	0.47	5.73	0.35	3.15e-8	Aortic root size;
SARC	cis	rs13202913	0.608	rs17054363	chr6:151746586	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.6	5.03	0.31	9.99e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs950169	1.000	rs62026530	chr15:84775840	G/T	cg17507749	chr15:85114479	UBE2QP1	0.76	9.25	0.52	1.47e-17	Schizophrenia;
SARC	cis	rs1348850	0.914	rs8941	chr2:178406481	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.75	9.49	0.53	2.83e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg13395646	chr4:1353034	KIAA1530	-0.53	-6.28	-0.38	1.64e-9	Obesity-related traits;
SARC	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg04546413	chr19:29218101	NA	0.63	8.52	0.49	2.01e-15	Methadone dose in opioid dependence;
SARC	cis	rs10463554	0.892	rs6871715	chr5:102266102	A/G	cg23492399	chr5:102201601	PAM	-0.47	-5.59	-0.34	6.48e-8	Parkinson's disease;
SARC	cis	rs36051895	0.589	rs16922779	chr9:5200127	G/A	cg02405213	chr9:5042618	JAK2	-0.41	-4.86	-0.3	2.13e-6	Pediatric autoimmune diseases;
SARC	cis	rs9916302	0.904	rs1619021	chr17:37739274	G/A	cg07936489	chr17:37558343	FBXL20	-0.68	-8.43	-0.48	3.57e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs11677370	0.561	rs13015012	chr2:3821252	C/G	cg17052675	chr2:3827356	NA	0.44	5.16	0.32	5.36e-7	Type 2 diabetes;
SARC	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	16.12	0.73	8.93e-40	Chronic sinus infection;
SARC	cis	rs17376456	0.877	rs10063045	chr5:93457584	A/T	cg21475434	chr5:93447410	FAM172A	0.83	6.78	0.41	9.66e-11	Diabetic retinopathy;
SARC	cis	rs10493773	0.532	rs1889919	chr1:86180034	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.61	-9.98	-0.55	9.28e-20	Urate levels in overweight individuals;
SARC	cis	rs11191193	0.736	rs11191189	chr10:103798260	A/G	cg15320455	chr10:103880129	LDB1	0.57	5.82	0.36	1.96e-8	Educational attainment;
SARC	cis	rs9650657	0.504	rs6601566	chr8:11042974	G/T	cg12395012	chr8:11607386	GATA4	0.31	5.2	0.32	4.43e-7	Neuroticism;
SARC	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg06634786	chr22:41940651	POLR3H	0.55	6.69	0.4	1.68e-10	Vitiligo;
SARC	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg07636037	chr3:49044803	WDR6	0.99	17.31	0.75	1.02e-43	Parkinson's disease;
SARC	cis	rs2439831	1.000	rs689647	chr15:43762196	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.04	11.03	0.59	4.93e-23	Lung cancer in ever smokers;
SARC	cis	rs3812831	0.661	rs2987458	chr13:114919835	A/G	cg08824895	chr13:115047677	UPF3A	0.53	6.88	0.41	5.58e-11	Schizophrenia;
SARC	cis	rs862034	0.531	rs8008540	chr14:74948180	C/T	cg16374328	chr14:74960395	NPC2;ISCA2	0.38	4.76	0.3	3.44e-6	Height;
SARC	cis	rs4761669	0.724	rs117798848	chr12:95219771	A/G	cg21533806	chr12:95267307	NA	0.42	5.18	0.32	4.7e-7	Common carotid intima-media thickness in HIV infection;
SARC	cis	rs1971762	0.563	rs3897117	chr12:54077407	T/G	cg06632207	chr12:54070931	ATP5G2	0.44	5.7	0.35	3.67e-8	Height;
SARC	cis	rs9411298	0.630	rs9411299	chr9:139938793	C/G	cg14024893	chr9:139943146	ENTPD2	-0.34	-4.93	-0.31	1.55e-6	Monocyte percentage of white cells;
SARC	cis	rs5753618	0.561	rs715510	chr22:31690528	T/A	cg02404636	chr22:31891804	SFI1	-0.48	-5.15	-0.32	5.56e-7	Colorectal cancer;
SARC	cis	rs62244186	0.659	rs56231820	chr3:44530329	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.47	5.7	0.35	3.6e-8	Depressive symptoms;
SARC	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg11301795	chr4:187892539	NA	-0.56	-7.06	-0.42	1.94e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11122272	0.735	rs2474631	chr1:231541341	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.14	-0.55	2.9e-20	Hemoglobin concentration;
SARC	cis	rs9479482	1.000	rs5006620	chr6:150336665	C/T	cg03788504	chr6:150331562	NA	-0.33	-5.34	-0.33	2.19e-7	Alopecia areata;
SARC	cis	rs4481887	0.927	rs4279879	chr1:248486475	A/G	cg01631408	chr1:248437212	OR2T33	-0.38	-4.74	-0.3	3.75e-6	Common traits (Other);
SARC	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg00040380	chr1:153963107	RPS27	-0.5	-6.6	-0.4	2.72e-10	Thyroid cancer;
SARC	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg11764359	chr7:65958608	NA	0.66	7.62	0.45	6.25e-13	Aortic root size;
SARC	cis	rs796364	0.806	rs112486506	chr2:201073947	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-5.91	-0.36	1.21e-8	Schizophrenia;
SARC	cis	rs6120849	0.754	rs6120804	chr20:33623701	C/A	cg24642439	chr20:33292090	TP53INP2	0.57	5.48	0.34	1.1e-7	Protein C levels;
SARC	cis	rs72781680	0.898	rs72788212	chr2:24087385	G/A	cg08917208	chr2:24149416	ATAD2B	0.75	7.33	0.43	3.77e-12	Lymphocyte counts;
SARC	cis	rs10779751	1.000	rs2076655	chr1:11289161	A/G	cg08854313	chr1:11322531	MTOR	-0.88	-13.5	-0.66	4.51e-31	Body mass index;
SARC	cis	rs11190604	1.000	rs2495751	chr10:102327260	A/G	cg07080220	chr10:102295463	HIF1AN	0.81	9.19	0.52	2.26e-17	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg06618935	chr21:46677482	NA	-0.37	-4.93	-0.31	1.56e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7819412	0.594	rs7460507	chr8:10969075	C/T	cg00262122	chr8:11665843	FDFT1	-0.41	-4.83	-0.3	2.46e-6	Triglycerides;
SARC	cis	rs8036030	0.604	rs11856835	chr15:74716174	G/A	cg14664628	chr15:75095509	CSK	-0.41	-4.82	-0.3	2.64e-6	Airflow obstruction;
SARC	cis	rs611744	0.870	rs613261	chr8:109165949	A/G	cg21045802	chr8:109455806	TTC35	0.51	6.27	0.38	1.69e-9	Dupuytren's disease;
SARC	cis	rs2635047	0.638	rs9961383	chr18:44604001	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.51	6.65	0.4	2.08e-10	Educational attainment;
SARC	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg22903657	chr4:1355424	KIAA1530	-0.43	-5.73	-0.35	3.08e-8	Obesity-related traits;
SARC	cis	rs12682352	0.602	rs28399241	chr8:8663215	C/T	cg06636001	chr8:8085503	FLJ10661	0.54	6.89	0.41	5.21e-11	Neuroticism;
SARC	cis	rs2075371	0.863	rs1646635	chr7:134006728	T/C	cg00033643	chr7:134001901	SLC35B4	0.5	6.28	0.38	1.61e-9	Mean platelet volume;
SARC	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg22105103	chr4:187893119	NA	0.49	6.75	0.4	1.14e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11098499	0.865	rs4507344	chr4:120307485	C/A	cg09307838	chr4:120376055	NA	0.91	12.88	0.65	4.9e-29	Corneal astigmatism;
SARC	cis	rs7465272	1.000	rs7835613	chr8:143682428	C/T	cg24634471	chr8:143751801	JRK	0.61	6.55	0.39	3.65e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs10791097	0.694	rs4264159	chr11:130755784	G/T	cg09137382	chr11:130731461	NA	0.31	4.72	0.3	4.06e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs365132	0.818	rs6879982	chr5:176351330	A/T	cg16309518	chr5:176445507	NA	-0.49	-6.23	-0.38	2.14e-9	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs1348850	0.872	rs4893824	chr2:178298104	G/A	cg23306229	chr2:178417860	TTC30B	0.5	5.59	0.34	6.4e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs6700896	0.897	rs1938494	chr1:66117691	G/T	cg04111102	chr1:66153794	NA	0.35	5.55	0.34	7.6e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs8084125	0.832	rs62105175	chr18:74948498	T/C	cg05528293	chr18:74961138	GALR1	0.51	5.88	0.36	1.43e-8	Obesity-related traits;
SARC	cis	rs7011049	1.000	rs11985185	chr8:53834494	T/C	cg26025543	chr8:53854495	NA	0.6	5.47	0.34	1.15e-7	Systolic blood pressure;
SARC	cis	rs9796	0.621	rs690733	chr15:41476465	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.55	-7.97	-0.46	6.97e-14	Menopause (age at onset);
SARC	cis	rs2033732	0.706	rs7835031	chr8:85076187	C/T	cg05716166	chr8:85095498	RALYL	0.49	5.64	0.35	4.82e-8	Body mass index;
SARC	cis	rs7769051	1.000	rs9493438	chr6:133098349	T/C	cg22852734	chr6:133119734	C6orf192	1.13	11.55	0.6	1.1e-24	Type 2 diabetes nephropathy;
SARC	cis	rs10504229	0.679	rs11783557	chr8:58030644	A/G	cg11062466	chr8:58055876	NA	0.53	5.25	0.33	3.36e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs78545713	0.536	rs78759249	chr6:26208956	G/A	cg00631329	chr6:26305371	NA	-0.73	-5.26	-0.33	3.25e-7	Iron status biomarkers (total iron binding capacity);
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg11422861	chr22:30821626	MTP18	0.5	6.53	0.39	4.14e-10	Lung adenocarcinoma;
SARC	cis	rs13390159	1.000	rs60593292	chr2:237156018	T/C	cg19324714	chr2:237145437	ASB18	0.49	4.85	0.3	2.28e-6	Response to statin therapy;
SARC	cis	rs8077889	0.871	rs8065043	chr17:41900984	G/A	cg26893861	chr17:41843967	DUSP3	0.86	10.74	0.58	4.09e-22	Triglycerides;
SARC	cis	rs10911363	0.592	rs2782411	chr1:183476929	G/A	cg09173681	chr1:183549694	NCF2	0.31	4.97	0.31	1.3e-6	Systemic lupus erythematosus;
SARC	cis	rs712039	0.652	rs7226252	chr17:35794912	C/G	cg16670864	chr17:35848621	DUSP14	0.45	5.03	0.31	9.95e-7	Tuberculosis;
SARC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg04234412	chr22:24373322	LOC391322	-0.49	-5.75	-0.35	2.83e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2153535	0.580	rs6597334	chr6:8504779	C/T	cg07606381	chr6:8435919	SLC35B3	0.79	11.04	0.59	4.5e-23	Motion sickness;
SARC	cis	rs6991838	0.584	rs16932245	chr8:66510045	A/C	cg13398993	chr8:66546079	ARMC1	-0.62	-8.37	-0.48	5.33e-15	Intelligence (multi-trait analysis);
SARC	cis	rs7587476	0.954	rs3768708	chr2:215645046	C/T	cg04530015	chr2:215796436	ABCA12	0.38	6.18	0.38	2.88e-9	Neuroblastoma;
SARC	trans	rs9388451	0.626	rs1343116	chr6:126069702	C/A	cg05039488	chr6:79577232	IRAK1BP1	-0.64	-8.22	-0.47	1.43e-14	Brugada syndrome;
SARC	cis	rs6089584	0.508	rs6061988	chr20:60626300	C/T	cg06108461	chr20:60628389	TAF4	-0.72	-9.38	-0.52	5.95e-18	Body mass index;
SARC	cis	rs79149102	0.649	rs3743487	chr15:75122856	C/T	cg17294928	chr15:75287854	SCAMP5	-0.99	-5.59	-0.34	6.38e-8	Lung cancer;
SARC	cis	rs12908161	0.959	rs1051168	chr15:85200520	G/T	cg17507749	chr15:85114479	UBE2QP1	0.59	6.74	0.4	1.22e-10	Schizophrenia;
SARC	cis	rs711245	0.573	rs11899523	chr2:36800918	T/C	cg09467607	chr2:36825704	FEZ2	0.57	7.78	0.45	2.33e-13	Height;
SARC	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg19223190	chr17:80058835	NA	0.44	6.19	0.38	2.68e-9	Life satisfaction;
SARC	cis	rs7129727	1	rs7129727	chr11:57484660	G/A	cg19752551	chr11:57585705	CTNND1	-0.4	-5.47	-0.34	1.14e-7	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg25703541	chr22:24373054	LOC391322	-0.77	-9.81	-0.54	3e-19	Liver enzyme levels (gamma-glutamyl transferase);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg16267304	chr21:44985357	HSF2BP	-0.8	-6.69	-0.4	1.63e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs10911232	0.507	rs10797819	chr1:183006911	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.34	0.56	7.2e-21	Hypertriglyceridemia;
SARC	cis	rs6667605	0.527	rs4422947	chr1:2539590	C/T	cg18854424	chr1:2615690	NA	0.32	5.12	0.32	6.25e-7	Inflammatory bowel disease;Ulcerative colitis;
SARC	cis	rs7605378	0.528	rs7592587	chr2:200786516	C/G	cg17644776	chr2:200775616	C2orf69	0.52	6.43	0.39	7.1e-10	Osteoporosis;
SARC	cis	rs644799	0.965	rs565771	chr11:95644179	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.66	8.48	0.49	2.55e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2290159	0.800	rs57884385	chr3:12673551	G/C	cg23032965	chr3:12705835	RAF1	0.76	8.31	0.48	7.75e-15	Cholesterol, total;
SARC	trans	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg17712092	chr4:129076599	LARP1B	0.62	8.06	0.47	3.95e-14	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs2075371	0.966	rs2544223	chr7:133995787	A/G	cg00033643	chr7:134001901	SLC35B4	0.43	5.21	0.32	4.14e-7	Mean platelet volume;
SARC	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg02841227	chr6:26021843	HIST1H4A	0.62	7.52	0.44	1.17e-12	Intelligence (multi-trait analysis);
SARC	cis	rs1957429	0.808	rs11628910	chr14:65332392	A/G	cg23373153	chr14:65346875	NA	0.91	9.52	0.53	2.26e-18	Pediatric areal bone mineral density (radius);
SARC	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg18357526	chr6:26021779	HIST1H4A	0.84	11.56	0.6	9.61e-25	Intelligence (multi-trait analysis);
SARC	cis	rs9914988	0.887	rs4795464	chr17:27146497	G/C	cg20469991	chr17:27169893	C17orf63	-0.52	-5.39	-0.33	1.74e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs9911578	0.967	rs6503893	chr17:57149695	G/A	cg05425664	chr17:57184151	TRIM37	-0.64	-8.01	-0.46	5.41e-14	Intelligence (multi-trait analysis);
SARC	cis	rs10752881	1.000	rs8179262	chr1:182973186	C/T	cg13390022	chr1:182993471	LAMC1	0.33	5.02	0.31	1.03e-6	Colorectal cancer;
SARC	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.31	-4.82	-0.3	2.61e-6	Total body bone mineral density;
SARC	cis	rs2439831	1.000	rs2439850	chr15:43784854	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.05	10.85	0.58	1.78e-22	Lung cancer in ever smokers;
SARC	cis	rs11098499	0.542	rs7677836	chr4:120310638	T/A	cg09160332	chr4:120329925	NA	-0.33	-4.77	-0.3	3.27e-6	Corneal astigmatism;
SARC	cis	rs35213789	0.768	rs2533447	chr7:69093051	T/C	cg10619644	chr7:69149951	AUTS2	-0.45	-5.66	-0.35	4.5e-8	Childhood ear infection;
SARC	cis	rs644799	0.930	rs631099	chr11:95563482	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.68	9.17	0.51	2.6e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg21782813	chr7:2030301	MAD1L1	0.37	5.69	0.35	3.72e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs28374715	0.617	rs16971735	chr15:41563970	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.7	-9.57	-0.53	1.64e-18	Ulcerative colitis;
SARC	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.5	5.41	0.33	1.54e-7	Renal function-related traits (BUN);
SARC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg26338869	chr17:61819248	STRADA	0.8	10.7	0.57	5.44e-22	Prudent dietary pattern;
SARC	cis	rs9790314	0.631	rs2061804	chr3:161102474	C/A	cg03342759	chr3:160939853	NMD3	-0.49	-5.88	-0.36	1.38e-8	Morning vs. evening chronotype;
SARC	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg03517284	chr6:25882590	NA	0.5	6.72	0.4	1.38e-10	Blood metabolite levels;
SARC	cis	rs17376456	0.569	rs68122392	chr5:93077807	A/T	cg25358565	chr5:93447407	FAM172A	0.94	10.4	0.56	4.74e-21	Diabetic retinopathy;
SARC	cis	rs7208859	0.673	rs61223749	chr17:29163747	G/A	cg13385521	chr17:29058706	SUZ12P	0.86	7.3	0.43	4.51e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs17401966	0.809	rs12406943	chr1:10308545	T/C	cg15208524	chr1:10270712	KIF1B	0.44	5.21	0.32	4.16e-7	Hepatocellular carcinoma;
SARC	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-7.97	-0.46	7.21e-14	Chronic sinus infection;
SARC	cis	rs9462027	0.628	rs2814959	chr6:34705947	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.88	-0.36	1.39e-8	Systemic lupus erythematosus;
SARC	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg13395646	chr4:1353034	KIAA1530	-0.58	-6.89	-0.41	5.04e-11	Obesity-related traits;
SARC	cis	rs35213789	0.760	rs12533544	chr7:69025010	C/T	cg10619644	chr7:69149951	AUTS2	-0.4	-5.34	-0.33	2.16e-7	Childhood ear infection;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg08054244	chr14:88789549	KCNK10	-0.79	-6.78	-0.41	1e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs57502260	0.704	rs41478448	chr11:68181621	A/G	cg01657329	chr11:68192670	LRP5	-0.54	-5.76	-0.35	2.7e-8	Total body bone mineral density (age 45-60);
SARC	cis	rs28374715	0.580	rs8030228	chr15:41636867	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.03	-16.27	-0.73	2.81e-40	Ulcerative colitis;
SARC	cis	rs875971	0.545	rs12671152	chr7:65776127	G/T	cg25894440	chr7:65020034	NA	0.53	4.88	0.3	1.95e-6	Aortic root size;
SARC	cis	rs10197940	0.550	rs77233070	chr2:152416477	G/A	cg19508488	chr2:152266495	RIF1	0.48	5.12	0.32	6.49e-7	Lung cancer;
SARC	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg08280861	chr8:58055591	NA	0.61	5.81	0.36	2.02e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2933343	0.951	rs9871612	chr3:128570402	C/T	cg24203234	chr3:128598194	ACAD9	0.46	4.93	0.31	1.57e-6	IgG glycosylation;
SARC	cis	rs721399	0.752	rs4921914	chr8:18272438	A/G	cg18736775	chr8:18248649	NAT2	-0.41	-5.02	-0.31	1.05e-6	Blood metabolite levels;
SARC	cis	rs10791323	0.569	rs2257004	chr11:133712473	C/T	cg15485101	chr11:133734466	NA	0.33	5.08	0.32	7.91e-7	Childhood ear infection;
SARC	cis	rs2070488	0.699	rs13078966	chr3:38517914	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.81	12.3	0.63	4.01e-27	Electrocardiographic conduction measures;
SARC	cis	rs73206853	0.841	rs56324794	chr12:111086449	T/A	cg10860002	chr12:110842031	ANAPC7	0.57	4.84	0.3	2.37e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs4803468	1.000	rs284658	chr19:41929988	G/A	cg14132834	chr19:41945861	ATP5SL	-0.59	-7.75	-0.45	2.89e-13	Height;
SARC	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg15448220	chr1:150897856	SETDB1	0.48	6.34	0.38	1.18e-9	Tonsillectomy;
SARC	cis	rs10876993	0.928	rs774890	chr12:58068388	C/T	cg18357645	chr12:58087776	OS9	0.46	5.99	0.37	8.07e-9	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs13256369	1.000	rs4841016	chr8:8572561	C/T	cg18904891	chr8:8559673	CLDN23	0.5	5.81	0.36	2e-8	Obesity-related traits;
SARC	cis	rs9487051	1.000	rs9480924	chr6:109617070	T/C	cg01475377	chr6:109611718	NA	-0.4	-5.64	-0.35	4.9e-8	Reticulocyte fraction of red cells;
SARC	cis	rs35110281	0.811	rs2838339	chr21:45075750	A/G	cg01579765	chr21:45077557	HSF2BP	0.37	6.22	0.38	2.24e-9	Mean corpuscular volume;
SARC	cis	rs239198	0.602	rs9390698	chr6:101296389	G/A	cg09795085	chr6:101329169	ASCC3	0.47	5.97	0.36	8.57e-9	Menarche (age at onset);
SARC	cis	rs2280018	0.538	rs7404526	chr16:15129162	A/G	cg27102117	chr16:15229624	NA	0.49	6.22	0.38	2.3e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs2153535	0.542	rs915353	chr6:8440370	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	7.12	0.42	1.3e-11	Motion sickness;
SARC	cis	rs6831352	1.000	rs1126670	chr4:100052733	C/A	cg13256891	chr4:100009986	ADH5	0.65	8.6	0.49	1.19e-15	Alcohol dependence;
SARC	cis	rs7246657	0.943	rs9917081	chr19:37876616	T/C	cg23950597	chr19:37808831	NA	-0.63	-6.07	-0.37	5.24e-9	Coronary artery calcification;
SARC	cis	rs7249142	0.506	rs8101388	chr19:19293938	A/C	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.23	4.8	0.3	2.78e-6	IgG glycosylation;
SARC	cis	rs72634258	0.945	rs2050198	chr1:8111839	T/G	cg00042356	chr1:8021962	PARK7	0.91	8.35	0.48	6.3e-15	Inflammatory bowel disease;
SARC	trans	rs3857536	0.505	rs208459	chr6:66911055	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.71	-8.02	-0.47	5.06e-14	Blood trace element (Cu levels);
SARC	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.5e-10	Life satisfaction;
SARC	cis	rs2153535	0.601	rs1855765	chr6:8444325	C/T	cg21535247	chr6:8435926	SLC35B3	0.56	7.01	0.42	2.6e-11	Motion sickness;
SARC	cis	rs6088590	0.735	rs6060003	chr20:33294945	T/C	cg24642439	chr20:33292090	TP53INP2	0.74	10.12	0.55	3.37e-20	Coronary artery disease;
SARC	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg00908189	chr16:619842	PIGQ	0.86	12.71	0.64	1.84e-28	Height;
SARC	cis	rs7712401	0.601	rs35256179	chr5:122334255	C/A	cg19412675	chr5:122181750	SNX24	-0.43	-5.43	-0.34	1.41e-7	Mean platelet volume;
SARC	cis	rs72945132	0.882	rs17160753	chr11:70131462	A/G	cg00319359	chr11:70116639	PPFIA1	0.68	6.35	0.38	1.14e-9	Coronary artery disease;
SARC	cis	rs12762955	0.507	rs10737004	chr10:1039019	T/C	cg18964960	chr10:1102726	WDR37	-0.59	-7.23	-0.43	7.08e-12	Response to angiotensin II receptor blocker therapy;
SARC	cis	rs7666738	0.830	rs59751489	chr4:98933802	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs11992186	0.505	rs7845203	chr8:8145440	A/G	cg06636001	chr8:8085503	FLJ10661	0.52	6.12	0.37	3.96e-9	Neuroticism;
SARC	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg18357526	chr6:26021779	HIST1H4A	0.45	5.64	0.35	5.01e-8	Blood metabolite levels;
SARC	cis	rs11190604	1.000	rs2273694	chr10:102256496	G/T	cg07080220	chr10:102295463	HIF1AN	0.83	9.96	0.55	1.08e-19	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs3540	0.574	rs2601205	chr15:90961813	A/G	cg22089800	chr15:90895588	ZNF774	0.65	8.11	0.47	2.92e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	trans	rs7824557	0.734	rs2293856	chr8:11177447	C/T	cg06636001	chr8:8085503	FLJ10661	0.58	7.09	0.42	1.59e-11	Retinal vascular caliber;
SARC	cis	rs1883415	0.534	rs760906	chr6:24479845	C/T	cg20631270	chr6:24437470	GPLD1	-0.39	-5.43	-0.34	1.41e-7	Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs7617773	0.784	rs9850672	chr3:48301172	C/A	cg11946769	chr3:48343235	NME6	0.7	9.38	0.52	6.06e-18	Coronary artery disease;
SARC	cis	rs2235544	0.565	rs650134	chr1:54467342	T/C	cg10336722	chr1:54665764	CYB5RL;MRPL37	-0.38	-4.74	-0.3	3.66e-6	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
SARC	cis	rs13034020	0.522	rs35976602	chr2:61241582	G/C	cg18625361	chr2:61244694	PEX13;PUS10	0.71	6.07	0.37	5.05e-9	Hodgkin's lymphoma;
SARC	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg20607798	chr8:58055168	NA	0.56	5.27	0.33	3.12e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs17685	0.712	rs11764119	chr7:75812358	T/G	cg19862616	chr7:65841803	NCRNA00174	0.61	7.57	0.44	8.42e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs6484504	0.576	rs158140	chr11:31212971	T/C	cg26647111	chr11:31128758	NA	-0.38	-5.04	-0.31	9.49e-7	Red blood cell count;
SARC	cis	rs8180040	0.726	rs6774733	chr3:46991241	G/A	cg02527881	chr3:46936655	PTH1R	-0.31	-4.81	-0.3	2.71e-6	Colorectal cancer;
SARC	cis	rs4819052	0.679	rs2838859	chr21:46684517	C/T	cg06618935	chr21:46677482	NA	-0.37	-5.03	-0.31	9.72e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg19346786	chr7:2764209	NA	-0.39	-5.77	-0.35	2.54e-8	Height;
SARC	cis	rs6795744	0.808	rs67138915	chr3:13907483	T/C	cg19554555	chr3:13937349	NA	0.52	4.76	0.3	3.46e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs644799	0.648	rs1255178	chr11:95471908	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.49	6.06	0.37	5.57e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs853679	0.882	rs9468287	chr6:28079741	G/T	cg19592336	chr6:28129416	ZNF389	0.59	4.84	0.3	2.33e-6	Depression;
SARC	cis	rs7223966	1.000	rs8067064	chr17:61825984	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.53	-5.54	-0.34	8.29e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6570726	0.935	rs434298	chr6:145846873	G/A	cg23711669	chr6:146136114	FBXO30	0.76	11.5	0.6	1.55e-24	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg13178873	chr1:172795457	NA	-0.43	-6.3	-0.38	1.46e-9	Thyroid stimulating hormone;
SARC	trans	rs11098499	0.954	rs35091806	chr4:120325529	G/A	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	cis	rs17376456	0.825	rs28610997	chr5:93248374	T/C	cg21475434	chr5:93447410	FAM172A	0.85	7.53	0.44	1.13e-12	Diabetic retinopathy;
SARC	cis	rs787274	0.764	rs1891402	chr9:115567184	T/C	cg13803584	chr9:115635662	SNX30	-0.83	-5.01	-0.31	1.08e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg06060754	chr5:176797920	RGS14	-0.64	-8.38	-0.48	5e-15	Hemoglobin concentration;Hematocrit;
SARC	cis	rs10751667	0.600	rs1128419	chr11:1010750	G/A	cg20946044	chr11:1010712	AP2A2	-0.39	-5.57	-0.34	6.86e-8	Alzheimer's disease (late onset);
SARC	cis	rs7617773	0.779	rs1045482	chr3:48312229	A/G	cg11946769	chr3:48343235	NME6	0.65	8.8	0.5	3.06e-16	Coronary artery disease;
SARC	cis	rs858239	0.539	rs10254544	chr7:23220235	T/C	cg23682824	chr7:23144976	KLHL7	0.66	8.34	0.48	6.4e-15	Cerebrospinal fluid biomarker levels;
SARC	cis	rs5762813	0.510	rs1222	chr22:29185113	G/T	cg15103426	chr22:29168792	CCDC117	-0.63	-5.88	-0.36	1.43e-8	Hematocrit;Hemoglobin concentration;
SARC	cis	rs9815354	1.000	rs6790732	chr3:41864872	C/T	cg03022575	chr3:42003672	ULK4	0.56	5.29	0.33	2.81e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs78487399	0.808	rs6757251	chr2:43734847	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-4.87	-0.3	2.07e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs3733585	0.673	rs4697914	chr4:9952266	G/A	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.94	-0.36	1.06e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7772486	0.686	rs857875	chr6:145980033	T/G	cg23711669	chr6:146136114	FBXO30	-0.78	-12.61	-0.64	3.75e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12545109	0.800	rs2670053	chr8:57421998	A/T	cg21220214	chr8:57350948	NA	-0.4	-4.84	-0.3	2.37e-6	Obesity-related traits;
SARC	cis	rs6088580	0.634	rs6087577	chr20:32955423	C/T	cg24642439	chr20:33292090	TP53INP2	0.63	8.12	0.47	2.63e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs9547692	0.877	rs12020203	chr13:37469287	G/A	cg01493522	chr13:37497338	NA	-0.44	-4.91	-0.31	1.75e-6	Coronary artery disease;
SARC	cis	rs3733585	0.699	rs1122142	chr4:9947548	G/C	cg00071950	chr4:10020882	SLC2A9	-0.39	-6.13	-0.37	3.75e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs1568889	0.838	rs10458896	chr11:28057957	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	14.89	0.7	1.1e-35	Bipolar disorder;
SARC	cis	rs9916302	0.861	rs11078913	chr17:37671714	G/T	cg00129232	chr17:37814104	STARD3	-0.64	-7.95	-0.46	8.02e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs60012524	1	rs60012524	chr2:99559117	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-8.08	-0.47	3.43e-14	Chronic sinus infection;
SARC	cis	rs9612	1.000	rs28373139	chr19:44246706	A/G	cg08581076	chr19:44259116	C19orf61	0.73	9.09	0.51	4.42e-17	Exhaled nitric oxide output;
SARC	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg11843238	chr5:131593191	PDLIM4	0.39	5.44	0.34	1.34e-7	Breast cancer;
SARC	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg04518342	chr5:131593106	PDLIM4	-0.45	-5.68	-0.35	3.9e-8	Blood metabolite levels;
SARC	cis	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg22496380	chr5:211416	CCDC127	-0.86	-9.02	-0.51	6.97e-17	Breast cancer;
SARC	cis	rs757110	0.526	rs757081	chr11:17351683	C/G	cg15432903	chr11:17409602	KCNJ11	-0.43	-6.28	-0.38	1.63e-9	Type 2 diabetes;
SARC	cis	rs2486288	0.656	rs8040185	chr15:45552081	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.51	-6.44	-0.39	6.68e-10	Glomerular filtration rate;
SARC	cis	rs9303401	0.527	rs34835800	chr17:56764990	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.08	11.72	0.61	3.11e-25	Cognitive test performance;
SARC	cis	rs4308124	0.708	rs56693625	chr2:111965155	G/A	cg04571233	chr2:111982156	NA	-0.48	-5.65	-0.35	4.7e-8	Vitiligo;
SARC	cis	rs6570726	0.791	rs387376	chr6:145822565	T/C	cg05347473	chr6:146136440	FBXO30	0.53	7.35	0.43	3.43e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1728785	1.000	rs7202306	chr16:68587684	G/A	cg02972257	chr16:68554789	NA	-0.45	-5.32	-0.33	2.48e-7	Ulcerative colitis;
SARC	cis	rs6582630	0.615	rs10880642	chr12:38554152	A/G	cg14851346	chr12:38532713	NA	-0.4	-4.9	-0.31	1.83e-6	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs611744	0.934	rs682954	chr8:109210559	C/T	cg21045802	chr8:109455806	TTC35	0.45	5.32	0.33	2.41e-7	Dupuytren's disease;
SARC	cis	rs72781680	1.000	rs963725	chr2:24148231	T/C	cg08917208	chr2:24149416	ATAD2B	0.93	8.7	0.5	6.18e-16	Lymphocyte counts;
SARC	cis	rs2439831	1.000	rs2251538	chr15:43767209	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.05	10.85	0.58	1.78e-22	Lung cancer in ever smokers;
SARC	cis	rs2153535	0.601	rs2143352	chr6:8530248	G/C	cg23788917	chr6:8435910	SLC35B3	0.62	8.31	0.48	8.11e-15	Motion sickness;
SARC	cis	rs9790314	0.723	rs10936223	chr3:160884313	C/A	cg03342759	chr3:160939853	NMD3	-0.59	-7.54	-0.44	1.05e-12	Morning vs. evening chronotype;
SARC	cis	rs713587	0.563	rs2384057	chr2:25100167	C/G	cg04586622	chr2:25135609	ADCY3	0.33	5.8	0.36	2.13e-8	Body mass index in non-asthmatics;
SARC	cis	rs644799	1.000	rs1784135	chr11:95531748	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	14.73	0.69	3.71e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9790314	0.871	rs336551	chr3:161109720	T/C	cg03342759	chr3:160939853	NMD3	-0.56	-6.9	-0.41	4.93e-11	Morning vs. evening chronotype;
SARC	cis	rs600231	0.577	rs35826299	chr11:65240964	T/C	cg17120908	chr11:65337727	SSSCA1	-0.45	-4.99	-0.31	1.17e-6	Bone mineral density;
SARC	trans	rs7824557	0.724	rs2251473	chr8:11177126	C/A	cg06636001	chr8:8085503	FLJ10661	0.69	9.32	0.52	9.17e-18	Retinal vascular caliber;
SARC	cis	rs16976116	0.901	rs62020097	chr15:55491007	A/T	cg11288833	chr15:55489084	RSL24D1	0.63	6.09	0.37	4.66e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs651907	0.535	rs13065944	chr3:101473088	G/A	cg12386194	chr3:101231763	SENP7	0.48	5.74	0.35	2.96e-8	Colorectal cancer;
SARC	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg26335602	chr6:28129616	ZNF389	0.5	5.56	0.34	7.55e-8	Depression;
SARC	cis	rs7633770	0.643	rs1581325	chr3:46691866	T/C	cg11219411	chr3:46661640	NA	-0.41	-6.27	-0.38	1.69e-9	Coronary artery disease;
SARC	cis	rs4427176	0.660	rs59004915	chr8:9580496	C/T	cg21625330	chr8:9911636	MSRA	-0.57	-4.75	-0.3	3.6e-6	Mosquito bite size;
SARC	cis	rs4595586	0.545	rs12827823	chr12:39392144	G/T	cg26384229	chr12:38710491	ALG10B	0.5	6.12	0.37	3.98e-9	Morning vs. evening chronotype;
SARC	cis	rs8014204	0.901	rs2080087	chr14:75365062	C/T	cg06637938	chr14:75390232	RPS6KL1	0.77	11.45	0.6	2.24e-24	Caffeine consumption;
SARC	cis	rs17345786	0.906	rs59359251	chr3:101146362	A/C	cg12386194	chr3:101231763	SENP7	0.81	9.48	0.53	3.02e-18	Colonoscopy-negative controls vs population controls;
SARC	cis	rs3820928	0.874	rs10202239	chr2:227901819	C/T	cg05526886	chr2:227700861	RHBDD1	-0.5	-5.95	-0.36	9.58e-9	Pulmonary function;
SARC	cis	rs11122272	0.701	rs2486725	chr1:231540288	G/C	cg06096015	chr1:231504339	EGLN1	0.38	5.58	0.34	6.77e-8	Hemoglobin concentration;
SARC	cis	rs17376456	0.877	rs13185660	chr5:93336500	G/A	cg25358565	chr5:93447407	FAM172A	1.3	14.45	0.69	3.26e-34	Diabetic retinopathy;
SARC	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.7	-8.4	-0.48	4.45e-15	Height;
SARC	cis	rs6545883	0.783	rs7355640	chr2:61845485	C/T	cg15711740	chr2:61764176	XPO1	-0.46	-5.74	-0.35	2.97e-8	Tuberculosis;
SARC	cis	rs9325144	0.560	rs6582561	chr12:38666821	G/A	cg13010199	chr12:38710504	ALG10B	-0.56	-6.97	-0.42	3.3e-11	Morning vs. evening chronotype;
SARC	cis	rs6964587	1.000	rs12539231	chr7:91634963	G/A	cg17063962	chr7:91808500	NA	0.95	15.96	0.72	3.08e-39	Breast cancer;
SARC	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg22535103	chr8:58192502	C8orf71	-0.79	-9.22	-0.52	1.77e-17	Developmental language disorder (linguistic errors);
SARC	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	10.82	0.58	2.26e-22	Platelet count;
SARC	cis	rs7729447	0.813	rs7715571	chr5:32690010	A/C	cg16267343	chr5:32710456	NPR3	0.62	8.26	0.48	1.09e-14	Blood pressure;
SARC	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg03806693	chr22:41940476	POLR3H	-0.93	-12.83	-0.64	7.61e-29	Vitiligo;
SARC	cis	rs4660261	0.526	rs2906466	chr1:44322220	A/G	cg12908607	chr1:44402522	ARTN	-0.34	-5.79	-0.35	2.23e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9840812	0.598	rs33999043	chr3:136100040	G/A	cg15507776	chr3:136538369	TMEM22	0.63	6.36	0.38	1.05e-9	Fibrinogen levels;
SARC	cis	rs9611519	0.542	rs8139770	chr22:41416181	C/T	cg03806693	chr22:41940476	POLR3H	-0.6	-7.98	-0.46	6.6e-14	Neuroticism;
SARC	cis	rs73206853	0.764	rs67828368	chr12:110546298	C/T	cg10860002	chr12:110842031	ANAPC7	0.65	5.19	0.32	4.51e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs950776	0.518	rs12906951	chr15:78825562	C/T	cg06917634	chr15:78832804	PSMA4	0.91	14.24	0.68	1.6e-33	Sudden cardiac arrest;
SARC	cis	rs5753618	0.504	rs5753669	chr22:31905819	T/G	cg02404636	chr22:31891804	SFI1	0.53	5.91	0.36	1.2e-8	Colorectal cancer;
SARC	cis	rs9640161	0.789	rs3735174	chr7:150020489	T/C	cg17279839	chr7:150038598	RARRES2	0.48	7.12	0.42	1.32e-11	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs56011263	0.687	rs4690188	chr4:703930	G/C	cg14024328	chr4:719362	PCGF3	-0.42	-5.62	-0.35	5.33e-8	White blood cell count;
SARC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg26338869	chr17:61819248	STRADA	0.79	10.59	0.57	1.17e-21	Prudent dietary pattern;
SARC	cis	rs7223966	1.000	rs7220821	chr17:61704147	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.45	5.05	0.31	8.71e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1865760	1.000	rs9358893	chr6:25921761	A/G	cg17691542	chr6:26056736	HIST1H1C	0.58	7.11	0.42	1.4e-11	Height;
SARC	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg15448220	chr1:150897856	SETDB1	0.51	6.52	0.39	4.3e-10	Melanoma;
SARC	cis	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg03060546	chr3:49711283	APEH	0.75	11.17	0.59	1.7e-23	Resting heart rate;
SARC	cis	rs9346455	0.614	rs2208845	chr6:71997278	T/C	cg27238071	chr6:71998145	OGFRL1	0.56	4.77	0.3	3.29e-6	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
SARC	cis	rs35110281	0.591	rs162369	chr21:44931965	G/A	cg01579765	chr21:45077557	HSF2BP	-0.34	-5.77	-0.35	2.49e-8	Mean corpuscular volume;
SARC	cis	rs9916302	0.904	rs8076546	chr17:37555403	G/A	cg15445000	chr17:37608096	MED1	-0.4	-4.8	-0.3	2.88e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs2421770	0.530	rs3858470	chr11:35365444	T/C	cg13971030	chr11:35366721	SLC1A2	-0.33	-4.99	-0.31	1.18e-6	Staphylococcus aureus nasal carriage (persistent);
SARC	cis	rs12579753	0.879	rs11615729	chr12:82128318	T/A	cg07988820	chr12:82153109	PPFIA2	-0.6	-7.09	-0.42	1.55e-11	Resting heart rate;
SARC	cis	rs965469	0.817	rs16988490	chr20:3335431	C/T	cg25506879	chr20:3388711	C20orf194	0.45	4.78	0.3	3.09e-6	IFN-related cytopenia;
SARC	cis	rs9479482	0.935	rs9479513	chr6:150367320	G/T	cg03788504	chr6:150331562	NA	-0.32	-5.23	-0.32	3.69e-7	Alopecia areata;
SARC	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7582720	0.943	rs72934734	chr2:203739970	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.28	0.43	5.16e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs11578119	0.933	rs72709772	chr1:170470418	C/G	cg09767346	chr1:170501363	GORAB	0.4	4.74	0.3	3.8e-6	Male-pattern baldness;
SARC	cis	rs72634258	0.554	rs17374781	chr1:7919363	A/G	cg05338066	chr1:7812865	CAMTA1	-0.53	-5.01	-0.31	1.06e-6	Inflammatory bowel disease;
SARC	cis	rs644148	0.836	rs2686775	chr19:45000059	C/T	cg15540054	chr19:45004280	ZNF180	-0.43	-5.02	-0.31	1.05e-6	Personality dimensions;
SARC	cis	rs7553864	0.835	rs4415539	chr1:87604245	C/T	cg18153957	chr1:87613403	LOC339524	0.41	4.93	0.31	1.59e-6	Smoking behavior;
SARC	cis	rs9398803	0.723	rs1101556	chr6:127067803	T/G	cg19875578	chr6:126661172	C6orf173	-0.59	-8.21	-0.47	1.53e-14	Male-pattern baldness;
SARC	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg05861140	chr6:150128134	PCMT1	-0.41	-5.15	-0.32	5.56e-7	Lung cancer;
SARC	cis	rs7659604	1.000	rs6846232	chr4:122664805	A/G	cg19671926	chr4:122722719	EXOSC9	-0.48	-5.92	-0.36	1.11e-8	Type 2 diabetes;
SARC	cis	rs228437	1.000	rs1474828	chr6:134926962	A/C	cg24504307	chr6:134963096	NA	0.52	6.11	0.37	4.11e-9	Melanoma;
SARC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg21724239	chr8:58056113	NA	0.61	6.43	0.39	7.16e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg01017244	chr2:74357527	NA	0.54	6.64	0.4	2.25e-10	Gestational age at birth (maternal effect);
SARC	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg03433033	chr1:76189801	ACADM	0.55	7.74	0.45	2.97e-13	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.48	-5.48	-0.34	1.12e-7	Huntington's disease progression;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg02399570	chr3:156877196	CCNL1	-0.57	-6.39	-0.39	9.15e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg11644478	chr21:40555479	PSMG1	1.04	13.13	0.65	7.33e-30	Cognitive function;
SARC	cis	rs4481887	0.830	rs10888341	chr1:248441995	T/C	cg13385794	chr1:248469461	NA	0.35	5.28	0.33	2.96e-7	Common traits (Other);
SARC	cis	rs17401966	1.000	rs1049887	chr1:10460485	T/C	cg15208524	chr1:10270712	KIF1B	0.48	4.97	0.31	1.32e-6	Hepatocellular carcinoma;
SARC	cis	rs910316	1.000	rs876403	chr14:75602834	A/T	cg11812906	chr14:75593930	NEK9	0.88	13.9	0.67	2.19e-32	Height;
SARC	cis	rs67311347	0.544	rs4974047	chr3:40339653	G/T	cg24209194	chr3:40518798	ZNF619	0.48	6.49	0.39	5.04e-10	Renal cell carcinoma;
SARC	cis	rs4919087	0.561	rs61861820	chr10:98998974	G/A	cg25902810	chr10:99078978	FRAT1	-0.54	-5.72	-0.35	3.29e-8	Monocyte count;
SARC	cis	rs2952156	0.883	rs907088	chr17:37833567	G/C	cg00129232	chr17:37814104	STARD3	-0.7	-10.11	-0.55	3.81e-20	Asthma;
SARC	cis	rs505401	0.504	rs114349183	chr19:6119517	G/A	cg18109231	chr19:6110877	RFX2	0.9	5.5	0.34	1.02e-7	Mean platelet volume;
SARC	cis	rs752010	0.806	rs1109255	chr1:42091708	C/T	cg06885757	chr1:42089581	HIVEP3	0.41	6.21	0.38	2.44e-9	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs9547692	1.000	rs9531993	chr13:37475197	G/C	cg01493522	chr13:37497338	NA	-0.45	-5.07	-0.32	8.06e-7	Coronary artery disease;
SARC	cis	rs7927771	0.832	rs4992357	chr11:47393638	C/T	cg20307385	chr11:47447363	PSMC3	-0.52	-6.48	-0.39	5.44e-10	Subjective well-being;
SARC	cis	rs193541	0.632	rs26370	chr5:122235192	T/C	cg19412675	chr5:122181750	SNX24	0.49	6.22	0.38	2.29e-9	Glucose homeostasis traits;
SARC	trans	rs2624839	0.639	rs2526389	chr3:50192826	C/T	cg21659725	chr3:3221576	CRBN	0.53	6.7	0.4	1.57e-10	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg11764359	chr7:65958608	NA	0.88	12.58	0.64	4.89e-28	Aortic root size;
SARC	cis	rs6456156	0.774	rs1556413	chr6:167524743	G/A	cg07741184	chr6:167504864	NA	-0.27	-4.98	-0.31	1.27e-6	Primary biliary cholangitis;
SARC	cis	rs10870270	1.000	rs7078692	chr10:133775370	T/A	cg26149184	chr10:133730230	NA	0.45	4.86	0.3	2.17e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs870825	0.655	rs28555435	chr4:185647300	C/A	cg04058563	chr4:185651563	MLF1IP	0.8	11.35	0.6	4.56e-24	Blood protein levels;
SARC	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg03060546	chr3:49711283	APEH	0.76	10.94	0.58	9.37e-23	Resting heart rate;
SARC	cis	rs2952156	0.920	rs12150298	chr17:37834541	T/C	cg00129232	chr17:37814104	STARD3	-0.7	-10.11	-0.55	3.81e-20	Asthma;
SARC	cis	rs72945132	0.598	rs61887433	chr11:70240997	A/G	cg05964544	chr11:70165517	PPFIA1	-0.66	-6.64	-0.4	2.14e-10	Coronary artery disease;
SARC	cis	rs412050	0.649	rs117808805	chr22:22246629	C/T	cg17089214	chr22:22089827	YPEL1	0.65	5.84	0.36	1.74e-8	Attention deficit hyperactivity disorder;
SARC	cis	rs10089	0.953	rs13358455	chr5:127365786	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.87	10.32	0.56	8.35e-21	Ileal carcinoids;
SARC	cis	rs599083	0.530	rs689179	chr11:68179166	A/G	cg01657329	chr11:68192670	LRP5	0.47	6.36	0.38	1.07e-9	Bone mineral density (spine);
SARC	cis	rs17253792	0.822	rs17253730	chr14:56157911	A/G	cg01858014	chr14:56050164	KTN1	-0.62	-4.78	-0.3	3.12e-6	Putamen volume;
SARC	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg06558623	chr16:89946397	TCF25	0.9	6.1	0.37	4.45e-9	Skin colour saturation;
SARC	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg03433033	chr1:76189801	ACADM	-0.47	-6.78	-0.41	9.69e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg07414643	chr4:187882934	NA	-0.36	-5.0	-0.31	1.11e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6815814	0.861	rs73142654	chr4:38785697	T/A	cg06935464	chr4:38784597	TLR10	0.5	5.69	0.35	3.82e-8	Breast cancer;
SARC	cis	rs35995292	0.534	rs2392604	chr7:38918012	C/T	cg19327137	chr7:38886074	VPS41	0.52	7.8	0.46	2.05e-13	Subjective well-being (multi-trait analysis);
SARC	cis	rs1707322	0.964	rs1768802	chr1:46547868	A/G	cg03146154	chr1:46216737	IPP	-0.48	-5.66	-0.35	4.54e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs61931739	0.613	rs61927732	chr12:33678166	T/C	cg26384229	chr12:38710491	ALG10B	-0.55	-6.82	-0.41	7.72e-11	Morning vs. evening chronotype;
SARC	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg02297831	chr4:17616191	MED28	0.51	6.6	0.4	2.78e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs8036030	0.604	rs11852686	chr15:74715205	A/G	cg10253484	chr15:75165896	SCAMP2	-0.49	-5.93	-0.36	1.09e-8	Airflow obstruction;
SARC	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg18876405	chr7:65276391	NA	-0.44	-4.91	-0.31	1.75e-6	Aortic root size;
SARC	cis	rs9911578	0.935	rs6503878	chr17:56884581	T/G	cg05425664	chr17:57184151	TRIM37	-0.65	-8.03	-0.47	4.77e-14	Intelligence (multi-trait analysis);
SARC	cis	rs76419734	1.000	rs111873045	chr4:106639712	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.84	5.41	0.33	1.59e-7	Post bronchodilator FEV1;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg06789412	chr3:101405552	RPL24	-0.62	-7.24	-0.43	6.42e-12	Brain volume in infants (cerebrospinal fluid);
SARC	trans	rs1814175	0.626	rs1722008	chr11:49897676	A/T	cg03929089	chr4:120376271	NA	-0.88	-14.27	-0.68	1.29e-33	Height;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg01729401	chr1:1750560	GNB1	0.45	6.25	0.38	1.93e-9	Thyroid stimulating hormone;
SARC	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.61	0.34	5.84e-8	Bipolar disorder;
SARC	cis	rs11190604	0.652	rs76629555	chr10:102191417	T/C	cg07080220	chr10:102295463	HIF1AN	0.71	8.15	0.47	2.29e-14	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs7089973	0.526	rs17722042	chr10:116738544	A/G	cg08188268	chr10:116634841	FAM160B1	0.4	5.17	0.32	5.02e-7	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg12311346	chr5:56204834	C5orf35	-0.61	-6.36	-0.38	1.08e-9	Initial pursuit acceleration;
SARC	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.57	-7.3	-0.43	4.5e-12	Mean platelet volume;
SARC	cis	rs3859192	0.599	rs12451897	chr17:38179275	G/T	cg17344932	chr17:38183730	MED24;SNORD124	0.4	7.49	0.44	1.38e-12	White blood cell count;
SARC	cis	rs3741151	0.773	rs58334887	chr11:73171510	A/C	cg17517138	chr11:73019481	ARHGEF17	0.92	6.86	0.41	6.23e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs7772486	0.625	rs2050027	chr6:146116113	C/G	cg05347473	chr6:146136440	FBXO30	-0.51	-7.16	-0.42	1.05e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9400467	0.537	rs12192695	chr6:111453046	C/T	cg15721981	chr6:111408429	SLC16A10	0.69	5.88	0.36	1.39e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs3126085	0.866	rs3126066	chr1:152276871	A/G	cg03465714	chr1:152285911	FLG	0.44	4.94	0.31	1.49e-6	Atopic dermatitis;
SARC	cis	rs79149102	0.522	rs7175512	chr15:74832981	G/T	cg09165964	chr15:75287851	SCAMP5	-0.66	-5.1	-0.32	7.06e-7	Lung cancer;
SARC	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg16325326	chr1:53192061	ZYG11B	-0.67	-9.94	-0.55	1.26e-19	Monocyte count;
SARC	cis	rs2072499	1.000	rs2241107	chr1:156182710	C/T	cg24450063	chr1:156163899	SLC25A44	-1.14	-19.86	-0.79	5.1e-52	Testicular germ cell tumor;
SARC	cis	rs709400	0.633	rs3783395	chr14:103895020	T/C	cg12935359	chr14:103987150	CKB	-0.41	-5.95	-0.36	9.71e-9	Body mass index;
SARC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.33	-5.0	-0.31	1.11e-6	Total body bone mineral density;
SARC	cis	rs9787249	0.957	rs1046988	chr1:40219065	A/G	cg02773041	chr1:40204384	PPIE	-0.52	-6.44	-0.39	6.73e-10	Blood protein levels;
SARC	cis	rs2504916	1.000	rs986666	chr6:160813408	A/G	cg20340146	chr6:160172821	WTAP	0.47	4.73	0.3	3.93e-6	Response to hepatitis C treatment;
SARC	cis	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg11987759	chr7:65425863	GUSB	-0.61	-8.19	-0.47	1.72e-14	Aortic root size;
SARC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg07332563	chr6:291687	DUSP22	0.6	8.27	0.48	1.01e-14	Menopause (age at onset);
SARC	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg11644478	chr21:40555479	PSMG1	-0.9	-11.49	-0.6	1.65e-24	Cognitive function;
SARC	cis	rs4423214	1.000	rs2002063	chr11:71163476	T/C	cg24826892	chr11:71159390	DHCR7	0.43	5.24	0.32	3.64e-7	Vitamin D levels;
SARC	cis	rs34172651	0.517	rs2303083	chr16:24835168	G/A	cg00339695	chr16:24857497	SLC5A11	0.42	5.54	0.34	8.03e-8	Intelligence (multi-trait analysis);
SARC	cis	rs957448	0.698	rs116348949	chr8:95569716	A/T	cg26464482	chr8:95565502	KIAA1429	0.43	5.17	0.32	4.96e-7	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg02297831	chr4:17616191	MED28	0.49	6.35	0.38	1.13e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2180341	1.000	rs9401950	chr6:127655485	C/T	cg27446573	chr6:127587934	RNF146	1.04	14.77	0.7	2.87e-35	Breast cancer;
SARC	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.57	6.85	0.41	6.47e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6831352	0.918	rs29001195	chr4:100054244	G/T	cg13256891	chr4:100009986	ADH5	-0.64	-8.0	-0.46	5.7e-14	Alcohol dependence;
SARC	cis	rs957448	0.948	rs72674867	chr8:95578201	A/T	cg26464482	chr8:95565502	KIAA1429	0.44	4.85	0.3	2.23e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg00684032	chr4:1343700	KIAA1530	0.48	6.91	0.41	4.49e-11	Obesity-related traits;
SARC	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg23758822	chr17:41437982	NA	0.88	11.24	0.59	1.04e-23	Menopause (age at onset);
SARC	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg21782813	chr7:2030301	MAD1L1	0.4	5.89	0.36	1.34e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs11997175	0.625	rs953617	chr8:33599158	G/C	ch.8.33884649F	chr8:33765107	NA	0.49	6.31	0.38	1.39e-9	Body mass index;
SARC	cis	rs8067545	0.641	rs203482	chr17:19827210	G/A	cg04132472	chr17:19861366	AKAP10	0.41	5.46	0.34	1.2e-7	Schizophrenia;
SARC	cis	rs1707322	0.717	rs1135812	chr1:46095272	T/C	cg03146154	chr1:46216737	IPP	0.51	6.07	0.37	5.01e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs61352607	0.920	rs7397189	chr12:57728776	T/G	cg02059047	chr12:57634677	NDUFA4L2	0.43	4.73	0.3	3.91e-6	Triglycerides;
SARC	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	cis	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg00071950	chr4:10020882	SLC2A9	0.41	6.61	0.4	2.57e-10	Bone mineral density;
SARC	cis	rs7520050	0.966	rs11211230	chr1:46406767	G/T	cg24296786	chr1:45957014	TESK2	0.38	4.8	0.3	2.82e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs9916302	0.706	rs582176	chr17:37453999	T/C	cg00129232	chr17:37814104	STARD3	0.54	5.76	0.35	2.7e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.65	0.53	9.21e-19	Prudent dietary pattern;
SARC	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg07636037	chr3:49044803	WDR6	0.64	8.43	0.48	3.62e-15	Resting heart rate;
SARC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg09373136	chr17:61933544	TCAM1	-0.45	-6.12	-0.37	3.92e-9	Prudent dietary pattern;
SARC	cis	rs9462027	0.628	rs28675115	chr6:34732514	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.85	-0.36	1.69e-8	Systemic lupus erythematosus;
SARC	cis	rs9486715	0.867	rs4598081	chr6:96975227	A/G	cg06623918	chr6:96969491	KIAA0776	0.94	14.14	0.68	3.42e-33	Headache;
SARC	cis	rs950027	0.620	rs1153857	chr15:45659095	G/T	cg21132104	chr15:45694354	SPATA5L1	0.55	7.07	0.42	1.84e-11	Response to fenofibrate (adiponectin levels);
SARC	cis	rs78487399	0.808	rs17030845	chr2:43687879	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-4.97	-0.31	1.31e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs2486288	0.656	rs2413773	chr15:45549442	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.45	-5.57	-0.34	7.07e-8	Glomerular filtration rate;
SARC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.33	-5.0	-0.31	1.11e-6	Total body bone mineral density;
SARC	cis	rs6580649	0.882	rs2286022	chr12:48436647	G/A	cg24011408	chr12:48396354	COL2A1	-0.51	-5.48	-0.34	1.12e-7	Lung cancer;
SARC	cis	rs3768617	0.706	rs10797801	chr1:182971965	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.67	9.77	0.54	4.08e-19	Fuchs's corneal dystrophy;
SARC	cis	rs4253772	0.591	rs8143066	chr22:46656607	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.63	6.75	0.4	1.17e-10	LDL cholesterol;Cholesterol, total;
SARC	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg26681399	chr22:41777847	TEF	-0.43	-4.81	-0.3	2.68e-6	Vitiligo;
SARC	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg05890377	chr2:74357713	NA	0.59	7.19	0.43	8.94e-12	Gestational age at birth (maternal effect);
SARC	cis	rs55692411	0.537	rs7648652	chr3:50135412	A/C	cg14019146	chr3:50243930	SLC38A3	-0.34	-4.8	-0.3	2.81e-6	Intelligence (multi-trait analysis);
SARC	cis	rs136211	0.929	rs2413399	chr22:36766481	A/G	cg16924664	chr22:36878180	TXN2	0.41	5.01	0.31	1.09e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2228479	0.702	rs2074963	chr16:89877269	T/C	cg00800038	chr16:89945340	TCF25	-0.83	-5.6	-0.34	6.1e-8	Skin colour saturation;
SARC	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs12586317	0.620	rs28404080	chr14:35539418	G/T	cg16230307	chr14:35515116	FAM177A1	0.93	10.88	0.58	1.49e-22	Psoriasis;
SARC	cis	rs9640161	0.750	rs1983440	chr7:150023941	G/C	cg17279839	chr7:150038598	RARRES2	0.47	6.62	0.4	2.5e-10	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs738322	0.753	rs2267372	chr22:38598234	A/G	cg25457927	chr22:38595422	NA	0.37	7.8	0.45	2.11e-13	Cutaneous nevi;
SARC	cis	rs4268898	1.000	rs6746005	chr2:24434345	G/A	cg26838691	chr2:24397539	C2orf84	0.38	5.12	0.32	6.42e-7	Asthma;
SARC	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg02951883	chr7:2050386	MAD1L1	-0.53	-6.83	-0.41	7.14e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg24110177	chr3:50126178	RBM5	0.39	5.04	0.31	9.18e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9816226	0.591	rs75160594	chr3:185810481	C/G	cg00760338	chr3:185826511	ETV5	-0.83	-8.15	-0.47	2.19e-14	Obesity;Body mass index;
SARC	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg18876405	chr7:65276391	NA	-0.45	-5.58	-0.34	6.61e-8	Aortic root size;
SARC	cis	rs7223966	1.000	rs6504169	chr17:61709145	A/G	cg00588841	chr17:61851480	DDX42;CCDC47	-0.6	-6.56	-0.39	3.52e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7819412	0.521	rs11777887	chr8:11036799	C/G	cg21775007	chr8:11205619	TDH	0.46	5.82	0.36	1.96e-8	Triglycerides;
SARC	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.95	-15.39	-0.71	2.34e-37	Chronic sinus infection;
SARC	cis	rs6840360	0.571	rs4696275	chr4:152530981	C/T	cg22705602	chr4:152727874	NA	-0.43	-6.76	-0.41	1.07e-10	Intelligence (multi-trait analysis);
SARC	cis	rs8180040	0.966	rs13064843	chr3:47415467	C/T	cg27129171	chr3:47204927	SETD2	0.66	9.06	0.51	5.37e-17	Colorectal cancer;
SARC	cis	rs8180040	0.764	rs13084117	chr3:47183239	C/A	cg02527881	chr3:46936655	PTH1R	-0.31	-4.91	-0.31	1.69e-6	Colorectal cancer;
SARC	cis	rs7937682	0.847	rs500163	chr11:111462649	T/G	cg09085632	chr11:111637200	PPP2R1B	-0.93	-14.06	-0.68	6.32e-33	Primary sclerosing cholangitis;
SARC	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg18252515	chr7:66147081	NA	-1.34	-11.74	-0.61	2.62e-25	Diabetic kidney disease;
SARC	cis	rs7617773	0.643	rs78159520	chr3:48349023	T/C	cg11946769	chr3:48343235	NME6	0.75	9.62	0.53	1.18e-18	Coronary artery disease;
SARC	cis	rs7084402	0.967	rs1649069	chr10:60303695	A/G	cg07615347	chr10:60278583	BICC1	-0.56	-8.01	-0.46	5.56e-14	Refractive error;
SARC	cis	rs9733	0.650	rs4970923	chr1:150608300	A/G	cg13175981	chr1:150552382	MCL1	0.69	9.34	0.52	8.2e-18	Tonsillectomy;
SARC	cis	rs7223966	0.921	rs67018565	chr17:61928055	C/A	cg26338869	chr17:61819248	STRADA	0.48	5.2	0.32	4.28e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6998277	0.830	rs965661	chr8:103597586	C/T	cg10187029	chr8:103597600	NA	0.89	12.66	0.64	2.61e-28	Migraine;
SARC	cis	rs524281	1.000	rs472518	chr11:65851902	A/G	cg14036092	chr11:66035641	RAB1B	0.51	5.81	0.36	2.06e-8	Electroencephalogram traits;
SARC	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg17376030	chr22:41985996	PMM1	0.78	9.84	0.54	2.55e-19	Vitiligo;
SARC	cis	rs6904897	0.538	rs4639353	chr6:135224328	A/G	cg22676075	chr6:135203613	NA	-0.7	-10.37	-0.56	5.93e-21	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs918629	0.567	rs2546191	chr5:95232541	G/A	cg16656078	chr5:95278638	ELL2	-0.52	-6.56	-0.39	3.46e-10	IgG glycosylation;
SARC	cis	rs12079745	0.623	rs115415855	chr1:169322993	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.98	-5.75	-0.35	2.79e-8	QT interval;
SARC	cis	rs9768139	0.566	rs729099	chr7:158114152	C/T	cg06219351	chr7:158114137	PTPRN2	-0.33	-5.83	-0.36	1.82e-8	Calcium levels;
SARC	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg12648201	chr2:27665141	KRTCAP3	-0.32	-4.87	-0.3	2.04e-6	Total body bone mineral density;
SARC	cis	rs12893668	0.667	rs71417869	chr14:104077434	A/G	cg26031613	chr14:104095156	KLC1	-0.54	-6.02	-0.37	6.59e-9	Reticulocyte count;
SARC	cis	rs11758351	1.000	rs80095925	chr6:26184942	C/T	cg23601095	chr6:26197514	HIST1H3D	0.65	5.34	0.33	2.17e-7	Gout;Renal underexcretion gout;
SARC	cis	rs9858542	0.537	rs115753735	chr3:49355005	T/C	cg00383909	chr3:49044727	WDR6	0.53	5.64	0.35	4.83e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs11122272	0.677	rs2808615	chr1:231550171	G/A	cg06096015	chr1:231504339	EGLN1	-0.38	-5.71	-0.35	3.37e-8	Hemoglobin concentration;
SARC	trans	rs7937682	0.961	rs552387	chr11:111490047	T/G	cg18187862	chr3:45730750	SACM1L	0.54	6.81	0.41	8.41e-11	Primary sclerosing cholangitis;
SARC	cis	rs9818758	0.882	rs74926817	chr3:49378833	C/G	cg00383909	chr3:49044727	WDR6	0.53	5.23	0.32	3.72e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs3126085	1.000	rs72696969	chr1:152196339	G/A	cg26876637	chr1:152193138	HRNR	-0.51	-5.25	-0.33	3.46e-7	Atopic dermatitis;
SARC	cis	rs957448	1.000	rs1048029	chr8:95522377	G/C	cg26464482	chr8:95565502	KIAA1429	0.43	4.74	0.3	3.73e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs17854409	0.803	rs1063247	chr20:61472118	C/G	cg05147244	chr20:61493195	TCFL5	0.94	6.03	0.37	6.42e-9	Obesity-related traits;
SARC	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg08859206	chr1:53392774	SCP2	-0.35	-4.95	-0.31	1.44e-6	Monocyte count;
SARC	cis	rs477692	0.789	rs506915	chr10:131398005	A/G	cg26102564	chr10:131424627	MGMT	0.29	4.89	0.3	1.9e-6	Response to temozolomide;
SARC	trans	rs7980799	0.649	rs2389218	chr12:33680929	C/A	cg13010199	chr12:38710504	ALG10B	0.59	6.81	0.41	8.08e-11	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs7223966	1.000	rs8081612	chr17:61724695	A/G	cg00588841	chr17:61851480	DDX42;CCDC47	0.57	6.48	0.39	5.36e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6685188	0.925	rs12752037	chr1:205661614	A/C	cg07157834	chr1:205819609	PM20D1	-0.4	-4.84	-0.3	2.34e-6	White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs35955747	0.838	rs28716	chr22:31730189	A/C	cg13145458	chr22:31556086	RNF185	-0.41	-5.2	-0.32	4.42e-7	Neutrophil count;Sum basophil neutrophil counts;
SARC	cis	rs11697848	1.000	rs75621680	chr20:48576524	G/A	cg17849948	chr20:48532315	SPATA2	0.92	5.49	0.34	1.05e-7	Systemic lupus erythematosus;
SARC	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg11366901	chr6:160182831	ACAT2	0.96	9.65	0.53	9.65e-19	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs2075371	1.000	rs1421486	chr7:133985196	T/C	cg11752832	chr7:134001865	SLC35B4	0.57	7.43	0.44	1.99e-12	Mean platelet volume;
SARC	cis	rs35306767	0.903	rs35968821	chr10:910225	A/G	cg20503657	chr10:835505	NA	0.88	8.33	0.48	6.91e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs4555082	0.915	rs79048296	chr14:105754944	G/A	cg06808227	chr14:105710500	BRF1	-0.5	-6.11	-0.37	4.17e-9	Mean platelet volume;Platelet distribution width;
SARC	cis	rs57506017	1.000	rs57506017	chr7:12245225	A/T	cg23422036	chr7:12250390	TMEM106B	0.43	5.01	0.31	1.07e-6	Neuroticism;
SARC	trans	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg20587970	chr11:113659929	NA	-1.38	-13.71	-0.67	8.88e-32	Hip circumference adjusted for BMI;
SARC	cis	rs7599312	0.534	rs7596285	chr2:213406961	G/A	cg20637307	chr2:213403960	ERBB4	0.8	12.33	0.63	3.21e-27	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg01570182	chr17:44337453	NA	-0.82	-9.75	-0.54	4.71e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs72945132	0.825	rs947811	chr11:70209142	A/T	cg00319359	chr11:70116639	PPFIA1	0.67	6.21	0.38	2.36e-9	Coronary artery disease;
SARC	trans	rs1994135	0.654	rs1447872	chr12:33718343	C/A	cg13010199	chr12:38710504	ALG10B	0.76	8.92	0.5	1.41e-16	Resting heart rate;
SARC	cis	rs4132509	0.793	rs7522883	chr1:243803022	C/T	cg21452805	chr1:244014465	NA	0.61	5.77	0.35	2.57e-8	RR interval (heart rate);
SARC	cis	rs10465746	0.725	rs2024591	chr1:84329235	C/T	cg10977910	chr1:84465055	TTLL7	0.49	5.93	0.36	1.1e-8	Obesity-related traits;
SARC	cis	rs116095464	0.558	rs9312978	chr5:221930	C/G	cg22857025	chr5:266934	NA	-1.11	-10.4	-0.56	4.74e-21	Breast cancer;
SARC	cis	rs6121246	0.559	rs1484994	chr20:30305975	A/G	cg13852791	chr20:30311386	BCL2L1	0.88	10.86	0.58	1.7e-22	Mean corpuscular hemoglobin;
SARC	cis	rs2070488	0.965	rs9877282	chr3:38541452	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.8	-12.9	-0.65	4.27e-29	Electrocardiographic conduction measures;
SARC	cis	rs17095355	1.000	rs12242642	chr10:111724213	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.42	-4.76	-0.3	3.35e-6	Biliary atresia;
SARC	cis	rs4242434	0.536	rs1871900	chr8:22481449	A/G	cg03733263	chr8:22462867	KIAA1967	0.8	11.66	0.61	4.87e-25	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg00933542	chr6:150070202	PCMT1	0.31	5.27	0.33	3.05e-7	Lung cancer;
SARC	cis	rs7043114	0.525	rs7863406	chr9:95053381	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-5.47	-0.34	1.16e-7	Height;
SARC	cis	rs4295623	0.585	rs13259242	chr8:11593033	T/G	cg00262122	chr8:11665843	FDFT1	-0.44	-5.19	-0.32	4.53e-7	Morning vs. evening chronotype;
SARC	cis	rs965469	0.779	rs6051780	chr20:3334167	A/C	cg25506879	chr20:3388711	C20orf194	-0.47	-5.11	-0.32	6.81e-7	IFN-related cytopenia;
SARC	cis	rs9818758	0.607	rs4855860	chr3:49526044	A/T	cg01304814	chr3:48885189	PRKAR2A	-0.78	-5.42	-0.33	1.46e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg08045932	chr20:61659980	NA	0.5	6.84	0.41	7.06e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs1865760	1.000	rs2071298	chr6:25914901	G/A	cg10373733	chr6:25993375	NA	0.41	4.83	0.3	2.42e-6	Height;
SARC	cis	rs8028182	0.549	rs11072542	chr15:75634599	G/A	cg20655648	chr15:75932815	IMP3	-0.65	-7.49	-0.44	1.38e-12	Sudden cardiac arrest;
SARC	cis	rs10875746	0.951	rs2269935	chr12:48516464	G/T	cg27446233	chr12:48516484	PFKM	-0.43	-4.79	-0.3	2.94e-6	Longevity (90 years and older);
SARC	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg18876405	chr7:65276391	NA	0.7	8.79	0.5	3.26e-16	Aortic root size;
SARC	cis	rs2180341	0.814	rs6919082	chr6:127737888	T/G	cg24812749	chr6:127587940	RNF146	0.78	9.68	0.54	7.39e-19	Breast cancer;
SARC	cis	rs7647973	0.710	rs7629322	chr3:49621994	C/T	cg06212747	chr3:49208901	KLHDC8B	0.74	6.68	0.4	1.72e-10	Menarche (age at onset);
SARC	cis	rs7681440	0.904	rs6817001	chr4:90766019	C/T	cg06632027	chr4:90757378	SNCA	0.39	5.66	0.35	4.49e-8	Dementia with Lewy bodies;
SARC	cis	rs2180341	0.597	rs11154397	chr6:127646649	G/C	cg27446573	chr6:127587934	RNF146	0.68	8.83	0.5	2.6e-16	Breast cancer;
SARC	cis	rs2658782	0.724	rs2605629	chr11:93264037	C/G	cg15737290	chr11:93063684	CCDC67	-0.74	-8.64	-0.49	8.96e-16	Pulmonary function decline;
SARC	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg26335602	chr6:28129616	ZNF389	0.53	5.88	0.36	1.43e-8	Depression;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg20762182	chr15:69727293	KIF23	0.53	6.8	0.41	8.65e-11	Schizophrenia;
SARC	cis	rs6667605	0.506	rs10797440	chr1:2541269	A/G	cg20673091	chr1:2541236	MMEL1	0.33	5.08	0.32	7.7e-7	Inflammatory bowel disease;Ulcerative colitis;
SARC	cis	rs986417	0.901	rs1956558	chr14:60975956	T/C	cg27398547	chr14:60952738	C14orf39	0.99	9.02	0.51	6.89e-17	Gut microbiota (bacterial taxa);
SARC	cis	rs9486719	1.000	rs2472890	chr6:96867646	C/T	cg06623918	chr6:96969491	KIAA0776	0.73	8.01	0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs12048904	0.505	rs11166508	chr1:101233511	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.53	-5.52	-0.34	8.93e-8	Multiple sclerosis;
SARC	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg11764359	chr7:65958608	NA	0.55	6.52	0.39	4.35e-10	Calcium levels;
SARC	trans	rs8007661	0.584	rs10147971	chr14:92466111	C/T	cg15331500	chr22:41779351	TEF	0.39	6.26	0.38	1.82e-9	Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
SARC	trans	rs6600671	0.934	rs12131379	chr1:121293437	T/C	cg00646200	chr1:148855367	NA	0.52	7.2	0.43	8.05e-12	Hip geometry;
SARC	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg11764359	chr7:65958608	NA	0.88	12.58	0.64	4.89e-28	Aortic root size;
SARC	trans	rs1814175	0.585	rs4881661	chr11:50000117	A/G	cg03929089	chr4:120376271	NA	-0.82	-11.88	-0.61	9.03e-26	Height;
SARC	trans	rs11098499	0.954	rs10518328	chr4:120401779	G/A	cg25214090	chr10:38739885	LOC399744	0.56	7.24	0.43	6.65e-12	Corneal astigmatism;
SARC	cis	rs12586317	0.508	rs10134914	chr14:35425012	T/G	cg16230307	chr14:35515116	FAM177A1	0.78	9.47	0.53	3.35e-18	Psoriasis;
SARC	cis	rs9503598	0.636	rs6596978	chr6:3468878	C/T	cg00476032	chr6:3446245	SLC22A23	0.39	6.06	0.37	5.56e-9	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
SARC	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg11644478	chr21:40555479	PSMG1	-0.87	-11.42	-0.6	2.82e-24	Cognitive function;
SARC	cis	rs9859260	0.744	rs492349	chr3:195784192	G/A	cg03462622	chr3:195777018	TFRC	-0.46	-5.38	-0.33	1.81e-7	Mean corpuscular volume;
SARC	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg16606324	chr3:10149918	C3orf24	0.49	4.82	0.3	2.58e-6	Alzheimer's disease;
SARC	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg22834771	chr12:69754056	YEATS4	-0.44	-5.78	-0.35	2.43e-8	Blood protein levels;
SARC	cis	rs9467773	1.000	rs9393732	chr6:26530898	G/A	cg11502198	chr6:26597334	ABT1	0.46	5.53	0.34	8.38e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg15049968	chr18:44337910	ST8SIA5	-0.33	-5.21	-0.32	4.15e-7	Personality dimensions;
SARC	cis	rs9462027	0.628	rs2815004	chr6:34636268	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-6.02	-0.37	6.85e-9	Systemic lupus erythematosus;
SARC	cis	rs6087990	0.806	rs4911254	chr20:31357579	C/A	cg13636640	chr20:31349939	DNMT3B	0.79	12.51	0.63	8.28e-28	Ulcerative colitis;
SARC	cis	rs35213789	0.762	rs576293	chr7:69190802	A/C	cg10619644	chr7:69149951	AUTS2	-0.36	-4.95	-0.31	1.44e-6	Childhood ear infection;
SARC	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	10.11	0.55	3.73e-20	Platelet count;
SARC	cis	rs3106136	0.967	rs282448	chr4:95141411	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.97	-0.36	8.92e-9	Capecitabine sensitivity;
SARC	cis	rs2952156	0.920	rs11078919	chr17:37835755	T/C	cg00129232	chr17:37814104	STARD3	-0.71	-10.13	-0.55	3.18e-20	Asthma;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg27088449	chr22:21272634	CRKL	0.48	6.27	0.38	1.77e-9	Electrocardiographic conduction measures;
SARC	cis	rs2916247	0.954	rs28707439	chr8:93070202	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.67	-6.81	-0.41	8.3e-11	Intelligence (multi-trait analysis);
SARC	cis	rs1784581	0.894	rs1626020	chr6:162383379	G/A	cg17173639	chr6:162384350	PARK2	-0.76	-10.79	-0.58	2.71e-22	Itch intensity from mosquito bite;
SARC	cis	rs1153858	1.000	rs4625670	chr15:45652926	C/T	cg03999130	chr15:45571217	NA	0.39	4.97	0.31	1.27e-6	Homoarginine levels;
SARC	cis	rs9916302	0.808	rs12943928	chr17:37611330	G/A	cg15445000	chr17:37608096	MED1	0.41	4.91	0.31	1.68e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs1050631	0.960	rs1789503	chr18:33696865	T/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.44	5.45	0.34	1.26e-7	Esophageal squamous cell cancer (length of survival);
SARC	trans	rs4295623	0.816	rs35558975	chr8:11584476	C/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.1	-0.42	1.48e-11	Morning vs. evening chronotype;
SARC	trans	rs1814175	0.817	rs7947286	chr11:49874657	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-18.12	-0.76	2.26e-46	Height;
SARC	trans	rs77956314	0.901	rs111865233	chr12:117332156	T/C	cg09757595	chr2:151504597	NA	-0.57	-6.35	-0.38	1.11e-9	Subcortical brain region volumes;Hippocampal volume;
SARC	cis	rs672059	0.513	rs627064	chr1:183165716	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	5.19	0.32	4.54e-7	Hypertriglyceridemia;
SARC	trans	rs13240504	0.557	rs73224943	chr7:126177159	C/T	cg12155036	chr3:194015171	NA	-0.55	-6.46	-0.39	6.17e-10	Anti-saccade response;
SARC	cis	rs12130219	0.500	rs4845743	chr1:152184149	A/G	cg09127314	chr1:152161683	NA	0.37	4.99	0.31	1.19e-6	Inflammatory skin disease;
SARC	cis	rs11105298	0.891	rs11105316	chr12:89925200	T/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-5.48	-0.34	1.09e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs9457247	0.765	rs1322077	chr6:167424293	T/C	cg23791538	chr6:167370224	RNASET2	-0.54	-7.05	-0.42	1.96e-11	Crohn's disease;
SARC	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg00329180	chr16:89395412	ANKRD11	-0.22	-4.82	-0.3	2.59e-6	Multiple myeloma (IgH translocation);
SARC	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.03	12.03	0.62	3.06e-26	Alzheimer's disease;
SARC	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg06271696	chr7:157225062	NA	-0.29	-4.97	-0.31	1.31e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs926392	0.547	rs8118808	chr20:37674996	C/G	cg16355469	chr20:37678765	NA	0.75	9.48	0.53	2.99e-18	Dialysis-related mortality;
SARC	trans	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg21659725	chr3:3221576	CRBN	0.57	6.51	0.39	4.57e-10	Resting heart rate;
SARC	cis	rs9341808	0.727	rs10943697	chr6:80931506	A/C	cg08355045	chr6:80787529	NA	0.33	5.11	0.32	6.8e-7	Sitting height ratio;
SARC	cis	rs8017423	0.967	rs2282030	chr14:90730265	G/A	cg20276874	chr14:90721474	PSMC1	-0.38	-5.25	-0.33	3.39e-7	Mortality in heart failure;
SARC	cis	rs11651000	0.817	rs7502875	chr17:45823227	A/C	cg24803719	chr17:45855879	NA	-0.48	-7.22	-0.43	7.15e-12	IgG glycosylation;
SARC	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg20007245	chr22:24372913	LOC391322	0.66	7.47	0.44	1.64e-12	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg07777115	chr5:623756	CEP72	-0.56	-4.84	-0.3	2.34e-6	Lung disease severity in cystic fibrosis;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg12050497	chr2:14773274	FAM84A	-0.46	-6.63	-0.4	2.29e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs1030877	1.000	rs2576743	chr2:105901337	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.57	8.3	0.48	8.23e-15	Obesity-related traits;
SARC	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg02725872	chr8:58115012	NA	-0.37	-6.52	-0.39	4.21e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg05368731	chr17:41323189	NBR1	0.74	8.85	0.5	2.19e-16	Menopause (age at onset);
SARC	cis	rs6121246	0.529	rs6060195	chr20:30185638	C/T	cg21427119	chr20:30132790	HM13	-0.48	-5.29	-0.33	2.84e-7	Mean corpuscular hemoglobin;
SARC	cis	rs2439831	0.557	rs13329084	chr15:44151063	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.79	-7.29	-0.43	4.66e-12	Lung cancer in ever smokers;
SARC	cis	rs7937682	1.000	rs7937682	chr11:111579939	C/G	cg22437258	chr11:111473054	SIK2	0.66	8.76	0.5	4.01e-16	Primary sclerosing cholangitis;
SARC	cis	rs826838	1.000	rs11609286	chr12:38875511	A/G	cg13010199	chr12:38710504	ALG10B	-0.78	-10.8	-0.58	2.55e-22	Heart rate;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11094939	chr2:65454430	ACTR2	-0.52	-6.65	-0.4	2.04e-10	Smoking initiation;
SARC	cis	rs6696846	0.630	rs6692706	chr1:205158561	G/T	cg00857998	chr1:205179979	DSTYK	0.51	6.27	0.38	1.73e-9	Red blood cell count;
SARC	cis	rs7130144	0.541	rs28875239	chr11:130459571	A/G	cg26307797	chr11:130446613	NA	-0.7	-5.81	-0.36	2.02e-8	Urate levels in lean individuals;
SARC	cis	rs4319547	0.695	rs55834409	chr12:122862560	C/G	cg23029597	chr12:123009494	RSRC2	0.41	5.09	0.32	7.41e-7	Body mass index;
SARC	cis	rs2694528	0.544	rs6449481	chr5:59911179	G/C	cg11474532	chr5:59995715	DEPDC1B	0.83	5.82	0.36	1.91e-8	Parkinson's disease;
SARC	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg18252515	chr7:66147081	NA	0.58	6.26	0.38	1.79e-9	Aortic root size;
SARC	cis	rs9790314	0.747	rs7650703	chr3:160851639	T/C	cg03342759	chr3:160939853	NMD3	-0.47	-5.81	-0.36	2.06e-8	Morning vs. evening chronotype;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg10254974	chr17:16342133	NCRNA00188;SNORD49B;SNORD49A	0.51	6.54	0.39	3.84e-10	Electrocardiographic conduction measures;
SARC	cis	rs6582630	0.638	rs10880620	chr12:38517467	A/G	cg13010199	chr12:38710504	ALG10B	-0.55	-6.84	-0.41	6.94e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs798554	0.591	rs757791	chr7:2867296	A/G	cg04166393	chr7:2884313	GNA12	0.44	5.3	0.33	2.67e-7	Height;
SARC	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg07701084	chr6:150067640	NUP43	0.4	5.37	0.33	1.91e-7	Lung cancer;
SARC	cis	rs1707322	1.000	rs10158032	chr1:46332701	T/C	cg03146154	chr1:46216737	IPP	0.47	5.63	0.35	5.03e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg05025164	chr4:1340916	KIAA1530	-0.85	-11.2	-0.59	1.36e-23	Longevity;
SARC	cis	rs7829975	0.684	rs488904	chr8:8587571	T/G	cg08975724	chr8:8085496	FLJ10661	-0.45	-5.3	-0.33	2.62e-7	Mood instability;
SARC	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg18252515	chr7:66147081	NA	0.45	5.0	0.31	1.13e-6	Aortic root size;
SARC	cis	rs17376456	0.877	rs12109629	chr5:93359702	A/G	cg21475434	chr5:93447410	FAM172A	0.87	7.91	0.46	1.06e-13	Diabetic retinopathy;
SARC	cis	rs155076	1.000	rs261431	chr13:21865738	A/G	cg14456004	chr13:21872349	NA	0.93	11.81	0.61	1.51e-25	White matter hyperintensity burden;
SARC	trans	rs7824557	0.564	rs2572394	chr8:11235393	A/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.71	-0.5	5.7e-16	Retinal vascular caliber;
SARC	cis	rs5997397	0.934	rs6005863	chr22:29156448	A/G	cg15103426	chr22:29168792	CCDC117	0.51	6.54	0.39	3.77e-10	Red cell distribution width;
SARC	cis	rs2806561	0.704	rs664301	chr1:23522522	C/T	cg12483005	chr1:23474871	LUZP1	0.47	6.11	0.37	4.15e-9	Height;
SARC	cis	rs8067545	0.532	rs12946508	chr17:19952059	A/T	cg13482628	chr17:19912719	NA	0.44	4.94	0.31	1.47e-6	Schizophrenia;
SARC	cis	rs10791097	0.694	rs876641	chr11:130752040	A/C	cg12179176	chr11:130786555	SNX19	0.74	11.18	0.59	1.62e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.55	-5.59	-0.34	6.35e-8	Lung cancer in ever smokers;
SARC	cis	rs9646954	0.542	rs4149513	chr2:101022726	C/T	cg14675211	chr2:100938903	LONRF2	0.52	7.83	0.46	1.75e-13	Intelligence (multi-trait analysis);
SARC	cis	rs7819412	0.775	rs11773990	chr8:10935082	T/C	cg21775007	chr8:11205619	TDH	-0.47	-5.93	-0.36	1.06e-8	Triglycerides;
SARC	cis	rs8141529	0.600	rs739196	chr22:29311271	G/A	cg15103426	chr22:29168792	CCDC117	0.61	6.22	0.38	2.32e-9	Lymphocyte counts;
SARC	cis	rs6121246	0.529	rs6088814	chr20:30218172	C/T	cg21427119	chr20:30132790	HM13	-0.46	-5.05	-0.31	8.92e-7	Mean corpuscular hemoglobin;
SARC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg20887711	chr4:1340912	KIAA1530	-0.76	-9.71	-0.54	6.27e-19	Longevity;
SARC	trans	rs2727020	0.729	rs2299650	chr11:49174007	A/C	cg03929089	chr4:120376271	NA	-0.7	-9.81	-0.54	3.03e-19	Coronary artery disease;
SARC	cis	rs77372450	0.636	rs77291311	chr5:157018650	T/C	cg23851860	chr5:157002805	ADAM19	0.52	4.85	0.3	2.28e-6	Bipolar disorder (body mass index interaction);
SARC	cis	rs4481887	0.927	rs4244181	chr1:248471118	A/G	cg00666640	chr1:248458726	OR2T12	0.37	6.18	0.38	2.86e-9	Common traits (Other);
SARC	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg03647317	chr4:187891568	NA	-0.35	-5.13	-0.32	6.24e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.42	0.56	3.95e-21	Prudent dietary pattern;
SARC	cis	rs10791323	0.720	rs2851117	chr11:133705905	A/G	cg14349672	chr11:133703707	NA	0.32	4.72	0.3	4.1e-6	Childhood ear infection;
SARC	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg22920501	chr2:26401640	FAM59B	-0.53	-6.68	-0.4	1.72e-10	Gut microbiome composition (summer);
SARC	cis	rs11168187	0.891	rs3764015	chr12:48121301	G/A	cg12761788	chr12:48120090	P11	0.4	5.11	0.32	6.63e-7	Vertical cup-disc ratio;
SARC	cis	rs6976053	0.518	rs314358	chr7:100410657	A/G	cg03098644	chr7:100410630	EPHB4	-0.52	-7.25	-0.43	6.25e-12	Plasminogen activator inhibitor type 1 levels (PAI-1);
SARC	cis	rs9325144	0.647	rs11168104	chr12:38857616	G/T	cg13010199	chr12:38710504	ALG10B	-0.46	-5.8	-0.35	2.19e-8	Morning vs. evening chronotype;
SARC	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg09839136	chr7:766187	HEATR2;PRKAR1B	0.57	4.88	0.3	1.93e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs7223966	1.000	rs11657081	chr17:61792339	C/T	cg26338869	chr17:61819248	STRADA	0.43	4.88	0.3	1.93e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6831352	0.734	rs3018046	chr4:100030388	C/T	cg13256891	chr4:100009986	ADH5	0.6	7.88	0.46	1.23e-13	Alcohol dependence;
SARC	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg26681399	chr22:41777847	TEF	-0.49	-5.47	-0.34	1.15e-7	Vitiligo;
SARC	cis	rs7587476	0.682	rs13009646	chr2:215691259	T/A	cg04530015	chr2:215796436	ABCA12	-0.41	-6.7	-0.4	1.56e-10	Neuroblastoma;
SARC	cis	rs2115630	0.875	rs8039472	chr15:85361644	A/G	cg12501888	chr15:85177176	SCAND2	-0.49	-5.84	-0.36	1.72e-8	P wave terminal force;
SARC	cis	rs3796352	0.881	rs35385050	chr3:52997945	C/A	cg15956490	chr3:53032818	SFMBT1	0.89	5.76	0.35	2.62e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg16434002	chr17:42200994	HDAC5	-0.46	-5.83	-0.36	1.84e-8	Total body bone mineral density;
SARC	cis	rs13401104	0.796	rs72620811	chr2:237118733	C/A	cg19324714	chr2:237145437	ASB18	0.57	5.66	0.35	4.32e-8	Educational attainment;
SARC	cis	rs7223966	0.960	rs113155878	chr17:61706560	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.49	-4.95	-0.31	1.42e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7005380	0.581	rs13265513	chr8:120919926	C/T	cg21744203	chr8:120868354	DSCC1	0.47	5.45	0.34	1.27e-7	Interstitial lung disease;
SARC	cis	rs7566780	0.656	rs6531162	chr2:16674191	C/T	cg09580478	chr2:16689509	NA	0.45	6.05	0.37	5.64e-9	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs17023223	0.537	rs10923756	chr1:119674648	A/T	cg05756136	chr1:119680316	WARS2	-0.45	-4.9	-0.31	1.83e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs910187	0.605	rs6066223	chr20:45803998	A/G	cg27589058	chr20:45804311	EYA2	0.32	5.1	0.32	7.2e-7	Migraine;
SARC	cis	rs6088580	0.634	rs4911418	chr20:32994257	G/A	cg24642439	chr20:33292090	TP53INP2	-0.68	-8.73	-0.5	4.96e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	19.9	0.79	3.8e-52	Prudent dietary pattern;
SARC	cis	rs9916302	0.706	rs9890198	chr17:37457480	A/C	cg20243544	chr17:37824526	PNMT	-0.54	-5.61	-0.35	5.6e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs34172651	0.583	rs4787649	chr16:24700215	C/T	cg00339695	chr16:24857497	SLC5A11	-0.42	-5.86	-0.36	1.58e-8	Intelligence (multi-trait analysis);
SARC	cis	rs1152591	0.524	rs1255992	chr14:64662895	A/G	cg23250157	chr14:64679961	SYNE2	0.43	5.91	0.36	1.21e-8	Atrial fibrillation;
SARC	cis	rs514024	0.668	rs2039204	chr9:130371107	T/A	cg13643465	chr9:130375613	STXBP1	0.42	5.27	0.33	3.04e-7	Eating disorders (purging via substances);
SARC	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1707322	0.964	rs1707339	chr1:46513179	A/G	cg03146154	chr1:46216737	IPP	-0.47	-5.65	-0.35	4.59e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg24549020	chr5:56110836	MAP3K1	0.75	7.7	0.45	3.89e-13	Initial pursuit acceleration;
SARC	cis	rs370915	0.542	rs7687552	chr4:187837862	G/C	cg19519643	chr4:187840862	NA	-0.5	-7.1	-0.42	1.5e-11	Gout;
SARC	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg13175981	chr1:150552382	MCL1	-0.54	-6.9	-0.41	4.97e-11	Tonsillectomy;
SARC	cis	rs7772486	0.727	rs11155442	chr6:146140725	T/C	cg23711669	chr6:146136114	FBXO30	0.86	14.73	0.69	3.83e-35	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs629535	0.773	rs655299	chr8:70074534	C/T	cg21567404	chr3:27674614	NA	1.04	13.3	0.66	2.13e-30	Dupuytren's disease;
SARC	cis	rs12048904	0.619	rs10875347	chr1:101333737	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.9	11.11	0.59	2.65e-23	Multiple sclerosis;
SARC	cis	rs12545109	0.800	rs1996106	chr8:57412963	A/G	cg19413350	chr8:57351067	NA	-0.43	-5.37	-0.33	1.88e-7	Obesity-related traits;
SARC	cis	rs9733	0.791	rs11204693	chr1:150647987	C/T	cg13175981	chr1:150552382	MCL1	0.64	8.93	0.51	1.28e-16	Tonsillectomy;
SARC	cis	rs1008375	0.966	rs1860599	chr4:17638900	T/C	cg27347728	chr4:17578864	LAP3	0.47	5.91	0.36	1.22e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7953249	0.618	rs2650000	chr12:121388962	G/T	cg25281562	chr12:121454272	C12orf43	0.48	5.81	0.36	2.02e-8	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs1568889	1.000	rs12803655	chr11:28060785	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	10.19	0.56	2.16e-20	Bipolar disorder;
SARC	cis	rs67460515	0.563	rs11717272	chr3:160810355	A/G	cg03342759	chr3:160939853	NMD3	-0.64	-7.61	-0.45	6.58e-13	Parkinson's disease;
SARC	cis	rs6938	0.563	rs12917376	chr15:75116167	C/T	cg14664628	chr15:75095509	CSK	-0.61	-8.0	-0.46	5.96e-14	Breast cancer;
SARC	cis	rs72945132	0.825	rs57871058	chr11:70192344	T/C	cg00319359	chr11:70116639	PPFIA1	0.68	6.32	0.38	1.29e-9	Coronary artery disease;
SARC	cis	rs4065321	0.522	rs3744245	chr17:38146542	C/G	cg17467752	chr17:38218738	THRA	-0.38	-4.82	-0.3	2.63e-6	White blood cell count (basophil);White blood cell count;
SARC	cis	rs72781680	0.593	rs72797817	chr2:24350569	A/G	cg08917208	chr2:24149416	ATAD2B	0.58	5.99	0.37	8.07e-9	Lymphocyte counts;
SARC	cis	rs2153535	0.580	rs1928184	chr6:8532108	T/A	cg23788917	chr6:8435910	SLC35B3	0.64	8.68	0.49	7.02e-16	Motion sickness;
SARC	trans	rs877282	0.842	rs7092986	chr10:756373	G/A	cg22713356	chr15:30763199	NA	0.99	9.88	0.54	1.92e-19	Uric acid levels;
SARC	cis	rs17539620	0.624	rs111484697	chr6:154838903	A/G	cg17771515	chr6:154831774	CNKSR3	0.53	4.88	0.3	1.97e-6	Lipoprotein (a) levels;
SARC	cis	rs1950500	0.565	rs3181248	chr14:24808168	G/A	cg22990158	chr14:24802150	ADCY4	-0.34	-5.64	-0.35	4.94e-8	Height;
SARC	cis	rs2153535	0.607	rs9502722	chr6:8541483	C/T	cg07606381	chr6:8435919	SLC35B3	0.77	10.77	0.58	3.36e-22	Motion sickness;
SARC	cis	rs7481584	0.581	rs420127	chr11:3077990	C/T	cg25174290	chr11:3078921	CARS	-0.54	-7.43	-0.44	2.1e-12	Calcium levels;
SARC	cis	rs7011049	1.000	rs72640852	chr8:53838084	G/A	cg26025543	chr8:53854495	NA	0.61	5.45	0.34	1.28e-7	Systolic blood pressure;
SARC	cis	rs6977660	0.714	rs12700077	chr7:19791607	A/G	cg05791153	chr7:19748676	TWISTNB	-0.72	-6.59	-0.4	2.99e-10	Thyroid stimulating hormone;
SARC	cis	rs4808199	0.948	rs11085261	chr19:19462606	G/A	cg03709012	chr19:19516395	GATAD2A	1.05	10.92	0.58	1.08e-22	Nonalcoholic fatty liver disease;
SARC	cis	rs7255045	0.742	rs10407116	chr19:12962272	G/A	cg21491176	chr19:12958399	MAST1	-0.34	-4.72	-0.3	4.14e-6	Mean corpuscular volume;
SARC	cis	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg12228919	chr15:44955936	SPG11	0.55	5.7	0.35	3.54e-8	Lung cancer in ever smokers;
SARC	cis	rs72781680	0.848	rs56021814	chr2:24073437	T/A	cg06627628	chr2:24431161	ITSN2	-0.68	-6.55	-0.39	3.56e-10	Lymphocyte counts;
SARC	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg23172400	chr8:95962367	TP53INP1	-0.31	-5.38	-0.33	1.8e-7	Type 2 diabetes;
SARC	cis	rs7826238	0.594	rs2948285	chr8:8130538	A/T	cg06636001	chr8:8085503	FLJ10661	0.77	11.0	0.58	6.3e-23	Systolic blood pressure;
SARC	cis	rs11098499	0.909	rs28571712	chr4:120375980	G/A	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs2380220	0.872	rs2613528	chr6:95939437	C/G	cg07718321	chr6:96025334	MANEA	-0.51	-4.78	-0.3	3.07e-6	Behavioural disinhibition (generation interaction);
SARC	cis	rs6840360	1.000	rs4696111	chr4:152671405	T/C	cg22705602	chr4:152727874	NA	-0.37	-6.58	-0.4	3.04e-10	Intelligence (multi-trait analysis);
SARC	cis	rs6121246	0.529	rs56153385	chr20:30187609	C/T	cg13852791	chr20:30311386	BCL2L1	0.66	5.92	0.36	1.15e-8	Mean corpuscular hemoglobin;
SARC	cis	rs9443189	0.526	rs9359132	chr6:76289553	G/A	cg01950844	chr6:76311363	SENP6	0.87	7.89	0.46	1.19e-13	Prostate cancer;
SARC	cis	rs2439831	0.850	rs544122	chr15:43775732	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	9.4	0.52	5.35e-18	Lung cancer in ever smokers;
SARC	cis	rs992157	1.000	rs992157	chr2:219154781	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.71	-10.37	-0.56	5.91e-21	Colorectal cancer;
SARC	cis	rs11758351	1.000	rs11758351	chr6:26203910	T/G	cg01420254	chr6:26195488	NA	0.53	4.74	0.3	3.74e-6	Gout;Renal underexcretion gout;
SARC	cis	rs12908161	1.000	rs62019469	chr15:85321220	T/C	cg17507749	chr15:85114479	UBE2QP1	0.55	6.27	0.38	1.69e-9	Schizophrenia;
SARC	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg18252515	chr7:66147081	NA	-0.57	-6.2	-0.38	2.51e-9	Aortic root size;
SARC	cis	rs13082711	0.911	rs35904501	chr3:27443317	T/C	cg02860705	chr3:27208620	NA	0.47	6.19	0.38	2.7e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs2304069	0.954	rs4705408	chr5:149412545	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.93	-10.35	-0.56	6.91e-21	HIV-1 control;
SARC	cis	rs9354308	0.646	rs4235974	chr6:66593661	A/T	cg07460842	chr6:66804631	NA	-0.41	-4.78	-0.3	3.04e-6	Metabolite levels;
SARC	cis	rs748404	0.697	rs493444	chr15:43566470	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	5.64	0.35	4.99e-8	Lung cancer;
SARC	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg20607798	chr8:58055168	NA	0.57	5.53	0.34	8.58e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs3126085	0.935	rs3126072	chr1:152279729	C/T	cg26876637	chr1:152193138	HRNR	-0.48	-5.33	-0.33	2.33e-7	Atopic dermatitis;
SARC	cis	rs2730245	0.527	rs1188971	chr7:158664463	G/T	cg24397884	chr7:158709396	WDR60	1.12	10.18	0.55	2.25e-20	Height;
SARC	cis	rs9868809	0.881	rs2286652	chr3:48689192	G/A	cg00383909	chr3:49044727	WDR6	0.57	4.9	0.31	1.82e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	trans	rs4295623	0.585	rs34421088	chr8:11589042	A/G	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.26	-0.38	1.82e-9	Morning vs. evening chronotype;
SARC	cis	rs3796352	1.000	rs11712653	chr3:53070875	A/C	cg07884673	chr3:53033167	SFMBT1	-0.76	-5.39	-0.33	1.7e-7	Immune reponse to smallpox (secreted IL-2);
SARC	trans	rs1493916	0.748	rs7230463	chr18:31309133	G/C	cg27147174	chr7:100797783	AP1S1	-0.52	-6.63	-0.4	2.37e-10	Life satisfaction;
SARC	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg02297831	chr4:17616191	MED28	0.51	6.63	0.4	2.36e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs11122272	0.668	rs2472261	chr1:231505701	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-9.74	-0.54	5.17e-19	Hemoglobin concentration;
SARC	cis	rs4810479	0.513	rs3746506	chr20:44586036	G/A	cg10662479	chr20:44420225	WFDC3;DNTTIP1	0.42	5.68	0.35	3.99e-8	Metabolite levels;
SARC	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg22920501	chr2:26401640	FAM59B	-0.58	-7.45	-0.44	1.83e-12	Gut microbiome composition (summer);
SARC	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.05	-18.23	-0.77	9.83e-47	Chronic sinus infection;
SARC	cis	rs10791097	0.694	rs4459316	chr11:130756176	T/C	cg12179176	chr11:130786555	SNX19	0.76	11.42	0.6	2.75e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg03185022	chr7:2884158	GNA12	0.49	5.42	0.33	1.47e-7	Height;
SARC	cis	rs2479724	0.870	rs6913232	chr6:41915143	C/T	cg17623882	chr6:41773611	USP49	0.42	5.39	0.33	1.73e-7	Menarche (age at onset);
SARC	cis	rs2712184	0.967	rs1014680	chr2:217672824	A/G	cg05032264	chr2:217675019	NA	0.67	9.12	0.51	3.58e-17	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
SARC	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-8.02	-0.47	5.12e-14	Chronic sinus infection;
SARC	cis	rs11098499	0.657	rs71614442	chr4:120379346	C/T	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs929354	0.772	rs2301914	chr7:157000176	T/C	cg05182265	chr7:156933206	UBE3C	-0.32	-4.86	-0.3	2.19e-6	Body mass index;
SARC	cis	rs7044106	0.791	rs4837793	chr9:123483621	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	6.08	0.37	4.92e-9	Hip circumference adjusted for BMI;
SARC	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg13206674	chr6:150067644	NUP43	0.48	6.36	0.38	1.07e-9	Lung cancer;
SARC	cis	rs6701037	1.000	rs6677097	chr1:175123897	C/G	cg17845761	chr1:175162550	KIAA0040	-0.29	-4.81	-0.3	2.66e-6	Alcohol dependence;
SARC	cis	rs870825	0.616	rs7678949	chr4:185635018	G/C	cg04058563	chr4:185651563	MLF1IP	0.84	11.31	0.6	6.15e-24	Blood protein levels;
SARC	cis	rs4974559	0.739	rs1250121	chr4:1263521	A/G	cg02980000	chr4:1222292	CTBP1	-0.66	-5.53	-0.34	8.77e-8	Systolic blood pressure;
SARC	trans	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg17830980	chr10:43048298	ZNF37B	-0.5	-6.57	-0.4	3.19e-10	Extrinsic epigenetic age acceleration;
SARC	cis	rs10490913	0.836	rs12219676	chr10:120159905	A/G	cg23160142	chr10:120154512	NA	0.34	4.97	0.31	1.27e-6	Cancer;
SARC	cis	rs1153858	1.000	rs11852800	chr15:45639131	A/G	cg03999130	chr15:45571217	NA	-0.4	-5.08	-0.32	7.83e-7	Homoarginine levels;
SARC	cis	rs2898681	0.528	rs73814883	chr4:53728054	G/C	cg00338735	chr4:53728038	RASL11B	0.49	4.95	0.31	1.44e-6	Optic nerve measurement (cup area);
SARC	cis	rs9388451	0.839	rs4897155	chr6:126095144	C/A	cg05901451	chr6:126070800	HEY2	-0.67	-9.24	-0.52	1.54e-17	Brugada syndrome;
SARC	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg02725872	chr8:58115012	NA	-0.27	-4.9	-0.31	1.77e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs72945132	0.714	rs72947077	chr11:70197431	A/G	cg00319359	chr11:70116639	PPFIA1	0.67	6.05	0.37	5.68e-9	Coronary artery disease;
SARC	cis	rs910316	0.967	rs11159121	chr14:75666029	A/T	cg08847533	chr14:75593920	NEK9	-0.85	-14.1	-0.68	4.82e-33	Height;
SARC	cis	rs6665290	0.669	rs3768419	chr1:227173477	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.0	-19.93	-0.79	2.93e-52	Myeloid white cell count;
SARC	cis	rs7945705	0.902	rs7479407	chr11:9023421	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.45	6.35	0.38	1.11e-9	Hemoglobin concentration;
SARC	cis	rs7520050	0.966	rs1768816	chr1:46528599	T/C	cg06784218	chr1:46089804	CCDC17	-0.26	-4.83	-0.3	2.43e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs9790314	0.631	rs2061804	chr3:161102474	C/A	cg04691961	chr3:161091175	C3orf57	-0.52	-6.69	-0.4	1.66e-10	Morning vs. evening chronotype;
SARC	cis	rs208520	0.586	rs208442	chr6:66900618	T/A	cg07460842	chr6:66804631	NA	-0.78	-9.47	-0.53	3.36e-18	Exhaled nitric oxide output;
SARC	trans	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg00938859	chr5:1591904	SDHAP3	0.78	7.58	0.44	8.08e-13	Breast cancer;
SARC	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg11062466	chr8:58055876	NA	0.61	5.64	0.35	5.01e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs8068544	0.818	rs79892925	chr17:40171819	A/G	cg26502583	chr17:39992600	KLHL10;NT5C3L	-0.87	-6.44	-0.39	6.79e-10	Reticulocyte fraction of red cells;Reticulocyte count;
SARC	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg17971929	chr21:40555470	PSMG1	-0.86	-11.56	-0.6	9.68e-25	Cognitive function;
SARC	cis	rs6429082	0.634	rs3856245	chr1:235571428	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.6	-7.05	-0.42	2e-11	Adiposity;
SARC	cis	rs13314892	0.728	rs62252174	chr3:69874383	T/A	cg17445875	chr3:69859618	MITF	-0.49	-5.12	-0.32	6.44e-7	QRS complex (12-leadsum);
SARC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg11494091	chr17:61959527	GH2	0.55	8.24	0.48	1.24e-14	Prudent dietary pattern;
SARC	cis	rs9473924	0.505	rs7768747	chr6:50931762	G/A	cg14470998	chr6:50812995	TFAP2B	0.76	6.79	0.41	9e-11	Body mass index;
SARC	cis	rs10992471	0.729	rs1022844	chr9:95553464	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-5.79	-0.35	2.3e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs449789	0.779	rs553197	chr6:159714625	G/T	cg14500486	chr6:159655392	FNDC1	-0.44	-5.02	-0.31	1.01e-6	Pulse pressure;
SARC	cis	rs2239547	0.603	rs12489490	chr3:53064022	C/A	cg22484793	chr3:52261325	TLR9	0.36	4.76	0.3	3.47e-6	Schizophrenia;
SARC	cis	rs7408868	1.000	rs10416389	chr19:15278674	G/C	cg14696996	chr19:15285081	NOTCH3	1.01	8.87	0.5	1.93e-16	Pulse pressure;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg26918105	chr5:41928727	FBXO4	0.58	8.07	0.47	3.73e-14	Thyroid stimulating hormone;
SARC	cis	rs10752881	1.000	rs10797813	chr1:182989366	C/T	cg13390022	chr1:182993471	LAMC1	0.34	5.23	0.32	3.82e-7	Colorectal cancer;
SARC	cis	rs7089973	0.604	rs2420065	chr10:116583753	A/G	cg08188268	chr10:116634841	FAM160B1	0.28	4.76	0.3	3.41e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg26335602	chr6:28129616	ZNF389	0.48	5.28	0.33	2.92e-7	Parkinson's disease;
SARC	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.44	5.44	0.34	1.37e-7	Tonsillectomy;
SARC	cis	rs834603	0.687	rs10280277	chr7:47467178	G/A	cg23694490	chr7:47445681	TNS3	0.34	6.03	0.37	6.27e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs9341808	0.622	rs682482	chr6:80961139	A/G	cg08355045	chr6:80787529	NA	-0.36	-5.8	-0.36	2.1e-8	Sitting height ratio;
SARC	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	0.85	7.58	0.44	7.95e-13	Alzheimer's disease;
SARC	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg19729930	chr2:74357872	NA	0.72	9.97	0.55	1.01e-19	Gestational age at birth (maternal effect);
SARC	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg22920501	chr2:26401640	FAM59B	-0.55	-7.14	-0.42	1.2e-11	Gut microbiome composition (summer);
SARC	cis	rs3087591	0.659	rs757377	chr17:29720426	G/A	cg24425628	chr17:29625626	OMG;NF1	0.41	5.12	0.32	6.34e-7	Hip circumference;
SARC	cis	rs1874564	1.000	rs1874564	chr4:77858105	A/G	cg00874691	chr4:77867684	NA	0.38	5.33	0.33	2.31e-7	Papillary thyroid cancer;Differentiated thyroid cancer;
SARC	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg08045932	chr20:61659980	NA	0.5	6.84	0.41	7.06e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs3762637	1.000	rs12630576	chr3:122139517	A/C	cg24169773	chr3:122142474	KPNA1	-0.56	-5.7	-0.35	3.6e-8	LDL cholesterol levels;
SARC	cis	rs2486288	0.656	rs1706768	chr15:45569443	T/C	cg19305227	chr15:45544335	SLC28A2	0.31	5.75	0.35	2.82e-8	Glomerular filtration rate;
SARC	cis	rs12142240	0.698	rs10158236	chr1:46820896	G/T	cg00530320	chr1:46809349	NSUN4	0.57	6.79	0.41	9.05e-11	Menopause (age at onset);
SARC	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg10523679	chr1:76189770	ACADM	0.43	5.1	0.32	7.05e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs1008375	0.966	rs2098152	chr4:17684392	G/T	cg02297831	chr4:17616191	MED28	0.43	5.41	0.33	1.55e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs11785400	1.000	rs4736365	chr8:143742197	A/G	cg10596483	chr8:143751796	JRK	0.64	8.65	0.49	8.4e-16	Schizophrenia;
SARC	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	0.39	4.73	0.3	3.89e-6	Tonsillectomy;
SARC	cis	rs9290065	0.519	rs10936216	chr3:160698314	G/C	cg03342759	chr3:160939853	NMD3	-0.52	-6.5	-0.39	4.75e-10	Kawasaki disease;
SARC	cis	rs7635838	0.859	rs6786166	chr3:11511424	T/C	cg00170343	chr3:11313890	ATG7	0.63	8.53	0.49	1.92e-15	HDL cholesterol;
SARC	cis	rs4711336	1.000	rs2296741	chr6:33659557	C/T	cg15676125	chr6:33679581	C6orf125	0.58	7.06	0.42	1.93e-11	Height;
SARC	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg17376030	chr22:41985996	PMM1	0.65	7.73	0.45	3.2e-13	Vitiligo;
SARC	cis	rs9322193	0.639	rs4869756	chr6:150207496	G/A	cg09699651	chr6:150184138	LRP11	0.44	4.74	0.3	3.8e-6	Lung cancer;
SARC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg18110333	chr6:292329	DUSP22	0.65	8.56	0.49	1.51e-15	Menopause (age at onset);
SARC	cis	rs644799	0.965	rs3789960	chr11:95509037	C/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	9.45	0.53	3.74e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs6670533	0.571	rs11801906	chr1:24861287	T/G	cg07475527	chr1:24864545	NA	-1.0	-5.65	-0.35	4.76e-8	Fasting blood insulin (BMI interaction);
SARC	cis	rs3820928	0.935	rs10203363	chr2:227896976	C/T	cg05526886	chr2:227700861	RHBDD1	-0.5	-5.98	-0.36	8.26e-9	Pulmonary function;
SARC	trans	rs330048	0.561	rs4840401	chr8:9148125	A/T	cg06636001	chr8:8085503	FLJ10661	-0.6	-7.52	-0.44	1.21e-12	Systemic lupus erythematosus;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg14139633	chr9:131103210	SLC27A4	0.49	6.58	0.4	3.04e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg15556689	chr8:8085844	FLJ10661	0.47	5.87	0.36	1.52e-8	Mood instability;
SARC	cis	rs1044826	0.597	rs6803593	chr3:139193987	T/C	cg15131784	chr3:139108705	COPB2	0.4	5.03	0.31	9.72e-7	Obesity-related traits;
SARC	cis	rs910316	0.737	rs175065	chr14:75494983	T/C	cg08847533	chr14:75593920	NEK9	-0.81	-11.51	-0.6	1.46e-24	Height;
SARC	cis	rs7769051	0.803	rs56148066	chr6:133230115	G/A	cg07930552	chr6:133119739	C6orf192	0.78	6.52	0.39	4.41e-10	Type 2 diabetes nephropathy;
SARC	cis	rs2594989	1.000	rs388407	chr3:11320709	C/T	cg00170343	chr3:11313890	ATG7	0.56	5.41	0.33	1.59e-7	Circulating chemerin levels;
SARC	cis	rs9790314	0.638	rs13064176	chr3:160644181	A/T	cg04691961	chr3:161091175	C3orf57	-0.62	-8.51	-0.49	2.13e-15	Morning vs. evening chronotype;
SARC	cis	rs4851254	0.961	rs13022707	chr2:100734946	C/A	cg04109781	chr2:100722022	AFF3	0.34	4.77	0.3	3.25e-6	Intelligence (multi-trait analysis);
SARC	cis	rs208520	0.874	rs208515	chr6:66945749	A/G	cg07460842	chr6:66804631	NA	-0.92	-10.86	-0.58	1.66e-22	Exhaled nitric oxide output;
SARC	cis	rs6459788	0.527	rs6980250	chr7:157228710	C/T	cg03453431	chr7:157225567	NA	-0.51	-7.7	-0.45	3.82e-13	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg18876405	chr7:65276391	NA	0.47	5.45	0.34	1.27e-7	Aortic root size;
SARC	cis	rs11098499	0.866	rs10518329	chr4:120401835	A/G	cg24375607	chr4:120327624	NA	0.38	4.82	0.3	2.59e-6	Corneal astigmatism;
SARC	cis	rs147120681	1	rs147120681	chr1:101239293	CT/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.45	-5.57	-0.34	7.12e-8	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
SARC	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg03060546	chr3:49711283	APEH	0.43	5.36	0.33	2.04e-7	Parkinson's disease;
SARC	cis	rs453301	0.624	rs2288673	chr8:8860276	G/T	cg11995313	chr8:8860691	ERI1	-0.43	-5.48	-0.34	1.08e-7	Joint mobility (Beighton score);
SARC	cis	rs79149102	0.737	rs75128970	chr15:75181397	C/T	cg09165964	chr15:75287851	SCAMP5	-1.11	-7.31	-0.43	4.37e-12	Lung cancer;
SARC	cis	rs6964587	0.633	rs13231620	chr7:91507859	G/A	cg17063962	chr7:91808500	NA	-0.9	-13.08	-0.65	1.07e-29	Breast cancer;
SARC	cis	rs3857536	0.813	rs6455090	chr6:66948909	G/A	cg07460842	chr6:66804631	NA	-0.45	-5.19	-0.32	4.5e-7	Blood trace element (Cu levels);
SARC	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.41	-6.33	-0.38	1.22e-9	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs4148883	0.675	rs116265877	chr4:100096896	G/A	cg13256891	chr4:100009986	ADH5	0.56	7.39	0.44	2.6e-12	Alcohol dependence;
SARC	cis	rs3820928	0.874	rs7421491	chr2:227839278	C/A	cg05526886	chr2:227700861	RHBDD1	-0.56	-6.82	-0.41	7.76e-11	Pulmonary function;
SARC	cis	rs3845702	0.668	rs3856415	chr2:180807367	G/A	cg01881094	chr2:180872142	CWC22	-1.12	-9.33	-0.52	8.63e-18	Schizophrenia;
SARC	cis	rs55728055	0.661	rs9619217	chr22:32043611	A/G	cg01338084	chr22:32026380	PISD	1.03	6.28	0.38	1.66e-9	Age-related hearing impairment;
SARC	cis	rs9640161	0.789	rs60283368	chr7:150023258	G/A	cg21361702	chr7:150065534	REPIN1	0.46	4.98	0.31	1.22e-6	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	12.91	0.65	3.97e-29	Chronic sinus infection;
SARC	cis	rs62344088	0.590	rs58563514	chr5:177837	C/T	cg22857025	chr5:266934	NA	-0.77	-5.59	-0.34	6.22e-8	Asthma (childhood onset);
SARC	cis	rs1983891	0.874	rs1326322	chr6:41512462	G/T	cg15051332	chr6:41514432	FOXP4	0.54	5.78	0.35	2.34e-8	Prostate cancer;
SARC	cis	rs7246657	1.000	rs1529957	chr19:37739801	A/G	cg14683738	chr19:37701593	ZNF585B	0.6	5.62	0.35	5.5e-8	Coronary artery calcification;
SARC	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg20607798	chr8:58055168	NA	0.49	5.02	0.31	1.03e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg12463550	chr7:65579703	CRCP	0.48	5.79	0.35	2.23e-8	Aortic root size;
SARC	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg10523679	chr1:76189770	ACADM	0.52	6.88	0.41	5.36e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg03213289	chr20:61660250	NA	0.46	6.43	0.39	7.22e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs6121246	0.529	rs73235789	chr20:30196148	T/C	cg21427119	chr20:30132790	HM13	-0.45	-4.98	-0.31	1.23e-6	Mean corpuscular hemoglobin;
SARC	cis	rs10791097	0.694	rs3190331	chr11:130748131	C/T	cg12179176	chr11:130786555	SNX19	-0.76	-11.43	-0.6	2.66e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg08219700	chr8:58056026	NA	0.69	6.39	0.39	8.93e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs12200560	0.524	rs1413525	chr6:97073096	C/T	cg06623918	chr6:96969491	KIAA0776	0.45	4.95	0.31	1.43e-6	Coronary heart disease;
SARC	cis	rs1697139	0.583	rs11739727	chr5:66540940	G/A	cg11553311	chr5:66541588	NA	0.32	5.05	0.31	9.05e-7	Breast cancer;
SARC	cis	rs73198271	0.583	rs11781985	chr8:8589783	C/T	cg01851573	chr8:8652454	MFHAS1	-0.37	-4.78	-0.3	3.04e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs2153535	0.580	rs2184584	chr6:8468407	T/C	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg17386128	chr2:173420391	PDK1	-0.49	-6.41	-0.39	7.91e-10	Tetralogy of Fallot;
SARC	cis	rs9309473	1.000	rs7583255	chr2:73797996	T/G	cg20560298	chr2:73613845	ALMS1	-0.48	-5.92	-0.36	1.14e-8	Metabolite levels;
SARC	cis	rs7681440	0.804	rs763443	chr4:90819961	T/C	cg01966878	chr4:90757139	SNCA	-0.37	-4.77	-0.3	3.2e-6	Dementia with Lewy bodies;
SARC	trans	rs2727020	0.595	rs10769583	chr11:49483193	G/A	cg15704280	chr7:45808275	SEPT13	-0.87	-14.41	-0.69	4.46e-34	Coronary artery disease;
SARC	cis	rs7000551	0.508	rs11780977	chr8:22245028	G/A	cg12081754	chr8:22256438	SLC39A14	0.87	11.94	0.62	5.86e-26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs3741404	0.620	rs2236647	chr11:63964605	A/G	cg04317338	chr11:64019027	PLCB3	-0.4	-4.92	-0.31	1.61e-6	Platelet count;
SARC	cis	rs9911578	0.967	rs1267542	chr17:56654690	T/C	cg05425664	chr17:57184151	TRIM37	0.66	8.29	0.48	8.87e-15	Intelligence (multi-trait analysis);
SARC	cis	rs10046574	0.731	rs10270842	chr7:135163062	A/G	cg27474649	chr7:135195673	CNOT4	0.85	6.98	0.42	3e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg00933542	chr6:150070202	PCMT1	0.3	5.06	0.31	8.36e-7	Lung cancer;
SARC	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.63e-10	Life satisfaction;
SARC	cis	rs910316	0.967	rs4899551	chr14:75660246	C/G	cg08847533	chr14:75593920	NEK9	-0.85	-13.33	-0.66	1.66e-30	Height;
SARC	cis	rs7647973	0.769	rs4974081	chr3:49070499	A/G	cg07636037	chr3:49044803	WDR6	-0.82	-9.22	-0.52	1.77e-17	Menarche (age at onset);
SARC	cis	rs5167	0.504	rs7258345	chr19:45453151	T/G	cg09555818	chr19:45449301	APOC2	0.56	8.96	0.51	1.05e-16	Blood protein levels;
SARC	cis	rs9916302	0.904	rs8076494	chr17:37516722	A/G	cg00129232	chr17:37814104	STARD3	0.66	7.7	0.45	3.76e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs8077889	1.000	rs8077889	chr17:41878166	G/T	cg26893861	chr17:41843967	DUSP3	-0.81	-9.58	-0.53	1.48e-18	Triglycerides;
SARC	cis	rs12681366	0.659	rs2470742	chr8:95398157	G/C	cg26464482	chr8:95565502	KIAA1429	-0.43	-5.25	-0.33	3.49e-7	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs9487051	0.676	rs4383852	chr6:109594475	G/A	cg01475377	chr6:109611718	NA	-0.35	-5.08	-0.32	7.66e-7	Reticulocyte fraction of red cells;
SARC	cis	rs116095464	0.558	rs62346506	chr5:201594	T/C	cg22496380	chr5:211416	CCDC127	-0.91	-8.14	-0.47	2.41e-14	Breast cancer;
SARC	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-9.17	-0.51	2.59e-17	Alzheimer's disease;
SARC	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg00149659	chr3:10157352	C3orf10	-1.09	-9.69	-0.54	7.11e-19	Alzheimer's disease;
SARC	cis	rs1348850	0.914	rs8941	chr2:178406481	C/T	cg23306229	chr2:178417860	TTC30B	0.57	6.5	0.39	4.94e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2295359	0.892	rs10889657	chr1:67615487	A/G	cg12940439	chr1:67600707	NA	0.47	6.76	0.4	1.1e-10	Psoriasis;
SARC	cis	rs9303401	0.573	rs62081879	chr17:57181524	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	10.79	0.58	2.88e-22	Cognitive test performance;
SARC	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg21782813	chr7:2030301	MAD1L1	0.39	6.21	0.38	2.38e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs7264396	0.790	rs1040695	chr20:34244829	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-8.17	-0.47	2.02e-14	Total cholesterol levels;
SARC	cis	rs208520	1.000	rs12189683	chr6:66977716	A/C	cg07460842	chr6:66804631	NA	-0.89	-10.25	-0.56	1.39e-20	Exhaled nitric oxide output;
SARC	cis	rs5758659	0.714	rs6002607	chr22:42496506	C/T	cg04733989	chr22:42467013	NAGA	-0.49	-5.9	-0.36	1.3e-8	Cognitive function;
SARC	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg00339695	chr16:24857497	SLC5A11	0.41	5.84	0.36	1.72e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg13206674	chr6:150067644	NUP43	0.41	5.19	0.32	4.51e-7	Lung cancer;
SARC	cis	rs17666538	0.585	rs6559065	chr8:623156	G/C	cg07234876	chr8:600039	NA	0.77	6.51	0.39	4.6e-10	IgG glycosylation;
SARC	cis	rs6570726	0.791	rs392612	chr6:145881586	C/G	cg05347473	chr6:146136440	FBXO30	-0.55	-7.7	-0.45	3.93e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7327064	0.666	rs9547431	chr13:36930263	G/T	cg13455704	chr13:36871754	C13orf38	0.6	6.47	0.39	5.6e-10	Economic and political preferences;
SARC	cis	rs9987353	0.522	rs2929466	chr8:9063899	G/T	cg08975724	chr8:8085496	FLJ10661	-0.4	-4.82	-0.3	2.64e-6	Recombination measurement;
SARC	cis	rs9902453	0.730	rs2020939	chr17:28550732	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.48	-5.89	-0.36	1.37e-8	Coffee consumption (cups per day);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg10715637	chr10:90751534	FAS;ACTA2	-0.5	-7.19	-0.43	8.6e-12	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs3796352	0.892	rs3821872	chr3:53080555	C/G	cg15956490	chr3:53032818	SFMBT1	-0.61	-4.81	-0.3	2.7e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg22857025	chr5:266934	NA	1.06	11.61	0.61	6.7e-25	Breast cancer;
SARC	cis	rs6088580	0.524	rs11167241	chr20:33250835	C/T	cg07148914	chr20:33460835	GGT7	-0.42	-5.16	-0.32	5.4e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs1008375	0.966	rs6837664	chr4:17697835	G/C	cg27347728	chr4:17578864	LAP3	0.44	5.67	0.35	4.13e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs3858526	0.883	rs1453429	chr11:5933478	C/T	cg13902645	chr11:5959945	NA	-0.42	-4.92	-0.31	1.67e-6	DNA methylation (variation);
SARC	cis	rs3771570	0.892	rs55751610	chr2:242346057	C/T	cg21155796	chr2:242212141	HDLBP	0.68	6.14	0.37	3.44e-9	Prostate cancer;
SARC	cis	rs3733585	0.673	rs4495037	chr4:9954050	C/G	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.94	-0.36	1.06e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.75	8.87	0.5	2.01e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg04944784	chr2:26401820	FAM59B	0.63	8.21	0.47	1.49e-14	Gut microbiome composition (summer);
SARC	cis	rs16976116	0.901	rs8028525	chr15:55492317	T/C	cg17854078	chr15:55489399	RSL24D1	0.69	6.65	0.4	2.07e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg13944838	chr5:179740914	GFPT2	-0.59	-7.4	-0.44	2.49e-12	Height;
SARC	cis	rs9325144	0.723	rs11169518	chr12:39177237	C/A	cg13010199	chr12:38710504	ALG10B	-0.49	-5.88	-0.36	1.41e-8	Morning vs. evening chronotype;
SARC	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	16.55	0.74	3.34e-41	Height;
SARC	cis	rs9987353	0.620	rs34455383	chr8:9066458	C/T	cg06636001	chr8:8085503	FLJ10661	-0.61	-7.35	-0.43	3.27e-12	Recombination measurement;
SARC	cis	rs7412746	0.611	rs4970984	chr1:150887377	T/C	cg10589385	chr1:150898437	SETDB1	0.4	5.33	0.33	2.32e-7	Melanoma;
SARC	cis	rs526231	0.543	rs42431	chr5:102400063	C/T	cg23492399	chr5:102201601	PAM	0.52	5.5	0.34	1.01e-7	Primary biliary cholangitis;
SARC	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg18404041	chr3:52824283	ITIH1	-0.42	-6.29	-0.38	1.56e-9	Bipolar disorder;
SARC	cis	rs3796352	1.000	rs71617204	chr3:53042951	G/A	cg15956490	chr3:53032818	SFMBT1	0.87	5.73	0.35	3.14e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2304069	0.954	rs4705409	chr5:149414899	A/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.68	6.63	0.4	2.37e-10	HIV-1 control;
SARC	cis	rs6088590	0.561	rs6088527	chr20:33155841	C/T	cg08999081	chr20:33150536	PIGU	0.44	6.78	0.41	9.96e-11	Coronary artery disease;
SARC	cis	rs9916302	0.904	rs4795355	chr17:37427382	C/T	cg07936489	chr17:37558343	FBXL20	-0.68	-9.22	-0.52	1.82e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg11764359	chr7:65958608	NA	0.59	7.09	0.42	1.56e-11	Calcium levels;
SARC	cis	rs995000	0.931	rs11207979	chr1:62982994	G/A	cg06896770	chr1:63153194	DOCK7	0.93	13.67	0.67	1.24e-31	Triglyceride levels;
SARC	cis	rs10465746	0.780	rs11163862	chr1:84355418	A/T	cg10977910	chr1:84465055	TTLL7	-0.4	-4.81	-0.3	2.66e-6	Obesity-related traits;
SARC	cis	rs711245	0.574	rs1179494	chr2:36809496	C/G	cg09467607	chr2:36825704	FEZ2	-0.5	-6.78	-0.41	9.54e-11	Height;
SARC	cis	rs9487051	0.676	rs9374077	chr6:109600194	C/T	cg01475377	chr6:109611718	NA	-0.35	-5.16	-0.32	5.41e-7	Reticulocyte fraction of red cells;
SARC	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg18876405	chr7:65276391	NA	-0.47	-5.3	-0.33	2.62e-7	Aortic root size;
SARC	cis	rs7937682	0.632	rs10891294	chr11:111699224	C/T	cg09085632	chr11:111637200	PPP2R1B	0.79	10.53	0.57	1.85e-21	Primary sclerosing cholangitis;
SARC	cis	rs1355223	0.902	rs860712	chr11:34743494	C/T	cg18508148	chr11:34937573	PDHX;APIP	-0.38	-4.83	-0.3	2.46e-6	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs34172651	0.917	rs11646987	chr16:24832408	G/T	cg04756594	chr16:24857601	SLC5A11	0.33	5.35	0.33	2.06e-7	Intelligence (multi-trait analysis);
SARC	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg03709012	chr19:19516395	GATAD2A	-1.03	-17.17	-0.75	2.89e-43	Tonsillectomy;
SARC	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg21433313	chr16:3507492	NAT15	0.34	4.82	0.3	2.63e-6	Tuberculosis;
SARC	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.39	-6.4	-0.39	8.67e-10	Menopause (age at onset);
SARC	cis	rs11190604	1.000	rs1080698	chr10:102295114	G/T	cg07080220	chr10:102295463	HIF1AN	0.78	9.16	0.51	2.84e-17	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg08715431	chr8:56986606	SNORD54;RPS20	-0.49	-6.43	-0.39	7.29e-10	Breast cancer;
SARC	cis	rs72781680	0.561	rs72783615	chr2:24296397	C/A	cg06627628	chr2:24431161	ITSN2	-0.57	-5.97	-0.36	8.85e-9	Lymphocyte counts;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg25348050	chr2:46986930	SOCS5	0.48	6.91	0.41	4.68e-11	Thyroid stimulating hormone;
SARC	cis	rs950169	0.881	rs4081123	chr15:84956235	A/G	cg24253500	chr15:84953950	NA	0.36	5.21	0.32	4.19e-7	Schizophrenia;
SARC	cis	rs7959452	0.535	rs10784771	chr12:69621264	A/G	cg22834771	chr12:69754056	YEATS4	-0.42	-5.55	-0.34	7.72e-8	Blood protein levels;
SARC	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg11062466	chr8:58055876	NA	0.61	5.6	0.34	6.04e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs55962025	0.883	rs82334	chr4:3225371	A/C	cg06533319	chr4:3265114	C4orf44	0.32	4.98	0.31	1.22e-6	Parental longevity (mother's age at death);
SARC	cis	rs9815354	0.812	rs61661916	chr3:41921915	T/C	cg03022575	chr3:42003672	ULK4	0.69	5.65	0.35	4.69e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs34779708	0.931	rs79749947	chr10:35277081	A/T	cg03585969	chr10:35415529	CREM	0.41	5.07	0.32	8.01e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs9807989	0.839	rs6543123	chr2:102977196	C/T	cg09003973	chr2:102972529	NA	0.41	5.64	0.35	4.85e-8	Asthma;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg02873427	chr8:145514720	BOP1;HSF1	-0.74	-7.93	-0.46	8.85e-14	Lung cancer in ever smokers;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg05414026	chr15:72410489	MYO9A;SENP8	0.49	6.52	0.39	4.39e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs7681440	0.538	rs1442149	chr4:90749132	A/T	cg06632027	chr4:90757378	SNCA	-0.42	-5.25	-0.33	3.41e-7	Dementia with Lewy bodies;
SARC	cis	rs11687170	0.882	rs76155537	chr2:237058409	A/G	cg19324714	chr2:237145437	ASB18	0.49	4.89	0.31	1.89e-6	Educational attainment;Educational attainment (years of education);
SARC	cis	rs1865760	0.588	rs9467658	chr6:26010881	T/G	cg10373733	chr6:25993375	NA	0.44	5.51	0.34	9.25e-8	Height;
SARC	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.37	0.39	9.97e-10	Bipolar disorder;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg26206990	chr15:63569719	APH1B	0.48	6.29	0.38	1.58e-9	Tetralogy of Fallot;
SARC	cis	rs2073499	1.000	rs57462170	chr3:50239803	G/A	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.58	5.02	0.31	1.03e-6	Schizophrenia;
SARC	cis	rs910316	0.737	rs175048	chr14:75479894	A/T	cg06637938	chr14:75390232	RPS6KL1	-0.42	-5.65	-0.35	4.71e-8	Height;
SARC	cis	rs6424115	1.000	rs7521961	chr1:24157634	C/T	cg15997130	chr1:24165203	NA	-0.49	-6.62	-0.4	2.42e-10	Immature fraction of reticulocytes;
SARC	cis	rs9325144	0.723	rs11169535	chr12:39183494	C/T	cg13010199	chr12:38710504	ALG10B	-0.51	-6.02	-0.37	6.83e-9	Morning vs. evening chronotype;
SARC	cis	rs7412746	0.611	rs10888395	chr1:150762171	C/T	cg15448220	chr1:150897856	SETDB1	0.48	6.09	0.37	4.61e-9	Melanoma;
SARC	cis	rs9381040	0.655	rs9381031	chr6:41044957	A/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.46	-5.27	-0.33	3.05e-7	Alzheimer's disease (late onset);
SARC	trans	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-6.7	-0.4	1.52e-10	Intelligence (multi-trait analysis);
SARC	cis	rs1003719	0.788	rs61701101	chr21:38450317	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.67	9.98	0.55	9.34e-20	Eye color traits;
SARC	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg11764359	chr7:65958608	NA	-0.79	-9.7	-0.54	6.48e-19	Aortic root size;
SARC	cis	rs240764	0.507	rs9390682	chr6:101219119	T/C	cg09795085	chr6:101329169	ASCC3	0.4	4.96	0.31	1.34e-6	Neuroticism;
SARC	cis	rs7223966	1.000	rs2854219	chr17:61942682	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.49	5.06	0.31	8.7e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6840360	0.593	rs28602726	chr4:152499788	T/C	cg22705602	chr4:152727874	NA	-0.41	-6.47	-0.39	5.71e-10	Intelligence (multi-trait analysis);
SARC	cis	rs10028773	0.700	rs7690338	chr4:120256468	C/G	cg09307838	chr4:120376055	NA	0.81	11.03	0.59	4.84e-23	Educational attainment;
SARC	cis	rs6058796	1.000	rs6058796	chr20:31255829	C/T	cg13636640	chr20:31349939	DNMT3B	0.56	4.94	0.31	1.48e-6	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg12042659	chr19:58951599	ZNF132	0.43	5.72	0.35	3.18e-8	Uric acid clearance;
SARC	cis	rs4642101	0.855	rs9873475	chr3:12845422	A/G	cg05775895	chr3:12838266	CAND2	0.74	12.08	0.62	2.01e-26	QRS complex (12-leadsum);
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg04389426	chr9:16871106	BNC2	-0.45	-6.55	-0.39	3.64e-10	Neuroticism;
SARC	cis	rs34172651	0.917	rs200529	chr16:24758502	T/C	cg04756594	chr16:24857601	SLC5A11	-0.37	-6.22	-0.38	2.22e-9	Intelligence (multi-trait analysis);
SARC	cis	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg07636037	chr3:49044803	WDR6	0.61	7.91	0.46	1.03e-13	Resting heart rate;
SARC	cis	rs11122272	0.766	rs2790871	chr1:231543555	G/C	cg06096015	chr1:231504339	EGLN1	0.38	5.59	0.34	6.26e-8	Hemoglobin concentration;
SARC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg22105103	chr4:187893119	NA	0.52	7.06	0.42	1.9e-11	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs61931739	0.500	rs11053194	chr12:34440841	A/G	cg13010199	chr12:38710504	ALG10B	0.75	10.81	0.58	2.48e-22	Morning vs. evening chronotype;
SARC	cis	rs7223966	1.000	rs6504182	chr17:61823672	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.44	4.87	0.3	2.09e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1609391	0.543	rs9828009	chr3:136631275	C/T	cg15507776	chr3:136538369	TMEM22	0.84	11.5	0.6	1.56e-24	Neuroticism;
SARC	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.53	-0.39	4.12e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg23172400	chr8:95962367	TP53INP1	-0.31	-5.3	-0.33	2.64e-7	Type 2 diabetes;
SARC	cis	rs2204008	0.619	rs11178987	chr12:38201258	C/T	cg26384229	chr12:38710491	ALG10B	-0.66	-8.64	-0.49	9.24e-16	Bladder cancer;
SARC	trans	rs2727020	0.894	rs1917328	chr11:49359606	G/A	cg15704280	chr7:45808275	SEPT13	-0.73	-9.61	-0.53	1.2e-18	Coronary artery disease;
SARC	cis	rs13401104	0.754	rs10929175	chr2:237117204	A/C	cg19324714	chr2:237145437	ASB18	0.58	5.83	0.36	1.87e-8	Educational attainment;
SARC	trans	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg17830980	chr10:43048298	ZNF37B	-0.52	-6.81	-0.41	8.04e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs4268898	0.636	rs72787371	chr2:24570073	T/A	cg26838691	chr2:24397539	C2orf84	-0.49	-5.7	-0.35	3.62e-8	Asthma;
SARC	cis	rs2425143	0.730	rs6058354	chr20:34491110	C/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	4.92	0.31	1.62e-6	Blood protein levels;
SARC	cis	rs7264396	0.616	rs6060744	chr20:34581555	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-5.58	-0.34	6.55e-8	Total cholesterol levels;
SARC	cis	rs4253772	0.591	rs6008365	chr22:46652929	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.64	7.09	0.42	1.61e-11	LDL cholesterol;Cholesterol, total;
SARC	cis	rs2204008	0.715	rs12368462	chr12:38336116	C/G	cg26384229	chr12:38710491	ALG10B	0.88	12.62	0.64	3.6e-28	Bladder cancer;
SARC	cis	rs4969178	0.965	rs3744217	chr17:76400258	G/A	cg20026190	chr17:76395443	PGS1	0.4	5.37	0.33	1.86e-7	HDL cholesterol levels;
SARC	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg11764359	chr7:65958608	NA	0.73	8.72	0.5	5.25e-16	Aortic root size;
SARC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	12.21	0.62	7.99e-27	Platelet count;
SARC	cis	rs7089973	0.966	rs61867966	chr10:116584362	T/C	cg08188268	chr10:116634841	FAM160B1	0.33	4.94	0.31	1.48e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg20818283	chr2:191399100	TMEM194B	0.45	5.76	0.35	2.63e-8	Pulse pressure;
SARC	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg11644478	chr21:40555479	PSMG1	1.02	14.53	0.69	1.73e-34	Cognitive function;
SARC	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg15448220	chr1:150897856	SETDB1	0.47	6.22	0.38	2.24e-9	Tonsillectomy;
SARC	cis	rs3087591	0.960	rs2066736	chr17:29559932	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.56	-6.87	-0.41	5.87e-11	Hip circumference;
SARC	cis	rs4243830	0.850	rs2412309	chr1:6603151	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.9	-9.26	-0.52	1.41e-17	Body mass index;
SARC	cis	rs9372253	0.645	rs7753212	chr6:110700229	T/C	cg01119278	chr6:110721349	DDO	-0.37	-4.89	-0.31	1.85e-6	Platelet distribution width;
SARC	trans	rs1814175	0.817	rs4881627	chr11:49953955	C/A	cg15704280	chr7:45808275	SEPT13	-0.97	-18.54	-0.77	9.52e-48	Height;
SARC	cis	rs7553864	0.614	rs1886634	chr1:87614821	C/T	cg17420885	chr1:87600446	LOC339524	0.37	5.37	0.33	1.89e-7	Smoking behavior;
SARC	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg18252515	chr7:66147081	NA	0.59	6.34	0.38	1.17e-9	Aortic root size;
SARC	cis	rs12458462	0.787	rs56006341	chr18:77439844	G/T	cg23301140	chr18:77439876	CTDP1	0.62	7.99	0.46	6.36e-14	Monocyte count;
SARC	cis	rs9303401	0.659	rs17822908	chr17:56801778	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	12.31	0.63	3.57e-27	Cognitive test performance;
SARC	cis	rs2380220	0.720	rs9374178	chr6:95979974	G/T	cg04719120	chr6:96025338	MANEA	0.55	6.18	0.38	2.83e-9	Behavioural disinhibition (generation interaction);
SARC	cis	rs9796	0.835	rs2927062	chr15:41302687	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.43	-6.0	-0.37	7.35e-9	Menopause (age at onset);
SARC	cis	rs12200782	0.505	rs1535275	chr6:26520767	G/C	cg11502198	chr6:26597334	ABT1	0.71	7.59	0.45	7.44e-13	Small cell lung carcinoma;
SARC	cis	rs10876993	0.928	rs1689587	chr12:58075398	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.43	-5.36	-0.33	1.96e-7	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs9660992	0.700	rs1172125	chr1:205258442	A/T	cg21643547	chr1:205240462	TMCC2	-0.55	-7.36	-0.43	3.15e-12	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs561341	0.700	rs2074101	chr17:30228656	G/A	cg12000587	chr17:30186630	C17orf79	-0.32	-4.73	-0.3	3.86e-6	Hip circumference adjusted for BMI;
SARC	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1018697	0.518	rs284846	chr10:104557290	T/C	cg04362960	chr10:104952993	NT5C2	-0.52	-5.33	-0.33	2.37e-7	Colorectal adenoma (advanced);
SARC	cis	rs12142240	0.698	rs3991877	chr1:46853749	C/A	cg10495392	chr1:46806563	NSUN4	0.65	6.88	0.41	5.6e-11	Menopause (age at onset);
SARC	trans	rs3942852	0.712	rs10742828	chr11:48104555	A/G	cg15704280	chr7:45808275	SEPT13	-0.58	-6.7	-0.4	1.55e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs933688	0.526	rs7727632	chr5:90609009	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.67	-5.84	-0.36	1.74e-8	Smoking behavior;
SARC	cis	rs2795502	0.882	rs3123754	chr10:43339011	G/A	cg20628663	chr10:43360327	NA	-0.47	-6.32	-0.38	1.33e-9	Blood protein levels;
SARC	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9818758	0.607	rs55873331	chr3:49597055	C/T	cg01304814	chr3:48885189	PRKAR2A	0.65	5.07	0.31	8.26e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs4642101	0.793	rs13320486	chr3:12822069	C/A	cg24848339	chr3:12840334	CAND2	0.33	4.93	0.31	1.59e-6	QRS complex (12-leadsum);
SARC	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg18876405	chr7:65276391	NA	0.7	8.68	0.49	6.76e-16	Aortic root size;
SARC	cis	rs12701220	0.817	rs1058727	chr7:1087095	A/G	cg02733842	chr7:1102375	C7orf50	-0.53	-6.85	-0.41	6.56e-11	Bronchopulmonary dysplasia;
SARC	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg02475777	chr4:1388615	CRIPAK	0.61	7.15	0.42	1.11e-11	Longevity;
SARC	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.6	-7.25	-0.43	6.02e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg20102877	chr2:27665638	KRTCAP3	-0.39	-5.41	-0.33	1.54e-7	Total body bone mineral density;
SARC	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg08280861	chr8:58055591	NA	0.61	5.81	0.36	2.02e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10100465	0.596	rs218009	chr8:118716275	A/G	cg22024281	chr8:119124108	EXT1	0.54	5.36	0.33	2.04e-7	Leprosy;
SARC	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg02733842	chr7:1102375	C7orf50	-0.62	-7.23	-0.43	6.98e-12	Bronchopulmonary dysplasia;
SARC	cis	rs9650657	0.504	rs10108347	chr8:11033517	G/C	cg21775007	chr8:11205619	TDH	-0.44	-5.46	-0.34	1.23e-7	Neuroticism;
SARC	cis	rs16854884	0.657	rs13078840	chr3:143700753	A/G	cg06585982	chr3:143692056	C3orf58	0.66	8.66	0.49	8.05e-16	Economic and political preferences (feminism/equality);
SARC	cis	rs6582630	0.519	rs8189599	chr12:38280748	A/G	cg13010199	chr12:38710504	ALG10B	0.81	11.31	0.6	6.15e-24	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg11891330	chr4:2010714	WHSC2	0.51	6.26	0.38	1.87e-9	Breast cancer;
SARC	cis	rs2204008	0.837	rs12581130	chr12:38319387	A/G	cg13010199	chr12:38710504	ALG10B	0.78	10.65	0.57	7.61e-22	Bladder cancer;
SARC	cis	rs6977660	0.714	rs6943204	chr7:19818671	A/G	cg05791153	chr7:19748676	TWISTNB	0.57	5.38	0.33	1.83e-7	Thyroid stimulating hormone;
SARC	cis	rs11122272	0.735	rs2808580	chr1:231509259	A/G	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg18156543	chr17:48172978	PDK2	-0.53	-6.83	-0.41	7.34e-11	Breast cancer;
SARC	cis	rs4689388	0.926	rs4343789	chr4:6285228	C/G	cg00701064	chr4:6280414	WFS1	0.56	8.99	0.51	8.59e-17	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs8044868	1.000	rs4238964	chr16:72175156	A/C	cg16558253	chr16:72132732	DHX38	-0.36	-5.0	-0.31	1.11e-6	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
SARC	cis	rs2576037	0.796	rs2571031	chr18:44577063	T/C	cg19077165	chr18:44547161	KATNAL2	0.44	6.19	0.38	2.66e-9	Personality dimensions;
SARC	cis	rs36051895	0.632	rs57698263	chr9:5143262	G/A	cg02405213	chr9:5042618	JAK2	-0.49	-5.99	-0.37	7.8e-9	Pediatric autoimmune diseases;
SARC	cis	rs9547692	0.877	rs9652258	chr13:37476123	G/C	cg01493522	chr13:37497338	NA	-0.46	-5.08	-0.32	7.88e-7	Coronary artery disease;
SARC	cis	rs854765	0.547	rs2955353	chr17:17948979	T/C	cg04398451	chr17:18023971	MYO15A	0.47	6.58	0.4	3.12e-10	Total body bone mineral density;
SARC	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg08219700	chr8:58056026	NA	0.6	6.42	0.39	7.59e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs10870270	1.000	rs10159943	chr10:133744744	T/C	cg17892150	chr10:133769511	PPP2R2D	-0.82	-10.71	-0.57	4.89e-22	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs2153535	0.580	rs2143355	chr6:8517856	T/A	cg23788917	chr6:8435910	SLC35B3	0.63	8.21	0.47	1.56e-14	Motion sickness;
SARC	cis	rs9467773	1.000	rs9393729	chr6:26514166	C/T	cg12292205	chr6:26970375	C6orf41	0.44	5.46	0.34	1.24e-7	Intelligence (multi-trait analysis);
SARC	trans	rs11722228	0.508	rs73212864	chr4:10104191	G/A	cg26043149	chr18:55253948	FECH	0.7	8.09	0.47	3.38e-14	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs4595586	0.545	rs6580910	chr12:39390052	C/A	cg26384229	chr12:38710491	ALG10B	0.5	6.12	0.37	3.98e-9	Morning vs. evening chronotype;
SARC	trans	rs1493916	1.000	rs12457802	chr18:31389865	A/G	cg27147174	chr7:100797783	AP1S1	0.58	7.59	0.45	7.55e-13	Life satisfaction;
SARC	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg02725872	chr8:58115012	NA	-0.37	-6.52	-0.39	4.21e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg02574844	chr11:5959923	NA	-0.39	-5.23	-0.32	3.7e-7	DNA methylation (variation);
SARC	cis	rs17376456	1.000	rs17376207	chr5:93545524	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.63	-5.76	-0.35	2.63e-8	Diabetic retinopathy;
SARC	cis	rs2120243	0.592	rs1869857	chr3:157123357	G/T	cg01018701	chr3:157155998	VEPH1;PTX3	-0.45	-5.85	-0.36	1.62e-8	Hepatocellular carcinoma in hepatitis B infection;
SARC	trans	rs2727020	0.729	rs10839283	chr11:49490943	T/C	cg15704280	chr7:45808275	SEPT13	0.82	10.98	0.58	6.94e-23	Coronary artery disease;
SARC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg11494091	chr17:61959527	GH2	0.53	7.95	0.46	7.95e-14	Prudent dietary pattern;
SARC	cis	rs9457247	0.905	rs444210	chr6:167390242	A/G	cg23791538	chr6:167370224	RNASET2	-0.62	-8.48	-0.49	2.56e-15	Crohn's disease;
SARC	cis	rs10493773	0.502	rs12066742	chr1:86081149	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.46	-6.21	-0.38	2.37e-9	Urate levels in overweight individuals;
SARC	cis	rs8180040	0.764	rs12629262	chr3:47196580	C/T	cg27129171	chr3:47204927	SETD2	0.67	9.52	0.53	2.32e-18	Colorectal cancer;
SARC	cis	rs5753618	0.539	rs2228619	chr22:31663842	C/G	cg13145458	chr22:31556086	RNF185	0.47	5.05	0.31	8.76e-7	Colorectal cancer;
SARC	cis	rs1348850	0.645	rs4893963	chr2:178430747	A/G	cg23306229	chr2:178417860	TTC30B	-0.69	-7.61	-0.45	6.56e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	trans	rs2637266	1.000	rs2637266	chr10:78331318	C/T	cg16624367	chr10:81971504	NA	0.48	7.01	0.42	2.52e-11	Pulmonary function;
SARC	cis	rs62064224	0.818	rs11080180	chr17:30682998	G/A	cg25809561	chr17:30822961	MYO1D	0.38	5.58	0.34	6.54e-8	Schizophrenia;
SARC	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg05313129	chr8:58192883	C8orf71	-0.65	-6.45	-0.39	6.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg22857025	chr5:266934	NA	-1.05	-11.36	-0.6	4.28e-24	Breast cancer;
SARC	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg26681399	chr22:41777847	TEF	-0.45	-4.85	-0.3	2.28e-6	Vitiligo;
SARC	cis	rs7568458	0.846	rs7605975	chr2:85772548	C/T	cg02493740	chr2:85810744	VAMP5	-0.36	-5.3	-0.33	2.66e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs1448094	0.512	rs61930861	chr12:86245023	G/T	cg02569458	chr12:86230093	RASSF9	0.38	5.39	0.33	1.71e-7	Major depressive disorder;
SARC	cis	rs3796352	0.881	rs35384050	chr3:53008769	G/T	cg27565382	chr3:53032988	SFMBT1	0.83	5.68	0.35	4e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg08859206	chr1:53392774	SCP2	0.38	5.43	0.34	1.43e-7	Monocyte count;
SARC	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg11764359	chr7:65958608	NA	-0.6	-7.06	-0.42	1.88e-11	Aortic root size;
SARC	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg11890956	chr21:40555474	PSMG1	1.17	18.71	0.77	2.56e-48	Cognitive function;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg14182682	chr14:57857589	NAA30	-0.78	-6.57	-0.4	3.25e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7566780	0.608	rs4467267	chr2:16675250	A/G	cg09580478	chr2:16689509	NA	0.46	6.2	0.38	2.55e-9	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg03185022	chr7:2884158	GNA12	0.44	4.73	0.3	3.89e-6	Height;
SARC	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.71	-7.21	-0.43	7.98e-12	Platelet count;
SARC	cis	rs2304069	0.954	rs1962603	chr5:149393006	G/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.67	6.49	0.39	5.15e-10	HIV-1 control;
SARC	cis	rs6108958	0.753	rs2423554	chr20:11489319	A/C	cg26705720	chr20:10652787	JAG1	0.41	4.72	0.3	4.03e-6	Gut microbiome composition (summer);
SARC	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg04772025	chr11:68637568	NA	0.48	5.76	0.35	2.68e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs13256369	1.000	rs4840352	chr8:8573508	A/G	cg17143192	chr8:8559678	CLDN23	0.54	6.13	0.37	3.79e-9	Obesity-related traits;
SARC	cis	rs2652822	0.571	rs11858666	chr15:63526239	G/C	cg02713581	chr15:63449717	RPS27L	0.54	6.41	0.39	8.05e-10	Metabolic traits;
SARC	cis	rs7829975	0.606	rs10112585	chr8:8795030	A/T	cg15556689	chr8:8085844	FLJ10661	-0.41	-5.1	-0.32	7.04e-7	Mood instability;
SARC	cis	rs916888	0.610	rs199453	chr17:44800946	C/T	cg01570182	chr17:44337453	NA	0.61	7.47	0.44	1.6e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs6665290	0.669	rs3795445	chr1:227180947	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.01	-20.19	-0.8	4.36e-53	Myeloid white cell count;
SARC	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg24675658	chr1:53192096	ZYG11B	-0.64	-9.45	-0.53	3.77e-18	Monocyte count;
SARC	cis	rs950027	0.620	rs872192	chr15:45614502	A/G	cg15395560	chr15:45543142	SLC28A2	-0.28	-5.31	-0.33	2.53e-7	Response to fenofibrate (adiponectin levels);
SARC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg11965913	chr1:205819406	PM20D1	-0.73	-11.97	-0.62	4.84e-26	Monocyte percentage of white cells;
SARC	cis	rs4243830	0.850	rs4908912	chr1:6599558	A/C	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.01	-9.9	-0.54	1.61e-19	Body mass index;
SARC	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg22920501	chr2:26401640	FAM59B	-0.54	-6.8	-0.41	8.56e-11	Gut microbiome composition (summer);
SARC	cis	rs6121246	0.908	rs6089094	chr20:30431771	C/T	cg13852791	chr20:30311386	BCL2L1	0.79	8.38	0.48	5.13e-15	Mean corpuscular hemoglobin;
SARC	cis	rs36715	1.000	rs36693	chr5:127548700	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.65	7.18	0.43	9.07e-12	Breast cancer;
SARC	cis	rs17376456	0.877	rs10060160	chr5:93387879	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.7	0.35	3.55e-8	Diabetic retinopathy;
SARC	cis	rs2916247	0.954	rs7839381	chr8:93158296	T/C	cg10183463	chr8:93005414	RUNX1T1	0.49	5.04	0.31	9.15e-7	Intelligence (multi-trait analysis);
SARC	cis	rs950027	0.620	rs1145089	chr15:45652054	G/C	cg21132104	chr15:45694354	SPATA5L1	0.55	7.09	0.42	1.59e-11	Response to fenofibrate (adiponectin levels);
SARC	cis	rs1059312	1.000	rs7136092	chr12:129280164	G/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.5	7.08	0.42	1.69e-11	Systemic lupus erythematosus;
SARC	cis	rs7666738	0.546	rs11097591	chr4:98910173	G/A	cg05340658	chr4:99064831	C4orf37	0.6	7.3	0.43	4.55e-12	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg24829409	chr8:58192753	C8orf71	-0.66	-6.29	-0.38	1.59e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.85	8.21	0.47	1.55e-14	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs9790314	1.000	rs7653361	chr3:160992291	C/T	cg04691961	chr3:161091175	C3orf57	-0.79	-11.72	-0.61	3.09e-25	Morning vs. evening chronotype;
SARC	cis	rs7829975	0.539	rs4841012	chr8:8551710	C/A	cg06636001	chr8:8085503	FLJ10661	-0.46	-5.58	-0.34	6.62e-8	Mood instability;
SARC	cis	rs644799	0.525	rs3016206	chr11:95536724	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.87	13.84	0.67	3.37e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9790314	0.967	rs6762645	chr3:160948349	T/G	cg04691961	chr3:161091175	C3orf57	-0.79	-11.72	-0.61	3.09e-25	Morning vs. evening chronotype;
SARC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg18402987	chr7:1209562	NA	0.42	5.41	0.33	1.54e-7	Longevity;Endometriosis;
SARC	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg27266027	chr21:40555129	PSMG1	-0.51	-5.61	-0.34	5.8e-8	Cognitive function;
SARC	cis	rs6835098	1.000	rs10031414	chr4:174084953	A/C	cg08422745	chr4:174089978	GALNT7	-0.77	-10.29	-0.56	1.06e-20	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs362272	0.505	rs10155132	chr4:3369500	A/G	cg08741688	chr4:3415352	RGS12	-0.49	-6.28	-0.38	1.6e-9	Serum sulfate level;
SARC	cis	rs6732160	0.588	rs28626211	chr2:73378522	G/A	cg01422370	chr2:73384389	NA	0.37	5.65	0.35	4.61e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg05861140	chr6:150128134	PCMT1	-0.38	-4.91	-0.31	1.75e-6	Lung cancer;
SARC	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-9.15	-0.51	2.85e-17	Alzheimer's disease;
SARC	cis	rs7833986	0.534	rs2667980	chr8:56896541	A/T	cg26371346	chr8:56986568	SNORD54;RPS20	0.68	6.48	0.39	5.31e-10	Height;
SARC	cis	rs9303401	0.659	rs17822837	chr17:56737838	C/T	cg25039879	chr17:56429692	SUPT4H1	0.66	6.52	0.39	4.4e-10	Cognitive test performance;
SARC	cis	rs9420	0.796	rs685149	chr11:57657413	A/G	cg23127183	chr11:57508653	C11orf31	0.42	4.79	0.3	2.91e-6	Schizophrenia;
SARC	cis	rs7659604	0.540	rs13140070	chr4:122713899	C/T	cg19748678	chr4:122722346	EXOSC9	-0.4	-4.87	-0.3	2.02e-6	Type 2 diabetes;
SARC	cis	rs72945132	0.882	rs55758686	chr11:70172204	C/T	cg00319359	chr11:70116639	PPFIA1	0.68	6.29	0.38	1.57e-9	Coronary artery disease;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg22336107	chr19:14606894	GIPC1	-0.51	-6.4	-0.39	8.39e-10	Schizophrenia;
SARC	cis	rs11098499	0.865	rs11722183	chr4:120280597	A/C	cg09160332	chr4:120329925	NA	-0.35	-5.0	-0.31	1.15e-6	Corneal astigmatism;
SARC	cis	rs6088580	0.634	rs6058051	chr20:33044862	G/A	cg24642439	chr20:33292090	TP53INP2	0.68	8.78	0.5	3.54e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs6088580	0.608	rs8114616	chr20:32969092	G/T	cg24642439	chr20:33292090	TP53INP2	-0.64	-8.15	-0.47	2.29e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs9733	0.744	rs11204737	chr1:150847647	C/T	cg13175981	chr1:150552382	MCL1	0.62	8.41	0.48	4.16e-15	Tonsillectomy;
SARC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.76	9.79	0.54	3.44e-19	Prudent dietary pattern;
SARC	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg10435706	chr6:150039699	LATS1	0.36	4.8	0.3	2.88e-6	Lung cancer;
SARC	cis	rs3741151	1.000	rs75004180	chr11:73024739	A/G	cg17517138	chr11:73019481	ARHGEF17	1.04	7.95	0.46	7.9e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	trans	rs2727020	0.894	rs3862342	chr11:49357043	C/T	cg03929089	chr4:120376271	NA	-0.72	-9.02	-0.51	6.92e-17	Coronary artery disease;
SARC	cis	rs1062177	0.855	rs6892117	chr5:151264985	C/T	cg00977110	chr5:151150581	G3BP1	-0.51	-5.46	-0.34	1.2e-7	Preschool internalizing problems;
SARC	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg12463550	chr7:65579703	CRCP	0.66	5.08	0.32	7.79e-7	Diabetic kidney disease;
SARC	cis	rs7666738	0.830	rs7664305	chr4:99037691	G/A	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs300703	0.719	rs389621	chr2:206636	C/T	cg21211680	chr2:198530	NA	-0.46	-5.5	-0.34	9.96e-8	Blood protein levels;
SARC	cis	rs6060717	0.536	rs8125966	chr20:34511823	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	4.95	0.31	1.42e-6	Hip circumference adjusted for BMI;
SARC	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg26119090	chr2:26468346	HADHA;HADHB	0.72	8.05	0.47	4.17e-14	Gut microbiome composition (summer);
SARC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg10295955	chr4:187884368	NA	1.08	18.22	0.77	1.03e-46	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs780094	0.585	rs3739095	chr2:27556721	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.38	-5.8	-0.36	2.12e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs67366981	0.925	rs41438045	chr14:77692781	A/T	cg06779847	chr14:77687015	TMEM63C	-0.49	-5.54	-0.34	8.17e-8	Obsessive-compulsive symptoms;
SARC	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg26335602	chr6:28129616	ZNF389	0.53	5.91	0.36	1.2e-8	Parkinson's disease;
SARC	cis	rs9368481	0.645	rs10456350	chr6:26975581	A/C	cg12292205	chr6:26970375	C6orf41	0.47	5.25	0.32	3.5e-7	Autism spectrum disorder or schizophrenia;
SARC	cis	rs79149102	0.579	rs12594117	chr15:75323648	C/G	cg09165964	chr15:75287851	SCAMP5	-1.02	-8.98	-0.51	9.6e-17	Lung cancer;
SARC	cis	rs733592	0.507	rs7138917	chr12:48455255	G/A	cg24011408	chr12:48396354	COL2A1	-0.5	-6.8	-0.41	8.93e-11	Plateletcrit;
SARC	cis	rs11638352	0.661	rs2615281	chr15:44450589	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.72	5.6	0.34	5.96e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	cis	rs2760061	0.505	rs708109	chr1:228190657	C/T	cg02753203	chr1:228287806	NA	0.81	11.43	0.6	2.62e-24	Diastolic blood pressure;
SARC	cis	rs9814567	0.806	rs7626557	chr3:134318213	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.51	-6.63	-0.4	2.36e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg05351201	chr14:89029602	ZC3H14	0.48	6.62	0.4	2.46e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg21581312	chr15:35529473	LOC723972	0.54	6.79	0.41	9.27e-11	Schizophrenia;
SARC	cis	rs2576037	0.796	rs2571018	chr18:44585344	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.49	6.42	0.39	7.64e-10	Personality dimensions;
SARC	cis	rs6594499	0.872	rs1379298	chr5:110435726	T/C	cg04022379	chr5:110408740	TSLP	0.43	5.32	0.33	2.48e-7	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs7223966	1.000	rs7222060	chr17:61868279	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	7.19	0.43	8.86e-12	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2732480	0.577	rs2732457	chr12:48758379	A/G	cg24011408	chr12:48396354	COL2A1	-0.45	-5.33	-0.33	2.3e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs2213920	0.568	rs6478166	chr9:118213548	T/C	cg13918206	chr9:118159781	DEC1	0.8	6.38	0.39	9.55e-10	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs7568458	0.684	rs1048740	chr2:85764966	A/T	cg23752985	chr2:85803571	VAMP8	0.45	5.76	0.35	2.64e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg08859206	chr1:53392774	SCP2	-0.4	-5.9	-0.36	1.26e-8	Monocyte count;
SARC	cis	rs2070488	0.804	rs13085153	chr3:38461279	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	12.54	0.63	6.76e-28	Electrocardiographic conduction measures;
SARC	cis	rs2228479	0.850	rs74251570	chr16:89910068	C/A	cg06558623	chr16:89946397	TCF25	0.93	6.61	0.4	2.59e-10	Skin colour saturation;
SARC	cis	rs6580649	0.941	rs7971668	chr12:48469696	T/C	cg24011408	chr12:48396354	COL2A1	-0.48	-5.36	-0.33	2.04e-7	Lung cancer;
SARC	cis	rs9326248	0.581	rs12804122	chr11:116902616	C/G	cg01368799	chr11:117014884	PAFAH1B2	0.68	8.62	0.49	1.06e-15	Blood protein levels;
SARC	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg12311346	chr5:56204834	C5orf35	-0.58	-6.01	-0.37	7.24e-9	Initial pursuit acceleration;
SARC	cis	rs3087591	1.000	rs2905795	chr17:29547601	A/G	cg24425628	chr17:29625626	OMG;NF1	0.49	6.0	0.37	7.3e-9	Hip circumference;
SARC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg09373136	chr17:61933544	TCAM1	-0.43	-5.97	-0.36	8.62e-9	Prudent dietary pattern;
SARC	cis	rs877282	0.533	rs10904565	chr10:819991	G/T	cg15764593	chr10:829463	NA	-0.44	-4.8	-0.3	2.78e-6	Uric acid levels;
SARC	cis	rs10876993	0.890	rs1689584	chr12:58081478	G/A	cg18357645	chr12:58087776	OS9	0.52	7.11	0.42	1.38e-11	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs7566780	0.630	rs4364023	chr2:16687496	A/G	cg09580478	chr2:16689509	NA	0.51	6.37	0.38	1.02e-9	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs6500395	1.000	rs1106386	chr16:48593065	C/A	cg04672837	chr16:48644449	N4BP1	0.46	6.1	0.37	4.27e-9	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.48	0.39	5.37e-10	Bipolar disorder;
SARC	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg13385521	chr17:29058706	SUZ12P	0.72	6.23	0.38	2.12e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs7717697	0.797	rs9293339	chr5:82736335	A/T	cg19814134	chr5:82768288	VCAN	-0.42	-4.99	-0.31	1.2e-6	Vertical cup-disc ratio;
SARC	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.57	-7.3	-0.43	4.51e-12	Mean platelet volume;
SARC	cis	rs2742234	0.541	rs10899778	chr10:43718509	G/C	cg15436174	chr10:43711423	RASGEF1A	0.43	5.07	0.32	8.1e-7	Hirschsprung disease;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg11317343	chr5:177580912	NHP2	0.53	6.5	0.39	4.92e-10	Breast cancer;
SARC	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.95	-13.96	-0.67	1.32e-32	Gut microbiome composition (summer);
SARC	cis	rs13006833	0.739	rs291428	chr2:191197226	G/T	cg25963032	chr2:191064776	C2orf88	0.36	5.01	0.31	1.1e-6	Urinary metabolites;
SARC	cis	rs10992471	0.756	rs10992303	chr9:95082804	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-6.69	-0.4	1.67e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs6693567	0.586	rs4970979	chr1:150483840	C/T	cg09579323	chr1:150459698	TARS2	0.41	5.31	0.33	2.62e-7	Migraine;
SARC	cis	rs116095464	0.558	rs7356535	chr5:284117	G/T	cg22857025	chr5:266934	NA	-1.1	-10.35	-0.56	6.84e-21	Breast cancer;
SARC	cis	rs7246657	0.943	rs7252099	chr19:37933780	G/A	cg23950597	chr19:37808831	NA	-0.63	-6.03	-0.37	6.33e-9	Coronary artery calcification;
SARC	cis	rs35110281	0.501	rs162378	chr21:44925905	A/G	cg21573476	chr21:45109991	RRP1B	0.39	5.53	0.34	8.77e-8	Mean corpuscular volume;
SARC	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg26335602	chr6:28129616	ZNF389	0.53	5.88	0.36	1.43e-8	Depression;
SARC	cis	rs2290402	0.536	rs56080039	chr4:886519	G/A	cg00846425	chr4:957561	DGKQ	-0.44	-4.99	-0.31	1.21e-6	Type 2 diabetes;
SARC	cis	rs7779181	0.516	rs75320928	chr7:32352560	T/A	cg16719466	chr7:32338569	NA	-0.65	-5.24	-0.32	3.61e-7	Body mass index;
SARC	cis	rs1865760	0.566	rs2032449	chr6:26026599	G/C	cg18357526	chr6:26021779	HIST1H4A	0.44	5.43	0.33	1.43e-7	Height;
SARC	cis	rs10791323	0.569	rs10750541	chr11:133713189	A/C	cg13461336	chr11:133711254	SPATA19	0.28	4.73	0.3	3.89e-6	Childhood ear infection;
SARC	cis	rs7811142	1.000	rs6953107	chr7:100095664	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	10.78	0.58	3.06e-22	Platelet count;
SARC	cis	rs17270561	0.666	rs12209856	chr6:25793673	G/A	cg16482183	chr6:26056742	HIST1H1C	0.45	5.59	0.34	6.45e-8	Iron status biomarkers;
SARC	cis	rs9303401	0.614	rs12950028	chr17:56510140	A/G	cg25039879	chr17:56429692	SUPT4H1	0.6	5.41	0.33	1.56e-7	Cognitive test performance;
SARC	cis	rs3008870	0.629	rs12742428	chr1:67426487	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.59	7.5	0.44	1.36e-12	Lymphocyte percentage of white cells;
SARC	cis	rs12701220	0.503	rs2949177	chr7:1211518	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.39	-5.0	-0.31	1.13e-6	Bronchopulmonary dysplasia;
SARC	cis	rs6831352	0.879	rs1230154	chr4:99988659	C/T	cg13256891	chr4:100009986	ADH5	0.65	8.55	0.49	1.68e-15	Alcohol dependence;
SARC	cis	rs4253772	0.591	rs6008538	chr22:46685963	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.72	7.48	0.44	1.46e-12	LDL cholesterol;Cholesterol, total;
SARC	cis	rs6963495	0.538	rs55967123	chr7:105163678	C/A	cg13798780	chr7:105162888	PUS7	0.6	5.45	0.34	1.31e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs1580019	0.523	rs13236410	chr7:32690663	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.51	6.45	0.39	6.41e-10	Cognitive ability;
SARC	cis	rs11786130	1.000	rs10808565	chr8:129007412	C/T	cg01765152	chr8:129005526	PVT1	-0.5	-8.37	-0.48	5.45e-15	Eosinophil counts;Sum eosinophil basophil counts;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg06464452	chr4:77227879	STBD1	-0.91	-8.01	-0.46	5.44e-14	Autism spectrum disorder or schizophrenia;
SARC	trans	rs1814175	0.817	rs11493756	chr11:50017885	T/C	cg03929089	chr4:120376271	NA	-0.9	-14.89	-0.7	1.14e-35	Height;
SARC	cis	rs4689388	0.853	rs11729672	chr4:6293838	A/G	cg25554036	chr4:6271136	WFS1	0.39	6.42	0.39	7.48e-10	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg18876405	chr7:65276391	NA	-0.46	-5.44	-0.34	1.34e-7	Aortic root size;
SARC	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg03354898	chr7:1950403	MAD1L1	-0.36	-4.84	-0.3	2.39e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg04317338	chr11:64019027	PLCB3	0.84	8.98	0.51	9.05e-17	Mean platelet volume;
SARC	cis	rs3008870	0.709	rs62883160	chr1:67392889	G/A	cg02640540	chr1:67518911	SLC35D1	0.45	5.09	0.32	7.23e-7	Lymphocyte percentage of white cells;
SARC	cis	rs7264396	0.563	rs2425071	chr20:34292961	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	-0.63	-5.76	-0.35	2.62e-8	Total cholesterol levels;
SARC	cis	rs7465272	1.000	rs13259747	chr8:143683567	A/C	cg10596483	chr8:143751796	JRK	0.58	6.3	0.38	1.48e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg03433033	chr1:76189801	ACADM	-0.52	-7.36	-0.43	3.14e-12	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg11764359	chr7:65958608	NA	0.88	12.58	0.64	4.89e-28	Aortic root size;
SARC	cis	rs7666738	0.888	rs13110683	chr4:98983368	G/C	cg05340658	chr4:99064831	C4orf37	0.57	7.15	0.42	1.12e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2180341	1.000	rs6569477	chr6:127589302	T/A	cg24812749	chr6:127587940	RNF146	0.95	12.41	0.63	1.74e-27	Breast cancer;
SARC	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg13395646	chr4:1353034	KIAA1530	-0.56	-6.75	-0.4	1.18e-10	Obesity-related traits;
SARC	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg04546413	chr19:29218101	NA	0.63	8.52	0.49	2.01e-15	Methadone dose in opioid dependence;
SARC	cis	rs2635047	0.806	rs9962602	chr18:44599057	G/A	cg19077165	chr18:44547161	KATNAL2	-0.41	-5.45	-0.34	1.27e-7	Educational attainment;
SARC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg09033563	chr22:24373618	LOC391322	-0.45	-5.04	-0.31	9.45e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1707322	0.691	rs61784803	chr1:46179271	C/A	cg06784218	chr1:46089804	CCDC17	-0.36	-6.17	-0.37	2.95e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg02406285	chr3:67048577	KBTBD8	0.5	6.27	0.38	1.73e-9	Breast cancer;
SARC	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg19077165	chr18:44547161	KATNAL2	-0.56	-7.93	-0.46	9.28e-14	Personality dimensions;
SARC	cis	rs9381040	0.655	rs7738684	chr6:41038552	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.48	-5.51	-0.34	9.45e-8	Alzheimer's disease (late onset);
SARC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg05863683	chr7:1912471	MAD1L1	0.34	5.05	0.31	8.82e-7	Bipolar disorder and schizophrenia;
SARC	trans	rs11098499	0.863	rs7664986	chr4:120429952	A/C	cg25214090	chr10:38739885	LOC399744	0.58	7.28	0.43	4.95e-12	Corneal astigmatism;
SARC	cis	rs1448094	0.967	rs10863109	chr12:86328415	A/G	cg02569458	chr12:86230093	RASSF9	0.4	5.8	0.36	2.17e-8	Major depressive disorder;
SARC	cis	rs2153535	0.601	rs1928183	chr6:8530018	A/G	cg07606381	chr6:8435919	SLC35B3	0.76	10.99	0.58	6.38e-23	Motion sickness;
SARC	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg18252515	chr7:66147081	NA	1.35	11.94	0.62	5.84e-26	Diabetic kidney disease;
SARC	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg22535103	chr8:58192502	C8orf71	-0.73	-7.24	-0.43	6.52e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs7296418	0.885	rs1790104	chr12:123709409	C/T	cg05973401	chr12:123451056	ABCB9	0.56	6.55	0.39	3.63e-10	Platelet count;
SARC	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg00684032	chr4:1343700	KIAA1530	0.46	6.49	0.39	5.19e-10	Obesity-related traits;
SARC	cis	rs4906332	1.000	rs12889703	chr14:103872951	T/A	cg26031613	chr14:104095156	KLC1	-0.53	-6.17	-0.37	3.07e-9	Coronary artery disease;
SARC	cis	rs76419734	1.000	rs72671836	chr4:106633045	T/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.84	5.56	0.34	7.44e-8	Post bronchodilator FEV1;
SARC	cis	rs2153904	0.793	rs12132270	chr1:205660940	C/T	cg14159672	chr1:205819179	PM20D1	-0.53	-4.72	-0.3	3.99e-6	Prostate-specific antigen levels;
SARC	cis	rs793571	0.502	rs387812	chr15:59074786	T/C	cg05156742	chr15:59063176	FAM63B	0.83	13.3	0.66	2.05e-30	Schizophrenia;
SARC	cis	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg08975724	chr8:8085496	FLJ10661	0.59	7.62	0.45	6.25e-13	Joint mobility (Beighton score);
SARC	cis	rs2576037	0.899	rs2060417	chr18:44576486	C/A	cg19077165	chr18:44547161	KATNAL2	0.49	6.75	0.4	1.17e-10	Personality dimensions;
SARC	cis	rs9372253	1.000	rs9384740	chr6:110716207	G/A	cg19196401	chr6:110721138	DDO	-0.41	-5.38	-0.33	1.78e-7	Platelet distribution width;
SARC	cis	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg18252515	chr7:66147081	NA	-1.22	-10.67	-0.57	6.88e-22	Diabetic kidney disease;
SARC	cis	rs7223966	1.000	rs3817181	chr17:61776538	G/C	cg00588841	chr17:61851480	DDX42;CCDC47	-0.65	-7.09	-0.42	1.62e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1949733	0.628	rs1543246	chr4:8504909	A/T	cg13073564	chr4:8508604	NA	-0.44	-7.36	-0.43	3.23e-12	Response to antineoplastic agents;
SARC	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg22903471	chr2:27725779	GCKR	-0.49	-7.42	-0.44	2.21e-12	Total body bone mineral density;
SARC	cis	rs9733	0.744	rs2039590	chr1:150813315	G/A	cg13175981	chr1:150552382	MCL1	0.61	8.31	0.48	7.74e-15	Tonsillectomy;
SARC	cis	rs2075371	0.501	rs1643057	chr7:134027521	A/G	cg00033643	chr7:134001901	SLC35B4	0.47	5.89	0.36	1.37e-8	Mean platelet volume;
SARC	cis	rs8180040	0.629	rs7426969	chr3:47091355	T/C	cg27129171	chr3:47204927	SETD2	0.69	9.48	0.53	3.01e-18	Colorectal cancer;
SARC	cis	rs1008375	0.866	rs2109518	chr4:17572162	G/A	cg02297831	chr4:17616191	MED28	0.46	5.72	0.35	3.33e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg05863683	chr7:1912471	MAD1L1	-0.36	-5.62	-0.35	5.37e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs7412746	0.611	rs2228099	chr1:150808889	C/G	cg13175981	chr1:150552382	MCL1	-0.47	-5.86	-0.36	1.57e-8	Melanoma;
SARC	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg19680485	chr15:31195859	MTMR15	-0.58	-6.95	-0.41	3.68e-11	Huntington's disease progression;
SARC	cis	rs8072100	0.807	rs2175290	chr17:45479917	C/A	cg08085267	chr17:45401833	C17orf57	-0.42	-5.02	-0.31	1.05e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs3784262	0.669	rs2414527	chr15:58256672	A/G	cg12031962	chr15:58353849	ALDH1A2	0.34	4.98	0.31	1.23e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs6772849	0.930	rs9868579	chr3:128351054	C/T	cg08795948	chr3:128337044	NA	-0.55	-7.79	-0.45	2.19e-13	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs975210	0.652	rs4777230	chr15:70365762	A/G	cg01666796	chr15:70364327	TLE3	-0.53	-4.77	-0.3	3.24e-6	Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
SARC	cis	rs77372450	0.636	rs10476093	chr5:157007001	C/A	cg23851860	chr5:157002805	ADAM19	0.51	4.91	0.31	1.72e-6	Bipolar disorder (body mass index interaction);
SARC	cis	rs793571	0.544	rs12912699	chr15:58917021	T/C	cg05156742	chr15:59063176	FAM63B	0.74	10.21	0.56	1.83e-20	Schizophrenia;
SARC	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg05368731	chr17:41323189	NBR1	0.79	9.83	0.54	2.62e-19	Menopause (age at onset);
SARC	cis	rs7681440	0.967	rs6532191	chr4:90745930	C/T	cg06632027	chr4:90757378	SNCA	0.42	6.04	0.37	6.03e-9	Dementia with Lewy bodies;
SARC	cis	rs12893668	0.572	rs4900590	chr14:104146421	C/T	cg26031613	chr14:104095156	KLC1	-0.54	-5.93	-0.36	1.06e-8	Reticulocyte count;
SARC	cis	rs7223966	1.000	rs6504167	chr17:61693194	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.45	4.84	0.3	2.36e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9790314	1.000	rs336548	chr3:161058412	T/C	cg03342759	chr3:160939853	NMD3	-0.58	-7.38	-0.44	2.76e-12	Morning vs. evening chronotype;
SARC	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg05025164	chr4:1340916	KIAA1530	-0.67	-7.89	-0.46	1.2e-13	Obesity-related traits;
SARC	cis	rs10905065	0.717	rs11254266	chr10:5750078	G/T	cg09072322	chr10:5726702	C10orf18	-0.39	-4.84	-0.3	2.33e-6	Menopause (age at onset);
SARC	cis	rs10949834	0.504	rs150862	chr7:73524207	C/T	cg07137043	chr7:73588983	EIF4H	0.55	4.98	0.31	1.22e-6	Verbal memory performance (residualized delayed recall change);
SARC	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2197308	0.655	rs1971964	chr12:37870474	C/T	cg26384229	chr12:38710491	ALG10B	0.91	13.4	0.66	9.65e-31	Morning vs. evening chronotype;
SARC	cis	rs2327429	0.858	rs34523729	chr6:134184826	C/A	cg25632230	chr6:134101081	NA	-0.47	-5.7	-0.35	3.59e-8	Coronary artery disease;
SARC	cis	rs4642101	0.765	rs6791647	chr3:12826425	C/T	cg05775895	chr3:12838266	CAND2	-0.74	-11.86	-0.61	1.04e-25	QRS complex (12-leadsum);
SARC	cis	rs2963155	0.518	rs72801054	chr5:142687742	T/C	cg17617527	chr5:142782415	NR3C1	0.81	5.64	0.35	4.92e-8	Breast cancer;
SARC	cis	rs2235642	0.928	rs1057610	chr16:1605537	T/C	cg09065629	chr16:1709722	CRAMP1L	0.36	5.01	0.31	1.05e-6	Coronary artery disease;
SARC	cis	rs4481887	0.927	rs4564179	chr1:248472422	T/C	cg00666640	chr1:248458726	OR2T12	0.34	5.7	0.35	3.65e-8	Common traits (Other);
SARC	cis	rs16976116	0.803	rs28530662	chr15:55498836	A/G	cg17854078	chr15:55489399	RSL24D1	0.64	6.28	0.38	1.62e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6121246	0.909	rs6058463	chr20:30385192	C/T	cg13852791	chr20:30311386	BCL2L1	0.85	8.88	0.5	1.83e-16	Mean corpuscular hemoglobin;
SARC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	10.24	0.56	1.52e-20	Platelet count;
SARC	cis	rs2050392	0.517	rs593400	chr10:30762088	A/G	cg25182066	chr10:30743637	MAP3K8	-0.44	-6.46	-0.39	6.04e-10	Inflammatory bowel disease;
SARC	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg19077165	chr18:44547161	KATNAL2	0.48	6.57	0.4	3.27e-10	Personality dimensions;
SARC	cis	rs1580019	0.587	rs2392069	chr7:32547154	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.53	6.84	0.41	7.05e-11	Cognitive ability;
SARC	cis	rs9467773	0.620	rs6925087	chr6:26592853	T/A	cg11502198	chr6:26597334	ABT1	0.66	8.87	0.5	1.97e-16	Intelligence (multi-trait analysis);
SARC	cis	rs4761669	0.958	rs10745694	chr12:95181478	T/C	cg21533806	chr12:95267307	NA	0.38	4.8	0.3	2.82e-6	Common carotid intima-media thickness in HIV infection;
SARC	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg16479474	chr6:28041457	NA	0.34	5.01	0.31	1.05e-6	Parkinson's disease;
SARC	trans	rs1994135	0.586	rs7308214	chr12:33713834	T/A	cg26384229	chr12:38710491	ALG10B	0.81	10.08	0.55	4.74e-20	Resting heart rate;
SARC	cis	rs11785400	0.793	rs4581034	chr8:143736968	G/A	cg24634471	chr8:143751801	JRK	0.59	7.62	0.45	6.34e-13	Schizophrenia;
SARC	cis	rs4319547	0.585	rs10846792	chr12:122882374	T/C	cg23029597	chr12:123009494	RSRC2	-0.41	-5.0	-0.31	1.12e-6	Body mass index;
SARC	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.68	6.64	0.4	2.16e-10	Platelet count;
SARC	cis	rs362296	0.698	rs3135172	chr4:3258735	A/G	cg06533319	chr4:3265114	C4orf44	0.31	4.76	0.3	3.37e-6	Parental longevity (mother's age at death);
SARC	cis	rs62408225	0.722	rs17712288	chr6:90909157	G/A	cg06866423	chr6:90926672	BACH2	0.32	4.94	0.31	1.48e-6	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs9325144	0.560	rs6582561	chr12:38666821	G/A	cg26384229	chr12:38710491	ALG10B	-0.63	-8.12	-0.47	2.64e-14	Morning vs. evening chronotype;
SARC	cis	rs7644634	0.531	rs13317635	chr3:105393335	C/G	cg23051926	chr3:105466016	CBLB	-0.45	-5.24	-0.32	3.63e-7	Itch intensity from mosquito bite;
SARC	cis	rs7843479	1.000	rs2054711	chr8:21818060	A/G	cg17168535	chr8:21777572	XPO7	0.62	8.02	0.46	5.22e-14	Mean corpuscular volume;
SARC	cis	rs9300255	0.739	rs1533703	chr12:123742093	T/G	cg05973401	chr12:123451056	ABCB9	0.44	4.86	0.3	2.19e-6	Neutrophil percentage of white cells;
SARC	cis	rs765787	0.530	rs11636410	chr15:45535913	A/C	cg25801113	chr15:45476975	SHF	-0.29	-4.79	-0.3	3e-6	Uric acid levels;
SARC	cis	rs147499554	1	rs147499554	chr15:78900650	C/T	cg06917634	chr15:78832804	PSMA4	-0.55	-5.87	-0.36	1.47e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg04317338	chr11:64019027	PLCB3	0.81	8.38	0.48	4.99e-15	Mean platelet volume;
SARC	cis	rs10463316	1.000	rs10463316	chr5:150746034	A/G	cg03212797	chr5:150827313	SLC36A1	-0.44	-5.23	-0.32	3.86e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg02725872	chr8:58115012	NA	-0.36	-5.52	-0.34	9.23e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs1945213	0.694	rs7116741	chr11:55862620	C/T	cg15704280	chr7:45808275	SEPT13	0.66	6.87	0.41	5.7e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs554111	0.593	rs4654906	chr1:21509642	A/T	cg08890418	chr1:21044141	KIF17	0.36	5.01	0.31	1.09e-6	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs7223966	0.883	rs2727317	chr17:61961302	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.46	4.97	0.31	1.32e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7937682	0.889	rs1940529	chr11:111498523	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.92	-14.73	-0.69	3.72e-35	Primary sclerosing cholangitis;
SARC	cis	rs9300255	0.510	rs1790109	chr12:123637752	C/G	cg00376283	chr12:123451042	ABCB9	0.58	6.88	0.41	5.39e-11	Neutrophil percentage of white cells;
SARC	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg11494091	chr17:61959527	GH2	-0.38	-5.21	-0.32	4.23e-7	Height;
SARC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg11494091	chr17:61959527	GH2	0.53	7.94	0.46	8.67e-14	Prudent dietary pattern;
SARC	cis	rs7617480	0.648	rs4858830	chr3:48734002	T/C	cg06212747	chr3:49208901	KLHDC8B	0.5	4.85	0.3	2.23e-6	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs6120849	0.708	rs6087659	chr20:33606383	C/A	cg24642439	chr20:33292090	TP53INP2	0.56	5.29	0.33	2.76e-7	Protein C levels;
SARC	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg19680485	chr15:31195859	MTMR15	0.52	6.11	0.37	4.22e-9	Huntington's disease progression;
SARC	cis	rs4588572	0.688	rs2362829	chr5:77724036	T/A	cg18281939	chr5:77783895	LHFPL2	0.34	4.74	0.3	3.78e-6	Triglycerides;
SARC	cis	rs7084402	0.935	rs10763559	chr10:60347410	C/T	cg07615347	chr10:60278583	BICC1	0.59	8.54	0.49	1.7e-15	Refractive error;
SARC	cis	rs503734	0.502	rs348876	chr3:100930989	A/G	cg27318481	chr3:100970896	IMPG2	-0.47	-5.66	-0.35	4.45e-8	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg18364779	chr6:26104403	HIST1H4C	0.44	5.21	0.32	4.07e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7103648	0.695	rs7933019	chr11:47509137	G/C	cg20307385	chr11:47447363	PSMC3	0.78	11.2	0.59	1.37e-23	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.47	5.29	0.33	2.75e-7	Renal function-related traits (BUN);
SARC	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg14664628	chr15:75095509	CSK	-0.47	-5.85	-0.36	1.63e-8	Breast cancer;
SARC	cis	rs9399135	0.967	rs12661423	chr6:135349570	C/T	cg24558204	chr6:135376177	HBS1L	0.45	6.03	0.37	6.22e-9	Red blood cell count;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg20800199	chr13:61068635	TDRD3	0.52	7.32	0.43	4.05e-12	Thyroid stimulating hormone;
SARC	cis	rs1008375	0.933	rs7689101	chr4:17694034	G/A	cg16339924	chr4:17578868	LAP3	0.56	7.0	0.42	2.67e-11	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7592578	0.882	rs2192010	chr2:191462133	C/T	cg10560079	chr2:191398806	TMEM194B	-0.79	-8.94	-0.51	1.22e-16	Diastolic blood pressure;
SARC	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg08219700	chr8:58056026	NA	0.49	4.96	0.31	1.36e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs4975616	0.869	rs455433	chr5:1336243	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.56	-7.74	-0.45	3.07e-13	Lung cancer;
SARC	cis	rs2832077	0.527	rs2776210	chr21:30268558	A/G	cg08807101	chr21:30365312	RNF160	0.6	6.82	0.41	7.95e-11	Cognitive test performance;
SARC	cis	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg03213289	chr20:61660250	NA	0.46	6.43	0.39	7.22e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs8064299	0.584	rs2384957	chr17:72784630	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.81	11.29	0.59	7.04e-24	Monocyte count;
SARC	cis	rs1200821	0.535	rs1208784	chr10:37768433	A/G	cg25427524	chr10:38739819	LOC399744	-0.44	-6.51	-0.39	4.56e-10	Hemostatic factors and hematological phenotypes;
SARC	cis	rs10089	1.000	rs1842006	chr5:127508687	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	9.01	0.51	7.68e-17	Ileal carcinoids;
SARC	cis	rs921968	0.608	rs7598056	chr2:219352511	A/C	cg02176678	chr2:219576539	TTLL4	0.36	5.53	0.34	8.72e-8	Mean corpuscular hemoglobin concentration;
SARC	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.41	-6.22	-0.38	2.33e-9	Total body bone mineral density;
SARC	cis	rs7089973	0.624	rs1359080	chr10:116582419	C/A	cg03647239	chr10:116582469	FAM160B1	0.49	6.24	0.38	2.01e-9	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs7000551	0.715	rs1600877	chr8:22378118	C/T	cg12081754	chr8:22256438	SLC39A14	0.57	7.98	0.46	6.78e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg12463550	chr7:65579703	CRCP	-0.5	-5.51	-0.34	9.48e-8	Aortic root size;
SARC	cis	rs2857078	0.745	rs4793085	chr17:42320732	A/C	cg19774624	chr17:42201019	HDAC5	0.44	5.84	0.36	1.71e-8	Red cell distribution width;Reticulocyte count;
SARC	cis	rs754466	0.580	rs2289308	chr10:79579251	G/A	cg17075019	chr10:79541650	NA	-0.81	-12.26	-0.63	5.45e-27	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.39	6.42	0.39	7.36e-10	Schizophrenia;
SARC	cis	rs6693567	0.565	rs12093148	chr1:150265173	G/A	cg09579323	chr1:150459698	TARS2	-0.42	-5.2	-0.32	4.28e-7	Migraine;
SARC	cis	rs2120019	0.935	rs34913788	chr15:75372617	A/C	cg17294928	chr15:75287854	SCAMP5	-0.9	-13.28	-0.66	2.39e-30	Blood trace element (Zn levels);
SARC	cis	rs10791323	0.569	rs2156679	chr11:133742304	C/T	cg15485101	chr11:133734466	NA	0.32	5.14	0.32	5.92e-7	Childhood ear infection;
SARC	cis	rs992157	0.710	rs10167446	chr2:219056866	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.63	8.74	0.5	4.56e-16	Colorectal cancer;
SARC	cis	rs6540556	0.521	rs1337531	chr1:209911988	T/G	cg23920097	chr1:209922102	NA	-0.51	-5.76	-0.35	2.61e-8	Red blood cell count;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg09444120	chr8:107227878	NA	-0.51	-6.39	-0.39	8.69e-10	Height;
SARC	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.97e-8	Aortic root size;
SARC	cis	rs11112613	0.609	rs11112585	chr12:105933442	A/G	cg03607813	chr12:105948248	NA	-0.45	-5.41	-0.33	1.57e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg09060608	chr5:178986726	RUFY1	0.35	5.2	0.32	4.27e-7	Lung cancer;
SARC	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg25072359	chr17:41440525	NA	0.5	5.76	0.35	2.67e-8	Menopause (age at onset);
SARC	cis	rs36051895	0.626	rs12349785	chr9:5076613	G/C	cg02405213	chr9:5042618	JAK2	-0.45	-5.13	-0.32	6.19e-7	Pediatric autoimmune diseases;
SARC	cis	rs9467773	0.620	rs2504566	chr6:26660488	G/C	cg11502198	chr6:26597334	ABT1	0.63	8.48	0.49	2.58e-15	Intelligence (multi-trait analysis);
SARC	cis	rs76419734	0.558	rs4326019	chr4:106527381	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.67	6.17	0.37	2.98e-9	Post bronchodilator FEV1;
SARC	cis	rs2073300	0.609	rs6137931	chr20:23376875	G/C	cg12062639	chr20:23401060	NAPB	0.95	6.5	0.39	4.74e-10	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-8.85	-0.5	2.28e-16	Alzheimer's disease;
SARC	cis	rs2153535	0.580	rs986060	chr6:8465428	T/C	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	cis	rs4689388	0.926	rs10937718	chr4:6295217	T/C	cg25554036	chr4:6271136	WFS1	0.39	6.42	0.39	7.48e-10	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs57083693	0.518	rs6538980	chr12:101692966	A/G	cg22051763	chr12:101673672	UTP20	-0.45	-5.49	-0.34	1.05e-7	Alcohol dependence (age at onset);
SARC	cis	rs9818758	0.607	rs13087930	chr3:48961726	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.64	-5.46	-0.34	1.22e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs918629	0.530	rs11744881	chr5:95240865	A/T	cg16656078	chr5:95278638	ELL2	0.57	7.2	0.43	8.08e-12	IgG glycosylation;
SARC	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg05368731	chr17:41323189	NBR1	0.79	9.83	0.54	2.62e-19	Menopause (age at onset);
SARC	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg04317338	chr11:64019027	PLCB3	0.6	7.04	0.42	2.16e-11	Platelet count;
SARC	trans	rs7824557	0.767	rs1897951	chr8:11169854	C/T	cg06636001	chr8:8085503	FLJ10661	0.57	6.95	0.41	3.58e-11	Retinal vascular caliber;
SARC	cis	rs9296092	0.538	rs62407566	chr6:33535786	C/T	cg13560919	chr6:33536144	NA	-0.58	-6.64	-0.4	2.18e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs453301	0.631	rs13250781	chr8:8793343	T/G	cg15556689	chr8:8085844	FLJ10661	-0.41	-5.0	-0.31	1.1e-6	Joint mobility (Beighton score);
SARC	cis	rs9914988	0.943	rs66588554	chr17:27141110	A/G	cg20469991	chr17:27169893	C17orf63	-0.51	-5.35	-0.33	2.14e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs920590	0.796	rs10788700	chr8:19635098	T/C	cg03894339	chr8:19674705	INTS10	0.55	6.68	0.4	1.74e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg19723775	chr5:179050963	HNRNPH1	0.41	5.21	0.32	4.21e-7	Lung cancer;
SARC	cis	rs3733585	0.624	rs76574510	chr4:9953252	T/A	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.39	-0.33	1.76e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg11494091	chr17:61959527	GH2	0.53	7.84	0.46	1.59e-13	Prudent dietary pattern;
SARC	cis	rs2732480	0.577	rs2634680	chr12:48734564	T/C	cg21466736	chr12:48725269	NA	-0.33	-5.12	-0.32	6.25e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg18252515	chr7:66147081	NA	1.14	10.38	0.56	5.43e-21	Diabetic kidney disease;
SARC	cis	rs9902453	0.935	rs9898424	chr17:28392946	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.54	-6.99	-0.42	2.8e-11	Coffee consumption (cups per day);
SARC	cis	rs62244186	0.632	rs1402751	chr3:44594030	C/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.43	5.45	0.34	1.26e-7	Depressive symptoms;
SARC	cis	rs4727027	0.899	rs11768971	chr7:148825826	C/G	cg23583168	chr7:148888333	NA	-0.74	-11.16	-0.59	1.9e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg20102877	chr2:27665638	KRTCAP3	-0.37	-5.17	-0.32	5.05e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg12564285	chr5:131593104	PDLIM4	0.36	5.38	0.33	1.81e-7	Breast cancer;
SARC	cis	rs1691799	0.867	rs1027400	chr12:66760922	A/T	cg16791601	chr12:66731901	HELB	-0.71	-10.69	-0.57	5.72e-22	White blood cell count (basophil);
SARC	cis	rs7772486	0.597	rs1970306	chr6:146154543	A/G	cg23711669	chr6:146136114	FBXO30	0.83	12.2	0.62	8.2e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs5753618	0.583	rs2899164	chr22:31790289	G/A	cg13145458	chr22:31556086	RNF185	-0.46	-4.83	-0.3	2.43e-6	Colorectal cancer;
SARC	cis	rs3771570	0.901	rs4675969	chr2:242217627	C/T	cg21155796	chr2:242212141	HDLBP	0.6	5.65	0.35	4.62e-8	Prostate cancer;
SARC	cis	rs6835098	0.887	rs12644699	chr4:174142874	A/G	cg08422745	chr4:174089978	GALNT7	0.69	8.81	0.5	2.97e-16	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs2760061	0.819	rs708115	chr1:228198046	C/T	cg02753203	chr1:228287806	NA	0.58	7.99	0.46	6.05e-14	Diastolic blood pressure;
SARC	cis	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg03213289	chr20:61660250	NA	0.45	6.08	0.37	4.87e-9	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs6570726	0.875	rs12524077	chr6:145866333	G/C	cg05347473	chr6:146136440	FBXO30	0.49	6.58	0.4	3.04e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs734999	0.545	rs12749591	chr1:2563250	G/T	cg20673091	chr1:2541236	MMEL1	-0.32	-5.0	-0.31	1.15e-6	Ulcerative colitis;
SARC	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.63	6.84	0.41	6.82e-11	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs8141529	0.509	rs12628211	chr22:29239250	T/C	cg02153584	chr22:29168773	CCDC117	0.67	8.95	0.51	1.15e-16	Lymphocyte counts;
SARC	cis	rs12145833	0.596	rs61833913	chr1:243440028	C/G	cg02356786	chr1:243265016	LOC731275	0.77	6.3	0.38	1.43e-9	Obesity (early onset extreme);
SARC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg06873352	chr17:61820015	STRADA	0.53	6.92	0.41	4.33e-11	Prudent dietary pattern;
SARC	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg04166393	chr7:2884313	GNA12	0.57	6.81	0.41	8.37e-11	Height;
SARC	cis	rs2933343	1.000	rs789227	chr3:128600585	C/G	cg25356066	chr3:128598488	ACAD9	0.6	6.91	0.41	4.64e-11	IgG glycosylation;
SARC	cis	rs7587476	0.689	rs10498025	chr2:215749256	A/G	cg04530015	chr2:215796436	ABCA12	-0.39	-6.29	-0.38	1.54e-9	Neuroblastoma;
SARC	cis	rs7940866	0.845	rs2324314	chr11:130834589	A/C	cg12179176	chr11:130786555	SNX19	0.67	9.35	0.52	7.47e-18	Schizophrenia;
SARC	cis	rs6723226	0.806	rs6543658	chr2:32718849	G/A	cg02381751	chr2:32503542	YIPF4	0.76	10.9	0.58	1.22e-22	Intelligence (multi-trait analysis);
SARC	cis	rs7208859	0.673	rs56846352	chr17:29119188	C/T	cg13385521	chr17:29058706	SUZ12P	0.83	7.55	0.44	9.72e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs3008870	0.755	rs2815374	chr1:67507387	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.61	7.76	0.45	2.66e-13	Lymphocyte percentage of white cells;
SARC	cis	rs453301	0.686	rs7017868	chr8:8873293	G/A	cg08975724	chr8:8085496	FLJ10661	-0.45	-5.63	-0.35	5.14e-8	Joint mobility (Beighton score);
SARC	cis	rs854765	0.575	rs2955357	chr17:17946401	T/C	cg04398451	chr17:18023971	MYO15A	0.45	6.46	0.39	6.13e-10	Total body bone mineral density;
SARC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg23034840	chr1:205782522	SLC41A1	0.64	8.22	0.47	1.38e-14	Menarche (age at onset);
SARC	cis	rs2439831	0.850	rs12101756	chr15:44053887	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	7.55	0.44	1.01e-12	Lung cancer in ever smokers;
SARC	cis	rs2710642	0.566	rs2710651	chr2:63166379	G/A	cg17519650	chr2:63277830	OTX1	0.46	6.2	0.38	2.57e-9	LDL cholesterol levels;LDL cholesterol;
SARC	cis	rs10189230	0.935	rs3755029	chr2:222345820	T/C	cg14652038	chr2:222343519	EPHA4	0.45	5.84	0.36	1.77e-8	Urate levels in lean individuals;
SARC	cis	rs72945132	0.882	rs67244582	chr11:70122009	G/A	cg00319359	chr11:70116639	PPFIA1	0.68	6.37	0.39	1.01e-9	Coronary artery disease;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg24847481	chr1:100435557	SLC35A3	0.51	6.25	0.38	1.98e-9	Height;
SARC	cis	rs76917914	1.000	rs7850685	chr9:100763890	C/G	cg03040243	chr9:100819229	NANS	-0.56	-5.77	-0.35	2.47e-8	Immature fraction of reticulocytes;
SARC	cis	rs72945132	0.882	rs7128969	chr11:70205017	C/A	cg05964544	chr11:70165517	PPFIA1	-0.56	-5.37	-0.33	1.93e-7	Coronary artery disease;
SARC	cis	rs55794721	0.543	rs1293260	chr1:25709104	C/G	cg27572855	chr1:25598939	RHD	0.56	9.55	0.53	1.94e-18	Plateletcrit;Mean corpuscular volume;
SARC	cis	rs7513165	0.551	rs12750834	chr1:204140784	G/A	cg23788856	chr1:204159729	KISS1	-0.43	-5.4	-0.33	1.61e-7	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
SARC	cis	rs1003719	0.680	rs2835668	chr21:38580151	C/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.17	-0.52	2.52e-17	Eye color traits;
SARC	cis	rs240764	0.725	rs11155477	chr6:100935505	T/A	cg09795085	chr6:101329169	ASCC3	-0.41	-5.19	-0.32	4.68e-7	Neuroticism;
SARC	cis	rs7084402	0.935	rs10763556	chr10:60341398	A/G	cg07615347	chr10:60278583	BICC1	-0.58	-8.55	-0.49	1.7e-15	Refractive error;
SARC	cis	rs7607369	0.759	rs10179708	chr2:219390967	T/A	cg02176678	chr2:219576539	TTLL4	-0.49	-7.62	-0.45	6.32e-13	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs12791968	1.000	rs1552300	chr11:45002594	G/A	cg11846598	chr11:44996168	LOC221122	-0.36	-5.52	-0.34	9.04e-8	Inhibitory control;
SARC	cis	rs554111	0.686	rs519209	chr1:21043790	C/T	cg08890418	chr1:21044141	KIF17	-0.42	-5.77	-0.35	2.5e-8	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs4243830	0.850	rs57203351	chr1:6601319	T/C	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.57	-5.02	-0.31	1.05e-6	Body mass index;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg03831465	chr11:34378797	ABTB2	0.47	6.41	0.39	7.86e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs5167	0.504	rs7257476	chr19:45453165	C/T	cg10169327	chr19:45448959	APOC2	0.31	5.11	0.32	6.65e-7	Blood protein levels;
SARC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg04013093	chr6:42928303	GNMT	0.32	4.72	0.3	3.99e-6	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs12477438	0.765	rs13406288	chr2:99589585	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-8.07	-0.47	3.62e-14	Chronic sinus infection;
SARC	trans	rs11039798	0.557	rs4436575	chr11:48398894	T/C	cg15704280	chr7:45808275	SEPT13	-0.63	-6.39	-0.39	8.74e-10	Axial length;
SARC	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg27170947	chr2:26402098	FAM59B	0.4	5.03	0.31	9.91e-7	Mean corpuscular hemoglobin;
SARC	cis	rs10791323	0.660	rs2156681	chr11:133731644	G/T	cg15485101	chr11:133734466	NA	0.3	4.97	0.31	1.32e-6	Childhood ear infection;
SARC	cis	rs3858526	0.916	rs11039551	chr11:5930773	C/T	cg13902645	chr11:5959945	NA	-0.45	-5.23	-0.32	3.7e-7	DNA methylation (variation);
SARC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.97	10.66	0.57	7.33e-22	Platelet count;
SARC	cis	rs1865063	1.000	rs56322906	chr19:11346155	G/A	cg00586551	chr19:11347513	LOC55908;DOCK6	0.84	7.42	0.44	2.24e-12	HDL cholesterol levels;
SARC	cis	rs4150161	0.591	rs1056616	chr16:84211718	C/T	cg10106505	chr16:84220380	TAF1C	-0.62	-5.44	-0.34	1.35e-7	Systolic blood pressure response to hydrochlorothiazide in hypertension;
SARC	cis	rs7647973	0.626	rs6809879	chr3:49834571	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.59	-5.63	-0.35	5.07e-8	Menarche (age at onset);
SARC	cis	rs2033732	0.954	rs10808859	chr8:85085400	A/T	cg05716166	chr8:85095498	RALYL	-0.55	-6.43	-0.39	7.15e-10	Body mass index;
SARC	cis	rs7833986	0.534	rs10504198	chr8:57006254	G/C	cg26371346	chr8:56986568	SNORD54;RPS20	0.73	7.47	0.44	1.56e-12	Height;
SARC	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg21782813	chr7:2030301	MAD1L1	0.39	6.14	0.37	3.58e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs763121	0.853	rs4821809	chr22:39065743	G/C	cg14440974	chr22:39074834	NA	-0.34	-4.96	-0.31	1.38e-6	Menopause (age at onset);
SARC	cis	rs33912345	0.695	rs1262173	chr14:60874311	T/C	cg27398547	chr14:60952738	C14orf39	-0.39	-4.73	-0.3	3.85e-6	Glaucoma (high intraocular pressure);
SARC	cis	rs7044106	0.762	rs3904197	chr9:123480378	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	6.29	0.38	1.59e-9	Hip circumference adjusted for BMI;
SARC	cis	rs11574514	0.661	rs116856853	chr16:67984804	G/A	cg01866162	chr16:67596514	CTCF	0.98	5.83	0.36	1.82e-8	Crohn's disease;
SARC	cis	rs10916814	0.610	rs1890005	chr1:20899016	T/C	cg24502330	chr1:20914028	CDA	-0.3	-5.33	-0.33	2.36e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs898097	0.607	rs2199111	chr17:80823203	A/G	cg10494973	chr17:80897199	TBCD	0.38	4.91	0.31	1.71e-6	Breast cancer;
SARC	cis	rs4319547	0.695	rs11836188	chr12:122865507	T/C	cg05707623	chr12:122985044	ZCCHC8	0.56	6.42	0.39	7.61e-10	Body mass index;
SARC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg11965913	chr1:205819406	PM20D1	0.88	14.25	0.68	1.5e-33	Menarche (age at onset);
SARC	cis	rs3126085	1.000	rs11590365	chr1:152165489	C/A	cg26876637	chr1:152193138	HRNR	-0.51	-5.25	-0.33	3.42e-7	Atopic dermatitis;
SARC	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg09455208	chr3:40491958	NA	0.4	5.81	0.36	2.05e-8	Renal cell carcinoma;
SARC	cis	rs208520	0.955	rs9453664	chr6:66976079	A/C	cg07460842	chr6:66804631	NA	0.79	8.89	0.5	1.68e-16	Exhaled nitric oxide output;
SARC	cis	rs929354	0.742	rs3808317	chr7:156944460	A/G	cg05182265	chr7:156933206	UBE3C	-0.34	-5.19	-0.32	4.49e-7	Body mass index;
SARC	cis	rs1949733	1.000	rs2631758	chr4:8495304	G/A	cg11789530	chr4:8429930	ACOX3	-0.82	-11.05	-0.59	4.38e-23	Response to antineoplastic agents;
SARC	cis	rs2549003	1.000	rs2070725	chr5:131821788	C/T	cg21138405	chr5:131827807	IRF1	0.27	5.32	0.33	2.4e-7	Asthma (sex interaction);
SARC	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg19223190	chr17:80058835	NA	0.44	6.19	0.38	2.67e-9	Life satisfaction;
SARC	cis	rs7044106	0.537	rs10818474	chr9:123489964	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	5.47	0.34	1.16e-7	Hip circumference adjusted for BMI;
SARC	cis	rs854765	0.583	rs7214536	chr17:17852446	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	9.85	0.54	2.34e-19	Total body bone mineral density;
SARC	trans	rs8073060	0.586	rs7214250	chr17:33981704	C/G	cg19694781	chr19:47549865	TMEM160	-0.67	-6.8	-0.41	8.8e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg00908189	chr16:619842	PIGQ	0.83	11.89	0.61	8.68e-26	Height;
SARC	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	8.3	0.48	8.39e-15	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg04546413	chr19:29218101	NA	-0.53	-6.06	-0.37	5.42e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs1152591	0.643	rs3020449	chr14:64773392	C/T	cg23250157	chr14:64679961	SYNE2	-0.46	-6.67	-0.4	1.88e-10	Atrial fibrillation;
SARC	cis	rs9399137	0.507	rs4520025	chr6:135278619	G/T	cg24558204	chr6:135376177	HBS1L	0.61	7.92	0.46	9.9e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs2276314	0.802	rs9963714	chr18:33592056	T/C	cg19628046	chr18:33552617	C18orf21	0.58	5.85	0.36	1.61e-8	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs6062302	0.522	rs2282157	chr20:62227180	C/G	cg09650180	chr20:62225654	GMEB2	-0.47	-5.69	-0.35	3.72e-8	Glioblastoma;
SARC	cis	rs10849893	0.576	rs7134248	chr12:121897052	T/C	cg01154721	chr12:121881891	KDM2B	-0.37	-5.13	-0.32	6.21e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs479844	1.000	rs479844	chr11:65551957	A/G	cg26695010	chr11:65641043	EFEMP2	0.42	5.24	0.32	3.53e-7	Allergic disease (asthma, hay fever or eczema);Atopic march;Atopic dermatitis;
SARC	cis	rs7929679	0.521	rs10768097	chr11:34792902	T/C	cg06937548	chr11:34938143	PDHX;APIP	0.36	4.76	0.3	3.47e-6	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
SARC	cis	rs9398803	0.713	rs1387916	chr6:126886731	G/C	cg20229609	chr6:126660872	C6orf173	0.37	5.4	0.33	1.66e-7	Male-pattern baldness;
SARC	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg11878867	chr6:150167359	LRP11	-0.35	-4.81	-0.3	2.76e-6	Lung cancer;
SARC	cis	rs9341808	0.718	rs9448908	chr6:80898069	C/T	cg08355045	chr6:80787529	NA	0.33	5.34	0.33	2.24e-7	Sitting height ratio;
SARC	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg03060546	chr3:49711283	APEH	0.54	7.05	0.42	1.98e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs6570726	0.791	rs12208812	chr6:145900924	T/G	cg05347473	chr6:146136440	FBXO30	0.55	7.51	0.44	1.24e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11638352	1.000	rs1808509	chr15:44409539	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.77	-5.84	-0.36	1.78e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	cis	rs9296092	0.560	rs9469505	chr6:33527348	A/G	cg13560919	chr6:33536144	NA	-0.52	-6.41	-0.39	8.07e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs2594989	0.831	rs9840982	chr3:11564940	C/A	cg00170343	chr3:11313890	ATG7	-0.57	-5.82	-0.36	1.89e-8	Circulating chemerin levels;
SARC	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg16479474	chr6:28041457	NA	0.35	5.26	0.33	3.28e-7	Parkinson's disease;
SARC	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg20607798	chr8:58055168	NA	-0.61	-5.32	-0.33	2.43e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs3820928	0.874	rs1114562	chr2:227788592	T/C	cg11843606	chr2:227700838	RHBDD1	-0.57	-7.27	-0.43	5.32e-12	Pulmonary function;
SARC	cis	rs11098499	0.754	rs10213267	chr4:120239074	A/G	cg09307838	chr4:120376055	NA	0.81	11.15	0.59	2.11e-23	Corneal astigmatism;
SARC	cis	rs9354308	0.933	rs10455586	chr6:66571498	T/C	cg07460842	chr6:66804631	NA	0.49	5.59	0.34	6.34e-8	Metabolite levels;
SARC	cis	rs933688	1.000	rs1035476	chr5:90745976	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.01	12.75	0.64	1.38e-28	Smoking behavior;
SARC	cis	rs76917914	0.780	rs1059273	chr9:100849500	G/T	cg03040243	chr9:100819229	NANS	0.63	6.45	0.39	6.41e-10	Immature fraction of reticulocytes;
SARC	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg12463550	chr7:65579703	CRCP	-0.47	-5.37	-0.33	1.93e-7	Aortic root size;
SARC	cis	rs600231	0.542	rs10896010	chr11:65246220	C/A	cg17120908	chr11:65337727	SSSCA1	-0.45	-5.0	-0.31	1.11e-6	Bone mineral density;
SARC	cis	rs2075371	1.000	rs2544213	chr7:133982867	G/C	cg00033643	chr7:134001901	SLC35B4	0.39	4.78	0.3	3.05e-6	Mean platelet volume;
SARC	cis	rs1348850	0.958	rs12471741	chr2:178448196	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.69	8.98	0.51	9.32e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs6815814	0.847	rs11725309	chr4:38783848	T/C	cg06935464	chr4:38784597	TLR10	0.61	6.02	0.37	6.56e-9	Breast cancer;
SARC	cis	rs1059312	0.808	rs900982	chr12:129304369	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.48	-5.86	-0.36	1.6e-8	Systemic lupus erythematosus;
SARC	cis	rs6782228	0.509	rs4481172	chr3:128372657	C/A	cg08795948	chr3:128337044	NA	0.38	5.13	0.32	6.03e-7	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
SARC	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg08280861	chr8:58055591	NA	0.6	5.28	0.33	2.92e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg16563178	chr3:50358443	HYAL2	0.49	6.44	0.39	6.85e-10	Chemerin levels;
SARC	cis	rs6667605	0.527	rs12046118	chr1:2540343	A/C	cg20673091	chr1:2541236	MMEL1	0.33	5.08	0.32	7.7e-7	Inflammatory bowel disease;Ulcerative colitis;
SARC	cis	rs9902453	0.967	rs1906450	chr17:28515744	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	6.57	0.4	3.32e-10	Coffee consumption (cups per day);
SARC	cis	rs2991971	0.933	rs2356553	chr1:46009313	G/C	cg24296786	chr1:45957014	TESK2	0.68	9.58	0.53	1.51e-18	High light scatter reticulocyte count;
SARC	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg13393036	chr8:95962371	TP53INP1	-0.35	-5.92	-0.36	1.15e-8	Type 2 diabetes;
SARC	cis	rs7216064	1.000	rs8067892	chr17:65837983	A/G	cg12091567	chr17:66097778	LOC651250	-0.74	-8.17	-0.47	1.97e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg23310975	chr8:121455224	MRPL13	0.47	6.78	0.41	9.55e-11	Thyroid stimulating hormone;
SARC	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg05185784	chr16:90016020	DEF8	-0.45	-4.76	-0.3	3.32e-6	Skin colour saturation;
SARC	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg26769984	chr7:1090371	C7orf50	0.51	5.25	0.33	3.36e-7	Bronchopulmonary dysplasia;
SARC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.3	-4.77	-0.3	3.24e-6	Total body bone mineral density;
SARC	trans	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-6.34	-0.38	1.2e-9	Intelligence (multi-trait analysis);
SARC	cis	rs8053891	0.906	rs12926408	chr16:71994451	G/C	cg16558253	chr16:72132732	DHX38	-0.41	-5.35	-0.33	2.14e-7	Coronary artery disease;
SARC	cis	rs4689388	0.926	rs9998835	chr4:6293237	C/G	cg25554036	chr4:6271136	WFS1	0.39	6.42	0.39	7.48e-10	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs3824867	0.920	rs4282946	chr11:47456202	G/A	cg20307385	chr11:47447363	PSMC3	0.49	5.32	0.33	2.47e-7	Mean corpuscular hemoglobin;
SARC	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg06212747	chr3:49208901	KLHDC8B	0.65	8.55	0.49	1.64e-15	Parkinson's disease;
SARC	trans	rs3942852	0.774	rs1039481	chr11:48182237	G/A	cg03929089	chr4:120376271	NA	-0.61	-6.92	-0.41	4.3e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg06634786	chr22:41940651	POLR3H	0.54	6.41	0.39	8.14e-10	Vitiligo;
SARC	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg11890956	chr21:40555474	PSMG1	-0.74	-9.87	-0.54	1.95e-19	Menarche (age at onset);
SARC	cis	rs9916302	0.904	rs12452880	chr17:37591149	G/C	cg00129232	chr17:37814104	STARD3	-0.63	-7.66	-0.45	5.09e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs9457247	0.935	rs427824	chr6:167403918	T/G	cg23791538	chr6:167370224	RNASET2	-0.62	-8.55	-0.49	1.65e-15	Crohn's disease;
SARC	cis	rs1865760	0.566	rs7772312	chr6:26049616	G/C	cg18357526	chr6:26021779	HIST1H4A	0.42	5.29	0.33	2.84e-7	Height;
SARC	cis	rs72781680	1.000	rs72781671	chr2:24231123	A/G	cg08917208	chr2:24149416	ATAD2B	0.94	9.2	0.52	2.17e-17	Lymphocyte counts;
SARC	cis	rs2486288	0.656	rs9921035	chr15:45546660	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.46	-5.62	-0.35	5.37e-8	Glomerular filtration rate;
SARC	cis	rs1318878	1.000	rs11056461	chr12:15558466	A/G	cg08258403	chr12:15378311	NA	0.48	6.11	0.37	4.11e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7914558	1.000	rs11191577	chr10:104902165	A/G	cg04362960	chr10:104952993	NT5C2	0.45	5.45	0.34	1.28e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs2985684	0.894	rs4900932	chr14:50022928	A/G	cg04989706	chr14:50066350	PPIL5	-0.51	-5.67	-0.35	4.12e-8	Carotid intima media thickness;
SARC	cis	rs7647973	0.626	rs1491985	chr3:49739507	G/C	cg06212747	chr3:49208901	KLHDC8B	0.55	5.52	0.34	9.13e-8	Menarche (age at onset);
SARC	cis	rs67311347	0.955	rs9821036	chr3:40379007	A/G	cg24209194	chr3:40518798	ZNF619	0.57	7.16	0.42	1.07e-11	Renal cell carcinoma;
SARC	cis	rs765787	0.530	rs2433227	chr15:45517119	A/T	cg25801113	chr15:45476975	SHF	0.28	4.72	0.3	4.06e-6	Uric acid levels;
SARC	cis	rs2594989	0.895	rs2606759	chr3:11349494	T/C	cg00170343	chr3:11313890	ATG7	0.57	5.59	0.34	6.27e-8	Circulating chemerin levels;
SARC	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg06618935	chr21:46677482	NA	-0.4	-5.4	-0.33	1.68e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs17376456	0.778	rs10476604	chr5:93461838	C/T	cg25358565	chr5:93447407	FAM172A	0.86	10.04	0.55	5.99e-20	Diabetic retinopathy;
SARC	cis	rs7589342	0.831	rs13429270	chr2:106453060	C/T	cg16077055	chr2:106428750	NCK2	0.4	7.5	0.44	1.31e-12	Addiction;
SARC	trans	rs8073060	0.545	rs3859282	chr17:34006111	T/C	cg19694781	chr19:47549865	TMEM160	-0.7	-6.92	-0.41	4.32e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs9443189	0.502	rs2312933	chr6:76577665	C/T	cg01950844	chr6:76311363	SENP6	-0.76	-4.78	-0.3	3.14e-6	Prostate cancer;
SARC	cis	rs262150	0.536	rs73167296	chr7:158783129	C/T	cg19418458	chr7:158789849	NA	0.43	4.75	0.3	3.5e-6	Facial morphology (factor 20);
SARC	trans	rs8073060	0.586	rs226087	chr17:34017652	T/C	cg19694781	chr19:47549865	TMEM160	-0.71	-6.94	-0.41	3.88e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg08219700	chr8:58056026	NA	0.7	6.64	0.4	2.22e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2342371	0.848	rs7433483	chr3:196217038	C/T	cg15048948	chr3:196158458	UBXN7	-0.54	-6.86	-0.41	6.3e-11	Fat distribution (HIV);
SARC	cis	rs1538970	0.748	rs11211137	chr1:46013892	T/A	cg05343316	chr1:45956843	TESK2	0.83	9.03	0.51	6.84e-17	Platelet count;
SARC	cis	rs9914988	0.887	rs28873200	chr17:27149512	A/G	cg20469991	chr17:27169893	C17orf63	-0.52	-5.39	-0.33	1.74e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs7617773	0.780	rs13066758	chr3:48343877	G/A	cg11946769	chr3:48343235	NME6	0.76	9.7	0.54	6.55e-19	Coronary artery disease;
SARC	trans	rs561341	1.000	rs530209	chr17:30315287	A/G	cg20587970	chr11:113659929	NA	-1.33	-13.84	-0.67	3.43e-32	Hip circumference adjusted for BMI;
SARC	cis	rs1267303	0.642	rs6670699	chr1:46997270	C/T	cg25110126	chr1:46999211	NA	0.92	9.6	0.53	1.38e-18	Monobrow;
SARC	cis	rs16854884	1.000	rs13067695	chr3:143781054	C/T	cg06585982	chr3:143692056	C3orf58	0.54	6.76	0.4	1.09e-10	Economic and political preferences (feminism/equality);
SARC	cis	rs9868809	0.505	rs56735597	chr3:48765168	A/G	cg07636037	chr3:49044803	WDR6	-0.79	-6.89	-0.41	5.07e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs13401104	0.796	rs1968708	chr2:237110654	G/A	cg19324714	chr2:237145437	ASB18	0.57	5.83	0.36	1.85e-8	Educational attainment;
SARC	cis	rs17666538	1.000	rs57896286	chr8:571479	T/C	cg07685180	chr8:600429	NA	-0.78	-5.71	-0.35	3.35e-8	IgG glycosylation;
SARC	cis	rs11190604	0.767	rs10883477	chr10:102161396	A/G	cg07080220	chr10:102295463	HIF1AN	0.65	7.27	0.43	5.25e-12	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs7223966	0.961	rs17631394	chr17:61646000	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.54	5.27	0.33	3.11e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9818758	0.556	rs9880309	chr3:49304329	G/C	cg07636037	chr3:49044803	WDR6	-0.75	-6.54	-0.39	3.94e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs9467773	0.620	rs2504571	chr6:26643435	C/T	cg12292205	chr6:26970375	C6orf41	0.41	5.1	0.32	7.12e-7	Intelligence (multi-trait analysis);
SARC	cis	rs10789491	1.000	rs601060	chr1:47139580	C/G	cg15501359	chr1:47185051	KIAA0494	-0.74	-8.08	-0.47	3.51e-14	Response to hepatitis C treatment;
SARC	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg00149659	chr3:10157352	C3orf10	1.09	10.0	0.55	7.87e-20	Alzheimer's disease;
SARC	cis	rs921968	0.541	rs17462853	chr2:219345637	T/G	cg02176678	chr2:219576539	TTLL4	-0.5	-7.57	-0.44	8.83e-13	Mean corpuscular hemoglobin concentration;
SARC	cis	rs12142240	0.698	rs112089006	chr1:46812360	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-5.48	-0.34	1.12e-7	Menopause (age at onset);
SARC	trans	rs2727020	0.930	rs1164686	chr11:49291822	C/T	cg03929089	chr4:120376271	NA	0.76	9.84	0.54	2.43e-19	Coronary artery disease;
SARC	cis	rs9503598	0.636	rs6596977	chr6:3466254	G/A	cg00476032	chr6:3446245	SLC22A23	0.39	6.27	0.38	1.72e-9	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
SARC	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg13939156	chr17:80058883	NA	-0.44	-6.71	-0.4	1.46e-10	Life satisfaction;
SARC	cis	rs28655083	1.000	rs8059347	chr16:77068259	C/T	cg01504555	chr16:77246968	SYCE1L	-0.39	-4.92	-0.31	1.61e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg19500275	chr17:80737654	TBCD	-0.37	-4.93	-0.31	1.57e-6	Glycated hemoglobin levels;
SARC	cis	rs7772486	0.790	rs7742333	chr6:146159029	A/G	cg05347473	chr6:146136440	FBXO30	-0.48	-6.58	-0.4	3.01e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs554111	0.679	rs906254	chr1:21324760	G/A	cg04902671	chr1:21058625	SH2D5	0.43	5.33	0.33	2.36e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs644799	1.000	rs7749	chr11:95565789	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.67	9.02	0.51	7.21e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7937682	0.663	rs7116280	chr11:111659111	T/C	cg22437258	chr11:111473054	SIK2	-0.5	-5.75	-0.35	2.8e-8	Primary sclerosing cholangitis;
SARC	cis	rs10958369	0.541	rs1477956	chr8:54435227	T/G	cg12485204	chr8:54507357	NA	0.46	6.46	0.39	6.03e-10	Response to antineoplastic agents;
SARC	cis	rs9640161	0.789	rs2159234	chr7:150020422	A/T	cg10018233	chr7:150070692	REPIN1	0.72	9.37	0.52	6.75e-18	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg22800045	chr5:56110881	MAP3K1	0.75	7.9	0.46	1.12e-13	Initial pursuit acceleration;
SARC	cis	rs17023223	0.537	rs4508058	chr1:119684250	T/C	cg05756136	chr1:119680316	WARS2	-0.48	-5.55	-0.34	7.84e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg11629460	chr3:141457364	RNF7	-0.54	-6.65	-0.4	2.04e-10	Height;
SARC	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg08742575	chr21:47604166	C21orf56	-0.47	-6.01	-0.37	6.94e-9	Testicular germ cell tumor;
SARC	cis	rs1728785	1.000	rs1094282	chr16:68577260	G/A	cg02972257	chr16:68554789	NA	-0.43	-5.01	-0.31	1.08e-6	Ulcerative colitis;
SARC	cis	rs7954584	0.505	rs11043278	chr12:122412145	C/T	cg21171335	chr12:122356390	WDR66	0.42	6.46	0.39	5.9e-10	Mean corpuscular volume;
SARC	cis	rs7666738	0.791	rs13128640	chr4:99003918	A/C	cg05340658	chr4:99064831	C4orf37	0.65	8.8	0.5	3.13e-16	Colonoscopy-negative controls vs population controls;
SARC	trans	rs1941687	0.527	rs2000945	chr18:31365336	A/G	cg27147174	chr7:100797783	AP1S1	-0.55	-6.81	-0.41	8.03e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
SARC	cis	rs9790314	0.747	rs4616689	chr3:160856269	A/G	cg03342759	chr3:160939853	NMD3	-0.42	-4.98	-0.31	1.25e-6	Morning vs. evening chronotype;
SARC	cis	rs6582630	0.519	rs8189561	chr12:38296178	G/A	cg13010199	chr12:38710504	ALG10B	0.79	11.02	0.59	5.26e-23	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs4919694	0.536	rs12256506	chr10:104963618	T/A	cg04362960	chr10:104952993	NT5C2	0.64	5.95	0.36	9.84e-9	Arsenic metabolism;
SARC	cis	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg05623727	chr3:50126028	RBM5	0.33	5.1	0.32	6.87e-7	Intelligence (multi-trait analysis);
SARC	cis	rs10911251	0.508	rs10797854	chr1:183106739	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.67	9.67	0.53	8.43e-19	Colorectal cancer;
SARC	cis	rs2070488	0.965	rs2300668	chr3:38540541	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.76	-11.62	-0.61	6.41e-25	Electrocardiographic conduction measures;
SARC	cis	rs2075671	0.855	rs11974395	chr7:100282538	G/A	cg16850897	chr7:100343110	ZAN	-0.64	-6.85	-0.41	6.38e-11	Other erythrocyte phenotypes;
SARC	cis	rs1008375	0.966	rs1860599	chr4:17638900	T/C	cg16339924	chr4:17578868	LAP3	0.67	8.96	0.51	1.05e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs79349575	0.687	rs12602179	chr17:47010034	G/T	cg16584676	chr17:46985605	UBE2Z	0.55	6.66	0.4	1.91e-10	Type 2 diabetes;
SARC	cis	rs7520050	0.898	rs34175029	chr1:46483871	C/T	cg24296786	chr1:45957014	TESK2	0.39	5.03	0.31	9.72e-7	Red blood cell count;Reticulocyte count;
SARC	cis	rs7312774	0.618	rs7979117	chr12:107345883	C/T	cg16260113	chr12:107380972	MTERFD3	0.93	7.82	0.46	1.85e-13	Severe influenza A (H1N1) infection;
SARC	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.59e-6	Depression;
SARC	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-15.16	-0.7	1.42e-36	Chronic sinus infection;
SARC	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg10523679	chr1:76189770	ACADM	-0.43	-5.28	-0.33	2.94e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs11098499	0.863	rs3822192	chr4:120445720	A/C	cg24375607	chr4:120327624	NA	0.43	5.08	0.32	7.89e-7	Corneal astigmatism;
SARC	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg02951883	chr7:2050386	MAD1L1	-0.48	-6.11	-0.37	4.1e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg07701084	chr6:150067640	NUP43	0.39	5.07	0.32	8.08e-7	Lung cancer;
SARC	cis	rs2073499	1.000	rs2073498	chr3:50369546	C/A	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.54	5.12	0.32	6.34e-7	Schizophrenia;
SARC	cis	rs6087990	0.865	rs6058859	chr20:31335157	A/G	cg13636640	chr20:31349939	DNMT3B	0.79	12.49	0.63	9.43e-28	Ulcerative colitis;
SARC	cis	rs57506017	0.565	rs6460896	chr7:12252659	G/A	cg23422036	chr7:12250390	TMEM106B	0.49	6.49	0.39	5.19e-10	Neuroticism;
SARC	cis	rs2304069	0.545	rs11167492	chr5:149403101	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.6	7.11	0.42	1.4e-11	HIV-1 control;
SARC	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg03433033	chr1:76189801	ACADM	0.51	6.88	0.41	5.5e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg11489262	chr17:43973426	MAPT;LOC100128977;LOC100130148	0.46	4.77	0.3	3.24e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs13191362	1.000	rs36042757	chr6:163004744	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.57	5.51	0.34	9.61e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg08219700	chr8:58056026	NA	0.51	5.18	0.32	4.74e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs3767633	0.925	rs6427639	chr1:161866372	C/A	cg09175582	chr1:161736000	ATF6	0.68	5.88	0.36	1.38e-8	IgG glycosylation;
SARC	cis	rs2836633	0.929	rs4143428	chr21:40030582	G/T	cg12884169	chr21:40033163	ERG	0.48	8.79	0.5	3.33e-16	Coronary artery disease;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg14634842	chr2:232574012	PTMA	0.52	6.43	0.39	7.29e-10	Breast cancer;
SARC	cis	rs4253772	0.550	rs6007830	chr22:46711323	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.61	4.93	0.31	1.6e-6	LDL cholesterol;Cholesterol, total;
SARC	cis	rs2204008	0.580	rs11520047	chr12:38051778	T/A	cg26384229	chr12:38710491	ALG10B	0.89	13.14	0.65	6.99e-30	Bladder cancer;
SARC	cis	rs1957429	0.808	rs1467573	chr14:65347583	T/C	cg23373153	chr14:65346875	NA	1.07	11.5	0.6	1.53e-24	Pediatric areal bone mineral density (radius);
SARC	cis	rs561341	0.843	rs2028067	chr17:30239698	T/C	cg13647721	chr17:30228624	UTP6	0.65	6.04	0.37	6e-9	Hip circumference adjusted for BMI;
SARC	cis	rs9309473	0.500	rs10189578	chr2:73728609	C/A	cg20560298	chr2:73613845	ALMS1	-0.51	-6.92	-0.41	4.31e-11	Metabolite levels;
SARC	cis	rs7762018	1.000	rs6942332	chr6:170131934	A/G	cg13891659	chr6:170190454	C6orf122;C6orf208	0.53	4.95	0.31	1.41e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs4481887	1.000	rs4409693	chr1:248479061	C/T	cg13385794	chr1:248469461	NA	0.37	5.48	0.34	1.08e-7	Common traits (Other);
SARC	cis	rs7524258	0.835	rs2412150	chr1:7303343	A/C	cg07173049	chr1:7289937	CAMTA1	0.39	7.57	0.44	8.55e-13	Tourette's syndrome or obsessive-compulsive disorder;
SARC	cis	rs6430585	0.528	rs309113	chr2:136737460	C/A	cg07169764	chr2:136633963	MCM6	0.94	12.26	0.63	5.59e-27	Corneal structure;
SARC	trans	rs61931739	0.500	rs7979240	chr12:34509026	C/T	cg26384229	chr12:38710491	ALG10B	0.91	13.47	0.66	5.86e-31	Morning vs. evening chronotype;
SARC	cis	rs11792861	0.962	rs72607161	chr9:111792640	T/C	cg13535736	chr9:111863775	C9orf5	-0.41	-5.05	-0.31	9.02e-7	Menarche (age at onset);
SARC	cis	rs6486730	0.508	rs7133440	chr12:129269244	A/C	cg09035930	chr12:129282057	SLC15A4	-0.4	-5.31	-0.33	2.57e-7	Systemic lupus erythematosus;
SARC	cis	rs7826238	0.720	rs12546760	chr8:8374836	A/G	cg15556689	chr8:8085844	FLJ10661	-0.39	-4.84	-0.3	2.39e-6	Systolic blood pressure;
SARC	cis	rs2797160	1.000	rs2211418	chr6:125995503	G/A	cg05901451	chr6:126070800	HEY2	-0.42	-5.15	-0.32	5.51e-7	Endometrial cancer;
SARC	trans	rs561341	1.000	rs555629	chr17:30294136	T/C	cg20587970	chr11:113659929	NA	-1.35	-13.48	-0.66	5.32e-31	Hip circumference adjusted for BMI;
SARC	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	5.34	0.33	2.17e-7	Tonsillectomy;
SARC	cis	rs6088580	0.634	rs6058052	chr20:33047084	A/G	cg08999081	chr20:33150536	PIGU	0.43	6.67	0.4	1.86e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs79149102	0.579	rs7172065	chr15:75321910	C/T	cg00629941	chr15:75287862	SCAMP5	-0.71	-4.95	-0.31	1.43e-6	Lung cancer;
SARC	cis	rs881375	1.000	rs10760121	chr9:123647915	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.41	4.91	0.31	1.71e-6	Rheumatoid arthritis;
SARC	cis	rs2230307	0.536	rs526128	chr1:100473427	T/A	cg24955406	chr1:100503596	HIAT1	0.7	7.09	0.42	1.59e-11	Carotid intima media thickness;
SARC	cis	rs9462027	0.628	rs4601124	chr6:34776910	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.86	-0.36	1.54e-8	Systemic lupus erythematosus;
SARC	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg20573242	chr4:122745356	CCNA2	0.67	8.8	0.5	3.09e-16	Type 2 diabetes;
SARC	cis	rs2832191	0.791	rs4817270	chr21:30480368	G/A	cg08807101	chr21:30365312	RNF160	-0.84	-11.81	-0.61	1.6e-25	Dental caries;
SARC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg21724239	chr8:58056113	NA	0.65	6.2	0.38	2.48e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7937682	0.575	rs7107213	chr11:111750430	A/G	cg09085632	chr11:111637200	PPP2R1B	0.79	10.75	0.58	3.68e-22	Primary sclerosing cholangitis;
SARC	cis	rs35110281	0.715	rs969060	chr21:45080852	T/G	cg01579765	chr21:45077557	HSF2BP	-0.36	-5.81	-0.36	2.09e-8	Mean corpuscular volume;
SARC	cis	rs6582630	0.577	rs12312748	chr12:38343326	T/C	cg13010199	chr12:38710504	ALG10B	-0.51	-6.13	-0.37	3.68e-9	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg25427524	chr10:38739819	LOC399744	-0.55	-8.74	-0.5	4.54e-16	Extrinsic epigenetic age acceleration;
SARC	cis	rs1153858	1.000	rs7494956	chr15:45668565	T/C	cg26924012	chr15:45694286	SPATA5L1	0.79	11.28	0.59	7.91e-24	Homoarginine levels;
SARC	cis	rs6582630	0.576	rs4403871	chr12:38292193	G/A	cg26384229	chr12:38710491	ALG10B	-0.62	-7.81	-0.46	2e-13	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs995000	0.931	rs1167996	chr1:62927797	T/G	cg06896770	chr1:63153194	DOCK7	-0.9	-13.83	-0.67	3.63e-32	Triglyceride levels;
SARC	cis	rs733592	0.507	rs10875739	chr12:48480919	C/T	cg24011408	chr12:48396354	COL2A1	0.5	6.25	0.38	1.92e-9	Plateletcrit;
SARC	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg15049968	chr18:44337910	ST8SIA5	-0.36	-5.79	-0.35	2.25e-8	Personality dimensions;
SARC	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	8.89	0.5	1.77e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs526231	0.511	rs10434792	chr5:102389602	G/C	cg23492399	chr5:102201601	PAM	-0.51	-5.55	-0.34	7.61e-8	Primary biliary cholangitis;
SARC	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.74	8.95	0.51	1.17e-16	Height;
SARC	cis	rs7727544	0.735	rs272875	chr5:131674888	T/C	cg24060327	chr5:131705240	SLC22A5	-0.65	-8.1	-0.47	3.16e-14	Blood metabolite levels;
SARC	cis	rs9359856	0.510	rs3736984	chr6:90408589	C/T	cg13799429	chr6:90582589	CASP8AP2	0.55	5.15	0.32	5.57e-7	Bipolar disorder;
SARC	trans	rs61931739	0.817	rs2203086	chr12:34232590	T/C	cg26384229	chr12:38710491	ALG10B	0.62	8.11	0.47	2.84e-14	Morning vs. evening chronotype;
SARC	cis	rs4971059	0.654	rs4971052	chr1:155126018	C/T	cg22049894	chr1:155113146	DPM3	0.41	5.07	0.32	8.18e-7	Breast cancer;
SARC	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg05896524	chr21:47604654	C21orf56	0.47	5.74	0.35	2.9e-8	Testicular germ cell tumor;
SARC	cis	rs34779708	0.931	rs34087268	chr10:35346724	T/G	cg03585969	chr10:35415529	CREM	0.4	4.93	0.31	1.58e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs12079745	0.793	rs57776592	chr1:169268023	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.84	-5.33	-0.33	2.36e-7	QT interval;
SARC	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	11.6	0.61	7.44e-25	Alzheimer's disease;
SARC	cis	rs72781680	0.716	rs2712086	chr2:24004739	G/C	cg06627628	chr2:24431161	ITSN2	-0.54	-5.49	-0.34	1.04e-7	Lymphocyte counts;
SARC	cis	rs9715521	0.677	rs62301200	chr4:59855179	G/A	cg11281224	chr4:60001000	NA	-0.46	-5.9	-0.36	1.29e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg09699651	chr6:150184138	LRP11	0.39	4.85	0.3	2.29e-6	Lung cancer;
SARC	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg05025164	chr4:1340916	KIAA1530	0.43	4.88	0.3	1.93e-6	Obesity-related traits;
SARC	cis	rs2559856	0.967	rs2695290	chr12:102087844	A/G	cg12924262	chr12:102091054	CHPT1	-0.57	-8.03	-0.47	4.78e-14	Blood protein levels;
SARC	cis	rs2239547	0.657	rs3755803	chr3:52866157	C/G	cg18404041	chr3:52824283	ITIH1	-0.4	-4.81	-0.3	2.76e-6	Schizophrenia;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg27328408	chr15:75615005	NA	0.5	6.38	0.39	9.64e-10	Blood pressure;
SARC	cis	rs6570726	0.905	rs421032	chr6:145827771	A/G	cg05347473	chr6:146136440	FBXO30	0.48	6.45	0.39	6.38e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9486719	0.843	rs3860230	chr6:97036560	T/A	cg18709589	chr6:96969512	KIAA0776	-0.51	-5.64	-0.35	4.81e-8	Migraine;Coronary artery disease;
SARC	cis	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg25427524	chr10:38739819	LOC399744	0.55	8.84	0.5	2.35e-16	Extrinsic epigenetic age acceleration;
SARC	cis	rs1881797	1.000	rs10158379	chr1:247686352	C/A	cg18198730	chr1:247681584	NA	0.48	5.29	0.33	2.85e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs10276381	0.786	rs28430601	chr7:28238811	A/G	cg23620719	chr7:28220237	JAZF1	0.71	5.34	0.33	2.2e-7	Crohn's disease;
SARC	cis	rs1448094	0.621	rs7315084	chr12:86283817	A/G	cg00310523	chr12:86230176	RASSF9	0.31	4.8	0.3	2.87e-6	Major depressive disorder;
SARC	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg19671926	chr4:122722719	EXOSC9	-0.55	-6.09	-0.37	4.6e-9	Type 2 diabetes;
SARC	cis	rs6120849	0.707	rs3746444	chr20:33578251	A/G	cg24642439	chr20:33292090	TP53INP2	0.57	5.47	0.34	1.13e-7	Protein C levels;
SARC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg09436375	chr6:42928200	GNMT	-0.37	-5.75	-0.35	2.79e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg09392046	chr2:3321210	TSSC1	-0.54	-6.84	-0.41	6.8e-11	Height;
SARC	cis	rs826838	0.874	rs10880943	chr12:38734317	C/T	cg13010199	chr12:38710504	ALG10B	0.82	11.79	0.61	1.86e-25	Heart rate;
SARC	cis	rs11155671	0.530	rs7758033	chr6:150208135	T/C	cg05036130	chr6:150231994	NA	0.29	4.97	0.31	1.32e-6	Testicular germ cell tumor;
SARC	cis	rs8067545	0.750	rs11868084	chr17:19992717	A/G	cg13482628	chr17:19912719	NA	0.53	7.02	0.42	2.44e-11	Schizophrenia;
SARC	cis	rs10088262	0.629	rs12549683	chr8:124798276	G/C	cg15047889	chr8:124780837	FAM91A1	-0.66	-7.32	-0.43	3.96e-12	Pancreatic cancer;
SARC	cis	rs12887734	0.546	rs12885509	chr14:104273325	T/C	cg26031613	chr14:104095156	KLC1	-0.46	-5.36	-0.33	1.96e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	cis	rs6540556	0.954	rs643118	chr1:209934841	C/T	cg05527609	chr1:210001259	C1orf107	-0.51	-5.36	-0.33	2.02e-7	Red blood cell count;
SARC	cis	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg20236533	chr4:99850271	EIF4E	-0.44	-5.34	-0.33	2.24e-7	Colonoscopy-negative controls vs population controls;
SARC	cis	rs12142240	0.698	rs12385696	chr1:46818836	A/G	cg00530320	chr1:46809349	NSUN4	0.54	6.61	0.4	2.6200000000000003e-10	Menopause (age at onset);
SARC	trans	rs2018683	0.933	rs12536127	chr7:28985967	T/C	cg19402173	chr7:128379420	CALU	-0.7	-9.09	-0.51	4.42e-17	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs9309473	0.607	rs6546824	chr2:73587331	G/A	cg20560298	chr2:73613845	ALMS1	-0.59	-7.42	-0.44	2.2e-12	Metabolite levels;
SARC	cis	rs13161895	0.941	rs6876648	chr5:179441842	T/C	cg06664874	chr5:179499304	RNF130	-0.49	-4.76	-0.3	3.39e-6	LDL cholesterol;
SARC	cis	rs10197940	0.571	rs13393021	chr2:152413258	A/C	cg19508488	chr2:152266495	RIF1	0.48	5.33	0.33	2.37e-7	Lung cancer;
SARC	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.56	-7.2	-0.43	8.01e-12	Mean platelet volume;
SARC	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg25072359	chr17:41440525	NA	0.48	5.62	0.35	5.43e-8	Menopause (age at onset);
SARC	cis	rs3768617	0.510	rs10797846	chr1:183087485	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.1	0.55	4.11e-20	Fuchs's corneal dystrophy;
SARC	trans	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.21	-0.43	7.82e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs7264396	0.508	rs6060739	chr20:34567592	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-6.57	-0.4	3.31e-10	Total cholesterol levels;
SARC	cis	rs12950390	0.893	rs11079789	chr17:45849715	A/G	cg03474202	chr17:45855739	NA	-0.46	-7.27	-0.43	5.31e-12	IgG glycosylation;
SARC	cis	rs2153535	0.580	rs9328478	chr6:8519183	A/G	cg07606381	chr6:8435919	SLC35B3	0.77	10.87	0.58	1.55e-22	Motion sickness;
SARC	cis	rs8014131	0.651	rs4899872	chr14:85983847	A/C	cg10406690	chr14:85995726	FLRT2	0.4	5.28	0.33	2.93e-7	Menarche (age at onset);
SARC	cis	rs2204008	0.775	rs8186812	chr12:38305055	C/T	cg13010199	chr12:38710504	ALG10B	0.78	10.85	0.58	1.81e-22	Bladder cancer;
SARC	cis	rs28374715	0.662	rs28382348	chr15:41487934	G/C	cg18705301	chr15:41695430	NDUFAF1	-1.0	-13.58	-0.66	2.57e-31	Ulcerative colitis;
SARC	cis	rs3126085	1.000	rs4845756	chr1:152254919	T/A	cg03465714	chr1:152285911	FLG	-0.46	-5.55	-0.34	7.61e-8	Atopic dermatitis;
SARC	cis	rs10754283	0.967	rs10737706	chr1:90112579	G/T	cg21401794	chr1:90099060	LRRC8C	0.62	8.55	0.49	1.68e-15	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs7264396	0.563	rs2425130	chr20:34335059	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	5.32	0.33	2.49e-7	Total cholesterol levels;
SARC	cis	rs4555082	0.957	rs3825762	chr14:105752404	T/C	cg06808227	chr14:105710500	BRF1	-0.54	-7.33	-0.43	3.87e-12	Mean platelet volume;Platelet distribution width;
SARC	cis	rs1348850	0.513	rs6730406	chr2:178492722	C/T	cg23306229	chr2:178417860	TTC30B	0.54	5.72	0.35	3.22e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs10949834	0.517	rs810536	chr7:73504233	G/A	cg07137043	chr7:73588983	EIF4H	0.54	6.36	0.38	1.06e-9	Verbal memory performance (residualized delayed recall change);
SARC	cis	rs453301	0.658	rs9650616	chr8:8869199	T/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-5.27	-0.33	3.18e-7	Joint mobility (Beighton score);
SARC	cis	rs11098499	0.954	rs10518328	chr4:120401779	G/A	cg24375607	chr4:120327624	NA	0.41	4.94	0.31	1.47e-6	Corneal astigmatism;
SARC	cis	rs9393692	0.905	rs6940237	chr6:26282322	T/C	cg13736514	chr6:26305472	NA	-0.61	-8.57	-0.49	1.47e-15	Educational attainment;
SARC	cis	rs6665290	0.904	rs1343744	chr1:227183022	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.09	-24.43	-0.85	3.44e-66	Myeloid white cell count;
SARC	cis	rs9815354	1.000	rs6599179	chr3:41855284	C/T	cg03022575	chr3:42003672	ULK4	0.57	5.37	0.33	1.87e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6568686	0.527	rs174396	chr6:111919334	A/G	cg15721981	chr6:111408429	SLC16A10	0.61	5.13	0.32	5.98e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs3126085	0.877	rs4457589	chr1:152247860	T/C	cg26876637	chr1:152193138	HRNR	0.45	5.21	0.32	4.07e-7	Atopic dermatitis;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg21602955	chr2:234763447	HJURP	-0.51	-6.23	-0.38	2.12e-9	Height;
SARC	cis	rs13256369	1.000	rs885000	chr8:8568875	G/T	cg17143192	chr8:8559678	CLDN23	0.52	6.0	0.37	7.31e-9	Obesity-related traits;
SARC	cis	rs2295359	1.000	rs736197	chr1:67607135	G/T	cg03340356	chr1:67600835	NA	0.34	4.97	0.31	1.31e-6	Psoriasis;
SARC	cis	rs9858542	0.953	rs11715915	chr3:49455330	A/G	cg07274523	chr3:49395745	GPX1	-0.46	-5.19	-0.32	4.62e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg15145296	chr3:125709740	NA	-0.51	-4.95	-0.31	1.44e-6	Blood pressure (smoking interaction);
SARC	cis	rs9398803	0.687	rs1269195	chr6:127031550	C/T	cg20229609	chr6:126660872	C6orf173	-0.35	-5.09	-0.32	7.54e-7	Male-pattern baldness;
SARC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg09373136	chr17:61933544	TCAM1	-0.45	-6.2	-0.38	2.48e-9	Prudent dietary pattern;
SARC	cis	rs4919694	1.000	rs12257935	chr10:104803062	C/A	cg04362960	chr10:104952993	NT5C2	0.65	5.56	0.34	7.45e-8	Arsenic metabolism;
SARC	cis	rs7582720	1.000	rs72936326	chr2:204054141	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	7.88	0.46	1.21e-13	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs3768617	0.510	rs10911249	chr1:183080690	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.8e-21	Fuchs's corneal dystrophy;
SARC	cis	rs1784581	0.507	rs1790020	chr6:162366266	C/T	cg17173639	chr6:162384350	PARK2	-0.45	-5.75	-0.35	2.8e-8	Itch intensity from mosquito bite;
SARC	cis	rs6674176	0.628	rs4660759	chr1:44432500	C/G	cg12908607	chr1:44402522	ARTN	-0.38	-6.51	-0.39	4.63e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs80130819	0.748	rs2258342	chr12:48690363	T/C	cg24011408	chr12:48396354	COL2A1	0.54	6.02	0.37	6.86e-9	Prostate cancer;
SARC	cis	rs8084125	1.000	rs62105176	chr18:74949427	A/G	cg07390210	chr18:74961196	GALR1	0.63	5.76	0.35	2.63e-8	Obesity-related traits;
SARC	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.46	-5.87	-0.36	1.53e-8	Gut microbiome composition (summer);
SARC	cis	rs7084402	0.967	rs1658423	chr10:60331627	T/G	cg07615347	chr10:60278583	BICC1	0.53	7.57	0.44	8.7e-13	Refractive error;
SARC	cis	rs8067545	1.000	rs4925067	chr17:19921222	C/G	cg13482628	chr17:19912719	NA	0.7	10.0	0.55	7.86e-20	Schizophrenia;
SARC	cis	rs2204008	0.805	rs7296063	chr12:37964775	T/G	cg26384229	chr12:38710491	ALG10B	0.9	13.37	0.66	1.22e-30	Bladder cancer;
SARC	cis	rs995000	0.783	rs993013	chr1:63111069	G/T	cg06896770	chr1:63153194	DOCK7	-0.92	-13.8	-0.67	4.64e-32	Triglyceride levels;
SARC	cis	rs921968	0.565	rs1541777	chr2:219587291	A/G	cg02176678	chr2:219576539	TTLL4	-0.33	-5.07	-0.32	8.2e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg10150615	chr22:24372951	LOC391322	0.45	4.96	0.31	1.37e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg08564027	chr20:61660810	NA	0.76	11.8	0.61	1.69e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs11168187	0.891	rs7133585	chr12:48128410	G/A	cg12761788	chr12:48120090	P11	0.39	4.99	0.31	1.19e-6	Vertical cup-disc ratio;
SARC	cis	rs11711311	0.911	rs9831422	chr3:113398195	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	8.19	0.47	1.72e-14	IgG glycosylation;
SARC	cis	rs4295623	0.553	rs11250163	chr8:11596437	G/T	cg00262122	chr8:11665843	FDFT1	0.47	5.67	0.35	4.28e-8	Morning vs. evening chronotype;
SARC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg06873352	chr17:61820015	STRADA	0.53	6.86	0.41	6.23e-11	Prudent dietary pattern;
SARC	cis	rs611744	0.647	rs13280487	chr8:109270263	G/C	cg21045802	chr8:109455806	TTC35	0.58	7.42	0.44	2.22e-12	Dupuytren's disease;
SARC	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg13877915	chr19:58951672	ZNF132	0.65	9.62	0.53	1.15e-18	Uric acid clearance;
SARC	cis	rs6120849	0.754	rs6088667	chr20:33566722	A/C	cg24642439	chr20:33292090	TP53INP2	0.58	5.75	0.35	2.84e-8	Protein C levels;
SARC	cis	rs57506017	0.561	rs3800847	chr7:12262242	G/A	cg23422036	chr7:12250390	TMEM106B	0.49	6.41	0.39	8.02e-10	Neuroticism;
SARC	cis	rs10463316	0.862	rs1983171	chr5:150778691	A/G	cg03212797	chr5:150827313	SLC36A1	-0.52	-6.13	-0.37	3.74e-9	Metabolite levels (Pyroglutamine);
SARC	trans	rs61931739	0.500	rs7295779	chr12:34460652	T/C	cg13010199	chr12:38710504	ALG10B	0.75	10.58	0.57	1.32e-21	Morning vs. evening chronotype;
SARC	cis	rs7481584	0.517	rs80872	chr11:3049984	G/T	cg05729581	chr11:3078854	CARS	0.57	7.4	0.44	2.45e-12	Calcium levels;
SARC	cis	rs6496667	1.000	rs3803539	chr15:90891982	A/G	cg22089800	chr15:90895588	ZNF774	0.53	4.88	0.3	1.98e-6	Rheumatoid arthritis;
SARC	cis	rs2976388	0.609	rs1594999	chr8:143790574	G/A	cg06565975	chr8:143823917	SLURP1	0.31	5.36	0.33	2.02e-7	Urinary tract infection frequency;
SARC	cis	rs912057	1.000	rs1294410	chr6:6738752	C/T	cg06612196	chr6:6737390	NA	-0.63	-9.29	-0.52	1.11e-17	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs9303401	0.538	rs2240259	chr17:56458129	A/C	cg25039879	chr17:56429692	SUPT4H1	0.63	5.54	0.34	7.99e-8	Cognitive test performance;
SARC	cis	rs2652834	0.904	rs7175602	chr15:63367032	T/C	cg05507819	chr15:63340323	TPM1	-0.62	-6.46	-0.39	5.98e-10	HDL cholesterol;
SARC	cis	rs9926296	0.744	rs164746	chr16:89709019	C/T	cg08949735	chr16:89699720	DPEP1	-0.34	-5.29	-0.33	2.75e-7	Vitiligo;
SARC	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg11764359	chr7:65958608	NA	0.65	7.58	0.44	7.92e-13	Aortic root size;
SARC	cis	rs4588572	0.643	rs10063319	chr5:77758425	T/C	cg11547950	chr5:77652471	NA	-0.41	-5.03	-0.31	9.75e-7	Triglycerides;
SARC	cis	rs79976124	0.879	rs78012385	chr6:66618091	G/A	cg07460842	chr6:66804631	NA	0.63	6.71	0.4	1.48e-10	Type 2 diabetes;
SARC	cis	rs6815814	0.731	rs66735315	chr4:38774180	G/T	cg06935464	chr4:38784597	TLR10	0.5	5.19	0.32	4.66e-7	Breast cancer;
SARC	cis	rs8031584	0.918	rs1425292	chr15:31285422	G/A	cg19680485	chr15:31195859	MTMR15	-0.56	-6.37	-0.39	9.93e-10	Huntington's disease progression;
SARC	cis	rs2933343	0.679	rs789254	chr3:128574593	A/G	cg24203234	chr3:128598194	ACAD9	0.63	8.02	0.47	5.12e-14	IgG glycosylation;
SARC	cis	rs8180040	0.726	rs7625070	chr3:47095518	A/G	cg27129171	chr3:47204927	SETD2	0.68	9.56	0.53	1.82e-18	Colorectal cancer;
SARC	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg05861140	chr6:150128134	PCMT1	-0.42	-5.45	-0.34	1.3e-7	Lung cancer;
SARC	cis	rs7264396	0.563	rs2425136	chr20:34344782	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.59	5.06	0.31	8.45e-7	Total cholesterol levels;
SARC	cis	rs3096299	0.838	rs3102384	chr16:89411661	T/G	cg02187348	chr16:89574699	SPG7	0.37	4.85	0.3	2.27e-6	Multiple myeloma (IgH translocation);
SARC	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg00149659	chr3:10157352	C3orf10	0.69	6.9	0.41	4.76e-11	Alzheimer's disease;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg16415121	chr6:88299659	ORC3L;RARS2	0.5	6.77	0.41	1.07e-10	Tetralogy of Fallot;
SARC	cis	rs12926788	0.689	rs1862450	chr16:24856775	A/G	cg00152838	chr16:24741724	TNRC6A	0.5	5.1	0.32	7.12e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs12190007	0.604	rs7382308	chr6:169732276	A/C	cg16388071	chr6:169726476	NA	-0.44	-6.33	-0.38	1.27e-9	Obesity-related traits;
SARC	cis	rs796364	1.000	rs11680723	chr2:200810957	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-5.93	-0.36	1.07e-8	Schizophrenia;
SARC	cis	rs4713118	0.540	rs469227	chr6:27970705	A/C	cg26335602	chr6:28129616	ZNF389	0.48	5.22	0.32	4.01e-7	Parkinson's disease;
SARC	cis	rs13082711	0.522	rs6551192	chr3:27343376	C/T	cg02860705	chr3:27208620	NA	0.42	5.7	0.35	3.54e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs4481887	0.927	rs4244184	chr1:248486895	G/T	cg01631408	chr1:248437212	OR2T33	-0.38	-4.74	-0.3	3.75e-6	Common traits (Other);
SARC	cis	rs7178572	0.568	rs11630689	chr15:77520094	C/T	cg22256960	chr15:77711686	NA	-0.5	-5.52	-0.34	8.84e-8	Type 2 diabetes;
SARC	trans	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg21659725	chr3:3221576	CRBN	-0.8	-12.22	-0.62	7.07e-27	Intelligence (multi-trait analysis);
SARC	cis	rs6582630	0.576	rs4882372	chr12:38356609	C/A	cg14851346	chr12:38532713	NA	-0.47	-5.62	-0.35	5.4e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2777491	0.915	rs7178777	chr15:41634588	C/A	cg01768344	chr15:41576519	LOC729082	0.45	4.97	0.31	1.31e-6	Ulcerative colitis;
SARC	cis	rs3768617	0.510	rs2333621	chr1:183090751	A/G	cg13390022	chr1:182993471	LAMC1	0.32	4.83	0.3	2.44e-6	Fuchs's corneal dystrophy;
SARC	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg10523679	chr1:76189770	ACADM	-0.5	-5.9	-0.36	1.26e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs600231	0.665	rs1626021	chr11:65226187	A/G	cg17120908	chr11:65337727	SSSCA1	-0.41	-5.32	-0.33	2.4e-7	Bone mineral density;
SARC	cis	rs1035144	0.505	rs2268459	chr14:81463041	A/G	cg06600135	chr14:81408086	NA	-0.47	-5.95	-0.36	9.92e-9	Male sexual orientation;
SARC	cis	rs13314892	0.802	rs62250980	chr3:69844608	G/A	cg17445875	chr3:69859618	MITF	-0.47	-4.78	-0.3	3.17e-6	QRS complex (12-leadsum);
SARC	cis	rs35123781	0.696	rs356433	chr5:139071193	C/T	cg10513866	chr5:139070639	NA	0.37	5.06	0.31	8.39e-7	Schizophrenia;
SARC	cis	rs7818688	0.697	rs2904889	chr8:95940598	T/G	cg13393036	chr8:95962371	TP53INP1	0.44	5.04	0.31	9.14e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs9398803	0.687	rs9491652	chr6:126943620	G/C	cg19875578	chr6:126661172	C6orf173	0.63	8.72	0.5	5.29e-16	Male-pattern baldness;
SARC	cis	rs7829975	0.711	rs1039916	chr8:8685854	A/G	cg08975724	chr8:8085496	FLJ10661	0.46	5.78	0.35	2.39e-8	Mood instability;
SARC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg20102877	chr2:27665638	KRTCAP3	-0.37	-5.25	-0.33	3.44e-7	Total body bone mineral density;
SARC	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg02733842	chr7:1102375	C7orf50	-0.42	-5.1	-0.32	7e-7	Bronchopulmonary dysplasia;
SARC	cis	rs10791097	0.694	rs1893018	chr11:130756632	T/C	cg12179176	chr11:130786555	SNX19	0.76	11.42	0.6	2.89e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs2153535	0.580	rs1932284	chr6:8477694	A/T	cg23788917	chr6:8435910	SLC35B3	0.62	8.24	0.48	1.23e-14	Motion sickness;
SARC	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg20607798	chr8:58055168	NA	0.55	5.12	0.32	6.52e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg11573308	chr7:2025483	MAD1L1	-0.48	-6.35	-0.38	1.14e-9	Electrocardiographic conduction measures;
SARC	cis	rs11756659	0.653	rs62394537	chr6:25963943	G/A	cg00631329	chr6:26305371	NA	-0.56	-5.66	-0.35	4.53e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;Red cell distribution width;
SARC	cis	rs35110281	0.632	rs9306160	chr21:45107562	T/C	cg01579765	chr21:45077557	HSF2BP	-0.38	-6.09	-0.37	4.6e-9	Mean corpuscular volume;
SARC	cis	rs950169	0.845	rs4106951	chr15:84833394	C/G	cg17507749	chr15:85114479	UBE2QP1	0.77	9.1	0.51	4.21e-17	Schizophrenia;
SARC	cis	rs453301	0.624	rs6987558	chr8:8862521	C/G	cg06636001	chr8:8085503	FLJ10661	0.44	5.66	0.35	4.38e-8	Joint mobility (Beighton score);
SARC	cis	rs2228479	0.717	rs11644967	chr16:89806614	T/A	cg06558623	chr16:89946397	TCF25	0.75	5.95	0.36	9.99e-9	Skin colour saturation;
SARC	cis	rs4566357	0.615	rs3769645	chr2:227913717	A/G	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.95	-0.36	9.79e-9	Coronary artery disease;
SARC	cis	rs910316	1.000	rs175492	chr14:75545220	A/C	cg08847533	chr14:75593920	NEK9	0.84	13.98	0.68	1.14e-32	Height;
SARC	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg02018176	chr4:1364513	KIAA1530	-0.34	-4.89	-0.31	1.85e-6	Obesity-related traits;
SARC	cis	rs796364	0.806	rs74938253	chr2:201008386	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.66	-6.39	-0.39	8.99e-10	Schizophrenia;
SARC	cis	rs919433	0.679	rs7564924	chr2:198513877	C/T	cg00792783	chr2:198669748	PLCL1	0.42	4.83	0.3	2.43e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
SARC	cis	rs73206853	0.688	rs56691704	chr12:110568623	A/G	cg10860002	chr12:110842031	ANAPC7	0.68	5.44	0.34	1.35e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs7223966	0.921	rs34699959	chr17:61960720	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.46	4.97	0.31	1.32e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs12971120	0.891	rs71359051	chr18:72169723	G/A	cg25817165	chr18:72167213	CNDP2	-0.53	-7.59	-0.45	7.66e-13	Refractive error;
SARC	cis	rs11770686	0.659	rs2705809	chr7:75305572	A/G	cg07211516	chr7:75296079	HIP1	-0.35	-4.78	-0.3	3.12e-6	Essential tremor;
SARC	cis	rs2732480	0.577	rs2634681	chr12:48733084	C/T	cg21466736	chr12:48725269	NA	0.32	4.97	0.31	1.28e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	11.37	0.6	3.9e-24	Platelet count;
SARC	cis	rs2735413	0.918	rs36068555	chr16:78077082	G/A	cg04733911	chr16:78082701	NA	-0.31	-5.61	-0.34	5.78e-8	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs2295359	0.892	rs11209005	chr1:67618678	A/G	cg11235152	chr1:67600687	NA	0.52	7.13	0.42	1.26e-11	Psoriasis;
SARC	cis	rs751728	0.717	rs3763260	chr6:33774070	C/T	cg15252951	chr6:33757062	LEMD2	0.45	4.83	0.3	2.42e-6	Crohn's disease;
SARC	cis	rs12950390	0.512	rs72831681	chr17:45847174	C/G	cg03474202	chr17:45855739	NA	-0.42	-5.13	-0.32	6e-7	IgG glycosylation;
SARC	cis	rs7666738	0.830	rs28785514	chr4:98959135	G/A	cg05340658	chr4:99064831	C4orf37	0.66	9.0	0.51	8.07e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg09373136	chr17:61933544	TCAM1	-0.48	-6.47	-0.39	5.66e-10	Prudent dietary pattern;
SARC	cis	rs2070997	0.667	rs12156431	chr9:133719540	A/G	cg11464064	chr9:133710261	ABL1	0.6	5.84	0.36	1.78e-8	Response to amphetamines;
SARC	cis	rs11578119	0.933	rs1412890	chr1:170413406	C/T	cg09767346	chr1:170501363	GORAB	0.41	4.84	0.3	2.41e-6	Male-pattern baldness;
SARC	cis	rs11711311	1.000	rs10934243	chr3:113430239	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	8.69	0.49	6.66e-16	IgG glycosylation;
SARC	cis	rs2645694	0.911	rs2703147	chr4:77831307	C/T	cg06046430	chr4:77819534	ANKRD56	0.43	5.99	0.37	7.87e-9	Emphysema distribution in smoking;
SARC	cis	rs12136530	0.593	rs11578302	chr1:19724835	A/G	cg18923740	chr1:19971790	NBL1	0.29	4.85	0.3	2.26e-6	Lead levels in blood;
SARC	trans	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg00938859	chr5:1591904	SDHAP3	0.79	7.66	0.45	5.1e-13	Breast cancer;
SARC	cis	rs12586317	0.534	rs1568200	chr14:35419592	C/T	cg16230307	chr14:35515116	FAM177A1	0.78	9.51	0.53	2.53e-18	Psoriasis;
SARC	cis	rs1580019	0.587	rs2392069	chr7:32547154	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.61	7.95	0.46	7.96e-14	Cognitive ability;
SARC	cis	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg11266682	chr4:10021025	SLC2A9	0.41	7.29	0.43	4.75e-12	Bone mineral density;
SARC	cis	rs7644634	0.531	rs3821488	chr3:105410694	C/T	cg23051926	chr3:105466016	CBLB	0.47	5.38	0.33	1.84e-7	Itch intensity from mosquito bite;
SARC	trans	rs12310956	0.515	rs11052934	chr12:33970381	T/C	cg26384229	chr12:38710491	ALG10B	0.73	10.31	0.56	8.93e-21	Morning vs. evening chronotype;
SARC	cis	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg25894440	chr7:65020034	NA	-0.73	-5.31	-0.33	2.5e-7	Diabetic kidney disease;
SARC	cis	rs4660306	1.000	rs6667191	chr1:45982844	A/G	cg24296786	chr1:45957014	TESK2	0.59	6.88	0.41	5.37e-11	Homocysteine levels;
SARC	cis	rs2404602	0.622	rs11632365	chr15:77139080	G/A	cg15268244	chr15:77196840	NA	0.44	4.85	0.3	2.25e-6	Blood metabolite levels;
SARC	cis	rs7772486	0.754	rs1415747	chr6:146077249	A/G	cg23711669	chr6:146136114	FBXO30	0.89	15.28	0.71	5.49e-37	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9486715	0.838	rs9320127	chr6:96865358	G/A	cg18709589	chr6:96969512	KIAA0776	0.54	6.66	0.4	1.95e-10	Headache;
SARC	cis	rs2273669	0.667	rs28504359	chr6:109330417	C/T	cg05315195	chr6:109294784	ARMC2	-0.63	-5.7	-0.35	3.6e-8	Prostate cancer;
SARC	cis	rs12911832	0.727	rs682619	chr15:59098773	T/C	cg05156742	chr15:59063176	FAM63B	0.71	10.06	0.55	5.21e-20	Schizophrenia;
SARC	trans	rs656319	0.702	rs477860	chr8:9811765	T/C	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.02	-0.42	2.34e-11	Myopia (pathological);
SARC	cis	rs7829975	0.617	rs4841072	chr8:8791253	C/A	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.8	-0.41	8.56e-11	Mood instability;
SARC	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg00800038	chr16:89945340	TCF25	-0.66	-5.63	-0.35	5.07e-8	Skin colour saturation;
SARC	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg22168489	chr12:122356033	WDR66	0.62	9.7	0.54	6.59e-19	Mean corpuscular volume;
SARC	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg21724239	chr8:58056113	NA	0.58	5.94	0.36	1.02e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.13	0.37	3.73e-9	Prudent dietary pattern;
SARC	cis	rs7624766	0.714	rs7640348	chr3:160515470	A/G	cg22637730	chr3:160473554	PPM1L	0.44	5.72	0.35	3.27e-8	Response to methotrexate in rheumatoid arthritis;
SARC	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg09455208	chr3:40491958	NA	0.4	5.9	0.36	1.29e-8	Renal cell carcinoma;
SARC	cis	rs2276314	0.857	rs9304155	chr18:33585710	A/C	cg05985134	chr18:33552581	C18orf21	0.71	7.39	0.44	2.58e-12	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs9788682	1.000	rs12438181	chr15:78812098	G/A	cg06917634	chr15:78832804	PSMA4	-0.58	-6.45	-0.39	6.34e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs11874712	0.899	rs56075249	chr18:43670863	T/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.53	6.35	0.38	1.14e-9	Migraine - clinic-based;
SARC	trans	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg00938859	chr5:1591904	SDHAP3	0.79	7.66	0.45	5.1e-13	Breast cancer;
SARC	cis	rs7662987	0.517	rs1154410	chr4:100006645	A/G	cg12011299	chr4:100065546	ADH4	0.34	5.63	0.35	5.28e-8	Smoking initiation;
SARC	cis	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg20965017	chr5:231967	SDHA	-0.55	-5.28	-0.33	2.98e-7	Breast cancer;
SARC	cis	rs666930	0.519	rs532303	chr1:120265444	A/G	cg19096424	chr1:120255104	PHGDH	0.83	10.19	0.56	2.11e-20	Breast cancer;
SARC	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg19223190	chr17:80058835	NA	-0.45	-6.47	-0.39	5.74e-10	Life satisfaction;
SARC	cis	rs9303401	0.614	rs7215900	chr17:56654850	A/T	cg25039879	chr17:56429692	SUPT4H1	0.63	5.63	0.35	5.1e-8	Cognitive test performance;
SARC	cis	rs11608355	1.000	rs10774695	chr12:109868040	G/A	cg05360138	chr12:110035743	NA	0.45	5.14	0.32	5.73e-7	Neuroticism;
SARC	cis	rs7917772	0.532	rs10748829	chr10:104527244	G/A	ch.10.2196322F	chr10:104248062	ACTR1A	-0.47	-5.52	-0.34	8.81e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs9790314	1.000	rs1478565	chr3:161027464	C/T	cg04691961	chr3:161091175	C3orf57	-0.79	-11.53	-0.6	1.27e-24	Morning vs. evening chronotype;
SARC	cis	rs8523	0.774	rs60273772	chr6:11075152	T/C	cg13562911	chr6:11044106	ELOVL2	0.46	6.14	0.37	3.52e-9	Red blood cell fatty acid levels;
SARC	cis	rs2228479	0.867	rs62056110	chr16:89946388	A/C	cg00800038	chr16:89945340	TCF25	-0.72	-5.75	-0.35	2.8e-8	Skin colour saturation;
SARC	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-5.96	-0.36	9.37e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6570726	0.846	rs426874	chr6:145880630	A/C	cg23711669	chr6:146136114	FBXO30	0.76	12.11	0.62	1.62e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2120243	0.539	rs1456105	chr3:157123461	A/C	cg24825693	chr3:157122686	VEPH1	-0.46	-6.45	-0.39	6.37e-10	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs941408	0.515	rs878893	chr19:2781325	A/G	cg06609049	chr19:2785107	THOP1	0.98	15.12	0.7	1.88e-36	Total cholesterol levels;
SARC	cis	rs4561483	0.801	rs8061189	chr16:11951749	C/G	cg08843971	chr16:11963173	GSPT1	0.44	5.44	0.34	1.38e-7	Testicular germ cell tumor;
SARC	cis	rs9859260	0.744	rs539816	chr3:195784076	T/A	cg03462622	chr3:195777018	TFRC	-0.46	-5.38	-0.33	1.81e-7	Mean corpuscular volume;
SARC	cis	rs11098499	0.775	rs10021601	chr4:120282563	G/A	cg09307838	chr4:120376055	NA	0.83	11.82	0.61	1.46e-25	Corneal astigmatism;
SARC	cis	rs13082711	0.911	rs2131205	chr3:27428501	A/G	cg02860705	chr3:27208620	NA	0.43	5.77	0.35	2.51e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs7647973	1.000	rs62259947	chr3:49439924	T/C	cg07636037	chr3:49044803	WDR6	-0.74	-7.53	-0.44	1.08e-12	Menarche (age at onset);
SARC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg05313129	chr8:58192883	C8orf71	-0.51	-4.96	-0.31	1.37e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg06969265	chr17:73775802	H3F3B	0.62	6.74	0.4	1.21e-10	Psoriasis;
SARC	cis	rs832540	0.931	rs702679	chr5:56221328	A/G	cg14703610	chr5:56206110	C5orf35	0.52	6.57	0.4	3.21e-10	Coronary artery disease;
SARC	cis	rs9549260	0.755	rs9549236	chr13:41147158	C/T	cg21288729	chr13:41239152	FOXO1	-0.55	-6.8	-0.41	8.47e-11	Red blood cell count;
SARC	trans	rs7824557	0.564	rs2043508	chr8:11227406	G/A	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.45	-0.39	6.23e-10	Retinal vascular caliber;
SARC	cis	rs60871478	0.947	rs62432255	chr7:804219	G/A	cg05535760	chr7:792225	HEATR2	0.77	7.94	0.46	8.38e-14	Cerebrospinal P-tau181p levels;
SARC	cis	rs7712401	0.791	rs154507	chr5:122200907	C/G	cg19412675	chr5:122181750	SNX24	-0.4	-5.32	-0.33	2.46e-7	Mean platelet volume;
SARC	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg03709012	chr19:19516395	GATAD2A	-0.93	-15.05	-0.7	3.29e-36	Tonsillectomy;
SARC	cis	rs654950	0.934	rs662999	chr1:42001160	A/C	cg06885757	chr1:42089581	HIVEP3	0.4	5.6	0.34	5.9e-8	Airway imaging phenotypes;
SARC	cis	rs11098499	0.954	rs71614438	chr4:120371252	G/A	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs2153535	0.580	rs1414348	chr6:8471940	A/G	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	cis	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg24110177	chr3:50126178	RBM5	0.57	7.71	0.45	3.66e-13	Intelligence (multi-trait analysis);
SARC	cis	rs7429990	0.965	rs7649981	chr3:47999337	T/A	cg11946769	chr3:48343235	NME6	0.46	5.39	0.33	1.75e-7	Educational attainment (years of education);
SARC	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg21782813	chr7:2030301	MAD1L1	0.48	7.73	0.45	3.16e-13	Bipolar disorder and schizophrenia;
SARC	cis	rs7000551	0.689	rs4872000	chr8:22337323	G/T	cg12081754	chr8:22256438	SLC39A14	0.57	7.91	0.46	1.01e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs6582630	0.502	rs12815350	chr12:38439921	A/T	cg26384229	chr12:38710491	ALG10B	0.82	10.95	0.58	9.1e-23	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7870753	0.786	rs7031099	chr9:99245690	T/C	cg25260653	chr9:99212216	HABP4	0.51	4.77	0.3	3.21e-6	Height;
SARC	cis	rs7769051	1.000	rs9399041	chr6:133096233	T/G	cg22852734	chr6:133119734	C6orf192	1.14	11.76	0.61	2.32e-25	Type 2 diabetes nephropathy;
SARC	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg02725872	chr8:58115012	NA	-0.36	-5.42	-0.33	1.5e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs561341	0.714	rs547473	chr17:30297560	T/G	cg20587970	chr11:113659929	NA	-1.26	-12.41	-0.63	1.72e-27	Hip circumference adjusted for BMI;
SARC	cis	rs6991838	0.557	rs67685675	chr8:66486606	T/C	cg13398993	chr8:66546079	ARMC1	-0.62	-8.36	-0.48	5.88e-15	Intelligence (multi-trait analysis);
SARC	cis	rs477692	1.000	rs580745	chr10:131414401	G/A	cg05714579	chr10:131428358	MGMT	0.57	7.49	0.44	1.4e-12	Response to temozolomide;
SARC	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg03806693	chr22:41940476	POLR3H	-1.01	-13.93	-0.67	1.68e-32	Vitiligo;
SARC	cis	rs7818345	0.967	rs11204040	chr8:19288525	T/A	cg11303988	chr8:19266685	CSGALNACT1	0.43	5.82	0.36	1.95e-8	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs9399137	0.507	rs61738647	chr6:135282735	T/C	cg22676075	chr6:135203613	NA	0.4	5.1	0.32	6.93e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs459571	0.839	rs10993895	chr9:136887726	C/T	cg01294253	chr9:136912663	BRD3	-0.4	-5.38	-0.33	1.83e-7	Platelet distribution width;
SARC	cis	rs7123876	0.587	rs11602616	chr11:72364077	T/C	cg03713592	chr11:72463424	ARAP1	0.56	5.08	0.32	7.89e-7	Body mass index;
SARC	cis	rs7945705	0.818	rs1988708	chr11:8882893	C/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-6.85	-0.41	6.45e-11	Hemoglobin concentration;
SARC	cis	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg05623727	chr3:50126028	RBM5	0.32	4.87	0.3	2.06e-6	Intelligence (multi-trait analysis);
SARC	cis	rs77372450	0.551	rs6872995	chr5:157045629	G/C	cg05585991	chr5:157099197	C5orf52	0.54	5.38	0.33	1.85e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg00684032	chr4:1343700	KIAA1530	0.37	5.33	0.33	2.28e-7	Obesity-related traits;
SARC	trans	rs1814175	0.533	rs4528310	chr11:49983106	C/A	cg03929089	chr4:120376271	NA	-0.82	-11.88	-0.61	9.2e-26	Height;
SARC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	12.4	0.63	1.87e-27	Platelet count;
SARC	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg09699651	chr6:150184138	LRP11	0.5	6.21	0.38	2.42e-9	Testicular germ cell tumor;
SARC	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg24060327	chr5:131705240	SLC22A5	0.74	9.37	0.52	6.45e-18	Breast cancer;
SARC	cis	rs362272	0.545	rs3129308	chr4:3309272	C/T	cg08741688	chr4:3415352	RGS12	-0.47	-5.93	-0.36	1.07e-8	Serum sulfate level;
SARC	cis	rs847851	0.617	rs9380478	chr6:34960811	A/T	cg13137465	chr6:34857473	ANKS1A	0.6	4.83	0.3	2.48e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1008375	0.931	rs6831211	chr4:17697009	G/A	cg27347728	chr4:17578864	LAP3	0.44	5.67	0.35	4.13e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7429990	0.965	rs2166770	chr3:48005673	A/C	cg11946769	chr3:48343235	NME6	0.45	5.29	0.33	2.82e-7	Educational attainment (years of education);
SARC	cis	rs9858542	0.953	rs34363169	chr3:49537712	G/A	cg07274523	chr3:49395745	GPX1	0.53	6.06	0.37	5.38e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs559928	0.606	rs1011219	chr11:63973396	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.65	-5.17	-0.32	4.95e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg13436679	chr7:64138755	ZNF107	0.51	7.18	0.43	9.32e-12	Thyroid stimulating hormone;
SARC	cis	rs6831352	0.918	rs29001216	chr4:100051556	A/T	cg12011299	chr4:100065546	ADH4	-0.34	-5.74	-0.35	2.97e-8	Alcohol dependence;
SARC	cis	rs782590	0.967	rs1975484	chr2:55803167	T/A	cg18811423	chr2:55921094	PNPT1	0.68	10.53	0.57	1.78e-21	Metabolic syndrome;
SARC	cis	rs9303401	0.703	rs8077052	chr17:57208921	T/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.69	8.22	0.47	1.44e-14	Cognitive test performance;
SARC	cis	rs9733	0.519	rs7529194	chr1:150622620	A/T	cg15448220	chr1:150897856	SETDB1	0.44	5.88	0.36	1.41e-8	Tonsillectomy;
SARC	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg06697600	chr4:7070879	GRPEL1	-0.36	-4.77	-0.3	3.25e-6	Monocyte percentage of white cells;
SARC	cis	rs763121	0.853	rs5750659	chr22:39068789	T/C	cg06022373	chr22:39101656	GTPBP1	0.86	10.88	0.58	1.41e-22	Menopause (age at onset);
SARC	cis	rs34421088	0.560	rs2245250	chr8:11400680	G/A	cg21775007	chr8:11205619	TDH	-0.4	-5.01	-0.31	1.08e-6	Neuroticism;
SARC	cis	rs2997447	0.846	rs2997445	chr1:26390154	C/T	cg19633962	chr1:26362018	EXTL1	-0.57	-4.85	-0.3	2.25e-6	QRS complex (12-leadsum);
SARC	cis	rs2115630	0.691	rs61322921	chr15:85163638	T/C	cg12501888	chr15:85177176	SCAND2	-0.5	-5.84	-0.36	1.73e-8	P wave terminal force;
SARC	cis	rs8180040	0.620	rs749511	chr3:47035735	A/C	cg27129171	chr3:47204927	SETD2	-0.7	-9.74	-0.54	5.05e-19	Colorectal cancer;
SARC	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg12310025	chr6:25882481	NA	-0.45	-5.76	-0.35	2.66e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2439831	0.867	rs2927072	chr15:43922398	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	8.21	0.47	1.53e-14	Lung cancer in ever smokers;
SARC	cis	rs526231	0.578	rs3776870	chr5:102295070	G/A	cg23492399	chr5:102201601	PAM	-0.47	-5.66	-0.35	4.35e-8	Primary biliary cholangitis;
SARC	cis	rs9815354	0.812	rs73069203	chr3:41938767	T/C	cg03022575	chr3:42003672	ULK4	0.7	5.7	0.35	3.66e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs651907	0.535	rs35799195	chr3:101521927	A/G	cg12386194	chr3:101231763	SENP7	0.46	5.22	0.32	4e-7	Colorectal cancer;
SARC	cis	rs734999	0.545	rs7368072	chr1:2556125	C/T	cg18854424	chr1:2615690	NA	0.31	4.87	0.3	2.09e-6	Ulcerative colitis;
SARC	cis	rs3754214	0.823	rs10888579	chr1:150261925	C/T	cg09579323	chr1:150459698	TARS2	-0.4	-4.96	-0.31	1.34e-6	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9486719	0.895	rs12195315	chr6:96905711	T/G	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.01	-0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13983893	chr1:91966802	CDC7	-0.51	-6.34	-0.38	1.2e-9	Smoking initiation;
SARC	cis	rs10193935	0.901	rs12615383	chr2:42610551	A/G	cg27598129	chr2:42591480	NA	0.43	6.01	0.37	7.25e-9	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6964587	0.967	rs10953063	chr7:91576958	A/G	cg17063962	chr7:91808500	NA	-0.94	-15.25	-0.71	6.82e-37	Breast cancer;
SARC	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg27541892	chr1:1571801	CDK11B	0.4	5.33	0.33	2.3e-7	Body mass index;
SARC	cis	rs929354	0.772	rs7778193	chr7:156980087	C/T	cg05182265	chr7:156933206	UBE3C	-0.33	-5.05	-0.31	8.89e-7	Body mass index;
SARC	cis	rs709400	1.000	rs7150141	chr14:104129352	G/A	cg26031613	chr14:104095156	KLC1	0.98	18.42	0.77	2.34e-47	Body mass index;
SARC	cis	rs3741404	0.791	rs2282491	chr11:63918373	T/C	cg18225595	chr11:63971243	STIP1	0.55	8.14	0.47	2.44e-14	Platelet count;
SARC	cis	rs8005677	1.000	rs2295683	chr14:23388382	A/C	cg01529538	chr14:23388837	RBM23	0.46	5.72	0.35	3.25e-8	Cognitive ability (multi-trait analysis);
SARC	cis	rs344364	0.511	rs337284	chr16:1954799	A/C	cg26617929	chr16:1858877	NA	-0.66	-5.42	-0.33	1.45e-7	Glomerular filtration rate in chronic kidney disease;
SARC	cis	rs7635838	0.654	rs347585	chr3:11286220	C/T	cg00170343	chr3:11313890	ATG7	0.52	6.44	0.39	6.84e-10	HDL cholesterol;
SARC	cis	rs5753618	0.561	rs5753521	chr22:31638027	T/C	cg02404636	chr22:31891804	SFI1	-0.48	-5.1	-0.32	7e-7	Colorectal cancer;
SARC	cis	rs7666738	0.830	rs11722272	chr4:99000839	C/T	cg05340658	chr4:99064831	C4orf37	0.59	7.81	0.46	1.9e-13	Colonoscopy-negative controls vs population controls;
SARC	cis	rs12216125	0.549	rs9358905	chr6:26077839	T/A	cg10373733	chr6:25993375	NA	0.41	4.98	0.31	1.27e-6	Iron status biomarkers;
SARC	cis	rs16976116	0.901	rs1061821	chr15:55496111	T/C	cg17854078	chr15:55489399	RSL24D1	0.66	6.53	0.39	4.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7772486	0.875	rs2748483	chr6:146335560	A/T	cg05347473	chr6:146136440	FBXO30	-0.46	-6.31	-0.38	1.42e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1669338	0.588	rs4684375	chr3:3170966	T/C	cg16797762	chr3:3221439	CRBN	-0.93	-9.28	-0.52	1.21e-17	White matter integrity;
SARC	cis	rs6912958	0.559	rs242281	chr6:88048916	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	10.92	0.58	1.11e-22	Monocyte percentage of white cells;
SARC	cis	rs453301	0.624	rs2979256	chr8:8871710	C/T	cg11995313	chr8:8860691	ERI1	-0.43	-5.54	-0.34	8.04e-8	Joint mobility (Beighton score);
SARC	cis	rs1864585	0.520	rs17721089	chr8:10705438	C/T	cg21775007	chr8:11205619	TDH	-0.48	-4.88	-0.3	1.97e-6	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
SARC	cis	rs651907	0.535	rs2290859	chr3:101525625	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	6.55	0.39	3.72e-10	Colorectal cancer;
SARC	cis	rs1348850	0.574	rs11691740	chr2:178445161	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.47	-5.02	-0.31	1.04e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs4722166	0.598	rs4722171	chr7:22785717	A/G	cg26061582	chr7:22766209	IL6	0.55	6.11	0.37	4.09e-9	Lung cancer;
SARC	cis	rs6964587	0.967	rs17164315	chr7:91659150	C/G	cg17063962	chr7:91808500	NA	0.93	15.78	0.72	1.19e-38	Breast cancer;
SARC	cis	rs7582720	1.000	rs72934513	chr2:203927587	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.72	0.45	3.5e-13	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs2288912	0.838	rs2239375	chr19:45459851	T/C	cg09555818	chr19:45449301	APOC2	0.56	9.11	0.51	3.97e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs9868809	0.505	rs13316551	chr3:48745167	A/C	cg00383909	chr3:49044727	WDR6	0.65	6.12	0.37	3.88e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs7769051	1.000	rs10484629	chr6:133117870	A/C	cg22852734	chr6:133119734	C6orf192	1.12	11.69	0.61	3.71e-25	Type 2 diabetes nephropathy;
SARC	cis	rs854765	0.583	rs6502627	chr17:17849671	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	9.78	0.54	3.88e-19	Total body bone mineral density;
SARC	cis	rs6942407	0.592	rs6465092	chr7:86750925	A/T	cg02420886	chr7:86849541	C7orf23	0.59	5.41	0.33	1.55e-7	Food allergy;
SARC	cis	rs10078	0.559	rs2671891	chr5:456386	A/G	cg07599136	chr5:415885	AHRR	0.66	5.83	0.36	1.81e-8	Fat distribution (HIV);
SARC	cis	rs1865721	0.682	rs35282535	chr18:73141206	G/A	cg26385618	chr18:73139727	C18orf62	-0.35	-5.04	-0.31	9.37e-7	Intelligence;
SARC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg20069020	chr7:108166782	PNPLA8	0.51	6.25	0.38	1.98e-9	Myopia (pathological);
SARC	cis	rs78456975	1.000	rs13397299	chr2:1564222	A/C	cg26248373	chr2:1572462	NA	-0.59	-6.14	-0.37	3.61e-9	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg00431813	chr7:1051703	C7orf50	-0.33	-4.97	-0.31	1.27e-6	Longevity;Endometriosis;
SARC	cis	rs7481584	0.624	rs449466	chr11:3047603	C/T	cg05729581	chr11:3078854	CARS	0.57	7.42	0.44	2.13e-12	Calcium levels;
SARC	cis	rs2236918	0.710	rs1776138	chr1:242027075	G/A	cg17736920	chr1:242011382	EXO1	0.66	9.02	0.51	7.17e-17	Menopause (age at onset);
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg02567082	chr3:186080180	DGKG	-0.53	-6.53	-0.39	4.09e-10	Blood pressure;
SARC	cis	rs2463822	1.000	rs12279819	chr11:62137245	G/A	cg06239285	chr11:62104954	ASRGL1	-0.86	-8.36	-0.48	5.71e-15	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs7552404	0.731	rs1770887	chr1:76401812	A/G	cg22875332	chr1:76189707	ACADM	-0.41	-4.91	-0.31	1.7e-6	Blood metabolite levels;Acylcarnitine levels;
SARC	trans	rs66573146	0.901	rs55882710	chr4:7030704	G/A	cg07817883	chr1:32538562	TMEM39B	1.34	8.12	0.47	2.78e-14	Granulocyte percentage of myeloid white cells;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg13883939	chr12:118541731	VSIG10	-0.78	-6.51	-0.39	4.6e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs4481887	1.000	rs4481887	chr1:248496863	A/G	cg01631408	chr1:248437212	OR2T33	-0.43	-5.4	-0.33	1.68e-7	Common traits (Other);
SARC	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg23205692	chr1:25664452	TMEM50A	0.4	4.95	0.31	1.42e-6	Erythrocyte sedimentation rate;
SARC	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg05861140	chr6:150128134	PCMT1	-0.37	-4.88	-0.3	2.01e-6	Lung cancer;
SARC	cis	rs4242434	0.819	rs7843128	chr8:22473465	T/C	cg03733263	chr8:22462867	KIAA1967	0.98	16.64	0.74	1.74e-41	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg11644478	chr21:40555479	PSMG1	1.02	14.09	0.68	5.12e-33	Cognitive function;
SARC	cis	rs1044826	1.000	rs13092507	chr3:139152480	A/G	cg15131784	chr3:139108705	COPB2	0.45	5.05	0.31	8.72e-7	Obesity-related traits;
SARC	cis	rs79349575	0.783	rs318095	chr17:46974734	T/C	cg16584676	chr17:46985605	UBE2Z	0.55	6.66	0.4	1.97e-10	Type 2 diabetes;
SARC	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6991838	0.584	rs4737749	chr8:66539907	A/C	cg13398993	chr8:66546079	ARMC1	0.62	8.19	0.47	1.72e-14	Intelligence (multi-trait analysis);
SARC	cis	rs2404602	0.716	rs7164813	chr15:76708066	T/C	cg22467129	chr15:76604101	ETFA	-0.36	-4.86	-0.3	2.15e-6	Blood metabolite levels;
SARC	cis	rs9640161	0.750	rs3800780	chr7:150027284	C/A	cg17279839	chr7:150038598	RARRES2	0.5	6.99	0.42	2.93e-11	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs2408955	0.500	rs12816820	chr12:48558325	A/G	cg24011408	chr12:48396354	COL2A1	0.41	5.02	0.31	1.05e-6	Glycated hemoglobin levels;
SARC	cis	rs1018836	0.923	rs6998150	chr8:91645969	A/C	cg16814680	chr8:91681699	NA	-0.85	-13.93	-0.67	1.68e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	trans	rs11722228	0.508	rs9732	chr4:10076658	T/C	cg26043149	chr18:55253948	FECH	0.7	8.0	0.46	5.88e-14	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs6545883	0.965	rs778752	chr2:61776902	C/G	cg15711740	chr2:61764176	XPO1	-0.45	-5.62	-0.35	5.43e-8	Tuberculosis;
SARC	cis	rs1728785	1.000	rs1645981	chr16:68571648	T/C	cg02972257	chr16:68554789	NA	-0.44	-5.15	-0.32	5.43e-7	Ulcerative colitis;
SARC	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg05896524	chr21:47604654	C21orf56	0.41	4.84	0.3	2.4e-6	Testicular germ cell tumor;
SARC	cis	rs6582630	0.502	rs1607867	chr12:38385463	C/T	cg13010199	chr12:38710504	ALG10B	0.78	10.77	0.58	3.24e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs34792	0.528	rs153800	chr16:15549757	A/G	cg07549590	chr16:15018862	NA	-0.31	-4.76	-0.3	3.41e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	trans	rs61931739	0.857	rs999715	chr12:34143253	G/C	cg26384229	chr12:38710491	ALG10B	0.57	7.66	0.45	4.96e-13	Morning vs. evening chronotype;
SARC	cis	rs2153535	0.580	rs4960413	chr6:8438466	C/T	cg21535247	chr6:8435926	SLC35B3	0.56	7.01	0.42	2.6e-11	Motion sickness;
SARC	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg06618935	chr21:46677482	NA	-0.42	-5.65	-0.35	4.7e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6912958	0.754	rs7762864	chr6:88236213	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-5.76	-0.35	2.65e-8	Monocyte percentage of white cells;
SARC	cis	rs9640161	0.750	rs3735173	chr7:150020526	C/T	cg21361702	chr7:150065534	REPIN1	0.45	4.94	0.31	1.5e-6	Blood protein levels;Circulating chemerin levels;
SARC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg00543658	chr7:30634387	GARS	-0.56	-6.26	-0.38	1.87e-9	Hepatitis;
SARC	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg22535103	chr8:58192502	C8orf71	-0.74	-8.66	-0.49	8.13e-16	Developmental language disorder (linguistic errors);
SARC	cis	rs9473924	0.505	rs9473949	chr6:50909659	T/A	cg14470998	chr6:50812995	TFAP2B	0.75	7.03	0.42	2.26e-11	Body mass index;
SARC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg20007245	chr22:24372913	LOC391322	-0.72	-8.86	-0.5	2.13e-16	Liver enzyme levels (gamma-glutamyl transferase);
SARC	trans	rs61931739	0.517	rs1843735	chr12:34047389	C/G	cg13010199	chr12:38710504	ALG10B	0.68	9.4	0.52	5.41e-18	Morning vs. evening chronotype;
SARC	cis	rs7264396	0.790	rs2425115	chr20:34322418	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-8.44	-0.48	3.47e-15	Total cholesterol levels;
SARC	cis	rs72634258	0.679	rs7523227	chr1:8180097	G/A	cg00042356	chr1:8021962	PARK7	0.59	5.52	0.34	9.08e-8	Inflammatory bowel disease;
SARC	cis	rs2075371	0.611	rs11762920	chr7:134018514	C/T	cg00033643	chr7:134001901	SLC35B4	0.43	5.27	0.33	3.17e-7	Mean platelet volume;
SARC	cis	rs8141529	0.529	rs34718288	chr22:29194797	C/G	cg02153584	chr22:29168773	CCDC117	0.65	6.65	0.4	2.02e-10	Lymphocyte counts;
SARC	cis	rs6450176	0.564	rs6874524	chr5:53343529	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.54	6.4	0.39	8.45e-10	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs113835537	0.935	rs117480267	chr11:66398596	C/T	cg24851651	chr11:66362959	CCS	0.47	5.1	0.32	6.97e-7	Airway imaging phenotypes;
SARC	cis	rs1008375	1.000	rs2109522	chr4:17658645	T/A	cg27347728	chr4:17578864	LAP3	0.47	5.88	0.36	1.42e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg13012494	chr21:47604986	C21orf56	-0.43	-5.05	-0.31	9.11e-7	Testicular germ cell tumor;
SARC	cis	rs2425143	1.000	rs6058311	chr20:34321895	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	5.11	0.32	6.74e-7	Blood protein levels;
SARC	cis	rs651907	0.514	rs55654108	chr3:101425703	A/G	cg12386194	chr3:101231763	SENP7	0.48	5.71	0.35	3.46e-8	Colorectal cancer;
SARC	cis	rs10080237	0.564	rs2490232	chr6:80814802	C/T	cg08355045	chr6:80787529	NA	-0.35	-5.44	-0.34	1.36e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
SARC	cis	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg15556689	chr8:8085844	FLJ10661	0.51	6.25	0.38	1.93e-9	Mood instability;
SARC	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg01341218	chr17:43662625	NA	-0.76	-8.5	-0.49	2.31e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs8044868	1.000	rs8052408	chr16:72158077	C/T	cg16558253	chr16:72132732	DHX38	-0.44	-6.0	-0.37	7.61e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
SARC	cis	rs7824557	0.628	rs7820301	chr8:11228672	G/A	cg21775007	chr8:11205619	TDH	0.66	9.21	0.52	1.97e-17	Retinal vascular caliber;
SARC	cis	rs7937682	0.632	rs4936800	chr11:111734097	T/A	cg22437258	chr11:111473054	SIK2	-0.49	-5.63	-0.35	5.13e-8	Primary sclerosing cholangitis;
SARC	cis	rs921968	0.541	rs588770	chr2:219494638	T/C	cg02176678	chr2:219576539	TTLL4	0.47	6.95	0.41	3.53e-11	Mean corpuscular hemoglobin concentration;
SARC	cis	rs6815814	0.861	rs10012017	chr4:38784633	G/T	cg06935464	chr4:38784597	TLR10	0.5	5.71	0.35	3.43e-8	Breast cancer;
SARC	cis	rs910316	0.789	rs12894419	chr14:75471802	C/T	cg08847533	chr14:75593920	NEK9	0.9	13.89	0.67	2.35e-32	Height;
SARC	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg05025164	chr4:1340916	KIAA1530	-0.47	-5.35	-0.33	2.14e-7	Obesity-related traits;
SARC	cis	rs910316	0.934	rs8006587	chr14:75664939	A/G	cg06637938	chr14:75390232	RPS6KL1	0.51	7.2	0.43	8.48e-12	Height;
SARC	cis	rs3760982	0.565	rs8104300	chr19:44293144	T/C	cg11993925	chr19:44307056	LYPD5	0.3	4.77	0.3	3.22e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
SARC	cis	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.57	8.77	0.5	3.7e-16	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs1318878	0.519	rs56060060	chr12:15505312	T/C	cg08258403	chr12:15378311	NA	0.49	6.83	0.41	7.14e-11	Intelligence (multi-trait analysis);
SARC	cis	rs9911578	1.000	rs9904879	chr17:56864422	G/A	cg12560992	chr17:57184187	TRIM37	0.89	12.39	0.63	2.03e-27	Intelligence (multi-trait analysis);
SARC	cis	rs896854	0.530	rs10956934	chr8:95992473	C/A	cg23172400	chr8:95962367	TP53INP1	-0.29	-4.86	-0.3	2.17e-6	Type 2 diabetes;
SARC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg02592271	chr2:27665507	KRTCAP3	-0.42	-6.42	-0.39	7.6e-10	Total body bone mineral density;
SARC	cis	rs854765	0.506	rs7210400	chr17:17949957	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.46	-5.95	-0.36	9.75e-9	Total body bone mineral density;
SARC	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-7.77	-0.45	2.42e-13	Chronic sinus infection;
SARC	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.58	0.34	6.8e-8	Bipolar disorder;
SARC	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg23982607	chr1:1823379	GNB1	0.66	11.28	0.59	8.01e-24	Body mass index;
SARC	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg13699009	chr12:122356056	WDR66	0.63	10.18	0.55	2.2e-20	Mean platelet volume;
SARC	cis	rs1784581	0.761	rs7741581	chr6:162435250	C/T	cg17173639	chr6:162384350	PARK2	0.65	8.91	0.5	1.54e-16	Itch intensity from mosquito bite;
SARC	cis	rs72781680	1.000	rs963725	chr2:24148231	T/C	cg06627628	chr2:24431161	ITSN2	-0.75	-6.81	-0.41	7.99e-11	Lymphocyte counts;
SARC	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg11987759	chr7:65425863	GUSB	-0.49	-5.8	-0.36	2.17e-8	Aortic root size;
SARC	cis	rs35306767	0.953	rs11253517	chr10:970524	A/G	cg20503657	chr10:835505	NA	-0.49	-5.02	-0.31	1.01e-6	Eosinophil percentage of granulocytes;
SARC	cis	rs138249	1.000	rs138250	chr22:50570361	A/G	cg24864161	chr22:50528282	MOV10L1	0.32	5.11	0.32	6.73e-7	Gestational age at birth in labor-initiated deliveries (child effect);
SARC	cis	rs12142240	0.698	rs6697123	chr1:46811310	A/C	cg00530320	chr1:46809349	NSUN4	0.58	7.07	0.42	1.83e-11	Menopause (age at onset);
SARC	cis	rs7633857	0.512	rs7611005	chr3:160698549	A/T	cg03342759	chr3:160939853	NMD3	-0.5	-6.17	-0.37	2.98e-9	Educational attainment (years of education);
SARC	cis	rs11658309	1	rs11658309	chr17:17762247	T/G	cg05444541	chr17:17804740	TOM1L2	0.31	5.27	0.33	3.04e-7	Strep throat;
SARC	cis	rs3126085	0.935	rs1390488	chr1:152199500	T/C	cg03465714	chr1:152285911	FLG	-0.44	-5.3	-0.33	2.63e-7	Atopic dermatitis;
SARC	cis	rs2239547	0.522	rs2710345	chr3:52976075	T/C	cg11645453	chr3:52864694	ITIH4	-0.34	-5.23	-0.32	3.7e-7	Schizophrenia;
SARC	cis	rs9326248	0.539	rs518181	chr11:116772787	C/A	cg01368799	chr11:117014884	PAFAH1B2	0.57	7.23	0.43	6.75e-12	Blood protein levels;
SARC	cis	rs9747201	0.962	rs34016823	chr17:80095428	G/T	cg17462356	chr17:80056334	FASN	0.46	5.28	0.33	2.96e-7	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs7412746	0.563	rs3768013	chr1:150815411	G/A	cg10589385	chr1:150898437	SETDB1	0.4	5.4	0.33	1.63e-7	Melanoma;
SARC	cis	rs6580649	0.883	rs879242	chr12:48503301	T/C	cg05342945	chr12:48394962	COL2A1	0.52	5.62	0.35	5.38e-8	Lung cancer;
SARC	cis	rs12956009	0.518	rs3902716	chr18:44889441	G/A	cg19077165	chr18:44547161	KATNAL2	-0.39	-5.06	-0.31	8.5e-7	Educational attainment (years of education);
SARC	cis	rs2439831	0.702	rs2467402	chr15:44024490	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.86	-8.13	-0.47	2.49e-14	Lung cancer in ever smokers;
SARC	cis	rs1153858	1.000	rs12909158	chr15:45621174	A/G	cg21132104	chr15:45694354	SPATA5L1	0.8	11.17	0.59	1.72e-23	Homoarginine levels;
SARC	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg13395646	chr4:1353034	KIAA1530	-0.48	-5.78	-0.35	2.39e-8	Obesity-related traits;
SARC	cis	rs4481887	0.927	rs10127803	chr1:248476196	A/T	cg13385794	chr1:248469461	NA	0.35	5.45	0.34	1.29e-7	Common traits (Other);
SARC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.76	9.94	0.55	1.22e-19	Prudent dietary pattern;
SARC	cis	rs2832077	0.527	rs1048546	chr21:30244877	G/T	cg24692254	chr21:30365293	RNF160	-0.56	-6.05	-0.37	5.81e-9	Cognitive test performance;
SARC	cis	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg18252515	chr7:66147081	NA	-1.27	-10.42	-0.56	3.95e-21	Diabetic kidney disease;
SARC	cis	rs1163251	0.869	rs487884	chr1:120217330	C/T	cg19096424	chr1:120255104	PHGDH	0.53	6.2	0.38	2.58e-9	Blood metabolite levels;
SARC	cis	rs4969178	0.931	rs3826323	chr17:76400268	C/G	cg02836325	chr17:76403955	PGS1	0.34	5.21	0.32	4.16e-7	HDL cholesterol levels;
SARC	cis	rs11581859	0.613	rs1482156	chr1:99223208	C/T	cg20286094	chr1:99190917	SNX7	-0.43	-5.05	-0.31	8.81e-7	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg12648201	chr2:27665141	KRTCAP3	-0.33	-5.0	-0.31	1.11e-6	Total body bone mineral density;
SARC	cis	rs2387326	0.717	rs11016101	chr10:129945003	C/T	cg16087940	chr10:129947807	NA	-0.48	-6.05	-0.37	5.73e-9	Select biomarker traits;
SARC	cis	rs4742903	0.935	rs10119876	chr9:106961080	T/G	cg14250997	chr9:106856677	SMC2	0.43	5.42	0.33	1.47e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs4689388	0.926	rs10937717	chr4:6295087	T/A	cg25554036	chr4:6271136	WFS1	0.4	6.67	0.4	1.8e-10	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs853679	0.723	rs9366718	chr6:28205502	A/T	cg26335602	chr6:28129616	ZNF389	0.51	4.96	0.31	1.35e-6	Depression;
SARC	trans	rs208520	0.690	rs12189780	chr6:66759619	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.07	14.28	0.68	1.18e-33	Exhaled nitric oxide output;
SARC	cis	rs7674212	0.537	rs2623060	chr4:104047504	G/A	cg16532752	chr4:104119610	CENPE	-0.47	-5.73	-0.35	3.07e-8	Type 2 diabetes;
SARC	cis	rs7027203	0.790	rs10123836	chr9:96584109	G/T	cg13679303	chr9:96623674	NA	-0.35	-5.04	-0.31	9.18e-7	DNA methylation (variation);
SARC	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4481887	0.830	rs28581861	chr1:248506028	T/G	cg00666640	chr1:248458726	OR2T12	0.34	5.81	0.36	2.07e-8	Common traits (Other);
SARC	cis	rs7666738	0.785	rs11944120	chr4:99079932	A/C	cg05340658	chr4:99064831	C4orf37	0.44	4.83	0.3	2.52e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg13206674	chr6:150067644	NUP43	0.47	6.04	0.37	6.14e-9	Lung cancer;
SARC	cis	rs2228479	0.702	rs62056087	chr16:89920383	C/A	cg12064134	chr16:90016061	DEF8	-0.56	-4.83	-0.3	2.47e-6	Skin colour saturation;
SARC	cis	rs2841277	0.712	rs2841280	chr14:105393556	G/C	cg19901468	chr14:105411992	AHNAK2	0.76	10.96	0.58	8.03e-23	Rheumatoid arthritis;
SARC	cis	rs898097	0.691	rs7222773	chr17:80907283	A/G	cg15664640	chr17:80829946	TBCD	0.4	6.2	0.38	2.51e-9	Breast cancer;
SARC	cis	rs910316	0.737	rs175077	chr14:75506875	G/A	cg11812906	chr14:75593930	NEK9	-0.76	-10.33	-0.56	7.81e-21	Height;
SARC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg21782813	chr7:2030301	MAD1L1	0.44	6.95	0.41	3.61e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs6570726	1.000	rs6570699	chr6:145920732	G/A	cg05220968	chr6:146057943	EPM2A	-0.3	-5.09	-0.32	7.26e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs73206853	0.841	rs56065235	chr12:111016287	C/T	cg08946844	chr12:110511112	NA	0.56	4.72	0.3	4.05e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs651907	0.535	rs58658478	chr3:101511667	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.47	5.37	0.33	1.87e-7	Colorectal cancer;
SARC	cis	rs10791323	0.546	rs55801927	chr11:133713094	A/C	cg15485101	chr11:133734466	NA	0.33	5.07	0.32	8.08e-7	Childhood ear infection;
SARC	cis	rs6463523	0.815	rs66886645	chr7:763853	C/A	cg24580076	chr7:915073	C7orf20	0.38	5.25	0.33	3.39e-7	Subjective well-being;
SARC	cis	rs7223966	1.000	rs6504182	chr17:61823672	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	6.9	0.41	4.81e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg07701084	chr6:150067640	NUP43	0.41	5.29	0.33	2.81e-7	Lung cancer;
SARC	cis	rs709400	0.663	rs7152202	chr14:103886757	A/G	cg12935359	chr14:103987150	CKB	-0.41	-6.01	-0.37	7.04e-9	Body mass index;
SARC	cis	rs2204008	0.521	rs7311188	chr12:38542813	C/G	cg14851346	chr12:38532713	NA	-0.48	-5.92	-0.36	1.17e-8	Bladder cancer;
SARC	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg11987759	chr7:65425863	GUSB	0.51	6.55	0.39	3.7e-10	Aortic root size;
SARC	trans	rs1814175	0.562	rs1794130	chr11:49903764	T/A	cg03929089	chr4:120376271	NA	-0.81	-11.76	-0.61	2.25e-25	Height;
SARC	cis	rs957448	1.000	rs12543207	chr8:95497430	C/T	cg26464482	chr8:95565502	KIAA1429	0.43	4.89	0.31	1.88e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs2276314	0.857	rs28540805	chr18:33641975	T/G	cg05985134	chr18:33552581	C18orf21	0.68	6.93	0.41	4.12e-11	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs4481887	0.893	rs10888347	chr1:248448566	T/C	cg00666640	chr1:248458726	OR2T12	0.33	5.35	0.33	2.11e-7	Common traits (Other);
SARC	cis	rs6540556	0.637	rs12060922	chr1:209904433	G/A	cg23920097	chr1:209922102	NA	-0.52	-5.26	-0.33	3.33e-7	Red blood cell count;
SARC	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	8.82	0.5	2.77e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6860806	0.507	rs2631371	chr5:131703691	G/A	cg11843238	chr5:131593191	PDLIM4	-0.41	-5.06	-0.31	8.42e-7	Breast cancer;
SARC	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg05368731	chr17:41323189	NBR1	0.81	9.93	0.55	1.35e-19	Menopause (age at onset);
SARC	cis	rs12824058	0.798	rs4759652	chr12:130808771	C/T	cg26677194	chr12:130822605	PIWIL1	0.53	7.24	0.43	6.35e-12	Menopause (age at onset);
SARC	cis	rs2013441	1.000	rs2703772	chr17:20131453	C/A	cg13482628	chr17:19912719	NA	-0.47	-6.22	-0.38	2.25e-9	Obesity-related traits;
SARC	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg25427524	chr10:38739819	LOC399744	-0.61	-9.92	-0.54	1.41e-19	Extrinsic epigenetic age acceleration;
SARC	trans	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg21659725	chr3:3221576	CRBN	0.56	6.55	0.39	3.57e-10	Resting heart rate;
SARC	cis	rs6121246	0.909	rs6060793	chr20:30288830	T/G	cg13852791	chr20:30311386	BCL2L1	0.86	9.14	0.51	3.15e-17	Mean corpuscular hemoglobin;
SARC	cis	rs11098499	0.691	rs17009144	chr4:120270795	C/T	cg09307838	chr4:120376055	NA	-0.75	-10.4	-0.56	4.68e-21	Corneal astigmatism;
SARC	cis	rs9916302	0.784	rs4795361	chr17:37573446	G/A	cg15445000	chr17:37608096	MED1	0.43	5.1	0.32	6.92e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs3204270	0.639	rs6565620	chr17:79658100	C/T	cg26965718	chr17:79658957	HGS	-0.62	-5.17	-0.32	5.05e-7	Dental caries;
SARC	cis	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg25894440	chr7:65020034	NA	-0.73	-5.54	-0.34	8.32e-8	Diabetic kidney disease;
SARC	cis	rs17023223	0.581	rs10923750	chr1:119650795	T/G	cg05756136	chr1:119680316	WARS2	-0.45	-5.0	-0.31	1.13e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs929354	0.772	rs3802120	chr7:156977794	C/T	cg05182265	chr7:156933206	UBE3C	-0.33	-5.02	-0.31	1.03e-6	Body mass index;
SARC	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg04287289	chr16:89883240	FANCA	0.87	15.4	0.71	2.13e-37	Vitiligo;
SARC	cis	rs2120243	0.539	rs722484	chr3:157100627	C/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.38	4.84	0.3	2.38e-6	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs6546550	0.901	rs6739780	chr2:70138111	G/A	cg02498382	chr2:70120550	SNRNP27	-0.32	-5.13	-0.32	6.02e-7	Prevalent atrial fibrillation;
SARC	cis	rs7644634	0.688	rs9880861	chr3:105449986	T/C	cg23051926	chr3:105466016	CBLB	0.44	5.52	0.34	9.1e-8	Itch intensity from mosquito bite;
SARC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg26338869	chr17:61819248	STRADA	0.81	10.89	0.58	1.38e-22	Prudent dietary pattern;
SARC	cis	rs9388451	0.874	rs3734634	chr6:126111800	G/A	cg06289844	chr6:126071538	HEY2	0.35	5.64	0.35	4.81e-8	Brugada syndrome;
SARC	cis	rs12586317	0.620	rs17091786	chr14:35565856	A/T	cg26967526	chr14:35346199	BAZ1A	-0.64	-6.63	-0.4	2.34e-10	Psoriasis;
SARC	cis	rs36051895	0.632	rs10217652	chr9:5119939	A/G	cg02405213	chr9:5042618	JAK2	-0.47	-5.75	-0.35	2.75e-8	Pediatric autoimmune diseases;
SARC	cis	rs7647973	0.554	rs13096480	chr3:49658084	A/G	cg07636037	chr3:49044803	WDR6	0.63	6.42	0.39	7.57e-10	Menarche (age at onset);
SARC	cis	rs7587476	0.906	rs2070096	chr2:215645545	C/G	cg04004882	chr2:215674386	BARD1	0.63	6.82	0.41	7.6e-11	Neuroblastoma;
SARC	trans	rs1814175	0.645	rs11040661	chr11:49952146	G/T	cg15704280	chr7:45808275	SEPT13	-0.89	-14.11	-0.68	4.34e-33	Height;
SARC	trans	rs637571	0.780	rs677029	chr11:65683531	A/G	cg17712092	chr4:129076599	LARP1B	0.78	11.08	0.59	3.46e-23	Eosinophil percentage of white cells;
SARC	cis	rs9660992	0.710	rs1668873	chr1:205235990	G/A	cg21643547	chr1:205240462	TMCC2	-0.66	-8.83	-0.5	2.63e-16	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg08280861	chr8:58055591	NA	0.6	5.28	0.33	2.92e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9326248	0.581	rs7120706	chr11:116830087	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.61	-7.86	-0.46	1.43e-13	Blood protein levels;
SARC	cis	rs10078	0.571	rs2561664	chr5:459793	T/C	cg26072250	chr5:443457	EXOC3;C5orf55	0.67	5.56	0.34	7.48e-8	Fat distribution (HIV);
SARC	cis	rs7824557	0.724	rs2251473	chr8:11177126	C/A	cg21775007	chr8:11205619	TDH	0.57	7.28	0.43	5.06e-12	Retinal vascular caliber;
SARC	cis	rs6570726	0.905	rs1355146	chr6:145781741	A/C	cg05220968	chr6:146057943	EPM2A	0.28	4.77	0.3	3.28e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs897080	0.794	rs936039	chr2:44759714	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.42	4.82	0.3	2.62e-6	Height;
SARC	cis	rs7520050	0.966	rs4134386	chr1:46395089	G/A	cg06784218	chr1:46089804	CCDC17	-0.26	-4.75	-0.3	3.57e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg07414643	chr4:187882934	NA	0.46	6.57	0.4	3.28e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs5753618	0.504	rs5753671	chr22:31910734	T/C	cg07713946	chr22:31675144	LIMK2	0.36	5.09	0.32	7.36e-7	Colorectal cancer;
SARC	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg07701084	chr6:150067640	NUP43	0.38	5.07	0.32	7.92e-7	Lung cancer;
SARC	cis	rs4481887	0.927	rs9651176	chr1:248447343	A/G	cg00666640	chr1:248458726	OR2T12	0.35	5.85	0.36	1.62e-8	Common traits (Other);
SARC	cis	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg06636001	chr8:8085503	FLJ10661	0.69	9.3	0.52	1.05e-17	Systolic blood pressure;
SARC	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg08677398	chr8:58056175	NA	0.44	5.25	0.33	3.38e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs4803455	0.565	rs1800470	chr19:41858921	G/A	cg09537434	chr19:41945824	ATP5SL	-0.63	-8.21	-0.47	1.54e-14	Migraine;Coronary artery disease;
SARC	cis	rs7959452	0.684	rs11177615	chr12:69754189	G/A	cg14784868	chr12:69753453	YEATS4	0.51	6.64	0.4	2.23e-10	Blood protein levels;
SARC	cis	rs854765	0.693	rs8080061	chr17:17776389	C/T	cg05444541	chr17:17804740	TOM1L2	0.3	5.15	0.32	5.65e-7	Total body bone mineral density;
SARC	trans	rs61931739	1.000	rs12427391	chr12:34022891	A/G	cg26384229	chr12:38710491	ALG10B	-0.56	-7.01	-0.42	2.55e-11	Morning vs. evening chronotype;
SARC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.93	10.56	0.57	1.51e-21	Platelet count;
SARC	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.62	5.44	0.34	1.33e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs826838	0.935	rs11168761	chr12:38997211	C/A	cg26384229	chr12:38710491	ALG10B	0.92	14.54	0.69	1.65e-34	Heart rate;
SARC	cis	rs965469	0.652	rs4507156	chr20:3228460	A/G	cg25506879	chr20:3388711	C20orf194	0.47	5.33	0.33	2.31e-7	IFN-related cytopenia;
SARC	cis	rs7617773	0.563	rs13082269	chr3:48392274	G/A	cg11946769	chr3:48343235	NME6	0.55	6.69	0.4	1.66e-10	Coronary artery disease;
SARC	cis	rs7481584	0.624	rs369461	chr11:3061992	A/G	cg20651018	chr11:3035856	CARS	0.38	5.87	0.36	1.46e-8	Calcium levels;
SARC	cis	rs9400467	0.537	rs584937	chr6:111481577	T/G	cg15721981	chr6:111408429	SLC16A10	0.64	5.65	0.35	4.55e-8	Blood metabolite levels;Amino acid levels;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg14032528	chr1:11866380	CLCN6;MTHFR	-0.51	-6.24	-0.38	2e-9	Height;
SARC	cis	rs7937682	0.889	rs1789355	chr11:111499718	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.92	-14.73	-0.69	3.72e-35	Primary sclerosing cholangitis;
SARC	trans	rs641862	1	rs641862	chr13:110790232	C/T	cg09626833	chr13:113174173	TUBGCP3	0.88	6.5	0.39	4.71e-10	Obesity-related traits;
SARC	cis	rs910316	0.763	rs4556	chr14:75476071	G/C	cg08847533	chr14:75593920	NEK9	0.89	13.62	0.67	1.79e-31	Height;
SARC	cis	rs240764	0.635	rs6901854	chr6:100932291	C/T	cg09795085	chr6:101329169	ASCC3	-0.41	-5.17	-0.32	5.04e-7	Neuroticism;
SARC	cis	rs7296418	0.961	rs10773921	chr12:123541606	C/T	cg16085171	chr12:123569118	PITPNM2	-0.38	-4.95	-0.31	1.44e-6	Platelet count;
SARC	cis	rs477692	0.905	rs508360	chr10:131424969	A/G	cg05714579	chr10:131428358	MGMT	0.57	7.57	0.44	8.6e-13	Response to temozolomide;
SARC	trans	rs1814175	0.647	rs28456013	chr11:50047629	T/C	cg15704280	chr7:45808275	SEPT13	-0.8	-12.82	-0.64	8.19e-29	Height;
SARC	cis	rs11997175	0.550	rs7459565	chr8:33836717	C/T	ch.8.33884649F	chr8:33765107	NA	0.5	6.07	0.37	5.17e-9	Body mass index;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg26910092	chr2:216300599	FN1	-0.49	-6.25	-0.38	1.96e-9	Schizophrenia;
SARC	cis	rs6570726	0.791	rs365869	chr6:145884751	C/T	cg23711669	chr6:146136114	FBXO30	0.87	14.69	0.69	4.99e-35	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7044106	0.791	rs10984994	chr9:123478769	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.75	-9.4	-0.52	5.35e-18	Hip circumference adjusted for BMI;
SARC	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg03647317	chr4:187891568	NA	-0.42	-6.15	-0.37	3.29e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6089584	0.606	rs7270469	chr20:60577258	G/A	cg13770153	chr20:60521292	NA	-0.39	-5.59	-0.34	6.2e-8	Body mass index;
SARC	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg00933542	chr6:150070202	PCMT1	0.31	5.23	0.32	3.72e-7	Lung cancer;
SARC	cis	rs11690935	0.959	rs10194102	chr2:172626143	G/C	cg13550731	chr2:172543902	DYNC1I2	-1.0	-15.73	-0.72	1.83e-38	Schizophrenia;
SARC	cis	rs7255045	0.664	rs4614850	chr19:12974636	G/T	cg21491176	chr19:12958399	MAST1	-0.35	-4.73	-0.3	3.91e-6	Mean corpuscular volume;
SARC	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.12	24.2	0.85	1.59e-65	Chronic sinus infection;
SARC	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg11764359	chr7:65958608	NA	0.88	12.58	0.64	4.89e-28	Aortic root size;
SARC	cis	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg06212747	chr3:49208901	KLHDC8B	0.51	6.45	0.39	6.22e-10	Resting heart rate;
SARC	cis	rs9467603	1.000	rs9467600	chr6:25792768	C/T	cg21479132	chr6:26055353	NA	0.77	5.1	0.32	7.06e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1678542	0.651	rs2888334	chr12:57976647	C/G	cg00677455	chr12:58241039	CTDSP2	-0.47	-5.39	-0.33	1.68e-7	Rheumatoid arthritis;
SARC	cis	rs34233420	1	rs34233420	chr17:38004929	GATTT/G	cg19468946	chr17:37922297	IKZF3	-0.31	-5.17	-0.32	5.12e-7	Lymphocyte counts;
SARC	cis	rs72653721	0.627	rs12662634	chr6:11074191	G/A	cg13562911	chr6:11044106	ELOVL2	0.57	6.49	0.39	5.2e-10	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	cis	rs7197653	0.748	rs8063446	chr16:68344363	A/C	cg05110241	chr16:68378359	PRMT7	-0.67	-5.8	-0.36	2.11e-8	Magnesium levels;
SARC	cis	rs3126085	0.935	rs1466757	chr1:152212469	G/A	cg03465714	chr1:152285911	FLG	-0.46	-5.64	-0.35	4.94e-8	Atopic dermatitis;
SARC	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	11.03	0.59	4.93e-23	Alzheimer's disease;
SARC	cis	rs2070488	0.775	rs6780349	chr3:38555178	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.74	-10.76	-0.58	3.39e-22	Electrocardiographic conduction measures;
SARC	cis	rs910316	0.737	rs175080	chr14:75513828	G/A	cg08847533	chr14:75593920	NEK9	-0.83	-12.01	-0.62	3.59e-26	Height;
SARC	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg16479474	chr6:28041457	NA	0.37	5.44	0.34	1.37e-7	Parkinson's disease;
SARC	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg11987759	chr7:65425863	GUSB	0.5	6.22	0.38	2.29e-9	Aortic root size;
SARC	cis	rs910316	0.967	rs11624893	chr14:75660124	A/G	cg08847533	chr14:75593920	NEK9	-0.84	-12.79	-0.64	1.01e-28	Height;
SARC	cis	rs6570726	0.905	rs1355146	chr6:145781741	A/C	cg05347473	chr6:146136440	FBXO30	-0.45	-6.06	-0.37	5.49e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs367943	1.000	rs348952	chr5:112821990	G/T	cg12552261	chr5:112820674	MCC	-0.46	-5.27	-0.33	3.05e-7	Type 2 diabetes;
SARC	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg00933542	chr6:150070202	PCMT1	0.3	5.08	0.32	7.56e-7	Lung cancer;
SARC	cis	rs6998277	0.830	rs6468836	chr8:103602630	A/G	cg10187029	chr8:103597600	NA	0.89	12.68	0.64	2.36e-28	Migraine;
SARC	cis	rs4430311	0.721	rs4610997	chr1:243946917	T/A	cg21452805	chr1:244014465	NA	-0.4	-5.18	-0.32	4.72e-7	Post-traumatic stress disorder (asjusted for relatedness);
SARC	trans	rs61931739	0.500	rs7977186	chr12:34431486	C/G	cg26384229	chr12:38710491	ALG10B	0.92	13.84	0.67	3.3e-32	Morning vs. evening chronotype;
SARC	cis	rs3733585	0.699	rs6449158	chr4:9960459	T/C	cg00071950	chr4:10020882	SLC2A9	-0.39	-6.02	-0.37	6.68e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs709400	0.663	rs62007681	chr14:103884651	G/A	cg12935359	chr14:103987150	CKB	-0.4	-5.88	-0.36	1.4e-8	Body mass index;
SARC	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg05861140	chr6:150128134	PCMT1	-0.37	-4.79	-0.3	2.92e-6	Lung cancer;
SARC	cis	rs3106136	0.837	rs2289186	chr4:95255637	T/G	cg11021082	chr4:95130006	SMARCAD1	0.4	6.15	0.37	3.35e-9	Capecitabine sensitivity;
SARC	cis	rs11608355	0.515	rs35691047	chr12:109932585	C/T	cg05360138	chr12:110035743	NA	0.92	9.39	0.52	5.78e-18	Neuroticism;
SARC	cis	rs7633857	0.536	rs1447609	chr3:160696311	A/G	cg17135325	chr3:160939158	NMD3	0.4	4.86	0.3	2.12e-6	Educational attainment (years of education);
SARC	cis	rs12249377	0.519	rs7906960	chr10:92586205	A/G	cg14313238	chr10:92632228	RPP30	0.43	5.14	0.32	5.91e-7	White matter microstructure (global fractional anisotropy);
SARC	cis	rs6088580	0.634	rs6141471	chr20:33006730	A/G	cg08999081	chr20:33150536	PIGU	-0.42	-6.39	-0.39	9.12e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7712401	0.580	rs30041	chr5:122275353	G/C	cg19412675	chr5:122181750	SNX24	0.4	5.09	0.32	7.55e-7	Mean platelet volume;
SARC	cis	rs9911578	0.933	rs2632508	chr17:56533235	G/A	cg05425664	chr17:57184151	TRIM37	-0.65	-7.91	-0.46	1.06e-13	Intelligence (multi-trait analysis);
SARC	cis	rs41271473	0.526	rs10916339	chr1:228716894	C/T	cg10167378	chr1:228756711	NA	0.56	5.2	0.32	4.39e-7	Chronic lymphocytic leukemia;
SARC	cis	rs9916302	0.904	rs55660616	chr17:37684990	C/A	cg15445000	chr17:37608096	MED1	0.42	4.93	0.31	1.59e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs6060960	0.502	rs15817	chr20:30193538	A/G	cg13852791	chr20:30311386	BCL2L1	0.66	5.92	0.36	1.15e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
SARC	cis	rs2549003	1.000	rs9282762	chr5:131822055	T/C	cg21138405	chr5:131827807	IRF1	0.27	5.32	0.33	2.4e-7	Asthma (sex interaction);
SARC	cis	rs7666738	0.830	rs13139024	chr4:99020700	C/T	cg05340658	chr4:99064831	C4orf37	0.66	9.04	0.51	6.35e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg02018176	chr4:1364513	KIAA1530	0.37	5.39	0.33	1.68e-7	Longevity;
SARC	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg17221315	chr6:27791827	HIST1H4J	0.46	4.83	0.3	2.53e-6	Depression;
SARC	cis	rs12451471	0.559	rs1042396	chr17:78084769	G/A	cg24585782	chr17:78113791	EIF4A3	-0.52	-5.85	-0.36	1.68e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
SARC	cis	rs2204008	0.569	rs11495449	chr12:37995753	C/T	cg26384229	chr12:38710491	ALG10B	0.89	13.14	0.65	6.99e-30	Bladder cancer;
SARC	cis	rs7615952	0.605	rs34865555	chr3:125304134	C/T	cg05084668	chr3:125655381	ALG1L	-0.62	-5.5	-0.34	9.75e-8	Blood pressure (smoking interaction);
SARC	cis	rs10892173	0.703	rs1014034	chr11:117661734	G/C	cg21014159	chr11:117668035	DSCAML1	0.35	4.87	0.3	2.1e-6	Myopia;
SARC	cis	rs9314323	0.729	rs7823021	chr8:26224958	G/T	cg11498726	chr8:26250323	BNIP3L	-0.59	-7.6	-0.45	7.08e-13	Red cell distribution width;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg18802601	chr5:34698640	RAI14	0.46	6.25	0.38	1.89e-9	Thyroid stimulating hormone;
SARC	cis	rs4891159	0.790	rs11872411	chr18:74132051	C/T	cg24786174	chr18:74118243	ZNF516	-0.64	-9.43	-0.53	4.4e-18	Longevity;
SARC	cis	rs1552244	0.688	rs113940455	chr3:10014165	A/C	cg00149659	chr3:10157352	C3orf10	0.73	7.13	0.42	1.27e-11	Alzheimer's disease;
SARC	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.72	-7.58	-0.44	8e-13	Platelet count;
SARC	cis	rs7937682	0.889	rs487985	chr11:111517908	G/A	cg22437258	chr11:111473054	SIK2	0.74	10.3	0.56	9.9e-21	Primary sclerosing cholangitis;
SARC	cis	rs12808519	0.646	rs12361755	chr11:69602646	C/T	cg19831575	chr11:69590090	FGF4	0.58	5.64	0.35	5.02e-8	Urate levels in overweight individuals;
SARC	cis	rs6500395	0.962	rs9938126	chr16:48572121	A/T	cg04672837	chr16:48644449	N4BP1	0.42	5.45	0.34	1.31e-7	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs11055034	0.560	rs2024385	chr12:12888438	A/T	cg04607235	chr12:12878440	APOLD1	0.46	5.98	0.36	8.43e-9	Birth weight;
SARC	cis	rs11583043	0.708	rs1060481	chr1:101546699	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.48	5.05	0.31	8.96e-7	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs3106136	0.967	rs35670996	chr4:95199479	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.4	-6.13	-0.37	3.68e-9	Capecitabine sensitivity;
SARC	cis	rs950776	1.000	rs950776	chr15:78926018	A/G	cg22563815	chr15:78856949	CHRNA5	0.35	5.68	0.35	4.1e-8	Sudden cardiac arrest;
SARC	cis	rs9948	0.655	rs6758151	chr2:97388884	A/G	cg01990225	chr2:97406019	LMAN2L	-0.81	-6.22	-0.38	2.25e-9	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg21724239	chr8:58056113	NA	0.72	6.57	0.4	3.18e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7408868	0.520	rs10417567	chr19:15308068	C/T	cg14696996	chr19:15285081	NOTCH3	-0.75	-6.49	-0.39	5.05e-10	Pulse pressure;
SARC	trans	rs1853207	0.737	rs77170107	chr10:96626365	C/T	cg02737782	chr1:8014393	NA	-0.97	-6.42	-0.39	7.44e-10	Blood metabolite levels;
SARC	cis	rs7264396	0.563	rs2425090	chr20:34304783	C/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	5.7	0.35	3.66e-8	Total cholesterol levels;
SARC	cis	rs10870270	1.000	rs7078692	chr10:133775370	T/A	cg08754478	chr10:133766260	PPP2R2D	-0.48	-5.41	-0.33	1.56e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs2952156	0.920	rs8078228	chr17:37834998	C/T	cg00129232	chr17:37814104	STARD3	-0.7	-10.11	-0.55	3.81e-20	Asthma;
SARC	cis	rs17826219	0.706	rs8075357	chr17:29057197	A/C	cg13385521	chr17:29058706	SUZ12P	0.89	8.0	0.46	5.9e-14	Body mass index;
SARC	trans	rs2856321	0.595	rs12828066	chr12:11891965	A/C	cg20056634	chr2:66796261	MEIS1	-0.51	-6.71	-0.4	1.44e-10	Height;
SARC	cis	rs6141769	0.542	rs28730896	chr20:31295844	A/G	cg17884169	chr20:31446444	EFCAB8	-0.45	-4.83	-0.3	2.46e-6	Subjective well-being;
SARC	cis	rs6446731	0.593	rs6446728	chr4:3275650	A/G	cg06533319	chr4:3265114	C4orf44	-0.3	-4.89	-0.31	1.86e-6	Mean platelet volume;
SARC	trans	rs9650657	0.770	rs9969626	chr8:10670801	A/C	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.53	-0.39	4.17e-10	Neuroticism;
SARC	cis	rs11098699	0.784	rs7693178	chr4:124247394	T/G	cg09941581	chr4:124220074	SPATA5	0.37	4.82	0.3	2.61e-6	Mosquito bite size;
SARC	cis	rs9324022	0.626	rs10873520	chr14:101175967	G/A	cg18089426	chr14:101175970	NA	0.56	5.98	0.36	8.29e-9	Plateletcrit;
SARC	trans	rs10771431	1.000	rs10771431	chr12:9380859	C/T	cg27600084	chr12:12264075	NA	0.57	7.95	0.46	8.15e-14	Breast size;
SARC	cis	rs737337	0.623	rs12974173	chr19:11333359	A/T	cg00586551	chr19:11347513	LOC55908;DOCK6	0.55	6.02	0.37	6.61e-9	HDL cholesterol;HDL cholesterol levels;
SARC	cis	rs11676348	0.774	rs57545959	chr2:219047718	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.44	5.57	0.34	6.95e-8	Ulcerative colitis;
SARC	trans	rs17685	0.753	rs1637045	chr7:75703895	T/C	cg19862616	chr7:65841803	NCRNA00174	0.64	7.83	0.46	1.73e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs4443100	0.958	rs13057385	chr22:23380955	G/A	cg14186256	chr22:23484241	RTDR1	0.46	4.71	0.3	4.2e-6	Serum parathyroid hormone levels;
SARC	cis	rs701145	0.529	rs355759	chr3:154008078	G/C	cg16511985	chr3:153974050	SGEF	0.41	4.75	0.3	3.53e-6	Coronary artery disease;
SARC	cis	rs787274	1.000	rs2645991	chr9:115519035	T/C	cg13803584	chr9:115635662	SNX30	-0.83	-4.9	-0.31	1.79e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	10.13	0.55	3.22e-20	Platelet count;
SARC	cis	rs698833	0.758	rs7586188	chr2:44544955	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.66	8.62	0.49	1.01e-15	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg21724239	chr8:58056113	NA	0.63	6.05	0.37	5.78e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs35213789	0.762	rs2851483	chr7:69128847	A/G	cg10619644	chr7:69149951	AUTS2	-0.35	-4.91	-0.31	1.69e-6	Childhood ear infection;
SARC	cis	rs2153535	0.563	rs4428546	chr6:8490376	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	8.2	0.47	1.57e-14	Motion sickness;
SARC	cis	rs554111	0.656	rs6695218	chr1:21190512	A/C	cg08890418	chr1:21044141	KIF17	-0.37	-5.15	-0.32	5.58e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs8031584	0.958	rs11637469	chr15:31238783	T/C	cg08109568	chr15:31115862	NA	-0.46	-5.75	-0.35	2.78e-8	Huntington's disease progression;
SARC	cis	rs10512697	0.685	rs11741304	chr5:3577245	C/T	cg19473799	chr5:3511975	NA	-0.68	-4.86	-0.3	2.11e-6	Immune response to smallpox vaccine (IL-6);
SARC	cis	rs4276643	0.805	rs2685413	chr8:27810577	T/G	cg25028855	chr8:28560486	EXTL3	0.27	4.72	0.3	4e-6	Low vWF levels;
SARC	cis	rs6570726	0.791	rs12208019	chr6:145935572	T/C	cg05347473	chr6:146136440	FBXO30	0.55	7.55	0.44	1.01e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12022452	0.506	rs11208363	chr1:41010454	A/G	cg25568243	chr1:40974465	DEM1	0.51	4.94	0.31	1.53e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-9.15	-0.51	2.85e-17	Alzheimer's disease;
SARC	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg11987759	chr7:65425863	GUSB	0.61	7.97	0.46	6.97e-14	Aortic root size;
SARC	cis	rs7945705	0.774	rs6486060	chr11:9024630	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.53	6.9	0.41	4.77e-11	Hemoglobin concentration;
SARC	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg17554472	chr22:41940697	POLR3H	-0.42	-4.79	-0.3	2.94e-6	Vitiligo;
SARC	cis	rs12303914	0.762	rs2537752	chr12:10467533	A/T	cg16417563	chr12:10365564	GABARAPL1	0.39	4.81	0.3	2.76e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs9462027	0.628	rs9462010	chr6:34716605	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.85	-0.36	1.63e-8	Systemic lupus erythematosus;
SARC	cis	rs72781680	0.898	rs6712524	chr2:24083925	T/C	cg06627628	chr2:24431161	ITSN2	-0.66	-6.47	-0.39	5.57e-10	Lymphocyte counts;
SARC	cis	rs9400467	0.537	rs12197886	chr6:111491405	C/G	cg15721981	chr6:111408429	SLC16A10	0.69	5.89	0.36	1.34e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs9902453	0.935	rs9911794	chr17:28349466	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.53	-6.96	-0.41	3.52e-11	Coffee consumption (cups per day);
SARC	cis	rs5753618	0.539	rs5997933	chr22:31672752	A/C	cg13145458	chr22:31556086	RNF185	0.47	5.06	0.31	8.47e-7	Colorectal cancer;
SARC	cis	rs4566357	0.615	rs6436644	chr2:227914275	T/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.86	-0.36	1.61e-8	Coronary artery disease;
SARC	cis	rs7937682	0.632	rs11608193	chr11:111732215	T/C	cg22437258	chr11:111473054	SIK2	-0.48	-5.55	-0.34	7.57e-8	Primary sclerosing cholangitis;
SARC	cis	rs4642101	0.561	rs6766744	chr3:12801843	C/T	cg12400702	chr3:12838781	CAND2	-0.26	-4.9	-0.31	1.79e-6	QRS complex (12-leadsum);
SARC	cis	rs6722750	0.870	rs35899183	chr2:64408776	C/G	cg09303977	chr2:63816220	MDH1;C2orf86	0.37	4.89	0.3	1.91e-6	Neuroticism;
SARC	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg00933542	chr6:150070202	PCMT1	0.31	5.42	0.33	1.47e-7	Lung cancer;
SARC	cis	rs7000551	0.725	rs2461483	chr8:22386479	C/T	cg12081754	chr8:22256438	SLC39A14	0.55	7.52	0.44	1.19e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg26769984	chr7:1090371	C7orf50	0.51	5.25	0.33	3.36e-7	Bronchopulmonary dysplasia;
SARC	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg23758822	chr17:41437982	NA	0.83	10.52	0.57	1.92e-21	Menopause (age at onset);
SARC	cis	rs3812831	0.543	rs389108	chr13:114925389	A/G	cg06611532	chr13:114900021	NA	0.35	5.74	0.35	2.88e-8	Schizophrenia;
SARC	cis	rs2760061	0.598	rs605410	chr1:228116281	A/G	cg02753203	chr1:228287806	NA	-0.54	-7.48	-0.44	1.54e-12	Diastolic blood pressure;
SARC	cis	rs240764	0.594	rs7356804	chr6:101078438	A/G	cg09795085	chr6:101329169	ASCC3	0.38	4.83	0.3	2.47e-6	Neuroticism;
SARC	cis	rs12079745	0.793	rs12074492	chr1:169215363	C/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.81	-5.41	-0.33	1.6e-7	QT interval;
SARC	cis	rs9322193	0.607	rs9371228	chr6:150243113	G/A	cg11878867	chr6:150167359	LRP11	0.39	4.94	0.31	1.51e-6	Lung cancer;
SARC	cis	rs9420	0.961	rs7936998	chr11:57639017	G/A	cg23127183	chr11:57508653	C11orf31	-0.59	-6.75	-0.4	1.18e-10	Schizophrenia;
SARC	cis	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg02487422	chr3:49467188	NICN1	0.5	6.85	0.41	6.52e-11	Resting heart rate;
SARC	cis	rs12142240	0.659	rs17361873	chr1:46832686	A/G	cg14993813	chr1:46806288	NSUN4	-0.53	-5.62	-0.35	5.48e-8	Menopause (age at onset);
SARC	trans	rs11098499	0.863	rs28718422	chr4:120466304	C/A	cg25214090	chr10:38739885	LOC399744	0.57	7.25	0.43	6.27e-12	Corneal astigmatism;
SARC	cis	rs62344088	1.000	rs6898413	chr5:173927	A/C	cg22857025	chr5:266934	NA	-0.82	-5.36	-0.33	1.98e-7	Asthma (childhood onset);
SARC	cis	rs7005606	1.000	rs4368937	chr8:32407737	T/C	cg14488905	chr8:32406789	NRG1	0.45	6.31	0.38	1.42e-9	Hirschsprung disease;
SARC	cis	rs7465272	1.000	rs7465272	chr8:143691838	A/T	cg24634471	chr8:143751801	JRK	0.61	6.67	0.4	1.88e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs4268898	0.662	rs9917355	chr2:24433400	C/T	cg26838691	chr2:24397539	C2orf84	-0.54	-6.2	-0.38	2.54e-9	Asthma;
SARC	trans	rs1814175	0.645	rs2140602	chr11:50022800	G/C	cg03929089	chr4:120376271	NA	-0.82	-11.88	-0.61	9.03e-26	Height;
SARC	cis	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg06636001	chr8:8085503	FLJ10661	0.61	8.29	0.48	8.95e-15	Mood instability;
SARC	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg24531977	chr5:56204891	C5orf35	-0.51	-5.22	-0.32	3.89e-7	Initial pursuit acceleration;
SARC	cis	rs3768617	0.510	rs1547712	chr1:183088013	T/A	cg13390022	chr1:182993471	LAMC1	0.32	4.83	0.3	2.44e-6	Fuchs's corneal dystrophy;
SARC	cis	rs9604529	0.532	rs41291213	chr13:114774991	C/T	cg13259177	chr13:114761607	RASA3	-0.59	-7.06	-0.42	1.9e-11	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs74781061	0.585	rs2899826	chr15:74734500	A/G	cg09165964	chr15:75287851	SCAMP5	-0.63	-4.99	-0.31	1.19e-6	Endometriosis;
SARC	trans	rs8002861	0.870	rs2121030	chr13:44444574	C/T	cg17145862	chr1:211918768	LPGAT1	-0.52	-7.94	-0.46	8.64e-14	Leprosy;
SARC	cis	rs7833790	0.632	rs6473308	chr8:82707708	G/A	cg06027949	chr8:82754900	SNX16	-0.48	-6.17	-0.37	2.93e-9	Diastolic blood pressure;
SARC	cis	rs8058578	1.000	rs7204278	chr16:30730274	A/G	cg02466173	chr16:30829666	NA	-0.45	-5.91	-0.36	1.2e-8	Multiple myeloma;
SARC	cis	rs7568458	0.811	rs1446668	chr2:85764960	G/T	cg02493740	chr2:85810744	VAMP5	-0.35	-5.29	-0.33	2.79e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs910316	0.934	rs7141705	chr14:75655352	G/C	cg11812906	chr14:75593930	NEK9	-0.83	-12.37	-0.63	2.36e-27	Height;
SARC	cis	rs910187	0.678	rs6124967	chr20:45813624	T/C	cg27589058	chr20:45804311	EYA2	-0.29	-4.72	-0.3	4.09e-6	Migraine;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg26166804	chr10:71812612	H2AFY2	0.52	7.05	0.42	2.04e-11	Lung adenocarcinoma;
SARC	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs2404602	0.647	rs11855296	chr15:77092962	C/T	cg15268244	chr15:77196840	NA	0.43	5.04	0.31	9.44e-7	Blood metabolite levels;
SARC	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg12310025	chr6:25882481	NA	0.49	6.44	0.39	6.73e-10	Blood metabolite levels;
SARC	cis	rs7481584	0.886	rs4758621	chr11:3009640	C/T	cg25174290	chr11:3078921	CARS	0.53	7.1	0.42	1.52e-11	Calcium levels;
SARC	cis	rs2228479	0.850	rs45524643	chr16:89815824	G/A	cg06558623	chr16:89946397	TCF25	0.88	6.21	0.38	2.39e-9	Skin colour saturation;
SARC	cis	rs9457247	0.765	rs4710171	chr6:167430186	A/G	cg23791538	chr6:167370224	RNASET2	-0.53	-6.91	-0.41	4.54e-11	Crohn's disease;
SARC	cis	rs739401	0.611	rs7394974	chr11:3038868	C/T	cg05729581	chr11:3078854	CARS	-0.45	-5.76	-0.35	2.66e-8	Longevity;
SARC	cis	rs2228479	0.850	rs11639925	chr16:89908250	C/T	cg00800038	chr16:89945340	TCF25	-0.79	-5.58	-0.34	6.75e-8	Skin colour saturation;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg06234063	chr12:65219392	NA	0.48	6.49	0.39	5.11e-10	Schizophrenia;
SARC	cis	rs2070677	0.736	rs7895560	chr10:135431038	G/A	cg20169779	chr10:135381914	SYCE1	-0.51	-5.4	-0.33	1.65e-7	Gout;
SARC	cis	rs1669338	0.588	rs3804783	chr3:3184442	C/T	cg16797762	chr3:3221439	CRBN	-0.92	-9.45	-0.53	3.9e-18	White matter integrity;
SARC	cis	rs2180341	0.924	rs6930849	chr6:127630963	A/T	cg24812749	chr6:127587940	RNF146	0.97	12.89	0.65	4.63e-29	Breast cancer;
SARC	cis	rs7927771	1.000	rs10838738	chr11:47663049	A/G	cg05585544	chr11:47624801	NA	-0.38	-5.14	-0.32	5.71e-7	Subjective well-being;
SARC	cis	rs1971762	0.563	rs4759285	chr12:54079513	G/T	cg06632207	chr12:54070931	ATP5G2	0.45	5.85	0.36	1.63e-8	Height;
SARC	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	15.01	0.7	4.48e-36	Chronic sinus infection;
SARC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.16	21.13	0.81	4.42e-56	Prudent dietary pattern;
SARC	cis	rs554111	0.963	rs710312	chr1:21042462	A/G	cg04902671	chr1:21058625	SH2D5	-0.42	-4.76	-0.3	3.44e-6	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg01238044	chr22:24384105	GSTT1	-0.55	-6.5	-0.39	4.93e-10	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs11249608	0.789	rs7733067	chr5:178425714	T/C	cg21905437	chr5:178450457	ZNF879	-0.45	-5.86	-0.36	1.6e-8	Pubertal anthropometrics;
SARC	cis	rs12824058	0.831	rs7485200	chr12:130811641	C/T	cg26677194	chr12:130822605	PIWIL1	0.55	7.74	0.45	3.06e-13	Menopause (age at onset);
SARC	cis	rs9818758	0.556	rs9835439	chr3:49220330	G/C	cg06212747	chr3:49208901	KLHDC8B	-0.74	-6.34	-0.38	1.19e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs1348850	0.768	rs57681892	chr2:178357645	G/C	cg23306229	chr2:178417860	TTC30B	0.57	6.84	0.41	6.79e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9325144	0.647	rs34311455	chr12:39060889	C/T	cg13010199	chr12:38710504	ALG10B	-0.54	-6.88	-0.41	5.36e-11	Morning vs. evening chronotype;
SARC	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg06212747	chr3:49208901	KLHDC8B	0.68	9.31	0.52	1.01e-17	Parkinson's disease;
SARC	cis	rs9921222	0.521	rs78867928	chr16:368986	C/T	cg00101154	chr16:420108	MRPL28	-0.46	-6.36	-0.38	1.04e-9	Bone mineral density (spine);Bone mineral density;
SARC	trans	rs561341	0.769	rs8074383	chr17:30178793	C/T	cg20587970	chr11:113659929	NA	1.01	8.32	0.48	7.61e-15	Hip circumference adjusted for BMI;
SARC	cis	rs7762018	0.943	rs11546265	chr6:170108363	G/A	cg13891659	chr6:170190454	C6orf122;C6orf208	0.56	4.84	0.3	2.32e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs1153858	1.000	rs4271549	chr15:45652730	G/A	cg26924012	chr15:45694286	SPATA5L1	0.78	11.14	0.59	2.18e-23	Homoarginine levels;
SARC	cis	rs11764590	0.694	rs56072378	chr7:2104364	A/G	cg21782813	chr7:2030301	MAD1L1	-0.37	-5.37	-0.33	1.86e-7	Neuroticism;
SARC	cis	rs1044826	0.642	rs176983	chr3:139213755	G/A	cg15131784	chr3:139108705	COPB2	0.39	4.9	0.31	1.83e-6	Obesity-related traits;
SARC	cis	rs2070488	0.761	rs6807940	chr3:38460062	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.78	11.76	0.61	2.3e-25	Electrocardiographic conduction measures;
SARC	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg11301795	chr4:187892539	NA	-0.73	-10.2	-0.56	1.98e-20	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2439831	0.867	rs76542740	chr15:43891512	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	7.5	0.44	1.33e-12	Lung cancer in ever smokers;
SARC	cis	rs28374715	0.662	rs111522288	chr15:41480169	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.99	-13.75	-0.67	7e-32	Ulcerative colitis;
SARC	cis	rs11098499	0.754	rs12507565	chr4:120251121	G/A	cg09307838	chr4:120376055	NA	0.81	11.03	0.59	4.84e-23	Corneal astigmatism;
SARC	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg25405998	chr7:65216604	CCT6P1	0.48	5.85	0.36	1.63e-8	Calcium levels;
SARC	cis	rs10046574	0.831	rs3812271	chr7:135054438	C/T	cg27474649	chr7:135195673	CNOT4	0.76	6.15	0.37	3.26e-9	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs870825	0.616	rs4416519	chr4:185639502	T/C	cg04058563	chr4:185651563	MLF1IP	0.81	11.3	0.6	6.58e-24	Blood protein levels;
SARC	cis	rs66887589	0.807	rs7694483	chr4:120405929	T/A	cg09307838	chr4:120376055	NA	0.52	7.04	0.42	2.16e-11	Diastolic blood pressure;
SARC	cis	rs11190604	1.000	rs4919464	chr10:102221195	A/G	cg07080220	chr10:102295463	HIF1AN	0.76	9.5	0.53	2.59e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg04944784	chr2:26401820	FAM59B	-0.48	-5.99	-0.37	7.95e-9	Gut microbiome composition (summer);
SARC	cis	rs2070997	0.816	rs9695008	chr9:133720877	C/T	cg03924115	chr9:133768966	QRFP	0.53	5.89	0.36	1.31e-8	Response to amphetamines;
SARC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.65	0.53	9.21e-19	Prudent dietary pattern;
SARC	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg22496380	chr5:211416	CCDC127	-0.86	-8.81	-0.5	3.01e-16	Breast cancer;
SARC	cis	rs4481887	0.927	rs4347240	chr1:248475403	C/G	cg00666640	chr1:248458726	OR2T12	0.32	5.45	0.34	1.25e-7	Common traits (Other);
SARC	cis	rs11785400	0.793	rs2978973	chr8:143747271	C/G	cg10596483	chr8:143751796	JRK	0.56	7.07	0.42	1.76e-11	Schizophrenia;
SARC	cis	rs703842	1.000	rs10783847	chr12:58196447	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.78	11.38	0.6	3.68e-24	Multiple sclerosis;
SARC	cis	rs34779708	0.966	rs2045915	chr10:35418616	G/C	cg03585969	chr10:35415529	CREM	0.38	4.82	0.3	2.65e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg24110177	chr3:50126178	RBM5	0.63	8.44	0.48	3.41e-15	Body mass index;
SARC	cis	rs6700896	0.931	rs10749755	chr1:66129530	C/T	cg04111102	chr1:66153794	NA	0.36	5.66	0.35	4.49e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs9398803	0.830	rs1361109	chr6:126771143	C/T	cg19875578	chr6:126661172	C6orf173	0.6	8.15	0.47	2.22e-14	Male-pattern baldness;
SARC	cis	rs7712401	0.601	rs154502	chr5:122207046	C/T	cg19412675	chr5:122181750	SNX24	0.43	5.46	0.34	1.24e-7	Mean platelet volume;
SARC	trans	rs61931739	0.591	rs4931764	chr12:33979423	A/G	cg13010199	chr12:38710504	ALG10B	0.54	6.9	0.41	5e-11	Morning vs. evening chronotype;
SARC	cis	rs9513627	1.000	rs7334844	chr13:100121047	G/C	cg25919922	chr13:100150906	NA	-0.69	-5.21	-0.32	4.14e-7	Obesity-related traits;
SARC	cis	rs7589728	0.844	rs77144652	chr2:88496684	G/A	cg04511125	chr2:88470314	THNSL2	0.77	6.69	0.4	1.61e-10	Plasma clusterin levels;
SARC	cis	rs1949733	0.523	rs16842560	chr4:8544238	G/A	cg13073564	chr4:8508604	NA	0.5	7.44	0.44	1.88e-12	Response to antineoplastic agents;
SARC	cis	rs3888647	0.622	rs4758618	chr11:2995186	A/T	cg25174290	chr11:3078921	CARS	0.56	8.03	0.47	4.68e-14	Type 2 diabetes;
SARC	cis	rs66887589	0.967	rs13104219	chr4:120438174	G/T	cg09307838	chr4:120376055	NA	0.52	7.19	0.43	8.78e-12	Diastolic blood pressure;
SARC	cis	rs6120849	0.754	rs6120828	chr20:33674460	A/G	cg24642439	chr20:33292090	TP53INP2	0.56	5.31	0.33	2.52e-7	Protein C levels;
SARC	cis	rs3768617	0.706	rs9943067	chr1:182975102	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.68	9.7	0.54	6.68e-19	Fuchs's corneal dystrophy;
SARC	cis	rs12451471	0.637	rs12452616	chr17:78090081	A/G	cg24585782	chr17:78113791	EIF4A3	0.53	5.91	0.36	1.22e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
SARC	cis	rs11098499	0.754	rs7672372	chr4:120248406	A/G	cg09307838	chr4:120376055	NA	0.81	10.98	0.58	6.97e-23	Corneal astigmatism;
SARC	cis	rs412050	1.000	rs75599828	chr22:22333062	G/C	cg17089214	chr22:22089827	YPEL1	0.62	5.53	0.34	8.61e-8	Attention deficit hyperactivity disorder;
SARC	cis	rs3091242	1.000	rs3091242	chr1:25674785	C/T	cg03650068	chr1:25596491	NA	0.34	5.28	0.33	2.97e-7	Erythrocyte sedimentation rate;
SARC	cis	rs12311304	0.965	rs7973089	chr12:15360454	A/G	cg08258403	chr12:15378311	NA	0.44	6.86	0.41	6.3e-11	Behavioural disinhibition (generation interaction);
SARC	cis	rs4803468	0.901	rs3745292	chr19:41888506	A/G	cg14132834	chr19:41945861	ATP5SL	-0.54	-7.17	-0.43	1e-11	Height;
SARC	cis	rs798554	0.634	rs6970963	chr7:2821271	C/T	cg13628971	chr7:2884303	GNA12	0.45	5.54	0.34	8.23e-8	Height;
SARC	cis	rs9796	0.870	rs7181816	chr15:41358720	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.43	-5.91	-0.36	1.2e-8	Menopause (age at onset);
SARC	cis	rs11690935	0.731	rs10930491	chr2:172569824	A/G	cg13550731	chr2:172543902	DYNC1I2	0.65	9.3	0.52	1.06e-17	Schizophrenia;
SARC	cis	rs2721195	0.549	rs2958492	chr8:145919126	C/T	cg12270520	chr8:146023939	ZNF517	0.42	4.97	0.31	1.31e-6	Age at first birth;
SARC	cis	rs7546668	0.640	rs3766161	chr1:15809036	G/A	cg21858823	chr1:15850916	CASP9	0.47	5.72	0.35	3.18e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs7937682	0.737	rs679032	chr11:111423286	G/T	cg22437258	chr11:111473054	SIK2	0.56	7.34	0.43	3.54e-12	Primary sclerosing cholangitis;
SARC	cis	rs1971762	0.527	rs7976398	chr12:54028862	T/C	cg06632207	chr12:54070931	ATP5G2	0.59	7.97	0.46	6.85e-14	Height;
SARC	cis	rs72627509	0.904	rs12645070	chr4:57770106	G/A	cg26694713	chr4:57773883	REST	0.62	6.18	0.38	2.82e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs6582630	0.555	rs2090785	chr12:38424342	G/A	cg13010199	chr12:38710504	ALG10B	0.75	10.24	0.56	1.42e-20	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg16405210	chr4:1374714	KIAA1530	-0.46	-5.87	-0.36	1.47e-8	Longevity;
SARC	cis	rs2153535	0.580	rs7742689	chr6:8452433	C/A	cg21535247	chr6:8435926	SLC35B3	0.55	6.84	0.41	6.72e-11	Motion sickness;
SARC	cis	rs7792596	0.894	rs6948901	chr7:93977748	T/C	cg20814616	chr7:94014465	NA	-0.46	-5.85	-0.36	1.62e-8	Intelligence;
SARC	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg24642844	chr7:1081250	C7orf50	-0.59	-6.05	-0.37	5.79e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	trans	rs11039798	0.588	rs11039807	chr11:48549391	T/A	cg15704280	chr7:45808275	SEPT13	0.63	6.71	0.4	1.43e-10	Axial length;
SARC	cis	rs9457247	0.967	rs388406	chr6:167409562	A/G	cg23791538	chr6:167370224	RNASET2	-0.6	-8.25	-0.48	1.15e-14	Crohn's disease;
SARC	cis	rs796364	0.589	rs55700082	chr2:201135669	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.53	-5.02	-0.31	1.04e-6	Schizophrenia;
SARC	cis	rs7216064	1.000	rs4791212	chr17:65975385	C/T	cg12091567	chr17:66097778	LOC651250	-0.67	-6.82	-0.41	7.92e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs10490913	0.806	rs11198395	chr10:120169144	G/A	cg23160142	chr10:120154512	NA	0.37	5.61	0.35	5.58e-8	Cancer;
SARC	cis	rs8014131	0.689	rs8003381	chr14:85983996	C/A	cg10406690	chr14:85995726	FLRT2	0.4	5.28	0.33	2.93e-7	Menarche (age at onset);
SARC	cis	rs910316	1.000	rs9805979	chr14:75566209	G/A	cg23033748	chr14:75592666	NEK9	0.37	5.19	0.32	4.58e-7	Height;
SARC	cis	rs2295359	1.000	rs4655683	chr1:67611613	C/T	cg12940439	chr1:67600707	NA	0.43	6.71	0.4	1.51e-10	Psoriasis;
SARC	cis	rs6759839	0.698	rs1430046	chr2:16646181	A/G	cg09580478	chr2:16689509	NA	0.46	6.09	0.37	4.66e-9	Mean platelet volume;
SARC	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg07167872	chr1:205819463	PM20D1	-0.41	-5.28	-0.33	2.93e-7	Menarche (age at onset);
SARC	cis	rs7824557	0.806	rs7007394	chr8:11094566	G/A	cg21775007	chr8:11205619	TDH	-0.45	-5.36	-0.33	1.99e-7	Retinal vascular caliber;
SARC	cis	rs3733585	0.673	rs4314284	chr4:9956096	C/T	cg11266682	chr4:10021025	SLC2A9	-0.36	-6.21	-0.38	2.47e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	10.94	0.58	9.63e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs8067545	0.641	rs203462	chr17:19812541	T/C	cg04132472	chr17:19861366	AKAP10	0.39	5.1	0.32	7.18e-7	Schizophrenia;
SARC	cis	rs34172651	0.876	rs2547033	chr16:24743657	C/T	cg06028605	chr16:24865363	SLC5A11	0.28	4.94	0.31	1.47e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2652834	0.851	rs4468558	chr15:63346681	T/C	cg05507819	chr15:63340323	TPM1	0.57	5.71	0.35	3.48e-8	HDL cholesterol;
SARC	cis	rs1003719	0.751	rs2835585	chr21:38460488	T/A	cg10648535	chr21:38446584	PIGP;TTC3	0.65	9.38	0.52	6.22e-18	Eye color traits;
SARC	cis	rs7005606	1.000	rs36213229	chr8:32405517	G/T	cg14488905	chr8:32406789	NRG1	0.46	6.44	0.39	6.63e-10	Hirschsprung disease;
SARC	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg20102877	chr2:27665638	KRTCAP3	-0.38	-5.28	-0.33	2.96e-7	Total body bone mineral density;
SARC	cis	rs4276643	0.531	rs2685403	chr8:27821832	T/C	cg25028855	chr8:28560486	EXTL3	0.33	5.13	0.32	6.12e-7	Low vWF levels;
SARC	cis	rs1832871	0.672	rs62437159	chr6:158697705	C/T	cg07165851	chr6:158734300	TULP4	0.51	6.18	0.38	2.85e-9	Height;
SARC	cis	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg05623727	chr3:50126028	RBM5	0.37	5.39	0.33	1.73e-7	Intelligence (multi-trait analysis);
SARC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg07157834	chr1:205819609	PM20D1	-0.61	-10.17	-0.55	2.4e-20	Monocyte percentage of white cells;
SARC	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg22535103	chr8:58192502	C8orf71	-0.6	-6.15	-0.37	3.42e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2230307	0.536	rs12733952	chr1:100611571	A/G	cg24955406	chr1:100503596	HIAT1	0.69	6.71	0.4	1.47e-10	Carotid intima media thickness;
SARC	cis	rs7666738	0.830	rs13148324	chr4:98833616	G/A	cg05340658	chr4:99064831	C4orf37	0.66	8.76	0.5	4.2e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7274811	0.711	rs293713	chr20:31942247	A/G	cg21523528	chr20:32077966	CBFA2T2	-0.41	-4.82	-0.3	2.58e-6	Height;
SARC	trans	rs3808502	0.503	rs34190028	chr8:11417150	G/T	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.8	-0.41	8.93e-11	Neuroticism;
SARC	cis	rs16854884	0.770	rs920158	chr3:143799289	A/T	cg06585982	chr3:143692056	C3orf58	0.62	8.22	0.47	1.38e-14	Economic and political preferences (feminism/equality);
SARC	cis	rs870825	0.616	rs7658186	chr4:185622509	T/C	cg04058563	chr4:185651563	MLF1IP	0.84	11.62	0.61	6.27e-25	Blood protein levels;
SARC	cis	rs7172677	1.000	rs4243032	chr15:75426884	C/G	cg14664628	chr15:75095509	CSK	-0.45	-4.73	-0.3	3.85e-6	Systemic lupus erythematosus and Systemic sclerosis;
SARC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg01171360	chr6:293285	DUSP22	-0.56	-7.19	-0.43	8.77e-12	Menopause (age at onset);
SARC	cis	rs1707322	0.721	rs11211166	chr1:46157942	G/A	cg06784218	chr1:46089804	CCDC17	0.36	6.17	0.37	2.95e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs12479064	0.694	rs4341989	chr2:100046783	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.59	-7.08	-0.42	1.64e-11	Chronic sinus infection;
SARC	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	0.32	4.83	0.3	2.52e-6	Total body bone mineral density;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg08246527	chr1:150336743	RPRD2	0.52	6.28	0.38	1.62e-9	Blood pressure;
SARC	cis	rs13191362	1.000	rs36113695	chr6:163004733	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.57	5.38	0.33	1.85e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs12545109	0.765	rs2610047	chr8:57412106	T/C	cg19413350	chr8:57351067	NA	-0.43	-5.37	-0.33	1.88e-7	Obesity-related traits;
SARC	cis	rs7429990	0.965	rs28637561	chr3:48021018	G/A	cg11946769	chr3:48343235	NME6	-0.46	-5.39	-0.33	1.75e-7	Educational attainment (years of education);
SARC	cis	rs72945132	0.825	rs2298411	chr11:70206046	G/A	cg00319359	chr11:70116639	PPFIA1	0.69	6.46	0.39	6.2e-10	Coronary artery disease;
SARC	cis	rs11509880	0.606	rs11971133	chr7:12256548	T/C	cg23422036	chr7:12250390	TMEM106B	0.5	6.54	0.39	3.77e-10	Coronary artery disease;
SARC	cis	rs6493487	0.512	rs11854729	chr15:51249128	T/C	cg02338191	chr15:51200825	AP4E1	0.53	4.91	0.31	1.73e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs651907	0.535	rs11716558	chr3:101528481	T/C	cg12386194	chr3:101231763	SENP7	0.48	5.44	0.34	1.34e-7	Colorectal cancer;
SARC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg09436375	chr6:42928200	GNMT	-0.32	-4.81	-0.3	2.71e-6	Alzheimer's disease in APOE e4+ carriers;
SARC	trans	rs1814175	0.817	rs7947286	chr11:49874657	C/T	cg03929089	chr4:120376271	NA	-0.89	-14.53	-0.69	1.73e-34	Height;
SARC	cis	rs4243830	0.677	rs6693922	chr1:6584804	A/T	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.56	-4.87	-0.3	2.03e-6	Body mass index;
SARC	cis	rs6089584	1.000	rs6089585	chr20:60564395	G/A	cg13770153	chr20:60521292	NA	-0.55	-7.62	-0.45	6.53e-13	Body mass index;
SARC	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg03264133	chr6:25882463	NA	-0.55	-7.04	-0.42	2.1e-11	Intelligence (multi-trait analysis);
SARC	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg22920501	chr2:26401640	FAM59B	0.61	8.16	0.47	2.11e-14	Gut microbiome composition (summer);
SARC	trans	rs459571	0.959	rs2073818	chr9:136918662	C/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.63	-7.3	-0.43	4.5e-12	Platelet distribution width;
SARC	cis	rs6061231	1.000	rs67941642	chr20:60958108	C/T	cg24112000	chr20:60950667	NA	-0.38	-5.93	-0.36	1.1e-8	Colorectal cancer;
SARC	cis	rs8038465	0.622	rs60696711	chr15:73873005	C/A	cg15420318	chr15:73925796	NPTN	0.6	6.75	0.4	1.16e-10	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2153535	0.526	rs1796689	chr6:8536433	A/C	cg21535247	chr6:8435926	SLC35B3	0.53	6.65	0.4	2.09e-10	Motion sickness;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg17169015	chr21:34007131	SYNJ1	0.46	6.77	0.41	1.05e-10	Thyroid stimulating hormone;
SARC	cis	rs870825	0.616	rs28558715	chr4:185627761	G/A	cg04058563	chr4:185651563	MLF1IP	0.81	11.25	0.59	9.68e-24	Blood protein levels;
SARC	cis	rs17345786	0.602	rs11923273	chr3:101337863	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.48	5.73	0.35	3.03e-8	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.36	5.01	0.31	1.09e-6	Total body bone mineral density;
SARC	cis	rs854765	0.547	rs2955380	chr17:17944349	A/G	cg04398451	chr17:18023971	MYO15A	0.47	6.55	0.39	3.55e-10	Total body bone mineral density;
SARC	cis	rs4906332	1.000	rs1951389	chr14:103898525	G/C	cg26031613	chr14:104095156	KLC1	-0.49	-5.74	-0.35	2.89e-8	Coronary artery disease;
SARC	cis	rs3733585	0.648	rs28513781	chr4:9959334	G/C	cg11266682	chr4:10021025	SLC2A9	-0.35	-6.03	-0.37	6.35e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.45	5.06	0.31	8.61e-7	Renal function-related traits (BUN);
SARC	cis	rs7587476	0.531	rs35933323	chr2:215674090	T/G	cg04530015	chr2:215796436	ABCA12	0.45	7.45	0.44	1.84e-12	Neuroblastoma;
SARC	cis	rs7208859	0.673	rs73263776	chr17:29211331	G/C	cg13385521	chr17:29058706	SUZ12P	0.86	7.34	0.43	3.54e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	trans	rs8073060	0.572	rs1634683	chr17:33941560	G/C	cg19694781	chr19:47549865	TMEM160	-0.65	-6.59	-0.4	2.92e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs7429990	0.901	rs9825114	chr3:48138082	A/G	cg11946769	chr3:48343235	NME6	-0.49	-5.49	-0.34	1.04e-7	Educational attainment (years of education);
SARC	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg13395646	chr4:1353034	KIAA1530	-0.43	-5.34	-0.33	2.19e-7	Longevity;
SARC	cis	rs1008375	0.932	rs11934968	chr4:17667766	A/G	cg02297831	chr4:17616191	MED28	0.42	5.19	0.32	4.56e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6963495	0.818	rs73190183	chr7:105163022	G/A	cg13798780	chr7:105162888	PUS7	0.6	5.45	0.34	1.31e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs7100689	0.646	rs10788562	chr10:82072310	C/T	cg00277334	chr10:82204260	NA	0.37	4.95	0.31	1.43e-6	Post bronchodilator FEV1;
SARC	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg05036130	chr6:150231994	NA	0.29	5.13	0.32	6.06e-7	Testicular germ cell tumor;
SARC	cis	rs10911251	0.528	rs2182020	chr1:183074964	C/T	cg13390022	chr1:182993471	LAMC1	0.32	4.78	0.3	3.07e-6	Colorectal cancer;
SARC	cis	rs7769051	1.000	rs9493446	chr6:133125643	C/T	cg07930552	chr6:133119739	C6orf192	0.91	8.4	0.48	4.29e-15	Type 2 diabetes nephropathy;
SARC	cis	rs2777491	0.957	rs16971798	chr15:41657144	A/T	cg01768344	chr15:41576519	LOC729082	-0.43	-4.85	-0.3	2.22e-6	Ulcerative colitis;
SARC	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg00149659	chr3:10157352	C3orf10	0.69	6.9	0.41	4.76e-11	Alzheimer's disease;
SARC	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg24642844	chr7:1081250	C7orf50	-0.57	-6.05	-0.37	5.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs4481887	0.893	rs10158180	chr1:248481423	C/T	cg13385794	chr1:248469461	NA	0.33	5.08	0.32	7.75e-7	Common traits (Other);
SARC	cis	rs1797081	1.000	rs1797081	chr10:16874565	A/G	cg23933602	chr10:16859644	RSU1	0.93	18.17	0.77	1.57e-46	Platelet distribution width;
SARC	cis	rs7520050	0.966	rs12139630	chr1:46350935	A/G	cg24296786	chr1:45957014	TESK2	0.39	4.89	0.31	1.88e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs9879311	1.000	rs9879311	chr3:10415343	C/T	cg11030744	chr3:10328490	GHRL;GHRLOS	0.42	5.18	0.32	4.89e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	cis	rs1784581	0.588	rs7451121	chr6:162412344	A/G	cg17173639	chr6:162384350	PARK2	0.52	6.55	0.39	3.57e-10	Itch intensity from mosquito bite;
SARC	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs6991838	0.671	rs13251307	chr8:66577146	T/G	cg13398993	chr8:66546079	ARMC1	0.44	5.59	0.34	6.19e-8	Intelligence (multi-trait analysis);
SARC	cis	rs3784262	0.669	rs7178598	chr15:58309016	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.35	-5.2	-0.32	4.27e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs875971	0.502	rs1796227	chr7:66087019	G/C	cg11764359	chr7:65958608	NA	-0.61	-5.94	-0.36	1.05e-8	Aortic root size;
SARC	cis	rs2228479	0.850	rs11649510	chr16:89851004	A/G	cg00800038	chr16:89945340	TCF25	-0.79	-5.47	-0.34	1.19e-7	Skin colour saturation;
SARC	cis	rs10782582	0.609	rs80059220	chr1:76279112	G/T	cg03433033	chr1:76189801	ACADM	-0.38	-4.85	-0.3	2.29e-6	Daytime sleep phenotypes;
SARC	cis	rs9815354	0.812	rs10510729	chr3:41831998	G/A	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.03	12.03	0.62	3.06e-26	Alzheimer's disease;
SARC	cis	rs17270561	0.609	rs7772382	chr6:25708116	C/T	cg17691542	chr6:26056736	HIST1H1C	0.59	7.3	0.43	4.39e-12	Iron status biomarkers;
SARC	cis	rs3796352	0.881	rs11710394	chr3:53015839	A/G	cg07884673	chr3:53033167	SFMBT1	0.77	5.03	0.31	1e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs17376456	1.000	rs34068652	chr5:93563319	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.6	5.49	0.34	1.03e-7	Diabetic retinopathy;
SARC	cis	rs651907	0.557	rs35117343	chr3:101445126	A/G	cg12386194	chr3:101231763	SENP7	0.48	5.74	0.35	2.96e-8	Colorectal cancer;
SARC	cis	rs898097	0.528	rs2243523	chr17:80680449	G/T	cg15369054	chr17:80825471	TBCD	0.36	5.07	0.32	8.01e-7	Breast cancer;
SARC	cis	rs1018836	0.828	rs9297870	chr8:91570691	C/G	cg16814680	chr8:91681699	NA	-0.76	-11.69	-0.61	3.73e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs240764	0.621	rs4840154	chr6:101225723	A/C	cg09795085	chr6:101329169	ASCC3	-0.44	-5.75	-0.35	2.75e-8	Neuroticism;
SARC	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	8.26	0.48	1.09e-14	Mean platelet volume;
SARC	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg20120463	chr17:44301886	NA	0.31	4.87	0.3	2.02e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg12310025	chr6:25882481	NA	-0.48	-6.6	-0.4	2.7e-10	Intelligence (multi-trait analysis);
SARC	cis	rs5167	0.504	rs4803781	chr19:45459671	C/T	cg09555818	chr19:45449301	APOC2	0.57	9.39	0.52	5.85e-18	Blood protein levels;
SARC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg26338869	chr17:61819248	STRADA	0.77	10.13	0.55	3.28e-20	Prudent dietary pattern;
SARC	cis	rs4727027	0.835	rs11767810	chr7:148774433	T/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.47	5.71	0.35	3.35e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg17747265	chr1:1875780	NA	-0.33	-4.8	-0.3	2.77e-6	Body mass index;
SARC	cis	rs4742903	0.509	rs7030599	chr9:106942611	C/A	cg14250997	chr9:106856677	SMC2	0.4	5.03	0.31	9.64e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg16606324	chr3:10149918	C3orf24	0.48	5.04	0.31	9.53e-7	Alzheimer's disease;
SARC	cis	rs8180040	0.620	rs9858443	chr3:47086048	G/A	cg27129171	chr3:47204927	SETD2	0.7	9.6	0.53	1.35e-18	Colorectal cancer;
SARC	cis	rs911555	0.755	rs6575988	chr14:103900827	G/T	cg24130564	chr14:104152367	KLC1	0.49	5.68	0.35	4.01e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7552404	0.924	rs1251075	chr1:76190569	C/G	cg10523679	chr1:76189770	ACADM	0.46	6.39	0.39	9.07e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs826838	1.000	rs7315028	chr12:38710523	G/A	cg26384229	chr12:38710491	ALG10B	0.97	15.82	0.72	8.64e-39	Heart rate;
SARC	cis	rs7296418	0.961	rs4275659	chr12:123447928	C/T	cg05973401	chr12:123451056	ABCB9	-0.63	-7.72	-0.45	3.32e-13	Platelet count;
SARC	cis	rs765787	0.530	rs4238377	chr15:45541981	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.67e-7	Uric acid levels;
SARC	cis	rs7818345	0.935	rs4333618	chr8:19283442	G/C	cg11303988	chr8:19266685	CSGALNACT1	0.42	5.61	0.34	5.84e-8	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs73635312	0.850	rs17413004	chr10:8949180	T/A	cg24467326	chr10:9646929	NA	0.64	5.23	0.32	3.69e-7	Basal cell carcinoma;
SARC	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg13395646	chr4:1353034	KIAA1530	-0.46	-5.31	-0.33	2.56e-7	Obesity-related traits;
SARC	cis	rs17539620	0.624	rs62432735	chr6:154834055	T/C	cg20019720	chr6:154832845	CNKSR3	0.42	4.9	0.31	1.83e-6	Lipoprotein (a) levels;
SARC	cis	rs17376456	0.877	rs10044139	chr5:93407803	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.86	0.36	1.59e-8	Diabetic retinopathy;
SARC	cis	rs9457247	0.565	rs2038580	chr6:167456490	A/T	cg07741184	chr6:167504864	NA	0.36	6.93	0.41	4.18e-11	Crohn's disease;
SARC	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg12463550	chr7:65579703	CRCP	-0.49	-5.42	-0.33	1.47e-7	Aortic root size;
SARC	cis	rs734999	0.566	rs6424092	chr1:2532899	C/A	cg20673091	chr1:2541236	MMEL1	-0.34	-5.28	-0.33	2.92e-7	Ulcerative colitis;
SARC	cis	rs2050392	0.590	rs685319	chr10:30719331	G/A	cg25182066	chr10:30743637	MAP3K8	0.43	5.8	0.36	2.17e-8	Inflammatory bowel disease;
SARC	cis	rs7945705	0.747	rs11042150	chr11:9010819	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-6.85	-0.41	6.39e-11	Hemoglobin concentration;
SARC	cis	rs7246657	0.943	rs7255972	chr19:37933841	T/C	cg23950597	chr19:37808831	NA	-0.63	-6.03	-0.37	6.33e-9	Coronary artery calcification;
SARC	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg18876405	chr7:65276391	NA	-0.42	-4.98	-0.31	1.25e-6	Aortic root size;
SARC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg16132339	chr22:24313637	DDTL;DDT	-0.38	-5.17	-0.32	5.02e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7588746	0.621	rs2060122	chr2:201153177	A/G	cg23649088	chr2:200775458	C2orf69	-0.5	-5.97	-0.36	8.89e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg09455208	chr3:40491958	NA	-0.37	-5.53	-0.34	8.71e-8	Renal cell carcinoma;
SARC	cis	rs9796	0.835	rs3100807	chr15:41292206	G/A	cg18705301	chr15:41695430	NDUFAF1	0.41	5.73	0.35	3.06e-8	Menopause (age at onset);
SARC	cis	rs12995491	0.933	rs34029976	chr2:88537797	T/C	cg04511125	chr2:88470314	THNSL2	-0.4	-5.9	-0.36	1.25e-8	Response to metformin (IC50);
SARC	cis	rs870825	0.616	rs1401358	chr4:185640057	C/T	cg04058563	chr4:185651563	MLF1IP	0.76	10.77	0.58	3.24e-22	Blood protein levels;
SARC	cis	rs7667	0.959	rs12030205	chr1:19740174	A/T	cg15311933	chr1:19638897	PQLC2;AKR7A2	-0.5	-5.91	-0.36	1.24e-8	Crohn's disease and psoriasis;
SARC	cis	rs12681288	0.862	rs2600487	chr8:1016903	C/T	cg15309053	chr8:964076	NA	0.44	7.23	0.43	6.7e-12	Schizophrenia;
SARC	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg09359103	chr1:154839909	KCNN3	-0.42	-6.88	-0.41	5.62e-11	Prostate cancer;
SARC	cis	rs8114671	0.805	rs6060168	chr20:33621017	C/T	cg24642439	chr20:33292090	TP53INP2	0.48	5.62	0.35	5.53e-8	Height;
SARC	cis	rs13191362	1.000	rs55847707	chr6:163003414	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.49	0.34	1.04e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2180341	0.920	rs9398836	chr6:127576497	T/G	cg27446573	chr6:127587934	RNF146	1.0	13.77	0.67	5.8e-32	Breast cancer;
SARC	cis	rs950027	0.620	rs1145093	chr15:45649813	C/A	cg21132104	chr15:45694354	SPATA5L1	0.55	7.09	0.42	1.59e-11	Response to fenofibrate (adiponectin levels);
SARC	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg16405210	chr4:1374714	KIAA1530	-0.48	-5.72	-0.35	3.29e-8	Obesity-related traits;
SARC	cis	rs2228479	0.850	rs17233448	chr16:89816424	G/T	cg26513180	chr16:89883248	FANCA	0.72	4.79	0.3	2.99e-6	Skin colour saturation;
SARC	cis	rs965469	0.779	rs8117749	chr20:3386692	A/C	cg25506879	chr20:3388711	C20orf194	-0.49	-5.28	-0.33	2.91e-7	IFN-related cytopenia;
SARC	cis	rs950169	0.519	rs7237	chr15:85186577	C/T	cg17507749	chr15:85114479	UBE2QP1	0.59	6.68	0.4	1.7e-10	Schizophrenia;
SARC	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg02018176	chr4:1364513	KIAA1530	0.33	4.98	0.31	1.21e-6	Longevity;
SARC	cis	rs9733	0.650	rs3738485	chr1:150552392	C/G	cg17724175	chr1:150552817	MCL1	-0.4	-5.12	-0.32	6.36e-7	Tonsillectomy;
SARC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg11494091	chr17:61959527	GH2	0.55	8.18	0.47	1.85e-14	Prudent dietary pattern;
SARC	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	13.06	0.65	1.26e-29	Chronic sinus infection;
SARC	cis	rs2072438	0.503	rs2146838	chr9:123876305	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.39	-4.87	-0.3	2.07e-6	Rheumatoid arthritis;
SARC	cis	rs9894429	1.000	rs9747349	chr17:79584297	C/T	cg18240062	chr17:79603768	NPLOC4	0.71	9.81	0.54	3.03e-19	Eye color traits;
SARC	cis	rs9359856	0.517	rs11962350	chr6:90592406	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.61	-5.04	-0.31	9.22e-7	Bipolar disorder;
SARC	cis	rs611744	0.967	rs612265	chr8:109188650	A/G	cg21045802	chr8:109455806	TTC35	0.44	5.3	0.33	2.64e-7	Dupuytren's disease;
SARC	cis	rs11997175	0.624	rs7819074	chr8:33682472	C/T	ch.8.33884649F	chr8:33765107	NA	0.61	8.15	0.47	2.16e-14	Body mass index;
SARC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg07308232	chr7:1071921	C7orf50	-0.47	-5.62	-0.35	5.3e-8	Longevity;Endometriosis;
SARC	cis	rs780094	0.528	rs1728918	chr2:27635463	C/T	cg04845466	chr2:27665079	KRTCAP3;NRBP1	0.36	5.14	0.32	5.81e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs9303401	0.555	rs8073699	chr17:57236317	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.63	7.63	0.45	6.06e-13	Cognitive test performance;
SARC	cis	rs12477438	0.765	rs17708262	chr2:99696313	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.69	-9.17	-0.51	2.66e-17	Chronic sinus infection;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg25456386	chr20:3801121	C20orf29	0.49	6.48	0.39	5.45e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs9858542	0.903	rs35999162	chr3:49597230	C/G	cg03060546	chr3:49711283	APEH	-0.62	-7.9	-0.46	1.09e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg08219700	chr8:58056026	NA	0.46	4.96	0.31	1.34e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs2295359	0.824	rs4655679	chr1:67599657	A/G	cg03340356	chr1:67600835	NA	-0.36	-4.81	-0.3	2.65e-6	Psoriasis;
SARC	cis	rs1707322	0.721	rs10789468	chr1:46124558	A/G	cg06784218	chr1:46089804	CCDC17	0.36	6.2	0.38	2.6e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs17270561	0.636	rs6923367	chr6:25745852	A/T	cg16482183	chr6:26056742	HIST1H1C	0.43	5.08	0.32	7.76e-7	Iron status biomarkers;
SARC	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg00149659	chr3:10157352	C3orf10	0.71	6.62	0.4	2.41e-10	Alzheimer's disease;
SARC	cis	rs10089	0.953	rs4836359	chr5:127385518	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	10.19	0.56	2.04e-20	Ileal carcinoids;
SARC	cis	rs12479064	0.724	rs10496336	chr2:99996165	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.67	-8.44	-0.48	3.42e-15	Chronic sinus infection;
SARC	cis	rs1348850	0.554	rs7595576	chr2:178371921	C/T	cg23306229	chr2:178417860	TTC30B	0.84	7.66	0.45	4.88e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7552404	0.924	rs1146581	chr1:76213024	T/G	cg10523679	chr1:76189770	ACADM	0.45	6.2	0.38	2.49e-9	Blood metabolite levels;Acylcarnitine levels;
SARC	trans	rs208520	0.690	rs1304672	chr6:66847973	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	11.19	0.59	1.52e-23	Exhaled nitric oxide output;
SARC	cis	rs12758548	0.801	rs1984403	chr1:172466855	G/T	cg24039962	chr1:172507360	C1orf9	0.36	4.72	0.3	4.01e-6	Erythrocyte cadmium concentration in never smokers;
SARC	cis	rs6696846	0.765	rs11240360	chr1:205083865	T/C	cg21643547	chr1:205240462	TMCC2	-0.59	-7.94	-0.46	8.31e-14	Red blood cell count;
SARC	cis	rs6503863	1	rs6503863	chr17:56517034	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.42	5.22	0.32	3.88e-7	Intelligence (multi-trait analysis);
SARC	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg01017244	chr2:74357527	NA	0.54	6.68	0.4	1.75e-10	Gestational age at birth (maternal effect);
SARC	cis	rs6582630	0.555	rs56228141	chr12:38518652	T/G	cg26384229	chr12:38710491	ALG10B	0.85	12.57	0.64	5.28e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9911578	1.000	rs4398153	chr17:56968181	T/C	cg12560992	chr17:57184187	TRIM37	-0.84	-11.38	-0.6	3.73e-24	Intelligence (multi-trait analysis);
SARC	cis	rs35110281	0.681	rs162343	chr21:44957072	A/G	cg21573476	chr21:45109991	RRP1B	-0.44	-6.39	-0.39	8.77e-10	Mean corpuscular volume;
SARC	cis	rs13082711	0.911	rs4973769	chr3:27425746	T/C	cg02860705	chr3:27208620	NA	0.47	6.24	0.38	2.05e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-8.78	-0.5	3.5e-16	Alzheimer's disease;
SARC	trans	rs1814175	0.817	rs4881648	chr11:49812901	A/G	cg15704280	chr7:45808275	SEPT13	-0.97	-17.96	-0.76	7.46e-46	Height;
SARC	cis	rs6831352	0.918	rs29001214	chr4:100051733	A/G	cg12011299	chr4:100065546	ADH4	-0.34	-5.67	-0.35	4.13e-8	Alcohol dependence;
SARC	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg16325326	chr1:53192061	ZYG11B	-0.83	-13.0	-0.65	2.09e-29	Monocyte count;
SARC	cis	rs763121	0.853	rs5750630	chr22:38985818	A/C	cg06022373	chr22:39101656	GTPBP1	0.89	11.55	0.6	1.04e-24	Menopause (age at onset);
SARC	cis	rs1707322	0.752	rs11488313	chr1:46224780	G/C	cg06784218	chr1:46089804	CCDC17	0.4	6.97	0.42	3.23e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg14541582	chr5:601475	NA	-0.4	-5.04	-0.31	9.47e-7	Obesity-related traits;
SARC	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg11764359	chr7:65958608	NA	0.66	7.83	0.46	1.7e-13	Aortic root size;
SARC	cis	rs7264396	0.790	rs6060541	chr20:34248066	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-8.22	-0.47	1.46e-14	Total cholesterol levels;
SARC	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs870825	0.616	rs28673855	chr4:185627416	T/G	cg04058563	chr4:185651563	MLF1IP	0.81	11.25	0.59	9.68e-24	Blood protein levels;
SARC	cis	rs13256369	0.951	rs12679360	chr8:8566269	G/T	cg18904891	chr8:8559673	CLDN23	-0.41	-4.72	-0.3	4.09e-6	Obesity-related traits;
SARC	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	8.97	0.51	1.03e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6665290	0.904	rs1045252	chr1:227181555	A/G	cg14016676	chr1:227182615	CDC42BPA	0.33	4.83	0.3	2.5e-6	Myeloid white cell count;
SARC	cis	rs9916302	0.904	rs6503507	chr17:37525274	C/T	cg20243544	chr17:37824526	PNMT	-0.55	-6.55	-0.39	3.61e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs67460515	0.892	rs73026974	chr3:160963231	A/C	cg04691961	chr3:161091175	C3orf57	-0.47	-5.82	-0.36	1.89e-8	Parkinson's disease;
SARC	cis	rs12545109	0.613	rs10958480	chr8:57278717	A/T	cg19413350	chr8:57351067	NA	-0.39	-4.89	-0.31	1.89e-6	Obesity-related traits;
SARC	cis	rs644799	0.965	rs534488	chr11:95562327	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.9	14.03	0.68	7.82e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs6089584	0.528	rs4925335	chr20:60627034	G/A	cg13770153	chr20:60521292	NA	-0.38	-5.41	-0.33	1.53e-7	Body mass index;
SARC	trans	rs75763843	0.689	rs12607156	chr18:42072529	C/T	cg07323648	chr17:35291127	NA	-0.56	-6.48	-0.39	5.35e-10	Mean platelet volume;
SARC	cis	rs3762637	0.823	rs59569049	chr3:122238788	A/T	cg24169773	chr3:122142474	KPNA1	-0.58	-5.86	-0.36	1.57e-8	LDL cholesterol levels;
SARC	cis	rs2180341	1.000	rs2144743	chr6:127633810	A/T	cg24812749	chr6:127587940	RNF146	0.97	12.89	0.65	4.63e-29	Breast cancer;
SARC	cis	rs6570726	0.935	rs380883	chr6:145822992	A/G	cg05220968	chr6:146057943	EPM2A	-0.32	-5.45	-0.34	1.26e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs427394	0.582	rs274667	chr5:6710771	A/G	cg10857441	chr5:6722123	POLS	0.34	4.87	0.3	2.03e-6	Menopause (age at onset);
SARC	cis	rs3754214	0.823	rs496203	chr1:150270025	A/G	cg09579323	chr1:150459698	TARS2	-0.42	-5.43	-0.33	1.44e-7	Cerebrospinal fluid biomarker levels;
SARC	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg11890956	chr21:40555474	PSMG1	1.18	20.15	0.8	5.81e-53	Cognitive function;
SARC	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.69	-6.46	-0.39	5.91e-10	Platelet count;
SARC	cis	rs112591243	0.614	rs78654337	chr21:47824372	A/G	cg26904215	chr21:47823096	PCNT	-0.79	-5.15	-0.32	5.59e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg12310025	chr6:25882481	NA	0.52	6.82	0.41	7.54e-11	Blood metabolite levels;
SARC	cis	rs883565	0.569	rs1274973	chr3:39160441	G/A	cg26331595	chr3:39149181	GORASP1;TTC21A	0.43	5.04	0.31	9.47e-7	Handedness;
SARC	cis	rs9911578	1.000	rs10401050	chr17:56953786	A/C	cg12560992	chr17:57184187	TRIM37	0.86	11.82	0.61	1.41e-25	Intelligence (multi-trait analysis);
SARC	trans	rs7615952	0.932	rs7629977	chr3:125649573	T/G	cg07211511	chr3:129823064	LOC729375	-0.94	-10.6	-0.57	1.13e-21	Blood pressure (smoking interaction);
SARC	cis	rs6546550	0.935	rs4853027	chr2:70039224	A/G	cg02498382	chr2:70120550	SNRNP27	0.39	6.5	0.39	4.73e-10	Prevalent atrial fibrillation;
SARC	cis	rs2120019	0.938	rs3850093	chr15:75318482	A/G	cg12414181	chr15:75287860	SCAMP5	0.46	4.87	0.3	2.04e-6	Blood trace element (Zn levels);
SARC	cis	rs6963495	0.818	rs73192144	chr7:105203535	C/T	cg13798780	chr7:105162888	PUS7	0.57	5.29	0.33	2.83e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs870825	0.929	rs72689272	chr4:185592515	T/C	cg04058563	chr4:185651563	MLF1IP	0.77	8.75	0.5	4.36e-16	Blood protein levels;
SARC	cis	rs6991838	0.584	rs3812412	chr8:66547092	G/A	cg13398993	chr8:66546079	ARMC1	0.62	8.19	0.47	1.72e-14	Intelligence (multi-trait analysis);
SARC	trans	rs36093844	0.800	rs76464398	chr11:85583898	C/T	cg27065003	chr5:122429449	PRDM6	-0.55	-6.46	-0.39	5.9e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	trans	rs1814175	0.817	rs4881627	chr11:49953955	C/A	cg03929089	chr4:120376271	NA	-0.89	-14.59	-0.69	1.1e-34	Height;
SARC	cis	rs3768617	0.510	rs10911243	chr1:183075415	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.17	0.55	2.42e-20	Fuchs's corneal dystrophy;
SARC	cis	rs1008375	1.000	rs114490726	chr4:17680898	T/C	cg16339924	chr4:17578868	LAP3	0.64	8.44	0.48	3.47e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2180341	0.960	rs1543432	chr6:127698018	T/C	cg17762328	chr6:126965162	NA	-0.44	-4.86	-0.3	2.13e-6	Breast cancer;
SARC	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg04944784	chr2:26401820	FAM59B	-0.59	-7.88	-0.46	1.25e-13	Gut microbiome composition (summer);
SARC	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	5.69	0.35	3.81e-8	Bipolar disorder;
SARC	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg04772025	chr11:68637568	NA	0.51	6.33	0.38	1.25e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs3126085	0.935	rs6587651	chr1:152193121	G/T	cg03465714	chr1:152285911	FLG	-0.48	-5.85	-0.36	1.66e-8	Atopic dermatitis;
SARC	cis	rs7626444	0.625	rs843539	chr3:196474856	T/C	cg12930392	chr3:196481615	PAK2	0.25	4.95	0.31	1.43e-6	Monocyte count;
SARC	cis	rs2050392	0.517	rs2771242	chr10:30762973	C/T	cg25182066	chr10:30743637	MAP3K8	0.41	5.68	0.35	3.93e-8	Inflammatory bowel disease;
SARC	cis	rs763121	0.853	rs6001184	chr22:39052116	C/T	cg06022373	chr22:39101656	GTPBP1	0.9	11.56	0.6	9.96e-25	Menopause (age at onset);
SARC	trans	rs9329221	0.683	rs688491	chr8:9884823	C/G	cg21775007	chr8:11205619	TDH	-0.51	-6.66	-0.4	1.9e-10	Neuroticism;
SARC	cis	rs9393777	0.513	rs7740197	chr6:26663478	C/T	cg12826209	chr6:26865740	GUSBL1	-0.6	-5.42	-0.33	1.51e-7	Intelligence (multi-trait analysis);
SARC	cis	rs288326	0.561	rs76304059	chr2:183779555	C/G	cg09997497	chr2:183902928	NCKAP1	0.75	5.13	0.32	6.18e-7	Blood protein levels;
SARC	cis	rs10752881	1.000	rs10797802	chr1:182973158	A/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.7	-10.5	-0.57	2.3e-21	Colorectal cancer;
SARC	cis	rs6546324	0.580	rs4362541	chr2:67842866	A/T	cg18237512	chr2:67827392	NA	-0.54	-6.25	-0.38	1.97e-9	Endometriosis;
SARC	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg22920501	chr2:26401640	FAM59B	0.61	8.19	0.47	1.71e-14	Gut microbiome composition (summer);
SARC	cis	rs6732160	0.934	rs2421390	chr2:73379103	T/C	cg01422370	chr2:73384389	NA	0.3	4.81	0.3	2.74e-6	Intelligence (multi-trait analysis);
SARC	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg17294928	chr15:75287854	SCAMP5	0.53	6.8	0.41	8.86e-11	Breast cancer;
SARC	cis	rs6674176	0.597	rs4660262	chr1:44382524	G/A	cg12908607	chr1:44402522	ARTN	-0.41	-7.29	-0.43	4.93e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg18252515	chr7:66147081	NA	-0.63	-6.76	-0.41	1.07e-10	Aortic root size;
SARC	cis	rs17030434	0.954	rs6847810	chr4:154752789	C/T	cg14289246	chr4:154710475	SFRP2	-0.73	-7.57	-0.44	8.58e-13	Electrocardiographic conduction measures;
SARC	cis	rs57994353	0.897	rs55824202	chr9:139357273	A/T	cg13611204	chr9:139324423	INPP5E	-0.28	-4.79	-0.3	2.99e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs13256369	0.802	rs1060107	chr8:8561399	G/T	cg18904891	chr8:8559673	CLDN23	0.47	5.32	0.33	2.45e-7	Obesity-related traits;
SARC	cis	rs11770686	1.000	rs11770686	chr7:75348306	A/T	cg17787366	chr7:75369077	HIP1	0.43	5.36	0.33	2.01e-7	Essential tremor;
SARC	cis	rs796364	0.806	rs203766	chr2:200902672	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.74	-6.22	-0.38	2.24e-9	Schizophrenia;
SARC	cis	rs3733346	0.553	rs2290403	chr4:942006	G/A	cg15105011	chr4:940614	TMEM175	0.35	4.9	0.31	1.78e-6	Sjögren's syndrome;
SARC	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg15448220	chr1:150897856	SETDB1	0.47	6.25	0.38	1.94e-9	Tonsillectomy;
SARC	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.62	7.45	0.44	1.8e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs16976116	0.532	rs6493754	chr15:55435798	G/A	cg11288833	chr15:55489084	RSL24D1	-0.57	-4.86	-0.3	2.19e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg10381488	chr15:45694016	SPATA5L1	-0.4	-4.83	-0.3	2.45e-6	Homoarginine levels;
SARC	cis	rs765787	0.530	rs28897155	chr15:45533974	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.67e-7	Uric acid levels;
SARC	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg19223190	chr17:80058835	NA	0.46	6.49	0.39	5.2400000000000005e-10	Life satisfaction;
SARC	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg20887711	chr4:1340912	KIAA1530	-0.61	-7.29	-0.43	4.7e-12	Obesity-related traits;
SARC	cis	rs11150038	0.826	rs8050709	chr16:78086427	T/G	cg04733911	chr16:78082701	NA	0.43	4.8	0.3	2.83e-6	Colorectal or endometrial cancer;
SARC	cis	rs6866344	0.569	rs56027952	chr5:178150181	C/A	cg03877680	chr5:178157825	ZNF354A	1.1	14.63	0.69	8.3e-35	Neutrophil percentage of white cells;
SARC	cis	rs251130	0.709	rs116071630	chr5:110849505	A/T	cg13674042	chr5:110848180	STARD4	0.47	5.3	0.33	2.63e-7	Menarche (age at onset);
SARC	cis	rs6120849	0.901	rs6060270	chr20:33736814	G/T	cg24642439	chr20:33292090	TP53INP2	0.52	5.22	0.32	4.05e-7	Protein C levels;
SARC	cis	rs8141529	0.509	rs5762864	chr22:29253364	T/C	cg02153584	chr22:29168773	CCDC117	0.7	9.45	0.53	3.82e-18	Lymphocyte counts;
SARC	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg22974920	chr21:40686053	BRWD1	-0.43	-4.81	-0.3	2.67e-6	Cognitive function;
SARC	cis	rs3749237	0.557	rs7631908	chr3:49425707	T/G	cg02487422	chr3:49467188	NICN1	0.5	6.51	0.39	4.57e-10	Resting heart rate;
SARC	cis	rs6840360	0.870	rs7680604	chr4:152469917	C/T	cg22705602	chr4:152727874	NA	-0.37	-6.09	-0.37	4.62e-9	Intelligence (multi-trait analysis);
SARC	cis	rs244293	0.695	rs9303360	chr17:53001456	T/C	cg19360675	chr17:53046073	COX11;STXBP4	-0.4	-4.75	-0.3	3.6e-6	Menarche (age at onset);
SARC	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	5.34	0.33	2.17e-7	Tonsillectomy;
SARC	cis	rs9660992	0.736	rs72745207	chr1:205251991	C/G	cg07972983	chr1:205091412	RBBP5	0.55	6.57	0.4	3.2e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg13206674	chr6:150067644	NUP43	0.52	6.65	0.4	2.05e-10	Lung cancer;
SARC	cis	rs2663905	0.664	rs2460855	chr15:81361729	G/T	cg09888468	chr15:81410853	NA	-0.4	-5.38	-0.33	1.84e-7	QT interval (drug interaction);
SARC	cis	rs4660306	0.961	rs7546268	chr1:45965340	T/C	cg24296786	chr1:45957014	TESK2	0.56	6.54	0.39	3.8e-10	Homocysteine levels;
SARC	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg06028808	chr11:68637592	NA	0.44	5.49	0.34	1.06e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs4481887	0.927	rs4537599	chr1:248508741	G/A	cg00666640	chr1:248458726	OR2T12	0.38	6.36	0.38	1.07e-9	Common traits (Other);
SARC	cis	rs9902453	0.902	rs4075014	chr17:28305674	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	6.83	0.41	7.35e-11	Coffee consumption (cups per day);
SARC	cis	rs472402	0.623	rs7727273	chr5:6635933	A/C	cg27314116	chr5:6583850	LOC255167	0.3	4.73	0.3	3.83e-6	Response to amphetamines;
SARC	trans	rs7815944	1.000	rs58299386	chr8:129451995	C/G	cg17342469	chr22:46473074	NA	0.69	6.67	0.4	1.88e-10	Atopic dermatitis;
SARC	cis	rs3820928	0.874	rs4675131	chr2:227836742	T/G	cg05526886	chr2:227700861	RHBDD1	-0.56	-6.86	-0.41	6.12e-11	Pulmonary function;
SARC	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg16405210	chr4:1374714	KIAA1530	0.51	6.18	0.38	2.85e-9	Obesity-related traits;
SARC	cis	rs796364	0.806	rs6435041	chr2:200867144	A/G	cg23649088	chr2:200775458	C2orf69	0.6	5.35	0.33	2.08e-7	Schizophrenia;
SARC	cis	rs3733585	0.699	rs11724510	chr4:9958583	C/T	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.35	-0.33	2.06e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7296418	0.580	rs78455769	chr12:123856443	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-5.38	-0.33	1.84e-7	Platelet count;
SARC	cis	rs2735413	0.918	rs4888733	chr16:78080523	C/T	cg04733911	chr16:78082701	NA	-0.3	-5.47	-0.34	1.14e-7	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs11718455	1.000	rs9858826	chr3:44031412	C/T	cg08738300	chr3:44038990	NA	-0.51	-5.79	-0.35	2.25e-8	Coronary artery disease;
SARC	cis	rs910316	0.737	rs175043	chr14:75471803	G/A	cg08847533	chr14:75593920	NEK9	-0.8	-11.11	-0.59	2.81e-23	Height;
SARC	cis	rs55692411	0.537	rs62262118	chr3:50003586	G/A	cg24110177	chr3:50126178	RBM5	-0.48	-5.39	-0.33	1.74e-7	Intelligence (multi-trait analysis);
SARC	trans	rs10448080	0.879	rs240946	chr8:28568905	A/G	cg10209083	chr8:30769602	NA	-0.5	-7.18	-0.43	9.49e-12	Height;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg03541381	chr16:790595	NARFL	-0.55	-7.17	-0.43	1e-11	Gallstone disease;
SARC	cis	rs9290065	0.519	rs1447608	chr3:160682019	G/T	cg04691961	chr3:161091175	C3orf57	-0.5	-6.28	-0.38	1.68e-9	Kawasaki disease;
SARC	cis	rs62244186	0.659	rs9855433	chr3:44468065	C/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.47	5.92	0.36	1.13e-8	Depressive symptoms;
SARC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg04013093	chr6:42928303	GNMT	-0.33	-4.98	-0.31	1.24e-6	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg24829409	chr8:58192753	C8orf71	-0.55	-6.18	-0.38	2.84e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9487051	0.735	rs882074	chr6:109611720	C/T	cg01475377	chr6:109611718	NA	-0.41	-5.9	-0.36	1.25e-8	Reticulocyte fraction of red cells;
SARC	trans	rs208515	0.525	rs12215007	chr6:66671008	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-11.56	-0.6	1.01e-24	Exhaled nitric oxide levels;
SARC	cis	rs644799	1.000	rs543530	chr11:95545170	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	14.15	0.68	3.08e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs4077515	0.577	rs3812584	chr9:139312719	C/T	cg14169450	chr9:139327907	INPP5E	-0.4	-5.16	-0.32	5.17e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs9790314	0.747	rs6789244	chr3:160866230	A/C	cg03342759	chr3:160939853	NMD3	-0.56	-7.23	-0.43	6.82e-12	Morning vs. evening chronotype;
SARC	trans	rs9427116	0.502	rs12125166	chr1:154582129	A/G	cg10535353	chr2:200323432	SATB2	-0.5	-6.25	-0.38	1.96e-9	Blood protein levels;
SARC	cis	rs796364	0.906	rs6740981	chr2:201060216	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.56	5.72	0.35	3.22e-8	Schizophrenia;
SARC	cis	rs6456156	0.716	rs6905876	chr6:167521562	C/T	cg07741184	chr6:167504864	NA	0.33	6.16	0.37	3.14e-9	Primary biliary cholangitis;
SARC	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg04944784	chr2:26401820	FAM59B	-0.47	-5.77	-0.35	2.47e-8	Gut microbiome composition (summer);
SARC	cis	rs6089584	0.566	rs6061964	chr20:60607536	G/A	cg06108461	chr20:60628389	TAF4	-0.72	-9.56	-0.53	1.73e-18	Body mass index;
SARC	cis	rs78545713	0.649	rs79759076	chr6:26223694	C/G	cg00631329	chr6:26305371	NA	-0.71	-5.14	-0.32	5.85e-7	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs1670533	0.932	rs2045067	chr4:1052355	C/T	cg27284194	chr4:1044797	NA	0.45	4.73	0.3	3.89e-6	Recombination rate (females);
SARC	trans	rs7824557	0.767	rs6985460	chr8:11171087	A/C	cg06636001	chr8:8085503	FLJ10661	0.54	6.63	0.4	2.32e-10	Retinal vascular caliber;
SARC	cis	rs4713118	0.869	rs9283882	chr6:27715258	A/C	cg17221315	chr6:27791827	HIST1H4J	0.49	5.33	0.33	2.26e-7	Parkinson's disease;
SARC	cis	rs1448094	0.967	rs2405789	chr12:86320466	C/T	cg02569458	chr12:86230093	RASSF9	-0.39	-5.64	-0.35	4.8e-8	Major depressive disorder;
SARC	cis	rs1371867	0.846	rs1692007	chr8:101268343	T/C	cg11906718	chr8:101322791	RNF19A	-0.67	-8.94	-0.51	1.26e-16	Atrioventricular conduction;
SARC	cis	rs7647973	0.626	rs62262672	chr3:49655927	T/A	cg03060546	chr3:49711283	APEH	-0.63	-6.18	-0.38	2.77e-9	Menarche (age at onset);
SARC	cis	rs2050392	0.557	rs306588	chr10:30723593	G/A	cg25182066	chr10:30743637	MAP3K8	0.41	5.59	0.34	6.27e-8	Inflammatory bowel disease;
SARC	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg09359103	chr1:154839909	KCNN3	-0.44	-7.59	-0.45	7.47e-13	Prostate cancer;
SARC	cis	rs11997175	0.574	rs12541661	chr8:33649856	T/G	ch.8.33884649F	chr8:33765107	NA	0.5	6.63	0.4	2.28e-10	Body mass index;
SARC	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.97e-8	Aortic root size;
SARC	cis	rs16937	0.711	rs10751429	chr1:205107478	C/T	cg21643547	chr1:205240462	TMCC2	-0.49	-6.03	-0.37	6.52e-9	Schizophrenia;
SARC	cis	rs6484504	0.576	rs208088	chr11:31192686	T/C	cg26647111	chr11:31128758	NA	-0.39	-5.1	-0.32	7.01e-7	Red blood cell count;
SARC	cis	rs12079745	0.590	rs10919100	chr1:169190401	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.88	-5.6	-0.34	5.96e-8	QT interval;
SARC	cis	rs920590	1.000	rs920590	chr8:19651161	A/G	cg03894339	chr8:19674705	INTS10	0.45	5.42	0.33	1.49e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs908922	0.676	rs7532535	chr1:152517597	T/A	cg09873164	chr1:152488093	CRCT1	0.64	8.6	0.49	1.16e-15	Hair morphology;
SARC	cis	rs7043114	0.525	rs2025388	chr9:95128740	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.81	-0.36	2.02e-8	Height;
SARC	cis	rs9902453	0.838	rs8064689	chr17:28217053	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	6.94	0.41	3.92e-11	Coffee consumption (cups per day);
SARC	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg07061783	chr6:25882402	NA	0.37	4.77	0.3	3.32e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7216064	1.000	rs7221651	chr17:65832390	A/G	cg12091567	chr17:66097778	LOC651250	0.74	8.13	0.47	2.54e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs854765	0.547	rs2955377	chr17:17932818	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.66	9.52	0.53	2.25e-18	Total body bone mineral density;
SARC	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg16479474	chr6:28041457	NA	0.36	5.45	0.34	1.25e-7	Parkinson's disease;
SARC	cis	rs9911578	1.000	rs304296	chr17:56834229	G/T	cg05425664	chr17:57184151	TRIM37	-0.66	-8.1	-0.47	3.14e-14	Intelligence (multi-trait analysis);
SARC	cis	rs11638352	0.661	rs2615269	chr15:44427956	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	5.91	0.36	1.23e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	cis	rs11997175	0.546	rs13282996	chr8:33596397	C/T	ch.8.33884649F	chr8:33765107	NA	0.48	6.1	0.37	4.3e-9	Body mass index;
SARC	cis	rs7833790	0.929	rs10958048	chr8:82792914	C/T	cg17211192	chr8:82754475	SNX16	0.55	6.1	0.37	4.35e-9	Diastolic blood pressure;
SARC	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg09455208	chr3:40491958	NA	0.4	5.85	0.36	1.66e-8	Renal cell carcinoma;
SARC	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg13902645	chr11:5959945	NA	-0.45	-5.98	-0.36	8.23e-9	DNA methylation (variation);
SARC	cis	rs2197308	0.765	rs12370231	chr12:37917881	T/C	cg26384229	chr12:38710491	ALG10B	0.9	13.3	0.66	2.04e-30	Morning vs. evening chronotype;
SARC	cis	rs7412746	0.588	rs10305664	chr1:150839686	A/C	cg10589385	chr1:150898437	SETDB1	0.42	5.56	0.34	7.45e-8	Melanoma;
SARC	trans	rs7824557	0.564	rs2736294	chr8:11234626	T/C	cg15556689	chr8:8085844	FLJ10661	-0.55	-6.96	-0.41	3.44e-11	Retinal vascular caliber;
SARC	cis	rs6089584	0.927	rs11697597	chr20:60584748	C/T	cg23262073	chr20:60523788	NA	-0.45	-6.54	-0.39	3.91e-10	Body mass index;
SARC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.35	0.52	7.64e-18	Prudent dietary pattern;
SARC	cis	rs9902453	0.845	rs2617865	chr17:28049804	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.54	-7.07	-0.42	1.83e-11	Coffee consumption (cups per day);
SARC	cis	rs6604026	0.656	rs11577636	chr1:93402849	T/C	cg17283838	chr1:93427260	FAM69A	0.41	4.76	0.3	3.35e-6	Multiple sclerosis;
SARC	trans	rs561341	0.843	rs879945	chr17:30242796	G/A	cg20587970	chr11:113659929	NA	-0.87	-8.76	-0.5	4.15e-16	Hip circumference adjusted for BMI;
SARC	cis	rs1153858	1.000	rs56669689	chr15:45637729	A/C	cg14582100	chr15:45693742	SPATA5L1	0.36	5.03	0.31	9.88e-7	Homoarginine levels;
SARC	cis	rs300703	0.719	rs385272	chr2:206704	A/G	cg21211680	chr2:198530	NA	-0.51	-5.95	-0.36	9.55e-9	Blood protein levels;
SARC	cis	rs8077889	0.917	rs6503479	chr17:41917003	A/G	cg26893861	chr17:41843967	DUSP3	0.81	10.07	0.55	4.9e-20	Triglycerides;
SARC	cis	rs7432375	0.610	rs7621932	chr3:136517016	C/T	cg15507776	chr3:136538369	TMEM22	0.61	7.58	0.44	8.18e-13	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	cis	rs4713118	0.869	rs9283881	chr6:27715255	A/T	cg17221315	chr6:27791827	HIST1H4J	0.49	5.33	0.33	2.26e-7	Parkinson's disease;
SARC	cis	rs6500395	1.000	rs9924078	chr16:48557918	A/C	cg04672837	chr16:48644449	N4BP1	-0.41	-4.96	-0.31	1.39e-6	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg25036284	chr2:26402008	FAM59B	0.46	5.7	0.35	3.59e-8	Gut microbiome composition (summer);
SARC	cis	rs607987	0.871	rs7125524	chr11:30330963	G/A	cg06241208	chr11:30344200	C11orf46	0.39	4.73	0.3	3.85e-6	Body mass index;
SARC	cis	rs503734	0.521	rs348881	chr3:100970920	A/C	cg27318481	chr3:100970896	IMPG2	-0.46	-5.48	-0.34	1.12e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg17971929	chr21:40555470	PSMG1	0.99	13.73	0.67	7.64e-32	Cognitive function;
SARC	cis	rs4481887	1.000	rs10788782	chr1:248496132	C/A	cg00666640	chr1:248458726	OR2T12	0.4	6.58	0.4	3.1e-10	Common traits (Other);
SARC	cis	rs4969178	0.930	rs4580257	chr17:76403028	T/G	cg02836325	chr17:76403955	PGS1	0.33	4.99	0.31	1.19e-6	HDL cholesterol levels;
SARC	cis	rs11209002	0.956	rs10749772	chr1:67586231	A/G	cg02640540	chr1:67518911	SLC35D1	0.48	4.87	0.3	2.03e-6	Crohn's disease;
SARC	cis	rs2652822	0.525	rs2899691	chr15:63519088	T/A	cg02713581	chr15:63449717	RPS27L	0.53	6.34	0.38	1.21e-9	Metabolic traits;
SARC	cis	rs1008375	0.931	rs6449310	chr4:17575530	T/C	cg27347728	chr4:17578864	LAP3	0.47	5.79	0.35	2.25e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs10825741	0.825	rs11005232	chr10:57919701	C/A	cg12948920	chr4:8609706	CPZ	0.53	6.31	0.38	1.38e-9	Night sleep phenotypes;
SARC	cis	rs11874712	1.000	rs1800639	chr18:43671240	G/T	cg25174615	chr18:43684699	ATP5A1;HAUS1	0.44	5.44	0.34	1.37e-7	Migraine - clinic-based;
SARC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.34	-5.29	-0.33	2.76e-7	Longevity;Endometriosis;
SARC	cis	rs17345786	0.906	rs12638137	chr3:101150964	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.46	-4.77	-0.3	3.23e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs877282	0.583	rs7072970	chr10:822757	G/A	cg15764593	chr10:829463	NA	-0.44	-4.8	-0.3	2.78e-6	Uric acid levels;
SARC	cis	rs637571	0.544	rs617791	chr11:65702523	C/G	cg26695010	chr11:65641043	EFEMP2	-0.55	-7.05	-0.42	2.02e-11	Eosinophil percentage of white cells;
SARC	cis	rs9815354	0.953	rs1717010	chr3:41946903	G/A	cg03022575	chr3:42003672	ULK4	-0.55	-5.22	-0.32	4.05e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs7779181	0.556	rs35513146	chr7:32353932	T/G	cg16719466	chr7:32338569	NA	-0.65	-5.24	-0.32	3.61e-7	Body mass index;
SARC	cis	rs9354308	0.868	rs9363460	chr6:66557539	C/A	cg07460842	chr6:66804631	NA	-0.44	-4.99	-0.31	1.2e-6	Metabolite levels;
SARC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg21280719	chr6:42927975	GNMT	-0.47	-8.26	-0.48	1.08e-14	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs10463316	0.894	rs954341	chr5:150751855	G/A	cg03212797	chr5:150827313	SLC36A1	-0.53	-6.34	-0.38	1.16e-9	Metabolite levels (Pyroglutamine);
SARC	cis	rs6772849	0.804	rs4857920	chr3:128407623	C/T	cg01163369	chr3:128370232	RPN1	-0.35	-4.82	-0.3	2.62e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs7589342	0.831	rs13429270	chr2:106453060	C/T	cg14210321	chr2:106509881	NCK2	-0.44	-5.13	-0.32	6.12e-7	Addiction;
SARC	cis	rs7786808	0.525	rs10253961	chr7:158194858	G/A	cg01191920	chr7:158217561	PTPRN2	0.35	5.96	0.36	9.08e-9	Obesity-related traits;
SARC	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg06618935	chr21:46677482	NA	-0.39	-5.12	-0.32	6.37e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4853012	0.887	rs6737314	chr2:74339586	A/G	cg01017244	chr2:74357527	NA	0.55	6.69	0.4	1.61e-10	Gestational age at birth (maternal effect);
SARC	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.38	5.02	0.31	1.02e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg07274523	chr3:49395745	GPX1	0.51	6.12	0.37	3.96e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs920590	0.684	rs3899017	chr8:19669198	A/T	cg03894339	chr8:19674705	INTS10	0.63	7.24	0.43	6.42e-12	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs568617	1.000	rs656980	chr11:65656282	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.47	5.45	0.34	1.31e-7	Crohn's disease;
SARC	cis	rs735396	0.770	rs2464196	chr12:121435427	G/A	cg04422896	chr12:121454269	C12orf43	0.39	4.74	0.3	3.75e-6	N-glycan levels;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg17024643	chr1:214725274	PTPN14	0.48	6.33	0.38	1.25e-9	Chemerin levels;
SARC	cis	rs9309473	1.000	rs2056486	chr2:73717567	G/T	cg07208825	chr2:73871855	ALMS1P	0.33	4.77	0.3	3.27e-6	Metabolite levels;
SARC	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg11366901	chr6:160182831	ACAT2	0.87	9.02	0.51	7.01e-17	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg03517284	chr6:25882590	NA	0.49	6.46	0.39	5.91e-10	Blood metabolite levels;
SARC	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg09323728	chr8:95962352	TP53INP1	-0.29	-4.81	-0.3	2.74e-6	Type 2 diabetes;
SARC	cis	rs7666738	0.645	rs10013290	chr4:99082799	G/A	cg05340658	chr4:99064831	C4orf37	0.57	7.33	0.43	3.8e-12	Colonoscopy-negative controls vs population controls;
SARC	cis	rs3126085	0.935	rs10888475	chr1:152226012	C/T	cg03465714	chr1:152285911	FLG	-0.45	-5.47	-0.34	1.15e-7	Atopic dermatitis;
SARC	cis	rs986417	1.000	rs1024223	chr14:60926119	C/T	cg27398547	chr14:60952738	C14orf39	1.02	9.54	0.53	2.06e-18	Gut microbiota (bacterial taxa);
SARC	cis	rs995000	0.931	rs1168085	chr1:63112320	C/G	cg06896770	chr1:63153194	DOCK7	-0.89	-13.41	-0.66	9.23e-31	Triglyceride levels;
SARC	cis	rs1451375	0.550	rs10239830	chr7:50603829	A/G	cg18232548	chr7:50535776	DDC	0.49	5.02	0.31	1.01e-6	Malaria;
SARC	cis	rs11792861	0.816	rs17792434	chr9:111667319	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.76	9.28	0.52	1.23e-17	Menarche (age at onset);
SARC	cis	rs4803468	1.000	rs1043413	chr19:41939297	C/G	cg08477640	chr19:41863820	B9D2	-0.41	-5.14	-0.32	5.85e-7	Height;
SARC	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg18252515	chr7:66147081	NA	-1.3	-11.62	-0.61	6.33e-25	Diabetic kidney disease;
SARC	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg04944784	chr2:26401820	FAM59B	-0.6	-7.95	-0.46	8.14e-14	Gut microbiome composition (summer);
SARC	cis	rs875971	0.545	rs13311962	chr7:66068129	C/T	cg11764359	chr7:65958608	NA	-0.62	-6.1	-0.37	4.36e-9	Aortic root size;
SARC	cis	rs9790314	0.690	rs7651087	chr3:160821929	T/C	cg04691961	chr3:161091175	C3orf57	-0.55	-7.19	-0.43	8.54e-12	Morning vs. evening chronotype;
SARC	cis	rs6089584	0.606	rs2273989	chr20:60579138	G/A	cg13770153	chr20:60521292	NA	-0.38	-5.47	-0.34	1.18e-7	Body mass index;
SARC	cis	rs11785400	0.793	rs4457308	chr8:143733922	G/A	cg10596483	chr8:143751796	JRK	0.58	7.68	0.45	4.43e-13	Schizophrenia;
SARC	cis	rs1865760	0.566	rs9358902	chr6:26058570	C/G	cg17691542	chr6:26056736	HIST1H1C	0.53	6.57	0.4	3.22e-10	Height;
SARC	cis	rs12079745	0.793	rs10800445	chr1:169374793	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.81	-5.31	-0.33	2.62e-7	QT interval;
SARC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.34	5.16	0.32	5.32e-7	Electroencephalogram traits;
SARC	cis	rs941408	1.000	rs1736184	chr19:2810248	G/A	cg06609049	chr19:2785107	THOP1	0.76	9.75	0.54	4.61e-19	Total cholesterol levels;
SARC	cis	rs2120019	0.938	rs35911108	chr15:75322179	G/A	cg00629941	chr15:75287862	SCAMP5	-0.7	-8.35	-0.48	6.18e-15	Blood trace element (Zn levels);
SARC	cis	rs9788682	1.000	rs7163730	chr15:78814681	A/G	cg24631222	chr15:78858424	CHRNA5	0.78	10.68	0.57	6.25e-22	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg14983838	chr19:29218262	NA	0.77	10.53	0.57	1.83e-21	Methadone dose in opioid dependence;
SARC	cis	rs6831352	0.959	rs4699710	chr4:100051819	C/T	cg12011299	chr4:100065546	ADH4	0.34	6.0	0.37	7.56e-9	Alcohol dependence;
SARC	cis	rs2834188	0.889	rs1467849	chr21:34682069	G/T	cg04842828	chr21:34696676	IFNAR1	0.42	5.07	0.31	8.28e-7	Narcolepsy;
SARC	cis	rs12142240	0.698	rs72890727	chr1:46860237	G/A	cg14993813	chr1:46806288	NSUN4	-0.52	-5.56	-0.34	7.46e-8	Menopause (age at onset);
SARC	cis	rs7917772	0.636	rs2250580	chr10:104505687	C/G	ch.10.2196322F	chr10:104248062	ACTR1A	0.46	5.18	0.32	4.76e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs9325144	0.555	rs7968322	chr12:38792348	T/C	cg26384229	chr12:38710491	ALG10B	-0.58	-7.67	-0.45	4.65e-13	Morning vs. evening chronotype;
SARC	cis	rs2985684	0.789	rs7161649	chr14:50064028	A/G	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.45	4.92	0.31	1.66e-6	Carotid intima media thickness;
SARC	cis	rs2816062	0.813	rs2816051	chr1:18895460	A/G	cg10574377	chr1:18908098	NA	0.35	4.93	0.31	1.55e-6	Urate levels in lean individuals;
SARC	cis	rs16854884	1.000	rs11924473	chr3:143787075	C/G	cg06585982	chr3:143692056	C3orf58	0.57	6.96	0.41	3.52e-11	Economic and political preferences (feminism/equality);
SARC	cis	rs4242434	0.927	rs13271626	chr8:22467760	C/G	cg03733263	chr8:22462867	KIAA1967	1.05	18.1	0.76	2.66e-46	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs959260	0.528	rs9909443	chr17:73308346	C/T	cg14668889	chr17:73230827	NUP85	0.6	7.59	0.45	7.58e-13	Systemic lupus erythematosus;
SARC	cis	rs240764	0.817	rs12199888	chr6:101154419	T/A	cg09795085	chr6:101329169	ASCC3	-0.47	-6.1	-0.37	4.41e-9	Neuroticism;
SARC	cis	rs7582180	0.739	rs11687352	chr2:100919888	A/C	cg14675211	chr2:100938903	LONRF2	0.53	7.9	0.46	1.1e-13	Intelligence (multi-trait analysis);
SARC	cis	rs9790314	0.521	rs1450523	chr3:161077270	G/A	cg03342759	chr3:160939853	NMD3	-0.57	-7.2	-0.43	8.42e-12	Morning vs. evening chronotype;
SARC	cis	rs3857536	0.813	rs7769683	chr6:66946256	G/A	cg07460842	chr6:66804631	NA	-0.45	-5.19	-0.32	4.5e-7	Blood trace element (Cu levels);
SARC	cis	rs2046867	0.818	rs1502758	chr3:72865126	A/G	cg25664220	chr3:72788482	NA	-0.29	-4.72	-0.3	3.98e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
SARC	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg06634786	chr22:41940651	POLR3H	0.55	6.53	0.39	3.99e-10	Vitiligo;
SARC	cis	rs27434	0.583	rs151911	chr5:96157084	A/G	cg16492584	chr5:96139282	ERAP1	-0.57	-7.08	-0.42	1.73e-11	Ankylosing spondylitis;
SARC	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.65	-6.91	-0.41	4.63e-11	Platelet count;
SARC	trans	rs7819412	0.805	rs2409710	chr8:10979821	A/G	cg08975724	chr8:8085496	FLJ10661	-0.56	-6.93	-0.41	3.99e-11	Triglycerides;
SARC	cis	rs300703	0.872	rs7568288	chr2:276908	C/G	cg21211680	chr2:198530	NA	0.59	5.53	0.34	8.61e-8	Blood protein levels;
SARC	cis	rs34779708	0.966	rs4934734	chr10:35434373	T/C	cg03585969	chr10:35415529	CREM	0.39	4.78	0.3	3.13e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs2645694	0.626	rs2703143	chr4:77830441	A/G	cg03477792	chr4:77819574	ANKRD56	0.41	6.1	0.37	4.34e-9	Emphysema distribution in smoking;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg02795678	chr10:14940698	SUV39H2	0.54	7.59	0.45	7.47e-13	Thyroid stimulating hormone;
SARC	cis	rs2439831	0.850	rs7181039	chr15:44179112	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	7.38	0.44	2.85e-12	Lung cancer in ever smokers;
SARC	cis	rs7296418	0.599	rs2277343	chr12:123794450	A/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.39	-5.23	-0.32	3.81e-7	Platelet count;
SARC	cis	rs4737010	0.501	rs990174	chr8:41632230	A/G	cg17182837	chr8:41585554	ANK1	-0.43	-4.78	-0.3	3.1e-6	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
SARC	cis	rs889312	0.500	rs252903	chr5:56117952	A/G	cg14703610	chr5:56206110	C5orf35	0.5	6.19	0.38	2.64e-9	Breast cancer;Breast cancer (early onset);
SARC	cis	rs4906332	1.000	rs12879663	chr14:103874215	A/G	cg20474699	chr14:102976161	ANKRD9	0.43	4.9	0.31	1.84e-6	Coronary artery disease;
SARC	cis	rs617791	0.530	rs7952056	chr11:65744597	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.42	-4.77	-0.3	3.25e-6	Breast cancer;
SARC	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg22974920	chr21:40686053	BRWD1	-0.43	-4.74	-0.3	3.78e-6	Cognitive function;
SARC	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg21724239	chr8:58056113	NA	0.61	5.05	0.31	9.01e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs875971	1.000	rs1183245	chr7:65541185	C/T	cg18876405	chr7:65276391	NA	-0.47	-5.68	-0.35	3.99e-8	Aortic root size;
SARC	cis	rs3733585	0.781	rs6449183	chr4:9970691	C/A	cg00071950	chr4:10020882	SLC2A9	-0.37	-5.88	-0.36	1.38e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg22875332	chr1:76189707	ACADM	0.49	6.88	0.41	5.5e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs17270561	0.609	rs1317816	chr6:25765390	T/C	cg17691542	chr6:26056736	HIST1H1C	0.57	7.0	0.42	2.78e-11	Iron status biomarkers;
SARC	cis	rs9814567	1.000	rs2370642	chr3:134222136	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-6.85	-0.41	6.7e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs2439831	0.681	rs2242067	chr15:43699303	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.76	6.84	0.41	7.01e-11	Lung cancer in ever smokers;
SARC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg25894440	chr7:65020034	NA	0.42	4.8	0.3	2.87e-6	Calcium levels;
SARC	cis	rs910316	1.000	rs10146482	chr14:75574087	C/T	cg11812906	chr14:75593930	NEK9	0.9	14.78	0.7	2.58e-35	Height;
SARC	cis	rs9894429	1.000	rs7213129	chr17:79581573	C/T	cg18240062	chr17:79603768	NPLOC4	0.71	9.81	0.54	3.03e-19	Eye color traits;
SARC	cis	rs240764	0.621	rs11155636	chr6:101201243	C/T	cg09795085	chr6:101329169	ASCC3	-0.5	-6.58	-0.4	3.06e-10	Neuroticism;
SARC	trans	rs2727020	0.729	rs10742932	chr11:49173234	T/C	cg03929089	chr4:120376271	NA	-0.67	-9.24	-0.52	1.62e-17	Coronary artery disease;
SARC	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg08219700	chr8:58056026	NA	0.57	5.51	0.34	9.69e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs933688	0.526	rs9293565	chr5:90609736	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.62	5.65	0.35	4.59e-8	Smoking behavior;
SARC	cis	rs12477438	1.000	rs1922624	chr2:99909958	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-8.15	-0.47	2.25e-14	Chronic sinus infection;
SARC	trans	rs1814175	0.715	rs10839409	chr11:49884647	G/T	cg15704280	chr7:45808275	SEPT13	-0.97	-18.12	-0.76	2.26e-46	Height;
SARC	cis	rs2921073	0.604	rs2979140	chr8:8267202	T/A	cg06636001	chr8:8085503	FLJ10661	0.56	6.65	0.4	2.1e-10	Parkinson's disease;
SARC	cis	rs9393692	0.537	rs2393594	chr6:26316289	G/A	cg05868516	chr6:26286170	HIST1H4H	0.48	4.76	0.3	3.46e-6	Educational attainment;
SARC	cis	rs17376456	0.877	rs9314092	chr5:93326362	A/G	cg25358565	chr5:93447407	FAM172A	1.25	13.45	0.66	6.8e-31	Diabetic retinopathy;
SARC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.74	9.84	0.54	2.51e-19	Lymphocyte counts;
SARC	cis	rs11098499	0.691	rs9995716	chr4:120264996	T/C	cg09307838	chr4:120376055	NA	0.75	10.43	0.56	3.87e-21	Corneal astigmatism;
SARC	cis	rs7412746	0.658	rs4970982	chr1:150865084	G/C	cg13175981	chr1:150552382	MCL1	-0.48	-5.86	-0.36	1.57e-8	Melanoma;
SARC	cis	rs372883	0.600	rs1153276	chr21:30661694	T/C	cg24692254	chr21:30365293	RNF160	-0.65	-8.31	-0.48	7.99e-15	Pancreatic cancer;
SARC	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg05025164	chr4:1340916	KIAA1530	0.49	6.2	0.38	2.5e-9	Longevity;
SARC	cis	rs3087591	0.959	rs9893872	chr17:29571195	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.5	-6.12	-0.37	3.93e-9	Hip circumference;
SARC	cis	rs11235843	0.866	rs72974869	chr11:73414846	G/A	cg18195628	chr11:73498948	MRPL48	0.64	4.87	0.3	2.06e-6	Hand grip strength;
SARC	cis	rs4595586	0.545	rs12828790	chr12:39401043	G/A	cg26384229	chr12:38710491	ALG10B	0.5	6.07	0.37	5.14e-9	Morning vs. evening chronotype;
SARC	cis	rs6582630	0.519	rs80226845	chr12:38528231	C/A	cg26384229	chr12:38710491	ALG10B	0.85	12.53	0.63	7.28e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg06074448	chr4:187884817	NA	-0.36	-4.95	-0.31	1.41e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs796364	0.951	rs1105964	chr2:201000776	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.56	-5.2	-0.32	4.29e-7	Schizophrenia;
SARC	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg04166393	chr7:2884313	GNA12	0.58	6.87	0.41	5.94e-11	Height;
SARC	cis	rs13392177	0.660	rs10932762	chr2:219076213	G/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.57	-7.33	-0.43	3.85e-12	Pyoderma gangrenosum in inflammatory bowel disease;
SARC	cis	rs7766436	0.885	rs4711020	chr6:22582920	A/G	cg13666174	chr6:22585274	NA	-0.6	-7.74	-0.45	3.04e-13	Coronary artery disease;
SARC	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg19077165	chr18:44547161	KATNAL2	-0.52	-7.03	-0.42	2.26e-11	Personality dimensions;
SARC	cis	rs2204008	0.811	rs2139752	chr12:38370398	C/T	cg26384229	chr12:38710491	ALG10B	0.87	12.65	0.64	2.85e-28	Bladder cancer;
SARC	cis	rs282587	0.530	rs282602	chr13:113392644	G/A	cg02820901	chr13:113351484	ATP11A	-0.53	-5.08	-0.32	7.67e-7	Glycated hemoglobin levels;
SARC	cis	rs965469	1.000	rs6051713	chr20:3265779	C/T	cg25506879	chr20:3388711	C20orf194	0.48	4.89	0.3	1.91e-6	IFN-related cytopenia;
SARC	cis	rs11122272	0.735	rs2256908	chr1:231506557	G/A	cg06096015	chr1:231504339	EGLN1	0.39	5.94	0.36	1.02e-8	Hemoglobin concentration;
SARC	cis	rs3126085	0.935	rs1390487	chr1:152194601	G/A	cg09127314	chr1:152161683	NA	0.42	4.81	0.3	2.7e-6	Atopic dermatitis;
SARC	cis	rs8062405	0.824	rs62034326	chr16:28539293	A/G	cg08761264	chr16:28874980	SH2B1	-0.43	-4.81	-0.3	2.7e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs2153535	0.580	rs1119690	chr6:8460660	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	10.63	0.57	9.19e-22	Motion sickness;
SARC	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg16405210	chr4:1374714	KIAA1530	-0.5	-5.8	-0.36	2.18e-8	Obesity-related traits;
SARC	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg05861140	chr6:150128134	PCMT1	-0.36	-4.73	-0.3	3.94e-6	Lung cancer;
SARC	cis	rs7647973	0.961	rs6778080	chr3:49317338	C/T	cg07636037	chr3:49044803	WDR6	-0.73	-8.42	-0.48	3.75e-15	Menarche (age at onset);
SARC	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg03264133	chr6:25882463	NA	-0.35	-4.78	-0.3	3.08e-6	Blood metabolite levels;
SARC	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg15049968	chr18:44337910	ST8SIA5	-0.37	-6.03	-0.37	6.28e-9	Personality dimensions;
SARC	cis	rs13401104	0.686	rs1530954	chr2:237110960	C/G	cg19324714	chr2:237145437	ASB18	0.58	6.02	0.37	6.73e-9	Educational attainment;
SARC	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg22834771	chr12:69754056	YEATS4	0.48	6.35	0.38	1.13e-9	Cerebrospinal fluid biomarker levels;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg00869533	chr2:58386677	VRK2;FANCL	0.46	6.48	0.39	5.38e-10	Thyroid stimulating hormone;
SARC	cis	rs12291225	0.679	rs11238	chr11:14288128	A/C	cg19336497	chr11:14380999	RRAS2	0.41	6.95	0.41	3.58e-11	Sense of smell;
SARC	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg24642844	chr7:1081250	C7orf50	-0.57	-6.05	-0.37	5.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs4253772	0.550	rs6008598	chr22:46704243	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.62	5.14	0.32	5.73e-7	LDL cholesterol;Cholesterol, total;
SARC	cis	rs4642101	0.597	rs9865624	chr3:12822786	T/A	cg12400702	chr3:12838781	CAND2	-0.26	-5.1	-0.32	7.04e-7	QRS complex (12-leadsum);
SARC	cis	rs9399135	0.967	rs4895434	chr6:135293365	G/A	cg24558204	chr6:135376177	HBS1L	0.44	5.79	0.35	2.23e-8	Red blood cell count;
SARC	cis	rs72945132	0.882	rs6592522	chr11:70128271	G/A	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.59	-0.34	6.4e-8	Coronary artery disease;
SARC	cis	rs910316	0.967	rs8007539	chr14:75664953	T/C	cg08847533	chr14:75593920	NEK9	-0.85	-13.64	-0.67	1.58e-31	Height;
SARC	cis	rs933688	0.639	rs332530	chr5:90789810	G/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.95	11.61	0.61	6.66e-25	Smoking behavior;
SARC	trans	rs1814175	0.647	rs61306292	chr11:49856040	G/C	cg15704280	chr7:45808275	SEPT13	-0.96	-17.78	-0.76	2.79e-45	Height;
SARC	cis	rs7666738	0.830	rs10034619	chr4:98970067	G/C	cg05340658	chr4:99064831	C4orf37	0.64	8.6	0.49	1.18e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg12257692	chr3:49977190	RBM6	-0.28	-5.03	-0.31	9.94e-7	Body mass index;
SARC	cis	rs12995491	0.933	rs34366691	chr2:88537451	G/A	cg07952391	chr2:88470173	THNSL2	-0.35	-4.71	-0.3	4.19e-6	Response to metformin (IC50);
SARC	cis	rs6439153	0.933	rs810952	chr3:128685905	A/G	cg25356066	chr3:128598488	ACAD9	0.47	5.57	0.34	7.04e-8	Pneumococcal bacteremia;
SARC	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg06028808	chr11:68637592	NA	0.4	5.07	0.32	8.2e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg00409905	chr10:38381863	ZNF37A	-0.55	-7.84	-0.46	1.65e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs7904368	0.754	rs12253908	chr10:16853358	T/C	cg14835575	chr10:16859367	RSU1	0.75	7.5	0.44	1.31e-12	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs3741151	1.000	rs7930880	chr11:73068769	A/C	cg17517138	chr11:73019481	ARHGEF17	0.73	6.35	0.38	1.11e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg03517284	chr6:25882590	NA	0.49	6.38	0.39	9.53e-10	Blood metabolite levels;
SARC	cis	rs6710529	1	rs6710529	chr2:219645553	G/A	cg02176678	chr2:219576539	TTLL4	-0.34	-5.17	-0.32	4.98e-7	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs1941687	0.505	rs12605642	chr18:31313965	G/T	cg27147174	chr7:100797783	AP1S1	-0.51	-6.3	-0.38	1.48e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
SARC	cis	rs2075371	0.966	rs1646676	chr7:133999267	G/A	cg11752832	chr7:134001865	SLC35B4	0.56	7.1	0.42	1.47e-11	Mean platelet volume;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg00047844	chr17:77752442	CBX2	0.48	6.41	0.39	7.97e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs854765	0.547	rs4643387	chr17:17972973	C/T	cg04398451	chr17:18023971	MYO15A	-0.48	-6.83	-0.41	7.17e-11	Total body bone mineral density;
SARC	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg00149659	chr3:10157352	C3orf10	0.7	6.56	0.39	3.38e-10	Alzheimer's disease;
SARC	cis	rs4951018	0.821	rs7529037	chr1:205637501	C/G	cg24503407	chr1:205819492	PM20D1	-0.41	-5.51	-0.34	9.3e-8	Prostate-specific antigen levels;
SARC	cis	rs397969	0.596	rs17668529	chr17:19899788	G/T	cg13482628	chr17:19912719	NA	0.43	4.73	0.3	3.97e-6	Platelet count;
SARC	cis	rs7312933	0.703	rs1059360	chr12:42554505	A/G	cg19980929	chr12:42632907	YAF2	0.44	6.08	0.37	4.82e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg22433210	chr17:43662623	NA	-0.95	-11.34	-0.6	4.92e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs4944092	1.000	rs7125695	chr11:75908131	A/G	cg04588336	chr11:75916460	WNT11	0.38	5.09	0.32	7.2e-7	PR interval;
SARC	cis	rs60752752	0.852	rs2916217	chr1:153353198	A/G	cg26882115	chr1:153603048	S100A1;S100A13	-0.63	-4.8	-0.3	2.82e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs13191362	1.000	rs34725898	chr6:163127302	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.71	6.21	0.38	2.37e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs6570726	0.967	rs403584	chr6:145807010	G/A	cg05220968	chr6:146057943	EPM2A	-0.27	-4.72	-0.3	4.09e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4648845	0.579	rs4592207	chr1:2369498	A/G	cg11214544	chr1:2391121	NA	-0.31	-5.2	-0.32	4.43e-7	Schizophrenia;
SARC	cis	rs7662987	0.517	rs2602878	chr4:100039953	T/G	cg12011299	chr4:100065546	ADH4	0.33	5.47	0.34	1.13e-7	Smoking initiation;
SARC	cis	rs4713118	0.824	rs9468229	chr6:27750086	G/A	cg17221315	chr6:27791827	HIST1H4J	0.47	5.1	0.32	6.97e-7	Parkinson's disease;
SARC	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg11987759	chr7:65425863	GUSB	-0.46	-6.29	-0.38	1.53e-9	Aortic root size;
SARC	cis	rs2952156	0.883	rs8077172	chr17:37834977	G/T	cg00129232	chr17:37814104	STARD3	-0.7	-10.11	-0.55	3.81e-20	Asthma;
SARC	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg06558623	chr16:89946397	TCF25	0.92	7.5	0.44	1.36e-12	Skin colour saturation;
SARC	cis	rs2197308	0.619	rs4002730	chr12:37876400	T/C	cg13010199	chr12:38710504	ALG10B	0.8	11.02	0.59	5.3e-23	Morning vs. evening chronotype;
SARC	cis	rs2370759	1.000	rs7910776	chr10:32639093	C/T	cg01819863	chr10:32635814	EPC1	0.98	9.93	0.55	1.36e-19	Sexual dysfunction (female);
SARC	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.79	-6.63	-0.4	2.31e-10	Alzheimer's disease;
SARC	cis	rs6570726	0.935	rs367612	chr6:145828987	A/G	cg23711669	chr6:146136114	FBXO30	0.76	11.32	0.6	5.68e-24	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9457247	1.000	rs389956	chr6:167407254	T/G	cg07741184	chr6:167504864	NA	0.29	5.6	0.34	5.95e-8	Crohn's disease;
SARC	cis	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg09021430	chr5:549028	NA	-0.45	-5.69	-0.35	3.83e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs7542091	0.748	rs2357231	chr1:210028454	A/C	cg06929287	chr1:210001192	C1orf107	0.4	4.89	0.31	1.85e-6	Monobrow;
SARC	cis	rs9988450	1	rs9988450	chr1:62924448	C/T	cg06896770	chr1:63153194	DOCK7	0.96	15.04	0.7	3.38e-36	Triglycerides;
SARC	cis	rs1401999	0.899	rs2313211	chr3:183738626	T/A	cg01324343	chr3:183735012	ABCC5	0.64	12.91	0.65	4.14e-29	Anterior chamber depth;
SARC	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.62	7.5	0.44	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9300255	0.543	rs1617156	chr12:123590165	T/C	cg05973401	chr12:123451056	ABCB9	0.53	5.78	0.35	2.35e-8	Neutrophil percentage of white cells;
SARC	trans	rs11039798	0.588	rs11039818	chr11:48562120	C/T	cg15704280	chr7:45808275	SEPT13	0.64	6.76	0.4	1.07e-10	Axial length;
SARC	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg11764359	chr7:65958608	NA	0.88	12.58	0.64	4.89e-28	Aortic root size;
SARC	trans	rs36093844	0.706	rs75334800	chr11:85586581	A/G	cg27065003	chr5:122429449	PRDM6	-0.55	-6.54	-0.39	3.91e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	trans	rs2388896	0.930	rs7477212	chr10:8963765	A/T	cg13445358	chr12:53661749	ESPL1	0.5	6.33	0.38	1.24e-9	Tetralogy of Fallot;
SARC	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.31	-4.94	-0.31	1.46e-6	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs72781680	1.000	rs72781683	chr2:24247423	T/C	cg06627628	chr2:24431161	ITSN2	-0.7	-6.66	-0.4	1.94e-10	Lymphocyte counts;
SARC	cis	rs7011049	1.000	rs72643583	chr8:53847269	C/G	cg26025543	chr8:53854495	NA	0.6	5.43	0.34	1.42e-7	Systolic blood pressure;
SARC	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg18876405	chr7:65276391	NA	-0.47	-5.76	-0.35	2.59e-8	Aortic root size;
SARC	trans	rs7432328	0.500	rs3885636	chr3:162246898	G/A	cg20246907	chr13:99316927	NA	0.52	6.28	0.38	1.63e-9	Response to radiotherapy in prostate cancer (toxicity, rectal bleeding);
SARC	cis	rs763121	0.819	rs5757133	chr22:38947835	A/G	cg06022373	chr22:39101656	GTPBP1	-0.79	-10.08	-0.55	4.51e-20	Menopause (age at onset);
SARC	cis	rs2361718	0.500	rs8064429	chr17:78096187	A/C	cg27427491	chr17:78079615	GAA	-0.31	-4.78	-0.3	3.13e-6	Yeast infection;
SARC	cis	rs7932354	0.528	rs11039097	chr11:47131881	C/T	cg03339077	chr11:47165057	C11orf49	-0.41	-5.55	-0.34	7.65e-8	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs7429990	0.901	rs6442102	chr3:48152562	A/G	cg11946769	chr3:48343235	NME6	-0.46	-5.46	-0.34	1.24e-7	Educational attainment (years of education);
SARC	cis	rs4851254	0.920	rs11123808	chr2:100750750	A/C	cg17356467	chr2:100759845	AFF3	0.28	4.77	0.3	3.26e-6	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg11764359	chr7:65958608	NA	0.79	9.6	0.53	1.38e-18	Aortic root size;
SARC	cis	rs4253772	0.591	rs6007795	chr22:46686792	C/G	cg24881330	chr22:46731750	TRMU	0.73	7.78	0.45	2.28e-13	LDL cholesterol;Cholesterol, total;
SARC	cis	rs2952156	0.959	rs1495102	chr17:37832093	T/C	cg20243544	chr17:37824526	PNMT	0.47	5.85	0.36	1.62e-8	Asthma;
SARC	cis	rs13314892	0.764	rs55738162	chr3:69859270	G/A	cg17445875	chr3:69859618	MITF	-0.49	-5.07	-0.32	7.95e-7	QRS complex (12-leadsum);
SARC	cis	rs9487051	0.872	rs9386794	chr6:109611521	A/C	cg01475377	chr6:109611718	NA	-0.41	-5.88	-0.36	1.39e-8	Reticulocyte fraction of red cells;
SARC	cis	rs9473924	0.542	rs9296645	chr6:50831194	A/G	cg14470998	chr6:50812995	TFAP2B	0.72	6.54	0.39	3.96e-10	Body mass index;
SARC	cis	rs7659604	1.000	rs28433617	chr4:122664138	C/A	cg19671926	chr4:122722719	EXOSC9	-0.48	-5.9	-0.36	1.27e-8	Type 2 diabetes;
SARC	cis	rs1580019	0.587	rs6972365	chr7:32548931	T/A	cg07520158	chr7:32535189	LSM5;AVL9	0.61	7.97	0.46	6.84e-14	Cognitive ability;
SARC	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg14829155	chr15:31115871	NA	-0.49	-6.29	-0.38	1.59e-9	Huntington's disease progression;
SARC	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg07701084	chr6:150067640	NUP43	0.41	5.39	0.33	1.68e-7	Lung cancer;
SARC	cis	rs9788682	1.000	rs35212593	chr15:78831826	G/A	cg24631222	chr15:78858424	CHRNA5	0.78	10.36	0.56	6.21e-21	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs1395	0.922	rs4665376	chr2:27509032	T/C	cg21747090	chr2:27597821	SNX17	-0.44	-5.31	-0.33	2.51e-7	Blood metabolite levels;
SARC	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg14159672	chr1:205819179	PM20D1	-0.43	-4.95	-0.31	1.45e-6	Parkinson's disease;
SARC	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg00933542	chr6:150070202	PCMT1	0.31	5.04	0.31	9.56e-7	Lung cancer;
SARC	cis	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg08564027	chr20:61660810	NA	0.76	11.8	0.61	1.69e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs981844	0.890	rs55917677	chr4:154701051	C/T	cg14289246	chr4:154710475	SFRP2	0.64	7.09	0.42	1.54e-11	Response to statins (LDL cholesterol change);
SARC	cis	rs12950390	0.853	rs11079792	chr17:45863311	T/C	cg24803719	chr17:45855879	NA	-0.46	-7.5	-0.44	1.34e-12	IgG glycosylation;
SARC	cis	rs6831352	0.734	rs3100630	chr4:100031715	T/A	cg13256891	chr4:100009986	ADH5	0.6	7.9	0.46	1.09e-13	Alcohol dependence;
SARC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.2	0.38	2.57e-9	Prudent dietary pattern;
SARC	cis	rs986417	0.901	rs8020084	chr14:61001495	C/T	cg27398547	chr14:60952738	C14orf39	1.02	8.11	0.47	2.92e-14	Gut microbiota (bacterial taxa);
SARC	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg00933542	chr6:150070202	PCMT1	0.31	5.36	0.33	2.04e-7	Lung cancer;
SARC	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg24633833	chr3:10029261	TMEM111	0.53	5.28	0.33	2.92e-7	Alzheimer's disease;
SARC	cis	rs7113850	0.541	rs76344090	chr11:24223375	C/G	ch.11.24196551F	chr11:24239977	NA	0.76	5.85	0.36	1.62e-8	Bone fracture in osteoporosis;
SARC	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg06028808	chr11:68637592	NA	0.46	5.94	0.36	1.01e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs4664304	0.710	rs9636280	chr2:160717852	C/T	cg02280532	chr2:160761244	LY75	-0.32	-4.92	-0.31	1.63e-6	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs72634258	0.945	rs36016881	chr1:8051241	A/G	cg00042356	chr1:8021962	PARK7	0.79	7.37	0.43	2.88e-12	Inflammatory bowel disease;
SARC	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg13395646	chr4:1353034	KIAA1530	-0.56	-6.74	-0.4	1.23e-10	Obesity-related traits;
SARC	cis	rs8017423	0.967	rs61231898	chr14:90691696	G/A	cg20276874	chr14:90721474	PSMC1	-0.34	-4.72	-0.3	4.02e-6	Mortality in heart failure;
SARC	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	11.64	0.61	5.7e-25	Alzheimer's disease;
SARC	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-8.89	-0.5	1.75e-16	Alzheimer's disease;
SARC	cis	rs7615952	0.866	rs11922276	chr3:125631326	G/T	cg05084668	chr3:125655381	ALG1L	-0.68	-6.71	-0.4	1.45e-10	Blood pressure (smoking interaction);
SARC	cis	rs957448	0.948	rs11992893	chr8:95520701	G/A	cg26464482	chr8:95565502	KIAA1429	0.43	4.74	0.3	3.73e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs9486719	0.894	rs34826652	chr6:96899085	A/G	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.01	-0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs9300255	0.596	rs11057202	chr12:123720775	G/T	cg00376283	chr12:123451042	ABCB9	0.56	6.58	0.4	3.1e-10	Neutrophil percentage of white cells;
SARC	cis	rs7772486	0.869	rs2777473	chr6:146301494	G/A	cg05347473	chr6:146136440	FBXO30	0.47	6.42	0.39	7.76e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs5758659	0.682	rs133306	chr22:42396150	G/A	cg04733989	chr22:42467013	NAGA	0.5	6.74	0.4	1.23e-10	Cognitive function;
SARC	cis	rs9393692	0.537	rs9358926	chr6:26323132	C/G	cg13736514	chr6:26305472	NA	-0.42	-4.98	-0.31	1.22e-6	Educational attainment;
SARC	cis	rs1448094	0.935	rs10746355	chr12:86330227	A/T	cg02569458	chr12:86230093	RASSF9	0.41	5.71	0.35	3.46e-8	Major depressive disorder;
SARC	cis	rs2985684	1.000	rs17121651	chr14:50097172	T/C	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.47	4.91	0.31	1.69e-6	Carotid intima media thickness;
SARC	trans	rs9329221	0.537	rs2062332	chr8:9980024	G/A	cg06636001	chr8:8085503	FLJ10661	0.54	7.44	0.44	1.87e-12	Neuroticism;
SARC	cis	rs79149102	0.579	rs74023908	chr15:75310710	T/C	cg00629941	chr15:75287862	SCAMP5	-0.7	-5.42	-0.33	1.47e-7	Lung cancer;
SARC	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg17376030	chr22:41985996	PMM1	-0.8	-10.12	-0.55	3.37e-20	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs1153858	1.000	rs4775909	chr15:45643042	T/C	cg26924012	chr15:45694286	SPATA5L1	0.73	10.12	0.55	3.52e-20	Homoarginine levels;
SARC	cis	rs4642101	0.512	rs9813960	chr3:12818205	A/G	cg05775895	chr3:12838266	CAND2	0.8	13.88	0.67	2.58e-32	QRS complex (12-leadsum);
SARC	cis	rs7666738	0.830	rs10028505	chr4:98962310	C/A	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs12142240	0.698	rs41294456	chr1:46809782	T/C	cg10495392	chr1:46806563	NSUN4	0.64	6.76	0.4	1.09e-10	Menopause (age at onset);
SARC	cis	rs911263	0.961	rs8008961	chr14:68752643	A/G	cg18825221	chr14:68749962	RAD51L1	0.48	8.42	0.48	3.96e-15	Primary biliary cholangitis;
SARC	cis	rs1451375	0.583	rs3779078	chr7:50610918	C/T	cg18232548	chr7:50535776	DDC	0.49	4.89	0.3	1.92e-6	Malaria;
SARC	cis	rs2228479	0.850	rs12598316	chr16:89916600	C/A	cg00800038	chr16:89945340	TCF25	-0.82	-5.8	-0.35	2.19e-8	Skin colour saturation;
SARC	cis	rs79349575	0.783	rs62075818	chr17:46982327	T/A	cg16584676	chr17:46985605	UBE2Z	0.54	6.59	0.4	2.95e-10	Type 2 diabetes;
SARC	cis	rs796364	0.806	rs11674293	chr2:201026743	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-5.08	-0.32	7.66e-7	Schizophrenia;
SARC	cis	rs3733585	0.664	rs28602527	chr4:9958327	G/A	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.55	-0.34	7.65e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs1348850	0.914	rs12469386	chr2:178358281	A/G	cg23306229	chr2:178417860	TTC30B	-0.55	-6.5	-0.39	4.84e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7829975	0.711	rs1039916	chr8:8685854	A/G	cg06636001	chr8:8085503	FLJ10661	0.62	8.23	0.47	1.3e-14	Mood instability;
SARC	cis	rs67460515	0.563	rs4521287	chr3:160812752	C/T	cg17135325	chr3:160939158	NMD3	0.64	7.75	0.45	2.9e-13	Parkinson's disease;
SARC	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg24060327	chr5:131705240	SLC22A5	0.61	7.17	0.43	9.77e-12	Breast cancer;
SARC	cis	rs72634258	0.554	rs7556518	chr1:7847846	G/A	cg05338066	chr1:7812865	CAMTA1	0.64	5.5	0.34	1e-7	Inflammatory bowel disease;
SARC	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.74	8.75	0.5	4.46e-16	Height;
SARC	trans	rs208520	0.690	rs207108	chr6:66794096	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.06	-14.41	-0.69	4.36e-34	Exhaled nitric oxide output;
SARC	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg22535103	chr8:58192502	C8orf71	-0.59	-6.2	-0.38	2.48e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg03213289	chr20:61660250	NA	0.48	6.64	0.4	2.17e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg01475735	chr3:40494733	NA	-0.46	-5.12	-0.32	6.52e-7	Renal cell carcinoma;
SARC	cis	rs62012628	0.527	rs12438008	chr15:79084680	C/T	cg04896959	chr15:78267971	NA	-0.47	-5.73	-0.35	3.11e-8	Diastolic blood pressure;
SARC	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg12463550	chr7:65579703	CRCP	-0.5	-5.55	-0.34	7.81e-8	Aortic root size;
SARC	cis	rs3796352	1.000	rs13058817	chr3:53024139	C/T	cg07884673	chr3:53033167	SFMBT1	0.9	5.87	0.36	1.49e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs1007738	0.542	rs7937410	chr11:47206082	C/G	cg03339077	chr11:47165057	C11orf49	0.41	5.0	0.31	1.14e-6	Bone mineral density (hip);
SARC	cis	rs2760061	0.626	rs635563	chr1:228136834	C/T	cg02753203	chr1:228287806	NA	-0.56	-7.98	-0.46	6.44e-14	Diastolic blood pressure;
SARC	cis	rs1008375	0.932	rs10029173	chr4:17659598	C/T	cg02297831	chr4:17616191	MED28	-0.5	-6.48	-0.39	5.38e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9389248	0.690	rs1028314	chr6:135255710	A/C	cg24558204	chr6:135376177	HBS1L	-0.52	-6.52	-0.39	4.26e-10	High light scatter reticulocyte percentage of red cells;
SARC	cis	rs4268898	0.662	rs72793213	chr2:24524725	A/G	cg06627628	chr2:24431161	ITSN2	-0.82	-10.09	-0.55	4.36e-20	Asthma;
SARC	cis	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg25833597	chr17:30823145	MYO1D	-0.5	-4.95	-0.31	1.43e-6	Hip circumference adjusted for BMI;
SARC	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg22968622	chr17:43663579	NA	1.14	15.17	0.7	1.31e-36	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs6598955	0.614	rs1134584	chr1:26608828	G/A	cg04990556	chr1:26633338	UBXN11	-0.59	-8.22	-0.47	1.43e-14	Obesity-related traits;
SARC	cis	rs9790314	1.000	rs1600209	chr3:161038217	A/T	cg04691961	chr3:161091175	C3orf57	-0.79	-11.56	-0.6	1.02e-24	Morning vs. evening chronotype;
SARC	cis	rs9325144	0.560	rs10785586	chr12:38676197	G/A	cg26384229	chr12:38710491	ALG10B	-0.66	-8.45	-0.48	3.27e-15	Morning vs. evening chronotype;
SARC	cis	rs6831352	0.840	rs34634551	chr4:100067362	C/A	cg13256891	chr4:100009986	ADH5	-0.65	-7.8	-0.45	2.07e-13	Alcohol dependence;
SARC	cis	rs12142240	0.698	rs45449893	chr1:46859024	A/G	cg10495392	chr1:46806563	NSUN4	0.65	6.88	0.41	5.6e-11	Menopause (age at onset);
SARC	cis	rs2742234	0.590	rs741968	chr10:43611708	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.42	-5.02	-0.31	1.01e-6	Hirschsprung disease;
SARC	cis	rs7769051	0.522	rs6927991	chr6:133113888	T/G	cg07930552	chr6:133119739	C6orf192	1.01	5.99	0.37	7.7e-9	Type 2 diabetes nephropathy;
SARC	cis	rs7666738	0.515	rs13142498	chr4:98792443	G/T	cg05340658	chr4:99064831	C4orf37	0.59	7.24	0.43	6.56e-12	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1881797	1.000	rs12081895	chr1:247686666	C/G	cg11166453	chr1:247681781	NA	0.46	5.18	0.32	4.74e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9309711	0.666	rs6723101	chr2:3484443	T/C	cg15506890	chr2:3487001	NA	-0.46	-6.14	-0.37	3.59e-9	Neurofibrillary tangles;
SARC	cis	rs6545883	0.929	rs12713436	chr2:61691260	T/C	cg15711740	chr2:61764176	XPO1	-0.42	-5.02	-0.31	1.05e-6	Tuberculosis;
SARC	cis	rs6665290	0.935	rs12403236	chr1:227196502	C/G	cg14016676	chr1:227182615	CDC42BPA	0.37	5.21	0.32	4.25e-7	Myeloid white cell count;
SARC	cis	rs6665290	0.836	rs12593	chr1:227172290	A/G	cg10327440	chr1:227177885	CDC42BPA	1.07	23.33	0.84	7.01e-63	Myeloid white cell count;
SARC	cis	rs9309711	0.772	rs9309714	chr2:3491830	G/C	cg10845886	chr2:3471009	TTC15	-0.59	-6.96	-0.41	3.5e-11	Neurofibrillary tangles;
SARC	cis	rs7666738	0.606	rs6839946	chr4:99076132	A/C	cg05340658	chr4:99064831	C4orf37	0.48	6.04	0.37	6.17e-9	Colonoscopy-negative controls vs population controls;
SARC	cis	rs72781680	0.716	rs2712079	chr2:24082061	G/A	cg08917208	chr2:24149416	ATAD2B	0.58	6.04	0.37	6.18e-9	Lymphocyte counts;
SARC	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg14582100	chr15:45693742	SPATA5L1	0.35	4.91	0.31	1.69e-6	Homoarginine levels;
SARC	trans	rs12310956	0.515	rs115836245	chr12:33951369	T/C	cg13010199	chr12:38710504	ALG10B	0.65	8.63	0.49	9.54e-16	Morning vs. evening chronotype;
SARC	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg18225595	chr11:63971243	STIP1	0.54	7.86	0.46	1.44e-13	Platelet count;
SARC	cis	rs10027350	0.514	rs3106320	chr4:25237158	A/C	cg04009456	chr4:25379436	ANAPC4	-0.45	-4.98	-0.31	1.24e-6	Childhood ear infection;
SARC	cis	rs2075371	0.932	rs2241333	chr7:133970750	C/T	cg00033643	chr7:134001901	SLC35B4	0.42	5.29	0.33	2.83e-7	Mean platelet volume;
SARC	cis	rs7772486	0.686	rs1337839	chr6:146010239	A/G	cg05347473	chr6:146136440	FBXO30	-0.52	-7.2	-0.43	8.02e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3126085	0.935	rs114825811	chr1:152231877	G/A	cg26876637	chr1:152193138	HRNR	-0.51	-5.19	-0.32	4.67e-7	Atopic dermatitis;
SARC	cis	rs2635047	0.648	rs4986203	chr18:44597092	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.54	7.22	0.43	7.15e-12	Educational attainment;
SARC	cis	rs80033912	0.640	rs6785832	chr3:49224316	C/T	cg07636037	chr3:49044803	WDR6	0.51	5.83	0.36	1.81e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg26874164	chr19:58962979	ZNF324B	0.53	6.8	0.41	8.61e-11	Uric acid clearance;
SARC	cis	rs734999	0.545	rs6666430	chr1:2698950	G/A	cg18854424	chr1:2615690	NA	0.32	5.2	0.32	4.37e-7	Ulcerative colitis;
SARC	cis	rs992157	0.717	rs3817266	chr2:219142594	C/T	cg00012203	chr2:219082015	ARPC2	-0.63	-9.14	-0.51	3.16e-17	Colorectal cancer;
SARC	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.75	7.37	0.43	2.91e-12	Platelet count;
SARC	cis	rs6860806	0.531	rs270607	chr5:131649186	A/G	cg12564285	chr5:131593104	PDLIM4	0.42	5.92	0.36	1.13e-8	Breast cancer;
SARC	cis	rs1153858	0.621	rs2413769	chr15:45561868	A/C	cg19305227	chr15:45544335	SLC28A2	-0.29	-5.17	-0.32	5.04e-7	Homoarginine levels;
SARC	cis	rs910316	0.935	rs11159119	chr14:75636967	C/T	cg23033748	chr14:75592666	NEK9	-0.35	-4.79	-0.3	2.97e-6	Height;
SARC	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg15052019	chr19:19431593	KIAA0892;SF4	-0.39	-4.75	-0.3	3.54e-6	Tonsillectomy;
SARC	cis	rs7223966	1.000	rs9903903	chr17:61762044	A/G	cg26338869	chr17:61819248	STRADA	0.44	5.14	0.32	5.82e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs826838	1.000	rs55828987	chr12:39056421	A/C	cg13010199	chr12:38710504	ALG10B	0.76	10.6	0.57	1.09e-21	Heart rate;
SARC	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg26116260	chr4:7069785	GRPEL1	0.82	8.86	0.5	2.13e-16	Monocyte percentage of white cells;
SARC	cis	rs5758659	0.652	rs133324	chr22:42406371	C/A	cg04733989	chr22:42467013	NAGA	0.5	6.7	0.4	1.52e-10	Cognitive function;
SARC	cis	rs9790314	0.696	rs9290069	chr3:160890946	A/G	cg03342759	chr3:160939853	NMD3	-0.53	-6.56	-0.39	3.4e-10	Morning vs. evening chronotype;
SARC	cis	rs17376456	0.935	rs10036891	chr5:93171738	T/A	cg25358565	chr5:93447407	FAM172A	1.22	10.56	0.57	1.45e-21	Diabetic retinopathy;
SARC	cis	rs8044995	0.563	rs7500163	chr16:68364358	C/G	cg05110241	chr16:68378359	PRMT7	-0.66	-6.23	-0.38	2.19e-9	Schizophrenia;
SARC	cis	rs2463822	0.507	rs72919442	chr11:62028707	A/G	cg06239285	chr11:62104954	ASRGL1	-0.87	-7.92	-0.46	9.4e-14	Chronic obstructive pulmonary disease-related biomarkers;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg15791348	chr19:1354663	MUM1	0.54	6.6	0.4	2.79e-10	Breast cancer;
SARC	cis	rs4144743	1.000	rs61312893	chr17:45325023	C/G	cg18085866	chr17:45331354	ITGB3	-0.72	-7.36	-0.43	3.22e-12	Body mass index;
SARC	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg03575189	chr17:44344142	NA	0.6	5.71	0.35	3.43e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs780096	1.000	rs780096	chr2:27741072	C/G	cg12000995	chr2:27665139	KRTCAP3	-0.28	-4.81	-0.3	2.77e-6	Total body bone mineral density;
SARC	cis	rs2645694	0.626	rs2703116	chr4:77824289	C/T	cg06046430	chr4:77819534	ANKRD56	-0.53	-7.78	-0.45	2.33e-13	Emphysema distribution in smoking;
SARC	cis	rs76917914	0.820	rs7848430	chr9:100810895	G/A	cg03040243	chr9:100819229	NANS	0.74	7.81	0.46	1.96e-13	Immature fraction of reticulocytes;
SARC	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg19223190	chr17:80058835	NA	-0.4	-5.56	-0.34	7.43e-8	Life satisfaction;
SARC	cis	rs7429990	0.965	rs9811277	chr3:48011638	A/G	cg11946769	chr3:48343235	NME6	0.47	5.45	0.34	1.28e-7	Educational attainment (years of education);
SARC	trans	rs116095464	0.558	rs56081398	chr5:247318	C/T	cg00938859	chr5:1591904	SDHAP3	0.79	6.57	0.4	3.28e-10	Breast cancer;
SARC	cis	rs11687170	0.882	rs56233108	chr2:237053799	A/G	cg19324714	chr2:237145437	ASB18	0.48	4.82	0.3	2.65e-6	Educational attainment;Educational attainment (years of education);
SARC	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.83	12.65	0.64	2.84e-28	Personality dimensions;
SARC	cis	rs2204008	0.557	rs11520191	chr12:38197057	T/A	cg13010199	chr12:38710504	ALG10B	0.78	10.64	0.57	8.11e-22	Bladder cancer;
SARC	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg19223190	chr17:80058835	NA	0.44	6.19	0.38	2.67e-9	Life satisfaction;
SARC	cis	rs78366141	0.649	rs112818517	chr4:89653103	G/A	cg01026744	chr4:89619053	NAP1L5;HERC3	0.91	4.82	0.3	2.58e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
SARC	cis	rs2153904	0.793	rs12132270	chr1:205660940	C/T	cg24503407	chr1:205819492	PM20D1	-0.56	-5.07	-0.32	8.26e-7	Prostate-specific antigen levels;
SARC	cis	rs1348850	0.958	rs4528793	chr2:178464271	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	7.64	0.45	5.64e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9467773	1.000	rs9467787	chr6:26556769	G/T	cg11502198	chr6:26597334	ABT1	0.5	6.09	0.37	4.53e-9	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg08280861	chr8:58055591	NA	0.69	5.66	0.35	4.36e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg03489969	chr8:98881623	MATN2	-0.5	-6.42	-0.39	7.4e-10	Schizophrenia;
SARC	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg18876405	chr7:65276391	NA	0.49	6.08	0.37	4.8e-9	Aortic root size;
SARC	cis	rs453301	0.579	rs10096850	chr8:8798222	A/T	cg15556689	chr8:8085844	FLJ10661	-0.42	-5.07	-0.31	8.27e-7	Joint mobility (Beighton score);
SARC	trans	rs11098499	0.909	rs2127821	chr4:120394535	T/C	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	cis	rs8114671	0.562	rs6120739	chr20:33405227	A/G	cg24642439	chr20:33292090	TP53INP2	0.54	6.82	0.41	7.7e-11	Height;
SARC	cis	rs1318878	0.679	rs1461032	chr12:15544888	T/C	cg08258403	chr12:15378311	NA	0.37	5.31	0.33	2.53e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7520050	0.667	rs11211176	chr1:46223086	C/T	cg06784218	chr1:46089804	CCDC17	-0.27	-4.85	-0.3	2.27e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs651907	0.535	rs13084113	chr3:101534039	C/G	cg12386194	chr3:101231763	SENP7	0.47	5.33	0.33	2.32e-7	Colorectal cancer;
SARC	cis	rs11676348	0.774	rs4672870	chr2:218941916	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.41	-5.22	-0.32	3.94e-7	Ulcerative colitis;
SARC	cis	rs4642101	0.511	rs9809596	chr3:12840513	C/G	cg05775895	chr3:12838266	CAND2	0.78	13.03	0.65	1.63e-29	QRS complex (12-leadsum);
SARC	cis	rs2760061	0.598	rs1774755	chr1:228115282	T/G	cg02753203	chr1:228287806	NA	-0.54	-7.44	-0.44	1.96e-12	Diastolic blood pressure;
SARC	cis	rs6700896	0.897	rs7518710	chr1:66168238	G/A	cg04111102	chr1:66153794	NA	-0.37	-5.52	-0.34	8.92e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs4481887	1.000	rs11204636	chr1:248492409	A/C	cg00666640	chr1:248458726	OR2T12	-0.41	-6.55	-0.39	3.61e-10	Common traits (Other);
SARC	cis	rs2658782	1.000	rs2605582	chr11:93163799	C/T	cg15737290	chr11:93063684	CCDC67	0.71	7.65	0.45	5.13e-13	Pulmonary function decline;
SARC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg21747090	chr2:27597821	SNX17	0.52	7.3	0.43	4.44e-12	Total body bone mineral density;
SARC	cis	rs7843479	0.582	rs11779655	chr8:21794041	A/G	cg17168535	chr8:21777572	XPO7	-0.88	-13.93	-0.67	1.68e-32	Mean corpuscular volume;
SARC	cis	rs79349575	0.783	rs9747646	chr17:47016882	C/T	cg16584676	chr17:46985605	UBE2Z	0.55	6.66	0.4	1.91e-10	Type 2 diabetes;
SARC	cis	rs4988958	0.565	rs3755265	chr2:103052816	C/A	cg03938978	chr2:103052716	IL18RAP	0.3	4.85	0.3	2.25e-6	Asthma (childhood onset);
SARC	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg06618935	chr21:46677482	NA	-0.42	-5.65	-0.35	4.7e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs17376456	0.825	rs13357713	chr5:93145423	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.7	6.26	0.38	1.82e-9	Diabetic retinopathy;
SARC	cis	rs12530134	0.519	rs3920484	chr6:170746081	A/G	cg03208893	chr6:170746098	NA	-0.65	-4.83	-0.3	2.46e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9324022	0.858	rs1004572	chr14:101178330	G/A	cg18089426	chr14:101175970	NA	0.57	5.7	0.35	3.55e-8	Plateletcrit;
SARC	trans	rs61931739	0.500	rs34287388	chr12:34444626	C/A	cg13010199	chr12:38710504	ALG10B	0.81	11.39	0.6	3.58e-24	Morning vs. evening chronotype;
SARC	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg13206674	chr6:150067644	NUP43	0.41	5.36	0.33	1.96e-7	Lung cancer;
SARC	cis	rs5769765	0.862	rs9616774	chr22:50290599	G/A	cg03033257	chr22:50311977	ALG12;CRELD2	0.52	5.33	0.33	2.28e-7	Schizophrenia;
SARC	cis	rs13161895	0.713	rs76315806	chr5:179485515	C/G	cg06664874	chr5:179499304	RNF130	0.58	5.18	0.32	4.86e-7	LDL cholesterol;
SARC	cis	rs7429990	0.932	rs6442101	chr3:48130893	C/T	cg11946769	chr3:48343235	NME6	-0.49	-5.38	-0.33	1.81e-7	Educational attainment (years of education);
SARC	cis	rs9790314	0.560	rs1450521	chr3:161091237	C/A	cg04691961	chr3:161091175	C3orf57	-0.58	-7.7	-0.45	3.81e-13	Morning vs. evening chronotype;
SARC	cis	rs10979	1.000	rs9376761	chr6:143887165	G/A	cg25407410	chr6:143891975	LOC285740	-0.62	-8.24	-0.47	1.27e-14	Hypospadias;
SARC	trans	rs1814175	0.817	rs7481230	chr11:49772235	G/A	cg03929089	chr4:120376271	NA	-0.9	-14.74	-0.69	3.46e-35	Height;
SARC	cis	rs2075671	0.903	rs4727459	chr7:100276821	T/C	cg20848291	chr7:100343083	ZAN	-0.65	-7.09	-0.42	1.58e-11	Other erythrocyte phenotypes;
SARC	cis	rs7249142	0.549	rs12975253	chr19:19279745	A/C	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.23	4.85	0.3	2.23e-6	IgG glycosylation;
SARC	cis	rs7647973	0.560	rs62262671	chr3:49649873	A/G	cg07636037	chr3:49044803	WDR6	-0.69	-5.57	-0.34	6.84e-8	Menarche (age at onset);
SARC	cis	rs12190007	0.508	rs6605537	chr6:169730781	G/A	cg16388071	chr6:169726476	NA	0.56	7.53	0.44	1.13e-12	Obesity-related traits;
SARC	cis	rs78456975	1.000	rs6730391	chr2:1566838	A/C	cg01028140	chr2:1542097	TPO	-0.49	-5.01	-0.31	1.09e-6	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs6866344	0.697	rs61247551	chr5:178133503	G/A	cg03877680	chr5:178157825	ZNF354A	1.02	12.68	0.64	2.26e-28	Neutrophil percentage of white cells;
SARC	cis	rs151234	0.676	rs231970	chr16:28567004	A/G	cg01378222	chr16:28622494	SULT1A1	-0.47	-5.48	-0.34	1.1e-7	Platelet distribution width;
SARC	cis	rs12477438	0.501	rs11899745	chr2:100064072	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.39	-4.76	-0.3	3.42e-6	Chronic sinus infection;
SARC	cis	rs1971762	0.527	rs11170590	chr12:53938913	G/A	cg06632207	chr12:54070931	ATP5G2	0.57	7.89	0.46	1.14e-13	Height;
SARC	cis	rs12142240	0.660	rs72885163	chr1:46807117	C/A	cg14993813	chr1:46806288	NSUN4	-0.52	-5.58	-0.34	6.8e-8	Menopause (age at onset);
SARC	cis	rs10256972	0.669	rs10229964	chr7:1051776	A/G	cg07308232	chr7:1071921	C7orf50	-0.45	-5.42	-0.33	1.52e-7	Longevity;Endometriosis;
SARC	cis	rs2832191	0.632	rs1984011	chr21:30337831	T/A	cg24692254	chr21:30365293	RNF160	-1.03	-18.29	-0.77	5.99e-47	Dental caries;
SARC	cis	rs35110281	0.641	rs9983670	chr21:45083425	A/G	cg21573476	chr21:45109991	RRP1B	-0.59	-8.55	-0.49	1.6e-15	Mean corpuscular volume;
SARC	cis	rs4642101	0.765	rs1985428	chr3:12829315	A/G	cg05775895	chr3:12838266	CAND2	-0.75	-11.85	-0.61	1.13e-25	QRS complex (12-leadsum);
SARC	cis	rs2153535	0.541	rs6908504	chr6:8456778	A/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.04e-14	Motion sickness;
SARC	cis	rs9814567	0.929	rs1534027	chr3:134284662	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.04	-0.42	2.19e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs6840360	0.615	rs7695412	chr4:152488075	A/G	cg22705602	chr4:152727874	NA	-0.4	-6.3	-0.38	1.46e-9	Intelligence (multi-trait analysis);
SARC	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg24399712	chr22:39784796	NA	-0.41	-5.49	-0.34	1.06e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7223966	1.000	rs11658175	chr17:61923838	G/A	cg26338869	chr17:61819248	STRADA	0.48	5.19	0.32	4.6e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg23758822	chr17:41437982	NA	0.86	10.56	0.57	1.52e-21	Menopause (age at onset);
SARC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.58	0.53	1.52e-18	Prudent dietary pattern;
SARC	trans	rs62103177	0.810	rs62103178	chr18:77624555	C/G	cg05926928	chr17:57297772	GDPD1	1.08	9.41	0.52	5.04e-18	Opioid sensitivity;
SARC	cis	rs9815354	1.000	rs7372217	chr3:41990122	G/A	cg03022575	chr3:42003672	ULK4	-0.58	-5.74	-0.35	2.92e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2342371	0.509	rs9683218	chr3:196211033	C/T	cg15048948	chr3:196158458	UBXN7	-0.42	-5.46	-0.34	1.22e-7	Fat distribution (HIV);
SARC	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg12463550	chr7:65579703	CRCP	0.5	5.9	0.36	1.27e-8	Aortic root size;
SARC	cis	rs2031365	1.000	rs2031367	chr6:87807180	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.42	-4.82	-0.3	2.55e-6	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
SARC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg06873352	chr17:61820015	STRADA	-0.54	-7.17	-0.43	9.65e-12	Prudent dietary pattern;
SARC	cis	rs4595586	0.545	rs4254106	chr12:39389342	G/A	cg26384229	chr12:38710491	ALG10B	0.5	6.12	0.37	3.98e-9	Morning vs. evening chronotype;
SARC	cis	rs6570726	0.935	rs12663204	chr6:145818373	G/A	cg05347473	chr6:146136440	FBXO30	0.49	6.48	0.39	5.27e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6952808	0.931	rs12537479	chr7:1868995	A/G	cg13880726	chr7:1868755	MAD1L1	-0.51	-6.01	-0.37	7.08e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs6696846	0.905	rs11240349	chr1:205041015	G/A	cg21643547	chr1:205240462	TMCC2	-0.54	-7.16	-0.42	1.07e-11	Red blood cell count;
SARC	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg16414030	chr3:133502952	NA	-0.36	-4.76	-0.3	3.39e-6	Iron status biomarkers;
SARC	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6912958	0.684	rs4707382	chr6:88320641	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-5.71	-0.35	3.51e-8	Monocyte percentage of white cells;
SARC	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs3749237	0.595	rs1568661	chr3:49520958	A/G	cg02487422	chr3:49467188	NICN1	0.52	6.86	0.41	6.07e-11	Resting heart rate;
SARC	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg00800038	chr16:89945340	TCF25	0.76	5.24	0.32	3.56e-7	Skin colour saturation;
SARC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.72	7.38	0.44	2.84e-12	Platelet count;
SARC	cis	rs12079745	0.793	rs12061405	chr1:169208368	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.91	-5.85	-0.36	1.62e-8	QT interval;
SARC	cis	rs7824557	0.614	rs17741537	chr8:11213092	A/G	cg21775007	chr8:11205619	TDH	0.72	9.56	0.53	1.71e-18	Retinal vascular caliber;
SARC	cis	rs2952156	0.876	rs903501	chr17:37839493	T/C	cg20243544	chr17:37824526	PNMT	0.5	6.07	0.37	5.15e-9	Asthma;
SARC	cis	rs9818758	0.607	rs61729488	chr3:49067904	T/C	cg07636037	chr3:49044803	WDR6	-0.78	-6.72	-0.4	1.37e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs2806561	0.765	rs641032	chr1:23513980	C/T	cg12483005	chr1:23474871	LUZP1	-0.44	-5.82	-0.36	1.96e-8	Height;
SARC	cis	rs8523	0.774	rs115367234	chr6:11044658	C/T	cg13562911	chr6:11044106	ELOVL2	0.56	7.67	0.45	4.59e-13	Red blood cell fatty acid levels;
SARC	cis	rs7904368	0.806	rs1130684	chr10:16859335	C/G	cg14835575	chr10:16859367	RSU1	0.89	9.78	0.54	3.78e-19	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs1215050	0.818	rs165238	chr4:98712138	G/T	cg05340658	chr4:99064831	C4orf37	0.42	5.58	0.34	6.78e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg20607798	chr8:58055168	NA	0.6	5.33	0.33	2.29e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.34	-5.17	-0.32	5.07e-7	Longevity;Endometriosis;
SARC	cis	rs1707322	0.685	rs6690926	chr1:46134978	T/C	cg06784218	chr1:46089804	CCDC17	0.36	6.25	0.38	1.93e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6484504	0.516	rs1999250	chr11:31287455	C/T	cg26647111	chr11:31128758	NA	-0.39	-5.14	-0.32	5.7e-7	Red blood cell count;
SARC	cis	rs6540556	0.769	rs909710	chr1:209930694	A/G	cg23920097	chr1:209922102	NA	0.58	5.97	0.36	8.98e-9	Red blood cell count;
SARC	cis	rs897080	0.515	rs698790	chr2:44683018	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	5.75	0.35	2.76e-8	Height;
SARC	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.94	10.04	0.55	5.91e-20	Platelet count;
SARC	cis	rs3857536	0.904	rs979694	chr6:66896457	G/C	cg07460842	chr6:66804631	NA	-0.44	-5.21	-0.32	4.14e-7	Blood trace element (Cu levels);
SARC	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg18252515	chr7:66147081	NA	0.47	5.25	0.32	3.5e-7	Aortic root size;
SARC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg26338869	chr17:61819248	STRADA	0.72	9.21	0.52	2e-17	Prudent dietary pattern;
SARC	cis	rs6500602	0.727	rs4238849	chr16:4538114	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.33	5.63	0.35	5.07e-8	Schizophrenia;
SARC	trans	rs7937682	0.824	rs577044	chr11:111490420	G/T	cg18187862	chr3:45730750	SACM1L	0.54	6.81	0.41	8.41e-11	Primary sclerosing cholangitis;
SARC	cis	rs6840360	0.593	rs4696106	chr4:152606818	A/G	cg22705602	chr4:152727874	NA	-0.49	-8.46	-0.48	2.88e-15	Intelligence (multi-trait analysis);
SARC	cis	rs9677476	0.863	rs58067379	chr2:232088295	A/T	cg23338755	chr2:231921595	PSMD1	0.43	5.06	0.31	8.43e-7	Food antigen IgG levels;
SARC	cis	rs7084402	0.934	rs1658441	chr10:60323021	G/C	cg07615347	chr10:60278583	BICC1	0.6	8.78	0.5	3.66e-16	Refractive error;
SARC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg21548813	chr6:291882	DUSP22	-0.6	-7.88	-0.46	1.29e-13	Menopause (age at onset);
SARC	cis	rs1784581	0.894	rs1790000	chr6:162388707	A/G	cg17173639	chr6:162384350	PARK2	0.79	11.36	0.6	4.41e-24	Itch intensity from mosquito bite;
SARC	cis	rs6665290	0.669	rs34267809	chr1:227176162	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.02	-20.72	-0.81	8.85e-55	Myeloid white cell count;
SARC	cis	rs9420	0.961	rs11602109	chr11:57435296	G/A	cg23127183	chr11:57508653	C11orf31	-0.56	-6.37	-0.39	9.97e-10	Schizophrenia;
SARC	cis	rs8064024	0.650	rs3813749	chr16:4919127	T/C	cg08329684	chr16:4932620	PPL	0.37	5.72	0.35	3.23e-8	Cancer;
SARC	cis	rs7647973	1.000	rs892974	chr3:49398514	C/A	cg06212747	chr3:49208901	KLHDC8B	0.56	5.43	0.34	1.39e-7	Menarche (age at onset);
SARC	cis	rs2120243	0.591	rs9871290	chr3:157099591	A/G	cg24825693	chr3:157122686	VEPH1	-0.45	-6.13	-0.37	3.66e-9	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg24642844	chr7:1081250	C7orf50	-0.36	-4.97	-0.31	1.28e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs1355223	0.583	rs2915177	chr11:34880266	A/G	cg18508148	chr11:34937573	PDHX;APIP	0.5	6.38	0.39	9.66e-10	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs6991952	0.627	rs13281291	chr8:25699664	C/T	cg21775463	chr8:25538546	NA	0.28	4.92	0.31	1.65e-6	Inguinal hernia;
SARC	cis	rs3768617	0.510	rs3768618	chr1:183092491	C/A	cg13390022	chr1:182993471	LAMC1	0.31	4.73	0.3	3.89e-6	Fuchs's corneal dystrophy;
SARC	cis	rs950169	0.580	rs11635597	chr15:85165699	C/T	cg17507749	chr15:85114479	UBE2QP1	0.58	6.74	0.4	1.22e-10	Schizophrenia;
SARC	cis	rs35110281	0.782	rs6518309	chr21:45047992	C/A	cg21573476	chr21:45109991	RRP1B	-0.57	-7.96	-0.46	7.71e-14	Mean corpuscular volume;
SARC	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg15448220	chr1:150897856	SETDB1	0.47	6.25	0.38	1.94e-9	Tonsillectomy;
SARC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.72	7.44	0.44	1.87e-12	Platelet count;
SARC	cis	rs13191362	1.000	rs34655790	chr6:163202739	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.65	5.77	0.35	2.51e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs8072100	0.713	rs1912486	chr17:45515167	A/G	cg08085267	chr17:45401833	C17orf57	-0.43	-5.03	-0.31	9.66e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs4595586	0.545	rs1839402	chr12:39371615	C/T	cg26384229	chr12:38710491	ALG10B	0.51	6.23	0.38	2.21e-9	Morning vs. evening chronotype;
SARC	cis	rs7208859	0.524	rs8065744	chr17:29099449	C/T	cg13385521	chr17:29058706	SUZ12P	0.84	7.05	0.42	2e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs2153535	0.580	rs9379210	chr6:8461928	C/G	cg21535247	chr6:8435926	SLC35B3	0.53	6.7	0.4	1.58e-10	Motion sickness;
SARC	cis	rs7020830	0.931	rs1388978	chr9:37144062	G/T	cg14294708	chr9:37120828	ZCCHC7	1.1	18.56	0.77	8.15e-48	Schizophrenia;
SARC	cis	rs2594989	0.943	rs2454501	chr3:11500089	A/G	cg00170343	chr3:11313890	ATG7	0.54	5.13	0.32	6.12e-7	Circulating chemerin levels;
SARC	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg12311346	chr5:56204834	C5orf35	-0.39	-4.75	-0.3	3.59e-6	Coronary artery disease;
SARC	cis	rs910316	0.503	rs12894709	chr14:75441734	G/A	cg08847533	chr14:75593920	NEK9	0.84	11.81	0.61	1.55e-25	Height;
SARC	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg00684032	chr4:1343700	KIAA1530	0.38	5.47	0.34	1.19e-7	Obesity-related traits;
SARC	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg07701084	chr6:150067640	NUP43	0.4	5.43	0.34	1.43e-7	Lung cancer;
SARC	cis	rs6570726	0.905	rs1355146	chr6:145781741	A/C	cg23711669	chr6:146136114	FBXO30	-0.71	-10.54	-0.57	1.71e-21	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6582630	0.599	rs7967598	chr12:38540760	C/T	cg26384229	chr12:38710491	ALG10B	-0.58	-7.39	-0.44	2.54e-12	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg05313129	chr8:58192883	C8orf71	-0.49	-4.74	-0.3	3.69e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs36051895	0.603	rs10974972	chr9:5130146	G/A	cg02405213	chr9:5042618	JAK2	-0.45	-5.49	-0.34	1.07e-7	Pediatric autoimmune diseases;
SARC	cis	rs3772190	0.528	rs10936603	chr3:169545652	G/T	cg08193579	chr3:169529701	LRRC34	0.42	4.87	0.3	2.04e-6	Glioma;
SARC	cis	rs2276314	1.000	rs4799832	chr18:33559646	T/C	cg19628046	chr18:33552617	C18orf21	0.56	5.92	0.36	1.16e-8	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs7112043	0.838	rs11032839	chr11:34777725	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.38	4.86	0.3	2.15e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs9486715	0.838	rs9386473	chr6:96873341	C/A	cg06623918	chr6:96969491	KIAA0776	0.83	11.86	0.61	1.04e-25	Headache;
SARC	trans	rs561341	0.609	rs2051810	chr17:30195841	C/T	cg20587970	chr11:113659929	NA	0.68	6.56	0.39	3.44e-10	Hip circumference adjusted for BMI;
SARC	cis	rs9393692	0.557	rs2893820	chr6:26295686	G/A	cg13736514	chr6:26305472	NA	-0.41	-5.03	-0.31	9.64e-7	Educational attainment;
SARC	cis	rs6700896	0.864	rs7515766	chr1:66167452	G/A	cg04111102	chr1:66153794	NA	-0.36	-5.41	-0.33	1.6e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs35146811	0.961	rs35991721	chr7:99728790	G/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.41	4.94	0.31	1.51e-6	Coronary artery disease;
SARC	cis	rs2439831	1.000	rs561863	chr15:43761352	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	8.35	0.48	6.17e-15	Lung cancer in ever smokers;
SARC	cis	rs2236918	0.710	rs1635510	chr1:242027500	G/T	cg17736920	chr1:242011382	EXO1	0.65	8.79	0.5	3.25e-16	Menopause (age at onset);
SARC	cis	rs6088813	0.961	rs981819	chr20:33924112	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.46	5.53	0.34	8.59e-8	Height;
SARC	trans	rs9951602	0.512	rs3859325	chr18:76652175	A/G	cg02800362	chr5:177631904	HNRNPAB	0.7	8.91	0.5	1.49e-16	Obesity-related traits;
SARC	cis	rs10979	0.557	rs9376767	chr6:143909380	G/A	cg25407410	chr6:143891975	LOC285740	-0.52	-6.03	-0.37	6.39e-9	Hypospadias;
SARC	cis	rs9291683	0.554	rs7668175	chr4:10125782	T/C	cg00071950	chr4:10020882	SLC2A9	-0.32	-5.04	-0.31	9.41e-7	Bone mineral density;
SARC	cis	rs9916302	0.904	rs600010	chr17:37433517	T/C	cg07936489	chr17:37558343	FBXL20	-0.68	-9.22	-0.52	1.82e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs12956009	0.518	rs1560902	chr18:44898765	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	7.64	0.45	5.68e-13	Educational attainment (years of education);
SARC	cis	rs7647973	0.593	rs7620848	chr3:49828021	G/C	cg06212747	chr3:49208901	KLHDC8B	-0.58	-5.81	-0.36	2e-8	Menarche (age at onset);
SARC	cis	rs853679	1.000	rs1936365	chr6:28268452	C/G	cg26450541	chr6:28235208	ZNF187	-0.6	-5.05	-0.31	9.06e-7	Depression;
SARC	cis	rs2075371	0.829	rs10954442	chr7:134007587	A/G	cg20476274	chr7:133979776	SLC35B4	-0.44	-5.55	-0.34	7.89e-8	Mean platelet volume;
SARC	cis	rs7084402	0.565	rs11006188	chr10:60333471	G/C	cg07615347	chr10:60278583	BICC1	0.41	5.58	0.34	6.56e-8	Refractive error;
SARC	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	12.37	0.63	2.38e-27	Chronic sinus infection;
SARC	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg11062466	chr8:58055876	NA	0.59	5.58	0.34	6.61e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1559088	0.901	rs12610053	chr19:33582606	A/G	cg17764715	chr19:33622953	WDR88	0.5	6.69	0.4	1.68e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs11098499	0.955	rs1551	chr4:120158500	T/G	cg24375607	chr4:120327624	NA	0.39	4.73	0.3	3.89e-6	Corneal astigmatism;
SARC	cis	rs7617773	0.780	rs11710257	chr3:48373214	T/G	cg11946769	chr3:48343235	NME6	0.77	9.63	0.53	1.05e-18	Coronary artery disease;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg26602477	chr1:1476845	C1orf70	0.47	6.7	0.4	1.58e-10	Schizophrenia;
SARC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg08280861	chr8:58055591	NA	0.61	5.96	0.36	9.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9467773	1.000	rs1321480	chr6:26532742	A/G	cg12292205	chr6:26970375	C6orf41	0.45	5.44	0.34	1.36e-7	Intelligence (multi-trait analysis);
SARC	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg06028605	chr16:24865363	SLC5A11	0.35	5.38	0.33	1.81e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2120243	0.539	rs9857875	chr3:157078897	C/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.4	4.94	0.31	1.48e-6	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs9815354	0.812	rs10510732	chr3:42007339	C/T	cg03022575	chr3:42003672	ULK4	0.74	6.14	0.37	3.51e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg12463550	chr7:65579703	CRCP	-0.47	-5.43	-0.34	1.38e-7	Aortic root size;
SARC	cis	rs453301	0.686	rs7814328	chr8:8876229	T/C	cg11608241	chr8:8085544	FLJ10661	-0.47	-6.0	-0.37	7.5e-9	Joint mobility (Beighton score);
SARC	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg11843238	chr5:131593191	PDLIM4	-0.45	-5.41	-0.33	1.58e-7	Breast cancer;
SARC	cis	rs4969178	0.965	rs12944051	chr17:76395856	C/T	cg20026190	chr17:76395443	PGS1	-0.5	-6.62	-0.4	2.51e-10	HDL cholesterol levels;
SARC	cis	rs6570726	0.791	rs407887	chr6:145843759	C/T	cg23711669	chr6:146136114	FBXO30	0.86	14.48	0.69	2.64e-34	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9788721	0.900	rs72740964	chr15:78868636	G/A	cg06917634	chr15:78832804	PSMA4	-0.53	-5.61	-0.34	5.84e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs6087990	0.899	rs4911110	chr20:31392366	C/T	cg13636640	chr20:31349939	DNMT3B	-0.75	-11.32	-0.6	5.75e-24	Ulcerative colitis;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg11071901	chr6:111766153	REV3L	0.48	6.72	0.4	1.42e-10	Thyroid stimulating hormone;
SARC	cis	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg12257692	chr3:49977190	RBM6	0.28	4.81	0.3	2.66e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7824557	0.564	rs2736293	chr8:11234613	T/A	cg21775007	chr8:11205619	TDH	-0.65	-8.64	-0.49	9.24e-16	Retinal vascular caliber;
SARC	cis	rs10463316	0.894	rs6880137	chr5:150755232	A/G	cg03212797	chr5:150827313	SLC36A1	-0.44	-5.21	-0.32	4.17e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs10752881	1.000	rs8179283	chr1:182974602	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.76	0.58	3.38e-22	Colorectal cancer;
SARC	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	12.85	0.64	6.39e-29	Platelet count;
SARC	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg12311346	chr5:56204834	C5orf35	-0.57	-6.1	-0.37	4.48e-9	Initial pursuit acceleration;
SARC	cis	rs72634258	0.945	rs12745223	chr1:8094978	C/T	cg00042356	chr1:8021962	PARK7	0.9	8.16	0.47	2.03e-14	Inflammatory bowel disease;
SARC	cis	rs2251381	0.750	rs2776250	chr21:30528094	T/G	cg08807101	chr21:30365312	RNF160	0.76	10.23	0.56	1.58e-20	Selective IgA deficiency;
SARC	cis	rs8079658	1.000	rs62065084	chr17:63822357	T/C	cg03442606	chr17:63822778	CCDC46	-0.39	-4.86	-0.3	2.13e-6	Post bronchodilator FEV1;
SARC	cis	rs1420338	0.933	rs62451689	chr7:34178719	C/T	cg01275685	chr7:34179230	BMPER	-0.44	-5.39	-0.33	1.74e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
SARC	cis	rs12545109	0.807	rs13263281	chr8:57346582	C/A	cg09654669	chr8:57350985	NA	-0.41	-5.03	-0.31	9.75e-7	Obesity-related traits;
SARC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.45	0.53	3.73e-18	Prudent dietary pattern;
SARC	cis	rs4481887	0.962	rs6587452	chr1:248485931	C/T	cg00666640	chr1:248458726	OR2T12	0.41	6.68	0.4	1.75e-10	Common traits (Other);
SARC	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg22968622	chr17:43663579	NA	-1.1	-15.36	-0.71	2.93e-37	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs6665290	0.901	rs61834001	chr1:227197411	C/T	cg14016676	chr1:227182615	CDC42BPA	0.38	5.55	0.34	7.71e-8	Myeloid white cell count;
SARC	cis	rs4713118	0.662	rs149948	chr6:27974817	C/G	cg26335602	chr6:28129616	ZNF389	0.47	5.02	0.31	1.01e-6	Parkinson's disease;
SARC	cis	rs2228479	0.850	rs17232630	chr16:89851179	C/T	cg12064134	chr16:90016061	DEF8	-0.59	-5.06	-0.31	8.56e-7	Skin colour saturation;
SARC	cis	rs1023500	0.506	rs6002625	chr22:42517689	A/G	cg15557168	chr22:42548783	NA	0.36	4.77	0.3	3.28e-6	Schizophrenia;
SARC	cis	rs7586879	0.639	rs6713978	chr2:25120851	T/C	cg04586622	chr2:25135609	ADCY3	0.33	5.67	0.35	4.19e-8	Body mass index;
SARC	cis	rs8044868	0.548	rs3909541	chr16:72201119	C/T	cg16558253	chr16:72132732	DHX38	0.43	6.51	0.39	4.63e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
SARC	cis	rs6604026	0.656	rs7515257	chr1:93393718	G/A	cg17283838	chr1:93427260	FAM69A	0.41	4.77	0.3	3.25e-6	Multiple sclerosis;
SARC	cis	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg01579765	chr21:45077557	HSF2BP	-0.35	-5.77	-0.35	2.49e-8	Mean corpuscular volume;
SARC	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.59	-7.01	-0.42	2.61e-11	Gut microbiome composition (summer);
SARC	cis	rs9462027	0.628	rs2744949	chr6:34633862	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-6.02	-0.37	6.85e-9	Systemic lupus erythematosus;
SARC	cis	rs6964587	0.692	rs2374550	chr7:91820987	A/G	cg17063962	chr7:91808500	NA	0.84	13.09	0.65	1.05e-29	Breast cancer;
SARC	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg06420487	chr17:61919686	SMARCD2	0.44	4.82	0.3	2.64e-6	Height;
SARC	cis	rs2380220	0.678	rs4308568	chr6:96009525	A/C	cg15832292	chr6:96025679	MANEA	-0.5	-5.42	-0.33	1.46e-7	Behavioural disinhibition (generation interaction);
SARC	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg15052019	chr19:19431593	KIAA0892;SF4	-0.4	-4.83	-0.3	2.51e-6	Tonsillectomy;
SARC	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg26681399	chr22:41777847	TEF	-0.49	-5.44	-0.34	1.36e-7	Vitiligo;
SARC	cis	rs2290159	0.800	rs7636754	chr3:12678725	C/G	cg23032965	chr3:12705835	RAF1	0.74	8.1	0.47	3.15e-14	Cholesterol, total;
SARC	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg13206674	chr6:150067644	NUP43	0.53	6.84	0.41	6.85e-11	Lung cancer;
SARC	cis	rs9398803	0.865	rs9372839	chr6:126809870	G/A	cg20229609	chr6:126660872	C6orf173	0.4	5.71	0.35	3.42e-8	Male-pattern baldness;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04629194	chr10:97050357	PDLIM1	0.49	6.3	0.38	1.49e-9	Smoking initiation;
SARC	cis	rs11785400	0.793	rs4430071	chr8:143737680	T/C	cg24634471	chr8:143751801	JRK	0.59	7.45	0.44	1.83e-12	Schizophrenia;
SARC	cis	rs2075371	1.000	rs2544210	chr7:133971535	C/T	cg11752832	chr7:134001865	SLC35B4	0.56	7.31	0.43	4.23e-12	Mean platelet volume;
SARC	cis	rs2075466	0.514	rs75804753	chr16:4943033	G/T	cg06965925	chr16:4818988	NA	0.4	5.0	0.31	1.15e-6	Colonoscopy-negative controls vs population controls;
SARC	trans	rs9427116	0.502	rs12125166	chr1:154582129	A/G	cg06527865	chr1:234746497	IRF2BP2	-0.52	-6.44	-0.39	6.71e-10	Blood protein levels;
SARC	cis	rs478304	0.651	rs11604451	chr11:65551710	C/T	cg26695010	chr11:65641043	EFEMP2	0.41	4.82	0.3	2.59e-6	Acne (severe);
SARC	cis	rs11785400	1.000	rs4736368	chr8:143748528	G/C	cg24634471	chr8:143751801	JRK	0.68	8.96	0.51	1.04e-16	Schizophrenia;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg11098622	chr5:102205822	PAM	0.5	6.96	0.41	3.48e-11	Thyroid stimulating hormone;
SARC	cis	rs7089973	0.604	rs7903663	chr10:116609904	G/A	cg08188268	chr10:116634841	FAM160B1	0.28	4.79	0.3	3.02e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs73206853	0.841	rs61663407	chr12:111055128	A/G	cg10860002	chr12:110842031	ANAPC7	0.63	5.16	0.32	5.39e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg18876405	chr7:65276391	NA	-0.53	-6.35	-0.38	1.13e-9	Calcium levels;
SARC	cis	rs10782582	0.609	rs11588643	chr1:76255613	A/G	cg03433033	chr1:76189801	ACADM	-0.4	-5.2	-0.32	4.46e-7	Daytime sleep phenotypes;
SARC	cis	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg09021430	chr5:549028	NA	-0.45	-5.73	-0.35	3.15e-8	Obesity-related traits;
SARC	cis	rs4481887	0.893	rs1934543	chr1:248505602	C/G	cg00666640	chr1:248458726	OR2T12	0.34	5.82	0.36	1.96e-8	Common traits (Other);
SARC	trans	rs17221829	0.733	rs11018668	chr11:89356178	C/T	cg09407339	chr3:122283684	PARP9;DTX3L	0.44	6.25	0.38	1.97e-9	Anxiety in major depressive disorder;
SARC	cis	rs2295359	0.892	rs72676067	chr1:67658803	G/A	cg11235152	chr1:67600687	NA	0.5	7.03	0.42	2.23e-11	Psoriasis;
SARC	cis	rs9457247	0.624	rs2239826	chr6:167504880	T/C	cg23791538	chr6:167370224	RNASET2	-0.52	-6.66	-0.4	1.99e-10	Crohn's disease;
SARC	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg11764359	chr7:65958608	NA	0.88	12.58	0.64	4.89e-28	Aortic root size;
SARC	cis	rs12545109	0.800	rs2670054	chr8:57421616	C/T	cg21220214	chr8:57350948	NA	-0.4	-4.84	-0.3	2.37e-6	Obesity-related traits;
SARC	cis	rs2153904	0.793	rs12118655	chr1:205663478	A/G	cg23034840	chr1:205782522	SLC41A1	-0.77	-6.35	-0.38	1.11e-9	Prostate-specific antigen levels;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg21680979	chr1:204485559	MDM4	0.48	6.42	0.39	7.55e-10	Chemerin levels;
SARC	cis	rs1348850	0.793	rs6734528	chr2:178493731	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.5	5.73	0.35	3.09e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2120243	0.572	rs3816528	chr3:157127290	C/T	cg01018701	chr3:157155998	VEPH1;PTX3	-0.4	-5.12	-0.32	6.45e-7	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs17376456	0.877	rs13153245	chr5:93374891	G/A	cg21475434	chr5:93447410	FAM172A	0.87	7.91	0.46	1.06e-13	Diabetic retinopathy;
SARC	cis	rs2153535	0.580	rs9378552	chr6:8463748	G/A	cg07606381	chr6:8435919	SLC35B3	0.76	10.78	0.58	3.09e-22	Motion sickness;
SARC	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg05368731	chr17:41323189	NBR1	0.63	6.53	0.39	3.99e-10	Menopause (age at onset);
SARC	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg11843238	chr5:131593191	PDLIM4	0.38	5.08	0.32	7.9e-7	Blood metabolite levels;
SARC	cis	rs554111	0.574	rs4060971	chr1:21506930	C/T	cg04902671	chr1:21058625	SH2D5	-0.45	-5.48	-0.34	1.08e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	trans	rs1814175	0.817	rs7932683	chr11:49983640	G/A	cg15704280	chr7:45808275	SEPT13	-0.98	-18.59	-0.77	6.51e-48	Height;
SARC	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg13902645	chr11:5959945	NA	0.51	6.95	0.41	3.58e-11	DNA methylation (variation);
SARC	cis	rs473651	0.935	rs578510	chr2:239343140	C/T	cg18131467	chr2:239335373	ASB1	0.94	15.66	0.72	2.93e-38	Multiple system atrophy;
SARC	cis	rs6570726	0.935	rs9390329	chr6:145828026	T/C	cg05220968	chr6:146057943	EPM2A	-0.29	-4.86	-0.3	2.17e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1539053	0.932	rs1404384	chr1:58109829	A/G	cg00026909	chr1:58089001	DAB1	0.23	4.8	0.3	2.82e-6	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
SARC	cis	rs6815814	0.808	rs11721824	chr4:38767749	G/A	cg06935464	chr4:38784597	TLR10	0.58	5.28	0.33	2.99e-7	Breast cancer;
SARC	cis	rs7647973	0.626	rs12715437	chr3:49751856	T/C	cg06212747	chr3:49208901	KLHDC8B	0.58	5.8	0.36	2.11e-8	Menarche (age at onset);
SARC	cis	rs2204008	0.805	rs10881112	chr12:37956611	G/A	cg13010199	chr12:38710504	ALG10B	-0.65	-8.65	-0.49	8.47e-16	Bladder cancer;
SARC	cis	rs9916302	0.660	rs4795367	chr17:37608843	G/C	cg15445000	chr17:37608096	MED1	0.45	4.83	0.3	2.48e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs57994353	0.897	rs72775772	chr9:139356738	C/T	cg14169450	chr9:139327907	INPP5E	0.43	5.57	0.34	7.16e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs12541335	0.536	rs4266653	chr8:22169087	A/G	cg26039829	chr8:22132926	PIWIL2	0.47	6.8	0.41	8.68e-11	Hypertriglyceridemia;
SARC	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs7954584	0.560	rs745327	chr12:122456524	T/C	cg22168489	chr12:122356033	WDR66	-0.55	-7.32	-0.43	4.01e-12	Mean corpuscular volume;
SARC	cis	rs8180040	0.676	rs7633698	chr3:47013452	A/T	cg27129171	chr3:47204927	SETD2	0.65	8.91	0.5	1.47e-16	Colorectal cancer;
SARC	cis	rs920590	0.879	rs67391684	chr8:19654642	A/T	cg01411142	chr8:19674711	INTS10	0.4	4.78	0.3	3.11e-6	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs7666738	0.830	rs34461023	chr4:99023751	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.88	0.5	1.84e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg22535103	chr8:58192502	C8orf71	-0.59	-6.21	-0.38	2.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs826838	0.651	rs1843896	chr12:38612913	G/C	cg13010199	chr12:38710504	ALG10B	0.7	9.16	0.51	2.74e-17	Heart rate;
SARC	cis	rs9436747	0.641	rs4655519	chr1:66039919	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.48	5.22	0.32	3.97e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs2070488	0.745	rs9838792	chr3:38546726	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.75	-10.76	-0.58	3.41e-22	Electrocardiographic conduction measures;
SARC	cis	rs73206853	0.764	rs28362526	chr12:110561779	C/A	cg10860002	chr12:110842031	ANAPC7	0.65	5.28	0.33	2.93e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg05793240	chr7:2802953	GNA12	-0.38	-5.42	-0.33	1.46e-7	Height;
SARC	cis	rs11122272	0.735	rs971534	chr1:231521971	C/A	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg12463550	chr7:65579703	CRCP	-0.47	-5.6	-0.34	5.99e-8	Aortic root size;
SARC	cis	rs13191362	1.000	rs28360546	chr6:163210973	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.65	5.74	0.35	2.95e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs7044106	0.762	rs10760115	chr9:123476952	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.18	0.52	2.34e-17	Hip circumference adjusted for BMI;
SARC	cis	rs728616	0.614	rs726014	chr10:81708744	T/C	cg05935833	chr10:81318306	SFTPA2	-0.4	-4.74	-0.3	3.73e-6	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg18404041	chr3:52824283	ITIH1	-0.44	-6.52	-0.39	4.21e-10	Bipolar disorder;
SARC	cis	rs72781680	0.611	rs56326157	chr2:24312407	T/C	cg06627628	chr2:24431161	ITSN2	-0.56	-5.79	-0.35	2.31e-8	Lymphocyte counts;
SARC	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg22168489	chr12:122356033	WDR66	0.61	8.85	0.5	2.29e-16	Mean corpuscular volume;
SARC	cis	rs314370	0.904	rs13244629	chr7:100509253	A/C	cg10426581	chr7:100472382	SRRT	0.59	6.39	0.39	8.77e-10	Resting heart rate;
SARC	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg20887711	chr4:1340912	KIAA1530	0.81	10.21	0.56	1.77e-20	Longevity;
SARC	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg14159672	chr1:205819179	PM20D1	-0.49	-6.36	-0.38	1.08e-9	Menarche (age at onset);
SARC	cis	rs1215050	0.755	rs811479	chr4:98727398	A/T	cg05340658	chr4:99064831	C4orf37	0.44	5.85	0.36	1.62e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs7555523	0.832	rs7524755	chr1:165694897	A/G	cg24409356	chr1:165738333	TMCO1	0.69	5.95	0.36	9.81e-9	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg12463550	chr7:65579703	CRCP	0.49	5.57	0.34	7.16e-8	Aortic root size;
SARC	cis	rs7843479	0.601	rs11780532	chr8:21838670	T/A	cg17168535	chr8:21777572	XPO7	0.86	13.62	0.67	1.84e-31	Mean corpuscular volume;
SARC	cis	rs1348850	0.874	rs1348848	chr2:178358233	A/C	cg23306229	chr2:178417860	TTC30B	-0.53	-6.2	-0.38	2.56e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg00149659	chr3:10157352	C3orf10	1.09	10.0	0.55	7.87e-20	Alzheimer's disease;
SARC	cis	rs9354308	0.868	rs9363456	chr6:66548343	G/A	cg07460842	chr6:66804631	NA	-0.45	-5.23	-0.32	3.77e-7	Metabolite levels;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg14825384	chr10:115438916	CASP7	0.53	6.32	0.38	1.3e-9	Blood pressure;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg02450646	chr4:25235614	PI4K2B	0.52	6.84	0.41	6.79e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs10982256	0.763	rs1535965	chr9:117273208	C/T	cg21159778	chr9:117266918	DFNB31	0.4	5.65	0.35	4.77e-8	Bipolar disorder;
SARC	cis	rs2153535	0.546	rs9378559	chr6:8539058	A/T	cg21535247	chr6:8435926	SLC35B3	0.52	6.49	0.39	5.16e-10	Motion sickness;
SARC	cis	rs10504073	0.647	rs12156111	chr8:50017328	G/C	cg00325661	chr8:49890786	NA	0.54	7.44	0.44	1.97e-12	Blood metabolite ratios;
SARC	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg13628971	chr7:2884303	GNA12	0.51	5.86	0.36	1.54e-8	Height;
SARC	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.36	5.0	0.31	1.15e-6	Total body bone mineral density;
SARC	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	5.4	0.33	1.66e-7	Personality dimensions;
SARC	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg22535103	chr8:58192502	C8orf71	-0.73	-7.24	-0.43	6.52e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs7772486	0.754	rs10872580	chr6:146140281	C/T	cg23711669	chr6:146136114	FBXO30	-0.86	-14.88	-0.7	1.22e-35	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg08048268	chr3:133502702	NA	-0.41	-5.42	-0.33	1.5e-7	Iron status biomarkers;
SARC	cis	rs1754541	0.957	rs6665378	chr1:101655778	C/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.44	4.96	0.31	1.33e-6	Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;
SARC	cis	rs6449957	0.639	rs831227	chr5:67517646	A/C	cg23036683	chr5:67512108	NA	0.4	4.9	0.31	1.77e-6	Cleft lip with or without cleft palate;
SARC	cis	rs35110281	0.666	rs2838348	chr21:45107285	C/G	cg04455712	chr21:45112962	RRP1B	-0.34	-4.77	-0.3	3.27e-6	Mean corpuscular volume;
SARC	cis	rs36715	1.000	rs36705	chr5:127554486	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.59	6.4	0.39	8.56e-10	Breast cancer;
SARC	cis	rs3820928	0.874	rs13423046	chr2:227901805	G/T	cg11843606	chr2:227700838	RHBDD1	-0.55	-6.8	-0.41	8.88e-11	Pulmonary function;
SARC	cis	rs9354308	0.781	rs9363455	chr6:66547322	T/G	cg07460842	chr6:66804631	NA	-0.42	-4.85	-0.3	2.27e-6	Metabolite levels;
SARC	cis	rs4927850	0.521	rs4927679	chr3:195658360	C/T	cg00031303	chr3:195681400	NA	-0.44	-5.68	-0.35	4.1e-8	Pancreatic cancer;
SARC	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg13395646	chr4:1353034	KIAA1530	-0.56	-6.68	-0.4	1.76e-10	Obesity-related traits;
SARC	trans	rs804280	0.509	rs13268030	chr8:11783073	C/T	cg06636001	chr8:8085503	FLJ10661	0.52	6.66	0.4	1.96e-10	Myopia (pathological);
SARC	cis	rs1949733	0.598	rs16842480	chr4:8535621	G/T	cg05004818	chr4:8539015	NA	0.37	4.93	0.31	1.57e-6	Response to antineoplastic agents;
SARC	cis	rs1874564	1.000	rs2645645	chr4:77859067	A/T	cg00874691	chr4:77867684	NA	0.36	5.12	0.32	6.54e-7	Papillary thyroid cancer;Differentiated thyroid cancer;
SARC	cis	rs921968	0.608	rs495855	chr2:219357858	A/G	cg02176678	chr2:219576539	TTLL4	0.37	5.52	0.34	8.97e-8	Mean corpuscular hemoglobin concentration;
SARC	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg03060546	chr3:49711283	APEH	0.42	5.26	0.33	3.24e-7	Parkinson's disease;
SARC	cis	rs2933343	0.621	rs728838	chr3:128589013	A/G	cg24203234	chr3:128598194	ACAD9	0.61	7.77	0.45	2.56e-13	IgG glycosylation;
SARC	cis	rs3087591	0.879	rs59015798	chr17:29580882	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.56	-6.77	-0.41	1.06e-10	Hip circumference;
SARC	cis	rs2153535	0.541	rs7774752	chr6:8468978	C/T	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	cis	rs7772486	0.764	rs7762562	chr6:146158994	T/C	cg23711669	chr6:146136114	FBXO30	0.84	14.07	0.68	5.89e-33	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs875971	0.545	rs17138156	chr7:65714695	C/T	cg11764359	chr7:65958608	NA	0.68	6.84	0.41	6.92e-11	Aortic root size;
SARC	trans	rs11722228	0.549	rs41268389	chr4:10099277	G/A	cg26043149	chr18:55253948	FECH	0.7	7.87	0.46	1.35e-13	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg16049864	chr8:95962084	TP53INP1	-0.46	-7.34	-0.43	3.58e-12	Type 2 diabetes;
SARC	cis	rs7940866	0.774	rs12420126	chr11:130834811	C/T	cg12179176	chr11:130786555	SNX19	0.65	8.84	0.5	2.35e-16	Schizophrenia;
SARC	cis	rs155076	1.000	rs598754	chr13:21845010	C/A	cg11317459	chr13:21872234	NA	-0.98	-12.36	-0.63	2.52e-27	White matter hyperintensity burden;
SARC	cis	rs2624839	0.704	rs14321	chr3:50226151	T/C	cg19755318	chr3:50243323	SLC38A3	0.29	4.88	0.3	1.98e-6	Intelligence (multi-trait analysis);
SARC	cis	rs34779708	0.931	rs13376871	chr10:35369056	A/G	cg03585969	chr10:35415529	CREM	0.39	5.04	0.31	9.4e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs6545883	0.894	rs9677047	chr2:61585295	C/G	cg15711740	chr2:61764176	XPO1	0.41	4.84	0.3	2.32e-6	Tuberculosis;
SARC	cis	rs2645694	0.626	rs2645704	chr4:77830805	T/C	cg10057126	chr4:77819792	ANKRD56	0.38	5.66	0.35	4.47e-8	Emphysema distribution in smoking;
SARC	cis	rs2486288	0.656	rs11632778	chr15:45551056	C/T	cg15395560	chr15:45543142	SLC28A2	0.29	5.63	0.35	5.17e-8	Glomerular filtration rate;
SARC	cis	rs787274	0.850	rs2645985	chr9:115510812	A/G	cg13803584	chr9:115635662	SNX30	0.82	4.84	0.3	2.37e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg22618164	chr12:122356400	WDR66	0.42	6.59	0.4	2.86e-10	Mean corpuscular volume;
SARC	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	-0.81	-8.09	-0.47	3.19e-14	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.68	-8.82	-0.5	2.66e-16	Chronic sinus infection;
SARC	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.47	5.22	0.32	4e-7	Renal function-related traits (BUN);
SARC	cis	rs9549260	0.564	rs4245402	chr13:41287540	C/T	cg21288729	chr13:41239152	FOXO1	0.51	6.75	0.4	1.19e-10	Red blood cell count;
SARC	cis	rs1915146	0.967	rs7086481	chr10:126844523	A/T	cg05090351	chr10:126851162	NA	-0.34	-6.22	-0.38	2.24e-9	Menarche (age at onset);
SARC	cis	rs7674212	0.541	rs4699051	chr4:104114394	T/C	cg16532752	chr4:104119610	CENPE	-0.48	-6.04	-0.37	5.93e-9	Type 2 diabetes;
SARC	cis	rs2153535	0.580	rs1119688	chr6:8460850	T/C	cg07606381	chr6:8435919	SLC35B3	0.76	10.66	0.57	7.23e-22	Motion sickness;
SARC	cis	rs8114671	0.562	rs34837802	chr20:33424908	C/G	cg24642439	chr20:33292090	TP53INP2	0.55	6.83	0.41	7.38e-11	Height;
SARC	cis	rs13082711	0.911	rs11718991	chr3:27452944	A/G	cg02860705	chr3:27208620	NA	0.46	5.8	0.36	2.12e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	trans	rs7927370	0.850	rs61894957	chr11:55049411	C/T	cg07162727	chr16:4848039	ROGDI	0.8	6.25	0.38	1.98e-9	Systemic lupus erythematosus;
SARC	cis	rs10463554	1.000	rs6879788	chr5:102314057	T/C	cg23492399	chr5:102201601	PAM	-0.48	-5.95	-0.36	9.66e-9	Parkinson's disease;
SARC	cis	rs7098414	0.531	rs3844126	chr10:82019997	T/G	cg00277334	chr10:82204260	NA	-0.34	-4.82	-0.3	2.57e-6	Post bronchodilator FEV1;
SARC	cis	rs10489525	0.583	rs12034918	chr1:115626285	C/T	cg01522456	chr1:115632236	TSPAN2	0.67	7.82	0.46	1.78e-13	Autism;
SARC	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg05863683	chr7:1912471	MAD1L1	0.37	5.7	0.35	3.58e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs611744	0.967	rs686584	chr8:109192357	G/A	cg21045802	chr8:109455806	TTC35	0.44	5.3	0.33	2.63e-7	Dupuytren's disease;
SARC	cis	rs7551222	0.680	rs2169137	chr1:204497913	G/C	cg20240347	chr1:204465584	NA	-0.32	-5.38	-0.33	1.85e-7	Schizophrenia;
SARC	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg16405210	chr4:1374714	KIAA1530	0.7	8.47	0.49	2.76e-15	Obesity-related traits;
SARC	cis	rs2635047	0.811	rs10502880	chr18:44770746	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	6.54	0.39	3.89e-10	Educational attainment;
SARC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg21782813	chr7:2030301	MAD1L1	-0.43	-6.98	-0.42	3.03e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs1348850	0.668	rs12618542	chr2:178494520	A/G	cg23306229	chr2:178417860	TTC30B	0.62	6.82	0.41	7.62e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7264396	0.580	rs2425173	chr20:34445142	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.51	4.78	0.3	3.04e-6	Total cholesterol levels;
SARC	cis	rs734999	0.870	rs2147905	chr1:2482921	C/T	cg18854424	chr1:2615690	NA	-0.34	-5.39	-0.33	1.76e-7	Ulcerative colitis;
SARC	cis	rs3812049	0.784	rs1560637	chr5:127448066	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.88	9.58	0.53	1.49e-18	Lymphocyte counts;Red cell distribution width;
SARC	cis	rs9309473	0.500	rs11688718	chr2:73760939	C/T	cg20560298	chr2:73613845	ALMS1	-0.49	-6.52	-0.39	4.24e-10	Metabolite levels;
SARC	cis	rs10463316	0.894	rs6579875	chr5:150782574	C/T	cg03212797	chr5:150827313	SLC36A1	-0.49	-5.81	-0.36	2.08e-8	Metabolite levels (Pyroglutamine);
SARC	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	5.34	0.33	2.17e-7	Tonsillectomy;
SARC	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg22535103	chr8:58192502	C8orf71	-0.72	-6.74	-0.4	1.25e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	5.4	0.33	1.62e-7	Bipolar disorder;
SARC	cis	rs4268898	0.722	rs35520052	chr2:24415277	C/T	cg06627628	chr2:24431161	ITSN2	0.54	7.24	0.43	6.38e-12	Asthma;
SARC	cis	rs6102059	0.503	rs6102033	chr20:39184691	C/G	cg06424997	chr20:39929561	ZHX3	0.4	5.28	0.33	2.9e-7	LDL cholesterol;
SARC	cis	rs8114671	0.562	rs6088640	chr20:33472509	C/T	cg24642439	chr20:33292090	TP53INP2	0.51	6.18	0.38	2.9e-9	Height;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg22448677	chr13:26796711	RNF6	0.48	6.62	0.4	2.47e-10	Breast cancer;
SARC	cis	rs33912345	0.695	rs1314343	chr14:60877634	T/G	cg27398547	chr14:60952738	C14orf39	-0.39	-4.73	-0.3	3.85e-6	Glaucoma (high intraocular pressure);
SARC	cis	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg22496380	chr5:211416	CCDC127	-0.89	-9.09	-0.51	4.34e-17	Breast cancer;
SARC	cis	rs798554	0.607	rs1182151	chr7:2909225	C/G	cg13628971	chr7:2884303	GNA12	0.6	6.08	0.37	4.99e-9	Height;
SARC	cis	rs9910055	0.529	rs228765	chr17:42186422	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.46	-5.43	-0.34	1.4e-7	Total body bone mineral density;
SARC	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg11247378	chr22:39784982	NA	-0.3	-4.88	-0.3	1.99e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7130144	0.541	rs7949571	chr11:130462430	A/G	cg26307797	chr11:130446613	NA	-0.68	-5.72	-0.35	3.31e-8	Urate levels in lean individuals;
SARC	cis	rs4969178	0.965	rs12451715	chr17:76397334	A/C	cg02836325	chr17:76403955	PGS1	0.33	5.01	0.31	1.07e-6	HDL cholesterol levels;
SARC	cis	rs11098499	0.954	rs6846442	chr4:120326323	G/A	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs651907	0.557	rs62284199	chr3:101478531	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	6.21	0.38	2.46e-9	Colorectal cancer;
SARC	cis	rs950776	0.752	rs7182583	chr15:78899210	G/C	cg22563815	chr15:78856949	CHRNA5	0.32	4.96	0.31	1.36e-6	Sudden cardiac arrest;
SARC	trans	rs61931739	0.620	rs708143	chr12:33719962	A/C	cg13010199	chr12:38710504	ALG10B	0.5	6.27	0.38	1.74e-9	Morning vs. evening chronotype;
SARC	cis	rs870825	0.616	rs6552808	chr4:185642865	G/T	cg04058563	chr4:185651563	MLF1IP	0.81	11.52	0.6	1.31e-24	Blood protein levels;
SARC	cis	rs1050631	0.592	rs948417	chr18:33711274	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.55	6.51	0.39	4.59e-10	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs4561483	0.801	rs154148	chr16:11956478	T/C	cg08843971	chr16:11963173	GSPT1	-0.45	-5.6	-0.34	6.01e-8	Testicular germ cell tumor;
SARC	cis	rs2204008	0.744	rs8189486	chr12:38244968	C/T	cg13010199	chr12:38710504	ALG10B	0.81	11.31	0.6	6.33e-24	Bladder cancer;
SARC	cis	rs56235845	0.694	rs11949401	chr5:176765989	A/G	cg06060754	chr5:176797920	RGS14	0.44	5.91	0.36	1.22e-8	Hemoglobin concentration;Hematocrit;
SARC	cis	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg18252515	chr7:66147081	NA	-1.43	-12.98	-0.65	2.35e-29	Gout;
SARC	cis	rs4889855	0.505	rs7501740	chr17:78610345	A/G	cg17956530	chr17:78667699	RPTOR	-0.46	-5.35	-0.33	2.13e-7	Fractional excretion of uric acid;
SARC	cis	rs11638352	0.661	rs2114415	chr15:44432894	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.76	-5.91	-0.36	1.23e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	cis	rs986417	0.681	rs17097373	chr14:60826810	T/C	cg27398547	chr14:60952738	C14orf39	-0.89	-6.22	-0.38	2.3e-9	Gut microbiota (bacterial taxa);
SARC	cis	rs11098499	0.909	rs71614422	chr4:120359340	G/A	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs13256369	0.851	rs11249890	chr8:8565245	G/T	cg18904891	chr8:8559673	CLDN23	0.49	5.49	0.34	1.04e-7	Obesity-related traits;
SARC	cis	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg24110177	chr3:50126178	RBM5	0.57	7.78	0.45	2.32e-13	Intelligence (multi-trait analysis);
SARC	cis	rs459482	0.504	rs469073	chr21:42816201	A/G	cg14166395	chr21:42792516	MX1	-0.42	-4.95	-0.31	1.43e-6	IgG glycosylation;
SARC	cis	rs11719291	0.833	rs34037363	chr3:48821036	C/T	cg00383909	chr3:49044727	WDR6	0.75	6.73	0.4	1.3e-10	Cognitive function;
SARC	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg13395646	chr4:1353034	KIAA1530	-0.56	-6.73	-0.4	1.29e-10	Obesity-related traits;
SARC	cis	rs17376456	0.825	rs28534784	chr5:93063332	C/A	cg21475434	chr5:93447410	FAM172A	0.77	6.75	0.4	1.15e-10	Diabetic retinopathy;
SARC	cis	rs2197308	0.631	rs4882308	chr12:38446252	G/C	cg13010199	chr12:38710504	ALG10B	-0.46	-5.63	-0.35	5.19e-8	Morning vs. evening chronotype;
SARC	cis	rs2230307	0.536	rs700533	chr1:100483822	A/G	cg24955406	chr1:100503596	HIAT1	0.69	6.86	0.41	6.08e-11	Carotid intima media thickness;
SARC	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg17971929	chr21:40555470	PSMG1	1.01	14.63	0.69	8.01e-35	Cognitive function;
SARC	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg09323728	chr8:95962352	TP53INP1	-0.29	-5.05	-0.31	8.88e-7	Type 2 diabetes;
SARC	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg03806693	chr22:41940476	POLR3H	0.97	13.48	0.66	5.37e-31	Vitiligo;
SARC	cis	rs1448094	0.791	rs10863114	chr12:86332325	T/C	cg02569458	chr12:86230093	RASSF9	0.45	6.45	0.39	6.55e-10	Major depressive disorder;
SARC	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg13175981	chr1:150552382	MCL1	-0.54	-6.84	-0.41	6.75e-11	Tonsillectomy;
SARC	cis	rs793571	0.784	rs28800895	chr15:59085036	T/C	cg05156742	chr15:59063176	FAM63B	0.5	4.8	0.3	2.77e-6	Schizophrenia;
SARC	cis	rs854765	0.583	rs11078406	chr17:17840823	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	9.98	0.55	9.38e-20	Total body bone mineral density;
SARC	cis	rs2559856	0.967	rs2695297	chr12:102082218	T/C	cg12924262	chr12:102091054	CHPT1	0.58	7.73	0.45	3.2e-13	Blood protein levels;
SARC	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.39	-6.49	-0.39	4.99e-10	Total body bone mineral density;
SARC	cis	rs4713675	0.584	rs3227	chr6:33662295	G/C	cg15676125	chr6:33679581	C6orf125	0.53	6.46	0.39	6.12e-10	Plateletcrit;
SARC	cis	rs483180	0.512	rs1163251	chr1:120209755	T/C	cg19096424	chr1:120255104	PHGDH	-0.51	-6.02	-0.37	6.82e-9	Macular telangiectasia type 2;
SARC	cis	rs765787	0.530	rs10467979	chr15:45521270	G/A	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.55e-10	Uric acid levels;
SARC	cis	rs3796352	0.881	rs34238610	chr3:53026480	A/T	cg07884673	chr3:53033167	SFMBT1	0.9	5.87	0.36	1.49e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs12912251	1.000	rs34356257	chr15:38989605	T/C	cg01338139	chr15:38987640	C15orf53	-0.45	-5.29	-0.33	2.79e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
SARC	cis	rs1348850	0.526	rs7582179	chr2:178370631	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	5.87	0.36	1.5e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs4141404	0.561	rs5994376	chr22:31563555	A/C	cg13145458	chr22:31556086	RNF185	0.44	5.38	0.33	1.81e-7	Paclitaxel-induced neuropathy;
SARC	trans	rs11098499	0.738	rs34965784	chr4:120361586	G/C	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg08859206	chr1:53392774	SCP2	-0.39	-5.55	-0.34	7.87e-8	Monocyte count;
SARC	cis	rs2816062	0.786	rs2745320	chr1:18893592	G/A	cg18795169	chr1:18902165	NA	-0.77	-12.11	-0.62	1.68e-26	Urate levels in lean individuals;
SARC	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg18225595	chr11:63971243	STIP1	0.45	5.43	0.34	1.38e-7	Attention deficit hyperactivity disorder;
SARC	cis	rs9399137	0.507	rs6940878	chr6:135366309	G/A	cg22676075	chr6:135203613	NA	0.41	5.05	0.31	8.95e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs9916302	0.904	rs7501488	chr17:37576417	T/G	cg15445000	chr17:37608096	MED1	0.42	5.02	0.31	1.02e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs11098499	0.754	rs9991959	chr4:120253773	C/T	cg09307838	chr4:120376055	NA	-0.8	-11.17	-0.59	1.71e-23	Corneal astigmatism;
SARC	cis	rs9840812	0.769	rs576771	chr3:135989292	C/T	cg15507776	chr3:136538369	TMEM22	0.44	4.86	0.3	2.12e-6	Fibrinogen levels;
SARC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	20.35	0.8	1.32e-53	Prudent dietary pattern;
SARC	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	7.34	0.43	3.43e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6815814	0.898	rs5743592	chr4:38803063	A/G	cg09316306	chr4:38807337	TLR1	0.46	4.79	0.3	3.03e-6	Breast cancer;
SARC	cis	rs2066819	0.818	rs773652	chr12:56674766	G/A	cg26734620	chr12:56694298	CS	-0.86	-6.37	-0.39	1.01e-9	Psoriasis vulgaris;
SARC	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg03452623	chr4:187889614	NA	-0.76	-12.04	-0.62	2.83e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2832077	1.000	rs9983229	chr21:30137674	A/G	cg03476357	chr21:30257390	N6AMT1	0.55	5.23	0.32	3.77e-7	Cognitive test performance;
SARC	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg22535103	chr8:58192502	C8orf71	-0.7	-8.43	-0.48	3.66e-15	Developmental language disorder (linguistic errors);
SARC	cis	rs10463316	0.894	rs7708499	chr5:150765906	A/C	cg03212797	chr5:150827313	SLC36A1	-0.44	-5.26	-0.33	3.34e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs6963495	0.818	rs73192149	chr7:105210910	A/G	cg13798780	chr7:105162888	PUS7	0.57	5.23	0.32	3.86e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs6665290	0.835	rs7549465	chr1:227214399	A/C	cg14016676	chr1:227182615	CDC42BPA	0.37	5.35	0.33	2.13e-7	Myeloid white cell count;
SARC	cis	rs17270561	0.609	rs7746609	chr6:25727996	C/T	cg16482183	chr6:26056742	HIST1H1C	-0.39	-4.9	-0.31	1.79e-6	Iron status biomarkers;
SARC	cis	rs208520	0.909	rs9354411	chr6:67019930	A/G	cg07460842	chr6:66804631	NA	0.84	8.59	0.49	1.29e-15	Exhaled nitric oxide output;
SARC	cis	rs9733	0.744	rs4970976	chr1:150779524	T/A	cg15448220	chr1:150897856	SETDB1	-0.36	-4.87	-0.3	2.1e-6	Tonsillectomy;
SARC	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg13939156	chr17:80058883	NA	0.36	5.62	0.35	5.52e-8	Life satisfaction;
SARC	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg22968622	chr17:43663579	NA	-0.9	-10.76	-0.58	3.56e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg07701084	chr6:150067640	NUP43	0.41	5.39	0.33	1.75e-7	Lung cancer;
SARC	cis	rs568617	0.953	rs658524	chr11:65647260	A/G	cg26695010	chr11:65641043	EFEMP2	0.5	5.78	0.35	2.36e-8	Crohn's disease;
SARC	cis	rs1568889	0.887	rs7102237	chr11:28344296	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	14.01	0.68	8.97e-33	Bipolar disorder;
SARC	cis	rs79057730	0.599	rs6951032	chr7:794092	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.64	4.72	0.3	4.08e-6	Initial pursuit acceleration;
SARC	cis	rs1003719	0.591	rs2018521	chr21:38517264	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.58	-8.33	-0.48	7.08e-15	Eye color traits;
SARC	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg13395646	chr4:1353034	KIAA1530	-0.5	-5.56	-0.34	7.28e-8	Obesity-related traits;
SARC	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg13385521	chr17:29058706	SUZ12P	0.69	5.71	0.35	3.44e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg09063859	chr10:1086904	IDI1;C10orf110	0.56	7.85	0.46	1.47e-13	Thyroid stimulating hormone;
SARC	cis	rs7208859	0.623	rs11650271	chr17:29213943	C/T	cg13385521	chr17:29058706	SUZ12P	0.86	7.34	0.43	3.54e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs6912958	0.967	rs6914299	chr6:88149176	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.52	-0.34	8.93e-8	Monocyte percentage of white cells;
SARC	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg12463550	chr7:65579703	CRCP	0.5	5.9	0.36	1.27e-8	Aortic root size;
SARC	cis	rs2204008	0.744	rs11514358	chr12:38255526	G/A	cg13010199	chr12:38710504	ALG10B	0.81	11.31	0.6	6.33e-24	Bladder cancer;
SARC	cis	rs79149102	0.579	rs73436579	chr15:75294514	C/T	cg00629941	chr15:75287862	SCAMP5	-0.64	-5.11	-0.32	6.76e-7	Lung cancer;
SARC	cis	rs13191362	1.000	rs67094146	chr6:163145412	G/C	cg21926612	chr6:163149169	PACRG;PARK2	0.62	5.44	0.34	1.33e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs12421382	0.659	rs35093943	chr11:109379872	C/A	cg16359550	chr11:109292809	C11orf87	0.33	4.97	0.31	1.31e-6	Schizophrenia;
SARC	cis	rs9393777	0.513	rs9368448	chr6:26649355	T/C	cg12826209	chr6:26865740	GUSBL1	0.66	5.87	0.36	1.47e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7712401	0.601	rs27976	chr5:122206460	C/T	cg19412675	chr5:122181750	SNX24	-0.41	-5.24	-0.32	3.6e-7	Mean platelet volume;
SARC	cis	rs2370759	1.000	rs16933243	chr10:32615135	T/C	cg18270830	chr10:32634957	EPC1	0.69	6.31	0.38	1.41e-9	Sexual dysfunction (female);
SARC	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg20887711	chr4:1340912	KIAA1530	0.78	9.96	0.55	1.04e-19	Longevity;
SARC	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg21724239	chr8:58056113	NA	0.58	6.13	0.37	3.65e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9788682	1.000	rs34138960	chr15:78831668	A/G	cg24631222	chr15:78858424	CHRNA5	0.77	10.35	0.56	6.66e-21	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg00684032	chr4:1343700	KIAA1530	0.39	5.67	0.35	4.23e-8	Obesity-related traits;
SARC	cis	rs72781680	1.000	rs72781658	chr2:24220141	A/G	cg08917208	chr2:24149416	ATAD2B	0.93	9.16	0.51	2.8e-17	Lymphocyte counts;
SARC	cis	rs981844	1.000	rs55702511	chr4:154665978	A/C	cg14289246	chr4:154710475	SFRP2	0.57	6.43	0.39	7.08e-10	Response to statins (LDL cholesterol change);
SARC	trans	rs208520	0.837	rs208489	chr6:66927584	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-11.06	-0.59	3.85e-23	Exhaled nitric oxide output;
SARC	cis	rs6696846	0.791	rs10158848	chr1:205061192	C/T	cg21643547	chr1:205240462	TMCC2	-0.59	-7.87	-0.46	1.35e-13	Red blood cell count;
SARC	cis	rs3008870	0.755	rs1570838	chr1:67403315	C/T	cg02640540	chr1:67518911	SLC35D1	0.45	5.19	0.32	4.55e-7	Lymphocyte percentage of white cells;
SARC	cis	rs9443189	0.762	rs2748955	chr6:76464302	C/G	cg01950844	chr6:76311363	SENP6	-0.8	-7.32	-0.43	3.99e-12	Prostate cancer;
SARC	cis	rs17270561	0.608	rs4711102	chr6:25742075	T/C	cg16482183	chr6:26056742	HIST1H1C	0.43	5.08	0.32	7.76e-7	Iron status biomarkers;
SARC	cis	rs9790314	0.747	rs1841526	chr3:160834682	A/G	cg04691961	chr3:161091175	C3orf57	-0.68	-9.55	-0.53	1.9e-18	Morning vs. evening chronotype;
SARC	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg05872129	chr22:39784769	NA	-0.42	-5.93	-0.36	1.06e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs2204008	0.550	rs11495600	chr12:38126654	C/T	cg13010199	chr12:38710504	ALG10B	0.78	10.64	0.57	8.61e-22	Bladder cancer;
SARC	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-4.74	-0.3	3.8e-6	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs17376456	1.000	rs10514382	chr5:93566534	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.44	0.34	1.36e-7	Diabetic retinopathy;
SARC	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-9.22	-0.52	1.78e-17	Alzheimer's disease;
SARC	cis	rs17384381	0.859	rs35761966	chr1:85918357	G/A	cg16011679	chr1:85725395	C1orf52	0.61	5.8	0.35	2.19e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7635838	0.573	rs73019547	chr3:11493323	A/C	cg00170343	chr3:11313890	ATG7	0.6	8.19	0.47	1.67e-14	HDL cholesterol;
SARC	cis	rs7666738	0.830	rs2865979	chr4:99027137	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.96	11.07	0.59	3.58e-23	Platelet count;
SARC	trans	rs1814175	0.781	rs11040681	chr11:49981654	G/T	cg15704280	chr7:45808275	SEPT13	-0.97	-18.54	-0.77	9.52e-48	Height;
SARC	cis	rs4481887	0.927	rs10749646	chr1:248429719	A/G	cg13385794	chr1:248469461	NA	-0.38	-5.74	-0.35	2.94e-8	Common traits (Other);
SARC	cis	rs2425143	1.000	rs1890470	chr20:34357008	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	5.19	0.32	4.57e-7	Blood protein levels;
SARC	cis	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.83	12.37	0.63	2.38e-27	Breast cancer;
SARC	cis	rs7659604	0.967	rs28529384	chr4:122664215	T/C	cg20573242	chr4:122745356	CCNA2	0.43	5.68	0.35	4.04e-8	Type 2 diabetes;
SARC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg25405998	chr7:65216604	CCT6P1	0.47	5.54	0.34	7.97e-8	Calcium levels;
SARC	cis	rs2976388	0.609	rs2717605	chr8:143801015	T/G	cg06565975	chr8:143823917	SLURP1	0.29	4.99	0.31	1.16e-6	Urinary tract infection frequency;
SARC	trans	rs9929218	0.953	rs11075696	chr16:68731365	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.69	-8.73	-0.5	4.94e-16	Colorectal cancer;
SARC	cis	rs262150	0.544	rs2428780	chr7:158812471	T/A	cg09640425	chr7:158790006	NA	-0.38	-5.48	-0.34	1.09e-7	Facial morphology (factor 20);
SARC	trans	rs7824557	0.527	rs2572376	chr8:11237756	C/A	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.68	-0.45	4.26e-13	Retinal vascular caliber;
SARC	cis	rs9467773	0.967	rs9467775	chr6:26513435	G/A	cg12292205	chr6:26970375	C6orf41	0.44	5.46	0.34	1.24e-7	Intelligence (multi-trait analysis);
SARC	cis	rs728616	0.614	rs2181204	chr10:81704512	A/G	cg05935833	chr10:81318306	SFTPA2	-0.41	-5.14	-0.32	5.89e-7	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs6570726	0.935	rs453609	chr6:145812332	T/C	cg05347473	chr6:146136440	FBXO30	0.49	6.48	0.39	5.27e-10	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg20723473	chr12:132520836	EP400	0.47	6.38	0.39	9.43e-10	Schizophrenia;
SARC	trans	rs7937682	1.000	rs10789843	chr11:111576158	C/T	cg18187862	chr3:45730750	SACM1L	-0.57	-7.1	-0.42	1.52e-11	Primary sclerosing cholangitis;
SARC	cis	rs4851254	0.920	rs13011874	chr2:100752497	C/T	cg17356467	chr2:100759845	AFF3	0.3	5.08	0.32	7.68e-7	Intelligence (multi-trait analysis);
SARC	cis	rs11785400	1.000	rs7459630	chr8:143738585	A/C	cg10596483	chr8:143751796	JRK	0.63	8.4	0.48	4.52e-15	Schizophrenia;
SARC	cis	rs6977660	0.507	rs4721822	chr7:19771693	T/C	cg05791153	chr7:19748676	TWISTNB	0.89	7.44	0.44	1.87e-12	Thyroid stimulating hormone;
SARC	trans	rs1493916	0.905	rs34165207	chr18:31400153	G/A	cg27147174	chr7:100797783	AP1S1	-0.57	-7.05	-0.42	1.96e-11	Life satisfaction;
SARC	cis	rs950776	0.616	rs647041	chr15:78880481	T/C	cg22563815	chr15:78856949	CHRNA5	-0.41	-6.85	-0.41	6.63e-11	Sudden cardiac arrest;
SARC	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg11301795	chr4:187892539	NA	-0.69	-10.28	-0.56	1.13e-20	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4595586	0.545	rs6580889	chr12:39369742	T/C	cg26384229	chr12:38710491	ALG10B	0.5	6.22	0.38	2.31e-9	Morning vs. evening chronotype;
SARC	cis	rs6674176	0.696	rs4448553	chr1:44411589	A/G	cg12908607	chr1:44402522	ARTN	-0.39	-6.76	-0.4	1.11e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs11249608	0.750	rs6891216	chr5:178447026	G/C	cg21905437	chr5:178450457	ZNF879	0.56	7.39	0.44	2.64e-12	Pubertal anthropometrics;
SARC	cis	rs7043114	0.525	rs1053446	chr9:95146761	T/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.81	-0.36	2.02e-8	Height;
SARC	cis	rs477895	1.000	rs7938380	chr11:64034866	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	6.64	0.4	2.24e-10	Mean platelet volume;
SARC	cis	rs1552244	0.688	rs113940455	chr3:10014165	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	10.32	0.56	8.27e-21	Alzheimer's disease;
SARC	cis	rs1950500	0.545	rs724165	chr14:24806229	G/A	cg22990158	chr14:24802150	ADCY4	-0.35	-5.79	-0.35	2.26e-8	Height;
SARC	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg13628971	chr7:2884303	GNA12	0.56	6.58	0.4	3.06e-10	Height;
SARC	cis	rs7647973	1.000	rs1009051	chr3:49521549	G/A	cg07636037	chr3:49044803	WDR6	0.8	9.36	0.52	6.83e-18	Menarche (age at onset);
SARC	cis	rs477692	0.699	rs471357	chr10:131389373	C/G	cg05714579	chr10:131428358	MGMT	0.55	7.2	0.43	8.07e-12	Response to temozolomide;
SARC	cis	rs9400467	0.506	rs17751426	chr6:111772223	T/C	cg15721981	chr6:111408429	SLC16A10	0.65	5.67	0.35	4.31e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.15	0.8	5.84e-53	Prudent dietary pattern;
SARC	cis	rs2276314	0.857	rs62101402	chr18:33629435	A/G	cg05985134	chr18:33552581	C18orf21	0.67	7.08	0.42	1.71e-11	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs939574	1.000	rs3817424	chr2:220096903	A/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.64	5.11	0.32	6.85e-7	Platelet distribution width;
SARC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.13	0.37	3.73e-9	Prudent dietary pattern;
SARC	cis	rs6866344	0.697	rs62392823	chr5:178126968	T/C	cg03877680	chr5:178157825	ZNF354A	1.02	12.27	0.63	4.82e-27	Neutrophil percentage of white cells;
SARC	cis	rs17345786	0.798	rs1609159	chr3:101275902	A/C	cg12386194	chr3:101231763	SENP7	0.62	7.46	0.44	1.67e-12	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2479724	0.901	rs6458244	chr6:41790455	C/T	cg17623882	chr6:41773611	USP49	0.47	5.87	0.36	1.48e-8	Menarche (age at onset);
SARC	cis	rs11608355	0.521	rs7972346	chr12:109808771	C/G	cg19025524	chr12:109796872	NA	0.39	5.93	0.36	1.08e-8	Neuroticism;
SARC	trans	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	7.03	0.42	2.21e-11	Intelligence (multi-trait analysis);
SARC	cis	rs9300255	0.739	rs1980252	chr12:123745178	C/G	cg05973401	chr12:123451056	ABCB9	0.44	4.78	0.3	3.11e-6	Neutrophil percentage of white cells;
SARC	cis	rs2742234	0.541	rs61268333	chr10:43721370	G/A	cg15436174	chr10:43711423	RASGEF1A	0.43	5.01	0.31	1.08e-6	Hirschsprung disease;
SARC	cis	rs7589342	0.929	rs7562054	chr2:106433513	G/C	cg16077055	chr2:106428750	NCK2	0.4	7.45	0.44	1.79e-12	Addiction;
SARC	cis	rs4646312	0.555	rs5748484	chr22:19922585	C/T	cg07194846	chr22:19930177	COMT;TXNRD2	0.5	6.45	0.39	6.23e-10	Schizophrenia;
SARC	cis	rs72781680	1.000	rs55982282	chr2:24188128	G/A	cg08917208	chr2:24149416	ATAD2B	0.87	8.41	0.48	4.03e-15	Lymphocyte counts;
SARC	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	6.81	0.41	8.16e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7945705	0.791	rs12421789	chr11:8813956	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.38	-5.32	-0.33	2.46e-7	Hemoglobin concentration;
SARC	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg12042659	chr19:58951599	ZNF132	0.41	5.47	0.34	1.15e-7	Uric acid clearance;
SARC	cis	rs1003719	0.788	rs9975168	chr21:38450557	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.68	-10.2	-0.56	1.8899999999999998e-20	Eye color traits;
SARC	cis	rs9399137	0.507	rs56164974	chr6:135288716	C/T	cg22676075	chr6:135203613	NA	0.39	4.97	0.31	1.32e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs7843479	0.601	rs2306646	chr8:21846586	C/G	cg17168535	chr8:21777572	XPO7	0.86	13.11	0.65	8.87e-30	Mean corpuscular volume;
SARC	cis	rs11225247	0.649	rs11607214	chr11:102225224	A/G	cg11690896	chr11:102217788	BIRC2	0.73	5.26	0.33	3.23e-7	Vein graft stenosis in coronary artery bypass grafting;
SARC	cis	rs2841233	0.791	rs2028415	chr14:105349220	T/G	cg11813489	chr14:105363835	NA	-0.37	-5.24	-0.32	3.65e-7	IgG glycosylation;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg23924603	chr19:38826365	CATSPERG	-0.6	-7.73	-0.45	3.27e-13	Gallstone disease;
SARC	cis	rs11690935	0.632	rs12052246	chr2:172895606	G/T	cg13550731	chr2:172543902	DYNC1I2	0.69	9.96	0.55	1.07e-19	Schizophrenia;
SARC	cis	rs3750965	0.959	rs11228490	chr11:68860872	C/G	cg06818126	chr11:68850279	TPCN2	0.41	4.74	0.3	3.75e-6	Hair color;
SARC	cis	rs6542838	0.580	rs1607256	chr2:99543444	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-5.99	-0.37	8.05e-9	Fear of minor pain;
SARC	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg00864171	chr11:67383662	NA	0.34	4.77	0.3	3.31e-6	Mean corpuscular volume;
SARC	cis	rs61989804	0.826	rs4899169	chr14:65710756	C/A	cg15999311	chr14:65749247	NA	0.52	5.01	0.31	1.09e-6	Midgestational circulating levels of PCBs (fetal genetic effect);
SARC	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg24829409	chr8:58192753	C8orf71	-0.65	-5.97	-0.36	8.98e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs11792861	0.926	rs1044905	chr9:111781495	G/A	cg13535736	chr9:111863775	C9orf5	-0.39	-4.8	-0.3	2.89e-6	Menarche (age at onset);
SARC	cis	rs4737010	0.530	rs4026	chr8:41645710	C/T	cg08923054	chr8:41654455	ANK1	0.7	8.46	0.48	3.06e-15	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
SARC	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.97	-15.87	-0.72	5.95e-39	Chronic sinus infection;
SARC	cis	rs6545883	0.718	rs6715259	chr2:61851845	G/T	cg15711740	chr2:61764176	XPO1	-0.4	-4.97	-0.31	1.3e-6	Tuberculosis;
SARC	cis	rs698833	0.741	rs2340808	chr2:44511861	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.69	8.46	0.48	3.04e-15	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs10465746	0.780	rs7529293	chr1:84331981	A/G	cg10977910	chr1:84465055	TTLL7	0.44	5.44	0.34	1.36e-7	Obesity-related traits;
SARC	cis	rs9786986	0.908	rs4659905	chr1:235664494	T/C	cg26050004	chr1:235667680	B3GALNT2	0.6	5.56	0.34	7.42e-8	Body mass index;
SARC	cis	rs1957429	0.614	rs7144637	chr14:65349709	A/G	cg23373153	chr14:65346875	NA	-0.96	-7.3	-0.43	4.39e-12	Pediatric areal bone mineral density (radius);
SARC	cis	rs4713118	0.662	rs175954	chr6:28011585	A/G	cg26335602	chr6:28129616	ZNF389	0.5	5.39	0.33	1.68e-7	Parkinson's disease;
SARC	cis	rs1008375	0.897	rs2315554	chr4:17660407	T/C	cg27347728	chr4:17578864	LAP3	0.48	5.84	0.36	1.71e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9911578	1.000	rs12936058	chr17:57017420	T/C	cg05425664	chr17:57184151	TRIM37	-0.66	-8.25	-0.48	1.17e-14	Intelligence (multi-trait analysis);
SARC	cis	rs7937682	0.889	rs1789359	chr11:111475995	T/A	cg09085632	chr11:111637200	PPP2R1B	-0.88	-13.97	-0.68	1.3e-32	Primary sclerosing cholangitis;
SARC	trans	rs877282	1.000	rs11253366	chr10:773386	C/T	cg22713356	chr15:30763199	NA	1.02	10.28	0.56	1.08e-20	Uric acid levels;
SARC	cis	rs8062405	0.792	rs12446550	chr16:28543381	G/A	cg08761264	chr16:28874980	SH2B1	-0.42	-4.75	-0.3	3.53e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg13939156	chr17:80058883	NA	-0.45	-6.85	-0.41	6.6e-11	Life satisfaction;
SARC	cis	rs965469	0.947	rs56689368	chr20:3332921	G/A	cg25506879	chr20:3388711	C20orf194	-0.51	-5.21	-0.32	4.1e-7	IFN-related cytopenia;
SARC	cis	rs1008375	0.932	rs4698650	chr4:17692878	G/C	cg27347728	chr4:17578864	LAP3	0.46	5.74	0.35	2.94e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg11366901	chr6:160182831	ACAT2	0.96	9.65	0.53	9.65e-19	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg25072359	chr17:41440525	NA	0.58	7.1	0.42	1.54e-11	Menopause (age at onset);
SARC	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	9.01	0.51	7.42e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg13395646	chr4:1353034	KIAA1530	-0.55	-6.58	-0.4	3.12e-10	Obesity-related traits;
SARC	cis	rs875971	0.545	rs6460281	chr7:65681115	A/C	cg25894440	chr7:65020034	NA	0.52	4.83	0.3	2.42e-6	Aortic root size;
SARC	cis	rs76419734	0.558	rs3796920	chr4:106544526	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.53	4.96	0.31	1.36e-6	Post bronchodilator FEV1;
SARC	cis	rs60871478	0.636	rs7792072	chr7:886239	C/T	cg05535760	chr7:792225	HEATR2	-0.73	-6.92	-0.41	4.27e-11	Cerebrospinal P-tau181p levels;
SARC	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg11062466	chr8:58055876	NA	0.55	5.06	0.31	8.4e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg24964793	chr2:145878989	NA	0.53	7.48	0.44	1.52e-12	Thyroid stimulating hormone;
SARC	cis	rs9303280	0.806	rs10852936	chr17:38031714	C/T	cg20243544	chr17:37824526	PNMT	0.4	5.21	0.32	4.23e-7	Self-reported allergy;
SARC	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg14829155	chr15:31115871	NA	-0.45	-5.52	-0.34	8.94e-8	Huntington's disease progression;
SARC	cis	rs7666738	0.716	rs6814353	chr4:99074202	A/G	cg05340658	chr4:99064831	C4orf37	0.56	7.14	0.42	1.2e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs13082711	0.911	rs11719386	chr3:27505636	G/C	cg02860705	chr3:27208620	NA	0.42	5.41	0.33	1.55e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg03188948	chr7:1209495	NA	0.48	6.41	0.39	7.9e-10	Longevity;Endometriosis;
SARC	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg06212747	chr3:49208901	KLHDC8B	0.76	11.07	0.59	3.64e-23	Menarche (age at onset);
SARC	cis	rs9896933	0.775	rs79299098	chr17:80830944	G/A	cg15369054	chr17:80825471	TBCD	0.45	4.78	0.3	3.15e-6	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24452663	chr2:128051856	ERCC3	0.51	6.27	0.38	1.74e-9	Fibrinogen levels;
SARC	cis	rs634534	0.622	rs552130	chr11:65732800	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.73	10.11	0.55	3.65e-20	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs765787	0.530	rs11070444	chr15:45513121	T/C	cg24006582	chr15:45444508	DUOX1	0.43	5.53	0.34	8.48e-8	Uric acid levels;
SARC	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg20607798	chr8:58055168	NA	0.56	5.27	0.33	3.12e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg11062466	chr8:58055876	NA	0.65	6.02	0.37	6.89e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs854765	0.583	rs5002487	chr17:17832460	A/G	cg04398451	chr17:18023971	MYO15A	-0.37	-5.24	-0.32	3.53e-7	Total body bone mineral density;
SARC	cis	rs8114671	0.967	rs2065978	chr20:33767291	C/T	cg24642439	chr20:33292090	TP53INP2	0.51	5.88	0.36	1.4e-8	Height;
SARC	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg16479474	chr6:28041457	NA	0.37	5.44	0.34	1.37e-7	Depression;
SARC	cis	rs6088590	1.000	rs6087623	chr20:33317662	C/G	cg24642439	chr20:33292090	TP53INP2	0.89	12.73	0.64	1.54e-28	Coronary artery disease;
SARC	cis	rs1008375	0.932	rs6814465	chr4:17659034	C/T	cg02297831	chr4:17616191	MED28	0.48	6.13	0.37	3.65e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg08219700	chr8:58056026	NA	0.67	6.12	0.37	3.99e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9914988	0.887	rs11656272	chr17:27091153	A/G	cg20469991	chr17:27169893	C17orf63	-0.49	-5.09	-0.32	7.41e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg11301795	chr4:187892539	NA	-0.69	-10.19	-0.56	2.09e-20	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6963495	0.818	rs73192105	chr7:105167945	T/C	cg19920283	chr7:105172520	RINT1	0.67	5.69	0.35	3.88e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs9486719	0.948	rs6920913	chr6:96874297	A/G	cg18709589	chr6:96969512	KIAA0776	0.47	4.99	0.31	1.16e-6	Migraine;Coronary artery disease;
SARC	cis	rs9868809	0.772	rs9841602	chr3:48713570	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.59	-5.36	-0.33	2.03e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs2120019	1.000	rs12901243	chr15:75374233	C/T	cg17294928	chr15:75287854	SCAMP5	-0.9	-13.28	-0.66	2.39e-30	Blood trace element (Zn levels);
SARC	cis	rs3733585	0.631	rs3822236	chr4:10119961	T/G	cg11266682	chr4:10021025	SLC2A9	-0.39	-6.41	-0.39	7.97e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7586879	0.681	rs6545800	chr2:25118885	A/G	cg04586622	chr2:25135609	ADCY3	-0.32	-5.54	-0.34	8.09e-8	Body mass index;
SARC	cis	rs2180341	1.000	rs6569483	chr6:127658855	G/A	cg24812749	chr6:127587940	RNF146	0.98	13.14	0.65	7.1e-30	Breast cancer;
SARC	cis	rs601339	0.938	rs1696344	chr12:123183059	C/T	cg18578876	chr12:123200353	GPR109B	0.43	4.82	0.3	2.63e-6	Adiponectin levels;
SARC	cis	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg24110177	chr3:50126178	RBM5	0.4	5.07	0.32	7.98e-7	Blood protein levels;
SARC	cis	rs11098499	0.691	rs12510133	chr4:120271344	A/C	cg09307838	chr4:120376055	NA	0.74	10.26	0.56	1.27e-20	Corneal astigmatism;
SARC	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg07685180	chr8:600429	NA	0.67	5.61	0.34	5.82e-8	IgG glycosylation;
SARC	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.62	-0.4	2.44e-10	Total body bone mineral density;
SARC	cis	rs473651	0.935	rs482775	chr2:239335403	G/C	cg21699342	chr2:239360505	ASB1	0.48	7.12	0.42	1.36e-11	Multiple system atrophy;
SARC	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg25036284	chr2:26402008	FAM59B	0.46	5.7	0.35	3.59e-8	Gut microbiome composition (summer);
SARC	cis	rs17376456	0.569	rs6881815	chr5:93105666	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.5	5.14	0.32	5.81e-7	Diabetic retinopathy;
SARC	trans	rs7819412	0.775	rs4841490	chr8:10936891	T/C	cg15556689	chr8:8085844	FLJ10661	-0.54	-7.07	-0.42	1.78e-11	Triglycerides;
SARC	cis	rs722599	0.683	rs7142898	chr14:75254310	A/T	cg06637938	chr14:75390232	RPS6KL1	0.38	4.76	0.3	3.42e-6	IgG glycosylation;
SARC	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.41	-5.56	-0.34	7.49e-8	Personality dimensions;
SARC	cis	rs3820928	0.874	rs7594505	chr2:227878562	C/G	cg05526886	chr2:227700861	RHBDD1	-0.5	-5.95	-0.36	9.59e-9	Pulmonary function;
SARC	cis	rs1153858	1.000	rs2114501	chr15:45670316	G/A	cg03999130	chr15:45571217	NA	0.39	4.97	0.31	1.3e-6	Homoarginine levels;
SARC	cis	rs796364	1.000	rs281759	chr2:200787719	T/C	cg23649088	chr2:200775458	C2orf69	0.63	5.88	0.36	1.39e-8	Schizophrenia;
SARC	cis	rs12586317	0.547	rs45531432	chr14:35484423	C/T	cg16230307	chr14:35515116	FAM177A1	1.02	11.85	0.61	1.18e-25	Psoriasis;
SARC	cis	rs7914558	0.966	rs7921574	chr10:104840970	T/C	cg04362960	chr10:104952993	NT5C2	0.41	5.01	0.31	1.05e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs9398803	0.865	rs9398808	chr6:126758791	G/T	cg20229609	chr6:126660872	C6orf173	0.4	5.8	0.36	2.1e-8	Male-pattern baldness;
SARC	cis	rs7412746	0.634	rs12096831	chr1:150864113	T/G	cg13175981	chr1:150552382	MCL1	-0.49	-5.93	-0.36	1.09e-8	Melanoma;
SARC	cis	rs9300255	0.602	rs6488864	chr12:123618362	G/C	cg00376283	chr12:123451042	ABCB9	0.55	5.38	0.33	1.8e-7	Neutrophil percentage of white cells;
SARC	cis	rs1005277	0.522	rs289645	chr10:37943642	T/C	cg00409905	chr10:38381863	ZNF37A	-0.52	-6.88	-0.41	5.4e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg00933542	chr6:150070202	PCMT1	0.33	5.7	0.35	3.7e-8	Lung cancer;
SARC	cis	rs9916302	0.904	rs2303316	chr17:37704217	A/G	cg07936489	chr17:37558343	FBXL20	-0.67	-8.49	-0.49	2.4e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs11583043	1.000	rs17100939	chr1:101443701	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.5	6.15	0.37	3.42e-9	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.72	-7.58	-0.44	8e-13	Platelet count;
SARC	cis	rs9393692	0.645	rs28446029	chr6:26305801	C/G	cg00631329	chr6:26305371	NA	-0.62	-7.99	-0.46	6.09e-14	Educational attainment;
SARC	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg06028605	chr16:24865363	SLC5A11	0.35	5.28	0.33	2.89e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	trans	rs453301	0.624	rs330058	chr8:9089809	G/A	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.76	-0.4	1.1e-10	Joint mobility (Beighton score);
SARC	cis	rs7084402	0.935	rs717453	chr10:60268398	C/T	cg07615347	chr10:60278583	BICC1	-0.58	-8.47	-0.49	2.82e-15	Refractive error;
SARC	cis	rs6540556	0.682	rs932335	chr1:209905734	G/C	cg23920097	chr1:209922102	NA	-0.54	-5.45	-0.34	1.27e-7	Red blood cell count;
SARC	cis	rs9322193	0.566	rs12528243	chr6:150219627	G/A	cg05036130	chr6:150231994	NA	0.31	4.89	0.31	1.88e-6	Lung cancer;
SARC	cis	rs79976124	0.879	rs17511467	chr6:66627293	T/C	cg07460842	chr6:66804631	NA	0.66	7.06	0.42	1.9e-11	Type 2 diabetes;
SARC	cis	rs28655083	0.673	rs2220233	chr16:77050294	A/G	cg01504555	chr16:77246968	SYCE1L	-0.43	-5.05	-0.31	8.88e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg22133161	chr19:49891603	CCDC155	0.42	4.72	0.3	4.01e-6	Multiple sclerosis;
SARC	cis	rs7819412	0.765	rs17783634	chr8:11054097	C/A	cg21775007	chr8:11205619	TDH	-0.41	-5.12	-0.32	6.55e-7	Triglycerides;
SARC	cis	rs6568686	0.577	rs174395	chr6:111919007	G/A	cg15721981	chr6:111408429	SLC16A10	0.6	5.07	0.32	8.05e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.8	10.38	0.56	5.49e-21	Prudent dietary pattern;
SARC	cis	rs6752107	1.000	rs3792112	chr2:234176609	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.49	6.45	0.39	6.34e-10	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs12541335	0.536	rs4266653	chr8:22169087	A/G	cg09517075	chr8:22133004	PIWIL2	0.36	5.03	0.31	9.79e-7	Hypertriglyceridemia;
SARC	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg08045932	chr20:61659980	NA	-0.49	-6.5	-0.39	4.74e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs3892630	0.824	rs34748593	chr19:33240447	T/C	cg22980127	chr19:33182716	NUDT19	1.03	9.16	0.51	2.81e-17	Red blood cell traits;
SARC	cis	rs8180040	0.701	rs62248439	chr3:46996448	A/G	cg27129171	chr3:47204927	SETD2	-0.69	-9.75	-0.54	4.68e-19	Colorectal cancer;
SARC	cis	rs7712401	0.601	rs30026	chr5:122284568	T/C	cg19412675	chr5:122181750	SNX24	0.4	5.13	0.32	5.98e-7	Mean platelet volume;
SARC	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg04287289	chr16:89883240	FANCA	0.87	15.4	0.71	2.13e-37	Vitiligo;
SARC	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg00933542	chr6:150070202	PCMT1	0.31	5.36	0.33	2.04e-7	Lung cancer;
SARC	cis	rs11098499	0.863	rs1383532	chr4:120434404	A/T	cg24375607	chr4:120327624	NA	-0.42	-4.98	-0.31	1.23e-6	Corneal astigmatism;
SARC	cis	rs965469	1.000	rs6139068	chr20:3284393	G/A	cg25506879	chr20:3388711	C20orf194	-0.5	-5.04	-0.31	9.37e-7	IFN-related cytopenia;
SARC	cis	rs9902453	0.874	rs7213517	chr17:28401740	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.23	-0.43	7.03e-12	Coffee consumption (cups per day);
SARC	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg18404041	chr3:52824283	ITIH1	-0.4	-5.75	-0.35	2.81e-8	Bipolar disorder;
SARC	cis	rs2933343	0.700	rs876754	chr3:128627753	T/C	cg24203234	chr3:128598194	ACAD9	0.65	8.37	0.48	5.51e-15	IgG glycosylation;
SARC	cis	rs8058578	1.000	rs3747481	chr16:30666367	C/T	cg02466173	chr16:30829666	NA	-0.47	-6.04	-0.37	6.07e-9	Multiple myeloma;
SARC	cis	rs11098499	0.865	rs10213221	chr4:120255926	G/A	cg09307838	chr4:120376055	NA	0.8	10.74	0.58	4.13e-22	Corneal astigmatism;
SARC	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg17376030	chr22:41985996	PMM1	0.64	7.84	0.46	1.59e-13	Vitiligo;
SARC	cis	rs7829975	0.684	rs474892	chr8:8596731	G/T	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.07	-0.47	3.67e-14	Mood instability;
SARC	cis	rs4128725	1.000	rs79433881	chr1:159412445	C/T	cg25076881	chr1:159409836	OR10J1	0.4	4.8	0.3	2.86e-6	Select biomarker traits;
SARC	trans	rs1814175	0.619	rs10769623	chr11:49865926	C/T	cg03929089	chr4:120376271	NA	-0.83	-12.22	-0.62	7.28e-27	Height;
SARC	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg20203395	chr5:56204925	C5orf35	-0.58	-5.17	-0.32	5.05e-7	Initial pursuit acceleration;
SARC	cis	rs6693567	0.565	rs11205371	chr1:150398510	A/G	cg09579323	chr1:150459698	TARS2	0.44	5.66	0.35	4.4e-8	Migraine;
SARC	cis	rs10791323	0.604	rs2723605	chr11:133711241	C/G	cg14349672	chr11:133703707	NA	-0.37	-5.42	-0.33	1.5e-7	Childhood ear infection;
SARC	cis	rs9303401	0.703	rs9909925	chr17:57210069	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.62	-7.59	-0.45	7.64e-13	Cognitive test performance;
SARC	cis	rs2421770	0.530	rs3847621	chr11:35364435	G/A	cg13971030	chr11:35366721	SLC1A2	-0.33	-4.99	-0.31	1.18e-6	Staphylococcus aureus nasal carriage (persistent);
SARC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg12648201	chr2:27665141	KRTCAP3	-0.33	-5.0	-0.31	1.11e-6	Total body bone mineral density;
SARC	cis	rs3092073	0.624	rs13040315	chr20:44585793	A/G	cg10662479	chr20:44420225	WFDC3;DNTTIP1	0.47	6.13	0.37	3.7e-9	Intelligence (multi-trait analysis);
SARC	cis	rs9467773	1.000	rs1321480	chr6:26532742	A/G	cg11502198	chr6:26597334	ABT1	0.46	5.61	0.34	5.8e-8	Intelligence (multi-trait analysis);
SARC	cis	rs1559088	0.576	rs10407255	chr19:33581150	A/G	cg17764715	chr19:33622953	WDR88	-0.58	-7.97	-0.46	6.91e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs13082711	0.911	rs35532045	chr3:27515870	A/G	cg02860705	chr3:27208620	NA	0.41	5.38	0.33	1.78e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs4642101	0.597	rs9839768	chr3:12821403	C/T	cg24848339	chr3:12840334	CAND2	0.36	5.85	0.36	1.64e-8	QRS complex (12-leadsum);
SARC	cis	rs1448094	0.556	rs17279916	chr12:86170647	G/A	cg00310523	chr12:86230176	RASSF9	0.33	5.01	0.31	1.07e-6	Major depressive disorder;
SARC	cis	rs12142240	0.698	rs6659228	chr1:46811027	C/G	cg00530320	chr1:46809349	NSUN4	0.58	7.09	0.42	1.62e-11	Menopause (age at onset);
SARC	cis	rs362272	0.524	rs6819202	chr4:3368264	G/A	cg08741688	chr4:3415352	RGS12	-0.47	-5.78	-0.35	2.4e-8	Serum sulfate level;
SARC	cis	rs950776	0.616	rs3743077	chr15:78894896	C/T	cg06917634	chr15:78832804	PSMA4	0.84	12.38	0.63	2.11e-27	Sudden cardiac arrest;
SARC	cis	rs870825	0.932	rs28702958	chr4:185575562	C/T	cg04058563	chr4:185651563	MLF1IP	0.79	8.98	0.51	9.58e-17	Blood protein levels;
SARC	cis	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg06558623	chr16:89946397	TCF25	0.89	6.23	0.38	2.14e-9	Skin colour saturation;
SARC	cis	rs9640161	0.783	rs35435439	chr7:150063534	C/T	cg10018233	chr7:150070692	REPIN1	0.71	9.99	0.55	8.5e-20	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs9325144	0.647	rs61931899	chr12:38892422	A/G	cg26384229	chr12:38710491	ALG10B	-0.53	-6.86	-0.41	6.21e-11	Morning vs. evening chronotype;
SARC	cis	rs5753618	0.509	rs5749224	chr22:31558549	C/T	cg13145458	chr22:31556086	RNF185	0.44	4.87	0.3	2.09e-6	Colorectal cancer;
SARC	cis	rs6717918	0.620	rs7570112	chr2:233150452	A/G	ch.2.233013039R	chr2:233304795	NA	0.39	4.97	0.31	1.27e-6	Height;
SARC	cis	rs1318878	0.565	rs10161274	chr12:15465378	T/A	cg08258403	chr12:15378311	NA	0.5	6.94	0.41	3.91e-11	Intelligence (multi-trait analysis);
SARC	cis	rs5769765	0.955	rs4075330	chr22:50303249	G/A	cg03033257	chr22:50311977	ALG12;CRELD2	0.52	5.21	0.32	4.1e-7	Schizophrenia;
SARC	cis	rs11874712	0.527	rs12955201	chr18:43643435	A/C	cg26436583	chr18:43649176	PSTPIP2	-0.44	-5.66	-0.35	4.36e-8	Migraine - clinic-based;
SARC	cis	rs9309711	0.506	rs9284794	chr2:3492052	G/A	cg15506890	chr2:3487001	NA	-0.48	-6.23	-0.38	2.18e-9	Neurofibrillary tangles;
SARC	cis	rs35995292	0.500	rs6955677	chr7:38933942	C/T	cg19327137	chr7:38886074	VPS41	0.49	7.24	0.43	6.36e-12	Subjective well-being (multi-trait analysis);
SARC	cis	rs524281	0.692	rs11227395	chr11:65829637	A/C	cg14036092	chr11:66035641	RAB1B	-0.6	-6.72	-0.4	1.37e-10	Electroencephalogram traits;
SARC	cis	rs7647973	1.000	rs7619789	chr3:49476263	T/C	cg07636037	chr3:49044803	WDR6	0.8	9.36	0.52	6.83e-18	Menarche (age at onset);
SARC	cis	rs2645694	0.911	rs2703147	chr4:77831307	C/T	cg10057126	chr4:77819792	ANKRD56	0.33	4.88	0.3	2.01e-6	Emphysema distribution in smoking;
SARC	cis	rs910316	1.000	rs7156328	chr14:75532941	T/C	cg06637938	chr14:75390232	RPS6KL1	0.57	8.13	0.47	2.53e-14	Height;
SARC	cis	rs9818758	0.607	rs34580506	chr3:49113713	C/A	cg01304814	chr3:48885189	PRKAR2A	0.65	5.25	0.33	3.43e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs2153535	0.601	rs7775274	chr6:8530303	A/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.19	0.47	1.75e-14	Motion sickness;
SARC	trans	rs2727020	0.688	rs11040338	chr11:49360601	A/G	cg15704280	chr7:45808275	SEPT13	0.79	12.43	0.63	1.46e-27	Coronary artery disease;
SARC	cis	rs9303401	0.527	rs7224468	chr17:56749943	C/T	cg25039879	chr17:56429692	SUPT4H1	0.67	6.06	0.37	5.48e-9	Cognitive test performance;
SARC	cis	rs10078	0.515	rs2672739	chr5:443447	A/C	cg26072250	chr5:443457	EXOC3;C5orf55	0.73	6.38	0.39	9.59e-10	Fat distribution (HIV);
SARC	cis	rs10754283	0.967	rs1320563	chr1:90121032	G/A	cg21401794	chr1:90099060	LRRC8C	0.57	7.9	0.46	1.1e-13	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs1971762	0.509	rs1247955	chr12:53964133	G/T	cg06632207	chr12:54070931	ATP5G2	-0.59	-8.05	-0.47	4.35e-14	Height;
SARC	cis	rs829883	0.668	rs829882	chr12:98880099	A/G	cg25150519	chr12:98850993	NA	0.4	5.19	0.32	4.58e-7	Colorectal adenoma (advanced);
SARC	cis	rs1568889	1.000	rs7949057	chr11:28255053	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	10.14	0.55	2.91e-20	Bipolar disorder;
SARC	cis	rs2204008	0.687	rs11181339	chr12:38322271	G/T	cg26384229	chr12:38710491	ALG10B	0.81	11.4	0.6	3.32e-24	Bladder cancer;
SARC	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg05368731	chr17:41323189	NBR1	0.78	9.29	0.52	1.13e-17	Menopause (age at onset);
SARC	cis	rs6005807	0.543	rs12168849	chr22:29202063	A/G	cg02153584	chr22:29168773	CCDC117	0.63	4.94	0.31	1.51e-6	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
SARC	cis	rs1784581	0.532	rs7767219	chr6:162423088	T/C	cg17173639	chr6:162384350	PARK2	0.51	6.48	0.39	5.48e-10	Itch intensity from mosquito bite;
SARC	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg11494091	chr17:61959527	GH2	0.36	5.11	0.32	6.66e-7	Height;
SARC	cis	rs72945132	0.825	rs2277273	chr11:70223992	T/C	cg00319359	chr11:70116639	PPFIA1	0.68	6.49	0.39	5.19e-10	Coronary artery disease;
SARC	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	11.31	0.6	6.28e-24	Alzheimer's disease;
SARC	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg23248424	chr5:179741104	GFPT2	-0.47	-5.85	-0.36	1.67e-8	Height;
SARC	trans	rs12310956	0.532	rs7967627	chr12:33974669	G/T	cg26384229	chr12:38710491	ALG10B	0.75	10.53	0.57	1.89e-21	Morning vs. evening chronotype;
SARC	cis	rs7539542	0.577	rs6662398	chr1:202888456	T/G	cg08940984	chr1:202857613	RABIF	0.38	5.3	0.33	2.73e-7	Mean platelet volume;
SARC	cis	rs950776	0.616	rs495090	chr15:78870003	A/G	cg22563815	chr15:78856949	CHRNA5	-0.34	-5.26	-0.33	3.29e-7	Sudden cardiac arrest;
SARC	cis	rs921968	0.565	rs6436071	chr2:219598041	A/T	cg02176678	chr2:219576539	TTLL4	-0.34	-5.14	-0.32	5.86e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs3733585	0.753	rs1122141	chr4:9947278	T/C	cg11266682	chr4:10021025	SLC2A9	-0.37	-6.63	-0.4	2.36e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg06212747	chr3:49208901	KLHDC8B	0.58	5.74	0.35	2.88e-8	Menarche (age at onset);
SARC	cis	rs739401	0.611	rs450817	chr11:3056712	A/G	cg05729581	chr11:3078854	CARS	-0.48	-6.25	-0.38	1.92e-9	Longevity;
SARC	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg19346786	chr7:2764209	NA	-0.42	-6.05	-0.37	5.67e-9	Height;
SARC	trans	rs61931739	0.517	rs11513277	chr12:34074799	G/T	cg13010199	chr12:38710504	ALG10B	0.77	10.36	0.56	6.42e-21	Morning vs. evening chronotype;
SARC	cis	rs9457247	0.508	rs2285147	chr6:167505548	G/A	cg23791538	chr6:167370224	RNASET2	-0.42	-5.29	-0.33	2.89e-7	Crohn's disease;
SARC	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg21442419	chr1:2182373	SKI	-0.47	-6.27	-0.38	1.71e-9	Height;
SARC	cis	rs10463316	0.894	rs7729216	chr5:150762277	A/G	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.28	-0.33	2.89e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs3106136	0.814	rs6825005	chr4:95277009	T/C	cg11021082	chr4:95130006	SMARCAD1	0.34	5.32	0.33	2.43e-7	Capecitabine sensitivity;
SARC	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg10523679	chr1:76189770	ACADM	0.54	6.93	0.41	4.14e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg03541846	chr1:15429881	KIAA1026	0.47	6.4	0.39	8.4e-10	Schizophrenia;
SARC	cis	rs796364	0.806	rs77853713	chr2:201006880	A/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-6.61	-0.4	2.59e-10	Schizophrenia;
SARC	cis	rs11644362	0.631	rs8054655	chr16:12965215	T/A	cg06890432	chr16:12997467	SHISA9	-0.43	-5.24	-0.32	3.52e-7	Positive affect;Subjective well-being;
SARC	cis	rs763121	0.752	rs5757222	chr22:39060473	C/T	cg06022373	chr22:39101656	GTPBP1	0.91	11.32	0.6	5.9e-24	Menopause (age at onset);
SARC	cis	rs10875746	0.903	rs17122666	chr12:48502574	C/T	cg27446233	chr12:48516484	PFKM	-0.42	-4.85	-0.3	2.25e-6	Longevity (90 years and older);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg26151283	chr1:27481658	SLC9A1	0.5	6.58	0.4	3.15e-10	Chemerin levels;
SARC	cis	rs7552404	0.731	rs1770885	chr1:76402212	C/T	cg22875332	chr1:76189707	ACADM	-0.42	-5.29	-0.33	2.89e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs911263	0.603	rs7148073	chr14:68777042	T/C	cg18825221	chr14:68749962	RAD51L1	0.43	7.78	0.45	2.31e-13	Primary biliary cholangitis;
SARC	cis	rs4243830	0.737	rs4908923	chr1:6614535	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.89	-8.4	-0.48	4.36e-15	Body mass index;
SARC	cis	rs7027203	0.828	rs4744291	chr9:96598297	A/G	cg14598338	chr9:96623480	NA	-0.54	-7.65	-0.45	5.18e-13	DNA methylation (variation);
SARC	cis	rs694739	0.536	rs11231740	chr11:64046641	C/T	cg05555928	chr11:63887634	MACROD1	0.31	4.76	0.3	3.43e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg03452623	chr4:187889614	NA	-0.78	-11.72	-0.61	2.97e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	-1.07	-12.74	-0.64	1.51e-28	Platelet count;
SARC	cis	rs17401966	1.000	rs3748578	chr1:10420918	A/G	cg15208524	chr1:10270712	KIF1B	-0.58	-6.56	-0.39	3.4e-10	Hepatocellular carcinoma;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg04151612	chr3:9932217	JAGN1	-0.51	-6.38	-0.39	9.33e-10	Breast cancer;
SARC	cis	rs9388451	0.531	rs9375414	chr6:126154475	G/A	cg05901451	chr6:126070800	HEY2	-0.5	-6.04	-0.37	5.89e-9	Brugada syndrome;
SARC	cis	rs854765	0.547	rs2955370	chr17:17966945	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.68	-9.79	-0.54	3.51e-19	Total body bone mineral density;
SARC	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg03264133	chr6:25882463	NA	-0.37	-4.9	-0.31	1.78e-6	Intelligence (multi-trait analysis);
SARC	cis	rs8040855	1.000	rs8040855	chr15:85699207	G/C	cg11864592	chr15:85833204	NA	0.34	4.76	0.3	3.47e-6	Bulimia nervosa;
SARC	cis	rs7927592	0.913	rs948316	chr11:68309670	G/T	cg01657329	chr11:68192670	LRP5	-0.39	-4.73	-0.3	3.83e-6	Total body bone mineral density;
SARC	cis	rs7904368	0.754	rs11254231	chr10:16870246	A/G	cg14835575	chr10:16859367	RSU1	0.69	6.66	0.4	1.98e-10	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs853679	0.760	rs9393910	chr6:28208192	C/G	cg26450541	chr6:28235208	ZNF187	0.58	5.17	0.32	5.05e-7	Depression;
SARC	cis	rs1348850	0.632	rs1405718	chr2:178499809	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.5	5.67	0.35	4.12e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2635047	0.638	rs2317324	chr18:44628687	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	5.95	0.36	9.63e-9	Educational attainment;
SARC	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg01316550	chr5:56110833	MAP3K1	0.52	4.82	0.3	2.56e-6	Initial pursuit acceleration;
SARC	cis	rs2153535	0.504	rs4493781	chr6:8473941	G/C	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg25036284	chr2:26402008	FAM59B	0.49	5.97	0.36	8.85e-9	Gut microbiome composition (summer);
SARC	trans	rs11098499	0.954	rs28685688	chr4:120420334	T/C	cg25214090	chr10:38739885	LOC399744	0.58	7.47	0.44	1.63e-12	Corneal astigmatism;
SARC	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg01017244	chr2:74357527	NA	0.56	7.26	0.43	5.8e-12	Gestational age at birth (maternal effect);
SARC	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg09699651	chr6:150184138	LRP11	0.39	4.87	0.3	2.04e-6	Lung cancer;
SARC	cis	rs58235267	0.543	rs2539990	chr2:63170185	C/T	cg17519650	chr2:63277830	OTX1	0.46	6.2	0.38	2.5e-9	Prostate-specific antigen levels (conditioned on lead SNPs);
SARC	cis	rs7005606	0.935	rs17646763	chr8:32411656	T/C	cg14488905	chr8:32406789	NRG1	0.46	6.35	0.38	1.12e-9	Hirschsprung disease;
SARC	cis	rs6558174	0.802	rs3758040	chr8:22487087	T/C	cg03733263	chr8:22462867	KIAA1967	0.5	5.78	0.35	2.39e-8	Breast cancer;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg02617837	chr12:107349530	C12orf23	-0.5	-6.42	-0.39	7.45e-10	Schizophrenia;
SARC	cis	rs12458462	0.892	rs2007483	chr18:77476131	A/T	cg11879182	chr18:77439856	CTDP1	0.83	11.54	0.6	1.16e-24	Monocyte count;
SARC	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg04234412	chr22:24373322	LOC391322	0.57	6.31	0.38	1.38e-9	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs11792861	0.591	rs11791855	chr9:111684139	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.7	9.1	0.51	4.23e-17	Menarche (age at onset);
SARC	cis	rs57506017	0.540	rs13237518	chr7:12269593	C/A	cg23422036	chr7:12250390	TMEM106B	0.47	6.06	0.37	5.5e-9	Neuroticism;
SARC	cis	rs11155671	0.530	rs1334510	chr6:150201179	A/G	cg00933542	chr6:150070202	PCMT1	0.31	4.95	0.31	1.42e-6	Testicular germ cell tumor;
SARC	cis	rs681343	1.000	rs516316	chr19:49206145	C/G	cg21064579	chr19:49206444	FUT2	0.36	5.18	0.32	4.77e-7	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
SARC	cis	rs11122272	0.735	rs2739515	chr1:231514681	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg08859206	chr1:53392774	SCP2	-0.41	-5.72	-0.35	3.25e-8	Monocyte count;
SARC	cis	rs7089973	0.872	rs7074729	chr10:116632257	C/G	cg08188268	chr10:116634841	FAM160B1	0.35	5.66	0.35	4.34e-8	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	10.18	0.55	2.28e-20	Platelet count;
SARC	cis	rs10845606	1.000	rs10845606	chr12:12834894	G/T	cg09462578	chr12:12878428	APOLD1	-0.53	-5.24	-0.32	3.66e-7	Systemic lupus erythematosus;
SARC	cis	rs796364	0.806	rs78037592	chr2:201105734	G/T	cg23649088	chr2:200775458	C2orf69	-0.61	-5.14	-0.32	5.73e-7	Schizophrenia;
SARC	cis	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg00071950	chr4:10020882	SLC2A9	0.39	6.31	0.38	1.4e-9	Bone mineral density;
SARC	cis	rs4319547	0.698	rs10744217	chr12:122942070	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.54	-6.26	-0.38	1.86e-9	Body mass index;
SARC	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg08219700	chr8:58056026	NA	0.61	6.36	0.38	1.05e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs8028182	0.549	rs56395816	chr15:75664571	A/T	cg20655648	chr15:75932815	IMP3	-0.64	-7.39	-0.44	2.54e-12	Sudden cardiac arrest;
SARC	cis	rs2732480	0.577	rs1489108	chr12:48738781	G/A	cg21466736	chr12:48725269	NA	-0.34	-5.31	-0.33	2.54e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg07414643	chr4:187882934	NA	0.5	7.49	0.44	1.45e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg12288994	chr5:1860383	NA	0.4	6.57	0.4	3.29e-10	Cardiovascular disease risk factors;
SARC	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg07308232	chr7:1071921	C7orf50	-0.48	-6.06	-0.37	5.58e-9	Longevity;Endometriosis;
SARC	cis	rs7249142	0.526	rs7256811	chr19:19283551	A/G	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.23	4.85	0.3	2.23e-6	IgG glycosylation;
SARC	cis	rs7826238	0.653	rs2979202	chr8:8344127	T/C	cg15556689	chr8:8085844	FLJ10661	0.4	5.12	0.32	6.39e-7	Systolic blood pressure;
SARC	cis	rs15676	0.783	rs2977996	chr9:131582625	C/T	cg00228799	chr9:131580591	ENDOG	0.64	7.88	0.46	1.24e-13	Blood metabolite levels;
SARC	cis	rs2845885	0.793	rs57779243	chr11:63882363	G/T	cg05555928	chr11:63887634	MACROD1	-0.63	-6.48	-0.39	5.5e-10	Body mass index;
SARC	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.31	-4.71	-0.3	4.17e-6	Total body bone mineral density;
SARC	cis	rs9430161	0.579	rs7542164	chr1:11040223	G/A	cg02454025	chr1:11042201	C1orf127	0.85	12.51	0.63	8.47e-28	Ewing sarcoma;
SARC	cis	rs9309473	0.519	rs2421583	chr2:73898785	C/G	cg20560298	chr2:73613845	ALMS1	0.51	6.96	0.41	3.52e-11	Metabolite levels;
SARC	cis	rs2463822	0.925	rs2513075	chr11:62102408	C/T	cg06239285	chr11:62104954	ASRGL1	0.9	9.65	0.53	9.5e-19	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	5.24	0.32	3.6e-7	Tonsillectomy;
SARC	cis	rs7223966	1.000	rs7223412	chr17:61808172	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-5.86	-0.36	1.6e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2304069	0.954	rs216125	chr5:149428395	C/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.63	6.3	0.38	1.47e-9	HIV-1 control;
SARC	cis	rs1008375	0.931	rs6449309	chr4:17573208	C/T	cg27347728	chr4:17578864	LAP3	0.48	5.82	0.36	1.96e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2718058	0.589	rs10258728	chr7:37792922	C/T	cg24998770	chr7:37888106	TXNDC3	-0.31	-4.71	-0.3	4.18e-6	Alzheimer's disease (late onset);
SARC	cis	rs2652834	1.000	rs2729781	chr15:63404265	T/A	cg05507819	chr15:63340323	TPM1	0.55	5.44	0.34	1.38e-7	HDL cholesterol;
SARC	cis	rs523395	0.630	rs616111	chr1:120269991	C/G	cg19096424	chr1:120255104	PHGDH	-0.58	-7.43	-0.44	2.04e-12	Red blood cell count;
SARC	cis	rs7659604	1.000	rs35224452	chr4:122664677	C/T	cg19748678	chr4:122722346	EXOSC9	0.41	5.16	0.32	5.39e-7	Type 2 diabetes;
SARC	cis	rs834603	0.547	rs834598	chr7:47463937	C/T	cg23694490	chr7:47445681	TNS3	-0.34	-6.12	-0.37	4.01e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs204247	0.565	rs411094	chr6:13718264	C/A	cg02206980	chr6:13574034	SIRT5	-0.36	-4.89	-0.3	1.92e-6	Breast cancer;
SARC	cis	rs79349575	0.783	rs12602746	chr17:47031741	A/C	cg07967210	chr17:47022446	SNF8	0.37	4.71	0.3	4.19e-6	Type 2 diabetes;
SARC	cis	rs10276381	1.000	rs10276381	chr7:28190121	A/G	cg23620719	chr7:28220237	JAZF1	-0.72	-5.83	-0.36	1.84e-8	Crohn's disease;
SARC	cis	rs1050631	0.592	rs1539823	chr18:33736261	T/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.55	6.41	0.39	8.08e-10	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs4803468	1.000	rs10417997	chr19:41902361	G/A	cg08477640	chr19:41863820	B9D2	0.42	5.3	0.33	2.72e-7	Height;
SARC	cis	rs10744422	1.000	rs936083	chr12:123338964	A/G	cg25930673	chr12:123319894	HIP1R	-0.64	-4.8	-0.3	2.84e-6	Schizophrenia;
SARC	cis	rs753778	0.628	rs1045248	chr8:142204326	C/G	cg16341495	chr8:142228727	SLC45A4	-0.39	-5.36	-0.33	2.01e-7	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs748404	0.697	rs505249	chr15:43559960	T/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	5.56	0.34	7.32e-8	Lung cancer;
SARC	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg16479474	chr6:28041457	NA	0.36	5.45	0.34	1.25e-7	Depression;
SARC	cis	rs11122272	0.766	rs2024879	chr1:231528638	A/G	cg06096015	chr1:231504339	EGLN1	0.39	5.84	0.36	1.7e-8	Hemoglobin concentration;
SARC	cis	rs634534	0.622	rs501353	chr11:65739549	T/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.76	10.39	0.56	5.03e-21	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs561341	0.663	rs72821936	chr17:30224068	C/G	cg13647721	chr17:30228624	UTP6	0.73	8.9	0.5	1.62e-16	Hip circumference adjusted for BMI;
SARC	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg23172400	chr8:95962367	TP53INP1	-0.33	-5.76	-0.35	2.59e-8	Type 2 diabetes;
SARC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg23131131	chr22:24373011	LOC391322	-0.48	-5.2	-0.32	4.28e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs4481887	0.861	rs10888345	chr1:248447533	A/G	cg13385794	chr1:248469461	NA	0.35	5.38	0.33	1.83e-7	Common traits (Other);
SARC	cis	rs60733400	0.500	rs72644697	chr1:2533605	G/A	cg20673091	chr1:2541236	MMEL1	0.33	5.1	0.32	6.91e-7	Multiple sclerosis;
SARC	cis	rs367615	0.679	rs11241021	chr5:108812090	T/G	cg17395555	chr5:108820864	NA	0.51	7.24	0.43	6.42e-12	Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs4481887	0.927	rs10888344	chr1:248446655	T/C	cg13385794	chr1:248469461	NA	0.34	5.13	0.32	6.09e-7	Common traits (Other);
SARC	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg03709012	chr19:19516395	GATAD2A	-0.93	-15.05	-0.7	3.29e-36	Tonsillectomy;
SARC	cis	rs17331151	0.573	rs11718060	chr3:52875546	G/A	cg27565382	chr3:53032988	SFMBT1	0.67	4.95	0.31	1.44e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs3096299	0.838	rs4785561	chr16:89429052	C/T	cg02187348	chr16:89574699	SPG7	0.4	5.07	0.32	8.04e-7	Multiple myeloma (IgH translocation);
SARC	cis	rs9443189	0.950	rs721264	chr6:76517896	G/A	cg01950844	chr6:76311363	SENP6	0.64	5.58	0.34	6.72e-8	Prostate cancer;
SARC	trans	rs7615952	0.688	rs9754526	chr3:125542866	C/A	cg07211511	chr3:129823064	LOC729375	-0.75	-8.71	-0.5	5.85e-16	Blood pressure (smoking interaction);
SARC	cis	rs3749237	0.595	rs2878298	chr3:49406080	T/C	cg02487422	chr3:49467188	NICN1	0.49	6.33	0.38	1.28e-9	Resting heart rate;
SARC	cis	rs10876993	0.928	rs10877001	chr12:58083077	T/C	cg18357645	chr12:58087776	OS9	-0.48	-6.37	-0.39	9.92e-10	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs34172651	0.537	rs8049014	chr16:24698903	A/G	cg00339695	chr16:24857497	SLC5A11	0.43	6.05	0.37	5.6e-9	Intelligence (multi-trait analysis);
SARC	cis	rs73206853	0.841	rs55754138	chr12:110869335	G/T	cg10860002	chr12:110842031	ANAPC7	0.6	4.75	0.3	3.61e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg06634786	chr22:41940651	POLR3H	0.48	5.96	0.36	9.38e-9	Vitiligo;
SARC	cis	rs4919694	0.901	rs79331374	chr10:104882913	G/A	cg04362960	chr10:104952993	NT5C2	0.62	4.98	0.31	1.24e-6	Arsenic metabolism;
SARC	cis	rs41271473	0.500	rs4440831	chr1:228887522	C/T	cg10167378	chr1:228756711	NA	-0.38	-4.73	-0.3	3.91e-6	Chronic lymphocytic leukemia;
SARC	cis	rs9815354	1.000	rs2683695	chr3:41914928	C/T	cg03022575	chr3:42003672	ULK4	0.55	5.26	0.33	3.22e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9868809	0.505	rs11708786	chr3:48752654	C/T	cg00383909	chr3:49044727	WDR6	0.64	6.02	0.37	6.63e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs1348850	0.918	rs12463893	chr2:178448559	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.68	8.69	0.49	6.32e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs644799	0.710	rs3748253	chr11:95519506	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.61	8.17	0.47	1.93e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	15.18	0.71	1.22e-36	Chronic sinus infection;
SARC	cis	rs897080	0.515	rs1067401	chr2:44676541	T/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	5.59	0.34	6.37e-8	Height;
SARC	cis	rs3126085	0.935	rs2184950	chr1:152272776	T/C	cg03465714	chr1:152285911	FLG	0.48	5.63	0.35	5.17e-8	Atopic dermatitis;
SARC	cis	rs9611565	0.802	rs9611577	chr22:41793090	T/G	cg06634786	chr22:41940651	POLR3H	-0.48	-5.94	-0.36	1.01e-8	Vitiligo;
SARC	cis	rs7223966	1.000	rs8075061	chr17:61804723	A/G	cg00588841	chr17:61851480	DDX42;CCDC47	-0.68	-7.6	-0.45	7.42e-13	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9398803	0.865	rs9375446	chr6:126835015	G/A	cg20229609	chr6:126660872	C6orf173	0.4	5.79	0.35	2.23e-8	Male-pattern baldness;
SARC	cis	rs748404	0.560	rs1869258	chr15:43803621	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	5.54	0.34	8.29e-8	Lung cancer;
SARC	cis	rs10992471	0.630	rs10453241	chr9:95198887	C/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.81	-0.36	2.06e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg17328964	chr8:145687451	CYHR1	-0.47	-6.67	-0.4	1.89e-10	Age at first birth;
SARC	cis	rs7666738	0.830	rs969048	chr4:98988921	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg16680214	chr1:154839983	KCNN3	-0.36	-5.7	-0.35	3.66e-8	Prostate cancer;
SARC	cis	rs9467773	0.525	rs1535274	chr6:26520747	A/C	cg11502198	chr6:26597334	ABT1	0.58	7.49	0.44	1.39e-12	Intelligence (multi-trait analysis);
SARC	cis	rs2235544	0.565	rs637590	chr1:54461703	A/G	cg10336722	chr1:54665764	CYB5RL;MRPL37	-0.39	-4.87	-0.3	2.03e-6	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
SARC	cis	rs72781680	0.821	rs17038360	chr2:24095798	A/G	cg06627628	chr2:24431161	ITSN2	-0.55	-5.9	-0.36	1.26e-8	Lymphocyte counts;
SARC	cis	rs6540556	0.954	rs7548219	chr1:209936466	A/G	cg05527609	chr1:210001259	C1orf107	-0.63	-6.42	-0.39	7.54e-10	Red blood cell count;
SARC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.67	8.59	0.49	1.29e-15	Prudent dietary pattern;
SARC	cis	rs7959452	0.640	rs10878957	chr12:69699638	G/C	cg20891283	chr12:69753455	YEATS4	0.41	5.42	0.33	1.48e-7	Blood protein levels;
SARC	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	17.66	0.76	7.16e-45	Height;
SARC	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-15.3	-0.71	4.75e-37	Chronic sinus infection;
SARC	cis	rs10911232	0.507	rs10752891	chr1:183023283	G/A	cg13390022	chr1:182993471	LAMC1	0.36	5.41	0.33	1.6e-7	Hypertriglyceridemia;
SARC	cis	rs7772486	0.727	rs10447449	chr6:146138707	A/G	cg05347473	chr6:146136440	FBXO30	0.52	7.33	0.43	3.66e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs8114671	0.527	rs6088650	chr20:33514465	C/T	cg24642439	chr20:33292090	TP53INP2	-0.49	-6.02	-0.37	6.8e-9	Height;
SARC	cis	rs9322817	0.583	rs9377667	chr6:105154880	G/A	cg02098413	chr6:105308735	HACE1	-0.37	-5.87	-0.36	1.47e-8	Thyroid stimulating hormone;
SARC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9914988	0.509	rs12453166	chr17:27298709	A/G	cg10538030	chr17:27276405	PHF12	-0.63	-5.1	-0.32	6.91e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs2952156	1.000	rs2934967	chr17:37870378	G/A	cg00129232	chr17:37814104	STARD3	-0.66	-8.34	-0.48	6.4e-15	Asthma;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg03785065	chr3:180707451	DNAJC19	0.56	7.28	0.43	5.22e-12	Breast cancer;
SARC	cis	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg14541582	chr5:601475	NA	-0.4	-5.02	-0.31	1.04e-6	Obesity-related traits;
SARC	cis	rs2290416	0.892	rs76225457	chr8:144666052	G/T	cg10810860	chr8:144639591	GSDMD	-0.72	-4.92	-0.31	1.66e-6	Attention deficit hyperactivity disorder;
SARC	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg11890956	chr21:40555474	PSMG1	1.05	15.59	0.71	5.18e-38	Cognitive function;
SARC	cis	rs9291683	0.679	rs2241483	chr4:10099831	A/G	cg00071950	chr4:10020882	SLC2A9	-0.37	-5.71	-0.35	3.39e-8	Bone mineral density;
SARC	cis	rs2075371	0.829	rs727202	chr7:133947942	A/G	cg11752832	chr7:134001865	SLC35B4	0.48	5.89	0.36	1.35e-8	Mean platelet volume;
SARC	cis	rs11190604	1.000	rs2003284	chr10:102202338	A/G	cg07080220	chr10:102295463	HIF1AN	0.77	9.5	0.53	2.71e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.8	10.35	0.56	6.69e-21	Prudent dietary pattern;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg24905370	chr5:74063138	NSA2;GFM2	0.51	6.45	0.39	6.53e-10	Breast cancer;
SARC	cis	rs2130604	0.888	rs1101560	chr6:127047776	C/A	cg19875578	chr6:126661172	C6orf173	-0.47	-5.36	-0.33	2.04e-7	Bone mineral density (paediatric, skull);
SARC	cis	rs6546550	0.713	rs6718517	chr2:70018462	T/C	cg02498382	chr2:70120550	SNRNP27	-0.32	-5.11	-0.32	6.74e-7	Prevalent atrial fibrillation;
SARC	cis	rs8114671	0.562	rs1018447	chr20:33401707	A/G	cg08999081	chr20:33150536	PIGU	-0.31	-4.74	-0.3	3.74e-6	Height;
SARC	cis	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg20965017	chr5:231967	SDHA	-0.55	-5.28	-0.33	2.98e-7	Breast cancer;
SARC	cis	rs11792861	0.591	rs10979613	chr9:111687584	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.78	10.37	0.56	5.87e-21	Menarche (age at onset);
SARC	cis	rs4481887	0.927	rs6678798	chr1:248476617	C/T	cg13385794	chr1:248469461	NA	0.35	5.45	0.34	1.29e-7	Common traits (Other);
SARC	cis	rs12681366	0.734	rs2515153	chr8:95423924	G/A	cg26464482	chr8:95565502	KIAA1429	-0.45	-5.6	-0.34	6.09e-8	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs7824557	0.675	rs2736265	chr8:11186674	A/G	cg21775007	chr8:11205619	TDH	0.66	8.85	0.5	2.2e-16	Retinal vascular caliber;
SARC	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg03517284	chr6:25882590	NA	-0.42	-5.44	-0.34	1.35e-7	Intelligence (multi-trait analysis);
SARC	cis	rs739401	0.588	rs10219272	chr11:3020789	G/A	cg25174290	chr11:3078921	CARS	0.55	7.84	0.46	1.61e-13	Longevity;
SARC	cis	rs4969178	0.931	rs3826323	chr17:76400268	C/G	cg20026190	chr17:76395443	PGS1	0.4	5.37	0.33	1.86e-7	HDL cholesterol levels;
SARC	cis	rs5762813	0.524	rs5762835	chr22:29230754	A/G	cg02153584	chr22:29168773	CCDC117	0.67	7.31	0.43	4.18e-12	Hematocrit;Hemoglobin concentration;
SARC	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg14582100	chr15:45693742	SPATA5L1	0.35	4.91	0.31	1.69e-6	Homoarginine levels;
SARC	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.78	-0.5	3.56e-16	Alzheimer's disease;
SARC	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs17270561	0.609	rs1937127	chr6:25769872	G/T	cg16482183	chr6:26056742	HIST1H1C	-0.49	-5.81	-0.36	2e-8	Iron status biomarkers;
SARC	cis	rs739401	0.572	rs389285	chr11:3062673	G/A	cg20651018	chr11:3035856	CARS	-0.45	-6.95	-0.41	3.55e-11	Longevity;
SARC	cis	rs796364	0.760	rs2202922	chr2:200882610	C/T	cg23649088	chr2:200775458	C2orf69	0.6	5.38	0.33	1.85e-7	Schizophrenia;
SARC	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg03264133	chr6:25882463	NA	-0.51	-6.71	-0.4	1.44e-10	Intelligence (multi-trait analysis);
SARC	cis	rs4276643	0.576	rs2726940	chr8:27823868	C/T	cg25028855	chr8:28560486	EXTL3	0.33	5.05	0.31	9.03e-7	Low vWF levels;
SARC	cis	rs17376456	0.542	rs10476588	chr5:93208330	C/T	cg25358565	chr5:93447407	FAM172A	-0.96	-10.91	-0.58	1.14e-22	Diabetic retinopathy;
SARC	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg25952890	chr19:58913133	NA	0.35	5.05	0.31	8.77e-7	Uric acid clearance;
SARC	cis	rs698833	0.848	rs696596	chr2:44718058	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.63	8.01	0.46	5.51e-14	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg02931644	chr1:25747376	RHCE	0.45	7.56	0.44	9.44e-13	Erythrocyte sedimentation rate;
SARC	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg11764359	chr7:65958608	NA	-0.67	-7.93	-0.46	8.82e-14	Aortic root size;
SARC	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	10.75	0.58	3.69e-22	Alzheimer's disease;
SARC	trans	rs9929218	0.906	rs10852450	chr16:68749529	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.63	-8.29	-0.48	9.04e-15	Colorectal cancer;
SARC	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg02951883	chr7:2050386	MAD1L1	-0.48	-6.18	-0.38	2.89e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs2486288	0.656	rs2413771	chr15:45553140	A/G	cg15395560	chr15:45543142	SLC28A2	0.3	5.99	0.37	8e-9	Glomerular filtration rate;
SARC	cis	rs72634258	0.945	rs225120	chr1:8046378	C/T	cg00042356	chr1:8021962	PARK7	0.57	5.57	0.34	6.94e-8	Inflammatory bowel disease;
SARC	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg22875332	chr1:76189707	ACADM	-0.43	-5.57	-0.34	6.88e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9326248	0.559	rs482371	chr11:116752163	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.62	7.67	0.45	4.53e-13	Blood protein levels;
SARC	cis	rs1448094	0.512	rs6539925	chr12:86244358	A/G	cg02569458	chr12:86230093	RASSF9	0.39	5.44	0.34	1.34e-7	Major depressive disorder;
SARC	cis	rs2295359	0.892	rs2064689	chr1:67653010	G/A	cg12940439	chr1:67600707	NA	0.47	6.71	0.4	1.47e-10	Psoriasis;
SARC	cis	rs4481887	0.741	rs7540715	chr1:248544206	C/T	cg00666640	chr1:248458726	OR2T12	0.34	5.96	0.36	9.33e-9	Common traits (Other);
SARC	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg11764359	chr7:65958608	NA	0.65	7.6	0.45	7.08e-13	Aortic root size;
SARC	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg04267008	chr7:1944627	MAD1L1	-0.49	-5.54	-0.34	8.07e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg16479474	chr6:28041457	NA	0.37	5.53	0.34	8.38e-8	Depression;
SARC	cis	rs9914988	0.887	rs4795463	chr17:27146389	G/C	cg20469991	chr17:27169893	C17orf63	-0.52	-5.39	-0.33	1.74e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	trans	rs7980799	0.654	rs10844618	chr12:33625010	A/G	cg26384229	chr12:38710491	ALG10B	-0.63	-7.77	-0.45	2.52e-13	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs2073300	0.609	rs3827085	chr20:23356985	A/T	cg16736954	chr20:23401023	NAPB	0.79	4.89	0.31	1.86e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs7481584	0.669	rs12793371	chr11:3034709	A/G	cg25174290	chr11:3078921	CARS	-0.53	-7.02	-0.42	2.39e-11	Calcium levels;
SARC	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg12463550	chr7:65579703	CRCP	-0.71	-5.42	-0.33	1.47e-7	Diabetic kidney disease;
SARC	cis	rs9291683	0.561	rs3733584	chr4:10036506	T/C	cg00071950	chr4:10020882	SLC2A9	0.4	6.29	0.38	1.54e-9	Bone mineral density;
SARC	cis	rs4851254	0.961	rs11680485	chr2:100749744	A/G	cg17356467	chr2:100759845	AFF3	0.3	5.08	0.32	7.68e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg06558623	chr16:89946397	TCF25	0.89	6.31	0.38	1.37e-9	Skin colour saturation;
SARC	cis	rs7666738	0.544	rs35160902	chr4:98974690	A/T	cg05340658	chr4:99064831	C4orf37	0.66	8.97	0.51	9.89e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9875589	0.747	rs1488378	chr3:14014725	G/A	cg19554555	chr3:13937349	NA	-0.44	-5.3	-0.33	2.65e-7	Ovarian reserve;
SARC	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.39	4.81	0.3	2.69e-6	Lymphocyte counts;
SARC	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg18252515	chr7:66147081	NA	0.57	6.1	0.37	4.4e-9	Aortic root size;
SARC	cis	rs4714291	0.963	rs1304602	chr6:40013471	T/G	cg09256477	chr6:40556568	LRFN2	0.27	4.84	0.3	2.37e-6	Strep throat;
SARC	cis	rs6582630	0.555	rs12828034	chr12:38274249	C/T	cg13010199	chr12:38710504	ALG10B	-0.52	-6.32	-0.38	1.28e-9	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7818345	0.967	rs11786847	chr8:19277200	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.43	5.92	0.36	1.12e-8	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs35213789	0.887	rs521259	chr7:69198745	C/T	cg10619644	chr7:69149951	AUTS2	0.42	5.64	0.35	4.9e-8	Childhood ear infection;
SARC	cis	rs1050631	1.000	rs1050631	chr18:33694120	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	-0.42	-5.03	-0.31	9.86e-7	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs6674176	0.597	rs2352990	chr1:44393276	T/A	cg12908607	chr1:44402522	ARTN	-0.38	-6.58	-0.4	3.02e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs449789	0.857	rs543547	chr6:159702351	A/G	cg14500486	chr6:159655392	FNDC1	-0.44	-5.02	-0.31	1.01e-6	Pulse pressure;
SARC	cis	rs11190604	1.000	rs6584379	chr10:102224490	G/A	cg07080220	chr10:102295463	HIF1AN	0.77	9.48	0.53	3.03e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg01475735	chr3:40494733	NA	-0.45	-5.09	-0.32	7.41e-7	Renal cell carcinoma;
SARC	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg26335602	chr6:28129616	ZNF389	0.52	5.88	0.36	1.44e-8	Depression;
SARC	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg11890956	chr21:40555474	PSMG1	-1.08	-17.2	-0.75	2.45e-43	Cognitive function;
SARC	cis	rs74181299	0.684	rs6713746	chr2:65324492	G/C	cg20592124	chr2:65290738	CEP68	-0.35	-4.78	-0.3	3.12e-6	Pulse pressure;
SARC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg07157834	chr1:205819609	PM20D1	0.71	11.07	0.59	3.75e-23	Menarche (age at onset);
SARC	cis	rs4319547	0.619	rs7973869	chr12:122874284	G/C	cg23029597	chr12:123009494	RSRC2	-0.41	-5.09	-0.32	7.41e-7	Body mass index;
SARC	cis	rs6700896	0.931	rs12034502	chr1:66099831	C/T	cg04111102	chr1:66153794	NA	0.35	5.53	0.34	8.41e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	trans	rs61931739	0.513	rs2200555	chr12:33899381	C/G	cg13010199	chr12:38710504	ALG10B	0.63	8.45	0.48	3.15e-15	Morning vs. evening chronotype;
SARC	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg03433033	chr1:76189801	ACADM	-0.48	-6.4	-0.39	8.36e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6991838	0.584	rs1053085	chr8:66515988	C/T	cg13398993	chr8:66546079	ARMC1	-0.62	-8.29	-0.48	8.75e-15	Intelligence (multi-trait analysis);
SARC	cis	rs7818345	0.967	rs4481612	chr8:19285336	T/G	cg11303988	chr8:19266685	CSGALNACT1	0.38	4.94	0.31	1.5e-6	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs9768139	0.634	rs56389048	chr7:158121368	T/A	cg25566285	chr7:158114605	PTPRN2	0.3	5.04	0.31	9.18e-7	Calcium levels;
SARC	trans	rs7615952	0.604	rs9837847	chr3:125623919	G/A	cg07211511	chr3:129823064	LOC729375	-0.84	-7.72	-0.45	3.42e-13	Blood pressure (smoking interaction);
SARC	cis	rs4713118	0.513	rs149962	chr6:28015918	G/A	cg16479474	chr6:28041457	NA	0.32	4.82	0.3	2.58e-6	Parkinson's disease;
SARC	cis	rs2439831	0.850	rs2228368	chr15:44102010	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	7.89	0.46	1.14e-13	Lung cancer in ever smokers;
SARC	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg22535103	chr8:58192502	C8orf71	-0.56	-5.98	-0.37	8.13e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs992157	0.835	rs12987219	chr2:219144149	G/A	cg00012203	chr2:219082015	ARPC2	-0.63	-9.09	-0.51	4.52e-17	Colorectal cancer;
SARC	cis	rs2204008	0.689	rs1581357	chr12:38391479	C/G	cg26384229	chr12:38710491	ALG10B	0.89	12.46	0.63	1.22e-27	Bladder cancer;
SARC	cis	rs7552404	0.731	rs1689275	chr1:76409655	T/C	cg22875332	chr1:76189707	ACADM	-0.42	-5.3	-0.33	2.72e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7829975	0.606	rs10112585	chr8:8795030	A/T	cg14343924	chr8:8086146	FLJ10661	-0.4	-4.92	-0.31	1.64e-6	Mood instability;
SARC	cis	rs4805272	0.512	rs11879141	chr19:29320335	G/A	cg14983838	chr19:29218262	NA	0.63	7.03	0.42	2.24e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs6815814	0.950	rs5743556	chr4:38806851	A/G	cg09316306	chr4:38807337	TLR1	0.5	5.16	0.32	5.23e-7	Breast cancer;
SARC	cis	rs752092	0.802	rs2412005	chr15:101767591	T/A	cg19997662	chr15:101784653	CHSY1	-0.45	-5.96	-0.36	9.4e-9	Corneal structure;
SARC	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9303401	0.614	rs34941454	chr17:57102742	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.97	9.91	0.54	1.5e-19	Cognitive test performance;
SARC	cis	rs6696846	0.791	rs7520752	chr1:205054114	C/T	cg07972983	chr1:205091412	RBBP5	-0.53	-6.83	-0.41	7.26e-11	Red blood cell count;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg27515369	chr3:140770599	SPSB4	0.5	7.09	0.42	1.63e-11	Breast cancer;
SARC	cis	rs73206853	0.841	rs111612251	chr12:111017607	T/C	cg10860002	chr12:110842031	ANAPC7	0.58	5.0	0.31	1.12e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs9398803	0.830	rs1490387	chr6:126834083	C/A	cg19875578	chr6:126661172	C6orf173	0.63	8.53	0.49	1.82e-15	Male-pattern baldness;
SARC	cis	rs80282103	0.764	rs7093915	chr10:1107341	A/G	cg08668510	chr10:1095578	IDI1	-0.67	-4.96	-0.31	1.33e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs17401966	0.964	rs2027331	chr1:10276718	C/T	cg15208524	chr1:10270712	KIF1B	0.58	6.65	0.4	2.04e-10	Hepatocellular carcinoma;
SARC	trans	rs17780086	0.527	rs72827711	chr17:30537920	T/A	cg20587970	chr11:113659929	NA	-1.29	-10.38	-0.56	5.42e-21	Height;
SARC	cis	rs116095464	0.558	rs9687621	chr5:229194	C/T	cg22857025	chr5:266934	NA	-1.08	-10.49	-0.57	2.38e-21	Breast cancer;
SARC	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg07701084	chr6:150067640	NUP43	0.39	5.14	0.32	5.83e-7	Lung cancer;
SARC	cis	rs2013441	0.965	rs7207611	chr17:20204516	C/T	cg13482628	chr17:19912719	NA	0.48	6.04	0.37	6.12e-9	Obesity-related traits;
SARC	cis	rs8014204	0.657	rs2884668	chr14:75281576	T/A	cg06637938	chr14:75390232	RPS6KL1	0.53	7.4	0.44	2.4e-12	Caffeine consumption;
SARC	trans	rs6911965	1.000	rs78420872	chr6:24464429	C/A	cg03607907	chr16:20083459	GPR139	0.58	6.38	0.39	9.52e-10	Hematological and biochemical traits;
SARC	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg26119090	chr2:26468346	HADHA;HADHB	0.95	13.96	0.67	1.32e-32	Gut microbiome composition (summer);
SARC	cis	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg05623727	chr3:50126028	RBM5	-0.34	-5.19	-0.32	4.53e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg05861140	chr6:150128134	PCMT1	-0.4	-5.23	-0.32	3.75e-7	Lung cancer;
SARC	cis	rs11583043	1.000	rs7535068	chr1:101490329	T/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.49	5.54	0.34	8.1e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs7937682	0.855	rs571462	chr11:111487106	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.89	-14.18	-0.68	2.61e-33	Primary sclerosing cholangitis;
SARC	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg04518342	chr5:131593106	PDLIM4	-0.42	-5.34	-0.33	2.19e-7	Breast cancer;
SARC	cis	rs9868809	0.505	rs35064573	chr3:48740280	C/A	cg06212747	chr3:49208901	KLHDC8B	-0.57	-5.28	-0.33	2.94e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs7712401	0.623	rs30057	chr5:122298118	C/T	cg19412675	chr5:122181750	SNX24	0.4	5.13	0.32	5.98e-7	Mean platelet volume;
SARC	cis	rs7223966	0.621	rs28571160	chr17:61638723	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.45	-4.8	-0.3	2.83e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6087990	0.701	rs1997797	chr20:31387954	C/G	cg13636640	chr20:31349939	DNMT3B	0.76	11.72	0.61	3.07e-25	Ulcerative colitis;
SARC	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	5.96	0.36	9.28e-9	Tonsillectomy;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg04383274	chr21:34863711	DNAJC28	-0.46	-6.23	-0.38	2.12e-9	Chemerin levels;
SARC	cis	rs7614311	0.689	rs2276863	chr3:63849043	C/A	cg22134162	chr3:63841271	THOC7	-0.47	-5.12	-0.32	6.41e-7	Lung function (FVC);Lung function (FEV1);
SARC	cis	rs7940866	0.774	rs10466547	chr11:130823576	T/C	cg12179176	chr11:130786555	SNX19	0.68	9.76	0.54	4.43e-19	Schizophrenia;
SARC	cis	rs9457247	1.000	rs408087	chr6:167398952	C/T	cg07741184	chr6:167504864	NA	0.31	5.95	0.36	9.65e-9	Crohn's disease;
SARC	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg05793240	chr7:2802953	GNA12	-0.36	-5.24	-0.32	3.56e-7	Height;
SARC	cis	rs9486719	0.843	rs3860231	chr6:97036563	G/A	cg18709589	chr6:96969512	KIAA0776	-0.51	-5.64	-0.35	4.81e-8	Migraine;Coronary artery disease;
SARC	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg23758822	chr17:41437982	NA	0.91	11.55	0.6	1.09e-24	Menopause (age at onset);
SARC	cis	rs9467773	0.620	rs1490488	chr6:26614808	T/C	cg12292205	chr6:26970375	C6orf41	0.4	5.0	0.31	1.14e-6	Intelligence (multi-trait analysis);
SARC	cis	rs41264869	0.628	rs1061132	chr1:205115150	C/A	cg21643547	chr1:205240462	TMCC2	0.46	5.03	0.31	9.79e-7	Blood protein levels;
SARC	cis	rs56011263	0.687	rs73221103	chr4:706740	T/C	cg05835009	chr4:710272	PCGF3	0.56	6.53	0.39	3.99e-10	White blood cell count;
SARC	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	8.78	0.5	3.6e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg17221315	chr6:27791827	HIST1H4J	0.47	5.44	0.34	1.35e-7	Cardiac Troponin-T levels;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg01772563	chr7:95064399	PON2	-0.51	-6.4	-0.39	8.41e-10	Schizophrenia;
SARC	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg09699651	chr6:150184138	LRP11	0.4	4.94	0.31	1.49e-6	Lung cancer;
SARC	cis	rs965469	1.000	rs2281494	chr20:3235494	A/G	cg25506879	chr20:3388711	C20orf194	-0.58	-5.74	-0.35	2.88e-8	IFN-related cytopenia;
SARC	cis	rs67311347	1.000	rs7648952	chr3:40457038	C/T	cg01475735	chr3:40494733	NA	0.44	5.18	0.32	4.72e-7	Renal cell carcinoma;
SARC	cis	rs7647973	1.000	rs2140270	chr3:49439440	A/G	cg07636037	chr3:49044803	WDR6	-0.75	-8.18	-0.47	1.88e-14	Menarche (age at onset);
SARC	cis	rs60871478	0.685	rs34421533	chr7:816638	A/G	cg19087971	chr7:751233	PRKAR1B	-0.46	-4.73	-0.3	3.9e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg15052019	chr19:19431593	KIAA0892;SF4	-0.4	-4.81	-0.3	2.73e-6	Tonsillectomy;
SARC	cis	rs1355223	0.902	rs12800220	chr11:34701617	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.27	-0.33	3.04e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs17125944	0.615	rs8003334	chr14:53374967	C/T	cg00686598	chr14:53173677	PSMC6	0.76	5.52	0.34	8.92e-8	Alzheimer's disease (late onset);
SARC	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg25072359	chr17:41440525	NA	0.49	5.72	0.35	3.19e-8	Menopause (age at onset);
SARC	cis	rs3008870	1.000	rs12039172	chr1:67447450	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.89	-11.03	-0.59	4.76e-23	Lymphocyte percentage of white cells;
SARC	cis	rs694739	0.595	rs11542299	chr11:64138805	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.52	5.52	0.34	8.81e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs7843479	0.965	rs11775479	chr8:21859991	C/T	cg17168535	chr8:21777572	XPO7	0.62	7.91	0.46	1.04e-13	Mean corpuscular volume;
SARC	trans	rs1945213	0.694	rs34828123	chr11:55837868	T/A	cg15704280	chr7:45808275	SEPT13	0.66	6.87	0.41	5.94e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs2228479	0.702	rs3819574	chr16:89826630	G/A	cg00800038	chr16:89945340	TCF25	-0.74	-5.14	-0.32	5.79e-7	Skin colour saturation;
SARC	cis	rs8114671	0.562	rs3746450	chr20:33508588	G/T	cg08999081	chr20:33150536	PIGU	0.32	4.72	0.3	3.99e-6	Height;
SARC	cis	rs11098499	0.954	rs13113483	chr4:120309039	C/T	cg09160332	chr4:120329925	NA	-0.33	-4.77	-0.3	3.27e-6	Corneal astigmatism;
SARC	cis	rs9948	0.786	rs72809850	chr2:97449762	A/C	cg01990225	chr2:97406019	LMAN2L	-0.96	-6.95	-0.41	3.73e-11	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs9814567	1.000	rs10935120	chr3:134233092	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.54	6.78	0.41	9.79e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs72781680	0.611	rs72783625	chr2:24315540	C/T	cg06627628	chr2:24431161	ITSN2	-0.5	-5.3	-0.33	2.66e-7	Lymphocyte counts;
SARC	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg05861140	chr6:150128134	PCMT1	-0.44	-5.34	-0.33	2.21e-7	Lung cancer;
SARC	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.05	0.37	5.62e-9	Height;
SARC	cis	rs3770770	0.855	rs62133107	chr2:37251019	A/T	cg14987922	chr2:37194071	STRN	-0.51	-5.0	-0.31	1.12e-6	QRS duration;
SARC	trans	rs8073060	0.586	rs72829923	chr17:34045089	T/A	cg19694781	chr19:47549865	TMEM160	0.72	6.95	0.41	3.67e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs2180341	0.920	rs1073932	chr6:127682009	G/T	cg24812749	chr6:127587940	RNF146	1.01	13.14	0.65	6.91e-30	Breast cancer;
SARC	cis	rs3858526	0.959	rs10838797	chr11:5920977	A/G	cg13902645	chr11:5959945	NA	-0.42	-4.79	-0.3	3e-6	DNA methylation (variation);
SARC	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg20607798	chr8:58055168	NA	0.67	5.66	0.35	4.42e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2070488	0.775	rs1073506	chr3:38566235	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.75	-11.48	-0.6	1.78e-24	Electrocardiographic conduction measures;
SARC	cis	rs75804782	0.625	rs1039887	chr2:239434892	A/G	cg18131467	chr2:239335373	ASB1	-0.58	-5.3	-0.33	2.63e-7	Morning vs. evening chronotype;Chronotype;
SARC	cis	rs10484885	0.878	rs72921916	chr6:90555990	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.61	-5.23	-0.32	3.71e-7	QRS interval (sulfonylurea treatment interaction);
SARC	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg03060546	chr3:49711283	APEH	0.48	6.28	0.38	1.65e-9	Menarche (age at onset);
SARC	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg16479474	chr6:28041457	NA	0.36	5.36	0.33	1.97e-7	Depression;
SARC	cis	rs6831352	0.691	rs2602887	chr4:100041473	A/G	cg12011299	chr4:100065546	ADH4	0.33	5.42	0.33	1.45e-7	Alcohol dependence;
SARC	cis	rs4984778	0.750	rs7198064	chr16:1272472	C/T	cg07748719	chr16:1272498	TPSG1	0.48	6.94	0.41	3.87e-11	Blood protein levels;
SARC	cis	rs950776	0.616	rs12901300	chr15:78892952	G/A	cg22563815	chr15:78856949	CHRNA5	0.37	6.3	0.38	1.45e-9	Sudden cardiac arrest;
SARC	cis	rs11997175	0.524	rs10954932	chr8:33650176	A/C	ch.8.33884649F	chr8:33765107	NA	0.5	6.62	0.4	2.42e-10	Body mass index;
SARC	cis	rs9325144	0.505	rs826893	chr12:39100536	A/G	cg13010199	chr12:38710504	ALG10B	-0.59	-8.07	-0.47	3.68e-14	Morning vs. evening chronotype;
SARC	cis	rs6120849	0.663	rs11698868	chr20:33549946	C/T	cg06115741	chr20:33292138	TP53INP2	0.55	5.42	0.33	1.49e-7	Protein C levels;
SARC	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg00933542	chr6:150070202	PCMT1	0.31	5.36	0.33	2.04e-7	Lung cancer;
SARC	cis	rs9436747	0.615	rs6676495	chr1:66052117	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.48	4.92	0.31	1.62e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs981844	0.740	rs6841173	chr4:154682563	A/G	cg14289246	chr4:154710475	SFRP2	-0.63	-7.27	-0.43	5.5e-12	Response to statins (LDL cholesterol change);
SARC	cis	rs752010	0.631	rs4660549	chr1:42088102	A/G	cg06885757	chr1:42089581	HIVEP3	0.57	8.19	0.47	1.69e-14	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs2592394	0.675	rs711819	chr2:176985696	C/T	cg13092806	chr2:177043255	NA	-0.49	-5.1	-0.32	7.09e-7	Magnesium levels;Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg06558623	chr16:89946397	TCF25	0.91	6.37	0.38	1.03e-9	Skin colour saturation;
SARC	cis	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg09021430	chr5:549028	NA	-0.44	-5.76	-0.35	2.6e-8	Obesity-related traits;
SARC	cis	rs1832871	0.711	rs6906854	chr6:158695000	C/T	cg07165851	chr6:158734300	TULP4	0.56	6.76	0.4	1.09e-10	Height;
SARC	cis	rs6429082	0.818	rs291386	chr1:235647050	C/T	cg26050004	chr1:235667680	B3GALNT2	0.68	8.53	0.49	1.82e-15	Adiposity;
SARC	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	12.23	0.63	6.97e-27	Chronic sinus infection;
SARC	cis	rs7647973	0.593	rs28535523	chr3:49848414	C/T	cg13072238	chr3:49761600	GMPPB	0.59	5.9	0.36	1.25e-8	Menarche (age at onset);
SARC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg23034840	chr1:205782522	SLC41A1	0.62	7.84	0.46	1.64e-13	Menarche (age at onset);
SARC	cis	rs244731	0.959	rs918459	chr5:176669030	C/T	cg17509989	chr5:176798049	RGS14	-0.66	-8.51	-0.49	2.16e-15	Urate levels in lean individuals;
SARC	cis	rs2077654	0.822	rs7932122	chr11:17431361	A/G	cg25308976	chr11:17434268	ABCC8	-0.6	-7.23	-0.43	6.83e-12	Gout;
SARC	cis	rs7647973	0.626	rs1586827	chr3:49671224	T/C	cg06212747	chr3:49208901	KLHDC8B	0.58	5.86	0.36	1.56e-8	Menarche (age at onset);
SARC	trans	rs3942852	0.622	rs6485806	chr11:48102806	A/G	cg15704280	chr7:45808275	SEPT13	0.58	6.7	0.4	1.57e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs4588572	0.686	rs4352584	chr5:77682948	C/G	cg11547950	chr5:77652471	NA	0.4	4.87	0.3	2.11e-6	Triglycerides;
SARC	trans	rs208520	1.000	rs12195505	chr6:66986279	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.83	9.35	0.52	7.46e-18	Exhaled nitric oxide output;
SARC	cis	rs240764	0.610	rs41288423	chr6:101166095	G/A	cg09795085	chr6:101329169	ASCC3	-0.47	-5.95	-0.36	9.73e-9	Neuroticism;
SARC	cis	rs6918586	0.658	rs198825	chr6:26122502	A/G	cg12298212	chr6:27065003	NA	-0.34	-4.76	-0.3	3.47e-6	Schizophrenia;
SARC	cis	rs2916247	0.908	rs6471321	chr8:93162098	G/A	cg10183463	chr8:93005414	RUNX1T1	0.47	4.86	0.3	2.2e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg18252515	chr7:66147081	NA	-1.33	-11.84	-0.61	1.22e-25	Diabetic kidney disease;
SARC	cis	rs7615952	0.800	rs13086460	chr3:125646417	C/T	cg05084668	chr3:125655381	ALG1L	-0.67	-6.7	-0.4	1.55e-10	Blood pressure (smoking interaction);
SARC	cis	rs1003719	0.667	rs6517404	chr21:38494918	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.58	8.11	0.47	2.88e-14	Eye color traits;
SARC	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg22903471	chr2:27725779	GCKR	-0.43	-6.4	-0.39	8.46e-10	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	trans	rs2727020	0.634	rs11040331	chr11:49345726	T/C	cg03929089	chr4:120376271	NA	-0.67	-7.25	-0.43	6.2e-12	Coronary artery disease;
SARC	cis	rs6977660	0.714	rs6943204	chr7:19818671	A/G	cg07541023	chr7:19748670	TWISTNB	0.51	4.95	0.31	1.44e-6	Thyroid stimulating hormone;
SARC	cis	rs986417	1.000	rs1272688	chr14:60920718	T/C	cg27398547	chr14:60952738	C14orf39	-1.01	-9.32	-0.52	8.92e-18	Gut microbiota (bacterial taxa);
SARC	cis	rs881375	1.000	rs7037140	chr9:123656327	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.42	5.0	0.31	1.11e-6	Rheumatoid arthritis;
SARC	cis	rs1023500	0.551	rs2859438	chr22:42466980	A/T	cg04733989	chr22:42467013	NAGA	0.77	10.92	0.58	1.11e-22	Schizophrenia;
SARC	cis	rs9788682	0.747	rs8042494	chr15:78908010	C/T	cg24631222	chr15:78858424	CHRNA5	0.72	9.8	0.54	3.22e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs6088580	0.524	rs6088568	chr20:33265971	A/C	cg24642439	chr20:33292090	TP53INP2	-0.54	-6.65	-0.4	2.07e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs965604	1.000	rs8042260	chr15:78774374	A/G	cg24631222	chr15:78858424	CHRNA5	-0.48	-6.17	-0.37	2.95e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs6424115	1.000	rs7515969	chr1:24158398	G/A	cg15997130	chr1:24165203	NA	-0.49	-6.62	-0.4	2.42e-10	Immature fraction of reticulocytes;
SARC	cis	rs7766436	0.848	rs13211568	chr6:22573180	A/T	cg13666174	chr6:22585274	NA	-0.56	-6.8	-0.41	8.6e-11	Coronary artery disease;
SARC	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg08219700	chr8:58056026	NA	0.59	6.29	0.38	1.55e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2204008	0.775	rs11514370	chr12:38305566	G/A	cg26384229	chr12:38710491	ALG10B	0.88	12.91	0.65	3.91e-29	Bladder cancer;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg15485645	chr19:52839738	ZNF610	-0.53	-6.78	-0.41	9.77e-11	Breast cancer;
SARC	trans	rs9329221	0.621	rs522483	chr8:9812969	C/G	cg06636001	chr8:8085503	FLJ10661	-0.7	-9.79	-0.54	3.66e-19	Neuroticism;
SARC	cis	rs3741151	0.892	rs7930454	chr11:73085034	T/C	cg17517138	chr11:73019481	ARHGEF17	0.63	5.29	0.33	2.88e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs11758351	1.000	rs112751982	chr6:26191958	C/T	cg23601095	chr6:26197514	HIST1H3D	0.63	5.43	0.34	1.4e-7	Gout;Renal underexcretion gout;
SARC	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs12310956	0.532	rs1525897	chr12:33941033	C/T	cg13010199	chr12:38710504	ALG10B	0.76	10.38	0.56	5.46e-21	Morning vs. evening chronotype;
SARC	trans	rs6894249	1.000	rs6894249	chr5:131797547	A/G	cg14815005	chr22:22222162	MAPK1	0.54	6.64	0.4	2.19e-10	Asthma;
SARC	cis	rs9309473	0.607	rs6740173	chr2:73602266	C/G	cg20560298	chr2:73613845	ALMS1	-0.55	-7.02	-0.42	2.36e-11	Metabolite levels;
SARC	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg13628971	chr7:2884303	GNA12	0.56	6.46	0.39	5.93e-10	Height;
SARC	cis	rs2635047	0.713	rs8086549	chr18:44756421	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.47	-6.27	-0.38	1.77e-9	Educational attainment;
SARC	cis	rs17666538	0.585	rs6559064	chr8:623061	G/A	cg07234876	chr8:600039	NA	0.77	6.51	0.39	4.6e-10	IgG glycosylation;
SARC	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg10207240	chr12:122356781	WDR66	0.31	5.13	0.32	6.1e-7	Mean corpuscular volume;
SARC	cis	rs6582630	0.576	rs4882258	chr12:38453686	C/T	cg14851346	chr12:38532713	NA	-0.48	-5.86	-0.36	1.55e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs155076	1.000	rs261423	chr13:21852331	A/C	cg11317459	chr13:21872234	NA	-0.97	-12.13	-0.62	1.42e-26	White matter hyperintensity burden;
SARC	cis	rs7945705	0.902	rs1560569	chr11:8939887	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.42	-6.04	-0.37	6.16e-9	Hemoglobin concentration;
SARC	cis	rs2908197	0.806	rs6465098	chr7:75972947	T/C	cg22830091	chr7:75961684	YWHAG	-0.32	-4.88	-0.3	2.01e-6	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg13939156	chr17:80058883	NA	0.4	6.22	0.38	2.23e-9	Life satisfaction;
SARC	cis	rs9291683	0.530	rs11723591	chr4:9985398	T/A	cg11266682	chr4:10021025	SLC2A9	0.4	6.99	0.42	2.85e-11	Bone mineral density;
SARC	trans	rs1814175	0.740	rs10839439	chr11:49918240	C/T	cg03929089	chr4:120376271	NA	-0.87	-14.15	-0.68	3.29e-33	Height;
SARC	cis	rs4689388	0.890	rs1801206	chr4:6302707	C/T	cg00701064	chr4:6280414	WFS1	0.58	9.7	0.54	6.63e-19	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs7613875	0.580	rs3774745	chr3:50204745	C/T	cg24110177	chr3:50126178	RBM5	0.43	5.4	0.33	1.67e-7	Body mass index;
SARC	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg00031303	chr3:195681400	NA	0.48	5.42	0.33	1.48e-7	Pancreatic cancer;
SARC	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.63	-0.4	2.28e-10	Total body bone mineral density;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg25617092	chr4:93225157	GRID2	-0.74	-6.51	-0.39	4.62e-10	Autism spectrum disorder or schizophrenia;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg00994411	chr8:52812171	PCMTD1	0.47	6.28	0.38	1.68e-9	Chemerin levels;
SARC	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg22920501	chr2:26401640	FAM59B	-0.51	-6.71	-0.4	1.5e-10	Gut microbiome composition (summer);
SARC	cis	rs8077889	0.703	rs231531	chr17:41946180	A/C	cg26893861	chr17:41843967	DUSP3	0.68	6.7	0.4	1.52e-10	Triglycerides;
SARC	cis	rs3540	0.597	rs1978149	chr15:91036976	A/G	cg22089800	chr15:90895588	ZNF774	0.64	8.3	0.48	8.33e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	trans	rs3942852	0.568	rs2904315	chr11:48109948	C/T	cg15704280	chr7:45808275	SEPT13	0.65	8.52	0.49	1.99e-15	Acute lymphoblastic leukemia (childhood);
SARC	trans	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-10.59	-0.57	1.18e-21	Intelligence (multi-trait analysis);
SARC	cis	rs6831352	0.840	rs29001223	chr4:100047433	C/T	cg13256891	chr4:100009986	ADH5	-0.66	-8.28	-0.48	9.71e-15	Alcohol dependence;
SARC	cis	rs7264396	0.563	rs17092980	chr20:34289005	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	5.69	0.35	3.71e-8	Total cholesterol levels;
SARC	trans	rs7824557	0.564	rs2736300	chr8:11235579	T/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.7	-0.5	6e-16	Retinal vascular caliber;
SARC	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.44	4.95	0.31	1.39e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs1113500	0.836	rs1122158	chr1:108588668	G/T	cg06207961	chr1:108661230	NA	0.43	5.62	0.35	5.31e-8	Growth-regulated protein alpha levels;
SARC	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg27170947	chr2:26402098	FAM59B	0.37	4.8	0.3	2.79e-6	Gut microbiome composition (summer);
SARC	cis	rs3106136	0.843	rs11727030	chr4:95262665	A/G	cg11021082	chr4:95130006	SMARCAD1	0.35	5.31	0.33	2.55e-7	Capecitabine sensitivity;
SARC	cis	rs7552404	0.920	rs1612097	chr1:76218875	C/T	cg22875332	chr1:76189707	ACADM	0.39	5.43	0.34	1.41e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs1538970	0.962	rs4660301	chr1:45820149	T/A	cg05343316	chr1:45956843	TESK2	0.67	7.83	0.46	1.76e-13	Platelet count;
SARC	trans	rs7937682	1.000	rs12363179	chr11:111568091	G/A	cg18187862	chr3:45730750	SACM1L	-0.55	-6.9	-0.41	4.84e-11	Primary sclerosing cholangitis;
SARC	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg10589385	chr1:150898437	SETDB1	0.42	5.53	0.34	8.69e-8	Melanoma;
SARC	cis	rs9372253	1.000	rs9386894	chr6:110718853	A/G	cg19196401	chr6:110721138	DDO	-0.39	-4.95	-0.31	1.39e-6	Platelet distribution width;
SARC	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.38	5.45	0.34	1.31e-7	Total body bone mineral density;
SARC	cis	rs35160687	0.901	rs12478575	chr2:86535314	C/G	cg10973622	chr2:86423274	IMMT	0.37	4.83	0.3	2.44e-6	Night sleep phenotypes;
SARC	cis	rs73206853	0.764	rs7312939	chr12:110564108	G/A	cg10860002	chr12:110842031	ANAPC7	0.64	5.15	0.32	5.67e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs7712401	0.623	rs30043	chr5:122272293	G/C	cg19412675	chr5:122181750	SNX24	0.4	5.09	0.32	7.55e-7	Mean platelet volume;
SARC	cis	rs2153535	0.584	rs9502721	chr6:8541379	G/A	cg07606381	chr6:8435919	SLC35B3	0.77	10.77	0.58	3.36e-22	Motion sickness;
SARC	cis	rs9916302	0.706	rs6503500	chr17:37485925	C/T	cg07936489	chr17:37558343	FBXL20	-0.76	-9.11	-0.51	3.92e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs1670533	1.000	rs11247972	chr4:1060550	A/G	cg27284194	chr4:1044797	NA	0.45	4.76	0.3	3.42e-6	Recombination rate (females);
SARC	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg17376030	chr22:41985996	PMM1	0.72	9.11	0.51	3.99e-17	Vitiligo;
SARC	cis	rs79149102	0.579	rs8040961	chr15:75291864	G/A	cg00629941	chr15:75287862	SCAMP5	-0.64	-5.11	-0.32	6.76e-7	Lung cancer;
SARC	cis	rs9399135	0.967	rs952674	chr6:135349157	A/G	cg24558204	chr6:135376177	HBS1L	0.45	6.07	0.37	5.25e-9	Red blood cell count;
SARC	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg11764359	chr7:65958608	NA	0.86	12.33	0.63	3.29e-27	Aortic root size;
SARC	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg06713675	chr4:122721982	EXOSC9	-0.51	-6.79	-0.41	9.05e-11	Type 2 diabetes;
SARC	cis	rs7927771	0.524	rs12286721	chr11:47701528	G/T	cg10504702	chr11:47789108	FNBP4	-0.39	-5.08	-0.32	7.8e-7	Subjective well-being;
SARC	cis	rs6690583	0.623	rs1371142	chr1:85455373	A/T	cg22153463	chr1:85462885	MCOLN2	0.72	6.92	0.41	4.32e-11	Serum sulfate level;
SARC	cis	rs7246657	0.943	rs713256	chr19:37865365	C/T	cg23950597	chr19:37808831	NA	-0.65	-6.26	-0.38	1.8e-9	Coronary artery calcification;
SARC	cis	rs651907	0.535	rs13085776	chr3:101505507	A/G	cg15564428	chr3:101498201	FAM55C	-0.53	-5.02	-0.31	1.01e-6	Colorectal cancer;
SARC	trans	rs1814175	0.541	rs12287397	chr11:49819799	G/A	cg15704280	chr7:45808275	SEPT13	-0.96	-17.84	-0.76	1.85e-45	Height;
SARC	cis	rs2115630	0.645	rs6496284	chr15:85178270	A/G	cg17507749	chr15:85114479	UBE2QP1	-0.52	-6.22	-0.38	2.32e-9	P wave terminal force;
SARC	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg02462569	chr6:150064036	NUP43	-0.37	-4.75	-0.3	3.53e-6	Lung cancer;
SARC	cis	rs709400	1.000	rs57218990	chr14:104128007	T/A	cg12935359	chr14:103987150	CKB	-0.35	-5.19	-0.32	4.62e-7	Body mass index;
SARC	cis	rs11122272	0.735	rs2250749	chr1:231485763	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-9.87	-0.54	1.98e-19	Hemoglobin concentration;
SARC	cis	rs4242434	0.927	rs11781149	chr8:22473158	C/T	cg03733263	chr8:22462867	KIAA1967	1.04	17.32	0.75	9.42e-44	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs4689388	0.793	rs4689393	chr4:6287241	T/C	cg00701064	chr4:6280414	WFS1	0.54	8.54	0.49	1.8e-15	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs995000	0.662	rs11208009	chr1:63195692	A/G	cg06896770	chr1:63153194	DOCK7	0.54	6.93	0.41	4.02e-11	Triglyceride levels;
SARC	cis	rs8017423	0.967	rs7147952	chr14:90720831	G/A	cg20276874	chr14:90721474	PSMC1	-0.37	-5.18	-0.32	4.75e-7	Mortality in heart failure;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg06107297	chr7:93633078	BET1	-0.48	-6.48	-0.39	5.37e-10	Neuroticism;
SARC	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	27.21	0.87	2.81e-74	Chronic sinus infection;
SARC	cis	rs4481887	0.741	rs6421453	chr1:248533285	A/G	cg13385794	chr1:248469461	NA	0.35	5.57	0.34	6.97e-8	Common traits (Other);
SARC	cis	rs10988449	0.657	rs12335819	chr9:132395316	A/G	cg18327994	chr9:132372705	NA	-0.41	-4.74	-0.3	3.78e-6	Response to anti-depressant treatment in major depressive disorder;
SARC	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.88	-11.87	-0.61	9.78e-26	Multiple sclerosis;
SARC	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg18252515	chr7:66147081	NA	0.58	6.24	0.38	2.02e-9	Aortic root size;
SARC	cis	rs1044826	0.667	rs2083336	chr3:139201272	T/G	cg15131784	chr3:139108705	COPB2	0.4	5.0	0.31	1.12e-6	Obesity-related traits;
SARC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.58	0.57	1.3e-21	Prudent dietary pattern;
SARC	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg04546413	chr19:29218101	NA	0.63	8.54	0.49	1.71e-15	Methadone dose in opioid dependence;
SARC	cis	rs2354432	0.607	rs4314933	chr1:146821386	T/C	cg25205988	chr1:146714368	CHD1L	0.96	7.4	0.44	2.45e-12	Mitochondrial DNA levels;
SARC	cis	rs12791968	0.765	rs11038250	chr11:45009114	A/G	cg11846598	chr11:44996168	LOC221122	-0.34	-4.95	-0.31	1.41e-6	Inhibitory control;
SARC	cis	rs55692411	0.537	rs13071931	chr3:50062878	G/A	cg24110177	chr3:50126178	RBM5	-0.48	-5.29	-0.33	2.85e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2594989	0.887	rs6442253	chr3:11474238	T/C	cg00170343	chr3:11313890	ATG7	0.57	5.36	0.33	1.97e-7	Circulating chemerin levels;
SARC	cis	rs12450688	1	rs12450688	chr17:38144229	G/A	cg17467752	chr17:38218738	THRA	-0.38	-4.91	-0.31	1.69e-6	Sum eosinophil basophil counts;
SARC	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.72	-8.45	-0.48	3.2e-15	Height;
SARC	cis	rs787274	0.543	rs10116897	chr9:115633479	C/T	cg13803584	chr9:115635662	SNX30	-0.86	-7.31	-0.43	4.13e-12	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs34375054	0.525	rs7136220	chr12:125602684	T/C	cg25124228	chr12:125621409	AACS	-0.64	-7.91	-0.46	1.05e-13	Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs4664308	0.870	rs2198918	chr2:161015052	C/T	cg03641300	chr2:160917029	PLA2R1	-0.64	-8.39	-0.48	4.59e-15	Idiopathic membranous nephropathy;
SARC	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	trans	rs6894249	1.000	rs6894249	chr5:131797547	A/G	cg16458021	chr21:43430507	ZNF295	0.5	6.33	0.38	1.23e-9	Asthma;
SARC	cis	rs17209837	1.000	rs58083477	chr7:87117706	T/C	cg00919237	chr7:87102261	ABCB4	-0.45	-4.76	-0.3	3.48e-6	Gallbladder cancer;
SARC	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg27266027	chr21:40555129	PSMG1	-0.5	-5.53	-0.34	8.41e-8	Cognitive function;
SARC	cis	rs6840360	0.571	rs4696279	chr4:152560449	G/A	cg22705602	chr4:152727874	NA	-0.43	-6.69	-0.4	1.66e-10	Intelligence (multi-trait analysis);
SARC	cis	rs9916302	0.851	rs9909064	chr17:37500434	G/T	cg20243544	chr17:37824526	PNMT	-0.53	-6.37	-0.39	9.76e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs73195822	0.527	rs55728229	chr12:111169374	T/A	cg10860002	chr12:110842031	ANAPC7	0.56	4.84	0.3	2.38e-6	Itch intensity from mosquito bite;
SARC	cis	rs2439831	0.867	rs496584	chr15:43831923	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	7.91	0.46	1.02e-13	Lung cancer in ever smokers;
SARC	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg24250549	chr1:154909240	PMVK	0.74	9.77	0.54	4.02e-19	Prostate cancer;
SARC	cis	rs7255436	1.000	rs7255436	chr19:8433196	C/A	cg10174797	chr19:8464628	RAB11B	0.45	6.44	0.39	6.74e-10	HDL cholesterol;
SARC	cis	rs10791323	0.693	rs10750544	chr11:133718740	A/G	cg15485101	chr11:133734466	NA	0.35	5.72	0.35	3.23e-8	Childhood ear infection;
SARC	cis	rs2235544	0.565	rs633315	chr1:54468689	G/A	cg10336722	chr1:54665764	CYB5RL;MRPL37	-0.38	-4.74	-0.3	3.66e-6	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
SARC	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.77	7.62	0.45	6.49e-13	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg05313129	chr8:58192883	C8orf71	-0.48	-5.72	-0.35	3.18e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4128725	1.000	rs4656232	chr1:159364129	G/A	cg25076881	chr1:159409836	OR10J1	0.4	4.78	0.3	3.16e-6	Select biomarker traits;
SARC	cis	rs3796352	0.571	rs11713926	chr3:53155072	C/T	cg15956490	chr3:53032818	SFMBT1	0.91	5.99	0.37	7.89e-9	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2425143	1.000	rs11696527	chr20:34245379	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.13	0.32	6.04e-7	Blood protein levels;
SARC	cis	rs17376456	0.825	rs10051878	chr5:93064164	T/G	cg21475434	chr5:93447410	FAM172A	0.72	6.33	0.38	1.25e-9	Diabetic retinopathy;
SARC	cis	rs2832191	0.791	rs57721945	chr21:30498744	T/C	cg24692254	chr21:30365293	RNF160	-0.84	-11.9	-0.61	8.25e-26	Dental caries;
SARC	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg05368731	chr17:41323189	NBR1	0.77	9.97	0.55	1.03e-19	Menopause (age at onset);
SARC	cis	rs3768617	0.811	rs10911200	chr1:182998377	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.62	8.36	0.48	5.62e-15	Fuchs's corneal dystrophy;
SARC	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg27572855	chr1:25598939	RHD	0.52	8.75	0.5	4.24e-16	Erythrocyte sedimentation rate;
SARC	cis	rs7829975	0.511	rs2955578	chr8:8137083	T/C	cg15556689	chr8:8085844	FLJ10661	0.55	6.95	0.41	3.7e-11	Mood instability;
SARC	cis	rs12681288	0.963	rs7822955	chr8:1029090	C/T	cg15309053	chr8:964076	NA	-0.37	-5.69	-0.35	3.85e-8	Schizophrenia;
SARC	cis	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg18252515	chr7:66147081	NA	-1.13	-9.94	-0.55	1.23e-19	Diabetic kidney disease;
SARC	cis	rs7252981	0.632	rs880090	chr19:19740729	C/G	cg03709012	chr19:19516395	GATAD2A	0.67	7.53	0.44	1.09e-12	Perceived unattractiveness to mosquitoes;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg26602666	chr7:144380035	TPK1	0.47	7.17	0.43	1.02e-11	Thyroid stimulating hormone;
SARC	cis	rs12682352	0.650	rs13265731	chr8:8673320	T/C	cg06636001	chr8:8085503	FLJ10661	0.54	6.87	0.41	5.84e-11	Neuroticism;
SARC	cis	rs986417	1.000	rs7159212	chr14:61068725	T/C	cg27398547	chr14:60952738	C14orf39	0.87	7.44	0.44	1.96e-12	Gut microbiota (bacterial taxa);
SARC	cis	rs2760061	0.819	rs964941	chr1:228193857	G/A	cg02753203	chr1:228287806	NA	0.58	7.99	0.46	6.13e-14	Diastolic blood pressure;
SARC	cis	rs7326068	0.595	rs2785741	chr13:21421240	C/T	cg16922012	chr13:21400325	XPO4	-0.41	-5.38	-0.33	1.8e-7	Schizophrenia, bipolar disorder and depression (combined);
SARC	cis	rs9818758	0.607	rs11710247	chr3:49249800	G/T	cg06212747	chr3:49208901	KLHDC8B	-0.72	-6.36	-0.38	1.06e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs4713118	0.869	rs6902689	chr6:27709441	C/T	cg17221315	chr6:27791827	HIST1H4J	0.49	5.36	0.33	1.99e-7	Parkinson's disease;
SARC	cis	rs2908197	0.699	rs2908191	chr7:75962322	A/G	cg22830091	chr7:75961684	YWHAG	-0.36	-5.44	-0.34	1.32e-7	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs7267979	0.844	rs6050477	chr20:25221547	C/T	cg13962466	chr20:25176127	ENTPD6	-0.46	-5.88	-0.36	1.38e-8	Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs79839061	0.610	rs11731387	chr4:851357	C/T	cg07828340	chr4:882639	GAK	0.75	5.9	0.36	1.29e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg12016809	chr21:47604291	C21orf56	0.48	5.89	0.36	1.36e-8	Testicular germ cell tumor;
SARC	cis	rs11574514	1.000	rs117199628	chr16:68286338	A/T	cg01866162	chr16:67596514	CTCF	1.15	6.5	0.39	4.93e-10	Crohn's disease;
SARC	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg00149659	chr3:10157352	C3orf10	0.64	6.07	0.37	5.22e-9	Alzheimer's disease;
SARC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg10150615	chr22:24372951	LOC391322	-0.47	-5.35	-0.33	2.07e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg06536200	chr11:44117561	EXT2	0.49	6.52	0.39	4.4e-10	Chemerin levels;
SARC	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg07061783	chr6:25882402	NA	-0.41	-4.8	-0.3	2.84e-6	Intelligence (multi-trait analysis);
SARC	cis	rs11235843	0.613	rs71464090	chr11:73596791	T/G	cg18195628	chr11:73498948	MRPL48	0.55	5.02	0.31	1.01e-6	Hand grip strength;
SARC	cis	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg20965017	chr5:231967	SDHA	-0.49	-5.02	-0.31	1.03e-6	Breast cancer;
SARC	cis	rs208520	0.779	rs208446	chr6:66903515	T/C	cg07460842	chr6:66804631	NA	-0.96	-11.34	-0.6	5.21e-24	Exhaled nitric oxide output;
SARC	cis	rs7927771	0.864	rs2053979	chr11:47439444	A/G	cg20307385	chr11:47447363	PSMC3	-0.6	-7.59	-0.45	7.67e-13	Subjective well-being;
SARC	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg24642844	chr7:1081250	C7orf50	-0.39	-5.39	-0.33	1.69e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs7644634	0.559	rs2301030	chr3:105469103	A/T	cg23051926	chr3:105466016	CBLB	0.47	5.35	0.33	2.13e-7	Itch intensity from mosquito bite;
SARC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg19318889	chr4:1322082	MAEA	0.43	5.31	0.33	2.58e-7	Longevity;
SARC	cis	rs9443189	1.000	rs1280048	chr6:76529583	C/T	cg01950844	chr6:76311363	SENP6	0.78	6.78	0.41	9.83e-11	Prostate cancer;
SARC	cis	rs6582630	0.598	rs12823134	chr12:38514347	T/A	cg26384229	chr12:38710491	ALG10B	-0.58	-7.34	-0.43	3.59e-12	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.53	-5.34	-0.33	2.15e-7	Lung function (FEV1/FVC);
SARC	cis	rs9916302	0.904	rs4795357	chr17:37569551	T/C	cg07936489	chr17:37558343	FBXL20	-0.71	-9.43	-0.53	4.43e-18	Glomerular filtration rate (creatinine);
SARC	cis	rs12421382	0.543	rs10890996	chr11:109328421	A/G	cg16359550	chr11:109292809	C11orf87	-0.45	-6.38	-0.39	9.71e-10	Schizophrenia;
SARC	cis	rs1008375	0.898	rs9998130	chr4:17593905	A/G	cg02297831	chr4:17616191	MED28	0.49	5.98	0.36	8.48e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs548181	0.611	rs562599	chr11:125459951	A/C	cg03464685	chr11:125439445	EI24	1.05	9.42	0.53	4.63e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.53	0.57	1.79e-21	Prudent dietary pattern;
SARC	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg24060327	chr5:131705240	SLC22A5	0.73	8.72	0.5	5.5e-16	Breast cancer;
SARC	cis	rs854765	0.547	rs7224047	chr17:17932931	G/A	cg04398451	chr17:18023971	MYO15A	-0.47	-6.63	-0.4	2.37e-10	Total body bone mineral density;
SARC	cis	rs9814567	1.000	rs2887797	chr3:134202506	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-7.06	-0.42	1.85e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs10078	0.515	rs1053299	chr5:470760	G/A	cg08916839	chr5:415575	AHRR	0.84	8.0	0.46	5.66e-14	Fat distribution (HIV);
SARC	cis	rs2645424	0.666	rs2272767	chr8:11711059	C/T	cg21281001	chr8:11725306	CTSB	0.5	6.13	0.37	3.77e-9	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
SARC	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg12463550	chr7:65579703	CRCP	0.67	5.06	0.31	8.43e-7	Diabetic kidney disease;
SARC	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs75804782	0.641	rs72987321	chr2:239352765	T/G	cg01134436	chr17:81009848	B3GNTL1	0.86	6.23	0.38	2.11e-9	Morning vs. evening chronotype;Chronotype;
SARC	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg21782813	chr7:2030301	MAD1L1	0.42	6.6	0.4	2.8e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs2153535	0.580	rs7761937	chr6:8459434	A/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.65	0.49	8.3e-16	Motion sickness;
SARC	cis	rs2380220	0.574	rs9400526	chr6:95998441	T/C	cg23517279	chr6:96025343	MANEA	0.51	5.92	0.36	1.15e-8	Behavioural disinhibition (generation interaction);
SARC	cis	rs4803455	0.565	rs2241713	chr19:41869468	C/G	cg08477640	chr19:41863820	B9D2	-0.59	-7.94	-0.46	8.77e-14	Migraine;Coronary artery disease;
SARC	cis	rs7666738	0.791	rs10017624	chr4:98984009	G/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs4843747	0.671	rs13334603	chr16:88116016	T/C	cg01573921	chr16:88061006	BANP	-0.5	-5.39	-0.33	1.69e-7	Menopause (age at onset);
SARC	cis	rs17270561	0.609	rs2275905	chr6:25768106	G/A	cg17691542	chr6:26056736	HIST1H1C	0.57	7.0	0.42	2.78e-11	Iron status biomarkers;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg20546810	chr20:2489835	ZNF343	-0.57	-6.53	-0.39	3.99e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs7617773	0.780	rs13082158	chr3:48372470	T/C	cg11946769	chr3:48343235	NME6	0.77	9.63	0.53	1.05e-18	Coronary artery disease;
SARC	cis	rs2486288	0.656	rs8037583	chr15:45546378	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.48	-5.91	-0.36	1.18e-8	Glomerular filtration rate;
SARC	cis	rs9325144	0.671	rs7306605	chr12:38730471	C/T	cg13010199	chr12:38710504	ALG10B	0.56	7.24	0.43	6.3e-12	Morning vs. evening chronotype;
SARC	cis	rs6901004	0.935	rs9487602	chr6:111560946	C/T	cg15721981	chr6:111408429	SLC16A10	0.46	5.53	0.34	8.74e-8	Blood metabolite levels;
SARC	cis	rs6570726	0.905	rs452770	chr6:145847162	T/C	cg05347473	chr6:146136440	FBXO30	0.49	6.55	0.39	3.56e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg12463550	chr7:65579703	CRCP	-0.47	-5.07	-0.31	8.3e-7	Aortic root size;
SARC	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg01017244	chr2:74357527	NA	0.55	6.65	0.4	2.11e-10	Gestational age at birth (maternal effect);
SARC	cis	rs910316	1.000	rs7156328	chr14:75532941	T/C	cg11812906	chr14:75593930	NEK9	0.89	13.67	0.67	1.25e-31	Height;
SARC	cis	rs7666738	0.830	rs6827516	chr4:98971740	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2242116	0.932	rs4683301	chr3:46931478	A/T	cg27129171	chr3:47204927	SETD2	-0.44	-5.69	-0.35	3.77e-8	Birth weight;
SARC	cis	rs1707322	0.717	rs3014246	chr1:46086077	C/T	cg06784218	chr1:46089804	CCDC17	-0.37	-6.55	-0.39	3.61e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs8017423	0.647	rs4904673	chr14:90817338	G/A	cg20276874	chr14:90721474	PSMC1	0.36	4.77	0.3	3.25e-6	Mortality in heart failure;
SARC	cis	rs2230307	0.536	rs834277	chr1:100510855	T/G	cg24955406	chr1:100503596	HIAT1	0.66	6.38	0.39	9.42e-10	Carotid intima media thickness;
SARC	cis	rs13108904	0.517	rs7671242	chr4:1339875	G/A	cg00684032	chr4:1343700	KIAA1530	0.45	6.51	0.39	4.61e-10	Obesity-related traits;
SARC	cis	rs10504229	0.679	rs16921677	chr8:58052431	T/C	cg08280861	chr8:58055591	NA	0.55	5.03	0.31	9.97e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs61931739	0.500	rs10772160	chr12:34456848	G/A	cg13010199	chr12:38710504	ALG10B	0.75	10.6	0.57	1.14e-21	Morning vs. evening chronotype;
SARC	cis	rs6687430	0.526	rs12127400	chr1:10613660	C/T	cg17425144	chr1:10567563	PEX14	0.38	5.66	0.35	4.47e-8	Hand grip strength;
SARC	cis	rs9486715	0.758	rs2971610	chr6:97027380	C/T	cg06623918	chr6:96969491	KIAA0776	-0.94	-14.49	-0.69	2.36e-34	Headache;
SARC	cis	rs1483890	0.723	rs2007578	chr3:69408982	T/A	cg22125112	chr3:69402811	FRMD4B	0.3	5.06	0.31	8.32e-7	Resting heart rate;
SARC	cis	rs10752881	0.905	rs12132262	chr1:182989949	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.69	0.57	6.02e-22	Colorectal cancer;
SARC	cis	rs17376456	0.877	rs9314093	chr5:93333347	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.84	0.36	1.72e-8	Diabetic retinopathy;
SARC	cis	rs56116382	0.604	rs9858428	chr3:49877585	G/T	cg00383909	chr3:49044727	WDR6	0.71	5.47	0.34	1.15e-7	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
SARC	cis	rs3106136	0.546	rs183993	chr4:95130025	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.47	-6.97	-0.42	3.14e-11	Capecitabine sensitivity;
SARC	cis	rs7944584	0.632	rs11606683	chr11:47302733	C/T	cg20307385	chr11:47447363	PSMC3	0.56	6.92	0.41	4.35e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs6450176	0.638	rs56220547	chr5:53287952	A/G	ch.5.1024479R	chr5:53302184	ARL15	-1.05	-12.18	-0.62	9.9e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs10870270	1.000	rs9971066	chr10:133788233	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.82	-9.8	-0.54	3.25e-19	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs1348850	0.914	rs1975544	chr2:178465423	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.65	7.33	0.43	3.75e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg07701084	chr6:150067640	NUP43	0.4	5.21	0.32	4.1e-7	Lung cancer;
SARC	cis	rs9788682	1.000	rs7181447	chr15:78814567	A/G	cg24631222	chr15:78858424	CHRNA5	0.72	9.67	0.54	8.32e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs12079745	0.826	rs12066676	chr1:169095382	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.67	-4.91	-0.31	1.73e-6	QT interval;
SARC	cis	rs6901004	0.839	rs783086	chr6:111561713	G/A	cg15721981	chr6:111408429	SLC16A10	-0.44	-5.31	-0.33	2.52e-7	Blood metabolite levels;
SARC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg10150615	chr22:24372951	LOC391322	-0.45	-5.08	-0.32	7.78e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs73206853	0.841	rs55885183	chr12:110877682	A/G	cg10860002	chr12:110842031	ANAPC7	0.63	4.98	0.31	1.22e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs7481584	0.624	rs397919	chr11:3063094	A/C	cg25174290	chr11:3078921	CARS	-0.57	-8.04	-0.47	4.52e-14	Calcium levels;
SARC	cis	rs155076	0.938	rs9509633	chr13:21844482	G/C	cg06138931	chr13:21896616	NA	-0.39	-5.08	-0.32	7.88e-7	White matter hyperintensity burden;
SARC	cis	rs7520050	1.000	rs12410070	chr1:46358882	T/C	cg24296786	chr1:45957014	TESK2	0.38	4.82	0.3	2.56e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs7520050	0.966	rs7550746	chr1:46351719	T/A	cg24296786	chr1:45957014	TESK2	0.39	4.89	0.31	1.88e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs9457247	1.000	rs386548	chr6:167385533	A/T	cg07741184	chr6:167504864	NA	-0.29	-5.57	-0.34	7.06e-8	Crohn's disease;
SARC	cis	rs8180040	0.615	rs13062681	chr3:47021124	A/G	cg27129171	chr3:47204927	SETD2	0.64	8.66	0.49	7.84e-16	Colorectal cancer;
SARC	cis	rs9858542	0.953	rs10640	chr3:49454277	G/A	cg07274523	chr3:49395745	GPX1	0.52	6.04	0.37	5.92e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs698813	0.637	rs4952706	chr2:44500536	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	6.32	0.38	1.31e-9	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.96	10.85	0.58	1.85e-22	Platelet count;
SARC	cis	rs3106136	0.843	rs6826671	chr4:95271881	T/C	cg11021082	chr4:95130006	SMARCAD1	0.33	5.17	0.32	5.12e-7	Capecitabine sensitivity;
SARC	cis	rs13082711	0.522	rs608374	chr3:27345397	G/A	cg02860705	chr3:27208620	NA	0.43	5.76	0.35	2.58e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs12458462	0.892	rs2007483	chr18:77476131	A/T	cg23301140	chr18:77439876	CTDP1	0.61	7.83	0.46	1.68e-13	Monocyte count;
SARC	cis	rs11098499	0.909	rs1546502	chr4:120235898	A/G	cg09307838	chr4:120376055	NA	0.9	12.37	0.63	2.28e-27	Corneal astigmatism;
SARC	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg12463550	chr7:65579703	CRCP	0.7	5.26	0.33	3.34e-7	Diabetic kidney disease;
SARC	cis	rs698813	0.543	rs12468824	chr2:44482448	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	5.99	0.37	7.83e-9	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs10934753	0.632	rs2001273	chr3:125926110	C/T	cg01346077	chr3:125931526	NA	0.38	4.86	0.3	2.14e-6	Plasma homocysteine levels (post-methionine load test);
SARC	cis	rs1707322	0.685	rs56177313	chr1:46225806	A/C	cg06784218	chr1:46089804	CCDC17	0.39	6.81	0.41	8.12e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.11	-18.93	-0.78	5.03e-49	Prudent dietary pattern;
SARC	cis	rs6831352	0.734	rs1154400	chr4:100010010	C/T	cg13256891	chr4:100009986	ADH5	0.6	7.89	0.46	1.2e-13	Alcohol dependence;
SARC	cis	rs7264396	0.563	rs7264869	chr20:34346502	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.56	-0.39	3.48e-10	Total cholesterol levels;
SARC	cis	rs7246760	0.867	rs66927855	chr19:9811728	C/T	cg16876255	chr19:9731953	ZNF561	0.79	4.88	0.3	1.96e-6	Pursuit maintenance gain;
SARC	cis	rs9325144	0.624	rs7979541	chr12:39129679	T/C	cg13010199	chr12:38710504	ALG10B	-0.49	-6.18	-0.38	2.81e-9	Morning vs. evening chronotype;
SARC	cis	rs10875746	0.855	rs10875728	chr12:48426392	T/G	cg26205652	chr12:48591994	NA	0.48	5.51	0.34	9.31e-8	Longevity (90 years and older);
SARC	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg10435706	chr6:150039699	LATS1	0.37	4.87	0.3	2.04e-6	Lung cancer;
SARC	cis	rs9486715	0.867	rs12207471	chr6:96963782	A/G	cg06623918	chr6:96969491	KIAA0776	0.88	12.63	0.64	3.28e-28	Headache;
SARC	cis	rs4765905	0.610	rs10848627	chr12:2312408	A/G	cg10668781	chr12:2307325	CACNA1C	-0.3	-4.76	-0.3	3.43e-6	Schizophrenia;
SARC	cis	rs501120	0.810	rs622472	chr10:44749211	A/C	cg09554077	chr10:44749378	NA	0.51	7.19	0.43	8.6e-12	Coronary artery disease;Coronary heart disease;
SARC	trans	rs12310956	0.532	rs6488186	chr12:33974122	G/A	cg26384229	chr12:38710491	ALG10B	0.75	10.53	0.57	1.89e-21	Morning vs. evening chronotype;
SARC	cis	rs9894429	0.621	rs9747119	chr17:79607017	A/G	cg18240062	chr17:79603768	NPLOC4	0.59	7.18	0.43	9.4e-12	Eye color traits;
SARC	cis	rs9902453	0.765	rs62068653	chr17:28212663	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	7.17	0.43	9.84e-12	Coffee consumption (cups per day);
SARC	cis	rs7927592	0.956	rs7124078	chr11:68298633	G/T	cg01657329	chr11:68192670	LRP5	-0.39	-4.94	-0.31	1.49e-6	Total body bone mineral density;
SARC	cis	rs1348850	0.914	rs4893944	chr2:178289357	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	7.85	0.46	1.49e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	trans	rs7615952	1.000	rs7615952	chr3:125649403	A/C	cg07211511	chr3:129823064	LOC729375	0.94	11.1	0.59	3.05e-23	Blood pressure (smoking interaction);
SARC	cis	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg25427524	chr10:38739819	LOC399744	-0.58	-8.97	-0.51	9.73e-17	Extrinsic epigenetic age acceleration;
SARC	cis	rs7005606	1.000	rs2439303	chr8:32430375	T/C	cg14488905	chr8:32406789	NRG1	-0.42	-5.86	-0.36	1.56e-8	Hirschsprung disease;
SARC	cis	rs6977660	0.652	rs12673842	chr7:19747437	T/C	cg05791153	chr7:19748676	TWISTNB	0.97	7.42	0.44	2.12e-12	Thyroid stimulating hormone;
SARC	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg17554472	chr22:41940697	POLR3H	-0.46	-5.03	-0.31	9.85e-7	Vitiligo;
SARC	cis	rs7937682	0.632	rs11214037	chr11:111773296	C/T	cg22437258	chr11:111473054	SIK2	-0.49	-5.61	-0.34	5.78e-8	Primary sclerosing cholangitis;
SARC	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg25072359	chr17:41440525	NA	0.52	6.55	0.39	3.71e-10	Menopause (age at onset);
SARC	cis	rs7917772	0.536	rs4919667	chr10:104426011	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.56	-6.77	-0.41	1.05e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs3126085	0.935	rs1390488	chr1:152199500	T/C	cg26876637	chr1:152193138	HRNR	0.44	5.11	0.32	6.62e-7	Atopic dermatitis;
SARC	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg24250549	chr1:154909240	PMVK	0.74	9.94	0.55	1.25e-19	Prostate cancer;
SARC	trans	rs3780486	0.846	rs7865745	chr9:33140976	A/G	cg20290983	chr6:43655470	MRPS18A	-1.14	-22.8	-0.83	2.92e-61	IgG glycosylation;
SARC	cis	rs916888	0.647	rs199524	chr17:44848438	G/T	cg01570182	chr17:44337453	NA	-0.66	-7.51	-0.44	1.25e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs2228479	0.867	rs12930606	chr16:89946682	A/G	cg06558623	chr16:89946397	TCF25	0.98	8.13	0.47	2.6e-14	Skin colour saturation;
SARC	cis	rs1322639	0.614	rs9689800	chr6:169572945	T/A	cg03254818	chr6:169586852	NA	-0.4	-5.1	-0.32	6.9e-7	Pulse pressure;
SARC	cis	rs7598759	0.712	rs6727372	chr2:232331906	T/G	cg19187155	chr2:232395269	NMUR1	0.6	8.52	0.49	2e-15	Noise-induced hearing loss;
SARC	cis	rs6493487	0.512	rs28642856	chr15:51245680	T/C	cg02338191	chr15:51200825	AP4E1	0.53	4.91	0.31	1.73e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs4974559	1.000	rs1882099	chr4:1352685	A/G	cg02980000	chr4:1222292	CTBP1	0.58	5.55	0.34	7.66e-8	Systolic blood pressure;
SARC	cis	rs1215050	0.791	rs165241	chr4:98681112	C/T	cg05340658	chr4:99064831	C4orf37	0.43	5.77	0.35	2.56e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs12824058	0.831	rs12314111	chr12:130813663	G/T	cg23887609	chr12:130822674	PIWIL1	0.37	5.13	0.32	6.23e-7	Menopause (age at onset);
SARC	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-5.73	-0.35	3.13e-8	Bipolar disorder;
SARC	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg05861140	chr6:150128134	PCMT1	-0.37	-4.84	-0.3	2.32e-6	Lung cancer;
SARC	cis	rs28386778	0.703	rs2286565	chr17:62010232	G/T	cg26338869	chr17:61819248	STRADA	-0.6	-7.37	-0.43	2.93e-12	Prudent dietary pattern;
SARC	trans	rs1814175	0.645	rs28839231	chr11:50044292	G/T	cg03929089	chr4:120376271	NA	-0.81	-11.64	-0.61	5.33e-25	Height;
SARC	cis	rs10870270	1.000	rs7077744	chr10:133770201	C/T	cg26149184	chr10:133730230	NA	0.46	5.02	0.31	1.05e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs4803468	1.000	rs878083	chr19:41897688	G/A	cg08477640	chr19:41863820	B9D2	0.49	6.43	0.39	7.22e-10	Height;
SARC	cis	rs735539	0.521	rs2818992	chr13:21398087	G/A	cg16922012	chr13:21400325	XPO4	-0.44	-6.07	-0.37	5.06e-9	Dental caries;
SARC	cis	rs1059312	0.808	rs4482069	chr12:129294252	G/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.49	7.2	0.43	8.31e-12	Systemic lupus erythematosus;
SARC	cis	rs2712184	0.967	rs11892032	chr2:217668981	G/A	cg05032264	chr2:217675019	NA	-0.63	-8.61	-0.49	1.14e-15	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
SARC	cis	rs648044	0.520	rs500629	chr11:114045560	G/T	cg01914181	chr11:114070210	ZBTB16	0.36	4.9	0.31	1.79e-6	Non-glioblastoma glioma;
SARC	cis	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg03213289	chr20:61660250	NA	0.46	6.43	0.39	7.22e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs9916302	0.706	rs9891892	chr17:37479856	A/C	cg07936489	chr17:37558343	FBXL20	0.76	9.22	0.52	1.85e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg00684032	chr4:1343700	KIAA1530	0.34	4.89	0.3	1.9e-6	Obesity-related traits;
SARC	cis	rs1635	0.655	rs60698636	chr6:28316045	A/G	cg15743358	chr6:28303923	ZNF323	-0.73	-4.87	-0.3	2.06e-6	Schizophrenia;
SARC	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg12000995	chr2:27665139	KRTCAP3	0.3	4.76	0.3	3.44e-6	Total body bone mineral density;
SARC	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg11987759	chr7:65425863	GUSB	0.47	5.73	0.35	3.15e-8	Aortic root size;
SARC	trans	rs2727020	0.734	rs1164663	chr11:49294723	A/T	cg03929089	chr4:120376271	NA	0.7	8.03	0.47	4.72e-14	Coronary artery disease;
SARC	cis	rs9322817	0.691	rs6929746	chr6:105167548	G/C	cg02098413	chr6:105308735	HACE1	-0.4	-6.28	-0.38	1.68e-9	Thyroid stimulating hormone;
SARC	cis	rs818427	0.964	rs151976	chr5:112236448	C/T	cg07820702	chr5:112228657	REEP5	-0.48	-5.2	-0.32	4.35e-7	Total body bone mineral density;
SARC	cis	rs2230307	0.518	rs12046458	chr1:100703069	C/T	cg24955406	chr1:100503596	HIAT1	-0.76	-7.17	-0.43	9.73e-12	Carotid intima media thickness;
SARC	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg27170947	chr2:26402098	FAM59B	0.37	4.8	0.3	2.79e-6	Gut microbiome composition (summer);
SARC	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg08219700	chr8:58056026	NA	0.62	6.52	0.39	4.28e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg12463550	chr7:65579703	CRCP	0.53	5.72	0.35	3.29e-8	Aortic root size;
SARC	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.68	7.44	0.44	1.97e-12	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs240764	0.697	rs239199	chr6:101134108	C/T	cg09795085	chr6:101329169	ASCC3	0.38	4.83	0.3	2.47e-6	Neuroticism;
SARC	cis	rs2576037	0.899	rs2246877	chr18:44577005	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.57	7.32	0.43	3.96e-12	Personality dimensions;
SARC	cis	rs7412746	0.658	rs7528773	chr1:150915875	G/A	cg13175981	chr1:150552382	MCL1	-0.48	-5.86	-0.36	1.57e-8	Melanoma;
SARC	cis	rs5167	0.525	rs10402642	chr19:45453878	G/A	cg09555818	chr19:45449301	APOC2	0.55	8.91	0.5	1.47e-16	Blood protein levels;
SARC	cis	rs10911251	0.528	rs10911255	chr1:183088868	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.1	0.55	4.11e-20	Colorectal cancer;
SARC	cis	rs6121246	0.559	rs6087782	chr20:30391580	C/T	cg13852791	chr20:30311386	BCL2L1	0.87	10.91	0.58	1.14e-22	Mean corpuscular hemoglobin;
SARC	cis	rs7726839	0.794	rs6883536	chr5:599274	G/A	cg16447950	chr5:562315	NA	-0.43	-4.95	-0.31	1.4e-6	Obesity-related traits;
SARC	cis	rs11122272	0.735	rs2749714	chr1:231538634	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.04	-0.55	6e-20	Hemoglobin concentration;
SARC	cis	rs72945132	0.714	rs57320340	chr11:70160010	G/C	cg05964544	chr11:70165517	PPFIA1	-0.61	-5.87	-0.36	1.5e-8	Coronary artery disease;
SARC	cis	rs921968	0.643	rs484085	chr2:219396684	C/T	cg02176678	chr2:219576539	TTLL4	0.36	5.61	0.34	5.83e-8	Mean corpuscular hemoglobin concentration;
SARC	cis	rs9814567	0.752	rs7633868	chr3:134331048	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.51	-6.61	-0.4	2.53e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs7647973	0.593	rs28535523	chr3:49848414	C/T	cg07636037	chr3:49044803	WDR6	-0.63	-6.43	-0.39	7.01e-10	Menarche (age at onset);
SARC	cis	rs12142240	0.698	rs17361812	chr1:46814008	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-5.46	-0.34	1.22e-7	Menopause (age at onset);
SARC	cis	rs9398803	0.687	rs1826189	chr6:126922214	C/T	cg20229609	chr6:126660872	C6orf173	0.37	5.39	0.33	1.74e-7	Male-pattern baldness;
SARC	cis	rs3091242	0.933	rs9645452	chr1:25668326	C/T	cg02931644	chr1:25747376	RHCE	-0.48	-8.07	-0.47	3.67e-14	Erythrocyte sedimentation rate;
SARC	cis	rs4889855	0.530	rs12603265	chr17:78618637	A/G	cg17956530	chr17:78667699	RPTOR	-0.46	-5.31	-0.33	2.58e-7	Fractional excretion of uric acid;
SARC	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg18404041	chr3:52824283	ITIH1	-0.41	-6.21	-0.38	2.38e-9	Bipolar disorder;
SARC	cis	rs546131	0.890	rs496558	chr11:34826425	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.5	6.49	0.39	5.11e-10	Lung disease severity in cystic fibrosis;
SARC	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg05025164	chr4:1340916	KIAA1530	0.49	5.98	0.36	8.34e-9	Longevity;
SARC	cis	rs4430311	0.723	rs11586029	chr1:243910067	C/T	cg21452805	chr1:244014465	NA	-0.41	-5.35	-0.33	2.1e-7	Post-traumatic stress disorder (asjusted for relatedness);
SARC	cis	rs7644634	0.649	rs2244737	chr3:105411449	A/G	cg23051926	chr3:105466016	CBLB	0.45	5.68	0.35	3.93e-8	Itch intensity from mosquito bite;
SARC	cis	rs9715521	0.868	rs12650159	chr4:59818550	C/T	cg11281224	chr4:60001000	NA	-0.38	-4.76	-0.3	3.38e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg18225595	chr11:63971243	STIP1	0.45	5.43	0.34	1.38e-7	Mean platelet volume;
SARC	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg09455208	chr3:40491958	NA	0.39	6.24	0.38	2.07e-9	Renal cell carcinoma;
SARC	cis	rs1801251	1.000	rs13013142	chr2:233600606	A/G	cg25237894	chr2:233734115	C2orf82	0.38	4.96	0.31	1.39e-6	Coronary artery disease;
SARC	cis	rs10771431	0.597	rs10771413	chr12:9354413	C/T	cg08997352	chr12:9597637	DDX12	-0.55	-7.51	-0.44	1.29e-12	Breast size;
SARC	cis	rs1008375	1.000	rs28552744	chr4:17620165	A/G	cg16339924	chr4:17578868	LAP3	0.66	8.56	0.49	1.59e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs959260	0.557	rs55762977	chr17:73309338	A/G	cg14668889	chr17:73230827	NUP85	0.59	7.53	0.44	1.14e-12	Systemic lupus erythematosus;
SARC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.65	0.53	9.21e-19	Prudent dietary pattern;
SARC	cis	rs35110281	0.748	rs162403	chr21:44963365	C/G	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.08	-0.37	4.98e-9	Mean corpuscular volume;
SARC	cis	rs2502731	0.539	rs3003610	chr9:130985525	G/A	cg13642260	chr9:130955380	CIZ1	0.37	5.05	0.31	9.1e-7	Attention deficit hyperactivity disorder;
SARC	cis	rs6964587	0.839	rs12536702	chr7:91471576	G/C	cg17063962	chr7:91808500	NA	0.8	11.32	0.6	5.78e-24	Breast cancer;
SARC	cis	rs3820928	0.839	rs35068645	chr2:227844265	T/C	cg05526886	chr2:227700861	RHBDD1	-0.56	-6.73	-0.4	1.3100000000000001e-10	Pulmonary function;
SARC	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg04267008	chr7:1944627	MAD1L1	-0.5	-5.7	-0.35	3.69e-8	Schizophrenia;
SARC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.22	0.81	2.28e-56	Prudent dietary pattern;
SARC	cis	rs7597155	0.846	rs6705820	chr2:69973737	C/T	cg02498382	chr2:70120550	SNRNP27	-0.35	-6.06	-0.37	5.55e-9	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg07157834	chr1:205819609	PM20D1	0.83	14.4	0.69	4.63e-34	Menarche (age at onset);
SARC	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg03806693	chr22:41940476	POLR3H	-0.87	-11.95	-0.62	5.34e-26	Vitiligo;
SARC	cis	rs9300255	0.602	rs4372492	chr12:123697357	T/C	cg05973401	chr12:123451056	ABCB9	0.52	5.89	0.36	1.34e-8	Neutrophil percentage of white cells;
SARC	cis	rs9473924	0.505	rs34793301	chr6:50859462	G/T	cg14470998	chr6:50812995	TFAP2B	0.74	6.48	0.39	5.53e-10	Body mass index;
SARC	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-5.62	-0.35	5.49e-8	Bipolar disorder;
SARC	cis	rs17209837	1.000	rs4148814	chr7:87091543	T/C	cg00919237	chr7:87102261	ABCB4	-0.47	-4.96	-0.31	1.38e-6	Gallbladder cancer;
SARC	cis	rs8180040	1.000	rs553989	chr3:47400328	A/G	cg27129171	chr3:47204927	SETD2	-0.68	-9.69	-0.54	7.24e-19	Colorectal cancer;
SARC	cis	rs829883	0.763	rs249843	chr12:98870987	G/A	cg25150519	chr12:98850993	NA	0.85	13.57	0.66	2.6e-31	Colorectal adenoma (advanced);
SARC	cis	rs4481887	0.927	rs4244185	chr1:248486913	A/G	cg00666640	chr1:248458726	OR2T12	0.38	6.17	0.37	2.94e-9	Common traits (Other);
SARC	cis	rs11155671	0.530	rs9383914	chr6:150207234	T/G	cg05036130	chr6:150231994	NA	0.29	5.05	0.31	8.9e-7	Testicular germ cell tumor;
SARC	cis	rs950776	0.518	rs4886572	chr15:78837452	A/G	cg17108064	chr15:78857060	CHRNA5	-0.28	-4.72	-0.3	3.98e-6	Sudden cardiac arrest;
SARC	cis	rs9399135	0.967	rs7741515	chr6:135374368	C/G	cg24558204	chr6:135376177	HBS1L	-0.45	-5.94	-0.36	1.02e-8	Red blood cell count;
SARC	trans	rs10506458	0.915	rs1009540	chr12:63414872	C/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.72	-6.65	-0.4	2.02e-10	Hemostatic factors and hematological phenotypes;
SARC	cis	rs7843479	0.526	rs34802507	chr8:21773853	C/T	cg17168535	chr8:21777572	XPO7	0.8	11.18	0.59	1.63e-23	Mean corpuscular volume;
SARC	cis	rs11786130	1.000	rs11786130	chr8:129004975	G/A	cg01765152	chr8:129005526	PVT1	-0.5	-8.32	-0.48	7.38e-15	Eosinophil counts;Sum eosinophil basophil counts;
SARC	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg18876405	chr7:65276391	NA	0.7	8.7	0.5	6.12e-16	Aortic root size;
SARC	cis	rs9303401	0.659	rs34818467	chr17:56643109	C/T	cg25039879	chr17:56429692	SUPT4H1	-0.59	-5.93	-0.36	1.08e-8	Cognitive test performance;
SARC	cis	rs2153535	0.541	rs4637688	chr6:8446501	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.1	0.59	2.96e-23	Motion sickness;
SARC	cis	rs4713675	0.584	rs942643	chr6:33668370	A/G	cg15676125	chr6:33679581	C6orf125	0.5	6.22	0.38	2.3e-9	Plateletcrit;
SARC	cis	rs11864453	0.647	rs2550035	chr16:72113416	C/G	cg16558253	chr16:72132732	DHX38	-0.52	-8.39	-0.48	4.64e-15	Fibrinogen levels;
SARC	cis	rs6840360	0.571	rs718801	chr4:152549247	C/T	cg22705602	chr4:152727874	NA	-0.44	-6.75	-0.4	1.15e-10	Intelligence (multi-trait analysis);
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg00235313	chr5:54749496	PPAP2A	-0.5	-6.47	-0.39	5.71e-10	Alcohol dependence;
SARC	cis	rs25645	0.800	rs11078935	chr17:38192137	T/G	cg17467752	chr17:38218738	THRA	-0.46	-5.89	-0.36	1.38e-8	Myeloid white cell count;
SARC	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg21724239	chr8:58056113	NA	0.75	6.81	0.41	7.99e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs7512552	1.000	rs7512552	chr1:150265704	T/C	cg15654264	chr1:150340011	RPRD2	-0.37	-4.87	-0.3	2.01e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs11155671	0.530	rs4869764	chr6:150211828	T/C	cg09699651	chr6:150184138	LRP11	0.52	6.59	0.4	2.86e-10	Testicular germ cell tumor;
SARC	cis	rs4356203	0.905	rs7478986	chr11:17131249	T/C	cg15432903	chr11:17409602	KCNJ11	-0.31	-4.96	-0.31	1.37e-6	Schizophrenia;Schizophrenia or bipolar disorder;
SARC	cis	rs4690686	0.500	rs12498564	chr4:177264827	T/C	cg17059388	chr4:177262070	NA	0.37	4.81	0.3	2.76e-6	Essential tremor;
SARC	cis	rs2230307	0.656	rs568089	chr1:100495392	A/G	cg24955406	chr1:100503596	HIAT1	0.72	5.47	0.34	1.13e-7	Carotid intima media thickness;
SARC	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg04772025	chr11:68637568	NA	0.58	7.0	0.42	2.78e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9916302	0.808	rs6503515	chr17:37606433	G/T	cg00129232	chr17:37814104	STARD3	-0.63	-7.8	-0.46	2.06e-13	Glomerular filtration rate (creatinine);
SARC	trans	rs6815916	1.000	rs59679048	chr4:182554820	G/C	cg13864546	chr1:2310327	MORN1	0.68	6.36	0.38	1.05e-9	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs11608355	1.000	rs10774690	chr12:109859682	G/A	cg19025524	chr12:109796872	NA	-0.4	-5.06	-0.31	8.4e-7	Neuroticism;
SARC	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg00684032	chr4:1343700	KIAA1530	0.38	5.41	0.33	1.57e-7	Obesity-related traits;
SARC	cis	rs76419734	1.000	rs11727745	chr4:106716527	T/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	5.5	0.34	9.92e-8	Post bronchodilator FEV1;
SARC	cis	rs2075371	1.000	rs2598291	chr7:133988313	C/G	cg20476274	chr7:133979776	SLC35B4	0.61	8.16	0.47	2.07e-14	Mean platelet volume;
SARC	cis	rs2718058	0.519	rs2722233	chr7:37875982	A/T	cg24998770	chr7:37888106	TXNDC3	0.37	5.59	0.34	6.38e-8	Alzheimer's disease (late onset);
SARC	cis	rs763121	0.785	rs5757199	chr22:39040617	T/G	cg21395723	chr22:39101663	GTPBP1	0.58	6.67	0.4	1.85e-10	Menopause (age at onset);
SARC	cis	rs7587476	0.601	rs1129804	chr2:215674323	C/G	cg04530015	chr2:215796436	ABCA12	0.45	7.54	0.44	1.01e-12	Neuroblastoma;
SARC	cis	rs8180040	0.620	rs17784127	chr3:47061700	T/C	cg27129171	chr3:47204927	SETD2	-0.68	-9.25	-0.52	1.5e-17	Colorectal cancer;
SARC	cis	rs73086581	1.000	rs56324992	chr20:3978153	C/A	cg02187196	chr20:3869020	PANK2	0.57	5.55	0.34	7.65e-8	Response to antidepressants in depression;
SARC	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg10207240	chr12:122356781	WDR66	0.36	6.08	0.37	4.98e-9	Mean corpuscular volume;
SARC	cis	rs1468333	1.000	rs17171772	chr5:137514853	A/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.8	11.22	0.59	1.18e-23	Resting heart rate;
SARC	cis	rs4919694	0.611	rs76695159	chr10:105070837	C/T	cg04362960	chr10:104952993	NT5C2	0.64	4.92	0.31	1.65e-6	Arsenic metabolism;
SARC	cis	rs611744	0.837	rs438191	chr8:109124222	A/G	cg21045802	chr8:109455806	TTC35	0.41	4.86	0.3	2.21e-6	Dupuytren's disease;
SARC	cis	rs763121	0.853	rs138706	chr22:39137834	C/G	cg21395723	chr22:39101663	GTPBP1	0.56	6.7	0.4	1.58e-10	Menopause (age at onset);
SARC	cis	rs9486715	1.000	rs6905568	chr6:97066382	T/C	cg18709589	chr6:96969512	KIAA0776	-0.59	-7.34	-0.43	3.61e-12	Headache;
SARC	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.92	10.24	0.56	1.46e-20	Platelet count;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	ch.21.551389R	chr21:40575736	BRWD1	-0.46	-6.43	-0.39	7.1e-10	Thyroid stimulating hormone;
SARC	cis	rs7659604	1.000	rs28618203	chr4:122663935	T/C	cg19671926	chr4:122722719	EXOSC9	-0.47	-5.65	-0.35	4.62e-8	Type 2 diabetes;
SARC	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-7.61	-0.45	6.63e-13	Chronic sinus infection;
SARC	cis	rs12579753	0.956	rs7959951	chr12:82231132	T/C	cg07988820	chr12:82153109	PPFIA2	-0.52	-6.07	-0.37	5.24e-9	Resting heart rate;
SARC	cis	rs4319547	0.615	rs2341439	chr12:122848096	C/G	cg23029597	chr12:123009494	RSRC2	-0.45	-5.84	-0.36	1.74e-8	Body mass index;
SARC	cis	rs1153858	1.000	rs56806728	chr15:45637814	A/G	cg21132104	chr15:45694354	SPATA5L1	0.78	11.03	0.59	4.99e-23	Homoarginine levels;
SARC	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	5.96	0.36	9.05e-9	Height;
SARC	cis	rs9303401	1.000	rs7218362	chr17:56888299	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.66	7.77	0.45	2.53e-13	Cognitive test performance;
SARC	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg02951883	chr7:2050386	MAD1L1	-0.39	-5.04	-0.31	9.38e-7	Schizophrenia;
SARC	cis	rs35110281	0.667	rs2250773	chr21:45087786	T/C	cg04455712	chr21:45112962	RRP1B	0.34	4.9	0.31	1.78e-6	Mean corpuscular volume;
SARC	cis	rs1008375	1.000	rs6449323	chr4:17683916	A/T	cg16339924	chr4:17578868	LAP3	0.66	8.36	0.48	5.61e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2180341	0.521	rs12203812	chr6:127617816	A/T	cg24812749	chr6:127587940	RNF146	0.48	5.61	0.34	5.79e-8	Breast cancer;
SARC	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg16606324	chr3:10149918	C3orf24	0.49	5.04	0.31	9.35e-7	Alzheimer's disease;
SARC	cis	rs922107	0.738	rs922106	chr1:90025519	C/A	cg15422784	chr1:90023713	LRRC8B	-0.32	-4.75	-0.3	3.56e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
SARC	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg23188684	chr11:67383651	NA	0.48	6.93	0.41	4.15e-11	Mean corpuscular volume;
SARC	cis	rs9790314	0.663	rs796609	chr3:160705600	C/G	cg04691961	chr3:161091175	C3orf57	-0.57	-7.72	-0.45	3.4e-13	Morning vs. evening chronotype;
SARC	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg15049968	chr18:44337910	ST8SIA5	-0.37	-5.84	-0.36	1.71e-8	Personality dimensions;
SARC	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg05025164	chr4:1340916	KIAA1530	-0.69	-8.26	-0.48	1.09e-14	Obesity-related traits;
SARC	cis	rs820218	0.886	rs2165635	chr17:73663296	C/A	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.7	9.64	0.53	9.89e-19	Rotator cuff tears;
SARC	cis	rs239198	0.568	rs9404059	chr6:101331497	T/C	cg09795085	chr6:101329169	ASCC3	0.45	5.68	0.35	4.07e-8	Menarche (age at onset);
SARC	cis	rs9486715	0.867	rs4839828	chr6:96863326	G/A	cg06623918	chr6:96969491	KIAA0776	0.88	12.7	0.64	1.95e-28	Headache;
SARC	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg05896524	chr21:47604654	C21orf56	-0.59	-7.2	-0.43	8.32e-12	Testicular germ cell tumor;
SARC	cis	rs7208859	0.673	rs9895684	chr17:29242600	G/A	cg13385521	chr17:29058706	SUZ12P	0.9	7.14	0.42	1.15e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs6840360	1.000	rs6818667	chr4:152598698	T/C	cg22705602	chr4:152727874	NA	-0.38	-6.51	-0.39	4.49e-10	Intelligence (multi-trait analysis);
SARC	trans	rs9329221	0.506	rs17689674	chr8:9981854	C/A	cg06636001	chr8:8085503	FLJ10661	0.56	7.9	0.46	1.1e-13	Neuroticism;
SARC	cis	rs2016266	1.000	rs2016266	chr12:53727955	A/G	cg26875137	chr12:53738046	NA	-0.38	-5.35	-0.33	2.09e-7	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs7635838	0.892	rs34830847	chr3:11437798	A/C	cg00170343	chr3:11313890	ATG7	0.61	8.29	0.48	8.94e-15	HDL cholesterol;
SARC	cis	rs9948	0.655	rs62156216	chr2:97405127	C/T	cg01990225	chr2:97406019	LMAN2L	-0.94	-6.38	-0.39	9.49e-10	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs4660306	0.614	rs781057	chr1:45936017	C/G	cg24296786	chr1:45957014	TESK2	-0.56	-5.58	-0.34	6.68e-8	Homocysteine levels;
SARC	cis	rs17376456	0.877	rs10476526	chr5:93461916	G/A	cg21475434	chr5:93447410	FAM172A	0.88	8.11	0.47	2.81e-14	Diabetic retinopathy;
SARC	cis	rs9300255	0.544	rs1727309	chr12:123658258	A/G	cg05973401	chr12:123451056	ABCB9	0.55	5.23	0.32	3.73e-7	Neutrophil percentage of white cells;
SARC	trans	rs16964211	0.702	rs12439794	chr15:51576638	A/G	cg09074755	chr12:29650711	OVCH1	-1.22	-6.59	-0.4	2.84e-10	Height;
SARC	cis	rs7644634	0.661	rs2399055	chr3:105470758	T/C	cg23051926	chr3:105466016	CBLB	0.45	5.7	0.35	3.67e-8	Itch intensity from mosquito bite;
SARC	cis	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg05623727	chr3:50126028	RBM5	-0.34	-5.19	-0.32	4.56e-7	Intelligence (multi-trait analysis);
SARC	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg19346786	chr7:2764209	NA	-0.33	-4.81	-0.3	2.75e-6	Height;
SARC	cis	rs2075371	0.796	rs1646644	chr7:134011817	A/T	cg00033643	chr7:134001901	SLC35B4	0.52	6.43	0.39	7.09e-10	Mean platelet volume;
SARC	cis	rs9517320	0.515	rs72646416	chr13:99232916	C/G	cg07423050	chr13:99094983	FARP1	-0.4	-5.02	-0.31	1e-6	Longevity;
SARC	cis	rs9381040	0.655	rs2294696	chr6:41036988	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	0.48	5.64	0.35	4.98e-8	Alzheimer's disease (late onset);
SARC	cis	rs10876993	0.890	rs115106209	chr12:58059331	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.47	-5.91	-0.36	1.22e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs9486719	0.857	rs4346856	chr6:96880270	C/T	cg06623918	chr6:96969491	KIAA0776	0.75	8.76	0.5	4.17e-16	Migraine;Coronary artery disease;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg01443832	chr7:29725145	LOC646762	-0.53	-6.71	-0.4	1.47e-10	Schizophrenia;
SARC	cis	rs2204008	0.653	rs11182569	chr12:38572452	G/A	cg26384229	chr12:38710491	ALG10B	0.89	13.34	0.66	1.5e-30	Bladder cancer;
SARC	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.56	-6.61	-0.4	2.66e-10	Renal function-related traits (BUN);
SARC	cis	rs11785400	0.963	rs9771845	chr8:143726577	C/G	cg10596483	chr8:143751796	JRK	0.64	8.46	0.48	2.97e-15	Schizophrenia;
SARC	cis	rs1552244	0.882	rs56125067	chr3:9984130	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	8.87	0.5	1.96e-16	Alzheimer's disease;
SARC	cis	rs9612	0.948	rs189408	chr19:44268006	T/C	cg08581076	chr19:44259116	C19orf61	0.61	7.32	0.43	4.1e-12	Exhaled nitric oxide output;
SARC	cis	rs11648796	0.757	rs6600231	chr16:766485	A/G	cg04709771	chr16:646395	RAB40C	-0.39	-5.09	-0.32	7.47e-7	Height;
SARC	cis	rs7000551	0.505	rs4872499	chr8:22293306	A/G	cg12081754	chr8:22256438	SLC39A14	-0.8	-10.01	-0.55	7.59e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg11987759	chr7:65425863	GUSB	0.5	6.21	0.38	2.36e-9	Aortic root size;
SARC	cis	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg12463550	chr7:65579703	CRCP	0.69	5.23	0.32	3.81e-7	Diabetic kidney disease;
SARC	cis	rs6500395	0.926	rs1039343	chr16:48577507	T/G	cg04672837	chr16:48644449	N4BP1	0.46	6.06	0.37	5.55e-9	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs2380220	0.678	rs4308568	chr6:96009525	A/C	cg07718321	chr6:96025334	MANEA	-0.47	-5.22	-0.32	3.87e-7	Behavioural disinhibition (generation interaction);
SARC	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg12373951	chr3:133503437	NA	-0.37	-5.43	-0.33	1.45e-7	Iron status biomarkers;
SARC	cis	rs11168187	0.843	rs6580636	chr12:48116633	G/C	cg12761788	chr12:48120090	P11	0.36	4.76	0.3	3.43e-6	Vertical cup-disc ratio;
SARC	cis	rs611744	0.647	rs11774904	chr8:109273435	G/A	cg21045802	chr8:109455806	TTC35	0.58	7.42	0.44	2.22e-12	Dupuytren's disease;
SARC	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg22535103	chr8:58192502	C8orf71	-0.67	-5.71	-0.35	3.5e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9462027	0.628	rs2395604	chr6:34787976	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-6.0	-0.37	7.61e-9	Systemic lupus erythematosus;
SARC	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg12463550	chr7:65579703	CRCP	0.43	5.02	0.31	1.01e-6	Aortic root size;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04446467	chr19:1580629	MBD3	0.51	6.44	0.39	6.89e-10	Smoking initiation;
SARC	cis	rs9325144	0.555	rs1813392	chr12:38692203	C/T	cg13010199	chr12:38710504	ALG10B	-0.58	-7.79	-0.45	2.17e-13	Morning vs. evening chronotype;
SARC	trans	rs36093844	0.800	rs78681528	chr11:85588156	T/G	cg27065003	chr5:122429449	PRDM6	-0.55	-6.54	-0.39	3.91e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs447735	0.587	rs11640702	chr16:89729169	A/G	cg03605463	chr16:89740564	NA	-0.39	-5.26	-0.33	3.3e-7	Hemoglobin concentration;
SARC	cis	rs6484504	0.553	rs2183484	chr11:31259370	G/A	cg26647111	chr11:31128758	NA	-0.39	-5.1	-0.32	6.91e-7	Red blood cell count;
SARC	cis	rs6867032	0.876	rs1552435	chr5:2018378	A/G	cg26168224	chr5:2018326	NA	0.93	16.34	0.73	1.62e-40	Gut microbiome composition (winter);
SARC	cis	rs2011503	1.000	rs77254326	chr19:19626781	T/G	cg03709012	chr19:19516395	GATAD2A	0.6	5.29	0.33	2.8e-7	Bipolar disorder;
SARC	cis	rs6733011	0.538	rs10175560	chr2:99465418	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-5.37	-0.33	1.92e-7	Bipolar disorder;
SARC	cis	rs9916302	0.904	rs588193	chr17:37440439	A/C	cg15445000	chr17:37608096	MED1	-0.41	-5.08	-0.32	7.88e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs10875746	0.903	rs12301339	chr12:48475233	T/C	cg26205652	chr12:48591994	NA	0.56	6.05	0.37	5.72e-9	Longevity (90 years and older);
SARC	cis	rs10140922	0.966	rs8003074	chr14:35821692	A/C	cg26967526	chr14:35346199	BAZ1A	-0.39	-4.92	-0.31	1.62e-6	Hip circumference adjusted for BMI;
SARC	cis	rs1801251	1.000	rs1947105	chr2:233721455	A/G	cg25237894	chr2:233734115	C2orf82	0.38	4.92	0.31	1.63e-6	Coronary artery disease;
SARC	cis	rs4148883	0.504	rs2000864	chr4:100123776	A/C	cg13256891	chr4:100009986	ADH5	0.52	6.93	0.41	4.17e-11	Alcohol dependence;
SARC	cis	rs12701220	0.503	rs12702024	chr7:1129820	G/C	cg02733842	chr7:1102375	C7orf50	-0.56	-6.58	-0.4	3.07e-10	Bronchopulmonary dysplasia;
SARC	cis	rs9902453	0.904	rs4547389	chr17:28364768	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.16	-0.42	1.02e-11	Coffee consumption (cups per day);
SARC	cis	rs72627509	0.904	rs58408429	chr4:57769824	T/C	cg26694713	chr4:57773883	REST	0.64	6.46	0.39	6.04e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs6582630	0.539	rs8189604	chr12:38308546	G/T	cg13010199	chr12:38710504	ALG10B	-0.53	-6.37	-0.39	9.86e-10	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg04772025	chr11:68637568	NA	0.55	7.0	0.42	2.72e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs17095355	1.000	rs11194923	chr10:111695762	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.41	-4.74	-0.3	3.74e-6	Biliary atresia;
SARC	cis	rs6665290	0.904	rs1045287	chr1:227178962	C/T	cg10327440	chr1:227177885	CDC42BPA	1.06	25.92	0.86	1.41e-70	Myeloid white cell count;
SARC	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg23262073	chr20:60523788	NA	0.58	8.33	0.48	7.13e-15	Obesity-related traits;
SARC	cis	rs950776	0.518	rs12906284	chr15:78825105	C/T	cg17108064	chr15:78857060	CHRNA5	0.29	4.93	0.31	1.56e-6	Sudden cardiac arrest;
SARC	cis	rs2760061	0.655	rs686533	chr1:228119604	A/G	cg02753203	chr1:228287806	NA	-0.58	-8.29	-0.48	8.83e-15	Diastolic blood pressure;
SARC	cis	rs7667	0.959	rs6662273	chr1:19740823	A/C	cg15311933	chr1:19638897	PQLC2;AKR7A2	0.45	5.43	0.34	1.42e-7	Crohn's disease and psoriasis;
SARC	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg13770153	chr20:60521292	NA	-0.52	-7.4	-0.44	2.47e-12	Body mass index;
SARC	cis	rs6912958	0.535	rs1753153	chr6:88032834	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.75	11.05	0.59	4.37e-23	Monocyte percentage of white cells;
SARC	cis	rs7949030	0.754	rs36104523	chr11:62395740	A/T	cg11742103	chr11:62369870	EML3;MTA2	-0.4	-5.87	-0.36	1.46e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs981844	0.601	rs1337	chr4:154631587	C/G	cg14289246	chr4:154710475	SFRP2	0.51	5.06	0.31	8.58e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs929354	0.772	rs1182448	chr7:157021415	G/A	cg05182265	chr7:156933206	UBE3C	0.32	4.82	0.3	2.59e-6	Body mass index;
SARC	cis	rs2033732	0.954	rs1550215	chr8:85093121	A/C	cg05716166	chr8:85095498	RALYL	0.56	6.45	0.39	6.53e-10	Body mass index;
SARC	cis	rs142518269	1	rs142518269	chr2:24087095	G/A	cg08917208	chr2:24149416	ATAD2B	0.91	8.94	0.51	1.26e-16	Mean corpuscular hemoglobin;
SARC	cis	rs8077889	0.871	rs72836549	chr17:41904360	G/T	cg26893861	chr17:41843967	DUSP3	0.92	11.34	0.6	4.92e-24	Triglycerides;
SARC	cis	rs6089584	0.546	rs6089308	chr20:60583529	C/T	cg23262073	chr20:60523788	NA	-0.36	-5.51	-0.34	9.36e-8	Body mass index;
SARC	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.93	-0.51	1.28e-16	Alzheimer's disease;
SARC	cis	rs634534	0.622	rs531612	chr11:65705432	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.66	-8.58	-0.49	1.39e-15	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs2387326	0.672	rs12254264	chr10:129945519	C/T	cg16087940	chr10:129947807	NA	-0.45	-5.79	-0.35	2.31e-8	Select biomarker traits;
SARC	cis	rs2180341	1.000	rs9398838	chr6:127635285	C/T	cg24812749	chr6:127587940	RNF146	0.97	12.95	0.65	2.97e-29	Breast cancer;
SARC	trans	rs61931739	0.500	rs11053278	chr12:34555955	T/C	cg13010199	chr12:38710504	ALG10B	0.78	11.09	0.59	3.19e-23	Morning vs. evening chronotype;
SARC	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg07636037	chr3:49044803	WDR6	1.01	17.88	0.76	1.35e-45	Parkinson's disease;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg10131879	chr7:8011594	GLCCI1	0.43	6.32	0.38	1.35e-9	Thyroid stimulating hormone;
SARC	trans	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg07211511	chr3:129823064	LOC729375	-0.56	-6.45	-0.39	6.56e-10	Blood pressure (smoking interaction);
SARC	cis	rs10504229	0.593	rs113184543	chr8:58042950	A/G	cg21724239	chr8:58056113	NA	0.61	6.24	0.38	2.04e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg11890956	chr21:40555474	PSMG1	-0.68	-9.01	-0.51	7.5e-17	Menarche (age at onset);
SARC	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg05025164	chr4:1340916	KIAA1530	0.48	5.91	0.36	1.2e-8	Longevity;
SARC	cis	rs7786808	0.644	rs4909081	chr7:158200785	G/A	cg01191920	chr7:158217561	PTPRN2	-0.34	-5.75	-0.35	2.86e-8	Obesity-related traits;
SARC	cis	rs10752881	1.000	rs6424880	chr1:182986679	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.7	0.57	5.56e-22	Colorectal cancer;
SARC	trans	rs3758785	0.586	rs637114	chr11:94070685	C/G	cg14164380	chr15:48938775	FBN1	0.38	6.29	0.38	1.56e-9	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
SARC	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg18252515	chr7:66147081	NA	-0.53	-5.69	-0.35	3.86e-8	Aortic root size;
SARC	cis	rs8028182	0.636	rs8028277	chr15:75684085	A/G	cg20655648	chr15:75932815	IMP3	0.62	7.29	0.43	4.69e-12	Sudden cardiac arrest;
SARC	cis	rs11992162	0.573	rs13264994	chr8:11782759	G/A	cg02127589	chr8:12458309	NA	-0.32	-4.77	-0.3	3.26e-6	Monocyte count;
SARC	cis	rs10493773	1.000	rs10493773	chr1:86125753	C/T	cg17807903	chr1:86174739	ZNHIT6	0.49	7.03	0.42	2.28e-11	Urate levels in overweight individuals;
SARC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.51	6.29	0.38	1.52e-9	Lymphocyte counts;
SARC	cis	rs7089973	0.872	rs17092497	chr10:116612628	G/A	cg08188268	chr10:116634841	FAM160B1	0.36	5.71	0.35	3.51e-8	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg24549020	chr5:56110836	MAP3K1	0.53	4.77	0.3	3.2e-6	Type 2 diabetes;
SARC	cis	rs965469	0.948	rs6051769	chr20:3326438	G/A	cg25506879	chr20:3388711	C20orf194	-0.53	-5.46	-0.34	1.21e-7	IFN-related cytopenia;
SARC	cis	rs2721195	0.626	rs59464125	chr8:145857786	G/A	cg11211951	chr8:145729740	GPT	-0.51	-7.48	-0.44	1.5e-12	Age at first birth;
SARC	cis	rs883565	0.655	rs6599275	chr3:39050758	C/A	cg01426195	chr3:39028469	NA	-0.36	-5.26	-0.33	3.29e-7	Handedness;
SARC	cis	rs17376456	0.877	rs10076052	chr5:93317762	C/T	cg21475434	chr5:93447410	FAM172A	0.84	7.56	0.44	9.44e-13	Diabetic retinopathy;
SARC	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg04944784	chr2:26401820	FAM59B	-0.59	-7.88	-0.46	1.25e-13	Gut microbiome composition (summer);
SARC	cis	rs4851254	0.920	rs11123816	chr2:100783653	G/A	cg17356467	chr2:100759845	AFF3	0.3	5.01	0.31	1.06e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7772486	0.686	rs4896827	chr6:145953338	T/A	cg05220968	chr6:146057943	EPM2A	-0.28	-4.88	-0.3	1.93e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs66716358	0.744	rs10769036	chr11:44321508	C/A	cg16977035	chr11:44330474	ALX4	0.26	4.85	0.3	2.29e-6	Monobrow;
SARC	cis	rs9894429	0.682	rs7406360	chr17:79591545	G/A	cg18240062	chr17:79603768	NPLOC4	0.88	13.61	0.67	1.92e-31	Eye color traits;
SARC	cis	rs3762637	1.000	rs7626861	chr3:122155196	T/C	cg24169773	chr3:122142474	KPNA1	-0.55	-5.55	-0.34	7.73e-8	LDL cholesterol levels;
SARC	cis	rs709400	0.659	rs3825566	chr14:103852725	C/T	cg12935359	chr14:103987150	CKB	0.4	5.86	0.36	1.57e-8	Body mass index;
SARC	cis	rs4332037	0.950	rs11767515	chr7:1941051	C/T	cg23422044	chr7:1970798	MAD1L1	-0.46	-4.86	-0.3	2.19e-6	Bipolar disorder;
SARC	cis	rs10992471	0.603	rs6479422	chr9:95190694	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.26	-0.33	3.34e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs1355223	0.902	rs10501134	chr11:34749137	T/C	cg18508148	chr11:34937573	PDHX;APIP	-0.4	-5.07	-0.32	8.17e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs60752752	0.777	rs2916194	chr1:153355392	G/T	cg26882115	chr1:153603048	S100A1;S100A13	-0.66	-4.99	-0.31	1.18e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg18252515	chr7:66147081	NA	0.45	4.87	0.3	2.04e-6	Aortic root size;
SARC	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg04772025	chr11:68637568	NA	0.5	6.34	0.38	1.2e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg23806715	chr17:73775811	H3F3B	0.6	6.19	0.38	2.65e-9	Psoriasis;
SARC	cis	rs1538970	0.962	rs7544178	chr1:45819069	C/T	cg05343316	chr1:45956843	TESK2	0.67	7.77	0.45	2.45e-13	Platelet count;
SARC	cis	rs9916302	0.706	rs28482878	chr17:37497100	A/G	cg00129232	chr17:37814104	STARD3	0.53	5.7	0.35	3.69e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs9381040	0.655	rs2294696	chr6:41036988	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	0.49	5.75	0.35	2.78e-8	Alzheimer's disease (late onset);
SARC	cis	rs2991971	0.934	rs7903	chr1:45976472	G/C	cg24296786	chr1:45957014	TESK2	0.65	9.36	0.52	6.96e-18	High light scatter reticulocyte count;
SARC	cis	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg14019146	chr3:50243930	SLC38A3	-0.33	-5.04	-0.31	9.25e-7	Intelligence (multi-trait analysis);
SARC	cis	rs26232	0.521	rs67019105	chr5:102374163	T/A	cg23492399	chr5:102201601	PAM	-0.52	-5.62	-0.35	5.55e-8	Rheumatoid arthritis;
SARC	cis	rs9394841	0.667	rs71558769	chr6:41782107	T/C	cg08135965	chr6:41755394	TOMM6	0.6	6.3	0.38	1.46e-9	Mean corpuscular hemoglobin;Red cell distribution width;
SARC	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg00933542	chr6:150070202	PCMT1	0.3	5.06	0.31	8.36e-7	Lung cancer;
SARC	cis	rs9868809	0.505	rs9877685	chr3:48748588	C/T	cg03060546	chr3:49711283	APEH	-0.51	-4.75	-0.3	3.52e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs2658782	0.901	rs10466368	chr11:93229756	T/C	cg15737290	chr11:93063684	CCDC67	0.64	6.74	0.4	1.24e-10	Pulmonary function decline;
SARC	cis	rs11098499	0.863	rs7695620	chr4:120452776	G/A	cg24375607	chr4:120327624	NA	0.42	4.9	0.31	1.76e-6	Corneal astigmatism;
SARC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg05552183	chr6:42928497	GNMT	0.58	8.02	0.47	5.13e-14	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs9660992	0.624	rs72745217	chr1:205261482	C/G	cg00857998	chr1:205179979	DSTYK	0.43	4.99	0.31	1.2e-6	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs6582630	0.554	rs7299735	chr12:38450890	A/C	cg14851346	chr12:38532713	NA	-0.45	-5.4	-0.33	1.61e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs4319547	1.000	rs6489156	chr12:123100397	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.57	-6.78	-0.41	9.86e-11	Body mass index;
SARC	cis	rs72634258	0.842	rs6668846	chr1:8152102	C/G	cg00042356	chr1:8021962	PARK7	-0.65	-5.92	-0.36	1.17e-8	Inflammatory bowel disease;
SARC	cis	rs1267303	0.682	rs1886117	chr1:46964909	T/A	cg22795216	chr1:47078649	MOBKL2C	0.44	5.28	0.33	2.89e-7	Monobrow;
SARC	cis	rs11214589	0.905	rs12804573	chr11:113241726	G/A	cg14159747	chr11:113255604	NA	0.34	4.86	0.3	2.12e-6	Neuroticism;
SARC	cis	rs950169	1.000	rs1818950	chr15:84722521	A/G	cg17507749	chr15:85114479	UBE2QP1	0.76	9.16	0.51	2.82e-17	Schizophrenia;
SARC	cis	rs9462027	0.628	rs6925623	chr6:34800896	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-6.14	-0.37	3.58e-9	Systemic lupus erythematosus;
SARC	trans	rs12310956	0.532	rs1589903	chr12:33943019	C/T	cg26384229	chr12:38710491	ALG10B	0.85	12.42	0.63	1.6e-27	Morning vs. evening chronotype;
SARC	cis	rs6502050	0.761	rs62078754	chr17:80058666	C/T	cg19223190	chr17:80058835	NA	-0.46	-6.69	-0.4	1.65e-10	Life satisfaction;
SARC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg22903471	chr2:27725779	GCKR	-0.49	-7.42	-0.44	2.21e-12	Total body bone mineral density;
SARC	cis	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg14541582	chr5:601475	NA	-0.4	-4.91	-0.31	1.72e-6	Obesity-related traits;
SARC	cis	rs950776	0.714	rs615470	chr15:78885988	T/C	cg17108064	chr15:78857060	CHRNA5	-0.29	-4.92	-0.31	1.66e-6	Sudden cardiac arrest;
SARC	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg11764359	chr7:65958608	NA	-0.55	-6.32	-0.38	1.35e-9	Aortic root size;
SARC	cis	rs7647973	0.626	rs9829155	chr3:49817450	T/C	cg07636037	chr3:49044803	WDR6	-0.62	-6.31	-0.38	1.41e-9	Menarche (age at onset);
SARC	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.17	-0.47	2.02e-14	Chronic sinus infection;
SARC	trans	rs656319	0.559	rs60384372	chr8:9974584	A/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.47	-0.44	1.62e-12	Myopia (pathological);
SARC	cis	rs12701220	0.503	rs12702047	chr7:1132720	G/A	cg02733842	chr7:1102375	C7orf50	-0.52	-5.95	-0.36	9.8e-9	Bronchopulmonary dysplasia;
SARC	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg22834771	chr12:69754056	YEATS4	-0.49	-6.42	-0.39	7.74e-10	Cerebrospinal fluid biomarker levels;
SARC	cis	rs12142240	0.698	rs112089006	chr1:46812360	C/T	cg00530320	chr1:46809349	NSUN4	0.58	7.07	0.42	1.83e-11	Menopause (age at onset);
SARC	cis	rs2742234	0.590	rs2115817	chr10:43686552	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.4	-4.74	-0.3	3.67e-6	Hirschsprung disease;
SARC	cis	rs17270561	0.609	rs1318016	chr6:25764704	A/T	cg17691542	chr6:26056736	HIST1H1C	0.57	7.0	0.42	2.78e-11	Iron status biomarkers;
SARC	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	16.17	0.73	5.96e-40	Chronic sinus infection;
SARC	cis	rs2303759	0.709	rs2278405	chr19:49812403	A/C	cg22590775	chr19:49891494	CCDC155	-0.46	-5.13	-0.32	6.03e-7	Multiple sclerosis;
SARC	cis	rs1003719	0.751	rs7280371	chr21:38450008	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.67	9.98	0.55	9.34e-20	Eye color traits;
SARC	cis	rs5167	0.506	rs35193317	chr19:45470344	C/T	cg10169327	chr19:45448959	APOC2	-0.3	-4.95	-0.31	1.4e-6	Blood protein levels;
SARC	cis	rs10465746	0.725	rs6694752	chr1:84389960	C/T	cg10977910	chr1:84465055	TTLL7	0.44	5.29	0.33	2.78e-7	Obesity-related traits;
SARC	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg12311346	chr5:56204834	C5orf35	-0.53	-5.42	-0.33	1.5e-7	Initial pursuit acceleration;
SARC	trans	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg21659725	chr3:3221576	CRBN	0.52	6.63	0.4	2.37e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7089973	0.604	rs11196943	chr10:116598865	T/C	cg03647239	chr10:116582469	FAM160B1	0.5	6.48	0.39	5.49e-10	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	trans	rs61931739	0.517	rs7313663	chr12:34417058	T/C	cg26384229	chr12:38710491	ALG10B	0.84	12.74	0.64	1.41e-28	Morning vs. evening chronotype;
SARC	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg26335602	chr6:28129616	ZNF389	0.47	5.68	0.35	4.09e-8	Depression;
SARC	cis	rs62064224	0.791	rs11653160	chr17:30717222	A/G	cg18200150	chr17:30822561	MYO1D	0.43	6.9	0.41	4.75e-11	Schizophrenia;
SARC	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg26681399	chr22:41777847	TEF	-0.45	-4.9	-0.31	1.81e-6	Vitiligo;
SARC	cis	rs412000	0.554	rs2680700	chr17:56440542	G/T	cg25039879	chr17:56429692	SUPT4H1	0.45	4.82	0.3	2.63e-6	Primary tooth development (time to first tooth eruption);
SARC	cis	rs10056811	0.538	rs4632781	chr5:74376658	G/C	cg06933384	chr5:74808293	COL4A3BP;POLK	0.49	4.82	0.3	2.59e-6	Coronary artery disease;
SARC	cis	rs6866344	0.697	rs56159071	chr5:178127246	T/A	cg03877680	chr5:178157825	ZNF354A	1.02	12.27	0.63	4.82e-27	Neutrophil percentage of white cells;
SARC	cis	rs6546324	0.959	rs2861694	chr2:67845739	A/G	cg18237512	chr2:67827392	NA	-0.42	-5.24	-0.32	3.57e-7	Endometriosis;
SARC	cis	rs3767633	0.925	rs1553444	chr1:161813515	C/T	cg09175582	chr1:161736000	ATF6	0.62	5.6	0.34	6.15e-8	IgG glycosylation;
SARC	trans	rs208520	0.690	rs12208977	chr6:66725257	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	14.02	0.68	8.69e-33	Exhaled nitric oxide output;
SARC	cis	rs3815700	1.000	rs2287670	chr19:33095057	G/A	cg02997394	chr19:33096574	ANKRD27	0.8	8.25	0.48	1.15e-14	Eosinophilic esophagitis;
SARC	cis	rs7647973	0.922	rs7620024	chr3:49451691	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.57	-5.8	-0.36	2.13e-8	Menarche (age at onset);
SARC	cis	rs73206853	0.841	rs57726737	chr12:110843701	A/G	cg10860002	chr12:110842031	ANAPC7	0.65	5.1	0.32	7.06e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg16083429	chr3:49237500	CCDC36	-0.39	-5.17	-0.32	4.98e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs10876993	0.821	rs1629032	chr12:58038686	C/T	cg18357645	chr12:58087776	OS9	0.45	5.88	0.36	1.39e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg03517284	chr6:25882590	NA	-0.48	-6.26	-0.38	1.88e-9	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg18252515	chr7:66147081	NA	0.58	6.24	0.38	2.01e-9	Aortic root size;
SARC	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.96	13.0	0.65	2.11e-29	Platelet count;
SARC	cis	rs12908161	1.000	rs34900908	chr15:85257599	G/A	cg17507749	chr15:85114479	UBE2QP1	0.58	6.68	0.4	1.77e-10	Schizophrenia;
SARC	cis	rs35110281	0.774	rs1378080	chr21:45011315	T/A	cg21573476	chr21:45109991	RRP1B	-0.48	-7.05	-0.42	2.06e-11	Mean corpuscular volume;
SARC	trans	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg21659725	chr3:3221576	CRBN	0.52	6.74	0.4	1.23e-10	Intelligence (multi-trait analysis);
SARC	cis	rs911263	0.561	rs8003738	chr14:68776208	A/G	cg18825221	chr14:68749962	RAD51L1	0.46	6.13	0.37	3.62e-9	Primary biliary cholangitis;
SARC	cis	rs2832191	0.791	rs7283853	chr21:30498515	G/A	cg08807101	chr21:30365312	RNF160	-0.79	-10.92	-0.58	1.06e-22	Dental caries;
SARC	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg11987759	chr7:65425863	GUSB	0.5	6.49	0.39	5.09e-10	Aortic root size;
SARC	trans	rs10085978	0.604	rs35213837	chr8:143225193	G/A	cg12891252	chr10:43902500	HNRNPF	0.52	6.42	0.39	7.54e-10	Mosquito bite size;
SARC	cis	rs3768617	0.510	rs2296293	chr1:183095477	G/A	cg13390022	chr1:182993471	LAMC1	0.31	4.79	0.3	3.01e-6	Fuchs's corneal dystrophy;
SARC	cis	rs1046896	0.731	rs8067667	chr17:80785875	A/G	cg02711726	chr17:80685570	FN3KRP	-0.56	-6.67	-0.4	1.87e-10	Glycated hemoglobin levels;
SARC	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg05368731	chr17:41323189	NBR1	0.81	9.93	0.55	1.35e-19	Menopause (age at onset);
SARC	cis	rs4588572	0.561	rs10942858	chr5:77803267	A/C	cg11547950	chr5:77652471	NA	-0.38	-4.76	-0.3	3.42e-6	Triglycerides;
SARC	cis	rs9815354	0.812	rs77047799	chr3:41958895	T/C	cg03022575	chr3:42003672	ULK4	0.71	5.82	0.36	1.89e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9359856	0.673	rs1179901	chr6:90321196	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.57	-5.1	-0.32	7.13e-7	Bipolar disorder;
SARC	cis	rs6496667	1.000	rs7182544	chr15:90897480	G/C	cg22089800	chr15:90895588	ZNF774	0.51	4.75	0.3	3.53e-6	Rheumatoid arthritis;
SARC	cis	rs1051424	0.651	rs1292063	chr17:57907768	T/A	cg13753209	chr17:57696993	CLTC	-0.67	-7.24	-0.43	6.66e-12	Obesity-related traits;
SARC	trans	rs3780486	0.505	rs10813958	chr9:33165985	A/G	cg04842962	chr6:43655489	MRPS18A	0.88	12.37	0.63	2.31e-27	IgG glycosylation;
SARC	cis	rs7927771	0.542	rs6485775	chr11:47773518	A/G	cg10504702	chr11:47789108	FNBP4	-0.45	-5.79	-0.35	2.25e-8	Subjective well-being;
SARC	cis	rs6964587	1.000	rs2282972	chr7:91666369	C/T	cg17063962	chr7:91808500	NA	0.95	16.02	0.72	1.87e-39	Breast cancer;
SARC	cis	rs9359856	0.623	rs1179907	chr6:90324849	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.52	-4.95	-0.31	1.4e-6	Bipolar disorder;
SARC	cis	rs916888	0.647	rs199524	chr17:44848438	G/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.6	-6.6	-0.4	2.69e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9443189	0.526	rs10943255	chr6:76225928	T/A	cg01950844	chr6:76311363	SENP6	0.88	7.14	0.42	1.15e-11	Prostate cancer;
SARC	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg07636037	chr3:49044803	WDR6	0.65	8.44	0.48	3.31e-15	Resting heart rate;
SARC	cis	rs10463554	0.892	rs158401	chr5:102415468	A/G	cg23492399	chr5:102201601	PAM	-0.46	-5.11	-0.32	6.71e-7	Parkinson's disease;
SARC	cis	rs9303401	0.573	rs67378767	chr17:57194237	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.97	9.96	0.55	1.09e-19	Cognitive test performance;
SARC	cis	rs17666538	1.000	rs17666538	chr8:566207	T/C	cg23958373	chr8:599963	NA	-0.95	-6.72	-0.4	1.37e-10	IgG glycosylation;
SARC	cis	rs2070488	0.804	rs13063978	chr3:38476538	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	12.8	0.64	9.33e-29	Electrocardiographic conduction measures;
SARC	cis	rs7429990	0.965	rs184388	chr3:47939626	G/A	cg11946769	chr3:48343235	NME6	0.46	5.26	0.33	3.26e-7	Educational attainment (years of education);
SARC	cis	rs9815354	0.812	rs60927633	chr3:41844010	C/T	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs10789491	0.953	rs11211337	chr1:47133811	T/C	cg15501359	chr1:47185051	KIAA0494	0.75	7.85	0.46	1.49e-13	Response to hepatitis C treatment;
SARC	cis	rs2204008	0.623	rs1663281	chr12:38120936	A/G	cg13010199	chr12:38710504	ALG10B	-0.59	-7.53	-0.44	1.12e-12	Bladder cancer;
SARC	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg00149659	chr3:10157352	C3orf10	0.69	6.44	0.39	6.6e-10	Alzheimer's disease;
SARC	cis	rs9457247	1.000	rs397713	chr6:167386714	G/A	cg23791538	chr6:167370224	RNASET2	-0.62	-8.66	-0.49	8.17e-16	Crohn's disease;
SARC	cis	rs72653721	0.730	rs12664138	chr6:11039799	T/C	cg13562911	chr6:11044106	ELOVL2	0.59	6.75	0.4	1.13e-10	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	trans	rs1994135	0.647	rs67243558	chr12:33695383	T/C	cg26384229	chr12:38710491	ALG10B	0.79	9.82	0.54	2.77e-19	Resting heart rate;
SARC	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-9.03	-0.51	6.6e-17	Alzheimer's disease;
SARC	cis	rs11122272	0.735	rs2749711	chr1:231537543	G/A	cg06096015	chr1:231504339	EGLN1	0.39	5.8	0.36	2.16e-8	Hemoglobin concentration;
SARC	cis	rs2228479	0.557	rs62056097	chr16:89933420	A/G	cg06558623	chr16:89946397	TCF25	0.87	6.41	0.39	7.81e-10	Skin colour saturation;
SARC	cis	rs4718428	0.672	rs13241598	chr7:66300652	A/G	cg12165864	chr7:66369176	NA	-0.44	-4.87	-0.3	2.07e-6	Corneal structure;
SARC	cis	rs10463316	0.894	rs11167542	chr5:150760282	A/G	cg03212797	chr5:150827313	SLC36A1	0.41	4.83	0.3	2.44e-6	Metabolite levels (Pyroglutamine);
SARC	cis	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg09021430	chr5:549028	NA	-0.43	-5.68	-0.35	3.92e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg18225595	chr11:63971243	STIP1	0.44	5.36	0.33	1.97e-7	Mean platelet volume;
SARC	cis	rs9303401	0.659	rs7223708	chr17:56896398	A/G	cg25039879	chr17:56429692	SUPT4H1	0.64	6.1	0.37	4.41e-9	Cognitive test performance;
SARC	cis	rs1008375	1.000	rs4235388	chr4:17682030	G/A	cg27347728	chr4:17578864	LAP3	0.46	5.71	0.35	3.5e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg27546118	chr12:3931453	PARP11	0.49	7.1	0.42	1.49e-11	Thyroid stimulating hormone;
SARC	cis	rs1865760	1.000	rs6938233	chr6:25914077	C/T	cg16482183	chr6:26056742	HIST1H1C	0.49	6.12	0.37	4.01e-9	Height;
SARC	cis	rs10046574	0.831	rs56101588	chr7:135128106	A/C	cg27474649	chr7:135195673	CNOT4	0.87	6.77	0.41	1.05e-10	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs115056730	0.520	rs113247402	chr2:98168573	T/C	cg26665480	chr2:98280029	ACTR1B	-0.63	-4.81	-0.3	2.72e-6	Monocyte chemoattractant protein-3 levels;
SARC	cis	rs7762018	0.891	rs1981069	chr6:170148837	G/A	cg13891659	chr6:170190454	C6orf122;C6orf208	0.55	4.88	0.3	2e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs854765	0.583	rs9635697	chr17:17870394	T/A	cg04398451	chr17:18023971	MYO15A	-0.41	-5.72	-0.35	3.2e-8	Total body bone mineral density;
SARC	cis	rs986417	1.000	rs1254303	chr14:60886301	A/G	cg27398547	chr14:60952738	C14orf39	-0.99	-9.0	-0.51	8.36e-17	Gut microbiota (bacterial taxa);
SARC	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	10.92	0.58	1.06e-22	Alzheimer's disease;
SARC	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	9.56	0.53	1.74e-18	Platelet count;
SARC	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg17376030	chr22:41985996	PMM1	0.64	7.52	0.44	1.15e-12	Vitiligo;
SARC	cis	rs208520	0.690	rs851459	chr6:66813989	A/G	cg07460842	chr6:66804631	NA	-1.07	-14.98	-0.7	5.39e-36	Exhaled nitric oxide output;
SARC	cis	rs10752881	0.935	rs12082051	chr1:183051614	C/T	cg13390022	chr1:182993471	LAMC1	0.33	5.06	0.31	8.41e-7	Colorectal cancer;
SARC	cis	rs6752107	1.000	rs6708373	chr2:234172846	A/G	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.48	6.36	0.38	1.04e-9	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg07685180	chr8:600429	NA	0.74	5.82	0.36	1.9e-8	IgG glycosylation;
SARC	cis	rs7552404	0.731	rs10873787	chr1:76367797	G/A	cg10523679	chr1:76189770	ACADM	0.46	5.35	0.33	2.11e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs950169	0.922	rs4842946	chr15:84942331	G/A	cg24253500	chr15:84953950	NA	0.36	5.1	0.32	6.9e-7	Schizophrenia;
SARC	cis	rs734999	0.566	rs6424092	chr1:2532899	C/A	cg00980319	chr1:2560884	MMEL1	0.34	4.85	0.3	2.22e-6	Ulcerative colitis;
SARC	cis	rs9875589	0.957	rs35485647	chr3:13937937	G/C	cg19554555	chr3:13937349	NA	0.54	6.94	0.41	3.94e-11	Ovarian reserve;
SARC	cis	rs10911363	0.592	rs10797886	chr1:183479090	T/C	cg09173681	chr1:183549694	NCF2	0.32	5.13	0.32	6.18e-7	Systemic lupus erythematosus;
SARC	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg20887711	chr4:1340912	KIAA1530	0.52	6.41	0.39	8.15e-10	Longevity;
SARC	cis	rs3813567	0.759	rs7163204	chr15:78953740	G/A	cg04896959	chr15:78267971	NA	-0.51	-5.23	-0.32	3.74e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
SARC	cis	rs6714710	0.603	rs7421146	chr2:98552271	G/C	cg26665480	chr2:98280029	ACTR1B	0.53	6.98	0.42	3.1e-11	Posterior cortical atrophy and Alzheimer's disease;
SARC	trans	rs7615952	0.611	rs72979452	chr3:125756178	C/T	cg07211511	chr3:129823064	LOC729375	-0.83	-6.53	-0.39	4.04e-10	Blood pressure (smoking interaction);
SARC	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg07701084	chr6:150067640	NUP43	0.43	5.62	0.35	5.4e-8	Lung cancer;
SARC	cis	rs796364	0.906	rs1658810	chr2:200816382	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.79	7.34	0.43	3.51e-12	Schizophrenia;
SARC	cis	rs7927592	0.913	rs10896346	chr11:68352671	C/T	cg01657329	chr11:68192670	LRP5	-0.43	-5.11	-0.32	6.59e-7	Total body bone mineral density;
SARC	cis	rs6570726	0.935	rs447247	chr6:145812678	G/T	cg05220968	chr6:146057943	EPM2A	-0.29	-4.83	-0.3	2.44e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg10862848	chr6:42927986	GNMT	-0.44	-7.35	-0.43	3.23e-12	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.97e-8	Aortic root size;
SARC	cis	rs6062302	0.522	rs11696202	chr20:62246292	G/C	cg16989086	chr20:62203971	PRIC285	0.47	4.73	0.3	3.92e-6	Glioblastoma;
SARC	cis	rs17600642	0.724	rs72814549	chr10:72458913	G/A	cg18679544	chr10:72432482	ADAMTS14	0.46	4.77	0.3	3.26e-6	Bipolar disorder;
SARC	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.59e-6	Depression;
SARC	cis	rs7647973	0.626	rs7649428	chr3:49868876	A/T	cg07636037	chr3:49044803	WDR6	-0.62	-6.27	-0.38	1.73e-9	Menarche (age at onset);
SARC	cis	rs2153535	0.580	rs6912193	chr6:8456306	T/G	cg21535247	chr6:8435926	SLC35B3	0.52	6.55	0.39	3.66e-10	Motion sickness;
SARC	cis	rs35110281	0.774	rs9978811	chr21:44998683	C/T	cg01579765	chr21:45077557	HSF2BP	-0.32	-5.38	-0.33	1.81e-7	Mean corpuscular volume;
SARC	trans	rs12310956	0.515	rs1830086	chr12:33958874	C/T	cg26384229	chr12:38710491	ALG10B	0.85	12.3	0.63	4.14e-27	Morning vs. evening chronotype;
SARC	cis	rs2766692	0.956	rs35696661	chr14:100742355	G/C	cg14866419	chr14:100704911	YY1	0.61	7.19	0.43	8.6e-12	Electroencephalographic traits in alcoholism;
SARC	cis	rs17376456	0.877	rs12374470	chr5:93481046	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.2	0.32	4.28e-7	Diabetic retinopathy;
SARC	cis	rs9902453	0.874	rs7220004	chr17:28369548	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.16	-0.42	1.02e-11	Coffee consumption (cups per day);
SARC	cis	rs3813567	0.702	rs7164665	chr15:78953919	T/C	cg24631222	chr15:78858424	CHRNA5	0.49	4.72	0.3	4.03e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
SARC	cis	rs12142240	0.698	rs58162700	chr1:46816659	T/A	cg14993813	chr1:46806288	NSUN4	-0.52	-5.46	-0.34	1.22e-7	Menopause (age at onset);
SARC	cis	rs1048238	0.846	rs945422	chr1:16345619	T/C	cg21385522	chr1:16154831	NA	0.5	6.06	0.37	5.3e-9	Systolic blood pressure;
SARC	cis	rs72717009	0.825	rs9427399	chr1:161476533	T/C	cg23840854	chr1:161414152	NA	-0.54	-5.07	-0.32	8.2e-7	Rheumatoid arthritis;
SARC	cis	rs10754283	0.870	rs2390764	chr1:90112827	T/G	cg21401794	chr1:90099060	LRRC8C	0.59	8.09	0.47	3.24e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs6546550	0.869	rs6712827	chr2:70156540	C/G	cg02498382	chr2:70120550	SNRNP27	-0.33	-5.31	-0.33	2.61e-7	Prevalent atrial fibrillation;
SARC	cis	rs4906332	1.000	rs17617935	chr14:103952886	A/T	cg26031613	chr14:104095156	KLC1	-0.49	-5.76	-0.35	2.64e-8	Coronary artery disease;
SARC	trans	rs61931739	0.963	rs3912355	chr12:34079616	A/G	cg13010199	chr12:38710504	ALG10B	0.55	6.73	0.4	1.33e-10	Morning vs. evening chronotype;
SARC	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg22683308	chr4:1340831	KIAA1530	0.46	5.45	0.34	1.27e-7	Longevity;
SARC	cis	rs4065321	0.522	rs11078930	chr17:38141955	C/T	cg17467752	chr17:38218738	THRA	-0.38	-4.85	-0.3	2.25e-6	White blood cell count (basophil);White blood cell count;
SARC	cis	rs76419734	1.000	rs11731417	chr4:106746012	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	5.33	0.33	2.37e-7	Post bronchodilator FEV1;
SARC	cis	rs6964587	1.000	rs13231238	chr7:91653851	T/G	cg17063962	chr7:91808500	NA	0.95	16.01	0.72	2.09e-39	Breast cancer;
SARC	cis	rs10982256	0.805	rs10759714	chr9:117267591	C/T	cg21159778	chr9:117266918	DFNB31	0.4	5.8	0.36	2.14e-8	Bipolar disorder;
SARC	cis	rs3820928	0.874	rs4675138	chr2:227884118	G/A	cg05526886	chr2:227700861	RHBDD1	-0.51	-6.12	-0.37	3.89e-9	Pulmonary function;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg08418750	chr12:104458125	HCFC2	-0.55	-6.77	-0.41	1.01e-10	Schizophrenia;
SARC	cis	rs12142240	0.621	rs13374968	chr1:46843908	T/G	cg10495392	chr1:46806563	NSUN4	0.65	6.88	0.41	5.6e-11	Menopause (age at onset);
SARC	cis	rs6815814	0.731	rs11734342	chr4:38773109	A/G	cg06935464	chr4:38784597	TLR10	0.52	5.62	0.35	5.45e-8	Breast cancer;
SARC	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg00933542	chr6:150070202	PCMT1	0.37	6.36	0.38	1.06e-9	Lung cancer;
SARC	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg18404041	chr3:52824283	ITIH1	-0.44	-6.59	-0.4	2.82e-10	Bipolar disorder;
SARC	cis	rs7474896	0.537	rs1208683	chr10:38093723	A/G	cg00409905	chr10:38381863	ZNF37A	0.43	4.76	0.3	3.37e-6	Obesity (extreme);
SARC	cis	rs10979	1.000	rs7774497	chr6:143889033	T/C	cg25407410	chr6:143891975	LOC285740	-0.64	-8.68	-0.49	6.88e-16	Hypospadias;
SARC	cis	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg07777115	chr5:623756	CEP72	-0.56	-4.81	-0.3	2.7e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg12257692	chr3:49977190	RBM6	-0.27	-4.8	-0.3	2.88e-6	Body mass index;
SARC	cis	rs2635047	0.638	rs55730206	chr18:44608230	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.51	6.63	0.4	2.32e-10	Educational attainment;
SARC	cis	rs8031584	0.918	rs61997139	chr15:31273602	C/G	cg08109568	chr15:31115862	NA	-0.47	-5.99	-0.37	7.96e-9	Huntington's disease progression;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg10083236	chr2:33824519	FAM98A	0.54	6.67	0.4	1.89e-10	Breast cancer;
SARC	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	11.07	0.59	3.6e-23	Alzheimer's disease;
SARC	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg02297831	chr4:17616191	MED28	0.51	6.63	0.4	2.36e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4742903	0.509	rs10991124	chr9:106917475	A/T	cg14250997	chr9:106856677	SMC2	0.43	5.14	0.32	5.71e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs3771570	1.000	rs62193175	chr2:242284405	G/A	cg21155796	chr2:242212141	HDLBP	0.67	5.76	0.35	2.67e-8	Prostate cancer;
SARC	cis	rs10876993	0.928	rs813854	chr12:58071347	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.46	-5.79	-0.35	2.29e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs17666538	0.710	rs1703941	chr8:658447	G/A	cg00450029	chr8:599525	NA	0.62	4.76	0.3	3.36e-6	IgG glycosylation;
SARC	trans	rs61931739	0.635	rs1852224	chr12:33963080	A/C	cg26384229	chr12:38710491	ALG10B	0.57	7.37	0.43	2.93e-12	Morning vs. evening chronotype;
SARC	cis	rs12681288	0.578	rs56702775	chr8:968860	G/A	cg15309053	chr8:964076	NA	0.48	7.76	0.45	2.64e-13	Schizophrenia;
SARC	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.93	-12.96	-0.65	2.73e-29	Platelet count;
SARC	cis	rs854765	0.547	rs6502632	chr17:17913057	A/G	cg04398451	chr17:18023971	MYO15A	-0.44	-6.33	-0.38	1.27e-9	Total body bone mineral density;
SARC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg22535103	chr8:58192502	C8orf71	-0.59	-6.21	-0.38	2.44e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs56279505	0.690	rs62307321	chr4:100279458	T/C	cg21156590	chr1:3420848	MEGF6	-0.83	-6.52	-0.39	4.31e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6580649	0.943	rs9651993	chr12:48404692	G/A	cg24011408	chr12:48396354	COL2A1	0.5	5.49	0.34	1.03e-7	Lung cancer;
SARC	cis	rs13065560	0.714	rs4280575	chr3:38937645	C/T	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.44	-5.28	-0.33	2.95e-7	Interleukin-18 levels;
SARC	cis	rs7766436	0.885	rs6935379	chr6:22581462	A/G	cg13666174	chr6:22585274	NA	-0.6	-7.74	-0.45	3.04e-13	Coronary artery disease;
SARC	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg11062466	chr8:58055876	NA	0.64	5.86	0.36	1.55e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg06618935	chr21:46677482	NA	-0.39	-5.2	-0.32	4.34e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs797680	0.964	rs12139009	chr1:93573493	A/G	cg01538778	chr1:93646459	TMED5;CCDC18	0.42	4.72	0.3	4.01e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
SARC	cis	rs2463822	0.592	rs72919486	chr11:62043501	G/C	cg06239285	chr11:62104954	ASRGL1	-0.9	-8.24	-0.48	1.22e-14	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs3741151	0.892	rs2027760	chr11:73036481	G/A	cg17517138	chr11:73019481	ARHGEF17	0.82	7.22	0.43	7.13e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs4481887	1.000	rs4372295	chr1:248464871	G/T	cg00666640	chr1:248458726	OR2T12	0.35	5.95	0.36	9.68e-9	Common traits (Other);
SARC	cis	rs288326	0.561	rs77024950	chr2:183797227	T/C	cg09997497	chr2:183902928	NCKAP1	0.75	5.13	0.32	6.18e-7	Blood protein levels;
SARC	cis	rs60871478	1.000	rs4720930	chr7:808073	G/A	cg19087971	chr7:751233	PRKAR1B	-0.42	-4.8	-0.3	2.79e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg20887711	chr4:1340912	KIAA1530	0.43	5.27	0.33	3.1e-7	Longevity;
SARC	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg12564285	chr5:131593104	PDLIM4	0.41	5.96	0.36	9.22e-9	Acylcarnitine levels;
SARC	cis	rs865483	1.000	rs865483	chr17:35851177	A/C	cg06561646	chr17:35873369	DUSP14	-0.49	-6.4	-0.39	8.63e-10	Monocyte count;
SARC	cis	rs9768139	0.935	rs10949715	chr7:158117246	G/T	cg25566285	chr7:158114605	PTPRN2	0.28	4.85	0.3	2.22e-6	Calcium levels;
SARC	trans	rs12310956	0.515	rs1852221	chr12:33945489	G/T	cg26384229	chr12:38710491	ALG10B	0.74	10.34	0.56	7.25e-21	Morning vs. evening chronotype;
SARC	cis	rs7560272	0.502	rs4513320	chr2:73920741	T/C	cg20560298	chr2:73613845	ALMS1	0.47	6.25	0.38	1.97e-9	Schizophrenia;
SARC	cis	rs3126085	0.778	rs10788828	chr1:152191879	G/A	cg09127314	chr1:152161683	NA	0.41	4.74	0.3	3.67e-6	Atopic dermatitis;
SARC	cis	rs7786808	0.741	rs11767875	chr7:158228923	A/G	cg09998033	chr7:158218633	PTPRN2	-0.33	-5.3	-0.33	2.7e-7	Obesity-related traits;
SARC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.53	0.57	1.89e-21	Prudent dietary pattern;
SARC	cis	rs1395	0.961	rs4665965	chr2:27536380	C/T	cg17158414	chr2:27665306	KRTCAP3	0.33	4.85	0.3	2.24e-6	Blood metabolite levels;
SARC	cis	rs986417	0.901	rs12883305	chr14:61006690	A/G	cg27398547	chr14:60952738	C14orf39	0.99	9.41	0.52	4.88e-18	Gut microbiota (bacterial taxa);
SARC	cis	rs743757	1.000	rs1107265	chr3:50431995	A/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.55	5.05	0.31	8.88e-7	Diastolic blood pressure;
SARC	cis	rs3796352	0.764	rs34872575	chr3:52986277	G/A	cg27565382	chr3:53032988	SFMBT1	0.95	6.34	0.38	1.17e-9	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs7772486	0.713	rs2328704	chr6:146020494	T/C	cg05347473	chr6:146136440	FBXO30	-0.5	-6.77	-0.41	1.01e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7772486	0.790	rs2265919	chr6:146221753	A/G	cg23711669	chr6:146136114	FBXO30	0.8	12.59	0.64	4.55e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12545109	0.643	rs1119707	chr8:57411548	T/C	cg19413350	chr8:57351067	NA	-0.43	-4.83	-0.3	2.45e-6	Obesity-related traits;
SARC	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg09699651	chr6:150184138	LRP11	0.39	4.83	0.3	2.5e-6	Lung cancer;
SARC	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg22920501	chr2:26401640	FAM59B	-0.56	-7.63	-0.45	6e-13	Gut microbiome composition (summer);
SARC	cis	rs12048904	0.541	rs6699536	chr1:101276544	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.63	6.79	0.41	9.09e-11	Multiple sclerosis;
SARC	cis	rs9527	0.590	rs1807298	chr10:104870218	G/A	cg04362960	chr10:104952993	NT5C2	0.43	4.94	0.31	1.47e-6	Arsenic metabolism;
SARC	cis	rs9467773	1.000	rs1056667	chr6:26510564	T/C	cg11502198	chr6:26597334	ABT1	0.48	5.98	0.36	8.37e-9	Intelligence (multi-trait analysis);
SARC	cis	rs460214	0.539	rs28718905	chr21:40032244	C/A	cg12884169	chr21:40033163	ERG	-0.35	-4.87	-0.3	2.05e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs910316	1.000	rs10136948	chr14:75511075	C/T	cg06637938	chr14:75390232	RPS6KL1	0.56	7.83	0.46	1.71e-13	Height;
SARC	cis	rs7246657	1.000	rs10426297	chr19:37798373	A/G	cg14683738	chr19:37701593	ZNF585B	0.6	5.51	0.34	9.46e-8	Coronary artery calcification;
SARC	cis	rs12681366	0.663	rs2919665	chr8:95465375	G/A	cg26464482	chr8:95565502	KIAA1429	0.42	5.24	0.32	3.64e-7	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs17533156	0.525	rs77932036	chr17:75207586	T/G	cg18815765	chr17:75136729	SEC14L1	0.68	7.21	0.43	7.59e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs7429990	0.932	rs810334	chr3:47935303	G/T	cg11946769	chr3:48343235	NME6	0.45	5.13	0.32	6e-7	Educational attainment (years of education);
SARC	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg22875332	chr1:76189707	ACADM	-0.46	-6.05	-0.37	5.79e-9	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg20607798	chr8:58055168	NA	0.71	6.18	0.38	2.87e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg06028808	chr11:68637592	NA	0.44	5.68	0.35	4.07e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs13191362	0.507	rs2849540	chr6:163094522	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.44	-4.8	-0.3	2.83e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs11122272	0.735	rs2749717	chr1:231489353	G/T	cg06096015	chr1:231504339	EGLN1	0.38	5.63	0.35	5.19e-8	Hemoglobin concentration;
SARC	cis	rs6582630	0.638	rs12423236	chr12:38548162	G/A	cg14851346	chr12:38532713	NA	-0.44	-5.29	-0.33	2.8e-7	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs61931739	0.500	rs10844863	chr12:34532284	C/T	cg13010199	chr12:38710504	ALG10B	0.78	11.07	0.59	3.68e-23	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.679	rs10504217	chr8:58037522	A/G	cg11062466	chr8:58055876	NA	0.49	4.88	0.3	1.95e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs4689388	0.890	rs4688991	chr4:6302220	C/G	cg14416269	chr4:6271139	WFS1	0.31	4.75	0.3	3.59e-6	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg11987759	chr7:65425863	GUSB	0.57	7.53	0.44	1.14e-12	Aortic root size;
SARC	cis	rs1707322	0.963	rs11211202	chr1:46292382	C/T	cg06784218	chr1:46089804	CCDC17	0.33	5.77	0.35	2.45e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2115630	0.691	rs8040066	chr15:85176465	G/C	cg17507749	chr15:85114479	UBE2QP1	-0.5	-5.91	-0.36	1.18e-8	P wave terminal force;
SARC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg17178900	chr1:205818956	PM20D1	-0.64	-8.66	-0.49	7.92e-16	Menarche (age at onset);
SARC	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg12311346	chr5:56204834	C5orf35	-0.55	-5.77	-0.35	2.56e-8	Initial pursuit acceleration;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg02262585	chr9:35604315	TESK1	0.53	6.6	0.4	2.78e-10	Breast cancer;
SARC	cis	rs10046574	0.764	rs28422979	chr7:135145924	C/T	cg27474649	chr7:135195673	CNOT4	0.86	7.01	0.42	2.55e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7980687	0.627	rs1727325	chr12:123698332	G/C	cg05973401	chr12:123451056	ABCB9	0.52	5.89	0.36	1.34e-8	Height;Educational attainment;Head circumference (infant);
SARC	cis	rs10465746	0.570	rs11163884	chr1:84472760	A/G	cg04407776	chr1:84465009	TTLL7	-0.42	-5.06	-0.31	8.62e-7	Obesity-related traits;
SARC	cis	rs7084402	0.967	rs1649043	chr10:60328209	C/T	cg07615347	chr10:60278583	BICC1	0.58	8.6	0.49	1.15e-15	Refractive error;
SARC	cis	rs9788721	0.836	rs72738718	chr15:78735438	G/C	cg18825076	chr15:78729989	IREB2	-0.52	-6.45	-0.39	6.47e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs1468333	0.897	rs6888877	chr5:137510357	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	-0.76	-9.78	-0.54	3.8e-19	Resting heart rate;
SARC	cis	rs3858526	0.920	rs11039548	chr11:5930283	G/A	cg13902645	chr11:5959945	NA	-0.45	-5.23	-0.32	3.7e-7	DNA methylation (variation);
SARC	cis	rs2425143	1.000	rs6060557	chr20:34270266	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-5.75	-0.35	2.78e-8	Blood protein levels;
SARC	cis	rs526231	0.511	rs1011453	chr5:102368027	C/T	cg23492399	chr5:102201601	PAM	-0.5	-5.49	-0.34	1.05e-7	Primary biliary cholangitis;
SARC	cis	rs11574514	0.744	rs28580313	chr16:67806351	G/A	cg01866162	chr16:67596514	CTCF	0.97	5.81	0.36	2.06e-8	Crohn's disease;
SARC	trans	rs7824557	0.606	rs2736273	chr8:11199938	C/A	cg06636001	chr8:8085503	FLJ10661	0.62	8.05	0.47	4.24e-14	Retinal vascular caliber;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg24375287	chr13:50366190	KPNA3	-0.5	-6.31	-0.38	1.39e-9	Schizophrenia;
SARC	cis	rs7681440	0.835	rs6831847	chr4:90785341	A/G	cg06632027	chr4:90757378	SNCA	-0.4	-5.71	-0.35	3.41e-8	Dementia with Lewy bodies;
SARC	cis	rs262150	0.522	rs2527182	chr7:158813812	A/G	cg09640425	chr7:158790006	NA	-0.39	-5.67	-0.35	4.2e-8	Facial morphology (factor 20);
SARC	cis	rs865483	0.861	rs56186148	chr17:35768827	T/A	cg06561646	chr17:35873369	DUSP14	0.47	6.08	0.37	4.92e-9	Monocyte count;
SARC	cis	rs9436747	0.641	rs10443259	chr1:66051350	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.48	4.92	0.31	1.62e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs7833790	0.632	rs6415653	chr8:82702536	A/G	cg17211192	chr8:82754475	SNX16	-0.49	-5.87	-0.36	1.46e-8	Diastolic blood pressure;
SARC	cis	rs2180341	0.920	rs1073932	chr6:127682009	G/T	cg27446573	chr6:127587934	RNF146	1.06	14.55	0.69	1.52e-34	Breast cancer;
SARC	cis	rs9814567	0.778	rs4955546	chr3:134334738	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.53	-6.8	-0.41	8.7e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs9790314	0.936	rs336572	chr3:161068014	G/A	cg03342759	chr3:160939853	NMD3	-0.62	-8.09	-0.47	3.19e-14	Morning vs. evening chronotype;
SARC	cis	rs1865760	0.927	rs6915834	chr6:25935427	A/C	cg16482183	chr6:26056742	HIST1H1C	0.53	6.69	0.4	1.67e-10	Height;
SARC	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg03060546	chr3:49711283	APEH	0.4	4.95	0.31	1.4e-6	Parkinson's disease;
SARC	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg04315214	chr1:2043799	PRKCZ	0.29	4.83	0.3	2.45e-6	Height;
SARC	cis	rs7223966	1.000	rs9891018	chr17:61827856	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-5.94	-0.36	1.04e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs4319547	0.656	rs10773075	chr12:122814236	G/A	cg23029597	chr12:123009494	RSRC2	-0.4	-5.04	-0.31	9.21e-7	Body mass index;
SARC	cis	rs12600053	0.554	rs4783077	chr16:84848221	A/G	cg16537028	chr16:84853380	CRISPLD2	0.38	4.78	0.3	3.07e-6	Asthma (childhood onset);
SARC	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg02841227	chr6:26021843	HIST1H4A	0.51	5.69	0.35	3.76e-8	Intelligence (multi-trait analysis);
SARC	cis	rs6977660	0.660	rs61670426	chr7:19790460	A/G	cg05791153	chr7:19748676	TWISTNB	0.72	6.28	0.38	1.65e-9	Thyroid stimulating hormone;
SARC	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.62	-7.48	-0.44	1.49e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg19223190	chr17:80058835	NA	-0.42	-5.85	-0.36	1.66e-8	Life satisfaction;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg15218456	chr17:25289681	NA	-0.6	-6.36	-0.38	1.03e-9	Lung cancer in ever smokers;
SARC	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	5.77	0.35	2.56e-8	Personality dimensions;
SARC	cis	rs999943	1.000	rs999943	chr6:33624733	A/G	cg14003231	chr6:33640908	ITPR3	0.45	7.53	0.44	1.1e-12	Obesity (extreme);
SARC	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg18876405	chr7:65276391	NA	-0.72	-9.19	-0.52	2.26e-17	Aortic root size;
SARC	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg24633833	chr3:10029261	TMEM111	0.53	5.29	0.33	2.89e-7	Alzheimer's disease;
SARC	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.46	-5.77	-0.35	2.54e-8	Gut microbiome composition (summer);
SARC	cis	rs9818758	0.545	rs9853352	chr3:49813258	C/T	cg03060546	chr3:49711283	APEH	0.56	5.07	0.32	8.01e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg06873352	chr17:61820015	STRADA	0.53	6.94	0.41	3.85e-11	Prudent dietary pattern;
SARC	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg13175981	chr1:150552382	MCL1	-0.54	-6.9	-0.41	4.97e-11	Tonsillectomy;
SARC	cis	rs7208859	0.673	rs9912122	chr17:29140716	C/A	cg13385521	chr17:29058706	SUZ12P	0.83	7.55	0.44	9.72e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs2412208	0.683	rs12091438	chr1:7069503	G/A	cg20434152	chr1:7120926	CAMTA1	-0.35	-5.24	-0.32	3.55e-7	Survival in sporadic amyotrophic lateral sclerosis;
SARC	cis	rs9790314	0.637	rs778649	chr3:160709377	C/T	cg04691961	chr3:161091175	C3orf57	-0.59	-8.01	-0.46	5.35e-14	Morning vs. evening chronotype;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg16430909	chr10:61469845	SLC16A9	0.5	7.05	0.42	1.99e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	trans	rs4332037	0.539	rs868754	chr7:2033780	G/C	cg11693508	chr17:37793320	STARD3	0.66	6.35	0.38	1.12e-9	Bipolar disorder;
SARC	cis	rs3820928	0.845	rs2177596	chr2:227890283	A/T	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.69	-0.35	3.82e-8	Pulmonary function;
SARC	cis	rs910316	1.000	rs13099	chr14:75599155	G/A	cg23033748	chr14:75592666	NEK9	-0.34	-4.73	-0.3	3.86e-6	Height;
SARC	cis	rs3767633	0.764	rs4657094	chr1:161713826	G/T	cg09175582	chr1:161736000	ATF6	0.68	4.74	0.3	3.66e-6	IgG glycosylation;
SARC	cis	rs874628	0.686	rs11666906	chr19:18241898	A/G	cg00493341	chr19:18228948	MAST3	0.46	5.07	0.32	8.17e-7	Multiple sclerosis;
SARC	cis	rs7640424	0.784	rs68044584	chr3:107845395	A/G	cg09227934	chr3:107805635	CD47	-0.33	-4.72	-0.3	4.06e-6	Body mass index;
SARC	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg21747090	chr2:27597821	SNX17	-0.52	-7.47	-0.44	1.64e-12	Total body bone mineral density;
SARC	cis	rs11690935	0.549	rs796839	chr2:172916214	A/C	cg13550731	chr2:172543902	DYNC1I2	0.61	8.5	0.49	2.32e-15	Schizophrenia;
SARC	cis	rs12291225	0.585	rs11023194	chr11:14369769	T/C	cg19336497	chr11:14380999	RRAS2	-0.45	-8.09	-0.47	3.26e-14	Sense of smell;
SARC	cis	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg03213289	chr20:61660250	NA	0.46	6.43	0.39	7.22e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs4588572	0.643	rs1560195	chr5:77701913	A/G	cg11547950	chr5:77652471	NA	0.4	4.91	0.31	1.71e-6	Triglycerides;
SARC	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg04277193	chr17:41438351	NA	0.45	4.84	0.3	2.41e-6	Menopause (age at onset);
SARC	cis	rs9818758	0.556	rs9880309	chr3:49304329	G/C	cg00383909	chr3:49044727	WDR6	0.72	6.24	0.38	2.04e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs9612	1.000	rs12611034	chr19:44268678	C/T	cg08581076	chr19:44259116	C19orf61	0.69	8.35	0.48	5.98e-15	Exhaled nitric oxide output;
SARC	cis	rs1153858	1.000	rs12437887	chr15:45669094	G/A	cg21132104	chr15:45694354	SPATA5L1	0.78	11.01	0.59	5.55e-23	Homoarginine levels;
SARC	cis	rs6089584	0.566	rs2146852	chr20:60616492	T/G	cg06108461	chr20:60628389	TAF4	-0.71	-9.42	-0.53	4.74e-18	Body mass index;
SARC	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg07701084	chr6:150067640	NUP43	0.41	5.39	0.33	1.68e-7	Lung cancer;
SARC	cis	rs7208859	0.623	rs73269945	chr17:29108759	G/A	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs13191362	1.000	rs13215491	chr6:163010325	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.56	5.35	0.33	2.07e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs11583043	0.918	rs58029001	chr1:101393409	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.47	5.47	0.34	1.14e-7	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs2425143	1.000	rs12481228	chr20:34218673	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.06	0.31	8.38e-7	Blood protein levels;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg10136773	chr11:94906134	SESN3	0.47	6.43	0.39	7.25e-10	Thyroid stimulating hormone;
SARC	cis	rs290268	0.874	rs290994	chr9:93559515	T/A	cg02608019	chr9:93564028	SYK	0.35	5.12	0.32	6.27e-7	Platelet count;
SARC	cis	rs9902453	0.765	rs2628191	chr17:28051140	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.53	-6.97	-0.42	3.23e-11	Coffee consumption (cups per day);
SARC	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg11764359	chr7:65958608	NA	0.61	6.78	0.41	9.79e-11	Aortic root size;
SARC	cis	rs1355223	0.583	rs2116085	chr11:34884001	C/A	cg18508148	chr11:34937573	PDHX;APIP	0.53	6.77	0.41	1.02e-10	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs765787	0.505	rs4439707	chr15:45524216	G/A	cg24006582	chr15:45444508	DUOX1	0.43	5.33	0.33	2.34e-7	Uric acid levels;
SARC	cis	rs9811216	1.000	rs9822885	chr3:169486144	A/G	cg14222479	chr3:169487675	ARPM1	0.44	5.29	0.33	2.86e-7	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs9393777	0.513	rs9393739	chr6:26646966	T/G	cg12826209	chr6:26865740	GUSBL1	0.66	5.87	0.36	1.47e-8	Intelligence (multi-trait analysis);
SARC	cis	rs1008375	0.931	rs3775926	chr4:17599837	G/A	cg16339924	chr4:17578868	LAP3	0.63	8.02	0.47	5.04e-14	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4820539	0.966	rs2267001	chr22:23456696	T/C	cg14186256	chr22:23484241	RTDR1	0.84	13.34	0.66	1.5e-30	Bone mineral density;
SARC	cis	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg21775007	chr8:11205619	TDH	0.56	7.23	0.43	7.08e-12	Retinal vascular caliber;
SARC	trans	rs1994135	0.669	rs10844628	chr12:33697065	T/C	cg26384229	chr12:38710491	ALG10B	0.68	8.4	0.48	4.48e-15	Resting heart rate;
SARC	cis	rs2011503	1.000	rs2905422	chr19:19460703	A/G	cg15839431	chr19:19639596	YJEFN3	0.5	4.75	0.3	3.63e-6	Bipolar disorder;
SARC	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg19223190	chr17:80058835	NA	0.44	6.19	0.38	2.67e-9	Life satisfaction;
SARC	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg11764359	chr7:65958608	NA	-0.72	-8.41	-0.48	4.1e-15	Aortic root size;
SARC	cis	rs834603	0.575	rs1799371	chr7:47467436	C/T	cg23694490	chr7:47445681	TNS3	-0.32	-5.86	-0.36	1.58e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs6088580	0.634	rs6120650	chr20:33039973	G/A	cg24642439	chr20:33292090	TP53INP2	0.68	8.78	0.5	3.54e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs7412746	0.658	rs6657388	chr1:150748786	A/G	cg13175981	chr1:150552382	MCL1	-0.48	-5.66	-0.35	4.42e-8	Melanoma;
SARC	cis	rs737337	0.623	rs4804154	chr19:11334179	C/T	cg00586551	chr19:11347513	LOC55908;DOCK6	0.54	5.86	0.36	1.58e-8	HDL cholesterol;HDL cholesterol levels;
SARC	cis	rs9921222	0.521	rs11649255	chr16:357140	A/G	cg00101154	chr16:420108	MRPL28	-0.44	-6.14	-0.37	3.59e-9	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs6831352	0.734	rs2851259	chr4:100033986	C/T	cg13256891	chr4:100009986	ADH5	0.6	7.9	0.46	1.09e-13	Alcohol dependence;
SARC	trans	rs12310956	0.510	rs4931743	chr12:33867588	T/C	cg13010199	chr12:38710504	ALG10B	0.57	7.5	0.44	1.32e-12	Morning vs. evening chronotype;
SARC	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg00933542	chr6:150070202	PCMT1	0.32	5.45	0.34	1.28e-7	Lung cancer;
SARC	cis	rs981844	0.775	rs17371336	chr4:154749525	A/G	cg14289246	chr4:154710475	SFRP2	0.58	6.57	0.4	3.22e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg24642844	chr7:1081250	C7orf50	-0.59	-5.98	-0.36	8.18e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs13256369	0.760	rs7816171	chr8:8575835	T/C	cg18904891	chr8:8559673	CLDN23	0.49	5.58	0.34	6.5e-8	Obesity-related traits;
SARC	cis	rs1559088	0.948	rs10406916	chr19:33590093	G/A	cg17764715	chr19:33622953	WDR88	0.49	6.72	0.4	1.4e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs7659604	0.628	rs3828485	chr4:122722368	G/A	cg19748678	chr4:122722346	EXOSC9	0.77	9.78	0.54	3.68e-19	Type 2 diabetes;
SARC	cis	rs721399	0.539	rs10103029	chr8:18267338	A/G	cg18736775	chr8:18248649	NAT2	-0.57	-5.66	-0.35	4.39e-8	Blood metabolite levels;
SARC	cis	rs9436747	0.585	rs11581702	chr1:65987659	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	-0.43	-5.63	-0.35	5.03e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	trans	rs7615952	0.866	rs13063119	chr3:125643847	G/A	cg07211511	chr3:129823064	LOC729375	-0.96	-11.09	-0.59	3.07e-23	Blood pressure (smoking interaction);
SARC	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg04267008	chr7:1944627	MAD1L1	-0.65	-7.78	-0.45	2.3e-13	Bipolar disorder and schizophrenia;
SARC	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg08067268	chr2:26466485	HADHB;HADHA	0.51	6.23	0.38	2.14e-9	Gut microbiome composition (summer);
SARC	cis	rs17376456	0.825	rs10057130	chr5:93282557	C/T	cg25358565	chr5:93447407	FAM172A	1.3	14.36	0.69	6.63e-34	Diabetic retinopathy;
SARC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.83	0.81	3.93e-55	Prudent dietary pattern;
SARC	cis	rs1318878	0.565	rs13313237	chr12:15481326	T/C	cg08258403	chr12:15378311	NA	0.51	7.0	0.42	2.68e-11	Intelligence (multi-trait analysis);
SARC	cis	rs9916302	0.595	rs4795371	chr17:37636695	T/G	cg20243544	chr17:37824526	PNMT	0.58	6.75	0.4	1.14e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs743757	1.000	rs2236973	chr3:50474284	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.51	4.83	0.3	2.45e-6	Diastolic blood pressure;
SARC	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg18252515	chr7:66147081	NA	0.49	5.18	0.32	4.9e-7	Aortic root size;
SARC	cis	rs7044106	0.762	rs4837790	chr9:123446325	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	8.98	0.51	9.61e-17	Hip circumference adjusted for BMI;
SARC	cis	rs12545109	0.800	rs2576592	chr8:57419357	A/C	cg09654669	chr8:57350985	NA	-0.39	-4.98	-0.31	1.26e-6	Obesity-related traits;
SARC	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.63	-7.18	-0.43	9.26e-12	Height;
SARC	cis	rs7236492	0.688	rs35455644	chr18:77184282	A/G	cg15644404	chr18:77186268	NFATC1	-0.66	-6.53	-0.39	4.15e-10	Inflammatory bowel disease;Crohn's disease;
SARC	trans	rs634534	0.563	rs470192	chr11:65724291	C/T	cg17712092	chr4:129076599	LARP1B	0.69	9.37	0.52	6.47e-18	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg07061783	chr6:25882402	NA	-0.42	-4.95	-0.31	1.41e-6	Intelligence (multi-trait analysis);
SARC	cis	rs10484885	0.878	rs72921934	chr6:90579464	T/A	cg13799429	chr6:90582589	CASP8AP2	-0.61	-5.23	-0.32	3.71e-7	QRS interval (sulfonylurea treatment interaction);
SARC	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.75	10.88	0.58	1.51e-22	Personality dimensions;
SARC	cis	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg09021430	chr5:549028	NA	-0.45	-5.72	-0.35	3.18e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs73195822	0.667	rs60579973	chr12:111245629	C/T	cg10860002	chr12:110842031	ANAPC7	0.66	4.91	0.31	1.69e-6	Itch intensity from mosquito bite;
SARC	cis	rs9399135	0.967	rs6908512	chr6:135367757	A/G	cg22676075	chr6:135203613	NA	0.34	4.75	0.3	3.59e-6	Red blood cell count;
SARC	cis	rs2204008	0.782	rs117824012	chr12:38215517	T/C	cg13010199	chr12:38710504	ALG10B	0.78	10.64	0.57	8.61e-22	Bladder cancer;
SARC	cis	rs6867032	1.000	rs61177713	chr5:2017255	G/A	cg26168224	chr5:2018326	NA	0.93	15.03	0.7	3.92e-36	Gut microbiome composition (winter);
SARC	cis	rs9303401	0.614	rs28687626	chr17:57191904	G/A	cg12560992	chr17:57184187	TRIM37	0.55	4.89	0.31	1.86e-6	Cognitive test performance;
SARC	cis	rs6546550	0.901	rs6716937	chr2:70127229	G/A	cg02498382	chr2:70120550	SNRNP27	-0.32	-5.13	-0.32	6.02e-7	Prevalent atrial fibrillation;
SARC	cis	rs9479482	0.967	rs1853664	chr6:150355266	A/G	cg03788504	chr6:150331562	NA	-0.31	-5.02	-0.31	1.05e-6	Alopecia areata;
SARC	trans	rs2727020	0.658	rs10839269	chr11:49385596	A/G	cg15704280	chr7:45808275	SEPT13	-0.85	-13.78	-0.67	5.21e-32	Coronary artery disease;
SARC	cis	rs9393777	0.528	rs7745603	chr6:27090404	C/T	cg12826209	chr6:26865740	GUSBL1	0.69	6.74	0.4	1.22e-10	Intelligence (multi-trait analysis);
SARC	cis	rs12478296	0.901	rs7423119	chr2:243005488	T/A	cg06360820	chr2:242988706	NA	-0.63	-5.84	-0.36	1.71e-8	Obesity-related traits;
SARC	cis	rs72945132	0.709	rs28634008	chr11:70225719	A/C	cg00319359	chr11:70116639	PPFIA1	0.67	6.17	0.37	3.03e-9	Coronary artery disease;
SARC	trans	rs7615952	0.551	rs12695470	chr3:125635718	C/A	cg07211511	chr3:129823064	LOC729375	-0.96	-10.53	-0.57	1.86e-21	Blood pressure (smoking interaction);
SARC	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg18252515	chr7:66147081	NA	0.5	5.38	0.33	1.79e-7	Aortic root size;
SARC	cis	rs193541	0.632	rs1363200	chr5:122163802	G/T	cg19412675	chr5:122181750	SNX24	0.49	6.36	0.38	1.05e-9	Glucose homeostasis traits;
SARC	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg20891283	chr12:69753455	YEATS4	0.55	7.55	0.44	9.74e-13	Blood protein levels;
SARC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg21747090	chr2:27597821	SNX17	-0.55	-7.68	-0.45	4.44e-13	Total body bone mineral density;
SARC	cis	rs1580019	0.587	rs1597555	chr7:32546118	T/G	cg07520158	chr7:32535189	LSM5;AVL9	0.61	7.95	0.46	7.96e-14	Cognitive ability;
SARC	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg05896524	chr21:47604654	C21orf56	0.57	7.04	0.42	2.18e-11	Testicular germ cell tumor;
SARC	cis	rs2387326	0.671	rs12268728	chr10:129945897	G/A	cg16087940	chr10:129947807	NA	-0.45	-5.76	-0.35	2.62e-8	Select biomarker traits;
SARC	cis	rs9457247	0.602	rs9459854	chr6:167465882	C/T	cg07741184	chr6:167504864	NA	0.37	7.07	0.42	1.76e-11	Crohn's disease;
SARC	cis	rs763121	0.853	rs5750621	chr22:38956166	C/T	cg06022373	chr22:39101656	GTPBP1	0.88	11.45	0.6	2.17e-24	Menopause (age at onset);
SARC	cis	rs2439831	1.000	rs690436	chr15:43761205	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.81	8.34	0.48	6.66e-15	Lung cancer in ever smokers;
SARC	cis	rs7523050	0.643	rs35924015	chr1:109404626	T/C	cg08274380	chr1:109419600	GPSM2	0.81	6.7	0.4	1.59e-10	Fat distribution (HIV);
SARC	cis	rs11098499	0.779	rs72918579	chr4:120333222	G/C	cg09307838	chr4:120376055	NA	0.91	12.74	0.64	1.47e-28	Corneal astigmatism;
SARC	cis	rs55823223	0.646	rs74410877	chr17:73832384	C/T	cg02397686	chr17:73851076	WBP2	0.58	4.91	0.31	1.7e-6	Psoriasis;
SARC	cis	rs4144743	1.000	rs4144745	chr17:45323349	T/C	cg18085866	chr17:45331354	ITGB3	-0.71	-7.35	-0.43	3.36e-12	Body mass index;
SARC	cis	rs79149102	0.579	rs9788648	chr15:75300284	A/G	cg00629941	chr15:75287862	SCAMP5	-0.65	-5.26	-0.33	3.2e-7	Lung cancer;
SARC	cis	rs67460515	0.852	rs2404341	chr3:161092405	T/C	cg03342759	chr3:160939853	NMD3	-0.65	-8.06	-0.47	3.98e-14	Parkinson's disease;
SARC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.65	0.53	9.21e-19	Prudent dietary pattern;
SARC	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg22857025	chr5:266934	NA	-1.09	-11.97	-0.62	4.86e-26	Breast cancer;
SARC	cis	rs7113874	0.659	rs12274454	chr11:8521966	G/C	cg09828998	chr11:8703972	RPL27A	0.5	5.31	0.33	2.53e-7	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs5167	0.743	rs8111069	chr19:45483438	A/C	cg09555818	chr19:45449301	APOC2	0.41	5.89	0.36	1.36e-8	Blood protein levels;
SARC	trans	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg21659725	chr3:3221576	CRBN	-0.54	-7.21	-0.43	7.54e-12	Intelligence (multi-trait analysis);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg08084737	chr7:43965691	URGCP;UBE2D4	-0.75	-6.35	-0.38	1.12e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg22974920	chr21:40686053	BRWD1	0.45	4.89	0.31	1.88e-6	Cognitive function;
SARC	trans	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg00938859	chr5:1591904	SDHAP3	0.79	7.66	0.45	5.1e-13	Breast cancer;
SARC	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.58	-6.15	-0.37	3.36e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs9790314	0.613	rs13092102	chr3:160598093	C/G	cg04691961	chr3:161091175	C3orf57	0.57	7.79	0.45	2.21e-13	Morning vs. evening chronotype;
SARC	cis	rs2153535	0.580	rs2184583	chr6:8447808	A/G	cg21535247	chr6:8435926	SLC35B3	0.55	6.87	0.41	5.72e-11	Motion sickness;
SARC	cis	rs12681366	0.762	rs6997115	chr8:95365885	C/T	cg13257157	chr8:95487014	RAD54B	0.45	5.37	0.33	1.93e-7	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs7312933	0.558	rs3747560	chr12:42719890	A/G	cg19980929	chr12:42632907	YAF2	-0.45	-6.73	-0.4	1.27e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs3218477	1.000	rs3218536	chr7:152346007	C/T	cg06618968	chr7:152373420	XRCC2	-0.72	-4.78	-0.3	3.17e-6	Mean platelet volume;
SARC	cis	rs67460515	0.500	rs9832109	chr3:160723364	T/C	cg03342759	chr3:160939853	NMD3	-0.49	-5.88	-0.36	1.42e-8	Parkinson's disease;
SARC	cis	rs1983170	0.808	rs1546449	chr1:92017391	G/A	cg25838465	chr1:92012736	NA	0.46	5.52	0.34	9.24e-8	Eosinophil percentage of white cells;
SARC	cis	rs12709013	0.559	rs8060721	chr16:58799485	A/C	cg04273148	chr16:57808038	KIFC3	0.32	4.72	0.3	4.08e-6	Blood metabolite ratios;
SARC	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg05313129	chr8:58192883	C8orf71	-0.51	-5.95	-0.36	9.74e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs73206853	0.764	rs60027620	chr12:111103669	T/G	cg10860002	chr12:110842031	ANAPC7	0.57	4.87	0.3	2.07e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs4481887	0.893	rs28787378	chr1:248504447	C/T	cg00666640	chr1:248458726	OR2T12	0.34	5.8	0.36	2.12e-8	Common traits (Other);
SARC	cis	rs2304069	0.507	rs13167061	chr5:149388624	T/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.59	6.94	0.41	3.86e-11	HIV-1 control;
SARC	cis	rs9436747	0.835	rs2209706	chr1:65931251	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	-0.48	-5.19	-0.32	4.49e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs12682352	0.602	rs6993494	chr8:8667444	C/T	cg08975724	chr8:8085496	FLJ10661	0.42	5.13	0.32	5.96e-7	Neuroticism;
SARC	cis	rs2204008	0.604	rs2320521	chr12:38253789	A/G	cg26384229	chr12:38710491	ALG10B	0.91	13.79	0.67	4.83e-32	Bladder cancer;
SARC	trans	rs1814175	0.869	rs10769600	chr11:49681832	C/T	cg15704280	chr7:45808275	SEPT13	-0.92	-16.39	-0.73	1.12e-40	Height;
SARC	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.45	5.14	0.32	5.93e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs11792861	0.890	rs3087979	chr9:111781779	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.68	7.79	0.45	2.2e-13	Menarche (age at onset);
SARC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.97	10.89	0.58	1.39e-22	Platelet count;
SARC	cis	rs365132	0.875	rs547798	chr5:176326721	C/A	cg16309518	chr5:176445507	NA	-0.47	-5.98	-0.36	8.18e-9	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs7927592	0.913	rs7109294	chr11:68332093	A/G	cg01657329	chr11:68192670	LRP5	-0.43	-5.12	-0.32	6.51e-7	Total body bone mineral density;
SARC	cis	rs73195822	0.614	rs17683336	chr12:111212712	C/T	cg10860002	chr12:110842031	ANAPC7	0.58	5.07	0.31	8.3e-7	Itch intensity from mosquito bite;
SARC	cis	rs6733011	0.502	rs6542847	chr2:99573471	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-4.78	-0.3	3.06e-6	Bipolar disorder;
SARC	cis	rs12421382	0.659	rs2028337	chr11:109380887	G/C	cg27471124	chr11:109292789	C11orf87	0.36	5.04	0.31	9.21e-7	Schizophrenia;
SARC	trans	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg21659725	chr3:3221576	CRBN	0.54	6.25	0.38	1.89e-9	Resting heart rate;
SARC	cis	rs10465746	0.780	rs2147392	chr1:84404154	C/A	cg10977910	chr1:84465055	TTLL7	0.46	5.8	0.36	2.18e-8	Obesity-related traits;
SARC	cis	rs9457247	0.638	rs239933	chr6:167413230	A/G	cg07741184	chr6:167504864	NA	0.33	6.45	0.39	6.25e-10	Crohn's disease;
SARC	cis	rs34172651	0.917	rs172066	chr16:24756449	C/T	cg00339695	chr16:24857497	SLC5A11	0.29	4.75	0.3	3.54e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7223966	1.000	rs11542436	chr17:61778689	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-6.0	-0.37	7.45e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg20607798	chr8:58055168	NA	0.58	5.57	0.34	6.9e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg24675658	chr1:53192096	ZYG11B	-0.6	-8.92	-0.5	1.41e-16	Monocyte count;
SARC	cis	rs9300255	0.596	rs11057207	chr12:123730891	T/G	cg00376283	chr12:123451042	ABCB9	0.56	6.58	0.4	3.1e-10	Neutrophil percentage of white cells;
SARC	cis	rs9322193	0.543	rs9371533	chr6:150210681	G/A	cg05036130	chr6:150231994	NA	0.28	4.79	0.3	2.96e-6	Lung cancer;
SARC	cis	rs7726839	0.578	rs10080150	chr5:593160	C/T	cg16447950	chr5:562315	NA	0.51	7.55	0.44	9.96e-13	Obesity-related traits;
SARC	cis	rs9296092	0.560	rs9469511	chr6:33530930	T/G	cg13560919	chr6:33536144	NA	-0.51	-6.06	-0.37	5.47e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs6912958	0.781	rs9450755	chr6:88303702	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.66	-0.4	1.96e-10	Monocyte percentage of white cells;
SARC	cis	rs1878931	0.580	rs3848355	chr16:3407489	A/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.87	13.66	0.67	1.37e-31	Body mass index (adult);
SARC	cis	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg22496380	chr5:211416	CCDC127	-0.88	-9.28	-0.52	1.21e-17	Breast cancer;
SARC	cis	rs10782582	0.593	rs12126155	chr1:76131555	C/G	cg10523679	chr1:76189770	ACADM	-0.44	-5.38	-0.33	1.85e-7	Daytime sleep phenotypes;
SARC	cis	rs11098499	0.863	rs6833334	chr4:120504227	C/T	cg09307838	chr4:120376055	NA	0.91	12.25	0.63	5.66e-27	Corneal astigmatism;
SARC	trans	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg23440882	chr1:875880	SAMD11	-0.71	-6.85	-0.41	6.43e-11	Cutaneous psoriasis;
SARC	trans	rs1994135	0.565	rs11052767	chr12:33731194	A/G	cg13010199	chr12:38710504	ALG10B	0.65	7.61	0.45	6.57e-13	Resting heart rate;
SARC	cis	rs1008375	0.966	rs10939735	chr4:17578891	A/G	cg16339924	chr4:17578868	LAP3	0.71	9.3	0.52	1.03e-17	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2075371	0.579	rs11766422	chr7:134018160	T/C	cg00033643	chr7:134001901	SLC35B4	0.43	5.27	0.33	3.17e-7	Mean platelet volume;
SARC	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg18252515	chr7:66147081	NA	-1.3	-11.5	-0.6	1.59e-24	Diabetic kidney disease;
SARC	cis	rs6693567	0.586	rs12031973	chr1:150485566	T/G	cg09579323	chr1:150459698	TARS2	0.41	5.23	0.32	3.77e-7	Migraine;
SARC	cis	rs7633857	0.512	rs1374787	chr3:160700144	C/T	cg03342759	chr3:160939853	NMD3	-0.5	-6.17	-0.37	2.98e-9	Educational attainment (years of education);
SARC	cis	rs6815814	0.904	rs73236628	chr4:38825443	C/T	cg06935464	chr4:38784597	TLR10	0.56	5.4	0.33	1.66e-7	Breast cancer;
SARC	cis	rs4481887	0.893	rs1339992	chr1:248509182	G/A	cg01631408	chr1:248437212	OR2T33	-0.43	-5.87	-0.36	1.46e-8	Common traits (Other);
SARC	trans	rs10754283	0.535	rs1215507	chr1:90088895	A/G	cg23963136	chr19:8372973	CD320	-0.5	-6.34	-0.38	1.18e-9	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs17739167	0.550	rs17739125	chr15:42234424	T/C	cg20935245	chr15:42234343	EHD4	-0.46	-6.03	-0.37	6.42e-9	Monocyte count;
SARC	cis	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg21775007	chr8:11205619	TDH	0.49	6.28	0.38	1.62e-9	Retinal vascular caliber;
SARC	cis	rs910316	1.000	rs10138183	chr14:75615227	T/C	cg23033748	chr14:75592666	NEK9	0.38	5.34	0.33	2.25e-7	Height;
SARC	cis	rs7659604	0.540	rs10007956	chr4:122700669	A/T	cg19748678	chr4:122722346	EXOSC9	-0.43	-5.38	-0.33	1.83e-7	Type 2 diabetes;
SARC	cis	rs7772486	0.790	rs2485632	chr6:146193228	A/G	cg23711669	chr6:146136114	FBXO30	0.84	13.76	0.67	6.41e-32	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9303401	0.659	rs12600349	chr17:57054245	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	-1.04	-11.78	-0.61	1.93e-25	Cognitive test performance;
SARC	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg21782813	chr7:2030301	MAD1L1	0.38	6.11	0.37	4.26e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs6582630	0.555	rs11180986	chr12:38264486	G/A	cg26384229	chr12:38710491	ALG10B	-0.58	-7.29	-0.43	4.75e-12	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1018836	0.923	rs7013893	chr8:91563137	G/A	cg16814680	chr8:91681699	NA	-0.8	-12.55	-0.64	5.96e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	9.68	0.54	7.66e-19	Platelet count;
SARC	cis	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg00409905	chr10:38381863	ZNF37A	-0.55	-7.94	-0.46	8.52e-14	Extrinsic epigenetic age acceleration;
SARC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg13397359	chr6:42928475	GNMT	0.6	8.16	0.47	2.12e-14	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs1018836	0.828	rs9297871	chr8:91572731	G/A	cg16814680	chr8:91681699	NA	-0.73	-11.21	-0.59	1.33e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs3099143	1.000	rs3099137	chr15:77123626	G/A	cg21673338	chr15:77095150	SCAPER	-0.6	-4.99	-0.31	1.18e-6	Recalcitrant atopic dermatitis;
SARC	cis	rs4481887	0.927	rs12744455	chr1:248479960	A/G	cg00666640	chr1:248458726	OR2T12	0.35	5.8	0.36	2.16e-8	Common traits (Other);
SARC	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.72	-7.08	-0.42	1.67e-11	Platelet count;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg22281935	chr2:162934111	NA	-0.45	-6.28	-0.38	1.64e-9	Electrocardiographic conduction measures;
SARC	cis	rs1912483	0.505	rs3760372	chr17:45380002	T/C	cg08085267	chr17:45401833	C17orf57	-0.53	-5.95	-0.36	9.94e-9	Coronary artery disease;
SARC	cis	rs5753037	0.653	rs131271	chr22:30151582	A/G	cg01021169	chr22:30184971	ASCC2	-0.45	-6.31	-0.38	1.38e-9	Type 1 diabetes;
SARC	cis	rs13191362	0.507	rs6907151	chr6:163200701	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.47	5.16	0.32	5.26e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs1878931	0.580	rs8062722	chr16:3409161	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.87	13.34	0.66	1.57e-30	Body mass index (adult);
SARC	cis	rs9462027	0.628	rs9469909	chr6:34813077	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-6.05	-0.37	5.63e-9	Systemic lupus erythematosus;
SARC	cis	rs7264396	0.623	rs2425127	chr20:34332037	T/C	cg01084648	chr20:34329383	RBM39	0.57	5.0	0.31	1.13e-6	Total cholesterol levels;
SARC	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	12.05	0.62	2.53e-26	Chronic sinus infection;
SARC	cis	rs898097	0.756	rs11655103	chr17:80813467	T/C	cg15664640	chr17:80829946	TBCD	-0.53	-8.23	-0.47	1.33e-14	Breast cancer;
SARC	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg04166393	chr7:2884313	GNA12	0.55	6.34	0.38	1.19e-9	Height;
SARC	cis	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg14019146	chr3:50243930	SLC38A3	-0.32	-5.12	-0.32	6.54e-7	Body mass index;
SARC	cis	rs2228479	0.850	rs11649510	chr16:89851004	A/G	cg06558623	chr16:89946397	TCF25	0.93	6.44	0.39	6.63e-10	Skin colour saturation;
SARC	cis	rs2749592	0.725	rs9417245	chr10:37826322	C/T	cg00409905	chr10:38381863	ZNF37A	0.51	6.21	0.38	2.35e-9	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs10465746	0.967	rs4907191	chr1:84444165	A/G	cg10977910	chr1:84465055	TTLL7	-0.38	-4.76	-0.3	3.46e-6	Obesity-related traits;
SARC	cis	rs4713675	0.584	rs9368776	chr6:33696405	A/G	cg15676125	chr6:33679581	C6orf125	0.53	6.35	0.38	1.12e-9	Plateletcrit;
SARC	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg13628971	chr7:2884303	GNA12	0.45	5.53	0.34	8.68e-8	Height;
SARC	cis	rs17376456	0.597	rs7728825	chr5:93384594	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.5	-5.48	-0.34	1.13e-7	Diabetic retinopathy;
SARC	cis	rs1185460	0.967	rs1177562	chr11:118949331	C/T	cg23280166	chr11:118938394	VPS11	0.82	11.64	0.61	5.36e-25	Coronary artery disease;
SARC	cis	rs637571	0.522	rs606978	chr11:65711517	A/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.81	11.64	0.61	5.71e-25	Eosinophil percentage of white cells;
SARC	cis	rs950776	0.714	rs660652	chr15:78887832	A/G	cg06917634	chr15:78832804	PSMA4	-0.76	-10.31	-0.56	8.82e-21	Sudden cardiac arrest;
SARC	cis	rs7914558	0.966	rs7085598	chr10:104650128	T/C	cg15744005	chr10:104629667	AS3MT	-0.27	-4.89	-0.3	1.91e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs4919087	1.000	rs4919090	chr10:99088419	C/G	cg25902810	chr10:99078978	FRAT1	-0.46	-5.69	-0.35	3.71e-8	Monocyte count;
SARC	cis	rs6815814	0.950	rs11722889	chr4:38810975	C/T	cg06935464	chr4:38784597	TLR10	0.63	6.34	0.38	1.16e-9	Breast cancer;
SARC	cis	rs80130819	0.591	rs17122651	chr12:48496660	C/T	cg24011408	chr12:48396354	COL2A1	-0.47	-5.23	-0.32	3.8e-7	Prostate cancer;
SARC	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg05234568	chr11:5960015	NA	-0.41	-5.55	-0.34	7.59e-8	DNA methylation (variation);
SARC	cis	rs9747201	1.000	rs4239020	chr17:80176641	C/T	cg09264619	chr17:80180166	NA	-0.53	-5.88	-0.36	1.39e-8	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs11718455	0.920	rs4682927	chr3:44033299	C/A	cg08738300	chr3:44038990	NA	0.51	5.7	0.35	3.66e-8	Coronary artery disease;
SARC	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg22535103	chr8:58192502	C8orf71	-0.78	-9.38	-0.52	6.05e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg20916646	chr4:852691	GAK	0.45	6.06	0.37	5.29e-9	Sjögren's syndrome;
SARC	cis	rs765787	0.530	rs11854690	chr15:45516016	C/T	cg25801113	chr15:45476975	SHF	0.28	4.72	0.3	4.06e-6	Uric acid levels;
SARC	cis	rs2933343	1.000	rs876756	chr3:128627623	G/A	cg24203234	chr3:128598194	ACAD9	0.56	6.27	0.38	1.75e-9	IgG glycosylation;
SARC	cis	rs526231	0.578	rs10515337	chr5:102301368	C/T	cg23492399	chr5:102201601	PAM	0.45	5.32	0.33	2.49e-7	Primary biliary cholangitis;
SARC	cis	rs7666738	0.830	rs11942114	chr4:99066261	C/G	cg05340658	chr4:99064831	C4orf37	0.63	8.4	0.48	4.4e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7100689	0.577	rs2342813	chr10:82046302	T/G	cg01528321	chr10:82214614	TSPAN14	0.66	8.71	0.5	5.84e-16	Post bronchodilator FEV1;
SARC	cis	rs1008375	0.932	rs1008894	chr4:17704667	C/T	cg27347728	chr4:17578864	LAP3	-0.49	-6.19	-0.38	2.67e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs12447804	0.871	rs2304488	chr16:58074210	A/G	cg03859792	chr16:58121049	NA	0.35	5.1	0.32	7.12e-7	Pulmonary function;Pulmonary function (smoking interaction);
SARC	cis	rs11098499	0.954	rs2306455	chr4:120421969	G/A	cg24375607	chr4:120327624	NA	0.41	4.86	0.3	2.12e-6	Corneal astigmatism;
SARC	cis	rs240764	0.658	rs846803	chr6:101272801	C/T	cg09795085	chr6:101329169	ASCC3	-0.49	-6.42	-0.39	7.41e-10	Neuroticism;
SARC	cis	rs2576037	0.796	rs2247021	chr18:44578794	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.67	9.74	0.54	4.87e-19	Personality dimensions;
SARC	cis	rs7662987	0.517	rs2851268	chr4:100027878	A/G	cg12011299	chr4:100065546	ADH4	0.32	5.26	0.33	3.23e-7	Smoking initiation;
SARC	cis	rs9457247	0.646	rs4710160	chr6:167409241	T/A	cg07741184	chr6:167504864	NA	0.3	5.6	0.34	5.91e-8	Crohn's disease;
SARC	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.53	5.93	0.36	1.09e-8	Renal function-related traits (BUN);
SARC	cis	rs9457247	0.967	rs385460	chr6:167403888	A/T	cg23791538	chr6:167370224	RNASET2	-0.63	-8.73	-0.5	4.84e-16	Crohn's disease;
SARC	cis	rs1113500	0.836	rs1618973	chr1:108586767	T/C	cg06207961	chr1:108661230	NA	-0.41	-5.31	-0.33	2.56e-7	Growth-regulated protein alpha levels;
SARC	cis	rs3862260	0.509	rs12076924	chr1:120165826	C/T	cg16322792	chr1:120165303	ZNF697	0.3	6.05	0.37	5.73e-9	Systemic lupus erythematosus;
SARC	cis	rs10979	1.000	rs35354710	chr6:143886454	A/G	cg25407410	chr6:143891975	LOC285740	-0.61	-8.14	-0.47	2.35e-14	Hypospadias;
SARC	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg16479474	chr6:28041457	NA	0.37	5.39	0.33	1.73e-7	Depression;
SARC	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg08067268	chr2:26466485	HADHB;HADHA	0.47	5.92	0.36	1.12e-8	Gut microbiome composition (summer);
SARC	cis	rs11190604	1.000	rs17113137	chr10:102241998	G/C	cg07080220	chr10:102295463	HIF1AN	0.72	7.75	0.45	2.9e-13	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs3743266	0.507	rs62003261	chr15:60761489	T/C	cg22293140	chr15:60689852	ANXA2	-0.53	-4.76	-0.3	3.42e-6	Menarche (age at onset);
SARC	cis	rs6570726	0.791	rs6570695	chr6:145911286	C/A	cg05347473	chr6:146136440	FBXO30	0.51	7.13	0.42	1.29e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg07234876	chr8:600039	NA	0.75	6.14	0.37	3.6e-9	IgG glycosylation;
SARC	cis	rs208520	0.690	rs7764570	chr6:66827600	G/C	cg07460842	chr6:66804631	NA	-1.01	-13.39	-0.66	1.01e-30	Exhaled nitric oxide output;
SARC	cis	rs7589342	0.536	rs10198057	chr2:106392799	A/C	cg16077055	chr2:106428750	NCK2	-0.31	-6.17	-0.37	2.94e-9	Addiction;
SARC	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg24675658	chr1:53192096	ZYG11B	0.65	9.21	0.52	1.91e-17	Monocyte count;
SARC	cis	rs7208859	0.623	rs73269923	chr17:29102571	C/T	cg13385521	chr17:29058706	SUZ12P	0.85	7.06	0.42	1.9e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs898097	0.510	rs10445242	chr17:80891666	G/T	cg15664640	chr17:80829946	TBCD	0.35	5.6	0.34	6.12e-8	Breast cancer;
SARC	cis	rs7829975	0.564	rs2921057	chr8:8318667	C/T	cg11608241	chr8:8085544	FLJ10661	0.38	4.72	0.3	4e-6	Mood instability;
SARC	cis	rs6138458	1.000	rs227627	chr20:24912107	T/C	cg26195577	chr20:24973756	C20orf3	0.88	9.75	0.54	4.69e-19	Blood protein levels;
SARC	cis	rs2718058	0.630	rs2709120	chr7:37809412	T/C	cg24998770	chr7:37888106	TXNDC3	0.36	5.18	0.32	4.85e-7	Alzheimer's disease (late onset);
SARC	cis	rs76419734	1.000	rs72671824	chr4:106623223	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.8	4.9	0.31	1.8e-6	Post bronchodilator FEV1;
SARC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg11494091	chr17:61959527	GH2	0.55	8.12	0.47	2.77e-14	Prudent dietary pattern;
SARC	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.97e-8	Aortic root size;
SARC	cis	rs6690583	1.000	rs2304641	chr1:85513398	C/T	cg22153463	chr1:85462885	MCOLN2	0.6	5.38	0.33	1.82e-7	Serum sulfate level;
SARC	trans	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg10869401	chr11:129802046	PRDM10	0.49	6.42	0.39	7.47e-10	Colonoscopy-negative controls vs population controls;
SARC	cis	rs3733585	0.673	rs7672947	chr4:9961368	G/C	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.6	-0.34	5.99e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs78545713	0.536	rs56119218	chr6:26225881	C/A	cg00631329	chr6:26305371	NA	-0.71	-5.14	-0.32	5.85e-7	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs3087591	0.922	rs11867284	chr17:29597464	G/A	cg24425628	chr17:29625626	OMG;NF1	0.53	6.56	0.39	3.43e-10	Hip circumference;
SARC	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.43	-5.38	-0.33	1.82e-7	Lymphocyte counts;
SARC	cis	rs644799	1.000	rs7749	chr11:95565789	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.89	14.0	0.68	9.8e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs6752107	1.000	rs13391356	chr2:234170369	T/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.5	6.85	0.41	6.48e-11	Crohn's disease;Inflammatory bowel disease;
SARC	trans	rs12310956	0.532	rs11052951	chr12:33986181	T/A	cg13010199	chr12:38710504	ALG10B	0.65	8.81	0.5	3.02e-16	Morning vs. evening chronotype;
SARC	cis	rs372883	0.600	rs1312254	chr21:30695401	A/G	cg08807101	chr21:30365312	RNF160	-0.6	-7.54	-0.44	1.06e-12	Pancreatic cancer;
SARC	cis	rs8031584	0.918	rs61997140	chr15:31277312	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.43	-4.76	-0.3	3.34e-6	Huntington's disease progression;
SARC	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.91	9.68	0.54	7.63e-19	Platelet count;
SARC	cis	rs12596210	0.925	rs36053329	chr16:54036177	C/T	cg00542139	chr16:53088674	CHD9	0.61	4.85	0.3	2.27e-6	Sex hormone-binding globulin levels;
SARC	cis	rs3762637	0.882	rs7630833	chr3:122190424	C/T	cg24169773	chr3:122142474	KPNA1	-0.55	-5.55	-0.34	7.73e-8	LDL cholesterol levels;
SARC	cis	rs453301	0.571	rs2929456	chr8:9083416	G/A	cg11995313	chr8:8860691	ERI1	0.41	5.09	0.32	7.21e-7	Joint mobility (Beighton score);
SARC	cis	rs7772486	0.743	rs111332144	chr6:146056681	C/T	cg05347473	chr6:146136440	FBXO30	-0.47	-6.2	-0.38	2.55e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg27286337	chr10:134555280	INPP5A	0.67	7.88	0.46	1.28e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg02187348	chr16:89574699	SPG7	0.66	9.54	0.53	1.96e-18	Multiple myeloma (IgH translocation);
SARC	cis	rs910316	0.737	rs108622	chr14:75481908	A/G	cg11812906	chr14:75593930	NEK9	-0.75	-10.01	-0.55	7.62e-20	Height;
SARC	cis	rs13401104	0.796	rs10929168	chr2:237115373	C/T	cg19324714	chr2:237145437	ASB18	-0.56	-5.76	-0.35	2.62e-8	Educational attainment;
SARC	cis	rs2204008	0.570	rs1315664	chr12:38138274	A/G	cg26384229	chr12:38710491	ALG10B	-0.68	-8.75	-0.5	4.27e-16	Bladder cancer;
SARC	cis	rs986417	0.711	rs761556	chr14:61061034	T/G	cg27398547	chr14:60952738	C14orf39	0.86	7.61	0.45	6.92e-13	Gut microbiota (bacterial taxa);
SARC	cis	rs67460515	0.859	rs7610800	chr3:161002582	C/T	cg17135325	chr3:160939158	NMD3	0.63	7.94	0.46	8.49e-14	Parkinson's disease;
SARC	cis	rs34172651	0.917	rs2059134	chr16:24816492	C/T	cg00339695	chr16:24857497	SLC5A11	-0.3	-4.73	-0.3	3.84e-6	Intelligence (multi-trait analysis);
SARC	cis	rs5744897	0.655	rs35131280	chr12:133275974	A/G	cg16945633	chr12:133170342	NA	0.51	4.86	0.3	2.13e-6	Urate levels in overweight individuals;
SARC	cis	rs8114671	0.562	rs2889861	chr20:33405664	C/T	cg07148914	chr20:33460835	GGT7	0.42	5.3	0.33	2.75e-7	Height;
SARC	cis	rs6964587	1.000	rs6956431	chr7:91750016	T/C	cg17063962	chr7:91808500	NA	0.93	15.65	0.72	3.24e-38	Breast cancer;
SARC	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg24675658	chr1:53192096	ZYG11B	-0.62	-8.59	-0.49	1.25e-15	Monocyte count;
SARC	cis	rs113835537	0.866	rs59566349	chr11:66365994	A/T	cg24851651	chr11:66362959	CCS	0.48	5.1	0.32	7.05e-7	Airway imaging phenotypes;
SARC	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg20887711	chr4:1340912	KIAA1530	0.78	10.01	0.55	7.46e-20	Longevity;
SARC	cis	rs11098499	0.954	rs10031483	chr4:120422636	T/C	cg09307838	chr4:120376055	NA	0.93	12.73	0.64	1.6e-28	Corneal astigmatism;
SARC	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg08219700	chr8:58056026	NA	0.6	5.82	0.36	1.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.56	8.66	0.49	7.98e-16	Eosinophil percentage of white cells;
SARC	trans	rs9929218	1.000	rs4500718	chr16:68754312	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.66	-8.16	-0.47	2.1e-14	Colorectal cancer;
SARC	cis	rs3008870	1.000	rs2985795	chr1:67426223	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.92	11.37	0.6	3.93e-24	Lymphocyte percentage of white cells;
SARC	cis	rs8114671	0.836	rs2425012	chr20:33581955	G/A	cg24642439	chr20:33292090	TP53INP2	-0.5	-5.94	-0.36	1.02e-8	Height;
SARC	cis	rs113835537	0.529	rs60358007	chr11:66222353	G/A	cg24851651	chr11:66362959	CCS	0.39	4.74	0.3	3.72e-6	Airway imaging phenotypes;
SARC	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg18876405	chr7:65276391	NA	-0.46	-5.18	-0.32	4.8e-7	Aortic root size;
SARC	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg22903471	chr2:27725779	GCKR	-0.49	-7.23	-0.43	6.96e-12	Total body bone mineral density;
SARC	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.9	-0.5	1.61e-16	Alzheimer's disease;
SARC	cis	rs7523050	0.643	rs34367763	chr1:109400805	C/T	cg08274380	chr1:109419600	GPSM2	1.07	8.3	0.48	8.22e-15	Fat distribution (HIV);
SARC	cis	rs6866344	0.697	rs11748495	chr5:178130000	A/G	cg10224037	chr5:178157518	ZNF354A	-0.96	-12.58	-0.64	4.94e-28	Neutrophil percentage of white cells;
SARC	cis	rs9911578	0.740	rs368243	chr17:56708979	T/C	cg05425664	chr17:57184151	TRIM37	-0.52	-6.32	-0.38	1.29e-9	Intelligence (multi-trait analysis);
SARC	cis	rs9905704	0.918	rs12952362	chr17:56900870	A/G	cg12560992	chr17:57184187	TRIM37	0.4	4.76	0.3	3.45e-6	Testicular germ cell tumor;
SARC	cis	rs6087990	0.806	rs4911258	chr20:31369479	G/A	cg13636640	chr20:31349939	DNMT3B	0.78	12.15	0.62	1.2e-26	Ulcerative colitis;
SARC	cis	rs1355223	1.000	rs11601923	chr11:34764354	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.49	-6.29	-0.38	1.53e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg12310025	chr6:25882481	NA	-0.54	-6.86	-0.41	6.21e-11	Intelligence (multi-trait analysis);
SARC	cis	rs3771570	0.818	rs73008126	chr2:242443157	A/C	cg21155796	chr2:242212141	HDLBP	0.62	5.5	0.34	1.02e-7	Prostate cancer;
SARC	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg10876282	chr6:28092338	ZSCAN16	-0.49	-5.04	-0.31	9.36e-7	Depression;
SARC	cis	rs6831352	0.918	rs7670241	chr4:100059619	G/T	cg13256891	chr4:100009986	ADH5	-0.64	-8.0	-0.46	5.7e-14	Alcohol dependence;
SARC	cis	rs5167	0.504	rs7257476	chr19:45453165	C/T	cg20090143	chr19:45452003	APOC2	0.3	4.89	0.31	1.85e-6	Blood protein levels;
SARC	cis	rs72766638	0.895	rs55924785	chr9:136929586	C/T	cg13789015	chr9:136890014	NCRNA00094	0.57	6.31	0.38	1.42e-9	Mosquito bite size;
SARC	cis	rs3768617	0.510	rs10797842	chr1:183081867	C/T	cg13390022	chr1:182993471	LAMC1	0.32	4.89	0.31	1.85e-6	Fuchs's corneal dystrophy;
SARC	cis	rs10791097	0.765	rs10894269	chr11:130722789	C/T	cg09137382	chr11:130731461	NA	0.32	5.03	0.31	9.86e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs9487051	1.000	rs9386795	chr6:109616528	G/A	cg01475377	chr6:109611718	NA	-0.41	-5.69	-0.35	3.7e-8	Reticulocyte fraction of red cells;
SARC	cis	rs6732160	0.774	rs11890053	chr2:73373448	G/A	cg01422370	chr2:73384389	NA	0.32	5.31	0.33	2.62e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6120849	0.951	rs6120848	chr20:33728678	T/C	cg24642439	chr20:33292090	TP53INP2	0.54	5.35	0.33	2.05e-7	Protein C levels;
SARC	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg22535103	chr8:58192502	C8orf71	-0.73	-7.24	-0.43	6.52e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs7659604	0.540	rs10004284	chr4:122699222	A/T	cg19671926	chr4:122722719	EXOSC9	0.65	8.59	0.49	1.25e-15	Type 2 diabetes;
SARC	trans	rs13046373	0.905	rs4816372	chr21:32077414	A/T	cg04738301	chr12:96184580	NTN4	-0.52	-6.69	-0.4	1.64e-10	HDL cholesterol;
SARC	cis	rs7264396	0.790	rs2425083	chr20:34300456	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	6.0	0.37	7.59e-9	Total cholesterol levels;
SARC	cis	rs60871478	0.545	rs35400476	chr7:795686	A/G	cg19087971	chr7:751233	PRKAR1B	-0.44	-5.02	-0.31	1.02e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs4851254	0.961	rs13019618	chr2:100753963	G/T	cg17356467	chr2:100759845	AFF3	0.29	4.75	0.3	3.53e-6	Intelligence (multi-trait analysis);
SARC	trans	rs7359257	1.000	rs55854539	chr15:67707832	G/C	cg14397500	chr7:2214759	MAD1L1	-0.41	-6.25	-0.38	1.95e-9	Menarche (age at onset);
SARC	cis	rs2832191	0.655	rs2247110	chr21:30323888	G/A	cg24692254	chr21:30365293	RNF160	-1.05	-19.37	-0.79	1.93e-50	Dental caries;
SARC	cis	rs6542838	0.702	rs4851177	chr2:99535188	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-6.01	-0.37	7.05e-9	Fear of minor pain;
SARC	cis	rs9316337	0.582	rs4770158	chr13:22023749	T/C	cg21080246	chr13:22033151	ZDHHC20	0.42	4.89	0.31	1.85e-6	Schizophrenia;
SARC	cis	rs858239	0.636	rs28706766	chr7:23169834	T/A	cg23682824	chr7:23144976	KLHL7	0.67	8.52	0.49	2.07e-15	Cerebrospinal fluid biomarker levels;
SARC	cis	rs708547	0.647	rs2293175	chr4:57861358	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.64	8.79	0.5	3.25e-16	Response to bleomycin (chromatid breaks);
SARC	cis	rs17376456	1.000	rs13163610	chr5:93548877	A/C	cg21475434	chr5:93447410	FAM172A	0.95	8.25	0.48	1.16e-14	Diabetic retinopathy;
SARC	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.74	8.74	0.5	4.81e-16	Height;
SARC	cis	rs56176327	0.600	rs7628207	chr3:49754970	T/C	cg13072238	chr3:49761600	GMPPB	-0.61	-6.34	-0.38	1.19e-9	Intelligence (multi-trait analysis);
SARC	cis	rs9399135	0.935	rs11754504	chr6:135321509	C/T	cg24558204	chr6:135376177	HBS1L	0.45	6.12	0.37	4e-9	Red blood cell count;
SARC	cis	rs3796352	1.000	rs11718538	chr3:52975987	C/G	cg27565382	chr3:53032988	SFMBT1	0.83	5.57	0.34	7.16e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs67460515	0.892	rs16832082	chr3:161043571	A/G	cg04691961	chr3:161091175	C3orf57	-0.49	-6.13	-0.37	3.69e-9	Parkinson's disease;
SARC	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg18404041	chr3:52824283	ITIH1	-0.43	-6.43	-0.39	7.12e-10	Bipolar disorder;
SARC	cis	rs559928	0.606	rs76653616	chr11:63936139	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	5.12	0.32	6.44e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs4427176	0.769	rs62491543	chr8:9506921	C/T	cg21625330	chr8:9911636	MSRA	-0.65	-5.52	-0.34	9.07e-8	Mosquito bite size;
SARC	cis	rs7264396	1.000	rs224440	chr20:34159447	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.45	-5.29	-0.33	2.79e-7	Total cholesterol levels;
SARC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg21747090	chr2:27597821	SNX17	-0.55	-7.68	-0.45	4.44e-13	Total body bone mineral density;
SARC	cis	rs2273669	0.915	rs4470881	chr6:109309287	A/G	cg01304950	chr6:109416612	SESN1;C6orf182	0.55	4.91	0.31	1.75e-6	Prostate cancer;
SARC	cis	rs7904368	0.568	rs10752061	chr10:16853900	A/G	cg23933602	chr10:16859644	RSU1	0.62	7.89	0.46	1.16e-13	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	trans	rs1945213	0.694	rs1384099	chr11:55866040	A/C	cg15704280	chr7:45808275	SEPT13	0.65	6.77	0.41	1.02e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9462027	0.628	rs1125340	chr6:34786408	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-6.17	-0.37	2.97e-9	Systemic lupus erythematosus;
SARC	cis	rs709400	0.663	rs3783402	chr14:103967929	C/G	cg12935359	chr14:103987150	CKB	-0.41	-6.08	-0.37	4.79e-9	Body mass index;
SARC	trans	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg15704280	chr7:45808275	SEPT13	-0.82	-10.49	-0.57	2.46e-21	Height;
SARC	cis	rs9902453	0.765	rs2628180	chr17:28101723	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.19	-0.43	8.82e-12	Coffee consumption (cups per day);
SARC	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg17294928	chr15:75287854	SCAMP5	0.58	7.7	0.45	3.96e-13	Breast cancer;
SARC	cis	rs9905704	0.846	rs7212271	chr17:56863918	C/T	cg12560992	chr17:57184187	TRIM37	0.45	5.24	0.32	3.56e-7	Testicular germ cell tumor;
SARC	cis	rs910316	1.000	rs7142235	chr14:75559963	T/C	cg11812906	chr14:75593930	NEK9	0.89	14.1	0.68	4.63e-33	Height;
SARC	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg26924012	chr15:45694286	SPATA5L1	0.77	10.99	0.58	6.8e-23	Homoarginine levels;
SARC	cis	rs11722228	0.522	rs73212817	chr4:10064011	T/C	cg11266682	chr4:10021025	SLC2A9	0.35	5.06	0.31	8.66e-7	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs920590	0.684	rs59565447	chr8:19668430	A/T	cg17834443	chr8:19674713	INTS10	0.63	7.4	0.44	2.41e-12	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs4660306	0.961	rs4660860	chr1:45946233	T/A	cg24296786	chr1:45957014	TESK2	0.58	6.72	0.4	1.35e-10	Homocysteine levels;
SARC	cis	rs11731606	0.583	rs7670371	chr4:95339036	C/T	cg20625393	chr4:95128694	SMARCAD1	0.52	4.76	0.3	3.34e-6	Mean platelet volume;
SARC	cis	rs1949733	1.000	rs3103072	chr4:8508431	C/T	cg11789530	chr4:8429930	ACOX3	-0.84	-11.35	-0.6	4.7e-24	Response to antineoplastic agents;
SARC	cis	rs13256369	0.802	rs12681326	chr8:8566389	G/A	cg17143192	chr8:8559678	CLDN23	0.52	5.86	0.36	1.6e-8	Obesity-related traits;
SARC	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg22974920	chr21:40686053	BRWD1	-0.44	-4.82	-0.3	2.54e-6	Cognitive function;
SARC	cis	rs4481887	0.927	rs11204631	chr1:248479530	A/G	cg13385794	chr1:248469461	NA	0.34	5.09	0.32	7.38e-7	Common traits (Other);
SARC	cis	rs9309473	0.898	rs11126404	chr2:73796924	T/A	cg07208825	chr2:73871855	ALMS1P	0.33	4.84	0.3	2.38e-6	Metabolite levels;
SARC	cis	rs36051895	0.632	rs62541899	chr9:5143291	C/T	cg02405213	chr9:5042618	JAK2	-0.45	-5.37	-0.33	1.91e-7	Pediatric autoimmune diseases;
SARC	cis	rs8067354	0.645	rs16943838	chr17:57839604	C/T	cg13753209	chr17:57696993	CLTC	0.63	6.35	0.38	1.09e-9	Hemoglobin concentration;
SARC	cis	rs9393692	0.557	rs12665035	chr6:26275649	T/C	cg13736514	chr6:26305472	NA	-0.41	-4.82	-0.3	2.62e-6	Educational attainment;
SARC	cis	rs999943	0.846	rs10947420	chr6:33611061	C/G	cg14003231	chr6:33640908	ITPR3	0.52	8.6	0.49	1.18e-15	Obesity (extreme);
SARC	cis	rs9815354	1.000	rs6768563	chr3:41865541	G/A	cg03022575	chr3:42003672	ULK4	0.56	5.02	0.31	1.05e-6	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg09455208	chr3:40491958	NA	0.38	5.57	0.34	6.97e-8	Renal cell carcinoma;
SARC	cis	rs2882667	0.824	rs12173085	chr5:138480025	A/G	cg04439458	chr5:138467593	SIL1	-0.29	-4.99	-0.31	1.19e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs7772486	0.712	rs6570726	chr6:146159460	T/C	cg05220968	chr6:146057943	EPM2A	-0.29	-4.96	-0.31	1.33e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7681440	0.904	rs28507349	chr4:90767063	G/A	cg06632027	chr4:90757378	SNCA	0.39	5.56	0.34	7.27e-8	Dementia with Lewy bodies;
SARC	cis	rs6582630	0.555	rs7978749	chr12:38527141	G/T	cg13010199	chr12:38710504	ALG10B	0.76	10.6	0.57	1.09e-21	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7824557	0.767	rs6991606	chr8:11176159	G/A	cg21775007	chr8:11205619	TDH	0.55	6.56	0.39	3.5e-10	Retinal vascular caliber;
SARC	cis	rs9303280	0.773	rs4795397	chr17:38023745	A/G	cg19468946	chr17:37922297	IKZF3	-0.3	-4.95	-0.31	1.43e-6	Self-reported allergy;
SARC	cis	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg08564027	chr20:61660810	NA	0.76	11.78	0.61	1.97e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-6.16	-0.37	3.15e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7829975	0.667	rs1877119	chr8:8707197	C/G	cg06636001	chr8:8085503	FLJ10661	0.59	7.53	0.44	1.13e-12	Mood instability;
SARC	cis	rs5758511	0.680	rs739146	chr22:42660414	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.43	6.47	0.39	5.63e-10	Birth weight;
SARC	cis	rs67460515	0.563	rs73023235	chr3:160864123	G/A	cg03342759	chr3:160939853	NMD3	-0.62	-7.51	-0.44	1.28e-12	Parkinson's disease;
SARC	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.1	0.37	4.43e-9	Height;
SARC	cis	rs1472147	1.000	rs4323418	chr7:128506970	C/T	cg00260937	chr7:128520193	KCP	-0.4	-4.86	-0.3	2.18e-6	Calcium levels;
SARC	trans	rs330048	0.561	rs330088	chr8:9149746	T/C	cg08975724	chr8:8085496	FLJ10661	0.5	6.4	0.39	8.4e-10	Systemic lupus erythematosus;
SARC	cis	rs198851	1.000	rs72834647	chr6:26043393	G/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.41	-5.17	-0.32	4.94e-7	Red cell distribution width;High light scatter reticulocyte percentage of red cells;Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg11890956	chr21:40555474	PSMG1	1.18	20.35	0.8	1.39e-53	Cognitive function;
SARC	cis	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg12463550	chr7:65579703	CRCP	0.7	5.12	0.32	6.52e-7	Diabetic kidney disease;
SARC	cis	rs2197308	0.765	rs11182481	chr12:37926019	T/C	cg26384229	chr12:38710491	ALG10B	0.88	12.52	0.63	7.58e-28	Morning vs. evening chronotype;
SARC	cis	rs6582630	0.519	rs8186881	chr12:38310285	A/G	cg13010199	chr12:38710504	ALG10B	0.78	10.82	0.58	2.18e-22	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs11039798	0.623	rs594615	chr11:48402804	T/C	cg15704280	chr7:45808275	SEPT13	-0.63	-6.39	-0.39	8.74e-10	Axial length;
SARC	cis	rs13202913	0.652	rs9371528	chr6:151832668	G/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.65	6.2	0.38	2.49e-9	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs13144136	0.710	rs10516208	chr4:10661734	C/T	cg10242279	chr4:10666415	CLNK	0.45	7.46	0.44	1.73e-12	Resistance to antihypertensive treatment in hypertension;
SARC	cis	rs7681440	0.566	rs356187	chr4:90692468	A/G	cg06632027	chr4:90757378	SNCA	0.39	4.78	0.3	3.16e-6	Dementia with Lewy bodies;
SARC	cis	rs36229146	1	rs36229146	chr7:22784486	TTATATATAAATATATATATATATATA/T	cg26061582	chr7:22766209	IL6	0.54	6.02	0.37	6.68e-9	Eosinophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
SARC	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg21016266	chr12:122356598	WDR66	0.31	4.77	0.3	3.24e-6	Mean platelet volume;
SARC	cis	rs9291683	0.595	rs10939665	chr4:10037628	T/C	cg11266682	chr4:10021025	SLC2A9	0.4	7.09	0.42	1.58e-11	Bone mineral density;
SARC	cis	rs2204008	0.715	rs12368462	chr12:38336116	C/G	cg13010199	chr12:38710504	ALG10B	0.8	10.9	0.58	1.23e-22	Bladder cancer;
SARC	cis	rs7666738	0.830	rs2865977	chr4:99017916	C/T	cg05340658	chr4:99064831	C4orf37	0.66	9.02	0.51	7.16e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2073300	0.609	rs77908916	chr20:23405626	C/G	cg12062639	chr20:23401060	NAPB	0.99	6.67	0.4	1.81e-10	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	trans	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.07	-0.42	1.77e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs72627123	0.867	rs112965033	chr14:74461117	T/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.77	5.86	0.36	1.6e-8	Morning vs. evening chronotype;
SARC	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg21226059	chr5:178986404	RUFY1	0.37	5.25	0.33	3.36e-7	Lung cancer;
SARC	cis	rs28655083	1.000	rs1843456	chr16:77072393	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.42	-5.97	-0.36	8.68e-9	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs11165623	0.602	rs7517055	chr1:97007781	C/G	cg10631902	chr5:14652156	NA	-0.41	-6.29	-0.38	1.53e-9	Hip circumference;Waist circumference;
SARC	cis	rs9513627	1.000	rs9513627	chr13:100196952	G/A	cg25919922	chr13:100150906	NA	0.69	5.19	0.32	4.61e-7	Obesity-related traits;
SARC	cis	rs7785360	0.800	rs9647932	chr7:69733502	A/G	cg10619644	chr7:69149951	AUTS2	0.42	4.9	0.31	1.77e-6	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
SARC	cis	rs3126085	0.597	rs12047544	chr1:152169922	C/T	cg09127314	chr1:152161683	NA	0.42	4.74	0.3	3.74e-6	Atopic dermatitis;
SARC	cis	rs910316	1.000	rs175512	chr14:75523382	T/C	cg11812906	chr14:75593930	NEK9	-0.87	-13.13	-0.65	7.62e-30	Height;
SARC	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg00629941	chr15:75287862	SCAMP5	0.39	4.74	0.3	3.77e-6	Breast cancer;
SARC	cis	rs2832077	0.506	rs2832088	chr21:30158620	G/A	cg08807101	chr21:30365312	RNF160	-0.52	-5.63	-0.35	5.07e-8	Cognitive test performance;
SARC	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	16.29	0.73	2.44e-40	Height;
SARC	cis	rs17376456	0.825	rs34967135	chr5:93221785	G/A	cg21475434	chr5:93447410	FAM172A	0.81	7.17	0.42	1.01e-11	Diabetic retinopathy;
SARC	cis	rs986417	1.000	rs1269984	chr14:60898138	C/G	cg27398547	chr14:60952738	C14orf39	-0.99	-9.0	-0.51	8.36e-17	Gut microbiota (bacterial taxa);
SARC	cis	rs933688	0.526	rs7727632	chr5:90609009	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.68	-5.79	-0.35	2.31e-8	Smoking behavior;
SARC	cis	rs798554	0.567	rs1182194	chr7:2868824	C/G	cg04166393	chr7:2884313	GNA12	0.4	4.78	0.3	3.11e-6	Height;
SARC	cis	rs11578119	0.933	rs11584810	chr1:170471343	C/T	cg09767346	chr1:170501363	GORAB	0.4	4.74	0.3	3.8e-6	Male-pattern baldness;
SARC	trans	rs459571	1.000	rs467387	chr9:136907005	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.64	-7.28	-0.43	5.07e-12	Platelet distribution width;
SARC	cis	rs7586879	0.639	rs2033656	chr2:25100902	C/G	cg04586622	chr2:25135609	ADCY3	0.32	5.55	0.34	7.58e-8	Body mass index;
SARC	cis	rs1153858	0.621	rs2687512	chr15:45581495	T/C	cg19305227	chr15:45544335	SLC28A2	0.29	5.05	0.31	8.94e-7	Homoarginine levels;
SARC	cis	rs959260	0.588	rs8079197	chr17:73316679	G/C	cg14668889	chr17:73230827	NUP85	-0.55	-7.1	-0.42	1.46e-11	Systemic lupus erythematosus;
SARC	cis	rs7005380	0.525	rs7000068	chr8:120922963	C/G	cg21744203	chr8:120868354	DSCC1	-0.47	-5.46	-0.34	1.23e-7	Interstitial lung disease;
SARC	cis	rs77372450	0.551	rs77213903	chr5:157106186	C/G	cg05585991	chr5:157099197	C5orf52	0.54	5.38	0.33	1.77e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs1153858	0.887	rs28569043	chr15:45730926	A/T	cg26924012	chr15:45694286	SPATA5L1	0.69	8.71	0.5	5.73e-16	Homoarginine levels;
SARC	cis	rs3617	0.572	rs2245538	chr3:52852060	T/C	cg18404041	chr3:52824283	ITIH1	-0.36	-5.29	-0.33	2.85e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.12	26.16	0.86	2.82e-71	Chronic sinus infection;
SARC	trans	rs61931739	0.929	rs2389272	chr12:34067771	T/C	cg26384229	chr12:38710491	ALG10B	-0.53	-7.12	-0.42	1.3e-11	Morning vs. evening chronotype;
SARC	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg24675658	chr1:53192096	ZYG11B	-0.66	-9.45	-0.53	3.74e-18	Monocyte count;
SARC	cis	rs644799	0.965	rs3016295	chr11:95554311	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	9.33	0.52	8.54e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs75920871	0.589	rs2306473	chr11:117097952	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.56	-4.96	-0.31	1.38e-6	Subjective well-being;
SARC	cis	rs9324022	0.722	rs111475476	chr14:101165917	C/T	cg18089426	chr14:101175970	NA	0.59	4.82	0.3	2.57e-6	Plateletcrit;
SARC	cis	rs7223966	0.883	rs2727317	chr17:61961302	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.46	5.12	0.32	6.53e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg16405210	chr4:1374714	KIAA1530	-0.42	-4.74	-0.3	3.78e-6	Obesity-related traits;
SARC	cis	rs8067545	0.750	rs11869616	chr17:19992713	G/A	cg13482628	chr17:19912719	NA	0.53	7.02	0.42	2.46e-11	Schizophrenia;
SARC	cis	rs1534166	0.601	rs13324779	chr3:133510413	G/A	cg01448562	chr3:133502909	NA	0.33	4.82	0.3	2.57e-6	Alcohol consumption (transferrin glycosylation);
SARC	cis	rs9398803	0.624	rs1378579	chr6:126655243	A/C	cg19875578	chr6:126661172	C6orf173	-0.47	-6.43	-0.39	7.35e-10	Male-pattern baldness;
SARC	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg21361702	chr7:150065534	REPIN1	0.49	4.88	0.3	2e-6	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs6938	0.534	rs11854704	chr15:75221015	C/T	cg14664628	chr15:75095509	CSK	-0.45	-5.55	-0.34	7.91e-8	Breast cancer;
SARC	cis	rs73086581	0.592	rs6037702	chr20:3936392	G/A	cg02187196	chr20:3869020	PANK2	-0.51	-5.91	-0.36	1.22e-8	Response to antidepressants in depression;
SARC	cis	rs9549367	0.789	rs7994324	chr13:113906497	T/C	cg18105134	chr13:113819100	PROZ	-0.38	-5.65	-0.35	4.64e-8	Platelet distribution width;
SARC	cis	rs2645694	0.603	rs2703123	chr4:77821154	C/T	cg06046430	chr4:77819534	ANKRD56	0.54	7.78	0.45	2.35e-13	Emphysema distribution in smoking;
SARC	cis	rs7980687	0.657	rs2851447	chr12:123665113	G/C	cg00376283	chr12:123451042	ABCB9	0.57	6.86	0.41	6.06e-11	Height;Educational attainment;Head circumference (infant);
SARC	cis	rs10931896	0.531	rs295118	chr2:201144004	C/T	cg23649088	chr2:200775458	C2orf69	0.6	8.58	0.49	1.35e-15	Systolic blood pressure;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg18075720	chr19:45349207	PVRL2	0.86	7.27	0.43	5.3e-12	Autism spectrum disorder or schizophrenia;
SARC	cis	rs4642101	0.511	rs9809596	chr3:12840513	C/G	cg24848339	chr3:12840334	CAND2	0.39	6.07	0.37	5.11e-9	QRS complex (12-leadsum);
SARC	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg13385521	chr17:29058706	SUZ12P	0.65	6.04	0.37	6.16e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	11.55	0.6	1.06e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg01448562	chr3:133502909	NA	-0.55	-8.42	-0.48	3.95e-15	Iron status biomarkers;
SARC	cis	rs1559088	1.000	rs1559087	chr19:33551041	A/G	cg17764715	chr19:33622953	WDR88	0.48	6.25	0.38	1.95e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg04546413	chr19:29218101	NA	0.63	8.52	0.49	2.01e-15	Methadone dose in opioid dependence;
SARC	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg13395646	chr4:1353034	KIAA1530	0.51	6.14	0.37	3.52e-9	Obesity-related traits;
SARC	cis	rs7408868	1.000	rs6512018	chr19:15282138	T/C	cg14696996	chr19:15285081	NOTCH3	1.01	8.87	0.5	1.93e-16	Pulse pressure;
SARC	cis	rs8114671	0.562	rs1801310	chr20:33517014	A/G	cg07148914	chr20:33460835	GGT7	0.45	5.45	0.34	1.29e-7	Height;
SARC	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg26335602	chr6:28129616	ZNF389	0.53	5.91	0.36	1.2e-8	Depression;
SARC	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.41	-5.76	-0.35	2.68e-8	Total body bone mineral density;
SARC	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg12311346	chr5:56204834	C5orf35	-0.57	-5.8	-0.36	2.1e-8	Initial pursuit acceleration;
SARC	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg13877915	chr19:58951672	ZNF132	0.64	9.35	0.52	7.5e-18	Uric acid clearance;
SARC	cis	rs4727027	0.901	rs6943937	chr7:148869915	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.52	6.36	0.38	1.05e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg09068993	chr10:95462173	C10orf4	0.53	6.86	0.41	6.15e-11	Breast cancer;
SARC	cis	rs8072100	0.840	rs2136751	chr17:45456093	A/G	cg08085267	chr17:45401833	C17orf57	-0.41	-4.86	-0.3	2.17e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	5.9	0.36	1.24e-8	Electroencephalogram traits;
SARC	cis	rs11711311	1.000	rs3732793	chr3:113442198	C/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.7	9.0	0.51	8.21e-17	IgG glycosylation;
SARC	cis	rs9911578	1.000	rs9907499	chr17:56949044	A/G	cg12560992	chr17:57184187	TRIM37	0.86	11.82	0.61	1.41e-25	Intelligence (multi-trait analysis);
SARC	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg03806693	chr22:41940476	POLR3H	-0.96	-13.58	-0.66	2.46e-31	Vitiligo;
SARC	cis	rs7945705	0.747	rs1980429	chr11:9010474	C/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.45	-6.43	-0.39	7.34e-10	Hemoglobin concentration;
SARC	cis	rs2180341	1.000	rs2326567	chr6:127606160	G/A	cg24812749	chr6:127587940	RNF146	0.97	12.76	0.64	1.23e-28	Breast cancer;
SARC	cis	rs6120849	0.754	rs17319032	chr20:33643296	T/C	cg06115741	chr20:33292138	TP53INP2	0.54	5.16	0.32	5.3e-7	Protein C levels;
SARC	cis	rs9840812	0.725	rs696517	chr3:136067655	T/C	cg15507776	chr3:136538369	TMEM22	0.53	5.54	0.34	8.2e-8	Fibrinogen levels;
SARC	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg18252515	chr7:66147081	NA	-0.62	-6.6	-0.4	2.77e-10	Aortic root size;
SARC	cis	rs1043515	0.748	rs11657530	chr17:36942814	T/C	cg20826740	chr17:37024042	NA	0.37	4.81	0.3	2.66e-6	Height;
SARC	cis	rs453301	0.686	rs6987107	chr8:8893581	A/G	cg11995313	chr8:8860691	ERI1	0.44	5.64	0.35	4.95e-8	Joint mobility (Beighton score);
SARC	cis	rs9291683	0.552	rs10939656	chr4:10014646	A/C	cg11266682	chr4:10021025	SLC2A9	0.42	7.65	0.45	5.26e-13	Bone mineral density;
SARC	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg12463550	chr7:65579703	CRCP	-0.65	-4.99	-0.31	1.18e-6	Diabetic kidney disease;
SARC	cis	rs10504073	0.584	rs4873092	chr8:49974053	T/C	cg00325661	chr8:49890786	NA	0.51	6.72	0.4	1.41e-10	Blood metabolite ratios;
SARC	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg08260549	chr8:21777063	XPO7	0.49	6.51	0.39	4.52e-10	Thyroid stimulating hormone;
SARC	cis	rs6604026	0.656	rs6604030	chr1:93398336	A/G	cg17283838	chr1:93427260	FAM69A	0.41	4.77	0.3	3.25e-6	Multiple sclerosis;
SARC	cis	rs2013441	1.000	rs17759923	chr17:20022035	G/A	cg13482628	chr17:19912719	NA	0.46	5.94	0.36	1.05e-8	Obesity-related traits;
SARC	cis	rs11155671	0.530	rs6933882	chr6:150210802	A/G	cg09699651	chr6:150184138	LRP11	0.52	6.59	0.4	2.86e-10	Testicular germ cell tumor;
SARC	cis	rs2204008	0.807	rs11182461	chr12:38539288	T/C	cg26384229	chr12:38710491	ALG10B	0.88	13.1	0.65	9.25e-30	Bladder cancer;
SARC	cis	rs10782582	0.609	rs12138898	chr1:76375183	G/T	cg03433033	chr1:76189801	ACADM	-0.4	-5.12	-0.32	6.39e-7	Daytime sleep phenotypes;
SARC	trans	rs116095464	0.614	rs10059220	chr5:242813	C/T	cg00938859	chr5:1591904	SDHAP3	0.78	6.51	0.39	4.53e-10	Breast cancer;
SARC	cis	rs1497406	0.744	rs10907282	chr1:16510139	A/G	cg06365898	chr1:16533907	ARHGEF19	0.37	5.09	0.32	7.48e-7	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9303401	0.527	rs34835800	chr17:56764990	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.11	12.12	0.62	1.52e-26	Cognitive test performance;
SARC	cis	rs10911363	0.592	rs2702205	chr1:183457198	A/G	cg09173681	chr1:183549694	NCF2	0.31	4.97	0.31	1.27e-6	Systemic lupus erythematosus;
SARC	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg06634786	chr22:41940651	POLR3H	-0.42	-5.0	-0.31	1.15e-6	Vitiligo;
SARC	cis	rs34172651	0.517	rs2303083	chr16:24835168	G/A	cg04756594	chr16:24857601	SLC5A11	0.41	5.18	0.32	4.84e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6088580	0.634	rs6059824	chr20:33014543	T/C	cg08999081	chr20:33150536	PIGU	0.43	6.52	0.39	4.28e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs9296092	0.538	rs9469491	chr6:33521545	A/G	cg13560919	chr6:33536144	NA	0.49	6.17	0.37	3.07e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs4713675	0.565	rs9469566	chr6:33667605	G/T	cg15676125	chr6:33679581	C6orf125	0.48	5.9	0.36	1.25e-8	Plateletcrit;
SARC	cis	rs7208859	0.623	rs55724095	chr17:29153058	A/G	cg13385521	chr17:29058706	SUZ12P	0.85	7.66	0.45	4.88e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg11644478	chr21:40555479	PSMG1	1.03	14.7	0.69	4.63e-35	Cognitive function;
SARC	cis	rs67311347	0.910	rs7617361	chr3:40373259	G/T	cg24209194	chr3:40518798	ZNF619	0.6	7.77	0.45	2.52e-13	Renal cell carcinoma;
SARC	cis	rs526231	0.511	rs55741939	chr5:102372688	T/C	cg23492399	chr5:102201601	PAM	-0.52	-5.67	-0.35	4.18e-8	Primary biliary cholangitis;
SARC	cis	rs8133932	0.608	rs403192	chr21:47360641	C/T	cg11214348	chr21:47283868	PCBP3	-0.39	-4.77	-0.3	3.18e-6	Schizophrenia;
SARC	cis	rs6545883	0.931	rs7557230	chr2:61736652	A/T	cg15711740	chr2:61764176	XPO1	-0.44	-5.45	-0.34	1.27e-7	Tuberculosis;
SARC	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg22920501	chr2:26401640	FAM59B	-0.61	-8.19	-0.47	1.71e-14	Gut microbiome composition (summer);
SARC	cis	rs9911578	1.000	rs9897326	chr17:56902297	A/G	cg05425664	chr17:57184151	TRIM37	-0.64	-7.98	-0.46	6.52e-14	Intelligence (multi-trait analysis);
SARC	cis	rs4595586	0.545	rs7307303	chr12:39368976	A/G	cg13010199	chr12:38710504	ALG10B	0.4	4.75	0.3	3.57e-6	Morning vs. evening chronotype;
SARC	cis	rs992157	0.560	rs6738394	chr2:219110625	G/A	cg00012203	chr2:219082015	ARPC2	-0.74	-11.16	-0.59	1.88e-23	Colorectal cancer;
SARC	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg01316550	chr5:56110833	MAP3K1	0.54	4.92	0.31	1.62e-6	Initial pursuit acceleration;
SARC	cis	rs1878931	0.507	rs67218524	chr16:3403057	G/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.57	-5.95	-0.36	9.76e-9	Body mass index (adult);
SARC	cis	rs963731	0.649	rs79361942	chr2:39336315	G/A	cg04010122	chr2:39346883	SOS1	1.11	6.38	0.39	9.36e-10	Corticobasal degeneration;
SARC	cis	rs10744422	1.000	rs10744434	chr12:123368419	T/A	cg25930673	chr12:123319894	HIP1R	-0.65	-4.73	-0.3	3.87e-6	Schizophrenia;
SARC	cis	rs9902453	0.769	rs7210288	chr17:28243473	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	6.94	0.41	3.92e-11	Coffee consumption (cups per day);
SARC	cis	rs7408868	0.831	rs1548555	chr19:15278057	A/G	cg14696996	chr19:15285081	NOTCH3	1.0	8.82	0.5	2.81e-16	Pulse pressure;
SARC	cis	rs7674212	0.540	rs2720469	chr4:104086484	C/T	cg16532752	chr4:104119610	CENPE	-0.48	-6.04	-0.37	6.16e-9	Type 2 diabetes;
SARC	cis	rs1050631	0.592	rs1789527	chr18:33712229	C/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.55	6.51	0.39	4.59e-10	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs9467773	0.836	rs1624440	chr6:26433329	G/A	cg11502198	chr6:26597334	ABT1	-0.48	-5.84	-0.36	1.76e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2832077	0.527	rs59730679	chr21:30226244	T/C	cg24692254	chr21:30365293	RNF160	-0.66	-7.6	-0.45	7.15e-13	Cognitive test performance;
SARC	cis	rs2295359	1.000	rs963427	chr1:67609347	A/G	cg11235152	chr1:67600687	NA	0.46	7.01	0.42	2.61e-11	Psoriasis;
SARC	cis	rs10752881	1.000	rs10752887	chr1:182990834	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.71	0.57	5.09e-22	Colorectal cancer;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg00452530	chr13:46543059	ZC3H13	-0.5	-6.48	-0.39	5.5e-10	Alcohol dependence;
SARC	cis	rs76419734	0.850	rs72671844	chr4:106642108	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.84	5.56	0.34	7.44e-8	Post bronchodilator FEV1;
SARC	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg08048268	chr3:133502702	NA	-0.46	-6.25	-0.38	1.97e-9	Iron status biomarkers;
SARC	cis	rs3733585	0.699	rs6449202	chr4:9974043	T/C	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.31	-0.33	2.61e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg09988853	chr19:50832728	KCNC3	0.49	6.43	0.39	7.28e-10	Breast cancer;
SARC	cis	rs8079658	1.000	rs11651498	chr17:63788615	C/T	cg03442606	chr17:63822778	CCDC46	-0.39	-4.97	-0.31	1.29e-6	Post bronchodilator FEV1;
SARC	cis	rs6840360	0.967	rs6832562	chr4:152602798	A/G	cg22705602	chr4:152727874	NA	-0.38	-6.54	-0.39	3.91e-10	Intelligence (multi-trait analysis);
SARC	cis	rs9911578	1.000	rs302859	chr17:56693132	C/T	cg12560992	chr17:57184187	TRIM37	0.83	11.32	0.6	5.91e-24	Intelligence (multi-trait analysis);
SARC	cis	rs554111	0.656	rs17450813	chr1:21264308	T/C	cg04902671	chr1:21058625	SH2D5	0.45	5.52	0.34	8.89e-8	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg05368731	chr17:41323189	NBR1	0.8	9.86	0.54	2.18e-19	Menopause (age at onset);
SARC	cis	rs524281	0.861	rs10791858	chr11:65978396	A/G	cg14036092	chr11:66035641	RAB1B	-0.52	-5.44	-0.34	1.33e-7	Electroencephalogram traits;
SARC	cis	rs1348850	0.567	rs3770012	chr2:178538023	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.42	-4.86	-0.3	2.13e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg07507251	chr3:52567010	NT5DC2	0.32	4.92	0.31	1.62e-6	Electroencephalogram traits;
SARC	cis	rs11645898	0.872	rs72787093	chr16:72190766	C/T	cg14768367	chr16:72042858	DHODH	-0.65	-5.71	-0.35	3.38e-8	Blood protein levels;
SARC	cis	rs9640161	0.789	rs10282458	chr7:150045302	C/T	cg21361702	chr7:150065534	REPIN1	0.51	5.69	0.35	3.75e-8	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.94	10.63	0.57	8.95e-22	Platelet count;
SARC	cis	rs79387448	0.745	rs7601773	chr2:103120483	G/T	cg09003973	chr2:102972529	NA	0.6	5.97	0.36	8.91e-9	Gut microbiota (bacterial taxa);
SARC	cis	rs7523050	0.730	rs11102650	chr1:109464228	C/G	cg22040431	chr1:109419606	GPSM2	0.65	4.75	0.3	3.63e-6	Fat distribution (HIV);
SARC	cis	rs916888	0.610	rs199436	chr17:44789285	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.54	-6.27	-0.38	1.75e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs1707322	0.721	rs10430123	chr1:46221440	T/C	cg03146154	chr1:46216737	IPP	0.53	6.37	0.39	1.01e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs748404	0.631	rs7167882	chr15:43678663	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.4	4.9	0.31	1.8e-6	Lung cancer;
SARC	cis	rs12497850	0.863	rs4974084	chr3:48939080	G/A	cg07636037	chr3:49044803	WDR6	1.01	17.62	0.76	1e-44	Parkinson's disease;
SARC	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg06212747	chr3:49208901	KLHDC8B	0.75	11.04	0.59	4.68e-23	Menarche (age at onset);
SARC	cis	rs7523050	1.000	rs7523050	chr1:109417679	C/A	cg08274380	chr1:109419600	GPSM2	0.75	6.55	0.39	3.55e-10	Fat distribution (HIV);
SARC	cis	rs9916302	0.904	rs11078897	chr17:37415870	C/T	cg20243544	chr17:37824526	PNMT	0.56	6.95	0.41	3.53e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs10189230	0.967	rs13026378	chr2:222352712	G/A	cg14652038	chr2:222343519	EPHA4	0.43	5.64	0.35	4.79e-8	Urate levels in lean individuals;
SARC	cis	rs7659604	1.000	rs7659604	chr4:122665514	A/G	cg19748678	chr4:122722346	EXOSC9	-0.41	-5.0	-0.31	1.14e-6	Type 2 diabetes;
SARC	cis	rs908922	0.887	rs6587688	chr1:152529622	C/T	cg09873164	chr1:152488093	CRCT1	-0.58	-7.04	-0.42	2.13e-11	Hair morphology;
SARC	cis	rs425277	1.000	rs427811	chr1:2075560	T/G	cg24578937	chr1:2090814	PRKCZ	0.31	5.86	0.36	1.61e-8	Height;
SARC	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg10591111	chr5:226296	SDHA	-0.55	-4.97	-0.31	1.31e-6	Breast cancer;
SARC	cis	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg24110177	chr3:50126178	RBM5	0.38	4.87	0.3	2.11e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7089973	0.604	rs11196932	chr10:116584386	C/T	cg08188268	chr10:116634841	FAM160B1	0.28	4.76	0.3	3.41e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs6570726	0.935	rs376991	chr6:145828073	G/C	cg23711669	chr6:146136114	FBXO30	0.78	11.86	0.61	1.04e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9341808	0.718	rs35447745	chr6:80816748	T/C	cg08355045	chr6:80787529	NA	0.34	5.48	0.34	1.09e-7	Sitting height ratio;
SARC	cis	rs208520	1.000	rs12193077	chr6:66989548	C/T	cg07460842	chr6:66804631	NA	0.89	10.27	0.56	1.22e-20	Exhaled nitric oxide output;
SARC	cis	rs7523050	0.643	rs17563938	chr1:109401654	C/T	cg08274380	chr1:109419600	GPSM2	1.03	7.67	0.45	4.7e-13	Fat distribution (HIV);
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg26879696	chr10:114206778	VTI1A;ZDHHC6	-0.5	-6.73	-0.4	1.3100000000000001e-10	Tetralogy of Fallot;
SARC	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs734999	0.545	rs28532547	chr1:2561286	T/G	cg20673091	chr1:2541236	MMEL1	-0.32	-4.98	-0.31	1.23e-6	Ulcerative colitis;
SARC	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg15847926	chr7:2749597	AMZ1	-0.3	-4.93	-0.31	1.54e-6	Height;
SARC	cis	rs7408868	1.000	rs2074622	chr19:15277620	G/C	cg14696996	chr19:15285081	NOTCH3	1.01	8.93	0.5	1.32e-16	Pulse pressure;
SARC	cis	rs5753037	0.653	rs105311	chr22:30137262	G/A	cg01021169	chr22:30184971	ASCC2	-0.46	-6.47	-0.39	5.87e-10	Type 1 diabetes;
SARC	cis	rs11997175	0.558	rs6468207	chr8:33798095	G/A	ch.8.33884649F	chr8:33765107	NA	-0.44	-5.31	-0.33	2.58e-7	Body mass index;
SARC	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg03709012	chr19:19516395	GATAD2A	-0.93	-14.98	-0.7	5.39e-36	Tonsillectomy;
SARC	cis	rs5995756	0.688	rs11705236	chr22:40010682	G/A	cg10455938	chr22:40058150	CACNA1I	-0.48	-6.24	-0.38	2.03e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.78	10.1	0.55	3.87e-20	Prudent dietary pattern;
SARC	cis	rs858239	0.600	rs10233039	chr7:23143113	G/A	cg23682824	chr7:23144976	KLHL7	0.7	9.5	0.53	2.73e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs10046574	0.831	rs10250306	chr7:135165275	G/A	cg27474649	chr7:135195673	CNOT4	0.85	6.98	0.42	3e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs2425143	1.000	rs2425149	chr20:34359587	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-6.34	-0.38	1.19e-9	Blood protein levels;
SARC	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg03351412	chr1:154909251	PMVK	-0.43	-5.43	-0.34	1.41e-7	Prostate cancer;
SARC	cis	rs9581943	0.967	rs9554197	chr13:28476978	C/T	cg16302790	chr13:28498334	PDX1	0.53	8.05	0.47	4.23e-14	Pancreatic cancer;
SARC	cis	rs8523	0.779	rs1323739	chr6:11004561	C/G	cg13562911	chr6:11044106	ELOVL2	-0.51	-7.07	-0.42	1.75e-11	Red blood cell fatty acid levels;
SARC	cis	rs4689388	0.926	rs9998835	chr4:6293237	C/G	cg14416269	chr4:6271139	WFS1	0.32	4.92	0.31	1.61e-6	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs11122272	0.735	rs2790897	chr1:231491712	C/A	cg06096015	chr1:231504339	EGLN1	0.37	5.46	0.34	1.2e-7	Hemoglobin concentration;
SARC	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg24503407	chr1:205819492	PM20D1	0.43	4.99	0.31	1.21e-6	Parkinson's disease;
SARC	cis	rs9457247	0.765	rs9457256	chr6:167436461	T/C	cg07741184	chr6:167504864	NA	0.38	7.27	0.43	5.42e-12	Crohn's disease;
SARC	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg11987759	chr7:65425863	GUSB	0.58	7.61	0.45	6.83e-13	Aortic root size;
SARC	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	15.35	0.71	3.17e-37	Chronic sinus infection;
SARC	cis	rs561341	0.710	rs9900031	chr17:30199537	T/C	cg13647721	chr17:30228624	UTP6	-0.66	-5.62	-0.35	5.42e-8	Hip circumference adjusted for BMI;
SARC	cis	rs7264396	0.528	rs3787174	chr20:34487921	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-6.55	-0.39	3.67e-10	Total cholesterol levels;
SARC	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg25036284	chr2:26402008	FAM59B	0.49	5.97	0.36	8.85e-9	Gut microbiome composition (summer);
SARC	cis	rs9300255	0.602	rs1051431	chr12:123645803	G/A	cg05973401	chr12:123451056	ABCB9	0.53	6.13	0.37	3.64e-9	Neutrophil percentage of white cells;
SARC	cis	rs11122272	0.735	rs11122279	chr1:231519804	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-9.7	-0.54	6.45e-19	Hemoglobin concentration;
SARC	cis	rs7582720	0.943	rs72934551	chr2:203984117	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	7.8	0.45	2.11e-13	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs9660992	0.512	rs12142402	chr1:205128215	A/T	cg21643547	chr1:205240462	TMCC2	-0.58	-7.89	-0.46	1.14e-13	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs4664308	0.692	rs4233681	chr2:160960058	T/C	cg03641300	chr2:160917029	PLA2R1	-0.52	-6.86	-0.41	6.11e-11	Idiopathic membranous nephropathy;
SARC	cis	rs698813	0.572	rs6544749	chr2:44478077	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.81	0.36	2.07e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs765787	0.530	rs2554454	chr15:45521536	A/G	cg24006582	chr15:45444508	DUOX1	-0.52	-6.96	-0.41	3.51e-11	Uric acid levels;
SARC	cis	rs12586317	0.547	rs12435454	chr14:35466997	A/G	cg16230307	chr14:35515116	FAM177A1	1.02	11.85	0.61	1.18e-25	Psoriasis;
SARC	cis	rs2797160	1.000	rs1935772	chr6:125994708	T/C	cg05901451	chr6:126070800	HEY2	-0.4	-4.82	-0.3	2.56e-6	Endometrial cancer;
SARC	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	8.8	0.5	3.1e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs3812831	0.654	rs6560933	chr13:114937294	A/G	cg15896084	chr13:114927664	NA	-0.42	-5.73	-0.35	3.06e-8	Schizophrenia;
SARC	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	5.08	0.32	7.56e-7	Personality dimensions;
SARC	cis	rs910316	0.789	rs12894419	chr14:75471802	C/T	cg23033748	chr14:75592666	NEK9	0.38	5.18	0.32	4.83e-7	Height;
SARC	cis	rs3858526	0.883	rs7481923	chr11:5933342	T/C	cg02574844	chr11:5959923	NA	-0.43	-5.35	-0.33	2.13e-7	DNA methylation (variation);
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg18555811	chr3:193852889	HES1	0.54	7.47	0.44	1.64e-12	Tetralogy of Fallot;
SARC	cis	rs6484504	0.600	rs12796587	chr11:31266443	T/C	cg26647111	chr11:31128758	NA	-0.39	-5.07	-0.32	8.23e-7	Red blood cell count;
SARC	cis	rs7937890	0.874	rs2303972	chr11:14303282	T/A	cg02886208	chr11:14281011	SPON1	0.39	5.49	0.34	1.06e-7	Mitochondrial DNA levels;
SARC	cis	rs12477438	0.765	rs13406288	chr2:99589585	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-15.22	-0.71	8.78e-37	Chronic sinus infection;
SARC	cis	rs644799	1.000	rs544119	chr11:95538624	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	15.35	0.71	3.21e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.03	0.37	6.27e-9	Prudent dietary pattern;
SARC	cis	rs7236492	0.572	rs7244366	chr18:77179746	C/T	cg15644404	chr18:77186268	NFATC1	-0.62	-4.83	-0.3	2.47e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs6667605	0.527	rs6673993	chr1:2552071	T/C	cg20673091	chr1:2541236	MMEL1	0.32	4.99	0.31	1.21e-6	Inflammatory bowel disease;Ulcerative colitis;
SARC	cis	rs829883	0.664	rs1096148	chr12:98851005	A/G	cg25150519	chr12:98850993	NA	0.84	13.52	0.66	4.05e-31	Colorectal adenoma (advanced);
SARC	cis	rs57994353	0.793	rs35531907	chr9:139327143	C/T	cg14169450	chr9:139327907	INPP5E	0.41	5.25	0.33	3.48e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs918629	0.567	rs1423268	chr5:95256974	T/C	cg16656078	chr5:95278638	ELL2	-0.54	-6.75	-0.4	1.16e-10	IgG glycosylation;
SARC	cis	rs2197308	0.765	rs12824529	chr12:37931656	T/C	cg13010199	chr12:38710504	ALG10B	0.8	11.14	0.59	2.24e-23	Morning vs. evening chronotype;
SARC	cis	rs13191362	1.000	rs13202339	chr6:163081812	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.69	6.04	0.37	5.94e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	0.87	7.85	0.46	1.54e-13	Alzheimer's disease;
SARC	trans	rs10242455	0.571	rs41258334	chr7:99271808	T/C	cg20468253	chr7:106685977	PRKAR2B	-1.06	-6.34	-0.38	1.18e-9	Blood metabolite levels;
SARC	trans	rs35851103	0.506	rs4841659	chr8:11828200	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	7.12	0.42	1.33e-11	Neuroticism;
SARC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg07414643	chr4:187882934	NA	0.44	6.43	0.39	7.31e-10	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg14531310	chr9:34401237	C9orf25	-0.51	-6.32	-0.38	1.32e-9	Migraine with aura;
SARC	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs12291225	0.546	rs11023199	chr11:14394258	A/G	cg19336497	chr11:14380999	RRAS2	-0.44	-7.64	-0.45	5.45e-13	Sense of smell;
SARC	cis	rs2303759	0.709	rs10422677	chr19:49824290	C/T	cg24324837	chr19:49891574	CCDC155	0.4	4.77	0.3	3.21e-6	Multiple sclerosis;
SARC	cis	rs4144743	1.000	rs3809861	chr17:45330066	A/G	cg18085866	chr17:45331354	ITGB3	-0.73	-7.41	-0.44	2.29e-12	Body mass index;
SARC	trans	rs2727020	0.734	rs1164663	chr11:49294723	A/T	cg15704280	chr7:45808275	SEPT13	0.67	7.89	0.46	1.15e-13	Coronary artery disease;
SARC	cis	rs4563143	0.514	rs55727361	chr19:29300415	A/T	cg12756686	chr19:29218302	NA	0.59	6.72	0.4	1.36e-10	Methadone dose in opioid dependence;
SARC	cis	rs208520	0.690	rs2144081	chr6:66824972	G/A	cg07460842	chr6:66804631	NA	-1.06	-14.03	-0.68	8.04e-33	Exhaled nitric oxide output;
SARC	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg22105103	chr4:187893119	NA	0.49	6.45	0.39	6.33e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs76419734	1.000	rs10516525	chr4:106668025	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.76	4.95	0.31	1.4e-6	Post bronchodilator FEV1;
SARC	cis	rs765787	0.530	rs4775837	chr15:45537684	G/T	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.81e-6	Uric acid levels;
SARC	cis	rs2576037	0.796	rs2576043	chr18:44573476	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.67	-9.79	-0.54	3.59e-19	Personality dimensions;
SARC	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg11644478	chr21:40555479	PSMG1	1.05	14.79	0.7	2.43e-35	Cognitive function;
SARC	cis	rs7208859	0.623	rs11651858	chr17:29170718	A/G	cg13385521	chr17:29058706	SUZ12P	0.86	7.34	0.43	3.52e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs7927771	0.839	rs7124681	chr11:47529947	C/A	cg05585544	chr11:47624801	NA	-0.34	-4.95	-0.31	1.42e-6	Subjective well-being;
SARC	cis	rs672059	1.000	rs660602	chr1:183162774	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.51	6.94	0.41	3.79e-11	Hypertriglyceridemia;
SARC	cis	rs10979	0.631	rs12530338	chr6:143872563	C/T	cg25407410	chr6:143891975	LOC285740	-0.46	-5.52	-0.34	8.8e-8	Hypospadias;
SARC	cis	rs7582180	0.663	rs2309800	chr2:100992086	C/T	cg14675211	chr2:100938903	LONRF2	0.54	7.89	0.46	1.21e-13	Intelligence (multi-trait analysis);
SARC	cis	rs2180341	0.695	rs6569487	chr6:127726196	C/T	cg24812749	chr6:127587940	RNF146	-0.69	-9.0	-0.51	8.17e-17	Breast cancer;
SARC	cis	rs11098499	0.820	rs13128602	chr4:120459366	C/T	cg24375607	chr4:120327624	NA	-0.44	-5.2	-0.32	4.28e-7	Corneal astigmatism;
SARC	cis	rs7327064	0.960	rs9602362	chr13:36743638	C/T	cg13455704	chr13:36871754	C13orf38	0.52	5.61	0.34	5.85e-8	Economic and political preferences;
SARC	cis	rs5753618	0.539	rs8135344	chr22:31671932	G/T	cg00478049	chr22:31556069	RNF185	0.44	4.78	0.3	3.16e-6	Colorectal cancer;
SARC	cis	rs459571	0.959	rs460888	chr9:136913123	C/G	cg13789015	chr9:136890014	NCRNA00094	0.63	8.64	0.49	9.18e-16	Platelet distribution width;
SARC	cis	rs3540	0.960	rs8030299	chr15:91026459	G/A	cg22089800	chr15:90895588	ZNF774	0.48	5.51	0.34	9.63e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs986417	1.000	rs8004736	chr14:61053061	T/C	cg27398547	chr14:60952738	C14orf39	0.87	7.66	0.45	5.1e-13	Gut microbiota (bacterial taxa);
SARC	cis	rs7829975	0.846	rs7005216	chr8:8547110	C/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-5.16	-0.32	5.19e-7	Mood instability;
SARC	cis	rs3741404	0.560	rs7938819	chr11:63910116	G/A	cg18225595	chr11:63971243	STIP1	-0.48	-7.4	-0.44	2.48e-12	Platelet count;
SARC	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg21782813	chr7:2030301	MAD1L1	0.48	7.75	0.45	2.91e-13	Bipolar disorder and schizophrenia;
SARC	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.97e-8	Aortic root size;
SARC	cis	rs9611519	0.531	rs1967708	chr22:41444444	G/C	cg17376030	chr22:41985996	PMM1	0.42	5.19	0.32	4.57e-7	Neuroticism;
SARC	cis	rs3768617	0.510	rs10797849	chr1:183088988	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.68	9.9	0.54	1.62e-19	Fuchs's corneal dystrophy;
SARC	cis	rs155076	1.000	rs484365	chr13:21845944	G/T	cg06138931	chr13:21896616	NA	-0.39	-5.08	-0.32	7.88e-7	White matter hyperintensity burden;
SARC	cis	rs36051895	0.589	rs7850294	chr9:5191128	C/T	cg02405213	chr9:5042618	JAK2	0.42	5.07	0.31	8.27e-7	Pediatric autoimmune diseases;
SARC	cis	rs11098499	0.954	rs56270433	chr4:120406030	C/T	cg09307838	chr4:120376055	NA	0.93	12.78	0.64	1.08e-28	Corneal astigmatism;
SARC	cis	rs4713118	0.869	rs9366700	chr6:27696951	C/T	cg17221315	chr6:27791827	HIST1H4J	0.49	5.29	0.33	2.77e-7	Parkinson's disease;
SARC	cis	rs6788895	1.000	rs73010965	chr3:150497570	G/C	cg09723797	chr3:150481914	SIAH2	0.78	5.13	0.32	6.09e-7	Breast cancer;
SARC	cis	rs4727443	0.899	rs6954978	chr7:99582212	A/G	cg22004693	chr7:99632812	ZKSCAN1	0.63	8.18	0.47	1.87e-14	Interstitial lung disease;
SARC	cis	rs6604026	0.656	rs4561051	chr1:93391346	A/C	cg17283838	chr1:93427260	FAM69A	0.41	4.77	0.3	3.25e-6	Multiple sclerosis;
SARC	cis	rs1008375	0.966	rs12509962	chr4:17680292	G/A	cg27347728	chr4:17578864	LAP3	0.46	5.76	0.35	2.66e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg13393036	chr8:95962371	TP53INP1	-0.39	-6.75	-0.4	1.13e-10	Type 2 diabetes;
SARC	cis	rs10992471	0.756	rs10115222	chr9:95128149	C/T	cg13798575	chr9:95087839	CENPP;NOL8	0.52	6.36	0.38	1.04e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs16912285	0.579	rs73438263	chr11:24265205	C/T	ch.11.24196551F	chr11:24239977	NA	0.63	4.81	0.3	2.71e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs722599	0.683	rs7145246	chr14:75242394	A/T	cg08847533	chr14:75593920	NEK9	-0.42	-4.74	-0.3	3.8e-6	IgG glycosylation;
SARC	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg12463550	chr7:65579703	CRCP	0.66	5.06	0.31	8.64e-7	Diabetic kidney disease;
SARC	cis	rs28795989	0.896	rs28370977	chr4:7894414	T/G	cg18538662	chr4:7941764	AFAP1	-0.38	-4.79	-0.3	3e-6	Intraocular pressure;
SARC	cis	rs7635838	0.654	rs4684766	chr3:11285474	G/A	cg00170343	chr3:11313890	ATG7	0.63	7.85	0.46	1.54e-13	HDL cholesterol;
SARC	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.95	11.92	0.62	6.96e-26	Age-related macular degeneration (geographic atrophy);
SARC	trans	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg23633993	chr2:32853151	TTC27	-0.52	-6.53	-0.39	4.05e-10	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9914544	0.545	rs2892015	chr17:18786849	C/T	cg25390199	chr17:18761479	PRPSAP2	0.46	6.05	0.37	5.66e-9	Educational attainment (years of education);
SARC	cis	rs4727443	1.000	rs6974373	chr7:99590893	C/G	cg22004693	chr7:99632812	ZKSCAN1	0.62	7.95	0.46	8.07e-14	Interstitial lung disease;
SARC	cis	rs7674212	0.541	rs2045746	chr4:104083578	A/C	cg16532752	chr4:104119610	CENPE	0.48	5.82	0.36	1.91e-8	Type 2 diabetes;
SARC	trans	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg21659725	chr3:3221576	CRBN	0.81	12.44	0.63	1.38e-27	Intelligence (multi-trait analysis);
SARC	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg16325326	chr1:53192061	ZYG11B	-0.83	-13.35	-0.66	1.47e-30	Monocyte count;
SARC	cis	rs6840360	0.615	rs6535822	chr4:152679722	A/G	cg22705602	chr4:152727874	NA	-0.49	-8.55	-0.49	1.66e-15	Intelligence (multi-trait analysis);
SARC	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg06634786	chr22:41940651	POLR3H	0.55	6.33	0.38	1.24e-9	Vitiligo;
SARC	cis	rs2658782	0.756	rs3019222	chr11:93079718	C/T	cg15737290	chr11:93063684	CCDC67	0.71	7.23	0.43	6.75e-12	Pulmonary function decline;
SARC	trans	rs208520	0.909	rs62414636	chr6:67015723	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.82	8.32	0.48	7.56e-15	Exhaled nitric oxide output;
SARC	cis	rs6429082	0.807	rs4659857	chr1:235581411	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.57	-7.52	-0.44	1.16e-12	Adiposity;
SARC	trans	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg06636001	chr8:8085503	FLJ10661	0.54	7.16	0.42	1.06e-11	Neuroticism;
SARC	cis	rs1943345	0.530	rs501155	chr11:82919893	G/T	cg07047830	chr11:82868014	PCF11	0.41	5.03	0.31	9.93e-7	Obesity-related traits;
SARC	cis	rs911555	0.755	rs12436729	chr14:103929889	G/C	cg24130564	chr14:104152367	KLC1	0.5	5.96	0.36	9.3e-9	Intelligence (multi-trait analysis);
SARC	cis	rs2120019	1.000	rs12185102	chr15:75352201	G/A	cg12414181	chr15:75287860	SCAMP5	-0.47	-5.4	-0.33	1.67e-7	Blood trace element (Zn levels);
SARC	cis	rs6840360	0.967	rs10028410	chr4:152606573	T/C	cg22705602	chr4:152727874	NA	-0.37	-6.34	-0.38	1.18e-9	Intelligence (multi-trait analysis);
SARC	cis	rs2302729	0.929	rs7306298	chr12:2777311	G/A	cg19945202	chr12:2788847	CACNA1C	-0.65	-7.1	-0.42	1.46e-11	Sleep quality;
SARC	cis	rs6439153	0.933	rs1871951	chr3:128720487	A/G	cg25356066	chr3:128598488	ACAD9	0.46	5.52	0.34	8.87e-8	Pneumococcal bacteremia;
SARC	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg06028605	chr16:24865363	SLC5A11	0.36	5.23	0.32	3.78e-7	Intelligence (multi-trait analysis);
SARC	cis	rs13256369	1.000	rs10095733	chr8:8574646	A/G	cg17143192	chr8:8559678	CLDN23	0.51	5.8	0.35	2.2e-8	Obesity-related traits;
SARC	cis	rs910316	1.000	rs1047418	chr14:75605792	A/G	cg23033748	chr14:75592666	NEK9	0.37	5.22	0.32	4.05e-7	Height;
SARC	cis	rs1707322	1.000	rs10890378	chr1:46410657	A/G	cg03146154	chr1:46216737	IPP	-0.46	-5.47	-0.34	1.14e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs826838	0.967	rs1486345	chr12:39131677	G/A	cg13010199	chr12:38710504	ALG10B	-0.64	-8.88	-0.5	1.85e-16	Heart rate;
SARC	cis	rs8060686	0.844	rs7196076	chr16:67887494	T/A	cg27539214	chr16:67997921	SLC12A4	-0.55	-4.74	-0.3	3.65e-6	HDL cholesterol;Metabolic syndrome;
SARC	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg03650068	chr1:25596491	NA	0.34	5.24	0.32	3.52e-7	Erythrocyte sedimentation rate;
SARC	cis	rs763121	0.626	rs5750643	chr22:39009017	A/G	cg06022373	chr22:39101656	GTPBP1	0.9	12.12	0.62	1.51e-26	Menopause (age at onset);
SARC	cis	rs12142240	0.660	rs6679080	chr1:46819779	A/T	cg14993813	chr1:46806288	NSUN4	-0.52	-5.46	-0.34	1.22e-7	Menopause (age at onset);
SARC	cis	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg24110177	chr3:50126178	RBM5	-0.55	-7.28	-0.43	5.15e-12	Intelligence (multi-trait analysis);
SARC	cis	rs4851254	0.961	rs11677607	chr2:100751150	C/T	cg17356467	chr2:100759845	AFF3	0.28	4.77	0.3	3.26e-6	Intelligence (multi-trait analysis);
SARC	trans	rs1814175	0.645	rs28538913	chr11:50040718	C/T	cg15704280	chr7:45808275	SEPT13	-0.89	-14.15	-0.68	3.23e-33	Height;
SARC	cis	rs12079745	0.793	rs12071122	chr1:169191749	C/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.77	-5.08	-0.32	7.79e-7	QT interval;
SARC	cis	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg06212747	chr3:49208901	KLHDC8B	0.52	6.5	0.39	4.81e-10	Resting heart rate;
SARC	cis	rs9916302	0.660	rs665413	chr17:37455678	T/A	cg15445000	chr17:37608096	MED1	-0.46	-4.97	-0.31	1.32e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs3768617	0.510	rs2333620	chr1:183100555	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.66e-21	Fuchs's corneal dystrophy;
SARC	cis	rs2013441	0.965	rs1544421	chr17:20114217	T/C	cg13482628	chr17:19912719	NA	-0.45	-5.89	-0.36	1.35e-8	Obesity-related traits;
SARC	cis	rs6866344	0.697	rs11748497	chr5:178130012	C/G	cg03877680	chr5:178157825	ZNF354A	1.03	13.01	0.65	1.92e-29	Neutrophil percentage of white cells;
SARC	cis	rs11122272	0.701	rs2790894	chr1:231505587	T/A	cg06096015	chr1:231504339	EGLN1	0.38	5.72	0.35	3.28e-8	Hemoglobin concentration;
SARC	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	8.54	0.49	1.71e-15	Alzheimer's disease;
SARC	cis	rs6918586	0.615	rs198841	chr6:26111671	G/T	cg18357526	chr6:26021779	HIST1H4A	-0.46	-5.84	-0.36	1.71e-8	Schizophrenia;
SARC	cis	rs1707322	1.000	rs1768807	chr1:46510570	A/G	cg06784218	chr1:46089804	CCDC17	-0.38	-6.71	-0.4	1.48e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6141769	0.542	rs6058819	chr20:31303942	T/C	cg17884169	chr20:31446444	EFCAB8	-0.44	-4.78	-0.3	3.09e-6	Subjective well-being;
SARC	cis	rs9660992	0.573	rs1172159	chr1:205207512	T/C	cg07972983	chr1:205091412	RBBP5	0.57	7.07	0.42	1.83e-11	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg14893161	chr1:205819251	PM20D1	-0.77	-13.04	-0.65	1.48e-29	Monocyte percentage of white cells;
SARC	cis	rs883565	0.502	rs4496420	chr3:38942716	A/C	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.43	-5.0	-0.31	1.13e-6	Handedness;
SARC	trans	rs2727020	0.729	rs2866328	chr11:49282421	A/G	cg03929089	chr4:120376271	NA	0.77	11.48	0.6	1.77e-24	Coronary artery disease;
SARC	cis	rs8014204	0.566	rs11629369	chr14:75162021	G/A	cg17347104	chr14:75034677	LTBP2	-0.5	-6.79	-0.41	9.29e-11	Caffeine consumption;
SARC	cis	rs7296418	0.517	rs73231928	chr12:123724325	T/C	cg05973401	chr12:123451056	ABCB9	0.49	5.8	0.36	2.15e-8	Platelet count;
SARC	cis	rs11264799	0.603	rs2224607	chr1:157571721	C/T	cg18268488	chr1:157545234	FCRL4	0.33	5.62	0.35	5.39e-8	IgA nephropathy;
SARC	cis	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg00409905	chr10:38381863	ZNF37A	-0.55	-7.71	-0.45	3.72e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs2180341	1.000	rs6903878	chr6:127638600	C/G	cg24812749	chr6:127587940	RNF146	0.98	12.95	0.65	2.92e-29	Breast cancer;
SARC	cis	rs2228479	0.867	rs12919804	chr16:89945369	G/A	cg00800038	chr16:89945340	TCF25	-0.72	-5.75	-0.35	2.8e-8	Skin colour saturation;
SARC	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs523522	0.962	rs4766969	chr12:120988238	A/G	cg27279351	chr12:120934652	DYNLL1	0.72	8.87	0.5	2.02e-16	High light scatter reticulocyte count;
SARC	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg24829409	chr8:58192753	C8orf71	0.66	6.17	0.37	2.98e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs644799	0.664	rs603625	chr11:95554283	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.96	16.12	0.73	8.89e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs11122272	0.735	rs2739507	chr1:231527329	T/C	cg06096015	chr1:231504339	EGLN1	0.38	5.63	0.35	5.06e-8	Hemoglobin concentration;
SARC	cis	rs6058796	1.000	rs57861317	chr20:31260708	C/T	cg13636640	chr20:31349939	DNMT3B	0.56	4.94	0.31	1.48e-6	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg19346786	chr7:2764209	NA	-0.38	-5.67	-0.35	4.21e-8	Height;
SARC	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg03264133	chr6:25882463	NA	-0.63	-8.35	-0.48	6.3e-15	Intelligence (multi-trait analysis);
SARC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg02018176	chr4:1364513	KIAA1530	0.63	9.54	0.53	2.06e-18	Longevity;
SARC	cis	rs240764	0.621	rs10457844	chr6:101196532	T/A	cg09795085	chr6:101329169	ASCC3	-0.5	-6.58	-0.4	3.06e-10	Neuroticism;
SARC	cis	rs6866344	0.570	rs1071882	chr5:178136040	C/T	cg03877680	chr5:178157825	ZNF354A	1.05	14.98	0.7	5.6e-36	Neutrophil percentage of white cells;
SARC	cis	rs7772486	0.720	rs4896837	chr6:146014168	C/T	cg05347473	chr6:146136440	FBXO30	-0.55	-7.76	-0.45	2.64e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg03161606	chr19:29218774	NA	0.47	6.75	0.4	1.16e-10	Methadone dose in opioid dependence;
SARC	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg11843238	chr5:131593191	PDLIM4	-0.39	-5.2	-0.32	4.27e-7	Acylcarnitine levels;
SARC	cis	rs1561176	0.505	rs10281391	chr7:155020225	A/G	cg09933929	chr7:154677023	DPP6	-0.52	-4.78	-0.3	3.12e-6	Personality dimensions;
SARC	cis	rs9790314	0.846	rs1478568	chr3:161014276	C/T	cg03342759	chr3:160939853	NMD3	-0.71	-9.4	-0.52	5.51e-18	Morning vs. evening chronotype;
SARC	cis	rs4938330	0.681	rs12271169	chr11:116980021	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.5	-5.15	-0.32	5.5e-7	Blood protein levels;
SARC	cis	rs826838	0.967	rs11169387	chr12:39145737	C/T	cg26384229	chr12:38710491	ALG10B	0.86	12.84	0.64	6.73e-29	Heart rate;
SARC	cis	rs2832191	1.000	rs2832183	chr21:30482150	G/A	cg08807101	chr21:30365312	RNF160	-0.75	-10.39	-0.56	4.97e-21	Dental caries;
SARC	cis	rs9309473	1.000	rs6756987	chr2:73687077	G/T	cg20560298	chr2:73613845	ALMS1	-0.51	-6.12	-0.37	3.98e-9	Metabolite levels;
SARC	cis	rs858239	0.669	rs10950940	chr7:23196816	C/T	cg23682824	chr7:23144976	KLHL7	-0.64	-8.08	-0.47	3.58e-14	Cerebrospinal fluid biomarker levels;
SARC	cis	rs11574514	1.000	rs116580887	chr16:68299502	G/A	cg01866162	chr16:67596514	CTCF	1.11	6.5	0.39	4.88e-10	Crohn's disease;
SARC	cis	rs7762018	1.000	rs73242927	chr6:170129573	T/A	cg15038512	chr6:170123185	PHF10	0.51	4.99	0.31	1.18e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs3733585	0.579	rs4235353	chr4:10122934	C/T	cg00071950	chr4:10020882	SLC2A9	-0.39	-5.7	-0.35	3.57e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs523522	0.962	rs7488320	chr12:120981630	G/T	cg12219531	chr12:120966889	COQ5	0.84	11.3	0.59	6.87e-24	High light scatter reticulocyte count;
SARC	cis	rs79149102	0.522	rs950323	chr15:74966529	T/A	cg09165964	chr15:75287851	SCAMP5	-0.58	-4.73	-0.3	3.88e-6	Lung cancer;
SARC	cis	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg00071950	chr4:10020882	SLC2A9	0.39	6.31	0.38	1.4e-9	Bone mineral density;
SARC	cis	rs2522056	1.000	rs7730247	chr5:131781288	A/C	cg24060327	chr5:131705240	SLC22A5	0.56	5.85	0.36	1.63e-8	Lymphocyte counts;Fibrinogen;
SARC	cis	rs4689388	0.889	rs13101355	chr4:6293446	T/C	cg00701064	chr4:6280414	WFS1	0.54	8.58	0.49	1.38e-15	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs17023223	0.537	rs2794311	chr1:119595949	A/G	cg05756136	chr1:119680316	WARS2	0.45	5.39	0.33	1.76e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.68	-8.88	-0.5	1.79e-16	Chronic sinus infection;
SARC	cis	rs9660992	0.674	rs17345837	chr1:205263122	C/T	cg21643547	chr1:205240462	TMCC2	-0.61	-7.74	-0.45	2.99e-13	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs7584330	0.657	rs10190310	chr2:238352282	C/T	cg14458575	chr2:238380390	NA	0.53	6.39	0.39	8.96e-10	Prostate cancer;
SARC	cis	rs9457247	1.000	rs385863	chr6:167386615	C/G	cg07741184	chr6:167504864	NA	0.29	5.49	0.34	1.04e-7	Crohn's disease;
SARC	cis	rs7937682	0.889	rs1784785	chr11:111483306	A/G	cg22437258	chr11:111473054	SIK2	0.76	10.68	0.57	6.13e-22	Primary sclerosing cholangitis;
SARC	cis	rs757081	0.671	rs214091	chr11:17296463	A/C	cg15432903	chr11:17409602	KCNJ11	-0.38	-4.86	-0.3	2.13e-6	Systolic blood pressure;
SARC	cis	rs2204008	0.805	rs11169513	chr12:37988640	G/A	cg26384229	chr12:38710491	ALG10B	0.88	12.9	0.65	4.41e-29	Bladder cancer;
SARC	cis	rs208520	0.690	rs12194057	chr6:66745616	A/G	cg07460842	chr6:66804631	NA	1.04	13.8	0.67	4.75e-32	Exhaled nitric oxide output;
SARC	cis	rs11761408	0.585	rs116124277	chr7:5252828	G/A	cg17652756	chr7:5252759	WIPI2	0.49	4.8	0.3	2.81e-6	Mean corpuscular volume;
SARC	cis	rs412050	0.947	rs239914	chr22:22317337	C/T	cg17089214	chr22:22089827	YPEL1	0.62	5.87	0.36	1.5e-8	Attention deficit hyperactivity disorder;
SARC	cis	rs3820928	0.904	rs2894623	chr2:227766112	T/C	cg11843606	chr2:227700838	RHBDD1	-0.56	-6.88	-0.41	5.4e-11	Pulmonary function;
SARC	cis	rs72627123	0.867	rs57482759	chr14:74485523	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.76	5.99	0.37	7.73e-9	Morning vs. evening chronotype;
SARC	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg11890956	chr21:40555474	PSMG1	1.18	20.03	0.8	1.43e-52	Cognitive function;
SARC	cis	rs6502050	0.787	rs62078746	chr17:80053590	G/A	cg13939156	chr17:80058883	NA	0.38	5.87	0.36	1.46e-8	Life satisfaction;
SARC	cis	rs7762018	0.556	rs75659875	chr6:170054800	A/C	cg19338460	chr6:170058176	WDR27	-0.84	-6.09	-0.37	4.52e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs9393692	0.905	rs6908328	chr6:26292855	C/A	cg00631329	chr6:26305371	NA	-0.63	-9.11	-0.51	3.86e-17	Educational attainment;
SARC	cis	rs9790314	0.690	rs1599390	chr3:160833246	A/G	cg04691961	chr3:161091175	C3orf57	-0.56	-7.35	-0.43	3.29e-12	Morning vs. evening chronotype;
SARC	cis	rs9479482	1.000	rs13198863	chr6:150350781	T/G	cg03788504	chr6:150331562	NA	-0.33	-5.49	-0.34	1.06e-7	Alopecia areata;
SARC	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	7.28	0.43	5.23e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9916302	0.904	rs12952384	chr17:37669536	T/C	cg20243544	chr17:37824526	PNMT	0.55	6.52	0.39	4.33e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg11965913	chr1:205819406	PM20D1	-0.45	-5.06	-0.31	8.53e-7	White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs7412746	0.658	rs12410394	chr1:150860186	G/A	cg15448220	chr1:150897856	SETDB1	0.51	6.56	0.39	3.46e-10	Melanoma;
SARC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.8	10.35	0.56	6.69e-21	Prudent dietary pattern;
SARC	cis	rs4805272	0.626	rs12610050	chr19:29331324	A/T	cg14983838	chr19:29218262	NA	0.58	6.83	0.41	7.45e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg09699651	chr6:150184138	LRP11	0.41	5.11	0.32	6.6e-7	Lung cancer;
SARC	cis	rs651907	0.557	rs11914318	chr3:101453858	C/T	cg12386194	chr3:101231763	SENP7	0.48	5.74	0.35	2.96e-8	Colorectal cancer;
SARC	cis	rs12142240	0.698	rs17357628	chr1:46808462	A/G	cg10495392	chr1:46806563	NSUN4	0.64	6.76	0.4	1.09e-10	Menopause (age at onset);
SARC	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg16606324	chr3:10149918	C3orf24	0.5	4.98	0.31	1.23e-6	Alzheimer's disease;
SARC	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg19223190	chr17:80058835	NA	0.45	6.35	0.38	1.13e-9	Life satisfaction;
SARC	cis	rs1044826	1.000	rs9289576	chr3:139200326	G/A	cg15131784	chr3:139108705	COPB2	0.45	5.19	0.32	4.69e-7	Obesity-related traits;
SARC	cis	rs2204008	0.806	rs11525001	chr12:38234397	A/G	cg26384229	chr12:38710491	ALG10B	0.9	13.02	0.65	1.78e-29	Bladder cancer;
SARC	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg26681399	chr22:41777847	TEF	0.47	5.33	0.33	2.33e-7	Vitiligo;
SARC	cis	rs921968	0.565	rs4672897	chr2:219588134	A/G	cg02176678	chr2:219576539	TTLL4	-0.33	-5.07	-0.32	8.2e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs112158604	1	rs112158604	chr1:150696792	TCTTCTGCAG/T	cg15448220	chr1:150897856	SETDB1	-0.37	-4.84	-0.3	2.36e-6	Lymphocyte counts;
SARC	cis	rs4563143	0.502	rs73029061	chr19:29283980	T/A	cg03161606	chr19:29218774	NA	0.47	6.57	0.4	3.17e-10	Methadone dose in opioid dependence;
SARC	cis	rs9467773	1.000	rs6940053	chr6:26562122	C/T	cg11502198	chr6:26597334	ABT1	0.5	6.11	0.37	4.1e-9	Intelligence (multi-trait analysis);
SARC	trans	rs641862	1	rs641862	chr13:110790232	C/T	cg03702675	chr13:113174184	TUBGCP3	0.88	6.74	0.4	1.26e-10	Obesity-related traits;
SARC	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg06221963	chr1:154839813	KCNN3	-0.53	-8.55	-0.49	1.68e-15	Prostate cancer;
SARC	cis	rs6840360	0.533	rs13147021	chr4:152722688	A/C	cg22705602	chr4:152727874	NA	0.47	8.15	0.47	2.28e-14	Intelligence (multi-trait analysis);
SARC	trans	rs13098911	0.540	rs34047915	chr3:46100491	C/T	cg03842258	chr15:67135396	NA	0.78	6.27	0.38	1.74e-9	Celiac disease;
SARC	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg20607798	chr8:58055168	NA	0.61	5.41	0.33	1.57e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs651907	0.535	rs58658478	chr3:101511667	G/A	cg12386194	chr3:101231763	SENP7	0.49	5.5	0.34	9.92e-8	Colorectal cancer;
SARC	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg06028605	chr16:24865363	SLC5A11	-0.35	-5.29	-0.33	2.76e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs8051517	1.000	rs71395858	chr16:68418811	C/T	cg01866162	chr16:67596514	CTCF	1.09	6.02	0.37	6.62e-9	Blood protein levels;
SARC	cis	rs751728	1.000	rs4713682	chr6:33757047	G/C	cg15252951	chr6:33757062	LEMD2	0.58	6.94	0.41	3.89e-11	Crohn's disease;
SARC	cis	rs10088262	0.527	rs3911939	chr8:124793744	T/G	cg15047889	chr8:124780837	FAM91A1	-0.72	-7.65	-0.45	5.3e-13	Pancreatic cancer;
SARC	cis	rs7296418	0.699	rs1109559	chr12:123757861	C/T	cg05973401	chr12:123451056	ABCB9	0.51	6.02	0.37	6.71e-9	Platelet count;
SARC	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg13849007	chr1:1677539	SLC35E2	-0.37	-4.77	-0.3	3.3e-6	Body mass index;
SARC	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.25	0.38	1.97e-9	Height;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg22747897	chr4:1005994	FGFRL1	0.53	6.41	0.39	8.13e-10	Breast cancer;
SARC	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.71	-9.13	-0.51	3.29e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4891159	0.790	rs7241485	chr18:74122325	C/T	cg24786174	chr18:74118243	ZNF516	-0.67	-9.83	-0.54	2.59e-19	Longevity;
SARC	cis	rs9300255	0.739	rs1969354	chr12:123741776	T/C	cg00376283	chr12:123451042	ABCB9	0.49	5.53	0.34	8.36e-8	Neutrophil percentage of white cells;
SARC	cis	rs7659604	0.540	rs67150579	chr4:122704331	T/A	cg19671926	chr4:122722719	EXOSC9	0.68	8.88	0.5	1.86e-16	Type 2 diabetes;
SARC	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.64	4.73	0.3	3.84e-6	Initial pursuit acceleration;
SARC	cis	rs1448094	0.836	rs7313442	chr12:86405642	C/T	cg02569458	chr12:86230093	RASSF9	0.38	5.63	0.35	5.04e-8	Major depressive disorder;
SARC	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg17376030	chr22:41985996	PMM1	0.64	7.9	0.46	1.07e-13	Vitiligo;
SARC	trans	rs61931739	0.500	rs11053166	chr12:34385898	A/C	cg13010199	chr12:38710504	ALG10B	-0.76	-10.33	-0.56	7.78e-21	Morning vs. evening chronotype;
SARC	cis	rs1957429	0.520	rs72625648	chr14:65344602	A/G	cg23373153	chr14:65346875	NA	-0.82	-5.71	-0.35	3.45e-8	Pediatric areal bone mineral density (radius);
SARC	cis	rs986417	0.901	rs1015119	chr14:61027510	G/T	cg27398547	chr14:60952738	C14orf39	0.94	8.6	0.49	1.2e-15	Gut microbiota (bacterial taxa);
SARC	cis	rs7106204	0.534	rs74650605	chr11:24253414	T/C	ch.11.24196551F	chr11:24239977	NA	0.73	6.26	0.38	1.84e-9	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg11987759	chr7:65425863	GUSB	0.51	6.48	0.39	5.36e-10	Aortic root size;
SARC	cis	rs17270561	0.609	rs3922842	chr6:25736564	T/C	cg16482183	chr6:26056742	HIST1H1C	0.43	5.22	0.32	3.92e-7	Iron status biomarkers;
SARC	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg22618164	chr12:122356400	WDR66	0.42	6.4	0.39	8.67e-10	Mean corpuscular volume;
SARC	cis	rs9303401	0.659	rs35828828	chr17:56718205	C/T	cg25039879	chr17:56429692	SUPT4H1	0.68	6.44	0.39	6.73e-10	Cognitive test performance;
SARC	cis	rs1784581	0.588	rs1789988	chr6:162408472	C/T	cg17173639	chr6:162384350	PARK2	-0.55	-6.81	-0.41	8.08e-11	Itch intensity from mosquito bite;
SARC	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg27572855	chr1:25598939	RHD	0.55	9.59	0.53	1.46e-18	Erythrocyte sedimentation rate;
SARC	cis	rs12291225	0.585	rs4517475	chr11:14386145	A/G	cg19336497	chr11:14380999	RRAS2	-0.45	-7.95	-0.46	8.23e-14	Sense of smell;
SARC	cis	rs6088813	1.000	rs4911492	chr20:33951799	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	-0.44	-5.35	-0.33	2.07e-7	Height;
SARC	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg05025164	chr4:1340916	KIAA1530	0.46	5.58	0.34	6.78e-8	Longevity;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg12605564	chr3:129035140	H1FX;C3orf47	0.57	7.68	0.45	4.37e-13	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs7937682	0.883	rs510388	chr11:111451869	G/T	cg09085632	chr11:111637200	PPP2R1B	0.83	12.78	0.64	1.05e-28	Primary sclerosing cholangitis;
SARC	cis	rs6426558	0.537	rs2718193	chr1:227404672	C/G	cg10327440	chr1:227177885	CDC42BPA	0.44	5.18	0.32	4.71e-7	Neutrophil percentage of white cells;
SARC	cis	rs7927592	0.513	rs608343	chr11:68196830	T/C	cg01657329	chr11:68192670	LRP5	-0.41	-5.61	-0.34	5.78e-8	Total body bone mineral density;
SARC	cis	rs35110281	0.774	rs162404	chr21:44963264	G/A	cg21573476	chr21:45109991	RRP1B	-0.47	-6.96	-0.41	3.4e-11	Mean corpuscular volume;
SARC	cis	rs6582630	0.555	rs10880625	chr12:38526612	A/C	cg26384229	chr12:38710491	ALG10B	0.88	13.18	0.65	5.37e-30	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg12311346	chr5:56204834	C5orf35	-0.4	-4.92	-0.31	1.66e-6	Coronary artery disease;
SARC	cis	rs9916302	0.706	rs590051	chr17:37446571	T/C	cg07936489	chr17:37558343	FBXL20	0.75	8.92	0.5	1.37e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs2180341	1.000	rs9285460	chr6:127640190	A/G	cg17762328	chr6:126965162	NA	-0.45	-5.06	-0.31	8.34e-7	Breast cancer;
SARC	cis	rs12142240	0.698	rs68083747	chr1:46807416	T/G	cg14993813	chr1:46806288	NSUN4	-0.52	-5.58	-0.34	6.8e-8	Menopause (age at onset);
SARC	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg09359103	chr1:154839909	KCNN3	-0.46	-7.7	-0.45	3.87e-13	Prostate cancer;
SARC	cis	rs9549260	0.755	rs2297627	chr13:41233931	A/G	cg21288729	chr13:41239152	FOXO1	0.63	8.07	0.47	3.83e-14	Red blood cell count;
SARC	cis	rs820218	0.743	rs9897994	chr17:73704865	C/T	cg01592526	chr17:73663357	RECQL5;SAP30BP	-0.58	-7.42	-0.44	2.13e-12	Rotator cuff tears;
SARC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg26338869	chr17:61819248	STRADA	0.8	10.72	0.57	4.8e-22	Prudent dietary pattern;
SARC	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg19223190	chr17:80058835	NA	0.44	6.19	0.38	2.67e-9	Life satisfaction;
SARC	cis	rs10979	0.557	rs9390116	chr6:143907577	A/G	cg25407410	chr6:143891975	LOC285740	-0.52	-6.0	-0.37	7.63e-9	Hypospadias;
SARC	cis	rs9457247	0.765	rs9459838	chr6:167426599	C/G	cg23791538	chr6:167370224	RNASET2	-0.53	-6.93	-0.41	4.17e-11	Crohn's disease;
SARC	cis	rs208515	0.525	rs12214310	chr6:66666308	A/G	cg07460842	chr6:66804631	NA	0.98	11.11	0.59	2.72e-23	Exhaled nitric oxide levels;
SARC	cis	rs7520050	0.966	rs6661910	chr1:46290632	A/T	cg24296786	chr1:45957014	TESK2	0.38	4.78	0.3	3.07e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs12135062	0.687	rs6685614	chr1:3108517	C/T	cg00254258	chr1:3105189	PRDM16	0.34	5.89	0.36	1.37e-8	Migraine;
SARC	cis	rs4969178	1.000	rs4969178	chr17:76388202	C/T	cg20026190	chr17:76395443	PGS1	-0.4	-5.3	-0.33	2.71e-7	HDL cholesterol levels;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg04875987	chr17:79981264	STRA13;LRRC45	0.49	6.53	0.39	4.15e-10	Tetralogy of Fallot;
SARC	cis	rs7959452	0.718	rs10878963	chr12:69717166	T/G	cg22834771	chr12:69754056	YEATS4	-0.39	-5.14	-0.32	5.7e-7	Blood protein levels;
SARC	cis	rs7555523	0.830	rs6660601	chr1:165695855	C/T	cg19769164	chr1:165738335	TMCO1	0.59	4.91	0.31	1.7e-6	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg11965913	chr1:205819406	PM20D1	0.45	4.94	0.31	1.47e-6	Parkinson's disease;
SARC	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg20607798	chr8:58055168	NA	0.6	5.34	0.33	2.19e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs477692	1.000	rs513736	chr10:131406489	C/T	cg05714579	chr10:131428358	MGMT	0.57	7.56	0.44	8.99e-13	Response to temozolomide;
SARC	cis	rs2153535	0.601	rs2327059	chr6:8447071	A/G	cg21535247	chr6:8435926	SLC35B3	0.55	6.87	0.41	5.72e-11	Motion sickness;
SARC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-8.85	-0.5	2.28e-16	Alzheimer's disease;
SARC	cis	rs651907	0.514	rs12636047	chr3:101434449	T/C	cg12386194	chr3:101231763	SENP7	0.48	5.74	0.35	2.96e-8	Colorectal cancer;
SARC	cis	rs2153535	0.580	rs6905237	chr6:8471790	A/T	cg21535247	chr6:8435926	SLC35B3	0.53	6.7	0.4	1.55e-10	Motion sickness;
SARC	cis	rs6912958	0.559	rs242267	chr6:88061837	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.41	-7.04	-0.42	2.08e-11	Monocyte percentage of white cells;
SARC	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7508	0.521	rs4377998	chr8:17923339	C/T	cg18067069	chr8:17937731	ASAH1	-0.43	-5.53	-0.34	8.74e-8	Atrial fibrillation;
SARC	cis	rs2463822	0.583	rs17709552	chr11:62040519	A/G	cg06239285	chr11:62104954	ASRGL1	-0.85	-8.05	-0.47	4.21e-14	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs798554	1.000	rs798563	chr7:2757867	A/C	cg13628971	chr7:2884303	GNA12	0.57	6.71	0.4	1.5e-10	Height;
SARC	cis	rs7727544	0.645	rs272857	chr5:131685297	G/A	cg07395648	chr5:131743802	NA	-0.44	-5.08	-0.32	7.76e-7	Blood metabolite levels;
SARC	cis	rs6540556	0.682	rs11119332	chr1:209892960	C/T	cg05527609	chr1:210001259	C1orf107	-0.57	-5.36	-0.33	2.02e-7	Red blood cell count;
SARC	cis	rs10979	0.603	rs9321920	chr6:143883588	C/G	cg25407410	chr6:143891975	LOC285740	-0.61	-7.36	-0.43	3.12e-12	Hypospadias;
SARC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg02725872	chr8:58115012	NA	-0.37	-6.47	-0.39	5.76e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1044826	0.913	rs9825064	chr3:139049804	C/T	cg15131784	chr3:139108705	COPB2	0.48	5.39	0.33	1.73e-7	Obesity-related traits;
SARC	trans	rs1945213	0.694	rs7131381	chr11:55858158	T/G	cg15704280	chr7:45808275	SEPT13	0.66	6.9	0.41	5e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs67311347	0.869	rs9832311	chr3:40381322	A/T	cg24209194	chr3:40518798	ZNF619	0.57	6.94	0.41	3.96e-11	Renal cell carcinoma;
SARC	cis	rs9398803	0.865	rs2152876	chr6:126761228	A/G	cg19875578	chr6:126661172	C6orf173	-0.63	-8.86	-0.5	2.03e-16	Male-pattern baldness;
SARC	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.83	8.3	0.48	8.42e-15	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs9398803	0.965	rs9388490	chr6:126704795	C/T	cg20229609	chr6:126660872	C6orf173	0.4	5.89	0.36	1.34e-8	Male-pattern baldness;
SARC	cis	rs889312	0.500	rs832585	chr5:56125904	T/C	cg14703610	chr5:56206110	C5orf35	0.53	6.65	0.4	2.04e-10	Breast cancer;Breast cancer (early onset);
SARC	cis	rs8180040	0.726	rs4682842	chr3:46982773	C/G	cg27129171	chr3:47204927	SETD2	-0.69	-9.77	-0.54	4.17e-19	Colorectal cancer;
SARC	cis	rs3820928	0.845	rs7570869	chr2:227878818	A/C	cg11843606	chr2:227700838	RHBDD1	-0.57	-7.15	-0.42	1.13e-11	Pulmonary function;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg22244076	chr20:33872703	EIF6	0.48	6.3	0.38	1.47e-9	Thyroid stimulating hormone;
SARC	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	7.34	0.43	3.43e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9747201	0.926	rs35131420	chr17:80103631	T/C	cg09264619	chr17:80180166	NA	0.49	5.76	0.35	2.64e-8	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg05025164	chr4:1340916	KIAA1530	0.61	7.68	0.45	4.24e-13	Longevity;
SARC	cis	rs7412746	0.658	rs1546376	chr1:150937661	A/G	cg13175981	chr1:150552382	MCL1	-0.49	-5.84	-0.36	1.76e-8	Melanoma;
SARC	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg19077165	chr18:44547161	KATNAL2	-0.51	-7.09	-0.42	1.58e-11	Personality dimensions;
SARC	cis	rs2200578	1.000	rs2200578	chr2:99876244	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.67	6.53	0.39	4.11e-10	IgG glycosylation;
SARC	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg03709012	chr19:19516395	GATAD2A	0.95	14.65	0.69	6.77e-35	Tonsillectomy;
SARC	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg06618935	chr21:46677482	NA	-0.4	-5.33	-0.33	2.35e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs10463554	0.963	rs7721530	chr5:102362192	T/C	cg23492399	chr5:102201601	PAM	-0.46	-5.09	-0.32	7.29e-7	Parkinson's disease;
SARC	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg25072359	chr17:41440525	NA	0.51	6.11	0.37	4.18e-9	Menopause (age at onset);
SARC	cis	rs72781680	0.898	rs72796154	chr2:23933839	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	8.58	0.49	1.32e-15	Lymphocyte counts;
SARC	cis	rs698833	0.828	rs786623	chr2:44606171	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.67	8.47	0.49	2.72e-15	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg00152838	chr16:24741724	TNRC6A	-0.61	-6.17	-0.37	3.03e-9	Intelligence (multi-trait analysis);
SARC	cis	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg26513180	chr16:89883248	FANCA	0.72	4.79	0.3	2.94e-6	Skin colour saturation;
SARC	cis	rs992157	0.735	rs13430006	chr2:219113089	A/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.65	-8.91	-0.5	1.52e-16	Colorectal cancer;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg21722680	chr12:64846210	TBK1	-0.85	-7.15	-0.42	1.11e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg05861140	chr6:150128134	PCMT1	-0.42	-5.44	-0.34	1.32e-7	Lung cancer;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg01177470	chr6:27870695	NA	-0.48	-6.47	-0.39	5.65e-10	Thyroid stimulating hormone;
SARC	cis	rs8017423	0.967	rs11159958	chr14:90716051	T/C	cg20276874	chr14:90721474	PSMC1	-0.37	-5.22	-0.32	4.01e-7	Mortality in heart failure;
SARC	cis	rs2191566	0.960	rs2270196	chr19:44506623	A/G	cg20607764	chr19:44506953	ZNF230	0.52	5.91	0.36	1.18e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg09373136	chr17:61933544	TCAM1	-0.45	-6.12	-0.37	3.97e-9	Prudent dietary pattern;
SARC	trans	rs61931739	0.534	rs2389276	chr12:34097891	T/C	cg13010199	chr12:38710504	ALG10B	0.67	8.9	0.5	1.56e-16	Morning vs. evening chronotype;
SARC	cis	rs13082711	1.000	rs13082711	chr3:27537909	T/C	cg02860705	chr3:27208620	NA	0.5	6.23	0.38	2.11e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs11690935	0.632	rs17581284	chr2:172659376	C/T	cg13550731	chr2:172543902	DYNC1I2	0.65	9.32	0.52	9.23e-18	Schizophrenia;
SARC	cis	rs9916302	0.706	rs2302073	chr17:37457342	A/G	cg20243544	chr17:37824526	PNMT	-0.56	-6.02	-0.37	6.66e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs4595586	0.545	rs12812959	chr12:39371197	T/C	cg26384229	chr12:38710491	ALG10B	0.51	6.25	0.38	1.9e-9	Morning vs. evening chronotype;
SARC	cis	rs9910055	0.530	rs2269908	chr17:42294198	G/C	cg19774624	chr17:42201019	HDAC5	-0.49	-6.67	-0.4	1.84e-10	Total body bone mineral density;
SARC	cis	rs12135062	0.851	rs2651926	chr1:3101820	C/T	cg00254258	chr1:3105189	PRDM16	-0.41	-7.03	-0.42	2.21e-11	Migraine;
SARC	trans	rs17221829	0.733	rs11018668	chr11:89356178	C/T	cg21146272	chr6:42858716	C6orf226	0.51	7.03	0.42	2.24e-11	Anxiety in major depressive disorder;
SARC	cis	rs3087591	0.537	rs75847291	chr17:29717854	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.52	-5.22	-0.32	3.88e-7	Hip circumference;
SARC	cis	rs2204008	0.630	rs12306932	chr12:38242029	C/T	cg26384229	chr12:38710491	ALG10B	-0.61	-7.74	-0.45	2.92e-13	Bladder cancer;
SARC	cis	rs8084125	0.832	rs62105174	chr18:74948324	G/A	cg26065057	chr18:74961000	GALR1	0.47	4.82	0.3	2.62e-6	Obesity-related traits;
SARC	cis	rs8014204	0.804	rs7154845	chr14:75247746	A/G	cg17347104	chr14:75034677	LTBP2	-0.4	-4.93	-0.31	1.57e-6	Caffeine consumption;
SARC	cis	rs7208859	0.524	rs73988172	chr17:29086332	A/C	cg13385521	chr17:29058706	SUZ12P	0.9	7.89	0.46	1.18e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9916302	0.904	rs602282	chr17:37433021	C/T	cg00129232	chr17:37814104	STARD3	-0.59	-7.39	-0.44	2.69e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs9393777	0.513	rs9379893	chr6:26584668	A/G	cg12826209	chr6:26865740	GUSBL1	-0.65	-5.96	-0.36	9.43e-9	Intelligence (multi-trait analysis);
SARC	cis	rs733592	0.504	rs2261608	chr12:48721634	A/T	cg21466736	chr12:48725269	NA	-0.37	-6.73	-0.4	1.28e-10	Plateletcrit;
SARC	cis	rs9399137	0.507	rs11754021	chr6:135308375	A/G	cg24558204	chr6:135376177	HBS1L	0.62	8.1	0.47	3.16e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs9916302	0.904	rs10432031	chr17:37397852	G/A	cg00129232	chr17:37814104	STARD3	-0.61	-7.49	-0.44	1.38e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs73206853	0.841	rs73206854	chr12:110731375	C/T	cg10860002	chr12:110842031	ANAPC7	0.63	5.25	0.33	3.4e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs7666738	0.861	rs5014702	chr4:99052102	C/A	cg05340658	chr4:99064831	C4orf37	0.66	8.77	0.5	3.91e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs910316	1.000	rs7156105	chr14:75541954	C/A	cg23033748	chr14:75592666	NEK9	0.38	5.3	0.33	2.64e-7	Height;
SARC	cis	rs12971120	0.891	rs2278159	chr18:72178161	T/C	cg25817165	chr18:72167213	CNDP2	-0.5	-6.78	-0.41	9.71e-11	Refractive error;
SARC	cis	rs7246865	0.510	rs8103578	chr19:17171227	C/T	cg16202187	chr19:17186497	HAUS8;MYO9B	0.39	4.78	0.3	3.15e-6	Reticulocyte fraction of red cells;
SARC	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7621025	0.755	rs1017881	chr3:136357693	A/G	cg15507776	chr3:136538369	TMEM22	0.45	4.98	0.31	1.25e-6	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
SARC	cis	rs73206853	0.841	rs7963504	chr12:110906880	C/A	cg10860002	chr12:110842031	ANAPC7	0.64	5.05	0.31	9.01e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs921968	0.541	rs933994	chr2:219650616	C/T	cg02176678	chr2:219576539	TTLL4	-0.36	-5.44	-0.34	1.33e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs17826219	0.568	rs2626985	chr17:29077437	A/G	cg13385521	chr17:29058706	SUZ12P	0.88	7.75	0.45	2.9e-13	Body mass index;
SARC	cis	rs4443100	0.670	rs9608071	chr22:23408118	G/T	cg14186256	chr22:23484241	RTDR1	0.55	5.58	0.34	6.8e-8	Serum parathyroid hormone levels;
SARC	trans	rs9329221	0.537	rs1484640	chr8:9983243	G/T	cg06636001	chr8:8085503	FLJ10661	0.57	8.01	0.46	5.6e-14	Neuroticism;
SARC	cis	rs7945705	0.846	rs11042055	chr11:8756856	G/A	cg14711859	chr11:8959438	ASCL3	-0.34	-5.38	-0.33	1.85e-7	Hemoglobin concentration;
SARC	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg13175981	chr1:150552382	MCL1	-0.54	-6.9	-0.41	4.97e-11	Tonsillectomy;
SARC	trans	rs1814175	0.817	rs10769618	chr11:49822336	A/G	cg03929089	chr4:120376271	NA	-0.9	-14.9	-0.7	1.02e-35	Height;
SARC	cis	rs240764	0.658	rs9322212	chr6:101248474	T/C	cg09795085	chr6:101329169	ASCC3	-0.44	-5.67	-0.35	4.21e-8	Neuroticism;
SARC	cis	rs6908034	0.607	rs77386860	chr6:19814755	A/C	cg02682789	chr6:19804855	NA	0.69	5.58	0.34	6.62e-8	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg04267008	chr7:1944627	MAD1L1	-0.53	-6.12	-0.37	3.98e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs80130819	0.636	rs4760623	chr12:48619256	A/C	cg24011408	chr12:48396354	COL2A1	0.53	5.97	0.36	8.96e-9	Prostate cancer;
SARC	trans	rs2727020	0.823	rs7102374	chr11:49261795	G/A	cg15704280	chr7:45808275	SEPT13	0.76	10.2	0.56	1.97e-20	Coronary artery disease;
SARC	cis	rs9916302	0.706	rs9890198	chr17:37457480	A/C	cg15445000	chr17:37608096	MED1	-0.45	-4.76	-0.3	3.42e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs765787	0.530	rs11858988	chr15:45522114	T/C	cg24006582	chr15:45444508	DUOX1	-0.5	-6.41	-0.39	8.17e-10	Uric acid levels;
SARC	cis	rs9303401	0.659	rs17822807	chr17:56687190	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	11.59	0.6	8.2e-25	Cognitive test performance;
SARC	cis	rs35110281	0.633	rs2329593	chr21:45121987	T/C	cg01579765	chr21:45077557	HSF2BP	-0.36	-5.72	-0.35	3.19e-8	Mean corpuscular volume;
SARC	cis	rs4803455	0.565	rs11670143	chr19:41864971	A/G	cg09537434	chr19:41945824	ATP5SL	-0.63	-8.34	-0.48	6.38e-15	Migraine;Coronary artery disease;
SARC	cis	rs4481887	0.927	rs4350233	chr1:248489994	G/A	cg00666640	chr1:248458726	OR2T12	0.35	5.75	0.35	2.83e-8	Common traits (Other);
SARC	cis	rs7119	0.717	rs11632729	chr15:77722006	G/A	cg17802220	chr15:77601643	NA	-0.44	-5.76	-0.35	2.65e-8	Type 2 diabetes;
SARC	cis	rs1215050	0.791	rs165244	chr4:98687889	C/T	cg05340658	chr4:99064831	C4orf37	0.43	5.65	0.35	4.62e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs72781680	0.716	rs2712056	chr2:23959131	C/T	cg08917208	chr2:24149416	ATAD2B	0.59	6.03	0.37	6.53e-9	Lymphocyte counts;
SARC	cis	rs1570884	0.890	rs7333969	chr13:50123317	C/T	cg08779649	chr13:50194554	NA	0.3	5.22	0.32	4.01e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg24829409	chr8:58192753	C8orf71	-0.54	-4.76	-0.3	3.46e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs7617773	0.780	rs34749846	chr3:48347168	T/G	cg11946769	chr3:48343235	NME6	0.76	9.7	0.54	6.55e-19	Coronary artery disease;
SARC	cis	rs6665290	0.669	rs3768424	chr1:227177444	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.02	-20.85	-0.81	3.42e-55	Myeloid white cell count;
SARC	cis	rs13191362	1.000	rs4260737	chr6:163137746	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.43	5.3	0.33	2.71e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs72634258	0.554	rs12061787	chr1:7888730	G/C	cg05338066	chr1:7812865	CAMTA1	0.64	5.63	0.35	5.2100000000000003e-08	Inflammatory bowel disease;
SARC	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg22968622	chr17:43663579	NA	1.21	16.18	0.73	5.59e-40	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg21724239	chr8:58056113	NA	0.61	5.93	0.36	1.1e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs240764	0.853	rs108422	chr6:101039279	G/C	cg09795085	chr6:101329169	ASCC3	0.47	6.13	0.37	3.63e-9	Neuroticism;
SARC	cis	rs2153535	0.580	rs2143357	chr6:8497196	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	8.05	0.47	4.24e-14	Motion sickness;
SARC	cis	rs7667	0.959	rs12022399	chr1:19726907	A/T	cg15311933	chr1:19638897	PQLC2;AKR7A2	-0.45	-5.36	-0.33	1.98e-7	Crohn's disease and psoriasis;
SARC	cis	rs4319547	0.737	rs11058226	chr12:122938958	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.53	-6.13	-0.37	3.8e-9	Body mass index;
SARC	cis	rs3093024	0.967	rs1571878	chr6:167540842	C/T	cg07741184	chr6:167504864	NA	-0.31	-6.05	-0.37	5.75e-9	Rheumatoid arthritis;
SARC	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	10.91	0.58	1.16e-22	Platelet count;
SARC	cis	rs2594989	0.943	rs9836989	chr3:11463637	G/A	cg00170343	chr3:11313890	ATG7	0.61	5.83	0.36	1.86e-8	Circulating chemerin levels;
SARC	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg18252515	chr7:66147081	NA	-0.54	-5.94	-0.36	1.01e-8	Aortic root size;
SARC	cis	rs11764590	0.694	rs3996323	chr7:2079428	G/T	cg23043544	chr7:2124092	MAD1L1	-0.35	-4.91	-0.31	1.74e-6	Neuroticism;
SARC	cis	rs62344088	0.590	rs6872820	chr5:178900	G/A	cg22496380	chr5:211416	CCDC127	-0.76	-5.65	-0.35	4.71e-8	Asthma (childhood onset);
SARC	cis	rs1580019	0.883	rs6945294	chr7:32472099	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.78	10.99	0.58	6.79e-23	Cognitive ability;
SARC	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs66573146	1.000	rs55672215	chr4:6970529	T/C	cg15105060	chr4:7024189	TBC1D14	-0.67	-4.72	-0.3	4.1e-6	Granulocyte percentage of myeloid white cells;
SARC	cis	rs854765	0.693	rs4924823	chr17:17764502	A/G	cg04398451	chr17:18023971	MYO15A	0.45	6.53	0.39	4.06e-10	Total body bone mineral density;
SARC	cis	rs9790314	1.000	rs7653361	chr3:160992291	C/T	cg03342759	chr3:160939853	NMD3	-0.61	-7.73	-0.45	3.22e-13	Morning vs. evening chronotype;
SARC	cis	rs4969178	0.965	rs938350	chr17:76399552	C/T	cg02836325	chr17:76403955	PGS1	0.34	5.27	0.33	3.05e-7	HDL cholesterol levels;
SARC	cis	rs7727544	0.684	rs272849	chr5:131690241	A/G	cg07395648	chr5:131743802	NA	-0.42	-5.02	-0.31	1.04e-6	Blood metabolite levels;
SARC	cis	rs787274	1.000	rs10733594	chr9:115552630	T/G	cg13803584	chr9:115635662	SNX30	-0.83	-5.06	-0.31	8.34e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs453301	0.506	rs686189	chr8:8623637	A/G	cg15556689	chr8:8085844	FLJ10661	-0.38	-4.83	-0.3	2.48e-6	Joint mobility (Beighton score);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg04648814	chr13:28713767	PAN3;LOC100288730	-0.63	-7.19	-0.43	8.54e-12	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs3008870	0.583	rs3008861	chr1:67396222	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.83	8.97	0.51	1.03e-16	Lymphocyte percentage of white cells;
SARC	cis	rs2439831	0.850	rs28413704	chr15:44148427	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	8.13	0.47	2.48e-14	Lung cancer in ever smokers;
SARC	cis	rs11718455	0.920	rs34909426	chr3:44000472	G/A	cg21419209	chr3:44054225	NA	-0.42	-5.24	-0.32	3.61e-7	Coronary artery disease;
SARC	cis	rs4243830	1.000	rs11811007	chr1:6584657	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	0.93	7.37	0.43	2.93e-12	Body mass index;
SARC	cis	rs9486719	1.000	rs34236778	chr6:96884556	C/A	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.01	-0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs3733585	0.673	rs6849729	chr4:9958732	T/C	cg11266682	chr4:10021025	SLC2A9	-0.35	-6.03	-0.37	6.35e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	trans	rs61931739	0.500	rs7307583	chr12:34521711	T/C	cg13010199	chr12:38710504	ALG10B	0.78	11.08	0.59	3.46e-23	Morning vs. evening chronotype;
SARC	cis	rs7647973	0.710	rs6446285	chr3:49626306	G/A	cg07636037	chr3:49044803	WDR6	0.76	6.32	0.38	1.3e-9	Menarche (age at onset);
SARC	cis	rs4742903	0.935	rs4742907	chr9:106968226	G/A	cg14250997	chr9:106856677	SMC2	0.43	5.39	0.33	1.71e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs8005677	0.962	rs10130756	chr14:23396600	C/G	cg01529538	chr14:23388837	RBM23	0.47	5.74	0.35	2.95e-8	Cognitive ability (multi-trait analysis);
SARC	cis	rs6815814	0.861	rs4543123	chr4:38792524	A/G	cg06935464	chr4:38784597	TLR10	0.52	5.45	0.34	1.3e-7	Breast cancer;
SARC	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.76	6.61	0.4	2.66e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg25894440	chr7:65020034	NA	0.45	5.06	0.31	8.58e-7	Calcium levels;
SARC	cis	rs7644634	0.531	rs9878058	chr3:105388605	G/A	cg23051926	chr3:105466016	CBLB	0.47	5.4	0.33	1.68e-7	Itch intensity from mosquito bite;
SARC	cis	rs709400	0.663	rs11623869	chr14:103883633	G/T	cg26031613	chr14:104095156	KLC1	0.8	11.21	0.59	1.31e-23	Body mass index;
SARC	trans	rs11098499	0.908	rs7695996	chr4:120322033	C/T	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.52e-12	Corneal astigmatism;
SARC	cis	rs1008375	1.000	rs2872959	chr4:17677163	G/A	cg16339924	chr4:17578868	LAP3	-0.65	-8.51	-0.49	2.15e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2832077	0.527	rs11088095	chr21:30223188	A/T	cg03476357	chr21:30257390	N6AMT1	-0.55	-6.17	-0.37	3.07e-9	Cognitive test performance;
SARC	cis	rs96067	0.740	rs10752586	chr1:36614713	C/G	cg24686825	chr1:36642396	MAP7D1	-0.57	-6.61	-0.4	2.59e-10	Corneal structure;
SARC	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg27347728	chr4:17578864	LAP3	0.49	6.11	0.37	4.17e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg13939156	chr17:80058883	NA	-0.42	-6.47	-0.39	5.68e-10	Life satisfaction;
SARC	cis	rs7481584	1.000	rs756693	chr11:3027889	A/G	cg25174290	chr11:3078921	CARS	-0.51	-6.63	-0.4	2.34e-10	Calcium levels;
SARC	cis	rs2153535	0.580	rs1410766	chr6:8525360	T/C	cg23788917	chr6:8435910	SLC35B3	0.64	8.61	0.49	1.07e-15	Motion sickness;
SARC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg02353165	chr6:42928485	GNMT	0.61	8.36	0.48	5.87e-15	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs712039	0.617	rs60118041	chr17:35803252	G/A	cg16670864	chr17:35848621	DUSP14	0.47	5.16	0.32	5.25e-7	Tuberculosis;
SARC	trans	rs8073060	0.586	rs225250	chr17:33941963	A/G	cg19694781	chr19:47549865	TMEM160	-0.64	-6.66	-0.4	1.97e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs240764	0.817	rs2036052	chr6:101154909	G/A	cg09795085	chr6:101329169	ASCC3	-0.47	-6.08	-0.37	4.76e-9	Neuroticism;
SARC	cis	rs2013441	1.000	rs12451216	chr17:20025840	C/A	cg13482628	chr17:19912719	NA	0.46	5.96	0.36	9.3e-9	Obesity-related traits;
SARC	cis	rs9400467	0.506	rs4639374	chr6:111458270	A/G	cg15721981	chr6:111408429	SLC16A10	0.64	5.67	0.35	4.19e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs1182196	0.502	rs757786	chr7:2836019	C/T	cg18446336	chr7:2847575	GNA12	-0.32	-4.74	-0.3	3.68e-6	Plateletcrit;
SARC	cis	rs2797160	0.875	rs12527010	chr6:125991507	A/G	cg05901451	chr6:126070800	HEY2	0.41	5.08	0.32	7.56e-7	Endometrial cancer;
SARC	cis	rs3820928	0.874	rs10177995	chr2:227781600	T/C	cg05526886	chr2:227700861	RHBDD1	-0.53	-6.44	-0.39	6.77e-10	Pulmonary function;
SARC	cis	rs6089584	0.821	rs4925332	chr20:60604639	C/T	cg23262073	chr20:60523788	NA	-0.41	-6.02	-0.37	6.77e-9	Body mass index;
SARC	cis	rs1949733	0.701	rs940136	chr4:8448992	G/A	cg13073564	chr4:8508604	NA	-0.44	-6.96	-0.41	3.4e-11	Response to antineoplastic agents;
SARC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.65	-6.44	-0.39	6.6e-10	Platelet count;
SARC	cis	rs911263	0.561	rs7150454	chr14:68765658	C/T	cg18825221	chr14:68749962	RAD51L1	0.41	5.62	0.35	5.33e-8	Primary biliary cholangitis;
SARC	cis	rs72949976	0.564	rs4673730	chr2:214024836	G/T	cg08319019	chr2:214017104	IKZF2	0.48	6.48	0.39	5.44e-10	Lung cancer;Squamous cell lung carcinoma;
SARC	cis	rs748404	0.631	rs1133395	chr15:43650384	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.41	4.93	0.31	1.55e-6	Lung cancer;
SARC	cis	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg00409905	chr10:38381863	ZNF37A	-0.5	-6.9	-0.41	4.93e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs72945132	0.882	rs12279046	chr11:70130388	A/G	cg00319359	chr11:70116639	PPFIA1	0.68	6.35	0.38	1.14e-9	Coronary artery disease;
SARC	cis	rs2304069	0.954	rs1469691	chr5:149386716	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.89	9.35	0.52	7.71e-18	HIV-1 control;
SARC	cis	rs7772486	0.754	rs864148	chr6:145976675	T/C	cg23711669	chr6:146136114	FBXO30	-0.84	-14.05	-0.68	7.09e-33	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7818688	0.697	rs11783878	chr8:95979261	C/T	cg13393036	chr8:95962371	TP53INP1	-0.43	-5.03	-0.31	9.71e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs7586879	0.639	rs2384058	chr2:25100328	A/G	cg04586622	chr2:25135609	ADCY3	0.31	5.14	0.32	5.72e-7	Body mass index;
SARC	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg22590775	chr19:49891494	CCDC155	0.53	6.16	0.37	3.14e-9	Multiple sclerosis;
SARC	cis	rs1594829	0.553	rs2046224	chr8:26151604	G/T	cg11498726	chr8:26250323	BNIP3L	-0.4	-5.27	-0.33	3.09e-7	Height;
SARC	trans	rs1814175	0.647	rs28456013	chr11:50047629	T/C	cg03929089	chr4:120376271	NA	-0.72	-10.31	-0.56	8.9e-21	Height;
SARC	cis	rs763121	0.925	rs1043312	chr22:39131727	T/G	cg21395723	chr22:39101663	GTPBP1	0.47	5.7	0.35	3.68e-8	Menopause (age at onset);
SARC	cis	rs76419734	1.000	rs72671858	chr4:106647679	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.84	5.41	0.33	1.59e-7	Post bronchodilator FEV1;
SARC	cis	rs72781680	0.821	rs56064672	chr2:24156769	G/T	cg06627628	chr2:24431161	ITSN2	-0.57	-5.91	-0.36	1.21e-8	Lymphocyte counts;
SARC	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg04944784	chr2:26401820	FAM59B	-0.47	-5.77	-0.35	2.47e-8	Gut microbiome composition (summer);
SARC	cis	rs6831352	0.918	rs7670638	chr4:100059807	G/C	cg12011299	chr4:100065546	ADH4	-0.35	-5.75	-0.35	2.8e-8	Alcohol dependence;
SARC	trans	rs208520	0.690	rs851468	chr6:66825875	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-13.6	-0.67	2.17e-31	Exhaled nitric oxide output;
SARC	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg03576123	chr11:487126	PTDSS2	-1.14	-11.76	-0.61	2.19e-25	Body mass index;
SARC	cis	rs4846217	1.000	rs4846215	chr1:10412636	A/T	cg19092837	chr1:10271724	KIF1B	0.42	5.56	0.34	7.21e-8	Platelet count;
SARC	cis	rs11997175	0.546	rs4733448	chr8:33628575	G/A	ch.8.33884649F	chr8:33765107	NA	0.51	6.5	0.39	4.78e-10	Body mass index;
SARC	cis	rs3820928	0.845	rs13384342	chr2:227805010	G/A	cg11843606	chr2:227700838	RHBDD1	-0.57	-7.27	-0.43	5.32e-12	Pulmonary function;
SARC	trans	rs7824557	0.670	rs2736381	chr8:11132766	A/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.13	-0.42	1.23e-11	Retinal vascular caliber;
SARC	trans	rs7819412	0.775	rs4841489	chr8:10936811	A/G	cg06636001	chr8:8085503	FLJ10661	-0.7	-9.92	-0.54	1.47e-19	Triglycerides;
SARC	cis	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg13072238	chr3:49761600	GMPPB	-0.64	-5.6	-0.34	5.9e-8	Menarche (age at onset);
SARC	cis	rs2836950	0.501	rs13047518	chr21:40707307	G/A	cg11644478	chr21:40555479	PSMG1	-0.53	-6.33	-0.38	1.26e-9	Menarche (age at onset);
SARC	cis	rs1878931	0.507	rs1218762	chr16:3405986	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.6	-6.37	-0.39	9.9e-10	Body mass index (adult);
SARC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg11494091	chr17:61959527	GH2	0.53	7.98	0.46	6.44e-14	Prudent dietary pattern;
SARC	cis	rs4481887	0.927	rs4336885	chr1:248473168	A/C	cg01631408	chr1:248437212	OR2T33	-0.38	-4.9	-0.31	1.76e-6	Common traits (Other);
SARC	cis	rs4253772	0.513	rs6008597	chr22:46703904	A/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.63	5.3	0.33	2.62e-7	LDL cholesterol;Cholesterol, total;
SARC	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg00933542	chr6:150070202	PCMT1	0.31	5.29	0.33	2.86e-7	Lung cancer;
SARC	cis	rs7429990	0.901	rs7431567	chr3:48027832	G/T	cg11946769	chr3:48343235	NME6	-0.48	-5.39	-0.33	1.76e-7	Educational attainment (years of education);
SARC	cis	rs6704644	0.584	rs56336977	chr2:234357496	C/T	cg27060346	chr2:234359958	DGKD	-0.81	-4.99	-0.31	1.16e-6	Bilirubin levels;
SARC	cis	rs4906332	0.899	rs12888042	chr14:103891709	G/A	cg26031613	chr14:104095156	KLC1	-0.5	-5.84	-0.36	1.72e-8	Coronary artery disease;
SARC	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg04267008	chr7:1944627	MAD1L1	-0.47	-5.3	-0.33	2.66e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs2985684	0.779	rs12160	chr14:50091932	T/A	cg04989706	chr14:50066350	PPIL5	-0.56	-5.95	-0.36	9.65e-9	Carotid intima media thickness;
SARC	cis	rs3741151	0.686	rs7129990	chr11:73124441	A/G	cg17517138	chr11:73019481	ARHGEF17	0.62	5.19	0.32	4.68e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs6568686	0.730	rs4947120	chr6:111819044	G/A	cg15721981	chr6:111408429	SLC16A10	-0.6	-4.72	-0.3	4.16e-6	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs7216064	0.636	rs4638	chr17:66039350	A/G	cg12091567	chr17:66097778	LOC651250	0.93	12.18	0.62	9.86e-27	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg11644478	chr21:40555479	PSMG1	0.9	11.72	0.61	3.11e-25	Cognitive function;
SARC	cis	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg25894440	chr7:65020034	NA	-0.78	-5.82	-0.36	1.93e-8	Diabetic kidney disease;
SARC	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg13206674	chr6:150067644	NUP43	0.4	5.23	0.32	3.8e-7	Lung cancer;
SARC	cis	rs7589342	0.628	rs35866817	chr2:106402569	T/C	cg16077055	chr2:106428750	NCK2	0.31	5.3	0.33	2.63e-7	Addiction;
SARC	cis	rs12477438	1.000	rs17760953	chr2:99859863	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-10.48	-0.57	2.7e-21	Chronic sinus infection;
SARC	cis	rs2290159	0.800	rs11709504	chr3:12674199	T/C	cg23032965	chr3:12705835	RAF1	0.74	8.1	0.47	3.1e-14	Cholesterol, total;
SARC	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg01475735	chr3:40494733	NA	-0.48	-5.29	-0.33	2.86e-7	Renal cell carcinoma;
SARC	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg24549020	chr5:56110836	MAP3K1	0.81	8.41	0.48	4.24e-15	Initial pursuit acceleration;
SARC	cis	rs7089973	0.604	rs3758603	chr10:116605368	T/C	cg03647239	chr10:116582469	FAM160B1	0.5	6.49	0.39	5.19e-10	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg02725872	chr8:58115012	NA	-0.37	-6.47	-0.39	5.76e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs3857536	0.741	rs4710582	chr6:66939984	T/G	cg07460842	chr6:66804631	NA	-0.51	-5.83	-0.36	1.86e-8	Blood trace element (Cu levels);
SARC	cis	rs7633857	0.512	rs2376477	chr3:160700699	G/T	cg17135325	chr3:160939158	NMD3	0.4	4.82	0.3	2.54e-6	Educational attainment (years of education);
SARC	cis	rs9911578	1.000	rs304292	chr17:56824123	G/A	cg05425664	chr17:57184151	TRIM37	-0.66	-8.17	-0.47	1.99e-14	Intelligence (multi-trait analysis);
SARC	cis	rs9487051	0.714	rs7757347	chr6:109633815	G/A	cg01475377	chr6:109611718	NA	-0.37	-5.25	-0.33	3.45e-7	Reticulocyte fraction of red cells;
SARC	cis	rs6840360	0.530	rs62327350	chr4:152641202	G/A	cg22705602	chr4:152727874	NA	-0.45	-6.98	-0.42	3.07e-11	Intelligence (multi-trait analysis);
SARC	cis	rs9462027	0.651	rs7752390	chr6:34790624	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-6.02	-0.37	6.89e-9	Systemic lupus erythematosus;
SARC	cis	rs9300255	0.544	rs1716175	chr12:123658388	A/T	cg00376283	chr12:123451042	ABCB9	0.58	6.82	0.41	7.75e-11	Neutrophil percentage of white cells;
SARC	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg03517284	chr6:25882590	NA	-0.46	-5.92	-0.36	1.14e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7772486	0.754	rs9390358	chr6:146145678	C/T	cg05347473	chr6:146136440	FBXO30	0.51	7.16	0.42	1.07e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1580019	0.961	rs958217	chr7:32493417	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.69	9.01	0.51	7.88e-17	Cognitive ability;
SARC	cis	rs9677476	0.863	rs16827863	chr2:232077670	C/T	cg23338755	chr2:231921595	PSMD1	-0.43	-5.22	-0.32	4.02e-7	Food antigen IgG levels;
SARC	cis	rs509477	0.718	rs273353	chr18:32599361	G/A	cg23791764	chr18:32556832	MAPRE2	0.42	5.18	0.32	4.89e-7	Cerebrospinal fluid AB1-42 levels;
SARC	trans	rs17685	0.712	rs60232511	chr7:75800082	A/G	cg19862616	chr7:65841803	NCRNA00174	0.65	8.08	0.47	3.46e-14	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs950776	0.518	rs12910289	chr15:78822065	T/G	cg06917634	chr15:78832804	PSMA4	0.91	14.24	0.68	1.6e-33	Sudden cardiac arrest;
SARC	cis	rs244731	1.000	rs244730	chr5:176539212	A/G	cg06060754	chr5:176797920	RGS14	-0.41	-4.92	-0.31	1.67e-6	Urate levels in lean individuals;
SARC	cis	rs9309473	0.539	rs6732440	chr2:73827099	T/G	cg20560298	chr2:73613845	ALMS1	0.52	7.01	0.42	2.6e-11	Metabolite levels;
SARC	cis	rs6088580	0.668	rs1205337	chr20:32926041	T/A	cg08999081	chr20:33150536	PIGU	-0.43	-6.51	-0.39	4.46e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs1728785	0.792	rs1111502	chr16:68581209	A/G	cg02972257	chr16:68554789	NA	-0.43	-5.01	-0.31	1.08e-6	Ulcerative colitis;
SARC	cis	rs17023223	0.537	rs6677107	chr1:119708765	C/T	cg05756136	chr1:119680316	WARS2	-0.49	-5.62	-0.35	5.47e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs2304069	0.955	rs4288106	chr5:149394872	A/G	cg12661370	chr5:149340060	SLC26A2	0.6	5.94	0.36	1.01e-8	HIV-1 control;
SARC	cis	rs734999	0.545	rs7368072	chr1:2556125	C/T	cg00980319	chr1:2560884	MMEL1	-0.35	-4.94	-0.31	1.47e-6	Ulcerative colitis;
SARC	cis	rs1950500	1.000	rs1950500	chr14:24830850	T/C	cg16194253	chr14:24768981	DHRS1;C14orf21	0.52	5.94	0.36	1.03e-8	Height;
SARC	cis	rs11025559	0.812	rs10766679	chr11:20509190	T/C	cg04101203	chr11:20408940	PRMT3	-0.48	-5.26	-0.33	3.22e-7	Pursuit maintenance gain;
SARC	cis	rs6815814	0.861	rs10004195	chr4:38784724	T/A	cg06935464	chr4:38784597	TLR10	0.5	5.62	0.35	5.31e-8	Breast cancer;
SARC	cis	rs6542838	0.609	rs13028500	chr2:99528296	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.38	-4.75	-0.3	3.56e-6	Fear of minor pain;
SARC	cis	rs11608355	0.846	rs61934479	chr12:109855111	A/G	cg05360138	chr12:110035743	NA	0.59	6.31	0.38	1.38e-9	Neuroticism;
SARC	cis	rs7264396	0.747	rs2425151	chr20:34394541	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-7.42	-0.44	2.19e-12	Total cholesterol levels;
SARC	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg06028605	chr16:24865363	SLC5A11	0.37	5.71	0.35	3.35e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2204008	0.805	rs11169513	chr12:37988640	G/A	cg13010199	chr12:38710504	ALG10B	0.78	10.59	0.57	1.19e-21	Bladder cancer;
SARC	trans	rs7618501	0.966	rs13085679	chr3:49869631	G/A	cg21659725	chr3:3221576	CRBN	0.8	11.8	0.61	1.66e-25	Intelligence (multi-trait analysis);
SARC	trans	rs61931739	0.517	rs1844525	chr12:34103183	T/A	cg26384229	chr12:38710491	ALG10B	0.87	12.44	0.63	1.37e-27	Morning vs. evening chronotype;
SARC	cis	rs7044106	0.762	rs1547267	chr9:123408736	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	4.97	0.31	1.33e-6	Hip circumference adjusted for BMI;
SARC	cis	rs9467773	0.620	rs1027204	chr6:26639613	T/C	cg12292205	chr6:26970375	C6orf41	0.41	5.12	0.32	6.46e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9420	0.961	rs11605731	chr11:57524089	C/G	cg23127183	chr11:57508653	C11orf31	-0.58	-6.74	-0.4	1.23e-10	Schizophrenia;
SARC	trans	rs61931739	0.534	rs10844767	chr12:34152368	C/G	cg26384229	chr12:38710491	ALG10B	0.83	12.08	0.62	2.02e-26	Morning vs. evening chronotype;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg27152661	chr10:99052555	ARHGAP19	-0.52	-6.48	-0.39	5.4e-10	Height;
SARC	cis	rs6089584	0.526	rs6089316	chr20:60627552	C/T	cg06108461	chr20:60628389	TAF4	-0.72	-9.38	-0.52	5.95e-18	Body mass index;
SARC	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg14784868	chr12:69753453	YEATS4	0.63	8.77	0.5	3.92e-16	Cerebrospinal fluid biomarker levels;
SARC	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg20887711	chr4:1340912	KIAA1530	0.5	6.31	0.38	1.41e-9	Longevity;
SARC	cis	rs10416265	0.527	rs11084699	chr19:33538393	A/T	cg27124370	chr19:33622961	WDR88	0.48	6.24	0.38	2.03e-9	Bone properties (heel);
SARC	cis	rs10512697	0.803	rs1867709	chr5:3576091	C/A	cg19473799	chr5:3511975	NA	-0.69	-5.2	-0.32	4.36e-7	Immune response to smallpox vaccine (IL-6);
SARC	cis	rs6545883	0.929	rs2256615	chr2:61679894	C/G	cg15711740	chr2:61764176	XPO1	-0.44	-5.2	-0.32	4.31e-7	Tuberculosis;
SARC	cis	rs6089584	0.927	rs2281734	chr20:60582401	C/A	cg23262073	chr20:60523788	NA	-0.45	-6.57	-0.4	3.3e-10	Body mass index;
SARC	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.74	-7.59	-0.45	7.59e-13	Platelet count;
SARC	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.77	-10.64	-0.57	8.32e-22	Intelligence (multi-trait analysis);
SARC	cis	rs12044355	0.892	rs10429979	chr1:231843569	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.53	6.97	0.42	3.21e-11	Alzheimer's disease;
SARC	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg23758822	chr17:41437982	NA	0.92	12.35	0.63	2.73e-27	Menopause (age at onset);
SARC	cis	rs9902453	0.874	rs3936006	chr17:28257660	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	6.99	0.42	2.84e-11	Coffee consumption (cups per day);
SARC	cis	rs6121246	0.567	rs2889488	chr20:30185758	G/A	cg13852791	chr20:30311386	BCL2L1	0.66	5.92	0.36	1.15e-8	Mean corpuscular hemoglobin;
SARC	cis	rs6429082	0.875	rs2291688	chr1:235594250	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.42	-5.59	-0.34	6.25e-8	Adiposity;
SARC	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-6.26	-0.38	1.81e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg15921436	chr17:44337874	NA	0.49	4.88	0.3	1.96e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	12.58	0.64	4.75e-28	Chronic sinus infection;
SARC	cis	rs9814567	1.000	rs4368544	chr3:134300014	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	6.89	0.41	5.31e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg16479474	chr6:28041457	NA	0.37	5.48	0.34	1.11e-7	Depression;
SARC	cis	rs11098499	0.535	rs10005542	chr4:120268302	T/C	cg09307838	chr4:120376055	NA	0.75	10.26	0.56	1.28e-20	Corneal astigmatism;
SARC	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg07701084	chr6:150067640	NUP43	0.41	5.37	0.33	1.87e-7	Lung cancer;
SARC	cis	rs13082711	0.953	rs35124294	chr3:27539526	A/G	cg02860705	chr3:27208620	NA	0.5	6.23	0.38	2.11e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs7918232	0.830	rs10764672	chr10:27392541	A/C	cg14240646	chr10:27532245	ACBD5	0.46	4.83	0.3	2.49e-6	Breast cancer;
SARC	cis	rs67311347	0.544	rs2278927	chr3:40350447	G/A	cg24209194	chr3:40518798	ZNF619	0.46	6.26	0.38	1.83e-9	Renal cell carcinoma;
SARC	cis	rs7666738	0.830	rs7697315	chr4:98938764	T/C	cg05340658	chr4:99064831	C4orf37	0.64	8.57	0.49	1.44e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2180341	0.960	rs7745944	chr6:127709574	A/G	cg17762328	chr6:126965162	NA	-0.44	-4.76	-0.3	3.47e-6	Breast cancer;
SARC	cis	rs1497406	0.898	rs36086195	chr1:16510894	C/T	cg06365898	chr1:16533907	ARHGEF19	0.39	5.12	0.32	6.45e-7	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7566780	0.772	rs35423711	chr2:16714210	T/C	cg09580478	chr2:16689509	NA	-0.51	-5.59	-0.34	6.19e-8	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	trans	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.55	-7.18	-0.43	9.4e-12	Intelligence (multi-trait analysis);
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg23988827	chr10:69676715	SIRT1	-0.56	-6.92	-0.41	4.39e-11	Alcohol dependence;
SARC	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg18876405	chr7:65276391	NA	-0.71	-9.07	-0.51	4.91e-17	Aortic root size;
SARC	cis	rs732765	0.602	rs2359192	chr14:75410523	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.43	-5.0	-0.31	1.14e-6	Non-small cell lung cancer;
SARC	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg25811766	chr13:21894605	NA	0.7	8.25	0.48	1.14e-14	White matter hyperintensity burden;
SARC	cis	rs9911578	0.967	rs1588322	chr17:56990099	T/C	cg05425664	chr17:57184151	TRIM37	-0.67	-8.33	-0.48	7.15e-15	Intelligence (multi-trait analysis);
SARC	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg06212747	chr3:49208901	KLHDC8B	0.66	8.8	0.5	3.19e-16	Parkinson's disease;
SARC	cis	rs72781680	0.898	rs72782117	chr2:24026921	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	8.76	0.5	4.07e-16	Lymphocyte counts;
SARC	cis	rs6500637	0.631	rs12921187	chr16:4943019	T/G	cg08329684	chr16:4932620	PPL	-0.4	-6.39	-0.39	8.89e-10	Cancer;
SARC	cis	rs17270561	0.583	rs7765833	chr6:25712433	C/A	cg17691542	chr6:26056736	HIST1H1C	0.53	6.67	0.4	1.86e-10	Iron status biomarkers;
SARC	cis	rs67311347	1.000	rs6599094	chr3:40399593	A/G	cg09455208	chr3:40491958	NA	0.4	6.36	0.38	1.08e-9	Renal cell carcinoma;
SARC	cis	rs7937682	0.575	rs7127010	chr11:111770782	C/T	cg22437258	chr11:111473054	SIK2	-0.48	-5.53	-0.34	8.7e-8	Primary sclerosing cholangitis;
SARC	cis	rs7428	0.527	rs7608892	chr2:85542718	G/A	cg03728395	chr2:85555865	TGOLN2	-0.49	-7.03	-0.42	2.33e-11	Ear protrusion;
SARC	cis	rs7561149	0.934	rs13006510	chr2:179682878	C/G	cg17765952	chr2:179737173	CCDC141	-0.41	-5.39	-0.33	1.73e-7	QT interval;
SARC	cis	rs7639513	0.591	rs9849171	chr3:12622623	G/C	cg23032965	chr3:12705835	RAF1	0.82	11.7	0.61	3.56e-25	Itch intensity from mosquito bite;
SARC	cis	rs13256369	0.802	rs11249888	chr8:8564934	T/C	cg18904891	chr8:8559673	CLDN23	0.49	5.49	0.34	1.04e-7	Obesity-related traits;
SARC	cis	rs3741151	0.773	rs73542979	chr11:73127526	G/C	cg17517138	chr11:73019481	ARHGEF17	0.91	6.77	0.41	1.04e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.56	6.64	0.4	2.23e-10	Renal function-related traits (BUN);
SARC	cis	rs2882667	0.824	rs11748097	chr5:138479887	C/A	cg04439458	chr5:138467593	SIL1	-0.29	-4.98	-0.31	1.25e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs10875746	0.903	rs58952582	chr12:48458448	T/G	cg26205652	chr12:48591994	NA	0.55	5.96	0.36	9.4e-9	Longevity (90 years and older);
SARC	cis	rs2635047	0.935	rs2635050	chr18:44664131	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.53	7.16	0.42	1.04e-11	Educational attainment;
SARC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg21724239	chr8:58056113	NA	0.69	6.34	0.38	1.16e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7726839	0.718	rs6887972	chr5:597274	C/G	cg16447950	chr5:562315	NA	-0.42	-4.81	-0.3	2.74e-6	Obesity-related traits;
SARC	cis	rs9914544	0.545	rs8067882	chr17:18807131	A/G	cg25390199	chr17:18761479	PRPSAP2	0.45	5.74	0.35	2.91e-8	Educational attainment (years of education);
SARC	cis	rs2354432	0.607	rs3820130	chr1:146724003	A/G	cg25205988	chr1:146714368	CHD1L	-1.03	-7.95	-0.46	8.01e-14	Mitochondrial DNA levels;
SARC	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	5.78	0.35	2.36e-8	Bipolar disorder;
SARC	cis	rs6484504	0.576	rs2616792	chr11:31324298	T/G	cg06552810	chr11:31128660	NA	0.31	4.86	0.3	2.2e-6	Red blood cell count;
SARC	cis	rs920590	0.684	rs57837509	chr8:19670088	A/G	cg03894339	chr8:19674705	INTS10	0.63	7.34	0.43	3.48e-12	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9814567	1.000	rs9863786	chr3:134247203	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-6.9	-0.41	4.82e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs12995491	0.698	rs34352413	chr2:88498754	T/G	cg04511125	chr2:88470314	THNSL2	-0.4	-6.06	-0.37	5.53e-9	Response to metformin (IC50);
SARC	trans	rs637571	0.522	rs556643	chr11:65733289	C/T	cg17712092	chr4:129076599	LARP1B	0.69	9.58	0.53	1.5e-18	Eosinophil percentage of white cells;
SARC	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg18876405	chr7:65276391	NA	-0.72	-9.0	-0.51	8.24e-17	Aortic root size;
SARC	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg16405210	chr4:1374714	KIAA1530	-0.52	-6.26	-0.38	1.81e-9	Obesity-related traits;
SARC	cis	rs5753037	0.702	rs5752961	chr22:30188084	C/T	cg01021169	chr22:30184971	ASCC2	-0.43	-5.94	-0.36	1.02e-8	Type 1 diabetes;
SARC	trans	rs1994135	0.692	rs1816958	chr12:33695066	A/T	cg13010199	chr12:38710504	ALG10B	0.62	7.39	0.44	2.64e-12	Resting heart rate;
SARC	cis	rs6088580	0.634	rs62212172	chr20:32987705	G/A	cg08999081	chr20:33150536	PIGU	-0.42	-6.49	-0.39	4.98e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs2439831	1.000	rs2584725	chr15:43793135	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.05	10.85	0.58	1.78e-22	Lung cancer in ever smokers;
SARC	cis	rs9393777	0.513	rs9393741	chr6:26654189	A/G	cg12826209	chr6:26865740	GUSBL1	0.66	5.87	0.36	1.47e-8	Intelligence (multi-trait analysis);
SARC	cis	rs13256369	0.802	rs12541520	chr8:8564146	G/T	cg18904891	chr8:8559673	CLDN23	0.51	6.09	0.37	4.71e-9	Obesity-related traits;
SARC	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-8.03	-0.47	4.67e-14	Chronic sinus infection;
SARC	cis	rs3772190	0.528	rs10936603	chr3:169545652	G/T	cg14222479	chr3:169487675	ARPM1	0.43	4.78	0.3	3.06e-6	Glioma;
SARC	cis	rs11997175	0.524	rs12164218	chr8:33669658	G/C	ch.8.33884649F	chr8:33765107	NA	0.46	5.52	0.34	8.82e-8	Body mass index;
SARC	cis	rs7635838	0.750	rs2648463	chr3:11403857	G/A	cg00170343	chr3:11313890	ATG7	0.63	8.78	0.5	3.53e-16	HDL cholesterol;
SARC	cis	rs7523050	0.643	rs35050241	chr1:109404876	T/C	cg08274380	chr1:109419600	GPSM2	0.99	7.56	0.44	9.38e-13	Fat distribution (HIV);
SARC	cis	rs7264396	0.563	rs7264869	chr20:34346502	A/G	cg01084648	chr20:34329383	RBM39	0.59	4.83	0.3	2.46e-6	Total cholesterol levels;
SARC	cis	rs965469	0.779	rs2236121	chr20:3304320	A/G	cg25506879	chr20:3388711	C20orf194	-0.45	-4.74	-0.3	3.64e-6	IFN-related cytopenia;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg09132121	chr2:178981007	RBM45	0.47	6.69	0.4	1.65e-10	Thyroid stimulating hormone;
SARC	cis	rs826838	1.000	rs1719848	chr12:39085586	A/G	cg26384229	chr12:38710491	ALG10B	-0.8	-12.53	-0.63	6.89e-28	Heart rate;
SARC	cis	rs7208859	0.673	rs56085216	chr17:29217234	T/C	cg13385521	chr17:29058706	SUZ12P	0.85	7.23	0.43	7.08e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs6502050	0.761	rs7225637	chr17:80059758	A/G	cg13939156	chr17:80058883	NA	-0.44	-7.06	-0.42	1.88e-11	Life satisfaction;
SARC	cis	rs711830	1.000	rs2857540	chr2:177026698	G/T	cg13092806	chr2:177043255	NA	0.67	6.68	0.4	1.77e-10	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
SARC	cis	rs1105228	0.918	rs93927	chr6:165714834	A/G	cg20535254	chr6:165714960	C6orf118	-0.29	-4.77	-0.3	3.2e-6	Number of pregnancies;Number of children;
SARC	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.85	-12.99	-0.65	2.21e-29	Age at first birth;
SARC	cis	rs2011503	1.000	rs8110171	chr19:19560063	C/T	cg15839431	chr19:19639596	YJEFN3	-0.47	-4.74	-0.3	3.78e-6	Bipolar disorder;
SARC	cis	rs611744	0.507	rs2121900	chr8:109333542	T/C	cg21045802	chr8:109455806	TTC35	0.68	8.36	0.48	5.56e-15	Dupuytren's disease;
SARC	cis	rs67311347	1.000	rs13324109	chr3:40460767	T/C	cg24209194	chr3:40518798	ZNF619	0.61	7.97	0.46	6.95e-14	Renal cell carcinoma;
SARC	cis	rs11098499	0.863	rs10009626	chr4:120470005	T/C	cg09307838	chr4:120376055	NA	0.91	12.25	0.63	5.66e-27	Corneal astigmatism;
SARC	cis	rs4727027	0.865	rs62505077	chr7:148849656	T/A	cg23583168	chr7:148888333	NA	-0.73	-11.13	-0.59	2.32e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs6674970	0.518	rs15740	chr1:151040435	G/A	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.56	-5.39	-0.33	1.69e-7	Childhood ear infection;
SARC	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg18364779	chr6:26104403	HIST1H4C	0.41	4.92	0.31	1.66e-6	Intelligence (multi-trait analysis);
SARC	cis	rs11581859	0.613	rs35016745	chr1:99230046	G/C	cg20286094	chr1:99190917	SNX7	-0.41	-4.9	-0.31	1.75e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg04277193	chr17:41438351	NA	0.46	5.0	0.31	1.13e-6	Menopause (age at onset);
SARC	cis	rs9611565	0.512	rs5758464	chr22:42171300	A/G	cg19744158	chr22:42196655	CCDC134	-0.57	-5.01	-0.31	1.08e-6	Vitiligo;
SARC	cis	rs1497406	0.744	rs1007887	chr1:16509029	C/T	cg06365898	chr1:16533907	ARHGEF19	0.38	5.25	0.33	3.49e-7	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs10911232	0.507	rs10911196	chr1:182995233	G/A	cg13390022	chr1:182993471	LAMC1	0.33	4.97	0.31	1.29e-6	Hypertriglyceridemia;
SARC	cis	rs17270561	0.609	rs1408271	chr6:25859621	T/A	cg16482183	chr6:26056742	HIST1H1C	0.51	6.61	0.4	2.56e-10	Iron status biomarkers;
SARC	cis	rs11583043	0.958	rs12730160	chr1:101438791	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.5	6.26	0.38	1.85e-9	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs9388451	0.807	rs1268070	chr6:126041164	A/G	cg05901451	chr6:126070800	HEY2	-0.57	-7.59	-0.45	7.57e-13	Brugada syndrome;
SARC	trans	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg22063056	chr1:109505929	CLCC1	-0.67	-6.32	-0.38	1.28e-9	Cutaneous psoriasis;
SARC	cis	rs6815814	0.950	rs66979032	chr4:38814700	A/G	cg06935464	chr4:38784597	TLR10	0.59	5.83	0.36	1.84e-8	Breast cancer;
SARC	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg18404041	chr3:52824283	ITIH1	-0.35	-5.34	-0.33	2.22e-7	Electroencephalogram traits;
SARC	cis	rs4938330	0.608	rs2277287	chr11:117096652	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.56	-5.92	-0.36	1.16e-8	Blood protein levels;
SARC	cis	rs9611519	0.929	rs926914	chr22:41418154	C/T	cg03806693	chr22:41940476	POLR3H	-0.59	-7.14	-0.42	1.21e-11	Neuroticism;
SARC	cis	rs9902453	1.000	rs55971458	chr17:28427016	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	6.71	0.4	1.5e-10	Coffee consumption (cups per day);
SARC	cis	rs1580019	0.885	rs4460270	chr7:32496450	C/T	cg14728415	chr7:32535168	LSM5;AVL9	0.43	5.04	0.31	9.3e-7	Cognitive ability;
SARC	cis	rs9309473	0.519	rs6746971	chr2:73669462	A/G	cg20560298	chr2:73613845	ALMS1	-0.51	-6.94	-0.41	3.94e-11	Metabolite levels;
SARC	cis	rs1348850	0.526	rs1345138	chr2:178387100	A/T	cg23306229	chr2:178417860	TTC30B	0.84	7.66	0.45	4.98e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs10927875	0.541	rs1048237	chr1:16341733	T/C	cg21385522	chr1:16154831	NA	0.55	6.64	0.4	2.24e-10	Dilated cardiomyopathy;
SARC	cis	rs10771431	0.713	rs17794353	chr12:9361783	C/T	cg08997352	chr12:9597637	DDX12	0.62	8.36	0.48	5.9e-15	Breast size;
SARC	cis	rs2073300	0.609	rs6137920	chr20:23363436	C/T	cg16736954	chr20:23401023	NAPB	0.79	4.95	0.31	1.44e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs6665290	0.901	rs68087483	chr1:227202668	T/C	cg14016676	chr1:227182615	CDC42BPA	0.38	5.39	0.33	1.7e-7	Myeloid white cell count;
SARC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.34	5.16	0.32	5.32e-7	Electroencephalogram traits;
SARC	cis	rs6570726	0.935	rs419847	chr6:145827278	A/G	cg05347473	chr6:146136440	FBXO30	0.5	6.66	0.4	1.9e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs593982	0.920	rs487264	chr11:65481465	A/C	cg08755490	chr11:65554678	OVOL1	0.97	8.9	0.5	1.57e-16	Atopic dermatitis;
SARC	cis	rs735396	1.000	rs2259852	chr12:121434833	G/A	cg02403541	chr12:121454288	C12orf43	0.72	9.5	0.53	2.6e-18	N-glycan levels;
SARC	cis	rs7647973	0.626	rs62262722	chr3:49769419	G/C	cg07636037	chr3:49044803	WDR6	-0.62	-5.59	-0.34	6.2e-8	Menarche (age at onset);
SARC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.52	6.89	0.41	5.07e-11	Lymphocyte counts;
SARC	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg04756594	chr16:24857601	SLC5A11	0.46	6.01	0.37	7.15e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7582180	0.614	rs9973737	chr2:100942296	T/C	cg14675211	chr2:100938903	LONRF2	0.5	7.4	0.44	2.51e-12	Intelligence (multi-trait analysis);
SARC	cis	rs2933343	0.729	rs1680794	chr3:128620390	A/G	cg25356066	chr3:128598488	ACAD9	0.71	9.37	0.52	6.47e-18	IgG glycosylation;
SARC	cis	rs897080	0.552	rs1067369	chr2:44652654	A/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	6.62	0.4	2.44e-10	Height;
SARC	cis	rs11969893	0.850	rs9791284	chr6:101353886	G/A	cg12253828	chr6:101329408	ASCC3	1.22	7.25	0.43	6.2e-12	Economic and political preferences (immigration/crime);
SARC	cis	rs6424115	0.793	rs2502998	chr1:24198327	T/A	cg09473613	chr1:24152604	HMGCL	0.33	4.75	0.3	3.49e-6	Immature fraction of reticulocytes;
SARC	cis	rs2439831	0.850	rs12442297	chr15:44168470	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	7.85	0.46	1.49e-13	Lung cancer in ever smokers;
SARC	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg06634786	chr22:41940651	POLR3H	-0.44	-5.15	-0.32	5.53e-7	Vitiligo;
SARC	cis	rs10876993	0.928	rs1678532	chr12:58055197	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.49	-6.22	-0.38	2.3e-9	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs6450176	0.625	rs16881958	chr5:53288201	C/G	ch.5.1024479R	chr5:53302184	ARL15	-0.85	-9.97	-0.55	9.95e-20	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs9400467	0.568	rs12213391	chr6:111800568	G/C	cg15721981	chr6:111408429	SLC16A10	0.65	5.71	0.35	3.5e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg07701084	chr6:150067640	NUP43	0.4	5.27	0.33	3.09e-7	Lung cancer;
SARC	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg00933542	chr6:150070202	PCMT1	0.31	5.13	0.32	6.04e-7	Testicular germ cell tumor;
SARC	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg02733842	chr7:1102375	C7orf50	0.59	7.09	0.42	1.58e-11	Bronchopulmonary dysplasia;
SARC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg22105103	chr4:187893119	NA	0.45	6.02	0.37	6.74e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6088590	1.000	rs11696546	chr20:33452999	C/G	cg06115741	chr20:33292138	TP53INP2	0.58	7.14	0.42	1.19e-11	Coronary artery disease;
SARC	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.49	7.2	0.43	8.31e-12	Systemic lupus erythematosus;
SARC	cis	rs9916302	0.706	rs2302073	chr17:37457342	A/G	cg00129232	chr17:37814104	STARD3	0.54	5.76	0.35	2.7e-8	Glomerular filtration rate (creatinine);
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg16025567	chr3:186285328	TBCCD1	-0.51	-6.38	-0.39	9.48e-10	Gallstone disease;
SARC	cis	rs35213789	0.878	rs12667561	chr7:69510532	C/G	cg10619644	chr7:69149951	AUTS2	0.4	5.04	0.31	9.14e-7	Childhood ear infection;
SARC	cis	rs4727027	0.901	rs7794500	chr7:148819519	C/T	cg23583168	chr7:148888333	NA	0.75	10.78	0.58	2.93e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	trans	rs61931739	0.500	rs9795938	chr12:34587739	C/T	cg13010199	chr12:38710504	ALG10B	-0.78	-11.12	-0.59	2.47e-23	Morning vs. evening chronotype;
SARC	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg02018176	chr4:1364513	KIAA1530	0.37	5.57	0.34	6.88e-8	Longevity;
SARC	cis	rs9395865	0.501	rs2067833	chr6:53330356	A/G	cg25020846	chr6:53659618	LRRC1	-0.4	-4.74	-0.3	3.68e-6	Electroencephalographic traits in alcoholism;
SARC	cis	rs10911232	0.507	rs11582514	chr1:182992161	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.36	0.56	6.15e-21	Hypertriglyceridemia;
SARC	cis	rs2013441	1.000	rs2034109	chr17:20196633	C/T	cg13482628	chr17:19912719	NA	-0.49	-6.36	-0.38	1.07e-9	Obesity-related traits;
SARC	cis	rs2070488	0.574	rs57754356	chr3:38488706	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.81	12.59	0.64	4.36e-28	Electrocardiographic conduction measures;
SARC	cis	rs1348850	0.526	rs10930797	chr2:178437553	C/G	cg23306229	chr2:178417860	TTC30B	0.85	8.49	0.49	2.48e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg06212747	chr3:49208901	KLHDC8B	0.51	6.4	0.39	8.5e-10	Resting heart rate;
SARC	cis	rs3796352	1.000	rs35576914	chr3:53092270	G/A	cg07884673	chr3:53033167	SFMBT1	0.86	5.68	0.35	3.95e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs981844	0.796	rs11099904	chr4:154681861	A/G	cg14289246	chr4:154710475	SFRP2	0.58	6.77	0.41	1.06e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs4423214	1.000	rs12419279	chr11:71139061	T/A	cg24826892	chr11:71159390	DHCR7	0.45	5.39	0.33	1.7e-7	Vitamin D levels;
SARC	cis	rs7092929	0.941	rs835325	chr10:3571175	A/G	cg14308648	chr10:3568949	NA	0.5	4.94	0.31	1.52e-6	Coronary artery calcification;
SARC	cis	rs992157	0.560	rs6436048	chr2:219109033	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.62	8.25	0.48	1.13e-14	Colorectal cancer;
SARC	cis	rs78487399	0.808	rs78191305	chr2:43673978	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-5.19	-0.32	4.52e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs35955747	0.871	rs2013254	chr22:31690803	G/A	cg13145458	chr22:31556086	RNF185	0.39	4.84	0.3	2.39e-6	Neutrophil count;Sum basophil neutrophil counts;
SARC	cis	rs9611565	0.525	rs9611549	chr22:41705909	C/G	cg03806693	chr22:41940476	POLR3H	-0.73	-9.67	-0.54	8.02e-19	Vitiligo;
SARC	trans	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg16141378	chr3:129829833	LOC729375	-0.53	-6.36	-0.38	1.05e-9	Neuroticism;
SARC	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-9.15	-0.51	2.85e-17	Alzheimer's disease;
SARC	cis	rs453301	0.522	rs2929455	chr8:9083433	A/T	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.08	-0.37	5e-9	Joint mobility (Beighton score);
SARC	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg11764359	chr7:65958608	NA	-0.83	-11.38	-0.6	3.87e-24	Aortic root size;
SARC	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg02841227	chr6:26021843	HIST1H4A	0.6	7.07	0.42	1.79e-11	Intelligence (multi-trait analysis);
SARC	cis	rs2952156	0.920	rs1565920	chr17:37831613	G/A	cg07936489	chr17:37558343	FBXL20	-0.4	-5.25	-0.33	3.45e-7	Asthma;
SARC	cis	rs6831352	0.918	rs34805407	chr4:100050786	C/A	cg12011299	chr4:100065546	ADH4	-0.34	-5.74	-0.35	2.97e-8	Alcohol dependence;
SARC	cis	rs963731	0.737	rs10194374	chr2:39244914	G/A	cg04010122	chr2:39346883	SOS1	-0.89	-5.1	-0.32	7.1e-7	Corticobasal degeneration;
SARC	cis	rs8038465	0.568	rs62004592	chr15:73878019	A/G	cg15420318	chr15:73925796	NPTN	0.63	7.13	0.42	1.22e-11	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs4925386	1.000	rs6121990	chr20:60919263	G/A	cg22633769	chr20:60982531	CABLES2	-0.45	-4.95	-0.31	1.41e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs4805272	0.512	rs11879141	chr19:29320335	G/A	cg04546413	chr19:29218101	NA	0.56	6.5	0.39	4.9e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs12586317	0.576	rs10143314	chr14:35637904	A/T	cg16230307	chr14:35515116	FAM177A1	-0.47	-5.9	-0.36	1.27e-8	Psoriasis;
SARC	cis	rs6782228	0.585	rs3122175	chr3:128361276	C/T	cg08795948	chr3:128337044	NA	0.37	5.03	0.31	9.79e-7	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
SARC	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg03647317	chr4:187891568	NA	-0.38	-5.31	-0.33	2.52e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs473651	0.935	rs578510	chr2:239343140	C/T	cg21699342	chr2:239360505	ASB1	0.5	7.45	0.44	1.83e-12	Multiple system atrophy;
SARC	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs3762637	1.000	rs9882100	chr3:122169908	T/C	cg24169773	chr3:122142474	KPNA1	-0.56	-5.73	-0.35	3.07e-8	LDL cholesterol levels;
SARC	cis	rs1448094	0.511	rs11117042	chr12:86207547	G/T	cg02569458	chr12:86230093	RASSF9	0.41	5.6	0.34	6.02e-8	Major depressive disorder;
SARC	cis	rs9840812	0.596	rs571513	chr3:136095035	A/G	cg15507776	chr3:136538369	TMEM22	0.54	5.94	0.36	1.04e-8	Fibrinogen levels;
SARC	cis	rs11608355	0.960	rs11066526	chr12:109854476	G/C	cg19025524	chr12:109796872	NA	-0.38	-4.92	-0.31	1.62e-6	Neuroticism;
SARC	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg26681399	chr22:41777847	TEF	0.47	5.17	0.32	4.92e-7	Vitiligo;
SARC	cis	rs7766436	0.621	rs1548236	chr6:22613919	G/A	cg13666174	chr6:22585274	NA	-0.48	-6.4	-0.39	8.24e-10	Coronary artery disease;
SARC	cis	rs9296092	0.538	rs56199698	chr6:33534505	G/C	cg13560919	chr6:33536144	NA	-0.53	-6.33	-0.38	1.23e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs1957429	0.614	rs61012404	chr14:65347649	C/T	cg23373153	chr14:65346875	NA	-0.96	-7.3	-0.43	4.39e-12	Pediatric areal bone mineral density (radius);
SARC	cis	rs950776	0.684	rs692780	chr15:78876505	C/G	cg17108064	chr15:78857060	CHRNA5	-0.29	-4.74	-0.3	3.79e-6	Sudden cardiac arrest;
SARC	cis	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg20965017	chr5:231967	SDHA	-0.55	-5.28	-0.33	2.98e-7	Breast cancer;
SARC	cis	rs2120019	0.567	rs68036747	chr15:75203200	A/C	cg09165964	chr15:75287851	SCAMP5	-0.96	-10.76	-0.58	3.44e-22	Blood trace element (Zn levels);
SARC	cis	rs10088262	0.629	rs7828192	chr8:124804669	C/T	cg02993010	chr8:124780839	FAM91A1	-0.78	-9.15	-0.51	2.86e-17	Pancreatic cancer;
SARC	cis	rs2153535	0.504	rs5001323	chr6:8451605	C/T	cg07606381	chr6:8435919	SLC35B3	0.78	10.98	0.58	7.14e-23	Motion sickness;
SARC	cis	rs1476587	0.527	rs1859127	chr7:86752142	T/A	cg02420886	chr7:86849541	C7orf23	0.6	5.44	0.34	1.33e-7	Brachial circumference;
SARC	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg15448220	chr1:150897856	SETDB1	0.47	6.22	0.38	2.24e-9	Tonsillectomy;
SARC	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg11764359	chr7:65958608	NA	0.59	7.09	0.42	1.56e-11	Calcium levels;
SARC	cis	rs17079247	1.000	rs9575814	chr13:85761093	T/C	ch.13.84760847R	chr13:85862846	NA	-0.57	-5.02	-0.31	1.05e-6	Bipolar disorder (mania);
SARC	cis	rs35110281	0.805	rs2838330	chr21:45023876	T/A	cg01579765	chr21:45077557	HSF2BP	-0.33	-5.49	-0.34	1.03e-7	Mean corpuscular volume;
SARC	cis	rs876084	0.524	rs4633103	chr8:121116156	A/G	cg06265175	chr8:121136014	COL14A1	-0.59	-7.85	-0.46	1.52e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs11098499	0.909	rs6842762	chr4:120398236	A/T	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg11987759	chr7:65425863	GUSB	0.5	6.22	0.38	2.3e-9	Aortic root size;
SARC	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg11301795	chr4:187892539	NA	-0.77	-11.54	-0.6	1.19e-24	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4563143	0.514	rs55727361	chr19:29300415	A/T	cg03161606	chr19:29218774	NA	0.4	5.08	0.32	7.85e-7	Methadone dose in opioid dependence;
SARC	cis	rs7727544	0.788	rs270613	chr5:131640583	A/G	cg24060327	chr5:131705240	SLC22A5	-0.65	-8.15	-0.47	2.23e-14	Blood metabolite levels;
SARC	cis	rs3808502	0.563	rs10098664	chr8:11417493	T/C	cg21775007	chr8:11205619	TDH	0.53	6.87	0.41	5.7e-11	Neuroticism;
SARC	cis	rs4820539	1.000	rs885964	chr22:23461003	G/C	cg14186256	chr22:23484241	RTDR1	0.89	14.28	0.68	1.14e-33	Bone mineral density;
SARC	cis	rs9916302	0.706	rs801418	chr17:37457982	G/C	cg00129232	chr17:37814104	STARD3	0.54	5.76	0.35	2.7e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg24209194	chr3:40518798	ZNF619	0.65	8.18	0.47	1.79e-14	Renal cell carcinoma;
SARC	cis	rs7932354	0.528	rs1872896	chr11:47160623	C/T	cg03339077	chr11:47165057	C11orf49	-0.48	-6.71	-0.4	1.5e-10	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg21782813	chr7:2030301	MAD1L1	0.44	7.11	0.42	1.39e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg03060546	chr3:49711283	APEH	-0.43	-5.58	-0.34	6.5e-8	Menarche (age at onset);
SARC	trans	rs2727020	0.521	rs4980445	chr11:49570183	C/T	cg15704280	chr7:45808275	SEPT13	-0.67	-8.08	-0.47	3.39e-14	Coronary artery disease;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg10322510	chr16:12136822	RUNDC2A	0.52	7.02	0.42	2.41e-11	Schizophrenia;
SARC	cis	rs7712401	0.601	rs144597	chr5:122223232	A/C	cg19412675	chr5:122181750	SNX24	0.41	5.23	0.32	3.8e-7	Mean platelet volume;
SARC	cis	rs4423214	1.000	rs3750997	chr11:71158841	A/C	cg05163923	chr11:71159392	DHCR7	0.68	9.48	0.53	3.03e-18	Vitamin D levels;
SARC	cis	rs6429082	0.818	rs61836206	chr1:235638754	C/G	cg26050004	chr1:235667680	B3GALNT2	0.66	7.87	0.46	1.33e-13	Adiposity;
SARC	cis	rs10779751	0.770	rs2015818	chr1:11170743	G/A	cg08854313	chr1:11322531	MTOR	0.88	13.0	0.65	2.04e-29	Body mass index;
SARC	cis	rs6688613	0.649	rs2294195	chr1:166838281	T/C	cg07049167	chr1:166818506	POGK	0.47	4.79	0.3	2.96e-6	Refractive astigmatism;
SARC	cis	rs910316	0.934	rs7141705	chr14:75655352	G/C	cg06637938	chr14:75390232	RPS6KL1	-0.47	-6.55	-0.39	3.57e-10	Height;
SARC	trans	rs208520	0.955	rs9453664	chr6:66976079	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.76	8.51	0.49	2.21e-15	Exhaled nitric oxide output;
SARC	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg00149659	chr3:10157352	C3orf10	0.64	6.07	0.37	5.22e-9	Alzheimer's disease;
SARC	cis	rs2014572	0.967	rs8112572	chr19:57759612	T/C	cg24459738	chr19:57751996	ZNF805	-0.46	-5.47	-0.34	1.18e-7	Hyperactive-impulsive symptoms;
SARC	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg10295955	chr4:187884368	NA	-1.0	-15.97	-0.72	2.76e-39	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7607369	0.500	rs6712856	chr2:219658617	A/T	cg02176678	chr2:219576539	TTLL4	-0.48	-7.65	-0.45	5.36e-13	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	trans	rs7824557	0.564	rs2736304	chr8:11236964	C/T	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.29	-0.48	9.23e-15	Retinal vascular caliber;
SARC	cis	rs644799	1.000	rs564675	chr11:95561873	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	14.89	0.7	1.07e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs6860806	0.507	rs200837	chr5:131699958	G/A	cg12564285	chr5:131593104	PDLIM4	0.46	6.23	0.38	2.15e-9	Breast cancer;
SARC	cis	rs1008375	1.000	rs1121090	chr4:17676437	C/G	cg16339924	chr4:17578868	LAP3	0.64	8.39	0.48	4.6e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs13191362	0.872	rs67712738	chr6:163245768	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.63	6.11	0.37	4.22e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg18404041	chr3:52824283	ITIH1	-0.44	-6.59	-0.4	2.9e-10	Bipolar disorder;
SARC	cis	rs3820928	0.967	rs2396435	chr2:227778397	G/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-6.63	-0.4	2.28e-10	Pulmonary function;
SARC	cis	rs4319547	0.695	rs10846699	chr12:122853073	A/G	cg05707623	chr12:122985044	ZCCHC8	0.59	7.11	0.42	1.44e-11	Body mass index;
SARC	trans	rs11098499	0.954	rs71614438	chr4:120371252	G/A	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	cis	rs2153535	0.580	rs2143356	chr6:8517675	C/T	cg21535247	chr6:8435926	SLC35B3	0.58	7.25	0.43	6.2e-12	Motion sickness;
SARC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg24101359	chr6:42928495	GNMT	0.35	4.91	0.31	1.72e-6	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg09373136	chr17:61933544	TCAM1	-0.45	-6.12	-0.37	3.83e-9	Prudent dietary pattern;
SARC	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg27347728	chr4:17578864	LAP3	0.48	6.1	0.37	4.32e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6809651	0.524	rs1356291	chr3:185824644	C/T	cg00760338	chr3:185826511	ETV5	0.88	11.21	0.59	1.28e-23	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
SARC	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-8.06	-0.47	4.07e-14	Chronic sinus infection;
SARC	cis	rs11638352	1.000	rs2615295	chr15:44412598	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.77	-5.84	-0.36	1.78e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	cis	rs240764	0.658	rs35168784	chr6:101183499	C/T	cg09795085	chr6:101329169	ASCC3	-0.5	-6.59	-0.4	2.98e-10	Neuroticism;
SARC	cis	rs6088580	0.524	rs1853056	chr20:33262058	C/T	cg08999081	chr20:33150536	PIGU	-0.35	-5.13	-0.32	6.11e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs981844	0.816	rs62325147	chr4:154727568	G/A	cg14289246	chr4:154710475	SFRP2	0.58	6.39	0.39	8.77e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs11770686	0.841	rs10281798	chr7:75321884	A/G	cg17787366	chr7:75369077	HIP1	0.44	5.47	0.34	1.17e-7	Essential tremor;
SARC	cis	rs8114671	0.562	rs6088655	chr20:33527838	A/G	cg08999081	chr20:33150536	PIGU	0.34	5.01	0.31	1.06e-6	Height;
SARC	cis	rs611744	0.806	rs2440387	chr8:109067078	A/G	cg21045802	chr8:109455806	TTC35	0.43	5.02	0.31	1.04e-6	Dupuytren's disease;
SARC	cis	rs7953249	0.773	rs7979478	chr12:121420263	A/G	cg25281562	chr12:121454272	C12orf43	-0.41	-4.95	-0.31	1.39e-6	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg25427524	chr10:38739819	LOC399744	-0.59	-9.55	-0.53	1.87e-18	Extrinsic epigenetic age acceleration;
SARC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.62	-8.04	-0.47	4.59e-14	Lymphocyte counts;
SARC	cis	rs12348691	0.503	rs1867279	chr9:100616041	T/C	cg13688889	chr9:100608707	NA	-0.47	-5.0	-0.31	1.15e-6	Alopecia areata;
SARC	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg25894440	chr7:65020034	NA	-0.72	-5.46	-0.34	1.2e-7	Diabetic kidney disease;
SARC	cis	rs9818758	0.607	rs11719220	chr3:49245201	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.74	-6.45	-0.39	6.51e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs501120	0.810	rs607592	chr10:44750215	A/G	cg09554077	chr10:44749378	NA	0.46	6.42	0.39	7.38e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs12950390	0.853	rs10445375	chr17:45864314	C/T	cg24803719	chr17:45855879	NA	0.47	7.65	0.45	5.21e-13	IgG glycosylation;
SARC	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg02841227	chr6:26021843	HIST1H4A	-0.48	-5.86	-0.36	1.59e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7586879	0.521	rs1865689	chr2:25108197	C/T	cg04586622	chr2:25135609	ADCY3	-0.32	-5.55	-0.34	7.91e-8	Body mass index;
SARC	cis	rs17030434	0.654	rs28640133	chr4:154645926	T/A	cg14289246	chr4:154710475	SFRP2	-0.55	-5.37	-0.33	1.87e-7	Electrocardiographic conduction measures;
SARC	trans	rs4332037	0.851	rs34040190	chr7:1920356	G/A	cg11693508	chr17:37793320	STARD3	0.76	7.01	0.42	2.57e-11	Bipolar disorder;
SARC	cis	rs6598163	0.517	rs10902453	chr12:132297091	G/T	cg22244940	chr12:132335942	MMP17	-0.46	-5.79	-0.35	2.29e-8	Migraine;
SARC	cis	rs1153858	1.000	rs11070456	chr15:45686835	G/A	cg26924012	chr15:45694286	SPATA5L1	0.78	10.68	0.57	6.18e-22	Homoarginine levels;
SARC	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg12311346	chr5:56204834	C5orf35	-0.58	-6.01	-0.37	7.24e-9	Initial pursuit acceleration;
SARC	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg22535103	chr8:58192502	C8orf71	-0.6	-6.15	-0.37	3.42e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7255436	0.928	rs7250870	chr19:8453682	C/T	cg10174797	chr19:8464628	RAB11B	0.44	6.33	0.38	1.26e-9	HDL cholesterol;
SARC	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg04772025	chr11:68637568	NA	0.53	6.92	0.41	4.24e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs4595586	0.545	rs7967295	chr12:39376866	G/A	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	cis	rs858239	0.601	rs10278776	chr7:23169759	C/T	cg23682824	chr7:23144976	KLHL7	0.73	9.84	0.54	2.45e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs1707322	0.686	rs1084086	chr1:46041100	A/C	cg06784218	chr1:46089804	CCDC17	-0.41	-7.01	-0.42	2.49e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg00908189	chr16:619842	PIGQ	0.83	12.03	0.62	2.92e-26	Height;
SARC	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg26769984	chr7:1090371	C7orf50	0.48	5.06	0.31	8.69e-7	Bronchopulmonary dysplasia;
SARC	cis	rs10845606	1.000	rs10845607	chr12:12835228	C/T	cg04607235	chr12:12878440	APOLD1	-0.54	-5.31	-0.33	2.55e-7	Systemic lupus erythematosus;
SARC	cis	rs7412746	0.658	rs2089082	chr1:150800090	T/G	cg10589385	chr1:150898437	SETDB1	0.41	5.45	0.34	1.29e-7	Melanoma;
SARC	cis	rs11098499	0.618	rs35265692	chr4:120325135	T/C	cg09307838	chr4:120376055	NA	0.89	12.16	0.62	1.15e-26	Corneal astigmatism;
SARC	cis	rs11155671	0.530	rs7758020	chr6:150208111	T/C	cg05036130	chr6:150231994	NA	0.29	5.06	0.31	8.64e-7	Testicular germ cell tumor;
SARC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.91	10.42	0.56	4.02e-21	Platelet count;
SARC	cis	rs79349575	0.783	rs4794003	chr17:47029904	C/T	cg16584676	chr17:46985605	UBE2Z	0.55	6.58	0.4	3.01e-10	Type 2 diabetes;
SARC	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg22496380	chr5:211416	CCDC127	-0.88	-9.35	-0.52	7.72e-18	Breast cancer;
SARC	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	7.14	0.42	1.15e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7043114	0.525	rs2516567	chr9:95187418	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.81	-0.36	2.07e-8	Height;
SARC	cis	rs17376456	0.569	rs10050364	chr5:93064127	T/C	cg25358565	chr5:93447407	FAM172A	0.95	10.57	0.57	1.37e-21	Diabetic retinopathy;
SARC	cis	rs738322	0.533	rs5756934	chr22:38547279	G/A	cg25457927	chr22:38595422	NA	-0.26	-4.92	-0.31	1.67e-6	Cutaneous nevi;
SARC	trans	rs988958	0.883	rs13383145	chr2:42305131	A/G	cg02435573	chr1:94712239	NA	0.51	6.53	0.39	3.98e-10	Hypospadias;
SARC	cis	rs7220711	0.902	rs9911277	chr17:41780484	G/A	cg26893861	chr17:41843967	DUSP3	0.38	4.73	0.3	3.81e-6	Bone mineral density (spine);Bone mineral density (hip);
SARC	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg15352829	chr14:105391018	PLD4	-0.33	-6.26	-0.38	1.84e-9	Rheumatoid arthritis;
SARC	cis	rs7714584	1.000	rs1000113	chr5:150240076	C/T	cg22134413	chr5:150180641	NA	0.85	7.24	0.43	6.52e-12	Crohn's disease;
SARC	cis	rs2273669	0.748	rs11759732	chr6:109370006	A/G	cg05315195	chr6:109294784	ARMC2	-0.52	-5.04	-0.31	9.22e-7	Prostate cancer;
SARC	cis	rs3020736	0.500	rs764481	chr22:42518426	G/A	cg15557168	chr22:42548783	NA	0.36	4.96	0.31	1.36e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2816062	0.775	rs2745315	chr1:18897118	G/A	cg18795169	chr1:18902165	NA	-0.78	-12.69	-0.64	2.13e-28	Urate levels in lean individuals;
SARC	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg05861140	chr6:150128134	PCMT1	-0.41	-5.28	-0.33	2.98e-7	Lung cancer;
SARC	cis	rs155076	1.000	rs12870992	chr13:21846019	A/G	cg14456004	chr13:21872349	NA	0.95	11.44	0.6	2.43e-24	White matter hyperintensity burden;
SARC	cis	rs7927592	0.913	rs10047412	chr11:68232912	T/C	cg01657329	chr11:68192670	LRP5	-0.41	-4.99	-0.31	1.18e-6	Total body bone mineral density;
SARC	cis	rs950027	0.620	rs1346267	chr15:45690989	A/G	cg15395560	chr15:45543142	SLC28A2	-0.27	-5.15	-0.32	5.51e-7	Response to fenofibrate (adiponectin levels);
SARC	cis	rs6704644	0.651	rs56266844	chr2:234360007	G/A	cg27060346	chr2:234359958	DGKD	-0.81	-4.99	-0.31	1.16e-6	Bilirubin levels;
SARC	cis	rs78487399	0.710	rs72879290	chr2:43633268	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-4.97	-0.31	1.27e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs12956009	0.507	rs1560900	chr18:44866849	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	6.28	0.38	1.64e-9	Educational attainment (years of education);
SARC	cis	rs2073300	0.609	rs6132609	chr20:23400412	A/C	cg12062639	chr20:23401060	NAPB	1.01	6.99	0.42	2.92e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg08219700	chr8:58056026	NA	0.68	6.44	0.39	6.92e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs11098499	0.909	rs35111518	chr4:120440682	A/G	cg09307838	chr4:120376055	NA	0.92	12.26	0.63	5.54e-27	Corneal astigmatism;
SARC	cis	rs11122272	0.735	rs2749708	chr1:231529610	G/A	cg06096015	chr1:231504339	EGLN1	0.39	5.81	0.36	1.99e-8	Hemoglobin concentration;
SARC	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg16479474	chr6:28041457	NA	0.37	5.25	0.33	3.45e-7	Parkinson's disease;
SARC	cis	rs9462027	0.651	rs6940395	chr6:34736553	G/T	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-6.17	-0.37	3.08e-9	Systemic lupus erythematosus;
SARC	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-4.82	-0.3	2.59e-6	Menopause (age at onset);
SARC	cis	rs3091242	0.900	rs1811832	chr1:25753565	G/A	cg03650068	chr1:25596491	NA	0.31	4.75	0.3	3.6e-6	Erythrocyte sedimentation rate;
SARC	trans	rs698833	0.538	rs1067396	chr2:44637738	A/G	cg19364021	chr13:53776396	NA	0.47	6.3	0.38	1.46e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs9660180	0.967	rs12040325	chr1:1702436	G/A	cg27541892	chr1:1571801	CDK11B	0.41	5.56	0.34	7.31e-8	Body mass index;
SARC	cis	rs965469	1.000	rs1331215	chr20:3376565	T/C	cg25506879	chr20:3388711	C20orf194	-0.5	-5.1	-0.32	6.93e-7	IFN-related cytopenia;
SARC	trans	rs3942852	0.726	rs10742836	chr11:48175831	G/A	cg03929089	chr4:120376271	NA	-0.61	-6.92	-0.41	4.3e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs787274	1.000	rs4979150	chr9:115553502	T/A	cg13803584	chr9:115635662	SNX30	-0.77	-5.88	-0.36	1.38e-8	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs6912958	0.781	rs9450712	chr6:88193175	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.51	-6.85	-0.41	6.69e-11	Monocyte percentage of white cells;
SARC	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	9.01	0.51	7.42e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1843834	0.574	rs6436499	chr2:225456551	A/T	cg22455342	chr2:225449267	CUL3	0.68	8.1	0.47	3.03e-14	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs10875746	0.951	rs7485355	chr12:48548342	G/A	cg26205652	chr12:48591994	NA	0.58	6.33	0.38	1.27e-9	Longevity (90 years and older);
SARC	trans	rs877282	1.000	rs12763443	chr10:771941	G/A	cg22713356	chr15:30763199	NA	1.04	10.16	0.55	2.56e-20	Uric acid levels;
SARC	cis	rs2276314	1.000	rs8086395	chr18:33564592	C/G	cg05985134	chr18:33552581	C18orf21	0.71	7.71	0.45	3.59e-13	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.95	12.84	0.64	6.94e-29	Platelet count;
SARC	cis	rs826838	0.967	rs4768329	chr12:39129394	T/C	cg13010199	chr12:38710504	ALG10B	-0.63	-8.88	-0.5	1.87e-16	Heart rate;
SARC	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg25894440	chr7:65020034	NA	-0.72	-5.46	-0.34	1.2e-7	Diabetic kidney disease;
SARC	cis	rs17384381	1.000	rs12140457	chr1:85860170	G/A	cg16011679	chr1:85725395	C1orf52	0.61	5.77	0.35	2.49e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4481887	0.861	rs6681336	chr1:248482756	C/T	cg13385794	chr1:248469461	NA	0.35	5.29	0.33	2.83e-7	Common traits (Other);
SARC	cis	rs9921222	0.656	rs12719801	chr16:381141	C/T	cg08923669	chr16:420230	MRPL28	-0.37	-5.4	-0.33	1.67e-7	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg25894440	chr7:65020034	NA	-0.74	-5.64	-0.35	4.95e-8	Diabetic kidney disease;
SARC	cis	rs56307353	0.513	rs2041120	chr19:1961474	C/T	cg11709110	chr19:1989583	BTBD2	-0.35	-4.93	-0.31	1.6e-6	Coronary artery disease;
SARC	cis	rs2404602	0.647	rs12440511	chr15:76993135	A/G	cg15268244	chr15:77196840	NA	0.44	5.17	0.32	5.06e-7	Blood metabolite levels;
SARC	cis	rs3733585	0.699	rs60045583	chr4:9971950	G/A	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.4	-0.33	1.66e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs9921222	0.500	rs11645742	chr16:367516	C/T	cg12437481	chr16:420112	MRPL28	-0.39	-5.18	-0.32	4.89e-7	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.73	10.4	0.56	4.57e-21	Menarche (age at onset);
SARC	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg20607798	chr8:58055168	NA	0.58	5.02	0.31	1.04e-6	Developmental language disorder (linguistic errors);
SARC	trans	rs1814175	0.527	rs3974435	chr11:49619533	G/A	cg15704280	chr7:45808275	SEPT13	-0.71	-8.6	-0.49	1.22e-15	Height;
SARC	cis	rs7735319	0.727	rs4030366	chr5:33114943	G/A	cg21580394	chr5:33502217	NA	-0.35	-4.72	-0.3	4.08e-6	Systolic blood pressure;
SARC	cis	rs17270561	0.609	rs1317817	chr6:25765377	G/A	cg16482183	chr6:26056742	HIST1H1C	0.51	6.35	0.38	1.12e-9	Iron status biomarkers;
SARC	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs4646312	0.555	rs9606190	chr22:19926004	T/C	cg07194846	chr22:19930177	COMT;TXNRD2	0.5	6.46	0.39	5.94e-10	Schizophrenia;
SARC	cis	rs1707322	0.721	rs10890346	chr1:46223892	C/T	cg06784218	chr1:46089804	CCDC17	-0.4	-6.97	-0.42	3.15e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9291683	0.530	rs17246501	chr4:9985710	A/C	cg11266682	chr4:10021025	SLC2A9	0.4	7.07	0.42	1.75e-11	Bone mineral density;
SARC	cis	rs1215050	0.740	rs6854802	chr4:99065480	A/C	cg05340658	chr4:99064831	C4orf37	0.47	6.26	0.38	1.79e-9	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg12000995	chr2:27665139	KRTCAP3	-0.3	-4.77	-0.3	3.24e-6	Total body bone mineral density;
SARC	cis	rs7524258	0.903	rs4908609	chr1:7292910	G/A	cg07173049	chr1:7289937	CAMTA1	0.41	7.97	0.46	7.07e-14	Tourette's syndrome or obsessive-compulsive disorder;
SARC	trans	rs11098499	0.697	rs6832410	chr4:120296800	A/G	cg25214090	chr10:38739885	LOC399744	0.55	7.14	0.42	1.15e-11	Corneal astigmatism;
SARC	cis	rs7520050	0.966	rs2486447	chr1:46545724	G/A	cg24296786	chr1:45957014	TESK2	0.38	4.83	0.3	2.45e-6	Red blood cell count;Reticulocyte count;
SARC	trans	rs1814175	0.645	rs10839448	chr11:49938930	G/A	cg15704280	chr7:45808275	SEPT13	-0.89	-14.11	-0.68	4.34e-33	Height;
SARC	cis	rs72781680	0.611	rs55983206	chr2:24333995	A/C	cg08917208	chr2:24149416	ATAD2B	0.61	6.31	0.38	1.4e-9	Lymphocyte counts;
SARC	cis	rs4568518	0.869	rs12699939	chr7:18036784	T/C	cg00911873	chr7:18067463	PRPS1L1	-0.34	-4.89	-0.31	1.89e-6	Measles;
SARC	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg17747265	chr1:1875780	NA	-0.34	-4.99	-0.31	1.17e-6	Body mass index;
SARC	trans	rs3942852	0.806	rs10838805	chr11:48118993	A/C	cg03929089	chr4:120376271	NA	-0.57	-6.26	-0.38	1.87e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg17376030	chr22:41985996	PMM1	0.76	9.28	0.52	1.25e-17	Vitiligo;
SARC	cis	rs9436747	0.641	rs11208678	chr1:66049691	A/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.48	4.97	0.31	1.29e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs950169	0.840	rs4842854	chr15:84942339	T/G	cg24253500	chr15:84953950	NA	0.36	5.1	0.32	6.9e-7	Schizophrenia;
SARC	cis	rs10489202	0.608	rs6657019	chr1:168079669	T/C	cg24449463	chr1:168025552	DCAF6	-0.58	-7.74	-0.45	3.01e-13	Schizophrenia;
SARC	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg20007245	chr22:24372913	LOC391322	-0.45	-5.14	-0.32	5.88e-7	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs10861342	1.000	rs12316054	chr12:105569143	T/C	cg23923672	chr12:105501055	KIAA1033	0.69	5.14	0.32	5.88e-7	IgG glycosylation;
SARC	cis	rs7385804	0.633	rs221795	chr7:100283261	C/T	cg16850897	chr7:100343110	ZAN	0.42	4.72	0.3	4.1e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
SARC	trans	rs1945213	0.694	rs11227181	chr11:55856053	C/T	cg15704280	chr7:45808275	SEPT13	0.66	6.9	0.41	5e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs10870270	1.000	rs7077744	chr10:133770201	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.48	-5.39	-0.33	1.72e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs6665290	0.669	rs7552783	chr1:227174145	T/C	cg14016676	chr1:227182615	CDC42BPA	0.34	4.89	0.3	1.9e-6	Myeloid white cell count;
SARC	cis	rs1348850	0.874	rs12996447	chr2:178283592	C/T	cg23306229	chr2:178417860	TTC30B	0.5	5.76	0.35	2.65e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2075371	0.863	rs1421479	chr7:133949345	T/G	cg20476274	chr7:133979776	SLC35B4	0.57	7.41	0.44	2.28e-12	Mean platelet volume;
SARC	cis	rs2806561	0.704	rs663942	chr1:23522476	G/A	cg12483005	chr1:23474871	LUZP1	0.47	6.11	0.37	4.15e-9	Height;
SARC	trans	rs7824557	0.564	rs2572379	chr8:11237480	A/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.8	-0.41	8.83e-11	Retinal vascular caliber;
SARC	cis	rs10504229	0.679	rs2218271	chr8:58052446	T/A	cg20607798	chr8:58055168	NA	0.6	5.52	0.34	9.04e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs912057	0.526	rs201061	chr6:6730512	C/T	cg06612196	chr6:6737390	NA	-0.67	-11.32	-0.6	6.02e-24	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs1008375	0.966	rs2315645	chr4:17579678	G/C	cg27347728	chr4:17578864	LAP3	0.49	6.06	0.37	5.46e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs3806933	0.522	rs11241100	chr5:110460958	C/T	cg04022379	chr5:110408740	TSLP	0.7	9.01	0.51	7.52e-17	Eosinophilic esophagitis;
SARC	cis	rs10463316	0.817	rs13355052	chr5:150802003	A/G	cg03212797	chr5:150827313	SLC36A1	-0.44	-5.18	-0.32	4.82e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs7914558	0.933	rs12763665	chr10:104653717	G/A	cg04362960	chr10:104952993	NT5C2	0.41	4.95	0.31	1.42e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg05424782	chr22:42017079	XRCC6;PPPDE2	0.52	6.42	0.39	7.76e-10	Breast cancer;
SARC	cis	rs854765	0.547	rs4365348	chr17:17912548	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	9.47	0.53	3.17e-18	Total body bone mineral density;
SARC	cis	rs9916302	0.904	rs9894500	chr17:37515735	G/C	cg07936489	chr17:37558343	FBXL20	0.68	9.2	0.52	2.14e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs921968	0.565	rs6708192	chr2:219592227	A/G	cg02176678	chr2:219576539	TTLL4	-0.32	-4.97	-0.31	1.29e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-9.8	-0.54	3.3e-19	Chronic sinus infection;
SARC	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg04398451	chr17:18023971	MYO15A	-0.39	-5.38	-0.33	1.77e-7	Total body bone mineral density;
SARC	cis	rs926938	0.584	rs2798663	chr1:115363582	G/A	cg12756093	chr1:115239321	AMPD1	0.39	5.11	0.32	6.67e-7	Autism;
SARC	cis	rs11098499	0.661	rs10015965	chr4:120268237	A/G	cg09307838	chr4:120376055	NA	0.75	10.26	0.56	1.28e-20	Corneal astigmatism;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg23773983	chr6:16761891	ATXN1	-0.79	-6.5	-0.39	4.85e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7582180	0.652	rs4443016	chr2:100876628	C/G	cg14675211	chr2:100938903	LONRF2	0.35	4.93	0.31	1.56e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9868809	0.881	rs13063312	chr3:48661985	G/A	cg00383909	chr3:49044727	WDR6	0.54	4.87	0.3	2.04e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs9527	0.590	rs7906754	chr10:104782557	T/C	cg04362960	chr10:104952993	NT5C2	0.45	5.39	0.33	1.72e-7	Arsenic metabolism;
SARC	cis	rs2948294	0.588	rs12544596	chr8:8116346	A/T	cg08975724	chr8:8085496	FLJ10661	0.52	6.06	0.37	5.36e-9	Red cell distribution width;
SARC	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.9	12.04	0.62	2.77e-26	Platelet count;
SARC	cis	rs12497850	1.000	rs12497850	chr3:48748989	G/T	cg03060546	chr3:49711283	APEH	0.42	5.32	0.33	2.48e-7	Parkinson's disease;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg07095671	chr8:86133288	C8orf59	0.47	6.79	0.41	9.08e-11	Electrocardiographic conduction measures;
SARC	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg22857025	chr5:266934	NA	-1.04	-11.74	-0.61	2.61e-25	Breast cancer;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg19026959	chr19:13049204	CALR	0.49	6.44	0.39	6.74e-10	Chemerin levels;
SARC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg09436375	chr6:42928200	GNMT	0.36	5.73	0.35	3.06e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg05793240	chr7:2802953	GNA12	-0.36	-5.18	-0.32	4.79e-7	Height;
SARC	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg20503657	chr10:835505	NA	1.14	10.3	0.56	9.76e-21	Eosinophil percentage of granulocytes;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg10192736	chr19:1028627	CNN2	0.5	6.58	0.4	3.15e-10	Chemerin levels;
SARC	cis	rs7666738	0.830	rs28587201	chr4:98991733	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.72	0.5	5.27e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg16325326	chr1:53192061	ZYG11B	-0.83	-13.35	-0.66	1.47e-30	Monocyte count;
SARC	cis	rs796364	0.951	rs12996313	chr2:200997916	C/T	cg23649088	chr2:200775458	C2orf69	-0.59	-5.78	-0.35	2.43e-8	Schizophrenia;
SARC	trans	rs3780486	0.846	rs10971419	chr9:33124161	T/C	cg20290983	chr6:43655470	MRPS18A	1.14	22.53	0.83	1.95e-60	IgG glycosylation;
SARC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg09373136	chr17:61933544	TCAM1	-0.45	-6.23	-0.38	2.18e-9	Prudent dietary pattern;
SARC	cis	rs3936840	0.861	rs1044502	chr14:102965897	G/A	cg18135206	chr14:102964638	TECPR2	0.42	5.2	0.32	4.32e-7	Plateletcrit;
SARC	cis	rs76917914	1.000	rs874610	chr9:100782695	G/T	cg03040243	chr9:100819229	NANS	0.58	6.06	0.37	5.55e-9	Immature fraction of reticulocytes;
SARC	cis	rs9398803	0.965	rs9491624	chr6:126679106	A/T	cg19875578	chr6:126661172	C6orf173	0.6	8.17	0.47	1.96e-14	Male-pattern baldness;
SARC	cis	rs7589342	0.899	rs10185551	chr2:106492201	A/C	cg16077055	chr2:106428750	NCK2	0.35	6.41	0.39	7.86e-10	Addiction;
SARC	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg17971929	chr21:40555470	PSMG1	-0.86	-11.04	-0.59	4.56e-23	Cognitive function;
SARC	cis	rs9309473	0.500	rs4852308	chr2:73834035	T/G	cg20560298	chr2:73613845	ALMS1	0.5	6.77	0.41	1.05e-10	Metabolite levels;
SARC	cis	rs400736	0.860	rs2294890	chr1:8086527	T/G	cg25007680	chr1:8021821	PARK7	0.48	6.13	0.37	3.64e-9	Response to antidepressants and depression;
SARC	cis	rs898097	0.812	rs56405605	chr17:80843663	T/C	cg15369054	chr17:80825471	TBCD	0.55	7.67	0.45	4.52e-13	Breast cancer;
SARC	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	7.34	0.43	3.43e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs11574514	1.000	rs79327462	chr16:67958058	G/A	cg01866162	chr16:67596514	CTCF	1.03	6.28	0.38	1.6e-9	Crohn's disease;
SARC	cis	rs7818688	0.697	rs11781397	chr8:95974506	G/T	cg13393036	chr8:95962371	TP53INP1	0.43	5.11	0.32	6.66e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs7106204	0.688	rs4462347	chr11:24218865	G/A	ch.11.24196551F	chr11:24239977	NA	0.7	6.56	0.4	3.37e-10	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs9818758	0.556	rs13086240	chr3:49001409	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.64	-5.46	-0.34	1.22e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg24675658	chr1:53192096	ZYG11B	-0.65	-9.59	-0.53	1.39e-18	Monocyte count;
SARC	cis	rs208520	0.690	rs207119	chr6:66786408	C/T	cg07460842	chr6:66804631	NA	-1.08	-15.02	-0.7	4.17e-36	Exhaled nitric oxide output;
SARC	cis	rs765787	0.530	rs1648289	chr15:45516494	A/G	cg25801113	chr15:45476975	SHF	0.29	4.85	0.3	2.27e-6	Uric acid levels;
SARC	cis	rs11676348	0.808	rs4674267	chr2:219046437	C/T	cg00012203	chr2:219082015	ARPC2	-0.43	-5.5	-0.34	9.84e-8	Ulcerative colitis;
SARC	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg18876405	chr7:65276391	NA	0.48	5.47	0.34	1.14e-7	Aortic root size;
SARC	cis	rs10088262	0.629	rs9918907	chr8:124816862	A/G	cg02993010	chr8:124780839	FAM91A1	-0.78	-9.16	-0.51	2.78e-17	Pancreatic cancer;
SARC	cis	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg06558623	chr16:89946397	TCF25	0.89	6.23	0.38	2.14e-9	Skin colour saturation;
SARC	cis	rs3018712	0.590	rs4930585	chr11:68411347	T/C	cg01657329	chr11:68192670	LRP5	0.58	5.28	0.33	3.01e-7	Total body bone mineral density;
SARC	cis	rs2273669	0.667	rs77936298	chr6:109350616	A/T	cg05315195	chr6:109294784	ARMC2	-0.63	-5.7	-0.35	3.6e-8	Prostate cancer;
SARC	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg10207240	chr12:122356781	WDR66	0.3	5.15	0.32	5.51e-7	Mean corpuscular volume;
SARC	cis	rs7247513	0.759	rs73002392	chr19:12768391	G/A	cg01871581	chr19:12707946	ZNF490	-0.75	-10.7	-0.57	5.51e-22	Bipolar disorder;
SARC	cis	rs3087591	0.960	rs2905803	chr17:29520056	T/C	cg24425628	chr17:29625626	OMG;NF1	0.5	6.11	0.37	4.05e-9	Hip circumference;
SARC	cis	rs2303745	0.589	rs751599	chr19:17396549	A/G	cg22549504	chr19:17448937	GTPBP3	0.47	4.73	0.3	3.95e-6	Systemic lupus erythematosus;
SARC	cis	rs2011503	1.000	rs11669730	chr19:19648713	G/A	cg03709012	chr19:19516395	GATAD2A	0.6	5.29	0.33	2.8e-7	Bipolar disorder;
SARC	cis	rs4268898	0.722	rs2288072	chr2:24390517	G/A	cg26838691	chr2:24397539	C2orf84	0.45	6.1	0.37	4.38e-9	Asthma;
SARC	cis	rs10911232	0.507	rs10911199	chr1:182998036	T/A	cg13390022	chr1:182993471	LAMC1	0.33	4.97	0.31	1.31e-6	Hypertriglyceridemia;
SARC	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg16606324	chr3:10149918	C3orf24	0.48	4.96	0.31	1.35e-6	Alzheimer's disease;
SARC	cis	rs2011503	0.882	rs2060276	chr19:19522491	T/G	cg15839431	chr19:19639596	YJEFN3	-0.51	-4.72	-0.3	4.11e-6	Bipolar disorder;
SARC	cis	rs6120849	0.754	rs1885116	chr20:33600560	A/G	cg06115741	chr20:33292138	TP53INP2	0.55	5.21	0.32	4.16e-7	Protein C levels;
SARC	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-5.68	-0.35	3.93e-8	Bipolar disorder;
SARC	cis	rs1800795	0.652	rs7802307	chr7:22766433	T/A	cg26061582	chr7:22766209	IL6	0.62	7.19	0.43	8.59e-12	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
SARC	cis	rs9457247	0.565	rs12178491	chr6:167512474	C/T	cg23791538	chr6:167370224	RNASET2	-0.49	-6.17	-0.37	2.99e-9	Crohn's disease;
SARC	cis	rs56036086	0.702	rs6010152	chr22:50618278	C/T	cg16473166	chr22:50639996	SELO	-0.65	-5.33	-0.33	2.3e-7	Platelet count;Plateletcrit;
SARC	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg03351412	chr1:154909251	PMVK	-0.59	-7.65	-0.45	5.12e-13	Prostate cancer;
SARC	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg24531977	chr5:56204891	C5orf35	-0.54	-5.58	-0.34	6.65e-8	Initial pursuit acceleration;
SARC	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg09455208	chr3:40491958	NA	0.39	5.72	0.35	3.24e-8	Renal cell carcinoma;
SARC	cis	rs8114671	0.562	rs6120763	chr20:33506400	C/G	cg07148914	chr20:33460835	GGT7	0.43	5.35	0.33	2.13e-7	Height;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg12159575	chr19:4910274	UHRF1	0.47	6.35	0.38	1.09e-9	Thyroid stimulating hormone;
SARC	cis	rs2115630	0.967	rs8028490	chr15:85277888	G/A	cg12501888	chr15:85177176	SCAND2	-0.44	-5.26	-0.33	3.29e-7	P wave terminal force;
SARC	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg26119090	chr2:26468346	HADHA;HADHB	0.95	13.1	0.65	9.86e-30	Gut microbiome composition (summer);
SARC	cis	rs1048238	0.846	rs945419	chr1:16344858	C/T	cg21385522	chr1:16154831	NA	0.51	6.13	0.37	3.68e-9	Systolic blood pressure;
SARC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.61	0.53	1.27e-18	Prudent dietary pattern;
SARC	cis	rs9398803	0.830	rs4053271	chr6:126830512	T/C	cg20229609	chr6:126660872	C6orf173	0.4	5.79	0.35	2.23e-8	Male-pattern baldness;
SARC	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	7.62	0.45	6.3e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg07234876	chr8:600039	NA	-0.7	-6.17	-0.37	3.03e-9	IgG glycosylation;
SARC	cis	rs9486715	1.000	rs9486725	chr6:97061159	C/T	cg06623918	chr6:96969491	KIAA0776	-0.84	-11.58	-0.6	8.62e-25	Headache;
SARC	cis	rs9920	1.000	rs9920	chr7:116200092	C/T	cg24770985	chr7:116166421	CAV1	-0.83	-5.7	-0.35	3.58e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Immature fraction of reticulocytes;QT interval;
SARC	cis	rs9816226	0.591	rs4234589	chr3:185818882	A/G	cg00760338	chr3:185826511	ETV5	-0.87	-8.54	-0.49	1.76e-15	Obesity;Body mass index;
SARC	cis	rs6598955	0.724	rs12754536	chr1:26639605	T/C	cg04990556	chr1:26633338	UBXN11	-0.6	-8.14	-0.47	2.43e-14	Obesity-related traits;
SARC	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg12463550	chr7:65579703	CRCP	0.5	5.9	0.36	1.27e-8	Aortic root size;
SARC	cis	rs854765	0.654	rs9911281	chr17:17762457	G/C	cg05444541	chr17:17804740	TOM1L2	0.31	5.16	0.32	5.27e-7	Total body bone mineral density;
SARC	cis	rs2204008	0.545	rs1663283	chr12:38132039	G/A	cg13010199	chr12:38710504	ALG10B	-0.59	-7.53	-0.44	1.12e-12	Bladder cancer;
SARC	cis	rs826838	1.000	rs1393537	chr12:38920961	C/T	cg26384229	chr12:38710491	ALG10B	0.92	14.17	0.68	2.66e-33	Heart rate;
SARC	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	9.96	0.55	1.08e-19	Platelet count;
SARC	cis	rs3768617	0.510	rs10911239	chr1:183062450	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.65	0.57	7.74e-22	Fuchs's corneal dystrophy;
SARC	cis	rs739401	0.611	rs494427	chr11:3048140	A/G	cg20651018	chr11:3035856	CARS	-0.49	-7.78	-0.45	2.36e-13	Longevity;
SARC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg11301795	chr4:187892539	NA	-0.69	-10.25	-0.56	1.41e-20	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9831754	0.906	rs9840031	chr3:78396140	C/T	cg06138941	chr3:78371609	NA	0.59	6.86	0.41	6.3e-11	Calcium levels;
SARC	cis	rs9486719	1.000	rs2472897	chr6:96870569	G/T	cg06623918	chr6:96969491	KIAA0776	0.75	7.82	0.46	1.83e-13	Migraine;Coronary artery disease;
SARC	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg13770153	chr20:60521292	NA	-0.46	-6.44	-0.39	6.66e-10	Body mass index;
SARC	cis	rs1395	0.778	rs2078616	chr2:27441904	A/G	cg21747090	chr2:27597821	SNX17	-0.53	-6.31	-0.38	1.36e-9	Blood metabolite levels;
SARC	cis	rs11112613	0.653	rs941101	chr12:105937098	T/G	cg03607813	chr12:105948248	NA	0.56	7.11	0.42	1.44e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs1267303	0.716	rs942255	chr1:46989792	C/T	cg25110126	chr1:46999211	NA	0.74	7.86	0.46	1.4e-13	Monobrow;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg18427987	chr14:74551089	LIN52;ALDH6A1	0.5	6.9	0.41	4.78e-11	Tetralogy of Fallot;
SARC	cis	rs782590	0.967	rs6545506	chr2:55798108	A/G	cg18811423	chr2:55921094	PNPT1	-0.7	-11.01	-0.59	5.51e-23	Metabolic syndrome;
SARC	cis	rs4481887	0.927	rs28524655	chr1:248474331	C/T	cg13385794	chr1:248469461	NA	0.35	5.45	0.34	1.29e-7	Common traits (Other);
SARC	cis	rs9467711	0.559	rs12176129	chr6:26514940	C/T	cg12826209	chr6:26865740	GUSBL1	0.74	5.18	0.32	4.91e-7	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg17554472	chr22:41940697	POLR3H	-0.48	-5.4	-0.33	1.6e-7	Vitiligo;
SARC	cis	rs7927592	0.513	rs7950129	chr11:68202903	A/G	cg01657329	chr11:68192670	LRP5	-0.38	-5.18	-0.32	4.69e-7	Total body bone mineral density;
SARC	cis	rs6121246	0.529	rs6060291	chr20:30198043	T/G	cg13852791	chr20:30311386	BCL2L1	0.68	5.91	0.36	1.2e-8	Mean corpuscular hemoglobin;
SARC	cis	rs344364	0.511	rs2917515	chr16:1945271	G/C	cg26617929	chr16:1858877	NA	-0.75	-6.22	-0.38	2.32e-9	Glomerular filtration rate in chronic kidney disease;
SARC	cis	rs995000	0.931	rs4350231	chr1:62922660	C/T	cg06896770	chr1:63153194	DOCK7	1.01	15.4	0.71	2.17e-37	Triglyceride levels;
SARC	cis	rs7550918	1	rs7550918	chr1:247675559	C/T	cg18198730	chr1:247681584	NA	-0.5	-5.53	-0.34	8.71e-8	Platelet count;
SARC	cis	rs600231	0.508	rs34582634	chr11:65220206	G/A	cg17120908	chr11:65337727	SSSCA1	-0.47	-5.12	-0.32	6.35e-7	Bone mineral density;
SARC	cis	rs10911232	0.507	rs10911195	chr1:182993438	T/C	cg13390022	chr1:182993471	LAMC1	0.33	4.96	0.31	1.34e-6	Hypertriglyceridemia;
SARC	trans	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.07	-0.42	1.8e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs10463316	0.862	rs59390562	chr5:150776092	A/G	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.37	-0.33	1.86e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs136211	0.619	rs9607337	chr22:36758849	A/T	cg11153328	chr22:36877737	TXN2	-0.4	-5.0	-0.31	1.14e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9902453	0.904	rs9905638	chr17:28261022	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	6.94	0.41	3.77e-11	Coffee consumption (cups per day);
SARC	cis	rs8141529	0.529	rs34718288	chr22:29194797	C/G	cg15103426	chr22:29168792	CCDC117	0.61	5.94	0.36	1.03e-8	Lymphocyte counts;
SARC	cis	rs9790314	0.846	rs6441371	chr3:161008727	C/A	cg03342759	chr3:160939853	NMD3	-0.63	-8.03	-0.47	4.72e-14	Morning vs. evening chronotype;
SARC	cis	rs4805272	0.512	rs12373558	chr19:29337692	A/G	cg14983838	chr19:29218262	NA	0.54	5.8	0.36	2.17e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs6991838	0.670	rs13275168	chr8:66597342	T/C	cg13398993	chr8:66546079	ARMC1	0.43	5.54	0.34	8.03e-8	Intelligence (multi-trait analysis);
SARC	cis	rs57506017	0.565	rs6460895	chr7:12252540	C/G	cg23422036	chr7:12250390	TMEM106B	-0.46	-6.05	-0.37	5.78e-9	Neuroticism;
SARC	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg22535103	chr8:58192502	C8orf71	-0.73	-8.66	-0.49	8.02e-16	Developmental language disorder (linguistic errors);
SARC	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg06558623	chr16:89946397	TCF25	0.92	6.39	0.39	8.93e-10	Skin colour saturation;
SARC	cis	rs4780401	0.609	rs16958588	chr16:11819330	G/A	cg01061890	chr16:11836724	TXNDC11	-0.62	-8.85	-0.5	2.2e-16	Rheumatoid arthritis;
SARC	cis	rs2153535	0.580	rs9505450	chr6:8469902	C/T	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	cis	rs1007738	0.580	rs10501319	chr11:47174062	C/T	cg03339077	chr11:47165057	C11orf49	0.4	4.76	0.3	3.32e-6	Bone mineral density (hip);
SARC	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	27.41	0.87	7.3e-75	Chronic sinus infection;
SARC	cis	rs6685188	0.925	rs12752037	chr1:205661614	A/C	cg24503407	chr1:205819492	PM20D1	-0.45	-5.38	-0.33	1.84e-7	White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs8180040	0.903	rs11710013	chr3:47296921	T/C	cg27129171	chr3:47204927	SETD2	0.69	9.53	0.53	2.17e-18	Colorectal cancer;
SARC	cis	rs3796352	1.000	rs11718834	chr3:52963668	A/C	cg12962167	chr3:53033115	SFMBT1	0.73	4.8	0.3	2.89e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2153535	0.580	rs1414345	chr6:8471537	T/G	cg23788917	chr6:8435910	SLC35B3	0.63	8.29	0.48	9.01e-15	Motion sickness;
SARC	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg08219700	chr8:58056026	NA	0.6	6.39	0.39	9.1e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7833790	0.700	rs28390260	chr8:82769175	A/T	cg27398817	chr8:82754497	SNX16	0.43	5.37	0.33	1.9e-7	Diastolic blood pressure;
SARC	cis	rs6089584	0.507	rs6061999	chr20:60637429	G/A	cg13770153	chr20:60521292	NA	-0.35	-5.01	-0.31	1.08e-6	Body mass index;
SARC	cis	rs240764	0.604	rs9404016	chr6:101177728	G/A	cg09795085	chr6:101329169	ASCC3	0.53	6.73	0.4	1.34e-10	Neuroticism;
SARC	cis	rs362272	0.545	rs2239725	chr4:3305739	C/T	cg08741688	chr4:3415352	RGS12	-0.48	-5.96	-0.36	9.49e-9	Serum sulfate level;
SARC	cis	rs11583043	0.918	rs6577216	chr1:101409972	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.48	5.8	0.36	2.18e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg26818010	chr10:134567672	INPP5A	-0.62	-6.49	-0.39	5.08e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs7296418	0.630	rs11057238	chr12:123767971	C/A	cg05973401	chr12:123451056	ABCB9	0.49	5.61	0.35	5.66e-8	Platelet count;
SARC	cis	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg05084668	chr3:125655381	ALG1L	-0.5	-5.24	-0.32	3.58e-7	Blood pressure (smoking interaction);
SARC	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg11062466	chr8:58055876	NA	0.61	5.75	0.35	2.74e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6089584	0.566	rs6061964	chr20:60607536	G/A	cg23262073	chr20:60523788	NA	-0.34	-5.18	-0.32	4.87e-7	Body mass index;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg27537600	chr8:101170391	SPAG1	-0.46	-6.38	-0.39	9.51e-10	Chemerin levels;
SARC	cis	rs1008375	0.966	rs4698638	chr4:17632988	G/C	cg27347728	chr4:17578864	LAP3	0.47	5.88	0.36	1.42e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2153535	0.580	rs2143356	chr6:8517675	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	8.28	0.48	9.37e-15	Motion sickness;
SARC	trans	rs9354308	0.809	rs9363461	chr6:66557574	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.55	-6.57	-0.4	3.2e-10	Metabolite levels;
SARC	cis	rs593982	0.843	rs565267	chr11:65473597	T/C	cg08755490	chr11:65554678	OVOL1	0.8	7.34	0.43	3.5e-12	Atopic dermatitis;
SARC	cis	rs9902453	0.967	rs12150261	chr17:28320473	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.51	-6.66	-0.4	1.96e-10	Coffee consumption (cups per day);
SARC	cis	rs1059312	0.771	rs11059922	chr12:129290418	C/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.49	7.16	0.42	1.05e-11	Systemic lupus erythematosus;
SARC	cis	rs1008375	0.966	rs12503517	chr4:17698725	G/A	cg27347728	chr4:17578864	LAP3	0.44	5.67	0.35	4.13e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7828089	0.819	rs4872488	chr8:22257012	G/A	cg12081754	chr8:22256438	SLC39A14	0.56	7.65	0.45	5.4e-13	Verbal declarative memory;
SARC	cis	rs9326248	0.510	rs4938332	chr11:116930798	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.65	8.3	0.48	8.38e-15	Blood protein levels;
SARC	cis	rs4332037	0.664	rs73046334	chr7:1887037	T/C	cg12591125	chr7:1885375	MAD1L1	0.5	5.25	0.33	3.37e-7	Bipolar disorder;
SARC	cis	rs2439831	0.850	rs7169988	chr15:44060435	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	8.6	0.49	1.21e-15	Lung cancer in ever smokers;
SARC	cis	rs6582630	0.555	rs8189479	chr12:38308240	C/T	cg14851346	chr12:38532713	NA	-0.45	-5.3	-0.33	2.66e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs116095464	1.000	rs6555160	chr5:311669	A/G	cg22496380	chr5:211416	CCDC127	0.77	6.25	0.38	1.97e-9	Breast cancer;
SARC	cis	rs6815464	1	rs6815464	chr4:1309901	C/G	cg07110949	chr4:1309878	MAEA	-0.76	-5.31	-0.33	2.58e-7	Type 2 diabetes;
SARC	cis	rs5762534	0.556	rs5762456	chr22:28427336	G/T	cg02153584	chr22:29168773	CCDC117	-0.61	-5.33	-0.33	2.28e-7	Menopause (age at onset);
SARC	cis	rs9788682	0.948	rs59133824	chr15:78833450	C/A	cg24631222	chr15:78858424	CHRNA5	0.75	9.63	0.53	1.04e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs4803468	1.000	rs284655	chr19:41928765	C/T	cg08477640	chr19:41863820	B9D2	0.44	5.53	0.34	8.62e-8	Height;
SARC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg02475777	chr4:1388615	CRIPAK	0.62	7.07	0.42	1.81e-11	Longevity;
SARC	cis	rs5167	0.525	rs11083752	chr19:45454363	G/A	cg10169327	chr19:45448959	APOC2	0.31	5.11	0.32	6.85e-7	Blood protein levels;
SARC	cis	rs2425143	1.000	rs73902908	chr20:34365112	G/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.68	5.36	0.33	2.04e-7	Blood protein levels;
SARC	cis	rs9807989	0.507	rs4851004	chr2:103009537	A/G	cg03938978	chr2:103052716	IL18RAP	-0.32	-5.2	-0.32	4.37e-7	Asthma;
SARC	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg25894440	chr7:65020034	NA	-0.73	-5.48	-0.34	1.09e-7	Diabetic kidney disease;
SARC	cis	rs12022452	0.591	rs4660415	chr1:40978491	C/A	cg25568243	chr1:40974465	DEM1	0.52	4.78	0.3	3.07e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs4423214	0.592	rs11233933	chr11:71210070	C/T	cg05163923	chr11:71159392	DHCR7	-0.49	-4.71	-0.3	4.18e-6	Vitamin D levels;
SARC	cis	rs9486715	0.867	rs4240553	chr6:96965324	T/C	cg18709589	chr6:96969512	KIAA0776	0.61	7.54	0.44	1.04e-12	Headache;
SARC	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg13866156	chr1:1669148	SLC35E2	-0.63	-9.43	-0.53	4.25e-18	Body mass index;
SARC	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.31	-4.74	-0.3	3.69e-6	Total body bone mineral density;
SARC	cis	rs8060686	0.545	rs12444188	chr16:68282077	G/A	cg27539214	chr16:67997921	SLC12A4	-0.59	-5.72	-0.35	3.25e-8	HDL cholesterol;Metabolic syndrome;
SARC	cis	rs10911232	0.507	rs10911234	chr1:183053001	A/C	cg13390022	chr1:182993471	LAMC1	0.33	5.06	0.31	8.41e-7	Hypertriglyceridemia;
SARC	cis	rs2043112	0.691	rs7729177	chr5:39090630	G/A	cg04869206	chr5:39074266	RICTOR	0.52	6.37	0.39	9.99e-10	Obesity-related traits;
SARC	cis	rs2120019	0.517	rs872263	chr15:75136444	C/T	cg09165964	chr15:75287851	SCAMP5	-0.92	-9.27	-0.52	1.28e-17	Blood trace element (Zn levels);
SARC	cis	rs911555	0.673	rs7144271	chr14:103890674	A/G	cg24130564	chr14:104152367	KLC1	-0.5	-5.8	-0.36	2.12e-8	Intelligence (multi-trait analysis);
SARC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg14159672	chr1:205819179	PM20D1	0.58	7.89	0.46	1.19e-13	Menarche (age at onset);
SARC	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg25894440	chr7:65020034	NA	-0.77	-5.85	-0.36	1.67e-8	Diabetic kidney disease;
SARC	cis	rs3126085	0.935	rs11204947	chr1:152218257	G/T	cg09127314	chr1:152161683	NA	-0.42	-4.79	-0.3	2.98e-6	Atopic dermatitis;
SARC	cis	rs10875746	0.904	rs10875750	chr12:48545630	C/T	cg27446233	chr12:48516484	PFKM	-0.46	-5.24	-0.32	3.59e-7	Longevity (90 years and older);
SARC	cis	rs644799	1.000	rs514170	chr11:95556696	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	14.89	0.7	1.07e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs1348850	0.634	rs2293471	chr2:178487729	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.48	4.85	0.3	2.24e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1355223	0.902	rs35032224	chr11:34698154	T/C	cg18508148	chr11:34937573	PDHX;APIP	-0.4	-5.11	-0.32	6.72e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg05084668	chr3:125655381	ALG1L	-0.5	-5.28	-0.33	2.92e-7	Blood pressure (smoking interaction);
SARC	cis	rs4253772	0.591	rs7286155	chr22:46714735	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.61	4.79	0.3	3e-6	LDL cholesterol;Cholesterol, total;
SARC	cis	rs6500602	0.727	rs55939215	chr16:4541390	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.34	5.66	0.35	4.43e-8	Schizophrenia;
SARC	cis	rs2280018	0.526	rs2941257	chr16:15166445	T/C	cg27102117	chr16:15229624	NA	0.57	7.05	0.42	2.04e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs4516970	0.826	rs59246098	chr6:160149462	C/CA	cg06131755	chr6:160182447	ACAT2	0.48	4.92	0.31	1.62e-6	Iron status biomarkers;
SARC	cis	rs559928	0.606	rs56207008	chr11:63883215	C/T	cg05555928	chr11:63887634	MACROD1	-0.51	-4.85	-0.3	2.26e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs911263	1.000	rs911263	chr14:68753593	C/T	cg18825221	chr14:68749962	RAD51L1	0.51	9.05	0.51	5.72e-17	Primary biliary cholangitis;
SARC	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg11764359	chr7:65958608	NA	0.88	12.58	0.64	4.89e-28	Aortic root size;
SARC	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg00149659	chr3:10157352	C3orf10	0.68	6.38	0.39	9.46e-10	Alzheimer's disease;
SARC	cis	rs6910061	0.830	rs9468404	chr6:11092858	C/A	cg27233058	chr6:11094804	LOC221710	0.6	5.51	0.34	9.49e-8	Diabetic kidney disease;
SARC	cis	rs7940866	0.874	rs10791113	chr11:130873165	A/G	cg12179176	chr11:130786555	SNX19	0.65	8.97	0.51	1e-16	Schizophrenia;
SARC	cis	rs72945132	0.678	rs35733235	chr11:70235595	C/T	cg05964544	chr11:70165517	PPFIA1	-0.66	-6.64	-0.4	2.14e-10	Coronary artery disease;
SARC	cis	rs3540	0.513	rs2601154	chr15:90894284	T/C	cg22089800	chr15:90895588	ZNF774	0.76	10.25	0.56	1.39e-20	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs11785400	1.000	rs6995314	chr8:143749718	A/G	cg10596483	chr8:143751796	JRK	-0.63	-8.53	-0.49	1.87e-15	Schizophrenia;
SARC	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg26335602	chr6:28129616	ZNF389	0.51	5.56	0.34	7.41e-8	Parkinson's disease;
SARC	cis	rs34792	0.528	rs153804	chr16:15553054	A/G	cg07549590	chr16:15018862	NA	-0.32	-4.89	-0.31	1.84e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	trans	rs61931739	0.534	rs1490109	chr12:34064077	T/C	cg13010199	chr12:38710504	ALG10B	0.67	8.92	0.5	1.36e-16	Morning vs. evening chronotype;
SARC	cis	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg22496380	chr5:211416	CCDC127	-0.88	-9.35	-0.52	7.72e-18	Breast cancer;
SARC	cis	rs11249608	0.511	rs58827878	chr5:178481936	C/G	cg21905437	chr5:178450457	ZNF879	0.52	6.2	0.38	2.55e-9	Pubertal anthropometrics;
SARC	cis	rs1008375	0.966	rs2010053	chr4:17583806	A/C	cg02297831	chr4:17616191	MED28	0.49	6.22	0.38	2.31e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs55794721	0.509	rs2982358	chr1:25745204	G/T	cg23205692	chr1:25664452	TMEM50A	0.41	4.85	0.3	2.26e-6	Plateletcrit;Mean corpuscular volume;
SARC	cis	rs2985684	0.948	rs12886130	chr14:50082753	T/C	cg04989706	chr14:50066350	PPIL5	-0.57	-6.11	-0.37	4.13e-9	Carotid intima media thickness;
SARC	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg08219700	chr8:58056026	NA	0.6	5.71	0.35	3.49e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs11809207	0.501	rs3762460	chr1:26495550	A/G	cg23602478	chr1:26503979	CNKSR1	0.29	5.12	0.32	6.52e-7	Height;
SARC	cis	rs7520050	0.966	rs6662641	chr1:46571509	T/A	cg24296786	chr1:45957014	TESK2	0.38	4.83	0.3	2.44e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs11166927	0.548	rs28366721	chr8:140827797	C/G	cg16909799	chr8:140841666	TRAPPC9	-0.39	-5.19	-0.32	4.67e-7	Pediatric non-alcoholic fatty liver disease activity score;
SARC	cis	rs644799	1.000	rs680134	chr11:95559517	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	14.89	0.7	1.07e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2730245	0.528	rs1188954	chr7:158691417	G/A	cg14689365	chr7:158441557	NCAPG2	0.4	4.76	0.3	3.42e-6	Height;
SARC	cis	rs920590	0.758	rs35280191	chr8:19665214	A/C	cg17834443	chr8:19674713	INTS10	0.62	7.61	0.45	6.8e-13	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg22903657	chr4:1355424	KIAA1530	-0.43	-6.0	-0.37	7.39e-9	Obesity-related traits;
SARC	cis	rs7264396	0.635	rs2064724	chr20:34522520	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-7.5	-0.44	1.37e-12	Total cholesterol levels;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg13677424	chr5:41925854	FBXO4	0.51	6.43	0.39	6.99e-10	Breast cancer;
SARC	cis	rs35213789	1.000	rs17458097	chr7:69292900	A/G	cg10619644	chr7:69149951	AUTS2	-0.42	-5.29	-0.33	2.82e-7	Childhood ear infection;
SARC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg09373136	chr17:61933544	TCAM1	-0.45	-6.19	-0.38	2.75e-9	Prudent dietary pattern;
SARC	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg00684032	chr4:1343700	KIAA1530	0.38	5.4	0.33	1.63e-7	Obesity-related traits;
SARC	cis	rs2075371	1.000	rs2544218	chr7:133992315	C/A	cg00033643	chr7:134001901	SLC35B4	0.4	4.85	0.3	2.25e-6	Mean platelet volume;
SARC	cis	rs765787	0.530	rs2554457	chr15:45520926	G/A	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.55e-10	Uric acid levels;
SARC	cis	rs3126085	0.935	rs7531094	chr1:152176850	A/G	cg26876637	chr1:152193138	HRNR	0.47	5.27	0.33	3.13e-7	Atopic dermatitis;
SARC	cis	rs12142240	0.730	rs56030283	chr1:46823093	C/G	cg00530320	chr1:46809349	NSUN4	0.57	6.79	0.41	9.05e-11	Menopause (age at onset);
SARC	trans	rs637571	0.522	rs550435	chr11:65732651	G/A	cg17712092	chr4:129076599	LARP1B	0.69	9.36	0.52	6.94e-18	Eosinophil percentage of white cells;
SARC	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg22800045	chr5:56110881	MAP3K1	0.74	7.83	0.46	1.74e-13	Initial pursuit acceleration;
SARC	cis	rs2529049	0.606	rs2721781	chr7:24725834	A/C	cg17569154	chr7:24781545	DFNA5	0.46	6.52	0.39	4.37e-10	Urate levels in obese individuals;
SARC	cis	rs72781680	0.768	rs112139157	chr2:24150783	A/C	cg08917208	chr2:24149416	ATAD2B	0.58	5.89	0.36	1.34e-8	Lymphocyte counts;
SARC	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg03264133	chr6:25882463	NA	0.5	6.59	0.4	2.98e-10	Blood metabolite levels;
SARC	cis	rs2916247	1.000	rs734113	chr8:93060095	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.58	-5.95	-0.36	1e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2120019	1.000	rs7173833	chr15:75369618	C/T	cg09165964	chr15:75287851	SCAMP5	-0.83	-12.1	-0.62	1.75e-26	Blood trace element (Zn levels);
SARC	cis	rs4851254	0.660	rs13430705	chr2:100690616	G/A	cg17356467	chr2:100759845	AFF3	0.32	4.81	0.3	2.74e-6	Intelligence (multi-trait analysis);
SARC	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg03351412	chr1:154909251	PMVK	0.63	8.34	0.48	6.44e-15	Prostate cancer;
SARC	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6733011	0.519	rs6739097	chr2:99458601	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.43	-5.27	-0.33	3.05e-7	Bipolar disorder;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg25025968	chr11:4116056	RRM1	-0.57	-6.46	-0.39	6.19e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg22974920	chr21:40686053	BRWD1	-0.42	-4.74	-0.3	3.75e-6	Cognitive function;
SARC	cis	rs796364	0.806	rs34582889	chr2:201010527	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.53	-4.87	-0.3	2.08e-6	Schizophrenia;
SARC	cis	rs35849525	0.814	rs35491931	chr3:49993462	T/A	cg24110177	chr3:50126178	RBM5	-0.51	-5.62	-0.35	5.4e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7589342	0.929	rs6719896	chr2:106428404	C/G	cg14210321	chr2:106509881	NCK2	0.45	5.29	0.33	2.78e-7	Addiction;
SARC	cis	rs4906332	1.000	rs35366629	chr14:103903054	A/G	cg26031613	chr14:104095156	KLC1	-0.49	-5.69	-0.35	3.75e-8	Coronary artery disease;
SARC	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg17971929	chr21:40555470	PSMG1	0.99	13.73	0.67	7.64e-32	Cognitive function;
SARC	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg04166393	chr7:2884313	GNA12	0.59	6.94	0.41	3.92e-11	Height;
SARC	cis	rs34779708	0.966	rs4934732	chr10:35431684	T/C	cg03585969	chr10:35415529	CREM	0.39	4.93	0.31	1.56e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg04234412	chr22:24373322	LOC391322	-0.53	-6.15	-0.37	3.33e-9	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9914988	0.943	rs59461345	chr17:27151852	G/T	cg20469991	chr17:27169893	C17orf63	-0.52	-5.4	-0.33	1.64e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg05332525	chr7:65337924	VKORC1L1	0.43	4.82	0.3	2.57e-6	Aortic root size;
SARC	cis	rs62408225	0.748	rs7744528	chr6:90916931	C/G	cg06866423	chr6:90926672	BACH2	0.32	5.2	0.32	4.28e-7	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs5758659	0.504	rs133367	chr22:42463366	A/G	cg04733989	chr22:42467013	NAGA	-0.56	-7.28	-0.43	5.12e-12	Cognitive function;
SARC	cis	rs950169	0.922	rs4842941	chr15:84831312	G/C	cg17507749	chr15:85114479	UBE2QP1	-0.78	-9.19	-0.52	2.28e-17	Schizophrenia;
SARC	cis	rs644799	0.544	rs1622515	chr11:95523433	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	6.08	0.37	4.99e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs9858542	0.953	rs11713474	chr3:49611457	A/G	cg21659725	chr3:3221576	CRBN	-0.54	-6.28	-0.38	1.66e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs11039798	0.588	rs12294395	chr11:48476860	C/T	cg15704280	chr7:45808275	SEPT13	0.64	6.49	0.39	5e-10	Axial length;
SARC	cis	rs6964587	1.000	rs2299232	chr7:91626699	A/C	cg17063962	chr7:91808500	NA	0.92	14.64	0.69	7.31e-35	Breast cancer;
SARC	cis	rs10958369	0.613	rs10095702	chr8:54436111	C/T	cg12485204	chr8:54507357	NA	0.47	6.6	0.4	2.81e-10	Response to antineoplastic agents;
SARC	cis	rs765787	0.530	rs2413786	chr15:45525394	C/A	cg25801113	chr15:45476975	SHF	0.29	4.87	0.3	2.02e-6	Uric acid levels;
SARC	cis	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg01181863	chr3:195395398	SDHAP2	0.66	8.34	0.48	6.38e-15	Bronchopulmonary dysplasia;
SARC	cis	rs11190604	1.000	rs3750629	chr10:102275727	A/G	cg14256752	chr10:102295592	HIF1AN	0.45	5.28	0.33	3.01e-7	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs2153535	0.601	rs6906170	chr6:8543128	T/A	cg07606381	chr6:8435919	SLC35B3	0.78	11.14	0.59	2.2e-23	Motion sickness;
SARC	cis	rs561341	0.609	rs4795659	chr17:30187139	C/G	cg13647721	chr17:30228624	UTP6	-0.73	-7.08	-0.42	1.73e-11	Hip circumference adjusted for BMI;
SARC	cis	rs7700895	0.737	rs3777208	chr5:95228836	A/G	cg16656078	chr5:95278638	ELL2	-0.54	-6.62	-0.4	2.42e-10	IgG glycosylation;
SARC	cis	rs2292864	0.764	rs35265764	chr17:45363546	G/T	cg18085866	chr17:45331354	ITGB3	-0.71	-5.65	-0.35	4.54e-8	Left atrial antero-posterior diameter;
SARC	cis	rs7584330	0.826	rs72620824	chr2:238381083	G/A	cg11271282	chr2:238384023	NA	0.52	5.16	0.32	5.28e-7	Prostate cancer;
SARC	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg00800038	chr16:89945340	TCF25	-0.72	-5.75	-0.35	2.8e-8	Skin colour saturation;
SARC	cis	rs4253772	0.550	rs12165597	chr22:46705584	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.61	5.02	0.31	1.05e-6	LDL cholesterol;Cholesterol, total;
SARC	cis	rs2075371	0.933	rs1421480	chr7:133958114	A/C	cg11752832	chr7:134001865	SLC35B4	0.54	6.89	0.41	5.12e-11	Mean platelet volume;
SARC	cis	rs7408868	1.000	rs1548554	chr19:15277938	C/T	cg14696996	chr19:15285081	NOTCH3	1.01	8.93	0.5	1.32e-16	Pulse pressure;
SARC	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.9	14.24	0.68	1.63e-33	Chronic sinus infection;
SARC	cis	rs35213789	0.878	rs6943610	chr7:69569109	A/G	cg10619644	chr7:69149951	AUTS2	0.43	5.05	0.31	9.08e-7	Childhood ear infection;
SARC	cis	rs3126085	0.544	rs3126074	chr1:152279841	G/C	cg26876637	chr1:152193138	HRNR	-0.48	-5.32	-0.33	2.49e-7	Atopic dermatitis;
SARC	cis	rs11785400	0.793	rs4567014	chr8:143737690	G/C	cg24634471	chr8:143751801	JRK	0.59	7.45	0.44	1.83e-12	Schizophrenia;
SARC	cis	rs668210	0.793	rs619701	chr11:65772080	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.5	-4.71	-0.3	4.18e-6	Cerebrospinal fluid biomarker levels;
SARC	cis	rs1707322	1.000	rs4660335	chr1:46474718	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.33	0.38	1.23e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs12310956	0.532	rs1589902	chr12:33989289	G/A	cg26384229	chr12:38710491	ALG10B	0.75	10.56	0.57	1.45e-21	Morning vs. evening chronotype;
SARC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.8	10.35	0.56	6.69e-21	Prudent dietary pattern;
SARC	cis	rs7681440	0.746	rs1442134	chr4:90819154	A/G	cg02192967	chr4:90758406	SNCA	0.39	5.33	0.33	2.27e-7	Dementia with Lewy bodies;
SARC	cis	rs9457247	0.602	rs10484530	chr6:167461562	C/T	cg07741184	chr6:167504864	NA	0.37	7.07	0.42	1.76e-11	Crohn's disease;
SARC	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg04166393	chr7:2884313	GNA12	0.55	6.43	0.39	7.2e-10	Height;
SARC	cis	rs6088590	0.930	rs6120723	chr20:33364655	C/T	cg06115741	chr20:33292138	TP53INP2	0.57	6.82	0.41	7.74e-11	Coronary artery disease;
SARC	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	cis	rs11608355	0.618	rs7958220	chr12:109830980	T/C	cg19025524	chr12:109796872	NA	-0.46	-6.95	-0.41	3.57e-11	Neuroticism;
SARC	cis	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg22857025	chr5:266934	NA	-1.06	-11.8	-0.61	1.74e-25	Breast cancer;
SARC	cis	rs7089973	0.604	rs1359079	chr10:116582502	A/G	cg08188268	chr10:116634841	FAM160B1	0.28	4.76	0.3	3.41e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs2276314	0.748	rs4799839	chr18:33597531	T/C	cg19628046	chr18:33552617	C18orf21	0.61	6.29	0.38	1.54e-9	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs4128725	1.000	rs9633340	chr1:159394080	T/C	cg25076881	chr1:159409836	OR10J1	0.4	4.78	0.3	3.16e-6	Select biomarker traits;
SARC	cis	rs16986825	0.570	rs5752822	chr22:29266025	A/G	cg02153584	chr22:29168773	CCDC117	0.67	7.8	0.46	2.01e-13	Pancreatic cancer;
SARC	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg11987759	chr7:65425863	GUSB	0.5	6.17	0.37	2.96e-9	Aortic root size;
SARC	cis	rs7644634	0.688	rs1867189	chr3:105447746	G/A	cg23051926	chr3:105466016	CBLB	0.44	5.52	0.34	9.1e-8	Itch intensity from mosquito bite;
SARC	trans	rs11098499	0.863	rs13134665	chr4:120426430	T/C	cg25214090	chr10:38739885	LOC399744	0.58	7.28	0.43	4.95e-12	Corneal astigmatism;
SARC	cis	rs7762018	0.607	rs75010113	chr6:170057441	C/T	cg19338460	chr6:170058176	WDR27	-0.83	-6.06	-0.37	5.32e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs2153535	0.580	rs7767756	chr6:8453428	A/C	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.49	1.52e-15	Motion sickness;
SARC	cis	rs7159888	0.577	rs1256540	chr14:65764069	A/G	cg15999311	chr14:65749247	NA	0.33	5.23	0.32	3.72e-7	IgG glycosylation;N-glycan levels;
SARC	trans	rs9929218	0.954	rs9928796	chr16:68820718	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.52	-6.5	-0.39	4.94e-10	Colorectal cancer;
SARC	cis	rs10463316	0.779	rs6871318	chr5:150801545	G/A	cg03212797	chr5:150827313	SLC36A1	-0.44	-5.32	-0.33	2.46e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs1784581	0.894	rs1784594	chr6:162382734	A/G	cg17173639	chr6:162384350	PARK2	-0.77	-10.8	-0.58	2.56e-22	Itch intensity from mosquito bite;
SARC	cis	rs10140922	0.966	rs10083387	chr14:35823669	G/A	cg26967526	chr14:35346199	BAZ1A	-0.4	-5.01	-0.31	1.09e-6	Hip circumference adjusted for BMI;
SARC	cis	rs7084402	0.935	rs1427195	chr10:60278967	T/C	cg07615347	chr10:60278583	BICC1	-0.6	-8.83	-0.5	2.51e-16	Refractive error;
SARC	trans	rs7937682	0.883	rs1784776	chr11:111472392	C/T	cg18187862	chr3:45730750	SACM1L	0.51	6.31	0.38	1.37e-9	Primary sclerosing cholangitis;
SARC	cis	rs861020	0.630	rs628445	chr1:210004953	C/T	cg23166289	chr1:210001082	C1orf107	0.39	4.74	0.3	3.66e-6	Orofacial clefts;
SARC	cis	rs11997175	0.624	rs6996590	chr8:33680486	A/G	ch.8.33884649F	chr8:33765107	NA	0.61	8.23	0.47	1.33e-14	Body mass index;
SARC	cis	rs9788721	1.000	rs8034191	chr15:78806023	A/G	cg18825076	chr15:78729989	IREB2	-0.42	-4.96	-0.31	1.35e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg03354898	chr7:1950403	MAD1L1	-0.38	-5.09	-0.32	7.46e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs17270561	0.553	rs6456696	chr6:25741408	A/G	cg17691542	chr6:26056736	HIST1H1C	0.61	7.36	0.43	3.06e-12	Iron status biomarkers;
SARC	cis	rs7412746	0.611	rs10888398	chr1:150886782	A/G	cg10589385	chr1:150898437	SETDB1	-0.4	-5.34	-0.33	2.22e-7	Melanoma;
SARC	cis	rs7870753	0.838	rs10820682	chr9:99241587	T/G	cg25260653	chr9:99212216	HABP4	0.51	4.77	0.3	3.21e-6	Height;
SARC	cis	rs11671005	0.736	rs11668201	chr19:59003632	A/T	cg21037935	chr19:58911965	NA	0.35	4.73	0.3	3.94e-6	Mean platelet volume;
SARC	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg01276201	chr10:134613136	NA	0.31	4.99	0.31	1.19e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs1348850	0.914	rs4893961	chr2:178411075	A/G	cg23306229	chr2:178417860	TTC30B	0.56	6.55	0.39	3.64e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs617791	0.508	rs2276132	chr11:65770545	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.6	7.47	0.44	1.57e-12	Breast cancer;
SARC	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg08219700	chr8:58056026	NA	0.71	6.75	0.4	1.16e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6570726	0.935	rs388394	chr6:145852689	C/T	cg05220968	chr6:146057943	EPM2A	-0.28	-4.88	-0.3	2.01e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6752107	1.000	rs35300242	chr2:234168790	G/A	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.48	6.38	0.39	9.36e-10	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.46	-5.73	-0.35	3.07e-8	Gut microbiome composition (summer);
SARC	cis	rs6580649	0.941	rs7312326	chr12:48480643	G/A	cg24011408	chr12:48396354	COL2A1	-0.48	-5.36	-0.33	2.04e-7	Lung cancer;
SARC	cis	rs10463316	0.894	rs7723016	chr5:150764828	T/C	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.28	-0.33	2.89e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs3008870	0.709	rs62883160	chr1:67392889	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.62	7.9	0.46	1.11e-13	Lymphocyte percentage of white cells;
SARC	trans	rs61931739	0.500	rs34167298	chr12:34534338	G/A	cg13010199	chr12:38710504	ALG10B	0.83	11.73	0.61	2.89e-25	Morning vs. evening chronotype;
SARC	cis	rs4535497	0.525	rs4975639	chr5:1108250	A/G	cg01551729	chr5:1099476	SLC12A7	0.34	5.08	0.32	7.81e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs7937682	0.575	rs7950926	chr11:111776437	G/C	cg22437258	chr11:111473054	SIK2	-0.52	-6.03	-0.37	6.3e-9	Primary sclerosing cholangitis;
SARC	cis	rs7786877	0.521	rs4729606	chr7:100321790	T/C	cg16850897	chr7:100343110	ZAN	-0.63	-6.84	-0.41	7.03e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs883565	0.569	rs2949565	chr3:39163425	G/A	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.43	-5.0	-0.31	1.14e-6	Handedness;
SARC	cis	rs673253	0.686	rs2842185	chr1:44019731	C/T	cg10881128	chr1:44031826	PTPRF	-0.39	-5.04	-0.31	9.47e-7	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg22535103	chr8:58192502	C8orf71	-0.74	-8.66	-0.49	8.13e-16	Developmental language disorder (linguistic errors);
SARC	cis	rs10089	1.000	rs10060390	chr5:127452947	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	10.32	0.56	8.06e-21	Ileal carcinoids;
SARC	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg22974920	chr21:40686053	BRWD1	0.45	4.86	0.3	2.13e-6	Cognitive function;
SARC	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg13206674	chr6:150067644	NUP43	0.42	5.41	0.33	1.59e-7	Lung cancer;
SARC	cis	rs7786808	0.536	rs4909210	chr7:158194376	T/C	cg01191920	chr7:158217561	PTPRN2	-0.33	-5.63	-0.35	5.04e-8	Obesity-related traits;
SARC	cis	rs6088580	0.634	rs4911420	chr20:32998654	A/G	cg08999081	chr20:33150536	PIGU	-0.41	-6.25	-0.38	1.94e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs920590	0.758	rs1907799	chr8:19664668	A/G	cg01411142	chr8:19674711	INTS10	-0.49	-5.82	-0.36	1.94e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs4268898	0.636	rs72787371	chr2:24570073	T/A	cg06627628	chr2:24431161	ITSN2	-0.81	-9.92	-0.54	1.4e-19	Asthma;
SARC	cis	rs2011503	1.000	rs61744761	chr19:19656615	C/T	cg15839431	chr19:19639596	YJEFN3	-0.49	-4.92	-0.31	1.63e-6	Bipolar disorder;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg07797221	chr5:175815620	HIGD2A;NOP16	0.52	6.58	0.4	3.12e-10	Gallstone disease;
SARC	cis	rs9715521	0.803	rs62301188	chr4:59840423	A/G	cg11281224	chr4:60001000	NA	-0.42	-5.23	-0.32	3.75e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs3733585	0.699	rs7657340	chr4:9966772	A/T	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.65	-0.35	4.69e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg11890956	chr21:40555474	PSMG1	1.19	20.22	0.8	3.51e-53	Cognitive function;
SARC	cis	rs10911251	0.528	rs6669199	chr1:183082421	C/A	cg13390022	chr1:182993471	LAMC1	0.32	4.88	0.3	1.95e-6	Colorectal cancer;
SARC	cis	rs7617773	0.817	rs11130162	chr3:48297611	A/G	cg11946769	chr3:48343235	NME6	0.65	8.71	0.5	5.88e-16	Coronary artery disease;
SARC	cis	rs11098499	0.691	rs28396837	chr4:120271541	G/A	cg24375607	chr4:120327624	NA	0.37	4.73	0.3	3.87e-6	Corneal astigmatism;
SARC	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg08280861	chr8:58055591	NA	0.58	5.66	0.35	4.45e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.73	9.93	0.55	1.35e-19	Personality dimensions;
SARC	cis	rs6912958	1.000	rs6454630	chr6:88171357	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.31	5.4	0.33	1.64e-7	Monocyte percentage of white cells;
SARC	cis	rs4481887	0.927	rs4460676	chr1:248431781	G/A	cg00666640	chr1:248458726	OR2T12	0.36	5.75	0.35	2.76e-8	Common traits (Other);
SARC	cis	rs56235845	0.665	rs4976685	chr5:176766177	C/T	cg16006841	chr5:176797999	RGS14	-0.51	-7.08	-0.42	1.65e-11	Hemoglobin concentration;Hematocrit;
SARC	cis	rs1348850	0.574	rs11691740	chr2:178445161	A/G	cg23306229	chr2:178417860	TTC30B	-0.64	-6.87	-0.41	5.69e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7223966	1.000	rs8078462	chr17:61857937	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	7.57	0.44	8.53e-13	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg11693508	chr17:37793320	STARD3	0.76	7.04	0.42	2.12e-11	Bipolar disorder;
SARC	cis	rs73206853	0.534	rs7131996	chr12:111073276	C/A	cg08946844	chr12:110511112	NA	0.52	4.88	0.3	1.93e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs7772486	0.754	rs4895682	chr6:146062861	G/A	cg05347473	chr6:146136440	FBXO30	-0.55	-7.64	-0.45	5.68e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs920590	0.643	rs2083640	chr8:19660212	T/C	cg03894339	chr8:19674705	INTS10	0.43	5.13	0.32	6.15e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs10927875	0.965	rs3961710	chr1:16313172	C/T	cg21385522	chr1:16154831	NA	-0.79	-10.07	-0.55	4.76e-20	Dilated cardiomyopathy;
SARC	cis	rs4887059	1	rs4887059	chr15:78782095	C/T	cg24631222	chr15:78858424	CHRNA5	-0.46	-5.94	-0.36	1.05e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
SARC	trans	rs62103177	0.810	rs62096746	chr18:77619556	T/A	cg05926928	chr17:57297772	GDPD1	1.08	9.29	0.52	1.12e-17	Opioid sensitivity;
SARC	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg19223190	chr17:80058835	NA	0.44	6.09	0.37	4.51e-9	Life satisfaction;
SARC	cis	rs6582630	0.519	rs11182457	chr12:38538331	G/A	cg13010199	chr12:38710504	ALG10B	0.79	10.96	0.58	8.1e-23	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs10870270	1.000	rs72636963	chr10:133771271	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.85	-10.44	-0.56	3.63e-21	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg13939156	chr17:80058883	NA	0.42	6.42	0.39	7.54e-10	Life satisfaction;
SARC	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.89	12.06	0.62	2.48e-26	Multiple sclerosis;
SARC	cis	rs739401	0.611	rs417957	chr11:3046231	A/G	cg25174290	chr11:3078921	CARS	0.57	8.19	0.47	1.73e-14	Longevity;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg21607141	chr4:119722917	SEC24D	0.44	6.5	0.39	4.7e-10	Thyroid stimulating hormone;
SARC	cis	rs2228479	0.850	rs79244293	chr16:89896220	T/C	cg12064134	chr16:90016061	DEF8	-0.56	-4.9	-0.31	1.77e-6	Skin colour saturation;
SARC	cis	rs9581943	0.901	rs9579127	chr13:28477268	A/G	cg16302790	chr13:28498334	PDX1	0.54	8.16	0.47	2.13e-14	Pancreatic cancer;
SARC	cis	rs8114671	0.551	rs4911162	chr20:33411425	G/C	cg24642439	chr20:33292090	TP53INP2	0.54	6.65	0.4	2.1e-10	Height;
SARC	cis	rs6904897	0.563	rs4896117	chr6:135229400	T/C	cg24558204	chr6:135376177	HBS1L	-0.38	-4.8	-0.3	2.88e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs950169	0.580	rs11634322	chr15:85172209	C/T	cg17507749	chr15:85114479	UBE2QP1	0.58	6.77	0.41	1.03e-10	Schizophrenia;
SARC	cis	rs2011503	1.000	rs4808970	chr19:19651140	A/G	cg03709012	chr19:19516395	GATAD2A	0.6	5.29	0.33	2.8e-7	Bipolar disorder;
SARC	cis	rs57083693	0.518	rs12317211	chr12:101704521	C/T	cg22051763	chr12:101673672	UTP20	-0.45	-5.45	-0.34	1.25e-7	Alcohol dependence (age at onset);
SARC	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg02725872	chr8:58115012	NA	-0.37	-6.52	-0.39	4.28e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.76	8.89	0.5	1.7e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9790314	1.000	rs163328	chr3:161073599	A/G	cg04691961	chr3:161091175	C3orf57	-0.81	-12.41	-0.63	1.74e-27	Morning vs. evening chronotype;
SARC	cis	rs10911232	0.507	rs10911222	chr1:183047363	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.08	0.55	4.44e-20	Hypertriglyceridemia;
SARC	cis	rs6693567	0.565	rs4926395	chr1:150405298	T/C	cg09579323	chr1:150459698	TARS2	0.44	5.69	0.35	3.76e-8	Migraine;
SARC	trans	rs9650657	0.504	rs7813802	chr8:11033976	C/T	cg06636001	chr8:8085503	FLJ10661	0.64	8.41	0.48	4.12e-15	Neuroticism;
SARC	cis	rs9747201	1.000	rs55638685	chr17:80107566	G/C	cg17462356	chr17:80056334	FASN	0.46	5.28	0.33	2.96e-7	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs11871801	0.517	rs646123	chr17:40720632	G/A	cg14558262	chr17:40713999	COASY	0.53	5.86	0.36	1.55e-8	Crohn's disease;
SARC	cis	rs7312774	0.881	rs12320167	chr12:107310167	G/A	cg16260113	chr12:107380972	MTERFD3	0.71	6.16	0.37	3.2e-9	Severe influenza A (H1N1) infection;
SARC	cis	rs7555523	0.887	rs4657471	chr1:165686873	T/C	cg24409356	chr1:165738333	TMCO1	0.85	6.76	0.41	1.07e-10	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	cis	rs644799	0.965	rs607039	chr11:95547086	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	14.15	0.68	3.08e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs10463316	0.894	rs7703283	chr5:150764904	C/T	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.28	-0.33	2.89e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs897080	0.552	rs1085443	chr2:44635015	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.7	0.4	1.59e-10	Height;
SARC	cis	rs1030877	0.960	rs3792049	chr2:105901908	A/C	cg02079111	chr2:105885981	TGFBRAP1	-0.57	-8.33	-0.48	7.08e-15	Obesity-related traits;
SARC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg14159672	chr1:205819179	PM20D1	0.87	14.63	0.69	7.89e-35	Menarche (age at onset);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg07755493	chr2:37787889	NA	0.46	7.05	0.42	1.98e-11	Thyroid stimulating hormone;
SARC	cis	rs2731664	0.740	rs2731670	chr5:176848019	G/T	cg23176889	chr5:176863531	GRK6	0.45	6.54	0.39	3.9e-10	Intelligence (multi-trait analysis);
SARC	cis	rs10791323	0.569	rs1119852	chr11:133743022	C/A	cg15485101	chr11:133734466	NA	0.32	5.14	0.32	5.92e-7	Childhood ear infection;
SARC	cis	rs7647973	0.961	rs10154992	chr3:49276077	C/T	cg07636037	chr3:49044803	WDR6	0.78	9.05	0.51	6e-17	Menarche (age at onset);
SARC	cis	rs6831352	0.838	rs2851250	chr4:100044113	G/C	cg13256891	chr4:100009986	ADH5	0.67	8.36	0.48	5.85e-15	Alcohol dependence;
SARC	cis	rs5753618	0.561	rs737684	chr22:31659827	C/G	cg13145458	chr22:31556086	RNF185	0.47	5.05	0.31	8.76e-7	Colorectal cancer;
SARC	cis	rs6912958	0.712	rs6454640	chr6:88370352	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.32	5.55	0.34	7.87e-8	Monocyte percentage of white cells;
SARC	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg02951883	chr7:2050386	MAD1L1	0.42	5.35	0.33	2.05e-7	Bipolar disorder and schizophrenia;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg11686722	chr15:37391721	MEIS2	-0.45	-6.49	-0.39	5.11e-10	Thyroid stimulating hormone;
SARC	cis	rs9625935	0.536	rs9608819	chr22:30260809	A/C	cg01021169	chr22:30184971	ASCC2	0.39	5.18	0.32	4.91e-7	Tonsillectomy;
SARC	cis	rs9467773	0.967	rs9358954	chr6:26531178	A/G	cg11502198	chr6:26597334	ABT1	0.46	5.53	0.34	8.38e-8	Intelligence (multi-trait analysis);
SARC	cis	rs765787	0.530	rs16941017	chr15:45543281	T/C	cg24006582	chr15:45444508	DUOX1	-0.52	-6.85	-0.41	6.5e-11	Uric acid levels;
SARC	cis	rs524281	0.861	rs6591207	chr11:65949674	A/T	cg14036092	chr11:66035641	RAB1B	-0.48	-4.93	-0.31	1.53e-6	Electroencephalogram traits;
SARC	trans	rs1814175	0.817	rs1996982	chr11:49972619	G/T	cg15704280	chr7:45808275	SEPT13	-0.98	-18.59	-0.77	6.51e-48	Height;
SARC	trans	rs36093844	0.800	rs17817326	chr11:85595213	C/T	cg27065003	chr5:122429449	PRDM6	-0.53	-6.53	-0.39	4.13e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs10193935	1.000	rs10190326	chr2:42388262	A/C	cg27598129	chr2:42591480	NA	0.34	4.73	0.3	3.95e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg02725872	chr8:58115012	NA	-0.34	-5.46	-0.34	1.19e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs35995292	1.000	rs35995292	chr7:38913017	T/G	cg19327137	chr7:38886074	VPS41	0.36	5.24	0.32	3.57e-7	Subjective well-being (multi-trait analysis);
SARC	cis	rs7769051	0.522	rs7759524	chr6:133109574	A/G	cg07930552	chr6:133119739	C6orf192	0.93	5.74	0.35	2.86e-8	Type 2 diabetes nephropathy;
SARC	cis	rs13082711	0.911	rs7640957	chr3:27514015	C/A	cg02860705	chr3:27208620	NA	0.47	5.89	0.36	1.35e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs2439831	0.867	rs933941	chr15:43632226	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.01	10.41	0.56	4.23e-21	Lung cancer in ever smokers;
SARC	cis	rs933688	1.000	rs332531	chr5:90790451	G/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.0	12.27	0.63	5.08e-27	Smoking behavior;
SARC	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg04518342	chr5:131593106	PDLIM4	0.45	5.87	0.36	1.51e-8	Blood metabolite levels;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg00160902	chr4:16944285	NA	-0.73	-6.3	-0.38	1.44e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1790761	0.520	rs4930461	chr11:67394895	A/G	cg23188684	chr11:67383651	NA	0.43	5.68	0.35	4.07e-8	Mean corpuscular volume;
SARC	cis	rs9322193	0.607	rs4869755	chr6:150207483	G/A	cg09699651	chr6:150184138	LRP11	0.44	4.74	0.3	3.8e-6	Lung cancer;
SARC	cis	rs9302635	0.550	rs35959677	chr16:72200801	G/T	cg16558253	chr16:72132732	DHX38	-0.53	-6.42	-0.39	7.53e-10	Blood protein levels;
SARC	cis	rs4619890	0.528	rs17770213	chr4:7896866	C/T	cg18538662	chr4:7941764	AFAP1	0.41	5.3	0.33	2.62e-7	Glaucoma (primary open-angle);
SARC	cis	rs910316	1.000	rs10149880	chr14:75633008	A/G	cg23033748	chr14:75592666	NEK9	-0.35	-4.75	-0.3	3.51e-6	Height;
SARC	cis	rs870825	0.616	rs7654208	chr4:185648877	C/T	cg04058563	chr4:185651563	MLF1IP	0.8	11.35	0.6	4.56e-24	Blood protein levels;
SARC	cis	rs17023223	0.537	rs12087987	chr1:119734821	C/A	cg05756136	chr1:119680316	WARS2	-0.49	-5.62	-0.35	5.54e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs2439831	1.000	rs2444029	chr15:43737484	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.06	10.75	0.58	3.82e-22	Lung cancer in ever smokers;
SARC	cis	rs4319547	0.656	rs10734918	chr12:122921512	A/C	cg23029597	chr12:123009494	RSRC2	-0.41	-5.01	-0.31	1.06e-6	Body mass index;
SARC	cis	rs1008375	1.000	rs2058338	chr4:17678600	A/G	cg02297831	chr4:17616191	MED28	-0.52	-6.83	-0.41	7.49e-11	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs3771570	1.000	rs56156035	chr2:242205955	T/A	cg21155796	chr2:242212141	HDLBP	0.69	5.96	0.36	9.37e-9	Prostate cancer;
SARC	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg05165339	chr4:1420672	NA	-0.22	-4.85	-0.3	2.22e-6	Longevity;
SARC	cis	rs9302635	0.513	rs8044555	chr16:72152755	T/C	cg16558253	chr16:72132732	DHX38	-0.56	-7.31	-0.43	4.17e-12	Blood protein levels;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg22276571	chr20:17549599	DSTN	-0.53	-6.89	-0.41	5.11e-11	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs55871839	0.643	rs10109566	chr8:59800446	A/G	cg07426533	chr8:59803705	TOX	-0.41	-5.4	-0.33	1.65e-7	Pneumonia;
SARC	cis	rs3018712	0.532	rs2510397	chr11:68419559	A/G	cg01657329	chr11:68192670	LRP5	0.59	5.38	0.33	1.81e-7	Total body bone mineral density;
SARC	cis	rs7582720	1.000	rs72928608	chr2:203836507	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg21573476	chr21:45109991	RRP1B	-0.55	-8.3	-0.48	8.51e-15	Mean corpuscular volume;
SARC	cis	rs2439831	0.681	rs28594657	chr15:43588888	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.13	10.23	0.56	1.6e-20	Lung cancer in ever smokers;
SARC	cis	rs8054556	0.787	rs11150581	chr16:30030699	T/C	cg06015834	chr16:30021696	DOC2A	-0.37	-4.98	-0.31	1.26e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2290402	0.536	rs4690204	chr4:881195	C/T	cg00846425	chr4:957561	DGKQ	-0.43	-4.83	-0.3	2.44e-6	Type 2 diabetes;
SARC	cis	rs9388451	0.869	rs7764016	chr6:126070789	T/G	cg06289844	chr6:126071538	HEY2	0.39	6.42	0.39	7.67e-10	Brugada syndrome;
SARC	cis	rs700651	0.789	rs1371663	chr2:198900305	C/T	cg00792783	chr2:198669748	PLCL1	-0.49	-5.46	-0.34	1.24e-7	Intracranial aneurysm;
SARC	cis	rs6088580	0.634	rs4277599	chr20:33008905	A/G	cg08999081	chr20:33150536	PIGU	-0.42	-6.48	-0.39	5.29e-10	Glomerular filtration rate (creatinine);
SARC	trans	rs7615952	0.673	rs9841194	chr3:125635739	C/T	cg07211511	chr3:129823064	LOC729375	-0.82	-7.49	-0.44	1.41e-12	Blood pressure (smoking interaction);
SARC	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg26335602	chr6:28129616	ZNF389	0.51	5.62	0.35	5.41e-8	Depression;
SARC	cis	rs3741151	0.773	rs17244602	chr11:73219907	A/G	cg17517138	chr11:73019481	ARHGEF17	-0.9	-7.41	-0.44	2.25e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-8.76	-0.5	4.15e-16	Alzheimer's disease;
SARC	trans	rs2816316	0.583	rs2760530	chr1:192538496	G/T	cg02079908	chr2:42411760	EML4	0.52	6.3	0.38	1.5e-9	Celiac disease;
SARC	cis	rs12479064	0.724	rs3792150	chr2:100041849	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.65	-8.05	-0.47	4.19e-14	Chronic sinus infection;
SARC	cis	rs11122272	0.735	rs2808592	chr1:231523757	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs6087990	0.735	rs2064350	chr20:31390533	T/C	cg13636640	chr20:31349939	DNMT3B	0.78	12.04	0.62	2.77e-26	Ulcerative colitis;
SARC	cis	rs554111	0.656	rs6695218	chr1:21190512	A/C	cg04902671	chr1:21058625	SH2D5	0.44	5.31	0.33	2.54e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs1949733	0.635	rs4358384	chr4:8536913	C/T	cg05004818	chr4:8539015	NA	0.35	4.77	0.3	3.25e-6	Response to antineoplastic agents;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg16715662	chr10:35456063	CREM	0.6	8.92	0.5	1.38e-16	Thyroid stimulating hormone;
SARC	cis	rs8180040	1.000	rs295458	chr3:47385585	C/A	cg27129171	chr3:47204927	SETD2	0.69	9.65	0.53	9.36e-19	Colorectal cancer;
SARC	cis	rs10189230	0.967	rs13012331	chr2:222350600	G/A	cg14652038	chr2:222343519	EPHA4	0.43	5.81	0.36	1.99e-8	Urate levels in lean individuals;
SARC	cis	rs6580649	1.000	rs7132668	chr12:48405860	C/T	cg05342945	chr12:48394962	COL2A1	-0.55	-5.91	-0.36	1.21e-8	Lung cancer;
SARC	cis	rs1691799	0.899	rs1168351	chr12:66752505	A/G	cg16791601	chr12:66731901	HELB	-0.71	-10.71	-0.57	5.14e-22	White blood cell count (basophil);
SARC	cis	rs806795	0.605	rs809871	chr6:26256526	C/G	cg00631329	chr6:26305371	NA	0.5	6.05	0.37	5.61e-9	Mosquito bite size;
SARC	cis	rs2836974	0.545	rs8128901	chr21:40710419	G/A	cg11890956	chr21:40555474	PSMG1	0.76	10.28	0.56	1.09e-20	Cognitive function;
SARC	cis	rs7084402	0.967	rs1649042	chr10:60328663	T/C	cg07615347	chr10:60278583	BICC1	0.58	8.58	0.49	1.36e-15	Refractive error;
SARC	cis	rs113835537	0.529	rs7950790	chr11:66258053	G/A	cg24851651	chr11:66362959	CCS	0.38	4.87	0.3	2.1e-6	Airway imaging phenotypes;
SARC	trans	rs2898290	0.593	rs1600252	chr8:11345644	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.49	-0.44	1.44e-12	Systolic blood pressure;
SARC	cis	rs2952156	0.920	rs2934956	chr17:37830447	T/A	cg07936489	chr17:37558343	FBXL20	-0.44	-5.73	-0.35	3.02e-8	Asthma;
SARC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg11494091	chr17:61959527	GH2	0.54	8.15	0.47	2.26e-14	Prudent dietary pattern;
SARC	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg02841227	chr6:26021843	HIST1H4A	0.68	8.22	0.47	1.38e-14	Intelligence (multi-trait analysis);
SARC	cis	rs1008375	0.897	rs6820164	chr4:17630115	G/A	cg27347728	chr4:17578864	LAP3	0.49	6.19	0.38	2.73e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg26818010	chr10:134567672	INPP5A	-0.63	-6.48	-0.39	5.31e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs73242632	1.000	rs3755901	chr4:57775996	T/A	cg20415529	chr4:57845134	POLR2B;C4orf14	1.03	6.22	0.38	2.26e-9	Congenital heart disease (maternal effect);
SARC	cis	rs7552404	0.727	rs2172508	chr1:76320215	A/G	cg03433033	chr1:76189801	ACADM	0.48	5.92	0.36	1.14e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg00933542	chr6:150070202	PCMT1	0.31	5.36	0.33	2.04e-7	Lung cancer;
SARC	cis	rs3771570	1.000	rs4675811	chr2:242402062	A/T	cg21155796	chr2:242212141	HDLBP	0.56	5.67	0.35	4.26e-8	Prostate cancer;
SARC	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg16606324	chr3:10149918	C3orf24	0.46	4.8	0.3	2.79e-6	Alzheimer's disease;
SARC	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg26335602	chr6:28129616	ZNF389	0.52	5.69	0.35	3.74e-8	Depression;
SARC	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	24.35	0.85	5.64e-66	Chronic sinus infection;
SARC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg07507251	chr3:52567010	NT5DC2	0.33	5.26	0.33	3.31e-7	Electroencephalogram traits;
SARC	cis	rs6450176	0.564	rs31227	chr5:53326467	G/C	ch.5.1024479R	chr5:53302184	ARL15	-0.55	-6.23	-0.38	2.11e-9	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg05861140	chr6:150128134	PCMT1	-0.36	-4.75	-0.3	3.5e-6	Lung cancer;
SARC	cis	rs4481887	0.893	rs4244186	chr1:248493319	A/G	cg01631408	chr1:248437212	OR2T33	-0.39	-4.86	-0.3	2.15e-6	Common traits (Other);
SARC	cis	rs7474896	0.559	rs1024202	chr10:38278977	A/C	cg25427524	chr10:38739819	LOC399744	0.45	5.47	0.34	1.18e-7	Obesity (extreme);
SARC	cis	rs72634258	0.786	rs4268374	chr1:8174083	G/T	cg00042356	chr1:8021962	PARK7	-0.64	-5.98	-0.36	8.49e-9	Inflammatory bowel disease;
SARC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-4.93	-0.31	1.59e-6	Total body bone mineral density;
SARC	cis	rs920590	0.758	rs2898491	chr8:19661883	C/T	cg03894339	chr8:19674705	INTS10	0.54	6.32	0.38	1.31e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs4642101	0.737	rs4299468	chr3:12825559	G/A	cg24848339	chr3:12840334	CAND2	0.32	4.94	0.31	1.48e-6	QRS complex (12-leadsum);
SARC	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg00933542	chr6:150070202	PCMT1	0.34	5.93	0.36	1.06e-8	Lung cancer;
SARC	cis	rs7000551	0.663	rs7827118	chr8:22334669	T/G	cg12081754	chr8:22256438	SLC39A14	0.58	8.13	0.47	2.55e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs4927850	1.000	rs4927704	chr3:195738228	C/T	cg00031303	chr3:195681400	NA	0.54	6.24	0.38	2.08e-9	Pancreatic cancer;
SARC	cis	rs7726839	0.540	rs72707016	chr5:665148	A/G	cg09021430	chr5:549028	NA	-0.4	-4.92	-0.31	1.67e-6	Obesity-related traits;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg13559233	chr1:82269258	LPHN2	-0.49	-6.63	-0.4	2.33e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs240764	0.717	rs10872622	chr6:101165017	C/T	cg09795085	chr6:101329169	ASCC3	-0.47	-5.92	-0.36	1.15e-8	Neuroticism;
SARC	cis	rs7223966	1.000	rs9893348	chr17:61676534	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	5.82	0.36	1.96e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs898097	0.625	rs6502017	chr17:80891135	C/T	cg02711726	chr17:80685570	FN3KRP	-0.35	-4.88	-0.3	1.93e-6	Breast cancer;
SARC	cis	rs1448094	0.967	rs1374995	chr12:86341764	A/G	cg02569458	chr12:86230093	RASSF9	0.4	5.73	0.35	3.13e-8	Major depressive disorder;
SARC	cis	rs477692	1.000	rs480643	chr10:131400308	A/G	cg05714579	chr10:131428358	MGMT	0.58	7.59	0.45	7.43e-13	Response to temozolomide;
SARC	cis	rs7412746	0.622	rs11552229	chr1:150783985	T/C	cg15448220	chr1:150897856	SETDB1	0.48	6.29	0.38	1.55e-9	Melanoma;
SARC	cis	rs6582630	0.512	rs11181007	chr12:38266700	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-7.72	-0.45	3.45e-13	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6142102	0.961	rs2300204	chr20:32588773	G/A	cg24642439	chr20:33292090	TP53INP2	0.44	4.81	0.3	2.69e-6	Skin pigmentation;
SARC	cis	rs694739	0.930	rs574087	chr11:64102948	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.69	8.8	0.5	3.2e-16	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs9420	0.922	rs35808061	chr11:57547000	T/C	cg19752551	chr11:57585705	CTNND1	-0.53	-7.23	-0.43	6.92e-12	Schizophrenia;
SARC	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-9.19	-0.52	2.22e-17	Alzheimer's disease;
SARC	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg18876405	chr7:65276391	NA	0.46	5.65	0.35	4.74e-8	Aortic root size;
SARC	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg16479474	chr6:28041457	NA	0.37	5.37	0.33	1.94e-7	Depression;
SARC	cis	rs6728642	0.908	rs11901495	chr2:98017804	A/G	cg26665480	chr2:98280029	ACTR1B	0.65	5.91	0.36	1.19e-8	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg06420487	chr17:61919686	SMARCD2	0.45	4.93	0.31	1.59e-6	Height;
SARC	cis	rs6500602	0.702	rs11645519	chr16:4538989	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.33	5.56	0.34	7.33e-8	Schizophrenia;
SARC	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg22862634	chr11:62369728	EML3;MTA2	0.54	8.59	0.49	1.25e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs5753618	0.583	rs9606843	chr22:31853371	A/C	cg07713946	chr22:31675144	LIMK2	0.36	5.07	0.32	8.03e-7	Colorectal cancer;
SARC	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg06028808	chr11:68637592	NA	0.48	6.23	0.38	2.15e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg10435706	chr6:150039699	LATS1	0.37	4.82	0.3	2.6e-6	Lung cancer;
SARC	cis	rs9948	1.000	rs62152793	chr2:97484948	C/T	cg01990225	chr2:97406019	LMAN2L	-0.9	-6.26	-0.38	1.81e-9	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs8017423	0.967	rs4904658	chr14:90721640	C/T	cg20276874	chr14:90721474	PSMC1	-0.38	-5.32	-0.33	2.41e-7	Mortality in heart failure;
SARC	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg13607699	chr17:42295918	UBTF	0.51	6.12	0.37	3.88e-9	Total body bone mineral density;
SARC	cis	rs4660306	1.000	rs6429567	chr1:45956700	C/A	cg24296786	chr1:45957014	TESK2	0.58	6.72	0.4	1.35e-10	Homocysteine levels;
SARC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.57	-6.67	-0.4	1.83e-10	Longevity;Endometriosis;
SARC	cis	rs9309473	1.000	rs56672945	chr2:73622663	C/T	cg20560298	chr2:73613845	ALMS1	-0.52	-6.26	-0.38	1.84e-9	Metabolite levels;
SARC	cis	rs9818758	0.607	rs113186424	chr3:49272726	T/C	cg07636037	chr3:49044803	WDR6	-0.76	-6.77	-0.41	1.03e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg13385521	chr17:29058706	SUZ12P	0.6	5.39	0.33	1.76e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9914988	0.943	rs9894335	chr17:27138483	C/A	cg20469991	chr17:27169893	C17orf63	-0.52	-5.41	-0.33	1.55e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs57994353	0.897	rs67220311	chr9:139376668	T/C	cg14169450	chr9:139327907	INPP5E	0.42	5.38	0.33	1.79e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs4906332	1.000	rs28711288	chr14:103906126	T/C	cg26031613	chr14:104095156	KLC1	-0.49	-5.78	-0.35	2.37e-8	Coronary artery disease;
SARC	cis	rs694739	0.726	rs516124	chr11:64128423	G/T	cg02228329	chr11:64053129	BAD;GPR137	0.52	5.67	0.35	4.25e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg15320075	chr8:145703422	NA	-0.57	-7.47	-0.44	1.58e-12	Age at first birth;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg11590780	chr7:128470419	FLNC	-0.54	-6.78	-0.41	9.76e-11	Gallstone disease;
SARC	cis	rs9920	0.585	rs17515960	chr7:116149576	A/G	cg24770985	chr7:116166421	CAV1	0.89	5.77	0.35	2.46e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Immature fraction of reticulocytes;QT interval;
SARC	cis	rs9303401	0.659	rs12948133	chr17:56673602	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	11.77	0.61	2.17e-25	Cognitive test performance;
SARC	cis	rs2011503	0.941	rs11670775	chr19:19649636	A/G	cg03709012	chr19:19516395	GATAD2A	0.6	5.29	0.33	2.8e-7	Bipolar disorder;
SARC	cis	rs644799	0.710	rs666398	chr11:95551136	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.95	16.03	0.72	1.73e-39	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs950169	0.800	rs4842847	chr15:84931199	G/A	cg24253500	chr15:84953950	NA	0.36	5.1	0.32	6.9e-7	Schizophrenia;
SARC	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg04166393	chr7:2884313	GNA12	0.54	6.23	0.38	2.12e-9	Height;
SARC	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg12756686	chr19:29218302	NA	0.69	9.02	0.51	7.08e-17	Methadone dose in opioid dependence;
SARC	cis	rs858239	0.600	rs1468592	chr7:23140647	C/T	cg23682824	chr7:23144976	KLHL7	-0.69	-9.37	-0.52	6.62e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg00933542	chr6:150070202	PCMT1	0.32	5.0	0.31	1.14e-6	Lung cancer;
SARC	cis	rs765787	0.530	rs1648286	chr15:45517386	G/C	cg24006582	chr15:45444508	DUOX1	-0.47	-6.24	-0.38	2.08e-9	Uric acid levels;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg05226292	chr8:71520850	TRAM1	0.5	6.38	0.39	9.67e-10	Height;
SARC	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg05368731	chr17:41323189	NBR1	0.8	9.59	0.53	1.43e-18	Menopause (age at onset);
SARC	trans	rs9329221	0.683	rs525726	chr8:9887797	G/C	cg08975724	chr8:8085496	FLJ10661	-0.53	-7.11	-0.42	1.43e-11	Neuroticism;
SARC	cis	rs9486719	1.000	rs4078038	chr6:96904366	A/G	cg18709589	chr6:96969512	KIAA0776	-0.48	-4.78	-0.3	3.15e-6	Migraine;Coronary artery disease;
SARC	cis	rs208520	0.690	rs7739253	chr6:66861052	A/G	cg07460842	chr6:66804631	NA	-1.06	-14.96	-0.7	6.65e-36	Exhaled nitric oxide output;
SARC	cis	rs76419734	1.000	rs11097901	chr4:106729933	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	5.35	0.33	2.11e-7	Post bronchodilator FEV1;
SARC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg06873352	chr17:61820015	STRADA	0.55	7.13	0.42	1.27e-11	Prudent dietary pattern;
SARC	cis	rs1953600	0.668	rs3122586	chr10:81950326	C/T	cg00277334	chr10:82204260	NA	0.35	4.88	0.3	1.97e-6	Sarcoidosis;
SARC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.44	-5.02	-0.31	1.04e-6	Longevity;Endometriosis;
SARC	cis	rs734999	0.549	rs3828154	chr1:2524943	G/A	cg00980319	chr1:2560884	MMEL1	-0.35	-4.91	-0.31	1.69e-6	Ulcerative colitis;
SARC	cis	rs67460515	0.926	rs11715591	chr3:161043137	C/T	cg03342759	chr3:160939853	NMD3	-0.67	-8.59	-0.49	1.3e-15	Parkinson's disease;
SARC	cis	rs13314892	0.726	rs78094954	chr3:69881136	G/A	cg17445875	chr3:69859618	MITF	-0.49	-5.13	-0.32	6.2e-7	QRS complex (12-leadsum);
SARC	cis	rs2153535	0.580	rs1855769	chr6:8473095	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	8.19	0.47	1.76e-14	Motion sickness;
SARC	cis	rs1153858	0.621	rs1706824	chr15:45579948	C/T	cg21132104	chr15:45694354	SPATA5L1	0.76	9.69	0.54	7.22e-19	Homoarginine levels;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg00931925	chr14:104041414	C14orf153	-0.72	-6.28	-0.38	1.6e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs240764	0.764	rs6910391	chr6:100925774	T/C	cg09795085	chr6:101329169	ASCC3	-0.4	-4.99	-0.31	1.21e-6	Neuroticism;
SARC	cis	rs72781680	0.950	rs72798404	chr2:24180125	C/T	cg06627628	chr2:24431161	ITSN2	-0.75	-7.03	-0.42	2.31e-11	Lymphocyte counts;
SARC	trans	rs17685	0.671	rs60303271	chr7:75760008	A/G	cg19862616	chr7:65841803	NCRNA00174	0.62	7.72	0.45	3.44e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-9.22	-0.52	1.78e-17	Alzheimer's disease;
SARC	cis	rs365132	0.875	rs4976665	chr5:176352736	C/T	cg16309518	chr5:176445507	NA	-0.48	-6.21	-0.38	2.42e-9	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs7395581	0.918	rs1449627	chr11:47290984	T/G	cg25783544	chr11:47291846	MADD	0.5	5.63	0.35	5.08e-8	HDL cholesterol;
SARC	cis	rs2439831	0.702	rs3759791	chr15:44090798	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.81	7.54	0.44	1.05e-12	Lung cancer in ever smokers;
SARC	cis	rs910316	0.935	rs3742771	chr14:75599647	A/G	cg11812906	chr14:75593930	NEK9	0.86	13.31	0.66	1.98e-30	Height;
SARC	cis	rs2718058	0.692	rs2718041	chr7:37783944	A/G	cg15028436	chr7:37888078	TXNDC3	0.36	5.0	0.31	1.12e-6	Alzheimer's disease (late onset);
SARC	cis	rs622217	0.596	rs3127570	chr6:160934825	C/T	cg12345982	chr6:160389645	IGF2R	-0.35	-5.34	-0.33	2.26e-7	Type 2 diabetes;
SARC	cis	rs12142240	0.698	rs79490411	chr1:46813568	G/A	cg14993813	chr1:46806288	NSUN4	-0.52	-5.32	-0.33	2.41e-7	Menopause (age at onset);
SARC	cis	rs7208859	0.673	rs73265633	chr17:29236306	G/T	cg13385521	chr17:29058706	SUZ12P	0.86	7.14	0.42	1.2e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs12956009	0.518	rs71352652	chr18:44869536	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.57	7.38	0.44	2.79e-12	Educational attainment (years of education);
SARC	cis	rs7959452	0.535	rs10878953	chr12:69674187	A/G	cg20891283	chr12:69753455	YEATS4	0.4	5.27	0.33	3.11e-7	Blood protein levels;
SARC	cis	rs6582630	0.502	rs11181475	chr12:38348922	G/A	cg26384229	chr12:38710491	ALG10B	0.87	12.85	0.64	6.2e-29	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg14784868	chr12:69753453	YEATS4	0.51	6.77	0.41	1.01e-10	Blood protein levels;
SARC	cis	rs910316	0.737	rs28687415	chr14:75495482	T/C	cg06637938	chr14:75390232	RPS6KL1	0.53	7.17	0.43	9.85e-12	Height;
SARC	cis	rs72945132	0.882	rs7943547	chr11:70133282	C/A	cg00319359	chr11:70116639	PPFIA1	0.68	6.37	0.39	1.01e-9	Coronary artery disease;
SARC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg09373136	chr17:61933544	TCAM1	-0.44	-6.06	-0.37	5.39e-9	Prudent dietary pattern;
SARC	cis	rs1256061	0.603	rs1256036	chr14:64743332	C/T	cg23250157	chr14:64679961	SYNE2	0.46	6.37	0.38	1.02e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs9467711	0.591	rs13201821	chr6:26057781	A/C	cg21479132	chr6:26055353	NA	1.0	7.58	0.44	7.9e-13	Autism spectrum disorder or schizophrenia;
SARC	cis	rs10791323	0.572	rs10894755	chr11:133739685	C/T	cg13461336	chr11:133711254	SPATA19	0.27	4.72	0.3	4.13e-6	Childhood ear infection;
SARC	cis	rs2425143	0.915	rs6060597	chr20:34370100	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	-0.64	-5.23	-0.32	3.83e-7	Blood protein levels;
SARC	cis	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg12463550	chr7:65579703	CRCP	0.69	5.29	0.33	2.86e-7	Diabetic kidney disease;
SARC	cis	rs1497406	0.802	rs11588341	chr1:16498048	A/G	cg20430773	chr1:16534157	ARHGEF19	0.44	6.68	0.4	1.73e-10	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7621025	0.500	rs12629000	chr3:136643571	T/A	cg15507776	chr3:136538369	TMEM22	0.94	10.83	0.58	2.09e-22	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
SARC	cis	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg05623727	chr3:50126028	RBM5	0.38	5.6	0.34	5.97e-8	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg11062466	chr8:58055876	NA	0.61	5.75	0.35	2.74e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4780401	0.642	rs7194145	chr16:11764615	T/G	cg01061890	chr16:11836724	TXNDC11	-0.46	-5.91	-0.36	1.19e-8	Rheumatoid arthritis;
SARC	cis	rs9916302	0.904	rs801426	chr17:37441109	C/T	cg07936489	chr17:37558343	FBXL20	0.7	9.31	0.52	1.02e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs7666738	0.512	rs6532704	chr4:98777562	C/T	cg05340658	chr4:99064831	C4orf37	0.44	5.85	0.36	1.62e-8	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9868809	0.656	rs13324119	chr3:48710606	G/C	cg00383909	chr3:49044727	WDR6	0.61	5.28	0.33	2.98e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs17376456	0.877	rs10057814	chr5:93399092	C/G	cg21475434	chr5:93447410	FAM172A	0.83	7.72	0.45	3.5e-13	Diabetic retinopathy;
SARC	cis	rs921968	0.565	rs11896209	chr2:219599268	C/T	cg02176678	chr2:219576539	TTLL4	-0.33	-5.08	-0.32	7.84e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg03188948	chr7:1209495	NA	0.46	6.16	0.37	3.17e-9	Longevity;Endometriosis;
SARC	cis	rs7647973	1.000	rs62259944	chr3:49430883	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.56	-5.35	-0.33	2.08e-7	Menarche (age at onset);
SARC	trans	rs561341	1.000	rs527256	chr17:30321293	C/G	cg20587970	chr11:113659929	NA	-1.34	-13.79	-0.67	4.87e-32	Hip circumference adjusted for BMI;
SARC	cis	rs554111	0.613	rs6699704	chr1:21241432	G/C	cg08890418	chr1:21044141	KIF17	-0.34	-4.81	-0.3	2.67e-6	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs7402982	0.625	rs4966008	chr15:99203445	A/G	cg03437748	chr15:99193247	IGF1R	-0.61	-7.73	-0.45	3.29e-13	Birth weight;
SARC	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg17971929	chr21:40555470	PSMG1	0.96	11.7	0.61	3.58e-25	Cognitive function;
SARC	cis	rs72781680	1.000	rs72781648	chr2:24210333	T/C	cg06627628	chr2:24431161	ITSN2	-0.7	-6.78	-0.41	9.65e-11	Lymphocyte counts;
SARC	cis	rs933688	1.000	rs61612071	chr5:90741470	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	12.57	0.64	5.35e-28	Smoking behavior;
SARC	cis	rs262150	0.659	rs2657340	chr7:158796968	C/T	cg04111992	chr7:158790115	NA	0.36	5.07	0.32	8.02e-7	Facial morphology (factor 20);
SARC	cis	rs13144136	0.687	rs12511309	chr4:10657137	A/G	cg10242279	chr4:10666415	CLNK	-0.42	-6.91	-0.41	4.71e-11	Resistance to antihypertensive treatment in hypertension;
SARC	cis	rs11168187	0.891	rs2003471	chr12:48124893	G/A	cg12761788	chr12:48120090	P11	0.41	5.22	0.32	3.95e-7	Vertical cup-disc ratio;
SARC	cis	rs12079745	0.793	rs12089602	chr1:169180898	T/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.76	-5.01	-0.31	1.06e-6	QT interval;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg19397221	chr4:71705056	GRSF1	0.54	6.6	0.4	2.78e-10	Fibrinogen levels;
SARC	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.57	8.82	0.5	2.72e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs12079745	0.590	rs80215043	chr1:169193763	T/C	cg09363564	chr1:169337483	NME7;BLZF1	-0.86	-5.46	-0.34	1.21e-7	QT interval;
SARC	cis	rs6450176	1.000	rs7735253	chr5:53297611	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.66	-7.64	-0.45	5.69e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs4481887	0.861	rs6669290	chr1:248476804	G/A	cg01631408	chr1:248437212	OR2T33	-0.39	-5.06	-0.31	8.56e-7	Common traits (Other);
SARC	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg20607798	chr8:58055168	NA	0.6	5.34	0.33	2.19e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg05823146	chr10:99496860	ZFYVE27	-0.49	-6.28	-0.38	1.61e-9	Chemerin levels;
SARC	cis	rs526231	0.511	rs58344084	chr5:102378212	C/T	cg23492399	chr5:102201601	PAM	-0.52	-5.62	-0.35	5.32e-8	Primary biliary cholangitis;
SARC	cis	rs7520050	0.807	rs12025621	chr1:46228391	G/A	cg06784218	chr1:46089804	CCDC17	-0.27	-4.83	-0.3	2.49e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg16134139	chr7:20042353	NA	0.42	5.59	0.34	6.43e-8	Thyroid stimulating hormone;
SARC	cis	rs8067354	0.645	rs2665403	chr17:57889985	G/A	cg02344993	chr17:57696989	CLTC	0.63	6.14	0.37	3.45e-9	Hemoglobin concentration;
SARC	cis	rs9513627	0.573	rs4771336	chr13:100210610	T/G	cg25919922	chr13:100150906	NA	0.66	6.36	0.38	1.08e-9	Obesity-related traits;
SARC	cis	rs826838	0.872	rs826878	chr12:39088837	A/T	cg13010199	chr12:38710504	ALG10B	-0.6	-8.31	-0.48	7.84e-15	Heart rate;
SARC	cis	rs12930096	1.000	rs12444633	chr16:11677857	A/C	cg07439791	chr16:11680400	LITAF	0.59	5.52	0.34	8.92e-8	QT interval;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg08263361	chr15:77713262	HMG20A	-0.58	-6.46	-0.39	6.21e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs1707322	0.685	rs11211177	chr1:46226349	A/G	cg03146154	chr1:46216737	IPP	0.48	5.64	0.35	4.8e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs11969893	0.737	rs4098482	chr6:101377808	C/T	cg12253828	chr6:101329408	ASCC3	0.97	6.62	0.4	2.48e-10	Economic and political preferences (immigration/crime);
SARC	cis	rs6088813	0.883	rs1406948	chr20:33905619	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.43	5.0	0.31	1.14e-6	Height;
SARC	cis	rs965469	1.000	rs2281500	chr20:3262824	C/T	cg25506879	chr20:3388711	C20orf194	-0.51	-5.22	-0.32	3.97e-7	IFN-related cytopenia;
SARC	cis	rs12101261	0.580	rs3783949	chr14:81448382	A/C	cg06600135	chr14:81408086	NA	0.42	5.27	0.33	3.18e-7	Graves' disease;
SARC	cis	rs7932354	0.528	rs4319472	chr11:47109514	G/C	cg03339077	chr11:47165057	C11orf49	0.41	5.56	0.34	7.54e-8	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs7264396	0.887	rs224419	chr20:34143092	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.46	-5.37	-0.33	1.89e-7	Total cholesterol levels;
SARC	cis	rs12908161	0.920	rs35738019	chr15:85280210	T/C	cg17507749	chr15:85114479	UBE2QP1	0.57	6.61	0.4	2.53e-10	Schizophrenia;
SARC	cis	rs2795502	1.000	rs2795496	chr10:43337842	G/A	cg20628663	chr10:43360327	NA	-0.47	-6.32	-0.38	1.34e-9	Blood protein levels;
SARC	cis	rs7208859	0.623	rs9899692	chr17:29156939	C/T	cg13385521	chr17:29058706	SUZ12P	0.87	7.83	0.46	1.76e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs1949733	0.701	rs871768	chr4:8454938	G/A	cg13073564	chr4:8508604	NA	-0.43	-6.64	-0.4	2.23e-10	Response to antineoplastic agents;
SARC	cis	rs2952156	0.959	rs1495101	chr17:37832103	C/A	cg20243544	chr17:37824526	PNMT	0.47	5.85	0.36	1.62e-8	Asthma;
SARC	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-5.56	-0.34	7.49e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs6121246	0.542	rs76513665	chr20:30450232	T/C	cg09796376	chr20:30640595	HCK	0.63	5.35	0.33	2.14e-7	Mean corpuscular hemoglobin;
SARC	cis	rs3749237	0.557	rs7631908	chr3:49425707	T/G	cg07636037	chr3:49044803	WDR6	0.64	8.25	0.48	1.2e-14	Resting heart rate;
SARC	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg00684032	chr4:1343700	KIAA1530	0.37	5.34	0.33	2.16e-7	Obesity-related traits;
SARC	cis	rs1536827	0.841	rs3813866	chr10:135339334	T/A	cg22671611	chr10:135291010	NA	-0.61	-5.16	-0.32	5.24e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs34172651	0.917	rs172066	chr16:24756449	C/T	cg06028605	chr16:24865363	SLC5A11	0.3	5.55	0.34	7.59e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2635047	0.875	rs2635040	chr18:44640972	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	8.11	0.47	2.86e-14	Educational attainment;
SARC	cis	rs4713118	0.513	rs149878	chr6:27878738	T/G	cg16479474	chr6:28041457	NA	0.31	4.72	0.3	4.06e-6	Parkinson's disease;
SARC	cis	rs2228479	0.850	rs62056103	chr16:89942781	G/A	cg00800038	chr16:89945340	TCF25	-0.75	-5.23	-0.32	3.75e-7	Skin colour saturation;
SARC	trans	rs1910358	0.554	rs10057796	chr5:23759746	C/T	cg05539622	chr2:73298971	SFXN5	0.57	6.48	0.39	5.37e-10	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs78545713	0.536	rs2179516	chr6:26229411	C/T	cg00631329	chr6:26305371	NA	-0.71	-5.17	-0.32	5.09e-7	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs4765905	0.609	rs2239027	chr12:2312301	A/C	cg10668781	chr12:2307325	CACNA1C	-0.3	-4.75	-0.3	3.56e-6	Schizophrenia;
SARC	cis	rs4938330	0.608	rs2238006	chr11:117087792	A/C	cg01368799	chr11:117014884	PAFAH1B2	-0.52	-5.45	-0.34	1.31e-7	Blood protein levels;
SARC	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg25072359	chr17:41440525	NA	0.49	5.8	0.36	2.15e-8	Menopause (age at onset);
SARC	trans	rs11098499	0.954	rs6838814	chr4:120392443	G/A	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	cis	rs17376456	0.825	rs17372725	chr5:93135588	C/A	cg25358565	chr5:93447407	FAM172A	1.17	12.32	0.63	3.32e-27	Diabetic retinopathy;
SARC	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg03650068	chr1:25596491	NA	0.33	5.09	0.32	7.36e-7	Erythrocyte sedimentation rate;
SARC	cis	rs7481584	1.000	rs12798150	chr11:3019260	C/T	cg25174290	chr11:3078921	CARS	-0.5	-6.49	-0.39	5.03e-10	Calcium levels;
SARC	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg11890956	chr21:40555474	PSMG1	1.17	19.37	0.79	1.93e-50	Cognitive function;
SARC	cis	rs6840360	0.967	rs10776524	chr4:152602585	G/A	cg22705602	chr4:152727874	NA	-0.38	-6.54	-0.39	3.91e-10	Intelligence (multi-trait analysis);
SARC	cis	rs793571	0.503	rs1427281	chr15:58959273	T/C	cg05156742	chr15:59063176	FAM63B	0.59	6.75	0.4	1.13e-10	Schizophrenia;
SARC	cis	rs1008375	1.000	rs1860597	chr4:17657650	C/T	cg16339924	chr4:17578868	LAP3	0.66	8.83	0.5	2.57e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg04234412	chr22:24373322	LOC391322	-0.63	-8.2	-0.47	1.65e-14	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs12586317	0.620	rs28870452	chr14:35536878	C/A	cg05294307	chr14:35346193	BAZ1A	-0.47	-4.72	-0.3	4.03e-6	Psoriasis;
SARC	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg16479474	chr6:28041457	NA	0.37	5.44	0.34	1.37e-7	Depression;
SARC	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg16479474	chr6:28041457	NA	0.37	5.37	0.33	1.94e-7	Depression;
SARC	cis	rs9660992	0.649	rs12128254	chr1:205268097	C/T	cg21643547	chr1:205240462	TMCC2	-0.59	-7.35	-0.43	3.31e-12	Mean corpuscular volume;Mean platelet volume;
SARC	trans	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg09610071	chr16:30773590	RNF40;C16orf93	-0.52	-6.55	-0.39	3.59e-10	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6088813	1.000	rs6142374	chr20:33985568	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	-0.45	-5.39	-0.33	1.71e-7	Height;
SARC	cis	rs854765	0.575	rs2955357	chr17:17946401	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.66	-9.66	-0.53	9.05e-19	Total body bone mineral density;
SARC	cis	rs3820928	0.839	rs58580037	chr2:227876274	G/T	cg11843606	chr2:227700838	RHBDD1	-0.55	-6.88	-0.41	5.45e-11	Pulmonary function;
SARC	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg04772025	chr11:68637568	NA	0.5	6.29	0.38	1.55e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg18305652	chr10:134549665	INPP5A	0.35	5.16	0.32	5.28e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs10789491	1.000	rs1440487	chr1:47167075	C/T	cg15501359	chr1:47185051	KIAA0494	-0.74	-8.0	-0.46	5.71e-14	Response to hepatitis C treatment;
SARC	trans	rs1941687	0.527	rs1493914	chr18:31362327	C/T	cg27147174	chr7:100797783	AP1S1	-0.54	-6.69	-0.4	1.6e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
SARC	cis	rs2075165	0.901	rs7542798	chr1:156224304	A/G	cg10544251	chr1:156215727	PAQR6	0.32	4.71	0.3	4.16e-6	Tonsillectomy;
SARC	cis	rs1790761	0.520	rs12805884	chr11:67387977	G/A	cg00864171	chr11:67383662	NA	-0.45	-5.95	-0.36	9.82e-9	Mean corpuscular volume;
SARC	cis	rs6500602	0.727	rs4786509	chr16:4568769	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.31	-5.24	-0.32	3.61e-7	Schizophrenia;
SARC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.39	-5.72	-0.35	3.2e-8	Longevity;Endometriosis;
SARC	cis	rs10911232	0.520	rs10797831	chr1:183036816	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.08	0.55	4.44e-20	Hypertriglyceridemia;
SARC	trans	rs9929218	1.000	rs2113199	chr16:68814502	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.54	-6.77	-0.41	1.05e-10	Colorectal cancer;
SARC	cis	rs965469	0.545	rs6051846	chr20:3403824	A/G	cg25506879	chr20:3388711	C20orf194	0.42	4.99	0.31	1.19e-6	IFN-related cytopenia;
SARC	cis	rs950169	0.840	rs4842853	chr15:84942304	G/T	cg24253500	chr15:84953950	NA	0.36	5.1	0.32	6.9e-7	Schizophrenia;
SARC	cis	rs981844	0.775	rs10517580	chr4:154744128	T/G	cg14289246	chr4:154710475	SFRP2	0.57	6.28	0.38	1.66e-9	Response to statins (LDL cholesterol change);
SARC	cis	rs2635047	0.967	rs2576060	chr18:44637106	C/T	cg19077165	chr18:44547161	KATNAL2	0.4	5.2	0.32	4.31e-7	Educational attainment;
SARC	cis	rs1008375	0.966	rs6837664	chr4:17697835	G/C	cg16339924	chr4:17578868	LAP3	0.52	6.67	0.4	1.8e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs3126085	0.935	rs6587666	chr1:152296863	C/T	cg03465714	chr1:152285911	FLG	0.48	5.59	0.34	6.32e-8	Atopic dermatitis;
SARC	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg11489262	chr17:43973426	MAPT;LOC100128977;LOC100130148	0.47	4.99	0.31	1.21e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs12545109	0.765	rs2055985	chr8:57410821	T/A	cg19413350	chr8:57351067	NA	-0.43	-5.36	-0.33	1.97e-7	Obesity-related traits;
SARC	cis	rs7089973	0.624	rs11196940	chr10:116593791	T/G	cg03647239	chr10:116582469	FAM160B1	0.48	6.17	0.37	3.02e-9	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg09021430	chr5:549028	NA	-0.44	-5.73	-0.35	3.02e-8	Obesity-related traits;
SARC	trans	rs629535	0.514	rs55653755	chr8:70154383	A/C	cg21567404	chr3:27674614	NA	-0.92	-9.79	-0.54	3.53e-19	Dupuytren's disease;
SARC	cis	rs1733410	0.504	rs11181874	chr12:37912890	C/A	cg13010199	chr12:38710504	ALG10B	-0.68	-9.06	-0.51	5.6e-17	Morning vs. evening chronotype;
SARC	cis	rs6831352	0.918	rs13127582	chr4:100058194	G/A	cg13256891	chr4:100009986	ADH5	-0.64	-8.0	-0.46	5.7e-14	Alcohol dependence;
SARC	cis	rs10513788	0.665	rs6777782	chr3:181994593	C/T	cg05977900	chr3:182512126	ATP11B	0.46	4.78	0.3	3.11e-6	Cognitive function;
SARC	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg17376030	chr22:41985996	PMM1	0.79	10.21	0.56	1.88e-20	Vitiligo;
SARC	cis	rs497273	0.534	rs13746	chr12:121201167	C/T	cg02403541	chr12:121454288	C12orf43	0.45	5.35	0.33	2.08e-7	Systemic lupus erythematosus;
SARC	cis	rs12586317	0.924	rs4981276	chr14:35696818	A/G	cg26967526	chr14:35346199	BAZ1A	-0.56	-5.94	-0.36	1.05e-8	Psoriasis;
SARC	cis	rs1692580	0.870	rs262680	chr1:2167149	C/T	cg21442419	chr1:2182373	SKI	-0.72	-11.88	-0.61	8.91e-26	Coronary artery disease;
SARC	cis	rs17270561	0.609	rs4711095	chr6:25726774	A/C	cg17691542	chr6:26056736	HIST1H1C	0.58	7.09	0.42	1.59e-11	Iron status biomarkers;
SARC	cis	rs4276643	1.000	rs7816579	chr8:27805815	A/G	cg26001764	chr8:28560637	EXTL3	-0.27	-4.77	-0.3	3.28e-6	Low vWF levels;
SARC	cis	rs9549260	0.632	rs7323267	chr13:41204015	A/G	cg21288729	chr13:41239152	FOXO1	0.57	5.93	0.36	1.08e-8	Red blood cell count;
SARC	cis	rs892961	0.932	rs67415822	chr17:75412678	A/G	cg05865280	chr17:75406074	SEPT9	0.57	8.47	0.48	2.87e-15	Airflow obstruction;
SARC	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg00149659	chr3:10157352	C3orf10	0.64	6.01	0.37	7.21e-9	Alzheimer's disease;
SARC	cis	rs9486719	1.000	rs11757063	chr6:96884886	C/T	cg18709589	chr6:96969512	KIAA0776	-0.47	-4.88	-0.3	1.98e-6	Migraine;Coronary artery disease;
SARC	cis	rs3784262	0.669	rs3784259	chr15:58257847	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.35	-5.21	-0.32	4.06e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs8180040	0.966	rs62260711	chr3:47564491	G/C	cg27129171	chr3:47204927	SETD2	-0.69	-9.49	-0.53	2.91e-18	Colorectal cancer;
SARC	cis	rs2916247	0.908	rs2339457	chr8:93103628	A/G	cg10183463	chr8:93005414	RUNX1T1	0.65	6.75	0.4	1.18e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7561273	0.586	rs11896092	chr2:24317827	G/A	cg08917208	chr2:24149416	ATAD2B	0.45	4.93	0.31	1.55e-6	Quantitative traits;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg00973653	chr1:70033627	NA	0.48	6.25	0.38	1.94e-9	Chemerin levels;
SARC	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg17376030	chr22:41985996	PMM1	0.72	8.51	0.49	2.13e-15	Vitiligo;
SARC	cis	rs554111	0.656	rs17450586	chr1:21254593	T/G	cg08890418	chr1:21044141	KIF17	-0.34	-4.76	-0.3	3.38e-6	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs7216064	0.636	rs62084696	chr17:66038181	C/G	cg12091567	chr17:66097778	LOC651250	0.94	12.18	0.62	9.64e-27	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs17666538	1.000	rs73177066	chr8:585750	C/T	cg02524346	chr8:600233	NA	-0.94	-7.06	-0.42	1.89e-11	IgG glycosylation;
SARC	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg11987759	chr7:65425863	GUSB	-0.5	-6.21	-0.38	2.43e-9	Aortic root size;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg19397221	chr4:71705056	GRSF1	0.56	7.17	0.43	1.01e-11	Lung adenocarcinoma;
SARC	cis	rs79149102	0.579	rs74023908	chr15:75310710	T/C	cg17294928	chr15:75287854	SCAMP5	-1.08	-9.43	-0.53	4.22e-18	Lung cancer;
SARC	cis	rs6582630	0.502	rs8186661	chr12:38380781	G/A	cg13010199	chr12:38710504	ALG10B	0.8	11.05	0.59	4.21e-23	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs10782582	0.593	rs17585530	chr1:76134990	G/A	cg03433033	chr1:76189801	ACADM	-0.41	-5.07	-0.32	8.04e-7	Daytime sleep phenotypes;
SARC	cis	rs10174077	0.687	rs10172023	chr2:152476028	C/G	cg19508488	chr2:152266495	RIF1	0.48	5.3	0.33	2.73e-7	Squamous cell lung carcinoma;
SARC	cis	rs9611565	0.802	rs132916	chr22:41806768	C/G	cg06634786	chr22:41940651	POLR3H	0.47	6.01	0.37	6.98e-9	Vitiligo;
SARC	cis	rs11098499	0.779	rs10857066	chr4:120286596	C/T	cg09307838	chr4:120376055	NA	0.83	11.82	0.61	1.46e-25	Corneal astigmatism;
SARC	cis	rs11581859	0.613	rs4298760	chr1:99201301	T/C	cg20286094	chr1:99190917	SNX7	-0.43	-5.04	-0.31	9.51e-7	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs965469	0.603	rs6051849	chr20:3404860	C/G	cg25506879	chr20:3388711	C20orf194	-0.42	-5.12	-0.32	6.4e-7	IFN-related cytopenia;
SARC	cis	rs4430311	0.723	rs2034915	chr1:243878503	A/G	cg21452805	chr1:244014465	NA	-0.45	-5.98	-0.36	8.26e-9	Post-traumatic stress disorder (asjusted for relatedness);
SARC	cis	rs524281	0.861	rs10896085	chr11:65913832	A/T	cg14036092	chr11:66035641	RAB1B	-0.51	-5.41	-0.33	1.55e-7	Electroencephalogram traits;
SARC	cis	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg03060546	chr3:49711283	APEH	0.75	11.17	0.59	1.7e-23	Resting heart rate;
SARC	cis	rs995000	0.929	rs12042319	chr1:63049819	C/T	cg06896770	chr1:63153194	DOCK7	0.94	13.97	0.68	1.25e-32	Triglyceride levels;
SARC	cis	rs7264396	0.779	rs6087723	chr20:34175783	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.54	5.87	0.36	1.52e-8	Total cholesterol levels;
SARC	cis	rs12586317	0.547	rs76770287	chr14:35487210	C/A	cg26967526	chr14:35346199	BAZ1A	-0.57	-5.71	-0.35	3.4e-8	Psoriasis;
SARC	cis	rs599083	0.530	rs667126	chr11:68177728	C/T	cg01657329	chr11:68192670	LRP5	0.48	6.53	0.39	4.19e-10	Bone mineral density (spine);
SARC	cis	rs11711311	1.000	rs9826808	chr3:113455644	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.69	8.9	0.5	1.64e-16	IgG glycosylation;
SARC	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg00800038	chr16:89945340	TCF25	-0.72	-4.72	-0.3	4.08e-6	Skin colour saturation;
SARC	cis	rs10979	0.597	rs9403515	chr6:143908013	A/G	cg25407410	chr6:143891975	LOC285740	-0.51	-5.82	-0.36	1.91e-8	Hypospadias;
SARC	cis	rs5769765	0.955	rs9616366	chr22:50301178	C/T	cg03033257	chr22:50311977	ALG12;CRELD2	0.52	5.39	0.33	1.73e-7	Schizophrenia;
SARC	cis	rs12044355	0.927	rs11122321	chr1:231835610	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.54	7.33	0.43	3.71e-12	Alzheimer's disease;
SARC	cis	rs66731853	0.769	rs476582	chr1:20894450	A/G	cg04087271	chr1:20915334	CDA	-0.32	-4.91	-0.31	1.69e-6	Mean corpuscular volume;
SARC	cis	rs12545109	0.800	rs2609978	chr8:57394467	T/C	cg19413350	chr8:57351067	NA	-0.42	-4.75	-0.3	3.63e-6	Obesity-related traits;
SARC	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg11764359	chr7:65958608	NA	0.87	12.3	0.63	4e-27	Aortic root size;
SARC	cis	rs7000551	0.642	rs2449328	chr8:22375043	A/G	cg12081754	chr8:22256438	SLC39A14	0.56	7.76	0.45	2.65e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs17376456	0.877	rs10055340	chr5:93317644	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.54	0.34	8.17e-8	Diabetic retinopathy;
SARC	cis	rs13401104	0.587	rs55801537	chr2:237145481	C/T	cg19324714	chr2:237145437	ASB18	0.63	6.71	0.4	1.5e-10	Educational attainment;
SARC	trans	rs12310956	0.532	rs1352210	chr12:33983187	A/G	cg26384229	chr12:38710491	ALG10B	0.74	10.45	0.56	3.31e-21	Morning vs. evening chronotype;
SARC	cis	rs6570726	0.791	rs7755253	chr6:145858893	C/G	cg23711669	chr6:146136114	FBXO30	0.87	14.71	0.69	4.26e-35	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg11494091	chr17:61959527	GH2	0.56	8.47	0.49	2.7e-15	Prudent dietary pattern;
SARC	cis	rs2997447	0.761	rs17356867	chr1:26448849	C/T	cg19633962	chr1:26362018	EXTL1	0.56	5.2	0.32	4.26e-7	QRS complex (12-leadsum);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg08826738	chr6:105585351	BVES	-0.59	-6.79	-0.41	9.02e-11	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs8054556	0.787	rs12444108	chr16:30027694	G/A	cg06015834	chr16:30021696	DOC2A	-0.35	-4.82	-0.3	2.65e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs4148883	0.689	rs1154415	chr4:99999033	T/C	cg12011299	chr4:100065546	ADH4	0.36	6.72	0.4	1.4e-10	Alcohol dependence;
SARC	cis	rs9467711	0.591	rs9461219	chr6:25836927	C/G	cg21479132	chr6:26055353	NA	-0.78	-5.0	-0.31	1.1e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg08677398	chr8:58056175	NA	0.44	5.25	0.33	3.38e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg16325326	chr1:53192061	ZYG11B	0.8	12.79	0.64	1.03e-28	Monocyte count;
SARC	cis	rs910316	0.663	rs175034	chr14:75463687	T/G	cg08847533	chr14:75593920	NEK9	-0.82	-11.54	-0.6	1.12e-24	Height;
SARC	cis	rs1797081	0.967	rs811912	chr10:16859618	G/C	cg23933602	chr10:16859644	RSU1	0.99	18.81	0.78	1.27e-48	Platelet distribution width;
SARC	cis	rs9457247	0.582	rs9459855	chr6:167466150	G/T	cg07741184	chr6:167504864	NA	0.37	7.07	0.42	1.76e-11	Crohn's disease;
SARC	cis	rs9325144	0.532	rs1352121	chr12:39130696	A/G	cg26384229	chr12:38710491	ALG10B	-0.57	-7.29	-0.43	4.8e-12	Morning vs. evening chronotype;
SARC	cis	rs9911578	1.000	rs2009948	chr17:56611920	A/C	cg05425664	chr17:57184151	TRIM37	0.65	7.98	0.46	6.49e-14	Intelligence (multi-trait analysis);
SARC	trans	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-10.59	-0.57	1.18e-21	Intelligence (multi-trait analysis);
SARC	cis	rs35110281	0.667	rs914197	chr21:45117439	A/G	cg21573476	chr21:45109991	RRP1B	-0.59	-8.34	-0.48	6.49e-15	Mean corpuscular volume;
SARC	trans	rs9650657	0.589	rs10107145	chr8:10758213	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.06	-0.42	1.94e-11	Neuroticism;
SARC	cis	rs3796352	0.892	rs2581807	chr3:53088844	G/A	cg15956490	chr3:53032818	SFMBT1	-0.66	-5.02	-0.31	1.01e-6	Immune reponse to smallpox (secreted IL-2);
SARC	trans	rs9929218	0.551	rs2296408	chr16:68713823	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.84	-14.35	-0.68	6.69e-34	Colorectal cancer;
SARC	cis	rs12681366	0.614	rs2921387	chr8:95458337	G/C	cg26464482	chr8:95565502	KIAA1429	0.43	5.23	0.32	3.76e-7	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs9902453	0.967	rs4429345	chr17:28458105	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.52	-6.75	-0.4	1.18e-10	Coffee consumption (cups per day);
SARC	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg16325326	chr1:53192061	ZYG11B	0.77	11.44	0.6	2.48e-24	Monocyte count;
SARC	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg08280861	chr8:58055591	NA	0.58	5.74	0.35	2.94e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.76	6.61	0.4	2.66e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg08975724	chr8:8085496	FLJ10661	0.52	6.76	0.4	1.09e-10	Mood instability;
SARC	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg22683308	chr4:1340831	KIAA1530	0.4	4.77	0.3	3.23e-6	Longevity;
SARC	cis	rs10513432	0.826	rs1065776	chr3:152553628	C/T	cg04845053	chr3:152552877	P2RY1	0.81	4.73	0.3	3.96e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs7512552	0.966	rs2274127	chr1:150252984	T/G	cg09579323	chr1:150459698	TARS2	-0.4	-4.71	-0.3	4.2e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs9399137	0.507	rs11758774	chr6:135383789	T/G	cg24558204	chr6:135376177	HBS1L	0.63	7.85	0.46	1.53e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs561341	0.739	rs8070554	chr17:30216868	A/T	cg13647721	chr17:30228624	UTP6	-0.7	-6.92	-0.41	4.3e-11	Hip circumference adjusted for BMI;
SARC	cis	rs17376456	1.000	rs12187701	chr5:93522290	A/G	cg21475434	chr5:93447410	FAM172A	0.92	7.81	0.46	1.91e-13	Diabetic retinopathy;
SARC	cis	rs2841277	0.712	rs2841280	chr14:105393556	G/C	cg15352829	chr14:105391018	PLD4	0.34	6.37	0.39	9.86e-10	Rheumatoid arthritis;
SARC	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-9.15	-0.51	2.85e-17	Alzheimer's disease;
SARC	cis	rs829880	0.570	rs844205	chr12:98846053	A/G	cg25150519	chr12:98850993	NA	0.77	10.94	0.58	9.62e-23	Colonoscopy-negative controls vs population controls;
SARC	cis	rs12709013	0.684	rs1646287	chr16:58787678	T/C	cg04273148	chr16:57808038	KIFC3	0.32	4.72	0.3	4.08e-6	Blood metabolite ratios;
SARC	trans	rs7922314	0.571	rs61865715	chr10:64737789	C/T	cg25304107	chr2:177017331	HOXD4	-0.78	-6.29	-0.38	1.52e-9	Cutaneous psoriasis;
SARC	cis	rs151234	0.676	rs508022	chr16:28573963	C/T	cg01378222	chr16:28622494	SULT1A1	-0.5	-5.78	-0.35	2.36e-8	Platelet distribution width;
SARC	cis	rs523522	0.962	rs4766968	chr12:120947788	G/C	cg27279351	chr12:120934652	DYNLL1	0.73	9.05	0.51	5.73e-17	High light scatter reticulocyte count;
SARC	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg06634786	chr22:41940651	POLR3H	0.54	6.41	0.39	8.14e-10	Vitiligo;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg04453488	chr8:145619577	CPSF1;MIR939	0.48	6.41	0.39	8.01e-10	Schizophrenia;
SARC	cis	rs41278232	0.557	rs817340	chr20:62606024	C/A	cg24354818	chr20:62328094	TNFRSF6B	0.35	4.83	0.3	2.43e-6	Tonsillectomy;
SARC	trans	rs61931739	0.534	rs10844767	chr12:34152368	C/G	cg13010199	chr12:38710504	ALG10B	0.72	9.68	0.54	7.76e-19	Morning vs. evening chronotype;
SARC	cis	rs6993244	1	rs6993244	chr8:8863059	C/G	cg06636001	chr8:8085503	FLJ10661	0.44	5.62	0.35	5.51e-8	Mean corpuscular hemoglobin;
SARC	cis	rs1163251	0.837	rs658442	chr1:120244858	T/G	cg19096424	chr1:120255104	PHGDH	0.59	6.95	0.41	3.61e-11	Blood metabolite levels;
SARC	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg12016809	chr21:47604291	C21orf56	0.49	5.93	0.36	1.09e-8	Testicular germ cell tumor;
SARC	cis	rs12887734	0.524	rs17791722	chr14:104286210	C/T	cg26031613	chr14:104095156	KLC1	-0.45	-5.22	-0.32	3.92e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	cis	rs13191362	1.000	rs13210756	chr6:163009030	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.57	5.51	0.34	9.35e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs4642101	0.597	rs9839768	chr3:12821403	C/T	cg05775895	chr3:12838266	CAND2	0.84	15.68	0.72	2.67e-38	QRS complex (12-leadsum);
SARC	cis	rs17376456	0.877	rs34673483	chr5:93315079	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.65	6.1	0.37	4.49e-9	Diabetic retinopathy;
SARC	cis	rs9911578	1.000	rs391370	chr17:56675050	A/C	cg05425664	chr17:57184151	TRIM37	-0.69	-8.63	-0.49	9.41e-16	Intelligence (multi-trait analysis);
SARC	cis	rs2396545	0.680	rs35467761	chr11:571568	A/G	cg16486109	chr11:613632	IRF7	0.44	5.56	0.34	7.48e-8	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs6815814	0.950	rs5743593	chr4:38802913	A/G	cg06935464	chr4:38784597	TLR10	0.64	6.55	0.39	3.58e-10	Breast cancer;
SARC	cis	rs6570726	0.902	rs9390326	chr6:145791222	A/G	cg05347473	chr6:146136440	FBXO30	-0.45	-6.12	-0.37	3.99e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6831352	0.918	rs2851247	chr4:100046091	C/G	cg13256891	chr4:100009986	ADH5	-0.72	-8.67	-0.49	7.23e-16	Alcohol dependence;
SARC	cis	rs1797885	0.510	rs2633442	chr3:12609937	A/G	cg05775895	chr3:12838266	CAND2	-0.38	-4.98	-0.31	1.26e-6	Immature fraction of reticulocytes;
SARC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg21280719	chr6:42927975	GNMT	0.44	7.72	0.45	3.51e-13	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs2070488	0.775	rs1073505	chr3:38566722	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.77	-11.55	-0.6	1.1e-24	Electrocardiographic conduction measures;
SARC	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.41	-6.27	-0.38	1.73e-9	Menopause (age at onset);
SARC	cis	rs7312933	0.558	rs4768399	chr12:42742696	G/A	cg19980929	chr12:42632907	YAF2	-0.45	-6.66	-0.4	1.95e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs453301	0.624	rs4841083	chr8:8870428	A/G	cg15556689	chr8:8085844	FLJ10661	0.38	4.72	0.3	4e-6	Joint mobility (Beighton score);
SARC	cis	rs6728642	0.572	rs13403225	chr2:97600827	A/G	cg26665480	chr2:98280029	ACTR1B	-0.66	-7.09	-0.42	1.63e-11	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs1003719	0.715	rs8129942	chr21:38552070	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.65	-9.7	-0.54	6.75e-19	Eye color traits;
SARC	cis	rs7639513	0.767	rs3806661	chr3:12705855	A/G	cg23032965	chr3:12705835	RAF1	0.85	12.32	0.63	3.57e-27	Itch intensity from mosquito bite;
SARC	cis	rs6964587	0.626	rs409	chr7:91556355	C/T	cg17063962	chr7:91808500	NA	0.81	12.13	0.62	1.48e-26	Breast cancer;
SARC	cis	rs875971	0.545	rs6460276	chr7:65647277	G/A	cg11764359	chr7:65958608	NA	0.67	6.66	0.4	1.92e-10	Aortic root size;
SARC	cis	rs10870270	0.913	rs4880326	chr10:133745547	C/A	cg17892150	chr10:133769511	PPP2R2D	-0.82	-10.71	-0.57	4.89e-22	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs76419734	1.000	rs17036310	chr4:106752340	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	5.31	0.33	2.52e-7	Post bronchodilator FEV1;
SARC	cis	rs6815814	0.950	rs5743789	chr4:38833173	A/T	cg06935464	chr4:38784597	TLR10	0.51	4.91	0.31	1.73e-6	Breast cancer;
SARC	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg18404041	chr3:52824283	ITIH1	-0.39	-5.98	-0.36	8.52e-9	Electroencephalogram traits;
SARC	cis	rs6484504	0.600	rs972714	chr11:31358875	T/G	cg26647111	chr11:31128758	NA	0.37	4.76	0.3	3.45e-6	Red blood cell count;
SARC	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg08280861	chr8:58055591	NA	0.6	5.28	0.33	2.92e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9291683	0.655	rs3822242	chr4:10094904	T/C	cg11266682	chr4:10021025	SLC2A9	-0.44	-7.98	-0.46	6.81e-14	Bone mineral density;
SARC	cis	rs2290159	0.752	rs3773352	chr3:12651982	G/C	cg23032965	chr3:12705835	RAF1	0.77	8.58	0.49	1.36e-15	Cholesterol, total;
SARC	cis	rs27434	0.607	rs26654	chr5:96140367	C/T	cg16492584	chr5:96139282	ERAP1	-0.59	-7.74	-0.45	2.93e-13	Ankylosing spondylitis;
SARC	cis	rs524281	0.682	rs4483592	chr11:65990439	C/T	cg14036092	chr11:66035641	RAB1B	-0.59	-6.23	-0.38	2.18e-9	Electroencephalogram traits;
SARC	cis	rs4713118	0.955	rs9468206	chr6:27690453	G/T	cg17221315	chr6:27791827	HIST1H4J	0.51	5.32	0.33	2.38e-7	Parkinson's disease;
SARC	cis	rs2070488	0.930	rs2370840	chr3:38529825	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.83	13.3	0.66	2.09e-30	Electrocardiographic conduction measures;
SARC	cis	rs34293785	0.565	rs59710023	chr1:66137193	T/C	cg04111102	chr1:66153794	NA	0.37	5.61	0.35	5.63e-8	Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;
SARC	trans	rs10435719	0.899	rs9693925	chr8:11789963	A/G	cg06636001	chr8:8085503	FLJ10661	0.5	6.3	0.38	1.47e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
SARC	cis	rs4481887	1.000	rs4916128	chr1:248466706	G/A	cg01631408	chr1:248437212	OR2T33	-0.44	-5.66	-0.35	4.35e-8	Common traits (Other);
SARC	cis	rs3741404	0.791	rs2282491	chr11:63918373	T/C	cg04317338	chr11:64019027	PLCB3	0.6	7.11	0.42	1.39e-11	Platelet count;
SARC	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.61	5.81	0.36	2.05e-8	Lung function (FEV1/FVC);
SARC	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg03664139	chr6:101329504	ASCC3	0.46	6.45	0.39	6.47e-10	Cancer;
SARC	cis	rs4805272	0.512	rs66830923	chr19:29321277	C/T	cg14983838	chr19:29218262	NA	0.63	7.08	0.42	1.72e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs10504073	0.584	rs56068225	chr8:49923988	A/G	cg00325661	chr8:49890786	NA	0.52	6.9	0.41	4.88e-11	Blood metabolite ratios;
SARC	cis	rs918629	0.567	rs3777204	chr5:95234350	A/G	cg16656078	chr5:95278638	ELL2	-0.51	-6.41	-0.39	8e-10	IgG glycosylation;
SARC	cis	rs6500395	0.962	rs9937623	chr16:48571590	A/T	cg04672837	chr16:48644449	N4BP1	-0.41	-5.28	-0.33	3.01e-7	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs2806561	0.704	rs667330	chr1:23515257	A/G	cg12483005	chr1:23474871	LUZP1	0.44	5.86	0.36	1.61e-8	Height;
SARC	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg06634786	chr22:41940651	POLR3H	-0.58	-6.68	-0.4	1.75e-10	Vitiligo;
SARC	cis	rs9436747	0.967	rs10889551	chr1:65906137	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	-0.45	-4.9	-0.31	1.82e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs748404	0.631	rs4296223	chr15:43645246	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.39	4.8	0.3	2.89e-6	Lung cancer;
SARC	cis	rs1348850	0.757	rs4893969	chr2:178478476	T/A	cg23306229	chr2:178417860	TTC30B	0.53	5.81	0.36	2.03e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs67366981	0.925	rs56245630	chr14:77714185	T/C	cg06779847	chr14:77687015	TMEM63C	-0.48	-5.41	-0.33	1.58e-7	Obsessive-compulsive symptoms;
SARC	cis	rs546131	0.928	rs516228	chr11:34838823	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.46	5.67	0.35	4.24e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg18252515	chr7:66147081	NA	-0.48	-5.24	-0.32	3.55e-7	Aortic root size;
SARC	trans	rs974515	0.513	rs6798302	chr3:3470152	C/T	cg10307152	chr1:12640678	DHRS3	-0.46	-6.28	-0.38	1.66e-9	Knee osteoarthritis;
SARC	cis	rs1336900	0.544	rs10888386	chr1:150611957	A/G	cg15448220	chr1:150897856	SETDB1	-0.46	-5.86	-0.36	1.54e-8	Blood protein levels;
SARC	cis	rs13191362	0.872	rs35672319	chr6:163245464	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.63	6.11	0.37	4.22e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs6570726	0.755	rs2092297	chr6:145893765	A/G	cg23711669	chr6:146136114	FBXO30	0.84	13.98	0.68	1.14e-32	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7680126	0.644	rs62288518	chr4:10087464	T/C	cg11266682	chr4:10021025	SLC2A9	-0.39	-5.28	-0.33	3.02e-7	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
SARC	trans	rs11250097	0.549	rs11784897	chr8:11310442	G/A	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.66	-0.4	1.97e-10	Neuroticism;
SARC	cis	rs13006833	0.739	rs291430	chr2:191198727	A/C	cg25963032	chr2:191064776	C2orf88	0.35	4.78	0.3	3.04e-6	Urinary metabolites;
SARC	cis	rs73198271	0.729	rs67653033	chr8:8605044	G/C	cg06636001	chr8:8085503	FLJ10661	-0.49	-4.83	-0.3	2.46e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs67460515	0.892	rs34896809	chr3:161059804	C/T	cg17135325	chr3:160939158	NMD3	0.63	8.16	0.47	2.08e-14	Parkinson's disease;
SARC	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg14784868	chr12:69753453	YEATS4	0.5	6.68	0.4	1.77e-10	Blood protein levels;
SARC	cis	rs35110281	0.667	rs914197	chr21:45117439	A/G	cg04455712	chr21:45112962	RRP1B	0.35	4.89	0.31	1.88e-6	Mean corpuscular volume;
SARC	cis	rs11249608	0.789	rs903989	chr5:178434434	C/T	cg21905437	chr5:178450457	ZNF879	0.49	6.51	0.39	4.45e-10	Pubertal anthropometrics;
SARC	cis	rs910316	0.737	rs424120	chr14:75482828	G/T	cg11812906	chr14:75593930	NEK9	-0.75	-10.03	-0.55	6.34e-20	Height;
SARC	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.31	-4.79	-0.3	2.98e-6	Total body bone mineral density;
SARC	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg26897989	chr16:1907736	C16orf73	-0.5	-4.74	-0.3	3.77e-6	Ankle injury;
SARC	cis	rs3540	0.960	rs2238325	chr15:91011262	C/T	cg22089800	chr15:90895588	ZNF774	-0.5	-5.66	-0.35	4.51e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg13939156	chr17:80058883	NA	0.46	7.17	0.43	9.82e-12	Life satisfaction;
SARC	cis	rs3018712	0.532	rs2510398	chr11:68421416	G/A	cg01657329	chr11:68192670	LRP5	0.58	5.35	0.33	2.07e-7	Total body bone mineral density;
SARC	cis	rs986417	0.688	rs1950317	chr14:61022789	T/G	cg27398547	chr14:60952738	C14orf39	0.85	8.56	0.49	1.52e-15	Gut microbiota (bacterial taxa);
SARC	cis	rs989128	0.600	rs739924	chr17:48631607	T/C	cg20467136	chr17:48638190	CACNA1G	0.46	5.36	0.33	2e-7	Type 2 diabetes;
SARC	cis	rs365132	0.934	rs149307	chr5:176471591	C/T	cg16309518	chr5:176445507	NA	-0.43	-5.49	-0.34	1.05e-7	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs9549260	0.709	rs4943795	chr13:41173433	C/T	cg21288729	chr13:41239152	FOXO1	-0.59	-6.68	-0.4	1.77e-10	Red blood cell count;
SARC	cis	rs10870270	0.956	rs11146425	chr10:133734261	C/T	cg26149184	chr10:133730230	NA	0.47	5.4	0.33	1.64e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs7766436	0.524	rs1317258	chr6:22513446	G/A	cg13666174	chr6:22585274	NA	-0.58	-6.56	-0.39	3.5e-10	Coronary artery disease;
SARC	cis	rs2200578	1.000	rs72954221	chr2:99899445	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.56	5.29	0.33	2.77e-7	IgG glycosylation;
SARC	cis	rs9583531	0.891	rs7999536	chr13:111382199	G/A	cg15841412	chr13:111365552	ING1	0.51	5.1	0.32	7.19e-7	Coronary artery disease;
SARC	cis	rs3820928	0.874	rs3752896	chr2:227886925	C/T	cg11843606	chr2:227700838	RHBDD1	-0.53	-6.49	-0.39	5.11e-10	Pulmonary function;
SARC	cis	rs2342371	0.545	rs7646174	chr3:196210808	T/C	cg15048948	chr3:196158458	UBXN7	-0.42	-5.46	-0.34	1.22e-7	Fat distribution (HIV);
SARC	trans	rs2018683	0.707	rs4722875	chr7:28969632	A/G	cg19402173	chr7:128379420	CALU	-0.5	-6.45	-0.39	6.55e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg16434002	chr17:42200994	HDAC5	-0.39	-4.82	-0.3	2.63e-6	Total body bone mineral density;
SARC	cis	rs2273669	0.588	rs78276890	chr6:109305299	G/A	cg05315195	chr6:109294784	ARMC2	-0.57	-5.24	-0.32	3.62e-7	Prostate cancer;
SARC	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg22484793	chr3:52261325	TLR9	0.29	4.73	0.3	3.83e-6	Bipolar disorder;
SARC	cis	rs2658782	0.704	rs2605614	chr11:93232745	A/G	cg15737290	chr11:93063684	CCDC67	0.74	8.72	0.5	5.19e-16	Pulmonary function decline;
SARC	cis	rs950776	0.518	rs12906846	chr15:78825295	G/A	cg06917634	chr15:78832804	PSMA4	0.91	14.24	0.68	1.6e-33	Sudden cardiac arrest;
SARC	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.46	-5.85	-0.36	1.7e-8	Personality dimensions;
SARC	cis	rs4889855	0.556	rs9897453	chr17:78634300	C/T	cg17956530	chr17:78667699	RPTOR	-0.47	-5.38	-0.33	1.83e-7	Fractional excretion of uric acid;
SARC	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg11843238	chr5:131593191	PDLIM4	0.41	5.45	0.34	1.29e-7	Acylcarnitine levels;
SARC	cis	rs9818758	0.607	rs71324929	chr3:49044713	C/T	cg07636037	chr3:49044803	WDR6	-0.82	-6.86	-0.41	5.99e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs11098499	0.863	rs3775843	chr4:120427844	T/C	cg09307838	chr4:120376055	NA	0.9	11.6	0.61	7.15e-25	Corneal astigmatism;
SARC	cis	rs2213920	0.915	rs980176	chr9:118260408	T/G	cg13918206	chr9:118159781	DEC1	0.75	6.18	0.38	2.84e-9	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs763121	0.853	rs5757187	chr22:39021522	A/G	cg06022373	chr22:39101656	GTPBP1	-0.88	-10.98	-0.58	6.82e-23	Menopause (age at onset);
SARC	cis	rs820218	0.798	rs2305529	chr17:73702253	G/A	cg01592526	chr17:73663357	RECQL5;SAP30BP	-0.6	-7.5	-0.44	1.31e-12	Rotator cuff tears;
SARC	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	13.25	0.66	3.03e-30	Chronic sinus infection;
SARC	cis	rs6582630	0.502	rs11520278	chr12:38359642	T/A	cg26384229	chr12:38710491	ALG10B	0.91	13.46	0.66	6.11e-31	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7429990	0.965	rs17785248	chr3:47672915	A/G	cg11946769	chr3:48343235	NME6	0.68	6.9	0.41	4.75e-11	Educational attainment (years of education);
SARC	cis	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg03060546	chr3:49711283	APEH	0.6	7.45	0.44	1.76e-12	Resting heart rate;
SARC	cis	rs4975616	0.869	rs455433	chr5:1336243	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.58	-8.69	-0.49	6.46e-16	Lung cancer;
SARC	cis	rs11864453	0.826	rs12325142	chr16:72138112	G/T	cg16558253	chr16:72132732	DHX38	-0.59	-9.62	-0.53	1.17e-18	Fibrinogen levels;
SARC	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg00933542	chr6:150070202	PCMT1	0.29	4.96	0.31	1.33e-6	Lung cancer;
SARC	cis	rs910316	0.737	rs175045	chr14:75475275	A/C	cg08847533	chr14:75593920	NEK9	-0.74	-9.49	-0.53	2.87e-18	Height;
SARC	trans	rs9650657	0.740	rs2277130	chr8:10677601	G/C	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.72	-0.4	1.37e-10	Neuroticism;
SARC	cis	rs13314892	0.689	rs79563518	chr3:69888242	C/A	cg17445875	chr3:69859618	MITF	-0.48	-4.95	-0.31	1.45e-6	QRS complex (12-leadsum);
SARC	cis	rs11997175	0.653	rs4268089	chr8:33626532	G/A	ch.8.33884649F	chr8:33765107	NA	0.52	6.72	0.4	1.41e-10	Body mass index;
SARC	cis	rs526231	0.543	rs28025	chr5:102537379	A/G	cg23492399	chr5:102201601	PAM	-0.51	-5.56	-0.34	7.21e-8	Primary biliary cholangitis;
SARC	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.4	-6.04	-0.37	5.89e-9	Total body bone mineral density;
SARC	cis	rs908922	0.627	rs1053588	chr1:152488063	C/T	cg09873164	chr1:152488093	CRCT1	0.66	8.86	0.5	2.13e-16	Hair morphology;
SARC	cis	rs73635312	0.850	rs80006116	chr10:8944623	G/A	cg24467326	chr10:9646929	NA	0.56	4.88	0.3	1.95e-6	Basal cell carcinoma;
SARC	cis	rs9931543	0.678	rs876245	chr16:56291212	A/G	cg02433656	chr16:56322654	GNAO1	0.38	5.43	0.34	1.39e-7	Subjective well-being;
SARC	cis	rs11697848	1.000	rs76488652	chr20:48510918	T/C	cg17849948	chr20:48532315	SPATA2	0.86	5.17	0.32	4.97e-7	Systemic lupus erythematosus;
SARC	cis	rs4727443	0.736	rs11761882	chr7:99581469	T/C	cg22004693	chr7:99632812	ZKSCAN1	0.66	8.84	0.5	2.37e-16	Interstitial lung disease;
SARC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg24503407	chr1:205819492	PM20D1	0.62	9.08	0.51	4.7e-17	Menarche (age at onset);
SARC	cis	rs9790314	1.000	rs1382426	chr3:161045933	G/A	cg03342759	chr3:160939853	NMD3	-0.57	-7.23	-0.43	6.78e-12	Morning vs. evening chronotype;
SARC	cis	rs9916302	0.904	rs8081338	chr17:37406139	C/T	cg00129232	chr17:37814104	STARD3	-0.61	-7.55	-0.44	9.5e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs13166103	0.657	rs62368203	chr5:57703412	C/A	cg10487770	chr5:57879443	RAB3C	0.52	5.58	0.34	6.7e-8	Type 2 diabetes (age of onset);
SARC	cis	rs4819052	0.679	rs2838859	chr21:46684517	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.52	6.37	0.39	1.01e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7829975	0.511	rs2921028	chr8:8340477	T/C	cg08975724	chr8:8085496	FLJ10661	0.47	6.17	0.37	2.97e-9	Mood instability;
SARC	cis	rs28719689	0.541	rs28376074	chr8:1274394	A/T	cg22761795	chr8:1265118	NA	0.56	5.32	0.33	2.42e-7	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4727027	0.866	rs3735311	chr7:148877737	T/C	cg23583168	chr7:148888333	NA	-0.71	-10.06	-0.55	5.26e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs10851411	0.730	rs2595938	chr15:42760159	A/G	cg21293051	chr15:42870591	STARD9	-0.46	-4.84	-0.3	2.33e-6	Glucose homeostasis traits;
SARC	cis	rs10751667	0.600	rs1128413	chr11:1010694	C/T	cg20946044	chr11:1010712	AP2A2	-0.43	-6.16	-0.37	3.21e-9	Alzheimer's disease (late onset);
SARC	cis	rs7953249	0.656	rs6489786	chr12:121397875	A/G	cg15155738	chr12:121454335	C12orf43	-0.45	-5.48	-0.34	1.13e-7	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	5.31	0.33	2.59e-7	Tonsillectomy;
SARC	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg16325326	chr1:53192061	ZYG11B	-0.94	-18.17	-0.77	1.55e-46	Monocyte count;
SARC	cis	rs6450176	1.000	rs4334836	chr5:53300835	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.67	-7.75	-0.45	2.78e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs5762813	0.566	rs5762818	chr22:29211435	C/T	cg15103426	chr22:29168792	CCDC117	0.61	5.94	0.36	1.03e-8	Hematocrit;Hemoglobin concentration;
SARC	cis	rs9920506	0.536	rs11072768	chr15:78929478	A/C	cg24631222	chr15:78858424	CHRNA5	-0.5	-5.77	-0.35	2.47e-8	Post bronchodilator FEV1;
SARC	cis	rs918629	0.798	rs7724599	chr5:95323378	T/C	cg16656078	chr5:95278638	ELL2	-0.6	-7.28	-0.43	5.04e-12	IgG glycosylation;
SARC	trans	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg21659725	chr3:3221576	CRBN	0.52	6.71	0.4	1.46e-10	Intelligence (multi-trait analysis);
SARC	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-7.06	-0.42	1.88e-11	Gut microbiome composition (summer);
SARC	trans	rs7615952	0.799	rs13315434	chr3:125641394	T/G	cg07211511	chr3:129823064	LOC729375	-0.95	-11.08	-0.59	3.52e-23	Blood pressure (smoking interaction);
SARC	cis	rs2180341	0.597	rs3798859	chr6:127663116	C/T	cg24812749	chr6:127587940	RNF146	0.59	7.26	0.43	5.75e-12	Breast cancer;
SARC	cis	rs2153535	0.542	rs915354	chr6:8440357	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	7.19	0.43	9e-12	Motion sickness;
SARC	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg04772025	chr11:68637568	NA	0.5	6.06	0.37	5.55e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs67460515	0.852	rs2404341	chr3:161092405	T/C	cg17135325	chr3:160939158	NMD3	0.61	7.53	0.44	1.1e-12	Parkinson's disease;
SARC	cis	rs2952156	1.000	rs2643195	chr17:37853118	A/G	cg00129232	chr17:37814104	STARD3	-0.66	-8.79	-0.5	3.27e-16	Asthma;
SARC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg22683308	chr4:1340831	KIAA1530	0.46	5.32	0.33	2.4e-7	Longevity;
SARC	trans	rs9329221	0.507	rs12678938	chr8:10016969	C/T	cg21775007	chr8:11205619	TDH	-0.56	-6.82	-0.41	7.88e-11	Neuroticism;
SARC	cis	rs3008870	1.000	rs2755246	chr1:67488984	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.84	10.27	0.56	1.22e-20	Lymphocyte percentage of white cells;
SARC	cis	rs881375	1.000	rs6478484	chr9:123652380	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.43	5.22	0.32	4.01e-7	Rheumatoid arthritis;
SARC	cis	rs8180040	1.000	rs295449	chr3:47375955	G/A	cg27129171	chr3:47204927	SETD2	0.68	9.56	0.53	1.72e-18	Colorectal cancer;
SARC	trans	rs6716963	0.585	rs11687224	chr2:194568323	A/G	cg03317400	chr1:40420823	MFSD2A	0.53	6.38	0.39	9.27e-10	Schizophrenia;
SARC	cis	rs2204008	0.715	rs11514282	chr12:38169056	G/T	cg13010199	chr12:38710504	ALG10B	0.78	10.64	0.57	8.61e-22	Bladder cancer;
SARC	cis	rs6429082	0.689	rs4659923	chr1:235709519	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.55	-6.27	-0.38	1.7e-9	Adiposity;
SARC	cis	rs2439831	1.000	rs2467739	chr15:43740196	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	10.69	0.57	5.72e-22	Lung cancer in ever smokers;
SARC	cis	rs6686643	0.762	rs9333432	chr1:165611159	A/G	cg19407955	chr1:165599744	MGST3	-0.59	-6.03	-0.37	6.22e-9	Total ventricular volume;
SARC	cis	rs1023500	1.000	rs3752591	chr22:42339516	A/G	cg17376030	chr22:41985996	PMM1	0.44	4.89	0.31	1.89e-6	Schizophrenia;
SARC	cis	rs477692	0.789	rs506915	chr10:131398005	A/G	cg05714579	chr10:131428358	MGMT	0.55	7.2	0.43	8.12e-12	Response to temozolomide;
SARC	cis	rs9549260	0.564	rs9549270	chr13:41284193	G/T	cg21288729	chr13:41239152	FOXO1	0.44	5.14	0.32	5.94e-7	Red blood cell count;
SARC	cis	rs3796352	1.000	rs3796352	chr3:52913279	C/T	cg15956490	chr3:53032818	SFMBT1	0.89	6.05	0.37	5.8e-9	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs4803468	0.934	rs11880674	chr19:41889423	A/T	cg09537434	chr19:41945824	ATP5SL	-0.93	-16.21	-0.73	4.56e-40	Height;
SARC	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg24675658	chr1:53192096	ZYG11B	0.67	9.98	0.55	9.19e-20	Monocyte count;
SARC	cis	rs11608355	0.960	rs10774691	chr12:109859830	C/T	cg19025524	chr12:109796872	NA	-0.4	-5.06	-0.31	8.4e-7	Neuroticism;
SARC	trans	rs61931739	0.500	rs1843736	chr12:34012080	C/G	cg26384229	chr12:38710491	ALG10B	0.85	12.17	0.62	1.1e-26	Morning vs. evening chronotype;
SARC	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg11764359	chr7:65958608	NA	-0.87	-12.4	-0.63	1.88e-27	Aortic root size;
SARC	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg26681399	chr22:41777847	TEF	0.43	4.85	0.3	2.24e-6	Vitiligo;
SARC	cis	rs4927850	1.000	rs6799572	chr3:195740408	C/T	cg01181863	chr3:195395398	SDHAP2	-0.58	-6.62	-0.4	2.41e-10	Pancreatic cancer;
SARC	cis	rs1008375	0.932	rs6841784	chr4:17626418	G/A	cg02297831	chr4:17616191	MED28	0.47	6.0	0.37	7.66e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7223966	1.000	rs8067064	chr17:61825984	A/C	cg00588841	chr17:61851480	DDX42;CCDC47	-0.68	-7.41	-0.44	2.32e-12	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9733	0.650	rs6698495	chr1:150564476	T/C	cg18016565	chr1:150552671	MCL1	-0.39	-5.44	-0.34	1.35e-7	Tonsillectomy;
SARC	cis	rs300703	0.542	rs415660	chr2:189972	C/T	cg21211680	chr2:198530	NA	0.41	4.77	0.3	3.19e-6	Blood protein levels;
SARC	cis	rs2387326	0.717	rs10829339	chr10:129943681	C/T	cg16087940	chr10:129947807	NA	-0.44	-5.48	-0.34	1.08e-7	Select biomarker traits;
SARC	cis	rs2933343	0.700	rs1683779	chr3:128642048	A/G	cg25356066	chr3:128598488	ACAD9	0.72	9.51	0.53	2.46e-18	IgG glycosylation;
SARC	cis	rs7592578	0.771	rs4439990	chr2:191398353	A/C	cg25963032	chr2:191064776	C2orf88	-0.46	-5.08	-0.32	7.8e-7	Diastolic blood pressure;
SARC	cis	rs35110281	0.782	rs2051407	chr21:45079245	T/C	cg21573476	chr21:45109991	RRP1B	-0.58	-8.42	-0.48	3.76e-15	Mean corpuscular volume;
SARC	cis	rs74181299	0.819	rs2723086	chr2:65297686	C/T	cg20592124	chr2:65290738	CEP68	0.48	7.05	0.42	1.96e-11	Pulse pressure;
SARC	cis	rs74544699	0.826	rs3756074	chr4:74848065	G/C	cg02530824	chr4:74847766	PF4	0.77	4.73	0.3	3.91e-6	Growth-regulated protein alpha levels;
SARC	cis	rs1448094	0.791	rs61929395	chr12:86331584	A/T	cg02569458	chr12:86230093	RASSF9	0.44	6.23	0.38	2.1e-9	Major depressive disorder;
SARC	cis	rs6141769	0.542	rs28456361	chr20:31299597	T/C	cg17884169	chr20:31446444	EFCAB8	-0.45	-4.83	-0.3	2.46e-6	Subjective well-being;
SARC	cis	rs9886651	0.935	rs4427135	chr8:128802021	A/C	cg24514600	chr8:128805414	PVT1	-0.46	-6.15	-0.37	3.29e-9	Epithelial ovarian cancer;Serous invasive ovarian cancer;
SARC	cis	rs72781680	0.611	rs7596820	chr2:24335036	G/C	cg08917208	chr2:24149416	ATAD2B	0.58	6.18	0.38	2.88e-9	Lymphocyte counts;
SARC	cis	rs2228479	0.702	rs62056087	chr16:89920383	C/A	cg00800038	chr16:89945340	TCF25	-0.82	-5.8	-0.35	2.19e-8	Skin colour saturation;
SARC	cis	rs8102137	0.672	rs12460611	chr19:30326600	A/G	cg27475126	chr19:30303651	CCNE1	-0.34	-4.72	-0.3	4.14e-6	Bladder cancer;
SARC	cis	rs3768617	0.706	rs11588675	chr1:182988052	C/T	cg13390022	chr1:182993471	LAMC1	0.32	4.76	0.3	3.37e-6	Fuchs's corneal dystrophy;
SARC	cis	rs7481584	0.669	rs12421922	chr11:3035070	A/G	cg05729581	chr11:3078854	CARS	0.54	7.12	0.42	1.34e-11	Calcium levels;
SARC	cis	rs2304069	0.954	rs9324638	chr5:149400718	A/G	cg12661370	chr5:149340060	SLC26A2	-0.6	-5.92	-0.36	1.13e-8	HIV-1 control;
SARC	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg04277193	chr17:41438351	NA	0.44	4.86	0.3	2.18e-6	Menopause (age at onset);
SARC	cis	rs1941023	0.584	rs950803	chr11:60152563	A/T	cg08716584	chr11:60157161	MS4A7	0.4	6.61	0.4	2.6200000000000003e-10	Congenital heart disease (maternal effect);
SARC	cis	rs1008375	0.900	rs6851783	chr4:17578469	A/G	cg27347728	chr4:17578864	LAP3	0.51	6.2	0.38	2.59e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7412746	0.611	rs3768018	chr1:150723747	T/C	cg13175981	chr1:150552382	MCL1	-0.54	-6.48	-0.39	5.32e-10	Melanoma;
SARC	cis	rs1784581	0.588	rs9346894	chr6:162430763	T/C	cg17173639	chr6:162384350	PARK2	0.52	6.59	0.4	2.96e-10	Itch intensity from mosquito bite;
SARC	cis	rs9660992	0.674	rs12122105	chr1:205256818	C/T	cg00857998	chr1:205179979	DSTYK	0.47	5.53	0.34	8.58e-8	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs11608355	0.545	rs11615336	chr12:109914802	C/A	cg05360138	chr12:110035743	NA	0.93	9.47	0.53	3.23e-18	Neuroticism;
SARC	cis	rs6912958	0.514	rs7767449	chr6:87887985	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.75	-11.58	-0.6	8.82e-25	Monocyte percentage of white cells;
SARC	cis	rs7246657	1.000	rs7247672	chr19:37743928	A/G	cg23950597	chr19:37808831	NA	-0.58	-5.34	-0.33	2.18e-7	Coronary artery calcification;
SARC	cis	rs4971059	0.507	rs11264321	chr1:155085898	C/A	cg22049894	chr1:155113146	DPM3	0.41	5.15	0.32	5.56e-7	Breast cancer;
SARC	cis	rs4319547	0.661	rs7398014	chr12:122943980	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.64	-7.58	-0.44	7.99e-13	Body mass index;
SARC	cis	rs17270561	0.609	rs9379789	chr6:25745579	A/G	cg17691542	chr6:26056736	HIST1H1C	0.61	7.36	0.43	3.06e-12	Iron status biomarkers;
SARC	cis	rs1215050	0.791	rs783960	chr4:98893437	A/G	cg05340658	chr4:99064831	C4orf37	-0.45	-6.12	-0.37	3.9e-9	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs4689388	0.926	rs11725500	chr4:6293919	C/G	cg25554036	chr4:6271136	WFS1	0.39	6.42	0.39	7.48e-10	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs74417235	0.610	rs35212808	chr5:154057808	A/G	cg08754654	chr5:154026448	NA	0.48	4.8	0.3	2.86e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
SARC	cis	rs9389248	0.737	rs12664956	chr6:135384188	T/C	cg22676075	chr6:135203613	NA	0.42	5.2	0.32	4.37e-7	High light scatter reticulocyte percentage of red cells;
SARC	trans	rs17685	0.672	rs1639623	chr7:75707951	A/G	cg19862616	chr7:65841803	NCRNA00174	0.63	7.77	0.45	2.42e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg27286337	chr10:134555280	INPP5A	0.67	7.85	0.46	1.49e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs1865760	0.566	rs3752420	chr6:26027135	G/A	cg02841227	chr6:26021843	HIST1H4A	0.39	4.76	0.3	3.4e-6	Height;
SARC	trans	rs1865760	0.929	rs9461224	chr6:25936402	G/T	cg26561196	chr16:68344680	SLC7A6OS;PRMT7	-0.55	-6.58	-0.4	3.09e-10	Height;
SARC	cis	rs7681440	0.835	rs6839608	chr4:90805493	T/C	cg02192967	chr4:90758406	SNCA	0.36	5.06	0.31	8.45e-7	Dementia with Lewy bodies;
SARC	cis	rs9818758	0.607	rs9847839	chr3:49289003	T/C	cg01304814	chr3:48885189	PRKAR2A	0.61	5.1	0.32	6.98e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs67460515	0.563	rs16831886	chr3:160799830	A/C	cg17135325	chr3:160939158	NMD3	0.64	7.44	0.44	1.91e-12	Parkinson's disease;
SARC	cis	rs62064224	0.606	rs61390192	chr17:30837447	C/T	cg25809561	chr17:30822961	MYO1D	0.46	6.67	0.4	1.86e-10	Schizophrenia;
SARC	cis	rs6542838	0.641	rs12478574	chr2:99476369	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-5.62	-0.35	5.53e-8	Fear of minor pain;
SARC	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.92	-13.1	-0.65	9.3e-30	Gut microbiome composition (summer);
SARC	cis	rs9290065	0.519	rs10513560	chr3:160710798	C/T	cg04691961	chr3:161091175	C3orf57	-0.49	-6.36	-0.38	1.04e-9	Kawasaki disease;
SARC	cis	rs1707322	0.721	rs28442079	chr1:46172001	A/G	cg06784218	chr1:46089804	CCDC17	0.36	6.17	0.37	2.95e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2304069	0.837	rs10041451	chr5:149385197	A/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.91	9.61	0.53	1.27e-18	HIV-1 control;
SARC	cis	rs2120243	0.539	rs1585080	chr3:157106982	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.42	5.4	0.33	1.66e-7	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs10078	0.571	rs890977	chr5:476910	T/C	cg26072250	chr5:443457	EXOC3;C5orf55	0.67	5.46	0.34	1.2e-7	Fat distribution (HIV);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg09164920	chr16:4526354	HMOX2;NMRAL1	0.56	7.16	0.42	1.07e-11	Breast cancer;
SARC	cis	rs62244186	0.659	rs62251383	chr3:44552421	A/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.44	5.46	0.34	1.21e-7	Depressive symptoms;
SARC	cis	rs34245846	0.769	rs12089942	chr1:154827522	T/C	cg24250549	chr1:154909240	PMVK	-0.44	-4.84	-0.3	2.39e-6	Atrial fibrillation;
SARC	cis	rs6120849	0.802	rs6087682	chr20:33752897	A/T	cg24642439	chr20:33292090	TP53INP2	0.49	4.82	0.3	2.57e-6	Protein C levels;
SARC	cis	rs6807306	1.000	rs60961670	chr3:167360410	T/G	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.53	5.27	0.33	3.18e-7	Mean platelet volume;
SARC	cis	rs1008375	0.966	rs10939755	chr4:17693755	T/C	cg27347728	chr4:17578864	LAP3	0.46	5.7	0.35	3.54e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs11088226	0.681	rs1015047	chr21:33949423	A/G	cg09050820	chr6:167586206	TCP10L2	0.6	6.83	0.41	7.5e-11	Gastritis;
SARC	cis	rs36051895	0.664	rs28378223	chr9:5113087	C/G	cg02405213	chr9:5042618	JAK2	-0.46	-5.63	-0.35	5.17e-8	Pediatric autoimmune diseases;
SARC	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg18904891	chr8:8559673	CLDN23	-0.48	-5.46	-0.34	1.23e-7	Obesity-related traits;
SARC	cis	rs72945132	0.714	rs57320340	chr11:70160010	G/C	cg00319359	chr11:70116639	PPFIA1	0.67	6.08	0.37	4.85e-9	Coronary artery disease;
SARC	cis	rs35955747	0.869	rs131213	chr22:31753849	C/T	cg13145458	chr22:31556086	RNF185	-0.43	-5.34	-0.33	2.22e-7	Neutrophil count;Sum basophil neutrophil counts;
SARC	cis	rs4243830	0.850	rs3761927	chr1:6601773	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.9	-9.21	-0.52	1.93e-17	Body mass index;
SARC	cis	rs11098499	0.954	rs6857105	chr4:120222298	C/G	cg09307838	chr4:120376055	NA	0.87	11.73	0.61	2.78e-25	Corneal astigmatism;
SARC	cis	rs2841277	0.741	rs9672139	chr14:105408182	T/G	cg14403583	chr14:105418241	AHNAK2	-0.67	-8.98	-0.51	9.6e-17	Rheumatoid arthritis;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg14940308	chr2:73144644	EMX1	-0.47	-6.37	-0.39	1.01e-9	Gallstone disease;
SARC	cis	rs763121	1.000	rs1946990	chr22:38912771	C/T	cg21395723	chr22:39101663	GTPBP1	-0.49	-5.89	-0.36	1.36e-8	Menopause (age at onset);
SARC	trans	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg08975724	chr8:8085496	FLJ10661	0.53	6.75	0.4	1.16e-10	Retinal vascular caliber;
SARC	cis	rs3741404	0.537	rs1123251	chr11:63917601	G/T	cg18225595	chr11:63971243	STIP1	-0.33	-5.17	-0.32	5.01e-7	Platelet count;
SARC	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg13206674	chr6:150067644	NUP43	0.45	5.88	0.36	1.38e-8	Lung cancer;
SARC	cis	rs6688613	0.729	rs7545806	chr1:166938555	T/C	cg07049167	chr1:166818506	POGK	0.5	5.2	0.32	4.39e-7	Refractive astigmatism;
SARC	cis	rs9467773	0.620	rs2504600	chr6:26648334	C/A	cg12292205	chr6:26970375	C6orf41	0.4	4.88	0.3	1.95e-6	Intelligence (multi-trait analysis);
SARC	cis	rs4713118	0.513	rs149944	chr6:28002818	C/T	cg26450541	chr6:28235208	ZNF187	0.46	4.86	0.3	2.14e-6	Parkinson's disease;
SARC	cis	rs7824557	0.736	rs10107010	chr8:11132712	C/A	cg21775007	chr8:11205619	TDH	-0.54	-6.45	-0.39	6.3e-10	Retinal vascular caliber;
SARC	cis	rs6088580	0.634	rs945673	chr20:32964265	C/A	cg24642439	chr20:33292090	TP53INP2	-0.65	-8.53	-0.49	1.85e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs7084402	1.000	rs36097682	chr10:60269738	G/A	cg07615347	chr10:60278583	BICC1	-0.58	-8.47	-0.49	2.84e-15	Refractive error;
SARC	cis	rs6088580	0.634	rs1890000	chr20:32968312	G/T	cg08999081	chr20:33150536	PIGU	-0.42	-6.43	-0.39	7.28e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs6138458	0.828	rs6138466	chr20:24997137	A/G	cg26195577	chr20:24973756	C20orf3	0.75	8.72	0.5	5.37e-16	Blood protein levels;
SARC	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg16606324	chr3:10149918	C3orf24	0.48	4.74	0.3	3.74e-6	Alzheimer's disease;
SARC	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	5.96	0.36	9.28e-9	Tonsillectomy;
SARC	cis	rs1018836	0.923	rs2213886	chr8:91554163	G/C	cg16814680	chr8:91681699	NA	-0.79	-12.6	-0.64	4.19e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs7617773	0.817	rs9834095	chr3:48327751	G/A	cg11946769	chr3:48343235	NME6	0.73	9.65	0.53	9.55e-19	Coronary artery disease;
SARC	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg21724239	chr8:58056113	NA	0.63	5.99	0.37	7.96e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7647973	1.000	rs74471041	chr3:49542543	T/G	cg06212747	chr3:49208901	KLHDC8B	-0.56	-5.94	-0.36	1.03e-8	Menarche (age at onset);
SARC	cis	rs6665290	0.669	rs3768424	chr1:227177444	A/G	cg14016676	chr1:227182615	CDC42BPA	0.35	5.13	0.32	6.02e-7	Myeloid white cell count;
SARC	cis	rs7621025	0.500	rs71630059	chr3:136581611	G/A	cg15507776	chr3:136538369	TMEM22	-0.99	-10.8	-0.58	2.64e-22	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
SARC	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	8.28	0.48	9.57e-15	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs34779708	0.897	rs34481177	chr10:35380913	C/T	cg03585969	chr10:35415529	CREM	0.41	5.01	0.31	1.1e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs7614311	0.636	rs66818634	chr3:63913222	G/A	cg22134162	chr3:63841271	THOC7	-0.47	-4.98	-0.31	1.24e-6	Lung function (FVC);Lung function (FEV1);
SARC	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg23958373	chr8:599963	NA	0.74	6.25	0.38	1.93e-9	IgG glycosylation;
SARC	cis	rs3816788	0.596	rs4872083	chr8:21770372	C/T	cg17168535	chr8:21777572	XPO7	0.72	9.7	0.54	6.55e-19	Lung cancer in ever smokers;
SARC	cis	rs9650657	0.740	rs12676417	chr8:10668634	C/T	cg21775007	chr8:11205619	TDH	0.39	4.73	0.3	3.83e-6	Neuroticism;
SARC	cis	rs2832191	0.933	rs2832236	chr21:30547602	C/T	cg24692254	chr21:30365293	RNF160	-0.75	-10.19	-0.56	2.14e-20	Dental caries;
SARC	cis	rs453301	0.686	rs11785819	chr8:8870378	T/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-5.48	-0.34	1.07e-7	Joint mobility (Beighton score);
SARC	cis	rs9911578	0.967	rs6503883	chr17:56917543	C/T	cg12560992	chr17:57184187	TRIM37	0.86	12.1	0.62	1.84e-26	Intelligence (multi-trait analysis);
SARC	cis	rs96067	0.805	rs4653160	chr1:36599547	C/T	cg24686825	chr1:36642396	MAP7D1	-0.42	-4.8	-0.3	2.8e-6	Corneal structure;
SARC	cis	rs9905820	0.620	rs757597	chr17:12641332	C/T	cg06013895	chr17:12332606	NA	-0.24	-5.0	-0.31	1.15e-6	Testosterone levels;
SARC	cis	rs72781680	0.851	rs72796397	chr2:24178211	T/A	cg06627628	chr2:24431161	ITSN2	-0.7	-6.71	-0.4	1.49e-10	Lymphocyte counts;
SARC	cis	rs10490913	0.836	rs2153953	chr10:120159880	A/G	cg23160142	chr10:120154512	NA	0.34	4.91	0.31	1.68e-6	Cancer;
SARC	cis	rs9815354	0.812	rs113144620	chr3:42008312	A/G	cg03022575	chr3:42003672	ULK4	0.67	5.8	0.36	2.14e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg19223190	chr17:80058835	NA	0.44	6.04	0.37	6.02e-9	Life satisfaction;
SARC	cis	rs924607	1.000	rs11746907	chr5:598224	G/A	cg09021430	chr5:549028	NA	0.34	6.32	0.38	1.3e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs7089973	0.604	rs17095662	chr10:116596071	A/C	cg08188268	chr10:116634841	FAM160B1	0.27	4.73	0.3	3.83e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs16921914	0.559	rs2985140	chr11:31315886	C/T	cg02090638	chr11:31391270	DNAJC24;DCDC1	0.42	5.27	0.33	3.08e-7	Bone mineral density (spine);
SARC	cis	rs11785400	1.000	rs4518642	chr8:143737396	T/C	cg10596483	chr8:143751796	JRK	0.65	8.84	0.5	2.33e-16	Schizophrenia;
SARC	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg18225595	chr11:63971243	STIP1	0.51	7.38	0.44	2.82e-12	Platelet count;
SARC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg03647317	chr4:187891568	NA	-0.35	-4.97	-0.31	1.27e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7208859	0.573	rs8064686	chr17:29134839	C/T	cg13385521	chr17:29058706	SUZ12P	0.89	7.85	0.46	1.49e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs2486288	0.656	rs6493145	chr15:45573862	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.53	-6.65	-0.4	2.03e-10	Glomerular filtration rate;
SARC	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg27211696	chr2:191398769	TMEM194B	0.5	6.87	0.41	5.93e-11	Pulse pressure;
SARC	cis	rs6860806	0.507	rs169256	chr5:131688533	A/G	cg24060327	chr5:131705240	SLC22A5	-0.62	-6.4	-0.39	8.55e-10	Breast cancer;
SARC	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg04277193	chr17:41438351	NA	0.44	4.73	0.3	3.83e-6	Menopause (age at onset);
SARC	cis	rs1073160	0.523	rs7955797	chr12:9047813	A/C	cg26114124	chr12:9217669	LOC144571	0.28	5.23	0.32	3.76e-7	Small cell lung carcinoma;
SARC	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg02733842	chr7:1102375	C7orf50	-0.59	-7.16	-0.42	1.05e-11	Bronchopulmonary dysplasia;
SARC	cis	rs3825932	0.778	rs11072817	chr15:79236815	G/A	cg25744700	chr15:79237217	CTSH	0.37	5.06	0.31	8.39e-7	Type 1 diabetes;
SARC	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.58	0.44	8.08e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs10782582	0.593	rs74968421	chr1:76233496	T/C	cg10523679	chr1:76189770	ACADM	-0.42	-5.12	-0.32	6.52e-7	Daytime sleep phenotypes;
SARC	cis	rs9344	0.837	rs1385874	chr11:69451580	G/A	cg09886342	chr11:69490314	ORAOV1	-0.37	-4.93	-0.31	1.6e-6	Immunoglobulin light chain (AL) amyloidosis (kidney involvement);Immunoglobulin light chain (AL) amyloidosis (serum Ig light chain only lambda/kappa based profile);Immunoglobulin light chain (AL) amyloidosis;Immunoglobulin light chain (AL) amyloidosis (heart involvement);Immunoglobulin light chain (AL) amyloidosis (serum Ig light chain only lambda based profile);Immunoglobulin light chain (AL) amyloidosis (serum Ig lambda profile);
SARC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg27588902	chr6:42928151	GNMT	-0.36	-5.4	-0.33	1.62e-7	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs593982	0.920	rs563427	chr11:65484569	A/G	cg08755490	chr11:65554678	OVOL1	0.85	7.95	0.46	7.92e-14	Atopic dermatitis;
SARC	cis	rs8114671	0.967	rs6142322	chr20:33788538	C/A	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.45	-0.34	1.28e-7	Height;
SARC	cis	rs524281	0.861	rs11607393	chr11:65875149	C/A	cg14036092	chr11:66035641	RAB1B	-0.51	-5.34	-0.33	2.16e-7	Electroencephalogram traits;
SARC	cis	rs34779708	0.966	rs1057108	chr10:35484949	T/G	cg03585969	chr10:35415529	CREM	0.4	4.99	0.31	1.21e-6	Inflammatory bowel disease;Crohn's disease;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg24047689	chr1:6614587	TAS1R1;NOL9	0.47	6.37	0.39	9.76e-10	Thyroid stimulating hormone;
SARC	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg17221315	chr6:27791827	HIST1H4J	0.43	4.75	0.3	3.59e-6	Cardiac Troponin-T levels;
SARC	cis	rs9513593	1.000	rs12875982	chr13:99850615	C/T	cg21788972	chr13:99853209	UBAC2	0.51	5.0	0.31	1.14e-6	Psoriasis;
SARC	cis	rs2070997	0.607	rs2855191	chr9:133708441	C/T	cg11464064	chr9:133710261	ABL1	-0.69	-6.56	-0.39	3.43e-10	Response to amphetamines;
SARC	cis	rs1983891	1.000	rs6458228	chr6:41543793	C/A	cg15051332	chr6:41514432	FOXP4	0.52	5.69	0.35	3.72e-8	Prostate cancer;
SARC	cis	rs6456156	0.565	rs6921588	chr6:167494397	G/T	cg23791538	chr6:167370224	RNASET2	-0.54	-6.89	-0.41	5.23e-11	Primary biliary cholangitis;
SARC	cis	rs72781680	0.898	rs72780188	chr2:24006065	G/A	cg08917208	chr2:24149416	ATAD2B	0.75	7.09	0.42	1.56e-11	Lymphocyte counts;
SARC	cis	rs367943	1.000	rs348957	chr5:112821178	C/T	cg12552261	chr5:112820674	MCC	0.45	5.19	0.32	4.65e-7	Type 2 diabetes;
SARC	trans	rs62103177	0.733	rs62103193	chr18:77629217	C/T	cg05926928	chr17:57297772	GDPD1	1.1	9.27	0.52	1.3e-17	Opioid sensitivity;
SARC	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg21782813	chr7:2030301	MAD1L1	0.38	6.22	0.38	2.22e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs12142240	0.660	rs112560929	chr1:46822297	A/G	cg10495392	chr1:46806563	NSUN4	0.65	6.8	0.41	8.89e-11	Menopause (age at onset);
SARC	cis	rs2153535	0.580	rs6926759	chr6:8456176	G/A	cg07606381	chr6:8435919	SLC35B3	0.76	10.68	0.57	6.14e-22	Motion sickness;
SARC	cis	rs6912958	1.000	rs9450701	chr6:88173167	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.35	-5.99	-0.37	8.01e-9	Monocyte percentage of white cells;
SARC	cis	rs8084125	0.832	rs62105179	chr18:74950858	A/G	cg26065057	chr18:74961000	GALR1	0.47	4.89	0.31	1.89e-6	Obesity-related traits;
SARC	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg06108461	chr20:60628389	TAF4	-0.92	-12.69	-0.64	2.14e-28	Body mass index;
SARC	cis	rs79149102	0.649	rs75985113	chr15:75379312	C/T	cg00629941	chr15:75287862	SCAMP5	-0.64	-4.91	-0.31	1.68e-6	Lung cancer;
SARC	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg15049968	chr18:44337910	ST8SIA5	-0.33	-5.14	-0.32	5.86e-7	Personality dimensions;
SARC	cis	rs1957429	0.614	rs117722345	chr14:65381464	C/G	cg23373153	chr14:65346875	NA	-1.03	-6.45	-0.39	6.24e-10	Pediatric areal bone mineral density (radius);
SARC	cis	rs10979	1.000	rs9484768	chr6:143887928	C/T	cg25407410	chr6:143891975	LOC285740	-0.62	-8.39	-0.48	4.84e-15	Hypospadias;
SARC	cis	rs6570726	0.846	rs870491	chr6:145933390	T/G	cg23711669	chr6:146136114	FBXO30	0.77	12.16	0.62	1.17e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9896052	0.580	rs8065142	chr17:73441060	G/A	cg04121983	chr17:73511085	CASKIN2	0.43	5.08	0.32	7.75e-7	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs7666738	0.830	rs10001479	chr4:98918764	A/G	cg05340658	chr4:99064831	C4orf37	-0.64	-8.31	-0.48	7.85e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9300255	0.602	rs1727296	chr12:123647725	G/C	cg00376283	chr12:123451042	ABCB9	0.58	6.9	0.41	4.89e-11	Neutrophil percentage of white cells;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg25883402	chr1:173837173	SNORD76;SNORD74;SNORD75;GAS5;ZBTB37	0.54	6.4	0.39	8.24e-10	Blood pressure;
SARC	cis	rs4481887	0.962	rs4244177	chr1:248468279	C/T	cg13385794	chr1:248469461	NA	0.36	5.59	0.34	6.44e-8	Common traits (Other);
SARC	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.38	4.71	0.3	4.2e-6	Tonsillectomy;
SARC	cis	rs6570726	0.791	rs427128	chr6:145865917	T/C	cg23711669	chr6:146136114	FBXO30	0.87	14.7	0.69	4.63e-35	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2072499	0.966	rs2253677	chr1:156171296	C/G	cg25208724	chr1:156163844	SLC25A44	-0.93	-12.81	-0.64	8.71e-29	Testicular germ cell tumor;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg04781839	chr16:1374937	UBE2I	0.44	6.24	0.38	2.09e-9	Schizophrenia;
SARC	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg24642844	chr7:1081250	C7orf50	-0.6	-6.11	-0.37	4.06e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs6089584	0.566	rs55881457	chr20:60608424	G/A	cg23262073	chr20:60523788	NA	-0.35	-5.33	-0.33	2.34e-7	Body mass index;
SARC	cis	rs4711350	0.911	rs9461907	chr6:33726990	A/C	cg07979401	chr6:33739406	LEMD2	-0.4	-4.77	-0.3	3.28e-6	Schizophrenia;
SARC	cis	rs295140	0.546	rs295134	chr2:201110223	A/G	cg17644776	chr2:200775616	C2orf69	-0.37	-4.97	-0.31	1.29e-6	QT interval;
SARC	cis	rs12612619	0.689	rs6711384	chr2:27280092	T/A	cg17611932	chr2:27505586	TRIM54	-0.27	-5.0	-0.31	1.12e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
SARC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg26338869	chr17:61819248	STRADA	0.78	10.5	0.57	2.32e-21	Prudent dietary pattern;
SARC	cis	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg13392534	chr20:3827558	MAVS	0.34	4.78	0.3	3.13e-6	Immature fraction of reticulocytes;
SARC	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg17376030	chr22:41985996	PMM1	-0.73	-9.01	-0.51	7.45e-17	Vitiligo;
SARC	cis	rs17666538	1.000	rs61064968	chr8:587933	T/C	cg02524346	chr8:600233	NA	-0.82	-6.5	-0.39	4.95e-10	IgG glycosylation;
SARC	cis	rs12950390	0.776	rs4793646	chr17:45853966	A/C	cg24803719	chr17:45855879	NA	-0.46	-7.55	-0.44	9.68e-13	IgG glycosylation;
SARC	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg21144161	chr5:423903	AHRR	0.31	4.84	0.3	2.39e-6	Cystic fibrosis severity;
SARC	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg18252515	chr7:66147081	NA	0.59	6.34	0.38	1.17e-9	Aortic root size;
SARC	cis	rs995000	0.965	rs1168046	chr1:62983693	A/C	cg06896770	chr1:63153194	DOCK7	-0.89	-12.89	-0.65	4.52e-29	Triglyceride levels;
SARC	cis	rs3741151	0.686	rs7944346	chr11:73244230	C/T	cg17517138	chr11:73019481	ARHGEF17	0.72	6.57	0.4	3.29e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs748404	0.631	rs7167882	chr15:43678663	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	5.86	0.36	1.61e-8	Lung cancer;
SARC	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.34	0.38	1.16e-9	Electroencephalogram traits;
SARC	cis	rs3820928	1.000	rs10204368	chr2:227774244	G/C	cg11843606	chr2:227700838	RHBDD1	-0.54	-6.81	-0.41	8.13e-11	Pulmonary function;
SARC	cis	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg27411982	chr8:10470053	RP1L1	-0.32	-5.32	-0.33	2.48e-7	Neuroticism;
SARC	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg20573242	chr4:122745356	CCNA2	0.66	8.25	0.48	1.16e-14	Type 2 diabetes;
SARC	cis	rs7615952	0.673	rs16834637	chr3:125605471	C/T	cg05084668	chr3:125655381	ALG1L	-0.77	-7.5	-0.44	1.34e-12	Blood pressure (smoking interaction);
SARC	cis	rs7700895	0.737	rs6556893	chr5:95226655	A/G	cg16656078	chr5:95278638	ELL2	-0.55	-6.74	-0.4	1.24e-10	IgG glycosylation;
SARC	cis	rs3126085	0.935	rs6587651	chr1:152193121	G/T	cg26876637	chr1:152193138	HRNR	0.5	5.83	0.36	1.79e-8	Atopic dermatitis;
SARC	trans	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg07211511	chr3:129823064	LOC729375	-0.56	-6.43	-0.39	7.18e-10	Blood pressure (smoking interaction);
SARC	cis	rs1707322	0.717	rs3014237	chr1:46090252	A/G	cg03146154	chr1:46216737	IPP	-0.5	-5.96	-0.36	9.35e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6964587	1.000	rs7811873	chr7:91751120	G/A	cg17063962	chr7:91808500	NA	0.95	16.01	0.72	2.02e-39	Breast cancer;
SARC	cis	rs7178572	1.000	rs34591043	chr15:77713586	A/G	cg22256960	chr15:77711686	NA	-0.56	-6.61	-0.4	2.65e-10	Type 2 diabetes;
SARC	cis	rs9398803	0.865	rs9398810	chr6:126815604	C/A	cg20229609	chr6:126660872	C6orf173	0.39	5.64	0.35	5.01e-8	Male-pattern baldness;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg03826535	chr12:113659136	TPCN1;IQCD	-0.56	-6.29	-0.38	1.58e-9	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg06618935	chr21:46677482	NA	-0.42	-5.65	-0.35	4.7e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs11122272	0.735	rs910823	chr1:231498766	G/T	cg06096015	chr1:231504339	EGLN1	0.41	6.08	0.37	4.91e-9	Hemoglobin concentration;
SARC	cis	rs3126085	0.736	rs11581433	chr1:152283236	T/C	cg26876637	chr1:152193138	HRNR	-0.5	-5.61	-0.34	5.74e-8	Atopic dermatitis;
SARC	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg08859206	chr1:53392774	SCP2	0.48	6.6	0.4	2.68e-10	Monocyte count;
SARC	cis	rs208520	0.661	rs7747492	chr6:66857788	A/T	cg07460842	chr6:66804631	NA	-1.07	-15.02	-0.7	4.15e-36	Exhaled nitric oxide output;
SARC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg22903471	chr2:27725779	GCKR	-0.49	-7.42	-0.44	2.21e-12	Total body bone mineral density;
SARC	cis	rs72766638	0.895	rs72766630	chr9:136926791	G/T	cg13789015	chr9:136890014	NCRNA00094	0.56	5.89	0.36	1.35e-8	Mosquito bite size;
SARC	cis	rs4319547	0.695	rs10773152	chr12:122910180	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.56	-6.29	-0.38	1.57e-9	Body mass index;
SARC	cis	rs9894429	1.000	rs7222241	chr17:79574714	C/G	cg18240062	chr17:79603768	NPLOC4	0.72	9.91	0.54	1.48e-19	Eye color traits;
SARC	cis	rs7005380	0.581	rs12679478	chr8:120916234	T/C	cg21744203	chr8:120868354	DSCC1	-0.48	-5.48	-0.34	1.08e-7	Interstitial lung disease;
SARC	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg26039829	chr8:22132926	PIWIL2	-0.47	-6.74	-0.4	1.23e-10	Hypertriglyceridemia;
SARC	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs3106136	0.933	rs34383543	chr4:95163792	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.39	-6.05	-0.37	5.83e-9	Capecitabine sensitivity;
SARC	cis	rs12311304	0.965	rs767201	chr12:15370878	A/G	cg08258403	chr12:15378311	NA	-0.45	-7.01	-0.42	2.49e-11	Behavioural disinhibition (generation interaction);
SARC	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg16405210	chr4:1374714	KIAA1530	-0.53	-6.45	-0.39	6.36e-10	Obesity-related traits;
SARC	cis	rs995000	0.895	rs597470	chr1:62917796	T/G	cg06896770	chr1:63153194	DOCK7	0.9	13.85	0.67	3.23e-32	Triglyceride levels;
SARC	cis	rs11718455	1.000	rs3856744	chr3:44045812	T/C	cg08738300	chr3:44038990	NA	0.54	5.75	0.35	2.78e-8	Coronary artery disease;
SARC	cis	rs6088580	0.634	rs2184836	chr20:32963369	A/G	cg08999081	chr20:33150536	PIGU	-0.44	-6.65	-0.4	2.07e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs3008870	0.755	rs1024230	chr1:67512920	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.38	4.75	0.3	3.51e-6	Lymphocyte percentage of white cells;
SARC	trans	rs9929218	0.954	rs4485355	chr16:68754730	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.61	-7.95	-0.46	7.83e-14	Colorectal cancer;
SARC	cis	rs9354308	0.933	rs2814131	chr6:66562051	T/A	cg07460842	chr6:66804631	NA	0.48	5.45	0.34	1.3e-7	Metabolite levels;
SARC	cis	rs9400467	0.506	rs77549436	chr6:111690730	T/G	cg15721981	chr6:111408429	SLC16A10	0.65	5.65	0.35	4.61e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs2072499	0.966	rs2842865	chr1:156159532	G/A	cg25208724	chr1:156163844	SLC25A44	0.92	12.68	0.64	2.29e-28	Testicular germ cell tumor;
SARC	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg05313129	chr8:58192883	C8orf71	-0.57	-6.37	-0.39	9.94e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs477692	0.935	rs554458	chr10:131427372	A/G	cg05714579	chr10:131428358	MGMT	0.56	7.41	0.44	2.32e-12	Response to temozolomide;
SARC	cis	rs28829049	0.508	rs4578242	chr1:19391565	G/C	cg13387374	chr1:19411106	UBR4	0.44	5.18	0.32	4.89e-7	QRS duration in Tripanosoma cruzi seropositivity;
SARC	cis	rs651907	0.535	rs34063583	chr3:101509948	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	5.91	0.36	1.22e-8	Colorectal cancer;
SARC	cis	rs16870629	0.541	rs2334955	chr5:1062444	A/G	cg17097710	chr5:1061055	SLC12A7	-0.49	-6.43	-0.39	7.13e-10	QT interval;
SARC	cis	rs34779708	0.931	rs7897457	chr10:35386040	A/G	cg03585969	chr10:35415529	CREM	0.4	5.07	0.32	7.94e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs11585357	1.000	rs11585357	chr1:17601165	C/T	cg08277548	chr1:17600880	PADI3	-0.52	-5.74	-0.35	2.88e-8	Hair shape;
SARC	cis	rs36051895	0.554	rs11789744	chr9:5134213	G/A	cg02405213	chr9:5042618	JAK2	-0.45	-5.36	-0.33	2.04e-7	Pediatric autoimmune diseases;
SARC	cis	rs509477	1.000	rs531558	chr18:32575286	A/T	cg23791764	chr18:32556832	MAPRE2	-0.57	-6.99	-0.42	2.93e-11	Cerebrospinal fluid AB1-42 levels;
SARC	cis	rs116095464	0.558	rs10065584	chr5:253997	G/A	cg22496380	chr5:211416	CCDC127	-0.97	-8.95	-0.51	1.13e-16	Breast cancer;
SARC	trans	rs1973993	0.672	rs17367240	chr1:96960057	G/A	cg10631902	chr5:14652156	NA	-0.42	-6.88	-0.41	5.46e-11	Weight;
SARC	cis	rs7940866	0.845	rs1991899	chr11:130801649	C/T	cg12179176	chr11:130786555	SNX19	-0.64	-9.13	-0.51	3.35e-17	Schizophrenia;
SARC	cis	rs10870270	1.000	rs72636963	chr10:133771271	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.47	-5.36	-0.33	1.99e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs9581857	0.615	rs79553479	chr13:28007862	G/A	cg01674679	chr13:27998804	GTF3A	-0.68	-5.31	-0.33	2.5e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg04267008	chr7:1944627	MAD1L1	-0.53	-6.09	-0.37	4.59e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg21724239	chr8:58056113	NA	0.72	6.49	0.39	5.22e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg11987759	chr7:65425863	GUSB	-0.6	-7.96	-0.46	7.64e-14	Aortic root size;
SARC	cis	rs765787	0.530	rs4775822	chr15:45527127	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.67e-7	Uric acid levels;
SARC	cis	rs2153535	0.935	rs11243254	chr6:8381242	C/T	cg23788917	chr6:8435910	SLC35B3	-0.41	-4.89	-0.3	1.9e-6	Motion sickness;
SARC	trans	rs36093844	0.752	rs56396016	chr11:85596390	C/A	cg27065003	chr5:122429449	PRDM6	-0.53	-6.53	-0.39	4.13e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs6674970	1.000	rs4970941	chr1:151068546	A/G	cg11822372	chr1:151115635	SEMA6C	0.44	5.35	0.33	2.15e-7	Childhood ear infection;
SARC	cis	rs9790314	0.747	rs7619011	chr3:160855676	A/G	cg03342759	chr3:160939853	NMD3	-0.48	-5.83	-0.36	1.81e-8	Morning vs. evening chronotype;
SARC	cis	rs9486719	0.656	rs4839826	chr6:96853616	A/G	cg06623918	chr6:96969491	KIAA0776	-0.61	-7.19	-0.43	9e-12	Migraine;Coronary artery disease;
SARC	cis	rs73206853	0.764	rs56123836	chr12:110999032	G/A	cg10860002	chr12:110842031	ANAPC7	0.6	5.11	0.32	6.71e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs1401999	1.000	rs6443927	chr3:183718864	A/G	cg01324343	chr3:183735012	ABCC5	0.66	13.2	0.65	4.53e-30	Anterior chamber depth;
SARC	cis	rs7264396	0.563	rs7264869	chr20:34346502	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	5.3	0.33	2.74e-7	Total cholesterol levels;
SARC	cis	rs12200560	0.505	rs211166	chr6:97068598	T/C	cg06623918	chr6:96969491	KIAA0776	0.48	5.43	0.33	1.45e-7	Coronary heart disease;
SARC	cis	rs3796352	1.000	rs13092352	chr3:52969697	C/T	cg27565382	chr3:53032988	SFMBT1	0.83	5.57	0.34	7.16e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs4805272	0.512	rs66830923	chr19:29321277	C/T	cg04546413	chr19:29218101	NA	0.56	6.46	0.39	6.2e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg07701084	chr6:150067640	NUP43	0.43	5.51	0.34	9.24e-8	Lung cancer;
SARC	cis	rs2153535	0.580	rs9328486	chr6:8528008	T/C	cg23788917	chr6:8435910	SLC35B3	0.62	8.31	0.48	8.11e-15	Motion sickness;
SARC	cis	rs6087990	0.735	rs910083	chr20:31378690	A/C	cg13636640	chr20:31349939	DNMT3B	0.79	12.72	0.64	1.65e-28	Ulcerative colitis;
SARC	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg25894440	chr7:65020034	NA	-0.74	-5.52	-0.34	9.22e-8	Diabetic kidney disease;
SARC	cis	rs607987	0.871	rs642126	chr11:30266370	G/A	cg06241208	chr11:30344200	C11orf46	-0.41	-4.9	-0.31	1.79e-6	Body mass index;
SARC	cis	rs453301	0.631	rs7843369	chr8:8797786	T/G	cg08975724	chr8:8085496	FLJ10661	-0.41	-4.91	-0.31	1.74e-6	Joint mobility (Beighton score);
SARC	cis	rs1865760	0.516	rs9379818	chr6:26023206	G/T	cg18357526	chr6:26021779	HIST1H4A	0.45	5.67	0.35	4.16e-8	Height;
SARC	cis	rs66561647	0.611	rs7004509	chr8:128973665	A/C	cg05480350	chr8:128972681	MIR1205;PVT1	0.4	5.65	0.35	4.77e-8	Hemoglobin concentration;
SARC	cis	rs7772486	0.754	rs6570708	chr6:145989428	C/T	cg23711669	chr6:146136114	FBXO30	-0.84	-13.96	-0.67	1.4e-32	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2370759	0.891	rs11592754	chr10:32619572	A/C	cg01819863	chr10:32635814	EPC1	0.96	7.21	0.43	7.99e-12	Sexual dysfunction (female);
SARC	cis	rs2070997	0.651	rs35218356	chr9:133669521	T/C	cg11464064	chr9:133710261	ABL1	0.59	5.67	0.35	4.12e-8	Response to amphetamines;
SARC	cis	rs367943	0.965	rs463249	chr5:112797430	A/C	cg12552261	chr5:112820674	MCC	-0.48	-5.46	-0.34	1.22e-7	Type 2 diabetes;
SARC	cis	rs944802	0.684	rs10757287	chr9:22143570	A/T	cg00491127	chr9:22154101	NA	-0.46	-5.26	-0.33	3.33e-7	White blood cell count;
SARC	cis	rs611744	0.810	rs619227	chr8:109215100	C/A	cg21045802	chr8:109455806	TTC35	0.5	6.19	0.38	2.64e-9	Dupuytren's disease;
SARC	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-8.89	-0.5	1.75e-16	Alzheimer's disease;
SARC	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg12311346	chr5:56204834	C5orf35	-0.55	-5.65	-0.35	4.71e-8	Initial pursuit acceleration;
SARC	cis	rs3126085	0.935	rs4845751	chr1:152208997	T/C	cg26876637	chr1:152193138	HRNR	0.46	5.37	0.33	1.88e-7	Atopic dermatitis;
SARC	cis	rs9393777	0.588	rs6933213	chr6:26493909	T/C	cg12826209	chr6:26865740	GUSBL1	0.79	7.68	0.45	4.43e-13	Intelligence (multi-trait analysis);
SARC	cis	rs11992162	0.591	rs35657308	chr8:11804402	G/A	cg12395012	chr8:11607386	GATA4	0.29	4.75	0.3	3.61e-6	Monocyte count;
SARC	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg04845466	chr2:27665079	KRTCAP3;NRBP1	0.33	4.89	0.31	1.88e-6	Total body bone mineral density;
SARC	cis	rs5758659	0.714	rs5758589	chr22:42518382	A/G	cg15128208	chr22:42549153	NA	0.36	5.16	0.32	5.29e-7	Cognitive function;
SARC	cis	rs7011049	1.000	rs72648403	chr8:53854848	T/C	cg26025543	chr8:53854495	NA	0.6	5.37	0.33	1.91e-7	Systolic blood pressure;
SARC	cis	rs9303401	0.659	rs9303399	chr17:56672309	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	11.78	0.61	2.02e-25	Cognitive test performance;
SARC	cis	rs6815814	0.950	rs5743557	chr4:38806827	G/A	cg06935464	chr4:38784597	TLR10	0.63	6.31	0.38	1.41e-9	Breast cancer;
SARC	cis	rs2153535	0.601	rs969420	chr6:8451966	T/A	cg21535247	chr6:8435926	SLC35B3	0.55	6.84	0.41	6.72e-11	Motion sickness;
SARC	cis	rs6665290	0.669	rs3768423	chr1:227177293	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.02	-20.85	-0.81	3.42e-55	Myeloid white cell count;
SARC	cis	rs3892630	0.588	rs12610342	chr19:33250690	C/T	cg22980127	chr19:33182716	NUDT19	1.09	11.24	0.59	1.03e-23	Red blood cell traits;
SARC	cis	rs526821	0.553	rs295597	chr11:55470003	T/C	cg04317927	chr11:55418816	OR4S2	0.41	5.68	0.35	4.07e-8	Pediatric bone mineral density (spine);
SARC	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg13395646	chr4:1353034	KIAA1530	-0.48	-5.78	-0.35	2.39e-8	Obesity-related traits;
SARC	cis	rs9303280	0.742	rs11557466	chr17:38024626	C/T	cg20243544	chr17:37824526	PNMT	0.43	5.59	0.34	6.33e-8	Self-reported allergy;
SARC	cis	rs1568889	0.838	rs10835299	chr11:28277693	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.88	-15.1	-0.7	2.2e-36	Bipolar disorder;
SARC	cis	rs1355223	0.506	rs1828299	chr11:34870418	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.49	-6.24	-0.38	2.02e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs2991971	0.782	rs10789463	chr1:45927848	C/A	cg24296786	chr1:45957014	TESK2	-0.58	-7.95	-0.46	7.86e-14	High light scatter reticulocyte count;
SARC	cis	rs8523	0.804	rs4711171	chr6:11074347	C/T	cg13562911	chr6:11044106	ELOVL2	0.46	6.24	0.38	2.05e-9	Red blood cell fatty acid levels;
SARC	cis	rs3020736	0.500	rs9620026	chr22:42498578	C/T	cg15557168	chr22:42548783	NA	0.35	4.8	0.3	2.85e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs4957048	0.577	rs56294732	chr5:568144	T/C	cg07777115	chr5:623756	CEP72	-0.56	-5.16	-0.32	5.32e-7	Ulcerative colitis;
SARC	cis	rs9916302	0.706	rs8073907	chr17:37424149	C/T	cg07936489	chr17:37558343	FBXL20	-0.75	-9.02	-0.51	7.13e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg24642844	chr7:1081250	C7orf50	-0.59	-6.06	-0.37	5.31e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs3540	0.533	rs7495080	chr15:91056681	G/A	cg22089800	chr15:90895588	ZNF774	-0.57	-7.27	-0.43	5.26e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.78	-0.5	3.56e-16	Alzheimer's disease;
SARC	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.46	-5.77	-0.35	2.56e-8	Personality dimensions;
SARC	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.99	11.43	0.6	2.69e-24	Platelet count;
SARC	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg11644478	chr21:40555479	PSMG1	1.05	14.79	0.7	2.43e-35	Cognitive function;
SARC	cis	rs2204008	0.744	rs67889662	chr12:38327042	T/A	cg13010199	chr12:38710504	ALG10B	0.79	10.69	0.57	5.92e-22	Bladder cancer;
SARC	cis	rs4919694	1.000	rs11191525	chr10:104793435	G/C	cg04362960	chr10:104952993	NT5C2	0.66	5.46	0.34	1.21e-7	Arsenic metabolism;
SARC	cis	rs11764590	0.671	rs12669370	chr7:2081914	G/A	cg23043544	chr7:2124092	MAD1L1	-0.37	-4.99	-0.31	1.16e-6	Neuroticism;
SARC	cis	rs3812049	0.826	rs17764730	chr5:127357526	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.87	9.34	0.52	8.1e-18	Lymphocyte counts;Red cell distribution width;
SARC	cis	rs1580019	0.534	rs13237495	chr7:32560687	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.98	17.96	0.76	7.46e-46	Cognitive ability;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg06831761	chr7:104885108	SRPK2	0.51	6.27	0.38	1.77e-9	Blood pressure;
SARC	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg24250549	chr1:154909240	PMVK	0.83	12.34	0.63	2.91e-27	Prostate cancer;
SARC	cis	rs2976388	0.609	rs1560986	chr8:143789775	T/C	cg06565975	chr8:143823917	SLURP1	0.32	5.53	0.34	8.39e-8	Urinary tract infection frequency;
SARC	cis	rs2235642	0.750	rs763152	chr16:1658056	T/C	cg09065629	chr16:1709722	CRAMP1L	0.35	4.89	0.3	1.89e-6	Coronary artery disease;
SARC	cis	rs897080	0.515	rs1065783	chr2:44660741	T/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	5.82	0.36	1.9e-8	Height;
SARC	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg22800045	chr5:56110881	MAP3K1	0.42	5.04	0.31	9.15e-7	Coronary artery disease;
SARC	cis	rs12579753	0.912	rs4417392	chr12:82158722	C/A	cg07988820	chr12:82153109	PPFIA2	-0.59	-7.06	-0.42	1.87e-11	Resting heart rate;
SARC	cis	rs636291	0.517	rs670666	chr1:10549380	C/T	cg07384165	chr1:10488281	NA	0.43	5.9	0.36	1.27e-8	Prostate cancer;
SARC	cis	rs1003719	0.591	rs2835633	chr21:38525019	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-8.08	-0.47	3.42e-14	Eye color traits;
SARC	cis	rs508618	0.697	rs7534248	chr1:231554531	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.55	6.61	0.4	2.52e-10	Red blood cell count;
SARC	cis	rs6831352	0.918	rs28987088	chr4:100059139	T/C	cg12011299	chr4:100065546	ADH4	-0.34	-5.74	-0.35	2.95e-8	Alcohol dependence;
SARC	cis	rs16850073	0.641	rs11730667	chr4:74600211	C/T	cg26611070	chr4:75482238	AREG	-0.3	-4.8	-0.3	2.8e-6	Granulocyte percentage of myeloid white cells;Blood protein levels;Monocyte percentage of white cells;Sum neutrophil eosinophil counts;White blood cell count;
SARC	cis	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg06636001	chr8:8085503	FLJ10661	0.53	7.16	0.42	1.04e-11	Joint mobility (Beighton score);
SARC	trans	rs61931739	0.500	rs56404399	chr12:34543101	A/G	cg26384229	chr12:38710491	ALG10B	0.91	13.78	0.67	5.4e-32	Morning vs. evening chronotype;
SARC	cis	rs13095912	1.000	rs7374856	chr3:185311964	A/C	cg11274856	chr3:185301563	NA	0.35	4.81	0.3	2.76e-6	Systolic blood pressure;
SARC	cis	rs599083	0.530	rs491347	chr11:68169688	G/A	cg01657329	chr11:68192670	LRP5	0.46	6.25	0.38	1.97e-9	Bone mineral density (spine);
SARC	cis	rs10982256	1.000	rs10982256	chr9:117260834	A/G	cg15903421	chr9:117267460	DFNB31	0.4	5.42	0.33	1.48e-7	Bipolar disorder;
SARC	cis	rs67311347	0.544	rs6769627	chr3:40327845	G/A	cg24209194	chr3:40518798	ZNF619	0.51	6.75	0.4	1.18e-10	Renal cell carcinoma;
SARC	cis	rs9902453	0.791	rs3115100	chr17:28045744	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	6.98	0.42	3.03e-11	Coffee consumption (cups per day);
SARC	cis	rs11608355	0.545	rs11613021	chr12:109897998	T/G	cg05360138	chr12:110035743	NA	0.92	9.65	0.53	9.69e-19	Neuroticism;
SARC	cis	rs733592	0.929	rs4760678	chr12:48461581	T/C	cg24011408	chr12:48396354	COL2A1	-0.46	-6.12	-0.37	3.97e-9	Plateletcrit;
SARC	cis	rs2832077	0.527	rs11088095	chr21:30223188	A/T	cg08807101	chr21:30365312	RNF160	-0.55	-6.29	-0.38	1.53e-9	Cognitive test performance;
SARC	cis	rs12044355	0.858	rs12040259	chr1:231826253	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.6	8.0	0.46	5.82e-14	Alzheimer's disease;
SARC	cis	rs9733	0.818	rs11204702	chr1:150663507	C/A	cg15448220	chr1:150897856	SETDB1	-0.36	-4.72	-0.3	4.13e-6	Tonsillectomy;
SARC	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg20887711	chr4:1340912	KIAA1530	0.4	4.75	0.3	3.48e-6	Longevity;
SARC	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg11987759	chr7:65425863	GUSB	0.48	5.94	0.36	1.06e-8	Aortic root size;
SARC	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg26924012	chr15:45694286	SPATA5L1	0.77	10.93	0.58	9.88e-23	Homoarginine levels;
SARC	cis	rs2486288	0.656	rs1060896	chr15:45554267	C/A	cg15395560	chr15:45543142	SLC28A2	0.29	5.67	0.35	4.18e-8	Glomerular filtration rate;
SARC	cis	rs3733585	0.648	rs13125029	chr4:9982029	A/G	cg11266682	chr4:10021025	SLC2A9	0.35	5.94	0.36	1.05e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs2439831	0.867	rs7170489	chr15:43636651	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.76	7.92	0.46	9.46e-14	Lung cancer in ever smokers;
SARC	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg24829409	chr8:58192753	C8orf71	-0.63	-6.45	-0.39	6.46e-10	Developmental language disorder (linguistic errors);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg22094205	chr11:74109076	PGM2L1	0.49	6.49	0.39	5.12e-10	Chemerin levels;
SARC	cis	rs12930096	1.000	rs12921437	chr16:11680148	T/C	cg07439791	chr16:11680400	LITAF	0.57	5.65	0.35	4.59e-8	QT interval;
SARC	cis	rs7208859	0.623	rs7503542	chr17:29073830	A/C	cg13385521	chr17:29058706	SUZ12P	0.88	7.94	0.46	8.37e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9660992	0.710	rs1668867	chr1:205240251	C/T	cg21545522	chr1:205238299	TMCC2	0.46	6.37	0.39	9.77e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs9300255	0.506	rs11057251	chr12:123791227	A/G	cg00376283	chr12:123451042	ABCB9	-0.56	-6.84	-0.41	6.72e-11	Neutrophil percentage of white cells;
SARC	cis	rs4900538	0.821	rs7012	chr14:102814945	C/T	cg18135206	chr14:102964638	TECPR2	-0.57	-7.52	-0.44	1.2e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs16976116	0.901	rs28489312	chr15:55494048	A/C	cg11288833	chr15:55489084	RSL24D1	0.63	6.13	0.37	3.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs546131	0.928	rs558967	chr11:34827168	T/A	cg06937548	chr11:34938143	PDHX;APIP	0.51	6.59	0.4	2.82e-10	Lung disease severity in cystic fibrosis;
SARC	cis	rs1580019	0.713	rs2122632	chr7:32524686	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.91	-14.94	-0.7	7.48e-36	Cognitive ability;
SARC	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg15049968	chr18:44337910	ST8SIA5	-0.38	-6.12	-0.37	3.84e-9	Personality dimensions;
SARC	cis	rs1707322	0.721	rs4559551	chr1:46167533	T/C	cg06784218	chr1:46089804	CCDC17	0.36	6.25	0.38	1.91e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs739401	0.572	rs739399	chr11:3016452	A/G	cg05729581	chr11:3078854	CARS	-0.52	-6.84	-0.41	7.04e-11	Longevity;
SARC	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg24642844	chr7:1081250	C7orf50	-0.49	-5.73	-0.35	3.06e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg16101101	chr1:153643504	ILF2	-0.6	-6.33	-0.38	1.26e-9	Lung cancer in ever smokers;
SARC	cis	rs12701220	0.744	rs10499317	chr7:1012103	C/G	cg02733842	chr7:1102375	C7orf50	-0.38	-5.18	-0.32	4.73e-7	Bronchopulmonary dysplasia;
SARC	cis	rs909674	0.775	rs4821896	chr22:39833437	T/C	cg11247378	chr22:39784982	NA	-0.31	-4.73	-0.3	3.97e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs4805272	0.512	rs4805278	chr19:29336664	C/T	cg14983838	chr19:29218262	NA	0.55	5.97	0.36	8.83e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.34	-5.33	-0.33	2.27e-7	Longevity;Endometriosis;
SARC	cis	rs1318878	0.565	rs73057225	chr12:15484882	G/C	cg08258403	chr12:15378311	NA	0.49	6.9	0.41	4.76e-11	Intelligence (multi-trait analysis);
SARC	cis	rs4481887	1.000	rs10788775	chr1:248471945	C/G	cg01631408	chr1:248437212	OR2T33	-0.44	-5.49	-0.34	1.03e-7	Common traits (Other);
SARC	cis	rs9814567	0.752	rs6779294	chr3:134329821	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.51	-6.61	-0.4	2.53e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs644799	1.000	rs12291986	chr11:95523030	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	14.28	0.68	1.22e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9467773	0.620	rs2451711	chr6:26663110	A/G	cg12292205	chr6:26970375	C6orf41	0.4	4.9	0.31	1.77e-6	Intelligence (multi-trait analysis);
SARC	trans	rs1814175	0.817	rs2866545	chr11:49630824	A/C	cg15704280	chr7:45808275	SEPT13	-0.96	-17.42	-0.75	4.5e-44	Height;
SARC	cis	rs2997447	0.501	rs2783635	chr1:26434527	T/C	cg19633962	chr1:26362018	EXTL1	-0.59	-5.38	-0.33	1.81e-7	QRS complex (12-leadsum);
SARC	cis	rs1878931	0.535	rs7188903	chr16:3412861	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.64	7.09	0.42	1.59e-11	Body mass index (adult);
SARC	cis	rs1552244	0.688	rs113940455	chr3:10014165	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-8.79	-0.5	3.33e-16	Alzheimer's disease;
SARC	cis	rs1580019	0.587	rs6968990	chr7:32552159	C/T	cg14728415	chr7:32535168	LSM5;AVL9	-0.53	-6.79	-0.41	9.42e-11	Cognitive ability;
SARC	cis	rs995000	0.965	rs3850634	chr1:63050598	T/G	cg06896770	chr1:63153194	DOCK7	0.98	15.38	0.71	2.54e-37	Triglyceride levels;
SARC	cis	rs1707322	0.686	rs1547924	chr1:46085112	C/T	cg03146154	chr1:46216737	IPP	0.5	6.03	0.37	6.44e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs317689	0.513	rs317659	chr12:69686132	T/A	cg20891283	chr12:69753455	YEATS4	0.4	4.96	0.31	1.34e-6	Response to diuretic therapy;
SARC	trans	rs11039571	0.544	rs7947811	chr11:48167738	C/T	cg15704280	chr7:45808275	SEPT13	-0.64	-6.44	-0.39	6.59e-10	D-dimer levels;
SARC	cis	rs7582720	1.000	rs72932572	chr2:203859391	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg26338869	chr17:61819248	STRADA	0.81	10.73	0.57	4.42e-22	Prudent dietary pattern;
SARC	cis	rs6840360	1.000	rs6834095	chr4:152603278	C/T	cg22705602	chr4:152727874	NA	-0.4	-6.9	-0.41	4.76e-11	Intelligence (multi-trait analysis);
SARC	cis	rs2730245	1.000	rs2527199	chr7:158737113	G/A	cg00815399	chr7:158750607	NA	-0.34	-4.8	-0.3	2.84e-6	Height;
SARC	cis	rs7552404	0.731	rs931507	chr1:76401577	G/A	cg22875332	chr1:76189707	ACADM	-0.4	-4.97	-0.31	1.32e-6	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs736801	0.740	rs17622378	chr5:131778452	A/G	cg07395648	chr5:131743802	NA	-0.42	-4.78	-0.3	3.09e-6	Breast cancer;Mosquito bite size;
SARC	cis	rs9486719	0.843	rs3860231	chr6:97036563	G/A	cg06623918	chr6:96969491	KIAA0776	-0.77	-9.37	-0.52	6.76e-18	Migraine;Coronary artery disease;
SARC	cis	rs9611519	0.580	rs7286603	chr22:41440061	T/C	cg03806693	chr22:41940476	POLR3H	-0.6	-7.97	-0.46	6.92e-14	Neuroticism;
SARC	cis	rs12464559	0.522	rs4664498	chr2:152575417	A/G	cg01189475	chr2:152685088	ARL5A	0.62	5.23	0.32	3.69e-7	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs6912958	0.967	rs9450688	chr6:88159276	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.62	-8.71	-0.5	5.53e-16	Monocyte percentage of white cells;
SARC	cis	rs778371	0.871	rs2675954	chr2:233750627	C/G	cg20388707	chr2:233749442	NGEF	0.33	4.86	0.3	2.2e-6	Schizophrenia;
SARC	cis	rs6831352	0.918	rs7694646	chr4:100059732	T/A	cg12011299	chr4:100065546	ADH4	-0.35	-5.75	-0.35	2.8e-8	Alcohol dependence;
SARC	cis	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg13072238	chr3:49761600	GMPPB	-0.41	-5.39	-0.33	1.7e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9840812	0.773	rs61789601	chr3:135954979	C/T	cg15507776	chr3:136538369	TMEM22	-0.5	-4.89	-0.31	1.84e-6	Fibrinogen levels;
SARC	cis	rs10791323	0.604	rs2723605	chr11:133711241	C/G	cg15485101	chr11:133734466	NA	0.33	5.07	0.32	8.08e-7	Childhood ear infection;
SARC	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg13175981	chr1:150552382	MCL1	-0.54	-6.9	-0.41	4.97e-11	Tonsillectomy;
SARC	cis	rs7666738	0.830	rs969049	chr4:98988857	C/T	cg05340658	chr4:99064831	C4orf37	0.65	9.02	0.51	7.08e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9815354	0.812	rs35263917	chr3:41952852	T/C	cg03022575	chr3:42003672	ULK4	0.7	5.7	0.35	3.66e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2289583	0.500	rs67168917	chr15:75391494	G/T	cg17294928	chr15:75287854	SCAMP5	-0.49	-6.41	-0.39	8.01e-10	Systemic lupus erythematosus;
SARC	cis	rs7432375	0.610	rs60574021	chr3:136520281	C/G	cg15507776	chr3:136538369	TMEM22	0.62	7.63	0.45	5.94e-13	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	cis	rs4761669	0.876	rs7972350	chr12:95160605	G/T	cg21533806	chr12:95267307	NA	-0.43	-5.47	-0.34	1.13e-7	Common carotid intima-media thickness in HIV infection;
SARC	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg12064134	chr16:90016061	DEF8	-0.49	-5.06	-0.31	8.35e-7	Skin colour saturation;
SARC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg03188948	chr7:1209495	NA	0.43	5.61	0.34	5.75e-8	Longevity;Endometriosis;
SARC	cis	rs478304	0.654	rs10896032	chr11:65459419	C/A	cg27068330	chr11:65405492	SIPA1	-0.42	-4.86	-0.3	2.18e-6	Acne (severe);
SARC	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg02592271	chr2:27665507	KRTCAP3	-0.37	-5.62	-0.35	5.49e-8	Total body bone mineral density;
SARC	cis	rs637571	0.522	rs493899	chr11:65747952	A/C	cg04055107	chr11:65626734	MUS81;CFL1	0.4	4.99	0.31	1.16e-6	Eosinophil percentage of white cells;
SARC	cis	rs9818758	0.607	rs34326553	chr3:49134429	A/G	cg07636037	chr3:49044803	WDR6	-0.78	-6.71	-0.4	1.47e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs1322639	0.668	rs9766666	chr6:169613541	G/T	cg03254818	chr6:169586852	NA	0.49	6.06	0.37	5.4e-9	Pulse pressure;
SARC	cis	rs7523050	0.730	rs12079547	chr1:109469314	A/C	cg22040431	chr1:109419606	GPSM2	0.7	4.98	0.31	1.25e-6	Fat distribution (HIV);
SARC	cis	rs8077889	0.917	rs72836553	chr17:41909851	A/G	cg26893861	chr17:41843967	DUSP3	0.92	11.34	0.6	4.92e-24	Triglycerides;
SARC	cis	rs6867032	0.958	rs4463207	chr5:2017118	G/T	cg26168224	chr5:2018326	NA	0.93	15.03	0.7	3.92e-36	Gut microbiome composition (winter);
SARC	cis	rs9393692	0.905	rs9393693	chr6:26277408	C/A	cg05868516	chr6:26286170	HIST1H4H	0.56	7.37	0.43	2.9e-12	Educational attainment;
SARC	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.69	0.57	5.65e-22	Prudent dietary pattern;
SARC	cis	rs7623687	0.892	rs73074830	chr3:49577017	A/C	cg19401529	chr3:49056140	DALRD3	0.64	5.0	0.31	1.11e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
SARC	cis	rs4974559	0.585	rs1680025	chr4:1265477	T/C	cg02980000	chr4:1222292	CTBP1	-0.59	-5.77	-0.35	2.46e-8	Systolic blood pressure;
SARC	cis	rs9547692	1.000	rs1328042	chr13:37466947	G/A	cg01493522	chr13:37497338	NA	-0.43	-4.81	-0.3	2.68e-6	Coronary artery disease;
SARC	cis	rs2916247	1.000	rs6982094	chr8:93047827	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.58	-6.03	-0.37	6.49e-9	Intelligence (multi-trait analysis);
SARC	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg12463550	chr7:65579703	CRCP	-0.45	-5.42	-0.33	1.48e-7	Aortic root size;
SARC	cis	rs3857067	0.806	rs10212784	chr4:95101638	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.07	-0.32	8.24e-7	QT interval;
SARC	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg08219700	chr8:58056026	NA	0.62	5.14	0.32	5.76e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg09439260	chr3:16645784	DAZL	0.52	7.19	0.43	8.49e-12	Thyroid stimulating hormone;
SARC	trans	rs1814175	0.817	rs1794162	chr11:49899506	A/C	cg03929089	chr4:120376271	NA	-0.88	-13.98	-0.68	1.18e-32	Height;
SARC	cis	rs11098499	0.562	rs13101722	chr4:120555975	C/A	cg09307838	chr4:120376055	NA	-0.7	-9.57	-0.53	1.7e-18	Corneal astigmatism;
SARC	cis	rs11608355	0.545	rs2302703	chr12:109898832	G/A	cg05360138	chr12:110035743	NA	0.92	9.65	0.53	9.69e-19	Neuroticism;
SARC	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.52	-6.62	-0.4	2.51e-10	Lymphocyte counts;
SARC	cis	rs2635047	0.682	rs4534948	chr18:44793419	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	6.28	0.38	1.6e-9	Educational attainment;
SARC	cis	rs1395	0.778	rs17005956	chr2:27451099	C/T	cg21747090	chr2:27597821	SNX17	-0.47	-5.54	-0.34	8.12e-8	Blood metabolite levels;
SARC	cis	rs11112613	0.713	rs73184082	chr12:105951748	T/C	cg03607813	chr12:105948248	NA	0.53	7.5	0.44	1.34e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs929354	0.772	rs6957939	chr7:156978485	T/C	cg05182265	chr7:156933206	UBE3C	-0.33	-5.02	-0.31	1.03e-6	Body mass index;
SARC	cis	rs7223966	1.000	rs7211213	chr17:61769456	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.48	-5.39	-0.33	1.73e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9682041	0.627	rs34392658	chr3:170091584	C/T	cg11886554	chr3:170076028	SKIL	0.67	6.54	0.39	3.8e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs637571	0.565	rs633800	chr11:65638719	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.52	-6.89	-0.41	5.14e-11	Eosinophil percentage of white cells;
SARC	cis	rs7223966	0.960	rs11659013	chr17:61869559	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.52	-5.5	-0.34	1.02e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs66569888	0.523	rs4522599	chr2:106926004	G/C	cg16099169	chr2:106886729	NA	0.42	4.76	0.3	3.33e-6	Facial morphology (factor 23);
SARC	cis	rs57502260	1.000	rs57502260	chr11:68220905	A/G	cg01657329	chr11:68192670	LRP5	-0.47	-4.86	-0.3	2.2e-6	Total body bone mineral density (age 45-60);
SARC	cis	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg14541582	chr5:601475	NA	-0.41	-5.06	-0.31	8.54e-7	Obesity-related traits;
SARC	cis	rs829661	0.532	rs12621663	chr2:30784540	G/A	cg12454169	chr2:30669597	LCLAT1	-0.42	-5.38	-0.33	1.85e-7	Midgestational circulating levels of PBDEs (fetal genetic effect);
SARC	cis	rs7264396	0.563	rs2425103	chr20:34312329	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	5.69	0.35	3.71e-8	Total cholesterol levels;
SARC	trans	rs11098499	0.863	rs2170276	chr4:120485824	A/C	cg25214090	chr10:38739885	LOC399744	0.57	7.25	0.43	6.27e-12	Corneal astigmatism;
SARC	cis	rs12824058	0.831	rs1390849	chr12:130811547	A/G	cg26677194	chr12:130822605	PIWIL1	0.54	7.4	0.44	2.4e-12	Menopause (age at onset);
SARC	cis	rs3771395	0.925	rs2234495	chr2:71127794	C/A	cg21294935	chr2:71128538	VAX2	0.66	5.42	0.33	1.46e-7	Corneal astigmatism;
SARC	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg13944838	chr5:179740914	GFPT2	0.56	7.09	0.42	1.59e-11	Height;
SARC	cis	rs1865760	0.516	rs9358903	chr6:26061949	A/C	cg18357526	chr6:26021779	HIST1H4A	0.45	5.75	0.35	2.86e-8	Height;
SARC	cis	rs12950390	0.853	rs56137679	chr17:45862112	C/G	cg03474202	chr17:45855739	NA	-0.43	-6.71	-0.4	1.44e-10	IgG glycosylation;
SARC	cis	rs1865760	0.566	rs9379821	chr6:26054268	A/C	cg18357526	chr6:26021779	HIST1H4A	0.42	5.29	0.33	2.84e-7	Height;
SARC	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	-0.39	-4.75	-0.3	3.54e-6	Tonsillectomy;
SARC	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg03351412	chr1:154909251	PMVK	0.57	7.1	0.42	1.52e-11	Prostate cancer;
SARC	cis	rs4481887	0.927	rs4581306	chr1:248476158	C/A	cg13385794	chr1:248469461	NA	0.35	5.45	0.34	1.29e-7	Common traits (Other);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg24537481	chr19:16653308	CHERP	0.5	6.82	0.41	7.73e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs76419734	0.718	rs11730660	chr4:106800379	A/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.89	4.91	0.31	1.7e-6	Post bronchodilator FEV1;
SARC	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg24250549	chr1:154909240	PMVK	-0.83	-12.43	-0.63	1.51e-27	Prostate cancer;
SARC	cis	rs66573146	0.572	rs68169399	chr4:6952491	T/A	cg26116260	chr4:7069785	GRPEL1	-0.68	-5.02	-0.31	1.04e-6	Granulocyte percentage of myeloid white cells;
SARC	cis	rs710216	0.957	rs859511	chr1:43430260	C/T	cg07803811	chr1:43423981	SLC2A1	0.52	5.15	0.32	5.57e-7	Red cell distribution width;
SARC	cis	rs2014572	0.967	rs10413671	chr19:57763489	G/A	cg24459738	chr19:57751996	ZNF805	-0.44	-5.06	-0.31	8.42e-7	Hyperactive-impulsive symptoms;
SARC	cis	rs9916302	0.706	rs11657153	chr17:37699729	A/G	cg20243544	chr17:37824526	PNMT	0.53	5.46	0.34	1.23e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs9611565	0.525	rs1883827	chr22:41703579	A/G	cg17376030	chr22:41985996	PMM1	0.55	6.91	0.41	4.48e-11	Vitiligo;
SARC	cis	rs1348850	0.874	rs2166558	chr2:178373652	G/T	cg23306229	chr2:178417860	TTC30B	0.55	6.32	0.38	1.35e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs4423214	0.559	rs10898203	chr11:71203436	C/T	cg05163923	chr11:71159392	DHCR7	-0.53	-5.28	-0.33	2.99e-7	Vitamin D levels;
SARC	cis	rs6060960	0.537	rs75351461	chr20:30458612	C/T	cg09796376	chr20:30640595	HCK	0.51	4.82	0.3	2.57e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
SARC	cis	rs7769051	1.000	rs12203977	chr6:133122760	A/G	cg07930552	chr6:133119739	C6orf192	0.91	8.4	0.48	4.29e-15	Type 2 diabetes nephropathy;
SARC	cis	rs9916302	0.904	rs8065963	chr17:37681332	C/T	cg15445000	chr17:37608096	MED1	0.43	5.01	0.31	1.08e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs72781680	1.000	rs72796327	chr2:24140372	T/C	cg06627628	chr2:24431161	ITSN2	-0.72	-6.72	-0.4	1.34e-10	Lymphocyte counts;
SARC	cis	rs2228479	0.850	rs12597296	chr16:89822331	C/T	cg00800038	chr16:89945340	TCF25	-0.74	-5.14	-0.32	5.75e-7	Skin colour saturation;
SARC	cis	rs189798	0.592	rs10111263	chr8:8969433	C/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-5.66	-0.35	4.51e-8	Myopia (pathological);
SARC	cis	rs9875589	0.509	rs2607757	chr3:14081948	A/G	cg19554555	chr3:13937349	NA	0.42	5.28	0.33	2.95e-7	Ovarian reserve;
SARC	cis	rs9309711	0.666	rs4321399	chr2:3481659	G/A	cg08493051	chr2:3487164	NA	-0.39	-4.95	-0.31	1.42e-6	Neurofibrillary tangles;
SARC	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg18252515	chr7:66147081	NA	-0.59	-6.33	-0.38	1.27e-9	Aortic root size;
SARC	cis	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg02487422	chr3:49467188	NICN1	0.5	6.83	0.41	7.5e-11	Resting heart rate;
SARC	cis	rs763121	0.853	rs2413545	chr22:39092524	C/T	cg06022373	chr22:39101656	GTPBP1	0.84	10.13	0.55	3.19e-20	Menopause (age at onset);
SARC	cis	rs12142240	0.698	rs28578741	chr1:46825176	T/C	cg14993813	chr1:46806288	NSUN4	-0.51	-5.34	-0.33	2.19e-7	Menopause (age at onset);
SARC	cis	rs2486288	0.656	rs8039153	chr15:45579813	T/C	cg19305227	chr15:45544335	SLC28A2	0.3	5.56	0.34	7.29e-8	Glomerular filtration rate;
SARC	cis	rs7474896	0.515	rs2749582	chr10:38275284	A/G	cg25427524	chr10:38739819	LOC399744	0.44	5.54	0.34	8.21e-8	Obesity (extreme);
SARC	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg18876405	chr7:65276391	NA	-0.44	-4.94	-0.31	1.48e-6	Aortic root size;
SARC	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-8.98	-0.51	9.19e-17	Alzheimer's disease;
SARC	cis	rs9788682	0.747	rs2938674	chr15:78757913	C/A	cg06917634	chr15:78832804	PSMA4	-0.54	-5.6	-0.34	6e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	trans	rs561341	1.000	rs546519	chr17:30297682	T/G	cg20587970	chr11:113659929	NA	-1.26	-12.41	-0.63	1.72e-27	Hip circumference adjusted for BMI;
SARC	cis	rs7481584	0.581	rs366422	chr11:3053873	C/T	cg05729581	chr11:3078854	CARS	0.57	7.47	0.44	1.62e-12	Calcium levels;
SARC	cis	rs6088580	0.668	rs1205340	chr20:32923871	G/A	cg08999081	chr20:33150536	PIGU	-0.43	-6.7	-0.4	1.53e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs488628	0.652	rs492668	chr3:118122816	C/T	cg15509235	chr3:117715573	NA	0.51	4.77	0.3	3.27e-6	White matter integrity (bipolar disorder risk interaction);
SARC	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg02463440	chr8:22132932	PIWIL2	0.47	6.66	0.4	1.97e-10	Hypertriglyceridemia;
SARC	cis	rs8014204	0.816	rs11159107	chr14:75341266	C/A	cg06637938	chr14:75390232	RPS6KL1	-0.53	-7.43	-0.44	2.1e-12	Caffeine consumption;
SARC	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg06420487	chr17:61919686	SMARCD2	0.43	4.76	0.3	3.33e-6	Height;
SARC	cis	rs2282802	0.677	rs9686454	chr5:139627813	T/C	cg26211634	chr5:139558579	C5orf32	0.38	4.89	0.3	1.91e-6	Intelligence (multi-trait analysis);
SARC	cis	rs6598955	0.543	rs112752634	chr1:26534217	G/A	cg04990556	chr1:26633338	UBXN11	0.76	7.72	0.45	3.49e-13	Obesity-related traits;
SARC	cis	rs9325144	0.560	rs11183189	chr12:38683770	T/A	cg13010199	chr12:38710504	ALG10B	0.53	6.77	0.41	1.06e-10	Morning vs. evening chronotype;
SARC	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg11987759	chr7:65425863	GUSB	-0.48	-5.87	-0.36	1.47e-8	Aortic root size;
SARC	cis	rs7589342	0.831	rs11124062	chr2:106455967	G/A	cg14210321	chr2:106509881	NCK2	-0.44	-5.13	-0.32	6.12e-7	Addiction;
SARC	cis	rs1983170	0.808	rs1949009	chr1:92016653	C/T	cg25838465	chr1:92012736	NA	-0.47	-5.8	-0.36	2.14e-8	Eosinophil percentage of white cells;
SARC	cis	rs4423214	1.000	rs2276362	chr11:71174452	A/G	cg24826892	chr11:71159390	DHCR7	0.48	6.19	0.38	2.73e-9	Vitamin D levels;
SARC	cis	rs17270561	0.609	rs9393658	chr6:25730438	C/T	cg17691542	chr6:26056736	HIST1H1C	0.58	7.09	0.42	1.59e-11	Iron status biomarkers;
SARC	cis	rs17376456	0.877	rs10073039	chr5:93467709	A/G	cg25358565	chr5:93447407	FAM172A	1.32	14.94	0.7	7.42e-36	Diabetic retinopathy;
SARC	cis	rs10492096	0.947	rs61918022	chr12:6614521	C/T	cg13857086	chr12:6580257	VAMP1	0.68	6.68	0.4	1.72e-10	Hip geometry;
SARC	cis	rs8028182	0.636	rs4486847	chr15:75728531	C/G	cg20655648	chr15:75932815	IMP3	0.64	7.61	0.45	6.67e-13	Sudden cardiac arrest;
SARC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg09033563	chr22:24373618	LOC391322	0.5	6.17	0.37	2.95e-9	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg25427524	chr10:38739819	LOC399744	-0.6	-9.67	-0.54	8.06e-19	Extrinsic epigenetic age acceleration;
SARC	cis	rs2204008	0.657	rs8186888	chr12:38334260	T/G	cg14851346	chr12:38532713	NA	0.45	5.09	0.32	7.48e-7	Bladder cancer;
SARC	cis	rs17253792	0.822	rs10083431	chr14:56068348	G/A	cg01858014	chr14:56050164	KTN1	-0.67	-5.16	-0.32	5.38e-7	Putamen volume;
SARC	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg23924603	chr19:38826365	CATSPERG	0.51	6.9	0.41	4.99e-11	Cancer;
SARC	cis	rs72901758	0.768	rs72901766	chr17:76245203	G/C	cg23302638	chr17:76210176	BIRC5	0.46	4.76	0.3	3.4e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
SARC	cis	rs10823500	0.777	rs10999196	chr10:71982305	T/C	cg04118878	chr10:71993077	PPA1	0.58	6.49	0.39	4.98e-10	Blood protein levels;
SARC	cis	rs34779708	0.966	rs17499811	chr10:35456215	G/A	cg03585969	chr10:35415529	CREM	0.39	4.81	0.3	2.67e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs7481584	1.000	rs7481584	chr11:3029089	G/A	cg08508325	chr11:3079039	CARS	0.22	4.85	0.3	2.23e-6	Calcium levels;
SARC	cis	rs77372450	0.551	rs11739081	chr5:157087119	C/G	cg05585991	chr5:157099197	C5orf52	0.52	5.31	0.33	2.52e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs11697848	0.867	rs55948305	chr20:48507406	T/C	cg17849948	chr20:48532315	SPATA2	0.86	5.17	0.32	4.97e-7	Systemic lupus erythematosus;
SARC	cis	rs2439831	0.867	rs16957632	chr15:43642897	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.04	10.9	0.58	1.25e-22	Lung cancer in ever smokers;
SARC	cis	rs4242434	0.854	rs11782130	chr8:22452357	G/T	cg03733263	chr8:22462867	KIAA1967	0.91	14.0	0.68	1.04e-32	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs7945705	0.791	rs4579928	chr11:8815704	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.41	5.45	0.34	1.26e-7	Hemoglobin concentration;
SARC	cis	rs6120849	0.754	rs6088667	chr20:33566722	A/C	cg06115741	chr20:33292138	TP53INP2	0.52	5.15	0.32	5.57e-7	Protein C levels;
SARC	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg11890956	chr21:40555474	PSMG1	1.17	19.24	0.78	5.09e-50	Cognitive function;
SARC	cis	rs763121	0.626	rs5757236	chr22:39073824	T/C	cg14440974	chr22:39074834	NA	-0.33	-4.77	-0.3	3.24e-6	Menopause (age at onset);
SARC	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg11987759	chr7:65425863	GUSB	-0.62	-8.61	-0.49	1.1e-15	Aortic root size;
SARC	cis	rs4588572	0.643	rs9293752	chr5:77798432	A/G	cg11547950	chr5:77652471	NA	0.37	4.76	0.3	3.37e-6	Triglycerides;
SARC	cis	rs1971762	0.583	rs3852561	chr12:54085842	C/T	cg06632207	chr12:54070931	ATP5G2	0.44	5.81	0.36	2.05e-8	Height;
SARC	cis	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg24110177	chr3:50126178	RBM5	-0.45	-5.47	-0.34	1.13e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1497406	0.744	rs4233540	chr1:16507384	A/G	cg20430773	chr1:16534157	ARHGEF19	-0.44	-6.39	-0.39	9.15e-10	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
SARC	trans	rs208520	0.690	rs12202401	chr6:66760544	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.07	14.11	0.68	4.36e-33	Exhaled nitric oxide output;
SARC	cis	rs4975616	0.839	rs2447853	chr5:1333077	A/G	cg26373071	chr5:1325741	CLPTM1L	0.3	4.94	0.31	1.48e-6	Lung cancer;
SARC	cis	rs3796352	0.881	rs13100714	chr3:53074824	T/G	cg07884673	chr3:53033167	SFMBT1	0.77	5.3	0.33	2.63e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs589448	0.535	rs12423794	chr12:69713018	G/A	cg22834771	chr12:69754056	YEATS4	-0.45	-5.94	-0.36	1.04e-8	Cerebrospinal fluid biomarker levels;
SARC	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.63	7.75	0.45	2.9e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs986417	0.901	rs1024224	chr14:60926942	C/G	cg27398547	chr14:60952738	C14orf39	1.02	9.54	0.53	2.06e-18	Gut microbiota (bacterial taxa);
SARC	cis	rs7395581	0.918	rs7120957	chr11:47340649	A/G	cg25783544	chr11:47291846	MADD	0.48	5.4	0.33	1.61e-7	HDL cholesterol;
SARC	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg06634786	chr22:41940651	POLR3H	-0.49	-5.97	-0.36	8.8e-9	Vitiligo;
SARC	trans	rs3780486	0.846	rs73484568	chr9:33132492	G/A	cg20290983	chr6:43655470	MRPS18A	1.15	22.78	0.83	3.27e-61	IgG glycosylation;
SARC	cis	rs9733	0.688	rs12725667	chr1:150766070	A/T	cg13175981	chr1:150552382	MCL1	0.61	8.19	0.47	1.7e-14	Tonsillectomy;
SARC	cis	rs7429990	0.965	rs319682	chr3:47915118	A/G	cg11946769	chr3:48343235	NME6	0.45	5.16	0.32	5.26e-7	Educational attainment (years of education);
SARC	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-5.61	-0.35	5.58e-8	Bipolar disorder;
SARC	trans	rs61931739	0.500	rs11053269	chr12:34545307	A/G	cg26384229	chr12:38710491	ALG10B	0.85	12.63	0.64	3.4e-28	Morning vs. evening chronotype;
SARC	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg12463550	chr7:65579703	CRCP	0.5	5.9	0.36	1.27e-8	Aortic root size;
SARC	cis	rs6089584	1.000	rs6089581	chr20:60562394	G/A	cg06108461	chr20:60628389	TAF4	-0.91	-11.96	-0.62	5.27e-26	Body mass index;
SARC	cis	rs5753618	0.561	rs9606830	chr22:31717799	T/G	cg07713946	chr22:31675144	LIMK2	0.36	4.96	0.31	1.38e-6	Colorectal cancer;
SARC	cis	rs7949030	0.653	rs2849030	chr11:62366986	G/A	cg22862634	chr11:62369728	EML3;MTA2	-0.55	-8.69	-0.49	6.4e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs11638352	0.661	rs2615286	chr15:44417068	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.76	-5.91	-0.36	1.23e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg13206674	chr6:150067644	NUP43	0.46	6.0	0.37	7.3e-9	Lung cancer;
SARC	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.48	-6.06	-0.37	5.38e-9	Lymphocyte counts;
SARC	cis	rs2204008	0.744	rs11182316	chr12:38499552	G/A	cg26384229	chr12:38710491	ALG10B	0.87	12.61	0.64	3.98e-28	Bladder cancer;
SARC	cis	rs6963495	0.818	rs117028299	chr7:105162310	T/C	cg13798780	chr7:105162888	PUS7	0.6	5.45	0.34	1.31e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg24675658	chr1:53192096	ZYG11B	-0.66	-9.33	-0.52	8.38e-18	Monocyte count;
SARC	cis	rs6121246	0.609	rs6060652	chr20:30266845	A/G	cg13852791	chr20:30311386	BCL2L1	0.81	9.95	0.55	1.16e-19	Mean corpuscular hemoglobin;
SARC	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.48	7.48	0.44	1.52e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs7520050	0.898	rs4660885	chr1:46243756	C/T	cg24296786	chr1:45957014	TESK2	0.39	5.08	0.32	7.87e-7	Red blood cell count;Reticulocyte count;
SARC	cis	rs8141529	0.504	rs6005915	chr22:29233262	A/G	cg02153584	chr22:29168773	CCDC117	0.7	9.04	0.51	6.39e-17	Lymphocyte counts;
SARC	cis	rs3820928	0.874	rs10933165	chr2:227883648	C/G	cg05526886	chr2:227700861	RHBDD1	0.5	5.94	0.36	1.03e-8	Pulmonary function;
SARC	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	10.18	0.55	2.28e-20	Platelet count;
SARC	cis	rs829883	0.659	rs11109528	chr12:98951362	G/A	cg25150519	chr12:98850993	NA	-0.6	-7.29	-0.43	4.9e-12	Colorectal adenoma (advanced);
SARC	cis	rs1003719	0.553	rs1063948	chr21:38574674	C/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-8.85	-0.5	2.2e-16	Eye color traits;
SARC	cis	rs826838	1.000	rs860400	chr12:39081279	A/G	cg26384229	chr12:38710491	ALG10B	-0.82	-12.57	-0.64	5.27e-28	Heart rate;
SARC	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg11987759	chr7:65425863	GUSB	-0.49	-6.35	-0.38	1.1e-9	Aortic root size;
SARC	cis	rs854765	0.693	rs4924823	chr17:17764502	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.43	-5.57	-0.34	7.15e-8	Total body bone mineral density;
SARC	cis	rs13401104	0.796	rs11680754	chr2:237112384	T/C	cg19324714	chr2:237145437	ASB18	0.58	6.05	0.37	5.77e-9	Educational attainment;
SARC	cis	rs10078	0.571	rs890977	chr5:476910	T/C	cg08916839	chr5:415575	AHRR	0.84	7.81	0.46	1.91e-13	Fat distribution (HIV);
SARC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.13	0.37	3.72e-9	Prudent dietary pattern;
SARC	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg23958373	chr8:599963	NA	0.73	5.45	0.34	1.3e-7	IgG glycosylation;
SARC	cis	rs2075371	1.000	rs2598286	chr7:133976029	G/A	cg11752832	chr7:134001865	SLC35B4	0.57	7.45	0.44	1.81e-12	Mean platelet volume;
SARC	cis	rs2204008	0.545	rs1663283	chr12:38132039	G/A	cg14851346	chr12:38532713	NA	-0.44	-5.33	-0.33	2.32e-7	Bladder cancer;
SARC	cis	rs155076	1.000	rs12870992	chr13:21846019	A/G	cg25811766	chr13:21894605	NA	0.48	4.97	0.31	1.32e-6	White matter hyperintensity burden;
SARC	cis	rs8072100	0.676	rs9908049	chr17:45502096	G/C	cg08085267	chr17:45401833	C17orf57	-0.42	-4.94	-0.31	1.49e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs2180341	0.924	rs877661	chr6:127587915	T/G	cg27446573	chr6:127587934	RNF146	1.01	14.05	0.68	6.71e-33	Breast cancer;
SARC	cis	rs1034435	0.547	rs5767174	chr22:48898857	A/G	cg05992904	chr22:48892994	FAM19A5	-0.42	-5.69	-0.35	3.73e-8	Late-onset Alzheimer's disease;
SARC	cis	rs7428	0.545	rs1053561	chr2:85546052	A/G	cg03728395	chr2:85555865	TGOLN2	-0.46	-6.45	-0.39	6.47e-10	Ear protrusion;
SARC	cis	rs11190604	1.000	rs2495742	chr10:102331364	C/T	cg07080220	chr10:102295463	HIF1AN	0.78	9.18	0.52	2.34e-17	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs6570726	1.000	rs441477	chr6:145848243	C/T	cg05220968	chr6:146057943	EPM2A	-0.29	-5.05	-0.31	9.02e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs936229	0.861	rs11634474	chr15:75116184	C/G	cg14664628	chr15:75095509	CSK	-1.05	-15.38	-0.71	2.56e-37	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs10465746	0.653	rs11163877	chr1:84441848	T/A	cg10977910	chr1:84465055	TTLL7	0.45	5.52	0.34	8.95e-8	Obesity-related traits;
SARC	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg09035930	chr12:129282057	SLC15A4	0.56	8.07	0.47	3.67e-14	Systemic lupus erythematosus;
SARC	cis	rs2221894	0.506	rs1512851	chr8:28770472	G/T	cg07962641	chr8:28805897	HMBOX1	-0.76	-7.42	-0.44	2.23e-12	Obesity-related traits;
SARC	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.56	7.09	0.42	1.58e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	5.92	0.36	1.16e-8	Prudent dietary pattern;
SARC	cis	rs11700980	0.636	rs114711857	chr21:30260199	T/C	cg24692254	chr21:30365293	RNF160	-0.65	-4.94	-0.31	1.51e-6	QRS complex (12-leadsum);
SARC	cis	rs7520050	0.897	rs4440807	chr1:46470878	T/C	cg24296786	chr1:45957014	TESK2	0.39	4.92	0.31	1.62e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs12579753	0.871	rs10862363	chr12:82201254	T/A	cg07988820	chr12:82153109	PPFIA2	-0.52	-6.11	-0.37	4.18e-9	Resting heart rate;
SARC	cis	rs12824058	0.831	rs12300308	chr12:130813825	G/A	cg23887609	chr12:130822674	PIWIL1	0.37	5.13	0.32	5.98e-7	Menopause (age at onset);
SARC	cis	rs34779708	0.931	rs7099036	chr10:35349574	C/T	cg03585969	chr10:35415529	CREM	0.39	4.97	0.31	1.32e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs7000551	0.689	rs7007673	chr8:22316687	G/T	cg12081754	chr8:22256438	SLC39A14	0.58	8.16	0.47	2.15e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg19077165	chr18:44547161	KATNAL2	-0.53	-7.06	-0.42	1.89e-11	Personality dimensions;
SARC	cis	rs1559088	0.522	rs7254912	chr19:33554151	A/G	cg27124370	chr19:33622961	WDR88	0.47	6.04	0.37	6.17e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg16405210	chr4:1374714	KIAA1530	-0.49	-5.75	-0.35	2.77e-8	Obesity-related traits;
SARC	cis	rs739401	1.000	rs739401	chr11:3036324	C/T	cg05729581	chr11:3078854	CARS	0.45	5.75	0.35	2.83e-8	Longevity;
SARC	cis	rs992157	0.698	rs6746089	chr2:219170377	A/G	cg00012203	chr2:219082015	ARPC2	0.63	9.16	0.51	2.8e-17	Colorectal cancer;
SARC	cis	rs12291225	0.535	rs16930126	chr11:14404983	C/T	cg19336497	chr11:14380999	RRAS2	0.33	5.67	0.35	4.26e-8	Sense of smell;
SARC	cis	rs1559088	0.947	rs12461219	chr19:33550633	C/G	cg27124370	chr19:33622961	WDR88	0.42	5.25	0.33	3.44e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs8016982	0.674	rs1951614	chr14:81672106	A/G	cg01989461	chr14:81687754	GTF2A1	-0.72	-10.94	-0.58	9.46e-23	Schizophrenia;
SARC	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg11890956	chr21:40555474	PSMG1	1.17	18.83	0.78	1.07e-48	Cognitive function;
SARC	cis	rs3892630	0.824	rs7247264	chr19:33239846	T/G	cg22980127	chr19:33182716	NUDT19	1.03	9.16	0.51	2.81e-17	Red blood cell traits;
SARC	cis	rs854765	0.618	rs9908017	chr17:17774422	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.64	-9.45	-0.53	3.65e-18	Total body bone mineral density;
SARC	cis	rs6831352	0.959	rs6532795	chr4:100042221	C/T	cg13256891	chr4:100009986	ADH5	-0.67	-9.1	-0.51	4.16e-17	Alcohol dependence;
SARC	cis	rs2425143	0.558	rs7274724	chr20:34539466	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-5.32	-0.33	2.42e-7	Blood protein levels;
SARC	cis	rs910316	0.737	rs175499	chr14:75535927	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.52	-7.06	-0.42	1.86e-11	Height;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg03554194	chr3:110831177	PVRL3	0.43	6.37	0.39	1e-9	Thyroid stimulating hormone;
SARC	cis	rs6918586	0.658	rs198819	chr6:26124430	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.45	-5.62	-0.35	5.41e-8	Schizophrenia;
SARC	cis	rs3820928	0.874	rs7562776	chr2:227806550	G/A	cg05526886	chr2:227700861	RHBDD1	-0.54	-6.65	-0.4	2.04e-10	Pulmonary function;
SARC	cis	rs6674176	0.597	rs9326136	chr1:44390392	A/G	cg12908607	chr1:44402522	ARTN	0.39	6.8	0.41	8.52e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs35110281	0.659	rs11909064	chr21:45092095	G/C	cg01579765	chr21:45077557	HSF2BP	-0.37	-5.9	-0.36	1.28e-8	Mean corpuscular volume;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg00040027	chr2:172747482	SLC25A12	0.47	6.79	0.41	9.29e-11	Thyroid stimulating hormone;
SARC	cis	rs875971	0.545	rs6970498	chr7:65740895	A/G	cg11764359	chr7:65958608	NA	0.65	6.48	0.39	5.45e-10	Aortic root size;
SARC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg11494091	chr17:61959527	GH2	0.53	7.94	0.46	8.72e-14	Prudent dietary pattern;
SARC	trans	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg21659725	chr3:3221576	CRBN	0.53	6.83	0.41	7.25e-11	Intelligence (multi-trait analysis);
SARC	cis	rs76419734	1.000	rs11728044	chr4:106604786	G/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.8	4.87	0.3	2.02e-6	Post bronchodilator FEV1;
SARC	cis	rs7296418	0.630	rs11608305	chr12:123791165	C/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.39	-5.15	-0.32	5.61e-7	Platelet count;
SARC	cis	rs7592578	0.766	rs62182885	chr2:191437024	A/G	cg10560079	chr2:191398806	TMEM194B	-0.83	-9.25	-0.52	1.51e-17	Diastolic blood pressure;
SARC	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg24642844	chr7:1081250	C7orf50	-0.57	-6.05	-0.37	5.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1728785	0.901	rs821169	chr16:68630184	C/T	cg02972257	chr16:68554789	NA	-0.43	-5.03	-0.31	9.85e-7	Ulcerative colitis;
SARC	cis	rs6582630	0.519	rs7305570	chr12:38349285	G/A	cg26384229	chr12:38710491	ALG10B	0.87	12.69	0.64	2.17e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs4792901	0.722	rs12603085	chr17:41545847	G/A	cg22562494	chr17:41607896	ETV4	-0.3	-4.78	-0.3	3.15e-6	Dupuytren's disease;
SARC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	20.72	0.81	9.12e-55	Prudent dietary pattern;
SARC	cis	rs67460515	0.529	rs11712713	chr3:160852471	A/G	cg03342759	chr3:160939853	NMD3	-0.59	-7.14	-0.42	1.21e-11	Parkinson's disease;
SARC	cis	rs9398803	0.624	rs1455737	chr6:126647204	T/G	cg19875578	chr6:126661172	C6orf173	0.46	6.24	0.38	2.07e-9	Male-pattern baldness;
SARC	trans	rs61931739	0.534	rs10844791	chr12:34211659	C/T	cg26384229	chr12:38710491	ALG10B	0.83	11.98	0.62	4.35e-26	Morning vs. evening chronotype;
SARC	cis	rs35110281	0.659	rs11702544	chr21:45091861	C/T	cg21573476	chr21:45109991	RRP1B	-0.6	-8.64	-0.49	9.17e-16	Mean corpuscular volume;
SARC	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.62	7.45	0.44	1.8e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs208520	0.661	rs207099	chr6:66796373	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-14.36	-0.69	6.28e-34	Exhaled nitric oxide output;
SARC	cis	rs10256972	0.630	rs10282584	chr7:1081442	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.34	-5.37	-0.33	1.9e-7	Longevity;Endometriosis;
SARC	cis	rs7833790	0.632	rs6415653	chr8:82702536	A/G	cg27398817	chr8:82754497	SNX16	-0.43	-5.12	-0.32	6.29e-7	Diastolic blood pressure;
SARC	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg06212747	chr3:49208901	KLHDC8B	0.76	11.07	0.59	3.64e-23	Menarche (age at onset);
SARC	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg24829409	chr8:58192753	C8orf71	-0.59	-5.12	-0.32	6.49e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg11987759	chr7:65425863	GUSB	0.47	5.71	0.35	3.48e-8	Aortic root size;
SARC	cis	rs60871478	1.000	rs4721124	chr7:823761	T/C	cg19087971	chr7:751233	PRKAR1B	-0.42	-4.79	-0.3	3.03e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs883565	0.655	rs7629839	chr3:39115294	G/A	cg01426195	chr3:39028469	NA	-0.33	-4.9	-0.31	1.8e-6	Handedness;
SARC	cis	rs694739	0.892	rs647152	chr11:64109118	T/G	cg02228329	chr11:64053129	BAD;GPR137	0.61	7.6	0.45	7.29e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs12216125	0.801	rs56107510	chr6:25987436	C/A	cg17691542	chr6:26056736	HIST1H1C	0.58	6.69	0.4	1.62e-10	Iron status biomarkers;
SARC	cis	rs950776	0.647	rs495956	chr15:78869930	C/T	cg06917634	chr15:78832804	PSMA4	-0.76	-10.29	-0.56	1.02e-20	Sudden cardiac arrest;
SARC	cis	rs1008375	0.966	rs6825133	chr4:17577776	C/T	cg02297831	chr4:17616191	MED28	0.49	6.22	0.38	2.31e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2504916	0.784	rs3004077	chr6:160767443	T/C	cg11170810	chr6:160389491	IGF2R	0.44	4.81	0.3	2.71e-6	Response to hepatitis C treatment;
SARC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg14159672	chr1:205819179	PM20D1	0.94	17.88	0.76	1.36e-45	Menarche (age at onset);
SARC	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.95	13.0	0.65	2.04e-29	Platelet count;
SARC	cis	rs4944092	0.855	rs608747	chr11:75916477	A/G	cg04588336	chr11:75916460	WNT11	-0.47	-6.33	-0.38	1.24e-9	PR interval;
SARC	cis	rs9303401	0.625	rs66508449	chr17:56691034	T/C	cg25039879	chr17:56429692	SUPT4H1	0.69	6.49	0.39	5.05e-10	Cognitive test performance;
SARC	cis	rs11098499	0.604	rs2389886	chr4:120570422	C/T	cg09307838	chr4:120376055	NA	0.81	10.65	0.57	7.74e-22	Corneal astigmatism;
SARC	cis	rs2070488	0.662	rs7372545	chr3:38507570	T/G	cg27533700	chr3:38537683	EXOG	-0.41	-5.15	-0.32	5.64e-7	Electrocardiographic conduction measures;
SARC	cis	rs10823500	0.777	rs2184335	chr10:72006891	C/T	cg04118878	chr10:71993077	PPA1	0.58	5.9	0.36	1.25e-8	Blood protein levels;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg13576061	chr5:55291172	IL6ST	0.47	6.32	0.38	1.32e-9	Lung adenocarcinoma;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg15592541	chr3:197519021	LRCH3	-0.61	-6.45	-0.39	6.41e-10	Lung cancer in ever smokers;
SARC	cis	rs2073300	0.609	rs6137920	chr20:23363436	C/T	cg12062639	chr20:23401060	NAPB	0.95	6.46	0.39	6.01e-10	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs1882538	0.503	rs13240997	chr7:133135373	C/A	cg10665199	chr7:133106180	EXOC4	0.4	4.88	0.3	1.95e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9486719	0.843	rs1009597	chr6:96843540	A/T	cg06623918	chr6:96969491	KIAA0776	0.75	7.39	0.44	2.65e-12	Migraine;Coronary artery disease;
SARC	cis	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg05623727	chr3:50126028	RBM5	0.33	4.95	0.31	1.4e-6	Intelligence (multi-trait analysis);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg08986653	chr3:40498475	RPL14	-0.49	-6.68	-0.4	1.77e-10	Chemerin levels;
SARC	cis	rs10463554	0.926	rs5855	chr5:102365186	G/A	cg23492399	chr5:102201601	PAM	0.45	5.02	0.31	1.03e-6	Parkinson's disease;
SARC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg06873352	chr17:61820015	STRADA	-0.48	-5.97	-0.36	9.01e-9	Prudent dietary pattern;
SARC	cis	rs9457247	1.000	rs405553	chr6:167395058	A/G	cg23791538	chr6:167370224	RNASET2	-0.62	-8.66	-0.49	8.16e-16	Crohn's disease;
SARC	cis	rs11690935	0.550	rs6718013	chr2:172869185	A/G	cg13550731	chr2:172543902	DYNC1I2	0.54	6.88	0.41	5.48e-11	Schizophrenia;
SARC	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg11764359	chr7:65958608	NA	-0.63	-7.7	-0.45	3.92e-13	Aortic root size;
SARC	cis	rs8078723	0.690	rs3785549	chr17:38149724	T/C	cg17467752	chr17:38218738	THRA	-0.38	-4.89	-0.31	1.88e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs9640161	0.789	rs1464753	chr7:150021350	G/C	cg17279839	chr7:150038598	RARRES2	0.47	6.62	0.4	2.5e-10	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs1568889	1.000	rs33937991	chr11:28045260	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	10.33	0.56	7.9e-21	Bipolar disorder;
SARC	cis	rs12956009	0.518	rs1434518	chr18:44833498	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	7.48	0.44	1.55e-12	Educational attainment (years of education);
SARC	cis	rs2242116	1.000	rs1138518	chr3:46944274	T/C	cg27129171	chr3:47204927	SETD2	0.52	6.63	0.4	2.31e-10	Birth weight;
SARC	cis	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg25894440	chr7:65020034	NA	-0.66	-5.4	-0.33	1.62e-7	Diabetic kidney disease;
SARC	cis	rs2239547	0.563	rs9839035	chr3:52909877	C/T	cg07507251	chr3:52567010	NT5DC2	0.38	4.79	0.3	2.97e-6	Schizophrenia;
SARC	cis	rs3796352	1.000	rs11712653	chr3:53070875	A/C	cg15956490	chr3:53032818	SFMBT1	-0.75	-5.4	-0.33	1.65e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs6582630	0.622	rs11182005	chr12:38441292	G/A	cg26384229	chr12:38710491	ALG10B	-0.55	-6.86	-0.41	6.16e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs11105298	0.891	rs3741899	chr12:89933931	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.55	-5.55	-0.34	7.56e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs12134245	1.000	rs12134245	chr1:92021464	C/T	cg02896835	chr1:92012615	NA	-0.52	-7.26	-0.43	5.71e-12	Breast cancer;
SARC	cis	rs1018836	0.923	rs2023626	chr8:91619264	G/T	cg16814680	chr8:91681699	NA	0.87	13.99	0.68	1.07e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs4820539	0.966	rs2157709	chr22:23457420	T/C	cg14186256	chr22:23484241	RTDR1	0.88	14.03	0.68	7.72e-33	Bone mineral density;
SARC	trans	rs877282	0.842	rs35117541	chr10:764683	C/T	cg22713356	chr15:30763199	NA	1.04	10.06	0.55	5.37e-20	Uric acid levels;
SARC	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg06108461	chr20:60628389	TAF4	-0.61	-6.58	-0.4	3.11e-10	Obesity-related traits;
SARC	cis	rs7296418	0.663	rs11057284	chr12:123830692	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-5.07	-0.31	8.3e-7	Platelet count;
SARC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg11203670	chr7:100026453	MEPCE;ZCWPW1	0.53	4.95	0.31	1.45e-6	Platelet count;
SARC	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg18876405	chr7:65276391	NA	-0.45	-5.13	-0.32	6.15e-7	Aortic root size;
SARC	cis	rs17666538	0.792	rs1979174	chr8:592274	C/A	cg07685180	chr8:600429	NA	0.68	5.67	0.35	4.13e-8	IgG glycosylation;
SARC	cis	rs4268898	0.662	rs2303292	chr2:24432138	C/T	cg26838691	chr2:24397539	C2orf84	-0.54	-6.2	-0.38	2.54e-9	Asthma;
SARC	cis	rs10463554	0.927	rs40061	chr5:102403116	G/A	cg23492399	chr5:102201601	PAM	-0.51	-5.67	-0.35	4.23e-8	Parkinson's disease;
SARC	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.79	7.8	0.45	2.08e-13	Platelet count;
SARC	cis	rs6570726	0.935	rs9390329	chr6:145828026	T/C	cg23711669	chr6:146136114	FBXO30	0.78	11.84	0.61	1.21e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12579753	0.913	rs12579018	chr12:82231943	T/C	cg07988820	chr12:82153109	PPFIA2	-0.54	-6.22	-0.38	2.22e-9	Resting heart rate;
SARC	cis	rs9487051	0.872	rs1111865	chr6:109610863	A/G	cg01475377	chr6:109611718	NA	0.41	5.9	0.36	1.29e-8	Reticulocyte fraction of red cells;
SARC	cis	rs7005380	0.556	rs4073559	chr8:120917443	G/C	cg21744203	chr8:120868354	DSCC1	-0.46	-4.97	-0.31	1.31e-6	Interstitial lung disease;
SARC	cis	rs644799	0.544	rs687559	chr11:95598629	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	-0.48	-5.64	-0.35	4.95e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg22857025	chr5:266934	NA	-1.06	-11.8	-0.61	1.74e-25	Breast cancer;
SARC	cis	rs8031584	1.000	rs35811129	chr15:31241346	G/A	cg19680485	chr15:31195859	MTMR15	-0.54	-5.71	-0.35	3.48e-8	Huntington's disease progression;
SARC	cis	rs116095464	1.000	rs6873902	chr5:313337	C/G	cg20965017	chr5:231967	SDHA	-0.7	-5.45	-0.34	1.28e-7	Breast cancer;
SARC	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.63	7.68	0.45	4.33e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg20607798	chr8:58055168	NA	0.61	5.41	0.33	1.57e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg06634786	chr22:41940651	POLR3H	-0.49	-5.7	-0.35	3.59e-8	Vitiligo;
SARC	cis	rs10876993	0.890	rs4760165	chr12:58063801	C/T	cg18357645	chr12:58087776	OS9	0.46	5.98	0.36	8.29e-9	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs10046574	0.656	rs76799185	chr7:135194266	G/C	cg27474649	chr7:135195673	CNOT4	0.87	8.04	0.47	4.54e-14	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs1707322	0.752	rs7541962	chr1:46235117	G/A	cg06784218	chr1:46089804	CCDC17	0.38	6.68	0.4	1.7e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9815354	1.000	rs2625667	chr3:41900951	C/A	cg03022575	chr3:42003672	ULK4	0.56	5.29	0.33	2.81e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs1349547	0.510	rs3852338	chr8:39496970	C/T	cg12140000	chr8:38554703	NA	0.31	4.74	0.3	3.71e-6	HIV-1 susceptibility;
SARC	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg17221315	chr6:27791827	HIST1H4J	0.47	4.97	0.31	1.32e-6	Parkinson's disease;
SARC	cis	rs1678542	0.679	rs10783834	chr12:57975953	G/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.54	6.16	0.37	3.14e-9	Rheumatoid arthritis;
SARC	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg06420487	chr17:61919686	SMARCD2	0.44	4.91	0.31	1.68e-6	Height;
SARC	cis	rs9987353	0.522	rs2929466	chr8:9063899	G/T	cg06636001	chr8:8085503	FLJ10661	-0.6	-7.61	-0.45	6.84e-13	Recombination measurement;
SARC	cis	rs950776	0.518	rs12916483	chr15:78832397	G/A	cg17108064	chr15:78857060	CHRNA5	0.29	4.87	0.3	2.03e-6	Sudden cardiac arrest;
SARC	cis	rs240764	0.583	rs11155638	chr6:101203801	T/A	cg09795085	chr6:101329169	ASCC3	-0.5	-6.68	-0.4	1.74e-10	Neuroticism;
SARC	cis	rs9814567	0.865	rs9834981	chr3:134282279	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-6.86	-0.41	6.13e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg03806693	chr22:41940476	POLR3H	0.86	11.91	0.62	7.51e-26	Vitiligo;
SARC	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg02725872	chr8:58115012	NA	-0.28	-4.98	-0.31	1.25e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs12600121	0.600	rs1035542	chr16:72023633	C/A	cg01557791	chr16:72042693	DHODH	0.42	5.29	0.33	2.82e-7	Intelligence (multi-trait analysis);
SARC	cis	rs11098499	0.908	rs11098527	chr4:120399906	A/G	cg09307838	chr4:120376055	NA	0.9	12.31	0.63	3.64e-27	Corneal astigmatism;
SARC	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg11644478	chr21:40555479	PSMG1	-0.52	-6.33	-0.38	1.27e-9	Menarche (age at onset);
SARC	cis	rs9462027	0.628	rs9462019	chr6:34748730	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.85	-0.36	1.69e-8	Systemic lupus erythematosus;
SARC	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg11764359	chr7:65958608	NA	-0.71	-8.42	-0.48	3.97e-15	Aortic root size;
SARC	cis	rs7818345	0.874	rs12674938	chr8:19300813	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.38	5.23	0.32	3.79e-7	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs9397240	0.789	rs9384303	chr6:155557068	T/C	cg07943832	chr6:155568918	TIAM2	-0.54	-5.15	-0.32	5.43e-7	Life satisfaction;
SARC	cis	rs2425143	1.000	rs2295356	chr20:34252856	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-5.75	-0.35	2.78e-8	Blood protein levels;
SARC	cis	rs4642101	0.640	rs7629354	chr3:12827746	T/G	cg24848339	chr3:12840334	CAND2	0.38	5.83	0.36	1.81e-8	QRS complex (12-leadsum);
SARC	cis	rs6121246	0.954	rs6060989	chr20:30429763	C/T	cg13852791	chr20:30311386	BCL2L1	0.85	9.16	0.51	2.77e-17	Mean corpuscular hemoglobin;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg07424342	chr16:89008460	CBFA2T3	0.49	6.45	0.39	6.57e-10	Lung adenocarcinoma;
SARC	cis	rs4481887	1.000	rs4244178	chr1:248468441	A/G	cg13385794	chr1:248469461	NA	0.36	5.48	0.34	1.09e-7	Common traits (Other);
SARC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg06873352	chr17:61820015	STRADA	0.52	6.8	0.41	8.81e-11	Prudent dietary pattern;
SARC	cis	rs6540556	0.723	rs6679099	chr1:209895852	T/G	cg05527609	chr1:210001259	C1orf107	-0.6	-5.61	-0.34	5.77e-8	Red blood cell count;
SARC	cis	rs4713118	0.869	rs7773070	chr6:27728827	T/C	cg17221315	chr6:27791827	HIST1H4J	0.48	5.26	0.33	3.32e-7	Parkinson's disease;
SARC	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg03517284	chr6:25882590	NA	-0.42	-5.44	-0.34	1.35e-7	Intelligence (multi-trait analysis);
SARC	cis	rs3785574	0.705	rs2665856	chr17:61982721	T/A	cg11494091	chr17:61959527	GH2	-0.47	-6.41	-0.39	7.95e-10	Height;
SARC	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg12756686	chr19:29218302	NA	0.68	8.99	0.51	8.47e-17	Methadone dose in opioid dependence;
SARC	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg10523679	chr1:76189770	ACADM	-0.69	-10.55	-0.57	1.54e-21	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs11098499	0.908	rs12504149	chr4:120318577	G/A	cg09307838	chr4:120376055	NA	0.89	12.27	0.63	4.85e-27	Corneal astigmatism;
SARC	cis	rs34375054	0.672	rs10400509	chr12:125592173	T/C	cg25124228	chr12:125621409	AACS	-0.55	-6.84	-0.41	6.77e-11	Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs2120243	0.539	rs4679793	chr3:157122661	A/C	cg24825693	chr3:157122686	VEPH1	0.45	6.06	0.37	5.41e-9	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs1153858	1.000	rs7179743	chr15:45638331	G/C	cg26924012	chr15:45694286	SPATA5L1	0.75	10.34	0.56	7.46e-21	Homoarginine levels;
SARC	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg02725872	chr8:58115012	NA	-0.32	-4.73	-0.3	3.91e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs12545912	0.586	rs60674203	chr8:9485687	A/C	cg21625330	chr8:9911636	MSRA	0.52	4.93	0.31	1.55e-6	Multiple myeloma (hyperdiploidy);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg08502240	chr19:984437	WDR18	0.52	7.15	0.42	1.12e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.54	6.14	0.37	3.56e-9	Prudent dietary pattern;
SARC	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg24675658	chr1:53192096	ZYG11B	-0.66	-9.74	-0.54	5.15e-19	Monocyte count;
SARC	cis	rs1395	0.744	rs62130714	chr2:27532870	A/G	cg21747090	chr2:27597821	SNX17	-0.56	-6.31	-0.38	1.4e-9	Blood metabolite levels;
SARC	cis	rs8031584	0.918	rs61997138	chr15:31270776	C/T	cg14829155	chr15:31115871	NA	-0.43	-5.37	-0.33	1.86e-7	Huntington's disease progression;
SARC	cis	rs875971	0.520	rs160645	chr7:65556307	A/G	cg11764359	chr7:65958608	NA	-0.64	-6.18	-0.38	2.87e-9	Aortic root size;
SARC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg02475777	chr4:1388615	CRIPAK	-0.59	-6.82	-0.41	7.78e-11	Longevity;
SARC	trans	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.21	-0.43	7.82e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs3126085	0.935	rs1496049	chr1:152161949	C/T	cg03465714	chr1:152285911	FLG	0.47	5.5	0.34	9.81e-8	Atopic dermatitis;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg09757709	chr11:93464721	SNORA32;SNORD6;SNORA25	0.51	6.86	0.41	6.05e-11	Thyroid stimulating hormone;
SARC	cis	rs3796352	0.881	rs11710394	chr3:53015839	A/G	cg15956490	chr3:53032818	SFMBT1	0.78	5.25	0.33	3.49e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs7520050	0.966	rs11579634	chr1:46466391	A/G	cg24296786	chr1:45957014	TESK2	-0.39	-4.78	-0.3	3.1e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs6580649	0.943	rs3803183	chr12:48398080	T/A	cg05342945	chr12:48394962	COL2A1	-0.53	-5.63	-0.35	5.19e-8	Lung cancer;
SARC	cis	rs9393692	0.905	rs7747133	chr6:26293470	C/T	cg05868516	chr6:26286170	HIST1H4H	0.57	7.61	0.45	6.62e-13	Educational attainment;
SARC	cis	rs957448	1.000	rs12679345	chr8:95564533	A/G	cg26464482	chr8:95565502	KIAA1429	0.43	4.73	0.3	3.84e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	6.91	0.41	4.63e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs8058578	1.000	rs56656810	chr16:30788759	C/A	cg00531865	chr16:30841666	NA	-0.51	-5.76	-0.35	2.69e-8	Multiple myeloma;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg12056618	chr15:31619949	KLF13	0.52	6.58	0.4	3.15e-10	Breast cancer;
SARC	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg06212747	chr3:49208901	KLHDC8B	0.72	9.85	0.54	2.27e-19	Parkinson's disease;
SARC	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg08219700	chr8:58056026	NA	0.76	6.91	0.41	4.56e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs2832077	0.943	rs11702320	chr21:30195251	A/T	cg24692254	chr21:30365293	RNF160	-0.52	-4.74	-0.3	3.66e-6	Cognitive test performance;
SARC	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg22920501	chr2:26401640	FAM59B	-0.54	-6.92	-0.41	4.24e-11	Gut microbiome composition (summer);
SARC	trans	rs1814175	0.791	rs9787917	chr11:49937281	C/T	cg15704280	chr7:45808275	SEPT13	-0.98	-18.3	-0.77	5.62e-47	Height;
SARC	cis	rs11122272	0.735	rs910822	chr1:231498721	G/A	cg06096015	chr1:231504339	EGLN1	0.39	5.88	0.36	1.41e-8	Hemoglobin concentration;
SARC	cis	rs760805	1.000	rs11249204	chr1:25261740	C/T	cg22509179	chr1:25234806	RUNX3	0.5	6.6	0.4	2.68e-10	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs7582180	0.568	rs10186134	chr2:100939501	T/A	cg14675211	chr2:100938903	LONRF2	0.49	7.27	0.43	5.48e-12	Intelligence (multi-trait analysis);
SARC	cis	rs4481887	0.893	rs4529743	chr1:248473683	G/C	cg13385794	chr1:248469461	NA	0.35	5.51	0.34	9.64e-8	Common traits (Other);
SARC	cis	rs7072216	0.621	rs3750604	chr10:100175581	G/A	cg22905282	chr10:100175540	PYROXD2	-0.31	-4.82	-0.3	2.59e-6	Metabolite levels;
SARC	cis	rs6714710	0.603	rs13008968	chr2:98435982	C/T	cg26665480	chr2:98280029	ACTR1B	0.51	6.84	0.41	6.93e-11	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg18252515	chr7:66147081	NA	-0.53	-5.69	-0.35	3.86e-8	Aortic root size;
SARC	cis	rs2153535	0.580	rs1328862	chr6:8526681	A/T	cg21535247	chr6:8435926	SLC35B3	0.54	6.84	0.41	6.76e-11	Motion sickness;
SARC	cis	rs2011503	0.882	rs2060276	chr19:19522491	T/G	cg03709012	chr19:19516395	GATAD2A	0.67	5.49	0.34	1.04e-7	Bipolar disorder;
SARC	cis	rs9393777	0.623	rs9348719	chr6:26470032	T/C	cg12826209	chr6:26865740	GUSBL1	0.83	7.61	0.45	6.76e-13	Intelligence (multi-trait analysis);
SARC	cis	rs11122272	0.735	rs2808595	chr1:231526238	G/A	cg06096015	chr1:231504339	EGLN1	0.44	6.56	0.39	3.46e-10	Hemoglobin concentration;
SARC	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg12463550	chr7:65579703	CRCP	0.5	5.55	0.34	7.6e-8	Aortic root size;
SARC	cis	rs644799	1.000	rs593665	chr11:95574302	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.66	8.88	0.5	1.8e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9612	1.000	rs2074634	chr19:44238347	C/T	cg08581076	chr19:44259116	C19orf61	-0.72	-9.14	-0.51	3.17e-17	Exhaled nitric oxide output;
SARC	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.7	-8.88	-0.5	1.8e-16	Height;
SARC	cis	rs75804782	0.641	rs72987304	chr2:239345532	C/T	cg21699342	chr2:239360505	ASB1	-0.6	-4.9	-0.31	1.82e-6	Morning vs. evening chronotype;Chronotype;
SARC	cis	rs10779751	0.770	rs1417131	chr1:11191922	T/C	cg08854313	chr1:11322531	MTOR	-0.83	-10.57	-0.57	1.39e-21	Body mass index;
SARC	cis	rs4737010	0.644	rs518718	chr8:41611375	T/C	cg08923054	chr8:41654455	ANK1	-0.39	-4.8	-0.3	2.81e-6	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
SARC	cis	rs2290159	0.800	rs6766666	chr3:12690855	A/C	cg23032965	chr3:12705835	RAF1	-0.77	-8.65	-0.49	8.71e-16	Cholesterol, total;
SARC	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg11764359	chr7:65958608	NA	-0.77	-10.0	-0.55	7.97e-20	Aortic root size;
SARC	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.45	-5.75	-0.35	2.81e-8	Gut microbiome composition (summer);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg13132016	chr14:58893740	KIAA0586;TIMM9	0.52	6.46	0.39	6.2e-10	Breast cancer;
SARC	cis	rs6665290	0.901	rs61834004	chr1:227202782	G/A	cg14016676	chr1:227182615	CDC42BPA	0.37	5.3	0.33	2.74e-7	Myeloid white cell count;
SARC	cis	rs7772486	0.790	rs3924498	chr6:146233338	A/T	cg23711669	chr6:146136114	FBXO30	-0.81	-12.96	-0.65	2.69e-29	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3136441	0.786	rs10838612	chr11:46701728	G/T	cg25783544	chr11:47291846	MADD	0.7	4.94	0.31	1.5e-6	HDL cholesterol;
SARC	cis	rs1865760	0.713	rs9461229	chr6:25992279	G/T	cg16482183	chr6:26056742	HIST1H1C	0.5	6.71	0.4	1.47e-10	Height;
SARC	cis	rs644799	1.000	rs516551	chr11:95588626	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	13.87	0.67	2.75e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs1348850	1.000	rs3927978	chr2:178443854	A/G	cg23306229	chr2:178417860	TTC30B	-0.61	-7.11	-0.42	1.42e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7666738	0.830	rs34164616	chr4:99015251	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg20891283	chr12:69753455	YEATS4	0.55	7.55	0.44	9.74e-13	Blood protein levels;
SARC	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg27286337	chr10:134555280	INPP5A	0.71	8.17	0.47	2.02e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg22535103	chr8:58192502	C8orf71	-0.59	-6.27	-0.38	1.69e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7216064	0.953	rs4790905	chr17:65863350	C/A	cg12091567	chr17:66097778	LOC651250	-0.7	-7.64	-0.45	5.5e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	trans	rs9325144	0.647	rs11168104	chr12:38857616	G/T	cg23762105	chr12:34175262	ALG10	0.5	6.56	0.39	3.35e-10	Morning vs. evening chronotype;
SARC	cis	rs449789	0.857	rs591953	chr6:159716746	G/A	cg14500486	chr6:159655392	FNDC1	-0.44	-5.02	-0.31	1.01e-6	Pulse pressure;
SARC	cis	rs738322	0.555	rs6001029	chr22:38555193	C/A	cg25457927	chr22:38595422	NA	-0.26	-4.89	-0.31	1.86e-6	Cutaneous nevi;
SARC	cis	rs6752107	1.000	rs2241879	chr2:234183468	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.51	6.66	0.4	1.95e-10	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs7684253	0.548	rs13106200	chr4:57718195	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.39	-4.79	-0.3	2.97e-6	Migraine;
SARC	cis	rs11143230	1.000	rs62564005	chr9:74888383	A/T	cg07476130	chr9:74525250	C9orf85;FAM108B1	-0.46	-4.92	-0.31	1.65e-6	Suicidal ideation;
SARC	trans	rs2727020	0.523	rs4115783	chr11:49556026	G/A	cg15704280	chr7:45808275	SEPT13	0.7	8.16	0.47	2.1e-14	Coronary artery disease;
SARC	cis	rs9650657	0.655	rs10093774	chr8:10703293	C/T	cg00262122	chr8:11665843	FDFT1	0.41	5.08	0.32	7.86e-7	Neuroticism;
SARC	cis	rs7674212	0.541	rs2720464	chr4:104073201	G/A	cg16532752	chr4:104119610	CENPE	-0.49	-5.81	-0.36	1.99e-8	Type 2 diabetes;
SARC	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg13206674	chr6:150067644	NUP43	0.42	5.46	0.34	1.2e-7	Lung cancer;
SARC	cis	rs6570726	0.935	rs384806	chr6:145814889	C/G	cg05347473	chr6:146136440	FBXO30	0.49	6.48	0.39	5.27e-10	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs7980799	0.654	rs1482987	chr12:33614283	G/C	cg26384229	chr12:38710491	ALG10B	-0.62	-7.6	-0.45	7.36e-13	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs35306767	0.903	rs12254002	chr10:929133	A/G	cg26597838	chr10:835615	NA	-0.69	-7.44	-0.44	1.89e-12	Eosinophil percentage of granulocytes;
SARC	cis	rs9911578	0.835	rs2301867	chr17:56480074	T/A	cg05425664	chr17:57184151	TRIM37	0.64	7.83	0.46	1.72e-13	Intelligence (multi-trait analysis);
SARC	cis	rs911555	0.755	rs11620897	chr14:103944861	T/G	cg12935359	chr14:103987150	CKB	-0.37	-5.18	-0.32	4.91e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7712401	0.601	rs374403	chr5:122341713	A/G	cg19412675	chr5:122181750	SNX24	-0.43	-5.43	-0.34	1.41e-7	Mean platelet volume;
SARC	cis	rs12079745	1.000	rs12079745	chr1:169101060	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.71	-4.96	-0.31	1.39e-6	QT interval;
SARC	cis	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg00409905	chr10:38381863	ZNF37A	-0.55	-7.71	-0.45	3.72e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs6834538	0.597	rs9991830	chr4:113485372	T/C	cg05193411	chr4:113558554	LARP7;C4orf21	0.4	4.93	0.31	1.55e-6	Free thyroxine concentration;
SARC	cis	rs7264396	0.563	rs2425114	chr20:34322346	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-7.01	-0.42	2.5e-11	Total cholesterol levels;
SARC	cis	rs17376456	1.000	rs17323433	chr5:93551028	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.17	0.32	5e-7	Diabetic retinopathy;
SARC	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.41	0.44	2.36e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9896052	0.608	rs9797247	chr17:73445814	C/T	cg25649188	chr17:73499917	CASKIN2	0.33	4.83	0.3	2.5e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs72945132	0.882	rs12282678	chr11:70152457	G/A	cg05964544	chr11:70165517	PPFIA1	-0.61	-5.87	-0.36	1.5e-8	Coronary artery disease;
SARC	cis	rs10791323	0.536	rs1944731	chr11:133726067	G/A	cg15485101	chr11:133734466	NA	0.32	5.01	0.31	1.06e-6	Childhood ear infection;
SARC	cis	rs67460515	0.892	rs4856769	chr3:161004549	C/A	cg17135325	chr3:160939158	NMD3	0.61	7.5	0.44	1.36e-12	Parkinson's disease;
SARC	cis	rs1865760	0.713	rs2013063	chr6:25994098	C/T	cg10373733	chr6:25993375	NA	0.46	5.86	0.36	1.58e-8	Height;
SARC	cis	rs1419980	0.673	rs4883421	chr12:7774028	A/G	cg10578777	chr12:7781093	NA	0.53	5.72	0.35	3.22e-8	HDL cholesterol levels;
SARC	cis	rs6582618	1	rs6582618	chr12:38726137	A/G	cg10518543	chr12:38710700	ALG10B	0.39	4.8	0.3	2.86e-6	Morning vs. evening chronotype;
SARC	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg18252515	chr7:66147081	NA	-0.49	-5.2	-0.32	4.46e-7	Aortic root size;
SARC	cis	rs3820928	0.810	rs10175929	chr2:227858609	T/C	cg05526886	chr2:227700861	RHBDD1	-0.49	-5.91	-0.36	1.22e-8	Pulmonary function;
SARC	cis	rs35110281	0.540	rs55840436	chr21:45118541	G/T	cg21573476	chr21:45109991	RRP1B	-0.6	-8.67	-0.49	7.63e-16	Mean corpuscular volume;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg10284115	chr3:15841404	ANKRD28	-0.55	-7.1	-0.42	1.51e-11	Alcohol dependence;
SARC	cis	rs6456156	0.846	rs7774396	chr6:167519786	G/A	cg07741184	chr6:167504864	NA	0.33	6.32	0.38	1.31e-9	Primary biliary cholangitis;
SARC	cis	rs5758659	0.652	rs129857	chr22:42399686	C/T	cg04733989	chr22:42467013	NAGA	-0.5	-6.8	-0.41	8.87e-11	Cognitive function;
SARC	cis	rs72781680	0.848	rs72798057	chr2:23976731	T/C	cg06627628	chr2:24431161	ITSN2	-0.68	-6.43	-0.39	7.31e-10	Lymphocyte counts;
SARC	cis	rs920590	0.502	rs2035891	chr8:19634395	G/C	cg03894339	chr8:19674705	INTS10	0.46	5.67	0.35	4.22e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9400467	0.506	rs12207616	chr6:111608797	A/T	cg15721981	chr6:111408429	SLC16A10	0.68	5.29	0.33	2.86e-7	Blood metabolite levels;Amino acid levels;
SARC	trans	rs208520	0.690	rs12194057	chr6:66745616	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	13.79	0.67	5.04e-32	Exhaled nitric oxide output;
SARC	cis	rs17209837	1.000	rs4148805	chr7:87106365	G/A	cg00919237	chr7:87102261	ABCB4	-0.46	-4.81	-0.3	2.66e-6	Gallbladder cancer;
SARC	cis	rs17270561	0.609	rs9358885	chr6:25758024	T/C	cg17691542	chr6:26056736	HIST1H1C	0.6	7.31	0.43	4.24e-12	Iron status biomarkers;
SARC	cis	rs9487051	0.676	rs2222392	chr6:109602303	T/C	cg01475377	chr6:109611718	NA	-0.36	-5.26	-0.33	3.25e-7	Reticulocyte fraction of red cells;
SARC	cis	rs6089584	1.000	rs6089587	chr20:60564829	C/T	cg13770153	chr20:60521292	NA	-0.55	-7.78	-0.45	2.37e-13	Body mass index;
SARC	cis	rs4481887	0.927	rs4405158	chr1:248490647	A/C	cg13385794	chr1:248469461	NA	0.33	4.96	0.31	1.35e-6	Common traits (Other);
SARC	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	13.6	0.67	2.11e-31	Chronic sinus infection;
SARC	cis	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg07636037	chr3:49044803	WDR6	0.64	6.51	0.39	4.58e-10	Menarche (age at onset);
SARC	trans	rs61931739	0.500	rs10844734	chr12:34043083	G/A	cg13010199	chr12:38710504	ALG10B	0.66	9.05	0.51	5.8e-17	Morning vs. evening chronotype;
SARC	cis	rs11264799	0.603	rs12731814	chr1:157585917	G/A	cg18268488	chr1:157545234	FCRL4	0.35	5.96	0.36	9.2e-9	IgA nephropathy;
SARC	cis	rs9341808	0.667	rs1575541	chr6:80917485	T/A	cg08355045	chr6:80787529	NA	0.36	5.69	0.35	3.75e-8	Sitting height ratio;
SARC	cis	rs10046574	0.908	rs28418917	chr7:135124905	T/C	cg27474649	chr7:135195673	CNOT4	0.88	7.17	0.43	9.89e-12	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs7100689	0.622	rs7090351	chr10:82142047	T/G	cg01528321	chr10:82214614	TSPAN14	0.73	10.16	0.55	2.53e-20	Post bronchodilator FEV1;
SARC	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-15.51	-0.71	9.76e-38	Chronic sinus infection;
SARC	cis	rs3087591	0.597	rs731759	chr17:29722809	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.44	-5.63	-0.35	5.22e-8	Hip circumference;
SARC	cis	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg24110177	chr3:50126178	RBM5	0.56	7.62	0.45	6.17e-13	Intelligence (multi-trait analysis);
SARC	cis	rs698833	0.886	rs786654	chr2:44581007	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.66	8.37	0.48	5.28e-15	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs9807989	0.507	rs4851572	chr2:103019031	G/A	cg03938978	chr2:103052716	IL18RAP	0.31	5.02	0.31	1.04e-6	Asthma;
SARC	cis	rs6502050	0.787	rs11653012	chr17:80058857	C/T	cg19223190	chr17:80058835	NA	-0.47	-6.77	-0.41	1.03e-10	Life satisfaction;
SARC	cis	rs12681288	0.823	rs2701908	chr8:1003250	T/C	cg04851639	chr8:1020857	NA	-0.27	-4.72	-0.3	4.03e-6	Schizophrenia;
SARC	cis	rs2304069	0.954	rs10068537	chr5:149403193	G/A	cg12661370	chr5:149340060	SLC26A2	0.61	6.03	0.37	6.32e-9	HIV-1 control;
SARC	cis	rs9916302	0.706	rs12937013	chr17:37665571	G/A	cg00129232	chr17:37814104	STARD3	-0.58	-6.16	-0.37	3.21e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs7932354	0.528	rs4752952	chr11:47082858	T/C	cg03339077	chr11:47165057	C11orf49	-0.45	-6.16	-0.37	3.17e-9	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs1055129	0.560	rs2608880	chr17:73938957	C/T	cg14829360	chr17:73884958	NA	-0.57	-8.65	-0.49	8.53e-16	White matter hyperintensity burden;
SARC	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	12.64	0.64	3.03e-28	Chronic sinus infection;
SARC	cis	rs950169	0.614	rs12911536	chr15:84673030	G/T	cg17507749	chr15:85114479	UBE2QP1	0.72	7.97	0.46	6.98e-14	Schizophrenia;
SARC	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg15556689	chr8:8085844	FLJ10661	0.4	4.75	0.3	3.55e-6	Mood instability;
SARC	cis	rs9316337	0.933	rs1409071	chr13:21962773	C/T	cg21080246	chr13:22033151	ZDHHC20	-0.4	-5.21	-0.32	4.22e-7	Schizophrenia;
SARC	cis	rs9457247	0.663	rs1894603	chr6:167434686	C/T	cg07741184	chr6:167504864	NA	-0.36	-7.27	-0.43	5.43e-12	Crohn's disease;
SARC	cis	rs80282103	0.867	rs74117668	chr10:1076620	C/T	cg08668510	chr10:1095578	IDI1	0.76	5.25	0.32	3.5e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs9899728	0.539	rs12940199	chr17:73054759	C/T	cg27626185	chr17:73056755	KCTD2	-0.93	-7.63	-0.45	5.8e-13	Alzheimer's disease or small vessel stroke;
SARC	cis	rs7264396	0.790	rs3787164	chr20:34228866	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-8.24	-0.47	1.27e-14	Total cholesterol levels;
SARC	trans	rs1994135	0.647	rs66542958	chr12:33695385	T/G	cg26384229	chr12:38710491	ALG10B	0.79	9.82	0.54	2.77e-19	Resting heart rate;
SARC	cis	rs9916302	0.904	rs12450559	chr17:37694709	G/A	cg15445000	chr17:37608096	MED1	0.42	4.93	0.31	1.59e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs12586317	0.514	rs61100068	chr14:35400232	A/T	cg16230307	chr14:35515116	FAM177A1	1.08	11.66	0.61	4.74e-25	Psoriasis;
SARC	cis	rs7666738	0.830	rs13140676	chr4:98804978	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.54	0.49	1.74e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2153535	0.580	rs6921036	chr6:8455400	G/A	cg21535247	chr6:8435926	SLC35B3	0.53	6.59	0.4	2.96e-10	Motion sickness;
SARC	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-6.14	-0.37	3.51e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9398803	0.624	rs1455739	chr6:126631789	A/T	cg19875578	chr6:126661172	C6orf173	-0.46	-6.21	-0.38	2.41e-9	Male-pattern baldness;
SARC	cis	rs5758511	0.680	rs739147	chr22:42671066	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.45	6.73	0.4	1.33e-10	Birth weight;
SARC	cis	rs6840360	0.571	rs2165789	chr4:152510130	A/T	cg22705602	chr4:152727874	NA	-0.44	-6.82	-0.41	7.54e-11	Intelligence (multi-trait analysis);
SARC	cis	rs2718058	0.630	rs2722227	chr7:37858610	G/A	cg15028436	chr7:37888078	TXNDC3	0.39	4.93	0.31	1.54e-6	Alzheimer's disease (late onset);
SARC	cis	rs1348850	0.561	rs4893956	chr2:178373452	C/T	cg23306229	chr2:178417860	TTC30B	0.79	7.68	0.45	4.31e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2070488	0.965	rs1046048	chr3:38524742	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	13.63	0.67	1.66e-31	Electrocardiographic conduction measures;
SARC	cis	rs10875746	0.903	rs12304476	chr12:48482153	T/C	cg26205652	chr12:48591994	NA	0.56	6.1	0.37	4.37e-9	Longevity (90 years and older);
SARC	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg08280861	chr8:58055591	NA	0.6	5.28	0.33	2.92e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs11122272	0.525	rs2739517	chr1:231537914	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.94	-0.55	1.26e-19	Hemoglobin concentration;
SARC	cis	rs6728642	0.708	rs115507803	chr2:97752054	T/C	cg26665480	chr2:98280029	ACTR1B	-0.64	-5.07	-0.32	8.2e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs7937682	0.575	rs7107213	chr11:111750430	A/G	cg22437258	chr11:111473054	SIK2	-0.51	-6.0	-0.37	7.52e-9	Primary sclerosing cholangitis;
SARC	cis	rs73242632	1.000	rs28719609	chr4:57881862	T/G	cg20415529	chr4:57845134	POLR2B;C4orf14	1.07	6.6	0.4	2.74e-10	Congenital heart disease (maternal effect);
SARC	cis	rs73086581	0.891	rs11907503	chr20:3887590	C/T	cg02187196	chr20:3869020	PANK2	0.64	5.81	0.36	2.02e-8	Response to antidepressants in depression;
SARC	cis	rs4588572	0.601	rs1529500	chr5:77721643	C/T	cg11547950	chr5:77652471	NA	-0.42	-5.09	-0.32	7.32e-7	Triglycerides;
SARC	cis	rs1153858	0.943	rs11070454	chr15:45680252	C/T	cg03999130	chr15:45571217	NA	0.39	4.98	0.31	1.25e-6	Homoarginine levels;
SARC	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.93	11.62	0.61	6.45e-25	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg18876405	chr7:65276391	NA	-0.44	-4.94	-0.31	1.48e-6	Aortic root size;
SARC	cis	rs4727027	0.782	rs10245343	chr7:148796333	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.57	6.36	0.38	1.06e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs9815354	1.000	rs6797165	chr3:41887777	A/G	cg03022575	chr3:42003672	ULK4	0.55	5.19	0.32	4.65e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs7769051	0.522	rs17061975	chr6:133240019	T/A	cg22852734	chr6:133119734	C6orf192	1.0	5.88	0.36	1.42e-8	Type 2 diabetes nephropathy;
SARC	cis	rs637571	0.522	rs542332	chr11:65744421	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.58	9.1	0.51	4.04e-17	Eosinophil percentage of white cells;
SARC	cis	rs6120849	0.663	rs13041792	chr20:33545055	G/A	cg06115741	chr20:33292138	TP53INP2	0.54	5.34	0.33	2.22e-7	Protein C levels;
SARC	cis	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg18252515	chr7:66147081	NA	-1.27	-11.31	-0.6	6.26e-24	Diabetic kidney disease;
SARC	cis	rs4304924	0.500	rs7339081	chr13:79235501	A/G	cg01819759	chr13:79234251	RNF219	0.54	6.27	0.38	1.78e-9	Large artery stroke;
SARC	cis	rs7824557	0.569	rs35418978	chr8:11186453	T/C	cg21775007	chr8:11205619	TDH	0.67	9.0	0.51	7.97e-17	Retinal vascular caliber;
SARC	cis	rs4820539	1.000	rs5759595	chr22:23471624	G/A	cg14186256	chr22:23484241	RTDR1	0.9	14.69	0.69	4.95e-35	Bone mineral density;
SARC	cis	rs7980687	0.657	rs10744151	chr12:123723735	G/C	cg05973401	chr12:123451056	ABCB9	0.52	5.89	0.36	1.37e-8	Height;Educational attainment;Head circumference (infant);
SARC	cis	rs2073300	0.609	rs3746737	chr20:23424638	C/T	cg12062639	chr20:23401060	NAPB	0.95	6.38	0.39	9.62e-10	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs8031584	1.000	rs1474380	chr15:31269235	T/C	cg08109568	chr15:31115862	NA	-0.48	-6.1	-0.37	4.41e-9	Huntington's disease progression;
SARC	cis	rs1865760	0.892	rs2328903	chr6:25935765	T/C	cg17691542	chr6:26056736	HIST1H1C	0.61	7.58	0.44	7.96e-13	Height;
SARC	cis	rs7224737	0.673	rs11079035	chr17:40289012	C/T	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-0.5	-4.82	-0.3	2.57e-6	Fibrinogen levels;
SARC	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.98	-16.12	-0.73	9.07e-40	Chronic sinus infection;
SARC	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg26752003	chr8:145688521	CYHR1	0.66	9.27	0.52	1.26e-17	Age at first birth;
SARC	cis	rs1568889	1.000	rs12287732	chr11:28120845	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.73	10.07	0.55	4.78e-20	Bipolar disorder;
SARC	cis	rs8067545	0.641	rs203460	chr17:19815286	G/C	cg13482628	chr17:19912719	NA	0.53	6.71	0.4	1.43e-10	Schizophrenia;
SARC	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg18252515	chr7:66147081	NA	0.58	6.24	0.38	2.02e-9	Aortic root size;
SARC	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg05332525	chr7:65337924	VKORC1L1	-0.43	-4.83	-0.3	2.49e-6	Aortic root size;
SARC	cis	rs2204008	0.540	rs1672425	chr12:38122842	G/A	cg13010199	chr12:38710504	ALG10B	-0.61	-7.72	-0.45	3.36e-13	Bladder cancer;
SARC	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	8.31	0.48	7.87e-15	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs11734570	0.581	rs76682731	chr4:38586045	T/C	cg18361445	chr4:38666374	KLF3;FLJ13197	0.57	6.49	0.39	5.23e-10	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs75920871	0.588	rs7101763	chr11:116941985	G/T	cg01368799	chr11:117014884	PAFAH1B2	-0.49	-4.95	-0.31	1.41e-6	Subjective well-being;
SARC	cis	rs477895	1.000	rs477895	chr11:64048912	C/T	cg04317338	chr11:64019027	PLCB3	-0.55	-5.12	-0.32	6.34e-7	Mean platelet volume;
SARC	cis	rs3768617	0.510	rs10752895	chr1:183068505	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.2	0.56	2e-20	Fuchs's corneal dystrophy;
SARC	cis	rs6840360	0.571	rs4696099	chr4:152501951	C/G	cg22705602	chr4:152727874	NA	-0.46	-6.81	-0.41	8.43e-11	Intelligence (multi-trait analysis);
SARC	cis	rs477692	0.905	rs514963	chr10:131419707	C/T	cg05714579	chr10:131428358	MGMT	0.53	6.8	0.41	8.56e-11	Response to temozolomide;
SARC	cis	rs11997175	0.646	rs7464237	chr8:33716596	C/T	ch.8.33884649F	chr8:33765107	NA	0.63	8.6	0.49	1.21e-15	Body mass index;
SARC	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg11987759	chr7:65425863	GUSB	-0.58	-7.64	-0.45	5.63e-13	Aortic root size;
SARC	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg18225595	chr11:63971243	STIP1	0.44	5.36	0.33	1.97e-7	Mean platelet volume;
SARC	cis	rs66573146	1.000	rs66573146	chr4:6984464	C/G	cg00086871	chr4:6988644	TBC1D14	0.99	5.28	0.33	2.99e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs7103648	0.669	rs12577383	chr11:47774238	C/T	cg20307385	chr11:47447363	PSMC3	0.76	10.21	0.56	1.77e-20	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs734999	0.588	rs867435	chr1:2523706	C/T	cg00980319	chr1:2560884	MMEL1	-0.36	-5.1	-0.32	7.06e-7	Ulcerative colitis;
SARC	cis	rs7223966	1.000	rs9891018	chr17:61827856	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.53	-5.6	-0.34	6.17e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs10876993	0.928	rs2928053	chr12:58063475	T/C	cg18357645	chr12:58087776	OS9	0.49	6.5	0.39	4.86e-10	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg13395646	chr4:1353034	KIAA1530	-0.56	-6.74	-0.4	1.23e-10	Obesity-related traits;
SARC	cis	rs2380220	0.576	rs4368819	chr6:96031109	T/G	cg04719120	chr6:96025338	MANEA	0.69	7.91	0.46	1.03e-13	Behavioural disinhibition (generation interaction);
SARC	cis	rs73086581	0.787	rs68127408	chr20:3868447	T/C	cg02187196	chr20:3869020	PANK2	0.67	5.88	0.36	1.38e-8	Response to antidepressants in depression;
SARC	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg02018176	chr4:1364513	KIAA1530	0.43	6.53	0.39	4.12e-10	Longevity;
SARC	cis	rs11874712	1.000	rs11082510	chr18:43656620	T/A	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.46	5.5	0.34	1.02e-7	Migraine - clinic-based;
SARC	cis	rs9325144	0.532	rs1352121	chr12:39130696	A/G	cg13010199	chr12:38710504	ALG10B	-0.49	-6.18	-0.38	2.81e-9	Morning vs. evening chronotype;
SARC	cis	rs11209002	0.567	rs983110	chr1:67539215	A/T	cg02640540	chr1:67518911	SLC35D1	0.59	6.66	0.4	1.99e-10	Crohn's disease;
SARC	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg01448562	chr3:133502909	NA	-0.49	-7.45	-0.44	1.79e-12	Iron status biomarkers;
SARC	trans	rs877282	1.000	rs11253361	chr10:770387	T/C	cg22713356	chr15:30763199	NA	1.02	9.93	0.55	1.29e-19	Uric acid levels;
SARC	cis	rs1003719	0.591	rs13046303	chr21:38551976	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.58	-7.89	-0.46	1.16e-13	Eye color traits;
SARC	cis	rs10992471	0.651	rs13296623	chr9:95301627	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.5	-6.15	-0.37	3.34e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg26425730	chr6:153304295	FBXO5	0.53	7.27	0.43	5.36e-12	Tetralogy of Fallot;
SARC	cis	rs7582720	1.000	rs72934711	chr2:203709997	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	7.55	0.44	1e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs5758659	0.652	rs133314	chr22:42401841	G/A	cg04733989	chr22:42467013	NAGA	0.5	6.73	0.4	1.29e-10	Cognitive function;
SARC	cis	rs3857536	0.813	rs4710581	chr6:66939954	T/C	cg07460842	chr6:66804631	NA	-0.51	-5.83	-0.36	1.86e-8	Blood trace element (Cu levels);
SARC	cis	rs8072100	0.727	rs4794052	chr17:45769236	T/C	cg08085267	chr17:45401833	C17orf57	-0.42	-4.95	-0.31	1.42e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs7412746	0.588	rs10305664	chr1:150839686	A/C	cg15448220	chr1:150897856	SETDB1	0.5	6.43	0.39	7.17e-10	Melanoma;
SARC	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg20607798	chr8:58055168	NA	0.56	5.27	0.33	3.12e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs141518190	1	rs141518190	chr15:78900647	A/G	cg18825076	chr15:78729989	IREB2	-0.43	-5.11	-0.32	6.81e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs2070488	0.965	rs1058945	chr3:38532511	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.85	-13.58	-0.66	2.4e-31	Electrocardiographic conduction measures;
SARC	cis	rs8523	0.697	rs59542081	chr6:11059209	T/G	cg13562911	chr6:11044106	ELOVL2	0.48	6.37	0.39	9.74e-10	Red blood cell fatty acid levels;
SARC	cis	rs7208859	0.623	rs9890862	chr17:29125450	C/A	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs72781680	0.898	rs72786298	chr2:24083011	C/T	cg06627628	chr2:24431161	ITSN2	-0.69	-6.53	-0.39	3.99e-10	Lymphocyte counts;
SARC	cis	rs3106136	0.872	rs13130583	chr4:95245543	T/C	cg11021082	chr4:95130006	SMARCAD1	0.39	5.94	0.36	1.05e-8	Capecitabine sensitivity;
SARC	cis	rs4319547	0.695	rs10773103	chr12:122856532	A/G	cg23029597	chr12:123009494	RSRC2	0.42	5.26	0.33	3.26e-7	Body mass index;
SARC	cis	rs10883723	0.810	rs2281879	chr10:104268877	C/G	cg22532475	chr10:104410764	TRIM8	-0.24	-4.85	-0.3	2.27e-6	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs6690583	1.000	rs10443172	chr1:85485768	T/C	cg22153463	chr1:85462885	MCOLN2	-0.67	-7.0	-0.42	2.65e-11	Serum sulfate level;
SARC	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg12310025	chr6:25882481	NA	0.52	6.82	0.41	7.85e-11	Blood metabolite levels;
SARC	cis	rs8072100	0.905	rs9901869	chr17:45575206	G/A	cg08085267	chr17:45401833	C17orf57	-0.42	-4.91	-0.31	1.74e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs4319547	0.915	rs10734924	chr12:123018894	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.66	-7.83	-0.46	1.67e-13	Body mass index;
SARC	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg17971929	chr21:40555470	PSMG1	-0.85	-11.04	-0.59	4.51e-23	Cognitive function;
SARC	cis	rs34779708	0.966	rs7070427	chr10:35485689	A/T	cg03585969	chr10:35415529	CREM	0.39	4.88	0.3	1.96e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg05861140	chr6:150128134	PCMT1	-0.42	-5.44	-0.34	1.32e-7	Lung cancer;
SARC	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg05368731	chr17:41323189	NBR1	0.77	9.47	0.53	3.29e-18	Menopause (age at onset);
SARC	cis	rs77741769	0.926	rs61946386	chr12:121364025	T/C	cg02403541	chr12:121454288	C12orf43	0.57	6.85	0.41	6.66e-11	Mean corpuscular volume;
SARC	cis	rs9420	0.961	rs499188	chr11:57434122	C/A	cg19752551	chr11:57585705	CTNND1	-0.39	-5.37	-0.33	1.87e-7	Schizophrenia;
SARC	cis	rs7223966	1.000	rs7223966	chr17:61893398	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.5	-5.2	-0.32	4.45e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs4423214	1.000	rs4944959	chr11:71168234	C/T	cg05163923	chr11:71159392	DHCR7	-0.67	-9.29	-0.52	1.13e-17	Vitamin D levels;
SARC	cis	rs7618501	0.519	rs3774750	chr3:50208406	C/G	cg24110177	chr3:50126178	RBM5	0.43	5.46	0.34	1.21e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1865760	1.000	rs9358895	chr6:25924655	C/T	cg16482183	chr6:26056742	HIST1H1C	0.5	6.21	0.38	2.4e-9	Height;
SARC	cis	rs763121	0.853	rs5750659	chr22:39068789	T/C	cg21395723	chr22:39101663	GTPBP1	0.54	6.14	0.37	3.53e-9	Menopause (age at onset);
SARC	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.88	13.12	0.65	8.35e-30	Chronic sinus infection;
SARC	cis	rs748404	0.697	rs492743	chr15:43560945	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.52	6.14	0.37	3.6e-9	Lung cancer;
SARC	cis	rs8017423	0.967	rs4904662	chr14:90729427	G/A	cg20276874	chr14:90721474	PSMC1	-0.38	-5.25	-0.33	3.39e-7	Mortality in heart failure;
SARC	cis	rs1421811	0.532	rs17540044	chr5:32692238	C/G	cg16267343	chr5:32710456	NPR3	-0.84	-11.02	-0.59	5.44e-23	Blood pressure;
SARC	cis	rs4919087	0.748	rs793516	chr10:98987985	G/T	cg25902810	chr10:99078978	FRAT1	-0.53	-6.0	-0.37	7.41e-9	Monocyte count;
SARC	cis	rs1062177	1.000	rs2915880	chr5:151147334	G/A	cg00977110	chr5:151150581	G3BP1	0.63	6.3	0.38	1.44e-9	Preschool internalizing problems;
SARC	cis	rs1538970	0.816	rs10789464	chr1:45959102	C/T	cg05343316	chr1:45956843	TESK2	0.82	8.76	0.5	3.98e-16	Platelet count;
SARC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg10862848	chr6:42927986	GNMT	-0.4	-6.23	-0.38	2.13e-9	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg24633833	chr3:10029261	TMEM111	0.52	5.25	0.33	3.43e-7	Alzheimer's disease;
SARC	cis	rs3820928	0.845	rs1917126	chr2:227840923	G/T	cg05526886	chr2:227700861	RHBDD1	-0.56	-6.77	-0.41	1.01e-10	Pulmonary function;
SARC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg26338869	chr17:61819248	STRADA	0.8	10.64	0.57	8.58e-22	Prudent dietary pattern;
SARC	cis	rs5758659	0.714	rs133373	chr22:42465788	G/A	cg04692870	chr22:42525206	CYP2D6	0.35	4.83	0.3	2.48e-6	Cognitive function;
SARC	cis	rs561341	0.700	rs79272796	chr17:30226974	T/C	cg18200150	chr17:30822561	MYO1D	-0.37	-4.75	-0.3	3.49e-6	Hip circumference adjusted for BMI;
SARC	cis	rs6582630	0.539	rs35114325	chr12:38320886	G/T	cg26384229	chr12:38710491	ALG10B	-0.57	-6.99	-0.42	2.9100000000000002e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg16325326	chr1:53192061	ZYG11B	-0.95	-18.36	-0.77	3.72e-47	Monocyte count;
SARC	cis	rs11581859	0.613	rs6656525	chr1:99200544	A/G	cg20286094	chr1:99190917	SNX7	-0.42	-4.93	-0.31	1.55e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs7113874	0.659	rs12295855	chr11:8527418	A/G	cg09828998	chr11:8703972	RPL27A	0.5	5.38	0.33	1.84e-7	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6545883	0.929	rs12612982	chr2:61747355	G/A	cg15711740	chr2:61764176	XPO1	-0.41	-5.15	-0.32	5.64e-7	Tuberculosis;
SARC	cis	rs17345786	0.953	rs78645744	chr3:101327789	T/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.49	5.46	0.34	1.21e-7	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9325144	0.600	rs10785615	chr12:38733627	G/C	cg26384229	chr12:38710491	ALG10B	0.59	7.82	0.46	1.84e-13	Morning vs. evening chronotype;
SARC	cis	rs11731606	0.712	rs28502775	chr4:95401945	A/G	cg00507259	chr4:95128692	SMARCAD1	0.52	5.04	0.31	9.15e-7	Mean platelet volume;
SARC	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.41	-4.76	-0.3	3.47e-6	Longevity;Endometriosis;
SARC	cis	rs3771570	1.000	rs62186422	chr2:242249499	A/G	cg21155796	chr2:242212141	HDLBP	0.67	6.16	0.37	3.17e-9	Prostate cancer;
SARC	cis	rs2011503	0.882	rs4808958	chr19:19571752	G/A	cg03709012	chr19:19516395	GATAD2A	0.65	5.71	0.35	3.5e-8	Bipolar disorder;
SARC	cis	rs7666738	0.962	rs17027204	chr4:98997049	G/A	cg05340658	chr4:99064831	C4orf37	0.57	7.09	0.42	1.58e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9815354	0.951	rs1717028	chr3:41902964	C/T	cg03022575	chr3:42003672	ULK4	0.56	5.29	0.33	2.81e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs1023500	0.573	rs4822088	chr22:42470589	G/C	cg15557168	chr22:42548783	NA	-0.35	-4.81	-0.3	2.67e-6	Schizophrenia;
SARC	cis	rs13256369	0.802	rs12681925	chr8:8561649	G/A	cg18904891	chr8:8559673	CLDN23	0.48	5.3	0.33	2.74e-7	Obesity-related traits;
SARC	cis	rs7481584	0.962	rs12805426	chr11:3020580	C/T	cg05729581	chr11:3078854	CARS	0.47	5.78	0.35	2.44e-8	Calcium levels;
SARC	cis	rs9733	0.818	rs12130363	chr1:150688596	T/C	cg13175981	chr1:150552382	MCL1	0.64	8.91	0.5	1.51e-16	Tonsillectomy;
SARC	cis	rs35110281	0.715	rs8129601	chr21:45119104	A/G	cg01579765	chr21:45077557	HSF2BP	-0.35	-5.71	-0.35	3.35e-8	Mean corpuscular volume;
SARC	cis	rs2354432	1.000	rs7514864	chr1:146690102	T/C	cg25205988	chr1:146714368	CHD1L	1.06	11.09	0.59	3.12e-23	Mitochondrial DNA levels;
SARC	cis	rs9807989	0.811	rs7608638	chr2:102970289	A/G	cg09003973	chr2:102972529	NA	0.41	5.6	0.34	6.11e-8	Asthma;
SARC	cis	rs13191362	1.000	rs35754151	chr6:163074867	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.38	4.75	0.3	3.6e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg22800045	chr5:56110881	MAP3K1	0.74	7.83	0.46	1.74e-13	Initial pursuit acceleration;
SARC	trans	rs66573146	0.831	rs67702333	chr4:6983040	C/G	cg07817883	chr1:32538562	TMEM39B	1.32	8.67	0.49	7.41e-16	Granulocyte percentage of myeloid white cells;
SARC	cis	rs7666738	0.791	rs7377018	chr4:99034962	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs929354	0.742	rs6956046	chr7:156962874	G/A	cg05182265	chr7:156933206	UBE3C	-0.33	-5.08	-0.32	7.67e-7	Body mass index;
SARC	cis	rs9354308	0.764	rs1938072	chr6:66583328	C/T	cg07460842	chr6:66804631	NA	0.42	4.91	0.31	1.73e-6	Metabolite levels;
SARC	cis	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg25427524	chr10:38739819	LOC399744	0.57	9.09	0.51	4.44e-17	Extrinsic epigenetic age acceleration;
SARC	cis	rs57244997	0.872	rs11759694	chr6:162405705	C/G	cg17173639	chr6:162384350	PARK2	0.51	4.93	0.31	1.55e-6	Mosquito bite size;
SARC	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.98	-16.02	-0.72	1.89e-39	Chronic sinus infection;
SARC	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg10591111	chr5:226296	SDHA	0.58	5.39	0.33	1.7e-7	Breast cancer;
SARC	cis	rs136211	0.929	rs6000262	chr22:36770038	A/G	cg16924664	chr22:36878180	TXN2	0.42	5.18	0.32	4.77e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs13191362	1.000	rs34591938	chr6:163087003	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.72	6.23	0.38	2.17e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs9611565	0.921	rs8137373	chr22:41729216	A/G	cg06634786	chr22:41940651	POLR3H	0.5	6.16	0.37	3.21e-9	Vitiligo;
SARC	cis	rs9300255	0.568	rs1627724	chr12:123638580	T/A	cg00376283	chr12:123451042	ABCB9	0.58	6.91	0.41	4.65e-11	Neutrophil percentage of white cells;
SARC	cis	rs7000551	0.619	rs2443506	chr8:22373383	T/C	cg12081754	chr8:22256438	SLC39A14	0.56	7.99	0.46	6.23e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	20.81	0.81	4.58e-55	Prudent dietary pattern;
SARC	cis	rs3126085	0.935	rs1858479	chr1:152294823	A/T	cg26876637	chr1:152193138	HRNR	-0.5	-5.58	-0.34	6.59e-8	Atopic dermatitis;
SARC	cis	rs637571	0.522	rs556643	chr11:65733289	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.83	12.61	0.64	3.84e-28	Eosinophil percentage of white cells;
SARC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	18.99	0.78	3.24e-49	Prudent dietary pattern;
SARC	cis	rs9303401	0.659	rs34818467	chr17:56643109	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.92	-10.67	-0.57	6.86e-22	Cognitive test performance;
SARC	cis	rs2734839	0.537	rs6277	chr11:113283459	G/A	cg14159747	chr11:113255604	NA	0.35	4.9	0.31	1.79e-6	Information processing speed;
SARC	cis	rs17401966	1.000	rs7530167	chr1:10453374	A/G	cg15208524	chr1:10270712	KIF1B	0.55	6.0	0.37	7.4e-9	Hepatocellular carcinoma;
SARC	cis	rs7937682	0.889	rs1789355	chr11:111499718	T/C	cg22437258	chr11:111473054	SIK2	0.74	10.03	0.55	6.36e-20	Primary sclerosing cholangitis;
SARC	cis	rs11098499	0.779	rs7674500	chr4:120303593	C/T	cg09307838	chr4:120376055	NA	0.91	12.88	0.65	4.9e-29	Corneal astigmatism;
SARC	cis	rs67478160	0.584	rs2295148	chr14:104195610	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.38	-5.5	-0.34	9.75e-8	Schizophrenia;
SARC	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg27170947	chr2:26402098	FAM59B	0.37	4.8	0.3	2.79e-6	Gut microbiome composition (summer);
SARC	cis	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg14541582	chr5:601475	NA	-0.38	-4.85	-0.3	2.24e-6	Obesity-related traits;
SARC	cis	rs9875589	0.957	rs1433358	chr3:13943862	A/C	cg19554555	chr3:13937349	NA	0.5	6.62	0.4	2.43e-10	Ovarian reserve;
SARC	cis	rs17023223	0.508	rs12096448	chr1:119683390	G/A	cg05756136	chr1:119680316	WARS2	-0.48	-5.55	-0.34	7.84e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs9341808	0.650	rs6909546	chr6:80869923	C/G	cg08355045	chr6:80787529	NA	0.34	5.48	0.34	1.08e-7	Sitting height ratio;
SARC	cis	rs4588572	0.643	rs1035950	chr5:77785858	G/A	cg11547950	chr5:77652471	NA	-0.42	-5.12	-0.32	6.5e-7	Triglycerides;
SARC	cis	rs2742234	0.590	rs1254962	chr10:43696992	G/A	cg15436174	chr10:43711423	RASGEF1A	0.41	4.81	0.3	2.7e-6	Hirschsprung disease;
SARC	cis	rs854765	0.618	rs9908017	chr17:17774422	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.45	-5.84	-0.36	1.74e-8	Total body bone mineral density;
SARC	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg13206674	chr6:150067644	NUP43	0.42	5.53	0.34	8.42e-8	Lung cancer;
SARC	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.7	6.55	0.39	3.61e-10	Platelet count;
SARC	cis	rs6493487	0.512	rs35416047	chr15:51188545	T/C	cg02338191	chr15:51200825	AP4E1	0.55	5.09	0.32	7.27e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg09699651	chr6:150184138	LRP11	0.39	4.87	0.3	2.06e-6	Lung cancer;
SARC	cis	rs2834188	1.000	rs2834187	chr21:34687410	A/G	cg14352951	chr21:34696688	IFNAR1	0.46	5.5	0.34	9.74e-8	Narcolepsy;
SARC	cis	rs2204008	0.665	rs11179830	chr12:38220966	T/C	cg13010199	chr12:38710504	ALG10B	0.73	9.63	0.53	1.11e-18	Bladder cancer;
SARC	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg09455208	chr3:40491958	NA	0.4	5.81	0.36	2.01e-8	Renal cell carcinoma;
SARC	cis	rs2075371	0.863	rs34231360	chr7:133944988	A/C	cg20476274	chr7:133979776	SLC35B4	0.58	7.61	0.45	6.67e-13	Mean platelet volume;
SARC	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg24642844	chr7:1081250	C7orf50	-0.59	-6.06	-0.37	5.31e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs11098499	0.687	rs71610270	chr4:120287436	A/G	cg09307838	chr4:120376055	NA	0.83	11.78	0.61	1.96e-25	Corneal astigmatism;
SARC	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg13175981	chr1:150552382	MCL1	-0.54	-6.88	-0.41	5.42e-11	Tonsillectomy;
SARC	cis	rs7000551	0.689	rs6996872	chr8:22316753	T/C	cg12081754	chr8:22256438	SLC39A14	0.56	7.91	0.46	1.01e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs9815354	0.812	rs59583650	chr3:41809063	A/G	cg03022575	chr3:42003672	ULK4	0.72	5.99	0.37	7.83e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.79	10.3	0.56	9.27e-21	Prudent dietary pattern;
SARC	cis	rs80178925	1.000	rs77741531	chr18:70749441	T/C	cg26966630	chr18:70211916	CBLN2	-0.72	-4.85	-0.3	2.24e-6	Pursuit maintenance gain;
SARC	cis	rs7223966	1.000	rs11654335	chr17:61797579	A/T	cg00588841	chr17:61851480	DDX42;CCDC47	-0.68	-7.6	-0.45	7.42e-13	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg16414030	chr3:133502952	NA	-0.39	-5.32	-0.33	2.48e-7	Iron status biomarkers;
SARC	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg22857025	chr5:266934	NA	-1.04	-11.74	-0.61	2.61e-25	Breast cancer;
SARC	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg22535103	chr8:58192502	C8orf71	-0.59	-6.21	-0.38	2.35e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs57502260	0.704	rs2186937	chr11:68256847	G/A	cg01657329	chr11:68192670	LRP5	-0.49	-5.12	-0.32	6.3e-7	Total body bone mineral density (age 45-60);
SARC	cis	rs10088262	0.634	rs7815695	chr8:124783978	C/G	cg15047889	chr8:124780837	FAM91A1	-0.72	-7.5	-0.44	1.35e-12	Pancreatic cancer;
SARC	trans	rs7819412	0.745	rs2898260	chr8:10939490	G/T	cg06636001	chr8:8085503	FLJ10661	-0.6	-8.38	-0.48	4.96e-15	Triglycerides;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg26297968	chr2:211035960	C2orf67	-0.87	-7.48	-0.44	1.54e-12	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg13175981	chr1:150552382	MCL1	-0.54	-6.9	-0.41	4.97e-11	Tonsillectomy;
SARC	cis	rs2120243	1.000	rs2120243	chr3:157147568	A/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.62	8.13	0.47	2.48e-14	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs453301	0.571	rs2929456	chr8:9083416	G/A	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.96	-0.41	3.53e-11	Joint mobility (Beighton score);
SARC	cis	rs9914988	0.778	rs9907185	chr17:27122414	C/T	cg20469991	chr17:27169893	C17orf63	-0.5	-5.21	-0.32	4.1e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs8044995	0.501	rs55793998	chr16:68378985	G/T	cg09835421	chr16:68378352	PRMT7	-0.65	-6.13	-0.37	3.63e-9	Schizophrenia;
SARC	cis	rs9457247	1.000	rs932644	chr6:167404187	A/C	cg07741184	chr6:167504864	NA	0.29	5.55	0.34	7.72e-8	Crohn's disease;
SARC	cis	rs8044995	0.563	rs3785127	chr16:68399590	C/G	cg09835421	chr16:68378352	PRMT7	-0.67	-6.3	-0.38	1.45e-9	Schizophrenia;
SARC	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1198872	0.563	rs1106185	chr2:10963570	C/T	cg15705551	chr2:10952987	PDIA6	-0.47	-6.11	-0.37	4.05e-9	Cardiac Troponin-T levels;
SARC	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg18252515	chr7:66147081	NA	-1.33	-11.84	-0.61	1.22e-25	Diabetic kidney disease;
SARC	cis	rs3008870	0.959	rs4655658	chr1:67389608	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.93	11.22	0.59	1.24e-23	Lymphocyte percentage of white cells;
SARC	cis	rs870825	0.616	rs4519838	chr4:185628457	A/G	cg04058563	chr4:185651563	MLF1IP	0.83	11.53	0.6	1.25e-24	Blood protein levels;
SARC	cis	rs9309473	0.950	rs10207264	chr2:73714097	G/A	cg20560298	chr2:73613845	ALMS1	-0.52	-6.19	-0.38	2.66e-9	Metabolite levels;
SARC	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg06618935	chr21:46677482	NA	-0.41	-5.39	-0.33	1.74e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs12311304	0.966	rs7310253	chr12:15381237	G/A	cg08258403	chr12:15378311	NA	0.47	7.43	0.44	2.06e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs911555	0.723	rs4906324	chr14:103923099	A/G	cg24130564	chr14:104152367	KLC1	0.5	5.86	0.36	1.55e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2549003	1.000	rs2549003	chr5:131829297	A/G	cg21138405	chr5:131827807	IRF1	0.27	5.59	0.34	6.25e-8	Asthma (sex interaction);
SARC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.72	7.45	0.44	1.79e-12	Platelet count;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg18219951	chr5:161494810	GABRG2	-0.76	-6.79	-0.41	9.07e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs17376456	0.825	rs10072232	chr5:93398890	G/A	cg21475434	chr5:93447410	FAM172A	0.85	7.56	0.44	9.4e-13	Diabetic retinopathy;
SARC	cis	rs9790314	0.521	rs1450523	chr3:161077270	G/A	cg04691961	chr3:161091175	C3orf57	-0.57	-7.49	-0.44	1.43e-12	Morning vs. evening chronotype;
SARC	cis	rs9291683	0.585	rs12648479	chr4:10104571	G/A	cg11266682	chr4:10021025	SLC2A9	-0.42	-7.56	-0.44	9.35e-13	Bone mineral density;
SARC	cis	rs9815354	0.953	rs1716655	chr3:41918706	A/G	cg03022575	chr3:42003672	ULK4	-0.52	-4.94	-0.31	1.51e-6	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs4268898	0.610	rs34216622	chr2:24463445	G/C	cg06627628	chr2:24431161	ITSN2	-0.82	-9.95	-0.55	1.18e-19	Asthma;
SARC	cis	rs787274	1.000	rs787295	chr9:115541606	C/G	cg13803584	chr9:115635662	SNX30	0.67	5.26	0.33	3.21e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	trans	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg25756680	chr11:67771726	UNC93B1	-0.65	-6.42	-0.39	7.41e-10	Cutaneous psoriasis;
SARC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg18110333	chr6:292329	DUSP22	-0.65	-8.43	-0.48	3.64e-15	Menopause (age at onset);
SARC	cis	rs1801251	0.778	rs709933	chr2:233733144	G/A	cg25237894	chr2:233734115	C2orf82	-0.36	-5.11	-0.32	6.56e-7	Coronary artery disease;
SARC	cis	rs9359856	0.564	rs76069351	chr6:90425043	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.58	-4.73	-0.3	3.81e-6	Bipolar disorder;
SARC	cis	rs8141529	0.748	rs5762874	chr22:29269658	C/G	cg02153584	chr22:29168773	CCDC117	0.77	11.45	0.6	2.28e-24	Lymphocyte counts;
SARC	trans	rs11554257	0.745	rs17292046	chr9:117587092	A/C	cg00627241	chr22:29711922	RASL10A	-0.59	-6.3	-0.38	1.5e-9	Inflammatory bowel disease;Ulcerative colitis;
SARC	cis	rs11190604	1.000	rs2495732	chr10:102357780	T/C	cg07080220	chr10:102295463	HIF1AN	0.79	8.31	0.48	8.01e-15	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs17125944	0.505	rs77433996	chr14:53212263	G/A	cg00686598	chr14:53173677	PSMC6	1.3	9.08	0.51	4.65e-17	Alzheimer's disease (late onset);
SARC	cis	rs7772486	0.754	rs702304	chr6:145990797	A/G	cg05347473	chr6:146136440	FBXO30	-0.54	-7.41	-0.44	2.37e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs703842	1.000	rs10747783	chr12:58176614	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.78	11.39	0.6	3.43e-24	Multiple sclerosis;
SARC	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs568617	1.000	rs694994	chr11:65653309	A/G	cg26695010	chr11:65641043	EFEMP2	-0.49	-5.75	-0.35	2.82e-8	Crohn's disease;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg15684210	chr5:89755537	MBLAC2	0.48	6.46	0.39	6.12e-10	Thyroid stimulating hormone;
SARC	cis	rs11574514	1.000	rs13339239	chr16:67809401	C/T	cg01866162	chr16:67596514	CTCF	0.97	5.81	0.36	2.08e-8	Crohn's disease;
SARC	cis	rs7524258	0.900	rs7514988	chr1:7271651	C/T	cg07173049	chr1:7289937	CAMTA1	0.34	6.71	0.4	1.46e-10	Tourette's syndrome or obsessive-compulsive disorder;
SARC	cis	rs7520050	0.931	rs6686134	chr1:46378268	A/G	cg24296786	chr1:45957014	TESK2	0.38	4.82	0.3	2.54e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs9916302	0.904	rs4357971	chr17:37717280	C/T	cg00129232	chr17:37814104	STARD3	-0.64	-7.82	-0.46	1.79e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs7647973	1.000	rs1464569	chr3:49460350	A/G	cg07636037	chr3:49044803	WDR6	0.8	9.36	0.52	6.83e-18	Menarche (age at onset);
SARC	cis	rs11997175	0.624	rs4593494	chr8:33692621	C/T	ch.8.33884649F	chr8:33765107	NA	0.56	7.19	0.43	8.79e-12	Body mass index;
SARC	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg11766577	chr21:47581405	C21orf56	-0.45	-5.5	-0.34	1.02e-7	Testicular germ cell tumor;
SARC	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg08645402	chr16:4508243	NA	0.4	4.81	0.3	2.68e-6	Schizophrenia;
SARC	cis	rs1008375	1.000	rs7688682	chr4:17693794	A/G	cg16339924	chr4:17578868	LAP3	-0.57	-7.11	-0.42	1.42e-11	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2279817	1.000	rs1339801	chr1:18020298	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.48	5.38	0.33	1.79e-7	Neuroticism;
SARC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg07308232	chr7:1071921	C7orf50	-0.48	-5.95	-0.36	9.6e-9	Longevity;Endometriosis;
SARC	cis	rs7666738	0.830	rs35531558	chr4:98938217	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6815814	0.950	rs11722788	chr4:38810738	C/G	cg09316306	chr4:38807337	TLR1	0.5	5.22	0.32	3.93e-7	Breast cancer;
SARC	cis	rs17125944	0.505	rs75194546	chr14:53212069	A/C	cg00686598	chr14:53173677	PSMC6	1.32	9.08	0.51	4.59e-17	Alzheimer's disease (late onset);
SARC	cis	rs4919087	0.851	rs2297987	chr10:98989454	C/T	cg25902810	chr10:99078978	FRAT1	-0.49	-6.16	-0.37	3.11e-9	Monocyte count;
SARC	cis	rs933688	1.000	rs11950530	chr5:90688740	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.07	13.53	0.66	3.66e-31	Smoking behavior;
SARC	cis	rs295137	0.836	rs1217456	chr2:201092279	C/T	cg23649088	chr2:200775458	C2orf69	0.49	6.83	0.41	7.37e-11	Asthma (bronchodilator response);
SARC	cis	rs7520050	0.931	rs35743647	chr1:46407252	T/C	cg24296786	chr1:45957014	TESK2	0.38	4.8	0.3	2.82e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs1784581	0.802	rs9458430	chr6:162426517	G/T	cg17173639	chr6:162384350	PARK2	-0.61	-8.31	-0.48	8.03e-15	Itch intensity from mosquito bite;
SARC	cis	rs9457247	0.663	rs9459839	chr6:167431829	T/C	cg07741184	chr6:167504864	NA	0.34	6.71	0.4	1.43e-10	Crohn's disease;
SARC	cis	rs870825	0.616	rs7692367	chr4:185651056	T/C	cg04058563	chr4:185651563	MLF1IP	0.8	11.37	0.6	3.9e-24	Blood protein levels;
SARC	cis	rs3749237	0.595	rs2878298	chr3:49406080	T/C	cg06212747	chr3:49208901	KLHDC8B	0.5	6.04	0.37	6.11e-9	Resting heart rate;
SARC	cis	rs10078	0.571	rs2561664	chr5:459793	T/C	cg08916839	chr5:415575	AHRR	0.84	8.0	0.46	5.66e-14	Fat distribution (HIV);
SARC	cis	rs651907	0.557	rs13077925	chr3:101488181	T/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	6.36	0.38	1.08e-9	Colorectal cancer;
SARC	cis	rs1153858	1.000	rs12594857	chr15:45667178	A/G	cg03999130	chr15:45571217	NA	0.39	4.98	0.31	1.25e-6	Homoarginine levels;
SARC	cis	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg06558623	chr16:89946397	TCF25	0.92	6.49	0.39	5.05e-10	Skin colour saturation;
SARC	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg05368731	chr17:41323189	NBR1	0.81	9.9	0.54	1.66e-19	Menopause (age at onset);
SARC	cis	rs6138458	1.000	rs2387362	chr20:24899906	C/T	cg26195577	chr20:24973756	C20orf3	-0.86	-9.47	-0.53	3.25e-18	Blood protein levels;
SARC	cis	rs80282103	0.867	rs7098169	chr10:1078601	G/A	cg08668510	chr10:1095578	IDI1	0.76	5.19	0.32	4.61e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs12995491	0.933	rs13008732	chr2:88528771	G/A	cg04511125	chr2:88470314	THNSL2	-0.38	-5.71	-0.35	3.43e-8	Response to metformin (IC50);
SARC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.74	-10.18	-0.55	2.26e-20	Lymphocyte counts;
SARC	cis	rs35110281	0.776	rs9983763	chr21:44990578	A/G	cg21573476	chr21:45109991	RRP1B	0.56	8.04	0.47	4.41e-14	Mean corpuscular volume;
SARC	cis	rs6665290	0.669	rs12406714	chr1:227177061	T/C	cg14016676	chr1:227182615	CDC42BPA	0.34	4.91	0.31	1.69e-6	Myeloid white cell count;
SARC	cis	rs7216064	0.553	rs62084690	chr17:66035411	A/G	cg12091567	chr17:66097778	LOC651250	0.76	9.5	0.53	2.71e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs2361718	0.500	rs8068856	chr17:78100731	A/G	cg27427491	chr17:78079615	GAA	-0.34	-4.93	-0.31	1.53e-6	Yeast infection;
SARC	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg13395646	chr4:1353034	KIAA1530	-0.52	-6.16	-0.37	3.09e-9	Obesity-related traits;
SARC	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg22974920	chr21:40686053	BRWD1	0.45	4.86	0.3	2.13e-6	Cognitive function;
SARC	cis	rs9467711	0.606	rs2393667	chr6:26421345	T/C	cg12826209	chr6:26865740	GUSBL1	0.8	4.92	0.31	1.62e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2576037	0.899	rs2576035	chr18:44587654	C/T	cg15049968	chr18:44337910	ST8SIA5	0.33	5.15	0.32	5.59e-7	Personality dimensions;
SARC	cis	rs12134245	0.747	rs11164912	chr1:92005191	A/T	cg02896835	chr1:92012615	NA	-0.54	-7.37	-0.43	2.9e-12	Breast cancer;
SARC	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg13395646	chr4:1353034	KIAA1530	-0.41	-4.94	-0.31	1.46e-6	Obesity-related traits;
SARC	cis	rs950169	0.810	rs62029594	chr15:84955252	T/C	cg17507749	chr15:85114479	UBE2QP1	0.77	9.42	0.53	4.67e-18	Schizophrenia;
SARC	cis	rs5753618	0.561	rs714909	chr22:31741067	G/A	cg07713946	chr22:31675144	LIMK2	0.38	5.43	0.33	1.44e-7	Colorectal cancer;
SARC	cis	rs6450176	0.633	rs389525	chr5:53333075	G/C	ch.5.1024479R	chr5:53302184	ARL15	-0.55	-6.23	-0.38	2.21e-9	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs950776	0.642	rs61630816	chr15:78965866	T/C	cg06917634	chr15:78832804	PSMA4	0.45	4.98	0.31	1.26e-6	Sudden cardiac arrest;
SARC	cis	rs17376456	0.877	rs7736620	chr5:93305762	C/T	cg25358565	chr5:93447407	FAM172A	1.28	14.54	0.69	1.6e-34	Diabetic retinopathy;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg10170637	chr12:49110646	CCNT1	-0.54	-6.75	-0.4	1.17e-10	Schizophrenia;
SARC	cis	rs4742903	0.935	rs1507509	chr9:106984902	A/T	cg14250997	chr9:106856677	SMC2	0.39	4.94	0.31	1.49e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.46	5.34	0.33	2.17e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs1957429	0.520	rs72625644	chr14:65342282	A/T	cg23373153	chr14:65346875	NA	-0.82	-5.63	-0.35	5.25e-8	Pediatric areal bone mineral density (radius);
SARC	cis	rs12824058	0.831	rs12300308	chr12:130813825	G/A	cg24838063	chr12:130822603	PIWIL1	0.62	8.89	0.5	1.76e-16	Menopause (age at onset);
SARC	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs921968	0.541	rs10200507	chr2:219335944	C/A	cg02176678	chr2:219576539	TTLL4	-0.5	-7.61	-0.45	6.69e-13	Mean corpuscular hemoglobin concentration;
SARC	cis	rs796364	0.806	rs10445791	chr2:201078307	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.61	-4.82	-0.3	2.64e-6	Schizophrenia;
SARC	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	8.82	0.5	2.77e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs17826219	0.500	rs2874724	chr17:29072433	T/C	cg13385521	chr17:29058706	SUZ12P	0.88	7.94	0.46	8.37e-14	Body mass index;
SARC	cis	rs2425143	1.000	rs2425142	chr20:34350346	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-6.39	-0.39	8.93e-10	Blood protein levels;
SARC	trans	rs61931739	0.500	rs10772163	chr12:34532950	T/C	cg26384229	chr12:38710491	ALG10B	0.85	12.63	0.64	3.4e-28	Morning vs. evening chronotype;
SARC	cis	rs9291683	0.620	rs11722946	chr4:10125990	A/G	cg00071950	chr4:10020882	SLC2A9	-0.31	-4.83	-0.3	2.43e-6	Bone mineral density;
SARC	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg13699009	chr12:122356056	WDR66	0.58	9.66	0.53	8.57e-19	Mean corpuscular volume;
SARC	cis	rs554111	0.685	rs113664832	chr1:21058655	G/A	cg08890418	chr1:21044141	KIF17	-0.45	-6.09	-0.37	4.68e-9	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs7123876	0.830	rs57614870	chr11:72435983	A/G	cg03713592	chr11:72463424	ARAP1	0.69	7.74	0.45	3.06e-13	Body mass index;
SARC	cis	rs7561149	0.768	rs883894	chr2:179724735	T/C	cg17765952	chr2:179737173	CCDC141	-0.47	-6.08	-0.37	4.96e-9	QT interval;
SARC	cis	rs1568889	1.000	rs66702115	chr11:28181703	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	10.09	0.55	4.22e-20	Bipolar disorder;
SARC	cis	rs698833	0.886	rs698824	chr2:44723123	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.61	7.87	0.46	1.37e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg11890956	chr21:40555474	PSMG1	-1.05	-15.92	-0.72	4.26e-39	Cognitive function;
SARC	cis	rs1153858	1.000	rs1980288	chr15:45620612	T/C	cg14582100	chr15:45693742	SPATA5L1	0.35	4.76	0.3	3.44e-6	Homoarginine levels;
SARC	cis	rs10463316	0.817	rs1810083	chr5:150776807	A/G	cg03212797	chr5:150827313	SLC36A1	0.46	5.4	0.33	1.66e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg02711726	chr17:80685570	FN3KRP	-0.56	-6.86	-0.41	6.21e-11	Glycated hemoglobin levels;
SARC	cis	rs35123781	0.654	rs356484	chr5:139084438	T/A	cg10513866	chr5:139070639	NA	0.38	5.0	0.31	1.11e-6	Schizophrenia;
SARC	cis	rs8114671	0.562	rs6088646	chr20:33505937	T/C	cg07148914	chr20:33460835	GGT7	0.43	5.35	0.33	2.13e-7	Height;
SARC	cis	rs854765	0.624	rs9899634	chr17:17727943	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.49	-7.05	-0.42	2.04e-11	Total body bone mineral density;
SARC	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg26924012	chr15:45694286	SPATA5L1	0.77	10.99	0.58	6.8e-23	Homoarginine levels;
SARC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.06	0.8	1.11e-52	Prudent dietary pattern;
SARC	cis	rs7904368	1.000	rs7904368	chr10:16858587	C/T	cg14835575	chr10:16859367	RSU1	0.77	9.02	0.51	6.94e-17	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg04277193	chr17:41438351	NA	0.44	4.82	0.3	2.59e-6	Menopause (age at onset);
SARC	cis	rs7223966	1.000	rs7220892	chr17:61908316	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.45	4.83	0.3	2.46e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2439831	0.850	rs7163245	chr15:43671294	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	8.28	0.48	9.93e-15	Lung cancer in ever smokers;
SARC	cis	rs644799	1.000	rs3748256	chr11:95521953	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.89	14.05	0.68	7.08e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg12373951	chr3:133503437	NA	0.36	5.3	0.33	2.68e-7	Iron status biomarkers;
SARC	cis	rs11155671	0.530	rs7758033	chr6:150208135	T/C	cg00933542	chr6:150070202	PCMT1	0.29	4.76	0.3	3.42e-6	Testicular germ cell tumor;
SARC	cis	rs7000551	0.638	rs2469771	chr8:22376627	T/C	cg12081754	chr8:22256438	SLC39A14	0.55	7.69	0.45	4.21e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	9.01	0.51	7.42e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7223966	1.000	rs7222060	chr17:61868279	C/T	cg26338869	chr17:61819248	STRADA	0.47	5.08	0.32	7.71e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg00160902	chr4:16944285	NA	-0.5	-6.5	-0.39	4.93e-10	Height;
SARC	cis	rs3796352	0.764	rs34872575	chr3:52986277	G/A	cg12962167	chr3:53033115	SFMBT1	0.83	5.32	0.33	2.41e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg17376030	chr22:41985996	PMM1	0.64	7.52	0.44	1.15e-12	Vitiligo;
SARC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.41	0.39	8.21e-10	Bipolar disorder;
SARC	cis	rs17376456	0.825	rs17314074	chr5:93161467	T/C	cg25358565	chr5:93447407	FAM172A	1.19	10.58	0.57	1.3e-21	Diabetic retinopathy;
SARC	cis	rs6988636	1.000	rs7002021	chr8:124185250	G/A	cg23067535	chr8:124195133	FAM83A	-0.64	-5.3	-0.33	2.72e-7	Urinary uromodulin levels;
SARC	cis	rs918629	0.567	rs17085266	chr5:95247634	A/C	cg16656078	chr5:95278638	ELL2	-0.52	-6.55	-0.39	3.74e-10	IgG glycosylation;
SARC	cis	rs7772486	0.754	rs4896841	chr6:146041522	T/C	cg23711669	chr6:146136114	FBXO30	-0.91	-15.68	-0.72	2.56e-38	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg22875332	chr1:76189707	ACADM	0.49	6.62	0.4	2.42e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2425143	1.000	rs2425143	chr20:34350666	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.63	5.19	0.32	4.53e-7	Blood protein levels;
SARC	cis	rs5753618	0.509	rs1034589	chr22:31579233	C/T	cg02404636	chr22:31891804	SFI1	-0.51	-5.64	-0.35	4.85e-8	Colorectal cancer;
SARC	trans	rs61931739	0.534	rs10844828	chr12:34303109	C/T	cg13010199	chr12:38710504	ALG10B	0.66	8.94	0.51	1.26e-16	Morning vs. evening chronotype;
SARC	cis	rs7666738	0.830	rs13101766	chr4:98957696	C/A	cg05340658	chr4:99064831	C4orf37	0.66	9.0	0.51	8.07e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7666738	0.648	rs33988750	chr4:98985386	T/C	cg05340658	chr4:99064831	C4orf37	0.52	5.7	0.35	3.65e-8	Colonoscopy-negative controls vs population controls;
SARC	cis	rs644799	0.664	rs603625	chr11:95554283	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.6	7.93	0.46	9.24e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs3087591	1.000	rs2051507	chr17:29700101	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.49	-6.06	-0.37	5.55e-9	Hip circumference;
SARC	cis	rs761746	0.960	rs7289075	chr22:32013745	T/C	cg15823100	chr22:32027580	PISD	-0.35	-5.21	-0.32	4.21e-7	Intelligence;
SARC	cis	rs1153858	1.000	rs10519021	chr15:45631795	G/A	cg14582100	chr15:45693742	SPATA5L1	0.36	4.92	0.31	1.66e-6	Homoarginine levels;
SARC	cis	rs80130819	0.688	rs10783232	chr12:48583491	A/G	cg24011408	chr12:48396354	COL2A1	0.54	6.05	0.37	5.77e-9	Prostate cancer;
SARC	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg16405210	chr4:1374714	KIAA1530	-0.55	-6.85	-0.41	6.37e-11	Longevity;
SARC	trans	rs56341938	0.757	rs1420465	chr3:168715138	C/G	cg19056593	chr18:29078478	DSG2	-0.51	-6.85	-0.41	6.62e-11	Lung function (FEV1/FVC);
SARC	cis	rs17270561	0.583	rs7749149	chr6:25781139	G/A	cg16482183	chr6:26056742	HIST1H1C	0.48	5.89	0.36	1.31e-8	Iron status biomarkers;
SARC	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg18252515	chr7:66147081	NA	0.57	6.1	0.37	4.4e-9	Aortic root size;
SARC	cis	rs6700896	0.931	rs11208711	chr1:66147846	G/T	cg04111102	chr1:66153794	NA	0.37	5.65	0.35	4.78e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs7659604	0.540	rs11098643	chr4:122701507	C/A	cg19748678	chr4:122722346	EXOSC9	-0.43	-5.38	-0.33	1.83e-7	Type 2 diabetes;
SARC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	19.76	0.79	1.04e-51	Prudent dietary pattern;
SARC	cis	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg18252515	chr7:66147081	NA	-1.39	-12.23	-0.63	6.97e-27	Gout;
SARC	cis	rs7772486	0.659	rs9376957	chr6:146011064	C/T	cg23711669	chr6:146136114	FBXO30	-0.8	-12.87	-0.64	5.56e-29	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4072980	0.545	rs16824518	chr1:38415315	A/C	cg12658694	chr1:38397304	INPP5B	-0.79	-9.47	-0.53	3.28e-18	Coronary artery disease;
SARC	cis	rs13191362	0.935	rs34603926	chr6:163266793	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.62	5.97	0.36	8.56e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs11098499	0.866	rs6857892	chr4:120282696	G/T	cg09307838	chr4:120376055	NA	0.83	11.82	0.61	1.46e-25	Corneal astigmatism;
SARC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.48	0.53	3.07e-18	Prudent dietary pattern;
SARC	cis	rs10513788	0.665	rs2879538	chr3:181989595	G/A	cg05977900	chr3:182512126	ATP11B	0.48	5.07	0.32	7.96e-7	Cognitive function;
SARC	cis	rs10754283	0.967	rs7515375	chr1:90109854	T/C	cg21401794	chr1:90099060	LRRC8C	0.59	8.09	0.47	3.24e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs8002861	0.870	rs9567293	chr13:44447243	A/G	cg19180546	chr13:44453867	C13orf31;CCDC122	0.45	5.4	0.33	1.67e-7	Leprosy;
SARC	cis	rs36051895	0.659	rs10283730	chr9:5073289	G/A	cg02405213	chr9:5042618	JAK2	-0.44	-4.97	-0.31	1.3e-6	Pediatric autoimmune diseases;
SARC	cis	rs4917300	0.606	rs10875481	chr8:143100478	G/A	cg06573787	chr8:143070187	NA	-0.36	-4.84	-0.3	2.41e-6	Amyotrophic lateral sclerosis;
SARC	cis	rs6138458	1.000	rs227618	chr20:24909472	T/C	cg26195577	chr20:24973756	C20orf3	0.88	9.75	0.54	4.69e-19	Blood protein levels;
SARC	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	16.56	0.74	3.18e-41	Height;
SARC	cis	rs559928	0.606	rs11231726	chr11:63987339	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.65	4.93	0.31	1.55e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs651907	0.557	rs7651721	chr3:101393583	C/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	6.25	0.38	1.92e-9	Colorectal cancer;
SARC	cis	rs950027	0.620	rs1145093	chr15:45649813	C/A	cg26924012	chr15:45694286	SPATA5L1	0.53	6.78	0.41	9.59e-11	Response to fenofibrate (adiponectin levels);
SARC	cis	rs12709013	0.636	rs191783	chr16:58793898	C/A	cg04273148	chr16:57808038	KIFC3	0.32	4.72	0.3	4.08e-6	Blood metabolite ratios;
SARC	cis	rs79839061	0.610	rs9994159	chr4:891150	C/T	cg07828340	chr4:882639	GAK	0.77	6.04	0.37	6.05e-9	Intelligence (multi-trait analysis);
SARC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg22713941	chr2:105953959	C2orf49	-0.57	-6.29	-0.38	1.54e-9	Hepatitis;
SARC	cis	rs6120849	0.707	rs6120798	chr20:33610822	T/G	cg24642439	chr20:33292090	TP53INP2	0.57	5.54	0.34	8.1e-8	Protein C levels;
SARC	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg07701084	chr6:150067640	NUP43	0.42	5.51	0.34	9.69e-8	Lung cancer;
SARC	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg22920501	chr2:26401640	FAM59B	0.61	8.19	0.47	1.71e-14	Gut microbiome composition (summer);
SARC	cis	rs2228479	0.717	rs1061647	chr16:89806063	G/C	cg06558623	chr16:89946397	TCF25	0.9	6.24	0.38	2.06e-9	Skin colour saturation;
SARC	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg22968622	chr17:43663579	NA	-1.13	-15.28	-0.71	5.37e-37	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9815354	1.000	rs7646144	chr3:41853125	T/A	cg03022575	chr3:42003672	ULK4	0.59	5.28	0.33	2.89e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs262150	0.574	rs2730273	chr7:158797754	A/C	cg19418458	chr7:158789849	NA	-0.46	-6.42	-0.39	7.63e-10	Facial morphology (factor 20);
SARC	cis	rs2635047	0.967	rs2684843	chr18:44726260	T/A	cg19077165	chr18:44547161	KATNAL2	-0.36	-4.88	-0.3	1.93e-6	Educational attainment;
SARC	cis	rs6540556	0.723	rs9430014	chr1:209905372	A/C	cg05527609	chr1:210001259	C1orf107	-0.62	-5.87	-0.36	1.46e-8	Red blood cell count;
SARC	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg02725872	chr8:58115012	NA	-0.37	-6.54	-0.39	3.94e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6582630	0.555	rs56228141	chr12:38518652	T/G	cg13010199	chr12:38710504	ALG10B	0.77	10.66	0.57	7.44e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7760949	0.889	rs9396272	chr6:13938080	C/T	cg27413430	chr6:13925136	RNF182	-0.42	-5.11	-0.32	6.85e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs7592578	0.679	rs62181018	chr2:191323295	C/T	cg10560079	chr2:191398806	TMEM194B	-0.72	-8.3	-0.48	8.24e-15	Diastolic blood pressure;
SARC	cis	rs7561149	1.000	rs7600330	chr2:179689985	C/G	cg17765952	chr2:179737173	CCDC141	-0.39	-5.15	-0.32	5.62e-7	QT interval;
SARC	cis	rs12142240	0.698	rs1057533	chr1:46815836	C/T	cg00530320	chr1:46809349	NSUN4	0.57	6.79	0.41	9.41e-11	Menopause (age at onset);
SARC	cis	rs713477	0.967	rs2152975	chr14:55907919	C/T	cg13175173	chr14:55914753	NA	-0.3	-4.75	-0.3	3.6e-6	Pediatric bone mineral content (femoral neck);
SARC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg06873352	chr17:61820015	STRADA	0.53	6.85	0.41	6.67e-11	Prudent dietary pattern;
SARC	cis	rs7208859	0.673	rs73277984	chr17:29196133	T/C	cg13385521	chr17:29058706	SUZ12P	0.86	7.34	0.43	3.54e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs34172651	0.917	rs11642302	chr16:24770856	G/A	cg06028605	chr16:24865363	SLC5A11	0.27	5.0	0.31	1.12e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9398803	0.661	rs1101557	chr6:127067996	T/C	cg19875578	chr6:126661172	C6orf173	-0.62	-8.62	-0.49	1.06e-15	Male-pattern baldness;
SARC	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg14784868	chr12:69753453	YEATS4	0.51	6.77	0.41	1.04e-10	Blood protein levels;
SARC	cis	rs11098499	1.000	rs6837898	chr4:120179154	C/T	cg09307838	chr4:120376055	NA	0.84	11.6	0.61	7.45e-25	Corneal astigmatism;
SARC	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg22903657	chr4:1355424	KIAA1530	-0.36	-4.91	-0.31	1.69e-6	Obesity-related traits;
SARC	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs155076	0.938	rs9509633	chr13:21844482	G/C	cg14456004	chr13:21872349	NA	-1.0	-12.77	-0.64	1.13e-28	White matter hyperintensity burden;
SARC	cis	rs1691799	0.899	rs1168357	chr12:66749879	T/C	cg16791601	chr12:66731901	HELB	-0.72	-10.84	-0.58	1.94e-22	White blood cell count (basophil);
SARC	cis	rs1865760	0.963	rs9356991	chr6:25901758	C/A	cg17691542	chr6:26056736	HIST1H1C	0.56	6.82	0.41	7.67e-11	Height;
SARC	cis	rs3923518	0.956	rs13088577	chr3:38929631	C/G	cg15678707	chr3:39149194	GORASP1;TTC21A	0.47	5.06	0.31	8.46e-7	Migraine;
SARC	cis	rs911263	0.603	rs2064911	chr14:68807298	T/C	cg18825221	chr14:68749962	RAD51L1	0.43	7.65	0.45	5.41e-13	Primary biliary cholangitis;
SARC	cis	rs4917300	0.650	rs4917268	chr8:143072510	G/A	cg06573787	chr8:143070187	NA	0.37	5.53	0.34	8.42e-8	Amyotrophic lateral sclerosis;
SARC	cis	rs9790314	0.936	rs336572	chr3:161068014	G/A	cg04691961	chr3:161091175	C3orf57	-0.75	-10.99	-0.58	6.58e-23	Morning vs. evening chronotype;
SARC	cis	rs4073582	0.595	rs10896104	chr11:66001869	C/T	cg14036092	chr11:66035641	RAB1B	0.62	8.86	0.5	2.1e-16	Gout;
SARC	cis	rs8053891	0.614	rs34235351	chr16:71987875	G/A	cg16558253	chr16:72132732	DHX38	-0.39	-5.05	-0.31	8.81e-7	Coronary artery disease;
SARC	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg16339924	chr4:17578868	LAP3	0.65	8.69	0.49	6.65e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9868809	0.881	rs2276852	chr3:48666923	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.54	-4.96	-0.31	1.39e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs8102137	1.000	rs59868991	chr19:30297577	G/A	cg27475126	chr19:30303651	CCNE1	-0.42	-5.87	-0.36	1.51e-8	Bladder cancer;
SARC	cis	rs6912958	0.781	rs7742965	chr6:88278196	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-6.8	-0.41	8.58e-11	Monocyte percentage of white cells;
SARC	cis	rs950776	0.518	rs2292117	chr15:78834689	C/T	cg22563815	chr15:78856949	CHRNA5	0.4	6.53	0.39	4.11e-10	Sudden cardiac arrest;
SARC	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg15448220	chr1:150897856	SETDB1	0.47	6.22	0.38	2.24e-9	Tonsillectomy;
SARC	cis	rs7980687	0.628	rs2102949	chr12:123676763	G/A	cg00376283	chr12:123451042	ABCB9	0.57	6.86	0.41	6.06e-11	Height;Educational attainment;Head circumference (infant);
SARC	cis	rs6580649	0.941	rs7971668	chr12:48469696	T/C	cg05342945	chr12:48394962	COL2A1	0.55	5.91	0.36	1.22e-8	Lung cancer;
SARC	cis	rs10464366	0.746	rs12670510	chr7:39142146	A/G	cg18850127	chr7:39170497	POU6F2	0.44	5.4	0.33	1.64e-7	IgG glycosylation;
SARC	cis	rs10752881	1.000	rs10752885	chr1:182982878	C/G	cg13390022	chr1:182993471	LAMC1	0.34	5.19	0.32	4.5e-7	Colorectal cancer;
SARC	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg07157834	chr1:205819609	PM20D1	-0.4	-4.8	-0.3	2.87e-6	Parkinson's disease;
SARC	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg05861140	chr6:150128134	PCMT1	-0.4	-5.11	-0.32	6.7e-7	Lung cancer;
SARC	cis	rs897984	0.646	rs9938088	chr16:30830004	G/A	cg02466173	chr16:30829666	NA	-0.52	-7.47	-0.44	1.56e-12	Dementia with Lewy bodies;
SARC	cis	rs11098499	0.954	rs10006525	chr4:120408931	T/G	cg09307838	chr4:120376055	NA	0.92	12.61	0.64	3.86e-28	Corneal astigmatism;
SARC	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg27266027	chr21:40555129	PSMG1	0.49	5.25	0.33	3.4e-7	Cognitive function;
SARC	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-7.01	-0.42	2.58e-11	Gut microbiome composition (summer);
SARC	cis	rs918629	0.567	rs7716691	chr5:95237040	C/T	cg16656078	chr5:95278638	ELL2	-0.51	-6.43	-0.39	7.3e-10	IgG glycosylation;
SARC	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg03433033	chr1:76189801	ACADM	0.55	7.75	0.45	2.76e-13	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg12564285	chr5:131593104	PDLIM4	0.44	6.1	0.37	4.44e-9	Breast cancer;
SARC	cis	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg05623727	chr3:50126028	RBM5	-0.33	-5.0	-0.31	1.14e-6	Blood protein levels;
SARC	cis	rs9296092	0.538	rs75501442	chr6:33519493	A/G	cg13560919	chr6:33536144	NA	-0.51	-6.24	-0.38	2.08e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs9790314	0.613	rs11716265	chr3:160602111	A/G	cg04691961	chr3:161091175	C3orf57	-0.56	-7.68	-0.45	4.26e-13	Morning vs. evening chronotype;
SARC	cis	rs7666738	0.830	rs60411337	chr4:99046617	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.87	0.5	1.92e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs8067354	0.872	rs7224006	chr17:57896338	C/T	cg13753209	chr17:57696993	CLTC	-0.53	-6.66	-0.4	1.9e-10	Hemoglobin concentration;
SARC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	6.09	0.37	4.61e-9	Prudent dietary pattern;
SARC	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg18404041	chr3:52824283	ITIH1	-0.39	-5.98	-0.36	8.52e-9	Bipolar disorder;
SARC	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg13206674	chr6:150067644	NUP43	0.42	5.39	0.33	1.76e-7	Lung cancer;
SARC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg22903471	chr2:27725779	GCKR	-0.48	-7.23	-0.43	6.88e-12	Total body bone mineral density;
SARC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.95	0.81	1.72e-55	Prudent dietary pattern;
SARC	cis	rs11608355	0.545	rs6606721	chr12:109891999	G/A	cg05360138	chr12:110035743	NA	0.92	9.61	0.53	1.27e-18	Neuroticism;
SARC	cis	rs9814567	1.000	rs13090969	chr3:134307257	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	6.89	0.41	5.31e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs35213789	0.887	rs2058395	chr7:69216669	G/A	cg10619644	chr7:69149951	AUTS2	-0.43	-5.77	-0.35	2.5e-8	Childhood ear infection;
SARC	cis	rs9911578	0.935	rs117819974	chr17:57002324	C/T	cg05425664	chr17:57184151	TRIM37	-0.67	-8.32	-0.48	7.53e-15	Intelligence (multi-trait analysis);
SARC	cis	rs16854884	0.586	rs4527375	chr3:143735515	A/T	cg06585982	chr3:143692056	C3orf58	-0.72	-9.67	-0.54	8.35e-19	Economic and political preferences (feminism/equality);
SARC	cis	rs748404	0.631	rs7166812	chr15:43644760	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	5.83	0.36	1.87e-8	Lung cancer;
SARC	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg21724239	chr8:58056113	NA	0.61	5.93	0.36	1.1e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs17376456	0.877	rs7701011	chr5:93311456	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.46	0.34	1.24e-7	Diabetic retinopathy;
SARC	cis	rs2635047	0.638	rs2635051	chr18:44645029	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	6.46	0.39	6.06e-10	Educational attainment;
SARC	cis	rs8084125	0.832	rs2156646	chr18:74946660	C/T	cg07390210	chr18:74961196	GALR1	0.51	5.89	0.36	1.32e-8	Obesity-related traits;
SARC	cis	rs76917914	0.820	rs58427887	chr9:100820671	C/T	cg03040243	chr9:100819229	NANS	0.71	7.81	0.46	1.93e-13	Immature fraction of reticulocytes;
SARC	cis	rs3008870	0.727	rs4582760	chr1:67464394	G/A	cg02640540	chr1:67518911	SLC35D1	-0.45	-5.22	-0.32	3.9e-7	Lymphocyte percentage of white cells;
SARC	cis	rs4727027	0.866	rs12666477	chr7:148812322	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.48	5.64	0.35	4.84e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	trans	rs7819412	0.522	rs3021495	chr8:10994743	C/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.53	-0.39	4.04e-10	Triglycerides;
SARC	cis	rs9457247	1.000	rs393558	chr6:167397750	A/C	cg07741184	chr6:167504864	NA	0.29	5.55	0.34	7.59e-8	Crohn's disease;
SARC	cis	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg21775007	chr8:11205619	TDH	-0.43	-5.42	-0.33	1.47e-7	Neuroticism;
SARC	cis	rs295140	0.803	rs4233994	chr2:201129211	G/C	cg05691004	chr2:201170426	SPATS2L	0.35	4.98	0.31	1.24e-6	QT interval;
SARC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg16132339	chr22:24313637	DDTL;DDT	0.41	5.6	0.34	5.96e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9393777	0.513	rs9379893	chr6:26584668	A/G	cg12292205	chr6:26970375	C6orf41	0.53	4.8	0.3	2.87e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg05623727	chr3:50126028	RBM5	0.33	5.03	0.31	9.72e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg17691542	chr6:26056736	HIST1H1C	0.42	5.03	0.31	9.96e-7	Height;
SARC	cis	rs9814567	1.000	rs6765505	chr3:134208132	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-6.96	-0.41	3.44e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs11155671	0.530	rs7742993	chr6:150205095	G/A	cg09699651	chr6:150184138	LRP11	0.52	6.59	0.4	2.9e-10	Testicular germ cell tumor;
SARC	cis	rs13191362	0.935	rs35378894	chr6:163123933	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.73	6.43	0.39	6.99e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg11764359	chr7:65958608	NA	0.76	8.78	0.5	3.62e-16	Aortic root size;
SARC	cis	rs10936632	0.728	rs10804840	chr3:170071807	G/A	cg11886554	chr3:170076028	SKIL	0.4	5.03	0.31	9.85e-7	Prostate cancer;
SARC	cis	rs57502260	0.679	rs72936524	chr11:68275898	G/A	cg01657329	chr11:68192670	LRP5	-0.5	-5.04	-0.31	9.14e-7	Total body bone mineral density (age 45-60);
SARC	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg06420487	chr17:61919686	SMARCD2	0.44	4.8	0.3	2.86e-6	Height;
SARC	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.44	-5.46	-0.34	1.22e-7	Lymphocyte counts;
SARC	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg10591111	chr5:226296	SDHA	-0.56	-5.1	-0.32	7.03e-7	Breast cancer;
SARC	cis	rs9815354	0.812	rs73828254	chr3:41810180	T/A	cg03022575	chr3:42003672	ULK4	0.72	5.99	0.37	7.83e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg24549020	chr5:56110836	MAP3K1	0.45	5.25	0.33	3.49e-7	Coronary artery disease;
SARC	cis	rs10504229	0.679	rs78941440	chr8:58052095	A/G	cg08280861	chr8:58055591	NA	0.55	5.03	0.31	9.82e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs61931739	0.500	rs11053272	chr12:34547020	C/G	cg26384229	chr12:38710491	ALG10B	0.91	13.78	0.67	5.4e-32	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg02725872	chr8:58115012	NA	-0.34	-5.37	-0.33	1.91e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7772486	0.686	rs4896833	chr6:145965673	T/G	cg23711669	chr6:146136114	FBXO30	0.78	12.3	0.63	4.07e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4595586	0.545	rs7294600	chr12:39373416	A/G	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	cis	rs4132509	0.744	rs10803146	chr1:243709454	T/G	cg21452805	chr1:244014465	NA	0.58	5.42	0.33	1.49e-7	RR interval (heart rate);
SARC	cis	rs6912958	0.781	rs4464759	chr6:88282621	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.51	-0.34	9.6e-8	Monocyte percentage of white cells;
SARC	cis	rs453301	0.606	rs7462373	chr8:8899318	G/C	cg08975724	chr8:8085496	FLJ10661	-0.48	-6.32	-0.38	1.33e-9	Joint mobility (Beighton score);
SARC	cis	rs9400467	0.537	rs3218591	chr6:111696129	T/A	cg15721981	chr6:111408429	SLC16A10	0.65	5.65	0.35	4.61e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg24531977	chr5:56204891	C5orf35	0.66	6.36	0.38	1.07e-9	Initial pursuit acceleration;
SARC	cis	rs6565681	1.000	rs4889848	chr17:78354661	C/T	cg15383979	chr17:78362278	RNF213;LOC100294362	-0.59	-4.93	-0.31	1.6e-6	Moyamoya disease;
SARC	cis	rs4664308	0.905	rs62177860	chr2:160960571	C/T	cg03641300	chr2:160917029	PLA2R1	-0.68	-9.32	-0.52	9.35e-18	Idiopathic membranous nephropathy;
SARC	cis	rs77633900	0.614	rs1905694	chr15:76951772	T/C	cg21673338	chr15:77095150	SCAPER	-0.77	-6.48	-0.39	5.51e-10	Non-glioblastoma glioma;Glioma;
SARC	cis	rs2832191	0.791	rs7282843	chr21:30475226	A/G	cg24692254	chr21:30365293	RNF160	0.93	13.66	0.67	1.32e-31	Dental caries;
SARC	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg03575189	chr17:44344142	NA	-0.48	-4.84	-0.3	2.41e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs644799	1.000	rs568668	chr11:95528209	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	14.15	0.68	3.08e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg24060327	chr5:131705240	SLC22A5	-0.48	-5.76	-0.35	2.65e-8	Acylcarnitine levels;
SARC	cis	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg07636037	chr3:49044803	WDR6	0.65	8.6	0.49	1.19e-15	Resting heart rate;
SARC	cis	rs7481584	0.624	rs440130	chr11:3051476	A/G	cg25174290	chr11:3078921	CARS	-0.6	-8.35	-0.48	6.26e-15	Calcium levels;
SARC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	21.26	0.81	1.8e-56	Prudent dietary pattern;
SARC	cis	rs4664304	0.900	rs62176692	chr2:160743463	C/T	cg02280532	chr2:160761244	LY75	-0.32	-4.95	-0.31	1.41e-6	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs13088281	1.000	rs13088281	chr3:53147576	A/C	cg27565382	chr3:53032988	SFMBT1	-0.77	-5.4	-0.33	1.61e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs4243830	0.850	rs10746502	chr1:6607199	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.9	-8.65	-0.49	8.76e-16	Body mass index;
SARC	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	11.99	0.62	4.13e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs1355223	0.902	rs7102625	chr11:34739717	A/C	cg18508148	chr11:34937573	PDHX;APIP	0.42	5.18	0.32	4.83e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs712039	0.652	rs853200	chr17:35804114	G/A	cg16670864	chr17:35848621	DUSP14	0.46	4.97	0.31	1.3e-6	Tuberculosis;
SARC	cis	rs172166	0.637	rs1233691	chr6:28153897	T/G	cg17221315	chr6:27791827	HIST1H4J	0.45	5.32	0.33	2.45e-7	Cardiac Troponin-T levels;
SARC	cis	rs155076	1.000	rs58519241	chr13:21845006	C/A	cg14456004	chr13:21872349	NA	-1.0	-12.77	-0.64	1.13e-28	White matter hyperintensity burden;
SARC	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg01341218	chr17:43662625	NA	0.9	10.06	0.55	5.21e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg00149659	chr3:10157352	C3orf10	0.69	6.9	0.41	4.76e-11	Alzheimer's disease;
SARC	cis	rs9916302	0.851	rs677888	chr17:37461018	T/G	cg07936489	chr17:37558343	FBXL20	0.65	8.05	0.47	4.3e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs921968	0.541	rs12619347	chr2:219419935	T/C	cg02176678	chr2:219576539	TTLL4	-0.53	-8.14	-0.47	2.34e-14	Mean corpuscular hemoglobin concentration;
SARC	cis	rs3018712	0.532	rs4930587	chr11:68415135	T/C	cg01657329	chr11:68192670	LRP5	0.59	5.38	0.33	1.81e-7	Total body bone mineral density;
SARC	cis	rs6912958	0.781	rs9450712	chr6:88193175	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.29	-5.0	-0.31	1.14e-6	Monocyte percentage of white cells;
SARC	cis	rs2033732	0.673	rs2401050	chr8:85054711	C/T	cg05716166	chr8:85095498	RALYL	0.47	5.63	0.35	5.1e-8	Body mass index;
SARC	cis	rs8180040	0.966	rs13079098	chr3:47442863	A/G	cg27129171	chr3:47204927	SETD2	0.65	9.25	0.52	1.46e-17	Colorectal cancer;
SARC	cis	rs2342371	0.527	rs7643192	chr3:196210590	A/G	cg15048948	chr3:196158458	UBXN7	-0.42	-5.34	-0.33	2.26e-7	Fat distribution (HIV);
SARC	cis	rs7937682	0.889	rs578022	chr11:111490552	G/T	cg09085632	chr11:111637200	PPP2R1B	-0.89	-14.18	-0.68	2.61e-33	Primary sclerosing cholangitis;
SARC	cis	rs770189	0.955	rs244759	chr5:88098545	T/C	cg18498987	chr5:88179539	MEF2C	0.38	4.71	0.3	4.19e-6	Tonometry;
SARC	cis	rs7223966	0.621	rs72845875	chr17:61639269	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	5.23	0.32	3.82e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.85	-11.44	-0.6	2.49e-24	Intelligence (multi-trait analysis);
SARC	cis	rs473651	0.904	rs62196716	chr2:239356977	C/G	cg21699342	chr2:239360505	ASB1	0.51	7.53	0.44	1.1e-12	Multiple system atrophy;
SARC	cis	rs2120243	0.539	rs12638732	chr3:157113871	T/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.39	5.06	0.31	8.57e-7	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs7296418	0.630	rs11057238	chr12:123767971	C/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.39	-5.15	-0.32	5.51e-7	Platelet count;
SARC	cis	rs2361718	0.522	rs11867921	chr17:78121170	G/T	cg23534315	chr17:78082725	GAA	0.4	4.87	0.3	2.04e-6	Yeast infection;
SARC	cis	rs11724804	0.532	rs62295557	chr4:855708	G/A	cg20916646	chr4:852691	GAK	0.55	6.79	0.41	9.37e-11	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
SARC	cis	rs7756236	0.538	rs6936598	chr6:36626096	T/C	cg08179530	chr6:36648295	CDKN1A	0.51	6.26	0.38	1.86e-9	QRS duration;
SARC	cis	rs2594989	0.943	rs346068	chr3:11302933	A/G	cg01796438	chr3:11312864	ATG7	-0.42	-5.01	-0.31	1.06e-6	Circulating chemerin levels;
SARC	cis	rs10046574	0.731	rs17481669	chr7:135193029	G/T	cg27474649	chr7:135195673	CNOT4	0.88	7.12	0.42	1.36e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg10523679	chr1:76189770	ACADM	-0.43	-5.31	-0.33	2.61e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs55962025	0.842	rs362272	chr4:3234980	C/T	cg06533319	chr4:3265114	C4orf44	0.34	5.05	0.31	9.05e-7	Parental longevity (mother's age at death);
SARC	cis	rs1044826	0.957	rs4544576	chr3:139143196	G/T	cg15131784	chr3:139108705	COPB2	0.45	5.18	0.32	4.87e-7	Obesity-related traits;
SARC	cis	rs4481887	0.893	rs4423045	chr1:248479495	T/C	cg13385794	chr1:248469461	NA	0.34	5.21	0.32	4.11e-7	Common traits (Other);
SARC	cis	rs796364	0.813	rs4672686	chr2:201065044	A/G	cg05691004	chr2:201170426	SPATS2L	-0.46	-5.07	-0.32	7.95e-7	Schizophrenia;
SARC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg24503407	chr1:205819492	PM20D1	0.95	17.68	0.76	6.25e-45	Menarche (age at onset);
SARC	cis	rs992157	0.560	rs4674275	chr2:219097738	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.59	-7.89	-0.46	1.14e-13	Colorectal cancer;
SARC	cis	rs2865116	0.888	rs41856	chr7:69009470	T/G	cg10619644	chr7:69149951	AUTS2	0.34	4.8	0.3	2.88e-6	Positive affect;
SARC	cis	rs1044826	1.000	rs3821544	chr3:139190188	C/T	cg15131784	chr3:139108705	COPB2	0.45	5.19	0.32	4.69e-7	Obesity-related traits;
SARC	cis	rs6570726	0.791	rs4896820	chr6:145894957	T/C	cg23711669	chr6:146136114	FBXO30	0.79	12.4	0.63	1.95e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4689388	0.889	rs13101355	chr4:6293446	T/C	cg25554036	chr4:6271136	WFS1	0.39	6.42	0.39	7.48e-10	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs7005606	1.000	rs2466100	chr8:32429349	T/A	cg14488905	chr8:32406789	NRG1	-0.43	-6.05	-0.37	5.7e-9	Hirschsprung disease;
SARC	cis	rs9902453	0.845	rs2628165	chr17:28121166	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	7.01	0.42	2.51e-11	Coffee consumption (cups per day);
SARC	cis	rs2153535	0.580	rs1335637	chr6:8465101	A/G	cg07606381	chr6:8435919	SLC35B3	0.77	10.83	0.58	2.14e-22	Motion sickness;
SARC	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg11987759	chr7:65425863	GUSB	0.47	5.77	0.35	2.51e-8	Aortic root size;
SARC	cis	rs9916302	0.904	rs7503705	chr17:37669704	A/G	cg20243544	chr17:37824526	PNMT	0.55	6.52	0.39	4.33e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs5753618	0.509	rs5997913	chr22:31593959	C/A	cg02404636	chr22:31891804	SFI1	-0.48	-5.05	-0.31	8.88e-7	Colorectal cancer;
SARC	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.56	-0.39	3.45e-10	Total body bone mineral density;
SARC	cis	rs7927771	1.000	rs12418852	chr11:47868853	C/G	cg20307385	chr11:47447363	PSMC3	-0.47	-5.59	-0.34	6.3e-8	Subjective well-being;
SARC	cis	rs9290065	0.519	rs956447	chr3:160668917	G/C	cg03342759	chr3:160939853	NMD3	-0.54	-6.49	-0.39	5.15e-10	Kawasaki disease;
SARC	cis	rs9290065	0.585	rs716779	chr3:160645428	G/A	cg04691961	chr3:161091175	C3orf57	0.5	6.69	0.4	1.68e-10	Kawasaki disease;
SARC	cis	rs2180341	1.000	rs2057223	chr6:127637374	T/C	cg24812749	chr6:127587940	RNF146	0.95	12.31	0.63	3.61e-27	Breast cancer;
SARC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg26338869	chr17:61819248	STRADA	0.79	10.68	0.57	6.16e-22	Prudent dietary pattern;
SARC	cis	rs7552404	0.731	rs11161845	chr1:76367559	T/C	cg22875332	chr1:76189707	ACADM	0.4	4.87	0.3	2.03e-6	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs11190604	1.000	rs57025426	chr10:102205868	A/G	cg07080220	chr10:102295463	HIF1AN	0.78	9.58	0.53	1.56e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs79149102	0.579	rs12594117	chr15:75323648	C/G	cg00629941	chr15:75287862	SCAMP5	-0.72	-5.51	-0.34	9.27e-8	Lung cancer;
SARC	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg13393036	chr8:95962371	TP53INP1	-0.35	-5.98	-0.36	8.46e-9	Type 2 diabetes;
SARC	cis	rs7582720	0.943	rs115827549	chr2:203725678	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.76	7.4	0.44	2.38e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	trans	rs1478897	0.898	rs2249040	chr8:11390779	A/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.12	-0.42	1.31e-11	Systemic lupus erythematosus;
SARC	cis	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg05623727	chr3:50126028	RBM5	0.34	5.16	0.32	5.24e-7	Intelligence (multi-trait analysis);
SARC	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg12463550	chr7:65579703	CRCP	-0.52	-5.56	-0.34	7.34e-8	Aortic root size;
SARC	cis	rs708547	0.581	rs781661	chr4:57780307	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.5	-5.46	-0.34	1.21e-7	Response to bleomycin (chromatid breaks);
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg18827097	chr2:3522506	ADI1	-0.5	-6.92	-0.41	4.22e-11	Gallstone disease;
SARC	cis	rs7829975	0.606	rs7819827	chr8:8797055	G/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.95	-0.41	3.68e-11	Mood instability;
SARC	cis	rs6582630	0.559	rs12318620	chr12:38522340	T/C	cg04568710	chr12:38710424	ALG10B	-0.39	-4.71	-0.3	4.18e-6	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs3126085	0.935	rs1858478	chr1:152257457	C/T	cg26876637	chr1:152193138	HRNR	-0.45	-5.21	-0.32	4.07e-7	Atopic dermatitis;
SARC	cis	rs4846217	1.000	rs6679596	chr1:10454502	A/T	cg19092837	chr1:10271724	KIF1B	0.41	5.47	0.34	1.17e-7	Platelet count;
SARC	cis	rs67366981	1.000	rs2287383	chr14:77713036	C/G	cg06779847	chr14:77687015	TMEM63C	-0.46	-5.15	-0.32	5.51e-7	Obsessive-compulsive symptoms;
SARC	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg04944784	chr2:26401820	FAM59B	0.49	5.72	0.35	3.18e-8	Gut microbiome composition (summer);
SARC	cis	rs6738485	0.507	rs66569888	chr2:106886967	G/A	cg16099169	chr2:106886729	NA	-0.64	-7.32	-0.43	4.06e-12	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
SARC	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	5.37	0.33	1.9e-7	Tonsillectomy;
SARC	cis	rs957448	1.000	rs72674861	chr8:95562279	C/T	cg26464482	chr8:95565502	KIAA1429	0.43	4.74	0.3	3.73e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.12	0.37	3.95e-9	Prudent dietary pattern;
SARC	cis	rs12681288	0.676	rs1562921	chr8:1021986	G/T	cg15309053	chr8:964076	NA	0.43	6.95	0.41	3.53e-11	Schizophrenia;
SARC	cis	rs11122272	0.735	rs2572253	chr1:231512768	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs10463554	0.963	rs26821	chr5:102520400	A/C	cg23492399	chr5:102201601	PAM	-0.44	-4.8	-0.3	2.86e-6	Parkinson's disease;
SARC	cis	rs13161895	1.000	rs34603792	chr5:179459287	A/G	cg02702477	chr5:179499311	RNF130	0.67	6.57	0.4	3.17e-10	LDL cholesterol;
SARC	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg02487422	chr3:49467188	NICN1	0.37	4.82	0.3	2.63e-6	Parkinson's disease;
SARC	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg05025164	chr4:1340916	KIAA1530	-0.67	-8.13	-0.47	2.61e-14	Obesity-related traits;
SARC	trans	rs641862	1	rs641862	chr13:110790232	C/T	ch.13.1810252F	chr13:111928457	ARHGEF7	-0.88	-6.48	-0.39	5.44e-10	Obesity-related traits;
SARC	cis	rs9807989	0.839	rs4988955	chr2:102967928	A/G	cg09003973	chr2:102972529	NA	0.45	6.18	0.38	2.77e-9	Asthma;
SARC	cis	rs34330	0.562	rs12229100	chr12:12865836	A/G	cg09462578	chr12:12878428	APOLD1	0.57	5.43	0.34	1.41e-7	Systemic lupus erythematosus;
SARC	trans	rs61931739	0.857	rs419112	chr12:34130528	A/G	cg13010199	chr12:38710504	ALG10B	0.55	7.39	0.44	2.68e-12	Morning vs. evening chronotype;
SARC	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg12373951	chr3:133503437	NA	0.36	5.28	0.33	2.97e-7	Iron status biomarkers;
SARC	cis	rs10464366	0.746	rs6945547	chr7:39145389	C/G	cg18850127	chr7:39170497	POU6F2	0.43	5.53	0.34	8.74e-8	IgG glycosylation;
SARC	cis	rs4853036	0.540	rs4852330	chr2:70004278	G/T	cg02498382	chr2:70120550	SNRNP27	-0.35	-4.8	-0.3	2.86e-6	Colorectal or endometrial cancer;
SARC	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg24642844	chr7:1081250	C7orf50	-0.41	-4.81	-0.3	2.71e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs1348850	0.874	rs6742951	chr2:178340766	G/C	cg23306229	chr2:178417860	TTC30B	0.56	6.27	0.38	1.71e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9911578	0.967	rs6503890	chr17:57064167	A/G	cg12560992	chr17:57184187	TRIM37	0.85	11.8	0.61	1.71e-25	Intelligence (multi-trait analysis);
SARC	cis	rs2576037	0.796	rs6507718	chr18:44581284	G/C	cg19077165	chr18:44547161	KATNAL2	0.45	6.22	0.38	2.27e-9	Personality dimensions;
SARC	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg05368731	chr17:41323189	NBR1	0.83	10.13	0.55	3.28e-20	Menopause (age at onset);
SARC	cis	rs9326248	0.559	rs10892064	chr11:116896553	G/C	cg01368799	chr11:117014884	PAFAH1B2	0.68	8.53	0.49	1.91e-15	Blood protein levels;
SARC	cis	rs6912958	0.703	rs9353483	chr6:88097180	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.74	11.02	0.59	5.2e-23	Monocyte percentage of white cells;
SARC	cis	rs13226913	0.967	rs2881755	chr7:7256439	C/T	cg19603390	chr7:7222222	C1GALT1	0.4	5.01	0.31	1.1e-6	Serum galactose-deficient IgA1 levels;
SARC	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg04277193	chr17:41438351	NA	0.47	5.04	0.31	9.3e-7	Menopause (age at onset);
SARC	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg08219700	chr8:58056026	NA	0.76	6.61	0.4	2.52e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7829975	0.514	rs2945873	chr8:8260445	C/T	cg08975724	chr8:8085496	FLJ10661	0.56	6.78	0.41	9.96e-11	Mood instability;
SARC	cis	rs17125944	1.000	rs17125944	chr14:53400629	C/T	cg00686598	chr14:53173677	PSMC6	-0.72	-5.48	-0.34	1.07e-7	Alzheimer's disease (late onset);
SARC	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg05861140	chr6:150128134	PCMT1	-0.38	-4.76	-0.3	3.35e-6	Lung cancer;
SARC	cis	rs11758351	1.000	rs41266807	chr6:26199822	A/G	cg23601095	chr6:26197514	HIST1H3D	0.63	5.46	0.34	1.24e-7	Gout;Renal underexcretion gout;
SARC	cis	rs3126085	0.877	rs868304	chr1:152178568	G/A	cg09127314	chr1:152161683	NA	0.41	4.76	0.3	3.39e-6	Atopic dermatitis;
SARC	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	12.05	0.62	2.52e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7412746	0.621	rs11204749	chr1:150929563	G/A	cg13175981	chr1:150552382	MCL1	-0.54	-6.58	-0.4	3.12e-10	Melanoma;
SARC	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg09165964	chr15:75287851	SCAMP5	0.5	6.66	0.4	1.98e-10	Breast cancer;
SARC	cis	rs7666738	0.830	rs34273190	chr4:99004568	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.8	0.5	3.13e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7681440	0.606	rs2619361	chr4:90757735	C/A	cg06632027	chr4:90757378	SNCA	-0.43	-5.34	-0.33	2.16e-7	Dementia with Lewy bodies;
SARC	cis	rs7929679	0.521	rs11032852	chr11:34788308	C/A	cg06937548	chr11:34938143	PDHX;APIP	0.36	4.76	0.3	3.47e-6	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
SARC	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	7.77	0.45	2.56e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1018836	0.818	rs715057	chr8:91624340	T/C	cg16814680	chr8:91681699	NA	-0.83	-14.19	-0.68	2.27e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs9393692	0.557	rs61534839	chr6:26305623	C/T	cg13736514	chr6:26305472	NA	-0.43	-5.15	-0.32	5.57e-7	Educational attainment;
SARC	cis	rs7584330	0.738	rs13398506	chr2:238374824	A/G	cg14458575	chr2:238380390	NA	0.4	4.75	0.3	3.54e-6	Prostate cancer;
SARC	trans	rs9929218	0.551	rs2281850	chr16:68718750	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.89	-14.33	-0.68	8.25e-34	Colorectal cancer;
SARC	trans	rs6716963	0.585	rs11687224	chr2:194568323	A/G	cg13430439	chr19:17326059	USE1	0.53	6.45	0.39	6.24e-10	Schizophrenia;
SARC	cis	rs6570726	0.905	rs442435	chr6:145815559	C/T	cg23711669	chr6:146136114	FBXO30	0.76	11.39	0.6	3.59e-24	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg12463550	chr7:65579703	CRCP	0.71	5.36	0.33	2.04e-7	Diabetic kidney disease;
SARC	cis	rs9393692	0.676	rs1543681	chr6:26187783	G/T	cg13736514	chr6:26305472	NA	-0.64	-8.24	-0.47	1.29e-14	Educational attainment;
SARC	cis	rs8114671	0.562	rs2378294	chr20:33500378	G/A	cg07148914	chr20:33460835	GGT7	0.42	5.09	0.32	7.24e-7	Height;
SARC	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg22903657	chr4:1355424	KIAA1530	-0.36	-4.89	-0.31	1.84e-6	Obesity-related traits;
SARC	cis	rs1707322	0.835	rs946525	chr1:46487277	A/T	cg03146154	chr1:46216737	IPP	-0.46	-5.59	-0.34	6.36e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg11644478	chr21:40555479	PSMG1	1.06	15.14	0.7	1.62e-36	Cognitive function;
SARC	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg16482183	chr6:26056742	HIST1H1C	0.42	5.35	0.33	2.07e-7	Height;
SARC	cis	rs3749237	0.964	rs10865959	chr3:49891002	G/C	cg07636037	chr3:49044803	WDR6	0.48	5.2	0.32	4.4e-7	Resting heart rate;
SARC	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg08677398	chr8:58056175	NA	0.43	4.71	0.3	4.2e-6	Developmental language disorder (linguistic errors);
SARC	trans	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg00938859	chr5:1591904	SDHAP3	0.8	7.48	0.44	1.47e-12	Breast cancer;
SARC	trans	rs453301	0.571	rs330057	chr8:9089793	C/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.41	-0.39	7.96e-10	Joint mobility (Beighton score);
SARC	cis	rs9788682	0.747	rs2568485	chr15:78752114	C/T	cg24631222	chr15:78858424	CHRNA5	-0.76	-9.48	-0.53	3.01e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs12142240	0.698	rs17361805	chr1:46813967	C/T	cg00530320	chr1:46809349	NSUN4	0.56	6.63	0.4	2.34e-10	Menopause (age at onset);
SARC	cis	rs2361718	0.590	rs4527052	chr17:78140910	A/G	cg06718696	chr17:78121285	EIF4A3	0.43	4.85	0.3	2.29e-6	Yeast infection;
SARC	cis	rs1349547	0.530	rs7842919	chr8:39501838	A/G	cg12140000	chr8:38554703	NA	0.31	4.74	0.3	3.71e-6	HIV-1 susceptibility;
SARC	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg08067268	chr2:26466485	HADHB;HADHA	0.49	6.07	0.37	5.23e-9	Gut microbiome composition (summer);
SARC	cis	rs7338174	0.655	rs9316535	chr13:51903465	A/G	cg11317909	chr13:51825057	FAM124A	-0.57	-4.84	-0.3	2.33e-6	Mitochondrial DNA levels;
SARC	cis	rs6867032	0.958	rs4975795	chr5:2015390	G/A	cg26168224	chr5:2018326	NA	0.92	15.02	0.7	4.03e-36	Gut microbiome composition (winter);
SARC	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg03060546	chr3:49711283	APEH	0.41	5.11	0.32	6.69e-7	Parkinson's disease;
SARC	cis	rs4727027	0.933	rs2158633	chr7:148832652	C/T	cg23583168	chr7:148888333	NA	-0.74	-11.29	-0.59	7.1e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs57994353	0.897	rs72775778	chr9:139381128	G/A	cg13611204	chr9:139324423	INPP5E	-0.28	-4.75	-0.3	3.51e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.36	-5.37	-0.33	1.91e-7	Lymphocyte counts;
SARC	cis	rs3741404	0.560	rs17699798	chr11:63898806	C/G	cg18225595	chr11:63971243	STIP1	-0.44	-6.82	-0.41	7.69e-11	Platelet count;
SARC	cis	rs10504073	0.584	rs56078938	chr8:49940342	A/C	cg00325661	chr8:49890786	NA	0.53	6.96	0.41	3.5e-11	Blood metabolite ratios;
SARC	cis	rs1692580	0.682	rs12045693	chr1:2205581	A/C	cg21442419	chr1:2182373	SKI	0.63	9.8	0.54	3.36e-19	Coronary artery disease;
SARC	cis	rs4595586	0.545	rs2388176	chr12:39372357	G/A	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	cis	rs123509	0.913	rs339686	chr3:42769688	T/C	cg12982090	chr3:42733453	KBTBD5	0.52	6.36	0.38	1.07e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7633770	0.805	rs12330414	chr3:46662428	T/C	cg11219411	chr3:46661640	NA	0.49	8.45	0.48	3.22e-15	Coronary artery disease;
SARC	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg11062466	chr8:58055876	NA	0.64	5.86	0.36	1.55e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs505401	0.554	rs17271924	chr19:6097509	A/G	cg18109231	chr19:6110877	RFX2	-0.65	-5.18	-0.32	4.77e-7	Mean platelet volume;
SARC	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg19077165	chr18:44547161	KATNAL2	-0.48	-6.61	-0.4	2.61e-10	Personality dimensions;
SARC	trans	rs10838798	0.504	rs7479393	chr11:48295303	G/C	cg15704280	chr7:45808275	SEPT13	-0.48	-6.51	-0.39	4.45e-10	Height;
SARC	cis	rs2832191	0.646	rs2832214	chr21:30517127	C/T	cg24692254	chr21:30365293	RNF160	-0.68	-8.0	-0.46	5.93e-14	Dental caries;
SARC	cis	rs5167	0.677	rs12709889	chr19:45453239	A/G	cg09555818	chr19:45449301	APOC2	-0.39	-5.18	-0.32	4.91e-7	Blood protein levels;
SARC	cis	rs12311304	0.965	rs12320285	chr12:15372062	G/T	cg08258403	chr12:15378311	NA	0.47	7.42	0.44	2.16e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg22535103	chr8:58192502	C8orf71	-0.77	-8.93	-0.51	1.27e-16	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.679	rs72649107	chr8:58030453	C/A	cg08219700	chr8:58056026	NA	0.6	6.12	0.37	3.98e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs12681366	0.683	rs2445721	chr8:95389311	C/T	cg26464482	chr8:95565502	KIAA1429	-0.44	-5.42	-0.33	1.49e-7	Nonsyndromic cleft lip with cleft palate;
SARC	trans	rs11098499	0.954	rs12507964	chr4:120413061	T/A	cg25214090	chr10:38739885	LOC399744	0.58	7.47	0.44	1.63e-12	Corneal astigmatism;
SARC	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.4	-4.77	-0.3	3.22e-6	Renal function-related traits (BUN);
SARC	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg16680214	chr1:154839983	KCNN3	-0.36	-5.63	-0.35	5.05e-8	Prostate cancer;
SARC	cis	rs8017423	0.935	rs3742668	chr14:90767759	G/A	cg20276874	chr14:90721474	PSMC1	0.36	4.85	0.3	2.24e-6	Mortality in heart failure;
SARC	cis	rs2486288	0.656	rs6493145	chr15:45573862	G/T	cg15395560	chr15:45543142	SLC28A2	0.3	5.78	0.35	2.41e-8	Glomerular filtration rate;
SARC	cis	rs1971762	0.545	rs11170632	chr12:54047935	C/T	cg06632207	chr12:54070931	ATP5G2	-0.59	-8.19	-0.47	1.77e-14	Height;
SARC	cis	rs7633770	0.786	rs1520489	chr3:46677519	A/G	cg11219411	chr3:46661640	NA	-0.41	-6.63	-0.4	2.28e-10	Coronary artery disease;
SARC	cis	rs11190604	1.000	rs7070776	chr10:102264672	A/G	cg07080220	chr10:102295463	HIF1AN	0.79	9.68	0.54	7.56e-19	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs986417	0.901	rs1955694	chr14:61020617	G/T	cg27398547	chr14:60952738	C14orf39	0.88	8.88	0.5	1.88e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs1707322	0.893	rs9919275	chr1:46441360	A/C	cg06784218	chr1:46089804	CCDC17	0.34	5.95	0.36	9.76e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs698833	0.828	rs6706053	chr2:44517662	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.56	-6.99	-0.42	2.84e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs910316	1.000	rs175449	chr14:75590846	A/T	cg06637938	chr14:75390232	RPS6KL1	-0.52	-7.4	-0.44	2.44e-12	Height;
SARC	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg05793240	chr7:2802953	GNA12	-0.34	-4.86	-0.3	2.15e-6	Height;
SARC	trans	rs9329221	0.655	rs656319	chr8:9814411	A/G	cg21775007	chr8:11205619	TDH	-0.52	-6.72	-0.4	1.34e-10	Neuroticism;
SARC	cis	rs9985766	0.959	rs56150320	chr4:151055219	G/A	cg05926478	chr4:151174724	DCLK2	-0.49	-4.76	-0.3	3.47e-6	Coronary artery disease;Myocardial infarction;
SARC	cis	rs2204008	0.683	rs11522927	chr12:38137537	C/T	cg13010199	chr12:38710504	ALG10B	0.77	10.46	0.57	3.06e-21	Bladder cancer;
SARC	cis	rs2073300	0.609	rs6137938	chr20:23389127	C/G	cg12062639	chr20:23401060	NAPB	0.97	6.8	0.41	8.58e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs6831352	0.879	rs1230154	chr4:99988659	C/T	cg12011299	chr4:100065546	ADH4	0.32	5.58	0.34	6.74e-8	Alcohol dependence;
SARC	cis	rs9527	0.668	rs7092815	chr10:104736345	G/T	cg04362960	chr10:104952993	NT5C2	0.42	4.88	0.3	1.93e-6	Arsenic metabolism;
SARC	trans	rs1814175	0.645	rs4411280	chr11:49962750	A/G	cg15704280	chr7:45808275	SEPT13	-0.89	-14.17	-0.68	2.8e-33	Height;
SARC	cis	rs6700896	0.931	rs59508186	chr1:66107881	C/A	cg04111102	chr1:66153794	NA	0.34	5.23	0.32	3.83e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg18876405	chr7:65276391	NA	0.48	5.79	0.35	2.26e-8	Aortic root size;
SARC	cis	rs3733585	0.673	rs7376505	chr4:9952744	C/A	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.39	-0.33	1.76e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg09638001	chr20:44520063	CTSA;NEURL2	-0.53	-6.43	-0.39	7.26e-10	Schizophrenia;
SARC	cis	rs8114671	0.836	rs6141526	chr20:33615255	G/T	cg08999081	chr20:33150536	PIGU	-0.36	-5.16	-0.32	5.21e-7	Height;
SARC	cis	rs17401966	1.000	rs17411502	chr1:10431158	T/C	cg15208524	chr1:10270712	KIF1B	0.59	6.51	0.39	4.62e-10	Hepatocellular carcinoma;
SARC	cis	rs2624839	0.704	rs2624838	chr3:50205642	C/G	cg14019146	chr3:50243930	SLC38A3	-0.32	-5.09	-0.32	7.22e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7605378	0.528	rs281767	chr2:200823281	C/A	cg17644776	chr2:200775616	C2orf69	0.54	7.09	0.42	1.56e-11	Osteoporosis;
SARC	cis	rs9858542	0.953	rs7646366	chr3:49470668	G/A	cg03060546	chr3:49711283	APEH	-0.58	-7.1	-0.42	1.49e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs2066819	1.000	rs2695782	chr12:56722830	C/T	cg26734620	chr12:56694298	CS	-0.87	-5.73	-0.35	3.11e-8	Psoriasis vulgaris;
SARC	cis	rs6732160	0.845	rs11894833	chr2:73388418	G/T	cg01422370	chr2:73384389	NA	-0.31	-5.27	-0.33	3.08e-7	Intelligence (multi-trait analysis);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg13437005	chr8:67976862	CSPP1	0.49	6.37	0.39	9.73e-10	Chemerin levels;
SARC	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg03354898	chr7:1950403	MAD1L1	-0.37	-5.11	-0.32	6.69e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs6809651	0.524	rs6444106	chr3:185811495	C/T	cg00760338	chr3:185826511	ETV5	-0.81	-10.53	-0.57	1.87e-21	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
SARC	cis	rs72781680	1.000	rs115861480	chr2:24129464	T/A	cg08917208	chr2:24149416	ATAD2B	0.95	8.9	0.5	1.55e-16	Lymphocyte counts;
SARC	cis	rs7617480	0.648	rs9848268	chr3:48762271	C/T	cg07636037	chr3:49044803	WDR6	0.85	8.49	0.49	2.37e-15	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs425277	1.000	rs262641	chr1:2104981	C/T	cg24578937	chr1:2090814	PRKCZ	-0.29	-5.36	-0.33	1.95e-7	Height;
SARC	cis	rs1348850	0.645	rs11887886	chr2:178425730	C/T	cg23306229	chr2:178417860	TTC30B	0.77	8.45	0.48	3.12e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs4619890	0.528	rs62289337	chr4:7877939	G/A	cg18538662	chr4:7941764	AFAP1	-0.41	-5.28	-0.33	2.95e-7	Glaucoma (primary open-angle);
SARC	cis	rs11608355	1.000	rs7958625	chr12:109869218	A/T	cg19025524	chr12:109796872	NA	-0.39	-5.08	-0.32	7.71e-7	Neuroticism;
SARC	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.43	-5.24	-0.32	3.63e-7	Tonsillectomy;
SARC	cis	rs1966248	0.543	rs1855895	chr6:134118977	A/G	cg25632230	chr6:134101081	NA	-0.55	-7.34	-0.43	3.63e-12	Coronary artery disease;
SARC	cis	rs9616064	0.853	rs7284865	chr22:46996529	C/T	cg25730555	chr22:47059586	GRAMD4	0.41	5.37	0.33	1.92e-7	Urate levels in obese individuals;
SARC	cis	rs6988636	1.000	rs11988157	chr8:124194740	A/G	cg23067535	chr8:124195133	FAM83A	0.62	5.51	0.34	9.38e-8	Urinary uromodulin levels;
SARC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.7	0.54	6.66e-19	Prudent dietary pattern;
SARC	cis	rs910187	0.605	rs6124960	chr20:45803866	G/C	cg27589058	chr20:45804311	EYA2	-0.32	-5.09	-0.32	7.31e-7	Migraine;
SARC	cis	rs11711311	0.747	rs11928590	chr3:113343478	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	7.34	0.43	3.58e-12	IgG glycosylation;
SARC	cis	rs2075371	0.932	rs11766132	chr7:133993062	T/C	cg20476274	chr7:133979776	SLC35B4	0.59	7.64	0.45	5.76e-13	Mean platelet volume;
SARC	cis	rs854765	0.583	rs9904163	chr17:17830553	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.43	5.57	0.34	7.01e-8	Total body bone mineral density;
SARC	cis	rs9462027	0.628	rs7776219	chr6:34784667	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-6.04	-0.37	5.95e-9	Systemic lupus erythematosus;
SARC	cis	rs1008375	0.932	rs4698650	chr4:17692878	G/C	cg02297831	chr4:17616191	MED28	0.39	4.86	0.3	2.14e-6	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6429082	0.714	rs184108	chr1:235646160	A/G	cg26050004	chr1:235667680	B3GALNT2	0.66	8.27	0.48	9.99e-15	Adiposity;
SARC	cis	rs11122272	0.764	rs4486439	chr1:231477470	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.54	-0.53	1.98e-18	Hemoglobin concentration;
SARC	cis	rs9291683	0.546	rs6820188	chr4:10051655	C/T	cg11266682	chr4:10021025	SLC2A9	0.41	7.19	0.43	8.92e-12	Bone mineral density;
SARC	cis	rs858239	0.536	rs6956974	chr7:23252318	C/G	cg23682824	chr7:23144976	KLHL7	-0.59	-7.29	-0.43	4.69e-12	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9303401	0.659	rs62083362	chr17:56846464	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.06	12.04	0.62	2.73e-26	Cognitive test performance;
SARC	cis	rs74781061	0.585	rs8041068	chr15:74730206	G/A	cg09165964	chr15:75287851	SCAMP5	-0.64	-4.89	-0.31	1.85e-6	Endometriosis;
SARC	cis	rs11264799	0.554	rs59424684	chr1:157586990	G/A	cg18268488	chr1:157545234	FCRL4	0.3	4.91	0.31	1.68e-6	IgA nephropathy;
SARC	cis	rs2153535	0.580	rs1115078	chr6:8449638	G/A	cg21535247	chr6:8435926	SLC35B3	0.55	6.91	0.41	4.48e-11	Motion sickness;
SARC	cis	rs1982346	1.000	rs2161046	chr4:106739973	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	-0.67	-4.74	-0.3	3.74e-6	Lung function (FEV1);
SARC	cis	rs9911578	1.000	rs4482353	chr17:56896834	A/G	cg05425664	chr17:57184151	TRIM37	-0.64	-7.94	-0.46	8.68e-14	Intelligence (multi-trait analysis);
SARC	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg22920501	chr2:26401640	FAM59B	-0.56	-7.39	-0.44	2.57e-12	Gut microbiome composition (summer);
SARC	cis	rs11997175	0.624	rs67643247	chr8:33700790	G/A	ch.8.33884649F	chr8:33765107	NA	0.59	7.56	0.44	9.39e-13	Body mass index;
SARC	trans	rs1814175	0.935	rs10839317	chr11:49657228	A/C	cg03929089	chr4:120376271	NA	-0.84	-12.91	-0.65	4.14e-29	Height;
SARC	cis	rs6840360	1.000	rs7669977	chr4:152677527	T/C	cg22705602	chr4:152727874	NA	-0.36	-6.32	-0.38	1.34e-9	Intelligence (multi-trait analysis);
SARC	cis	rs17270561	0.609	rs9358871	chr6:25726675	G/A	cg17691542	chr6:26056736	HIST1H1C	0.58	7.09	0.42	1.59e-11	Iron status biomarkers;
SARC	cis	rs858239	1.000	rs156421	chr7:23312487	A/G	cg23682824	chr7:23144976	KLHL7	0.61	7.46	0.44	1.71e-12	Cerebrospinal fluid biomarker levels;
SARC	cis	rs2832191	0.755	rs2832193	chr21:30493589	T/C	cg08807101	chr21:30365312	RNF160	-0.82	-11.17	-0.59	1.7e-23	Dental caries;
SARC	cis	rs483180	0.531	rs662243	chr1:120209564	A/C	cg19096424	chr1:120255104	PHGDH	0.48	5.59	0.34	6.44e-8	Macular telangiectasia type 2;
SARC	cis	rs763121	0.853	rs9607566	chr22:39075434	C/G	cg21395723	chr22:39101663	GTPBP1	0.52	5.79	0.35	2.3e-8	Menopause (age at onset);
SARC	cis	rs9470366	0.545	rs6930083	chr6:36634156	A/G	cg08179530	chr6:36648295	CDKN1A	-0.63	-8.37	-0.48	5.5e-15	QRS duration;
SARC	cis	rs765787	0.530	rs11070445	chr15:45513163	T/A	cg26924012	chr15:45694286	SPATA5L1	0.43	5.34	0.33	2.2e-7	Uric acid levels;
SARC	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg20102877	chr2:27665638	KRTCAP3	-0.35	-4.9	-0.31	1.83e-6	Total body bone mineral density;
SARC	cis	rs644799	0.623	rs17207890	chr11:95490754	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	10.05	0.55	5.79e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs896854	0.714	rs572547	chr8:95966286	A/G	cg16049864	chr8:95962084	TP53INP1	0.4	6.28	0.38	1.6e-9	Type 2 diabetes;
SARC	cis	rs2576037	0.899	rs2060417	chr18:44576486	C/A	cg15049968	chr18:44337910	ST8SIA5	0.32	5.08	0.32	7.71e-7	Personality dimensions;
SARC	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg17221315	chr6:27791827	HIST1H4J	0.47	4.84	0.3	2.37e-6	Depression;
SARC	cis	rs422249	0.512	rs1535	chr11:61597972	A/G	cg19610905	chr11:61596333	FADS2	-0.41	-4.8	-0.3	2.87e-6	Trans fatty acid levels;
SARC	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg07701084	chr6:150067640	NUP43	0.39	5.21	0.32	4.23e-7	Lung cancer;
SARC	cis	rs67460515	0.665	rs28384382	chr3:160939141	C/T	cg17135325	chr3:160939158	NMD3	0.71	9.16	0.51	2.81e-17	Parkinson's disease;
SARC	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.46	0.39	5.9e-10	Bipolar disorder;
SARC	cis	rs6120849	0.754	rs3746436	chr20:33586193	C/T	cg24642439	chr20:33292090	TP53INP2	0.59	5.67	0.35	4.13e-8	Protein C levels;
SARC	cis	rs140365914	1	rs140365914	chr7:155106570	C/T	cg04811098	chr7:155088454	INSIG1	0.33	4.86	0.3	2.11e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs2301436	0.512	rs6925969	chr6:167501738	C/A	cg23791538	chr6:167370224	RNASET2	-0.52	-6.7	-0.4	1.53e-10	Crohn's disease;
SARC	trans	rs6882716	0.636	rs1470023	chr5:10800150	A/G	cg14547461	chr8:48176671	KIAA0146	-0.51	-6.32	-0.38	1.32e-9	Alcohol consumption (maxi-drinks);
SARC	cis	rs17376456	0.877	rs10035340	chr5:93490465	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.02	0.31	1.01e-6	Diabetic retinopathy;
SARC	cis	rs17376456	0.825	rs17372615	chr5:93124768	C/T	cg21475434	chr5:93447410	FAM172A	0.72	6.25	0.38	1.92e-9	Diabetic retinopathy;
SARC	cis	rs876084	0.505	rs4336644	chr8:121136128	G/C	cg06265175	chr8:121136014	COL14A1	0.55	7.18	0.43	9.33e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs6908034	0.607	rs80355837	chr6:19808343	C/G	cg02682789	chr6:19804855	NA	0.72	5.71	0.35	3.37e-8	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs3771570	1.000	rs59536819	chr2:242272388	A/G	cg21155796	chr2:242212141	HDLBP	0.67	5.74	0.35	2.99e-8	Prostate cancer;
SARC	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9388451	0.839	rs11154331	chr6:126111429	A/T	cg05901451	chr6:126070800	HEY2	-0.66	-9.28	-0.52	1.18e-17	Brugada syndrome;
SARC	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg22974920	chr21:40686053	BRWD1	-0.43	-4.74	-0.3	3.78e-6	Cognitive function;
SARC	cis	rs17401966	1.000	rs17410793	chr1:10391886	A/G	cg15208524	chr1:10270712	KIF1B	0.6	6.67	0.4	1.84e-10	Hepatocellular carcinoma;
SARC	cis	rs71636778	0.631	rs71636787	chr1:27185115	T/A	cg04852280	chr1:26496234	ZNF593	0.51	4.72	0.3	4.1e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs4481887	0.741	rs1361413	chr1:248529521	C/G	cg00666640	chr1:248458726	OR2T12	-0.34	-6.1	-0.37	4.38e-9	Common traits (Other);
SARC	cis	rs7223966	1.000	rs8069687	chr17:61883023	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	5.45	0.34	1.3e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9660992	0.710	rs1668872	chr1:205236069	G/A	cg00857998	chr1:205179979	DSTYK	0.52	6.31	0.38	1.41e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs6665290	0.835	rs11578479	chr1:227210888	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.05	-23.12	-0.83	2.91e-62	Myeloid white cell count;
SARC	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg05255149	chr17:80675120	FN3KRP	-0.42	-4.83	-0.3	2.46e-6	Glycated hemoglobin levels;
SARC	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg23172400	chr8:95962367	TP53INP1	-0.31	-5.38	-0.33	1.83e-7	Type 2 diabetes;
SARC	cis	rs1318878	0.565	rs1479410	chr12:15463417	A/C	cg08258403	chr12:15378311	NA	0.5	6.93	0.41	3.99e-11	Intelligence (multi-trait analysis);
SARC	cis	rs7829975	0.502	rs7820738	chr8:8702607	C/G	cg15556689	chr8:8085844	FLJ10661	-0.39	-4.88	-0.3	1.97e-6	Mood instability;
SARC	cis	rs4280164	0.887	rs11158634	chr14:24776457	C/G	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.59	-5.56	-0.34	7.38e-8	Parent of origin effect on language impairment (paternal);
SARC	cis	rs7044106	0.762	rs966396	chr9:123453281	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	8.57	0.49	1.46e-15	Hip circumference adjusted for BMI;
SARC	cis	rs16976116	0.901	rs56328329	chr15:55502977	A/T	cg11288833	chr15:55489084	RSL24D1	0.63	6.08	0.37	4.81e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7766436	0.614	rs11753751	chr6:22567273	C/T	cg13666174	chr6:22585274	NA	-0.58	-5.99	-0.37	7.93e-9	Coronary artery disease;
SARC	cis	rs2204008	0.840	rs7957966	chr12:37953629	A/G	cg26384229	chr12:38710491	ALG10B	-0.8	-11.44	-0.6	2.44e-24	Bladder cancer;
SARC	cis	rs4243830	0.737	rs11122088	chr1:6603677	T/G	cg05709478	chr1:6581295	PLEKHG5	-0.48	-4.8	-0.3	2.87e-6	Body mass index;
SARC	cis	rs7086627	0.515	rs7088877	chr10:82208860	C/G	cg01528321	chr10:82214614	TSPAN14	0.58	8.56	0.49	1.5e-15	Post bronchodilator FEV1;
SARC	cis	rs644799	0.648	rs1255181	chr11:95472148	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.67	8.97	0.51	9.75e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs10982256	0.817	rs10817631	chr9:117267942	G/T	cg21159778	chr9:117266918	DFNB31	0.4	5.8	0.36	2.14e-8	Bipolar disorder;
SARC	cis	rs11756659	0.697	rs7746105	chr6:25944278	G/T	cg00631329	chr6:26305371	NA	0.47	5.02	0.31	1.01e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;Red cell distribution width;
SARC	cis	rs9733	0.791	rs11800059	chr1:150651175	C/T	cg15448220	chr1:150897856	SETDB1	-0.36	-4.72	-0.3	4.13e-6	Tonsillectomy;
SARC	cis	rs1270639	0.778	rs1465250	chr7:157439075	C/G	cg13357408	chr7:157437802	PTPRN2	0.46	4.92	0.31	1.61e-6	Colorectal cancer;
SARC	cis	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg14019146	chr3:50243930	SLC38A3	-0.32	-5.05	-0.31	8.92e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg12463550	chr7:65579703	CRCP	0.71	5.4	0.33	1.6e-7	Diabetic kidney disease;
SARC	cis	rs9948	0.786	rs111237064	chr2:97456578	T/C	cg01990225	chr2:97406019	LMAN2L	-1.0	-7.3	-0.43	4.63e-12	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg11494091	chr17:61959527	GH2	0.54	8.17	0.47	1.92e-14	Prudent dietary pattern;
SARC	cis	rs11098499	0.754	rs28652763	chr4:120242312	C/T	cg09307838	chr4:120376055	NA	0.81	11.15	0.59	2.11e-23	Corneal astigmatism;
SARC	cis	rs1559088	0.948	rs10408093	chr19:33597816	T/C	cg17764715	chr19:33622953	WDR88	0.49	6.72	0.4	1.4e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs77633900	0.614	rs12442966	chr15:76918290	G/T	cg21673338	chr15:77095150	SCAPER	0.68	5.89	0.36	1.32e-8	Non-glioblastoma glioma;Glioma;
SARC	cis	rs400736	0.740	rs225129	chr1:8094164	T/A	cg25007680	chr1:8021821	PARK7	0.48	6.07	0.37	5.16e-9	Response to antidepressants and depression;
SARC	cis	rs66561647	0.929	rs67423398	chr8:128972220	C/T	cg05480350	chr8:128972681	MIR1205;PVT1	0.42	5.1	0.32	7.19e-7	Hemoglobin concentration;
SARC	cis	rs10782582	0.593	rs12142247	chr1:76235746	C/T	cg10523679	chr1:76189770	ACADM	-0.43	-5.17	-0.32	4.94e-7	Daytime sleep phenotypes;
SARC	cis	rs9329289	0.590	rs11251295	chr10:2563183	C/T	cg15501526	chr10:2543763	NA	0.49	7.2	0.43	8.16e-12	Age-related hearing impairment;
SARC	cis	rs7587476	0.784	rs13026390	chr2:215687075	C/T	cg04004882	chr2:215674386	BARD1	-0.54	-6.24	-0.38	2.01e-9	Neuroblastoma;
SARC	cis	rs9911578	1.000	rs2531732	chr17:56548420	T/A	cg05425664	chr17:57184151	TRIM37	0.66	8.06	0.47	4.04e-14	Intelligence (multi-trait analysis);
SARC	cis	rs4974559	0.790	rs10012582	chr4:1324481	G/A	cg02980000	chr4:1222292	CTBP1	0.64	5.91	0.36	1.24e-8	Systolic blood pressure;
SARC	cis	rs76917914	0.820	rs6478539	chr9:100818720	C/T	cg03040243	chr9:100819229	NANS	0.72	7.9	0.46	1.13e-13	Immature fraction of reticulocytes;
SARC	trans	rs9929218	0.520	rs1078621	chr16:68778996	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.7	9.87	0.54	2.03e-19	Colorectal cancer;
SARC	cis	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg06636001	chr8:8085503	FLJ10661	0.7	9.52	0.53	2.35e-18	Systolic blood pressure;
SARC	cis	rs1865760	0.602	rs2157050	chr6:26020431	C/T	cg02841227	chr6:26021843	HIST1H4A	0.4	4.85	0.3	2.3e-6	Height;
SARC	cis	rs2282526	0.615	rs162377	chr21:44926001	A/G	cg17809849	chr21:44073912	PDE9A	0.4	5.01	0.31	1.09e-6	Mean corpuscular hemoglobin;
SARC	cis	rs854765	0.619	rs1101727	chr17:18016148	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.56	7.69	0.45	4.01e-13	Total body bone mineral density;
SARC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg23034840	chr1:205782522	SLC41A1	0.64	8.16	0.47	2.11e-14	Menarche (age at onset);
SARC	cis	rs3793683	0.825	rs3793674	chr10:134555773	C/T	cg27286337	chr10:134555280	INPP5A	-0.87	-14.43	-0.69	3.63e-34	Migraine;
SARC	cis	rs7833986	0.501	rs72651502	chr8:56875533	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.59	5.23	0.32	3.78e-7	Height;
SARC	cis	rs2197308	0.740	rs11182251	chr12:37919611	C/T	cg26384229	chr12:38710491	ALG10B	-0.81	-11.63	-0.61	6.08e-25	Morning vs. evening chronotype;
SARC	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.58	7.55	0.44	9.91e-13	Menarche (age at onset);
SARC	trans	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.48	-0.44	1.53e-12	Neuroticism;
SARC	cis	rs712039	0.652	rs853196	chr17:35848659	A/T	cg16670864	chr17:35848621	DUSP14	0.44	4.87	0.3	2.1e-6	Tuberculosis;
SARC	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg06618935	chr21:46677482	NA	-0.39	-5.2	-0.32	4.34e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7829975	0.582	rs11783950	chr8:8597831	A/C	cg06636001	chr8:8085503	FLJ10661	-0.44	-5.45	-0.34	1.3e-7	Mood instability;
SARC	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg18252515	chr7:66147081	NA	-0.52	-5.58	-0.34	6.58e-8	Aortic root size;
SARC	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg18876405	chr7:65276391	NA	0.49	6.04	0.37	6e-9	Aortic root size;
SARC	cis	rs72781680	0.678	rs872169	chr2:24259188	C/G	cg06627628	chr2:24431161	ITSN2	-0.62	-6.17	-0.37	3.02e-9	Lymphocyte counts;
SARC	cis	rs7084402	0.967	rs1658491	chr10:60281354	C/T	cg07615347	chr10:60278583	BICC1	-0.6	-8.82	-0.5	2.71e-16	Refractive error;
SARC	cis	rs6964587	0.773	rs38793	chr7:92027187	A/G	cg17063962	chr7:91808500	NA	-0.9	-12.74	-0.64	1.41e-28	Breast cancer;
SARC	cis	rs9399135	0.933	rs28384512	chr6:135376232	C/T	cg22676075	chr6:135203613	NA	0.34	4.75	0.3	3.59e-6	Red blood cell count;
SARC	cis	rs3749237	0.595	rs7621003	chr3:49411404	T/C	cg02487422	chr3:49467188	NICN1	0.5	6.51	0.39	4.57e-10	Resting heart rate;
SARC	cis	rs477692	1.000	rs485576	chr10:131425496	G/C	cg26102564	chr10:131424627	MGMT	0.29	4.72	0.3	4.09e-6	Response to temozolomide;
SARC	cis	rs9303401	0.614	rs12947982	chr17:57140301	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.97	9.91	0.54	1.5e-19	Cognitive test performance;
SARC	cis	rs7005380	0.531	rs7388491	chr8:120925877	G/A	cg21744203	chr8:120868354	DSCC1	-0.47	-5.13	-0.32	5.96e-7	Interstitial lung disease;
SARC	cis	rs6570726	0.764	rs9399553	chr6:145873664	A/T	cg23711669	chr6:146136114	FBXO30	0.87	14.67	0.69	5.76e-35	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	12.45	0.63	1.33e-27	Platelet count;
SARC	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg10591111	chr5:226296	SDHA	-0.56	-5.08	-0.32	7.89e-7	Breast cancer;
SARC	cis	rs4727027	0.704	rs1123992	chr7:148907201	C/G	cg23583168	chr7:148888333	NA	-0.65	-8.63	-0.49	9.74e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs7647973	0.626	rs62260723	chr3:49872124	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.59	-5.94	-0.36	1.01e-8	Menarche (age at onset);
SARC	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg11764359	chr7:65958608	NA	-0.75	-9.18	-0.52	2.35e-17	Aortic root size;
SARC	trans	rs6815916	0.619	rs56240729	chr4:182553564	C/A	cg13864546	chr1:2310327	MORN1	0.68	6.41	0.39	7.98e-10	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.09	0.8	9.09e-53	Prudent dietary pattern;
SARC	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg08280861	chr8:58055591	NA	0.67	5.28	0.33	2.97e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1023500	0.551	rs133379	chr22:42468535	A/G	cg04733989	chr22:42467013	NAGA	0.76	10.19	0.56	2.03e-20	Schizophrenia;
SARC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.42	-6.42	-0.39	7.6e-10	Total body bone mineral density;
SARC	cis	rs7582180	0.638	rs6734316	chr2:100976210	A/G	cg14675211	chr2:100938903	LONRF2	0.52	7.69	0.45	4.09e-13	Intelligence (multi-trait analysis);
SARC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg04234412	chr22:24373322	LOC391322	-0.53	-6.26	-0.38	1.88e-9	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg15448220	chr1:150897856	SETDB1	0.47	6.22	0.38	2.24e-9	Tonsillectomy;
SARC	cis	rs826838	0.967	rs826858	chr12:39116731	A/G	cg13010199	chr12:38710504	ALG10B	-0.69	-9.76	-0.54	4.27e-19	Heart rate;
SARC	cis	rs1003719	0.788	rs2835589	chr21:38463342	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.63	9.05	0.51	5.67e-17	Eye color traits;
SARC	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg07308232	chr7:1071921	C7orf50	-0.55	-6.97	-0.42	3.3e-11	Longevity;Endometriosis;
SARC	cis	rs748404	0.697	rs491804	chr15:43560825	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.52	6.14	0.37	3.6e-9	Lung cancer;
SARC	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg25894440	chr7:65020034	NA	0.73	5.51	0.34	9.25e-8	Diabetic kidney disease;
SARC	cis	rs959260	0.800	rs9895739	chr17:73399916	C/T	cg14668889	chr17:73230827	NUP85	-0.44	-4.79	-0.3	2.91e-6	Systemic lupus erythematosus;
SARC	trans	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.75	10.78	0.58	3.03e-22	Intelligence (multi-trait analysis);
SARC	cis	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg25894440	chr7:65020034	NA	-0.72	-5.33	-0.33	2.32e-7	Diabetic kidney disease;
SARC	cis	rs6570726	0.935	rs422540	chr6:145837815	G/T	cg05347473	chr6:146136440	FBXO30	0.48	6.42	0.39	7.51e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs425277	1.000	rs385039	chr1:2077409	C/T	cg24578937	chr1:2090814	PRKCZ	-0.3	-5.63	-0.35	5.25e-8	Height;
SARC	cis	rs55692411	0.537	rs13071931	chr3:50062878	G/A	cg14019146	chr3:50243930	SLC38A3	-0.37	-5.22	-0.32	3.94e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7223966	1.000	rs7214312	chr17:61870863	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	7.19	0.43	8.86e-12	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs61931739	0.517	rs12816423	chr12:34067736	G/A	cg13010199	chr12:38710504	ALG10B	0.77	10.36	0.56	6.42e-21	Morning vs. evening chronotype;
SARC	cis	rs344364	0.511	rs1742469	chr16:1950244	C/T	cg26617929	chr16:1858877	NA	-0.71	-6.06	-0.37	5.5e-9	Glomerular filtration rate in chronic kidney disease;
SARC	trans	rs9650657	0.770	rs6601529	chr8:10670550	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.71	-0.4	1.48e-10	Neuroticism;
SARC	cis	rs7296418	0.961	rs4148863	chr12:123569375	A/G	cg05973401	chr12:123451056	ABCB9	0.58	7.03	0.42	2.25e-11	Platelet count;
SARC	cis	rs6459788	0.720	rs11768765	chr7:157253133	C/T	cg03453431	chr7:157225567	NA	-0.43	-6.5	-0.39	4.8e-10	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs1559088	0.901	rs12610053	chr19:33582606	A/G	cg27124370	chr19:33622961	WDR88	0.45	5.91	0.36	1.22e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg13206674	chr6:150067644	NUP43	0.47	6.14	0.37	3.55e-9	Lung cancer;
SARC	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg22618164	chr12:122356400	WDR66	0.43	7.02	0.42	2.46e-11	Mean corpuscular volume;
SARC	cis	rs1669338	0.507	rs4685607	chr3:3179400	C/T	cg16797762	chr3:3221439	CRBN	0.92	9.61	0.53	1.27e-18	White matter integrity;
SARC	cis	rs10752881	1.000	rs4233192	chr1:182970837	A/C	ch.1.3577855R	chr1:183094577	LAMC1	-0.71	-10.78	-0.58	2.99e-22	Colorectal cancer;
SARC	trans	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	6.96	0.41	3.35e-11	Intelligence (multi-trait analysis);
SARC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	5.9	0.36	1.28e-8	Prudent dietary pattern;
SARC	trans	rs1814175	0.754	rs28593359	chr11:50042357	C/T	cg03929089	chr4:120376271	NA	-0.89	-14.58	-0.69	1.16e-34	Height;
SARC	cis	rs4713118	0.513	rs149989	chr6:27998184	T/A	cg26335602	chr6:28129616	ZNF389	0.45	5.32	0.33	2.42e-7	Parkinson's disease;
SARC	cis	rs9326248	0.581	rs7120515	chr11:116991926	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.65	8.58	0.49	1.34e-15	Blood protein levels;
SARC	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg22168489	chr12:122356033	WDR66	0.66	10.27	0.56	1.15e-20	Mean corpuscular volume;
SARC	cis	rs7666738	0.830	rs9307218	chr4:99024885	T/C	cg05340658	chr4:99064831	C4orf37	0.64	8.6	0.49	1.18e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6912958	0.967	rs6914299	chr6:88149176	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.62	-8.7	-0.5	6.03e-16	Monocyte percentage of white cells;
SARC	cis	rs2303759	0.709	rs3760667	chr19:49814832	C/T	cg22590775	chr19:49891494	CCDC155	0.47	5.27	0.33	3.05e-7	Multiple sclerosis;
SARC	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg23982607	chr1:1823379	GNB1	-0.64	-10.65	-0.57	7.88e-22	Body mass index;
SARC	cis	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg08564027	chr20:61660810	NA	0.76	11.8	0.61	1.69e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs79149102	0.579	rs7168638	chr15:75280826	T/C	cg09165964	chr15:75287851	SCAMP5	-1.02	-9.08	-0.51	4.73e-17	Lung cancer;
SARC	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg13395646	chr4:1353034	KIAA1530	-0.52	-6.29	-0.38	1.53e-9	Obesity-related traits;
SARC	cis	rs533581	0.816	rs1559446	chr16:88975332	A/G	cg16701003	chr16:89028210	CBFA2T3	0.47	7.06	0.42	1.92e-11	Social autistic-like traits;
SARC	cis	rs2479724	0.905	rs2274578	chr6:41888827	C/G	cg08135965	chr6:41755394	TOMM6	0.41	4.92	0.31	1.63e-6	Menarche (age at onset);
SARC	cis	rs78487399	0.710	rs76857293	chr2:43591676	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-5.01	-0.31	1.06e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs7659604	0.540	rs4833769	chr4:122672970	A/C	cg19671926	chr4:122722719	EXOSC9	-0.55	-7.0	-0.42	2.65e-11	Type 2 diabetes;
SARC	cis	rs2576037	1.000	rs2576037	chr18:44585420	C/T	cg19077165	chr18:44547161	KATNAL2	0.5	6.86	0.41	6.2e-11	Personality dimensions;
SARC	cis	rs832540	0.656	rs2408597	chr5:56098632	G/A	cg12311346	chr5:56204834	C5orf35	-0.39	-4.83	-0.3	2.45e-6	Coronary artery disease;
SARC	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.54e-6	Depression;
SARC	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg24250549	chr1:154909240	PMVK	0.82	11.83	0.61	1.3e-25	Prostate cancer;
SARC	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg15049968	chr18:44337910	ST8SIA5	-0.36	-5.65	-0.35	4.77e-8	Personality dimensions;
SARC	cis	rs4803468	1.000	rs2241706	chr19:41912807	A/G	cg08477640	chr19:41863820	B9D2	0.46	5.85	0.36	1.64e-8	Height;
SARC	cis	rs372883	0.648	rs4817279	chr21:30638285	T/C	cg08807101	chr21:30365312	RNF160	-0.59	-7.47	-0.44	1.61e-12	Pancreatic cancer;
SARC	cis	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg03060546	chr3:49711283	APEH	0.6	7.45	0.44	1.76e-12	Resting heart rate;
SARC	cis	rs739401	0.572	rs384490	chr11:3078885	A/C	cg20651018	chr11:3035856	CARS	-0.47	-7.43	-0.44	2.02e-12	Longevity;
SARC	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg03060546	chr3:49711283	APEH	0.42	5.23	0.32	3.76e-7	Parkinson's disease;
SARC	cis	rs3825932	0.778	rs1369324	chr15:79239719	C/T	cg25744700	chr15:79237217	CTSH	-0.38	-5.12	-0.32	6.39e-7	Type 1 diabetes;
SARC	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg26450541	chr6:28235208	ZNF187	0.49	5.02	0.31	1.01e-6	Cardiac Troponin-T levels;
SARC	cis	rs644799	1.000	rs474252	chr11:95619292	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.68	8.72	0.5	5.41e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7130144	0.541	rs7949893	chr11:130462408	G/A	cg26307797	chr11:130446613	NA	-0.68	-5.72	-0.35	3.31e-8	Urate levels in lean individuals;
SARC	cis	rs11608355	0.597	rs7300290	chr12:109832545	T/G	cg19025524	chr12:109796872	NA	-0.46	-6.95	-0.41	3.57e-11	Neuroticism;
SARC	cis	rs1153858	0.723	rs1719238	chr15:45594766	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.77	-10.0	-0.55	8.12e-20	Homoarginine levels;
SARC	cis	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg05623727	chr3:50126028	RBM5	-0.34	-5.18	-0.32	4.8e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7555523	0.887	rs10918274	chr1:165714416	T/C	cg19769164	chr1:165738335	TMCO1	0.59	4.91	0.31	1.7e-6	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	trans	rs877282	0.685	rs56234340	chr10:781339	A/G	cg22713356	chr15:30763199	NA	0.93	9.43	0.53	4.31e-18	Uric acid levels;
SARC	cis	rs9660992	0.512	rs12123773	chr1:205122420	C/G	cg21643547	chr1:205240462	TMCC2	-0.58	-8.01	-0.46	5.44e-14	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs9517313	0.707	rs9517298	chr13:99095003	C/T	cg07423050	chr13:99094983	FARP1	-0.51	-7.68	-0.45	4.45e-13	Neuroticism;
SARC	trans	rs1853207	0.867	rs9332141	chr10:96721662	T/C	cg02737782	chr1:8014393	NA	-0.89	-6.4	-0.39	8.69e-10	Blood metabolite levels;
SARC	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg05793240	chr7:2802953	GNA12	-0.34	-4.86	-0.3	2.19e-6	Height;
SARC	cis	rs7635838	0.619	rs346087	chr3:11274354	A/G	cg00170343	chr3:11313890	ATG7	0.6	7.66	0.45	4.84e-13	HDL cholesterol;
SARC	cis	rs11758351	0.660	rs55643278	chr6:26222888	C/A	cg01420254	chr6:26195488	NA	0.56	4.75	0.3	3.49e-6	Gout;Renal underexcretion gout;
SARC	trans	rs4076764	0.958	rs6688181	chr1:163384193	C/T	cg00173785	chr15:64126425	HERC1	0.47	6.55	0.39	3.7e-10	Motion sickness;
SARC	cis	rs9914544	0.545	rs34417974	chr17:18773636	T/C	cg25390199	chr17:18761479	PRPSAP2	0.45	5.94	0.36	1.03e-8	Educational attainment (years of education);
SARC	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9916302	0.555	rs12940193	chr17:37652178	T/G	cg07936489	chr17:37558343	FBXL20	-0.68	-8.92	-0.5	1.43e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs9325144	0.681	rs7957376	chr12:39096518	C/T	cg13010199	chr12:38710504	ALG10B	0.57	5.73	0.35	3.05e-8	Morning vs. evening chronotype;
SARC	cis	rs9815354	0.812	rs73071352	chr3:41828300	A/G	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs362296	0.698	rs3135168	chr4:3262699	T/C	cg06533319	chr4:3265114	C4orf44	0.34	5.61	0.35	5.59e-8	Parental longevity (mother's age at death);
SARC	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg16606324	chr3:10149918	C3orf24	0.49	5.04	0.31	9.35e-7	Alzheimer's disease;
SARC	cis	rs11676348	0.818	rs7423433	chr2:218985084	G/A	cg00012203	chr2:219082015	ARPC2	-0.55	-7.32	-0.43	3.92e-12	Ulcerative colitis;
SARC	cis	rs2120243	0.592	rs1456110	chr3:157106072	G/A	cg01018701	chr3:157155998	VEPH1;PTX3	0.45	5.88	0.36	1.42e-8	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg24209194	chr3:40518798	ZNF619	0.64	7.77	0.45	2.56e-13	Renal cell carcinoma;
SARC	cis	rs10504229	0.593	rs16921589	chr8:58024387	C/A	cg11062466	chr8:58055876	NA	0.58	5.5	0.34	1e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg05255149	chr17:80675120	FN3KRP	0.43	4.86	0.3	2.15e-6	Glycated hemoglobin levels;
SARC	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg05332525	chr7:65337924	VKORC1L1	0.43	4.83	0.3	2.44e-6	Calcium levels;
SARC	cis	rs2075371	0.933	rs1833475	chr7:133958263	C/T	cg11752832	chr7:134001865	SLC35B4	0.54	6.89	0.41	5.12e-11	Mean platelet volume;
SARC	cis	rs7615952	0.512	rs2979336	chr3:125357470	G/A	cg21696256	chr3:125484277	NA	-0.35	-5.01	-0.31	1.08e-6	Blood pressure (smoking interaction);
SARC	cis	rs6570726	0.791	rs374478	chr6:145840022	C/T	cg05347473	chr6:146136440	FBXO30	0.53	7.29	0.43	4.79e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7481584	0.624	rs412149	chr11:3069943	G/A	cg20651018	chr11:3035856	CARS	0.4	5.85	0.36	1.64e-8	Calcium levels;
SARC	trans	rs561341	1.000	rs498391	chr17:30328704	G/A	cg20587970	chr11:113659929	NA	-1.24	-13.18	-0.65	5.16e-30	Hip circumference adjusted for BMI;
SARC	cis	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg13072238	chr3:49761600	GMPPB	0.44	5.64	0.35	4.82e-8	Intelligence (multi-trait analysis);
SARC	cis	rs739401	0.572	rs389285	chr11:3062673	G/A	cg08508325	chr11:3079039	CARS	-0.32	-7.7	-0.45	3.97e-13	Longevity;
SARC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg02353165	chr6:42928485	GNMT	0.61	8.48	0.49	2.61e-15	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs9916302	0.861	rs4795377	chr17:37669056	C/T	cg20243544	chr17:37824526	PNMT	0.55	6.52	0.39	4.33e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs478304	0.593	rs9666878	chr11:65475816	A/C	cg27068330	chr11:65405492	SIPA1	0.4	4.81	0.3	2.71e-6	Acne (severe);
SARC	cis	rs2290402	0.536	rs4690340	chr4:848280	G/T	cg00846425	chr4:957561	DGKQ	-0.42	-4.86	-0.3	2.12e-6	Type 2 diabetes;
SARC	trans	rs2727020	0.521	rs11040408	chr11:49534880	A/T	cg03929089	chr4:120376271	NA	0.69	7.89	0.46	1.18e-13	Coronary artery disease;
SARC	cis	rs78456975	1.000	rs4073861	chr2:1563611	G/A	cg26248373	chr2:1572462	NA	-0.64	-6.52	-0.39	4.22e-10	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs2882877	0.648	rs11677494	chr2:190401729	C/G	cg21926118	chr2:190387206	NA	-0.43	-5.36	-0.33	2.03e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs9916302	0.706	rs2879259	chr17:37410892	C/G	cg00129232	chr17:37814104	STARD3	-0.56	-6.13	-0.37	3.66e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs9398803	0.796	rs1361107	chr6:126767511	A/C	cg19875578	chr6:126661172	C6orf173	0.62	8.51	0.49	2.2e-15	Male-pattern baldness;
SARC	cis	rs10193935	0.901	rs10169411	chr2:42637749	G/A	cg27598129	chr2:42591480	NA	-0.38	-5.3	-0.33	2.74e-7	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.74	8.05	0.47	4.33e-14	Platelet count;
SARC	cis	rs1322639	0.614	rs9294967	chr6:169565406	C/T	cg03254818	chr6:169586852	NA	-0.73	-7.57	-0.44	8.52e-13	Pulse pressure;
SARC	cis	rs9398803	0.835	rs1602278	chr6:126838605	A/C	cg20229609	chr6:126660872	C6orf173	0.39	5.48	0.34	1.09e-7	Male-pattern baldness;
SARC	cis	rs7666738	0.830	rs10021709	chr4:99030587	G/A	cg05340658	chr4:99064831	C4orf37	0.66	8.92	0.5	1.42e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6964587	1.000	rs9691325	chr7:91731047	G/A	cg17063962	chr7:91808500	NA	0.94	15.85	0.72	7.05e-39	Breast cancer;
SARC	cis	rs9486719	0.843	rs3860229	chr6:97036559	T/C	cg06623918	chr6:96969491	KIAA0776	-0.77	-9.37	-0.52	6.76e-18	Migraine;Coronary artery disease;
SARC	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.77	8.78	0.5	3.66e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4803468	1.000	rs3810174	chr19:41904165	C/T	cg14132834	chr19:41945861	ATP5SL	-0.56	-7.51	-0.44	1.24e-12	Height;
SARC	cis	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg14541582	chr5:601475	NA	-0.39	-4.91	-0.31	1.71e-6	Obesity-related traits;
SARC	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.47	0.44	1.61e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg03352830	chr11:487213	PTDSS2	0.62	6.4	0.39	8.41e-10	Body mass index;
SARC	cis	rs11997175	0.902	rs7009022	chr8:33700404	A/G	ch.8.33884649F	chr8:33765107	NA	0.6	8.25	0.48	1.14e-14	Body mass index;
SARC	cis	rs8020289	0.581	rs8003145	chr14:77271421	A/G	cg23436960	chr14:77239540	VASH1	-0.32	-4.8	-0.3	2.83e-6	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);
SARC	cis	rs1865760	1.000	rs9358893	chr6:25921761	A/G	cg16482183	chr6:26056742	HIST1H1C	0.51	6.31	0.38	1.37e-9	Height;
SARC	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg04944784	chr2:26401820	FAM59B	-0.48	-5.99	-0.37	7.95e-9	Gut microbiome composition (summer);
SARC	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg00825309	chr19:58991885	ZNF446	-0.56	-7.99	-0.46	6.14e-14	Uric acid clearance;
SARC	cis	rs11651000	0.841	rs11650451	chr17:45809822	G/A	cg24803719	chr17:45855879	NA	-0.44	-5.12	-0.32	6.34e-7	IgG glycosylation;
SARC	trans	rs561341	0.623	rs4795665	chr17:30233657	C/T	cg20587970	chr11:113659929	NA	-0.73	-7.25	-0.43	6.04e-12	Hip circumference adjusted for BMI;
SARC	cis	rs3820928	0.874	rs10169717	chr2:227796911	T/G	cg05526886	chr2:227700861	RHBDD1	-0.54	-6.65	-0.4	2.04e-10	Pulmonary function;
SARC	cis	rs6582630	0.519	rs4294627	chr12:38293982	C/T	cg13010199	chr12:38710504	ALG10B	0.79	11.02	0.59	5.26e-23	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7513165	0.935	rs4951319	chr1:204162230	A/G	cg23788856	chr1:204159729	KISS1	-0.34	-5.35	-0.33	2.12e-7	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
SARC	cis	rs926938	0.765	rs1884296	chr1:115235716	A/C	cg12756093	chr1:115239321	AMPD1	-0.37	-4.81	-0.3	2.72e-6	Autism;
SARC	cis	rs3820928	0.874	rs59630650	chr2:227786514	T/C	cg05526886	chr2:227700861	RHBDD1	-0.54	-6.67	-0.4	1.8e-10	Pulmonary function;
SARC	cis	rs1348850	0.632	rs4470372	chr2:178505857	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.48	5.48	0.34	1.09e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9660992	0.649	rs12128229	chr1:205268014	C/A	cg21545522	chr1:205238299	TMCC2	0.44	5.86	0.36	1.61e-8	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs11864453	1.000	rs7201491	chr16:72034312	G/A	cg01557791	chr16:72042693	DHODH	-0.67	-9.24	-0.52	1.58e-17	Fibrinogen levels;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg03582286	chr4:71571171	RUFY3	0.48	6.39	0.39	9.02e-10	Chemerin levels;
SARC	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg24642844	chr7:1081250	C7orf50	-0.6	-6.11	-0.37	4.06e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs7589342	0.831	rs10169998	chr2:106452253	A/G	cg14210321	chr2:106509881	NCK2	-0.44	-5.1	-0.32	7.14e-7	Addiction;
SARC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	5.98	0.36	8.19e-9	Prudent dietary pattern;
SARC	cis	rs763121	0.853	rs9622833	chr22:39000397	G/A	cg21395723	chr22:39101663	GTPBP1	0.55	6.14	0.37	3.57e-9	Menopause (age at onset);
SARC	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg11062466	chr8:58055876	NA	0.58	5.61	0.35	5.65e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs60733400	0.500	rs72644697	chr1:2533605	G/A	cg18854424	chr1:2615690	NA	0.3	4.8	0.3	2.79e-6	Multiple sclerosis;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg12159575	chr19:4910274	UHRF1	0.51	6.9	0.41	4.96e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs936229	0.813	rs4886619	chr15:75106138	C/T	cg14664628	chr15:75095509	CSK	-1.05	-14.96	-0.7	6.65e-36	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs13082711	0.522	rs640065	chr3:27363937	A/T	cg02860705	chr3:27208620	NA	0.46	5.99	0.37	7.78e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs7914558	1.000	rs1890184	chr10:104748459	A/C	cg04362960	chr10:104952993	NT5C2	0.41	5.05	0.31	8.91e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs7551222	0.714	rs4951401	chr1:204537648	G/A	cg20240347	chr1:204465584	NA	-0.29	-5.0	-0.31	1.14e-6	Schizophrenia;
SARC	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg07414643	chr4:187882934	NA	0.5	7.52	0.44	1.18e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10958369	0.934	rs2068035	chr8:54414255	A/C	cg12485204	chr8:54507357	NA	0.34	4.97	0.31	1.29e-6	Response to antineoplastic agents;
SARC	cis	rs6500395	1.000	rs11641458	chr16:48670845	C/T	cg04672837	chr16:48644449	N4BP1	0.47	6.24	0.38	2.05e-9	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs9420	1.000	rs543725	chr11:57483039	A/T	cg19752551	chr11:57585705	CTNND1	-0.43	-5.94	-0.36	1.04e-8	Schizophrenia;
SARC	cis	rs4803468	1.000	rs8105833	chr19:41896145	G/A	cg14132834	chr19:41945861	ATP5SL	-0.55	-7.35	-0.43	3.29e-12	Height;
SARC	cis	rs9381040	0.599	rs2057001	chr6:41022947	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.42	-4.87	-0.3	2.08e-6	Alzheimer's disease (late onset);
SARC	cis	rs12701220	0.744	rs10499317	chr7:1012103	C/G	cg10374962	chr7:1011985	COX19	-0.5	-6.77	-0.41	1.05e-10	Bronchopulmonary dysplasia;
SARC	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg05368731	chr17:41323189	NBR1	0.79	9.83	0.54	2.62e-19	Menopause (age at onset);
SARC	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg24675658	chr1:53192096	ZYG11B	-0.7	-10.55	-0.57	1.55e-21	Monocyte count;
SARC	cis	rs12681288	0.676	rs935819	chr8:1021814	T/C	cg15309053	chr8:964076	NA	0.41	6.54	0.39	3.8e-10	Schizophrenia;
SARC	cis	rs9733	0.818	rs10888388	chr1:150687296	C/T	cg13175981	chr1:150552382	MCL1	0.64	8.91	0.5	1.51e-16	Tonsillectomy;
SARC	cis	rs2645694	0.651	rs2703144	chr4:77830505	C/G	cg03477792	chr4:77819574	ANKRD56	0.41	6.06	0.37	5.3300000000000004e-09	Emphysema distribution in smoking;
SARC	cis	rs10876993	0.855	rs1678520	chr12:58049319	C/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.5	-6.26	-0.38	1.82e-9	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs4268898	0.662	rs55661701	chr2:24400769	A/C	cg26838691	chr2:24397539	C2orf84	-0.55	-6.33	-0.38	1.24e-9	Asthma;
SARC	cis	rs2153535	0.580	rs1335628	chr6:8491742	A/T	cg23788917	chr6:8435910	SLC35B3	0.64	8.44	0.48	3.45e-15	Motion sickness;
SARC	cis	rs1059312	0.545	rs7312683	chr12:129280105	T/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.44	5.54	0.34	8.33e-8	Systemic lupus erythematosus;
SARC	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg03060546	chr3:49711283	APEH	0.48	6.31	0.38	1.37e-9	Menarche (age at onset);
SARC	cis	rs9400467	0.506	rs79788276	chr6:111599214	C/T	cg15721981	chr6:111408429	SLC16A10	0.67	5.7	0.35	3.54e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg26338869	chr17:61819248	STRADA	0.8	10.78	0.58	3.11e-22	Prudent dietary pattern;
SARC	cis	rs7520050	0.807	rs6656279	chr1:46124088	C/G	cg24296786	chr1:45957014	TESK2	-0.44	-5.69	-0.35	3.74e-8	Red blood cell count;Reticulocyte count;
SARC	cis	rs1865760	1.000	rs1865760	chr6:25916979	C/T	cg16482183	chr6:26056742	HIST1H1C	0.5	6.15	0.37	3.38e-9	Height;
SARC	trans	rs6600671	0.934	rs11249348	chr1:121188302	T/C	cg00646200	chr1:148855367	NA	0.5	7.07	0.42	1.75e-11	Hip geometry;
SARC	cis	rs56330463	0.967	rs11746634	chr5:148202668	C/G	cg21580376	chr5:148206412	ADRB2	0.42	5.74	0.35	2.95e-8	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Monocyte percentage of white cells;Eosinophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;
SARC	cis	rs2522056	1.000	rs757105	chr5:131795663	C/T	cg24060327	chr5:131705240	SLC22A5	0.48	4.76	0.3	3.38e-6	Lymphocyte counts;Fibrinogen;
SARC	cis	rs9457247	0.765	rs1060404	chr6:167429467	A/G	cg07741184	chr6:167504864	NA	0.35	6.64	0.4	2.2e-10	Crohn's disease;
SARC	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg11764359	chr7:65958608	NA	0.81	11.11	0.59	2.76e-23	Aortic root size;
SARC	cis	rs6120849	0.754	rs6120790	chr20:33599090	A/T	cg06115741	chr20:33292138	TP53INP2	0.59	5.59	0.34	6.2e-8	Protein C levels;
SARC	trans	rs9395865	0.864	rs4712029	chr6:53317012	A/G	cg15964163	chr8:67837689	SNHG6	-0.58	-6.38	-0.39	9.59e-10	Electroencephalographic traits in alcoholism;
SARC	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg12373951	chr3:133503437	NA	0.36	5.17	0.32	5.09e-7	Iron status biomarkers;
SARC	cis	rs2120243	0.572	rs6441129	chr3:157125828	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	-0.39	-5.02	-0.31	1.02e-6	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.7	9.58	0.53	1.56e-18	Lymphocyte counts;
SARC	cis	rs698813	0.674	rs7590224	chr2:44501209	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	6.23	0.38	2.16e-9	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs28669119	0.722	rs302485	chr5:88137481	T/A	cg18498987	chr5:88179539	MEF2C	0.56	5.29	0.33	2.78e-7	Schizophrenia;
SARC	cis	rs8067545	0.641	rs203462	chr17:19812541	T/C	cg13482628	chr17:19912719	NA	0.53	6.71	0.4	1.43e-10	Schizophrenia;
SARC	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	9.68	0.54	7.66e-19	Platelet count;
SARC	cis	rs17666538	1.000	rs61064968	chr8:587933	T/C	cg00450029	chr8:599525	NA	-0.69	-5.42	-0.33	1.49e-7	IgG glycosylation;
SARC	cis	rs10911232	0.507	rs4651138	chr1:183001312	C/A	cg13390022	chr1:182993471	LAMC1	0.33	4.97	0.31	1.31e-6	Hypertriglyceridemia;
SARC	cis	rs9322817	0.902	rs7764251	chr6:105197091	G/T	cg02098413	chr6:105308735	HACE1	-0.33	-4.78	-0.3	3.16e-6	Thyroid stimulating hormone;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg03015358	chr10:119088971	PDZD8	0.55	7.81	0.46	1.96e-13	Thyroid stimulating hormone;
SARC	cis	rs13390159	0.883	rs13390270	chr2:237156689	G/A	cg19324714	chr2:237145437	ASB18	0.48	4.73	0.3	3.84e-6	Response to statin therapy;
SARC	cis	rs11690935	0.885	rs6725388	chr2:172730015	G/C	cg13550731	chr2:172543902	DYNC1I2	-0.92	-13.3	-0.66	2.09e-30	Schizophrenia;
SARC	trans	rs3808502	0.549	rs11991139	chr8:11428395	C/T	cg06636001	chr8:8085503	FLJ10661	-0.66	-9.34	-0.52	7.94e-18	Neuroticism;
SARC	cis	rs12142240	0.698	rs17357676	chr1:46812444	A/G	cg10495392	chr1:46806563	NSUN4	0.65	6.8	0.41	8.47e-11	Menopause (age at onset);
SARC	cis	rs11583043	1.000	rs3861734	chr1:101489461	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.49	5.72	0.35	3.19e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs734999	0.588	rs11585048	chr1:2534087	C/T	cg00980319	chr1:2560884	MMEL1	-0.33	-4.75	-0.3	3.55e-6	Ulcerative colitis;
SARC	trans	rs61931739	0.534	rs7133262	chr12:34279444	G/A	cg13010199	chr12:38710504	ALG10B	0.74	9.98	0.55	9.21e-20	Morning vs. evening chronotype;
SARC	cis	rs910316	1.000	rs11623413	chr14:75588824	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.53	-7.51	-0.44	1.29e-12	Height;
SARC	cis	rs7481584	0.624	rs421196	chr11:3048582	T/G	cg20651018	chr11:3035856	CARS	0.41	6.12	0.37	4.01e-9	Calcium levels;
SARC	cis	rs12893668	0.572	rs7148857	chr14:104143237	C/G	cg26031613	chr14:104095156	KLC1	-0.53	-5.82	-0.36	1.98e-8	Reticulocyte count;
SARC	cis	rs208520	0.690	rs12197578	chr6:66725905	C/T	cg07460842	chr6:66804631	NA	1.05	14.04	0.68	7.33e-33	Exhaled nitric oxide output;
SARC	cis	rs11809207	0.574	rs2783630	chr1:26504741	G/A	cg23602478	chr1:26503979	CNKSR1	0.27	5.0	0.31	1.11e-6	Height;
SARC	cis	rs11122272	0.735	rs2749714	chr1:231538634	G/C	cg06096015	chr1:231504339	EGLN1	0.38	5.58	0.34	6.77e-8	Hemoglobin concentration;
SARC	cis	rs7223966	0.960	rs7212379	chr17:61706122	G/A	cg00588841	chr17:61851480	DDX42;CCDC47	-0.63	-7.09	-0.42	1.6e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg26335602	chr6:28129616	ZNF389	0.53	5.88	0.36	1.43e-8	Depression;
SARC	cis	rs7772486	0.754	rs9497401	chr6:146051271	T/C	cg23711669	chr6:146136114	FBXO30	-0.93	-16.44	-0.73	7.78e-41	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2295359	1.000	rs11465754	chr1:67631431	A/G	cg12940439	chr1:67600707	NA	0.41	6.37	0.38	1.02e-9	Psoriasis;
SARC	cis	rs554111	0.858	rs10916855	chr1:21056382	T/C	cg04902671	chr1:21058625	SH2D5	-0.44	-4.97	-0.31	1.3e-6	Facial morphology (factor 17, height of vermillion upper lip);
SARC	trans	rs36093844	0.800	rs78356210	chr11:85581267	G/A	cg15359163	chr5:122429178	PRDM6	-0.55	-6.52	-0.39	4.36e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs8044995	0.706	rs111948678	chr16:68255959	G/A	cg27539214	chr16:67997921	SLC12A4	-0.53	-4.99	-0.31	1.19e-6	Schizophrenia;
SARC	cis	rs10791097	0.694	rs2236717	chr11:130739887	G/T	cg09137382	chr11:130731461	NA	0.31	4.77	0.3	3.2e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs4727027	0.868	rs10952799	chr7:148840772	C/T	cg23583168	chr7:148888333	NA	-0.74	-11.26	-0.59	9.42e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs9814567	1.000	rs9985356	chr3:134232920	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.55	7.02	0.42	2.44e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs9285223	0.843	rs9510226	chr13:23142389	T/A	cg08083251	chr13:23309930	NA	-0.48	-5.04	-0.31	9.14e-7	Idiopathic osteonecrosis of the femoral head;
SARC	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg09699651	chr6:150184138	LRP11	0.47	5.56	0.34	7.48e-8	Lung cancer;
SARC	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.39	-4.76	-0.3	3.4e-6	Lymphocyte counts;
SARC	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg18099408	chr3:52552593	STAB1	-0.41	-5.33	-0.33	2.32e-7	Electroencephalogram traits;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg12012699	chr18:46986876	DYM	-0.51	-6.57	-0.4	3.33e-10	Electrocardiographic conduction measures;
SARC	trans	rs3780486	0.846	rs10971420	chr9:33125000	T/C	cg04842962	chr6:43655489	MRPS18A	1.08	19.82	0.79	6.49e-52	IgG glycosylation;
SARC	cis	rs4481887	1.000	rs4306162	chr1:248468509	C/T	cg13385794	chr1:248469461	NA	0.36	5.59	0.34	6.44e-8	Common traits (Other);
SARC	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	10.82	0.58	2.32e-22	Alzheimer's disease;
SARC	cis	rs172166	0.652	rs476167	chr6:28065888	T/C	cg17221315	chr6:27791827	HIST1H4J	0.45	4.95	0.31	1.41e-6	Cardiac Troponin-T levels;
SARC	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg08219700	chr8:58056026	NA	-0.6	-6.37	-0.39	1e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs13256369	0.802	rs1060106	chr8:8561452	A/G	cg17143192	chr8:8559678	CLDN23	0.52	5.74	0.35	2.9e-8	Obesity-related traits;
SARC	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg18252515	chr7:66147081	NA	0.45	4.91	0.31	1.68e-6	Aortic root size;
SARC	cis	rs13256369	0.590	rs10113115	chr8:8559588	A/G	cg17143192	chr8:8559678	CLDN23	0.5	5.98	0.36	8.3e-9	Obesity-related traits;
SARC	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg05313129	chr8:58192883	C8orf71	-0.68	-6.63	-0.4	2.34e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9300255	0.602	rs11057192	chr12:123693420	T/C	cg00376283	chr12:123451042	ABCB9	0.55	6.53	0.39	4.09e-10	Neutrophil percentage of white cells;
SARC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.76	-9.94	-0.55	1.24e-19	Prudent dietary pattern;
SARC	cis	rs2075371	0.501	rs1646653	chr7:134024686	A/G	cg11752832	chr7:134001865	SLC35B4	0.46	5.7	0.35	3.65e-8	Mean platelet volume;
SARC	cis	rs72945132	0.769	rs680571	chr11:70187441	G/A	cg05964544	chr11:70165517	PPFIA1	-0.56	-5.53	-0.34	8.7e-8	Coronary artery disease;
SARC	cis	rs7582720	0.945	rs114604411	chr2:203811912	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs2361718	0.500	rs4889818	chr17:78085228	A/G	cg27427491	chr17:78079615	GAA	-0.37	-5.17	-0.32	5.12e-7	Yeast infection;
SARC	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg11764359	chr7:65958608	NA	0.88	12.58	0.64	4.89e-28	Aortic root size;
SARC	cis	rs920590	0.918	rs11777075	chr8:19655666	G/A	cg17834443	chr8:19674713	INTS10	0.5	6.2	0.38	2.58e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs78487399	0.908	rs17031079	chr2:43804933	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.49	-4.75	-0.3	3.51e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	trans	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg21659725	chr3:3221576	CRBN	0.52	6.74	0.4	1.23e-10	Intelligence (multi-trait analysis);
SARC	cis	rs2694528	0.686	rs7729781	chr5:59872406	C/T	cg11474532	chr5:59995715	DEPDC1B	0.94	6.5	0.39	4.76e-10	Parkinson's disease;
SARC	cis	rs881375	1.000	rs1609810	chr9:123642351	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.43	5.14	0.32	5.86e-7	Rheumatoid arthritis;
SARC	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg00149659	chr3:10157352	C3orf10	0.69	6.58	0.4	3.1e-10	Alzheimer's disease;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg23179321	chr10:15138793	C10orf111;RPP38	-0.55	-6.3	-0.38	1.44e-9	Brain volume in infants (cerebrospinal fluid);
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg24529269	chr15:89164510	AEN	0.62	6.42	0.39	7.62e-10	Lung cancer in ever smokers;
SARC	cis	rs9790314	1.000	rs456611	chr3:161097268	A/G	cg03342759	chr3:160939853	NMD3	-0.6	-7.57	-0.44	8.51e-13	Morning vs. evening chronotype;
SARC	cis	rs6835098	0.961	rs2877748	chr4:174102397	G/A	cg08422745	chr4:174089978	GALNT7	-0.72	-9.33	-0.52	8.47e-18	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs4711336	0.509	rs764753	chr6:33658109	A/T	cg15676125	chr6:33679581	C6orf125	0.45	4.84	0.3	2.4e-6	Height;
SARC	cis	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg20965017	chr5:231967	SDHA	-0.57	-5.57	-0.34	7.12e-8	Breast cancer;
SARC	cis	rs933688	1.000	rs332544	chr5:90778848	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.97	12.44	0.63	1.4e-27	Smoking behavior;
SARC	cis	rs7592578	0.771	rs1128723	chr2:191366707	A/G	cg10560079	chr2:191398806	TMEM194B	-0.79	-8.9	-0.5	1.61e-16	Diastolic blood pressure;
SARC	trans	rs1478897	0.898	rs2248700	chr8:11393745	G/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.36	-0.43	3.12e-12	Systemic lupus erythematosus;
SARC	cis	rs2251381	0.606	rs8129515	chr21:30520167	C/G	cg08807101	chr21:30365312	RNF160	0.73	9.56	0.53	1.73e-18	Selective IgA deficiency;
SARC	cis	rs4803468	0.967	rs3745290	chr19:41890003	C/T	cg08477640	chr19:41863820	B9D2	0.44	5.66	0.35	4.39e-8	Height;
SARC	cis	rs9807989	0.507	rs10200952	chr2:103027651	A/C	cg03938978	chr2:103052716	IL18RAP	0.31	5.04	0.31	9.37e-7	Asthma;
SARC	cis	rs9303401	0.538	rs3785493	chr17:56472119	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	-1.01	-9.96	-0.55	1.08e-19	Cognitive test performance;
SARC	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg13877915	chr19:58951672	ZNF132	0.66	9.97	0.55	9.87e-20	Uric acid clearance;
SARC	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg20102877	chr2:27665638	KRTCAP3	-0.38	-5.45	-0.34	1.3e-7	Total body bone mineral density;
SARC	cis	rs995000	0.931	rs10889339	chr1:63012056	A/G	cg06896770	chr1:63153194	DOCK7	-0.92	-13.65	-0.67	1.48e-31	Triglyceride levels;
SARC	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg18404041	chr3:52824283	ITIH1	-0.43	-6.53	-0.39	4.04e-10	Bipolar disorder;
SARC	cis	rs11190604	0.790	rs11190535	chr10:102197441	A/T	cg07080220	chr10:102295463	HIF1AN	0.71	8.15	0.47	2.29e-14	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs28374715	0.532	rs1899	chr15:41689232	C/T	cg01768344	chr15:41576519	LOC729082	0.5	4.78	0.3	3.09e-6	Ulcerative colitis;
SARC	cis	rs6964587	1.000	rs2299238	chr7:91654517	G/A	cg17063962	chr7:91808500	NA	0.95	16.01	0.72	2.09e-39	Breast cancer;
SARC	cis	rs9341808	0.530	rs3805876	chr6:81031539	C/A	cg08355045	chr6:80787529	NA	0.32	4.94	0.31	1.52e-6	Sitting height ratio;
SARC	cis	rs2370759	0.891	rs76164690	chr10:32590362	T/G	cg05361325	chr10:32636312	EPC1	-0.68	-4.87	-0.3	2.04e-6	Sexual dysfunction (female);
SARC	cis	rs8141529	0.748	rs715531	chr22:29282679	A/G	cg02153584	chr22:29168773	CCDC117	0.78	11.38	0.6	3.9e-24	Lymphocyte counts;
SARC	cis	rs1865760	0.516	rs9393683	chr6:26066198	A/G	cg02841227	chr6:26021843	HIST1H4A	0.4	4.94	0.31	1.47e-6	Height;
SARC	cis	rs739401	0.611	rs391188	chr11:3047634	G/A	cg25174290	chr11:3078921	CARS	0.57	8.08	0.47	3.52e-14	Longevity;
SARC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	10.66	0.57	7.14e-22	Platelet count;
SARC	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg25894440	chr7:65020034	NA	-0.72	-5.46	-0.34	1.2e-7	Diabetic kidney disease;
SARC	cis	rs7666738	0.830	rs6811940	chr4:98777898	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.54	0.49	1.74e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7769051	1.000	rs10484629	chr6:133117870	A/C	cg07930552	chr6:133119739	C6orf192	0.96	9.03	0.51	6.67e-17	Type 2 diabetes nephropathy;
SARC	cis	rs2075371	0.932	rs2598290	chr7:133987736	C/G	cg11752832	chr7:134001865	SLC35B4	0.57	7.43	0.44	1.99e-12	Mean platelet volume;
SARC	cis	rs752010	0.967	rs752011	chr1:42092929	C/T	cg06885757	chr1:42089581	HIVEP3	0.36	5.59	0.34	6.19e-8	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs11098499	0.954	rs13145352	chr4:120409963	C/T	cg24375607	chr4:120327624	NA	-0.41	-4.91	-0.31	1.74e-6	Corneal astigmatism;
SARC	cis	rs787274	0.543	rs10114623	chr9:115631360	G/A	cg13803584	chr9:115635662	SNX30	-0.83	-7.03	-0.42	2.25e-11	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs2228479	0.850	rs1108063	chr16:89893983	A/G	cg00800038	chr16:89945340	TCF25	-0.82	-5.8	-0.36	2.19e-8	Skin colour saturation;
SARC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg05552183	chr6:42928497	GNMT	0.53	7.21	0.43	7.99e-12	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs9457247	1.000	rs4710147	chr6:167374239	G/A	cg07741184	chr6:167504864	NA	-0.3	-5.61	-0.35	5.69e-8	Crohn's disease;
SARC	cis	rs6807306	0.666	rs13090569	chr3:167471545	C/T	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.47	4.72	0.3	4.1e-6	Mean platelet volume;
SARC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg16405210	chr4:1374714	KIAA1530	-0.86	-11.39	-0.6	3.5e-24	Longevity;
SARC	cis	rs27434	0.583	rs34756	chr5:96152383	C/T	cg16492584	chr5:96139282	ERAP1	0.56	7.12	0.42	1.35e-11	Ankylosing spondylitis;
SARC	trans	rs61931739	0.890	rs11053018	chr12:34105962	T/G	cg26384229	chr12:38710491	ALG10B	-0.59	-7.85	-0.46	1.53e-13	Morning vs. evening chronotype;
SARC	cis	rs4689388	0.816	rs13147655	chr4:6293474	A/G	cg25554036	chr4:6271136	WFS1	0.39	6.42	0.39	7.48e-10	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg27121462	chr16:89883253	FANCA	-0.59	-8.04	-0.47	4.55e-14	Vitiligo;
SARC	cis	rs1707322	0.758	rs10789474	chr1:46250040	G/T	cg06784218	chr1:46089804	CCDC17	0.36	6.39	0.39	8.93e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs34779708	0.966	rs7077242	chr10:35481965	A/C	cg03585969	chr10:35415529	CREM	-0.38	-4.71	-0.3	4.2e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs523522	0.924	rs11065150	chr12:120958875	T/G	cg27279351	chr12:120934652	DYNLL1	0.73	8.95	0.51	1.11e-16	High light scatter reticulocyte count;
SARC	cis	rs2153535	0.580	rs1360054	chr6:8520377	C/A	cg21535247	chr6:8435926	SLC35B3	0.54	6.92	0.41	4.29e-11	Motion sickness;
SARC	cis	rs8079658	0.586	rs9894277	chr17:63856501	T/G	cg03442606	chr17:63822778	CCDC46	0.36	4.73	0.3	3.85e-6	Post bronchodilator FEV1;
SARC	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg01448562	chr3:133502909	NA	-0.49	-7.48	-0.44	1.47e-12	Iron status biomarkers;
SARC	cis	rs10791323	0.628	rs10750543	chr11:133718467	G/A	cg14349672	chr11:133703707	NA	-0.33	-4.92	-0.31	1.62e-6	Childhood ear infection;
SARC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg09033563	chr22:24373618	LOC391322	0.45	5.03	0.31	9.99e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg22800045	chr5:56110881	MAP3K1	-0.6	-5.65	-0.35	4.67e-8	Initial pursuit acceleration;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg14516246	chr6:27440625	ZNF184	0.52	7.1	0.42	1.5e-11	Chemerin levels;
SARC	cis	rs9486719	1.000	rs2472888	chr6:96865501	T/C	cg06623918	chr6:96969491	KIAA0776	0.73	8.01	0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs240764	0.658	rs9404053	chr6:101254456	G/A	cg09795085	chr6:101329169	ASCC3	-0.42	-5.39	-0.33	1.76e-7	Neuroticism;
SARC	trans	rs7937682	0.883	rs631490	chr11:111452040	G/C	cg18187862	chr3:45730750	SACM1L	0.54	6.77	0.41	1.05e-10	Primary sclerosing cholangitis;
SARC	cis	rs11098499	0.863	rs1480936	chr4:120462861	C/T	cg09160332	chr4:120329925	NA	-0.35	-4.77	-0.3	3.19e-6	Corneal astigmatism;
SARC	trans	rs7824557	0.564	rs2572399	chr8:11234520	A/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.87	-0.41	5.91e-11	Retinal vascular caliber;
SARC	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg17971929	chr21:40555470	PSMG1	-0.58	-7.17	-0.42	1.02e-11	Menarche (age at onset);
SARC	cis	rs2952156	0.684	rs881844	chr17:37810218	C/G	cg07936489	chr17:37558343	FBXL20	-0.42	-5.35	-0.33	2.12e-7	Asthma;
SARC	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg11644478	chr21:40555479	PSMG1	-0.55	-6.66	-0.4	1.94e-10	Menarche (age at onset);
SARC	cis	rs9291683	0.632	rs13137074	chr4:10042842	C/T	cg00071950	chr4:10020882	SLC2A9	0.39	6.29	0.38	1.52e-9	Bone mineral density;
SARC	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg02951883	chr7:2050386	MAD1L1	-0.51	-6.86	-0.41	6.06e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs6701037	0.555	rs10912898	chr1:175120469	A/G	cg08873628	chr1:175162347	KIAA0040	-0.39	-5.35	-0.33	2.08e-7	Alcohol dependence;
SARC	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-6.38	-0.39	9.2e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs546131	0.928	rs552868	chr11:34830694	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.56	7.39	0.44	2.65e-12	Lung disease severity in cystic fibrosis;
SARC	cis	rs2290159	0.752	rs3773349	chr3:12649732	T/C	cg23032965	chr3:12705835	RAF1	0.77	8.56	0.49	1.52e-15	Cholesterol, total;
SARC	cis	rs6088580	0.660	rs6087592	chr20:33114503	A/G	cg24642439	chr20:33292090	TP53INP2	0.66	8.72	0.5	5.23e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs7264396	0.511	rs2425102	chr20:34312303	G/A	cg01084648	chr20:34329383	RBM39	0.57	4.98	0.31	1.25e-6	Total cholesterol levels;
SARC	cis	rs7260598	0.539	rs115825618	chr19:24065018	G/T	cg27517351	chr19:23941871	ZNF681	0.54	4.73	0.3	3.86e-6	Response to taxane treatment (placlitaxel);
SARC	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg15448220	chr1:150897856	SETDB1	0.47	6.22	0.38	2.24e-9	Tonsillectomy;
SARC	cis	rs1185460	0.967	rs1786690	chr11:118942067	A/G	cg23280166	chr11:118938394	VPS11	0.77	10.86	0.58	1.7e-22	Coronary artery disease;
SARC	cis	rs765787	0.530	rs4270107	chr15:45535350	A/G	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.51e-10	Uric acid levels;
SARC	cis	rs9733	0.650	rs9803935	chr1:150552622	T/G	cg18016565	chr1:150552671	MCL1	-0.39	-5.41	-0.33	1.57e-7	Tonsillectomy;
SARC	cis	rs2370759	1.000	rs76467481	chr10:32610740	T/G	cg18270830	chr10:32634957	EPC1	0.68	6.24	0.38	2.04e-9	Sexual dysfunction (female);
SARC	cis	rs7011049	1.000	rs72643574	chr8:53844501	G/C	cg26025543	chr8:53854495	NA	0.61	5.45	0.34	1.28e-7	Systolic blood pressure;
SARC	cis	rs5758511	0.680	rs1033459	chr22:42619067	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.46	6.9	0.41	4.87e-11	Birth weight;
SARC	cis	rs4481887	0.893	rs4275482	chr1:248473506	T/C	cg13385794	chr1:248469461	NA	0.34	5.32	0.33	2.46e-7	Common traits (Other);
SARC	cis	rs2948294	0.588	rs4840913	chr8:8116906	A/C	cg08975724	chr8:8085496	FLJ10661	0.5	5.72	0.35	3.2e-8	Red cell distribution width;
SARC	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg04944784	chr2:26401820	FAM59B	0.65	8.44	0.48	3.46e-15	Mean corpuscular hemoglobin;
SARC	cis	rs4144743	0.938	rs7225134	chr17:45326932	C/T	cg18085866	chr17:45331354	ITGB3	-0.73	-7.41	-0.44	2.29e-12	Body mass index;
SARC	cis	rs865483	0.860	rs2522968	chr17:35830300	G/A	cg06561646	chr17:35873369	DUSP14	-0.49	-6.55	-0.39	3.6e-10	Monocyte count;
SARC	cis	rs703842	0.616	rs4760332	chr12:58222672	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.66	-8.81	-0.5	2.96e-16	Multiple sclerosis;
SARC	cis	rs7772486	0.738	rs2246334	chr6:146183635	G/A	cg05347473	chr6:146136440	FBXO30	0.52	7.3	0.43	4.64e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6815814	0.950	rs5743557	chr4:38806827	G/A	cg02016764	chr4:38805732	TLR1	-0.42	-4.89	-0.31	1.89e-6	Breast cancer;
SARC	cis	rs9916302	0.706	rs4287601	chr17:37513852	T/C	cg15445000	chr17:37608096	MED1	-0.47	-5.08	-0.32	7.63e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs6908034	0.607	rs73376651	chr6:19805559	C/G	cg02682789	chr6:19804855	NA	0.72	5.45	0.34	1.31e-7	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg12463550	chr7:65579703	CRCP	0.5	5.9	0.36	1.27e-8	Aortic root size;
SARC	cis	rs2153535	0.580	rs9328486	chr6:8528008	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	10.6	0.57	1.12e-21	Motion sickness;
SARC	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	12.62	0.64	3.5e-28	Chronic sinus infection;
SARC	cis	rs6089584	0.924	rs6142906	chr20:60552554	G/C	cg06108461	chr20:60628389	TAF4	-0.92	-12.08	-0.62	2.13e-26	Body mass index;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg26396707	chr1:161129261	USP21	0.47	6.32	0.38	1.3e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs826838	1.000	rs1719830	chr12:39096992	T/G	cg13010199	chr12:38710504	ALG10B	-0.63	-9.02	-0.51	6.97e-17	Heart rate;
SARC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg09373136	chr17:61933544	TCAM1	-0.39	-5.48	-0.34	1.11e-7	Prudent dietary pattern;
SARC	trans	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg00938859	chr5:1591904	SDHAP3	0.78	7.47	0.44	1.57e-12	Breast cancer;
SARC	cis	rs2991971	0.810	rs2036021	chr1:45901370	G/A	cg05343316	chr1:45956843	TESK2	-0.43	-5.27	-0.33	3.06e-7	High light scatter reticulocyte count;
SARC	cis	rs9660992	0.639	rs1151786	chr1:205227760	G/C	cg00857998	chr1:205179979	DSTYK	0.55	6.68	0.4	1.69e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs2204008	0.557	rs11520191	chr12:38197057	T/A	cg26384229	chr12:38710491	ALG10B	0.89	13.09	0.65	1.03e-29	Bladder cancer;
SARC	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg08677398	chr8:58056175	NA	0.42	5.03	0.31	1e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs34779708	0.931	rs7079498	chr10:35375344	C/T	cg03585969	chr10:35415529	CREM	0.39	4.94	0.31	1.53e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs1468333	1.000	rs2906124	chr5:137528835	A/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.82	11.82	0.61	1.39e-25	Resting heart rate;
SARC	cis	rs12956009	0.518	rs11663852	chr18:44887542	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	7.64	0.45	5.68e-13	Educational attainment (years of education);
SARC	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg13939156	chr17:80058883	NA	0.4	6.22	0.38	2.23e-9	Life satisfaction;
SARC	cis	rs1580019	0.922	rs1376289	chr7:32486980	C/G	cg14728415	chr7:32535168	LSM5;AVL9	-0.41	-4.89	-0.31	1.85e-6	Cognitive ability;
SARC	cis	rs174601	0.861	rs174547	chr11:61570783	C/T	cg19610905	chr11:61596333	FADS2	0.41	4.85	0.3	2.26e-6	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
SARC	trans	rs7824557	0.713	rs6601575	chr8:11097804	A/C	cg06636001	chr8:8085503	FLJ10661	0.61	8.05	0.47	4.13e-14	Retinal vascular caliber;
SARC	trans	rs2727020	0.894	rs10839265	chr11:49369733	C/T	cg03929089	chr4:120376271	NA	-0.72	-9.07	-0.51	4.97e-17	Coronary artery disease;
SARC	cis	rs709400	0.628	rs7154246	chr14:103876794	G/A	cg12935359	chr14:103987150	CKB	0.41	6.01	0.37	7.25e-9	Body mass index;
SARC	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg26338869	chr17:61819248	STRADA	-0.62	-7.99	-0.46	6.1e-14	Prudent dietary pattern;
SARC	cis	rs1322639	0.575	rs9294966	chr6:169565318	G/T	cg03254818	chr6:169586852	NA	0.74	7.6	0.45	7.02e-13	Pulse pressure;
SARC	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg23758822	chr17:41437982	NA	0.88	10.76	0.58	3.47e-22	Menopause (age at onset);
SARC	cis	rs4727027	0.933	rs10238826	chr7:148830888	A/G	cg23583168	chr7:148888333	NA	-0.74	-11.01	-0.59	5.64e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs16866061	0.515	rs1027340	chr2:225370554	C/A	cg22509189	chr2:225307070	NA	-0.4	-5.06	-0.31	8.48e-7	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	cis	rs2153535	0.560	rs2210798	chr6:8481522	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	8.24	0.48	1.24e-14	Motion sickness;
SARC	cis	rs6701037	0.512	rs2285216	chr1:175133012	C/T	cg00321850	chr1:175162397	KIAA0040	0.37	5.89	0.36	1.33e-8	Alcohol dependence;
SARC	cis	rs9790314	0.631	rs9867582	chr3:160797405	A/G	cg04691961	chr3:161091175	C3orf57	-0.52	-6.71	-0.4	1.5e-10	Morning vs. evening chronotype;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg23779421	chr18:68098095	NA	-0.4	-6.26	-0.38	1.8e-9	Electrocardiographic conduction measures;
SARC	cis	rs2342371	0.565	rs9858020	chr3:196219794	A/G	cg15048948	chr3:196158458	UBXN7	0.44	5.7	0.35	3.57e-8	Fat distribution (HIV);
SARC	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.41	-4.9	-0.31	1.78e-6	Renal function-related traits (BUN);
SARC	cis	rs1538970	0.962	rs3219472	chr1:45804050	A/G	cg16078521	chr1:45672383	ZSWIM5	-0.45	-4.72	-0.3	4.02e-6	Platelet count;
SARC	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg22834771	chr12:69754056	YEATS4	-0.48	-6.33	-0.38	1.25e-9	Cerebrospinal fluid biomarker levels;
SARC	cis	rs367615	0.704	rs55956735	chr5:108845042	A/G	cg17395555	chr5:108820864	NA	0.48	6.91	0.41	4.59e-11	Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs5753618	0.583	rs5753601	chr22:31798259	G/T	cg07713946	chr22:31675144	LIMK2	0.35	4.88	0.3	1.94e-6	Colorectal cancer;
SARC	cis	rs2933343	0.818	rs6764681	chr3:128568380	G/C	cg24203234	chr3:128598194	ACAD9	-0.53	-5.76	-0.35	2.6e-8	IgG glycosylation;
SARC	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg22535103	chr8:58192502	C8orf71	-0.59	-6.21	-0.38	2.35e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7566780	0.772	rs62114566	chr2:16709774	T/C	cg09580478	chr2:16689509	NA	-0.51	-5.52	-0.34	8.91e-8	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs7666738	0.830	rs7669407	chr4:98750251	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.54	0.49	1.74e-15	Colonoscopy-negative controls vs population controls;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg08312191	chr2:70520937	SNRPG	0.49	6.33	0.38	1.27e-9	Lung adenocarcinoma;
SARC	cis	rs10463554	0.824	rs3776868	chr5:102298716	T/G	cg23492399	chr5:102201601	PAM	-0.48	-5.64	-0.35	4.84e-8	Parkinson's disease;
SARC	cis	rs9309473	0.539	rs6745560	chr2:73827117	C/T	cg20560298	chr2:73613845	ALMS1	-0.48	-6.4	-0.39	8.49e-10	Metabolite levels;
SARC	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg11644478	chr21:40555479	PSMG1	1.03	14.57	0.69	1.33e-34	Cognitive function;
SARC	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg09699651	chr6:150184138	LRP11	0.5	6.07	0.37	5.19e-9	Lung cancer;
SARC	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs796364	0.951	rs6722092	chr2:201059371	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.57	5.77	0.35	2.48e-8	Schizophrenia;
SARC	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg16405210	chr4:1374714	KIAA1530	-0.43	-5.13	-0.32	6.04e-7	Obesity-related traits;
SARC	cis	rs6788895	0.661	rs73010956	chr3:150492724	A/G	cg09723797	chr3:150481914	SIAH2	0.78	5.13	0.32	6.09e-7	Breast cancer;
SARC	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg11987759	chr7:65425863	GUSB	-0.61	-8.35	-0.48	5.95e-15	Calcium levels;
SARC	cis	rs1971762	0.563	rs4759284	chr12:54079491	G/A	cg06632207	chr12:54070931	ATP5G2	0.43	5.66	0.35	4.4e-8	Height;
SARC	cis	rs11252926	0.674	rs11598550	chr10:504778	A/C	cg16386425	chr10:429943	DIP2C	0.47	5.44	0.34	1.37e-7	Psychosis in Alzheimer's disease;
SARC	cis	rs12579753	1.000	rs7300900	chr12:82166821	G/T	cg07988820	chr12:82153109	PPFIA2	-0.57	-6.51	-0.39	4.63e-10	Resting heart rate;
SARC	cis	rs6696846	0.691	rs11240370	chr1:205118336	T/G	cg21545522	chr1:205238299	TMCC2	0.36	5.07	0.32	8.01e-7	Red blood cell count;
SARC	cis	rs826838	0.616	rs2200605	chr12:38624088	G/A	cg13010199	chr12:38710504	ALG10B	0.53	6.67	0.4	1.81e-10	Heart rate;
SARC	cis	rs6604026	0.656	rs6694051	chr1:93392760	A/G	cg17283838	chr1:93427260	FAM69A	0.41	4.77	0.3	3.25e-6	Multiple sclerosis;
SARC	cis	rs9300255	0.544	rs1727310	chr12:123660510	A/G	cg05973401	chr12:123451056	ABCB9	0.55	5.19	0.32	4.48e-7	Neutrophil percentage of white cells;
SARC	cis	rs17600642	0.724	rs748165	chr10:72460655	C/T	cg19779893	chr10:72451501	ADAMTS14	-0.39	-6.15	-0.37	3.36e-9	Bipolar disorder;
SARC	cis	rs1348850	0.914	rs10497503	chr2:178371739	G/T	cg23306229	chr2:178417860	TTC30B	0.55	6.61	0.4	2.64e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs4820539	1.000	rs4822358	chr22:23474795	A/G	cg14186256	chr22:23484241	RTDR1	0.91	14.97	0.7	6.15e-36	Bone mineral density;
SARC	cis	rs7587476	0.736	rs62202002	chr2:215690600	T/C	cg04004882	chr2:215674386	BARD1	0.56	6.4	0.39	8.5e-10	Neuroblastoma;
SARC	cis	rs9296092	0.538	rs62407564	chr6:33534010	C/T	cg13560919	chr6:33536144	NA	-0.53	-6.33	-0.38	1.23e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs2952156	0.920	rs2941506	chr17:37833035	A/G	cg00129232	chr17:37814104	STARD3	-0.69	-9.9	-0.54	1.58e-19	Asthma;
SARC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.72	-8.69	-0.49	6.49e-16	Prudent dietary pattern;
SARC	trans	rs11098499	0.542	rs10440343	chr4:120309787	G/C	cg25214090	chr10:38739885	LOC399744	0.55	7.14	0.42	1.15e-11	Corneal astigmatism;
SARC	cis	rs7769051	0.808	rs1467404	chr6:133090141	A/G	cg22852734	chr6:133119734	C6orf192	-1.13	-11.5	-0.6	1.5e-24	Type 2 diabetes nephropathy;
SARC	cis	rs17376456	0.825	rs56108532	chr5:93276342	C/T	cg25358565	chr5:93447407	FAM172A	1.29	14.23	0.68	1.68e-33	Diabetic retinopathy;
SARC	cis	rs2562456	0.792	rs2562398	chr19:21722949	A/G	cg00806126	chr19:22604979	ZNF98	0.47	4.77	0.3	3.22e-6	Pain;
SARC	cis	rs6782228	0.509	rs2811495	chr3:128359957	A/G	cg08795948	chr3:128337044	NA	0.37	5.01	0.31	1.1e-6	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg24917645	chr20:3801318	C20orf29	-0.5	-6.32	-0.38	1.3e-9	Gallstone disease;
SARC	cis	rs2070677	1.000	rs12263487	chr10:135403585	A/G	cg20169779	chr10:135381914	SYCE1	-0.58	-6.61	-0.4	2.65e-10	Gout;
SARC	cis	rs2115630	1.000	rs11073730	chr15:85354596	C/T	cg12501888	chr15:85177176	SCAND2	-0.49	-5.97	-0.36	8.99e-9	P wave terminal force;
SARC	cis	rs3540	0.512	rs3862434	chr15:91080387	C/T	cg22089800	chr15:90895588	ZNF774	0.57	7.2	0.43	8.06e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs72781680	0.800	rs56398785	chr2:24091515	T/A	cg08917208	chr2:24149416	ATAD2B	0.91	9.12	0.51	3.51e-17	Lymphocyte counts;
SARC	cis	rs6542838	0.780	rs981601	chr2:99463882	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.4	-5.03	-0.31	9.75e-7	Fear of minor pain;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg07160630	chr14:53197308	STYX	0.49	6.65	0.4	2.09e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg15921436	chr17:44337874	NA	0.53	5.33	0.33	2.36e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7937682	0.847	rs583032	chr11:111432757	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.89	-13.05	-0.65	1.39e-29	Primary sclerosing cholangitis;
SARC	cis	rs7927592	0.913	rs4988291	chr11:68381607	G/A	cg01657329	chr11:68192670	LRP5	-0.44	-5.23	-0.32	3.81e-7	Total body bone mineral density;
SARC	cis	rs477692	0.685	rs534430	chr10:131398734	A/C	cg05714579	chr10:131428358	MGMT	0.51	6.78	0.41	9.97e-11	Response to temozolomide;
SARC	cis	rs9393692	0.572	rs4145878	chr6:26198046	A/T	cg05868516	chr6:26286170	HIST1H4H	0.6	7.61	0.45	6.61e-13	Educational attainment;
SARC	cis	rs67311347	0.544	rs2278930	chr3:40351092	C/T	cg24209194	chr3:40518798	ZNF619	0.5	6.62	0.4	2.41e-10	Renal cell carcinoma;
SARC	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg22800045	chr5:56110881	MAP3K1	0.41	4.96	0.31	1.36e-6	Coronary artery disease;
SARC	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.63	5.99	0.37	7.8e-9	Lung function (FEV1/FVC);
SARC	cis	rs7216064	1.000	rs12451707	chr17:65871598	G/A	cg12091567	chr17:66097778	LOC651250	-0.64	-6.46	-0.39	6.11e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs2486288	0.656	rs7162022	chr15:45565253	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.53	-6.52	-0.39	4.2e-10	Glomerular filtration rate;
SARC	cis	rs796364	0.951	rs12620298	chr2:201047184	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.56	-5.54	-0.34	8.25e-8	Schizophrenia;
SARC	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg12463550	chr7:65579703	CRCP	-0.45	-5.04	-0.31	9.24e-7	Aortic root size;
SARC	cis	rs73157695	1.000	rs11089031	chr21:47350796	G/A	cg00682050	chr21:47343716	PCBP3	-0.44	-5.13	-0.32	6.07e-7	Myopia;
SARC	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.3	-4.74	-0.3	3.7e-6	Total body bone mineral density;
SARC	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg22535103	chr8:58192502	C8orf71	-0.71	-6.82	-0.41	7.76e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs2153535	0.580	rs915352	chr6:8442766	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs2204008	0.744	rs11168870	chr12:37973333	A/G	cg26384229	chr12:38710491	ALG10B	0.89	13.46	0.66	6.13e-31	Bladder cancer;
SARC	cis	rs9916302	0.904	rs4795384	chr17:37716771	C/G	cg00129232	chr17:37814104	STARD3	-0.65	-7.94	-0.46	8.31e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs965469	1.000	rs6051763	chr20:3321616	T/G	cg25506879	chr20:3388711	C20orf194	-0.53	-5.42	-0.33	1.5e-7	IFN-related cytopenia;
SARC	cis	rs7918232	0.825	rs4749233	chr10:27467967	G/A	cg14442939	chr10:27389572	ANKRD26	0.67	6.0	0.37	7.38e-9	Breast cancer;
SARC	cis	rs7481584	0.624	rs80871	chr11:3049843	A/C	cg05729581	chr11:3078854	CARS	0.57	7.4	0.44	2.45e-12	Calcium levels;
SARC	cis	rs995000	0.899	rs11577840	chr1:62991369	T/C	cg06896770	chr1:63153194	DOCK7	-0.88	-12.57	-0.64	5.16e-28	Triglyceride levels;
SARC	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg22857025	chr5:266934	NA	-1.09	-11.97	-0.62	4.86e-26	Breast cancer;
SARC	cis	rs2273669	0.915	rs6651002	chr6:109318516	G/C	cg01304950	chr6:109416612	SESN1;C6orf182	0.52	4.73	0.3	3.87e-6	Prostate cancer;
SARC	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg00684032	chr4:1343700	KIAA1530	0.37	5.34	0.33	2.24e-7	Obesity-related traits;
SARC	cis	rs12908161	1.000	rs34570071	chr15:85280212	T/A	cg17507749	chr15:85114479	UBE2QP1	0.57	6.61	0.4	2.53e-10	Schizophrenia;
SARC	cis	rs7582720	1.000	rs76298043	chr2:203814694	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17825298	chr7:151573262	PRKAG2	0.5	6.3	0.38	1.44e-9	Smoking initiation;
SARC	cis	rs4742903	0.967	rs10991119	chr9:106905277	C/T	cg14250997	chr9:106856677	SMC2	-0.45	-5.87	-0.36	1.53e-8	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs2075371	0.527	rs1862046	chr7:134023524	T/C	cg00033643	chr7:134001901	SLC35B4	0.45	5.4	0.33	1.66e-7	Mean platelet volume;
SARC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg07157834	chr1:205819609	PM20D1	0.82	13.83	0.67	3.67e-32	Menarche (age at onset);
SARC	trans	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg21659725	chr3:3221576	CRBN	0.79	11.7	0.61	3.5e-25	Intelligence (multi-trait analysis);
SARC	cis	rs449789	0.857	rs1875816	chr6:159720314	A/G	cg14500486	chr6:159655392	FNDC1	-0.44	-5.02	-0.31	1.01e-6	Pulse pressure;
SARC	cis	rs10791323	0.628	rs1893850	chr11:133705356	T/C	cg14349672	chr11:133703707	NA	-0.39	-5.83	-0.36	1.85e-8	Childhood ear infection;
SARC	cis	rs709400	0.663	rs28444993	chr14:103930564	T/C	cg26031613	chr14:104095156	KLC1	0.82	11.93	0.62	6.36e-26	Body mass index;
SARC	cis	rs921968	0.643	rs508157	chr2:219435288	G/A	cg02176678	chr2:219576539	TTLL4	0.37	5.49	0.34	1.02e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs2011503	0.941	rs72999068	chr19:19380685	A/G	cg03709012	chr19:19516395	GATAD2A	0.59	5.29	0.33	2.85e-7	Bipolar disorder;
SARC	cis	rs9325144	0.647	rs61930266	chr12:38922048	A/G	cg26384229	chr12:38710491	ALG10B	-0.57	-7.34	-0.43	3.46e-12	Morning vs. evening chronotype;
SARC	cis	rs6834538	0.858	rs6816782	chr4:113559353	T/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.48	5.67	0.35	4.24e-8	Free thyroxine concentration;
SARC	cis	rs4891159	0.526	rs2848961	chr18:74129886	C/G	cg24786174	chr18:74118243	ZNF516	-0.7	-11.74	-0.61	2.59e-25	Longevity;
SARC	cis	rs9790314	1.000	rs9846756	chr3:160983809	A/C	cg04691961	chr3:161091175	C3orf57	-0.78	-11.51	-0.6	1.39e-24	Morning vs. evening chronotype;
SARC	trans	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg00938859	chr5:1591904	SDHAP3	0.79	7.61	0.45	6.69e-13	Breast cancer;
SARC	cis	rs6908034	0.607	rs75060331	chr6:19812956	C/T	cg02682789	chr6:19804855	NA	0.69	5.56	0.34	7.3900000000000007e-08	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs6964587	1.000	rs13231820	chr7:91663529	A/G	cg17063962	chr7:91808500	NA	0.95	15.35	0.71	3.15e-37	Breast cancer;
SARC	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg24829409	chr8:58192753	C8orf71	-0.59	-5.1	-0.32	7.19e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs763121	0.853	rs4820345	chr22:39091151	T/C	cg21395723	chr22:39101663	GTPBP1	0.51	5.66	0.35	4.47e-8	Menopause (age at onset);
SARC	cis	rs2559856	1.000	rs2559856	chr12:102089561	A/G	cg12924262	chr12:102091054	CHPT1	0.57	7.7	0.45	3.81e-13	Blood protein levels;
SARC	cis	rs734999	0.550	rs2985855	chr1:2531372	A/C	cg00980319	chr1:2560884	MMEL1	0.35	4.95	0.31	1.42e-6	Ulcerative colitis;
SARC	trans	rs877282	0.853	rs12763400	chr10:763617	C/T	cg22713356	chr15:30763199	NA	1.04	10.13	0.55	3.18e-20	Uric acid levels;
SARC	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg25036284	chr2:26402008	FAM59B	0.46	5.7	0.35	3.59e-8	Gut microbiome composition (summer);
SARC	cis	rs6840360	0.554	rs58751443	chr4:152709905	A/G	cg22705602	chr4:152727874	NA	-0.48	-8.27	-0.48	1e-14	Intelligence (multi-trait analysis);
SARC	cis	rs7833790	1.000	rs28696138	chr8:82770794	G/A	cg17211192	chr8:82754475	SNX16	0.6	6.51	0.39	4.64e-10	Diastolic blood pressure;
SARC	cis	rs7727544	0.740	rs419291	chr5:131633355	T/C	cg24060327	chr5:131705240	SLC22A5	-0.69	-8.67	-0.49	7.44e-16	Blood metabolite levels;
SARC	cis	rs1355223	0.583	rs1828298	chr11:34870439	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.76	10.87	0.58	1.62e-22	Systemic lupus erythematosus and Systemic sclerosis;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg25958740	chr3:179281560	ACTL6A	0.53	6.69	0.4	1.66e-10	Breast cancer;
SARC	cis	rs910316	1.000	rs10138183	chr14:75615227	T/C	cg11812906	chr14:75593930	NEK9	0.89	13.88	0.67	2.45e-32	Height;
SARC	cis	rs8067354	0.681	rs9907923	chr17:57824927	C/T	cg13753209	chr17:57696993	CLTC	0.67	7.24	0.43	6.46e-12	Hemoglobin concentration;
SARC	cis	rs4900538	0.821	rs8016191	chr14:102825340	G/A	cg18135206	chr14:102964638	TECPR2	-0.58	-7.49	-0.44	1.4e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs2120243	0.539	rs2124497	chr3:157120259	T/G	cg24825693	chr3:157122686	VEPH1	-0.46	-6.42	-0.39	7.36e-10	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs113835537	0.597	rs2305534	chr11:66313203	T/C	cg24851651	chr11:66362959	CCS	0.39	4.94	0.31	1.5e-6	Airway imaging phenotypes;
SARC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	8.99	0.51	8.59e-17	Prudent dietary pattern;
SARC	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg12463550	chr7:65579703	CRCP	-0.48	-5.25	-0.33	3.44e-7	Aortic root size;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg03946899	chr15:98503444	ARRDC4	0.48	6.38	0.39	9.43e-10	Chemerin levels;
SARC	cis	rs6871536	1.000	rs56183820	chr5:131965606	C/T	cg11797159	chr5:131991491	NA	0.38	4.93	0.31	1.56e-6	Asthma (childhood onset);
SARC	cis	rs11718455	0.960	rs13065591	chr3:43996585	T/C	cg21419209	chr3:44054225	NA	-0.43	-5.21	-0.32	4.06e-7	Coronary artery disease;
SARC	cis	rs4481887	0.927	rs4517383	chr1:248426484	C/T	cg13385794	chr1:248469461	NA	0.37	5.59	0.34	6.43e-8	Common traits (Other);
SARC	cis	rs11098499	0.866	rs13105020	chr4:120285688	G/T	cg09307838	chr4:120376055	NA	0.83	11.82	0.61	1.46e-25	Corneal astigmatism;
SARC	cis	rs8078723	1.000	rs4794823	chr17:38166265	A/T	cg17467752	chr17:38218738	THRA	0.47	5.94	0.36	1.01e-8	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs7819412	0.522	rs11776603	chr8:11020313	G/T	cg12395012	chr8:11607386	GATA4	0.28	4.77	0.3	3.23e-6	Triglycerides;
SARC	cis	rs2730245	0.527	rs842693	chr7:158660491	C/T	cg24397884	chr7:158709396	WDR60	1.1	9.71	0.54	6.03e-19	Height;
SARC	cis	rs6088590	0.901	rs6087631	chr20:33403509	T/C	cg24642439	chr20:33292090	TP53INP2	0.86	12.24	0.63	6.32e-27	Coronary artery disease;
SARC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg09373136	chr17:61933544	TCAM1	-0.44	-6.07	-0.37	5.25e-9	Prudent dietary pattern;
SARC	cis	rs10089	0.904	rs2228112	chr5:127469859	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.83	10.24	0.56	1.49e-20	Ileal carcinoids;
SARC	cis	rs826838	0.586	rs10785554	chr12:38628749	T/A	cg26384229	chr12:38710491	ALG10B	0.59	7.8	0.46	2.04e-13	Heart rate;
SARC	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg03709012	chr19:19516395	GATAD2A	1.0	17.11	0.75	4.6e-43	Tonsillectomy;
SARC	cis	rs929354	0.772	rs6971896	chr7:156978412	C/T	cg05182265	chr7:156933206	UBE3C	-0.33	-5.02	-0.31	1.03e-6	Body mass index;
SARC	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg06618935	chr21:46677482	NA	-0.42	-5.65	-0.35	4.7e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9660992	0.539	rs113699533	chr1:205122895	G/A	cg21545522	chr1:205238299	TMCC2	0.35	4.95	0.31	1.42e-6	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.48	0.53	3.07e-18	Prudent dietary pattern;
SARC	cis	rs7560272	0.538	rs12053242	chr2:73937168	G/A	cg20560298	chr2:73613845	ALMS1	0.42	5.51	0.34	9.54e-8	Schizophrenia;
SARC	cis	rs12540874	0.698	rs10899736	chr7:50546925	C/T	cg18232548	chr7:50535776	DDC	-0.45	-5.42	-0.33	1.45e-7	Systemic sclerosis;
SARC	cis	rs10861342	0.892	rs77479670	chr12:105516631	C/T	cg23923672	chr12:105501055	KIAA1033	0.7	5.14	0.32	5.77e-7	IgG glycosylation;
SARC	cis	rs9787249	0.957	rs6670841	chr1:40220284	C/G	cg24920358	chr1:40204285	PPIE	0.43	5.22	0.32	4.01e-7	Blood protein levels;
SARC	cis	rs2742234	0.590	rs1254960	chr10:43699657	C/T	cg15436174	chr10:43711423	RASGEF1A	0.41	4.81	0.3	2.7e-6	Hirschsprung disease;
SARC	cis	rs9291683	0.546	rs6820188	chr4:10051655	C/T	cg00071950	chr4:10020882	SLC2A9	0.34	5.18	0.32	4.74e-7	Bone mineral density;
SARC	cis	rs7766436	0.767	rs13200993	chr6:22612912	C/T	cg13666174	chr6:22585274	NA	-0.5	-6.64	-0.4	2.14e-10	Coronary artery disease;
SARC	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg25036284	chr2:26402008	FAM59B	0.46	5.7	0.35	3.59e-8	Gut microbiome composition (summer);
SARC	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg25427524	chr10:38739819	LOC399744	-0.6	-9.26	-0.52	1.4e-17	Extrinsic epigenetic age acceleration;
SARC	cis	rs17376456	1.000	rs34013242	chr5:93507947	C/T	cg25358565	chr5:93447407	FAM172A	1.34	14.13	0.68	3.63e-33	Diabetic retinopathy;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg20795500	chr2:174970644	OLA1	0.53	7.41	0.44	2.3e-12	Thyroid stimulating hormone;
SARC	cis	rs8180040	0.764	rs12630534	chr3:47001043	T/C	cg27129171	chr3:47204927	SETD2	0.66	9.26	0.52	1.41e-17	Colorectal cancer;
SARC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg09373136	chr17:61933544	TCAM1	-0.45	-6.2	-0.38	2.48e-9	Prudent dietary pattern;
SARC	cis	rs35955747	0.869	rs5753576	chr22:31757735	C/T	cg13145458	chr22:31556086	RNF185	-0.39	-4.92	-0.31	1.62e-6	Neutrophil count;Sum basophil neutrophil counts;
SARC	cis	rs1448094	0.556	rs17279916	chr12:86170647	G/A	cg02569458	chr12:86230093	RASSF9	0.38	5.09	0.32	7.38e-7	Major depressive disorder;
SARC	cis	rs16854884	0.657	rs12107291	chr3:143739547	T/C	cg06585982	chr3:143692056	C3orf58	0.67	9.14	0.51	3.13e-17	Economic and political preferences (feminism/equality);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg27158084	chr6:149813350	NA	-0.82	-6.82	-0.41	7.95e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6426558	0.537	rs2813950	chr1:227426072	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.43	-4.98	-0.31	1.24e-6	Neutrophil percentage of white cells;
SARC	cis	rs7666738	0.819	rs62318904	chr4:99036101	A/T	cg05340658	chr4:99064831	C4orf37	0.66	8.81	0.5	2.97e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg24324837	chr19:49891574	CCDC155	0.43	5.32	0.33	2.43e-7	Multiple sclerosis;
SARC	cis	rs1348850	0.874	rs952746	chr2:178306584	A/G	cg23306229	chr2:178417860	TTC30B	0.52	6.21	0.38	2.4e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9467603	1.000	rs1892250	chr6:25769024	T/C	cg21479132	chr6:26055353	NA	-0.75	-4.75	-0.3	3.55e-6	Intelligence (multi-trait analysis);
SARC	cis	rs4906332	1.000	rs12896612	chr14:103877868	A/G	cg15820818	chr14:102984158	NA	0.38	4.74	0.3	3.67e-6	Coronary artery disease;
SARC	cis	rs10504073	0.669	rs57085792	chr8:50018355	T/C	cg00325661	chr8:49890786	NA	0.53	7.35	0.43	3.36e-12	Blood metabolite ratios;
SARC	cis	rs7223966	1.000	rs9912201	chr17:61763208	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.51	-5.36	-0.33	1.99e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs721399	0.752	rs1495741	chr8:18272881	G/A	cg18736775	chr8:18248649	NAT2	0.43	5.29	0.33	2.82e-7	Blood metabolite levels;
SARC	cis	rs2859741	0.967	rs494157	chr1:37512995	C/T	cg09363841	chr1:37513479	NA	0.3	5.47	0.34	1.16e-7	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
SARC	cis	rs2197308	0.623	rs1672426	chr12:38118671	C/T	cg13010199	chr12:38710504	ALG10B	-0.61	-7.68	-0.45	4.41e-13	Morning vs. evening chronotype;
SARC	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs734999	0.505	rs4073285	chr1:2539796	C/T	cg20673091	chr1:2541236	MMEL1	0.34	5.22	0.32	4.01e-7	Ulcerative colitis;
SARC	cis	rs7772486	0.658	rs6570706	chr6:145962922	T/C	cg23711669	chr6:146136114	FBXO30	0.77	12.31	0.63	3.69e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9814567	0.896	rs1357764	chr3:134344928	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.49	6.27	0.38	1.73e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs7113850	0.541	rs78363992	chr11:24232126	C/T	ch.11.24196551F	chr11:24239977	NA	0.73	5.37	0.33	1.91e-7	Bone fracture in osteoporosis;
SARC	cis	rs9467773	1.000	rs4713008	chr6:26538268	T/C	cg11502198	chr6:26597334	ABT1	0.46	5.61	0.34	5.83e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2760061	0.583	rs708123	chr1:228220495	A/G	cg02753203	chr1:228287806	NA	0.83	12.53	0.63	6.93e-28	Diastolic blood pressure;
SARC	cis	rs7246657	1.000	rs7247672	chr19:37743928	A/G	cg14683738	chr19:37701593	ZNF585B	0.61	5.52	0.34	8.9e-8	Coronary artery calcification;
SARC	cis	rs6942407	0.592	rs56327053	chr7:86748539	G/A	cg02420886	chr7:86849541	C7orf23	0.59	5.41	0.33	1.55e-7	Food allergy;
SARC	cis	rs9398803	0.865	rs1120786	chr6:126808637	T/G	cg19875578	chr6:126661172	C6orf173	0.63	8.72	0.5	5.32e-16	Male-pattern baldness;
SARC	cis	rs17376456	0.877	rs17315943	chr5:93442830	T/C	cg25358565	chr5:93447407	FAM172A	1.32	14.94	0.7	7.42e-36	Diabetic retinopathy;
SARC	cis	rs6912958	1.000	rs6937823	chr6:88160386	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.64	-8.72	-0.5	5.35e-16	Monocyte percentage of white cells;
SARC	cis	rs854765	0.623	rs9893690	chr17:17753846	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.62	-9.07	-0.51	5.07e-17	Total body bone mineral density;
SARC	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg15448220	chr1:150897856	SETDB1	0.48	6.38	0.39	9.29e-10	Tonsillectomy;
SARC	cis	rs10789491	1.000	rs11211342	chr1:47163098	T/C	cg15501359	chr1:47185051	KIAA0494	0.76	8.15	0.47	2.25e-14	Response to hepatitis C treatment;
SARC	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg11644478	chr21:40555479	PSMG1	0.86	11.05	0.59	4.27e-23	Cognitive function;
SARC	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg11644478	chr21:40555479	PSMG1	1.05	14.93	0.7	7.9e-36	Cognitive function;
SARC	cis	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg18252515	chr7:66147081	NA	-1.3	-11.63	-0.61	5.98e-25	Diabetic kidney disease;
SARC	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg24250549	chr1:154909240	PMVK	0.82	11.83	0.61	1.3e-25	Prostate cancer;
SARC	cis	rs4144743	1.000	rs3809862	chr17:45330428	C/T	cg18085866	chr17:45331354	ITGB3	-0.73	-7.41	-0.44	2.29e-12	Body mass index;
SARC	cis	rs10870270	1.000	rs4880250	chr10:133773919	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.48	-5.51	-0.34	9.46e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs2439831	0.850	rs28504496	chr15:44016883	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	8.51	0.49	2.14e-15	Lung cancer in ever smokers;
SARC	trans	rs9329221	0.678	rs560638	chr8:9882767	A/G	cg06636001	chr8:8085503	FLJ10661	-0.69	-9.79	-0.54	3.54e-19	Neuroticism;
SARC	cis	rs2439831	0.850	rs2957637	chr15:43951118	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	7.93	0.46	9.32e-14	Lung cancer in ever smokers;
SARC	cis	rs7438	0.505	rs6553441	chr4:170448464	C/T	cg07701716	chr4:170533879	NEK1	0.43	5.14	0.32	5.86e-7	Schizophrenia;
SARC	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg07701084	chr6:150067640	NUP43	0.4	5.27	0.33	3.09e-7	Lung cancer;
SARC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.8	0.58	2.71e-22	Prudent dietary pattern;
SARC	cis	rs9291683	0.595	rs3733585	chr4:10036339	A/G	cg11266682	chr4:10021025	SLC2A9	0.4	7.09	0.42	1.55e-11	Bone mineral density;
SARC	cis	rs33912345	0.750	rs1254304	chr14:60886974	C/A	cg27398547	chr14:60952738	C14orf39	-0.39	-4.78	-0.3	3.09e-6	Glaucoma (high intraocular pressure);
SARC	cis	rs7927592	0.731	rs643609	chr11:68241833	A/G	cg01657329	chr11:68192670	LRP5	-0.36	-5.06	-0.31	8.4e-7	Total body bone mineral density;
SARC	cis	rs2933343	0.951	rs789220	chr3:128592135	A/G	cg25356066	chr3:128598488	ACAD9	-0.58	-6.55	-0.39	3.64e-10	IgG glycosylation;
SARC	cis	rs7010267	0.692	rs2073618	chr8:119964052	G/C	cg13268132	chr8:119964037	TNFRSF11B	0.38	4.74	0.3	3.72e-6	Total body bone mineral density (age 45-60);
SARC	cis	rs9393813	0.967	rs764284	chr6:27312078	C/T	cg11502198	chr6:26597334	ABT1	-0.41	-4.94	-0.31	1.51e-6	Bipolar disorder;
SARC	cis	rs10267417	0.544	rs2072185	chr7:19748700	G/A	cg05791153	chr7:19748676	TWISTNB	0.95	10.07	0.55	4.86e-20	Night sleep phenotypes;
SARC	cis	rs6500395	1.000	rs8052640	chr16:48604096	G/T	cg04672837	chr16:48644449	N4BP1	0.52	7.02	0.42	2.39e-11	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs11645898	0.935	rs72787094	chr16:72192613	C/A	cg14768367	chr16:72042858	DHODH	-0.61	-5.43	-0.34	1.43e-7	Blood protein levels;
SARC	cis	rs2797160	1.000	rs2211419	chr6:125995533	C/T	cg05901451	chr6:126070800	HEY2	0.4	4.87	0.3	2.06e-6	Endometrial cancer;
SARC	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	-0.47	-5.55	-0.34	7.63e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg17376030	chr22:41985996	PMM1	0.7	8.38	0.48	5.11e-15	Vitiligo;
SARC	cis	rs7246657	0.943	rs10415358	chr19:37808863	C/A	cg23950597	chr19:37808831	NA	-0.6	-5.84	-0.36	1.72e-8	Coronary artery calcification;
SARC	cis	rs6963495	0.745	rs73192150	chr7:105211610	A/C	cg19920283	chr7:105172520	RINT1	0.68	5.79	0.35	2.21e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg01181863	chr3:195395398	SDHAP2	0.56	6.36	0.38	1.06e-9	Pancreatic cancer;
SARC	cis	rs9611519	0.964	rs5995992	chr22:41487218	T/C	cg03806693	chr22:41940476	POLR3H	-0.61	-7.37	-0.43	3.01e-12	Neuroticism;
SARC	cis	rs17001868	0.568	rs9607699	chr22:40737036	G/A	cg07138101	chr22:40742427	ADSL	0.54	5.94	0.36	1.01e-8	Mammographic density (dense area);
SARC	cis	rs1580019	0.587	rs9638880	chr7:32552401	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.98	17.72	0.76	4.72e-45	Cognitive ability;
SARC	cis	rs72781680	0.583	rs6731333	chr2:24113354	C/T	cg08917208	chr2:24149416	ATAD2B	0.59	6.16	0.37	3.13e-9	Lymphocyte counts;
SARC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	12.4	0.63	1.87e-27	Platelet count;
SARC	cis	rs5769765	1.000	rs4824112	chr22:50284345	A/G	cg03033257	chr22:50311977	ALG12;CRELD2	0.63	6.34	0.38	1.17e-9	Schizophrenia;
SARC	cis	rs2115630	1.000	rs11854313	chr15:85304048	G/C	cg12501888	chr15:85177176	SCAND2	-0.5	-6.08	-0.37	4.91e-9	P wave terminal force;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg02400139	chr5:145890299	TCERG1	0.52	7.23	0.43	6.93e-12	Thyroid stimulating hormone;
SARC	cis	rs2865126	0.743	rs8084621	chr18:10749429	T/C	cg21165219	chr18:10698044	FAM38B	-0.47	-4.74	-0.3	3.71e-6	Metabolite levels (5-HIAA/ MHPG Ratio);
SARC	cis	rs7084402	0.967	rs1658467	chr10:60295316	A/G	cg07615347	chr10:60278583	BICC1	0.61	8.98	0.51	9.64e-17	Refractive error;
SARC	cis	rs5753618	0.539	rs737888	chr22:31611549	A/G	cg07713946	chr22:31675144	LIMK2	-0.39	-5.33	-0.33	2.36e-7	Colorectal cancer;
SARC	cis	rs11190604	1.000	rs3793706	chr10:102269085	A/C	cg14256752	chr10:102295592	HIF1AN	-0.42	-4.75	-0.3	3.5e-6	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs34779708	0.966	rs11592567	chr10:35409369	C/T	cg03585969	chr10:35415529	CREM	0.42	5.17	0.32	5.03e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs10504229	0.680	rs16921675	chr8:58052082	A/G	cg22535103	chr8:58192502	C8orf71	-0.56	-5.58	-0.34	6.75e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs72634258	0.786	rs4405150	chr1:8173672	T/C	cg00042356	chr1:8021962	PARK7	-0.65	-6.1	-0.37	4.3e-9	Inflammatory bowel disease;
SARC	cis	rs17376456	0.877	rs10476526	chr5:93461916	G/A	cg25358565	chr5:93447407	FAM172A	1.31	15.17	0.7	1.33e-36	Diabetic retinopathy;
SARC	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg12696929	chr3:195401817	SDHAP2	0.39	5.18	0.32	4.78e-7	Pancreatic cancer;
SARC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg09373136	chr17:61933544	TCAM1	-0.43	-5.97	-0.36	8.62e-9	Prudent dietary pattern;
SARC	cis	rs1144333	0.655	rs79376884	chr1:76465401	C/T	cg03433033	chr1:76189801	ACADM	0.63	5.15	0.32	5.47e-7	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs820218	0.926	rs820211	chr17:73650686	A/C	cg01592526	chr17:73663357	RECQL5;SAP30BP	-0.68	-9.25	-0.52	1.51e-17	Rotator cuff tears;
SARC	cis	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg25894440	chr7:65020034	NA	0.78	6.17	0.37	3.01e-9	Diabetic kidney disease;
SARC	cis	rs2933343	1.000	rs1683782	chr3:128640277	A/G	cg25356066	chr3:128598488	ACAD9	0.6	6.85	0.41	6.69e-11	IgG glycosylation;
SARC	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg16049864	chr8:95962084	TP53INP1	-0.49	-8.11	-0.47	2.87e-14	Type 2 diabetes;
SARC	cis	rs1008375	1.000	rs4698649	chr4:17692782	A/G	cg02297831	chr4:17616191	MED28	0.39	4.86	0.3	2.14e-6	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs17401966	0.931	rs3737155	chr1:10459779	G/A	cg15208524	chr1:10270712	KIF1B	0.43	4.96	0.31	1.39e-6	Hepatocellular carcinoma;
SARC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.1	0.37	4.28e-9	Prudent dietary pattern;
SARC	cis	rs2228479	0.850	rs2286393	chr16:89809548	C/A	cg06558623	chr16:89946397	TCF25	0.88	6.13	0.37	3.79e-9	Skin colour saturation;
SARC	cis	rs6582630	0.555	rs35284307	chr12:38509999	T/G	cg26384229	chr12:38710491	ALG10B	0.85	12.35	0.63	2.74e-27	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg25894440	chr7:65020034	NA	-0.76	-5.79	-0.35	2.21e-8	Diabetic kidney disease;
SARC	cis	rs9910055	0.530	rs7222349	chr17:42304644	C/T	cg13607699	chr17:42295918	UBTF	0.87	14.02	0.68	8.93e-33	Total body bone mineral density;
SARC	cis	rs11711311	1.000	rs7633832	chr3:113472292	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	8.4	0.48	4.35e-15	IgG glycosylation;
SARC	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg20891558	chr2:74357851	NA	0.67	8.58	0.49	1.32e-15	Gestational age at birth (maternal effect);
SARC	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg04317338	chr11:64019027	PLCB3	0.84	8.98	0.51	9.05e-17	Mean platelet volume;
SARC	cis	rs6542838	0.641	rs12467189	chr2:99495820	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-5.88	-0.36	1.42e-8	Fear of minor pain;
SARC	cis	rs7089973	0.966	rs12772800	chr10:116630962	A/G	cg08188268	chr10:116634841	FAM160B1	0.34	4.95	0.31	1.4e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs11731606	0.508	rs7696494	chr4:95285174	G/A	cg20625393	chr4:95128694	SMARCAD1	0.57	5.6	0.34	6.12e-8	Mean platelet volume;
SARC	cis	rs7714584	1.000	rs12656538	chr5:150251380	A/G	cg22134413	chr5:150180641	NA	0.93	7.27	0.43	5.4e-12	Crohn's disease;
SARC	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg24531977	chr5:56204891	C5orf35	-0.64	-6.03	-0.37	6.52e-9	Initial pursuit acceleration;
SARC	cis	rs9398803	0.713	rs9375447	chr6:126874091	A/G	cg20229609	chr6:126660872	C6orf173	0.37	5.31	0.33	2.52e-7	Male-pattern baldness;
SARC	cis	rs6840360	1.000	rs6823194	chr4:152604543	T/C	cg22705602	chr4:152727874	NA	-0.37	-6.28	-0.38	1.66e-9	Intelligence (multi-trait analysis);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg27629023	chr11:62648823	SLC3A2	0.52	6.69	0.4	1.67e-10	Height;
SARC	cis	rs10463316	0.817	rs6879238	chr5:150820574	G/C	cg03212797	chr5:150827313	SLC36A1	-0.42	-4.91	-0.31	1.74e-6	Metabolite levels (Pyroglutamine);
SARC	cis	rs9790314	0.846	rs9834659	chr3:160980947	A/C	cg04691961	chr3:161091175	C3orf57	-0.64	-8.7	-0.5	5.91e-16	Morning vs. evening chronotype;
SARC	trans	rs61931739	0.513	rs10844698	chr12:33890158	C/T	cg26384229	chr12:38710491	ALG10B	0.61	8.04	0.47	4.53e-14	Morning vs. evening chronotype;
SARC	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg09060608	chr5:178986726	RUFY1	0.34	4.97	0.31	1.29e-6	Lung cancer;
SARC	cis	rs9341808	0.538	rs9343980	chr6:81023432	A/G	cg08355045	chr6:80787529	NA	-0.34	-5.17	-0.32	4.99e-7	Sitting height ratio;
SARC	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg27572855	chr1:25598939	RHD	0.54	9.2	0.52	2.05e-17	Erythrocyte sedimentation rate;
SARC	cis	rs9303401	0.659	rs35539277	chr17:56853833	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.09	11.58	0.6	8.6e-25	Cognitive test performance;
SARC	cis	rs11112613	0.713	rs73184081	chr12:105951745	C/T	cg03607813	chr12:105948248	NA	0.54	7.55	0.44	1.01e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs7223966	1.000	rs73337598	chr17:61732576	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.48	-5.25	-0.33	3.39e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-7.01	-0.42	2.61e-11	Gut microbiome composition (summer);
SARC	cis	rs1920116	0.778	rs6807681	chr3:169562443	C/T	cg14222479	chr3:169487675	ARPM1	0.44	5.14	0.32	5.7e-7	Glioma (high-grade);
SARC	cis	rs9467773	0.549	rs9467805	chr6:26583366	C/T	cg11502198	chr6:26597334	ABT1	0.64	8.61	0.49	1.14e-15	Intelligence (multi-trait analysis);
SARC	trans	rs9329221	0.662	rs34155841	chr8:10247529	T/G	cg06636001	chr8:8085503	FLJ10661	0.6	7.57	0.44	8.76e-13	Neuroticism;
SARC	cis	rs412050	0.696	rs41283227	chr22:22275524	C/T	cg17089214	chr22:22089827	YPEL1	0.63	5.77	0.35	2.57e-8	Attention deficit hyperactivity disorder;
SARC	cis	rs7635838	0.684	rs2594968	chr3:11352442	T/C	cg00170343	chr3:11313890	ATG7	0.64	8.83	0.5	2.64e-16	HDL cholesterol;
SARC	cis	rs114858855	1.000	rs7768577	chr6:109880735	T/G	cg26835506	chr6:109038353	NA	-0.61	-4.98	-0.31	1.26e-6	Plasma trimethylamine N-oxide levels;
SARC	cis	rs12478296	1.000	rs55767645	chr2:242999350	G/A	cg06360820	chr2:242988706	NA	-0.81	-6.14	-0.37	3.51e-9	Obesity-related traits;
SARC	cis	rs9473924	0.542	rs9473952	chr6:50921779	T/C	cg14470998	chr6:50812995	TFAP2B	0.7	6.3	0.38	1.47e-9	Body mass index;
SARC	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg25703541	chr22:24373054	LOC391322	0.74	8.73	0.5	5.05e-16	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg17376030	chr22:41985996	PMM1	-0.79	-9.86	-0.54	2.19e-19	Vitiligo;
SARC	cis	rs7089973	0.872	rs11818115	chr10:116634891	G/A	cg08188268	chr10:116634841	FAM160B1	0.36	5.74	0.35	2.86e-8	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs7666738	0.791	rs60028147	chr4:99046618	G/A	cg05340658	chr4:99064831	C4orf37	0.64	8.55	0.49	1.7e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs3741404	0.560	rs17699798	chr11:63898806	C/G	cg04317338	chr11:64019027	PLCB3	-0.42	-5.09	-0.32	7.38e-7	Platelet count;
SARC	cis	rs4308124	0.708	rs6747657	chr2:112003163	C/T	cg04571233	chr2:111982156	NA	-0.47	-5.49	-0.34	1.07e-7	Vitiligo;
SARC	cis	rs10465746	0.714	rs12730621	chr1:84433745	C/G	cg10977910	chr1:84465055	TTLL7	0.43	5.28	0.33	2.91e-7	Obesity-related traits;
SARC	cis	rs8114671	0.562	rs1018447	chr20:33401707	A/G	cg24642439	chr20:33292090	TP53INP2	-0.52	-6.8	-0.41	8.53e-11	Height;
SARC	cis	rs9814567	0.712	rs4245905	chr3:134328864	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.51	-6.61	-0.4	2.53e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg00933542	chr6:150070202	PCMT1	0.3	5.1	0.32	7.09e-7	Lung cancer;
SARC	cis	rs11785400	0.793	rs11785376	chr8:143730412	C/T	cg10596483	chr8:143751796	JRK	0.57	7.39	0.44	2.61e-12	Schizophrenia;
SARC	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg20607798	chr8:58055168	NA	0.61	5.45	0.34	1.27e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs6894249	1.000	rs6894249	chr5:131797547	A/G	cg20926183	chr4:8379573	ACOX3	-0.43	-6.24	-0.38	1.99e-9	Asthma;
SARC	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs9818758	0.607	rs11706052	chr3:49064110	A/G	cg07636037	chr3:49044803	WDR6	-0.78	-6.72	-0.4	1.37e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	8.81	0.5	2.93e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg08048268	chr3:133502702	NA	-0.43	-5.79	-0.35	2.21e-8	Iron status biomarkers;
SARC	cis	rs6793245	0.810	rs1805126	chr3:38592406	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.47	5.66	0.35	4.33e-8	QT interval;
SARC	cis	rs2952156	0.883	rs2517960	chr17:37846521	T/C	cg07936489	chr17:37558343	FBXL20	-0.44	-5.66	-0.35	4.38e-8	Asthma;
SARC	cis	rs7666738	0.830	rs13134216	chr4:98919765	C/T	cg05340658	chr4:99064831	C4orf37	0.68	9.2	0.52	2.08e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs72945132	0.882	rs12278125	chr11:70134016	T/C	cg00319359	chr11:70116639	PPFIA1	0.68	6.37	0.39	1.01e-9	Coronary artery disease;
SARC	cis	rs208520	0.802	rs851600	chr6:66893754	T/C	cg07460842	chr6:66804631	NA	-1.03	-13.2	-0.65	4.48e-30	Exhaled nitric oxide output;
SARC	cis	rs739401	0.572	rs389128	chr11:3083873	G/T	cg25174290	chr11:3078921	CARS	0.6	8.63	0.49	9.770000000000001e-16	Longevity;
SARC	cis	rs6942407	0.542	rs6958797	chr7:86751668	A/C	cg02420886	chr7:86849541	C7orf23	0.6	5.44	0.34	1.32e-7	Food allergy;
SARC	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2594989	0.887	rs7632902	chr3:11476884	T/C	cg00170343	chr3:11313890	ATG7	0.57	5.38	0.33	1.79e-7	Circulating chemerin levels;
SARC	cis	rs6088590	1.000	rs2378256	chr20:33292127	G/C	cg24642439	chr20:33292090	TP53INP2	0.89	12.95	0.65	3.04e-29	Coronary artery disease;
SARC	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg12310025	chr6:25882481	NA	-0.45	-5.89	-0.36	1.37e-8	Intelligence (multi-trait analysis);
SARC	cis	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.71	10.26	0.56	1.27e-20	Spherical equivalent (joint analysis main effects and education interaction);
SARC	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg27266027	chr21:40555129	PSMG1	-0.47	-5.2	-0.32	4.38e-7	Cognitive function;
SARC	cis	rs9814567	1.000	rs55913793	chr3:134285968	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.04	-0.42	2.19e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs4951011	0.938	rs2095757	chr1:203760115	T/C	cg05526099	chr1:203152295	CHI3L1	0.35	4.82	0.3	2.55e-6	Breast cancer;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg23855257	chr13:27746147	USP12	0.48	6.41	0.39	8.16e-10	Thyroid stimulating hormone;
SARC	cis	rs854765	0.547	rs2955384	chr17:17939573	C/T	cg04398451	chr17:18023971	MYO15A	-0.48	-6.69	-0.4	1.63e-10	Total body bone mineral density;
SARC	cis	rs17036023	1	rs17036023	chr1:117129711	C/T	cg01932843	chr1:117113824	CD58	-0.7	-4.86	-0.3	2.19e-6	Asthma (childhood onset);
SARC	trans	rs36093844	0.898	rs11234458	chr11:85591370	A/C	cg27065003	chr5:122429449	PRDM6	-0.49	-6.24	-0.38	2.06e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs7089973	0.624	rs17586888	chr10:116598121	T/C	cg03647239	chr10:116582469	FAM160B1	0.5	6.48	0.39	5.49e-10	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs918629	0.530	rs3777197	chr5:95237916	T/C	cg16656078	chr5:95278638	ELL2	-0.51	-6.5	-0.39	4.87e-10	IgG glycosylation;
SARC	cis	rs9291683	0.588	rs35866697	chr4:10018604	C/A	cg00071950	chr4:10020882	SLC2A9	0.39	6.26	0.38	1.82e-9	Bone mineral density;
SARC	cis	rs763121	0.815	rs12168758	chr22:38997269	C/G	cg06022373	chr22:39101656	GTPBP1	0.79	9.95	0.55	1.13e-19	Menopause (age at onset);
SARC	cis	rs9611565	0.592	rs9611612	chr22:41961189	T/C	cg06634786	chr22:41940651	POLR3H	-0.57	-6.77	-0.41	1.01e-10	Vitiligo;
SARC	cis	rs36051895	0.632	rs11788164	chr9:5129395	A/G	cg02405213	chr9:5042618	JAK2	-0.41	-4.87	-0.3	2.09e-6	Pediatric autoimmune diseases;
SARC	cis	rs523522	0.962	rs10849754	chr12:120940418	A/C	cg12219531	chr12:120966889	COQ5	0.83	11.18	0.59	1.61e-23	High light scatter reticulocyte count;
SARC	cis	rs5753618	0.583	rs5753628	chr22:31860322	A/G	cg07713946	chr22:31675144	LIMK2	0.35	4.87	0.3	2.05e-6	Colorectal cancer;
SARC	trans	rs208520	0.507	rs7755710	chr6:66783355	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.11	-22.05	-0.82	5.76e-59	Exhaled nitric oxide output;
SARC	cis	rs7223966	1.000	rs2854218	chr17:61942940	A/G	cg26338869	chr17:61819248	STRADA	0.51	5.42	0.33	1.5e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs453301	0.686	rs28665409	chr8:8869277	G/A	cg08975724	chr8:8085496	FLJ10661	-0.42	-5.14	-0.32	5.93e-7	Joint mobility (Beighton score);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg15837119	chr8:28479995	NA	0.48	6.43	0.39	7.21e-10	Chemerin levels;
SARC	cis	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg08045932	chr20:61659980	NA	0.5	6.84	0.41	7.06e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs9916302	0.851	rs11657899	chr17:37626963	G/A	cg07936489	chr17:37558343	FBXL20	-0.69	-9.02	-0.51	7.36e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs11585357	0.501	rs17458002	chr1:17591524	A/G	cg08277548	chr1:17600880	PADI3	-0.53	-5.37	-0.33	1.86e-7	Hair shape;
SARC	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg18252515	chr7:66147081	NA	1.29	11.17	0.59	1.7e-23	Diabetic kidney disease;
SARC	cis	rs9457247	0.544	rs6920858	chr6:167464630	G/A	cg07741184	chr6:167504864	NA	0.37	7.07	0.42	1.76e-11	Crohn's disease;
SARC	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg21016266	chr12:122356598	WDR66	0.31	4.77	0.3	3.28e-6	Mean corpuscular volume;
SARC	trans	rs3804024	1.000	rs13052117	chr21:41978670	T/C	cg03228353	chr1:161520094	FCGR3A	0.58	7.07	0.42	1.79e-11	Obesity-related traits;
SARC	cis	rs2412459	0.536	rs7173301	chr15:40269843	C/T	cg25407064	chr15:40226267	EIF2AK4	0.54	4.75	0.3	3.55e-6	Response to haloperidol in psychosis;
SARC	cis	rs71636778	0.631	rs34924059	chr1:27158844	G/T	cg04852280	chr1:26496234	ZNF593	0.59	5.52	0.34	8.98e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs78456975	1.000	rs6720874	chr2:1580504	A/G	cg26248373	chr2:1572462	NA	-0.55	-5.75	-0.35	2.83e-8	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs910316	1.000	rs12588240	chr14:75612083	C/A	cg11812906	chr14:75593930	NEK9	0.88	13.97	0.68	1.27e-32	Height;
SARC	cis	rs1355223	0.902	rs1578622	chr11:34725915	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.22	-0.32	3.96e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs3126085	0.935	rs11588174	chr1:152175970	C/T	cg26876637	chr1:152193138	HRNR	-0.5	-5.64	-0.35	4.84e-8	Atopic dermatitis;
SARC	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg00149659	chr3:10157352	C3orf10	0.64	6.03	0.37	6.37e-9	Alzheimer's disease;
SARC	cis	rs796364	0.760	rs2202922	chr2:200882610	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.77	6.8	0.41	8.96e-11	Schizophrenia;
SARC	cis	rs7726839	0.540	rs61731455	chr5:665295	A/G	cg09021430	chr5:549028	NA	-0.4	-4.95	-0.31	1.41e-6	Obesity-related traits;
SARC	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.87	12.31	0.63	3.81e-27	Gut microbiome composition (summer);
SARC	cis	rs73198271	0.565	rs575920	chr8:8594254	C/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-4.76	-0.3	3.35e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs1018836	0.632	rs2879361	chr8:91481909	C/T	cg16814680	chr8:91681699	NA	0.71	10.24	0.56	1.44e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs2011503	1.000	rs77427798	chr19:19652982	T/C	cg15839431	chr19:19639596	YJEFN3	-0.48	-4.77	-0.3	3.32e-6	Bipolar disorder;
SARC	cis	rs4689388	0.926	rs3821940	chr4:6286711	C/A	cg14416269	chr4:6271139	WFS1	0.36	5.53	0.34	8.65e-8	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs9300255	0.544	rs1716174	chr12:123660717	T/C	cg05973401	chr12:123451056	ABCB9	0.55	5.26	0.33	3.28e-7	Neutrophil percentage of white cells;
SARC	cis	rs9467773	1.000	rs1884946	chr6:26545308	C/G	cg12292205	chr6:26970375	C6orf41	0.44	5.28	0.33	2.92e-7	Intelligence (multi-trait analysis);
SARC	cis	rs881375	0.692	rs2072438	chr9:123651301	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	7.59	0.45	7.52e-13	Rheumatoid arthritis;
SARC	cis	rs4481887	1.000	rs4593862	chr1:248480176	G/T	cg13385794	chr1:248469461	NA	0.37	5.48	0.34	1.08e-7	Common traits (Other);
SARC	cis	rs3743266	0.507	rs9630426	chr15:60739053	C/T	cg22293140	chr15:60689852	ANXA2	-0.55	-5.09	-0.32	7.5e-7	Menarche (age at onset);
SARC	cis	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg25894440	chr7:65020034	NA	-0.77	-5.95	-0.36	9.84e-9	Diabetic kidney disease;
SARC	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg26681399	chr22:41777847	TEF	-0.45	-4.85	-0.3	2.26e-6	Vitiligo;
SARC	cis	rs6484504	0.652	rs674035	chr11:31399014	G/A	cg02090638	chr11:31391270	DNAJC24;DCDC1	0.37	4.78	0.3	3.17e-6	Red blood cell count;
SARC	cis	rs1348850	0.872	rs7559521	chr2:178452328	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.62	-7.45	-0.44	1.86e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg26335602	chr6:28129616	ZNF389	0.52	5.94	0.36	1.04e-8	Depression;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg20089365	chr19:45515525	RELB	0.49	6.27	0.38	1.77e-9	Blood pressure;
SARC	cis	rs6449957	0.832	rs12660017	chr5:67450350	T/C	cg23036683	chr5:67512108	NA	0.53	6.04	0.37	6.07e-9	Cleft lip with or without cleft palate;
SARC	cis	rs4689592	0.546	rs907523	chr4:7052777	A/G	cg06697600	chr4:7070879	GRPEL1	-0.37	-4.72	-0.3	4.15e-6	Monocyte percentage of white cells;
SARC	cis	rs11734570	0.581	rs73811715	chr4:38590569	A/C	cg18361445	chr4:38666374	KLF3;FLJ13197	0.6	6.46	0.39	6.18e-10	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs6570726	0.526	rs4896805	chr6:145735429	C/A	cg23711669	chr6:146136114	FBXO30	-0.63	-8.17	-0.47	1.99e-14	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg22800045	chr5:56110881	MAP3K1	0.74	7.83	0.46	1.74e-13	Initial pursuit acceleration;
SARC	cis	rs7264396	0.563	rs6058312	chr20:34324484	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-7.01	-0.42	2.5e-11	Total cholesterol levels;
SARC	cis	rs75920871	0.588	rs1815789	chr11:116834953	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.47	-4.93	-0.31	1.54e-6	Subjective well-being;
SARC	trans	rs12310956	0.515	rs1405031	chr12:33958931	A/C	cg26384229	chr12:38710491	ALG10B	0.73	10.1	0.55	4.11e-20	Morning vs. evening chronotype;
SARC	cis	rs8141529	0.732	rs6005881	chr22:29183133	A/G	cg02153584	chr22:29168773	CCDC117	0.82	12.61	0.64	3.8e-28	Lymphocyte counts;
SARC	cis	rs2204008	0.692	rs11613378	chr12:38213138	T/A	cg26384229	chr12:38710491	ALG10B	0.88	12.94	0.65	3.26e-29	Bladder cancer;
SARC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg04267008	chr7:1944627	MAD1L1	0.57	6.48	0.39	5.41e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs17095355	1.000	rs12267704	chr10:111722008	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.42	-4.81	-0.3	2.65e-6	Biliary atresia;
SARC	cis	rs7524258	0.868	rs4243824	chr1:7289777	G/A	cg07173049	chr1:7289937	CAMTA1	0.39	7.59	0.45	7.46e-13	Tourette's syndrome or obsessive-compulsive disorder;
SARC	cis	rs6912958	0.516	rs242278	chr6:88047059	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.34	5.92	0.36	1.17e-8	Monocyte percentage of white cells;
SARC	cis	rs876084	0.527	rs7460965	chr8:121164389	C/T	cg06265175	chr8:121136014	COL14A1	0.52	6.59	0.4	2.94e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg20607798	chr8:58055168	NA	0.72	6.05	0.37	5.67e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs11169225	0.756	rs3759124	chr12:50343166	G/A	cg04450003	chr12:50355995	AQP5	0.54	8.04	0.47	4.51e-14	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs765787	0.530	rs2899378	chr15:45537584	C/T	cg24006582	chr15:45444508	DUOX1	0.45	5.62	0.35	5.53e-8	Uric acid levels;
SARC	cis	rs7792596	0.565	rs10464587	chr7:93982039	G/A	cg20814616	chr7:94014465	NA	-0.48	-5.27	-0.33	3.06e-7	Intelligence;
SARC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg26338869	chr17:61819248	STRADA	0.8	10.81	0.58	2.5e-22	Prudent dietary pattern;
SARC	cis	rs7255436	0.965	rs7254882	chr19:8453822	A/G	cg10174797	chr19:8464628	RAB11B	0.43	6.22	0.38	2.31e-9	HDL cholesterol;
SARC	cis	rs10791323	0.569	rs1944734	chr11:133720077	G/A	cg14349672	chr11:133703707	NA	-0.34	-4.94	-0.31	1.46e-6	Childhood ear infection;
SARC	cis	rs3768617	0.510	rs10737245	chr1:183100884	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.66e-21	Fuchs's corneal dystrophy;
SARC	cis	rs7666738	0.791	rs11735105	chr4:98937357	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9815354	1.000	rs9854833	chr3:41775577	C/T	cg03022575	chr3:42003672	ULK4	0.65	5.52	0.34	8.91e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs477895	1.000	rs12785488	chr11:64107521	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.65	5.12	0.32	6.27e-7	Mean platelet volume;
SARC	cis	rs9916302	0.861	rs8079590	chr17:37426201	T/C	cg20243544	chr17:37824526	PNMT	0.56	6.94	0.41	3.95e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs10911232	0.507	rs10911195	chr1:182993438	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.64	0.57	8.13e-22	Hypertriglyceridemia;
SARC	cis	rs708547	0.830	rs1713994	chr4:57868367	G/A	cg14719990	chr4:57843890	C4orf14;POLR2B	0.43	5.08	0.32	7.59e-7	Response to bleomycin (chromatid breaks);
SARC	cis	rs4417855	0.761	rs1851682	chr3:187416089	A/C	cg08969912	chr3:187456781	BCL6	-0.4	-4.78	-0.3	3.12e-6	Granulocyte percentage of myeloid white cells;
SARC	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg22535103	chr8:58192502	C8orf71	-0.71	-6.82	-0.41	7.73e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs78456975	1.000	rs10208340	chr2:1563100	G/A	cg01028140	chr2:1542097	TPO	-0.5	-4.97	-0.31	1.3e-6	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg13397359	chr6:42928475	GNMT	0.6	8.12	0.47	2.67e-14	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs72945132	0.598	rs61887433	chr11:70240997	A/G	cg00319359	chr11:70116639	PPFIA1	0.56	5.19	0.32	4.56e-7	Coronary artery disease;
SARC	cis	rs763121	0.853	rs4821811	chr22:39075145	C/T	cg14440974	chr22:39074834	NA	-0.33	-4.73	-0.3	3.85e-6	Menopause (age at onset);
SARC	cis	rs7726839	0.561	rs3915384	chr5:573395	G/T	cg14541582	chr5:601475	NA	-0.38	-4.85	-0.3	2.23e-6	Obesity-related traits;
SARC	cis	rs4479964	0.580	rs17811583	chr6:129962392	T/G	cg27192990	chr6:129479024	LAMA2	0.29	4.77	0.3	3.2e-6	Gut microbiome composition (summer);
SARC	cis	rs1008375	0.863	rs4698632	chr4:17614894	T/C	cg27347728	chr4:17578864	LAP3	0.44	5.39	0.33	1.71e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg11987759	chr7:65425863	GUSB	-0.51	-6.52	-0.39	4.32e-10	Aortic root size;
SARC	trans	rs116095464	0.558	rs10065584	chr5:253997	G/A	cg00938859	chr5:1591904	SDHAP3	0.79	6.57	0.4	3.28e-10	Breast cancer;
SARC	cis	rs734999	0.588	rs2843403	chr1:2529097	T/C	cg20673091	chr1:2541236	MMEL1	-0.33	-5.07	-0.32	8.06e-7	Ulcerative colitis;
SARC	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg07701084	chr6:150067640	NUP43	0.4	5.19	0.32	4.61e-7	Lung cancer;
SARC	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg16479474	chr6:28041457	NA	0.37	5.39	0.33	1.73e-7	Depression;
SARC	cis	rs7223966	0.921	rs2854207	chr17:61947107	C/G	cg00588841	chr17:61851480	DDX42;CCDC47	-0.59	-6.3	-0.38	1.48e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs208520	0.837	rs208471	chr6:66916749	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.93	-11.11	-0.59	2.7e-23	Exhaled nitric oxide output;
SARC	cis	rs2239547	0.522	rs4519686	chr3:52997871	C/T	cg11645453	chr3:52864694	ITIH4	0.33	5.31	0.33	2.51e-7	Schizophrenia;
SARC	cis	rs4742903	0.527	rs10991144	chr9:106938984	C/T	cg14250997	chr9:106856677	SMC2	0.42	5.16	0.32	5.37e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs6500395	0.926	rs1039344	chr16:48577569	A/G	cg04672837	chr16:48644449	N4BP1	0.42	5.51	0.34	9.57e-8	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg10792982	chr14:105748885	BRF1	0.49	7.36	0.43	3.08e-12	Mean platelet volume;Platelet distribution width;
SARC	cis	rs4481887	1.000	rs4593862	chr1:248480176	G/T	cg00666640	chr1:248458726	OR2T12	0.39	6.51	0.39	4.66e-10	Common traits (Other);
SARC	cis	rs9790314	0.605	rs13089559	chr3:160641688	T/A	cg04691961	chr3:161091175	C3orf57	0.63	8.78	0.5	3.63e-16	Morning vs. evening chronotype;
SARC	cis	rs9462027	0.606	rs2814987	chr6:34605145	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-6.01	-0.37	6.92e-9	Systemic lupus erythematosus;
SARC	trans	rs11098499	0.863	rs2306457	chr4:120472839	T/A	cg25214090	chr10:38739885	LOC399744	0.59	7.51	0.44	1.24e-12	Corneal astigmatism;
SARC	cis	rs314370	0.951	rs12705092	chr7:100473550	G/A	cg10426581	chr7:100472382	SRRT	0.62	6.48	0.39	5.32e-10	Resting heart rate;
SARC	cis	rs3768617	0.706	rs8179460	chr1:183056222	T/C	cg13390022	chr1:182993471	LAMC1	0.33	4.97	0.31	1.3e-6	Fuchs's corneal dystrophy;
SARC	cis	rs7633857	0.512	rs10936215	chr3:160652271	A/G	cg03342759	chr3:160939853	NMD3	-0.5	-5.95	-0.36	9.71e-9	Educational attainment (years of education);
SARC	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg24675658	chr1:53192096	ZYG11B	0.74	11.08	0.59	3.4e-23	Monocyte count;
SARC	cis	rs8114671	0.570	rs3761144	chr20:33544075	C/G	cg24642439	chr20:33292090	TP53INP2	0.43	5.18	0.32	4.83e-7	Height;
SARC	cis	rs11574514	1.000	rs1107767	chr16:68020063	C/G	cg01866162	chr16:67596514	CTCF	1.0	6.45	0.39	6.24e-10	Crohn's disease;
SARC	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg12463550	chr7:65579703	CRCP	-0.49	-5.69	-0.35	3.86e-8	Aortic root size;
SARC	trans	rs3942852	0.568	rs7479361	chr11:48109793	C/T	cg15704280	chr7:45808275	SEPT13	-0.66	-8.56	-0.49	1.52e-15	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg11301795	chr4:187892539	NA	0.74	11.61	0.61	6.96e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7084402	1.000	rs7910442	chr10:60270260	T/G	cg07615347	chr10:60278583	BICC1	-0.58	-8.47	-0.49	2.84e-15	Refractive error;
SARC	cis	rs76382185	0.756	rs34749125	chr1:101588379	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.5	4.75	0.3	3.58e-6	Lymphocyte counts;
SARC	cis	rs9948	0.529	rs62152773	chr2:97448073	T/C	cg01990225	chr2:97406019	LMAN2L	-0.96	-6.95	-0.41	3.73e-11	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs568617	0.859	rs1204650	chr11:65645580	A/C	cg26695010	chr11:65641043	EFEMP2	0.5	5.78	0.35	2.36e-8	Crohn's disease;
SARC	cis	rs910316	1.000	rs3742780	chr14:75505008	G/C	cg08847533	chr14:75593920	NEK9	0.94	15.15	0.7	1.53e-36	Height;
SARC	cis	rs7666738	0.546	rs11727151	chr4:98837353	A/C	cg05340658	chr4:99064831	C4orf37	0.59	7.18	0.43	9.13e-12	Colonoscopy-negative controls vs population controls;
SARC	cis	rs910316	0.967	rs2010678	chr14:75567178	C/T	cg08847533	chr14:75593920	NEK9	0.94	16.23	0.73	3.82e-40	Height;
SARC	cis	rs1559088	0.895	rs1974784	chr19:33551563	T/G	cg17764715	chr19:33622953	WDR88	0.49	6.29	0.38	1.51e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg02951883	chr7:2050386	MAD1L1	-0.38	-4.76	-0.3	3.42e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg22857025	chr5:266934	NA	0.94	10.21	0.56	1.81e-20	Breast cancer;
SARC	cis	rs9400467	0.506	rs12199233	chr6:111592317	G/A	cg15721981	chr6:111408429	SLC16A10	0.68	5.85	0.36	1.66e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs1865760	0.865	rs9467650	chr6:25958235	A/G	cg16482183	chr6:26056742	HIST1H1C	0.51	6.59	0.4	2.94e-10	Height;
SARC	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg18252515	chr7:66147081	NA	0.45	4.93	0.31	1.6e-6	Aortic root size;
SARC	cis	rs1348850	0.567	rs1405714	chr2:178538584	A/G	cg22681709	chr2:178499509	PDE11A	0.37	5.18	0.32	4.86e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7264396	0.563	rs2425119	chr20:34324216	C/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	5.68	0.35	4.03e-8	Total cholesterol levels;
SARC	cis	rs12042938	0.579	rs980394	chr1:231779507	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-7.5	-0.44	1.3e-12	Neuranatomic and neurocognitive phenotypes;
SARC	cis	rs4243830	0.850	rs932112	chr1:6591937	A/G	cg04093404	chr1:6614507	TAS1R1;NOL9	0.57	5.09	0.32	7.37e-7	Body mass index;
SARC	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg08219700	chr8:58056026	NA	0.48	5.01	0.31	1.08e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg17221315	chr6:27791827	HIST1H4J	0.49	5.0	0.31	1.15e-6	Parkinson's disease;
SARC	cis	rs10870270	1.000	rs10870271	chr10:133754807	A/G	cg17892150	chr10:133769511	PPP2R2D	0.85	11.14	0.59	2.19e-23	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs12421382	0.543	rs10890996	chr11:109328421	A/G	cg27471124	chr11:109292789	C11orf87	-0.55	-7.47	-0.44	1.57e-12	Schizophrenia;
SARC	cis	rs7568458	0.905	rs10198569	chr2:85794415	C/T	cg17127132	chr2:85788382	GGCX	-0.41	-5.22	-0.32	4.05e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.94	13.16	0.65	5.86e-30	Gut microbiome composition (summer);
SARC	trans	rs9532669	0.963	rs9532662	chr13:41500351	A/C	cg25696485	chr21:38445943	PIGP;TTC3	0.52	6.86	0.41	6.1e-11	Cervical cancer;
SARC	cis	rs2204008	0.837	rs7308714	chr12:38274307	T/C	cg13010199	chr12:38710504	ALG10B	0.81	11.31	0.6	6.15e-24	Bladder cancer;
SARC	cis	rs472402	0.623	rs7707877	chr5:6635946	C/G	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.39	-4.86	-0.3	2.18e-6	Response to amphetamines;
SARC	trans	rs1160133	0.774	rs12681674	chr8:59297629	A/G	cg10471544	chr16:1820375	NME3	0.46	6.25	0.38	1.96e-9	Gut microbiome composition (summer);
SARC	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg16680214	chr1:154839983	KCNN3	-0.38	-6.06	-0.37	5.53e-9	Prostate cancer;
SARC	cis	rs7674212	0.570	rs2069274	chr4:104020781	C/G	cg16532752	chr4:104119610	CENPE	-0.47	-5.81	-0.36	2.07e-8	Type 2 diabetes;
SARC	cis	rs72781680	0.898	rs56413706	chr2:24086961	G/A	cg08917208	chr2:24149416	ATAD2B	0.91	8.94	0.51	1.26e-16	Lymphocyte counts;
SARC	cis	rs636291	0.517	rs12565133	chr1:10544988	A/C	cg07384165	chr1:10488281	NA	0.46	6.45	0.39	6.24e-10	Prostate cancer;
SARC	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg11764359	chr7:65958608	NA	-0.69	-7.89	-0.46	1.15e-13	Aortic root size;
SARC	cis	rs7296418	0.517	rs73231928	chr12:123724325	T/C	cg00376283	chr12:123451042	ABCB9	0.57	7.07	0.42	1.84e-11	Platelet count;
SARC	cis	rs1832871	0.683	rs11756200	chr6:158657736	A/G	cg07165851	chr6:158734300	TULP4	0.56	6.64	0.4	2.24e-10	Height;
SARC	cis	rs10883723	0.773	rs2296578	chr10:104240974	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	8.16	0.47	2.06e-14	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs2153535	0.580	rs9406167	chr6:8502852	T/C	cg23788917	chr6:8435910	SLC35B3	0.64	8.3	0.48	8.36e-15	Motion sickness;
SARC	cis	rs7236492	0.572	rs34712138	chr18:77179833	G/A	cg15644404	chr18:77186268	NFATC1	-0.62	-4.83	-0.3	2.47e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs950776	0.518	rs952215	chr15:78819153	C/T	cg22563815	chr15:78856949	CHRNA5	-0.41	-6.84	-0.41	6.74e-11	Sudden cardiac arrest;
SARC	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg17971929	chr21:40555470	PSMG1	-0.85	-11.53	-0.6	1.2e-24	Cognitive function;
SARC	cis	rs2072499	1.000	rs2540173	chr1:156188214	A/G	cg25208724	chr1:156163844	SLC25A44	0.81	10.42	0.56	3.97e-21	Testicular germ cell tumor;
SARC	cis	rs7766436	0.885	rs1418311	chr6:22594964	T/G	cg13666174	chr6:22585274	NA	-0.61	-7.98	-0.46	6.78e-14	Coronary artery disease;
SARC	cis	rs7312933	0.703	rs10880264	chr12:42586535	A/G	cg19980929	chr12:42632907	YAF2	0.46	6.62	0.4	2.39e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs933688	1.000	rs332531	chr5:90790451	G/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.01	12.25	0.63	6e-27	Smoking behavior;
SARC	cis	rs6484504	0.600	rs2616815	chr11:31327316	C/T	cg26647111	chr11:31128758	NA	0.39	5.0	0.31	1.12e-6	Red blood cell count;
SARC	cis	rs950169	0.922	rs67804993	chr15:85104030	T/G	cg24253500	chr15:84953950	NA	0.37	5.36	0.33	1.98e-7	Schizophrenia;
SARC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg02592271	chr2:27665507	KRTCAP3	-0.43	-6.58	-0.4	3.14e-10	Total body bone mineral density;
SARC	cis	rs372883	0.563	rs1153293	chr21:30691325	C/T	cg08807101	chr21:30365312	RNF160	0.58	7.3	0.43	4.63e-12	Pancreatic cancer;
SARC	cis	rs9303401	0.659	rs12940212	chr17:56674474	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	11.21	0.59	1.35e-23	Cognitive test performance;
SARC	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg04518342	chr5:131593106	PDLIM4	0.4	5.47	0.34	1.16e-7	Acylcarnitine levels;
SARC	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg23758822	chr17:41437982	NA	0.89	11.4	0.6	3.19e-24	Menopause (age at onset);
SARC	cis	rs524281	0.773	rs11227447	chr11:66048280	G/C	cg14036092	chr11:66035641	RAB1B	-0.58	-5.75	-0.35	2.74e-8	Electroencephalogram traits;
SARC	cis	rs3020736	0.500	rs4147640	chr22:42485292	T/C	cg04733989	chr22:42467013	NAGA	-0.76	-10.7	-0.57	5.23e-22	Autism spectrum disorder or schizophrenia;
SARC	cis	rs13040088	0.872	rs13039291	chr20:61572760	C/T	cg23096297	chr20:61557774	DIDO1	0.92	9.75	0.54	4.65e-19	Menopause (age at onset);
SARC	cis	rs10979	0.964	rs9496683	chr6:143898845	G/A	cg25407410	chr6:143891975	LOC285740	-0.63	-8.46	-0.48	2.95e-15	Hypospadias;
SARC	cis	rs761746	0.847	rs4820976	chr22:31876466	G/A	cg15162869	chr22:32027605	PISD	0.41	5.59	0.34	6.29e-8	Intelligence;
SARC	cis	rs1395	1.000	rs4665958	chr2:27443196	A/G	cg21747090	chr2:27597821	SNX17	-0.39	-4.85	-0.3	2.24e-6	Blood metabolite levels;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg23581698	chr14:81686396	GTF2A1	0.49	6.33	0.38	1.26e-9	Lung adenocarcinoma;
SARC	cis	rs12130219	0.500	rs4845743	chr1:152184149	A/G	cg25272121	chr1:152190972	HRNR	-0.41	-5.64	-0.35	4.9e-8	Inflammatory skin disease;
SARC	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.66	0.35	4.44e-8	Bipolar disorder;
SARC	cis	rs12579753	0.879	rs7971664	chr12:82264101	T/C	cg07988820	chr12:82153109	PPFIA2	-0.5	-5.94	-0.36	1.03e-8	Resting heart rate;
SARC	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg24250549	chr1:154909240	PMVK	0.77	10.8	0.58	2.67e-22	Prostate cancer;
SARC	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg00933542	chr6:150070202	PCMT1	0.31	5.42	0.33	1.47e-7	Lung cancer;
SARC	cis	rs10465746	0.570	rs11163887	chr1:84474718	C/T	cg04407776	chr1:84465009	TTLL7	-0.44	-5.3	-0.33	2.65e-7	Obesity-related traits;
SARC	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg26119090	chr2:26468346	HADHA;HADHB	0.95	13.87	0.67	2.75e-32	Gut microbiome composition (summer);
SARC	cis	rs12369635	1.000	rs12372807	chr12:129561332	C/T	cg01909103	chr12:129572610	TMEM132D	-0.65	-6.57	-0.4	3.25e-10	Schizophrenia (inflammation and infection response interaction);
SARC	cis	rs76419734	1.000	rs17036189	chr4:106687959	A/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.81	5.48	0.34	1.08e-7	Post bronchodilator FEV1;
SARC	cis	rs1008375	0.931	rs10939733	chr4:17570658	T/C	cg16339924	chr4:17578868	LAP3	0.67	8.64	0.49	8.93e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs61931739	0.534	rs11053014	chr12:34103519	G/A	cg26384229	chr12:38710491	ALG10B	0.87	12.44	0.63	1.37e-27	Morning vs. evening chronotype;
SARC	cis	rs9325144	0.534	rs4882283	chr12:38710249	C/T	cg13010199	chr12:38710504	ALG10B	0.58	7.88	0.46	1.22e-13	Morning vs. evening chronotype;
SARC	cis	rs6920364	1	rs6920364	chr6:167376466	G/C	cg07741184	chr6:167504864	NA	-0.3	-5.74	-0.35	2.93e-8	Lung cancer;
SARC	cis	rs4481887	1.000	rs4244183	chr1:248471222	G/A	cg01631408	chr1:248437212	OR2T33	-0.42	-5.3	-0.33	2.68e-7	Common traits (Other);
SARC	cis	rs7927771	0.965	rs4752845	chr11:47539697	T/C	cg20307385	chr11:47447363	PSMC3	-0.51	-6.28	-0.38	1.65e-9	Subjective well-being;
SARC	cis	rs9309473	0.519	rs6730785	chr2:73642403	A/C	cg20560298	chr2:73613845	ALMS1	0.51	6.88	0.41	5.45e-11	Metabolite levels;
SARC	cis	rs7772486	0.790	rs2253768	chr6:146199922	A/G	cg05347473	chr6:146136440	FBXO30	0.55	7.76	0.45	2.68e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10911232	0.524	rs10737238	chr1:183025303	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.1	0.55	4.11e-20	Hypertriglyceridemia;
SARC	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.41	-6.93	-0.41	4.16e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg12463550	chr7:65579703	CRCP	-0.48	-5.58	-0.34	6.74e-8	Aortic root size;
SARC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.78	9.89	0.54	1.81e-19	Prudent dietary pattern;
SARC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg11965913	chr1:205819406	PM20D1	0.9	15.03	0.7	3.78e-36	Menarche (age at onset);
SARC	cis	rs898097	0.627	rs3785514	chr17:80888905	A/G	cg15664640	chr17:80829946	TBCD	0.52	7.44	0.44	1.88e-12	Breast cancer;
SARC	cis	rs950169	0.922	rs4586394	chr15:84822385	G/A	cg24253500	chr15:84953950	NA	-0.35	-4.81	-0.3	2.71e-6	Schizophrenia;
SARC	cis	rs35160687	0.901	rs34069316	chr2:86529792	T/C	cg10973622	chr2:86423274	IMMT	0.38	4.9	0.31	1.77e-6	Night sleep phenotypes;
SARC	cis	rs751728	1.000	rs1359781	chr6:33762104	T/C	cg15252951	chr6:33757062	LEMD2	0.57	6.81	0.41	8.32e-11	Crohn's disease;
SARC	cis	rs770189	0.628	rs244749	chr5:88140962	T/C	cg18498987	chr5:88179539	MEF2C	0.5	5.41	0.33	1.59e-7	Tonometry;
SARC	cis	rs7103648	1.000	rs7103648	chr11:47461783	A/G	cg10504702	chr11:47789108	FNBP4	0.6	7.82	0.46	1.84e-13	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs1153858	1.000	rs16942000	chr15:45633003	C/T	cg26924012	chr15:45694286	SPATA5L1	0.76	10.58	0.57	1.3e-21	Homoarginine levels;
SARC	cis	rs7727544	0.606	rs10058074	chr5:131686146	G/A	cg24060327	chr5:131705240	SLC22A5	-0.42	-4.88	-0.3	1.94e-6	Blood metabolite levels;
SARC	cis	rs2033732	0.706	rs966286	chr8:85068865	C/T	cg05716166	chr8:85095498	RALYL	-0.47	-5.67	-0.35	4.31e-8	Body mass index;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01892655	chr3:185216546	TMEM41A	0.6	7.66	0.45	5e-13	Smoking initiation;
SARC	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg14343924	chr8:8086146	FLJ10661	-0.4	-5.11	-0.32	6.61e-7	Mood instability;
SARC	cis	rs1113500	0.787	rs11185266	chr1:108642664	G/A	cg06207961	chr1:108661230	NA	0.37	4.8	0.3	2.8e-6	Growth-regulated protein alpha levels;
SARC	cis	rs9325144	0.555	rs10748433	chr12:38696352	C/G	cg04568710	chr12:38710424	ALG10B	0.38	4.74	0.3	3.69e-6	Morning vs. evening chronotype;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg24376286	chr2:198245629	NA	0.49	6.35	0.38	1.14e-9	Breast cancer;
SARC	cis	rs9875589	0.957	rs6768050	chr3:13930490	A/G	cg19554555	chr3:13937349	NA	0.51	6.67	0.4	1.8e-10	Ovarian reserve;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg10669351	chr3:24007477	NR1D2	0.45	6.36	0.38	1.05e-9	Thyroid stimulating hormone;
SARC	cis	rs9325144	0.600	rs10785621	chr12:38744912	C/T	cg13010199	chr12:38710504	ALG10B	0.55	7.08	0.42	1.68e-11	Morning vs. evening chronotype;
SARC	cis	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg02487422	chr3:49467188	NICN1	0.48	6.39	0.39	8.9e-10	Resting heart rate;
SARC	cis	rs10782582	0.609	rs5745325	chr1:76269460	G/A	cg10523679	chr1:76189770	ACADM	-0.41	-5.0	-0.31	1.14e-6	Daytime sleep phenotypes;
SARC	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg15847926	chr7:2749597	AMZ1	-0.29	-4.76	-0.3	3.45e-6	Height;
SARC	cis	rs2120019	0.938	rs5020842	chr15:75322310	T/C	cg00629941	chr15:75287862	SCAMP5	-0.68	-8.08	-0.47	3.52e-14	Blood trace element (Zn levels);
SARC	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg14517863	chr17:44321492	NA	-0.32	-4.76	-0.3	3.46e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9487051	0.676	rs1608041	chr6:109595903	G/A	cg01475377	chr6:109611718	NA	-0.35	-5.08	-0.32	7.8e-7	Reticulocyte fraction of red cells;
SARC	trans	rs7070797	0.735	rs74993661	chr10:63534303	C/T	cg06731886	chr7:73284078	NA	-0.51	-6.42	-0.39	7.77e-10	Takotsubo syndrome;
SARC	cis	rs644799	0.710	rs3017756	chr11:95537358	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.95	16.03	0.72	1.74e-39	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg01172785	chr16:50092553	NA	-0.49	-6.44	-0.39	6.71e-10	Height;
SARC	cis	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.75	-0.45	2.87e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs505401	0.504	rs59583096	chr19:6117078	C/T	cg18109231	chr19:6110877	RFX2	0.96	5.92	0.36	1.12e-8	Mean platelet volume;
SARC	cis	rs2997447	0.846	rs3008415	chr1:26404441	C/T	cg19633962	chr1:26362018	EXTL1	-0.59	-5.37	-0.33	1.87e-7	QRS complex (12-leadsum);
SARC	cis	rs17270561	0.609	rs9379783	chr6:25725207	C/T	cg17691542	chr6:26056736	HIST1H1C	0.56	6.75	0.4	1.16e-10	Iron status biomarkers;
SARC	trans	rs61931739	0.500	rs11053248	chr12:34518011	G/A	cg26384229	chr12:38710491	ALG10B	0.91	13.63	0.67	1.63e-31	Morning vs. evening chronotype;
SARC	cis	rs6570726	0.526	rs9403699	chr6:145730685	G/T	cg23711669	chr6:146136114	FBXO30	0.65	8.24	0.48	1.23e-14	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10463316	0.925	rs6877344	chr5:150742650	C/T	cg03212797	chr5:150827313	SLC36A1	-0.44	-5.19	-0.32	4.6e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs748404	0.697	rs501884	chr15:43553982	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	6.69	0.4	1.61e-10	Lung cancer;
SARC	cis	rs7927771	1.000	rs12421210	chr11:47779586	C/T	cg05585544	chr11:47624801	NA	-0.36	-4.82	-0.3	2.59e-6	Subjective well-being;
SARC	cis	rs17253792	0.822	rs58569951	chr14:56152245	T/C	cg01858014	chr14:56050164	KTN1	-0.62	-4.74	-0.3	3.79e-6	Putamen volume;
SARC	cis	rs9388451	0.626	rs1739384	chr6:126099246	C/A	cg06289844	chr6:126071538	HEY2	0.33	5.17	0.32	4.95e-7	Brugada syndrome;
SARC	cis	rs6815814	0.950	rs67206233	chr4:38807853	T/C	cg09316306	chr4:38807337	TLR1	0.5	5.16	0.32	5.23e-7	Breast cancer;
SARC	cis	rs17376456	1.000	rs6867042	chr5:93555761	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.14	0.32	5.94e-7	Diabetic retinopathy;
SARC	cis	rs2153535	0.580	rs1410766	chr6:8525360	T/C	cg07606381	chr6:8435919	SLC35B3	0.76	11.08	0.59	3.49e-23	Motion sickness;
SARC	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg15049968	chr18:44337910	ST8SIA5	-0.31	-4.88	-0.3	1.96e-6	Personality dimensions;
SARC	cis	rs11792861	0.926	rs7855282	chr9:111802614	T/A	cg13535736	chr9:111863775	C9orf5	-0.39	-4.79	-0.3	2.93e-6	Menarche (age at onset);
SARC	cis	rs9650657	0.547	rs11250099	chr8:10818657	C/T	cg21775007	chr8:11205619	TDH	0.43	5.36	0.33	1.97e-7	Neuroticism;
SARC	cis	rs6701037	0.566	rs1014555	chr1:175134249	C/T	cg08873628	chr1:175162347	KIAA0040	0.34	4.79	0.3	2.94e-6	Alcohol dependence;
SARC	cis	rs9314323	0.708	rs1594829	chr8:26206077	C/T	cg11498726	chr8:26250323	BNIP3L	0.61	6.56	0.39	3.45e-10	Red cell distribution width;
SARC	cis	rs7647973	0.626	rs4855882	chr3:49715354	G/T	cg03060546	chr3:49711283	APEH	0.59	5.79	0.35	2.21e-8	Menarche (age at onset);
SARC	cis	rs1468333	1.000	rs217274	chr5:137490974	A/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.76	10.16	0.55	2.6e-20	Resting heart rate;
SARC	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg02725872	chr8:58115012	NA	-0.37	-6.54	-0.39	3.94e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg24110177	chr3:50126178	RBM5	0.65	8.81	0.5	2.95e-16	Body mass index;
SARC	cis	rs7084402	0.967	rs1658452	chr10:60311114	A/T	cg07615347	chr10:60278583	BICC1	0.59	8.61	0.49	1.12e-15	Refractive error;
SARC	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg08048268	chr3:133502702	NA	-0.43	-5.85	-0.36	1.64e-8	Iron status biomarkers;
SARC	cis	rs11687170	0.882	rs76018591	chr2:237060057	G/T	cg19324714	chr2:237145437	ASB18	0.49	4.89	0.31	1.89e-6	Educational attainment;Educational attainment (years of education);
SARC	cis	rs7932354	0.502	rs57323109	chr11:47193367	T/G	cg03339077	chr11:47165057	C11orf49	0.43	5.76	0.35	2.62e-8	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs12956009	0.583	rs12960952	chr18:44857476	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	7.45	0.44	1.83e-12	Educational attainment (years of education);
SARC	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg00933542	chr6:150070202	PCMT1	0.31	5.15	0.32	5.59e-7	Lung cancer;
SARC	cis	rs2832077	0.943	rs11701445	chr21:30160807	C/T	cg03476357	chr21:30257390	N6AMT1	-0.63	-5.98	-0.36	8.32e-9	Cognitive test performance;
SARC	trans	rs629535	0.551	rs62513429	chr8:70149995	A/C	cg21567404	chr3:27674614	NA	-0.92	-9.79	-0.54	3.53e-19	Dupuytren's disease;
SARC	trans	rs1814175	0.587	rs7948538	chr11:50021353	A/C	cg15704280	chr7:45808275	SEPT13	-0.91	-14.68	-0.69	5.63e-35	Height;
SARC	cis	rs501120	0.925	rs559469	chr10:44752118	C/T	cg09554077	chr10:44749378	NA	-0.42	-6.18	-0.38	2.87e-9	Coronary artery disease;Coronary heart disease;
SARC	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg24675658	chr1:53192096	ZYG11B	-0.63	-9.38	-0.52	6.23e-18	Monocyte count;
SARC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg06873352	chr17:61820015	STRADA	0.53	6.9	0.41	4.75e-11	Prudent dietary pattern;
SARC	cis	rs12458462	0.892	rs58675823	chr18:77463672	G/A	cg11879182	chr18:77439856	CTDP1	0.89	13.28	0.66	2.47e-30	Monocyte count;
SARC	cis	rs10752881	1.000	rs12403189	chr1:182983832	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.72	10.87	0.58	1.56e-22	Colorectal cancer;
SARC	cis	rs7819412	0.745	rs2898260	chr8:10939490	G/T	cg21775007	chr8:11205619	TDH	-0.4	-5.07	-0.32	8.13e-7	Triglycerides;
SARC	cis	rs27434	0.583	rs149431	chr5:96157541	T/C	cg16492584	chr5:96139282	ERAP1	-0.57	-7.11	-0.42	1.4e-11	Ankylosing spondylitis;
SARC	cis	rs2289583	0.503	rs113742359	chr15:75261643	A/G	cg10253484	chr15:75165896	SCAMP2	0.49	5.4	0.33	1.66e-7	Systemic lupus erythematosus;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg07533159	chr6:126307930	TRMT11	0.78	6.35	0.38	1.13e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs79349575	0.745	rs170319	chr17:46991531	T/C	cg16584676	chr17:46985605	UBE2Z	0.53	6.38	0.39	9.28e-10	Type 2 diabetes;
SARC	cis	rs2576037	0.796	rs2571030	chr18:44573854	G/A	cg19077165	chr18:44547161	KATNAL2	0.43	6.01	0.37	6.97e-9	Personality dimensions;
SARC	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.8	12.25	0.63	5.69e-27	Personality dimensions;
SARC	cis	rs698833	0.509	rs12987415	chr2:44530423	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.63	7.26	0.43	5.82e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs8084125	0.832	rs62105180	chr18:74951197	C/G	cg07390210	chr18:74961196	GALR1	0.56	6.39	0.39	8.73e-10	Obesity-related traits;
SARC	cis	rs7826238	0.653	rs2979202	chr8:8344127	T/C	cg06636001	chr8:8085503	FLJ10661	0.62	8.56	0.49	1.5e-15	Systolic blood pressure;
SARC	cis	rs2204008	0.729	rs114133083	chr12:38182923	G/C	cg14851346	chr12:38532713	NA	-0.43	-5.12	-0.32	6.25e-7	Bladder cancer;
SARC	cis	rs6570726	0.846	rs409553	chr6:145886963	C/T	cg05347473	chr6:146136440	FBXO30	0.52	7.14	0.42	1.15e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2898681	0.519	rs73814886	chr4:53733251	C/T	cg00338735	chr4:53728038	RASL11B	0.49	5.46	0.34	1.24e-7	Optic nerve measurement (cup area);
SARC	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.5	-5.74	-0.35	2.94e-8	Bipolar disorder;
SARC	cis	rs6964587	0.869	rs10250641	chr7:91490746	C/T	cg17063962	chr7:91808500	NA	0.81	11.55	0.6	1.03e-24	Breast cancer;
SARC	cis	rs2228479	0.702	rs62056090	chr16:89930087	T/A	cg06558623	chr16:89946397	TCF25	0.87	6.41	0.39	7.81e-10	Skin colour saturation;
SARC	cis	rs11690935	0.959	rs66835971	chr2:172677459	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.97	-14.8	-0.7	2.17e-35	Schizophrenia;
SARC	cis	rs3784262	0.692	rs4646581	chr15:58307898	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.33	-4.88	-0.3	1.99e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs9815354	0.951	rs73830511	chr3:41864643	G/T	cg03022575	chr3:42003672	ULK4	0.57	5.32	0.33	2.38e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs10504073	0.584	rs11776843	chr8:49928449	C/T	cg00325661	chr8:49890786	NA	0.51	6.82	0.41	7.54e-11	Blood metabolite ratios;
SARC	cis	rs6121246	0.583	rs28815498	chr20:30351560	T/C	cg13852791	chr20:30311386	BCL2L1	0.88	11.05	0.59	4.19e-23	Mean corpuscular hemoglobin;
SARC	cis	rs920590	0.796	rs7820505	chr8:19634829	A/G	cg03894339	chr8:19674705	INTS10	-0.58	-6.93	-0.41	4.01e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs12950390	0.853	rs8078052	chr17:45859434	A/G	cg24803719	chr17:45855879	NA	-0.46	-7.5	-0.44	1.34e-12	IgG glycosylation;
SARC	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg12016809	chr21:47604291	C21orf56	-0.47	-5.63	-0.35	5.24e-8	Testicular germ cell tumor;
SARC	cis	rs17376456	0.569	rs6895356	chr5:93060781	A/G	cg21475434	chr5:93447410	FAM172A	0.62	6.08	0.37	4.75e-9	Diabetic retinopathy;
SARC	cis	rs9905704	0.624	rs6503891	chr17:57065924	A/C	cg12560992	chr17:57184187	TRIM37	0.41	4.79	0.3	2.96e-6	Testicular germ cell tumor;
SARC	cis	rs6835098	1.000	rs1054497	chr4:174089048	A/T	cg08422745	chr4:174089978	GALNT7	0.76	10.5	0.57	2.35e-21	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs11792861	0.926	rs72607163	chr9:111803128	G/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.68	7.72	0.45	3.51e-13	Menarche (age at onset);
SARC	cis	rs6963495	0.818	rs116457537	chr7:105152072	A/G	cg13798780	chr7:105162888	PUS7	0.58	5.28	0.33	2.95e-7	Bipolar disorder (body mass index interaction);
SARC	trans	rs1814175	0.645	rs7119101	chr11:49955665	G/A	cg15704280	chr7:45808275	SEPT13	-0.89	-14.17	-0.68	2.8e-33	Height;
SARC	cis	rs6435862	0.636	rs717548	chr2:215676905	G/A	cg04004882	chr2:215674386	BARD1	-0.65	-8.3	-0.48	8.33e-15	Neuroblastoma (high-risk);
SARC	cis	rs7717697	0.830	rs11746897	chr5:82747765	C/A	cg19814134	chr5:82768288	VCAN	0.44	5.18	0.32	4.78e-7	Vertical cup-disc ratio;
SARC	cis	rs3213545	0.700	rs2260445	chr12:121468863	C/A	cg25281562	chr12:121454272	C12orf43	0.5	6.35	0.38	1.11e-9	Subjective well-being;Cardiovascular disease risk factors;
SARC	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg24209194	chr3:40518798	ZNF619	-0.65	-8.08	-0.47	3.47e-14	Renal cell carcinoma;
SARC	cis	rs4906332	1.000	rs11541718	chr14:103852164	C/G	cg26031613	chr14:104095156	KLC1	-0.53	-6.14	-0.37	3.55e-9	Coronary artery disease;
SARC	cis	rs11098499	0.909	rs35165976	chr4:120325630	G/A	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	cis	rs77741769	0.700	rs61946385	chr12:121362330	G/A	cg02403541	chr12:121454288	C12orf43	0.47	5.32	0.33	2.44e-7	Mean corpuscular volume;
SARC	cis	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-5.63	-0.35	5.25e-8	Joint mobility (Beighton score);
SARC	cis	rs10876993	0.890	rs1678516	chr12:58047458	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.48	-6.16	-0.37	3.15e-9	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs3820928	0.874	rs2229813	chr2:227892720	C/T	cg11843606	chr2:227700838	RHBDD1	-0.55	-6.84	-0.41	6.97e-11	Pulmonary function;
SARC	cis	rs9815354	0.951	rs12492599	chr3:42005734	C/A	cg03022575	chr3:42003672	ULK4	-0.55	-5.35	-0.33	2.08e-7	Pulse pressure;Diastolic blood pressure;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg27472151	chr11:118956135	HMBS	0.49	6.38	0.39	9.4e-10	Chemerin levels;
SARC	cis	rs8067545	0.750	rs4925085	chr17:20000131	G/T	cg13482628	chr17:19912719	NA	0.5	6.65	0.4	2.09e-10	Schizophrenia;
SARC	cis	rs3760982	0.585	rs67773424	chr19:44293994	G/A	cg11993925	chr19:44307056	LYPD5	0.3	4.74	0.3	3.73e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg17239140	chr15:41836578	RPAP1	0.85	7.12	0.42	1.29e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2180341	0.538	rs11556354	chr6:127664661	G/A	cg24812749	chr6:127587940	RNF146	0.5	6.05	0.37	5.74e-9	Breast cancer;
SARC	cis	rs4423214	1.000	rs11600860	chr11:71164019	T/C	cg05163923	chr11:71159392	DHCR7	0.65	8.66	0.49	8.18e-16	Vitamin D levels;
SARC	cis	rs4595586	0.505	rs12827467	chr12:39374014	A/G	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	cis	rs6918586	0.658	rs198838	chr6:26113340	C/T	cg18357526	chr6:26021779	HIST1H4A	0.44	5.77	0.35	2.54e-8	Schizophrenia;
SARC	cis	rs11792861	0.781	rs72607159	chr9:111764270	C/T	cg13535736	chr9:111863775	C9orf5	-0.38	-4.71	-0.3	4.2e-6	Menarche (age at onset);
SARC	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.8	-11.2	-0.59	1.38e-23	Chronic sinus infection;
SARC	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg07636037	chr3:49044803	WDR6	1.0	17.36	0.75	6.97e-44	Parkinson's disease;
SARC	cis	rs13095912	1.000	rs34965813	chr3:185333012	T/C	cg11274856	chr3:185301563	NA	0.35	4.94	0.31	1.48e-6	Systolic blood pressure;
SARC	cis	rs34779708	0.931	rs3740083	chr10:35320383	C/T	cg03585969	chr10:35415529	CREM	0.39	4.99	0.31	1.16e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs8141529	0.529	rs5752796	chr22:29178856	G/A	cg15103426	chr22:29168792	CCDC117	0.62	5.95	0.36	9.69e-9	Lymphocyte counts;
SARC	cis	rs870825	0.616	rs4444872	chr4:185628405	A/G	cg04058563	chr4:185651563	MLF1IP	0.81	10.75	0.58	3.9e-22	Blood protein levels;
SARC	cis	rs7937682	0.737	rs682239	chr11:111425105	A/G	cg22437258	chr11:111473054	SIK2	-0.55	-7.24	-0.43	6.41e-12	Primary sclerosing cholangitis;
SARC	cis	rs9486715	1.000	rs6905737	chr6:97066659	A/T	cg18709589	chr6:96969512	KIAA0776	-0.59	-7.38	-0.44	2.7e-12	Headache;
SARC	cis	rs11098499	0.954	rs10031483	chr4:120422636	T/C	cg24375607	chr4:120327624	NA	0.41	4.86	0.3	2.12e-6	Corneal astigmatism;
SARC	cis	rs981844	0.816	rs62325151	chr4:154730595	A/G	cg14289246	chr4:154710475	SFRP2	0.6	6.59	0.4	2.86e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs11997175	0.625	rs4733172	chr8:33618049	T/C	ch.8.33884649F	chr8:33765107	NA	0.52	6.54	0.39	3.76e-10	Body mass index;
SARC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg25703541	chr22:24373054	LOC391322	-0.88	-13.01	-0.65	1.88e-29	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg25427524	chr10:38739819	LOC399744	-0.56	-8.73	-0.5	5.08e-16	Extrinsic epigenetic age acceleration;
SARC	trans	rs12935229	1.000	rs17769712	chr16:77322499	C/T	cg26529044	chr13:43354767	C13orf30	0.5	6.55	0.39	3.71e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
SARC	cis	rs10193935	0.901	rs10171643	chr2:42532912	C/T	cg27598129	chr2:42591480	NA	-0.37	-4.79	-0.3	2.99e-6	Colonoscopy-negative controls vs population controls;
SARC	trans	rs61931739	0.817	rs304313	chr12:34216898	C/T	cg26384229	chr12:38710491	ALG10B	0.59	8.01	0.46	5.32e-14	Morning vs. evening chronotype;
SARC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	5.98	0.36	8.32e-9	Prudent dietary pattern;
SARC	cis	rs2327429	0.767	rs12190287	chr6:134214525	C/G	cg25632230	chr6:134101081	NA	0.39	4.77	0.3	3.31e-6	Coronary artery disease;
SARC	cis	rs8014204	0.570	rs7147721	chr14:75186010	A/G	cg06637938	chr14:75390232	RPS6KL1	0.73	10.85	0.58	1.8e-22	Caffeine consumption;
SARC	cis	rs826838	0.935	rs4583043	chr12:38645147	T/G	cg13010199	chr12:38710504	ALG10B	0.81	11.54	0.6	1.12e-24	Heart rate;
SARC	trans	rs208520	0.674	rs207103	chr6:66795568	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.06	-14.41	-0.69	4.36e-34	Exhaled nitric oxide output;
SARC	cis	rs7223966	1.000	rs112143304	chr17:61822401	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.48	-4.74	-0.3	3.78e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs710216	0.957	rs3738514	chr1:43426591	A/G	cg03128534	chr1:43423976	SLC2A1	-0.64	-6.61	-0.4	2.53e-10	Red cell distribution width;
SARC	cis	rs9910055	0.529	rs190144	chr17:42164584	A/G	cg19774624	chr17:42201019	HDAC5	0.56	6.63	0.4	2.27e-10	Total body bone mineral density;
SARC	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg21782813	chr7:2030301	MAD1L1	0.45	7.27	0.43	5.43e-12	Bipolar disorder and schizophrenia;
SARC	cis	rs16986825	0.546	rs9625612	chr22:29258140	T/A	cg15103426	chr22:29168792	CCDC117	0.69	7.06	0.42	1.93e-11	Pancreatic cancer;
SARC	cis	rs55794721	0.509	rs909834	chr1:25757996	A/G	cg02931644	chr1:25747376	RHCE	0.42	6.96	0.41	3.49e-11	Plateletcrit;Mean corpuscular volume;
SARC	cis	rs6540556	0.723	rs10863783	chr1:209889802	T/C	cg05527609	chr1:210001259	C1orf107	-0.56	-5.02	-0.31	1.01e-6	Red blood cell count;
SARC	cis	rs17376456	0.877	rs35075119	chr5:93385457	T/C	cg25358565	chr5:93447407	FAM172A	1.3	14.78	0.7	2.47e-35	Diabetic retinopathy;
SARC	cis	rs2075371	0.637	rs13245165	chr7:133951492	A/T	cg11752832	chr7:134001865	SLC35B4	0.48	5.85	0.36	1.66e-8	Mean platelet volume;
SARC	cis	rs2115630	1.000	rs6496441	chr15:85363348	A/G	cg17507749	chr15:85114479	UBE2QP1	-0.46	-5.6	-0.34	6.16e-8	P wave terminal force;
SARC	cis	rs2075371	1.000	rs2241335	chr7:133979368	C/T	cg20476274	chr7:133979776	SLC35B4	0.61	8.4	0.48	4.43e-15	Mean platelet volume;
SARC	cis	rs7223966	1.000	rs8078462	chr17:61857937	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.49	5.21	0.32	4.06e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs370915	0.564	rs10027461	chr4:187837608	T/C	cg19519643	chr4:187840862	NA	-0.55	-7.68	-0.45	4.33e-13	Gout;
SARC	cis	rs2180341	0.532	rs6933893	chr6:127707250	A/G	cg24812749	chr6:127587940	RNF146	0.56	6.7	0.4	1.57e-10	Breast cancer;
SARC	cis	rs6540556	0.769	rs6665715	chr1:209931353	A/C	cg05527609	chr1:210001259	C1orf107	0.55	5.53	0.34	8.45e-8	Red blood cell count;
SARC	cis	rs9467773	1.000	rs4713006	chr6:26519872	A/G	cg11502198	chr6:26597334	ABT1	0.47	5.93	0.36	1.1e-8	Intelligence (multi-trait analysis);
SARC	trans	rs61931739	0.500	rs11053212	chr12:34466116	T/G	cg13010199	chr12:38710504	ALG10B	0.81	11.23	0.59	1.12e-23	Morning vs. evening chronotype;
SARC	cis	rs829661	0.532	rs2363073	chr2:30796008	A/C	cg12454169	chr2:30669597	LCLAT1	-0.45	-5.68	-0.35	3.96e-8	Midgestational circulating levels of PBDEs (fetal genetic effect);
SARC	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg24633833	chr3:10029261	TMEM111	0.52	5.25	0.33	3.43e-7	Alzheimer's disease;
SARC	cis	rs3741151	1.000	rs60924672	chr11:73098724	A/C	cg17517138	chr11:73019481	ARHGEF17	0.86	6.25	0.38	1.89e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.57	8.77	0.5	3.76e-16	Eosinophil percentage of white cells;
SARC	cis	rs6484504	0.625	rs796341	chr11:31414151	G/A	cg26647111	chr11:31128758	NA	0.37	4.74	0.3	3.72e-6	Red blood cell count;
SARC	cis	rs2204008	0.640	rs2320744	chr12:38162389	A/G	cg26384229	chr12:38710491	ALG10B	0.88	12.94	0.65	3.26e-29	Bladder cancer;
SARC	cis	rs854765	0.663	rs4925120	chr17:17754633	C/T	cg05444541	chr17:17804740	TOM1L2	0.3	5.13	0.32	6.02e-7	Total body bone mineral density;
SARC	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg11764359	chr7:65958608	NA	-0.58	-6.5	-0.39	4.85e-10	Aortic root size;
SARC	trans	rs36093844	0.752	rs80193798	chr11:85577529	C/T	cg27065003	chr5:122429449	PRDM6	-0.54	-6.37	-0.39	9.73e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg05332525	chr7:65337924	VKORC1L1	0.43	4.84	0.3	2.38e-6	Aortic root size;
SARC	cis	rs6138458	0.961	rs11700073	chr20:24975215	C/G	cg26195577	chr20:24973756	C20orf3	0.91	10.03	0.55	6.38e-20	Blood protein levels;
SARC	cis	rs4595586	0.545	rs6580888	chr12:39369704	C/T	cg26384229	chr12:38710491	ALG10B	0.51	6.25	0.38	1.9e-9	Morning vs. evening chronotype;
SARC	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg25072359	chr17:41440525	NA	0.49	5.8	0.36	2.15e-8	Menopause (age at onset);
SARC	cis	rs9399137	0.507	rs6569986	chr6:135311641	T/C	cg22676075	chr6:135203613	NA	0.38	4.84	0.3	2.32e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg08045932	chr20:61659980	NA	0.52	7.12	0.42	1.33e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs483180	0.511	rs496198	chr1:120207177	A/G	cg19096424	chr1:120255104	PHGDH	-0.51	-5.94	-0.36	1.04e-8	Macular telangiectasia type 2;
SARC	cis	rs6690583	0.560	rs1561460	chr1:85545423	A/G	cg22153463	chr1:85462885	MCOLN2	-0.55	-5.35	-0.33	2.1e-7	Serum sulfate level;
SARC	cis	rs4148883	0.675	rs10000357	chr4:100099942	G/C	cg13256891	chr4:100009986	ADH5	0.56	7.39	0.44	2.6e-12	Alcohol dependence;
SARC	trans	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg15452590	chr11:607997	PHRF1	0.48	6.8	0.41	8.88e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2380220	0.574	rs9374322	chr6:95998994	G/A	cg23517279	chr6:96025343	MANEA	0.51	5.92	0.36	1.15e-8	Behavioural disinhibition (generation interaction);
SARC	cis	rs6964587	0.900	rs7783674	chr7:91784212	T/A	cg17063962	chr7:91808500	NA	0.98	17.35	0.75	7.27e-44	Breast cancer;
SARC	cis	rs7395581	0.918	rs1375688	chr11:47327217	G/A	cg25783544	chr11:47291846	MADD	0.5	5.64	0.35	4.82e-8	HDL cholesterol;
SARC	cis	rs644799	0.672	rs11021307	chr11:95501407	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.61	8.27	0.48	1.05e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs4742903	0.527	rs10991151	chr9:106952655	T/G	cg14250997	chr9:106856677	SMC2	0.39	4.85	0.3	2.3e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs2075371	0.501	rs1646652	chr7:134024515	A/T	cg00033643	chr7:134001901	SLC35B4	0.47	5.97	0.36	8.62e-9	Mean platelet volume;
SARC	cis	rs9322817	0.691	rs2499660	chr6:105285750	T/C	cg02098413	chr6:105308735	HACE1	0.37	5.79	0.35	2.22e-8	Thyroid stimulating hormone;
SARC	cis	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg05623727	chr3:50126028	RBM5	-0.32	-4.9	-0.31	1.76e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9309473	0.555	rs2901437	chr2:73597024	T/G	cg20560298	chr2:73613845	ALMS1	-0.54	-6.87	-0.41	5.76e-11	Metabolite levels;
SARC	cis	rs7429990	0.930	rs7374516	chr3:48002640	T/C	cg11946769	chr3:48343235	NME6	0.45	5.31	0.33	2.53e-7	Educational attainment (years of education);
SARC	cis	rs9290065	0.519	rs2376475	chr3:160708942	C/T	cg04691961	chr3:161091175	C3orf57	-0.49	-6.32	-0.38	1.31e-9	Kawasaki disease;
SARC	cis	rs7639513	0.520	rs12714875	chr3:12731007	T/G	cg23032965	chr3:12705835	RAF1	0.66	7.63	0.45	6.13e-13	Itch intensity from mosquito bite;
SARC	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.53	-6.01	-0.37	7.22e-9	Blood metabolite levels;
SARC	cis	rs6688613	0.694	rs1476347	chr1:166815587	G/T	cg07049167	chr1:166818506	POGK	0.46	4.91	0.31	1.71e-6	Refractive astigmatism;
SARC	cis	rs986417	0.681	rs76776170	chr14:60812419	A/T	cg27398547	chr14:60952738	C14orf39	-1.05	-5.64	-0.35	4.97e-8	Gut microbiota (bacterial taxa);
SARC	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.59	5.59	0.34	6.34e-8	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs910316	0.737	rs175065	chr14:75494983	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.52	-6.91	-0.41	4.57e-11	Height;
SARC	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg00933542	chr6:150070202	PCMT1	0.31	5.36	0.33	2.04e-7	Lung cancer;
SARC	cis	rs11098499	0.863	rs1155576	chr4:120450159	A/C	cg09307838	chr4:120376055	NA	0.93	12.94	0.65	3.31e-29	Corneal astigmatism;
SARC	cis	rs6910061	0.830	rs6456830	chr6:11093298	G/A	cg27233058	chr6:11094804	LOC221710	0.6	5.51	0.34	9.49e-8	Diabetic kidney disease;
SARC	cis	rs4481887	0.830	rs4916126	chr1:248466604	G/A	cg01631408	chr1:248437212	OR2T33	-0.44	-5.66	-0.35	4.35e-8	Common traits (Other);
SARC	cis	rs9916302	0.718	rs10445306	chr17:37591422	A/G	cg15445000	chr17:37608096	MED1	0.43	5.1	0.32	6.92e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs1707322	0.686	rs3014236	chr1:46091305	T/C	cg03146154	chr1:46216737	IPP	-0.51	-6.17	-0.37	3.06e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs34779708	0.931	rs11010083	chr10:35351531	C/G	cg03585969	chr10:35415529	CREM	0.39	4.97	0.31	1.32e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs7621025	0.630	rs1681818	chr3:136473673	A/G	cg15507776	chr3:136538369	TMEM22	-0.51	-5.57	-0.34	7.09e-8	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
SARC	cis	rs1920116	0.778	rs59800107	chr3:169556383	T/C	cg08193579	chr3:169529701	LRRC34	0.4	4.82	0.3	2.63e-6	Glioma (high-grade);
SARC	cis	rs9815354	1.000	rs3774372	chr3:41877414	A/G	cg03022575	chr3:42003672	ULK4	0.65	5.75	0.35	2.8e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs473651	0.935	rs558924	chr2:239339511	A/G	cg18131467	chr2:239335373	ASB1	0.98	12.45	0.63	1.28e-27	Multiple system atrophy;
SARC	cis	rs1949733	0.701	rs940134	chr4:8454870	C/T	cg13073564	chr4:8508604	NA	-0.43	-6.64	-0.4	2.23e-10	Response to antineoplastic agents;
SARC	cis	rs2710642	0.888	rs2539985	chr2:63134507	T/A	cg17519650	chr2:63277830	OTX1	0.42	5.29	0.33	2.76e-7	LDL cholesterol levels;LDL cholesterol;
SARC	cis	rs9807989	0.839	rs13392100	chr2:102982094	C/A	cg09003973	chr2:102972529	NA	0.42	5.67	0.35	4.12e-8	Asthma;
SARC	cis	rs7020830	0.931	rs7851239	chr9:37138672	A/G	cg14294708	chr9:37120828	ZCCHC7	-1.08	-16.49	-0.73	5.47e-41	Schizophrenia;
SARC	cis	rs9905704	0.647	rs33922512	chr17:57114148	C/G	cg12560992	chr17:57184187	TRIM37	-0.44	-5.32	-0.33	2.4e-7	Testicular germ cell tumor;
SARC	cis	rs9811216	1.000	rs1920120	chr3:169502180	T/C	cg14222479	chr3:169487675	ARPM1	0.43	5.26	0.33	3.3e-7	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg23205692	chr1:25664452	TMEM50A	0.42	5.12	0.32	6.33e-7	Erythrocyte sedimentation rate;
SARC	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg00908189	chr16:619842	PIGQ	0.85	12.49	0.63	9.84e-28	Height;
SARC	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.75	10.66	0.57	7e-22	Personality dimensions;
SARC	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg15049968	chr18:44337910	ST8SIA5	-0.35	-5.65	-0.35	4.75e-8	Personality dimensions;
SARC	cis	rs7937682	0.632	rs57414412	chr11:111769431	G/A	cg09085632	chr11:111637200	PPP2R1B	0.82	10.92	0.58	1.09e-22	Primary sclerosing cholangitis;
SARC	cis	rs7808935	0.958	rs17156041	chr7:27975745	C/T	cg05786569	chr7:27702416	HIBADH	0.54	5.6	0.34	5.97e-8	Prostate cancer;
SARC	cis	rs11249608	0.548	rs62393072	chr5:178450056	C/T	cg21905437	chr5:178450457	ZNF879	0.57	7.5	0.44	1.36e-12	Pubertal anthropometrics;
SARC	cis	rs8013055	0.846	rs10139300	chr14:105974501	A/G	cg19700328	chr14:106028568	NA	-0.6	-8.51	-0.49	2.19e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
SARC	cis	rs10911251	0.546	rs2274984	chr1:183107446	A/C	ch.1.3577855R	chr1:183094577	LAMC1	-0.68	-9.87	-0.54	1.98e-19	Colorectal cancer;
SARC	cis	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg09021430	chr5:549028	NA	-0.42	-5.52	-0.34	8.82e-8	Obesity-related traits;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg12306444	chr21:29093202	NCRNA00113	0.42	6.27	0.38	1.73e-9	Thyroid stimulating hormone;
SARC	cis	rs738322	0.553	rs28565947	chr22:38570775	C/G	cg25457927	chr22:38595422	NA	-0.25	-4.78	-0.3	3.11e-6	Cutaneous nevi;
SARC	trans	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.07	-0.42	1.8e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs7843479	1.000	rs7843479	chr8:21820813	G/T	cg17168535	chr8:21777572	XPO7	0.6	7.57	0.44	8.62e-13	Mean corpuscular volume;
SARC	cis	rs13401104	0.796	rs56338351	chr2:237119104	G/A	cg19324714	chr2:237145437	ASB18	0.57	5.66	0.35	4.32e-8	Educational attainment;
SARC	cis	rs2479724	0.755	rs4318867	chr6:41753670	G/T	cg17623882	chr6:41773611	USP49	0.42	5.28	0.33	2.91e-7	Menarche (age at onset);
SARC	cis	rs1003719	0.788	rs2835579	chr21:38457965	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.65	9.46	0.53	3.43e-18	Eye color traits;
SARC	cis	rs1059312	1.000	rs12814773	chr12:129280786	C/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.5	7.08	0.42	1.69e-11	Systemic lupus erythematosus;
SARC	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.47e-10	Life satisfaction;
SARC	cis	rs10504229	0.871	rs56048296	chr8:58163781	C/T	cg14926445	chr8:58193284	C8orf71	-0.4	-4.78	-0.3	3.12e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs1707322	1.000	rs785490	chr1:46577124	T/C	cg06784218	chr1:46089804	CCDC17	-0.35	-6.01	-0.37	7.21e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4689388	0.856	rs3200	chr4:6304878	C/T	cg00701064	chr4:6280414	WFS1	0.57	9.29	0.52	1.16e-17	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs12586317	0.582	rs731906	chr14:35604543	C/T	cg16230307	chr14:35515116	FAM177A1	0.99	11.46	0.6	2.02e-24	Psoriasis;
SARC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg05709568	chr12:121790321	ANAPC5	0.62	8.25	0.48	1.18e-14	Myopia (pathological);
SARC	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg08219700	chr8:58056026	NA	0.62	6.52	0.39	4.28e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs3796352	1.000	rs13072395	chr3:52980573	T/C	cg15956490	chr3:53032818	SFMBT1	0.89	5.66	0.35	4.36e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs637571	0.522	rs550435	chr11:65732651	G/A	cg26695010	chr11:65641043	EFEMP2	-0.55	-7.21	-0.43	7.8e-12	Eosinophil percentage of white cells;
SARC	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg04267008	chr7:1944627	MAD1L1	-0.66	-7.83	-0.46	1.71e-13	Bipolar disorder and schizophrenia;
SARC	cis	rs9818758	0.607	rs35673421	chr3:49139406	G/A	cg00383909	chr3:49044727	WDR6	0.76	6.56	0.39	3.52e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg03574289	chr7:149571017	LOC401431;ATP6V0E2	0.49	6.29	0.38	1.52e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs2439831	0.867	rs2278860	chr15:43659046	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.8	-8.62	-0.49	1.07e-15	Lung cancer in ever smokers;
SARC	cis	rs7599312	0.534	rs2371615	chr2:213405660	G/T	cg16329650	chr2:213403929	ERBB4	0.68	10.37	0.56	5.84e-21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg22433210	chr17:43662623	NA	-0.9	-10.96	-0.58	7.9e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs6665290	0.669	rs3795446	chr1:227180981	C/T	cg10327440	chr1:227177885	CDC42BPA	1.01	19.77	0.79	9.75e-52	Myeloid white cell count;
SARC	cis	rs2486288	0.656	rs11632651	chr15:45550838	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.51	-6.44	-0.39	6.68e-10	Glomerular filtration rate;
SARC	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg07701084	chr6:150067640	NUP43	0.4	5.37	0.33	1.91e-7	Lung cancer;
SARC	cis	rs1957429	0.901	rs1467571	chr14:65347682	C/T	cg23373153	chr14:65346875	NA	1.07	11.5	0.6	1.53e-24	Pediatric areal bone mineral density (radius);
SARC	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-5.73	-0.35	3.13e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs11578119	0.933	rs12724601	chr1:170427510	C/G	cg09767346	chr1:170501363	GORAB	0.44	5.15	0.32	5.49e-7	Male-pattern baldness;
SARC	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg25036284	chr2:26402008	FAM59B	0.46	5.7	0.35	3.59e-8	Gut microbiome composition (summer);
SARC	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.78	7.71	0.45	3.6e-13	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs3741151	0.686	rs7114009	chr11:73115314	C/T	cg17517138	chr11:73019481	ARHGEF17	-0.65	-5.65	-0.35	4.61e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	trans	rs1865760	0.929	rs9461224	chr6:25936402	G/T	cg18350792	chr12:112563442	TRAFD1	-0.53	-6.46	-0.39	5.96e-10	Height;
SARC	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9815354	1.000	rs10865914	chr3:41919499	C/T	cg03022575	chr3:42003672	ULK4	-0.54	-5.12	-0.32	6.5e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs910316	0.763	rs175036	chr14:75464295	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.41	-5.5	-0.34	9.74e-8	Height;
SARC	cis	rs9790314	0.690	rs6783085	chr3:160830929	A/G	cg04691961	chr3:161091175	C3orf57	-0.56	-7.35	-0.43	3.29e-12	Morning vs. evening chronotype;
SARC	cis	rs427394	0.582	rs274661	chr5:6704848	C/T	cg10857441	chr5:6722123	POLS	-0.33	-4.73	-0.3	3.83e-6	Menopause (age at onset);
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg06535952	chr19:56126775	NA	0.5	6.98	0.42	3.12e-11	Schizophrenia;
SARC	cis	rs763121	1.000	rs138457	chr22:38898051	T/C	cg06022373	chr22:39101656	GTPBP1	-0.77	-10.17	-0.55	2.5e-20	Menopause (age at onset);
SARC	cis	rs17270561	0.583	rs6926425	chr6:25785304	T/C	cg16482183	chr6:26056742	HIST1H1C	0.48	6.23	0.38	2.11e-9	Iron status biomarkers;
SARC	cis	rs7681440	0.543	rs2736997	chr4:90754557	G/A	cg06632027	chr4:90757378	SNCA	-0.44	-5.44	-0.34	1.32e-7	Dementia with Lewy bodies;
SARC	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.5	-6.32	-0.38	1.29e-9	Lymphocyte counts;
SARC	cis	rs9467773	0.933	rs2024970	chr6:26497520	T/A	cg11502198	chr6:26597334	ABT1	0.47	5.5	0.34	9.89e-8	Intelligence (multi-trait analysis);
SARC	cis	rs57920188	0.535	rs112660254	chr1:4089921	T/G	cg20703997	chr1:4087676	NA	0.54	5.56	0.34	7.31e-8	Interleukin-17 levels;
SARC	trans	rs7731657	0.509	rs1009686	chr5:129863694	A/C	cg00505597	chr19:10668268	KRI1	0.46	6.23	0.38	2.13e-9	Fasting plasma glucose;
SARC	cis	rs4253772	0.550	rs6007818	chr22:46703776	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.61	5.07	0.32	7.96e-7	LDL cholesterol;Cholesterol, total;
SARC	cis	rs6484504	0.576	rs208093	chr11:31184400	C/T	cg02090638	chr11:31391270	DNAJC24;DCDC1	0.38	4.81	0.3	2.74e-6	Red blood cell count;
SARC	cis	rs1034435	0.505	rs5768690	chr22:48902117	G/A	cg05992904	chr22:48892994	FAM19A5	-0.42	-5.49	-0.34	1.07e-7	Late-onset Alzheimer's disease;
SARC	cis	rs6580649	0.941	rs7957764	chr12:48429701	C/T	cg24011408	chr12:48396354	COL2A1	-0.51	-5.44	-0.34	1.32e-7	Lung cancer;
SARC	cis	rs7210086	0.606	rs72849437	chr17:70631124	T/C	cg04206342	chr17:70636940	NA	-0.52	-5.36	-0.33	2.04e-7	Ulcerative colitis;
SARC	cis	rs11792861	0.962	rs11789624	chr9:111796231	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.68	7.78	0.45	2.34e-13	Menarche (age at onset);
SARC	cis	rs4563143	0.514	rs73029081	chr19:29295583	C/G	cg03161606	chr19:29218774	NA	0.4	5.1	0.32	7.2e-7	Methadone dose in opioid dependence;
SARC	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg24531977	chr5:56204891	C5orf35	-0.51	-5.21	-0.32	4.25e-7	Initial pursuit acceleration;
SARC	cis	rs7584330	0.780	rs12474519	chr2:238377012	G/A	cg11271282	chr2:238384023	NA	0.44	4.96	0.31	1.36e-6	Prostate cancer;
SARC	cis	rs72945132	0.882	rs17160762	chr11:70134766	A/G	cg00319359	chr11:70116639	PPFIA1	-0.68	-6.57	-0.4	3.21e-10	Coronary artery disease;
SARC	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.48	-6.12	-0.37	4.02e-9	Lymphocyte counts;
SARC	cis	rs959260	0.528	rs4559942	chr17:73309269	G/A	cg23660755	chr17:73110554	ARMC7	-0.41	-4.75	-0.3	3.55e-6	Systemic lupus erythematosus;
SARC	cis	rs7647973	0.925	rs11130183	chr3:49228946	A/G	cg07636037	chr3:49044803	WDR6	0.8	9.19	0.52	2.19e-17	Menarche (age at onset);
SARC	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg13206674	chr6:150067644	NUP43	0.41	5.3	0.33	2.66e-7	Lung cancer;
SARC	cis	rs8180040	0.966	rs7649234	chr3:47494380	G/C	cg27129171	chr3:47204927	SETD2	0.66	9.46	0.53	3.46e-18	Colorectal cancer;
SARC	cis	rs7833986	0.818	rs79824205	chr8:57093233	A/T	cg26371346	chr8:56986568	SNORD54;RPS20	0.6	5.33	0.33	2.36e-7	Height;
SARC	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg22857025	chr5:266934	NA	-1.06	-11.8	-0.61	1.74e-25	Breast cancer;
SARC	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg18252515	chr7:66147081	NA	0.56	5.86	0.36	1.55e-8	Aortic root size;
SARC	cis	rs477692	1.000	rs567700	chr10:131423126	C/T	cg05714579	chr10:131428358	MGMT	0.55	7.13	0.42	1.23e-11	Response to temozolomide;
SARC	cis	rs3749237	0.595	rs4855877	chr3:49448527	T/C	cg06212747	chr3:49208901	KLHDC8B	0.51	6.21	0.38	2.37e-9	Resting heart rate;
SARC	cis	rs921968	0.509	rs626432	chr2:219355658	C/A	cg02176678	chr2:219576539	TTLL4	0.46	7.12	0.42	1.33e-11	Mean corpuscular hemoglobin concentration;
SARC	cis	rs4888262	0.545	rs36097721	chr16:74648267	C/G	ch.16.1684049R	chr16:74565916	GLG1	0.35	4.72	0.3	4.1e-6	Testicular germ cell tumor;
SARC	cis	rs9815354	0.812	rs73073326	chr3:41834195	G/T	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	trans	rs1814175	0.645	rs10444311	chr11:49986906	A/G	cg03929089	chr4:120376271	NA	-0.82	-11.88	-0.61	9.2e-26	Height;
SARC	cis	rs6674176	0.593	rs6675620	chr1:44417630	C/T	cg13606994	chr1:44402422	ARTN	-0.34	-5.36	-0.33	2.02e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg05025164	chr4:1340916	KIAA1530	-0.68	-8.1	-0.47	3.08e-14	Obesity-related traits;
SARC	cis	rs4853036	0.672	rs12995760	chr2:70029812	C/T	cg02498382	chr2:70120550	SNRNP27	-0.36	-4.97	-0.31	1.28e-6	Colorectal or endometrial cancer;
SARC	cis	rs1348850	0.513	rs6730406	chr2:178492722	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.45	4.81	0.3	2.65e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg12463550	chr7:65579703	CRCP	-0.7	-5.34	-0.33	2.21e-7	Diabetic kidney disease;
SARC	cis	rs12442242	0.522	rs16966213	chr15:38361447	C/T	cg19084031	chr15:38361362	NA	0.69	4.78	0.3	3.08e-6	Total body bone mineral density;
SARC	cis	rs9916302	0.706	rs8182252	chr17:37727950	T/C	cg20243544	chr17:37824526	PNMT	-0.54	-5.83	-0.36	1.87e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg11608241	chr8:8085544	FLJ10661	0.43	5.21	0.32	4.2e-7	Mood instability;
SARC	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg05313129	chr8:58192883	C8orf71	-0.51	-5.85	-0.36	1.63e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs854765	0.647	rs854790	chr17:18028318	C/G	cg05444541	chr17:17804740	TOM1L2	-0.3	-4.88	-0.3	1.92e-6	Total body bone mineral density;
SARC	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg00933542	chr6:150070202	PCMT1	0.33	5.61	0.35	5.58e-8	Lung cancer;
SARC	cis	rs6964587	0.869	rs7810391	chr7:91520227	G/A	cg17063962	chr7:91808500	NA	-0.91	-13.72	-0.67	8.19e-32	Breast cancer;
SARC	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg02018176	chr4:1364513	KIAA1530	0.37	5.37	0.33	1.95e-7	Obesity-related traits;
SARC	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg14517863	chr17:44321492	NA	0.43	6.34	0.38	1.15e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs6759839	0.591	rs4240227	chr2:16688657	G/A	cg09580478	chr2:16689509	NA	0.43	5.8	0.35	2.2e-8	Mean platelet volume;
SARC	cis	rs733592	0.507	rs7299704	chr12:48444488	A/G	cg21466736	chr12:48725269	NA	-0.32	-5.65	-0.35	4.66e-8	Plateletcrit;
SARC	cis	rs9398803	0.723	rs853968	chr6:127071753	C/T	cg19875578	chr6:126661172	C6orf173	-0.62	-8.6	-0.49	1.17e-15	Male-pattern baldness;
SARC	cis	rs10992471	0.756	rs2761681	chr9:95186937	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-6.68	-0.4	1.73e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs3749237	0.615	rs55957735	chr3:49438158	G/A	cg06212747	chr3:49208901	KLHDC8B	0.51	6.24	0.38	1.99e-9	Resting heart rate;
SARC	cis	rs1439620	0.542	rs12900800	chr15:93512678	G/A	cg15576342	chr15:93139511	NA	-0.37	-4.83	-0.3	2.5e-6	Body mass index;
SARC	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg11987759	chr7:65425863	GUSB	-0.47	-6.27	-0.38	1.7e-9	Aortic root size;
SARC	cis	rs611744	0.870	rs2212703	chr8:109198401	G/C	cg21045802	chr8:109455806	TTC35	0.49	6.06	0.37	5.54e-9	Dupuytren's disease;
SARC	cis	rs67311347	0.869	rs6790495	chr3:40366770	C/T	cg09455208	chr3:40491958	NA	0.38	5.93	0.36	1.1e-8	Renal cell carcinoma;
SARC	cis	rs2882877	0.620	rs62184660	chr2:190383525	C/T	cg21926118	chr2:190387206	NA	-0.39	-4.85	-0.3	2.3e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs17345786	0.861	rs11707689	chr3:101086475	A/G	cg12386194	chr3:101231763	SENP7	0.81	9.48	0.53	3.14e-18	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg17691542	chr6:26056736	HIST1H1C	0.48	5.87	0.36	1.48e-8	Height;
SARC	cis	rs2380220	0.516	rs7748108	chr6:96008082	T/C	cg04719120	chr6:96025338	MANEA	0.65	7.83	0.46	1.72e-13	Behavioural disinhibition (generation interaction);
SARC	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg18305652	chr10:134549665	INPP5A	0.32	4.76	0.3	3.36e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs17270561	0.609	rs2275905	chr6:25768106	G/A	cg16482183	chr6:26056742	HIST1H1C	0.48	5.95	0.36	9.58e-9	Iron status biomarkers;
SARC	cis	rs9790314	0.690	rs7617204	chr3:160821969	A/G	cg03342759	chr3:160939853	NMD3	-0.59	-7.41	-0.44	2.29e-12	Morning vs. evening chronotype;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg14084424	chr6:88182590	SLC35A1	0.51	6.52	0.39	4.35e-10	Lung adenocarcinoma;
SARC	cis	rs7762018	0.770	rs3823466	chr6:170189926	C/T	cg00262263	chr6:170184901	NA	0.41	4.92	0.31	1.61e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs2289583	0.517	rs2004278	chr15:75264363	C/T	cg10253484	chr15:75165896	SCAMP2	0.5	5.39	0.33	1.71e-7	Systemic lupus erythematosus;
SARC	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg21724239	chr8:58056113	NA	0.66	6.19	0.38	2.74e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10876993	0.855	rs1689604	chr12:58048304	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.48	-6.1	-0.37	4.42e-9	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs765787	0.530	rs12906537	chr15:45520061	T/C	cg21132104	chr15:45694354	SPATA5L1	0.41	4.8	0.3	2.79e-6	Uric acid levels;
SARC	cis	rs8067545	0.641	rs1479129	chr17:19845769	A/G	cg13482628	chr17:19912719	NA	0.52	6.51	0.39	4.67e-10	Schizophrenia;
SARC	cis	rs8038465	0.638	rs8036954	chr15:73974282	T/C	cg15420318	chr15:73925796	NPTN	0.53	6.16	0.37	3.17e-9	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs10791323	0.572	rs4412766	chr11:133742811	A/C	cg15485101	chr11:133734466	NA	0.31	4.98	0.31	1.25e-6	Childhood ear infection;
SARC	cis	rs73206853	0.841	rs17619763	chr12:110645829	C/T	cg08946844	chr12:110511112	NA	0.59	4.81	0.3	2.67e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs9393777	0.588	rs11967935	chr6:26560672	A/C	cg12292205	chr6:26970375	C6orf41	-0.53	-4.84	-0.3	2.36e-6	Intelligence (multi-trait analysis);
SARC	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg03351412	chr1:154909251	PMVK	0.64	8.17	0.47	2e-14	Prostate cancer;
SARC	cis	rs561341	0.739	rs8070554	chr17:30216868	A/T	cg12000587	chr17:30186630	C17orf79	0.38	4.98	0.31	1.21e-6	Hip circumference adjusted for BMI;
SARC	cis	rs11623869	0.614	rs11627052	chr14:103863476	A/G	cg26031613	chr14:104095156	KLC1	-0.71	-8.38	-0.48	5.14e-15	Bone mineral density;
SARC	cis	rs4423214	1.000	rs11233746	chr11:71171440	A/G	cg24826892	chr11:71159390	DHCR7	0.48	6.21	0.38	2.46e-9	Vitamin D levels;
SARC	cis	rs2425143	1.000	rs8116836	chr20:34453362	T/A	cg01084648	chr20:34329383	RBM39	0.67	5.51	0.34	9.55e-8	Blood protein levels;
SARC	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	11.31	0.6	6.28e-24	Alzheimer's disease;
SARC	trans	rs2396442	1.000	rs2256819	chr6:45418402	A/G	cg23284323	chr21:40685679	BRWD1	-0.58	-6.55	-0.39	3.62e-10	Left ventricle wall thickness;
SARC	cis	rs12912251	0.947	rs7171233	chr15:38988760	T/A	cg01338139	chr15:38987640	C15orf53	-0.46	-5.41	-0.33	1.6e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
SARC	cis	rs9640161	0.742	rs2159235	chr7:150017228	T/C	cg10018233	chr7:150070692	REPIN1	0.69	9.29	0.52	1.1e-17	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs7792596	0.964	rs2374716	chr7:93973175	A/T	cg20814616	chr7:94014465	NA	-0.45	-5.61	-0.34	5.79e-8	Intelligence;
SARC	cis	rs4853036	0.540	rs4852331	chr2:70004368	T/C	cg02498382	chr2:70120550	SNRNP27	-0.35	-4.8	-0.3	2.86e-6	Colorectal or endometrial cancer;
SARC	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg12667521	chr19:29218732	NA	0.4	5.41	0.33	1.56e-7	Methadone dose in opioid dependence;
SARC	cis	rs614226	1.000	rs1167725	chr12:120968559	A/T	cg01236616	chr12:121019343	POP5	1.26	18.33	0.77	4.69e-47	Type 1 diabetes nephropathy;
SARC	cis	rs7011049	1.000	rs72640849	chr8:53836430	A/T	cg26025543	chr8:53854495	NA	0.62	5.59	0.34	6.2e-8	Systolic blood pressure;
SARC	cis	rs1215050	0.791	rs4699318	chr4:98664370	T/G	cg05340658	chr4:99064831	C4orf37	-0.44	-5.78	-0.35	2.38e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs7666738	0.791	rs11097610	chr4:99011795	C/G	cg05340658	chr4:99064831	C4orf37	0.67	8.98	0.51	9.41e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs12971120	1.000	rs3829640	chr18:72174980	A/G	cg26446133	chr18:72167187	CNDP2	-0.44	-6.73	-0.4	1.33e-10	Refractive error;
SARC	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg09359103	chr1:154839909	KCNN3	0.42	7.04	0.42	2.17e-11	Prostate cancer;
SARC	cis	rs9788721	1.000	rs931794	chr15:78826180	G/A	cg06917634	chr15:78832804	PSMA4	0.51	5.61	0.34	5.86e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs992157	0.835	rs2045434	chr2:219144498	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.7	-10.25	-0.56	1.35e-20	Colorectal cancer;
SARC	cis	rs2073300	0.609	rs6137939	chr20:23390206	C/T	cg12062639	chr20:23401060	NAPB	-1.02	-6.94	-0.41	3.87e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg15773090	chr12:42632129	YAF2	0.64	6.4	0.39	8.65e-10	Lung cancer in ever smokers;
SARC	cis	rs4481887	1.000	rs4244183	chr1:248471222	G/A	cg00666640	chr1:248458726	OR2T12	0.38	6.42	0.39	7.43e-10	Common traits (Other);
SARC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg11203670	chr7:100026453	MEPCE;ZCWPW1	0.47	4.76	0.3	3.4e-6	Platelet count;
SARC	cis	rs12142240	0.698	rs72677593	chr1:46824363	T/C	cg00530320	chr1:46809349	NSUN4	0.57	6.79	0.41	9.05e-11	Menopause (age at onset);
SARC	cis	rs10791097	0.547	rs10791101	chr11:130739133	C/T	cg12179176	chr11:130786555	SNX19	0.72	10.55	0.57	1.58e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs17125944	0.542	rs75723366	chr14:53256882	T/C	cg00686598	chr14:53173677	PSMC6	1.26	8.79	0.5	3.33e-16	Alzheimer's disease (late onset);
SARC	cis	rs11711311	1.000	rs9879760	chr3:113457948	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.69	8.9	0.5	1.64e-16	IgG glycosylation;
SARC	cis	rs317689	0.876	rs547332	chr12:69743639	C/G	cg20891283	chr12:69753455	YEATS4	0.49	5.71	0.35	3.43e-8	Response to diuretic therapy;
SARC	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg18404041	chr3:52824283	ITIH1	-0.37	-5.57	-0.34	7.13e-8	Electroencephalogram traits;
SARC	cis	rs752092	1.000	rs752092	chr15:101781934	C/T	cg19997662	chr15:101784653	CHSY1	0.43	5.59	0.34	6.26e-8	Corneal structure;
SARC	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg05896524	chr21:47604654	C21orf56	-0.59	-7.2	-0.43	8.45e-12	Testicular germ cell tumor;
SARC	cis	rs11098499	0.818	rs55825515	chr4:120486402	A/G	cg09307838	chr4:120376055	NA	0.91	11.78	0.61	2.01e-25	Corneal astigmatism;
SARC	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.62	-6.73	-0.4	1.29e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9581943	0.967	rs8000004	chr13:28477590	A/G	cg16302790	chr13:28498334	PDX1	0.54	8.16	0.47	2.13e-14	Pancreatic cancer;
SARC	cis	rs17345786	0.861	rs74768235	chr3:101142821	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.45	-4.72	-0.3	4.16e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs11711311	0.955	rs3796254	chr3:113380332	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	8.17	0.47	1.91e-14	IgG glycosylation;
SARC	cis	rs11209002	0.614	rs7544189	chr1:67568351	C/T	cg02640540	chr1:67518911	SLC35D1	0.51	6.0	0.37	7.65e-9	Crohn's disease;
SARC	trans	rs904095	0.562	rs1229849	chr4:100284685	A/T	cg09604489	chr8:22994223	TNFRSF10D	-0.46	-6.24	-0.38	2.05e-9	Alcohol dependence;
SARC	cis	rs10870270	0.956	rs7904594	chr10:133734671	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.45	-5.37	-0.33	1.93e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs72945132	0.598	rs61887432	chr11:70239065	A/C	cg00319359	chr11:70116639	PPFIA1	0.56	5.19	0.32	4.56e-7	Coronary artery disease;
SARC	cis	rs894734	0.535	rs7301643	chr12:54325796	G/T	cg17708016	chr12:54321992	NA	0.46	5.82	0.36	1.9e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
SARC	cis	rs9303401	0.659	rs61291849	chr17:56909867	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.07	12.11	0.62	1.62e-26	Cognitive test performance;
SARC	cis	rs9503598	0.714	rs11242859	chr6:3454032	G/A	cg00476032	chr6:3446245	SLC22A23	0.33	5.09	0.32	7.44e-7	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
SARC	cis	rs2075371	0.796	rs10954440	chr7:134005657	C/T	cg11752832	chr7:134001865	SLC35B4	0.54	6.79	0.41	9.03e-11	Mean platelet volume;
SARC	cis	rs3888647	0.622	rs4758618	chr11:2995186	A/T	cg05729581	chr11:3078854	CARS	-0.54	-7.18	-0.43	9.03e-12	Type 2 diabetes;
SARC	cis	rs6484504	0.576	rs11031323	chr11:31245413	T/G	cg26647111	chr11:31128758	NA	-0.4	-5.21	-0.32	4.21e-7	Red blood cell count;
SARC	cis	rs3857536	0.785	rs2157964	chr6:66938419	A/G	cg07460842	chr6:66804631	NA	-0.51	-5.83	-0.36	1.86e-8	Blood trace element (Cu levels);
SARC	trans	rs7615952	0.800	rs13086460	chr3:125646417	C/T	cg07211511	chr3:129823064	LOC729375	-0.96	-10.77	-0.58	3.18e-22	Blood pressure (smoking interaction);
SARC	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg00684032	chr4:1343700	KIAA1530	0.39	5.76	0.35	2.65e-8	Obesity-related traits;
SARC	cis	rs734999	0.545	rs28568531	chr1:2555640	T/A	cg18854424	chr1:2615690	NA	0.31	4.89	0.3	1.9e-6	Ulcerative colitis;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg27632268	chr1:221915475	DUSP10	-0.49	-6.32	-0.38	1.33e-9	Electrocardiographic conduction measures;
SARC	cis	rs858239	0.896	rs1637193	chr7:23260251	G/T	cg23682824	chr7:23144976	KLHL7	0.6	7.61	0.45	6.75e-13	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9911578	0.933	rs2632508	chr17:56533235	G/A	cg12560992	chr17:57184187	TRIM37	0.81	10.79	0.58	2.83e-22	Intelligence (multi-trait analysis);
SARC	cis	rs13418717	0.793	rs4663054	chr2:127639995	C/T	cg25501666	chr2:127640322	NA	-0.79	-5.11	-0.32	6.68e-7	Heart failure;
SARC	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg14664628	chr15:75095509	CSK	-0.52	-6.49	-0.39	4.98e-10	Breast cancer;
SARC	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg16680214	chr1:154839983	KCNN3	-0.35	-5.66	-0.35	4.46e-8	Prostate cancer;
SARC	cis	rs11098499	0.779	rs7699346	chr4:120310542	C/T	cg09307838	chr4:120376055	NA	0.89	12.19	0.62	8.98e-27	Corneal astigmatism;
SARC	cis	rs72781680	0.821	rs72790329	chr2:24129277	A/G	cg08917208	chr2:24149416	ATAD2B	0.59	5.93	0.36	1.1e-8	Lymphocyte counts;
SARC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.62	-6.69	-0.4	1.66e-10	Platelet count;
SARC	cis	rs12142240	0.698	rs112089006	chr1:46812360	C/T	cg10495392	chr1:46806563	NSUN4	0.65	6.8	0.41	8.47e-11	Menopause (age at onset);
SARC	cis	rs11098499	0.954	rs3733520	chr4:120423480	C/G	cg09307838	chr4:120376055	NA	0.94	13.12	0.65	7.93e-30	Corneal astigmatism;
SARC	cis	rs921968	0.541	rs585185	chr2:219457741	G/A	cg02176678	chr2:219576539	TTLL4	0.46	6.89	0.41	5.03e-11	Mean corpuscular hemoglobin concentration;
SARC	cis	rs986417	0.901	rs1955698	chr14:61029936	C/T	cg27398547	chr14:60952738	C14orf39	0.83	8.17	0.47	1.98e-14	Gut microbiota (bacterial taxa);
SARC	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg11764359	chr7:65958608	NA	0.77	9.41	0.52	5.12e-18	Aortic root size;
SARC	cis	rs1971762	0.563	rs10747678	chr12:54077687	A/C	cg06632207	chr12:54070931	ATP5G2	-0.43	-5.46	-0.34	1.2e-7	Height;
SARC	cis	rs9911578	0.805	rs12601867	chr17:56455260	C/G	cg05425664	chr17:57184151	TRIM37	0.59	7.37	0.43	2.9e-12	Intelligence (multi-trait analysis);
SARC	cis	rs4642101	0.793	rs13086170	chr3:12832604	G/C	cg12400702	chr3:12838781	CAND2	-0.26	-5.2	-0.32	4.26e-7	QRS complex (12-leadsum);
SARC	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg03517284	chr6:25882590	NA	0.43	5.56	0.34	7.36e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9467603	1.000	rs9467606	chr6:25809218	A/G	cg21479132	chr6:26055353	NA	0.77	5.1	0.32	7.06e-7	Intelligence (multi-trait analysis);
SARC	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg26335602	chr6:28129616	ZNF389	0.51	5.65	0.35	4.6e-8	Depression;
SARC	cis	rs2120019	1.000	rs7175720	chr15:75348962	C/G	cg09165964	chr15:75287851	SCAMP5	0.9	13.29	0.66	2.27e-30	Blood trace element (Zn levels);
SARC	cis	rs8018808	0.522	rs8007669	chr14:77965748	G/C	cg16049707	chr14:77965284	ISM2	0.4	5.38	0.33	1.8e-7	Myeloid white cell count;
SARC	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.97e-8	Aortic root size;
SARC	cis	rs3758785	0.597	rs615465	chr11:94086254	T/C	cg13023536	chr11:94226537	MRE11A;ANKRD49	-0.45	-5.82	-0.36	1.96e-8	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
SARC	cis	rs4481887	0.927	rs10127803	chr1:248476196	A/T	cg00666640	chr1:248458726	OR2T12	0.34	5.7	0.35	3.65e-8	Common traits (Other);
SARC	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg08280861	chr8:58055591	NA	0.7	5.87	0.36	1.49e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2273669	0.915	rs2038542	chr6:109295293	T/C	cg05315195	chr6:109294784	ARMC2	-0.48	-4.79	-0.3	2.96e-6	Prostate cancer;
SARC	cis	rs73198271	0.603	rs546606	chr8:8595843	A/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-4.94	-0.31	1.48e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs1046896	0.562	rs9912684	chr17:80873067	C/T	cg19500275	chr17:80737654	TBCD	0.44	5.17	0.32	5.02e-7	Glycated hemoglobin levels;
SARC	cis	rs7296418	0.675	rs1879379	chr12:123727443	G/A	cg05973401	chr12:123451056	ABCB9	0.49	5.82	0.36	1.96e-8	Platelet count;
SARC	cis	rs614226	0.938	rs787824	chr12:120924638	A/G	cg01236616	chr12:121019343	POP5	-1.25	-17.61	-0.76	1.02e-44	Type 1 diabetes nephropathy;
SARC	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg00149659	chr3:10157352	C3orf10	0.69	6.38	0.39	9.6e-10	Alzheimer's disease;
SARC	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg01341218	chr17:43662625	NA	-0.84	-9.47	-0.53	3.19e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs8078723	1.000	rs3826331	chr17:38150492	T/C	cg17467752	chr17:38218738	THRA	-0.48	-6.2	-0.38	2.54e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs644799	0.862	rs1150361	chr11:95633805	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.87	12.37	0.63	2.43e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7617773	0.539	rs11706939	chr3:48383992	G/T	cg11946769	chr3:48343235	NME6	0.56	6.78	0.41	9.53e-11	Coronary artery disease;
SARC	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg18252515	chr7:66147081	NA	-0.44	-4.75	-0.3	3.5e-6	Aortic root size;
SARC	trans	rs7824557	0.701	rs2060465	chr8:11162609	T/C	cg06636001	chr8:8085503	FLJ10661	0.58	7.08	0.42	1.72e-11	Retinal vascular caliber;
SARC	cis	rs3126085	0.935	rs2291770	chr1:152179792	G/C	cg09127314	chr1:152161683	NA	0.41	4.76	0.3	3.39e-6	Atopic dermatitis;
SARC	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg06420487	chr17:61919686	SMARCD2	0.43	4.83	0.3	2.44e-6	Height;
SARC	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg11644478	chr21:40555479	PSMG1	-0.61	-7.58	-0.44	8.25e-13	Menarche (age at onset);
SARC	cis	rs12155623	0.619	rs11775403	chr8:49877323	A/T	cg06076277	chr8:49783056	NA	0.31	5.14	0.32	5.93e-7	Sudden cardiac arrest;
SARC	cis	rs1008375	0.606	rs6828925	chr4:17561139	C/T	cg27347728	chr4:17578864	LAP3	0.47	5.7	0.35	3.53e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.28	0.38	1.6e-9	Height;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg22265110	chr17:4871194	SPAG7	-0.51	-6.6	-0.4	2.68e-10	Schizophrenia;
SARC	cis	rs920590	0.573	rs6986456	chr8:19680562	A/G	cg01411142	chr8:19674711	INTS10	0.48	5.66	0.35	4.46e-8	Acute lymphoblastic leukemia (childhood);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg23986671	chr21:28339262	ADAMTS5	-0.56	-6.33	-0.38	1.23e-9	Brain volume in infants (cerebrospinal fluid);
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg19554454	chr19:3522972	FZR1	0.51	6.48	0.39	5.26e-10	Schizophrenia;
SARC	cis	rs6060717	0.536	rs11167279	chr20:34509107	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	4.95	0.31	1.42e-6	Hip circumference adjusted for BMI;
SARC	cis	rs6089584	0.526	rs6089619	chr20:60610916	C/T	cg06108461	chr20:60628389	TAF4	-0.65	-8.35	-0.48	5.93e-15	Body mass index;
SARC	cis	rs28374715	0.510	rs8034073	chr15:41545613	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.64	-8.92	-0.5	1.37e-16	Ulcerative colitis;
SARC	cis	rs11997175	0.713	rs4733455	chr8:33651290	C/T	ch.8.33884649F	chr8:33765107	NA	-0.55	-7.45	-0.44	1.85e-12	Body mass index;
SARC	cis	rs9487051	0.802	rs9487039	chr6:109610163	A/T	cg01475377	chr6:109611718	NA	-0.41	-5.92	-0.36	1.13e-8	Reticulocyte fraction of red cells;
SARC	cis	rs36051895	0.632	rs12343038	chr9:5178579	A/G	cg02405213	chr9:5042618	JAK2	0.43	5.06	0.31	8.34e-7	Pediatric autoimmune diseases;
SARC	cis	rs5167	0.504	rs7258345	chr19:45453151	T/G	cg13119609	chr19:45449297	APOC2	0.5	8.43	0.48	3.58e-15	Blood protein levels;
SARC	cis	rs11731606	0.508	rs28623728	chr4:95290861	C/T	cg00507259	chr4:95128692	SMARCAD1	0.56	5.4	0.33	1.64e-7	Mean platelet volume;
SARC	cis	rs13082711	0.554	rs6804440	chr3:27398150	C/T	cg02860705	chr3:27208620	NA	0.64	7.94	0.46	8.59e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg27018254	chr22:37956429	CDC42EP1	0.56	7.73	0.45	3.23e-13	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs11122272	0.735	rs2790873	chr1:231539685	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.93	-0.55	1.29e-19	Hemoglobin concentration;
SARC	cis	rs703842	1.000	rs11172335	chr12:58175201	C/T	cg00677455	chr12:58241039	CTDSP2	0.5	6.53	0.39	4.05e-10	Multiple sclerosis;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg12012699	chr18:46986876	DYM	-0.52	-6.39	-0.39	8.8e-10	Height;
SARC	cis	rs2213920	0.569	rs4979524	chr9:118177617	C/G	cg13918206	chr9:118159781	DEC1	0.7	5.99	0.37	7.83e-9	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs10875746	0.551	rs12322347	chr12:48707698	T/G	cg26205652	chr12:48591994	NA	0.45	4.78	0.3	3.04e-6	Longevity (90 years and older);
SARC	trans	rs1814175	0.645	rs28627251	chr11:50048125	G/T	cg15704280	chr7:45808275	SEPT13	-0.91	-14.49	-0.69	2.43e-34	Height;
SARC	cis	rs858239	0.600	rs6960001	chr7:23130876	T/C	cg23682824	chr7:23144976	KLHL7	0.71	9.6	0.53	1.34e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg11965913	chr1:205819406	PM20D1	1.0	19.55	0.79	4.89e-51	Menarche (age at onset);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg09760210	chr2:192289158	MYO1B	0.5	7.5	0.44	1.31e-12	Thyroid stimulating hormone;
SARC	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg15921436	chr17:44337874	NA	0.48	4.74	0.3	3.74e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs2282802	0.651	rs6863474	chr5:139630862	C/T	cg26211634	chr5:139558579	C5orf32	0.41	5.28	0.33	2.98e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6456156	0.792	rs10946214	chr6:167516122	G/A	cg07741184	chr6:167504864	NA	0.37	7.04	0.42	2.2e-11	Primary biliary cholangitis;
SARC	cis	rs1059312	0.808	rs4482069	chr12:129294252	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.45	-5.59	-0.34	6.28e-8	Systemic lupus erythematosus;
SARC	cis	rs6500602	0.702	rs56895104	chr16:4548132	G/A	cg08645402	chr16:4508243	NA	0.44	6.01	0.37	7.13e-9	Schizophrenia;
SARC	cis	rs10875746	0.855	rs12296244	chr12:48441479	C/G	cg26205652	chr12:48591994	NA	0.53	5.71	0.35	3.49e-8	Longevity (90 years and older);
SARC	trans	rs1908814	0.510	rs57655799	chr8:11782417	A/C	cg06636001	chr8:8085503	FLJ10661	0.53	6.77	0.41	1.07e-10	Neuroticism;
SARC	cis	rs911263	0.524	rs1956526	chr14:68799787	G/T	cg18825221	chr14:68749962	RAD51L1	-0.36	-6.47	-0.39	5.69e-10	Primary biliary cholangitis;
SARC	cis	rs896854	0.738	rs2515226	chr8:95965743	G/A	cg09323728	chr8:95962352	TP53INP1	0.29	4.76	0.3	3.33e-6	Type 2 diabetes;
SARC	cis	rs2115630	0.902	rs8023276	chr15:85219638	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.48	-5.82	-0.36	1.95e-8	P wave terminal force;
SARC	cis	rs1878931	0.582	rs9921152	chr16:3421199	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.68	7.72	0.45	3.36e-13	Body mass index (adult);
SARC	cis	rs4851254	0.660	rs56037757	chr2:100690130	A/G	cg17356467	chr2:100759845	AFF3	0.33	4.8	0.3	2.9e-6	Intelligence (multi-trait analysis);
SARC	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg12564285	chr5:131593104	PDLIM4	0.44	6.06	0.37	5.32e-9	Acylcarnitine levels;
SARC	cis	rs11864453	0.826	rs6499560	chr16:72147666	G/T	cg16558253	chr16:72132732	DHX38	0.57	9.35	0.52	7.51e-18	Fibrinogen levels;
SARC	cis	rs4689388	0.853	rs6446479	chr4:6291737	G/C	cg14416269	chr4:6271139	WFS1	0.33	4.99	0.31	1.18e-6	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs12421382	0.659	rs12417251	chr11:109386273	G/T	cg16359550	chr11:109292809	C11orf87	0.38	5.47	0.34	1.14e-7	Schizophrenia;
SARC	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs17376456	0.825	rs17372649	chr5:93126096	C/G	cg25358565	chr5:93447407	FAM172A	1.18	12.07	0.62	2.21e-26	Diabetic retinopathy;
SARC	cis	rs11155671	0.530	rs7768626	chr6:150207962	G/T	cg09699651	chr6:150184138	LRP11	0.51	6.55	0.39	3.7e-10	Testicular germ cell tumor;
SARC	cis	rs4481887	0.800	rs10788780	chr1:248483598	G/A	cg13385794	chr1:248469461	NA	0.34	5.22	0.32	3.88e-7	Common traits (Other);
SARC	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg00933542	chr6:150070202	PCMT1	0.29	4.96	0.31	1.34e-6	Lung cancer;
SARC	cis	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg22857025	chr5:266934	NA	-1.06	-11.8	-0.61	1.74e-25	Breast cancer;
SARC	cis	rs4972806	0.849	rs1542180	chr2:177028767	C/T	cg14236662	chr2:176988284	HOXD9	0.38	5.33	0.33	2.32e-7	IgG glycosylation;
SARC	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg11764359	chr7:65958608	NA	-0.87	-12.67	-0.64	2.52e-28	Aortic root size;
SARC	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg08280861	chr8:58055591	NA	0.58	5.63	0.35	5.17e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9916302	0.904	rs11867312	chr17:37597748	C/T	cg20243544	chr17:37824526	PNMT	0.56	6.69	0.4	1.68e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs7927771	1.000	rs9909	chr11:47799775	C/G	cg20307385	chr11:47447363	PSMC3	-0.47	-5.59	-0.34	6.3e-8	Subjective well-being;
SARC	cis	rs834603	0.710	rs11761475	chr7:47444807	C/T	cg23694490	chr7:47445681	TNS3	0.37	6.6	0.4	2.71e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs3784262	0.669	rs12915508	chr15:58302036	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.34	-5.21	-0.32	4.21e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs9640161	0.750	rs3800780	chr7:150027284	C/A	cg21361702	chr7:150065534	REPIN1	0.53	5.42	0.33	1.5e-7	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg24549020	chr5:56110836	MAP3K1	0.83	8.59	0.49	1.23e-15	Initial pursuit acceleration;
SARC	cis	rs9393692	0.905	rs7746807	chr6:26293338	C/A	cg00631329	chr6:26305371	NA	-0.63	-9.11	-0.51	3.86e-17	Educational attainment;
SARC	cis	rs7666738	0.830	rs4699603	chr4:99056172	T/C	cg05340658	chr4:99064831	C4orf37	0.64	8.68	0.49	7.17e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs367615	0.679	rs4259216	chr5:108841817	A/G	cg17395555	chr5:108820864	NA	0.47	6.75	0.4	1.13e-10	Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs854765	0.583	rs28428991	chr17:17827649	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.43	5.57	0.34	7.01e-8	Total body bone mineral density;
SARC	cis	rs3825932	1.000	rs3825932	chr15:79235446	A/G	cg25744700	chr15:79237217	CTSH	0.37	5.06	0.31	8.65e-7	Type 1 diabetes;
SARC	cis	rs703842	0.964	rs10431552	chr12:58178148	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.78	11.39	0.6	3.43e-24	Multiple sclerosis;
SARC	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg27541892	chr1:1571801	CDK11B	0.41	5.56	0.34	7.31e-8	Body mass index;
SARC	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg22535103	chr8:58192502	C8orf71	-0.73	-7.24	-0.43	6.52e-12	Developmental language disorder (linguistic errors);
SARC	trans	rs61931739	0.500	rs11053140	chr12:34316122	T/C	cg13010199	chr12:38710504	ALG10B	0.75	10.02	0.55	7.16e-20	Morning vs. evening chronotype;
SARC	cis	rs2486288	0.656	rs11631021	chr15:45556829	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.56	-7.32	-0.43	3.91e-12	Glomerular filtration rate;
SARC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg22535103	chr8:58192502	C8orf71	-0.59	-6.21	-0.38	2.35e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg03735888	chr19:58951602	ZNF132	0.39	5.19	0.32	4.58e-7	Uric acid clearance;
SARC	cis	rs17376456	0.877	rs10044066	chr5:93437580	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.79	0.35	2.3e-8	Diabetic retinopathy;
SARC	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg11987759	chr7:65425863	GUSB	0.51	6.55	0.39	3.69e-10	Aortic root size;
SARC	cis	rs10892173	0.765	rs1892903	chr11:117669619	A/G	cg21640587	chr11:117668038	DSCAML1	0.48	6.87	0.41	5.91e-11	Myopia;
SARC	cis	rs72627509	0.857	rs2227901	chr4:57798189	A/G	cg26694713	chr4:57773883	REST	-0.64	-6.69	-0.4	1.6e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	6.07	0.37	5.03e-9	Prudent dietary pattern;
SARC	cis	rs6772849	1.000	rs6772849	chr3:128306418	T/C	cg08795948	chr3:128337044	NA	0.38	4.99	0.31	1.16e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.34	-5.15	-0.32	5.55e-7	Total body bone mineral density;
SARC	cis	rs2806561	0.765	rs1757046	chr1:23511821	T/C	cg12483005	chr1:23474871	LUZP1	0.42	5.41	0.33	1.53e-7	Height;
SARC	cis	rs2153535	0.601	rs9505473	chr6:8538777	T/C	cg07606381	chr6:8435919	SLC35B3	0.77	10.96	0.58	7.97e-23	Motion sickness;
SARC	cis	rs2075371	0.966	rs1901204	chr7:133985896	A/G	cg11752832	chr7:134001865	SLC35B4	0.59	7.66	0.45	5.02e-13	Mean platelet volume;
SARC	cis	rs2153535	0.601	rs4960414	chr6:8438541	A/G	cg07606381	chr6:8435919	SLC35B3	0.78	11.09	0.59	3.11e-23	Motion sickness;
SARC	cis	rs918629	0.798	rs2548595	chr5:95284341	C/T	cg16656078	chr5:95278638	ELL2	-0.63	-7.66	-0.45	5.03e-13	IgG glycosylation;
SARC	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.44	7.07	0.42	1.84e-11	Schizophrenia;
SARC	cis	rs7590368	0.779	rs3856465	chr2:10916670	C/T	cg25617230	chr2:10952979	PDIA6	0.5	5.04	0.31	9.48e-7	Educational attainment (years of education);
SARC	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.98	10.61	0.57	1.02e-21	Platelet count;
SARC	trans	rs2727020	0.729	rs1164685	chr11:49293660	G/A	cg15704280	chr7:45808275	SEPT13	0.83	13.67	0.67	1.22e-31	Coronary artery disease;
SARC	cis	rs8072100	0.905	rs11651766	chr17:45574931	G/T	cg08085267	chr17:45401833	C17orf57	-0.42	-4.91	-0.31	1.74e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg01316550	chr5:56110833	MAP3K1	0.54	4.92	0.31	1.62e-6	Initial pursuit acceleration;
SARC	cis	rs6940638	0.688	rs1028308	chr6:27129757	G/A	cg12826209	chr6:26865740	GUSBL1	0.55	6.01	0.37	6.91e-9	Intelligence (multi-trait analysis);
SARC	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg12311346	chr5:56204834	C5orf35	-0.57	-6.06	-0.37	5.4e-9	Initial pursuit acceleration;
SARC	cis	rs12142240	0.660	rs7520497	chr1:46824919	C/A	cg14993813	chr1:46806288	NSUN4	-0.51	-5.34	-0.33	2.19e-7	Menopause (age at onset);
SARC	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.51	6.55	0.39	3.61e-10	Personality dimensions;
SARC	cis	rs75804782	0.690	rs56198112	chr2:239348887	A/G	cg21699342	chr2:239360505	ASB1	-0.58	-4.81	-0.3	2.68e-6	Morning vs. evening chronotype;Chronotype;
SARC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.67	0.54	8.17e-19	Prudent dietary pattern;
SARC	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg24060327	chr5:131705240	SLC22A5	-0.71	-8.69	-0.49	6.4e-16	Breast cancer;
SARC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs611744	0.967	rs652485	chr8:109202696	G/A	cg21045802	chr8:109455806	TTC35	0.45	5.32	0.33	2.43e-7	Dupuytren's disease;
SARC	cis	rs6964587	1.000	rs7802788	chr7:91736874	A/G	cg17063962	chr7:91808500	NA	0.96	16.59	0.74	2.42e-41	Breast cancer;
SARC	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg08219700	chr8:58056026	NA	0.61	6.36	0.38	1.05e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs898097	0.841	rs9896263	chr17:80902741	A/G	cg20578329	chr17:80767326	TBCD	0.47	6.57	0.4	3.19e-10	Breast cancer;
SARC	trans	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg00938859	chr5:1591904	SDHAP3	0.79	7.66	0.45	5.1e-13	Breast cancer;
SARC	cis	rs9916302	0.706	rs4516267	chr17:37471482	G/T	cg07936489	chr17:37558343	FBXL20	0.75	8.92	0.5	1.37e-16	Glomerular filtration rate (creatinine);
SARC	trans	rs9650657	0.769	rs6601527	chr8:10665444	C/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.5	-0.39	4.8e-10	Neuroticism;
SARC	cis	rs11638352	1.000	rs7166715	chr15:44417606	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.77	-5.84	-0.36	1.78e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	cis	rs10861342	0.892	rs10459207	chr12:105531072	C/T	cg23923672	chr12:105501055	KIAA1033	0.76	5.88	0.36	1.39e-8	IgG glycosylation;
SARC	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg11890956	chr21:40555474	PSMG1	-0.67	-8.81	-0.5	2.86e-16	Menarche (age at onset);
SARC	cis	rs7568458	0.636	rs11126995	chr2:85792408	A/T	cg23752985	chr2:85803571	VAMP8	0.43	5.41	0.33	1.57e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs79149102	0.579	rs8031545	chr15:75290496	T/C	cg17294928	chr15:75287854	SCAMP5	-0.99	-8.87	-0.5	1.91e-16	Lung cancer;
SARC	cis	rs710216	0.843	rs3768043	chr1:43419354	C/A	cg03128534	chr1:43423976	SLC2A1	-0.62	-6.81	-0.41	8.18e-11	Red cell distribution width;
SARC	cis	rs4891159	0.790	rs35516239	chr18:74129942	C/T	cg24786174	chr18:74118243	ZNF516	-0.65	-9.64	-0.53	1e-18	Longevity;
SARC	cis	rs870825	0.860	rs72689295	chr4:185600930	T/C	cg04058563	chr4:185651563	MLF1IP	0.8	9.84	0.54	2.51e-19	Blood protein levels;
SARC	cis	rs9875589	0.509	rs4685062	chr3:14066409	T/C	cg19554555	chr3:13937349	NA	-0.4	-5.14	-0.32	5.95e-7	Ovarian reserve;
SARC	cis	rs9486719	1.000	rs9373978	chr6:97056255	T/C	cg18709589	chr6:96969512	KIAA0776	-0.57	-5.71	-0.35	3.45e-8	Migraine;Coronary artery disease;
SARC	cis	rs2304069	0.545	rs7445660	chr5:149413610	A/C	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.42	4.73	0.3	3.81e-6	HIV-1 control;
SARC	cis	rs9398803	0.830	rs1415671	chr6:126759587	T/G	cg20229609	chr6:126660872	C6orf173	0.4	5.73	0.35	3.09e-8	Male-pattern baldness;
SARC	cis	rs6582630	0.638	rs12831496	chr12:38552604	G/A	cg26384229	chr12:38710491	ALG10B	-0.57	-7.24	-0.43	6.33e-12	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.61	-6.2	-0.38	2.5e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs11191193	0.686	rs10883699	chr10:103715522	A/T	cg15320455	chr10:103880129	LDB1	-0.57	-6.15	-0.37	3.4e-9	Educational attainment;
SARC	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg21782813	chr7:2030301	MAD1L1	0.39	6.2	0.38	2.57e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs9611519	0.754	rs4820435	chr22:41652846	G/T	cg17376030	chr22:41985996	PMM1	0.6	7.32	0.43	3.92e-12	Neuroticism;
SARC	cis	rs8141529	0.529	rs5752796	chr22:29178856	G/A	cg02153584	chr22:29168773	CCDC117	0.66	6.71	0.4	1.44e-10	Lymphocyte counts;
SARC	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg11301795	chr4:187892539	NA	-0.7	-10.5	-0.57	2.28e-21	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg13206674	chr6:150067644	NUP43	0.42	5.41	0.33	1.59e-7	Lung cancer;
SARC	cis	rs595982	0.527	rs12151238	chr19:49368613	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.65	-7.34	-0.43	3.65e-12	Red cell distribution width;
SARC	cis	rs2153535	0.563	rs1796687	chr6:8536118	C/G	cg21535247	chr6:8435926	SLC35B3	0.53	6.25	0.38	1.89e-9	Motion sickness;
SARC	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg03709012	chr19:19516395	GATAD2A	1.0	17.2	0.75	2.27e-43	Tonsillectomy;
SARC	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg07308232	chr7:1071921	C7orf50	-0.55	-7.0	-0.42	2.69e-11	Longevity;Endometriosis;
SARC	cis	rs7940866	0.903	rs7942900	chr11:130839244	G/A	cg12179176	chr11:130786555	SNX19	0.64	8.51	0.49	2.21e-15	Schizophrenia;
SARC	cis	rs9815354	0.857	rs1474219	chr3:42000913	G/A	cg03022575	chr3:42003672	ULK4	-0.59	-5.67	-0.35	4.16e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2712184	0.756	rs2712161	chr2:217662384	G/A	cg05032264	chr2:217675019	NA	-0.49	-6.44	-0.39	6.59e-10	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
SARC	cis	rs2404602	0.647	rs920712	chr15:77033934	G/A	cg15268244	chr15:77196840	NA	0.42	4.91	0.31	1.74e-6	Blood metabolite levels;
SARC	cis	rs854765	0.547	rs4072739	chr17:17884660	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.43	5.31	0.33	2.5e-7	Total body bone mineral density;
SARC	cis	rs2070677	1.000	rs2070677	chr10:135351174	A/T	cg20169779	chr10:135381914	SYCE1	-0.42	-5.72	-0.35	3.32e-8	Gout;
SARC	cis	rs13314892	0.764	rs55890624	chr3:69858976	G/A	cg17445875	chr3:69859618	MITF	-0.48	-5.03	-0.31	9.72e-7	QRS complex (12-leadsum);
SARC	cis	rs9911578	0.933	rs11868348	chr17:57179238	C/T	cg20303301	chr17:57937339	TUBD1	-0.34	-4.87	-0.3	2.04e-6	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg18252515	chr7:66147081	NA	0.48	5.14	0.32	5.88e-7	Aortic root size;
SARC	cis	rs995000	0.899	rs1168030	chr1:62968491	C/T	cg06896770	chr1:63153194	DOCK7	-0.89	-12.99	-0.65	2.12e-29	Triglyceride levels;
SARC	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg05025164	chr4:1340916	KIAA1530	0.59	7.28	0.43	5.07e-12	Longevity;
SARC	cis	rs748404	0.723	rs560134	chr15:43555699	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	6.69	0.4	1.61e-10	Lung cancer;
SARC	cis	rs35213789	0.881	rs12698826	chr7:69425893	T/G	cg10619644	chr7:69149951	AUTS2	0.45	5.54	0.34	8.25e-8	Childhood ear infection;
SARC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg11494091	chr17:61959527	GH2	0.53	8.02	0.47	5.12e-14	Prudent dietary pattern;
SARC	cis	rs7582720	1.000	rs72926769	chr2:203798318	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs12142240	0.698	rs66972124	chr1:46807445	A/G	cg00530320	chr1:46809349	NSUN4	0.55	6.71	0.4	1.47e-10	Menopause (age at onset);
SARC	cis	rs6912958	0.781	rs9444519	chr6:88290398	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-6.8	-0.41	8.58e-11	Monocyte percentage of white cells;
SARC	cis	rs7779181	0.556	rs10951330	chr7:32353777	C/A	cg16719466	chr7:32338569	NA	-0.65	-5.24	-0.32	3.61e-7	Body mass index;
SARC	cis	rs6591182	0.504	rs7130955	chr11:65372580	C/T	cg27068330	chr11:65405492	SIPA1	-0.45	-5.52	-0.34	9.12e-8	Non-alcoholic fatty liver disease histology (lobular);
SARC	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg02725872	chr8:58115012	NA	-0.33	-5.33	-0.33	2.33e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2235544	0.565	rs665421	chr1:54469883	T/C	cg10336722	chr1:54665764	CYB5RL;MRPL37	-0.39	-4.81	-0.3	2.75e-6	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
SARC	cis	rs3740540	0.507	rs897293	chr10:126290050	T/G	cg04949429	chr10:126290192	LHPP	0.42	5.84	0.36	1.75e-8	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg13866156	chr1:1669148	SLC35E2	-0.63	-9.43	-0.53	4.22e-18	Body mass index;
SARC	cis	rs2153535	0.580	rs9378554	chr6:8488468	C/T	cg07606381	chr6:8435919	SLC35B3	0.78	11.09	0.59	3.13e-23	Motion sickness;
SARC	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.86	-11.99	-0.62	4.04e-26	Gut microbiome composition (summer);
SARC	cis	rs7553864	0.966	rs4529687	chr1:87614083	T/C	cg17420885	chr1:87600446	LOC339524	-0.32	-4.74	-0.3	3.76e-6	Smoking behavior;
SARC	cis	rs3126085	0.935	rs4845733	chr1:152162568	T/C	cg26876637	chr1:152193138	HRNR	0.5	5.67	0.35	4.14e-8	Atopic dermatitis;
SARC	cis	rs7011049	1.000	rs74457055	chr8:53842669	T/G	cg26025543	chr8:53854495	NA	0.6	5.43	0.34	1.42e-7	Systolic blood pressure;
SARC	cis	rs916888	0.610	rs142167	chr17:44795234	C/T	cg01570182	chr17:44337453	NA	-0.6	-7.05	-0.42	2e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg18876405	chr7:65276391	NA	0.47	5.72	0.35	3.3e-8	Aortic root size;
SARC	cis	rs4688759	0.719	rs73079018	chr3:49875327	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.62	-5.1	-0.32	7.15e-7	Blood protein levels;
SARC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.53	6.77	0.41	1.04e-10	Lymphocyte counts;
SARC	cis	rs1707322	0.691	rs12031182	chr1:46220999	C/T	cg03146154	chr1:46216737	IPP	0.53	6.37	0.39	1.01e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7566780	0.661	rs4393752	chr2:16652659	T/C	cg09580478	chr2:16689509	NA	0.51	5.97	0.36	8.84e-9	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs4974559	0.739	rs10032327	chr4:1323537	C/T	cg02980000	chr4:1222292	CTBP1	0.72	5.31	0.33	2.57e-7	Systolic blood pressure;
SARC	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg03999130	chr15:45571217	NA	0.39	5.09	0.32	7.55e-7	Homoarginine levels;
SARC	cis	rs9916302	0.861	rs8081033	chr17:37506650	A/G	cg15445000	chr17:37608096	MED1	-0.44	-5.39	-0.33	1.71e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs838147	0.537	rs504963	chr19:49208865	G/A	cg21064579	chr19:49206444	FUT2	0.35	4.89	0.31	1.84e-6	Dietary macronutrient intake;
SARC	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg02018176	chr4:1364513	KIAA1530	0.35	5.01	0.31	1.09e-6	Obesity-related traits;
SARC	cis	rs6502050	0.787	rs62078746	chr17:80053590	G/A	cg19223190	chr17:80058835	NA	-0.44	-6.32	-0.38	1.32e-9	Life satisfaction;
SARC	cis	rs8072100	0.666	rs6503804	chr17:45772447	G/A	cg08085267	chr17:45401833	C17orf57	-0.44	-5.15	-0.32	5.55e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg11764359	chr7:65958608	NA	0.88	12.58	0.64	4.89e-28	Aortic root size;
SARC	cis	rs7829975	0.522	rs6601689	chr8:8172283	C/T	cg08975724	chr8:8085496	FLJ10661	0.49	5.96	0.36	9.06e-9	Mood instability;
SARC	cis	rs2599510	0.811	rs176413	chr2:32646847	G/A	cg02381751	chr2:32503542	YIPF4	-0.49	-6.17	-0.37	2.93e-9	Interleukin-18 levels;
SARC	cis	rs8017423	0.967	rs28424204	chr14:90705669	G/C	cg20276874	chr14:90721474	PSMC1	-0.36	-5.03	-0.31	9.98e-7	Mortality in heart failure;
SARC	cis	rs9398803	0.965	rs17754780	chr6:126664333	C/T	cg19875578	chr6:126661172	C6orf173	0.6	8.17	0.47	1.96e-14	Male-pattern baldness;
SARC	cis	rs9899728	0.520	rs12936866	chr17:73052050	A/G	cg27626185	chr17:73056755	KCTD2	-0.92	-7.75	-0.45	2.86e-13	Alzheimer's disease or small vessel stroke;
SARC	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg25894440	chr7:65020034	NA	-0.72	-5.46	-0.34	1.23e-7	Diabetic kidney disease;
SARC	cis	rs2228479	0.850	rs62054224	chr16:89892071	C/T	cg00800038	chr16:89945340	TCF25	-0.82	-5.77	-0.35	2.46e-8	Skin colour saturation;
SARC	cis	rs910316	1.000	rs1047418	chr14:75605792	A/G	cg11812906	chr14:75593930	NEK9	0.86	13.44	0.66	7.23e-31	Height;
SARC	cis	rs2594989	0.887	rs2616535	chr3:11595167	A/G	cg00170343	chr3:11313890	ATG7	0.53	5.26	0.33	3.23e-7	Circulating chemerin levels;
SARC	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg20607798	chr8:58055168	NA	0.61	5.41	0.33	1.57e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs3749237	0.595	rs1464567	chr3:49459252	C/G	cg07636037	chr3:49044803	WDR6	-0.67	-8.52	-0.49	1.97e-15	Resting heart rate;
SARC	cis	rs4917300	0.659	rs11167110	chr8:143097423	A/G	cg06573787	chr8:143070187	NA	0.44	6.04	0.37	5.94e-9	Amyotrophic lateral sclerosis;
SARC	cis	rs17376456	0.877	rs17083462	chr5:93462401	T/G	cg21475434	chr5:93447410	FAM172A	0.88	8.11	0.47	2.81e-14	Diabetic retinopathy;
SARC	cis	rs1707322	0.638	rs9429095	chr1:46603348	A/C	cg03146154	chr1:46216737	IPP	-0.41	-4.91	-0.31	1.68e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs651907	0.535	rs11717638	chr3:101505468	A/G	cg12386194	chr3:101231763	SENP7	0.49	5.62	0.35	5.36e-8	Colorectal cancer;
SARC	cis	rs820218	0.892	rs820215	chr17:73693810	A/G	cg01592526	chr17:73663357	RECQL5;SAP30BP	-0.67	-8.83	-0.5	2.51e-16	Rotator cuff tears;
SARC	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg17221315	chr6:27791827	HIST1H4J	0.45	4.95	0.31	1.41e-6	Cardiac Troponin-T levels;
SARC	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg05861140	chr6:150128134	PCMT1	-0.41	-5.34	-0.33	2.19e-7	Lung cancer;
SARC	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg08859206	chr1:53392774	SCP2	-0.35	-5.07	-0.32	8.1e-7	Monocyte count;
SARC	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg12756686	chr19:29218302	NA	0.68	8.99	0.51	8.47e-17	Methadone dose in opioid dependence;
SARC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg26338869	chr17:61819248	STRADA	0.8	10.67	0.57	6.8e-22	Prudent dietary pattern;
SARC	cis	rs17376456	0.825	rs28412976	chr5:93248377	T/C	cg25358565	chr5:93447407	FAM172A	1.3	14.17	0.68	2.82e-33	Diabetic retinopathy;
SARC	cis	rs9733	0.596	rs7412396	chr1:150666797	C/T	cg13175981	chr1:150552382	MCL1	-0.54	-5.81	-0.36	2.08e-8	Tonsillectomy;
SARC	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg00149659	chr3:10157352	C3orf10	0.64	5.82	0.36	1.97e-8	Alzheimer's disease;
SARC	cis	rs8141529	0.871	rs5762877	chr22:29277555	G/A	cg02153584	chr22:29168773	CCDC117	0.79	11.32	0.6	6.02e-24	Lymphocyte counts;
SARC	cis	rs2011503	0.714	rs7250233	chr19:19630948	C/T	cg15839431	chr19:19639596	YJEFN3	-0.48	-4.77	-0.3	3.32e-6	Bipolar disorder;
SARC	cis	rs2153535	0.504	rs5001323	chr6:8451605	C/T	cg23788917	chr6:8435910	SLC35B3	0.64	8.43	0.48	3.62e-15	Motion sickness;
SARC	cis	rs7412746	0.634	rs12562939	chr1:150951452	A/C	cg13175981	chr1:150552382	MCL1	-0.46	-5.45	-0.34	1.28e-7	Melanoma;
SARC	cis	rs2645694	0.626	rs2703151	chr4:77834095	A/G	cg10057126	chr4:77819792	ANKRD56	0.41	6.1	0.37	4.37e-9	Emphysema distribution in smoking;
SARC	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg13206674	chr6:150067644	NUP43	0.45	5.83	0.36	1.86e-8	Lung cancer;
SARC	cis	rs72634258	0.572	rs66692705	chr1:7938565	T/C	cg00042356	chr1:8021962	PARK7	0.64	5.46	0.34	1.2e-7	Inflammatory bowel disease;
SARC	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg26597838	chr10:835615	NA	-1.02	-10.3	-0.56	9.35e-21	Eosinophil percentage of granulocytes;
SARC	cis	rs10886503	0.777	rs7101354	chr10:121267016	C/T	cg17804342	chr10:121271663	RGS10	0.53	4.81	0.3	2.69e-6	Obstetric antiphospholipid syndrome;
SARC	cis	rs9818758	0.607	rs34784192	chr3:49274823	G/T	cg07636037	chr3:49044803	WDR6	-0.76	-6.77	-0.41	1.03e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg15320075	chr8:145703422	NA	0.68	9.38	0.52	5.92e-18	Age at first birth;
SARC	cis	rs7681440	0.967	rs920624	chr4:90748195	T/A	cg06632027	chr4:90757378	SNCA	0.39	5.57	0.34	7.02e-8	Dementia with Lewy bodies;
SARC	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg16049864	chr8:95962084	TP53INP1	-0.52	-8.51	-0.49	2.09e-15	Type 2 diabetes;
SARC	cis	rs9815354	1.000	rs1564716	chr3:41862613	A/G	cg03022575	chr3:42003672	ULK4	0.57	5.33	0.33	2.34e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6058796	0.892	rs34894833	chr20:31247154	G/A	cg13636640	chr20:31349939	DNMT3B	0.52	4.79	0.3	2.97e-6	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
SARC	trans	rs61931739	0.534	rs2636082	chr12:34061848	T/A	cg26384229	chr12:38710491	ALG10B	0.73	10.39	0.56	4.9e-21	Morning vs. evening chronotype;
SARC	cis	rs4595586	0.545	rs1607042	chr12:39368028	A/G	cg26384229	chr12:38710491	ALG10B	0.51	6.25	0.38	1.9e-9	Morning vs. evening chronotype;
SARC	cis	rs35110281	0.744	rs230646	chr21:44918788	A/G	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.04	-0.37	6.16e-9	Mean corpuscular volume;
SARC	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg04287289	chr16:89883240	FANCA	0.89	15.05	0.7	3.15e-36	Vitiligo;
SARC	cis	rs780094	0.585	rs3739095	chr2:27556721	C/T	cg21747090	chr2:27597821	SNX17	-0.52	-7.18	-0.43	9.04e-12	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs3782089	1.000	rs1194337	chr11:65259471	C/T	cg00206168	chr11:65308501	LTBP3	0.69	4.82	0.3	2.54e-6	Height;
SARC	cis	rs7216064	0.601	rs35453056	chr17:66039668	A/G	cg12091567	chr17:66097778	LOC651250	0.93	12.18	0.62	9.86e-27	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs10992471	0.528	rs6479423	chr9:95265580	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.43	-4.9	-0.31	1.8e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs1843834	0.929	rs4674934	chr2:225516468	A/T	cg22455342	chr2:225449267	CUL3	-0.43	-5.72	-0.35	3.33e-8	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs950169	0.580	rs11633762	chr15:85187152	T/C	cg17507749	chr15:85114479	UBE2QP1	0.6	6.89	0.41	5.27e-11	Schizophrenia;
SARC	cis	rs8084125	0.832	rs62105182	chr18:74951407	T/C	cg19705131	chr18:74961163	GALR1	0.42	4.75	0.3	3.55e-6	Obesity-related traits;
SARC	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg06420487	chr17:61919686	SMARCD2	0.44	4.91	0.31	1.68e-6	Height;
SARC	cis	rs4975709	0.610	rs6886669	chr5:1867830	T/C	cg14773178	chr5:1868261	NA	0.3	4.74	0.3	3.72e-6	Cardiovascular disease risk factors;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg12538597	chr11:85906334	NA	-0.47	-6.31	-0.38	1.42e-9	Electrocardiographic conduction measures;
SARC	cis	rs10752881	1.000	rs10797807	chr1:182978873	T/C	cg13390022	chr1:182993471	LAMC1	0.33	5.06	0.31	8.36e-7	Colorectal cancer;
SARC	cis	rs10493773	0.618	rs34746573	chr1:86075360	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.46	-6.26	-0.38	1.83e-9	Urate levels in overweight individuals;
SARC	cis	rs4713675	0.565	rs4711341	chr6:33690797	A/G	cg15676125	chr6:33679581	C6orf125	0.51	6.22	0.38	2.27e-9	Plateletcrit;
SARC	cis	rs9840812	0.906	rs61791757	chr3:135905325	G/A	cg15507776	chr3:136538369	TMEM22	-0.51	-5.09	-0.32	7.43e-7	Fibrinogen levels;
SARC	trans	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.05	-0.42	2.06e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs13343954	0.825	rs7254716	chr19:33532128	T/C	cg17764715	chr19:33622953	WDR88	0.5	5.44	0.34	1.34e-7	Colorectal cancer;
SARC	cis	rs9790314	0.967	rs7623206	chr3:160971518	G/A	cg03342759	chr3:160939853	NMD3	-0.61	-7.73	-0.45	3.22e-13	Morning vs. evening chronotype;
SARC	cis	rs6912958	0.547	rs451089	chr6:88041859	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.33	5.84	0.36	1.77e-8	Monocyte percentage of white cells;
SARC	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg11987759	chr7:65425863	GUSB	0.48	5.94	0.36	1.06e-8	Aortic root size;
SARC	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg15506890	chr2:3487001	NA	-0.44	-5.79	-0.35	2.22e-8	Neurofibrillary tangles;
SARC	cis	rs2204008	0.805	rs11522896	chr12:38234427	T/C	cg13010199	chr12:38710504	ALG10B	0.81	11.19	0.59	1.51e-23	Bladder cancer;
SARC	cis	rs6088580	0.634	rs3746455	chr20:32957216	G/A	cg08999081	chr20:33150536	PIGU	-0.45	-6.77	-0.41	1.02e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.8	8.0	0.46	5.8e-14	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs881375	0.669	rs73541868	chr9:123639264	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.54	7.27	0.43	5.43e-12	Rheumatoid arthritis;
SARC	trans	rs11098499	0.863	rs3775847	chr4:120447642	A/C	cg25214090	chr10:38739885	LOC399744	0.57	7.35	0.43	3.31e-12	Corneal astigmatism;
SARC	cis	rs6866344	0.697	rs56159071	chr5:178127246	T/A	cg10224037	chr5:178157518	ZNF354A	0.99	11.97	0.62	4.81e-26	Neutrophil percentage of white cells;
SARC	cis	rs1670533	1.000	rs10031302	chr4:1059664	G/A	cg27284194	chr4:1044797	NA	0.45	4.86	0.3	2.18e-6	Recombination rate (females);
SARC	cis	rs597539	0.521	rs2060982	chr11:68612927	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.44	5.64	0.35	4.8e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs16937	0.662	rs10900456	chr1:205145005	C/T	cg21643547	chr1:205240462	TMCC2	-0.43	-5.22	-0.32	3.94e-7	Schizophrenia;
SARC	cis	rs9393692	0.875	rs12526215	chr6:26262916	T/C	cg13736514	chr6:26305472	NA	-0.62	-8.52	-0.49	2.01e-15	Educational attainment;
SARC	cis	rs6582630	0.539	rs12308081	chr12:38342881	C/G	cg13010199	chr12:38710504	ALG10B	-0.49	-5.91	-0.36	1.21e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2235544	0.565	rs7513522	chr1:54465705	A/G	cg10336722	chr1:54665764	CYB5RL;MRPL37	-0.39	-4.8	-0.3	2.82e-6	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
SARC	cis	rs10463554	0.926	rs26429	chr5:102366053	C/T	cg23492399	chr5:102201601	PAM	0.46	5.15	0.32	5.45e-7	Parkinson's disease;
SARC	cis	rs7937682	0.847	rs11213948	chr11:111464401	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.93	-14.06	-0.68	6.32e-33	Primary sclerosing cholangitis;
SARC	cis	rs858239	1.000	rs858239	chr7:23286315	G/A	cg23682824	chr7:23144976	KLHL7	0.62	7.66	0.45	4.83e-13	Cerebrospinal fluid biomarker levels;
SARC	cis	rs7727544	0.636	rs2631365	chr5:131705949	T/C	cg07395648	chr5:131743802	NA	0.41	4.82	0.3	2.63e-6	Blood metabolite levels;
SARC	cis	rs3733585	0.605	rs4235355	chr4:10123078	C/A	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.27	-0.33	3.11e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs1355223	0.902	rs12802323	chr11:34747739	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-5.94	-0.36	1.06e-8	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs9902453	0.730	rs4583306	chr17:28538715	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.47	-5.83	-0.36	1.8e-8	Coffee consumption (cups per day);
SARC	cis	rs2425143	1.000	rs7264414	chr20:34446826	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.67	5.43	0.34	1.42e-7	Blood protein levels;
SARC	cis	rs12200782	0.530	rs9379892	chr6:26582414	G/A	cg11502198	chr6:26597334	ABT1	0.74	7.77	0.45	2.56e-13	Small cell lung carcinoma;
SARC	cis	rs7084402	0.967	rs1658459	chr10:60299246	C/A	cg07615347	chr10:60278583	BICC1	0.59	8.77	0.5	3.93e-16	Refractive error;
SARC	cis	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg18252515	chr7:66147081	NA	-1.38	-12.57	-0.64	5.19e-28	Diabetic kidney disease;
SARC	cis	rs17539620	0.624	rs62432737	chr6:154834772	G/A	cg20019720	chr6:154832845	CNKSR3	0.42	4.93	0.31	1.57e-6	Lipoprotein (a) levels;
SARC	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7412746	0.658	rs7521719	chr1:150913134	G/A	cg10589385	chr1:150898437	SETDB1	0.42	5.64	0.35	4.91e-8	Melanoma;
SARC	cis	rs67133203	0.606	rs11169729	chr12:51558955	T/C	cg15029631	chr12:52078762	SCN8A	-0.42	-4.84	-0.3	2.39e-6	Urinary tract infection frequency;
SARC	trans	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.55	7.09	0.42	1.62e-11	Intelligence (multi-trait analysis);
SARC	cis	rs9457247	0.765	rs9457249	chr6:167426438	A/G	cg23791538	chr6:167370224	RNASET2	-0.54	-7.05	-0.42	1.96e-11	Crohn's disease;
SARC	cis	rs637571	0.522	rs649000	chr11:65742933	T/C	cg04055107	chr11:65626734	MUS81;CFL1	0.41	5.07	0.32	8.06e-7	Eosinophil percentage of white cells;
SARC	cis	rs11770686	0.666	rs2260430	chr7:75308473	A/G	cg17787366	chr7:75369077	HIP1	0.39	5.03	0.31	9.98e-7	Essential tremor;
SARC	cis	rs1670533	1.000	rs6827357	chr4:1059202	A/C	cg27284194	chr4:1044797	NA	0.47	4.92	0.31	1.61e-6	Recombination rate (females);
SARC	cis	rs6087990	1.000	rs1007123	chr20:31345840	G/A	cg13636640	chr20:31349939	DNMT3B	0.81	12.8	0.64	9.27e-29	Ulcerative colitis;
SARC	cis	rs6840360	1.000	rs1355413	chr4:152633667	C/T	cg22705602	chr4:152727874	NA	-0.38	-6.6	-0.4	2.74e-10	Intelligence (multi-trait analysis);
SARC	cis	rs908922	0.676	rs945789	chr1:152512705	C/A	cg09873164	chr1:152488093	CRCT1	0.65	8.66	0.49	7.93e-16	Hair morphology;
SARC	cis	rs763121	0.853	rs5750622	chr22:38956464	C/G	cg21395723	chr22:39101663	GTPBP1	0.58	6.62	0.4	2.44e-10	Menopause (age at onset);
SARC	cis	rs9303401	0.659	rs56162835	chr17:56687315	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	12.72	0.64	1.64e-28	Cognitive test performance;
SARC	cis	rs2014572	0.967	rs8111977	chr19:57759158	T/A	cg24459738	chr19:57751996	ZNF805	-0.46	-5.46	-0.34	1.23e-7	Hyperactive-impulsive symptoms;
SARC	cis	rs1270639	0.778	rs2530403	chr7:157445639	C/T	cg13357408	chr7:157437802	PTPRN2	0.45	4.85	0.3	2.21e-6	Colorectal cancer;
SARC	cis	rs4924590	0.531	rs2114477	chr15:42227441	C/T	cg20935245	chr15:42234343	EHD4	-0.45	-5.86	-0.36	1.61e-8	Lymphocyte percentage of white cells;Sum basophil neutrophil counts;Granulocyte count;
SARC	cis	rs910316	0.789	rs12894419	chr14:75471802	C/T	cg06637938	chr14:75390232	RPS6KL1	0.43	5.69	0.35	3.8e-8	Height;
SARC	cis	rs10905065	0.610	rs55913768	chr10:5749449	G/A	cg09072322	chr10:5726702	C10orf18	0.43	4.86	0.3	2.13e-6	Menopause (age at onset);
SARC	cis	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg03213289	chr20:61660250	NA	0.46	6.36	0.38	1.08e-9	Prostate cancer (SNP x SNP interaction);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg00678005	chr8:9597722	TNKS;MIR597	0.47	6.55	0.39	3.56e-10	Thyroid stimulating hormone;
SARC	cis	rs4481887	0.854	rs4534423	chr1:248474993	G/C	cg01631408	chr1:248437212	OR2T33	-0.38	-4.8	-0.3	2.78e-6	Common traits (Other);
SARC	cis	rs13161895	1.000	rs248320	chr5:179432096	G/A	cg02702477	chr5:179499311	RNF130	0.66	6.56	0.4	3.36e-10	LDL cholesterol;
SARC	cis	rs11874712	1.000	rs56181324	chr18:43678024	G/A	cg25174615	chr18:43684699	ATP5A1;HAUS1	0.42	4.9	0.31	1.76e-6	Migraine - clinic-based;
SARC	cis	rs78366141	0.649	rs78959409	chr4:89659712	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	0.91	4.82	0.3	2.58e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
SARC	cis	rs425277	0.958	rs262639	chr1:2107061	G/T	cg21442419	chr1:2182373	SKI	-0.52	-6.41	-0.39	8.19e-10	Height;
SARC	cis	rs78320035	1.000	rs74415683	chr1:168125913	A/G	cg17113809	chr1:168148080	TIPRL	1.32	7.13	0.42	1.23e-11	Red cell distribution width;
SARC	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg07701084	chr6:150067640	NUP43	0.39	5.02	0.31	1.01e-6	Lung cancer;
SARC	cis	rs995000	0.931	rs1184547	chr1:63007228	G/A	cg06896770	chr1:63153194	DOCK7	-0.9	-13.49	-0.66	5.08e-31	Triglyceride levels;
SARC	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg02018176	chr4:1364513	KIAA1530	-0.34	-4.88	-0.3	1.94e-6	Obesity-related traits;
SARC	cis	rs11764590	0.666	rs3996325	chr7:2053747	T/C	cg24858417	chr7:2057703	MAD1L1	0.44	5.04	0.31	9.33e-7	Neuroticism;
SARC	cis	rs1468333	0.667	rs10515499	chr5:137705218	A/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.72	8.23	0.47	1.29e-14	Resting heart rate;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg16887385	chr2:61351337	KIAA1841	0.48	6.8	0.41	8.53e-11	Thyroid stimulating hormone;
SARC	cis	rs986417	0.748	rs10150234	chr14:61031284	C/G	cg27398547	chr14:60952738	C14orf39	-0.84	-7.54	-0.44	1.01e-12	Gut microbiota (bacterial taxa);
SARC	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-7.29	-0.43	4.92e-12	Alzheimer's disease;
SARC	cis	rs2017305	0.834	rs12244293	chr10:70783580	A/G	cg01024728	chr10:70782572	NA	0.62	5.5	0.34	9.78e-8	Depression (quantitative trait);
SARC	cis	rs6963495	0.818	rs73190189	chr7:105164452	G/A	cg19920283	chr7:105172520	RINT1	0.65	5.53	0.34	8.43e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg11764359	chr7:65958608	NA	0.78	9.86	0.54	2.14e-19	Aortic root size;
SARC	cis	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg08045932	chr20:61659980	NA	0.5	6.84	0.41	7.06e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs2985684	0.894	rs8005990	chr14:50022248	G/A	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.43	4.73	0.3	3.81e-6	Carotid intima media thickness;
SARC	cis	rs12188164	0.965	rs77101200	chr5:443059	G/T	cg21144161	chr5:423903	AHRR	0.32	4.97	0.31	1.3e-6	Cystic fibrosis severity;
SARC	cis	rs909341	0.537	rs6089971	chr20:62385846	G/A	cg14758556	chr20:62440591	NA	0.51	5.01	0.31	1.07e-6	Atopic dermatitis;
SARC	cis	rs7551222	0.752	rs2369244	chr1:204515299	C/G	cg07972458	chr1:204535000	NA	-0.37	-4.98	-0.31	1.25e-6	Schizophrenia;
SARC	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg21724239	chr8:58056113	NA	0.57	6.07	0.37	5.07e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2273669	0.915	rs3734651	chr6:109295040	T/C	cg05315195	chr6:109294784	ARMC2	-0.48	-4.79	-0.3	2.96e-6	Prostate cancer;
SARC	cis	rs3204270	0.639	rs62080213	chr17:79642531	C/T	cg26965718	chr17:79658957	HGS	-0.62	-5.16	-0.32	5.28e-7	Dental caries;
SARC	cis	rs240764	0.687	rs239209	chr6:101140977	T/C	cg09795085	chr6:101329169	ASCC3	0.45	5.63	0.35	5.24e-8	Neuroticism;
SARC	cis	rs6582630	0.502	rs4385963	chr12:38295264	G/A	cg26384229	chr12:38710491	ALG10B	0.87	12.86	0.64	6.01e-29	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2506889	0.553	rs17035189	chr1:10597024	A/G	cg17425144	chr1:10567563	PEX14	0.42	6.77	0.41	1.02e-10	Breast cancer;
SARC	cis	rs7223966	1.000	rs8075061	chr17:61804723	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	6.88	0.41	5.45e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6570726	0.559	rs11754523	chr6:145727951	A/G	cg05347473	chr6:146136440	FBXO30	-0.45	-5.53	-0.34	8.62e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9290065	0.519	rs7644586	chr3:160674133	T/C	cg03342759	chr3:160939853	NMD3	-0.5	-5.99	-0.37	8.04e-9	Kawasaki disease;
SARC	cis	rs2242116	0.592	rs2290545	chr3:46967040	C/T	cg27129171	chr3:47204927	SETD2	0.61	6.82	0.41	7.61e-11	Birth weight;
SARC	trans	rs7980799	0.682	rs4931719	chr12:33602986	G/A	cg26384229	chr12:38710491	ALG10B	-0.61	-7.6	-0.45	7.38e-13	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.73	-7.62	-0.45	6.21e-13	Platelet count;
SARC	cis	rs9815354	1.000	rs1607908	chr3:41905196	T/G	cg03022575	chr3:42003672	ULK4	0.56	5.29	0.33	2.81e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg03185022	chr7:2884158	GNA12	0.48	5.53	0.34	8.75e-8	Height;
SARC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg21280719	chr6:42927975	GNMT	-0.44	-7.45	-0.44	1.77e-12	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs921968	0.607	rs529474	chr2:219463283	C/T	cg02176678	chr2:219576539	TTLL4	0.36	5.27	0.33	3.05e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs10791323	0.582	rs2851120	chr11:133708065	A/G	cg15485101	chr11:133734466	NA	0.33	5.0	0.31	1.15e-6	Childhood ear infection;
SARC	trans	rs61931739	0.517	rs11612493	chr12:34114272	A/C	cg13010199	chr12:38710504	ALG10B	0.71	9.57	0.53	1.61e-18	Morning vs. evening chronotype;
SARC	cis	rs9325144	0.555	rs6582607	chr12:38717678	T/C	cg26384229	chr12:38710491	ALG10B	-0.64	-8.36	-0.48	5.61e-15	Morning vs. evening chronotype;
SARC	cis	rs3087591	0.919	rs11080148	chr17:29609922	T/C	cg24425628	chr17:29625626	OMG;NF1	-0.59	-7.24	-0.43	6.42e-12	Hip circumference;
SARC	cis	rs9467773	1.000	rs6924838	chr6:26571756	C/T	cg11502198	chr6:26597334	ABT1	0.53	6.46	0.39	6.05e-10	Intelligence (multi-trait analysis);
SARC	trans	rs6894249	1.000	rs6894249	chr5:131797547	A/G	cg20156080	chr11:68703600	IGHMBP2	-0.48	-6.23	-0.38	2.12e-9	Asthma;
SARC	cis	rs35955747	0.669	rs878718	chr22:31552702	C/T	cg13145458	chr22:31556086	RNF185	-0.4	-4.97	-0.31	1.33e-6	Neutrophil count;Sum basophil neutrophil counts;
SARC	cis	rs546131	0.642	rs561477	chr11:34852152	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.43	5.06	0.31	8.61e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs12048904	0.595	rs2295280	chr1:101342497	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.54	6.75	0.4	1.18e-10	Multiple sclerosis;
SARC	cis	rs826838	0.967	rs7136593	chr12:39128265	C/T	cg26384229	chr12:38710491	ALG10B	-0.76	-11.59	-0.6	7.97e-25	Heart rate;
SARC	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg23758822	chr17:41437982	NA	0.86	10.56	0.57	1.52e-21	Menopause (age at onset);
SARC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg21856205	chr7:94953877	PON1	-0.36	-5.69	-0.35	3.87e-8	Paraoxonase activity;
SARC	cis	rs1023500	0.551	rs133371	chr22:42465574	G/A	cg04733989	chr22:42467013	NAGA	0.76	10.78	0.58	2.96e-22	Schizophrenia;
SARC	cis	rs17826219	0.706	rs2322197	chr17:29105805	T/C	cg13385521	chr17:29058706	SUZ12P	0.89	7.77	0.45	2.44e-13	Body mass index;
SARC	cis	rs941408	0.515	rs12610096	chr19:2778129	C/T	cg06609049	chr19:2785107	THOP1	0.98	15.15	0.7	1.5e-36	Total cholesterol levels;
SARC	cis	rs11204677	1	rs11204677	chr1:150574695	C/G	cg13175981	chr1:150552382	MCL1	0.69	9.35	0.52	7.76e-18	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs796364	0.616	rs2140486	chr2:200690102	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.55	4.74	0.3	3.76e-6	Schizophrenia;
SARC	cis	rs8114671	0.967	rs6142320	chr20:33788193	A/G	cg24642439	chr20:33292090	TP53INP2	-0.48	-5.52	-0.34	8.89e-8	Height;
SARC	cis	rs1003719	0.788	rs2835597	chr21:38466539	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.63	9.05	0.51	5.67e-17	Eye color traits;
SARC	cis	rs1003719	0.788	rs11911508	chr21:38470504	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.63	9.05	0.51	5.67e-17	Eye color traits;
SARC	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg03517284	chr6:25882590	NA	-0.6	-8.24	-0.48	1.25e-14	Uric acid levels;
SARC	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg18252515	chr7:66147081	NA	0.59	6.34	0.38	1.17e-9	Aortic root size;
SARC	cis	rs2153535	0.526	rs9406179	chr6:8538224	G/A	cg23788917	chr6:8435910	SLC35B3	0.64	8.4	0.48	4.5e-15	Motion sickness;
SARC	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg10128416	chr1:75198403	TYW3;CRYZ	-0.39	-4.76	-0.3	3.38e-6	Resistin levels;
SARC	cis	rs365132	0.875	rs2454952	chr5:176376493	C/T	cg16309518	chr5:176445507	NA	-0.49	-6.3	-0.38	1.46e-9	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs9467773	0.620	rs2504592	chr6:26640951	C/G	cg11502198	chr6:26597334	ABT1	0.63	8.48	0.49	2.6e-15	Intelligence (multi-trait analysis);
SARC	cis	rs5753037	0.639	rs5997534	chr22:30220190	G/A	cg01021169	chr22:30184971	ASCC2	-0.39	-5.19	-0.32	4.61e-7	Type 1 diabetes;
SARC	cis	rs2841277	0.834	rs2841281	chr14:105394669	C/T	cg14403583	chr14:105418241	AHNAK2	0.61	7.89	0.46	1.2e-13	Rheumatoid arthritis;
SARC	cis	rs17572109	0.666	rs4674297	chr2:219229147	A/G	cg00012203	chr2:219082015	ARPC2	0.54	5.58	0.34	6.56e-8	Platelet count;Platelet distribution width;Mean platelet volume;
SARC	cis	rs2425143	1.000	rs2378409	chr20:34392464	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-5.86	-0.36	1.57e-8	Blood protein levels;
SARC	cis	rs936229	0.768	rs11072509	chr15:75114374	C/G	cg14664628	chr15:75095509	CSK	-1.06	-14.87	-0.7	1.25e-35	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs67460515	0.563	rs6794882	chr3:160851849	G/A	cg17135325	chr3:160939158	NMD3	0.62	7.68	0.45	4.46e-13	Parkinson's disease;
SARC	cis	rs77106637	0.860	rs1552224	chr11:72433098	A/C	cg03713592	chr11:72463424	ARAP1	1.04	9.94	0.55	1.23e-19	Type 2 diabetes;
SARC	cis	rs453301	0.686	rs6987107	chr8:8893581	A/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.25	-0.38	1.97e-9	Joint mobility (Beighton score);
SARC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.3	-4.77	-0.3	3.24e-6	Total body bone mineral density;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg11388866	chr21:40752116	WRB	-0.52	-6.38	-0.39	9.28e-10	Schizophrenia;
SARC	cis	rs734999	0.545	rs4074789	chr1:2537464	A/G	cg18854424	chr1:2615690	NA	0.32	5.15	0.32	5.59e-7	Ulcerative colitis;
SARC	cis	rs9911578	0.935	rs7216698	chr17:57007495	G/A	cg12560992	chr17:57184187	TRIM37	0.69	8.75	0.5	4.33e-16	Intelligence (multi-trait analysis);
SARC	cis	rs9640161	0.830	rs11768108	chr7:150064150	C/T	cg10018233	chr7:150070692	REPIN1	0.71	10.09	0.55	4.4e-20	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg07701084	chr6:150067640	NUP43	0.44	5.69	0.35	3.87e-8	Lung cancer;
SARC	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg12564285	chr5:131593104	PDLIM4	-0.46	-6.22	-0.38	2.24e-9	Breast cancer;
SARC	cis	rs1580019	0.539	rs11769109	chr7:32571352	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.97	17.74	0.76	3.9e-45	Cognitive ability;
SARC	cis	rs7589342	0.899	rs879900	chr2:106494347	A/G	cg16077055	chr2:106428750	NCK2	0.35	6.23	0.38	2.13e-9	Addiction;
SARC	trans	rs61931739	0.500	rs11053201	chr12:34453903	T/A	cg26384229	chr12:38710491	ALG10B	0.92	13.8	0.67	4.45e-32	Morning vs. evening chronotype;
SARC	cis	rs1559088	0.576	rs11084707	chr19:33612873	C/T	cg17764715	chr19:33622953	WDR88	0.61	8.49	0.49	2.39e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs7084402	0.967	rs1658439	chr10:60325986	A/G	cg07615347	chr10:60278583	BICC1	0.59	8.76	0.5	4.06e-16	Refractive error;
SARC	trans	rs1814175	0.647	rs10769646	chr11:49992204	C/A	cg15704280	chr7:45808275	SEPT13	-0.89	-14.17	-0.68	2.8e-33	Height;
SARC	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2412459	0.611	rs4924402	chr15:40245754	C/T	cg22077389	chr15:40226273	EIF2AK4	-0.59	-5.6	-0.34	5.93e-8	Response to haloperidol in psychosis;
SARC	cis	rs3733585	0.654	rs4447863	chr4:9938969	T/C	cg00071950	chr4:10020882	SLC2A9	-0.4	-6.28	-0.38	1.63e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs2795502	1.000	rs2796575	chr10:43374911	A/G	cg20628663	chr10:43360327	NA	0.48	6.11	0.37	4.18e-9	Blood protein levels;
SARC	cis	rs1881797	0.872	rs2141544	chr1:247690800	A/G	cg11166453	chr1:247681781	NA	0.47	5.81	0.36	2.03e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg24531977	chr5:56204891	C5orf35	-0.54	-5.52	-0.34	9.06e-8	Initial pursuit acceleration;
SARC	cis	rs6546550	0.935	rs10865380	chr2:70091246	T/C	cg02498382	chr2:70120550	SNRNP27	-0.35	-5.87	-0.36	1.5e-8	Prevalent atrial fibrillation;
SARC	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg08859206	chr1:53392774	SCP2	0.39	5.64	0.35	4.87e-8	Monocyte count;
SARC	cis	rs7666738	0.570	rs11097612	chr4:99079772	T/C	cg05340658	chr4:99064831	C4orf37	0.48	6.07	0.37	5.16e-9	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7582720	1.000	rs72932793	chr2:203701004	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	7.55	0.44	1e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs10492096	0.947	rs11559082	chr12:6602367	C/T	cg13857086	chr12:6580257	VAMP1	0.69	6.85	0.41	6.6e-11	Hip geometry;
SARC	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg18252515	chr7:66147081	NA	-1.3	-11.5	-0.6	1.59e-24	Diabetic kidney disease;
SARC	cis	rs1348850	0.645	rs10164417	chr2:178444130	A/G	cg23306229	chr2:178417860	TTC30B	0.73	8.2	0.47	1.6e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1878931	0.582	rs27225	chr16:3428060	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.67	-7.45	-0.44	1.78e-12	Body mass index (adult);
SARC	cis	rs1549733	0.559	rs16857982	chr2:218458111	G/A	cg15248979	chr2:219434002	USP37;RQCD1	0.58	4.92	0.31	1.6e-6	Optic disc area;
SARC	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg17971929	chr21:40555470	PSMG1	0.96	12.06	0.62	2.49e-26	Cognitive function;
SARC	cis	rs742614	1.000	rs742614	chr20:32482632	A/G	cg06304546	chr20:32448765	NA	-0.41	-5.01	-0.31	1.06e-6	Stearic acid (18:0) levels;
SARC	cis	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg05623727	chr3:50126028	RBM5	-0.34	-5.19	-0.32	4.52e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg04267008	chr7:1944627	MAD1L1	-0.49	-5.48	-0.34	1.08e-7	Bipolar disorder and schizophrenia;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg09600247	chr12:11140560	PRR4;PRH1;TAS2R50	0.52	7.39	0.44	2.69e-12	Thyroid stimulating hormone;
SARC	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg19223190	chr17:80058835	NA	0.44	6.19	0.38	2.67e-9	Life satisfaction;
SARC	cis	rs13343954	0.825	rs12462077	chr19:33529231	C/G	cg24009623	chr19:33667908	NA	0.46	5.0	0.31	1.14e-6	Colorectal cancer;
SARC	cis	rs9399135	0.967	rs4896122	chr6:135295081	T/C	cg24558204	chr6:135376177	HBS1L	0.44	5.97	0.36	8.77e-9	Red blood cell count;
SARC	cis	rs995000	0.931	rs11207983	chr1:63012107	C/T	cg06896770	chr1:63153194	DOCK7	-0.92	-13.65	-0.67	1.48e-31	Triglyceride levels;
SARC	cis	rs1318878	0.565	rs1117153	chr12:15437905	C/T	cg08258403	chr12:15378311	NA	-0.47	-6.43	-0.39	7.32e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7208859	0.623	rs7212991	chr17:29143749	T/C	cg13385521	chr17:29058706	SUZ12P	0.9	7.58	0.44	7.91e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs72945132	0.882	rs3133179	chr11:70187574	T/G	cg00319359	chr11:70116639	PPFIA1	0.71	6.62	0.4	2.42e-10	Coronary artery disease;
SARC	cis	rs12079745	1.000	rs12095171	chr1:169114829	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.7	-4.89	-0.31	1.88e-6	QT interval;
SARC	cis	rs35160687	0.901	rs34048420	chr2:86529748	A/G	cg10973622	chr2:86423274	IMMT	0.38	4.9	0.31	1.77e-6	Night sleep phenotypes;
SARC	cis	rs2033711	0.870	rs4801583	chr19:58918405	A/G	cg03735888	chr19:58951602	ZNF132	0.4	5.28	0.33	3e-7	Uric acid clearance;
SARC	cis	rs6011674	1.000	rs6011674	chr20:61854452	A/G	cg06763829	chr20:61885236	FLJ16779;NKAIN4	-0.62	-5.53	-0.34	8.69e-8	Response to cytadine analogues (cytosine arabinoside);
SARC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg11905131	chr22:24372483	LOC391322	-0.51	-5.53	-0.34	8.45e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7216064	1.000	rs1976054	chr17:65833224	T/G	cg12091567	chr17:66097778	LOC651250	-0.75	-8.21	-0.47	1.5e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg15847926	chr7:2749597	AMZ1	-0.31	-5.05	-0.31	8.84e-7	Height;
SARC	trans	rs61931739	0.500	rs10844848	chr12:34409705	A/C	cg26384229	chr12:38710491	ALG10B	0.92	13.89	0.67	2.39e-32	Morning vs. evening chronotype;
SARC	cis	rs826838	0.933	rs980573	chr12:39127811	T/C	cg13010199	chr12:38710504	ALG10B	-0.63	-8.88	-0.5	1.87e-16	Heart rate;
SARC	cis	rs6570726	0.791	rs9390336	chr6:145896823	A/T	cg05347473	chr6:146136440	FBXO30	0.51	7.2	0.43	8.39e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12155623	0.592	rs12682003	chr8:49865454	G/T	cg22283653	chr8:49824208	NA	0.36	5.03	0.31	9.63e-7	Sudden cardiac arrest;
SARC	cis	rs11723261	0.582	rs7679573	chr4:151605	G/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.37	4.74	0.3	3.73e-6	Immune response to smallpox vaccine (IL-6);
SARC	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg05793240	chr7:2802953	GNA12	-0.37	-5.46	-0.34	1.21e-7	Height;
SARC	cis	rs6831352	0.703	rs2602854	chr4:100028651	C/T	cg12011299	chr4:100065546	ADH4	0.28	4.85	0.3	2.25e-6	Alcohol dependence;
SARC	cis	rs13326165	0.585	rs73088773	chr3:52286585	G/A	cg01348873	chr3:52349823	DNAH1	0.56	4.73	0.3	3.93e-6	HDL cholesterol;HDL cholesterol levels;
SARC	cis	rs2303759	0.709	rs7256363	chr19:49827804	C/T	cg22307029	chr19:49891270	CCDC155	0.58	6.58	0.4	3.1e-10	Multiple sclerosis;
SARC	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg22618164	chr12:122356400	WDR66	0.43	6.88	0.41	5.45e-11	Mean corpuscular volume;
SARC	cis	rs12500482	0.509	rs1203784	chr4:2427108	T/C	cg27416412	chr4:2435825	NA	0.35	4.95	0.31	1.39e-6	Cognitive function;
SARC	cis	rs7412746	0.658	rs11204723	chr1:150731618	T/C	cg15448220	chr1:150897856	SETDB1	0.47	6.07	0.37	5.12e-9	Melanoma;
SARC	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg17971929	chr21:40555470	PSMG1	-0.57	-7.21	-0.43	7.55e-12	Menarche (age at onset);
SARC	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg14893161	chr1:205819251	PM20D1	0.42	5.15	0.32	5.49e-7	Menarche (age at onset);
SARC	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg05313129	chr8:58192883	C8orf71	-0.5	-5.89	-0.36	1.31e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs11098499	0.863	rs1480936	chr4:120462861	C/T	cg24375607	chr4:120327624	NA	0.42	4.94	0.31	1.52e-6	Corneal astigmatism;
SARC	cis	rs7818345	0.935	rs4633071	chr8:19275852	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.41	5.57	0.34	7.15e-8	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs12586317	0.620	rs58320987	chr14:35587726	T/C	cg26967526	chr14:35346199	BAZ1A	-0.62	-6.5	-0.39	4.7e-10	Psoriasis;
SARC	cis	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg22496380	chr5:211416	CCDC127	-0.88	-9.35	-0.52	7.72e-18	Breast cancer;
SARC	cis	rs796364	0.806	rs35200468	chr2:201110368	G/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.67	-5.25	-0.33	3.42e-7	Schizophrenia;
SARC	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg16325326	chr1:53192061	ZYG11B	-0.82	-13.46	-0.66	6.13e-31	Monocyte count;
SARC	cis	rs6582630	0.555	rs7133706	chr12:38475465	G/A	cg13010199	chr12:38710504	ALG10B	-0.7	-9.53	-0.53	2.23e-18	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs10782582	0.609	rs5745543	chr1:76365111	A/T	cg03433033	chr1:76189801	ACADM	-0.4	-5.12	-0.32	6.32e-7	Daytime sleep phenotypes;
SARC	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg21724239	chr8:58056113	NA	0.62	6.3	0.38	1.43e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6582630	0.502	rs11520261	chr12:38332019	T/G	cg26384229	chr12:38710491	ALG10B	0.86	12.08	0.62	2.05e-26	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs11608355	0.810	rs2217972	chr12:109857612	C/T	cg05360138	chr12:110035743	NA	0.58	6.13	0.37	3.7e-9	Neuroticism;
SARC	cis	rs7945705	0.818	rs10769948	chr11:8761782	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.42	-5.64	-0.35	4.95e-8	Hemoglobin concentration;
SARC	cis	rs9300255	0.620	rs7313483	chr12:123726834	C/T	cg00376283	chr12:123451042	ABCB9	0.52	5.98	0.36	8.35e-9	Neutrophil percentage of white cells;
SARC	cis	rs13191362	1.000	rs28360546	chr6:163210973	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.41	5.18	0.32	4.71e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg06212747	chr3:49208901	KLHDC8B	0.69	9.39	0.52	5.77e-18	Parkinson's disease;
SARC	cis	rs13314892	0.728	rs62252229	chr3:69888407	C/G	cg17445875	chr3:69859618	MITF	-0.48	-4.88	-0.3	1.97e-6	QRS complex (12-leadsum);
SARC	cis	rs763121	0.853	rs5750668	chr22:39079964	T/C	cg06022373	chr22:39101656	GTPBP1	0.84	10.32	0.56	8.51e-21	Menopause (age at onset);
SARC	cis	rs7617773	0.780	rs35190747	chr3:48343290	C/T	cg11946769	chr3:48343235	NME6	0.76	9.7	0.54	6.55e-19	Coronary artery disease;
SARC	cis	rs9788682	0.747	rs2938671	chr15:78732754	A/G	cg24631222	chr15:78858424	CHRNA5	-0.76	-9.37	-0.52	6.62e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg27266027	chr21:40555129	PSMG1	0.49	5.4	0.33	1.62e-7	Cognitive function;
SARC	cis	rs9810259	0.649	rs35854524	chr3:12295787	G/A	cg04748988	chr3:12329223	PPARG	-0.38	-4.85	-0.3	2.29e-6	Platelet count;
SARC	cis	rs9911578	0.935	rs9893351	chr17:57023326	G/A	cg12560992	chr17:57184187	TRIM37	0.68	8.6	0.49	1.19e-15	Intelligence (multi-trait analysis);
SARC	cis	rs12950390	0.853	rs11079790	chr17:45853626	G/A	cg03474202	chr17:45855739	NA	-0.44	-7.03	-0.42	2.23e-11	IgG glycosylation;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg07908229	chr1:182353640	GLUL	-0.54	-6.88	-0.41	5.43e-11	Height;
SARC	trans	rs2727020	0.755	rs652655	chr11:49251293	G/A	cg15704280	chr7:45808275	SEPT13	0.83	13.29	0.66	2.25e-30	Coronary artery disease;
SARC	cis	rs950776	0.720	rs11637890	chr15:78935419	C/G	cg22563815	chr15:78856949	CHRNA5	-0.31	-4.97	-0.31	1.3e-6	Sudden cardiac arrest;
SARC	cis	rs1497406	0.898	rs36086195	chr1:16510894	C/T	cg20430773	chr1:16534157	ARHGEF19	0.45	6.63	0.4	2.35e-10	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs858239	0.539	rs6975852	chr7:23186654	T/C	cg23682824	chr7:23144976	KLHL7	0.65	7.97	0.46	7.26e-14	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg13206674	chr6:150067644	NUP43	0.44	5.77	0.35	2.51e-8	Lung cancer;
SARC	cis	rs4951018	0.821	rs7529037	chr1:205637501	C/G	cg26354017	chr1:205819088	PM20D1	-0.41	-5.37	-0.33	1.93e-7	Prostate-specific antigen levels;
SARC	cis	rs12908161	0.959	rs35557864	chr15:85331629	A/G	cg17507749	chr15:85114479	UBE2QP1	0.53	6.04	0.37	6.03e-9	Schizophrenia;
SARC	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg12696929	chr3:195401817	SDHAP2	0.37	4.83	0.3	2.44e-6	Pancreatic cancer;
SARC	cis	rs12586317	0.525	rs10144430	chr14:35433682	T/A	cg05294307	chr14:35346193	BAZ1A	-0.45	-4.91	-0.31	1.73e-6	Psoriasis;
SARC	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg08280861	chr8:58055591	NA	0.59	5.8	0.36	2.12e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs62064224	0.720	rs8078837	chr17:30763537	A/G	cg25809561	chr17:30822961	MYO1D	0.33	4.88	0.3	1.98e-6	Schizophrenia;
SARC	cis	rs6500602	0.893	rs8061742	chr16:4489436	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.36	5.89	0.36	1.31e-8	Schizophrenia;
SARC	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg14983838	chr19:29218262	NA	0.51	6.01	0.37	6.94e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs240764	0.817	rs239206	chr6:101137332	T/G	cg09795085	chr6:101329169	ASCC3	0.45	5.8	0.36	2.16e-8	Neuroticism;
SARC	cis	rs10911232	0.507	rs4596846	chr1:182976034	C/T	cg13390022	chr1:182993471	LAMC1	0.33	5.06	0.31	8.36e-7	Hypertriglyceridemia;
SARC	cis	rs6665290	0.904	rs2297418	chr1:227192579	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.09	-25.57	-0.86	1.46e-69	Myeloid white cell count;
SARC	cis	rs709400	0.663	rs28444993	chr14:103930564	T/C	cg12935359	chr14:103987150	CKB	-0.39	-5.79	-0.35	2.22e-8	Body mass index;
SARC	cis	rs3820928	0.904	rs10188570	chr2:227792540	G/A	cg11843606	chr2:227700838	RHBDD1	-0.52	-5.9	-0.36	1.29e-8	Pulmonary function;
SARC	cis	rs7829975	0.533	rs13274028	chr8:8729193	A/C	cg08975724	chr8:8085496	FLJ10661	0.52	6.3	0.38	1.46e-9	Mood instability;
SARC	cis	rs8067354	0.872	rs2645488	chr17:57889405	T/G	cg02344993	chr17:57696989	CLTC	0.43	4.94	0.31	1.51e-6	Hemoglobin concentration;
SARC	cis	rs8180040	0.932	rs11712445	chr3:47434552	T/C	cg27129171	chr3:47204927	SETD2	0.66	9.12	0.51	3.55e-17	Colorectal cancer;
SARC	cis	rs4927850	0.752	rs7624460	chr3:195748530	C/T	cg01181863	chr3:195395398	SDHAP2	-0.63	-7.64	-0.45	5.73e-13	Pancreatic cancer;
SARC	cis	rs5753618	0.561	rs9609264	chr22:31746719	C/G	cg07713946	chr22:31675144	LIMK2	0.36	5.05	0.31	9.1e-7	Colorectal cancer;
SARC	cis	rs56235845	0.694	rs11949401	chr5:176765989	A/G	cg17509989	chr5:176798049	RGS14	0.55	7.68	0.45	4.51e-13	Hemoglobin concentration;Hematocrit;
SARC	cis	rs4780401	0.703	rs3190321	chr16:11773662	C/G	cg01061890	chr16:11836724	TXNDC11	-0.48	-6.3	-0.38	1.45e-9	Rheumatoid arthritis;
SARC	cis	rs240764	0.725	rs239212	chr6:101145178	G/A	cg09795085	chr6:101329169	ASCC3	0.39	5.05	0.31	9.11e-7	Neuroticism;
SARC	cis	rs7762018	0.891	rs4716343	chr6:170143817	C/G	cg13891659	chr6:170190454	C6orf122;C6orf208	0.55	4.88	0.3	2e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg02574844	chr11:5959923	NA	0.42	5.94	0.36	1.02e-8	DNA methylation (variation);
SARC	cis	rs4555082	1.000	rs4555082	chr14:105758964	C/T	cg06808227	chr14:105710500	BRF1	-0.45	-5.59	-0.34	6.45e-8	Mean platelet volume;Platelet distribution width;
SARC	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg13877915	chr19:58951672	ZNF132	0.66	9.73	0.54	5.36e-19	Uric acid clearance;
SARC	cis	rs2816062	0.775	rs2816048	chr1:18893763	T/C	cg18795169	chr1:18902165	NA	-0.77	-12.06	-0.62	2.35e-26	Urate levels in lean individuals;
SARC	cis	rs10416265	0.527	rs7246814	chr19:33538414	G/T	cg17764715	chr19:33622953	WDR88	0.55	7.26	0.43	5.89e-12	Bone properties (heel);
SARC	cis	rs981844	0.714	rs2405204	chr4:154705248	A/G	cg14289246	chr4:154710475	SFRP2	-0.58	-6.83	-0.41	7.45e-11	Response to statins (LDL cholesterol change);
SARC	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg00933542	chr6:150070202	PCMT1	0.31	5.02	0.31	1.04e-6	Lung cancer;
SARC	cis	rs7520050	0.931	rs6698247	chr1:46371486	C/T	cg06784218	chr1:46089804	CCDC17	-0.26	-4.79	-0.3	2.97e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs2180341	0.920	rs7756880	chr6:127683999	A/T	cg17762328	chr6:126965162	NA	-0.45	-4.96	-0.31	1.33e-6	Breast cancer;
SARC	cis	rs6704644	1.000	rs10929178	chr2:234396566	C/G	cg16719865	chr2:234394478	USP40	-0.61	-4.97	-0.31	1.33e-6	Bilirubin levels;
SARC	cis	rs798554	0.610	rs2644297	chr7:2858906	A/C	cg03185022	chr7:2884158	GNA12	0.4	4.73	0.3	3.94e-6	Height;
SARC	cis	rs7552404	0.727	rs61770533	chr1:76306490	C/G	cg22875332	chr1:76189707	ACADM	0.45	5.52	0.34	8.96e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6831352	0.918	rs4699712	chr4:100060490	A/T	cg13256891	chr4:100009986	ADH5	-0.65	-8.0	-0.46	5.94e-14	Alcohol dependence;
SARC	cis	rs7412746	0.622	rs72704654	chr1:150826410	G/A	cg15448220	chr1:150897856	SETDB1	0.51	6.52	0.39	4.3e-10	Melanoma;
SARC	cis	rs6570726	0.846	rs9399559	chr6:145945778	C/T	cg05347473	chr6:146136440	FBXO30	0.51	7.13	0.42	1.25e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs35213789	0.760	rs34519726	chr7:69547916	A/G	cg10619644	chr7:69149951	AUTS2	0.41	5.07	0.32	8.06e-7	Childhood ear infection;
SARC	cis	rs5758659	1.000	rs5758677	chr22:42643039	A/C	cg15128208	chr22:42549153	NA	-0.38	-5.52	-0.34	9.12e-8	Cognitive function;
SARC	cis	rs899997	1.000	rs4887078	chr15:79011073	C/T	cg04896959	chr15:78267971	NA	0.53	6.34	0.38	1.16e-9	Coronary artery disease or large artery stroke;
SARC	cis	rs12754538	0.850	rs12040962	chr1:8536901	A/C	cg13785123	chr1:8931135	ENO1	-0.47	-5.27	-0.33	3.03e-7	Subjective well-being;
SARC	cis	rs3008870	0.755	rs2815365	chr1:67499628	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.6	7.71	0.45	3.55e-13	Lymphocyte percentage of white cells;
SARC	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs17401966	0.838	rs11580854	chr1:10293565	G/A	cg15208524	chr1:10270712	KIF1B	0.46	5.34	0.33	2.26e-7	Hepatocellular carcinoma;
SARC	cis	rs17539620	0.624	rs4566892	chr6:154837346	C/T	cg17771515	chr6:154831774	CNKSR3	0.53	5.07	0.32	8.2e-7	Lipoprotein (a) levels;
SARC	cis	rs57221529	0.766	rs56278696	chr5:582669	A/G	cg14541582	chr5:601475	NA	-0.4	-4.8	-0.3	2.89e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs818427	0.927	rs153548	chr5:112237724	A/C	cg07820702	chr5:112228657	REEP5	-0.5	-5.41	-0.33	1.56e-7	Total body bone mineral density;
SARC	cis	rs66573146	1.000	rs55833486	chr4:6978729	C/A	cg00086871	chr4:6988644	TBC1D14	0.89	5.29	0.33	2.88e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs6089584	0.606	rs7270666	chr20:60577598	C/T	cg13770153	chr20:60521292	NA	-0.41	-6.07	-0.37	5.1e-9	Body mass index;
SARC	cis	rs11581859	0.613	rs4908333	chr1:99207971	G/T	cg20286094	chr1:99190917	SNX7	-0.43	-5.21	-0.32	4.23e-7	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg15556689	chr8:8085844	FLJ10661	0.51	6.23	0.38	2.15e-9	Mood instability;
SARC	cis	rs1559088	0.847	rs2287679	chr19:33600764	T/C	cg17764715	chr19:33622953	WDR88	0.49	6.72	0.4	1.4e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs4128725	1.000	rs12144848	chr1:159388240	C/T	cg25076881	chr1:159409836	OR10J1	0.4	4.78	0.3	3.16e-6	Select biomarker traits;
SARC	cis	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg22496380	chr5:211416	CCDC127	-0.89	-9.31	-0.52	9.87e-18	Breast cancer;
SARC	cis	rs1322639	0.614	rs6900200	chr6:169566173	T/C	cg04662567	chr6:169592167	NA	-0.47	-4.84	-0.3	2.42e-6	Pulse pressure;
SARC	cis	rs10779751	0.734	rs2261317	chr1:11124979	A/G	cg08854313	chr1:11322531	MTOR	0.82	11.26	0.59	8.86e-24	Body mass index;
SARC	cis	rs892961	1.000	rs892961	chr17:75400100	A/T	cg05865280	chr17:75406074	SEPT9	0.6	5.35	0.33	2.07e-7	Airflow obstruction;
SARC	cis	rs13314892	0.770	rs79502300	chr3:69856753	C/T	cg17445875	chr3:69859618	MITF	-0.57	-5.65	-0.35	4.78e-8	QRS complex (12-leadsum);
SARC	cis	rs9436747	0.681	rs1782762	chr1:66019566	C/G	cg14976592	chr1:65886160	LEPROT;LEPR	-0.52	-5.1	-0.32	7.17e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	trans	rs3780486	0.522	rs7029897	chr9:33124042	T/C	cg20290983	chr6:43655470	MRPS18A	0.92	13.5	0.66	4.53e-31	IgG glycosylation;
SARC	cis	rs367615	0.704	rs6889301	chr5:108835181	C/T	cg17395555	chr5:108820864	NA	0.49	7.0	0.42	2.7e-11	Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs34779708	0.931	rs58159560	chr10:35351249	C/T	cg03585969	chr10:35415529	CREM	0.4	4.93	0.31	1.58e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs2228479	0.850	rs3785281	chr16:89824263	G/C	cg06558623	chr16:89946397	TCF25	0.88	6.21	0.38	2.39e-9	Skin colour saturation;
SARC	cis	rs35213789	0.762	rs532820	chr7:69178648	C/T	cg10619644	chr7:69149951	AUTS2	-0.35	-4.78	-0.3	3.16e-6	Childhood ear infection;
SARC	cis	rs6088580	0.634	rs6059850	chr20:33044784	C/G	cg24642439	chr20:33292090	TP53INP2	0.66	8.43	0.48	3.57e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs2594989	0.837	rs2454497	chr3:11501597	T/C	cg00170343	chr3:11313890	ATG7	0.55	5.35	0.33	2.11e-7	Circulating chemerin levels;
SARC	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.42	-5.17	-0.32	5.08e-7	Tonsillectomy;
SARC	cis	rs9807989	0.811	rs4485584	chr2:102970750	T/C	cg09003973	chr2:102972529	NA	0.41	5.6	0.34	6.11e-8	Asthma;
SARC	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg25072359	chr17:41440525	NA	0.5	5.76	0.35	2.67e-8	Menopause (age at onset);
SARC	cis	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg13647721	chr17:30228624	UTP6	0.61	5.38	0.33	1.84e-7	Hip circumference adjusted for BMI;
SARC	cis	rs2153535	0.580	rs9505446	chr6:8448691	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	8.38	0.48	5.16e-15	Motion sickness;
SARC	cis	rs9916302	0.718	rs7219909	chr17:37706243	C/T	cg07936489	chr17:37558343	FBXL20	-0.68	-8.8	-0.5	3.12e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs6908034	0.607	rs77791009	chr6:19812602	A/G	cg02682789	chr6:19804855	NA	0.69	5.56	0.34	7.3900000000000007e-08	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs910316	0.967	rs2024653	chr14:75595154	G/A	cg23033748	chr14:75592666	NEK9	0.37	5.22	0.32	4.05e-7	Height;
SARC	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg00149659	chr3:10157352	C3orf10	0.69	6.76	0.4	1.1e-10	Alzheimer's disease;
SARC	cis	rs2735413	0.918	rs56397244	chr16:78081366	A/T	cg04733911	chr16:78082701	NA	-0.3	-5.47	-0.34	1.17e-7	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.42	-0.44	2.12e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs4481887	0.927	rs4376768	chr1:248476088	A/G	cg00666640	chr1:248458726	OR2T12	-0.3	-5.06	-0.31	8.49e-7	Common traits (Other);
SARC	cis	rs9527	0.615	rs2152915	chr10:104691732	A/T	cg04362960	chr10:104952993	NT5C2	0.41	4.84	0.3	2.35e-6	Arsenic metabolism;
SARC	cis	rs1662342	1.000	rs7811	chr18:3256112	A/G	cg14211874	chr18:3262499	MYL12B	-0.69	-5.19	-0.32	4.51e-7	QRS duration;
SARC	cis	rs36051895	0.594	rs7029244	chr9:5180961	A/C	cg02405213	chr9:5042618	JAK2	-0.45	-5.32	-0.33	2.41e-7	Pediatric autoimmune diseases;
SARC	cis	rs818427	0.896	rs712662	chr5:112222694	C/G	cg07820702	chr5:112228657	REEP5	0.45	5.02	0.31	1.03e-6	Total body bone mineral density;
SARC	cis	rs734999	0.588	rs11585048	chr1:2534087	C/T	cg20673091	chr1:2541236	MMEL1	0.33	5.1	0.32	6.91e-7	Ulcerative colitis;
SARC	cis	rs10078	0.571	rs2671890	chr5:456457	A/G	cg26072250	chr5:443457	EXOC3;C5orf55	0.69	5.77	0.35	2.52e-8	Fat distribution (HIV);
SARC	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg17221315	chr6:27791827	HIST1H4J	0.52	5.33	0.33	2.3e-7	Parkinson's disease;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg23249710	chr6:117996544	NUS1	0.49	6.63	0.4	2.37e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs4481887	1.000	rs4244174	chr1:248467956	A/G	cg01631408	chr1:248437212	OR2T33	-0.42	-5.3	-0.33	2.68e-7	Common traits (Other);
SARC	cis	rs7998202	0.667	rs665813	chr13:113355765	A/G	cg02820901	chr13:113351484	ATP11A	0.56	5.06	0.31	8.58e-7	Glycated hemoglobin levels;
SARC	cis	rs2072438	0.505	rs7034074	chr9:123923029	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	5.06	0.31	8.63e-7	Rheumatoid arthritis;
SARC	cis	rs41264869	0.657	rs11811115	chr1:205134090	A/G	cg21643547	chr1:205240462	TMCC2	0.46	5.12	0.32	6.28e-7	Blood protein levels;
SARC	cis	rs13082711	0.554	rs73055750	chr3:27401505	C/G	cg02860705	chr3:27208620	NA	0.64	7.86	0.46	1.39e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs2652822	0.525	rs17828874	chr15:63516266	C/G	cg02713581	chr15:63449717	RPS27L	-0.52	-6.28	-0.38	1.61e-9	Metabolic traits;
SARC	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg20102877	chr2:27665638	KRTCAP3	-0.36	-5.16	-0.32	5.3e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs12711979	0.509	rs10205540	chr2:3827839	A/G	cg17052675	chr2:3827356	NA	-0.56	-8.35	-0.48	6.02e-15	Itch intensity from mosquito bite adjusted by bite size;
SARC	cis	rs1949733	0.656	rs2631762	chr4:8423122	A/T	cg11789530	chr4:8429930	ACOX3	0.84	11.09	0.59	3.24e-23	Response to antineoplastic agents;
SARC	cis	rs2594989	1.000	rs2606747	chr3:11374955	T/C	cg00170343	chr3:11313890	ATG7	0.54	5.2	0.32	4.35e-7	Circulating chemerin levels;
SARC	cis	rs7635838	0.718	rs2248971	chr3:11403441	T/C	cg00170343	chr3:11313890	ATG7	0.63	8.78	0.5	3.53e-16	HDL cholesterol;
SARC	cis	rs3126085	0.935	rs11204980	chr1:152296191	G/C	cg26876637	chr1:152193138	HRNR	-0.5	-5.61	-0.34	5.74e-8	Atopic dermatitis;
SARC	cis	rs9309473	0.583	rs35885918	chr2:73612234	T/C	cg20560298	chr2:73613845	ALMS1	-0.54	-7.02	-0.42	2.46e-11	Metabolite levels;
SARC	cis	rs12681366	0.708	rs2470728	chr8:95366370	C/T	cg26464482	chr8:95565502	KIAA1429	-0.45	-5.53	-0.34	8.75e-8	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs7246657	1.000	rs34544865	chr19:37801242	G/C	cg14683738	chr19:37701593	ZNF585B	0.59	4.92	0.31	1.66e-6	Coronary artery calcification;
SARC	cis	rs910316	0.783	rs11850751	chr14:75590113	A/T	cg08847533	chr14:75593920	NEK9	0.9	15.15	0.7	1.56e-36	Height;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg23634678	chr11:102963104	DCUN1D5	-0.57	-6.65	-0.4	2.11e-10	Brain volume in infants (cerebrospinal fluid);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg14475772	chr1:150207136	ANP32E	0.5	6.49	0.39	5.13e-10	Chemerin levels;
SARC	cis	rs78545713	0.892	rs11751286	chr6:26241361	C/G	cg00631329	chr6:26305371	NA	-0.7	-6.33	-0.38	1.22e-9	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs11098499	0.954	rs1546505	chr4:120241224	A/G	cg09307838	chr4:120376055	NA	0.9	12.47	0.63	1.12e-27	Corneal astigmatism;
SARC	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg21724239	chr8:58056113	NA	0.45	4.88	0.3	1.99e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg22800045	chr5:56110881	MAP3K1	0.74	7.92	0.46	9.76e-14	Initial pursuit acceleration;
SARC	trans	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg20587970	chr11:113659929	NA	-1.01	-10.18	-0.55	2.18e-20	Hip circumference adjusted for BMI;
SARC	trans	rs1994135	0.692	rs1579909	chr12:33694780	T/C	cg13010199	chr12:38710504	ALG10B	0.62	7.39	0.44	2.64e-12	Resting heart rate;
SARC	trans	rs11098499	0.954	rs6847248	chr4:120225955	A/G	cg25214090	chr10:38739885	LOC399744	0.52	6.44	0.39	6.72e-10	Corneal astigmatism;
SARC	cis	rs2011503	1.000	rs1036215	chr19:19657198	C/T	cg03709012	chr19:19516395	GATAD2A	0.58	4.88	0.3	2e-6	Bipolar disorder;
SARC	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg18404041	chr3:52824283	ITIH1	-0.38	-5.69	-0.35	3.87e-8	Intelligence (multi-trait analysis);
SARC	cis	rs6088813	1.000	rs6060402	chr20:34005240	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	-0.43	-5.13	-0.32	6.17e-7	Height;
SARC	cis	rs7868228	1.000	rs7868228	chr9:21667762	A/G	cg23029519	chr9:21187344	IFNA4	-0.42	-4.8	-0.3	2.9e-6	Gut microbiome composition (winter);
SARC	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg16325326	chr1:53192061	ZYG11B	0.95	18.17	0.77	1.52e-46	Monocyte count;
SARC	cis	rs7412746	0.658	rs59024312	chr1:150909005	T/G	cg13175981	chr1:150552382	MCL1	-0.48	-5.86	-0.36	1.57e-8	Melanoma;
SARC	cis	rs9868809	0.656	rs13324119	chr3:48710606	G/C	cg04581018	chr3:49236808	CCDC36	0.48	4.81	0.3	2.7e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs12464559	0.522	rs7583148	chr2:152620986	C/T	cg01189475	chr2:152685088	ARL5A	0.59	4.91	0.31	1.73e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg16405210	chr4:1374714	KIAA1530	-0.5	-5.82	-0.36	1.99e-8	Obesity-related traits;
SARC	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg26681399	chr22:41777847	TEF	-0.43	-4.97	-0.31	1.28e-6	Vitiligo;
SARC	cis	rs933688	1.000	rs12651840	chr5:90729592	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.05	13.15	0.65	6.48e-30	Smoking behavior;
SARC	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg12564285	chr5:131593104	PDLIM4	-0.46	-6.28	-0.38	1.64e-9	Breast cancer;
SARC	cis	rs826838	0.616	rs9668847	chr12:38614669	C/T	cg13010199	chr12:38710504	ALG10B	0.52	6.58	0.4	3.09e-10	Heart rate;
SARC	cis	rs11249608	0.548	rs12152869	chr5:178462520	A/G	cg01312482	chr5:178451176	ZNF879	-0.37	-4.74	-0.3	3.69e-6	Pubertal anthropometrics;
SARC	cis	rs9910055	0.529	rs190144	chr17:42164584	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.47	-5.45	-0.34	1.28e-7	Total body bone mineral density;
SARC	cis	rs11581859	0.613	rs4268372	chr1:99197041	T/C	cg20286094	chr1:99190917	SNX7	-0.42	-4.99	-0.31	1.2e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs28374715	0.578	rs17730888	chr15:41637547	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.14	-19.01	-0.78	2.72e-49	Ulcerative colitis;
SARC	cis	rs11098499	0.644	rs7676296	chr4:120555687	A/G	cg09307838	chr4:120376055	NA	0.76	10.31	0.56	8.82e-21	Corneal astigmatism;
SARC	cis	rs644799	0.610	rs1255179	chr11:95472097	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.71	9.9	0.54	1.58e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs6429082	0.633	rs1416473	chr1:235563259	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.6	-7.06	-0.42	1.87e-11	Adiposity;
SARC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.53	0.57	1.79e-21	Prudent dietary pattern;
SARC	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg13939156	chr17:80058883	NA	0.42	6.41	0.39	8.17e-10	Life satisfaction;
SARC	trans	rs7819412	0.521	rs10110684	chr8:11039159	G/C	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.29	-0.38	1.53e-9	Triglycerides;
SARC	cis	rs10435719	0.580	rs13260712	chr8:11782570	A/C	cg02127589	chr8:12458309	NA	-0.32	-4.74	-0.3	3.75e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
SARC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg14159672	chr1:205819179	PM20D1	0.85	13.86	0.67	2.86e-32	Menarche (age at onset);
SARC	trans	rs7980799	0.682	rs1601007	chr12:33609675	C/G	cg26384229	chr12:38710491	ALG10B	0.61	7.57	0.44	8.91e-13	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs477895	1.000	rs2286614	chr11:64068310	C/T	cg04317338	chr11:64019027	PLCB3	0.62	5.05	0.31	8.86e-7	Mean platelet volume;
SARC	cis	rs2153535	0.580	rs1832101	chr6:8460177	A/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.19	0.47	1.76e-14	Motion sickness;
SARC	cis	rs1559088	0.625	rs10411739	chr19:33616327	T/C	cg27124370	chr19:33622961	WDR88	0.54	7.15	0.42	1.13e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs526231	0.578	rs34794	chr5:102423368	T/A	cg23492399	chr5:102201601	PAM	-0.53	-5.72	-0.35	3.23e-8	Primary biliary cholangitis;
SARC	cis	rs6912958	0.712	rs2814712	chr6:88396322	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.46	6.02	0.37	6.89e-9	Monocyte percentage of white cells;
SARC	cis	rs739401	0.611	rs7109088	chr11:3027485	G/T	cg05729581	chr11:3078854	CARS	-0.49	-6.37	-0.38	1.02e-9	Longevity;
SARC	cis	rs62191099	0.885	rs62191102	chr2:239861798	A/G	cg07215236	chr2:239865226	NA	0.37	4.98	0.31	1.21e-6	Alcohol dependence;
SARC	trans	rs7824557	0.564	rs7839307	chr8:11198792	A/G	cg06636001	chr8:8085503	FLJ10661	0.62	8.15	0.47	2.19e-14	Retinal vascular caliber;
SARC	cis	rs12188164	0.620	rs1043356	chr5:480948	C/T	cg21144161	chr5:423903	AHRR	-0.33	-4.82	-0.3	2.56e-6	Cystic fibrosis severity;
SARC	cis	rs6088590	0.561	rs6088528	chr20:33156742	G/A	cg08999081	chr20:33150536	PIGU	0.44	6.78	0.41	9.96e-11	Coronary artery disease;
SARC	cis	rs4478037	0.822	rs59834381	chr3:33116313	G/A	cg19404215	chr3:33155277	CRTAP	0.75	5.88	0.36	1.44e-8	Major depressive disorder;
SARC	cis	rs7927771	0.832	rs67116452	chr11:47385194	G/A	cg20307385	chr11:47447363	PSMC3	-0.57	-7.0	-0.42	2.74e-11	Subjective well-being;
SARC	cis	rs1050631	0.592	rs1010955	chr18:33710610	T/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.59	7.11	0.42	1.41e-11	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs41271473	0.526	rs12353961	chr1:228738252	G/C	cg10167378	chr1:228756711	NA	0.61	5.33	0.33	2.27e-7	Chronic lymphocytic leukemia;
SARC	cis	rs2120243	0.592	rs1456110	chr3:157106072	G/A	cg24825693	chr3:157122686	VEPH1	-0.43	-5.98	-0.36	8.5e-9	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs1008375	0.966	rs7675735	chr4:17587137	T/A	cg02297831	chr4:17616191	MED28	0.49	6.22	0.38	2.31e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7020830	0.898	rs308521	chr9:37367094	T/C	cg14294708	chr9:37120828	ZCCHC7	1.06	17.72	0.76	4.58e-45	Schizophrenia;
SARC	cis	rs1950500	0.509	rs12895424	chr14:24823186	G/T	cg22990158	chr14:24802150	ADCY4	-0.34	-5.77	-0.35	2.5e-8	Height;
SARC	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg16325326	chr1:53192061	ZYG11B	-0.82	-13.46	-0.66	6.13e-31	Monocyte count;
SARC	cis	rs10089	1.000	rs10478796	chr5:127436187	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	10.32	0.56	8.06e-21	Ileal carcinoids;
SARC	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg20607798	chr8:58055168	NA	0.61	5.45	0.34	1.27e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1348850	0.574	rs13431105	chr2:178434674	A/G	cg23306229	chr2:178417860	TTC30B	0.86	8.27	0.48	1.06e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	12.62	0.64	3.53e-28	Chronic sinus infection;
SARC	cis	rs8077889	0.672	rs1234612	chr17:41840802	A/G	cg26893861	chr17:41843967	DUSP3	0.99	15.68	0.72	2.67e-38	Triglycerides;
SARC	cis	rs1348850	0.526	rs6433672	chr2:178378175	G/T	cg23306229	chr2:178417860	TTC30B	0.78	7.45	0.44	1.8e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.51	5.72	0.35	3.25e-8	Prudent dietary pattern;
SARC	cis	rs11792861	0.926	rs1051474	chr9:111881856	T/C	cg13535736	chr9:111863775	C9orf5	-0.4	-4.99	-0.31	1.18e-6	Menarche (age at onset);
SARC	cis	rs875971	0.830	rs427973	chr7:65526648	C/A	cg11764359	chr7:65958608	NA	0.79	10.78	0.58	3.08e-22	Aortic root size;
SARC	cis	rs7953249	0.807	rs2393791	chr12:121423956	A/G	cg25281562	chr12:121454272	C12orf43	0.4	4.88	0.3	1.93e-6	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs7824557	0.583	rs2263511	chr8:11233318	A/C	cg21775007	chr8:11205619	TDH	-0.63	-8.37	-0.48	5.38e-15	Retinal vascular caliber;
SARC	cis	rs12079745	0.793	rs113298876	chr1:169280579	C/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.83	-5.12	-0.32	6.39e-7	QT interval;
SARC	cis	rs2898681	0.770	rs62336795	chr4:53737772	G/A	cg00338735	chr4:53728038	RASL11B	0.38	4.9	0.31	1.81e-6	Optic nerve measurement (cup area);
SARC	cis	rs826838	1.000	rs10880963	chr12:38748408	T/C	cg13010199	chr12:38710504	ALG10B	0.82	11.78	0.61	1.96e-25	Heart rate;
SARC	cis	rs77741769	0.571	rs11065311	chr12:121324115	A/T	cg02403541	chr12:121454288	C12orf43	-0.42	-5.27	-0.33	3.16e-7	Mean corpuscular volume;
SARC	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg06212747	chr3:49208901	KLHDC8B	0.67	8.9	0.5	1.62e-16	Parkinson's disease;
SARC	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg11764359	chr7:65958608	NA	-0.79	-9.75	-0.54	4.53e-19	Aortic root size;
SARC	cis	rs73206853	0.534	rs13313211	chr12:110509616	A/T	cg08946844	chr12:110511112	NA	0.63	5.02	0.31	1.03e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs2303759	0.709	rs10411679	chr19:49826480	A/T	cg22307029	chr19:49891270	CCDC155	0.6	6.76	0.4	1.1e-10	Multiple sclerosis;
SARC	trans	rs17685	0.753	rs4732542	chr7:75663203	A/G	cg19862616	chr7:65841803	NCRNA00174	0.61	7.62	0.45	6.39e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs870825	0.929	rs72689269	chr4:185592085	T/C	cg04058563	chr4:185651563	MLF1IP	0.77	8.75	0.5	4.36e-16	Blood protein levels;
SARC	cis	rs8101881	0.535	rs9304839	chr19:33365186	T/C	cg02997394	chr19:33096574	ANKRD27	-0.42	-4.85	-0.3	2.25e-6	Blood metabolite levels;Urinary metabolites;Urinary metabolites (H-NMR features);
SARC	cis	rs116095464	1.000	rs3777237	chr5:307641	C/T	cg22496380	chr5:211416	CCDC127	-0.88	-5.72	-0.35	3.17e-8	Breast cancer;
SARC	cis	rs910316	0.664	rs2098252	chr14:75492732	T/C	cg11812906	chr14:75593930	NEK9	0.77	10.34	0.56	7.35e-21	Height;
SARC	cis	rs6456156	0.586	rs2017338	chr6:167471714	G/A	cg23791538	chr6:167370224	RNASET2	-0.52	-6.81	-0.41	8.22e-11	Primary biliary cholangitis;
SARC	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.61	-6.27	-0.38	1.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs11785400	0.793	rs4587307	chr8:143738529	G/A	cg24634471	chr8:143751801	JRK	0.59	7.45	0.44	1.83e-12	Schizophrenia;
SARC	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg00933542	chr6:150070202	PCMT1	0.31	5.36	0.33	2.04e-7	Lung cancer;
SARC	cis	rs9513627	1.000	rs73556172	chr13:100121684	A/G	cg25919922	chr13:100150906	NA	-0.7	-5.26	-0.33	3.26e-7	Obesity-related traits;
SARC	cis	rs16976116	0.901	rs28541469	chr15:55500788	G/A	cg17854078	chr15:55489399	RSL24D1	0.66	6.53	0.39	4.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs3760982	0.585	rs62116964	chr19:44291986	T/C	cg11993925	chr19:44307056	LYPD5	0.3	4.77	0.3	3.22e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
SARC	cis	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg21775007	chr8:11205619	TDH	-0.49	-6.37	-0.39	9.96e-10	Neuroticism;
SARC	cis	rs6496667	1.000	rs16944254	chr15:90898527	C/T	cg22089800	chr15:90895588	ZNF774	0.51	4.79	0.3	2.95e-6	Rheumatoid arthritis;
SARC	cis	rs1153858	0.943	rs4774580	chr15:45652086	G/A	cg14582100	chr15:45693742	SPATA5L1	0.35	4.8	0.3	2.86e-6	Homoarginine levels;
SARC	trans	rs1814175	0.817	rs10128730	chr11:50023369	G/T	cg15704280	chr7:45808275	SEPT13	-0.97	-18.31	-0.77	5.28e-47	Height;
SARC	cis	rs36051895	0.659	rs7025540	chr9:5043152	T/C	cg02405213	chr9:5042618	JAK2	-0.51	-5.99	-0.37	7.88e-9	Pediatric autoimmune diseases;
SARC	cis	rs1215050	0.740	rs783924	chr4:98969234	C/T	cg05340658	chr4:99064831	C4orf37	-0.47	-6.47	-0.39	5.84e-10	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs11077998	0.967	rs7350963	chr17:80491067	G/A	cg10255544	chr17:80519551	FOXK2	0.45	6.52	0.39	4.25e-10	Reticulocyte fraction of red cells;
SARC	cis	rs208520	0.690	rs3899423	chr6:66835285	A/G	cg07460842	chr6:66804631	NA	-1.08	-14.78	-0.7	2.48e-35	Exhaled nitric oxide output;
SARC	cis	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg26116260	chr4:7069785	GRPEL1	-0.81	-8.52	-0.49	2.01e-15	Monocyte percentage of white cells;
SARC	cis	rs13202913	0.837	rs9397052	chr6:151779228	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.63	5.34	0.33	2.18e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs2153535	0.580	rs1932283	chr6:8477661	C/T	cg21535247	chr6:8435926	SLC35B3	0.57	7.27	0.43	5.31e-12	Motion sickness;
SARC	cis	rs748404	0.660	rs542898	chr15:43719392	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.4	4.78	0.3	3.13e-6	Lung cancer;
SARC	cis	rs1697139	0.583	rs17289614	chr5:66541592	G/A	cg11553311	chr5:66541588	NA	0.31	4.96	0.31	1.33e-6	Breast cancer;
SARC	cis	rs7588746	0.521	rs73054585	chr2:201144386	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.49	-4.94	-0.31	1.52e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs17376456	0.877	rs9314093	chr5:93333347	G/A	cg21475434	chr5:93447410	FAM172A	0.86	7.68	0.45	4.4e-13	Diabetic retinopathy;
SARC	trans	rs1814175	0.817	rs11040700	chr11:50023832	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-18.31	-0.77	5.28e-47	Height;
SARC	cis	rs291671	0.867	rs75399011	chr20:32069986	G/A	cg05840533	chr20:31755943	C20orf70	-0.82	-5.28	-0.33	2.95e-7	Hair color;
SARC	cis	rs898097	0.578	rs6502021	chr17:80907728	T/C	cg20578329	chr17:80767326	TBCD	0.36	5.04	0.31	9.14e-7	Breast cancer;
SARC	cis	rs9948	0.655	rs17119562	chr2:97381844	G/C	cg01990225	chr2:97406019	LMAN2L	-1.0	-7.24	-0.43	6.58e-12	Erectile dysfunction and prostate cancer treatment;
SARC	trans	rs1853207	0.867	rs9332108	chr10:96699980	T/C	cg02737782	chr1:8014393	NA	-0.92	-6.26	-0.38	1.86e-9	Blood metabolite levels;
SARC	cis	rs9398803	0.865	rs2184968	chr6:126760994	A/G	cg20229609	chr6:126660872	C6orf173	0.38	5.56	0.34	7.27e-8	Male-pattern baldness;
SARC	cis	rs12893668	0.608	rs12889721	chr14:104034863	C/T	cg26031613	chr14:104095156	KLC1	-0.53	-5.67	-0.35	4.22e-8	Reticulocyte count;
SARC	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg13395646	chr4:1353034	KIAA1530	-0.47	-5.64	-0.35	5.01e-8	Obesity-related traits;
SARC	cis	rs875971	0.545	rs7787063	chr7:65628999	G/A	cg11764359	chr7:65958608	NA	0.67	6.65	0.4	2.03e-10	Aortic root size;
SARC	cis	rs7937890	0.874	rs6486191	chr11:14403739	G/A	cg02886208	chr11:14281011	SPON1	-0.36	-4.92	-0.31	1.64e-6	Mitochondrial DNA levels;
SARC	cis	rs9388451	0.531	rs9321057	chr6:126156943	G/A	cg05901451	chr6:126070800	HEY2	-0.49	-5.83	-0.36	1.84e-8	Brugada syndrome;
SARC	cis	rs2354432	1.000	rs2354432	chr1:146693229	C/T	cg25205988	chr1:146714368	CHD1L	1.1	11.91	0.62	7.61e-26	Mitochondrial DNA levels;
SARC	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg16743903	chr16:89593216	SPG7	-0.36	-4.84	-0.3	2.31e-6	Multiple myeloma (IgH translocation);
SARC	cis	rs7113874	0.659	rs1867810	chr11:8505528	A/T	cg09828998	chr11:8703972	RPL27A	0.47	4.94	0.31	1.46e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs67478160	0.643	rs12880821	chr14:104276049	C/T	cg08213375	chr14:104286397	PPP1R13B	0.26	4.74	0.3	3.79e-6	Schizophrenia;
SARC	cis	rs7412746	0.611	rs12085336	chr1:150775780	A/T	cg15448220	chr1:150897856	SETDB1	0.47	6.12	0.37	3.85e-9	Melanoma;
SARC	cis	rs2070997	0.534	rs6597640	chr9:133669338	G/T	cg11464064	chr9:133710261	ABL1	0.58	5.77	0.35	2.52e-8	Response to amphetamines;
SARC	cis	rs9398803	0.687	rs4243491	chr6:126938536	T/C	cg20229609	chr6:126660872	C6orf173	0.37	5.39	0.33	1.74e-7	Male-pattern baldness;
SARC	cis	rs637571	0.544	rs617791	chr11:65702523	C/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.63	8.21	0.47	1.56e-14	Eosinophil percentage of white cells;
SARC	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg24531977	chr5:56204891	C5orf35	-0.52	-5.24	-0.32	3.63e-7	Initial pursuit acceleration;
SARC	cis	rs9344	0.806	rs2450255	chr11:69452358	T/C	cg09886342	chr11:69490314	ORAOV1	-0.37	-4.93	-0.31	1.6e-6	Immunoglobulin light chain (AL) amyloidosis (kidney involvement);Immunoglobulin light chain (AL) amyloidosis (serum Ig light chain only lambda/kappa based profile);Immunoglobulin light chain (AL) amyloidosis;Immunoglobulin light chain (AL) amyloidosis (heart involvement);Immunoglobulin light chain (AL) amyloidosis (serum Ig light chain only lambda based profile);Immunoglobulin light chain (AL) amyloidosis (serum Ig lambda profile);
SARC	cis	rs920590	0.704	rs7008703	chr8:19656648	C/T	cg17834443	chr8:19674713	INTS10	0.41	5.18	0.32	4.81e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs56235845	0.694	rs6876677	chr5:176755342	T/C	cg17509989	chr5:176798049	RGS14	0.58	7.93	0.46	9.25e-14	Hemoglobin concentration;Hematocrit;
SARC	cis	rs79387448	0.638	rs11465670	chr2:103034440	A/G	cg09003973	chr2:102972529	NA	0.76	7.25	0.43	6.05e-12	Gut microbiota (bacterial taxa);
SARC	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg05890377	chr2:74357713	NA	0.58	7.09	0.42	1.57e-11	Gestational age at birth (maternal effect);
SARC	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg06634786	chr22:41940651	POLR3H	0.57	6.71	0.4	1.47e-10	Vitiligo;
SARC	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6546550	0.901	rs6741449	chr2:70156589	A/G	cg02498382	chr2:70120550	SNRNP27	-0.33	-5.4	-0.33	1.66e-7	Prevalent atrial fibrillation;
SARC	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg02018176	chr4:1364513	KIAA1530	0.34	5.07	0.31	8.29e-7	Obesity-related traits;
SARC	cis	rs910316	0.687	rs11627442	chr14:75669649	A/G	cg23033748	chr14:75592666	NEK9	-0.36	-4.88	-0.3	1.96e-6	Height;
SARC	cis	rs288326	0.561	rs17265866	chr2:183822374	G/C	cg09997497	chr2:183902928	NCKAP1	0.74	5.1	0.32	6.97e-7	Blood protein levels;
SARC	cis	rs9309473	0.950	rs6546854	chr2:73834034	A/G	cg07208825	chr2:73871855	ALMS1P	0.32	4.71	0.3	4.16e-6	Metabolite levels;
SARC	cis	rs10979	1.000	rs9399448	chr6:143896315	G/T	cg25407410	chr6:143891975	LOC285740	-0.64	-8.78	-0.5	3.67e-16	Hypospadias;
SARC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.54	6.14	0.37	3.48e-9	Prudent dietary pattern;
SARC	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.45	-5.49	-0.34	1.06e-7	Tonsillectomy;
SARC	cis	rs4555082	0.957	rs8022526	chr14:105756485	A/G	cg06808227	chr14:105710500	BRF1	-0.53	-7.03	-0.42	2.31e-11	Mean platelet volume;Platelet distribution width;
SARC	cis	rs2028299	0.879	rs8034631	chr15:90422665	A/T	cg19708238	chr15:90437601	AP3S2	0.44	4.96	0.31	1.35e-6	Type 2 diabetes;
SARC	cis	rs1023500	0.505	rs134889	chr22:42674350	A/T	cg15557168	chr22:42548783	NA	-0.4	-5.66	-0.35	4.39e-8	Schizophrenia;
SARC	trans	rs208520	0.802	rs4710315	chr6:66887594	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.03	-12.94	-0.65	3.28e-29	Exhaled nitric oxide output;
SARC	cis	rs9303280	0.901	rs9303277	chr17:37976469	C/T	cg20243544	chr17:37824526	PNMT	0.41	5.49	0.34	1.05e-7	Self-reported allergy;
SARC	cis	rs9398803	0.661	rs1262543	chr6:127032499	G/A	cg20229609	chr6:126660872	C6orf173	-0.35	-5.08	-0.32	7.69e-7	Male-pattern baldness;
SARC	cis	rs2916247	1.000	rs2920466	chr8:92998096	A/T	cg10183463	chr8:93005414	RUNX1T1	-0.56	-5.73	-0.35	3.13e-8	Intelligence (multi-trait analysis);
SARC	cis	rs3956705	0.866	rs71532543	chr7:32998910	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.42	4.93	0.31	1.59e-6	Red cell distribution width;
SARC	cis	rs35110281	0.782	rs9981790	chr21:45045052	G/C	cg21573476	chr21:45109991	RRP1B	-0.49	-7.35	-0.43	3.32e-12	Mean corpuscular volume;
SARC	cis	rs7681440	0.838	rs1348224	chr4:90761946	G/A	cg02192967	chr4:90758406	SNCA	0.35	5.04	0.31	9.42e-7	Dementia with Lewy bodies;
SARC	cis	rs963731	0.649	rs4670901	chr2:39199271	T/C	cg04010122	chr2:39346883	SOS1	-0.88	-5.65	-0.35	4.77e-8	Corticobasal degeneration;
SARC	cis	rs8027181	0.839	rs8024986	chr15:73024868	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	-0.4	-5.4	-0.33	1.6e-7	Triglyceride levels;
SARC	cis	rs2777491	1.000	rs2730057	chr15:41736275	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.83	-12.27	-0.63	4.83e-27	Ulcerative colitis;
SARC	cis	rs2013441	1.000	rs2703799	chr17:20085768	G/T	cg13482628	chr17:19912719	NA	-0.48	-6.16	-0.37	3.1e-9	Obesity-related traits;
SARC	cis	rs58235267	0.656	rs12713469	chr2:63059927	C/T	cg17519650	chr2:63277830	OTX1	-0.53	-6.79	-0.41	9.05e-11	Prostate-specific antigen levels (conditioned on lead SNPs);
SARC	cis	rs7666738	0.830	rs28769113	chr4:98950371	T/G	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs12295403	0.723	rs12787397	chr11:18687025	C/T	cg09201001	chr11:18656081	SPTY2D1	0.46	4.86	0.3	2.14e-6	Ovarian reserve;
SARC	cis	rs62244186	0.659	rs12489887	chr3:44547124	A/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.44	5.5	0.34	1.02e-7	Depressive symptoms;
SARC	cis	rs7824557	0.591	rs2572452	chr8:11228254	C/T	cg21775007	chr8:11205619	TDH	-0.67	-9.47	-0.53	3.24e-18	Retinal vascular caliber;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg13216124	chr8:23285320	NA	0.49	6.89	0.41	5.23e-11	Thyroid stimulating hormone;
SARC	cis	rs854765	0.655	rs4470201	chr17:17844870	G/A	cg05444541	chr17:17804740	TOM1L2	-0.3	-5.12	-0.32	6.48e-7	Total body bone mineral density;
SARC	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg00149659	chr3:10157352	C3orf10	0.65	6.21	0.38	2.38e-9	Alzheimer's disease;
SARC	cis	rs34172651	0.687	rs8044992	chr16:24811207	T/C	cg06028605	chr16:24865363	SLC5A11	0.29	5.06	0.31	8.31e-7	Intelligence (multi-trait analysis);
SARC	cis	rs4711350	0.765	rs6921772	chr6:33749686	A/G	cg18005901	chr6:33739558	LEMD2	-0.42	-4.83	-0.3	2.52e-6	Schizophrenia;
SARC	cis	rs7666738	0.830	rs1593573	chr4:98925293	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4792901	0.959	rs12103443	chr17:41631258	A/G	cg22562494	chr17:41607896	ETV4	-0.33	-5.25	-0.32	3.51e-7	Dupuytren's disease;
SARC	cis	rs10845606	1.000	rs10845610	chr12:12839107	G/A	cg04607235	chr12:12878440	APOLD1	-0.52	-5.13	-0.32	6.11e-7	Systemic lupus erythematosus;
SARC	cis	rs28386778	0.700	rs4968672	chr17:62011352	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.65	-7.77	-0.45	2.47e-13	Prudent dietary pattern;
SARC	cis	rs11098499	0.754	rs12509621	chr4:120249660	T/C	cg09307838	chr4:120376055	NA	0.81	11.03	0.59	4.84e-23	Corneal astigmatism;
SARC	cis	rs854765	0.583	rs9913724	chr17:17819101	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.43	5.67	0.35	4.17e-8	Total body bone mineral density;
SARC	cis	rs7904368	0.806	rs4612698	chr10:16855070	C/A	cg23933602	chr10:16859644	RSU1	0.59	5.94	0.36	1.02e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs4356932	1.000	rs4302486	chr4:76953077	C/T	cg24176760	chr4:76958061	ART3;CXCL11	0.29	4.83	0.3	2.46e-6	Blood protein levels;
SARC	cis	rs9467773	1.000	rs9295695	chr6:26528250	C/T	cg11502198	chr6:26597334	ABT1	-0.49	-6.07	-0.37	5.18e-9	Intelligence (multi-trait analysis);
SARC	cis	rs2380220	0.810	rs877096	chr6:95937046	A/G	cg04719120	chr6:96025338	MANEA	-0.64	-6.4	-0.39	8.45e-10	Behavioural disinhibition (generation interaction);
SARC	cis	rs7264396	0.690	rs2425180	chr20:34447160	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.47	-0.44	1.58e-12	Total cholesterol levels;
SARC	cis	rs270601	0.866	rs460271	chr5:131630062	C/G	cg12564285	chr5:131593104	PDLIM4	0.4	5.33	0.33	2.34e-7	Acylcarnitine levels;
SARC	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg21644426	chr2:191273491	MFSD6	-0.51	-6.51	-0.39	4.46e-10	Pulse pressure;
SARC	cis	rs11585357	0.895	rs72633828	chr1:17632251	G/A	cg08277548	chr1:17600880	PADI3	-0.45	-5.32	-0.33	2.42e-7	Hair shape;
SARC	cis	rs2933343	0.700	rs789240	chr3:128630635	T/C	cg25356066	chr3:128598488	ACAD9	0.7	9.3	0.52	1.08e-17	IgG glycosylation;
SARC	cis	rs9902453	0.808	rs76515799	chr17:28169491	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	7.16	0.42	1.07e-11	Coffee consumption (cups per day);
SARC	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.49	-6.16	-0.37	3.17e-9	Intelligence (multi-trait analysis);
SARC	cis	rs4969178	0.965	rs11077364	chr17:76400337	C/A	cg20026190	chr17:76395443	PGS1	0.4	5.35	0.33	2.05e-7	HDL cholesterol levels;
SARC	cis	rs11098499	0.954	rs13151285	chr4:120314741	C/A	cg09160332	chr4:120329925	NA	-0.33	-4.77	-0.3	3.27e-6	Corneal astigmatism;
SARC	cis	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg25427524	chr10:38739819	LOC399744	-0.58	-9.06	-0.51	5.4e-17	Extrinsic epigenetic age acceleration;
SARC	cis	rs708547	0.647	rs781668	chr4:57825140	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.49	-5.92	-0.36	1.12e-8	Response to bleomycin (chromatid breaks);
SARC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.6	7.69	0.45	4.03e-13	Lymphocyte counts;
SARC	cis	rs9790314	0.663	rs7630674	chr3:160813597	G/A	cg03342759	chr3:160939853	NMD3	-0.52	-6.43	-0.39	6.96e-10	Morning vs. evening chronotype;
SARC	cis	rs921968	0.541	rs933995	chr2:219650718	G/A	cg02176678	chr2:219576539	TTLL4	-0.33	-5.07	-0.32	8.06e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs2712184	0.756	rs2712163	chr2:217660346	G/A	cg05032264	chr2:217675019	NA	-0.52	-6.77	-0.41	1.03e-10	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
SARC	cis	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg00071950	chr4:10020882	SLC2A9	0.39	6.31	0.38	1.4e-9	Bone mineral density;
SARC	cis	rs8141529	0.748	rs6519766	chr22:29269991	A/G	cg02153584	chr22:29168773	CCDC117	-0.77	-11.22	-0.59	1.19e-23	Lymphocyte counts;
SARC	cis	rs1569175	0.677	rs67647314	chr2:200818928	G/A	cg23649088	chr2:200775458	C2orf69	-0.87	-5.11	-0.32	6.59e-7	Response to treatment for acute lymphoblastic leukemia;
SARC	cis	rs637571	0.544	rs617791	chr11:65702523	C/G	cg04055107	chr11:65626734	MUS81;CFL1	0.42	5.18	0.32	4.71e-7	Eosinophil percentage of white cells;
SARC	cis	rs9611519	0.542	rs8139770	chr22:41416181	C/T	cg06634786	chr22:41940651	POLR3H	-0.38	-4.93	-0.31	1.54e-6	Neuroticism;
SARC	trans	rs61931739	0.817	rs10743842	chr12:34306859	C/T	cg26384229	chr12:38710491	ALG10B	0.62	8.36	0.48	5.78e-15	Morning vs. evening chronotype;
SARC	cis	rs705471	0.762	rs555978	chr10:3662558	G/A	cg14308648	chr10:3568949	NA	0.57	7.78	0.45	2.31e-13	Capecitabine sensitivity;
SARC	cis	rs5997397	1.000	rs5997397	chr22:29154455	A/G	cg02153584	chr22:29168773	CCDC117	0.55	7.41	0.44	2.32e-12	Red cell distribution width;
SARC	cis	rs10979	0.571	rs6909701	chr6:143922918	C/G	cg25407410	chr6:143891975	LOC285740	-0.49	-5.36	-0.33	2.02e-7	Hypospadias;
SARC	cis	rs4906332	0.966	rs17679729	chr14:103924312	A/G	cg26031613	chr14:104095156	KLC1	-0.49	-5.74	-0.35	2.87e-8	Coronary artery disease;
SARC	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg01316550	chr5:56110833	MAP3K1	0.54	4.95	0.31	1.39e-6	Initial pursuit acceleration;
SARC	cis	rs6912958	0.559	rs451465	chr6:88043372	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-5.96	-0.36	9.48e-9	Monocyte percentage of white cells;
SARC	cis	rs7696431	0.933	rs6854026	chr4:169690814	T/C	cg07840446	chr4:169690674	PALLD	0.36	5.3	0.33	2.66e-7	Coronary artery disease;
SARC	cis	rs1003719	0.788	rs2835574	chr21:38455324	C/A	cg10648535	chr21:38446584	PIGP;TTC3	0.65	9.46	0.53	3.43e-18	Eye color traits;
SARC	cis	rs1008375	0.966	rs6832387	chr4:17697546	G/T	cg16339924	chr4:17578868	LAP3	0.52	6.67	0.4	1.8e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs8067545	0.750	rs9896411	chr17:19987610	A/T	cg13482628	chr17:19912719	NA	0.54	7.13	0.42	1.25e-11	Schizophrenia;
SARC	cis	rs5758511	0.680	rs5758667	chr22:42633204	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.46	6.9	0.41	4.87e-11	Birth weight;
SARC	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg19901468	chr14:105411992	AHNAK2	-0.7	-10.23	-0.56	1.58e-20	Rheumatoid arthritis;
SARC	cis	rs13256369	0.802	rs11249884	chr8:8561552	C/T	cg18904891	chr8:8559673	CLDN23	-0.45	-5.01	-0.31	1.1e-6	Obesity-related traits;
SARC	cis	rs1878931	0.501	rs9635563	chr16:3416940	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.74	9.51	0.53	2.48e-18	Body mass index (adult);
SARC	cis	rs11509153	0.687	rs1435543	chr7:12263234	C/T	cg23422036	chr7:12250390	TMEM106B	0.47	6.04	0.37	6.14e-9	Residual cognition;
SARC	cis	rs950169	0.810	rs2879976	chr15:85109578	G/A	cg03959625	chr15:84868606	LOC388152	0.36	4.89	0.3	1.9e-6	Schizophrenia;
SARC	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg22920501	chr2:26401640	FAM59B	0.61	8.19	0.47	1.71e-14	Gut microbiome composition (summer);
SARC	cis	rs1691799	0.899	rs1168308	chr12:66742183	A/G	cg16791601	chr12:66731901	HELB	-0.72	-10.75	-0.58	3.75e-22	White blood cell count (basophil);
SARC	cis	rs10508881	0.935	rs9804352	chr10:44541780	A/G	cg09554077	chr10:44749378	NA	-0.27	-4.75	-0.3	3.55e-6	Endometriosis;
SARC	cis	rs2120019	0.935	rs8042409	chr15:75350433	G/A	cg12414181	chr15:75287860	SCAMP5	-0.47	-5.36	-0.33	2e-7	Blood trace element (Zn levels);
SARC	cis	rs10089	0.953	rs10463839	chr5:127519675	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	8.33	0.48	6.91e-15	Ileal carcinoids;
SARC	cis	rs2439831	0.681	rs1095386	chr15:43609509	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	12.07	0.62	2.17e-26	Lung cancer in ever smokers;
SARC	cis	rs10782582	0.593	rs6704444	chr1:76205108	T/C	cg10523679	chr1:76189770	ACADM	-0.44	-5.5	-0.34	9.95e-8	Daytime sleep phenotypes;
SARC	cis	rs4975709	0.569	rs4975742	chr5:1858612	T/C	cg15595755	chr5:1867978	NA	0.5	6.69	0.4	1.68e-10	Cardiovascular disease risk factors;
SARC	cis	rs11190604	1.000	rs9420785	chr10:102240451	C/G	cg07080220	chr10:102295463	HIF1AN	0.7	8.13	0.47	2.6e-14	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs12142240	0.698	rs1135460	chr1:46815970	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-5.46	-0.34	1.22e-7	Menopause (age at onset);
SARC	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg06636001	chr8:8085503	FLJ10661	0.71	10.25	0.56	1.33e-20	Mood instability;
SARC	trans	rs2727020	0.615	rs4980435	chr11:49591576	G/A	cg03929089	chr4:120376271	NA	-0.81	-12.54	-0.63	6.72e-28	Coronary artery disease;
SARC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg08219700	chr8:58056026	NA	0.74	6.82	0.41	7.6e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.36	0.8	1.22e-53	Prudent dietary pattern;
SARC	cis	rs62432291	0.764	rs433256	chr6:159660105	C/T	cg14500486	chr6:159655392	FNDC1	-0.64	-6.37	-0.39	9.75e-10	Joint mobility (Beighton score);
SARC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg22903471	chr2:27725779	GCKR	-0.49	-7.42	-0.44	2.21e-12	Total body bone mineral density;
SARC	trans	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg18328404	chr5:133706819	UBE2B	-0.65	-6.23	-0.38	2.12e-9	Cutaneous psoriasis;
SARC	cis	rs986417	0.748	rs9989223	chr14:60942525	C/A	cg27398547	chr14:60952738	C14orf39	0.88	8.66	0.49	7.84e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs7412746	0.611	rs752376	chr1:150941381	C/T	cg15448220	chr1:150897856	SETDB1	0.52	6.79	0.41	9.19e-11	Melanoma;
SARC	cis	rs2120019	1.000	rs7167285	chr15:75368769	A/G	cg00629941	chr15:75287862	SCAMP5	-0.6	-7.27	-0.43	5.46e-12	Blood trace element (Zn levels);
SARC	cis	rs7216064	1.000	rs62084251	chr17:65878736	G/A	cg12091567	chr17:66097778	LOC651250	-0.64	-6.45	-0.39	6.56e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs9916302	0.904	rs585961	chr17:37444036	G/A	cg20243544	chr17:37824526	PNMT	-0.55	-6.62	-0.4	2.51e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg05025164	chr4:1340916	KIAA1530	0.88	11.48	0.6	1.86e-24	Longevity;
SARC	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg09699651	chr6:150184138	LRP11	0.4	5.02	0.31	1.04e-6	Lung cancer;
SARC	cis	rs1568889	1.000	rs16917735	chr11:28119980	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.7	-9.39	-0.52	5.8e-18	Bipolar disorder;
SARC	cis	rs9916302	0.706	rs9893735	chr17:37469858	A/C	cg20243544	chr17:37824526	PNMT	-0.56	-6.02	-0.37	6.66e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs9467773	0.596	rs2451750	chr6:26646579	A/T	cg12292205	chr6:26970375	C6orf41	0.4	4.88	0.3	1.95e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7945705	0.875	rs4929914	chr11:8824388	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.4	-5.49	-0.34	1.03e-7	Hemoglobin concentration;
SARC	cis	rs710216	0.536	rs710221	chr1:43414200	G/A	cg03128534	chr1:43423976	SLC2A1	0.76	11.04	0.59	4.6e-23	Red cell distribution width;
SARC	cis	rs2204008	0.744	rs11495519	chr12:38060546	C/A	cg26384229	chr12:38710491	ALG10B	0.89	13.14	0.65	6.99e-30	Bladder cancer;
SARC	cis	rs7011049	1.000	rs72640857	chr8:53839067	T/A	cg26025543	chr8:53854495	NA	0.6	5.43	0.34	1.42e-7	Systolic blood pressure;
SARC	cis	rs1707322	1.000	rs7538978	chr1:46505054	C/T	cg06784218	chr1:46089804	CCDC17	-0.35	-6.17	-0.37	2.92e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7660520	0.524	rs4862100	chr4:183732709	G/T	cg04181038	chr4:183730758	NA	0.56	5.83	0.36	1.86e-8	Pediatric autoimmune diseases;
SARC	cis	rs9814567	0.679	rs1880379	chr3:134330612	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.51	-6.61	-0.4	2.53e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs2380220	0.606	rs7747776	chr6:96005852	C/T	cg04719120	chr6:96025338	MANEA	0.61	7.03	0.42	2.23e-11	Behavioural disinhibition (generation interaction);
SARC	cis	rs3820928	0.874	rs2272198	chr2:227893017	A/G	cg05526886	chr2:227700861	RHBDD1	0.48	5.44	0.34	1.35e-7	Pulmonary function;
SARC	trans	rs7824557	0.564	rs7821459	chr8:11236681	T/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.72	-0.5	5.49e-16	Retinal vascular caliber;
SARC	cis	rs1395	0.778	rs724311	chr2:27441645	A/G	cg21747090	chr2:27597821	SNX17	-0.49	-5.85	-0.36	1.64e-8	Blood metabolite levels;
SARC	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg09359103	chr1:154839909	KCNN3	-0.45	-7.34	-0.43	3.47e-12	Prostate cancer;
SARC	cis	rs7756236	0.521	rs6930671	chr6:36625272	T/C	cg08179530	chr6:36648295	CDKN1A	0.53	6.45	0.39	6.33e-10	QRS duration;
SARC	cis	rs6570726	0.791	rs378937	chr6:145834745	C/T	cg05347473	chr6:146136440	FBXO30	0.52	7.23	0.43	6.95e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504073	0.647	rs6997703	chr8:49998364	T/C	cg00325661	chr8:49890786	NA	0.54	7.24	0.43	6.46e-12	Blood metabolite ratios;
SARC	cis	rs6484504	0.576	rs158136	chr11:31220712	C/T	cg26647111	chr11:31128758	NA	-0.39	-5.1	-0.32	7.11e-7	Red blood cell count;
SARC	cis	rs7727544	0.735	rs2569266	chr5:131706791	T/C	cg07395648	chr5:131743802	NA	0.41	4.81	0.3	2.68e-6	Blood metabolite levels;
SARC	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg26119090	chr2:26468346	HADHA;HADHB	0.95	13.96	0.67	1.32e-32	Gut microbiome composition (summer);
SARC	cis	rs9325144	0.872	rs11183390	chr12:38729942	G/T	cg26384229	chr12:38710491	ALG10B	-0.61	-7.34	-0.43	3.45e-12	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg24642844	chr7:1081250	C7orf50	-0.54	-5.75	-0.35	2.82e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs6964587	0.773	rs10488514	chr7:91951842	C/A	cg17063962	chr7:91808500	NA	0.91	12.54	0.63	6.78e-28	Breast cancer;
SARC	cis	rs13040088	1.000	rs10854167	chr20:61533039	G/C	cg23096297	chr20:61557774	DIDO1	0.96	10.72	0.57	4.62e-22	Menopause (age at onset);
SARC	cis	rs208520	0.609	rs208436	chr6:66897470	G/A	cg07460842	chr6:66804631	NA	-0.78	-9.53	-0.53	2.22e-18	Exhaled nitric oxide output;
SARC	cis	rs7740797	0.791	rs7757635	chr6:155093771	C/T	cg02865717	chr6:155053990	RBM16	-0.33	-4.8	-0.3	2.84e-6	Colorectal or endometrial cancer;
SARC	cis	rs7647973	1.000	rs9860055	chr3:49506900	C/T	cg07636037	chr3:49044803	WDR6	-0.76	-8.65	-0.49	8.36e-16	Menarche (age at onset);
SARC	cis	rs9325144	0.600	rs6582634	chr12:38748041	G/A	cg04568710	chr12:38710424	ALG10B	0.39	4.79	0.3	2.97e-6	Morning vs. evening chronotype;
SARC	cis	rs7578035	0.935	rs7573844	chr2:99384024	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.38	4.78	0.3	3.13e-6	Bipolar disorder;
SARC	cis	rs2404602	0.735	rs2048856	chr15:76800083	C/T	cg15268244	chr15:77196840	NA	0.42	5.17	0.32	4.92e-7	Blood metabolite levels;
SARC	cis	rs4319547	0.662	rs35417323	chr12:123090572	G/T	cg05707623	chr12:122985044	ZCCHC8	-0.48	-6.23	-0.38	2.19e-9	Body mass index;
SARC	cis	rs921968	0.529	rs6729341	chr2:219611434	T/G	cg02176678	chr2:219576539	TTLL4	-0.32	-4.89	-0.3	1.91e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs7208859	0.673	rs73263755	chr17:29198972	A/G	cg13385521	chr17:29058706	SUZ12P	0.86	7.34	0.43	3.54e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg11494091	chr17:61959527	GH2	0.53	7.94	0.46	8.67e-14	Prudent dietary pattern;
SARC	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg05861140	chr6:150128134	PCMT1	0.43	5.56	0.34	7.3e-8	Lung cancer;
SARC	cis	rs453301	0.686	rs28482034	chr8:8869664	G/A	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.2	-0.38	2.52e-9	Joint mobility (Beighton score);
SARC	cis	rs34779708	0.931	rs12773169	chr10:35366462	G/C	cg03585969	chr10:35415529	CREM	0.39	5.01	0.31	1.08e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs2227564	0.700	rs2688612	chr10:75653205	G/T	cg16540259	chr10:75572220	NDST2	0.34	4.95	0.31	1.42e-6	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg18876405	chr7:65276391	NA	0.47	5.55	0.34	7.86e-8	Aortic root size;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg05970768	chr5:171682616	UBTD2	0.51	6.28	0.38	1.62e-9	Schizophrenia;
SARC	cis	rs7582720	1.000	rs114155121	chr2:203718682	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.76	7.4	0.44	2.38e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	9.11	0.51	3.85e-17	Prudent dietary pattern;
SARC	cis	rs8031584	0.918	rs61997138	chr15:31270776	C/T	cg14298792	chr15:30685198	CHRFAM7A	-0.43	-4.76	-0.3	3.34e-6	Huntington's disease progression;
SARC	cis	rs2204008	0.744	rs8186814	chr12:38335169	C/T	cg13010199	chr12:38710504	ALG10B	0.79	10.83	0.58	2.12e-22	Bladder cancer;
SARC	cis	rs56330463	0.967	rs11168066	chr5:148201255	G/T	cg21580376	chr5:148206412	ADRB2	0.4	5.62	0.35	5.55e-8	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Monocyte percentage of white cells;Eosinophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;
SARC	cis	rs3091242	0.967	rs3091240	chr1:25676935	G/T	cg27572855	chr1:25598939	RHD	0.58	9.89	0.54	1.76e-19	Erythrocyte sedimentation rate;
SARC	trans	rs11098499	0.779	rs7699346	chr4:120310542	C/T	cg25214090	chr10:38739885	LOC399744	0.56	7.31	0.43	4.31e-12	Corneal astigmatism;
SARC	cis	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg08564027	chr20:61660810	NA	0.76	11.8	0.61	1.69e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs7927771	1.000	rs11039255	chr11:47495746	G/T	cg05585544	chr11:47624801	NA	-0.38	-5.16	-0.32	5.26e-7	Subjective well-being;
SARC	cis	rs17376456	0.825	rs74825443	chr5:93254973	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	5.84	0.36	1.75e-8	Diabetic retinopathy;
SARC	cis	rs9398803	0.965	rs2326387	chr6:126680489	G/A	cg20229609	chr6:126660872	C6orf173	0.4	5.76	0.35	2.62e-8	Male-pattern baldness;
SARC	cis	rs916888	0.610	rs199453	chr17:44800946	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.53	6.19	0.38	2.63e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs11097912	0.632	rs7662219	chr4:107185759	C/A	cg09646026	chr4:107269030	AIMP1	-0.43	-4.75	-0.3	3.53e-6	Airflow obstruction;
SARC	cis	rs9790314	0.690	rs1903423	chr3:160842252	A/G	cg04691961	chr3:161091175	C3orf57	-0.56	-7.35	-0.43	3.29e-12	Morning vs. evening chronotype;
SARC	cis	rs76419734	0.850	rs11726674	chr4:106745751	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	5.33	0.33	2.37e-7	Post bronchodilator FEV1;
SARC	cis	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg13647721	chr17:30228624	UTP6	0.62	5.93	0.36	1.09e-8	Hip circumference adjusted for BMI;
SARC	cis	rs7247513	0.866	rs2861405	chr19:12722332	A/C	cg01871581	chr19:12707946	ZNF490	-0.87	-12.08	-0.62	2.14e-26	Bipolar disorder;
SARC	cis	rs55882075	0.936	rs34646062	chr5:179186318	A/G	cg14593053	chr5:179126677	CANX	-0.42	-5.36	-0.33	2.02e-7	Monocyte percentage of white cells;
SARC	cis	rs9916302	0.706	rs649180	chr17:37464959	A/C	cg07936489	chr17:37558343	FBXL20	0.76	8.91	0.5	1.48e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs6429082	0.967	rs704709	chr1:235620964	C/T	cg26050004	chr1:235667680	B3GALNT2	0.41	5.02	0.31	1.02e-6	Adiposity;
SARC	cis	rs12142240	0.667	rs55887761	chr1:46826587	C/A	cg10495392	chr1:46806563	NSUN4	0.65	6.8	0.41	8.89e-11	Menopause (age at onset);
SARC	cis	rs4481887	0.861	rs4575112	chr1:248473534	A/G	cg00666640	chr1:248458726	OR2T12	0.34	5.7	0.35	3.65e-8	Common traits (Other);
SARC	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg13206674	chr6:150067644	NUP43	0.42	5.41	0.33	1.59e-7	Lung cancer;
SARC	cis	rs72781680	0.660	rs72780104	chr2:23983715	A/G	cg06627628	chr2:24431161	ITSN2	-0.68	-6.49	-0.39	5.15e-10	Lymphocyte counts;
SARC	cis	rs10421328	0.821	rs2288867	chr19:19765568	C/T	cg03709012	chr19:19516395	GATAD2A	0.52	5.67	0.35	4.27e-8	Parental longevity (combined parental age at death);
SARC	cis	rs9906944	0.703	rs940088	chr17:47145848	T/C	cg16584676	chr17:46985605	UBE2Z	-0.43	-5.08	-0.32	7.81e-7	Intelligence (multi-trait analysis);Body fat percentage;
SARC	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg18876405	chr7:65276391	NA	-0.72	-9.54	-0.53	2.08e-18	Aortic root size;
SARC	trans	rs11098499	0.863	rs13140391	chr4:120503437	A/G	cg25214090	chr10:38739885	LOC399744	0.57	7.25	0.43	6.27e-12	Corneal astigmatism;
SARC	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg12463550	chr7:65579703	CRCP	0.54	5.69	0.35	3.85e-8	Aortic root size;
SARC	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg03806693	chr22:41940476	POLR3H	-0.91	-12.57	-0.64	5.2e-28	Vitiligo;
SARC	cis	rs11264799	0.603	rs2208753	chr1:157584301	A/C	cg18268488	chr1:157545234	FCRL4	0.34	5.8	0.35	2.2e-8	IgA nephropathy;
SARC	cis	rs2180341	0.618	rs12210968	chr6:127596985	A/G	cg24812749	chr6:127587940	RNF146	0.57	7.12	0.42	1.32e-11	Breast cancer;
SARC	cis	rs2070488	0.775	rs6599211	chr3:38558830	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.78	-11.6	-0.61	7.25e-25	Electrocardiographic conduction measures;
SARC	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs870825	0.616	rs4623061	chr4:185643161	A/C	cg04058563	chr4:185651563	MLF1IP	0.81	11.52	0.6	1.31e-24	Blood protein levels;
SARC	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg08975724	chr8:8085496	FLJ10661	-0.68	-9.28	-0.52	1.23e-17	Schizophrenia;
SARC	cis	rs4737010	0.501	rs2111805	chr8:41643457	G/C	cg17182837	chr8:41585554	ANK1	-0.47	-5.29	-0.33	2.83e-7	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
SARC	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg20607798	chr8:58055168	NA	0.54	5.15	0.32	5.5e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs950169	0.881	rs62029596	chr15:84955434	A/G	cg17507749	chr15:85114479	UBE2QP1	0.77	9.42	0.53	4.67e-18	Schizophrenia;
SARC	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.92	9.5	0.53	2.64e-18	Platelet count;
SARC	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg11987759	chr7:65425863	GUSB	0.57	7.38	0.44	2.72e-12	Aortic root size;
SARC	cis	rs59112743	0.588	rs2769563	chr6:15671731	T/C	cg06375068	chr6:15849678	NA	0.55	5.01	0.31	1.1e-6	Multiple keratinocyte cancers;
SARC	cis	rs7666738	0.800	rs7684523	chr4:98983175	G/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs12220238	0.722	rs10509350	chr10:76383071	A/C	cg19889307	chr10:75911429	ADK;AP3M1	-0.45	-5.01	-0.31	1.09e-6	Soluble interleukin-2 receptor subunit alpha;
SARC	cis	rs17401966	0.838	rs912963	chr1:10348042	C/T	cg15208524	chr1:10270712	KIF1B	0.45	5.24	0.32	3.67e-7	Hepatocellular carcinoma;
SARC	cis	rs8067545	0.532	rs12936794	chr17:19912570	C/T	cg13482628	chr17:19912719	NA	0.43	4.72	0.3	4.16e-6	Schizophrenia;
SARC	cis	rs1355223	0.833	rs286885	chr11:34687346	G/T	cg18508148	chr11:34937573	PDHX;APIP	0.36	4.8	0.3	2.82e-6	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs9329221	0.870	rs11777976	chr8:10255402	A/G	cg21775007	chr8:11205619	TDH	-0.42	-5.07	-0.32	8.23e-7	Neuroticism;
SARC	cis	rs9768139	0.901	rs56113702	chr7:158117938	C/T	cg25566285	chr7:158114605	PTPRN2	-0.31	-5.41	-0.33	1.56e-7	Calcium levels;
SARC	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg11890956	chr21:40555474	PSMG1	1.05	14.98	0.7	5.46e-36	Cognitive function;
SARC	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.42	6.38	0.39	9.37e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg06299186	chr18:20513667	RBBP8	0.49	6.29	0.38	1.59e-9	Breast cancer;
SARC	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg24642844	chr7:1081250	C7orf50	-0.52	-5.89	-0.36	1.35e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg06221963	chr1:154839813	KCNN3	-0.51	-8.12	-0.47	2.74e-14	Prostate cancer;
SARC	cis	rs2204008	0.599	rs2320526	chr12:38220405	T/A	cg26384229	chr12:38710491	ALG10B	0.86	12.31	0.63	3.57e-27	Bladder cancer;
SARC	cis	rs889312	0.923	rs1862625	chr5:56032719	G/A	cg14703610	chr5:56206110	C5orf35	0.44	5.11	0.32	6.68e-7	Breast cancer;Breast cancer (early onset);
SARC	cis	rs6121246	0.529	rs6060142	chr20:30178028	A/G	cg13852791	chr20:30311386	BCL2L1	0.66	5.87	0.36	1.45e-8	Mean corpuscular hemoglobin;
SARC	cis	rs76419734	1.000	rs10050333	chr4:106765813	T/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.73	5.35	0.33	2.06e-7	Post bronchodilator FEV1;
SARC	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg03033257	chr22:50311977	ALG12;CRELD2	0.6	5.8	0.35	2.19e-8	Schizophrenia;
SARC	cis	rs3099143	1.000	rs7172639	chr15:77165288	G/A	cg21673338	chr15:77095150	SCAPER	0.6	5.09	0.32	7.43e-7	Recalcitrant atopic dermatitis;
SARC	cis	rs10771431	1.000	rs10771431	chr12:9380859	C/T	cg08997352	chr12:9597637	DDX12	-0.55	-7.79	-0.45	2.15e-13	Breast size;
SARC	cis	rs7937682	0.562	rs955744	chr11:111374334	C/T	cg09085632	chr11:111637200	PPP2R1B	0.57	7.6	0.45	7.17e-13	Primary sclerosing cholangitis;
SARC	cis	rs963731	0.649	rs77498284	chr2:39349726	C/A	cg04010122	chr2:39346883	SOS1	1.11	6.38	0.39	9.36e-10	Corticobasal degeneration;
SARC	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg11890956	chr21:40555474	PSMG1	-0.68	-9.07	-0.51	5.03e-17	Menarche (age at onset);
SARC	cis	rs897080	0.515	rs1085486	chr2:44617324	T/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.62	7.43	0.44	2e-12	Height;
SARC	trans	rs7824557	0.564	rs11781637	chr8:11214972	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.73	-0.4	1.3100000000000001e-10	Retinal vascular caliber;
SARC	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg24209194	chr3:40518798	ZNF619	-0.65	-8.29	-0.48	9.13e-15	Renal cell carcinoma;
SARC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg04234412	chr22:24373322	LOC391322	-0.65	-8.59	-0.49	1.28e-15	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs614226	1.000	rs563920	chr12:121017439	A/G	cg01236616	chr12:121019343	POP5	1.24	18.34	0.77	4.16e-47	Type 1 diabetes nephropathy;
SARC	cis	rs7219021	0.705	rs2270576	chr17:47007963	C/T	cg16584676	chr17:46985605	UBE2Z	-0.48	-5.67	-0.35	4.17e-8	Schizophrenia or bipolar disorder;
SARC	cis	rs908922	0.887	rs1415432	chr1:152480654	G/A	cg09873164	chr1:152488093	CRCT1	0.69	8.04	0.47	4.64e-14	Hair morphology;
SARC	cis	rs1832871	0.643	rs7750656	chr6:158725907	C/T	cg07165851	chr6:158734300	TULP4	0.53	6.36	0.38	1.07e-9	Height;
SARC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.5	-8.23	-0.47	1.35e-14	Longevity;Endometriosis;
SARC	cis	rs3818285	1.000	rs10787218	chr10:111621456	A/C	cg00817464	chr10:111662876	XPNPEP1	-0.4	-4.95	-0.31	1.42e-6	Superior crus of antihelix expression;
SARC	cis	rs6964587	0.626	rs7785941	chr7:91531024	T/C	cg17063962	chr7:91808500	NA	-0.78	-11.47	-0.6	1.95e-24	Breast cancer;
SARC	cis	rs193541	0.632	rs154512	chr5:122195040	T/C	cg19412675	chr5:122181750	SNX24	0.5	6.61	0.4	2.6e-10	Glucose homeostasis traits;
SARC	cis	rs7551222	0.749	rs6682208	chr1:204566183	T/C	cg20240347	chr1:204465584	NA	-0.27	-4.93	-0.31	1.58e-6	Schizophrenia;
SARC	cis	rs1008375	1.000	rs2286771	chr4:17643848	G/A	cg16339924	chr4:17578868	LAP3	0.67	8.96	0.51	1.05e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs78311490	1.000	rs7687602	chr4:107849340	C/T	cg18976797	chr7:56434617	NA	0.55	6.28	0.38	1.61e-9	Male-pattern baldness;
SARC	cis	rs6089584	0.566	rs2146852	chr20:60616492	T/G	cg13770153	chr20:60521292	NA	-0.38	-5.52	-0.34	8.9e-8	Body mass index;
SARC	cis	rs2273669	0.504	rs74421833	chr6:109409274	A/G	cg05315195	chr6:109294784	ARMC2	-0.6	-5.02	-0.31	1.01e-6	Prostate cancer;
SARC	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg06028808	chr11:68637592	NA	0.45	5.8	0.36	2.14e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7712401	0.601	rs30047	chr5:122270524	G/A	cg19412675	chr5:122181750	SNX24	0.41	5.21	0.32	4.23e-7	Mean platelet volume;
SARC	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg21644426	chr2:191273491	MFSD6	0.53	7.18	0.43	9.16e-12	Pulse pressure;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg16339185	chr3:20227809	SGOL1	-0.47	-6.35	-0.38	1.1e-9	Schizophrenia;
SARC	cis	rs933688	0.532	rs12514092	chr5:90540522	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.5	-5.62	-0.35	5.37e-8	Smoking behavior;
SARC	cis	rs10875746	0.669	rs4760701	chr12:48698518	A/G	cg26205652	chr12:48591994	NA	0.43	4.78	0.3	3.1e-6	Longevity (90 years and older);
SARC	cis	rs1009170	0.522	rs8004117	chr14:92638468	A/G	ch.14.1475328F	chr14:92585817	NDUFB1	0.38	4.8	0.3	2.84e-6	Dialysis-related mortality;
SARC	cis	rs9486715	0.758	rs9386528	chr6:96928514	G/A	cg06623918	chr6:96969491	KIAA0776	-0.82	-11.03	-0.59	4.88e-23	Headache;
SARC	cis	rs9611519	0.603	rs9607764	chr22:41411804	G/C	cg17376030	chr22:41985996	PMM1	0.39	4.88	0.3	1.99e-6	Neuroticism;
SARC	trans	rs9650657	0.771	rs4840516	chr8:10667335	C/G	cg06636001	chr8:8085503	FLJ10661	0.51	6.83	0.41	7.47e-11	Neuroticism;
SARC	cis	rs667920	0.512	rs13069695	chr3:136291562	T/C	cg15507776	chr3:136538369	TMEM22	-0.94	-7.75	-0.45	2.87e-13	Coronary artery disease;
SARC	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg01570182	chr17:44337453	NA	0.86	9.63	0.53	1.1e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs1784581	0.500	rs9355379	chr6:162421466	C/T	cg17173639	chr6:162384350	PARK2	0.57	5.63	0.35	5.05e-8	Itch intensity from mosquito bite;
SARC	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg10591111	chr5:226296	SDHA	-0.51	-4.79	-0.3	3e-6	Breast cancer;
SARC	cis	rs67311347	0.544	rs2887965	chr3:40334154	A/G	cg24209194	chr3:40518798	ZNF619	-0.48	-6.52	-0.39	4.43e-10	Renal cell carcinoma;
SARC	cis	rs4595586	0.545	rs11615638	chr12:39364766	A/C	cg26384229	chr12:38710491	ALG10B	0.51	6.25	0.38	1.9e-9	Morning vs. evening chronotype;
SARC	cis	rs1865760	1.000	rs2071297	chr6:25924513	C/G	cg17691542	chr6:26056736	HIST1H1C	-0.58	-7.13	-0.42	1.22e-11	Height;
SARC	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg17971929	chr21:40555470	PSMG1	-0.6	-7.47	-0.44	1.59e-12	Menarche (age at onset);
SARC	cis	rs7084402	0.967	rs1427200	chr10:60274928	C/T	cg07615347	chr10:60278583	BICC1	-0.57	-8.4	-0.48	4.36e-15	Refractive error;
SARC	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg23262073	chr20:60523788	NA	-0.39	-5.43	-0.34	1.38e-7	Body mass index;
SARC	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.63	7.72	0.45	3.41e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg02841227	chr6:26021843	HIST1H4A	-0.45	-5.26	-0.33	3.26e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6121246	0.779	rs6060763	chr20:30282223	A/G	cg13852791	chr20:30311386	BCL2L1	0.82	8.58	0.49	1.33e-15	Mean corpuscular hemoglobin;
SARC	cis	rs9300255	0.544	rs1790100	chr12:123656725	G/T	cg05973401	chr12:123451056	ABCB9	0.53	5.95	0.36	9.6e-9	Neutrophil percentage of white cells;
SARC	cis	rs644799	0.542	rs10831416	chr11:95467220	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.67	8.49	0.49	2.45e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs514406	0.861	rs7518390	chr1:53233374	A/G	cg24675658	chr1:53192096	ZYG11B	0.55	7.57	0.44	8.55e-13	Monocyte count;
SARC	cis	rs865483	0.895	rs4795200	chr17:35817105	A/G	cg06561646	chr17:35873369	DUSP14	-0.47	-6.25	-0.38	1.9e-9	Monocyte count;
SARC	cis	rs7592578	0.766	rs62182865	chr2:191434180	T/C	cg25963032	chr2:191064776	C2orf88	-0.45	-4.91	-0.31	1.75e-6	Diastolic blood pressure;
SARC	cis	rs7847628	0.666	rs2031974	chr9:123527521	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	6.09	0.37	4.52e-9	Birth weight;
SARC	cis	rs7011049	1.000	rs72648407	chr8:53857144	C/T	cg26025543	chr8:53854495	NA	0.6	5.37	0.33	1.91e-7	Systolic blood pressure;
SARC	cis	rs10779751	0.734	rs12569242	chr1:11127511	A/C	cg08854313	chr1:11322531	MTOR	0.82	11.18	0.59	1.59e-23	Body mass index;
SARC	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg00450029	chr8:599525	NA	0.81	6.02	0.37	6.79e-9	IgG glycosylation;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg26205026	chr15:66080704	DENND4A	0.5	6.94	0.41	3.83e-11	Thyroid stimulating hormone;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg11493139	chr10:32217547	ARHGAP12	0.48	6.38	0.39	9.54e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs826838	0.935	rs1843639	chr12:39178919	C/A	cg26384229	chr12:38710491	ALG10B	0.89	12.84	0.64	6.61e-29	Heart rate;
SARC	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg12064134	chr16:90016061	DEF8	0.43	4.82	0.3	2.61e-6	Skin colour saturation;
SARC	cis	rs34779708	0.931	rs59418206	chr10:35331624	G/A	cg03585969	chr10:35415529	CREM	0.41	5.11	0.32	6.57e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs10979	0.894	rs6924940	chr6:143906183	C/T	cg25407410	chr6:143891975	LOC285740	-0.61	-7.93	-0.46	8.82e-14	Hypospadias;
SARC	cis	rs9457247	1.000	rs2013815	chr6:167373812	T/A	cg23791538	chr6:167370224	RNASET2	0.63	8.74	0.5	4.81e-16	Crohn's disease;
SARC	cis	rs1153858	0.887	rs28569043	chr15:45730926	A/T	cg21132104	chr15:45694354	SPATA5L1	0.71	9.05	0.51	5.82e-17	Homoarginine levels;
SARC	cis	rs13166103	0.628	rs62368176	chr5:57689875	G/A	cg10487770	chr5:57879443	RAB3C	0.52	5.34	0.33	2.17e-7	Type 2 diabetes (age of onset);
SARC	cis	rs7659604	0.521	rs9993206	chr4:122686957	A/G	cg19671926	chr4:122722719	EXOSC9	0.62	8.0	0.46	5.68e-14	Type 2 diabetes;
SARC	cis	rs35110281	0.600	rs11089092	chr21:45120994	A/C	cg21573476	chr21:45109991	RRP1B	-0.56	-7.76	-0.45	2.67e-13	Mean corpuscular volume;
SARC	cis	rs2153535	0.580	rs9406169	chr6:8509470	A/T	cg23788917	chr6:8435910	SLC35B3	0.64	8.77	0.5	3.85e-16	Motion sickness;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg11099291	chr17:1620044	C17orf91;WDR81	-0.52	-6.77	-0.41	1.02e-10	Neuroticism;
SARC	cis	rs7264396	0.563	rs2425071	chr20:34292961	A/C	cg01084648	chr20:34329383	RBM39	-0.57	-4.9	-0.31	1.83e-6	Total cholesterol levels;
SARC	cis	rs832540	0.656	rs832567	chr5:56152416	C/A	cg24549020	chr5:56110836	MAP3K1	0.45	5.24	0.32	3.59e-7	Coronary artery disease;
SARC	cis	rs6665290	0.935	rs6670924	chr1:227196048	A/C	cg14016676	chr1:227182615	CDC42BPA	0.39	5.59	0.34	6.27e-8	Myeloid white cell count;
SARC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg20007245	chr22:24372913	LOC391322	-0.86	-12.95	-0.65	2.96e-29	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg20965017	chr5:231967	SDHA	-0.55	-5.26	-0.33	3.23e-7	Breast cancer;
SARC	cis	rs2197308	0.765	rs68029712	chr12:37906585	T/G	cg26384229	chr12:38710491	ALG10B	0.9	13.3	0.66	2.04e-30	Morning vs. evening chronotype;
SARC	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg07930192	chr7:1003750	NA	-0.36	-4.81	-0.3	2.71e-6	Longevity;Endometriosis;
SARC	cis	rs7246657	0.943	rs10422074	chr19:37894236	T/C	cg23950597	chr19:37808831	NA	-0.62	-6.05	-0.37	5.66e-9	Coronary artery calcification;
SARC	cis	rs2841233	0.681	rs2582558	chr14:105347488	A/G	cg16576083	chr14:105354267	KIAA0284	-0.48	-7.08	-0.42	1.68e-11	IgG glycosylation;
SARC	cis	rs4761669	0.527	rs2008023	chr12:95160155	C/T	cg21533806	chr12:95267307	NA	0.37	5.01	0.31	1.07e-6	Common carotid intima-media thickness in HIV infection;
SARC	cis	rs72781680	0.898	rs56179550	chr2:23934867	C/T	cg06627628	chr2:24431161	ITSN2	-0.63	-5.59	-0.34	6.42e-8	Lymphocyte counts;
SARC	cis	rs3808502	0.526	rs11985709	chr8:11423083	A/C	cg21775007	chr8:11205619	TDH	-0.46	-5.91	-0.36	1.18e-8	Neuroticism;
SARC	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg11987759	chr7:65425863	GUSB	0.47	6.19	0.38	2.63e-9	Aortic root size;
SARC	cis	rs1865760	0.964	rs6932113	chr6:25913098	C/T	cg17691542	chr6:26056736	HIST1H1C	0.57	7.08	0.42	1.71e-11	Height;
SARC	cis	rs9814567	1.000	rs3846056	chr3:134227292	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-7.02	-0.42	2.38e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg18404041	chr3:52824283	ITIH1	-0.38	-5.63	-0.35	5.2e-8	Bipolar disorder;
SARC	cis	rs4423214	0.840	rs1792233	chr11:71182179	G/A	cg05163923	chr11:71159392	DHCR7	-0.6	-7.16	-0.42	1.07e-11	Vitamin D levels;
SARC	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs3540	0.597	rs1978151	chr15:91037300	C/T	cg22089800	chr15:90895588	ZNF774	0.63	8.02	0.46	5.22e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	trans	rs9929218	0.861	rs3114409	chr16:68732049	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.67	-8.6	-0.49	1.19e-15	Colorectal cancer;
SARC	cis	rs920590	0.721	rs920587	chr8:19663339	C/A	cg01411142	chr8:19674711	INTS10	0.5	5.95	0.36	9.57e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs1983170	0.808	rs6668067	chr1:92018613	G/A	cg25838465	chr1:92012736	NA	0.44	5.38	0.33	1.82e-7	Eosinophil percentage of white cells;
SARC	cis	rs7027203	0.576	rs7851269	chr9:96540530	C/T	cg14598338	chr9:96623480	NA	0.34	4.77	0.3	3.29e-6	DNA methylation (variation);
SARC	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.03	11.11	0.59	2.83e-23	Platelet count;
SARC	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg22857025	chr5:266934	NA	-1.06	-11.8	-0.61	1.74e-25	Breast cancer;
SARC	cis	rs7520050	0.966	rs4660910	chr1:46548402	G/T	cg06784218	chr1:46089804	CCDC17	-0.26	-4.82	-0.3	2.57e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg11952622	chr19:58962976	ZNF324B	0.58	7.66	0.45	5.08e-13	Uric acid clearance;
SARC	cis	rs2629540	0.824	rs1552345	chr10:126477406	A/G	cg08799069	chr10:126477246	METTL10	-0.66	-7.19	-0.43	8.54e-12	Cocaine dependence;
SARC	cis	rs763121	0.819	rs5757237	chr22:39073835	G/C	cg21395723	chr22:39101663	GTPBP1	0.52	5.8	0.36	2.17e-8	Menopause (age at onset);
SARC	cis	rs9297145	0.761	rs28545226	chr7:98732472	A/T	cg05967295	chr7:98741636	SMURF1	0.78	8.1	0.47	3.06e-14	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
SARC	cis	rs4906332	1.000	rs55731474	chr14:103878481	G/A	cg15820818	chr14:102984158	NA	0.38	4.77	0.3	3.18e-6	Coronary artery disease;
SARC	cis	rs4803468	0.901	rs3745292	chr19:41888506	A/G	cg08477640	chr19:41863820	B9D2	0.4	5.11	0.32	6.6e-7	Height;
SARC	cis	rs9527	0.501	rs12244388	chr10:104640052	G/A	cg04362960	chr10:104952993	NT5C2	0.39	4.74	0.3	3.77e-6	Arsenic metabolism;
SARC	cis	rs9420	0.925	rs78587207	chr11:57654991	T/G	cg23127183	chr11:57508653	C11orf31	-0.58	-6.33	-0.38	1.21e-9	Schizophrenia;
SARC	cis	rs13392177	0.543	rs12623716	chr2:219073018	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.59	-7.49	-0.44	1.4e-12	Pyoderma gangrenosum in inflammatory bowel disease;
SARC	trans	rs7824557	0.592	rs2736280	chr8:11223022	C/A	cg06636001	chr8:8085503	FLJ10661	0.58	7.4	0.44	2.45e-12	Retinal vascular caliber;
SARC	cis	rs1971762	0.545	rs10783586	chr12:53980821	C/T	cg06632207	chr12:54070931	ATP5G2	0.55	7.4	0.44	2.5e-12	Height;
SARC	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	23.05	0.83	5.02e-62	Chronic sinus infection;
SARC	cis	rs57221529	0.608	rs11749927	chr5:668842	C/T	cg09021430	chr5:549028	NA	-0.36	-4.75	-0.3	3.55e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs4595586	0.679	rs11169992	chr12:39317207	C/T	cg26384229	chr12:38710491	ALG10B	0.42	5.2	0.32	4.4e-7	Morning vs. evening chronotype;
SARC	cis	rs711830	0.931	rs717852	chr2:177031623	C/T	cg13092806	chr2:177043255	NA	0.63	6.45	0.39	6.52e-10	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg12012699	chr18:46986876	DYM	0.55	6.84	0.41	6.82e-11	Breast cancer;
SARC	cis	rs10779751	0.881	rs2744820	chr1:11365015	G/A	cg08854313	chr1:11322531	MTOR	-0.73	-9.73	-0.54	5.47e-19	Body mass index;
SARC	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg21017887	chr14:105400489	NA	0.52	7.49	0.44	1.38e-12	Rheumatoid arthritis;
SARC	cis	rs9400467	0.506	rs12209435	chr6:111643037	G/A	cg15721981	chr6:111408429	SLC16A10	0.69	5.85	0.36	1.67e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg06634786	chr22:41940651	POLR3H	0.51	6.09	0.37	4.52e-9	Vitiligo;
SARC	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg00933542	chr6:150070202	PCMT1	0.3	5.1	0.32	7.09e-7	Lung cancer;
SARC	cis	rs1215050	0.791	rs1585088	chr4:98675071	C/A	cg05340658	chr4:99064831	C4orf37	-0.44	-5.78	-0.35	2.38e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg21634602	chr5:112073570	APC	-0.75	-6.32	-0.38	1.33e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs72781680	0.665	rs2675356	chr2:24074734	C/T	cg08917208	chr2:24149416	ATAD2B	0.59	6.08	0.37	4.87e-9	Lymphocyte counts;
SARC	cis	rs6831352	0.879	rs2851255	chr4:100042103	C/G	cg12011299	chr4:100065546	ADH4	0.34	5.79	0.35	2.32e-8	Alcohol dependence;
SARC	cis	rs7937682	0.855	rs521947	chr11:111492616	A/G	cg22437258	chr11:111473054	SIK2	0.74	10.24	0.56	1.44e-20	Primary sclerosing cholangitis;
SARC	cis	rs12681366	0.614	rs2930969	chr8:95464085	C/T	cg26464482	chr8:95565502	KIAA1429	0.43	5.23	0.32	3.76e-7	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs9815354	0.767	rs11917248	chr3:41885723	T/C	cg03022575	chr3:42003672	ULK4	0.57	5.4	0.33	1.61e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs734999	0.566	rs6664969	chr1:2534978	G/A	cg00980319	chr1:2560884	MMEL1	-0.34	-4.73	-0.3	3.82e-6	Ulcerative colitis;
SARC	trans	rs3780486	0.846	rs10116966	chr9:33122370	T/A	cg20290983	chr6:43655470	MRPS18A	1.14	23.71	0.84	4.87e-64	IgG glycosylation;
SARC	trans	rs7395662	0.517	rs11039885	chr11:48647107	A/G	cg15704280	chr7:45808275	SEPT13	-0.52	-7.05	-0.42	2e-11	HDL cholesterol;
SARC	cis	rs763121	0.853	rs6519124	chr22:39045099	T/C	cg06022373	chr22:39101656	GTPBP1	0.92	12.73	0.64	1.6e-28	Menopause (age at onset);
SARC	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg22484793	chr3:52261325	TLR9	0.32	5.11	0.32	6.65e-7	Bipolar disorder;
SARC	cis	rs11792861	0.926	rs118011482	chr9:111770626	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.71	8.24	0.48	1.22e-14	Menarche (age at onset);
SARC	cis	rs9398803	0.687	rs9388507	chr6:126970895	G/T	cg19875578	chr6:126661172	C6orf173	0.62	8.4	0.48	4.45e-15	Male-pattern baldness;
SARC	cis	rs2180341	1.000	rs6569477	chr6:127589302	T/A	cg27446573	chr6:127587934	RNF146	1.01	14.01	0.68	9.13e-33	Breast cancer;
SARC	cis	rs317689	0.718	rs315130	chr12:69761444	T/C	cg14784868	chr12:69753453	YEATS4	0.47	5.29	0.33	2.78e-7	Response to diuretic therapy;
SARC	cis	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg13147721	chr7:65941812	NA	-0.52	-4.76	-0.3	3.38e-6	Diabetic kidney disease;
SARC	cis	rs7829975	0.510	rs2921073	chr8:8307643	C/T	cg15556689	chr8:8085844	FLJ10661	0.59	7.6	0.45	7.32e-13	Mood instability;
SARC	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg11366901	chr6:160182831	ACAT2	1.02	10.79	0.58	2.78e-22	Age-related macular degeneration (geographic atrophy);
SARC	trans	rs208520	0.560	rs2351880	chr6:66863707	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-13.93	-0.67	1.73e-32	Exhaled nitric oxide output;
SARC	trans	rs57083693	0.956	rs10507130	chr12:101753954	G/A	cg16818830	chr17:37379606	STAC2	0.46	6.32	0.38	1.35e-9	Alcohol dependence (age at onset);
SARC	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg11987759	chr7:65425863	GUSB	-0.48	-6.14	-0.37	3.55e-9	Aortic root size;
SARC	cis	rs62408225	0.802	rs10806425	chr6:90926612	C/A	cg06866423	chr6:90926672	BACH2	0.34	5.41	0.33	1.58e-7	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.77	9.74	0.54	5.03e-19	Prudent dietary pattern;
SARC	cis	rs710216	0.957	rs3806401	chr1:43426212	G/T	cg03128534	chr1:43423976	SLC2A1	-0.69	-6.83	-0.41	7.53e-11	Red cell distribution width;
SARC	cis	rs10046574	0.831	rs10251162	chr7:135190264	C/T	cg27474649	chr7:135195673	CNOT4	0.87	7.13	0.42	1.25e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs9902453	0.967	rs3813034	chr17:28524804	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	6.92	0.41	4.35e-11	Coffee consumption (cups per day);
SARC	cis	rs6121246	0.529	rs6060210	chr20:30187681	C/T	cg13852791	chr20:30311386	BCL2L1	0.68	5.91	0.36	1.2e-8	Mean corpuscular hemoglobin;
SARC	trans	rs17038463	1.000	rs17193320	chr3:1393853	T/C	cg18003583	chr5:176819624	SLC34A1	1.01	6.31	0.38	1.39e-9	Neurocognitive impairment in HIV-1 infection (continuous);
SARC	cis	rs4919694	1.000	rs12252500	chr10:104794984	G/C	cg04362960	chr10:104952993	NT5C2	0.66	5.46	0.34	1.21e-7	Arsenic metabolism;
SARC	cis	rs9303401	0.615	rs7502342	chr17:56922629	C/A	cg25039879	chr17:56429692	SUPT4H1	0.65	6.13	0.37	3.77e-9	Cognitive test performance;
SARC	cis	rs568617	0.953	rs645900	chr11:65648135	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.47	-5.47	-0.34	1.15e-7	Crohn's disease;
SARC	cis	rs9910055	0.530	rs2269908	chr17:42294198	G/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.46	6.14	0.37	3.44e-9	Total body bone mineral density;
SARC	cis	rs56145559	1	rs56145559	chr2:73623439	C/T	cg20560298	chr2:73613845	ALMS1	-0.53	-6.28	-0.38	1.65e-9	Schizophrenia;
SARC	cis	rs854765	0.693	rs35451946	chr17:17764061	C/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.44	-5.72	-0.35	3.18e-8	Total body bone mineral density;
SARC	cis	rs6570726	0.935	rs391524	chr6:145823844	A/G	cg05347473	chr6:146136440	FBXO30	0.48	6.42	0.39	7.51e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg20891283	chr12:69753455	YEATS4	0.56	7.62	0.45	6.42e-13	Blood protein levels;
SARC	cis	rs2013441	0.606	rs12942179	chr17:19999781	G/A	cg13482628	chr17:19912719	NA	0.4	4.97	0.31	1.28e-6	Obesity-related traits;
SARC	cis	rs1920116	0.778	rs9831336	chr3:169558373	C/G	cg14222479	chr3:169487675	ARPM1	-0.44	-5.1	-0.32	7.14e-7	Glioma (high-grade);
SARC	cis	rs96067	0.711	rs4653164	chr1:36627542	A/G	cg24686825	chr1:36642396	MAP7D1	0.51	6.16	0.37	3.22e-9	Corneal structure;
SARC	cis	rs2997447	0.761	rs61776618	chr1:26456709	A/G	cg19633962	chr1:26362018	EXTL1	-0.57	-4.93	-0.31	1.54e-6	QRS complex (12-leadsum);
SARC	cis	rs4969178	0.832	rs4969185	chr17:76398157	G/C	cg02836325	chr17:76403955	PGS1	0.34	5.18	0.32	4.71e-7	HDL cholesterol levels;
SARC	cis	rs73001065	0.636	rs56241616	chr19:19506092	C/T	cg03709012	chr19:19516395	GATAD2A	1.1	8.27	0.48	1.06e-14	LDL cholesterol;
SARC	cis	rs9910055	0.529	rs228757	chr17:42164885	G/C	cg19774624	chr17:42201019	HDAC5	0.55	6.57	0.4	3.34e-10	Total body bone mineral density;
SARC	cis	rs9436747	0.748	rs1177681	chr1:65999119	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	-0.53	-5.19	-0.32	4.49e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	trans	rs6477998	1.000	rs6477998	chr9:115997249	A/C	cg00179787	chr4:37979303	TBC1D1	0.48	6.24	0.38	2.03e-9	Hematology traits;
SARC	cis	rs9831754	0.704	rs9823412	chr3:78457646	T/C	cg06138941	chr3:78371609	NA	-0.55	-6.56	-0.39	3.39e-10	Calcium levels;
SARC	cis	rs10788972	0.510	rs665817	chr1:54469948	T/G	cg10336722	chr1:54665764	CYB5RL;MRPL37	-0.38	-4.72	-0.3	4.04e-6	Parkinson disease and lewy body pathology;
SARC	cis	rs12421382	0.690	rs2716049	chr11:109609889	A/C	cg16359550	chr11:109292809	C11orf87	0.4	5.69	0.35	3.73e-8	Schizophrenia;
SARC	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg22496380	chr5:211416	CCDC127	-0.88	-9.35	-0.52	7.72e-18	Breast cancer;
SARC	cis	rs6062302	0.548	rs6089940	chr20:62252695	C/T	cg16989086	chr20:62203971	PRIC285	0.47	4.73	0.3	3.92e-6	Glioblastoma;
SARC	cis	rs2115630	0.791	rs2008262	chr15:85305270	C/T	cg12501888	chr15:85177176	SCAND2	-0.44	-5.16	-0.32	5.17e-7	P wave terminal force;
SARC	cis	rs10513788	0.865	rs4859214	chr3:182027106	G/A	cg05977900	chr3:182512126	ATP11B	0.45	4.72	0.3	4e-6	Cognitive function;
SARC	cis	rs6088580	0.524	rs6088575	chr20:33273403	C/T	cg24642439	chr20:33292090	TP53INP2	0.57	7.06	0.42	1.93e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg22307029	chr19:49891270	CCDC155	0.59	6.86	0.41	6.14e-11	Multiple sclerosis;
SARC	cis	rs1707322	0.752	rs61784793	chr1:46149285	G/A	cg03146154	chr1:46216737	IPP	0.52	6.24	0.38	2.07e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg10876282	chr6:28092338	ZSCAN16	0.46	4.75	0.3	3.54e-6	Parkinson's disease;
SARC	cis	rs787274	0.867	rs786968	chr9:115449110	C/T	cg13803584	chr9:115635662	SNX30	0.69	4.77	0.3	3.27e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs9815354	0.812	rs73069209	chr3:41939781	G/A	cg03022575	chr3:42003672	ULK4	0.7	5.7	0.35	3.66e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg06028808	chr11:68637592	NA	0.46	5.74	0.35	2.89e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs17539620	0.624	rs117591255	chr6:154839118	G/A	cg20019720	chr6:154832845	CNKSR3	0.41	4.83	0.3	2.48e-6	Lipoprotein (a) levels;
SARC	cis	rs9733	0.519	rs7529194	chr1:150622620	A/T	cg13175981	chr1:150552382	MCL1	-0.45	-5.71	-0.35	3.42e-8	Tonsillectomy;
SARC	cis	rs1008375	0.966	rs11947836	chr4:17697187	A/G	cg16339924	chr4:17578868	LAP3	-0.54	-7.0	-0.42	2.72e-11	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg19723775	chr5:179050963	HNRNPH1	0.48	6.43	0.39	7.3e-10	Lung cancer;
SARC	trans	rs11165623	0.792	rs9437607	chr1:96977788	G/A	cg10631902	chr5:14652156	NA	-0.45	-7.4	-0.44	2.53e-12	Hip circumference;Waist circumference;
SARC	cis	rs1003719	0.646	rs2835671	chr21:38581125	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.18	-0.52	2.43e-17	Eye color traits;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg19285752	chr17:17699461	RAI1	0.45	6.24	0.38	1.99e-9	Schizophrenia;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg09458820	chr11:64073710	ESRRA	0.5	6.67	0.4	1.82e-10	Chemerin levels;
SARC	cis	rs262150	0.659	rs2527237	chr7:158798494	A/G	cg19418458	chr7:158789849	NA	0.46	6.5	0.39	4.8e-10	Facial morphology (factor 20);
SARC	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.38	-4.78	-0.3	3.08e-6	Lymphocyte counts;
SARC	cis	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg03354898	chr7:1950403	MAD1L1	-0.38	-5.16	-0.32	5.38e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg23205692	chr1:25664452	TMEM50A	0.4	4.9	0.31	1.77e-6	Erythrocyte sedimentation rate;
SARC	cis	rs11122272	0.701	rs1009227	chr1:231480507	A/G	cg06096015	chr1:231504339	EGLN1	0.38	5.61	0.34	5.71e-8	Hemoglobin concentration;
SARC	cis	rs910316	0.737	rs175084	chr14:75519175	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.52	-7.18	-0.43	9.28e-12	Height;
SARC	cis	rs9902453	0.791	rs2628166	chr17:28113123	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.23	-0.43	6.86e-12	Coffee consumption (cups per day);
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg17851105	chr16:1464982	UNKL	-0.62	-7.12	-0.42	1.31e-11	Lung cancer in ever smokers;
SARC	cis	rs6988636	0.710	rs62521806	chr8:124161054	C/T	cg23067535	chr8:124195133	FAM83A	-0.68	-4.89	-0.3	1.89e-6	Urinary uromodulin levels;
SARC	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg08280861	chr8:58055591	NA	0.7	6.12	0.37	3.95e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs514024	0.700	rs554160	chr9:130491633	T/C	cg13643465	chr9:130375613	STXBP1	0.46	5.69	0.35	3.77e-8	Eating disorders (purging via substances);
SARC	cis	rs1048238	0.506	rs10927866	chr1:16175317	C/T	cg21385522	chr1:16154831	NA	0.48	6.08	0.37	4.8e-9	Systolic blood pressure;
SARC	cis	rs1707322	0.963	rs34907901	chr1:46405214	T/G	cg03146154	chr1:46216737	IPP	0.48	5.62	0.35	5.5e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7481584	0.624	rs438384	chr11:3045651	A/G	cg08508325	chr11:3079039	CARS	0.25	5.24	0.32	3.58e-7	Calcium levels;
SARC	cis	rs240764	0.658	rs11155618	chr6:101181811	C/T	cg09795085	chr6:101329169	ASCC3	-0.49	-6.42	-0.39	7.54e-10	Neuroticism;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg15187882	chr19:6459536	SLC25A23	0.49	7.05	0.42	2.01e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs2011503	1.000	rs58074958	chr19:19570555	G/C	cg15839431	chr19:19639596	YJEFN3	-0.47	-4.72	-0.3	4.04e-6	Bipolar disorder;
SARC	cis	rs2180341	0.960	rs3756996	chr6:127664258	G/C	cg24812749	chr6:127587940	RNF146	0.98	13.06	0.65	1.25e-29	Breast cancer;
SARC	trans	rs11722228	0.521	rs62288520	chr4:10099674	G/A	cg26043149	chr18:55253948	FECH	0.7	7.87	0.46	1.35e-13	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs10483282	1.000	rs10130690	chr14:24252547	G/C	cg02879798	chr14:24800305	ADCY4	-0.31	-4.86	-0.3	2.15e-6	Alcohol dependence;
SARC	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg26335602	chr6:28129616	ZNF389	0.51	5.58	0.34	6.82e-8	Parkinson's disease;
SARC	cis	rs3741151	0.773	rs17244596	chr11:73179236	A/G	cg17517138	chr11:73019481	ARHGEF17	0.92	6.85	0.41	6.4e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg08219700	chr8:58056026	NA	0.49	5.02	0.31	1.03e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs6582630	0.537	rs66855609	chr12:38299029	T/C	cg26384229	chr12:38710491	ALG10B	0.86	12.23	0.63	6.59e-27	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7618915	0.773	rs10510760	chr3:52650348	G/A	cg18404041	chr3:52824283	ITIH1	-0.38	-5.27	-0.33	3.17e-7	Bipolar disorder;
SARC	cis	rs1153858	0.895	rs12593402	chr15:45617392	G/A	cg15395560	chr15:45543142	SLC28A2	-0.26	-4.85	-0.3	2.31e-6	Homoarginine levels;
SARC	cis	rs11997175	0.646	rs4593495	chr8:33692649	C/T	ch.8.33884649F	chr8:33765107	NA	0.63	8.6	0.49	1.21e-15	Body mass index;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg17468841	chr3:105588020	CBLB	0.6	7.77	0.45	2.44e-13	Breast cancer;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg05567709	chr16:68057128	DUS2L;DDX28	0.5	6.89	0.41	5.04e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs3733589	0.744	rs2276963	chr4:10022839	G/A	cg16430538	chr4:10459836	ZNF518B	0.61	4.92	0.31	1.62e-6	Renal overload gout;
SARC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.61	8.04	0.47	4.55e-14	Lymphocyte counts;
SARC	cis	rs6439153	0.967	rs12695512	chr3:128722082	T/G	cg25356066	chr3:128598488	ACAD9	0.46	5.51	0.34	9.37e-8	Pneumococcal bacteremia;
SARC	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg00933542	chr6:150070202	PCMT1	0.31	5.26	0.33	3.34e-7	Lung cancer;
SARC	cis	rs6545883	0.929	rs1186711	chr2:61688505	T/C	cg15711740	chr2:61764176	XPO1	-0.42	-5.03	-0.31	9.82e-7	Tuberculosis;
SARC	cis	rs2153535	0.504	rs5001323	chr6:8451605	C/T	cg21535247	chr6:8435926	SLC35B3	0.55	6.78	0.41	9.58e-11	Motion sickness;
SARC	cis	rs6500395	0.926	rs1120275	chr16:48598737	T/G	cg04672837	chr16:48644449	N4BP1	0.42	5.59	0.34	6.36e-8	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg23262073	chr20:60523788	NA	-0.38	-5.3	-0.33	2.74e-7	Body mass index;
SARC	cis	rs10754283	0.967	rs10737707	chr1:90119304	A/G	cg21401794	chr1:90099060	LRRC8C	0.6	8.45	0.48	3.16e-15	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs7647973	0.626	rs62260720	chr3:49853796	T/A	cg07636037	chr3:49044803	WDR6	-0.63	-6.43	-0.39	7.01e-10	Menarche (age at onset);
SARC	cis	rs17253792	0.822	rs2296181	chr14:56107051	G/A	cg01858014	chr14:56050164	KTN1	-0.69	-5.41	-0.33	1.53e-7	Putamen volume;
SARC	cis	rs7635838	0.619	rs347616	chr3:11277927	G/A	cg00170343	chr3:11313890	ATG7	0.63	7.77	0.45	2.5e-13	HDL cholesterol;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg10348368	chr14:105851883	PACS2	0.49	6.65	0.4	2.04e-10	Schizophrenia;
SARC	cis	rs897080	0.515	rs1067346	chr2:44618811	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.62	7.47	0.44	1.63e-12	Height;
SARC	cis	rs1018836	0.798	rs4735295	chr8:91671608	C/A	cg16814680	chr8:91681699	NA	-0.97	-17.47	-0.75	2.99e-44	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs12142240	0.698	rs17361833	chr1:46828700	A/G	cg00530320	chr1:46809349	NSUN4	0.58	7.07	0.42	1.78e-11	Menopause (age at onset);
SARC	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.7	5.25	0.33	3.49e-7	Initial pursuit acceleration;
SARC	cis	rs3126085	0.877	rs1552992	chr1:152171625	C/G	cg09127314	chr1:152161683	NA	0.43	4.87	0.3	2.06e-6	Atopic dermatitis;
SARC	cis	rs459571	0.606	rs457420	chr9:136909261	A/G	cg13789015	chr9:136890014	NCRNA00094	-0.53	-7.87	-0.46	1.31e-13	Platelet distribution width;
SARC	cis	rs4689388	0.824	rs4467645	chr4:6294305	C/T	cg14416269	chr4:6271139	WFS1	0.32	4.89	0.31	1.86e-6	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs7667	1.000	rs10917440	chr1:19715602	T/A	cg15311933	chr1:19638897	PQLC2;AKR7A2	-0.46	-5.51	-0.34	9.45e-8	Crohn's disease and psoriasis;
SARC	cis	rs6582630	0.598	rs10880645	chr12:38556172	G/A	cg26384229	chr12:38710491	ALG10B	-0.59	-7.59	-0.45	7.7e-13	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9467773	0.596	rs62396201	chr6:26668216	G/A	cg11502198	chr6:26597334	ABT1	0.69	9.12	0.51	3.71e-17	Intelligence (multi-trait analysis);
SARC	cis	rs2425143	0.818	rs2378414	chr20:34534374	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-5.32	-0.33	2.42e-7	Blood protein levels;
SARC	cis	rs6918586	0.658	rs198840	chr6:26112164	T/G	cg18357526	chr6:26021779	HIST1H4A	-0.46	-5.84	-0.36	1.71e-8	Schizophrenia;
SARC	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.58	-0.4	3.05e-10	Menopause (age at onset);
SARC	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg02733842	chr7:1102375	C7orf50	-0.59	-6.7	-0.4	1.51e-10	Bronchopulmonary dysplasia;
SARC	cis	rs9300255	0.509	rs641760	chr12:123518866	T/C	cg05973401	chr12:123451056	ABCB9	0.5	5.18	0.32	4.75e-7	Neutrophil percentage of white cells;
SARC	cis	rs1707322	0.716	rs10890342	chr1:46157087	C/T	cg03146154	chr1:46216737	IPP	0.52	6.28	0.38	1.6e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg04234412	chr22:24373322	LOC391322	0.56	6.55	0.39	3.71e-10	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs10463554	0.927	rs257312	chr5:102419627	T/A	cg23492399	chr5:102201601	PAM	-0.47	-5.18	-0.32	4.86e-7	Parkinson's disease;
SARC	cis	rs12971120	0.838	rs2241510	chr18:72180739	G/A	cg25817165	chr18:72167213	CNDP2	-0.51	-6.95	-0.41	3.72e-11	Refractive error;
SARC	cis	rs6693567	0.565	rs1313570	chr1:150342642	T/C	cg09579323	chr1:150459698	TARS2	0.45	5.83	0.36	1.83e-8	Migraine;
SARC	cis	rs3796352	1.000	rs35720014	chr3:52982110	A/C	cg07884673	chr3:53033167	SFMBT1	0.79	4.89	0.3	1.9e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs9325144	0.723	rs11169518	chr12:39177237	C/A	cg26384229	chr12:38710491	ALG10B	-0.6	-7.46	-0.44	1.74e-12	Morning vs. evening chronotype;
SARC	cis	rs4664308	0.870	rs55959207	chr2:161016981	A/C	cg03641300	chr2:160917029	PLA2R1	-0.64	-8.39	-0.48	4.59e-15	Idiopathic membranous nephropathy;
SARC	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg05313129	chr8:58192883	C8orf71	-0.51	-4.85	-0.3	2.27e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs2013441	1.000	rs2703774	chr17:20133538	C/T	cg13482628	chr17:19912719	NA	-0.47	-6.16	-0.37	3.18e-9	Obesity-related traits;
SARC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg11203670	chr7:100026453	MEPCE;ZCWPW1	0.48	4.83	0.3	2.47e-6	Platelet count;
SARC	cis	rs1580019	0.844	rs4723159	chr7:32512804	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.79	11.08	0.59	3.32e-23	Cognitive ability;
SARC	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	13.02	0.65	1.75e-29	Chronic sinus infection;
SARC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg02475777	chr4:1388615	CRIPAK	0.6	7.1	0.42	1.5e-11	Longevity;
SARC	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.43	6.4	0.39	8.27e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs950776	0.518	rs4243083	chr15:78833830	C/G	cg22563815	chr15:78856949	CHRNA5	-0.4	-6.75	-0.4	1.15e-10	Sudden cardiac arrest;
SARC	cis	rs834603	0.575	rs834597	chr7:47464488	A/T	cg23694490	chr7:47445681	TNS3	-0.33	-5.9	-0.36	1.29e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg11987759	chr7:65425863	GUSB	-0.64	-8.39	-0.48	4.69e-15	Aortic root size;
SARC	cis	rs9733	0.650	rs2048558	chr1:150571730	A/G	cg18016565	chr1:150552671	MCL1	-0.39	-5.33	-0.33	2.28e-7	Tonsillectomy;
SARC	cis	rs763121	0.853	rs5757141	chr22:38957483	G/A	cg21395723	chr22:39101663	GTPBP1	0.59	6.71	0.4	1.43e-10	Menopause (age at onset);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg14190740	chr2:113033328	ZC3H6	0.49	6.49	0.39	5e-10	Chemerin levels;
SARC	cis	rs9303401	0.555	rs8073699	chr17:57236317	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.66	8.03	0.47	4.91e-14	Cognitive test performance;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg15813550	chr20:62221886	GMEB2	0.49	6.27	0.38	1.71e-9	Schizophrenia;
SARC	cis	rs12586317	0.557	rs8004288	chr14:35679288	A/G	cg16230307	chr14:35515116	FAM177A1	0.43	5.24	0.32	3.54e-7	Psoriasis;
SARC	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg11890956	chr21:40555474	PSMG1	-0.7	-9.08	-0.51	4.81e-17	Menarche (age at onset);
SARC	cis	rs7927771	0.524	rs1563820	chr11:47833398	A/T	cg20307385	chr11:47447363	PSMC3	-0.49	-6.63	-0.4	2.36e-10	Subjective well-being;
SARC	cis	rs2153535	0.601	rs4140584	chr6:8540614	C/G	cg23788917	chr6:8435910	SLC35B3	-0.62	-8.19	-0.47	1.69e-14	Motion sickness;
SARC	cis	rs7246657	0.943	rs7252346	chr19:37914682	G/A	cg23950597	chr19:37808831	NA	-0.57	-5.67	-0.35	4.24e-8	Coronary artery calcification;
SARC	cis	rs7940866	0.834	rs2324315	chr11:130839772	C/G	cg12179176	chr11:130786555	SNX19	0.65	8.71	0.5	5.62e-16	Schizophrenia;
SARC	cis	rs6696846	0.740	rs11240369	chr1:205115099	G/A	cg00857998	chr1:205179979	DSTYK	0.51	6.61	0.4	2.6200000000000003e-10	Red blood cell count;
SARC	cis	rs8068544	0.606	rs77681389	chr17:40154419	T/C	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.05	-8.34	-0.48	6.37e-15	Reticulocyte fraction of red cells;Reticulocyte count;
SARC	cis	rs3540	0.574	rs2657946	chr15:90967513	G/C	cg22089800	chr15:90895588	ZNF774	0.66	8.45	0.48	3.2e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs12586317	0.513	rs17102962	chr14:35478782	A/T	cg16230307	chr14:35515116	FAM177A1	1.02	11.84	0.61	1.2e-25	Psoriasis;
SARC	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg10560079	chr2:191398806	TMEM194B	0.64	9.34	0.52	7.94e-18	Pulse pressure;
SARC	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	5.31	0.33	2.59e-7	Tonsillectomy;
SARC	cis	rs9611519	0.894	rs4821990	chr22:41438710	A/C	cg03806693	chr22:41940476	POLR3H	-0.6	-7.58	-0.44	8.36e-13	Neuroticism;
SARC	cis	rs57221529	0.766	rs12519469	chr5:581772	A/G	cg09021430	chr5:549028	NA	-0.45	-5.65	-0.35	4.73e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg10523679	chr1:76189770	ACADM	-0.52	-6.83	-0.41	7.12e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs72945132	0.619	rs34053053	chr11:70260598	C/T	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.09	-0.32	7.52e-7	Coronary artery disease;
SARC	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg12648201	chr2:27665141	KRTCAP3	-0.33	-4.89	-0.31	1.89e-6	Total body bone mineral density;
SARC	cis	rs6831352	0.918	rs29001231	chr4:100046680	T/C	cg12011299	chr4:100065546	ADH4	-0.34	-5.64	-0.35	4.82e-8	Alcohol dependence;
SARC	cis	rs9420	1.000	rs543725	chr11:57483039	A/T	cg23127183	chr11:57508653	C11orf31	-0.5	-5.77	-0.35	2.46e-8	Schizophrenia;
SARC	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.5	5.61	0.34	5.77e-8	Renal function-related traits (BUN);
SARC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg17178900	chr1:205818956	PM20D1	0.77	11.64	0.61	5.35e-25	Menarche (age at onset);
SARC	cis	rs11785400	1.000	rs3802232	chr8:143746701	A/G	cg24634471	chr8:143751801	JRK	0.67	9.04	0.51	6.02e-17	Schizophrenia;
SARC	cis	rs367943	1.000	rs1057827	chr5:112823768	T/C	cg12552261	chr5:112820674	MCC	0.46	5.27	0.33	3.05e-7	Type 2 diabetes;
SARC	cis	rs35160687	0.862	rs13023154	chr2:86516984	A/G	cg10973622	chr2:86423274	IMMT	-0.4	-5.01	-0.31	1.08e-6	Night sleep phenotypes;
SARC	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	5.52	0.34	8.9e-8	Personality dimensions;
SARC	trans	rs2018683	0.677	rs55718000	chr7:28975625	T/C	cg19402173	chr7:128379420	CALU	-0.53	-6.85	-0.41	6.67e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs9715521	0.775	rs62301195	chr4:59846934	G/T	cg11281224	chr4:60001000	NA	-0.42	-5.25	-0.33	3.48e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs262150	0.842	rs2657398	chr7:158784911	T/C	cg07977927	chr7:158815555	LOC154822	0.28	5.12	0.32	6.4e-7	Facial morphology (factor 20);
SARC	cis	rs6062509	0.965	rs2315008	chr20:62343956	T/G	cg27236539	chr20:62289627	RTEL1	0.5	5.73	0.35	3.04e-8	Prostate cancer;
SARC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg11905131	chr22:24372483	LOC391322	-0.51	-5.69	-0.35	3.81e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7011049	1.000	rs11997538	chr8:53832663	A/C	cg26025543	chr8:53854495	NA	0.65	6.04	0.37	6.08e-9	Systolic blood pressure;
SARC	cis	rs3762637	0.882	rs9818537	chr3:122086457	G/T	cg24169773	chr3:122142474	KPNA1	-0.58	-5.7	-0.35	3.63e-8	LDL cholesterol levels;
SARC	cis	rs12540874	0.522	rs4947641	chr7:50489038	C/T	cg18232548	chr7:50535776	DDC	-0.52	-6.59	-0.4	2.84e-10	Systemic sclerosis;
SARC	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg17294928	chr15:75287854	SCAMP5	0.54	6.97	0.42	3.15e-11	Breast cancer;
SARC	cis	rs3956705	0.798	rs1045530	chr7:32908135	C/G	cg06627557	chr7:32535165	LSM5;AVL9	0.47	5.72	0.35	3.31e-8	Red cell distribution width;
SARC	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg13126279	chr21:47581558	C21orf56	-0.43	-5.21	-0.32	4.18e-7	Testicular germ cell tumor;
SARC	cis	rs7592578	0.664	rs10931461	chr2:191405280	T/A	cg27211696	chr2:191398769	TMEM194B	0.57	5.94	0.36	1.04e-8	Diastolic blood pressure;
SARC	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg20607798	chr8:58055168	NA	0.56	5.27	0.33	3.12e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7116495	0.529	rs575871	chr11:71778822	A/G	cg10381502	chr11:71823885	C11orf51	-0.78	-4.95	-0.31	1.45e-6	Severe influenza A (H1N1) infection;
SARC	cis	rs9858542	0.953	rs11719996	chr3:49525958	T/C	cg07274523	chr3:49395745	GPX1	0.53	6.1	0.37	4.27e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs6496667	0.509	rs57962570	chr15:90985596	C/G	cg22089800	chr15:90895588	ZNF774	0.42	4.78	0.3	3.11e-6	Rheumatoid arthritis;
SARC	cis	rs11874712	0.966	rs8093880	chr18:43666786	C/T	cg25174615	chr18:43684699	ATP5A1;HAUS1	0.4	4.75	0.3	3.52e-6	Migraine - clinic-based;
SARC	cis	rs677665	0.537	rs6688233	chr1:9335745	A/G	cg25755851	chr1:9335794	NA	-0.62	-8.72	-0.5	5.48e-16	Eosinophil percentage of white cells;
SARC	cis	rs9309473	0.950	rs10169213	chr2:73787234	G/C	cg20560298	chr2:73613845	ALMS1	-0.48	-5.89	-0.36	1.31e-8	Metabolite levels;
SARC	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.33	-0.43	3.74e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs9291683	0.679	rs3756225	chr4:10094133	G/C	cg00071950	chr4:10020882	SLC2A9	-0.34	-5.22	-0.32	3.97e-7	Bone mineral density;
SARC	cis	rs4924997	0.772	rs2018675	chr17:19441531	A/G	cg21692194	chr17:19436881	SLC47A1	0.35	4.82	0.3	2.6e-6	Lymphocyte counts;
SARC	cis	rs1949733	0.656	rs2688224	chr4:8404700	C/G	cg11789530	chr4:8429930	ACOX3	0.84	10.97	0.58	7.62e-23	Response to antineoplastic agents;
SARC	cis	rs9398803	0.713	rs6921183	chr6:126869029	A/T	cg20229609	chr6:126660872	C6orf173	0.37	5.31	0.33	2.52e-7	Male-pattern baldness;
SARC	cis	rs9768139	0.708	rs921616	chr7:158117960	A/G	cg25566285	chr7:158114605	PTPRN2	0.31	5.19	0.32	4.66e-7	Calcium levels;
SARC	cis	rs2180341	1.000	rs4895822	chr6:127642703	T/C	cg17762328	chr6:126965162	NA	-0.45	-5.06	-0.31	8.34e-7	Breast cancer;
SARC	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg00409905	chr10:38381863	ZNF37A	-0.49	-6.74	-0.4	1.22e-10	Extrinsic epigenetic age acceleration;
SARC	cis	rs1559088	0.948	rs10410778	chr19:33592301	C/A	cg17764715	chr19:33622953	WDR88	0.49	6.72	0.4	1.4e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs3768617	0.565	rs10752897	chr1:183071024	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.64	9.03	0.51	6.77e-17	Fuchs's corneal dystrophy;
SARC	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg25072359	chr17:41440525	NA	0.48	5.62	0.35	5.43e-8	Menopause (age at onset);
SARC	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg05861140	chr6:150128134	PCMT1	-0.41	-5.34	-0.33	2.19e-7	Lung cancer;
SARC	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg07701084	chr6:150067640	NUP43	0.42	5.07	0.32	8.2e-7	Lung cancer;
SARC	cis	rs2652822	1.000	rs1126308	chr15:63429086	G/T	cg02713581	chr15:63449717	RPS27L	-0.72	-9.95	-0.55	1.16e-19	Metabolic traits;
SARC	cis	rs986417	0.748	rs4899011	chr14:60986698	A/G	cg27398547	chr14:60952738	C14orf39	0.87	8.61	0.49	1.14e-15	Gut microbiota (bacterial taxa);
SARC	cis	rs9486715	1.000	rs9373985	chr6:97063522	C/G	cg06623918	chr6:96969491	KIAA0776	-0.8	-10.9	-0.58	1.31e-22	Headache;
SARC	cis	rs2153535	0.580	rs6905242	chr6:8471799	A/C	cg21535247	chr6:8435926	SLC35B3	0.54	6.76	0.4	1.13e-10	Motion sickness;
SARC	cis	rs10782582	0.609	rs1770889	chr1:76401166	A/G	cg03433033	chr1:76189801	ACADM	-0.4	-5.22	-0.32	3.9e-7	Daytime sleep phenotypes;
SARC	cis	rs4808199	0.948	rs12982276	chr19:19459800	T/C	cg03709012	chr19:19516395	GATAD2A	1.09	11.67	0.61	4.51e-25	Nonalcoholic fatty liver disease;
SARC	trans	rs1493916	0.905	rs7239283	chr18:31395397	G/A	cg27147174	chr7:100797783	AP1S1	-0.57	-7.33	-0.43	3.87e-12	Life satisfaction;
SARC	cis	rs2439831	0.867	rs2447196	chr15:43893818	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.95	-8.8	-0.5	3.07e-16	Lung cancer in ever smokers;
SARC	cis	rs60871478	1.000	rs67721251	chr7:825114	T/C	cg19087971	chr7:751233	PRKAR1B	-0.43	-4.92	-0.31	1.67e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs7552404	0.731	rs11161845	chr1:76367559	T/C	cg10523679	chr1:76189770	ACADM	0.46	5.35	0.33	2.11e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs3008870	0.755	rs1121824	chr1:67475616	C/A	cg02640540	chr1:67518911	SLC35D1	0.46	5.26	0.33	3.34e-7	Lymphocyte percentage of white cells;
SARC	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg14664628	chr15:75095509	CSK	0.47	5.93	0.36	1.08e-8	Breast cancer;
SARC	cis	rs76419734	1.000	rs114171212	chr4:106616191	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.82	5.06	0.31	8.65e-7	Post bronchodilator FEV1;
SARC	cis	rs202126107	1	rs202126107	chr17:38006767	GCATATTATA/G	cg20243544	chr17:37824526	PNMT	0.4	5.27	0.33	3.11e-7	Eosinophil percentage of white cells;
SARC	cis	rs2288073	0.965	rs13395596	chr2:24410738	T/C	cg06627628	chr2:24431161	ITSN2	-0.63	-7.66	-0.45	4.86e-13	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs11792861	0.566	rs6477687	chr9:111837791	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.44	-5.5	-0.34	9.88e-8	Menarche (age at onset);
SARC	cis	rs654950	0.776	rs2759252	chr1:42021854	G/A	cg06885757	chr1:42089581	HIVEP3	-0.46	-6.69	-0.4	1.68e-10	Airway imaging phenotypes;
SARC	cis	rs1008375	0.932	rs12500947	chr4:17603424	C/T	cg27347728	chr4:17578864	LAP3	0.46	5.6	0.34	6.12e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9911578	1.000	rs2611782	chr17:56717956	T/C	cg05425664	chr17:57184151	TRIM37	-0.68	-8.49	-0.49	2.48e-15	Intelligence (multi-trait analysis);
SARC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg23029363	chr5:137803326	EGR1	-0.49	-6.4	-0.39	8.65e-10	Gut microbiota (bacterial taxa);
SARC	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg03433033	chr1:76189801	ACADM	-0.53	-7.62	-0.45	6.49e-13	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs950776	0.507	rs12912673	chr15:78810216	T/C	cg22563815	chr15:78856949	CHRNA5	0.41	6.74	0.4	1.21e-10	Sudden cardiac arrest;
SARC	cis	rs2806561	0.765	rs623988	chr1:23519477	C/T	cg12483005	chr1:23474871	LUZP1	0.45	5.9	0.36	1.3e-8	Height;
SARC	cis	rs2011503	1.000	rs2916072	chr19:19525712	G/A	cg15839431	chr19:19639596	YJEFN3	-0.49	-4.82	-0.3	2.62e-6	Bipolar disorder;
SARC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.13	0.37	3.73e-9	Prudent dietary pattern;
SARC	cis	rs6831352	0.918	rs2602896	chr4:100046207	C/T	cg12011299	chr4:100065546	ADH4	-0.32	-5.32	-0.33	2.45e-7	Alcohol dependence;
SARC	cis	rs7020830	0.898	rs308523	chr9:37338785	C/T	cg14294708	chr9:37120828	ZCCHC7	1.09	20.06	0.8	1.16e-52	Schizophrenia;
SARC	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg07414643	chr4:187882934	NA	0.46	6.56	0.39	3.45e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6582630	0.593	rs11182590	chr12:38574274	A/T	cg26384229	chr12:38710491	ALG10B	0.7	9.2	0.52	2.14e-17	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs936229	0.813	rs7085	chr15:75095483	T/C	cg10253484	chr15:75165896	SCAMP2	-0.44	-4.76	-0.3	3.41e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs7589728	1.000	rs75181745	chr2:88520408	C/T	cg04511125	chr2:88470314	THNSL2	0.67	5.96	0.36	9.19e-9	Plasma clusterin levels;
SARC	cis	rs16944613	0.588	rs10852136	chr15:91139798	T/G	cg26821196	chr15:91095069	CRTC3	0.52	5.35	0.33	2.13e-7	Colorectal cancer;
SARC	cis	rs2120019	1.000	rs2415253	chr15:75375699	A/G	cg00629941	chr15:75287862	SCAMP5	-0.6	-7.26	-0.43	5.68e-12	Blood trace element (Zn levels);
SARC	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg16405210	chr4:1374714	KIAA1530	0.78	10.0	0.55	7.88e-20	Longevity;
SARC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg23696834	chr6:42928345	GNMT	-0.32	-4.81	-0.3	2.77e-6	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg11062466	chr8:58055876	NA	0.6	5.71	0.35	3.44e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9790314	0.871	rs339114	chr3:161109220	C/T	cg04691961	chr3:161091175	C3orf57	0.71	9.94	0.55	1.22e-19	Morning vs. evening chronotype;
SARC	cis	rs7223966	1.000	rs7216798	chr17:61740963	G/A	cg00588841	chr17:61851480	DDX42;CCDC47	-0.59	-6.86	-0.41	6.03e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg08975724	chr8:8085496	FLJ10661	0.56	7.16	0.42	1.05e-11	Neuroticism;
SARC	cis	rs7769051	0.522	rs6911773	chr6:133128848	T/C	cg22852734	chr6:133119734	C6orf192	1.19	7.51	0.44	1.24e-12	Type 2 diabetes nephropathy;
SARC	cis	rs11785400	0.793	rs9774627	chr8:143731267	G/A	cg10596483	chr8:143751796	JRK	0.57	7.39	0.44	2.61e-12	Schizophrenia;
SARC	cis	rs2075371	0.933	rs1421482	chr7:133964383	A/G	cg20476274	chr7:133979776	SLC35B4	0.59	7.94	0.46	8.47e-14	Mean platelet volume;
SARC	cis	rs16976116	0.855	rs28522816	chr15:55495114	C/G	cg17854078	chr15:55489399	RSL24D1	0.66	6.53	0.39	4.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9650657	0.504	rs7813802	chr8:11033976	C/T	cg21775007	chr8:11205619	TDH	0.43	5.25	0.33	3.43e-7	Neuroticism;
SARC	cis	rs6450176	0.830	rs7718193	chr5:53291591	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.64	-7.22	-0.43	7.11e-12	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs8014204	0.967	rs4903266	chr14:75344941	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.77	-11.31	-0.6	6.08e-24	Caffeine consumption;
SARC	cis	rs981844	0.712	rs1037646	chr4:154738015	C/T	cg14289246	chr4:154710475	SFRP2	-0.45	-5.2	-0.32	4.29e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg06212747	chr3:49208901	KLHDC8B	0.66	8.8	0.5	3.19e-16	Parkinson's disease;
SARC	cis	rs9303401	0.659	rs35103007	chr17:56900738	G/A	cg25039879	chr17:56429692	SUPT4H1	0.65	6.13	0.37	3.77e-9	Cognitive test performance;
SARC	cis	rs3126085	0.935	rs11204939	chr1:152200942	G/C	cg26876637	chr1:152193138	HRNR	0.47	5.44	0.34	1.35e-7	Atopic dermatitis;
SARC	cis	rs668210	0.739	rs1151511	chr11:65756283	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.7	7.6	0.45	7.24e-13	Cerebrospinal fluid biomarker levels;
SARC	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg18404041	chr3:52824283	ITIH1	-0.42	-6.34	-0.38	1.17e-9	Bipolar disorder;
SARC	cis	rs3768617	0.510	rs10797849	chr1:183088988	A/G	cg13390022	chr1:182993471	LAMC1	0.32	4.76	0.3	3.44e-6	Fuchs's corneal dystrophy;
SARC	cis	rs6759839	0.565	rs9967813	chr2:16679863	T/C	cg09580478	chr2:16689509	NA	0.54	6.63	0.4	2.26e-10	Mean platelet volume;
SARC	cis	rs9467773	1.000	rs6926629	chr6:26499903	T/C	cg11502198	chr6:26597334	ABT1	0.49	6.0	0.37	7.6e-9	Intelligence (multi-trait analysis);
SARC	cis	rs1707322	0.963	rs12022335	chr1:46402732	C/A	cg06784218	chr1:46089804	CCDC17	0.34	5.97	0.36	8.98e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	7.45	0.44	1.78e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg21775007	chr8:11205619	TDH	0.51	6.28	0.38	1.61e-9	Neuroticism;
SARC	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg11987759	chr7:65425863	GUSB	0.48	5.91	0.36	1.22e-8	Aortic root size;
SARC	cis	rs9747201	1.000	rs62078307	chr17:80090053	G/T	cg17462356	chr17:80056334	FASN	0.45	5.08	0.32	7.6e-7	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg12463550	chr7:65579703	CRCP	-0.51	-5.53	-0.34	8.73e-8	Aortic root size;
SARC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.04	0.37	6e-9	Prudent dietary pattern;
SARC	cis	rs3845702	0.866	rs3914458	chr2:180862606	A/G	cg01881094	chr2:180872142	CWC22	-0.6	-5.42	-0.33	1.51e-7	Schizophrenia;
SARC	cis	rs7659604	0.967	rs10008348	chr4:122666987	A/C	cg20573242	chr4:122745356	CCNA2	0.43	5.55	0.34	7.61e-8	Type 2 diabetes;
SARC	cis	rs2204008	0.777	rs6582664	chr12:37947022	A/G	cg13010199	chr12:38710504	ALG10B	-0.66	-8.89	-0.5	1.72e-16	Bladder cancer;
SARC	cis	rs9398803	0.687	rs9388507	chr6:126970895	G/T	cg20229609	chr6:126660872	C6orf173	0.37	5.38	0.33	1.85e-7	Male-pattern baldness;
SARC	cis	rs838147	0.507	rs692854	chr19:49209464	C/A	cg21064579	chr19:49206444	FUT2	0.35	4.84	0.3	2.37e-6	Dietary macronutrient intake;
SARC	cis	rs12497850	1.000	rs1352420	chr3:48757291	A/G	cg07636037	chr3:49044803	WDR6	0.94	15.45	0.71	1.55e-37	Parkinson's disease;
SARC	cis	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg12463550	chr7:65579703	CRCP	0.68	5.21	0.32	4.1e-7	Diabetic kidney disease;
SARC	cis	rs7044106	0.791	rs7036196	chr9:123479457	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	9.74	0.54	4.98e-19	Hip circumference adjusted for BMI;
SARC	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg11987759	chr7:65425863	GUSB	-0.49	-6.21	-0.38	2.46e-9	Aortic root size;
SARC	cis	rs6545883	0.895	rs2421192	chr2:61643631	T/C	cg15711740	chr2:61764176	XPO1	0.4	4.87	0.3	2.08e-6	Tuberculosis;
SARC	cis	rs228769	0.673	rs375677	chr17:42108974	A/C	cg19774624	chr17:42201019	HDAC5	0.44	4.77	0.3	3.18e-6	Bone mineral density (hip);Bone mineral density (spine);
SARC	cis	rs79839061	0.610	rs1564282	chr4:852313	C/T	cg07828340	chr4:882639	GAK	0.75	5.45	0.34	1.26e-7	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg20607798	chr8:58055168	NA	0.57	5.55	0.34	7.8e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg16405210	chr4:1374714	KIAA1530	-0.58	-7.17	-0.43	9.95e-12	Longevity;
SARC	cis	rs7412746	0.658	rs12410394	chr1:150860186	G/A	cg10589385	chr1:150898437	SETDB1	0.41	5.48	0.34	1.12e-7	Melanoma;
SARC	cis	rs4243830	0.737	rs4908909	chr1:6599041	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.01	-9.9	-0.54	1.61e-19	Body mass index;
SARC	cis	rs262150	0.567	rs2527177	chr7:158804737	T/C	cg19418458	chr7:158789849	NA	-0.42	-6.05	-0.37	5.58e-9	Facial morphology (factor 20);
SARC	cis	rs870825	0.616	rs28442259	chr4:185646962	T/G	cg04058563	chr4:185651563	MLF1IP	0.8	11.35	0.6	4.56e-24	Blood protein levels;
SARC	cis	rs1784581	0.588	rs9885762	chr6:162411954	G/A	cg17173639	chr6:162384350	PARK2	0.51	6.43	0.39	7.27e-10	Itch intensity from mosquito bite;
SARC	cis	rs2070433	0.539	rs56157650	chr21:47957959	T/C	cg12379764	chr21:47803548	PCNT	0.52	5.62	0.35	5.32e-8	Lymphocyte counts;
SARC	cis	rs2273669	0.915	rs67708237	chr6:109292058	G/A	cg01304950	chr6:109416612	SESN1;C6orf182	0.54	4.74	0.3	3.75e-6	Prostate cancer;
SARC	cis	rs7582180	0.629	rs11694642	chr2:100957813	A/G	cg14675211	chr2:100938903	LONRF2	0.51	7.51	0.44	1.24e-12	Intelligence (multi-trait analysis);
SARC	trans	rs11098499	0.954	rs17005535	chr4:120411562	C/T	cg25214090	chr10:38739885	LOC399744	0.58	7.47	0.44	1.63e-12	Corneal astigmatism;
SARC	cis	rs6693567	0.516	rs519126	chr1:150288859	T/G	cg09579323	chr1:150459698	TARS2	-0.4	-5.15	-0.32	5.57e-7	Migraine;
SARC	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.27	-0.52	1.34e-17	Developmental language disorder (linguistic errors);
SARC	cis	rs12586317	0.534	rs28384418	chr14:35452126	C/A	cg26967526	chr14:35346199	BAZ1A	-0.57	-6.73	-0.4	1.34e-10	Psoriasis;
SARC	cis	rs514406	0.505	rs405208	chr1:53176674	C/T	cg08859206	chr1:53392774	SCP2	-0.35	-5.07	-0.32	8.02e-7	Monocyte count;
SARC	cis	rs1153858	1.000	rs2467863	chr15:45641880	G/A	cg26924012	chr15:45694286	SPATA5L1	0.75	10.36	0.56	6.21e-21	Homoarginine levels;
SARC	cis	rs9611565	0.506	rs2024567	chr22:41699206	G/C	cg03806693	chr22:41940476	POLR3H	-0.7	-9.21	-0.52	1.97e-17	Vitiligo;
SARC	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg18305652	chr10:134549665	INPP5A	0.36	5.15	0.32	5.46e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs6582630	0.502	rs4559747	chr12:38436235	G/A	cg13010199	chr12:38710504	ALG10B	0.74	10.09	0.55	4.35e-20	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs959260	0.588	rs9894003	chr17:73405860	T/G	cg00200289	chr17:73401734	GRB2	-0.61	-5.64	-0.35	4.92e-8	Systemic lupus erythematosus;
SARC	cis	rs1348850	0.750	rs12997716	chr2:178494629	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.5	5.72	0.35	3.2e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1401999	1.000	rs6443924	chr3:183679532	A/G	cg01324343	chr3:183735012	ABCC5	0.67	13.43	0.66	7.75e-31	Anterior chamber depth;
SARC	cis	rs9660992	0.710	rs4951184	chr1:205240659	A/T	cg00857998	chr1:205179979	DSTYK	0.48	5.95	0.36	9.56e-9	Mean corpuscular volume;Mean platelet volume;
SARC	trans	rs57046232	0.502	rs13036588	chr20:6462428	T/C	cg00270625	chr22:51017019	CPT1B;CHKB-CPT1B	0.61	6.82	0.41	7.94e-11	Colorectal cancer;
SARC	cis	rs763121	0.853	rs2072796	chr22:39064230	A/G	cg14440974	chr22:39074834	NA	-0.34	-5.08	-0.32	7.65e-7	Menopause (age at onset);
SARC	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg00149659	chr3:10157352	C3orf10	0.62	5.73	0.35	3.06e-8	Alzheimer's disease;
SARC	cis	rs3733585	0.726	rs4306953	chr4:9955776	G/A	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.39	-0.33	1.73e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs66573146	0.572	rs66819208	chr4:6946128	A/G	cg26116260	chr4:7069785	GRPEL1	-0.69	-5.09	-0.32	7.44e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs6484504	0.532	rs1929019	chr11:31267030	C/T	cg19308365	chr11:31391254	DNAJC24;DCDC1	-0.38	-4.73	-0.3	3.98e-6	Red blood cell count;
SARC	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	5.69	0.35	3.71e-8	Bipolar disorder;
SARC	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg13849007	chr1:1677539	SLC35E2	-0.37	-4.76	-0.3	3.39e-6	Body mass index;
SARC	cis	rs6546550	0.867	rs7592647	chr2:70139134	C/T	cg02498382	chr2:70120550	SNRNP27	-0.32	-5.13	-0.32	6.14e-7	Prevalent atrial fibrillation;
SARC	cis	rs4595586	0.545	rs6580892	chr12:39370237	G/C	cg26384229	chr12:38710491	ALG10B	0.51	6.25	0.38	1.9e-9	Morning vs. evening chronotype;
SARC	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg18252515	chr7:66147081	NA	-0.48	-5.24	-0.32	3.55e-7	Aortic root size;
SARC	cis	rs7927771	1.000	rs9909	chr11:47799775	C/G	cg05585544	chr11:47624801	NA	-0.36	-4.82	-0.3	2.59e-6	Subjective well-being;
SARC	cis	rs3733585	0.673	rs9993410	chr4:9951264	C/T	cg11266682	chr4:10021025	SLC2A9	-0.35	-6.0	-0.37	7.36e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg13206674	chr6:150067644	NUP43	0.41	5.37	0.33	1.92e-7	Lung cancer;
SARC	cis	rs11785400	0.612	rs10110864	chr8:143750072	A/G	cg24634471	chr8:143751801	JRK	0.6	7.85	0.46	1.48e-13	Schizophrenia;
SARC	cis	rs1059312	1.000	rs7970815	chr12:129288366	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.5	7.01	0.42	2.51e-11	Systemic lupus erythematosus;
SARC	cis	rs9436747	0.739	rs1171267	chr1:66003854	T/G	cg14976592	chr1:65886160	LEPROT;LEPR	-0.45	-5.13	-0.32	6.2e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs6502050	0.787	rs11653012	chr17:80058857	C/T	cg13939156	chr17:80058883	NA	0.4	6.39	0.39	8.99e-10	Life satisfaction;
SARC	cis	rs6752107	1.000	rs2241879	chr2:234183468	G/A	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.46	6.24	0.38	1.99e-9	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg26335602	chr6:28129616	ZNF389	0.52	5.88	0.36	1.44e-8	Depression;
SARC	cis	rs9393692	0.905	rs9366649	chr6:26329103	A/T	cg05868516	chr6:26286170	HIST1H4H	-0.51	-6.59	-0.4	2.95e-10	Educational attainment;
SARC	cis	rs28829049	0.597	rs12566296	chr1:19498443	A/C	cg13387374	chr1:19411106	UBR4	0.42	5.02	0.31	1.03e-6	QRS duration in Tripanosoma cruzi seropositivity;
SARC	cis	rs1215050	0.791	rs1648546	chr4:98899294	T/C	cg05340658	chr4:99064831	C4orf37	-0.44	-5.85	-0.36	1.69e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs2288884	0.541	rs8107827	chr19:52465481	A/G	cg24732339	chr19:52471368	ZNF350	-0.56	-4.88	-0.3	1.93e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
SARC	cis	rs734999	0.588	rs3748819	chr1:2524966	C/T	cg00980319	chr1:2560884	MMEL1	-0.35	-4.93	-0.31	1.58e-6	Ulcerative colitis;
SARC	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg11764359	chr7:65958608	NA	0.88	12.58	0.64	4.89e-28	Aortic root size;
SARC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg06873352	chr17:61820015	STRADA	0.53	6.92	0.41	4.3e-11	Prudent dietary pattern;
SARC	cis	rs17376456	0.690	rs6892055	chr5:93113023	A/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.67	6.06	0.37	5.34e-9	Diabetic retinopathy;
SARC	cis	rs7589728	0.688	rs76734941	chr2:88530454	T/C	cg04511125	chr2:88470314	THNSL2	0.69	5.36	0.33	2.02e-7	Plasma clusterin levels;
SARC	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	13.79	0.67	4.82e-32	Chronic sinus infection;
SARC	cis	rs2425143	1.000	rs55761608	chr20:34344226	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-5.75	-0.35	2.72e-8	Blood protein levels;
SARC	cis	rs74181299	0.571	rs71424153	chr2:65280894	G/C	cg20592124	chr2:65290738	CEP68	0.39	5.18	0.32	4.74e-7	Pulse pressure;
SARC	cis	rs2153535	0.580	rs1414340	chr6:8491139	G/A	cg23788917	chr6:8435910	SLC35B3	0.64	8.44	0.48	3.45e-15	Motion sickness;
SARC	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.68	6.6	0.4	2.67e-10	Platelet count;
SARC	trans	rs3780486	0.541	rs10738909	chr9:33148834	T/C	cg04842962	chr6:43655489	MRPS18A	0.84	11.76	0.61	2.23e-25	IgG glycosylation;
SARC	cis	rs7927771	0.524	rs10838769	chr11:47825333	A/G	cg10504702	chr11:47789108	FNBP4	-0.43	-5.62	-0.35	5.52e-8	Subjective well-being;
SARC	cis	rs7615952	0.534	rs1503072	chr3:125754691	C/T	cg15145296	chr3:125709740	NA	-0.49	-4.82	-0.3	2.64e-6	Blood pressure (smoking interaction);
SARC	cis	rs11098499	0.754	rs11732087	chr4:120239831	A/G	cg09307838	chr4:120376055	NA	0.81	11.15	0.59	2.11e-23	Corneal astigmatism;
SARC	cis	rs7208859	0.673	rs9889755	chr17:29234505	A/G	cg13385521	chr17:29058706	SUZ12P	-0.62	-5.65	-0.35	4.64e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg21144161	chr5:423903	AHRR	0.31	4.84	0.3	2.39e-6	Cystic fibrosis severity;
SARC	cis	rs9467711	0.651	rs68194335	chr6:25866243	A/T	cg21479132	chr6:26055353	NA	0.77	4.79	0.3	3.02e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7412746	0.611	rs11204748	chr1:150927369	G/T	cg10589385	chr1:150898437	SETDB1	0.39	5.23	0.32	3.77e-7	Melanoma;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg23526861	chr3:46924956	PTH1R	0.52	6.39	0.39	8.77e-10	Blood pressure;
SARC	cis	rs79839061	0.656	rs11726508	chr4:888937	C/T	cg07828340	chr4:882639	GAK	0.59	5.1	0.32	7.03e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1865760	0.929	rs9461224	chr6:25936402	G/T	cg16482183	chr6:26056742	HIST1H1C	0.46	5.64	0.35	4.98e-8	Height;
SARC	cis	rs4601821	0.789	rs7123797	chr11:113262571	A/G	cg14159747	chr11:113255604	NA	0.37	4.91	0.31	1.75e-6	Alcoholic chronic pancreatitis;
SARC	cis	rs911555	0.706	rs10129426	chr14:104018455	C/T	cg12935359	chr14:103987150	CKB	-0.38	-5.83	-0.36	1.81e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg18357526	chr6:26021779	HIST1H4A	0.93	13.11	0.65	8.65e-30	Intelligence (multi-trait analysis);
SARC	cis	rs2929278	0.617	rs12908467	chr15:44047430	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.43	-4.91	-0.31	1.71e-6	Schizophrenia;
SARC	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg26513180	chr16:89883248	FANCA	0.72	4.78	0.3	3.05e-6	Skin colour saturation;
SARC	cis	rs875971	1.000	rs1144894	chr7:65542894	A/G	cg18876405	chr7:65276391	NA	-0.47	-5.68	-0.35	3.99e-8	Aortic root size;
SARC	cis	rs9303401	1.000	rs9303401	chr17:56847945	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.68	7.91	0.46	1.01e-13	Cognitive test performance;
SARC	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg14500267	chr11:67383377	NA	0.39	5.74	0.35	2.96e-8	Mean corpuscular volume;
SARC	trans	rs208520	0.690	rs207114	chr6:66791703	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-14.17	-0.68	2.8e-33	Exhaled nitric oxide output;
SARC	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg11644478	chr21:40555479	PSMG1	1.03	14.28	0.68	1.16e-33	Cognitive function;
SARC	cis	rs8027181	0.839	rs8033073	chr15:73051093	G/A	cg25996835	chr15:72978165	BBS4;HIGD2B	0.46	5.91	0.36	1.18e-8	Triglyceride levels;
SARC	cis	rs3796352	1.000	rs11706035	chr3:53011868	A/T	cg15956490	chr3:53032818	SFMBT1	0.71	4.88	0.3	1.97e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs7618501	0.966	rs13085679	chr3:49869631	G/A	cg05623727	chr3:50126028	RBM5	0.33	4.94	0.31	1.48e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9341808	0.739	rs4706831	chr6:81007699	T/C	cg08355045	chr6:80787529	NA	0.37	5.86	0.36	1.61e-8	Sitting height ratio;
SARC	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg25072359	chr17:41440525	NA	0.48	5.55	0.34	7.82e-8	Menopause (age at onset);
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	ch.8.137615416R	chr8:137546234	NA	0.5	6.55	0.39	3.62e-10	Blood pressure;
SARC	cis	rs7223966	1.000	rs9908044	chr17:61747032	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.48	-5.35	-0.33	2.07e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs3126085	0.935	rs3126043	chr1:152256030	C/G	cg03465714	chr1:152285911	FLG	-0.47	-5.7	-0.35	3.58e-8	Atopic dermatitis;
SARC	cis	rs7937682	0.632	rs4441050	chr11:111772506	C/T	cg22437258	chr11:111473054	SIK2	-0.49	-5.61	-0.34	5.78e-8	Primary sclerosing cholangitis;
SARC	cis	rs4243830	1.000	rs34757678	chr1:6583270	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.93	7.37	0.43	2.93e-12	Body mass index;
SARC	cis	rs1707322	0.929	rs785513	chr1:46538320	T/C	cg03146154	chr1:46216737	IPP	-0.49	-5.81	-0.36	2.01e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7179456	0.635	rs6416469	chr15:59261203	A/G	cg05156742	chr15:59063176	FAM63B	0.57	7.34	0.43	3.57e-12	Asperger disorder;
SARC	trans	rs2727020	0.553	rs7479975	chr11:49581964	C/G	cg15704280	chr7:45808275	SEPT13	-0.83	-13.24	-0.66	3.37e-30	Coronary artery disease;
SARC	cis	rs7264396	0.635	rs6060656	chr20:34466382	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.51	5.19	0.32	4.66e-7	Total cholesterol levels;
SARC	cis	rs910316	0.967	rs2010678	chr14:75567178	C/T	cg06637938	chr14:75390232	RPS6KL1	0.54	7.72	0.45	3.4e-13	Height;
SARC	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-7.89	-0.46	1.16e-13	Chronic sinus infection;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg21494973	chr12:102091324	CHPT1	0.49	6.61	0.4	2.53e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs7011049	1.000	rs117708010	chr8:53844026	G/A	cg26025543	chr8:53854495	NA	0.6	5.43	0.34	1.42e-7	Systolic blood pressure;
SARC	cis	rs36051895	0.664	rs7852755	chr9:5100862	C/T	cg02405213	chr9:5042618	JAK2	-0.44	-5.44	-0.34	1.36e-7	Pediatric autoimmune diseases;
SARC	cis	rs965469	1.000	rs6051709	chr20:3263685	T/C	cg25506879	chr20:3388711	C20orf194	-0.49	-4.91	-0.31	1.7e-6	IFN-related cytopenia;
SARC	cis	rs3796352	1.000	rs3097417	chr3:53088601	C/G	cg15956490	chr3:53032818	SFMBT1	-0.72	-5.27	-0.33	3.06e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs1215050	0.791	rs1215054	chr4:98863009	T/G	cg05340658	chr4:99064831	C4orf37	-0.45	-6.03	-0.37	6.53e-9	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs1278769	0.786	rs9577175	chr13:113543355	C/T	cg01161842	chr13:113518337	ATP11A	0.41	4.81	0.3	2.72e-6	Interstitial lung disease;
SARC	cis	rs1003719	0.641	rs13046844	chr21:38517603	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.27	-0.52	1.33e-17	Eye color traits;
SARC	cis	rs7843479	0.544	rs7839925	chr8:21792983	G/C	cg17168535	chr8:21777572	XPO7	0.84	12.74	0.64	1.43e-28	Mean corpuscular volume;
SARC	cis	rs6840360	0.571	rs17275577	chr4:152519899	G/A	cg22705602	chr4:152727874	NA	-0.44	-6.82	-0.41	7.54e-11	Intelligence (multi-trait analysis);
SARC	cis	rs12142240	0.698	rs66847432	chr1:46832013	G/A	cg10495392	chr1:46806563	NSUN4	0.64	6.83	0.41	7.39e-11	Menopause (age at onset);
SARC	cis	rs11098499	0.863	rs6835635	chr4:120458867	A/G	cg09160332	chr4:120329925	NA	-0.34	-4.74	-0.3	3.71e-6	Corneal astigmatism;
SARC	cis	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg06558623	chr16:89946397	TCF25	0.92	6.39	0.39	8.93e-10	Skin colour saturation;
SARC	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg09359103	chr1:154839909	KCNN3	-0.48	-8.12	-0.47	2.73e-14	Prostate cancer;
SARC	cis	rs11785400	0.612	rs10110864	chr8:143750072	A/G	cg10596483	chr8:143751796	JRK	0.55	7.2	0.43	8.36e-12	Schizophrenia;
SARC	cis	rs6088813	1.000	rs224333	chr20:34023962	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.46	5.57	0.34	6.85e-8	Height;
SARC	cis	rs2735413	0.918	rs4888731	chr16:78080418	A/G	cg04733911	chr16:78082701	NA	-0.28	-5.13	-0.32	6.03e-7	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs8067545	0.616	rs203477	chr17:19831819	A/C	cg13482628	chr17:19912719	NA	0.54	6.84	0.41	6.97e-11	Schizophrenia;
SARC	cis	rs9291683	0.526	rs6827785	chr4:10018205	C/T	cg00071950	chr4:10020882	SLC2A9	0.32	4.89	0.31	1.86e-6	Bone mineral density;
SARC	cis	rs2153535	0.563	rs7739249	chr6:8534590	C/G	cg23788917	chr6:8435910	SLC35B3	0.61	7.77	0.45	2.54e-13	Motion sickness;
SARC	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.94	10.14	0.55	2.91e-20	Platelet count;
SARC	cis	rs7772486	0.727	rs12190966	chr6:146146820	T/G	cg23711669	chr6:146136114	FBXO30	0.81	13.47	0.66	5.53e-31	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.95	-15.08	-0.7	2.51e-36	Chronic sinus infection;
SARC	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg27594834	chr19:11708137	ZNF627	-0.52	-6.37	-0.39	9.87e-10	Migraine with aura;
SARC	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg05313129	chr8:58192883	C8orf71	-0.62	-6.34	-0.38	1.18e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1448094	0.511	rs4462416	chr12:86150966	T/C	cg00310523	chr12:86230176	RASSF9	-0.3	-4.71	-0.3	4.18e-6	Major depressive disorder;
SARC	cis	rs8017423	0.967	rs8015510	chr14:90729984	C/T	cg20276874	chr14:90721474	PSMC1	-0.38	-5.25	-0.33	3.39e-7	Mortality in heart failure;
SARC	cis	rs7647973	0.559	rs9586	chr3:49213637	C/T	cg07636037	chr3:49044803	WDR6	0.87	9.32	0.52	9.05e-18	Menarche (age at onset);
SARC	cis	rs950027	0.620	rs2461700	chr15:45640627	T/C	cg21132104	chr15:45694354	SPATA5L1	0.55	7.1	0.42	1.49e-11	Response to fenofibrate (adiponectin levels);
SARC	trans	rs13325613	0.915	rs34745455	chr3:46267333	T/C	cg12387106	chr12:133178249	NA	0.84	6.57	0.4	3.25e-10	Monocyte count;
SARC	cis	rs9840812	0.522	rs711976	chr3:136229022	A/G	cg15507776	chr3:136538369	TMEM22	0.53	5.94	0.36	1e-8	Fibrinogen levels;
SARC	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg00933542	chr6:150070202	PCMT1	0.3	5.14	0.32	5.77e-7	Lung cancer;
SARC	cis	rs7552404	0.731	rs12078299	chr1:76365764	T/A	cg03433033	chr1:76189801	ACADM	0.47	5.68	0.35	3.99e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg07977927	chr7:158815555	LOC154822	0.25	4.78	0.3	3.16e-6	Facial morphology (factor 20);
SARC	cis	rs6570726	0.791	rs447992	chr6:145817184	C/T	cg05347473	chr6:146136440	FBXO30	0.53	7.35	0.43	3.43e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs67460515	0.892	rs4856769	chr3:161004549	C/A	cg03342759	chr3:160939853	NMD3	-0.7	-8.86	-0.5	2.05e-16	Parkinson's disease;
SARC	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg11062466	chr8:58055876	NA	0.53	5.55	0.34	7.79e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-8.39	-0.48	4.59e-15	Chronic sinus infection;
SARC	cis	rs7197653	0.748	rs8060690	chr16:68340085	G/T	cg09835421	chr16:68378352	PRMT7	-0.67	-5.81	-0.36	2.04e-8	Magnesium levels;
SARC	cis	rs300774	1.000	rs300782	chr2:110345	C/T	cg06380356	chr2:467891	NA	-0.35	-4.82	-0.3	2.61e-6	Suicide attempts in bipolar disorder;
SARC	cis	rs1538970	0.924	rs4660851	chr1:45843810	A/T	cg05343316	chr1:45956843	TESK2	0.64	7.62	0.45	6.54e-13	Platelet count;
SARC	cis	rs17173637	0.867	rs73165531	chr7:150533073	C/T	cg26935020	chr7:151217007	RHEB	-0.74	-4.82	-0.3	2.64e-6	HDL cholesterol;HDL cholesterol levels;
SARC	cis	rs60871478	0.588	rs56205589	chr7:910419	G/A	cg05535760	chr7:792225	HEATR2	-0.74	-6.86	-0.41	6.16e-11	Cerebrospinal P-tau181p levels;
SARC	cis	rs3092073	0.624	rs11696623	chr20:44580380	C/T	cg17986701	chr20:44574422	PCIF1	0.36	5.01	0.31	1.09e-6	Intelligence (multi-trait analysis);
SARC	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg26119090	chr2:26468346	HADHA;HADHB	0.95	13.96	0.67	1.32e-32	Gut microbiome composition (summer);
SARC	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	11.07	0.59	3.6e-23	Alzheimer's disease;
SARC	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	5.59	0.34	6.48e-8	Electroencephalogram traits;
SARC	cis	rs17253792	0.822	rs76055105	chr14:56069127	A/G	cg01858014	chr14:56050164	KTN1	-0.67	-5.16	-0.32	5.38e-7	Putamen volume;
SARC	cis	rs6977660	0.507	rs72591449	chr7:19775443	T/C	cg07541023	chr7:19748670	TWISTNB	0.93	8.12	0.47	2.77e-14	Thyroid stimulating hormone;
SARC	cis	rs9788682	0.947	rs7169584	chr15:78822660	A/T	cg24631222	chr15:78858424	CHRNA5	0.76	10.22	0.56	1.7e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs400736	0.894	rs226242	chr1:8033468	G/A	cg25007680	chr1:8021821	PARK7	0.53	6.81	0.41	8.29e-11	Response to antidepressants and depression;
SARC	cis	rs7824557	0.767	rs11775635	chr8:11164865	G/A	cg21775007	chr8:11205619	TDH	0.52	6.18	0.38	2.79e-9	Retinal vascular caliber;
SARC	cis	rs798554	0.679	rs798499	chr7:2792013	G/A	cg13628971	chr7:2884303	GNA12	0.46	5.71	0.35	3.47e-8	Height;
SARC	cis	rs10791323	0.593	rs2156676	chr11:133715791	G/C	cg14349672	chr11:133703707	NA	-0.35	-4.97	-0.31	1.31e-6	Childhood ear infection;
SARC	cis	rs1055129	0.655	rs7223416	chr17:73836162	C/G	cg14829360	chr17:73884958	NA	-0.43	-5.94	-0.36	1.03e-8	White matter hyperintensity burden;
SARC	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg00933542	chr6:150070202	PCMT1	0.31	5.36	0.33	2.04e-7	Lung cancer;
SARC	cis	rs12142240	0.698	rs72677585	chr1:46812374	T/C	cg00530320	chr1:46809349	NSUN4	0.58	7.07	0.42	1.83e-11	Menopause (age at onset);
SARC	cis	rs4481887	0.790	rs10888364	chr1:248488387	T/G	cg13385794	chr1:248469461	NA	0.34	5.1	0.32	6.89e-7	Common traits (Other);
SARC	cis	rs7617773	0.780	rs4392440	chr3:48343920	C/T	cg11946769	chr3:48343235	NME6	0.76	9.7	0.54	6.55e-19	Coronary artery disease;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg10583683	chr15:23034700	NIPA2	-0.55	-6.33	-0.38	1.26e-9	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs546131	0.642	rs12808574	chr11:34852120	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.44	4.78	0.3	3.14e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg22903471	chr2:27725779	GCKR	-0.46	-6.78	-0.41	1.01e-10	Total body bone mineral density;
SARC	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	10.61	0.57	1.01e-21	Platelet count;
SARC	cis	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg14019146	chr3:50243930	SLC38A3	-0.31	-4.84	-0.3	2.4e-6	Body mass index;
SARC	cis	rs12044355	0.929	rs1954175	chr1:231855410	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.52	6.92	0.41	4.32e-11	Alzheimer's disease;
SARC	cis	rs11225247	0.881	rs11225235	chr11:102247361	G/A	cg11690896	chr11:102217788	BIRC2	0.78	5.27	0.33	3.1e-7	Vein graft stenosis in coronary artery bypass grafting;
SARC	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg12463550	chr7:65579703	CRCP	0.42	4.97	0.31	1.32e-6	Aortic root size;
SARC	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg00825309	chr19:58991885	ZNF446	-0.57	-7.72	-0.45	3.5e-13	Uric acid clearance;
SARC	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.9	-14.71	-0.69	4.49e-35	Birth weight;
SARC	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9902453	0.845	rs58606097	chr17:28020379	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	7.08	0.42	1.73e-11	Coffee consumption (cups per day);
SARC	cis	rs11792861	0.888	rs72607168	chr9:111832192	G/C	cg13535736	chr9:111863775	C9orf5	-0.41	-5.07	-0.32	8.13e-7	Menarche (age at onset);
SARC	cis	rs1355223	0.902	rs1258468	chr11:34729731	G/A	cg18508148	chr11:34937573	PDHX;APIP	-0.38	-4.82	-0.3	2.64e-6	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg07701084	chr6:150067640	NUP43	0.41	5.39	0.33	1.75e-7	Lung cancer;
SARC	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg07701084	chr6:150067640	NUP43	0.4	5.37	0.33	1.91e-7	Lung cancer;
SARC	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.44	4.83	0.3	2.5e-6	Renal function-related traits (BUN);
SARC	cis	rs1050631	0.564	rs948416	chr18:33715673	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.56	6.5	0.39	4.8e-10	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs11719291	0.833	rs34037363	chr3:48821036	C/T	cg01304814	chr3:48885189	PRKAR2A	0.62	5.12	0.32	6.37e-7	Cognitive function;
SARC	cis	rs9398803	0.713	rs1490384	chr6:126851160	C/T	cg19875578	chr6:126661172	C6orf173	0.64	8.82	0.5	2.71e-16	Male-pattern baldness;
SARC	cis	rs6582630	0.516	rs12814528	chr12:38296111	G/A	cg13010199	chr12:38710504	ALG10B	-0.55	-6.73	-0.4	1.3e-10	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2834188	1.000	rs2252930	chr21:34704201	C/G	cg14352951	chr21:34696688	IFNAR1	-0.46	-5.44	-0.34	1.35e-7	Narcolepsy;
SARC	cis	rs67460515	0.892	rs13059340	chr3:161062631	T/C	cg03342759	chr3:160939853	NMD3	-0.66	-8.44	-0.48	3.3e-15	Parkinson's disease;
SARC	cis	rs2841277	0.771	rs2819469	chr14:105394859	G/A	cg14403583	chr14:105418241	AHNAK2	0.61	7.91	0.46	1.04e-13	Rheumatoid arthritis;
SARC	cis	rs1707322	0.963	rs10890371	chr1:46390897	T/G	cg03146154	chr1:46216737	IPP	0.46	5.54	0.34	7.97e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs72781680	0.898	rs12622290	chr2:23979894	C/G	cg08917208	chr2:24149416	ATAD2B	0.76	7.16	0.42	1.08e-11	Lymphocyte counts;
SARC	cis	rs7700895	0.578	rs147295	chr5:95219261	A/G	cg16656078	chr5:95278638	ELL2	0.41	5.27	0.33	3.16e-7	IgG glycosylation;
SARC	cis	rs3796352	1.000	rs13091844	chr3:53010271	C/T	cg15956490	chr3:53032818	SFMBT1	0.71	4.88	0.3	1.97e-6	Immune reponse to smallpox (secreted IL-2);
SARC	trans	rs11098499	0.863	rs1480940	chr4:120457682	T/C	cg25214090	chr10:38739885	LOC399744	0.58	7.4	0.44	2.39e-12	Corneal astigmatism;
SARC	cis	rs892961	0.867	rs312909	chr17:75413954	T/C	cg05865280	chr17:75406074	SEPT9	0.56	8.32	0.48	7.56e-15	Airflow obstruction;
SARC	cis	rs6964587	0.626	rs404	chr7:91544316	G/T	cg17063962	chr7:91808500	NA	-0.77	-11.41	-0.6	3.08e-24	Breast cancer;
SARC	cis	rs67460515	0.892	rs2054710	chr3:161090616	C/T	cg04691961	chr3:161091175	C3orf57	-0.51	-6.4	-0.39	8.68e-10	Parkinson's disease;
SARC	cis	rs7647973	0.626	rs9830730	chr3:49675875	G/C	cg03060546	chr3:49711283	APEH	0.7	7.46	0.44	1.72e-12	Menarche (age at onset);
SARC	cis	rs2916247	0.954	rs6471319	chr8:93090594	G/A	cg10183463	chr8:93005414	RUNX1T1	0.65	6.68	0.4	1.7e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7914558	1.000	rs7077097	chr10:104945463	G/A	cg04362960	chr10:104952993	NT5C2	0.4	4.73	0.3	3.95e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs7223966	1.000	rs2874121	chr17:61731024	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.22	0.38	2.31e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2072499	0.932	rs2736613	chr1:156196016	T/C	cg24450063	chr1:156163899	SLC25A44	1.1	16.92	0.74	2.05e-42	Testicular germ cell tumor;
SARC	trans	rs12310956	0.532	rs10844719	chr12:33987714	A/G	cg13010199	chr12:38710504	ALG10B	0.65	8.68	0.49	7.12e-16	Morning vs. evening chronotype;
SARC	cis	rs6138458	1.000	rs4273288	chr20:24900873	G/A	cg26195577	chr20:24973756	C20orf3	-0.86	-9.46	-0.53	3.56e-18	Blood protein levels;
SARC	cis	rs9747201	1.000	rs9303023	chr17:80175920	C/T	cg09264619	chr17:80180166	NA	-0.53	-5.88	-0.36	1.39e-8	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs11098499	0.738	rs28408407	chr4:120376030	C/G	cg09307838	chr4:120376055	NA	0.92	13.13	0.65	7.35e-30	Corneal astigmatism;
SARC	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs17666538	0.901	rs73177064	chr8:585293	C/G	cg07685180	chr8:600429	NA	-0.8	-6.13	-0.37	3.67e-9	IgG glycosylation;
SARC	cis	rs526231	0.547	rs72783895	chr5:102287496	C/A	cg23492399	chr5:102201601	PAM	-0.51	-5.98	-0.36	8.22e-9	Primary biliary cholangitis;
SARC	cis	rs1953600	0.754	rs2573348	chr10:81925785	C/T	cg00277334	chr10:82204260	NA	-0.36	-5.21	-0.32	4.25e-7	Sarcoidosis;
SARC	cis	rs2635047	1.000	rs2635049	chr18:44687303	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.55	-7.5	-0.44	1.37e-12	Educational attainment;
SARC	cis	rs2295359	1.000	rs10889664	chr1:67635475	C/T	cg12940439	chr1:67600707	NA	0.46	6.92	0.41	4.28e-11	Psoriasis;
SARC	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg23262073	chr20:60523788	NA	-0.6	-8.81	-0.5	3e-16	Obesity-related traits;
SARC	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg17376030	chr22:41985996	PMM1	-0.64	-8.25	-0.48	1.19e-14	Vitiligo;
SARC	cis	rs9457247	0.967	rs430145	chr6:167410369	C/T	cg07741184	chr6:167504864	NA	0.3	5.6	0.34	5.91e-8	Crohn's disease;
SARC	cis	rs35164067	0.662	rs11666164	chr19:10576270	C/T	cg21868191	chr19:10515988	NA	-0.5	-6.25	-0.38	1.93e-9	Inflammatory bowel disease;
SARC	cis	rs7568458	0.837	rs35565292	chr2:85790316	T/A	cg02493740	chr2:85810744	VAMP5	-0.34	-4.76	-0.3	3.43e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.42	0.53	4.71e-18	Prudent dietary pattern;
SARC	cis	rs3126085	0.935	rs7550106	chr1:152197202	C/T	cg03465714	chr1:152285911	FLG	0.46	5.77	0.35	2.58e-8	Atopic dermatitis;
SARC	cis	rs910316	0.967	rs175432	chr14:75615246	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.46	-6.32	-0.38	1.3e-9	Height;
SARC	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg18876405	chr7:65276391	NA	0.45	5.15	0.32	5.51e-7	Aortic root size;
SARC	cis	rs2200578	1.000	rs72954221	chr2:99899445	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.66	6.54	0.39	3.84e-10	IgG glycosylation;
SARC	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg16479474	chr6:28041457	NA	0.37	5.44	0.34	1.37e-7	Depression;
SARC	cis	rs3741151	0.773	rs73544710	chr11:73162273	A/G	cg17517138	chr11:73019481	ARHGEF17	0.92	6.85	0.41	6.4e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs5753618	0.561	rs9606830	chr22:31717799	T/G	cg13145458	chr22:31556086	RNF185	-0.47	-4.93	-0.31	1.55e-6	Colorectal cancer;
SARC	cis	rs2854207	0.505	rs2466957	chr17:61961230	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.45	4.76	0.3	3.48e-6	Height;
SARC	cis	rs10992471	0.603	rs7868013	chr9:95240173	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.25	-0.33	3.37e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs13191362	1.000	rs67094146	chr6:163145412	G/C	cg18825119	chr6:163149453	PACRG;PARK2	0.38	4.93	0.31	1.53e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg13206674	chr6:150067644	NUP43	0.43	5.64	0.35	4.99e-8	Lung cancer;
SARC	cis	rs6693567	0.565	rs696615	chr1:150338988	A/C	cg09579323	chr1:150459698	TARS2	0.43	5.5	0.34	9.79e-8	Migraine;
SARC	cis	rs4846217	1.000	rs12141192	chr1:10431132	C/T	cg19092837	chr1:10271724	KIF1B	0.42	5.63	0.35	5.13e-8	Platelet count;
SARC	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg04277193	chr17:41438351	NA	0.44	4.86	0.3	2.18e-6	Menopause (age at onset);
SARC	cis	rs1008375	0.900	rs10019460	chr4:17686337	T/C	cg27347728	chr4:17578864	LAP3	-0.48	-5.89	-0.36	1.34e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs796364	0.806	rs11688194	chr2:200916239	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-6.61	-0.4	2.63e-10	Schizophrenia;
SARC	cis	rs7219021	0.739	rs4793993	chr17:47008546	C/T	cg16584676	chr17:46985605	UBE2Z	-0.49	-5.68	-0.35	3.94e-8	Schizophrenia or bipolar disorder;
SARC	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg12463550	chr7:65579703	CRCP	-0.49	-5.74	-0.35	2.93e-8	Aortic root size;
SARC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg21747090	chr2:27597821	SNX17	-0.55	-7.68	-0.45	4.44e-13	Total body bone mineral density;
SARC	cis	rs7197653	0.667	rs16957831	chr16:68378341	C/T	cg09835421	chr16:68378352	PRMT7	-0.65	-6.13	-0.37	3.63e-9	Magnesium levels;
SARC	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg22535103	chr8:58192502	C8orf71	-0.6	-6.15	-0.37	3.42e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg11987759	chr7:65425863	GUSB	-0.47	-6.31	-0.38	1.39e-9	Aortic root size;
SARC	cis	rs7647973	0.626	rs1996664	chr3:49878395	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.59	-5.95	-0.36	9.6e-9	Menarche (age at onset);
SARC	cis	rs6740322	0.895	rs6744746	chr2:43555805	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.59	6.88	0.41	5.32e-11	Coronary artery disease;
SARC	cis	rs763121	0.853	rs2235230	chr22:39124467	A/G	cg06022373	chr22:39101656	GTPBP1	-0.86	-10.07	-0.55	4.83e-20	Menopause (age at onset);
SARC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg09373136	chr17:61933544	TCAM1	-0.45	-6.18	-0.38	2.87e-9	Prudent dietary pattern;
SARC	cis	rs17253792	0.822	rs74053651	chr14:56125366	C/T	cg01858014	chr14:56050164	KTN1	-0.7	-5.91	-0.36	1.2e-8	Putamen volume;
SARC	cis	rs2235544	0.588	rs662603	chr1:54467767	T/C	cg10336722	chr1:54665764	CYB5RL;MRPL37	-0.38	-4.74	-0.3	3.66e-6	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
SARC	cis	rs4595586	0.545	rs2388174	chr12:39389237	G/A	cg26384229	chr12:38710491	ALG10B	0.5	6.18	0.38	2.84e-9	Morning vs. evening chronotype;
SARC	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.59	5.49	0.34	1.03e-7	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg22535103	chr8:58192502	C8orf71	-0.59	-6.27	-0.38	1.69e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg22168489	chr12:122356033	WDR66	0.64	10.03	0.55	6.65e-20	Mean corpuscular volume;
SARC	cis	rs8114671	0.562	rs1013677	chr20:33468793	C/T	cg07148914	chr20:33460835	GGT7	0.45	5.63	0.35	5.15e-8	Height;
SARC	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-8.16	-0.47	2.11e-14	Chronic sinus infection;
SARC	trans	rs1814175	0.645	rs1721997	chr11:49916653	T/C	cg03929089	chr4:120376271	NA	-0.81	-11.69	-0.61	3.89e-25	Height;
SARC	cis	rs79839061	0.610	rs12651368	chr4:856787	G/A	cg07828340	chr4:882639	GAK	0.76	5.74	0.35	2.95e-8	Intelligence (multi-trait analysis);
SARC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg03188948	chr7:1209495	NA	0.41	5.23	0.32	3.69e-7	Longevity;Endometriosis;
SARC	cis	rs2204008	0.713	rs12366709	chr12:38210179	G/A	cg13010199	chr12:38710504	ALG10B	0.78	10.64	0.57	8.61e-22	Bladder cancer;
SARC	cis	rs1008375	1.000	rs6449323	chr4:17683916	A/T	cg02297831	chr4:17616191	MED28	0.5	6.23	0.38	2.19e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9322817	0.691	rs2486143	chr6:105308593	A/G	cg02098413	chr6:105308735	HACE1	0.38	5.89	0.36	1.33e-8	Thyroid stimulating hormone;
SARC	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg19318889	chr4:1322082	MAEA	0.4	4.9	0.31	1.78e-6	Longevity;
SARC	cis	rs2404602	0.647	rs1443115	chr15:77041829	T/C	cg15268244	chr15:77196840	NA	0.44	5.13	0.32	6.08e-7	Blood metabolite levels;
SARC	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	8.71	0.5	5.56e-16	Alzheimer's disease;
SARC	cis	rs72945132	0.825	rs58532402	chr11:70189491	C/T	cg00319359	chr11:70116639	PPFIA1	0.68	6.34	0.38	1.15e-9	Coronary artery disease;
SARC	cis	rs13256369	0.951	rs13260947	chr8:8565883	A/G	cg18904891	chr8:8559673	CLDN23	0.49	5.45	0.34	1.27e-7	Obesity-related traits;
SARC	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.98	-15.93	-0.72	3.79e-39	Chronic sinus infection;
SARC	cis	rs3858526	0.883	rs11039584	chr11:5935251	C/G	cg02574844	chr11:5959923	NA	-0.43	-5.42	-0.33	1.47e-7	DNA methylation (variation);
SARC	cis	rs1153858	1.000	rs12441971	chr15:45671957	A/T	cg26924012	chr15:45694286	SPATA5L1	0.79	11.28	0.59	7.91e-24	Homoarginine levels;
SARC	cis	rs9815354	0.812	rs17282671	chr3:41887455	T/C	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2997447	0.761	rs55960411	chr1:26437741	G/C	cg19633962	chr1:26362018	EXTL1	-0.57	-5.05	-0.31	8.95e-7	QRS complex (12-leadsum);
SARC	cis	rs3796352	1.000	rs11710707	chr3:52975916	A/G	cg12962167	chr3:53033115	SFMBT1	0.83	5.32	0.33	2.41e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs9303401	0.646	rs7213269	chr17:57237796	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.6	7.17	0.43	9.69e-12	Cognitive test performance;
SARC	cis	rs2153535	0.601	rs7738877	chr6:8542230	A/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.01	0.46	5.53e-14	Motion sickness;
SARC	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-10.87	-0.58	1.61e-22	Gut microbiome composition (summer);
SARC	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.05	15.8	0.72	1.02e-38	Height;
SARC	cis	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg18252515	chr7:66147081	NA	-1.29	-11.49	-0.6	1.7e-24	Diabetic kidney disease;
SARC	cis	rs7582720	1.000	rs72926783	chr2:203815740	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs1691799	0.528	rs1472314	chr12:66788838	C/G	cg16791601	chr12:66731901	HELB	-0.61	-8.2	-0.47	1.62e-14	White blood cell count (basophil);
SARC	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg11890956	chr21:40555474	PSMG1	-1.05	-15.51	-0.71	9.36e-38	Cognitive function;
SARC	cis	rs3820928	0.874	rs4675133	chr2:227843010	A/G	cg05526886	chr2:227700861	RHBDD1	0.52	6.26	0.38	1.84e-9	Pulmonary function;
SARC	trans	rs2727020	0.658	rs4980431	chr11:49350071	G/T	cg03929089	chr4:120376271	NA	-0.74	-10.88	-0.58	1.48e-22	Coronary artery disease;
SARC	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg09060608	chr5:178986726	RUFY1	0.35	4.88	0.3	1.97e-6	Lung cancer;
SARC	cis	rs698833	0.729	rs4952708	chr2:44517072	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.6	7.74	0.45	3.03e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs6429082	0.715	rs2291687	chr1:235594182	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.61	-7.48	-0.44	1.47e-12	Adiposity;
SARC	cis	rs2250402	0.510	rs2898984	chr15:40324075	G/C	cg16127683	chr15:40268777	EIF2AK4	-0.57	-4.91	-0.31	1.7e-6	Corneal curvature;
SARC	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg26924012	chr15:45694286	SPATA5L1	0.77	10.99	0.58	6.8e-23	Homoarginine levels;
SARC	cis	rs1318878	1.000	rs55851576	chr12:15543906	A/G	cg08258403	chr12:15378311	NA	0.47	6.05	0.37	5.63e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7829975	0.511	rs1401390	chr8:8136410	C/T	cg15556689	chr8:8085844	FLJ10661	0.55	6.93	0.41	4.14e-11	Mood instability;
SARC	trans	rs61931739	0.500	rs11053277	chr12:34553835	T/A	cg13010199	chr12:38710504	ALG10B	0.78	11.09	0.59	3.19e-23	Morning vs. evening chronotype;
SARC	cis	rs13191362	1.000	rs13192894	chr6:163052444	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.64	5.59	0.34	6.38e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg12373951	chr3:133503437	NA	0.38	5.26	0.33	3.24e-7	Iron status biomarkers;
SARC	cis	rs5760092	0.755	rs6003959	chr22:24264395	C/T	cg16132339	chr22:24313637	DDTL;DDT	-0.42	-4.94	-0.31	1.46e-6	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	trans	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg26821823	chr11:75875926	NA	0.39	6.27	0.38	1.77e-9	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.03	12.03	0.62	3.06e-26	Alzheimer's disease;
SARC	cis	rs7582720	1.000	rs72928613	chr2:203839628	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.14	0.42	1.16e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs3809566	1.000	rs4775610	chr15:63332057	C/T	cg05507819	chr15:63340323	TPM1	-0.54	-6.06	-0.37	5.43e-9	Platelet count;
SARC	cis	rs921968	0.541	rs561570	chr2:219379348	T/A	cg02176678	chr2:219576539	TTLL4	0.47	7.26	0.43	5.63e-12	Mean corpuscular hemoglobin concentration;
SARC	cis	rs1348850	0.757	rs2166554	chr2:178455824	A/G	cg23306229	chr2:178417860	TTC30B	0.59	6.73	0.4	1.29e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs17376456	0.778	rs72786662	chr5:93137630	C/T	cg25358565	chr5:93447407	FAM172A	1.18	12.38	0.63	2.25e-27	Diabetic retinopathy;
SARC	cis	rs17270561	0.609	rs6924794	chr6:25735874	A/G	cg16482183	chr6:26056742	HIST1H1C	0.43	5.22	0.32	3.92e-7	Iron status biomarkers;
SARC	cis	rs12702595	0.505	rs7811763	chr7:7266601	T/C	cg04827551	chr7:7268805	C1GALT1	0.4	4.85	0.3	2.24e-6	Serum dimethylarginine levels (asymmetric/symetric ratio);Symmetrical dimethylarginine levels;
SARC	cis	rs73635312	0.714	rs117694039	chr10:8962129	G/A	cg24467326	chr10:9646929	NA	0.61	5.08	0.32	7.78e-7	Basal cell carcinoma;
SARC	cis	rs11731606	0.712	rs17378658	chr4:95390157	A/G	cg00507259	chr4:95128692	SMARCAD1	-0.54	-5.48	-0.34	1.11e-7	Mean platelet volume;
SARC	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg11952622	chr19:58962976	ZNF324B	0.84	10.8	0.58	2.55e-22	Mean platelet volume;
SARC	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg09033563	chr22:24373618	LOC391322	0.51	5.45	0.34	1.25e-7	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs1059312	0.808	rs4760537	chr12:129301299	C/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.5	7.35	0.43	3.37e-12	Systemic lupus erythematosus;
SARC	cis	rs735539	0.521	rs2585898	chr13:21400301	T/C	cg16922012	chr13:21400325	XPO4	-0.42	-5.79	-0.35	2.21e-8	Dental caries;
SARC	cis	rs7044106	0.791	rs10985009	chr9:123493039	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.75	-10.04	-0.55	6.07e-20	Hip circumference adjusted for BMI;
SARC	cis	rs11098499	0.691	rs9996494	chr4:120238880	C/A	cg09307838	chr4:120376055	NA	0.84	11.54	0.6	1.15e-24	Corneal astigmatism;
SARC	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.98	12.13	0.62	1.41e-26	Smoking behavior;
SARC	cis	rs854765	0.693	rs4924823	chr17:17764502	A/G	cg16928487	chr17:17741425	SREBF1	0.23	4.87	0.3	2.1e-6	Total body bone mineral density;
SARC	cis	rs6582630	0.555	rs11182217	chr12:38480030	G/A	cg26384229	chr12:38710491	ALG10B	0.88	12.67	0.64	2.51e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs11711311	0.910	rs62265549	chr3:113396234	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	8.19	0.47	1.72e-14	IgG glycosylation;
SARC	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg03060546	chr3:49711283	APEH	0.41	5.14	0.32	5.86e-7	Parkinson's disease;
SARC	cis	rs963731	0.649	rs297129	chr2:39299271	C/T	cg04010122	chr2:39346883	SOS1	0.96	6.44	0.39	6.69e-10	Corticobasal degeneration;
SARC	cis	rs9513627	0.588	rs9585073	chr13:100128516	A/G	cg25919922	chr13:100150906	NA	-0.64	-4.81	-0.3	2.66e-6	Obesity-related traits;
SARC	cis	rs8051517	0.744	rs117130031	chr16:68345644	T/C	cg01866162	chr16:67596514	CTCF	1.06	6.14	0.37	3.54e-9	Blood protein levels;
SARC	cis	rs7223966	1.000	rs8074771	chr17:61735865	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.5	-5.26	-0.33	3.26e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9818758	0.607	rs34823813	chr3:49749976	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.64	-5.31	-0.33	2.55e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs9325144	0.534	rs1973293	chr12:38679575	C/T	cg13010199	chr12:38710504	ALG10B	0.56	7.48	0.44	1.51e-12	Morning vs. evening chronotype;
SARC	cis	rs748404	0.660	rs548704	chr15:43791706	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	5.58	0.34	6.68e-8	Lung cancer;
SARC	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg24209194	chr3:40518798	ZNF619	-0.65	-8.2	-0.47	1.63e-14	Renal cell carcinoma;
SARC	cis	rs2762353	0.562	rs1165206	chr6:25867566	G/A	cg16482183	chr6:26056742	HIST1H1C	0.42	5.52	0.34	8.87e-8	Blood metabolite levels;
SARC	cis	rs7808935	0.914	rs757136	chr7:27988939	C/T	cg05786569	chr7:27702416	HIBADH	-0.58	-5.94	-0.36	1.04e-8	Prostate cancer;
SARC	cis	rs9788682	0.747	rs2036533	chr15:78781687	G/A	cg24631222	chr15:78858424	CHRNA5	0.74	9.03	0.51	6.82e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs4971059	0.629	rs4246529	chr1:155115260	T/C	cg22049894	chr1:155113146	DPM3	0.42	5.26	0.33	3.32e-7	Breast cancer;
SARC	cis	rs12477438	0.765	rs13390672	chr2:99589829	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-9.87	-0.54	1.98e-19	Chronic sinus infection;
SARC	cis	rs8141529	0.764	rs8137969	chr22:29228484	G/C	cg02153584	chr22:29168773	CCDC117	0.8	11.78	0.61	1.93e-25	Lymphocyte counts;
SARC	cis	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg12463550	chr7:65579703	CRCP	0.69	5.29	0.33	2.86e-7	Diabetic kidney disease;
SARC	cis	rs6772849	0.796	rs9841521	chr3:128392274	A/G	cg08795948	chr3:128337044	NA	0.54	7.55	0.44	9.74e-13	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs139156536	1	rs139156536	chr17:38164432	TTTTA/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.29	-5.18	-0.32	4.84e-7	Lymphocyte percentage of white cells;
SARC	trans	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg15556689	chr8:8085844	FLJ10661	0.47	6.41	0.39	7.78e-10	Neuroticism;
SARC	cis	rs2486288	0.656	rs11632920	chr15:45551264	C/T	cg15395560	chr15:45543142	SLC28A2	0.28	5.29	0.33	2.81e-7	Glomerular filtration rate;
SARC	cis	rs6570726	0.738	rs4495284	chr6:145916617	T/A	cg05347473	chr6:146136440	FBXO30	0.54	7.41	0.44	2.38e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6493487	0.512	rs1438926	chr15:51351145	G/T	cg02338191	chr15:51200825	AP4E1	0.54	4.86	0.3	2.18e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs2153535	0.580	rs9405391	chr6:8466548	C/T	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	cis	rs910316	1.000	rs7145159	chr14:75583268	A/G	cg11812906	chr14:75593930	NEK9	0.89	13.71	0.67	9.14e-32	Height;
SARC	cis	rs11645898	0.935	rs72787077	chr16:72156674	C/T	cg14768367	chr16:72042858	DHODH	-0.63	-5.72	-0.35	3.21e-8	Blood protein levels;
SARC	trans	rs1814175	0.546	rs1614397	chr11:49913384	G/C	cg15704280	chr7:45808275	SEPT13	-0.97	-18.22	-0.77	1.07e-46	Height;
SARC	cis	rs7662987	0.517	rs2034696	chr4:100024322	C/G	cg12011299	chr4:100065546	ADH4	0.32	5.26	0.33	3.23e-7	Smoking initiation;
SARC	cis	rs4689388	0.727	rs1801213	chr4:6293696	C/G	cg25554036	chr4:6271136	WFS1	0.42	6.25	0.38	1.92e-9	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs908922	0.676	rs10888494	chr1:152514709	T/C	cg09873164	chr1:152488093	CRCT1	0.64	8.6	0.49	1.16e-15	Hair morphology;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg15651835	chr1:226497333	LIN9	0.49	6.38	0.39	9.64e-10	Chemerin levels;
SARC	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-7.97	-0.46	7.21e-14	Chronic sinus infection;
SARC	cis	rs35955747	0.838	rs5997900	chr22:31580346	C/A	cg02404636	chr22:31891804	SFI1	-0.4	-4.91	-0.31	1.7e-6	Neutrophil count;Sum basophil neutrophil counts;
SARC	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	-0.39	-4.73	-0.3	3.9e-6	Tonsillectomy;
SARC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg09373136	chr17:61933544	TCAM1	-0.45	-6.2	-0.38	2.48e-9	Prudent dietary pattern;
SARC	cis	rs9911578	0.967	rs3826353	chr17:57075299	C/T	cg05425664	chr17:57184151	TRIM37	-0.64	-7.93	-0.46	9.23e-14	Intelligence (multi-trait analysis);
SARC	cis	rs2658782	0.654	rs2605622	chr11:93248242	A/G	cg15737290	chr11:93063684	CCDC67	0.74	8.62	0.49	1.04e-15	Pulmonary function decline;
SARC	cis	rs7615952	0.609	rs13088451	chr3:125553499	G/C	cg05084668	chr3:125655381	ALG1L	-0.47	-4.89	-0.31	1.88e-6	Blood pressure (smoking interaction);
SARC	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg11062466	chr8:58055876	NA	0.58	5.61	0.35	5.65e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs8072100	0.581	rs4267364	chr17:45781264	A/G	cg08085267	chr17:45401833	C17orf57	-0.41	-4.72	-0.3	4.14e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs7296418	0.961	rs10773921	chr12:123541606	C/T	cg00376283	chr12:123451042	ABCB9	0.66	8.54	0.49	1.77e-15	Platelet count;
SARC	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg09699651	chr6:150184138	LRP11	0.39	4.83	0.3	2.5e-6	Lung cancer;
SARC	cis	rs7647973	1.000	rs8897	chr3:49460407	A/G	cg07636037	chr3:49044803	WDR6	0.7	8.35	0.48	5.92e-15	Menarche (age at onset);
SARC	cis	rs4481887	1.000	rs4457616	chr1:248492198	A/G	cg13385794	chr1:248469461	NA	0.36	5.39	0.33	1.74e-7	Common traits (Other);
SARC	cis	rs992157	0.710	rs12996912	chr2:219110555	A/G	cg00012203	chr2:219082015	ARPC2	0.86	14.07	0.68	5.9e-33	Colorectal cancer;
SARC	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg18404041	chr3:52824283	ITIH1	-0.36	-5.3	-0.33	2.72e-7	Bipolar disorder;
SARC	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg03161606	chr19:29218774	NA	0.48	6.87	0.41	5.87e-11	Methadone dose in opioid dependence;
SARC	cis	rs2439831	0.681	rs511673	chr15:43618863	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.05	11.91	0.62	7.27e-26	Lung cancer in ever smokers;
SARC	cis	rs4481887	1.000	rs6659039	chr1:248465689	C/T	cg00666640	chr1:248458726	OR2T12	0.37	6.32	0.38	1.29e-9	Common traits (Other);
SARC	cis	rs2120019	0.938	rs8030089	chr15:75290377	C/T	cg12414181	chr15:75287860	SCAMP5	-0.47	-5.28	-0.33	2.96e-7	Blood trace element (Zn levels);
SARC	cis	rs858239	0.899	rs7794684	chr7:23310805	A/G	cg23682824	chr7:23144976	KLHL7	0.58	7.16	0.42	1.05e-11	Cerebrospinal fluid biomarker levels;
SARC	cis	rs12142240	0.698	rs56049453	chr1:46835468	A/G	cg00530320	chr1:46809349	NSUN4	0.57	7.0	0.42	2.74e-11	Menopause (age at onset);
SARC	cis	rs17023223	0.581	rs61808932	chr1:119643820	T/C	cg05756136	chr1:119680316	WARS2	-0.46	-5.02	-0.31	1.03e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg20573242	chr4:122745356	CCNA2	0.67	8.49	0.49	2.42e-15	Type 2 diabetes;
SARC	cis	rs722599	0.651	rs12887044	chr14:75255659	C/T	cg06637938	chr14:75390232	RPS6KL1	0.38	4.76	0.3	3.42e-6	IgG glycosylation;
SARC	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg26839252	chr6:160211577	TCP1;MRPL18	0.68	7.44	0.44	1.97e-12	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs36051895	0.593	rs12340303	chr9:5176147	C/T	cg02405213	chr9:5042618	JAK2	-0.46	-5.56	-0.34	7.53e-8	Pediatric autoimmune diseases;
SARC	cis	rs12681366	0.553	rs2930967	chr8:95462599	A/G	cg26464482	chr8:95565502	KIAA1429	-0.45	-5.53	-0.34	8.65e-8	Nonsyndromic cleft lip with cleft palate;
SARC	trans	rs3808502	0.526	rs11783065	chr8:11417257	A/G	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.77	-0.41	1.06e-10	Neuroticism;
SARC	cis	rs2594989	0.779	rs111827101	chr3:11587736	T/C	cg00170343	chr3:11313890	ATG7	-0.55	-5.94	-0.36	1.05e-8	Circulating chemerin levels;
SARC	cis	rs5769765	1.000	rs5769764	chr22:50270784	G/A	cg03033257	chr22:50311977	ALG12;CRELD2	-0.54	-5.64	-0.35	4.81e-8	Schizophrenia;
SARC	trans	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg16141378	chr3:129829833	LOC729375	-0.6	-7.33	-0.43	3.66e-12	Mood instability;
SARC	cis	rs3741151	0.773	rs79915238	chr11:73272947	C/T	cg17517138	chr11:73019481	ARHGEF17	0.93	6.88	0.41	5.4e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg20607798	chr8:58055168	NA	0.56	5.33	0.33	2.28e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2652834	1.000	rs2134265	chr15:63398196	G/A	cg05507819	chr15:63340323	TPM1	0.54	5.34	0.33	2.23e-7	HDL cholesterol;
SARC	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs4727027	0.870	rs62507512	chr7:148799338	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	5.84	0.36	1.72e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs9790314	1.000	rs28515190	chr3:161028605	G/A	cg03342759	chr3:160939853	NMD3	-0.59	-7.41	-0.44	2.26e-12	Morning vs. evening chronotype;
SARC	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.95	15.94	0.72	3.65e-39	Chronic sinus infection;
SARC	cis	rs36051895	0.593	rs62541903	chr9:5146952	G/C	cg02405213	chr9:5042618	JAK2	-0.45	-5.31	-0.33	2.53e-7	Pediatric autoimmune diseases;
SARC	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg07701084	chr6:150067640	NUP43	0.41	5.39	0.33	1.75e-7	Lung cancer;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg20583150	chr6:43946161	NA	-0.49	-6.51	-0.39	4.55e-10	Thyroid stimulating hormone;
SARC	cis	rs6580649	0.941	rs1859441	chr12:48423233	C/T	cg24011408	chr12:48396354	COL2A1	-0.51	-5.47	-0.34	1.15e-7	Lung cancer;
SARC	cis	rs3096299	0.586	rs4572400	chr16:89533516	T/A	cg02187348	chr16:89574699	SPG7	0.67	9.76	0.54	4.27e-19	Multiple myeloma (IgH translocation);
SARC	cis	rs6815814	0.851	rs11466617	chr4:38780471	T/C	cg09316306	chr4:38807337	TLR1	0.52	5.23	0.32	3.81e-7	Breast cancer;
SARC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg09373136	chr17:61933544	TCAM1	-0.45	-6.2	-0.38	2.48e-9	Prudent dietary pattern;
SARC	cis	rs3857067	0.806	rs2171379	chr4:95100243	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.32	-4.75	-0.3	3.49e-6	QT interval;
SARC	cis	rs2180341	0.924	rs877661	chr6:127587915	T/G	cg24812749	chr6:127587940	RNF146	0.95	12.49	0.63	9.24e-28	Breast cancer;
SARC	cis	rs1568889	1.000	rs9783375	chr11:28033667	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.72	9.2	0.52	2.14e-17	Bipolar disorder;
SARC	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg03647317	chr4:187891568	NA	-0.37	-5.1	-0.32	7.18e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12348691	0.503	rs6478423	chr9:100592030	C/T	cg13688889	chr9:100608707	NA	-0.46	-4.85	-0.3	2.25e-6	Alopecia areata;
SARC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg09373136	chr17:61933544	TCAM1	-0.48	-6.69	-0.4	1.66e-10	Prudent dietary pattern;
SARC	cis	rs2504916	1.000	rs2246531	chr6:160838648	G/A	cg20340146	chr6:160172821	WTAP	0.47	4.83	0.3	2.49e-6	Response to hepatitis C treatment;
SARC	cis	rs950027	0.595	rs2486288	chr15:45712339	T/C	cg21132104	chr15:45694354	SPATA5L1	0.54	6.72	0.4	1.41e-10	Response to fenofibrate (adiponectin levels);
SARC	cis	rs11785693	0.909	rs62489557	chr8:4968371	A/G	cg26367366	chr8:4980734	NA	0.72	6.23	0.38	2.19e-9	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs56036086	0.877	rs73187247	chr22:50629872	C/T	cg16473166	chr22:50639996	SELO	0.57	5.02	0.31	1.02e-6	Platelet count;Plateletcrit;
SARC	cis	rs10512697	0.803	rs34924743	chr5:3575736	A/G	cg19473799	chr5:3511975	NA	-0.66	-4.86	-0.3	2.16e-6	Immune response to smallpox vaccine (IL-6);
SARC	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg05368731	chr17:41323189	NBR1	0.77	9.24	0.52	1.58e-17	Menopause (age at onset);
SARC	trans	rs2018683	0.707	rs917215	chr7:28971367	C/T	cg19402173	chr7:128379420	CALU	-0.53	-6.95	-0.41	3.6e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs34172651	0.837	rs1978451	chr16:24818286	C/G	cg00152838	chr16:24741724	TNRC6A	-0.49	-5.88	-0.36	1.43e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9443189	0.813	rs3798439	chr6:76566734	T/G	cg01950844	chr6:76311363	SENP6	-0.74	-6.41	-0.39	8.13e-10	Prostate cancer;
SARC	cis	rs10504229	0.679	rs2218271	chr8:58052446	T/A	cg08280861	chr8:58055591	NA	0.55	5.03	0.31	9.97e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs62344088	0.590	rs60845955	chr5:185094	C/T	cg22496380	chr5:211416	CCDC127	-0.8	-6.0	-0.37	7.68e-9	Asthma (childhood onset);
SARC	cis	rs9896052	0.649	rs6501797	chr17:73444312	G/A	cg04121983	chr17:73511085	CASKIN2	0.43	5.08	0.32	7.85e-7	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs9398803	0.865	rs2130603	chr6:126826819	A/C	cg19875578	chr6:126661172	C6orf173	0.61	8.31	0.48	7.93e-15	Male-pattern baldness;
SARC	cis	rs7582720	0.943	rs72934762	chr2:203756677	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.31	0.43	4.24e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs6604026	0.541	rs6698082	chr1:93390645	G/A	cg17283838	chr1:93427260	FAM69A	0.41	4.77	0.3	3.25e-6	Multiple sclerosis;
SARC	cis	rs2652834	1.000	rs2729830	chr15:63395812	G/C	cg05507819	chr15:63340323	TPM1	0.54	5.46	0.34	1.19e-7	HDL cholesterol;
SARC	cis	rs8036030	0.604	rs11852686	chr15:74715205	A/G	cg14664628	chr15:75095509	CSK	-0.41	-4.79	-0.3	3.03e-6	Airflow obstruction;
SARC	cis	rs10880689	1	rs10880689	chr12:37930102	A/G	cg26384229	chr12:38710491	ALG10B	0.87	12.53	0.63	6.93e-28	Resting heart rate;
SARC	cis	rs11097912	0.574	rs12645255	chr4:107199977	A/G	cg09646026	chr4:107269030	AIMP1	-0.45	-4.86	-0.3	2.2e-6	Airflow obstruction;
SARC	cis	rs12142240	0.659	rs72677602	chr1:46837487	G/A	cg10495392	chr1:46806563	NSUN4	0.67	6.96	0.41	3.45e-11	Menopause (age at onset);
SARC	cis	rs8180040	0.726	rs6785790	chr3:47146932	C/T	cg02527881	chr3:46936655	PTH1R	-0.32	-5.05	-0.31	9.05e-7	Colorectal cancer;
SARC	cis	rs6450176	1.000	rs3776718	chr5:53298714	G/C	ch.5.1024479R	chr5:53302184	ARL15	-0.67	-7.8	-0.46	2.06e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg18252515	chr7:66147081	NA	1.35	12.11	0.62	1.7e-26	Diabetic kidney disease;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg08309023	chr2:148839265	NA	0.55	8.15	0.47	2.2e-14	Thyroid stimulating hormone;
SARC	cis	rs10875746	0.903	rs10875738	chr12:48473739	T/A	cg26205652	chr12:48591994	NA	0.56	6.05	0.37	5.72e-9	Longevity (90 years and older);
SARC	cis	rs6782228	0.606	rs2712419	chr3:128340896	T/C	cg08795948	chr3:128337044	NA	0.36	4.92	0.31	1.62e-6	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg08403428	chr12:124899777	NCOR2	-0.46	-6.47	-0.39	5.6e-10	Chemerin levels;
SARC	cis	rs761746	0.960	rs9621279	chr22:31949800	T/A	cg15823100	chr22:32027580	PISD	-0.32	-4.72	-0.3	4.05e-6	Intelligence;
SARC	cis	rs1030877	0.515	rs920217	chr2:105904662	C/T	cg02079111	chr2:105885981	TGFBRAP1	-0.54	-6.44	-0.39	6.79e-10	Obesity-related traits;
SARC	cis	rs2439831	0.681	rs7168940	chr15:43633334	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	10.86	0.58	1.71e-22	Lung cancer in ever smokers;
SARC	cis	rs76419734	0.510	rs12511885	chr4:106662118	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.77	9.23	0.52	1.67e-17	Post bronchodilator FEV1;
SARC	cis	rs7659604	0.605	rs67772833	chr4:122723106	G/A	cg20573242	chr4:122745356	CCNA2	0.59	7.5	0.44	1.34e-12	Type 2 diabetes;
SARC	cis	rs7219014	1	rs7219014	chr17:37624790	A/G	cg00129232	chr17:37814104	STARD3	-0.64	-7.9	-0.46	1.09e-13	Urinary metabolites;
SARC	cis	rs9788721	0.902	rs951266	chr15:78878541	C/T	cg18825076	chr15:78729989	IREB2	-0.44	-5.27	-0.33	3.16e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs11190604	0.767	rs10883489	chr10:102194532	T/C	cg07080220	chr10:102295463	HIF1AN	0.71	8.15	0.47	2.29e-14	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg13866156	chr1:1669148	SLC35E2	-0.64	-9.66	-0.53	8.65e-19	Body mass index;
SARC	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg16479474	chr6:28041457	NA	-0.37	-5.5	-0.34	9.79e-8	Depression;
SARC	cis	rs449789	0.857	rs625687	chr6:159703294	G/A	cg14500486	chr6:159655392	FNDC1	-0.44	-5.02	-0.31	1.01e-6	Pulse pressure;
SARC	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg17221315	chr6:27791827	HIST1H4J	0.46	4.83	0.3	2.53e-6	Depression;
SARC	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg03806693	chr22:41940476	POLR3H	-0.95	-13.66	-0.67	1.3e-31	Vitiligo;
SARC	cis	rs710216	0.797	rs1770811	chr1:43400547	A/T	cg03128534	chr1:43423976	SLC2A1	0.59	5.65	0.35	4.65e-8	Red cell distribution width;
SARC	cis	rs2239547	0.522	rs6792578	chr3:53004604	G/A	cg07507251	chr3:52567010	NT5DC2	0.37	4.76	0.3	3.34e-6	Schizophrenia;
SARC	cis	rs910316	1.000	rs7156328	chr14:75532941	T/C	cg23033748	chr14:75592666	NEK9	0.35	4.78	0.3	3.1e-6	Height;
SARC	cis	rs4481887	0.800	rs10788780	chr1:248483598	G/A	cg00666640	chr1:248458726	OR2T12	0.35	5.73	0.35	3.07e-8	Common traits (Other);
SARC	cis	rs2732480	0.577	rs2634693	chr12:48706498	C/T	cg21466736	chr12:48725269	NA	-0.32	-4.92	-0.31	1.62e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs854765	0.547	rs9897761	chr17:17912011	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.64	9.45	0.53	3.79e-18	Total body bone mineral density;
SARC	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg13206674	chr6:150067644	NUP43	0.44	5.68	0.35	4e-8	Lung cancer;
SARC	cis	rs9916302	0.904	rs4794814	chr17:37696852	G/A	cg20243544	chr17:37824526	PNMT	0.53	6.09	0.37	4.5e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs9911578	0.967	rs4932693	chr17:57110327	T/C	cg12560992	chr17:57184187	TRIM37	-0.87	-12.54	-0.63	6.5e-28	Intelligence (multi-trait analysis);
SARC	cis	rs9916302	0.904	rs11078915	chr17:37715426	T/C	cg07936489	chr17:37558343	FBXL20	-0.68	-8.7	-0.5	5.96e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs2073300	0.609	rs79250740	chr20:23417165	G/A	cg12062639	chr20:23401060	NAPB	0.98	6.65	0.4	2.09e-10	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs2997447	0.723	rs2802337	chr1:26474398	G/C	cg19633962	chr1:26362018	EXTL1	-0.54	-4.77	-0.3	3.25e-6	QRS complex (12-leadsum);
SARC	cis	rs2250402	0.510	rs6492926	chr15:40325829	T/G	cg10636054	chr15:40330586	SRP14	0.98	7.36	0.43	3.17e-12	Corneal curvature;
SARC	cis	rs7914558	1.000	rs11191539	chr10:104819770	A/G	cg04362960	chr10:104952993	NT5C2	0.42	5.12	0.32	6.3e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs8180040	0.764	rs11712716	chr3:47193432	T/C	cg27129171	chr3:47204927	SETD2	0.67	9.52	0.53	2.32e-18	Colorectal cancer;
SARC	cis	rs7605378	0.528	rs281780	chr2:200756331	G/C	cg17644776	chr2:200775616	C2orf69	0.52	6.4	0.39	8.34e-10	Osteoporosis;
SARC	cis	rs9790314	0.846	rs4470535	chr3:160974468	G/A	cg04691961	chr3:161091175	C3orf57	-0.68	-9.44	-0.53	4.07e-18	Morning vs. evening chronotype;
SARC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.82	10.68	0.57	6.47e-22	Prudent dietary pattern;
SARC	cis	rs2624839	0.602	rs2526398	chr3:50187596	G/C	cg24110177	chr3:50126178	RBM5	-0.47	-5.9	-0.36	1.28e-8	Intelligence (multi-trait analysis);
SARC	trans	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.6	7.83	0.46	1.75e-13	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs17376456	1.000	rs13174700	chr5:93554644	G/A	cg21475434	chr5:93447410	FAM172A	0.95	8.25	0.48	1.16e-14	Diabetic retinopathy;
SARC	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg03575189	chr17:44344142	NA	0.62	6.11	0.37	4.11e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs4727027	0.651	rs12704068	chr7:148856153	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.48	5.48	0.34	1.07e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs6807306	1.000	rs13317559	chr3:167427574	G/A	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.53	5.19	0.32	4.51e-7	Mean platelet volume;
SARC	cis	rs883565	0.502	rs11129810	chr3:38946064	C/T	cg26331595	chr3:39149181	GORASP1;TTC21A	0.43	5.08	0.32	7.6e-7	Handedness;
SARC	cis	rs12681366	0.620	rs2930968	chr8:95462695	C/T	cg13257157	chr8:95487014	RAD54B	0.39	4.91	0.31	1.68e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.63	-0.4	2.28e-10	Total body bone mineral density;
SARC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	21.26	0.81	1.8e-56	Prudent dietary pattern;
SARC	cis	rs60871478	0.735	rs4721501	chr7:862166	G/T	cg05535760	chr7:792225	HEATR2	-0.71	-6.6	-0.4	2.78e-10	Cerebrospinal P-tau181p levels;
SARC	cis	rs765787	0.530	rs11858988	chr15:45522114	T/C	cg25801113	chr15:45476975	SHF	0.31	5.12	0.32	6.38e-7	Uric acid levels;
SARC	cis	rs13166103	0.657	rs17766240	chr5:57719874	A/G	cg10487770	chr5:57879443	RAB3C	0.51	5.43	0.33	1.45e-7	Type 2 diabetes (age of onset);
SARC	cis	rs17826219	0.733	rs7221691	chr17:28723619	C/T	cg13385521	chr17:29058706	SUZ12P	-0.65	-5.54	-0.34	8.26e-8	Body mass index;
SARC	cis	rs10916814	0.655	rs4291476	chr1:20897019	A/G	cg24502330	chr1:20914028	CDA	-0.29	-5.1	-0.32	7.19e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	trans	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg00938859	chr5:1591904	SDHAP3	0.79	7.66	0.45	5.1e-13	Breast cancer;
SARC	cis	rs55823223	0.564	rs936391	chr17:73847799	A/G	cg10935138	chr17:73851978	WBP2	-0.51	-5.95	-0.36	9.55e-9	Psoriasis;
SARC	cis	rs7084402	1.000	rs12257983	chr10:60266555	A/C	cg07615347	chr10:60278583	BICC1	-0.59	-8.29	-0.48	9.25e-15	Refractive error;
SARC	cis	rs9462027	0.651	rs9469884	chr6:34758703	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.79	-0.35	2.3e-8	Systemic lupus erythematosus;
SARC	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	8.91	0.5	1.49e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs17376456	0.877	rs10044139	chr5:93407803	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.68	0.35	3.93e-8	Diabetic retinopathy;
SARC	cis	rs1336900	0.513	rs56253522	chr1:150614869	C/A	cg15448220	chr1:150897856	SETDB1	0.46	5.99	0.37	7.9e-9	Blood protein levels;
SARC	cis	rs1153858	1.000	rs7167900	chr15:45639471	A/G	cg14582100	chr15:45693742	SPATA5L1	0.37	5.03	0.31	9.67e-7	Homoarginine levels;
SARC	cis	rs6570726	0.967	rs7772286	chr6:145930423	A/T	cg05347473	chr6:146136440	FBXO30	-0.49	-6.75	-0.4	1.15e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg13628971	chr7:2884303	GNA12	0.64	7.56	0.44	9.07e-13	Height;
SARC	cis	rs10463554	0.667	rs57714862	chr5:102382729	G/C	cg23492399	chr5:102201601	PAM	-0.47	-5.16	-0.32	5.18e-7	Parkinson's disease;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg22281935	chr2:162934111	NA	0.48	6.43	0.39	7.04e-10	Breast cancer;
SARC	cis	rs11098499	0.826	rs4472123	chr4:120236630	T/A	cg09307838	chr4:120376055	NA	0.79	10.41	0.56	4.47e-21	Corneal astigmatism;
SARC	cis	rs9303542	0.625	rs17703636	chr17:46566890	C/T	cg04904318	chr17:46607828	HOXB1	0.46	5.27	0.33	3.1e-7	Ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs3818285	0.556	rs3758409	chr10:111669239	A/C	cg00817464	chr10:111662876	XPNPEP1	-0.57	-7.24	-0.43	6.4e-12	Superior crus of antihelix expression;
SARC	cis	rs1008375	0.797	rs6843530	chr4:17593605	G/T	cg27347728	chr4:17578864	LAP3	0.47	5.76	0.35	2.71e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs11098499	0.863	rs6534139	chr4:120449456	A/G	cg25214090	chr10:38739885	LOC399744	-0.56	-7.15	-0.42	1.14e-11	Corneal astigmatism;
SARC	cis	rs11122272	0.735	rs1416916	chr1:231533027	A/G	cg06096015	chr1:231504339	EGLN1	0.38	5.64	0.35	4.92e-8	Hemoglobin concentration;
SARC	cis	rs9911578	1.000	rs12940681	chr17:56933622	T/C	cg12560992	chr17:57184187	TRIM37	0.86	12.1	0.62	1.84e-26	Intelligence (multi-trait analysis);
SARC	cis	rs9329289	0.590	rs11251295	chr10:2563183	C/T	cg05625103	chr10:2543513	NA	0.32	4.98	0.31	1.25e-6	Age-related hearing impairment;
SARC	cis	rs1124376	0.882	rs7618597	chr3:20134588	C/A	cg05072819	chr3:20081367	KAT2B	0.5	4.89	0.31	1.85e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs11098499	0.863	rs7699064	chr4:120428309	A/G	cg24375607	chr4:120327624	NA	-0.42	-4.82	-0.3	2.53e-6	Corneal astigmatism;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg21893154	chr20:62493317	C20orf135	0.5	6.39	0.39	8.85e-10	Schizophrenia;
SARC	cis	rs2832191	0.791	rs2832187	chr21:30485543	T/C	cg08807101	chr21:30365312	RNF160	-0.84	-11.99	-0.62	4.02e-26	Dental caries;
SARC	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.91	11.07	0.59	3.6e-23	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs9858542	1.000	rs9822268	chr3:49719729	G/A	cg07274523	chr3:49395745	GPX1	0.5	5.72	0.35	3.31e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.93	10.53	0.57	1.83e-21	Platelet count;
SARC	cis	rs7592578	0.882	rs61117285	chr2:191468986	G/C	cg25963032	chr2:191064776	C2orf88	-0.45	-4.98	-0.31	1.23e-6	Diastolic blood pressure;
SARC	cis	rs6582630	0.576	rs4882375	chr12:38371939	G/T	cg14851346	chr12:38532713	NA	-0.45	-5.4	-0.33	1.6e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs921968	0.643	rs600057	chr2:219456737	A/G	cg02176678	chr2:219576539	TTLL4	0.35	5.34	0.33	2.2e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg24503407	chr1:205819492	PM20D1	0.79	12.51	0.63	8.02e-28	Menarche (age at onset);
SARC	cis	rs10504229	0.679	rs78941440	chr8:58052095	A/G	cg11062466	chr8:58055876	NA	0.5	4.85	0.3	2.21e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs17270561	0.609	rs9358878	chr6:25740273	C/T	cg17691542	chr6:26056736	HIST1H1C	0.6	7.38	0.44	2.8e-12	Iron status biomarkers;
SARC	cis	rs6089584	1.000	rs6142910	chr20:60562181	C/A	cg13770153	chr20:60521292	NA	-0.55	-7.78	-0.45	2.37e-13	Body mass index;
SARC	cis	rs2239815	0.515	rs5762839	chr22:29231447	C/T	cg15103426	chr22:29168792	CCDC117	0.63	6.54	0.39	3.78e-10	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
SARC	cis	rs12142240	0.731	rs6681857	chr1:46850124	T/C	cg00530320	chr1:46809349	NSUN4	0.57	6.66	0.4	1.97e-10	Menopause (age at onset);
SARC	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-9.14	-0.51	3.2e-17	Alzheimer's disease;
SARC	cis	rs10927875	0.631	rs945418	chr1:16344730	T/C	cg21385522	chr1:16154831	NA	0.7	8.86	0.5	2.04e-16	Dilated cardiomyopathy;
SARC	cis	rs7819412	0.875	rs6981523	chr8:11061792	C/T	cg21775007	chr8:11205619	TDH	-0.41	-5.16	-0.32	5.33e-7	Triglycerides;
SARC	cis	rs13161895	1.000	rs27018	chr5:179405144	A/G	cg02702477	chr5:179499311	RNF130	0.63	5.96	0.36	9.1e-9	LDL cholesterol;
SARC	cis	rs2120243	0.539	rs1456097	chr3:157098630	T/C	cg24825693	chr3:157122686	VEPH1	-0.45	-6.27	-0.38	1.74e-9	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs9843304	0.528	rs11919764	chr3:149187235	C/T	cg08667024	chr3:149219783	TM4SF4	-0.39	-5.74	-0.35	2.89e-8	Gallstone disease;
SARC	cis	rs910316	1.000	rs175492	chr14:75545220	A/C	cg06637938	chr14:75390232	RPS6KL1	0.52	7.7	0.45	3.97e-13	Height;
SARC	cis	rs1215050	0.791	rs165242	chr4:98686482	A/C	cg05340658	chr4:99064831	C4orf37	-0.4	-5.16	-0.32	5.39e-7	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs7027203	0.828	rs4743934	chr9:96581893	A/G	cg14598338	chr9:96623480	NA	-0.55	-7.98	-0.46	6.69e-14	DNA methylation (variation);
SARC	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs796364	1.000	rs281783	chr2:200751582	G/A	cg23649088	chr2:200775458	C2orf69	0.62	5.65	0.35	4.7e-8	Schizophrenia;
SARC	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg09359103	chr1:154839909	KCNN3	-0.39	-6.43	-0.39	7.08e-10	Prostate cancer;
SARC	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg08859206	chr1:53392774	SCP2	0.36	5.22	0.32	3.96e-7	Monocyte count;
SARC	cis	rs7520050	1.000	rs785511	chr1:46534498	T/C	cg24296786	chr1:45957014	TESK2	0.38	4.82	0.3	2.58e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs11105298	0.891	rs10858879	chr12:89886578	A/T	cg08166232	chr12:89918718	WDR51B;GALNT4	0.53	5.2	0.32	4.3e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs11098499	0.863	rs34868248	chr4:120442430	A/G	cg09307838	chr4:120376055	NA	0.91	12.31	0.63	3.63e-27	Corneal astigmatism;
SARC	cis	rs35849525	0.776	rs7615318	chr3:49987475	C/T	cg19755318	chr3:50243323	SLC38A3	-0.3	-4.77	-0.3	3.2e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7336332	0.800	rs9805452	chr13:28047908	C/T	cg22138327	chr13:27999177	GTF3A	0.53	5.57	0.34	7.05e-8	Weight;
SARC	cis	rs7617773	0.780	rs34523942	chr3:48342669	C/T	cg11946769	chr3:48343235	NME6	0.74	9.79	0.54	3.55e-19	Coronary artery disease;
SARC	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg17294928	chr15:75287854	SCAMP5	0.55	7.0	0.42	2.74e-11	Breast cancer;
SARC	cis	rs9300255	0.602	rs10846486	chr12:123709927	G/A	cg05973401	chr12:123451056	ABCB9	0.49	5.44	0.34	1.37e-7	Neutrophil percentage of white cells;
SARC	cis	rs9788721	1.000	rs10519203	chr15:78814046	C/T	cg06917634	chr15:78832804	PSMA4	0.49	5.47	0.34	1.13e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs6665290	0.836	rs56029302	chr1:227203390	G/A	cg14016676	chr1:227182615	CDC42BPA	0.38	5.45	0.34	1.26e-7	Myeloid white cell count;
SARC	cis	rs7714584	1.000	rs11740172	chr5:150300278	A/G	cg22134413	chr5:150180641	NA	0.8	6.59	0.4	2.97e-10	Crohn's disease;
SARC	cis	rs4642101	0.737	rs4447735	chr3:12825513	C/T	cg12400702	chr3:12838781	CAND2	-0.26	-5.29	-0.33	2.85e-7	QRS complex (12-leadsum);
SARC	cis	rs7659604	0.967	rs34949254	chr4:122664344	G/A	cg19748678	chr4:122722346	EXOSC9	0.44	5.52	0.34	9.21e-8	Type 2 diabetes;
SARC	cis	rs7178572	0.568	rs12912050	chr15:77689423	C/T	cg22256960	chr15:77711686	NA	-0.51	-5.58	-0.34	6.55e-8	Type 2 diabetes;
SARC	cis	rs7666738	0.752	rs62318905	chr4:99036103	T/G	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs8141529	0.719	rs2097461	chr22:29191879	T/C	cg02153584	chr22:29168773	CCDC117	0.82	12.32	0.63	3.36e-27	Lymphocyte counts;
SARC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.7	-9.54	-0.53	1.97e-18	Lymphocyte counts;
SARC	cis	rs2011503	1.000	rs11670687	chr19:19621752	A/G	cg15839431	chr19:19639596	YJEFN3	-0.48	-4.77	-0.3	3.32e-6	Bipolar disorder;
SARC	cis	rs818427	1.000	rs382260	chr5:112210344	A/G	cg07820702	chr5:112228657	REEP5	-0.46	-5.22	-0.32	3.88e-7	Total body bone mineral density;
SARC	cis	rs9788682	0.655	rs578776	chr15:78888400	G/A	cg24631222	chr15:78858424	CHRNA5	0.62	8.42	0.48	3.84e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs7106204	0.748	rs4360697	chr11:24217160	A/G	ch.11.24196551F	chr11:24239977	NA	0.6	6.37	0.39	9.87e-10	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs9513627	0.573	rs7325697	chr13:100117793	A/G	cg15490075	chr13:100150979	NA	0.51	4.96	0.31	1.39e-6	Obesity-related traits;
SARC	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg25427524	chr10:38739819	LOC399744	-0.56	-8.73	-0.5	5.08e-16	Extrinsic epigenetic age acceleration;
SARC	cis	rs2050392	0.630	rs303427	chr10:30739780	G/A	cg25182066	chr10:30743637	MAP3K8	0.41	5.52	0.34	8.81e-8	Inflammatory bowel disease;
SARC	trans	rs1945213	0.694	rs34390414	chr11:55863367	T/G	cg15704280	chr7:45808275	SEPT13	0.65	6.77	0.41	1.02e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs7220711	0.934	rs8079336	chr17:41782831	C/T	cg26893861	chr17:41843967	DUSP3	0.4	5.07	0.32	7.97e-7	Bone mineral density (spine);Bone mineral density (hip);
SARC	cis	rs9640161	0.702	rs3735175	chr7:150020457	C/T	cg10018233	chr7:150070692	REPIN1	0.72	9.37	0.52	6.75e-18	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs8072100	0.811	rs1912483	chr17:45443494	A/G	cg08085267	chr17:45401833	C17orf57	-0.43	-5.24	-0.32	3.66e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs7216064	0.953	rs4790981	chr17:65921834	A/G	cg12091567	chr17:66097778	LOC651250	-0.75	-8.31	-0.48	7.82e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs546131	0.642	rs12793173	chr11:34834204	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-4.83	-0.3	2.52e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg21724239	chr8:58056113	NA	0.69	6.57	0.4	3.22e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9398803	0.865	rs4897181	chr6:126753564	C/T	cg20229609	chr6:126660872	C6orf173	0.4	5.77	0.35	2.49e-8	Male-pattern baldness;
SARC	cis	rs4595586	0.545	rs925827	chr12:39364307	C/T	cg26384229	chr12:38710491	ALG10B	0.53	6.52	0.39	4.44e-10	Morning vs. evening chronotype;
SARC	cis	rs2153535	0.580	rs4140586	chr6:8503192	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	7.28	0.43	4.95e-12	Motion sickness;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg15997635	chr19:6737431	GPR108	0.47	6.4	0.39	8.62e-10	Thyroid stimulating hormone;
SARC	cis	rs2361710	0.704	rs12937349	chr17:78120320	G/C	cg23534315	chr17:78082725	GAA	0.34	5.11	0.32	6.72e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
SARC	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg22968622	chr17:43663579	NA	-1.12	-15.05	-0.7	3.24e-36	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs13191362	1.000	rs13210756	chr6:163009030	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.56	5.39	0.33	1.71e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg00149659	chr3:10157352	C3orf10	0.64	6.01	0.37	7.21e-9	Alzheimer's disease;
SARC	cis	rs35213789	0.878	rs17365011	chr7:69528580	C/T	cg10619644	chr7:69149951	AUTS2	0.42	5.06	0.31	8.48e-7	Childhood ear infection;
SARC	cis	rs6964587	1.000	rs6964587	chr7:91630620	G/T	cg17063962	chr7:91808500	NA	0.93	15.72	0.72	1.97e-38	Breast cancer;
SARC	cis	rs9547692	1.000	rs61950374	chr13:37475485	C/T	cg01493522	chr13:37497338	NA	-0.46	-5.17	-0.32	4.98e-7	Coronary artery disease;
SARC	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs950776	0.695	rs1878399	chr15:78912003	G/C	cg23880581	chr15:78912387	CHRNA3	-0.36	-4.98	-0.31	1.23e-6	Sudden cardiac arrest;
SARC	cis	rs67460515	0.563	rs9883566	chr3:160770323	C/T	cg04691961	chr3:161091175	C3orf57	0.43	4.9	0.31	1.81e-6	Parkinson's disease;
SARC	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-5.72	-0.35	3.18e-8	Lung cancer;
SARC	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg16479474	chr6:28041457	NA	0.33	5.01	0.31	1.09e-6	Cardiac Troponin-T levels;
SARC	cis	rs644799	0.540	rs10831422	chr11:95478968	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.76	10.25	0.56	1.38e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg14829155	chr15:31115871	NA	-0.49	-6.29	-0.38	1.59e-9	Huntington's disease progression;
SARC	cis	rs7672847	0.500	rs7441335	chr4:170349540	C/A	cg00846720	chr4:170533756	NEK1	-0.57	-4.72	-0.3	4.06e-6	Subjective well-being;
SARC	cis	rs651907	0.513	rs34963630	chr3:101504817	C/T	cg12386194	chr3:101231763	SENP7	0.48	5.54	0.34	8e-8	Colorectal cancer;
SARC	cis	rs10782582	0.593	rs11801414	chr1:76124517	G/A	cg10523679	chr1:76189770	ACADM	-0.4	-5.02	-0.31	1.02e-6	Daytime sleep phenotypes;
SARC	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg08280861	chr8:58055591	NA	0.68	5.89	0.36	1.31e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg15448220	chr1:150897856	SETDB1	0.49	6.45	0.39	6.34e-10	Melanoma;
SARC	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg11878867	chr6:150167359	LRP11	-0.38	-4.97	-0.31	1.32e-6	Lung cancer;
SARC	cis	rs12477438	0.834	rs11903311	chr2:99701807	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-14.85	-0.7	1.49e-35	Chronic sinus infection;
SARC	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg13393036	chr8:95962371	TP53INP1	-0.36	-6.15	-0.37	3.29e-9	Type 2 diabetes;
SARC	cis	rs2115536	0.967	rs4778734	chr15:80210851	A/G	cg00225070	chr15:80189496	MTHFS	0.65	8.59	0.49	1.24e-15	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
SARC	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	-0.66	-5.19	-0.32	4.61e-7	Initial pursuit acceleration;
SARC	cis	rs4803455	0.565	rs11083616	chr19:41865643	A/G	cg14132834	chr19:41945861	ATP5SL	0.39	4.86	0.3	2.13e-6	Migraine;Coronary artery disease;
SARC	cis	rs7084402	0.967	rs1649060	chr10:60310480	C/G	cg07615347	chr10:60278583	BICC1	-0.56	-7.95	-0.46	7.78e-14	Refractive error;
SARC	cis	rs2153535	0.580	rs7747306	chr6:8453663	C/G	cg07606381	chr6:8435919	SLC35B3	-0.78	-10.98	-0.58	7.23e-23	Motion sickness;
SARC	cis	rs9790314	1.000	rs336591	chr3:161078080	A/G	cg03342759	chr3:160939853	NMD3	-0.59	-7.53	-0.44	1.13e-12	Morning vs. evening chronotype;
SARC	cis	rs6696846	0.715	rs12139373	chr1:205054879	A/C	cg21643547	chr1:205240462	TMCC2	-0.56	-7.58	-0.44	8.36e-13	Red blood cell count;
SARC	cis	rs8005677	1.000	rs7145494	chr14:23399790	T/C	cg01529538	chr14:23388837	RBM23	0.44	5.32	0.33	2.46e-7	Cognitive ability (multi-trait analysis);
SARC	cis	rs3741798	1.000	rs77559638	chr12:12499909	T/A	cg08615371	chr12:12503544	MANSC1	0.75	5.92	0.36	1.14e-8	Cerebrospinal fluid biomarker levels;
SARC	cis	rs11764590	0.694	rs4721321	chr7:2068470	A/G	cg21782813	chr7:2030301	MAD1L1	-0.31	-4.72	-0.3	3.99e-6	Neuroticism;
SARC	cis	rs910316	1.000	rs1047418	chr14:75605792	A/G	cg06637938	chr14:75390232	RPS6KL1	0.5	7.13	0.42	1.25e-11	Height;
SARC	cis	rs17270561	0.609	rs17267614	chr6:25730027	A/C	cg17691542	chr6:26056736	HIST1H1C	0.56	6.86	0.41	6.28e-11	Iron status biomarkers;
SARC	cis	rs8141529	0.600	rs739196	chr22:29311271	G/A	cg02153584	chr22:29168773	CCDC117	0.68	7.35	0.43	3.28e-12	Lymphocyte counts;
SARC	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg27541892	chr1:1571801	CDK11B	0.4	5.47	0.34	1.19e-7	Body mass index;
SARC	trans	rs1994135	0.586	rs7308214	chr12:33713834	T/A	cg13010199	chr12:38710504	ALG10B	0.73	8.71	0.5	5.89e-16	Resting heart rate;
SARC	cis	rs920590	0.643	rs6982084	chr8:19669333	G/A	cg03894339	chr8:19674705	INTS10	-0.42	-5.08	-0.32	7.7e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs1707322	0.656	rs9429172	chr1:46092476	C/G	cg06784218	chr1:46089804	CCDC17	-0.37	-6.56	-0.4	3.37e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7582180	0.676	rs11680660	chr2:100931738	G/C	cg14675211	chr2:100938903	LONRF2	0.49	7.22	0.43	7.35e-12	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.522	rs9530	chr7:65425894	A/G	cg11764359	chr7:65958608	NA	0.55	6.4	0.39	8.53e-10	Aortic root size;
SARC	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg04267008	chr7:1944627	MAD1L1	-0.54	-6.19	-0.38	2.68e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs35213789	0.920	rs12698820	chr7:69415279	C/T	cg10619644	chr7:69149951	AUTS2	-0.46	-5.89	-0.36	1.31e-8	Childhood ear infection;
SARC	trans	rs17221829	0.733	rs11018668	chr11:89356178	C/T	cg02392575	chr12:100536662	UHRF1BP1L	-0.55	-7.52	-0.44	1.16e-12	Anxiety in major depressive disorder;
SARC	cis	rs3820928	0.874	rs13419455	chr2:227850465	C/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-6.4	-0.39	8.54e-10	Pulmonary function;
SARC	trans	rs7819412	0.749	rs11991118	chr8:10939273	A/C	cg06636001	chr8:8085503	FLJ10661	0.62	8.75	0.5	4.29e-16	Triglycerides;
SARC	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg23205692	chr1:25664452	TMEM50A	0.39	4.78	0.3	3.11e-6	Plateletcrit;Mean corpuscular volume;
SARC	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.12	23.94	0.84	9.77e-65	Chronic sinus infection;
SARC	cis	rs2963155	0.518	rs853176	chr5:142636456	A/G	cg17617527	chr5:142782415	NR3C1	-0.83	-5.98	-0.36	8.46e-9	Breast cancer;
SARC	cis	rs12950390	0.893	rs72831644	chr17:45824391	T/C	cg03474202	chr17:45855739	NA	-0.46	-7.22	-0.43	7.11e-12	IgG glycosylation;
SARC	cis	rs739401	0.611	rs401707	chr11:3050965	T/C	cg20651018	chr11:3035856	CARS	-0.46	-7.13	-0.42	1.22e-11	Longevity;
SARC	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg20818283	chr2:191399100	TMEM194B	0.44	5.67	0.35	4.29e-8	Pulse pressure;
SARC	cis	rs7635838	0.751	rs9811658	chr3:11395833	A/G	cg00170343	chr3:11313890	ATG7	0.57	7.62	0.45	6.4e-13	HDL cholesterol;
SARC	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg05313129	chr8:58192883	C8orf71	-0.49	-4.73	-0.3	3.87e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs11203032	0.831	rs7902290	chr10:90931602	T/C	cg16672925	chr10:90967113	CH25H	0.54	5.54	0.34	8.13e-8	Heart failure;
SARC	cis	rs9388451	0.868	rs1268083	chr6:126049040	T/C	cg05901451	chr6:126070800	HEY2	0.61	8.12	0.47	2.68e-14	Brugada syndrome;
SARC	cis	rs2718058	0.630	rs2722359	chr7:37839764	T/C	cg15028436	chr7:37888078	TXNDC3	0.39	4.99	0.31	1.16e-6	Alzheimer's disease (late onset);
SARC	cis	rs12142240	0.698	rs17361791	chr1:46812519	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-5.48	-0.34	1.12e-7	Menopause (age at onset);
SARC	cis	rs1153858	1.000	rs67461176	chr15:45676819	C/T	cg21132104	chr15:45694354	SPATA5L1	0.78	11.01	0.59	5.55e-23	Homoarginine levels;
SARC	cis	rs911263	0.603	rs7147852	chr14:68796799	C/T	cg18825221	chr14:68749962	RAD51L1	0.4	7.08	0.42	1.65e-11	Primary biliary cholangitis;
SARC	cis	rs17376456	0.825	rs10058331	chr5:93279115	T/G	cg25358565	chr5:93447407	FAM172A	1.3	14.17	0.68	2.82e-33	Diabetic retinopathy;
SARC	cis	rs8180040	0.701	rs1079276	chr3:47045739	C/G	cg27129171	chr3:47204927	SETD2	0.66	9.06	0.51	5.45e-17	Colorectal cancer;
SARC	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.46	5.77	0.35	2.54e-8	Gut microbiome composition (summer);
SARC	cis	rs524281	0.773	rs79770412	chr11:66045344	G/C	cg14036092	chr11:66035641	RAB1B	-0.59	-6.01	-0.37	7.02e-9	Electroencephalogram traits;
SARC	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.41	0.44	2.36e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6500602	0.727	rs10451135	chr16:4580214	T/C	cg08645402	chr16:4508243	NA	0.41	5.25	0.33	3.49e-7	Schizophrenia;
SARC	cis	rs7843479	0.601	rs10109521	chr8:21829948	G/A	cg17168535	chr8:21777572	XPO7	0.84	12.86	0.64	5.76e-29	Mean corpuscular volume;
SARC	cis	rs427394	0.659	rs187295	chr5:6734326	C/T	cg10857441	chr5:6722123	POLS	-0.34	-4.99	-0.31	1.16e-6	Menopause (age at onset);
SARC	cis	rs9398803	0.965	rs9388486	chr6:126661154	C/T	cg19875578	chr6:126661172	C6orf173	-0.6	-8.2	-0.47	1.56e-14	Male-pattern baldness;
SARC	cis	rs12477438	1.000	rs1922624	chr2:99909958	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-10.23	-0.56	1.61e-20	Chronic sinus infection;
SARC	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.48	7.66	0.45	5.05e-13	Schizophrenia;
SARC	cis	rs2180341	1.000	rs7776136	chr6:127638348	A/T	cg27446573	chr6:127587934	RNF146	1.04	14.92	0.7	8.51e-36	Breast cancer;
SARC	cis	rs9322193	0.566	rs4869767	chr6:150245110	A/G	cg01145232	chr6:150245071	RAET1G	-0.42	-4.8	-0.3	2.82e-6	Lung cancer;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg16495696	chr15:90792869	TTLL13	0.45	6.37	0.39	9.97e-10	Lung adenocarcinoma;
SARC	cis	rs7412746	0.658	rs6660845	chr1:150841066	G/A	cg10589385	chr1:150898437	SETDB1	0.43	5.64	0.35	4.92e-8	Melanoma;
SARC	cis	rs7588746	0.621	rs1816541	chr2:201151011	T/C	cg23649088	chr2:200775458	C2orf69	-0.5	-5.97	-0.36	8.89e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs12291225	0.585	rs10832242	chr11:14340504	C/T	cg19336497	chr11:14380999	RRAS2	0.44	7.74	0.45	3.08e-13	Sense of smell;
SARC	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg21724239	chr8:58056113	NA	0.6	5.85	0.36	1.64e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7208859	0.573	rs4055105	chr17:29102550	A/G	cg13385521	chr17:29058706	SUZ12P	0.84	7.02	0.42	2.44e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.42	-5.21	-0.32	4.2e-7	Lymphocyte counts;
SARC	cis	rs3820928	0.845	rs13419076	chr2:227873028	A/G	cg05526886	chr2:227700861	RHBDD1	-0.5	-6.12	-0.37	3.92e-9	Pulmonary function;
SARC	cis	rs2916247	1.000	rs746142	chr8:93060566	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.58	-6.05	-0.37	5.62e-9	Intelligence (multi-trait analysis);
SARC	cis	rs10927875	0.632	rs1122068	chr1:16127480	G/C	cg21385522	chr1:16154831	NA	-0.92	-13.17	-0.65	5.55e-30	Dilated cardiomyopathy;
SARC	cis	rs835154	0.845	rs835155	chr5:14875868	A/G	cg18064842	chr5:14874549	NA	0.68	10.8	0.58	2.56e-22	Blood metabolite levels;
SARC	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg12564285	chr5:131593104	PDLIM4	-0.48	-6.37	-0.39	1e-9	Blood metabolite levels;
SARC	cis	rs4851254	0.961	rs7596385	chr2:100796598	A/T	cg17356467	chr2:100759845	AFF3	0.28	4.73	0.3	3.9e-6	Intelligence (multi-trait analysis);
SARC	cis	rs12681288	0.823	rs2701906	chr8:1003316	T/C	cg04851639	chr8:1020857	NA	-0.27	-4.82	-0.3	2.55e-6	Schizophrenia;
SARC	cis	rs734999	0.545	rs10910106	chr1:2538886	G/T	cg18854424	chr1:2615690	NA	0.32	5.04	0.31	9.14e-7	Ulcerative colitis;
SARC	cis	rs11122272	0.735	rs2009873	chr1:231499236	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.11	-0.55	3.67e-20	Hemoglobin concentration;
SARC	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg08219700	chr8:58056026	NA	0.65	6.14	0.37	3.57e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7575873	1	rs7575873	chr2:23962647	A/G	cg08917208	chr2:24149416	ATAD2B	0.92	8.85	0.5	2.28e-16	Birth weight;
SARC	cis	rs7223966	1.000	rs11658329	chr17:61763031	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	6.76	0.41	1.07e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs911555	0.755	rs11627446	chr14:103946450	G/C	cg12935359	chr14:103987150	CKB	-0.37	-5.18	-0.32	4.91e-7	Intelligence (multi-trait analysis);
SARC	cis	rs826838	1.000	rs10880963	chr12:38748408	T/C	cg26384229	chr12:38710491	ALG10B	0.97	15.78	0.72	1.23e-38	Heart rate;
SARC	trans	rs208520	0.802	rs208499	chr6:66932146	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.87	-10.23	-0.56	1.57e-20	Exhaled nitric oxide output;
SARC	cis	rs10992471	0.513	rs710163	chr9:95059804	C/T	cg13798575	chr9:95087839	CENPP;NOL8	0.41	4.92	0.31	1.6e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs73206853	0.686	rs73194021	chr12:111131893	G/A	cg10860002	chr12:110842031	ANAPC7	0.63	5.23	0.32	3.79e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg11266682	chr4:10021025	SLC2A9	0.41	7.29	0.43	4.74e-12	Bone mineral density;
SARC	cis	rs73036520	1.000	rs11666251	chr19:45741609	T/C	cg01416317	chr19:45737208	EXOC3L2	0.36	4.96	0.31	1.39e-6	Monocyte percentage of white cells;
SARC	cis	rs12824058	0.831	rs4759658	chr12:130815872	C/T	cg24838063	chr12:130822603	PIWIL1	0.63	9.06	0.51	5.5e-17	Menopause (age at onset);
SARC	cis	rs9309473	0.500	rs1528169	chr2:73669186	T/C	cg20560298	chr2:73613845	ALMS1	0.53	7.15	0.42	1.08e-11	Metabolite levels;
SARC	cis	rs4568518	0.903	rs12155344	chr7:18035383	T/C	cg00911873	chr7:18067463	PRPS1L1	-0.34	-4.84	-0.3	2.42e-6	Measles;
SARC	trans	rs2727020	0.587	rs1164658	chr11:49298551	C/A	cg15704280	chr7:45808275	SEPT13	0.83	13.58	0.66	2.51e-31	Coronary artery disease;
SARC	cis	rs7829975	0.511	rs2948286	chr8:8130160	A/G	cg06636001	chr8:8085503	FLJ10661	0.79	11.24	0.59	1.06e-23	Mood instability;
SARC	cis	rs11718455	0.767	rs11130019	chr3:43989348	C/A	cg08738300	chr3:44038990	NA	0.52	5.67	0.35	4.11e-8	Coronary artery disease;
SARC	cis	rs3796352	1.000	rs34244302	chr3:53102236	C/G	cg12962167	chr3:53033115	SFMBT1	0.78	5.03	0.31	9.65e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg17971929	chr21:40555470	PSMG1	-0.57	-7.21	-0.43	7.81e-12	Menarche (age at onset);
SARC	cis	rs6120849	0.754	rs8501	chr20:33590584	T/C	cg24642439	chr20:33292090	TP53INP2	0.57	5.54	0.34	7.99e-8	Protein C levels;
SARC	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs8017423	0.904	rs11848894	chr14:90723660	C/A	cg20276874	chr14:90721474	PSMC1	-0.39	-5.49	-0.34	1.06e-7	Mortality in heart failure;
SARC	cis	rs7429990	0.965	rs6770467	chr3:48019232	A/G	cg11946769	chr3:48343235	NME6	-0.46	-5.39	-0.33	1.75e-7	Educational attainment (years of education);
SARC	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg10523679	chr1:76189770	ACADM	0.54	7.07	0.42	1.81e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg13206674	chr6:150067644	NUP43	0.43	5.28	0.33	3.01e-7	Lung cancer;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg23643360	chr10:118562628	NA	-0.71	-6.43	-0.39	7.11e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2204008	0.744	rs1115514	chr12:38280140	C/T	cg26384229	chr12:38710491	ALG10B	0.89	13.06	0.65	1.31e-29	Bladder cancer;
SARC	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.46	-5.65	-0.35	4.63e-8	Intelligence (multi-trait analysis);
SARC	cis	rs796364	1.000	rs35220450	chr2:200780737	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.74	-6.2	-0.38	2.58e-9	Schizophrenia;
SARC	cis	rs1941023	0.584	rs7935082	chr11:60155000	T/C	cg08716584	chr11:60157161	MS4A7	-0.39	-6.23	-0.38	2.1e-9	Congenital heart disease (maternal effect);
SARC	cis	rs7264396	0.790	rs6058294	chr20:34259396	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	5.94	0.36	1.03e-8	Total cholesterol levels;
SARC	cis	rs10870270	0.956	rs10870293	chr10:133771413	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.83	-10.26	-0.56	1.3e-20	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs4268898	0.795	rs12470303	chr2:24619883	C/T	cg06627628	chr2:24431161	ITSN2	-0.51	-6.98	-0.42	3.02e-11	Asthma;
SARC	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg11987759	chr7:65425863	GUSB	-0.42	-5.77	-0.35	2.5e-8	Aortic root size;
SARC	trans	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg17712092	chr4:129076599	LARP1B	0.62	8.1	0.47	3.09e-14	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg14159672	chr1:205819179	PM20D1	-0.85	-14.34	-0.68	7.26e-34	Menarche (age at onset);
SARC	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg07701084	chr6:150067640	NUP43	0.43	5.5	0.34	9.92e-8	Lung cancer;
SARC	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg22920501	chr2:26401640	FAM59B	-0.57	-7.45	-0.44	1.82e-12	Gut microbiome composition (summer);
SARC	cis	rs1008375	1.000	rs10805357	chr4:17652352	G/A	cg02297831	chr4:17616191	MED28	0.49	6.31	0.38	1.39e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9902453	0.967	rs28792710	chr17:28450015	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	6.64	0.4	2.23e-10	Coffee consumption (cups per day);
SARC	trans	rs9354308	0.868	rs9363465	chr6:66557802	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.55	-6.43	-0.39	7.26e-10	Metabolite levels;
SARC	cis	rs910316	0.763	rs175435	chr14:75612025	A/G	cg06637938	chr14:75390232	RPS6KL1	0.47	6.31	0.38	1.42e-9	Height;
SARC	cis	rs1256061	0.576	rs960070	chr14:64745179	C/G	cg23250157	chr14:64679961	SYNE2	0.43	5.93	0.36	1.06e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs7089973	0.525	rs11196945	chr10:116600424	G/A	cg03647239	chr10:116582469	FAM160B1	0.51	6.49	0.39	5.19e-10	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs2594989	0.831	rs6803125	chr3:11583228	A/G	cg00170343	chr3:11313890	ATG7	-0.59	-5.89	-0.36	1.37e-8	Circulating chemerin levels;
SARC	cis	rs6582630	0.548	rs1607870	chr12:38385964	G/T	cg13010199	chr12:38710504	ALG10B	-0.48	-5.85	-0.36	1.62e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9894429	0.608	rs7406382	chr17:79597786	T/C	cg10661904	chr17:79619235	PDE6G	-0.45	-6.33	-0.38	1.22e-9	Eye color traits;
SARC	cis	rs910316	1.000	rs175443	chr14:75601963	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.51	-7.14	-0.42	1.18e-11	Height;
SARC	cis	rs11122272	0.735	rs2739513	chr1:231515201	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-9.36	-0.52	7e-18	Hemoglobin concentration;
SARC	cis	rs34172651	0.917	rs8049667	chr16:24773524	G/A	cg00152838	chr16:24741724	TNRC6A	-0.5	-6.19	-0.38	2.75e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7626444	0.625	rs1798635	chr3:196474289	C/T	cg12930392	chr3:196481615	PAK2	0.26	5.2	0.32	4.44e-7	Monocyte count;
SARC	cis	rs7560272	0.723	rs6743576	chr2:73814333	G/A	cg20560298	chr2:73613845	ALMS1	-0.52	-7.03	-0.42	2.23e-11	Schizophrenia;
SARC	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg24829409	chr8:58192753	C8orf71	-0.56	-4.93	-0.31	1.58e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs4668356	0.543	rs1989613	chr2:172034292	A/G	cg13882835	chr2:172017928	TLK1	-0.74	-6.12	-0.37	3.96e-9	Cognitive performance;
SARC	cis	rs1018836	0.828	rs7014967	chr8:91557843	G/T	cg16814680	chr8:91681699	NA	-0.75	-11.64	-0.61	5.6e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs66887589	0.870	rs59590064	chr4:120539753	T/C	cg09307838	chr4:120376055	NA	-0.54	-7.42	-0.44	2.14e-12	Diastolic blood pressure;
SARC	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg22875332	chr1:76189707	ACADM	-0.47	-6.32	-0.38	1.3e-9	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7808935	0.958	rs67152137	chr7:27975919	G/C	cg05786569	chr7:27702416	HIBADH	0.48	5.19	0.32	4.55e-7	Prostate cancer;
SARC	cis	rs12477438	0.765	rs2278895	chr2:99613484	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-9.87	-0.54	1.98e-19	Chronic sinus infection;
SARC	cis	rs7659604	0.540	rs4075065	chr4:122683906	A/G	cg19671926	chr4:122722719	EXOSC9	0.54	6.74	0.4	1.25e-10	Type 2 diabetes;
SARC	cis	rs7681440	0.583	rs2736995	chr4:90762197	G/T	cg06632027	chr4:90757378	SNCA	0.44	5.47	0.34	1.15e-7	Dementia with Lewy bodies;
SARC	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg12463550	chr7:65579703	CRCP	0.69	5.24	0.32	3.54e-7	Diabetic kidney disease;
SARC	cis	rs1865760	0.865	rs2164485	chr6:25952106	G/A	cg16482183	chr6:26056742	HIST1H1C	0.51	6.48	0.39	5.36e-10	Height;
SARC	cis	rs3020736	0.500	rs7292241	chr22:42492063	G/A	cg04733989	chr22:42467013	NAGA	-0.77	-10.67	-0.57	6.65e-22	Autism spectrum disorder or schizophrenia;
SARC	cis	rs634534	0.563	rs470192	chr11:65724291	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.43	-5.39	-0.33	1.7e-7	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg17376030	chr22:41985996	PMM1	0.75	9.13	0.51	3.45e-17	Vitiligo;
SARC	cis	rs644799	0.710	rs11021311	chr11:95505227	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.61	8.17	0.47	2e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs66573146	1.000	rs56350643	chr4:7017591	G/A	cg00086871	chr4:6988644	TBC1D14	1.0	5.23	0.32	3.81e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs10463554	1.000	rs1593842	chr5:102334722	A/C	cg23492399	chr5:102201601	PAM	-0.49	-5.94	-0.36	1.06e-8	Parkinson's disease;
SARC	cis	rs807669	0.903	rs1780642	chr22:19170604	T/C	cg02655711	chr22:19163373	SLC25A1	0.56	7.96	0.46	7.73e-14	Metabolite levels;
SARC	cis	rs17154702	0.510	rs7831224	chr8:8656647	C/T	cg01851573	chr8:8652454	MFHAS1	0.37	4.72	0.3	4.01e-6	Neurocognitive impairment in HIV-1 infection (continuous);
SARC	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg13607699	chr17:42295918	UBTF	0.49	5.9	0.36	1.25e-8	Total body bone mineral density;
SARC	trans	rs1814175	0.904	rs1846289	chr11:49620253	G/A	cg15704280	chr7:45808275	SEPT13	-0.91	-16.05	-0.72	1.56e-39	Height;
SARC	trans	rs8073060	0.586	rs3859284	chr17:34012792	C/T	cg19694781	chr19:47549865	TMEM160	-0.71	-6.94	-0.41	3.88e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs853679	1.000	rs6905391	chr6:28262686	G/A	cg26450541	chr6:28235208	ZNF187	0.57	4.8	0.3	2.88e-6	Depression;
SARC	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs7769051	0.711	rs7758703	chr6:133085417	T/C	cg22852734	chr6:133119734	C6orf192	1.09	10.4	0.56	4.59e-21	Type 2 diabetes nephropathy;
SARC	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg13175981	chr1:150552382	MCL1	-0.5	-6.14	-0.37	3.53e-9	Melanoma;
SARC	cis	rs1008375	1.000	rs10440301	chr4:17663199	G/A	cg27347728	chr4:17578864	LAP3	0.5	6.12	0.37	3.93e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10131894	0.611	rs174994	chr14:75434102	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.56	-7.57	-0.44	8.91e-13	Coronary artery disease;
SARC	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg02574844	chr11:5959923	NA	-0.36	-5.19	-0.32	4.47e-7	DNA methylation (variation);
SARC	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg19223190	chr17:80058835	NA	0.45	6.35	0.38	1.13e-9	Life satisfaction;
SARC	cis	rs2481665	0.680	rs2481671	chr1:62611666	A/C	cg18591186	chr1:62594603	INADL	-0.52	-7.33	-0.43	3.78e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg22105103	chr4:187893119	NA	0.45	6.02	0.37	6.81e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1949733	0.675	rs2688219	chr4:8444631	T/C	cg13073564	chr4:8508604	NA	-0.44	-7.04	-0.42	2.12e-11	Response to antineoplastic agents;
SARC	cis	rs1468333	0.598	rs4639219	chr5:137699620	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.65	7.76	0.45	2.59e-13	Resting heart rate;
SARC	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg22974920	chr21:40686053	BRWD1	-0.44	-4.83	-0.3	2.42e-6	Cognitive function;
SARC	cis	rs12586317	0.507	rs4982250	chr14:35716132	C/T	cg16230307	chr14:35515116	FAM177A1	0.44	5.21	0.32	4.06e-7	Psoriasis;
SARC	cis	rs3888647	0.561	rs4758617	chr11:2995185	T/A	cg08508325	chr11:3079039	CARS	-0.32	-7.91	-0.46	1.05e-13	Type 2 diabetes;
SARC	cis	rs72781680	1.000	rs72796337	chr2:24142957	G/A	cg06627628	chr2:24431161	ITSN2	-0.68	-6.44	-0.39	6.58e-10	Lymphocyte counts;
SARC	cis	rs4742903	0.935	rs1507507	chr9:106949429	A/G	cg14250997	chr9:106856677	SMC2	0.43	5.32	0.33	2.44e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs2380220	0.808	rs72922390	chr6:95934317	G/A	cg04719120	chr6:96025338	MANEA	-0.64	-6.4	-0.39	8.45e-10	Behavioural disinhibition (generation interaction);
SARC	cis	rs1941023	0.584	rs2241920	chr11:60164204	A/G	cg08716584	chr11:60157161	MS4A7	0.4	6.45	0.39	6.27e-10	Congenital heart disease (maternal effect);
SARC	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg04267008	chr7:1944627	MAD1L1	-0.65	-7.37	-0.43	2.96e-12	Bipolar disorder and schizophrenia;
SARC	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg22683308	chr4:1340831	KIAA1530	0.43	5.03	0.31	9.74e-7	Longevity;
SARC	cis	rs875971	1.000	rs2220626	chr7:65546062	C/T	cg11987759	chr7:65425863	GUSB	0.45	5.87	0.36	1.47e-8	Aortic root size;
SARC	cis	rs2235642	0.826	rs8053605	chr16:1594158	G/A	cg26528668	chr16:1614120	IFT140	0.36	4.72	0.3	4.11e-6	Coronary artery disease;
SARC	cis	rs6834538	0.577	rs10034556	chr4:113449650	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.53	7.21	0.43	7.68e-12	Free thyroxine concentration;
SARC	cis	rs10782582	0.609	rs1251584	chr1:76424440	C/T	cg03433033	chr1:76189801	ACADM	0.39	5.17	0.32	5.1e-7	Daytime sleep phenotypes;
SARC	cis	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg11266682	chr4:10021025	SLC2A9	0.41	7.32	0.43	3.99e-12	Bone mineral density;
SARC	cis	rs425277	1.000	rs262647	chr1:2095699	C/T	cg24578937	chr1:2090814	PRKCZ	0.31	5.96	0.36	9.17e-9	Height;
SARC	cis	rs8008758	0.517	rs1772024	chr14:101695220	A/C	cg26224664	chr14:101693935	NA	0.47	9.42	0.53	4.67e-18	Body mass index (alcohol intake interaction);
SARC	cis	rs4889855	0.530	rs9914854	chr17:78598662	A/G	cg17956530	chr17:78667699	RPTOR	-0.47	-5.4	-0.33	1.65e-7	Fractional excretion of uric acid;
SARC	cis	rs897080	0.515	rs698818	chr2:44709769	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	6.3	0.38	1.44e-9	Height;
SARC	cis	rs9807989	0.507	rs2110659	chr2:103043867	G/A	cg03938978	chr2:103052716	IL18RAP	0.32	5.18	0.32	4.72e-7	Asthma;
SARC	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg02524346	chr8:600233	NA	0.97	7.15	0.42	1.09e-11	IgG glycosylation;
SARC	cis	rs11723261	0.582	rs3747693	chr4:124375	T/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.41	5.43	0.34	1.41e-7	Immune response to smallpox vaccine (IL-6);
SARC	cis	rs11122272	0.735	rs11122279	chr1:231519804	A/G	cg06096015	chr1:231504339	EGLN1	0.4	5.85	0.36	1.64e-8	Hemoglobin concentration;
SARC	cis	rs17384381	0.953	rs1498374	chr1:85787334	C/T	cg16011679	chr1:85725395	C1orf52	0.6	5.09	0.32	7.3e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6582630	0.519	rs10880629	chr12:38533611	T/G	cg26384229	chr12:38710491	ALG10B	0.85	12.53	0.63	7.28e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs55823223	0.564	rs58363746	chr17:73850819	C/T	cg08125733	chr17:73851984	WBP2	0.56	6.44	0.39	6.89e-10	Psoriasis;
SARC	cis	rs6580649	0.574	rs7964359	chr12:48410566	T/A	cg05342945	chr12:48394962	COL2A1	-0.42	-5.11	-0.32	6.62e-7	Lung cancer;
SARC	cis	rs9581857	0.556	rs1885991	chr13:28040470	G/A	cg01674679	chr13:27998804	GTF3A	-0.6	-5.9	-0.36	1.27e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg11301795	chr4:187892539	NA	-0.7	-10.5	-0.57	2.28e-21	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11608355	0.521	rs10850131	chr12:109837052	A/G	cg19025524	chr12:109796872	NA	0.41	6.13	0.37	3.72e-9	Neuroticism;
SARC	trans	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg07211511	chr3:129823064	LOC729375	-0.61	-6.46	-0.39	6.08e-10	Blood pressure (smoking interaction);
SARC	cis	rs965469	1.000	rs6037554	chr20:3315613	G/A	cg25506879	chr20:3388711	C20orf194	-0.5	-5.18	-0.32	4.79e-7	IFN-related cytopenia;
SARC	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg11987759	chr7:65425863	GUSB	0.47	5.85	0.36	1.64e-8	Aortic root size;
SARC	cis	rs367943	1.000	rs348928	chr5:112815295	C/T	cg12552261	chr5:112820674	MCC	-0.45	-5.21	-0.32	4.24e-7	Type 2 diabetes;
SARC	cis	rs708547	0.874	rs1718837	chr4:57871203	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.44	-4.99	-0.31	1.16e-6	Response to bleomycin (chromatid breaks);
SARC	cis	rs2832191	0.632	rs2246777	chr21:30309586	T/C	cg24692254	chr21:30365293	RNF160	-1.05	-19.01	-0.78	2.8e-49	Dental caries;
SARC	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg03060546	chr3:49711283	APEH	-0.47	-6.3	-0.38	1.48e-9	Menarche (age at onset);
SARC	cis	rs2180341	1.000	rs13218061	chr6:127653758	G/A	cg17762328	chr6:126965162	NA	-0.45	-5.11	-0.32	6.78e-7	Breast cancer;
SARC	cis	rs4642101	0.640	rs7629354	chr3:12827746	T/G	cg05775895	chr3:12838266	CAND2	0.72	10.9	0.58	1.24e-22	QRS complex (12-leadsum);
SARC	cis	rs240764	0.621	rs12175456	chr6:101219511	A/T	cg09795085	chr6:101329169	ASCC3	-0.44	-5.64	-0.35	4.9e-8	Neuroticism;
SARC	cis	rs3741151	0.773	rs73542976	chr11:73127471	A/G	cg17517138	chr11:73019481	ARHGEF17	0.91	6.77	0.41	1.04e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg00933542	chr6:150070202	PCMT1	0.31	5.03	0.31	9.61e-7	Lung cancer;
SARC	cis	rs11122272	0.735	rs2790893	chr1:231508976	T/G	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs6088813	1.000	rs1406947	chr20:33969530	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	-0.46	-5.55	-0.34	7.89e-8	Height;
SARC	cis	rs7552404	0.924	rs1146580	chr1:76209935	T/C	cg22875332	chr1:76189707	ACADM	0.4	5.7	0.35	3.55e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg25427524	chr10:38739819	LOC399744	-0.52	-8.23	-0.47	1.32e-14	Extrinsic epigenetic age acceleration;
SARC	cis	rs920590	0.684	rs57837509	chr8:19670088	A/G	cg17834443	chr8:19674713	INTS10	0.63	7.54	0.44	1.07e-12	Acute lymphoblastic leukemia (childhood);
SARC	trans	rs9329221	0.736	rs11249999	chr8:10251265	C/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.05	-0.42	2.01e-11	Neuroticism;
SARC	trans	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg21659725	chr3:3221576	CRBN	-0.54	-7.03	-0.42	2.32e-11	Intelligence (multi-trait analysis);
SARC	cis	rs523522	0.962	rs11065149	chr12:120956963	G/A	cg12219531	chr12:120966889	COQ5	0.84	11.36	0.6	4.3e-24	High light scatter reticulocyte count;
SARC	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg04518342	chr5:131593106	PDLIM4	0.44	5.66	0.35	4.37e-8	Breast cancer;
SARC	cis	rs2204008	0.806	rs7305409	chr12:38349133	G/A	cg13010199	chr12:38710504	ALG10B	0.8	11.05	0.59	4.21e-23	Bladder cancer;
SARC	cis	rs1348850	0.846	rs4893962	chr2:178421106	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.66	8.29	0.48	8.81e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs858239	0.601	rs6962526	chr7:23158233	G/A	cg23682824	chr7:23144976	KLHL7	0.73	9.83	0.54	2.71e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg25036284	chr2:26402008	FAM59B	-0.4	-4.78	-0.3	3.09e-6	Gut microbiome composition (summer);
SARC	cis	rs3857067	0.806	rs2865343	chr4:95103005	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.08	-0.32	7.69e-7	QT interval;
SARC	cis	rs10791097	0.667	rs4937585	chr11:130741940	A/G	cg12179176	chr11:130786555	SNX19	0.73	10.91	0.58	1.19e-22	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs10791323	0.592	rs2851115	chr11:133705381	C/A	cg13461336	chr11:133711254	SPATA19	-0.28	-4.72	-0.3	4e-6	Childhood ear infection;
SARC	cis	rs2204008	0.775	rs12369238	chr12:38176051	A/G	cg13010199	chr12:38710504	ALG10B	0.74	9.75	0.54	4.75e-19	Bladder cancer;
SARC	cis	rs897080	0.515	rs1067357	chr2:44663064	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	6.14	0.37	3.48e-9	Height;
SARC	cis	rs826838	0.559	rs1843891	chr12:38617018	T/C	cg26384229	chr12:38710491	ALG10B	0.6	7.81	0.46	1.9e-13	Heart rate;
SARC	cis	rs6815814	0.950	rs56408159	chr4:38812116	T/A	cg06935464	chr4:38784597	TLR10	0.63	6.34	0.38	1.16e-9	Breast cancer;
SARC	cis	rs3126085	0.935	rs11589587	chr1:152184129	T/C	cg03465714	chr1:152285911	FLG	0.44	4.78	0.3	3.07e-6	Atopic dermatitis;
SARC	cis	rs4906332	0.933	rs35999760	chr14:103924481	A/C	cg26031613	chr14:104095156	KLC1	-0.49	-5.74	-0.35	2.88e-8	Coronary artery disease;
SARC	trans	rs7824557	0.564	rs35009431	chr8:11232788	G/A	cg06636001	chr8:8085503	FLJ10661	-0.62	-8.04	-0.47	4.57e-14	Retinal vascular caliber;
SARC	cis	rs870825	0.616	rs7683799	chr4:185632164	T/C	cg04058563	chr4:185651563	MLF1IP	0.85	11.37	0.6	4.03e-24	Blood protein levels;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg01708236	chr6:44233446	NFKBIE	0.49	6.29	0.38	1.53e-9	Height;
SARC	cis	rs9788682	0.748	rs569207	chr15:78873119	A/G	cg24631222	chr15:78858424	CHRNA5	-0.74	-9.79	-0.54	3.48e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs2354432	0.607	rs11579626	chr1:146741960	A/C	cg25205988	chr1:146714368	CHD1L	-1.0	-7.56	-0.44	9.4e-13	Mitochondrial DNA levels;
SARC	cis	rs710216	0.957	rs710215	chr1:43429105	T/C	cg22176566	chr1:43424700	SLC2A1	0.52	5.15	0.32	5.47e-7	Red cell distribution width;
SARC	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg13393036	chr8:95962371	TP53INP1	-0.37	-6.3	-0.38	1.49e-9	Type 2 diabetes;
SARC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.65	0.53	9.21e-19	Prudent dietary pattern;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg06214606	chr13:111303340	CARS2	-0.6	-5.34	-0.33	2.21e-7	Obesity-related traits;
SARC	cis	rs2839186	0.508	rs12626873	chr21:47714848	G/T	cg12379764	chr21:47803548	PCNT	-0.48	-5.0	-0.31	1.15e-6	Testicular germ cell tumor;
SARC	cis	rs3812831	0.695	rs10467349	chr13:114939441	A/G	cg08824895	chr13:115047677	UPF3A	0.51	6.78	0.41	9.63e-11	Schizophrenia;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg14381972	chr4:149365342	NA	-0.47	-6.26	-0.38	1.86e-9	Electrocardiographic conduction measures;
SARC	cis	rs2576037	0.796	rs2571031	chr18:44577063	T/C	cg15049968	chr18:44337910	ST8SIA5	0.33	5.43	0.34	1.39e-7	Personality dimensions;
SARC	cis	rs910316	0.839	rs35977276	chr14:75637359	A/C	cg11812906	chr14:75593930	NEK9	-0.87	-12.46	-0.63	1.23e-27	Height;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg06754565	chr16:57023317	NLRC5	0.54	6.85	0.41	6.64e-11	Lung adenocarcinoma;
SARC	cis	rs3126085	0.935	rs10788824	chr1:152161694	A/G	cg26876637	chr1:152193138	HRNR	0.49	5.39	0.33	1.75e-7	Atopic dermatitis;
SARC	cis	rs1048238	0.506	rs12039892	chr1:16167974	A/G	cg21385522	chr1:16154831	NA	0.47	5.77	0.35	2.46e-8	Systolic blood pressure;
SARC	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg21747090	chr2:27597821	SNX17	0.46	6.36	0.38	1.05e-9	Total body bone mineral density;
SARC	cis	rs17270561	0.608	rs9358875	chr6:25738008	G/A	cg16482183	chr6:26056742	HIST1H1C	0.43	5.22	0.32	3.92e-7	Iron status biomarkers;
SARC	trans	rs7980799	0.649	rs12819439	chr12:33684509	A/C	cg13010199	chr12:38710504	ALG10B	0.58	6.72	0.4	1.35e-10	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg22903471	chr2:27725779	GCKR	-0.48	-7.23	-0.43	6.88e-12	Total body bone mineral density;
SARC	cis	rs2718058	0.606	rs2722273	chr7:37808298	T/C	cg24998770	chr7:37888106	TXNDC3	0.36	5.18	0.32	4.85e-7	Alzheimer's disease (late onset);
SARC	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.0	15.96	0.72	2.99e-39	Chronic sinus infection;
SARC	cis	rs7223966	1.000	rs11658740	chr17:61751069	A/G	cg00588841	chr17:61851480	DDX42;CCDC47	-0.61	-6.68	-0.4	1.76e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg12401625	chr5:53281666	ARL15	0.44	6.33	0.38	1.23e-9	Thyroid stimulating hormone;
SARC	cis	rs6911965	0.578	rs16889389	chr6:24487576	T/G	cg20631270	chr6:24437470	GPLD1	0.51	4.82	0.3	2.59e-6	Hematological and biochemical traits;
SARC	cis	rs2576037	0.901	rs2576036	chr18:44587102	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-6.27	-0.38	1.72e-9	Personality dimensions;
SARC	cis	rs854765	0.583	rs11078404	chr17:17820487	A/T	cg04398451	chr17:18023971	MYO15A	-0.37	-5.29	-0.33	2.76e-7	Total body bone mineral density;
SARC	cis	rs13191362	1.000	rs35723993	chr6:163008197	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.5	0.34	1.01e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs644799	0.930	rs3802764	chr11:95514599	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.68	9.44	0.53	3.97e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg07308232	chr7:1071921	C7orf50	-0.45	-5.31	-0.33	2.53e-7	Longevity;Endometriosis;
SARC	cis	rs9612	1.000	rs346545	chr19:44256386	T/C	cg08581076	chr19:44259116	C19orf61	0.64	7.92	0.46	9.53e-14	Exhaled nitric oxide output;
SARC	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg16486109	chr11:613632	IRF7	0.44	5.96	0.36	9.24e-9	Systemic lupus erythematosus;
SARC	cis	rs240764	0.658	rs10457849	chr6:101245591	A/G	cg09795085	chr6:101329169	ASCC3	0.51	6.71	0.4	1.47e-10	Neuroticism;
SARC	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs10463316	0.817	rs10040628	chr5:150821027	T/G	cg03212797	chr5:150827313	SLC36A1	-0.43	-4.97	-0.31	1.31e-6	Metabolite levels (Pyroglutamine);
SARC	cis	rs2153535	0.580	rs9328488	chr6:8529411	G/C	cg21535247	chr6:8435926	SLC35B3	0.51	6.48	0.39	5.5e-10	Motion sickness;
SARC	cis	rs7666738	0.830	rs7672127	chr4:98938477	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.98	0.51	9.46e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.84	12.42	0.63	1.65e-27	Eosinophil percentage of white cells;
SARC	cis	rs1008375	1.000	rs1006722	chr4:17618713	A/G	cg27347728	chr4:17578864	LAP3	-0.46	-5.6	-0.34	5.96e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7666738	0.830	rs6839203	chr4:98839814	C/G	cg05340658	chr4:99064831	C4orf37	0.66	8.76	0.5	4.2e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs11122272	0.735	rs10489610	chr1:231517765	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg13939156	chr17:80058883	NA	-0.43	-6.53	-0.39	4.12e-10	Life satisfaction;
SARC	trans	rs7824557	0.569	rs35418978	chr8:11186453	T/C	cg06636001	chr8:8085503	FLJ10661	0.6	7.84	0.46	1.56e-13	Retinal vascular caliber;
SARC	cis	rs3815700	1.000	rs10406750	chr19:33097144	C/T	cg24916020	chr19:33096688	ANKRD27	0.53	5.35	0.33	2.05e-7	Eosinophilic esophagitis;
SARC	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg01570182	chr17:44337453	NA	0.87	9.82	0.54	2.78e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg22834771	chr12:69754056	YEATS4	-0.47	-6.3	-0.38	1.51e-9	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9303401	0.538	rs35454383	chr17:56475599	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.02	10.01	0.55	7.73e-20	Cognitive test performance;
SARC	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	11.03	0.59	4.93e-23	Alzheimer's disease;
SARC	cis	rs1153858	1.000	rs4534782	chr15:45652933	G/A	cg14582100	chr15:45693742	SPATA5L1	0.35	4.82	0.3	2.64e-6	Homoarginine levels;
SARC	cis	rs6540556	0.769	rs12030655	chr1:209922123	G/T	cg23920097	chr1:209922102	NA	-0.63	-7.15	-0.42	1.13e-11	Red blood cell count;
SARC	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg24399712	chr22:39784796	NA	0.42	5.63	0.35	5.1e-8	Intelligence (multi-trait analysis);
SARC	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg05793240	chr7:2802953	GNA12	-0.37	-5.33	-0.33	2.36e-7	Height;
SARC	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg26335602	chr6:28129616	ZNF389	0.53	5.91	0.36	1.2e-8	Depression;
SARC	cis	rs4481887	0.676	rs6691314	chr1:248548020	G/A	cg00666640	chr1:248458726	OR2T12	0.3	5.38	0.33	1.79e-7	Common traits (Other);
SARC	cis	rs9398803	0.678	rs4895811	chr6:126899853	T/A	cg19875578	chr6:126661172	C6orf173	0.6	8.29	0.48	9.04e-15	Male-pattern baldness;
SARC	trans	rs7824557	0.545	rs34482136	chr8:11227885	C/T	cg06636001	chr8:8085503	FLJ10661	-0.6	-7.94	-0.46	8.66e-14	Retinal vascular caliber;
SARC	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg26354017	chr1:205819088	PM20D1	0.44	4.9	0.31	1.79e-6	Parkinson's disease;
SARC	cis	rs7312933	0.533	rs17551006	chr12:42848738	G/C	cg19980929	chr12:42632907	YAF2	0.46	6.47	0.39	5.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs10782582	0.609	rs78748984	chr1:76340467	G/A	cg03433033	chr1:76189801	ACADM	-0.37	-4.85	-0.3	2.22e-6	Daytime sleep phenotypes;
SARC	cis	rs7647973	1.000	rs11130189	chr3:49347357	C/A	cg07636037	chr3:49044803	WDR6	0.71	8.06	0.47	3.87e-14	Menarche (age at onset);
SARC	cis	rs12701220	0.690	rs10243973	chr7:1064983	T/C	cg26769984	chr7:1090371	C7orf50	0.45	4.95	0.31	1.46e-6	Bronchopulmonary dysplasia;
SARC	cis	rs477692	1.000	rs553371	chr10:131413676	T/C	cg05714579	chr10:131428358	MGMT	0.57	7.48	0.44	1.46e-12	Response to temozolomide;
SARC	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg08280861	chr8:58055591	NA	0.69	5.78	0.35	2.33e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9300255	0.596	rs10732573	chr12:123743883	G/C	cg00376283	chr12:123451042	ABCB9	0.51	5.73	0.35	3.04e-8	Neutrophil percentage of white cells;
SARC	cis	rs9807989	0.507	rs6745614	chr2:102991213	A/G	cg03938978	chr2:103052716	IL18RAP	0.31	4.98	0.31	1.22e-6	Asthma;
SARC	cis	rs55871839	0.708	rs2326213	chr8:59812459	A/G	cg07426533	chr8:59803705	TOX	-0.43	-5.77	-0.35	2.51e-8	Pneumonia;
SARC	trans	rs13325613	0.915	rs71327040	chr3:46263208	G/T	cg12387106	chr12:133178249	NA	0.84	6.58	0.4	3e-10	Monocyte count;
SARC	cis	rs11608355	1.000	rs10774692	chr12:109862324	G/T	cg19025524	chr12:109796872	NA	-0.4	-5.06	-0.31	8.4e-7	Neuroticism;
SARC	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg06634786	chr22:41940651	POLR3H	0.52	6.08	0.37	4.88e-9	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs3820928	0.874	rs4144328	chr2:227790187	A/C	cg11843606	chr2:227700838	RHBDD1	-0.54	-6.85	-0.41	6.62e-11	Pulmonary function;
SARC	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg04546413	chr19:29218101	NA	0.47	5.86	0.36	1.55e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	ch.7.134603089F	chr7:134952549	NA	-0.52	-6.28	-0.38	1.62e-9	Alcohol dependence;
SARC	cis	rs9640161	0.742	rs2108853	chr7:150017589	A/C	cg21361702	chr7:150065534	REPIN1	0.46	4.78	0.3	3.04e-6	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs11644362	1.000	rs12918494	chr16:12988455	C/T	cg06890432	chr16:12997467	SHISA9	-0.55	-7.34	-0.43	3.46e-12	Positive affect;Subjective well-being;
SARC	cis	rs2288073	0.619	rs6713263	chr2:24375463	A/G	cg06627628	chr2:24431161	ITSN2	-0.55	-7.32	-0.43	4.06e-12	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs9372253	0.934	rs9320327	chr6:110715194	T/A	cg19196401	chr6:110721138	DDO	-0.41	-5.37	-0.33	1.92e-7	Platelet distribution width;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg26829758	chr6:22000644	FLJ22536	0.5	6.97	0.42	3.19e-11	Thyroid stimulating hormone;
SARC	cis	rs1008375	0.933	rs10939757	chr4:17694125	T/C	cg16339924	chr4:17578868	LAP3	0.56	7.0	0.42	2.67e-11	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10046574	0.831	rs10276768	chr7:135064346	A/G	cg27474649	chr7:135195673	CNOT4	0.89	7.28	0.43	5.14e-12	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs9362426	1.000	rs173334	chr6:88080223	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.41	4.96	0.31	1.35e-6	Depressive episodes in bipolar disorder;
SARC	cis	rs77972916	0.536	rs7562101	chr2:43592756	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.47	-5.23	-0.32	3.85e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.62	0.45	6.48e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2306786	0.558	rs78346178	chr15:59504364	A/G	cg23054309	chr15:59226205	SLTM	0.76	4.89	0.3	1.91e-6	Metabolite levels;
SARC	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg11987759	chr7:65425863	GUSB	0.62	8.24	0.48	1.25e-14	Aortic root size;
SARC	cis	rs722599	0.748	rs731165	chr14:75352555	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.41	-5.17	-0.32	5.13e-7	IgG glycosylation;
SARC	cis	rs9325144	0.723	rs3887436	chr12:39189526	A/C	cg13010199	chr12:38710504	ALG10B	-0.49	-5.89	-0.36	1.34e-8	Morning vs. evening chronotype;
SARC	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg16049864	chr8:95962084	TP53INP1	-0.48	-7.83	-0.46	1.72e-13	Type 2 diabetes;
SARC	trans	rs877282	0.898	rs11253339	chr10:759640	C/T	cg22713356	chr15:30763199	NA	0.96	9.76	0.54	4.28e-19	Uric acid levels;
SARC	cis	rs1355223	0.506	rs6484738	chr11:34860858	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.49	-6.24	-0.38	2.09e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs5995756	0.761	rs1534883	chr22:40005425	T/C	cg10455938	chr22:40058150	CACNA1I	-0.49	-6.42	-0.39	7.52e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg11608241	chr8:8085544	FLJ10661	0.43	5.17	0.32	4.96e-7	Systolic blood pressure;
SARC	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg11211951	chr8:145729740	GPT	-0.43	-6.17	-0.37	3.06e-9	Age at first birth;
SARC	cis	rs6665290	0.904	rs6684821	chr1:227190233	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.09	-25.26	-0.86	1.16e-68	Myeloid white cell count;
SARC	cis	rs6594499	0.500	rs10491424	chr5:110453806	T/C	cg04022379	chr5:110408740	TSLP	0.58	7.81	0.46	1.93e-13	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs554111	0.660	rs667687	chr1:21072577	A/G	cg04902671	chr1:21058625	SH2D5	-0.5	-6.15	-0.37	3.42e-9	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg02487422	chr3:49467188	NICN1	0.52	6.94	0.41	3.82e-11	Resting heart rate;
SARC	cis	rs453301	0.686	rs10217044	chr8:8894752	A/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-8.2	-0.47	1.57e-14	Joint mobility (Beighton score);
SARC	cis	rs12956009	0.583	rs9653018	chr18:44895853	A/G	cg15049968	chr18:44337910	ST8SIA5	-0.31	-4.74	-0.3	3.67e-6	Educational attainment (years of education);
SARC	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg18252515	chr7:66147081	NA	0.54	5.71	0.35	3.39e-8	Aortic root size;
SARC	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.39	-4.8	-0.3	2.83e-6	Lymphocyte counts;
SARC	cis	rs611744	0.905	rs610891	chr8:109161003	C/T	cg21045802	chr8:109455806	TTC35	-0.43	-4.95	-0.31	1.44e-6	Dupuytren's disease;
SARC	cis	rs6908034	0.607	rs74573060	chr6:19806032	T/A	cg02682789	chr6:19804855	NA	0.72	5.45	0.34	1.31e-7	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs4460629	0.521	rs7367897	chr1:155083289	A/T	cg22049894	chr1:155113146	DPM3	0.42	5.39	0.33	1.76e-7	Serum magnesium levels;
SARC	cis	rs9875589	0.957	rs1579551	chr3:13945571	C/G	cg19554555	chr3:13937349	NA	-0.52	-6.77	-0.41	1.02e-10	Ovarian reserve;
SARC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg13272280	chr6:74019653	C6orf147	0.5	6.85	0.41	6.49e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs13191362	0.935	rs34035978	chr6:163165336	G/C	cg18825119	chr6:163149453	PACRG;PARK2	0.36	4.74	0.3	3.68e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs10754283	0.934	rs10493829	chr1:90117833	T/C	cg21401794	chr1:90099060	LRRC8C	0.59	8.18	0.47	1.83e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs34375054	0.672	rs58416336	chr12:125606428	G/T	cg25124228	chr12:125621409	AACS	-0.56	-6.96	-0.41	3.51e-11	Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs16976116	0.901	rs2899581	chr15:55491643	T/C	cg11288833	chr15:55489084	RSL24D1	0.63	6.09	0.37	4.66e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg03517284	chr6:25882590	NA	-0.55	-7.2	-0.43	8.32e-12	Intelligence (multi-trait analysis);
SARC	cis	rs748404	0.697	rs564946	chr15:43556272	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.41	5.09	0.32	7.44e-7	Lung cancer;
SARC	trans	rs11250098	0.503	rs13270870	chr8:10770782	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.42	-0.39	7.62e-10	Morning vs. evening chronotype;
SARC	cis	rs11155671	0.530	rs1334510	chr6:150201179	A/G	cg09699651	chr6:150184138	LRP11	0.54	6.69	0.4	1.67e-10	Testicular germ cell tumor;
SARC	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.62	7.53	0.44	1.08e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1580019	0.922	rs1466147	chr7:32486262	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.8	11.31	0.6	6.22e-24	Cognitive ability;
SARC	cis	rs12478296	1.000	rs11899408	chr2:243014630	A/G	cg06360820	chr2:242988706	NA	-0.55	-5.06	-0.31	8.62e-7	Obesity-related traits;
SARC	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs8002861	0.870	rs4942254	chr13:44451820	C/T	cg17145862	chr1:211918768	LPGAT1	0.51	8.0	0.46	5.81e-14	Leprosy;
SARC	cis	rs6484504	0.532	rs11031332	chr11:31278962	T/C	cg02090638	chr11:31391270	DNAJC24;DCDC1	-0.43	-5.39	-0.33	1.72e-7	Red blood cell count;
SARC	cis	rs7833986	0.501	rs2953909	chr8:56968200	T/C	cg26371346	chr8:56986568	SNORD54;RPS20	0.72	7.24	0.43	6.48e-12	Height;
SARC	cis	rs7312774	0.609	rs2374656	chr12:107380411	A/C	cg16260113	chr12:107380972	MTERFD3	1.19	8.32	0.48	7.26e-15	Severe influenza A (H1N1) infection;
SARC	cis	rs709400	0.663	rs62007683	chr14:103894071	G/T	cg12935359	chr14:103987150	CKB	-0.4	-5.88	-0.36	1.4e-8	Body mass index;
SARC	cis	rs1355223	0.872	rs7112608	chr11:34699269	G/T	cg18508148	chr11:34937573	PDHX;APIP	-0.41	-5.19	-0.32	4.55e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs7937682	0.681	rs2156580	chr11:111394328	C/G	cg09085632	chr11:111637200	PPP2R1B	0.46	5.74	0.35	2.88e-8	Primary sclerosing cholangitis;
SARC	cis	rs4073582	1.000	rs4073582	chr11:66050712	G/A	cg14036092	chr11:66035641	RAB1B	0.54	6.48	0.39	5.45e-10	Gout;
SARC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg09373136	chr17:61933544	TCAM1	0.48	6.7	0.4	1.56e-10	Prudent dietary pattern;
SARC	cis	rs2439831	0.850	rs3742982	chr15:44176681	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	7.79	0.45	2.24e-13	Lung cancer in ever smokers;
SARC	cis	rs11697848	1.000	rs117900399	chr20:48511139	A/G	cg17849948	chr20:48532315	SPATA2	0.86	5.17	0.32	4.97e-7	Systemic lupus erythematosus;
SARC	trans	rs11098499	0.954	rs56270433	chr4:120406030	C/T	cg25214090	chr10:38739885	LOC399744	0.57	7.33	0.43	3.83e-12	Corneal astigmatism;
SARC	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg11987759	chr7:65425863	GUSB	-0.47	-6.27	-0.38	1.7e-9	Aortic root size;
SARC	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6964587	1.000	rs7785971	chr7:91736794	T/A	cg17063962	chr7:91808500	NA	0.96	16.59	0.74	2.42e-41	Breast cancer;
SARC	cis	rs8072100	0.840	rs9895746	chr17:45479099	C/A	cg08085267	chr17:45401833	C17orf57	-0.42	-5.02	-0.31	1.05e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	trans	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.69	-9.64	-0.53	1.03e-18	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9393692	0.645	rs28446029	chr6:26305801	C/G	cg13736514	chr6:26305472	NA	-0.71	-9.21	-0.52	2e-17	Educational attainment;
SARC	cis	rs3768617	0.510	rs6691755	chr1:183099821	G/A	cg13390022	chr1:182993471	LAMC1	0.31	4.79	0.3	3.01e-6	Fuchs's corneal dystrophy;
SARC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg16132339	chr22:24313637	DDTL;DDT	-0.36	-4.78	-0.3	3.09e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7555523	0.779	rs6662839	chr1:165722646	T/G	cg24409356	chr1:165738333	TMCO1	0.8	6.67	0.4	1.88e-10	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	cis	rs35213789	0.878	rs12698841	chr7:69530248	A/T	cg10619644	chr7:69149951	AUTS2	0.41	5.09	0.32	7.28e-7	Childhood ear infection;
SARC	cis	rs6665290	0.669	rs3768421	chr1:227177193	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.01	-19.96	-0.79	2.35e-52	Myeloid white cell count;
SARC	cis	rs1401999	0.606	rs939335	chr3:183745663	A/G	cg01324343	chr3:183735012	ABCC5	0.57	10.82	0.58	2.35e-22	Anterior chamber depth;
SARC	cis	rs6691722	0.506	rs12030365	chr1:24739220	T/A	cg18323236	chr1:24743029	NIPAL3	0.36	4.96	0.31	1.39e-6	Response to interferon beta in multiple sclerosis;
SARC	cis	rs1395	0.710	rs1992291	chr2:27504312	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.35	-4.97	-0.31	1.3e-6	Blood metabolite levels;
SARC	cis	rs7592578	0.713	rs60915953	chr2:191331304	G/C	cg25963032	chr2:191064776	C2orf88	-0.46	-4.86	-0.3	2.17e-6	Diastolic blood pressure;
SARC	cis	rs2273669	0.667	rs79285264	chr6:109318279	G/T	cg05315195	chr6:109294784	ARMC2	-0.58	-5.17	-0.32	5.02e-7	Prostate cancer;
SARC	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg02951883	chr7:2050386	MAD1L1	-0.42	-5.48	-0.34	1.08e-7	Schizophrenia;
SARC	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg00149659	chr3:10157352	C3orf10	0.64	6.01	0.37	7.21e-9	Alzheimer's disease;
SARC	trans	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg06636001	chr8:8085503	FLJ10661	0.58	7.48	0.44	1.53e-12	Retinal vascular caliber;
SARC	cis	rs12079745	0.826	rs3766045	chr1:169098275	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.68	-4.82	-0.3	2.62e-6	QT interval;
SARC	cis	rs35146811	0.520	rs1015538	chr7:99626035	A/G	cg22004693	chr7:99632812	ZKSCAN1	0.49	5.68	0.35	3.96e-8	Coronary artery disease;
SARC	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg18876405	chr7:65276391	NA	-0.43	-5.3	-0.33	2.69e-7	Aortic root size;
SARC	cis	rs9916302	0.851	rs11870631	chr17:37645129	C/T	cg20243544	chr17:37824526	PNMT	0.56	6.58	0.4	3.13e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs12586317	0.547	rs4982234	chr14:35460106	T/A	cg16230307	chr14:35515116	FAM177A1	1.02	11.85	0.61	1.18e-25	Psoriasis;
SARC	trans	rs61931739	0.559	rs4385974	chr12:34313128	G/C	cg26384229	chr12:38710491	ALG10B	0.63	8.38	0.48	5.01e-15	Morning vs. evening chronotype;
SARC	cis	rs17401966	0.838	rs2182326	chr1:10385664	G/A	cg15208524	chr1:10270712	KIF1B	0.47	5.65	0.35	4.77e-8	Hepatocellular carcinoma;
SARC	cis	rs372883	0.600	rs2832294	chr21:30739671	A/C	cg24692254	chr21:30365293	RNF160	0.66	8.55	0.49	1.7e-15	Pancreatic cancer;
SARC	cis	rs10791323	0.569	rs11223609	chr11:133741766	C/T	cg15485101	chr11:133734466	NA	0.32	5.26	0.33	3.21e-7	Childhood ear infection;
SARC	cis	rs765787	0.530	rs2413782	chr15:45538490	A/C	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.81e-6	Uric acid levels;
SARC	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg12042659	chr19:58951599	ZNF132	0.43	5.81	0.36	2.03e-8	Uric acid clearance;
SARC	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg11890956	chr21:40555474	PSMG1	-1.05	-15.78	-0.72	1.19e-38	Cognitive function;
SARC	cis	rs6500395	1.000	rs9937610	chr16:48671274	C/G	cg04672837	chr16:48644449	N4BP1	0.5	6.52	0.39	4.27e-10	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs1355223	1.000	rs11602909	chr11:34768003	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.51	-6.56	-0.4	3.35e-10	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs4794202	0.836	rs11079798	chr17:45936887	G/C	cg23391107	chr17:45924227	SP6	-0.52	-4.79	-0.3	3e-6	Alzheimer's disease (cognitive decline);
SARC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg07308232	chr7:1071921	C7orf50	-0.64	-7.83	-0.46	1.71e-13	Longevity;Endometriosis;
SARC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg07157834	chr1:205819609	PM20D1	0.51	7.6	0.45	6.98e-13	Menarche (age at onset);
SARC	cis	rs17376456	0.825	rs17314762	chr5:93231200	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.52	0.34	9.08e-8	Diabetic retinopathy;
SARC	cis	rs4555082	1.000	rs4334224	chr14:105759198	C/T	cg13114125	chr14:105738426	BRF1	-0.8	-11.76	-0.61	2.32e-25	Mean platelet volume;Platelet distribution width;
SARC	cis	rs733592	0.507	rs7299704	chr12:48444488	A/G	cg24011408	chr12:48396354	COL2A1	0.52	7.19	0.43	8.82e-12	Plateletcrit;
SARC	cis	rs6570726	0.846	rs973856	chr6:145781916	C/T	cg05220968	chr6:146057943	EPM2A	0.28	4.9	0.31	1.77e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg20102877	chr2:27665638	KRTCAP3	-0.38	-5.33	-0.33	2.31e-7	Menopause (age at onset);
SARC	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.33	-5.0	-0.31	1.13e-6	Total body bone mineral density;
SARC	cis	rs9309473	0.898	rs7580750	chr2:73788126	A/G	cg20560298	chr2:73613845	ALMS1	-0.46	-5.55	-0.34	7.78e-8	Metabolite levels;
SARC	cis	rs9640161	0.750	rs4395803	chr7:150025367	A/C	cg17279839	chr7:150038598	RARRES2	0.48	6.72	0.4	1.35e-10	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs6815814	0.731	rs10776483	chr4:38775040	A/G	cg06935464	chr4:38784597	TLR10	0.5	5.19	0.32	4.66e-7	Breast cancer;
SARC	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg00149659	chr3:10157352	C3orf10	0.69	6.9	0.41	4.76e-11	Alzheimer's disease;
SARC	cis	rs4887067	1	rs4887067	chr15:78886947	G/A	cg06917634	chr15:78832804	PSMA4	-0.58	-6.04	-0.37	6.18e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs6121246	0.697	rs6088857	chr20:30226764	G/C	cg13852791	chr20:30311386	BCL2L1	0.77	8.17	0.47	1.99e-14	Mean corpuscular hemoglobin;
SARC	cis	rs6121246	0.567	rs6060261	chr20:30192948	C/G	cg13852791	chr20:30311386	BCL2L1	0.68	5.91	0.36	1.2e-8	Mean corpuscular hemoglobin;
SARC	cis	rs763121	0.853	rs5995610	chr22:39064681	C/T	cg21395723	chr22:39101663	GTPBP1	0.54	6.03	0.37	6.24e-9	Menopause (age at onset);
SARC	cis	rs1957429	0.520	rs72625641	chr14:65335761	C/T	cg23373153	chr14:65346875	NA	-0.79	-5.4	-0.33	1.64e-7	Pediatric areal bone mineral density (radius);
SARC	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg12463550	chr7:65579703	CRCP	-0.5	-5.56	-0.34	7.28e-8	Aortic root size;
SARC	cis	rs751728	0.931	rs2296746	chr6:33744711	C/T	cg25922239	chr6:33757077	LEMD2	0.79	10.41	0.56	4.24e-21	Crohn's disease;
SARC	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg23248424	chr5:179741104	GFPT2	-0.48	-5.86	-0.36	1.59e-8	Height;
SARC	cis	rs7624766	0.743	rs12486979	chr3:160483785	A/C	cg22637730	chr3:160473554	PPM1L	0.43	5.66	0.35	4.47e-8	Response to methotrexate in rheumatoid arthritis;
SARC	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.68	6.53	0.39	4.02e-10	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs1035144	0.506	rs7150858	chr14:81280425	T/C	cg06600135	chr14:81408086	NA	-0.44	-4.99	-0.31	1.17e-6	Male sexual orientation;
SARC	cis	rs4803468	1.000	rs4803468	chr19:41922352	A/G	cg08477640	chr19:41863820	B9D2	0.46	5.88	0.36	1.43e-8	Height;
SARC	cis	rs17345786	0.911	rs10936707	chr3:101324063	G/A	cg12386194	chr3:101231763	SENP7	0.72	8.53	0.49	1.82e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg04944784	chr2:26401820	FAM59B	0.57	7.6	0.45	7.08e-13	Gut microbiome composition (summer);
SARC	cis	rs7927592	0.871	rs871212	chr11:68348695	T/A	cg01657329	chr11:68192670	LRP5	-0.4	-4.87	-0.3	2.02e-6	Total body bone mineral density;
SARC	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg06634786	chr22:41940651	POLR3H	-0.58	-6.85	-0.41	6.41e-11	Vitiligo;
SARC	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg03185022	chr7:2884158	GNA12	0.46	5.1	0.32	6.93e-7	Height;
SARC	trans	rs61931739	0.513	rs2200555	chr12:33899381	C/G	cg26384229	chr12:38710491	ALG10B	0.69	9.44	0.53	4.15e-18	Morning vs. evening chronotype;
SARC	cis	rs2952156	0.684	rs931992	chr17:37821435	G/T	cg00129232	chr17:37814104	STARD3	-0.8	-11.95	-0.62	5.45e-26	Asthma;
SARC	cis	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg01579765	chr21:45077557	HSF2BP	-0.37	-6.3	-0.38	1.46e-9	Mean corpuscular volume;
SARC	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg11890956	chr21:40555474	PSMG1	-0.7	-9.08	-0.51	4.71e-17	Menarche (age at onset);
SARC	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg07701084	chr6:150067640	NUP43	0.39	5.26	0.33	3.19e-7	Lung cancer;
SARC	cis	rs6430585	0.528	rs309120	chr2:136708787	G/C	cg07169764	chr2:136633963	MCM6	0.93	12.29	0.63	4.26e-27	Corneal structure;
SARC	cis	rs3126085	0.935	rs1552993	chr1:152171483	A/G	cg26876637	chr1:152193138	HRNR	0.47	5.33	0.33	2.33e-7	Atopic dermatitis;
SARC	cis	rs6964587	0.692	rs10227225	chr7:91571074	A/G	cg17063962	chr7:91808500	NA	-0.81	-11.92	-0.62	7.07e-26	Breast cancer;
SARC	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg03806693	chr22:41940476	POLR3H	-0.83	-11.7	-0.61	3.44e-25	Vitiligo;
SARC	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg19748678	chr4:122722346	EXOSC9	0.78	9.79	0.54	3.6e-19	Type 2 diabetes;
SARC	cis	rs9486715	0.830	rs2255552	chr6:96999643	A/G	cg18709589	chr6:96969512	KIAA0776	-0.62	-7.87	-0.46	1.37e-13	Headache;
SARC	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg15556689	chr8:8085844	FLJ10661	0.61	7.71	0.45	3.59e-13	Neuroticism;
SARC	trans	rs6934651	0.529	rs59211371	chr6:85933194	G/C	cg04848555	chr14:53975804	NA	0.65	6.33	0.38	1.25e-9	Breast cancer;
SARC	cis	rs751728	0.687	rs943471	chr6:33738314	C/T	cg15252951	chr6:33757062	LEMD2	0.42	5.01	0.31	1.09e-6	Crohn's disease;
SARC	cis	rs4853036	0.586	rs7559354	chr2:70019868	C/G	cg02498382	chr2:70120550	SNRNP27	-0.35	-4.72	-0.3	4.05e-6	Colorectal or endometrial cancer;
SARC	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.63	7.51	0.44	1.28e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs12140703	0.510	rs1572993	chr1:205045087	G/A	cg21643547	chr1:205240462	TMCC2	0.49	6.67	0.4	1.84e-10	Reticulocyte count;
SARC	cis	rs643506	1.000	rs4936675	chr11:111623088	T/A	cg09085632	chr11:111637200	PPP2R1B	0.51	5.71	0.35	3.37e-8	Breast cancer;
SARC	cis	rs13082711	0.911	rs34316374	chr3:27437385	G/C	cg02860705	chr3:27208620	NA	0.47	6.19	0.38	2.7e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	trans	rs11250098	0.548	rs7837038	chr8:10783074	G/A	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.82	-0.41	7.64e-11	Morning vs. evening chronotype;
SARC	cis	rs17600642	0.724	rs72814537	chr10:72451659	C/G	cg19779893	chr10:72451501	ADAMTS14	-0.37	-5.77	-0.35	2.53e-8	Bipolar disorder;
SARC	cis	rs7106204	0.609	rs12790279	chr11:24286221	C/G	ch.11.24196551F	chr11:24239977	NA	0.61	5.69	0.35	3.83e-8	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs8031584	0.958	rs11293	chr15:31234981	G/A	cg19680485	chr15:31195859	MTMR15	-0.52	-6.0	-0.37	7.53e-9	Huntington's disease progression;
SARC	cis	rs8114671	0.869	rs2145559	chr20:33651725	G/A	cg24642439	chr20:33292090	TP53INP2	-0.56	-6.51	-0.39	4.62e-10	Height;
SARC	cis	rs1881797	1.000	rs10925062	chr1:247658978	G/C	cg18198730	chr1:247681584	NA	0.5	5.38	0.33	1.85e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs1371867	0.846	rs1660329	chr8:101304048	G/T	cg11906718	chr8:101322791	RNF19A	0.7	8.98	0.51	9.31e-17	Atrioventricular conduction;
SARC	cis	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg12463550	chr7:65579703	CRCP	0.68	5.21	0.32	4.1e-7	Diabetic kidney disease;
SARC	cis	rs1568889	0.877	rs12786351	chr11:28271122	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.76	8.81	0.5	2.96e-16	Bipolar disorder;
SARC	cis	rs6463523	0.815	rs66886645	chr7:763853	C/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.93	15.16	0.7	1.43e-36	Subjective well-being;
SARC	cis	rs782590	0.805	rs782578	chr2:55915904	A/C	cg18811423	chr2:55921094	PNPT1	0.78	12.0	0.62	3.92e-26	Metabolic syndrome;
SARC	cis	rs10771431	0.597	rs10843142	chr12:9357502	A/G	cg08997352	chr12:9597637	DDX12	-0.56	-7.7	-0.45	3.84e-13	Breast size;
SARC	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg12756686	chr19:29218302	NA	0.73	9.61	0.53	1.24e-18	Methadone dose in opioid dependence;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg24857238	chr12:133287306	PGAM5	0.5	6.36	0.38	1.08e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg11890956	chr21:40555474	PSMG1	-1.06	-15.63	-0.72	3.88e-38	Cognitive function;
SARC	cis	rs35955747	0.902	rs7288643	chr22:31679669	C/A	cg13145458	chr22:31556086	RNF185	0.4	4.91	0.31	1.71e-6	Neutrophil count;Sum basophil neutrophil counts;
SARC	cis	rs4888262	0.545	rs4243108	chr16:74692453	A/G	cg05580060	chr16:74700937	RFWD3	-0.39	-4.81	-0.3	2.77e-6	Testicular germ cell tumor;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg21547979	chr19:49141364	SEC1;DBP;CA11	0.5	6.39	0.39	8.77e-10	Breast cancer;
SARC	cis	rs2050392	0.517	rs589980	chr10:30756385	T/A	cg25182066	chr10:30743637	MAP3K8	0.5	7.49	0.44	1.4e-12	Inflammatory bowel disease;
SARC	trans	rs3857536	0.740	rs7745163	chr6:66889936	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.6	-7.14	-0.42	1.16e-11	Blood trace element (Cu levels);
SARC	cis	rs11155671	0.530	rs7764376	chr6:150210344	A/G	cg00933542	chr6:150070202	PCMT1	0.29	4.81	0.3	2.77e-6	Testicular germ cell tumor;
SARC	cis	rs11098499	0.954	rs9998585	chr4:120396802	T/A	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg20887711	chr4:1340912	KIAA1530	-0.69	-8.31	-0.48	7.94e-15	Longevity;
SARC	cis	rs11190604	0.943	rs9420792	chr10:102258439	C/T	cg07080220	chr10:102295463	HIF1AN	0.81	9.53	0.53	2.24e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs9393692	0.846	rs9366651	chr6:26336696	G/T	cg00631329	chr6:26305371	NA	-0.63	-9.12	-0.51	3.62e-17	Educational attainment;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg14964274	chr1:215796556	USH2A	0.44	6.59	0.4	2.87e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs910316	0.737	rs175065	chr14:75494983	T/C	cg11812906	chr14:75593930	NEK9	-0.76	-10.05	-0.55	5.81e-20	Height;
SARC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg17178900	chr1:205818956	PM20D1	-0.66	-10.31	-0.56	8.7e-21	Monocyte percentage of white cells;
SARC	cis	rs7927771	0.832	rs4752993	chr11:47410951	T/C	cg20307385	chr11:47447363	PSMC3	0.58	7.37	0.43	2.98e-12	Subjective well-being;
SARC	cis	rs7666738	0.830	rs7679961	chr4:99000202	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2204008	0.811	rs4882300	chr12:38415224	A/T	cg14851346	chr12:38532713	NA	-0.4	-4.88	-0.3	1.94e-6	Bladder cancer;
SARC	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-7.06	-0.42	1.89e-11	Personality dimensions;
SARC	cis	rs72781680	1.000	rs72796357	chr2:24160131	A/G	cg08917208	chr2:24149416	ATAD2B	0.77	7.15	0.42	1.12e-11	Lymphocyte counts;
SARC	cis	rs11574514	0.744	rs117539386	chr16:67916047	C/G	cg01866162	chr16:67596514	CTCF	1.11	6.4	0.39	8.22e-10	Crohn's disease;
SARC	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg06028808	chr11:68637592	NA	0.45	5.76	0.35	2.66e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs2439831	0.867	rs2470134	chr15:43849886	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.93	-8.16	-0.47	2.06e-14	Lung cancer in ever smokers;
SARC	cis	rs2303759	0.914	rs2288481	chr19:49878196	G/A	cg24324837	chr19:49891574	CCDC155	0.45	4.94	0.31	1.49e-6	Multiple sclerosis;
SARC	cis	rs9457247	0.967	rs2149084	chr6:167370988	G/C	cg07741184	chr6:167504864	NA	-0.29	-5.4	-0.33	1.63e-7	Crohn's disease;
SARC	cis	rs2898681	0.519	rs3811781	chr4:53729166	T/G	cg00338735	chr4:53728038	RASL11B	0.49	5.49	0.34	1.06e-7	Optic nerve measurement (cup area);
SARC	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg05861140	chr6:150128134	PCMT1	-0.41	-5.41	-0.33	1.53e-7	Lung cancer;
SARC	cis	rs1878931	0.582	rs4785933	chr16:3419741	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.68	7.72	0.45	3.36e-13	Body mass index (adult);
SARC	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg05313129	chr8:58192883	C8orf71	-0.57	-6.56	-0.39	3.39e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9815354	1.000	rs7624372	chr3:41881107	T/A	cg03022575	chr3:42003672	ULK4	0.55	5.22	0.32	3.95e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.79	9.99	0.55	8.71e-20	Prudent dietary pattern;
SARC	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.99	11.36	0.6	4.27e-24	Platelet count;
SARC	cis	rs72781680	0.752	rs72780185	chr2:24003967	G/A	cg06627628	chr2:24431161	ITSN2	-0.66	-6.26	-0.38	1.83e-9	Lymphocyte counts;
SARC	cis	rs11112613	0.713	rs73184084	chr12:105952615	T/A	cg03607813	chr12:105948248	NA	0.54	7.74	0.45	3.01e-13	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs4927850	0.794	rs13070153	chr3:195741185	A/T	cg01181863	chr3:195395398	SDHAP2	-0.82	-9.19	-0.52	2.29e-17	Pancreatic cancer;
SARC	cis	rs9309473	0.607	rs10198301	chr2:73581600	T/A	cg20560298	chr2:73613845	ALMS1	-0.59	-7.42	-0.44	2.2e-12	Metabolite levels;
SARC	cis	rs9815354	1.000	rs73079316	chr3:41863859	G/A	cg03022575	chr3:42003672	ULK4	0.62	5.43	0.34	1.39e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs17376456	0.757	rs6859757	chr5:93206042	C/T	cg21475434	chr5:93447410	FAM172A	0.79	6.7	0.4	1.59e-10	Diabetic retinopathy;
SARC	trans	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg27662379	chr3:128369753	RPN1	-0.67	-6.27	-0.38	1.69e-9	Cutaneous psoriasis;
SARC	cis	rs17376456	0.877	rs10476601	chr5:93402522	G/A	cg25358565	chr5:93447407	FAM172A	1.3	14.56	0.69	1.43e-34	Diabetic retinopathy;
SARC	cis	rs2153535	0.580	rs9328483	chr6:8521295	A/G	cg07606381	chr6:8435919	SLC35B3	0.76	11.08	0.59	3.38e-23	Motion sickness;
SARC	cis	rs7746199	0.736	rs6904596	chr6:27491299	G/A	cg12826209	chr6:26865740	GUSBL1	0.82	5.0	0.31	1.12e-6	Gait speed in old age;Autism spectrum disorder or schizophrenia;
SARC	cis	rs7592578	0.537	rs62180982	chr2:191264485	G/T	cg25963032	chr2:191064776	C2orf88	-0.48	-5.4	-0.33	1.64e-7	Diastolic blood pressure;
SARC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg02353165	chr6:42928485	GNMT	0.59	8.18	0.47	1.79e-14	Alzheimer's disease in APOE e4+ carriers;
SARC	trans	rs3808502	0.526	rs1042701	chr8:11422045	G/A	cg08975724	chr8:8085496	FLJ10661	-0.48	-6.26	-0.38	1.84e-9	Neuroticism;
SARC	cis	rs12586317	0.620	rs2295104	chr14:35579927	A/G	cg26967526	chr14:35346199	BAZ1A	0.64	6.35	0.38	1.13e-9	Psoriasis;
SARC	cis	rs7412746	0.611	rs2256355	chr1:150811794	A/G	cg10589385	chr1:150898437	SETDB1	0.41	5.47	0.34	1.18e-7	Melanoma;
SARC	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg22857025	chr5:266934	NA	-1.05	-11.9	-0.61	7.87e-26	Breast cancer;
SARC	cis	rs7605378	0.528	rs281767	chr2:200823281	C/A	cg23649088	chr2:200775458	C2orf69	0.78	11.42	0.6	2.78e-24	Osteoporosis;
SARC	cis	rs10782582	0.609	rs5745485	chr1:76349534	C/G	cg03433033	chr1:76189801	ACADM	-0.39	-5.03	-0.31	1e-6	Daytime sleep phenotypes;
SARC	cis	rs9399135	0.967	rs1590975	chr6:135352088	C/T	cg24558204	chr6:135376177	HBS1L	0.46	6.19	0.38	2.67e-9	Red blood cell count;
SARC	cis	rs875971	0.545	rs1796226	chr7:66087710	C/T	cg11764359	chr7:65958608	NA	0.63	6.33	0.38	1.22e-9	Aortic root size;
SARC	cis	rs1865760	0.827	rs9295680	chr6:25944103	T/C	cg10373733	chr6:25993375	NA	0.39	4.76	0.3	3.34e-6	Height;
SARC	trans	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.53	-6.93	-0.41	3.99e-11	Intelligence (multi-trait analysis);
SARC	cis	rs910316	1.000	rs12589876	chr14:75544189	G/A	cg08847533	chr14:75593920	NEK9	0.94	15.68	0.72	2.68e-38	Height;
SARC	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg12000995	chr2:27665139	KRTCAP3	-0.31	-4.92	-0.31	1.62e-6	Total body bone mineral density;
SARC	cis	rs114858855	1.000	rs9398205	chr6:109864951	C/T	cg26835506	chr6:109038353	NA	-0.61	-4.98	-0.31	1.26e-6	Plasma trimethylamine N-oxide levels;
SARC	cis	rs1949733	1.000	rs1916326	chr4:8500023	G/A	cg11789530	chr4:8429930	ACOX3	-0.83	-11.23	-0.59	1.15e-23	Response to antineoplastic agents;
SARC	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg18252515	chr7:66147081	NA	0.45	4.8	0.3	2.84e-6	Aortic root size;
SARC	cis	rs6964587	1.000	rs28735847	chr7:91592755	T/C	cg17063962	chr7:91808500	NA	0.95	15.95	0.72	3.15e-39	Breast cancer;
SARC	cis	rs12497850	0.863	rs4974084	chr3:48939080	G/A	cg03060546	chr3:49711283	APEH	0.43	5.29	0.33	2.85e-7	Parkinson's disease;
SARC	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg12463550	chr7:65579703	CRCP	0.5	5.43	0.33	1.45e-7	Aortic root size;
SARC	cis	rs4481887	0.861	rs10788776	chr1:248479177	T/C	cg00666640	chr1:248458726	OR2T12	0.35	5.8	0.36	2.16e-8	Common traits (Other);
SARC	cis	rs5762813	0.524	rs5752815	chr22:29230733	C/A	cg02153584	chr22:29168773	CCDC117	0.67	7.31	0.43	4.18e-12	Hematocrit;Hemoglobin concentration;
SARC	cis	rs17401966	0.838	rs34565762	chr1:10300119	T/C	cg15208524	chr1:10270712	KIF1B	0.47	5.42	0.33	1.5e-7	Hepatocellular carcinoma;
SARC	cis	rs8141529	0.600	rs16986825	chr22:29300306	C/T	cg15103426	chr22:29168792	CCDC117	0.62	6.34	0.38	1.21e-9	Lymphocyte counts;
SARC	cis	rs10979	1.000	rs6570566	chr6:143899534	G/A	cg25407410	chr6:143891975	LOC285740	-0.62	-8.37	-0.48	5.21e-15	Hypospadias;
SARC	cis	rs72945132	0.678	rs7113595	chr11:70236819	T/C	cg05964544	chr11:70165517	PPFIA1	-0.66	-6.7	-0.4	1.55e-10	Coronary artery disease;
SARC	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg26681399	chr22:41777847	TEF	0.43	4.89	0.3	1.92e-6	Vitiligo;
SARC	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg02951883	chr7:2050386	MAD1L1	-0.42	-5.44	-0.34	1.32e-7	Bipolar disorder and schizophrenia;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg16635874	chr2:181884064	UBE2E3	0.5	7.04	0.42	2.19e-11	Thyroid stimulating hormone;
SARC	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg18370025	chr7:2749541	AMZ1	-0.29	-4.73	-0.3	3.85e-6	Height;
SARC	cis	rs876084	0.505	rs7840588	chr8:121108256	G/T	cg06265175	chr8:121136014	COL14A1	0.58	7.56	0.44	9.46e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs3796352	1.000	rs11713206	chr3:52999243	A/G	cg07884673	chr3:53033167	SFMBT1	0.84	5.07	0.32	8.02e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs3087591	0.960	rs757384	chr17:29596135	C/T	cg24425628	chr17:29625626	OMG;NF1	0.54	6.72	0.4	1.41e-10	Hip circumference;
SARC	cis	rs2070488	0.560	rs1381798	chr3:38437471	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.56	-6.64	-0.4	2.16e-10	Electrocardiographic conduction measures;
SARC	cis	rs9457247	1.000	rs407515	chr6:167407544	G/C	cg07741184	chr6:167504864	NA	0.3	5.6	0.34	5.91e-8	Crohn's disease;
SARC	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg22535103	chr8:58192502	C8orf71	-0.73	-7.31	-0.43	4.37e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs8067545	0.750	rs11867585	chr17:19992607	A/G	cg13482628	chr17:19912719	NA	0.53	7.11	0.42	1.39e-11	Schizophrenia;
SARC	cis	rs6089584	0.927	rs2281734	chr20:60582401	C/A	cg13770153	chr20:60521292	NA	-0.52	-7.4	-0.44	2.47e-12	Body mass index;
SARC	cis	rs7568458	0.837	rs12714145	chr2:85787341	C/T	cg17127132	chr2:85788382	GGCX	0.41	5.24	0.32	3.62e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs644799	0.625	rs1255175	chr11:95471186	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	6.2	0.38	2.59e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs8141529	0.529	rs36112964	chr22:29178130	T/C	cg02153584	chr22:29168773	CCDC117	0.65	6.65	0.4	2.02e-10	Lymphocyte counts;
SARC	cis	rs7681440	0.904	rs28777703	chr4:90769924	A/G	cg02192967	chr4:90758406	SNCA	-0.35	-4.88	-0.3	1.96e-6	Dementia with Lewy bodies;
SARC	cis	rs12600121	0.600	rs9925967	chr16:72024846	C/T	cg01557791	chr16:72042693	DHODH	0.42	5.35	0.33	2.14e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2273669	0.667	rs17070139	chr6:109358345	C/G	cg05315195	chr6:109294784	ARMC2	-0.64	-5.7	-0.35	3.68e-8	Prostate cancer;
SARC	cis	rs1153858	1.000	rs2114501	chr15:45670316	G/A	cg26924012	chr15:45694286	SPATA5L1	0.79	11.22	0.59	1.22e-23	Homoarginine levels;
SARC	cis	rs9761603	0.812	rs9685314	chr4:138411620	C/T	cg12033966	chr4:138453416	PCDH18	0.55	7.29	0.43	4.88e-12	Diastolic blood pressure;
SARC	cis	rs4481887	0.927	rs7534188	chr1:248434303	C/T	cg00666640	chr1:248458726	OR2T12	-0.33	-5.4	-0.33	1.67e-7	Common traits (Other);
SARC	cis	rs75804782	0.641	rs3769123	chr2:239349328	C/G	cg21699342	chr2:239360505	ASB1	-0.58	-4.81	-0.3	2.68e-6	Morning vs. evening chronotype;Chronotype;
SARC	cis	rs748404	0.697	rs498227	chr15:43573052	A/G	cg12308275	chr15:43558855	TGM5	-0.4	-4.86	-0.3	2.14e-6	Lung cancer;
SARC	cis	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg24110177	chr3:50126178	RBM5	-0.63	-8.28	-0.48	9.53e-15	Body mass index;
SARC	cis	rs9309711	0.666	rs6723126	chr2:3484500	T/C	cg08493051	chr2:3487164	NA	-0.4	-5.06	-0.31	8.4e-7	Neurofibrillary tangles;
SARC	cis	rs9329289	0.603	rs2458698	chr10:2548452	C/T	cg15501526	chr10:2543763	NA	0.52	7.62	0.45	6.32e-13	Age-related hearing impairment;
SARC	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg04166393	chr7:2884313	GNA12	0.67	8.06	0.47	3.94e-14	Height;
SARC	trans	rs7931462	0.655	rs6483208	chr11:92705844	A/C	cg06219670	chr11:95886395	MAML2	-0.77	-6.5	-0.39	4.76e-10	DNA methylation (parent-of-origin);
SARC	cis	rs5758511	0.514	rs5751221	chr22:42516366	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.42	6.15	0.37	3.41e-9	Birth weight;
SARC	cis	rs17376456	1.000	rs34756085	chr5:93556294	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.14	0.32	5.94e-7	Diabetic retinopathy;
SARC	cis	rs10875746	0.903	rs4760681	chr12:48505230	C/T	cg26205652	chr12:48591994	NA	0.56	6.21	0.38	2.45e-9	Longevity (90 years and older);
SARC	cis	rs9660992	0.710	rs1668869	chr1:205239779	G/C	cg07972983	chr1:205091412	RBBP5	0.56	6.69	0.4	1.6e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg18876405	chr7:65276391	NA	0.45	5.13	0.32	6.07e-7	Aortic root size;
SARC	cis	rs651907	0.535	rs4342086	chr3:101503765	G/A	cg12386194	chr3:101231763	SENP7	0.51	5.94	0.36	1.04e-8	Colorectal cancer;
SARC	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.57	-7.43	-0.44	2.1e-12	Mean platelet volume;
SARC	cis	rs4595586	0.545	rs7967931	chr12:39375162	A/C	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg24642844	chr7:1081250	C7orf50	-0.59	-6.23	-0.38	2.16e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs34779708	0.931	rs9663401	chr10:35278849	G/T	cg03585969	chr10:35415529	CREM	0.41	5.03	0.31	9.77e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg01577475	chr2:114033581	PAX8;LOC440839	-0.34	-5.12	-0.32	6.44e-7	Lymphocyte counts;
SARC	trans	rs208520	0.661	rs6937856	chr6:66867468	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-14.2	-0.68	2.26e-33	Exhaled nitric oxide output;
SARC	cis	rs10504229	0.679	rs11783557	chr8:58030644	A/G	cg20607798	chr8:58055168	NA	0.55	5.1	0.32	7.12e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg22857025	chr5:266934	NA	-1.06	-11.8	-0.61	1.74e-25	Breast cancer;
SARC	cis	rs2011503	0.941	rs11555053	chr19:19390185	G/A	cg03709012	chr19:19516395	GATAD2A	0.59	5.29	0.33	2.85e-7	Bipolar disorder;
SARC	trans	rs3780486	0.505	rs1411609	chr9:33137303	C/T	cg04842962	chr6:43655489	MRPS18A	0.88	12.51	0.63	8.3e-28	IgG glycosylation;
SARC	cis	rs734999	0.566	rs4648563	chr1:2536002	C/G	cg20673091	chr1:2541236	MMEL1	0.34	5.25	0.33	3.46e-7	Ulcerative colitis;
SARC	cis	rs892961	1.000	rs2117924	chr17:75401310	C/T	cg05865280	chr17:75406074	SEPT9	0.51	7.3	0.43	4.46e-12	Airflow obstruction;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03375579	chr4:174293063	SAP30	-0.51	-6.68	-0.4	1.76e-10	Smoking initiation;
SARC	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg08219700	chr8:58056026	NA	0.65	6.14	0.37	3.57e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg15145296	chr3:125709740	NA	0.53	5.39	0.33	1.72e-7	Blood pressure (smoking interaction);
SARC	cis	rs6964587	0.967	rs10246036	chr7:91558523	G/A	cg17063962	chr7:91808500	NA	-0.93	-14.77	-0.7	2.86e-35	Breast cancer;
SARC	trans	rs7395662	0.611	rs7478698	chr11:48549139	T/C	cg15704280	chr7:45808275	SEPT13	-0.49	-6.6	-0.4	2.81e-10	HDL cholesterol;
SARC	cis	rs3771570	1.000	rs62193202	chr2:242303717	G/A	cg21155796	chr2:242212141	HDLBP	0.68	6.1	0.37	4.3e-9	Prostate cancer;
SARC	cis	rs7937682	0.640	rs587010	chr11:111425658	C/A	cg22437258	chr11:111473054	SIK2	0.56	7.34	0.43	3.54e-12	Primary sclerosing cholangitis;
SARC	cis	rs67460515	0.563	rs16831886	chr3:160799830	A/C	cg03342759	chr3:160939853	NMD3	-0.68	-7.86	-0.46	1.4e-13	Parkinson's disease;
SARC	trans	rs7815944	1.000	rs6651251	chr8:129422806	T/C	cg17342469	chr22:46473074	NA	0.71	6.7	0.4	1.58e-10	Atopic dermatitis;
SARC	cis	rs79149102	0.579	rs76518150	chr15:75292721	C/G	cg17294928	chr15:75287854	SCAMP5	-1.05	-9.01	-0.51	7.57e-17	Lung cancer;
SARC	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg11890956	chr21:40555474	PSMG1	-1.15	-18.63	-0.77	4.64e-48	Cognitive function;
SARC	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg20607798	chr8:58055168	NA	0.66	5.15	0.32	5.52e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9322817	0.653	rs9486002	chr6:105162823	A/G	cg02098413	chr6:105308735	HACE1	-0.39	-6.16	-0.37	3.11e-9	Thyroid stimulating hormone;
SARC	cis	rs13096760	1	rs13096760	chr3:49476806	T/C	cg06212747	chr3:49208901	KLHDC8B	0.51	6.45	0.39	6.22e-10	Intelligence (multi-trait analysis);
SARC	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.43	-5.38	-0.33	1.82e-7	Lymphocyte counts;
SARC	cis	rs2380220	0.541	rs9285413	chr6:96023439	G/A	cg15832292	chr6:96025679	MANEA	0.53	5.59	0.34	6.45e-8	Behavioural disinhibition (generation interaction);
SARC	trans	rs7819412	0.595	rs10106914	chr8:10987651	T/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.82	-0.46	1.8e-13	Triglycerides;
SARC	cis	rs2408955	0.522	rs4760612	chr12:48421856	C/T	cg24011408	chr12:48396354	COL2A1	-0.43	-5.07	-0.32	8.13e-7	Glycated hemoglobin levels;
SARC	cis	rs2370759	0.945	rs74625866	chr10:32597618	A/T	cg05361325	chr10:32636312	EPC1	-0.72	-6.3	-0.38	1.47e-9	Sexual dysfunction (female);
SARC	cis	rs738321	0.671	rs3761446	chr22:38595483	G/A	cg25457927	chr22:38595422	NA	-0.31	-5.55	-0.34	7.58e-8	Breast cancer;
SARC	cis	rs921968	0.519	rs62191659	chr2:219630510	C/T	cg02176678	chr2:219576539	TTLL4	-0.33	-5.03	-0.31	9.92e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs3820928	1.000	rs2163041	chr2:227772480	T/C	cg11843606	chr2:227700838	RHBDD1	-0.54	-6.81	-0.41	8.13e-11	Pulmonary function;
SARC	cis	rs668210	0.793	rs522553	chr11:65771669	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	5.37	0.33	1.87e-7	Cerebrospinal fluid biomarker levels;
SARC	cis	rs909674	0.818	rs5757680	chr22:39844793	C/T	cg05872129	chr22:39784769	NA	0.42	5.73	0.35	3.08e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs4917300	0.657	rs6996685	chr8:143071894	C/A	cg06573787	chr8:143070187	NA	0.37	5.53	0.34	8.42e-8	Amyotrophic lateral sclerosis;
SARC	cis	rs8180040	0.676	rs7636252	chr3:47013542	T/G	cg02527881	chr3:46936655	PTH1R	-0.31	-4.78	-0.3	3.07e-6	Colorectal cancer;
SARC	cis	rs7666738	0.830	rs4699584	chr4:98952019	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10089	1.000	rs17164310	chr5:127493679	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	8.91	0.5	1.49e-16	Ileal carcinoids;
SARC	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg08219700	chr8:58056026	NA	0.47	4.87	0.3	2.04e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs9814567	0.752	rs4306899	chr3:134334513	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.5	6.2	0.38	2.48e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs12291225	0.585	rs10832246	chr11:14380828	G/A	cg19336497	chr11:14380999	RRAS2	-0.46	-8.17	-0.47	1.96e-14	Sense of smell;
SARC	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg03806693	chr22:41940476	POLR3H	0.93	13.19	0.65	4.83e-30	Vitiligo;
SARC	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg00101154	chr16:420108	MRPL28	-0.61	-10.57	-0.57	1.35e-21	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs10779751	0.770	rs1057079	chr1:11205058	A/G	cg08854313	chr1:11322531	MTOR	-0.87	-12.64	-0.64	2.99e-28	Body mass index;
SARC	cis	rs13191362	1.000	rs13220048	chr6:163004325	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.49	0.34	1.04e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	trans	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg17712092	chr4:129076599	LARP1B	0.69	9.39	0.52	5.6e-18	Eosinophil percentage of white cells;
SARC	cis	rs6493487	0.512	rs7175024	chr15:51257790	A/G	cg02338191	chr15:51200825	AP4E1	0.54	4.98	0.31	1.26e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs1355223	0.583	rs2941058	chr11:34880245	C/G	cg11058730	chr11:34937778	PDHX;APIP	0.77	10.43	0.56	3.7e-21	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs9868809	0.505	rs9811027	chr3:48725014	G/C	cg00383909	chr3:49044727	WDR6	0.66	6.21	0.38	2.46e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg08859206	chr1:53392774	SCP2	0.41	5.92	0.36	1.12e-8	Monocyte count;
SARC	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg15049968	chr18:44337910	ST8SIA5	-0.32	-5.03	-0.31	9.65e-7	Personality dimensions;
SARC	cis	rs73086581	0.947	rs11906612	chr20:3903634	C/T	cg02187196	chr20:3869020	PANK2	0.67	5.96	0.36	9.02e-9	Response to antidepressants in depression;
SARC	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg19223190	chr17:80058835	NA	0.44	6.19	0.38	2.67e-9	Life satisfaction;
SARC	cis	rs4319547	0.656	rs7294559	chr12:122837564	C/A	cg23029597	chr12:123009494	RSRC2	-0.42	-5.41	-0.33	1.52e-7	Body mass index;
SARC	cis	rs5167	0.566	rs204905	chr19:45460764	G/A	cg09555818	chr19:45449301	APOC2	0.58	9.51	0.53	2.42e-18	Blood protein levels;
SARC	cis	rs6598955	0.670	rs6676619	chr1:26539035	T/G	cg04990556	chr1:26633338	UBXN11	-0.6	-8.41	-0.48	4.25e-15	Obesity-related traits;
SARC	cis	rs10979	1.000	rs9386036	chr6:143890709	A/G	cg25407410	chr6:143891975	LOC285740	-0.64	-8.68	-0.49	6.88e-16	Hypospadias;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg03375703	chr2:160176473	BAZ2B	0.46	6.48	0.39	5.39e-10	Thyroid stimulating hormone;
SARC	cis	rs950169	0.887	rs71395453	chr15:85113490	G/C	cg24253500	chr15:84953950	NA	0.37	5.34	0.33	2.24e-7	Schizophrenia;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg09311964	chr17:40831349	NA	-0.6	-6.46	-0.39	6.1e-10	Lung cancer in ever smokers;
SARC	cis	rs3845702	0.736	rs2367990	chr2:180843126	C/T	cg01881094	chr2:180872142	CWC22	-1.12	-9.3	-0.52	1.07e-17	Schizophrenia;
SARC	cis	rs7264396	0.676	rs1341603	chr20:34556216	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	5.3	0.33	2.71e-7	Total cholesterol levels;
SARC	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg08219700	chr8:58056026	NA	0.59	6.3	0.38	1.51e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg25894440	chr7:65020034	NA	-0.75	-5.64	-0.35	5e-8	Diabetic kidney disease;
SARC	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg27541892	chr1:1571801	CDK11B	0.41	5.57	0.34	6.93e-8	Body mass index;
SARC	cis	rs2276314	0.857	rs6507157	chr18:33631703	A/C	cg19628046	chr18:33552617	C18orf21	0.58	5.9	0.36	1.27e-8	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs9581943	0.967	rs9579128	chr13:28481938	A/G	cg17352152	chr13:28491409	NA	0.37	4.92	0.31	1.65e-6	Pancreatic cancer;
SARC	trans	rs11098499	0.863	rs7678400	chr4:120461957	G/A	cg25214090	chr10:38739885	LOC399744	0.59	7.45	0.44	1.85e-12	Corneal astigmatism;
SARC	cis	rs6545883	0.868	rs6752938	chr2:61841588	C/T	cg15711740	chr2:61764176	XPO1	-0.45	-5.54	-0.34	8.08e-8	Tuberculosis;
SARC	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.52	5.1	0.32	7.15e-7	Lung function (FEV1/FVC);
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg12207922	chr5:74063060	GFM2;NSA2	0.62	6.34	0.38	1.2e-9	Lung cancer in ever smokers;
SARC	cis	rs698833	0.926	rs786407	chr2:44735865	T/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.68	8.51	0.49	2.11e-15	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs4295623	0.789	rs12541318	chr8:11594970	G/T	cg00262122	chr8:11665843	FDFT1	-0.41	-4.79	-0.3	3e-6	Morning vs. evening chronotype;
SARC	cis	rs11581859	0.613	rs12403305	chr1:99217904	G/T	cg20286094	chr1:99190917	SNX7	-0.43	-5.05	-0.31	8.81e-7	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg24399712	chr22:39784796	NA	-0.47	-6.55	-0.39	3.62e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs9303401	0.921	rs34102441	chr17:56877414	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.7	8.27	0.48	1.01e-14	Cognitive test performance;
SARC	cis	rs16854884	0.837	rs989665	chr3:143792854	C/T	cg06585982	chr3:143692056	C3orf58	0.6	7.74	0.45	3.08e-13	Economic and political preferences (feminism/equality);
SARC	cis	rs9816226	1.000	rs61587156	chr3:185831583	T/G	cg00760338	chr3:185826511	ETV5	-0.88	-9.72	-0.54	5.87e-19	Obesity;Body mass index;
SARC	cis	rs8180040	0.764	rs11718795	chr3:47218727	G/A	cg27129171	chr3:47204927	SETD2	0.67	9.52	0.53	2.31e-18	Colorectal cancer;
SARC	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs11098499	0.863	rs3822190	chr4:120428098	G/A	cg09307838	chr4:120376055	NA	0.88	11.06	0.59	3.91e-23	Corneal astigmatism;
SARC	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg04277193	chr17:41438351	NA	0.47	5.04	0.31	9.3e-7	Menopause (age at onset);
SARC	cis	rs10493773	0.577	rs17398175	chr1:86074710	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.46	-6.25	-0.38	1.93e-9	Urate levels in overweight individuals;
SARC	cis	rs17539620	0.624	rs7770107	chr6:154836862	A/G	cg20019720	chr6:154832845	CNKSR3	0.41	4.84	0.3	2.39e-6	Lipoprotein (a) levels;
SARC	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg22535103	chr8:58192502	C8orf71	-0.74	-8.66	-0.49	8.13e-16	Developmental language disorder (linguistic errors);
SARC	cis	rs703842	1.000	rs6581155	chr12:58178162	A/G	cg00677455	chr12:58241039	CTDSP2	0.52	6.89	0.41	5.13e-11	Multiple sclerosis;
SARC	cis	rs7264396	0.561	rs6060753	chr20:34598430	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-5.42	-0.33	1.47e-7	Total cholesterol levels;
SARC	cis	rs4128725	1.000	rs74571338	chr1:159356046	T/C	cg25076881	chr1:159409836	OR10J1	0.4	4.78	0.3	3.16e-6	Select biomarker traits;
SARC	cis	rs7523050	0.643	rs35438081	chr1:109402831	G/T	cg08274380	chr1:109419600	GPSM2	1.02	7.68	0.45	4.37e-13	Fat distribution (HIV);
SARC	cis	rs986417	0.818	rs10873125	chr14:61035024	G/A	cg27398547	chr14:60952738	C14orf39	0.88	8.33	0.48	6.86e-15	Gut microbiota (bacterial taxa);
SARC	cis	rs6088580	0.524	rs1321306	chr20:33266379	T/A	cg08999081	chr20:33150536	PIGU	-0.34	-4.99	-0.31	1.17e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg00933542	chr6:150070202	PCMT1	0.3	5.08	0.32	7.56e-7	Lung cancer;
SARC	cis	rs1707322	0.896	rs946528	chr1:46485562	C/T	cg03146154	chr1:46216737	IPP	-0.5	-6.13	-0.37	3.82e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6545883	0.868	rs7594191	chr2:61840018	A/G	cg15711740	chr2:61764176	XPO1	0.43	5.3	0.33	2.7e-7	Tuberculosis;
SARC	cis	rs6815814	0.678	rs9715841	chr4:38774503	T/C	cg06935464	chr4:38784597	TLR10	0.5	5.19	0.32	4.66e-7	Breast cancer;
SARC	cis	rs7635838	0.751	rs2437681	chr3:11594075	A/G	cg00170343	chr3:11313890	ATG7	-0.59	-8.03	-0.47	4.91e-14	HDL cholesterol;
SARC	trans	rs641862	1	rs641862	chr13:110790232	C/T	cg25347801	chr13:113525763	ATP11A	0.74	6.33	0.38	1.24e-9	Obesity-related traits;
SARC	cis	rs1348850	0.554	rs11679519	chr2:178432110	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.56	5.87	0.36	1.5e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg16049864	chr8:95962084	TP53INP1	-0.54	-8.85	-0.5	2.29e-16	Type 2 diabetes;
SARC	cis	rs1007738	0.542	rs901747	chr11:47204981	G/C	cg03339077	chr11:47165057	C11orf49	-0.41	-5.04	-0.31	9.29e-7	Bone mineral density (hip);
SARC	cis	rs858239	0.600	rs28499396	chr7:23124098	A/G	cg23682824	chr7:23144976	KLHL7	0.71	9.57	0.53	1.59e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg12463550	chr7:65579703	CRCP	-0.46	-5.51	-0.34	9.35e-8	Aortic root size;
SARC	cis	rs6696846	0.765	rs11576867	chr1:205064676	C/T	cg21545522	chr1:205238299	TMCC2	0.34	4.78	0.3	3.1e-6	Red blood cell count;
SARC	cis	rs9814567	1.000	rs6787371	chr3:134254991	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.07	-0.42	1.77e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs67311347	1.000	rs2305521	chr3:40429183	A/G	cg09455208	chr3:40491958	NA	0.4	6.22	0.38	2.26e-9	Renal cell carcinoma;
SARC	cis	rs826838	0.616	rs2200605	chr12:38624088	G/A	cg14851346	chr12:38532713	NA	0.4	4.83	0.3	2.49e-6	Heart rate;
SARC	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg17971929	chr21:40555470	PSMG1	-0.86	-11.35	-0.6	4.61e-24	Cognitive function;
SARC	cis	rs6087990	0.735	rs2424907	chr20:31359819	C/T	cg13636640	chr20:31349939	DNMT3B	0.75	11.49	0.6	1.68e-24	Ulcerative colitis;
SARC	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg13891659	chr6:170190454	C6orf122;C6orf208	0.65	7.56	0.44	8.95e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs5753618	0.561	rs4820043	chr22:31647094	A/G	cg07713946	chr22:31675144	LIMK2	-0.4	-5.59	-0.34	6.23e-8	Colorectal cancer;
SARC	cis	rs34779708	0.931	rs13377158	chr10:35370465	A/C	cg03585969	chr10:35415529	CREM	-0.38	-4.98	-0.31	1.25e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs2070488	0.775	rs6599204	chr3:38525734	C/T	cg27533700	chr3:38537683	EXOG	-0.37	-4.85	-0.3	2.26e-6	Electrocardiographic conduction measures;
SARC	cis	rs1707322	0.721	rs61784796	chr1:46163256	A/G	cg06784218	chr1:46089804	CCDC17	0.36	6.17	0.37	2.95e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9911578	0.934	rs8081967	chr17:57072701	T/C	cg12560992	chr17:57184187	TRIM37	0.89	12.63	0.64	3.42e-28	Intelligence (multi-trait analysis);
SARC	cis	rs9341808	0.591	rs6454147	chr6:80916328	G/A	cg08355045	chr6:80787529	NA	0.37	5.84	0.36	1.75e-8	Sitting height ratio;
SARC	cis	rs7312933	1.000	rs11181308	chr12:42445259	A/G	cg19980929	chr12:42632907	YAF2	0.34	4.81	0.3	2.76e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs9325144	0.560	rs7314632	chr12:38636979	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-8.34	-0.48	6.55e-15	Morning vs. evening chronotype;
SARC	trans	rs62103177	0.810	rs62096745	chr18:77619135	A/G	cg05926928	chr17:57297772	GDPD1	1.11	9.6	0.53	1.36e-18	Opioid sensitivity;
SARC	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg13271783	chr10:134563150	INPP5A	0.41	5.31	0.33	2.51e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs4689388	0.890	rs11732208	chr4:6292716	G/C	cg25554036	chr4:6271136	WFS1	0.4	6.5	0.39	4.93e-10	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs826838	0.616	rs4619214	chr12:38614704	C/A	cg13010199	chr12:38710504	ALG10B	0.52	6.58	0.4	3.09e-10	Heart rate;
SARC	cis	rs995000	0.931	rs10158897	chr1:62912919	C/T	cg06896770	chr1:63153194	DOCK7	1.0	15.99	0.72	2.38e-39	Triglyceride levels;
SARC	cis	rs765787	0.530	rs11854689	chr15:45516052	A/G	cg24006582	chr15:45444508	DUOX1	-0.49	-6.47	-0.39	5.7e-10	Uric acid levels;
SARC	cis	rs11785693	0.862	rs62491200	chr8:4998001	A/C	cg26367366	chr8:4980734	NA	0.71	6.31	0.38	1.36e-9	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs6121246	0.529	rs73235789	chr20:30196148	T/C	cg13852791	chr20:30311386	BCL2L1	0.66	5.92	0.36	1.15e-8	Mean corpuscular hemoglobin;
SARC	cis	rs765787	0.530	rs7167731	chr15:45510900	T/C	cg26924012	chr15:45694286	SPATA5L1	0.43	5.23	0.32	3.86e-7	Uric acid levels;
SARC	cis	rs709400	0.628	rs6575984	chr14:103876454	A/G	cg12935359	chr14:103987150	CKB	0.41	6.01	0.37	7.25e-9	Body mass index;
SARC	cis	rs2130604	0.888	rs1262554	chr6:127079341	C/T	cg19875578	chr6:126661172	C6orf173	-0.43	-4.88	-0.3	1.94e-6	Bone mineral density (paediatric, skull);
SARC	cis	rs6088580	0.634	rs6088498	chr20:33020446	A/G	cg08999081	chr20:33150536	PIGU	0.42	6.29	0.38	1.53e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg15448220	chr1:150897856	SETDB1	0.47	6.24	0.38	2.06e-9	Tonsillectomy;
SARC	cis	rs4711336	1.000	rs2296740	chr6:33659536	A/G	cg15676125	chr6:33679581	C6orf125	0.54	6.77	0.41	1.06e-10	Height;
SARC	cis	rs4722166	0.630	rs7808457	chr7:22798265	A/T	cg26061582	chr7:22766209	IL6	-0.73	-7.55	-0.44	9.88e-13	Lung cancer;
SARC	cis	rs8067545	0.611	rs2703786	chr17:20156369	T/C	cg13482628	chr17:19912719	NA	-0.53	-6.9	-0.41	4.96e-11	Schizophrenia;
SARC	cis	rs6912958	0.559	rs369674	chr6:88043402	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-5.67	-0.35	4.22e-8	Monocyte percentage of white cells;
SARC	cis	rs56114371	0.530	rs169262	chr6:27770890	C/T	cg17221315	chr6:27791827	HIST1H4J	0.52	4.88	0.3	2.01e-6	Breast cancer;
SARC	cis	rs4803468	1.000	rs2241708	chr19:41912270	C/T	cg09537434	chr19:41945824	ATP5SL	-0.98	-17.49	-0.75	2.57e-44	Height;
SARC	cis	rs870825	0.616	rs7678864	chr4:185635158	C/T	cg04058563	chr4:185651563	MLF1IP	0.84	11.31	0.6	6.15e-24	Blood protein levels;
SARC	cis	rs2985684	0.841	rs2281836	chr14:50065717	G/C	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.45	4.83	0.3	2.53e-6	Carotid intima media thickness;
SARC	cis	rs1008375	0.933	rs10939757	chr4:17694125	T/C	cg27347728	chr4:17578864	LAP3	0.46	5.73	0.35	3.07e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs4332037	0.950	rs11771828	chr7:1941003	T/C	cg11693508	chr17:37793320	STARD3	0.72	6.54	0.39	3.95e-10	Bipolar disorder;
SARC	cis	rs6964587	0.610	rs10953056	chr7:91466700	C/T	cg17063962	chr7:91808500	NA	0.69	9.81	0.54	3.02e-19	Breast cancer;
SARC	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg10523679	chr1:76189770	ACADM	-0.7	-10.86	-0.58	1.71e-22	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6120849	0.586	rs2025096	chr20:33540000	G/A	cg24642439	chr20:33292090	TP53INP2	0.6	5.95	0.36	9.91e-9	Protein C levels;
SARC	trans	rs78382112	0.908	rs6659139	chr1:181581923	C/T	cg23731742	chr1:879958	NOC2L;SAMD11	0.7	6.5	0.39	4.88e-10	Intelligence (multi-trait analysis);
SARC	cis	rs9916302	0.653	rs11654954	chr17:37745979	C/T	cg07936489	chr17:37558343	FBXL20	0.63	6.99	0.42	2.84e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs832540	0.801	rs7731700	chr5:56111927	C/T	cg12311346	chr5:56204834	C5orf35	-0.38	-4.75	-0.3	3.52e-6	Coronary artery disease;
SARC	cis	rs918629	0.761	rs57243277	chr5:95288165	G/A	cg16656078	chr5:95278638	ELL2	-0.7	-8.29	-0.48	8.84e-15	IgG glycosylation;
SARC	cis	rs12824058	0.798	rs4759652	chr12:130808771	C/T	cg23887609	chr12:130822674	PIWIL1	0.39	5.34	0.33	2.2e-7	Menopause (age at onset);
SARC	cis	rs921968	0.565	rs6436084	chr2:219639782	A/G	cg02176678	chr2:219576539	TTLL4	-0.33	-5.03	-0.31	9.92e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg14298792	chr15:30685198	CHRFAM7A	0.48	5.46	0.34	1.24e-7	Huntington's disease progression;
SARC	cis	rs6493487	0.512	rs17521467	chr15:51214926	T/C	cg02338191	chr15:51200825	AP4E1	0.55	5.09	0.32	7.27e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs6696239	0.513	rs28407112	chr1:227736752	A/G	cg26340147	chr1:227730820	NA	0.33	4.77	0.3	3.23e-6	Height;
SARC	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.61	-6.45	-0.39	6.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg20957382	chr12:105501358	KIAA1033	0.81	6.93	0.41	4.04e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs3018712	0.532	rs2513294	chr11:68421194	C/T	cg01657329	chr11:68192670	LRP5	0.56	5.21	0.32	4.08e-7	Total body bone mineral density;
SARC	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.7	-7.36	-0.43	3.1e-12	Platelet count;
SARC	cis	rs10214930	0.560	rs42089	chr7:27702940	C/T	cg05786569	chr7:27702416	HIBADH	-0.45	-5.32	-0.33	2.48e-7	Hypospadias;
SARC	cis	rs1707322	0.686	rs2152078	chr1:46055600	C/T	cg03146154	chr1:46216737	IPP	-0.51	-6.07	-0.37	5.12e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs400736	0.930	rs226249	chr1:8021778	A/G	cg25007680	chr1:8021821	PARK7	0.57	7.19	0.43	9e-12	Response to antidepressants and depression;
SARC	cis	rs8180040	0.654	rs1466740	chr3:47245883	C/T	cg27129171	chr3:47204927	SETD2	-0.69	-9.46	-0.53	3.57e-18	Colorectal cancer;
SARC	cis	rs908922	0.676	rs12129646	chr1:152518816	C/T	cg09873164	chr1:152488093	CRCT1	0.6	7.77	0.45	2.51e-13	Hair morphology;
SARC	cis	rs13006833	0.635	rs291460	chr2:191181585	G/A	cg25963032	chr2:191064776	C2orf88	0.36	4.99	0.31	1.16e-6	Urinary metabolites;
SARC	cis	rs611744	0.870	rs650925	chr8:109196725	T/C	cg21045802	chr8:109455806	TTC35	0.49	6.07	0.37	5.07e-9	Dupuytren's disease;
SARC	cis	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg20965017	chr5:231967	SDHA	-0.56	-5.36	-0.33	2e-7	Breast cancer;
SARC	cis	rs9911578	0.967	rs2333410	chr17:57137129	G/A	cg12560992	chr17:57184187	TRIM37	-0.86	-12.41	-0.63	1.81e-27	Intelligence (multi-trait analysis);
SARC	cis	rs950027	0.620	rs1049518	chr15:45653367	G/A	cg26924012	chr15:45694286	SPATA5L1	0.53	6.78	0.41	9.59e-11	Response to fenofibrate (adiponectin levels);
SARC	cis	rs7647973	0.626	rs9835157	chr3:49797769	G/A	cg07636037	chr3:49044803	WDR6	-0.62	-6.31	-0.38	1.41e-9	Menarche (age at onset);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg18831262	chr19:7599614	PNPLA6	-0.55	-6.85	-0.41	6.58e-11	Breast cancer;
SARC	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg00450029	chr8:599525	NA	0.64	5.22	0.32	3.92e-7	IgG glycosylation;
SARC	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg22920501	chr2:26401640	FAM59B	-0.57	-7.45	-0.44	1.82e-12	Gut microbiome composition (summer);
SARC	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg12564285	chr5:131593104	PDLIM4	0.34	5.15	0.32	5.48e-7	Breast cancer;
SARC	cis	rs2197308	0.765	rs11182434	chr12:37923968	C/A	cg26384229	chr12:38710491	ALG10B	0.9	13.3	0.66	2.04e-30	Morning vs. evening chronotype;
SARC	cis	rs9916302	0.706	rs903507	chr17:37726423	A/G	cg00129232	chr17:37814104	STARD3	-0.61	-6.31	-0.38	1.36e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs12701220	0.689	rs12530960	chr7:1095471	G/A	cg02733842	chr7:1102375	C7orf50	-0.6	-6.97	-0.42	3.23e-11	Bronchopulmonary dysplasia;
SARC	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg22433210	chr17:43662623	NA	0.98	11.87	0.61	9.85e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs3762637	0.943	rs28372690	chr3:122283095	G/A	cg24169773	chr3:122142474	KPNA1	-0.55	-5.58	-0.34	6.82e-8	LDL cholesterol levels;
SARC	cis	rs113835537	0.529	rs11227525	chr11:66308065	T/G	cg24851651	chr11:66362959	CCS	0.39	4.96	0.31	1.34e-6	Airway imaging phenotypes;
SARC	cis	rs2204008	0.639	rs7311462	chr12:38278130	G/A	cg13010199	chr12:38710504	ALG10B	0.81	11.31	0.6	6.33e-24	Bladder cancer;
SARC	cis	rs854765	0.583	rs12603148	chr17:17865257	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.42	5.22	0.32	3.87e-7	Total body bone mineral density;
SARC	cis	rs8053891	0.756	rs12708922	chr16:72001629	A/G	cg16558253	chr16:72132732	DHX38	-0.38	-4.86	-0.3	2.12e-6	Coronary artery disease;
SARC	cis	rs11719291	0.833	rs34037363	chr3:48821036	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.63	-5.41	-0.33	1.56e-7	Cognitive function;
SARC	cis	rs2729354	0.514	rs1967179	chr11:57348483	C/T	cg02958346	chr11:57425731	CLP1	0.48	5.99	0.37	7.96e-9	Blood protein levels;
SARC	cis	rs910316	0.737	rs175049	chr14:75481368	C/T	cg11812906	chr14:75593930	NEK9	-0.76	-10.2	-0.56	1.99e-20	Height;
SARC	cis	rs6558174	0.965	rs4072394	chr8:22490800	C/T	cg03733263	chr8:22462867	KIAA1967	0.46	5.33	0.33	2.27e-7	Breast cancer;
SARC	cis	rs208520	0.526	rs1385219	chr6:66754476	C/T	cg07460842	chr6:66804631	NA	1.06	19.65	0.79	2.39e-51	Exhaled nitric oxide output;
SARC	trans	rs11098499	1.000	rs11098500	chr4:120219239	T/A	cg25214090	chr10:38739885	LOC399744	0.53	6.88	0.41	5.41e-11	Corneal astigmatism;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg08215925	chr3:71633214	FOXP1	-0.55	-6.29	-0.38	1.58e-9	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg04166393	chr7:2884313	GNA12	0.54	6.22	0.38	2.31e-9	Height;
SARC	cis	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg06558623	chr16:89946397	TCF25	0.94	6.59	0.4	2.87e-10	Skin colour saturation;
SARC	cis	rs554111	0.679	rs906254	chr1:21324760	G/A	cg08890418	chr1:21044141	KIF17	-0.35	-4.92	-0.31	1.62e-6	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs9790314	0.664	rs723757	chr3:160645435	C/T	cg04691961	chr3:161091175	C3orf57	0.61	8.4	0.48	4.48e-15	Morning vs. evening chronotype;
SARC	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg02581963	chr10:102133317	C10orf75	-0.52	-6.85	-0.41	6.61e-11	Gut microbiota (bacterial taxa);
SARC	cis	rs7617480	0.648	rs9882443	chr3:48749064	G/A	cg07636037	chr3:49044803	WDR6	0.84	8.74	0.5	4.52e-16	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs9486719	0.857	rs4346856	chr6:96880270	C/T	cg18709589	chr6:96969512	KIAA0776	0.51	5.53	0.34	8.52e-8	Migraine;Coronary artery disease;
SARC	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg02462569	chr6:150064036	NUP43	-0.37	-4.84	-0.3	2.39e-6	Lung cancer;
SARC	cis	rs28374715	0.532	rs1899	chr15:41689232	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.13	-18.15	-0.77	1.71e-46	Ulcerative colitis;
SARC	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg24829409	chr8:58192753	C8orf71	-0.63	-6.01	-0.37	7.13e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.63	-7.22	-0.43	7.25e-12	Gut microbiome composition (summer);
SARC	cis	rs2213920	0.522	rs4978639	chr9:118241443	G/A	cg13918206	chr9:118159781	DEC1	0.45	4.86	0.3	2.13e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	trans	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg07399299	chr4:84406520	FAM175A	-0.66	-6.35	-0.38	1.12e-9	Cutaneous psoriasis;
SARC	cis	rs4718428	0.705	rs13220977	chr7:66337648	A/T	cg18252515	chr7:66147081	NA	0.54	5.83	0.36	1.84e-8	Corneal structure;
SARC	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg07701084	chr6:150067640	NUP43	0.4	5.37	0.33	1.93e-7	Lung cancer;
SARC	cis	rs10979	1.000	rs9390104	chr6:143890978	T/C	cg25407410	chr6:143891975	LOC285740	-0.64	-8.68	-0.49	6.88e-16	Hypospadias;
SARC	cis	rs28530618	0.603	rs4594522	chr20:31254984	T/C	cg13636640	chr20:31349939	DNMT3B	-0.41	-4.79	-0.3	3.01e-6	Birth weight;
SARC	cis	rs7568458	0.663	rs699664	chr2:85780536	A/G	cg17127132	chr2:85788382	GGCX	-0.42	-5.01	-0.31	1.07e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg08219700	chr8:58056026	NA	0.6	5.71	0.35	3.49e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4242434	0.757	rs2280104	chr8:22525980	C/T	cg03733263	chr8:22462867	KIAA1967	0.91	14.75	0.69	3.26e-35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg22800045	chr5:56110881	MAP3K1	0.73	7.85	0.46	1.52e-13	Initial pursuit acceleration;
SARC	cis	rs9715521	0.868	rs62301181	chr4:59834246	A/G	cg11281224	chr4:60001000	NA	-0.39	-5.02	-0.31	1.01e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs10892173	0.703	rs1014034	chr11:117661734	G/C	cg21640587	chr11:117668038	DSCAML1	0.43	5.77	0.35	2.53e-8	Myopia;
SARC	cis	rs9325144	0.624	rs7309400	chr12:39150369	G/C	cg26384229	chr12:38710491	ALG10B	-0.57	-7.15	-0.42	1.12e-11	Morning vs. evening chronotype;
SARC	cis	rs2370759	1.000	rs79806114	chr10:32618022	T/C	cg01819863	chr10:32635814	EPC1	1.02	10.19	0.56	2.06e-20	Sexual dysfunction (female);
SARC	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg16479474	chr6:28041457	NA	0.34	5.16	0.32	5.2e-7	Cardiac Troponin-T levels;
SARC	cis	rs7208859	0.725	rs7342938	chr17:29189830	A/G	cg13385521	chr17:29058706	SUZ12P	0.76	6.76	0.4	1.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs6484504	0.576	rs208091	chr11:31190099	G/C	cg02090638	chr11:31391270	DNAJC24;DCDC1	-0.38	-4.85	-0.3	2.21e-6	Red blood cell count;
SARC	cis	rs2506889	0.553	rs7548453	chr1:10589836	A/G	cg07384165	chr1:10488281	NA	-0.45	-6.21	-0.38	2.35e-9	Breast cancer;
SARC	cis	rs57506017	0.585	rs7792410	chr7:12267614	A/G	cg23422036	chr7:12250390	TMEM106B	0.45	5.74	0.35	3e-8	Neuroticism;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg10724491	chr3:112738377	C3orf17	0.51	6.71	0.4	1.47e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs2645694	0.626	rs2703124	chr4:77820626	G/T	cg18351406	chr4:77819688	ANKRD56	0.45	6.31	0.38	1.37e-9	Emphysema distribution in smoking;
SARC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg26338869	chr17:61819248	STRADA	0.79	10.63	0.57	8.77e-22	Prudent dietary pattern;
SARC	cis	rs17376456	0.877	rs10040648	chr5:93490301	G/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.09	0.32	7.32e-7	Diabetic retinopathy;
SARC	cis	rs35160687	0.901	rs6713456	chr2:86507653	T/A	cg10973622	chr2:86423274	IMMT	0.36	4.74	0.3	3.73e-6	Night sleep phenotypes;
SARC	cis	rs11209002	0.592	rs7551197	chr1:67588090	A/T	cg02640540	chr1:67518911	SLC35D1	0.51	5.93	0.36	1.07e-8	Crohn's disease;
SARC	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	10.99	0.58	6.62e-23	Alzheimer's disease;
SARC	cis	rs4969178	0.965	rs3744217	chr17:76400258	G/A	cg02836325	chr17:76403955	PGS1	0.34	5.21	0.32	4.16e-7	HDL cholesterol levels;
SARC	cis	rs3812831	0.654	rs367312	chr13:114930195	G/A	cg06611532	chr13:114900021	NA	0.3	4.96	0.31	1.37e-6	Schizophrenia;
SARC	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	11.35	0.6	4.58e-24	Platelet count;
SARC	cis	rs26868	0.742	rs26848	chr16:2263516	A/G	cg02248941	chr16:2239361	CASKIN1	0.32	5.2	0.32	4.42e-7	Height;
SARC	cis	rs1468333	0.824	rs9327809	chr5:137587806	A/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.79	10.32	0.56	8.29e-21	Resting heart rate;
SARC	trans	rs3780486	0.757	rs10121987	chr9:33119818	A/G	cg20290983	chr6:43655470	MRPS18A	1.14	23.4	0.84	4.36e-63	IgG glycosylation;
SARC	cis	rs1920116	1.000	rs4955676	chr3:169568492	A/G	cg14222479	chr3:169487675	ARPM1	0.44	5.48	0.34	1.09e-7	Glioma (high-grade);
SARC	cis	rs2832077	0.527	rs2250141	chr21:30241984	A/T	cg08807101	chr21:30365312	RNF160	0.52	5.63	0.35	5.2e-8	Cognitive test performance;
SARC	cis	rs4150161	0.591	rs3785036	chr16:84219810	T/G	cg10106505	chr16:84220380	TAF1C	-0.75	-6.02	-0.37	6.85e-9	Systolic blood pressure response to hydrochlorothiazide in hypertension;
SARC	cis	rs57994353	0.897	rs35526483	chr9:139364940	G/A	cg13611204	chr9:139324423	INPP5E	-0.28	-4.92	-0.31	1.64e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs7264396	0.563	rs2425116	chr20:34323553	T/C	cg01084648	chr20:34329383	RBM39	0.58	5.03	0.31	9.74e-7	Total cholesterol levels;
SARC	cis	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg26695010	chr11:65641043	EFEMP2	-0.52	-6.73	-0.4	1.28e-10	Eosinophil percentage of white cells;
SARC	cis	rs9549260	0.755	rs4943797	chr13:41201633	A/G	cg21288729	chr13:41239152	FOXO1	-0.62	-8.26	-0.48	1.07e-14	Red blood cell count;
SARC	cis	rs34172651	0.583	rs4787649	chr16:24700215	C/T	cg06028605	chr16:24865363	SLC5A11	-0.33	-4.91	-0.31	1.72e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2075371	1.000	rs2598294	chr7:133991690	C/T	cg11752832	chr7:134001865	SLC35B4	0.57	7.43	0.44	1.99e-12	Mean platelet volume;
SARC	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg20818283	chr2:191399100	TMEM194B	-0.45	-5.65	-0.35	4.68e-8	Pulse pressure;
SARC	cis	rs920590	0.758	rs35896770	chr8:19665616	G/C	cg01411142	chr8:19674711	INTS10	0.52	6.07	0.37	5.06e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs3857067	0.806	rs28408270	chr4:95114572	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.08	-0.32	7.57e-7	QT interval;
SARC	cis	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg03213289	chr20:61660250	NA	0.44	5.84	0.36	1.77e-8	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs747650	0.859	rs4567413	chr11:47232184	A/G	cg03339077	chr11:47165057	C11orf49	-0.45	-6.28	-0.38	1.67e-9	Acne (severe);
SARC	cis	rs9457247	1.000	rs407515	chr6:167407544	G/C	cg23791538	chr6:167370224	RNASET2	-0.6	-8.22	-0.47	1.39e-14	Crohn's disease;
SARC	cis	rs1005277	0.522	rs289650	chr10:37975505	G/T	cg25427524	chr10:38739819	LOC399744	-0.56	-9.09	-0.51	4.45e-17	Extrinsic epigenetic age acceleration;
SARC	cis	rs1784581	0.674	rs1789990	chr6:162406957	G/T	cg17173639	chr6:162384350	PARK2	-0.54	-7.03	-0.42	2.24e-11	Itch intensity from mosquito bite;
SARC	cis	rs12579753	0.879	rs7131927	chr12:82166313	T/C	cg07988820	chr12:82153109	PPFIA2	-0.58	-6.92	-0.41	4.35e-11	Resting heart rate;
SARC	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	11.75	0.61	2.36e-25	Alzheimer's disease;
SARC	cis	rs4555082	0.834	rs4412909	chr14:105759226	T/C	cg10792982	chr14:105748885	BRF1	0.54	7.69	0.45	4.16e-13	Mean platelet volume;Platelet distribution width;
SARC	cis	rs7829975	0.846	rs1879957	chr8:8544808	T/C	cg06636001	chr8:8085503	FLJ10661	-0.64	-8.39	-0.48	4.75e-15	Mood instability;
SARC	cis	rs9309473	1.000	rs6707722	chr2:73654363	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-5.64	-0.35	4.8e-8	Metabolite levels;
SARC	cis	rs13161895	1.000	rs6873781	chr5:179436734	A/C	cg02702477	chr5:179499311	RNF130	-0.65	-6.46	-0.39	5.92e-10	LDL cholesterol;
SARC	cis	rs6570726	0.935	rs409725	chr6:145840340	G/A	cg23711669	chr6:146136114	FBXO30	0.78	11.86	0.61	1.04e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7937682	1.000	rs9734135	chr11:111536190	G/A	cg22437258	chr11:111473054	SIK2	0.74	10.14	0.55	3.05e-20	Primary sclerosing cholangitis;
SARC	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	24.35	0.85	5.64e-66	Chronic sinus infection;
SARC	cis	rs6687430	0.562	rs6676491	chr1:10633421	A/C	cg17425144	chr1:10567563	PEX14	0.34	5.03	0.31	9.64e-7	Hand grip strength;
SARC	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg12463550	chr7:65579703	CRCP	0.67	5.06	0.31	8.43e-7	Diabetic kidney disease;
SARC	cis	rs1008375	1.000	rs7436403	chr4:17692685	T/G	cg16339924	chr4:17578868	LAP3	-0.6	-7.51	-0.44	1.22e-12	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-4.83	-0.3	2.44e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.99	11.37	0.6	4.16e-24	Platelet count;
SARC	cis	rs2153535	0.580	rs2143355	chr6:8517856	T/A	cg07606381	chr6:8435919	SLC35B3	0.77	10.9	0.58	1.28e-22	Motion sickness;
SARC	cis	rs3733585	0.699	rs6856127	chr4:9965443	T/C	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.56	-0.34	7.37e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs11608355	0.597	rs2304548	chr12:109795166	T/G	cg05360138	chr12:110035743	NA	0.44	5.21	0.32	4.07e-7	Neuroticism;
SARC	cis	rs2952156	0.920	rs9303274	chr17:37836353	T/C	cg07936489	chr17:37558343	FBXL20	-0.42	-5.45	-0.34	1.25e-7	Asthma;
SARC	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg07343612	chr16:622815	PIGQ	-0.59	-8.27	-0.48	1.03e-14	Height;
SARC	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs2043112	0.965	rs6865364	chr5:39063890	G/A	cg04869206	chr5:39074266	RICTOR	0.53	6.46	0.39	6.08e-10	Obesity-related traits;
SARC	cis	rs9400467	0.537	rs12194283	chr6:111426029	A/G	cg15721981	chr6:111408429	SLC16A10	0.7	5.89	0.36	1.36e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs5753618	0.509	rs1034589	chr22:31579233	C/T	cg13145458	chr22:31556086	RNF185	0.48	5.23	0.32	3.72e-7	Colorectal cancer;
SARC	cis	rs10744422	0.925	rs3825143	chr12:123352179	C/T	cg25930673	chr12:123319894	HIP1R	-0.71	-5.17	-0.32	4.92e-7	Schizophrenia;
SARC	cis	rs10782582	0.593	rs6673786	chr1:76149637	C/T	cg10523679	chr1:76189770	ACADM	-0.44	-5.28	-0.33	2.91e-7	Daytime sleep phenotypes;
SARC	cis	rs2073300	0.609	rs6137945	chr20:23406136	C/T	cg12062639	chr20:23401060	NAPB	0.99	6.67	0.4	1.81e-10	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs12681288	0.676	rs2701914	chr8:999935	C/T	cg15309053	chr8:964076	NA	0.45	7.2	0.43	8.16e-12	Schizophrenia;
SARC	trans	rs61931739	0.534	rs11053131	chr12:34282109	A/G	cg13010199	chr12:38710504	ALG10B	0.65	8.72	0.5	5.21e-16	Morning vs. evening chronotype;
SARC	cis	rs7264396	0.528	rs3787174	chr20:34487921	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.52	4.92	0.31	1.66e-6	Total cholesterol levels;
SARC	cis	rs72634258	0.945	rs12727642	chr1:8046672	C/A	cg00042356	chr1:8021962	PARK7	0.79	7.37	0.43	2.88e-12	Inflammatory bowel disease;
SARC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-4.93	-0.31	1.59e-6	Total body bone mineral density;
SARC	cis	rs4430311	0.688	rs12142652	chr1:243953583	A/G	cg21452805	chr1:244014465	NA	-0.39	-5.1	-0.32	6.99e-7	Post-traumatic stress disorder (asjusted for relatedness);
SARC	cis	rs4699052	0.963	rs11097801	chr4:104150323	A/G	cg16532752	chr4:104119610	CENPE	-0.42	-5.0	-0.31	1.15e-6	Testicular germ cell tumor;
SARC	trans	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg00938859	chr5:1591904	SDHAP3	0.79	7.56	0.44	9.16e-13	Breast cancer;
SARC	cis	rs709400	0.597	rs1013650	chr14:103909203	G/A	cg12935359	chr14:103987150	CKB	-0.41	-5.96	-0.36	9.33e-9	Body mass index;
SARC	cis	rs2273669	0.667	rs76732622	chr6:109318280	A/T	cg05315195	chr6:109294784	ARMC2	-0.58	-5.17	-0.32	5.02e-7	Prostate cancer;
SARC	cis	rs7681440	0.904	rs12331318	chr4:90770255	A/G	cg01966878	chr4:90757139	SNCA	-0.35	-4.78	-0.3	3.05e-6	Dementia with Lewy bodies;
SARC	cis	rs11191270	1.000	rs4919624	chr10:104021085	A/G	cg15320455	chr10:103880129	LDB1	0.67	6.79	0.41	9.37e-11	Intelligence (multi-trait analysis);
SARC	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg04267008	chr7:1944627	MAD1L1	-0.5	-5.79	-0.35	2.24e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs3733585	0.624	rs7376154	chr4:9952587	C/A	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.39	-0.33	1.76e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg08219700	chr8:58056026	NA	0.61	6.36	0.38	1.05e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9911578	0.967	rs4132925	chr17:56938016	C/G	cg12560992	chr17:57184187	TRIM37	-0.89	-12.23	-0.63	6.97e-27	Intelligence (multi-trait analysis);
SARC	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.39	-4.77	-0.3	3.23e-6	Lymphocyte counts;
SARC	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg25767906	chr1:53392781	SCP2	0.32	4.82	0.3	2.65e-6	Monocyte count;
SARC	cis	rs7626444	0.625	rs9826214	chr3:196478213	C/T	cg12930392	chr3:196481615	PAK2	0.25	4.88	0.3	2e-6	Monocyte count;
SARC	cis	rs6912958	0.535	rs448580	chr6:88040399	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.36	6.19	0.38	2.75e-9	Monocyte percentage of white cells;
SARC	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.32	-4.86	-0.3	2.21e-6	Menopause (age at onset);
SARC	cis	rs6866344	0.697	rs17184281	chr5:178127563	G/A	cg10224037	chr5:178157518	ZNF354A	0.99	11.97	0.62	4.81e-26	Neutrophil percentage of white cells;
SARC	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg27266027	chr21:40555129	PSMG1	0.52	5.68	0.35	3.9e-8	Cognitive function;
SARC	cis	rs2153535	0.580	rs9392224	chr6:8472614	G/A	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs11578119	0.933	rs10919417	chr1:170442454	A/C	cg09767346	chr1:170501363	GORAB	0.45	5.25	0.33	3.42e-7	Male-pattern baldness;
SARC	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg27266027	chr21:40555129	PSMG1	-0.51	-5.69	-0.35	3.74e-8	Cognitive function;
SARC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg26338869	chr17:61819248	STRADA	-0.67	-8.88	-0.5	1.88e-16	Prudent dietary pattern;
SARC	cis	rs897080	0.552	rs1067365	chr2:44655398	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.58	0.4	3.06e-10	Height;
SARC	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg23172400	chr8:95962367	TP53INP1	-0.34	-5.82	-0.36	1.93e-8	Type 2 diabetes;
SARC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg05552183	chr6:42928497	GNMT	0.55	7.4	0.44	2.47e-12	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg05623727	chr3:50126028	RBM5	0.32	4.8	0.3	2.83e-6	Intelligence (multi-trait analysis);
SARC	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg18135555	chr8:22132992	PIWIL2	0.4	5.96	0.36	9.11e-9	Hypertriglyceridemia;
SARC	cis	rs7474896	0.537	rs1779068	chr10:38250785	G/A	cg25427524	chr10:38739819	LOC399744	0.47	5.7	0.35	3.55e-8	Obesity (extreme);
SARC	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.31	-4.85	-0.3	2.27e-6	Total body bone mineral density;
SARC	cis	rs7681440	0.904	rs6532192	chr4:90764131	G/A	cg02192967	chr4:90758406	SNCA	0.36	5.14	0.32	5.76e-7	Dementia with Lewy bodies;
SARC	cis	rs2273669	0.667	rs7765732	chr6:109347057	A/C	cg05315195	chr6:109294784	ARMC2	-0.63	-5.7	-0.35	3.6e-8	Prostate cancer;
SARC	cis	rs763121	0.853	rs5757200	chr22:39043491	T/G	cg21395723	chr22:39101663	GTPBP1	0.58	6.67	0.4	1.85e-10	Menopause (age at onset);
SARC	cis	rs3820928	0.874	rs13403281	chr2:227880769	G/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-6.77	-0.41	1.04e-10	Pulmonary function;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg13196216	chr6:34231128	NA	-0.5	-6.23	-0.38	2.13e-9	Height;
SARC	cis	rs72781680	0.799	rs17508218	chr2:23976536	C/T	cg08917208	chr2:24149416	ATAD2B	0.77	7.21	0.43	7.98e-12	Lymphocyte counts;
SARC	cis	rs826838	1.000	rs10880914	chr12:38720543	C/T	cg26384229	chr12:38710491	ALG10B	0.97	15.71	0.72	2.12e-38	Heart rate;
SARC	cis	rs3772130	0.583	rs28497949	chr3:121448675	T/A	cg20356878	chr3:121714668	ILDR1	0.39	6.14	0.37	3.56e-9	Cognitive performance;
SARC	cis	rs7084402	0.967	rs1658458	chr10:60301382	T/C	cg07615347	chr10:60278583	BICC1	0.59	8.77	0.5	3.93e-16	Refractive error;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg03548285	chr5:130762714	RAPGEF6	0.46	6.38	0.39	9.58e-10	Thyroid stimulating hormone;
SARC	cis	rs2273669	0.667	rs113477421	chr6:109310268	C/T	cg05315195	chr6:109294784	ARMC2	-0.6	-5.43	-0.34	1.38e-7	Prostate cancer;
SARC	cis	rs7312933	0.524	rs11181465	chr12:42765098	T/G	cg19980929	chr12:42632907	YAF2	0.49	7.0	0.42	2.79e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg22535103	chr8:58192502	C8orf71	-0.7	-8.43	-0.48	3.66e-15	Developmental language disorder (linguistic errors);
SARC	cis	rs425277	0.606	rs3128295	chr1:2068480	C/T	cg21442419	chr1:2182373	SKI	0.45	5.72	0.35	3.27e-8	Height;
SARC	cis	rs5167	0.505	rs7257468	chr19:45453144	C/T	cg10169327	chr19:45448959	APOC2	0.31	5.11	0.32	6.7e-7	Blood protein levels;
SARC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.45	0.53	3.79e-18	Prudent dietary pattern;
SARC	cis	rs12586317	0.547	rs10145723	chr14:35460954	G/A	cg16230307	chr14:35515116	FAM177A1	1.02	11.85	0.61	1.18e-25	Psoriasis;
SARC	cis	rs3741151	0.687	rs7933355	chr11:73236817	G/C	cg17517138	chr11:73019481	ARHGEF17	0.82	6.28	0.38	1.68e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs2439831	0.867	rs2242068	chr15:43699304	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.09	10.69	0.57	5.68e-22	Lung cancer in ever smokers;
SARC	cis	rs7715806	0.509	rs34349	chr5:74944868	A/G	cg06933384	chr5:74808293	COL4A3BP;POLK	-0.59	-5.65	-0.35	4.63e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4664308	1.000	rs10929966	chr2:160908341	C/T	cg03641300	chr2:160917029	PLA2R1	-0.67	-8.93	-0.51	1.29e-16	Idiopathic membranous nephropathy;
SARC	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg11764359	chr7:65958608	NA	0.6	7.09	0.42	1.56e-11	Aortic root size;
SARC	cis	rs3857067	0.806	rs11943926	chr4:95136512	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.12	-0.32	6.27e-7	QT interval;
SARC	cis	rs9815354	0.904	rs73073235	chr3:42012693	C/A	cg03022575	chr3:42003672	ULK4	0.71	5.98	0.36	8.48e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs3820928	0.904	rs10933161	chr2:227764872	A/G	cg05526886	chr2:227700861	RHBDD1	-0.5	-6.01	-0.37	7.18e-9	Pulmonary function;
SARC	cis	rs7824557	0.602	rs7839053	chr8:11207431	C/T	cg21775007	chr8:11205619	TDH	0.68	8.79	0.5	3.34e-16	Retinal vascular caliber;
SARC	cis	rs2070677	0.935	rs11101887	chr10:135418062	G/A	cg20169779	chr10:135381914	SYCE1	-0.55	-6.49	-0.39	5.16e-10	Gout;
SARC	trans	rs7815944	1.000	rs1464156	chr8:129444147	A/T	cg17342469	chr22:46473074	NA	0.71	6.7	0.4	1.58e-10	Atopic dermatitis;
SARC	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.89e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1153858	1.000	rs12440038	chr15:45706739	A/G	cg21132104	chr15:45694354	SPATA5L1	0.78	10.53	0.57	1.86e-21	Homoarginine levels;
SARC	cis	rs9660992	0.762	rs1172129	chr1:205244972	T/A	cg07972983	chr1:205091412	RBBP5	0.54	6.61	0.4	2.64e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg15506972	chr13:111367570	ING1	-0.88	-6.76	-0.41	1.09e-10	Obesity-related traits;
SARC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.39	0.56	4.87e-21	Prudent dietary pattern;
SARC	cis	rs10911251	0.528	rs6669199	chr1:183082421	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.8e-21	Colorectal cancer;
SARC	cis	rs11792861	0.926	rs75128146	chr9:111833791	G/T	cg13535736	chr9:111863775	C9orf5	-0.41	-5.11	-0.32	6.66e-7	Menarche (age at onset);
SARC	cis	rs950169	0.922	rs11631096	chr15:85100929	G/C	cg24253500	chr15:84953950	NA	0.38	5.46	0.34	1.21e-7	Schizophrenia;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg21795699	chr17:15903687	ZSWIM7;TTC19	-0.65	-7.39	-0.44	2.55e-12	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	trans	rs1945213	0.659	rs11227133	chr11:55836620	T/C	cg15704280	chr7:45808275	SEPT13	0.66	6.87	0.41	5.94e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg08280861	chr8:58055591	NA	0.61	5.94	0.36	1.01e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs1814175	0.781	rs1851872	chr11:50009770	A/G	cg03929089	chr4:120376271	NA	-0.87	-13.86	-0.67	2.91e-32	Height;
SARC	cis	rs858239	0.806	rs10268610	chr7:23274764	A/G	cg23682824	chr7:23144976	KLHL7	0.61	7.82	0.46	1.87e-13	Cerebrospinal fluid biomarker levels;
SARC	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg22920501	chr2:26401640	FAM59B	0.61	8.19	0.47	1.71e-14	Gut microbiome composition (summer);
SARC	cis	rs561341	1.000	rs498391	chr17:30328704	G/A	cg00745463	chr17:30367425	LRRC37B	-0.62	-5.09	-0.32	7.42e-7	Hip circumference adjusted for BMI;
SARC	cis	rs7666738	0.830	rs10019087	chr4:99030211	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7264396	0.635	rs6060660	chr20:34476649	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-7.69	-0.45	4.06e-13	Total cholesterol levels;
SARC	cis	rs2153535	0.580	rs1034273	chr6:8468145	A/G	cg07606381	chr6:8435919	SLC35B3	0.77	10.83	0.58	2.14e-22	Motion sickness;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg13132016	chr14:58893740	KIAA0586;TIMM9	-0.8	-6.54	-0.39	3.87e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs3126085	0.877	rs1552992	chr1:152171625	C/G	cg03465714	chr1:152285911	FLG	-0.47	-5.56	-0.34	7.25e-8	Atopic dermatitis;
SARC	cis	rs8067545	0.574	rs62067483	chr17:19948394	C/T	cg13482628	chr17:19912719	NA	0.43	4.87	0.3	2.07e-6	Schizophrenia;
SARC	cis	rs9858542	0.953	rs11922013	chr3:49458355	G/C	cg07274523	chr3:49395745	GPX1	0.53	6.13	0.37	3.68e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs2658782	1.000	rs2019814	chr11:93168885	A/G	cg15737290	chr11:93063684	CCDC67	0.71	7.59	0.45	7.65e-13	Pulmonary function decline;
SARC	cis	rs7005380	0.581	rs9987140	chr8:120936874	G/A	cg21744203	chr8:120868354	DSCC1	0.45	5.29	0.33	2.75e-7	Interstitial lung disease;
SARC	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg03806693	chr22:41940476	POLR3H	-0.96	-13.01	-0.65	1.85e-29	Vitiligo;
SARC	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg13206674	chr6:150067644	NUP43	0.44	5.68	0.35	4e-8	Lung cancer;
SARC	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.79	-11.57	-0.6	9.16e-25	Personality dimensions;
SARC	cis	rs453301	0.631	rs11780774	chr8:8799111	C/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.93	-0.41	4.03e-11	Joint mobility (Beighton score);
SARC	cis	rs4481887	0.741	rs6587458	chr1:248532290	T/A	cg13385794	chr1:248469461	NA	0.35	5.57	0.34	6.97e-8	Common traits (Other);
SARC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg02725872	chr8:58115012	NA	-0.37	-6.47	-0.39	5.76e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs5769765	0.908	rs9627788	chr22:50300438	T/C	cg03033257	chr22:50311977	ALG12;CRELD2	0.51	5.31	0.33	2.55e-7	Schizophrenia;
SARC	cis	rs7481584	0.603	rs399467	chr11:3072348	G/A	cg25174290	chr11:3078921	CARS	-0.57	-7.96	-0.46	7.45e-14	Calcium levels;
SARC	cis	rs72945132	0.714	rs117232799	chr11:70157182	G/A	cg05964544	chr11:70165517	PPFIA1	-0.63	-5.9	-0.36	1.27e-8	Coronary artery disease;
SARC	cis	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg13647721	chr17:30228624	UTP6	0.62	5.66	0.35	4.39e-8	Hip circumference adjusted for BMI;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg14346362	chr20:5918840	TRMT6	0.47	6.42	0.39	7.41e-10	Thyroid stimulating hormone;
SARC	cis	rs9430161	0.611	rs35033941	chr1:11034382	C/T	cg27631724	chr1:11040367	C1orf127	0.33	4.71	0.3	4.2e-6	Ewing sarcoma;
SARC	cis	rs3733585	0.673	rs7672947	chr4:9961368	G/C	cg11266682	chr4:10021025	SLC2A9	-0.36	-6.04	-0.37	5.91e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg19318889	chr4:1322082	MAEA	0.4	4.98	0.31	1.26e-6	Longevity;
SARC	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg11843238	chr5:131593191	PDLIM4	0.39	5.47	0.34	1.14e-7	Breast cancer;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg15750611	chr11:68191055	LRP5	0.45	6.45	0.39	6.44e-10	Neuroticism;
SARC	cis	rs870825	0.860	rs61165411	chr4:185604461	G/A	cg04058563	chr4:185651563	MLF1IP	0.81	9.77	0.54	4.03e-19	Blood protein levels;
SARC	cis	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg18252515	chr7:66147081	NA	-1.38	-12.57	-0.64	5.19e-28	Diabetic kidney disease;
SARC	cis	rs9612	1.000	rs2277745	chr19:44259077	C/T	cg07522664	chr19:44259120	C19orf61	0.46	5.26	0.33	3.25e-7	Exhaled nitric oxide output;
SARC	cis	rs7647973	0.710	rs6446284	chr3:49616997	A/G	cg06212747	chr3:49208901	KLHDC8B	0.73	6.49	0.39	5.02e-10	Menarche (age at onset);
SARC	cis	rs2120019	0.567	rs8029351	chr15:75177237	A/C	cg09165964	chr15:75287851	SCAMP5	-0.95	-10.7	-0.57	5.56e-22	Blood trace element (Zn levels);
SARC	cis	rs7662987	0.517	rs2602858	chr4:100030461	T/C	cg12011299	chr4:100065546	ADH4	0.33	5.57	0.34	6.86e-8	Smoking initiation;
SARC	cis	rs362296	0.661	rs3095079	chr4:3265414	A/G	cg06533319	chr4:3265114	C4orf44	-0.35	-5.72	-0.35	3.19e-8	Parental longevity (mother's age at death);
SARC	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg05890377	chr2:74357713	NA	0.61	7.34	0.43	3.62e-12	Gestational age at birth (maternal effect);
SARC	cis	rs908922	0.676	rs4112785	chr1:152533115	G/C	cg09873164	chr1:152488093	CRCT1	0.59	7.72	0.45	3.34e-13	Hair morphology;
SARC	trans	rs561341	1.000	rs550264	chr17:30317540	G/T	cg20587970	chr11:113659929	NA	-1.33	-13.74	-0.67	7.52e-32	Hip circumference adjusted for BMI;
SARC	trans	rs7824557	0.564	rs2572386	chr8:11236975	A/G	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.32	-0.38	1.32e-9	Retinal vascular caliber;
SARC	cis	rs881375	0.933	rs4837799	chr9:123668326	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	4.87	0.3	2.03e-6	Rheumatoid arthritis;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg13445984	chr19:53117087	ZNF83	-0.52	-6.52	-0.39	4.43e-10	Height;
SARC	cis	rs6546324	0.694	rs1023692	chr2:67868756	T/C	cg18237512	chr2:67827392	NA	-0.51	-6.25	-0.38	1.98e-9	Endometriosis;
SARC	cis	rs1215050	0.682	rs6839343	chr4:98839732	G/A	cg05340658	chr4:99064831	C4orf37	0.4	4.77	0.3	3.32e-6	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs62244186	0.566	rs6766221	chr3:44882784	C/T	cg15687855	chr3:44754131	ZNF502	-0.35	-5.28	-0.33	2.91e-7	Depressive symptoms;
SARC	cis	rs4919087	0.748	rs701817	chr10:98977329	G/C	cg25902810	chr10:99078978	FRAT1	-0.55	-6.22	-0.38	2.25e-9	Monocyte count;
SARC	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg19774624	chr17:42201019	HDAC5	-0.8	-11.43	-0.6	2.52e-24	Total body bone mineral density;
SARC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg26338869	chr17:61819248	STRADA	0.81	10.95	0.58	8.96e-23	Prudent dietary pattern;
SARC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.63	-7.84	-0.46	1.62e-13	Longevity;Endometriosis;
SARC	cis	rs920590	1.000	rs6995371	chr8:19650268	A/G	cg03894339	chr8:19674705	INTS10	0.48	5.95	0.36	9.6e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs6580649	0.941	rs4589362	chr12:48478664	T/C	cg05342945	chr12:48394962	COL2A1	0.55	5.91	0.36	1.22e-8	Lung cancer;
SARC	cis	rs10463316	0.862	rs10062928	chr5:150768355	C/T	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.23	-0.32	3.86e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg02711726	chr17:80685570	FN3KRP	-0.55	-6.69	-0.4	1.68e-10	Glycated hemoglobin levels;
SARC	cis	rs13191362	1.000	rs36113695	chr6:163004733	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.49	0.34	1.04e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs4144743	0.528	rs12940207	chr17:45352194	G/T	cg18085866	chr17:45331354	ITGB3	-0.8	-6.47	-0.39	5.76e-10	Body mass index;
SARC	cis	rs6088580	0.634	rs6059856	chr20:33057954	G/C	cg08999081	chr20:33150536	PIGU	0.43	6.57	0.4	3.3e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs7647973	0.667	rs6446286	chr3:49681704	A/G	cg06212747	chr3:49208901	KLHDC8B	0.58	5.74	0.35	2.88e-8	Menarche (age at onset);
SARC	cis	rs7772486	0.790	rs2265918	chr6:146219164	A/G	cg23711669	chr6:146136114	FBXO30	0.8	12.59	0.64	4.55e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2559856	0.967	rs2559863	chr12:102087108	C/T	cg12924262	chr12:102091054	CHPT1	0.56	7.6	0.45	7.35e-13	Blood protein levels;
SARC	cis	rs7665147	1	rs7665147	chr4:57767327	T/A	cg26694713	chr4:57773883	REST	0.63	6.42	0.39	7.6e-10	Platelet count;
SARC	cis	rs9902453	0.791	rs3098950	chr17:27998385	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	7.27	0.43	5.49e-12	Coffee consumption (cups per day);
SARC	cis	rs11608355	0.545	rs12818120	chr12:109901916	C/T	cg05360138	chr12:110035743	NA	0.93	9.68	0.54	7.53e-19	Neuroticism;
SARC	cis	rs6088590	0.687	rs6088580	chr20:33285053	G/C	cg08999081	chr20:33150536	PIGU	0.43	6.43	0.39	6.98e-10	Coronary artery disease;
SARC	cis	rs35955747	0.902	rs713947	chr22:31639509	G/T	cg13145458	chr22:31556086	RNF185	0.43	5.36	0.33	2.05e-7	Neutrophil count;Sum basophil neutrophil counts;
SARC	cis	rs6676180	0.555	rs947430	chr1:119778734	G/A	cg05756136	chr1:119680316	WARS2	-0.39	-5.19	-0.32	4.53e-7	Monobrow;
SARC	cis	rs995000	0.899	rs1167998	chr1:62931632	C/A	cg06896770	chr1:63153194	DOCK7	-0.91	-13.93	-0.67	1.67e-32	Triglyceride levels;
SARC	trans	rs615632	0.570	rs17734541	chr8:9708433	A/G	cg06636001	chr8:8085503	FLJ10661	0.57	7.38	0.44	2.7e-12	Neuroticism;
SARC	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg19346786	chr7:2764209	NA	-0.39	-5.74	-0.35	2.99e-8	Height;
SARC	cis	rs9300255	0.602	rs1569068	chr12:123632276	A/G	cg05973401	chr12:123451056	ABCB9	-0.59	-6.46	-0.39	5.97e-10	Neutrophil percentage of white cells;
SARC	cis	rs460214	0.553	rs9976546	chr21:40028193	C/G	cg12884169	chr21:40033163	ERG	-0.33	-4.72	-0.3	4.11e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs10463554	0.963	rs40093	chr5:102439825	A/T	cg23492399	chr5:102201601	PAM	-0.47	-5.2	-0.32	4.32e-7	Parkinson's disease;
SARC	cis	rs501120	1.000	rs605445	chr10:44756779	C/T	cg09554077	chr10:44749378	NA	0.48	6.49	0.39	5.12e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs67311347	1.000	rs7636719	chr3:40432084	C/T	cg09455208	chr3:40491958	NA	0.41	6.33	0.38	1.27e-9	Renal cell carcinoma;
SARC	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg11965913	chr1:205819406	PM20D1	1.0	19.55	0.79	4.89e-51	Menarche (age at onset);
SARC	cis	rs7208859	0.623	rs9893422	chr17:29111715	A/G	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs936229	1.000	rs4886615	chr15:75131661	A/G	cg14664628	chr15:75095509	CSK	-1.01	-12.69	-0.64	2.18e-28	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs2073499	0.872	rs41291724	chr3:50294066	C/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.61	5.47	0.34	1.17e-7	Schizophrenia;
SARC	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg02711726	chr17:80685570	FN3KRP	-0.52	-6.18	-0.38	2.79e-9	Glycated hemoglobin levels;
SARC	cis	rs7772486	0.790	rs2253768	chr6:146199922	A/G	cg23711669	chr6:146136114	FBXO30	0.84	13.77	0.67	5.8e-32	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1580019	0.563	rs4723169	chr7:32567577	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.61	8.14	0.47	2.31e-14	Cognitive ability;
SARC	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg18135555	chr8:22132992	PIWIL2	0.41	6.27	0.38	1.76e-9	Hypertriglyceridemia;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg11154384	chr15:67814409	C15orf61	0.5	6.72	0.4	1.42e-10	Lung adenocarcinoma;
SARC	cis	rs17376456	0.825	rs6874766	chr5:93213807	C/G	cg21475434	chr5:93447410	FAM172A	-0.79	-6.37	-0.39	9.93e-10	Diabetic retinopathy;
SARC	cis	rs6088580	0.601	rs6059827	chr20:33016358	C/T	cg08999081	chr20:33150536	PIGU	0.45	6.9	0.41	4.93e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.45	-5.49	-0.34	1.05e-7	Gut microbiome composition (summer);
SARC	cis	rs4853036	1.000	rs56223710	chr2:70049715	C/T	cg02498382	chr2:70120550	SNRNP27	-0.42	-5.68	-0.35	3.94e-8	Colorectal or endometrial cancer;
SARC	cis	rs2153535	0.580	rs4404802	chr6:8442052	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs62158211	0.955	rs1823125	chr2:114090412	C/T	cg17784749	chr2:114082611	LOC440839	-0.66	-6.91	-0.41	4.54e-11	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
SARC	cis	rs1050631	0.592	rs1632169	chr18:33709762	G/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.55	6.38	0.39	9.31e-10	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs77106637	0.722	rs11605691	chr11:72419514	C/T	cg03713592	chr11:72463424	ARAP1	1.08	9.7	0.54	6.65e-19	Type 2 diabetes;
SARC	cis	rs3857067	0.806	rs6817795	chr4:95127716	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.06	-0.31	8.38e-7	QT interval;
SARC	cis	rs2732480	0.577	rs2732486	chr12:48737834	G/A	cg21466736	chr12:48725269	NA	-0.34	-5.31	-0.33	2.54e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg18252515	chr7:66147081	NA	-1.43	-12.98	-0.65	2.35e-29	Gout;
SARC	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg11644478	chr21:40555479	PSMG1	-0.58	-7.24	-0.43	6.36e-12	Menarche (age at onset);
SARC	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg03806693	chr22:41940476	POLR3H	-0.96	-13.34	-0.66	1.6e-30	Vitiligo;
SARC	cis	rs7615952	0.546	rs2979340	chr3:125341384	C/T	cg05084668	chr3:125655381	ALG1L	-0.53	-5.01	-0.31	1.1e-6	Blood pressure (smoking interaction);
SARC	cis	rs55883249	1.000	rs62119423	chr2:9726601	C/T	cg23886495	chr2:9695866	ADAM17	0.69	6.98	0.42	3.12e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs9896052	0.534	rs8065160	chr17:73441090	A/G	cg25649188	chr17:73499917	CASKIN2	-0.37	-5.2	-0.32	4.26e-7	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg05660315	chr16:30543920	ZNF747	0.52	6.58	0.4	3.15e-10	Schizophrenia;
SARC	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg18252515	chr7:66147081	NA	-0.65	-6.9	-0.41	4.73e-11	Aortic root size;
SARC	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg13939156	chr17:80058883	NA	0.36	5.62	0.35	5.52e-8	Life satisfaction;
SARC	cis	rs72945132	0.882	rs7943547	chr11:70133282	C/A	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.78	-0.35	2.39e-8	Coronary artery disease;
SARC	cis	rs9902453	0.845	rs3115101	chr17:28041627	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	7.08	0.42	1.69e-11	Coffee consumption (cups per day);
SARC	cis	rs782590	0.522	rs12329050	chr2:55894428	G/A	cg18811423	chr2:55921094	PNPT1	-0.59	-7.59	-0.45	7.56e-13	Metabolic syndrome;
SARC	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg22105103	chr4:187893119	NA	0.5	6.47	0.39	5.84e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7647973	0.848	rs4955426	chr3:49143438	C/A	cg07636037	chr3:49044803	WDR6	0.83	8.38	0.48	5e-15	Menarche (age at onset);
SARC	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-8.45	-0.48	3.24e-15	Alzheimer's disease;
SARC	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg03806693	chr22:41940476	POLR3H	-0.94	-12.83	-0.64	7.2e-29	Vitiligo;
SARC	cis	rs9858542	0.953	rs6766131	chr3:49538932	T/C	cg07274523	chr3:49395745	GPX1	0.53	6.13	0.37	3.82e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs7566780	0.772	rs35207525	chr2:16728141	C/T	cg09580478	chr2:16689509	NA	-0.52	-5.64	-0.35	4.89e-8	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs3092073	0.624	rs13040315	chr20:44585793	A/G	cg17986701	chr20:44574422	PCIF1	0.34	4.81	0.3	2.77e-6	Intelligence (multi-trait analysis);
SARC	cis	rs8017423	0.935	rs9944124	chr14:90791501	T/C	cg20276874	chr14:90721474	PSMC1	-0.38	-5.13	-0.32	6.2e-7	Mortality in heart failure;
SARC	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg22535103	chr8:58192502	C8orf71	-0.59	-6.21	-0.38	2.35e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg16308533	chr17:40838983	CNTNAP1	0.38	5.49	0.34	1.05e-7	Colorectal or endometrial cancer;
SARC	cis	rs7709377	0.951	rs2112570	chr5:115547594	C/G	cg26201826	chr5:114598579	PGGT1B	0.43	4.78	0.3	3.16e-6	Metabolite levels  (X-11787);
SARC	cis	rs11225247	0.772	rs35623064	chr11:102237391	T/C	cg11690896	chr11:102217788	BIRC2	0.72	5.19	0.32	4.65e-7	Vein graft stenosis in coronary artery bypass grafting;
SARC	cis	rs6088590	1.000	rs6120750	chr20:33465289	A/C	cg06115741	chr20:33292138	TP53INP2	0.61	7.58	0.44	8.13e-13	Coronary artery disease;
SARC	cis	rs6909752	0.611	rs7770180	chr6:22565043	T/C	cg13666174	chr6:22585274	NA	-0.43	-4.88	-0.3	1.99e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
SARC	cis	rs17376456	0.877	rs10055741	chr5:93297187	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.8	0.35	2.2e-8	Diabetic retinopathy;
SARC	cis	rs9902453	0.845	rs12602426	chr17:28158815	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	7.16	0.42	1.07e-11	Coffee consumption (cups per day);
SARC	cis	rs6840258	1.000	rs72667759	chr4:87952199	C/G	cg11209507	chr4:87813803	C4orf36	0.43	4.74	0.3	3.74e-6	Mean corpuscular volume;Basophil percentage of granulocytes;
SARC	cis	rs2832191	0.765	rs2832162	chr21:30461808	G/A	cg24692254	chr21:30365293	RNF160	1.0	17.0	0.74	1.05e-42	Dental caries;
SARC	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg22857025	chr5:266934	NA	-1.04	-11.74	-0.61	2.61e-25	Breast cancer;
SARC	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.89	11.86	0.61	1.05e-25	Platelet count;
SARC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.4	4.93	0.31	1.55e-6	Electroencephalogram traits;
SARC	cis	rs778371	0.697	rs11893358	chr2:233636922	T/C	cg20388707	chr2:233749442	NGEF	-0.35	-5.26	-0.33	3.2e-7	Schizophrenia;
SARC	cis	rs55879323	1	rs55879323	chr1:152168740	C/T	cg25272121	chr1:152190972	HRNR	-0.39	-5.18	-0.32	4.71e-7	Inflammatory skin disease;
SARC	cis	rs11122272	0.735	rs2790876	chr1:231536033	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.08	-0.55	4.68e-20	Hemoglobin concentration;
SARC	cis	rs7560272	0.501	rs2006997	chr2:73947846	G/A	cg20560298	chr2:73613845	ALMS1	0.46	6.07	0.37	5.19e-9	Schizophrenia;
SARC	cis	rs9462027	0.588	rs13215181	chr6:34759881	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.85	-0.36	1.63e-8	Systemic lupus erythematosus;
SARC	cis	rs2486288	0.656	rs11632777	chr15:45551045	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.51	-6.44	-0.39	6.68e-10	Glomerular filtration rate;
SARC	cis	rs57083693	0.518	rs7315815	chr12:101747517	C/G	cg22051763	chr12:101673672	UTP20	-0.47	-5.68	-0.35	4.03e-8	Alcohol dependence (age at onset);
SARC	cis	rs6141769	0.569	rs6058799	chr20:31257732	A/G	cg17884169	chr20:31446444	EFCAB8	-0.44	-4.76	-0.3	3.46e-6	Subjective well-being;
SARC	trans	rs11098499	0.955	rs7684942	chr4:120162201	C/T	cg25214090	chr10:38739885	LOC399744	0.52	6.86	0.41	6.19e-11	Corneal astigmatism;
SARC	cis	rs9291683	0.527	rs73212848	chr4:10093299	T/C	cg00071950	chr4:10020882	SLC2A9	-0.39	-5.83	-0.36	1.83e-8	Bone mineral density;
SARC	cis	rs1005277	0.540	rs289638	chr10:37923731	G/A	cg25427524	chr10:38739819	LOC399744	-0.51	-7.78	-0.45	2.39e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs7833986	0.501	rs2976044	chr8:56986737	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.63	6.98	0.42	2.98e-11	Height;
SARC	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9650657	0.644	rs6601535	chr8:10695652	G/C	cg21775007	chr8:11205619	TDH	-0.39	-4.82	-0.3	2.58e-6	Neuroticism;
SARC	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-9.87	-0.54	1.98e-19	Chronic sinus infection;
SARC	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg06634786	chr22:41940651	POLR3H	-0.51	-6.15	-0.37	3.43e-9	Vitiligo;
SARC	trans	rs1814175	0.645	rs7115592	chr11:50013243	A/G	cg03929089	chr4:120376271	NA	-0.82	-11.88	-0.61	9.03e-26	Height;
SARC	cis	rs4243830	0.522	rs11122086	chr1:6601246	T/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.89	-9.21	-0.52	2.01e-17	Body mass index;
SARC	cis	rs4642101	0.765	rs4321514	chr3:12825901	C/T	cg05775895	chr3:12838266	CAND2	0.75	12.1	0.62	1.82e-26	QRS complex (12-leadsum);
SARC	cis	rs1568889	0.838	rs1525717	chr11:28081205	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.87	14.89	0.7	1.06e-35	Bipolar disorder;
SARC	cis	rs9815354	0.830	rs1716698	chr3:41957466	T/G	cg03022575	chr3:42003672	ULK4	-0.55	-5.26	-0.33	3.22e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs787274	0.867	rs786983	chr9:115458629	T/C	cg13803584	chr9:115635662	SNX30	0.75	5.85	0.36	1.63e-8	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs950169	0.922	rs12912934	chr15:85114447	C/T	cg17507749	chr15:85114479	UBE2QP1	0.79	9.46	0.53	3.42e-18	Schizophrenia;
SARC	cis	rs9325144	0.624	rs10783330	chr12:39114084	A/G	cg26384229	chr12:38710491	ALG10B	-0.59	-7.5	-0.44	1.34e-12	Morning vs. evening chronotype;
SARC	cis	rs5769765	0.913	rs4824111	chr22:50284305	A/G	cg03033257	chr22:50311977	ALG12;CRELD2	-0.63	-6.34	-0.38	1.17e-9	Schizophrenia;
SARC	cis	rs9788721	0.933	rs72738786	chr15:78828086	G/T	cg18825076	chr15:78729989	IREB2	-0.46	-5.53	-0.34	8.46e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	0.69	7.06	0.42	1.87e-11	Platelet count;
SARC	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg00684032	chr4:1343700	KIAA1530	0.39	5.72	0.35	3.28e-8	Obesity-related traits;
SARC	cis	rs2916247	0.909	rs13259499	chr8:93057823	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.57	-5.88	-0.36	1.38e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7043114	0.563	rs7848391	chr9:95337520	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.74	-0.35	2.88e-8	Height;
SARC	trans	rs208515	0.525	rs10755508	chr6:66675790	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.9	10.58	0.57	1.26e-21	Exhaled nitric oxide levels;
SARC	trans	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg07500501	chr5:54603554	SKIV2L2;DHX29	0.46	6.29	0.38	1.55e-9	Immature fraction of reticulocytes;
SARC	trans	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg20587970	chr11:113659929	NA	-1.21	-12.66	-0.64	2.66e-28	Hip circumference adjusted for BMI;
SARC	cis	rs10927875	0.619	rs12121764	chr1:16138059	A/T	cg21385522	chr1:16154831	NA	-0.61	-8.38	-0.48	5.02e-15	Dilated cardiomyopathy;
SARC	cis	rs9916302	0.665	rs4795369	chr17:37609120	G/A	cg00129232	chr17:37814104	STARD3	-0.58	-7.06	-0.42	1.86e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs12579753	1.000	rs10862373	chr12:82250657	A/G	cg07988820	chr12:82153109	PPFIA2	-0.54	-6.18	-0.38	2.86e-9	Resting heart rate;
SARC	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg02592271	chr2:27665507	KRTCAP3	0.41	6.2	0.38	2.5e-9	Total body bone mineral density;
SARC	cis	rs7264396	0.690	rs17093156	chr20:34438583	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-7.07	-0.42	1.76e-11	Total cholesterol levels;
SARC	cis	rs6570726	0.738	rs6925594	chr6:145898454	T/C	cg05347473	chr6:146136440	FBXO30	0.51	7.2	0.43	8.39e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.79	7.88	0.46	1.24e-13	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs739401	0.611	rs450817	chr11:3056712	A/G	cg08508325	chr11:3079039	CARS	-0.32	-7.71	-0.45	3.74e-13	Longevity;
SARC	cis	rs4243830	1.000	rs10158949	chr1:6583701	T/C	cg04093404	chr1:6614507	TAS1R1;NOL9	0.69	4.78	0.3	3.09e-6	Body mass index;
SARC	trans	rs3857536	0.706	rs7755994	chr6:66891747	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.6	-7.14	-0.42	1.19e-11	Blood trace element (Cu levels);
SARC	cis	rs7617773	0.743	rs13071960	chr3:48367537	A/G	cg11946769	chr3:48343235	NME6	0.77	9.81	0.54	2.97e-19	Coronary artery disease;
SARC	cis	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg07777115	chr5:623756	CEP72	-0.65	-6.05	-0.37	5.86e-9	Obesity-related traits;
SARC	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg12463550	chr7:65579703	CRCP	-0.46	-4.88	-0.3	2.01e-6	Aortic root size;
SARC	trans	rs9302817	0.891	rs2343522	chr16:6163660	G/T	cg20068074	chr3:48672407	SLC26A6	-0.7	-6.54	-0.39	3.84e-10	Body mass index;
SARC	cis	rs17253792	0.822	rs17253716	chr14:56153661	G/C	cg01858014	chr14:56050164	KTN1	-0.63	-4.8	-0.3	2.9e-6	Putamen volume;
SARC	cis	rs17376456	0.757	rs10066431	chr5:93198204	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.7	6.29	0.38	1.52e-9	Diabetic retinopathy;
SARC	cis	rs9325144	0.600	rs6582630	chr12:38743508	A/G	cg13010199	chr12:38710504	ALG10B	-0.56	-7.28	-0.43	5e-12	Morning vs. evening chronotype;
SARC	cis	rs734999	0.588	rs2764842	chr1:2529192	A/G	cg00980319	chr1:2560884	MMEL1	0.35	4.91	0.31	1.7e-6	Ulcerative colitis;
SARC	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg16479474	chr6:28041457	NA	0.36	5.23	0.32	3.68e-7	Depression;
SARC	cis	rs4268898	0.662	rs72793967	chr2:24422902	C/T	cg06627628	chr2:24431161	ITSN2	-0.84	-10.15	-0.55	2.89e-20	Asthma;
SARC	cis	rs11190604	1.000	rs10883510	chr10:102297018	C/T	cg07080220	chr10:102295463	HIF1AN	0.78	8.81	0.5	2.92e-16	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs1034435	0.755	rs5767172	chr22:48892314	A/C	cg05992904	chr22:48892994	FAM19A5	-0.49	-7.3	-0.43	4.45e-12	Late-onset Alzheimer's disease;
SARC	cis	rs10988449	0.891	rs7856232	chr9:132393777	A/C	cg18327994	chr9:132372705	NA	-0.5	-5.05	-0.31	9.01e-7	Response to anti-depressant treatment in major depressive disorder;
SARC	cis	rs12579753	0.917	rs7954438	chr12:82184419	T/C	cg07988820	chr12:82153109	PPFIA2	-0.52	-6.21	-0.38	2.35e-9	Resting heart rate;
SARC	trans	rs7980799	0.682	rs61927702	chr12:33631695	A/G	cg13010199	chr12:38710504	ALG10B	-0.53	-6.29	-0.38	1.54e-9	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs6582630	0.555	rs34884627	chr12:38443831	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-6.86	-0.41	6.16e-11	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs561341	1.000	rs55962687	chr17:30260369	C/T	cg20587970	chr11:113659929	NA	-1.3	-12.75	-0.64	1.39e-28	Hip circumference adjusted for BMI;
SARC	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg08219700	chr8:58056026	NA	0.62	6.52	0.39	4.28e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7617773	0.780	rs6793223	chr3:48364101	C/T	cg11946769	chr3:48343235	NME6	0.77	9.81	0.54	2.97e-19	Coronary artery disease;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg18280492	chr10:124913593	BUB3	0.51	6.35	0.38	1.13e-9	Lung adenocarcinoma;
SARC	cis	rs698833	0.926	rs1067370	chr2:44652343	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.63	8.07	0.47	3.82e-14	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs11700980	0.636	rs35497275	chr21:30275022	G/A	cg24692254	chr21:30365293	RNF160	-0.7	-5.35	-0.33	2.09e-7	QRS complex (12-leadsum);
SARC	cis	rs9911578	0.933	rs2531725	chr17:56517962	G/A	cg12560992	chr17:57184187	TRIM37	0.78	10.13	0.55	3.16e-20	Intelligence (multi-trait analysis);
SARC	cis	rs796364	1.000	rs281785	chr2:200749566	A/G	cg23649088	chr2:200775458	C2orf69	0.59	5.32	0.33	2.43e-7	Schizophrenia;
SARC	cis	rs7829975	0.572	rs7005000	chr8:8796602	A/G	cg14343924	chr8:8086146	FLJ10661	-0.4	-4.95	-0.31	1.41e-6	Mood instability;
SARC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.28	0.8	2.29e-53	Prudent dietary pattern;
SARC	cis	rs67478160	0.595	rs2295146	chr14:104199356	C/T	cg26031613	chr14:104095156	KLC1	-0.42	-5.15	-0.32	5.61e-7	Schizophrenia;
SARC	cis	rs2576037	0.796	rs2247221	chr18:44580082	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.49	6.54	0.39	3.94e-10	Personality dimensions;
SARC	cis	rs933688	1.000	rs6452953	chr5:90723034	T/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.02	13.39	0.66	1.04e-30	Smoking behavior;
SARC	cis	rs2276314	0.857	rs7237599	chr18:33639396	T/C	cg19628046	chr18:33552617	C18orf21	0.55	5.87	0.36	1.5e-8	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg13395646	chr4:1353034	KIAA1530	-0.41	-4.95	-0.31	1.45e-6	Longevity;
SARC	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg09165964	chr15:75287851	SCAMP5	0.59	7.96	0.46	7.74e-14	Breast cancer;
SARC	cis	rs910316	0.737	rs175077	chr14:75506875	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.5	-6.73	-0.4	1.3e-10	Height;
SARC	cis	rs2921073	0.510	rs2976945	chr8:8270871	G/T	cg08975724	chr8:8085496	FLJ10661	0.55	6.62	0.4	2.4e-10	Parkinson's disease;
SARC	cis	rs870825	0.550	rs35981185	chr4:185639720	A/C	cg04058563	chr4:185651563	MLF1IP	0.79	11.24	0.59	1.03e-23	Blood protein levels;
SARC	cis	rs1008375	1.000	rs10939747	chr4:17691166	C/A	cg27347728	chr4:17578864	LAP3	0.46	5.71	0.35	3.38e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg11062466	chr8:58055876	NA	0.61	5.64	0.35	5.01e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs644799	0.601	rs7902	chr11:95565288	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	11.17	0.59	1.76e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg13939156	chr17:80058883	NA	-0.44	-6.84	-0.41	6.73e-11	Life satisfaction;
SARC	cis	rs10916814	0.610	rs4655222	chr1:20901418	C/T	cg24502330	chr1:20914028	CDA	-0.29	-4.99	-0.31	1.16e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs5753618	0.561	rs2413047	chr22:31666026	A/G	cg00478049	chr22:31556069	RNF185	0.44	4.84	0.3	2.37e-6	Colorectal cancer;
SARC	cis	rs3092073	0.617	rs17448680	chr20:44594726	T/C	cg00981651	chr20:44574847	PCIF1	-0.33	-5.23	-0.32	3.75e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6003958	1	rs6003958	chr22:24264089	T/G	cg16132339	chr22:24313637	DDTL;DDT	-0.42	-4.94	-0.31	1.46e-6	S-phenylmercapturic acid levels in smokers;
SARC	trans	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg15556689	chr8:8085844	FLJ10661	0.55	7.05	0.42	1.96e-11	Triglycerides;
SARC	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	15.35	0.71	3.17e-37	Chronic sinus infection;
SARC	cis	rs459571	0.876	rs2520095	chr9:136919568	A/G	cg13789015	chr9:136890014	NCRNA00094	0.61	8.48	0.49	2.57e-15	Platelet distribution width;
SARC	trans	rs208520	0.661	rs7766144	chr6:66827795	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-13.6	-0.67	2.17e-31	Exhaled nitric oxide output;
SARC	trans	rs2727020	0.619	rs1829979	chr11:49436875	T/G	cg03929089	chr4:120376271	NA	-0.71	-7.87	-0.46	1.35e-13	Coronary artery disease;
SARC	cis	rs2836974	0.653	rs8130556	chr21:40516872	C/T	cg11644478	chr21:40555479	PSMG1	1.01	13.5	0.66	4.41e-31	Cognitive function;
SARC	cis	rs826838	0.678	rs11182781	chr12:38610178	C/T	cg26384229	chr12:38710491	ALG10B	0.89	13.47	0.66	5.74e-31	Heart rate;
SARC	cis	rs2250402	0.510	rs6492926	chr15:40325829	T/G	cg01081584	chr15:40268610	EIF2AK4	-0.73	-6.2	-0.38	2.5e-9	Corneal curvature;
SARC	cis	rs9733	0.818	rs4970924	chr1:150633079	A/G	cg15448220	chr1:150897856	SETDB1	-0.36	-4.72	-0.3	4.13e-6	Tonsillectomy;
SARC	cis	rs2033732	0.643	rs10101396	chr8:85060125	A/G	cg05716166	chr8:85095498	RALYL	0.47	5.62	0.35	5.51e-8	Body mass index;
SARC	cis	rs9682041	0.877	rs10804841	chr3:170072031	T/A	cg11886554	chr3:170076028	SKIL	0.63	6.33	0.38	1.24e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs3923518	1.000	rs11928473	chr3:38897271	T/C	cg15678707	chr3:39149194	GORASP1;TTC21A	0.48	5.12	0.32	6.5e-7	Migraine;
SARC	cis	rs9436747	0.566	rs112314233	chr1:65973295	C/G	cg14976592	chr1:65886160	LEPROT;LEPR	-0.42	-5.37	-0.33	1.93e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs7000551	0.725	rs4871998	chr8:22308150	A/T	cg12081754	chr8:22256438	SLC39A14	0.61	8.45	0.48	3.13e-15	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.69	7.32	0.43	4.08e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7412746	0.611	rs10888394	chr1:150749913	C/T	cg15448220	chr1:150897856	SETDB1	0.48	6.25	0.38	1.99e-9	Melanoma;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg14562158	chr9:117880491	TNC	-0.48	-6.54	-0.39	3.79e-10	Chemerin levels;
SARC	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg12463550	chr7:65579703	CRCP	0.66	5.06	0.31	8.64e-7	Diabetic kidney disease;
SARC	cis	rs9916302	0.706	rs3744349	chr17:37414842	C/T	cg00129232	chr17:37814104	STARD3	-0.55	-5.96	-0.36	9.13e-9	Glomerular filtration rate (creatinine);
SARC	trans	rs2727020	0.658	rs7111215	chr11:49430552	T/C	cg15704280	chr7:45808275	SEPT13	-0.86	-14.07	-0.68	5.88e-33	Coronary artery disease;
SARC	cis	rs1832871	0.711	rs9457300	chr6:158714609	G/C	cg07165851	chr6:158734300	TULP4	0.54	6.51	0.39	4.65e-10	Height;
SARC	cis	rs9326248	1.000	rs9326248	chr11:116999225	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.51	5.59	0.34	6.45e-8	Blood protein levels;
SARC	cis	rs6121246	0.559	rs6058468	chr20:30406448	C/A	cg13852791	chr20:30311386	BCL2L1	0.88	10.78	0.58	3.12e-22	Mean corpuscular hemoglobin;
SARC	cis	rs1003719	0.725	rs2187101	chr21:38452379	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.65	9.46	0.53	3.54e-18	Eye color traits;
SARC	cis	rs9790314	0.936	rs466399	chr3:161091194	G/T	cg03342759	chr3:160939853	NMD3	-0.59	-7.58	-0.44	7.99e-13	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg08219700	chr8:58056026	NA	0.66	6.25	0.38	1.97e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2230307	0.572	rs6677080	chr1:100633469	A/T	cg24955406	chr1:100503596	HIAT1	0.69	6.52	0.39	4.29e-10	Carotid intima media thickness;
SARC	cis	rs6693567	0.545	rs9436009	chr1:150459426	T/A	cg09579323	chr1:150459698	TARS2	0.43	5.51	0.34	9.7e-8	Migraine;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg08434152	chr2:74405770	MOBKL1B	0.55	6.8	0.41	8.73e-11	Breast cancer;
SARC	cis	rs5753618	0.561	rs4603880	chr22:31744721	T/C	cg02404636	chr22:31891804	SFI1	0.49	5.4	0.33	1.68e-7	Colorectal cancer;
SARC	cis	rs4742903	0.904	rs28658011	chr9:107006925	G/A	cg14250997	chr9:106856677	SMC2	0.38	4.73	0.3	3.88e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg22535103	chr8:58192502	C8orf71	-0.73	-7.24	-0.43	6.52e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs7312774	0.618	rs28716736	chr12:107364410	A/G	cg16260113	chr12:107380972	MTERFD3	1.09	8.72	0.5	5.32e-16	Severe influenza A (H1N1) infection;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg12955121	chr20:33680750	TRPC4AP	-0.5	-6.63	-0.4	2.36e-10	Chemerin levels;
SARC	trans	rs877282	0.842	rs35872126	chr10:764545	G/A	cg22713356	chr15:30763199	NA	1.04	10.06	0.55	5.37e-20	Uric acid levels;
SARC	cis	rs2013441	1.000	rs2703794	chr17:20073338	T/C	cg13482628	chr17:19912719	NA	0.48	6.15	0.37	3.36e-9	Obesity-related traits;
SARC	cis	rs4969178	0.965	rs12451791	chr17:76397343	G/A	cg20026190	chr17:76395443	PGS1	0.4	5.37	0.33	1.94e-7	HDL cholesterol levels;
SARC	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg13206674	chr6:150067644	NUP43	0.42	5.58	0.34	6.82e-8	Lung cancer;
SARC	cis	rs12950390	0.853	rs11655112	chr17:45856563	T/C	cg24803719	chr17:45855879	NA	-0.47	-7.63	-0.45	6.05e-13	IgG glycosylation;
SARC	cis	rs1163251	0.837	rs595283	chr1:120247887	C/G	cg19096424	chr1:120255104	PHGDH	-0.56	-6.81	-0.41	8.34e-11	Blood metabolite levels;
SARC	cis	rs62432291	0.681	rs423533	chr6:159664516	G/T	cg14500486	chr6:159655392	FNDC1	-0.57	-5.88	-0.36	1.43e-8	Joint mobility (Beighton score);
SARC	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg11814155	chr7:99998594	ZCWPW1	0.44	4.73	0.3	3.84e-6	Platelet count;
SARC	cis	rs9807989	0.507	rs6726985	chr2:103048580	G/A	cg03938978	chr2:103052716	IL18RAP	0.32	5.18	0.32	4.72e-7	Asthma;
SARC	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg16479474	chr6:28041457	NA	0.37	5.44	0.34	1.37e-7	Depression;
SARC	cis	rs2425143	0.822	rs6060677	chr20:34499368	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.73	6.06	0.37	5.53e-9	Blood protein levels;
SARC	cis	rs1983170	0.808	rs4658230	chr1:92019325	T/C	cg25838465	chr1:92012736	NA	0.44	5.29	0.33	2.86e-7	Eosinophil percentage of white cells;
SARC	cis	rs9381107	0.858	rs6458230	chr6:9465363	G/A	cg14735645	chr6:9486422	NA	-0.44	-4.85	-0.3	2.22e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs7520050	0.966	rs785481	chr1:46554518	G/A	cg06784218	chr1:46089804	CCDC17	-0.26	-4.82	-0.3	2.57e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs709400	0.663	rs10141388	chr14:103939679	A/G	cg12935359	chr14:103987150	CKB	-0.38	-5.43	-0.34	1.43e-7	Body mass index;
SARC	cis	rs55692411	0.537	rs71326904	chr3:49991060	C/T	cg19755318	chr3:50243323	SLC38A3	-0.3	-4.73	-0.3	3.82e-6	Intelligence (multi-trait analysis);
SARC	cis	rs1593	0.734	rs4253407	chr4:187193308	A/T	cg02012338	chr4:187126139	CYP4V2	0.6	5.19	0.32	4.49e-7	Activated partial thromboplastin time;
SARC	cis	rs10504229	0.679	rs1596142	chr8:58032406	G/A	cg22535103	chr8:58192502	C8orf71	-0.55	-5.6	-0.34	5.89e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs17376456	0.877	rs7701011	chr5:93311456	G/A	cg21475434	chr5:93447410	FAM172A	0.84	7.56	0.44	9.44e-13	Diabetic retinopathy;
SARC	cis	rs4319547	1.000	rs7307735	chr12:123087442	A/G	cg23029597	chr12:123009494	RSRC2	-0.39	-4.96	-0.31	1.37e-6	Body mass index;
SARC	cis	rs1401999	0.966	rs2292998	chr3:183663833	T/C	cg01324343	chr3:183735012	ABCC5	0.67	13.51	0.66	4.31e-31	Anterior chamber depth;
SARC	cis	rs7927592	0.913	rs11228292	chr11:68379772	C/T	cg01657329	chr11:68192670	LRP5	-0.43	-5.18	-0.32	4.76e-7	Total body bone mineral density;
SARC	cis	rs55794721	0.509	rs6699896	chr1:25762902	A/T	cg27572855	chr1:25598939	RHD	0.55	9.17	0.52	2.54e-17	Plateletcrit;Mean corpuscular volume;
SARC	cis	rs875971	0.545	rs313830	chr7:65551931	T/C	cg11764359	chr7:65958608	NA	-0.64	-6.18	-0.38	2.87e-9	Aortic root size;
SARC	cis	rs6696846	0.765	rs61822565	chr1:205077332	T/C	cg21643547	chr1:205240462	TMCC2	-0.57	-7.61	-0.45	6.61e-13	Red blood cell count;
SARC	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.85	-11.9	-0.61	7.82e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9487051	0.802	rs6568558	chr6:109592701	A/T	cg01475377	chr6:109611718	NA	-0.41	-5.84	-0.36	1.73e-8	Reticulocyte fraction of red cells;
SARC	cis	rs1059312	0.808	rs2170989	chr12:129291317	T/C	cg09035930	chr12:129282057	SLC15A4	-0.54	-7.69	-0.45	4.22e-13	Systemic lupus erythematosus;
SARC	cis	rs6963495	0.818	rs73192107	chr7:105168095	G/A	cg19920283	chr7:105172520	RINT1	0.67	5.69	0.35	3.88e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs910316	1.000	rs12889309	chr14:75593902	C/T	cg08847533	chr14:75593920	NEK9	0.92	15.73	0.72	1.77e-38	Height;
SARC	cis	rs4689388	0.890	rs9993624	chr4:6286528	C/T	cg14416269	chr4:6271139	WFS1	0.37	5.73	0.35	3.09e-8	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg27347728	chr4:17578864	LAP3	0.48	6.1	0.37	4.5e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs877282	0.733	rs11253342	chr10:765072	A/G	cg22713356	chr15:30763199	NA	1.04	10.06	0.55	5.37e-20	Uric acid levels;
SARC	trans	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg21659725	chr3:3221576	CRBN	-0.8	-12.22	-0.62	7.09e-27	Intelligence (multi-trait analysis);
SARC	cis	rs2635047	0.601	rs2684842	chr18:44725289	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.48	-6.13	-0.37	3.65e-9	Educational attainment;
SARC	cis	rs7223966	1.000	rs7222060	chr17:61868279	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.52	-5.5	-0.34	1.02e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs939574	1.000	rs1109866	chr2:220083279	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.53	-4.87	-0.3	2.03e-6	Platelet distribution width;
SARC	cis	rs10512697	0.803	rs71594961	chr5:3578056	T/C	cg19473799	chr5:3511975	NA	-0.68	-4.86	-0.3	2.11e-6	Immune response to smallpox vaccine (IL-6);
SARC	cis	rs7568458	0.846	rs6743030	chr2:85763520	C/T	cg02493740	chr2:85810744	VAMP5	-0.38	-5.64	-0.35	4.93e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	trans	rs9395865	0.520	rs6903708	chr6:53332940	A/G	cg05140069	chr1:13910667	PDPN	-0.48	-6.26	-0.38	1.85e-9	Electroencephalographic traits in alcoholism;
SARC	cis	rs28655083	0.956	rs1485792	chr16:77100439	G/T	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.4	-5.58	-0.34	6.81e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg05025164	chr4:1340916	KIAA1530	0.49	6.01	0.37	7.23e-9	Longevity;
SARC	cis	rs826838	1.000	rs860400	chr12:39081279	A/G	cg13010199	chr12:38710504	ALG10B	-0.68	-9.6	-0.53	1.29e-18	Heart rate;
SARC	cis	rs2361718	0.501	rs11869566	chr17:78143248	T/C	cg23534315	chr17:78082725	GAA	0.43	5.55	0.34	7.68e-8	Yeast infection;
SARC	cis	rs2276314	1.000	rs58054756	chr18:33554053	G/C	cg19628046	chr18:33552617	C18orf21	0.56	5.98	0.36	8.25e-9	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs17376456	0.825	rs10078941	chr5:93279029	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	5.82	0.36	1.93e-8	Diabetic retinopathy;
SARC	cis	rs3733585	0.699	rs4473653	chr4:9971058	A/G	cg00071950	chr4:10020882	SLC2A9	-0.38	-5.79	-0.35	2.24e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs13191362	0.507	rs2023037	chr6:163120385	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.44	4.74	0.3	3.69e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs72781680	1.000	rs75046532	chr2:24167267	A/G	cg08917208	chr2:24149416	ATAD2B	0.8	7.58	0.44	8.31e-13	Lymphocyte counts;
SARC	cis	rs611744	0.934	rs672408	chr8:109224390	A/G	cg21045802	chr8:109455806	TTC35	0.46	5.43	0.34	1.38e-7	Dupuytren's disease;
SARC	trans	rs916888	0.647	rs199524	chr17:44848438	G/T	cg01341218	chr17:43662625	NA	-0.76	-8.5	-0.49	2.31e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9398803	0.865	rs9375439	chr6:126758540	C/G	cg20229609	chr6:126660872	C6orf173	0.4	5.8	0.36	2.1e-8	Male-pattern baldness;
SARC	cis	rs585510	1	rs585510	chr12:121000133	A/G	cg27279351	chr12:120934652	DYNLL1	0.71	8.82	0.5	2.71e-16	Reticulocyte fraction of red cells;
SARC	cis	rs56036086	1.000	rs56036086	chr22:50628996	G/A	cg16473166	chr22:50639996	SELO	0.58	5.05	0.31	9.05e-7	Platelet count;Plateletcrit;
SARC	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg24829409	chr8:58192753	C8orf71	-0.62	-5.91	-0.36	1.2e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4268898	0.636	rs9636438	chr2:24460566	C/T	cg26838691	chr2:24397539	C2orf84	0.49	5.62	0.35	5.3e-8	Asthma;
SARC	cis	rs4423214	0.840	rs3794057	chr11:71186744	G/A	cg05163923	chr11:71159392	DHCR7	-0.6	-7.21	-0.43	7.58e-12	Vitamin D levels;
SARC	cis	rs897984	0.520	rs4889614	chr16:30862135	G/A	cg00531865	chr16:30841666	NA	0.45	4.74	0.3	3.8e-6	Dementia with Lewy bodies;
SARC	cis	rs4901847	0.643	rs1998101	chr14:58598706	T/C	cg15908186	chr14:58618357	C14orf37	0.6	7.75	0.45	2.74e-13	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs240764	0.618	rs846778	chr6:101273147	T/C	cg09795085	chr6:101329169	ASCC3	0.44	5.66	0.35	4.46e-8	Neuroticism;
SARC	cis	rs6060717	0.536	rs6060704	chr20:34530270	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	4.95	0.31	1.4e-6	Hip circumference adjusted for BMI;
SARC	cis	rs28655083	1.000	rs11864710	chr16:77075284	A/T	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.43	-6.1	-0.37	4.34e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9611565	0.506	rs1883825	chr22:41703408	A/G	cg17376030	chr22:41985996	PMM1	0.55	6.91	0.41	4.48e-11	Vitiligo;
SARC	cis	rs2075371	0.966	rs1901204	chr7:133985896	A/G	cg20476274	chr7:133979776	SLC35B4	0.6	8.07	0.47	3.65e-14	Mean platelet volume;
SARC	cis	rs11758351	0.660	rs2143345	chr6:26229148	C/T	cg23601095	chr6:26197514	HIST1H3D	0.61	5.15	0.32	5.53e-7	Gout;Renal underexcretion gout;
SARC	cis	rs9325144	0.600	rs7965877	chr12:38743697	G/T	cg26384229	chr12:38710491	ALG10B	0.61	8.02	0.47	5.07e-14	Morning vs. evening chronotype;
SARC	cis	rs7927771	0.965	rs56400411	chr11:47586376	T/G	cg05585544	chr11:47624801	NA	-0.36	-4.85	-0.3	2.27e-6	Subjective well-being;
SARC	cis	rs10512697	0.803	rs13173352	chr5:3578681	A/G	cg19473799	chr5:3511975	NA	-0.68	-4.86	-0.3	2.11e-6	Immune response to smallpox vaccine (IL-6);
SARC	cis	rs6993270	1.000	rs1519810	chr8:120936177	C/A	cg21659575	chr8:120844832	TAF2	0.49	4.74	0.3	3.68e-6	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs5758659	0.714	rs7245	chr22:42481849	G/A	cg15128208	chr22:42549153	NA	0.37	5.14	0.32	5.75e-7	Cognitive function;
SARC	cis	rs4141404	0.851	rs8135417	chr22:31559255	G/A	cg02404636	chr22:31891804	SFI1	-0.46	-5.47	-0.34	1.16e-7	Paclitaxel-induced neuropathy;
SARC	cis	rs6570726	0.791	rs11155433	chr6:145907831	A/G	cg23711669	chr6:146136114	FBXO30	-0.86	-13.94	-0.67	1.6e-32	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs950027	0.787	rs1547487	chr15:45723983	A/G	cg21132104	chr15:45694354	SPATA5L1	0.52	6.28	0.38	1.6e-9	Response to fenofibrate (adiponectin levels);
SARC	cis	rs8027181	0.839	rs8025333	chr15:73025121	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	0.42	5.61	0.35	5.67e-8	Triglyceride levels;
SARC	cis	rs2228479	0.557	rs62056064	chr16:89903843	G/A	cg06558623	chr16:89946397	TCF25	0.93	6.63	0.4	2.29e-10	Skin colour saturation;
SARC	trans	rs2727020	0.563	rs10769582	chr11:49474040	T/C	cg15704280	chr7:45808275	SEPT13	-0.86	-14.14	-0.68	3.48e-33	Coronary artery disease;
SARC	cis	rs1707322	0.717	rs10890345	chr1:46213927	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.37	0.38	1.03e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs2727020	0.729	rs10742932	chr11:49173234	T/C	cg15704280	chr7:45808275	SEPT13	-0.73	-10.97	-0.58	7.39e-23	Coronary artery disease;
SARC	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg05535760	chr7:792225	HEATR2	-0.85	-8.28	-0.48	9.4e-15	Cerebrospinal P-tau181p levels;
SARC	cis	rs8067354	0.645	rs2173120	chr17:57892640	A/T	cg02344993	chr17:57696989	CLTC	0.63	6.14	0.37	3.45e-9	Hemoglobin concentration;
SARC	cis	rs2180341	0.960	rs1543432	chr6:127698018	T/C	cg27446573	chr6:127587934	RNF146	1.06	14.34	0.68	7.2e-34	Breast cancer;
SARC	cis	rs9902453	0.817	rs2729449	chr17:28089751	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.56	-7.46	-0.44	1.7e-12	Coffee consumption (cups per day);
SARC	cis	rs8180040	0.654	rs4682831	chr3:47027138	A/G	cg27129171	chr3:47204927	SETD2	-0.59	-7.96	-0.46	7.75e-14	Colorectal cancer;
SARC	cis	rs262150	0.819	rs6956589	chr7:158769301	C/T	cg04111992	chr7:158790115	NA	-0.36	-4.72	-0.3	4.01e-6	Facial morphology (factor 20);
SARC	cis	rs524281	0.861	rs11227411	chr11:65879478	C/T	cg14036092	chr11:66035641	RAB1B	-0.51	-5.4	-0.33	1.64e-7	Electroencephalogram traits;
SARC	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg25072359	chr17:41440525	NA	0.49	5.9	0.36	1.3e-8	Menopause (age at onset);
SARC	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg06028808	chr11:68637592	NA	0.47	5.85	0.36	1.68e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7769051	0.808	rs1467403	chr6:133089952	T/A	cg22852734	chr6:133119734	C6orf192	1.08	10.94	0.58	9.14e-23	Type 2 diabetes nephropathy;
SARC	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.58	7.13	0.42	1.25e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6121246	0.954	rs6058470	chr20:30416827	A/T	cg13852791	chr20:30311386	BCL2L1	0.85	9.3	0.52	1.03e-17	Mean corpuscular hemoglobin;
SARC	cis	rs870825	0.581	rs28602720	chr4:185630598	T/C	cg04058563	chr4:185651563	MLF1IP	0.82	11.01	0.58	5.81e-23	Blood protein levels;
SARC	cis	rs1697139	0.583	rs13186050	chr5:66528139	C/T	cg11553311	chr5:66541588	NA	0.3	4.78	0.3	3.1e-6	Breast cancer;
SARC	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg25036284	chr2:26402008	FAM59B	-0.46	-5.7	-0.35	3.59e-8	Gut microbiome composition (summer);
SARC	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg06634786	chr22:41940651	POLR3H	-0.51	-6.15	-0.37	3.43e-9	Vitiligo;
SARC	cis	rs3733585	0.588	rs6449154	chr4:9956404	C/T	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.95	-0.36	9.9e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg06873352	chr17:61820015	STRADA	0.54	7.01	0.42	2.57e-11	Prudent dietary pattern;
SARC	cis	rs881375	0.715	rs11794516	chr9:123640230	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	7.47	0.44	1.57e-12	Rheumatoid arthritis;
SARC	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2204008	0.630	rs12306932	chr12:38242029	C/T	cg04568710	chr12:38710424	ALG10B	-0.4	-4.77	-0.3	3.21e-6	Bladder cancer;
SARC	cis	rs6456156	0.586	rs1358882	chr6:167467101	G/A	cg23791538	chr6:167370224	RNASET2	-0.52	-6.81	-0.41	8.22e-11	Primary biliary cholangitis;
SARC	trans	rs1635	0.655	rs723476	chr6:28305104	C/T	cg08080395	chr15:65488966	CILP	0.62	6.26	0.38	1.88e-9	Schizophrenia;
SARC	cis	rs8005677	1.000	rs4981446	chr14:23381413	A/G	cg01529538	chr14:23388837	RBM23	0.46	5.63	0.35	5.2e-8	Cognitive ability (multi-trait analysis);
SARC	cis	rs4713675	0.546	rs9348925	chr6:33710696	C/T	cg15676125	chr6:33679581	C6orf125	0.57	6.93	0.41	4.05e-11	Plateletcrit;
SARC	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg22484793	chr3:52261325	TLR9	0.29	4.8	0.3	2.81e-6	Bipolar disorder;
SARC	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg04772025	chr11:68637568	NA	0.55	7.01	0.42	2.51e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs10911232	0.507	rs5022057	chr1:182997761	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.67	0.57	6.63e-22	Hypertriglyceridemia;
SARC	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg18404041	chr3:52824283	ITIH1	-0.35	-5.26	-0.33	3.34e-7	Electroencephalogram traits;
SARC	cis	rs7644634	0.688	rs13093260	chr3:105475939	C/T	cg23051926	chr3:105466016	CBLB	0.46	5.78	0.35	2.39e-8	Itch intensity from mosquito bite;
SARC	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg03709012	chr19:19516395	GATAD2A	1.01	17.65	0.76	7.75e-45	Tonsillectomy;
SARC	trans	rs208520	0.565	rs1385222	chr6:66753013	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.07	19.01	0.78	2.75e-49	Exhaled nitric oxide output;
SARC	cis	rs7005606	1.000	rs7005606	chr8:32401501	G/T	cg14488905	chr8:32406789	NRG1	-0.47	-6.86	-0.41	6.31e-11	Hirschsprung disease;
SARC	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg02461776	chr11:598696	PHRF1	0.49	5.24	0.32	3.63e-7	Systemic lupus erythematosus;
SARC	cis	rs57561814	0.655	rs8180726	chr7:22749306	A/C	cg26061582	chr7:22766209	IL6	1.09	8.4	0.48	4.33e-15	Tonsillectomy;
SARC	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg24642844	chr7:1081250	C7orf50	-0.6	-6.12	-0.37	4.02e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs9831754	0.906	rs1588650	chr3:78410750	T/G	cg06138941	chr3:78371609	NA	-0.59	-6.86	-0.41	6.06e-11	Calcium levels;
SARC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.93	-14.73	-0.69	3.8e-35	Prudent dietary pattern;
SARC	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg01316550	chr5:56110833	MAP3K1	0.54	4.92	0.31	1.62e-6	Initial pursuit acceleration;
SARC	cis	rs2153535	0.580	rs6937186	chr6:8494493	A/C	cg21535247	chr6:8435926	SLC35B3	0.57	7.27	0.43	5.44e-12	Motion sickness;
SARC	cis	rs2952156	0.920	rs2517954	chr17:37843550	T/C	cg20243544	chr17:37824526	PNMT	0.5	6.01	0.37	6.93e-9	Asthma;
SARC	cis	rs1348850	0.914	rs12104588	chr2:178253675	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.72	9.2	0.52	2.1e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs12956009	0.583	rs16951972	chr18:44898600	C/T	cg15049968	chr18:44337910	ST8SIA5	-0.31	-4.72	-0.3	4.11e-6	Educational attainment (years of education);
SARC	cis	rs7223966	1.000	rs7220821	chr17:61704147	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.5	-5.52	-0.34	8.95e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7914558	0.966	rs10786725	chr10:104682357	T/C	cg04362960	chr10:104952993	NT5C2	0.41	4.9	0.31	1.78e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs16854884	0.770	rs6782024	chr3:143816936	G/C	cg06585982	chr3:143692056	C3orf58	0.64	8.39	0.48	4.66e-15	Economic and political preferences (feminism/equality);
SARC	cis	rs9911578	0.967	rs8182277	chr17:57144367	C/T	cg20303301	chr17:57937339	TUBD1	-0.34	-4.95	-0.31	1.42e-6	Intelligence (multi-trait analysis);
SARC	trans	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg00938859	chr5:1591904	SDHAP3	0.79	7.66	0.45	5.1e-13	Breast cancer;
SARC	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg00339695	chr16:24857497	SLC5A11	0.41	5.49	0.34	1.02e-7	Intelligence (multi-trait analysis);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg13180232	chr10:35425499	CREM	0.43	6.24	0.38	2.03e-9	Thyroid stimulating hormone;
SARC	cis	rs2070677	0.935	rs2070676	chr10:135351137	C/G	cg20169779	chr10:135381914	SYCE1	0.43	5.68	0.35	3.96e-8	Gout;
SARC	cis	rs9912789	0.807	rs9896850	chr17:79191726	C/T	cg25342872	chr17:79175132	AZI1	-0.46	-6.58	-0.4	3.07e-10	Frontotemporal dementia;
SARC	cis	rs8067354	0.645	rs11079389	chr17:57887952	G/A	cg02344993	chr17:57696989	CLTC	0.61	6.0	0.37	7.48e-9	Hemoglobin concentration;
SARC	cis	rs4689388	0.853	rs11729672	chr4:6293838	A/G	cg00701064	chr4:6280414	WFS1	0.54	8.58	0.49	1.38e-15	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs6540556	0.954	rs6696463	chr1:209933757	G/C	cg05527609	chr1:210001259	C1orf107	-0.56	-5.75	-0.35	2.85e-8	Red blood cell count;
SARC	cis	rs1580019	0.844	rs4723159	chr7:32512804	T/C	cg14728415	chr7:32535168	LSM5;AVL9	0.46	5.53	0.34	8.71e-8	Cognitive ability;
SARC	cis	rs7113874	0.578	rs67067089	chr11:8530027	C/A	cg09828998	chr11:8703972	RPL27A	0.48	4.78	0.3	3.06e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7223966	0.921	rs11655493	chr17:61733052	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.56	-6.0	-0.37	7.49e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs3741151	0.773	rs28400367	chr11:73112421	C/A	cg17517138	chr11:73019481	ARHGEF17	0.91	6.71	0.4	1.43e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs1008375	0.900	rs10019460	chr4:17686337	T/C	cg16339924	chr4:17578868	LAP3	-0.6	-7.52	-0.44	1.21e-12	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2204008	0.630	rs7314669	chr12:38203602	G/A	cg26384229	chr12:38710491	ALG10B	-0.67	-8.56	-0.49	1.53e-15	Bladder cancer;
SARC	cis	rs709400	0.663	rs17617941	chr14:103953032	T/C	cg12935359	chr14:103987150	CKB	-0.39	-5.71	-0.35	3.38e-8	Body mass index;
SARC	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg10523679	chr1:76189770	ACADM	-0.43	-5.31	-0.33	2.61e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7786808	0.741	rs11765319	chr7:158226790	A/G	cg05645440	chr7:158792487	NA	-0.23	-5.13	-0.32	6.12e-7	Obesity-related traits;
SARC	cis	rs1003719	0.751	rs10154032	chr21:38453459	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.65	9.46	0.53	3.43e-18	Eye color traits;
SARC	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	24.35	0.85	5.64e-66	Chronic sinus infection;
SARC	cis	rs12474201	0.894	rs34401107	chr2:46972768	A/C	cg06386533	chr2:46925753	SOCS5	0.87	14.06	0.68	6.52e-33	Height;
SARC	cis	rs13082711	0.911	rs6776318	chr3:27523457	T/C	cg02860705	chr3:27208620	NA	0.43	5.41	0.33	1.54e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs9616064	0.506	rs737135	chr22:47061791	C/T	cg05621596	chr22:47072043	GRAMD4	-0.5	-7.12	-0.42	1.34e-11	Urate levels in obese individuals;
SARC	cis	rs3087591	0.887	rs2905796	chr17:29537586	G/A	cg24425628	chr17:29625626	OMG;NF1	0.47	5.71	0.35	3.41e-8	Hip circumference;
SARC	cis	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg08564027	chr20:61660810	NA	0.76	11.57	0.6	9.45e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs1003719	1.000	rs2154536	chr21:38492147	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.66	9.04	0.51	6.33e-17	Eye color traits;
SARC	cis	rs2153535	0.563	rs7739249	chr6:8534590	C/G	cg21535247	chr6:8435926	SLC35B3	0.5	6.07	0.37	5.19e-9	Motion sickness;
SARC	cis	rs7465272	1.000	rs35900184	chr8:143693411	C/T	cg24634471	chr8:143751801	JRK	0.6	6.48	0.39	5.48e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs9400467	0.506	rs12203741	chr6:111677544	A/T	cg15721981	chr6:111408429	SLC16A10	0.63	5.45	0.34	1.25e-7	Blood metabolite levels;Amino acid levels;
SARC	cis	rs11098499	0.954	rs10005644	chr4:120298477	T/C	cg09160332	chr4:120329925	NA	-0.33	-4.77	-0.3	3.27e-6	Corneal astigmatism;
SARC	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg09699651	chr6:150184138	LRP11	0.39	4.86	0.3	2.13e-6	Lung cancer;
SARC	cis	rs9291683	0.546	rs12504565	chr4:10045145	G/A	cg00071950	chr4:10020882	SLC2A9	0.33	4.98	0.31	1.26e-6	Bone mineral density;
SARC	cis	rs1707322	1.000	rs10890382	chr1:46469674	A/G	cg06784218	chr1:46089804	CCDC17	0.36	6.3	0.38	1.44e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg18758796	chr5:131593413	PDLIM4	0.37	4.77	0.3	3.25e-6	Acylcarnitine levels;
SARC	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg14582100	chr15:45693742	SPATA5L1	0.35	4.91	0.31	1.69e-6	Metabolite levels (small molecules and protein measures);
SARC	cis	rs3762637	1.000	rs7615673	chr3:122125544	G/C	cg24169773	chr3:122142474	KPNA1	-0.56	-5.65	-0.35	4.57e-8	LDL cholesterol levels;
SARC	trans	rs629535	0.821	rs680993	chr8:70050247	G/A	cg21567404	chr3:27674614	NA	1.04	13.82	0.67	3.98e-32	Dupuytren's disease;
SARC	cis	rs273218	0.590	rs156828	chr5:53364230	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.42	5.05	0.31	8.96e-7	Migraine;
SARC	cis	rs6835098	0.924	rs12639929	chr4:174156538	C/T	cg08422745	chr4:174089978	GALNT7	-0.71	-9.07	-0.51	5.03e-17	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg20607798	chr8:58055168	NA	0.58	5.57	0.34	6.9e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs11098499	0.954	rs11098526	chr4:120390359	C/T	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	cis	rs10927875	0.631	rs28579893	chr1:16347534	A/G	cg21385522	chr1:16154831	NA	0.71	9.1	0.51	4.19e-17	Dilated cardiomyopathy;
SARC	cis	rs1971762	0.527	rs9737721	chr12:54074696	A/T	cg06632207	chr12:54070931	ATP5G2	0.52	6.81	0.41	8.38e-11	Height;
SARC	cis	rs5417	0.662	rs8067500	chr17:7172631	A/G	cg13768953	chr17:7114967	DLG4	-0.35	-5.34	-0.33	2.22e-7	Diastolic blood pressure;
SARC	cis	rs995000	0.965	rs10889338	chr1:62984897	C/T	cg06896770	chr1:63153194	DOCK7	0.97	14.27	0.68	1.28e-33	Triglyceride levels;
SARC	cis	rs36051895	0.632	rs62541944	chr9:5159318	G/T	cg02405213	chr9:5042618	JAK2	-0.43	-4.95	-0.31	1.4e-6	Pediatric autoimmune diseases;
SARC	cis	rs5167	0.781	rs2075619	chr19:45495682	A/G	cg09555818	chr19:45449301	APOC2	0.41	5.87	0.36	1.5e-8	Blood protein levels;
SARC	cis	rs1153858	1.000	rs60476496	chr15:45713801	C/T	cg26924012	chr15:45694286	SPATA5L1	0.78	10.67	0.57	6.94e-22	Homoarginine levels;
SARC	cis	rs6540556	0.736	rs2076152	chr1:209936060	A/G	cg23920097	chr1:209922102	NA	-0.55	-6.49	-0.39	5.11e-10	Red blood cell count;
SARC	cis	rs67311347	1.000	rs34762643	chr3:40475433	C/T	cg24209194	chr3:40518798	ZNF619	0.61	7.87	0.46	1.35e-13	Renal cell carcinoma;
SARC	cis	rs7587476	1.000	rs3768707	chr2:215645135	C/T	cg04530015	chr2:215796436	ABCA12	-0.38	-6.18	-0.38	2.86e-9	Neuroblastoma;
SARC	cis	rs1832871	0.672	rs56075516	chr6:158745752	G/A	cg07165851	chr6:158734300	TULP4	0.58	6.77	0.41	1.05e-10	Height;
SARC	cis	rs2333194	0.844	rs17182286	chr14:73748908	C/T	cg09844916	chr14:74004424	HEATR4;ACOT1	0.38	4.79	0.3	2.95e-6	Bipolar disorder with mood-incongruent psychosis;
SARC	cis	rs1707322	0.963	rs11211238	chr1:46449415	G/A	cg03146154	chr1:46216737	IPP	0.45	5.41	0.33	1.57e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs7624766	0.555	rs2049214	chr3:160512501	C/T	cg22637730	chr3:160473554	PPM1L	0.38	4.85	0.3	2.24e-6	Response to methotrexate in rheumatoid arthritis;
SARC	cis	rs651907	0.557	rs59596156	chr3:101394217	C/T	cg12386194	chr3:101231763	SENP7	0.49	5.84	0.36	1.77e-8	Colorectal cancer;
SARC	cis	rs2652822	0.550	rs11853804	chr15:63528256	C/A	cg02713581	chr15:63449717	RPS27L	0.51	5.93	0.36	1.09e-8	Metabolic traits;
SARC	cis	rs9843304	0.565	rs9857136	chr3:149209853	T/A	cg08667024	chr3:149219783	TM4SF4	0.47	7.11	0.42	1.39e-11	Gallstone disease;
SARC	cis	rs2952156	0.920	rs2934951	chr17:37833328	A/G	cg00129232	chr17:37814104	STARD3	-0.69	-9.9	-0.54	1.58e-19	Asthma;
SARC	cis	rs4891159	0.790	rs17059379	chr18:74160316	A/T	cg24786174	chr18:74118243	ZNF516	0.64	9.24	0.52	1.64e-17	Longevity;
SARC	cis	rs2153535	0.580	rs7753192	chr6:8482637	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	8.24	0.48	1.24e-14	Motion sickness;
SARC	cis	rs72766638	0.806	rs56303154	chr9:136936376	C/T	cg13789015	chr9:136890014	NCRNA00094	0.6	6.49	0.39	5.14e-10	Mosquito bite size;
SARC	trans	rs208515	0.556	rs10455193	chr6:66691456	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.99	11.59	0.6	8.2e-25	Exhaled nitric oxide levels;
SARC	cis	rs9611519	1.000	rs5758264	chr22:41616284	T/G	cg03806693	chr22:41940476	POLR3H	-0.52	-6.37	-0.39	1.01e-9	Neuroticism;
SARC	cis	rs9296092	0.521	rs6929165	chr6:33515958	T/G	cg13560919	chr6:33536144	NA	-0.49	-6.2	-0.38	2.59e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg21747090	chr2:27597821	SNX17	-0.55	-7.75	-0.45	2.9e-13	Total body bone mineral density;
SARC	cis	rs6963495	0.818	rs117028299	chr7:105162310	T/C	cg19920283	chr7:105172520	RINT1	0.65	5.48	0.34	1.09e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg12463550	chr7:65579703	CRCP	0.65	5.04	0.31	9.53e-7	Diabetic kidney disease;
SARC	cis	rs9303401	0.659	rs17741087	chr17:56550300	C/T	cg25039879	chr17:56429692	SUPT4H1	0.63	5.77	0.35	2.51e-8	Cognitive test performance;
SARC	cis	rs11098499	0.863	rs1480936	chr4:120462861	C/T	cg09307838	chr4:120376055	NA	0.93	12.66	0.64	2.64e-28	Corneal astigmatism;
SARC	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg00149659	chr3:10157352	C3orf10	0.68	6.79	0.41	9.14e-11	Alzheimer's disease;
SARC	cis	rs713477	0.967	rs11158039	chr14:55906696	A/T	cg13175173	chr14:55914753	NA	-0.31	-4.8	-0.3	2.85e-6	Pediatric bone mineral content (femoral neck);
SARC	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg11766577	chr21:47581405	C21orf56	-0.51	-6.26	-0.38	1.87e-9	Testicular germ cell tumor;
SARC	cis	rs735539	0.521	rs2585901	chr13:21420271	G/A	cg16922012	chr13:21400325	XPO4	-0.43	-5.82	-0.36	1.95e-8	Dental caries;
SARC	cis	rs1707322	0.789	rs7540578	chr1:46252144	C/T	cg06784218	chr1:46089804	CCDC17	0.35	6.41	0.39	8.18e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2295359	1.000	rs9729046	chr1:67607082	C/G	cg08029281	chr1:67600428	NA	0.38	5.37	0.33	1.88e-7	Psoriasis;
SARC	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg18876405	chr7:65276391	NA	0.46	5.7	0.35	3.69e-8	Aortic root size;
SARC	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg05332525	chr7:65337924	VKORC1L1	0.44	4.94	0.31	1.49e-6	Aortic root size;
SARC	cis	rs9303401	0.614	rs3803753	chr17:56540110	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.05	11.45	0.6	2.3e-24	Cognitive test performance;
SARC	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.73	-7.21	-0.43	7.72e-12	Platelet count;
SARC	cis	rs112591243	0.685	rs115448966	chr21:47988420	G/A	cg10657630	chr21:48055338	PRMT2	0.85	5.4	0.33	1.63e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs818427	0.621	rs1625623	chr5:112301096	C/T	cg07820702	chr5:112228657	REEP5	-0.43	-5.06	-0.31	8.36e-7	Total body bone mineral density;
SARC	cis	rs2235642	0.691	rs2281235	chr16:1603535	T/C	cg09065629	chr16:1709722	CRAMP1L	0.37	5.1	0.32	7.14e-7	Coronary artery disease;
SARC	cis	rs34330	0.562	rs11055025	chr12:12866619	A/T	cg09462578	chr12:12878428	APOLD1	-0.53	-5.16	-0.32	5.28e-7	Systemic lupus erythematosus;
SARC	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg13628971	chr7:2884303	GNA12	0.55	6.37	0.39	9.83e-10	Height;
SARC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg01238044	chr22:24384105	GSTT1	0.57	6.33	0.38	1.23e-9	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2120019	1.000	rs34237279	chr15:75361121	A/G	cg12414181	chr15:75287860	SCAMP5	-0.43	-4.9	-0.31	1.78e-6	Blood trace element (Zn levels);
SARC	cis	rs10870270	1.000	rs11146354	chr10:133774757	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.85	-10.49	-0.57	2.46e-21	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs1957429	0.520	rs77606588	chr14:65356268	G/A	cg23373153	chr14:65346875	NA	-1.03	-6.46	-0.39	6.18e-10	Pediatric areal bone mineral density (radius);
SARC	cis	rs7647973	0.626	rs1491985	chr3:49739507	G/C	cg07636037	chr3:49044803	WDR6	0.59	6.09	0.37	4.71e-9	Menarche (age at onset);
SARC	cis	rs79149102	0.579	rs7172989	chr15:75295905	C/T	cg09165964	chr15:75287851	SCAMP5	-0.95	-8.78	-0.5	3.63e-16	Lung cancer;
SARC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg11203670	chr7:100026453	MEPCE;ZCWPW1	0.52	4.84	0.3	2.4e-6	Platelet count;
SARC	cis	rs7937682	0.562	rs519850	chr11:111376888	A/T	cg22437258	chr11:111473054	SIK2	0.43	5.19	0.32	4.48e-7	Primary sclerosing cholangitis;
SARC	cis	rs1538970	0.924	rs11211117	chr1:45930246	C/T	cg05343316	chr1:45956843	TESK2	0.77	8.64	0.49	9.03e-16	Platelet count;
SARC	cis	rs9581857	0.547	rs4612914	chr13:28049128	A/G	cg01674679	chr13:27998804	GTF3A	-0.65	-5.03	-0.31	9.95e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	cis	rs2075371	1.000	rs2241334	chr7:133979225	C/G	cg11752832	chr7:134001865	SLC35B4	0.6	7.8	0.46	2.03e-13	Mean platelet volume;
SARC	cis	rs7607369	0.648	rs7599984	chr2:219656713	T/G	cg02176678	chr2:219576539	TTLL4	-0.51	-8.24	-0.47	1.27e-14	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs644799	1.000	rs611020	chr11:95567905	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	14.82	0.7	1.89e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9814567	1.000	rs934093	chr3:134195885	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-7.08	-0.42	1.68e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs12118280	0.612	rs591141	chr1:108694894	A/G	cg11967332	chr1:108735228	SLC25A24	0.53	6.15	0.37	3.38e-9	Myeloid white cell count;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg00112042	chr1:146555865	NA	0.8	6.68	0.4	1.7e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg07636037	chr3:49044803	WDR6	1.01	17.88	0.76	1.35e-45	Parkinson's disease;
SARC	cis	rs7412746	0.611	rs111905669	chr1:150777565	T/C	cg15448220	chr1:150897856	SETDB1	0.48	6.32	0.38	1.33e-9	Melanoma;
SARC	cis	rs10489202	0.683	rs2294817	chr1:168073601	C/A	cg24449463	chr1:168025552	DCAF6	-0.6	-7.75	-0.45	2.9e-13	Schizophrenia;
SARC	cis	rs2228479	0.619	rs78001663	chr16:89896331	C/A	cg00800038	chr16:89945340	TCF25	-0.82	-5.9	-0.36	1.27e-8	Skin colour saturation;
SARC	cis	rs34172651	0.917	rs172066	chr16:24756449	C/T	cg04756594	chr16:24857601	SLC5A11	0.37	6.09	0.37	4.56e-9	Intelligence (multi-trait analysis);
SARC	cis	rs6570726	0.791	rs443628	chr6:145883484	T/C	cg23711669	chr6:146136114	FBXO30	0.84	13.61	0.67	1.96e-31	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg18404041	chr3:52824283	ITIH1	-0.42	-6.29	-0.38	1.56e-9	Bipolar disorder;
SARC	cis	rs7223966	1.000	rs8070650	chr17:61744040	A/G	cg00588841	chr17:61851480	DDX42;CCDC47	-0.61	-6.68	-0.4	1.76e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6502050	0.761	rs62078747	chr17:80055206	C/G	cg13939156	chr17:80058883	NA	0.37	5.9	0.36	1.27e-8	Life satisfaction;
SARC	cis	rs2115536	1.000	rs2903105	chr15:80189523	C/G	cg00225070	chr15:80189496	MTHFS	0.66	8.83	0.5	2.5e-16	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
SARC	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg26335602	chr6:28129616	ZNF389	0.52	5.94	0.36	1.04e-8	Depression;
SARC	cis	rs17376456	0.825	rs10214278	chr5:93237679	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.61	-5.67	-0.35	4.22e-8	Diabetic retinopathy;
SARC	cis	rs7246657	0.525	rs1667359	chr19:37486172	G/A	cg14683738	chr19:37701593	ZNF585B	0.57	5.09	0.32	7.49e-7	Coronary artery calcification;
SARC	cis	rs35306767	0.903	rs7074642	chr10:878359	A/G	cg26597838	chr10:835615	NA	0.8	8.33	0.48	6.91e-15	Eosinophil percentage of granulocytes;
SARC	trans	rs1814175	0.817	rs10769641	chr11:49960141	A/G	cg15704280	chr7:45808275	SEPT13	-0.97	-18.54	-0.77	9.52e-48	Height;
SARC	trans	rs7573615	0.636	rs62138396	chr2:53270347	T/C	cg12257439	chr2:97360893	FER1L5	-0.72	-6.53	-0.39	4e-10	Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs7296418	0.961	rs12425850	chr12:123501972	T/C	cg05973401	chr12:123451056	ABCB9	0.59	7.04	0.42	2.11e-11	Platelet count;
SARC	cis	rs453301	0.686	rs7814328	chr8:8876229	T/C	cg08975724	chr8:8085496	FLJ10661	-0.47	-5.96	-0.36	9.18e-9	Joint mobility (Beighton score);
SARC	cis	rs614226	1.000	rs616157	chr12:120925795	T/C	cg01236616	chr12:121019343	POP5	-1.18	-14.59	-0.69	1.11e-34	Type 1 diabetes nephropathy;
SARC	cis	rs13191362	1.000	rs13200329	chr6:163004418	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.57	5.51	0.34	9.61e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg11987759	chr7:65425863	GUSB	0.48	5.76	0.35	2.6e-8	Aortic root size;
SARC	cis	rs651907	0.535	rs13094753	chr3:101525082	A/G	cg12386194	chr3:101231763	SENP7	0.48	5.44	0.34	1.34e-7	Colorectal cancer;
SARC	cis	rs7296418	0.816	rs1790096	chr12:123710364	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-5.27	-0.33	3.05e-7	Platelet count;
SARC	cis	rs6772849	0.930	rs9873888	chr3:128360987	G/A	cg01163369	chr3:128370232	RPN1	-0.34	-4.93	-0.31	1.56e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.63	7.75	0.45	2.76e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6669008	1.000	rs55912359	chr1:114167099	C/T	cg26035817	chr1:114414802	PTPN22	0.47	5.57	0.34	7.12e-8	Bacteremia;
SARC	cis	rs2479724	0.868	rs2249703	chr6:41814760	A/G	cg17623882	chr6:41773611	USP49	-0.47	-5.97	-0.36	8.84e-9	Menarche (age at onset);
SARC	cis	rs910187	0.605	rs8184673	chr20:45806262	C/T	cg27589058	chr20:45804311	EYA2	-0.33	-5.34	-0.33	2.21e-7	Migraine;
SARC	cis	rs7826238	0.601	rs2976907	chr8:8345168	C/T	cg08975724	chr8:8085496	FLJ10661	0.53	7.09	0.42	1.55e-11	Systolic blood pressure;
SARC	cis	rs2749592	1.000	rs2749592	chr10:38258842	A/C	cg25427524	chr10:38739819	LOC399744	-0.42	-5.12	-0.32	6.37e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs9309711	0.623	rs7569694	chr2:3483390	T/G	cg15506890	chr2:3487001	NA	-0.46	-6.14	-0.37	3.59e-9	Neurofibrillary tangles;
SARC	cis	rs17125944	0.615	rs12589020	chr14:53312002	C/T	cg00686598	chr14:53173677	PSMC6	0.78	5.5	0.34	9.73e-8	Alzheimer's disease (late onset);
SARC	cis	rs7520050	0.966	rs12139630	chr1:46350935	A/G	cg06784218	chr1:46089804	CCDC17	-0.26	-4.83	-0.3	2.5e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg19087971	chr7:751233	PRKAR1B	-0.44	-4.81	-0.3	2.75e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs9815354	0.951	rs17060938	chr3:41759191	T/C	cg03022575	chr3:42003672	ULK4	0.56	5.32	0.33	2.41e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs10992471	0.603	rs7872610	chr9:95299137	G/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-5.65	-0.35	4.6e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs472402	0.580	rs8192186	chr5:6652009	G/A	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.43	-5.14	-0.32	5.77e-7	Response to amphetamines;
SARC	trans	rs208520	0.754	rs12204635	chr6:66740779	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	13.86	0.67	2.98e-32	Exhaled nitric oxide output;
SARC	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	11.35	0.6	4.58e-24	Platelet count;
SARC	cis	rs644799	1.000	rs568668	chr11:95528209	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	15.35	0.71	3.21e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs910316	0.967	rs175498	chr14:75536369	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.58	-8.25	-0.48	1.19e-14	Height;
SARC	cis	rs9660992	0.710	rs1172111	chr1:205232980	C/T	cg21643547	chr1:205240462	TMCC2	-0.66	-8.93	-0.51	1.29e-16	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs6665290	0.669	rs6426558	chr1:227175367	G/T	cg14016676	chr1:227182615	CDC42BPA	0.34	4.87	0.3	2.09e-6	Myeloid white cell count;
SARC	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.22	0.38	2.3e-9	Electroencephalogram traits;
SARC	cis	rs3091242	0.967	rs3093614	chr1:25677844	T/A	cg03650068	chr1:25596491	NA	-0.34	-5.19	-0.32	4.64e-7	Erythrocyte sedimentation rate;
SARC	cis	rs1865760	0.892	rs9379806	chr6:25940958	G/A	cg10373733	chr6:25993375	NA	0.4	4.82	0.3	2.62e-6	Height;
SARC	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg16479474	chr6:28041457	NA	0.36	5.36	0.33	1.97e-7	Depression;
SARC	cis	rs6088580	0.634	rs6059835	chr20:33020141	A/G	cg08999081	chr20:33150536	PIGU	0.44	6.59	0.4	2.97e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs6570726	0.935	rs447818	chr6:145868996	C/T	cg05347473	chr6:146136440	FBXO30	0.48	6.55	0.39	3.57e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs701145	0.556	rs355764	chr3:154013480	A/T	cg16511985	chr3:153974050	SGEF	0.43	5.12	0.32	6.52e-7	Coronary artery disease;
SARC	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg24549020	chr5:56110836	MAP3K1	0.83	8.67	0.49	7.61e-16	Initial pursuit acceleration;
SARC	trans	rs7824557	0.767	rs718427	chr8:11139038	C/G	cg06636001	chr8:8085503	FLJ10661	0.6	7.13	0.42	1.28e-11	Retinal vascular caliber;
SARC	cis	rs6840360	0.571	rs10026670	chr4:152539212	C/T	cg22705602	chr4:152727874	NA	-0.41	-6.43	-0.39	7.24e-10	Intelligence (multi-trait analysis);
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg03193865	chr8:145510099	BOP1	0.5	6.28	0.38	1.63e-9	Schizophrenia;
SARC	trans	rs79976124	0.877	rs79507557	chr6:66640908	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	7.86	0.46	1.41e-13	Type 2 diabetes;
SARC	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg00149659	chr3:10157352	C3orf10	0.69	6.9	0.41	4.76e-11	Alzheimer's disease;
SARC	cis	rs12478296	0.591	rs4973646	chr2:243001373	C/T	cg06360820	chr2:242988706	NA	0.48	5.2	0.32	4.37e-7	Obesity-related traits;
SARC	cis	rs9359856	0.564	rs17292768	chr6:90379311	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.61	-4.79	-0.3	2.93e-6	Bipolar disorder;
SARC	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg11890956	chr21:40555474	PSMG1	-1.04	-15.4	-0.71	2.25e-37	Cognitive function;
SARC	cis	rs10504229	0.679	rs72649107	chr8:58030453	C/A	cg21724239	chr8:58056113	NA	0.61	6.37	0.38	1.02e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10089	1.000	rs9968597	chr5:127455383	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.82	10.13	0.55	3.25e-20	Ileal carcinoids;
SARC	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg01316550	chr5:56110833	MAP3K1	0.54	4.98	0.31	1.25e-6	Initial pursuit acceleration;
SARC	cis	rs6430585	0.591	rs77096272	chr2:136663605	C/A	cg07169764	chr2:136633963	MCM6	1.05	13.59	0.66	2.31e-31	Corneal structure;
SARC	cis	rs4423214	1.000	rs11546509	chr11:71162785	A/G	cg05163923	chr11:71159392	DHCR7	0.65	8.57	0.49	1.4e-15	Vitamin D levels;
SARC	cis	rs1707322	1.000	rs6429580	chr1:46275648	A/G	cg06784218	chr1:46089804	CCDC17	0.33	5.76	0.35	2.66e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs920590	0.573	rs4392917	chr8:19680635	G/C	cg17834443	chr8:19674713	INTS10	-0.51	-6.18	-0.38	2.86e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs12956009	0.583	rs16952069	chr18:44904220	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	7.79	0.45	2.22e-13	Educational attainment (years of education);
SARC	cis	rs7264396	0.563	rs2066066	chr20:34329359	T/C	cg01084648	chr20:34329383	RBM39	0.59	5.13	0.32	6e-7	Total cholesterol levels;
SARC	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.98	11.32	0.6	5.67e-24	Platelet count;
SARC	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg13770153	chr20:60521292	NA	-0.46	-6.33	-0.38	1.24e-9	Body mass index;
SARC	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.83	8.49	0.49	2.52e-15	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs9322817	0.691	rs4142531	chr6:105324811	G/A	cg02098413	chr6:105308735	HACE1	0.38	5.92	0.36	1.17e-8	Thyroid stimulating hormone;
SARC	cis	rs11122272	0.766	rs2790870	chr1:231543823	A/G	cg06096015	chr1:231504339	EGLN1	0.38	5.59	0.34	6.26e-8	Hemoglobin concentration;
SARC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.89	0.54	1.78e-19	Prudent dietary pattern;
SARC	cis	rs10512697	0.803	rs17637361	chr5:3580421	G/C	cg19473799	chr5:3511975	NA	-0.63	-4.8	-0.3	2.84e-6	Immune response to smallpox vaccine (IL-6);
SARC	cis	rs9858542	0.953	rs9818590	chr3:49525096	A/G	cg03060546	chr3:49711283	APEH	-0.57	-7.03	-0.42	2.31e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs12477438	0.765	rs6722164	chr2:99561527	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-14.98	-0.7	5.49e-36	Chronic sinus infection;
SARC	cis	rs11122272	0.735	rs2486729	chr1:231535584	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-9.67	-0.54	7.93e-19	Hemoglobin concentration;
SARC	cis	rs854765	0.583	rs4925123	chr17:17784374	A/G	cg05444541	chr17:17804740	TOM1L2	0.31	5.4	0.33	1.62e-7	Total body bone mineral density;
SARC	cis	rs4268898	0.662	rs74470633	chr2:24438712	A/G	cg06627628	chr2:24431161	ITSN2	-0.82	-9.95	-0.55	1.17e-19	Asthma;
SARC	cis	rs6840360	0.615	rs72728179	chr4:152477877	A/G	cg22705602	chr4:152727874	NA	-0.42	-6.51	-0.39	4.59e-10	Intelligence (multi-trait analysis);
SARC	cis	rs72781680	0.848	rs56218741	chr2:23977377	A/C	cg08917208	chr2:24149416	ATAD2B	0.76	7.16	0.42	1.08e-11	Lymphocyte counts;
SARC	cis	rs9326248	0.520	rs7127881	chr11:116880798	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.61	7.65	0.45	5.17e-13	Blood protein levels;
SARC	cis	rs1043515	1.000	rs2075060	chr17:36925750	G/A	cg09592244	chr17:37024020	NA	0.39	4.85	0.3	2.31e-6	Height;
SARC	cis	rs35110281	0.633	rs762400	chr21:45113629	C/G	cg21573476	chr21:45109991	RRP1B	0.56	8.21	0.47	1.49e-14	Mean corpuscular volume;
SARC	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	5.73	0.35	3.17e-8	Bipolar disorder;
SARC	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg03060546	chr3:49711283	APEH	0.44	5.61	0.34	5.8e-8	Parkinson's disease;
SARC	cis	rs11190604	1.000	rs4604805	chr10:102261409	C/G	cg07080220	chr10:102295463	HIF1AN	0.77	9.22	0.52	1.84e-17	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs644799	1.000	rs651445	chr11:95539122	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	14.15	0.68	3.08e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg25894440	chr7:65020034	NA	-0.75	-5.59	-0.34	6.48e-8	Diabetic kidney disease;
SARC	cis	rs11690935	0.959	rs10166005	chr2:172607294	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.0	-15.73	-0.72	1.83e-38	Schizophrenia;
SARC	cis	rs9911578	0.803	rs8069033	chr17:57131581	T/A	cg12560992	chr17:57184187	TRIM37	-0.87	-12.54	-0.63	6.5e-28	Intelligence (multi-trait analysis);
SARC	cis	rs3857536	0.740	rs7751095	chr6:66891318	A/G	cg07460842	chr6:66804631	NA	-0.6	-7.16	-0.42	1.04e-11	Blood trace element (Cu levels);
SARC	cis	rs738322	0.718	rs3761445	chr22:38595411	G/A	cg25457927	chr22:38595422	NA	0.38	8.44	0.48	3.45e-15	Cutaneous nevi;
SARC	cis	rs1079204	1.000	rs10178462	chr2:219083353	G/T	cg05728596	chr2:219128475	GPBAR1	0.74	5.37	0.33	1.93e-7	Smooth-surface caries;
SARC	cis	rs2882877	0.648	rs11677198	chr2:190386579	A/C	cg21926118	chr2:190387206	NA	0.39	4.73	0.3	3.83e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg00933542	chr6:150070202	PCMT1	0.31	5.29	0.33	2.83e-7	Lung cancer;
SARC	cis	rs920590	0.600	rs4921678	chr8:19663449	A/G	cg17834443	chr8:19674713	INTS10	0.49	6.12	0.37	3.86e-9	Acute lymphoblastic leukemia (childhood);
SARC	trans	rs73158705	0.790	rs10488600	chr7:136605458	A/G	cg01529538	chr14:23388837	RBM23	-0.75	-6.34	-0.38	1.17e-9	Resting heart rate;
SARC	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg05861140	chr6:150128134	PCMT1	-0.41	-5.24	-0.32	3.6e-7	Lung cancer;
SARC	cis	rs6546550	0.935	rs1377995	chr2:70064155	C/G	cg02498382	chr2:70120550	SNRNP27	-0.42	-7.08	-0.42	1.67e-11	Prevalent atrial fibrillation;
SARC	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg00933542	chr6:150070202	PCMT1	0.31	5.13	0.32	6.04e-7	Testicular germ cell tumor;
SARC	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg07061783	chr6:25882402	NA	-0.42	-5.03	-0.31	9.93e-7	Intelligence (multi-trait analysis);
SARC	cis	rs10463316	0.894	rs7707745	chr5:150765198	G/T	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.29	-0.33	2.8e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs7923609	0.811	rs7899657	chr10:65323265	G/A	cg01631684	chr10:65280961	REEP3	0.36	4.76	0.3	3.36e-6	Educational attainment;Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs2463822	0.858	rs2513077	chr11:62105925	A/G	cg06239285	chr11:62104954	ASRGL1	-0.91	-9.44	-0.53	4e-18	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	11.64	0.61	5.7e-25	Alzheimer's disease;
SARC	cis	rs72945132	0.882	rs56770826	chr11:70128874	A/G	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.78	-0.35	2.39e-8	Coronary artery disease;
SARC	cis	rs4819052	0.788	rs35323494	chr21:46703739	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.63	7.46	0.44	1.65e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg21659725	chr3:3221576	CRBN	0.56	6.55	0.39	3.57e-10	Resting heart rate;
SARC	cis	rs9467160	1.000	rs9467161	chr6:24441963	C/T	cg16211469	chr6:24423932	MRS2	0.38	4.79	0.3	2.95e-6	Liver enzyme levels;
SARC	cis	rs854765	0.575	rs7207821	chr17:17891781	A/G	cg04398451	chr17:18023971	MYO15A	-0.48	-6.78	-0.41	9.98e-11	Total body bone mineral density;
SARC	cis	rs2327429	0.858	rs7769943	chr6:134196327	C/T	cg25632230	chr6:134101081	NA	-0.46	-5.5	-0.34	9.97e-8	Coronary artery disease;
SARC	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg15448220	chr1:150897856	SETDB1	-0.48	-6.29	-0.38	1.58e-9	Tonsillectomy;
SARC	cis	rs2952156	0.959	rs2934952	chr17:37832366	G/A	cg00129232	chr17:37814104	STARD3	-0.69	-9.53	-0.53	2.22e-18	Asthma;
SARC	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg11987759	chr7:65425863	GUSB	-0.47	-6.27	-0.38	1.7e-9	Aortic root size;
SARC	cis	rs35110281	0.805	rs2838317	chr21:44991791	A/C	cg01579765	chr21:45077557	HSF2BP	-0.31	-5.28	-0.33	2.96e-7	Mean corpuscular volume;
SARC	cis	rs1185460	0.967	rs1784302	chr11:118940957	C/G	cg01677386	chr11:118938358	VPS11	-0.39	-4.74	-0.3	3.77e-6	Coronary artery disease;
SARC	cis	rs4819052	1.000	rs2297284	chr21:46705345	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.77	8.69	0.49	6.36e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.97	-15.56	-0.71	6.41e-38	Chronic sinus infection;
SARC	cis	rs6542838	0.609	rs12712043	chr2:99541494	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-5.98	-0.36	8.16e-9	Fear of minor pain;
SARC	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg18876405	chr7:65276391	NA	0.53	6.63	0.4	2.28e-10	Calcium levels;
SARC	cis	rs1865760	0.892	rs9379806	chr6:25940958	G/A	cg16482183	chr6:26056742	HIST1H1C	0.52	6.61	0.4	2.56e-10	Height;
SARC	cis	rs3812831	0.599	rs428637	chr13:114927139	T/G	cg08824895	chr13:115047677	UPF3A	0.47	6.0	0.37	7.67e-9	Schizophrenia;
SARC	cis	rs950169	0.686	rs12906474	chr15:85109237	A/G	cg17507749	chr15:85114479	UBE2QP1	0.8	9.5	0.53	2.65e-18	Schizophrenia;
SARC	cis	rs703842	0.963	rs2291617	chr12:58166403	T/G	cg00677455	chr12:58241039	CTDSP2	0.51	6.56	0.39	3.5e-10	Multiple sclerosis;
SARC	cis	rs4481887	1.000	rs11204626	chr1:248458974	T/A	cg01631408	chr1:248437212	OR2T33	-0.4	-5.08	-0.32	7.75e-7	Common traits (Other);
SARC	cis	rs1113500	0.933	rs11185250	chr1:108616417	A/G	cg06207961	chr1:108661230	NA	0.45	5.93	0.36	1.06e-8	Growth-regulated protein alpha levels;
SARC	cis	rs807669	0.565	rs5746682	chr22:19185526	C/T	cg02655711	chr22:19163373	SLC25A1	0.5	7.28	0.43	5.06e-12	Metabolite levels;
SARC	cis	rs9399135	0.967	rs4142299	chr6:135377186	G/T	cg24558204	chr6:135376177	HBS1L	0.47	6.3	0.38	1.44e-9	Red blood cell count;
SARC	cis	rs16976116	0.901	rs8027256	chr15:55492323	C/A	cg11288833	chr15:55489084	RSL24D1	0.65	6.14	0.37	3.54e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs79976124	0.719	rs34488909	chr6:66637850	T/C	cg07460842	chr6:66804631	NA	0.63	7.01	0.42	2.5e-11	Type 2 diabetes;
SARC	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg15448220	chr1:150897856	SETDB1	0.46	6.02	0.37	6.66e-9	Tonsillectomy;
SARC	cis	rs6964587	0.621	rs39744	chr7:92043016	A/G	cg17063962	chr7:91808500	NA	0.75	10.74	0.58	3.91e-22	Breast cancer;
SARC	cis	rs13191362	0.507	rs2849540	chr6:163094522	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.5	-5.56	-0.34	7.5e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs477692	0.569	rs1762418	chr10:131303353	G/A	cg05714579	chr10:131428358	MGMT	0.56	7.77	0.45	2.48e-13	Response to temozolomide;
SARC	cis	rs9314323	0.767	rs7012604	chr8:26204089	G/A	cg11498726	chr8:26250323	BNIP3L	-0.61	-7.66	-0.45	5.1e-13	Red cell distribution width;
SARC	cis	rs748404	0.723	rs512431	chr15:43541939	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.46	-5.76	-0.35	2.61e-8	Lung cancer;
SARC	cis	rs6565180	0.926	rs4787643	chr16:30393660	G/A	cg17640201	chr16:30407289	ZNF48	0.95	14.73	0.69	3.62e-35	Tonsillectomy;
SARC	cis	rs3799379	0.530	rs10456045	chr6:26404958	A/G	cg12826209	chr6:26865740	GUSBL1	-0.51	-5.39	-0.33	1.75e-7	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg08219700	chr8:58056026	NA	0.47	5.04	0.31	9.15e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7772486	0.597	rs6570732	chr6:146245151	G/A	cg23711669	chr6:146136114	FBXO30	-0.86	-12.13	-0.62	1.42e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6570726	0.791	rs12208019	chr6:145935572	T/C	cg23711669	chr6:146136114	FBXO30	0.89	15.28	0.71	5.63e-37	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7208859	0.673	rs9909497	chr17:29173228	C/A	cg13385521	chr17:29058706	SUZ12P	0.86	7.34	0.43	3.52e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs6582630	0.573	rs12319414	chr12:38267440	T/C	cg26384229	chr12:38710491	ALG10B	-0.6	-7.56	-0.44	9.4e-13	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs79149102	0.579	rs7179097	chr15:75279240	T/G	cg00629941	chr15:75287862	SCAMP5	-0.64	-5.17	-0.32	5.08e-7	Lung cancer;
SARC	cis	rs6918586	0.658	rs198825	chr6:26122502	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.45	-5.73	-0.35	3.04e-8	Schizophrenia;
SARC	cis	rs10911232	0.507	rs4652765	chr1:182994147	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.67	0.57	6.63e-22	Hypertriglyceridemia;
SARC	cis	rs2153535	0.563	rs1737585	chr6:8536594	A/G	cg21535247	chr6:8435926	SLC35B3	-0.55	-6.94	-0.41	3.77e-11	Motion sickness;
SARC	cis	rs950027	0.620	rs872192	chr15:45614502	A/G	cg21132104	chr15:45694354	SPATA5L1	0.58	7.27	0.43	5.25e-12	Response to fenofibrate (adiponectin levels);
SARC	cis	rs79839061	0.611	rs2279183	chr4:882404	T/C	cg07828340	chr4:882639	GAK	0.52	5.22	0.32	4.05e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6831352	0.801	rs2602897	chr4:100046293	A/T	cg13256891	chr4:100009986	ADH5	0.66	8.4	0.48	4.51e-15	Alcohol dependence;
SARC	cis	rs10979	1.000	rs9403506	chr6:143887805	C/G	cg25407410	chr6:143891975	LOC285740	-0.64	-8.58	-0.49	1.32e-15	Hypospadias;
SARC	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	-0.96	-10.17	-0.55	2.39e-20	Platelet count;
SARC	cis	rs9611519	0.929	rs2064560	chr22:41530040	A/G	cg17376030	chr22:41985996	PMM1	0.47	5.25	0.33	3.43e-7	Neuroticism;
SARC	cis	rs10752881	1.000	rs12028732	chr1:182985525	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.7	0.57	5.56e-22	Colorectal cancer;
SARC	cis	rs950169	0.920	rs17300048	chr15:84749477	C/T	cg24253500	chr15:84953950	NA	0.36	5.24	0.32	3.66e-7	Schizophrenia;
SARC	cis	rs7917772	0.502	rs2296583	chr10:104244322	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	8.29	0.48	9.23e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg04277193	chr17:41438351	NA	0.47	5.02	0.31	1.02e-6	Menopause (age at onset);
SARC	cis	rs2273669	0.667	rs12195372	chr6:109284223	A/G	cg05315195	chr6:109294784	ARMC2	-0.57	-5.14	-0.32	5.94e-7	Prostate cancer;
SARC	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg05535760	chr7:792225	HEATR2	0.84	8.35	0.48	6.04e-15	Cerebrospinal P-tau181p levels;
SARC	cis	rs17125944	0.615	rs4901301	chr14:53306485	C/T	cg00686598	chr14:53173677	PSMC6	-0.72	-5.46	-0.34	1.22e-7	Alzheimer's disease (late onset);
SARC	cis	rs554111	0.634	rs34740989	chr1:21316782	C/T	cg08890418	chr1:21044141	KIF17	-0.36	-5.02	-0.31	1.05e-6	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs9399135	0.967	rs4895439	chr6:135318854	A/T	cg24558204	chr6:135376177	HBS1L	0.45	6.12	0.37	4e-9	Red blood cell count;
SARC	cis	rs2013441	1.000	rs2703801	chr17:20100600	T/C	cg13482628	chr17:19912719	NA	-0.48	-6.16	-0.37	3.1e-9	Obesity-related traits;
SARC	cis	rs72781680	0.561	rs72783615	chr2:24296397	C/A	cg08917208	chr2:24149416	ATAD2B	0.62	6.34	0.38	1.18e-9	Lymphocyte counts;
SARC	cis	rs2147959	0.739	rs11587839	chr1:228630979	C/T	cg16894439	chr1:228634806	NA	-0.44	-4.74	-0.3	3.74e-6	Adult asthma;
SARC	trans	rs1422110	0.647	rs10063838	chr5:85530546	T/C	cg01787110	chr1:109008453	NBPF6	-0.45	-6.24	-0.38	2e-9	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs1707322	1.000	rs12077974	chr1:46384141	G/A	cg03146154	chr1:46216737	IPP	0.46	5.17	0.32	4.96e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg12696929	chr3:195401817	SDHAP2	0.39	5.23	0.32	3.7e-7	Pancreatic cancer;
SARC	cis	rs763121	0.853	rs4821809	chr22:39065743	G/C	cg21395723	chr22:39101663	GTPBP1	0.52	5.81	0.36	2.02e-8	Menopause (age at onset);
SARC	cis	rs13191362	1.000	rs34228197	chr6:163008232	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.57	5.51	0.34	9.35e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs11871801	0.517	rs645692	chr17:40701073	C/T	cg20126647	chr17:40714003	COASY	0.5	5.35	0.33	2.12e-7	Crohn's disease;
SARC	cis	rs7412746	0.611	rs4319334	chr1:150766822	G/A	cg13175981	chr1:150552382	MCL1	-0.55	-6.72	-0.4	1.37e-10	Melanoma;
SARC	cis	rs7666738	0.830	rs4699580	chr4:98930673	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	trans	rs11098499	0.863	rs1383533	chr4:120434576	G/A	cg25214090	chr10:38739885	LOC399744	0.57	7.35	0.43	3.31e-12	Corneal astigmatism;
SARC	cis	rs8180040	0.726	rs1869869	chr3:47027833	G/A	cg27129171	chr3:47204927	SETD2	0.64	8.53	0.49	1.85e-15	Colorectal cancer;
SARC	cis	rs2153535	0.601	rs2015281	chr6:8539673	G/A	cg21535247	chr6:8435926	SLC35B3	0.52	6.46	0.39	6.2e-10	Motion sickness;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg08587415	chr6:79788107	PHIP	-0.51	-6.49	-0.39	5.15e-10	Schizophrenia;
SARC	cis	rs7312933	0.703	rs12370778	chr12:42599696	T/A	cg19980929	chr12:42632907	YAF2	0.44	6.04	0.37	6.04e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs1150668	0.830	rs2531831	chr6:28388765	C/G	cg13525197	chr6:28411240	ZSCAN23	-0.42	-5.03	-0.31	9.67e-7	Pubertal anthropometrics;
SARC	cis	rs644799	0.562	rs669973	chr11:95571839	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.71	9.55	0.53	1.83e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg01570182	chr17:44337453	NA	0.8	9.22	0.52	1.77e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs611744	0.503	rs13282220	chr8:109263043	T/C	cg21045802	chr8:109455806	TTC35	0.63	7.68	0.45	4.5e-13	Dupuytren's disease;
SARC	cis	rs9815354	0.812	rs17215988	chr3:41851320	A/C	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg04944784	chr2:26401820	FAM59B	0.6	7.95	0.46	8.14e-14	Gut microbiome composition (summer);
SARC	cis	rs7216064	0.684	rs7406031	chr17:66021753	C/T	cg12091567	chr17:66097778	LOC651250	0.94	12.15	0.62	1.21e-26	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs17270561	0.609	rs9379786	chr6:25730255	T/C	cg17691542	chr6:26056736	HIST1H1C	0.58	7.09	0.42	1.59e-11	Iron status biomarkers;
SARC	cis	rs9486719	0.857	rs2971606	chr6:97043025	C/G	cg06623918	chr6:96969491	KIAA0776	-0.78	-9.63	-0.53	1.09e-18	Migraine;Coronary artery disease;
SARC	cis	rs1728785	1.000	rs1170442	chr16:68574064	G/T	cg02972257	chr16:68554789	NA	-0.43	-5.07	-0.32	8.03e-7	Ulcerative colitis;
SARC	cis	rs6690583	0.623	rs12042845	chr1:85429801	A/G	cg22153463	chr1:85462885	MCOLN2	0.68	6.51	0.39	4.64e-10	Serum sulfate level;
SARC	cis	rs6963495	0.745	rs75805443	chr7:105162828	A/G	cg19920283	chr7:105172520	RINT1	0.65	5.48	0.34	1.09e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg05863683	chr7:1912471	MAD1L1	-0.35	-5.15	-0.32	5.52e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs8078723	0.866	rs7502514	chr17:38188844	A/G	cg17467752	chr17:38218738	THRA	-0.54	-7.22	-0.43	7.13e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	trans	rs3780486	0.505	rs7868663	chr9:33141229	A/G	cg20290983	chr6:43655470	MRPS18A	0.93	13.59	0.66	2.38e-31	IgG glycosylation;
SARC	cis	rs7296418	0.961	rs1790106	chr12:123591596	G/T	cg16085171	chr12:123569118	PITPNM2	-0.38	-4.95	-0.31	1.4e-6	Platelet count;
SARC	cis	rs9398803	0.865	rs1538171	chr6:126752884	C/G	cg20229609	chr6:126660872	C6orf173	0.38	5.47	0.34	1.14e-7	Male-pattern baldness;
SARC	cis	rs910316	1.000	rs4903279	chr14:75546583	C/T	cg11812906	chr14:75593930	NEK9	0.87	13.66	0.67	1.39e-31	Height;
SARC	cis	rs10752881	0.839	rs2093983	chr1:183094210	T/C	cg13390022	chr1:182993471	LAMC1	0.31	4.79	0.3	3.01e-6	Colorectal cancer;
SARC	cis	rs2303759	0.666	rs66967196	chr19:49808894	G/A	cg24324837	chr19:49891574	CCDC155	0.4	4.74	0.3	3.68e-6	Multiple sclerosis;
SARC	cis	rs2153535	0.504	rs9328472	chr6:8470848	G/A	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	cis	rs1050631	1.000	rs1789550	chr18:33699553	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	-0.41	-5.1	-0.32	7.12e-7	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs17376456	0.569	rs6881815	chr5:93105666	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.56	5.89	0.36	1.37e-8	Diabetic retinopathy;
SARC	trans	rs208520	0.690	rs12213561	chr6:66705646	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	14.02	0.68	8.85e-33	Exhaled nitric oxide output;
SARC	cis	rs11638352	1.000	rs2706473	chr15:44417735	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	-0.78	-5.75	-0.35	2.82e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	cis	rs751728	1.000	rs747695	chr6:33736672	G/A	cg15252951	chr6:33757062	LEMD2	0.6	6.99	0.42	2.93e-11	Crohn's disease;
SARC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg06873352	chr17:61820015	STRADA	0.53	6.92	0.41	4.3e-11	Prudent dietary pattern;
SARC	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs7223966	1.000	rs7216798	chr17:61740963	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.48	-5.35	-0.33	2.07e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg22535103	chr8:58192502	C8orf71	-0.72	-6.63	-0.4	2.34e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs16854884	0.657	rs16854816	chr3:143734147	A/G	cg06585982	chr3:143692056	C3orf58	0.67	9.14	0.51	3.13e-17	Economic and political preferences (feminism/equality);
SARC	cis	rs2273669	0.667	rs12210444	chr6:109305743	T/C	cg05315195	chr6:109294784	ARMC2	-0.57	-5.24	-0.32	3.62e-7	Prostate cancer;
SARC	cis	rs7084402	0.967	rs1658432	chr10:60329069	C/G	cg07615347	chr10:60278583	BICC1	0.58	8.58	0.49	1.36e-15	Refractive error;
SARC	cis	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg09021430	chr5:549028	NA	-0.42	-5.6	-0.34	6.02e-8	Obesity-related traits;
SARC	cis	rs7624766	0.555	rs972909	chr3:160509506	C/T	cg22637730	chr3:160473554	PPM1L	0.38	4.86	0.3	2.12e-6	Response to methotrexate in rheumatoid arthritis;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg11869233	chr2:48009809	MSH6	-0.48	-6.3	-0.38	1.49e-9	Chemerin levels;
SARC	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg11890956	chr21:40555474	PSMG1	-1.04	-16.07	-0.72	1.33e-39	Cognitive function;
SARC	cis	rs12421382	0.659	rs12420684	chr11:109391788	T/C	cg27471124	chr11:109292789	C11orf87	0.4	5.46	0.34	1.23e-7	Schizophrenia;
SARC	cis	rs787274	0.867	rs787269	chr9:115548676	T/C	cg13803584	chr9:115635662	SNX30	-0.78	-5.66	-0.35	4.47e-8	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs2730245	0.645	rs4909282	chr7:158699797	T/C	cg24397884	chr7:158709396	WDR60	0.71	8.79	0.5	3.28e-16	Height;
SARC	cis	rs2239547	0.603	rs7644973	chr3:53082937	C/T	cg11645453	chr3:52864694	ITIH4	0.32	4.89	0.3	1.9e-6	Schizophrenia;
SARC	cis	rs16976116	0.901	rs28564077	chr15:55495151	G/A	cg17854078	chr15:55489399	RSL24D1	0.66	6.53	0.39	4.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2635047	0.713	rs28666933	chr18:44762408	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	6.43	0.39	7.08e-10	Educational attainment;
SARC	cis	rs1878931	1.000	rs1878931	chr16:3450907	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.88	13.39	0.66	1.04e-30	Body mass index (adult);
SARC	cis	rs17376456	0.569	rs1349711	chr5:93179032	C/T	cg21475434	chr5:93447410	FAM172A	-0.61	-6.16	-0.37	3.12e-9	Diabetic retinopathy;
SARC	cis	rs2204008	0.630	rs12306932	chr12:38242029	C/T	cg13010199	chr12:38710504	ALG10B	-0.53	-6.63	-0.4	2.35e-10	Bladder cancer;
SARC	cis	rs11758351	0.866	rs2069019	chr6:26205604	C/T	cg23601095	chr6:26197514	HIST1H3D	0.55	4.86	0.3	2.19e-6	Gout;Renal underexcretion gout;
SARC	cis	rs1559088	0.895	rs1974784	chr19:33551563	T/G	cg27124370	chr19:33622961	WDR88	0.42	5.27	0.33	3.1e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs10504229	0.679	rs6474100	chr8:58031161	G/A	cg21724239	chr8:58056113	NA	0.6	6.2	0.38	2.51e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7223966	0.655	rs9906882	chr17:61634382	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.47	5.13	0.32	6.05e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs854765	0.693	rs9907287	chr17:17774118	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.44	-5.68	-0.35	4.02e-8	Total body bone mineral density;
SARC	cis	rs17376456	0.825	rs10056879	chr5:93282218	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.68	5.77	0.35	2.57e-8	Diabetic retinopathy;
SARC	cis	rs1448094	0.512	rs7308229	chr12:86239849	A/T	cg02569458	chr12:86230093	RASSF9	-0.37	-5.19	-0.32	4.65e-7	Major depressive disorder;
SARC	cis	rs17539620	0.624	rs62432746	chr6:154838986	A/G	cg17771515	chr6:154831774	CNKSR3	0.53	5.07	0.31	8.28e-7	Lipoprotein (a) levels;
SARC	cis	rs826838	0.967	rs1719858	chr12:39124505	C/T	cg26384229	chr12:38710491	ALG10B	-0.76	-11.6	-0.61	7.32e-25	Heart rate;
SARC	cis	rs7833986	0.534	rs17759244	chr8:57033768	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.73	7.47	0.44	1.56e-12	Height;
SARC	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg22535103	chr8:58192502	C8orf71	-0.7	-8.43	-0.48	3.66e-15	Developmental language disorder (linguistic errors);
SARC	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg20102877	chr2:27665638	KRTCAP3	-0.37	-5.17	-0.32	5.05e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs1008375	0.800	rs28754811	chr4:17612312	C/T	cg27347728	chr4:17578864	LAP3	0.45	5.55	0.34	7.89e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs929354	0.772	rs933344	chr7:157011265	A/T	cg05182265	chr7:156933206	UBE3C	-0.31	-4.79	-0.3	2.93e-6	Body mass index;
SARC	cis	rs7223966	1.000	rs13380863	chr17:61780793	G/A	cg26338869	chr17:61819248	STRADA	0.46	4.91	0.31	1.7e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg01579765	chr21:45077557	HSF2BP	-0.37	-6.18	-0.38	2.87e-9	Mean corpuscular volume;
SARC	cis	rs2412459	0.831	rs6492924	chr15:40272391	G/A	cg09159619	chr15:40331526	SRP14	0.73	5.5	0.34	1e-7	Response to haloperidol in psychosis;
SARC	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg03433033	chr1:76189801	ACADM	-0.47	-5.72	-0.35	3.33e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg15049968	chr18:44337910	ST8SIA5	-0.38	-6.06	-0.37	5.4e-9	Personality dimensions;
SARC	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg12751644	chr20:60527061	NA	-0.42	-5.42	-0.33	1.51e-7	Obesity-related traits;
SARC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg13397359	chr6:42928475	GNMT	0.58	8.15	0.47	2.28e-14	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs9291683	0.526	rs12506122	chr4:10033538	C/A	cg11266682	chr4:10021025	SLC2A9	0.4	6.9	0.41	4.99e-11	Bone mineral density;
SARC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg11494091	chr17:61959527	GH2	0.54	8.15	0.47	2.26e-14	Prudent dietary pattern;
SARC	cis	rs8141529	0.529	rs5762812	chr22:29200117	T/C	cg15103426	chr22:29168792	CCDC117	0.6	5.68	0.35	4.06e-8	Lymphocyte counts;
SARC	cis	rs4566357	0.615	rs4675139	chr2:227908527	G/A	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.93	-0.36	1.08e-8	Coronary artery disease;
SARC	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg10130564	chr11:117069849	TAGLN	0.22	5.02	0.31	1.03e-6	Blood protein levels;
SARC	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs116095464	0.850	rs6896163	chr5:303686	A/G	cg20965017	chr5:231967	SDHA	-0.66	-4.86	-0.3	2.21e-6	Breast cancer;
SARC	cis	rs787274	0.619	rs10115576	chr9:115617822	T/C	cg13803584	chr9:115635662	SNX30	-0.68	-5.16	-0.32	5.28e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg02841227	chr6:26021843	HIST1H4A	0.47	5.07	0.32	8.14e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7769051	1.000	rs5006218	chr6:133126220	T/G	cg22852734	chr6:133119734	C6orf192	1.1	11.43	0.6	2.68e-24	Type 2 diabetes nephropathy;
SARC	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg25894440	chr7:65020034	NA	-0.73	-5.48	-0.34	1.09e-7	Diabetic kidney disease;
SARC	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg24829409	chr8:58192753	C8orf71	-0.65	-6.15	-0.37	3.28e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10927875	0.541	rs1048245	chr1:16341354	T/G	cg21385522	chr1:16154831	NA	0.55	6.64	0.4	2.24e-10	Dilated cardiomyopathy;
SARC	cis	rs2463822	0.513	rs72919445	chr11:62029078	A/C	cg06239285	chr11:62104954	ASRGL1	-0.8	-7.48	-0.44	1.52e-12	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg13206674	chr6:150067644	NUP43	-0.44	-5.65	-0.35	4.72e-8	Lung cancer;
SARC	cis	rs17376456	0.825	rs36042718	chr5:93180997	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.7	6.25	0.38	1.94e-9	Diabetic retinopathy;
SARC	cis	rs2075371	1.000	rs2075371	chr7:133984127	A/G	cg20476274	chr7:133979776	SLC35B4	0.62	8.49	0.49	2.43e-15	Mean platelet volume;
SARC	cis	rs9486715	0.838	rs9486275	chr6:96901187	C/T	cg18709589	chr6:96969512	KIAA0776	0.58	7.27	0.43	5.5e-12	Headache;
SARC	cis	rs898097	0.578	rs2380173	chr17:80909157	G/T	cg20578329	chr17:80767326	TBCD	-0.4	-5.86	-0.36	1.56e-8	Breast cancer;
SARC	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg00825309	chr19:58991885	ZNF446	-0.58	-7.97	-0.46	7.16e-14	Uric acid clearance;
SARC	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs8031584	0.918	rs35784593	chr15:31254588	G/A	cg14298792	chr15:30685198	CHRFAM7A	-0.44	-4.83	-0.3	2.5e-6	Huntington's disease progression;
SARC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg21747090	chr2:27597821	SNX17	-0.55	-7.68	-0.45	4.44e-13	Total body bone mineral density;
SARC	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-5.72	-0.35	3.23e-8	Electroencephalogram traits;
SARC	cis	rs9916302	0.904	rs8079303	chr17:37530755	G/C	cg15445000	chr17:37608096	MED1	-0.42	-5.14	-0.32	5.86e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs2760061	0.626	rs596208	chr1:228117982	G/C	cg02753203	chr1:228287806	NA	-0.54	-7.45	-0.44	1.79e-12	Diastolic blood pressure;
SARC	cis	rs1044826	1.000	rs9860201	chr3:139091444	G/C	cg15131784	chr3:139108705	COPB2	0.46	5.32	0.33	2.38e-7	Obesity-related traits;
SARC	cis	rs57502260	0.680	rs55654976	chr11:68393541	C/T	cg01657329	chr11:68192670	LRP5	-0.56	-5.35	-0.33	2.14e-7	Total body bone mineral density (age 45-60);
SARC	cis	rs957448	1.000	rs2381882	chr8:95547724	G/T	cg26464482	chr8:95565502	KIAA1429	0.43	4.79	0.3	2.99e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs7617773	0.743	rs71323397	chr3:48374874	A/G	cg11946769	chr3:48343235	NME6	0.76	9.57	0.53	1.63e-18	Coronary artery disease;
SARC	cis	rs7808935	0.768	rs757138	chr7:27989403	T/G	cg05786569	chr7:27702416	HIBADH	0.46	5.14	0.32	5.72e-7	Prostate cancer;
SARC	cis	rs3741404	0.574	rs638227	chr11:63871549	T/C	cg18225595	chr11:63971243	STIP1	0.4	5.65	0.35	4.71e-8	Platelet count;
SARC	cis	rs3733585	0.699	rs12498150	chr4:9950537	C/T	cg11266682	chr4:10021025	SLC2A9	-0.35	-6.01	-0.37	7.18e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs4642101	0.560	rs4535210	chr3:12839617	T/G	cg12400702	chr3:12838781	CAND2	-0.26	-5.06	-0.31	8.47e-7	QRS complex (12-leadsum);
SARC	cis	rs17376456	0.877	rs114256265	chr5:93473130	T/A	cg21475434	chr5:93447410	FAM172A	0.92	8.26	0.48	1.08e-14	Diabetic retinopathy;
SARC	cis	rs6545883	0.931	rs9807965	chr2:61732159	T/C	cg15711740	chr2:61764176	XPO1	-0.42	-5.17	-0.32	5.02e-7	Tuberculosis;
SARC	cis	rs3859192	0.561	rs34453912	chr17:38180352	T/A	cg17467752	chr17:38218738	THRA	-0.38	-4.74	-0.3	3.66e-6	White blood cell count;
SARC	cis	rs1707322	0.721	rs11211158	chr1:46132850	C/G	cg06784218	chr1:46089804	CCDC17	0.36	6.25	0.38	1.93e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg01516881	chr6:292596	DUSP22	-0.63	-7.92	-0.46	9.58e-14	Menopause (age at onset);
SARC	cis	rs28374715	0.609	rs8043237	chr15:41514298	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.99	-14.1	-0.68	4.52e-33	Ulcerative colitis;
SARC	cis	rs67478160	0.584	rs2295147	chr14:104195664	A/G	cg01849466	chr14:104193079	ZFYVE21	0.39	5.6	0.34	6.06e-8	Schizophrenia;
SARC	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.4	-0.48	4.37e-15	Alzheimer's disease;
SARC	cis	rs910316	1.000	rs3742778	chr14:75538217	A/C	cg11812906	chr14:75593930	NEK9	-0.89	-14.3	-0.68	1.03e-33	Height;
SARC	cis	rs62064224	0.791	rs11654833	chr17:30667728	C/T	cg18200150	chr17:30822561	MYO1D	0.39	6.19	0.38	2.62e-9	Schizophrenia;
SARC	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.46	5.77	0.35	2.54e-8	Gut microbiome composition (summer);
SARC	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg26335602	chr6:28129616	ZNF389	0.55	5.95	0.36	9.89e-9	Parkinson's disease;
SARC	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg11890956	chr21:40555474	PSMG1	-0.71	-9.34	-0.52	8.3e-18	Menarche (age at onset);
SARC	trans	rs61931739	0.517	rs11611190	chr12:34015697	G/A	cg13010199	chr12:38710504	ALG10B	0.75	10.14	0.55	3.05e-20	Morning vs. evening chronotype;
SARC	cis	rs6503863	1	rs6503863	chr17:56517034	G/A	cg12560992	chr17:57184187	TRIM37	0.51	6.44	0.39	6.68e-10	Intelligence (multi-trait analysis);
SARC	cis	rs734999	0.588	rs78506337	chr1:2537095	G/A	cg20673091	chr1:2541236	MMEL1	0.33	5.11	0.32	6.58e-7	Ulcerative colitis;
SARC	cis	rs7937682	0.575	rs34558891	chr11:111737912	C/T	cg22437258	chr11:111473054	SIK2	-0.49	-5.63	-0.35	5.13e-8	Primary sclerosing cholangitis;
SARC	cis	rs910316	0.763	rs13712	chr14:75483812	T/C	cg06637938	chr14:75390232	RPS6KL1	0.46	6.12	0.37	3.86e-9	Height;
SARC	cis	rs2070997	0.607	rs11244147	chr9:133677168	T/G	cg11464064	chr9:133710261	ABL1	0.57	5.32	0.33	2.42e-7	Response to amphetamines;
SARC	cis	rs9818758	0.607	rs34823813	chr3:49749976	G/A	cg03060546	chr3:49711283	APEH	-0.6	-5.17	-0.32	5e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs7089973	0.604	rs7923693	chr10:116619566	A/G	cg03647239	chr10:116582469	FAM160B1	0.54	7.03	0.42	2.32e-11	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.44	6.57	0.4	3.3e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs6504663	1.000	rs6504661	chr17:48580126	A/T	cg03168497	chr17:48586147	MYCBPAP	-0.5	-6.21	-0.38	2.41e-9	Visceral fat;
SARC	cis	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg25427524	chr10:38739819	LOC399744	-0.52	-8.23	-0.47	1.32e-14	Extrinsic epigenetic age acceleration;
SARC	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg11062466	chr8:58055876	NA	0.54	5.49	0.34	1.04e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs959260	0.588	rs2385263	chr17:73321117	T/C	cg07104495	chr17:73266070	MIF4GD	-0.33	-4.95	-0.31	1.4e-6	Systemic lupus erythematosus;
SARC	cis	rs644799	1.000	rs472231	chr11:95532166	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.7	9.55	0.53	1.87e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg21747090	chr2:27597821	SNX17	-0.53	-7.14	-0.42	1.17e-11	Total body bone mineral density;
SARC	cis	rs193541	0.564	rs407230	chr5:122345727	G/A	cg19412675	chr5:122181750	SNX24	-0.49	-6.27	-0.38	1.72e-9	Glucose homeostasis traits;
SARC	cis	rs7044106	0.762	rs7024046	chr9:123419178	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	4.89	0.31	1.86e-6	Hip circumference adjusted for BMI;
SARC	cis	rs4742903	0.527	rs7350223	chr9:106885332	A/G	cg14250997	chr9:106856677	SMC2	0.5	6.29	0.38	1.6e-9	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.5e-10	Life satisfaction;
SARC	cis	rs67460515	0.892	rs11718905	chr3:161051793	G/A	cg04691961	chr3:161091175	C3orf57	-0.49	-6.02	-0.37	6.59e-9	Parkinson's disease;
SARC	cis	rs11792861	0.888	rs75543406	chr9:111816903	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.68	7.68	0.45	4.3e-13	Menarche (age at onset);
SARC	cis	rs6582630	0.585	rs12422588	chr12:38478675	C/T	cg26384229	chr12:38710491	ALG10B	-0.56	-7.06	-0.42	1.89e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7481584	0.624	rs451060	chr11:3056389	G/A	cg25174290	chr11:3078921	CARS	-0.6	-8.32	-0.48	7.6e-15	Calcium levels;
SARC	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.47	-5.9	-0.36	1.27e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7220711	0.902	rs12603100	chr17:41781344	T/G	cg26893861	chr17:41843967	DUSP3	0.42	5.43	0.33	1.44e-7	Bone mineral density (spine);Bone mineral density (hip);
SARC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg20607798	chr8:58055168	NA	0.58	5.55	0.34	7.69e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs11098499	0.909	rs28571712	chr4:120375980	G/A	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	cis	rs5753618	0.561	rs4141404	chr22:31675185	A/C	cg02404636	chr22:31891804	SFI1	-0.49	-5.22	-0.32	3.99e-7	Colorectal cancer;
SARC	cis	rs4891159	0.536	rs690392	chr18:74152618	G/A	cg24786174	chr18:74118243	ZNF516	0.72	11.85	0.61	1.11e-25	Longevity;
SARC	cis	rs921968	0.541	rs581013	chr2:219432040	G/T	cg02176678	chr2:219576539	TTLL4	0.47	7.13	0.42	1.28e-11	Mean corpuscular hemoglobin concentration;
SARC	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg16325326	chr1:53192061	ZYG11B	-0.85	-14.04	-0.68	7.45e-33	Monocyte count;
SARC	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg02524346	chr8:600233	NA	0.67	5.01	0.31	1.08e-6	IgG glycosylation;
SARC	cis	rs9916302	0.752	rs8071300	chr17:37508524	G/C	cg15445000	chr17:37608096	MED1	-0.46	-5.04	-0.31	9.46e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs7208859	0.573	rs73267829	chr17:29003939	G/A	cg13385521	chr17:29058706	SUZ12P	0.81	6.15	0.37	3.27e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	trans	rs6894249	1.000	rs6894249	chr5:131797547	A/G	cg15853350	chr17:58120343	NA	-0.45	-6.28	-0.38	1.67e-9	Asthma;
SARC	cis	rs12545109	0.800	rs1837614	chr8:57414497	T/A	cg19413350	chr8:57351067	NA	-0.43	-5.32	-0.33	2.38e-7	Obesity-related traits;
SARC	cis	rs7264396	0.528	rs7273880	chr20:34551507	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	5.3	0.33	2.71e-7	Total cholesterol levels;
SARC	cis	rs116095464	0.558	rs6866632	chr5:264429	C/G	cg22496380	chr5:211416	CCDC127	-0.9	-9.05	-0.51	5.64e-17	Breast cancer;
SARC	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg09699651	chr6:150184138	LRP11	0.39	4.96	0.31	1.35e-6	Lung cancer;
SARC	cis	rs9921222	0.500	rs11645742	chr16:367516	C/T	cg00101154	chr16:420108	MRPL28	-0.5	-6.69	-0.4	1.62e-10	Bone mineral density (spine);Bone mineral density;
SARC	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg22433210	chr17:43662623	NA	0.85	9.85	0.54	2.26e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg11965913	chr1:205819406	PM20D1	0.9	15.03	0.7	3.78e-36	Menarche (age at onset);
SARC	cis	rs6062509	0.929	rs6062510	chr20:62372148	G/C	cg27236539	chr20:62289627	RTEL1	0.52	5.73	0.35	3.16e-8	Prostate cancer;
SARC	cis	rs1023500	0.505	rs134899	chr22:42683030	T/G	cg04733989	chr22:42467013	NAGA	0.54	7.18	0.43	9.29e-12	Schizophrenia;
SARC	cis	rs7785360	0.719	rs66936223	chr7:69748625	A/G	cg10619644	chr7:69149951	AUTS2	0.44	4.86	0.3	2.13e-6	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
SARC	cis	rs35213789	0.762	rs2533458	chr7:69144192	T/C	cg10619644	chr7:69149951	AUTS2	-0.36	-5.0	-0.31	1.11e-6	Childhood ear infection;
SARC	cis	rs5167	0.586	rs4803774	chr19:45450872	A/G	cg13119609	chr19:45449297	APOC2	0.52	8.55	0.49	1.61e-15	Blood protein levels;
SARC	cis	rs6835098	0.828	rs28612521	chr4:174085294	G/A	cg08422745	chr4:174089978	GALNT7	-0.77	-10.28	-0.56	1.09e-20	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs2916247	0.954	rs990746	chr8:93173405	C/G	cg10183463	chr8:93005414	RUNX1T1	0.57	5.81	0.36	2.04e-8	Intelligence (multi-trait analysis);
SARC	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.1	21.62	0.82	1.29e-57	Chronic sinus infection;
SARC	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg04518342	chr5:131593106	PDLIM4	-0.45	-5.61	-0.34	5.86e-8	Breast cancer;
SARC	cis	rs834603	0.575	rs1799376	chr7:47479583	C/T	cg23694490	chr7:47445681	TNS3	-0.32	-5.87	-0.36	1.47e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs11687170	0.882	rs35248881	chr2:237062517	T/A	cg19324714	chr2:237145437	ASB18	0.47	4.73	0.3	3.82e-6	Educational attainment;Educational attainment (years of education);
SARC	cis	rs6908034	0.607	rs76413455	chr6:19808964	T/G	cg02682789	chr6:19804855	NA	0.72	5.85	0.36	1.68e-8	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg08859206	chr1:53392774	SCP2	0.36	5.22	0.32	3.96e-7	Monocyte count;
SARC	trans	rs4716055	0.568	rs7768421	chr6:9792596	T/C	cg11146081	chr14:75514134	MLH3	0.9	6.37	0.39	9.94e-10	Adiponectin levels;
SARC	cis	rs73001065	0.551	rs56397647	chr19:19642795	C/T	cg03709012	chr19:19516395	GATAD2A	1.08	8.45	0.48	3.17e-15	LDL cholesterol;
SARC	cis	rs13144136	0.643	rs4339204	chr4:10661011	A/T	cg10242279	chr4:10666415	CLNK	-0.45	-7.39	-0.44	2.54e-12	Resistance to antihypertensive treatment in hypertension;
SARC	cis	rs7666738	0.830	rs62321565	chr4:98976571	G/A	cg05340658	chr4:99064831	C4orf37	0.64	8.6	0.49	1.18e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg21644426	chr2:191273491	MFSD6	0.53	7.18	0.43	9.16e-12	Pulse pressure;
SARC	cis	rs7904368	0.754	rs7076779	chr10:16852667	C/T	cg14835575	chr10:16859367	RSU1	0.63	6.26	0.38	1.8e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs6807306	1.000	rs9813276	chr3:167440206	T/G	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.5	4.86	0.3	2.19e-6	Mean platelet volume;
SARC	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg18252515	chr7:66147081	NA	0.56	5.86	0.36	1.55e-8	Aortic root size;
SARC	cis	rs981844	0.796	rs17030437	chr4:154704225	A/C	cg14289246	chr4:154710475	SFRP2	-0.63	-7.15	-0.42	1.13e-11	Response to statins (LDL cholesterol change);
SARC	cis	rs73001065	0.901	rs3794991	chr19:19610596	C/T	cg03709012	chr19:19516395	GATAD2A	1.02	6.38	0.39	9.56e-10	LDL cholesterol;
SARC	cis	rs5753037	0.702	rs249398	chr22:30214704	G/C	cg01021169	chr22:30184971	ASCC2	-0.44	-5.86	-0.36	1.59e-8	Type 1 diabetes;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg24180402	chr17:43221464	ACBD4	0.49	6.23	0.38	2.13e-9	Blood pressure;
SARC	cis	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg25427524	chr10:38739819	LOC399744	-0.54	-8.59	-0.49	1.26e-15	Extrinsic epigenetic age acceleration;
SARC	cis	rs4319547	0.656	rs10161534	chr12:122873864	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.53	-6.12	-0.37	3.88e-9	Body mass index;
SARC	cis	rs854765	0.547	rs2955359	chr17:17946730	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.41	-5.13	-0.32	6.16e-7	Total body bone mineral density;
SARC	cis	rs4689592	0.546	rs907523	chr4:7052777	A/G	cg26116260	chr4:7069785	GRPEL1	0.96	12.07	0.62	2.31e-26	Monocyte percentage of white cells;
SARC	cis	rs34779708	0.931	rs2148482	chr10:35348910	A/G	cg03585969	chr10:35415529	CREM	0.4	5.08	0.32	7.91e-7	Inflammatory bowel disease;Crohn's disease;
SARC	trans	rs9354308	0.899	rs1938059	chr6:66539291	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.57	6.69	0.4	1.68e-10	Metabolite levels;
SARC	cis	rs35110281	0.667	rs7282122	chr21:45082365	G/A	cg01579765	chr21:45077557	HSF2BP	-0.34	-5.5	-0.34	9.84e-8	Mean corpuscular volume;
SARC	cis	rs6141769	0.542	rs28523897	chr20:31301248	C/T	cg17884169	chr20:31446444	EFCAB8	-0.45	-4.83	-0.3	2.46e-6	Subjective well-being;
SARC	cis	rs933688	1.000	rs2052553	chr5:90729906	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.09	13.76	0.67	6.21e-32	Smoking behavior;
SARC	cis	rs709400	0.633	rs8013101	chr14:103951772	G/C	cg26031613	chr14:104095156	KLC1	0.82	11.93	0.62	6.36e-26	Body mass index;
SARC	cis	rs1580019	0.961	rs4255041	chr7:32496383	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.43	5.04	0.31	9.3e-7	Cognitive ability;
SARC	cis	rs6728642	0.519	rs6721921	chr2:97566501	G/A	cg26665480	chr2:98280029	ACTR1B	-0.58	-5.28	-0.33	3.01e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg21782813	chr7:2030301	MAD1L1	0.35	5.37	0.33	1.89e-7	Bipolar disorder and schizophrenia;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg24793584	chr17:80557532	FOXK2	0.45	6.33	0.38	1.28e-9	Schizophrenia;
SARC	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg24675658	chr1:53192096	ZYG11B	0.66	9.47	0.53	3.3e-18	Monocyte count;
SARC	cis	rs17376456	0.877	rs12374463	chr5:93483569	C/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.2	0.32	4.28e-7	Diabetic retinopathy;
SARC	cis	rs9467773	0.935	rs1884947	chr6:26553273	G/T	cg11502198	chr6:26597334	ABT1	0.45	5.37	0.33	1.91e-7	Intelligence (multi-trait analysis);
SARC	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg26769984	chr7:1090371	C7orf50	0.52	5.32	0.33	2.46e-7	Bronchopulmonary dysplasia;
SARC	cis	rs561341	0.709	rs8068049	chr17:30183857	T/C	cg13647721	chr17:30228624	UTP6	-0.72	-5.55	-0.34	7.7e-8	Hip circumference adjusted for BMI;
SARC	cis	rs453301	0.686	rs6601281	chr8:8911004	A/G	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.5	-0.39	4.76e-10	Joint mobility (Beighton score);
SARC	cis	rs11098499	0.605	rs6833140	chr4:120266822	G/A	cg09307838	chr4:120376055	NA	0.75	10.42	0.56	4.08e-21	Corneal astigmatism;
SARC	cis	rs698833	0.962	rs698830	chr2:44730863	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.66	7.98	0.46	6.73e-14	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs11690935	0.921	rs908670	chr2:172690180	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.97	-14.9	-0.7	9.87e-36	Schizophrenia;
SARC	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg02463440	chr8:22132932	PIWIL2	0.47	6.61	0.4	2.65e-10	Hypertriglyceridemia;
SARC	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg05368731	chr17:41323189	NBR1	0.8	9.59	0.53	1.43e-18	Menopause (age at onset);
SARC	trans	rs208520	0.690	rs176289	chr6:66766522	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-14.08	-0.68	5.37e-33	Exhaled nitric oxide output;
SARC	cis	rs12824058	0.831	rs11060825	chr12:130807905	A/G	cg23887609	chr12:130822674	PIWIL1	0.39	5.37	0.33	1.92e-7	Menopause (age at onset);
SARC	cis	rs995000	0.931	rs597078	chr1:62917857	G/A	cg06896770	chr1:63153194	DOCK7	0.9	13.85	0.67	3.23e-32	Triglyceride levels;
SARC	cis	rs9303401	0.659	rs9303399	chr17:56672309	C/T	cg25039879	chr17:56429692	SUPT4H1	0.7	6.57	0.4	3.22e-10	Cognitive test performance;
SARC	cis	rs959260	0.925	rs4788890	chr17:73389446	A/G	cg14668889	chr17:73230827	NUP85	-0.43	-4.78	-0.3	3.06e-6	Systemic lupus erythematosus;
SARC	cis	rs8017423	0.935	rs8012303	chr14:90715829	G/A	cg20276874	chr14:90721474	PSMC1	-0.37	-5.09	-0.32	7.21e-7	Mortality in heart failure;
SARC	cis	rs34172651	0.917	rs6497760	chr16:24806535	G/A	cg00152838	chr16:24741724	TNRC6A	-0.5	-6.01	-0.37	7e-9	Intelligence (multi-trait analysis);
SARC	cis	rs986417	0.901	rs12436953	chr14:61001546	C/T	cg27398547	chr14:60952738	C14orf39	1.01	9.67	0.54	8e-19	Gut microbiota (bacterial taxa);
SARC	cis	rs17376456	0.825	rs10038828	chr5:93124056	C/T	cg25358565	chr5:93447407	FAM172A	1.18	12.07	0.62	2.21e-26	Diabetic retinopathy;
SARC	cis	rs2197308	0.715	rs11181816	chr12:37911626	A/G	cg13010199	chr12:38710504	ALG10B	-0.68	-9.06	-0.51	5.6e-17	Morning vs. evening chronotype;
SARC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	4.79	0.3	2.98e-6	Bipolar disorder;
SARC	cis	rs4803455	0.586	rs4803457	chr19:41861359	T/C	cg09537434	chr19:41945824	ATP5SL	-0.63	-8.36	-0.48	5.72e-15	Migraine;Coronary artery disease;
SARC	cis	rs1966248	0.543	rs4895991	chr6:134116003	C/T	cg25632230	chr6:134101081	NA	-0.53	-7.09	-0.42	1.6e-11	Coronary artery disease;
SARC	cis	rs933688	1.000	rs2059207	chr5:90731931	C/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.0	13.51	0.66	4.2e-31	Smoking behavior;
SARC	cis	rs2228479	0.702	rs62053701	chr16:89860584	G/A	cg00800038	chr16:89945340	TCF25	-0.8	-5.6	-0.34	6.15e-8	Skin colour saturation;
SARC	cis	rs9309473	0.898	rs11126404	chr2:73796924	T/A	cg20560298	chr2:73613845	ALMS1	-0.46	-5.53	-0.34	8.77e-8	Metabolite levels;
SARC	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg00031303	chr3:195681400	NA	0.48	5.42	0.33	1.48e-7	Pancreatic cancer;
SARC	cis	rs79149102	0.579	rs3910748	chr15:75318652	A/G	cg00629941	chr15:75287862	SCAMP5	-0.7	-5.42	-0.33	1.47e-7	Lung cancer;
SARC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg01238044	chr22:24384105	GSTT1	-0.56	-6.22	-0.38	2.29e-9	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9393692	0.905	rs9358919	chr6:26287862	C/T	cg13736514	chr6:26305472	NA	-0.6	-8.29	-0.48	9e-15	Educational attainment;
SARC	cis	rs6570726	0.764	rs9403733	chr6:145912311	A/C	cg23711669	chr6:146136114	FBXO30	0.88	14.58	0.69	1.2e-34	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12477438	0.822	rs6727170	chr2:99588042	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.9	-11.51	-0.6	1.44e-24	Chronic sinus infection;
SARC	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg05340658	chr4:99064831	C4orf37	0.57	7.16	0.42	1.02e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7216064	0.817	rs28609796	chr17:65855104	T/A	cg12091567	chr17:66097778	LOC651250	-0.65	-6.49	-0.39	5.2e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs2730245	0.527	rs2527187	chr7:158716912	T/C	cg24397884	chr7:158709396	WDR60	-1.19	-11.61	-0.61	7.08e-25	Height;
SARC	cis	rs9660992	0.573	rs4400674	chr1:205218425	A/C	cg00857998	chr1:205179979	DSTYK	-0.53	-6.77	-0.41	1.01e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg07414643	chr4:187882934	NA	0.46	6.47	0.39	5.61e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2153535	0.580	rs7341381	chr6:8470537	A/G	cg07606381	chr6:8435919	SLC35B3	0.77	11.16	0.59	1.85e-23	Motion sickness;
SARC	cis	rs9911578	1.000	rs8071916	chr17:56660279	A/G	cg05425664	chr17:57184151	TRIM37	-0.61	-7.59	-0.45	7.68e-13	Intelligence (multi-trait analysis);
SARC	trans	rs11250097	0.535	rs11250086	chr8:10769783	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.62	-0.4	2.5e-10	Neuroticism;
SARC	cis	rs1580019	0.885	rs4460269	chr7:32496445	T/C	cg14728415	chr7:32535168	LSM5;AVL9	0.43	5.04	0.31	9.3e-7	Cognitive ability;
SARC	cis	rs644799	0.965	rs1944080	chr11:95503636	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.88	13.76	0.67	6.16e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg00149659	chr3:10157352	C3orf10	0.7	6.89	0.41	5.14e-11	Alzheimer's disease;
SARC	cis	rs14978	0.628	rs4721058	chr7:12267256	C/T	cg23422036	chr7:12250390	TMEM106B	0.45	5.73	0.35	3.01e-8	Response to amphetamines;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg01028360	chr8:12869510	C8orf79	0.51	7.44	0.44	1.94e-12	Thyroid stimulating hormone;
SARC	cis	rs9527	0.641	rs34130454	chr10:104903638	A/G	cg04362960	chr10:104952993	NT5C2	0.44	5.18	0.32	4.78e-7	Arsenic metabolism;
SARC	cis	rs796364	0.760	rs56225698	chr2:200910653	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.69	-5.65	-0.35	4.63e-8	Schizophrenia;
SARC	cis	rs6723226	0.598	rs2710629	chr2:32765844	C/T	cg02381751	chr2:32503542	YIPF4	0.72	9.97	0.55	1.02e-19	Intelligence (multi-trait analysis);
SARC	cis	rs986417	0.901	rs7150630	chr14:61019458	T/A	cg27398547	chr14:60952738	C14orf39	0.97	8.82	0.5	2.72e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs870825	1.000	rs870825	chr4:185588045	A/G	cg04058563	chr4:185651563	MLF1IP	0.69	8.07	0.47	3.64e-14	Blood protein levels;
SARC	cis	rs7617773	0.563	rs62263035	chr3:48391569	C/T	cg11946769	chr3:48343235	NME6	0.53	6.49	0.39	5.07e-10	Coronary artery disease;
SARC	cis	rs9790314	1.000	rs4597724	chr3:160963110	A/G	cg03342759	chr3:160939853	NMD3	-0.61	-7.71	-0.45	3.64e-13	Morning vs. evening chronotype;
SARC	cis	rs2404602	0.716	rs7179142	chr15:76698268	G/A	cg22467129	chr15:76604101	ETFA	-0.36	-4.86	-0.3	2.12e-6	Blood metabolite levels;
SARC	cis	rs3020736	0.500	rs4147638	chr22:42487900	G/A	cg04733989	chr22:42467013	NAGA	-0.77	-10.92	-0.58	1.11e-22	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg11366901	chr6:160182831	ACAT2	0.96	9.97	0.55	9.69e-20	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs796364	0.806	rs76112266	chr2:201087157	C/G	cg23649088	chr2:200775458	C2orf69	-0.67	-5.84	-0.36	1.71e-8	Schizophrenia;
SARC	cis	rs2370759	0.898	rs113412621	chr10:32579306	C/T	cg01819863	chr10:32635814	EPC1	1.02	9.93	0.55	1.37e-19	Sexual dysfunction (female);
SARC	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg05025164	chr4:1340916	KIAA1530	0.61	7.39	0.44	2.53e-12	Obesity-related traits;
SARC	cis	rs9467773	0.620	rs2494700	chr6:26631306	C/T	cg12292205	chr6:26970375	C6orf41	0.41	5.12	0.32	6.46e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2276314	0.857	rs8087539	chr18:33631537	C/T	cg19628046	chr18:33552617	C18orf21	0.57	5.9	0.36	1.24e-8	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs3768716	0.500	rs777329	chr2:215742595	A/G	cg04004882	chr2:215674386	BARD1	-0.56	-6.38	-0.39	9.34e-10	Neuroblastoma;
SARC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.08	18.15	0.77	1.83e-46	Prudent dietary pattern;
SARC	cis	rs67478160	0.634	rs941473	chr14:104201869	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.36	-4.93	-0.31	1.56e-6	Schizophrenia;
SARC	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.79	10.46	0.57	3.13e-21	Chronic sinus infection;
SARC	cis	rs957448	1.000	rs72674866	chr8:95576847	A/G	cg26464482	chr8:95565502	KIAA1429	0.44	4.85	0.3	2.23e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs56011263	0.687	rs4690292	chr4:703712	A/G	cg14024328	chr4:719362	PCGF3	-0.42	-5.62	-0.35	5.33e-8	White blood cell count;
SARC	cis	rs1008375	0.866	rs12233712	chr4:17570063	T/A	cg02297831	chr4:17616191	MED28	0.42	5.05	0.31	9.03e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	8.8	0.5	3.14e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6424115	0.830	rs2502999	chr1:24198321	A/G	cg15997130	chr1:24165203	NA	0.41	5.51	0.34	9.33e-8	Immature fraction of reticulocytes;
SARC	cis	rs12586317	0.532	rs2415268	chr14:35638753	C/T	cg16230307	chr14:35515116	FAM177A1	0.46	5.84	0.36	1.78e-8	Psoriasis;
SARC	cis	rs748404	0.697	rs564946	chr15:43556272	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.53	6.37	0.39	9.92e-10	Lung cancer;
SARC	cis	rs1355223	0.902	rs836466	chr11:34737366	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.34	-0.33	2.21e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs10911232	0.507	rs4652764	chr1:182994115	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.55	0.57	1.55e-21	Hypertriglyceridemia;
SARC	cis	rs7044106	0.762	rs1411158	chr9:123464804	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	5.44	0.34	1.32e-7	Hip circumference adjusted for BMI;
SARC	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg11366901	chr6:160182831	ACAT2	0.99	10.05	0.55	5.66e-20	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs950776	0.518	rs12903129	chr15:78819606	C/T	cg06917634	chr15:78832804	PSMA4	0.89	13.45	0.66	6.44e-31	Sudden cardiac arrest;
SARC	cis	rs12681366	0.537	rs2197004	chr8:95456976	A/G	cg13257157	chr8:95487014	RAD54B	0.4	4.81	0.3	2.76e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-6.47	-0.39	5.84e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9905704	0.671	rs4337355	chr17:56950920	C/T	cg12560992	chr17:57184187	TRIM37	0.42	5.16	0.32	5.26e-7	Testicular germ cell tumor;
SARC	cis	rs11098499	0.908	rs28499576	chr4:120386677	G/A	cg09307838	chr4:120376055	NA	0.92	13.06	0.65	1.3e-29	Corneal astigmatism;
SARC	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg11965913	chr1:205819406	PM20D1	-0.45	-5.15	-0.32	5.48e-7	Parkinson's disease;
SARC	cis	rs796364	0.813	rs4672686	chr2:201065044	A/G	cg23649088	chr2:200775458	C2orf69	0.66	7.18	0.43	9.21e-12	Schizophrenia;
SARC	cis	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg14541582	chr5:601475	NA	-0.41	-5.15	-0.32	5.42e-7	Obesity-related traits;
SARC	cis	rs6088590	0.930	rs6087618	chr20:33288407	C/T	cg06115741	chr20:33292138	TP53INP2	0.53	6.45	0.39	6.26e-10	Coronary artery disease;
SARC	cis	rs9457247	0.967	rs443570	chr6:167389925	G/A	cg23791538	chr6:167370224	RNASET2	-0.62	-8.66	-0.49	8.17e-16	Crohn's disease;
SARC	cis	rs796364	0.951	rs769952	chr2:200734368	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.53	0.39	4.05e-10	Schizophrenia;
SARC	cis	rs2180341	0.814	rs9321085	chr6:127735361	T/C	cg27446573	chr6:127587934	RNF146	0.79	10.27	0.56	1.21e-20	Breast cancer;
SARC	cis	rs5750830	0.620	rs1007337	chr22:39781585	C/T	cg05872129	chr22:39784769	NA	-0.44	-6.19	-0.38	2.67e-9	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg11764359	chr7:65958608	NA	0.73	8.72	0.5	5.25e-16	Aortic root size;
SARC	cis	rs4927850	0.521	rs4927679	chr3:195658360	C/T	cg01181863	chr3:195395398	SDHAP2	0.66	9.04	0.51	6.25e-17	Pancreatic cancer;
SARC	cis	rs6834538	0.965	rs4834294	chr4:113529020	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.47	5.6	0.34	6.16e-8	Free thyroxine concentration;
SARC	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg02461776	chr11:598696	PHRF1	0.48	5.28	0.33	2.89e-7	Systemic lupus erythematosus;
SARC	cis	rs7310409	0.544	rs1169292	chr12:121426478	C/T	cg02403541	chr12:121454288	C12orf43	0.78	10.79	0.58	2.76e-22	Liver enzyme levels (gamma-glutamyl transferase);C-reactive protein;Pancreatic cancer;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg25099438	chr2:207024027	EEF1B2;NDUFS1	0.6	6.29	0.38	1.53e-9	Lung cancer in ever smokers;
SARC	cis	rs7216064	1.000	rs12451511	chr17:65874861	T/G	cg12091567	chr17:66097778	LOC651250	-0.64	-6.45	-0.39	6.56e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs7772486	0.790	rs4896852	chr6:146284621	T/C	cg23711669	chr6:146136114	FBXO30	-0.84	-13.42	-0.66	8.23e-31	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs28669119	0.778	rs244752	chr5:88144669	T/C	cg18498987	chr5:88179539	MEF2C	0.54	5.09	0.32	7.35e-7	Schizophrenia;
SARC	cis	rs2070488	0.965	rs3749386	chr3:38496065	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	14.64	0.69	7.7e-35	Electrocardiographic conduction measures;
SARC	cis	rs6582630	0.533	rs11504406	chr12:38334580	C/T	cg14851346	chr12:38532713	NA	-0.47	-5.49	-0.34	1.04e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7615952	0.512	rs11921452	chr3:125359750	A/G	cg21696256	chr3:125484277	NA	-0.35	-5.05	-0.31	8.97e-7	Blood pressure (smoking interaction);
SARC	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg11843238	chr5:131593191	PDLIM4	0.39	4.79	0.3	3.02e-6	Breast cancer;
SARC	cis	rs9486715	0.867	rs9486181	chr6:96868132	G/A	cg18709589	chr6:96969512	KIAA0776	0.58	7.27	0.43	5.5e-12	Headache;
SARC	cis	rs2070997	0.818	rs10901282	chr9:133662303	A/T	cg11464064	chr9:133710261	ABL1	0.71	5.13	0.32	6.03e-7	Response to amphetamines;
SARC	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg05313129	chr8:58192883	C8orf71	-0.57	-6.29	-0.38	1.58e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg12016809	chr21:47604291	C21orf56	0.46	5.48	0.34	1.11e-7	Testicular germ cell tumor;
SARC	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg12373951	chr3:133503437	NA	-0.33	-4.94	-0.31	1.47e-6	Iron status biomarkers;
SARC	trans	rs7016717	1.000	rs79105160	chr8:78285648	T/A	cg09446250	chr11:82430349	NA	0.95	6.34	0.38	1.19e-9	Resistance to antihypertensive treatment in hypertension;
SARC	cis	rs9807989	0.839	rs3755276	chr2:102978459	C/T	cg09003973	chr2:102972529	NA	0.41	5.64	0.35	4.86e-8	Asthma;
SARC	cis	rs8067545	1.000	rs2108980	chr17:19920518	G/A	cg13482628	chr17:19912719	NA	0.7	10.0	0.55	7.86e-20	Schizophrenia;
SARC	cis	rs7481584	0.564	rs7948848	chr11:2981896	G/A	cg08508325	chr11:3079039	CARS	0.22	5.28	0.33	2.89e-7	Calcium levels;
SARC	cis	rs2228479	0.702	rs17177891	chr16:89799950	C/T	cg00800038	chr16:89945340	TCF25	-0.71	-4.77	-0.3	3.19e-6	Skin colour saturation;
SARC	cis	rs2933343	0.700	rs2630257	chr3:128644015	T/C	cg24203234	chr3:128598194	ACAD9	0.64	8.2	0.47	1.61e-14	IgG glycosylation;
SARC	cis	rs6540556	0.723	rs9430012	chr1:209900615	G/C	cg23920097	chr1:209922102	NA	-0.49	-4.91	-0.31	1.68e-6	Red blood cell count;
SARC	cis	rs3768617	0.528	rs6686682	chr1:183080539	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.8e-21	Fuchs's corneal dystrophy;
SARC	cis	rs9640161	0.783	rs1132261	chr7:150059987	G/A	cg17279839	chr7:150038598	RARRES2	0.34	4.9	0.31	1.79e-6	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs9916302	0.706	rs594794	chr17:37453485	T/C	cg07936489	chr17:37558343	FBXL20	0.75	8.92	0.5	1.37e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs6540556	0.769	rs6679405	chr1:209926468	A/C	cg23920097	chr1:209922102	NA	-0.57	-6.66	-0.4	2e-10	Red blood cell count;
SARC	cis	rs72627509	0.767	rs6853156	chr4:57774843	C/T	cg26694713	chr4:57773883	REST	0.64	6.46	0.39	6.04e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs2439831	0.702	rs8033995	chr15:44013509	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	7.58	0.44	8.35e-13	Lung cancer in ever smokers;
SARC	trans	rs1865760	0.929	rs9461224	chr6:25936402	G/T	cg18751306	chr15:81294292	MESDC1	-0.51	-6.25	-0.38	1.89e-9	Height;
SARC	cis	rs9513593	1.000	rs9585019	chr13:99850487	T/C	cg21788972	chr13:99853209	UBAC2	0.51	4.99	0.31	1.2e-6	Psoriasis;
SARC	cis	rs35213789	0.762	rs2851484	chr7:69134923	C/T	cg10619644	chr7:69149951	AUTS2	-0.36	-4.95	-0.31	1.44e-6	Childhood ear infection;
SARC	cis	rs2016266	0.806	rs11170494	chr12:53665164	C/A	cg06632207	chr12:54070931	ATP5G2	0.42	4.92	0.31	1.62e-6	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs763121	0.853	rs5750630	chr22:38985818	A/C	cg21395723	chr22:39101663	GTPBP1	0.59	6.87	0.41	5.95e-11	Menopause (age at onset);
SARC	cis	rs3126085	0.877	rs2338431	chr1:152169305	A/G	cg03465714	chr1:152285911	FLG	-0.47	-5.65	-0.35	4.71e-8	Atopic dermatitis;
SARC	cis	rs910316	0.737	rs2098251	chr14:75492696	G/A	cg06637938	chr14:75390232	RPS6KL1	0.53	7.17	0.43	9.85e-12	Height;
SARC	cis	rs6121246	0.909	rs6119725	chr20:30385557	G/T	cg13852791	chr20:30311386	BCL2L1	0.86	9.09	0.51	4.55e-17	Mean corpuscular hemoglobin;
SARC	cis	rs11097912	0.603	rs12645743	chr4:107188431	G/A	cg09646026	chr4:107269030	AIMP1	-0.44	-4.74	-0.3	3.68e-6	Airflow obstruction;
SARC	cis	rs926392	0.640	rs2867899	chr20:37694622	C/A	cg16355469	chr20:37678765	NA	0.73	9.82	0.54	2.78e-19	Dialysis-related mortality;
SARC	cis	rs910316	0.664	rs2098252	chr14:75492732	T/C	cg06637938	chr14:75390232	RPS6KL1	0.53	7.17	0.43	9.85e-12	Height;
SARC	cis	rs1865760	0.865	rs10946800	chr6:25957773	C/T	cg10373733	chr6:25993375	NA	0.4	4.81	0.3	2.74e-6	Height;
SARC	cis	rs8044868	1.000	rs11075922	chr16:72157718	C/T	cg16558253	chr16:72132732	DHX38	-0.39	-5.59	-0.34	6.37e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
SARC	cis	rs7084402	0.967	rs1658434	chr10:60328756	G/C	cg07615347	chr10:60278583	BICC1	0.57	8.5	0.49	2.24e-15	Refractive error;
SARC	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg22535103	chr8:58192502	C8orf71	0.75	7.34	0.43	3.55e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg13175981	chr1:150552382	MCL1	-0.5	-6.06	-0.37	5.3e-9	Melanoma;
SARC	cis	rs748404	0.631	rs2467745	chr15:43722742	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	5.75	0.35	2.76e-8	Lung cancer;
SARC	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.12	24.57	0.85	1.28e-66	Chronic sinus infection;
SARC	cis	rs3099143	0.901	rs76101229	chr15:77134975	C/T	cg21673338	chr15:77095150	SCAPER	-0.75	-5.76	-0.35	2.64e-8	Recalcitrant atopic dermatitis;
SARC	cis	rs6546550	0.935	rs2168115	chr2:70034793	A/G	cg02498382	chr2:70120550	SNRNP27	-0.37	-6.0	-0.37	7.37e-9	Prevalent atrial fibrillation;
SARC	cis	rs3809566	1.000	rs3809566	chr15:63333724	A/G	cg05507819	chr15:63340323	TPM1	0.57	6.38	0.39	9.4e-10	Platelet count;
SARC	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg20887711	chr4:1340912	KIAA1530	0.54	6.68	0.4	1.75e-10	Longevity;
SARC	cis	rs9807989	0.507	rs6710528	chr2:103016142	A/G	cg03938978	chr2:103052716	IL18RAP	-0.32	-5.25	-0.33	3.36e-7	Asthma;
SARC	cis	rs910316	0.789	rs175444	chr14:75601782	G/C	cg11812906	chr14:75593930	NEK9	-0.74	-10.35	-0.56	6.66e-21	Height;
SARC	cis	rs9715521	0.868	rs6848053	chr4:59839309	T/C	cg11281224	chr4:60001000	NA	-0.43	-5.46	-0.34	1.23e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs2204008	0.837	rs11612125	chr12:38213212	C/T	cg13010199	chr12:38710504	ALG10B	0.78	10.64	0.57	8.61e-22	Bladder cancer;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg16362014	chr5:118321556	DTWD2	0.49	6.54	0.39	3.89e-10	Thyroid stimulating hormone;
SARC	cis	rs7412746	0.586	rs2864882	chr1:150883037	C/T	cg10589385	chr1:150898437	SETDB1	0.4	5.38	0.33	1.8e-7	Melanoma;
SARC	cis	rs34779708	0.931	rs4934710	chr10:35350416	T/C	cg03585969	chr10:35415529	CREM	0.38	4.85	0.3	2.27e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs6545883	0.929	rs2252662	chr2:61670731	T/C	cg15711740	chr2:61764176	XPO1	-0.42	-5.03	-0.31	9.64e-7	Tuberculosis;
SARC	cis	rs4481887	0.741	rs28468416	chr1:248564451	G/T	cg00666640	chr1:248458726	OR2T12	0.31	5.52	0.34	8.85e-8	Common traits (Other);
SARC	cis	rs11874712	0.965	rs12954944	chr18:43664115	T/C	cg25174615	chr18:43684699	ATP5A1;HAUS1	0.4	4.75	0.3	3.52e-6	Migraine - clinic-based;
SARC	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg17971929	chr21:40555470	PSMG1	0.98	13.62	0.67	1.77e-31	Cognitive function;
SARC	cis	rs950169	0.840	rs72748702	chr15:84915246	A/G	cg24253500	chr15:84953950	NA	0.38	5.34	0.33	2.21e-7	Schizophrenia;
SARC	trans	rs1814175	0.645	rs2140602	chr11:50022800	G/C	cg15704280	chr7:45808275	SEPT13	-0.9	-14.33	-0.68	7.84e-34	Height;
SARC	cis	rs2153535	0.580	rs6900007	chr6:8474035	C/T	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs911186	0.730	rs2393911	chr6:27057079	C/T	cg12826209	chr6:26865740	GUSBL1	0.62	5.99	0.37	8.02e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg11764359	chr7:65958608	NA	0.87	12.57	0.64	5.29e-28	Aortic root size;
SARC	cis	rs10411936	0.712	rs8103521	chr19:16589750	A/G	cg10248733	chr19:16607483	C19orf44;CALR3	0.63	7.65	0.45	5.22e-13	White blood cell count;Multiple sclerosis;
SARC	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg07701084	chr6:150067640	NUP43	0.37	4.91	0.31	1.69e-6	Lung cancer;
SARC	cis	rs11214589	0.774	rs877137	chr11:113256330	C/T	cg14159747	chr11:113255604	NA	0.36	5.21	0.32	4.16e-7	Neuroticism;
SARC	cis	rs2730245	0.645	rs4909282	chr7:158699797	T/C	cg17136484	chr7:158649327	WDR60	0.47	5.48	0.34	1.08e-7	Height;
SARC	cis	rs7726839	0.794	rs10474792	chr5:600058	G/A	cg16447950	chr5:562315	NA	-0.45	-5.13	-0.32	6.2e-7	Obesity-related traits;
SARC	cis	rs1865760	0.865	rs4478388	chr6:25953633	A/G	cg16482183	chr6:26056742	HIST1H1C	0.51	6.55	0.39	3.64e-10	Height;
SARC	cis	rs6840360	0.509	rs62327273	chr4:152547594	A/G	cg22705602	chr4:152727874	NA	-0.43	-6.74	-0.4	1.22e-10	Intelligence (multi-trait analysis);
SARC	cis	rs709400	0.627	rs55859054	chr14:103953666	T/A	cg12935359	chr14:103987150	CKB	-0.37	-5.31	-0.33	2.57e-7	Body mass index;
SARC	cis	rs6582630	0.638	rs11182428	chr12:38526387	T/C	cg04568710	chr12:38710424	ALG10B	-0.42	-5.05	-0.31	8.84e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs10461617	0.541	rs7715822	chr5:56043600	G/T	cg24531977	chr5:56204891	C5orf35	-0.52	-4.76	-0.3	3.34e-6	Type 2 diabetes;
SARC	cis	rs6963495	0.818	rs73192144	chr7:105203535	C/T	cg19920283	chr7:105172520	RINT1	0.69	6.04	0.37	6.07e-9	Bipolar disorder (body mass index interaction);
SARC	cis	rs35160687	0.901	rs12714180	chr2:86525323	G/T	cg10973622	chr2:86423274	IMMT	0.38	4.89	0.31	1.87e-6	Night sleep phenotypes;
SARC	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg04518342	chr5:131593106	PDLIM4	0.43	5.52	0.34	9.21e-8	Breast cancer;
SARC	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg26839252	chr6:160211577	TCP1;MRPL18	0.6	5.67	0.35	4.16e-8	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs62344088	0.590	rs7700533	chr5:180646	C/T	cg22496380	chr5:211416	CCDC127	-0.77	-5.5	-0.34	9.86e-8	Asthma (childhood onset);
SARC	cis	rs9316337	0.582	rs7329073	chr13:22017890	C/T	cg21080246	chr13:22033151	ZDHHC20	0.43	5.03	0.31	9.71e-7	Schizophrenia;
SARC	cis	rs854765	0.663	rs16960744	chr17:17755259	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.39	-5.13	-0.32	6.04e-7	Total body bone mineral density;
SARC	cis	rs7512552	0.839	rs11205357	chr1:150267798	T/C	cg15654264	chr1:150340011	RPRD2	-0.37	-4.81	-0.3	2.7e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg23172400	chr8:95962367	TP53INP1	-0.32	-5.57	-0.34	6.97e-8	Type 2 diabetes;
SARC	trans	rs2727020	0.595	rs11040328	chr11:49339055	T/C	cg15704280	chr7:45808275	SEPT13	-0.66	-9.63	-0.53	1.06e-18	Coronary artery disease;
SARC	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg10207240	chr12:122356781	WDR66	0.29	4.95	0.31	1.43e-6	Mean corpuscular volume;
SARC	trans	rs11098499	0.954	rs11734241	chr4:120416872	A/G	cg25214090	chr10:38739885	LOC399744	0.58	7.47	0.44	1.63e-12	Corneal astigmatism;
SARC	cis	rs965469	1.000	rs6051708	chr20:3262493	A/G	cg25506879	chr20:3388711	C20orf194	-0.5	-5.09	-0.32	7.3e-7	IFN-related cytopenia;
SARC	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.42	-5.43	-0.34	1.43e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6141769	0.542	rs6119939	chr20:31315153	T/C	cg13636640	chr20:31349939	DNMT3B	-0.45	-4.78	-0.3	3.08e-6	Subjective well-being;
SARC	cis	rs8114671	0.562	rs6087643	chr20:33474462	C/T	cg24642439	chr20:33292090	TP53INP2	0.51	6.18	0.38	2.9e-9	Height;
SARC	cis	rs2421770	0.530	rs6484784	chr11:35368347	A/C	cg13971030	chr11:35366721	SLC1A2	0.35	5.23	0.32	3.73e-7	Staphylococcus aureus nasal carriage (persistent);
SARC	cis	rs12701220	0.817	rs7798459	chr7:1087965	C/T	cg26769984	chr7:1090371	C7orf50	0.47	5.46	0.34	1.21e-7	Bronchopulmonary dysplasia;
SARC	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg12000995	chr2:27665139	KRTCAP3	0.33	5.14	0.32	5.68e-7	Total body bone mineral density;
SARC	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9354308	0.933	rs12203567	chr6:66589062	T/C	cg07460842	chr6:66804631	NA	0.49	5.59	0.34	6.34e-8	Metabolite levels;
SARC	cis	rs11674184	0.659	rs59129126	chr2:11728388	T/C	cg07314298	chr2:11723111	GREB1	-0.5	-6.42	-0.39	7.66e-10	Endometriosis;
SARC	cis	rs78545713	0.649	rs74928264	chr6:26224343	C/G	cg00631329	chr6:26305371	NA	-0.71	-5.14	-0.32	5.85e-7	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs559928	0.606	rs55970968	chr11:63961433	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	5.09	0.32	7.3e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs2797160	0.651	rs6939969	chr6:126034563	C/T	cg06289844	chr6:126071538	HEY2	-0.32	-4.89	-0.3	1.9e-6	Endometrial cancer;
SARC	cis	rs11997175	0.583	rs7009719	chr8:33834824	C/G	ch.8.33884649F	chr8:33765107	NA	0.5	6.37	0.39	9.72e-10	Body mass index;
SARC	cis	rs9660992	0.762	rs1172130	chr1:205244953	G/A	cg07972983	chr1:205091412	RBBP5	0.54	6.61	0.4	2.64e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs2075371	0.863	rs1646635	chr7:134006728	T/C	cg20476274	chr7:133979776	SLC35B4	0.56	7.6	0.45	7.32e-13	Mean platelet volume;
SARC	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.03	-0.37	6.4e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1044826	0.642	rs167187	chr3:139237008	C/T	cg15131784	chr3:139108705	COPB2	-0.39	-4.97	-0.31	1.31e-6	Obesity-related traits;
SARC	cis	rs6582630	0.516	rs8186746	chr12:38347638	G/T	cg26384229	chr12:38710491	ALG10B	-0.58	-7.12	-0.42	1.32e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9309473	1.000	rs10169714	chr2:73808773	T/G	cg20560298	chr2:73613845	ALMS1	-0.48	-5.92	-0.36	1.17e-8	Metabolite levels;
SARC	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg08219700	chr8:58056026	NA	0.61	6.36	0.38	1.05e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs546131	0.571	rs4593984	chr11:34856934	G/A	cg06937548	chr11:34938143	PDHX;APIP	-0.44	-4.73	-0.3	3.81e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs477895	1.000	rs7938380	chr11:64034866	G/A	cg04317338	chr11:64019027	PLCB3	0.7	6.26	0.38	1.79e-9	Mean platelet volume;
SARC	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg11644478	chr21:40555479	PSMG1	-0.59	-7.27	-0.43	5.48e-12	Menarche (age at onset);
SARC	cis	rs2834188	0.924	rs2409487	chr21:34684958	C/T	cg15382669	chr21:34697036	IFNAR1	0.42	4.81	0.3	2.77e-6	Narcolepsy;
SARC	cis	rs1865760	0.516	rs9393684	chr6:26075531	G/C	cg16482183	chr6:26056742	HIST1H1C	0.45	5.69	0.35	3.8e-8	Height;
SARC	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg22974920	chr21:40686053	BRWD1	0.44	4.73	0.3	3.82e-6	Cognitive function;
SARC	cis	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg08975724	chr8:8085496	FLJ10661	0.48	6.25	0.38	1.97e-9	Mood instability;
SARC	trans	rs56279505	0.629	rs34178057	chr4:100268602	A/C	cg18024358	chr1:3420815	MEGF6	-0.83	-6.4	-0.39	8.29e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg07636037	chr3:49044803	WDR6	0.62	8.07	0.47	3.68e-14	Resting heart rate;
SARC	cis	rs3845702	0.736	rs6727890	chr2:180832675	T/C	cg01881094	chr2:180872142	CWC22	-1.12	-9.33	-0.52	8.56e-18	Schizophrenia;
SARC	trans	rs61931739	0.892	rs73309466	chr12:34093146	A/G	cg26384229	chr12:38710491	ALG10B	-0.54	-6.71	-0.4	1.48e-10	Morning vs. evening chronotype;
SARC	cis	rs3733585	0.631	rs4697925	chr4:10124330	G/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-6.85	-0.41	6.38e-11	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs6500395	1.000	rs8059905	chr16:48629934	C/T	cg04672837	chr16:48644449	N4BP1	0.51	7.1	0.42	1.48e-11	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs7250849	0.565	rs7255319	chr19:52167906	C/G	cg03965138	chr19:52134393	SIGLEC5	-0.36	-4.74	-0.3	3.71e-6	Blood protein levels;
SARC	cis	rs5753618	0.561	rs737887	chr22:31696615	A/G	cg13145458	chr22:31556086	RNF185	0.47	5.03	0.31	9.68e-7	Colorectal cancer;
SARC	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg17554472	chr22:41940697	POLR3H	-0.48	-5.44	-0.34	1.32e-7	Vitiligo;
SARC	cis	rs992157	0.796	rs55680399	chr2:219160621	T/C	cg00012203	chr2:219082015	ARPC2	0.66	9.48	0.53	2.97e-18	Colorectal cancer;
SARC	cis	rs10267417	0.514	rs2072184	chr7:19748883	A/G	cg07541023	chr7:19748670	TWISTNB	0.95	10.18	0.55	2.33e-20	Night sleep phenotypes;
SARC	cis	rs8180040	0.932	rs11711265	chr3:47558448	T/C	cg27129171	chr3:47204927	SETD2	0.67	9.09	0.51	4.56e-17	Colorectal cancer;
SARC	cis	rs698833	0.926	rs786620	chr2:44595803	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.67	8.28	0.48	9.77e-15	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg27286337	chr10:134555280	INPP5A	0.71	8.17	0.47	2.02e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg11764359	chr7:65958608	NA	-0.59	-7.02	-0.42	2.38e-11	Calcium levels;
SARC	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg25072359	chr17:41440525	NA	0.52	6.17	0.37	3.06e-9	Menopause (age at onset);
SARC	cis	rs9443189	1.000	rs6905047	chr6:76498109	C/T	cg01950844	chr6:76311363	SENP6	0.77	6.51	0.39	4.45e-10	Prostate cancer;
SARC	cis	rs3741404	0.609	rs641430	chr11:63869531	C/T	cg18225595	chr11:63971243	STIP1	-0.4	-5.81	-0.36	2.06e-8	Platelet count;
SARC	cis	rs526231	0.543	rs34783	chr5:102457041	C/A	cg23492399	chr5:102201601	PAM	-0.52	-5.62	-0.35	5.5e-8	Primary biliary cholangitis;
SARC	cis	rs9868809	0.505	rs11706203	chr3:48746239	T/A	cg00383909	chr3:49044727	WDR6	0.65	6.12	0.37	3.88e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs13401104	0.732	rs11692797	chr2:237110032	C/A	cg19324714	chr2:237145437	ASB18	0.57	5.6	0.34	5.92e-8	Educational attainment;
SARC	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg11987759	chr7:65425863	GUSB	-0.47	-6.27	-0.38	1.7e-9	Aortic root size;
SARC	cis	rs748404	0.697	rs554001	chr15:43551919	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	6.69	0.4	1.61e-10	Lung cancer;
SARC	cis	rs3741151	0.773	rs7950375	chr11:73281345	G/A	cg17517138	chr11:73019481	ARHGEF17	0.91	6.79	0.41	9.4e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	12.47	0.63	1.09e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.99	11.43	0.6	2.69e-24	Platelet count;
SARC	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg25072359	chr17:41440525	NA	0.48	5.62	0.35	5.43e-8	Menopause (age at onset);
SARC	cis	rs963731	0.649	rs6752850	chr2:39220655	C/T	cg04010122	chr2:39346883	SOS1	-1.06	-6.29	-0.38	1.58e-9	Corticobasal degeneration;
SARC	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg02891314	chr5:179741120	GFPT2	-0.51	-6.21	-0.38	2.35e-9	Height;
SARC	cis	rs2011503	1.000	rs76095338	chr19:19633908	G/A	cg15839431	chr19:19639596	YJEFN3	-0.48	-4.77	-0.3	3.32e-6	Bipolar disorder;
SARC	trans	rs208520	1.000	rs208535	chr6:66962286	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.82	-8.98	-0.51	9.32e-17	Exhaled nitric oxide output;
SARC	cis	rs9310709	0.517	rs616006	chr3:23037791	T/C	cg00327796	chr3:23032191	NA	-0.37	-5.22	-0.32	4.03e-7	Chronic kidney disease and serum creatinine levels;
SARC	cis	rs6138458	1.000	rs7269416	chr20:24976196	T/G	cg26195577	chr20:24973756	C20orf3	0.91	9.89	0.54	1.77e-19	Blood protein levels;
SARC	cis	rs6546550	0.901	rs13015457	chr2:70125763	G/T	cg02498382	chr2:70120550	SNRNP27	-0.32	-5.13	-0.32	6.02e-7	Prevalent atrial fibrillation;
SARC	cis	rs6831352	0.918	rs35662508	chr4:100050974	C/G	cg12011299	chr4:100065546	ADH4	-0.34	-5.74	-0.35	2.97e-8	Alcohol dependence;
SARC	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.57	5.28	0.33	2.98e-7	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg08645402	chr16:4508243	NA	0.43	4.95	0.31	1.44e-6	Schizophrenia;
SARC	cis	rs7520050	0.966	rs12144263	chr1:46352446	G/A	cg24296786	chr1:45957014	TESK2	0.39	4.89	0.31	1.88e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs920590	0.879	rs67391684	chr8:19654642	A/T	cg03894339	chr8:19674705	INTS10	0.54	6.68	0.4	1.76e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9436747	0.740	rs4655598	chr1:65932185	T/A	cg14976592	chr1:65886160	LEPROT;LEPR	-0.41	-4.98	-0.31	1.22e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg25427524	chr10:38739819	LOC399744	-0.55	-8.75	-0.5	4.44e-16	Extrinsic epigenetic age acceleration;
SARC	cis	rs735396	1.000	rs1169313	chr12:121442670	C/T	cg15155738	chr12:121454335	C12orf43	-0.49	-6.07	-0.37	5.03e-9	N-glycan levels;
SARC	cis	rs28386778	0.700	rs4968672	chr17:62011352	G/A	cg11494091	chr17:61959527	GH2	-0.45	-6.36	-0.38	1.05e-9	Prudent dietary pattern;
SARC	cis	rs453301	0.686	rs11787026	chr8:8902371	A/T	cg06636001	chr8:8085503	FLJ10661	0.62	8.52	0.49	2.03e-15	Joint mobility (Beighton score);
SARC	cis	rs2342371	0.805	rs55997345	chr3:196218353	T/C	cg15048948	chr3:196158458	UBXN7	0.55	6.81	0.41	8.25e-11	Fat distribution (HIV);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg25602930	chr2:9533887	ASAP2	0.45	6.32	0.38	1.35e-9	Thyroid stimulating hormone;
SARC	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	7.2	0.43	8.13e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1729951	0.575	rs16844326	chr3:136678385	G/C	cg15507776	chr3:136538369	TMEM22	0.52	5.76	0.35	2.66e-8	Neuroticism;
SARC	cis	rs11651000	0.947	rs59216876	chr17:45832965	G/A	cg24803719	chr17:45855879	NA	-0.42	-5.31	-0.33	2.55e-7	IgG glycosylation;
SARC	cis	rs17401966	1.000	rs1339458	chr1:10328338	C/T	cg15208524	chr1:10270712	KIF1B	0.58	6.71	0.4	1.47e-10	Hepatocellular carcinoma;
SARC	cis	rs7246657	0.943	rs10405064	chr19:37861861	C/T	cg23950597	chr19:37808831	NA	-0.6	-5.85	-0.36	1.67e-8	Coronary artery calcification;
SARC	cis	rs1865760	0.566	rs2032445	chr6:26044812	T/A	cg16482183	chr6:26056742	HIST1H1C	0.49	6.31	0.38	1.41e-9	Height;
SARC	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg21724239	chr8:58056113	NA	0.54	5.72	0.35	3.29e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10463554	0.892	rs3776874	chr5:102282317	C/T	cg23492399	chr5:102201601	PAM	-0.44	-5.3	-0.33	2.7e-7	Parkinson's disease;
SARC	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg20573242	chr4:122745356	CCNA2	0.68	8.67	0.49	7.41e-16	Type 2 diabetes;
SARC	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg06028605	chr16:24865363	SLC5A11	0.37	5.34	0.33	2.19e-7	Intelligence (multi-trait analysis);
SARC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg09373136	chr17:61933544	TCAM1	-0.45	-6.12	-0.37	3.83e-9	Prudent dietary pattern;
SARC	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg02951883	chr7:2050386	MAD1L1	-0.47	-6.21	-0.38	2.35e-9	Schizophrenia;
SARC	cis	rs9815354	1.000	rs2272007	chr3:41996136	A/G	cg03022575	chr3:42003672	ULK4	-0.57	-5.58	-0.34	6.81e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs1801251	1.000	rs35212961	chr2:233582762	C/T	cg25237894	chr2:233734115	C2orf82	0.37	4.79	0.3	2.98e-6	Coronary artery disease;
SARC	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg20203395	chr5:56204925	C5orf35	0.57	5.0	0.31	1.13e-6	Initial pursuit acceleration;
SARC	cis	rs7727544	0.684	rs274546	chr5:131699867	A/G	cg07395648	chr5:131743802	NA	-0.43	-5.07	-0.31	8.3e-7	Blood metabolite levels;
SARC	cis	rs9457247	0.602	rs2239827	chr6:167490945	G/A	cg07741184	chr6:167504864	NA	0.39	7.5	0.44	1.36e-12	Crohn's disease;
SARC	cis	rs7667	0.959	rs58441212	chr1:19725615	G/A	cg15311933	chr1:19638897	PQLC2;AKR7A2	-0.46	-5.45	-0.34	1.28e-7	Crohn's disease and psoriasis;
SARC	cis	rs2120019	0.938	rs8033925	chr15:75311959	A/G	cg00629941	chr15:75287862	SCAMP5	-0.7	-8.35	-0.48	6.18e-15	Blood trace element (Zn levels);
SARC	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg18876405	chr7:65276391	NA	0.46	5.11	0.32	6.58e-7	Aortic root size;
SARC	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg00339695	chr16:24857497	SLC5A11	0.41	5.58	0.34	6.68e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg07701084	chr6:150067640	NUP43	0.4	5.26	0.33	3.31e-7	Lung cancer;
SARC	cis	rs3096299	0.606	rs8052103	chr16:89541243	A/T	cg02187348	chr16:89574699	SPG7	-0.58	-6.94	-0.41	3.78e-11	Multiple myeloma (IgH translocation);
SARC	cis	rs10791097	0.739	rs4936120	chr11:130723452	G/A	cg12179176	chr11:130786555	SNX19	0.63	8.76	0.5	4.2e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs7607369	0.714	rs55900247	chr2:219618708	T/C	cg02176678	chr2:219576539	TTLL4	-0.48	-7.55	-0.44	1.01e-12	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs4742903	1.000	rs3739736	chr9:106857908	G/A	cg14250997	chr9:106856677	SMC2	0.52	6.86	0.41	6.13e-11	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg20607798	chr8:58055168	NA	0.59	5.21	0.32	4.2e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7666738	0.927	rs4699328	chr4:99055890	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.8	0.5	3.12e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2439831	1.000	rs537115	chr15:43729948	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	8.19	0.47	1.77e-14	Lung cancer in ever smokers;
SARC	cis	rs1536827	0.841	rs10857737	chr10:135336716	T/A	cg22671611	chr10:135291010	NA	-0.45	-4.74	-0.3	3.69e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs4555082	0.874	rs28625632	chr14:105748849	G/T	cg13114125	chr14:105738426	BRF1	-0.79	-11.51	-0.6	1.41e-24	Mean platelet volume;Platelet distribution width;
SARC	cis	rs2221894	0.506	rs77628389	chr8:28845548	T/C	cg07962641	chr8:28805897	HMBOX1	-0.78	-7.69	-0.45	4.02e-13	Obesity-related traits;
SARC	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg11890956	chr21:40555474	PSMG1	-1.06	-15.95	-0.72	3.38e-39	Cognitive function;
SARC	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg04267008	chr7:1944627	MAD1L1	-0.51	-5.8	-0.36	2.12e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs4555082	0.834	rs2735825	chr14:105710900	G/A	cg06808227	chr14:105710500	BRF1	-0.51	-6.51	-0.39	4.46e-10	Mean platelet volume;Platelet distribution width;
SARC	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg11644478	chr21:40555479	PSMG1	1.05	14.79	0.7	2.43e-35	Cognitive function;
SARC	cis	rs9341808	0.754	rs9352808	chr6:80997342	G/T	cg08355045	chr6:80787529	NA	0.36	5.65	0.35	4.54e-8	Sitting height ratio;
SARC	cis	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg05623727	chr3:50126028	RBM5	-0.34	-5.19	-0.32	4.52e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9790314	0.586	rs16832246	chr3:161109916	A/G	cg03342759	chr3:160939853	NMD3	0.56	6.8	0.41	8.53e-11	Morning vs. evening chronotype;
SARC	cis	rs3092073	0.624	rs34293711	chr20:44587186	C/T	cg17986701	chr20:44574422	PCIF1	0.34	4.79	0.3	3e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7412746	0.611	rs10888394	chr1:150749913	C/T	cg10589385	chr1:150898437	SETDB1	0.4	5.31	0.33	2.53e-7	Melanoma;
SARC	cis	rs9329289	0.888	rs11251273	chr10:2540300	G/C	cg15501526	chr10:2543763	NA	0.53	8.41	0.48	4.1e-15	Age-related hearing impairment;
SARC	cis	rs28374715	0.532	rs11854632	chr15:41682094	A/G	cg18705301	chr15:41695430	NDUFAF1	1.17	19.99	0.79	1.9e-52	Ulcerative colitis;
SARC	cis	rs2073300	0.609	rs6132617	chr20:23420151	G/C	cg12062639	chr20:23401060	NAPB	0.92	6.6	0.4	2.77e-10	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs7667	0.728	rs10458381	chr1:19769243	C/T	cg15311933	chr1:19638897	PQLC2;AKR7A2	-0.42	-4.93	-0.31	1.59e-6	Crohn's disease and psoriasis;
SARC	cis	rs62432291	0.681	rs2932987	chr6:159655673	C/G	cg14500486	chr6:159655392	FNDC1	0.58	6.02	0.37	6.81e-9	Joint mobility (Beighton score);
SARC	cis	rs189798	0.807	rs330912	chr8:8996294	C/T	cg06636001	chr8:8085503	FLJ10661	0.43	4.82	0.3	2.62e-6	Myopia (pathological);
SARC	cis	rs6141769	0.518	rs6058847	chr20:31324135	C/T	cg13636640	chr20:31349939	DNMT3B	-0.44	-4.77	-0.3	3.2e-6	Subjective well-being;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg11215015	chr1:197116161	ASPM	-0.47	-6.7	-0.4	1.56e-10	Thyroid stimulating hormone;
SARC	cis	rs11697848	1.000	rs56366827	chr20:48543851	C/A	cg17849948	chr20:48532315	SPATA2	0.87	5.2	0.32	4.3e-7	Systemic lupus erythematosus;
SARC	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg11764359	chr7:65958608	NA	-0.67	-7.95	-0.46	7.86e-14	Aortic root size;
SARC	cis	rs2153535	0.601	rs9505472	chr6:8538765	T/C	cg07606381	chr6:8435919	SLC35B3	0.77	10.96	0.58	7.97e-23	Motion sickness;
SARC	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg01448562	chr3:133502909	NA	-0.48	-7.29	-0.43	4.66e-12	Iron status biomarkers;
SARC	cis	rs12545109	0.800	rs2670054	chr8:57421616	C/T	cg19413350	chr8:57351067	NA	-0.43	-5.4	-0.33	1.67e-7	Obesity-related traits;
SARC	cis	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg14343924	chr8:8086146	FLJ10661	0.43	5.25	0.33	3.46e-7	Mood instability;
SARC	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg08392591	chr16:89556376	ANKRD11	0.38	5.06	0.31	8.41e-7	Multiple myeloma (IgH translocation);
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg00763094	chr1:171455187	BAT2L2	-0.49	-6.7	-0.4	1.55e-10	Neuroticism;
SARC	cis	rs7666738	0.830	rs1124253	chr4:98949682	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs72781680	0.848	rs72798057	chr2:23976731	T/C	cg08917208	chr2:24149416	ATAD2B	0.77	7.21	0.43	7.98e-12	Lymphocyte counts;
SARC	cis	rs2197308	0.740	rs11182967	chr12:37935140	A/C	cg13010199	chr12:38710504	ALG10B	0.8	11.14	0.59	2.24e-23	Morning vs. evening chronotype;
SARC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.44	0.53	4.08e-18	Prudent dietary pattern;
SARC	cis	rs7615952	0.932	rs7630077	chr3:125649676	T/C	cg05084668	chr3:125655381	ALG1L	-0.69	-6.95	-0.41	3.56e-11	Blood pressure (smoking interaction);
SARC	cis	rs17376456	0.877	rs10055340	chr5:93317644	T/C	cg21475434	chr5:93447410	FAM172A	0.85	7.72	0.45	3.4e-13	Diabetic retinopathy;
SARC	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg11890956	chr21:40555474	PSMG1	1.16	19.69	0.79	1.79e-51	Cognitive function;
SARC	cis	rs9309473	1.000	rs7576245	chr2:73829678	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-5.48	-0.34	1.1e-7	Metabolite levels;
SARC	trans	rs3808502	0.526	rs1042701	chr8:11422045	G/A	cg06636001	chr8:8085503	FLJ10661	-0.66	-9.2	-0.52	2.05e-17	Neuroticism;
SARC	cis	rs6840360	1.000	rs6810860	chr4:152603164	C/T	cg22705602	chr4:152727874	NA	0.39	6.46	0.39	5.89e-10	Intelligence (multi-trait analysis);
SARC	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg13393036	chr8:95962371	TP53INP1	-0.36	-6.18	-0.38	2.83e-9	Type 2 diabetes;
SARC	cis	rs644799	0.544	rs498553	chr11:95534441	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	6.03	0.37	6.31e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg17216904	chr3:57262489	APPL1	0.5	6.3	0.38	1.46e-9	Height;
SARC	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg13206674	chr6:150067644	NUP43	0.46	6.03	0.37	6.45e-9	Lung cancer;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg07751222	chr4:102268245	PPP3CA	-0.49	-6.27	-0.38	1.71e-9	Schizophrenia;
SARC	cis	rs921968	0.643	rs563268	chr2:219372912	T/G	cg02176678	chr2:219576539	TTLL4	0.37	5.52	0.34	8.97e-8	Mean corpuscular hemoglobin concentration;
SARC	cis	rs9399135	0.967	rs4451151	chr6:135310546	C/T	cg24558204	chr6:135376177	HBS1L	0.45	5.95	0.36	9.6e-9	Red blood cell count;
SARC	cis	rs9790314	0.613	rs55956394	chr3:160590693	C/T	cg04691961	chr3:161091175	C3orf57	0.58	7.85	0.46	1.53e-13	Morning vs. evening chronotype;
SARC	cis	rs17376456	0.877	rs7701974	chr5:93311417	C/T	cg21475434	chr5:93447410	FAM172A	0.84	7.56	0.44	9.44e-13	Diabetic retinopathy;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg22506413	chr7:54902079	NA	-0.71	-6.62	-0.4	2.47e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs787274	1.000	rs787278	chr9:115473531	C/A	cg13803584	chr9:115635662	SNX30	0.87	5.32	0.33	2.45e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs941764	0.965	rs941765	chr14:91841358	G/C	cg10511902	chr14:91842949	CCDC88C	0.32	5.26	0.33	3.19e-7	Breast cancer;
SARC	cis	rs4689388	0.890	rs4688989	chr4:6290594	T/C	cg25554036	chr4:6271136	WFS1	0.4	6.51	0.39	4.46e-10	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs12142240	0.698	rs17361812	chr1:46814008	C/T	cg10495392	chr1:46806563	NSUN4	0.65	6.83	0.41	7.25e-11	Menopause (age at onset);
SARC	cis	rs11786130	0.544	rs4733823	chr8:129014697	C/T	cg17583432	chr8:129005567	PVT1	0.29	4.79	0.3	3.03e-6	Eosinophil counts;Sum eosinophil basophil counts;
SARC	cis	rs78487399	0.710	rs78314405	chr2:43604741	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-4.85	-0.3	2.26e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs6815814	0.950	rs5743560	chr4:38806200	G/T	cg02016764	chr4:38805732	TLR1	-0.42	-4.89	-0.31	1.89e-6	Breast cancer;
SARC	cis	rs2645694	0.626	rs2703124	chr4:77820626	G/T	cg03477792	chr4:77819574	ANKRD56	0.5	7.5	0.44	1.35e-12	Emphysema distribution in smoking;
SARC	cis	rs113835537	0.529	rs17147644	chr11:66256660	C/T	cg24851651	chr11:66362959	CCS	0.39	4.87	0.3	2.02e-6	Airway imaging phenotypes;
SARC	cis	rs7666738	0.830	rs1559859	chr4:99024325	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg09455208	chr3:40491958	NA	0.4	6.18	0.38	2.91e-9	Renal cell carcinoma;
SARC	trans	rs503734	0.643	rs2317749	chr3:101121980	C/T	cg21076271	chr14:32546633	ARHGAP5;C14orf128	-0.5	-6.47	-0.39	5.61e-10	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs10140922	0.966	rs10140133	chr14:35819834	C/G	cg26967526	chr14:35346199	BAZ1A	-0.39	-4.79	-0.3	2.96e-6	Hip circumference adjusted for BMI;
SARC	cis	rs9487051	1.000	rs1546723	chr6:109625879	G/A	cg01475377	chr6:109611718	NA	-0.44	-6.12	-0.37	4.02e-9	Reticulocyte fraction of red cells;
SARC	cis	rs4713118	0.513	rs200971	chr6:27858904	C/T	cg17221315	chr6:27791827	HIST1H4J	0.43	4.8	0.3	2.89e-6	Parkinson's disease;
SARC	cis	rs7819412	0.749	rs11991118	chr8:10939273	A/C	cg16664915	chr8:10907788	XKR6	0.35	4.89	0.3	1.9e-6	Triglycerides;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg05202084	chr12:95467612	NR2C1	-0.48	-6.41	-0.39	8.1e-10	Neuroticism;
SARC	cis	rs7727544	0.548	rs4705938	chr5:131694077	A/G	cg24060327	chr5:131705240	SLC22A5	-0.51	-5.93	-0.36	1.1e-8	Blood metabolite levels;
SARC	cis	rs3540	0.553	rs4031431	chr15:90990782	G/T	cg22089800	chr15:90895588	ZNF774	0.67	8.67	0.49	7.25e-16	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs7223966	1.000	rs7222060	chr17:61868279	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.5	-5.18	-0.32	4.77e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	-0.65	-8.6	-0.49	1.17e-15	Menarche (age at onset);
SARC	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-15.26	-0.71	6.64e-37	Chronic sinus infection;
SARC	cis	rs35213789	0.762	rs593063	chr7:69191399	C/G	cg10619644	chr7:69149951	AUTS2	-0.36	-4.93	-0.31	1.59e-6	Childhood ear infection;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg25521047	chr19:37341219	ZNF345	0.5	6.72	0.4	1.41e-10	Chemerin levels;
SARC	cis	rs7833986	0.501	rs2719245	chr8:56894359	G/C	cg26371346	chr8:56986568	SNORD54;RPS20	0.68	6.78	0.41	1e-10	Height;
SARC	cis	rs72945132	0.882	rs7932431	chr11:70166059	A/T	cg05964544	chr11:70165517	PPFIA1	-0.61	-5.87	-0.36	1.5e-8	Coronary artery disease;
SARC	cis	rs13126513	0.519	rs7659550	chr4:100554402	G/T	cg05468953	chr4:100565104	NA	0.34	5.03	0.31	9.66e-7	Metabolite levels (MHPG);
SARC	cis	rs2243123	0.602	rs2133310	chr3:159716352	A/G	cg12780433	chr3:159481918	SCHIP1	-0.43	-5.27	-0.33	3.17e-7	Multiple sclerosis;
SARC	cis	rs1008375	0.835	rs9760627	chr4:17651508	C/T	cg16339924	chr4:17578868	LAP3	0.65	8.67	0.49	7.21e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs763121	0.819	rs3747173	chr22:39069045	A/G	cg14440974	chr22:39074834	NA	-0.33	-4.8	-0.3	2.84e-6	Menopause (age at onset);
SARC	cis	rs35110281	0.607	rs4819212	chr21:44977455	G/A	cg21573476	chr21:45109991	RRP1B	-0.4	-5.78	-0.35	2.44e-8	Mean corpuscular volume;
SARC	cis	rs7223966	1.000	rs8078862	chr17:61854068	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	7.12	0.42	1.35e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs4919694	1.000	rs78214351	chr10:104822688	A/G	cg04362960	chr10:104952993	NT5C2	0.64	5.43	0.34	1.4e-7	Arsenic metabolism;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg19646445	chr1:215740697	KCTD3	-0.82	-7.4	-0.44	2.42e-12	Autism spectrum disorder or schizophrenia;
SARC	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg00339695	chr16:24857497	SLC5A11	0.42	5.92	0.36	1.14e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs2153535	0.601	rs2327054	chr6:8443130	T/C	cg23788917	chr6:8435910	SLC35B3	0.65	8.39	0.48	4.78e-15	Motion sickness;
SARC	cis	rs116979167	0.575	rs818470	chr7:105165350	A/C	cg19920283	chr7:105172520	RINT1	0.58	5.72	0.35	3.31e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs62432291	0.681	rs3003174	chr6:159655326	T/C	cg14500486	chr6:159655392	FNDC1	-0.62	-6.03	-0.37	6.44e-9	Joint mobility (Beighton score);
SARC	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg20891558	chr2:74357851	NA	0.7	9.67	0.54	8.18e-19	Gestational age at birth (maternal effect);
SARC	trans	rs9650657	0.572	rs4841465	chr8:10819854	C/T	cg08975724	chr8:8085496	FLJ10661	-0.55	-7.06	-0.42	1.87e-11	Neuroticism;
SARC	cis	rs4481887	1.000	rs7511706	chr1:248467360	G/A	cg01631408	chr1:248437212	OR2T33	-0.42	-5.3	-0.33	2.68e-7	Common traits (Other);
SARC	cis	rs7223966	1.000	rs11079511	chr17:61858537	C/G	cg00588841	chr17:61851480	DDX42;CCDC47	-0.65	-6.83	-0.41	7.48e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg19223190	chr17:80058835	NA	0.44	6.16	0.37	3.17e-9	Life satisfaction;
SARC	cis	rs3733585	0.699	rs1122142	chr4:9947548	G/C	cg11266682	chr4:10021025	SLC2A9	-0.38	-6.49	-0.39	5.2e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7582180	0.764	rs7425797	chr2:100928337	T/C	cg14675211	chr2:100938903	LONRF2	0.52	7.62	0.45	6.2800000000000005e-13	Intelligence (multi-trait analysis);
SARC	cis	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg22496380	chr5:211416	CCDC127	-0.88	-9.35	-0.52	7.72e-18	Breast cancer;
SARC	cis	rs1550582	1.000	rs4909827	chr8:135517576	C/T	cg17885191	chr8:135476712	NA	0.59	6.09	0.37	4.63e-9	Educational attainment;
SARC	cis	rs1401999	1.000	rs869417	chr3:183689138	T/C	cg01324343	chr3:183735012	ABCC5	0.67	13.43	0.66	7.75e-31	Anterior chamber depth;
SARC	cis	rs9303401	0.659	rs16943176	chr17:56769887	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	11.87	0.61	9.72e-26	Cognitive test performance;
SARC	cis	rs1401999	0.546	rs4148593	chr3:183649870	A/G	cg01324343	chr3:183735012	ABCC5	0.5	9.0	0.51	8.35e-17	Anterior chamber depth;
SARC	cis	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg24110177	chr3:50126178	RBM5	-0.55	-7.31	-0.43	4.36e-12	Intelligence (multi-trait analysis);
SARC	cis	rs992157	0.661	rs17653757	chr2:219109364	G/C	cg20019365	chr2:219134978	PNKD;AAMP	0.67	9.47	0.53	3.28e-18	Colorectal cancer;
SARC	cis	rs11098499	0.697	rs10016448	chr4:120298845	A/G	cg09160332	chr4:120329925	NA	-0.33	-4.77	-0.3	3.27e-6	Corneal astigmatism;
SARC	cis	rs933688	0.941	rs2887007	chr5:90740531	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.96	12.39	0.63	2.01e-27	Smoking behavior;
SARC	trans	rs1994135	0.654	rs11052759	chr12:33724126	G/A	cg13010199	chr12:38710504	ALG10B	0.76	8.92	0.5	1.41e-16	Resting heart rate;
SARC	cis	rs13191362	0.507	rs13197051	chr6:163201728	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.47	5.16	0.32	5.26e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2228479	0.850	rs62056091	chr16:89930414	G/A	cg00800038	chr16:89945340	TCF25	-0.82	-5.81	-0.36	2e-8	Skin colour saturation;
SARC	cis	rs7843479	0.526	rs3816788	chr8:21832494	A/C	cg17168535	chr8:21777572	XPO7	0.85	12.84	0.64	6.98e-29	Mean corpuscular volume;
SARC	cis	rs9916302	0.904	rs600010	chr17:37433517	T/C	cg00129232	chr17:37814104	STARD3	-0.59	-7.37	-0.43	2.9e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs10927875	0.562	rs10803401	chr1:16147377	G/A	cg07117364	chr1:16154769	NA	-0.45	-5.32	-0.33	2.46e-7	Dilated cardiomyopathy;
SARC	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg04317338	chr11:64019027	PLCB3	-0.82	-9.07	-0.51	5.25e-17	Mean platelet volume;
SARC	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg27170947	chr2:26402098	FAM59B	0.38	4.93	0.31	1.59e-6	Gut microbiome composition (summer);
SARC	cis	rs7917772	0.636	rs10786708	chr10:104526245	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	6.19	0.38	2.76e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs2652834	1.000	rs2652834	chr15:63396867	A/G	cg05507819	chr15:63340323	TPM1	0.54	5.36	0.33	2e-7	HDL cholesterol;
SARC	cis	rs17030434	0.784	rs10032475	chr4:154674748	C/T	cg14289246	chr4:154710475	SFRP2	-0.46	-5.4	-0.33	1.66e-7	Electrocardiographic conduction measures;
SARC	cis	rs9790314	0.645	rs6778254	chr3:160892792	T/C	cg03342759	chr3:160939853	NMD3	-0.52	-6.34	-0.38	1.21e-9	Morning vs. evening chronotype;
SARC	cis	rs554111	0.636	rs10916935	chr1:21432112	T/C	cg08890418	chr1:21044141	KIF17	-0.36	-5.11	-0.32	6.62e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs7659604	0.846	rs60340409	chr4:122666355	G/C	cg19671926	chr4:122722719	EXOSC9	-0.51	-6.24	-0.38	2.04e-9	Type 2 diabetes;
SARC	cis	rs2180341	0.782	rs6569490	chr6:127729615	C/T	cg24812749	chr6:127587940	RNF146	0.78	9.92	0.55	1.39e-19	Breast cancer;
SARC	cis	rs734999	0.549	rs6670198	chr1:2520527	T/C	cg18854424	chr1:2615690	NA	0.3	4.76	0.3	3.47e-6	Ulcerative colitis;
SARC	cis	rs554111	0.891	rs531044	chr1:21057011	T/C	cg08890418	chr1:21044141	KIF17	0.51	7.1	0.42	1.47e-11	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs875971	0.545	rs10950027	chr7:65634151	C/T	cg11764359	chr7:65958608	NA	0.67	6.66	0.4	1.92e-10	Aortic root size;
SARC	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.77	-8.03	-0.47	4.84e-14	Alzheimer's disease;
SARC	cis	rs34779708	0.931	rs1926554	chr10:35344969	C/T	cg03585969	chr10:35415529	CREM	0.38	4.85	0.3	2.27e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs8114671	0.562	rs6058137	chr20:33475074	G/A	cg24642439	chr20:33292090	TP53INP2	0.48	5.72	0.35	3.21e-8	Height;
SARC	trans	rs61931739	0.500	rs11053213	chr12:34466395	G/T	cg13010199	chr12:38710504	ALG10B	0.81	11.23	0.59	1.12e-23	Morning vs. evening chronotype;
SARC	cis	rs2070997	0.607	rs9919036	chr9:133684844	A/G	cg11464064	chr9:133710261	ABL1	0.53	4.82	0.3	2.54e-6	Response to amphetamines;
SARC	cis	rs477692	0.673	rs1078847	chr10:131352115	T/C	cg05714579	chr10:131428358	MGMT	0.55	7.16	0.42	1.06e-11	Response to temozolomide;
SARC	cis	rs9326248	0.530	rs473188	chr11:116812029	C/G	cg01368799	chr11:117014884	PAFAH1B2	0.57	4.9	0.31	1.79e-6	Blood protein levels;
SARC	cis	rs72781680	1.000	rs72781665	chr2:24223086	G/A	cg08917208	chr2:24149416	ATAD2B	0.79	7.66	0.45	4.81e-13	Lymphocyte counts;
SARC	cis	rs6674176	0.932	rs7412307	chr1:44433864	C/G	cg12908607	chr1:44402522	ARTN	0.37	6.19	0.38	2.68e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg22857025	chr5:266934	NA	-1.09	-11.68	-0.61	4.19e-25	Breast cancer;
SARC	cis	rs711830	1.000	rs2249131	chr2:177032095	C/T	cg13092806	chr2:177043255	NA	0.63	6.45	0.39	6.52e-10	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
SARC	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg14784868	chr12:69753453	YEATS4	0.65	9.07	0.51	5.01e-17	Cerebrospinal fluid biomarker levels;
SARC	cis	rs1545257	0.550	rs66943245	chr2:24631075	G/A	cg06627628	chr2:24431161	ITSN2	-0.54	-6.91	-0.41	4.48e-11	Sjögren's syndrome;
SARC	cis	rs12681288	0.862	rs7814070	chr8:1020991	A/G	cg15309053	chr8:964076	NA	0.42	7.09	0.42	1.58e-11	Schizophrenia;
SARC	cis	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.66	9.45	0.53	3.77e-18	Spherical equivalent (joint analysis main effects and education interaction);
SARC	cis	rs7635838	0.819	rs4684782	chr3:11518755	C/T	cg00170343	chr3:11313890	ATG7	-0.61	-8.39	-0.48	4.66e-15	HDL cholesterol;
SARC	cis	rs2479724	0.870	rs7766960	chr6:41918190	T/G	cg17623882	chr6:41773611	USP49	-0.45	-5.75	-0.35	2.72e-8	Menarche (age at onset);
SARC	cis	rs9388451	0.626	rs3799708	chr6:126078530	C/T	cg06289844	chr6:126071538	HEY2	0.33	5.37	0.33	1.88e-7	Brugada syndrome;
SARC	cis	rs9911578	0.933	rs2531726	chr17:56522533	C/T	cg05425664	chr17:57184151	TRIM37	0.57	6.97	0.42	3.15e-11	Intelligence (multi-trait analysis);
SARC	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.6	-6.31	-0.38	1.42e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs10861342	0.786	rs11112386	chr12:105538758	A/G	cg23923672	chr12:105501055	KIAA1033	0.65	4.88	0.3	1.95e-6	IgG glycosylation;
SARC	cis	rs13256369	1.000	rs4840351	chr8:8573148	A/G	cg17143192	chr8:8559678	CLDN23	0.53	6.2	0.38	2.55e-9	Obesity-related traits;
SARC	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.91	-14.54	-0.69	1.6e-34	Chronic sinus infection;
SARC	cis	rs748404	0.578	rs2278856	chr15:43631356	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	6.79	0.41	9.38e-11	Lung cancer;
SARC	cis	rs4430311	0.688	rs1352162	chr1:243717682	A/G	cg21452805	chr1:244014465	NA	-0.38	-4.73	-0.3	3.93e-6	Post-traumatic stress disorder (asjusted for relatedness);
SARC	cis	rs2204008	0.837	rs12369089	chr12:38060263	G/A	cg26384229	chr12:38710491	ALG10B	0.88	12.91	0.65	3.88e-29	Bladder cancer;
SARC	cis	rs12824058	0.831	rs4759658	chr12:130815872	C/T	cg23887609	chr12:130822674	PIWIL1	0.36	5.07	0.32	8.17e-7	Menopause (age at onset);
SARC	cis	rs6540556	0.906	rs6540554	chr1:209932297	A/T	cg05527609	chr1:210001259	C1orf107	0.56	5.72	0.35	3.26e-8	Red blood cell count;
SARC	cis	rs9914988	0.667	rs17794574	chr17:27254179	C/T	cg10538030	chr17:27276405	PHF12	-0.59	-4.75	-0.3	3.5e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs4481887	0.800	rs10888342	chr1:248441999	A/G	cg00666640	chr1:248458726	OR2T12	0.29	4.77	0.3	3.22e-6	Common traits (Other);
SARC	cis	rs2013441	1.000	rs2120282	chr17:20209474	C/T	cg13482628	chr17:19912719	NA	-0.49	-6.33	-0.38	1.23e-9	Obesity-related traits;
SARC	cis	rs1401999	1.000	rs4148579	chr3:183685249	T/C	cg01324343	chr3:183735012	ABCC5	0.67	13.43	0.66	7.75e-31	Anterior chamber depth;
SARC	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg16405210	chr4:1374714	KIAA1530	-0.51	-5.95	-0.36	1e-8	Obesity-related traits;
SARC	cis	rs11785400	0.762	rs9694556	chr8:143727841	A/G	cg24634471	chr8:143751801	JRK	0.59	7.69	0.45	4.22e-13	Schizophrenia;
SARC	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg04277193	chr17:41438351	NA	0.43	4.76	0.3	3.42e-6	Menopause (age at onset);
SARC	cis	rs524281	0.861	rs9736673	chr11:65924024	T/A	cg14036092	chr11:66035641	RAB1B	-0.49	-5.32	-0.33	2.42e-7	Electroencephalogram traits;
SARC	cis	rs9640161	0.830	rs35840727	chr7:150063204	A/G	cg17279839	chr7:150038598	RARRES2	0.36	5.22	0.32	3.96e-7	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs861020	0.959	rs641348	chr1:209992043	A/G	cg05527609	chr1:210001259	C1orf107	0.97	11.01	0.58	5.82e-23	Orofacial clefts;
SARC	cis	rs2075371	0.734	rs13225086	chr7:134011411	C/T	cg00033643	chr7:134001901	SLC35B4	0.46	5.48	0.34	1.08e-7	Mean platelet volume;
SARC	cis	rs2153535	0.601	rs969420	chr6:8451966	T/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.49	1.52e-15	Motion sickness;
SARC	cis	rs2230307	0.572	rs11805428	chr1:100641716	T/C	cg24955406	chr1:100503596	HIAT1	-0.64	-5.92	-0.36	1.16e-8	Carotid intima media thickness;
SARC	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg14664628	chr15:75095509	CSK	-0.47	-5.9	-0.36	1.28e-8	Breast cancer;
SARC	cis	rs56235845	0.694	rs4532376	chr5:176774403	G/A	cg06060754	chr5:176797920	RGS14	0.48	6.15	0.37	3.35e-9	Hemoglobin concentration;Hematocrit;
SARC	cis	rs2439831	0.571	rs689883	chr15:43812596	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.97	9.37	0.52	6.6e-18	Lung cancer in ever smokers;
SARC	cis	rs4713118	0.513	rs149941	chr6:28001033	T/C	cg26450541	chr6:28235208	ZNF187	0.46	4.82	0.3	2.55e-6	Parkinson's disease;
SARC	cis	rs4555082	0.915	rs2816632	chr14:105741355	C/T	cg10792982	chr14:105748885	BRF1	-0.48	-7.43	-0.44	1.99e-12	Mean platelet volume;Platelet distribution width;
SARC	cis	rs7584330	0.737	rs1390985	chr2:238367420	G/A	cg14458575	chr2:238380390	NA	0.44	5.41	0.33	1.6e-7	Prostate cancer;
SARC	cis	rs7833986	0.501	rs72653917	chr8:56892844	T/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.64	6.46	0.39	6.16e-10	Height;
SARC	cis	rs933688	1.000	rs1035476	chr5:90745976	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.02	12.73	0.64	1.57e-28	Smoking behavior;
SARC	cis	rs6840360	0.809	rs6846809	chr4:152730201	A/G	cg22705602	chr4:152727874	NA	0.39	6.83	0.41	7.37e-11	Intelligence (multi-trait analysis);
SARC	cis	rs2463822	0.748	rs2513038	chr11:62081329	A/C	cg06239285	chr11:62104954	ASRGL1	0.79	8.1	0.47	3.04e-14	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs1784581	0.588	rs4131681	chr6:162422167	T/G	cg17173639	chr6:162384350	PARK2	0.51	6.48	0.39	5.48e-10	Itch intensity from mosquito bite;
SARC	cis	rs7769051	0.522	rs10457596	chr6:133169974	T/G	cg22852734	chr6:133119734	C6orf192	0.93	6.78	0.41	9.66e-11	Type 2 diabetes nephropathy;
SARC	trans	rs2727020	0.729	rs10839268	chr11:49380328	G/A	cg03929089	chr4:120376271	NA	-0.75	-11.11	-0.59	2.79e-23	Coronary artery disease;
SARC	cis	rs9910055	0.530	rs2269907	chr17:42294215	G/A	cg19774624	chr17:42201019	HDAC5	-0.49	-6.67	-0.4	1.84e-10	Total body bone mineral density;
SARC	cis	rs2230307	0.656	rs7531066	chr1:100463804	A/G	cg24955406	chr1:100503596	HIAT1	0.71	5.83	0.36	1.83e-8	Carotid intima media thickness;
SARC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg10150615	chr22:24372951	LOC391322	-0.43	-4.82	-0.3	2.56e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7940866	0.903	rs7130842	chr11:130836269	A/G	cg12179176	chr11:130786555	SNX19	0.63	8.25	0.48	1.18e-14	Schizophrenia;
SARC	cis	rs73086581	0.838	rs73088424	chr20:4001006	T/G	cg02187196	chr20:3869020	PANK2	0.58	5.53	0.34	8.45e-8	Response to antidepressants in depression;
SARC	cis	rs2120019	0.935	rs8042409	chr15:75350433	G/A	cg00629941	chr15:75287862	SCAMP5	-0.67	-8.06	-0.47	3.92e-14	Blood trace element (Zn levels);
SARC	cis	rs6568686	0.786	rs4145457	chr6:111821182	T/C	cg15721981	chr6:111408429	SLC16A10	-0.61	-4.78	-0.3	3.08e-6	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs1790761	0.520	rs7124513	chr11:67395714	C/T	cg24690094	chr11:67383802	NA	-0.44	-6.25	-0.38	1.95e-9	Mean corpuscular volume;
SARC	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg16325326	chr1:53192061	ZYG11B	0.83	13.23	0.65	3.6e-30	Monocyte count;
SARC	cis	rs10197940	0.510	rs7602715	chr2:152421937	A/G	cg19508488	chr2:152266495	RIF1	0.47	4.88	0.3	1.93e-6	Lung cancer;
SARC	cis	rs7178572	0.568	rs12901297	chr15:77386675	G/A	cg22256960	chr15:77711686	NA	-0.51	-5.36	-0.33	1.98e-7	Type 2 diabetes;
SARC	cis	rs281408	0.559	rs281381	chr19:49214748	C/T	cg13540341	chr19:49222985	MAMSTR	-0.33	-5.56	-0.34	7.42e-8	Urinary metabolites (H-NMR features);
SARC	cis	rs9894429	1.000	rs7406003	chr17:79597597	C/T	cg18240062	chr17:79603768	NPLOC4	0.74	10.13	0.55	3.28e-20	Eye color traits;
SARC	cis	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg00800038	chr16:89945340	TCF25	-0.79	-5.45	-0.34	1.26e-7	Skin colour saturation;
SARC	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg24250549	chr1:154909240	PMVK	0.76	10.26	0.56	1.3e-20	Prostate cancer;
SARC	cis	rs9303401	0.659	rs12952325	chr17:56899371	G/A	cg25039879	chr17:56429692	SUPT4H1	0.64	6.07	0.37	5.16e-9	Cognitive test performance;
SARC	trans	rs6815916	0.619	rs62339498	chr4:182553633	C/A	cg13864546	chr1:2310327	MORN1	0.68	6.41	0.39	7.98e-10	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs8141529	0.529	rs2267131	chr22:29190471	T/C	cg02153584	chr22:29168773	CCDC117	0.65	6.65	0.4	2.02e-10	Lymphocyte counts;
SARC	cis	rs7566780	0.714	rs62122693	chr2:16734878	G/A	cg09580478	chr2:16689509	NA	-0.5	-5.44	-0.34	1.38e-7	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg24549020	chr5:56110836	MAP3K1	0.81	8.4	0.48	4.37e-15	Initial pursuit acceleration;
SARC	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.58	5.39	0.33	1.71e-7	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs1882538	0.538	rs7783217	chr7:133104117	C/G	cg10665199	chr7:133106180	EXOC4	-0.42	-5.41	-0.33	1.6e-7	Intelligence (multi-trait analysis);
SARC	cis	rs46522	0.585	rs79049364	chr17:47014991	T/A	cg07967210	chr17:47022446	SNF8	0.38	4.85	0.3	2.27e-6	Coronary heart disease;
SARC	cis	rs753778	0.962	rs4961341	chr8:142235154	G/T	cg18755752	chr8:142205143	DENND3	-0.47	-6.12	-0.37	3.93e-9	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs4132509	1.000	rs10927040	chr1:243731693	T/C	cg21452805	chr1:244014465	NA	0.49	5.52	0.34	9.13e-8	RR interval (heart rate);
SARC	cis	rs35110281	0.667	rs2838354	chr21:45119857	T/C	cg01579765	chr21:45077557	HSF2BP	-0.36	-5.71	-0.35	3.38e-8	Mean corpuscular volume;
SARC	cis	rs2694528	0.844	rs1444238	chr5:60064844	A/G	cg11474532	chr5:59995715	DEPDC1B	0.69	4.89	0.31	1.87e-6	Parkinson's disease;
SARC	cis	rs9467773	0.596	rs3001369	chr6:26670969	C/T	cg11502198	chr6:26597334	ABT1	0.61	8.08	0.47	3.56e-14	Intelligence (multi-trait analysis);
SARC	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.43	-5.4	-0.33	1.65e-7	Lymphocyte counts;
SARC	cis	rs6062302	0.522	rs3787112	chr20:62222411	G/A	cg09650180	chr20:62225654	GMEB2	-0.45	-5.56	-0.34	7.24e-8	Glioblastoma;
SARC	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg19077165	chr18:44547161	KATNAL2	0.56	7.83	0.46	1.72e-13	Personality dimensions;
SARC	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg03517284	chr6:25882590	NA	-0.7	-9.5	-0.53	2.64e-18	Urate levels;
SARC	cis	rs2075371	1.000	rs2598296	chr7:133992985	C/T	cg20476274	chr7:133979776	SLC35B4	0.62	8.42	0.48	3.75e-15	Mean platelet volume;
SARC	cis	rs2916247	1.000	rs4735044	chr8:93057478	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.57	-6.04	-0.37	6.18e-9	Intelligence (multi-trait analysis);
SARC	cis	rs9487051	1.000	rs9386796	chr6:109618704	C/T	cg01475377	chr6:109611718	NA	-0.41	-5.71	-0.35	3.36e-8	Reticulocyte fraction of red cells;
SARC	cis	rs1662342	0.800	rs16944619	chr18:3278633	A/G	cg14211874	chr18:3262499	MYL12B	-0.6	-5.15	-0.32	5.45e-7	QRS duration;
SARC	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg18876405	chr7:65276391	NA	0.64	8.06	0.47	4.06e-14	Aortic root size;
SARC	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg03806693	chr22:41940476	POLR3H	0.88	12.27	0.63	5.13e-27	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg00149659	chr3:10157352	C3orf10	0.8	7.49	0.44	1.39e-12	Alzheimer's disease;
SARC	cis	rs6542838	0.641	rs12712042	chr2:99534401	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.52	-6.74	-0.4	1.24e-10	Fear of minor pain;
SARC	cis	rs765787	0.530	rs2413785	chr15:45530381	T/C	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.81e-6	Uric acid levels;
SARC	cis	rs7829975	0.572	rs7005000	chr8:8796602	A/G	cg15556689	chr8:8085844	FLJ10661	-0.4	-4.86	-0.3	2.12e-6	Mood instability;
SARC	cis	rs10782582	0.532	rs78106188	chr1:76137836	A/G	cg10523679	chr1:76189770	ACADM	-0.43	-5.22	-0.32	4e-7	Daytime sleep phenotypes;
SARC	cis	rs1018836	0.608	rs1015994	chr8:91465011	T/C	cg16814680	chr8:91681699	NA	-0.65	-9.23	-0.52	1.65e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs10411936	0.712	rs8100755	chr19:16593415	G/A	cg10248733	chr19:16607483	C19orf44;CALR3	0.62	7.44	0.44	1.97e-12	White blood cell count;Multiple sclerosis;
SARC	cis	rs6459804	1.000	rs6459806	chr7:157510483	C/G	cg05731713	chr7:157510257	PTPRN2	0.31	5.97	0.36	8.65e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg13175981	chr1:150552382	MCL1	-0.54	-6.9	-0.41	4.97e-11	Tonsillectomy;
SARC	cis	rs9420	0.925	rs488769	chr11:57450720	A/C	cg19752551	chr11:57585705	CTNND1	-0.39	-5.3	-0.33	2.66e-7	Schizophrenia;
SARC	cis	rs780094	0.606	rs6729709	chr2:27583156	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.32	-4.83	-0.3	2.47e-6	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs73242632	1.000	rs73242618	chr4:57809549	A/G	cg20415529	chr4:57845134	POLR2B;C4orf14	0.99	5.73	0.35	3.07e-8	Congenital heart disease (maternal effect);
SARC	cis	rs9916302	0.821	rs12938268	chr17:37572139	G/A	cg07936489	chr17:37558343	FBXL20	-0.71	-9.43	-0.53	4.43e-18	Glomerular filtration rate (creatinine);
SARC	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg15049968	chr18:44337910	ST8SIA5	-0.36	-5.64	-0.35	4.98e-8	Personality dimensions;
SARC	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg13939156	chr17:80058883	NA	0.4	6.37	0.39	1.01e-9	Life satisfaction;
SARC	cis	rs7246657	0.943	rs12709813	chr19:37844983	G/A	cg23950597	chr19:37808831	NA	-0.54	-5.47	-0.34	1.15e-7	Coronary artery calcification;
SARC	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg20818283	chr2:191399100	TMEM194B	0.45	5.8	0.35	2.2e-8	Pulse pressure;
SARC	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg21724239	chr8:58056113	NA	0.59	5.55	0.34	7.85e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2327429	0.858	rs7769954	chr6:134196381	A/G	cg25632230	chr6:134101081	NA	-0.44	-5.23	-0.32	3.81e-7	Coronary artery disease;
SARC	cis	rs2075371	1.000	rs2544213	chr7:133982867	G/C	cg11752832	chr7:134001865	SLC35B4	0.56	7.34	0.43	3.51e-12	Mean platelet volume;
SARC	cis	rs2997447	0.688	rs17257100	chr1:26439586	C/T	cg19633962	chr1:26362018	EXTL1	-0.57	-5.02	-0.31	1.01e-6	QRS complex (12-leadsum);
SARC	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg13206674	chr6:150067644	NUP43	0.46	6.0	0.37	7.55e-9	Lung cancer;
SARC	cis	rs2050392	0.687	rs608693	chr10:30734971	G/A	cg25182066	chr10:30743637	MAP3K8	0.39	5.34	0.33	2.21e-7	Inflammatory bowel disease;
SARC	cis	rs11098499	0.954	rs12499324	chr4:120393786	C/T	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	cis	rs3815700	1.000	rs3815700	chr19:33093252	T/C	cg24916020	chr19:33096688	ANKRD27	0.56	5.41	0.33	1.59e-7	Eosinophilic esophagitis;
SARC	cis	rs17023223	0.537	rs12085616	chr1:119689148	A/C	cg05756136	chr1:119680316	WARS2	-0.48	-5.55	-0.34	7.84e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs9914988	0.943	rs4795467	chr17:27180784	C/T	cg20469991	chr17:27169893	C17orf63	-0.63	-5.58	-0.34	6.81e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs524281	0.817	rs7115081	chr11:65853541	A/G	cg14036092	chr11:66035641	RAB1B	-0.51	-5.34	-0.33	2.16e-7	Electroencephalogram traits;
SARC	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg00684032	chr4:1343700	KIAA1530	0.38	5.53	0.34	8.45e-8	Obesity-related traits;
SARC	cis	rs9309473	1.000	rs1881245	chr2:73649928	G/A	cg20560298	chr2:73613845	ALMS1	-0.44	-5.35	-0.33	2.06e-7	Metabolite levels;
SARC	cis	rs2153535	0.580	rs9379215	chr6:8481225	G/A	cg23788917	chr6:8435910	SLC35B3	0.64	8.59	0.49	1.25e-15	Motion sickness;
SARC	cis	rs10504229	0.679	rs78941440	chr8:58052095	A/G	cg21724239	chr8:58056113	NA	0.57	5.75	0.35	2.79e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9325144	0.541	rs7303395	chr12:38664124	C/T	cg13010199	chr12:38710504	ALG10B	-0.56	-6.97	-0.42	3.3e-11	Morning vs. evening chronotype;
SARC	cis	rs4601821	0.823	rs17115439	chr11:113264272	T/C	cg14159747	chr11:113255604	NA	0.39	5.17	0.32	4.99e-7	Alcoholic chronic pancreatitis;
SARC	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.95	10.3	0.56	9.29e-21	Platelet count;
SARC	cis	rs1008375	1.000	rs2315561	chr4:17679695	C/T	cg27347728	chr4:17578864	LAP3	0.45	5.6	0.34	6.1e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg14517863	chr17:44321492	NA	0.43	6.3	0.38	1.44e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs637571	0.522	rs550435	chr11:65732651	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.41	5.08	0.32	7.75e-7	Eosinophil percentage of white cells;
SARC	cis	rs8031584	0.918	rs61997138	chr15:31270776	C/T	cg19680485	chr15:31195859	MTMR15	-0.52	-6.11	-0.37	4.2e-9	Huntington's disease progression;
SARC	cis	rs4372836	0.658	rs56178008	chr2:29098543	T/A	cg09522027	chr2:28974177	PPP1CB	-0.36	-4.91	-0.31	1.71e-6	Body mass index;
SARC	cis	rs3733585	0.624	rs58130873	chr4:9972081	T/C	cg00071950	chr4:10020882	SLC2A9	-0.37	-5.6	-0.34	6.11e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs72945132	0.882	rs3781648	chr11:70190058	T/C	cg00319359	chr11:70116639	PPFIA1	0.68	6.34	0.38	1.15e-9	Coronary artery disease;
SARC	cis	rs7666738	0.830	rs10856936	chr4:99011319	T/C	cg05340658	chr4:99064831	C4orf37	0.64	8.59	0.49	1.22e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7786808	0.653	rs7810861	chr7:158212633	G/A	cg01191920	chr7:158217561	PTPRN2	-0.33	-5.66	-0.35	4.36e-8	Obesity-related traits;
SARC	cis	rs7666738	0.716	rs28792413	chr4:99083707	G/A	cg05340658	chr4:99064831	C4orf37	0.57	7.28	0.43	5.16e-12	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2239547	0.618	rs3733047	chr3:52871929	A/G	cg11645453	chr3:52864694	ITIH4	-0.31	-4.73	-0.3	3.94e-6	Schizophrenia;
SARC	cis	rs11214589	0.806	rs4551806	chr11:113250540	T/A	cg14159747	chr11:113255604	NA	0.35	4.92	0.31	1.64e-6	Neuroticism;
SARC	cis	rs3617	0.625	rs11715347	chr3:52883070	C/T	cg04865290	chr3:52927548	TMEM110	0.34	4.97	0.31	1.29e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	trans	rs12310956	0.510	rs2054867	chr12:33835462	C/G	cg26384229	chr12:38710491	ALG10B	-0.65	-8.77	-0.5	3.77e-16	Morning vs. evening chronotype;
SARC	trans	rs3780486	1.000	rs10813951	chr9:33128021	C/T	cg04842962	chr6:43655489	MRPS18A	-0.93	-12.76	-0.64	1.28e-28	IgG glycosylation;
SARC	cis	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg07777115	chr5:623756	CEP72	-0.64	-5.75	-0.35	2.8e-8	Obesity-related traits;
SARC	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.5	-6.24	-0.38	2e-9	Lymphocyte counts;
SARC	cis	rs9547996	0.959	rs9548003	chr13:38233206	A/G	cg17979426	chr13:38220150	TRPC4	-0.48	-5.42	-0.33	1.48e-7	Diastolic blood pressure;
SARC	cis	rs62064224	0.791	rs11656289	chr17:30761160	T/C	cg09324608	chr17:30823087	MYO1D	0.32	4.79	0.3	3.03e-6	Schizophrenia;
SARC	cis	rs4834770	0.668	rs1397610	chr4:120127761	G/C	cg09307838	chr4:120376055	NA	-0.48	-5.08	-0.32	7.75e-7	Blood protein levels;
SARC	cis	rs9788682	0.694	rs10851906	chr15:78774676	A/G	cg06917634	chr15:78832804	PSMA4	-0.53	-5.45	-0.34	1.26e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs6665290	0.870	rs17600725	chr1:227204231	A/G	cg14016676	chr1:227182615	CDC42BPA	0.37	5.44	0.34	1.36e-7	Myeloid white cell count;
SARC	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg22307029	chr19:49891270	CCDC155	0.65	7.56	0.44	9e-13	Multiple sclerosis;
SARC	cis	rs2486288	0.656	rs9920290	chr15:45548035	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.5	-6.29	-0.38	1.57e-9	Glomerular filtration rate;
SARC	cis	rs9394841	0.667	rs1891453	chr6:41765265	T/C	cg08135965	chr6:41755394	TOMM6	0.62	6.55	0.39	3.7e-10	Mean corpuscular hemoglobin;Red cell distribution width;
SARC	cis	rs3796352	1.000	rs11718752	chr3:53130745	T/C	cg27565382	chr3:53032988	SFMBT1	0.7	4.92	0.31	1.62e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs11155671	0.530	rs4458704	chr6:150232879	A/C	cg05036130	chr6:150231994	NA	0.31	5.33	0.33	2.34e-7	Testicular germ cell tumor;
SARC	cis	rs3784262	0.669	rs4646645	chr15:58245151	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.35	-5.13	-0.32	6.08e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs698833	0.509	rs2341457	chr2:44768102	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.43	5.54	0.34	8.11e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg24250549	chr1:154909240	PMVK	0.84	12.21	0.62	8.01e-27	Prostate cancer;
SARC	cis	rs2070433	0.756	rs9637220	chr21:47887436	T/C	cg12379764	chr21:47803548	PCNT	0.5	4.86	0.3	2.16e-6	Lymphocyte counts;
SARC	cis	rs2033711	0.654	rs734380	chr19:58898963	A/C	cg26874164	chr19:58962979	ZNF324B	0.42	5.14	0.32	5.93e-7	Uric acid clearance;
SARC	cis	rs9646954	0.542	rs4149510	chr2:101023635	G/A	cg14675211	chr2:100938903	LONRF2	0.52	7.8	0.46	2.01e-13	Intelligence (multi-trait analysis);
SARC	cis	rs17125944	0.572	rs79312783	chr14:53250296	A/T	cg00686598	chr14:53173677	PSMC6	1.27	8.86	0.5	2.11e-16	Alzheimer's disease (late onset);
SARC	cis	rs10089	1.000	rs1962291	chr5:127445373	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.84	-10.8	-0.58	2.59e-22	Ileal carcinoids;
SARC	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.51	-5.88	-0.36	1.44e-8	Systemic lupus erythematosus;
SARC	cis	rs10875746	0.669	rs10467101	chr12:48607737	T/C	cg26205652	chr12:48591994	NA	0.48	5.18	0.32	4.78e-7	Longevity (90 years and older);
SARC	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg08677398	chr8:58056175	NA	0.44	5.25	0.33	3.38e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs13077101	0.530	rs2331541	chr3:120473038	C/G	cg24332942	chr3:120408071	RABL3	-0.36	-4.76	-0.3	3.47e-6	Obesity-related traits;
SARC	cis	rs4820539	0.966	rs5996470	chr22:23483255	G/A	cg14186256	chr22:23484241	RTDR1	0.89	14.6	0.69	1.04e-34	Bone mineral density;
SARC	cis	rs7599312	0.534	rs10180824	chr2:213407975	G/A	cg16329650	chr2:213403929	ERBB4	0.69	10.27	0.56	1.16e-20	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs6582630	0.576	rs4882258	chr12:38453686	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-6.82	-0.41	7.6e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6061231	1.000	rs13043313	chr20:60958269	A/G	cg22601191	chr20:60968625	CABLES2	0.37	4.95	0.31	1.42e-6	Colorectal cancer;
SARC	cis	rs17270561	0.609	rs9379788	chr6:25742759	A/C	cg16482183	chr6:26056742	HIST1H1C	0.43	5.08	0.32	7.76e-7	Iron status biomarkers;
SARC	cis	rs208520	0.526	rs9354370	chr6:66808209	C/T	cg07460842	chr6:66804631	NA	1.09	21.55	0.82	2.17e-57	Exhaled nitric oxide output;
SARC	cis	rs4919087	1.000	rs7078288	chr10:99086361	C/T	cg25902810	chr10:99078978	FRAT1	-0.47	-5.79	-0.35	2.31e-8	Monocyte count;
SARC	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg13902645	chr11:5959945	NA	-0.42	-5.39	-0.33	1.69e-7	DNA methylation (variation);
SARC	cis	rs7582720	1.000	rs72934554	chr2:203987806	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	7.8	0.45	2.11e-13	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs9303401	0.659	rs12602808	chr17:56698420	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	12.09	0.62	2e-26	Cognitive test performance;
SARC	cis	rs17376456	0.877	rs10060462	chr5:93455073	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.73	0.35	3.03e-8	Diabetic retinopathy;
SARC	cis	rs7264396	0.563	rs2425121	chr20:34326186	A/T	cg01084648	chr20:34329383	RBM39	0.58	5.03	0.31	9.74e-7	Total cholesterol levels;
SARC	cis	rs67311347	1.000	rs9834052	chr3:40399060	G/A	cg24209194	chr3:40518798	ZNF619	0.58	7.23	0.43	6.77e-12	Renal cell carcinoma;
SARC	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg11764359	chr7:65958608	NA	-0.79	-9.77	-0.54	4.17e-19	Aortic root size;
SARC	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs8114671	0.562	rs4911161	chr20:33402231	C/T	cg07148914	chr20:33460835	GGT7	0.41	5.2	0.32	4.36e-7	Height;
SARC	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.75	-9.31	-0.52	1.01e-17	Prudent dietary pattern;
SARC	cis	rs11874712	1.000	rs9945751	chr18:43673265	G/A	cg25174615	chr18:43684699	ATP5A1;HAUS1	0.4	4.77	0.3	3.31e-6	Migraine - clinic-based;
SARC	cis	rs3820928	0.874	rs55748731	chr2:227818629	C/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-6.79	-0.41	8.97e-11	Pulmonary function;
SARC	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg16405210	chr4:1374714	KIAA1530	-0.44	-4.85	-0.3	2.26e-6	Obesity-related traits;
SARC	cis	rs2502731	1.000	rs2502731	chr9:130976557	A/G	cg09976142	chr9:130955436	CIZ1	-0.48	-7.04	-0.42	2.1e-11	Attention deficit hyperactivity disorder;
SARC	cis	rs9916302	0.851	rs11078906	chr17:37662767	C/T	cg00129232	chr17:37814104	STARD3	-0.65	-7.99	-0.46	6.36e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs6772849	0.901	rs9289330	chr3:128311067	C/G	cg08795948	chr3:128337044	NA	0.37	4.94	0.31	1.51e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs12950390	0.512	rs56254413	chr17:45857545	G/T	cg03474202	chr17:45855739	NA	-0.42	-5.13	-0.32	6.08e-7	IgG glycosylation;
SARC	cis	rs17826219	0.636	rs12946563	chr17:29103166	C/G	cg13385521	chr17:29058706	SUZ12P	0.9	7.76	0.45	2.66e-13	Body mass index;
SARC	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg11644478	chr21:40555479	PSMG1	-1.03	-14.98	-0.7	5.58e-36	Cognitive function;
SARC	cis	rs9899728	0.539	rs57813751	chr17:73053512	C/T	cg27626185	chr17:73056755	KCTD2	-0.91	-7.6	-0.45	7.21e-13	Alzheimer's disease or small vessel stroke;
SARC	cis	rs6430585	0.528	rs309172	chr2:136674028	A/G	cg07169764	chr2:136633963	MCM6	1.01	15.2	0.71	1.06e-36	Corneal structure;
SARC	cis	rs2658782	0.724	rs2605626	chr11:93253903	A/G	cg15737290	chr11:93063684	CCDC67	0.71	7.97	0.46	7e-14	Pulmonary function decline;
SARC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg26338869	chr17:61819248	STRADA	0.8	10.65	0.57	7.56e-22	Prudent dietary pattern;
SARC	cis	rs1062177	1.000	rs2964585	chr5:151141895	C/T	cg00977110	chr5:151150581	G3BP1	0.62	6.11	0.37	4.05e-9	Preschool internalizing problems;
SARC	cis	rs6450176	1.000	rs3776707	chr5:53304873	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-7.97	-0.46	6.84e-14	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs1448094	0.621	rs7133309	chr12:86284078	T/C	cg02569458	chr12:86230093	RASSF9	0.41	5.58	0.34	6.67e-8	Major depressive disorder;
SARC	cis	rs4689388	0.889	rs13101355	chr4:6293446	T/C	cg14416269	chr4:6271139	WFS1	0.32	4.92	0.31	1.61e-6	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs854765	0.583	rs9908832	chr17:17871068	C/T	cg05444541	chr17:17804740	TOM1L2	-0.31	-5.06	-0.31	8.54e-7	Total body bone mineral density;
SARC	cis	rs9487051	0.652	rs9372210	chr6:109601703	G/C	cg01475377	chr6:109611718	NA	-0.35	-5.17	-0.32	4.92e-7	Reticulocyte fraction of red cells;
SARC	cis	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg00071950	chr4:10020882	SLC2A9	0.39	6.31	0.38	1.4e-9	Bone mineral density;
SARC	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	0.78	11.17	0.59	1.72e-23	Total body bone mineral density;
SARC	cis	rs9902453	0.874	rs62070271	chr17:28268358	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	6.94	0.41	3.77e-11	Coffee consumption (cups per day);
SARC	cis	rs1707322	1.000	rs4660895	chr1:46329739	C/T	cg03146154	chr1:46216737	IPP	0.47	5.67	0.35	4.31e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs12142240	0.692	rs7532149	chr1:46824932	A/C	cg10495392	chr1:46806563	NSUN4	0.65	6.8	0.41	8.89e-11	Menopause (age at onset);
SARC	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg05872129	chr22:39784769	NA	-0.42	-5.93	-0.36	1.06e-8	Intelligence (multi-trait analysis);
SARC	cis	rs1200821	0.529	rs2505707	chr10:37801254	T/C	cg25427524	chr10:38739819	LOC399744	-0.46	-6.9	-0.41	4.95e-11	Hemostatic factors and hematological phenotypes;
SARC	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg24829409	chr8:58192753	C8orf71	-0.62	-6.41	-0.39	8.1e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg06618935	chr21:46677482	NA	-0.39	-5.14	-0.32	5.72e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs67311347	0.866	rs3214006	chr3:40352134	C/T	cg24209194	chr3:40518798	ZNF619	0.56	6.99	0.42	2.9e-11	Renal cell carcinoma;
SARC	cis	rs2486288	0.656	rs11854365	chr15:45558083	G/A	cg15395560	chr15:45543142	SLC28A2	0.29	5.68	0.35	3.91e-8	Glomerular filtration rate;
SARC	cis	rs7264396	0.563	rs6060566	chr20:34288226	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-7.26	-0.43	5.75e-12	Total cholesterol levels;
SARC	cis	rs763121	0.853	rs138716	chr22:39146527	C/T	cg21395723	chr22:39101663	GTPBP1	0.56	6.23	0.38	2.15e-9	Menopause (age at onset);
SARC	cis	rs854765	0.583	rs4077198	chr17:17834563	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.43	5.58	0.34	6.58e-8	Total body bone mineral density;
SARC	cis	rs440932	1.000	rs378974	chr8:9026639	C/T	cg06636001	chr8:8085503	FLJ10661	0.57	6.88	0.41	5.62e-11	High light scatter reticulocyte percentage of red cells;
SARC	cis	rs11792861	0.962	rs3829084	chr9:111801724	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.71	-8.02	-0.46	5.25e-14	Menarche (age at onset);
SARC	cis	rs1345301	1.000	rs12475055	chr2:102878891	G/T	cg12451869	chr2:102867685	NA	-0.36	-5.03	-0.31	9.76e-7	Waist circumference;
SARC	cis	rs453301	0.631	rs17700611	chr8:8793654	A/G	cg08975724	chr8:8085496	FLJ10661	-0.4	-4.86	-0.3	2.16e-6	Joint mobility (Beighton score);
SARC	cis	rs12079745	0.793	rs12062884	chr1:169209513	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.81	-5.41	-0.33	1.6e-7	QT interval;
SARC	cis	rs631288	0.557	rs894470	chr1:146671947	A/G	cg25205988	chr1:146714368	CHD1L	1.08	6.4	0.39	8.34e-10	PR interval in Tripanosoma cruzi seropositivity;
SARC	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-8.03	-0.47	4.67e-14	Chronic sinus infection;
SARC	cis	rs7818345	0.967	rs4921638	chr8:19274793	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.42	5.65	0.35	4.76e-8	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs7659604	1.000	rs7659943	chr4:122665560	C/T	cg19748678	chr4:122722346	EXOSC9	0.4	4.81	0.3	2.68e-6	Type 2 diabetes;
SARC	cis	rs3126085	1.000	rs12405278	chr1:152282267	G/A	cg26876637	chr1:152193138	HRNR	-0.51	-5.28	-0.33	2.92e-7	Atopic dermatitis;
SARC	cis	rs1035144	0.505	rs6574617	chr14:81457615	G/A	cg06600135	chr14:81408086	NA	-0.46	-5.9	-0.36	1.26e-8	Male sexual orientation;
SARC	cis	rs950169	0.840	rs4842853	chr15:84942304	G/T	cg17507749	chr15:85114479	UBE2QP1	0.79	9.66	0.53	8.73e-19	Schizophrenia;
SARC	trans	rs656319	0.629	rs10111315	chr8:9865588	G/A	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.67	-0.45	4.76e-13	Myopia (pathological);
SARC	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7178909	0.872	rs17241560	chr15:90429202	T/A	cg19708238	chr15:90437601	AP3S2	0.6	7.88	0.46	1.22e-13	Common traits (Other);
SARC	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.7	6.76	0.4	1.11e-10	Platelet count;
SARC	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg03264133	chr6:25882463	NA	0.57	7.51	0.44	1.27e-12	Blood metabolite levels;
SARC	trans	rs11098499	0.955	rs6815725	chr4:120158410	C/A	cg25214090	chr10:38739885	LOC399744	0.53	6.9	0.41	4.97e-11	Corneal astigmatism;
SARC	cis	rs2153535	0.935	rs11243254	chr6:8381242	C/T	cg21535247	chr6:8435926	SLC35B3	-0.41	-4.77	-0.3	3.22e-6	Motion sickness;
SARC	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.71	-0.5	5.58e-16	Mood instability;
SARC	cis	rs7412746	0.634	rs12562939	chr1:150951452	A/C	cg15448220	chr1:150897856	SETDB1	0.49	6.26	0.38	1.8e-9	Melanoma;
SARC	cis	rs7666738	0.830	rs1426662	chr4:98990319	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6582630	0.537	rs10785436	chr12:38461040	G/C	cg13010199	chr12:38710504	ALG10B	0.75	10.24	0.56	1.45e-20	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6570726	0.846	rs6899900	chr6:145883873	T/G	cg23711669	chr6:146136114	FBXO30	0.77	12.32	0.63	3.32e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs753778	0.602	rs9792	chr8:142205237	C/T	cg16341495	chr8:142228727	SLC45A4	0.42	5.74	0.35	2.97e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg27266027	chr21:40555129	PSMG1	0.48	5.2	0.32	4.34e-7	Cognitive function;
SARC	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg04944784	chr2:26401820	FAM59B	0.58	7.3	0.43	4.5e-12	Gut microbiome composition (summer);
SARC	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.63	7.75	0.45	2.75e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs896854	0.738	rs2515226	chr8:95965743	G/A	cg16049864	chr8:95962084	TP53INP1	0.4	6.28	0.38	1.6e-9	Type 2 diabetes;
SARC	cis	rs7429990	0.870	rs13089844	chr3:48140231	G/A	cg11946769	chr3:48343235	NME6	-0.46	-5.42	-0.33	1.46e-7	Educational attainment (years of education);
SARC	cis	rs9790314	0.586	rs16832279	chr3:161120483	C/T	cg04691961	chr3:161091175	C3orf57	-0.47	-5.87	-0.36	1.46e-8	Morning vs. evening chronotype;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg10916569	chr9:16726860	BNC2	-0.41	-6.28	-0.38	1.65e-9	Neuroticism;
SARC	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg00629941	chr15:75287862	SCAMP5	0.42	5.03	0.31	9.85e-7	Breast cancer;
SARC	cis	rs9309473	1.000	rs7607014	chr2:73730174	C/T	cg20560298	chr2:73613845	ALMS1	0.5	5.99	0.37	8.11e-9	Metabolite levels;
SARC	cis	rs13082711	0.906	rs34775440	chr3:27447333	G/T	cg02860705	chr3:27208620	NA	0.46	5.91	0.36	1.19e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs6141769	0.569	rs6057618	chr20:31264083	A/G	cg17884169	chr20:31446444	EFCAB8	-0.46	-4.85	-0.3	2.25e-6	Subjective well-being;
SARC	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.56	-7.23	-0.43	6.71e-12	Mean platelet volume;
SARC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg25703541	chr22:24373054	LOC391322	-0.81	-11.33	-0.6	5.37e-24	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1256335	0.723	rs1256344	chr1:21874042	C/G	cg22620027	chr1:21824391	NA	0.42	5.05	0.31	9.11e-7	Folate pathway vitamin levels;
SARC	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg13866156	chr1:1669148	SLC35E2	-0.63	-9.69	-0.54	7.17e-19	Body mass index;
SARC	cis	rs9916302	0.904	rs1966916	chr17:37425238	T/G	cg20243544	chr17:37824526	PNMT	0.56	6.87	0.41	5.87e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs11097912	0.603	rs12645698	chr4:107188432	C/T	cg09646026	chr4:107269030	AIMP1	-0.44	-4.74	-0.3	3.68e-6	Airflow obstruction;
SARC	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg11905131	chr22:24372483	LOC391322	-0.5	-5.49	-0.34	1.07e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2370759	1.000	rs11599522	chr10:32568434	G/C	cg05361325	chr10:32636312	EPC1	-0.74	-6.55	-0.39	3.71e-10	Sexual dysfunction (female);
SARC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg22105103	chr4:187893119	NA	0.51	6.91	0.41	4.69e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs709400	0.663	rs7152202	chr14:103886757	A/G	cg26031613	chr14:104095156	KLC1	0.78	11.03	0.59	4.78e-23	Body mass index;
SARC	cis	rs4974559	0.947	rs10000012	chr4:1357325	C/G	cg09010372	chr4:1323433	MAEA	0.47	4.84	0.3	2.41e-6	Systolic blood pressure;
SARC	cis	rs6840360	0.615	rs12647462	chr4:152607278	C/T	cg22705602	chr4:152727874	NA	-0.48	-8.45	-0.48	3.28e-15	Intelligence (multi-trait analysis);
SARC	cis	rs1784581	0.588	rs9346893	chr6:162417511	C/G	cg17173639	chr6:162384350	PARK2	0.5	6.42	0.39	7.43e-10	Itch intensity from mosquito bite;
SARC	cis	rs910316	1.000	rs8003506	chr14:75586288	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.53	-7.4	-0.44	2.48e-12	Height;
SARC	cis	rs11758351	0.660	rs16891455	chr6:26230485	G/A	cg01420254	chr6:26195488	NA	0.55	4.75	0.3	3.49e-6	Gout;Renal underexcretion gout;
SARC	cis	rs2576037	0.796	rs2571020	chr18:44584189	A/T	cg15049968	chr18:44337910	ST8SIA5	0.31	5.01	0.31	1.05e-6	Personality dimensions;
SARC	cis	rs17376456	0.825	rs17314762	chr5:93231200	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.62	5.57	0.34	6.83e-8	Diabetic retinopathy;
SARC	cis	rs1395	0.744	rs7600932	chr2:27474869	G/A	cg21747090	chr2:27597821	SNX17	-0.46	-5.62	-0.35	5.42e-8	Blood metabolite levels;
SARC	cis	rs8016982	0.698	rs12590764	chr14:81704417	G/A	cg01989461	chr14:81687754	GTF2A1	0.73	10.76	0.58	3.41e-22	Schizophrenia;
SARC	cis	rs7762018	0.607	rs80106119	chr6:170048309	T/C	cg13891659	chr6:170190454	C6orf122;C6orf208	0.76	5.02	0.31	1.03e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs2730245	1.000	rs2730245	chr7:158724789	G/C	cg14689365	chr7:158441557	NCAPG2	-0.43	-4.93	-0.31	1.56e-6	Height;
SARC	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg07308232	chr7:1071921	C7orf50	-0.46	-5.85	-0.36	1.62e-8	Longevity;Endometriosis;
SARC	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg11965913	chr1:205819406	PM20D1	0.43	4.9	0.31	1.83e-6	Parkinson's disease;
SARC	cis	rs7605378	0.688	rs769961	chr2:200712141	C/A	cg17644776	chr2:200775616	C2orf69	0.54	6.55	0.39	3.64e-10	Osteoporosis;
SARC	cis	rs9420	0.961	rs79260745	chr11:57612960	T/C	cg19752551	chr11:57585705	CTNND1	-0.49	-6.75	-0.4	1.15e-10	Schizophrenia;
SARC	cis	rs1865760	0.963	rs9356991	chr6:25901758	C/A	cg16482183	chr6:26056742	HIST1H1C	0.49	6.08	0.37	4.92e-9	Height;
SARC	cis	rs17345786	0.861	rs17402964	chr3:101067945	C/T	cg12386194	chr3:101231763	SENP7	0.81	9.48	0.53	3.14e-18	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9715521	0.935	rs6818912	chr4:59834738	A/G	cg11281224	chr4:60001000	NA	-0.38	-4.94	-0.31	1.48e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9905704	0.647	rs6503888	chr17:57028126	T/C	cg12560992	chr17:57184187	TRIM37	0.39	4.72	0.3	4e-6	Testicular germ cell tumor;
SARC	cis	rs5753618	0.561	rs13054220	chr22:31704492	A/G	cg00478049	chr22:31556069	RNF185	-0.44	-4.73	-0.3	3.94e-6	Colorectal cancer;
SARC	cis	rs9611565	0.921	rs2281332	chr22:41746212	T/C	cg17376030	chr22:41985996	PMM1	0.52	6.69	0.4	1.65e-10	Vitiligo;
SARC	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	5.92	0.36	1.14e-8	Electroencephalogram traits;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg21746459	chr9:104160900	MRPL50;ZNF189	0.52	6.39	0.39	9.05e-10	Breast cancer;
SARC	trans	rs1957429	0.520	rs2181127	chr14:65336455	C/T	cg10286983	chr6:24494717	ALDH5A1	-0.71	-6.29	-0.38	1.52e-9	Pediatric areal bone mineral density (radius);
SARC	cis	rs7808935	0.768	rs757137	chr7:27989343	T/C	cg05786569	chr7:27702416	HIBADH	0.47	5.23	0.32	3.72e-7	Prostate cancer;
SARC	cis	rs3820928	0.904	rs1835159	chr2:227764057	A/G	cg05526886	chr2:227700861	RHBDD1	-0.5	-6.02	-0.37	6.79e-9	Pulmonary function;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg19964303	chr2:220080850	ABCB6	-0.67	-6.34	-0.38	1.15e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg22903471	chr2:27725779	GCKR	-0.49	-7.42	-0.44	2.21e-12	Total body bone mineral density;
SARC	cis	rs13161895	1.000	rs864482	chr5:179427873	A/G	cg02702477	chr5:179499311	RNF130	0.65	6.46	0.39	5.92e-10	LDL cholesterol;
SARC	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.93	9.72	0.54	5.77e-19	Platelet count;
SARC	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg11764359	chr7:65958608	NA	-0.54	-6.39	-0.39	8.81e-10	Corneal structure;
SARC	cis	rs7589342	0.894	rs7557976	chr2:106435061	C/A	cg16077055	chr2:106428750	NCK2	0.4	7.49	0.44	1.44e-12	Addiction;
SARC	trans	rs561341	1.000	rs8069199	chr17:30281845	A/G	cg20587970	chr11:113659929	NA	-1.26	-12.41	-0.63	1.72e-27	Hip circumference adjusted for BMI;
SARC	cis	rs6963495	0.818	rs56251768	chr7:105165591	A/G	cg13798780	chr7:105162888	PUS7	0.6	5.56	0.34	7.22e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs412050	0.547	rs17821500	chr22:22152480	T/C	cg17089214	chr22:22089827	YPEL1	0.78	6.87	0.41	5.78e-11	Attention deficit hyperactivity disorder;
SARC	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg07701084	chr6:150067640	NUP43	0.43	5.63	0.35	5.26e-8	Lung cancer;
SARC	cis	rs6582630	0.519	rs8189618	chr12:38276281	A/C	cg26384229	chr12:38710491	ALG10B	0.91	13.79	0.67	4.83e-32	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs796364	0.806	rs11694236	chr2:200916230	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.67	-5.68	-0.35	4.06e-8	Schizophrenia;
SARC	cis	rs137603	0.603	rs137581	chr22:39677838	C/T	cg01093212	chr22:39715156	SNORD43;RPL3	-0.48	-5.71	-0.35	3.47e-8	Primary biliary cholangitis;
SARC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.62	-6.6	-0.4	2.8e-10	Platelet count;
SARC	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg09359103	chr1:154839909	KCNN3	-0.48	-8.39	-0.48	4.62e-15	Prostate cancer;
SARC	cis	rs950169	0.579	rs881983	chr15:84647308	C/T	cg17507749	chr15:85114479	UBE2QP1	0.68	7.12	0.42	1.33e-11	Schizophrenia;
SARC	cis	rs4722166	0.541	rs1800795	chr7:22766645	C/G	cg26061582	chr7:22766209	IL6	0.59	6.82	0.41	7.56e-11	Lung cancer;
SARC	cis	rs2404602	0.692	rs36070630	chr15:76949259	T/C	cg22467129	chr15:76604101	ETFA	-0.37	-4.76	-0.3	3.34e-6	Blood metabolite levels;
SARC	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg24633833	chr3:10029261	TMEM111	0.52	5.25	0.33	3.43e-7	Alzheimer's disease;
SARC	cis	rs2239547	0.522	rs2581780	chr3:53058960	C/T	cg11645453	chr3:52864694	ITIH4	-0.33	-5.16	-0.32	5.25e-7	Schizophrenia;
SARC	cis	rs2806561	0.734	rs1952527	chr1:23400969	T/C	cg12483005	chr1:23474871	LUZP1	0.41	5.31	0.33	2.62e-7	Height;
SARC	cis	rs9914988	0.943	rs9890377	chr17:27111111	A/G	cg20469991	chr17:27169893	C17orf63	-0.49	-5.05	-0.31	8.74e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs11785400	0.701	rs9297967	chr8:143723002	A/C	cg10596483	chr8:143751796	JRK	0.58	7.53	0.44	1.08e-12	Schizophrenia;
SARC	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-4.99	-0.31	1.21e-6	Total body bone mineral density;
SARC	cis	rs7219021	0.705	rs1962412	chr17:46970259	T/C	cg16584676	chr17:46985605	UBE2Z	0.52	6.21	0.38	2.46e-9	Schizophrenia or bipolar disorder;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg20974482	chr6:37321680	RNF8	-0.53	-6.37	-0.39	1.02e-9	Fibrinogen levels;
SARC	cis	rs9875589	0.794	rs2117039	chr3:13963330	T/C	cg19554555	chr3:13937349	NA	0.51	6.74	0.4	1.23e-10	Ovarian reserve;
SARC	cis	rs950169	0.840	rs62029595	chr15:84955301	C/T	cg24253500	chr15:84953950	NA	0.36	5.21	0.32	4.12e-7	Schizophrenia;
SARC	cis	rs12545109	0.837	rs4738500	chr8:57356193	G/A	cg19413350	chr8:57351067	NA	-0.45	-4.91	-0.31	1.68e-6	Obesity-related traits;
SARC	cis	rs17376456	1.000	rs17376207	chr5:93545524	C/T	cg21475434	chr5:93447410	FAM172A	-0.9	-8.25	-0.48	1.2e-14	Diabetic retinopathy;
SARC	cis	rs6060717	0.536	rs6060699	chr20:34523833	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-6.52	-0.39	4.4e-10	Hip circumference adjusted for BMI;
SARC	cis	rs10463554	0.927	rs257306	chr5:102417474	T/C	cg23492399	chr5:102201601	PAM	-0.52	-5.7	-0.35	3.63e-8	Parkinson's disease;
SARC	cis	rs995000	0.868	rs6666816	chr1:63171199	C/T	cg06896770	chr1:63153194	DOCK7	-0.85	-12.94	-0.65	3.09e-29	Triglyceride levels;
SARC	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg08280861	chr8:58055591	NA	0.61	5.96	0.36	9.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg07777115	chr5:623756	CEP72	-0.55	-4.98	-0.31	1.25e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs6831352	0.879	rs36034266	chr4:100061388	T/C	cg13256891	chr4:100009986	ADH5	-0.66	-8.16	-0.47	2.08e-14	Alcohol dependence;
SARC	cis	rs5753618	0.555	rs5749286	chr22:31900359	G/T	cg02404636	chr22:31891804	SFI1	0.55	6.18	0.38	2.91e-9	Colorectal cancer;
SARC	cis	rs13096357	0.520	rs17080319	chr3:48732480	T/C	cg03060546	chr3:49711283	APEH	-0.51	-4.75	-0.3	3.52e-6	Cognitive ability (multi-trait analysis);
SARC	cis	rs7247513	0.759	rs73002392	chr19:12768391	G/A	cg04657146	chr19:12876947	HOOK2	0.44	5.33	0.33	2.34e-7	Bipolar disorder;
SARC	cis	rs9733	0.744	rs11204725	chr1:150742700	T/C	cg13175981	chr1:150552382	MCL1	0.61	8.2	0.47	1.66e-14	Tonsillectomy;
SARC	trans	rs10506458	1.000	rs73128779	chr12:63441852	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.76	-6.85	-0.41	6.41e-11	Hemostatic factors and hematological phenotypes;
SARC	cis	rs7647973	0.731	rs13084037	chr3:49214066	G/A	cg06212747	chr3:49208901	KLHDC8B	0.87	8.55	0.49	1.67e-15	Menarche (age at onset);
SARC	cis	rs1707322	0.721	rs10789471	chr1:46215619	G/A	cg06784218	chr1:46089804	CCDC17	0.36	6.37	0.38	1.03e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg22105103	chr4:187893119	NA	0.45	6.16	0.37	3.18e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7568458	0.684	rs6731700	chr2:85760991	C/G	cg23752985	chr2:85803571	VAMP8	0.44	5.62	0.35	5.42e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.34	-4.95	-0.31	1.44e-6	Longevity;Endometriosis;
SARC	cis	rs41433250	1	rs41433250	chr13:31495835	A/G	cg08646372	chr13:31191727	USPL1	-0.67	-5.04	-0.31	9.3e-7	Influenza A (H1N1) infection;Mild influenza (H1N1) infection;
SARC	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg12463550	chr7:65579703	CRCP	0.66	5.05	0.31	9.09e-7	Diabetic kidney disease;
SARC	cis	rs734999	0.588	rs2985859	chr1:2532416	T/C	cg20673091	chr1:2541236	MMEL1	-0.33	-5.13	-0.32	5.98e-7	Ulcerative colitis;
SARC	cis	rs738322	0.967	rs132985	chr22:38563471	C/T	cg25457927	chr22:38595422	NA	-0.27	-5.64	-0.35	4.88e-8	Cutaneous nevi;
SARC	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg05368731	chr17:41323189	NBR1	0.8	9.72	0.54	5.86e-19	Menopause (age at onset);
SARC	cis	rs11112613	0.713	rs11112587	chr12:105941285	G/A	cg03607813	chr12:105948248	NA	0.54	7.26	0.43	5.79e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs208520	0.955	rs28684412	chr6:66979430	A/C	cg07460842	chr6:66804631	NA	0.9	10.32	0.56	8.16e-21	Exhaled nitric oxide output;
SARC	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.61	-6.2	-0.38	2.5e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs7589342	0.792	rs13426321	chr2:106500280	G/A	cg16077055	chr2:106428750	NCK2	0.36	6.5	0.39	4.93e-10	Addiction;
SARC	cis	rs1059312	1.000	rs7135987	chr12:129280117	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.5	7.08	0.42	1.69e-11	Systemic lupus erythematosus;
SARC	cis	rs941408	1.000	rs2260416	chr19:2796355	G/A	cg06609049	chr19:2785107	THOP1	0.77	9.9	0.54	1.65e-19	Total cholesterol levels;
SARC	cis	rs4803468	1.000	rs4803469	chr19:41922775	A/C	cg08477640	chr19:41863820	B9D2	0.46	5.88	0.36	1.43e-8	Height;
SARC	cis	rs6088813	1.000	rs6088799	chr20:33934301	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	-0.43	-5.17	-0.32	5.11e-7	Height;
SARC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg11494091	chr17:61959527	GH2	0.52	7.8	0.45	2.09e-13	Prudent dietary pattern;
SARC	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg16479474	chr6:28041457	NA	0.36	5.27	0.33	3.04e-7	Depression;
SARC	cis	rs7223966	1.000	rs56383601	chr17:61929968	A/C	cg26338869	chr17:61819248	STRADA	0.53	5.52	0.34	9.04e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs4803468	0.967	rs3826713	chr19:41892269	C/T	cg14132834	chr19:41945861	ATP5SL	-0.56	-7.54	-0.44	1.04e-12	Height;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg18887680	chr5:78907942	PAPD4	-0.5	-7.11	-0.42	1.38e-11	Chemerin levels;
SARC	cis	rs4969178	0.965	rs2292642	chr17:76395430	C/T	cg20026190	chr17:76395443	PGS1	0.4	5.36	0.33	2.03e-7	HDL cholesterol levels;
SARC	cis	rs16937	0.711	rs12142514	chr1:205122529	A/G	cg21643547	chr1:205240462	TMCC2	-0.42	-5.23	-0.32	3.8e-7	Schizophrenia;
SARC	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg05861140	chr6:150128134	PCMT1	-0.37	-4.84	-0.3	2.35e-6	Lung cancer;
SARC	cis	rs6762	0.550	rs8672	chr11:838634	C/G	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.57	-7.31	-0.43	4.23e-12	Mean platelet volume;
SARC	cis	rs2204008	0.774	rs8186954	chr12:38318566	C/A	cg13010199	chr12:38710504	ALG10B	0.78	10.65	0.57	7.99e-22	Bladder cancer;
SARC	cis	rs7931462	0.655	rs6483208	chr11:92705844	A/C	cg08970795	chr11:93517154	MED17	0.61	4.99	0.31	1.16e-6	DNA methylation (parent-of-origin);
SARC	cis	rs73206853	0.764	rs73205079	chr12:110599953	C/T	cg10860002	chr12:110842031	ANAPC7	0.65	5.26	0.33	3.3e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs6665290	0.904	rs1045285	chr1:227179054	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.07	-24.42	-0.85	3.66e-66	Myeloid white cell count;
SARC	cis	rs7714584	1.000	rs11748151	chr5:150226292	C/T	cg22134413	chr5:150180641	NA	0.78	6.56	0.39	3.42e-10	Crohn's disease;
SARC	cis	rs7617773	0.817	rs11928691	chr3:48286765	C/T	cg11946769	chr3:48343235	NME6	0.67	8.78	0.5	3.61e-16	Coronary artery disease;
SARC	cis	rs3008870	0.755	rs1121824	chr1:67475616	C/A	cg08660285	chr1:67390436	MIER1;WDR78	0.59	7.6	0.45	7e-13	Lymphocyte percentage of white cells;
SARC	trans	rs2727020	0.894	rs1880438	chr11:49370698	A/G	cg15704280	chr7:45808275	SEPT13	-0.73	-9.61	-0.53	1.2e-18	Coronary artery disease;
SARC	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg02841227	chr6:26021843	HIST1H4A	-0.46	-5.38	-0.33	1.79e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg16680214	chr1:154839983	KCNN3	-0.36	-5.69	-0.35	3.7e-8	Prostate cancer;
SARC	cis	rs6088590	0.965	rs6120727	chr20:33374102	T/C	cg06115741	chr20:33292138	TP53INP2	0.57	6.83	0.41	7.46e-11	Coronary artery disease;
SARC	cis	rs6546550	0.867	rs1048266	chr2:70132676	A/G	cg02498382	chr2:70120550	SNRNP27	-0.32	-5.13	-0.32	6.02e-7	Prevalent atrial fibrillation;
SARC	cis	rs4727027	0.901	rs1534198	chr7:148772323	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.47	5.61	0.34	5.72e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	9.16	0.51	2.7e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9858542	0.953	rs9862080	chr3:49674458	A/G	cg03060546	chr3:49711283	APEH	-0.66	-8.29	-0.48	9.28e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs7178572	0.568	rs28584877	chr15:77599003	C/A	cg22256960	chr15:77711686	NA	0.48	5.18	0.32	4.76e-7	Type 2 diabetes;
SARC	cis	rs4975616	0.714	rs37007	chr5:1352372	G/C	cg06550200	chr5:1325588	CLPTM1L	-0.38	-5.44	-0.34	1.33e-7	Lung cancer;
SARC	cis	rs12142240	0.698	rs68012736	chr1:46839510	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-5.56	-0.34	7.46e-8	Menopause (age at onset);
SARC	cis	rs2916247	0.954	rs11784233	chr8:93080925	C/A	cg10183463	chr8:93005414	RUNX1T1	-0.65	-6.57	-0.4	3.34e-10	Intelligence (multi-trait analysis);
SARC	cis	rs4713675	0.565	rs9366828	chr6:33672798	G/A	cg15676125	chr6:33679581	C6orf125	0.52	6.47	0.39	5.59e-10	Plateletcrit;
SARC	cis	rs67460515	0.500	rs6806015	chr3:160724766	G/A	cg03342759	chr3:160939853	NMD3	-0.49	-5.9	-0.36	1.29e-8	Parkinson's disease;
SARC	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.49	-6.26	-0.38	1.85e-9	Personality dimensions;
SARC	cis	rs9420	0.961	rs11604333	chr11:57467035	C/G	cg19752551	chr11:57585705	CTNND1	-0.5	-6.74	-0.4	1.24e-10	Schizophrenia;
SARC	cis	rs9814567	1.000	rs7619451	chr3:134233238	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-6.84	-0.41	6.93e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs6121246	0.567	rs6060295	chr20:30198473	C/T	cg21427119	chr20:30132790	HM13	-0.48	-5.29	-0.33	2.84e-7	Mean corpuscular hemoglobin;
SARC	cis	rs7635838	0.686	rs347588	chr3:11287504	C/T	cg00170343	chr3:11313890	ATG7	0.62	7.73	0.45	3.1400000000000003e-13	HDL cholesterol;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg21543519	chr1:168147972	TIPRL	-0.47	-6.54	-0.39	3.96e-10	Neuroticism;
SARC	cis	rs35213789	0.762	rs626767	chr7:69156077	T/C	cg10619644	chr7:69149951	AUTS2	-0.35	-4.82	-0.3	2.57e-6	Childhood ear infection;
SARC	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg17971929	chr21:40555470	PSMG1	-0.56	-7.02	-0.42	2.39e-11	Menarche (age at onset);
SARC	cis	rs7027203	0.828	rs4744291	chr9:96598297	A/G	cg13679303	chr9:96623674	NA	-0.34	-4.9	-0.31	1.79e-6	DNA methylation (variation);
SARC	cis	rs6570726	0.967	rs413880	chr6:145804822	G/A	cg05347473	chr6:146136440	FBXO30	0.45	6.12	0.37	3.93e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg06221963	chr1:154839813	KCNN3	-0.51	-8.24	-0.47	1.27e-14	Prostate cancer;
SARC	cis	rs55823223	0.503	rs9906971	chr17:73848477	A/G	cg08125733	chr17:73851984	WBP2	0.57	6.65	0.4	2.03e-10	Psoriasis;
SARC	cis	rs2327429	0.519	rs2876224	chr6:134153509	G/A	cg25632230	chr6:134101081	NA	-0.41	-5.19	-0.32	4.51e-7	Coronary artery disease;
SARC	cis	rs2933343	1.000	rs789213	chr3:128616359	C/G	cg24203234	chr3:128598194	ACAD9	-0.53	-5.86	-0.36	1.55e-8	IgG glycosylation;
SARC	cis	rs9309473	0.898	rs6546861	chr2:73849861	C/T	cg20560298	chr2:73613845	ALMS1	-0.45	-5.48	-0.34	1.08e-7	Metabolite levels;
SARC	trans	rs8002861	0.870	rs4942255	chr13:44451844	A/T	cg17145862	chr1:211918768	LPGAT1	-0.53	-7.73	-0.45	3.3e-13	Leprosy;
SARC	cis	rs6089584	0.566	rs2181589	chr20:60622817	C/T	cg23262073	chr20:60523788	NA	0.34	5.26	0.33	3.2e-7	Body mass index;
SARC	cis	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg06558623	chr16:89946397	TCF25	0.91	6.37	0.39	9.81e-10	Skin colour saturation;
SARC	cis	rs10791097	0.694	rs7106995	chr11:130758152	G/T	cg12179176	chr11:130786555	SNX19	0.75	11.4	0.6	3.36e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs739401	0.572	rs739399	chr11:3016452	A/G	cg08508325	chr11:3079039	CARS	-0.34	-8.41	-0.48	4.15e-15	Longevity;
SARC	cis	rs10254118	0.757	rs6467491	chr7:133138761	A/G	cg10665199	chr7:133106180	EXOC4	0.4	5.06	0.31	8.42e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6446731	0.734	rs9996868	chr4:3275484	C/T	cg06533319	chr4:3265114	C4orf44	-0.31	-5.08	-0.32	7.71e-7	Mean platelet volume;
SARC	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg20607798	chr8:58055168	NA	0.69	5.89	0.36	1.36e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs7395662	0.591	rs11039766	chr11:48488715	T/C	cg15704280	chr7:45808275	SEPT13	-0.5	-6.82	-0.41	7.58e-11	HDL cholesterol;
SARC	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg14926445	chr8:58193284	C8orf71	-0.42	-4.76	-0.3	3.45e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg07701084	chr6:150067640	NUP43	0.41	5.33	0.33	2.33e-7	Lung cancer;
SARC	cis	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg26116260	chr4:7069785	GRPEL1	-0.85	-9.1	-0.51	4.16e-17	Monocyte percentage of white cells;
SARC	cis	rs6963495	1.000	rs6963495	chr7:105166853	T/C	cg13798780	chr7:105162888	PUS7	0.57	4.84	0.3	2.33e-6	Bipolar disorder (body mass index interaction);
SARC	cis	rs2948294	0.545	rs11776397	chr8:8115161	C/T	cg08975724	chr8:8085496	FLJ10661	0.55	6.3	0.38	1.47e-9	Red cell distribution width;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg06053173	chr3:140696586	SLC25A36	-0.49	-6.3	-0.38	1.5e-9	Gallstone disease;
SARC	cis	rs3808502	0.526	rs36048422	chr8:11417144	T/C	cg21775007	chr8:11205619	TDH	-0.44	-5.68	-0.35	4.03e-8	Neuroticism;
SARC	cis	rs3820928	0.845	rs10165767	chr2:227781863	G/A	cg05526886	chr2:227700861	RHBDD1	-0.55	-6.67	-0.4	1.79e-10	Pulmonary function;
SARC	cis	rs950776	0.745	rs36045869	chr15:78929498	C/T	cg06917634	chr15:78832804	PSMA4	0.66	8.38	0.48	4.93e-15	Sudden cardiac arrest;
SARC	cis	rs9902453	0.817	rs12051834	chr17:28192785	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	7.39	0.44	2.64e-12	Coffee consumption (cups per day);
SARC	cis	rs73198271	0.653	rs3827811	chr8:8659038	C/T	cg01851573	chr8:8652454	MFHAS1	0.33	4.95	0.31	1.43e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs7005606	1.000	rs73234136	chr8:32406382	T/C	cg14488905	chr8:32406789	NRG1	0.45	6.31	0.38	1.42e-9	Hirschsprung disease;
SARC	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg22903471	chr2:27725779	GCKR	-0.46	-6.78	-0.41	1.01e-10	Menopause (age at onset);
SARC	cis	rs7560272	0.538	rs1806683	chr2:73939812	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-6.15	-0.37	3.39e-9	Schizophrenia;
SARC	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg21433313	chr16:3507492	NAT15	0.35	5.07	0.32	8.21e-7	Tuberculosis;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg27134364	chr16:70380729	DDX19A	0.47	6.24	0.38	2.08e-9	Chemerin levels;
SARC	cis	rs2120243	0.539	rs6441126	chr3:157095016	C/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.4	4.95	0.31	1.41e-6	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs4595586	0.545	rs6580895	chr12:39372011	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-6.48	-0.39	5.42e-10	Morning vs. evening chronotype;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg14465769	chr3:197021243	DLG1	0.45	6.25	0.38	1.95e-9	Thyroid stimulating hormone;
SARC	cis	rs9818758	0.607	rs9311439	chr3:49310408	A/G	cg00383909	chr3:49044727	WDR6	0.72	6.24	0.38	2.04e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs7264396	0.580	rs2425181	chr20:34447709	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.55	5.28	0.33	3.03e-7	Total cholesterol levels;
SARC	cis	rs6690583	0.623	rs12037219	chr1:85505951	G/A	cg22488158	chr1:85528044	WDR63	0.66	5.3	0.33	2.62e-7	Serum sulfate level;
SARC	cis	rs35213789	0.919	rs13231497	chr7:69495934	A/G	cg10619644	chr7:69149951	AUTS2	0.41	5.09	0.32	7.26e-7	Childhood ear infection;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg07003673	chr12:123459818	ABCB9;OGFOD2	0.51	6.64	0.4	2.16e-10	Lung adenocarcinoma;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg03093398	chr4:76598524	G3BP2	0.76	6.36	0.38	1.05e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs752010	1.000	rs2077172	chr1:42093340	A/G	cg06885757	chr1:42089581	HIVEP3	0.34	5.48	0.34	1.11e-7	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg16479474	chr6:28041457	NA	0.36	5.45	0.34	1.25e-7	Parkinson's disease;
SARC	cis	rs6714710	0.603	rs78006955	chr2:98455510	G/C	cg26665480	chr2:98280029	ACTR1B	0.49	6.63	0.4	2.34e-10	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs7552404	0.924	rs7550974	chr1:76204185	A/G	cg03433033	chr1:76189801	ACADM	0.51	7.44	0.44	1.95e-12	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2180341	0.781	rs877102	chr6:127587086	T/C	cg24812749	chr6:127587940	RNF146	0.85	11.59	0.6	7.87e-25	Breast cancer;
SARC	cis	rs7520050	0.778	rs3014218	chr1:46026328	A/C	cg06784218	chr1:46089804	CCDC17	-0.28	-5.04	-0.31	9.54e-7	Red blood cell count;Reticulocyte count;
SARC	cis	rs7617773	0.779	rs11718329	chr3:48309828	C/G	cg11946769	chr3:48343235	NME6	0.69	9.12	0.51	3.54e-17	Coronary artery disease;
SARC	cis	rs3784262	0.631	rs4646625	chr15:58256296	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.35	-5.21	-0.32	4.06e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs9790314	0.765	rs4856768	chr3:161004392	G/A	cg04691961	chr3:161091175	C3orf57	-0.68	-9.34	-0.52	7.88e-18	Morning vs. evening chronotype;
SARC	cis	rs1167827	0.805	rs809439	chr7:75161318	T/A	cg09988129	chr7:74988866	PMS2L2;STAG3L1	-0.58	-7.15	-0.42	1.13e-11	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg00339695	chr16:24857497	SLC5A11	0.41	5.81	0.36	2.03e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg26354017	chr1:205819088	PM20D1	0.95	16.0	0.72	2.19e-39	Menarche (age at onset);
SARC	cis	rs5753618	0.561	rs4603880	chr22:31744721	T/C	cg13145458	chr22:31556086	RNF185	-0.49	-5.41	-0.33	1.57e-7	Colorectal cancer;
SARC	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg21171335	chr12:122356390	WDR66	0.41	6.49	0.39	5.21e-10	Mean corpuscular volume;
SARC	cis	rs7927771	1.000	rs4752797	chr11:47874364	C/T	cg05585544	chr11:47624801	NA	-0.35	-4.74	-0.3	3.8e-6	Subjective well-being;
SARC	cis	rs17376456	0.825	rs12153021	chr5:93073913	A/G	cg25358565	chr5:93447407	FAM172A	1.2	12.05	0.62	2.67e-26	Diabetic retinopathy;
SARC	cis	rs6831352	0.879	rs29001196	chr4:100054116	C/T	cg12011299	chr4:100065546	ADH4	-0.34	-5.74	-0.35	2.95e-8	Alcohol dependence;
SARC	cis	rs6120849	0.901	rs6058194	chr20:33739831	G/A	cg24642439	chr20:33292090	TP53INP2	0.51	5.11	0.32	6.77e-7	Protein C levels;
SARC	cis	rs7605378	0.752	rs769960	chr2:200710706	G/T	cg17644776	chr2:200775616	C2orf69	-0.53	-6.61	-0.4	2.61e-10	Osteoporosis;
SARC	cis	rs9309473	0.898	rs6546852	chr2:73833431	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-5.4	-0.33	1.64e-7	Metabolite levels;
SARC	cis	rs74781061	0.585	rs1866114	chr15:74733806	G/C	cg09165964	chr15:75287851	SCAMP5	-0.62	-4.86	-0.3	2.13e-6	Endometriosis;
SARC	cis	rs3858526	0.920	rs11039698	chr11:5950907	C/T	cg13902645	chr11:5959945	NA	-0.45	-5.2	-0.32	4.44e-7	DNA methylation (variation);
SARC	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg16606324	chr3:10149918	C3orf24	0.49	4.82	0.3	2.56e-6	Alzheimer's disease;
SARC	cis	rs3796352	1.000	rs71301814	chr3:53117663	G/A	cg07884673	chr3:53033167	SFMBT1	0.78	4.94	0.31	1.47e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs921968	0.541	rs636723	chr2:219373197	A/G	cg02176678	chr2:219576539	TTLL4	0.46	7.12	0.42	1.33e-11	Mean corpuscular hemoglobin concentration;
SARC	cis	rs2153535	0.580	rs1414344	chr6:8471365	C/A	cg07606381	chr6:8435919	SLC35B3	0.77	11.16	0.59	1.85e-23	Motion sickness;
SARC	cis	rs9790314	0.586	rs67077657	chr3:161138521	A/G	cg17135325	chr3:160939158	NMD3	0.52	6.42	0.39	7.76e-10	Morning vs. evening chronotype;
SARC	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg12310025	chr6:25882481	NA	0.52	6.75	0.4	1.16e-10	Blood metabolite levels;
SARC	cis	rs2304069	0.909	rs2544931	chr5:149367837	C/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	-0.69	-6.42	-0.39	7.36e-10	HIV-1 control;
SARC	cis	rs7552404	0.731	rs2029683	chr1:76341643	T/G	cg03433033	chr1:76189801	ACADM	-0.43	-5.44	-0.34	1.34e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs763121	0.853	rs2076028	chr22:39150450	G/A	cg21395723	chr22:39101663	GTPBP1	0.54	6.15	0.37	3.29e-9	Menopause (age at onset);
SARC	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs853679	1.000	rs1679732	chr6:28221264	G/A	cg26450541	chr6:28235208	ZNF187	-0.6	-4.79	-0.3	2.95e-6	Depression;
SARC	cis	rs35213789	0.722	rs2533456	chr7:69056780	A/C	cg10619644	chr7:69149951	AUTS2	-0.41	-5.35	-0.33	2.08e-7	Childhood ear infection;
SARC	cis	rs3087591	0.960	rs11868459	chr17:29458197	C/T	cg24425628	chr17:29625626	OMG;NF1	0.56	7.13	0.42	1.25e-11	Hip circumference;
SARC	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	9.01	0.51	7.74e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg19346786	chr7:2764209	NA	-0.33	-4.91	-0.31	1.74e-6	Height;
SARC	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg05872129	chr22:39784769	NA	-0.43	-5.88	-0.36	1.45e-8	Intelligence (multi-trait analysis);
SARC	cis	rs28374715	0.532	rs11070328	chr15:41651569	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.19	-20.1	-0.8	8.77e-53	Ulcerative colitis;
SARC	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg10374962	chr7:1011985	COX19	-0.45	-5.15	-0.32	5.46e-7	Bronchopulmonary dysplasia;
SARC	cis	rs2304069	1.000	rs2304069	chr5:149406733	G/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.68	6.89	0.41	5.12e-11	HIV-1 control;
SARC	cis	rs72634258	0.554	rs13306061	chr1:7913445	C/T	cg00042356	chr1:8021962	PARK7	0.65	5.37	0.33	1.86e-7	Inflammatory bowel disease;
SARC	cis	rs7635838	0.684	rs346079	chr3:11328139	G/A	cg00170343	chr3:11313890	ATG7	0.64	8.83	0.5	2.59e-16	HDL cholesterol;
SARC	cis	rs72781680	0.950	rs72796343	chr2:24147631	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	8.7	0.5	6.18e-16	Lymphocyte counts;
SARC	cis	rs1008375	0.966	rs10939758	chr4:17698255	C/T	cg27347728	chr4:17578864	LAP3	0.44	5.65	0.35	4.72e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs240764	0.697	rs846799	chr6:101270345	A/G	cg09795085	chr6:101329169	ASCC3	0.43	5.45	0.34	1.26e-7	Neuroticism;
SARC	cis	rs7587476	0.784	rs62202001	chr2:215690359	C/G	cg04530015	chr2:215796436	ABCA12	-0.41	-6.7	-0.4	1.56e-10	Neuroblastoma;
SARC	cis	rs9906944	0.933	rs4794018	chr17:47093398	T/C	cg16584676	chr17:46985605	UBE2Z	-0.44	-5.31	-0.33	2.5e-7	Intelligence (multi-trait analysis);Body fat percentage;
SARC	cis	rs3815700	1.000	rs3815700	chr19:33093252	T/C	cg02997394	chr19:33096574	ANKRD27	0.8	8.23	0.47	1.36e-14	Eosinophilic esophagitis;
SARC	cis	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg11266682	chr4:10021025	SLC2A9	0.41	7.27	0.43	5.51e-12	Bone mineral density;
SARC	cis	rs8062405	0.754	rs62034323	chr16:28536473	C/T	cg08761264	chr16:28874980	SH2B1	-0.43	-4.81	-0.3	2.7e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs8044995	0.501	rs7189887	chr16:68353915	C/T	cg05110241	chr16:68378359	PRMT7	-0.66	-5.97	-0.36	8.59e-9	Schizophrenia;
SARC	cis	rs2153535	0.623	rs2152346	chr6:8454652	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	8.29	0.48	8.89e-15	Motion sickness;
SARC	trans	rs877282	0.898	rs11253341	chr10:765008	G/C	cg22713356	chr15:30763199	NA	1.04	10.06	0.55	5.37e-20	Uric acid levels;
SARC	cis	rs9814567	0.929	rs1863912	chr3:134205227	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-6.89	-0.41	5.19e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs17345786	1.000	rs997739	chr3:101313940	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.49	5.46	0.34	1.21e-7	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2380220	0.872	rs66723559	chr6:95956338	T/C	cg04719120	chr6:96025338	MANEA	-0.64	-6.4	-0.39	8.45e-10	Behavioural disinhibition (generation interaction);
SARC	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg01341218	chr17:43662625	NA	-0.85	-9.46	-0.53	3.62e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9815354	0.812	rs73073337	chr3:41837497	T/C	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg18876405	chr7:65276391	NA	-0.72	-9.19	-0.52	2.26e-17	Aortic root size;
SARC	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg12648201	chr2:27665141	KRTCAP3	-0.32	-4.91	-0.31	1.74e-6	Total body bone mineral density;
SARC	cis	rs3106136	0.967	rs11097411	chr4:95222626	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.4	-6.14	-0.37	3.53e-9	Capecitabine sensitivity;
SARC	cis	rs7000551	0.560	rs4872483	chr8:22255684	C/T	cg12081754	chr8:22256438	SLC39A14	0.73	10.17	0.55	2.5e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs8077889	0.672	rs1230400	chr17:41845451	G/A	cg26893861	chr17:41843967	DUSP3	-1.0	-16.19	-0.73	5.19e-40	Triglycerides;
SARC	cis	rs36051895	0.664	rs3780373	chr9:5098223	T/C	cg02405213	chr9:5042618	JAK2	-0.44	-5.5	-0.34	1.02e-7	Pediatric autoimmune diseases;
SARC	cis	rs9303542	0.527	rs62066689	chr17:46609092	T/C	cg04904318	chr17:46607828	HOXB1	-0.43	-4.76	-0.3	3.45e-6	Ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs36051895	0.659	rs10974938	chr9:5056037	A/G	cg02405213	chr9:5042618	JAK2	-0.55	-5.84	-0.36	1.72e-8	Pediatric autoimmune diseases;
SARC	cis	rs4481887	0.597	rs2185358	chr1:248585259	T/A	cg00666640	chr1:248458726	OR2T12	0.3	4.9	0.31	1.82e-6	Common traits (Other);
SARC	cis	rs9435341	0.896	rs1730851	chr1:107596443	A/G	cg09367891	chr1:107599246	PRMT6	-0.72	-8.72	-0.5	5.26e-16	Facial morphology (factor 21, depth of nasal alae);
SARC	cis	rs2952156	0.959	rs1565922	chr17:37831035	A/G	cg00129232	chr17:37814104	STARD3	-0.69	-9.57	-0.53	1.67e-18	Asthma;
SARC	cis	rs3859192	0.599	rs2270401	chr17:38176256	A/T	cg17467752	chr17:38218738	THRA	-0.38	-4.79	-0.3	2.94e-6	White blood cell count;
SARC	cis	rs2034088	0.965	rs4968070	chr17:446162	A/G	cg06217071	chr17:408420	NA	0.44	7.25	0.43	6e-12	Hip circumference adjusted for BMI;
SARC	cis	rs11792861	0.926	rs12683988	chr9:111867290	T/C	cg13535736	chr9:111863775	C9orf5	-0.4	-4.89	-0.31	1.87e-6	Menarche (age at onset);
SARC	cis	rs9916302	0.904	rs9904334	chr17:37468336	G/A	cg00129232	chr17:37814104	STARD3	0.59	7.27	0.43	5.32e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs4555082	0.645	rs2816605	chr14:105715515	C/T	cg13114125	chr14:105738426	BRF1	-0.83	-12.21	-0.62	7.84e-27	Mean platelet volume;Platelet distribution width;
SARC	cis	rs7666738	0.822	rs13110418	chr4:99046963	G/A	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs72945132	0.882	rs72949081	chr11:70219070	A/G	cg00319359	chr11:70116639	PPFIA1	0.69	6.39	0.39	9.15e-10	Coronary artery disease;
SARC	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg13206674	chr6:150067644	NUP43	0.4	5.21	0.32	4.17e-7	Lung cancer;
SARC	cis	rs7772486	0.846	rs6908063	chr6:146403618	T/C	cg23711669	chr6:146136114	FBXO30	0.72	10.99	0.58	6.81e-23	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2120019	0.938	rs35911108	chr15:75322179	G/A	cg17294928	chr15:75287854	SCAMP5	-1.01	-15.27	-0.71	6.03e-37	Blood trace element (Zn levels);
SARC	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg20102877	chr2:27665638	KRTCAP3	0.36	4.94	0.31	1.49e-6	Total body bone mineral density;
SARC	trans	rs9951602	0.512	rs9946120	chr18:76654548	A/T	cg02800362	chr5:177631904	HNRNPAB	0.7	8.92	0.5	1.38e-16	Obesity-related traits;
SARC	cis	rs672059	1.000	rs672059	chr1:183162539	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.5	6.93	0.41	4.01e-11	Hypertriglyceridemia;
SARC	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg22974920	chr21:40686053	BRWD1	0.46	4.9	0.31	1.81e-6	Cognitive function;
SARC	cis	rs12079745	0.793	rs12092952	chr1:169389715	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.9	-5.72	-0.35	3.26e-8	QT interval;
SARC	cis	rs735396	1.000	rs1169306	chr12:121438311	C/T	cg15155738	chr12:121454335	C12orf43	0.5	6.05	0.37	5.81e-9	N-glycan levels;
SARC	cis	rs6714710	0.603	rs4311104	chr2:98424802	A/G	cg26665480	chr2:98280029	ACTR1B	0.51	6.84	0.41	6.93e-11	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.91	9.83	0.54	2.61e-19	Platelet count;
SARC	cis	rs6964587	0.869	rs10241720	chr7:91527367	G/T	cg17063962	chr7:91808500	NA	-0.91	-14.0	-0.68	9.98e-33	Breast cancer;
SARC	cis	rs5753618	0.509	rs5997902	chr22:31583007	A/G	cg07713946	chr22:31675144	LIMK2	-0.37	-5.21	-0.32	4.25e-7	Colorectal cancer;
SARC	cis	rs709400	0.628	rs4906321	chr14:103878882	C/T	cg12935359	chr14:103987150	CKB	-0.41	-5.94	-0.36	1.03e-8	Body mass index;
SARC	cis	rs6912958	0.781	rs9450738	chr6:88267314	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-6.8	-0.41	8.81e-11	Monocyte percentage of white cells;
SARC	cis	rs73635312	0.850	rs79833063	chr10:8942149	C/T	cg24467326	chr10:9646929	NA	0.56	4.88	0.3	1.95e-6	Basal cell carcinoma;
SARC	trans	rs1814175	0.645	rs866427	chr11:49923853	G/A	cg03929089	chr4:120376271	NA	-0.81	-11.69	-0.61	3.89e-25	Height;
SARC	cis	rs7617773	0.925	rs6442105	chr3:48182326	A/G	cg11946769	chr3:48343235	NME6	-0.53	-6.35	-0.38	1.11e-9	Coronary artery disease;
SARC	cis	rs5753037	0.564	rs131298	chr22:30180001	C/T	cg01021169	chr22:30184971	ASCC2	0.51	7.14	0.42	1.16e-11	Type 1 diabetes;
SARC	cis	rs372883	0.648	rs1003772	chr21:30736145	A/T	cg24692254	chr21:30365293	RNF160	0.64	8.2	0.47	1.66e-14	Pancreatic cancer;
SARC	cis	rs10911232	0.507	rs4651138	chr1:183001312	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.67	0.57	6.63e-22	Hypertriglyceridemia;
SARC	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg24675658	chr1:53192096	ZYG11B	0.59	8.28	0.48	9.42e-15	Monocyte count;
SARC	cis	rs7666738	0.830	rs7673385	chr4:99024922	T/G	cg05340658	chr4:99064831	C4orf37	0.64	8.6	0.49	1.18e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs11792861	0.926	rs76689835	chr9:111833792	G/A	cg13535736	chr9:111863775	C9orf5	-0.41	-5.11	-0.32	6.66e-7	Menarche (age at onset);
SARC	trans	rs6964833	0.935	rs7795282	chr7:74122857	A/G	cg07504079	chr7:72649617	NCF1B	-0.59	-6.44	-0.39	6.84e-10	Menarche (age at onset);
SARC	cis	rs3733585	0.699	rs4515163	chr4:9959603	C/T	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.55	-0.34	7.65e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs3857536	0.813	rs1029399	chr6:66952476	G/C	cg07460842	chr6:66804631	NA	-0.45	-5.07	-0.32	8.17e-7	Blood trace element (Cu levels);
SARC	cis	rs7617773	0.780	rs71323395	chr3:48374077	G/A	cg11946769	chr3:48343235	NME6	0.77	9.63	0.53	1.05e-18	Coronary artery disease;
SARC	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg12564285	chr5:131593104	PDLIM4	0.42	6.19	0.38	2.67e-9	Acylcarnitine levels;
SARC	trans	rs208520	0.909	rs9345809	chr6:67017543	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.82	8.32	0.48	7.56e-15	Exhaled nitric oxide output;
SARC	cis	rs7084402	0.967	rs1896243	chr10:60276291	C/T	cg07615347	chr10:60278583	BICC1	-0.59	-8.62	-0.49	1.01e-15	Refractive error;
SARC	cis	rs11155671	0.530	rs7768665	chr6:150208024	G/A	cg09699651	chr6:150184138	LRP11	0.51	6.55	0.39	3.7e-10	Testicular germ cell tumor;
SARC	trans	rs17685	0.587	rs1623759	chr7:75724679	A/T	cg19862616	chr7:65841803	NCRNA00174	0.63	7.83	0.46	1.68e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs16976116	0.951	rs8043029	chr15:55486011	C/G	cg11288833	chr15:55489084	RSL24D1	0.63	6.17	0.37	3.01e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7084402	0.870	rs4948525	chr10:60361270	G/A	cg07615347	chr10:60278583	BICC1	0.6	8.53	0.49	1.9e-15	Refractive error;
SARC	cis	rs1048238	0.506	rs56352596	chr1:16297592	G/A	cg21385522	chr1:16154831	NA	0.49	6.32	0.38	1.3e-9	Systolic blood pressure;
SARC	cis	rs6835098	0.692	rs6822683	chr4:174063974	G/A	cg08422745	chr4:174089978	GALNT7	-0.63	-7.9	-0.46	1.1e-13	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs6087990	1.000	rs2424900	chr20:31344342	G/C	cg13636640	chr20:31349939	DNMT3B	0.81	12.8	0.64	9.27e-29	Ulcerative colitis;
SARC	cis	rs7149337	0.805	rs7146561	chr14:51608889	C/G	cg23942311	chr14:51606299	NA	0.3	5.48	0.34	1.1e-7	Cancer;
SARC	cis	rs6733011	0.578	rs1878585	chr2:99501698	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-5.65	-0.35	4.63e-8	Bipolar disorder;
SARC	cis	rs66887589	0.616	rs11731675	chr4:120212514	T/C	cg09307838	chr4:120376055	NA	0.61	8.07	0.47	3.67e-14	Diastolic blood pressure;
SARC	cis	rs9381040	0.655	rs9394756	chr6:41016183	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-5.34	-0.33	2.18e-7	Alzheimer's disease (late onset);
SARC	cis	rs2120019	1.000	rs2415253	chr15:75375699	A/G	cg17294928	chr15:75287854	SCAMP5	-0.91	-13.41	-0.66	9.18e-31	Blood trace element (Zn levels);
SARC	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg05872129	chr22:39784769	NA	-0.43	-5.76	-0.35	2.58e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs2204008	0.591	rs11495396	chr12:38380182	C/T	cg26384229	chr12:38710491	ALG10B	0.87	12.69	0.64	2.17e-28	Bladder cancer;
SARC	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg04546413	chr19:29218101	NA	0.59	7.0	0.42	2.76e-11	Methadone dose in opioid dependence;
SARC	cis	rs6910061	1.000	rs10080950	chr6:11116467	T/G	cg27233058	chr6:11094804	LOC221710	0.58	5.66	0.35	4.42e-8	Diabetic kidney disease;
SARC	cis	rs10932679	0.901	rs72958213	chr2:217646523	C/T	cg05032264	chr2:217675019	NA	0.56	5.35	0.33	2.1e-7	Pulse pressure;
SARC	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg22920501	chr2:26401640	FAM59B	-0.55	-7.29	-0.43	4.79e-12	Gut microbiome composition (summer);
SARC	cis	rs4144743	1.000	rs67923812	chr17:45326151	T/G	cg18085866	chr17:45331354	ITGB3	-0.73	-7.41	-0.44	2.29e-12	Body mass index;
SARC	cis	rs72627509	0.857	rs56155140	chr4:57824451	G/A	cg26694713	chr4:57773883	REST	0.65	6.49	0.39	5.1e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs2644899	0.859	rs2545755	chr19:41293162	T/G	cg24958765	chr19:41283667	RAB4B	-0.57	-6.28	-0.38	1.67e-9	Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs12995491	0.731	rs13019346	chr2:88509321	A/G	cg04511125	chr2:88470314	THNSL2	-0.42	-6.45	-0.39	6.3e-10	Response to metformin (IC50);
SARC	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg11764359	chr7:65958608	NA	-0.69	-8.18	-0.47	1.88e-14	Aortic root size;
SARC	cis	rs2882667	0.858	rs11959851	chr5:138421405	C/G	cg04439458	chr5:138467593	SIL1	-0.28	-4.74	-0.3	3.7e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs1005277	0.522	rs9418276	chr10:37940116	G/T	cg25427524	chr10:38739819	LOC399744	-0.51	-7.66	-0.45	4.89e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs1348850	0.914	rs12616443	chr2:178315751	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.63	8.07	0.47	3.75e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg18404041	chr3:52824283	ITIH1	0.43	6.46	0.39	6.03e-10	Bipolar disorder;
SARC	cis	rs4862307	0.514	rs7696176	chr4:185014390	A/G	cg06737308	chr4:185021514	ENPP6	0.55	8.07	0.47	3.64e-14	Serum dimethylarginine levels (asymmetric/symetric ratio);
SARC	cis	rs12135062	0.687	rs6685614	chr1:3108517	C/T	cg21609526	chr1:3105151	PRDM16	0.31	5.33	0.33	2.31e-7	Migraine;
SARC	cis	rs9858542	0.953	rs1987628	chr3:49399259	G/A	cg03060546	chr3:49711283	APEH	-0.58	-7.24	-0.43	6.34e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10175719	chr10:28592238	NA	0.5	6.36	0.38	1.04e-9	Smoking initiation;
SARC	cis	rs1008375	0.863	rs2058336	chr4:17608299	T/C	cg27347728	chr4:17578864	LAP3	0.45	5.52	0.34	8.94e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs861020	0.771	rs629150	chr1:209998467	C/T	cg05527609	chr1:210001259	C1orf107	1.02	12.0	0.62	3.67e-26	Orofacial clefts;
SARC	cis	rs6912958	0.559	rs242267	chr6:88061837	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.88	-13.76	-0.67	6.15e-32	Monocyte percentage of white cells;
SARC	cis	rs7106204	0.534	rs78879754	chr11:24279312	G/A	ch.11.24196551F	chr11:24239977	NA	0.65	4.85	0.3	2.29e-6	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs10463316	0.832	rs246483	chr5:150731062	C/G	cg03212797	chr5:150827313	SLC36A1	-0.51	-6.29	-0.38	1.6e-9	Metabolite levels (Pyroglutamine);
SARC	cis	rs7264396	0.563	rs2425100	chr20:34310115	A/G	cg01084648	chr20:34329383	RBM39	0.56	4.93	0.31	1.57e-6	Total cholesterol levels;
SARC	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg18876405	chr7:65276391	NA	-0.74	-9.42	-0.53	4.63e-18	Aortic root size;
SARC	cis	rs10189230	0.868	rs1367242	chr2:222353441	A/G	cg14652038	chr2:222343519	EPHA4	0.45	6.05	0.37	5.72e-9	Urate levels in lean individuals;
SARC	cis	rs9473924	0.580	rs60100577	chr6:50816134	C/T	cg14470998	chr6:50812995	TFAP2B	0.66	6.02	0.37	6.73e-9	Body mass index;
SARC	cis	rs7681440	0.746	rs10001067	chr4:90818216	C/G	cg06632027	chr4:90757378	SNCA	0.39	5.39	0.33	1.72e-7	Dementia with Lewy bodies;
SARC	cis	rs9311474	0.598	rs1010554	chr3:52542919	T/C	cg07507251	chr3:52567010	NT5DC2	-0.32	-5.05	-0.31	8.87e-7	Electroencephalogram traits;
SARC	cis	rs4280164	0.551	rs2295300	chr14:24805117	C/T	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.51	-5.44	-0.34	1.32e-7	Parent of origin effect on language impairment (paternal);
SARC	cis	rs9457247	0.534	rs2345568	chr6:167381804	A/G	cg23791538	chr6:167370224	RNASET2	0.66	9.32	0.52	9.17e-18	Crohn's disease;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg15219262	chr22:18111629	ATP6V1E1	0.78	6.51	0.39	4.45e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7937682	0.924	rs495460	chr11:111504777	G/A	cg22437258	chr11:111473054	SIK2	0.74	10.3	0.56	9.9e-21	Primary sclerosing cholangitis;
SARC	cis	rs12824058	0.831	rs4759657	chr12:130815818	G/A	cg23887609	chr12:130822674	PIWIL1	0.36	5.07	0.32	8.17e-7	Menopause (age at onset);
SARC	cis	rs7552404	0.920	rs1612097	chr1:76218875	C/T	cg10523679	chr1:76189770	ACADM	0.44	5.92	0.36	1.16e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6448317	0.556	rs2602738	chr4:24901114	A/G	cg21108841	chr4:24914750	CCDC149	-0.5	-4.81	-0.3	2.76e-6	Heschl's gyrus morphology;
SARC	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg07234876	chr8:600039	NA	0.77	6.35	0.38	1.13e-9	IgG glycosylation;
SARC	cis	rs2295359	0.892	rs56920441	chr1:67652012	A/G	cg11235152	chr1:67600687	NA	0.5	7.09	0.42	1.6e-11	Psoriasis;
SARC	cis	rs7647973	0.626	rs9870858	chr3:49769071	C/T	cg06212747	chr3:49208901	KLHDC8B	0.55	5.53	0.34	8.7e-8	Menarche (age at onset);
SARC	cis	rs6942407	0.592	rs4728689	chr7:86851097	T/G	cg02420886	chr7:86849541	C7orf23	0.71	6.17	0.37	2.99e-9	Food allergy;
SARC	cis	rs9788682	1.000	rs12441354	chr15:78821016	G/A	cg06917634	chr15:78832804	PSMA4	-0.58	-6.62	-0.4	2.43e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs6834538	0.597	rs4834291	chr4:113482718	C/T	cg05193411	chr4:113558554	LARP7;C4orf21	0.39	4.79	0.3	2.94e-6	Free thyroxine concentration;
SARC	cis	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg00409905	chr10:38381863	ZNF37A	-0.55	-7.94	-0.46	8.52e-14	Extrinsic epigenetic age acceleration;
SARC	cis	rs7178572	0.962	rs12324627	chr15:77767539	A/G	cg22256960	chr15:77711686	NA	-0.56	-6.64	-0.4	2.2e-10	Type 2 diabetes;
SARC	cis	rs4481887	0.854	rs4534423	chr1:248474993	G/C	cg00666640	chr1:248458726	OR2T12	0.36	5.91	0.36	1.21e-8	Common traits (Other);
SARC	cis	rs7587476	0.906	rs16852750	chr2:215646683	A/G	cg11970703	chr2:215861251	ABCA12	-0.39	-5.78	-0.35	2.4e-8	Neuroblastoma;
SARC	cis	rs9290065	0.519	rs7613316	chr3:160674533	A/G	cg03342759	chr3:160939853	NMD3	-0.47	-5.67	-0.35	4.19e-8	Kawasaki disease;
SARC	cis	rs3126085	1.000	rs3126098	chr1:152311923	T/C	cg26876637	chr1:152193138	HRNR	-0.45	-4.79	-0.3	3e-6	Atopic dermatitis;
SARC	cis	rs2153535	0.563	rs1737584	chr6:8536742	C/T	cg23788917	chr6:8435910	SLC35B3	0.62	8.2	0.47	1.63e-14	Motion sickness;
SARC	cis	rs12479064	0.724	rs2305352	chr2:100015124	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.56	-6.47	-0.39	5.73e-10	Chronic sinus infection;
SARC	cis	rs6963495	0.818	rs73192143	chr7:105202415	A/G	cg13798780	chr7:105162888	PUS7	0.57	5.23	0.32	3.86e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs6732160	0.613	rs57208378	chr2:73389999	G/A	cg01422370	chr2:73384389	NA	0.38	5.81	0.36	2.03e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9341808	0.718	rs10080237	chr6:80854470	T/C	cg08355045	chr6:80787529	NA	0.35	5.58	0.34	6.55e-8	Sitting height ratio;
SARC	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg18252515	chr7:66147081	NA	0.53	5.6	0.34	5.91e-8	Aortic root size;
SARC	cis	rs1348850	0.554	rs7595576	chr2:178371921	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.69	6.26	0.38	1.81e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2439831	0.867	rs2255042	chr15:43834318	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.94	-9.05	-0.51	5.94e-17	Lung cancer in ever smokers;
SARC	cis	rs929354	0.772	rs3802117	chr7:156987000	C/T	cg05182265	chr7:156933206	UBE3C	-0.33	-5.02	-0.31	1.03e-6	Body mass index;
SARC	cis	rs4555082	1.000	rs4277291	chr14:105759009	A/G	cg10792982	chr14:105748885	BRF1	0.52	7.71	0.45	3.67e-13	Mean platelet volume;Platelet distribution width;
SARC	cis	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg12463550	chr7:65579703	CRCP	0.67	5.15	0.32	5.59e-7	Diabetic kidney disease;
SARC	cis	rs6570726	0.791	rs6918814	chr6:145906028	G/A	cg05347473	chr6:146136440	FBXO30	0.49	6.77	0.41	1.06e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11785400	1.000	rs6988393	chr8:143740596	A/G	cg10596483	chr8:143751796	JRK	0.64	8.65	0.49	8.4e-16	Schizophrenia;
SARC	cis	rs4713118	0.824	rs9366702	chr6:27734470	T/C	cg17221315	chr6:27791827	HIST1H4J	0.49	5.39	0.33	1.74e-7	Parkinson's disease;
SARC	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg27266027	chr21:40555129	PSMG1	0.5	5.0	0.31	1.12e-6	Cognitive function;
SARC	cis	rs28530618	0.580	rs4607010	chr20:31255271	G/C	cg13636640	chr20:31349939	DNMT3B	-0.46	-5.1	-0.32	6.92e-7	Birth weight;
SARC	cis	rs854765	0.547	rs4072739	chr17:17884660	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.68	9.72	0.54	5.9e-19	Total body bone mineral density;
SARC	cis	rs709400	1.000	rs709400	chr14:104149475	A/G	cg26031613	chr14:104095156	KLC1	0.97	17.59	0.76	1.24e-44	Body mass index;
SARC	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg18404041	chr3:52824283	ITIH1	-0.37	-5.49	-0.34	1.04e-7	Bipolar disorder;
SARC	cis	rs372883	0.530	rs55921835	chr21:30544623	A/G	cg24692254	chr21:30365293	RNF160	-0.39	-4.83	-0.3	2.46e-6	Pancreatic cancer;
SARC	cis	rs3126085	0.935	rs4845431	chr1:152227977	A/G	cg03465714	chr1:152285911	FLG	-0.44	-5.16	-0.32	5.29e-7	Atopic dermatitis;
SARC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg11905131	chr22:24372483	LOC391322	0.51	5.57	0.34	7.08e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg19223190	chr17:80058835	NA	-0.44	-6.04	-0.37	6.02e-9	Life satisfaction;
SARC	cis	rs1949733	1.000	rs1357481	chr4:8496221	A/T	cg13073564	chr4:8508604	NA	-0.47	-7.79	-0.45	2.2e-13	Response to antineoplastic agents;
SARC	cis	rs9399135	0.967	rs9376075	chr6:135296963	A/G	cg24558204	chr6:135376177	HBS1L	0.44	5.98	0.36	8.5e-9	Red blood cell count;
SARC	cis	rs6665290	0.901	rs3795453	chr1:227205331	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.05	-22.88	-0.83	1.65e-61	Myeloid white cell count;
SARC	cis	rs1185460	0.967	rs1168568	chr11:118949799	G/A	cg23280166	chr11:118938394	VPS11	0.81	11.65	0.61	5.06e-25	Coronary artery disease;
SARC	cis	rs112591243	0.685	rs78443123	chr21:47953331	G/T	cg10657630	chr21:48055338	PRMT2	0.78	4.89	0.31	1.86e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs2549003	1.000	rs2070731	chr5:131819798	T/C	cg21138405	chr5:131827807	IRF1	0.27	5.29	0.33	2.8e-7	Asthma (sex interaction);
SARC	cis	rs2180341	1.000	rs6937287	chr6:127645719	T/A	cg17762328	chr6:126965162	NA	-0.45	-5.06	-0.31	8.34e-7	Breast cancer;
SARC	cis	rs721399	0.752	rs1495743	chr8:18273300	C/G	cg18736775	chr8:18248649	NAT2	0.42	5.12	0.32	6.25e-7	Blood metabolite levels;
SARC	cis	rs2439831	0.867	rs2264876	chr15:43757419	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.05	10.98	0.58	7.25e-23	Lung cancer in ever smokers;
SARC	cis	rs17376456	0.877	rs13165147	chr5:93422214	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.71	0.35	3.39e-8	Diabetic retinopathy;
SARC	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg11987759	chr7:65425863	GUSB	0.57	7.52	0.44	1.18e-12	Aortic root size;
SARC	cis	rs73242632	0.881	rs7699276	chr4:57923557	G/C	cg20415529	chr4:57845134	POLR2B;C4orf14	0.88	5.31	0.33	2.5e-7	Congenital heart disease (maternal effect);
SARC	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg18252515	chr7:66147081	NA	-1.29	-10.95	-0.58	8.61e-23	Diabetic kidney disease;
SARC	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg20573242	chr4:122745356	CCNA2	0.68	8.67	0.49	7.41e-16	Type 2 diabetes;
SARC	cis	rs9902453	0.868	rs8066731	chr17:28523121	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	6.8	0.41	8.66e-11	Coffee consumption (cups per day);
SARC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg06873352	chr17:61820015	STRADA	0.53	6.88	0.41	5.32e-11	Prudent dietary pattern;
SARC	cis	rs8031584	0.958	rs1043742	chr15:31232581	A/C	cg19680485	chr15:31195859	MTMR15	-0.52	-5.94	-0.36	1e-8	Huntington's disease progression;
SARC	cis	rs2486288	0.656	rs9920290	chr15:45548035	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.45	-5.55	-0.34	7.66e-8	Glomerular filtration rate;
SARC	cis	rs9296092	0.521	rs9461886	chr6:33526770	T/C	cg13560919	chr6:33536144	NA	-0.52	-6.41	-0.39	8.07e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs35110281	0.667	rs7282122	chr21:45082365	G/A	cg21573476	chr21:45109991	RRP1B	-0.55	-7.8	-0.46	2.06e-13	Mean corpuscular volume;
SARC	cis	rs11155671	0.546	rs1999633	chr6:150187712	C/T	cg09699651	chr6:150184138	LRP11	0.54	5.78	0.35	2.39e-8	Testicular germ cell tumor;
SARC	cis	rs1707322	0.752	rs28507722	chr1:46206540	A/G	cg03146154	chr1:46216737	IPP	0.52	6.29	0.38	1.56e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs561341	1.000	rs15654	chr17:30326360	A/C	cg00745463	chr17:30367425	LRRC37B	-0.69	-5.53	-0.34	8.77e-8	Hip circumference adjusted for BMI;
SARC	cis	rs4243830	0.677	rs1556035	chr1:6579607	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.87	-8.13	-0.47	2.53e-14	Body mass index;
SARC	cis	rs8072100	0.713	rs2136750	chr17:45456100	A/G	cg08085267	chr17:45401833	C17orf57	-0.42	-4.86	-0.3	2.16e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs7766436	0.583	rs7757926	chr6:22561611	C/A	cg13666174	chr6:22585274	NA	-0.56	-5.86	-0.36	1.59e-8	Coronary artery disease;
SARC	trans	rs1814175	0.619	rs847644	chr11:49918418	G/A	cg03929089	chr4:120376271	NA	-0.81	-11.69	-0.61	3.89e-25	Height;
SARC	cis	rs6565681	0.943	rs6565683	chr17:78362300	A/T	cg15383979	chr17:78362278	RNF213;LOC100294362	-0.57	-4.75	-0.3	3.6e-6	Moyamoya disease;
SARC	cis	rs2075371	0.637	rs2544165	chr7:133920443	A/G	cg20476274	chr7:133979776	SLC35B4	-0.53	-7.12	-0.42	1.3e-11	Mean platelet volume;
SARC	cis	rs67311347	1.000	rs28434528	chr3:40484893	A/G	cg24209194	chr3:40518798	ZNF619	0.61	7.88	0.46	1.24e-13	Renal cell carcinoma;
SARC	cis	rs13191362	0.935	rs35537826	chr6:163145867	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.59	5.19	0.32	4.59e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs4713118	0.868	rs7756968	chr6:27734954	C/G	cg17221315	chr6:27791827	HIST1H4J	0.56	5.75	0.35	2.84e-8	Parkinson's disease;
SARC	cis	rs8031584	0.958	rs11293	chr15:31234981	G/A	cg14829155	chr15:31115871	NA	-0.42	-5.22	-0.32	3.89e-7	Huntington's disease progression;
SARC	cis	rs6991838	0.584	rs6472218	chr8:66547737	G/C	cg13398993	chr8:66546079	ARMC1	0.62	8.25	0.48	1.21e-14	Intelligence (multi-trait analysis);
SARC	cis	rs834603	0.546	rs1704973	chr7:47483705	T/C	cg23694490	chr7:47445681	TNS3	-0.32	-5.69	-0.35	3.78e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs72781680	0.948	rs72796385	chr2:24170360	T/A	cg06627628	chr2:24431161	ITSN2	-0.7	-6.69	-0.4	1.64e-10	Lymphocyte counts;
SARC	cis	rs7020830	0.830	rs13296413	chr9:37258105	C/T	cg14294708	chr9:37120828	ZCCHC7	1.1	18.95	0.78	4.26e-49	Schizophrenia;
SARC	cis	rs3733585	0.563	rs881971	chr4:9930962	A/G	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.73	-0.35	3.08e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg10523679	chr1:76189770	ACADM	0.44	5.32	0.33	2.43e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7027203	0.576	rs7848045	chr9:96551824	G/A	cg14598338	chr9:96623480	NA	0.35	4.83	0.3	2.45e-6	DNA methylation (variation);
SARC	cis	rs9291683	0.530	rs35908990	chr4:9976105	G/A	cg00071950	chr4:10020882	SLC2A9	0.4	6.37	0.39	9.82e-10	Bone mineral density;
SARC	cis	rs76419734	1.000	rs72671866	chr4:106657658	T/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.84	5.41	0.33	1.59e-7	Post bronchodilator FEV1;
SARC	cis	rs10504229	0.679	rs4737454	chr8:58033965	A/T	cg11062466	chr8:58055876	NA	0.53	5.25	0.33	3.36e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg27266027	chr21:40555129	PSMG1	0.51	5.17	0.32	4.99e-7	Cognitive function;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg09883264	chr5:141489170	NDFIP1	-0.57	-6.52	-0.39	4.39e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.8	12.02	0.62	3.22e-26	Menarche (age at onset);
SARC	trans	rs9650657	0.589	rs6985109	chr8:10761585	A/G	cg06636001	chr8:8085503	FLJ10661	0.53	6.91	0.41	4.52e-11	Neuroticism;
SARC	cis	rs17376456	0.569	rs896729	chr5:93222178	A/G	cg21475434	chr5:93447410	FAM172A	-0.61	-6.1	-0.37	4.38e-9	Diabetic retinopathy;
SARC	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg08677398	chr8:58056175	NA	0.43	5.13	0.32	6.16e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1371867	0.555	rs2861348	chr8:101285074	A/G	cg11906718	chr8:101322791	RNF19A	0.66	8.78	0.5	3.67e-16	Atrioventricular conduction;
SARC	trans	rs9650657	0.836	rs6601523	chr8:10635141	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.94	-0.41	3.92e-11	Neuroticism;
SARC	cis	rs2276314	0.857	rs28435069	chr18:33628475	A/G	cg19628046	chr18:33552617	C18orf21	0.57	5.9	0.36	1.24e-8	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs870825	0.616	rs57086463	chr4:185639525	G/A	cg04058563	chr4:185651563	MLF1IP	0.79	11.24	0.59	1.03e-23	Blood protein levels;
SARC	cis	rs9596270	0.772	rs11842790	chr13:50924448	A/G	cg12964420	chr13:50975679	NA	-0.49	-6.28	-0.38	1.63e-9	Multiple sclerosis;
SARC	cis	rs11097912	0.632	rs17333732	chr4:107205009	C/T	cg09646026	chr4:107269030	AIMP1	-0.45	-4.86	-0.3	2.13e-6	Airflow obstruction;
SARC	cis	rs752010	0.714	rs2148635	chr1:42082452	C/T	cg06885757	chr1:42089581	HIVEP3	-0.4	-6.08	-0.37	4.83e-9	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs6570726	0.791	rs12205752	chr6:145896118	A/G	cg05347473	chr6:146136440	FBXO30	0.51	7.17	0.43	9.59e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2439831	0.764	rs2447193	chr15:43929733	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.93	8.34	0.48	6.57e-15	Lung cancer in ever smokers;
SARC	cis	rs76419734	1.000	rs72671815	chr4:106618219	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.8	4.9	0.31	1.8e-6	Post bronchodilator FEV1;
SARC	cis	rs7216064	1.000	rs6504542	chr17:65836642	T/C	cg12091567	chr17:66097778	LOC651250	-0.74	-8.17	-0.47	1.97e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs6582630	0.593	rs7299329	chr12:38447943	G/C	cg26384229	chr12:38710491	ALG10B	0.84	12.0	0.62	3.64e-26	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs3091242	0.967	rs3093614	chr1:25677844	T/A	cg23205692	chr1:25664452	TMEM50A	-0.45	-5.51	-0.34	9.39e-8	Erythrocyte sedimentation rate;
SARC	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg26335602	chr6:28129616	ZNF389	0.51	5.56	0.34	7.41e-8	Parkinson's disease;
SARC	cis	rs11628569	0.703	rs11626274	chr14:103125079	C/G	cg23071808	chr14:103021642	NA	0.42	4.77	0.3	3.19e-6	Immature fraction of reticulocytes;
SARC	cis	rs3766606	0.505	rs67002863	chr1:7923478	G/A	cg00042356	chr1:8021962	PARK7	0.63	5.32	0.33	2.46e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs4970966	0.904	rs12131809	chr1:150544640	C/T	cg13175981	chr1:150552382	MCL1	0.53	5.22	0.32	3.99e-7	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
SARC	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.44	5.41	0.33	1.53e-7	Electroencephalogram traits;
SARC	trans	rs8073060	0.505	rs225270	chr17:33968871	A/T	cg19694781	chr19:47549865	TMEM160	-0.68	-6.84	-0.41	7.09e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs9436747	0.641	rs11208677	chr1:66048417	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.48	4.97	0.31	1.29e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.3	-4.75	-0.3	3.51e-6	Total body bone mineral density;
SARC	cis	rs208520	0.955	rs12202599	chr6:67001573	A/G	cg07460842	chr6:66804631	NA	0.86	9.79	0.54	3.48e-19	Exhaled nitric oxide output;
SARC	cis	rs1401999	1.000	rs7632670	chr3:183713877	A/G	cg01324343	chr3:183735012	ABCC5	0.67	13.45	0.66	6.63e-31	Anterior chamber depth;
SARC	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg08219700	chr8:58056026	NA	0.5	5.18	0.32	4.76e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs9395865	0.520	rs6903708	chr6:53332940	A/G	cg00101986	chr1:25071756	CLIC4	-0.5	-6.31	-0.38	1.38e-9	Electroencephalographic traits in alcoholism;
SARC	cis	rs9902453	0.845	rs12452201	chr17:28214173	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	7.03	0.42	2.22e-11	Coffee consumption (cups per day);
SARC	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg25036284	chr2:26402008	FAM59B	0.49	5.95	0.36	1e-8	Gut microbiome composition (summer);
SARC	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-6.53	-0.39	4.14e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs698813	0.851	rs786413	chr2:44702758	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	5.58	0.34	6.49e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs950027	0.620	rs2467862	chr15:45643843	T/G	cg15395560	chr15:45543142	SLC28A2	-0.27	-5.2	-0.32	4.3e-7	Response to fenofibrate (adiponectin levels);
SARC	cis	rs11122272	0.735	rs2749707	chr1:231527316	C/T	cg06096015	chr1:231504339	EGLN1	0.39	5.83	0.36	1.88e-8	Hemoglobin concentration;
SARC	cis	rs17381785	0.586	rs1874205	chr4:14971155	T/C	cg12377275	chr4:15005593	CPEB2	0.78	10.66	0.57	7.09e-22	Urate levels in overweight individuals;
SARC	cis	rs950169	0.512	rs4374136	chr15:84645007	C/G	cg17507749	chr15:85114479	UBE2QP1	0.65	7.13	0.42	1.25e-11	Schizophrenia;
SARC	cis	rs12956009	0.583	rs9653016	chr18:44894189	G/A	cg15049968	chr18:44337910	ST8SIA5	-0.31	-4.72	-0.3	4.11e-6	Educational attainment (years of education);
SARC	cis	rs6696846	0.765	rs61822619	chr1:205090885	C/G	cg00857998	chr1:205179979	DSTYK	0.49	6.13	0.37	3.73e-9	Red blood cell count;
SARC	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg07343612	chr16:622815	PIGQ	-0.62	-8.71	-0.5	5.73e-16	Height;
SARC	cis	rs9581943	0.967	rs11618581	chr13:28476911	C/T	cg16302790	chr13:28498334	PDX1	0.53	7.84	0.46	1.59e-13	Pancreatic cancer;
SARC	cis	rs9457247	0.967	rs2769355	chr6:167380493	G/A	cg23791538	chr6:167370224	RNASET2	0.63	8.68	0.49	6.8e-16	Crohn's disease;
SARC	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg18404041	chr3:52824283	ITIH1	0.5	7.49	0.44	1.44e-12	Bipolar disorder;
SARC	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg22535103	chr8:58192502	C8orf71	-0.73	-7.31	-0.43	4.37e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg16414030	chr3:133502952	NA	-0.4	-5.4	-0.33	1.67e-7	Iron status biomarkers;
SARC	cis	rs12594515	1.000	rs6493167	chr15:45986809	G/A	cg14863074	chr15:45997064	NA	0.34	5.24	0.32	3.57e-7	Waist circumference;Weight;
SARC	trans	rs9329221	0.651	rs2975648	chr8:10135976	C/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.76	-0.4	1.08e-10	Neuroticism;
SARC	cis	rs367943	0.966	rs348924	chr5:112817930	T/G	cg12552261	chr5:112820674	MCC	-0.45	-5.21	-0.32	4.24e-7	Type 2 diabetes;
SARC	cis	rs1059312	0.808	rs4760537	chr12:129301299	C/A	cg09035930	chr12:129282057	SLC15A4	0.55	7.82	0.46	1.81e-13	Systemic lupus erythematosus;
SARC	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg05863683	chr7:1912471	MAD1L1	0.33	4.92	0.31	1.61e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs4975616	0.839	rs2447853	chr5:1333077	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.58	-8.61	-0.49	1.11e-15	Lung cancer;
SARC	cis	rs636291	0.517	rs12565133	chr1:10544988	A/C	cg17425144	chr1:10567563	PEX14	-0.41	-6.86	-0.41	6.14e-11	Prostate cancer;
SARC	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg16680214	chr1:154839983	KCNN3	-0.36	-5.72	-0.35	3.2e-8	Prostate cancer;
SARC	cis	rs10870270	1.000	rs7199	chr10:133769848	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.48	-5.41	-0.33	1.53e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg06558623	chr16:89946397	TCF25	0.93	7.0	0.42	2.69e-11	Skin colour saturation;
SARC	cis	rs17376456	1.000	rs17376207	chr5:93545524	C/T	cg25358565	chr5:93447407	FAM172A	-1.3	-14.61	-0.69	9.39e-35	Diabetic retinopathy;
SARC	cis	rs6456156	0.586	rs911632	chr6:167471461	T/C	cg23791538	chr6:167370224	RNASET2	-0.52	-6.81	-0.41	8.22e-11	Primary biliary cholangitis;
SARC	trans	rs2727020	0.729	rs7924782	chr11:49267249	A/G	cg15704280	chr7:45808275	SEPT13	-0.84	-13.2	-0.65	4.43e-30	Coronary artery disease;
SARC	cis	rs2463822	0.583	rs72919467	chr11:62040102	G/A	cg06239285	chr11:62104954	ASRGL1	-0.88	-8.09	-0.47	3.35e-14	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs7592578	0.639	rs61709084	chr2:191287685	A/C	cg25963032	chr2:191064776	C2orf88	-0.47	-5.54	-0.34	8.21e-8	Diastolic blood pressure;
SARC	cis	rs2839627	0.561	rs9808758	chr21:44262390	G/C	cg03543861	chr21:44258195	NA	0.46	5.04	0.31	9.49e-7	Information processing speed;
SARC	cis	rs7818345	0.967	rs4546679	chr8:19283335	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.42	5.61	0.34	5.84e-8	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs7084402	0.967	rs7097576	chr10:60277055	G/A	cg07615347	chr10:60278583	BICC1	-0.59	-8.54	-0.49	1.76e-15	Refractive error;
SARC	cis	rs56176327	0.532	rs9849038	chr3:49771990	A/G	cg06212747	chr3:49208901	KLHDC8B	0.55	5.53	0.34	8.7e-8	Intelligence (multi-trait analysis);
SARC	trans	rs561341	0.709	rs8068049	chr17:30183857	T/C	cg20587970	chr11:113659929	NA	1.05	9.02	0.51	7.06e-17	Hip circumference adjusted for BMI;
SARC	cis	rs4819052	0.679	rs2838859	chr21:46684517	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	6.48	0.39	5.36e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9309711	0.736	rs9678647	chr2:3497036	A/G	cg10845886	chr2:3471009	TTC15	0.49	5.58	0.34	6.64e-8	Neurofibrillary tangles;
SARC	trans	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg21659725	chr3:3221576	CRBN	-0.64	-6.3	-0.38	1.43e-9	Menarche (age at onset);
SARC	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg22535103	chr8:58192502	C8orf71	-0.6	-6.15	-0.37	3.42e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg11027127	chr17:29233864	C17orf42	-0.56	-6.34	-0.38	1.18e-9	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs734999	1.000	rs734999	chr1:2513216	C/T	cg18854424	chr1:2615690	NA	0.3	4.87	0.3	2.1e-6	Ulcerative colitis;
SARC	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-8.04	-0.47	4.4e-14	Chronic sinus infection;
SARC	cis	rs9843304	0.721	rs4681176	chr3:149201954	A/G	cg08667024	chr3:149219783	TM4SF4	-0.36	-5.35	-0.33	2.15e-7	Gallstone disease;
SARC	cis	rs2594989	0.831	rs7620624	chr3:11476270	C/G	cg00170343	chr3:11313890	ATG7	0.59	5.68	0.35	3.98e-8	Circulating chemerin levels;
SARC	cis	rs6540556	0.954	rs3753606	chr1:209937212	C/T	cg23920097	chr1:209922102	NA	0.51	6.18	0.38	2.87e-9	Red blood cell count;
SARC	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.93	-0.51	1.28e-16	Alzheimer's disease;
SARC	cis	rs12442242	0.522	rs16966212	chr15:38360289	T/C	cg19084031	chr15:38361362	NA	0.7	4.82	0.3	2.63e-6	Total body bone mineral density;
SARC	cis	rs2075371	0.796	rs12154724	chr7:133943443	G/A	cg11752832	chr7:134001865	SLC35B4	0.48	5.8	0.36	2.16e-8	Mean platelet volume;
SARC	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.44	5.49	0.34	1.06e-7	Tonsillectomy;
SARC	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg22903471	chr2:27725779	GCKR	-0.47	-6.89	-0.41	5.17e-11	Total body bone mineral density;
SARC	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg13395646	chr4:1353034	KIAA1530	-0.47	-5.46	-0.34	1.2e-7	Obesity-related traits;
SARC	cis	rs79976124	0.842	rs74881738	chr6:66621825	T/G	cg07460842	chr6:66804631	NA	0.63	6.95	0.41	3.69e-11	Type 2 diabetes;
SARC	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg09359103	chr1:154839909	KCNN3	-0.46	-7.83	-0.46	1.75e-13	Prostate cancer;
SARC	cis	rs13082711	1.000	rs34234262	chr3:27539188	G/A	cg02860705	chr3:27208620	NA	0.5	6.23	0.38	2.11e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs1008375	0.966	rs2159582	chr4:17695655	T/C	cg16339924	chr4:17578868	LAP3	0.51	6.54	0.39	3.87e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4566357	0.615	rs12328876	chr2:227918899	G/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.63	-0.35	5.2100000000000003e-08	Coronary artery disease;
SARC	cis	rs950776	0.518	rs62008174	chr15:78808947	C/T	cg22563815	chr15:78856949	CHRNA5	0.41	6.73	0.4	1.29e-10	Sudden cardiac arrest;
SARC	cis	rs1003719	0.715	rs2835658	chr21:38565201	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.3	-0.52	1.05e-17	Eye color traits;
SARC	cis	rs1003719	0.762	rs34273703	chr21:38475019	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.63	9.05	0.51	5.67e-17	Eye color traits;
SARC	cis	rs1008375	1.000	rs6449323	chr4:17683916	A/T	cg27347728	chr4:17578864	LAP3	0.49	5.95	0.36	9.58e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs362272	0.545	rs2236052	chr4:3318413	C/T	cg08741688	chr4:3415352	RGS12	0.41	5.31	0.33	2.56e-7	Serum sulfate level;
SARC	cis	rs1843834	0.539	rs1494109	chr2:225441833	G/A	cg22509189	chr2:225307070	NA	-0.66	-8.05	-0.47	4.12e-14	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs6448317	0.954	rs11946846	chr4:24922703	G/A	cg21108841	chr4:24914750	CCDC149	-0.56	-5.94	-0.36	1.02e-8	Heschl's gyrus morphology;
SARC	cis	rs11785400	1.000	rs6997670	chr8:143737915	G/A	cg24634471	chr8:143751801	JRK	0.68	9.17	0.52	2.5e-17	Schizophrenia;
SARC	cis	rs4742903	1.000	rs3818625	chr9:106856452	G/A	cg14250997	chr9:106856677	SMC2	0.52	6.86	0.41	6.13e-11	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs79146658	0.736	rs11884950	chr2:179746213	C/T	cg17765952	chr2:179737173	CCDC141	0.58	5.02	0.31	1.05e-6	Diastolic blood pressure;
SARC	cis	rs2688419	0.565	rs1094607	chr3:23062581	C/A	cg00327796	chr3:23032191	NA	-0.4	-5.7	-0.35	3.66e-8	Type 2 diabetes;
SARC	cis	rs7208859	0.623	rs11652358	chr17:29205480	T/C	cg13385521	chr17:29058706	SUZ12P	0.86	7.34	0.43	3.54e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9376098	0.698	rs7774081	chr6:135460999	A/G	cg03340261	chr6:135375900	HBS1L	-0.41	-5.1	-0.32	6.95e-7	Basophil percentage of granulocytes;Basophil percentage of white cells;White blood cell count (basophil);
SARC	cis	rs4427176	0.598	rs12542420	chr8:9451815	A/G	cg21625330	chr8:9911636	MSRA	-0.64	-5.03	-0.31	9.99e-7	Mosquito bite size;
SARC	cis	rs7931462	0.655	rs6483208	chr11:92705844	A/C	cg05662582	chr11:93517353	MED17	0.66	5.28	0.33	2.9e-7	DNA methylation (parent-of-origin);
SARC	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg22535103	chr8:58192502	C8orf71	-0.66	-5.66	-0.35	4.4e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7843479	0.601	rs2306645	chr8:21845428	C/T	cg17168535	chr8:21777572	XPO7	-0.78	-11.48	-0.6	1.86e-24	Mean corpuscular volume;
SARC	trans	rs9329221	1.000	rs9329221	chr8:10240202	G/T	cg06636001	chr8:8085503	FLJ10661	0.58	7.27	0.43	5.44e-12	Neuroticism;
SARC	cis	rs7927771	0.524	rs7124396	chr11:47787434	T/G	cg10504702	chr11:47789108	FNBP4	-0.43	-5.62	-0.35	5.45e-8	Subjective well-being;
SARC	cis	rs2120019	1.000	rs12903201	chr15:75370776	A/C	cg00629941	chr15:75287862	SCAMP5	-0.6	-7.27	-0.43	5.46e-12	Blood trace element (Zn levels);
SARC	cis	rs35110281	0.774	rs141521	chr21:44963686	G/A	cg21573476	chr21:45109991	RRP1B	-0.47	-6.86	-0.41	6.07e-11	Mean corpuscular volume;
SARC	cis	rs7927771	0.894	rs12798346	chr11:47583121	C/T	cg05585544	chr11:47624801	NA	-0.36	-4.85	-0.3	2.27e-6	Subjective well-being;
SARC	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg19223190	chr17:80058835	NA	0.44	6.19	0.38	2.67e-9	Life satisfaction;
SARC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.8	10.34	0.56	7.23e-21	Prudent dietary pattern;
SARC	cis	rs193541	0.632	rs246276	chr5:122239957	G/A	cg19412675	chr5:122181750	SNX24	0.49	6.21	0.38	2.4e-9	Glucose homeostasis traits;
SARC	cis	rs6430585	0.528	rs309158	chr2:136680534	A/G	cg07169764	chr2:136633963	MCM6	1.01	15.39	0.71	2.32e-37	Corneal structure;
SARC	cis	rs9916302	0.904	rs11867312	chr17:37597748	C/T	cg15445000	chr17:37608096	MED1	0.42	5.01	0.31	1.09e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg12463550	chr7:65579703	CRCP	0.67	5.06	0.31	8.43e-7	Diabetic kidney disease;
SARC	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg15847926	chr7:2749597	AMZ1	-0.29	-4.77	-0.3	3.22e-6	Height;
SARC	cis	rs995000	0.826	rs12023489	chr1:62923858	G/A	cg06896770	chr1:63153194	DOCK7	0.96	15.04	0.7	3.38e-36	Triglyceride levels;
SARC	cis	rs7666738	1.000	rs880471	chr4:98922541	C/T	cg05340658	chr4:99064831	C4orf37	0.55	6.93	0.41	4.1e-11	Colonoscopy-negative controls vs population controls;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg22411068	chr5:10442103	ROPN1L	-0.48	-6.43	-0.39	7.06e-10	Electrocardiographic conduction measures;
SARC	cis	rs2153535	0.580	rs7743995	chr6:8496212	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	7.3	0.43	4.43e-12	Motion sickness;
SARC	cis	rs1153858	1.000	rs4775895	chr15:45617957	T/A	cg21132104	chr15:45694354	SPATA5L1	0.81	11.21	0.59	1.27e-23	Homoarginine levels;
SARC	cis	rs711830	0.587	rs10188827	chr2:177007664	C/T	cg13092806	chr2:177043255	NA	0.57	5.96	0.36	9.43e-9	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
SARC	cis	rs11209002	0.614	rs7519768	chr1:67555522	C/T	cg02640540	chr1:67518911	SLC35D1	0.54	6.34	0.38	1.19e-9	Crohn's disease;
SARC	cis	rs1018836	0.770	rs13266461	chr8:91652817	T/C	cg16814680	chr8:91681699	NA	-0.96	-17.49	-0.75	2.58e-44	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs1003719	0.762	rs2835590	chr21:38463406	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.63	9.05	0.51	5.67e-17	Eye color traits;
SARC	cis	rs1059312	1.000	rs7136092	chr12:129280164	G/C	cg09035930	chr12:129282057	SLC15A4	0.61	8.74	0.5	4.7e-16	Systemic lupus erythematosus;
SARC	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg09455208	chr3:40491958	NA	0.38	5.51	0.34	9.28e-8	Renal cell carcinoma;
SARC	trans	rs7824557	0.564	rs2736301	chr8:11236413	C/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.0	-0.42	2.66e-11	Retinal vascular caliber;
SARC	cis	rs6121246	0.529	rs112367115	chr20:30178627	G/A	cg13852791	chr20:30311386	BCL2L1	0.63	4.89	0.31	1.84e-6	Mean corpuscular hemoglobin;
SARC	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg11764359	chr7:65958608	NA	0.86	12.33	0.63	3.29e-27	Aortic root size;
SARC	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg06618935	chr21:46677482	NA	-0.41	-5.39	-0.33	1.72e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2404602	0.536	rs7163946	chr15:76766049	C/G	cg22467129	chr15:76604101	ETFA	-0.37	-4.89	-0.31	1.87e-6	Blood metabolite levels;
SARC	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg05313129	chr8:58192883	C8orf71	-0.62	-6.34	-0.38	1.18e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10489202	0.909	rs61809580	chr1:168091602	A/C	cg17859187	chr1:168147929	TIPRL	0.51	5.3	0.33	2.69e-7	Schizophrenia;
SARC	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg08219700	chr8:58056026	NA	0.57	6.12	0.37	3.95e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs67311347	1.000	rs11716675	chr3:40485280	G/T	cg24209194	chr3:40518798	ZNF619	0.61	7.88	0.46	1.24e-13	Renal cell carcinoma;
SARC	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg10295955	chr4:187884368	NA	-1.05	-19.5	-0.79	7.42e-51	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg09263875	chr16:632152	PIGQ	0.52	7.98	0.46	6.75e-14	Height;
SARC	cis	rs8070128	0.583	rs7406982	chr17:17942613	C/T	cg05444541	chr17:17804740	TOM1L2	-0.3	-4.87	-0.3	2.1e-6	Total body bone mineral density;
SARC	trans	rs1814175	0.616	rs4881723	chr11:49788566	G/T	cg15704280	chr7:45808275	SEPT13	-0.88	-13.89	-0.67	2.29e-32	Height;
SARC	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg17971929	chr21:40555470	PSMG1	-0.59	-7.32	-0.43	4.08e-12	Menarche (age at onset);
SARC	cis	rs2070488	0.804	rs13100195	chr3:38482539	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	12.8	0.64	9.33e-29	Electrocardiographic conduction measures;
SARC	cis	rs2295359	1.000	rs10889664	chr1:67635475	C/T	cg08029281	chr1:67600428	NA	0.38	5.21	0.32	4.11e-7	Psoriasis;
SARC	cis	rs13064447	0.967	rs7644528	chr3:12767194	T/C	cg05775895	chr3:12838266	CAND2	0.37	4.78	0.3	3.08e-6	Major depression and alcohol dependence;
SARC	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg14829155	chr15:31115871	NA	-0.48	-6.26	-0.38	1.8e-9	Huntington's disease progression;
SARC	cis	rs9399135	0.967	rs9389251	chr6:135325717	A/G	cg24558204	chr6:135376177	HBS1L	0.45	6.11	0.37	4.1e-9	Red blood cell count;
SARC	cis	rs2439831	0.867	rs2447211	chr15:43936351	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	7.52	0.44	1.19e-12	Lung cancer in ever smokers;
SARC	cis	rs11673344	0.566	rs185369	chr19:37867039	T/C	cg14683738	chr19:37701593	ZNF585B	0.45	5.48	0.34	1.11e-7	Obesity-related traits;
SARC	cis	rs2327429	0.858	rs2209042	chr6:134188439	A/T	cg25632230	chr6:134101081	NA	-0.46	-5.5	-0.34	9.97e-8	Coronary artery disease;
SARC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg11965913	chr1:205819406	PM20D1	0.77	12.3	0.63	4.09e-27	Monocyte percentage of white cells;
SARC	cis	rs2439831	0.717	rs2447198	chr15:43895118	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	8.27	0.48	9.95e-15	Lung cancer in ever smokers;
SARC	cis	rs7772486	0.686	rs857882	chr6:145969716	T/G	cg05347473	chr6:146136440	FBXO30	-0.54	-7.43	-0.44	2.02e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9329289	1.000	rs9329289	chr10:2542389	A/G	cg15501526	chr10:2543763	NA	0.51	8.08	0.47	3.57e-14	Age-related hearing impairment;
SARC	cis	rs4595586	0.545	rs12814188	chr12:39380853	C/T	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	cis	rs7953249	0.722	rs2255531	chr12:121414915	G/A	cg15155738	chr12:121454335	C12orf43	0.44	5.56	0.34	7.19e-8	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs11098499	0.739	rs6534130	chr4:120131339	A/T	cg09307838	chr4:120376055	NA	-0.78	-10.41	-0.56	4.42e-21	Corneal astigmatism;
SARC	cis	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg18252515	chr7:66147081	NA	-1.3	-11.63	-0.61	5.98e-25	Diabetic kidney disease;
SARC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg09373136	chr17:61933544	TCAM1	-0.45	-6.19	-0.38	2.75e-9	Prudent dietary pattern;
SARC	trans	rs7824557	0.614	rs2736286	chr8:11227104	A/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.4	-0.44	2.52e-12	Retinal vascular caliber;
SARC	cis	rs8014204	0.836	rs7150254	chr14:75299101	G/A	cg06637938	chr14:75390232	RPS6KL1	0.69	10.1	0.55	4.11e-20	Caffeine consumption;
SARC	cis	rs6912958	0.712	rs6930600	chr6:88349787	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.54	-0.34	8.34e-8	Monocyte percentage of white cells;
SARC	cis	rs73242632	0.867	rs28545156	chr4:57879340	C/T	cg20415529	chr4:57845134	POLR2B;C4orf14	1.07	6.6	0.4	2.74e-10	Congenital heart disease (maternal effect);
SARC	cis	rs3087591	1.000	rs2525578	chr17:29711411	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.51	-6.29	-0.38	1.59e-9	Hip circumference;
SARC	cis	rs12973672	0.904	rs12974791	chr19:35767218	A/G	cg12095397	chr19:35769544	USF2	0.38	4.89	0.31	1.88e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs748404	0.578	rs4547312	chr15:43632138	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.42	5.34	0.33	2.23e-7	Lung cancer;
SARC	cis	rs36051895	0.695	rs10124627	chr9:5025746	T/G	cg02405213	chr9:5042618	JAK2	-0.5	-5.68	-0.35	4.03e-8	Pediatric autoimmune diseases;
SARC	cis	rs3820928	0.934	rs66959645	chr2:227761582	C/A	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.87	-0.36	1.47e-8	Pulmonary function;
SARC	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.48	5.97	0.36	8.97e-9	Tonsillectomy;
SARC	cis	rs17401966	0.965	rs12751375	chr1:10291874	C/G	cg15208524	chr1:10270712	KIF1B	0.59	6.72	0.4	1.38e-10	Hepatocellular carcinoma;
SARC	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg12667521	chr19:29218732	NA	0.4	5.4	0.33	1.61e-7	Methadone dose in opioid dependence;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg13425677	chr5:56112090	MAP3K1	-0.59	-6.71	-0.4	1.45e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs4713675	0.565	rs4713668	chr6:33690796	C/T	cg15676125	chr6:33679581	C6orf125	0.52	6.26	0.38	1.88e-9	Plateletcrit;
SARC	cis	rs7959452	0.535	rs7308481	chr12:69659299	A/G	cg14784868	chr12:69753453	YEATS4	0.41	5.46	0.34	1.2e-7	Blood protein levels;
SARC	cis	rs35110281	0.714	rs2282526	chr21:45080552	A/T	cg01579765	chr21:45077557	HSF2BP	-0.37	-6.04	-0.37	6.05e-9	Mean corpuscular volume;
SARC	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg22920501	chr2:26401640	FAM59B	0.6	7.86	0.46	1.38e-13	Gut microbiome composition (summer);
SARC	trans	rs61931739	0.534	rs4539411	chr12:34014807	T/C	cg13010199	chr12:38710504	ALG10B	0.65	8.77	0.5	3.82e-16	Morning vs. evening chronotype;
SARC	cis	rs7615952	0.611	rs7632305	chr3:125634767	C/T	cg05084668	chr3:125655381	ALG1L	-0.92	-8.62	-0.49	1.04e-15	Blood pressure (smoking interaction);
SARC	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg03806693	chr22:41940476	POLR3H	-0.93	-12.83	-0.64	7.61e-29	Vitiligo;
SARC	cis	rs6732160	0.809	rs13416592	chr2:73365056	C/T	cg01422370	chr2:73384389	NA	0.33	5.42	0.33	1.49e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2303745	0.589	rs1864116	chr19:17393015	C/T	cg22549504	chr19:17448937	GTPBP3	0.48	4.88	0.3	1.94e-6	Systemic lupus erythematosus;
SARC	cis	rs7216064	0.648	rs61676547	chr17:65892507	G/C	cg12091567	chr17:66097778	LOC651250	-0.75	-8.1	-0.47	3.1e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs10875746	0.859	rs3782910	chr12:48483507	T/C	cg26205652	chr12:48591994	NA	0.56	6.1	0.37	4.37e-9	Longevity (90 years and older);
SARC	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg05872129	chr22:39784769	NA	-0.45	-5.84	-0.36	1.71e-8	Intelligence (multi-trait analysis);
SARC	cis	rs865483	0.826	rs853198	chr17:35849342	A/C	cg06561646	chr17:35873369	DUSP14	-0.48	-6.41	-0.39	7.9e-10	Monocyte count;
SARC	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg19077165	chr18:44547161	KATNAL2	-0.52	-7.13	-0.42	1.26e-11	Personality dimensions;
SARC	cis	rs67460515	0.892	rs7610985	chr3:161062848	G/A	cg03342759	chr3:160939853	NMD3	-0.67	-8.54	-0.49	1.71e-15	Parkinson's disease;
SARC	cis	rs2120019	1.000	rs12898259	chr15:75369780	G/A	cg12414181	chr15:75287860	SCAMP5	-0.42	-4.89	-0.31	1.87e-6	Blood trace element (Zn levels);
SARC	cis	rs7424096	0.613	rs111805423	chr2:37248924	G/T	cg14987922	chr2:37194071	STRN	0.58	6.52	0.39	4.34e-10	High light scatter reticulocyte percentage of red cells;
SARC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.28	0.8	2.29e-53	Prudent dietary pattern;
SARC	cis	rs9300255	0.537	rs2695482	chr12:123623174	C/T	cg05973401	chr12:123451056	ABCB9	0.53	5.92	0.36	1.16e-8	Neutrophil percentage of white cells;
SARC	cis	rs73198271	0.603	rs571130	chr8:8593691	A/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-4.72	-0.3	4.07e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs6665290	0.904	rs6664955	chr1:227183434	T/C	cg14016676	chr1:227182615	CDC42BPA	0.36	5.18	0.32	4.73e-7	Myeloid white cell count;
SARC	cis	rs9612	0.948	rs12609056	chr19:44258702	G/T	cg07522664	chr19:44259120	C19orf61	0.44	5.09	0.32	7.3e-7	Exhaled nitric oxide output;
SARC	cis	rs2816062	0.813	rs2816051	chr1:18895460	A/G	cg18795169	chr1:18902165	NA	-0.78	-12.27	-0.63	4.82e-27	Urate levels in lean individuals;
SARC	cis	rs1784581	0.855	rs1893101	chr6:162384371	G/C	cg17173639	chr6:162384350	PARK2	-0.79	-11.12	-0.59	2.5e-23	Itch intensity from mosquito bite;
SARC	cis	rs4891159	0.790	rs1056714	chr18:74149526	A/G	cg24786174	chr18:74118243	ZNF516	-0.62	-9.24	-0.52	1.59e-17	Longevity;
SARC	cis	rs9790314	0.601	rs1450519	chr3:161094930	A/G	cg04691961	chr3:161091175	C3orf57	-0.55	-7.35	-0.43	3.23e-12	Morning vs. evening chronotype;
SARC	cis	rs56116382	0.604	rs9858428	chr3:49877585	G/T	cg06212747	chr3:49208901	KLHDC8B	-0.66	-5.01	-0.31	1.08e-6	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
SARC	cis	rs72945132	0.556	rs57172967	chr11:70160060	G/A	cg05964544	chr11:70165517	PPFIA1	-0.61	-5.87	-0.36	1.5e-8	Coronary artery disease;
SARC	cis	rs17401966	0.898	rs11582123	chr1:10303942	A/T	cg15208524	chr1:10270712	KIF1B	0.5	5.97	0.36	8.97e-9	Hepatocellular carcinoma;
SARC	cis	rs2832191	0.692	rs2776240	chr21:30310639	C/T	cg24692254	chr21:30365293	RNF160	1.01	17.99	0.76	5.85e-46	Dental caries;
SARC	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-8.06	-0.47	3.95e-14	Alzheimer's disease;
SARC	cis	rs7481584	0.624	rs449164	chr11:3053454	C/T	cg25174290	chr11:3078921	CARS	-0.58	-8.07	-0.47	3.68e-14	Calcium levels;
SARC	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.65	-6.91	-0.41	4.63e-11	Platelet count;
SARC	cis	rs3126085	0.935	rs2184951	chr1:152273168	T/G	cg26876637	chr1:152193138	HRNR	-0.49	-5.26	-0.33	3.23e-7	Atopic dermatitis;
SARC	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg18225595	chr11:63971243	STIP1	0.45	5.46	0.34	1.22e-7	Mean platelet volume;
SARC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg22105103	chr4:187893119	NA	0.51	6.91	0.41	4.69e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11098499	0.738	rs10026493	chr4:120384194	C/G	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	trans	rs1814175	0.645	rs10128563	chr11:50023681	T/C	cg03929089	chr4:120376271	NA	-0.82	-11.88	-0.61	9.03e-26	Height;
SARC	cis	rs12142240	0.698	rs41534051	chr1:46828734	A/G	cg10495392	chr1:46806563	NSUN4	0.6	6.36	0.38	1.08e-9	Menopause (age at onset);
SARC	trans	rs2727020	0.702	rs609054	chr11:49219725	C/G	cg03929089	chr4:120376271	NA	0.77	10.7	0.57	5.33e-22	Coronary artery disease;
SARC	cis	rs4595586	0.505	rs11615603	chr12:39409450	C/G	cg26384229	chr12:38710491	ALG10B	0.49	5.91	0.36	1.19e-8	Morning vs. evening chronotype;
SARC	trans	rs8073060	0.586	rs225305	chr17:33921160	C/T	cg19694781	chr19:47549865	TMEM160	-0.66	-6.5	-0.39	4.81e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg11890956	chr21:40555474	PSMG1	1.14	18.82	0.78	1.14e-48	Cognitive function;
SARC	cis	rs651907	0.535	rs13094753	chr3:101525082	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	5.84	0.36	1.72e-8	Colorectal cancer;
SARC	cis	rs2425143	1.000	rs117010355	chr20:34343442	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.69	5.74	0.35	2.91e-8	Blood protein levels;
SARC	cis	rs11583043	0.708	rs12754497	chr1:101571888	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.44	-5.02	-0.31	1.02e-6	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs1050631	0.592	rs1785900	chr18:33710170	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.57	6.88	0.41	5.59e-11	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs2735413	0.914	rs11150035	chr16:78066449	G/C	cg04733911	chr16:78082701	NA	-0.28	-4.96	-0.31	1.34e-6	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.74	0.54	4.92e-19	Prudent dietary pattern;
SARC	cis	rs1569175	1.000	rs17591301	chr2:200854215	A/G	cg23649088	chr2:200775458	C2orf69	-0.72	-5.11	-0.32	6.74e-7	Response to treatment for acute lymphoblastic leukemia;
SARC	cis	rs3820928	0.874	rs13403281	chr2:227880769	G/A	cg05526886	chr2:227700861	RHBDD1	-0.5	-6.05	-0.37	5.82e-9	Pulmonary function;
SARC	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg02725872	chr8:58115012	NA	-0.36	-6.12	-0.37	3.91e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6696239	0.513	rs1021553	chr1:227743987	G/T	cg26340147	chr1:227730820	NA	0.33	4.77	0.3	3.23e-6	Height;
SARC	cis	rs2594989	0.943	rs4365605	chr3:11452793	G/A	cg00170343	chr3:11313890	ATG7	0.62	6.02	0.37	6.86e-9	Circulating chemerin levels;
SARC	cis	rs2479724	0.935	rs2254936	chr6:41846569	A/G	cg17623882	chr6:41773611	USP49	-0.46	-5.71	-0.35	3.39e-8	Menarche (age at onset);
SARC	cis	rs6998277	0.830	rs6981007	chr8:103598257	G/C	cg10187029	chr8:103597600	NA	0.89	12.66	0.64	2.61e-28	Migraine;
SARC	trans	rs61931739	0.500	rs6488221	chr12:34525671	A/G	cg13010199	chr12:38710504	ALG10B	0.78	11.07	0.59	3.76e-23	Morning vs. evening chronotype;
SARC	cis	rs7766436	0.848	rs11759474	chr6:22580980	G/T	cg13666174	chr6:22585274	NA	-0.66	-8.53	-0.49	1.9e-15	Coronary artery disease;
SARC	cis	rs8078723	1.000	rs8070454	chr17:38160754	C/T	cg17467752	chr17:38218738	THRA	0.46	5.86	0.36	1.55e-8	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs832540	0.931	rs2662040	chr5:56246610	A/G	cg14703610	chr5:56206110	C5orf35	-0.53	-6.64	-0.4	2.22e-10	Coronary artery disease;
SARC	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg12463550	chr7:65579703	CRCP	-0.49	-5.34	-0.33	2.21e-7	Aortic root size;
SARC	trans	rs8073060	0.614	rs225275	chr17:33972567	G/C	cg19694781	chr19:47549865	TMEM160	-0.67	-6.82	-0.41	7.85e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs6908034	1.000	rs6908034	chr6:19773930	G/A	cg02682789	chr6:19804855	NA	0.55	5.35	0.33	2.14e-7	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	trans	rs1814175	0.669	rs10839315	chr11:49654406	G/A	cg03929089	chr4:120376271	NA	-0.71	-10.02	-0.55	6.96e-20	Height;
SARC	cis	rs8180040	0.966	rs6765990	chr3:47542894	G/A	cg27129171	chr3:47204927	SETD2	0.67	9.28	0.52	1.21e-17	Colorectal cancer;
SARC	cis	rs5753618	0.519	rs5997939	chr22:31677130	C/G	cg13145458	chr22:31556086	RNF185	0.47	5.01	0.31	1.06e-6	Colorectal cancer;
SARC	trans	rs61931739	0.517	rs11053224	chr12:34484919	G/A	cg13010199	chr12:38710504	ALG10B	0.8	11.1	0.59	2.94e-23	Morning vs. evening chronotype;
SARC	trans	rs12460587	0.587	rs10415150	chr19:52604625	C/G	cg01011614	chr20:44600351	ZNF335	0.49	6.35	0.38	1.12e-9	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
SARC	cis	rs1707322	0.686	rs11211179	chr1:46228082	A/C	cg06784218	chr1:46089804	CCDC17	0.4	6.99	0.42	2.84e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs739401	0.611	rs2239900	chr11:3030992	C/T	cg20651018	chr11:3035856	CARS	-0.46	-6.97	-0.42	3.3e-11	Longevity;
SARC	cis	rs288326	0.561	rs17265824	chr2:183711970	C/G	cg09997497	chr2:183902928	NCKAP1	0.69	4.81	0.3	2.67e-6	Blood protein levels;
SARC	cis	rs13082711	0.911	rs57992391	chr3:27511567	A/C	cg02860705	chr3:27208620	NA	0.4	5.29	0.33	2.79e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg12564285	chr5:131593104	PDLIM4	0.4	5.8	0.36	2.16e-8	Acylcarnitine levels;
SARC	cis	rs11608355	0.545	rs2302707	chr12:109893797	G/A	cg05360138	chr12:110035743	NA	0.92	9.61	0.53	1.27e-18	Neuroticism;
SARC	cis	rs4727027	0.933	rs9718383	chr7:148857624	A/T	cg23583168	chr7:148888333	NA	0.73	10.91	0.58	1.22e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs3540	0.512	rs8033595	chr15:91083353	G/A	cg22089800	chr15:90895588	ZNF774	-0.57	-7.12	-0.42	1.29e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg20007245	chr22:24372913	LOC391322	-0.62	-8.14	-0.47	2.4e-14	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs4711350	0.765	rs756139	chr6:33755541	G/A	cg18005901	chr6:33739558	LEMD2	-0.41	-4.76	-0.3	3.35e-6	Schizophrenia;
SARC	cis	rs35213789	0.535	rs2253711	chr7:69061698	G/C	cg10619644	chr7:69149951	AUTS2	-0.38	-4.83	-0.3	2.47e-6	Childhood ear infection;
SARC	cis	rs9467773	0.967	rs6941022	chr6:26553531	T/C	cg11502198	chr6:26597334	ABT1	0.5	6.09	0.37	4.53e-9	Intelligence (multi-trait analysis);
SARC	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg22920501	chr2:26401640	FAM59B	-0.55	-7.06	-0.42	1.92e-11	Gut microbiome composition (summer);
SARC	cis	rs748404	0.578	rs552701	chr15:43613810	T/C	cg08831455	chr15:43942014	CATSPER2	-0.4	-4.74	-0.3	3.79e-6	Lung cancer;
SARC	cis	rs2303759	0.670	rs45549132	chr19:49794028	G/T	cg24324837	chr19:49891574	CCDC155	0.41	4.86	0.3	2.11e-6	Multiple sclerosis;
SARC	cis	rs72945132	0.825	rs7941965	chr11:70213182	T/C	cg00319359	chr11:70116639	PPFIA1	0.68	6.33	0.38	1.23e-9	Coronary artery disease;
SARC	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg11301795	chr4:187892539	NA	-0.71	-10.15	-0.55	2.76e-20	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg18483322	chr2:97523826	ANKRD39	0.85	7.09	0.42	1.55e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs4699052	0.963	rs6816055	chr4:104143160	T/C	cg16532752	chr4:104119610	CENPE	-0.42	-5.01	-0.31	1.06e-6	Testicular germ cell tumor;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg26887302	chr17:27181995	ERAL1	-0.56	-6.47	-0.39	5.66e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs2929278	0.617	rs4617832	chr15:44030579	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	-0.45	-4.98	-0.31	1.25e-6	Schizophrenia;
SARC	cis	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg03060546	chr3:49711283	APEH	0.61	7.56	0.44	9.13e-13	Resting heart rate;
SARC	trans	rs2898290	0.622	rs13272061	chr8:11352261	G/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.29	-0.43	4.69e-12	Systolic blood pressure;
SARC	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg12463550	chr7:65579703	CRCP	-0.49	-5.3	-0.33	2.64e-7	Aortic root size;
SARC	cis	rs2204008	0.522	rs117743143	chr12:38030824	C/T	cg13010199	chr12:38710504	ALG10B	0.65	8.69	0.49	6.59e-16	Bladder cancer;
SARC	cis	rs2635047	0.934	rs11663321	chr18:44622704	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.58	7.84	0.46	1.66e-13	Educational attainment;
SARC	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg02891314	chr5:179741120	GFPT2	-0.5	-6.33	-0.38	1.27e-9	Height;
SARC	cis	rs2228479	0.850	rs3785281	chr16:89824263	G/C	cg26513180	chr16:89883248	FANCA	0.72	4.79	0.3	2.99e-6	Skin colour saturation;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg14831746	chr12:49961631	MCRS1	0.51	6.43	0.39	7.32e-10	Lung adenocarcinoma;
SARC	cis	rs918629	0.530	rs56156268	chr5:95240659	G/A	cg16656078	chr5:95278638	ELL2	-0.6	-7.07	-0.42	1.76e-11	IgG glycosylation;
SARC	trans	rs7819412	0.561	rs2001328	chr8:10987199	T/C	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.46	-0.39	5.91e-10	Triglycerides;
SARC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.3	-4.77	-0.3	3.24e-6	Total body bone mineral density;
SARC	cis	rs6831352	0.918	rs29001216	chr4:100051556	A/T	cg13256891	chr4:100009986	ADH5	-0.65	-8.11	-0.47	2.83e-14	Alcohol dependence;
SARC	cis	rs240764	0.658	rs10457077	chr6:101196767	C/T	cg09795085	chr6:101329169	ASCC3	-0.49	-6.42	-0.39	7.72e-10	Neuroticism;
SARC	cis	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg14541582	chr5:601475	NA	-0.4	-4.8	-0.3	2.85e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs2933343	0.951	rs789217	chr3:128593201	C/T	cg24203234	chr3:128598194	ACAD9	0.51	5.78	0.35	2.33e-8	IgG glycosylation;
SARC	cis	rs12421382	0.659	rs1371331	chr11:109382578	G/A	cg16359550	chr11:109292809	C11orf87	0.35	5.1	0.32	7.18e-7	Schizophrenia;
SARC	cis	rs2204008	0.774	rs2387811	chr12:38369794	C/A	cg26384229	chr12:38710491	ALG10B	0.91	13.42	0.66	8.57e-31	Bladder cancer;
SARC	cis	rs16870629	0.541	rs2334955	chr5:1062444	A/G	cg00278107	chr5:1061253	SLC12A7	-0.71	-9.72	-0.54	5.96e-19	QT interval;
SARC	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.58	-7.29	-0.43	4.93e-12	Personality dimensions;
SARC	cis	rs7223966	1.000	rs8078462	chr17:61857937	T/G	cg26338869	chr17:61819248	STRADA	0.49	5.22	0.32	3.92e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg11494091	chr17:61959527	GH2	0.54	8.07	0.47	3.81e-14	Prudent dietary pattern;
SARC	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg02018176	chr4:1364513	KIAA1530	-0.53	-7.69	-0.45	3.99e-13	Longevity;
SARC	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg03806693	chr22:41940476	POLR3H	0.87	11.46	0.6	2.15e-24	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs8078723	0.630	rs60137005	chr17:38129996	A/T	cg17467752	chr17:38218738	THRA	0.37	4.76	0.3	3.45e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs7829975	0.514	rs2945873	chr8:8260445	C/T	cg06636001	chr8:8085503	FLJ10661	0.64	8.03	0.47	4.69e-14	Mood instability;
SARC	cis	rs6835098	0.962	rs3733477	chr4:174090004	G/A	cg08422745	chr4:174089978	GALNT7	-0.76	-10.12	-0.55	3.42e-20	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs1395	1.000	rs1275538	chr2:27441397	C/T	cg21747090	chr2:27597821	SNX17	-0.4	-4.9	-0.31	1.78e-6	Blood metabolite levels;
SARC	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.55	-7.08	-0.42	1.64e-11	Mean platelet volume;
SARC	cis	rs9916302	0.904	rs4795357	chr17:37569551	T/C	cg20243544	chr17:37824526	PNMT	0.57	6.94	0.41	3.95e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs7615952	0.512	rs4679430	chr3:125357893	T/C	cg21696256	chr3:125484277	NA	-0.35	-5.05	-0.31	8.97e-7	Blood pressure (smoking interaction);
SARC	cis	rs546131	0.928	rs547504	chr11:34847225	G/T	cg06937548	chr11:34938143	PDHX;APIP	0.52	6.83	0.41	7.27e-11	Lung disease severity in cystic fibrosis;
SARC	cis	rs17376456	0.569	rs7713956	chr5:93133185	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.52	-5.31	-0.33	2.54e-7	Diabetic retinopathy;
SARC	cis	rs4319547	0.956	rs7397990	chr12:123119472	T/C	cg23029597	chr12:123009494	RSRC2	-0.43	-5.44	-0.34	1.33e-7	Body mass index;
SARC	cis	rs818427	0.896	rs9011	chr5:112212608	G/A	cg07820702	chr5:112228657	REEP5	0.46	5.18	0.32	4.87e-7	Total body bone mineral density;
SARC	cis	rs17345786	0.511	rs12639028	chr3:101346033	G/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	6.11	0.37	4.2e-9	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2120243	0.647	rs7632702	chr3:157145903	C/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.51	6.59	0.4	2.94e-10	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg24399712	chr22:39784796	NA	-0.45	-6.12	-0.37	4.01e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs79149102	0.579	rs12592477	chr15:75292699	C/T	cg00629941	chr15:75287862	SCAMP5	-0.67	-5.11	-0.32	6.66e-7	Lung cancer;
SARC	cis	rs2204008	0.604	rs11172718	chr12:38069819	T/C	cg26384229	chr12:38710491	ALG10B	0.86	12.39	0.63	2.06e-27	Bladder cancer;
SARC	cis	rs4742903	0.967	rs2274725	chr9:106864570	C/T	cg14250997	chr9:106856677	SMC2	0.53	7.08	0.42	1.68e-11	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs2832191	0.597	rs8127842	chr21:30516461	G/A	cg24692254	chr21:30365293	RNF160	-0.68	-8.07	-0.47	3.79e-14	Dental caries;
SARC	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg12463550	chr7:65579703	CRCP	0.54	5.74	0.35	2.97e-8	Aortic root size;
SARC	cis	rs7833986	1.000	rs34608229	chr8:57097017	T/C	cg26371346	chr8:56986568	SNORD54;RPS20	0.6	5.33	0.33	2.36e-7	Height;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg05489143	chr3:40498640	RPL14	-0.66	-7.7	-0.45	3.95e-13	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.79	11.96	0.62	5.2e-26	Personality dimensions;
SARC	cis	rs9948	1.000	rs2276654	chr2:97492479	G/A	cg01990225	chr2:97406019	LMAN2L	-0.9	-6.26	-0.38	1.81e-9	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs483180	0.512	rs598685	chr1:120215269	G/A	cg19096424	chr1:120255104	PHGDH	0.51	6.03	0.37	6.42e-9	Macular telangiectasia type 2;
SARC	cis	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg26850624	chr5:429559	AHRR	-0.31	-4.77	-0.3	3.21e-6	Cystic fibrosis severity;
SARC	cis	rs9747201	0.962	rs35051180	chr17:80135046	G/A	cg17462356	chr17:80056334	FASN	0.48	5.44	0.34	1.38e-7	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs1008375	1.000	rs28501187	chr4:17643620	G/A	cg02297831	chr4:17616191	MED28	0.5	6.49	0.39	5.05e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs3126085	0.935	rs10749669	chr1:152177289	A/C	cg09127314	chr1:152161683	NA	-0.4	-4.72	-0.3	4.11e-6	Atopic dermatitis;
SARC	cis	rs1559088	0.576	rs7251626	chr19:33578470	C/A	cg27124370	chr19:33622961	WDR88	0.5	6.73	0.4	1.29e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs2980439	0.557	rs2976876	chr8:8318850	T/C	cg08975724	chr8:8085496	FLJ10661	0.54	6.92	0.41	4.38e-11	Neuroticism;
SARC	cis	rs9303401	0.614	rs34900851	chr17:56566399	G/A	cg25039879	chr17:56429692	SUPT4H1	0.63	5.77	0.35	2.51e-8	Cognitive test performance;
SARC	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg18404041	chr3:52824283	ITIH1	-0.38	-5.72	-0.35	3.23e-8	Electroencephalogram traits;
SARC	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg11764359	chr7:65958608	NA	-0.75	-8.74	-0.5	4.7e-16	Aortic root size;
SARC	cis	rs10504229	0.679	rs12375445	chr8:58040082	A/G	cg21724239	chr8:58056113	NA	0.62	6.38	0.39	9.6e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs11724804	0.532	rs62295557	chr4:855708	G/A	cg16931447	chr4:875861	GAK	-0.53	-5.56	-0.34	7.51e-8	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
SARC	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg04518342	chr5:131593106	PDLIM4	0.37	5.27	0.33	3.18e-7	Breast cancer;
SARC	cis	rs9398803	0.671	rs1155939	chr6:126866133	C/A	cg19875578	chr6:126661172	C6orf173	0.64	8.82	0.5	2.71e-16	Male-pattern baldness;
SARC	cis	rs17376456	0.569	rs7736892	chr5:93205597	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.49	-4.92	-0.31	1.66e-6	Diabetic retinopathy;
SARC	cis	rs9329221	0.905	rs28507213	chr8:10250849	C/T	cg21775007	chr8:11205619	TDH	-0.39	-4.76	-0.3	3.43e-6	Neuroticism;
SARC	cis	rs3091242	1.000	rs646867	chr1:25709258	A/C	cg02931644	chr1:25747376	RHCE	0.47	7.89	0.46	1.2e-13	Erythrocyte sedimentation rate;
SARC	cis	rs6582630	0.539	rs4882324	chr12:38499180	T/C	cg26384229	chr12:38710491	ALG10B	-0.58	-7.35	-0.43	3.38e-12	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg22433210	chr17:43662623	NA	1.07	12.99	0.65	2.26e-29	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9393692	0.905	rs7761298	chr6:26278436	C/T	cg05868516	chr6:26286170	HIST1H4H	0.56	7.37	0.43	2.9e-12	Educational attainment;
SARC	cis	rs2806561	0.765	rs641808	chr1:23514123	T/G	cg12483005	chr1:23474871	LUZP1	0.45	5.9	0.36	1.29e-8	Height;
SARC	cis	rs9814567	1.000	rs9884031	chr3:134256500	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.1	-0.42	1.49e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs2652834	0.904	rs2729827	chr15:63360564	C/T	cg05507819	chr15:63340323	TPM1	0.59	6.06	0.37	5.4e-9	HDL cholesterol;
SARC	cis	rs9527	0.590	rs10883836	chr10:104891198	T/C	cg04362960	chr10:104952993	NT5C2	0.44	5.15	0.32	5.58e-7	Arsenic metabolism;
SARC	cis	rs10927875	0.541	rs761759	chr1:16342350	A/T	cg21385522	chr1:16154831	NA	0.55	6.64	0.4	2.24e-10	Dilated cardiomyopathy;
SARC	cis	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg22496380	chr5:211416	CCDC127	-0.86	-8.95	-0.51	1.15e-16	Breast cancer;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg23348158	chr19:50316579	FUZ	0.51	6.65	0.4	2.09e-10	Electrocardiographic conduction measures;
SARC	cis	rs1348850	0.914	rs4893938	chr2:178250095	T/C	cg23306229	chr2:178417860	TTC30B	0.57	6.8	0.41	8.58e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs897080	0.515	rs1067345	chr2:44618897	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.62	7.47	0.44	1.63e-12	Height;
SARC	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs28830936	0.510	rs12440605	chr15:42102285	A/G	cg17847044	chr15:42102381	MAPKBP1	0.49	7.82	0.46	1.8e-13	Diastolic blood pressure;
SARC	cis	rs9816226	0.591	rs78785910	chr3:185812634	G/A	cg00760338	chr3:185826511	ETV5	-0.82	-8.09	-0.47	3.21e-14	Obesity;Body mass index;
SARC	cis	rs6570726	0.935	rs367643	chr6:145859602	A/C	cg23711669	chr6:146136114	FBXO30	0.78	12.0	0.62	3.86e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg22920501	chr2:26401640	FAM59B	0.54	6.41	0.39	8.17e-10	Gut microbiome composition (summer);
SARC	cis	rs12432203	1.000	rs4566067	chr14:51729487	A/G	cg20256059	chr14:52103470	FRMD6	-0.62	-5.56	-0.34	7.49e-8	Cancer;
SARC	cis	rs2952156	0.920	rs903502	chr17:37829604	C/T	cg07936489	chr17:37558343	FBXL20	-0.43	-5.62	-0.35	5.49e-8	Asthma;
SARC	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg18876405	chr7:65276391	NA	-0.45	-5.34	-0.33	2.18e-7	Aortic root size;
SARC	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.48	-0.39	5.43e-10	Total body bone mineral density;
SARC	cis	rs17376456	0.825	rs10056879	chr5:93282218	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	5.65	0.35	4.61e-8	Diabetic retinopathy;
SARC	cis	rs644799	0.672	rs11021347	chr11:95653494	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.81	12.14	0.62	1.37e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7587476	0.906	rs17487792	chr2:215643500	A/G	cg04004882	chr2:215674386	BARD1	-0.59	-5.96	-0.36	9.46e-9	Neuroblastoma;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg14458328	chr5:41925210	FBXO4	0.53	6.42	0.39	7.52e-10	Breast cancer;
SARC	cis	rs11098499	0.779	rs80242894	chr4:120375752	G/A	cg09307838	chr4:120376055	NA	0.9	12.43	0.63	1.45e-27	Corneal astigmatism;
SARC	cis	rs149163995	1	rs149163995	chr2:203777226	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Migraine;
SARC	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.62	5.44	0.34	1.33e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs12971120	0.891	rs3764510	chr18:72166846	A/G	cg25817165	chr18:72167213	CNDP2	-0.54	-7.62	-0.45	6.2e-13	Refractive error;
SARC	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.33	0.38	1.22e-9	Height;
SARC	cis	rs9362426	1.000	rs9294377	chr6:88084839	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.4	4.93	0.31	1.53e-6	Depressive episodes in bipolar disorder;
SARC	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1348850	0.526	rs1345138	chr2:178387100	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.69	6.24	0.38	2.08e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs875971	0.545	rs1065265	chr7:65841203	C/T	cg11764359	chr7:65958608	NA	0.67	6.66	0.4	1.97e-10	Aortic root size;
SARC	cis	rs11190604	1.000	rs4919471	chr10:102299239	A/G	cg07080220	chr10:102295463	HIF1AN	0.83	9.6	0.53	1.36e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg00745463	chr17:30367425	LRRC37B	-0.69	-5.28	-0.33	2.96e-7	Hip circumference adjusted for BMI;
SARC	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg18404041	chr3:52824283	ITIH1	-0.41	-6.05	-0.37	5.72e-9	Bipolar disorder;
SARC	cis	rs9911578	1.000	rs7342903	chr17:56914588	C/G	cg12560992	chr17:57184187	TRIM37	0.86	12.1	0.62	1.84e-26	Intelligence (multi-trait analysis);
SARC	cis	rs7296418	0.961	rs11613937	chr12:123520071	C/T	cg00376283	chr12:123451042	ABCB9	0.68	8.7	0.5	6.17e-16	Platelet count;
SARC	cis	rs875971	0.545	rs11767262	chr7:65767224	T/A	cg25894440	chr7:65020034	NA	0.51	4.78	0.3	3.08e-6	Aortic root size;
SARC	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg20607798	chr8:58055168	NA	0.55	5.37	0.33	1.89e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1018836	0.886	rs10956750	chr8:91621704	G/C	cg16814680	chr8:91681699	NA	-0.85	-13.99	-0.68	1.06e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs739401	0.611	rs2301140	chr11:3022629	C/T	cg05729581	chr11:3078854	CARS	-0.47	-5.88	-0.36	1.4e-8	Longevity;
SARC	cis	rs67311347	0.956	rs12633446	chr3:40505661	G/A	cg09455208	chr3:40491958	NA	-0.42	-6.53	-0.39	3.98e-10	Renal cell carcinoma;
SARC	trans	rs9402682	0.592	rs9385716	chr6:135455329	A/G	cg19991079	chr5:74162458	FAM169A	-0.54	-6.34	-0.38	1.21e-9	Eosinophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;
SARC	cis	rs17345786	0.906	rs11710016	chr3:101120030	A/C	cg11279151	chr3:101281821	RG9MTD1	0.48	4.93	0.31	1.58e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4969178	0.965	rs8071884	chr17:76398058	C/G	cg20026190	chr17:76395443	PGS1	0.41	5.38	0.33	1.82e-7	HDL cholesterol levels;
SARC	cis	rs11697848	1.000	rs79631274	chr20:48517853	C/G	cg17849948	chr20:48532315	SPATA2	0.86	5.17	0.32	4.97e-7	Systemic lupus erythematosus;
SARC	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg00933542	chr6:150070202	PCMT1	0.34	5.95	0.36	9.85e-9	Lung cancer;
SARC	cis	rs9914544	0.545	rs8073436	chr17:18801841	A/G	cg25390199	chr17:18761479	PRPSAP2	0.47	6.07	0.37	5.06e-9	Educational attainment (years of education);
SARC	cis	rs7178572	0.568	rs12916731	chr15:77507021	C/T	cg22256960	chr15:77711686	NA	-0.51	-5.58	-0.34	6.56e-8	Type 2 diabetes;
SARC	cis	rs6429082	0.783	rs390539	chr1:235679690	A/C	cg26050004	chr1:235667680	B3GALNT2	0.66	7.87	0.46	1.36e-13	Adiposity;
SARC	cis	rs6598955	0.670	rs3795685	chr1:26601385	A/G	cg04990556	chr1:26633338	UBXN11	0.59	8.11	0.47	2.94e-14	Obesity-related traits;
SARC	cis	rs826838	0.935	rs1684407	chr12:39127270	C/T	cg26384229	chr12:38710491	ALG10B	-0.76	-11.59	-0.6	7.97e-25	Heart rate;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg19406736	chr19:37096010	ZNF529;ZNF382	0.55	7.35	0.43	3.35e-12	Breast cancer;
SARC	cis	rs968567	0.539	rs174560	chr11:61581764	T/C	cg19610905	chr11:61596333	FADS2	-0.4	-4.76	-0.3	3.34e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
SARC	cis	rs6570726	0.875	rs12524077	chr6:145866333	G/C	cg05220968	chr6:146057943	EPM2A	-0.3	-5.08	-0.32	7.76e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7824557	0.564	rs2572395	chr8:11235360	A/C	cg21775007	chr8:11205619	TDH	-0.65	-8.61	-0.49	1.12e-15	Retinal vascular caliber;
SARC	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg08219700	chr8:58056026	NA	0.47	4.84	0.3	2.39e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs9486719	0.948	rs6920913	chr6:96874297	A/G	cg06623918	chr6:96969491	KIAA0776	0.73	8.33	0.48	6.81e-15	Migraine;Coronary artery disease;
SARC	cis	rs7824557	0.592	rs2736280	chr8:11223022	C/A	cg21775007	chr8:11205619	TDH	0.71	9.79	0.54	3.64e-19	Retinal vascular caliber;
SARC	cis	rs72781680	0.898	rs72780111	chr2:23991146	G/A	cg08917208	chr2:24149416	ATAD2B	0.77	7.29	0.43	4.79e-12	Lymphocyte counts;
SARC	trans	rs2018683	0.649	rs12536605	chr7:28970500	C/T	cg19402173	chr7:128379420	CALU	-0.5	-6.34	-0.38	1.21e-9	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs10782582	0.609	rs11584577	chr1:76242378	A/G	cg03433033	chr1:76189801	ACADM	-0.4	-5.07	-0.31	8.29e-7	Daytime sleep phenotypes;
SARC	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg15448220	chr1:150897856	SETDB1	0.47	6.17	0.37	3.05e-9	Tonsillectomy;
SARC	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.43	6.64	0.4	2.15e-10	Schizophrenia;
SARC	cis	rs17401966	1.000	rs12734068	chr1:10376803	G/A	cg15208524	chr1:10270712	KIF1B	0.63	7.02	0.42	2.42e-11	Hepatocellular carcinoma;
SARC	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-8.76	-0.5	4.15e-16	Alzheimer's disease;
SARC	cis	rs35306767	0.855	rs11253465	chr10:897208	A/C	cg20503657	chr10:835505	NA	0.88	8.42	0.48	3.99e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs926938	0.527	rs360684	chr1:115499001	A/G	cg12756093	chr1:115239321	AMPD1	0.38	4.8	0.3	2.89e-6	Autism;
SARC	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg26874164	chr19:58962979	ZNF324B	0.46	6.04	0.37	6.12e-9	Uric acid clearance;
SARC	cis	rs11711311	1.000	rs11711311	chr3:113430599	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.69	8.8	0.5	3.03e-16	IgG glycosylation;
SARC	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.97e-8	Aortic root size;
SARC	cis	rs7587476	0.784	rs13008641	chr2:215698033	T/C	cg04530015	chr2:215796436	ABCA12	-0.41	-6.71	-0.4	1.44e-10	Neuroblastoma;
SARC	cis	rs981844	0.826	rs4585278	chr4:154684145	A/G	cg14289246	chr4:154710475	SFRP2	0.63	7.35	0.43	3.28e-12	Response to statins (LDL cholesterol change);
SARC	cis	rs9948	1.000	rs59244622	chr2:97501632	C/T	cg01990225	chr2:97406019	LMAN2L	-0.75	-5.4	-0.33	1.66e-7	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs6670533	0.571	rs10489444	chr1:24863530	A/G	cg07475527	chr1:24864545	NA	0.99	5.69	0.35	3.89e-8	Fasting blood insulin (BMI interaction);
SARC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.8	10.38	0.56	5.49e-21	Prudent dietary pattern;
SARC	cis	rs4481887	0.893	rs4512685	chr1:248446246	C/T	cg00666640	chr1:248458726	OR2T12	0.34	5.62	0.35	5.47e-8	Common traits (Other);
SARC	cis	rs3540	0.576	rs1974519	chr15:91036460	A/G	cg22089800	chr15:90895588	ZNF774	0.66	8.46	0.48	3e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs6484504	0.600	rs10835763	chr11:31345574	G/A	cg26647111	chr11:31128758	NA	0.38	4.88	0.3	1.95e-6	Red blood cell count;
SARC	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg09323728	chr8:95962352	TP53INP1	-0.29	-4.96	-0.31	1.35e-6	Type 2 diabetes;
SARC	cis	rs5753618	0.561	rs2078803	chr22:31652852	G/A	cg00478049	chr22:31556069	RNF185	0.44	4.85	0.3	2.21e-6	Colorectal cancer;
SARC	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg25894440	chr7:65020034	NA	-0.72	-5.46	-0.34	1.2e-7	Diabetic kidney disease;
SARC	cis	rs16976116	0.619	rs7168057	chr15:55465483	G/A	cg11288833	chr15:55489084	RSL24D1	-0.61	-5.24	-0.32	3.62e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6088580	0.524	rs4911437	chr20:33266149	G/T	cg07148914	chr20:33460835	GGT7	-0.43	-5.15	-0.32	5.63e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs2153535	0.580	rs6597337	chr6:8531652	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	8.57	0.49	1.43e-15	Motion sickness;
SARC	cis	rs599083	0.829	rs314751	chr11:68179560	C/T	cg24974729	chr11:67764320	UNC93B1	-0.32	-4.8	-0.3	2.89e-6	Bone mineral density (spine);
SARC	cis	rs9399137	0.507	rs13064	chr6:135287533	A/G	cg22676075	chr6:135203613	NA	0.39	4.97	0.31	1.32e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs870825	0.616	rs1401360	chr4:185643571	T/C	cg04058563	chr4:185651563	MLF1IP	0.81	11.52	0.6	1.31e-24	Blood protein levels;
SARC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg25703541	chr22:24373054	LOC391322	0.81	10.3	0.56	9.91e-21	Liver enzyme levels (gamma-glutamyl transferase);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg15793456	chr2:183888544	NCKAP1	0.52	7.31	0.43	4.13e-12	Thyroid stimulating hormone;
SARC	cis	rs7927592	0.913	rs11228276	chr11:68307525	A/G	cg01657329	chr11:68192670	LRP5	-0.39	-4.72	-0.3	4.1e-6	Total body bone mineral density;
SARC	cis	rs950027	0.572	rs12910764	chr15:45609360	T/C	cg15395560	chr15:45543142	SLC28A2	0.3	5.72	0.35	3.29e-8	Response to fenofibrate (adiponectin levels);
SARC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg10950202	chr3:12882711	RPL32;SNORA7A	0.58	6.67	0.4	1.87e-10	Myopia (pathological);
SARC	trans	rs56279505	0.690	rs62305762	chr4:100287247	T/C	cg18024358	chr1:3420815	MEGF6	-0.79	-6.28	-0.38	1.61e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs12142240	0.698	rs68191463	chr1:46808695	T/C	cg10495392	chr1:46806563	NSUN4	0.64	6.76	0.4	1.09e-10	Menopause (age at onset);
SARC	cis	rs3762637	0.941	rs112768052	chr3:122169384	G/A	cg24169773	chr3:122142474	KPNA1	-0.56	-5.67	-0.35	4.18e-8	LDL cholesterol levels;
SARC	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg13939156	chr17:80058883	NA	0.37	5.65	0.35	4.6e-8	Life satisfaction;
SARC	cis	rs1348850	0.793	rs6736390	chr2:178480314	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.55	6.1	0.37	4.42e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg07061783	chr6:25882402	NA	-0.49	-5.83	-0.36	1.88e-8	Intelligence (multi-trait analysis);
SARC	cis	rs765787	0.530	rs28815867	chr15:45526805	G/C	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.51e-10	Uric acid levels;
SARC	cis	rs9303401	0.659	rs56162835	chr17:56687315	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	12.15	0.62	1.19e-26	Cognitive test performance;
SARC	cis	rs12134245	0.874	rs34842487	chr1:92021611	C/T	cg25838465	chr1:92012736	NA	-0.57	-7.89	-0.46	1.16e-13	Breast cancer;
SARC	cis	rs11169225	0.906	rs3782319	chr12:50345079	G/A	cg23855989	chr12:50355821	AQP5	0.52	6.3	0.38	1.45e-9	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs80130819	0.688	rs2468945	chr12:48652414	G/A	cg24011408	chr12:48396354	COL2A1	0.52	5.87	0.36	1.46e-8	Prostate cancer;
SARC	cis	rs4242434	0.927	rs2291232	chr8:22464064	A/G	cg03733263	chr8:22462867	KIAA1967	1.06	17.77	0.76	3.01e-45	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs4805272	0.539	rs1422212	chr19:29330191	T/A	cg14983838	chr19:29218262	NA	0.61	6.91	0.41	4.59e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs911263	0.561	rs1810623	chr14:68805725	T/C	cg18825221	chr14:68749962	RAD51L1	0.45	6.3	0.38	1.44e-9	Primary biliary cholangitis;
SARC	cis	rs2652834	1.000	rs7182618	chr15:63398622	T/C	cg05507819	chr15:63340323	TPM1	0.54	5.34	0.33	2.23e-7	HDL cholesterol;
SARC	cis	rs67311347	1.000	rs7631893	chr3:40440869	C/T	cg24209194	chr3:40518798	ZNF619	0.63	8.13	0.47	2.59e-14	Renal cell carcinoma;
SARC	cis	rs9527	0.590	rs4917992	chr10:104786313	G/A	cg04362960	chr10:104952993	NT5C2	0.44	5.21	0.32	4.19e-7	Arsenic metabolism;
SARC	cis	rs9398803	0.652	rs853961	chr6:127003464	G/T	cg20229609	chr6:126660872	C6orf173	-0.34	-4.82	-0.3	2.58e-6	Male-pattern baldness;
SARC	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.69	8.87	0.5	2.02e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7208859	0.623	rs34756112	chr17:29113016	A/G	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs112591243	0.570	rs2839340	chr21:47989804	C/T	cg10657630	chr21:48055338	PRMT2	0.83	5.74	0.35	2.91e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs1018836	0.923	rs7007102	chr8:91629730	T/A	cg16814680	chr8:91681699	NA	-0.85	-13.87	-0.67	2.65e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs6568686	0.786	rs7450789	chr6:111816975	G/T	cg15721981	chr6:111408429	SLC16A10	-0.63	-5.34	-0.33	2.16e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs7666738	0.830	rs6532724	chr4:99060993	C/T	cg05340658	chr4:99064831	C4orf37	0.64	8.66	0.49	7.7e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10504073	0.565	rs35282337	chr8:49920994	G/A	cg00325661	chr8:49890786	NA	0.51	6.82	0.41	7.54e-11	Blood metabolite ratios;
SARC	cis	rs7617773	0.539	rs17593974	chr3:48387334	G/T	cg11946769	chr3:48343235	NME6	0.54	6.64	0.4	2.13e-10	Coronary artery disease;
SARC	cis	rs7113850	0.541	rs4536215	chr11:24245374	C/A	ch.11.24196551F	chr11:24239977	NA	0.74	5.42	0.33	1.51e-7	Bone fracture in osteoporosis;
SARC	cis	rs7659604	0.540	rs116452657	chr4:122674147	A/G	cg19671926	chr4:122722719	EXOSC9	0.55	6.99	0.42	2.87e-11	Type 2 diabetes;
SARC	cis	rs4974559	0.690	rs28641665	chr4:1288781	G/T	cg02980000	chr4:1222292	CTBP1	0.73	5.6	0.34	5.97e-8	Systolic blood pressure;
SARC	cis	rs1568889	1.000	rs34337978	chr11:28136746	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.71	9.21	0.52	1.96e-17	Bipolar disorder;
SARC	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-6.53	-0.39	4.14e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs3733585	0.753	rs12500805	chr4:10017979	C/T	cg00071950	chr4:10020882	SLC2A9	0.33	5.04	0.31	9.35e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs6963495	0.818	rs73190167	chr7:105160418	A/G	cg19920283	chr7:105172520	RINT1	0.65	5.48	0.34	1.09e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg23982607	chr1:1823379	GNB1	-0.65	-10.92	-0.58	1.09e-22	Body mass index;
SARC	cis	rs6674176	0.628	rs3791116	chr1:44414156	T/A	cg13246856	chr1:44399776	ARTN	0.3	4.83	0.3	2.51e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs7264396	0.528	rs6058370	chr20:34518592	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-7.4	-0.44	2.44e-12	Total cholesterol levels;
SARC	trans	rs61931739	0.534	rs11053029	chr12:34131766	G/T	cg13010199	chr12:38710504	ALG10B	0.77	10.39	0.56	4.92e-21	Morning vs. evening chronotype;
SARC	cis	rs796364	1.000	rs281760	chr2:200787804	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.77	7.14	0.42	1.2e-11	Schizophrenia;
SARC	cis	rs1707322	0.721	rs10789471	chr1:46215619	G/A	cg03146154	chr1:46216737	IPP	0.52	6.29	0.38	1.56e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs13144136	0.647	rs12509884	chr4:10654043	C/T	cg10242279	chr4:10666415	CLNK	-0.42	-6.81	-0.41	8.15e-11	Resistance to antihypertensive treatment in hypertension;
SARC	cis	rs881375	0.967	rs1548783	chr9:123658639	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.44	5.04	0.31	9.35e-7	Rheumatoid arthritis;
SARC	cis	rs6714710	0.663	rs71429376	chr2:98534412	T/C	cg26665480	chr2:98280029	ACTR1B	0.5	6.7	0.4	1.55e-10	Posterior cortical atrophy and Alzheimer's disease;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg09664975	chr1:84543551	PRKACB	-0.77	-6.35	-0.38	1.1e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs4563143	0.514	rs73029079	chr19:29294903	A/G	cg14983838	chr19:29218262	NA	0.67	7.72	0.45	3.33e-13	Methadone dose in opioid dependence;
SARC	cis	rs1568889	1.000	rs7931847	chr11:28175245	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.72	9.32	0.52	8.94e-18	Bipolar disorder;
SARC	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg16049864	chr8:95962084	TP53INP1	-0.47	-7.53	-0.44	1.08e-12	Type 2 diabetes;
SARC	trans	rs11098499	0.779	rs72918579	chr4:120333222	G/C	cg25214090	chr10:38739885	LOC399744	0.55	7.08	0.42	1.69e-11	Corneal astigmatism;
SARC	cis	rs611744	0.967	rs628340	chr8:109189425	A/G	cg21045802	chr8:109455806	TTC35	0.44	5.3	0.33	2.64e-7	Dupuytren's disease;
SARC	cis	rs6430585	0.528	rs3098102	chr2:136654833	C/T	cg07169764	chr2:136633963	MCM6	0.99	13.05	0.65	1.42e-29	Corneal structure;
SARC	trans	rs1814175	0.645	rs7119101	chr11:49955665	G/A	cg03929089	chr4:120376271	NA	-0.82	-11.88	-0.61	9.2e-26	Height;
SARC	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg20965017	chr5:231967	SDHA	-0.56	-5.3	-0.33	2.71e-7	Breast cancer;
SARC	cis	rs1448094	0.717	rs7298614	chr12:86296513	C/T	cg02569458	chr12:86230093	RASSF9	0.37	4.89	0.31	1.87e-6	Major depressive disorder;
SARC	cis	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg01366467	chr20:3185206	DDRGK1	0.38	5.12	0.32	6.45e-7	Immature fraction of reticulocytes;
SARC	cis	rs644799	1.000	rs474442	chr11:95583995	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	15.07	0.7	2.82e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs8114671	0.647	rs945959	chr20:33734905	G/C	cg24642439	chr20:33292090	TP53INP2	0.48	5.81	0.36	2.06e-8	Height;
SARC	cis	rs6539267	0.885	rs34762209	chr12:106722466	T/C	cg00173435	chr12:106696525	TCP11L2	0.73	7.41	0.44	2.26e-12	Tourette syndrome;
SARC	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg03709012	chr19:19516395	GATAD2A	0.95	14.76	0.7	2.9e-35	Tonsillectomy;
SARC	cis	rs1008375	0.800	rs62296338	chr4:17613425	G/T	cg27347728	chr4:17578864	LAP3	0.44	5.44	0.34	1.35e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs208520	0.690	rs851458	chr6:66813279	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.04	-14.09	-0.68	5.12e-33	Exhaled nitric oxide output;
SARC	cis	rs17376456	0.569	rs35878747	chr5:93094070	C/A	cg21475434	chr5:93447410	FAM172A	0.61	5.95	0.36	9.98e-9	Diabetic retinopathy;
SARC	cis	rs1545257	0.537	rs2702088	chr2:24642535	G/C	cg06627628	chr2:24431161	ITSN2	-0.56	-7.13	-0.42	1.23e-11	Sjögren's syndrome;
SARC	cis	rs9810259	0.614	rs67216730	chr3:12364377	T/C	cg04748988	chr3:12329223	PPARG	-0.44	-5.45	-0.34	1.26e-7	Platelet count;
SARC	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg26516362	chr5:178986906	RUFY1	0.34	4.8	0.3	2.81e-6	Lung cancer;
SARC	cis	rs921943	0.957	rs6859544	chr5:78310877	C/G	cg26802063	chr5:78281964	ARSB	0.45	4.96	0.31	1.38e-6	Blood and toenail selenium levels;Blood trace element (Se levels);
SARC	cis	rs986417	0.901	rs1989477	chr14:61024867	T/C	cg27398547	chr14:60952738	C14orf39	0.96	8.7	0.49	6.29e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs9931543	0.504	rs9922112	chr16:56314687	A/C	cg02433656	chr16:56322654	GNAO1	0.42	6.49	0.39	5.25e-10	Subjective well-being;
SARC	cis	rs9916302	0.808	rs12948906	chr17:37644854	C/T	cg00129232	chr17:37814104	STARD3	-0.66	-8.03	-0.47	4.68e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.43	4.95	0.31	1.44e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg11062466	chr8:58055876	NA	0.56	5.69	0.35	3.79e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9768139	0.708	rs896782	chr7:158114115	G/A	cg25566285	chr7:158114605	PTPRN2	0.34	5.85	0.36	1.66e-8	Calcium levels;
SARC	cis	rs9581857	0.725	rs9319366	chr13:28017722	C/T	cg01674679	chr13:27998804	GTF3A	-0.63	-4.97	-0.31	1.32e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	trans	rs9325144	0.650	rs6582624	chr12:38733475	A/T	cg23762105	chr12:34175262	ALG10	0.51	6.45	0.39	6.29e-10	Morning vs. evening chronotype;
SARC	cis	rs9393777	0.623	rs9366658	chr6:26469866	G/A	cg12826209	chr6:26865740	GUSBL1	0.83	7.61	0.45	6.76e-13	Intelligence (multi-trait analysis);
SARC	cis	rs7824557	0.564	rs4631424	chr8:11236809	T/C	cg21775007	chr8:11205619	TDH	-0.65	-8.62	-0.49	1.01e-15	Retinal vascular caliber;
SARC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg05552183	chr6:42928497	GNMT	-0.55	-7.66	-0.45	5.07e-13	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs11098499	0.954	rs3733523	chr4:120423719	C/T	cg09307838	chr4:120376055	NA	0.93	12.73	0.64	1.6e-28	Corneal astigmatism;
SARC	cis	rs607987	0.713	rs2947888	chr11:30340635	C/CT	cg06241208	chr11:30344200	C11orf46	0.39	4.86	0.3	2.17e-6	Body mass index;
SARC	cis	rs7824557	0.606	rs2736270	chr8:11192593	G/A	cg21775007	chr8:11205619	TDH	0.68	9.03	0.51	6.5e-17	Retinal vascular caliber;
SARC	cis	rs12472274	0.536	rs12619455	chr2:239080149	A/C	cg17459225	chr2:239074497	NA	0.6	5.9	0.36	1.27e-8	Phospholipid levels (plasma);
SARC	cis	rs10752881	0.602	rs9425569	chr1:182942202	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.51	6.65	0.4	2.11e-10	Colorectal cancer;
SARC	cis	rs9381040	0.655	rs2268193	chr6:41024625	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.41	-4.85	-0.3	2.31e-6	Alzheimer's disease (late onset);
SARC	cis	rs6815814	0.851	rs73235002	chr4:38769018	A/G	cg09316306	chr4:38807337	TLR1	0.49	4.77	0.3	3.22e-6	Breast cancer;
SARC	cis	rs16866061	0.890	rs72972401	chr2:225404668	T/C	cg12698349	chr2:225449008	CUL3	0.72	10.54	0.57	1.73e-21	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	cis	rs959260	0.588	rs12938183	chr17:73320433	G/C	cg07104495	chr17:73266070	MIF4GD	-0.33	-4.99	-0.31	1.2e-6	Systemic lupus erythematosus;
SARC	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg07343612	chr16:622815	PIGQ	-0.61	-8.58	-0.49	1.32e-15	Height;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg00367659	chr17:33288544	CCT6B;ZNF830	-0.58	-6.59	-0.4	2.95e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs561341	1.000	rs484175	chr17:30309041	G/A	cg00745463	chr17:30367425	LRRC37B	-0.67	-5.32	-0.33	2.4e-7	Hip circumference adjusted for BMI;
SARC	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg00409905	chr10:38381863	ZNF37A	-0.49	-6.63	-0.4	2.32e-10	Extrinsic epigenetic age acceleration;
SARC	cis	rs12681366	0.663	rs10216902	chr8:95479978	A/G	cg13257157	chr8:95487014	RAD54B	0.42	5.35	0.33	2.14e-7	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs9486715	0.838	rs9320127	chr6:96865358	G/A	cg06623918	chr6:96969491	KIAA0776	0.84	11.84	0.61	1.24e-25	Headache;
SARC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg05025164	chr4:1340916	KIAA1530	0.86	11.05	0.59	4.23e-23	Longevity;
SARC	cis	rs7666738	0.830	rs28761309	chr4:98867393	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.59	0.49	1.24e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2730245	0.636	rs2657382	chr7:158650941	G/A	cg11945929	chr7:158750384	NA	0.34	4.99	0.31	1.19e-6	Height;
SARC	cis	rs3784262	0.669	rs7180059	chr15:58288172	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.36	-5.34	-0.33	2.25e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs7084402	0.935	rs1632584	chr10:60282078	T/C	cg07615347	chr10:60278583	BICC1	-0.6	-8.82	-0.5	2.71e-16	Refractive error;
SARC	cis	rs7264396	0.790	rs6121026	chr20:34266883	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-8.23	-0.47	1.36e-14	Total cholesterol levels;
SARC	cis	rs6604026	0.656	rs7417198	chr1:93391445	T/C	cg17283838	chr1:93427260	FAM69A	0.41	4.77	0.3	3.25e-6	Multiple sclerosis;
SARC	cis	rs1008375	1.000	rs9291659	chr4:17662360	A/C	cg02297831	chr4:17616191	MED28	0.41	5.21	0.32	4.15e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9297145	0.761	rs12534399	chr7:98746401	A/G	cg05967295	chr7:98741636	SMURF1	0.76	7.73	0.45	3.27e-13	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
SARC	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.41	0.39	7.86e-10	Bipolar disorder;
SARC	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg16414030	chr3:133502952	NA	-0.39	-5.34	-0.33	2.18e-7	Iron status biomarkers;
SARC	cis	rs9398803	0.687	rs12208811	chr6:126926898	T/G	cg20229609	chr6:126660872	C6orf173	0.37	5.39	0.33	1.74e-7	Male-pattern baldness;
SARC	cis	rs67460515	0.892	rs11718905	chr3:161051793	G/A	cg03342759	chr3:160939853	NMD3	-0.69	-8.8	-0.5	3.07e-16	Parkinson's disease;
SARC	trans	rs66573146	0.831	rs56300156	chr4:6990813	G/C	cg07817883	chr1:32538562	TMEM39B	1.25	8.25	0.48	1.19e-14	Granulocyte percentage of myeloid white cells;
SARC	cis	rs9682041	0.808	rs9875109	chr3:170064776	A/G	cg11886554	chr3:170076028	SKIL	-0.67	-6.53	-0.39	4.05e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs6496667	0.557	rs2601201	chr15:90958000	C/T	cg22089800	chr15:90895588	ZNF774	0.43	4.9	0.31	1.8e-6	Rheumatoid arthritis;
SARC	cis	rs9303401	0.659	rs34468504	chr17:56648277	C/T	cg25039879	chr17:56429692	SUPT4H1	0.67	6.21	0.38	2.4e-9	Cognitive test performance;
SARC	cis	rs1707322	1.000	rs785506	chr1:46540652	C/T	cg03146154	chr1:46216737	IPP	-0.48	-5.64	-0.35	4.92e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9467773	0.620	rs2494701	chr6:26634432	C/T	cg12292205	chr6:26970375	C6orf41	0.41	5.12	0.32	6.46e-7	Intelligence (multi-trait analysis);
SARC	cis	rs826838	0.967	rs34496261	chr12:39023829	G/A	cg13010199	chr12:38710504	ALG10B	0.77	10.76	0.58	3.54e-22	Heart rate;
SARC	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg06558623	chr16:89946397	TCF25	0.97	7.62	0.45	6.38e-13	Skin colour saturation;
SARC	cis	rs208520	0.690	rs207102	chr6:66795671	G/A	cg07460842	chr6:66804631	NA	-1.08	-15.02	-0.7	4.17e-36	Exhaled nitric oxide output;
SARC	cis	rs11997175	0.580	rs34398087	chr8:33813800	A/G	ch.8.33884649F	chr8:33765107	NA	-0.45	-5.69	-0.35	3.78e-8	Body mass index;
SARC	cis	rs796364	0.806	rs203766	chr2:200902672	T/C	cg23649088	chr2:200775458	C2orf69	-0.66	-5.82	-0.36	1.97e-8	Schizophrenia;
SARC	cis	rs9487051	0.676	rs13195816	chr6:109598624	T/C	cg01475377	chr6:109611718	NA	-0.36	-5.16	-0.32	5.27e-7	Reticulocyte fraction of red cells;
SARC	cis	rs981844	0.740	rs7653960	chr4:154697430	T/G	cg14289246	chr4:154710475	SFRP2	-0.61	-7.04	-0.42	2.08e-11	Response to statins (LDL cholesterol change);
SARC	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg15448220	chr1:150897856	SETDB1	0.47	6.22	0.38	2.24e-9	Urate levels;
SARC	cis	rs1008375	0.932	rs4235390	chr4:17696378	G/T	cg27347728	chr4:17578864	LAP3	0.44	5.67	0.35	4.14e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs644799	1.000	rs611020	chr11:95567905	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.66	8.87	0.5	1.96e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9300255	0.602	rs2682434	chr12:123694724	C/T	cg00376283	chr12:123451042	ABCB9	0.55	6.53	0.39	4.09e-10	Neutrophil percentage of white cells;
SARC	cis	rs34779708	0.931	rs2384289	chr10:35343525	G/A	cg03585969	chr10:35415529	CREM	0.38	4.87	0.3	2.1e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs698813	0.637	rs7579841	chr2:44498887	T/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	5.46	0.34	1.19e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21273366	chr13:50656391	DLEU1;DLEU2	-0.47	-6.53	-0.39	4.14e-10	Smoking initiation;
SARC	cis	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg06636001	chr8:8085503	FLJ10661	0.61	8.1	0.47	3.1e-14	Mood instability;
SARC	cis	rs1113500	0.933	rs3909076	chr1:108631760	T/C	cg06207961	chr1:108661230	NA	0.44	5.82	0.36	1.93e-8	Growth-regulated protein alpha levels;
SARC	cis	rs2952156	0.920	rs2952152	chr17:37832735	T/C	cg07936489	chr17:37558343	FBXL20	-0.4	-5.17	-0.32	4.98e-7	Asthma;
SARC	cis	rs981844	1.000	rs56331473	chr4:154668052	C/A	cg14289246	chr4:154710475	SFRP2	0.57	6.43	0.39	7.08e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs3091242	0.809	rs660129	chr1:25727438	C/T	cg27572855	chr1:25598939	RHD	0.56	9.63	0.53	1.09e-18	Erythrocyte sedimentation rate;
SARC	cis	rs9457247	0.624	rs17524252	chr6:167466978	T/G	cg23791538	chr6:167370224	RNASET2	-0.53	-7.01	-0.42	2.51e-11	Crohn's disease;
SARC	cis	rs9733	0.650	rs9803935	chr1:150552622	T/G	cg17724175	chr1:150552817	MCL1	-0.39	-5.01	-0.31	1.08e-6	Tonsillectomy;
SARC	cis	rs6807306	1.000	rs9819968	chr3:167350204	C/T	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.49	4.78	0.3	3.15e-6	Mean platelet volume;
SARC	cis	rs17376456	0.809	rs13177800	chr5:93307350	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.62	5.64	0.35	4.98e-8	Diabetic retinopathy;
SARC	cis	rs1215050	0.791	rs1215055	chr4:98865454	C/T	cg05340658	chr4:99064831	C4orf37	-0.44	-5.89	-0.36	1.32e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg21171335	chr12:122356390	WDR66	0.4	6.36	0.38	1.07e-9	Mean corpuscular volume;
SARC	cis	rs3820928	1.000	rs2396433	chr2:227772502	A/G	cg05526886	chr2:227700861	RHBDD1	-0.5	-6.11	-0.37	4.08e-9	Pulmonary function;
SARC	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg05890377	chr2:74357713	NA	0.61	7.47	0.44	1.58e-12	Gestational age at birth (maternal effect);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg03386556	chr1:113499109	SLC16A1	0.57	7.12	0.42	1.33e-11	Breast cancer;
SARC	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg05861140	chr6:150128134	PCMT1	-0.4	-5.19	-0.32	4.55e-7	Lung cancer;
SARC	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg03806693	chr22:41940476	POLR3H	-0.79	-11.07	-0.59	3.53e-23	Vitiligo;
SARC	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg11764359	chr7:65958608	NA	-0.77	-9.16	-0.51	2.79e-17	Aortic root size;
SARC	cis	rs9486715	0.867	rs2499775	chr6:97007340	C/T	cg06623918	chr6:96969491	KIAA0776	-0.94	-14.56	-0.69	1.37e-34	Headache;
SARC	cis	rs2016266	0.929	rs7399003	chr12:53659536	C/T	cg06632207	chr12:54070931	ATP5G2	0.41	4.91	0.31	1.72e-6	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs3857067	0.806	rs722486	chr4:95092315	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.34	-4.97	-0.31	1.27e-6	QT interval;
SARC	cis	rs7647973	0.710	rs1532204	chr3:49609477	C/G	cg03060546	chr3:49711283	APEH	0.72	6.71	0.4	1.44e-10	Menarche (age at onset);
SARC	cis	rs10911232	0.542	rs12128323	chr1:183050087	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.09	0.55	4.13e-20	Hypertriglyceridemia;
SARC	cis	rs7264396	0.563	rs73902913	chr20:34432784	A/G	cg01084648	chr20:34329383	RBM39	0.62	4.99	0.31	1.19e-6	Total cholesterol levels;
SARC	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg24675658	chr1:53192096	ZYG11B	0.66	9.42	0.53	4.66e-18	Monocyte count;
SARC	cis	rs4601821	0.823	rs10891546	chr11:113265292	C/T	cg14159747	chr11:113255604	NA	-0.41	-5.57	-0.34	6.84e-8	Alcoholic chronic pancreatitis;
SARC	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg13944838	chr5:179740914	GFPT2	-0.54	-6.87	-0.41	5.93e-11	Height;
SARC	cis	rs7762018	1.000	rs6942332	chr6:170131934	A/G	cg17545662	chr6:170176663	C6orf70	0.41	4.77	0.3	3.21e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs1348850	0.793	rs12990917	chr2:178487259	T/G	cg22681709	chr2:178499509	PDE11A	-0.4	-5.14	-0.32	5.87e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7647973	1.000	rs2312462	chr3:49601255	A/G	cg06212747	chr3:49208901	KLHDC8B	0.56	6.1	0.37	4.48e-9	Menarche (age at onset);
SARC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.14	0.8	6.21e-53	Prudent dietary pattern;
SARC	cis	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg07636037	chr3:49044803	WDR6	0.48	5.61	0.35	5.67e-8	Resting heart rate;
SARC	cis	rs10979	0.597	rs9390118	chr6:143907610	A/G	cg25407410	chr6:143891975	LOC285740	-0.52	-6.0	-0.37	7.63e-9	Hypospadias;
SARC	cis	rs9513627	1.000	rs7334274	chr13:100120801	G/A	cg25919922	chr13:100150906	NA	-0.7	-5.29	-0.33	2.86e-7	Obesity-related traits;
SARC	cis	rs870825	0.616	rs7680835	chr4:185652992	C/G	cg04058563	chr4:185651563	MLF1IP	-0.79	-11.07	-0.59	3.63e-23	Blood protein levels;
SARC	cis	rs7561528	0.501	rs72838285	chr2:127891795	A/G	cg12632573	chr2:127783243	NA	0.64	5.8	0.36	2.11e-8	Alzheimer's disease;Alzheimer's disease (late onset);
SARC	cis	rs79349575	0.783	rs62075820	chr17:46983171	G/C	cg16584676	chr17:46985605	UBE2Z	0.54	6.59	0.4	2.95e-10	Type 2 diabetes;
SARC	cis	rs9916302	0.851	rs11078906	chr17:37662767	C/T	cg20243544	chr17:37824526	PNMT	0.55	6.45	0.39	6.26e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg23262073	chr20:60523788	NA	-0.39	-5.64	-0.35	5.03e-8	Body mass index;
SARC	cis	rs6570726	0.811	rs375873	chr6:145812371	G/T	cg05347473	chr6:146136440	FBXO30	0.48	6.46	0.39	6.14e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg18252515	chr7:66147081	NA	-1.31	-11.71	-0.61	3.25e-25	Diabetic kidney disease;
SARC	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg02725872	chr8:58115012	NA	-0.34	-5.37	-0.33	1.91e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10791323	0.569	rs10791335	chr11:133739571	A/T	cg15485101	chr11:133734466	NA	0.32	5.26	0.33	3.24e-7	Childhood ear infection;
SARC	cis	rs4268898	0.560	rs2384007	chr2:24514841	A/G	cg06627628	chr2:24431161	ITSN2	-0.78	-9.08	-0.51	4.68e-17	Asthma;
SARC	cis	rs12824058	0.831	rs4759452	chr12:130812799	G/A	cg23887609	chr12:130822674	PIWIL1	0.37	5.15	0.32	5.52e-7	Menopause (age at onset);
SARC	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.45	-5.59	-0.34	6.28e-8	Systemic lupus erythematosus;
SARC	cis	rs7666738	0.830	rs11097609	chr4:99011707	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs12142240	0.698	rs55971480	chr1:46823206	G/T	cg00530320	chr1:46809349	NSUN4	0.57	6.79	0.41	9.05e-11	Menopause (age at onset);
SARC	cis	rs7582180	0.629	rs11686649	chr2:100946701	T/C	cg14675211	chr2:100938903	LONRF2	0.51	7.57	0.44	8.42e-13	Intelligence (multi-trait analysis);
SARC	cis	rs4144743	0.702	rs7208055	chr17:45330827	C/A	cg18085866	chr17:45331354	ITGB3	-0.78	-6.94	-0.41	3.78e-11	Body mass index;
SARC	cis	rs8114671	0.647	rs6060268	chr20:33734293	T/C	cg24642439	chr20:33292090	TP53INP2	0.48	5.81	0.36	2.06e-8	Height;
SARC	cis	rs12540874	0.670	rs3887826	chr7:50544961	G/A	cg18232548	chr7:50535776	DDC	-0.42	-4.98	-0.31	1.22e-6	Systemic sclerosis;
SARC	cis	rs4423214	0.802	rs2276358	chr11:71184498	G/A	cg05163923	chr11:71159392	DHCR7	-0.6	-7.21	-0.43	7.58e-12	Vitamin D levels;
SARC	cis	rs1983891	0.742	rs6920495	chr6:41554182	A/G	cg15051332	chr6:41514432	FOXP4	0.48	5.06	0.31	8.57e-7	Prostate cancer;
SARC	cis	rs933688	1.000	rs332531	chr5:90790451	G/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.94	11.44	0.6	2.45e-24	Smoking behavior;
SARC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.8	10.35	0.56	6.69e-21	Prudent dietary pattern;
SARC	cis	rs2898681	0.519	rs7670068	chr4:53733984	T/G	cg00338735	chr4:53728038	RASL11B	0.49	5.46	0.34	1.24e-7	Optic nerve measurement (cup area);
SARC	cis	rs4689388	0.890	rs4688991	chr4:6302220	C/G	cg00701064	chr4:6280414	WFS1	0.55	9.14	0.51	3.13e-17	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg19223190	chr17:80058835	NA	-0.37	-5.07	-0.32	8.08e-7	Life satisfaction;
SARC	cis	rs918629	0.528	rs2547997	chr5:95254171	G/T	cg16656078	chr5:95278638	ELL2	-0.53	-6.65	-0.4	2.05e-10	IgG glycosylation;
SARC	cis	rs2153535	0.542	rs1120393	chr6:8486890	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	8.16	0.47	2.14e-14	Motion sickness;
SARC	cis	rs6540556	0.769	rs2272867	chr1:209929579	C/A	cg23920097	chr1:209922102	NA	-0.57	-5.53	-0.34	8.67e-8	Red blood cell count;
SARC	cis	rs11711311	1.000	rs2566970	chr3:113462123	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.61	-7.32	-0.43	4.01e-12	IgG glycosylation;
SARC	cis	rs7264396	0.790	rs6060519	chr20:34217383	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.55	5.58	0.34	6.59e-8	Total cholesterol levels;
SARC	cis	rs3784262	1.000	rs10851631	chr15:58242193	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.38	-5.59	-0.34	6.36e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs2197308	0.667	rs61920838	chr12:37856814	T/C	cg26384229	chr12:38710491	ALG10B	-0.83	-12.27	-0.63	4.8400000000000004e-27	Morning vs. evening chronotype;
SARC	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg05861140	chr6:150128134	PCMT1	-0.37	-4.82	-0.3	2.57e-6	Lung cancer;
SARC	cis	rs763121	0.819	rs8137829	chr22:39061030	G/A	cg06022373	chr22:39101656	GTPBP1	0.91	11.32	0.6	5.9e-24	Menopause (age at onset);
SARC	cis	rs9393692	0.905	rs7450556	chr6:26299900	C/T	cg00631329	chr6:26305371	NA	-0.63	-9.37	-0.52	6.46e-18	Educational attainment;
SARC	cis	rs6963495	0.818	rs73190155	chr7:105153535	T/A	cg13798780	chr7:105162888	PUS7	0.6	5.5	0.34	9.98e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs12681288	0.823	rs2701903	chr8:1004029	A/G	cg15309053	chr8:964076	NA	-0.4	-6.76	-0.4	1.09e-10	Schizophrenia;
SARC	cis	rs3756766	0.500	rs12514117	chr5:137656477	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.51	6.2	0.38	2.5e-9	Schizophrenia;
SARC	cis	rs7712401	0.720	rs12109791	chr5:122146831	C/T	cg19412675	chr5:122181750	SNX24	0.38	5.13	0.32	6.21e-7	Mean platelet volume;
SARC	cis	rs2204008	0.837	rs11519926	chr12:38348992	G/A	cg26384229	chr12:38710491	ALG10B	0.91	13.46	0.66	6.11e-31	Bladder cancer;
SARC	cis	rs7582180	0.630	rs13021801	chr2:100935129	C/A	cg14675211	chr2:100938903	LONRF2	0.5	7.41	0.44	2.27e-12	Intelligence (multi-trait analysis);
SARC	cis	rs3741798	1.000	rs118108016	chr12:12482820	C/A	cg08615371	chr12:12503544	MANSC1	0.85	6.51	0.39	4.6e-10	Cerebrospinal fluid biomarker levels;
SARC	trans	rs6964833	0.935	rs35735900	chr7:74066227	T/C	cg07504079	chr7:72649617	NCF1B	-0.6	-6.51	-0.39	4.51e-10	Menarche (age at onset);
SARC	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg08859206	chr1:53392774	SCP2	-0.38	-5.45	-0.34	1.3e-7	Monocyte count;
SARC	cis	rs12477438	0.539	rs12999417	chr2:99865548	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.87	-13.59	-0.66	2.32e-31	Chronic sinus infection;
SARC	cis	rs6138458	0.626	rs6050259	chr20:25011423	A/G	cg26195577	chr20:24973756	C20orf3	0.7	8.37	0.48	5.46e-15	Blood protein levels;
SARC	cis	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg00745463	chr17:30367425	LRRC37B	-0.68	-5.23	-0.32	3.82e-7	Hip circumference adjusted for BMI;
SARC	cis	rs6871536	1.000	rs2301713	chr5:131951996	C/T	cg11797159	chr5:131991491	NA	-0.37	-4.92	-0.31	1.63e-6	Asthma (childhood onset);
SARC	cis	rs5753618	0.561	rs715510	chr22:31690528	T/A	cg13145458	chr22:31556086	RNF185	0.48	5.11	0.32	6.69e-7	Colorectal cancer;
SARC	cis	rs6496667	1.000	rs1452408	chr15:90891117	A/C	cg22089800	chr15:90895588	ZNF774	0.53	5.02	0.31	1.03e-6	Rheumatoid arthritis;
SARC	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg00933542	chr6:150070202	PCMT1	0.31	5.42	0.33	1.47e-7	Lung cancer;
SARC	trans	rs2727020	0.658	rs7120136	chr11:49384358	A/C	cg15704280	chr7:45808275	SEPT13	-0.85	-13.8	-0.67	4.71e-32	Coronary artery disease;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	ch.2.4215183F	chr2:211401919	CPS1	-0.54	-7.49	-0.44	1.39e-12	Thyroid stimulating hormone;
SARC	cis	rs1678542	1.000	rs1678542	chr12:57968715	C/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.37	-4.76	-0.3	3.46e-6	Rheumatoid arthritis;
SARC	cis	rs9325144	0.624	rs10783330	chr12:39114084	A/G	cg13010199	chr12:38710504	ALG10B	-0.51	-6.37	-0.38	1.02e-9	Morning vs. evening chronotype;
SARC	cis	rs72781680	1.000	rs72796389	chr2:24171761	A/G	cg06627628	chr2:24431161	ITSN2	-0.7	-6.69	-0.4	1.64e-10	Lymphocyte counts;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg18358662	chr13:111305805	CARS2	0.87	7.21	0.43	7.85e-12	Obesity-related traits;
SARC	cis	rs10752881	0.875	rs10797825	chr1:183024581	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.09	0.55	4.29e-20	Colorectal cancer;
SARC	trans	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	7.04	0.42	2.17e-11	Intelligence (multi-trait analysis);
SARC	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.31	-4.95	-0.31	1.42e-6	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs6700896	0.931	rs1938497	chr1:66100450	G/A	cg04111102	chr1:66153794	NA	0.35	5.53	0.34	8.41e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs2916247	0.908	rs6471318	chr8:93086731	C/G	cg10183463	chr8:93005414	RUNX1T1	0.65	6.68	0.4	1.7e-10	Intelligence (multi-trait analysis);
SARC	cis	rs4714291	0.928	rs1923461	chr6:39984670	A/T	cg09256477	chr6:40556568	LRFN2	0.26	4.76	0.3	3.42e-6	Strep throat;
SARC	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.79	-11.56	-0.6	1.01e-24	Personality dimensions;
SARC	cis	rs7714584	1.000	rs7705542	chr5:150228318	G/A	cg22134413	chr5:150180641	NA	0.78	6.54	0.39	3.82e-10	Crohn's disease;
SARC	cis	rs2380220	0.720	rs9400397	chr6:95980623	C/A	cg23517279	chr6:96025343	MANEA	0.49	5.61	0.34	5.85e-8	Behavioural disinhibition (generation interaction);
SARC	cis	rs514024	0.700	rs472144	chr9:130489558	A/G	cg13643465	chr9:130375613	STXBP1	0.43	5.35	0.33	2.14e-7	Eating disorders (purging via substances);
SARC	cis	rs858239	0.601	rs6461693	chr7:23160133	A/G	cg23682824	chr7:23144976	KLHL7	-0.72	-9.69	-0.54	7.08e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs611744	0.647	rs7016198	chr8:109262752	G/A	cg21045802	chr8:109455806	TTC35	0.57	7.21	0.43	7.54e-12	Dupuytren's disease;
SARC	cis	rs7582720	1.000	rs72934738	chr2:203740861	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.28	0.43	5.16e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs1832871	0.711	rs7747669	chr6:158664345	A/G	cg07165851	chr6:158734300	TULP4	0.56	6.79	0.41	9.29e-11	Height;
SARC	cis	rs57221529	0.766	rs56278696	chr5:582669	A/G	cg09021430	chr5:549028	NA	-0.45	-5.72	-0.35	3.18e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs6060717	0.536	rs11699815	chr20:34543125	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-5.33	-0.33	2.27e-7	Hip circumference adjusted for BMI;
SARC	cis	rs7586879	0.558	rs6718510	chr2:25122323	A/C	cg04586622	chr2:25135609	ADCY3	0.32	5.35	0.33	2.13e-7	Body mass index;
SARC	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.66	-6.65	-0.4	2.05e-10	Platelet count;
SARC	cis	rs9733	0.650	rs3738485	chr1:150552392	C/G	cg13175981	chr1:150552382	MCL1	0.7	9.46	0.53	3.48e-18	Tonsillectomy;
SARC	cis	rs12042938	0.600	rs1865225	chr1:231763004	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-8.5	-0.49	2.24e-15	Neuranatomic and neurocognitive phenotypes;
SARC	cis	rs7264396	0.747	rs2425158	chr20:34419664	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	5.3	0.33	2.65e-7	Total cholesterol levels;
SARC	trans	rs9325144	0.555	rs11183215	chr12:38693127	G/A	cg23762105	chr12:34175262	ALG10	0.52	6.72	0.4	1.36e-10	Morning vs. evening chronotype;
SARC	cis	rs10979	1.000	rs9285500	chr6:143897614	G/C	cg25407410	chr6:143891975	LOC285740	-0.64	-8.78	-0.5	3.67e-16	Hypospadias;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg24555591	chr2:145149645	ZEB2	0.44	6.33	0.38	1.22e-9	Thyroid stimulating hormone;
SARC	cis	rs910316	0.763	rs1548807	chr14:75479582	T/G	cg08847533	chr14:75593920	NEK9	0.9	14.03	0.68	7.7e-33	Height;
SARC	cis	rs7208859	0.623	rs9899268	chr17:29150255	T/C	cg13385521	chr17:29058706	SUZ12P	0.9	7.36	0.43	3.12e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs240764	0.782	rs369125	chr6:101118400	G/A	cg09795085	chr6:101329169	ASCC3	0.44	5.69	0.35	3.74e-8	Neuroticism;
SARC	cis	rs6429082	0.702	rs7532018	chr1:235706290	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.51	-5.64	-0.35	4.92e-8	Adiposity;
SARC	cis	rs911263	0.603	rs11158728	chr14:68762205	G/T	cg18825221	chr14:68749962	RAD51L1	0.44	8.03	0.47	4.85e-14	Primary biliary cholangitis;
SARC	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg22683308	chr4:1340831	KIAA1530	0.46	5.41	0.33	1.55e-7	Longevity;
SARC	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg24209194	chr3:40518798	ZNF619	-0.62	-8.14	-0.47	2.41e-14	Renal cell carcinoma;
SARC	trans	rs9858542	0.903	rs35999162	chr3:49597230	C/G	cg21659725	chr3:3221576	CRBN	-0.54	-6.24	-0.38	2.02e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs2549003	1.000	rs2706384	chr5:131826880	G/T	cg21138405	chr5:131827807	IRF1	-0.28	-5.54	-0.34	8.04e-8	Asthma (sex interaction);
SARC	cis	rs4951018	0.821	rs7529037	chr1:205637501	C/G	cg07167872	chr1:205819463	PM20D1	-0.39	-5.29	-0.33	2.76e-7	Prostate-specific antigen levels;
SARC	cis	rs13166103	0.657	rs13187020	chr5:57711027	C/A	cg10487770	chr5:57879443	RAB3C	0.52	5.46	0.34	1.19e-7	Type 2 diabetes (age of onset);
SARC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg21724239	chr8:58056113	NA	0.61	6.43	0.39	7.16e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs892961	0.932	rs7208671	chr17:75413129	T/C	cg05865280	chr17:75406074	SEPT9	0.57	8.47	0.48	2.87e-15	Airflow obstruction;
SARC	cis	rs2242116	0.734	rs4683294	chr3:46979013	C/G	cg27129171	chr3:47204927	SETD2	-0.58	-7.46	-0.44	1.72e-12	Birth weight;
SARC	cis	rs9916302	0.706	rs1877030	chr17:37740161	T/C	cg00129232	chr17:37814104	STARD3	-0.61	-6.19	-0.38	2.63e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs9625935	0.518	rs9614086	chr22:30259608	A/C	cg01021169	chr22:30184971	ASCC2	0.4	5.27	0.33	3.05e-7	Tonsillectomy;
SARC	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg14517863	chr17:44321492	NA	0.39	5.74	0.35	2.96e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	trans	rs11165623	0.792	rs1125358	chr1:96971800	T/C	cg10631902	chr5:14652156	NA	-0.46	-7.47	-0.44	1.6e-12	Hip circumference;Waist circumference;
SARC	cis	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg15556689	chr8:8085844	FLJ10661	0.48	6.03	0.37	6.38e-9	Mood instability;
SARC	trans	rs12310956	0.532	rs11052922	chr12:33957476	A/G	cg26384229	chr12:38710491	ALG10B	0.73	10.21	0.56	1.84e-20	Morning vs. evening chronotype;
SARC	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg07414643	chr4:187882934	NA	0.43	6.26	0.38	1.81e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2236918	1.000	rs1776133	chr1:242025098	C/T	cg17736920	chr1:242011382	EXO1	0.73	9.61	0.53	1.25e-18	Menopause (age at onset);
SARC	cis	rs2795502	0.882	rs2744091	chr10:43339441	A/G	cg20628663	chr10:43360327	NA	-0.47	-6.22	-0.38	2.26e-9	Blood protein levels;
SARC	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg03999130	chr15:45571217	NA	0.39	5.09	0.32	7.55e-7	Homoarginine levels;
SARC	cis	rs17253792	0.822	rs8013714	chr14:56172286	T/C	cg01858014	chr14:56050164	KTN1	-0.64	-5.22	-0.32	4.02e-7	Putamen volume;
SARC	cis	rs73086581	0.838	rs11907416	chr20:4005619	G/C	cg02187196	chr20:3869020	PANK2	0.57	5.37	0.33	1.88e-7	Response to antidepressants in depression;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg01108230	chr17:12921051	ELAC2	0.5	6.62	0.4	2.45e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg02524346	chr8:600233	NA	0.71	5.96	0.36	9.39e-9	IgG glycosylation;
SARC	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg13206674	chr6:150067644	NUP43	0.46	6.03	0.37	6.45e-9	Lung cancer;
SARC	cis	rs2239547	0.563	rs2581820	chr3:53020544	A/G	cg18404041	chr3:52824283	ITIH1	0.38	4.87	0.3	2.02e-6	Schizophrenia;
SARC	cis	rs1976403	0.659	rs10799699	chr1:21820961	C/T	cg07708622	chr1:21763251	NA	0.34	5.31	0.33	2.51e-7	Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-5.96	-0.36	9.37e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg05313129	chr8:58192883	C8orf71	-0.62	-6.46	-0.39	6.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1707322	1.000	rs12077546	chr1:46431806	C/T	cg06784218	chr1:46089804	CCDC17	0.34	5.98	0.36	8.31e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs9329221	0.527	rs7833781	chr8:10333477	A/G	cg06636001	chr8:8085503	FLJ10661	0.6	8.48	0.49	2.62e-15	Neuroticism;
SARC	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg27266027	chr21:40555129	PSMG1	0.54	5.8	0.35	2.19e-8	Cognitive function;
SARC	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs4243830	0.850	rs12744992	chr1:6601290	G/A	cg04093404	chr1:6614507	TAS1R1;NOL9	0.56	4.95	0.31	1.41e-6	Body mass index;
SARC	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg17971929	chr21:40555470	PSMG1	-0.59	-7.5	-0.44	1.36e-12	Menarche (age at onset);
SARC	cis	rs7914558	1.000	rs7067970	chr10:104913870	C/T	cg04362960	chr10:104952993	NT5C2	0.42	4.93	0.31	1.54e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	trans	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg21659725	chr3:3221576	CRBN	-0.81	-12.46	-0.63	1.19e-27	Intelligence (multi-trait analysis);
SARC	cis	rs3857067	0.806	rs72665608	chr4:95093501	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.34	-4.97	-0.31	1.27e-6	QT interval;
SARC	trans	rs11098499	1.000	rs12506395	chr4:120185094	C/T	cg25214090	chr10:38739885	LOC399744	0.53	6.93	0.41	4.17e-11	Corneal astigmatism;
SARC	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.47	-5.88	-0.36	1.44e-8	Personality dimensions;
SARC	cis	rs208520	1.000	rs208535	chr6:66962286	G/A	cg07460842	chr6:66804631	NA	-0.86	-9.56	-0.53	1.79e-18	Exhaled nitric oxide output;
SARC	cis	rs12142240	0.698	rs6429599	chr1:46827871	G/A	cg00530320	chr1:46809349	NSUN4	0.58	7.07	0.42	1.78e-11	Menopause (age at onset);
SARC	cis	rs12824058	0.831	rs4759451	chr12:130812739	G/A	cg26677194	chr12:130822605	PIWIL1	0.54	7.41	0.44	2.25e-12	Menopause (age at onset);
SARC	cis	rs11731606	0.508	rs9993839	chr4:95307863	T/C	cg00507259	chr4:95128692	SMARCAD1	0.5	4.97	0.31	1.27e-6	Mean platelet volume;
SARC	cis	rs72634258	0.945	rs12736494	chr1:8136016	G/A	cg00042356	chr1:8021962	PARK7	0.94	8.38	0.48	5.12e-15	Inflammatory bowel disease;
SARC	cis	rs35995292	0.500	rs7776996	chr7:38919762	G/C	cg19327137	chr7:38886074	VPS41	0.5	7.3	0.43	4.4e-12	Subjective well-being (multi-trait analysis);
SARC	cis	rs644799	0.603	rs1255180	chr11:95472134	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.67	8.97	0.51	9.75e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7044106	0.791	rs10984994	chr9:123478769	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.5	-5.96	-0.36	9.47e-9	Hip circumference adjusted for BMI;
SARC	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg25072359	chr17:41440525	NA	0.56	6.8	0.41	8.7e-11	Menopause (age at onset);
SARC	cis	rs10256972	0.647	rs10233430	chr7:1051664	T/C	cg07308232	chr7:1071921	C7orf50	-0.45	-5.48	-0.34	1.08e-7	Longevity;Endometriosis;
SARC	cis	rs593982	0.920	rs76925283	chr11:65548108	C/T	cg08755490	chr11:65554678	OVOL1	-1.02	-10.85	-0.58	1.76e-22	Atopic dermatitis;
SARC	cis	rs67311347	1.000	rs1466237	chr3:40462026	C/G	cg24209194	chr3:40518798	ZNF619	0.61	7.97	0.46	6.95e-14	Renal cell carcinoma;
SARC	cis	rs1355223	0.902	rs680727	chr11:34704446	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.43	5.49	0.34	1.07e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg12463550	chr7:65579703	CRCP	-0.49	-5.3	-0.33	2.65e-7	Aortic root size;
SARC	cis	rs12893668	0.572	rs2273175	chr14:104160141	T/C	cg26031613	chr14:104095156	KLC1	-0.52	-5.81	-0.36	2.05e-8	Reticulocyte count;
SARC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg09373136	chr17:61933544	TCAM1	-0.45	-6.12	-0.37	3.83e-9	Prudent dietary pattern;
SARC	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg06028808	chr11:68637592	NA	0.47	5.95	0.36	9.97e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs1348850	0.874	rs6742951	chr2:178340766	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.74	9.24	0.52	1.58e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2115630	0.967	rs28595395	chr15:85334952	T/C	cg17507749	chr15:85114479	UBE2QP1	-0.43	-5.0	-0.31	1.12e-6	P wave terminal force;
SARC	cis	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg13072238	chr3:49761600	GMPPB	-0.42	-5.43	-0.34	1.4e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg09699651	chr6:150184138	LRP11	-0.38	-4.75	-0.3	3.59e-6	Lung cancer;
SARC	cis	rs747650	0.961	rs7945315	chr11:47110652	A/C	cg03339077	chr11:47165057	C11orf49	-0.43	-5.87	-0.36	1.51e-8	Acne (severe);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg02895278	chr8:26195897	PPP2R2A	0.53	7.34	0.43	3.5e-12	Thyroid stimulating hormone;
SARC	cis	rs74181299	0.892	rs2540945	chr2:65289825	A/G	cg20592124	chr2:65290738	CEP68	0.52	7.72	0.45	3.32e-13	Pulse pressure;
SARC	cis	rs1008375	0.931	rs3775926	chr4:17599837	G/A	cg27347728	chr4:17578864	LAP3	0.46	5.62	0.35	5.46e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	8.4	0.48	4.36e-15	Mean platelet volume;
SARC	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	5.82	0.36	1.91e-8	Bipolar disorder;
SARC	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg25072359	chr17:41440525	NA	0.49	5.8	0.36	2.15e-8	Menopause (age at onset);
SARC	cis	rs4660306	1.000	rs2993259	chr1:46001550	T/C	cg24296786	chr1:45957014	TESK2	0.56	6.6	0.4	2.7e-10	Homocysteine levels;
SARC	cis	rs7937682	0.924	rs12791699	chr11:111505880	T/C	cg22437258	chr11:111473054	SIK2	0.74	10.3	0.56	9.9e-21	Primary sclerosing cholangitis;
SARC	cis	rs13256369	1.000	rs9329165	chr8:8576642	C/T	cg17143192	chr8:8559678	CLDN23	-0.53	-6.2	-0.38	2.5e-9	Obesity-related traits;
SARC	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg16405210	chr4:1374714	KIAA1530	-0.51	-5.92	-0.36	1.13e-8	Obesity-related traits;
SARC	cis	rs6977660	0.652	rs10267417	chr7:19843797	C/T	cg07541023	chr7:19748670	TWISTNB	0.58	4.82	0.3	2.62e-6	Thyroid stimulating hormone;
SARC	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-8.89	-0.5	1.75e-16	Alzheimer's disease;
SARC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg11203670	chr7:100026453	MEPCE;ZCWPW1	0.48	4.75	0.3	3.55e-6	Platelet count;
SARC	cis	rs9682041	0.825	rs6785326	chr3:170095145	T/C	cg11886554	chr3:170076028	SKIL	1.07	8.49	0.49	2.41e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg06636001	chr8:8085503	FLJ10661	-0.62	-8.28	-0.48	9.94e-15	Mood instability;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg08339719	chr10:103347733	POLL;RP11-529I10.4	-0.52	-6.25	-0.38	1.95e-9	Fibrinogen levels;
SARC	cis	rs9796	0.870	rs1001341	chr15:41261491	T/A	cg18705301	chr15:41695430	NDUFAF1	0.41	5.62	0.35	5.45e-8	Menopause (age at onset);
SARC	cis	rs240764	0.853	rs17303769	chr6:100967531	G/A	cg09795085	chr6:101329169	ASCC3	-0.45	-5.92	-0.36	1.14e-8	Neuroticism;
SARC	cis	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg26850624	chr5:429559	AHRR	-0.31	-4.77	-0.3	3.21e-6	Cystic fibrosis severity;
SARC	cis	rs7727544	0.735	rs273913	chr5:131661156	A/G	cg24060327	chr5:131705240	SLC22A5	-0.63	-8.2	-0.47	1.67e-14	Blood metabolite levels;
SARC	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg17143192	chr8:8559678	CLDN23	-0.52	-5.86	-0.36	1.54e-8	Obesity-related traits;
SARC	cis	rs7223966	0.921	rs2727300	chr17:61965398	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.52	-5.22	-0.32	4e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1707322	0.752	rs4586014	chr1:46150443	A/G	cg03146154	chr1:46216737	IPP	0.52	6.24	0.38	2.07e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs7824557	0.527	rs2572449	chr8:11239137	A/G	cg06636001	chr8:8085503	FLJ10661	0.58	7.71	0.45	3.73e-13	Retinal vascular caliber;
SARC	cis	rs2235642	0.821	rs8051895	chr16:1602811	A/G	cg26528668	chr16:1614120	IFT140	0.36	4.77	0.3	3.28e-6	Coronary artery disease;
SARC	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg00933542	chr6:150070202	PCMT1	0.32	5.54	0.34	8.35e-8	Lung cancer;
SARC	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg05165339	chr4:1420672	NA	-0.23	-4.94	-0.31	1.51e-6	Longevity;
SARC	trans	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg00938859	chr5:1591904	SDHAP3	0.79	7.61	0.45	6.69e-13	Breast cancer;
SARC	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg08280861	chr8:58055591	NA	0.68	5.89	0.36	1.31e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg24110177	chr3:50126178	RBM5	0.54	7.28	0.43	5.15e-12	Intelligence (multi-trait analysis);
SARC	cis	rs34172651	0.917	rs200529	chr16:24758502	T/C	cg00339695	chr16:24857497	SLC5A11	-0.28	-4.77	-0.3	3.26e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9457247	0.765	rs6904946	chr6:167433948	C/T	cg07741184	chr6:167504864	NA	-0.33	-6.56	-0.39	3.47e-10	Crohn's disease;
SARC	trans	rs61931739	0.517	rs4931748	chr12:34140827	C/T	cg13010199	chr12:38710504	ALG10B	0.74	9.97	0.55	9.96e-20	Morning vs. evening chronotype;
SARC	cis	rs4853012	0.887	rs6737314	chr2:74339586	A/G	cg20891558	chr2:74357851	NA	0.69	9.39	0.52	5.69e-18	Gestational age at birth (maternal effect);
SARC	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.41	4.9	0.31	1.82e-6	Tonsillectomy;
SARC	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg09455208	chr3:40491958	NA	0.37	5.56	0.34	7.43e-8	Renal cell carcinoma;
SARC	trans	rs11098499	0.863	rs1480936	chr4:120462861	C/T	cg25214090	chr10:38739885	LOC399744	0.59	7.45	0.44	1.85e-12	Corneal astigmatism;
SARC	cis	rs929354	0.713	rs6946947	chr7:156948787	T/C	cg05182265	chr7:156933206	UBE3C	-0.34	-5.19	-0.32	4.49e-7	Body mass index;
SARC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg09373136	chr17:61933544	TCAM1	-0.45	-6.12	-0.37	3.83e-9	Prudent dietary pattern;
SARC	cis	rs2731664	0.765	rs2630766	chr5:176874941	A/C	cg23176889	chr5:176863531	GRK6	-0.53	-7.93	-0.46	9.37e-14	Intelligence (multi-trait analysis);
SARC	cis	rs4742903	0.509	rs7863548	chr9:106962177	G/A	cg14250997	chr9:106856677	SMC2	0.39	4.8	0.3	2.81e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs2153535	0.623	rs2327055	chr6:8443145	A/G	cg07606381	chr6:8435919	SLC35B3	0.8	11.25	0.59	9.89e-24	Motion sickness;
SARC	cis	rs7223966	0.921	rs3020612	chr17:61960878	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.46	4.97	0.31	1.32e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg08280861	chr8:58055591	NA	0.58	5.23	0.32	3.69e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg15049968	chr18:44337910	ST8SIA5	-0.36	-5.74	-0.35	2.9e-8	Personality dimensions;
SARC	cis	rs6088813	1.000	rs735531	chr20:33947730	T/C	cg14752227	chr20:34000481	UQCC	-0.37	-4.85	-0.3	2.26e-6	Height;
SARC	cis	rs6732160	0.845	rs6546805	chr2:73386115	G/T	cg01422370	chr2:73384389	NA	0.32	5.47	0.34	1.18e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg22875332	chr1:76189707	ACADM	-0.63	-10.19	-0.56	2.14e-20	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7647973	0.710	rs1532204	chr3:49609477	C/G	cg06212747	chr3:49208901	KLHDC8B	0.73	6.49	0.39	5.02e-10	Menarche (age at onset);
SARC	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg23758822	chr17:41437982	NA	0.88	11.24	0.59	1.04e-23	Menopause (age at onset);
SARC	cis	rs881375	1.000	rs10818480	chr9:123643170	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.43	5.22	0.32	4.01e-7	Rheumatoid arthritis;
SARC	cis	rs12142240	0.698	rs6696777	chr1:46810970	A/G	cg00530320	chr1:46809349	NSUN4	0.58	7.07	0.42	1.83e-11	Menopause (age at onset);
SARC	cis	rs12458462	0.859	rs35493271	chr18:77448793	G/T	cg11879182	chr18:77439856	CTDP1	0.89	13.07	0.65	1.22e-29	Monocyte count;
SARC	cis	rs7429990	0.965	rs9846062	chr3:47998966	A/G	cg11946769	chr3:48343235	NME6	0.45	5.34	0.33	2.17e-7	Educational attainment (years of education);
SARC	cis	rs11969893	0.737	rs6930051	chr6:101406108	A/G	cg12253828	chr6:101329408	ASCC3	0.91	6.2	0.38	2.55e-9	Economic and political preferences (immigration/crime);
SARC	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg11062466	chr8:58055876	NA	0.59	5.72	0.35	3.33e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7264396	0.676	rs6060723	chr20:34549947	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	5.3	0.33	2.71e-7	Total cholesterol levels;
SARC	cis	rs6604026	0.656	rs9439948	chr1:93370800	A/G	cg17283838	chr1:93427260	FAM69A	-0.42	-4.75	-0.3	3.59e-6	Multiple sclerosis;
SARC	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg07061783	chr6:25882402	NA	-0.49	-5.92	-0.36	1.17e-8	Intelligence (multi-trait analysis);
SARC	cis	rs3741151	0.773	rs73542938	chr11:73103012	G/C	cg17517138	chr11:73019481	ARHGEF17	0.86	6.41	0.39	7.94e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs4660306	0.614	rs1007859	chr1:45911906	C/T	cg24296786	chr1:45957014	TESK2	-0.53	-5.15	-0.32	5.63e-7	Homocysteine levels;
SARC	cis	rs4595586	0.525	rs34204378	chr12:39425759	C/T	cg13010199	chr12:38710504	ALG10B	0.45	4.75	0.3	3.59e-6	Morning vs. evening chronotype;
SARC	trans	rs11174478	0.597	rs2896825	chr12:40432262	G/A	cg17715141	chr4:182609697	NA	-0.41	-6.24	-0.38	2.09e-9	Insomnia;
SARC	cis	rs865483	0.860	rs862490	chr17:35850275	T/C	cg06561646	chr17:35873369	DUSP14	-0.48	-6.33	-0.38	1.21e-9	Monocyte count;
SARC	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg20607798	chr8:58055168	NA	0.49	4.75	0.3	3.49e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs6088580	0.634	rs6142157	chr20:32984172	C/G	cg08999081	chr20:33150536	PIGU	-0.42	-6.49	-0.39	4.98e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs3820928	0.900	rs6754155	chr2:227784961	A/G	cg11843606	chr2:227700838	RHBDD1	-0.57	-7.27	-0.43	5.52e-12	Pulmonary function;
SARC	cis	rs9296092	0.538	rs115770720	chr6:33517032	A/T	cg13560919	chr6:33536144	NA	-0.51	-6.2	-0.38	2.48e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs9325144	0.624	rs10783329	chr12:39113951	C/T	cg26384229	chr12:38710491	ALG10B	-0.59	-7.49	-0.44	1.44e-12	Morning vs. evening chronotype;
SARC	cis	rs7264396	0.790	rs6060518	chr20:34217309	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-7.69	-0.45	4.04e-13	Total cholesterol levels;
SARC	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg13175981	chr1:150552382	MCL1	-0.54	-6.9	-0.41	4.97e-11	Tonsillectomy;
SARC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg05313129	chr8:58192883	C8orf71	-0.51	-4.79	-0.3	2.93e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg19774624	chr17:42201019	HDAC5	-0.87	-12.76	-0.64	1.26e-28	Total body bone mineral density;
SARC	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg15556689	chr8:8085844	FLJ10661	0.54	6.82	0.41	7.65e-11	Systolic blood pressure;
SARC	trans	rs656319	0.580	rs17690549	chr8:9998538	C/G	cg06636001	chr8:8085503	FLJ10661	-0.6	-7.73	-0.45	3.24e-13	Myopia (pathological);
SARC	cis	rs4803468	0.905	rs284662	chr19:41932275	T/C	cg14132834	chr19:41945861	ATP5SL	-0.58	-7.66	-0.45	4.89e-13	Height;
SARC	cis	rs7674212	0.507	rs6843738	chr4:103936001	G/A	cg16532752	chr4:104119610	CENPE	-0.41	-4.74	-0.3	3.74e-6	Type 2 diabetes;
SARC	cis	rs2072499	0.966	rs2984615	chr1:156165317	G/C	cg24450063	chr1:156163899	SLC25A44	1.18	21.2	0.81	2.66e-56	Testicular germ cell tumor;
SARC	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg13395646	chr4:1353034	KIAA1530	-0.58	-6.9	-0.41	4.8e-11	Obesity-related traits;
SARC	cis	rs9291683	0.566	rs13122689	chr4:10044648	A/G	cg00071950	chr4:10020882	SLC2A9	0.33	4.98	0.31	1.26e-6	Bone mineral density;
SARC	cis	rs9747201	0.925	rs11867806	chr17:80072049	A/G	cg09264619	chr17:80180166	NA	0.53	6.12	0.37	3.98e-9	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs10979	0.644	rs12527367	chr6:143918718	C/T	cg25407410	chr6:143891975	LOC285740	-0.51	-6.29	-0.38	1.53e-9	Hypospadias;
SARC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg11965913	chr1:205819406	PM20D1	0.99	19.07	0.78	1.73e-49	Menarche (age at onset);
SARC	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.4	-5.17	-0.32	5.14e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9300255	0.506	rs61388686	chr12:123810873	G/A	cg05973401	chr12:123451056	ABCB9	0.5	5.74	0.35	3e-8	Neutrophil percentage of white cells;
SARC	cis	rs765787	0.530	rs28897155	chr15:45533974	T/C	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.81e-6	Uric acid levels;
SARC	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg16049864	chr8:95962084	TP53INP1	-0.55	-8.87	-0.5	1.9e-16	Type 2 diabetes;
SARC	cis	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg22496380	chr5:211416	CCDC127	-0.88	-9.23	-0.52	1.67e-17	Breast cancer;
SARC	cis	rs72781680	0.898	rs113027486	chr2:24098371	G/A	cg08917208	chr2:24149416	ATAD2B	0.75	7.33	0.43	3.77e-12	Lymphocyte counts;
SARC	cis	rs6580649	0.883	rs4075913	chr12:48537624	A/G	cg24011408	chr12:48396354	COL2A1	0.47	5.22	0.32	3.95e-7	Lung cancer;
SARC	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.54	8.13	0.47	2.5e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs425277	1.000	rs262676	chr1:2078482	T/A	cg21442419	chr1:2182373	SKI	-0.52	-6.68	-0.4	1.76e-10	Height;
SARC	cis	rs2235544	0.565	rs634532	chr1:54468947	G/C	cg10336722	chr1:54665764	CYB5RL;MRPL37	-0.38	-4.74	-0.3	3.66e-6	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg07939768	chr17:27621433	NUFIP2	-0.56	-6.37	-0.39	9.83e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg20607798	chr8:58055168	NA	0.65	5.59	0.34	6.26e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2439831	0.702	rs7175032	chr15:44060236	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	8.6	0.49	1.21e-15	Lung cancer in ever smokers;
SARC	cis	rs7644634	0.688	rs894937	chr3:105442953	T/C	cg23051926	chr3:105466016	CBLB	0.44	5.52	0.34	9.1e-8	Itch intensity from mosquito bite;
SARC	cis	rs13166103	0.657	rs62368206	chr5:57707216	A/G	cg10487770	chr5:57879443	RAB3C	0.52	5.54	0.34	8.05e-8	Type 2 diabetes (age of onset);
SARC	cis	rs11155671	0.530	rs4869763	chr6:150211684	T/C	cg05036130	chr6:150231994	NA	0.28	4.87	0.3	2.04e-6	Testicular germ cell tumor;
SARC	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg18252515	chr7:66147081	NA	-1.3	-11.62	-0.61	6.33e-25	Diabetic kidney disease;
SARC	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg22800045	chr5:56110881	MAP3K1	0.74	7.98	0.46	6.46e-14	Initial pursuit acceleration;
SARC	cis	rs986417	0.818	rs12880313	chr14:60935504	T/C	cg27398547	chr14:60952738	C14orf39	1.01	9.11	0.51	3.86e-17	Gut microbiota (bacterial taxa);
SARC	cis	rs4713118	0.527	rs36042294	chr6:27720712	C/G	cg17221315	chr6:27791827	HIST1H4J	0.4	4.94	0.31	1.49e-6	Parkinson's disease;
SARC	cis	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg20965017	chr5:231967	SDHA	-0.56	-5.32	-0.33	2.4e-7	Breast cancer;
SARC	cis	rs11687170	0.938	rs73131625	chr2:237059794	T/C	cg19324714	chr2:237145437	ASB18	0.49	4.89	0.31	1.89e-6	Educational attainment;Educational attainment (years of education);
SARC	cis	rs4711350	0.765	rs943476	chr6:33750086	A/G	cg07979401	chr6:33739406	LEMD2	-0.38	-4.8	-0.3	2.77e-6	Schizophrenia;
SARC	cis	rs11264799	0.501	rs849827	chr1:157545231	G/T	cg18268488	chr1:157545234	FCRL4	0.32	5.75	0.35	2.73e-8	IgA nephropathy;
SARC	cis	rs317689	0.918	rs610192	chr12:69739941	T/C	cg14784868	chr12:69753453	YEATS4	0.44	4.74	0.3	3.68e-6	Response to diuretic therapy;
SARC	cis	rs13314892	0.728	rs62250982	chr3:69844845	C/T	cg17445875	chr3:69859618	MITF	-0.47	-4.88	-0.3	1.98e-6	QRS complex (12-leadsum);
SARC	cis	rs12824058	0.831	rs12831363	chr12:130814013	C/T	cg26677194	chr12:130822605	PIWIL1	-0.56	-7.67	-0.45	4.69e-13	Menopause (age at onset);
SARC	cis	rs11190604	1.000	rs2495753	chr10:102325640	C/T	cg07080220	chr10:102295463	HIF1AN	0.8	8.86	0.5	2.12e-16	Palmitoleic acid (16:1n-7) levels;
SARC	trans	rs656319	0.585	rs13272731	chr8:9906934	C/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.1	-0.47	3e-14	Myopia (pathological);
SARC	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7589342	0.566	rs11890447	chr2:106389691	T/C	cg16077055	chr2:106428750	NCK2	0.32	6.27	0.38	1.71e-9	Addiction;
SARC	cis	rs4555082	0.874	rs11622166	chr14:105759763	C/A	cg06808227	chr14:105710500	BRF1	-0.51	-6.28	-0.38	1.67e-9	Mean platelet volume;Platelet distribution width;
SARC	cis	rs2576037	0.796	rs2247221	chr18:44580082	C/T	cg19077165	chr18:44547161	KATNAL2	0.43	6.03	0.37	6.27e-9	Personality dimensions;
SARC	cis	rs10752881	0.967	rs4652757	chr1:182974750	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.76	0.58	3.38e-22	Colorectal cancer;
SARC	cis	rs4273100	0.646	rs1472932	chr17:19220666	C/T	cg25447019	chr17:19030144	GRAPL	0.36	5.48	0.34	1.09e-7	Schizophrenia;
SARC	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg18252515	chr7:66147081	NA	-1.33	-11.84	-0.61	1.22e-25	Diabetic kidney disease;
SARC	cis	rs11644362	1.000	rs4781349	chr16:12987249	T/C	cg06890432	chr16:12997467	SHISA9	-0.54	-7.1	-0.42	1.51e-11	Positive affect;Subjective well-being;
SARC	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-6.38	-0.39	9.39e-10	Personality dimensions;
SARC	cis	rs11785693	0.602	rs73190403	chr8:4954798	T/C	cg26367366	chr8:4980734	NA	0.57	4.81	0.3	2.67e-6	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg08280861	chr8:58055591	NA	0.6	5.28	0.33	2.92e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs72781680	0.611	rs72783619	chr2:24311607	G/A	cg06627628	chr2:24431161	ITSN2	-0.56	-5.81	-0.36	2e-8	Lymphocyte counts;
SARC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.45	5.41	0.33	1.57e-7	Calcium levels;
SARC	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg02725872	chr8:58115012	NA	-0.36	-5.47	-0.34	1.16e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs918629	0.761	rs3777166	chr5:95291056	G/C	cg16656078	chr5:95278638	ELL2	-0.7	-8.3	-0.48	8.46e-15	IgG glycosylation;
SARC	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg13206674	chr6:150067644	NUP43	0.42	5.41	0.33	1.59e-7	Lung cancer;
SARC	cis	rs3087591	0.960	rs2905802	chr17:29520084	T/C	cg24425628	chr17:29625626	OMG;NF1	0.5	6.11	0.37	4.05e-9	Hip circumference;
SARC	cis	rs2204008	0.563	rs2320512	chr12:38266913	G/A	cg26384229	chr12:38710491	ALG10B	-0.62	-7.75	-0.45	2.8e-13	Bladder cancer;
SARC	cis	rs12451471	0.667	rs12942002	chr17:78101629	C/G	cg24585782	chr17:78113791	EIF4A3	-0.56	-6.39	-0.39	8.92e-10	Plateletcrit;Mean corpuscular hemoglobin concentration;
SARC	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg06634786	chr22:41940651	POLR3H	-0.56	-6.5	-0.39	4.93e-10	Vitiligo;
SARC	cis	rs10489202	0.657	rs201540	chr1:167992883	G/A	cg17859187	chr1:168147929	TIPRL	0.39	4.71	0.3	4.17e-6	Schizophrenia;
SARC	cis	rs1707322	0.752	rs12027622	chr1:46130252	A/C	cg06784218	chr1:46089804	CCDC17	0.36	6.25	0.38	1.97e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1322639	0.618	rs9505942	chr6:169591793	T/C	cg04662567	chr6:169592167	NA	-0.53	-5.33	-0.33	2.37e-7	Pulse pressure;
SARC	trans	rs1994135	0.654	rs1384591	chr12:33734170	T/C	cg13010199	chr12:38710504	ALG10B	0.59	6.98	0.42	3.05e-11	Resting heart rate;
SARC	cis	rs2197308	0.605	rs2387437	chr12:37919367	T/C	cg13010199	chr12:38710504	ALG10B	0.76	10.14	0.55	2.95e-20	Morning vs. evening chronotype;
SARC	cis	rs8067545	1.000	rs4925066	chr17:19915292	A/G	cg13482628	chr17:19912719	NA	0.67	9.57	0.53	1.67e-18	Schizophrenia;
SARC	cis	rs12802200	0.561	rs746707	chr11:571984	C/T	cg01842473	chr11:617407	IRF7;MUPCDH	-0.39	-4.77	-0.3	3.28e-6	Systemic lupus erythematosus;
SARC	cis	rs5753037	0.653	rs140129	chr22:30150549	C/T	cg01021169	chr22:30184971	ASCC2	-0.44	-6.27	-0.38	1.69e-9	Type 1 diabetes;
SARC	cis	rs9787249	0.874	rs7520588	chr1:40214525	T/A	cg24920358	chr1:40204285	PPIE	0.43	5.25	0.33	3.45e-7	Blood protein levels;
SARC	cis	rs72781680	1.000	rs61739076	chr2:24149439	G/A	cg06627628	chr2:24431161	ITSN2	-0.75	-6.81	-0.41	7.99e-11	Lymphocyte counts;
SARC	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg05025164	chr4:1340916	KIAA1530	0.47	5.57	0.34	7.15e-8	Obesity-related traits;
SARC	cis	rs4975616	0.869	rs467095	chr5:1336221	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.61	-9.01	-0.51	7.8e-17	Lung cancer;
SARC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg06873352	chr17:61820015	STRADA	0.53	6.87	0.41	5.67e-11	Prudent dietary pattern;
SARC	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg05255149	chr17:80675120	FN3KRP	0.44	4.89	0.3	1.92e-6	Glycated hemoglobin levels;
SARC	cis	rs7592578	0.679	rs62181018	chr2:191323295	C/T	cg27211696	chr2:191398769	TMEM194B	-0.5	-5.41	-0.33	1.58e-7	Diastolic blood pressure;
SARC	cis	rs9325144	0.555	rs2387855	chr12:38687964	T/G	cg26384229	chr12:38710491	ALG10B	0.59	7.85	0.46	1.51e-13	Morning vs. evening chronotype;
SARC	cis	rs9398803	0.698	rs1101563	chr6:127049198	T/C	cg20229609	chr6:126660872	C6orf173	-0.34	-4.85	-0.3	2.29e-6	Male-pattern baldness;
SARC	cis	rs4589502	0.925	rs57729347	chr15:67136438	G/A	cg12317470	chr15:67143691	NA	0.73	7.33	0.43	3.75e-12	Lung cancer (smoking interaction);
SARC	cis	rs3820928	0.810	rs10175929	chr2:227858609	T/C	cg11843606	chr2:227700838	RHBDD1	-0.5	-6.16	-0.37	3.21e-9	Pulmonary function;
SARC	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	7.23	0.43	6.7e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6582630	0.538	rs7971292	chr12:38498151	A/G	cg26384229	chr12:38710491	ALG10B	-0.57	-7.2	-0.43	8.4e-12	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs734999	0.588	rs876938	chr1:2523212	G/C	cg18854424	chr1:2615690	NA	0.32	5.1	0.32	7.02e-7	Ulcerative colitis;
SARC	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg04944784	chr2:26401820	FAM59B	-0.47	-5.77	-0.35	2.47e-8	Gut microbiome composition (summer);
SARC	trans	rs6600671	0.902	rs2222371	chr1:121289118	T/C	cg00646200	chr1:148855367	NA	-0.51	-6.92	-0.41	4.28e-11	Hip geometry;
SARC	cis	rs965469	1.000	rs6051762	chr20:3321590	T/C	cg25506879	chr20:3388711	C20orf194	-0.54	-5.54	-0.34	7.95e-8	IFN-related cytopenia;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg04467034	chr13:111567140	ANKRD10	0.71	4.84	0.3	2.36e-6	Obesity-related traits;
SARC	cis	rs17376456	0.825	rs35426871	chr5:93291613	C/T	cg21475434	chr5:93447410	FAM172A	0.86	7.62	0.45	6.29e-13	Diabetic retinopathy;
SARC	trans	rs3942852	0.774	rs11039519	chr11:48130094	G/C	cg15704280	chr7:45808275	SEPT13	-0.58	-6.72	-0.4	1.42e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9818758	0.505	rs67286839	chr3:49265744	C/T	cg07636037	chr3:49044803	WDR6	-0.78	-6.83	-0.41	7.41e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg22920501	chr2:26401640	FAM59B	-0.55	-6.98	-0.42	2.99e-11	Gut microbiome composition (summer);
SARC	cis	rs7208859	0.623	rs9906957	chr17:29157755	C/T	cg13385521	chr17:29058706	SUZ12P	0.87	7.83	0.46	1.76e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs6570726	0.791	rs1280276	chr6:145892350	A/C	cg05347473	chr6:146136440	FBXO30	0.53	7.1	0.42	1.49e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs372883	0.583	rs117214	chr21:30720834	A/G	cg08807101	chr21:30365312	RNF160	0.48	6.05	0.37	5.63e-9	Pancreatic cancer;
SARC	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg26335602	chr6:28129616	ZNF389	0.47	5.48	0.34	1.13e-7	Depression;
SARC	cis	rs2467099	0.504	rs2666005	chr17:73944596	T/G	cg14829360	chr17:73884958	NA	-0.46	-6.28	-0.38	1.68e-9	Systolic blood pressure;
SARC	trans	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg00938859	chr5:1591904	SDHAP3	0.75	7.25	0.43	5.92e-12	Breast cancer;
SARC	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg00933542	chr6:150070202	PCMT1	0.31	5.29	0.33	2.78e-7	Lung cancer;
SARC	cis	rs2770228	1.000	rs9300412	chr13:98097280	A/G	cg18050715	chr13:97996992	MBNL2	0.68	5.08	0.32	7.7300000000000005e-07	Metabolite levels (Dihydroxy docosatrienoic acid);
SARC	cis	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg14541582	chr5:601475	NA	-0.39	-4.89	-0.31	1.89e-6	Obesity-related traits;
SARC	cis	rs11249608	0.548	rs7707587	chr5:178462590	G/C	cg21905437	chr5:178450457	ZNF879	0.57	7.47	0.44	1.63e-12	Pubertal anthropometrics;
SARC	cis	rs910316	1.000	rs12589376	chr14:75561152	C/T	cg08847533	chr14:75593920	NEK9	0.93	15.86	0.72	6.47e-39	Height;
SARC	cis	rs2228479	0.557	rs11641726	chr16:89891619	G/A	cg00800038	chr16:89945340	TCF25	-0.82	-5.77	-0.35	2.46e-8	Skin colour saturation;
SARC	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.44	-5.64	-0.35	4.97e-8	Personality dimensions;
SARC	cis	rs9341808	0.667	rs2490244	chr6:80891112	A/T	cg08355045	chr6:80787529	NA	0.36	5.72	0.35	3.27e-8	Sitting height ratio;
SARC	cis	rs9790314	0.718	rs1599383	chr3:160829820	T/C	cg03342759	chr3:160939853	NMD3	-0.49	-6.02	-0.37	6.64e-9	Morning vs. evening chronotype;
SARC	cis	rs9309473	1.000	rs6546839	chr2:73680508	G/C	cg20560298	chr2:73613845	ALMS1	-0.51	-6.12	-0.37	3.98e-9	Metabolite levels;
SARC	cis	rs3796352	0.667	rs17331178	chr3:52847544	C/A	cg27565382	chr3:53032988	SFMBT1	0.77	5.04	0.31	9.18e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs7589342	0.628	rs35482041	chr2:106409436	A/G	cg16077055	chr2:106428750	NCK2	0.33	5.54	0.34	8.2e-8	Addiction;
SARC	cis	rs9303401	0.659	rs11079358	chr17:56920949	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.07	12.11	0.62	1.62e-26	Cognitive test performance;
SARC	cis	rs7824557	0.767	rs7837036	chr8:11175489	A/G	cg21775007	chr8:11205619	TDH	0.53	6.34	0.38	1.16e-9	Retinal vascular caliber;
SARC	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg14895029	chr7:2775587	GNA12	-0.4	-4.93	-0.31	1.59e-6	Height;
SARC	cis	rs6690583	0.623	rs61770879	chr1:85504938	A/C	cg22488158	chr1:85528044	WDR63	0.66	5.3	0.33	2.62e-7	Serum sulfate level;
SARC	cis	rs72781680	0.898	rs72782138	chr2:24048162	T/C	cg08917208	chr2:24149416	ATAD2B	0.78	7.41	0.44	2.26e-12	Lymphocyte counts;
SARC	cis	rs1707322	1.000	rs1768817	chr1:46514534	C/G	cg03146154	chr1:46216737	IPP	-0.47	-5.65	-0.35	4.59e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2439831	0.850	rs56909447	chr15:44137618	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.76	7.53	0.44	1.14e-12	Lung cancer in ever smokers;
SARC	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg24675658	chr1:53192096	ZYG11B	0.6	8.35	0.48	6.11e-15	Monocyte count;
SARC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg24829409	chr8:58192753	C8orf71	-0.59	-5.33	-0.33	2.32e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg18252515	chr7:66147081	NA	1.34	11.82	0.61	1.44e-25	Diabetic kidney disease;
SARC	cis	rs76419734	1.000	rs34072732	chr4:106604364	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.8	4.87	0.3	2.02e-6	Post bronchodilator FEV1;
SARC	cis	rs73206853	0.764	rs7980838	chr12:110672978	T/A	cg10860002	chr12:110842031	ANAPC7	0.64	5.24	0.32	3.54e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs35955747	0.870	rs7289189	chr22:31657182	C/T	cg13145458	chr22:31556086	RNF185	0.4	4.89	0.31	1.86e-6	Neutrophil count;Sum basophil neutrophil counts;
SARC	cis	rs1941023	0.584	rs2197236	chr11:60168859	T/C	cg08716584	chr11:60157161	MS4A7	-0.41	-6.65	-0.4	2.09e-10	Congenital heart disease (maternal effect);
SARC	cis	rs12472274	0.646	rs10929269	chr2:239097423	A/G	cg17459225	chr2:239074497	NA	0.6	6.17	0.37	2.93e-9	Phospholipid levels (plasma);
SARC	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.68	6.53	0.39	4.09e-10	Platelet count;
SARC	cis	rs8180040	0.726	rs13094672	chr3:47149439	C/T	cg27129171	chr3:47204927	SETD2	0.67	9.36	0.52	6.78e-18	Colorectal cancer;
SARC	cis	rs12681366	0.593	rs2515154	chr8:95388903	T/C	cg26464482	chr8:95565502	KIAA1429	-0.44	-5.42	-0.33	1.49e-7	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg11494091	chr17:61959527	GH2	0.55	8.31	0.48	7.99e-15	Prudent dietary pattern;
SARC	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.67	9.18	0.52	2.48e-17	Menarche (age at onset);
SARC	cis	rs9815354	1.000	rs6781326	chr3:41777028	T/C	cg03022575	chr3:42003672	ULK4	0.57	5.48	0.34	1.1e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs270601	0.913	rs273899	chr5:131695178	G/A	cg12564285	chr5:131593104	PDLIM4	0.46	6.23	0.38	2.15e-9	Acylcarnitine levels;
SARC	cis	rs2273669	0.667	rs7761290	chr6:109326621	T/G	cg05315195	chr6:109294784	ARMC2	-0.59	-5.45	-0.34	1.28e-7	Prostate cancer;
SARC	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg00684032	chr4:1343700	KIAA1530	0.38	5.52	0.34	9.14e-8	Obesity-related traits;
SARC	cis	rs2404602	0.647	rs10851889	chr15:77023336	C/T	cg15268244	chr15:77196840	NA	0.42	4.87	0.3	2.06e-6	Blood metabolite levels;
SARC	cis	rs2204008	0.837	rs11168334	chr12:37961768	A/G	cg13010199	chr12:38710504	ALG10B	0.79	10.96	0.58	8.31e-23	Bladder cancer;
SARC	cis	rs7582720	0.943	rs72936839	chr2:203773237	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.31	0.43	4.24e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	trans	rs61931739	0.517	rs11513277	chr12:34074799	G/T	cg26384229	chr12:38710491	ALG10B	0.87	12.36	0.63	2.53e-27	Morning vs. evening chronotype;
SARC	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	15.01	0.7	4.48e-36	Chronic sinus infection;
SARC	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg15352829	chr14:105391018	PLD4	-0.34	-6.56	-0.39	3.4e-10	Rheumatoid arthritis;
SARC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	9.23	0.52	1.67e-17	Prudent dietary pattern;
SARC	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg01765077	chr12:122356316	WDR66	0.32	4.97	0.31	1.32e-6	Mean corpuscular volume;
SARC	cis	rs76419734	1.000	rs72671886	chr4:106670589	G/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.76	4.98	0.31	1.23e-6	Post bronchodilator FEV1;
SARC	cis	rs4332037	0.851	rs34040190	chr7:1920356	G/A	cg23422044	chr7:1970798	MAD1L1	-0.49	-5.27	-0.33	3.05e-7	Bipolar disorder;
SARC	cis	rs2120019	0.938	rs2289582	chr15:75310394	T/C	cg17294928	chr15:75287854	SCAMP5	-1.03	-14.77	-0.7	2.86e-35	Blood trace element (Zn levels);
SARC	cis	rs11098499	0.955	rs1397608	chr4:120161744	A/G	cg09307838	chr4:120376055	NA	0.84	11.55	0.6	1.04e-24	Corneal astigmatism;
SARC	cis	rs1729951	0.575	rs75976	chr3:136700455	G/A	cg15507776	chr3:136538369	TMEM22	0.49	5.32	0.33	2.4e-7	Neuroticism;
SARC	cis	rs7666738	0.830	rs11725095	chr4:99009711	T/A	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg01881761	chr2:170366961	KBTBD10	0.52	7.48	0.44	1.5e-12	Thyroid stimulating hormone;
SARC	cis	rs6582630	0.555	rs6582503	chr12:38557886	A/C	cg13010199	chr12:38710504	ALG10B	0.79	11.02	0.59	5.37e-23	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7615952	0.932	rs13325495	chr3:125637416	T/G	cg05084668	chr3:125655381	ALG1L	-0.66	-6.36	-0.38	1.07e-9	Blood pressure (smoking interaction);
SARC	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg16325326	chr1:53192061	ZYG11B	-0.94	-18.17	-0.77	1.55e-46	Monocyte count;
SARC	cis	rs733592	0.931	rs765260	chr12:48431936	C/T	cg24011408	chr12:48396354	COL2A1	-0.48	-6.46	-0.39	5.88e-10	Plateletcrit;
SARC	cis	rs7772486	0.655	rs2142981	chr6:146071695	G/C	cg05347473	chr6:146136440	FBXO30	-0.56	-7.76	-0.45	2.73e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9814567	1.000	rs4974493	chr3:134219993	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.08	-0.42	1.7e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs4689388	0.890	rs4501291	chr4:6298582	C/T	cg14416269	chr4:6271139	WFS1	0.33	5.09	0.32	7.43e-7	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs10779751	0.686	rs2791656	chr1:11128329	A/G	cg08854313	chr1:11322531	MTOR	0.78	10.02	0.55	7.11e-20	Body mass index;
SARC	cis	rs4423214	0.879	rs1792277	chr11:71138918	C/T	cg05163923	chr11:71159392	DHCR7	-0.59	-6.85	-0.41	6.51e-11	Vitamin D levels;
SARC	cis	rs7560272	0.669	rs7598660	chr2:73740425	C/T	cg20560298	chr2:73613845	ALMS1	-0.43	-5.87	-0.36	1.48e-8	Schizophrenia;
SARC	cis	rs7089973	0.872	rs7918388	chr10:116614563	T/C	cg08188268	chr10:116634841	FAM160B1	0.36	5.8	0.36	2.13e-8	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs2280018	0.581	rs7404524	chr16:15129158	A/G	cg07549590	chr16:15018862	NA	-0.44	-5.88	-0.36	1.45e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg24160582	chr14:81610002	TSHR	-0.48	-6.68	-0.4	1.76e-10	Lung adenocarcinoma;
SARC	cis	rs2075371	0.966	rs2544225	chr7:133995838	A/C	cg00033643	chr7:134001901	SLC35B4	0.42	5.15	0.32	5.55e-7	Mean platelet volume;
SARC	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg07685180	chr8:600429	NA	0.84	6.48	0.39	5.37e-10	IgG glycosylation;
SARC	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg24829409	chr8:58192753	C8orf71	-0.62	-6.51	-0.39	4.69e-10	Developmental language disorder (linguistic errors);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg25976004	chr4:56815073	CEP135	0.48	6.74	0.4	1.24e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs3768617	0.677	rs12739316	chr1:183052080	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.65	9.24	0.52	1.62e-17	Fuchs's corneal dystrophy;
SARC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg09033563	chr22:24373618	LOC391322	-0.43	-4.84	-0.3	2.32e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6714710	0.603	rs35424768	chr2:98395653	A/C	cg26665480	chr2:98280029	ACTR1B	0.49	6.49	0.39	5.15e-10	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg10351095	chr21:47802916	PCNT	-0.41	-4.84	-0.3	2.37e-6	Testicular germ cell tumor;
SARC	cis	rs9868809	0.772	rs9811318	chr3:48702606	A/G	cg07636037	chr3:49044803	WDR6	-0.69	-6.38	-0.39	9.4e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	trans	rs11098499	0.955	rs7685268	chr4:120162188	G/A	cg25214090	chr10:38739885	LOC399744	0.52	6.86	0.41	6.19e-11	Corneal astigmatism;
SARC	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg24633833	chr3:10029261	TMEM111	0.52	5.25	0.33	3.43e-7	Alzheimer's disease;
SARC	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.4	-6.04	-0.37	6.11e-9	Total body bone mineral density;
SARC	cis	rs10028773	0.506	rs12374346	chr4:120281705	G/A	cg09307838	chr4:120376055	NA	0.83	11.82	0.61	1.46e-25	Educational attainment;
SARC	cis	rs5753618	0.504	rs5753661	chr22:31899797	C/A	cg02404636	chr22:31891804	SFI1	0.54	5.95	0.36	9.81e-9	Colorectal cancer;
SARC	cis	rs228437	1.000	rs73775366	chr6:134963061	T/C	cg24504307	chr6:134963096	NA	-0.54	-6.23	-0.38	2.19e-9	Melanoma;
SARC	cis	rs12579753	1.000	rs10862371	chr12:82249298	C/T	cg07988820	chr12:82153109	PPFIA2	-0.55	-6.48	-0.39	5.55e-10	Resting heart rate;
SARC	cis	rs4888262	0.545	rs4243108	chr16:74692453	A/G	cg02853019	chr16:75273486	BCAR1	-0.36	-4.87	-0.3	2.05e-6	Testicular germ cell tumor;
SARC	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg18225595	chr11:63971243	STIP1	0.44	5.26	0.33	3.27e-7	Mean platelet volume;
SARC	cis	rs2228479	0.850	rs11644526	chr16:89898660	C/T	cg12064134	chr16:90016061	DEF8	-0.56	-4.79	-0.3	2.91e-6	Skin colour saturation;
SARC	cis	rs9916302	0.904	rs55660616	chr17:37684990	C/A	cg20243544	chr17:37824526	PNMT	0.53	6.17	0.37	2.93e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs7647973	1.000	rs11130190	chr3:49402137	T/C	cg06212747	chr3:49208901	KLHDC8B	0.56	5.75	0.35	2.8e-8	Menarche (age at onset);
SARC	trans	rs61931739	0.500	rs11519123	chr12:34436478	A/G	cg26384229	chr12:38710491	ALG10B	0.84	12.74	0.64	1.41e-28	Morning vs. evening chronotype;
SARC	cis	rs1355223	0.583	rs2941043	chr11:34870994	A/G	cg18508148	chr11:34937573	PDHX;APIP	-0.49	-6.39	-0.39	9.18e-10	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs9393692	0.557	rs62394768	chr6:26326033	C/T	cg13736514	chr6:26305472	NA	-0.39	-4.75	-0.3	3.58e-6	Educational attainment;
SARC	cis	rs2075371	0.796	rs12154724	chr7:133943443	G/A	cg20476274	chr7:133979776	SLC35B4	0.54	6.89	0.41	5.05e-11	Mean platelet volume;
SARC	cis	rs751728	1.000	rs4342423	chr6:33732679	C/T	cg15252951	chr6:33757062	LEMD2	0.58	6.76	0.4	1.11e-10	Crohn's disease;
SARC	cis	rs2777491	0.522	rs7173571	chr15:41712807	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.4	-5.38	-0.33	1.82e-7	Ulcerative colitis;
SARC	cis	rs921968	0.565	rs13412324	chr2:219620521	T/C	cg02176678	chr2:219576539	TTLL4	-0.32	-4.88	-0.3	1.93e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1957429	0.808	rs8009510	chr14:65351338	T/G	cg23373153	chr14:65346875	NA	1.1	11.91	0.62	7.39e-26	Pediatric areal bone mineral density (radius);
SARC	cis	rs713477	0.817	rs55868790	chr14:55913275	T/C	cg13175173	chr14:55914753	NA	-0.31	-4.77	-0.3	3.29e-6	Pediatric bone mineral content (femoral neck);
SARC	cis	rs17376456	0.597	rs10866760	chr5:93338335	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.49	-5.32	-0.33	2.42e-7	Diabetic retinopathy;
SARC	cis	rs7223966	1.000	rs8078862	chr17:61854068	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-5.76	-0.35	2.6e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2153535	0.580	rs965706	chr6:8464708	G/A	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	trans	rs11098499	0.909	rs28555550	chr4:120211040	C/G	cg25214090	chr10:38739885	LOC399744	0.54	7.07	0.42	1.75e-11	Corneal astigmatism;
SARC	cis	rs17270561	0.609	rs7769908	chr6:25760539	G/A	cg16482183	chr6:26056742	HIST1H1C	0.48	5.95	0.36	9.58e-9	Iron status biomarkers;
SARC	cis	rs4273100	0.688	rs4924980	chr17:19204863	T/C	cg18906043	chr17:18967111	NA	-0.44	-4.89	-0.31	1.87e-6	Schizophrenia;
SARC	cis	rs8114671	0.967	rs6088734	chr20:33745046	A/T	cg24642439	chr20:33292090	TP53INP2	0.53	6.03	0.37	6.49e-9	Height;
SARC	cis	rs763121	0.853	rs5757232	chr22:39071677	C/T	cg21395723	chr22:39101663	GTPBP1	0.54	6.04	0.37	6.17e-9	Menopause (age at onset);
SARC	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg13395646	chr4:1353034	KIAA1530	-0.53	-6.33	-0.38	1.23e-9	Obesity-related traits;
SARC	cis	rs9467711	0.591	rs60512607	chr6:26054171	T/A	cg21479132	chr6:26055353	NA	1.01	7.64	0.45	5.77e-13	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7412746	0.586	rs2864882	chr1:150883037	C/T	cg13175981	chr1:150552382	MCL1	-0.51	-6.28	-0.38	1.64e-9	Melanoma;
SARC	cis	rs6565189	0.865	rs4500746	chr16:30504344	T/C	cg17640201	chr16:30407289	ZNF48	0.5	5.22	0.32	4.01e-7	Tonsillectomy;
SARC	cis	rs17376456	0.504	rs7702649	chr5:93065149	C/A	cg21475434	chr5:93447410	FAM172A	0.65	6.37	0.39	9.96e-10	Diabetic retinopathy;
SARC	trans	rs17685	0.725	rs7807647	chr7:75628669	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.6	-7.41	-0.44	2.32e-12	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs1799949	0.827	rs74252763	chr17:41402020	C/T	cg23758822	chr17:41437982	NA	0.93	11.43	0.6	2.58e-24	Menopause (age at onset);
SARC	cis	rs2760061	0.603	rs697761	chr1:228192397	G/A	cg01200585	chr1:228362443	C1orf69	0.46	5.69	0.35	3.75e-8	Diastolic blood pressure;
SARC	trans	rs56279505	0.690	rs2165670	chr4:100286085	G/A	cg21156590	chr1:3420848	MEGF6	-0.78	-6.26	-0.38	1.79e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2273669	0.667	rs11153147	chr6:109304058	A/G	cg05315195	chr6:109294784	ARMC2	-0.57	-5.24	-0.32	3.62e-7	Prostate cancer;
SARC	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg13880726	chr7:1868755	MAD1L1	0.53	6.13	0.37	3.72e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs9815354	1.000	rs9875107	chr3:41822313	A/T	cg03022575	chr3:42003672	ULK4	0.59	5.73	0.35	3.05e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs12586317	0.513	rs17102962	chr14:35478782	A/T	cg26967526	chr14:35346199	BAZ1A	-0.57	-5.73	-0.35	3.02e-8	Psoriasis;
SARC	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg01238044	chr22:24384105	GSTT1	-0.57	-6.3	-0.38	1.44e-9	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs26232	0.583	rs26430	chr5:102365932	G/A	cg23492399	chr5:102201601	PAM	0.45	5.02	0.31	1.03e-6	Rheumatoid arthritis;
SARC	cis	rs1050631	1.000	rs719147	chr18:33698192	T/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.42	5.06	0.31	8.67e-7	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg06873352	chr17:61820015	STRADA	0.53	6.85	0.41	6.67e-11	Prudent dietary pattern;
SARC	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg19223190	chr17:80058835	NA	-0.43	-6.02	-0.37	6.57e-9	Life satisfaction;
SARC	cis	rs2985684	0.948	rs4900925	chr14:50012325	A/G	cg04989706	chr14:50066350	PPIL5	0.5	4.87	0.3	2.06e-6	Carotid intima media thickness;
SARC	cis	rs2011503	0.882	rs751857	chr19:19602873	G/T	cg15839431	chr19:19639596	YJEFN3	-0.48	-4.78	-0.3	3.15e-6	Bipolar disorder;
SARC	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg07701084	chr6:150067640	NUP43	0.41	5.29	0.33	2.81e-7	Lung cancer;
SARC	cis	rs7100689	0.646	rs7092237	chr10:82165640	A/G	cg00277334	chr10:82204260	NA	-0.39	-5.17	-0.32	5.08e-7	Post bronchodilator FEV1;
SARC	cis	rs9462027	0.540	rs9469867	chr6:34742449	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.75	-0.35	2.85e-8	Systemic lupus erythematosus;
SARC	cis	rs9916302	0.904	rs620686	chr17:37453617	A/G	cg00129232	chr17:37814104	STARD3	0.59	7.27	0.43	5.32e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs763121	0.853	rs2072795	chr22:39064209	A/G	cg21395723	chr22:39101663	GTPBP1	-0.55	-6.17	-0.37	3.02e-9	Menopause (age at onset);
SARC	cis	rs7103648	1.000	rs12292911	chr11:47449072	C/T	cg20307385	chr11:47447363	PSMC3	0.88	14.28	0.68	1.18e-33	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs9811216	0.917	rs13069553	chr3:169508272	A/G	cg14222479	chr3:169487675	ARPM1	0.45	5.23	0.32	3.82e-7	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs2153535	0.580	rs6905237	chr6:8471790	A/T	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.01e-14	Motion sickness;
SARC	cis	rs6429082	0.818	rs291383	chr1:235643100	G/A	cg26050004	chr1:235667680	B3GALNT2	0.67	8.37	0.48	5.2e-15	Adiposity;
SARC	cis	rs12134245	0.874	rs34842487	chr1:92021611	C/T	cg02896835	chr1:92012615	NA	-0.45	-6.14	-0.37	3.55e-9	Breast cancer;
SARC	cis	rs56235845	0.694	rs11738681	chr5:176761535	A/G	cg16006841	chr5:176797999	RGS14	0.51	6.9	0.41	4.85e-11	Hemoglobin concentration;Hematocrit;
SARC	cis	rs7560272	0.501	rs12713793	chr2:73956114	T/C	cg20560298	chr2:73613845	ALMS1	0.43	5.73	0.35	3.09e-8	Schizophrenia;
SARC	cis	rs11155671	0.530	rs7768665	chr6:150208024	G/A	cg05036130	chr6:150231994	NA	0.29	5.05	0.31	8.9e-7	Testicular germ cell tumor;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg23145206	chr10:35463958	CREM	0.49	6.74	0.4	1.24e-10	Thyroid stimulating hormone;
SARC	cis	rs2832191	0.791	rs2832198	chr21:30498240	C/T	cg08807101	chr21:30365312	RNF160	0.79	10.69	0.57	5.78e-22	Dental caries;
SARC	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg11764359	chr7:65958608	NA	-0.53	-6.07	-0.37	5.09e-9	Aortic root size;
SARC	cis	rs9818758	0.607	rs9311439	chr3:49310408	A/G	cg07636037	chr3:49044803	WDR6	-0.75	-6.54	-0.39	3.94e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs3796352	1.000	rs58660500	chr3:53086573	C/T	cg12962167	chr3:53033115	SFMBT1	0.81	5.46	0.34	1.22e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs8017423	0.967	rs11627528	chr14:90719697	C/A	cg20276874	chr14:90721474	PSMC1	0.36	4.93	0.31	1.54e-6	Mortality in heart failure;
SARC	cis	rs4243830	0.737	rs11122083	chr1:6593532	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.05	-10.52	-0.57	2e-21	Body mass index;
SARC	cis	rs2073300	0.609	rs34648279	chr20:23402935	T/G	cg16736954	chr20:23401023	NAPB	0.77	4.76	0.3	3.39e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs4969178	0.965	rs16971105	chr17:76393975	G/T	cg02836325	chr17:76403955	PGS1	0.32	4.98	0.31	1.21e-6	HDL cholesterol levels;
SARC	cis	rs9902453	0.904	rs10853136	chr17:28406018	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.56	-7.24	-0.43	6.54e-12	Coffee consumption (cups per day);
SARC	cis	rs1707322	0.721	rs10430124	chr1:46221617	C/T	cg06784218	chr1:46089804	CCDC17	0.37	6.44	0.39	6.9e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs501120	0.657	rs649192	chr10:44741179	G/C	cg09554077	chr10:44749378	NA	0.4	5.08	0.32	7.67e-7	Coronary artery disease;Coronary heart disease;
SARC	cis	rs2795502	1.000	rs2795502	chr10:43340662	G/A	cg20628663	chr10:43360327	NA	-0.47	-6.29	-0.38	1.52e-9	Blood protein levels;
SARC	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg02187348	chr16:89574699	SPG7	-0.62	-9.19	-0.52	2.22e-17	Multiple myeloma (IgH translocation);
SARC	cis	rs7615952	0.611	rs78137633	chr3:125775061	C/T	cg05084668	chr3:125655381	ALG1L	-0.91	-7.39	-0.44	2.6e-12	Blood pressure (smoking interaction);
SARC	cis	rs7250872	0.619	rs2396359	chr19:1819125	T/C	cg05970437	chr19:1864622	KLF16	0.44	4.85	0.3	2.23e-6	Bipolar disorder;
SARC	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg12463550	chr7:65579703	CRCP	0.67	5.06	0.31	8.43e-7	Diabetic kidney disease;
SARC	cis	rs3087591	0.683	rs12602834	chr17:29637308	G/A	cg24425628	chr17:29625626	OMG;NF1	0.44	5.58	0.34	6.79e-8	Hip circumference;
SARC	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg07701084	chr6:150067640	NUP43	0.4	5.38	0.33	1.84e-7	Lung cancer;
SARC	cis	rs9790314	0.934	rs465985	chr3:161098552	T/C	cg03342759	chr3:160939853	NMD3	-0.55	-6.7	-0.4	1.51e-10	Morning vs. evening chronotype;
SARC	cis	rs854765	0.616	rs8076747	chr17:17853595	C/T	cg05444541	chr17:17804740	TOM1L2	-0.3	-4.98	-0.31	1.22e-6	Total body bone mineral density;
SARC	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg18404041	chr3:52824283	ITIH1	-0.44	-6.62	-0.4	2.44e-10	Bipolar disorder;
SARC	cis	rs35213789	0.878	rs7800759	chr7:69482645	C/T	cg10619644	chr7:69149951	AUTS2	0.44	5.42	0.33	1.45e-7	Childhood ear infection;
SARC	cis	rs631288	0.793	rs11239952	chr1:146715204	A/G	cg25205988	chr1:146714368	CHD1L	1.06	6.89	0.41	5.04e-11	PR interval in Tripanosoma cruzi seropositivity;
SARC	cis	rs2070488	0.804	rs1817364	chr3:38474513	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	12.8	0.64	9.33e-29	Electrocardiographic conduction measures;
SARC	cis	rs7520050	0.807	rs3013595	chr1:46153203	G/A	cg24296786	chr1:45957014	TESK2	-0.44	-5.69	-0.35	3.76e-8	Red blood cell count;Reticulocyte count;
SARC	cis	rs7103648	0.735	rs3824869	chr11:47378245	T/C	cg20307385	chr11:47447363	PSMC3	-0.78	-10.89	-0.58	1.32e-22	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs734999	0.566	rs10752747	chr1:2524915	G/T	cg20673091	chr1:2541236	MMEL1	0.34	5.19	0.32	4.64e-7	Ulcerative colitis;
SARC	cis	rs4589502	1.000	rs4589502	chr15:67155069	C/T	cg12317470	chr15:67143691	NA	0.65	4.93	0.31	1.59e-6	Lung cancer (smoking interaction);
SARC	trans	rs61931739	0.517	rs34760282	chr12:34153711	G/T	cg13010199	chr12:38710504	ALG10B	0.72	9.71	0.54	6.29e-19	Morning vs. evening chronotype;
SARC	cis	rs41278232	0.557	rs817351	chr20:62610447	T/C	cg07620230	chr20:62328084	TNFRSF6B	0.34	4.81	0.3	2.73e-6	Tonsillectomy;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg02513409	chr19:17559666	NA	0.47	6.29	0.38	1.56e-9	Breast cancer;
SARC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg07167872	chr1:205819463	PM20D1	-0.75	-11.91	-0.62	7.6e-26	Menarche (age at onset);
SARC	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg15105011	chr4:940614	TMEM175	0.39	5.6	0.34	6.14e-8	Sjögren's syndrome;
SARC	cis	rs12541335	0.639	rs68063696	chr8:22153236	A/G	cg02788857	chr8:22132959	PIWIL2	0.36	5.04	0.31	9.14e-7	Hypertriglyceridemia;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg04865506	chr17:29422776	NF1	0.51	6.37	0.39	9.89e-10	Blood pressure;
SARC	cis	rs7729447	0.776	rs7738037	chr5:32696549	C/T	cg16267343	chr5:32710456	NPR3	0.63	8.43	0.48	3.58e-15	Blood pressure;
SARC	cis	rs9828933	0.766	rs864975	chr3:63885615	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	0.86	7.09	0.42	1.55e-11	Type 2 diabetes;
SARC	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg19223190	chr17:80058835	NA	0.43	6.05	0.37	5.72e-9	Life satisfaction;
SARC	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-4.72	-0.3	4.08e-6	Total body bone mineral density;
SARC	cis	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg09021430	chr5:549028	NA	-0.48	-6.39	-0.39	9.17e-10	Obesity-related traits;
SARC	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg07701084	chr6:150067640	NUP43	0.42	5.49	0.34	1.05e-7	Lung cancer;
SARC	cis	rs7524258	0.868	rs1304712	chr1:7270538	C/T	cg07173049	chr1:7289937	CAMTA1	0.37	7.28	0.43	5.11e-12	Tourette's syndrome or obsessive-compulsive disorder;
SARC	cis	rs9388451	0.839	rs980014	chr6:126068001	T/G	cg05901451	chr6:126070800	HEY2	-0.68	-9.52	-0.53	2.33e-18	Brugada syndrome;
SARC	cis	rs524281	0.861	rs7941431	chr11:65960157	C/T	cg14036092	chr11:66035641	RAB1B	-0.48	-4.95	-0.31	1.42e-6	Electroencephalogram traits;
SARC	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg00800038	chr16:89945340	TCF25	-0.76	-5.12	-0.32	6.35e-7	Skin colour saturation;
SARC	cis	rs870825	0.616	rs6833858	chr4:185639961	C/T	cg04058563	chr4:185651563	MLF1IP	0.77	10.63	0.57	8.69e-22	Blood protein levels;
SARC	cis	rs11098499	0.863	rs6853998	chr4:120475860	C/A	cg24375607	chr4:120327624	NA	0.42	4.92	0.31	1.64e-6	Corneal astigmatism;
SARC	cis	rs6570726	0.935	rs451349	chr6:145820894	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.48	0.39	5.27e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9457247	0.967	rs2149083	chr6:167370971	G/C	cg07741184	chr6:167504864	NA	-0.29	-5.4	-0.33	1.63e-7	Crohn's disease;
SARC	cis	rs2180341	1.000	rs3798852	chr6:127636733	A/G	cg24812749	chr6:127587940	RNF146	0.97	12.57	0.64	5.39e-28	Breast cancer;
SARC	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg18404041	chr3:52824283	ITIH1	-0.4	-6.0	-0.37	7.68e-9	Electroencephalogram traits;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg06333435	chr8:22102724	POLR3D;MIR320A	0.5	6.61	0.4	2.55e-10	Tetralogy of Fallot;
SARC	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.64	-7.41	-0.44	2.37e-12	Gut microbiome composition (summer);
SARC	cis	rs9400467	0.537	rs12213248	chr6:111499394	G/C	cg15721981	chr6:111408429	SLC16A10	0.69	5.95	0.36	9.55e-9	Blood metabolite levels;Amino acid levels;
SARC	cis	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg05623727	chr3:50126028	RBM5	0.33	4.95	0.31	1.4e-6	Intelligence (multi-trait analysis);
SARC	cis	rs10206020	0.885	rs6720923	chr2:1574197	T/C	cg01028140	chr2:1542097	TPO	-0.4	-5.41	-0.33	1.54e-7	IgG glycosylation;
SARC	cis	rs1609391	0.567	rs835633	chr3:136676496	T/C	cg15507776	chr3:136538369	TMEM22	0.52	5.76	0.35	2.64e-8	Neuroticism;
SARC	cis	rs77106637	0.932	rs7109082	chr11:72707441	A/C	cg03713592	chr11:72463424	ARAP1	0.88	8.54	0.49	1.74e-15	Type 2 diabetes;
SARC	cis	rs9341808	0.538	rs667097	chr6:80978943	G/A	cg08355045	chr6:80787529	NA	-0.36	-5.43	-0.34	1.41e-7	Sitting height ratio;
SARC	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22996534	chr8:17658847	MTUS1	-0.51	-6.69	-0.4	1.61e-10	Smoking initiation;
SARC	cis	rs9467603	1.000	rs13200921	chr6:25790378	T/C	cg21479132	chr6:26055353	NA	0.76	4.96	0.31	1.33e-6	Intelligence (multi-trait analysis);
SARC	cis	rs36051895	0.664	rs62543877	chr9:5093465	C/A	cg02405213	chr9:5042618	JAK2	-0.46	-5.44	-0.34	1.35e-7	Pediatric autoimmune diseases;
SARC	cis	rs2522056	1.000	rs2522056	chr5:131801726	C/T	cg24060327	chr5:131705240	SLC22A5	0.47	4.73	0.3	3.85e-6	Lymphocyte counts;Fibrinogen;
SARC	cis	rs6782228	0.565	rs2811496	chr3:128359958	A/T	cg08795948	chr3:128337044	NA	0.37	5.01	0.31	1.1e-6	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
SARC	cis	rs1215050	0.791	rs260899	chr4:98707046	G/A	cg05340658	chr4:99064831	C4orf37	0.44	5.85	0.36	1.62e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs950169	0.922	rs11630507	chr15:85095725	A/G	cg24253500	chr15:84953950	NA	0.38	5.57	0.34	6.85e-8	Schizophrenia;
SARC	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg18876405	chr7:65276391	NA	-0.45	-5.26	-0.33	3.2e-7	Aortic root size;
SARC	cis	rs9303280	0.806	rs2305480	chr17:38062196	G/A	cg20243544	chr17:37824526	PNMT	0.44	5.77	0.35	2.56e-8	Self-reported allergy;
SARC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.99	12.15	0.62	1.2e-26	Platelet count;
SARC	cis	rs2916247	0.954	rs7839095	chr8:93158052	T/C	cg10183463	chr8:93005414	RUNX1T1	0.53	5.33	0.33	2.36e-7	Intelligence (multi-trait analysis);
SARC	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg07308232	chr7:1071921	C7orf50	-0.54	-7.06	-0.42	1.89e-11	Longevity;Endometriosis;
SARC	cis	rs6580649	0.941	rs78649179	chr12:48508196	T/A	cg24011408	chr12:48396354	COL2A1	-0.47	-5.28	-0.33	2.92e-7	Lung cancer;
SARC	cis	rs10489202	0.632	rs202273	chr1:167919963	A/G	cg24449463	chr1:168025552	DCAF6	-0.68	-9.39	-0.52	5.55e-18	Schizophrenia;
SARC	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg03060546	chr3:49711283	APEH	0.44	5.55	0.34	7.66e-8	Parkinson's disease;
SARC	cis	rs6674176	0.597	rs6671164	chr1:44403489	G/T	cg13606994	chr1:44402422	ARTN	-0.36	-5.81	-0.36	2.06e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs8014204	0.762	rs10148293	chr14:75296831	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.53	-7.51	-0.44	1.26e-12	Caffeine consumption;
SARC	cis	rs4689388	0.926	rs4458523	chr4:6289986	G/T	cg14416269	chr4:6271139	WFS1	-0.35	-5.41	-0.33	1.54e-7	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs2193412	0.620	rs12463983	chr2:51191432	G/A	cg00345522	chr2:51260399	NRXN1	0.34	4.83	0.3	2.5e-6	Response to zileuton treatment in asthma (FEV1 change interaction);
SARC	cis	rs116095464	0.558	rs56081398	chr5:247318	C/T	cg22496380	chr5:211416	CCDC127	-0.97	-8.95	-0.51	1.13e-16	Breast cancer;
SARC	cis	rs3136441	1.000	rs60258676	chr11:46897787	T/C	cg25783544	chr11:47291846	MADD	0.57	5.29	0.33	2.83e-7	HDL cholesterol;
SARC	cis	rs66573146	0.901	rs55882710	chr4:7030704	G/A	cg00086871	chr4:6988644	TBC1D14	0.88	4.83	0.3	2.44e-6	Granulocyte percentage of myeloid white cells;
SARC	cis	rs12579753	1.000	rs11519754	chr12:82209181	A/T	cg07988820	chr12:82153109	PPFIA2	-0.57	-6.6	-0.4	2.67e-10	Resting heart rate;
SARC	cis	rs1580019	0.587	rs34488151	chr7:32548146	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.61	7.95	0.46	7.96e-14	Cognitive ability;
SARC	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg11987759	chr7:65425863	GUSB	0.5	6.21	0.38	2.36e-9	Aortic root size;
SARC	cis	rs17270561	0.609	rs1318016	chr6:25764704	A/T	cg16482183	chr6:26056742	HIST1H1C	0.48	5.95	0.36	9.58e-9	Iron status biomarkers;
SARC	cis	rs2239547	0.563	rs9839035	chr3:52909877	C/T	cg11645453	chr3:52864694	ITIH4	0.33	4.94	0.31	1.48e-6	Schizophrenia;
SARC	cis	rs9486715	0.830	rs1475748	chr6:97034143	T/C	cg18709589	chr6:96969512	KIAA0776	-0.59	-7.44	-0.44	1.88e-12	Headache;
SARC	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg16606324	chr3:10149918	C3orf24	-0.49	-4.86	-0.3	2.14e-6	Alzheimer's disease;
SARC	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg16083429	chr3:49237500	CCDC36	-0.39	-5.2	-0.32	4.43e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	trans	rs9388451	0.805	rs1028481	chr6:126106573	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.56	-7.31	-0.43	4.35e-12	Brugada syndrome;
SARC	cis	rs713587	0.563	rs1529897	chr2:25086827	T/G	cg04586622	chr2:25135609	ADCY3	0.33	5.61	0.34	5.77e-8	Body mass index in non-asthmatics;
SARC	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg00149659	chr3:10157352	C3orf10	0.69	6.4	0.39	8.64e-10	Alzheimer's disease;
SARC	cis	rs9322193	0.607	rs12527391	chr6:150203292	T/C	cg09699651	chr6:150184138	LRP11	0.45	4.78	0.3	3.15e-6	Lung cancer;
SARC	cis	rs2153535	0.542	rs4440510	chr6:8471818	C/T	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.01e-14	Motion sickness;
SARC	cis	rs10870270	0.956	rs7915388	chr10:133734972	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.45	-5.37	-0.33	1.93e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs9790314	0.967	rs457272	chr3:161096746	A/G	cg03342759	chr3:160939853	NMD3	-0.6	-7.57	-0.44	8.51e-13	Morning vs. evening chronotype;
SARC	cis	rs736408	0.500	rs2878762	chr3:52919002	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-5.49	-0.34	1.03e-7	Bipolar disorder;
SARC	cis	rs7223966	1.000	rs9899491	chr17:61934384	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.48	-4.72	-0.3	4.03e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs12579753	0.872	rs12319937	chr12:82182545	T/G	cg07988820	chr12:82153109	PPFIA2	-0.53	-6.35	-0.38	1.11e-9	Resting heart rate;
SARC	cis	rs2213920	0.749	rs4978637	chr9:118222448	T/A	cg13918206	chr9:118159781	DEC1	0.76	6.2	0.38	2.54e-9	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs865483	0.895	rs2680718	chr17:35816451	T/C	cg06561646	chr17:35873369	DUSP14	-0.46	-6.2	-0.38	2.6e-9	Monocyte count;
SARC	cis	rs4713118	0.955	rs34752872	chr6:27683244	A/T	cg17221315	chr6:27791827	HIST1H4J	0.5	5.03	0.31	9.57e-7	Parkinson's disease;
SARC	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg00800038	chr16:89945340	TCF25	-0.66	-5.63	-0.35	5.07e-8	Skin colour saturation;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg11208313	chr17:27276484	PHF12	-0.83	-7.06	-0.42	1.93e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg07701084	chr6:150067640	NUP43	0.41	5.39	0.33	1.75e-7	Lung cancer;
SARC	cis	rs3008870	1.000	rs3008859	chr1:67390999	G/C	cg08660285	chr1:67390436	MIER1;WDR78	0.93	11.48	0.6	1.77e-24	Lymphocyte percentage of white cells;
SARC	cis	rs6860806	0.507	rs270608	chr5:131648406	C/T	cg12564285	chr5:131593104	PDLIM4	0.46	6.13	0.37	3.67e-9	Breast cancer;
SARC	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg07701084	chr6:150067640	NUP43	0.41	5.39	0.33	1.75e-7	Lung cancer;
SARC	cis	rs11792861	0.619	rs2289481	chr9:111712924	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.79	10.42	0.56	4.05e-21	Menarche (age at onset);
SARC	cis	rs10791323	0.628	rs10750543	chr11:133718467	G/A	cg15485101	chr11:133734466	NA	0.35	5.51	0.34	9.27e-8	Childhood ear infection;
SARC	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg15966229	chr18:44337664	ST8SIA5	0.39	4.95	0.31	1.39e-6	Personality dimensions;
SARC	cis	rs1832871	0.711	rs9459877	chr6:158692331	G/A	cg07165851	chr6:158734300	TULP4	0.56	6.76	0.4	1.09e-10	Height;
SARC	cis	rs2011503	1.000	rs76790018	chr19:19652157	G/A	cg03709012	chr19:19516395	GATAD2A	0.6	5.29	0.33	2.8e-7	Bipolar disorder;
SARC	cis	rs67311347	0.544	rs9833640	chr3:40354941	T/A	cg09455208	chr3:40491958	NA	0.3	4.93	0.31	1.56e-6	Renal cell carcinoma;
SARC	cis	rs7589342	0.536	rs10177914	chr2:106386693	G/T	cg16077055	chr2:106428750	NCK2	0.3	6.16	0.37	3.19e-9	Addiction;
SARC	cis	rs6570726	0.935	rs366621	chr6:145861275	A/G	cg05220968	chr6:146057943	EPM2A	-0.29	-5.03	-0.31	9.65e-7	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg25974308	chr4:99852387	EIF4E	0.47	6.35	0.38	1.11e-9	Thyroid stimulating hormone;
SARC	cis	rs72781680	0.611	rs72781696	chr2:24267014	C/T	cg08917208	chr2:24149416	ATAD2B	0.66	6.39	0.39	8.72e-10	Lymphocyte counts;
SARC	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg14784868	chr12:69753453	YEATS4	0.5	6.69	0.4	1.63e-10	Blood protein levels;
SARC	cis	rs1728785	1.000	rs1645923	chr16:68581051	G/A	cg02972257	chr16:68554789	NA	-0.43	-5.01	-0.31	1.08e-6	Ulcerative colitis;
SARC	cis	rs449789	0.857	rs10455775	chr6:159723721	C/T	cg14500486	chr6:159655392	FNDC1	-0.42	-4.84	-0.3	2.33e-6	Pulse pressure;
SARC	cis	rs9911578	0.967	rs6416932	chr17:57148991	G/A	cg20303301	chr17:57937339	TUBD1	-0.34	-4.96	-0.31	1.37e-6	Intelligence (multi-trait analysis);
SARC	cis	rs8133932	0.654	rs420386	chr21:47364816	G/A	cg11214348	chr21:47283868	PCBP3	-0.39	-4.72	-0.3	4.11e-6	Schizophrenia;
SARC	cis	rs3008870	0.959	rs2985826	chr1:67412918	G/C	cg08660285	chr1:67390436	MIER1;WDR78	0.92	11.4	0.6	3.22e-24	Lymphocyte percentage of white cells;
SARC	cis	rs10883723	0.775	rs2296579	chr10:104241375	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	8.16	0.47	2.06e-14	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs7666738	0.830	rs3846445	chr4:99032939	T/A	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs3617	0.652	rs7630552	chr3:52891570	G/C	cg04865290	chr3:52927548	TMEM110	0.35	4.96	0.31	1.37e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs34330	0.562	rs11055024	chr12:12858969	A/G	cg09462578	chr12:12878428	APOLD1	-0.6	-5.78	-0.35	2.43e-8	Systemic lupus erythematosus;
SARC	cis	rs875971	1.000	rs1167411	chr7:65539264	C/G	cg18876405	chr7:65276391	NA	-0.47	-5.73	-0.35	3.06e-8	Aortic root size;
SARC	cis	rs4919087	0.748	rs1147600	chr10:98981643	T/C	cg25902810	chr10:99078978	FRAT1	-0.55	-6.13	-0.37	3.79e-9	Monocyte count;
SARC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg20102877	chr2:27665638	KRTCAP3	-0.38	-5.45	-0.34	1.3e-7	Total body bone mineral density;
SARC	cis	rs9314323	0.767	rs6557915	chr8:26209062	C/A	cg11498726	chr8:26250323	BNIP3L	-0.58	-7.43	-0.44	2.05e-12	Red cell distribution width;
SARC	cis	rs559928	0.606	rs12417635	chr11:63912728	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	5.26	0.33	3.29e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs7762018	0.941	rs4716387	chr6:170136777	G/C	cg15038512	chr6:170123185	PHF10	0.52	4.78	0.3	3.04e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6991952	0.627	rs7465298	chr8:25699665	A/G	cg21775463	chr8:25538546	NA	0.28	4.8	0.3	2.83e-6	Inguinal hernia;
SARC	cis	rs7681440	0.606	rs2619350	chr4:90747004	A/G	cg06632027	chr4:90757378	SNCA	-0.43	-5.32	-0.33	2.4e-7	Dementia with Lewy bodies;
SARC	cis	rs7264396	0.690	rs2425171	chr20:34443173	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.51	5.08	0.32	7.84e-7	Total cholesterol levels;
SARC	cis	rs11122272	0.735	rs2808597	chr1:231532351	T/C	cg06096015	chr1:231504339	EGLN1	0.38	5.7	0.35	3.54e-8	Hemoglobin concentration;
SARC	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg21747090	chr2:27597821	SNX17	-0.5	-6.73	-0.4	1.3100000000000001e-10	Total body bone mineral density;
SARC	cis	rs2204008	0.837	rs11180482	chr12:38235950	G/A	cg26384229	chr12:38710491	ALG10B	0.92	13.59	0.66	2.33e-31	Bladder cancer;
SARC	cis	rs9303401	0.659	rs36109237	chr17:56653834	A/G	cg25039879	chr17:56429692	SUPT4H1	0.67	6.21	0.38	2.4e-9	Cognitive test performance;
SARC	cis	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg25427524	chr10:38739819	LOC399744	-0.53	-8.44	-0.48	3.37e-15	Extrinsic epigenetic age acceleration;
SARC	cis	rs17376456	0.741	rs12374432	chr5:93481348	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.55	0.34	7.72e-8	Diabetic retinopathy;
SARC	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg06028808	chr11:68637592	NA	0.46	5.9	0.36	1.26e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs1355223	0.867	rs2281908	chr11:34683578	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-5.83	-0.36	1.86e-8	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs6088813	1.000	rs4911491	chr20:33947285	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.44	-5.35	-0.33	2.07e-7	Height;
SARC	cis	rs11105298	0.891	rs11105299	chr12:89877943	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.53	-5.39	-0.33	1.69e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs1881797	1.000	rs12061460	chr1:247686787	G/A	cg11166453	chr1:247681781	NA	0.46	5.18	0.32	4.74e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg16339924	chr4:17578868	LAP3	0.68	9.17	0.52	2.49e-17	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs12134245	0.742	rs17501381	chr1:92003919	A/G	cg21854759	chr1:92012499	NA	-0.35	-4.75	-0.3	3.56e-6	Breast cancer;
SARC	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg02018176	chr4:1364513	KIAA1530	-0.45	-6.33	-0.38	1.23e-9	Obesity-related traits;
SARC	cis	rs6717918	0.816	rs11901692	chr2:233149739	A/G	ch.2.233013039R	chr2:233304795	NA	-0.36	-4.75	-0.3	3.58e-6	Height;
SARC	trans	rs1814175	0.817	rs12277258	chr11:49940216	T/C	cg03929089	chr4:120376271	NA	-0.88	-13.88	-0.67	2.51e-32	Height;
SARC	trans	rs1814175	0.817	rs10839351	chr11:49758153	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-18.54	-0.77	9.7e-48	Height;
SARC	cis	rs67478160	0.506	rs6575998	chr14:104250417	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.38	-5.26	-0.33	3.2e-7	Schizophrenia;
SARC	cis	rs524281	0.861	rs6591208	chr11:65949689	A/C	cg14036092	chr11:66035641	RAB1B	-0.51	-5.52	-0.34	9.19e-8	Electroencephalogram traits;
SARC	cis	rs11122272	0.735	rs2808586	chr1:231515559	C/T	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs10504229	0.679	rs16921677	chr8:58052431	T/C	cg21724239	chr8:58056113	NA	0.58	5.84	0.36	1.71e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs11697848	1.000	rs2268325	chr20:48529565	G/A	cg17849948	chr20:48532315	SPATA2	0.87	5.2	0.32	4.3e-7	Systemic lupus erythematosus;
SARC	cis	rs9640161	0.742	rs2108851	chr7:150019634	T/C	cg10018233	chr7:150070692	REPIN1	0.68	9.04	0.51	6.03e-17	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs568617	0.716	rs77779142	chr11:65599656	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.64	6.71	0.4	1.43e-10	Crohn's disease;
SARC	cis	rs11687170	0.816	rs6431434	chr2:237059900	A/C	cg19324714	chr2:237145437	ASB18	0.47	4.73	0.3	3.86e-6	Educational attainment;Educational attainment (years of education);
SARC	trans	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.74	10.81	0.58	2.44e-22	Intelligence (multi-trait analysis);
SARC	cis	rs11623869	0.614	rs11627052	chr14:103863476	A/G	cg12935359	chr14:103987150	CKB	0.49	6.69	0.4	1.6e-10	Bone mineral density;
SARC	cis	rs12142240	0.698	rs7525309	chr1:46809025	G/T	cg14993813	chr1:46806288	NSUN4	-0.52	-5.45	-0.34	1.28e-7	Menopause (age at onset);
SARC	cis	rs1348850	0.914	rs6710575	chr2:178377311	C/T	cg23306229	chr2:178417860	TTC30B	0.57	6.58	0.4	3.06e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7666738	0.609	rs28833816	chr4:98868866	T/C	cg05340658	chr4:99064831	C4orf37	0.57	7.03	0.42	2.28e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs73635312	0.850	rs76141549	chr10:8940954	G/A	cg24467326	chr10:9646929	NA	0.64	5.15	0.32	5.54e-7	Basal cell carcinoma;
SARC	cis	rs9788721	0.836	rs72738718	chr15:78735438	G/C	cg06917634	chr15:78832804	PSMA4	-0.54	-5.98	-0.36	8.51e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs4481887	0.927	rs7521689	chr1:248435831	G/T	cg00666640	chr1:248458726	OR2T12	0.35	5.59	0.34	6.46e-8	Common traits (Other);
SARC	cis	rs854765	0.547	rs2955372	chr17:17970229	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.69	-10.03	-0.55	6.47e-20	Total body bone mineral density;
SARC	cis	rs9790314	0.967	rs336586	chr3:161081347	G/A	cg04691961	chr3:161091175	C3orf57	-0.8	-11.79	-0.61	1.78e-25	Morning vs. evening chronotype;
SARC	cis	rs9290065	0.519	rs6770180	chr3:160703786	C/T	cg03342759	chr3:160939853	NMD3	-0.49	-5.94	-0.36	1.01e-8	Kawasaki disease;
SARC	cis	rs559928	0.606	rs1011219	chr11:63973396	A/G	cg23796481	chr11:64053134	BAD;GPR137	-0.64	-5.2	-0.32	4.35e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs7684253	0.548	rs13108002	chr4:57718253	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.4	-5.04	-0.31	9.25e-7	Migraine;
SARC	cis	rs6087771	0.926	rs6058431	chr20:30297133	C/T	cg13852791	chr20:30311386	BCL2L1	0.83	9.95	0.55	1.19e-19	Subcortical brain region volumes;Putamen volume;
SARC	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg22535103	chr8:58192502	C8orf71	-0.71	-8.47	-0.49	2.77e-15	Developmental language disorder (linguistic errors);
SARC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg06873352	chr17:61820015	STRADA	0.53	6.86	0.41	6.24e-11	Prudent dietary pattern;
SARC	cis	rs2486288	0.656	rs8040185	chr15:45552081	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.45	-5.57	-0.34	7.07e-8	Glomerular filtration rate;
SARC	trans	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg08975724	chr8:8085496	FLJ10661	0.61	8.12	0.47	2.7e-14	Triglycerides;
SARC	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg08280861	chr8:58055591	NA	0.57	4.88	0.3	1.95e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs4974559	0.947	rs10018627	chr4:1356358	G/A	cg02980000	chr4:1222292	CTBP1	0.63	4.79	0.3	2.91e-6	Systolic blood pressure;
SARC	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg10253484	chr15:75165896	SCAMP2	-0.39	-4.73	-0.3	3.9e-6	Breast cancer;
SARC	cis	rs6484504	0.576	rs16922084	chr11:31371109	C/T	cg02090638	chr11:31391270	DNAJC24;DCDC1	0.4	5.09	0.32	7.49e-7	Red blood cell count;
SARC	cis	rs9399135	0.904	rs4895438	chr6:135317665	G/T	cg24558204	chr6:135376177	HBS1L	0.45	6.07	0.37	5.16e-9	Red blood cell count;
SARC	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg07701084	chr6:150067640	NUP43	0.41	5.35	0.33	2.05e-7	Lung cancer;
SARC	cis	rs9815354	0.951	rs9849393	chr3:41875369	G/C	cg03022575	chr3:42003672	ULK4	0.62	5.43	0.34	1.39e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2011503	1.000	rs75453386	chr19:19637781	C/T	cg15839431	chr19:19639596	YJEFN3	-0.48	-4.77	-0.3	3.32e-6	Bipolar disorder;
SARC	cis	rs4481887	0.597	rs6587475	chr1:248578622	C/T	cg00666640	chr1:248458726	OR2T12	0.3	4.81	0.3	2.69e-6	Common traits (Other);
SARC	cis	rs12142240	0.698	rs17361887	chr1:46834775	A/G	cg10495392	chr1:46806563	NSUN4	0.67	6.98	0.42	3.07e-11	Menopause (age at onset);
SARC	cis	rs929354	0.629	rs6950739	chr7:156982450	T/C	cg05182265	chr7:156933206	UBE3C	-0.33	-5.03	-0.31	9.83e-7	Body mass index;
SARC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg06873352	chr17:61820015	STRADA	0.54	7.03	0.42	2.25e-11	Prudent dietary pattern;
SARC	cis	rs9902453	0.935	rs9909093	chr17:28271207	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	6.94	0.41	3.77e-11	Coffee consumption (cups per day);
SARC	cis	rs7945705	0.806	rs12224436	chr11:8815825	C/A	cg21881798	chr11:8931708	C11orf17;ST5	0.38	4.97	0.31	1.32e-6	Hemoglobin concentration;
SARC	cis	rs11098499	0.954	rs17009122	chr4:120362403	G/A	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs6728642	0.708	rs56807297	chr2:97861340	A/C	cg26665480	chr2:98280029	ACTR1B	-0.67	-6.07	-0.37	5.01e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs12216125	0.554	rs6942196	chr6:26072804	A/G	cg18357526	chr6:26021779	HIST1H4A	0.42	5.16	0.32	5.17e-7	Iron status biomarkers;
SARC	cis	rs3859192	0.539	rs2302774	chr17:38183090	G/T	cg17344932	chr17:38183730	MED24;SNORD124	0.41	7.55	0.44	9.85e-13	White blood cell count;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg03087855	chr10:92661845	RPP30	-0.53	-6.53	-0.39	4.11e-10	Alcohol dependence;
SARC	cis	rs1957429	0.808	rs1951492	chr14:65346895	G/A	cg23373153	chr14:65346875	NA	1.07	11.42	0.6	2.73e-24	Pediatric areal bone mineral density (radius);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg15692086	chr6:89340909	RNGTT	0.43	7.03	0.42	2.23e-11	Thyroid stimulating hormone;
SARC	cis	rs7412746	0.658	rs7526489	chr1:150726238	C/T	cg10589385	chr1:150898437	SETDB1	0.38	5.02	0.31	1.04e-6	Melanoma;
SARC	cis	rs317689	0.581	rs315132	chr12:69761996	G/C	cg20891283	chr12:69753455	YEATS4	0.5	6.17	0.37	3.06e-9	Response to diuretic therapy;
SARC	cis	rs10490913	0.806	rs10787825	chr10:120164583	A/G	cg23160142	chr10:120154512	NA	0.36	5.28	0.33	2.98e-7	Cancer;
SARC	cis	rs2760061	0.626	rs672907	chr1:228120345	G/A	cg02753203	chr1:228287806	NA	-0.54	-7.53	-0.44	1.08e-12	Diastolic blood pressure;
SARC	cis	rs12530134	0.523	rs7762088	chr6:170794570	T/C	cg16453901	chr6:170730693	NA	-0.88	-6.97	-0.42	3.16e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs10927875	0.632	rs10927864	chr1:16165661	C/G	cg07117364	chr1:16154769	NA	-0.47	-5.79	-0.35	2.23e-8	Dilated cardiomyopathy;
SARC	cis	rs920590	0.679	rs4577973	chr8:19658017	A/G	cg03894339	chr8:19674705	INTS10	0.49	6.18	0.38	2.86e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs6912958	0.712	rs6454641	chr6:88371060	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.46	-5.93	-0.36	1.07e-8	Monocyte percentage of white cells;
SARC	cis	rs6840360	0.571	rs4696098	chr4:152489053	C/T	cg22705602	chr4:152727874	NA	-0.43	-6.66	-0.4	1.91e-10	Intelligence (multi-trait analysis);
SARC	trans	rs1814175	0.765	rs1794141	chr11:49914135	G/C	cg03929089	chr4:120376271	NA	-0.88	-13.88	-0.67	2.51e-32	Height;
SARC	cis	rs4481887	0.861	rs4644528	chr1:248472508	T/A	cg01631408	chr1:248437212	OR2T33	-0.39	-5.06	-0.31	8.56e-7	Common traits (Other);
SARC	cis	rs3815700	1.000	rs10404211	chr19:33093565	C/T	cg02997394	chr19:33096574	ANKRD27	0.74	6.49	0.39	5.19e-10	Eosinophilic esophagitis;
SARC	cis	rs6964587	0.869	rs406	chr7:91546526	C/A	cg17063962	chr7:91808500	NA	-0.9	-13.21	-0.65	4.26e-30	Breast cancer;
SARC	trans	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-10.49	-0.57	2.48e-21	Intelligence (multi-trait analysis);
SARC	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg02951883	chr7:2050386	MAD1L1	-0.39	-4.75	-0.3	3.54e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs920590	1.000	rs920590	chr8:19651161	A/G	cg17834443	chr8:19674713	INTS10	0.47	5.68	0.35	4.03e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg13393036	chr8:95962371	TP53INP1	-0.39	-6.76	-0.4	1.12e-10	Type 2 diabetes;
SARC	cis	rs7828089	0.522	rs4872484	chr8:22255859	C/T	cg12081754	chr8:22256438	SLC39A14	0.73	10.2	0.56	1.98e-20	Verbal declarative memory;
SARC	cis	rs9381040	0.610	rs2057002	chr6:41022962	G/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.39	-4.75	-0.3	3.63e-6	Alzheimer's disease (late onset);
SARC	cis	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.75	-0.45	2.91e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.54	6.65	0.4	2.08e-10	Lymphocyte counts;
SARC	cis	rs12980942	0.872	rs2053086	chr19:41799475	C/T	cg25627403	chr19:41769009	HNRNPUL1	-0.6	-4.99	-0.31	1.16e-6	Coronary artery disease;
SARC	cis	rs892961	0.932	rs8066646	chr17:75414192	C/T	cg05865280	chr17:75406074	SEPT9	0.56	8.32	0.48	7.56e-15	Airflow obstruction;
SARC	cis	rs17376456	0.597	rs1031423	chr5:93276883	A/G	cg25358565	chr5:93447407	FAM172A	-0.84	-10.02	-0.55	6.89e-20	Diabetic retinopathy;
SARC	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg14343924	chr8:8086146	FLJ10661	-0.41	-5.1	-0.32	6.9e-7	Mood instability;
SARC	trans	rs7937682	0.889	rs493810	chr11:111491888	G/T	cg18187862	chr3:45730750	SACM1L	0.55	6.99	0.42	2.93e-11	Primary sclerosing cholangitis;
SARC	cis	rs72781680	0.612	rs33913065	chr2:24344060	T/G	cg06627628	chr2:24431161	ITSN2	-0.48	-4.99	-0.31	1.19e-6	Lymphocyte counts;
SARC	cis	rs9868809	0.772	rs9821797	chr3:48718253	T/A	cg06212747	chr3:49208901	KLHDC8B	-0.6	-5.45	-0.34	1.28e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs1003719	0.715	rs9980353	chr21:38558812	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.29	-0.52	1.11e-17	Eye color traits;
SARC	cis	rs986417	0.748	rs1955700	chr14:61046481	A/G	cg27398547	chr14:60952738	C14orf39	0.78	7.75	0.45	2.74e-13	Gut microbiota (bacterial taxa);
SARC	cis	rs3812565	0.530	rs10781538	chr9:139320929	C/G	cg14169450	chr9:139327907	INPP5E	-0.45	-6.51	-0.39	4.68e-10	Granulocyte percentage of myeloid white cells;
SARC	cis	rs34375054	0.738	rs10773145	chr12:125625603	C/T	cg25124228	chr12:125621409	AACS	0.55	7.53	0.44	1.13e-12	Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs9309473	0.898	rs6546851	chr2:73833283	C/T	cg07208825	chr2:73871855	ALMS1P	0.33	4.79	0.3	2.9e-6	Metabolite levels;
SARC	cis	rs2107732	0.778	rs3735487	chr7:45105146	C/T	cg17387670	chr7:44281560	CAMK2B	-0.32	-4.77	-0.3	3.23e-6	Coronary artery disease;
SARC	cis	rs7681440	0.606	rs356184	chr4:90703233	A/G	cg06632027	chr4:90757378	SNCA	0.42	5.15	0.32	5.47e-7	Dementia with Lewy bodies;
SARC	trans	rs9329221	0.716	rs11989640	chr8:10256054	A/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-6.85	-0.41	6.42e-11	Neuroticism;
SARC	cis	rs2204008	0.715	rs11514342	chr12:38236710	T/A	cg26384229	chr12:38710491	ALG10B	0.92	13.59	0.66	2.33e-31	Bladder cancer;
SARC	cis	rs752010	0.714	rs10890144	chr1:42085397	G/T	cg06885757	chr1:42089581	HIVEP3	0.38	5.86	0.36	1.58e-8	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs6540556	0.834	rs11119337	chr1:209934133	A/G	cg05527609	chr1:210001259	C1orf107	-0.46	-4.81	-0.3	2.69e-6	Red blood cell count;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg16717773	chr1:155211079	GBA	0.5	6.32	0.38	1.29e-9	Lung adenocarcinoma;
SARC	cis	rs2304069	0.954	rs216127	chr5:149428890	A/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.64	6.31	0.38	1.42e-9	HIV-1 control;
SARC	cis	rs96067	0.711	rs272833	chr1:36622870	C/G	cg24686825	chr1:36642396	MAP7D1	-0.62	-7.95	-0.46	8.06e-14	Corneal structure;
SARC	cis	rs7568458	0.875	rs2044474	chr2:85758790	G/A	cg17127132	chr2:85788382	GGCX	0.42	5.5	0.34	1.02e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs26232	0.517	rs154356	chr5:102499144	A/G	cg23492399	chr5:102201601	PAM	-0.48	-5.28	-0.33	2.9e-7	Rheumatoid arthritis;
SARC	cis	rs5167	0.506	rs35193317	chr19:45470344	C/T	cg09555818	chr19:45449301	APOC2	-0.58	-9.51	-0.53	2.42e-18	Blood protein levels;
SARC	trans	rs656319	0.652	rs7816333	chr8:9808809	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.95	-0.41	3.56e-11	Myopia (pathological);
SARC	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	11.08	0.59	3.32e-23	Alzheimer's disease;
SARC	cis	rs11770686	0.666	rs2260429	chr7:75308494	A/G	cg17787366	chr7:75369077	HIP1	0.39	5.0	0.31	1.14e-6	Essential tremor;
SARC	cis	rs17023223	0.537	rs2765530	chr1:119584396	G/A	cg05756136	chr1:119680316	WARS2	-0.45	-5.44	-0.34	1.35e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs10504229	0.679	rs1596142	chr8:58032406	G/A	cg08219700	chr8:58056026	NA	0.59	5.99	0.37	7.69e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs524281	0.773	rs2155198	chr11:66014300	C/T	cg14036092	chr11:66035641	RAB1B	-0.59	-6.28	-0.38	1.67e-9	Electroencephalogram traits;
SARC	cis	rs16866061	1.000	rs11681451	chr2:225334104	T/C	cg12698349	chr2:225449008	CUL3	0.71	10.28	0.56	1.1e-20	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	trans	rs1814175	0.817	rs10769598	chr11:49669326	C/G	cg15704280	chr7:45808275	SEPT13	-0.96	-17.08	-0.75	5.78e-43	Height;
SARC	cis	rs76917914	0.561	rs2224773	chr9:100824223	C/A	cg03040243	chr9:100819229	NANS	0.59	6.75	0.4	1.15e-10	Immature fraction of reticulocytes;
SARC	cis	rs6912958	0.684	rs4707382	chr6:88320641	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.61	-0.4	2.63e-10	Monocyte percentage of white cells;
SARC	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg18364779	chr6:26104403	HIST1H4C	0.42	5.03	0.31	9.85e-7	Intelligence (multi-trait analysis);
SARC	cis	rs365132	0.934	rs6861925	chr5:176324729	C/G	cg16309518	chr5:176445507	NA	-0.42	-5.32	-0.33	2.38e-7	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs1801251	0.778	rs2250665	chr2:233752639	A/T	cg25237894	chr2:233734115	C2orf82	-0.35	-4.97	-0.31	1.31e-6	Coronary artery disease;
SARC	cis	rs7666738	0.830	rs7696715	chr4:98938486	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7843479	0.544	rs11135735	chr8:21791557	C/T	cg17168535	chr8:21777572	XPO7	0.84	12.87	0.64	5.62e-29	Mean corpuscular volume;
SARC	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg00152838	chr16:24741724	TNRC6A	-0.58	-6.09	-0.37	4.71e-9	Intelligence (multi-trait analysis);
SARC	cis	rs17666538	0.591	rs7818950	chr8:643831	C/T	cg23958373	chr8:599963	NA	0.81	6.98	0.42	3.04e-11	IgG glycosylation;
SARC	cis	rs6866344	0.697	rs11749438	chr5:178131245	C/T	cg10224037	chr5:178157518	ZNF354A	1.01	12.71	0.64	1.83e-28	Neutrophil percentage of white cells;
SARC	cis	rs4642101	0.662	rs9840766	chr3:12821870	G/A	cg24848339	chr3:12840334	CAND2	0.36	5.73	0.35	3.07e-8	QRS complex (12-leadsum);
SARC	cis	rs4242434	0.689	rs4872006	chr8:22536502	T/C	cg03733263	chr8:22462867	KIAA1967	-0.86	-13.21	-0.65	4.08e-30	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg16486109	chr11:613632	IRF7	0.45	6.04	0.37	6.13e-9	Systemic lupus erythematosus;
SARC	cis	rs72792276	1.000	rs17164395	chr5:127395526	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	5.99	0.37	7.97e-9	Red cell distribution width;
SARC	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.38	-4.82	-0.3	2.54e-6	Lymphocyte counts;
SARC	cis	rs7587476	1.000	rs7587476	chr2:215653887	T/C	cg04004882	chr2:215674386	BARD1	-0.57	-6.54	-0.39	3.86e-10	Neuroblastoma;
SARC	cis	rs7589342	0.895	rs11901644	chr2:106432113	T/G	cg16077055	chr2:106428750	NCK2	0.4	7.43	0.44	2.06e-12	Addiction;
SARC	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg12463550	chr7:65579703	CRCP	0.69	5.26	0.33	3.2e-7	Diabetic kidney disease;
SARC	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg26338869	chr17:61819248	STRADA	-0.63	-8.17	-0.47	1.99e-14	Prudent dietary pattern;
SARC	cis	rs981844	1.000	rs62325083	chr4:154661775	T/C	cg14289246	chr4:154710475	SFRP2	0.59	6.74	0.4	1.25e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg13206674	chr6:150067644	NUP43	0.46	6.1	0.37	4.29e-9	Lung cancer;
SARC	cis	rs1865760	0.929	rs9358896	chr6:25943197	C/A	cg10373733	chr6:25993375	NA	0.41	4.97	0.31	1.32e-6	Height;
SARC	cis	rs7044106	0.762	rs10984974	chr9:123421556	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	5.4	0.33	1.66e-7	Hip circumference adjusted for BMI;
SARC	cis	rs3099143	0.908	rs3102716	chr15:77051003	T/G	cg21673338	chr15:77095150	SCAPER	-0.6	-5.06	-0.31	8.57e-7	Recalcitrant atopic dermatitis;
SARC	cis	rs6963495	0.818	rs55740553	chr7:105159551	A/G	cg13798780	chr7:105162888	PUS7	0.6	5.45	0.34	1.31e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg00149659	chr3:10157352	C3orf10	0.64	6.05	0.37	5.76e-9	Alzheimer's disease;
SARC	cis	rs2153535	0.580	rs9406174	chr6:8516764	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	8.28	0.48	9.37e-15	Motion sickness;
SARC	cis	rs950173	1.000	rs950173	chr2:172570419	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.8	-5.59	-0.34	6.34e-8	Hippocampal volume;
SARC	cis	rs6665290	0.904	rs6690803	chr1:227189106	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.07	-23.49	-0.84	2.22e-63	Myeloid white cell count;
SARC	cis	rs73635312	0.850	rs75806674	chr10:8957355	T/C	cg24467326	chr10:9646929	NA	0.61	5.09	0.32	7.53e-7	Basal cell carcinoma;
SARC	cis	rs66573146	0.831	rs1048009	chr4:6988677	G/A	cg00086871	chr4:6988644	TBC1D14	0.95	6.16	0.37	3.15e-9	Granulocyte percentage of myeloid white cells;
SARC	cis	rs11690935	0.655	rs1028127	chr2:172530036	T/C	cg13550731	chr2:172543902	DYNC1I2	0.68	9.4	0.52	5.49e-18	Schizophrenia;
SARC	trans	rs2243123	0.602	rs2133310	chr3:159716352	A/G	cg06247172	chr6:34216481	C6orf1	0.54	6.8	0.41	8.93e-11	Multiple sclerosis;
SARC	cis	rs611744	0.967	rs610452	chr8:109188263	T/C	cg21045802	chr8:109455806	TTC35	0.44	5.3	0.33	2.64e-7	Dupuytren's disease;
SARC	cis	rs9486719	1.000	rs11752584	chr6:96884952	C/A	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.01	-0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs17125944	0.686	rs7155860	chr14:53335229	G/C	cg00686598	chr14:53173677	PSMC6	-0.62	-4.77	-0.3	3.3e-6	Alzheimer's disease (late onset);
SARC	cis	rs4253772	0.637	rs9627350	chr22:46663017	A/G	cg24881330	chr22:46731750	TRMU	0.62	6.92	0.41	4.22e-11	LDL cholesterol;Cholesterol, total;
SARC	cis	rs17376456	1.000	rs6867042	chr5:93555761	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.61	5.23	0.32	3.75e-7	Diabetic retinopathy;
SARC	trans	rs453301	0.624	rs330056	chr8:9089695	A/T	cg06636001	chr8:8085503	FLJ10661	-0.71	-9.89	-0.54	1.72e-19	Joint mobility (Beighton score);
SARC	cis	rs9467711	0.591	rs67296946	chr6:26048559	T/G	cg21479132	chr6:26055353	NA	0.99	7.56	0.44	9.11e-13	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9398803	0.613	rs6918725	chr6:126990392	T/G	cg19875578	chr6:126661172	C6orf173	0.63	8.42	0.48	3.97e-15	Male-pattern baldness;
SARC	trans	rs13130787	0.966	rs13105254	chr4:94842776	C/T	cg25692259	chr2:223520658	FARSB	0.49	6.24	0.38	2e-9	Colorectal cancer;
SARC	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg03351412	chr1:154909251	PMVK	-0.67	-8.9	-0.5	1.55e-16	Prostate cancer;
SARC	cis	rs2425143	1.000	rs11696527	chr20:34245379	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-5.75	-0.35	2.78e-8	Blood protein levels;
SARC	cis	rs8058578	1.000	rs3747481	chr16:30666367	C/T	cg00531865	chr16:30841666	NA	-0.51	-5.58	-0.34	6.79e-8	Multiple myeloma;
SARC	cis	rs2933343	1.000	rs6785869	chr3:128643144	G/A	cg25356066	chr3:128598488	ACAD9	0.62	6.96	0.41	3.44e-11	IgG glycosylation;
SARC	cis	rs11601602	0.576	rs4075635	chr11:28511643	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.64	7.54	0.44	1.02e-12	Obesity-related traits;
SARC	cis	rs6964587	0.967	rs6980247	chr7:91594228	T/A	cg17063962	chr7:91808500	NA	0.94	16.0	0.72	2.29e-39	Breast cancer;
SARC	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg02574844	chr11:5959923	NA	-0.37	-5.22	-0.32	3.99e-7	DNA methylation (variation);
SARC	cis	rs9815354	1.000	rs17064124	chr3:41890803	A/G	cg03022575	chr3:42003672	ULK4	0.56	5.29	0.33	2.86e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs7020830	0.867	rs56098516	chr9:37362220	A/G	cg14294708	chr9:37120828	ZCCHC7	1.1	19.54	0.79	5.25e-51	Schizophrenia;
SARC	trans	rs1973993	0.691	rs1980683	chr1:96890379	A/G	cg10631902	chr5:14652156	NA	0.49	8.44	0.48	3.49e-15	Weight;
SARC	cis	rs1707322	1.000	rs12124291	chr1:46432132	G/A	cg03146154	chr1:46216737	IPP	0.46	5.5	0.34	9.8e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs17039065	0.920	rs1017431	chr4:109474091	A/C	cg16022748	chr4:109541635	LOC285456;RPL34	0.59	5.22	0.32	3.89e-7	Gut microbiome composition (summer);
SARC	cis	rs433852	1.000	rs433852	chr19:49117104	C/T	cg21547979	chr19:49141364	SEC1;DBP;CA11	-0.5	-5.5	-0.34	1e-7	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs9660992	0.710	rs1668867	chr1:205240251	C/T	cg07972983	chr1:205091412	RBBP5	0.56	7.0	0.42	2.72e-11	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs780094	0.606	rs6729709	chr2:27583156	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.32	-4.91	-0.31	1.7e-6	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs12142240	0.698	rs1475389	chr1:46816429	T/C	cg00530320	chr1:46809349	NSUN4	0.57	6.92	0.41	4.4e-11	Menopause (age at onset);
SARC	cis	rs1801251	1.000	rs2592102	chr2:233726772	G/T	cg25237894	chr2:233734115	C2orf82	-0.38	-5.07	-0.32	8.13e-7	Coronary artery disease;
SARC	cis	rs11676348	0.729	rs13013361	chr2:218947515	A/T	cg00012203	chr2:219082015	ARPC2	-0.5	-6.57	-0.4	3.33e-10	Ulcerative colitis;
SARC	trans	rs12310956	0.532	rs1352209	chr12:33983408	G/A	cg26384229	chr12:38710491	ALG10B	0.75	10.56	0.57	1.45e-21	Morning vs. evening chronotype;
SARC	trans	rs9929218	1.000	rs13330350	chr16:68800849	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.53	-6.72	-0.4	1.41e-10	Colorectal cancer;
SARC	cis	rs7927592	0.956	rs10896348	chr11:68357368	T/C	cg01657329	chr11:68192670	LRP5	-0.39	-4.85	-0.3	2.28e-6	Total body bone mineral density;
SARC	cis	rs34779708	0.931	rs2384275	chr10:35297142	A/G	cg03585969	chr10:35415529	CREM	0.38	4.81	0.3	2.77e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs2303759	0.709	rs8102574	chr19:49828897	A/G	cg22590775	chr19:49891494	CCDC155	0.47	5.23	0.32	3.75e-7	Multiple sclerosis;
SARC	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg14820908	chr5:178986412	RUFY1	0.36	5.14	0.32	5.86e-7	Lung cancer;
SARC	cis	rs6815814	0.950	rs73236632	chr4:38836071	G/A	cg06935464	chr4:38784597	TLR10	0.51	4.97	0.31	1.28e-6	Breast cancer;
SARC	cis	rs854765	0.547	rs4925135	chr17:17952868	T/C	cg04398451	chr17:18023971	MYO15A	0.47	6.55	0.39	3.55e-10	Total body bone mineral density;
SARC	cis	rs10992471	0.603	rs9299405	chr9:95284873	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.38	-0.33	1.78e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs3820928	0.874	rs10439363	chr2:227815065	C/T	cg11843606	chr2:227700838	RHBDD1	-0.57	-7.29	-0.43	4.68e-12	Pulmonary function;
SARC	cis	rs10754283	0.967	rs7546518	chr1:90109956	C/T	cg21401794	chr1:90099060	LRRC8C	0.58	8.03	0.47	4.69e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs10870270	1.000	rs11146354	chr10:133774757	A/G	cg26149184	chr10:133730230	NA	0.45	4.86	0.3	2.17e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	trans	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg08975724	chr8:8085496	FLJ10661	0.49	6.3	0.38	1.49e-9	Retinal vascular caliber;
SARC	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg02725872	chr8:58115012	NA	-0.34	-5.05	-0.31	9.12e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs5753618	0.539	rs2106294	chr22:31645759	C/T	cg07713946	chr22:31675144	LIMK2	-0.38	-5.36	-0.33	2e-7	Colorectal cancer;
SARC	cis	rs11997175	0.766	rs4733178	chr8:33691899	A/T	ch.8.33884649F	chr8:33765107	NA	0.57	7.72	0.45	3.31e-13	Body mass index;
SARC	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs3820928	0.874	rs10167086	chr2:227792729	A/T	cg11843606	chr2:227700838	RHBDD1	0.56	7.07	0.42	1.79e-11	Pulmonary function;
SARC	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg24503407	chr1:205819492	PM20D1	0.44	5.08	0.32	7.74e-7	Parkinson's disease;
SARC	trans	rs61931739	0.534	rs10844801	chr12:34230940	A/T	cg13010199	chr12:38710504	ALG10B	0.7	9.22	0.52	1.84e-17	Morning vs. evening chronotype;
SARC	cis	rs12579753	0.869	rs17692407	chr12:82171369	G/C	cg07988820	chr12:82153109	PPFIA2	-0.58	-6.74	-0.4	1.26e-10	Resting heart rate;
SARC	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg14829155	chr15:31115871	NA	-0.49	-6.29	-0.38	1.59e-9	Huntington's disease progression;
SARC	cis	rs9790314	0.871	rs336551	chr3:161109720	T/C	cg04691961	chr3:161091175	C3orf57	-0.75	-10.56	-0.57	1.54e-21	Morning vs. evening chronotype;
SARC	cis	rs9916302	0.851	rs9909064	chr17:37500434	G/T	cg15445000	chr17:37608096	MED1	-0.45	-5.48	-0.34	1.1e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs644799	0.965	rs10831430	chr11:95509638	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	15.25	0.71	6.82e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.45	5.28	0.33	3.01e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9611565	0.802	rs132916	chr22:41806768	C/G	cg03806693	chr22:41940476	POLR3H	0.8	11.49	0.6	1.64e-24	Vitiligo;
SARC	cis	rs6933660	0.512	rs9383905	chr6:151804296	C/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.64	5.43	0.34	1.39e-7	Menarche (age at onset);
SARC	trans	rs7824557	0.564	rs12547100	chr8:11242632	G/A	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.65	-0.4	2.01e-10	Retinal vascular caliber;
SARC	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	7.3	0.43	4.48e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9457247	0.663	rs2237274	chr6:167442995	C/G	cg23791538	chr6:167370224	RNASET2	-0.52	-6.79	-0.41	9.3e-11	Crohn's disease;
SARC	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg07167872	chr1:205819463	PM20D1	0.41	5.43	0.34	1.39e-7	Menarche (age at onset);
SARC	cis	rs9788682	0.747	rs12101809	chr15:78779801	C/T	cg06917634	chr15:78832804	PSMA4	-0.53	-5.5	-0.34	1.01e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs13401104	0.796	rs10929164	chr2:237110321	C/T	cg19324714	chr2:237145437	ASB18	0.57	5.6	0.34	5.92e-8	Educational attainment;
SARC	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg00684032	chr4:1343700	KIAA1530	0.38	5.52	0.34	9.23e-8	Obesity-related traits;
SARC	cis	rs10463554	0.927	rs158399	chr5:102413268	C/T	cg23492399	chr5:102201601	PAM	-0.52	-5.7	-0.35	3.63e-8	Parkinson's disease;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg24842967	chr1:156084750	LMNA	0.51	6.94	0.41	3.96e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs7474896	0.561	rs2474603	chr10:38445682	C/T	cg25427524	chr10:38739819	LOC399744	-0.52	-5.61	-0.35	5.68e-8	Obesity (extreme);
SARC	cis	rs56330463	0.967	rs11959615	chr5:148201316	A/T	cg21580376	chr5:148206412	ADRB2	0.41	5.72	0.35	3.17e-8	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Monocyte percentage of white cells;Eosinophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;
SARC	cis	rs35306767	0.855	rs2050944	chr10:918910	T/C	cg20503657	chr10:835505	NA	0.89	8.27	0.48	1e-14	Eosinophil percentage of granulocytes;
SARC	cis	rs5167	0.601	rs892131	chr19:45496996	C/T	cg13119609	chr19:45449297	APOC2	0.39	5.55	0.34	7.65e-8	Blood protein levels;
SARC	trans	rs1814175	0.817	rs10769613	chr11:49769692	G/A	cg03929089	chr4:120376271	NA	-0.9	-14.74	-0.69	3.46e-35	Height;
SARC	cis	rs17030434	0.863	rs17030382	chr4:154650887	A/G	cg14289246	chr4:154710475	SFRP2	-0.61	-6.05	-0.37	5.66e-9	Electrocardiographic conduction measures;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg23556447	chr6:90529595	MDN1	-0.66	-7.65	-0.45	5.22e-13	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs9420	0.961	rs11229131	chr11:57562525	G/A	cg23127183	chr11:57508653	C11orf31	-0.6	-6.86	-0.41	6.03e-11	Schizophrenia;
SARC	cis	rs559928	0.606	rs60394481	chr11:63909035	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	5.26	0.33	3.29e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs611744	0.967	rs645241	chr8:109190963	C/T	cg21045802	chr8:109455806	TTC35	0.46	5.4	0.33	1.67e-7	Dupuytren's disease;
SARC	cis	rs9399135	0.967	rs2327578	chr6:135329969	C/T	cg24558204	chr6:135376177	HBS1L	0.45	6.04	0.37	6.18e-9	Red blood cell count;
SARC	cis	rs10782582	0.569	rs74090722	chr1:76197262	A/G	cg03433033	chr1:76189801	ACADM	-0.42	-5.4	-0.33	1.64e-7	Daytime sleep phenotypes;
SARC	cis	rs77372450	0.551	rs61663448	chr5:157077191	T/C	cg05585991	chr5:157099197	C5orf52	0.51	5.16	0.32	5.4e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs1691799	0.899	rs1183272	chr12:66735421	T/C	cg16791601	chr12:66731901	HELB	-0.71	-10.62	-0.57	9.76e-22	White blood cell count (basophil);
SARC	cis	rs1018836	0.892	rs4735224	chr8:91567046	C/A	cg16814680	chr8:91681699	NA	-0.75	-11.5	-0.6	1.54e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs17079773	1.000	rs17079773	chr13:24598384	A/G	cg03829318	chr13:24462838	PCOTH;MIPEP	-0.56	-5.06	-0.31	8.5e-7	Inattentive symptoms;
SARC	cis	rs10992471	0.756	rs7848055	chr9:95115492	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.54	-6.62	-0.4	2.46e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg26681399	chr22:41777847	TEF	0.47	5.13	0.32	6.11e-7	Vitiligo;
SARC	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs2486288	0.656	rs6493145	chr15:45573862	G/T	cg19305227	chr15:45544335	SLC28A2	0.3	5.63	0.35	5.06e-8	Glomerular filtration rate;
SARC	cis	rs13401104	0.796	rs12471212	chr2:237112191	G/C	cg19324714	chr2:237145437	ASB18	0.58	6.05	0.37	5.77e-9	Educational attainment;
SARC	cis	rs77956314	0.515	rs12299065	chr12:117442304	A/G	cg02017074	chr12:117425053	FBXW8	0.55	6.72	0.4	1.35e-10	Subcortical brain region volumes;Hippocampal volume;
SARC	cis	rs6582630	0.638	rs1829584	chr12:38526299	G/T	cg04568710	chr12:38710424	ALG10B	-0.39	-4.71	-0.3	4.18e-6	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7178572	0.625	rs12905285	chr15:77845812	T/C	cg22256960	chr15:77711686	NA	-0.46	-5.71	-0.35	3.44e-8	Type 2 diabetes;
SARC	cis	rs634534	0.561	rs655744	chr11:65776585	G/T	cg26695010	chr11:65641043	EFEMP2	0.53	7.02	0.42	2.48e-11	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg25072359	chr17:41440525	NA	0.5	5.94	0.36	1.04e-8	Menopause (age at onset);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg12056618	chr15:31619949	KLF13	-0.78	-6.54	-0.39	3.79e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs911263	0.603	rs11627646	chr14:68809564	A/T	cg18825221	chr14:68749962	RAD51L1	-0.42	-7.44	-0.44	1.97e-12	Primary biliary cholangitis;
SARC	cis	rs2836950	0.545	rs2836949	chr21:40602456	C/A	cg17971929	chr21:40555470	PSMG1	-0.56	-6.86	-0.41	6e-11	Menarche (age at onset);
SARC	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg27347728	chr4:17578864	LAP3	0.48	6.1	0.37	4.5e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1559088	0.948	rs12610071	chr19:33582687	A/C	cg27124370	chr19:33622961	WDR88	0.45	5.91	0.36	1.22e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs11724804	0.532	rs7657611	chr4:880558	G/C	cg08222618	chr4:941054	TMEM175	0.42	5.57	0.34	7.12e-8	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
SARC	cis	rs12586317	1.000	rs12586317	chr14:35682172	T/C	cg16230307	chr14:35515116	FAM177A1	0.8	9.02	0.51	7.12e-17	Psoriasis;
SARC	cis	rs7326068	0.610	rs2772169	chr13:21314725	T/C	cg16922012	chr13:21400325	XPO4	-0.42	-5.7	-0.35	3.52e-8	Schizophrenia, bipolar disorder and depression (combined);
SARC	cis	rs3733585	0.699	rs4588456	chr4:9963895	A/T	cg11266682	chr4:10021025	SLC2A9	-0.35	-6.03	-0.37	6.35e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs6582630	0.519	rs8189599	chr12:38280748	A/G	cg26384229	chr12:38710491	ALG10B	0.91	13.79	0.67	4.83e-32	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs611744	0.967	rs660065	chr8:109191932	G/C	cg21045802	chr8:109455806	TTC35	0.44	5.3	0.33	2.64e-7	Dupuytren's disease;
SARC	cis	rs9527	0.590	rs7917650	chr10:104937100	G/C	cg04362960	chr10:104952993	NT5C2	0.42	5.03	0.31	1e-6	Arsenic metabolism;
SARC	cis	rs4803468	1.000	rs11670757	chr19:41913431	G/T	cg09537434	chr19:41945824	ATP5SL	-0.97	-17.11	-0.75	4.82e-43	Height;
SARC	cis	rs72627123	0.867	rs8018226	chr14:74471377	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.79	5.88	0.36	1.38e-8	Morning vs. evening chronotype;
SARC	cis	rs908922	0.887	rs7535188	chr1:152475899	G/A	cg09873164	chr1:152488093	CRCT1	0.61	7.13	0.42	1.27e-11	Hair morphology;
SARC	trans	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg26269797	chr7:130353928	TSGA13;COPG2	-0.52	-6.49	-0.39	5.16e-10	Colonoscopy-negative controls vs population controls;
SARC	trans	rs459571	1.000	rs2810489	chr9:136922700	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.64	-7.32	-0.43	4.11e-12	Platelet distribution width;
SARC	cis	rs72781680	0.821	rs113014365	chr2:24159903	C/T	cg08917208	chr2:24149416	ATAD2B	0.58	5.89	0.36	1.34e-8	Lymphocyte counts;
SARC	cis	rs9398803	0.865	rs9372839	chr6:126809870	G/A	cg19875578	chr6:126661172	C6orf173	0.63	8.72	0.5	5.32e-16	Male-pattern baldness;
SARC	cis	rs10489202	1.000	rs17485889	chr1:168018840	G/T	cg24449463	chr1:168025552	DCAF6	-0.61	-6.64	-0.4	2.23e-10	Schizophrenia;
SARC	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.43	0.44	2.1e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg24623196	chr12:49076058	C12orf41	0.51	6.46	0.39	6.2e-10	Lung adenocarcinoma;
SARC	cis	rs4810685	0.509	rs8114940	chr20:46411490	T/C	cg08288986	chr20:46415360	SULF2	0.52	5.88	0.36	1.43e-8	Attention deficit hyperactivity disorder (time to onset);
SARC	trans	rs561341	1.000	rs537166	chr17:30326827	C/T	cg20587970	chr11:113659929	NA	-1.22	-12.41	-0.63	1.8e-27	Hip circumference adjusted for BMI;
SARC	cis	rs11785400	0.793	rs2976399	chr8:143746050	C/T	cg24634471	chr8:143751801	JRK	0.6	7.72	0.45	3.51e-13	Schizophrenia;
SARC	cis	rs950776	0.593	rs621849	chr15:78872861	G/A	cg06917634	chr15:78832804	PSMA4	-0.84	-12.6	-0.64	4.24e-28	Sudden cardiac arrest;
SARC	cis	rs6963495	0.872	rs1569134	chr7:105158228	T/C	cg19920283	chr7:105172520	RINT1	0.65	5.48	0.34	1.09e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs73635312	0.850	rs79186901	chr10:8947608	T/C	cg24467326	chr10:9646929	NA	0.64	5.22	0.32	3.88e-7	Basal cell carcinoma;
SARC	cis	rs1355223	0.902	rs12802120	chr11:34747650	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-5.98	-0.36	8.22e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs4148883	0.645	rs2851287	chr4:100014548	G/A	cg13256891	chr4:100009986	ADH5	0.59	7.91	0.46	1.02e-13	Alcohol dependence;
SARC	cis	rs9815354	0.812	rs73081361	chr3:41912535	G/A	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg02018176	chr4:1364513	KIAA1530	-0.35	-5.11	-0.32	6.59e-7	Obesity-related traits;
SARC	cis	rs2529049	0.527	rs2721807	chr7:24779987	T/G	cg17569154	chr7:24781545	DFNA5	0.47	6.38	0.39	9.65e-10	Urate levels in obese individuals;
SARC	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg11366901	chr6:160182831	ACAT2	0.91	9.18	0.52	2.39e-17	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs1949733	0.701	rs871768	chr4:8454938	G/A	cg11789530	chr4:8429930	ACOX3	0.83	10.77	0.58	3.24e-22	Response to antineoplastic agents;
SARC	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg17376030	chr22:41985996	PMM1	-0.73	-9.01	-0.51	7.45e-17	Vitiligo;
SARC	cis	rs3812831	0.643	rs7322339	chr13:114929726	C/A	cg06611532	chr13:114900021	NA	0.34	5.64	0.35	4.97e-8	Schizophrenia;
SARC	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg03647317	chr4:187891568	NA	-0.35	-5.03	-0.31	9.95e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg00149659	chr3:10157352	C3orf10	0.65	6.21	0.38	2.38e-9	Alzheimer's disease;
SARC	trans	rs61931739	0.534	rs7965503	chr12:34199349	A/G	cg26384229	chr12:38710491	ALG10B	0.84	12.12	0.62	1.49e-26	Morning vs. evening chronotype;
SARC	cis	rs11690935	0.921	rs6710698	chr2:172596078	G/C	cg13550731	chr2:172543902	DYNC1I2	-0.98	-15.94	-0.72	3.63e-39	Schizophrenia;
SARC	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg25952890	chr19:58913133	NA	0.38	5.4	0.33	1.66e-7	Uric acid clearance;
SARC	cis	rs13161895	0.941	rs12519642	chr5:179438626	T/G	cg02702477	chr5:179499311	RNF130	-0.65	-6.46	-0.39	5.92e-10	LDL cholesterol;
SARC	cis	rs1355223	0.506	rs7130774	chr11:34869267	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.08	-0.37	4.82e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg04317338	chr11:64019027	PLCB3	0.84	9.15	0.51	2.99e-17	Mean platelet volume;
SARC	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs11711311	1.000	rs9830975	chr3:113486019	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.69	8.82	0.5	2.69e-16	IgG glycosylation;
SARC	cis	rs11583043	0.958	rs12746722	chr1:101464789	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.49	5.93	0.36	1.09e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs11608355	0.508	rs12822899	chr12:109800978	A/G	cg05360138	chr12:110035743	NA	0.57	6.33	0.38	1.24e-9	Neuroticism;
SARC	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg09699651	chr6:150184138	LRP11	0.39	4.87	0.3	2.04e-6	Lung cancer;
SARC	cis	rs7590368	0.683	rs12471762	chr2:10958258	C/T	cg25617230	chr2:10952979	PDIA6	0.51	4.72	0.3	4.09e-6	Educational attainment (years of education);
SARC	cis	rs9611519	0.828	rs4822008	chr22:41539206	C/G	cg03806693	chr22:41940476	POLR3H	-0.54	-6.11	-0.37	4.24e-9	Neuroticism;
SARC	cis	rs9388451	0.626	rs1343116	chr6:126069702	C/A	cg05901451	chr6:126070800	HEY2	-0.52	-6.45	-0.39	6.31e-10	Brugada syndrome;
SARC	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg11301795	chr4:187892539	NA	-0.69	-9.85	-0.54	2.39e-19	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6701037	0.566	rs10753091	chr1:175134571	T/C	cg00321850	chr1:175162397	KIAA0040	0.38	5.92	0.36	1.13e-8	Alcohol dependence;
SARC	trans	rs6582618	1	rs6582618	chr12:38726137	A/G	cg23762105	chr12:34175262	ALG10	-0.53	-6.87	-0.41	5.79e-11	Morning vs. evening chronotype;
SARC	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg05313129	chr8:58192883	C8orf71	-0.55	-6.15	-0.37	3.34e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7246657	1.000	rs1823061	chr19:37800626	G/A	cg14683738	chr19:37701593	ZNF585B	0.6	5.51	0.34	9.46e-8	Coronary artery calcification;
SARC	cis	rs765787	0.530	rs2668751	chr15:45517293	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.4	-4.86	-0.3	2.19e-6	Uric acid levels;
SARC	cis	rs2832191	0.791	rs2832202	chr21:30501342	G/A	cg24692254	chr21:30365293	RNF160	-0.87	-12.51	-0.63	8.46e-28	Dental caries;
SARC	cis	rs7772486	0.686	rs9403741	chr6:146030548	G/A	cg05347473	chr6:146136440	FBXO30	-0.5	-6.87	-0.41	5.72e-11	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg26030832	chr2:32502794	YIPF4	-0.46	-6.23	-0.38	2.14e-9	Thyroid stimulating hormone;
SARC	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	8.71	0.5	5.56e-16	Alzheimer's disease;
SARC	cis	rs9814567	0.752	rs6764764	chr3:134331167	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.48	6.01	0.37	6.99e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs3749237	0.929	rs62260715	chr3:49829326	G/A	cg03060546	chr3:49711283	APEH	0.6	7.27	0.43	5.31e-12	Resting heart rate;
SARC	cis	rs2985684	0.789	rs1957979	chr14:50063332	A/G	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.45	4.92	0.31	1.66e-6	Carotid intima media thickness;
SARC	cis	rs4595586	0.546	rs11609849	chr12:39258090	C/G	cg13010199	chr12:38710504	ALG10B	0.57	6.67	0.4	1.85e-10	Morning vs. evening chronotype;
SARC	cis	rs6088590	1.000	rs11698977	chr20:33449691	C/T	cg06115741	chr20:33292138	TP53INP2	0.55	6.72	0.4	1.38e-10	Coronary artery disease;
SARC	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.7	-8.64	-0.49	8.86e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9807989	0.507	rs6755905	chr2:103048207	C/A	cg03938978	chr2:103052716	IL18RAP	0.32	5.18	0.32	4.72e-7	Asthma;
SARC	cis	rs1881797	1.000	rs10925062	chr1:247658978	G/C	cg11166453	chr1:247681781	NA	0.45	4.86	0.3	2.14e-6	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs12044355	0.964	rs12045144	chr1:231844248	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.52	6.9	0.41	4.95e-11	Alzheimer's disease;
SARC	cis	rs10911232	0.507	rs10797832	chr1:183044034	A/G	cg13390022	chr1:182993471	LAMC1	0.34	5.08	0.32	7.69e-7	Hypertriglyceridemia;
SARC	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg00149659	chr3:10157352	C3orf10	-0.63	-5.75	-0.35	2.82e-8	Alzheimer's disease;
SARC	cis	rs77372450	0.551	rs62387669	chr5:157071930	A/G	cg05585991	chr5:157099197	C5orf52	0.52	5.11	0.32	6.68e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs924607	0.900	rs1697950	chr5:616890	G/A	cg09021430	chr5:549028	NA	0.33	6.33	0.38	1.28e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg08219700	chr8:58056026	NA	0.71	6.75	0.4	1.16e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs8067545	0.611	rs2526482	chr17:20119133	C/T	cg13482628	chr17:19912719	NA	-0.52	-6.71	-0.4	1.48e-10	Schizophrenia;
SARC	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg12437481	chr16:420112	MRPL28	-0.39	-6.02	-0.37	6.68e-9	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs6582630	0.638	rs10880620	chr12:38517467	A/G	cg14851346	chr12:38532713	NA	-0.42	-5.0	-0.31	1.11e-6	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg25072359	chr17:41440525	NA	0.56	6.91	0.41	4.65e-11	Menopause (age at onset);
SARC	cis	rs9660992	0.710	rs1668872	chr1:205236069	G/A	cg21545522	chr1:205238299	TMCC2	0.49	6.84	0.41	6.81e-11	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg10963375	chr1:205815865	PM20D1	0.33	5.04	0.31	9.3e-7	Menarche (age at onset);
SARC	cis	rs8180040	0.726	rs61729713	chr3:47027192	A/G	cg27129171	chr3:47204927	SETD2	-0.58	-7.84	-0.46	1.61e-13	Colorectal cancer;
SARC	trans	rs11098499	0.954	rs13133522	chr4:120324424	A/T	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	cis	rs13082711	0.595	rs4973762	chr3:27364789	A/T	cg02860705	chr3:27208620	NA	0.59	6.99	0.42	2.88e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg13353311	chr5:59996240	DEPDC1B	0.49	6.39	0.39	9.02e-10	Blood pressure;
SARC	cis	rs7647973	0.626	rs7637711	chr3:49829653	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.6	-6.21	-0.38	2.41e-9	Menarche (age at onset);
SARC	cis	rs1538970	0.924	rs7528573	chr1:45913860	T/C	cg05343316	chr1:45956843	TESK2	0.78	8.86	0.5	2.1e-16	Platelet count;
SARC	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg00933542	chr6:150070202	PCMT1	0.32	5.36	0.33	2.01e-7	Lung cancer;
SARC	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg11764359	chr7:65958608	NA	-0.67	-7.97	-0.46	7.26e-14	Aortic root size;
SARC	cis	rs2204008	0.627	rs10878486	chr12:38148601	T/G	cg26384229	chr12:38710491	ALG10B	0.89	12.84	0.64	6.93e-29	Bladder cancer;
SARC	cis	rs7592578	0.771	rs75579212	chr2:191376575	C/T	cg25963032	chr2:191064776	C2orf88	-0.47	-5.23	-0.32	3.72e-7	Diastolic blood pressure;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg27193021	chr11:14284425	SPON1	0.56	6.39	0.39	8.86e-10	Brain volume in infants (cerebrospinal fluid);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg11195034	chr6:20493106	E2F3	0.48	6.65	0.4	2.05e-10	Thyroid stimulating hormone;
SARC	cis	rs8072100	0.875	rs4794047	chr17:45763005	A/T	cg08085267	chr17:45401833	C17orf57	0.42	5.07	0.32	8.05e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	trans	rs61931739	0.500	rs6488215	chr12:34434803	A/T	cg13010199	chr12:38710504	ALG10B	0.75	10.66	0.57	7.34e-22	Morning vs. evening chronotype;
SARC	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg26425730	chr6:153304295	FBXO5	0.49	6.81	0.41	8.06e-11	Cancer;
SARC	trans	rs66573146	0.656	rs111560662	chr4:6952766	C/T	cg07817883	chr1:32538562	TMEM39B	1.12	8.17	0.47	2.01e-14	Granulocyte percentage of myeloid white cells;
SARC	cis	rs4595586	0.505	rs6580897	chr12:39372254	A/G	cg26384229	chr12:38710491	ALG10B	0.51	6.33	0.38	1.23e-9	Morning vs. evening chronotype;
SARC	cis	rs9914988	0.887	rs2070265	chr17:27075423	A/G	cg20469991	chr17:27169893	C17orf63	0.49	5.19	0.32	4.5e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs7674212	0.507	rs223322	chr4:103800194	G/A	cg16532752	chr4:104119610	CENPE	-0.43	-4.91	-0.31	1.74e-6	Type 2 diabetes;
SARC	cis	rs6964587	1.000	rs7811564	chr7:91663364	A/G	cg17063962	chr7:91808500	NA	0.95	16.02	0.72	1.87e-39	Breast cancer;
SARC	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg16414030	chr3:133502952	NA	0.49	6.76	0.41	1.09e-10	Iron status biomarkers;
SARC	cis	rs2073300	0.609	rs6137936	chr20:23385232	C/T	cg16736954	chr20:23401023	NAPB	0.79	4.94	0.31	1.5e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs35661897	0.920	rs34550030	chr2:227339970	C/T	cg03426602	chr2:227312417	NA	-0.54	-5.16	-0.32	5.27e-7	Urinary tract infection frequency;
SARC	cis	rs9341808	0.519	rs7771593	chr6:81036127	T/C	cg08355045	chr6:80787529	NA	-0.37	-5.5	-0.34	1.01e-7	Sitting height ratio;
SARC	cis	rs7666738	0.861	rs13139309	chr4:99020916	A/G	cg05340658	chr4:99064831	C4orf37	0.66	9.04	0.51	6.35e-17	Colonoscopy-negative controls vs population controls;
SARC	trans	rs3780486	0.505	rs10758194	chr9:33157419	G/T	cg04842962	chr6:43655489	MRPS18A	0.88	12.37	0.63	2.28e-27	IgG glycosylation;
SARC	cis	rs7044106	0.791	rs10984997	chr9:123481206	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	5.97	0.36	8.88e-9	Hip circumference adjusted for BMI;
SARC	cis	rs644799	0.544	rs498553	chr11:95534441	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.74	9.85	0.54	2.25e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs34779708	0.931	rs11596502	chr10:35387187	A/C	cg03585969	chr10:35415529	CREM	0.41	5.09	0.32	7.48e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs9325144	0.555	rs12424003	chr12:38688140	C/T	cg13010199	chr12:38710504	ALG10B	-0.54	-6.97	-0.42	3.24e-11	Morning vs. evening chronotype;
SARC	cis	rs9581943	0.967	rs11618581	chr13:28476911	C/T	cg17352152	chr13:28491409	NA	0.38	4.99	0.31	1.17e-6	Pancreatic cancer;
SARC	cis	rs9399135	0.935	rs9376086	chr6:135371329	T/C	cg24558204	chr6:135376177	HBS1L	0.46	6.24	0.38	2.09e-9	Red blood cell count;
SARC	cis	rs9868809	0.505	rs9882549	chr3:48749358	C/T	cg00383909	chr3:49044727	WDR6	0.6	5.67	0.35	4.29e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs1707322	0.721	rs4660314	chr1:46229885	T/C	cg06784218	chr1:46089804	CCDC17	0.39	6.86	0.41	6.15e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2486288	0.656	rs8039138	chr15:45551592	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.51	-6.44	-0.39	6.68e-10	Glomerular filtration rate;
SARC	cis	rs2120019	0.567	rs8025170	chr15:75170983	A/G	cg09165964	chr15:75287851	SCAMP5	0.92	10.45	0.56	3.34e-21	Blood trace element (Zn levels);
SARC	cis	rs17376456	1.000	rs35184505	chr5:93561535	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.28	0.33	2.89e-7	Diabetic retinopathy;
SARC	cis	rs12824058	0.831	rs11608407	chr12:130805869	G/A	cg24838063	chr12:130822603	PIWIL1	0.63	8.81	0.5	2.9e-16	Menopause (age at onset);
SARC	trans	rs8064100	0.526	rs8045545	chr16:56730361	C/G	cg17872999	chr7:104653783	MLL5;LOC100216545	-0.51	-6.38	-0.39	9.44e-10	Gambling;
SARC	cis	rs1371867	0.846	rs1660351	chr8:101275034	C/T	cg11906718	chr8:101322791	RNF19A	0.73	9.59	0.53	1.4e-18	Atrioventricular conduction;
SARC	cis	rs7635838	0.892	rs6792718	chr3:11434380	A/G	cg00170343	chr3:11313890	ATG7	0.61	8.2	0.47	1.66e-14	HDL cholesterol;
SARC	cis	rs4430311	0.723	rs12125920	chr1:243911397	A/C	cg21452805	chr1:244014465	NA	-0.4	-5.26	-0.33	3.27e-7	Post-traumatic stress disorder (asjusted for relatedness);
SARC	cis	rs7762018	0.607	rs77392231	chr6:170057634	G/A	cg14662283	chr6:170068385	WDR27	-0.64	-4.74	-0.3	3.67e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs9303401	0.614	rs68100606	chr17:56500898	G/A	cg25039879	chr17:56429692	SUPT4H1	0.58	5.19	0.32	4.61e-7	Cognitive test performance;
SARC	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg22800045	chr5:56110881	MAP3K1	0.74	7.83	0.46	1.74e-13	Initial pursuit acceleration;
SARC	cis	rs1472147	1.000	rs6970221	chr7:128511024	A/G	cg00260937	chr7:128520193	KCP	0.41	4.82	0.3	2.54e-6	Calcium levels;
SARC	cis	rs1707322	0.963	rs11211238	chr1:46449415	G/A	cg06784218	chr1:46089804	CCDC17	0.34	5.95	0.36	9.76e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4243830	0.850	rs10746502	chr1:6607199	A/G	cg04093404	chr1:6614507	TAS1R1;NOL9	0.63	5.27	0.33	3.13e-7	Body mass index;
SARC	trans	rs61931739	0.500	rs11053199	chr12:34450534	C/T	cg26384229	chr12:38710491	ALG10B	-0.83	-12.28	-0.63	4.57e-27	Morning vs. evening chronotype;
SARC	cis	rs9467773	1.000	rs9986382	chr6:26550619	T/C	cg11502198	chr6:26597334	ABT1	0.48	5.87	0.36	1.51e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7617773	0.817	rs79310258	chr3:48259667	C/G	cg11946769	chr3:48343235	NME6	0.72	9.31	0.52	9.97e-18	Coronary artery disease;
SARC	cis	rs4423214	1.000	rs3794060	chr11:71187679	C/T	cg05163923	chr11:71159392	DHCR7	0.65	9.03	0.51	6.47e-17	Vitamin D levels;
SARC	cis	rs4722166	0.630	rs1581497	chr7:22779503	C/A	cg26061582	chr7:22766209	IL6	0.57	6.28	0.38	1.6e-9	Lung cancer;
SARC	cis	rs1395	0.744	rs11679220	chr2:27476378	G/A	cg21747090	chr2:27597821	SNX17	-0.49	-5.86	-0.36	1.59e-8	Blood metabolite levels;
SARC	cis	rs7103648	0.553	rs12803857	chr11:47890172	G/A	cg20307385	chr11:47447363	PSMC3	0.66	7.95	0.46	8.15e-14	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs933688	1.000	rs6865495	chr5:90746424	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.99	12.79	0.64	1e-28	Smoking behavior;
SARC	cis	rs7666738	0.546	rs10461174	chr4:98698293	G/A	cg05340658	chr4:99064831	C4orf37	0.6	7.27	0.43	5.37e-12	Colonoscopy-negative controls vs population controls;
SARC	cis	rs765787	0.530	rs2458224	chr15:45522130	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.41	-4.9	-0.31	1.82e-6	Uric acid levels;
SARC	cis	rs2070488	0.804	rs2268755	chr3:38501916	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.77	-12.33	-0.63	3.26e-27	Electrocardiographic conduction measures;
SARC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg02475777	chr4:1388615	CRIPAK	-0.63	-7.46	-0.44	1.67e-12	Longevity;
SARC	cis	rs4711350	0.765	rs2182658	chr6:33748831	G/T	cg07979401	chr6:33739406	LEMD2	0.39	4.99	0.31	1.18e-6	Schizophrenia;
SARC	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	11.03	0.59	4.93e-23	Alzheimer's disease;
SARC	cis	rs427394	0.802	rs274712	chr5:6723950	G/A	cg10857441	chr5:6722123	POLS	-0.34	-5.1	-0.32	7.2e-7	Menopause (age at onset);
SARC	cis	rs6546550	0.901	rs7598283	chr2:70128717	A/G	cg02498382	chr2:70120550	SNRNP27	-0.31	-5.04	-0.31	9.3e-7	Prevalent atrial fibrillation;
SARC	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg25894440	chr7:65020034	NA	0.75	5.67	0.35	4.21e-8	Diabetic kidney disease;
SARC	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg22857025	chr5:266934	NA	-1.08	-11.87	-0.61	1.02e-25	Breast cancer;
SARC	cis	rs34172651	0.917	rs2112786	chr16:24778944	C/T	cg00339695	chr16:24857497	SLC5A11	0.29	4.82	0.3	2.54e-6	Intelligence (multi-trait analysis);
SARC	cis	rs793571	0.543	rs4775087	chr15:58974904	T/C	cg05156742	chr15:59063176	FAM63B	0.71	9.52	0.53	2.39e-18	Schizophrenia;
SARC	cis	rs3126085	0.935	rs4326625	chr1:152223996	C/T	cg03465714	chr1:152285911	FLG	-0.47	-5.83	-0.36	1.87e-8	Atopic dermatitis;
SARC	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg24675658	chr1:53192096	ZYG11B	0.67	9.89	0.54	1.7e-19	Monocyte count;
SARC	cis	rs4722166	0.508	rs2069832	chr7:22767433	A/G	cg26061582	chr7:22766209	IL6	0.59	6.69	0.4	1.68e-10	Lung cancer;
SARC	cis	rs16912285	0.688	rs7124856	chr11:24324926	C/T	ch.11.24196551F	chr11:24239977	NA	0.57	5.73	0.35	3.06e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs4128725	0.925	rs12142583	chr1:159477947	A/G	cg25076881	chr1:159409836	OR10J1	0.46	5.49	0.34	1.04e-7	Select biomarker traits;
SARC	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg08859206	chr1:53392774	SCP2	-0.41	-5.86	-0.36	1.56e-8	Monocyte count;
SARC	cis	rs9660992	0.674	rs1151785	chr1:205232299	C/T	cg07972983	chr1:205091412	RBBP5	0.56	6.69	0.4	1.6e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs9916302	0.904	rs650106	chr17:37451559	A/G	cg15445000	chr17:37608096	MED1	-0.44	-5.31	-0.33	2.6e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs9790314	0.812	rs7631479	chr3:161139566	C/T	cg04691961	chr3:161091175	C3orf57	-0.63	-8.86	-0.5	2.08e-16	Morning vs. evening chronotype;
SARC	cis	rs8114671	0.562	rs6088642	chr20:33483186	G/T	cg24642439	chr20:33292090	TP53INP2	0.49	5.96	0.36	9.15e-9	Height;
SARC	cis	rs9788682	0.748	rs2456020	chr15:78868398	C/T	cg06917634	chr15:78832804	PSMA4	-0.51	-5.65	-0.35	4.64e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs17666538	0.585	rs6559063	chr8:623051	C/T	cg23958373	chr8:599963	NA	0.66	5.08	0.32	7.68e-7	IgG glycosylation;
SARC	cis	rs9733	0.650	rs11204680	chr1:150587140	T/G	cg13175981	chr1:150552382	MCL1	0.69	9.41	0.52	4.83e-18	Tonsillectomy;
SARC	cis	rs3091242	0.933	rs10903130	chr1:25769221	A/T	cg27572855	chr1:25598939	RHD	0.53	9.15	0.51	2.95e-17	Erythrocyte sedimentation rate;
SARC	trans	rs2814331	0.544	rs10788487	chr10:88030550	A/G	cg22530449	chr3:184560962	VPS8	-0.48	-6.29	-0.38	1.53e-9	Balding;
SARC	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg05368731	chr17:41323189	NBR1	0.79	9.57	0.53	1.59e-18	Menopause (age at onset);
SARC	cis	rs2204008	0.630	rs1283300	chr12:38150227	C/T	cg14851346	chr12:38532713	NA	-0.44	-5.25	-0.33	3.48e-7	Bladder cancer;
SARC	cis	rs9400467	0.537	rs12202418	chr6:111451467	A/G	cg15721981	chr6:111408429	SLC16A10	0.69	5.91	0.36	1.22e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg18225595	chr11:63971243	STIP1	0.47	5.36	0.33	1.99e-7	Mean platelet volume;
SARC	cis	rs1568889	1.000	rs11603799	chr11:28196488	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	10.16	0.55	2.62e-20	Bipolar disorder;
SARC	trans	rs66573146	1.000	rs66519732	chr4:6990569	C/G	cg07817883	chr1:32538562	TMEM39B	1.42	8.51	0.49	2.16e-15	Granulocyte percentage of myeloid white cells;
SARC	cis	rs1448094	0.836	rs6539935	chr12:86376809	T/C	cg02569458	chr12:86230093	RASSF9	0.4	5.99	0.37	7.92e-9	Major depressive disorder;
SARC	cis	rs754466	0.580	rs11002289	chr10:79532580	G/A	cg17075019	chr10:79541650	NA	-0.85	-13.14	-0.65	7.08e-30	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1355223	0.506	rs1509659	chr11:34865133	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.25	-0.38	1.89e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs12497850	0.644	rs11928552	chr3:48739883	T/C	cg06212747	chr3:49208901	KLHDC8B	0.64	8.54	0.49	1.73e-15	Parkinson's disease;
SARC	cis	rs12956009	0.583	rs1115360	chr18:44894550	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	7.64	0.45	5.6e-13	Educational attainment (years of education);
SARC	cis	rs11785693	0.909	rs11784246	chr8:4970497	A/G	cg26367366	chr8:4980734	NA	0.71	6.31	0.38	1.36e-9	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs2292864	0.681	rs35735886	chr17:45374277	G/T	cg18085866	chr17:45331354	ITGB3	-0.82	-6.14	-0.37	3.51e-9	Left atrial antero-posterior diameter;
SARC	cis	rs554111	0.656	rs6685914	chr1:21362378	G/A	cg04902671	chr1:21058625	SH2D5	0.44	5.31	0.33	2.49e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs472402	0.623	rs8192133	chr5:6636645	A/G	cg27314116	chr5:6583850	LOC255167	0.31	4.9	0.31	1.81e-6	Response to amphetamines;
SARC	cis	rs908922	0.676	rs2105117	chr1:152484129	G/A	cg09873164	chr1:152488093	CRCT1	0.65	8.39	0.48	4.83e-15	Hair morphology;
SARC	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg23248424	chr5:179741104	GFPT2	-0.46	-5.74	-0.35	2.97e-8	Height;
SARC	cis	rs9677476	0.516	rs6727962	chr2:232045268	G/A	cg23338755	chr2:231921595	PSMD1	0.4	4.85	0.3	2.26e-6	Food antigen IgG levels;
SARC	cis	rs7766436	0.885	rs765782	chr6:22592216	A/G	cg13666174	chr6:22585274	NA	-0.56	-7.41	-0.44	2.35e-12	Coronary artery disease;
SARC	cis	rs1790761	0.520	rs1551884	chr11:67399601	C/G	cg24690094	chr11:67383802	NA	-0.45	-6.29	-0.38	1.55e-9	Mean corpuscular volume;
SARC	cis	rs9457247	0.967	rs1794696	chr6:167396174	T/C	cg23791538	chr6:167370224	RNASET2	-0.62	-8.55	-0.49	1.68e-15	Crohn's disease;
SARC	cis	rs28795989	0.828	rs34701321	chr4:7889792	T/G	cg18538662	chr4:7941764	AFAP1	-0.37	-4.73	-0.3	3.83e-6	Intraocular pressure;
SARC	cis	rs1008375	0.864	rs4698196	chr4:17574735	T/C	cg16339924	chr4:17578868	LAP3	0.7	9.0	0.51	8.02e-17	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg11764359	chr7:65958608	NA	0.77	9.41	0.52	5.12e-18	Aortic root size;
SARC	cis	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.52	-0.39	4.34e-10	Joint mobility (Beighton score);
SARC	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.62	7.28	0.43	5.04e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs3540	0.553	rs2158406	chr15:90994499	T/C	cg22089800	chr15:90895588	ZNF774	0.67	8.67	0.49	7.25e-16	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg00933542	chr6:150070202	PCMT1	0.34	5.91	0.36	1.23e-8	Lung cancer;
SARC	trans	rs656319	0.513	rs34990153	chr8:9996389	A/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.6	-0.45	7.41e-13	Myopia (pathological);
SARC	cis	rs787274	0.867	rs786981	chr9:115457856	T/G	cg13803584	chr9:115635662	SNX30	0.73	5.69	0.35	3.83e-8	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs965604	1.000	rs8043227	chr15:78768871	C/G	cg24631222	chr15:78858424	CHRNA5	-0.42	-5.59	-0.34	6.3e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs4595586	0.545	rs17546137	chr12:39401124	G/A	cg26384229	chr12:38710491	ALG10B	0.51	5.96	0.36	9.45e-9	Morning vs. evening chronotype;
SARC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg11494091	chr17:61959527	GH2	-0.52	-7.55	-0.44	1e-12	Prudent dietary pattern;
SARC	cis	rs9640161	0.636	rs3735171	chr7:150033882	A/G	cg10018233	chr7:150070692	REPIN1	0.67	8.56	0.49	1.57e-15	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg15049968	chr18:44337910	ST8SIA5	-0.35	-5.54	-0.34	8.09e-8	Personality dimensions;
SARC	cis	rs7666738	0.830	rs28818180	chr4:98953625	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	trans	rs11098499	0.863	rs13136462	chr4:120543173	C/T	cg25214090	chr10:38739885	LOC399744	0.51	6.61	0.4	2.54e-10	Corneal astigmatism;
SARC	cis	rs6866344	0.697	rs72812613	chr5:178135257	G/A	cg10224037	chr5:178157518	ZNF354A	1.0	12.24	0.63	6.38e-27	Neutrophil percentage of white cells;
SARC	cis	rs11190604	1.000	rs2295770	chr10:102239829	G/A	cg07080220	chr10:102295463	HIF1AN	0.76	8.74	0.5	4.67e-16	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs7917772	0.636	rs2249845	chr10:104512095	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-6.23	-0.38	2.14e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs1008375	0.932	rs7677212	chr4:17675932	A/G	cg16339924	chr4:17578868	LAP3	-0.64	-8.12	-0.47	2.75e-14	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9747201	0.862	rs57596657	chr17:80147978	C/T	cg17462356	chr17:80056334	FASN	-0.47	-5.24	-0.32	3.56e-7	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	trans	rs11039798	0.623	rs635632	chr11:48399532	T/C	cg15704280	chr7:45808275	SEPT13	-0.63	-6.39	-0.39	8.74e-10	Axial length;
SARC	cis	rs2204008	0.694	rs1672436	chr12:38132547	G/T	cg26384229	chr12:38710491	ALG10B	-0.66	-8.58	-0.49	1.37e-15	Bladder cancer;
SARC	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg16479474	chr6:28041457	NA	0.36	5.45	0.34	1.25e-7	Depression;
SARC	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs16976116	0.951	rs3809540	chr15:55489412	A/C	cg17854078	chr15:55489399	RSL24D1	0.63	6.38	0.39	9.4e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9300255	0.639	rs1716171	chr12:123716376	C/T	cg00376283	chr12:123451042	ABCB9	0.52	6.03	0.37	6.37e-9	Neutrophil percentage of white cells;
SARC	cis	rs2153535	0.580	rs1034272	chr6:8469335	G/C	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	cis	rs2288073	0.965	rs6545335	chr2:24422011	G/A	cg06627628	chr2:24431161	ITSN2	-0.65	-7.93	-0.46	9.28e-14	Venous thromboembolism (SNP x SNP interaction);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg20776722	chr5:130970743	RAPGEF6	0.53	6.75	0.4	1.17e-10	Breast cancer;
SARC	cis	rs80130819	0.515	rs1476608	chr12:48493731	C/T	cg24011408	chr12:48396354	COL2A1	0.5	5.54	0.34	8.27e-8	Prostate cancer;
SARC	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg19077165	chr18:44547161	KATNAL2	-0.52	-6.91	-0.41	4.61e-11	Personality dimensions;
SARC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg12000995	chr2:27665139	KRTCAP3	-0.3	-4.77	-0.3	3.24e-6	Total body bone mineral density;
SARC	cis	rs2479724	0.935	rs62396748	chr6:41782007	A/G	cg17623882	chr6:41773611	USP49	0.46	6.04	0.37	6.04e-9	Menarche (age at onset);
SARC	cis	rs1059312	0.808	rs900982	chr12:129304369	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.5	7.19	0.43	8.74e-12	Systemic lupus erythematosus;
SARC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg11965913	chr1:205819406	PM20D1	0.91	15.19	0.71	1.13e-36	Menarche (age at onset);
SARC	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.48	5.41	0.33	1.53e-7	Renal function-related traits (BUN);
SARC	cis	rs829883	0.646	rs1641638	chr12:98891031	A/G	cg25150519	chr12:98850993	NA	0.43	5.43	0.34	1.42e-7	Colorectal adenoma (advanced);
SARC	cis	rs2276314	1.000	rs8086395	chr18:33564592	C/G	cg19628046	chr18:33552617	C18orf21	0.56	5.92	0.36	1.16e-8	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs79390637	1	rs79390637	chr11:47456867	C/A	cg20307385	chr11:47447363	PSMC3	0.49	5.32	0.33	2.47e-7	Intraocular pressure;
SARC	cis	rs10779751	1.000	rs12032364	chr1:11286872	G/T	cg08854313	chr1:11322531	MTOR	0.8	11.4	0.6	3.16e-24	Body mass index;
SARC	cis	rs11785400	0.890	rs13279182	chr8:143720544	A/G	cg10596483	chr8:143751796	JRK	0.65	8.56	0.49	1.5e-15	Schizophrenia;
SARC	cis	rs3126085	0.935	rs2338430	chr1:152214420	C/T	cg26876637	chr1:152193138	HRNR	-0.46	-5.28	-0.33	2.9e-7	Atopic dermatitis;
SARC	cis	rs2594989	0.943	rs2606737	chr3:11398654	A/G	cg00170343	chr3:11313890	ATG7	0.58	5.53	0.34	8.4e-8	Circulating chemerin levels;
SARC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg16080015	chr7:5085479	RBAK	0.49	6.44	0.39	6.76e-10	Myopia (pathological);
SARC	cis	rs644799	0.932	rs10831447	chr11:95663017	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.7	-9.04	-0.51	6.27e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs722599	0.748	rs17102884	chr14:75374899	C/T	cg08847533	chr14:75593920	NEK9	-0.42	-4.78	-0.3	3.14e-6	IgG glycosylation;
SARC	cis	rs9911578	1.000	rs9907499	chr17:56949044	A/G	cg05425664	chr17:57184151	TRIM37	-0.65	-8.0	-0.46	5.84e-14	Intelligence (multi-trait analysis);
SARC	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.46	5.87	0.36	1.53e-8	Gut microbiome composition (summer);
SARC	cis	rs11583043	0.918	rs3850453	chr1:101408933	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.48	5.8	0.36	2.18e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs9341808	0.538	rs12176343	chr6:81027387	G/A	cg08355045	chr6:80787529	NA	-0.36	-5.43	-0.33	1.44e-7	Sitting height ratio;
SARC	cis	rs950027	0.620	rs1153862	chr15:45631868	A/G	cg26924012	chr15:45694286	SPATA5L1	0.52	6.57	0.4	3.26e-10	Response to fenofibrate (adiponectin levels);
SARC	cis	rs10958369	0.613	rs7812717	chr8:54433922	A/C	cg12485204	chr8:54507357	NA	0.46	6.53	0.39	3.97e-10	Response to antineoplastic agents;
SARC	cis	rs12908161	0.683	rs12903256	chr15:85308141	G/T	cg17507749	chr15:85114479	UBE2QP1	0.45	5.33	0.33	2.37e-7	Schizophrenia;
SARC	cis	rs9611519	0.929	rs12484971	chr22:41439304	A/T	cg17376030	chr22:41985996	PMM1	0.49	6.06	0.37	5.3e-9	Neuroticism;
SARC	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	10.55	0.57	1.54e-21	Platelet count;
SARC	trans	rs7824557	0.564	rs2572394	chr8:11235393	A/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-6.99	-0.42	2.8e-11	Retinal vascular caliber;
SARC	cis	rs11264799	0.603	rs12744410	chr1:157566211	A/G	cg18268488	chr1:157545234	FCRL4	0.31	5.34	0.33	2.19e-7	IgA nephropathy;
SARC	cis	rs870825	0.616	rs6810600	chr4:185616814	T/C	cg04058563	chr4:185651563	MLF1IP	0.82	11.18	0.59	1.58e-23	Blood protein levels;
SARC	cis	rs6495122	0.501	rs12101482	chr15:75344784	A/T	cg09165964	chr15:75287851	SCAMP5	-0.49	-6.5	-0.39	4.76e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	cis	rs11690935	0.959	rs6738445	chr2:172599615	T/C	cg13550731	chr2:172543902	DYNC1I2	0.98	15.05	0.7	3.33e-36	Schizophrenia;
SARC	cis	rs2559856	1.000	rs2695288	chr12:102088112	T/C	cg12924262	chr12:102091054	CHPT1	0.57	7.78	0.45	2.35e-13	Blood protein levels;
SARC	cis	rs6912958	1.000	rs6933587	chr6:88175577	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.51	-0.34	9.24e-8	Monocyte percentage of white cells;
SARC	cis	rs950169	0.922	rs11635505	chr15:85097034	A/C	cg24253500	chr15:84953950	NA	-0.37	-5.38	-0.33	1.8e-7	Schizophrenia;
SARC	cis	rs12586317	0.547	rs10130773	chr14:35445299	G/A	cg26967526	chr14:35346199	BAZ1A	-0.57	-5.7	-0.35	3.53e-8	Psoriasis;
SARC	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg19223190	chr17:80058835	NA	0.45	6.18	0.38	2.83e-9	Life satisfaction;
SARC	cis	rs644148	0.785	rs117048220	chr19:44965555	G/A	cg15540054	chr19:45004280	ZNF180	0.46	5.54	0.34	7.99e-8	Personality dimensions;
SARC	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg21724239	chr8:58056113	NA	0.61	5.93	0.36	1.1e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs36051895	0.632	rs2381213	chr9:5168871	A/G	cg02405213	chr9:5042618	JAK2	0.52	5.64	0.35	4.97e-8	Pediatric autoimmune diseases;
SARC	cis	rs78456975	0.943	rs6721243	chr2:1580250	A/G	cg26248373	chr2:1572462	NA	-0.54	-6.0	-0.37	7.35e-9	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg08280861	chr8:58055591	NA	0.57	5.14	0.32	5.73e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg14403583	chr14:105418241	AHNAK2	-0.58	-7.76	-0.45	2.7e-13	Rheumatoid arthritis;
SARC	cis	rs9916302	0.904	rs8065879	chr17:37515978	G/A	cg07936489	chr17:37558343	FBXL20	0.68	9.16	0.51	2.78e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg17221315	chr6:27791827	HIST1H4J	0.46	4.83	0.3	2.53e-6	Depression;
SARC	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg27532560	chr4:187881888	NA	-0.36	-4.94	-0.31	1.5e-6	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs1814175	0.817	rs12287396	chr11:49819798	G/C	cg15704280	chr7:45808275	SEPT13	-0.97	-17.66	-0.76	7.4e-45	Height;
SARC	cis	rs9790314	0.723	rs1026572	chr3:160887654	A/G	cg04691961	chr3:161091175	C3orf57	-0.59	-7.77	-0.45	2.43e-13	Morning vs. evening chronotype;
SARC	cis	rs3106136	0.772	rs2865353	chr4:95270878	T/C	cg11021082	chr4:95130006	SMARCAD1	0.33	5.17	0.32	5.12e-7	Capecitabine sensitivity;
SARC	trans	rs61931739	0.500	rs10772163	chr12:34532950	T/C	cg13010199	chr12:38710504	ALG10B	0.78	11.07	0.59	3.68e-23	Morning vs. evening chronotype;
SARC	cis	rs6674970	0.933	rs11204772	chr1:151056305	C/T	cg11822372	chr1:151115635	SEMA6C	0.44	5.38	0.33	1.81e-7	Childhood ear infection;
SARC	cis	rs9894429	0.538	rs9747080	chr17:79606704	A/G	cg10661904	chr17:79619235	PDE6G	-0.42	-5.94	-0.36	1.04e-8	Eye color traits;
SARC	cis	rs8067545	0.641	rs203482	chr17:19827210	G/A	cg13482628	chr17:19912719	NA	0.51	6.42	0.39	7.41e-10	Schizophrenia;
SARC	cis	rs2153535	0.580	rs6914276	chr6:8450435	A/T	cg21535247	chr6:8435926	SLC35B3	-0.54	-6.69	-0.4	1.65e-10	Motion sickness;
SARC	cis	rs12142240	0.698	rs67200518	chr1:46835777	T/C	cg00530320	chr1:46809349	NSUN4	0.57	7.0	0.42	2.74e-11	Menopause (age at onset);
SARC	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg09455208	chr3:40491958	NA	0.42	6.44	0.39	6.61e-10	Renal cell carcinoma;
SARC	cis	rs6752107	0.967	rs6431661	chr2:234167421	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.5	6.74	0.4	1.23e-10	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg22974920	chr21:40686053	BRWD1	0.46	4.95	0.31	1.43e-6	Cognitive function;
SARC	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg00933542	chr6:150070202	PCMT1	0.31	5.31	0.33	2.55e-7	Lung cancer;
SARC	cis	rs897080	0.552	rs1067375	chr2:44650118	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.51	-6.22	-0.38	2.33e-9	Height;
SARC	cis	rs910316	0.712	rs175037	chr14:75465038	T/C	cg08847533	chr14:75593920	NEK9	-0.86	-13.01	-0.65	1.82e-29	Height;
SARC	cis	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg05623727	chr3:50126028	RBM5	-0.33	-4.98	-0.31	1.25e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9467773	1.000	rs4713008	chr6:26538268	T/C	cg12292205	chr6:26970375	C6orf41	0.45	5.42	0.33	1.45e-7	Intelligence (multi-trait analysis);
SARC	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg02574844	chr11:5959923	NA	-0.39	-5.27	-0.33	3.13e-7	DNA methylation (variation);
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg10961240	chr6:64345449	NA	-0.49	-6.73	-0.4	1.27e-10	Electrocardiographic conduction measures;
SARC	cis	rs9435341	0.965	rs61798468	chr1:107569316	T/G	cg09367891	chr1:107599246	PRMT6	0.73	9.32	0.52	9.02e-18	Facial morphology (factor 21, depth of nasal alae);
SARC	cis	rs2997447	0.601	rs61776580	chr1:26432719	C/T	cg19633962	chr1:26362018	EXTL1	-0.57	-5.05	-0.31	8.95e-7	QRS complex (12-leadsum);
SARC	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg11644478	chr21:40555479	PSMG1	1.03	13.97	0.68	1.25e-32	Cognitive function;
SARC	trans	rs2243123	0.602	rs2133310	chr3:159716352	A/G	cg24858658	chr1:33502741	AK2	0.5	6.35	0.38	1.13e-9	Multiple sclerosis;
SARC	cis	rs9354352	0.967	rs6455062	chr6:66694131	T/A	cg07460842	chr6:66804631	NA	0.59	7.68	0.45	4.46e-13	Initial pursuit acceleration in psychotic disorders;
SARC	cis	rs1865760	0.534	rs2032444	chr6:26046744	T/G	cg17691542	chr6:26056736	HIST1H1C	0.63	7.18	0.43	9.16e-12	Height;
SARC	cis	rs6424115	1.000	rs1018396	chr1:24133612	G/A	cg15997130	chr1:24165203	NA	0.48	6.66	0.4	1.9e-10	Immature fraction of reticulocytes;
SARC	cis	rs9355610	0.609	rs7772112	chr6:167408896	G/A	cg23791538	chr6:167370224	RNASET2	0.52	5.85	0.36	1.7e-8	Graves' disease;
SARC	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg23758822	chr17:41437982	NA	0.9	11.44	0.6	2.35e-24	Menopause (age at onset);
SARC	cis	rs10197940	0.662	rs4467261	chr2:152281391	G/C	cg19508488	chr2:152266495	RIF1	0.47	5.16	0.32	5.27e-7	Lung cancer;
SARC	cis	rs911555	0.755	rs35233301	chr14:103885291	A/G	cg24130564	chr14:104152367	KLC1	0.5	5.9	0.36	1.24e-8	Intelligence (multi-trait analysis);
SARC	cis	rs116095464	0.558	rs10055993	chr5:264296	A/C	cg22857025	chr5:266934	NA	-1.08	-9.93	-0.55	1.35e-19	Breast cancer;
SARC	cis	rs11997175	0.562	rs58955533	chr8:33829692	C/T	ch.8.33884649F	chr8:33765107	NA	0.45	5.72	0.35	3.29e-8	Body mass index;
SARC	cis	rs3126085	0.935	rs56013982	chr1:152176503	C/T	cg26876637	chr1:152193138	HRNR	-0.5	-5.15	-0.32	5.6e-7	Atopic dermatitis;
SARC	cis	rs1865760	1.000	rs2071301	chr6:25914263	G/T	cg16482183	chr6:26056742	HIST1H1C	0.51	6.34	0.38	1.19e-9	Height;
SARC	cis	rs7959452	0.535	rs11177577	chr12:69671791	C/T	cg22834771	chr12:69754056	YEATS4	-0.38	-5.0	-0.31	1.15e-6	Blood protein levels;
SARC	cis	rs829661	0.512	rs1113661	chr2:30805280	C/T	cg12454169	chr2:30669597	LCLAT1	-0.4	-4.94	-0.31	1.48e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
SARC	cis	rs637571	0.522	rs538954	chr11:65756808	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.54	8.6	0.49	1.21e-15	Eosinophil percentage of white cells;
SARC	cis	rs6546550	0.935	rs13017134	chr2:70090579	C/G	cg02498382	chr2:70120550	SNRNP27	-0.37	-6.04	-0.37	6.06e-9	Prevalent atrial fibrillation;
SARC	trans	rs1814175	0.616	rs1794139	chr11:49910855	C/T	cg15704280	chr7:45808275	SEPT13	-0.89	-14.06	-0.68	6.43e-33	Height;
SARC	cis	rs55871839	0.643	rs7004274	chr8:59810378	T/A	cg07426533	chr8:59803705	TOX	-0.39	-5.08	-0.32	7.71e-7	Pneumonia;
SARC	cis	rs7586879	0.616	rs6722587	chr2:25132192	C/A	cg04586622	chr2:25135609	ADCY3	0.3	5.08	0.32	7.84e-7	Body mass index;
SARC	cis	rs7223966	0.921	rs34699959	chr17:61960720	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	7.13	0.42	1.25e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs526231	0.511	rs62362545	chr5:102347452	A/G	cg23492399	chr5:102201601	PAM	-0.51	-5.77	-0.35	2.47e-8	Primary biliary cholangitis;
SARC	cis	rs7696431	0.901	rs999958	chr4:169698873	C/A	cg07840446	chr4:169690674	PALLD	0.34	4.88	0.3	1.97e-6	Coronary artery disease;
SARC	cis	rs734999	0.566	rs10752747	chr1:2524915	G/T	cg00980319	chr1:2560884	MMEL1	-0.35	-4.95	-0.31	1.41e-6	Ulcerative colitis;
SARC	cis	rs1034435	0.755	rs5767173	chr22:48892473	T/C	cg05992904	chr22:48892994	FAM19A5	-0.46	-6.75	-0.4	1.17e-10	Late-onset Alzheimer's disease;
SARC	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg12463550	chr7:65579703	CRCP	0.53	5.72	0.35	3.29e-8	Aortic root size;
SARC	cis	rs9916302	0.904	rs755500	chr17:37409865	C/T	cg20243544	chr17:37824526	PNMT	0.6	7.53	0.44	1.09e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	10.42	0.56	3.99e-21	Platelet count;
SARC	cis	rs72945132	0.882	rs61177215	chr11:70129534	G/A	cg00319359	chr11:70116639	PPFIA1	0.68	6.35	0.38	1.14e-9	Coronary artery disease;
SARC	cis	rs6493487	0.512	rs117335843	chr15:51314455	C/G	cg02338191	chr15:51200825	AP4E1	0.53	4.82	0.3	2.54e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs6977660	0.714	rs12530537	chr7:19822641	A/G	cg05791153	chr7:19748676	TWISTNB	-0.56	-5.34	-0.33	2.22e-7	Thyroid stimulating hormone;
SARC	cis	rs5753037	0.653	rs131282	chr22:30156608	A/C	cg01021169	chr22:30184971	ASCC2	-0.44	-6.06	-0.37	5.45e-9	Type 1 diabetes;
SARC	cis	rs2439831	0.702	rs7175032	chr15:44060236	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.81	7.61	0.45	6.95e-13	Lung cancer in ever smokers;
SARC	cis	rs4481887	0.508	rs6695316	chr1:248394322	G/C	cg13385794	chr1:248469461	NA	0.37	5.03	0.31	9.79e-7	Common traits (Other);
SARC	cis	rs765787	0.505	rs1648302	chr15:45494238	A/G	cg25801113	chr15:45476975	SHF	0.28	4.77	0.3	3.27e-6	Uric acid levels;
SARC	cis	rs11711311	1.000	rs9865435	chr3:113450046	G/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.69	8.9	0.5	1.64e-16	IgG glycosylation;
SARC	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg23758822	chr17:41437982	NA	0.91	11.49	0.6	1.7e-24	Menopause (age at onset);
SARC	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.5	5.88	0.36	1.39e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg01316550	chr5:56110833	MAP3K1	0.54	4.92	0.31	1.62e-6	Initial pursuit acceleration;
SARC	cis	rs7520050	0.966	rs785489	chr1:46576390	A/G	cg24296786	chr1:45957014	TESK2	0.38	4.82	0.3	2.56e-6	Red blood cell count;Reticulocyte count;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg10302505	chr8:128748092	MYC	-0.56	-7.23	-0.43	6.77e-12	Gallstone disease;
SARC	cis	rs734999	0.505	rs60687045	chr1:2539603	G/A	cg20673091	chr1:2541236	MMEL1	0.34	5.26	0.33	3.24e-7	Ulcerative colitis;
SARC	cis	rs57561814	0.510	rs1524107	chr7:22768219	C/T	cg01770232	chr7:22766155	IL6	0.68	5.62	0.35	5.34e-8	Tonsillectomy;
SARC	cis	rs2288912	0.838	rs7251503	chr19:45455715	C/G	cg13119609	chr19:45449297	APOC2	0.5	8.44	0.48	3.42e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs10791323	0.604	rs2723598	chr11:133711652	G/A	cg15485101	chr11:133734466	NA	0.33	5.08	0.32	7.91e-7	Childhood ear infection;
SARC	cis	rs1707322	0.691	rs11211175	chr1:46220884	C/G	cg03146154	chr1:46216737	IPP	0.5	6.06	0.37	5.56e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs477692	0.685	rs551491	chr10:131397821	G/A	cg05714579	chr10:131428358	MGMT	0.51	6.8	0.41	8.68e-11	Response to temozolomide;
SARC	cis	rs4423214	1.000	rs4944959	chr11:71168234	C/T	cg24826892	chr11:71159390	DHCR7	-0.49	-6.31	-0.38	1.39e-9	Vitamin D levels;
SARC	cis	rs72945132	0.882	rs72949078	chr11:70217708	T/C	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.74	-0.35	2.91e-8	Coronary artery disease;
SARC	cis	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg25427524	chr10:38739819	LOC399744	-0.52	-8.25	-0.48	1.17e-14	Extrinsic epigenetic age acceleration;
SARC	cis	rs10870270	1.000	rs4880250	chr10:133773919	G/A	cg26149184	chr10:133730230	NA	0.48	5.28	0.33	2.99e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs7512552	0.839	rs11587575	chr1:150451863	T/C	cg15654264	chr1:150340011	RPRD2	0.37	4.73	0.3	3.93e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs12956009	0.518	rs1560902	chr18:44898765	T/C	cg15049968	chr18:44337910	ST8SIA5	-0.31	-4.74	-0.3	3.67e-6	Educational attainment (years of education);
SARC	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg05332525	chr7:65337924	VKORC1L1	-0.44	-4.9	-0.31	1.79e-6	Aortic root size;
SARC	cis	rs6088580	0.524	rs6088564	chr20:33249444	A/G	cg24642439	chr20:33292090	TP53INP2	-0.54	-6.65	-0.4	2.07e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs6582630	0.504	rs4882367	chr12:38330878	A/T	cg14851346	chr12:38532713	NA	-0.47	-5.48	-0.34	1.09e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs60871478	0.636	rs4721834	chr7:896142	C/T	cg05535760	chr7:792225	HEATR2	-0.73	-6.9	-0.41	4.97e-11	Cerebrospinal P-tau181p levels;
SARC	cis	rs769267	0.566	rs9304962	chr19:19679992	G/C	cg03709012	chr19:19516395	GATAD2A	-0.76	-10.0	-0.55	8.1e-20	Tonsillectomy;
SARC	cis	rs2153535	0.580	rs7747306	chr6:8453663	C/G	cg21535247	chr6:8435926	SLC35B3	-0.56	-6.99	-0.42	2.85e-11	Motion sickness;
SARC	cis	rs526231	0.575	rs55652053	chr5:102337170	T/A	cg23492399	chr5:102201601	PAM	-0.51	-5.93	-0.36	1.1e-8	Primary biliary cholangitis;
SARC	cis	rs2235544	0.565	rs635509	chr1:54469227	A/G	cg10336722	chr1:54665764	CYB5RL;MRPL37	-0.38	-4.74	-0.3	3.66e-6	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg08763666	chr10:123719887	NSMCE4A	0.47	6.55	0.39	3.56e-10	Thyroid stimulating hormone;
SARC	trans	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.74	10.56	0.57	1.45e-21	Intelligence (multi-trait analysis);
SARC	cis	rs67311347	0.568	rs57287242	chr3:40335538	T/C	cg09455208	chr3:40491958	NA	0.3	4.92	0.31	1.66e-6	Renal cell carcinoma;
SARC	cis	rs4792901	0.765	rs34778116	chr17:41539698	G/T	cg22562494	chr17:41607896	ETV4	-0.3	-4.71	-0.3	4.18e-6	Dupuytren's disease;
SARC	cis	rs6733011	0.518	rs12712033	chr2:99457973	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.45	-5.67	-0.35	4.31e-8	Bipolar disorder;
SARC	cis	rs3812831	0.695	rs913526	chr13:114928946	G/C	cg08824895	chr13:115047677	UPF3A	0.51	6.61	0.4	2.63e-10	Schizophrenia;
SARC	cis	rs1497406	0.744	rs12057222	chr1:16508534	A/G	cg06365898	chr1:16533907	ARHGEF19	0.43	5.65	0.35	4.63e-8	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9486715	0.867	rs2223238	chr6:96871855	G/A	cg06623918	chr6:96969491	KIAA0776	0.87	12.59	0.64	4.52e-28	Headache;
SARC	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg11764359	chr7:65958608	NA	0.88	12.58	0.64	4.89e-28	Aortic root size;
SARC	cis	rs3087591	0.960	rs9898664	chr17:29567152	T/C	cg24425628	chr17:29625626	OMG;NF1	-0.52	-6.38	-0.39	9.41e-10	Hip circumference;
SARC	cis	rs6963495	0.818	rs6955796	chr7:105170321	T/G	cg13798780	chr7:105162888	PUS7	0.6	5.55	0.34	7.84e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs72945132	0.579	rs61341131	chr11:70246956	C/A	cg05964544	chr11:70165517	PPFIA1	-0.63	-6.11	-0.37	4.1e-9	Coronary artery disease;
SARC	cis	rs8084125	0.832	rs62105178	chr18:74950635	C/T	cg26065057	chr18:74961000	GALR1	0.47	4.86	0.3	2.14e-6	Obesity-related traits;
SARC	cis	rs2361710	0.611	rs12451471	chr17:78102517	C/T	cg06718696	chr17:78121285	EIF4A3	0.62	7.32	0.43	3.91e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
SARC	cis	rs72781680	0.821	rs72781644	chr2:24209348	T/C	cg08917208	chr2:24149416	ATAD2B	0.58	6.09	0.37	4.69e-9	Lymphocyte counts;
SARC	cis	rs9612	0.718	rs346536	chr19:44251470	A/T	cg08581076	chr19:44259116	C19orf61	0.59	7.54	0.44	1.06e-12	Exhaled nitric oxide output;
SARC	cis	rs12594515	0.967	rs12595138	chr15:45986108	G/C	cg14863074	chr15:45997064	NA	0.34	5.19	0.32	4.48e-7	Waist circumference;Weight;
SARC	cis	rs950027	0.620	rs2461700	chr15:45640627	T/C	cg15395560	chr15:45543142	SLC28A2	-0.27	-5.17	-0.32	5.14e-7	Response to fenofibrate (adiponectin levels);
SARC	cis	rs933688	0.938	rs12110065	chr5:90718474	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.03	13.02	0.65	1.72e-29	Smoking behavior;
SARC	cis	rs9303401	0.614	rs3887355	chr17:56538639	T/C	cg25039879	chr17:56429692	SUPT4H1	0.63	5.77	0.35	2.51e-8	Cognitive test performance;
SARC	cis	rs7937682	0.883	rs484834	chr11:111465761	G/C	cg22437258	chr11:111473054	SIK2	0.76	9.87	0.54	2.07e-19	Primary sclerosing cholangitis;
SARC	cis	rs933688	1.000	rs6867219	chr5:90718008	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.08	13.76	0.67	6.36e-32	Smoking behavior;
SARC	cis	rs611744	0.538	rs2298605	chr8:109272006	T/C	cg21045802	chr8:109455806	TTC35	0.59	7.76	0.45	2.71e-13	Dupuytren's disease;
SARC	cis	rs9916302	0.904	rs9905432	chr17:37555918	C/A	cg15445000	chr17:37608096	MED1	-0.42	-5.02	-0.31	1.02e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs7927771	0.965	rs4752845	chr11:47539697	T/C	cg05585544	chr11:47624801	NA	-0.36	-4.88	-0.3	2e-6	Subjective well-being;
SARC	cis	rs2180341	0.814	rs6914131	chr6:127737489	T/C	cg27446573	chr6:127587934	RNF146	0.8	10.39	0.56	4.87e-21	Breast cancer;
SARC	cis	rs6977660	0.714	rs10231980	chr7:19789383	C/G	cg07541023	chr7:19748670	TWISTNB	0.74	6.89	0.41	5.29e-11	Thyroid stimulating hormone;
SARC	cis	rs950169	1.000	rs79318564	chr15:84786150	G/A	cg24253500	chr15:84953950	NA	0.38	5.49	0.34	1.07e-7	Schizophrenia;
SARC	cis	rs5758659	0.623	rs133328	chr22:42408079	T/C	cg04733989	chr22:42467013	NAGA	0.54	7.19	0.43	9e-12	Cognitive function;
SARC	cis	rs240764	0.669	rs846800	chr6:101270498	C/G	cg09795085	chr6:101329169	ASCC3	0.48	6.25	0.38	1.91e-9	Neuroticism;
SARC	cis	rs7219021	0.961	rs9901447	chr17:46872346	C/T	cg16584676	chr17:46985605	UBE2Z	-0.44	-4.95	-0.31	1.41e-6	Schizophrenia or bipolar disorder;
SARC	cis	rs9818758	0.607	rs73074866	chr3:49626666	C/T	cg07636037	chr3:49044803	WDR6	-0.8	-6.62	-0.4	2.41e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	5.55	0.34	7.8e-8	Bipolar disorder;
SARC	cis	rs2273669	0.667	rs76094073	chr6:109288036	C/G	cg05315195	chr6:109294784	ARMC2	-0.58	-5.1	-0.32	6.89e-7	Prostate cancer;
SARC	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg11890956	chr21:40555474	PSMG1	1.14	18.82	0.78	1.14e-48	Cognitive function;
SARC	cis	rs1580019	0.961	rs1868776	chr7:32494435	G/T	cg14728415	chr7:32535168	LSM5;AVL9	-0.46	-5.45	-0.34	1.28e-7	Cognitive ability;
SARC	cis	rs763121	0.853	rs6001188	chr22:39062194	T/C	cg21395723	chr22:39101663	GTPBP1	0.58	6.46	0.39	6.16e-10	Menopause (age at onset);
SARC	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.28	0.38	1.68e-9	Bipolar disorder;
SARC	cis	rs1003719	0.707	rs9976360	chr21:38587860	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-9.14	-0.51	3.11e-17	Eye color traits;
SARC	trans	rs9929218	0.954	rs1981871	chr16:68819007	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.5	-6.34	-0.38	1.18e-9	Colorectal cancer;
SARC	cis	rs7216064	1.000	rs9915108	chr17:65874463	T/C	cg12091567	chr17:66097778	LOC651250	-0.7	-7.64	-0.45	5.5e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg19223190	chr17:80058835	NA	0.41	5.71	0.35	3.45e-8	Life satisfaction;
SARC	cis	rs55823223	0.648	rs11867582	chr17:73857306	A/G	cg14829360	chr17:73884958	NA	-0.62	-7.94	-0.46	8.27e-14	Psoriasis;
SARC	cis	rs7296418	0.961	rs12425850	chr12:123501972	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.43	-5.81	-0.36	2e-8	Platelet count;
SARC	cis	rs3796352	0.881	rs35384050	chr3:53008769	G/T	cg15956490	chr3:53032818	SFMBT1	0.75	4.99	0.31	1.2e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg17691542	chr6:26056736	HIST1H1C	0.42	5.08	0.32	7.9e-7	Blood metabolite levels;
SARC	cis	rs10876993	0.890	rs1585781	chr12:58056701	T/G	cg18357645	chr12:58087776	OS9	0.49	6.53	0.39	4.11e-10	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs453301	0.631	rs13250781	chr8:8793343	T/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.42	-0.39	7.56e-10	Joint mobility (Beighton score);
SARC	cis	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg15145296	chr3:125709740	NA	-0.48	-4.86	-0.3	2.19e-6	Blood pressure (smoking interaction);
SARC	cis	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg09201264	chr20:3748382	C20orf27	0.36	4.71	0.3	4.19e-6	Immature fraction of reticulocytes;
SARC	cis	rs208520	0.690	rs207108	chr6:66794096	T/C	cg07460842	chr6:66804631	NA	-1.08	-15.02	-0.7	4.17e-36	Exhaled nitric oxide output;
SARC	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	13.66	0.67	1.39e-31	Chronic sinus infection;
SARC	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg06618935	chr21:46677482	NA	-0.41	-5.36	-0.33	2.03e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg17940198	chr18:74204830	NA	0.48	6.4	0.39	8.63e-10	Lung adenocarcinoma;
SARC	cis	rs4974559	0.501	rs1732115	chr4:1244416	C/T	cg02980000	chr4:1222292	CTBP1	0.77	6.21	0.38	2.45e-9	Systolic blood pressure;
SARC	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg01475735	chr3:40494733	NA	-0.49	-5.37	-0.33	1.95e-7	Renal cell carcinoma;
SARC	cis	rs12791968	0.765	rs2279359	chr11:44999605	A/G	cg11846598	chr11:44996168	LOC221122	0.33	4.82	0.3	2.55e-6	Inhibitory control;
SARC	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg06771923	chr16:23607815	NDUFAB1	-0.49	-6.26	-0.38	1.87e-9	Thyroid cancer;
SARC	cis	rs11122272	0.735	rs2474623	chr1:231513993	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg04944784	chr2:26401820	FAM59B	0.47	5.98	0.36	8.52e-9	Gut microbiome composition (summer);
SARC	cis	rs9916302	0.904	rs8079560	chr17:37497661	C/T	cg07936489	chr17:37558343	FBXL20	0.68	9.16	0.51	2.78e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs9467773	1.000	rs2255070	chr6:26501777	C/G	cg11502198	chr6:26597334	ABT1	0.48	5.98	0.36	8.43e-9	Intelligence (multi-trait analysis);
SARC	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg24549020	chr5:56110836	MAP3K1	0.7	7.17	0.42	1.01e-11	Initial pursuit acceleration;
SARC	cis	rs6141769	0.569	rs6057616	chr20:31259279	A/T	cg17884169	chr20:31446444	EFCAB8	-0.44	-4.76	-0.3	3.46e-6	Subjective well-being;
SARC	cis	rs55871839	0.708	rs4738735	chr8:59816985	T/C	cg07426533	chr8:59803705	TOX	-0.4	-5.12	-0.32	6.32e-7	Pneumonia;
SARC	cis	rs9660992	0.547	rs12143121	chr1:205199142	A/G	cg07972983	chr1:205091412	RBBP5	0.57	7.02	0.42	2.35e-11	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs16976116	0.901	rs1061874	chr15:55496287	A/T	cg17854078	chr15:55489399	RSL24D1	0.66	6.53	0.39	4.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs910316	0.967	rs4899545	chr14:75568138	A/G	cg11812906	chr14:75593930	NEK9	0.89	14.34	0.68	7.33e-34	Height;
SARC	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg05025164	chr4:1340916	KIAA1530	0.67	8.55	0.49	1.61e-15	Longevity;
SARC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg01238044	chr22:24384105	GSTT1	-0.52	-5.8	-0.36	2.15e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2153535	0.580	rs9328478	chr6:8519183	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	8.28	0.48	9.37e-15	Motion sickness;
SARC	cis	rs898097	0.691	rs7222745	chr17:80907253	C/T	cg15664640	chr17:80829946	TBCD	-0.42	-6.48	-0.39	5.3e-10	Breast cancer;
SARC	cis	rs17125944	0.615	rs7151643	chr14:53313661	G/C	cg00686598	chr14:53173677	PSMC6	-0.67	-4.99	-0.31	1.16e-6	Alzheimer's disease (late onset);
SARC	cis	rs11613048	0.830	rs12810865	chr12:30333240	C/G	cg12718339	chr12:29936407	TMTC1	-0.36	-4.87	-0.3	2.1e-6	Major depressive disorder;
SARC	cis	rs8072100	0.745	rs7214410	chr17:45422628	A/G	cg08085267	chr17:45401833	C17orf57	-0.43	-5.24	-0.32	3.66e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs1008375	0.932	rs6844593	chr4:17659039	T/C	cg02297831	chr4:17616191	MED28	0.48	6.13	0.37	3.65e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs829883	0.664	rs249833	chr12:98832189	T/C	cg25150519	chr12:98850993	NA	0.79	12.95	0.65	2.9e-29	Colorectal adenoma (advanced);
SARC	cis	rs6696846	0.765	rs11577406	chr1:205065733	G/T	cg21545522	chr1:205238299	TMCC2	0.34	4.75	0.3	3.56e-6	Red blood cell count;
SARC	cis	rs4727027	0.727	rs1568944	chr7:148873497	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	5.98	0.37	8.12e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg06108461	chr20:60628389	TAF4	-0.92	-12.69	-0.64	2.14e-28	Body mass index;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg16714616	chr20:40247229	CHD6	0.52	6.59	0.4	2.95e-10	Breast cancer;
SARC	cis	rs2153535	0.580	rs1577472	chr6:8486215	G/A	cg21535247	chr6:8435926	SLC35B3	0.56	6.93	0.41	3.98e-11	Motion sickness;
SARC	cis	rs67311347	0.544	rs12054197	chr3:40337562	C/T	cg09455208	chr3:40491958	NA	0.3	5.01	0.31	1.08e-6	Renal cell carcinoma;
SARC	cis	rs11112613	0.713	rs11112592	chr12:105951702	C/T	cg03607813	chr12:105948248	NA	-0.47	-6.74	-0.4	1.2e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg07636037	chr3:49044803	WDR6	0.62	6.3	0.38	1.49e-9	Menarche (age at onset);
SARC	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9916302	0.861	rs12150493	chr17:37586154	T/C	cg15445000	chr17:37608096	MED1	0.42	5.02	0.31	1.02e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-6.26	-0.38	1.79e-9	Personality dimensions;
SARC	cis	rs644799	0.509	rs580181	chr11:95643040	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	5.9	0.36	1.26e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs1044826	1.000	rs13089007	chr3:139095587	T/C	cg15131784	chr3:139108705	COPB2	0.46	5.27	0.33	3.09e-7	Obesity-related traits;
SARC	cis	rs796364	1.000	rs281762	chr2:200799201	C/G	cg23649088	chr2:200775458	C2orf69	0.64	6.06	0.37	5.52e-9	Schizophrenia;
SARC	cis	rs9790314	0.905	rs6789388	chr3:160970437	G/A	cg04691961	chr3:161091175	C3orf57	-0.75	-10.85	-0.58	1.88e-22	Morning vs. evening chronotype;
SARC	cis	rs7582720	1.000	rs72936332	chr2:204056678	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	7.88	0.46	1.21e-13	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs55823223	0.564	rs4572466	chr17:73846314	A/C	cg23806715	chr17:73775811	H3F3B	0.45	4.79	0.3	2.94e-6	Psoriasis;
SARC	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg07701084	chr6:150067640	NUP43	0.44	5.69	0.35	3.87e-8	Lung cancer;
SARC	cis	rs9810259	0.525	rs310749	chr3:12273768	A/C	cg23514324	chr3:12329213	PPARG	-0.39	-5.09	-0.32	7.27e-7	Platelet count;
SARC	cis	rs1023500	0.551	rs61665536	chr22:42512613	A/G	cg15557168	chr22:42548783	NA	0.36	4.92	0.31	1.62e-6	Schizophrenia;
SARC	cis	rs9650657	0.615	rs6601534	chr8:10691993	A/G	cg21775007	chr8:11205619	TDH	-0.4	-4.92	-0.31	1.64e-6	Neuroticism;
SARC	cis	rs3858526	0.839	rs10466484	chr11:5943696	A/G	cg02574844	chr11:5959923	NA	-0.41	-4.99	-0.31	1.16e-6	DNA methylation (variation);
SARC	cis	rs2191566	0.761	rs446016	chr19:44501518	A/G	cg20607764	chr19:44506953	ZNF230	-0.48	-5.49	-0.34	1.05e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg13939156	chr17:80058883	NA	-0.43	-6.61	-0.4	2.55e-10	Life satisfaction;
SARC	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg06634786	chr22:41940651	POLR3H	0.5	6.12	0.37	3.99e-9	Vitiligo;
SARC	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg23758822	chr17:41437982	NA	0.88	11.24	0.59	1.04e-23	Menopause (age at onset);
SARC	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg03433033	chr1:76189801	ACADM	0.55	7.82	0.46	1.86e-13	Blood metabolite levels;Acylcarnitine levels;
SARC	trans	rs877282	0.898	rs11253350	chr10:765968	G/A	cg22713356	chr15:30763199	NA	1.04	10.06	0.55	5.37e-20	Uric acid levels;
SARC	cis	rs6446731	0.734	rs7675084	chr4:3273908	C/T	cg06533319	chr4:3265114	C4orf44	-0.32	-5.27	-0.33	3.16e-7	Mean platelet volume;
SARC	cis	rs453301	0.624	rs2979256	chr8:8871710	C/T	cg06636001	chr8:8085503	FLJ10661	0.43	5.46	0.34	1.19e-7	Joint mobility (Beighton score);
SARC	cis	rs601339	1.000	rs4759361	chr12:123178280	T/A	cg18578876	chr12:123200353	GPR109B	0.45	5.09	0.32	7.46e-7	Adiponectin levels;
SARC	cis	rs6540556	0.723	rs3766619	chr1:209895298	C/G	cg23920097	chr1:209922102	NA	-0.51	-5.17	-0.32	4.97e-7	Red blood cell count;
SARC	cis	rs1691799	0.899	rs1168294	chr12:66733988	T/C	cg16791601	chr12:66731901	HELB	-0.71	-10.67	-0.57	6.75e-22	White blood cell count (basophil);
SARC	cis	rs754466	0.580	rs12356063	chr10:79558131	G/C	cg17075019	chr10:79541650	NA	-0.85	-13.26	-0.66	2.82e-30	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg11764359	chr7:65958608	NA	0.79	9.45	0.53	3.74e-18	Aortic root size;
SARC	cis	rs9815354	1.000	rs79548696	chr3:41803385	C/T	cg03022575	chr3:42003672	ULK4	0.6	5.81	0.36	2.07e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs8141529	0.732	rs3788409	chr22:29198151	T/G	cg15103426	chr22:29168792	CCDC117	0.68	9.22	0.52	1.87e-17	Lymphocyte counts;
SARC	trans	rs9650657	0.740	rs12676417	chr8:10668634	C/T	cg06636001	chr8:8085503	FLJ10661	0.52	6.7	0.4	1.53e-10	Neuroticism;
SARC	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.77	10.99	0.58	6.7e-23	Personality dimensions;
SARC	cis	rs1008375	0.966	rs11722132	chr4:17697217	T/C	cg27347728	chr4:17578864	LAP3	0.44	5.67	0.35	4.13e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg01475735	chr3:40494733	NA	-0.46	-5.12	-0.32	6.47e-7	Renal cell carcinoma;
SARC	cis	rs5995756	0.712	rs9611205	chr22:40010521	G/A	cg10455938	chr22:40058150	CACNA1I	-0.49	-6.34	-0.38	1.15e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7681440	0.583	rs2165614	chr4:90805724	A/C	cg06632027	chr4:90757378	SNCA	-0.46	-5.53	-0.34	8.69e-8	Dementia with Lewy bodies;
SARC	cis	rs2273669	0.915	rs4992383	chr6:109292816	C/A	cg01304950	chr6:109416612	SESN1;C6orf182	0.54	4.8	0.3	2.87e-6	Prostate cancer;
SARC	cis	rs2120019	0.935	rs12591119	chr15:75355944	A/G	cg00629941	chr15:75287862	SCAMP5	-0.64	-7.52	-0.44	1.18e-12	Blood trace element (Zn levels);
SARC	cis	rs9814567	0.896	rs6763188	chr3:134349995	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.49	6.23	0.38	2.21e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs6674176	0.628	rs3828146	chr1:44428715	C/T	cg13246856	chr1:44399776	ARTN	0.29	4.73	0.3	3.83e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg06636001	chr8:8085503	FLJ10661	-0.63	-7.93	-0.46	8.99e-14	Mood instability;
SARC	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg11764359	chr7:65958608	NA	0.76	8.99	0.51	8.48e-17	Aortic root size;
SARC	cis	rs4253772	0.591	rs6519993	chr22:46656479	A/G	cg24881330	chr22:46731750	TRMU	0.62	6.86	0.41	6.14e-11	LDL cholesterol;Cholesterol, total;
SARC	cis	rs9660992	0.542	rs17345153	chr1:205179997	A/G	cg21545522	chr1:205238299	TMCC2	0.37	4.97	0.31	1.3e-6	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg18357526	chr6:26021779	HIST1H4A	0.46	5.85	0.36	1.64e-8	Blood metabolite levels;
SARC	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg11890956	chr21:40555474	PSMG1	1.18	19.84	0.79	5.73e-52	Cognitive function;
SARC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg02018176	chr4:1364513	KIAA1530	0.63	9.73	0.54	5.5e-19	Longevity;
SARC	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg22535103	chr8:58192502	C8orf71	-0.8	-9.15	-0.51	2.94e-17	Developmental language disorder (linguistic errors);
SARC	cis	rs765787	0.530	rs4775844	chr15:45542048	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.67e-7	Uric acid levels;
SARC	cis	rs2011503	1.000	rs8101219	chr19:19643715	G/A	cg15839431	chr19:19639596	YJEFN3	-0.48	-4.77	-0.3	3.32e-6	Bipolar disorder;
SARC	cis	rs5753618	0.561	rs13054220	chr22:31704492	A/G	cg02404636	chr22:31891804	SFI1	0.49	5.19	0.32	4.65e-7	Colorectal cancer;
SARC	cis	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg07777115	chr5:623756	CEP72	-0.56	-4.84	-0.3	2.34e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg00031303	chr3:195681400	NA	0.5	5.76	0.35	2.67e-8	Pancreatic cancer;
SARC	cis	rs10979	1.000	rs9496671	chr6:143884742	G/A	cg25407410	chr6:143891975	LOC285740	-0.61	-8.01	-0.46	5.52e-14	Hypospadias;
SARC	cis	rs10421328	0.784	rs11667828	chr19:19768474	G/T	cg03709012	chr19:19516395	GATAD2A	-0.54	-6.11	-0.37	4.21e-9	Parental longevity (combined parental age at death);
SARC	cis	rs864537	0.676	rs3108155	chr1:167422057	C/G	cg09179987	chr1:167433047	CD247	0.38	6.04	0.37	6.03e-9	Celiac disease or Rheumatoid arthritis;Celiac disease;
SARC	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.49	5.95	0.36	9.64e-9	Gut microbiome composition (summer);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg11601120	chr7:108112767	PNPLA8	0.59	8.55	0.49	1.7e-15	Thyroid stimulating hormone;
SARC	cis	rs7587476	0.643	rs6714373	chr2:215719014	A/G	cg04004882	chr2:215674386	BARD1	0.58	6.47	0.39	5.75e-10	Neuroblastoma;
SARC	cis	rs7113874	0.659	rs12577287	chr11:8519917	A/T	cg09828998	chr11:8703972	RPL27A	0.5	5.31	0.33	2.53e-7	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg26338869	chr17:61819248	STRADA	0.8	10.61	0.57	1.06e-21	Prudent dietary pattern;
SARC	cis	rs66887589	0.616	rs1052633	chr4:120215314	A/G	cg09307838	chr4:120376055	NA	0.62	8.17	0.47	1.94e-14	Diastolic blood pressure;
SARC	cis	rs2486288	0.656	rs9921025	chr15:45546602	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.45	-5.55	-0.34	7.94e-8	Glomerular filtration rate;
SARC	cis	rs11098499	0.789	rs10212719	chr4:120254437	T/C	cg09307838	chr4:120376055	NA	0.79	10.36	0.56	6.3e-21	Corneal astigmatism;
SARC	cis	rs7829975	0.577	rs17684466	chr8:8545233	G/A	cg06636001	chr8:8085503	FLJ10661	-0.48	-5.73	-0.35	3.16e-8	Mood instability;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg11833660	chr12:109181397	SSH1	-0.48	-6.26	-0.38	1.8e-9	Electrocardiographic conduction measures;
SARC	cis	rs17376456	0.809	rs12152763	chr5:93405509	T/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.51	0.34	9.53e-8	Diabetic retinopathy;
SARC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.46	0.57	3.12e-21	Prudent dietary pattern;
SARC	cis	rs7843479	0.601	rs11135764	chr8:21814004	A/G	cg17168535	chr8:21777572	XPO7	0.86	13.38	0.66	1.16e-30	Mean corpuscular volume;
SARC	cis	rs9790314	0.503	rs6441374	chr3:161064540	A/T	cg03342759	chr3:160939853	NMD3	-0.59	-7.27	-0.43	5.39e-12	Morning vs. evening chronotype;
SARC	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg11644478	chr21:40555479	PSMG1	-0.56	-6.95	-0.41	3.64e-11	Menarche (age at onset);
SARC	cis	rs9875589	0.509	rs4047237	chr3:14012861	T/C	cg19554555	chr3:13937349	NA	-0.4	-5.14	-0.32	5.95e-7	Ovarian reserve;
SARC	cis	rs921968	0.565	rs3731876	chr2:219602819	G/A	cg02176678	chr2:219576539	TTLL4	-0.32	-4.78	-0.3	3.13e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg18252515	chr7:66147081	NA	-1.27	-11.31	-0.6	6.26e-24	Diabetic kidney disease;
SARC	cis	rs9611519	0.639	rs7290458	chr22:41476337	C/T	cg03806693	chr22:41940476	POLR3H	0.54	6.92	0.41	4.22e-11	Neuroticism;
SARC	cis	rs2033711	0.654	rs734380	chr19:58898963	A/C	cg11952622	chr19:58962976	ZNF324B	0.48	5.92	0.36	1.14e-8	Uric acid clearance;
SARC	cis	rs12134245	0.776	rs12124682	chr1:91995542	A/G	cg02896835	chr1:92012615	NA	-0.52	-7.07	-0.42	1.74e-11	Breast cancer;
SARC	cis	rs8114671	0.869	rs1544047	chr20:33670753	T/C	cg08999081	chr20:33150536	PIGU	-0.34	-4.87	-0.3	2.06e-6	Height;
SARC	cis	rs2180341	0.960	rs7766802	chr6:127709871	T/G	cg24812749	chr6:127587940	RNF146	1.02	13.13	0.65	7.8e-30	Breast cancer;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg11219407	chr1:154531432	UBE2Q1	0.52	6.56	0.39	3.37e-10	Breast cancer;
SARC	cis	rs739401	0.611	rs2239899	chr11:3024624	A/G	cg05729581	chr11:3078854	CARS	0.49	6.26	0.38	1.86e-9	Longevity;
SARC	cis	rs35213789	1.000	rs60739014	chr7:69280975	G/T	cg10619644	chr7:69149951	AUTS2	0.45	5.68	0.35	4.1e-8	Childhood ear infection;
SARC	cis	rs778371	0.752	rs283487	chr2:233644011	A/G	cg16596103	chr2:233749413	NGEF	-0.34	-5.08	-0.32	7.65e-7	Schizophrenia;
SARC	cis	rs72781680	0.898	rs55846516	chr2:24158003	T/C	cg06627628	chr2:24431161	ITSN2	-0.69	-6.48	-0.39	5.36e-10	Lymphocyte counts;
SARC	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg05861140	chr6:150128134	PCMT1	-0.4	-5.23	-0.32	3.76e-7	Lung cancer;
SARC	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg19223190	chr17:80058835	NA	-0.43	-6.02	-0.37	6.57e-9	Life satisfaction;
SARC	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg07061783	chr6:25882402	NA	0.43	5.09	0.32	7.26e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2652834	1.000	rs2652816	chr15:63403368	C/T	cg05507819	chr15:63340323	TPM1	0.55	5.44	0.34	1.38e-7	HDL cholesterol;
SARC	cis	rs3741404	0.609	rs651855	chr11:63870810	T/C	cg04317338	chr11:64019027	PLCB3	0.48	5.51	0.34	9.63e-8	Platelet count;
SARC	cis	rs9359856	0.623	rs1179903	chr6:90321736	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.54	-5.04	-0.31	9.17e-7	Bipolar disorder;
SARC	cis	rs922107	0.738	rs2169065	chr1:90031987	A/G	cg15422784	chr1:90023713	LRRC8B	-0.32	-4.75	-0.3	3.56e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
SARC	cis	rs36051895	0.593	rs12340379	chr9:5176352	C/T	cg02405213	chr9:5042618	JAK2	-0.45	-5.42	-0.33	1.48e-7	Pediatric autoimmune diseases;
SARC	cis	rs3845702	0.935	rs6433822	chr2:180840422	G/C	cg01881094	chr2:180872142	CWC22	-0.71	-6.62	-0.4	2.45e-10	Schizophrenia;
SARC	trans	rs2727020	0.573	rs7925419	chr11:49231859	C/T	cg00717180	chr2:96193071	NA	-0.4	-6.58	-0.4	3.1e-10	Coronary artery disease;
SARC	cis	rs73242632	1.000	rs73242625	chr4:57856339	A/G	cg20415529	chr4:57845134	POLR2B;C4orf14	1.03	6.26	0.38	1.87e-9	Congenital heart disease (maternal effect);
SARC	cis	rs17345786	0.906	rs12638137	chr3:101150964	C/T	cg12386194	chr3:101231763	SENP7	0.82	9.54	0.53	1.97e-18	Colonoscopy-negative controls vs population controls;
SARC	cis	rs787274	1.000	rs1539338	chr9:115586187	A/G	cg13803584	chr9:115635662	SNX30	-0.83	-5.03	-0.31	9.96e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	trans	rs66573146	0.831	rs56081162	chr4:6989718	C/T	cg07817883	chr1:32538562	TMEM39B	1.26	8.27	0.48	1.04e-14	Granulocyte percentage of myeloid white cells;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg19753255	chr1:45476701	HECTD3;UROD	0.48	6.47	0.39	5.69e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs8072100	0.713	rs4968318	chr17:45451894	G/A	cg08085267	chr17:45401833	C17orf57	-0.41	-4.81	-0.3	2.76e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs7772486	0.805	rs4896831	chr6:145959481	T/C	cg23711669	chr6:146136114	FBXO30	0.79	12.42	0.63	1.6e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	11.15	0.59	2.1e-23	Platelet count;
SARC	cis	rs6582630	0.502	rs4309219	chr12:38293584	A/G	cg26384229	chr12:38710491	ALG10B	0.86	12.35	0.63	2.69e-27	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg03433033	chr1:76189801	ACADM	-0.42	-5.4	-0.33	1.66e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2694528	0.764	rs1816862	chr5:60011636	G/A	cg11474532	chr5:59995715	DEPDC1B	0.69	5.0	0.31	1.13e-6	Parkinson's disease;
SARC	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg22834771	chr12:69754056	YEATS4	-0.44	-5.74	-0.35	2.95e-8	Blood protein levels;
SARC	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg20120463	chr17:44301886	NA	-0.39	-6.02	-0.37	6.7e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg11062466	chr8:58055876	NA	0.56	5.14	0.32	5.84e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7590368	0.600	rs3856466	chr2:10916770	C/T	cg25617230	chr2:10952979	PDIA6	0.66	5.35	0.33	2.11e-7	Educational attainment (years of education);
SARC	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg22535103	chr8:58192502	C8orf71	-0.59	-6.08	-0.37	4.78e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9790314	0.871	rs336561	chr3:161125305	C/T	cg04691961	chr3:161091175	C3orf57	-0.74	-10.45	-0.57	3.18e-21	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg22535103	chr8:58192502	C8orf71	-0.8	-7.83	-0.46	1.69e-13	Developmental language disorder (linguistic errors);
SARC	cis	rs933688	0.639	rs332530	chr5:90789810	G/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.02	12.65	0.64	2.95e-28	Smoking behavior;
SARC	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg09165964	chr15:75287851	SCAMP5	0.57	7.72	0.45	3.44e-13	Breast cancer;
SARC	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg02951883	chr7:2050386	MAD1L1	-0.5	-6.18	-0.38	2.86e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg24060327	chr5:131705240	SLC22A5	-0.72	-8.86	-0.5	2.1e-16	Blood metabolite levels;
SARC	cis	rs73206853	0.640	rs2098140	chr12:110726081	T/A	cg10860002	chr12:110842031	ANAPC7	0.65	5.3	0.33	2.69e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs9393692	0.875	rs9358917	chr6:26284417	T/C	cg05868516	chr6:26286170	HIST1H4H	0.55	7.3	0.43	4.58e-12	Educational attainment;
SARC	cis	rs3815700	0.841	rs10410895	chr19:33093655	T/G	cg24916020	chr19:33096688	ANKRD27	0.56	5.41	0.33	1.59e-7	Eosinophilic esophagitis;
SARC	cis	rs8067545	0.611	rs2526477	chr17:20131193	A/G	cg13482628	chr17:19912719	NA	-0.5	-6.46	-0.39	5.88e-10	Schizophrenia;
SARC	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg21724239	chr8:58056113	NA	0.6	6.27	0.38	1.72e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg11764359	chr7:65958608	NA	-0.69	-8.18	-0.47	1.88e-14	Aortic root size;
SARC	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg00933542	chr6:150070202	PCMT1	0.31	5.39	0.33	1.75e-7	Lung cancer;
SARC	cis	rs7551222	0.716	rs7541589	chr1:204542521	G/A	cg20240347	chr1:204465584	NA	-0.32	-5.68	-0.35	3.94e-8	Schizophrenia;
SARC	cis	rs7769051	0.711	rs7738071	chr6:133085116	G/A	cg22852734	chr6:133119734	C6orf192	1.05	9.28	0.52	1.21e-17	Type 2 diabetes nephropathy;
SARC	cis	rs8072100	0.576	rs7216112	chr17:45406345	C/T	cg08085267	chr17:45401833	C17orf57	0.59	6.77	0.41	1.03e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs477692	0.544	rs7904404	chr10:131447612	G/A	cg05714579	chr10:131428358	MGMT	-0.66	-8.69	-0.49	6.74e-16	Response to temozolomide;
SARC	cis	rs10489525	0.502	rs12026930	chr1:115597836	G/A	cg01522456	chr1:115632236	TSPAN2	0.43	5.08	0.32	7.78e-7	Autism;
SARC	cis	rs3768617	0.510	rs723014	chr1:183076287	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.19	0.56	2.1e-20	Fuchs's corneal dystrophy;
SARC	cis	rs7429990	0.965	rs4858880	chr3:48104449	C/A	cg11946769	chr3:48343235	NME6	-0.47	-5.42	-0.33	1.47e-7	Educational attainment (years of education);
SARC	cis	rs1003719	0.788	rs2835584	chr21:38460338	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.7	10.33	0.56	7.89e-21	Eye color traits;
SARC	cis	rs965469	0.779	rs1884563	chr20:3335540	T/C	cg25506879	chr20:3388711	C20orf194	-0.46	-4.99	-0.31	1.17e-6	IFN-related cytopenia;
SARC	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg11062466	chr8:58055876	NA	0.61	5.75	0.35	2.74e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg13617204	chr6:27832869	HIST1H2AL	0.43	4.88	0.3	1.96e-6	Cardiac Troponin-T levels;
SARC	cis	rs1497406	0.744	rs6677710	chr1:16507618	A/G	cg06365898	chr1:16533907	ARHGEF19	0.43	5.77	0.35	2.5e-8	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7296418	0.699	rs11057219	chr12:123750073	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-5.09	-0.32	7.32e-7	Platelet count;
SARC	cis	rs6815814	0.851	rs4129009	chr4:38774889	T/C	cg09316306	chr4:38807337	TLR1	0.49	4.77	0.3	3.22e-6	Breast cancer;
SARC	cis	rs7274811	0.681	rs291670	chr20:31945861	G/A	cg21523528	chr20:32077966	CBFA2T2	-0.42	-4.92	-0.31	1.61e-6	Height;
SARC	cis	rs3762637	1.000	rs9878699	chr3:122194231	T/A	cg24169773	chr3:122142474	KPNA1	-0.57	-5.85	-0.36	1.67e-8	LDL cholesterol levels;
SARC	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7727544	0.507	rs9791170	chr5:131569627	A/G	cg11843238	chr5:131593191	PDLIM4	0.36	4.95	0.31	1.45e-6	Blood metabolite levels;
SARC	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg09033563	chr22:24373618	LOC391322	0.49	5.41	0.33	1.59e-7	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs4319547	0.915	rs1473553	chr12:122985057	G/T	cg23029597	chr12:123009494	RSRC2	-0.41	-5.13	-0.32	6.22e-7	Body mass index;
SARC	cis	rs16866061	0.515	rs1027340	chr2:225370554	C/A	cg12698349	chr2:225449008	CUL3	0.83	14.12	0.68	4.02e-33	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	cis	rs7208859	0.673	rs17826219	chr17:29161845	G/A	cg13385521	chr17:29058706	SUZ12P	0.86	7.3	0.43	4.51e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9916302	0.768	rs62077464	chr17:37656056	C/G	cg00129232	chr17:37814104	STARD3	-0.64	-7.98	-0.46	6.65e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg13939156	chr17:80058883	NA	-0.41	-6.37	-0.39	1.01e-9	Life satisfaction;
SARC	cis	rs9815354	1.000	rs1717027	chr3:41987920	T/C	cg03022575	chr3:42003672	ULK4	-0.58	-5.74	-0.35	2.88e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg24531977	chr5:56204891	C5orf35	-0.51	-5.29	-0.33	2.86e-7	Initial pursuit acceleration;
SARC	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg24399712	chr22:39784796	NA	0.4	5.36	0.33	1.96e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs7481584	0.624	rs375579	chr11:3065300	G/C	cg08508325	chr11:3079039	CARS	0.21	4.72	0.3	4.06e-6	Calcium levels;
SARC	trans	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg17830980	chr10:43048298	ZNF37B	-0.48	-6.33	-0.38	1.28e-9	Extrinsic epigenetic age acceleration;
SARC	cis	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg20965017	chr5:231967	SDHA	-0.58	-5.63	-0.35	5.16e-8	Breast cancer;
SARC	cis	rs654950	0.901	rs594656	chr1:41999873	C/T	cg06885757	chr1:42089581	HIVEP3	-0.4	-5.38	-0.33	1.81e-7	Airway imaging phenotypes;
SARC	cis	rs7586879	0.551	rs7565460	chr2:25130073	C/T	cg04586622	chr2:25135609	ADCY3	0.31	5.29	0.33	2.8e-7	Body mass index;
SARC	cis	rs7582180	0.676	rs6542940	chr2:100982144	A/T	cg14675211	chr2:100938903	LONRF2	0.5	7.36	0.43	3.21e-12	Intelligence (multi-trait analysis);
SARC	cis	rs1215050	0.765	rs783947	chr4:99012943	T/C	cg05340658	chr4:99064831	C4orf37	-0.49	-6.68	-0.4	1.74e-10	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs7246865	0.510	rs7253742	chr19:17171689	C/T	cg16202187	chr19:17186497	HAUS8;MYO9B	-0.4	-4.81	-0.3	2.69e-6	Reticulocyte fraction of red cells;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg15893678	chr10:99496835	ZFYVE27	0.51	6.25	0.38	1.99e-9	Breast cancer;
SARC	cis	rs8031584	0.958	rs61997079	chr15:31238271	G/C	cg14829155	chr15:31115871	NA	-0.42	-5.28	-0.33	2.91e-7	Huntington's disease progression;
SARC	cis	rs708547	0.830	rs1713983	chr4:57883084	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.46	-5.16	-0.32	5.32e-7	Response to bleomycin (chromatid breaks);
SARC	cis	rs9467711	0.517	rs16901784	chr6:26555433	C/A	cg12826209	chr6:26865740	GUSBL1	0.74	5.24	0.32	3.57e-7	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9987353	0.544	rs2929470	chr8:9062490	A/G	cg06636001	chr8:8085503	FLJ10661	-0.6	-7.87	-0.46	1.36e-13	Recombination measurement;
SARC	cis	rs7769051	0.522	rs6928933	chr6:133116073	G/A	cg07930552	chr6:133119739	C6orf192	1.01	5.99	0.37	7.7e-9	Type 2 diabetes nephropathy;
SARC	cis	rs7666738	0.830	rs6834014	chr4:98951431	G/A	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs16866061	0.888	rs6748341	chr2:225377574	C/G	cg12698349	chr2:225449008	CUL3	0.68	9.45	0.53	3.65e-18	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	cis	rs72634258	0.945	rs12748993	chr1:8129507	A/G	cg00042356	chr1:8021962	PARK7	0.87	8.06	0.47	3.9e-14	Inflammatory bowel disease;
SARC	cis	rs35110281	0.591	rs162390	chr21:44936826	C/T	cg21573476	chr21:45109991	RRP1B	-0.5	-7.48	-0.44	1.52e-12	Mean corpuscular volume;
SARC	cis	rs8180040	0.627	rs9821119	chr3:47198437	C/G	cg27129171	chr3:47204927	SETD2	0.69	9.4	0.52	5.41e-18	Colorectal cancer;
SARC	cis	rs7474896	0.522	rs117157955	chr10:37984164	G/T	cg25427524	chr10:38739819	LOC399744	-0.43	-4.99	-0.31	1.21e-6	Obesity (extreme);
SARC	trans	rs11722228	0.521	rs56403947	chr4:10112529	T/G	cg26043149	chr18:55253948	FECH	0.72	8.18	0.47	1.84e-14	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg24829409	chr8:58192753	C8orf71	-0.62	-6.4	-0.39	8.61e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs72781680	0.898	rs72782136	chr2:24047344	A/G	cg06627628	chr2:24431161	ITSN2	-0.67	-6.37	-0.38	1.02e-9	Lymphocyte counts;
SARC	cis	rs12579753	0.871	rs4255611	chr12:82215969	C/A	cg07988820	chr12:82153109	PPFIA2	-0.49	-5.48	-0.34	1.12e-7	Resting heart rate;
SARC	cis	rs910316	1.000	rs3742778	chr14:75538217	A/C	cg23033748	chr14:75592666	NEK9	-0.39	-5.55	-0.34	7.9e-8	Height;
SARC	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg22857025	chr5:266934	NA	-1.03	-11.6	-0.61	7.47e-25	Breast cancer;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg08260549	chr8:21777063	XPO7	0.54	7.27	0.43	5.55e-12	Tetralogy of Fallot;
SARC	cis	rs72945132	0.882	rs67244582	chr11:70122009	G/A	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.78	-0.35	2.39e-8	Coronary artery disease;
SARC	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg18876405	chr7:65276391	NA	0.74	9.28	0.52	1.2e-17	Aortic root size;
SARC	cis	rs9810089	0.843	rs696081	chr3:136047189	C/T	cg15507776	chr3:136538369	TMEM22	-0.43	-4.79	-0.3	3.03e-6	Gestational age at birth (child effect);
SARC	cis	rs7474896	0.583	rs4934898	chr10:37990395	G/C	cg25427524	chr10:38739819	LOC399744	-0.42	-4.85	-0.3	2.26e-6	Obesity (extreme);
SARC	cis	rs7954584	0.505	rs11043278	chr12:122412145	C/T	cg13699009	chr12:122356056	WDR66	0.6	9.34	0.52	8.25e-18	Mean corpuscular volume;
SARC	trans	rs6601450	0.547	rs10105843	chr8:10197863	A/G	cg21775007	chr8:11205619	TDH	0.51	6.35	0.38	1.13e-9	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg14893161	chr1:205819251	PM20D1	0.94	16.26	0.73	3.09e-40	Menarche (age at onset);
SARC	cis	rs17253792	0.822	rs75555677	chr14:56096429	G/A	cg01858014	chr14:56050164	KTN1	-0.68	-5.37	-0.33	1.86e-7	Putamen volume;
SARC	cis	rs9291683	0.530	rs11723970	chr4:9980462	T/C	cg11266682	chr4:10021025	SLC2A9	0.39	7.04	0.42	2.15e-11	Bone mineral density;
SARC	cis	rs523522	0.962	rs2235218	chr12:120888619	A/C	cg12219531	chr12:120966889	COQ5	0.81	10.53	0.57	1.79e-21	High light scatter reticulocyte count;
SARC	cis	rs12754538	0.808	rs2024774	chr1:8570456	C/G	cg13785123	chr1:8931135	ENO1	-0.47	-5.38	-0.33	1.82e-7	Subjective well-being;
SARC	cis	rs6933660	0.744	rs35143743	chr6:151768532	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.48	5.95	0.36	9.62e-9	Menarche (age at onset);
SARC	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.48	-6.04	-0.37	6.07e-9	Lymphocyte counts;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg18237510	chr1:153919190	DENND4B	0.49	6.39	0.39	8.82e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg21926612	chr6:163149169	PACRG;PARK2	0.75	6.56	0.39	3.51e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg06634786	chr22:41940651	POLR3H	-0.58	-6.76	-0.4	1.12e-10	Vitiligo;
SARC	cis	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg25427524	chr10:38739819	LOC399744	-0.54	-8.57	-0.49	1.43e-15	Extrinsic epigenetic age acceleration;
SARC	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg20607798	chr8:58055168	NA	0.57	5.33	0.33	2.27e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg24829409	chr8:58192753	C8orf71	-0.68	-6.28	-0.38	1.63e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs12893668	0.637	rs4525427	chr14:104072793	C/A	cg26031613	chr14:104095156	KLC1	-0.56	-6.04	-0.37	6.03e-9	Reticulocyte count;
SARC	cis	rs4901847	0.577	rs11158199	chr14:58585354	T/C	cg15908186	chr14:58618357	C14orf37	0.6	7.64	0.45	5.49e-13	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg08045932	chr20:61659980	NA	0.51	6.99	0.42	2.85e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs11945232	1.000	rs28630962	chr4:88336386	C/T	cg23841344	chr4:88312519	HSD17B11	-0.58	-7.44	-0.44	1.95e-12	Intelligence (multi-trait analysis);
SARC	cis	rs7264396	0.836	rs1886695	chr20:34180535	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.54	5.82	0.36	1.89e-8	Total cholesterol levels;
SARC	cis	rs11252926	0.673	rs553326	chr10:749238	G/T	cg08603382	chr10:743973	NA	-0.42	-5.52	-0.34	8.93e-8	Psychosis in Alzheimer's disease;
SARC	cis	rs10754283	0.901	rs6663526	chr1:90110862	T/C	cg21401794	chr1:90099060	LRRC8C	0.59	8.09	0.47	3.24e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs7617480	0.648	rs4974088	chr3:48898749	T/C	cg07636037	chr3:49044803	WDR6	0.88	8.96	0.51	1.1e-16	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs4819052	0.788	rs2236449	chr21:46702506	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.61	6.93	0.41	3.98e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6582630	0.502	rs2204008	chr12:38439203	C/T	cg26384229	chr12:38710491	ALG10B	0.83	11.13	0.59	2.43e-23	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs11690935	0.959	rs973889	chr2:172579954	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.99	-15.94	-0.72	3.4e-39	Schizophrenia;
SARC	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg08219700	chr8:58056026	NA	0.62	6.52	0.39	4.28e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6580649	0.941	rs4760614	chr12:48427884	A/G	cg05342945	chr12:48394962	COL2A1	0.57	6.13	0.37	3.81e-9	Lung cancer;
SARC	cis	rs9911578	1.000	rs9897326	chr17:56902297	A/G	cg12560992	chr17:57184187	TRIM37	0.86	12.1	0.62	1.84e-26	Intelligence (multi-trait analysis);
SARC	cis	rs3781913	0.874	rs12363065	chr11:72370899	C/T	cg03713592	chr11:72463424	ARAP1	-0.45	-5.3	-0.33	2.72e-7	Rheumatoid arthritis;
SARC	cis	rs4141404	0.923	rs2413046	chr22:31665909	C/A	cg00478049	chr22:31556069	RNF185	0.44	4.84	0.3	2.37e-6	Paclitaxel-induced neuropathy;
SARC	trans	rs637571	0.522	rs566590	chr11:65754062	C/T	cg17712092	chr4:129076599	LARP1B	0.68	9.19	0.52	2.21e-17	Eosinophil percentage of white cells;
SARC	cis	rs244731	0.920	rs244707	chr5:176555636	A/T	cg16006841	chr5:176797999	RGS14	0.57	6.66	0.4	1.97e-10	Urate levels in lean individuals;
SARC	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg10523679	chr1:76189770	ACADM	0.51	6.75	0.4	1.16e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs13144136	0.687	rs11723949	chr4:10658093	G/T	cg10242279	chr4:10666415	CLNK	-0.44	-7.13	-0.42	1.22e-11	Resistance to antihypertensive treatment in hypertension;
SARC	cis	rs10489202	0.632	rs275137	chr1:168051266	A/C	cg17859187	chr1:168147929	TIPRL	-0.43	-5.18	-0.32	4.88e-7	Schizophrenia;
SARC	cis	rs7666738	0.830	rs13121766	chr4:98935766	A/C	cg05340658	chr4:99064831	C4orf37	0.65	8.73	0.5	5.13e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs921968	0.541	rs578450	chr2:219401237	C/T	cg02176678	chr2:219576539	TTLL4	0.47	7.16	0.42	1.06e-11	Mean corpuscular hemoglobin concentration;
SARC	cis	rs17376456	0.825	rs7715562	chr5:93222034	C/T	cg25358565	chr5:93447407	FAM172A	-1.24	-13.33	-0.66	1.63e-30	Diabetic retinopathy;
SARC	cis	rs7633770	0.622	rs34063921	chr3:46689922	A/G	cg11219411	chr3:46661640	NA	-0.4	-6.05	-0.37	5.67e-9	Coronary artery disease;
SARC	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg19223190	chr17:80058835	NA	0.45	6.28	0.38	1.63e-9	Life satisfaction;
SARC	cis	rs7296418	0.663	rs28450974	chr12:123861420	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-5.41	-0.33	1.59e-7	Platelet count;
SARC	cis	rs9916302	0.851	rs12947620	chr17:37605364	T/C	cg00129232	chr17:37814104	STARD3	-0.63	-7.8	-0.46	2.06e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs4883201	0.656	rs10743568	chr12:9110792	T/C	cg24352934	chr17:1053717	ABR	0.56	6.26	0.38	1.79e-9	Cholesterol, total;Total cholesterol levels;
SARC	cis	rs804280	1.000	rs804280	chr8:11612698	G/T	cg12395012	chr8:11607386	GATA4	-0.32	-5.27	-0.33	3.11e-7	Myopia (pathological);
SARC	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg11062466	chr8:58055876	NA	0.53	5.53	0.34	8.39e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4901847	0.933	rs11623561	chr14:58556776	G/T	cg15908186	chr14:58618357	C14orf37	-0.43	-5.06	-0.31	8.66e-7	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs66887589	0.592	rs28580295	chr4:120278873	C/T	cg09307838	chr4:120376055	NA	0.61	8.44	0.48	3.49e-15	Diastolic blood pressure;
SARC	cis	rs7216064	1.000	rs62084249	chr17:65874998	A/G	cg12091567	chr17:66097778	LOC651250	-0.64	-6.45	-0.39	6.56e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs921968	0.540	rs7582329	chr2:219620909	C/T	cg02176678	chr2:219576539	TTLL4	-0.32	-4.88	-0.3	1.93e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs365132	0.818	rs251843	chr5:176476106	A/G	cg16309518	chr5:176445507	NA	-0.43	-5.55	-0.34	7.89e-8	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs2204008	0.774	rs10400552	chr12:38393577	C/G	cg13010199	chr12:38710504	ALG10B	0.76	10.23	0.56	1.61e-20	Bladder cancer;
SARC	cis	rs883565	0.542	rs6802490	chr3:39033907	T/A	cg26331595	chr3:39149181	GORASP1;TTC21A	0.41	4.78	0.3	3.17e-6	Handedness;
SARC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg10928925	chr10:81205554	ZCCHC24	0.51	6.46	0.39	6.21e-10	Myopia (pathological);
SARC	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg18357526	chr6:26021779	HIST1H4A	0.72	8.27	0.48	1.05e-14	Intelligence (multi-trait analysis);
SARC	cis	rs7772486	0.686	rs857877	chr6:145976230	A/C	cg23711669	chr6:146136114	FBXO30	-0.86	-14.16	-0.68	3.03e-33	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg22496380	chr5:211416	CCDC127	-0.88	-9.21	-0.52	1.91e-17	Breast cancer;
SARC	cis	rs1949733	1.000	rs868105	chr4:8501030	G/T	cg13073564	chr4:8508604	NA	0.48	7.9	0.46	1.1e-13	Response to antineoplastic agents;
SARC	cis	rs9296092	0.517	rs62405949	chr6:33522800	G/A	cg13560919	chr6:33536144	NA	-0.49	-5.95	-0.36	9.74e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg09699651	chr6:150184138	LRP11	0.41	5.11	0.32	6.6e-7	Lung cancer;
SARC	cis	rs73198271	0.740	rs1039910	chr8:8648066	T/C	cg06636001	chr8:8085503	FLJ10661	-0.48	-5.25	-0.33	3.41e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg04234412	chr22:24373322	LOC391322	-0.65	-8.7	-0.5	6.17e-16	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg18876405	chr7:65276391	NA	-0.43	-4.76	-0.3	3.43e-6	Aortic root size;
SARC	cis	rs7953249	0.514	rs1169312	chr12:121441461	G/T	cg25281562	chr12:121454272	C12orf43	0.51	6.16	0.37	3.11e-9	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs137603	0.644	rs137619	chr22:39706360	A/C	cg01093212	chr22:39715156	SNORD43;RPL3	-0.52	-5.97	-0.36	8.56e-9	Primary biliary cholangitis;
SARC	cis	rs34779708	0.931	rs4934731	chr10:35431636	T/C	cg03585969	chr10:35415529	CREM	0.38	4.82	0.3	2.62e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs1538970	0.669	rs3219476	chr1:45802670	A/C	cg16078521	chr1:45672383	ZSWIM5	-0.45	-4.94	-0.31	1.47e-6	Platelet count;
SARC	trans	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg11693508	chr17:37793320	STARD3	0.72	6.66	0.4	1.99e-10	Bipolar disorder;
SARC	cis	rs10911232	0.507	rs12037623	chr1:183000148	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.67	0.57	6.63e-22	Hypertriglyceridemia;
SARC	cis	rs1707322	0.717	rs12023439	chr1:46104636	C/T	cg03146154	chr1:46216737	IPP	0.51	6.1	0.37	4.38e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg03033257	chr22:50311977	ALG12;CRELD2	0.6	5.65	0.35	4.59e-8	Schizophrenia;
SARC	cis	rs748404	0.631	rs7163288	chr15:43671355	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.44	5.3	0.33	2.67e-7	Lung cancer;
SARC	cis	rs9400467	0.506	rs12192837	chr6:111784240	C/G	cg15721981	chr6:111408429	SLC16A10	0.65	5.64	0.35	4.87e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg06108461	chr20:60628389	TAF4	-0.58	-6.13	-0.37	3.63e-9	Obesity-related traits;
SARC	cis	rs6772849	0.775	rs67105978	chr3:128415180	C/A	cg01163369	chr3:128370232	RPN1	-0.35	-4.88	-0.3	1.96e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg16606324	chr3:10149918	C3orf24	0.48	5.04	0.31	9.53e-7	Alzheimer's disease;
SARC	cis	rs12142240	0.698	rs17361819	chr1:46828109	A/G	cg10495392	chr1:46806563	NSUN4	0.64	6.83	0.41	7.39e-11	Menopause (age at onset);
SARC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.34	-5.24	-0.32	3.67e-7	Longevity;Endometriosis;
SARC	cis	rs7481584	0.624	rs413368	chr11:3047646	C/G	cg08508325	chr11:3079039	CARS	0.23	5.13	0.32	6.14e-7	Calcium levels;
SARC	cis	rs80130819	0.636	rs2732470	chr12:48664757	T/G	cg05342945	chr12:48394962	COL2A1	-0.54	-5.75	-0.35	2.8e-8	Prostate cancer;
SARC	cis	rs13191362	1.000	rs67646369	chr6:163003233	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.49	0.34	1.04e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs412050	0.793	rs17821866	chr22:22342464	A/C	cg17089214	chr22:22089827	YPEL1	0.6	5.62	0.35	5.42e-8	Attention deficit hyperactivity disorder;
SARC	cis	rs6815814	0.851	rs4274855	chr4:38777471	C/T	cg06935464	chr4:38784597	TLR10	0.63	5.98	0.36	8.46e-9	Breast cancer;
SARC	cis	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg08045932	chr20:61659980	NA	0.52	7.08	0.42	1.66e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg02725872	chr8:58115012	NA	-0.37	-6.54	-0.39	3.81e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2953145	0.568	rs1133354	chr2:241522450	A/G	cg07929629	chr2:241523174	NA	0.36	4.73	0.3	3.9e-6	Bipolar disorder;
SARC	cis	rs637571	0.512	rs660118	chr11:65735174	G/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.57	8.77	0.5	3.93e-16	Eosinophil percentage of white cells;
SARC	cis	rs1023500	0.596	rs5758562	chr22:42448238	C/G	cg04733989	chr22:42467013	NAGA	0.73	9.89	0.54	1.73e-19	Schizophrenia;
SARC	cis	rs7615952	0.800	rs2062773	chr3:125639648	T/C	cg05084668	chr3:125655381	ALG1L	-0.62	-6.23	-0.38	2.18e-9	Blood pressure (smoking interaction);
SARC	cis	rs881375	0.967	rs10739580	chr9:123695282	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	5.44	0.34	1.33e-7	Rheumatoid arthritis;
SARC	cis	rs7712401	0.601	rs30035	chr5:122278545	A/G	cg19412675	chr5:122181750	SNX24	0.39	4.95	0.31	1.45e-6	Mean platelet volume;
SARC	cis	rs11098499	0.954	rs11935596	chr4:120412457	G/C	cg24375607	chr4:120327624	NA	0.41	4.86	0.3	2.12e-6	Corneal astigmatism;
SARC	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg08677398	chr8:58056175	NA	0.43	5.05	0.31	8.92e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg21226059	chr5:178986404	RUFY1	-0.34	-4.81	-0.3	2.65e-6	Lung cancer;
SARC	cis	rs7712401	0.567	rs154516	chr5:122191139	G/A	cg19412675	chr5:122181750	SNX24	0.38	4.9	0.31	1.81e-6	Mean platelet volume;
SARC	cis	rs10504073	0.669	rs341799	chr8:50036574	A/G	cg00325661	chr8:49890786	NA	0.52	6.97	0.42	3.18e-11	Blood metabolite ratios;
SARC	cis	rs9905704	0.836	rs170024	chr17:56831887	T/C	cg12560992	chr17:57184187	TRIM37	0.45	5.24	0.32	3.56e-7	Testicular germ cell tumor;
SARC	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg12923728	chr3:195709715	SDHAP1	-0.69	-8.63	-0.49	9.95e-16	Pancreatic cancer;
SARC	cis	rs9325144	0.647	rs7316392	chr12:39064381	T/G	cg13010199	chr12:38710504	ALG10B	-0.55	-6.97	-0.42	3.25e-11	Morning vs. evening chronotype;
SARC	cis	rs10876993	0.890	rs799575	chr12:58069107	A/G	cg18357645	chr12:58087776	OS9	0.46	6.03	0.37	6.54e-9	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs7945705	0.776	rs2316865	chr11:8815470	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.38	5.04	0.31	9.22e-7	Hemoglobin concentration;
SARC	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg16405210	chr4:1374714	KIAA1530	-0.53	-6.45	-0.39	6.34e-10	Longevity;
SARC	cis	rs1559088	0.847	rs8110181	chr19:33605939	G/A	cg27124370	chr19:33622961	WDR88	0.43	5.63	0.35	5.15e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs11574514	1.000	rs16957524	chr16:67798005	A/G	cg01866162	chr16:67596514	CTCF	0.85	6.06	0.37	5.3e-9	Crohn's disease;
SARC	cis	rs2952156	0.684	rs931992	chr17:37821435	G/T	cg20243544	chr17:37824526	PNMT	0.63	8.42	0.48	3.81e-15	Asthma;
SARC	trans	rs1268083	0.546	rs9398785	chr6:126057748	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.54	-6.35	-0.38	1.1e-9	Migraine;
SARC	cis	rs11190604	0.697	rs10748795	chr10:102194818	A/T	cg07080220	chr10:102295463	HIF1AN	-0.69	-8.38	-0.48	4.91e-15	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs7044106	0.791	rs10985008	chr9:123492960	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	6.81	0.41	8.04e-11	Hip circumference adjusted for BMI;
SARC	trans	rs9354308	0.901	rs2814121	chr6:66566915	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.58	6.82	0.41	7.77e-11	Metabolite levels;
SARC	cis	rs7084921	0.533	rs12765091	chr10:101855231	G/C	cg11888571	chr10:102027403	CWF19L1	-0.4	-4.79	-0.3	2.9e-6	Bone mineral density;
SARC	cis	rs2204008	0.701	rs3898237	chr12:38219714	A/G	cg13010199	chr12:38710504	ALG10B	0.77	10.51	0.57	2.11e-21	Bladder cancer;
SARC	cis	rs798554	0.610	rs2248390	chr7:2855594	T/C	cg13628971	chr7:2884303	GNA12	0.48	5.95	0.36	9.6e-9	Height;
SARC	cis	rs1387259	0.929	rs11168460	chr12:48597365	A/G	cg24011408	chr12:48396354	COL2A1	0.46	5.37	0.33	1.89e-7	Obstructive sleep apnea trait (apnea hypopnea index);
SARC	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg13206674	chr6:150067644	NUP43	0.49	6.18	0.38	2.77e-9	Lung cancer;
SARC	cis	rs910187	0.605	rs6066224	chr20:45806632	T/A	cg27589058	chr20:45804311	EYA2	-0.31	-5.0	-0.31	1.13e-6	Migraine;
SARC	cis	rs644799	0.710	rs10831429	chr11:95508524	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.94	16.11	0.73	9.39e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs10876993	0.890	rs810204	chr12:58075733	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.46	-5.88	-0.36	1.39e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs7223966	1.000	rs11658329	chr17:61763031	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	5.49	0.34	1.07e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg25427524	chr10:38739819	LOC399744	-0.56	-8.73	-0.5	5.08e-16	Extrinsic epigenetic age acceleration;
SARC	cis	rs9818941	0.744	rs13098886	chr3:157613783	C/T	cg02399570	chr3:156877196	CCNL1	0.48	5.46	0.34	1.19e-7	Height;
SARC	cis	rs9309473	0.660	rs11686541	chr2:73704475	C/G	cg20560298	chr2:73613845	ALMS1	-0.55	-5.35	-0.33	2.13e-7	Metabolite levels;
SARC	cis	rs3126085	0.935	rs12729662	chr1:152185750	G/A	cg03465714	chr1:152285911	FLG	0.48	5.62	0.35	5.53e-8	Atopic dermatitis;
SARC	cis	rs208515	0.525	rs10498841	chr6:66663706	C/T	cg07460842	chr6:66804631	NA	0.98	11.21	0.59	1.3e-23	Exhaled nitric oxide levels;
SARC	cis	rs7953249	0.514	rs1169312	chr12:121441461	G/T	cg15155738	chr12:121454335	C12orf43	0.49	5.99	0.37	7.88e-9	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs9329289	0.550	rs11251294	chr10:2562328	C/T	cg18171855	chr10:2543474	NA	-0.37	-5.13	-0.32	6.2e-7	Age-related hearing impairment;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg22943243	chr1:26232311	STMN1	-0.54	-6.74	-0.4	1.25e-10	Height;
SARC	cis	rs34779708	0.966	rs4934538	chr10:35472150	T/C	cg03585969	chr10:35415529	CREM	0.42	5.13	0.32	6.12e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs1318878	0.565	rs73057222	chr12:15480619	G/A	cg08258403	chr12:15378311	NA	0.49	6.8	0.41	8.67e-11	Intelligence (multi-trait analysis);
SARC	cis	rs11608355	0.545	rs4766474	chr12:109908084	G/C	cg05360138	chr12:110035743	NA	0.93	9.71	0.54	6.21e-19	Neuroticism;
SARC	cis	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg13072238	chr3:49761600	GMPPB	-0.42	-5.43	-0.34	1.4e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg00933542	chr6:150070202	PCMT1	0.31	5.43	0.33	1.45e-7	Lung cancer;
SARC	cis	rs2730245	0.527	rs2730237	chr7:158706166	A/G	cg24397884	chr7:158709396	WDR60	1.12	9.74	0.54	5.07e-19	Height;
SARC	cis	rs4481887	1.000	rs6697863	chr1:248495588	G/A	cg00666640	chr1:248458726	OR2T12	0.4	6.58	0.4	3.1e-10	Common traits (Other);
SARC	cis	rs7766436	0.583	rs988973	chr6:22558822	A/G	cg13666174	chr6:22585274	NA	-0.6	-6.42	-0.39	7.44e-10	Coronary artery disease;
SARC	cis	rs2070677	0.877	rs8192777	chr10:135350871	G/T	cg20169779	chr10:135381914	SYCE1	0.45	5.86	0.36	1.59e-8	Gout;
SARC	cis	rs5753618	0.583	rs7293171	chr22:31802324	T/C	cg07713946	chr22:31675144	LIMK2	0.35	4.85	0.3	2.27e-6	Colorectal cancer;
SARC	cis	rs204247	0.565	rs411094	chr6:13718264	C/A	cg07534331	chr6:13574296	SIRT5	0.62	7.01	0.42	2.6e-11	Breast cancer;
SARC	cis	rs1707322	1.000	rs11211222	chr1:46367757	T/C	cg06784218	chr1:46089804	CCDC17	0.34	6.03	0.37	6.51e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9457247	0.967	rs376097	chr6:167410878	A/G	cg07741184	chr6:167504864	NA	0.3	5.6	0.34	5.91e-8	Crohn's disease;
SARC	cis	rs34779708	0.931	rs35886556	chr10:35334985	C/T	cg03585969	chr10:35415529	CREM	0.4	4.97	0.31	1.3e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs9309473	0.948	rs2421550	chr2:73658686	A/G	cg20560298	chr2:73613845	ALMS1	-0.51	-6.08	-0.37	4.87e-9	Metabolite levels;
SARC	cis	rs9790314	0.540	rs35462273	chr3:160991877	C/T	cg04691961	chr3:161091175	C3orf57	-0.5	-6.17	-0.37	3.03e-9	Morning vs. evening chronotype;
SARC	cis	rs11249608	0.636	rs62393070	chr5:178447943	A/G	cg21905437	chr5:178450457	ZNF879	0.56	7.39	0.44	2.54e-12	Pubertal anthropometrics;
SARC	cis	rs4642101	0.561	rs7638333	chr3:12806142	T/C	cg05775895	chr3:12838266	CAND2	0.54	7.56	0.44	9.36e-13	QRS complex (12-leadsum);
SARC	cis	rs12824058	0.831	rs11060825	chr12:130807905	A/G	cg24838063	chr12:130822603	PIWIL1	0.62	8.84	0.5	2.36e-16	Menopause (age at onset);
SARC	cis	rs9788682	1.000	rs12441426	chr15:78812329	T/C	cg24631222	chr15:78858424	CHRNA5	0.77	10.15	0.55	2.76e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg02487422	chr3:49467188	NICN1	-0.48	-6.55	-0.39	3.69e-10	Resting heart rate;
SARC	cis	rs11718455	0.960	rs34019365	chr3:44004735	G/A	cg21419209	chr3:44054225	NA	-0.41	-5.02	-0.31	1.02e-6	Coronary artery disease;
SARC	cis	rs2075371	0.796	rs12672752	chr7:134007382	C/T	cg00033643	chr7:134001901	SLC35B4	0.47	5.68	0.35	4.08e-8	Mean platelet volume;
SARC	cis	rs73206853	0.841	rs73206845	chr12:110660556	T/C	cg10860002	chr12:110842031	ANAPC7	0.65	5.13	0.32	5.97e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	trans	rs61931739	0.963	rs59195137	chr12:34091838	G/A	cg26384229	chr12:38710491	ALG10B	-0.54	-6.68	-0.4	1.71e-10	Morning vs. evening chronotype;
SARC	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg22974920	chr21:40686053	BRWD1	-0.43	-4.74	-0.3	3.7e-6	Cognitive function;
SARC	cis	rs734999	0.588	rs745367	chr1:2524457	T/C	cg00980319	chr1:2560884	MMEL1	-0.35	-4.91	-0.31	1.69e-6	Ulcerative colitis;
SARC	cis	rs9790314	0.846	rs9809522	chr3:160983768	G/C	cg04691961	chr3:161091175	C3orf57	-0.64	-8.7	-0.5	5.91e-16	Morning vs. evening chronotype;
SARC	cis	rs7644516	0.607	rs2912565	chr3:25919088	A/G	cg11227576	chr3:25825146	NGLY1	-0.55	-4.78	-0.3	3.12e-6	DNA methylation (variation);
SARC	cis	rs9354308	0.901	rs2814096	chr6:66566131	G/A	cg07460842	chr6:66804631	NA	0.48	5.45	0.34	1.3e-7	Metabolite levels;
SARC	cis	rs11583043	1.000	rs12567858	chr1:101517688	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.48	5.24	0.32	3.63e-7	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs2985684	0.948	rs12886130	chr14:50082753	T/C	cg23336454	chr14:50234671	KLHDC2	-0.43	-4.72	-0.3	4.02e-6	Carotid intima media thickness;
SARC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg26354017	chr1:205819088	PM20D1	0.55	7.21	0.43	7.78e-12	Menarche (age at onset);
SARC	cis	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg15145296	chr3:125709740	NA	-0.49	-4.93	-0.31	1.57e-6	Blood pressure (smoking interaction);
SARC	cis	rs9325144	0.560	rs2013804	chr12:38631079	C/T	cg26384229	chr12:38710491	ALG10B	-0.66	-8.75	-0.5	4.25e-16	Morning vs. evening chronotype;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg07176514	chr1:185126191	C1orf25;C1orf26	0.49	6.31	0.38	1.42e-9	Breast cancer;
SARC	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-5.73	-0.35	3.13e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs6912958	0.781	rs9450723	chr6:88226641	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.33	5.77	0.35	2.52e-8	Monocyte percentage of white cells;
SARC	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg21747090	chr2:27597821	SNX17	-0.55	-7.65	-0.45	5.38e-13	Total body bone mineral density;
SARC	cis	rs12545109	0.800	rs1467126	chr8:57418452	C/T	cg09654669	chr8:57350985	NA	-0.39	-4.98	-0.31	1.26e-6	Obesity-related traits;
SARC	cis	rs644799	0.687	rs3748252	chr11:95519195	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.79	-12.01	-0.62	3.63e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs10504229	0.680	rs16921675	chr8:58052082	A/G	cg08219700	chr8:58056026	NA	0.59	5.93	0.36	1.06e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1865760	1.000	rs1865760	chr6:25916979	C/T	cg17691542	chr6:26056736	HIST1H1C	0.56	6.83	0.41	7.18e-11	Height;
SARC	cis	rs11227306	0.934	rs7102454	chr11:65594820	C/T	cg26695010	chr11:65641043	EFEMP2	0.49	6.24	0.38	2e-9	DNA methylation (variation);
SARC	trans	rs9329221	0.736	rs12548025	chr8:10260921	A/T	cg06636001	chr8:8085503	FLJ10661	0.58	7.22	0.43	7.38e-12	Neuroticism;
SARC	cis	rs35160687	0.901	rs13017338	chr2:86501553	T/C	cg10973622	chr2:86423274	IMMT	0.37	4.77	0.3	3.31e-6	Night sleep phenotypes;
SARC	cis	rs13082711	0.911	rs73046191	chr3:27454398	T/A	cg02860705	chr3:27208620	NA	0.45	5.87	0.36	1.51e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs3008870	1.000	rs3008855	chr1:67386204	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.9	-10.56	-0.57	1.44e-21	Lymphocyte percentage of white cells;
SARC	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg01276201	chr10:134613136	NA	-0.29	-4.88	-0.3	1.99e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg16606324	chr3:10149918	C3orf24	0.52	5.27	0.33	3.08e-7	Alzheimer's disease;
SARC	cis	rs9393692	0.846	rs9366651	chr6:26336696	G/T	cg13736514	chr6:26305472	NA	-0.64	-8.83	-0.5	2.53e-16	Educational attainment;
SARC	cis	rs2153535	0.580	rs3938660	chr6:8443335	G/A	cg07606381	chr6:8435919	SLC35B3	0.78	11.09	0.59	3.11e-23	Motion sickness;
SARC	cis	rs2304069	0.565	rs13183261	chr5:149421847	T/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.58	6.71	0.4	1.47e-10	HIV-1 control;
SARC	cis	rs9790314	0.846	rs12495310	chr3:160970956	T/A	cg04691961	chr3:161091175	C3orf57	-0.64	-8.7	-0.5	5.91e-16	Morning vs. evening chronotype;
SARC	cis	rs950169	0.881	rs34117475	chr15:85108443	T/C	cg03959625	chr15:84868606	LOC388152	0.36	4.89	0.3	1.9e-6	Schizophrenia;
SARC	cis	rs6912958	0.677	rs111990232	chr6:88022240	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.54	7.11	0.42	1.39e-11	Monocyte percentage of white cells;
SARC	cis	rs9814567	0.727	rs4245908	chr3:134349205	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.49	-6.33	-0.38	1.26e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs644799	0.965	rs598876	chr11:95560853	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.9	14.03	0.68	7.82e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs11719291	0.833	rs11713694	chr3:48833615	G/T	cg01304814	chr3:48885189	PRKAR2A	0.63	5.21	0.32	4.2e-7	Cognitive function;
SARC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.44	0.53	4.08e-18	Prudent dietary pattern;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg13866129	chr11:62623438	SNORD27;SLC3A2;SNORD28;SNORD25;SNORD26;SNHG1	0.46	6.26	0.38	1.79e-9	Chemerin levels;
SARC	cis	rs28374715	0.532	rs316607	chr15:41772693	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.15	-17.69	-0.76	5.77e-45	Ulcerative colitis;
SARC	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg02725872	chr8:58115012	NA	-0.36	-6.47	-0.39	5.59e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg20102877	chr2:27665638	KRTCAP3	-0.36	-5.15	-0.32	5.52e-7	Total body bone mineral density;
SARC	cis	rs3796352	0.764	rs34872575	chr3:52986277	G/A	cg07884673	chr3:53033167	SFMBT1	0.8	4.95	0.31	1.43e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs5167	0.645	rs1130742	chr19:45452812	C/T	cg13119609	chr19:45449297	APOC2	0.36	4.99	0.31	1.17e-6	Blood protein levels;
SARC	cis	rs7264396	0.790	rs6060530	chr20:34227663	C/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	5.89	0.36	1.33e-8	Total cholesterol levels;
SARC	cis	rs1559088	1.000	rs1559088	chr19:33551061	C/T	cg27124370	chr19:33622961	WDR88	0.43	5.33	0.33	2.31e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg21747090	chr2:27597821	SNX17	-0.54	-7.58	-0.44	8.33e-13	Total body bone mineral density;
SARC	cis	rs6570726	0.846	rs441575	chr6:145849205	A/C	cg23711669	chr6:146136114	FBXO30	0.78	12.08	0.62	2.13e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6568686	0.527	rs174407	chr6:111931687	C/T	cg15721981	chr6:111408429	SLC16A10	0.69	5.91	0.36	1.2e-8	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs4718428	0.705	rs10267335	chr7:66403220	G/T	cg18252515	chr7:66147081	NA	-0.56	-6.08	-0.37	4.96e-9	Corneal structure;
SARC	cis	rs9486715	0.867	rs2475025	chr6:96988696	A/T	cg18709589	chr6:96969512	KIAA0776	-0.62	-7.79	-0.45	2.16e-13	Headache;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg08002795	chr4:83351453	HNRPDL;ENOPH1	0.56	6.43	0.39	7.03e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs748404	0.697	rs475261	chr15:43546456	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.42	5.25	0.33	3.37e-7	Lung cancer;
SARC	cis	rs4141404	0.923	rs2413035	chr22:31600460	A/G	cg07713946	chr22:31675144	LIMK2	-0.36	-4.88	-0.3	1.95e-6	Paclitaxel-induced neuropathy;
SARC	cis	rs9436747	0.605	rs7526141	chr1:65975275	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.42	-5.37	-0.33	1.94e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs6456156	0.766	rs150112	chr6:167509878	C/T	cg23791538	chr6:167370224	RNASET2	0.39	5.03	0.31	9.95e-7	Primary biliary cholangitis;
SARC	cis	rs1318878	0.522	rs11831208	chr12:15507223	G/A	cg08258403	chr12:15378311	NA	0.35	5.14	0.32	5.81e-7	Intelligence (multi-trait analysis);
SARC	cis	rs10193935	0.901	rs10170082	chr2:42623452	T/C	cg27598129	chr2:42591480	NA	-0.38	-5.22	-0.32	3.87e-7	Colonoscopy-negative controls vs population controls;
SARC	trans	rs2736345	0.788	rs2618476	chr8:11352541	A/G	cg06636001	chr8:8085503	FLJ10661	0.54	6.31	0.38	1.36e-9	Sjögren's syndrome;Systemic lupus erythematosus;
SARC	cis	rs2898681	0.561	rs2200225	chr4:53738411	A/G	cg00338735	chr4:53728038	RASL11B	0.45	5.08	0.32	7.63e-7	Optic nerve measurement (cup area);
SARC	cis	rs2832191	1.000	rs9984793	chr21:30486471	T/C	cg08807101	chr21:30365312	RNF160	-0.75	-10.39	-0.56	4.97e-21	Dental caries;
SARC	cis	rs75557865	1	rs75557865	chr3:121652141	G/A	cg20356878	chr3:121714668	ILDR1	0.4	6.44	0.39	6.58e-10	Allergic disease (asthma, hay fever or eczema);
SARC	trans	rs2727020	0.538	rs61885230	chr11:49128958	T/C	cg03929089	chr4:120376271	NA	-0.51	-6.53	-0.39	3.99e-10	Coronary artery disease;
SARC	trans	rs8020941	0.585	rs74394311	chr14:97496508	C/T	cg05136476	chr3:53190709	NA	-0.62	-6.39	-0.39	8.71e-10	Diabetic kidney disease;
SARC	trans	rs2727020	0.894	rs2866361	chr11:49372481	A/G	cg03929089	chr4:120376271	NA	-0.73	-9.2	-0.52	2.04e-17	Coronary artery disease;
SARC	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg24531977	chr5:56204891	C5orf35	-0.53	-5.36	-0.33	2.02e-7	Initial pursuit acceleration;
SARC	trans	rs2727020	0.615	rs35423199	chr11:49514914	T/C	cg03929089	chr4:120376271	NA	-0.8	-12.03	-0.62	3.1e-26	Coronary artery disease;
SARC	cis	rs17376456	0.877	rs10070390	chr5:93452345	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	6.14	0.37	3.45e-9	Diabetic retinopathy;
SARC	cis	rs9393777	1.000	rs9393777	chr6:26942027	T/C	cg12826209	chr6:26865740	GUSBL1	0.83	5.65	0.35	4.59e-8	Intelligence (multi-trait analysis);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg04111999	chr10:22615540	BMI1	0.47	6.68	0.4	1.78e-10	Thyroid stimulating hormone;
SARC	cis	rs7786808	0.741	rs11769149	chr7:158227127	A/G	cg09998033	chr7:158218633	PTPRN2	0.36	5.71	0.35	3.5e-8	Obesity-related traits;
SARC	cis	rs3796352	1.000	rs11713206	chr3:52999243	A/G	cg15956490	chr3:53032818	SFMBT1	0.9	5.62	0.35	5.38e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs66887589	0.934	rs41464847	chr4:120532401	A/G	cg09307838	chr4:120376055	NA	-0.49	-6.7	-0.4	1.52e-10	Diastolic blood pressure;
SARC	cis	rs2629540	0.847	rs12763093	chr10:126395688	C/G	cg08799069	chr10:126477246	METTL10	-0.59	-6.65	-0.4	2.02e-10	Cocaine dependence;
SARC	cis	rs5769765	0.773	rs138861	chr22:50202276	A/G	cg03033257	chr22:50311977	ALG12;CRELD2	0.49	4.76	0.3	3.38e-6	Schizophrenia;
SARC	cis	rs3768617	0.510	rs1413387	chr1:183096774	G/A	cg13390022	chr1:182993471	LAMC1	0.31	4.71	0.3	4.18e-6	Fuchs's corneal dystrophy;
SARC	cis	rs4805272	0.512	rs765484	chr19:29344663	A/G	cg12756686	chr19:29218302	NA	0.49	5.26	0.33	3.23e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg05623727	chr3:50126028	RBM5	0.33	4.87	0.3	2.06e-6	Body mass index;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg27211204	chr15:99791508	LRRC28	0.81	6.83	0.41	7.39e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs798554	0.704	rs798513	chr7:2782493	C/T	cg13628971	chr7:2884303	GNA12	0.5	6.17	0.37	2.95e-9	Height;
SARC	cis	rs9479482	1.000	rs9478362	chr6:150340526	T/C	cg03788504	chr6:150331562	NA	-0.33	-5.44	-0.34	1.34e-7	Alopecia areata;
SARC	cis	rs16976116	0.901	rs9920737	chr15:55505761	C/G	cg11288833	chr15:55489084	RSL24D1	0.6	5.49	0.34	1.03e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4481887	1.000	rs10736378	chr1:248455769	T/G	cg01631408	chr1:248437212	OR2T33	-0.41	-5.21	-0.32	4.07e-7	Common traits (Other);
SARC	cis	rs1865760	0.516	rs10807007	chr6:26048931	A/C	cg18357526	chr6:26021779	HIST1H4A	0.44	5.63	0.35	5.27e-8	Height;
SARC	cis	rs2153535	0.580	rs2327053	chr6:8443127	A/G	cg23788917	chr6:8435910	SLC35B3	0.67	8.75	0.5	4.46e-16	Motion sickness;
SARC	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg08677398	chr8:58056175	NA	0.44	5.22	0.32	4e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6582630	0.537	rs11520294	chr12:38402705	C/A	cg26384229	chr12:38710491	ALG10B	0.89	12.72	0.64	1.75e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1865760	0.713	rs1130000	chr6:25985396	A/G	cg10373733	chr6:25993375	NA	0.46	5.89	0.36	1.32e-8	Height;
SARC	cis	rs8042849	1	rs8042849	chr15:78817929	C/T	cg18825076	chr15:78729989	IREB2	0.4	4.87	0.3	2.02e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Parental lifespan;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg23758822	chr17:41437982	NA	0.88	11.32	0.6	6.01e-24	Menopause (age at onset);
SARC	cis	rs9886651	0.935	rs4733759	chr8:128804840	C/T	cg24514600	chr8:128805414	PVT1	-0.41	-5.34	-0.33	2.17e-7	Epithelial ovarian cancer;Serous invasive ovarian cancer;
SARC	cis	rs9815354	0.812	rs10510733	chr3:42009192	T/C	cg03022575	chr3:42003672	ULK4	0.71	6.03	0.37	6.5e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6582630	0.502	rs4385963	chr12:38295264	G/A	cg13010199	chr12:38710504	ALG10B	0.79	11.02	0.59	5.26e-23	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg24600983	chr7:90043213	CLDN12	0.49	7.0	0.42	2.76e-11	Thyroid stimulating hormone;
SARC	cis	rs72781680	0.898	rs10490751	chr2:24001356	A/G	cg06627628	chr2:24431161	ITSN2	-0.66	-6.26	-0.38	1.83e-9	Lymphocyte counts;
SARC	cis	rs4141404	0.673	rs1968023	chr22:31942770	A/G	cg02404636	chr22:31891804	SFI1	-0.54	-5.41	-0.33	1.56e-7	Paclitaxel-induced neuropathy;
SARC	cis	rs748404	0.697	rs530188	chr15:43545314	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	5.83	0.36	1.83e-8	Lung cancer;
SARC	cis	rs765787	0.530	rs28756676	chr15:45540360	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.67e-7	Uric acid levels;
SARC	cis	rs36051895	0.659	rs3780366	chr9:5068596	T/C	cg02405213	chr9:5042618	JAK2	-0.47	-5.3	-0.33	2.65e-7	Pediatric autoimmune diseases;
SARC	cis	rs735396	0.965	rs2257962	chr12:121445808	T/C	cg02403541	chr12:121454288	C12orf43	0.7	9.29	0.52	1.17e-17	N-glycan levels;
SARC	cis	rs453301	0.686	rs2409120	chr8:8882571	G/C	cg15556689	chr8:8085844	FLJ10661	-0.53	-7.08	-0.42	1.65e-11	Joint mobility (Beighton score);
SARC	cis	rs9796	0.870	rs4923890	chr15:41258990	T/C	cg18705301	chr15:41695430	NDUFAF1	0.4	5.48	0.34	1.11e-7	Menopause (age at onset);
SARC	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-9.15	-0.51	2.85e-17	Alzheimer's disease;
SARC	cis	rs7662987	0.517	rs1311615	chr4:100012261	G/A	cg13256891	chr4:100009986	ADH5	0.66	8.33	0.48	7.17e-15	Smoking initiation;
SARC	cis	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.63	-0.45	5.88e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs7617480	0.616	rs7429596	chr3:48808531	T/C	cg07636037	chr3:49044803	WDR6	0.86	8.94	0.51	1.2e-16	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs820218	0.962	rs820131	chr17:73669915	T/C	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.7	9.61	0.53	1.25e-18	Rotator cuff tears;
SARC	cis	rs11122272	0.705	rs2486742	chr1:231507254	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-9.76	-0.54	4.37e-19	Hemoglobin concentration;
SARC	cis	rs4689388	0.926	rs10937717	chr4:6295087	T/A	cg00701064	chr4:6280414	WFS1	0.56	9.11	0.51	3.88e-17	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.95	13.1	0.65	9.86e-30	Gut microbiome composition (summer);
SARC	cis	rs546131	0.642	rs35617374	chr11:34832373	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-5.11	-0.32	6.76e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs796364	0.806	rs78527234	chr2:200913453	C/T	cg23649088	chr2:200775458	C2orf69	-0.6	-5.31	-0.33	2.51e-7	Schizophrenia;
SARC	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.91	11.07	0.59	3.6e-23	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs72781680	0.898	rs56413706	chr2:24086961	G/A	cg06627628	chr2:24431161	ITSN2	-0.69	-6.52	-0.39	4.34e-10	Lymphocyte counts;
SARC	cis	rs1594829	0.553	rs2046225	chr8:26151802	A/C	cg11498726	chr8:26250323	BNIP3L	0.4	5.23	0.32	3.74e-7	Height;
SARC	trans	rs3780486	0.846	rs7849148	chr9:33138352	A/T	cg04842962	chr6:43655489	MRPS18A	1.09	19.67	0.79	2.1e-51	IgG glycosylation;
SARC	cis	rs7412746	0.658	rs11582281	chr1:150826831	T/C	cg13175981	chr1:150552382	MCL1	-0.48	-5.73	-0.35	3.16e-8	Melanoma;
SARC	cis	rs763121	0.853	rs5750672	chr22:39104168	C/T	cg21395723	chr22:39101663	GTPBP1	-0.62	-7.24	-0.43	6.38e-12	Menopause (age at onset);
SARC	cis	rs6546550	0.935	rs11673826	chr2:70041033	G/A	cg02498382	chr2:70120550	SNRNP27	-0.39	-6.18	-0.38	2.8e-9	Prevalent atrial fibrillation;
SARC	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg16325326	chr1:53192061	ZYG11B	-0.83	-13.0	-0.65	2.09e-29	Monocyte count;
SARC	cis	rs4803468	1.000	rs11670668	chr19:41920454	G/C	cg08477640	chr19:41863820	B9D2	0.45	5.68	0.35	3.94e-8	Height;
SARC	trans	rs61931739	0.517	rs2636073	chr12:34063049	C/T	cg13010199	chr12:38710504	ALG10B	0.66	8.76	0.5	4.04e-16	Morning vs. evening chronotype;
SARC	cis	rs3762637	1.000	rs7615930	chr3:122125750	G/T	cg24169773	chr3:122142474	KPNA1	-0.61	-6.37	-0.38	1.03e-9	LDL cholesterol levels;
SARC	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg15448220	chr1:150897856	SETDB1	0.48	6.38	0.39	9.29e-10	Tonsillectomy;
SARC	cis	rs5753037	0.653	rs131272	chr22:30153655	A/G	cg01021169	chr22:30184971	ASCC2	-0.45	-6.31	-0.38	1.39e-9	Type 1 diabetes;
SARC	cis	rs7607369	0.536	rs6436089	chr2:219668813	A/G	cg02176678	chr2:219576539	TTLL4	-0.38	-5.67	-0.35	4.2e-8	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg06873352	chr17:61820015	STRADA	0.53	6.85	0.41	6.67e-11	Prudent dietary pattern;
SARC	cis	rs9443189	0.570	rs72884926	chr6:76266208	T/C	cg01950844	chr6:76311363	SENP6	0.87	7.79	0.45	2.23e-13	Prostate cancer;
SARC	cis	rs9640161	0.702	rs3735175	chr7:150020457	C/T	cg17279839	chr7:150038598	RARRES2	0.47	6.56	0.39	3.44e-10	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs6840360	1.000	rs6840678	chr4:152604331	C/G	cg22705602	chr4:152727874	NA	0.4	6.77	0.41	1.05e-10	Intelligence (multi-trait analysis);
SARC	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg04944784	chr2:26401820	FAM59B	-0.48	-6.1	-0.37	4.49e-9	Gut microbiome composition (summer);
SARC	cis	rs3818285	0.679	rs612155	chr10:111630731	C/G	cg00817464	chr10:111662876	XPNPEP1	0.51	8.3	0.48	8.21e-15	Superior crus of antihelix expression;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg08631890	chr19:39902969	PLEKHG2	0.51	6.25	0.38	1.95e-9	Blood pressure;
SARC	cis	rs57994353	0.600	rs13295852	chr9:139308426	G/A	cg14169450	chr9:139327907	INPP5E	0.42	5.01	0.31	1.06e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg09323728	chr8:95962352	TP53INP1	-0.33	-5.41	-0.33	1.6e-7	Type 2 diabetes;
SARC	cis	rs6061231	0.834	rs2427307	chr20:60966686	G/A	cg22601191	chr20:60968625	CABLES2	0.38	5.2	0.32	4.27e-7	Colorectal cancer;
SARC	cis	rs8044995	0.563	rs8059585	chr16:68376811	G/A	cg09835421	chr16:68378352	PRMT7	-0.62	-5.9	-0.36	1.29e-8	Schizophrenia;
SARC	cis	rs4276643	0.531	rs2685403	chr8:27821832	T/C	cg26001764	chr8:28560637	EXTL3	0.34	4.8	0.3	2.84e-6	Low vWF levels;
SARC	cis	rs9291683	0.551	rs62295971	chr4:9978142	G/A	cg11266682	chr4:10021025	SLC2A9	0.39	6.99	0.42	2.85e-11	Bone mineral density;
SARC	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg00933542	chr6:150070202	PCMT1	0.3	5.08	0.32	7.64e-7	Lung cancer;
SARC	cis	rs9796	0.866	rs516156	chr15:41381257	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.43	-5.88	-0.36	1.4e-8	Menopause (age at onset);
SARC	cis	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg25894440	chr7:65020034	NA	-0.73	-5.58	-0.34	6.58e-8	Diabetic kidney disease;
SARC	cis	rs5758659	0.714	rs5751216	chr22:42508937	G/T	cg04692870	chr22:42525206	CYP2D6	-0.35	-4.74	-0.3	3.78e-6	Cognitive function;
SARC	cis	rs10463554	0.963	rs62364876	chr5:102394158	T/C	cg23492399	chr5:102201601	PAM	-0.52	-5.73	-0.35	3.13e-8	Parkinson's disease;
SARC	cis	rs6442522	0.966	rs3856828	chr3:15488997	T/C	cg16303742	chr3:15540471	COLQ	0.33	4.77	0.3	3.32e-6	Uric acid levels;
SARC	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg27170947	chr2:26402098	FAM59B	0.37	4.8	0.3	2.79e-6	Gut microbiome composition (summer);
SARC	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg22920501	chr2:26401640	FAM59B	-0.54	-7.07	-0.42	1.83e-11	Gut microbiome composition (summer);
SARC	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.35	4.76	0.3	3.35e-6	Personality dimensions;
SARC	cis	rs2933343	0.700	rs6787833	chr3:128656184	A/G	cg24203234	chr3:128598194	ACAD9	0.63	8.01	0.46	5.52e-14	IgG glycosylation;
SARC	cis	rs9896933	0.778	rs80112422	chr17:80827719	G/T	cg15369054	chr17:80825471	TBCD	0.46	4.94	0.31	1.46e-6	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
SARC	cis	rs6964587	1.000	rs10234290	chr7:91716951	T/C	cg17063962	chr7:91808500	NA	0.96	16.21	0.73	4.62e-40	Breast cancer;
SARC	cis	rs9527	0.590	rs763914	chr10:104841587	T/C	cg04362960	chr10:104952993	NT5C2	0.42	4.92	0.31	1.65e-6	Arsenic metabolism;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg16537028	chr16:84853380	CRISPLD2	0.51	6.57	0.4	3.29e-10	Breast cancer;
SARC	cis	rs8141529	0.711	rs5752797	chr22:29179998	C/T	cg02153584	chr22:29168773	CCDC117	0.73	8.81	0.5	2.99e-16	Lymphocyte counts;
SARC	cis	rs7555523	0.887	rs4657477	chr1:165736175	C/T	cg24409356	chr1:165738333	TMCO1	0.78	6.58	0.4	3.14e-10	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	cis	rs13161895	1.000	rs3797763	chr5:179439516	C/T	cg06664874	chr5:179499304	RNF130	-0.49	-4.78	-0.3	3.14e-6	LDL cholesterol;
SARC	cis	rs7246657	0.943	rs10415937	chr19:37830064	T/G	cg14683738	chr19:37701593	ZNF585B	0.51	4.99	0.31	1.16e-6	Coronary artery calcification;
SARC	cis	rs7927771	1.000	rs2290850	chr11:47807774	T/C	cg05585544	chr11:47624801	NA	-0.36	-4.77	-0.3	3.31e-6	Subjective well-being;
SARC	cis	rs372883	0.648	rs1153292	chr21:30689195	G/T	cg24692254	chr21:30365293	RNF160	-0.64	-8.25	-0.48	1.19e-14	Pancreatic cancer;
SARC	cis	rs870825	0.616	rs28666955	chr4:185631338	A/G	cg04058563	chr4:185651563	MLF1IP	0.82	11.01	0.58	5.81e-23	Blood protein levels;
SARC	cis	rs6089584	1.000	rs3787425	chr20:60559256	C/T	cg23262073	chr20:60523788	NA	-0.44	-6.42	-0.39	7.39e-10	Body mass index;
SARC	cis	rs55871839	0.708	rs12114218	chr8:59817454	T/C	cg07426533	chr8:59803705	TOX	-0.37	-4.83	-0.3	2.5e-6	Pneumonia;
SARC	cis	rs921968	0.565	rs2272189	chr2:219610322	G/A	cg02176678	chr2:219576539	TTLL4	-0.33	-4.95	-0.31	1.42e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs66573146	0.831	rs56300156	chr4:6990813	G/C	cg00086871	chr4:6988644	TBC1D14	0.86	5.15	0.32	5.57e-7	Granulocyte percentage of myeloid white cells;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg07013940	chr5:162887219	HMMR;NUDCD2	-0.85	-7.42	-0.44	2.15e-12	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg22800045	chr5:56110881	MAP3K1	0.73	7.82	0.46	1.79e-13	Initial pursuit acceleration;
SARC	cis	rs9815354	0.812	rs73073230	chr3:42008263	G/A	cg03022575	chr3:42003672	ULK4	0.68	5.89	0.36	1.34e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6542838	0.703	rs7593332	chr2:99467991	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-6.42	-0.39	7.46e-10	Fear of minor pain;
SARC	cis	rs765787	0.530	rs10467979	chr15:45521270	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.41	-5.08	-0.32	7.58e-7	Uric acid levels;
SARC	cis	rs240764	0.645	rs454747	chr6:101055566	T/C	cg09795085	chr6:101329169	ASCC3	0.41	5.22	0.32	4.02e-7	Neuroticism;
SARC	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg13175981	chr1:150552382	MCL1	-0.54	-6.9	-0.41	4.97e-11	Tonsillectomy;
SARC	trans	rs925098	0.558	rs4698656	chr4:17887131	A/T	cg08521178	chr6:170491202	NA	0.44	6.81	0.41	8.05e-11	Birth weight;Height;
SARC	cis	rs9814567	1.000	rs35718987	chr3:134272783	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	7.08	0.42	1.73e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs12044355	0.927	rs16854809	chr1:231839247	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.54	7.21	0.43	7.71e-12	Alzheimer's disease;
SARC	cis	rs7839435	0.866	rs73229093	chr8:27442329	C/T	cg01579299	chr8:27450062	NA	0.55	4.94	0.31	1.47e-6	Lung adenocarcinoma;
SARC	cis	rs9916302	0.731	rs11868030	chr17:37650332	A/G	cg20243544	chr17:37824526	PNMT	0.55	6.53	0.39	4.05e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs11792861	0.926	rs2271878	chr9:111868885	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.69	7.9	0.46	1.08e-13	Menarche (age at onset);
SARC	cis	rs317689	0.702	rs544696	chr12:69749939	T/C	cg20891283	chr12:69753455	YEATS4	0.5	6.0	0.37	7.6e-9	Response to diuretic therapy;
SARC	cis	rs4319547	0.697	rs7974262	chr12:122896385	C/T	cg05707623	chr12:122985044	ZCCHC8	0.53	5.94	0.36	1.01e-8	Body mass index;
SARC	cis	rs9400467	0.506	rs12191195	chr6:111712718	C/G	cg15721981	chr6:111408429	SLC16A10	0.65	5.65	0.35	4.61e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs3780378	1.000	rs7847294	chr9:5097281	A/C	cg02405213	chr9:5042618	JAK2	-0.45	-5.73	-0.35	3.12e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
SARC	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg04267008	chr7:1944627	MAD1L1	-0.45	-4.81	-0.3	2.71e-6	Schizophrenia, schizoaffective disorder or bipolar disorder;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg26854234	chr15:85259674	SEC11A	0.48	6.53	0.39	4.04e-10	Chemerin levels;
SARC	cis	rs7937682	0.632	rs4936834	chr11:111764017	T/A	cg22437258	chr11:111473054	SIK2	-0.49	-5.53	-0.34	8.46e-8	Primary sclerosing cholangitis;
SARC	cis	rs1371867	0.846	rs1788203	chr8:101303721	T/C	cg11906718	chr8:101322791	RNF19A	0.7	8.89	0.5	1.76e-16	Atrioventricular conduction;
SARC	cis	rs9640161	0.659	rs77354576	chr7:150013300	A/C	cg17279839	chr7:150038598	RARRES2	0.41	6.08	0.37	4.77e-9	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs7223966	1.000	rs3817181	chr17:61776538	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.52	-5.48	-0.34	1.13e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs12950390	0.853	rs56387656	chr17:45860189	C/G	cg24803719	chr17:45855879	NA	-0.46	-7.5	-0.44	1.34e-12	IgG glycosylation;
SARC	trans	rs56279505	0.690	rs78234152	chr4:100279889	G/A	cg21156590	chr1:3420848	MEGF6	-0.83	-6.52	-0.39	4.31e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg20102877	chr2:27665638	KRTCAP3	-0.34	-4.76	-0.3	3.34e-6	Total body bone mineral density;
SARC	cis	rs11997175	0.583	rs7829680	chr8:33794207	C/T	ch.8.33884649F	chr8:33765107	NA	-0.5	-6.51	-0.39	4.66e-10	Body mass index;
SARC	cis	rs7659604	1.000	rs6846232	chr4:122664805	A/G	cg20573242	chr4:122745356	CCNA2	0.43	5.7	0.35	3.52e-8	Type 2 diabetes;
SARC	cis	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.56	8.69	0.49	6.41e-16	Eosinophil percentage of white cells;
SARC	cis	rs7659604	1.000	rs72678650	chr4:122666000	A/G	cg19671926	chr4:122722719	EXOSC9	-0.51	-6.14	-0.37	3.44e-9	Type 2 diabetes;
SARC	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-8.89	-0.5	1.75e-16	Alzheimer's disease;
SARC	cis	rs2645694	0.651	rs2703128	chr4:77819187	C/G	cg18351406	chr4:77819688	ANKRD56	0.46	6.44	0.39	6.9e-10	Emphysema distribution in smoking;
SARC	cis	rs7429990	0.813	rs7627568	chr3:48093052	A/T	cg11946769	chr3:48343235	NME6	-0.44	-5.08	-0.32	7.75e-7	Educational attainment (years of education);
SARC	cis	rs2204008	0.702	rs3849999	chr12:38483498	G/A	cg13010199	chr12:38710504	ALG10B	-0.48	-5.91	-0.36	1.2e-8	Bladder cancer;
SARC	cis	rs9948	1.000	rs10203346	chr2:97517237	A/G	cg01990225	chr2:97406019	LMAN2L	-0.87	-5.9	-0.36	1.24e-8	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs6087990	0.735	rs6119946	chr20:31329704	A/G	cg13636640	chr20:31349939	DNMT3B	-0.78	-12.13	-0.62	1.45e-26	Ulcerative colitis;
SARC	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg05863683	chr7:1912471	MAD1L1	0.34	5.11	0.32	6.69e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs9815354	0.767	rs73079325	chr3:41864565	G/A	cg03022575	chr3:42003672	ULK4	0.57	5.32	0.33	2.38e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9513627	0.665	rs79036236	chr13:100116405	C/T	cg25919922	chr13:100150906	NA	-0.74	-5.53	-0.34	8.51e-8	Obesity-related traits;
SARC	cis	rs34172651	0.876	rs964782	chr16:24811740	T/C	cg06028605	chr16:24865363	SLC5A11	0.28	4.77	0.3	3.29e-6	Intelligence (multi-trait analysis);
SARC	cis	rs710216	0.917	rs3754223	chr1:43419091	A/T	cg07803811	chr1:43423981	SLC2A1	0.49	5.07	0.32	8.08e-7	Red cell distribution width;
SARC	cis	rs7481584	0.624	rs412842	chr11:3047448	A/G	cg20651018	chr11:3035856	CARS	0.41	6.08	0.37	4.91e-9	Calcium levels;
SARC	cis	rs7615952	1.000	rs9289275	chr3:125648659	A/T	cg05084668	chr3:125655381	ALG1L	-0.77	-7.8	-0.46	2.06e-13	Blood pressure (smoking interaction);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg14895945	chr19:12889086	NA	0.58	7.44	0.44	1.87e-12	Breast cancer;
SARC	trans	rs1814175	0.781	rs12286395	chr11:49954062	C/G	cg03929089	chr4:120376271	NA	-0.89	-14.59	-0.69	1.1e-34	Height;
SARC	cis	rs6121246	0.529	rs58757492	chr20:30181425	G/A	cg21427119	chr20:30132790	HM13	-0.48	-5.27	-0.33	3.16e-7	Mean corpuscular hemoglobin;
SARC	cis	rs11581859	0.613	rs12401685	chr1:99205172	T/G	cg20286094	chr1:99190917	SNX7	-0.42	-4.89	-0.31	1.86e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg03033257	chr22:50311977	ALG12;CRELD2	0.57	5.01	0.31	1.07e-6	Schizophrenia;
SARC	cis	rs17784882	0.521	rs11713693	chr3:47074906	T/C	cg27129171	chr3:47204927	SETD2	-0.68	-9.01	-0.51	7.38e-17	QT interval;
SARC	cis	rs10752881	1.000	rs4454510	chr1:182982303	A/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.73	-11.54	-0.6	1.13e-24	Colorectal cancer;
SARC	trans	rs208520	0.690	rs3846808	chr6:66818604	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-13.76	-0.67	6.3e-32	Exhaled nitric oxide output;
SARC	cis	rs7000551	0.751	rs1116084	chr8:22395309	C/T	cg12081754	chr8:22256438	SLC39A14	0.58	7.93	0.46	8.98e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg21724239	chr8:58056113	NA	0.61	5.93	0.36	1.1e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6964587	0.933	rs10271174	chr7:91785970	A/G	cg17063962	chr7:91808500	NA	0.99	17.43	0.75	3.98e-44	Breast cancer;
SARC	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg04944784	chr2:26401820	FAM59B	0.6	7.24	0.43	6.31e-12	Gut microbiome composition (summer);
SARC	cis	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg06636001	chr8:8085503	FLJ10661	0.74	10.27	0.56	1.19e-20	Mood instability;
SARC	cis	rs4689388	0.890	rs11732208	chr4:6292716	G/C	cg14416269	chr4:6271139	WFS1	0.32	4.98	0.31	1.23e-6	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs7555523	0.779	rs2790049	chr1:165743523	A/G	cg19769164	chr1:165738335	TMCO1	0.57	4.78	0.3	3.13e-6	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	cis	rs8180040	0.966	rs11710322	chr3:47331136	C/T	cg27129171	chr3:47204927	SETD2	-0.69	-9.6	-0.53	1.3e-18	Colorectal cancer;
SARC	cis	rs6964587	0.755	rs13229505	chr7:91444679	G/T	cg17063962	chr7:91808500	NA	0.84	11.69	0.61	3.89e-25	Breast cancer;
SARC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg24846343	chr22:24311635	DDTL	0.51	7.36	0.43	3.09e-12	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs72777070	0.895	rs12615784	chr2:9789403	A/G	cg14973360	chr2:9800511	NA	-0.53	-5.36	-0.33	1.97e-7	Platelet-derived growth factor BB levels;
SARC	cis	rs3741404	0.609	rs592271	chr11:63872029	G/T	cg18225595	chr11:63971243	STIP1	0.4	5.65	0.35	4.71e-8	Platelet count;
SARC	cis	rs9393777	0.588	rs11967935	chr6:26560672	A/C	cg12826209	chr6:26865740	GUSBL1	0.66	6.12	0.37	3.87e-9	Intelligence (multi-trait analysis);
SARC	trans	rs1814175	0.645	rs847639	chr11:49919603	C/T	cg03929089	chr4:120376271	NA	-0.81	-11.69	-0.61	3.89e-25	Height;
SARC	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg12564285	chr5:131593104	PDLIM4	-0.44	-6.05	-0.37	5.78e-9	Breast cancer;
SARC	cis	rs11718455	0.767	rs6782500	chr3:43990260	A/G	cg08738300	chr3:44038990	NA	-0.52	-5.7	-0.35	3.53e-8	Coronary artery disease;
SARC	cis	rs9875589	0.509	rs2129888	chr3:14013826	A/T	cg19554555	chr3:13937349	NA	-0.39	-5.0	-0.31	1.13e-6	Ovarian reserve;
SARC	cis	rs9611519	0.732	rs1883826	chr22:41703428	G/A	cg03806693	chr22:41940476	POLR3H	-0.73	-9.59	-0.53	1.38e-18	Neuroticism;
SARC	cis	rs4481887	0.927	rs4307598	chr1:248474544	T/C	cg00666640	chr1:248458726	OR2T12	0.32	5.45	0.34	1.25e-7	Common traits (Other);
SARC	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg07636037	chr3:49044803	WDR6	1.0	17.63	0.76	9.36e-45	Parkinson's disease;
SARC	cis	rs9517320	0.515	rs9556969	chr13:99195948	T/C	cg07423050	chr13:99094983	FARP1	-0.41	-5.45	-0.34	1.31e-7	Longevity;
SARC	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.63	-7.36	-0.43	3.13e-12	Gut microbiome composition (summer);
SARC	cis	rs7130144	0.541	rs7110730	chr11:130457867	C/T	cg26307797	chr11:130446613	NA	-0.69	-5.65	-0.35	4.71e-8	Urate levels in lean individuals;
SARC	cis	rs9790314	0.580	rs960212	chr3:161047974	C/T	cg04691961	chr3:161091175	C3orf57	-0.57	-7.5	-0.44	1.31e-12	Morning vs. evening chronotype;
SARC	cis	rs28795989	0.896	rs7663205	chr4:7889096	C/T	cg18538662	chr4:7941764	AFAP1	-0.37	-4.73	-0.3	3.83e-6	Intraocular pressure;
SARC	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.59	-7.23	-0.43	7.06e-12	Prudent dietary pattern;
SARC	cis	rs832540	0.931	rs33319	chr5:56206675	C/A	cg14703610	chr5:56206110	C5orf35	0.54	6.83	0.41	7.18e-11	Coronary artery disease;
SARC	cis	rs1468333	0.537	rs4317313	chr5:137699592	A/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.65	7.76	0.45	2.59e-13	Resting heart rate;
SARC	cis	rs6484504	0.532	rs2616799	chr11:31319044	T/C	cg26647111	chr11:31128758	NA	0.39	4.98	0.31	1.25e-6	Red blood cell count;
SARC	cis	rs7011049	1.000	rs11995106	chr8:53834768	C/T	cg26025543	chr8:53854495	NA	0.6	5.47	0.34	1.15e-7	Systolic blood pressure;
SARC	cis	rs17401966	0.838	rs17034643	chr1:10332102	A/G	cg15208524	chr1:10270712	KIF1B	-0.49	-5.73	-0.35	3.14e-8	Hepatocellular carcinoma;
SARC	cis	rs72781680	0.846	rs55770503	chr2:24030126	A/T	cg08917208	chr2:24149416	ATAD2B	0.78	7.49	0.44	1.42e-12	Lymphocyte counts;
SARC	cis	rs10504229	0.813	rs6999878	chr8:58197243	C/G	cg22535103	chr8:58192502	C8orf71	-0.73	-7.51	-0.44	1.24e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs910316	0.967	rs175498	chr14:75536369	G/A	cg08847533	chr14:75593920	NEK9	-0.88	-13.76	-0.67	6.49e-32	Height;
SARC	cis	rs9341808	0.935	rs942381	chr6:80880150	T/G	cg08355045	chr6:80787529	NA	0.36	5.96	0.36	9.14e-9	Sitting height ratio;
SARC	cis	rs75646498	0.677	rs8042917	chr15:29868600	C/T	cg08904058	chr15:29859427	FAM189A1	-0.46	-4.9	-0.31	1.82e-6	Diisocyanate-induced asthma;
SARC	cis	rs6496667	0.557	rs2601203	chr15:90958129	T/G	cg22089800	chr15:90895588	ZNF774	0.44	5.0	0.31	1.15e-6	Rheumatoid arthritis;
SARC	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg20607798	chr8:58055168	NA	0.72	6.21	0.38	2.36e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6088765	0.606	rs2425024	chr20:33844938	G/T	cg24642439	chr20:33292090	TP53INP2	-0.44	-4.85	-0.3	2.22e-6	Ulcerative colitis;
SARC	cis	rs9322817	0.691	rs2499658	chr6:105291412	A/G	cg02098413	chr6:105308735	HACE1	0.38	5.91	0.36	1.18e-8	Thyroid stimulating hormone;
SARC	cis	rs3008870	0.920	rs975452	chr1:67480190	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.91	11.06	0.59	3.94e-23	Lymphocyte percentage of white cells;
SARC	trans	rs9929218	1.000	rs67359183	chr16:68814204	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.54	-6.77	-0.41	1.05e-10	Colorectal cancer;
SARC	trans	rs12310956	0.510	rs10844690	chr12:33854752	C/A	cg13010199	chr12:38710504	ALG10B	0.59	7.67	0.45	4.64e-13	Morning vs. evening chronotype;
SARC	cis	rs9420	0.961	rs12807250	chr11:57600285	C/T	cg23127183	chr11:57508653	C11orf31	-0.6	-6.97	-0.42	3.2e-11	Schizophrenia;
SARC	cis	rs889312	0.500	rs832552	chr5:56113850	A/C	cg14703610	chr5:56206110	C5orf35	-0.46	-5.58	-0.34	6.78e-8	Breast cancer;Breast cancer (early onset);
SARC	cis	rs6831352	0.918	rs13133647	chr4:100058727	C/T	cg13256891	chr4:100009986	ADH5	-0.64	-8.0	-0.46	5.7e-14	Alcohol dependence;
SARC	cis	rs6693567	0.565	rs698913	chr1:150299145	G/A	cg09579323	chr1:150459698	TARS2	0.42	5.31	0.33	2.56e-7	Migraine;
SARC	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg11987759	chr7:65425863	GUSB	0.47	5.64	0.35	4.96e-8	Aortic root size;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg26928497	chr16:22217548	EEF2K	0.48	6.27	0.38	1.69e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs710216	0.957	rs859511	chr1:43430260	C/T	cg03128534	chr1:43423976	SLC2A1	0.65	6.61	0.4	2.59e-10	Red cell distribution width;
SARC	cis	rs735396	0.770	rs2257764	chr12:121446446	T/A	cg15155738	chr12:121454335	C12orf43	-0.52	-6.57	-0.4	3.31e-10	N-glycan levels;
SARC	cis	rs60752752	0.852	rs3006476	chr1:153349110	C/A	cg26882115	chr1:153603048	S100A1;S100A13	-0.63	-4.83	-0.3	2.49e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs4803468	1.000	rs878083	chr19:41897688	G/A	cg14132834	chr19:41945861	ATP5SL	-0.57	-7.64	-0.45	5.45e-13	Height;
SARC	cis	rs4268898	0.662	rs9917355	chr2:24433400	C/T	cg06627628	chr2:24431161	ITSN2	-0.84	-10.12	-0.55	3.39e-20	Asthma;
SARC	cis	rs9650657	0.504	rs2409724	chr8:11041642	A/T	cg21775007	chr8:11205619	TDH	-0.43	-5.3	-0.33	2.7e-7	Neuroticism;
SARC	cis	rs10782582	0.593	rs12131344	chr1:76136437	C/T	cg03433033	chr1:76189801	ACADM	-0.39	-4.8	-0.3	2.89e-6	Daytime sleep phenotypes;
SARC	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg04944784	chr2:26401820	FAM59B	-0.47	-5.77	-0.35	2.47e-8	Gut microbiome composition (summer);
SARC	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg24675658	chr1:53192096	ZYG11B	-0.66	-9.87	-0.54	2e-19	Monocyte count;
SARC	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg27541892	chr1:1571801	CDK11B	0.41	5.61	0.34	5.8e-8	Body mass index;
SARC	cis	rs7937682	0.883	rs529529	chr11:111461128	C/T	cg22437258	chr11:111473054	SIK2	0.76	9.87	0.54	2.07e-19	Primary sclerosing cholangitis;
SARC	cis	rs2832191	0.716	rs8132085	chr21:30501389	G/T	cg24692254	chr21:30365293	RNF160	-0.94	-15.06	-0.7	2.99e-36	Dental caries;
SARC	cis	rs1865760	1.000	rs6938233	chr6:25914077	C/T	cg10373733	chr6:25993375	NA	0.42	4.97	0.31	1.28e-6	Height;
SARC	cis	rs950169	0.922	rs11633075	chr15:85113972	C/A	cg17507749	chr15:85114479	UBE2QP1	0.79	9.45	0.53	3.89e-18	Schizophrenia;
SARC	cis	rs8141529	0.529	rs66471734	chr22:29215803	G/A	cg15103426	chr22:29168792	CCDC117	0.61	5.94	0.36	1.03e-8	Lymphocyte counts;
SARC	cis	rs17376456	0.825	rs17314797	chr5:93234845	T/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.7	0.35	3.54e-8	Diabetic retinopathy;
SARC	trans	rs17221829	0.733	rs11018668	chr11:89356178	C/T	cg26394572	chr15:64126094	HERC1	-0.47	-6.38	-0.39	9.24e-10	Anxiety in major depressive disorder;
SARC	cis	rs2204008	0.754	rs11181643	chr12:38380553	G/A	cg13010199	chr12:38710504	ALG10B	0.78	10.77	0.58	3.24e-22	Bladder cancer;
SARC	cis	rs7412746	0.658	rs3843843	chr1:150918084	C/T	cg10589385	chr1:150898437	SETDB1	0.43	5.7	0.35	3.65e-8	Melanoma;
SARC	cis	rs17376456	0.825	rs34592268	chr5:93232751	G/C	cg25358565	chr5:93447407	FAM172A	1.28	14.23	0.68	1.75e-33	Diabetic retinopathy;
SARC	cis	rs644799	0.710	rs10831427	chr11:95508383	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.87	14.1	0.68	4.78e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9443189	0.570	rs276687	chr6:76429995	G/T	cg01950844	chr6:76311363	SENP6	-0.75	-6.87	-0.41	5.81e-11	Prostate cancer;
SARC	cis	rs2120243	0.539	rs1545596	chr3:157118526	C/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.39	4.96	0.31	1.37e-6	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs10463316	0.894	rs6891272	chr5:150762842	G/T	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.28	-0.33	2.89e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs2074585	0.647	rs2601188	chr15:90929563	A/G	cg22089800	chr15:90895588	ZNF774	-0.72	-9.23	-0.52	1.73e-17	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg22920501	chr2:26401640	FAM59B	0.61	8.19	0.47	1.71e-14	Gut microbiome composition (summer);
SARC	cis	rs6964587	0.869	rs10250014	chr7:91490208	T/C	cg17063962	chr7:91808500	NA	-0.89	-13.51	-0.66	4.14e-31	Breast cancer;
SARC	cis	rs17345786	0.954	rs17508319	chr3:101318903	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.49	5.46	0.34	1.21e-7	Colonoscopy-negative controls vs population controls;
SARC	cis	rs13161895	1.000	rs248320	chr5:179432096	G/A	cg04265672	chr5:179402240	RNF130	-0.53	-5.21	-0.32	4.1e-7	LDL cholesterol;
SARC	cis	rs7043114	0.507	rs10992340	chr9:95209693	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.49	-0.34	1.05e-7	Height;
SARC	cis	rs7904368	0.806	rs7900527	chr10:16857992	C/G	cg14835575	chr10:16859367	RSU1	0.86	9.16	0.51	2.77e-17	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs6456156	0.528	rs6936261	chr6:167469676	A/C	cg07741184	chr6:167504864	NA	0.35	6.87	0.41	5.87e-11	Primary biliary cholangitis;
SARC	cis	rs9467711	0.591	rs9295675	chr6:25918473	C/T	cg21479132	chr6:26055353	NA	0.75	4.73	0.3	3.85e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs4803468	0.967	rs892044	chr19:41903671	A/G	cg08477640	chr19:41863820	B9D2	0.48	6.27	0.38	1.77e-9	Height;
SARC	trans	rs11098499	0.863	rs59732491	chr4:120489588	G/C	cg25214090	chr10:38739885	LOC399744	0.57	7.25	0.43	6.27e-12	Corneal astigmatism;
SARC	cis	rs9814567	1.000	rs4955555	chr3:134286427	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.04	-0.42	2.19e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs7432375	0.641	rs835649	chr3:136671890	G/A	cg15507776	chr3:136538369	TMEM22	0.61	7.8	0.46	2.02e-13	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	cis	rs25645	0.744	rs66826786	chr17:38206092	T/C	cg17467752	chr17:38218738	THRA	-0.46	-5.92	-0.36	1.16e-8	Myeloid white cell count;
SARC	cis	rs6011002	0.504	rs76257944	chr20:62243219	A/G	cg23957118	chr20:62200850	PRIC285	0.87	6.3	0.38	1.47e-9	Dental caries;
SARC	cis	rs2204008	0.775	rs11182513	chr12:38560252	G/C	cg26384229	chr12:38710491	ALG10B	0.89	13.3	0.66	2.15e-30	Bladder cancer;
SARC	cis	rs2180341	1.000	rs7756336	chr6:127650299	T/C	cg17762328	chr6:126965162	NA	-0.45	-5.11	-0.32	6.78e-7	Breast cancer;
SARC	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.0	11.56	0.6	9.83e-25	Platelet count;
SARC	cis	rs7712401	0.623	rs538424	chr5:122228763	G/A	cg19412675	chr5:122181750	SNX24	0.41	5.23	0.32	3.8e-7	Mean platelet volume;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg08731084	chr12:44229880	TMEM117	-0.57	-7.24	-0.43	6.56e-12	Schizophrenia;
SARC	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg16405210	chr4:1374714	KIAA1530	-0.56	-6.86	-0.41	6.19e-11	Obesity-related traits;
SARC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.33	-5.01	-0.31	1.1e-6	Total body bone mineral density;
SARC	cis	rs62244186	0.593	rs9814298	chr3:44871899	T/A	cg15687855	chr3:44754131	ZNF502	-0.32	-4.8	-0.3	2.82e-6	Depressive symptoms;
SARC	cis	rs6963495	0.818	rs6961863	chr7:105180953	C/T	cg19920283	chr7:105172520	RINT1	0.69	6.11	0.37	4.2e-9	Bipolar disorder (body mass index interaction);
SARC	cis	rs3741151	0.773	rs57354084	chr11:73139376	A/T	cg17517138	chr11:73019481	ARHGEF17	0.91	6.77	0.41	1.04e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg22974920	chr21:40686053	BRWD1	-0.44	-4.99	-0.31	1.18e-6	Cognitive function;
SARC	cis	rs7568458	0.783	rs1561198	chr2:85809989	C/T	cg02493740	chr2:85810744	VAMP5	-0.35	-5.3	-0.33	2.67e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs4711336	0.664	rs4713663	chr6:33674197	G/A	cg15676125	chr6:33679581	C6orf125	0.5	6.05	0.37	5.87e-9	Height;
SARC	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg16482183	chr6:26056742	HIST1H1C	0.42	5.34	0.33	2.26e-7	Height;
SARC	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg03806693	chr22:41940476	POLR3H	0.9	12.49	0.63	9.65e-28	Vitiligo;
SARC	cis	rs72627509	1.000	rs57265257	chr4:57839280	A/T	cg26694713	chr4:57773883	REST	0.69	6.9	0.41	5.01e-11	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs6688613	0.765	rs56229522	chr1:166816108	T/A	cg07049167	chr1:166818506	POGK	0.42	4.71	0.3	4.18e-6	Refractive astigmatism;
SARC	cis	rs637571	0.522	rs566590	chr11:65754062	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.39	4.9	0.31	1.78e-6	Eosinophil percentage of white cells;
SARC	cis	rs9397240	0.789	rs12198973	chr6:155601928	C/G	cg07943832	chr6:155568918	TIAM2	-0.6	-5.77	-0.35	2.54e-8	Life satisfaction;
SARC	cis	rs11718455	0.920	rs34909426	chr3:44000472	G/A	cg08738300	chr3:44038990	NA	0.55	6.18	0.38	2.89e-9	Coronary artery disease;
SARC	cis	rs708547	0.647	rs1718878	chr4:57876955	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.57	7.18	0.43	9.05e-12	Response to bleomycin (chromatid breaks);
SARC	cis	rs7528684	0.546	rs2785666	chr1:157625122	G/A	cg18268488	chr1:157545234	FCRL4	0.26	4.8	0.3	2.88e-6	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;
SARC	cis	rs73198271	0.740	rs10092600	chr8:8649023	A/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-5.13	-0.32	6.21e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs7639513	0.767	rs13060705	chr3:12710016	C/A	cg23032965	chr3:12705835	RAF1	0.85	12.42	0.63	1.59e-27	Itch intensity from mosquito bite;
SARC	cis	rs2153535	0.580	rs6597327	chr6:8482157	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	8.24	0.48	1.24e-14	Motion sickness;
SARC	cis	rs3768617	0.510	rs12086466	chr1:183075778	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.69	-10.12	-0.55	3.51e-20	Fuchs's corneal dystrophy;
SARC	cis	rs7551222	0.721	rs4951402	chr1:204539122	C/T	cg20240347	chr1:204465584	NA	-0.33	-5.74	-0.35	2.89e-8	Schizophrenia;
SARC	cis	rs7582720	1.000	rs72936348	chr2:204064839	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	7.88	0.46	1.21e-13	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs3213787	1.000	rs6746564	chr2:45608409	G/A	cg02630207	chr2:45839653	SRBD1	-0.64	-4.89	-0.3	1.92e-6	Glaucoma;
SARC	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg11890956	chr21:40555474	PSMG1	1.17	19.29	0.78	3.44e-50	Cognitive function;
SARC	cis	rs3784262	0.669	rs12148281	chr15:58311061	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.33	-4.88	-0.3	1.97e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs611744	0.647	rs585077	chr8:109245497	C/T	cg21045802	chr8:109455806	TTC35	0.6	7.65	0.45	5.26e-13	Dupuytren's disease;
SARC	cis	rs6665290	0.904	rs10916075	chr1:227184074	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.08	-24.62	-0.85	8.84e-67	Myeloid white cell count;
SARC	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs10892173	0.566	rs10892174	chr11:117672565	A/C	cg07621104	chr11:117668040	DSCAML1	0.61	7.99	0.46	6.4e-14	Myopia;
SARC	cis	rs7937682	0.575	rs1940391	chr11:111776891	G/A	cg22437258	chr11:111473054	SIK2	-0.49	-5.75	-0.35	2.83e-8	Primary sclerosing cholangitis;
SARC	cis	rs3767633	0.925	rs2499855	chr1:161929761	C/T	cg09175582	chr1:161736000	ATF6	0.66	5.73	0.35	3.03e-8	IgG glycosylation;
SARC	cis	rs6088590	1.000	rs3787222	chr20:33333040	T/A	cg24642439	chr20:33292090	TP53INP2	0.89	12.73	0.64	1.56e-28	Coronary artery disease;
SARC	cis	rs12541335	0.579	rs59283125	chr8:22212311	G/A	cg02788857	chr8:22132959	PIWIL2	0.36	5.0	0.31	1.15e-6	Hypertriglyceridemia;
SARC	cis	rs5769765	0.773	rs9616391	chr22:50314573	C/T	cg03033257	chr22:50311977	ALG12;CRELD2	0.6	5.39	0.33	1.75e-7	Schizophrenia;
SARC	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg12373951	chr3:133503437	NA	0.37	5.3	0.33	2.73e-7	Iron status biomarkers;
SARC	trans	rs61931739	0.500	rs7489132	chr12:34539712	C/T	cg13010199	chr12:38710504	ALG10B	0.83	11.73	0.61	2.89e-25	Morning vs. evening chronotype;
SARC	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.75	11.01	0.59	5.53e-23	Menarche (age at onset);
SARC	cis	rs4742903	0.584	rs10217250	chr9:106911633	A/T	cg14250997	chr9:106856677	SMC2	0.47	6.14	0.37	3.51e-9	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.62	-6.69	-0.4	1.66e-10	Platelet count;
SARC	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg04317338	chr11:64019027	PLCB3	0.76	7.98	0.46	6.8e-14	Mean platelet volume;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg12548629	chr7:92463334	CDK6	0.52	6.39	0.39	9.05e-10	Breast cancer;
SARC	cis	rs7027203	0.576	rs7855940	chr9:96535966	C/G	cg14598338	chr9:96623480	NA	-0.36	-5.02	-0.31	1.03e-6	DNA methylation (variation);
SARC	trans	rs1814175	0.817	rs2866545	chr11:49630824	A/C	cg03929089	chr4:120376271	NA	-0.89	-14.2	-0.68	2.17e-33	Height;
SARC	cis	rs17665859	0.669	rs56187424	chr8:447194	A/G	cg17960703	chr8:356704	FBXO25	0.59	4.82	0.3	2.6e-6	Bilirubin levels;
SARC	cis	rs73198271	0.603	rs557892	chr8:8596048	A/C	cg06636001	chr8:8085503	FLJ10661	-0.46	-4.85	-0.3	2.3e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs10791097	0.653	rs11222362	chr11:130731425	T/C	cg12179176	chr11:130786555	SNX19	0.67	9.34	0.52	8.15e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	ch.9.98989607R	chr9:99949786	NA	-0.47	-6.28	-0.38	1.68e-9	Neuroticism;
SARC	cis	rs7927771	0.864	rs7937331	chr11:47430458	T/C	cg20307385	chr11:47447363	PSMC3	0.58	7.48	0.44	1.48e-12	Subjective well-being;
SARC	cis	rs6665290	0.904	rs2297415	chr1:227172903	G/A	cg14016676	chr1:227182615	CDC42BPA	0.34	5.02	0.31	1.02e-6	Myeloid white cell count;
SARC	cis	rs9381040	0.655	rs7738684	chr6:41038552	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-5.16	-0.32	5.23e-7	Alzheimer's disease (late onset);
SARC	cis	rs3820928	0.709	rs2894627	chr2:227910171	A/G	cg11843606	chr2:227700838	RHBDD1	-0.5	-5.83	-0.36	1.86e-8	Pulmonary function;
SARC	cis	rs818427	0.858	rs429427	chr5:112194693	C/T	cg07820702	chr5:112228657	REEP5	-0.46	-5.28	-0.33	2.9e-7	Total body bone mineral density;
SARC	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg11644478	chr21:40555479	PSMG1	-0.57	-6.96	-0.41	3.49e-11	Menarche (age at onset);
SARC	cis	rs2832191	0.655	rs2247110	chr21:30323888	G/A	cg08807101	chr21:30365312	RNF160	-0.91	-14.5	-0.69	2.15e-34	Dental caries;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg25746746	chr12:109531439	ALKBH2	0.49	6.44	0.39	6.7e-10	Chemerin levels;
SARC	cis	rs17125944	0.505	rs2295827	chr14:53174981	C/T	cg13660082	chr14:53194042	PSMC6	-0.76	-4.79	-0.3	2.95e-6	Alzheimer's disease (late onset);
SARC	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg18404041	chr3:52824283	ITIH1	-0.44	-6.66	-0.4	1.97e-10	Bipolar disorder;
SARC	cis	rs73198271	0.740	rs28521727	chr8:8647217	T/C	cg06636001	chr8:8085503	FLJ10661	-0.47	-5.0	-0.31	1.15e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs12142240	0.698	rs56284503	chr1:46847127	C/G	cg10495392	chr1:46806563	NSUN4	0.65	6.88	0.41	5.6e-11	Menopause (age at onset);
SARC	cis	rs6088590	0.687	rs13044899	chr20:33287078	G/A	cg08999081	chr20:33150536	PIGU	0.41	6.14	0.37	3.48e-9	Coronary artery disease;
SARC	trans	rs9929218	1.000	rs8056538	chr16:68802282	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.53	-6.51	-0.39	4.44e-10	Colorectal cancer;
SARC	trans	rs12310956	0.532	rs11052948	chr12:33981973	T/C	cg26384229	chr12:38710491	ALG10B	0.85	12.42	0.63	1.57e-27	Morning vs. evening chronotype;
SARC	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg15448220	chr1:150897856	SETDB1	0.47	6.25	0.38	1.94e-9	Tonsillectomy;
SARC	cis	rs6582630	0.555	rs8189479	chr12:38308240	C/T	cg26384229	chr12:38710491	ALG10B	-0.6	-7.47	-0.44	1.6e-12	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs796364	0.906	rs6740981	chr2:201060216	T/C	cg23649088	chr2:200775458	C2orf69	0.66	7.33	0.43	3.87e-12	Schizophrenia;
SARC	cis	rs2153535	0.601	rs2143352	chr6:8530248	G/C	cg21535247	chr6:8435926	SLC35B3	0.52	6.53	0.39	4.11e-10	Motion sickness;
SARC	cis	rs35955747	0.778	rs9609263	chr22:31745274	G/T	cg02404636	chr22:31891804	SFI1	-0.41	-5.1	-0.32	6.99e-7	Neutrophil count;Sum basophil neutrophil counts;
SARC	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg22974920	chr21:40686053	BRWD1	-0.43	-4.77	-0.3	3.3e-6	Cognitive function;
SARC	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	13.06	0.65	1.26e-29	Chronic sinus infection;
SARC	cis	rs9527	0.590	rs7912517	chr10:104905529	G/A	cg04362960	chr10:104952993	NT5C2	0.42	4.93	0.31	1.56e-6	Arsenic metabolism;
SARC	cis	rs2573652	0.723	rs2727201	chr15:100515311	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.41	-5.15	-0.32	5.6e-7	Height;
SARC	cis	rs9788721	0.836	rs55983731	chr15:78735269	C/T	cg06917634	chr15:78832804	PSMA4	-0.54	-5.98	-0.36	8.51e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs11630290	0.592	rs12594446	chr15:64156674	G/T	cg12036633	chr15:63758958	NA	0.48	4.97	0.31	1.27e-6	Iris characteristics;
SARC	cis	rs9303280	0.806	rs62067034	chr17:38063738	C/T	cg20243544	chr17:37824526	PNMT	0.45	6.07	0.37	5.01e-9	Self-reported allergy;
SARC	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg16186051	chr20:40247245	CHD6	-0.49	-6.29	-0.38	1.58e-9	Thyroid cancer;
SARC	trans	rs7937682	0.924	rs4630327	chr11:111539327	C/T	cg18187862	chr3:45730750	SACM1L	-0.51	-6.52	-0.39	4.37e-10	Primary sclerosing cholangitis;
SARC	cis	rs9325144	0.560	rs7980635	chr12:38668355	G/T	cg13010199	chr12:38710504	ALG10B	-0.56	-6.95	-0.41	3.58e-11	Morning vs. evening chronotype;
SARC	cis	rs1843834	0.539	rs2047135	chr2:225427302	G/C	cg12698349	chr2:225449008	CUL3	0.68	8.93	0.51	1.28e-16	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs2486288	0.656	rs6493144	chr15:45573489	C/G	cg19305227	chr15:45544335	SLC28A2	-0.3	-5.56	-0.34	7.46e-8	Glomerular filtration rate;
SARC	cis	rs6500602	0.702	rs4786493	chr16:4500122	C/T	cg08645402	chr16:4508243	NA	0.45	5.88	0.36	1.43e-8	Schizophrenia;
SARC	cis	rs1865760	1.000	rs2071299	chr6:25914801	G/A	cg16482183	chr6:26056742	HIST1H1C	0.5	6.15	0.37	3.38e-9	Height;
SARC	cis	rs881375	0.715	rs10760119	chr9:123646060	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	7.03	0.42	2.25e-11	Rheumatoid arthritis;
SARC	cis	rs7130144	0.541	rs56097840	chr11:130462749	C/T	cg26307797	chr11:130446613	NA	-0.67	-5.51	-0.34	9.61e-8	Urate levels in lean individuals;
SARC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg24846343	chr22:24311635	DDTL	0.52	7.63	0.45	6.16e-13	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs11792861	0.926	rs10512391	chr9:111809530	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.66	7.73	0.45	3.18e-13	Menarche (age at onset);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg24529996	chr7:55640396	VOPP1	0.51	6.29	0.38	1.56e-9	Breast cancer;
SARC	cis	rs13392177	0.647	rs6718220	chr2:219066518	T/C	cg00012203	chr2:219082015	ARPC2	-0.69	-9.53	-0.53	2.15e-18	Pyoderma gangrenosum in inflammatory bowel disease;
SARC	cis	rs7223966	1.000	rs6504167	chr17:61693194	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	6.55	0.39	3.58e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1843834	0.539	rs1494109	chr2:225441833	G/A	cg22455342	chr2:225449267	CUL3	0.69	8.68	0.49	6.82e-16	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs6735179	0.647	rs749089	chr2:1763213	T/C	cg08534653	chr2:1747700	PXDN	0.38	4.8	0.3	2.79e-6	Response to antipsychotic treatment;
SARC	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg13939156	chr17:80058883	NA	0.39	5.96	0.36	9.34e-9	Life satisfaction;
SARC	cis	rs9815354	0.812	rs73073361	chr3:41842926	C/G	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg06819704	chr5:159707559	CCNJL	-0.45	-6.49	-0.39	5.02e-10	Height;
SARC	cis	rs11608355	0.515	rs61941592	chr12:109930497	G/A	cg05360138	chr12:110035743	NA	0.92	9.38	0.52	5.97e-18	Neuroticism;
SARC	cis	rs4319547	0.695	rs10734915	chr12:122873408	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.53	-6.12	-0.37	3.88e-9	Body mass index;
SARC	cis	rs1348850	0.567	rs3770011	chr2:178537890	C/T	cg23306229	chr2:178417860	TTC30B	0.43	4.98	0.31	1.22e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg17870792	chr1:82266841	LPHN2	-0.76	-6.35	-0.38	1.14e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs35213789	1.000	rs17353815	chr7:69266221	A/G	cg10619644	chr7:69149951	AUTS2	0.45	5.68	0.35	3.99e-8	Childhood ear infection;
SARC	cis	rs986417	0.748	rs4901986	chr14:60969333	T/C	cg27398547	chr14:60952738	C14orf39	0.87	8.58	0.49	1.33e-15	Gut microbiota (bacterial taxa);
SARC	cis	rs9354308	0.579	rs1938091	chr6:66517697	A/T	cg07460842	chr6:66804631	NA	-0.4	-4.78	-0.3	3.04e-6	Metabolite levels;
SARC	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg16606324	chr3:10149918	C3orf24	0.46	4.8	0.3	2.79e-6	Alzheimer's disease;
SARC	trans	rs61931739	0.571	rs4001689	chr12:34243271	C/T	cg26384229	chr12:38710491	ALG10B	0.82	12.02	0.62	3.34e-26	Morning vs. evening chronotype;
SARC	cis	rs13191362	1.000	rs35575481	chr6:163007746	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.49	0.34	1.04e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs34779708	0.966	rs35079558	chr10:35479886	A/G	cg03585969	chr10:35415529	CREM	0.4	4.94	0.31	1.47e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs6991838	0.702	rs13274205	chr8:66620359	G/A	cg13398993	chr8:66546079	ARMC1	0.39	5.05	0.31	9.07e-7	Intelligence (multi-trait analysis);
SARC	trans	rs1493916	0.870	rs7239173	chr18:31395534	A/T	cg27147174	chr7:100797783	AP1S1	-0.57	-7.33	-0.43	3.87e-12	Life satisfaction;
SARC	cis	rs2120019	1.000	rs12910644	chr15:75358388	A/G	cg00629941	chr15:75287862	SCAMP5	-0.64	-7.52	-0.44	1.18e-12	Blood trace element (Zn levels);
SARC	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg18225595	chr11:63971243	STIP1	0.43	5.19	0.32	4.65e-7	Mean platelet volume;
SARC	trans	rs2257129	1.000	rs10886863	chr10:122929493	C/T	cg23424357	chr10:88779941	FAM25A	0.76	6.26	0.38	1.79e-9	Coronary artery disease;Body mass index;
SARC	cis	rs1008375	0.966	rs4235389	chr4:17696280	A/G	cg27347728	chr4:17578864	LAP3	0.46	5.75	0.35	2.78e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7582180	0.627	rs4407265	chr2:101005846	C/G	cg14675211	chr2:100938903	LONRF2	0.54	7.88	0.46	1.21e-13	Intelligence (multi-trait analysis);
SARC	cis	rs1538970	0.924	rs2088100	chr1:45877575	C/T	cg05343316	chr1:45956843	TESK2	0.72	8.62	0.49	1.01e-15	Platelet count;
SARC	cis	rs2120019	1.000	rs67544533	chr15:75361539	A/G	cg09165964	chr15:75287851	SCAMP5	-0.91	-13.51	-0.66	4.31e-31	Blood trace element (Zn levels);
SARC	cis	rs751728	0.638	rs4713686	chr6:33787506	C/T	cg15252951	chr6:33757062	LEMD2	0.43	4.73	0.3	3.88e-6	Crohn's disease;
SARC	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg22800045	chr5:56110881	MAP3K1	0.65	6.86	0.41	6.06e-11	Initial pursuit acceleration;
SARC	cis	rs72717009	0.825	rs12746613	chr1:161467042	A/G	cg23840854	chr1:161414152	NA	0.52	4.95	0.31	1.41e-6	Rheumatoid arthritis;
SARC	cis	rs55692411	0.517	rs62262106	chr3:49991427	A/G	cg19755318	chr3:50243323	SLC38A3	-0.3	-4.73	-0.3	3.82e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg25703541	chr22:24373054	LOC391322	-0.8	-10.31	-0.56	9.12e-21	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs4642101	0.680	rs6442330	chr3:12820501	A/G	cg05775895	chr3:12838266	CAND2	0.71	10.56	0.57	1.52e-21	QRS complex (12-leadsum);
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg13443385	chr2:192245185	MYO1B	0.53	7.62	0.45	6.49e-13	Tetralogy of Fallot;
SARC	cis	rs9768139	0.566	rs729099	chr7:158114152	C/T	cg25566285	chr7:158114605	PTPRN2	0.29	5.0	0.31	1.15e-6	Calcium levels;
SARC	cis	rs72634258	0.945	rs12730860	chr1:8132462	T/C	cg00042356	chr1:8021962	PARK7	0.92	8.46	0.48	2.96e-15	Inflammatory bowel disease;
SARC	cis	rs17376456	0.569	rs12653528	chr5:93212833	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.49	-4.95	-0.31	1.4e-6	Diabetic retinopathy;
SARC	cis	rs73198271	0.562	rs17154743	chr8:8650787	A/G	cg01851573	chr8:8652454	MFHAS1	0.41	5.11	0.32	6.57e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs6459788	0.934	rs10237947	chr7:157258109	G/T	cg03453431	chr7:157225567	NA	0.39	5.59	0.34	6.31e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg21724239	chr8:58056113	NA	0.6	6.27	0.38	1.72e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7760949	0.963	rs9382681	chr6:13915051	A/G	cg27413430	chr6:13925136	RNF182	0.41	5.11	0.32	6.56e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs926392	0.799	rs742274	chr20:37680944	T/C	cg16355469	chr20:37678765	NA	0.57	7.36	0.43	3.16e-12	Dialysis-related mortality;
SARC	cis	rs9329289	0.510	rs1155447	chr10:2553240	C/T	cg15501526	chr10:2543763	NA	0.37	5.61	0.34	5.77e-8	Age-related hearing impairment;
SARC	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg04944784	chr2:26401820	FAM59B	-0.48	-5.91	-0.36	1.2e-8	Gut microbiome composition (summer);
SARC	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg20607798	chr8:58055168	NA	0.6	5.33	0.33	2.29e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.09	-0.42	1.54e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs965469	1.000	rs6051779	chr20:3333449	A/G	cg25506879	chr20:3388711	C20orf194	-0.51	-5.21	-0.32	4.1e-7	IFN-related cytopenia;
SARC	cis	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg12463550	chr7:65579703	CRCP	0.7	5.34	0.33	2.23e-7	Diabetic kidney disease;
SARC	cis	rs12421382	0.659	rs1371332	chr11:109381687	A/T	cg27471124	chr11:109292789	C11orf87	0.38	5.21	0.32	4.25e-7	Schizophrenia;
SARC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg22903471	chr2:27725779	GCKR	-0.49	-7.42	-0.44	2.21e-12	Total body bone mineral density;
SARC	cis	rs4803455	0.565	rs1025497	chr19:41871254	A/G	cg08477640	chr19:41863820	B9D2	0.61	8.39	0.48	4.63e-15	Migraine;Coronary artery disease;
SARC	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs897984	0.644	rs73524556	chr16:30823162	G/A	cg02466173	chr16:30829666	NA	-0.49	-6.94	-0.41	3.86e-11	Dementia with Lewy bodies;
SARC	cis	rs6685188	0.925	rs12752037	chr1:205661614	A/C	cg26354017	chr1:205819088	PM20D1	-0.47	-5.47	-0.34	1.18e-7	White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs10463316	0.823	rs7700342	chr5:150776323	C/T	cg03212797	chr5:150827313	SLC36A1	-0.51	-6.1	-0.37	4.44e-9	Metabolite levels (Pyroglutamine);
SARC	cis	rs9486715	1.000	rs2273621	chr6:97058553	A/G	cg06623918	chr6:96969491	KIAA0776	-0.87	-12.01	-0.62	3.38e-26	Headache;
SARC	cis	rs9399135	0.660	rs4646868	chr6:135271946	A/G	cg24558204	chr6:135376177	HBS1L	0.47	6.16	0.37	3.13e-9	Red blood cell count;
SARC	cis	rs9910055	0.529	rs183462	chr17:42183376	G/C	cg19774624	chr17:42201019	HDAC5	0.55	6.69	0.4	1.63e-10	Total body bone mineral density;
SARC	cis	rs7681440	0.874	rs1442151	chr4:90775491	T/A	cg06632027	chr4:90757378	SNCA	0.4	5.68	0.35	3.91e-8	Dementia with Lewy bodies;
SARC	cis	rs2153535	0.580	rs2225765	chr6:8481785	A/G	cg21535247	chr6:8435926	SLC35B3	0.56	7.03	0.42	2.23e-11	Motion sickness;
SARC	cis	rs7020830	0.894	rs28766572	chr9:37093872	G/T	cg14294708	chr9:37120828	ZCCHC7	1.14	21.53	0.82	2.5e-57	Schizophrenia;
SARC	cis	rs7264396	0.690	rs2425178	chr20:34446395	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.47	-0.44	1.58e-12	Total cholesterol levels;
SARC	cis	rs2070488	0.804	rs7646429	chr3:38467713	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	12.58	0.64	4.94e-28	Electrocardiographic conduction measures;
SARC	cis	rs11690935	0.610	rs59844139	chr2:172731983	C/A	cg13550731	chr2:172543902	DYNC1I2	0.63	8.63	0.49	9.62e-16	Schizophrenia;
SARC	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	cis	rs13314892	0.764	rs79658882	chr3:69881186	T/A	cg17445875	chr3:69859618	MITF	-0.49	-5.13	-0.32	6.2e-7	QRS complex (12-leadsum);
SARC	cis	rs514024	0.729	rs7852204	chr9:130373596	T/C	cg13643465	chr9:130375613	STXBP1	0.45	5.6	0.34	6.08e-8	Eating disorders (purging via substances);
SARC	cis	rs10870270	1.000	rs7898755	chr10:133777122	G/A	cg26149184	chr10:133730230	NA	0.45	4.86	0.3	2.17e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs2777491	0.574	rs11635906	chr15:41779260	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.11	-16.73	-0.74	8.31e-42	Ulcerative colitis;
SARC	cis	rs9467603	1.000	rs9467609	chr6:25809751	A/G	cg21479132	chr6:26055353	NA	0.77	5.1	0.32	7.06e-7	Intelligence (multi-trait analysis);
SARC	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg26335602	chr6:28129616	ZNF389	0.53	5.95	0.36	9.59e-9	Depression;
SARC	cis	rs16976116	0.901	rs9920220	chr15:55503982	T/C	cg17854078	chr15:55489399	RSL24D1	0.65	6.33	0.38	1.23e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9814567	0.752	rs13064209	chr3:134335993	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.51	6.53	0.39	4e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg00450029	chr8:599525	NA	0.59	4.84	0.3	2.35e-6	IgG glycosylation;
SARC	cis	rs13314892	0.770	rs62252225	chr3:69884055	C/T	cg17445875	chr3:69859618	MITF	-0.5	-5.23	-0.32	3.75e-7	QRS complex (12-leadsum);
SARC	cis	rs701145	0.556	rs355763	chr3:154012881	C/T	cg16511985	chr3:153974050	SGEF	0.41	4.78	0.3	3.07e-6	Coronary artery disease;
SARC	cis	rs910187	0.605	rs6124961	chr20:45804467	G/C	cg27589058	chr20:45804311	EYA2	-0.33	-5.3	-0.33	2.69e-7	Migraine;
SARC	cis	rs2832077	0.506	rs2832081	chr21:30152992	A/C	cg03476357	chr21:30257390	N6AMT1	0.47	5.04	0.31	9.25e-7	Cognitive test performance;
SARC	cis	rs7769051	1.000	rs7765224	chr6:133101624	T/C	cg22852734	chr6:133119734	C6orf192	1.13	11.55	0.6	1.1e-24	Type 2 diabetes nephropathy;
SARC	cis	rs7113850	0.541	rs7928230	chr11:24220604	A/G	ch.11.24196551F	chr11:24239977	NA	0.74	5.75	0.35	2.84e-8	Bone fracture in osteoporosis;
SARC	cis	rs11874712	1.000	rs1800640	chr18:43671400	A/G	cg25174615	chr18:43684699	ATP5A1;HAUS1	0.41	4.81	0.3	2.75e-6	Migraine - clinic-based;
SARC	cis	rs13191362	1.000	rs4489133	chr6:163137793	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.43	5.3	0.33	2.71e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs11792861	0.926	rs7046725	chr9:111882729	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.69	8.05	0.47	4.34e-14	Menarche (age at onset);
SARC	cis	rs9916302	0.706	rs7503081	chr17:37482673	A/G	cg15445000	chr17:37608096	MED1	-0.47	-5.08	-0.32	7.63e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs9914988	0.613	rs34120713	chr17:27272875	C/T	cg10538030	chr17:27276405	PHF12	-0.58	-4.74	-0.3	3.65e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs9916302	0.904	rs2303316	chr17:37704217	A/G	cg20243544	chr17:37824526	PNMT	0.57	6.76	0.41	1.08e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg18252515	chr7:66147081	NA	1.35	12.11	0.62	1.7e-26	Diabetic kidney disease;
SARC	cis	rs9790314	0.875	rs55688744	chr3:160944222	G/A	cg04691961	chr3:161091175	C3orf57	-0.64	-8.7	-0.5	6.2e-16	Morning vs. evening chronotype;
SARC	cis	rs2153535	0.580	rs9406172	chr6:8515464	T/A	cg07606381	chr6:8435919	SLC35B3	0.77	10.87	0.58	1.55e-22	Motion sickness;
SARC	cis	rs7029536	0.515	rs1138739	chr9:130164993	C/T	cg09445097	chr9:130186736	ZNF79	0.58	5.37	0.33	1.88e-7	Metabolite levels (HVA);
SARC	cis	rs7551222	0.752	rs12133735	chr1:204556836	G/T	cg20240347	chr1:204465584	NA	-0.28	-5.09	-0.32	7.36e-7	Schizophrenia;
SARC	cis	rs6976053	0.518	rs144173	chr7:100416250	A/G	cg03098644	chr7:100410630	EPHB4	-0.52	-7.17	-0.43	9.81e-12	Plasminogen activator inhibitor type 1 levels (PAI-1);
SARC	cis	rs17600642	0.724	rs72814518	chr10:72440845	C/T	cg19779893	chr10:72451501	ADAMTS14	-0.35	-5.2	-0.32	4.31e-7	Bipolar disorder;
SARC	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.7	6.75	0.4	1.17e-10	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg18876405	chr7:65276391	NA	0.49	6.04	0.37	6e-9	Aortic root size;
SARC	cis	rs9457247	0.967	rs424185	chr6:167410907	C/T	cg23791538	chr6:167370224	RNASET2	-0.6	-8.22	-0.47	1.39e-14	Crohn's disease;
SARC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg21782813	chr7:2030301	MAD1L1	0.43	6.74	0.4	1.22e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs7246657	0.943	rs10405325	chr19:37883477	G/C	cg23950597	chr19:37808831	NA	-0.62	-6.05	-0.37	5.66e-9	Coronary artery calcification;
SARC	cis	rs9790314	1.000	rs336579	chr3:161086610	G/A	cg03342759	chr3:160939853	NMD3	-0.55	-6.97	-0.42	3.23e-11	Morning vs. evening chronotype;
SARC	cis	rs5167	0.566	rs35080293	chr19:45496624	T/G	cg09555818	chr19:45449301	APOC2	0.38	5.04	0.31	9.47e-7	Blood protein levels;
SARC	cis	rs11249608	0.789	rs903989	chr5:178434434	C/T	cg01312482	chr5:178451176	ZNF879	-0.35	-4.77	-0.3	3.25e-6	Pubertal anthropometrics;
SARC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg09373136	chr17:61933544	TCAM1	-0.45	-6.13	-0.37	3.66e-9	Prudent dietary pattern;
SARC	cis	rs910316	0.819	rs175461	chr14:75581816	G/A	cg11812906	chr14:75593930	NEK9	-0.81	-11.49	-0.6	1.71e-24	Height;
SARC	cis	rs561341	0.941	rs4795664	chr17:30233467	C/T	cg13647721	chr17:30228624	UTP6	0.65	5.37	0.33	1.89e-7	Hip circumference adjusted for BMI;
SARC	cis	rs9914988	0.943	rs2046759	chr17:27138817	T/C	cg20469991	chr17:27169893	C17orf63	-0.52	-5.39	-0.33	1.74e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg02576503	chr19:17581430	SLC27A1	0.5	6.24	0.38	2e-9	Lung adenocarcinoma;
SARC	cis	rs2916247	0.954	rs28625919	chr8:93030325	T/A	cg10183463	chr8:93005414	RUNX1T1	-0.58	-6.05	-0.37	5.83e-9	Intelligence (multi-trait analysis);
SARC	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg19223190	chr17:80058835	NA	0.45	6.35	0.38	1.13e-9	Life satisfaction;
SARC	trans	rs61931739	0.534	rs11052959	chr12:33997095	T/C	cg26384229	chr12:38710491	ALG10B	0.86	12.43	0.63	1.52e-27	Morning vs. evening chronotype;
SARC	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg08045932	chr20:61659980	NA	0.5	6.93	0.41	4.09e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs372883	0.648	rs382732	chr21:30719010	A/G	cg08807101	chr21:30365312	RNF160	0.54	6.56	0.4	3.35e-10	Pancreatic cancer;
SARC	cis	rs3020736	0.500	rs28791586	chr22:42500483	A/G	cg15557168	chr22:42548783	NA	0.35	4.8	0.3	2.85e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1448094	0.556	rs11614513	chr12:86167756	G/C	cg02569458	chr12:86230093	RASSF9	0.37	5.03	0.31	9.77e-7	Major depressive disorder;
SARC	cis	rs9399135	0.967	rs3756799	chr6:135341011	A/G	cg24558204	chr6:135376177	HBS1L	0.43	5.73	0.35	3.04e-8	Red blood cell count;
SARC	cis	rs9296092	0.560	rs9469502	chr6:33526648	G/A	cg13560919	chr6:33536144	NA	-0.52	-6.41	-0.39	8.07e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs898097	0.783	rs11650335	chr17:80835111	A/G	cg15664640	chr17:80829946	TBCD	-0.55	-8.3	-0.48	8.6e-15	Breast cancer;
SARC	cis	rs7762018	0.770	rs3823466	chr6:170189926	C/T	cg15038512	chr6:170123185	PHF10	0.53	5.03	0.31	9.83e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs3087591	0.708	rs2854305	chr17:29647003	G/A	cg24425628	chr17:29625626	OMG;NF1	0.42	5.36	0.33	1.98e-7	Hip circumference;
SARC	cis	rs4595586	0.525	rs7136425	chr12:39376005	C/A	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	cis	rs12545912	0.821	rs10112600	chr8:9461534	T/A	cg21625330	chr8:9911636	MSRA	-0.53	-5.06	-0.31	8.7e-7	Multiple myeloma (hyperdiploidy);
SARC	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg05896524	chr21:47604654	C21orf56	0.53	6.53	0.39	4.07e-10	Testicular germ cell tumor;
SARC	cis	rs9398803	0.865	rs1120786	chr6:126808637	T/G	cg20229609	chr6:126660872	C6orf173	0.4	5.71	0.35	3.42e-8	Male-pattern baldness;
SARC	cis	rs2070997	0.667	rs7851946	chr9:133719256	A/T	cg11464064	chr9:133710261	ABL1	-0.57	-5.72	-0.35	3.26e-8	Response to amphetamines;
SARC	cis	rs1538970	0.504	rs3790585	chr1:46023356	A/T	cg05343316	chr1:45956843	TESK2	0.6	4.97	0.31	1.29e-6	Platelet count;
SARC	cis	rs2836633	0.929	rs58120977	chr21:40037346	C/T	cg12884169	chr21:40033163	ERG	0.49	9.02	0.51	7.18e-17	Coronary artery disease;
SARC	cis	rs3126085	0.935	rs7533529	chr1:152176871	T/C	cg09127314	chr1:152161683	NA	0.42	4.76	0.3	3.44e-6	Atopic dermatitis;
SARC	cis	rs10911232	0.507	rs10752890	chr1:183021910	A/G	cg13390022	chr1:182993471	LAMC1	0.36	5.42	0.33	1.46e-7	Hypertriglyceridemia;
SARC	cis	rs9303401	0.625	rs10515159	chr17:56802693	G/C	cg25039879	chr17:56429692	SUPT4H1	0.68	6.4	0.39	8.57e-10	Cognitive test performance;
SARC	cis	rs7000551	0.751	rs1482337	chr8:22395509	A/G	cg12081754	chr8:22256438	SLC39A14	-0.5	-6.74	-0.4	1.22e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg13126279	chr21:47581558	C21orf56	-0.41	-4.94	-0.31	1.46e-6	Testicular germ cell tumor;
SARC	cis	rs6582630	0.502	rs11182760	chr12:38606273	A/T	cg26384229	chr12:38710491	ALG10B	0.89	13.47	0.66	5.74e-31	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs911555	0.755	rs10144051	chr14:103885931	A/C	cg12935359	chr14:103987150	CKB	-0.38	-5.24	-0.32	3.57e-7	Intelligence (multi-trait analysis);
SARC	cis	rs4853036	1.000	rs12614581	chr2:70079400	C/G	cg02498382	chr2:70120550	SNRNP27	-0.39	-5.23	-0.32	3.72e-7	Colorectal or endometrial cancer;
SARC	cis	rs10484885	0.824	rs72919981	chr6:90528977	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.6	-5.15	-0.32	5.58e-7	QRS interval (sulfonylurea treatment interaction);
SARC	cis	rs7223966	1.000	rs2013288	chr17:61785904	C/T	cg00588841	chr17:61851480	DDX42;CCDC47	-0.64	-7.21	-0.43	7.65e-12	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1153858	1.000	rs1890565	chr15:45663299	T/C	cg26924012	chr15:45694286	SPATA5L1	0.79	11.27	0.59	8.66e-24	Homoarginine levels;
SARC	cis	rs9810259	0.522	rs9875338	chr3:12296469	A/G	cg04748988	chr3:12329223	PPARG	0.43	5.86	0.36	1.58e-8	Platelet count;
SARC	cis	rs3099143	1.000	rs3099134	chr15:77133168	T/G	cg21673338	chr15:77095150	SCAPER	-0.76	-6.25	-0.38	1.93e-9	Recalcitrant atopic dermatitis;
SARC	cis	rs8005677	0.828	rs12589539	chr14:23396680	A/G	cg01529538	chr14:23388837	RBM23	0.42	4.88	0.3	1.96e-6	Cognitive ability (multi-trait analysis);
SARC	cis	rs2120243	0.539	rs35218020	chr3:157115416	G/A	cg01018701	chr3:157155998	VEPH1;PTX3	0.39	4.96	0.31	1.34e-6	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.5	-5.96	-0.36	9.45e-9	Renal function-related traits (BUN);
SARC	cis	rs1983891	0.779	rs4714475	chr6:41509901	G/T	cg15051332	chr6:41514432	FOXP4	0.48	4.75	0.3	3.51e-6	Prostate cancer;
SARC	cis	rs9549367	1.000	rs9549367	chr13:113911532	C/G	cg18105134	chr13:113819100	PROZ	-0.43	-6.33	-0.38	1.27e-9	Platelet distribution width;
SARC	trans	rs208520	0.802	rs851600	chr6:66893754	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-12.56	-0.64	5.74e-28	Exhaled nitric oxide output;
SARC	cis	rs11122272	0.735	rs2808596	chr1:231530723	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.94	-0.55	1.27e-19	Hemoglobin concentration;
SARC	cis	rs1062177	1.000	rs2915878	chr5:151149662	A/G	cg00977110	chr5:151150581	G3BP1	0.63	6.39	0.39	8.91e-10	Preschool internalizing problems;
SARC	cis	rs1729951	0.575	rs747842	chr3:136703121	A/C	cg15507776	chr3:136538369	TMEM22	0.49	5.34	0.33	2.18e-7	Neuroticism;
SARC	cis	rs2908197	0.713	rs2961038	chr7:75952070	G/C	cg22830091	chr7:75961684	YWHAG	-0.35	-5.22	-0.32	3.93e-7	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs965469	0.948	rs2236094	chr20:3260368	C/G	cg25506879	chr20:3388711	C20orf194	0.47	4.78	0.3	3.05e-6	IFN-related cytopenia;
SARC	cis	rs763121	0.853	rs2072795	chr22:39064209	A/G	cg14440974	chr22:39074834	NA	0.34	4.95	0.31	1.41e-6	Menopause (age at onset);
SARC	cis	rs12545109	0.800	rs1561224	chr8:57419922	T/C	cg19413350	chr8:57351067	NA	-0.43	-5.4	-0.33	1.67e-7	Obesity-related traits;
SARC	cis	rs523522	0.962	rs11065154	chr12:120971417	T/C	cg12219531	chr12:120966889	COQ5	0.84	11.3	0.59	6.87e-24	High light scatter reticulocyte count;
SARC	cis	rs11122272	0.766	rs1435166	chr1:231502310	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-9.63	-0.53	1.09e-18	Hemoglobin concentration;
SARC	cis	rs9896052	0.591	rs7212620	chr17:73461930	A/T	cg04121983	chr17:73511085	CASKIN2	0.4	5.28	0.33	2.97e-7	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs3857067	0.806	rs6858342	chr4:95112318	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.05	-0.31	8.98e-7	QT interval;
SARC	cis	rs79149102	0.649	rs75725543	chr15:75097737	T/C	cg09165964	chr15:75287851	SCAMP5	-0.88	-5.05	-0.31	9.08e-7	Lung cancer;
SARC	trans	rs9532669	0.963	rs9532662	chr13:41500351	A/C	cg24738475	chr1:89149492	PKN2	0.52	6.73	0.4	1.28e-10	Cervical cancer;
SARC	cis	rs1408799	0.704	rs10960781	chr9:12762374	C/T	cg05274944	chr9:12693694	TYRP1	0.34	4.97	0.31	1.27e-6	Eye color;Blue vs. green eyes;
SARC	cis	rs7312933	0.501	rs7296357	chr12:42729891	T/G	cg19980929	chr12:42632907	YAF2	-0.45	-6.68	-0.4	1.75e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs9807989	0.765	rs6704565	chr2:102967431	G/A	cg09003973	chr2:102972529	NA	0.41	5.6	0.34	6.11e-8	Asthma;
SARC	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg18357526	chr6:26021779	HIST1H4A	0.9	12.56	0.64	5.71e-28	Intelligence (multi-trait analysis);
SARC	trans	rs8073060	0.586	rs4796101	chr17:33998593	C/T	cg19694781	chr19:47549865	TMEM160	-0.7	-6.93	-0.41	4e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs2439831	0.850	rs28509275	chr15:44098105	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	7.26	0.43	5.67e-12	Lung cancer in ever smokers;
SARC	cis	rs6546550	0.901	rs13028508	chr2:70118427	A/T	cg02498382	chr2:70120550	SNRNP27	0.33	5.17	0.32	5.14e-7	Prevalent atrial fibrillation;
SARC	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg12373951	chr3:133503437	NA	0.39	5.66	0.35	4.34e-8	Iron status biomarkers;
SARC	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg06634786	chr22:41940651	POLR3H	-0.48	-5.59	-0.34	6.47e-8	Vitiligo;
SARC	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg24060327	chr5:131705240	SLC22A5	0.75	8.92	0.5	1.35e-16	Breast cancer;
SARC	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg10435706	chr6:150039699	LATS1	0.36	4.81	0.3	2.7e-6	Lung cancer;
SARC	cis	rs668210	0.793	rs534201	chr11:65776728	A/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.75	7.86	0.46	1.44e-13	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9303401	0.614	rs3887355	chr17:56538639	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.05	11.45	0.6	2.3e-24	Cognitive test performance;
SARC	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg27541892	chr1:1571801	CDK11B	-0.43	-6.05	-0.37	5.78e-9	Body mass index;
SARC	cis	rs763121	0.853	rs5757231	chr22:39071658	C/T	cg06022373	chr22:39101656	GTPBP1	-0.87	-10.58	-0.57	1.29e-21	Menopause (age at onset);
SARC	cis	rs644799	1.000	rs473155	chr11:95596873	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.9	13.41	0.66	9.2e-31	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs76917914	1.000	rs4743150	chr9:100740124	C/T	cg03040243	chr9:100819229	NANS	0.59	6.22	0.38	2.34e-9	Immature fraction of reticulocytes;
SARC	cis	rs7647973	0.626	rs9824435	chr3:49674343	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.56	-5.41	-0.33	1.57e-7	Menarche (age at onset);
SARC	cis	rs208520	0.661	rs851466	chr6:66840476	A/G	cg07460842	chr6:66804631	NA	-1.04	-14.38	-0.69	5.61e-34	Exhaled nitric oxide output;
SARC	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.74	-8.08	-0.47	3.46e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs12586317	0.547	rs3759548	chr14:35450333	C/T	cg26967526	chr14:35346199	BAZ1A	-0.55	-5.43	-0.34	1.41e-7	Psoriasis;
SARC	cis	rs611744	0.967	rs702805	chr8:109235929	G/A	cg21045802	chr8:109455806	TTC35	0.46	5.43	0.34	1.38e-7	Dupuytren's disease;
SARC	cis	rs992157	0.710	rs12694432	chr2:219082330	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.67	9.38	0.52	5.91e-18	Colorectal cancer;
SARC	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.51	4.75	0.3	3.49e-6	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg13114125	chr14:105738426	BRF1	-0.79	-11.46	-0.6	2.15e-24	Mean platelet volume;Platelet distribution width;
SARC	cis	rs7927592	0.956	rs7102273	chr11:68385579	T/C	cg20283391	chr11:68216788	NA	-0.42	-4.78	-0.3	3.11e-6	Total body bone mineral density;
SARC	cis	rs7647973	0.626	rs11709734	chr3:49745235	G/A	cg07636037	chr3:49044803	WDR6	0.59	6.09	0.37	4.71e-9	Menarche (age at onset);
SARC	cis	rs10504229	0.593	rs58647001	chr8:58025132	G/A	cg08280861	chr8:58055591	NA	0.57	5.35	0.33	2.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs3796352	1.000	rs13072457	chr3:53102389	G/A	cg07884673	chr3:53033167	SFMBT1	0.79	5.04	0.31	9.33e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs10992471	0.603	rs747628	chr9:95289532	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.38	-0.33	1.78e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs950027	0.787	rs2433616	chr15:45728599	A/G	cg26924012	chr15:45694286	SPATA5L1	0.49	6.01	0.37	7.22e-9	Response to fenofibrate (adiponectin levels);
SARC	cis	rs9916302	0.904	rs4795355	chr17:37427382	C/T	cg15445000	chr17:37608096	MED1	0.42	5.16	0.32	5.37e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs11098499	0.779	rs10016060	chr4:120298412	A/G	cg09307838	chr4:120376055	NA	0.91	12.88	0.65	4.9e-29	Corneal astigmatism;
SARC	cis	rs1395	0.885	rs7575245	chr2:27527321	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.34	-4.85	-0.3	2.22e-6	Blood metabolite levels;
SARC	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg20203395	chr5:56204925	C5orf35	0.6	5.38	0.33	1.82e-7	Initial pursuit acceleration;
SARC	cis	rs10911232	0.507	rs4422969	chr1:183020762	G/A	cg13390022	chr1:182993471	LAMC1	0.36	5.42	0.33	1.46e-7	Hypertriglyceridemia;
SARC	cis	rs4713118	0.869	rs6930992	chr6:27712120	A/C	cg17221315	chr6:27791827	HIST1H4J	0.49	5.29	0.33	2.77e-7	Parkinson's disease;
SARC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg09373136	chr17:61933544	TCAM1	-0.48	-6.47	-0.39	5.66e-10	Prudent dietary pattern;
SARC	cis	rs1113500	1.000	rs1113500	chr1:108595442	G/T	cg06207961	chr1:108661230	NA	-0.43	-5.55	-0.34	7.74e-8	Growth-regulated protein alpha levels;
SARC	trans	rs1853207	1.000	rs78261998	chr10:96630716	G/A	cg02737782	chr1:8014393	NA	-0.97	-6.42	-0.39	7.44e-10	Blood metabolite levels;
SARC	cis	rs4253772	0.637	rs8135997	chr22:46651366	G/A	cg24881330	chr22:46731750	TRMU	0.62	6.72	0.4	1.41e-10	LDL cholesterol;Cholesterol, total;
SARC	cis	rs7824557	0.843	rs2736375	chr8:11115749	C/T	cg21775007	chr8:11205619	TDH	-0.43	-5.07	-0.32	8.01e-7	Retinal vascular caliber;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg26976450	chr2:201768554	NIF3L1	0.44	6.57	0.4	3.22e-10	Thyroid stimulating hormone;
SARC	cis	rs1865760	0.963	rs9356991	chr6:25901758	C/A	cg10373733	chr6:25993375	NA	0.42	4.94	0.31	1.47e-6	Height;
SARC	cis	rs7772486	0.558	rs702322	chr6:146007166	G/A	cg23711669	chr6:146136114	FBXO30	-0.81	-11.87	-0.61	9.73e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.35	4.78	0.3	3.08e-6	Total body bone mineral density;
SARC	cis	rs11645898	1.000	rs72791117	chr16:72217385	T/C	cg14768367	chr16:72042858	DHODH	-0.6	-5.6	-0.34	5.88e-8	Blood protein levels;
SARC	cis	rs7769051	0.614	rs62426674	chr6:133227476	G/A	cg22852734	chr6:133119734	C6orf192	0.86	5.5	0.34	9.89e-8	Type 2 diabetes nephropathy;
SARC	cis	rs12142240	0.621	rs66828173	chr1:46818166	G/A	cg14993813	chr1:46806288	NSUN4	-0.52	-5.46	-0.34	1.22e-7	Menopause (age at onset);
SARC	cis	rs9467773	1.000	rs9357010	chr6:26527945	C/G	cg12292205	chr6:26970375	C6orf41	0.4	4.89	0.31	1.89e-6	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg11987759	chr7:65425863	GUSB	0.48	5.94	0.36	1.06e-8	Aortic root size;
SARC	trans	rs634534	0.561	rs613924	chr11:65769295	C/T	cg17712092	chr4:129076599	LARP1B	0.7	9.51	0.53	2.43e-18	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs7539409	0.651	rs910182	chr1:84297117	A/G	cg10977910	chr1:84465055	TTLL7	0.6	5.56	0.34	7.36e-8	Alzheimer's disease;
SARC	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.84	-0.5	2.32e-16	Alzheimer's disease;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg01588449	chr2:242682104	D2HGDH	0.48	6.46	0.39	5.91e-10	Schizophrenia;
SARC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg03188948	chr7:1209495	NA	0.46	6.16	0.37	3.17e-9	Longevity;Endometriosis;
SARC	cis	rs73195822	0.667	rs7967278	chr12:111239011	C/T	cg10860002	chr12:110842031	ANAPC7	0.66	4.92	0.31	1.63e-6	Itch intensity from mosquito bite;
SARC	cis	rs7474896	0.616	rs1985260	chr10:38434090	C/T	cg25427524	chr10:38739819	LOC399744	-0.52	-5.52	-0.34	8.96e-8	Obesity (extreme);
SARC	cis	rs7843479	0.562	rs11774629	chr8:21859315	C/T	cg17168535	chr8:21777572	XPO7	0.85	12.96	0.65	2.78e-29	Mean corpuscular volume;
SARC	cis	rs2380220	0.574	rs7766765	chr6:95997362	G/A	cg23517279	chr6:96025343	MANEA	0.51	5.87	0.36	1.52e-8	Behavioural disinhibition (generation interaction);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg10277546	chr21:34960952	DONSON	0.47	6.53	0.39	4.01e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs11776272	0.623	rs11992609	chr8:21895146	C/T	cg17168535	chr8:21777572	XPO7	0.41	4.74	0.3	3.7e-6	Obesity-related traits;
SARC	cis	rs9899728	0.539	rs113775187	chr17:73047290	A/G	cg27626185	chr17:73056755	KCTD2	-0.97	-7.9	-0.46	1.12e-13	Alzheimer's disease or small vessel stroke;
SARC	cis	rs2075371	0.966	rs2244690	chr7:133987039	A/G	cg00033643	chr7:134001901	SLC35B4	0.39	4.77	0.3	3.25e-6	Mean platelet volume;
SARC	cis	rs4589502	1.000	rs8023363	chr15:67154654	G/A	cg12317470	chr15:67143691	NA	0.72	5.08	0.32	7.89e-7	Lung cancer (smoking interaction);
SARC	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg06713675	chr4:122721982	EXOSC9	-0.5	-6.59	-0.4	2.96e-10	Type 2 diabetes;
SARC	cis	rs6484504	0.600	rs7122895	chr11:31346620	G/C	cg26647111	chr11:31128758	NA	0.38	4.88	0.3	1.95e-6	Red blood cell count;
SARC	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg00933542	chr6:150070202	PCMT1	0.33	5.51	0.34	9.62e-8	Lung cancer;
SARC	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg00149659	chr3:10157352	C3orf10	-0.72	-6.9	-0.41	4.93e-11	Alzheimer's disease;
SARC	cis	rs4664308	0.967	rs17241792	chr2:160915205	C/T	cg03641300	chr2:160917029	PLA2R1	-0.68	-9.29	-0.52	1.1e-17	Idiopathic membranous nephropathy;
SARC	trans	rs6600671	1.000	rs11249350	chr1:121178446	C/T	cg00646200	chr1:148855367	NA	0.53	7.3	0.43	4.45e-12	Hip geometry;
SARC	cis	rs7412746	0.611	rs7532045	chr1:150821847	G/A	cg13175981	chr1:150552382	MCL1	-0.55	-6.73	-0.4	1.33e-10	Melanoma;
SARC	cis	rs8014204	0.753	rs6574199	chr14:75356103	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.78	-11.9	-0.61	7.78e-26	Caffeine consumption;
SARC	cis	rs1348850	0.872	rs4893825	chr2:178298687	A/G	cg23306229	chr2:178417860	TTC30B	0.53	5.81	0.36	2.06e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg15966229	chr18:44337664	ST8SIA5	-0.37	-4.8	-0.3	2.9e-6	Personality dimensions;
SARC	cis	rs600231	0.542	rs11227196	chr11:65234922	G/A	cg17120908	chr11:65337727	SSSCA1	-0.45	-4.99	-0.31	1.17e-6	Bone mineral density;
SARC	cis	rs4851254	0.961	rs7583067	chr2:100796850	C/T	cg17356467	chr2:100759845	AFF3	0.28	4.73	0.3	3.9e-6	Intelligence (multi-trait analysis);
SARC	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg24549020	chr5:56110836	MAP3K1	-0.67	-5.95	-0.36	9.76e-9	Initial pursuit acceleration;
SARC	cis	rs7582180	0.764	rs1967341	chr2:100924559	T/C	cg14675211	chr2:100938903	LONRF2	0.51	7.37	0.44	2.87e-12	Intelligence (multi-trait analysis);
SARC	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg22433210	chr17:43662623	NA	0.69	8.18	0.47	1.82e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs12824058	0.678	rs11614163	chr12:130814621	C/G	cg24838063	chr12:130822603	PIWIL1	0.67	9.55	0.53	1.93e-18	Menopause (age at onset);
SARC	cis	rs11785400	0.793	rs4736364	chr8:143742113	C/T	cg24634471	chr8:143751801	JRK	0.62	8.02	0.46	5.27e-14	Schizophrenia;
SARC	cis	rs17376456	0.877	rs55832164	chr5:93436579	C/T	cg25358565	chr5:93447407	FAM172A	1.32	14.94	0.7	7.42e-36	Diabetic retinopathy;
SARC	trans	rs11098499	0.909	rs10002083	chr4:120311152	C/T	cg25214090	chr10:38739885	LOC399744	0.55	7.14	0.42	1.15e-11	Corneal astigmatism;
SARC	cis	rs11608355	1.000	rs11066523	chr12:109851899	A/G	cg05360138	chr12:110035743	NA	-0.43	-4.94	-0.31	1.51e-6	Neuroticism;
SARC	trans	rs12967884	0.892	rs12959999	chr18:76558732	A/T	cg10946435	chr1:154843044	KCNN3	0.57	6.36	0.38	1.06e-9	Subcutaneous adipose tissue;
SARC	cis	rs2836974	0.545	rs3167757	chr21:40714478	C/T	cg11644478	chr21:40555479	PSMG1	0.67	8.64	0.49	9.33e-16	Cognitive function;
SARC	cis	rs12711979	0.509	rs13035992	chr2:3826597	G/A	cg17052675	chr2:3827356	NA	-0.55	-8.21	-0.47	1.47e-14	Itch intensity from mosquito bite adjusted by bite size;
SARC	trans	rs561341	0.602	rs114562703	chr17:30233899	G/T	cg20587970	chr11:113659929	NA	-0.73	-7.25	-0.43	6.04e-12	Hip circumference adjusted for BMI;
SARC	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg24250549	chr1:154909240	PMVK	0.83	11.99	0.62	4.03e-26	Prostate cancer;
SARC	cis	rs35160687	0.862	rs17737955	chr2:86508014	C/T	cg10973622	chr2:86423274	IMMT	0.4	5.04	0.31	9.47e-7	Night sleep phenotypes;
SARC	cis	rs6977660	0.714	rs10252597	chr7:19791171	G/T	cg07541023	chr7:19748670	TWISTNB	-0.75	-6.83	-0.41	7.45e-11	Thyroid stimulating hormone;
SARC	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg12463550	chr7:65579703	CRCP	0.52	5.95	0.36	1e-8	Aortic root size;
SARC	cis	rs79149102	0.737	rs7163332	chr15:75193623	C/T	cg17294928	chr15:75287854	SCAMP5	-0.83	-5.68	-0.35	4.06e-8	Lung cancer;
SARC	cis	rs7582720	1.000	rs72934714	chr2:203711581	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	7.55	0.44	9.63e-13	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs2153535	0.967	rs10484750	chr6:8378609	A/G	cg07606381	chr6:8435919	SLC35B3	-0.47	-5.64	-0.35	5e-8	Motion sickness;
SARC	cis	rs4742903	0.967	rs7048372	chr9:106859738	T/C	cg14250997	chr9:106856677	SMC2	0.53	7.14	0.42	1.15e-11	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs7937890	1.000	rs7937890	chr11:14396485	C/T	cg02886208	chr11:14281011	SPON1	-0.41	-5.68	-0.35	3.92e-8	Mitochondrial DNA levels;
SARC	cis	rs8064299	0.597	rs9893035	chr17:72783798	A/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.8	10.78	0.58	2.94e-22	Monocyte count;
SARC	cis	rs79149102	0.579	rs58645417	chr15:75325858	T/G	cg17294928	chr15:75287854	SCAMP5	-1.09	-9.42	-0.53	4.6e-18	Lung cancer;
SARC	cis	rs4243830	1.000	rs12401795	chr1:6594773	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	1.04	8.66	0.49	8.16e-16	Body mass index;
SARC	trans	rs2727020	0.521	rs10839296	chr11:49537617	T/C	cg15704280	chr7:45808275	SEPT13	0.7	8.12	0.47	2.72e-14	Coronary artery disease;
SARC	cis	rs7937682	0.855	rs539553	chr11:111477333	C/T	cg22437258	chr11:111473054	SIK2	0.75	10.48	0.57	2.56e-21	Primary sclerosing cholangitis;
SARC	cis	rs911555	0.755	rs2273702	chr14:103918182	C/G	cg12935359	chr14:103987150	CKB	0.39	5.51	0.34	9.61e-8	Intelligence (multi-trait analysis);
SARC	cis	rs6570726	0.935	rs384519	chr6:145846017	C/A	cg23711669	chr6:146136114	FBXO30	0.78	12.08	0.62	2.13e-26	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg17712092	chr4:129076599	LARP1B	0.71	9.73	0.54	5.41e-19	Eosinophil percentage of white cells;
SARC	cis	rs6500602	0.627	rs709632	chr16:4587811	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.36	-5.83	-0.36	1.8e-8	Schizophrenia;
SARC	cis	rs10791323	0.660	rs2156681	chr11:133731644	G/T	cg13461336	chr11:133711254	SPATA19	-0.27	-5.03	-0.31	9.8e-7	Childhood ear infection;
SARC	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg16680214	chr1:154839983	KCNN3	-0.34	-5.28	-0.33	2.98e-7	Prostate cancer;
SARC	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg20607798	chr8:58055168	NA	0.72	5.84	0.36	1.71e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs79149102	0.649	rs12594158	chr15:75109953	C/T	cg17294928	chr15:75287854	SCAMP5	-0.87	-4.96	-0.31	1.37e-6	Lung cancer;
SARC	cis	rs2290402	0.536	rs4690203	chr4:881228	C/T	cg00846425	chr4:957561	DGKQ	-0.42	-4.74	-0.3	3.8e-6	Type 2 diabetes;
SARC	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg01448562	chr3:133502909	NA	-0.48	-7.3	-0.43	4.53e-12	Iron status biomarkers;
SARC	cis	rs9913156	0.515	rs11658808	chr17:4577112	C/T	cg19197139	chr17:4613644	ARRB2	-0.66	-8.51	-0.49	2.14e-15	Lymphocyte counts;
SARC	cis	rs11122272	0.735	rs2749704	chr1:231526243	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.92	-0.54	1.45e-19	Hemoglobin concentration;
SARC	cis	rs60871478	1.000	rs62432860	chr7:807522	G/C	cg19087971	chr7:751233	PRKAR1B	-0.43	-4.88	-0.3	2.01e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs933688	0.877	rs1477349	chr5:90707773	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.07	13.53	0.66	3.66e-31	Smoking behavior;
SARC	cis	rs7615952	0.932	rs13314869	chr3:125644669	G/A	cg05084668	chr3:125655381	ALG1L	-0.67	-6.62	-0.4	2.4e-10	Blood pressure (smoking interaction);
SARC	cis	rs6693567	0.586	rs9661040	chr1:150483236	A/C	cg09579323	chr1:150459698	TARS2	0.4	5.12	0.32	6.42e-7	Migraine;
SARC	cis	rs36051895	0.697	rs11788790	chr9:5092263	G/T	cg02405213	chr9:5042618	JAK2	-0.46	-5.44	-0.34	1.35e-7	Pediatric autoimmune diseases;
SARC	cis	rs4925114	0.568	rs4925109	chr17:17661802	A/G	cg04398451	chr17:18023971	MYO15A	0.39	5.6	0.34	5.93e-8	Body mass index;
SARC	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	10.47	0.57	2.77e-21	Platelet count;
SARC	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs4803468	1.000	rs284654	chr19:41928724	G/A	cg09537434	chr19:41945824	ATP5SL	-1.0	-17.83	-0.76	1.94e-45	Height;
SARC	cis	rs1707322	1.000	rs6677777	chr1:46475836	A/G	cg06784218	chr1:46089804	CCDC17	0.37	6.24	0.38	2.04e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs12200782	0.505	rs7765920	chr6:26514771	C/T	cg11502198	chr6:26597334	ABT1	0.71	7.87	0.46	1.36e-13	Small cell lung carcinoma;
SARC	trans	rs61931739	0.500	rs11053212	chr12:34466116	T/G	cg26384229	chr12:38710491	ALG10B	0.91	13.65	0.67	1.42e-31	Morning vs. evening chronotype;
SARC	cis	rs67311347	1.000	rs7642906	chr3:40492633	G/A	cg01475735	chr3:40494733	NA	0.44	5.21	0.32	4.08e-7	Renal cell carcinoma;
SARC	cis	rs910316	0.967	rs2024653	chr14:75595154	G/A	cg08847533	chr14:75593920	NEK9	0.91	15.37	0.71	2.71e-37	Height;
SARC	cis	rs943466	1.000	rs6933607	chr6:33743997	G/A	cg04676172	chr6:33757040	LEMD2	0.48	5.05	0.31	8.99e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
SARC	cis	rs3126085	0.935	rs56013982	chr1:152176503	C/T	cg03465714	chr1:152285911	FLG	0.46	4.88	0.3	1.98e-6	Atopic dermatitis;
SARC	cis	rs858239	0.601	rs6980224	chr7:23149137	C/T	cg23682824	chr7:23144976	KLHL7	0.72	9.69	0.54	7.22e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs8180040	0.726	rs11130110	chr3:47000606	T/C	cg27129171	chr3:47204927	SETD2	0.66	9.26	0.52	1.4e-17	Colorectal cancer;
SARC	cis	rs3767633	0.925	rs2499856	chr1:161926637	C/T	cg09175582	chr1:161736000	ATF6	-0.64	-5.69	-0.35	3.71e-8	IgG glycosylation;
SARC	cis	rs4889855	0.585	rs17848706	chr17:78704618	G/T	cg17956530	chr17:78667699	RPTOR	0.47	5.18	0.32	4.92e-7	Fractional excretion of uric acid;
SARC	cis	rs3087591	0.960	rs12603885	chr17:29466722	C/T	cg24425628	chr17:29625626	OMG;NF1	0.55	7.12	0.42	1.34e-11	Hip circumference;
SARC	cis	rs6502050	0.787	rs7222326	chr17:80057272	T/C	cg19223190	chr17:80058835	NA	-0.44	-6.38	-0.39	9.63e-10	Life satisfaction;
SARC	cis	rs2153535	0.580	rs1577472	chr6:8486215	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	8.16	0.47	2.14e-14	Motion sickness;
SARC	cis	rs4423214	0.840	rs1123007	chr11:71185357	G/A	cg05163923	chr11:71159392	DHCR7	-0.6	-7.21	-0.43	7.58e-12	Vitamin D levels;
SARC	cis	rs9896933	0.887	rs78483419	chr17:80870884	T/C	cg20578329	chr17:80767326	TBCD	-0.69	-8.06	-0.47	4.03e-14	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
SARC	trans	rs1994135	0.617	rs10844642	chr12:33730368	A/C	cg26384229	chr12:38710491	ALG10B	0.69	8.14	0.47	2.38e-14	Resting heart rate;
SARC	cis	rs67311347	1.000	rs7625736	chr3:40441345	C/G	cg09455208	chr3:40491958	NA	-0.38	-6.04	-0.37	5.96e-9	Renal cell carcinoma;
SARC	cis	rs17376456	0.825	rs10038831	chr5:93124115	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.7	6.39	0.39	8.96e-10	Diabetic retinopathy;
SARC	cis	rs6582630	0.519	rs1851130	chr12:38507819	C/T	cg26384229	chr12:38710491	ALG10B	0.85	12.24	0.63	6.08e-27	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs5753618	0.561	rs5753521	chr22:31638027	T/C	cg00478049	chr22:31556069	RNF185	0.44	4.72	0.3	3.99e-6	Colorectal cancer;
SARC	cis	rs854765	0.583	rs6502627	chr17:17849671	C/T	cg04398451	chr17:18023971	MYO15A	-0.4	-5.51	-0.34	9.59e-8	Total body bone mineral density;
SARC	cis	rs2228479	0.702	rs62056090	chr16:89930087	T/A	cg00800038	chr16:89945340	TCF25	-0.72	-5.22	-0.32	3.97e-7	Skin colour saturation;
SARC	cis	rs67311347	1.000	rs28434528	chr3:40484893	A/G	cg09455208	chr3:40491958	NA	0.42	6.69	0.4	1.63e-10	Renal cell carcinoma;
SARC	cis	rs11690935	0.918	rs12692978	chr2:172725981	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.96	-13.58	-0.66	2.41e-31	Schizophrenia;
SARC	cis	rs9300255	0.830	rs28413626	chr12:123861452	G/A	cg05973401	chr12:123451056	ABCB9	-0.46	-4.79	-0.3	2.94e-6	Neutrophil percentage of white cells;
SARC	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg23758822	chr17:41437982	NA	0.91	11.49	0.6	1.7e-24	Menopause (age at onset);
SARC	cis	rs10504073	0.647	rs62507252	chr8:50028795	C/G	cg00325661	chr8:49890786	NA	0.53	7.08	0.42	1.67e-11	Blood metabolite ratios;
SARC	cis	rs10492096	1.000	rs11064218	chr12:6586261	C/T	cg13857086	chr12:6580257	VAMP1	0.75	7.47	0.44	1.65e-12	Hip geometry;
SARC	cis	rs826838	0.967	rs11169387	chr12:39145737	C/T	cg13010199	chr12:38710504	ALG10B	0.71	9.66	0.53	8.59e-19	Heart rate;
SARC	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg21442419	chr1:2182373	SKI	0.46	6.0	0.37	7.42e-9	Height;
SARC	cis	rs7647973	0.626	rs9830730	chr3:49675875	G/C	cg07636037	chr3:49044803	WDR6	0.65	6.58	0.4	3.07e-10	Menarche (age at onset);
SARC	cis	rs17376456	0.825	rs55724660	chr5:93276636	A/G	cg25358565	chr5:93447407	FAM172A	1.3	14.32	0.68	8.73e-34	Diabetic retinopathy;
SARC	cis	rs67460515	0.892	rs6780536	chr3:161058726	T/C	cg03342759	chr3:160939853	NMD3	-0.68	-8.85	-0.5	2.23e-16	Parkinson's disease;
SARC	cis	rs34172651	0.917	rs200536	chr16:24749203	G/A	cg00339695	chr16:24857497	SLC5A11	-0.32	-5.16	-0.32	5.36e-7	Intelligence (multi-trait analysis);
SARC	cis	rs3812831	0.654	rs9314900	chr13:114937618	A/C	cg06611532	chr13:114900021	NA	0.31	4.98	0.31	1.26e-6	Schizophrenia;
SARC	cis	rs7712401	0.601	rs62377430	chr5:122334688	A/G	cg19412675	chr5:122181750	SNX24	-0.43	-5.43	-0.34	1.41e-7	Mean platelet volume;
SARC	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg22800045	chr5:56110881	MAP3K1	-0.67	-6.31	-0.38	1.38e-9	Initial pursuit acceleration;
SARC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.51	0.57	2.13e-21	Prudent dietary pattern;
SARC	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg04944784	chr2:26401820	FAM59B	-0.51	-6.34	-0.38	1.18e-9	Gut microbiome composition (summer);
SARC	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.7	7.03	0.42	2.3e-11	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs2235642	0.750	rs2974845	chr16:1648162	T/C	cg09065629	chr16:1709722	CRAMP1L	0.37	5.0	0.31	1.14e-6	Coronary artery disease;
SARC	cis	rs7605378	1.000	rs2577852	chr2:200687248	C/T	cg23649088	chr2:200775458	C2orf69	0.51	5.98	0.36	8.38e-9	Osteoporosis;
SARC	cis	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg06636001	chr8:8085503	FLJ10661	0.64	7.81	0.46	1.96e-13	Mood instability;
SARC	cis	rs1003719	0.788	rs3787782	chr21:38462909	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.63	9.05	0.51	5.67e-17	Eye color traits;
SARC	cis	rs9486719	1.000	rs12201449	chr6:96959382	C/T	cg06623918	chr6:96969491	KIAA0776	-0.73	-7.94	-0.46	8.49e-14	Migraine;Coronary artery disease;
SARC	cis	rs981844	0.712	rs4302444	chr4:154745663	A/G	cg14289246	chr4:154710475	SFRP2	-0.46	-5.4	-0.33	1.6e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg00800038	chr16:89945340	TCF25	-0.79	-5.47	-0.34	1.19e-7	Skin colour saturation;
SARC	cis	rs2153535	0.601	rs4140584	chr6:8540614	C/G	cg21535247	chr6:8435926	SLC35B3	-0.48	-5.91	-0.36	1.19e-8	Motion sickness;
SARC	cis	rs9868809	0.505	rs11708786	chr3:48752654	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.53	-4.88	-0.3	2.01e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs6964587	0.692	rs418	chr7:91583334	C/T	cg17063962	chr7:91808500	NA	-0.81	-12.06	-0.62	2.43e-26	Breast cancer;
SARC	cis	rs9467773	1.000	rs2224380	chr6:26553943	G/A	cg12292205	chr6:26970375	C6orf41	0.46	5.51	0.34	9.65e-8	Intelligence (multi-trait analysis);
SARC	trans	rs9650657	0.515	rs7820860	chr8:10950396	C/G	cg06636001	chr8:8085503	FLJ10661	-0.74	-10.4	-0.56	4.65e-21	Neuroticism;
SARC	cis	rs2361710	0.704	rs4889979	chr17:78121707	T/A	cg06718696	chr17:78121285	EIF4A3	0.39	4.75	0.3	3.53e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
SARC	cis	rs262150	0.567	rs2040897	chr7:158803848	C/T	cg04111992	chr7:158790115	NA	-0.37	-5.18	-0.32	4.88e-7	Facial morphology (factor 20);
SARC	cis	rs9325144	0.647	rs17518186	chr12:38883665	T/C	cg13010199	chr12:38710504	ALG10B	-0.45	-5.69	-0.35	3.85e-8	Morning vs. evening chronotype;
SARC	cis	rs11608355	0.545	rs4766475	chr12:109908373	G/A	cg05360138	chr12:110035743	NA	0.93	9.71	0.54	6.21e-19	Neuroticism;
SARC	cis	rs11098499	0.909	rs10026736	chr4:120384322	G/C	cg09307838	chr4:120376055	NA	0.88	11.96	0.62	5.06e-26	Corneal astigmatism;
SARC	cis	rs12893668	0.697	rs67899457	chr14:104060066	A/T	cg26031613	chr14:104095156	KLC1	-0.61	-6.96	-0.42	3.37e-11	Reticulocyte count;
SARC	cis	rs10463554	0.927	rs464720	chr5:102406887	C/T	cg23492399	chr5:102201601	PAM	-0.46	-5.09	-0.32	7.29e-7	Parkinson's disease;
SARC	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.39	-4.79	-0.3	2.93e-6	Intelligence (multi-trait analysis);
SARC	cis	rs4481887	0.927	rs4376768	chr1:248476088	A/G	cg13385794	chr1:248469461	NA	-0.34	-5.31	-0.33	2.59e-7	Common traits (Other);
SARC	cis	rs826838	0.967	rs73096706	chr12:38860563	G/A	cg13010199	chr12:38710504	ALG10B	0.77	10.67	0.57	6.78e-22	Heart rate;
SARC	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg05313129	chr8:58192883	C8orf71	-0.62	-6.46	-0.39	6.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs981844	0.754	rs897608	chr4:154754960	C/T	cg14289246	chr4:154710475	SFRP2	0.44	5.13	0.32	6.13e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs7223966	1.000	rs9901112	chr17:61730617	C/G	cg00588841	chr17:61851480	DDX42;CCDC47	-0.6	-6.29	-0.38	1.57e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs13191362	1.000	rs13215491	chr6:163010325	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.5	0.34	1.01e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs10992471	0.603	rs11788523	chr9:95256593	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.4	-0.33	1.65e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs10782582	0.609	rs5745553	chr1:76379135	A/T	cg03433033	chr1:76189801	ACADM	-0.4	-5.14	-0.32	5.81e-7	Daytime sleep phenotypes;
SARC	cis	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg06558623	chr16:89946397	TCF25	0.91	6.37	0.39	9.81e-10	Skin colour saturation;
SARC	cis	rs910316	1.000	rs12589376	chr14:75561152	C/T	cg23033748	chr14:75592666	NEK9	0.37	5.19	0.32	4.58e-7	Height;
SARC	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg11247378	chr22:39784982	NA	-0.29	-4.78	-0.3	3.17e-6	Intelligence (multi-trait analysis);
SARC	cis	rs12142240	0.738	rs41293275	chr1:46806429	A/T	cg14993813	chr1:46806288	NSUN4	-0.52	-5.55	-0.34	7.87e-8	Menopause (age at onset);
SARC	cis	rs240764	0.631	rs9322174	chr6:101204193	G/C	cg09795085	chr6:101329169	ASCC3	-0.45	-5.81	-0.36	2.09e-8	Neuroticism;
SARC	cis	rs12893668	0.644	rs12890820	chr14:104034849	T/C	cg26031613	chr14:104095156	KLC1	-0.52	-5.64	-0.35	4.82e-8	Reticulocyte count;
SARC	cis	rs11971779	0.680	rs6962366	chr7:139043867	G/A	cg23387468	chr7:139079360	LUC7L2	0.33	4.71	0.3	4.2e-6	Diisocyanate-induced asthma;
SARC	trans	rs3780486	0.522	rs1328898	chr9:33163271	A/G	cg20290983	chr6:43655470	MRPS18A	0.94	13.7	0.67	1.02e-31	IgG glycosylation;
SARC	cis	rs711245	0.572	rs3821150	chr2:36795233	G/A	cg09467607	chr2:36825704	FEZ2	0.57	7.52	0.44	1.18e-12	Height;
SARC	trans	rs1853207	1.000	rs9332137	chr10:96712978	T/C	cg02737782	chr1:8014393	NA	-0.89	-6.4	-0.39	8.69e-10	Blood metabolite levels;
SARC	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg22455342	chr2:225449267	CUL3	-0.67	-8.24	-0.48	1.21e-14	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs1966248	0.543	rs12213745	chr6:134111891	G/A	cg25632230	chr6:134101081	NA	-0.54	-7.27	-0.43	5.56e-12	Coronary artery disease;
SARC	cis	rs11155671	0.530	rs7758033	chr6:150208135	T/C	cg09699651	chr6:150184138	LRP11	0.48	6.06	0.37	5.31e-9	Testicular germ cell tumor;
SARC	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6690583	0.697	rs10782537	chr1:85484473	C/T	cg22153463	chr1:85462885	MCOLN2	-0.72	-8.24	-0.48	1.23e-14	Serum sulfate level;
SARC	cis	rs10782582	0.609	rs11161848	chr1:76367722	A/G	cg03433033	chr1:76189801	ACADM	-0.39	-4.92	-0.31	1.66e-6	Daytime sleep phenotypes;
SARC	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.14	-0.47	2.34e-14	Chronic sinus infection;
SARC	cis	rs9467773	0.620	rs2494692	chr6:26615223	G/A	cg11502198	chr6:26597334	ABT1	0.62	8.29	0.48	8.89e-15	Intelligence (multi-trait analysis);
SARC	cis	rs735396	0.770	rs2259820	chr12:121435342	C/T	cg25281562	chr12:121454272	C12orf43	0.57	7.09	0.42	1.62e-11	N-glycan levels;
SARC	cis	rs12956009	0.518	rs3889651	chr18:44865012	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.56	7.2	0.43	8.36e-12	Educational attainment (years of education);
SARC	cis	rs4925386	0.625	rs3810550	chr20:60912117	C/T	cg24112000	chr20:60950667	NA	-0.36	-5.04	-0.31	9.24e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
SARC	trans	rs2727020	0.575	rs10769587	chr11:49549849	C/G	cg03929089	chr4:120376271	NA	-0.75	-11.2	-0.59	1.4e-23	Coronary artery disease;
SARC	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg18252515	chr7:66147081	NA	1.33	11.9	0.61	8.08e-26	Diabetic kidney disease;
SARC	cis	rs7264396	0.563	rs2425079	chr20:34298191	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-7.17	-0.43	9.99e-12	Total cholesterol levels;
SARC	cis	rs7412746	0.611	rs111905669	chr1:150777565	T/C	cg13175981	chr1:150552382	MCL1	-0.55	-6.83	-0.41	7.21e-11	Melanoma;
SARC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.8	-10.57	-0.57	1.39e-21	Prudent dietary pattern;
SARC	cis	rs965469	1.000	rs8123289	chr20:3253831	T/C	cg25506879	chr20:3388711	C20orf194	-0.5	-5.11	-0.32	6.73e-7	IFN-related cytopenia;
SARC	cis	rs6570726	0.967	rs413880	chr6:145804822	G/A	cg23711669	chr6:146136114	FBXO30	0.71	10.61	0.57	1.05e-21	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg11301795	chr4:187892539	NA	0.77	11.1	0.59	2.95e-23	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9733	0.744	rs12126004	chr1:150889877	T/C	cg15448220	chr1:150897856	SETDB1	-0.41	-5.52	-0.34	9.23e-8	Tonsillectomy;
SARC	cis	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg11266682	chr4:10021025	SLC2A9	0.41	7.49	0.44	1.46e-12	Bone mineral density;
SARC	cis	rs7829975	0.846	rs6601724	chr8:8544872	C/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-5.82	-0.36	1.89e-8	Mood instability;
SARC	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.76	-10.1	-0.55	3.85e-20	Chronic sinus infection;
SARC	cis	rs826838	0.967	rs1719854	chr12:39127707	G/A	cg13010199	chr12:38710504	ALG10B	-0.63	-8.88	-0.5	1.87e-16	Heart rate;
SARC	cis	rs12421382	0.614	rs12418827	chr11:109390649	G/C	cg16359550	chr11:109292809	C11orf87	0.34	5.15	0.32	5.59e-7	Schizophrenia;
SARC	cis	rs735396	0.770	rs2464196	chr12:121435427	G/A	cg15155738	chr12:121454335	C12orf43	0.52	6.47	0.39	5.58e-10	N-glycan levels;
SARC	cis	rs3204270	0.684	rs57405099	chr17:79637065	T/C	cg26965718	chr17:79658957	HGS	-0.62	-5.16	-0.32	5.2e-7	Dental caries;
SARC	cis	rs2834188	0.883	rs16997869	chr21:34696867	C/T	cg15382669	chr21:34697036	IFNAR1	-0.41	-4.71	-0.3	4.19e-6	Narcolepsy;
SARC	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg05313129	chr8:58192883	C8orf71	-0.51	-5.85	-0.36	1.63e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6912958	0.712	rs6454641	chr6:88371060	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.3	-5.17	-0.32	4.93e-7	Monocyte percentage of white cells;
SARC	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg11987759	chr7:65425863	GUSB	0.5	6.22	0.38	2.3e-9	Aortic root size;
SARC	cis	rs62283056	1.000	rs62283056	chr4:6276630	G/C	cg00701064	chr4:6280414	WFS1	-0.54	-5.85	-0.36	1.63e-8	Cisplatin-induced ototoxicity;
SARC	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg03433033	chr1:76189801	ACADM	0.54	7.65	0.45	5.14e-13	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs950169	0.840	rs4842854	chr15:84942339	T/G	cg17507749	chr15:85114479	UBE2QP1	0.79	9.66	0.53	8.73e-19	Schizophrenia;
SARC	cis	rs1046896	0.594	rs9914570	chr17:80783721	C/T	cg05255149	chr17:80675120	FN3KRP	0.45	4.9	0.31	1.79e-6	Glycated hemoglobin levels;
SARC	cis	rs1034435	0.547	rs6008741	chr22:48897881	G/A	cg05992904	chr22:48892994	FAM19A5	-0.4	-5.5	-0.34	9.96e-8	Late-onset Alzheimer's disease;
SARC	cis	rs10178409	1	rs10178409	chr2:73855507	G/T	cg20560298	chr2:73613845	ALMS1	-0.45	-5.52	-0.34	8.95e-8	Urinary metabolites;
SARC	cis	rs6696846	0.777	rs2369526	chr1:205054406	C/T	cg21643547	chr1:205240462	TMCC2	-0.51	-6.5	-0.39	4.8e-10	Red blood cell count;
SARC	cis	rs9814567	1.000	rs28409322	chr3:134252385	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	7.08	0.42	1.73e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs651907	0.557	rs3806653	chr3:101396972	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	6.65	0.4	2.01e-10	Colorectal cancer;
SARC	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg13607699	chr17:42295918	UBTF	-0.58	-7.08	-0.42	1.67e-11	Total body bone mineral density;
SARC	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg04317338	chr11:64019027	PLCB3	0.81	8.68	0.49	6.79e-16	Mean platelet volume;
SARC	cis	rs9868809	0.772	rs12107418	chr3:48689787	A/G	cg07636037	chr3:49044803	WDR6	-0.69	-6.55	-0.39	3.74e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg10141332	chr9:108282077	FSD1L	-0.79	-6.5	-0.39	4.87e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs35213789	0.878	rs13229395	chr7:69499944	T/C	cg10619644	chr7:69149951	AUTS2	0.41	5.09	0.32	7.26e-7	Childhood ear infection;
SARC	cis	rs17376456	0.809	rs10476602	chr5:93445255	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.79	0.35	2.3e-8	Diabetic retinopathy;
SARC	cis	rs908922	0.676	rs6587686	chr1:152528948	C/T	cg09873164	chr1:152488093	CRCT1	0.61	7.89	0.46	1.18e-13	Hair morphology;
SARC	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg17971929	chr21:40555470	PSMG1	-0.57	-7.12	-0.42	1.35e-11	Menarche (age at onset);
SARC	cis	rs763121	0.719	rs9610995	chr22:39057763	C/T	cg14440974	chr22:39074834	NA	-0.34	-4.89	-0.3	1.9e-6	Menopause (age at onset);
SARC	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg10351095	chr21:47802916	PCNT	0.41	4.87	0.3	2.1e-6	Testicular germ cell tumor;
SARC	trans	rs11098499	0.863	rs3733525	chr4:120447048	A/G	cg25214090	chr10:38739885	LOC399744	0.57	7.35	0.43	3.31e-12	Corneal astigmatism;
SARC	cis	rs72945132	0.882	rs67529561	chr11:70162055	G/T	cg05964544	chr11:70165517	PPFIA1	-0.61	-5.87	-0.36	1.5e-8	Coronary artery disease;
SARC	cis	rs67311347	0.955	rs11719205	chr3:40417258	G/A	cg24209194	chr3:40518798	ZNF619	0.59	7.49	0.44	1.45e-12	Renal cell carcinoma;
SARC	cis	rs3857536	0.740	rs4710574	chr6:66890631	T/G	cg07460842	chr6:66804631	NA	-0.6	-7.16	-0.42	1.04e-11	Blood trace element (Cu levels);
SARC	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg20573242	chr4:122745356	CCNA2	0.64	8.11	0.47	2.93e-14	Type 2 diabetes;
SARC	trans	rs208520	0.690	rs1885100	chr6:66871047	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-14.2	-0.68	2.26e-33	Exhaled nitric oxide output;
SARC	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.6	-6.31	-0.38	1.42e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg11644478	chr21:40555479	PSMG1	-0.87	-11.42	-0.6	2.82e-24	Cognitive function;
SARC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg15242686	chr22:24348715	GSTTP1	0.41	4.96	0.31	1.38e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs559928	0.597	rs2096706	chr11:63924446	T/G	cg05555928	chr11:63887634	MACROD1	-0.49	-4.76	-0.3	3.42e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs9818758	0.607	rs9855123	chr3:49229457	C/T	cg07636037	chr3:49044803	WDR6	-0.78	-6.86	-0.41	6.17e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs6840360	0.901	rs4696293	chr4:152707380	C/T	cg22705602	chr4:152727874	NA	0.38	6.53	0.39	4.16e-10	Intelligence (multi-trait analysis);
SARC	cis	rs921968	0.643	rs3931102	chr2:219520405	C/T	cg02176678	chr2:219576539	TTLL4	0.36	5.39	0.33	1.76e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs2842992	0.747	rs4709379	chr6:160227530	A/G	cg11366901	chr6:160182831	ACAT2	1.0	9.46	0.53	3.4e-18	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs1949733	0.701	rs2631735	chr4:8476118	A/G	cg11789530	chr4:8429930	ACOX3	0.75	8.86	0.5	2.05e-16	Response to antineoplastic agents;
SARC	trans	rs634534	0.622	rs552130	chr11:65732800	T/C	cg17712092	chr4:129076599	LARP1B	0.6	7.86	0.46	1.38e-13	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg25036284	chr2:26402008	FAM59B	0.49	5.97	0.36	8.85e-9	Gut microbiome composition (summer);
SARC	cis	rs7264396	0.623	rs2425123	chr20:34329547	A/G	cg01084648	chr20:34329383	RBM39	0.59	5.13	0.32	6e-7	Total cholesterol levels;
SARC	cis	rs2204008	0.775	rs12099736	chr12:38344111	C/G	cg26384229	chr12:38710491	ALG10B	0.88	12.61	0.64	3.88e-28	Bladder cancer;
SARC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.97	10.82	0.58	2.23e-22	Platelet count;
SARC	trans	rs3942852	0.726	rs1503171	chr11:48175152	T/C	cg03929089	chr4:120376271	NA	-0.61	-6.92	-0.41	4.3e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs3106136	0.967	rs12643901	chr4:95145132	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.97	-0.36	8.92e-9	Capecitabine sensitivity;
SARC	cis	rs7927771	0.864	rs4752999	chr11:47428565	C/T	cg20307385	chr11:47447363	PSMC3	-0.58	-7.35	-0.43	3.29e-12	Subjective well-being;
SARC	cis	rs8028182	0.636	rs4886699	chr15:75692303	A/C	cg20655648	chr15:75932815	IMP3	0.61	7.18	0.43	9.01e-12	Sudden cardiac arrest;
SARC	cis	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg09021430	chr5:549028	NA	-0.44	-5.71	-0.35	3.51e-8	Obesity-related traits;
SARC	cis	rs3815700	1.000	rs8109768	chr19:33095463	A/G	cg02997394	chr19:33096574	ANKRD27	0.8	8.25	0.48	1.15e-14	Eosinophilic esophagitis;
SARC	cis	rs72945132	0.882	rs3900797	chr11:70186614	C/T	cg05964544	chr11:70165517	PPFIA1	-0.56	-5.51	-0.34	9.64e-8	Coronary artery disease;
SARC	cis	rs7937682	1.000	rs11213980	chr11:111562692	A/T	cg22437258	chr11:111473054	SIK2	-0.65	-8.52	-0.49	1.99e-15	Primary sclerosing cholangitis;
SARC	cis	rs17345786	0.906	rs72946021	chr3:101250008	T/G	cg12386194	chr3:101231763	SENP7	0.82	9.96	0.55	1.1e-19	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7659604	0.791	rs57316471	chr4:122663939	A/G	cg19748678	chr4:122722346	EXOSC9	0.56	7.06	0.42	1.93e-11	Type 2 diabetes;
SARC	cis	rs367615	0.704	rs4286723	chr5:108835959	G/A	cg17395555	chr5:108820864	NA	0.48	6.85	0.41	6.63e-11	Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs8141529	0.588	rs10222249	chr22:29257147	A/G	cg15103426	chr22:29168792	CCDC117	0.6	6.99	0.42	2.87e-11	Lymphocyte counts;
SARC	cis	rs854765	0.583	rs8073001	chr17:17831716	A/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.44	-5.72	-0.35	3.27e-8	Total body bone mineral density;
SARC	cis	rs4713675	0.525	rs622917	chr6:33702869	C/T	cg15676125	chr6:33679581	C6orf125	-0.51	-5.95	-0.36	9.62e-9	Plateletcrit;
SARC	cis	rs9399137	0.507	rs11754021	chr6:135308375	A/G	cg22676075	chr6:135203613	NA	0.37	4.76	0.3	3.33e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs17384381	0.906	rs2300639	chr1:85823676	T/A	cg16011679	chr1:85725395	C1orf52	0.65	6.02	0.37	6.61e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs35213789	0.768	rs6978134	chr7:69352713	A/C	cg10619644	chr7:69149951	AUTS2	0.38	4.74	0.3	3.73e-6	Childhood ear infection;
SARC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.3	0.56	9.5e-21	Prudent dietary pattern;
SARC	cis	rs6502050	0.712	rs8077079	chr17:80059011	C/T	cg13939156	chr17:80058883	NA	0.42	6.67	0.4	1.8e-10	Life satisfaction;
SARC	cis	rs5753618	0.561	rs737684	chr22:31659827	C/G	cg07713946	chr22:31675144	LIMK2	-0.37	-5.15	-0.32	5.57e-7	Colorectal cancer;
SARC	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg13012494	chr21:47604986	C21orf56	-0.57	-6.7	-0.4	1.52e-10	Testicular germ cell tumor;
SARC	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg21724239	chr8:58056113	NA	0.58	5.69	0.35	3.74e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs17539620	0.506	rs62432749	chr6:154839219	G/A	cg17771515	chr6:154831774	CNKSR3	0.53	4.99	0.31	1.21e-6	Lipoprotein (a) levels;
SARC	cis	rs57506017	0.585	rs5011436	chr7:12268758	A/C	cg23422036	chr7:12250390	TMEM106B	0.46	5.97	0.36	8.8e-9	Neuroticism;
SARC	cis	rs789859	0.869	rs1773225	chr3:194403578	A/G	cg06483076	chr3:194406458	FAM43A	0.43	5.25	0.33	3.5e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs17376456	0.569	rs11948511	chr5:93286601	A/C	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.44	-4.86	-0.3	2.15e-6	Diabetic retinopathy;
SARC	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg11366901	chr6:160182831	ACAT2	1.02	10.77	0.58	3.16e-22	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.52	6.77	0.41	1.06e-10	Lymphocyte counts;
SARC	cis	rs1045529	0.524	rs34251783	chr8:8891376	T/C	cg06636001	chr8:8085503	FLJ10661	-0.61	-8.27	-0.48	9.97e-15	Myopia;Myopia (pathological);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg19954374	chr2:198570639	MARS2	0.55	6.78	0.41	9.52e-11	Breast cancer;
SARC	cis	rs2797160	0.967	rs2226158	chr6:125995467	C/T	cg05901451	chr6:126070800	HEY2	-0.45	-5.5	-0.34	9.96e-8	Endometrial cancer;
SARC	cis	rs3820928	0.934	rs4675117	chr2:227769794	A/G	cg11843606	chr2:227700838	RHBDD1	0.48	5.61	0.34	5.71e-8	Pulmonary function;
SARC	cis	rs2834188	1.000	rs9982088	chr21:34686841	A/G	cg14352951	chr21:34696688	IFNAR1	0.44	5.32	0.33	2.4e-7	Narcolepsy;
SARC	cis	rs55871839	0.708	rs6651298	chr8:59808307	C/G	cg07426533	chr8:59803705	TOX	-0.44	-5.87	-0.36	1.47e-8	Pneumonia;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg12657025	chr1:234878498	NA	0.48	6.33	0.38	1.22e-9	Breast cancer;
SARC	cis	rs73198271	0.531	rs112930476	chr8:8671551	G/A	cg01851573	chr8:8652454	MFHAS1	0.41	5.03	0.31	9.96e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs7520050	0.931	rs11211189	chr1:46261584	A/T	cg06784218	chr1:46089804	CCDC17	-0.26	-4.83	-0.3	2.43e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs9314323	1.000	rs9314323	chr8:26243136	A/G	cg11498726	chr8:26250323	BNIP3L	-0.62	-8.14	-0.47	2.44e-14	Red cell distribution width;
SARC	cis	rs9818758	0.556	rs9835439	chr3:49220330	G/C	cg03060546	chr3:49711283	APEH	-0.56	-4.78	-0.3	3.09e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg22683308	chr4:1340831	KIAA1530	0.45	5.25	0.33	3.49e-7	Longevity;
SARC	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg11878867	chr6:150167359	LRP11	-0.34	-4.72	-0.3	4.01e-6	Lung cancer;
SARC	cis	rs918629	0.599	rs4563648	chr5:95265556	G/A	cg16656078	chr5:95278638	ELL2	-0.55	-6.94	-0.41	3.93e-11	IgG glycosylation;
SARC	cis	rs2594989	0.943	rs6442251	chr3:11417477	A/G	cg00170343	chr3:11313890	ATG7	0.58	5.66	0.35	4.48e-8	Circulating chemerin levels;
SARC	cis	rs2425143	1.000	rs6060588	chr20:34337480	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-6.06	-0.37	5.49e-9	Blood protein levels;
SARC	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg07701084	chr6:150067640	NUP43	0.42	5.51	0.34	9.26e-8	Lung cancer;
SARC	cis	rs5758511	0.514	rs5758580	chr22:42493875	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.42	6.04	0.37	6.11e-9	Birth weight;
SARC	cis	rs34172651	0.917	rs8043962	chr16:24781372	A/G	cg04756594	chr16:24857601	SLC5A11	0.35	5.8	0.36	2.13e-8	Intelligence (multi-trait analysis);
SARC	cis	rs992157	0.835	rs13005100	chr2:219151767	C/T	cg00012203	chr2:219082015	ARPC2	-0.63	-9.11	-0.51	3.96e-17	Colorectal cancer;
SARC	cis	rs6500395	0.584	rs8059077	chr16:48742029	T/C	cg04672837	chr16:48644449	N4BP1	0.42	4.81	0.3	2.72e-6	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs933688	0.583	rs10036206	chr5:90609178	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.61	5.6	0.34	6.07e-8	Smoking behavior;
SARC	cis	rs55692411	0.537	rs35012435	chr3:50031840	C/T	cg14019146	chr3:50243930	SLC38A3	-0.37	-5.25	-0.33	3.42e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1865721	0.804	rs7229401	chr18:73148127	T/G	cg26385618	chr18:73139727	C18orf62	-0.37	-5.04	-0.31	9.47e-7	Intelligence;
SARC	cis	rs7811142	1.000	rs6953107	chr7:100095664	C/T	cg11203670	chr7:100026453	MEPCE;ZCWPW1	0.49	4.77	0.3	3.21e-6	Platelet count;
SARC	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg19223190	chr17:80058835	NA	0.41	5.71	0.35	3.45e-8	Life satisfaction;
SARC	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg25072359	chr17:41440525	NA	0.5	5.94	0.36	1.04e-8	Menopause (age at onset);
SARC	cis	rs2197308	0.765	rs11182992	chr12:37935572	G/C	cg26384229	chr12:38710491	ALG10B	0.9	13.38	0.66	1.18e-30	Morning vs. evening chronotype;
SARC	cis	rs9815354	1.000	rs9869282	chr3:41756064	A/G	cg03022575	chr3:42003672	ULK4	0.57	5.34	0.33	2.22e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9858542	0.953	rs6446264	chr3:49417243	C/A	cg07274523	chr3:49395745	GPX1	0.53	6.25	0.38	1.94e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	trans	rs61931739	0.517	rs7958856	chr12:34294737	T/C	cg26384229	chr12:38710491	ALG10B	0.84	11.77	0.61	2.04e-25	Morning vs. evening chronotype;
SARC	cis	rs116095464	0.558	rs9687621	chr5:229194	C/T	cg22496380	chr5:211416	CCDC127	-0.96	-9.19	-0.52	2.31e-17	Breast cancer;
SARC	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg23758822	chr17:41437982	NA	0.86	10.56	0.57	1.52e-21	Menopause (age at onset);
SARC	cis	rs9914988	0.887	rs11650282	chr17:27090741	C/G	cg20469991	chr17:27169893	C17orf63	-0.49	-5.09	-0.32	7.41e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs2180341	1.000	rs9388561	chr6:127634921	C/T	cg17762328	chr6:126965162	NA	-0.46	-5.29	-0.33	2.88e-7	Breast cancer;
SARC	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg18668041	chr19:41190396	NUMBL	-0.51	-6.35	-0.38	1.11e-9	Migraine with aura;
SARC	cis	rs11997175	0.625	rs7825931	chr8:33583627	A/C	ch.8.33884649F	chr8:33765107	NA	-0.45	-5.76	-0.35	2.62e-8	Body mass index;
SARC	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.46	5.77	0.35	2.54e-8	Gut microbiome composition (summer);
SARC	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg05025164	chr4:1340916	KIAA1530	-0.68	-8.15	-0.47	2.16e-14	Obesity-related traits;
SARC	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.55	5.02	0.31	1.04e-6	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs9316337	0.557	rs9509659	chr13:21924162	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.57	-7.26	-0.43	5.77e-12	Schizophrenia;
SARC	cis	rs35213789	0.562	rs7805381	chr7:69037846	A/G	cg10619644	chr7:69149951	AUTS2	-0.36	-5.07	-0.32	8.07e-7	Childhood ear infection;
SARC	trans	rs931812	0.895	rs13251731	chr8:101902528	C/G	cg20993868	chr7:22813445	NA	0.46	6.28	0.38	1.65e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs11122272	0.735	rs2491412	chr1:231535880	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-9.72	-0.54	5.66e-19	Hemoglobin concentration;
SARC	cis	rs981844	0.603	rs13132437	chr4:154748006	T/G	cg14289246	chr4:154710475	SFRP2	-0.46	-5.38	-0.33	1.84e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs9868809	0.505	rs11706983	chr3:48738678	A/G	cg00383909	chr3:49044727	WDR6	0.65	6.19	0.38	2.63e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs11098499	0.779	rs6815934	chr4:120267310	T/C	cg09307838	chr4:120376055	NA	0.75	10.42	0.56	4.08e-21	Corneal astigmatism;
SARC	cis	rs4803468	1.000	rs10853751	chr19:41903220	G/A	cg08477640	chr19:41863820	B9D2	0.47	6.1	0.37	4.26e-9	Height;
SARC	cis	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg25894440	chr7:65020034	NA	-0.77	-5.9	-0.36	1.24e-8	Diabetic kidney disease;
SARC	cis	rs920590	0.921	rs4922099	chr8:19648486	T/C	cg17834443	chr8:19674713	INTS10	0.46	5.73	0.35	3.07e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs734999	0.588	rs2843403	chr1:2529097	T/C	cg18854424	chr1:2615690	NA	-0.32	-5.11	-0.32	6.76e-7	Ulcerative colitis;
SARC	cis	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg03213289	chr20:61660250	NA	0.46	6.43	0.39	7.22e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs62344088	0.590	rs6872820	chr5:178900	G/A	cg22857025	chr5:266934	NA	-0.78	-5.66	-0.35	4.34e-8	Asthma (childhood onset);
SARC	trans	rs61931739	0.500	rs11053198	chr12:34444013	G/C	cg13010199	chr12:38710504	ALG10B	0.76	10.71	0.57	5.2e-22	Morning vs. evening chronotype;
SARC	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg25894440	chr7:65020034	NA	-0.75	-5.62	-0.35	5.47e-8	Diabetic kidney disease;
SARC	cis	rs208515	0.556	rs12201658	chr6:66678457	T/C	cg07460842	chr6:66804631	NA	0.86	9.87	0.54	2.02e-19	Exhaled nitric oxide levels;
SARC	cis	rs34779708	0.931	rs12767414	chr10:35390193	C/T	cg03585969	chr10:35415529	CREM	0.38	4.87	0.3	2.1e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs1395	0.677	rs113353646	chr2:27492674	C/T	cg21747090	chr2:27597821	SNX17	-0.52	-6.22	-0.38	2.23e-9	Blood metabolite levels;
SARC	cis	rs2204008	0.712	rs12371182	chr12:38321143	A/C	cg26384229	chr12:38710491	ALG10B	0.92	13.3	0.66	2.01e-30	Bladder cancer;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg06032483	chr8:9599206	MIR597;TNKS	0.47	6.8	0.41	8.86e-11	Thyroid stimulating hormone;
SARC	cis	rs6500602	0.647	rs4786519	chr16:4584406	C/T	cg08645402	chr16:4508243	NA	0.39	4.94	0.31	1.5e-6	Schizophrenia;
SARC	trans	rs7615952	0.611	rs9681518	chr3:125615130	A/G	cg07211511	chr3:129823064	LOC729375	-0.84	-7.96	-0.46	7.61e-14	Blood pressure (smoking interaction);
SARC	cis	rs722599	0.639	rs12882676	chr14:75272433	A/G	cg06637938	chr14:75390232	RPS6KL1	0.39	4.84	0.3	2.39e-6	IgG glycosylation;
SARC	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg05863683	chr7:1912471	MAD1L1	0.34	4.99	0.31	1.19e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs7829975	0.514	rs2920983	chr8:8268063	G/C	cg06636001	chr8:8085503	FLJ10661	0.63	7.82	0.46	1.85e-13	Mood instability;
SARC	cis	rs8141529	0.636	rs5762799	chr22:29187380	G/T	cg15103426	chr22:29168792	CCDC117	0.6	6.74	0.4	1.23e-10	Lymphocyte counts;
SARC	cis	rs9393692	0.645	rs2179152	chr6:26325888	T/C	cg00631329	chr6:26305371	NA	-0.64	-8.28	-0.48	9.63e-15	Educational attainment;
SARC	trans	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.74	-10.56	-0.57	1.45e-21	Intelligence (multi-trait analysis);
SARC	cis	rs10490913	0.806	rs1857269	chr10:120172638	G/T	cg23160142	chr10:120154512	NA	0.38	5.77	0.35	2.45e-8	Cancer;
SARC	cis	rs6459804	0.844	rs76501205	chr7:157508941	A/T	cg05731713	chr7:157510257	PTPRN2	0.29	5.72	0.35	3.3e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs2777491	0.507	rs11854081	chr15:41646398	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.19	-20.13	-0.8	7.02e-53	Ulcerative colitis;
SARC	cis	rs9916302	0.706	rs8067511	chr17:37611352	C/T	cg20243544	chr17:37824526	PNMT	0.51	5.26	0.33	3.21e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs6088580	0.634	rs4911153	chr20:32961547	C/T	cg08999081	chr20:33150536	PIGU	-0.43	-6.7	-0.4	1.56e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs4642101	0.824	rs9820977	chr3:12842932	G/A	cg05775895	chr3:12838266	CAND2	0.74	12.08	0.62	2.01e-26	QRS complex (12-leadsum);
SARC	cis	rs6604026	0.656	rs6604029	chr1:93394125	C/G	cg17283838	chr1:93427260	FAM69A	0.41	4.77	0.3	3.25e-6	Multiple sclerosis;
SARC	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg12463550	chr7:65579703	CRCP	-0.49	-5.35	-0.33	2.12e-7	Aortic root size;
SARC	cis	rs9581857	0.547	rs9319374	chr13:28047587	A/C	cg01674679	chr13:27998804	GTF3A	-0.64	-4.92	-0.31	1.61e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	trans	rs7819412	0.527	rs7821914	chr8:10805015	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.58	-0.4	3.12e-10	Triglycerides;
SARC	cis	rs6120849	0.754	rs8501	chr20:33590584	T/C	cg06115741	chr20:33292138	TP53INP2	0.54	5.24	0.32	3.64e-7	Protein C levels;
SARC	cis	rs4761669	0.636	rs9634213	chr12:95223273	C/T	cg21533806	chr12:95267307	NA	0.42	5.18	0.32	4.7e-7	Common carotid intima-media thickness in HIV infection;
SARC	cis	rs7712401	0.546	rs30021	chr5:122285894	G/A	cg19412675	chr5:122181750	SNX24	0.4	5.13	0.32	5.98e-7	Mean platelet volume;
SARC	cis	rs9815354	0.812	rs17283677	chr3:41926148	C/T	cg03022575	chr3:42003672	ULK4	-0.67	-5.91	-0.36	1.19e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs12135062	0.851	rs2651927	chr1:3101762	A/C	cg00254258	chr1:3105189	PRDM16	-0.39	-6.73	-0.4	1.3100000000000001e-10	Migraine;
SARC	cis	rs2153535	0.601	rs9505473	chr6:8538777	T/C	cg21535247	chr6:8435926	SLC35B3	0.55	6.82	0.41	7.81e-11	Motion sickness;
SARC	cis	rs12142240	0.738	rs41293277	chr1:46806550	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-5.55	-0.34	7.87e-8	Menopause (age at onset);
SARC	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg16325326	chr1:53192061	ZYG11B	0.92	14.89	0.7	1.13e-35	Monocyte count;
SARC	cis	rs933688	1.000	rs11948075	chr5:90680579	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.02	12.69	0.64	2.13e-28	Smoking behavior;
SARC	cis	rs796364	0.951	rs12463436	chr2:201061962	C/G	cg05691004	chr2:201170426	SPATS2L	-0.45	-5.0	-0.31	1.15e-6	Schizophrenia;
SARC	cis	rs7833790	0.724	rs6473311	chr8:82726682	G/A	cg17211192	chr8:82754475	SNX16	-0.5	-6.35	-0.38	1.12e-9	Diastolic blood pressure;
SARC	cis	rs72781680	0.716	rs6718631	chr2:24036086	A/G	cg08917208	chr2:24149416	ATAD2B	-0.56	-5.82	-0.36	1.96e-8	Lymphocyte counts;
SARC	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	11.64	0.61	5.7e-25	Alzheimer's disease;
SARC	cis	rs7179456	0.513	rs640704	chr15:59049021	A/G	cg05156742	chr15:59063176	FAM63B	0.68	8.8	0.5	3.08e-16	Asperger disorder;
SARC	cis	rs4430311	0.571	rs1486475	chr1:243868398	T/C	cg21452805	chr1:244014465	NA	-0.45	-5.91	-0.36	1.19e-8	Post-traumatic stress disorder (asjusted for relatedness);
SARC	cis	rs9291683	0.620	rs717615	chr4:10104670	C/T	cg11266682	chr4:10021025	SLC2A9	0.42	7.57	0.44	8.73e-13	Bone mineral density;
SARC	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg13939156	chr17:80058883	NA	0.4	6.25	0.38	1.92e-9	Life satisfaction;
SARC	cis	rs1057510	0.858	rs66627071	chr12:6705380	C/T	cg13857086	chr12:6580257	VAMP1	0.62	4.83	0.3	2.48e-6	Myopia (pathological);
SARC	cis	rs611744	0.506	rs13280454	chr8:109263240	A/G	cg21045802	chr8:109455806	TTC35	0.58	7.25	0.43	6.22e-12	Dupuytren's disease;
SARC	cis	rs1497406	0.744	rs924203	chr1:16511539	G/T	cg06365898	chr1:16533907	ARHGEF19	0.39	5.32	0.33	2.47e-7	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7552404	0.924	rs2173378	chr1:76201992	G/T	cg22875332	chr1:76189707	ACADM	0.4	5.72	0.35	3.18e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs59227481	1	rs59227481	chr12:110007993	A/G	cg08884029	chr12:110012500	MVK;MMAB	-0.38	-5.74	-0.35	2.98e-8	Age-related nuclear cataracts;
SARC	cis	rs9911578	0.967	rs7503190	chr17:57184162	A/C	cg12560992	chr17:57184187	TRIM37	0.87	12.41	0.63	1.71e-27	Intelligence (multi-trait analysis);
SARC	cis	rs6840360	1.000	rs6535818	chr4:152650882	T/G	cg22705602	chr4:152727874	NA	-0.37	-6.51	-0.39	4.45e-10	Intelligence (multi-trait analysis);
SARC	cis	rs11997175	0.784	rs36083407	chr8:33812930	G/T	ch.8.33884649F	chr8:33765107	NA	0.48	6.28	0.38	1.68e-9	Body mass index;
SARC	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg04944784	chr2:26401820	FAM59B	-0.48	-5.95	-0.36	9.93e-9	Gut microbiome composition (summer);
SARC	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs4481887	1.000	rs6666690	chr1:248465323	T/C	cg00666640	chr1:248458726	OR2T12	0.36	6.13	0.37	3.71e-9	Common traits (Other);
SARC	cis	rs910316	1.000	rs175449	chr14:75590846	A/T	cg08847533	chr14:75593920	NEK9	-0.86	-13.54	-0.66	3.39e-31	Height;
SARC	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg02725872	chr8:58115012	NA	-0.27	-4.94	-0.31	1.48e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs9325144	0.577	rs12314639	chr12:39119869	T/C	cg26384229	chr12:38710491	ALG10B	-0.59	-7.46	-0.44	1.75e-12	Morning vs. evening chronotype;
SARC	cis	rs6061231	1.000	rs67941642	chr20:60958108	C/T	cg22601191	chr20:60968625	CABLES2	0.37	4.97	0.31	1.31e-6	Colorectal cancer;
SARC	cis	rs4727027	0.737	rs10278971	chr7:148780659	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	5.85	0.36	1.69e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs950027	0.549	rs11070452	chr15:45594836	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.47	-5.6	-0.34	5.87e-8	Response to fenofibrate (adiponectin levels);
SARC	cis	rs1018836	0.608	rs11997663	chr8:91474484	A/C	cg16814680	chr8:91681699	NA	-0.65	-9.2	-0.52	2.14e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7568458	0.684	rs67988001	chr2:85787123	C/T	cg23752985	chr2:85803571	VAMP8	0.44	5.56	0.34	7.5e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs3733585	0.673	rs6840802	chr4:9965633	C/G	cg11266682	chr4:10021025	SLC2A9	0.36	6.03	0.37	6.47e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.63	7.75	0.45	2.76e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1008375	1.000	rs7694020	chr4:17682597	C/T	cg27347728	chr4:17578864	LAP3	0.45	5.65	0.35	4.69e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg14893161	chr1:205819251	PM20D1	-0.48	-5.56	-0.34	7.29e-8	Parkinson's disease;
SARC	cis	rs2718058	0.519	rs2598047	chr7:37888488	G/T	cg24998770	chr7:37888106	TXNDC3	0.41	6.07	0.37	5.03e-9	Alzheimer's disease (late onset);
SARC	cis	rs2204008	0.560	rs1315354	chr12:38165716	A/G	cg13010199	chr12:38710504	ALG10B	-0.63	-7.94	-0.46	8.81e-14	Bladder cancer;
SARC	trans	rs12310956	0.510	rs1825903	chr12:33870437	G/C	cg26384229	chr12:38710491	ALG10B	0.61	8.03	0.47	4.97e-14	Morning vs. evening chronotype;
SARC	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg22920501	chr2:26401640	FAM59B	-0.55	-7.24	-0.43	6.61e-12	Gut microbiome composition (summer);
SARC	cis	rs2075671	0.855	rs62483567	chr7:100286435	G/A	cg16850897	chr7:100343110	ZAN	-0.64	-6.84	-0.41	7.06e-11	Other erythrocyte phenotypes;
SARC	cis	rs9388451	0.839	rs1811852	chr6:126071575	G/C	cg05901451	chr6:126070800	HEY2	-0.69	-9.64	-0.53	1.02e-18	Brugada syndrome;
SARC	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg02725872	chr8:58115012	NA	-0.37	-6.54	-0.39	3.94e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7312933	0.703	rs2406567	chr12:42551479	G/C	cg19980929	chr12:42632907	YAF2	0.42	5.83	0.36	1.85e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg27069263	chr2:55278118	RTN4	0.5	6.62	0.4	2.4e-10	Electrocardiographic conduction measures;
SARC	cis	rs11578119	0.933	rs10919403	chr1:170414584	A/G	cg09767346	chr1:170501363	GORAB	0.41	4.84	0.3	2.41e-6	Male-pattern baldness;
SARC	cis	rs7216064	0.589	rs7213585	chr17:66062316	A/T	cg12091567	chr17:66097778	LOC651250	-0.89	-11.54	-0.6	1.14e-24	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs2242116	1.000	rs2168443	chr3:46947087	A/T	cg27129171	chr3:47204927	SETD2	-0.48	-6.21	-0.38	2.45e-9	Birth weight;
SARC	cis	rs36051895	0.623	rs1555476	chr9:5233054	T/C	cg02405213	chr9:5042618	JAK2	-0.44	-4.89	-0.3	1.92e-6	Pediatric autoimmune diseases;
SARC	cis	rs9296092	0.538	rs62405948	chr6:33522753	A/C	cg13560919	chr6:33536144	NA	-0.5	-6.31	-0.38	1.38e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs1008375	0.900	rs4698625	chr4:17599500	G/T	cg16339924	chr4:17578868	LAP3	0.69	8.82	0.5	2.79e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1949733	0.655	rs2631736	chr4:8478421	C/G	cg11789530	chr4:8429930	ACOX3	-0.76	-9.86	-0.54	2.21e-19	Response to antineoplastic agents;
SARC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg05552183	chr6:42928497	GNMT	0.52	7.1	0.42	1.48e-11	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs9398803	0.865	rs4422634	chr6:126806676	A/G	cg19875578	chr6:126661172	C6orf173	0.58	7.81	0.46	1.93e-13	Male-pattern baldness;
SARC	cis	rs17376456	0.825	rs55724660	chr5:93276636	A/G	cg21475434	chr5:93447410	FAM172A	0.85	7.57	0.44	8.53e-13	Diabetic retinopathy;
SARC	cis	rs1949733	0.656	rs6845969	chr4:8402465	A/T	cg11789530	chr4:8429930	ACOX3	0.8	10.67	0.57	6.76e-22	Response to antineoplastic agents;
SARC	cis	rs6570726	0.905	rs406799	chr6:145821837	G/C	cg05347473	chr6:146136440	FBXO30	0.49	6.48	0.39	5.27e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg13939156	chr17:80058883	NA	0.4	6.25	0.38	1.92e-9	Life satisfaction;
SARC	cis	rs6938	0.618	rs12912839	chr15:75221245	C/T	cg17294928	chr15:75287854	SCAMP5	0.53	6.7	0.4	1.56e-10	Breast cancer;
SARC	cis	rs10779751	0.734	rs1130683	chr1:11132217	G/A	cg08854313	chr1:11322531	MTOR	0.82	11.29	0.59	7.2e-24	Body mass index;
SARC	cis	rs8141529	0.509	rs5762864	chr22:29253364	T/C	cg15103426	chr22:29168792	CCDC117	0.63	7.85	0.46	1.55e-13	Lymphocyte counts;
SARC	cis	rs6087990	0.735	rs2424921	chr20:31385814	C/T	cg13636640	chr20:31349939	DNMT3B	0.76	11.73	0.61	2.8e-25	Ulcerative colitis;
SARC	cis	rs936229	0.749	rs6495127	chr15:75194490	C/T	cg10253484	chr15:75165896	SCAMP2	-0.53	-5.79	-0.35	2.28e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg22875332	chr1:76189707	ACADM	-0.46	-5.2	-0.32	4.39e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs5417	0.689	rs55868524	chr17:7170665	G/A	cg14438174	chr17:7137923	DVL2	-0.5	-6.65	-0.4	2.11e-10	Diastolic blood pressure;
SARC	cis	rs11874712	1.000	rs8089150	chr18:43674300	A/G	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.46	5.49	0.34	1.06e-7	Migraine - clinic-based;
SARC	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg07648498	chr16:89883185	FANCA	0.43	5.84	0.36	1.74e-8	Vitiligo;
SARC	cis	rs3091242	0.933	rs1534954	chr1:25761924	A/T	cg02931644	chr1:25747376	RHCE	0.43	6.96	0.41	3.49e-11	Erythrocyte sedimentation rate;
SARC	cis	rs9359856	0.510	rs2768940	chr6:90436319	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.53	-5.02	-0.31	1.01e-6	Bipolar disorder;
SARC	cis	rs6910061	1.000	rs73445479	chr6:11114770	T/C	cg27233058	chr6:11094804	LOC221710	0.58	5.66	0.35	4.42e-8	Diabetic kidney disease;
SARC	cis	rs12545109	0.800	rs1960725	chr8:57411807	C/T	cg19413350	chr8:57351067	NA	-0.43	-5.37	-0.33	1.88e-7	Obesity-related traits;
SARC	cis	rs10489202	1.000	rs7520232	chr1:168011995	T/C	cg24449463	chr1:168025552	DCAF6	-0.63	-6.87	-0.41	5.86e-11	Schizophrenia;
SARC	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg16049864	chr8:95962084	TP53INP1	-0.4	-6.49	-0.39	5.21e-10	Type 2 diabetes;
SARC	cis	rs7599312	0.534	rs7607373	chr2:213409719	G/A	cg20637307	chr2:213403960	ERBB4	0.77	11.61	0.61	6.71e-25	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2635047	0.967	rs2668786	chr18:44708472	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.51	6.72	0.4	1.42e-10	Educational attainment;
SARC	cis	rs3796352	1.000	rs11718752	chr3:53130745	T/C	cg04865290	chr3:52927548	TMEM110	-0.59	-4.77	-0.3	3.31e-6	Immune reponse to smallpox (secreted IL-2);
SARC	trans	rs877282	0.898	rs11253343	chr10:765117	C/T	cg22713356	chr15:30763199	NA	1.04	10.06	0.55	5.37e-20	Uric acid levels;
SARC	cis	rs4803468	1.000	rs284656	chr19:41929251	T/C	cg08477640	chr19:41863820	B9D2	0.44	5.53	0.34	8.62e-8	Height;
SARC	cis	rs7084402	0.967	rs1649057	chr10:60318114	C/T	cg07615347	chr10:60278583	BICC1	0.56	7.75	0.45	2.89e-13	Refractive error;
SARC	cis	rs7566780	0.656	rs1346753	chr2:16678781	A/G	cg09580478	chr2:16689509	NA	0.43	5.86	0.36	1.58e-8	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg00933542	chr6:150070202	PCMT1	0.31	5.32	0.33	2.46e-7	Lung cancer;
SARC	cis	rs6772849	0.775	rs66822528	chr3:128415097	G/A	cg01163369	chr3:128370232	RPN1	-0.35	-4.89	-0.31	1.86e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs7681440	0.583	rs2736993	chr4:90772851	A/C	cg06632027	chr4:90757378	SNCA	-0.47	-5.84	-0.36	1.75e-8	Dementia with Lewy bodies;
SARC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg11494091	chr17:61959527	GH2	0.53	7.94	0.46	8.67e-14	Prudent dietary pattern;
SARC	trans	rs2727020	0.729	rs2204366	chr11:49349367	A/C	cg03929089	chr4:120376271	NA	0.73	10.81	0.58	2.38e-22	Coronary artery disease;
SARC	cis	rs11608355	0.672	rs9943689	chr12:109890339	G/A	cg05360138	chr12:110035743	NA	0.54	5.67	0.35	4.16e-8	Neuroticism;
SARC	cis	rs9902453	1.000	rs4533340	chr17:28277951	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	6.78	0.41	9.52e-11	Coffee consumption (cups per day);
SARC	cis	rs6570726	0.764	rs9386125	chr6:145911677	C/T	cg05347473	chr6:146136440	FBXO30	0.51	7.13	0.42	1.29e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg06558623	chr16:89946397	TCF25	0.85	7.34	0.43	3.63e-12	Skin colour saturation;
SARC	cis	rs4141404	0.851	rs5749248	chr22:31683711	C/A	cg13145458	chr22:31556086	RNF185	0.57	5.71	0.35	3.38e-8	Paclitaxel-induced neuropathy;
SARC	cis	rs4642101	0.618	rs11128614	chr3:12819212	A/G	cg05775895	chr3:12838266	CAND2	0.81	14.97	0.7	5.87e-36	QRS complex (12-leadsum);
SARC	cis	rs9309473	1.000	rs11899740	chr2:73631212	G/A	cg20560298	chr2:73613845	ALMS1	-0.5	-5.95	-0.36	9.77e-9	Metabolite levels;
SARC	cis	rs739401	1.000	rs739401	chr11:3036324	C/T	cg08508325	chr11:3079039	CARS	0.28	6.54	0.39	3.75e-10	Longevity;
SARC	cis	rs11792861	0.926	rs72607170	chr9:111836941	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.67	7.73	0.45	3.27e-13	Menarche (age at onset);
SARC	trans	rs877282	0.583	rs11253441	chr10:828288	C/T	cg22713356	chr15:30763199	NA	-0.91	-8.82	-0.5	2.83e-16	Uric acid levels;
SARC	cis	rs943466	0.614	rs4711345	chr6:33730954	G/A	cg25922239	chr6:33757077	LEMD2	-0.44	-5.41	-0.33	1.55e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
SARC	cis	rs2404602	0.647	rs11629727	chr15:77009038	G/C	cg15268244	chr15:77196840	NA	0.46	5.31	0.33	2.53e-7	Blood metabolite levels;
SARC	trans	rs9650657	0.585	rs7830317	chr8:10700254	A/C	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.87	-0.41	5.87e-11	Neuroticism;
SARC	cis	rs453301	0.624	rs2288673	chr8:8860276	G/T	cg06636001	chr8:8085503	FLJ10661	0.45	5.58	0.34	6.64e-8	Joint mobility (Beighton score);
SARC	cis	rs2070997	0.607	rs4602941	chr9:133663776	C/T	cg11464064	chr9:133710261	ABL1	0.58	5.38	0.33	1.85e-7	Response to amphetamines;
SARC	cis	rs9611519	0.929	rs4820425	chr22:41431342	C/A	cg17376030	chr22:41985996	PMM1	0.51	6.2	0.38	2.54e-9	Neuroticism;
SARC	cis	rs36051895	0.664	rs884132	chr9:5114522	G/A	cg02405213	chr9:5042618	JAK2	-0.42	-4.95	-0.31	1.4e-6	Pediatric autoimmune diseases;
SARC	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg22903657	chr4:1355424	KIAA1530	-0.36	-4.91	-0.31	1.69e-6	Obesity-related traits;
SARC	cis	rs10463554	0.892	rs1898673	chr5:102293380	G/C	cg23492399	chr5:102201601	PAM	-0.44	-5.29	-0.33	2.77e-7	Parkinson's disease;
SARC	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg24642844	chr7:1081250	C7orf50	-0.6	-6.11	-0.37	4.06e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs13401104	0.786	rs56257332	chr2:237107405	G/A	cg19324714	chr2:237145437	ASB18	0.59	5.76	0.35	2.69e-8	Educational attainment;
SARC	cis	rs992157	0.798	rs10932772	chr2:219177148	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.63	8.88	0.5	1.79e-16	Colorectal cancer;
SARC	cis	rs9902453	0.933	rs8074028	chr17:28461687	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	6.64	0.4	2.23e-10	Coffee consumption (cups per day);
SARC	cis	rs11638352	0.661	rs2042738	chr15:44426553	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.76	-5.91	-0.36	1.23e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.56	5.25	0.33	3.41e-7	Lung function (FEV1/FVC);
SARC	cis	rs2273669	0.588	rs11153158	chr6:109376118	T/C	cg05315195	chr6:109294784	ARMC2	-0.64	-5.17	-0.32	5.03e-7	Prostate cancer;
SARC	cis	rs80130819	0.688	rs1552551	chr12:48643101	C/A	cg24011408	chr12:48396354	COL2A1	0.53	5.94	0.36	1.01e-8	Prostate cancer;
SARC	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg25427524	chr10:38739819	LOC399744	-0.61	-9.92	-0.54	1.41e-19	Extrinsic epigenetic age acceleration;
SARC	cis	rs16854884	0.657	rs35085196	chr3:143712210	C/T	cg06585982	chr3:143692056	C3orf58	0.68	9.26	0.52	1.36e-17	Economic and political preferences (feminism/equality);
SARC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg06074448	chr4:187884817	NA	-0.38	-5.22	-0.32	4.04e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12594515	0.967	rs11856523	chr15:45989495	C/T	cg14863074	chr15:45997064	NA	0.34	5.21	0.32	4.07e-7	Waist circumference;Weight;
SARC	cis	rs17125944	0.686	rs7143400	chr14:53324891	A/C	cg00686598	chr14:53173677	PSMC6	-0.68	-5.1	-0.32	7.06e-7	Alzheimer's disease (late onset);
SARC	cis	rs3126085	0.935	rs12045496	chr1:152253910	A/G	cg03465714	chr1:152285911	FLG	-0.45	-5.45	-0.34	1.25e-7	Atopic dermatitis;
SARC	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg05368731	chr17:41323189	NBR1	0.79	9.36	0.52	7.2e-18	Menopause (age at onset);
SARC	cis	rs6570726	0.935	rs447818	chr6:145868996	C/T	cg23711669	chr6:146136114	FBXO30	0.75	11.29	0.59	7.15e-24	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1865760	1.000	rs7739966	chr6:25906040	T/C	cg17691542	chr6:26056736	HIST1H1C	0.58	7.18	0.43	9.15e-12	Height;
SARC	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg24675658	chr1:53192096	ZYG11B	-0.57	-7.94	-0.46	8.69e-14	Monocyte count;
SARC	cis	rs8017423	0.935	rs10147186	chr14:90779879	G/C	cg20276874	chr14:90721474	PSMC1	-0.37	-5.03	-0.31	9.68e-7	Mortality in heart failure;
SARC	cis	rs2832191	0.933	rs2832236	chr21:30547602	C/T	cg08807101	chr21:30365312	RNF160	-0.69	-9.1	-0.51	4.28e-17	Dental caries;
SARC	cis	rs8013055	0.796	rs4075104	chr14:106000214	C/A	cg19700328	chr14:106028568	NA	-0.6	-8.15	-0.47	2.22e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
SARC	cis	rs7412746	0.658	rs11581757	chr1:150892244	A/G	cg13175981	chr1:150552382	MCL1	-0.48	-5.86	-0.36	1.57e-8	Melanoma;
SARC	cis	rs5769765	0.955	rs2295406	chr22:50260169	G/A	cg03033257	chr22:50311977	ALG12;CRELD2	-0.54	-5.64	-0.35	4.81e-8	Schizophrenia;
SARC	cis	rs66887589	0.967	rs7678973	chr4:120511817	T/C	cg09307838	chr4:120376055	NA	-0.52	-7.01	-0.42	2.49e-11	Diastolic blood pressure;
SARC	cis	rs8079658	1.000	rs62065085	chr17:63822828	G/C	cg03442606	chr17:63822778	CCDC46	-0.39	-4.86	-0.3	2.13e-6	Post bronchodilator FEV1;
SARC	cis	rs1113500	0.965	rs10881495	chr1:108610986	C/A	cg06207961	chr1:108661230	NA	0.42	5.58	0.34	6.6e-8	Growth-regulated protein alpha levels;
SARC	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg20607798	chr8:58055168	NA	0.56	5.33	0.33	2.31e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs33912345	0.695	rs1313684	chr14:60877740	C/A	cg27398547	chr14:60952738	C14orf39	-0.39	-4.73	-0.3	3.85e-6	Glaucoma (high intraocular pressure);
SARC	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg26335602	chr6:28129616	ZNF389	0.53	5.88	0.36	1.43e-8	Depression;
SARC	cis	rs9914544	0.505	rs59633160	chr17:18761396	C/T	cg25390199	chr17:18761479	PRPSAP2	0.43	5.66	0.35	4.41e-8	Educational attainment (years of education);
SARC	cis	rs4566357	0.615	rs3769642	chr2:227917323	T/C	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.97	-0.36	8.81e-9	Coronary artery disease;
SARC	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg01475735	chr3:40494733	NA	-0.46	-5.08	-0.32	7.58e-7	Renal cell carcinoma;
SARC	cis	rs9322817	0.691	rs9391244	chr6:105257690	G/A	cg02098413	chr6:105308735	HACE1	-0.38	-5.91	-0.36	1.18e-8	Thyroid stimulating hormone;
SARC	cis	rs73086581	1.000	rs17215529	chr20:3975402	A/G	cg02187196	chr20:3869020	PANK2	0.57	5.56	0.34	7.21e-8	Response to antidepressants in depression;
SARC	cis	rs2115536	0.692	rs6495451	chr15:80164053	C/T	cg00225070	chr15:80189496	MTHFS	0.53	6.83	0.41	7.5e-11	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
SARC	cis	rs477895	1.000	rs41294396	chr11:64078581	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	5.49	0.34	1.04e-7	Mean platelet volume;
SARC	cis	rs7937682	0.889	rs559482	chr11:111497902	G/A	cg22437258	chr11:111473054	SIK2	0.74	10.03	0.55	6.36e-20	Primary sclerosing cholangitis;
SARC	cis	rs910316	0.712	rs175074	chr14:75504454	G/A	cg11812906	chr14:75593930	NEK9	-0.78	-10.8	-0.58	2.58e-22	Height;
SARC	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg24531977	chr5:56204891	C5orf35	-0.53	-5.34	-0.33	2.23e-7	Initial pursuit acceleration;
SARC	cis	rs12824058	0.831	rs11609362	chr12:130810526	T/C	cg26677194	chr12:130822605	PIWIL1	0.54	7.4	0.44	2.4e-12	Menopause (age at onset);
SARC	cis	rs9354308	0.933	rs1938068	chr6:66607807	T/C	cg07460842	chr6:66804631	NA	0.5	5.67	0.35	4.1e-8	Metabolite levels;
SARC	cis	rs6493487	0.512	rs1904432	chr15:51249851	G/T	cg02338191	chr15:51200825	AP4E1	0.53	4.91	0.31	1.73e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	trans	rs3808502	0.549	rs4841564	chr8:11425809	T/G	cg08975724	chr8:8085496	FLJ10661	-0.47	-6.29	-0.38	1.53e-9	Neuroticism;
SARC	cis	rs4660306	0.961	rs1494813	chr1:45957290	T/C	cg24296786	chr1:45957014	TESK2	0.58	6.72	0.4	1.35e-10	Homocysteine levels;
SARC	cis	rs7712401	0.755	rs965821	chr5:122137708	A/G	cg19412675	chr5:122181750	SNX24	0.36	4.76	0.3	3.46e-6	Mean platelet volume;
SARC	cis	rs8141529	0.748	rs6005936	chr22:29289250	T/C	cg02153584	chr22:29168773	CCDC117	0.78	11.41	0.6	3.08e-24	Lymphocyte counts;
SARC	cis	rs881375	1.000	rs10760118	chr9:123641616	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.44	5.23	0.32	3.84e-7	Rheumatoid arthritis;
SARC	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg13395646	chr4:1353034	KIAA1530	-0.46	-5.75	-0.35	2.84e-8	Longevity;
SARC	cis	rs4972806	0.739	rs10834	chr2:177042087	A/G	cg14324370	chr2:177042789	NA	0.48	5.89	0.36	1.36e-8	IgG glycosylation;
SARC	cis	rs2354432	0.556	rs66501488	chr1:146853992	T/C	cg25205988	chr1:146714368	CHD1L	-0.94	-6.8	-0.41	8.81e-11	Mitochondrial DNA levels;
SARC	trans	rs10085978	0.604	rs13248223	chr8:143225413	A/G	cg12891252	chr10:43902500	HNRNPF	0.51	6.38	0.39	9.53e-10	Mosquito bite size;
SARC	cis	rs875971	0.545	rs1909508	chr7:65766353	G/T	cg11764359	chr7:65958608	NA	0.63	6.23	0.38	2.15e-9	Aortic root size;
SARC	cis	rs11249608	0.744	rs4701025	chr5:178444474	G/A	cg21905437	chr5:178450457	ZNF879	-0.52	-7.17	-0.43	9.74e-12	Pubertal anthropometrics;
SARC	cis	rs36051895	0.659	rs12339666	chr9:5063296	A/C	cg02405213	chr9:5042618	JAK2	0.5	5.93	0.36	1.07e-8	Pediatric autoimmune diseases;
SARC	cis	rs8067354	0.872	rs2645466	chr17:57853214	A/C	cg13753209	chr17:57696993	CLTC	0.51	6.21	0.38	2.44e-9	Hemoglobin concentration;
SARC	cis	rs12930096	1.000	rs8050192	chr16:11678582	C/T	cg07439791	chr16:11680400	LITAF	0.6	5.88	0.36	1.38e-8	QT interval;
SARC	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg13880726	chr7:1868755	MAD1L1	0.5	6.07	0.37	5.24e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.71	-7.47	-0.44	1.63e-12	Platelet count;
SARC	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg11062466	chr8:58055876	NA	0.64	5.98	0.36	8.43e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6732160	0.741	rs6546806	chr2:73386160	T/C	cg01422370	chr2:73384389	NA	0.32	5.52	0.34	9.11e-8	Intelligence (multi-trait analysis);
SARC	cis	rs3782089	1.000	rs11602375	chr11:65296540	C/T	cg00206168	chr11:65308501	LTBP3	0.93	5.59	0.34	6.42e-8	Height;
SARC	cis	rs1784581	0.588	rs1784583	chr6:162410132	C/T	cg17173639	chr6:162384350	PARK2	-0.51	-6.4	-0.39	8.36e-10	Itch intensity from mosquito bite;
SARC	cis	rs950776	0.752	rs62010327	chr15:78892784	G/A	cg06917634	chr15:78832804	PSMA4	0.82	11.22	0.59	1.26e-23	Sudden cardiac arrest;
SARC	cis	rs6582630	0.537	rs7299661	chr12:38527713	C/T	cg26384229	chr12:38710491	ALG10B	0.84	12.51	0.63	8.09e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7412746	0.634	rs2124952	chr1:150923774	T/A	cg15448220	chr1:150897856	SETDB1	0.51	6.65	0.4	2.02e-10	Melanoma;
SARC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg21724239	chr8:58056113	NA	0.61	6.43	0.39	7.16e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9457247	1.000	rs415890	chr6:167406633	C/G	cg07741184	chr6:167504864	NA	-0.28	-5.32	-0.33	2.44e-7	Crohn's disease;
SARC	cis	rs2120019	0.567	rs28844983	chr15:75178088	T/A	cg17294928	chr15:75287854	SCAMP5	-0.9	-9.43	-0.53	4.46e-18	Blood trace element (Zn levels);
SARC	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg22920501	chr2:26401640	FAM59B	0.61	8.19	0.47	1.71e-14	Gut microbiome composition (summer);
SARC	cis	rs10504229	0.679	rs72649131	chr8:58054288	G/T	cg20607798	chr8:58055168	NA	0.62	5.71	0.35	3.46e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7617773	0.778	rs11707997	chr3:48377875	A/G	cg11946769	chr3:48343235	NME6	0.77	9.63	0.53	1.05e-18	Coronary artery disease;
SARC	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg05872129	chr22:39784769	NA	-0.42	-5.93	-0.36	1.07e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2425143	0.512	rs2425126	chr20:34331730	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.59	5.42	0.33	1.51e-7	Blood protein levels;
SARC	cis	rs5167	0.601	rs73047694	chr19:45497852	G/A	cg09555818	chr19:45449301	APOC2	0.39	5.2	0.32	4.38e-7	Blood protein levels;
SARC	cis	rs2278491	0.502	rs10095889	chr8:117758844	C/T	cg23513447	chr8:117778558	UTP23	-0.48	-5.17	-0.32	5.01e-7	Body mass index;
SARC	cis	rs10791323	0.569	rs10750542	chr11:133713436	T/C	cg14349672	chr11:133703707	NA	-0.36	-5.3	-0.33	2.7e-7	Childhood ear infection;
SARC	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg08859206	chr1:53392774	SCP2	0.37	5.47	0.34	1.16e-7	Monocyte count;
SARC	cis	rs9291683	0.507	rs6827754	chr4:10018153	A/C	cg11266682	chr4:10021025	SLC2A9	-0.34	-5.74	-0.35	2.98e-8	Bone mineral density;
SARC	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg09165964	chr15:75287851	SCAMP5	0.5	6.64	0.4	2.22e-10	Breast cancer;
SARC	trans	rs6600671	0.899	rs2319971	chr1:121226982	A/C	cg00646200	chr1:148855367	NA	0.49	6.7	0.4	1.57e-10	Hip geometry;
SARC	trans	rs11722228	0.539	rs62287552	chr4:10153197	C/T	cg26043149	chr18:55253948	FECH	0.77	9.27	0.52	1.33e-17	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs2797160	1.000	rs1935773	chr6:125996475	A/G	cg05901451	chr6:126070800	HEY2	-0.41	-4.87	-0.3	2.03e-6	Endometrial cancer;
SARC	cis	rs2304069	0.954	rs1433010	chr5:149383954	C/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	-0.7	-6.85	-0.41	6.45e-11	HIV-1 control;
SARC	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg04756594	chr16:24857601	SLC5A11	0.46	6.02	0.37	6.57e-9	Intelligence (multi-trait analysis);
SARC	cis	rs9916302	0.706	rs2338799	chr17:37513941	G/A	cg20243544	chr17:37824526	PNMT	-0.54	-5.76	-0.35	2.67e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs2997447	0.655	rs55820521	chr1:26374286	C/T	cg19633962	chr1:26362018	EXTL1	-0.81	-7.5	-0.44	1.34e-12	QRS complex (12-leadsum);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg06972998	chr10:76585851	MYST4	-0.77	-6.4	-0.39	8.22e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2092850	1	rs2092850	chr6:88100419	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.45	-5.33	-0.33	2.3e-7	Itch intensity from mosquito bite;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg06735849	chr2:169526280	LASS6	0.46	6.96	0.41	3.43e-11	Thyroid stimulating hormone;
SARC	cis	rs13256369	0.851	rs12541477	chr8:8563895	G/A	cg18904891	chr8:8559673	CLDN23	0.49	5.55	0.34	7.83e-8	Obesity-related traits;
SARC	trans	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.73	10.55	0.57	1.63e-21	Intelligence (multi-trait analysis);
SARC	cis	rs7712401	0.715	rs407392	chr5:122360994	C/T	cg19412675	chr5:122181750	SNX24	-0.42	-5.3	-0.33	2.65e-7	Mean platelet volume;
SARC	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.4	-4.84	-0.3	2.31e-6	Lymphocyte counts;
SARC	cis	rs7829975	0.508	rs1594437	chr8:8825875	T/C	cg11995313	chr8:8860691	ERI1	-0.45	-5.39	-0.33	1.75e-7	Mood instability;
SARC	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg16049864	chr8:95962084	TP53INP1	-0.48	-7.83	-0.46	1.71e-13	Type 2 diabetes;
SARC	trans	rs561341	0.941	rs501773	chr17:30314435	T/G	cg20587970	chr11:113659929	NA	-1.25	-12.78	-0.64	1.07e-28	Hip circumference adjusted for BMI;
SARC	cis	rs1153858	1.000	rs7167900	chr15:45639471	A/G	cg03999130	chr15:45571217	NA	0.39	4.93	0.31	1.58e-6	Homoarginine levels;
SARC	cis	rs6815814	0.851	rs11466645	chr4:38778203	A/T	cg09316306	chr4:38807337	TLR1	0.52	5.23	0.32	3.81e-7	Breast cancer;
SARC	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg00031303	chr3:195681400	NA	0.51	5.73	0.35	3.15e-8	Pancreatic cancer;
SARC	cis	rs7917772	0.636	rs7897384	chr10:104529042	T/G	ch.10.2196322F	chr10:104248062	ACTR1A	-0.47	-5.57	-0.34	6.9e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs9788682	0.747	rs7183604	chr15:78899213	T/C	cg24631222	chr15:78858424	CHRNA5	-0.72	-9.81	-0.54	3.04e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs2777491	0.915	rs28526381	chr15:41621842	A/C	cg01768344	chr15:41576519	LOC729082	0.44	4.9	0.31	1.76e-6	Ulcerative colitis;
SARC	trans	rs73158705	0.789	rs58394792	chr7:136626027	G/A	cg24291203	chr8:100025000	VPS13B	0.77	6.28	0.38	1.66e-9	Resting heart rate;
SARC	cis	rs9815354	0.904	rs73079327	chr3:41864697	A/T	cg03022575	chr3:42003672	ULK4	0.56	5.29	0.33	2.81e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9660992	0.710	rs7367930	chr1:205235512	A/G	cg21545522	chr1:205238299	TMCC2	0.49	6.84	0.41	6.81e-11	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs9487051	0.872	rs9386790	chr6:109608460	G/T	cg01475377	chr6:109611718	NA	0.42	6.04	0.37	6.14e-9	Reticulocyte fraction of red cells;
SARC	cis	rs11719291	0.504	rs34571182	chr3:49209057	T/A	cg06212747	chr3:49208901	KLHDC8B	-0.71	-6.31	-0.38	1.42e-9	Cognitive function;
SARC	cis	rs4803468	0.967	rs4605279	chr19:41888131	C/G	cg14132834	chr19:41945861	ATP5SL	-0.53	-7.24	-0.43	6.51e-12	Height;
SARC	cis	rs920590	0.758	rs7011322	chr8:19661937	C/T	cg03894339	chr8:19674705	INTS10	0.54	6.32	0.38	1.31e-9	Acute lymphoblastic leukemia (childhood);
SARC	trans	rs1493916	0.870	rs8097667	chr18:31387003	C/T	cg27147174	chr7:100797783	AP1S1	-0.57	-7.22	-0.43	7.12e-12	Life satisfaction;
SARC	cis	rs7953249	0.656	rs2251468	chr12:121405126	A/C	cg25281562	chr12:121454272	C12orf43	0.48	6.0	0.37	7.55e-9	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg12311346	chr5:56204834	C5orf35	-0.55	-5.64	-0.35	4.98e-8	Initial pursuit acceleration;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg05951308	chr12:72080128	TMEM19	0.49	6.61	0.4	2.57e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg25513531	chr10:69644407	SIRT1	-0.45	-5.61	-0.34	5.77e-8	Schizophrenia;
SARC	cis	rs9858542	0.953	rs34588335	chr3:49407660	G/C	cg07274523	chr3:49395745	GPX1	0.53	6.26	0.38	1.8e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg22903471	chr2:27725779	GCKR	0.45	6.52	0.39	4.4e-10	Total body bone mineral density;
SARC	cis	rs4144743	0.702	rs16941733	chr17:45318289	T/C	cg18085866	chr17:45331354	ITGB3	-0.74	-6.4	-0.39	8.43e-10	Body mass index;
SARC	cis	rs7917772	0.636	rs2486757	chr10:104535145	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	6.14	0.37	3.49e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs11155671	0.530	rs3823021	chr6:150210999	G/C	cg09699651	chr6:150184138	LRP11	0.52	6.59	0.4	2.86e-10	Testicular germ cell tumor;
SARC	cis	rs6120849	0.754	rs6120812	chr20:33629427	T/C	cg06115741	chr20:33292138	TP53INP2	0.54	5.16	0.32	5.3e-7	Protein C levels;
SARC	cis	rs6840360	0.615	rs4696290	chr4:152631472	A/G	cg22705602	chr4:152727874	NA	-0.49	-8.37	-0.48	5.2e-15	Intelligence (multi-trait analysis);
SARC	cis	rs79149102	0.579	rs8034149	chr15:75311842	G/C	cg09165964	chr15:75287851	SCAMP5	-1.02	-9.02	-0.51	7.12e-17	Lung cancer;
SARC	cis	rs7980687	0.628	rs2851443	chr12:123694250	C/T	cg00376283	chr12:123451042	ABCB9	0.57	6.86	0.41	6.06e-11	Height;Educational attainment;Head circumference (infant);
SARC	trans	rs1994135	0.669	rs10844629	chr12:33697096	T/A	cg26384229	chr12:38710491	ALG10B	0.68	8.4	0.48	4.48e-15	Resting heart rate;
SARC	cis	rs476633	0.691	rs28568756	chr15:41539371	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.56	-7.97	-0.46	7.14e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs1059312	0.966	rs7135968	chr12:129280066	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.48	-5.86	-0.36	1.56e-8	Systemic lupus erythematosus;
SARC	cis	rs2251666	0.514	rs2271135	chr16:4929392	A/G	cg06965925	chr16:4818988	NA	0.38	4.83	0.3	2.53e-6	Cancer;
SARC	cis	rs8067545	0.578	rs9901336	chr17:20064190	G/A	cg13482628	chr17:19912719	NA	0.55	7.18	0.43	9.49e-12	Schizophrenia;
SARC	cis	rs6500395	0.775	rs4471681	chr16:48665946	C/T	cg04672837	chr16:48644449	N4BP1	0.41	5.63	0.35	5.04e-8	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs9611519	0.780	rs2284079	chr22:41658632	C/T	cg03806693	chr22:41940476	POLR3H	-0.67	-8.91	-0.5	1.53e-16	Neuroticism;
SARC	cis	rs7223966	1.000	rs8073373	chr17:61703320	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.5	-5.52	-0.34	8.95e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs4243830	0.850	rs2274553	chr1:6586553	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.8	-8.02	-0.46	5.26e-14	Body mass index;
SARC	cis	rs17030434	0.954	rs17030570	chr4:154755186	A/G	cg14289246	chr4:154710475	SFRP2	0.76	7.62	0.45	6.37e-13	Electrocardiographic conduction measures;
SARC	cis	rs3793683	1.000	rs3793683	chr10:134568387	G/T	cg27286337	chr10:134555280	INPP5A	-0.88	-14.79	-0.7	2.36e-35	Migraine;
SARC	trans	rs561341	1.000	rs56903735	chr17:30254393	T/A	cg20587970	chr11:113659929	NA	-1.23	-11.7	-0.61	3.63e-25	Hip circumference adjusted for BMI;
SARC	cis	rs8060686	0.545	rs12444313	chr16:68254404	A/C	cg27539214	chr16:67997921	SLC12A4	-0.53	-4.99	-0.31	1.19e-6	HDL cholesterol;Metabolic syndrome;
SARC	cis	rs6450176	0.564	rs401449	chr5:53326735	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.55	-6.23	-0.38	2.11e-9	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs55794721	0.509	rs7554255	chr1:25778106	C/T	cg27572855	chr1:25598939	RHD	0.54	9.04	0.51	6.32e-17	Plateletcrit;Mean corpuscular volume;
SARC	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg22535103	chr8:58192502	C8orf71	-0.69	-6.18	-0.38	2.82e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs17376456	0.504	rs6898507	chr5:93082343	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.5	5.05	0.31	8.86e-7	Diabetic retinopathy;
SARC	cis	rs13256369	0.851	rs13249700	chr8:8563637	C/T	cg17143192	chr8:8559678	CLDN23	0.52	5.81	0.36	1.99e-8	Obesity-related traits;
SARC	cis	rs8027181	0.839	rs11072385	chr15:73020839	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	0.4	5.4	0.33	1.64e-7	Triglyceride levels;
SARC	cis	rs10791097	0.547	rs12365680	chr11:130749059	C/T	cg12179176	chr11:130786555	SNX19	0.7	10.38	0.56	5.46e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs13082711	0.863	rs36055621	chr3:27436797	T/C	cg02860705	chr3:27208620	NA	0.45	6.03	0.37	6.45e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg21171335	chr12:122356390	WDR66	0.37	5.72	0.35	3.27e-8	Mean corpuscular volume;
SARC	cis	rs3857536	0.674	rs9345798	chr6:66951331	A/G	cg07460842	chr6:66804631	NA	-0.44	-5.04	-0.31	9.2e-7	Blood trace element (Cu levels);
SARC	cis	rs34779708	0.898	rs4934695	chr10:35280605	C/T	cg03585969	chr10:35415529	CREM	0.42	5.14	0.32	5.83e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs35213789	0.760	rs36017873	chr7:69020417	T/C	cg10619644	chr7:69149951	AUTS2	0.39	5.12	0.32	6.42e-7	Childhood ear infection;
SARC	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg04267008	chr7:1944627	MAD1L1	-0.66	-7.96	-0.46	7.37e-14	Bipolar disorder and schizophrenia;
SARC	trans	rs66573146	0.831	rs6851488	chr4:6987412	C/T	cg07817883	chr1:32538562	TMEM39B	1.1	7.55	0.44	9.55e-13	Granulocyte percentage of myeloid white cells;
SARC	cis	rs2228479	0.717	rs11649210	chr16:89807233	C/G	cg04287289	chr16:89883240	FANCA	0.6	4.93	0.31	1.57e-6	Skin colour saturation;
SARC	cis	rs67311347	0.544	rs13098483	chr3:40342743	G/C	cg09455208	chr3:40491958	NA	0.29	4.86	0.3	2.2e-6	Renal cell carcinoma;
SARC	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg18850127	chr7:39170497	POU6F2	0.41	5.23	0.32	3.71e-7	IgG glycosylation;
SARC	trans	rs9650657	0.812	rs6601522	chr8:10629061	G/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.57	-0.4	3.32e-10	Neuroticism;
SARC	cis	rs1018836	0.851	rs6986359	chr8:91643162	A/G	cg16814680	chr8:91681699	NA	-0.79	-13.05	-0.65	1.38e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs12908161	0.959	rs12908699	chr15:85240403	G/T	cg17507749	chr15:85114479	UBE2QP1	0.58	6.68	0.4	1.77e-10	Schizophrenia;
SARC	cis	rs1008375	1.000	rs10009541	chr4:17682218	C/T	cg16339924	chr4:17578868	LAP3	-0.64	-8.18	-0.47	1.85e-14	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs763121	0.853	rs5750673	chr22:39110124	G/A	cg14440974	chr22:39074834	NA	-0.33	-4.82	-0.3	2.54e-6	Menopause (age at onset);
SARC	cis	rs1707322	0.752	rs12027622	chr1:46130252	A/C	cg03146154	chr1:46216737	IPP	0.52	6.25	0.38	1.92e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7769051	1.000	rs7769051	chr6:133146796	G/T	cg07930552	chr6:133119739	C6orf192	0.86	7.45	0.44	1.8e-12	Type 2 diabetes nephropathy;
SARC	cis	rs1545257	0.505	rs13016195	chr2:24634942	T/C	cg06627628	chr2:24431161	ITSN2	-0.56	-7.2	-0.43	8.28e-12	Sjögren's syndrome;
SARC	cis	rs4595586	0.545	rs12823586	chr12:39391677	C/G	cg26384229	chr12:38710491	ALG10B	0.5	6.12	0.37	3.98e-9	Morning vs. evening chronotype;
SARC	cis	rs4805272	0.512	rs8105613	chr19:29339151	C/T	cg12756686	chr19:29218302	NA	0.49	5.32	0.33	2.49e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs9303401	0.659	rs72828726	chr17:56951217	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.05	11.71	0.61	3.38e-25	Cognitive test performance;
SARC	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg00684032	chr4:1343700	KIAA1530	0.37	5.45	0.34	1.27e-7	Obesity-related traits;
SARC	cis	rs11758351	0.925	rs78932312	chr6:26194869	A/G	cg23601095	chr6:26197514	HIST1H3D	0.62	5.39	0.33	1.68e-7	Gout;Renal underexcretion gout;
SARC	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg16339924	chr4:17578868	LAP3	0.66	8.76	0.5	4e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg18876405	chr7:65276391	NA	-0.46	-5.15	-0.32	5.63e-7	Aortic root size;
SARC	cis	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg20879272	chr20:3996372	RNF24	0.38	5.2	0.32	4.41e-7	Immature fraction of reticulocytes;
SARC	cis	rs2204008	0.619	rs11178987	chr12:38201258	C/T	cg13010199	chr12:38710504	ALG10B	-0.59	-7.53	-0.44	1.12e-12	Bladder cancer;
SARC	cis	rs10465746	0.725	rs980417	chr1:84365331	C/A	cg10977910	chr1:84465055	TTLL7	0.45	5.53	0.34	8.42e-8	Obesity-related traits;
SARC	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg24250549	chr1:154909240	PMVK	0.81	11.77	0.61	2.16e-25	Prostate cancer;
SARC	cis	rs2404602	0.647	rs12913024	chr15:77145216	C/T	cg15268244	chr15:77196840	NA	0.45	5.17	0.32	4.97e-7	Blood metabolite levels;
SARC	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg25072359	chr17:41440525	NA	0.5	5.94	0.36	1.04e-8	Menopause (age at onset);
SARC	cis	rs3126085	0.935	rs11588174	chr1:152175970	C/T	cg03465714	chr1:152285911	FLG	0.46	5.37	0.33	1.89e-7	Atopic dermatitis;
SARC	cis	rs477895	0.938	rs28395875	chr11:64024048	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.75	6.72	0.4	1.35e-10	Mean platelet volume;
SARC	cis	rs7714584	1.000	rs10051804	chr5:150226424	T/C	cg22134413	chr5:150180641	NA	0.78	6.56	0.39	3.42e-10	Crohn's disease;
SARC	cis	rs910316	1.000	rs175436	chr14:75608683	C/G	cg23033748	chr14:75592666	NEK9	-0.36	-4.95	-0.31	1.45e-6	Height;
SARC	cis	rs7772486	0.686	rs1337841	chr6:146059487	A/G	cg05347473	chr6:146136440	FBXO30	-0.51	-7.05	-0.42	2.04e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg12564285	chr5:131593104	PDLIM4	0.35	5.16	0.32	5.29e-7	Breast cancer;
SARC	cis	rs10193935	0.901	rs2374429	chr2:42677888	A/G	cg27598129	chr2:42591480	NA	-0.36	-4.98	-0.31	1.24e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs11574514	1.000	rs10775302	chr16:67792439	C/T	cg01866162	chr16:67596514	CTCF	0.97	5.75	0.35	2.76e-8	Crohn's disease;
SARC	cis	rs73635312	0.500	rs74913673	chr10:8942048	T/C	cg24467326	chr10:9646929	NA	0.59	4.96	0.31	1.35e-6	Basal cell carcinoma;
SARC	cis	rs367943	0.901	rs171180	chr5:112817093	A/C	cg12552261	chr5:112820674	MCC	-0.45	-5.21	-0.32	4.24e-7	Type 2 diabetes;
SARC	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg15448220	chr1:150897856	SETDB1	0.47	6.17	0.37	3.05e-9	Tonsillectomy;
SARC	cis	rs2273669	0.667	rs2273668	chr6:109323519	G/T	cg05315195	chr6:109294784	ARMC2	-0.6	-5.43	-0.34	1.38e-7	Prostate cancer;
SARC	cis	rs897080	0.552	rs1067397	chr2:44679285	A/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	6.28	0.38	1.62e-9	Height;
SARC	trans	rs2727020	0.595	rs10839281	chr11:49483373	A/C	cg03929089	chr4:120376271	NA	-0.8	-12.04	-0.62	2.73e-26	Coronary artery disease;
SARC	cis	rs9457247	0.663	rs10946205	chr6:167451311	A/G	cg23791538	chr6:167370224	RNASET2	-0.53	-7.02	-0.42	2.37e-11	Crohn's disease;
SARC	cis	rs9581857	0.685	rs11839899	chr13:28041780	G/A	cg01674679	chr13:27998804	GTF3A	-0.64	-4.86	-0.3	2.19e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	cis	rs2276314	1.000	rs62101367	chr18:33550884	C/T	cg05985134	chr18:33552581	C18orf21	0.74	7.91	0.46	1.02e-13	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs651907	0.557	rs11924013	chr3:101366698	G/A	cg12386194	chr3:101231763	SENP7	0.5	6.0	0.37	7.67e-9	Colorectal cancer;
SARC	cis	rs10493773	0.962	rs6698578	chr1:86236676	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.51	-7.25	-0.43	6e-12	Urate levels in overweight individuals;
SARC	cis	rs853679	0.666	rs200956	chr6:27839746	A/G	cg17221315	chr6:27791827	HIST1H4J	0.55	5.04	0.31	9.32e-7	Depression;
SARC	trans	rs61931739	0.500	rs12832312	chr12:34031199	G/A	cg13010199	chr12:38710504	ALG10B	0.76	10.36	0.56	6.16e-21	Morning vs. evening chronotype;
SARC	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg14582100	chr15:45693742	SPATA5L1	0.35	4.91	0.31	1.69e-6	Homoarginine levels;
SARC	cis	rs2120243	0.565	rs13087207	chr3:157099638	G/A	cg24825693	chr3:157122686	VEPH1	-0.45	-6.27	-0.38	1.74e-9	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg20120463	chr17:44301886	NA	-0.39	-5.95	-0.36	9.7e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9916302	0.904	rs12450559	chr17:37694709	G/A	cg07936489	chr17:37558343	FBXL20	-0.68	-8.81	-0.5	2.97e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs10911363	0.592	rs2761581	chr1:183474850	G/C	cg09173681	chr1:183549694	NCF2	0.32	5.14	0.32	5.74e-7	Systemic lupus erythematosus;
SARC	cis	rs72781680	1.000	rs72781653	chr2:24215633	T/C	cg08917208	chr2:24149416	ATAD2B	0.79	7.66	0.45	4.81e-13	Lymphocyte counts;
SARC	cis	rs709400	1.000	rs10135248	chr14:104122310	T/C	cg26031613	chr14:104095156	KLC1	0.99	18.47	0.77	1.54e-47	Body mass index;
SARC	cis	rs12594515	1.000	rs6493175	chr15:45989898	T/C	cg14863074	chr15:45997064	NA	0.34	5.24	0.32	3.57e-7	Waist circumference;Weight;
SARC	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg00990874	chr7:1149470	C7orf50	-0.53	-5.77	-0.35	2.46e-8	Bronchopulmonary dysplasia;
SARC	cis	rs11098499	0.820	rs11737395	chr4:120520704	C/G	cg09307838	chr4:120376055	NA	0.91	12.18	0.62	9.9e-27	Corneal astigmatism;
SARC	cis	rs6693567	0.565	rs12736375	chr1:150411912	T/C	cg09579323	chr1:150459698	TARS2	0.44	5.58	0.34	6.5e-8	Migraine;
SARC	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.44	5.59	0.34	6.33e-8	Intelligence (multi-trait analysis);
SARC	cis	rs870825	0.587	rs58332461	chr4:185639742	G/A	cg04058563	chr4:185651563	MLF1IP	0.79	11.24	0.59	1.03e-23	Blood protein levels;
SARC	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg11764359	chr7:65958608	NA	-0.72	-8.45	-0.48	3.08e-15	Aortic root size;
SARC	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg21442419	chr1:2182373	SKI	-0.39	-5.07	-0.32	8e-7	Height;
SARC	cis	rs548181	0.604	rs11608103	chr11:125627917	G/A	cg03464685	chr11:125439445	EI24	-0.84	-8.58	-0.49	1.32e-15	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs698813	0.851	rs2592199	chr2:44710169	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	5.39	0.33	1.7e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg18876405	chr7:65276391	NA	-0.45	-5.12	-0.32	6.37e-7	Aortic root size;
SARC	cis	rs7937682	0.924	rs513425	chr11:111504861	C/T	cg22437258	chr11:111473054	SIK2	0.74	10.3	0.56	9.9e-21	Primary sclerosing cholangitis;
SARC	cis	rs1865760	0.566	rs2032449	chr6:26026599	G/C	cg02841227	chr6:26021843	HIST1H4A	0.39	4.74	0.3	3.74e-6	Height;
SARC	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg21724239	chr8:58056113	NA	0.6	6.26	0.38	1.88e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1670533	1.000	rs4690213	chr4:1054868	C/T	cg27284194	chr4:1044797	NA	0.47	4.96	0.31	1.37e-6	Recombination rate (females);
SARC	cis	rs8072100	0.817	rs9912101	chr17:45547078	A/G	cg08085267	chr17:45401833	C17orf57	-0.49	-6.13	-0.37	3.68e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs4481887	0.888	rs4525076	chr1:248456876	T/G	cg13385794	chr1:248469461	NA	0.33	5.04	0.31	9.35e-7	Common traits (Other);
SARC	cis	rs9814567	1.000	rs2056603	chr3:134312749	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-6.93	-0.41	4.14e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs6570726	0.791	rs379040	chr6:145889035	T/C	cg05347473	chr6:146136440	FBXO30	0.51	7.04	0.42	2.08e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg24829409	chr8:58192753	C8orf71	-0.57	-5.14	-0.32	5.91e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2718058	0.613	rs2597272	chr7:37759710	C/G	cg24998770	chr7:37888106	TXNDC3	-0.31	-4.74	-0.3	3.71e-6	Alzheimer's disease (late onset);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg21813473	chr20:40247231	CHD6	-0.9	-7.5	-0.44	1.31e-12	Autism spectrum disorder or schizophrenia;
SARC	cis	rs4595586	0.679	rs4768471	chr12:39325960	G/A	cg26384229	chr12:38710491	ALG10B	0.44	5.37	0.33	1.91e-7	Morning vs. evening chronotype;
SARC	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg21017887	chr14:105400489	NA	-0.52	-7.42	-0.44	2.19e-12	Rheumatoid arthritis;
SARC	cis	rs9303401	0.614	rs34683543	chr17:56520036	C/A	cg25039879	chr17:56429692	SUPT4H1	0.59	5.45	0.34	1.29e-7	Cognitive test performance;
SARC	cis	rs12142240	0.698	rs72677587	chr1:46813982	G/A	cg00530320	chr1:46809349	NSUN4	0.57	6.92	0.41	4.4e-11	Menopause (age at onset);
SARC	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg06221963	chr1:154839813	KCNN3	-0.51	-8.05	-0.47	4.32e-14	Prostate cancer;
SARC	cis	rs13256369	1.000	rs13267501	chr8:8574058	G/A	cg18904891	chr8:8559673	CLDN23	0.48	5.53	0.34	8.72e-8	Obesity-related traits;
SARC	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg11764359	chr7:65958608	NA	0.6	7.22	0.43	7.41e-12	Calcium levels;
SARC	cis	rs11758351	0.660	rs16891443	chr6:26221937	A/C	cg01420254	chr6:26195488	NA	0.55	4.72	0.3	4.01e-6	Gout;Renal underexcretion gout;
SARC	cis	rs7824557	0.602	rs10110557	chr8:11207508	T/C	cg21775007	chr8:11205619	TDH	0.68	8.79	0.5	3.34e-16	Retinal vascular caliber;
SARC	trans	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg00938859	chr5:1591904	SDHAP3	0.79	7.66	0.45	5.1e-13	Breast cancer;
SARC	cis	rs6904897	0.538	rs4639353	chr6:135224328	A/G	cg12549451	chr6:135224345	NA	-0.43	-5.77	-0.35	2.46e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs2929278	0.589	rs2411284	chr15:44038899	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.43	-4.85	-0.3	2.23e-6	Schizophrenia;
SARC	cis	rs854765	0.547	rs2955380	chr17:17944349	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.41	-5.13	-0.32	6.16e-7	Total body bone mineral density;
SARC	cis	rs6912958	0.781	rs3757368	chr6:88224495	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.52	-7.03	-0.42	2.22e-11	Monocyte percentage of white cells;
SARC	cis	rs2014572	0.933	rs8107516	chr19:57758445	A/G	cg24459738	chr19:57751996	ZNF805	-0.47	-5.6	-0.34	5.9e-8	Hyperactive-impulsive symptoms;
SARC	cis	rs2624839	0.630	rs2624841	chr3:50198415	C/T	cg14019146	chr3:50243930	SLC38A3	-0.39	-6.23	-0.38	2.14e-9	Intelligence (multi-trait analysis);
SARC	cis	rs4141404	0.816	rs5749227	chr22:31581166	A/G	cg13145458	chr22:31556086	RNF185	0.58	5.58	0.34	6.52e-8	Paclitaxel-induced neuropathy;
SARC	cis	rs1153858	0.887	rs7171163	chr15:45636395	A/C	cg03999130	chr15:45571217	NA	0.4	5.21	0.32	4.21e-7	Homoarginine levels;
SARC	cis	rs17345786	1.000	rs55641278	chr3:101290577	G/A	cg12386194	chr3:101231763	SENP7	0.7	8.16	0.47	2.07e-14	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg09699651	chr6:150184138	LRP11	0.43	4.93	0.31	1.59e-6	Lung cancer;
SARC	cis	rs1008375	1.000	rs6849704	chr4:17652031	G/C	cg16339924	chr4:17578868	LAP3	0.66	8.83	0.5	2.57e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7224737	1.000	rs2240009	chr17:40283142	C/G	cg20291162	chr17:40259547	DHX58	-0.33	-4.87	-0.3	2.08e-6	Fibrinogen levels;
SARC	cis	rs9392918	0.902	rs1923409	chr6:7728212	G/A	cg23089261	chr6:7723385	NA	0.41	5.45	0.34	1.25e-7	Height;
SARC	cis	rs4689388	0.926	rs10937720	chr4:6295451	A/G	cg00701064	chr4:6280414	WFS1	0.54	8.58	0.49	1.38e-15	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs921968	0.541	rs733925	chr2:219302466	G/A	cg02176678	chr2:219576539	TTLL4	-0.41	-6.22	-0.38	2.25e-9	Mean corpuscular hemoglobin concentration;
SARC	cis	rs9549260	0.604	rs56302456	chr13:41295887	G/T	cg21288729	chr13:41239152	FOXO1	0.54	4.79	0.3	2.99e-6	Red blood cell count;
SARC	cis	rs7674212	0.570	rs6841136	chr4:104103509	A/C	cg16532752	chr4:104119610	CENPE	-0.44	-5.4	-0.33	1.62e-7	Type 2 diabetes;
SARC	cis	rs2153535	0.541	rs9328477	chr6:8519109	T/C	cg07606381	chr6:8435919	SLC35B3	0.77	10.87	0.58	1.55e-22	Motion sickness;
SARC	trans	rs61931739	0.929	rs2389272	chr12:34067771	T/C	cg13010199	chr12:38710504	ALG10B	-0.5	-6.74	-0.4	1.25e-10	Morning vs. evening chronotype;
SARC	cis	rs16854884	0.586	rs7642551	chr3:143732167	C/T	cg06585982	chr3:143692056	C3orf58	0.68	9.45	0.53	3.78e-18	Economic and political preferences (feminism/equality);
SARC	cis	rs7587476	0.784	rs13032278	chr2:215698034	G/A	cg04004882	chr2:215674386	BARD1	0.57	6.53	0.39	4.09e-10	Neuroblastoma;
SARC	cis	rs2115536	1.000	rs2115540	chr15:80190308	A/G	cg00225070	chr15:80189496	MTHFS	0.66	8.85	0.5	2.31e-16	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
SARC	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg12311346	chr5:56204834	C5orf35	-0.58	-6.02	-0.37	6.85e-9	Initial pursuit acceleration;
SARC	cis	rs6723226	0.721	rs10172510	chr2:32620888	A/G	cg02381751	chr2:32503542	YIPF4	0.57	7.5	0.44	1.32e-12	Intelligence (multi-trait analysis);
SARC	cis	rs6121246	0.567	rs6060297	chr20:30198560	A/G	cg13852791	chr20:30311386	BCL2L1	0.68	5.91	0.36	1.2e-8	Mean corpuscular hemoglobin;
SARC	cis	rs2075671	0.903	rs11520986	chr7:100276994	A/G	cg20848291	chr7:100343083	ZAN	-0.66	-7.23	-0.43	6.86e-12	Other erythrocyte phenotypes;
SARC	cis	rs7617773	0.746	rs11713476	chr3:48375434	C/T	cg11946769	chr3:48343235	NME6	0.73	9.38	0.52	5.96e-18	Coronary artery disease;
SARC	cis	rs113835537	0.735	rs519380	chr11:66409409	G/A	cg24851651	chr11:66362959	CCS	0.42	5.14	0.32	5.68e-7	Airway imaging phenotypes;
SARC	cis	rs787274	1.000	rs787275	chr9:115550523	C/G	cg13803584	chr9:115635662	SNX30	-0.75	-5.49	-0.34	1.04e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs501120	1.000	rs1746047	chr10:44774086	T/G	cg09554077	chr10:44749378	NA	0.47	6.39	0.39	8.81e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs9790314	0.540	rs9844862	chr3:161076188	G/A	cg03342759	chr3:160939853	NMD3	-0.57	-7.2	-0.43	8.42e-12	Morning vs. evening chronotype;
SARC	cis	rs2153535	0.580	rs7748455	chr6:8453625	C/T	cg23788917	chr6:8435910	SLC35B3	0.64	8.52	0.49	1.95e-15	Motion sickness;
SARC	trans	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.53	6.85	0.41	6.38e-11	Intelligence (multi-trait analysis);
SARC	cis	rs6598163	0.564	rs12319878	chr12:132289989	C/T	cg22244940	chr12:132335942	MMP17	0.46	5.75	0.35	2.83e-8	Migraine;
SARC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.56	-6.79	-0.41	9.48e-11	Prudent dietary pattern;
SARC	cis	rs6831352	0.918	rs7669636	chr4:100059312	G/A	cg12011299	chr4:100065546	ADH4	-0.34	-5.64	-0.35	4.95e-8	Alcohol dependence;
SARC	cis	rs11785693	0.730	rs62489549	chr8:4954185	G/C	cg26367366	chr8:4980734	NA	0.57	4.81	0.3	2.67e-6	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs7808935	0.958	rs10486567	chr7:27976563	G/A	cg05786569	chr7:27702416	HIBADH	0.48	5.19	0.32	4.55e-7	Prostate cancer;
SARC	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg05368731	chr17:41323189	NBR1	0.79	9.49	0.53	2.9e-18	Menopause (age at onset);
SARC	cis	rs644799	0.562	rs1313288	chr11:95520695	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	9.83	0.54	2.62e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7395581	0.918	rs3847502	chr11:47333685	C/A	cg25783544	chr11:47291846	MADD	0.49	5.51	0.34	9.63e-8	HDL cholesterol;
SARC	cis	rs601339	1.000	rs7969523	chr12:123168636	T/G	cg18578876	chr12:123200353	GPR109B	0.43	4.87	0.3	2.08e-6	Adiponectin levels;
SARC	cis	rs35110281	0.511	rs2298562	chr21:45085236	A/G	cg04455712	chr21:45112962	RRP1B	0.37	5.29	0.33	2.85e-7	Mean corpuscular volume;
SARC	cis	rs7216064	1.000	rs56393562	chr17:65933918	C/T	cg12091567	chr17:66097778	LOC651250	-0.7	-7.28	-0.43	4.96e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs15676	0.783	rs10988120	chr9:131564695	G/C	cg00228799	chr9:131580591	ENDOG	-0.56	-7.09	-0.42	1.59e-11	Blood metabolite levels;
SARC	cis	rs3820928	0.874	rs1917123	chr2:227889783	T/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-6.47	-0.39	5.84e-10	Pulmonary function;
SARC	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg12310025	chr6:25882481	NA	-0.41	-5.29	-0.33	2.8e-7	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg11764359	chr7:65958608	NA	-0.78	-9.49	-0.53	2.76e-18	Aortic root size;
SARC	cis	rs1545257	0.514	rs2584940	chr2:24641639	A/C	cg06627628	chr2:24431161	ITSN2	-0.51	-6.58	-0.4	3.11e-10	Sjögren's syndrome;
SARC	cis	rs7587476	0.906	rs16852750	chr2:215646683	A/G	cg04530015	chr2:215796436	ABCA12	-0.4	-6.02	-0.37	6.64e-9	Neuroblastoma;
SARC	cis	rs1949733	1.000	rs6837429	chr4:8502374	A/G	cg11789530	chr4:8429930	ACOX3	0.83	11.23	0.59	1.15e-23	Response to antineoplastic agents;
SARC	cis	rs7681440	0.874	rs7687945	chr4:90764699	C/T	cg06632027	chr4:90757378	SNCA	0.41	5.88	0.36	1.38e-8	Dementia with Lewy bodies;
SARC	cis	rs3741151	0.773	rs7110369	chr11:73160946	C/A	cg17517138	chr11:73019481	ARHGEF17	0.92	6.85	0.41	6.4e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs262150	0.788	rs2657408	chr7:158782275	A/G	cg19418458	chr7:158789849	NA	-0.43	-5.94	-0.36	1.05e-8	Facial morphology (factor 20);
SARC	cis	rs7178909	0.902	rs8034116	chr15:90441568	A/G	cg19708238	chr15:90437601	AP3S2	0.64	8.64	0.49	8.91e-16	Common traits (Other);
SARC	cis	rs9920	0.585	rs76633992	chr7:116141830	G/T	cg24770985	chr7:116166421	CAV1	0.81	5.59	0.34	6.29e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Immature fraction of reticulocytes;QT interval;
SARC	cis	rs4808199	0.948	rs2074301	chr19:19381715	G/A	cg03709012	chr19:19516395	GATAD2A	1.1	10.61	0.57	1.07e-21	Nonalcoholic fatty liver disease;
SARC	cis	rs912057	0.671	rs1294433	chr6:6745163	G/A	cg06612196	chr6:6737390	NA	0.63	9.62	0.53	1.15e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	trans	rs561341	1.000	rs548957	chr17:30302411	G/A	cg20587970	chr11:113659929	NA	-1.33	-13.84	-0.67	3.43e-32	Hip circumference adjusted for BMI;
SARC	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg15049968	chr18:44337910	ST8SIA5	-0.35	-5.65	-0.35	4.75e-8	Personality dimensions;
SARC	cis	rs4689388	0.890	rs3821941	chr4:6286954	A/G	cg14416269	chr4:6271139	WFS1	0.36	5.57	0.34	6.89e-8	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs854765	0.547	rs4459604	chr17:17888549	A/G	cg04398451	chr17:18023971	MYO15A	-0.46	-6.6	-0.4	2.67e-10	Total body bone mineral density;
SARC	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg11987759	chr7:65425863	GUSB	-0.47	-6.27	-0.38	1.7e-9	Aortic root size;
SARC	cis	rs6570726	0.935	rs382910	chr6:145865941	G/A	cg05347473	chr6:146136440	FBXO30	0.48	6.55	0.39	3.57e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs854765	0.587	rs4077828	chr17:17833644	A/T	cg05444541	chr17:17804740	TOM1L2	-0.3	-5.06	-0.31	8.38e-7	Total body bone mineral density;
SARC	cis	rs3796352	0.667	rs9831977	chr3:52854140	T/G	cg15956490	chr3:53032818	SFMBT1	0.76	5.18	0.32	4.71e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs4443100	0.917	rs5996460	chr22:23393090	G/A	cg14186256	chr22:23484241	RTDR1	0.48	4.95	0.31	1.45e-6	Serum parathyroid hormone levels;
SARC	trans	rs61931739	0.500	rs7306435	chr12:34482933	A/G	cg26384229	chr12:38710491	ALG10B	-0.91	-13.66	-0.67	1.3e-31	Morning vs. evening chronotype;
SARC	trans	rs1425869	0.509	rs7119096	chr11:127948238	C/T	cg13696300	chr17:18162128	FLII	0.48	6.28	0.38	1.68e-9	Mean corpuscular hemoglobin;
SARC	cis	rs11098499	0.818	rs55825515	chr4:120486402	A/G	cg24375607	chr4:120327624	NA	0.46	5.37	0.33	1.94e-7	Corneal astigmatism;
SARC	cis	rs3762637	0.943	rs78429050	chr3:122252428	T/C	cg24169773	chr3:122142474	KPNA1	-0.56	-5.71	-0.35	3.46e-8	LDL cholesterol levels;
SARC	cis	rs11509153	0.648	rs3800844	chr7:12264220	G/C	cg23422036	chr7:12250390	TMEM106B	0.45	5.86	0.36	1.53e-8	Residual cognition;
SARC	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg18876405	chr7:65276391	NA	0.74	9.39	0.52	5.66e-18	Aortic root size;
SARC	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg11965913	chr1:205819406	PM20D1	0.44	4.89	0.31	1.85e-6	Parkinson's disease;
SARC	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg13395646	chr4:1353034	KIAA1530	-0.56	-6.75	-0.4	1.18e-10	Obesity-related traits;
SARC	trans	rs3942852	0.550	rs1113480	chr11:48058313	G/T	cg15704280	chr7:45808275	SEPT13	-0.59	-6.95	-0.41	3.64e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs995000	0.931	rs1629122	chr1:63046578	C/A	cg06896770	chr1:63153194	DOCK7	-0.89	-13.19	-0.65	4.67e-30	Triglyceride levels;
SARC	cis	rs67460515	0.892	rs7647374	chr3:160975576	T/A	cg03342759	chr3:160939853	NMD3	-0.71	-9.12	-0.51	3.55e-17	Parkinson's disease;
SARC	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg09323728	chr8:95962352	TP53INP1	-0.29	-4.92	-0.31	1.65e-6	Type 2 diabetes;
SARC	cis	rs910316	0.967	rs8007539	chr14:75664953	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.47	-6.65	-0.4	2.01e-10	Height;
SARC	cis	rs4595586	0.545	rs925827	chr12:39364307	C/T	cg13010199	chr12:38710504	ALG10B	0.42	5.02	0.31	1.05e-6	Morning vs. evening chronotype;
SARC	cis	rs9398803	0.673	rs1262556	chr6:127054435	G/C	cg19875578	chr6:126661172	C6orf173	-0.64	-8.71	-0.5	5.84e-16	Male-pattern baldness;
SARC	cis	rs7107217	1.000	rs1873872	chr11:129473993	A/T	cg20873801	chr11:129771917	PRDM10	0.37	5.17	0.32	4.97e-7	Breast cancer;Type 2 diabetes;
SARC	cis	rs473651	0.935	rs472357	chr2:239355454	A/G	cg21699342	chr2:239360505	ASB1	-0.5	-7.54	-0.44	1.03e-12	Multiple system atrophy;
SARC	cis	rs78487399	0.710	rs80147536	chr2:43698028	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-4.93	-0.31	1.59e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs7647973	0.593	rs7652179	chr3:49808618	T/A	cg07636037	chr3:49044803	WDR6	-0.6	-5.72	-0.35	3.31e-8	Menarche (age at onset);
SARC	cis	rs10911232	0.507	rs10911206	chr1:183012423	A/G	cg13390022	chr1:182993471	LAMC1	0.36	5.42	0.33	1.48e-7	Hypertriglyceridemia;
SARC	cis	rs8067545	0.611	rs2703775	chr17:20134466	A/G	cg13482628	chr17:19912719	NA	-0.53	-6.84	-0.41	7.08e-11	Schizophrenia;
SARC	cis	rs2908197	0.713	rs2961037	chr7:75952212	G/T	cg22830091	chr7:75961684	YWHAG	-0.35	-5.22	-0.32	4.02e-7	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs4713118	0.619	rs200486	chr6:27779506	C/T	cg17221315	chr6:27791827	HIST1H4J	0.56	5.35	0.33	2.13e-7	Parkinson's disease;
SARC	cis	rs6545883	0.826	rs1186697	chr2:61661417	G/A	cg15711740	chr2:61764176	XPO1	-0.44	-5.19	-0.32	4.54e-7	Tuberculosis;
SARC	cis	rs34779708	0.833	rs12777517	chr10:35473927	T/G	cg03585969	chr10:35415529	CREM	0.41	5.02	0.31	1.02e-6	Inflammatory bowel disease;Crohn's disease;
SARC	trans	rs1865760	0.929	rs9461224	chr6:25936402	G/T	cg04757074	chr12:67663012	CAND1	-0.52	-6.33	-0.38	1.22e-9	Height;
SARC	cis	rs35362007	0.530	rs17835086	chr14:96012465	A/G	cg02940042	chr14:96000874	GLRX5;SNHG10;SCARNA13	0.62	5.38	0.33	1.82e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs7714584	1.000	rs10058943	chr5:150226586	A/G	cg22134413	chr5:150180641	NA	0.78	6.54	0.39	3.82e-10	Crohn's disease;
SARC	cis	rs3824867	0.920	rs7105907	chr11:47450318	A/T	cg20307385	chr11:47447363	PSMC3	-0.47	-5.14	-0.32	5.71e-7	Mean corpuscular hemoglobin;
SARC	cis	rs16976116	0.951	rs3759862	chr15:55483104	C/A	cg11288833	chr15:55489084	RSL24D1	0.62	6.05	0.37	5.78e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg13206674	chr6:150067644	NUP43	0.49	6.3	0.38	1.44e-9	Lung cancer;
SARC	cis	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg25427524	chr10:38739819	LOC399744	-0.52	-8.25	-0.48	1.17e-14	Extrinsic epigenetic age acceleration;
SARC	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10463554	0.892	rs59292735	chr5:102382751	T/C	cg23492399	chr5:102201601	PAM	-0.52	-5.65	-0.35	4.66e-8	Parkinson's disease;
SARC	cis	rs765787	0.530	rs2413782	chr15:45538490	A/C	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.51e-10	Uric acid levels;
SARC	cis	rs12908161	1.000	rs11638290	chr15:85227636	C/T	cg17507749	chr15:85114479	UBE2QP1	0.58	6.68	0.4	1.77e-10	Schizophrenia;
SARC	cis	rs2013441	1.000	rs11871945	chr17:20206883	A/G	cg13482628	chr17:19912719	NA	-0.49	-6.33	-0.38	1.23e-9	Obesity-related traits;
SARC	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg11987759	chr7:65425863	GUSB	0.5	6.55	0.39	3.66e-10	Aortic root size;
SARC	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg04756594	chr16:24857601	SLC5A11	0.44	6.11	0.37	4.19e-9	Intelligence (multi-trait analysis);
SARC	trans	rs17685	0.753	rs10264760	chr7:75749694	A/G	cg19862616	chr7:65841803	NCRNA00174	0.6	7.35	0.43	3.25e-12	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs748404	0.631	rs3809482	chr15:43661802	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.41	4.97	0.31	1.33e-6	Lung cancer;
SARC	cis	rs6582630	0.555	rs10880624	chr12:38526316	C/T	cg26384229	chr12:38710491	ALG10B	0.85	12.59	0.64	4.39e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.47	5.48	0.34	1.11e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs78456975	0.943	rs13421238	chr2:1576879	G/A	cg26248373	chr2:1572462	NA	-0.58	-5.98	-0.36	8.14e-9	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs1784581	0.761	rs6455791	chr6:162418533	G/A	cg17173639	chr6:162384350	PARK2	0.55	6.98	0.42	2.96e-11	Itch intensity from mosquito bite;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg07399312	chr1:156470683	MEF2D	0.53	6.56	0.39	3.45e-10	Breast cancer;
SARC	cis	rs3812831	0.669	rs7327370	chr13:114946858	A/G	cg06611532	chr13:114900021	NA	0.33	5.79	0.35	2.24e-8	Schizophrenia;
SARC	cis	rs9682041	0.561	rs6790483	chr3:170154406	G/A	cg11886554	chr3:170076028	SKIL	1.05	7.35	0.43	3.27e-12	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg22800045	chr5:56110881	MAP3K1	0.67	6.15	0.37	3.32e-9	Type 2 diabetes;
SARC	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg24675658	chr1:53192096	ZYG11B	-0.56	-7.6	-0.45	7.41e-13	Monocyte count;
SARC	cis	rs1318878	0.518	rs1461034	chr12:15508221	C/A	cg08258403	chr12:15378311	NA	0.48	6.67	0.4	1.87e-10	Intelligence (multi-trait analysis);
SARC	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg17971929	chr21:40555470	PSMG1	-0.88	-11.94	-0.62	5.88e-26	Cognitive function;
SARC	cis	rs9868809	0.656	rs13324119	chr3:48710606	G/C	cg12468774	chr3:49236860	CCDC36	0.5	5.04	0.31	9.25e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs11098499	0.954	rs59866101	chr4:120296591	T/G	cg09160332	chr4:120329925	NA	-0.33	-4.77	-0.3	3.27e-6	Corneal astigmatism;
SARC	cis	rs10838532	0.548	rs11038716	chr11:45958444	G/A	cg24204282	chr11:45944920	GYLTL1B	0.42	4.73	0.3	3.95e-6	Axial length;
SARC	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg24531977	chr5:56204891	C5orf35	-0.54	-5.45	-0.34	1.26e-7	Initial pursuit acceleration;
SARC	cis	rs992157	0.717	rs11692780	chr2:219149163	A/G	cg00012203	chr2:219082015	ARPC2	-0.63	-9.09	-0.51	4.3e-17	Colorectal cancer;
SARC	cis	rs1790761	0.692	rs10896179	chr11:67316928	C/A	cg00290607	chr11:67383545	NA	0.36	4.92	0.31	1.67e-6	Mean corpuscular volume;
SARC	cis	rs11098499	0.866	rs9991221	chr4:120292107	G/C	cg09307838	chr4:120376055	NA	0.83	11.82	0.61	1.46e-25	Corneal astigmatism;
SARC	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg24675658	chr1:53192096	ZYG11B	-0.55	-7.63	-0.45	5.9e-13	Monocyte count;
SARC	cis	rs4372836	0.729	rs4638745	chr2:29093803	A/G	cg09522027	chr2:28974177	PPP1CB	-0.35	-4.73	-0.3	3.81e-6	Body mass index;
SARC	cis	rs4423214	0.879	rs1790345	chr11:71145941	G/A	cg05163923	chr11:71159392	DHCR7	-0.61	-7.24	-0.43	6.55e-12	Vitamin D levels;
SARC	cis	rs4742903	0.509	rs58883324	chr9:106969430	T/C	cg14250997	chr9:106856677	SMC2	0.39	4.79	0.3	2.91e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.77	-8.03	-0.47	4.84e-14	Alzheimer's disease;
SARC	cis	rs11098499	0.863	rs6534139	chr4:120449456	A/G	cg24375607	chr4:120327624	NA	-0.42	-4.92	-0.31	1.61e-6	Corneal astigmatism;
SARC	cis	rs12048904	0.930	rs11166529	chr1:101333733	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.41	4.87	0.3	2.05e-6	Multiple sclerosis;
SARC	cis	rs6580649	0.941	rs60681522	chr12:48464195	T/C	cg05342945	chr12:48394962	COL2A1	0.56	6.03	0.37	6.35e-9	Lung cancer;
SARC	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg03213289	chr20:61660250	NA	0.46	6.43	0.39	7.22e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs4555082	0.874	rs2816606	chr14:105716034	C/T	cg10792982	chr14:105748885	BRF1	0.54	7.8	0.46	2.06e-13	Mean platelet volume;Platelet distribution width;
SARC	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg08045932	chr20:61659980	NA	0.5	6.84	0.41	7.06e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg25894440	chr7:65020034	NA	-0.77	-5.95	-0.36	9.84e-9	Diabetic kidney disease;
SARC	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg01448562	chr3:133502909	NA	-0.49	-7.47	-0.44	1.64e-12	Iron status biomarkers;
SARC	cis	rs3796352	1.000	rs35174175	chr3:53041509	T/C	cg12962167	chr3:53033115	SFMBT1	0.82	5.4	0.33	1.61e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs7027203	0.797	rs7870672	chr9:96606693	A/C	cg13679303	chr9:96623674	NA	-0.35	-5.0	-0.31	1.14e-6	DNA methylation (variation);
SARC	cis	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg14343924	chr8:8086146	FLJ10661	0.44	5.58	0.34	6.78e-8	Mood instability;
SARC	cis	rs2120019	1.000	rs1867146	chr15:75354971	C/G	cg00629941	chr15:75287862	SCAMP5	-0.65	-7.55	-0.44	9.64e-13	Blood trace element (Zn levels);
SARC	cis	rs2836633	1.000	rs2836631	chr21:40065906	G/T	cg12884169	chr21:40033163	ERG	-0.44	-7.8	-0.46	2.02e-13	Coronary artery disease;
SARC	trans	rs7819412	0.668	rs920047	chr8:11087475	C/T	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.44	-0.48	3.49e-15	Triglycerides;
SARC	cis	rs7568458	0.709	rs11895401	chr2:85753847	C/T	cg02493740	chr2:85810744	VAMP5	-0.42	-5.5	-0.34	9.81e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs995000	0.899	rs1183260	chr1:62945418	A/G	cg06896770	chr1:63153194	DOCK7	-0.89	-13.31	-0.66	2.01e-30	Triglyceride levels;
SARC	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg23262073	chr20:60523788	NA	-0.38	-5.27	-0.33	3.1e-7	Body mass index;
SARC	cis	rs10782582	0.593	rs6675212	chr1:76230829	C/A	cg03433033	chr1:76189801	ACADM	-0.42	-5.36	-0.33	2.04e-7	Daytime sleep phenotypes;
SARC	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs7552404	0.731	rs61770552	chr1:76373050	T/C	cg10523679	chr1:76189770	ACADM	0.45	5.19	0.32	4.68e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs908922	0.676	rs7529441	chr1:152531629	A/G	cg09873164	chr1:152488093	CRCT1	-0.58	-7.55	-0.44	9.7e-13	Hair morphology;
SARC	cis	rs1881797	1.000	rs10158379	chr1:247686352	C/A	cg11166453	chr1:247681781	NA	0.46	5.18	0.32	4.74e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs7044106	0.708	rs10984992	chr9:123473416	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.18	0.52	2.34e-17	Hip circumference adjusted for BMI;
SARC	cis	rs1707322	1.000	rs11211222	chr1:46367757	T/C	cg03146154	chr1:46216737	IPP	0.47	5.64	0.35	4.94e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs918629	0.754	rs2112566	chr5:95288618	G/A	cg16656078	chr5:95278638	ELL2	-0.68	-8.16	-0.47	2.07e-14	IgG glycosylation;
SARC	trans	rs459571	0.834	rs379417	chr9:136890704	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.58	-6.63	-0.4	2.37e-10	Platelet distribution width;
SARC	cis	rs7824557	0.713	rs6601575	chr8:11097804	A/C	cg21775007	chr8:11205619	TDH	0.46	5.7	0.35	3.52e-8	Retinal vascular caliber;
SARC	cis	rs2070488	1.000	rs7433707	chr3:38443180	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	14.45	0.69	3.14e-34	Electrocardiographic conduction measures;
SARC	cis	rs1348850	0.507	rs10186934	chr2:178425998	T/C	cg23306229	chr2:178417860	TTC30B	0.83	7.44	0.44	1.91e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7785360	0.800	rs6945241	chr7:69736122	T/C	cg10619644	chr7:69149951	AUTS2	0.43	5.0	0.31	1.13e-6	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
SARC	trans	rs2727020	0.521	rs11039902	chr11:48679467	A/G	cg15704280	chr7:45808275	SEPT13	-0.53	-7.19	-0.43	8.66e-12	Coronary artery disease;
SARC	cis	rs6088580	0.634	rs6059860	chr20:33063830	A/C	cg24642439	chr20:33292090	TP53INP2	0.68	8.78	0.5	3.54e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs7582720	1.000	rs114079739	chr2:203825106	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs922107	0.738	rs2045581	chr1:90047068	T/C	cg15422784	chr1:90023713	LRRC8B	-0.32	-4.72	-0.3	4.11e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
SARC	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg19077165	chr18:44547161	KATNAL2	-0.48	-6.68	-0.4	1.73e-10	Personality dimensions;
SARC	cis	rs995000	0.965	rs10789118	chr1:63094692	A/G	cg06896770	chr1:63153194	DOCK7	0.98	15.08	0.7	2.62e-36	Triglyceride levels;
SARC	cis	rs9916302	0.904	rs2338755	chr17:37419317	C/T	cg07936489	chr17:37558343	FBXL20	0.68	9.23	0.52	1.69e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs11874712	1.000	rs28699609	chr18:43674879	A/T	cg25174615	chr18:43684699	ATP5A1;HAUS1	0.4	4.77	0.3	3.31e-6	Migraine - clinic-based;
SARC	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg03351412	chr1:154909251	PMVK	0.56	6.72	0.4	1.37e-10	Prostate cancer;
SARC	cis	rs17376456	0.877	rs10065056	chr5:93380123	G/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.76	0.35	2.64e-8	Diabetic retinopathy;
SARC	cis	rs4423214	1.000	rs2852853	chr11:71150217	C/T	cg05163923	chr11:71159392	DHCR7	0.65	8.74	0.5	4.52e-16	Vitamin D levels;
SARC	cis	rs6546550	0.933	rs6546555	chr2:70135760	A/G	cg02498382	chr2:70120550	SNRNP27	-0.31	-5.04	-0.31	9.3e-7	Prevalent atrial fibrillation;
SARC	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg13902645	chr11:5959945	NA	-0.4	-5.4	-0.33	1.64e-7	DNA methylation (variation);
SARC	cis	rs8114671	0.527	rs2253484	chr20:33405263	A/T	cg07148914	chr20:33460835	GGT7	-0.41	-4.99	-0.31	1.19e-6	Height;
SARC	cis	rs10089	0.857	rs7718286	chr5:127459414	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	10.26	0.56	1.31e-20	Ileal carcinoids;
SARC	cis	rs9640161	0.742	rs2108852	chr7:150019628	T/C	cg17279839	chr7:150038598	RARRES2	0.47	6.62	0.4	2.44e-10	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs7044106	0.537	rs4434680	chr9:123489688	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	8.5	0.49	2.31e-15	Hip circumference adjusted for BMI;
SARC	cis	rs4820539	0.966	rs2267005	chr22:23461723	A/G	cg14186256	chr22:23484241	RTDR1	0.89	13.87	0.67	2.79e-32	Bone mineral density;
SARC	cis	rs7666738	0.830	rs11947027	chr4:99005941	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.95	9.94	0.55	1.23e-19	Platelet count;
SARC	cis	rs2073300	0.609	rs6137914	chr20:23358364	C/T	cg16736954	chr20:23401023	NAPB	0.82	5.08	0.32	7.78e-7	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs703842	1.000	rs2072052	chr12:58146719	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.76	11.21	0.59	1.3e-23	Multiple sclerosis;
SARC	cis	rs3126085	0.935	rs12742573	chr1:152260103	A/C	cg03465714	chr1:152285911	FLG	0.5	5.72	0.35	3.24e-8	Atopic dermatitis;
SARC	cis	rs17376456	0.825	rs10476590	chr5:93244884	A/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.82	0.36	1.92e-8	Diabetic retinopathy;
SARC	cis	rs6500395	0.584	rs4028684	chr16:48741222	A/G	cg04672837	chr16:48644449	N4BP1	0.41	4.72	0.3	4.02e-6	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg15242686	chr22:24348715	GSTTP1	-0.44	-5.34	-0.33	2.17e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs908922	0.847	rs499697	chr1:152493154	A/G	cg09873164	chr1:152488093	CRCT1	-0.65	-7.73	-0.45	3.29e-13	Hair morphology;
SARC	cis	rs7703051	0.585	rs918623	chr5:74596682	A/C	cg19683494	chr5:74908142	NA	0.49	5.55	0.34	7.76e-8	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
SARC	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg24250549	chr1:154909240	PMVK	0.74	9.77	0.54	4.18e-19	Prostate cancer;
SARC	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg22800045	chr5:56110881	MAP3K1	0.77	8.18	0.47	1.86e-14	Initial pursuit acceleration;
SARC	trans	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.11	-0.42	1.43e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs2963155	0.518	rs853179	chr5:142634773	G/T	cg17617527	chr5:142782415	NR3C1	0.81	5.67	0.35	4.31e-8	Breast cancer;
SARC	cis	rs2153535	0.563	rs3117071	chr6:8537908	C/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.47	0.49	2.82e-15	Motion sickness;
SARC	trans	rs10838798	0.504	rs1483123	chr11:48326773	G/A	cg15704280	chr7:45808275	SEPT13	-0.5	-6.91	-0.41	4.51e-11	Height;
SARC	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg02951883	chr7:2050386	MAD1L1	-0.38	-4.81	-0.3	2.76e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs9393692	0.557	rs9358924	chr6:26322473	G/A	cg13736514	chr6:26305472	NA	-0.42	-4.98	-0.31	1.22e-6	Educational attainment;
SARC	cis	rs35110281	0.776	rs2838316	chr21:44990036	C/T	cg21573476	chr21:45109991	RRP1B	-0.53	-7.72	-0.45	3.44e-13	Mean corpuscular volume;
SARC	cis	rs9291683	0.620	rs4383618	chr4:10125151	T/C	cg11266682	chr4:10021025	SLC2A9	-0.37	-6.5	-0.39	4.77e-10	Bone mineral density;
SARC	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg26116260	chr4:7069785	GRPEL1	0.8	8.5	0.49	2.29e-15	Monocyte percentage of white cells;
SARC	cis	rs3087591	0.683	rs2854306	chr17:29648146	G/A	cg24425628	chr17:29625626	OMG;NF1	0.42	5.36	0.33	1.98e-7	Hip circumference;
SARC	cis	rs9291683	0.530	rs4235346	chr4:9945296	C/T	cg00071950	chr4:10020882	SLC2A9	-0.41	-6.49	-0.39	5.22e-10	Bone mineral density;
SARC	cis	rs7772486	0.701	rs7772717	chr6:145954854	T/C	cg23711669	chr6:146136114	FBXO30	0.88	15.07	0.7	2.69e-36	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg06636001	chr8:8085503	FLJ10661	0.75	10.38	0.56	5.51e-21	Joint mobility (Beighton score);
SARC	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg11987759	chr7:65425863	GUSB	0.49	6.35	0.38	1.13e-9	Aortic root size;
SARC	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg22968622	chr17:43663579	NA	-1.13	-15.28	-0.71	5.37e-37	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs3820928	0.839	rs35068645	chr2:227844265	T/C	cg11843606	chr2:227700838	RHBDD1	-0.54	-6.68	-0.4	1.7e-10	Pulmonary function;
SARC	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg24642844	chr7:1081250	C7orf50	-0.38	-5.24	-0.32	3.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs7516138	1.000	rs4240895	chr1:9713386	C/T	cg26573321	chr1:9711663	PIK3CD	0.45	5.85	0.36	1.62e-8	Monocyte count;
SARC	cis	rs11758351	1.000	rs11754744	chr6:26202605	G/A	cg23601095	chr6:26197514	HIST1H3D	0.6	5.26	0.33	3.27e-7	Gout;Renal underexcretion gout;
SARC	cis	rs3733585	0.683	rs13112015	chr4:9933796	C/T	cg00071950	chr4:10020882	SLC2A9	-0.4	-6.44	-0.39	6.95e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs12478296	0.786	rs13409307	chr2:242995499	G/C	cg06360820	chr2:242988706	NA	-0.66	-6.41	-0.39	7.79e-10	Obesity-related traits;
SARC	cis	rs763121	0.853	rs2413544	chr22:39059404	A/C	cg21395723	chr22:39101663	GTPBP1	0.58	6.43	0.39	7.23e-10	Menopause (age at onset);
SARC	cis	rs1008375	0.931	rs2098151	chr4:17577490	T/C	cg02297831	chr4:17616191	MED28	0.47	5.93	0.36	1.09e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7829975	0.582	rs448231	chr8:8790059	A/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-5.98	-0.36	8.5e-9	Mood instability;
SARC	cis	rs2072499	0.750	rs57056972	chr1:156159064	C/A	cg24450063	chr1:156163899	SLC25A44	1.09	14.4	0.69	4.79e-34	Testicular germ cell tumor;
SARC	cis	rs2315504	0.626	rs57976804	chr17:38982245	G/A	cg05063374	chr17:38953512	KRT28	0.27	4.73	0.3	3.9e-6	Height;
SARC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg18402987	chr7:1209562	NA	0.45	6.14	0.37	3.59e-9	Longevity;Endometriosis;
SARC	cis	rs6693567	0.565	rs834237	chr1:150363930	A/G	cg09579323	chr1:150459698	TARS2	0.46	5.8	0.36	2.11e-8	Migraine;
SARC	cis	rs1451375	0.617	rs1376524	chr7:50563582	G/A	cg18232548	chr7:50535776	DDC	-0.47	-4.89	-0.31	1.86e-6	Malaria;
SARC	cis	rs1920116	0.778	rs13074500	chr3:169565571	C/T	cg14222479	chr3:169487675	ARPM1	-0.44	-5.12	-0.32	6.47e-7	Glioma (high-grade);
SARC	cis	rs2228479	0.867	rs73276534	chr16:89950557	A/G	cg06558623	chr16:89946397	TCF25	0.78	6.85	0.41	6.69e-11	Skin colour saturation;
SARC	cis	rs7223966	1.000	rs11654335	chr17:61797579	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	6.88	0.41	5.45e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs986417	0.901	rs1950313	chr14:60997782	A/G	cg27398547	chr14:60952738	C14orf39	0.95	8.45	0.48	3.2e-15	Gut microbiota (bacterial taxa);
SARC	cis	rs2439831	0.867	rs3213990	chr15:43670226	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.04	10.9	0.58	1.25e-22	Lung cancer in ever smokers;
SARC	cis	rs2735413	0.813	rs11644471	chr16:78077237	A/T	cg04733911	chr16:78082701	NA	-0.31	-5.61	-0.34	5.78e-8	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs17376456	0.877	rs67066109	chr5:93494101	G/C	cg25358565	chr5:93447407	FAM172A	1.35	14.13	0.68	3.59e-33	Diabetic retinopathy;
SARC	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg10523679	chr1:76189770	ACADM	0.45	5.59	0.34	6.47e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg05368731	chr17:41323189	NBR1	0.79	9.75	0.54	4.8e-19	Menopause (age at onset);
SARC	cis	rs9290065	0.519	rs956447	chr3:160668917	G/C	cg17135325	chr3:160939158	NMD3	0.43	5.12	0.32	6.27e-7	Kawasaki disease;
SARC	cis	rs9715521	0.775	rs12646141	chr4:59846130	G/C	cg11281224	chr4:60001000	NA	-0.42	-5.25	-0.33	3.48e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg12463550	chr7:65579703	CRCP	-0.67	-5.06	-0.31	8.43e-7	Diabetic kidney disease;
SARC	cis	rs1348850	0.526	rs9288003	chr2:178446572	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.57	5.84	0.36	1.74e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs262150	0.536	rs4909109	chr7:158787168	C/G	cg19418458	chr7:158789849	NA	0.4	4.72	0.3	4.14e-6	Facial morphology (factor 20);
SARC	cis	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg15556689	chr8:8085844	FLJ10661	0.47	5.89	0.36	1.38e-8	Mood instability;
SARC	cis	rs12421382	0.881	rs1808843	chr11:109389471	A/G	cg15948088	chr11:109293068	C11orf87	0.41	5.39	0.33	1.69e-7	Schizophrenia;
SARC	cis	rs11997175	0.646	rs6984073	chr8:33700070	G/A	ch.8.33884649F	chr8:33765107	NA	0.63	8.6	0.49	1.21e-15	Body mass index;
SARC	cis	rs5753618	0.583	rs2273249	chr22:31836486	T/C	cg13145458	chr22:31556086	RNF185	-0.44	-4.8	-0.3	2.82e-6	Colorectal cancer;
SARC	cis	rs2730245	0.636	rs710421	chr7:158668575	T/C	cg24397884	chr7:158709396	WDR60	0.78	10.12	0.55	3.53e-20	Height;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg14249877	chr10:32322959	KIF5B	0.47	6.42	0.39	7.69e-10	Tetralogy of Fallot;
SARC	cis	rs4481887	0.927	rs4453080	chr1:248474671	T/C	cg00666640	chr1:248458726	OR2T12	0.34	5.7	0.35	3.65e-8	Common traits (Other);
SARC	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg18357526	chr6:26021779	HIST1H4A	0.5	5.8	0.36	2.14e-8	Blood metabolite levels;
SARC	cis	rs11190604	1.000	rs11190587	chr10:102266638	C/T	cg07080220	chr10:102295463	HIF1AN	0.75	8.5	0.49	2.24e-15	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg02487422	chr3:49467188	NICN1	0.5	6.83	0.41	7.5e-11	Resting heart rate;
SARC	cis	rs2204008	0.687	rs1733404	chr12:38123395	G/T	cg26384229	chr12:38710491	ALG10B	-0.85	-12.47	-0.63	1.15e-27	Bladder cancer;
SARC	cis	rs4253772	0.626	rs9615960	chr22:46752307	G/A	cg24881330	chr22:46731750	TRMU	0.71	4.85	0.3	2.26e-6	LDL cholesterol;Cholesterol, total;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg07949612	chr2:69664562	NFU1	0.49	6.39	0.39	8.9e-10	Chemerin levels;
SARC	cis	rs965469	1.000	rs6037590	chr20:3374085	G/A	cg25506879	chr20:3388711	C20orf194	-0.52	-5.41	-0.33	1.55e-7	IFN-related cytopenia;
SARC	cis	rs7639513	0.545	rs13061104	chr3:12717321	G/T	cg23032965	chr3:12705835	RAF1	0.71	8.01	0.46	5.43e-14	Itch intensity from mosquito bite;
SARC	cis	rs17376456	0.877	rs10057814	chr5:93399092	C/G	cg25358565	chr5:93447407	FAM172A	1.28	14.98	0.7	5.44e-36	Diabetic retinopathy;
SARC	cis	rs1971762	0.542	rs12303370	chr12:54091807	A/C	cg06632207	chr12:54070931	ATP5G2	0.4	5.11	0.32	6.76e-7	Height;
SARC	trans	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg20587970	chr11:113659929	NA	-1.34	-13.94	-0.67	1.57e-32	Hip circumference adjusted for BMI;
SARC	cis	rs3741404	0.594	rs11231704	chr11:63898182	C/T	cg18225595	chr11:63971243	STIP1	-0.34	-5.31	-0.33	2.55e-7	Platelet count;
SARC	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.41	-0.44	2.32e-12	Gut microbiome composition (summer);
SARC	cis	rs397969	0.646	rs1638528	chr17:19837929	A/G	cg04132472	chr17:19861366	AKAP10	0.4	4.88	0.3	1.98e-6	Platelet count;
SARC	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg18135555	chr8:22132992	PIWIL2	0.41	6.15	0.37	3.33e-9	Hypertriglyceridemia;
SARC	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg00933542	chr6:150070202	PCMT1	0.34	5.73	0.35	3.08e-8	Lung cancer;
SARC	cis	rs9467711	0.591	rs13207673	chr6:25901133	C/T	cg21479132	chr6:26055353	NA	0.76	4.79	0.3	2.93e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg19223190	chr17:80058835	NA	0.49	6.86	0.41	6.02e-11	Life satisfaction;
SARC	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg21361702	chr7:150065534	REPIN1	0.5	5.18	0.32	4.7e-7	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg11878867	chr6:150167359	LRP11	-0.34	-4.72	-0.3	4.01e-6	Lung cancer;
SARC	cis	rs7520050	0.807	rs4660312	chr1:46110572	A/G	cg06784218	chr1:46089804	CCDC17	0.26	4.74	0.3	3.73e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs60871478	1.000	rs7795258	chr7:795227	A/G	cg05535760	chr7:792225	HEATR2	0.75	7.81	0.46	1.9e-13	Cerebrospinal P-tau181p levels;
SARC	cis	rs56036086	0.938	rs6712	chr22:50637922	C/G	cg16473166	chr22:50639996	SELO	0.59	5.18	0.32	4.73e-7	Platelet count;Plateletcrit;
SARC	cis	rs7824557	0.592	rs920044	chr8:11224313	C/T	cg21775007	chr8:11205619	TDH	0.71	9.74	0.54	4.92e-19	Retinal vascular caliber;
SARC	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg21171335	chr12:122356390	WDR66	0.41	6.35	0.38	1.11e-9	Mean corpuscular volume;
SARC	cis	rs3770770	1.000	rs3770770	chr2:37192866	A/G	cg14987922	chr2:37194071	STRN	0.48	4.78	0.3	3.11e-6	QRS duration;
SARC	cis	rs826838	1.000	rs12366971	chr12:38737687	T/G	cg13010199	chr12:38710504	ALG10B	0.83	11.97	0.62	4.63e-26	Heart rate;
SARC	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg11062466	chr8:58055876	NA	0.61	5.75	0.35	2.74e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg16325326	chr1:53192061	ZYG11B	-0.97	-18.69	-0.77	3.09e-48	Monocyte count;
SARC	cis	rs933688	1.000	rs2059208	chr5:90732065	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.0	12.91	0.65	3.94e-29	Smoking behavior;
SARC	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg26335602	chr6:28129616	ZNF389	0.53	5.92	0.36	1.12e-8	Depression;
SARC	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg22496380	chr5:211416	CCDC127	-0.84	-8.6	-0.49	1.19e-15	Breast cancer;
SARC	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10463316	0.855	rs13359064	chr5:150765575	G/A	cg03212797	chr5:150827313	SLC36A1	-0.46	-5.39	-0.33	1.7e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs2230307	0.706	rs12127209	chr1:100562955	T/C	cg24955406	chr1:100503596	HIAT1	0.74	5.33	0.33	2.33e-7	Carotid intima media thickness;
SARC	cis	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg18252515	chr7:66147081	NA	-1.34	-11.93	-0.62	6.47e-26	Diabetic kidney disease;
SARC	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg08219700	chr8:58056026	NA	0.48	4.93	0.31	1.55e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.679	rs16921623	chr8:58039473	G/C	cg11062466	chr8:58055876	NA	0.52	5.02	0.31	1.01e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs9818758	0.607	rs10049462	chr3:49309684	C/T	cg07636037	chr3:49044803	WDR6	-0.75	-6.54	-0.39	3.94e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs2070488	1.000	rs2276540	chr3:38512507	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	14.62	0.69	9.03e-35	Electrocardiographic conduction measures;
SARC	cis	rs7647973	0.710	rs6797299	chr3:49609794	G/T	cg06212747	chr3:49208901	KLHDC8B	0.73	6.49	0.39	5.02e-10	Menarche (age at onset);
SARC	cis	rs453301	0.686	rs11785634	chr8:8892597	G/T	cg11608241	chr8:8085544	FLJ10661	-0.43	-5.47	-0.34	1.17e-7	Joint mobility (Beighton score);
SARC	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg05793240	chr7:2802953	GNA12	-0.36	-5.09	-0.32	7.25e-7	Height;
SARC	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	5.48	0.34	1.07e-7	Personality dimensions;
SARC	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg04166393	chr7:2884313	GNA12	0.65	7.86	0.46	1.43e-13	Height;
SARC	cis	rs1983170	0.736	rs745731	chr1:92011467	G/T	cg25838465	chr1:92012736	NA	0.57	5.89	0.36	1.34e-8	Eosinophil percentage of white cells;
SARC	cis	rs748404	0.578	rs510108	chr15:43605439	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	6.71	0.4	1.46e-10	Lung cancer;
SARC	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg11062466	chr8:58055876	NA	0.53	5.53	0.34	8.39e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs34172651	0.917	rs8043962	chr16:24781372	A/G	cg00339695	chr16:24857497	SLC5A11	0.29	4.87	0.3	2.04e-6	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg20607798	chr8:58055168	NA	0.58	5.57	0.34	6.9e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9815354	1.000	rs1052501	chr3:41925398	C/T	cg03022575	chr3:42003672	ULK4	-0.56	-5.38	-0.33	1.79e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9379850	0.730	rs9393738	chr6:26620658	G/A	cg12826209	chr6:26865740	GUSBL1	0.69	6.15	0.37	3.39e-9	Intelligence (multi-trait analysis);
SARC	cis	rs614226	0.935	rs17431717	chr12:120912210	G/A	cg01236616	chr12:121019343	POP5	-1.16	-15.12	-0.7	1.87e-36	Type 1 diabetes nephropathy;
SARC	cis	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg08045932	chr20:61659980	NA	0.52	7.12	0.42	1.33e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg11890956	chr21:40555474	PSMG1	0.68	9.05	0.51	5.92e-17	Menarche (age at onset);
SARC	cis	rs9303401	0.659	rs62081316	chr17:56781499	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	12.31	0.63	3.57e-27	Cognitive test performance;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg18439323	chr14:23755769	HOMEZ	0.49	6.3	0.38	1.46e-9	Lung adenocarcinoma;
SARC	trans	rs7824557	0.872	rs1347410	chr8:11111242	G/A	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.1	-0.42	1.49e-11	Retinal vascular caliber;
SARC	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg03806693	chr22:41940476	POLR3H	0.83	11.73	0.61	2.8e-25	Vitiligo;
SARC	cis	rs2200578	1.000	rs116648076	chr2:99882347	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.55	5.26	0.33	3.26e-7	IgG glycosylation;
SARC	cis	rs9911578	0.704	rs72628393	chr17:56585314	A/T	cg05425664	chr17:57184151	TRIM37	0.63	7.55	0.44	9.61e-13	Intelligence (multi-trait analysis);
SARC	cis	rs1707322	0.721	rs10890344	chr1:46166090	C/T	cg03146154	chr1:46216737	IPP	0.53	6.35	0.38	1.12e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs834603	0.575	rs834609	chr7:47456846	T/C	cg23694490	chr7:47445681	TNS3	-0.34	-6.12	-0.37	4.03e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs6570726	0.902	rs396681	chr6:145853603	T/C	cg05220968	chr6:146057943	EPM2A	-0.3	-5.11	-0.32	6.75e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	12.58	0.64	4.75e-28	Chronic sinus infection;
SARC	cis	rs858239	0.601	rs764534	chr7:23153935	C/T	cg23682824	chr7:23144976	KLHL7	0.66	8.55	0.49	1.68e-15	Cerebrospinal fluid biomarker levels;
SARC	cis	rs6582630	0.555	rs11182217	chr12:38480030	G/A	cg13010199	chr12:38710504	ALG10B	0.77	10.36	0.56	6.35e-21	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6674176	0.593	rs6675620	chr1:44417630	C/T	cg12908607	chr1:44402522	ARTN	-0.38	-6.28	-0.38	1.62e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs1401999	0.966	rs4148585	chr3:183670642	A/G	cg01324343	chr3:183735012	ABCC5	0.67	13.35	0.66	1.47e-30	Anterior chamber depth;
SARC	cis	rs3617	0.625	rs2240915	chr3:52859526	T/A	cg18404041	chr3:52824283	ITIH1	-0.36	-5.3	-0.33	2.73e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs2011503	1.000	rs2965179	chr19:19512755	G/A	cg15839431	chr19:19639596	YJEFN3	-0.5	-4.9	-0.31	1.78e-6	Bipolar disorder;
SARC	cis	rs9517320	0.515	rs4772101	chr13:99207554	G/A	cg07423050	chr13:99094983	FARP1	-0.42	-5.4	-0.33	1.67e-7	Longevity;
SARC	cis	rs11608355	0.960	rs3742021	chr12:109883117	T/C	cg19025524	chr12:109796872	NA	-0.4	-5.19	-0.32	4.63e-7	Neuroticism;
SARC	cis	rs8053891	0.906	rs12149877	chr16:71996067	T/C	cg16558253	chr16:72132732	DHX38	-0.41	-5.37	-0.33	1.94e-7	Coronary artery disease;
SARC	cis	rs1707322	1.000	rs11211244	chr1:46456673	G/A	cg03146154	chr1:46216737	IPP	0.46	5.59	0.34	6.25e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs10089	1.000	rs13355233	chr5:127425350	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.82	-10.44	-0.56	3.45e-21	Ileal carcinoids;
SARC	cis	rs73001065	0.591	rs57962361	chr19:19425025	C/T	cg03709012	chr19:19516395	GATAD2A	1.09	7.12	0.42	1.35e-11	LDL cholesterol;
SARC	cis	rs7937682	0.889	rs10749984	chr11:111492861	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.89	-14.18	-0.68	2.61e-33	Primary sclerosing cholangitis;
SARC	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg18252515	chr7:66147081	NA	-1.25	-10.99	-0.58	6.44e-23	Diabetic kidney disease;
SARC	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg16479474	chr6:28041457	NA	0.38	5.53	0.34	8.36e-8	Depression;
SARC	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg03185022	chr7:2884158	GNA12	-0.42	-4.72	-0.3	4.16e-6	Height;
SARC	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.4	-4.99	-0.31	1.18e-6	Lymphocyte counts;
SARC	cis	rs11112613	0.938	rs2374513	chr12:106007300	C/T	cg03607813	chr12:105948248	NA	0.52	6.18	0.38	2.88e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg20818283	chr2:191399100	TMEM194B	0.43	5.51	0.34	9.68e-8	Pulse pressure;
SARC	cis	rs9788721	0.934	rs1317286	chr15:78896129	A/G	cg06917634	chr15:78832804	PSMA4	-0.54	-5.85	-0.36	1.69e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs748404	0.660	rs2249952	chr15:43720533	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.4	4.78	0.3	3.13e-6	Lung cancer;
SARC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg07167872	chr1:205819463	PM20D1	0.47	6.3	0.38	1.5e-9	Menarche (age at onset);
SARC	cis	rs4718428	0.705	rs13220977	chr7:66337648	A/T	cg12165864	chr7:66369176	NA	0.46	5.17	0.32	5.12e-7	Corneal structure;
SARC	cis	rs71636778	0.524	rs78614739	chr1:27174180	C/T	cg04852280	chr1:26496234	ZNF593	0.52	5.0	0.31	1.11e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs7949030	0.590	rs12225213	chr11:62350248	T/A	cg22862634	chr11:62369728	EML3;MTA2	0.52	7.93	0.46	8.84e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs561341	0.654	rs6505265	chr17:30172580	C/T	cg13647721	chr17:30228624	UTP6	-0.71	-6.52	-0.39	4.39e-10	Hip circumference adjusted for BMI;
SARC	cis	rs2731664	0.756	rs335433	chr5:176867207	T/C	cg23176889	chr5:176863531	GRK6	-0.57	-8.43	-0.48	3.58e-15	Intelligence (multi-trait analysis);
SARC	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.02	-16.67	-0.74	1.31e-41	Prudent dietary pattern;
SARC	cis	rs3892630	0.588	rs28787932	chr19:33226229	T/C	cg22980127	chr19:33182716	NUDT19	1.1	11.04	0.59	4.54e-23	Red blood cell traits;
SARC	cis	rs2153535	0.580	rs1335641	chr6:8487860	G/T	cg21535247	chr6:8435926	SLC35B3	0.55	6.9	0.41	4.76e-11	Motion sickness;
SARC	cis	rs477692	1.000	rs506274	chr10:131409392	T/A	cg05714579	chr10:131428358	MGMT	0.6	7.81	0.46	1.94e-13	Response to temozolomide;
SARC	cis	rs644799	0.648	rs1255178	chr11:95471908	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.71	9.9	0.54	1.58e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.54	6.95	0.41	3.63e-11	Personality dimensions;
SARC	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4969178	0.896	rs11077361	chr17:76397128	A/G	cg02836325	chr17:76403955	PGS1	0.33	5.01	0.31	1.07e-6	HDL cholesterol levels;
SARC	cis	rs2645694	0.533	rs2645681	chr4:77820949	G/A	cg06046430	chr4:77819534	ANKRD56	0.54	7.78	0.45	2.35e-13	Emphysema distribution in smoking;
SARC	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.75	6.56	0.39	3.51e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs6582630	0.502	rs1115515	chr12:38279830	C/T	cg13010199	chr12:38710504	ALG10B	0.81	11.31	0.6	6.15e-24	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs3762637	1.000	rs9867429	chr3:122232668	T/C	cg24169773	chr3:122142474	KPNA1	-0.56	-5.67	-0.35	4.18e-8	LDL cholesterol levels;
SARC	cis	rs2153535	0.580	rs6937186	chr6:8494493	A/C	cg07606381	chr6:8435919	SLC35B3	0.79	11.44	0.6	2.41e-24	Motion sickness;
SARC	trans	rs2018683	0.899	rs10479817	chr7:28978148	A/C	cg19402173	chr7:128379420	CALU	-0.67	-8.76	-0.5	4.15e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs4900538	0.927	rs1190547	chr14:102905087	G/C	cg18135206	chr14:102964638	TECPR2	-0.69	-9.42	-0.53	4.68e-18	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs7520050	0.933	rs6656022	chr1:46394315	A/G	cg24296786	chr1:45957014	TESK2	0.39	4.9	0.31	1.77e-6	Red blood cell count;Reticulocyte count;
SARC	trans	rs3808502	0.503	rs2061830	chr8:11397457	C/G	cg06636001	chr8:8085503	FLJ10661	0.69	9.79	0.54	3.59e-19	Neuroticism;
SARC	cis	rs7818688	0.697	rs11787303	chr8:95972864	C/T	cg13393036	chr8:95962371	TP53INP1	0.41	4.81	0.3	2.65e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.06	17.67	0.76	6.52e-45	Height;
SARC	cis	rs6545883	0.929	rs13413337	chr2:61747123	A/G	cg15711740	chr2:61764176	XPO1	-0.42	-5.22	-0.32	3.9e-7	Tuberculosis;
SARC	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg12463550	chr7:65579703	CRCP	-0.49	-5.28	-0.33	2.93e-7	Aortic root size;
SARC	cis	rs17376456	0.825	rs13361613	chr5:93272176	C/T	cg25358565	chr5:93447407	FAM172A	1.29	14.23	0.68	1.68e-33	Diabetic retinopathy;
SARC	cis	rs17023223	0.537	rs10802073	chr1:119604655	T/C	cg05756136	chr1:119680316	WARS2	-0.43	-5.03	-0.31	9.81e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs7364180	0.515	rs6002503	chr22:42208672	A/G	cg03806693	chr22:41940476	POLR3H	-0.62	-8.46	-0.48	2.97e-15	Alzheimer's disease biomarkers;
SARC	cis	rs637571	0.584	rs7107912	chr11:65603252	G/A	cg26695010	chr11:65641043	EFEMP2	0.77	11.7	0.61	3.43e-25	Eosinophil percentage of white cells;
SARC	cis	rs7208859	0.673	rs9913782	chr17:29237384	A/G	cg13385521	chr17:29058706	SUZ12P	0.86	7.14	0.42	1.19e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs17023223	0.537	rs2361270	chr1:119603322	T/C	cg05756136	chr1:119680316	WARS2	-0.43	-5.03	-0.31	9.81e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs796364	0.951	rs12613687	chr2:200999256	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.58	-5.34	-0.33	2.21e-7	Schizophrenia;
SARC	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg13206674	chr6:150067644	NUP43	0.42	5.54	0.34	8.16e-8	Lung cancer;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg17214676	chr8:92260467	SLC26A7	0.46	6.61	0.4	2.66e-10	Thyroid stimulating hormone;
SARC	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg11644478	chr21:40555479	PSMG1	0.91	12.25	0.63	5.69e-27	Cognitive function;
SARC	cis	rs7264396	0.790	rs11697903	chr20:34272224	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	5.78	0.35	2.33e-8	Total cholesterol levels;
SARC	cis	rs4319547	1.000	rs4319547	chr12:123079035	A/G	cg23029597	chr12:123009494	RSRC2	-0.39	-4.97	-0.31	1.33e-6	Body mass index;
SARC	cis	rs9911578	0.874	rs302865	chr17:56756977	A/G	cg12560992	chr17:57184187	TRIM37	0.83	11.31	0.6	6.15e-24	Intelligence (multi-trait analysis);
SARC	cis	rs2731664	0.792	rs163199	chr5:176890067	A/G	cg23176889	chr5:176863531	GRK6	-0.57	-8.66	-0.49	8.11e-16	Intelligence (multi-trait analysis);
SARC	cis	rs3820928	0.967	rs4675114	chr2:227768362	C/T	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.86	-0.36	1.56e-8	Pulmonary function;
SARC	cis	rs7103648	0.735	rs3824869	chr11:47378245	T/C	cg10504702	chr11:47789108	FNBP4	-0.55	-6.65	-0.4	2.12e-10	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs4253772	0.591	rs6008361	chr22:46652372	A/G	cg24881330	chr22:46731750	TRMU	-0.64	-7.0	-0.42	2.69e-11	LDL cholesterol;Cholesterol, total;
SARC	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg04772025	chr11:68637568	NA	0.53	6.53	0.39	4.19e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg13939156	chr17:80058883	NA	0.4	6.25	0.38	1.92e-9	Life satisfaction;
SARC	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg11764359	chr7:65958608	NA	-0.75	-8.74	-0.5	4.75e-16	Aortic root size;
SARC	cis	rs924607	1.000	rs2455331	chr5:643593	T/C	cg09021430	chr5:549028	NA	-0.32	-6.13	-0.37	3.64e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg19346786	chr7:2764209	NA	-0.4	-6.04	-0.37	6.07e-9	Height;
SARC	cis	rs854765	0.547	rs2955385	chr17:17939247	C/T	cg04398451	chr17:18023971	MYO15A	-0.46	-6.5	-0.39	4.85e-10	Total body bone mineral density;
SARC	cis	rs453301	0.631	rs7843369	chr8:8797786	T/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-5.27	-0.33	3.06e-7	Joint mobility (Beighton score);
SARC	cis	rs6430585	0.528	rs3099429	chr2:136655582	T/A	cg07169764	chr2:136633963	MCM6	0.99	12.82	0.64	7.77e-29	Corneal structure;
SARC	cis	rs4713118	0.868	rs35069907	chr6:27746692	T/C	cg17221315	chr6:27791827	HIST1H4J	0.53	5.31	0.33	2.51e-7	Parkinson's disease;
SARC	cis	rs274567	0.602	rs272853	chr5:131688561	A/G	cg11843238	chr5:131593191	PDLIM4	0.37	4.82	0.3	2.53e-6	Blood metabolite levels;
SARC	trans	rs629535	0.814	rs558511	chr8:70069908	C/A	cg21567404	chr3:27674614	NA	1.04	13.3	0.66	2.13e-30	Dupuytren's disease;
SARC	cis	rs2933343	0.679	rs789221	chr3:128591625	A/G	cg24203234	chr3:128598194	ACAD9	0.63	7.95	0.46	7.89e-14	IgG glycosylation;
SARC	cis	rs2652834	1.000	rs2652833	chr15:63396885	C/A	cg05507819	chr15:63340323	TPM1	0.54	5.36	0.33	2e-7	HDL cholesterol;
SARC	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg11764359	chr7:65958608	NA	-0.78	-9.48	-0.53	3e-18	Aortic root size;
SARC	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg16414030	chr3:133502952	NA	-0.4	-5.49	-0.34	1.06e-7	Iron status biomarkers;
SARC	cis	rs853679	0.599	rs149990	chr6:27998258	G/A	cg19592336	chr6:28129416	ZNF389	0.66	5.07	0.31	8.27e-7	Depression;
SARC	cis	rs1707322	1.000	rs12097799	chr1:46459886	C/A	cg06784218	chr1:46089804	CCDC17	0.35	6.07	0.37	5.11e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg22920501	chr2:26401640	FAM59B	-0.53	-6.56	-0.4	3.37e-10	Gut microbiome composition (summer);
SARC	cis	rs2153535	0.580	rs9406163	chr6:8466642	C/T	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	cis	rs7608910	0.556	rs10181042	chr2:61224259	A/G	cg10580144	chr2:61372316	C2orf74	-0.39	-5.31	-0.33	2.59e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs8067354	0.831	rs2333617	chr17:57896220	T/A	cg13753209	chr17:57696993	CLTC	-0.53	-6.66	-0.4	1.9e-10	Hemoglobin concentration;
SARC	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg11644478	chr21:40555479	PSMG1	1.04	14.71	0.69	4.31e-35	Cognitive function;
SARC	cis	rs4555082	0.834	rs4412909	chr14:105759226	T/C	cg13114125	chr14:105738426	BRF1	-0.79	-11.12	-0.59	2.53e-23	Mean platelet volume;Platelet distribution width;
SARC	cis	rs9303401	0.659	rs34382037	chr17:56643550	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	11.65	0.61	5.15e-25	Cognitive test performance;
SARC	cis	rs7582720	1.000	rs72936846	chr2:203774734	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.26	0.43	5.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg12229505	chr15:80351983	ZFAND6	0.52	6.55	0.39	3.63e-10	Breast cancer;
SARC	cis	rs2072499	1.000	rs2253809	chr1:156172125	T/C	cg24450063	chr1:156163899	SLC25A44	1.14	19.67	0.79	2.06e-51	Testicular germ cell tumor;
SARC	cis	rs6088813	0.857	rs1886692	chr20:33986549	C/T	cg14752227	chr20:34000481	UQCC	-0.38	-4.84	-0.3	2.31e-6	Height;
SARC	cis	rs2439831	0.850	rs3742982	chr15:44176681	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.81	7.57	0.44	8.72e-13	Lung cancer in ever smokers;
SARC	trans	rs11098499	0.779	rs10016060	chr4:120298412	A/G	cg25214090	chr10:38739885	LOC399744	0.55	7.14	0.42	1.15e-11	Corneal astigmatism;
SARC	cis	rs11758351	0.866	rs56186759	chr6:26207181	C/T	cg01420254	chr6:26195488	NA	0.53	4.82	0.3	2.63e-6	Gout;Renal underexcretion gout;
SARC	cis	rs3099143	1.000	rs3102712	chr15:77058926	G/A	cg21673338	chr15:77095150	SCAPER	-0.76	-6.31	-0.38	1.42e-9	Recalcitrant atopic dermatitis;
SARC	cis	rs7223966	1.000	rs56057198	chr17:61733332	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	6.1	0.37	4.46e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs67311347	1.000	rs2887995	chr3:40409029	C/G	cg24209194	chr3:40518798	ZNF619	0.59	7.46	0.44	1.69e-12	Renal cell carcinoma;
SARC	cis	rs11792861	0.816	rs72607157	chr9:111748001	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.74	8.66	0.49	8.11e-16	Menarche (age at onset);
SARC	cis	rs6448317	0.638	rs35772326	chr4:24923871	G/A	cg21108841	chr4:24914750	CCDC149	-0.52	-4.72	-0.3	4e-6	Heschl's gyrus morphology;
SARC	cis	rs7043114	0.525	rs7850432	chr9:95130510	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.81	-0.36	2.02e-8	Height;
SARC	cis	rs10504229	0.636	rs114725691	chr8:58054292	C/T	cg21724239	chr8:58056113	NA	0.59	5.94	0.36	1.05e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg11062466	chr8:58055876	NA	-0.63	-5.85	-0.36	1.67e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs61931739	0.534	rs4001713	chr12:34154195	A/C	cg13010199	chr12:38710504	ALG10B	-0.73	-9.5	-0.53	2.74e-18	Morning vs. evening chronotype;
SARC	cis	rs6582630	0.502	rs4559747	chr12:38436235	G/A	cg26384229	chr12:38710491	ALG10B	0.83	12.05	0.62	2.65e-26	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg00053292	chr17:61678300	TACO1	-0.52	-6.48	-0.39	5.45e-10	Height;
SARC	cis	rs11122272	0.701	rs2749702	chr1:231523808	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs12586317	0.620	rs76293361	chr14:35570889	G/A	cg05294307	chr14:35346193	BAZ1A	-0.48	-4.93	-0.31	1.59e-6	Psoriasis;
SARC	cis	rs7103648	1.000	rs2293579	chr11:47440758	G/A	cg10504702	chr11:47789108	FNBP4	0.59	7.7	0.45	3.88e-13	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg12463550	chr7:65579703	CRCP	-0.69	-5.48	-0.34	1.08e-7	Diabetic kidney disease;
SARC	cis	rs2251381	0.778	rs2471947	chr21:30534219	G/T	cg08807101	chr21:30365312	RNF160	0.76	10.34	0.56	7.36e-21	Selective IgA deficiency;
SARC	cis	rs651907	0.535	rs13094911	chr3:101519021	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	5.8	0.36	2.13e-8	Colorectal cancer;
SARC	cis	rs2250402	0.510	rs2291619	chr15:40329033	C/T	cg01081584	chr15:40268610	EIF2AK4	0.66	5.63	0.35	5.27e-8	Corneal curvature;
SARC	cis	rs10504073	0.669	rs11779189	chr8:50030592	C/G	cg00325661	chr8:49890786	NA	-0.56	-7.69	-0.45	4.07e-13	Blood metabolite ratios;
SARC	cis	rs4481887	0.962	rs6587452	chr1:248485931	C/T	cg13385794	chr1:248469461	NA	0.36	5.35	0.33	2.14e-7	Common traits (Other);
SARC	cis	rs992157	0.764	rs10932774	chr2:219191569	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.63	8.38	0.48	4.95e-15	Colorectal cancer;
SARC	cis	rs72945132	0.709	rs28634008	chr11:70225719	A/C	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.69	-0.35	3.74e-8	Coronary artery disease;
SARC	cis	rs4243830	0.579	rs10779794	chr1:6612651	C/G	cg04093404	chr1:6614507	TAS1R1;NOL9	0.59	4.93	0.31	1.59e-6	Body mass index;
SARC	cis	rs16866061	0.515	rs13020268	chr2:225437923	C/T	cg12698349	chr2:225449008	CUL3	0.86	15.79	0.72	1.09e-38	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	cis	rs4595586	0.679	rs1356264	chr12:39393754	A/T	cg26384229	chr12:38710491	ALG10B	0.43	5.42	0.33	1.46e-7	Morning vs. evening chronotype;
SARC	cis	rs2576037	0.796	rs2571020	chr18:44584189	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.36	-5.02	-0.31	1.03e-6	Personality dimensions;
SARC	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg15448220	chr1:150897856	SETDB1	0.47	6.25	0.38	1.94e-9	Tonsillectomy;
SARC	cis	rs963731	0.649	rs2305516	chr2:39198966	C/T	cg04010122	chr2:39346883	SOS1	0.87	5.95	0.36	9.87e-9	Corticobasal degeneration;
SARC	cis	rs7914558	0.933	rs1538204	chr10:104733893	T/A	cg04362960	chr10:104952993	NT5C2	0.41	5.0	0.31	1.14e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs273218	1.000	rs156385	chr5:53370749	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.62	6.88	0.41	5.34e-11	Migraine;
SARC	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg06618935	chr21:46677482	NA	-0.38	-5.09	-0.32	7.31e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs829883	0.659	rs11109524	chr12:98939172	G/A	cg25150519	chr12:98850993	NA	-0.6	-7.41	-0.44	2.34e-12	Colorectal adenoma (advanced);
SARC	trans	rs61931739	0.500	rs10844863	chr12:34532284	C/T	cg26384229	chr12:38710491	ALG10B	0.85	12.63	0.64	3.4e-28	Morning vs. evening chronotype;
SARC	cis	rs916888	0.610	rs142167	chr17:44795234	C/T	cg15921436	chr17:44337874	NA	-0.46	-5.17	-0.32	5.08e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs5167	0.533	rs11083755	chr19:45490065	C/T	cg09555818	chr19:45449301	APOC2	0.39	5.17	0.32	5.11e-7	Blood protein levels;
SARC	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg18225595	chr11:63971243	STIP1	0.46	5.39	0.33	1.77e-7	Mean platelet volume;
SARC	cis	rs116095464	0.558	rs6879656	chr5:264428	T/C	cg22496380	chr5:211416	CCDC127	-0.94	-9.15	-0.51	2.86e-17	Breast cancer;
SARC	cis	rs4851254	0.961	rs11691486	chr2:100796182	T/C	cg17356467	chr2:100759845	AFF3	0.28	4.73	0.3	3.9e-6	Intelligence (multi-trait analysis);
SARC	cis	rs995000	0.868	rs4409689	chr1:63177365	A/G	cg06896770	chr1:63153194	DOCK7	0.86	13.23	0.65	3.61e-30	Triglyceride levels;
SARC	cis	rs9296092	0.517	rs9461876	chr6:33516657	C/T	cg13560919	chr6:33536144	NA	-0.5	-5.91	-0.36	1.22e-8	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs13082711	0.595	rs6778612	chr3:27370789	T/C	cg02860705	chr3:27208620	NA	-0.53	-6.77	-0.41	1.01e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs1729951	0.575	rs361245	chr3:136695706	A/G	cg15507776	chr3:136538369	TMEM22	0.49	5.4	0.33	1.66e-7	Neuroticism;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg07240937	chr1:153650963	NPR1	-0.61	-7.4	-0.44	2.42e-12	Alcohol dependence;
SARC	cis	rs16944613	0.528	rs6416554	chr15:91138290	T/C	cg26821196	chr15:91095069	CRTC3	0.52	5.31	0.33	2.51e-7	Colorectal cancer;
SARC	cis	rs67311347	1.000	rs56992941	chr3:40472434	A/T	cg09455208	chr3:40491958	NA	0.42	6.66	0.4	1.92e-10	Renal cell carcinoma;
SARC	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg06634786	chr22:41940651	POLR3H	0.51	6.09	0.37	4.6e-9	Vitiligo;
SARC	cis	rs6580649	0.941	rs72644842	chr12:48448274	A/G	cg24011408	chr12:48396354	COL2A1	-0.48	-5.38	-0.33	1.78e-7	Lung cancer;
SARC	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg15352829	chr14:105391018	PLD4	0.34	6.39	0.39	9.01e-10	Rheumatoid arthritis;
SARC	cis	rs7255436	0.965	rs28729307	chr19:8452742	A/G	cg10174797	chr19:8464628	RAB11B	0.44	6.28	0.38	1.63e-9	HDL cholesterol;
SARC	cis	rs10979	1.000	rs9386038	chr6:143896358	A/G	cg25407410	chr6:143891975	LOC285740	-0.64	-8.78	-0.5	3.67e-16	Hypospadias;
SARC	cis	rs7772486	0.790	rs9497431	chr6:146248177	T/C	cg05347473	chr6:146136440	FBXO30	-0.5	-6.79	-0.41	9.48e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2115630	0.936	rs8033459	chr15:85253258	C/T	cg12501888	chr15:85177176	SCAND2	-0.46	-5.57	-0.34	7.18e-8	P wave terminal force;
SARC	cis	rs7647973	0.922	rs57273516	chr3:49483074	A/G	cg06212747	chr3:49208901	KLHDC8B	0.57	6.19	0.38	2.71e-9	Menarche (age at onset);
SARC	cis	rs7959452	0.640	rs1598543	chr12:69688757	G/T	cg20891283	chr12:69753455	YEATS4	0.41	5.46	0.34	1.22e-7	Blood protein levels;
SARC	trans	rs12310956	0.532	rs11052933	chr12:33969881	G/A	cg26384229	chr12:38710491	ALG10B	0.85	12.42	0.63	1.57e-27	Morning vs. evening chronotype;
SARC	cis	rs240764	0.817	rs240110	chr6:101059629	T/C	cg09795085	chr6:101329169	ASCC3	0.45	5.59	0.34	6.2e-8	Neuroticism;
SARC	cis	rs6570726	0.846	rs6914304	chr6:145921017	T/C	cg05347473	chr6:146136440	FBXO30	0.5	6.89	0.41	5.18e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs57920188	0.568	rs10915665	chr1:4093717	G/T	cg20703997	chr1:4087676	NA	0.5	5.08	0.32	7.64e-7	Interleukin-17 levels;
SARC	cis	rs7520050	0.966	rs61102033	chr1:46382441	G/T	cg06784218	chr1:46089804	CCDC17	-0.26	-4.75	-0.3	3.57e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs9815354	0.812	rs73071222	chr3:41986896	C/T	cg03022575	chr3:42003672	ULK4	0.72	6.26	0.38	1.79e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2120243	0.539	rs6441127	chr3:157095507	T/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.39	4.9	0.31	1.78e-6	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg11987759	chr7:65425863	GUSB	-0.5	-6.52	-0.39	4.3e-10	Aortic root size;
SARC	cis	rs4481887	0.927	rs6666903	chr1:248465582	T/A	cg13385794	chr1:248469461	NA	0.32	5.13	0.32	6.13e-7	Common traits (Other);
SARC	trans	rs2486950	1.000	rs2244783	chr1:203188093	A/G	cg08259168	chr1:78509494	NA	0.38	6.41	0.39	8.18e-10	Blood protein levels;
SARC	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg27266027	chr21:40555129	PSMG1	0.52	5.68	0.35	3.9e-8	Cognitive function;
SARC	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg16479474	chr6:28041457	NA	0.37	5.37	0.33	1.94e-7	Depression;
SARC	cis	rs7582720	1.000	rs72934505	chr2:203916487	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	7.57	0.44	8.6e-13	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs9788721	0.902	rs7180002	chr15:78873993	A/T	cg06917634	chr15:78832804	PSMA4	-0.53	-5.76	-0.35	2.67e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs2455601	0.608	rs11042104	chr11:8890924	C/G	cg21881798	chr11:8931708	C11orf17;ST5	0.4	4.87	0.3	2.05e-6	Schizophrenia;
SARC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg11494091	chr17:61959527	GH2	0.53	7.96	0.46	7.52e-14	Prudent dietary pattern;
SARC	cis	rs473651	0.935	rs1103770	chr2:239339281	G/C	cg21699342	chr2:239360505	ASB1	0.49	5.95	0.36	9.57e-9	Multiple system atrophy;
SARC	cis	rs910316	0.935	rs175076	chr14:75505486	A/G	cg08847533	chr14:75593920	NEK9	-0.9	-13.88	-0.67	2.49e-32	Height;
SARC	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg11987759	chr7:65425863	GUSB	-0.47	-6.27	-0.38	1.7e-9	Aortic root size;
SARC	cis	rs9916302	0.851	rs7225096	chr17:37664443	T/C	cg20243544	chr17:37824526	PNMT	0.55	6.53	0.39	4.05e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs2236918	0.643	rs1776139	chr1:242027363	T/G	cg17736920	chr1:242011382	EXO1	0.65	8.89	0.5	1.76e-16	Menopause (age at onset);
SARC	cis	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg08975724	chr8:8085496	FLJ10661	0.49	6.12	0.37	4.01e-9	Mood instability;
SARC	cis	rs9818758	0.607	rs66991555	chr3:49228643	A/G	cg00383909	chr3:49044727	WDR6	0.66	5.77	0.35	2.45e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	trans	rs9329221	0.537	rs6601415	chr8:9976805	C/A	cg06636001	chr8:8085503	FLJ10661	0.57	7.78	0.45	2.39e-13	Neuroticism;
SARC	trans	rs7824557	0.527	rs57629785	chr8:11235150	C/A	cg15556689	chr8:8085844	FLJ10661	-0.55	-6.99	-0.42	2.9e-11	Retinal vascular caliber;
SARC	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg18876405	chr7:65276391	NA	0.48	5.79	0.35	2.26e-8	Aortic root size;
SARC	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg17376030	chr22:41985996	PMM1	0.77	9.47	0.53	3.31e-18	Vitiligo;
SARC	cis	rs4430311	0.723	rs4639743	chr1:243946072	G/A	cg21452805	chr1:244014465	NA	-0.38	-4.91	-0.31	1.71e-6	Post-traumatic stress disorder (asjusted for relatedness);
SARC	cis	rs1150668	0.796	rs728122	chr6:28399124	G/A	cg13525197	chr6:28411240	ZSCAN23	-0.43	-5.25	-0.33	3.44e-7	Pubertal anthropometrics;
SARC	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg16316162	chr8:144660157	NAPRT1	-0.62	-5.61	-0.35	5.58e-8	Attention deficit hyperactivity disorder;
SARC	cis	rs7412746	0.524	rs58304714	chr1:150831561	T/A	cg13175981	chr1:150552382	MCL1	-0.5	-6.06	-0.37	5.3e-9	Melanoma;
SARC	cis	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg22857025	chr5:266934	NA	-1.06	-11.8	-0.61	1.74e-25	Breast cancer;
SARC	cis	rs12681288	0.712	rs2600488	chr8:1021266	A/C	cg15309053	chr8:964076	NA	0.41	7.03	0.42	2.24e-11	Schizophrenia;
SARC	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs796364	0.625	rs13035260	chr2:201132377	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.62	-5.83	-0.36	1.86e-8	Schizophrenia;
SARC	cis	rs6908034	0.556	rs77486465	chr6:19803862	T/G	cg02682789	chr6:19804855	NA	0.72	5.08	0.32	7.8e-7	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg09359103	chr1:154839909	KCNN3	-0.46	-7.8	-0.46	2e-13	Prostate cancer;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg03031660	chr17:73257791	MRPS7;GGA3	-0.59	-6.67	-0.4	1.8e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs2180341	0.883	rs7760748	chr6:127690062	C/T	cg17762328	chr6:126965162	NA	-0.45	-4.98	-0.31	1.21e-6	Breast cancer;
SARC	trans	rs12121840	0.607	rs285435	chr1:165518480	G/A	cg13809270	chr4:830645	NA	0.53	6.24	0.38	2.07e-9	Interleukin-1-receptor antagonist levels;
SARC	cis	rs17376456	0.825	rs13171131	chr5:93223028	C/T	cg25358565	chr5:93447407	FAM172A	1.24	13.22	0.65	3.96e-30	Diabetic retinopathy;
SARC	cis	rs10504229	0.680	rs16921675	chr8:58052082	A/G	cg11062466	chr8:58055876	NA	0.5	4.85	0.3	2.21e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs9916302	0.904	rs6503519	chr17:37706578	A/G	cg15445000	chr17:37608096	MED1	0.42	4.91	0.31	1.68e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs9916302	0.904	rs11869109	chr17:37518205	G/T	cg20243544	chr17:37824526	PNMT	-0.53	-6.37	-0.39	9.76e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs34779708	0.931	rs12248333	chr10:35362977	A/G	cg03585969	chr10:35415529	CREM	0.38	4.79	0.3	3e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs875971	0.545	rs316323	chr7:65610989	C/T	cg11764359	chr7:65958608	NA	-0.65	-6.42	-0.39	7.5e-10	Aortic root size;
SARC	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	8.98	0.51	9.16e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7769051	0.711	rs7770081	chr6:133089569	G/T	cg22852734	chr6:133119734	C6orf192	1.09	10.62	0.57	9.6e-22	Type 2 diabetes nephropathy;
SARC	cis	rs7103648	0.897	rs11606287	chr11:47407439	C/A	cg20307385	chr11:47447363	PSMC3	0.8	11.61	0.61	7.11e-25	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg13206674	chr6:150067644	NUP43	0.39	5.04	0.31	9.19e-7	Lung cancer;
SARC	cis	rs4595586	0.545	rs11611625	chr12:39387207	T/C	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	cis	rs7084402	0.967	rs12261597	chr10:60297662	T/C	cg07615347	chr10:60278583	BICC1	-0.55	-8.09	-0.47	3.35e-14	Refractive error;
SARC	cis	rs3020736	0.500	rs6519306	chr22:42501217	T/C	cg15557168	chr22:42548783	NA	0.35	4.8	0.3	2.85e-6	Autism spectrum disorder or schizophrenia;
SARC	trans	rs9329221	0.512	rs7843924	chr8:9976540	C/T	cg06636001	chr8:8085503	FLJ10661	0.56	7.69	0.45	4.06e-13	Neuroticism;
SARC	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	12.32	0.63	3.57e-27	Personality dimensions;
SARC	cis	rs4713118	0.869	rs9295742	chr6:27702832	G/A	cg17221315	chr6:27791827	HIST1H4J	0.49	5.29	0.33	2.77e-7	Parkinson's disease;
SARC	cis	rs763121	0.719	rs9610995	chr22:39057763	C/T	cg06022373	chr22:39101656	GTPBP1	0.91	11.32	0.6	5.9e-24	Menopause (age at onset);
SARC	cis	rs1865760	0.623	rs12216125	chr6:25997458	C/T	cg27312087	chr6:25913102	SLC17A2	-0.36	-4.96	-0.31	1.35e-6	Height;
SARC	cis	rs7223966	1.000	rs7222060	chr17:61868279	C/T	cg00588841	chr17:61851480	DDX42;CCDC47	-0.64	-6.93	-0.41	4.06e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6545883	0.929	rs2593625	chr2:61668769	C/T	cg15711740	chr2:61764176	XPO1	-0.42	-5.19	-0.32	4.65e-7	Tuberculosis;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg21973248	chr5:137549036	CDC23	0.48	6.44	0.39	6.84e-10	Lung adenocarcinoma;
SARC	cis	rs12594515	1.000	rs8025258	chr15:45987554	C/A	cg14863074	chr15:45997064	NA	0.34	5.24	0.32	3.57e-7	Waist circumference;Weight;
SARC	cis	rs897080	0.515	rs698795	chr2:44689326	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.13	0.37	3.69e-9	Height;
SARC	cis	rs7568458	0.870	rs6719046	chr2:85757371	G/A	cg23752985	chr2:85803571	VAMP8	0.34	4.93	0.31	1.57e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs6696846	0.791	rs11240352	chr1:205051711	C/G	cg21545522	chr1:205238299	TMCC2	-0.34	-4.87	-0.3	2.06e-6	Red blood cell count;
SARC	cis	rs826838	0.510	rs17523988	chr12:39222785	A/C	cg13010199	chr12:38710504	ALG10B	0.59	6.92	0.41	4.25e-11	Heart rate;
SARC	cis	rs79149102	0.522	rs4887156	chr15:74831185	G/A	cg09165964	chr15:75287851	SCAMP5	-0.65	-5.01	-0.31	1.05e-6	Lung cancer;
SARC	cis	rs8068544	0.818	rs7209012	chr17:40161323	C/T	cg26502583	chr17:39992600	KLHL10;NT5C3L	-0.87	-6.46	-0.39	6.07e-10	Reticulocyte fraction of red cells;Reticulocyte count;
SARC	cis	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg08975724	chr8:8085496	FLJ10661	-0.45	-5.38	-0.33	1.8e-7	Mood instability;
SARC	cis	rs11645898	0.574	rs17604349	chr16:72210865	C/T	cg14768367	chr16:72042858	DHODH	-0.51	-4.9	-0.31	1.78e-6	Blood protein levels;
SARC	cis	rs1904096	0.506	rs2632412	chr4:95149319	A/C	cg11021082	chr4:95130006	SMARCAD1	0.42	6.24	0.38	1.99e-9	Type 2 diabetes;
SARC	cis	rs9322193	0.607	rs9383941	chr6:150233236	A/G	cg01145232	chr6:150245071	RAET1G	-0.44	-4.96	-0.31	1.34e-6	Lung cancer;
SARC	cis	rs4242434	0.672	rs10099266	chr8:22484268	C/G	cg03733263	chr8:22462867	KIAA1967	0.85	13.15	0.65	6.66e-30	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs4319547	1.000	rs7295397	chr12:123116209	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.62	-7.22	-0.43	7.27e-12	Body mass index;
SARC	cis	rs3768617	0.565	rs3768626	chr1:183078462	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.8e-21	Fuchs's corneal dystrophy;
SARC	cis	rs9467773	1.000	rs9467779	chr6:26536687	A/T	cg12292205	chr6:26970375	C6orf41	-0.45	-5.43	-0.34	1.42e-7	Intelligence (multi-trait analysis);
SARC	cis	rs3770770	0.500	rs80173200	chr2:37206921	G/C	cg14987922	chr2:37194071	STRN	-0.73	-4.99	-0.31	1.17e-6	QRS duration;
SARC	cis	rs12545109	0.807	rs13263281	chr8:57346582	C/A	cg21220214	chr8:57350948	NA	-0.45	-5.13	-0.32	6.03e-7	Obesity-related traits;
SARC	cis	rs4919694	0.572	rs12240508	chr10:104939232	G/A	cg04362960	chr10:104952993	NT5C2	0.59	5.43	0.34	1.41e-7	Arsenic metabolism;
SARC	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg06618935	chr21:46677482	NA	-0.36	-4.83	-0.3	2.42e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs34779708	0.966	rs2045917	chr10:35418526	G/A	cg03585969	chr10:35415529	CREM	0.39	4.89	0.31	1.88e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs459571	1.000	rs456207	chr9:136911140	G/A	cg13789015	chr9:136890014	NCRNA00094	0.6	8.38	0.48	5.17e-15	Platelet distribution width;
SARC	cis	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg00745463	chr17:30367425	LRRC37B	-0.55	-4.81	-0.3	2.68e-6	Hip circumference adjusted for BMI;
SARC	cis	rs5769765	0.954	rs5769762	chr22:50264042	G/A	cg03033257	chr22:50311977	ALG12;CRELD2	-0.54	-5.64	-0.35	4.81e-8	Schizophrenia;
SARC	cis	rs2425143	1.000	rs78421482	chr20:34376486	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.67	5.26	0.33	3.2e-7	Blood protein levels;
SARC	cis	rs9640161	0.673	rs34489187	chr7:150044379	G/A	cg10018233	chr7:150070692	REPIN1	0.67	8.54	0.49	1.77e-15	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.31	-0.38	1.36e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1008375	0.931	rs7672369	chr4:17604825	A/G	cg16339924	chr4:17578868	LAP3	0.64	8.34	0.48	6.37e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg26660792	chr13:53049959	CKAP2	0.45	6.34	0.38	1.2e-9	Thyroid stimulating hormone;
SARC	cis	rs2760061	0.583	rs697763	chr1:228192622	G/C	cg01200585	chr1:228362443	C1orf69	0.46	5.69	0.35	3.75e-8	Diastolic blood pressure;
SARC	cis	rs11644362	0.966	rs1433746	chr16:12992204	T/C	cg06890432	chr16:12997467	SHISA9	-0.5	-6.5	-0.39	4.77e-10	Positive affect;Subjective well-being;
SARC	cis	rs12681366	0.537	rs2381886	chr8:95477053	T/C	cg13257157	chr8:95487014	RAD54B	0.4	4.81	0.3	2.67e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs908922	0.676	rs578382	chr1:152514054	A/G	cg09873164	chr1:152488093	CRCT1	-0.64	-8.2	-0.47	1.6e-14	Hair morphology;
SARC	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg05313129	chr8:58192883	C8orf71	-0.63	-6.51	-0.39	4.44e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9747201	1.000	rs9747668	chr17:80161081	A/G	cg17462356	chr17:80056334	FASN	-0.44	-4.94	-0.31	1.49e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	trans	rs1814175	0.817	rs1988416	chr11:49932324	G/A	cg15704280	chr7:45808275	SEPT13	-0.98	-18.3	-0.77	5.62e-47	Height;
SARC	cis	rs11098499	0.909	rs10020034	chr4:120294331	A/G	cg09307838	chr4:120376055	NA	0.88	12.29	0.63	4.31e-27	Corneal astigmatism;
SARC	trans	rs3734266	0.702	rs11968954	chr6:34741174	C/T	cg08157914	chr7:2646478	IQCE	0.52	6.24	0.38	2.1e-9	Systemic lupus erythematosus;
SARC	cis	rs875971	0.545	rs2279757	chr7:65828663	T/C	cg11764359	chr7:65958608	NA	0.67	6.66	0.4	1.97e-10	Aortic root size;
SARC	cis	rs7027203	0.538	rs2244395	chr9:96520723	A/G	cg14598338	chr9:96623480	NA	-0.34	-4.76	-0.3	3.43e-6	DNA methylation (variation);
SARC	cis	rs3733585	0.673	rs10018204	chr4:9964570	C/T	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.55	-0.34	7.65e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs4619890	0.528	rs62289340	chr4:7879027	C/T	cg18538662	chr4:7941764	AFAP1	-0.4	-5.14	-0.32	5.86e-7	Glaucoma (primary open-angle);
SARC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg23034840	chr1:205782522	SLC41A1	0.6	7.45	0.44	1.8e-12	Menarche (age at onset);
SARC	cis	rs2952156	0.920	rs9675194	chr17:37833805	A/G	cg07936489	chr17:37558343	FBXL20	-0.42	-5.26	-0.33	3.2e-7	Asthma;
SARC	cis	rs7561149	0.902	rs6729746	chr2:179649349	G/A	cg17765952	chr2:179737173	CCDC141	-0.36	-4.75	-0.3	3.56e-6	QT interval;
SARC	cis	rs6690583	0.524	rs12045710	chr1:85451765	T/C	cg22153463	chr1:85462885	MCOLN2	0.72	6.96	0.42	3.33e-11	Serum sulfate level;
SARC	cis	rs17376456	0.569	rs10057664	chr5:93182274	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.55	-5.75	-0.35	2.82e-8	Diabetic retinopathy;
SARC	cis	rs8114671	0.562	rs6087651	chr20:33518353	C/T	cg24642439	chr20:33292090	TP53INP2	0.51	6.17	0.37	3.06e-9	Height;
SARC	cis	rs9858542	1.000	rs13085791	chr3:49721798	C/A	cg03060546	chr3:49711283	APEH	-0.63	-7.86	-0.46	1.42e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs55823223	0.648	rs11867560	chr17:73857206	A/G	cg06969265	chr17:73775802	H3F3B	0.58	6.12	0.37	3.94e-9	Psoriasis;
SARC	cis	rs9322193	0.607	rs9383941	chr6:150233236	A/G	cg11878867	chr6:150167359	LRP11	0.39	4.77	0.3	3.29e-6	Lung cancer;
SARC	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg18876405	chr7:65276391	NA	0.44	4.91	0.31	1.71e-6	Aortic root size;
SARC	cis	rs1971762	0.545	rs10747675	chr12:54000031	A/G	cg06632207	chr12:54070931	ATP5G2	-0.5	-6.65	-0.4	2.07e-10	Height;
SARC	cis	rs526231	0.511	rs55896090	chr5:102362004	G/C	cg23492399	chr5:102201601	PAM	-0.5	-5.51	-0.34	9.29e-8	Primary biliary cholangitis;
SARC	cis	rs6582630	0.519	rs7305570	chr12:38349285	G/A	cg13010199	chr12:38710504	ALG10B	0.78	10.77	0.58	3.24e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6866344	0.661	rs72812606	chr5:178129094	A/T	cg10224037	chr5:178157518	ZNF354A	0.99	12.08	0.62	2.08e-26	Neutrophil percentage of white cells;
SARC	cis	rs734999	0.545	rs4474198	chr1:2553758	C/T	cg00980319	chr1:2560884	MMEL1	-0.34	-4.82	-0.3	2.61e-6	Ulcerative colitis;
SARC	cis	rs981844	1.000	rs2579916	chr4:154659972	G/T	cg14289246	chr4:154710475	SFRP2	0.58	6.64	0.4	2.14e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs858239	0.539	rs10247268	chr7:23187179	G/A	cg23682824	chr7:23144976	KLHL7	0.65	8.12	0.47	2.63e-14	Cerebrospinal fluid biomarker levels;
SARC	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg11764359	chr7:65958608	NA	0.81	11.11	0.59	2.76e-23	Aortic root size;
SARC	cis	rs7937682	0.889	rs493810	chr11:111491888	G/T	cg09085632	chr11:111637200	PPP2R1B	-0.89	-14.18	-0.68	2.61e-33	Primary sclerosing cholangitis;
SARC	cis	rs9640161	0.830	rs36069544	chr7:150061538	G/A	cg10018233	chr7:150070692	REPIN1	0.7	10.3	0.56	9.37e-21	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs986417	1.000	rs1116854	chr14:60917496	C/A	cg27398547	chr14:60952738	C14orf39	-1.02	-9.54	-0.53	2.06e-18	Gut microbiota (bacterial taxa);
SARC	cis	rs6835098	0.961	rs1574314	chr4:174106663	C/T	cg08422745	chr4:174089978	GALNT7	-0.73	-9.31	-0.52	9.57e-18	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs72717009	0.825	rs10494360	chr1:161475750	G/A	cg23840854	chr1:161414152	NA	-0.54	-5.07	-0.32	8.2e-7	Rheumatoid arthritis;
SARC	cis	rs9309473	1.000	rs7604682	chr2:73788026	G/A	cg07208825	chr2:73871855	ALMS1P	0.32	4.78	0.3	3.16e-6	Metabolite levels;
SARC	cis	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg13072238	chr3:49761600	GMPPB	-0.42	-5.54	-0.34	8.33e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9790314	0.746	rs898680	chr3:160772853	G/A	cg04691961	chr3:161091175	C3orf57	-0.6	-8.16	-0.47	2.05e-14	Morning vs. evening chronotype;
SARC	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.23e-9	Life satisfaction;
SARC	cis	rs3733585	0.638	rs6414766	chr4:9956474	G/A	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.39	-0.33	1.73e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7523050	0.643	rs34920128	chr1:109400889	C/T	cg08274380	chr1:109419600	GPSM2	1.07	8.3	0.48	8.22e-15	Fat distribution (HIV);
SARC	cis	rs1920116	1.000	rs4955678	chr3:169574912	T/C	cg14222479	chr3:169487675	ARPM1	0.43	5.17	0.32	4.97e-7	Glioma (high-grade);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg09597195	chr6:116575322	TSPYL4	-0.73	-6.26	-0.38	1.79e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7539542	0.556	rs4950888	chr1:202872625	C/T	cg08940984	chr1:202857613	RABIF	0.39	5.28	0.33	3.01e-7	Mean platelet volume;
SARC	cis	rs5769765	0.908	rs9627800	chr22:50319351	T/C	cg03033257	chr22:50311977	ALG12;CRELD2	0.48	4.71	0.3	4.18e-6	Schizophrenia;
SARC	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg24633833	chr3:10029261	TMEM111	0.52	5.25	0.33	3.43e-7	Alzheimer's disease;
SARC	cis	rs7772486	0.754	rs6922507	chr6:146250155	A/T	cg05347473	chr6:146136440	FBXO30	-0.48	-6.53	-0.39	4.1e-10	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs925098	0.577	rs2724469	chr4:18004090	T/C	cg08521178	chr6:170491202	NA	0.42	6.5	0.39	4.8e-10	Birth weight;Height;
SARC	trans	rs61931739	0.500	rs34418276	chr12:34535976	C/T	cg26384229	chr12:38710491	ALG10B	0.93	14.14	0.68	3.56e-33	Morning vs. evening chronotype;
SARC	cis	rs4975616	0.869	rs465498	chr5:1325803	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.53	-7.78	-0.45	2.28e-13	Lung cancer;
SARC	cis	rs8523	0.901	rs9295752	chr6:11010800	T/G	cg13562911	chr6:11044106	ELOVL2	0.36	4.78	0.3	3.11e-6	Red blood cell fatty acid levels;
SARC	cis	rs6496667	1.000	rs1839972	chr15:90891354	A/G	cg22089800	chr15:90895588	ZNF774	0.52	4.93	0.31	1.58e-6	Rheumatoid arthritis;
SARC	cis	rs4803468	1.000	rs166925	chr19:41926098	T/C	cg09537434	chr19:41945824	ATP5SL	-0.98	-17.34	-0.75	8.42e-44	Height;
SARC	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg13206674	chr6:150067644	NUP43	0.48	6.36	0.38	1.07e-9	Lung cancer;
SARC	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg18357526	chr6:26021779	HIST1H4A	0.9	12.5	0.63	8.9e-28	Intelligence (multi-trait analysis);
SARC	cis	rs921968	0.643	rs497983	chr2:219415189	A/G	cg02176678	chr2:219576539	TTLL4	0.37	5.58	0.34	6.61e-8	Mean corpuscular hemoglobin concentration;
SARC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg02725872	chr8:58115012	NA	-0.37	-6.47	-0.39	5.76e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg25072359	chr17:41440525	NA	0.48	5.58	0.34	6.58e-8	Menopause (age at onset);
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg06119275	chr12:133384736	GOLGA3	0.55	7.43	0.44	2.03e-12	Schizophrenia;
SARC	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg18252515	chr7:66147081	NA	0.53	5.6	0.34	5.91e-8	Aortic root size;
SARC	cis	rs79839061	0.536	rs3775128	chr4:885828	T/C	cg07828340	chr4:882639	GAK	0.51	5.1	0.32	6.94e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9916302	0.752	rs676882	chr17:37433424	A/T	cg20243544	chr17:37824526	PNMT	-0.56	-5.55	-0.34	7.63e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	9.17	0.51	2.6e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1949733	0.585	rs2631768	chr4:8473050	A/G	cg13073564	chr4:8508604	NA	0.39	6.04	0.37	6.14e-9	Response to antineoplastic agents;
SARC	cis	rs7647973	1.000	rs62259933	chr3:49469703	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.56	-5.94	-0.36	1.03e-8	Menarche (age at onset);
SARC	cis	rs12421382	0.507	rs10890995	chr11:109327622	A/G	cg27471124	chr11:109292789	C11orf87	-0.52	-7.2	-0.43	8.15e-12	Schizophrenia;
SARC	cis	rs3784262	0.669	rs10851632	chr15:58242475	A/T	cg12031962	chr15:58353849	ALDH1A2	-0.32	-4.77	-0.3	3.24e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg11987759	chr7:65425863	GUSB	-0.61	-8.0	-0.46	5.89e-14	Aortic root size;
SARC	cis	rs897984	0.683	rs72799316	chr16:30827205	A/G	cg02466173	chr16:30829666	NA	-0.53	-7.65	-0.45	5.13e-13	Dementia with Lewy bodies;
SARC	cis	rs2153535	0.580	rs7775909	chr6:8477778	A/G	cg07606381	chr6:8435919	SLC35B3	0.76	10.74	0.58	4.06e-22	Motion sickness;
SARC	cis	rs16976116	0.855	rs28649719	chr15:55500211	C/T	cg17854078	chr15:55489399	RSL24D1	0.66	6.53	0.39	4.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs11710567	0.734	rs13098785	chr3:57876987	T/C	cg01127878	chr19:42811035	PRR19	-0.44	-6.33	-0.38	1.24e-9	Granulocyte percentage of myeloid white cells;
SARC	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg23758822	chr17:41437982	NA	0.89	11.4	0.6	3.3e-24	Menopause (age at onset);
SARC	cis	rs4930561	0.739	rs10896303	chr11:67974292	C/A	cg16338278	chr11:67432957	ALDH3B2	0.33	5.37	0.33	1.87e-7	Breast cancer in childhood cancer survivors;IgG glycosylation;
SARC	cis	rs6424115	0.708	rs2076343	chr1:24129126	A/G	cg15997130	chr1:24165203	NA	-0.44	-5.49	-0.34	1.03e-7	Immature fraction of reticulocytes;
SARC	trans	rs9329221	0.905	rs4610752	chr8:10248962	A/G	cg08975724	chr8:8085496	FLJ10661	-0.54	-6.97	-0.42	3.25e-11	Neuroticism;
SARC	cis	rs4595586	0.545	rs12833238	chr12:39373898	T/C	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	cis	rs8072100	0.713	rs4968257	chr17:45430534	A/G	cg08085267	chr17:45401833	C17orf57	-0.44	-5.14	-0.32	5.77e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs7829975	0.606	rs10112585	chr8:8795030	A/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.27	-0.43	5.47e-12	Mood instability;
SARC	cis	rs10876993	0.928	rs1628552	chr12:58082142	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.42	-5.25	-0.33	3.43e-7	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.65	-6.91	-0.41	4.63e-11	Platelet count;
SARC	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg05368731	chr17:41323189	NBR1	0.79	9.36	0.52	7.2e-18	Menopause (age at onset);
SARC	cis	rs6952809	0.532	rs6461361	chr7:2432167	A/G	cg23289794	chr7:2394357	EIF3B	-0.74	-7.11	-0.42	1.38e-11	Multiple sclerosis;
SARC	cis	rs2997447	0.761	rs2783637	chr1:26439226	C/T	cg19633962	chr1:26362018	EXTL1	-0.6	-5.59	-0.34	6.23e-8	QRS complex (12-leadsum);
SARC	cis	rs763121	0.853	rs1569716	chr22:38998519	C/A	cg06022373	chr22:39101656	GTPBP1	0.9	11.89	0.61	8.76e-26	Menopause (age at onset);
SARC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-4.93	-0.31	1.59e-6	Total body bone mineral density;
SARC	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg18758796	chr5:131593413	PDLIM4	0.4	5.23	0.32	3.8e-7	Blood metabolite levels;
SARC	cis	rs920590	0.758	rs7012358	chr8:19662498	C/T	cg17834443	chr8:19674713	INTS10	0.58	7.0	0.42	2.74e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs6772849	0.805	rs61159406	chr3:128336009	G/A	cg08795948	chr3:128337044	NA	0.55	7.8	0.45	2.08e-13	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs3126085	0.935	rs1858480	chr1:152301735	A/G	cg03465714	chr1:152285911	FLG	0.45	5.46	0.34	1.25e-7	Atopic dermatitis;
SARC	cis	rs7084402	0.967	rs2438182	chr10:60314815	A/T	cg07615347	chr10:60278583	BICC1	0.59	8.65	0.49	8.56e-16	Refractive error;
SARC	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg11644478	chr21:40555479	PSMG1	0.9	11.65	0.61	5.16e-25	Cognitive function;
SARC	cis	rs6570726	0.791	rs370654	chr6:145879005	C/G	cg23711669	chr6:146136114	FBXO30	0.83	13.68	0.67	1.11e-31	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7766436	0.770	rs11751669	chr6:22571037	A/G	cg13666174	chr6:22585274	NA	-0.56	-6.94	-0.41	3.94e-11	Coronary artery disease;
SARC	cis	rs2011503	1.000	rs8105642	chr19:19558468	G/A	cg15839431	chr19:19639596	YJEFN3	-0.47	-4.74	-0.3	3.78e-6	Bipolar disorder;
SARC	cis	rs11578119	0.898	rs10919424	chr1:170481571	G/A	cg09767346	chr1:170501363	GORAB	0.4	4.73	0.3	3.91e-6	Male-pattern baldness;
SARC	cis	rs6087990	0.735	rs1003522	chr20:31368560	T/C	cg13636640	chr20:31349939	DNMT3B	0.8	12.42	0.63	1.66e-27	Ulcerative colitis;
SARC	cis	rs4332037	0.615	rs62435134	chr7:1895463	T/G	cg12591125	chr7:1885375	MAD1L1	0.5	4.92	0.31	1.66e-6	Bipolar disorder;
SARC	cis	rs908922	0.676	rs7529136	chr1:152516389	T/C	cg09873164	chr1:152488093	CRCT1	0.65	8.67	0.49	7.67e-16	Hair morphology;
SARC	cis	rs12579753	0.956	rs34146892	chr12:82188581	T/G	cg07988820	chr12:82153109	PPFIA2	-0.55	-6.34	-0.38	1.17e-9	Resting heart rate;
SARC	cis	rs1707322	0.835	rs946525	chr1:46487277	A/T	cg06784218	chr1:46089804	CCDC17	-0.34	-6.0	-0.37	7.61e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4713675	0.565	rs1555965	chr6:33677400	A/G	cg15676125	chr6:33679581	C6orf125	0.53	6.43	0.39	7.09e-10	Plateletcrit;
SARC	cis	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg05623727	chr3:50126028	RBM5	-0.34	-5.19	-0.32	4.56e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7264396	0.563	rs2425094	chr20:34306974	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	5.69	0.35	3.71e-8	Total cholesterol levels;
SARC	cis	rs1707322	0.752	rs28568986	chr1:46207743	C/T	cg03146154	chr1:46216737	IPP	0.52	6.29	0.38	1.56e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs8044995	0.563	rs8058517	chr16:68379860	A/G	cg05110241	chr16:68378359	PRMT7	0.66	5.94	0.36	1.02e-8	Schizophrenia;
SARC	cis	rs875971	0.545	rs1547529	chr7:65723846	T/C	cg25894440	chr7:65020034	NA	0.5	4.72	0.3	4.08e-6	Aortic root size;
SARC	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg19223190	chr17:80058835	NA	0.44	6.14	0.37	3.52e-9	Life satisfaction;
SARC	cis	rs11644362	0.932	rs34290494	chr16:12987705	A/C	cg06890432	chr16:12997467	SHISA9	-0.54	-7.1	-0.42	1.51e-11	Positive affect;Subjective well-being;
SARC	cis	rs920590	0.573	rs4392917	chr8:19680635	G/C	cg03894339	chr8:19674705	INTS10	-0.52	-6.26	-0.38	1.87e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg20607798	chr8:58055168	NA	0.56	5.27	0.33	3.12e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs854765	0.583	rs9904163	chr17:17830553	C/T	cg04398451	chr17:18023971	MYO15A	-0.39	-5.53	-0.34	8.65e-8	Total body bone mineral density;
SARC	cis	rs6964587	0.692	rs12536220	chr7:91805595	T/G	cg17063962	chr7:91808500	NA	0.8	12.31	0.63	3.7e-27	Breast cancer;
SARC	cis	rs950776	0.518	rs12900783	chr15:78815523	G/A	cg22563815	chr15:78856949	CHRNA5	0.42	7.02	0.42	2.38e-11	Sudden cardiac arrest;
SARC	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg17376030	chr22:41985996	PMM1	-0.73	-8.89	-0.5	1.73e-16	Vitiligo;
SARC	cis	rs79349575	0.783	rs318096	chr17:46975370	G/A	cg07967210	chr17:47022446	SNF8	0.38	4.79	0.3	2.91e-6	Type 2 diabetes;
SARC	cis	rs2908197	0.653	rs2961034	chr7:75961550	T/C	cg07849177	chr7:76178544	LOC100133091	-0.43	-4.92	-0.31	1.66e-6	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs17376456	0.877	rs28633397	chr5:93447048	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	6.14	0.37	3.45e-9	Diabetic retinopathy;
SARC	cis	rs614226	0.938	rs12857	chr12:120933946	T/G	cg01236616	chr12:121019343	POP5	1.2	16.95	0.74	1.64e-42	Type 1 diabetes nephropathy;
SARC	cis	rs7929679	0.521	rs10836304	chr11:34794024	C/T	cg06937548	chr11:34938143	PDHX;APIP	-0.37	-4.87	-0.3	2.06e-6	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
SARC	cis	rs12980942	0.630	rs11881940	chr19:41808432	A/T	cg25627403	chr19:41769009	HNRNPUL1	0.59	4.73	0.3	3.98e-6	Coronary artery disease;
SARC	cis	rs734999	0.545	rs7368105	chr1:2556548	C/T	cg00980319	chr1:2560884	MMEL1	-0.34	-4.9	-0.31	1.83e-6	Ulcerative colitis;
SARC	trans	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.75	10.78	0.58	3.03e-22	Intelligence (multi-trait analysis);
SARC	cis	rs2729354	0.514	rs1967179	chr11:57348483	C/T	cg17237962	chr11:57479805	MED19;TMX2	0.4	5.0	0.31	1.15e-6	Blood protein levels;
SARC	cis	rs2836633	0.895	rs2836598	chr21:40024758	C/G	cg12884169	chr21:40033163	ERG	0.47	8.52	0.49	1.96e-15	Coronary artery disease;
SARC	cis	rs12142240	0.698	rs17357635	chr1:46808668	G/A	cg14993813	chr1:46806288	NSUN4	-0.52	-5.45	-0.34	1.28e-7	Menopause (age at onset);
SARC	cis	rs793571	0.590	rs4775094	chr15:59115995	A/G	cg05156742	chr15:59063176	FAM63B	0.7	9.45	0.53	3.83e-18	Schizophrenia;
SARC	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg08219700	chr8:58056026	NA	0.46	4.96	0.31	1.34e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg11644478	chr21:40555479	PSMG1	1.04	14.21	0.68	2.04e-33	Cognitive function;
SARC	cis	rs4423214	1.000	rs1044482	chr11:71155171	C/T	cg24826892	chr11:71159390	DHCR7	0.49	6.16	0.37	3.25e-9	Vitamin D levels;
SARC	cis	rs4713118	0.662	rs149900	chr6:28014597	C/T	cg26335602	chr6:28129616	ZNF389	0.5	5.32	0.33	2.41e-7	Parkinson's disease;
SARC	cis	rs12142240	0.698	rs12385696	chr1:46818836	A/G	cg10495392	chr1:46806563	NSUN4	0.64	6.87	0.41	5.74e-11	Menopause (age at onset);
SARC	cis	rs10875746	0.903	rs886588	chr12:48477422	A/G	cg26205652	chr12:48591994	NA	0.56	6.05	0.37	5.72e-9	Longevity (90 years and older);
SARC	cis	rs8077889	0.917	rs9901676	chr17:41911818	T/C	cg26893861	chr17:41843967	DUSP3	0.85	10.66	0.57	6.96e-22	Triglycerides;
SARC	cis	rs7953249	0.807	rs2393791	chr12:121423956	A/G	cg02403541	chr12:121454288	C12orf43	0.55	6.9	0.41	4.86e-11	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs4927850	0.501	rs9881504	chr3:195656614	A/G	cg12923728	chr3:195709715	SDHAP1	-0.5	-5.84	-0.36	1.75e-8	Pancreatic cancer;
SARC	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.44	6.57	0.4	3.3e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs9902453	0.904	rs6505148	chr17:28289818	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	6.95	0.41	3.58e-11	Coffee consumption (cups per day);
SARC	cis	rs17376456	0.825	rs17372725	chr5:93135588	C/A	cg21475434	chr5:93447410	FAM172A	0.74	6.49	0.39	4.97e-10	Diabetic retinopathy;
SARC	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg06634786	chr22:41940651	POLR3H	-0.55	-6.38	-0.39	9.5e-10	Vitiligo;
SARC	cis	rs7223966	1.000	rs992416	chr17:61745905	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.56	-5.99	-0.37	7.8e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2439831	1.000	rs2256764	chr15:43735763	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.04	9.2	0.52	2.07e-17	Lung cancer in ever smokers;
SARC	cis	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg12463550	chr7:65579703	CRCP	0.71	5.72	0.35	3.21e-8	Diabetic kidney disease;
SARC	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg06074448	chr4:187884817	NA	0.39	5.19	0.32	4.48e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1865760	0.865	rs9467651	chr6:25958257	C/G	cg10373733	chr6:25993375	NA	0.39	4.78	0.3	3.17e-6	Height;
SARC	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-6.5	-0.39	4.93e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs765787	0.530	rs12910270	chr15:45512086	G/A	cg24006582	chr15:45444508	DUOX1	0.43	5.5	0.34	9.82e-8	Uric acid levels;
SARC	cis	rs6138458	1.000	rs6106984	chr20:24977006	T/C	cg26195577	chr20:24973756	C20orf3	0.91	9.89	0.54	1.77e-19	Blood protein levels;
SARC	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg10523679	chr1:76189770	ACADM	0.52	6.86	0.41	6.1e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2043112	0.965	rs6864478	chr5:38922826	A/G	cg04869206	chr5:39074266	RICTOR	0.48	5.86	0.36	1.55e-8	Obesity-related traits;
SARC	cis	rs9393692	0.905	rs9393693	chr6:26277408	C/A	cg00631329	chr6:26305371	NA	-0.58	-8.36	-0.48	5.54e-15	Educational attainment;
SARC	cis	rs9341808	0.700	rs12215236	chr6:80975058	A/T	cg08355045	chr6:80787529	NA	0.35	5.65	0.35	4.77e-8	Sitting height ratio;
SARC	cis	rs10046574	0.831	rs17479687	chr7:135074833	C/G	cg27474649	chr7:135195673	CNOT4	0.85	7.03	0.42	2.3e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs13082711	0.871	rs35701251	chr3:27529753	T/A	cg02860705	chr3:27208620	NA	0.45	5.69	0.35	3.84e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs9354352	0.818	rs9453548	chr6:66691885	T/C	cg07460842	chr6:66804631	NA	-0.58	-7.15	-0.42	1.13e-11	Initial pursuit acceleration in psychotic disorders;
SARC	cis	rs7561273	0.609	rs3795953	chr2:24345707	C/G	cg07265300	chr2:24346000	PFN4;LOC375190	-0.42	-4.77	-0.3	3.26e-6	Quantitative traits;
SARC	cis	rs7169223	0.653	rs1564499	chr15:79084808	C/T	cg06917634	chr15:78832804	PSMA4	0.47	5.21	0.32	4.21e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
SARC	cis	rs1322639	0.614	rs9364356	chr6:169567108	G/A	cg03254818	chr6:169586852	NA	0.73	7.34	0.43	3.63e-12	Pulse pressure;
SARC	cis	rs7236492	0.748	rs78531995	chr18:77198370	C/T	cg15644404	chr18:77186268	NFATC1	-0.66	-6.68	-0.4	1.77e-10	Inflammatory bowel disease;Crohn's disease;
SARC	trans	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg17830980	chr10:43048298	ZNF37B	-0.48	-6.33	-0.38	1.28e-9	Extrinsic epigenetic age acceleration;
SARC	cis	rs2816062	0.786	rs742486	chr1:18900829	G/A	cg18795169	chr1:18902165	NA	-0.82	-13.2	-0.65	4.51e-30	Urate levels in lean individuals;
SARC	cis	rs1322639	1.000	rs9689079	chr6:169587148	A/G	cg03254818	chr6:169586852	NA	-0.66	-8.75	-0.5	4.37e-16	Pulse pressure;
SARC	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg04546413	chr19:29218101	NA	0.63	8.54	0.49	1.71e-15	Methadone dose in opioid dependence;
SARC	cis	rs4144743	0.877	rs7218773	chr17:45324211	C/T	cg18085866	chr17:45331354	ITGB3	-0.71	-7.35	-0.43	3.36e-12	Body mass index;
SARC	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg06028808	chr11:68637592	NA	0.4	5.05	0.31	8.83e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg05793240	chr7:2802953	GNA12	-0.34	-5.07	-0.32	8e-7	Height;
SARC	cis	rs187455071	1	rs187455071	chr4:106805884	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.89	4.91	0.31	1.7e-6	Post bronchodilator FEV1;
SARC	cis	rs77372450	0.591	rs11740603	chr5:157098756	G/T	cg05585991	chr5:157099197	C5orf52	0.54	5.46	0.34	1.24e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs7560272	0.723	rs780395	chr2:73700853	G/A	cg20560298	chr2:73613845	ALMS1	0.54	7.28	0.43	5.19e-12	Schizophrenia;
SARC	cis	rs11711311	0.824	rs9876528	chr3:113357196	G/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	7.49	0.44	1.45e-12	IgG glycosylation;
SARC	cis	rs1983891	0.742	rs9367109	chr6:41562530	A/G	cg15051332	chr6:41514432	FOXP4	0.52	5.53	0.34	8.41e-8	Prostate cancer;
SARC	cis	rs1865760	0.534	rs2032444	chr6:26046744	T/G	cg16482183	chr6:26056742	HIST1H1C	0.51	5.81	0.36	2.07e-8	Height;
SARC	cis	rs7512552	0.839	rs1260367	chr1:150344514	C/T	cg15654264	chr1:150340011	RPRD2	0.38	4.81	0.3	2.7e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs9815354	0.812	rs73073371	chr3:41843443	A/G	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6728642	0.803	rs11891457	chr2:97632449	G/T	cg26665480	chr2:98280029	ACTR1B	-0.66	-6.52	-0.39	4.35e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs4072980	0.545	rs7519947	chr1:38447725	T/C	cg12658694	chr1:38397304	INPP5B	-0.82	-8.94	-0.51	1.25e-16	Coronary artery disease;
SARC	cis	rs1008375	1.000	rs4642241	chr4:17617111	T/C	cg16339924	chr4:17578868	LAP3	0.66	8.67	0.49	7.3e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg00262122	chr8:11665843	FDFT1	-0.43	-5.22	-0.32	3.89e-7	Retinal vascular caliber;
SARC	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg23758822	chr17:41437982	NA	0.87	10.68	0.57	6.2e-22	Menopause (age at onset);
SARC	cis	rs26868	0.690	rs26835	chr16:2237549	C/T	cg02248941	chr16:2239361	CASKIN1	0.38	6.17	0.37	3.04e-9	Height;
SARC	cis	rs7762018	0.891	rs73242950	chr6:170144737	C/T	cg13891659	chr6:170190454	C6orf122;C6orf208	0.55	4.88	0.3	2e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs7937682	0.602	rs503905	chr11:111390762	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.56	-7.42	-0.44	2.19e-12	Primary sclerosing cholangitis;
SARC	cis	rs6598163	0.517	rs11246827	chr12:132296423	G/A	cg22244940	chr12:132335942	MMP17	0.46	5.69	0.35	3.84e-8	Migraine;
SARC	cis	rs6893300	0.785	rs6895902	chr5:179201847	C/T	cg14593053	chr5:179126677	CANX	-0.38	-5.0	-0.31	1.15e-6	Resting heart rate;
SARC	cis	rs4642101	0.597	rs9839769	chr3:12821405	C/T	cg05775895	chr3:12838266	CAND2	0.84	15.68	0.72	2.67e-38	QRS complex (12-leadsum);
SARC	cis	rs9388451	0.626	rs2875881	chr6:126072853	C/G	cg06289844	chr6:126071538	HEY2	0.36	5.59	0.34	6.38e-8	Brugada syndrome;
SARC	cis	rs4273100	0.688	rs4924980	chr17:19204863	T/C	cg25447019	chr17:19030144	GRAPL	0.36	5.52	0.34	9.16e-8	Schizophrenia;
SARC	cis	rs947211	0.898	rs1772153	chr1:205745782	C/T	cg07167872	chr1:205819463	PM20D1	-0.4	-4.75	-0.3	3.5e-6	Parkinson's disease;
SARC	cis	rs1371867	0.846	rs1660324	chr8:101281271	C/T	cg11906718	chr8:101322791	RNF19A	0.71	9.27	0.52	1.3e-17	Atrioventricular conduction;
SARC	cis	rs1983891	1.000	rs4714486	chr6:41542417	C/T	cg15051332	chr6:41514432	FOXP4	0.52	5.69	0.35	3.72e-8	Prostate cancer;
SARC	cis	rs7568458	0.846	rs6743030	chr2:85763520	C/T	cg17127132	chr2:85788382	GGCX	0.46	6.27	0.38	1.78e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs9790314	0.875	rs163327	chr3:161062724	A/G	cg17135325	chr3:160939158	NMD3	0.47	5.83	0.36	1.88e-8	Morning vs. evening chronotype;
SARC	cis	rs3126085	0.935	rs10888468	chr1:152181539	C/T	cg03465714	chr1:152285911	FLG	-0.46	-5.51	-0.34	9.24e-8	Atopic dermatitis;
SARC	cis	rs77972916	0.611	rs11693190	chr2:43602415	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-6.3	-0.38	1.47e-9	Granulocyte percentage of myeloid white cells;
SARC	cis	rs694739	0.628	rs11606081	chr11:64137875	T/C	cg23796481	chr11:64053134	BAD;GPR137	0.66	7.6	0.45	7e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg23262073	chr20:60523788	NA	-0.45	-6.76	-0.41	1.08e-10	Body mass index;
SARC	cis	rs116095464	0.558	rs10060089	chr5:205565	G/A	cg22857025	chr5:266934	NA	-1.13	-10.64	-0.57	8.44e-22	Breast cancer;
SARC	cis	rs4742903	0.935	rs10991186	chr9:106996153	C/T	cg14250997	chr9:106856677	SMC2	-0.37	-4.74	-0.3	3.76e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs3087591	1.000	rs4795579	chr17:29458682	T/C	cg24425628	chr17:29625626	OMG;NF1	0.56	7.13	0.42	1.25e-11	Hip circumference;
SARC	cis	rs13166103	0.571	rs15915	chr5:57755843	C/T	cg10487770	chr5:57879443	RAB3C	0.52	5.35	0.33	2.12e-7	Type 2 diabetes (age of onset);
SARC	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg02018176	chr4:1364513	KIAA1530	-0.34	-4.84	-0.3	2.31e-6	Obesity-related traits;
SARC	cis	rs2439831	0.867	rs76542740	chr15:43891512	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	8.13	0.47	2.56e-14	Lung cancer in ever smokers;
SARC	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg06108461	chr20:60628389	TAF4	-0.92	-12.68	-0.64	2.37e-28	Body mass index;
SARC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	19.57	0.79	4.3e-51	Prudent dietary pattern;
SARC	cis	rs2072499	0.966	rs2842865	chr1:156159532	G/A	cg24450063	chr1:156163899	SLC25A44	1.18	21.59	0.82	1.66e-57	Testicular germ cell tumor;
SARC	cis	rs4819052	0.788	rs9978857	chr21:46705155	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.61	6.99	0.42	2.81e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6752107	0.901	rs11687982	chr2:234149039	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.49	6.35	0.38	1.14e-9	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs4689388	0.853	rs13108780	chr4:6294630	A/G	cg14416269	chr4:6271139	WFS1	0.32	4.92	0.31	1.61e-6	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg11965913	chr1:205819406	PM20D1	0.48	5.46	0.34	1.21e-7	Parkinson's disease;
SARC	cis	rs1707322	0.656	rs2991981	chr1:46057144	A/G	cg06784218	chr1:46089804	CCDC17	-0.4	-7.08	-0.42	1.71e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs8141529	0.529	rs5762767	chr22:29141241	C/T	cg02153584	chr22:29168773	CCDC117	0.63	6.34	0.38	1.2e-9	Lymphocyte counts;
SARC	cis	rs2439831	1.000	rs2467426	chr15:43989518	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.77	7.51	0.44	1.28e-12	Lung cancer in ever smokers;
SARC	cis	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.8	-0.46	2.01e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs3808502	0.647	rs7821302	chr8:11236572	T/A	cg21775007	chr8:11205619	TDH	-0.65	-8.62	-0.49	1.01e-15	Neuroticism;
SARC	cis	rs2576037	0.796	rs2571032	chr18:44578250	T/A	cg19077165	chr18:44547161	KATNAL2	0.44	6.19	0.38	2.66e-9	Personality dimensions;
SARC	cis	rs820218	0.728	rs820182	chr17:73617104	A/C	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.49	6.06	0.37	5.38e-9	Rotator cuff tears;
SARC	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg11764359	chr7:65958608	NA	-0.78	-9.41	-0.52	4.86e-18	Aortic root size;
SARC	cis	rs1008375	0.800	rs62296338	chr4:17613425	G/T	cg02297831	chr4:17616191	MED28	0.49	6.28	0.38	1.61e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg08677398	chr8:58056175	NA	0.43	5.05	0.31	8.92e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7582180	0.629	rs2309796	chr2:100954385	C/T	cg14675211	chr2:100938903	LONRF2	0.48	7.13	0.42	1.25e-11	Intelligence (multi-trait analysis);
SARC	cis	rs72653721	0.730	rs9468309	chr6:11044080	G/A	cg13562911	chr6:11044106	ELOVL2	0.5	5.75	0.35	2.74e-8	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	trans	rs2727020	0.930	rs1164688	chr11:49290604	C/G	cg03929089	chr4:120376271	NA	0.77	10.12	0.55	3.45e-20	Coronary artery disease;
SARC	cis	rs7412746	0.611	rs7556661	chr1:150892009	C/T	cg13175981	chr1:150552382	MCL1	-0.48	-5.86	-0.36	1.57e-8	Melanoma;
SARC	cis	rs148387471	1	rs148387471	chr3:127057551	ATAG/A	cg27326032	chr3:127006922	NA	-0.56	-6.38	-0.39	9.22e-10	Interleukin-10 levels;Interleukin-13 levels;
SARC	cis	rs7659604	0.540	rs34445121	chr4:122710889	G/A	cg19748678	chr4:122722346	EXOSC9	-0.4	-4.9	-0.31	1.81e-6	Type 2 diabetes;
SARC	cis	rs9840812	0.861	rs687339	chr3:135932359	C/T	cg15507776	chr3:136538369	TMEM22	0.52	5.51	0.34	9.42e-8	Fibrinogen levels;
SARC	cis	rs912057	0.901	rs744056	chr6:6733540	A/G	cg06612196	chr6:6737390	NA	0.58	8.54	0.49	1.79e-15	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg25894440	chr7:65020034	NA	-0.72	-5.44	-0.34	1.34e-7	Diabetic kidney disease;
SARC	trans	rs9929218	1.000	rs13334471	chr16:68800452	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.53	-6.72	-0.4	1.41e-10	Colorectal cancer;
SARC	cis	rs9868809	0.772	rs9836462	chr3:48712791	C/T	cg07636037	chr3:49044803	WDR6	0.68	6.18	0.38	2.76e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs10744422	1.000	rs921808	chr12:123323135	A/G	cg25930673	chr12:123319894	HIP1R	0.61	4.77	0.3	3.2e-6	Schizophrenia;
SARC	cis	rs7666738	0.515	rs10015315	chr4:98700137	A/G	cg05340658	chr4:99064831	C4orf37	0.58	7.12	0.42	1.32e-11	Colonoscopy-negative controls vs population controls;
SARC	trans	rs7937682	0.961	rs7106104	chr11:111635655	T/C	cg18187862	chr3:45730750	SACM1L	-0.58	-7.14	-0.42	1.16e-11	Primary sclerosing cholangitis;
SARC	cis	rs17445774	1.000	rs17445774	chr2:200859249	A/G	cg23649088	chr2:200775458	C2orf69	-0.62	-8.13	-0.47	2.46e-14	LDL cholesterol to HDL cholesterol ratio;
SARC	cis	rs7712401	0.623	rs7723798	chr5:122369717	C/G	cg19412675	chr5:122181750	SNX24	0.41	5.47	0.34	1.14e-7	Mean platelet volume;
SARC	trans	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg21659725	chr3:3221576	CRBN	-0.81	-12.46	-0.63	1.2e-27	Intelligence (multi-trait analysis);
SARC	cis	rs17270561	0.609	rs2000351	chr6:25759783	T/C	cg16482183	chr6:26056742	HIST1H1C	0.48	5.95	0.36	9.58e-9	Iron status biomarkers;
SARC	cis	rs7818688	0.745	rs16917117	chr8:95909498	C/T	cg13393036	chr8:95962371	TP53INP1	-0.41	-4.84	-0.3	2.39e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs7086627	0.515	rs11202959	chr10:82209672	A/G	cg00277334	chr10:82204260	NA	-0.56	-9.34	-0.52	7.82e-18	Post bronchodilator FEV1;
SARC	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg22834771	chr12:69754056	YEATS4	-0.44	-5.78	-0.35	2.43e-8	Blood protein levels;
SARC	cis	rs9300255	0.602	rs1716172	chr12:123712712	G/T	cg00376283	chr12:123451042	ABCB9	0.53	6.18	0.38	2.8e-9	Neutrophil percentage of white cells;
SARC	cis	rs35213789	0.762	rs595681	chr7:69190837	C/T	cg10619644	chr7:69149951	AUTS2	-0.36	-5.07	-0.32	8.05e-7	Childhood ear infection;
SARC	cis	rs9902453	0.791	rs2729451	chr17:28131334	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.07	-0.42	1.78e-11	Coffee consumption (cups per day);
SARC	cis	rs67460515	0.531	rs13315565	chr3:160754626	G/C	cg17135325	chr3:160939158	NMD3	0.57	6.65	0.4	2.08e-10	Parkinson's disease;
SARC	cis	rs11583043	0.872	rs1326380	chr1:101293753	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.48	5.56	0.34	7.47e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg27266027	chr21:40555129	PSMG1	0.48	4.83	0.3	2.51e-6	Cognitive function;
SARC	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg18252515	chr7:66147081	NA	0.45	4.88	0.3	1.99e-6	Aortic root size;
SARC	cis	rs7937682	0.883	rs484834	chr11:111465761	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.93	-14.06	-0.68	6.32e-33	Primary sclerosing cholangitis;
SARC	cis	rs17376456	0.825	rs34967135	chr5:93221785	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.59	0.34	6.21e-8	Diabetic retinopathy;
SARC	cis	rs2153535	0.541	rs6905934	chr6:8440043	C/A	cg23788917	chr6:8435910	SLC35B3	0.63	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs4535301	0.745	rs4296648	chr4:170473757	G/A	cg07701716	chr4:170533879	NEK1	0.39	4.74	0.3	3.71e-6	Night sleep phenotypes;
SARC	cis	rs910316	0.967	rs4899551	chr14:75660246	C/G	cg11812906	chr14:75593930	NEK9	-0.81	-11.97	-0.62	4.6e-26	Height;
SARC	cis	rs2295359	0.892	rs56920441	chr1:67652012	A/G	cg08029281	chr1:67600428	NA	0.38	5.06	0.31	8.59e-7	Psoriasis;
SARC	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg02475777	chr4:1388615	CRIPAK	0.61	7.15	0.42	1.11e-11	Longevity;
SARC	cis	rs12478296	1.000	rs59036157	chr2:243040228	C/A	cg06360820	chr2:242988706	NA	-0.62	-4.93	-0.31	1.53e-6	Obesity-related traits;
SARC	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	-0.4	-4.83	-0.3	2.51e-6	Tonsillectomy;
SARC	cis	rs7106204	0.748	rs4598670	chr11:24236524	G/A	ch.11.24196551F	chr11:24239977	NA	0.57	5.88	0.36	1.42e-8	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs6570726	0.791	rs9399558	chr6:145911730	T/C	cg23711669	chr6:146136114	FBXO30	0.88	14.58	0.69	1.2e-34	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9486719	1.000	rs12190508	chr6:96898269	T/C	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.01	-0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs2236918	0.687	rs2797600	chr1:242029331	C/T	cg17736920	chr1:242011382	EXO1	0.64	8.69	0.49	6.61e-16	Menopause (age at onset);
SARC	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1044826	1.000	rs13060697	chr3:139101777	G/A	cg15131784	chr3:139108705	COPB2	0.45	5.25	0.33	3.38e-7	Obesity-related traits;
SARC	cis	rs9788682	0.747	rs12101809	chr15:78779801	C/T	cg24631222	chr15:78858424	CHRNA5	0.73	8.78	0.5	3.49e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs1448094	0.817	rs12370270	chr12:86343303	T/G	cg02569458	chr12:86230093	RASSF9	0.43	6.21	0.38	2.43e-9	Major depressive disorder;
SARC	cis	rs965604	1.000	rs12904234	chr15:78779384	C/T	cg24631222	chr15:78858424	CHRNA5	-0.48	-6.19	-0.38	2.74e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs4481887	0.741	rs28616194	chr1:248531904	T/A	cg13385794	chr1:248469461	NA	0.35	5.57	0.34	6.97e-8	Common traits (Other);
SARC	cis	rs2916247	0.862	rs7012347	chr8:93116149	T/C	cg10183463	chr8:93005414	RUNX1T1	0.57	5.87	0.36	1.52e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg18252515	chr7:66147081	NA	-1.27	-11.28	-0.59	7.97e-24	Diabetic kidney disease;
SARC	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg00684032	chr4:1343700	KIAA1530	0.36	5.08	0.32	7.9e-7	Obesity-related traits;
SARC	cis	rs7635838	0.859	rs9869977	chr3:11480081	C/A	cg00170343	chr3:11313890	ATG7	0.63	8.64	0.49	9.34e-16	HDL cholesterol;
SARC	trans	rs17685	0.753	rs11764129	chr7:75761890	T/C	cg19862616	chr7:65841803	NCRNA00174	0.62	7.72	0.45	3.44e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-5.76	-0.35	2.6e-8	Bipolar disorder;
SARC	cis	rs7103648	0.695	rs12577643	chr11:47467172	A/T	cg10504702	chr11:47789108	FNBP4	0.66	8.23	0.47	1.32e-14	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs2180341	0.960	rs9375503	chr6:127677071	T/C	cg17762328	chr6:126965162	NA	-0.44	-4.91	-0.31	1.68e-6	Breast cancer;
SARC	cis	rs9814567	0.806	rs9841371	chr3:134320765	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.51	-6.63	-0.4	2.36e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs12220238	1.000	rs10824102	chr10:75948915	C/A	cg19889307	chr10:75911429	ADK;AP3M1	0.57	5.63	0.35	5.04e-8	Soluble interleukin-2 receptor subunit alpha;
SARC	cis	rs6011674	1.000	rs6011691	chr20:61867454	A/G	cg06763829	chr20:61885236	FLJ16779;NKAIN4	0.63	4.84	0.3	2.39e-6	Response to cytadine analogues (cytosine arabinoside);
SARC	cis	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg00071950	chr4:10020882	SLC2A9	0.34	5.37	0.33	1.93e-7	Bone mineral density;
SARC	cis	rs7633857	0.512	rs1868109	chr3:160682500	G/A	cg03342759	chr3:160939853	NMD3	-0.5	-5.96	-0.36	9.08e-9	Educational attainment (years of education);
SARC	cis	rs3008870	1.000	rs7511948	chr1:67430427	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.92	11.37	0.6	3.93e-24	Lymphocyte percentage of white cells;
SARC	cis	rs2952156	0.920	rs2517957	chr17:37838716	G/A	cg20243544	chr17:37824526	PNMT	0.56	7.21	0.43	7.6e-12	Asthma;
SARC	cis	rs67460515	0.500	rs1562464	chr3:160681614	G/A	cg17135325	chr3:160939158	NMD3	0.54	6.3	0.38	1.5e-9	Parkinson's disease;
SARC	cis	rs79349575	0.783	rs12453374	chr17:46994846	G/C	cg16584676	chr17:46985605	UBE2Z	0.53	6.38	0.39	9.28e-10	Type 2 diabetes;
SARC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.45	0.56	3.24e-21	Prudent dietary pattern;
SARC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.53	-5.97	-0.36	8.85e-9	Longevity;Endometriosis;
SARC	cis	rs9302635	0.513	rs8050238	chr16:72154187	C/T	cg01557791	chr16:72042693	DHODH	-0.53	-5.76	-0.35	2.68e-8	Blood protein levels;
SARC	cis	rs883565	0.528	rs11716902	chr3:38958010	G/T	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.44	-5.21	-0.32	4.25e-7	Handedness;
SARC	cis	rs113835537	0.529	rs7928882	chr11:66234765	C/T	cg24851651	chr11:66362959	CCS	0.38	4.75	0.3	3.51e-6	Airway imaging phenotypes;
SARC	cis	rs1355223	0.902	rs286858	chr11:34717357	T/C	cg11058730	chr11:34937778	PDHX;APIP	0.41	5.24	0.32	3.56e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs6582630	0.519	rs7294292	chr12:38349540	C/T	cg13010199	chr12:38710504	ALG10B	0.78	10.77	0.58	3.24e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2921073	0.605	rs2976933	chr8:8254875	A/G	cg06636001	chr8:8085503	FLJ10661	0.61	7.08	0.42	1.69e-11	Parkinson's disease;
SARC	cis	rs56330463	0.967	rs34064454	chr5:148201569	A/G	cg21580376	chr5:148206412	ADRB2	0.41	5.78	0.35	2.38e-8	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Monocyte percentage of white cells;Eosinophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;
SARC	cis	rs1348850	0.918	rs12622298	chr2:178450651	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.68	8.74	0.5	4.61e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6952808	0.931	rs12537479	chr7:1868995	A/G	cg21782813	chr7:2030301	MAD1L1	-0.34	-5.2	-0.32	4.41e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs3741151	0.773	rs73544716	chr11:73170061	C/T	cg17517138	chr11:73019481	ARHGEF17	0.92	6.85	0.41	6.4e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs28829049	0.597	rs1009806	chr1:19500551	T/C	cg13387374	chr1:19411106	UBR4	0.43	5.05	0.31	8.85e-7	QRS duration in Tripanosoma cruzi seropositivity;
SARC	cis	rs11758351	1.000	rs1341759	chr6:26195502	G/A	cg01420254	chr6:26195488	NA	0.55	4.8	0.3	2.79e-6	Gout;Renal underexcretion gout;
SARC	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg11168104	chr5:1857477	NA	-0.35	-4.96	-0.31	1.37e-6	Cardiovascular disease risk factors;
SARC	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg11987759	chr7:65425863	GUSB	0.46	5.86	0.36	1.59e-8	Aortic root size;
SARC	cis	rs9467773	1.000	rs6456733	chr6:26566804	C/T	cg12292205	chr6:26970375	C6orf41	0.45	5.42	0.33	1.46e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7412746	0.658	rs6658066	chr1:150918937	T/G	cg10589385	chr1:150898437	SETDB1	0.38	5.05	0.31	9.12e-7	Melanoma;
SARC	cis	rs1348850	0.519	rs1544002	chr2:178529534	C/T	cg22681709	chr2:178499509	PDE11A	-0.35	-4.79	-0.3	3.01e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs55986470	0.763	rs10188853	chr2:239430558	G/C	cg18131467	chr2:239335373	ASB1	-0.54	-4.95	-0.31	1.4e-6	Chronotype;
SARC	cis	rs2204008	0.569	rs11495449	chr12:37995753	C/T	cg13010199	chr12:38710504	ALG10B	0.78	10.73	0.57	4.45e-22	Bladder cancer;
SARC	cis	rs10791097	0.694	rs4936123	chr11:130740967	G/A	cg12179176	chr11:130786555	SNX19	0.75	11.2	0.59	1.4e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	trans	rs61931739	0.500	rs11053218	chr12:34474792	A/C	cg26384229	chr12:38710491	ALG10B	-0.87	-12.12	-0.62	1.5e-26	Morning vs. evening chronotype;
SARC	cis	rs6540556	0.608	rs4844891	chr1:209914409	A/C	cg23920097	chr1:209922102	NA	-0.5	-5.55	-0.34	7.8e-8	Red blood cell count;
SARC	cis	rs2070433	0.752	rs60290737	chr21:47837630	C/A	cg12379764	chr21:47803548	PCNT	0.55	4.74	0.3	3.8e-6	Lymphocyte counts;
SARC	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg03060546	chr3:49711283	APEH	0.39	4.89	0.31	1.89e-6	Parkinson's disease;
SARC	cis	rs9916302	0.847	rs7218670	chr17:37500424	G/A	cg20243544	chr17:37824526	PNMT	-0.53	-6.37	-0.39	9.76e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg03806693	chr22:41940476	POLR3H	-0.93	-12.51	-0.63	8.22e-28	Vitiligo;
SARC	cis	rs8141529	0.732	rs5762784	chr22:29171298	C/T	cg02153584	chr22:29168773	CCDC117	0.82	12.41	0.63	1.74e-27	Lymphocyte counts;
SARC	cis	rs6582630	0.599	rs4882313	chr12:38454011	G/A	cg13010199	chr12:38710504	ALG10B	-0.46	-5.64	-0.35	4.97e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg13628971	chr7:2884303	GNA12	0.54	6.0	0.37	7.38e-9	Height;
SARC	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg18305652	chr10:134549665	INPP5A	0.34	5.34	0.33	2.17e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs7833986	0.534	rs2667972	chr8:56906661	C/T	cg26371346	chr8:56986568	SNORD54;RPS20	0.67	6.53	0.39	4.13e-10	Height;
SARC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg07167872	chr1:205819463	PM20D1	0.75	11.77	0.61	2.16e-25	Menarche (age at onset);
SARC	cis	rs514024	0.729	rs2256139	chr9:130486915	T/C	cg13643465	chr9:130375613	STXBP1	0.43	5.36	0.33	1.97e-7	Eating disorders (purging via substances);
SARC	trans	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg00938859	chr5:1591904	SDHAP3	0.79	7.66	0.45	5.1e-13	Breast cancer;
SARC	cis	rs910316	0.967	rs4903285	chr14:75609268	A/T	cg11812906	chr14:75593930	NEK9	0.87	13.79	0.67	4.97e-32	Height;
SARC	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg16606324	chr3:10149918	C3orf24	0.52	4.93	0.31	1.57e-6	Alzheimer's disease;
SARC	cis	rs9611565	0.559	rs1006407	chr22:41972032	T/C	cg03806693	chr22:41940476	POLR3H	-0.95	-11.62	-0.61	6.44e-25	Vitiligo;
SARC	cis	rs11574514	1.000	rs116908316	chr16:67804955	C/T	cg01866162	chr16:67596514	CTCF	1.1	6.42	0.39	7.68e-10	Crohn's disease;
SARC	cis	rs12079745	0.793	rs12074013	chr1:169133621	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.76	-4.98	-0.31	1.26e-6	QT interval;
SARC	cis	rs9457247	1.000	rs430097	chr6:167405073	A/G	cg07741184	chr6:167504864	NA	0.29	5.55	0.34	7.72e-8	Crohn's disease;
SARC	cis	rs13095912	1.000	rs13072759	chr3:185326391	G/A	cg11274856	chr3:185301563	NA	0.36	4.98	0.31	1.24e-6	Systolic blood pressure;
SARC	cis	rs155076	0.938	rs261375	chr13:21871882	A/G	cg11317459	chr13:21872234	NA	1.06	12.23	0.63	6.99e-27	White matter hyperintensity burden;
SARC	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg02841227	chr6:26021843	HIST1H4A	0.56	6.47	0.39	5.59e-10	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.593	rs2317990	chr8:58024168	G/T	cg22535103	chr8:58192502	C8orf71	-0.6	-5.76	-0.35	2.61e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs761746	0.960	rs4820980	chr22:31917415	A/G	cg15162869	chr22:32027605	PISD	0.34	4.72	0.3	4.06e-6	Intelligence;
SARC	cis	rs5758659	0.714	rs133376	chr22:42466905	C/T	cg04733989	chr22:42467013	NAGA	0.49	5.87	0.36	1.47e-8	Cognitive function;
SARC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg09373136	chr17:61933544	TCAM1	-0.45	-6.23	-0.38	2.18e-9	Prudent dietary pattern;
SARC	cis	rs4819052	0.788	rs35323494	chr21:46703739	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.67	7.97	0.46	7.07e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs13040088	1.000	rs12480117	chr20:61558274	G/A	cg23096297	chr20:61557774	DIDO1	0.89	8.81	0.5	3e-16	Menopause (age at onset);
SARC	cis	rs9457247	0.967	rs425039	chr6:167410527	C/T	cg07741184	chr6:167504864	NA	0.3	5.6	0.34	5.91e-8	Crohn's disease;
SARC	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg08109568	chr15:31115862	NA	-0.47	-5.71	-0.35	3.38e-8	Huntington's disease progression;
SARC	cis	rs8523	0.901	rs9393818	chr6:10967918	T/G	cg13562911	chr6:11044106	ELOVL2	0.44	5.86	0.36	1.56e-8	Red blood cell fatty acid levels;
SARC	cis	rs12142240	0.698	rs67941619	chr1:46838219	A/G	cg10495392	chr1:46806563	NSUN4	0.65	6.88	0.41	5.6e-11	Menopause (age at onset);
SARC	cis	rs10463316	0.894	rs6864722	chr5:150752942	G/A	cg03212797	chr5:150827313	SLC36A1	-0.46	-5.47	-0.34	1.16e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs2204008	0.748	rs11180579	chr12:38237830	A/G	cg26384229	chr12:38710491	ALG10B	0.91	13.43	0.66	7.61e-31	Bladder cancer;
SARC	cis	rs7772486	0.686	rs9497395	chr6:146013592	A/G	cg23711669	chr6:146136114	FBXO30	-0.8	-12.66	-0.64	2.72e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs959260	1.000	rs4788892	chr17:73391277	A/G	cg14668889	chr17:73230827	NUP85	-0.43	-4.74	-0.3	3.7e-6	Systemic lupus erythematosus;
SARC	cis	rs11608355	1.000	rs11066591	chr12:109880523	G/A	cg19025524	chr12:109796872	NA	-0.4	-5.13	-0.32	6.17e-7	Neuroticism;
SARC	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg20891283	chr12:69753455	YEATS4	0.68	9.8	0.54	3.24e-19	Cerebrospinal fluid biomarker levels;
SARC	trans	rs9354308	0.840	rs1827157	chr6:66615761	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.58	6.6	0.4	2.69e-10	Metabolite levels;
SARC	cis	rs4268898	0.965	rs13033241	chr2:24476118	G/C	cg06627628	chr2:24431161	ITSN2	0.61	8.5	0.49	2.35e-15	Asthma;
SARC	cis	rs7264396	0.635	rs6058351	chr20:34486093	A/G	cg12579300	chr20:34535607	PHF20	-0.41	-4.78	-0.3	3.06e-6	Total cholesterol levels;
SARC	cis	rs4711350	0.765	rs756138	chr6:33755711	G/C	cg18005901	chr6:33739558	LEMD2	-0.41	-4.76	-0.3	3.35e-6	Schizophrenia;
SARC	cis	rs17666538	0.901	rs73177064	chr8:585293	C/G	cg26554054	chr8:600488	NA	-0.62	-4.96	-0.31	1.35e-6	IgG glycosylation;
SARC	cis	rs6570726	0.791	rs6902404	chr6:145905254	G/A	cg23711669	chr6:146136114	FBXO30	0.79	12.4	0.63	1.95e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1707322	1.000	rs6429588	chr1:46454058	T/G	cg06784218	chr1:46089804	CCDC17	0.35	6.07	0.37	5.11e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg20607798	chr8:58055168	NA	0.56	5.27	0.33	3.12e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs73206853	0.841	rs56184938	chr12:110817193	T/C	cg10860002	chr12:110842031	ANAPC7	0.63	5.03	0.31	9.95e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs2816062	0.813	rs2816044	chr1:18892826	A/G	cg10574377	chr1:18908098	NA	0.36	5.16	0.32	5.25e-7	Urate levels in lean individuals;
SARC	cis	rs2120019	0.938	rs2289582	chr15:75310394	T/C	cg09165964	chr15:75287851	SCAMP5	-0.95	-13.67	-0.67	1.28e-31	Blood trace element (Zn levels);
SARC	trans	rs61931739	0.929	rs2389274	chr12:34075149	T/C	cg13010199	chr12:38710504	ALG10B	-0.5	-6.74	-0.4	1.26e-10	Morning vs. evening chronotype;
SARC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg23034840	chr1:205782522	SLC41A1	0.61	7.79	0.45	2.17e-13	Menarche (age at onset);
SARC	cis	rs1153858	1.000	rs7171577	chr15:45627979	G/A	cg03999130	chr15:45571217	NA	0.42	5.4	0.33	1.62e-7	Homoarginine levels;
SARC	cis	rs1865760	0.929	rs12195653	chr6:25958621	A/G	cg10373733	chr6:25993375	NA	0.41	4.99	0.31	1.18e-6	Height;
SARC	cis	rs2991971	0.967	rs512026	chr1:46009946	G/T	cg24296786	chr1:45957014	TESK2	0.64	9.09	0.51	4.5e-17	High light scatter reticulocyte count;
SARC	cis	rs12824058	0.831	rs12320318	chr12:130812335	T/C	cg23887609	chr12:130822674	PIWIL1	0.37	5.15	0.32	5.52e-7	Menopause (age at onset);
SARC	cis	rs1153858	0.943	rs12439575	chr15:45684816	T/G	cg03999130	chr15:45571217	NA	0.39	4.93	0.31	1.53e-6	Homoarginine levels;
SARC	cis	rs11214589	0.905	rs2186799	chr11:113242533	G/T	cg14159747	chr11:113255604	NA	0.34	4.94	0.31	1.48e-6	Neuroticism;
SARC	cis	rs644799	0.542	rs10831417	chr11:95467262	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	-0.49	-5.92	-0.36	1.16e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9527	0.545	rs7100369	chr10:104956218	C/A	cg04362960	chr10:104952993	NT5C2	0.43	5.06	0.31	8.57e-7	Arsenic metabolism;
SARC	cis	rs7927771	0.965	rs11039416	chr11:47846711	G/A	cg05585544	chr11:47624801	NA	-0.36	-4.82	-0.3	2.59e-6	Subjective well-being;
SARC	cis	rs1348850	0.645	rs7571386	chr2:178442687	A/C	cg23306229	chr2:178417860	TTC30B	0.76	8.57	0.49	1.48e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs9914988	0.943	rs9902953	chr17:27139834	C/A	cg20469991	chr17:27169893	C17orf63	-0.52	-5.39	-0.33	1.74e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs911555	0.755	rs12435516	chr14:103954404	T/C	cg12935359	chr14:103987150	CKB	0.38	5.28	0.33	2.99e-7	Intelligence (multi-trait analysis);
SARC	cis	rs910316	0.737	rs175084	chr14:75519175	C/T	cg11812906	chr14:75593930	NEK9	-0.77	-10.58	-0.57	1.29e-21	Height;
SARC	cis	rs3126085	0.935	rs7540844	chr1:152230586	A/T	cg03465714	chr1:152285911	FLG	-0.45	-5.38	-0.33	1.85e-7	Atopic dermatitis;
SARC	cis	rs6450176	0.909	rs6884936	chr5:53293198	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.65	-7.35	-0.43	3.24e-12	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs11676348	0.791	rs4133195	chr2:218951245	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.49	6.5	0.39	4.78e-10	Ulcerative colitis;
SARC	cis	rs10463316	0.894	rs6579862	chr5:150761717	T/G	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.29	-0.33	2.8e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs8063160	0.628	rs258322	chr16:89755903	C/T	cg07984980	chr16:89898383	SPIRE2	0.52	4.84	0.3	2.32e-6	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
SARC	cis	rs1707322	0.721	rs56255771	chr1:46224319	C/T	cg03146154	chr1:46216737	IPP	0.48	5.68	0.35	3.99e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs8072100	0.688	rs8079142	chr17:45442049	G/A	cg08085267	chr17:45401833	C17orf57	-0.44	-5.14	-0.32	5.77e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs8084125	0.832	rs62105172	chr18:74946703	C/T	cg07390210	chr18:74961196	GALR1	0.52	5.89	0.36	1.32e-8	Obesity-related traits;
SARC	cis	rs10791097	0.694	rs10791100	chr11:130738946	T/A	cg09137382	chr11:130731461	NA	0.31	4.77	0.3	3.2e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs710216	0.843	rs1385129	chr1:43408966	G/A	cg07803811	chr1:43423981	SLC2A1	0.56	5.75	0.35	2.76e-8	Red cell distribution width;
SARC	cis	rs1348850	0.651	rs4893931	chr2:178228212	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.59	7.67	0.45	4.55e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs67460515	0.892	rs11711413	chr3:160998910	C/G	cg04691961	chr3:161091175	C3orf57	-0.47	-5.79	-0.35	2.29e-8	Parkinson's disease;
SARC	cis	rs898097	0.585	rs9893200	chr17:80893028	A/C	cg10494973	chr17:80897199	TBCD	-0.43	-5.88	-0.36	1.42e-8	Breast cancer;
SARC	cis	rs11697848	1.000	rs118191427	chr20:48500969	G/A	cg17849948	chr20:48532315	SPATA2	0.86	5.17	0.32	4.97e-7	Systemic lupus erythematosus;
SARC	cis	rs11097912	0.632	rs61544154	chr4:107189771	C/T	cg09646026	chr4:107269030	AIMP1	-0.44	-4.74	-0.3	3.68e-6	Airflow obstruction;
SARC	cis	rs870825	0.616	rs28649620	chr4:185648997	G/A	cg04058563	chr4:185651563	MLF1IP	0.8	11.35	0.6	4.56e-24	Blood protein levels;
SARC	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg16479474	chr6:28041457	NA	0.36	5.25	0.33	3.43e-7	Parkinson's disease;
SARC	cis	rs13191362	0.872	rs67712738	chr6:163245768	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.63	6.01	0.37	7.15e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	trans	rs1814175	0.817	rs11040651	chr11:49938395	G/A	cg03929089	chr4:120376271	NA	-0.89	-14.41	-0.69	4.28e-34	Height;
SARC	cis	rs9393692	0.557	rs7755741	chr6:26337264	G/A	cg13736514	chr6:26305472	NA	-0.44	-5.11	-0.32	6.57e-7	Educational attainment;
SARC	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg27572855	chr1:25598939	RHD	0.56	9.6	0.53	1.34e-18	Erythrocyte sedimentation rate;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg17367356	chr11:45907078	MAPK8IP1	0.51	6.5	0.39	4.85e-10	Height;
SARC	cis	rs2120243	0.539	rs1840668	chr3:157098721	T/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.38	4.84	0.3	2.38e-6	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg13939156	chr17:80058883	NA	-0.43	-6.53	-0.39	4.19e-10	Life satisfaction;
SARC	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg06108461	chr20:60628389	TAF4	-0.87	-11.64	-0.61	5.68e-25	Body mass index;
SARC	trans	rs1961637	0.603	rs1550423	chr2:223885812	C/T	cg23059868	chr1:1649451	CDK11A;CDK11B	-0.5	-6.44	-0.39	6.93e-10	Oropharynx cancer;
SARC	cis	rs9291683	0.655	rs55941493	chr4:10100341	G/A	cg11266682	chr4:10021025	SLC2A9	-0.47	-8.54	-0.49	1.71e-15	Bone mineral density;
SARC	cis	rs796364	0.806	rs1509832	chr2:200874443	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.77	6.8	0.41	8.96e-11	Schizophrenia;
SARC	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg03517284	chr6:25882590	NA	-0.51	-6.73	-0.4	1.34e-10	Blood metabolite levels;
SARC	cis	rs11864453	0.826	rs12325142	chr16:72138112	G/T	cg01557791	chr16:72042693	DHODH	-0.65	-9.17	-0.51	2.6e-17	Fibrinogen levels;
SARC	cis	rs4835937	0.590	rs6871743	chr5:127310093	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.61	5.21	0.32	4.12e-7	Cancer;
SARC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg07332563	chr6:291687	DUSP22	-0.57	-7.75	-0.45	2.8e-13	Menopause (age at onset);
SARC	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg04772025	chr11:68637568	NA	-0.45	-5.63	-0.35	5.19e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7560272	0.501	rs12713789	chr2:73945600	A/G	cg20560298	chr2:73613845	ALMS1	0.44	5.89	0.36	1.33e-8	Schizophrenia;
SARC	trans	rs6716963	0.585	rs11687224	chr2:194568323	A/G	cg08265790	chr5:141704696	SPRY4	0.52	6.29	0.38	1.55e-9	Schizophrenia;
SARC	cis	rs9768139	0.733	rs35016950	chr7:158118710	C/A	cg25566285	chr7:158114605	PTPRN2	0.31	5.12	0.32	6.49e-7	Calcium levels;
SARC	cis	rs4481887	1.000	rs7527822	chr1:248467301	A/G	cg13385794	chr1:248469461	NA	0.36	5.52	0.34	8.89e-8	Common traits (Other);
SARC	cis	rs7937682	0.889	rs1784787	chr11:111486125	T/A	cg22437258	chr11:111473054	SIK2	0.74	10.24	0.56	1.44e-20	Primary sclerosing cholangitis;
SARC	cis	rs9467773	0.572	rs13213953	chr6:26594534	T/A	cg11502198	chr6:26597334	ABT1	0.62	7.66	0.45	4.82e-13	Intelligence (multi-trait analysis);
SARC	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg13395646	chr4:1353034	KIAA1530	-0.46	-5.42	-0.33	1.51e-7	Obesity-related traits;
SARC	cis	rs2985684	0.894	rs4900927	chr14:50018741	G/T	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.46	5.07	0.32	7.95e-7	Carotid intima media thickness;
SARC	cis	rs9462027	0.539	rs2814963	chr6:34708908	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.87	-0.36	1.5e-8	Systemic lupus erythematosus;
SARC	cis	rs7561149	1.000	rs7591782	chr2:179693013	C/G	cg17765952	chr2:179737173	CCDC141	-0.37	-4.81	-0.3	2.66e-6	QT interval;
SARC	cis	rs2297440	0.506	rs2236504	chr20:62224762	C/T	cg09650180	chr20:62225654	GMEB2	-0.47	-5.74	-0.35	2.92e-8	Glioma;Non-glioblastoma glioma;Glioblastoma;
SARC	cis	rs17376456	0.569	rs1349711	chr5:93179032	C/T	cg25358565	chr5:93447407	FAM172A	-0.93	-10.64	-0.57	8.33e-22	Diabetic retinopathy;
SARC	cis	rs2180341	1.000	rs2038378	chr6:127590400	C/T	cg24812749	chr6:127587940	RNF146	0.95	12.41	0.63	1.74e-27	Breast cancer;
SARC	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg23758822	chr17:41437982	NA	0.86	10.56	0.57	1.52e-21	Menopause (age at onset);
SARC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg26338869	chr17:61819248	STRADA	0.8	10.8	0.58	2.52e-22	Prudent dietary pattern;
SARC	cis	rs2230307	0.656	rs521348	chr1:100481162	C/A	cg24955406	chr1:100503596	HIAT1	0.69	5.59	0.34	6.48e-8	Carotid intima media thickness;
SARC	cis	rs597539	0.727	rs632984	chr11:68620271	C/T	cg04772025	chr11:68637568	NA	0.5	6.06	0.37	5.55e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg13206674	chr6:150067644	NUP43	0.46	6.1	0.37	4.29e-9	Lung cancer;
SARC	cis	rs7762018	0.556	rs78864023	chr6:170059755	T/A	cg14662283	chr6:170068385	WDR27	-0.64	-4.73	-0.3	3.83e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs9296092	0.517	rs7743178	chr6:33470462	G/A	cg13560919	chr6:33536144	NA	-0.44	-5.07	-0.32	8.23e-7	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs17376456	1.000	rs6867042	chr5:93555761	C/T	cg21475434	chr5:93447410	FAM172A	0.92	7.81	0.46	1.91e-13	Diabetic retinopathy;
SARC	cis	rs875589	0.522	rs1440873	chr13:73228179	A/G	cg08910551	chr13:73356572	DIS3;PIBF1	-0.46	-4.84	-0.3	2.32e-6	Diastolic blood pressure;
SARC	cis	rs9549260	0.755	rs9549244	chr13:41218685	C/T	cg21288729	chr13:41239152	FOXO1	0.64	8.74	0.5	4.76e-16	Red blood cell count;
SARC	cis	rs3126085	0.877	rs7535536	chr1:152193544	A/G	cg26876637	chr1:152193138	HRNR	0.48	5.65	0.35	4.71e-8	Atopic dermatitis;
SARC	cis	rs9843304	1.000	rs9843304	chr3:149211387	C/T	cg08667024	chr3:149219783	TM4SF4	0.39	6.08	0.37	4.79e-9	Gallstone disease;
SARC	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg05025164	chr4:1340916	KIAA1530	0.46	5.67	0.35	4.26e-8	Longevity;
SARC	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg04546413	chr19:29218101	NA	0.63	8.52	0.49	1.98e-15	Methadone dose in opioid dependence;
SARC	cis	rs3796352	1.000	rs10510761	chr3:52965255	A/G	cg12962167	chr3:53033115	SFMBT1	-0.75	-5.25	-0.33	3.47e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs826838	0.616	rs10880738	chr12:38617762	C/T	cg13010199	chr12:38710504	ALG10B	-0.52	-6.43	-0.39	7.32e-10	Heart rate;
SARC	cis	rs208520	0.690	rs12202805	chr6:66703903	A/G	cg07460842	chr6:66804631	NA	-1.06	-14.71	-0.69	4.45e-35	Exhaled nitric oxide output;
SARC	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.08	22.41	0.83	4.65e-60	Chronic sinus infection;
SARC	cis	rs80282103	0.717	rs74117685	chr10:1100410	A/G	cg08668510	chr10:1095578	IDI1	0.89	5.41	0.33	1.54e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs986417	1.000	rs2350900	chr14:60938681	T/A	cg27398547	chr14:60952738	C14orf39	1.03	9.68	0.54	7.63e-19	Gut microbiota (bacterial taxa);
SARC	cis	rs6912958	0.559	rs107690	chr6:88069352	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.38	-7.0	-0.42	2.63e-11	Monocyte percentage of white cells;
SARC	cis	rs2014572	1.000	rs2014572	chr19:57760018	G/A	cg24459738	chr19:57751996	ZNF805	-0.45	-5.2	-0.32	4.3e-7	Hyperactive-impulsive symptoms;
SARC	cis	rs13082711	0.871	rs35572617	chr3:27499247	A/T	cg02860705	chr3:27208620	NA	0.48	6.07	0.37	5.13e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs607987	0.836	rs1222204	chr11:30333224	T/C	cg06241208	chr11:30344200	C11orf46	-0.39	-4.73	-0.3	3.85e-6	Body mass index;
SARC	cis	rs1580019	0.563	rs13225132	chr7:32800975	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.58	7.33	0.43	3.7e-12	Cognitive ability;
SARC	cis	rs8114671	0.562	rs6120739	chr20:33405227	A/G	cg07148914	chr20:33460835	GGT7	0.39	4.82	0.3	2.59e-6	Height;
SARC	cis	rs425277	1.000	rs196128	chr1:2078444	T/G	cg21442419	chr1:2182373	SKI	-0.52	-6.68	-0.4	1.76e-10	Height;
SARC	cis	rs7980687	0.628	rs1609520	chr12:123735937	A/G	cg00376283	chr12:123451042	ABCB9	-0.57	-6.63	-0.4	2.26e-10	Height;Educational attainment;Head circumference (infant);
SARC	cis	rs6912958	0.781	rs9444512	chr6:88223397	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-6.99	-0.42	2.87e-11	Monocyte percentage of white cells;
SARC	trans	rs4481887	0.893	rs4529743	chr1:248473683	G/C	cg12668902	chr6:7261808	NA	-0.5	-6.27	-0.38	1.78e-9	Common traits (Other);
SARC	cis	rs1669338	0.588	rs6784329	chr3:3200013	C/T	cg16797762	chr3:3221439	CRBN	-0.94	-9.62	-0.53	1.14e-18	White matter integrity;
SARC	cis	rs2742234	0.578	rs2435354	chr10:43652445	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.41	-4.87	-0.3	2.05e-6	Hirschsprung disease;
SARC	cis	rs10916814	0.632	rs10916817	chr1:20897294	C/T	cg24502330	chr1:20914028	CDA	-0.29	-5.1	-0.32	7.19e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	trans	rs11098499	0.657	rs71614442	chr4:120379346	C/T	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	cis	rs66573146	0.808	rs55942328	chr4:6990960	T/G	cg15105060	chr4:7024189	TBC1D14	-0.66	-4.75	-0.3	3.49e-6	Granulocyte percentage of myeloid white cells;
SARC	cis	rs2295359	0.724	rs10489630	chr1:67662622	G/T	cg11235152	chr1:67600687	NA	-0.37	-5.56	-0.34	7.53e-8	Psoriasis;
SARC	cis	rs4974559	0.501	rs2101094	chr4:1235643	A/G	cg02980000	chr4:1222292	CTBP1	-0.87	-6.81	-0.41	8.13e-11	Systolic blood pressure;
SARC	cis	rs2742234	0.590	rs2435339	chr10:43642173	G/C	cg15436174	chr10:43711423	RASGEF1A	-0.4	-4.93	-0.31	1.56e-6	Hirschsprung disease;
SARC	cis	rs7772486	0.720	rs4896837	chr6:146014168	C/T	cg23711669	chr6:146136114	FBXO30	-0.87	-14.73	-0.69	3.63e-35	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11098499	0.865	rs4001305	chr4:120359236	G/T	cg09160332	chr4:120329925	NA	-0.33	-4.74	-0.3	3.75e-6	Corneal astigmatism;
SARC	cis	rs1865760	0.516	rs9379818	chr6:26023206	G/T	cg17691542	chr6:26056736	HIST1H1C	0.51	6.47	0.39	5.75e-10	Height;
SARC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg09373136	chr17:61933544	TCAM1	-0.49	-6.63	-0.4	2.28e-10	Prudent dietary pattern;
SARC	cis	rs12477438	1.000	rs11897712	chr2:99735697	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-6.41	-0.39	7.99e-10	Chronic sinus infection;
SARC	cis	rs13096357	0.520	rs17080319	chr3:48732480	T/C	cg00383909	chr3:49044727	WDR6	0.65	6.21	0.38	2.36e-9	Cognitive ability (multi-trait analysis);
SARC	cis	rs921968	0.541	rs3821031	chr2:219295249	C/T	cg02176678	chr2:219576539	TTLL4	-0.41	-6.15	-0.37	3.41e-9	Mean corpuscular hemoglobin concentration;
SARC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg09436375	chr6:42928200	GNMT	0.36	5.71	0.35	3.5e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs910316	0.967	rs4903292	chr14:75656245	A/G	cg06637938	chr14:75390232	RPS6KL1	0.5	6.78	0.41	9.96e-11	Height;
SARC	cis	rs9300255	0.602	rs1716168	chr12:123651966	C/G	cg00376283	chr12:123451042	ABCB9	-0.58	-6.96	-0.41	3.49e-11	Neutrophil percentage of white cells;
SARC	cis	rs9818758	0.607	rs9850917	chr3:49286983	A/G	cg00383909	chr3:49044727	WDR6	0.67	5.91	0.36	1.24e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	trans	rs17685	0.753	rs10476	chr7:75696420	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.64	-7.9	-0.46	1.11e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.5	5.69	0.35	3.83e-8	Renal function-related traits (BUN);
SARC	cis	rs34779708	0.966	rs4934536	chr10:35441169	A/G	cg03585969	chr10:35415529	CREM	0.39	4.79	0.3	2.91e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs7103648	0.742	rs34937994	chr11:47389638	C/T	cg10504702	chr11:47789108	FNBP4	0.54	6.58	0.4	3.11e-10	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs11997175	0.625	rs7460540	chr8:33597907	A/G	ch.8.33884649F	chr8:33765107	NA	0.48	6.05	0.37	5.66e-9	Body mass index;
SARC	cis	rs11718455	0.960	rs13083325	chr3:44005333	T/C	cg21419209	chr3:44054225	NA	-0.41	-4.99	-0.31	1.21e-6	Coronary artery disease;
SARC	cis	rs76419734	1.000	rs72671805	chr4:106603014	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.8	4.87	0.3	2.02e-6	Post bronchodilator FEV1;
SARC	cis	rs459571	0.920	rs460154	chr9:136909309	C/T	cg01294253	chr9:136912663	BRD3	0.4	5.31	0.33	2.62e-7	Platelet distribution width;
SARC	cis	rs8114671	0.551	rs4911162	chr20:33411425	G/C	cg07148914	chr20:33460835	GGT7	0.42	5.13	0.32	6.07e-7	Height;
SARC	cis	rs17023223	0.537	rs4590715	chr1:119750201	C/T	cg05756136	chr1:119680316	WARS2	-0.46	-5.27	-0.33	3.08e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs763121	1.000	rs1946990	chr22:38912771	C/T	cg06022373	chr22:39101656	GTPBP1	-0.77	-10.23	-0.56	1.55e-20	Menopause (age at onset);
SARC	cis	rs561341	0.609	rs2051810	chr17:30195841	C/T	cg13647721	chr17:30228624	UTP6	-0.73	-7.02	-0.42	2.36e-11	Hip circumference adjusted for BMI;
SARC	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg08280861	chr8:58055591	NA	0.61	5.96	0.36	9.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10752881	1.000	rs12035773	chr1:182985716	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.7	0.57	5.56e-22	Colorectal cancer;
SARC	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg13175981	chr1:150552382	MCL1	-0.54	-6.87	-0.41	5.83e-11	Tonsillectomy;
SARC	cis	rs228437	0.874	rs7743660	chr6:134943460	A/G	cg24504307	chr6:134963096	NA	0.43	4.92	0.31	1.64e-6	Melanoma;
SARC	cis	rs1048257	0.682	rs2582514	chr14:105413204	G/T	cg14403583	chr14:105418241	AHNAK2	-0.56	-7.25	-0.43	6.2e-12	Systemic lupus erythematosus;
SARC	cis	rs6866344	0.561	rs55974982	chr5:178141421	G/A	cg10224037	chr5:178157518	ZNF354A	0.97	13.68	0.67	1.11e-31	Neutrophil percentage of white cells;
SARC	cis	rs13191362	1.000	rs36107456	chr6:162997399	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.56	5.41	0.33	1.53e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs9911578	1.000	rs12938772	chr17:56776320	T/C	cg12560992	chr17:57184187	TRIM37	0.82	10.85	0.58	1.82e-22	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg20607798	chr8:58055168	NA	0.61	5.41	0.33	1.57e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs17270561	0.609	rs6924782	chr6:25735816	C/G	cg17691542	chr6:26056736	HIST1H1C	0.58	7.09	0.42	1.6e-11	Iron status biomarkers;
SARC	cis	rs10876993	0.890	rs1092472	chr12:58036688	G/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.46	-5.89	-0.36	1.32e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs7647973	0.667	rs9869256	chr3:49624095	T/G	cg07636037	chr3:49044803	WDR6	0.76	6.32	0.38	1.3e-9	Menarche (age at onset);
SARC	cis	rs7296418	0.961	rs4148863	chr12:123569375	A/G	cg16085171	chr12:123569118	PITPNM2	-0.39	-5.01	-0.31	1.07e-6	Platelet count;
SARC	cis	rs1943345	0.686	rs10898088	chr11:82874970	G/A	cg07047830	chr11:82868014	PCF11	0.63	8.21	0.47	1.55e-14	Obesity-related traits;
SARC	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg13126279	chr21:47581558	C21orf56	-0.5	-6.09	-0.37	4.59e-9	Testicular germ cell tumor;
SARC	cis	rs12479064	0.671	rs4851207	chr2:100105775	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.69	-8.4	-0.48	4.55e-15	Chronic sinus infection;
SARC	cis	rs9788682	0.747	rs2568497	chr15:78721397	G/T	cg06917634	chr15:78832804	PSMA4	0.53	5.3	0.33	2.67e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs2075371	0.933	rs2544181	chr7:133944934	C/T	cg20476274	chr7:133979776	SLC35B4	0.6	8.18	0.47	1.85e-14	Mean platelet volume;
SARC	cis	rs7224737	1.000	rs731152	chr17:40279680	G/A	cg20291162	chr17:40259547	DHX58	-0.33	-4.87	-0.3	2.08e-6	Fibrinogen levels;
SARC	trans	rs7824557	0.606	rs1047950	chr8:11185096	G/C	cg06636001	chr8:8085503	FLJ10661	0.61	7.97	0.46	7.14e-14	Retinal vascular caliber;
SARC	cis	rs4974559	0.739	rs4333131	chr4:1323789	A/G	cg02980000	chr4:1222292	CTBP1	0.63	6.14	0.37	3.48e-9	Systolic blood pressure;
SARC	trans	rs7819412	0.668	rs4841507	chr8:11046394	C/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.56	-0.44	8.96e-13	Triglycerides;
SARC	cis	rs2354432	0.607	rs4950385	chr1:146656292	A/G	cg25205988	chr1:146714368	CHD1L	1.08	8.83	0.5	2.51e-16	Mitochondrial DNA levels;
SARC	cis	rs6120849	0.754	rs36003887	chr20:33589107	G/A	cg24642439	chr20:33292090	TP53INP2	0.57	5.54	0.34	7.99e-8	Protein C levels;
SARC	cis	rs2204008	0.749	rs10880692	chr12:38592918	C/G	cg13010199	chr12:38710504	ALG10B	-0.8	-11.2	-0.59	1.4e-23	Bladder cancer;
SARC	cis	rs4833079	0.562	rs11944291	chr4:38631620	T/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.4	5.14	0.32	5.85e-7	Body mass index;
SARC	cis	rs4148883	0.603	rs6833176	chr4:100131163	G/C	cg13256891	chr4:100009986	ADH5	-0.51	-6.52	-0.39	4.26e-10	Alcohol dependence;
SARC	cis	rs41271473	0.526	rs12143098	chr1:228720965	A/C	cg16512390	chr1:228756714	NA	0.61	5.45	0.34	1.26e-7	Chronic lymphocytic leukemia;
SARC	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg19077165	chr18:44547161	KATNAL2	0.56	7.82	0.46	1.79e-13	Personality dimensions;
SARC	cis	rs9814567	0.806	rs4245903	chr3:134317074	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.48	-6.38	-0.39	9.5e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs6504663	0.558	rs11871603	chr17:48559037	T/G	cg22571038	chr17:48585470	MYCBPAP	0.47	5.43	0.34	1.4e-7	Visceral fat;
SARC	cis	rs412050	0.547	rs112153746	chr22:22138691	G/A	cg17089214	chr22:22089827	YPEL1	0.8	6.92	0.41	4.29e-11	Attention deficit hyperactivity disorder;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg21581312	chr15:35529473	LOC723972	-0.54	-6.84	-0.41	6.79e-11	Height;
SARC	cis	rs911263	0.521	rs3825729	chr14:68773744	T/G	cg18825221	chr14:68749962	RAD51L1	0.43	7.55	0.44	9.91e-13	Primary biliary cholangitis;
SARC	cis	rs4805272	0.512	rs12373558	chr19:29337692	A/G	cg04546413	chr19:29218101	NA	0.45	5.0	0.31	1.14e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs7836436	0.686	rs7006901	chr8:120954780	C/G	cg21659575	chr8:120844832	TAF2	0.71	5.35	0.33	2.05e-7	HIV-1 viral setpoint;
SARC	cis	rs57920188	0.584	rs12080562	chr1:4089697	C/A	cg20703997	chr1:4087676	NA	0.49	5.34	0.33	2.21e-7	Interleukin-17 levels;
SARC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.67	9.09	0.51	4.41e-17	Lymphocyte counts;
SARC	cis	rs7635838	0.718	rs2594973	chr3:11395821	C/G	cg00170343	chr3:11313890	ATG7	0.64	9.04	0.51	6.1e-17	HDL cholesterol;
SARC	cis	rs568617	1.000	rs694994	chr11:65653309	A/G	cg00576331	chr11:65640516	EFEMP2	-0.46	-5.41	-0.33	1.53e-7	Crohn's disease;
SARC	cis	rs2273669	0.667	rs11153153	chr6:109356104	A/T	cg05315195	chr6:109294784	ARMC2	-0.64	-5.7	-0.35	3.68e-8	Prostate cancer;
SARC	cis	rs7824557	0.527	rs4631425	chr8:11239054	C/T	cg21775007	chr8:11205619	TDH	-0.58	-7.71	-0.45	3.68e-13	Retinal vascular caliber;
SARC	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg12667521	chr19:29218732	NA	0.4	5.48	0.34	1.08e-7	Methadone dose in opioid dependence;
SARC	cis	rs11098499	0.954	rs35063680	chr4:120387102	T/C	cg09307838	chr4:120376055	NA	0.9	12.47	0.63	1.13e-27	Corneal astigmatism;
SARC	cis	rs7766436	0.648	rs2876643	chr6:22591525	C/A	cg13666174	chr6:22585274	NA	-0.55	-7.28	-0.43	5e-12	Coronary artery disease;
SARC	cis	rs765787	0.530	rs1706764	chr15:45524256	T/A	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.24	-0.32	3.62e-7	Uric acid levels;
SARC	cis	rs11097912	0.632	rs17274248	chr4:107205662	C/T	cg09646026	chr4:107269030	AIMP1	-0.45	-4.86	-0.3	2.13e-6	Airflow obstruction;
SARC	cis	rs3796352	1.000	rs71617204	chr3:53042951	G/A	cg07884673	chr3:53033167	SFMBT1	0.9	5.87	0.36	1.49e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs9486719	1.000	rs28623445	chr6:96899116	G/T	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.01	-0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs76419734	0.850	rs72670002	chr4:106594516	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	4.91	0.31	1.75e-6	Post bronchodilator FEV1;
SARC	cis	rs11992186	0.505	rs7845203	chr8:8145440	A/G	cg08975724	chr8:8085496	FLJ10661	0.47	5.37	0.33	1.86e-7	Neuroticism;
SARC	cis	rs6504663	0.525	rs557	chr17:48563234	C/T	cg03611598	chr17:48586076	MYCBPAP	0.5	5.62	0.35	5.36e-8	Visceral fat;
SARC	cis	rs1568889	0.938	rs11601602	chr11:28233768	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	9.37	0.52	6.49e-18	Bipolar disorder;
SARC	trans	rs6819266	0.636	rs13148734	chr4:63330858	A/G	cg17014718	chr3:174095241	NA	0.49	6.56	0.39	3.49e-10	Age-related macular degeneration;
SARC	cis	rs7927771	1.000	rs10838738	chr11:47663049	A/G	cg20307385	chr11:47447363	PSMC3	-0.53	-6.49	-0.39	5.02e-10	Subjective well-being;
SARC	trans	rs9388451	0.839	rs3799709	chr6:126078361	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.56	-7.36	-0.43	3.15e-12	Brugada syndrome;
SARC	cis	rs2370759	1.000	rs79442609	chr10:32608749	C/T	cg01819863	chr10:32635814	EPC1	1.02	10.19	0.56	2.11e-20	Sexual dysfunction (female);
SARC	cis	rs892961	0.899	rs3650	chr17:75415835	T/C	cg05865280	chr17:75406074	SEPT9	0.55	8.09	0.47	3.24e-14	Airflow obstruction;
SARC	cis	rs6964587	0.692	rs17672805	chr7:91573466	A/G	cg17063962	chr7:91808500	NA	-0.81	-11.84	-0.61	1.24e-25	Breast cancer;
SARC	cis	rs7666738	0.546	rs13105521	chr4:98734419	C/T	cg05340658	chr4:99064831	C4orf37	0.58	7.15	0.42	1.09e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg19077165	chr18:44547161	KATNAL2	-0.45	-6.06	-0.37	5.49e-9	Personality dimensions;
SARC	cis	rs9486719	1.000	rs4262195	chr6:96929475	T/C	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.01	-0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs9300255	0.537	rs1790101	chr12:123704844	T/C	cg00376283	chr12:123451042	ABCB9	0.55	6.53	0.39	4.09e-10	Neutrophil percentage of white cells;
SARC	cis	rs7917772	0.636	rs4919676	chr10:104524352	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-6.38	-0.39	9.19e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26718510	chr12:44200307	TWF1	-0.53	-6.91	-0.41	4.69e-11	Smoking initiation;
SARC	cis	rs7635838	0.827	rs4273358	chr3:11415160	T/G	cg00170343	chr3:11313890	ATG7	0.61	8.17	0.47	2.02e-14	HDL cholesterol;
SARC	cis	rs9916302	0.904	rs9904334	chr17:37468336	G/A	cg15445000	chr17:37608096	MED1	-0.44	-5.31	-0.33	2.6e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs2816062	0.760	rs2745319	chr1:18895078	G/A	cg18795169	chr1:18902165	NA	-0.78	-12.27	-0.63	4.91e-27	Urate levels in lean individuals;
SARC	cis	rs10463554	0.926	rs34778	chr5:102452556	C/T	cg23492399	chr5:102201601	PAM	-0.47	-5.26	-0.33	3.23e-7	Parkinson's disease;
SARC	cis	rs1448094	0.872	rs10863146	chr12:86408326	C/G	cg02569458	chr12:86230093	RASSF9	0.37	5.33	0.33	2.27e-7	Major depressive disorder;
SARC	cis	rs9341808	0.667	rs10943698	chr6:80934301	C/T	cg08355045	chr6:80787529	NA	0.37	5.9	0.36	1.28e-8	Sitting height ratio;
SARC	cis	rs3820928	0.874	rs7594505	chr2:227878562	C/G	cg11843606	chr2:227700838	RHBDD1	-0.56	-6.96	-0.42	3.35e-11	Pulmonary function;
SARC	cis	rs7824557	0.606	rs2736270	chr8:11192593	G/A	cg12395012	chr8:11607386	GATA4	-0.29	-4.73	-0.3	3.87e-6	Retinal vascular caliber;
SARC	cis	rs11650776	1	rs11650776	chr17:37641402	G/A	cg00129232	chr17:37814104	STARD3	-0.64	-7.7	-0.45	3.85e-13	Lung function (FEV1);
SARC	cis	rs4481887	1.000	rs10888362	chr1:248483975	A/G	cg13385794	chr1:248469461	NA	-0.35	-5.42	-0.33	1.45e-7	Common traits (Other);
SARC	cis	rs4148883	0.689	rs2851275	chr4:100024883	A/G	cg13256891	chr4:100009986	ADH5	0.64	8.86	0.5	2.03e-16	Alcohol dependence;
SARC	cis	rs7959452	0.868	rs12812860	chr12:69746671	T/C	cg22834771	chr12:69754056	YEATS4	-0.45	-6.02	-0.37	6.86e-9	Blood protein levels;
SARC	cis	rs9894429	0.646	rs7405870	chr17:79617284	G/A	cg10661904	chr17:79619235	PDE6G	-0.44	-6.13	-0.37	3.69e-9	Eye color traits;
SARC	cis	rs3733585	0.699	rs11724510	chr4:9958583	C/T	cg11266682	chr4:10021025	SLC2A9	-0.34	-5.85	-0.36	1.62e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs1318878	0.565	rs11056433	chr12:15497942	G/T	cg08258403	chr12:15378311	NA	0.46	6.51	0.39	4.53e-10	Intelligence (multi-trait analysis);
SARC	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg04277193	chr17:41438351	NA	0.45	4.79	0.3	2.96e-6	Menopause (age at onset);
SARC	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg11062466	chr8:58055876	NA	0.56	5.69	0.35	3.79e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg11905131	chr22:24372483	LOC391322	-0.42	-4.98	-0.31	1.26e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs3126085	1.000	rs72697000	chr1:152276772	C/A	cg26876637	chr1:152193138	HRNR	-0.52	-5.29	-0.33	2.88e-7	Atopic dermatitis;
SARC	cis	rs2153535	0.580	rs2327057	chr6:8443319	G/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.13	0.59	2.34e-23	Motion sickness;
SARC	cis	rs10872587	0.657	rs11155459	chr6:146578751	A/G	cg05347473	chr6:146136440	FBXO30	-0.64	-6.75	-0.4	1.13e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7264396	0.635	rs6058375	chr20:34531997	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.16	-0.42	1.03e-11	Total cholesterol levels;
SARC	cis	rs5753618	0.561	rs13054220	chr22:31704492	A/G	cg07713946	chr22:31675144	LIMK2	0.37	5.22	0.32	4e-7	Colorectal cancer;
SARC	cis	rs5753618	0.539	rs8135344	chr22:31671932	G/T	cg02404636	chr22:31891804	SFI1	-0.49	-5.3	-0.33	2.67e-7	Colorectal cancer;
SARC	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg18252515	chr7:66147081	NA	0.44	4.91	0.31	1.71e-6	Aortic root size;
SARC	cis	rs7945705	0.747	rs10840158	chr11:9020897	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.46	-6.48	-0.39	5.45e-10	Hemoglobin concentration;
SARC	cis	rs6693567	0.565	rs10157197	chr1:150250636	G/A	cg09579323	chr1:150459698	TARS2	-0.41	-4.91	-0.31	1.74e-6	Migraine;
SARC	cis	rs4803468	1.000	rs10417311	chr19:41902038	G/A	cg08477640	chr19:41863820	B9D2	0.47	6.1	0.37	4.26e-9	Height;
SARC	cis	rs4243830	0.850	rs4908558	chr1:6584101	A/G	cg04093404	chr1:6614507	TAS1R1;NOL9	0.55	4.73	0.3	3.86e-6	Body mass index;
SARC	cis	rs1215050	0.791	rs155019	chr4:98759126	G/A	cg05340658	chr4:99064831	C4orf37	0.44	5.85	0.36	1.62e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs910316	1.000	rs7303	chr14:75520065	T/C	cg08847533	chr14:75593920	NEK9	0.96	16.08	0.73	1.2e-39	Height;
SARC	cis	rs6840360	1.000	rs10049991	chr4:152664163	A/T	cg22705602	chr4:152727874	NA	-0.36	-6.3	-0.38	1.5e-9	Intelligence (multi-trait analysis);
SARC	cis	rs523522	1.000	rs523522	chr12:121020250	A/T	cg12219531	chr12:120966889	COQ5	0.8	10.38	0.56	5.33e-21	High light scatter reticulocyte count;
SARC	cis	rs698833	0.892	rs1067322	chr2:44630107	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.71	9.31	0.52	9.69e-18	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg18876405	chr7:65276391	NA	-0.45	-4.94	-0.31	1.46e-6	Aortic root size;
SARC	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg11987759	chr7:65425863	GUSB	0.47	5.87	0.36	1.52e-8	Aortic root size;
SARC	cis	rs1008375	0.966	rs2302393	chr4:17654341	G/A	cg27347728	chr4:17578864	LAP3	0.47	5.91	0.36	1.18e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2075671	0.903	rs62482252	chr7:100274063	C/A	cg16850897	chr7:100343110	ZAN	-0.66	-6.77	-0.41	1.03e-10	Other erythrocyte phenotypes;
SARC	cis	rs11608355	0.515	rs1045582	chr12:109915727	G/T	cg05360138	chr12:110035743	NA	0.93	9.47	0.53	3.23e-18	Neuroticism;
SARC	cis	rs6991952	0.676	rs6983496	chr8:25697059	G/A	cg21775463	chr8:25538546	NA	0.28	4.93	0.31	1.55e-6	Inguinal hernia;
SARC	cis	rs9341808	0.556	rs1535075	chr6:81034806	A/G	cg08355045	chr6:80787529	NA	0.32	4.95	0.31	1.45e-6	Sitting height ratio;
SARC	cis	rs6840360	0.615	rs4696096	chr4:152475387	A/G	cg22705602	chr4:152727874	NA	-0.4	-6.25	-0.38	1.92e-9	Intelligence (multi-trait analysis);
SARC	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg02841227	chr6:26021843	HIST1H4A	0.69	8.46	0.48	3.01e-15	Intelligence (multi-trait analysis);
SARC	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg24642844	chr7:1081250	C7orf50	-0.59	-6.23	-0.38	2.22e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs55871839	0.598	rs4737525	chr8:59799781	G/A	cg07426533	chr8:59803705	TOX	-0.41	-5.34	-0.33	2.22e-7	Pneumonia;
SARC	cis	rs73206853	0.686	rs73206895	chr12:110879968	A/G	cg10860002	chr12:110842031	ANAPC7	0.64	5.11	0.32	6.75e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg17376030	chr22:41985996	PMM1	0.73	9.22	0.52	1.89e-17	Vitiligo;
SARC	cis	rs858239	1.000	rs199351	chr7:23300049	A/C	cg23682824	chr7:23144976	KLHL7	0.62	7.64	0.45	5.49e-13	Cerebrospinal fluid biomarker levels;
SARC	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg11644478	chr21:40555479	PSMG1	1.06	14.73	0.69	3.65e-35	Cognitive function;
SARC	cis	rs1832871	0.672	rs9457362	chr6:158772052	C/T	cg07165851	chr6:158734300	TULP4	0.53	6.34	0.38	1.16e-9	Height;
SARC	cis	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg25427524	chr10:38739819	LOC399744	0.55	8.66	0.49	7.8e-16	Extrinsic epigenetic age acceleration;
SARC	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg17221315	chr6:27791827	HIST1H4J	0.47	5.39	0.33	1.71e-7	Depression;
SARC	cis	rs4689388	0.890	rs4481292	chr4:6298375	C/T	cg00701064	chr4:6280414	WFS1	0.55	8.88	0.5	1.78e-16	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs926392	0.640	rs62202616	chr20:37692775	G/C	cg16355469	chr20:37678765	NA	0.75	9.75	0.54	4.8e-19	Dialysis-related mortality;
SARC	cis	rs1153858	1.000	rs11070457	chr15:45686943	A/C	cg21132104	chr15:45694354	SPATA5L1	0.78	10.56	0.57	1.54e-21	Homoarginine levels;
SARC	cis	rs6807306	1.000	rs7615915	chr3:167435193	A/G	cg24249075	chr3:167452484	PDCD10;SERPINI1	-0.52	-5.02	-0.31	1.03e-6	Mean platelet volume;
SARC	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg17554472	chr22:41940697	POLR3H	-0.44	-4.74	-0.3	3.77e-6	Vitiligo;
SARC	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg12311346	chr5:56204834	C5orf35	-0.58	-6.01	-0.37	7.24e-9	Initial pursuit acceleration;
SARC	cis	rs7296418	0.961	rs10848428	chr12:123572495	C/T	cg00376283	chr12:123451042	ABCB9	0.66	8.55	0.49	1.61e-15	Platelet count;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg27558006	chr16:19563474	CP110	0.49	6.69	0.4	1.68e-10	Thyroid stimulating hormone;
SARC	cis	rs2290159	0.800	rs2290162	chr3:12647457	A/G	cg23032965	chr3:12705835	RAF1	0.74	7.99	0.46	6.38e-14	Cholesterol, total;
SARC	cis	rs6439153	1.000	rs6439153	chr3:128701130	T/C	cg25356066	chr3:128598488	ACAD9	0.47	5.53	0.34	8.74e-8	Pneumococcal bacteremia;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg06856563	chr7:75623987	TMEM120A	-0.83	-7.02	-0.42	2.4e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs41271473	0.526	rs56043220	chr1:228783474	G/C	cg16512390	chr1:228756714	NA	0.64	5.71	0.35	3.45e-8	Chronic lymphocytic leukemia;
SARC	cis	rs748404	0.604	rs2278857	chr15:43632549	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.42	5.28	0.33	2.94e-7	Lung cancer;
SARC	cis	rs11190604	1.000	rs2495747	chr10:102328247	C/T	cg07080220	chr10:102295463	HIF1AN	0.76	9.07	0.51	5.12e-17	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs7089973	0.604	rs1359079	chr10:116582502	A/G	cg03647239	chr10:116582469	FAM160B1	0.49	6.31	0.38	1.42e-9	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg13647721	chr17:30228624	UTP6	0.55	4.99	0.31	1.21e-6	Hip circumference adjusted for BMI;
SARC	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg06028605	chr16:24865363	SLC5A11	0.37	5.46	0.34	1.22e-7	Intelligence (multi-trait analysis);
SARC	cis	rs17376456	0.569	rs7732578	chr5:93410244	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.5	-5.48	-0.34	1.13e-7	Diabetic retinopathy;
SARC	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg11644478	chr21:40555479	PSMG1	1.03	14.41	0.69	4.23e-34	Cognitive function;
SARC	cis	rs3936840	0.565	rs8011721	chr14:102986388	C/G	cg18135206	chr14:102964638	TECPR2	-0.41	-5.04	-0.31	9.25e-7	Plateletcrit;
SARC	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg25036284	chr2:26402008	FAM59B	-0.45	-5.61	-0.34	5.83e-8	Gut microbiome composition (summer);
SARC	cis	rs2043112	0.867	rs1239276	chr5:39008914	A/G	cg04869206	chr5:39074266	RICTOR	0.46	5.6	0.34	6.01e-8	Obesity-related traits;
SARC	cis	rs11098499	0.820	rs13122709	chr4:120555356	T/A	cg09307838	chr4:120376055	NA	0.83	11.36	0.6	4.34e-24	Corneal astigmatism;
SARC	trans	rs61931739	0.500	rs11053217	chr12:34470036	A/C	cg13010199	chr12:38710504	ALG10B	0.76	10.78	0.58	2.96e-22	Morning vs. evening chronotype;
SARC	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6088580	0.524	rs4911437	chr20:33266149	G/T	cg24642439	chr20:33292090	TP53INP2	-0.54	-6.48	-0.39	5.33e-10	Glomerular filtration rate (creatinine);
SARC	trans	rs36093844	0.800	rs59179556	chr11:85573897	A/G	cg15359163	chr5:122429178	PRDM6	-0.52	-6.49	-0.39	5.01e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs10752881	1.000	rs10797800	chr1:182969828	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.3	0.56	9.62e-21	Colorectal cancer;
SARC	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg08280861	chr8:58055591	NA	0.7	5.97	0.36	8.85e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9503598	0.778	rs1328688	chr6:3468508	G/A	cg00476032	chr6:3446245	SLC22A23	0.4	6.12	0.37	3.92e-9	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
SARC	cis	rs4566357	0.595	rs10206912	chr2:227921095	A/T	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.84	-0.36	1.71e-8	Coronary artery disease;
SARC	cis	rs11123694	1.000	rs11123694	chr2:109064563	C/T	cg23706161	chr2:109336669	RANBP2	-0.42	-5.53	-0.34	8.65e-8	Mean platelet volume;
SARC	cis	rs739401	0.611	rs12284275	chr11:3024384	T/C	cg25174290	chr11:3078921	CARS	0.57	7.98	0.46	6.48e-14	Longevity;
SARC	cis	rs748404	0.697	rs579651	chr15:43558376	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.41	5.12	0.32	6.27e-7	Lung cancer;
SARC	cis	rs10508881	1.000	rs10508881	chr10:44541565	A/G	cg09554077	chr10:44749378	NA	-0.27	-4.72	-0.3	4.13e-6	Endometriosis;
SARC	cis	rs7927771	0.524	rs4752798	chr11:47886364	T/C	cg10504702	chr11:47789108	FNBP4	-0.43	-5.62	-0.35	5.38e-8	Subjective well-being;
SARC	cis	rs7772486	0.654	rs4896829	chr6:145953675	T/A	cg05347473	chr6:146136440	FBXO30	0.5	6.71	0.4	1.5e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2013441	0.965	rs2703808	chr17:20109665	A/C	cg13482628	chr17:19912719	NA	-0.46	-5.98	-0.36	8.48e-9	Obesity-related traits;
SARC	cis	rs1550582	1.000	rs16905157	chr8:135519964	C/T	cg17885191	chr8:135476712	NA	0.57	5.94	0.36	1.05e-8	Educational attainment;
SARC	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg14159672	chr1:205819179	PM20D1	0.57	6.31	0.38	1.4e-9	Prostate-specific antigen levels;
SARC	cis	rs6088580	0.634	rs6059878	chr20:33087166	A/T	cg08999081	chr20:33150536	PIGU	0.45	6.91	0.41	4.59e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg07274523	chr3:49395745	GPX1	0.49	5.43	0.34	1.43e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs2762353	0.562	rs1165206	chr6:25867566	G/A	cg17691542	chr6:26056736	HIST1H1C	0.45	5.75	0.35	2.77e-8	Blood metabolite levels;
SARC	cis	rs6570726	0.875	rs368744	chr6:145812622	A/G	cg23711669	chr6:146136114	FBXO30	0.76	11.38	0.6	3.66e-24	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.44	4.99	0.31	1.16e-6	Renal function-related traits (BUN);
SARC	cis	rs1008375	1.000	rs3815414	chr4:17606659	A/G	cg27347728	chr4:17578864	LAP3	-0.46	-5.63	-0.35	5.2e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2230307	0.536	rs534252	chr1:100472604	A/G	cg24955406	chr1:100503596	HIAT1	0.7	7.09	0.42	1.59e-11	Carotid intima media thickness;
SARC	cis	rs796364	1.000	rs1509835	chr2:200814809	C/G	cg23649088	chr2:200775458	C2orf69	0.62	5.8	0.35	2.19e-8	Schizophrenia;
SARC	cis	rs7027203	0.557	rs9299411	chr9:96523104	C/A	cg14598338	chr9:96623480	NA	-0.34	-4.76	-0.3	3.43e-6	DNA methylation (variation);
SARC	trans	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg21659725	chr3:3221576	CRBN	-0.64	-6.3	-0.38	1.43e-9	Menarche (age at onset);
SARC	cis	rs67366981	0.720	rs4396457	chr14:77685379	G/A	cg06779847	chr14:77687015	TMEM63C	-0.45	-4.87	-0.3	2.09e-6	Obsessive-compulsive symptoms;
SARC	cis	rs7264396	0.635	rs6058365	chr20:34508092	C/T	cg12579300	chr20:34535607	PHF20	-0.43	-4.99	-0.31	1.21e-6	Total cholesterol levels;
SARC	cis	rs2120019	0.935	rs8043181	chr15:75380424	T/C	cg12414181	chr15:75287860	SCAMP5	-0.41	-4.84	-0.3	2.36e-6	Blood trace element (Zn levels);
SARC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg11494091	chr17:61959527	GH2	0.53	8.02	0.47	5.12e-14	Prudent dietary pattern;
SARC	cis	rs6456156	0.846	rs9364891	chr6:167516319	C/T	cg07741184	chr6:167504864	NA	-0.33	-6.13	-0.37	3.68e-9	Primary biliary cholangitis;
SARC	cis	rs1904096	0.506	rs28522293	chr4:95167087	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.47	-6.81	-0.41	8.11e-11	Type 2 diabetes;
SARC	cis	rs1448094	0.842	rs10779231	chr12:86462237	T/C	cg02569458	chr12:86230093	RASSF9	-0.38	-5.44	-0.34	1.34e-7	Major depressive disorder;
SARC	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg25072359	chr17:41440525	NA	0.53	6.33	0.38	1.26e-9	Menopause (age at onset);
SARC	cis	rs7726839	0.561	rs3915384	chr5:573395	G/T	cg07777115	chr5:623756	CEP72	-0.68	-6.38	-0.39	9.69e-10	Obesity-related traits;
SARC	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg25703541	chr22:24373054	LOC391322	-0.82	-11.01	-0.58	5.71e-23	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7712401	0.601	rs35479600	chr5:122324470	G/T	cg19412675	chr5:122181750	SNX24	-0.42	-5.31	-0.33	2.61e-7	Mean platelet volume;
SARC	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg20965017	chr5:231967	SDHA	-0.58	-5.73	-0.35	3.14e-8	Breast cancer;
SARC	cis	rs9325144	0.555	rs28738714	chr12:38706912	G/A	cg13010199	chr12:38710504	ALG10B	-0.54	-7.01	-0.42	2.62e-11	Morning vs. evening chronotype;
SARC	cis	rs644799	1.000	rs473148	chr11:95628606	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	13.75	0.67	6.85e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs7815944	1.000	rs16902863	chr8:129415706	T/G	cg25487405	chr22:46473039	NA	0.64	6.37	0.39	1e-9	Atopic dermatitis;
SARC	trans	rs17780086	0.527	rs72827712	chr17:30538600	A/G	cg20587970	chr11:113659929	NA	-1.15	-9.01	-0.51	7.82e-17	Height;
SARC	cis	rs11098499	0.954	rs13133522	chr4:120324424	A/T	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs12134245	0.747	rs17501512	chr1:92012481	C/G	cg25838465	chr1:92012736	NA	0.69	9.74	0.54	5.05e-19	Breast cancer;
SARC	cis	rs4853036	0.629	rs13018262	chr2:70020333	A/G	cg02498382	chr2:70120550	SNRNP27	-0.35	-4.89	-0.31	1.89e-6	Colorectal or endometrial cancer;
SARC	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg17971929	chr21:40555470	PSMG1	-0.86	-11.03	-0.59	4.8e-23	Cognitive function;
SARC	cis	rs10927875	0.541	rs1739843	chr1:16343254	T/C	cg21385522	chr1:16154831	NA	0.55	6.64	0.4	2.24e-10	Dilated cardiomyopathy;
SARC	cis	rs41271473	0.500	rs4606285	chr1:228887544	G/T	cg00850481	chr1:228891306	NA	-0.3	-4.74	-0.3	3.65e-6	Chronic lymphocytic leukemia;
SARC	cis	rs9640161	0.750	rs59211922	chr7:150023790	T/G	cg17279839	chr7:150038598	RARRES2	0.49	7.39	0.44	2.64e-12	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg24829409	chr8:58192753	C8orf71	-0.54	-5.85	-0.36	1.62e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10911232	0.507	rs4652765	chr1:182994147	C/T	cg13390022	chr1:182993471	LAMC1	0.33	4.97	0.31	1.31e-6	Hypertriglyceridemia;
SARC	cis	rs9818758	0.607	rs73074866	chr3:49626666	C/T	cg03060546	chr3:49711283	APEH	-0.63	-5.25	-0.33	3.43e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs3126085	1.000	rs55957623	chr1:152223196	T/A	cg03465714	chr1:152285911	FLG	0.46	4.95	0.31	1.42e-6	Atopic dermatitis;
SARC	cis	rs6540556	0.723	rs11119336	chr1:209930585	G/C	cg23920097	chr1:209922102	NA	-0.56	-5.76	-0.35	2.64e-8	Red blood cell count;
SARC	cis	rs7412746	0.658	rs8444	chr1:150938571	G/A	cg15448220	chr1:150897856	SETDB1	0.51	6.54	0.39	3.77e-10	Melanoma;
SARC	cis	rs9790314	0.967	rs336541	chr3:161056698	A/C	cg03342759	chr3:160939853	NMD3	-0.58	-7.38	-0.44	2.77e-12	Morning vs. evening chronotype;
SARC	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.97e-8	Aortic root size;
SARC	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9916302	0.904	rs8065879	chr17:37515978	G/A	cg15445000	chr17:37608096	MED1	-0.44	-5.39	-0.33	1.71e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs372883	0.967	rs1153287	chr21:30685611	C/T	cg24692254	chr21:30365293	RNF160	-0.38	-4.72	-0.3	4e-6	Pancreatic cancer;
SARC	cis	rs4660261	0.562	rs3011223	chr1:44318286	T/C	cg13606994	chr1:44402422	ARTN	-0.29	-4.73	-0.3	3.81e-6	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg11987759	chr7:65425863	GUSB	0.48	5.94	0.36	1.06e-8	Aortic root size;
SARC	cis	rs10744422	1.000	rs4993320	chr12:123338092	T/C	cg25930673	chr12:123319894	HIP1R	-0.64	-4.8	-0.3	2.84e-6	Schizophrenia;
SARC	cis	rs13006833	0.765	rs291431	chr2:191199530	G/A	cg25963032	chr2:191064776	C2orf88	0.36	4.95	0.31	1.45e-6	Urinary metabolites;
SARC	cis	rs8014204	0.816	rs4903262	chr14:75340818	A/G	cg06637938	chr14:75390232	RPS6KL1	0.54	7.58	0.44	8.18e-13	Caffeine consumption;
SARC	cis	rs2075371	0.796	rs35336643	chr7:134010640	G/A	cg00033643	chr7:134001901	SLC35B4	0.48	5.78	0.35	2.43e-8	Mean platelet volume;
SARC	cis	rs4834770	0.668	rs11737086	chr4:120127117	T/C	cg09307838	chr4:120376055	NA	-0.48	-5.13	-0.32	6.08e-7	Blood protein levels;
SARC	cis	rs7520050	0.966	rs12410071	chr1:46358886	T/C	cg24296786	chr1:45957014	TESK2	0.38	4.82	0.3	2.56e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs208520	0.690	rs12208977	chr6:66725257	G/A	cg07460842	chr6:66804631	NA	1.05	14.04	0.68	7.33e-33	Exhaled nitric oxide output;
SARC	cis	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg03213289	chr20:61660250	NA	0.47	6.59	0.4	2.98e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg06873352	chr17:61820015	STRADA	0.53	6.8	0.41	8.86e-11	Prudent dietary pattern;
SARC	cis	rs644799	1.000	rs632388	chr11:95563775	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	14.89	0.7	1.07e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs7824557	0.527	rs2736296	chr8:11234844	G/A	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.82	-0.5	2.8e-16	Retinal vascular caliber;
SARC	cis	rs9733	0.818	rs4970924	chr1:150633079	A/G	cg13175981	chr1:150552382	MCL1	0.65	8.99	0.51	8.45e-17	Tonsillectomy;
SARC	cis	rs2404602	0.647	rs907593	chr15:77196953	G/A	cg15268244	chr15:77196840	NA	0.44	5.14	0.32	5.7e-7	Blood metabolite levels;
SARC	cis	rs7223966	1.000	rs11870797	chr17:61804622	C/T	cg00588841	chr17:61851480	DDX42;CCDC47	-0.68	-7.6	-0.45	7.42e-13	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs11764590	0.694	rs4721359	chr7:2104951	A/G	cg23043544	chr7:2124092	MAD1L1	-0.35	-4.78	-0.3	3.11e-6	Neuroticism;
SARC	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg11366901	chr6:160182831	ACAT2	1.02	10.34	0.56	7.29e-21	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs10489202	0.608	rs35059151	chr1:168079393	C/A	cg24449463	chr1:168025552	DCAF6	-0.58	-7.75	-0.45	2.77e-13	Schizophrenia;
SARC	cis	rs7113850	0.541	rs4360696	chr11:24217119	C/G	ch.11.24196551F	chr11:24239977	NA	0.69	6.65	0.4	2.01e-10	Bone fracture in osteoporosis;
SARC	cis	rs2230307	0.518	rs2810425	chr1:100665072	G/C	cg24955406	chr1:100503596	HIAT1	-0.68	-6.65	-0.4	2.08e-10	Carotid intima media thickness;
SARC	cis	rs9815354	0.812	rs73071341	chr3:41826211	C/T	cg03022575	chr3:42003672	ULK4	0.71	5.89	0.36	1.34e-8	Pulse pressure;Diastolic blood pressure;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg03144560	chr20:55043299	C20orf43	0.52	6.75	0.4	1.15e-10	Height;
SARC	cis	rs7843479	0.543	rs10866823	chr8:21781629	C/T	cg17168535	chr8:21777572	XPO7	0.89	13.41	0.66	9.38e-31	Mean corpuscular volume;
SARC	cis	rs9527	0.590	rs11191513	chr10:104772984	T/G	cg04362960	chr10:104952993	NT5C2	0.45	5.48	0.34	1.1e-7	Arsenic metabolism;
SARC	cis	rs698833	0.624	rs2166453	chr2:44693424	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.48	-6.21	-0.38	2.44e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs12142240	0.698	rs1475390	chr1:46816340	A/G	cg00530320	chr1:46809349	NSUN4	0.57	6.92	0.41	4.4e-11	Menopause (age at onset);
SARC	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg18252515	chr7:66147081	NA	-1.29	-11.31	-0.6	6.31e-24	Diabetic kidney disease;
SARC	cis	rs9611519	0.780	rs2235849	chr22:41653540	T/G	cg17376030	chr22:41985996	PMM1	0.54	6.83	0.41	7.31e-11	Neuroticism;
SARC	cis	rs9611519	0.602	rs8138520	chr22:41412928	A/G	cg17376030	chr22:41985996	PMM1	0.39	4.85	0.3	2.29e-6	Neuroticism;
SARC	cis	rs831571	0.955	rs35837	chr3:64013249	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	-0.53	-4.92	-0.31	1.64e-6	Type 2 diabetes;
SARC	cis	rs751728	1.000	rs4342423	chr6:33732679	C/T	cg25922239	chr6:33757077	LEMD2	0.8	10.52	0.57	1.94e-21	Crohn's disease;
SARC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	4.93	0.31	1.54e-6	Bipolar disorder;
SARC	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg11644478	chr21:40555479	PSMG1	1.03	14.57	0.69	1.33e-34	Cognitive function;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg13801347	chr4:114460056	CAMK2D	0.55	7.69	0.45	4e-13	Thyroid stimulating hormone;
SARC	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6570726	0.935	rs1883406	chr6:145823205	A/G	cg23711669	chr6:146136114	FBXO30	0.78	11.86	0.61	1.04e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1153858	1.000	rs12437887	chr15:45669094	G/A	cg26924012	chr15:45694286	SPATA5L1	0.79	11.28	0.59	7.91e-24	Homoarginine levels;
SARC	cis	rs7959452	0.640	rs1598543	chr12:69688757	G/T	cg22834771	chr12:69754056	YEATS4	-0.41	-5.48	-0.34	1.09e-7	Blood protein levels;
SARC	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg01475735	chr3:40494733	NA	-0.47	-5.22	-0.32	3.87e-7	Renal cell carcinoma;
SARC	cis	rs6696846	0.936	rs1042831	chr1:205043250	G/C	cg07972983	chr1:205091412	RBBP5	0.42	5.32	0.33	2.46e-7	Red blood cell count;
SARC	cis	rs6120849	0.617	rs12480442	chr20:33648388	C/G	cg06115741	chr20:33292138	TP53INP2	0.57	5.33	0.33	2.35e-7	Protein C levels;
SARC	cis	rs77633900	0.614	rs2439989	chr15:76883862	G/C	cg21673338	chr15:77095150	SCAPER	-0.75	-6.16	-0.37	3.1e-9	Non-glioblastoma glioma;Glioma;
SARC	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg21724239	chr8:58056113	NA	0.6	6.31	0.38	1.43e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs713477	0.967	rs8020152	chr14:55907025	T/A	cg13175173	chr14:55914753	NA	-0.31	-4.73	-0.3	3.97e-6	Pediatric bone mineral content (femoral neck);
SARC	cis	rs10489525	0.583	rs1967711	chr1:115630967	C/T	cg01522456	chr1:115632236	TSPAN2	0.7	7.83	0.46	1.72e-13	Autism;
SARC	cis	rs936229	0.656	rs12898397	chr15:75130093	T/C	cg09165964	chr15:75287851	SCAMP5	0.41	4.89	0.31	1.85e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs4900538	0.963	rs942023	chr14:102972170	T/C	cg18135206	chr14:102964638	TECPR2	0.68	8.94	0.51	1.2e-16	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs11122272	0.766	rs2790867	chr1:231548059	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.68	10.05	0.55	5.86e-20	Hemoglobin concentration;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg26374058	chr20:50768183	ZFP64	0.52	7.41	0.44	2.3e-12	Thyroid stimulating hormone;
SARC	cis	rs11785400	1.000	rs11785400	chr8:143730456	C/T	cg24634471	chr8:143751801	JRK	0.67	8.93	0.5	1.34e-16	Schizophrenia;
SARC	cis	rs9291683	0.595	rs3733585	chr4:10036339	A/G	cg00071950	chr4:10020882	SLC2A9	0.4	6.29	0.38	1.54e-9	Bone mineral density;
SARC	cis	rs66569888	0.754	rs6719028	chr2:106895212	T/C	cg15412446	chr2:106886593	NA	0.62	7.18	0.43	9.17e-12	Facial morphology (factor 23);
SARC	cis	rs3126085	0.935	rs4595369	chr1:152248193	G/A	cg26876637	chr1:152193138	HRNR	0.46	5.29	0.33	2.86e-7	Atopic dermatitis;
SARC	cis	rs7481584	0.624	rs12417389	chr11:3035304	G/C	cg05729581	chr11:3078854	CARS	0.56	7.25	0.43	6.08e-12	Calcium levels;
SARC	cis	rs9486719	0.948	rs11152952	chr6:96894303	A/G	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.01	-0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs2075671	0.855	rs11974395	chr7:100282538	G/A	cg03098644	chr7:100410630	EPHB4	0.47	5.13	0.32	6.07e-7	Other erythrocyte phenotypes;
SARC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	11.37	0.6	3.9e-24	Platelet count;
SARC	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.43	-5.16	-0.32	5.2e-7	Renal function-related traits (BUN);
SARC	cis	rs7523050	0.730	rs12729728	chr1:109431110	C/A	cg08274380	chr1:109419600	GPSM2	1.09	8.48	0.49	2.64e-15	Fat distribution (HIV);
SARC	cis	rs798554	0.548	rs1639064	chr7:2896544	G/A	cg13628971	chr7:2884303	GNA12	0.48	5.7	0.35	3.67e-8	Height;
SARC	cis	rs11585357	0.793	rs112597506	chr1:17628832	A/G	cg08277548	chr1:17600880	PADI3	-0.46	-5.39	-0.33	1.75e-7	Hair shape;
SARC	cis	rs870825	0.616	rs28563856	chr4:185635581	G/A	cg04058563	chr4:185651563	MLF1IP	0.84	11.39	0.6	3.49e-24	Blood protein levels;
SARC	cis	rs1007738	0.542	rs4752970	chr11:47208982	A/G	cg03339077	chr11:47165057	C11orf49	-0.41	-5.02	-0.31	1.03e-6	Bone mineral density (hip);
SARC	cis	rs4595586	0.525	rs11612680	chr12:39344443	A/G	cg13010199	chr12:38710504	ALG10B	0.41	4.73	0.3	3.93e-6	Morning vs. evening chronotype;
SARC	cis	rs1008375	1.000	rs7671752	chr4:17661398	C/T	cg16339924	chr4:17578868	LAP3	0.63	8.28	0.48	9.5e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10979	0.571	rs7764231	chr6:143919151	C/G	cg25407410	chr6:143891975	LOC285740	-0.5	-5.48	-0.34	1.11e-7	Hypospadias;
SARC	cis	rs7703051	0.513	rs6895057	chr5:74624234	G/A	cg00601450	chr5:74908170	NA	-0.38	-5.0	-0.31	1.11e-6	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
SARC	cis	rs883565	0.543	rs784488	chr3:39173135	C/G	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.46	-5.39	-0.33	1.76e-7	Handedness;
SARC	cis	rs7429990	1.000	rs319680	chr3:47898307	A/G	cg11946769	chr3:48343235	NME6	0.61	6.78	0.41	9.67e-11	Educational attainment (years of education);
SARC	cis	rs6815814	0.898	rs5743562	chr4:38806096	T/C	cg09316306	chr4:38807337	TLR1	0.5	5.16	0.32	5.23e-7	Breast cancer;
SARC	cis	rs3824867	0.804	rs12419342	chr11:47468545	C/T	cg20307385	chr11:47447363	PSMC3	0.51	5.53	0.34	8.44e-8	Mean corpuscular hemoglobin;
SARC	cis	rs35110281	0.744	rs230645	chr21:44918607	A/G	cg01579765	chr21:45077557	HSF2BP	0.33	5.76	0.35	2.61e-8	Mean corpuscular volume;
SARC	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg13880726	chr7:1868755	MAD1L1	0.5	5.93	0.36	1.06e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs644799	0.931	rs496305	chr11:95567035	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.89	13.96	0.67	1.39e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg00800038	chr16:89945340	TCF25	-0.76	-5.29	-0.33	2.81e-7	Skin colour saturation;
SARC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg18099408	chr3:52552593	STAB1	-0.4	-5.31	-0.33	2.53e-7	Electroencephalogram traits;
SARC	cis	rs13191362	1.000	rs13200329	chr6:163004418	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.56	5.41	0.33	1.53e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2594989	0.831	rs13324245	chr3:11570769	T/G	cg00170343	chr3:11313890	ATG7	-0.57	-5.96	-0.36	9.21e-9	Circulating chemerin levels;
SARC	cis	rs7481584	0.624	rs428726	chr11:3046201	G/A	cg08508325	chr11:3079039	CARS	0.23	5.23	0.32	3.72e-7	Calcium levels;
SARC	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.69	-9.22	-0.52	1.83e-17	Chronic sinus infection;
SARC	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg00933542	chr6:150070202	PCMT1	0.33	5.74	0.35	2.95e-8	Lung cancer;
SARC	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	11.07	0.59	3.59e-23	Alzheimer's disease;
SARC	cis	rs7043114	0.507	rs10992291	chr9:95033009	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.49	-0.34	1.05e-7	Height;
SARC	cis	rs7582180	0.585	rs12999151	chr2:100939333	G/A	cg14675211	chr2:100938903	LONRF2	0.51	7.68	0.45	4.44e-13	Intelligence (multi-trait analysis);
SARC	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.31	-4.76	-0.3	3.39e-6	Total body bone mineral density;
SARC	cis	rs10979	0.965	rs9390109	chr6:143892806	T/C	cg25407410	chr6:143891975	LOC285740	-0.64	-8.72	-0.5	5.26e-16	Hypospadias;
SARC	cis	rs7681440	0.904	rs3756063	chr4:90757394	G/C	cg06632027	chr4:90757378	SNCA	0.4	5.74	0.35	3.01e-8	Dementia with Lewy bodies;
SARC	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg23758822	chr17:41437982	NA	0.9	11.45	0.6	2.28e-24	Menopause (age at onset);
SARC	trans	rs1814175	0.754	rs7103235	chr11:49699191	A/G	cg03929089	chr4:120376271	NA	-0.84	-11.82	-0.61	1.43e-25	Height;
SARC	cis	rs208520	0.661	rs1776361	chr6:66822270	G/A	cg07460842	chr6:66804631	NA	-1.09	-15.25	-0.71	7.18e-37	Exhaled nitric oxide output;
SARC	cis	rs10193935	0.901	rs13429697	chr2:42529818	C/T	cg27598129	chr2:42591480	NA	-0.37	-5.08	-0.32	7.72e-7	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9814567	1.000	rs9819532	chr3:134288644	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.04	-0.42	2.19e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg18404041	chr3:52824283	ITIH1	-0.35	-5.15	-0.32	5.48e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7666738	0.830	rs28818218	chr4:98880575	A/C	cg05340658	chr4:99064831	C4orf37	0.65	8.72	0.5	5.23e-16	Colonoscopy-negative controls vs population controls;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg10639440	chr7:30029231	SCRN1	0.53	7.24	0.43	6.47e-12	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs2916247	0.954	rs4735059	chr8:93080265	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.67	-7.15	-0.42	1.1e-11	Intelligence (multi-trait analysis);
SARC	cis	rs1355223	0.902	rs1588353	chr11:34730814	A/T	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-5.27	-0.33	3.1e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs7818345	1.000	rs11780343	chr8:19290963	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.42	5.66	0.35	4.53e-8	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs3784262	0.739	rs1530293	chr15:58210398	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.35	-5.07	-0.32	8.23e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs3768617	0.510	rs2296293	chr1:183095477	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.82e-21	Fuchs's corneal dystrophy;
SARC	cis	rs897080	0.515	rs1067332	chr2:44626972	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.62	7.48	0.44	1.52e-12	Height;
SARC	cis	rs2594989	0.943	rs2442769	chr3:11491086	A/G	cg00170343	chr3:11313890	ATG7	-0.54	-5.04	-0.31	9.34e-7	Circulating chemerin levels;
SARC	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg17221315	chr6:27791827	HIST1H4J	0.45	4.74	0.3	3.76e-6	Depression;
SARC	cis	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg00071950	chr4:10020882	SLC2A9	0.39	6.4	0.39	8.5e-10	Bone mineral density;
SARC	cis	rs2221894	0.632	rs10503835	chr8:28823095	C/T	cg07962641	chr8:28805897	HMBOX1	0.47	5.27	0.33	3.09e-7	Obesity-related traits;
SARC	cis	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg07274523	chr3:49395745	GPX1	0.49	5.5	0.34	9.87e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs9987353	0.589	rs1053036	chr8:9060077	A/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.19	-0.38	2.66e-9	Recombination measurement;
SARC	cis	rs752010	0.808	rs7529858	chr1:42086606	G/C	cg06885757	chr1:42089581	HIVEP3	0.43	6.68	0.4	1.7e-10	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg15556689	chr8:8085844	FLJ10661	0.49	6.1	0.37	4.32e-9	Mood instability;
SARC	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg17689763	chr4:710664	PCGF3	-0.65	-9.06	-0.51	5.54e-17	White blood cell count;
SARC	trans	rs208515	0.525	rs12214310	chr6:66666308	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.01	11.59	0.6	7.98e-25	Exhaled nitric oxide levels;
SARC	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg20102877	chr2:27665638	KRTCAP3	-0.37	-5.38	-0.33	1.82e-7	Total body bone mineral density;
SARC	cis	rs60695258	1.000	rs60695258	chr4:88022709	C/T	cg11209507	chr4:87813803	C4orf36	0.38	5.06	0.31	8.53e-7	Hematocrit;
SARC	cis	rs9503598	0.636	rs6596974	chr6:3465833	C/T	cg00476032	chr6:3446245	SLC22A23	0.38	5.92	0.36	1.12e-8	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
SARC	cis	rs365132	0.875	rs353495	chr5:176430723	T/C	cg16309518	chr5:176445507	NA	-0.49	-6.33	-0.38	1.26e-9	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs35110281	0.744	rs162398	chr21:44949285	T/C	cg21573476	chr21:45109991	RRP1B	-0.47	-6.96	-0.41	3.47e-11	Mean corpuscular volume;
SARC	cis	rs9486715	0.825	rs211158	chr6:97022938	C/G	cg06623918	chr6:96969491	KIAA0776	-0.89	-13.32	-0.66	1.74e-30	Headache;
SARC	cis	rs11122272	0.675	rs1416913	chr1:231533206	A/C	cg06096015	chr1:231504339	EGLN1	0.38	5.64	0.35	4.92e-8	Hemoglobin concentration;
SARC	cis	rs9790314	0.875	rs163327	chr3:161062724	A/G	cg03342759	chr3:160939853	NMD3	-0.52	-6.37	-0.38	1.02e-9	Morning vs. evening chronotype;
SARC	cis	rs4073582	0.595	rs9326370	chr11:65992008	A/G	cg14036092	chr11:66035641	RAB1B	0.61	8.69	0.49	6.6e-16	Gout;
SARC	cis	rs11758351	0.866	rs2069019	chr6:26205604	C/T	cg01420254	chr6:26195488	NA	0.56	5.01	0.31	1.05e-6	Gout;Renal underexcretion gout;
SARC	cis	rs4819052	0.679	rs8132135	chr21:46694782	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.6	7.58	0.44	8.15e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs8114671	0.647	rs1124511	chr20:33736697	A/C	cg24642439	chr20:33292090	TP53INP2	0.46	5.48	0.34	1.12e-7	Height;
SARC	cis	rs2841277	0.509	rs11850949	chr14:105408827	A/C	cg21017887	chr14:105400489	NA	0.52	7.4	0.44	2.45e-12	Rheumatoid arthritis;
SARC	trans	rs629535	0.773	rs72654090	chr8:70118666	G/A	cg21567404	chr3:27674614	NA	-1.05	-13.48	-0.66	5.33e-31	Dupuytren's disease;
SARC	cis	rs6964587	0.967	rs12531966	chr7:91765840	A/G	cg17063962	chr7:91808500	NA	0.96	15.75	0.72	1.5e-38	Breast cancer;
SARC	cis	rs79149102	0.579	rs74023935	chr15:75359184	T/C	cg00629941	chr15:75287862	SCAMP5	-0.7	-5.17	-0.32	5e-7	Lung cancer;
SARC	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg11247378	chr22:39784982	NA	0.32	5.27	0.33	3.09e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs2576037	0.899	rs2246877	chr18:44577005	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.37	-4.9	-0.31	1.79e-6	Personality dimensions;
SARC	trans	rs10085978	0.604	rs11167128	chr8:143225883	A/G	cg15602359	chr22:50144431	NA	0.33	6.57	0.4	3.18e-10	Mosquito bite size;
SARC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.79	10.06	0.55	5.11e-20	Prudent dietary pattern;
SARC	cis	rs6901250	0.655	rs1398403	chr6:117122646	T/C	cg12892004	chr6:117198278	RFX6	0.34	4.73	0.3	3.9e-6	C-reactive protein levels;
SARC	cis	rs858239	0.899	rs10262243	chr7:23290987	G/A	cg23682824	chr7:23144976	KLHL7	0.57	7.26	0.43	5.73e-12	Cerebrospinal fluid biomarker levels;
SARC	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.36	0.38	1.07e-9	Bipolar disorder;
SARC	cis	rs3733585	0.699	rs6852441	chr4:9973744	C/T	cg11266682	chr4:10021025	SLC2A9	-0.39	-6.56	-0.39	3.49e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg26874164	chr19:58962979	ZNF324B	0.46	6.05	0.37	5.8e-9	Uric acid clearance;
SARC	cis	rs7786877	0.723	rs73407376	chr7:100215200	C/T	cg20848291	chr7:100343083	ZAN	-0.6	-5.76	-0.35	2.62e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs2732480	0.537	rs1061986	chr12:48736439	T/C	cg24011408	chr12:48396354	COL2A1	0.43	5.07	0.32	8.23e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs6570726	0.935	rs366308	chr6:145814532	T/A	cg05347473	chr6:146136440	FBXO30	0.49	6.48	0.39	5.27e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7647973	0.626	rs62260720	chr3:49853796	T/A	cg13072238	chr3:49761600	GMPPB	0.59	5.9	0.36	1.25e-8	Menarche (age at onset);
SARC	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg08280861	chr8:58055591	NA	0.57	5.14	0.32	5.73e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9393692	0.627	rs1059486	chr6:26200083	A/G	cg13736514	chr6:26305472	NA	-0.57	-7.44	-0.44	1.96e-12	Educational attainment;
SARC	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg18252515	chr7:66147081	NA	-1.29	-11.53	-0.6	1.26e-24	Diabetic kidney disease;
SARC	cis	rs7264396	0.635	rs6058344	chr20:34475038	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-7.59	-0.45	7.53e-13	Total cholesterol levels;
SARC	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg14159672	chr1:205819179	PM20D1	0.44	4.99	0.31	1.15e-6	Parkinson's disease;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg13465554	chr11:88243417	GRM5	0.48	6.55	0.39	3.64e-10	Thyroid stimulating hormone;
SARC	cis	rs17401966	0.838	rs4846197	chr1:10282166	G/A	cg15208524	chr1:10270712	KIF1B	0.48	5.65	0.35	4.77e-8	Hepatocellular carcinoma;
SARC	cis	rs943466	0.911	rs72880511	chr6:33729820	G/A	cg04676172	chr6:33757040	LEMD2	0.47	4.75	0.3	3.51e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
SARC	cis	rs1185460	0.967	rs1307145	chr11:118950217	C/G	cg23280166	chr11:118938394	VPS11	0.81	11.65	0.61	5.06e-25	Coronary artery disease;
SARC	trans	rs7615952	0.932	rs13314869	chr3:125644669	G/A	cg07211511	chr3:129823064	LOC729375	-0.97	-10.84	-0.58	1.94e-22	Blood pressure (smoking interaction);
SARC	cis	rs73242632	1.000	rs28681160	chr4:57889166	C/T	cg20415529	chr4:57845134	POLR2B;C4orf14	1.07	6.6	0.4	2.74e-10	Congenital heart disease (maternal effect);
SARC	cis	rs950776	0.518	rs12591557	chr15:78811732	A/G	cg06917634	chr15:78832804	PSMA4	0.87	12.84	0.64	6.7e-29	Sudden cardiac arrest;
SARC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.06	0.8	1.11e-52	Prudent dietary pattern;
SARC	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg02297831	chr4:17616191	MED28	0.51	6.63	0.4	2.36e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg03709012	chr19:19516395	GATAD2A	0.95	14.76	0.7	2.9e-35	Tonsillectomy;
SARC	cis	rs7770848	1	rs7770848	chr6:44769237	A/C	cg12942320	chr6:44354771	CDC5L	0.51	5.38	0.33	1.85e-7	Asthma (childhood onset);
SARC	cis	rs7927771	1.000	rs4752857	chr11:47655752	C/T	cg20307385	chr11:47447363	PSMC3	-0.53	-6.48	-0.39	5.32e-10	Subjective well-being;
SARC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.64	-7.82	-0.46	1.82e-13	Longevity;Endometriosis;
SARC	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg03709012	chr19:19516395	GATAD2A	-0.94	-14.73	-0.69	3.75e-35	Tonsillectomy;
SARC	cis	rs9322817	0.691	rs2486141	chr6:105299930	G/A	cg02098413	chr6:105308735	HACE1	0.38	5.9	0.36	1.25e-8	Thyroid stimulating hormone;
SARC	cis	rs1215050	0.740	rs9994227	chr4:98767094	T/G	cg05340658	chr4:99064831	C4orf37	0.44	5.85	0.36	1.62e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.48	5.68	0.35	4.1e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs5753618	0.519	rs5997939	chr22:31677130	C/G	cg00478049	chr22:31556069	RNF185	0.44	4.81	0.3	2.71e-6	Colorectal cancer;
SARC	trans	rs7615952	0.736	rs13063122	chr3:125643860	G/A	cg07211511	chr3:129823064	LOC729375	-0.95	-11.08	-0.59	3.33e-23	Blood pressure (smoking interaction);
SARC	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg04944784	chr2:26401820	FAM59B	-0.48	-5.99	-0.37	7.95e-9	Gut microbiome composition (summer);
SARC	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg00149659	chr3:10157352	C3orf10	0.68	6.38	0.39	9.46e-10	Alzheimer's disease;
SARC	cis	rs72945132	0.882	rs7122057	chr11:70201430	T/C	cg05964544	chr11:70165517	PPFIA1	-0.57	-5.55	-0.34	7.66e-8	Coronary artery disease;
SARC	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg26752003	chr8:145688521	CYHR1	0.67	9.33	0.52	8.61e-18	Age at first birth;
SARC	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg11987759	chr7:65425863	GUSB	0.46	5.86	0.36	1.59e-8	Aortic root size;
SARC	cis	rs7666738	0.546	rs34621463	chr4:98793357	G/C	cg05340658	chr4:99064831	C4orf37	0.59	7.17	0.43	9.77e-12	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9916302	0.904	rs7503069	chr17:37697128	C/G	cg07936489	chr17:37558343	FBXL20	-0.68	-8.81	-0.5	2.97e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs11718455	1.000	rs9854785	chr3:44031295	A/G	cg21419209	chr3:44054225	NA	-0.4	-4.82	-0.3	2.55e-6	Coronary artery disease;
SARC	cis	rs9398803	0.661	rs1101557	chr6:127067996	T/C	cg20229609	chr6:126660872	C6orf173	-0.33	-4.78	-0.3	3.1e-6	Male-pattern baldness;
SARC	cis	rs3824867	0.920	rs3740685	chr11:47468791	C/T	cg20307385	chr11:47447363	PSMC3	0.49	5.43	0.34	1.42e-7	Mean corpuscular hemoglobin;
SARC	cis	rs2153535	0.580	rs9406159	chr6:8464859	C/G	cg23788917	chr6:8435910	SLC35B3	0.64	8.39	0.48	4.57e-15	Motion sickness;
SARC	cis	rs9467711	0.591	rs67844427	chr6:25931020	G/A	cg21479132	chr6:26055353	NA	0.83	5.14	0.32	5.94e-7	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7524258	0.900	rs6577426	chr1:7306451	A/G	cg07173049	chr1:7289937	CAMTA1	0.34	6.53	0.39	4.15e-10	Tourette's syndrome or obsessive-compulsive disorder;
SARC	cis	rs672059	1.000	rs575474	chr1:183158599	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.52	7.16	0.42	1.04e-11	Hypertriglyceridemia;
SARC	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg22509189	chr2:225307070	NA	-0.71	-9.03	-0.51	6.52e-17	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs362272	0.524	rs7435601	chr4:3369645	A/G	cg08741688	chr4:3415352	RGS12	-0.48	-6.15	-0.37	3.28e-9	Serum sulfate level;
SARC	cis	rs1707322	0.752	rs8179402	chr1:46142466	C/A	cg06784218	chr1:46089804	CCDC17	0.36	6.25	0.38	1.93e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs644799	0.965	rs11021310	chr11:95502106	A/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.89	14.01	0.68	9.21e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7223966	1.000	rs6504171	chr17:61710010	G/A	cg00588841	chr17:61851480	DDX42;CCDC47	-0.59	-6.7	-0.4	1.59e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	11.55	0.6	1.04e-24	Platelet count;
SARC	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg07701084	chr6:150067640	NUP43	0.4	5.09	0.32	7.26e-7	Lung cancer;
SARC	cis	rs6952808	0.929	rs2280548	chr7:1976667	G/T	cg21782813	chr7:2030301	MAD1L1	0.42	6.37	0.39	1.01e-9	Bipolar disorder and schizophrenia;
SARC	trans	rs6076960	0.684	rs6054049	chr20:6254909	A/G	cg21095983	chr6:86352623	SYNCRIP	-0.46	-6.76	-0.4	1.09e-10	Smooth-surface caries;
SARC	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.39	4.73	0.3	3.81e-6	Tonsillectomy;
SARC	cis	rs3008870	0.920	rs1925413	chr1:67417101	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.91	11.08	0.59	3.51e-23	Lymphocyte percentage of white cells;
SARC	cis	rs78456975	1.000	rs55761535	chr2:1561450	A/G	cg26248373	chr2:1572462	NA	-0.6	-5.91	-0.36	1.2e-8	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg02725872	chr8:58115012	NA	-0.34	-5.37	-0.33	1.91e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs16976116	0.572	rs28704633	chr15:55446541	T/G	cg11288833	chr15:55489084	RSL24D1	0.62	5.37	0.33	1.94e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6570726	0.791	rs6914203	chr6:145899975	C/A	cg05347473	chr6:146136440	FBXO30	0.52	7.33	0.43	3.74e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg02475777	chr4:1388615	CRIPAK	0.68	7.89	0.46	1.2e-13	Longevity;
SARC	cis	rs6450176	1.000	rs7736354	chr5:53297591	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.66	-7.64	-0.45	5.69e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg13889221	chr9:131186701	CERCAM	-0.53	-6.47	-0.39	5.73e-10	Migraine with aura;
SARC	cis	rs9747201	1.000	rs58119191	chr17:80155329	T/C	cg09264619	chr17:80180166	NA	-0.52	-6.01	-0.37	7.09e-9	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs4595586	0.545	rs12812762	chr12:39371141	T/C	cg13010199	chr12:38710504	ALG10B	0.4	4.75	0.3	3.57e-6	Morning vs. evening chronotype;
SARC	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg00149659	chr3:10157352	C3orf10	1.02	8.46	0.48	2.92e-15	Alzheimer's disease;
SARC	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg11062466	chr8:58055876	NA	0.66	6.12	0.37	3.97e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-15.42	-0.71	1.84e-37	Chronic sinus infection;
SARC	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg06108461	chr20:60628389	TAF4	-0.87	-11.72	-0.61	3.13e-25	Body mass index;
SARC	trans	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg21659725	chr3:3221576	CRBN	-0.55	-7.22	-0.43	7.2e-12	Intelligence (multi-trait analysis);
SARC	cis	rs7408868	0.908	rs10416777	chr19:15276923	C/T	cg14696996	chr19:15285081	NOTCH3	1.02	8.7	0.5	6e-16	Pulse pressure;
SARC	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg05313129	chr8:58192883	C8orf71	0.59	6.38	0.39	9.52e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs698833	0.892	rs1067371	chr2:44651982	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.63	8.07	0.47	3.82e-14	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs2602836	0.830	rs2602874	chr4:100039396	A/T	cg12011299	chr4:100065546	ADH4	0.31	5.95	0.36	9.81e-9	HDL cholesterol;HDL cholesterol levels;
SARC	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	-0.48	-5.74	-0.35	3e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs644799	0.763	rs2950521	chr11:95536870	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	14.22	0.68	1.83e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs526821	0.553	rs519637	chr11:55295935	A/T	cg04317927	chr11:55418816	OR4S2	0.38	5.55	0.34	7.78e-8	Pediatric bone mineral density (spine);
SARC	cis	rs7666738	0.830	rs4699597	chr4:99019031	G/A	cg05340658	chr4:99064831	C4orf37	0.66	9.04	0.51	6.35e-17	Colonoscopy-negative controls vs population controls;
SARC	trans	rs8073060	0.544	rs225274	chr17:33971221	C/T	cg19694781	chr19:47549865	TMEM160	0.68	7.21	0.43	7.97e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs35213789	0.534	rs7786584	chr7:69008238	G/T	cg10619644	chr7:69149951	AUTS2	0.35	4.86	0.3	2.17e-6	Childhood ear infection;
SARC	cis	rs62064224	0.658	rs62065460	chr17:30715007	A/G	cg25809561	chr17:30822961	MYO1D	0.38	5.69	0.35	3.83e-8	Schizophrenia;
SARC	cis	rs8060686	0.668	rs255056	chr16:68016185	G/C	cg06378129	chr16:67998246	SLC12A4	-0.47	-4.73	-0.3	3.91e-6	HDL cholesterol;Metabolic syndrome;
SARC	cis	rs634534	0.561	rs613924	chr11:65769295	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.57	8.78	0.5	3.51e-16	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs9486715	0.867	rs4839687	chr6:96951732	C/A	cg06623918	chr6:96969491	KIAA0776	0.89	12.91	0.65	3.96e-29	Headache;
SARC	cis	rs11583043	0.918	rs17525451	chr1:101422409	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.48	6.03	0.37	6.33e-9	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs317689	0.680	rs315140	chr12:69790780	A/T	cg20891283	chr12:69753455	YEATS4	0.5	5.67	0.35	4.22e-8	Response to diuretic therapy;
SARC	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg05368731	chr17:41323189	NBR1	0.79	9.6	0.53	1.34e-18	Menopause (age at onset);
SARC	trans	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg00938859	chr5:1591904	SDHAP3	0.79	7.66	0.45	5.1e-13	Breast cancer;
SARC	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg06212747	chr3:49208901	KLHDC8B	0.66	8.7	0.5	5.92e-16	Parkinson's disease;
SARC	trans	rs2727020	0.521	rs4980445	chr11:49570183	C/T	cg03929089	chr4:120376271	NA	-0.65	-7.55	-0.44	9.74e-13	Coronary artery disease;
SARC	cis	rs2239815	0.515	rs9625591	chr22:29232564	A/G	cg02153584	chr22:29168773	CCDC117	0.65	7.1	0.42	1.49e-11	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
SARC	cis	rs9309473	1.000	rs1534471	chr2:73647508	G/A	cg20560298	chr2:73613845	ALMS1	-0.45	-5.45	-0.34	1.25e-7	Metabolite levels;
SARC	cis	rs668210	0.739	rs1151511	chr11:65756283	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.55	5.64	0.35	4.95e-8	Cerebrospinal fluid biomarker levels;
SARC	cis	rs4481887	1.000	rs6683717	chr1:248476792	A/G	cg00666640	chr1:248458726	OR2T12	0.37	6.1	0.37	4.39e-9	Common traits (Other);
SARC	cis	rs7712401	0.601	rs417268	chr5:122345012	A/G	cg19412675	chr5:122181750	SNX24	-0.43	-5.43	-0.34	1.41e-7	Mean platelet volume;
SARC	cis	rs11731606	0.508	rs28623728	chr4:95290861	C/T	cg20625393	chr4:95128694	SMARCAD1	0.57	5.58	0.34	6.62e-8	Mean platelet volume;
SARC	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs67311347	1.000	rs4246666	chr3:40407670	C/T	cg24209194	chr3:40518798	ZNF619	0.59	7.46	0.44	1.69e-12	Renal cell carcinoma;
SARC	trans	rs61931739	0.500	rs10844789	chr12:34202279	C/G	cg13010199	chr12:38710504	ALG10B	0.74	10.02	0.55	6.89e-20	Morning vs. evening chronotype;
SARC	cis	rs7560272	0.538	rs13000788	chr2:73918312	C/T	cg20560298	chr2:73613845	ALMS1	0.48	6.38	0.39	9.46e-10	Schizophrenia;
SARC	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg24642844	chr7:1081250	C7orf50	-0.6	-6.11	-0.37	4.06e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs4423214	0.840	rs1792227	chr11:71177412	A/G	cg05163923	chr11:71159392	DHCR7	-0.61	-7.39	-0.44	2.64e-12	Vitamin D levels;
SARC	cis	rs1401999	0.898	rs9876143	chr3:183731362	C/G	cg01324343	chr3:183735012	ABCC5	0.66	13.36	0.66	1.33e-30	Anterior chamber depth;
SARC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg11062466	chr8:58055876	NA	0.54	5.53	0.34	8.37e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg00908189	chr16:619842	PIGQ	0.87	12.82	0.64	8e-29	Height;
SARC	cis	rs2251381	0.520	rs873651	chr21:30781848	G/A	cg08807101	chr21:30365312	RNF160	0.51	6.81	0.41	8.32e-11	Selective IgA deficiency;
SARC	trans	rs9354308	0.677	rs9363462	chr6:66557612	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.55	-6.4	-0.39	8.68e-10	Metabolite levels;
SARC	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg13175981	chr1:150552382	MCL1	0.54	7.02	0.42	2.36e-11	Tonsillectomy;
SARC	cis	rs6570726	0.846	rs6570698	chr6:145918635	C/G	cg05347473	chr6:146136440	FBXO30	0.5	6.89	0.41	5.18e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7811142	1.000	rs6972167	chr7:100080013	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.03	12.28	0.63	4.7e-27	Platelet count;
SARC	cis	rs7432375	0.609	rs835637	chr3:136673157	A/T	cg15507776	chr3:136538369	TMEM22	0.61	7.73	0.45	3.11e-13	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	cis	rs12586317	0.511	rs11540758	chr14:35498485	C/T	cg16230307	chr14:35515116	FAM177A1	1.02	11.85	0.61	1.18e-25	Psoriasis;
SARC	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg18876405	chr7:65276391	NA	-0.41	-4.74	-0.3	3.77e-6	Aortic root size;
SARC	cis	rs1348850	0.914	rs7565022	chr2:178320222	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	7.86	0.46	1.46e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2066819	1.000	rs116535779	chr12:56739261	A/G	cg26316697	chr12:56727976	PAN2	0.92	6.51	0.39	4.64e-10	Psoriasis vulgaris;
SARC	cis	rs10789491	1.000	rs2218191	chr1:47130628	C/T	cg15501359	chr1:47185051	KIAA0494	0.6	6.81	0.41	8.11e-11	Response to hepatitis C treatment;
SARC	cis	rs2599510	0.807	rs176416	chr2:32652223	A/G	cg02381751	chr2:32503542	YIPF4	-0.52	-6.48	-0.39	5.52e-10	Interleukin-18 levels;
SARC	cis	rs9381040	0.610	rs717883	chr6:41045270	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.43	-4.9	-0.31	1.78e-6	Alzheimer's disease (late onset);
SARC	cis	rs4481887	0.745	rs4540687	chr1:248476099	C/G	cg01631408	chr1:248437212	OR2T33	-0.38	-4.92	-0.31	1.67e-6	Common traits (Other);
SARC	cis	rs7552404	0.731	rs10732723	chr1:76392437	C/T	cg10523679	chr1:76189770	ACADM	-0.44	-5.16	-0.32	5.27e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7786808	0.649	rs1377374	chr7:158215647	G/T	cg01191920	chr7:158217561	PTPRN2	0.35	6.06	0.37	5.45e-9	Obesity-related traits;
SARC	cis	rs2635047	0.569	rs9958817	chr18:44786481	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.4	5.14	0.32	5.8e-7	Educational attainment;
SARC	trans	rs2727020	0.573	rs7925419	chr11:49231859	C/T	cg03929089	chr4:120376271	NA	-0.52	-6.66	-0.4	1.98e-10	Coronary artery disease;
SARC	cis	rs7264396	0.635	rs6060710	chr20:34536055	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-7.75	-0.45	2.78e-13	Total cholesterol levels;
SARC	cis	rs2718058	0.565	rs2598078	chr7:37864078	G/C	cg24998770	chr7:37888106	TXNDC3	0.35	5.08	0.32	7.79e-7	Alzheimer's disease (late onset);
SARC	cis	rs13314892	0.806	rs2163326	chr3:69876683	A/C	cg17445875	chr3:69859618	MITF	-0.48	-4.99	-0.31	1.16e-6	QRS complex (12-leadsum);
SARC	cis	rs9341808	0.538	rs615585	chr6:80986153	T/C	cg08355045	chr6:80787529	NA	-0.33	-4.89	-0.31	1.85e-6	Sitting height ratio;
SARC	cis	rs4253772	0.637	rs6008339	chr22:46650846	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.64	6.81	0.41	8.27e-11	LDL cholesterol;Cholesterol, total;
SARC	cis	rs61935443	0.673	rs11107770	chr12:95275147	C/T	cg21533806	chr12:95267307	NA	-0.67	-8.21	-0.47	1.55e-14	Schizophrenia;
SARC	cis	rs9916302	0.851	rs6503518	chr17:37660469	A/G	cg15445000	chr17:37608096	MED1	0.41	4.83	0.3	2.48e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	12.02	0.62	3.2e-26	Chronic sinus infection;
SARC	cis	rs6665290	0.904	rs3795449	chr1:227181838	T/G	cg10327440	chr1:227177885	CDC42BPA	-1.07	-24.81	-0.85	2.56e-67	Myeloid white cell count;
SARC	cis	rs9902453	0.845	rs2259855	chr17:28097860	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.56	-7.2	-0.43	8.26e-12	Coffee consumption (cups per day);
SARC	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg22974920	chr21:40686053	BRWD1	-0.43	-4.85	-0.3	2.22e-6	Cognitive function;
SARC	cis	rs561341	1.000	rs693116	chr17:30246124	C/T	cg00745463	chr17:30367425	LRRC37B	-0.66	-4.98	-0.31	1.24e-6	Hip circumference adjusted for BMI;
SARC	cis	rs7772486	0.712	rs1292335	chr6:145967877	G/T	cg05220968	chr6:146057943	EPM2A	-0.29	-4.79	-0.3	2.91e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6500395	1.000	rs9930365	chr16:48682154	A/C	cg04672837	chr16:48644449	N4BP1	0.46	6.28	0.38	1.65e-9	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs2075371	1.000	rs8134	chr7:133974519	A/G	cg20476274	chr7:133979776	SLC35B4	0.61	8.35	0.48	6.24e-15	Mean platelet volume;
SARC	cis	rs17001868	0.568	rs9611314	chr22:40735798	C/G	cg07138101	chr22:40742427	ADSL	0.54	5.94	0.36	1.01e-8	Mammographic density (dense area);
SARC	cis	rs10089	1.000	rs10478798	chr5:127442394	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	10.32	0.56	8.06e-21	Ileal carcinoids;
SARC	cis	rs6582630	0.560	rs4882325	chr12:38510037	C/T	cg13010199	chr12:38710504	ALG10B	-0.5	-6.24	-0.38	2.05e-9	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs5762813	0.515	rs5762822	chr22:29219601	A/G	cg15103426	chr22:29168792	CCDC117	0.61	5.94	0.36	1.03e-8	Hematocrit;Hemoglobin concentration;
SARC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg26338869	chr17:61819248	STRADA	0.8	10.7	0.57	5.44e-22	Prudent dietary pattern;
SARC	cis	rs11711311	1.000	rs9288983	chr3:113488699	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	8.6	0.49	1.15e-15	IgG glycosylation;
SARC	trans	rs7824557	0.679	rs7004362	chr8:11135974	G/A	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.15	-0.42	1.1e-11	Retinal vascular caliber;
SARC	cis	rs10214930	0.697	rs6942908	chr7:27905918	G/A	cg05786569	chr7:27702416	HIBADH	0.47	5.02	0.31	1.02e-6	Hypospadias;
SARC	cis	rs7904368	0.754	rs7091240	chr10:16855683	G/A	cg14835575	chr10:16859367	RSU1	0.78	7.79	0.45	2.21e-13	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs72945132	0.638	rs627079	chr11:70165505	G/T	cg05964544	chr11:70165517	PPFIA1	-0.71	-7.23	-0.43	6.85e-12	Coronary artery disease;
SARC	cis	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg06636001	chr8:8085503	FLJ10661	0.59	7.66	0.45	5.01e-13	Mood instability;
SARC	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg11247378	chr22:39784982	NA	0.32	5.09	0.32	7.48e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7044106	0.648	rs2031369	chr9:123360294	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	4.95	0.31	1.39e-6	Hip circumference adjusted for BMI;
SARC	cis	rs965469	0.603	rs6115892	chr20:3411569	C/T	cg25506879	chr20:3388711	C20orf194	-0.44	-5.28	-0.33	2.99e-7	IFN-related cytopenia;
SARC	cis	rs7674212	0.541	rs4699050	chr4:104114297	A/G	cg16532752	chr4:104119610	CENPE	-0.48	-5.82	-0.36	1.94e-8	Type 2 diabetes;
SARC	cis	rs2777491	0.872	rs7176588	chr15:41588872	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.71	-10.53	-0.57	1.89e-21	Ulcerative colitis;
SARC	cis	rs6752107	0.967	rs11694081	chr2:234148586	A/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.46	6.24	0.38	2.08e-9	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs4919087	0.926	rs2861875	chr10:98990139	C/G	cg25902810	chr10:99078978	FRAT1	-0.46	-5.88	-0.36	1.43e-8	Monocyte count;
SARC	cis	rs637571	0.726	rs669371	chr11:65674153	G/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.48	-5.45	-0.34	1.31e-7	Eosinophil percentage of white cells;
SARC	cis	rs9399137	0.507	rs6940878	chr6:135366309	G/A	cg24558204	chr6:135376177	HBS1L	0.62	7.76	0.45	2.7e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs9291683	0.609	rs12507050	chr4:10007305	G/T	cg11266682	chr4:10021025	SLC2A9	0.42	7.54	0.44	1.07e-12	Bone mineral density;
SARC	trans	rs561341	0.739	rs4795663	chr17:30214542	T/C	cg20587970	chr11:113659929	NA	0.56	6.3	0.38	1.47e-9	Hip circumference adjusted for BMI;
SARC	cis	rs11608355	0.545	rs2302706	chr12:109894028	A/G	cg05360138	chr12:110035743	NA	0.92	9.61	0.53	1.27e-18	Neuroticism;
SARC	cis	rs523522	0.962	rs4766969	chr12:120988238	A/G	cg12219531	chr12:120966889	COQ5	0.83	11.21	0.59	1.28e-23	High light scatter reticulocyte count;
SARC	cis	rs6998277	1.000	rs6998277	chr8:103639941	T/C	cg10187029	chr8:103597600	NA	0.69	7.09	0.42	1.61e-11	Migraine;
SARC	cis	rs5758511	0.680	rs5758657	chr22:42618669	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.46	6.9	0.41	4.87e-11	Birth weight;
SARC	cis	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg18876405	chr7:65276391	NA	0.61	7.45	0.44	1.8e-12	Aortic root size;
SARC	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg05896524	chr21:47604654	C21orf56	-0.51	-6.15	-0.37	3.3e-9	Testicular germ cell tumor;
SARC	cis	rs6840360	0.593	rs6855883	chr4:152688997	A/G	cg22705602	chr4:152727874	NA	-0.5	-8.96	-0.51	1.09e-16	Intelligence (multi-trait analysis);
SARC	cis	rs7586879	0.616	rs10206196	chr2:25137323	T/C	cg04586622	chr2:25135609	ADCY3	0.31	5.11	0.32	6.61e-7	Body mass index;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg07148914	chr20:33460835	GGT7	-0.77	-6.45	-0.39	6.52e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs3126085	0.877	rs4456098	chr1:152176034	C/T	cg03465714	chr1:152285911	FLG	-0.47	-5.59	-0.34	6.22e-8	Atopic dermatitis;
SARC	cis	rs7296418	0.961	rs1790094	chr12:123586688	T/C	cg16085171	chr12:123569118	PITPNM2	-0.38	-4.83	-0.3	2.48e-6	Platelet count;
SARC	cis	rs7216064	1.000	rs12602655	chr17:65909442	A/G	cg12091567	chr17:66097778	LOC651250	-0.71	-7.18	-0.43	9.54e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs8114671	0.562	rs6120763	chr20:33506400	C/G	cg08999081	chr20:33150536	PIGU	0.32	4.72	0.3	3.99e-6	Height;
SARC	cis	rs7618915	1.000	rs3852063	chr3:52349204	A/G	cg18404041	chr3:52824283	ITIH1	-0.36	-4.81	-0.3	2.65e-6	Bipolar disorder;
SARC	cis	rs6732160	0.809	rs13406142	chr2:73384098	A/G	cg01422370	chr2:73384389	NA	0.32	5.38	0.33	1.81e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg11366901	chr6:160182831	ACAT2	1.02	10.79	0.58	2.78e-22	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg22834771	chr12:69754056	YEATS4	-0.47	-6.29	-0.38	1.54e-9	Cerebrospinal fluid biomarker levels;
SARC	cis	rs7246657	0.943	rs13343471	chr19:37932130	A/G	cg23950597	chr19:37808831	NA	-0.6	-5.49	-0.34	1.07e-7	Coronary artery calcification;
SARC	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg06618935	chr21:46677482	NA	-0.38	-5.21	-0.32	4.23e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4664308	1.000	rs56297666	chr2:160902023	G/C	cg03641300	chr2:160917029	PLA2R1	-0.64	-8.15	-0.47	2.24e-14	Idiopathic membranous nephropathy;
SARC	cis	rs11608355	0.618	rs7958220	chr12:109830980	T/C	cg05360138	chr12:110035743	NA	0.38	4.72	0.3	4.13e-6	Neuroticism;
SARC	cis	rs672059	1.000	rs551569	chr1:183158293	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.52	7.16	0.42	1.04e-11	Hypertriglyceridemia;
SARC	cis	rs9300255	0.602	rs1569068	chr12:123632276	A/G	cg00376283	chr12:123451042	ABCB9	-0.6	-6.78	-0.41	1e-10	Neutrophil percentage of white cells;
SARC	cis	rs7429990	0.965	rs319696	chr3:47943861	T/C	cg11946769	chr3:48343235	NME6	0.46	5.26	0.33	3.26e-7	Educational attainment (years of education);
SARC	cis	rs12681366	0.708	rs2445699	chr8:95346517	G/T	cg26464482	chr8:95565502	KIAA1429	-0.47	-5.83	-0.36	1.82e-8	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs798554	0.660	rs2527687	chr7:2838485	G/A	cg04166393	chr7:2884313	GNA12	0.44	5.31	0.33	2.58e-7	Height;
SARC	cis	rs6429082	0.783	rs291364	chr1:235687179	A/G	cg26050004	chr1:235667680	B3GALNT2	0.64	8.32	0.48	7.56e-15	Adiposity;
SARC	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg21724239	chr8:58056113	NA	0.6	5.87	0.36	1.45e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9815354	0.812	rs17215498	chr3:41829679	G/C	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-5.68	-0.35	4.08e-8	Bipolar disorder;
SARC	cis	rs8072100	1.000	rs8065437	chr17:45721653	C/T	cg08085267	chr17:45401833	C17orf57	-0.42	-4.77	-0.3	3.24e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	trans	rs1814175	0.817	rs11040700	chr11:50023832	C/T	cg03929089	chr4:120376271	NA	-0.87	-13.86	-0.67	2.91e-32	Height;
SARC	cis	rs35995292	1.000	rs10266891	chr7:38914805	A/G	cg19327137	chr7:38886074	VPS41	0.37	5.26	0.33	3.28e-7	Subjective well-being (multi-trait analysis);
SARC	cis	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg00745463	chr17:30367425	LRRC37B	-0.69	-5.53	-0.34	8.77e-8	Hip circumference adjusted for BMI;
SARC	cis	rs9868809	0.505	rs13434258	chr3:48738491	T/C	cg07636037	chr3:49044803	WDR6	-0.69	-6.61	-0.4	2.58e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs6570726	0.791	rs9403734	chr6:145931459	C/G	cg23711669	chr6:146136114	FBXO30	0.9	15.27	0.71	5.88e-37	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs6716963	0.585	rs11687224	chr2:194568323	A/G	cg13689156	chr12:50017412	PRPF40B	0.54	6.4	0.39	8.34e-10	Schizophrenia;
SARC	trans	rs11098499	0.954	rs10031665	chr4:120422852	T/C	cg25214090	chr10:38739885	LOC399744	0.58	7.47	0.44	1.63e-12	Corneal astigmatism;
SARC	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-8.76	-0.5	4.15e-16	Alzheimer's disease;
SARC	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg11644478	chr21:40555479	PSMG1	-0.53	-6.45	-0.39	6.26e-10	Menarche (age at onset);
SARC	cis	rs2481665	0.772	rs6661862	chr1:62534854	A/C	cg18591186	chr1:62594603	INADL	0.53	7.14	0.42	1.16e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg12667521	chr19:29218732	NA	0.4	5.4	0.33	1.61e-7	Methadone dose in opioid dependence;
SARC	cis	rs2486288	0.656	rs12908818	chr15:45571668	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.55	-6.77	-0.41	1.02e-10	Glomerular filtration rate;
SARC	cis	rs2576037	0.796	rs2576038	chr18:44582200	C/G	cg15049968	chr18:44337910	ST8SIA5	0.33	5.45	0.34	1.28e-7	Personality dimensions;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg04903157	chr22:35795952	MCM5	0.47	6.62	0.4	2.5e-10	Chemerin levels;
SARC	cis	rs3857536	0.817	rs9345777	chr6:66899540	A/C	cg07460842	chr6:66804631	NA	-0.44	-5.26	-0.33	3.22e-7	Blood trace element (Cu levels);
SARC	trans	rs9329221	0.506	rs6993610	chr8:10330994	C/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-8.58	-0.49	1.37e-15	Neuroticism;
SARC	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg20573242	chr4:122745356	CCNA2	0.59	7.38	0.44	2.8e-12	Type 2 diabetes;
SARC	cis	rs6582630	0.516	rs12814528	chr12:38296111	G/A	cg14851346	chr12:38532713	NA	-0.46	-5.39	-0.33	1.69e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg05368731	chr17:41323189	NBR1	0.81	9.82	0.54	2.91e-19	Menopause (age at onset);
SARC	trans	rs3780486	0.846	rs4584234	chr9:33147479	G/A	cg04842962	chr6:43655489	MRPS18A	1.01	17.16	0.75	3.11e-43	IgG glycosylation;
SARC	cis	rs6570726	1.000	rs386678	chr6:145869010	A/G	cg05220968	chr6:146057943	EPM2A	-0.29	-4.99	-0.31	1.2e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg05368731	chr17:41323189	NBR1	0.79	9.36	0.52	7.2e-18	Menopause (age at onset);
SARC	cis	rs208520	0.690	rs2208442	chr6:66867004	T/C	cg07460842	chr6:66804631	NA	-1.09	-15.3	-0.71	4.9e-37	Exhaled nitric oxide output;
SARC	cis	rs644799	0.710	rs12273579	chr11:95524421	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.88	13.98	0.68	1.14e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2486288	0.656	rs7165039	chr15:45570413	C/G	cg19305227	chr15:45544335	SLC28A2	0.31	5.75	0.35	2.86e-8	Glomerular filtration rate;
SARC	cis	rs12912251	0.948	rs34281605	chr15:38989674	G/A	cg01338139	chr15:38987640	C15orf53	-0.45	-5.29	-0.33	2.79e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
SARC	cis	rs981844	0.712	rs4525952	chr4:154746606	G/T	cg14289246	chr4:154710475	SFRP2	0.44	5.02	0.31	1.05e-6	Response to statins (LDL cholesterol change);
SARC	cis	rs2354432	0.943	rs6660219	chr1:146691404	A/T	cg25205988	chr1:146714368	CHD1L	1.08	11.86	0.61	1.05e-25	Mitochondrial DNA levels;
SARC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.32	-5.01	-0.31	1.1e-6	Total body bone mineral density;
SARC	trans	rs6600671	1.000	rs4844381	chr1:121184898	C/T	cg00646200	chr1:148855367	NA	0.54	7.52	0.44	1.14e-12	Hip geometry;
SARC	cis	rs2204008	0.774	rs11495721	chr12:38337224	A/C	cg26384229	chr12:38710491	ALG10B	0.88	12.91	0.65	3.96e-29	Bladder cancer;
SARC	cis	rs7766436	0.727	rs2066339	chr6:22610612	T/C	cg13666174	chr6:22585274	NA	-0.49	-6.7	-0.4	1.51e-10	Coronary artery disease;
SARC	cis	rs477692	0.569	rs10764883	chr10:131307817	A/G	cg05714579	chr10:131428358	MGMT	0.55	7.46	0.44	1.72e-12	Response to temozolomide;
SARC	cis	rs7681440	0.583	rs2583959	chr4:90721637	C/G	cg06632027	chr4:90757378	SNCA	-0.47	-5.72	-0.35	3.23e-8	Dementia with Lewy bodies;
SARC	cis	rs6500395	1.000	rs9939103	chr16:48592376	G/C	cg04672837	chr16:48644449	N4BP1	0.46	6.1	0.37	4.27e-9	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs7223966	1.000	rs8070650	chr17:61744040	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.56	-5.99	-0.37	7.8e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs10870270	0.957	rs9971084	chr10:133788747	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.82	-9.69	-0.54	6.88e-19	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.04	0.37	6e-9	Prudent dietary pattern;
SARC	cis	rs734999	0.505	rs4445406	chr1:2539400	T/C	cg20673091	chr1:2541236	MMEL1	0.33	4.99	0.31	1.16e-6	Ulcerative colitis;
SARC	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg13206674	chr6:150067644	NUP43	0.46	6.03	0.37	6.45e-9	Lung cancer;
SARC	cis	rs4921915	0.598	rs4646243	chr8:18247609	T/C	cg18736775	chr8:18248649	NAT2	-0.61	-6.09	-0.37	4.52e-9	Iron status biomarkers (transferrin levels);
SARC	cis	rs7937682	0.824	rs510866	chr11:111484113	A/C	cg22437258	chr11:111473054	SIK2	0.76	10.55	0.57	1.58e-21	Primary sclerosing cholangitis;
SARC	cis	rs7672847	0.547	rs10017918	chr4:170352033	A/G	cg00846720	chr4:170533756	NEK1	-0.59	-4.86	-0.3	2.15e-6	Subjective well-being;
SARC	cis	rs3733585	0.699	rs4515163	chr4:9959603	C/T	cg11266682	chr4:10021025	SLC2A9	-0.35	-6.03	-0.37	6.35e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs12311304	0.965	rs7977262	chr12:15367769	A/G	cg08258403	chr12:15378311	NA	0.48	7.45	0.44	1.86e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs7178572	0.598	rs907373	chr15:77844554	T/C	cg22256960	chr15:77711686	NA	-0.46	-5.61	-0.34	5.78e-8	Type 2 diabetes;
SARC	cis	rs933688	1.000	rs10073657	chr5:90689749	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.99	12.97	0.65	2.53e-29	Smoking behavior;
SARC	cis	rs208520	0.802	rs208496	chr6:66930786	G/C	cg07460842	chr6:66804631	NA	-0.98	-11.58	-0.6	8.34e-25	Exhaled nitric oxide output;
SARC	cis	rs1799949	1.000	rs4793236	chr17:41436440	T/C	cg25072359	chr17:41440525	NA	0.52	6.23	0.38	2.17e-9	Menopause (age at onset);
SARC	cis	rs1728785	1.000	rs1069288	chr16:68585285	C/G	cg02972257	chr16:68554789	NA	-0.46	-5.48	-0.34	1.1e-7	Ulcerative colitis;
SARC	cis	rs3768617	0.528	rs10911240	chr1:183062948	T/C	cg13390022	chr1:182993471	LAMC1	0.33	4.94	0.31	1.49e-6	Fuchs's corneal dystrophy;
SARC	cis	rs4481887	0.861	rs10788778	chr1:248481551	T/C	cg13385794	chr1:248469461	NA	0.37	5.48	0.34	1.08e-7	Common traits (Other);
SARC	cis	rs4242434	0.699	rs878053	chr8:22483849	T/C	cg03733263	chr8:22462867	KIAA1967	0.86	13.41	0.66	8.74e-31	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs3099143	0.901	rs1611866	chr15:77236291	A/C	cg21673338	chr15:77095150	SCAPER	-0.69	-5.39	-0.33	1.72e-7	Recalcitrant atopic dermatitis;
SARC	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg04944784	chr2:26401820	FAM59B	-0.49	-6.02	-0.37	6.74e-9	Gut microbiome composition (summer);
SARC	cis	rs7824557	0.583	rs4448232	chr8:11231354	G/T	cg12395012	chr8:11607386	GATA4	-0.29	-4.81	-0.3	2.76e-6	Retinal vascular caliber;
SARC	cis	rs4727027	0.868	rs10952799	chr7:148840772	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	5.41	0.33	1.53e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg15212455	chr7:39170539	POU6F2	0.44	5.47	0.34	1.16e-7	IgG glycosylation;
SARC	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg01475735	chr3:40494733	NA	-0.46	-5.03	-0.31	9.7e-7	Renal cell carcinoma;
SARC	cis	rs6582630	0.548	rs1607870	chr12:38385964	G/T	cg26384229	chr12:38710491	ALG10B	-0.57	-7.11	-0.42	1.43e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg16479474	chr6:28041457	NA	0.37	5.41	0.33	1.54e-7	Depression;
SARC	cis	rs6570726	0.967	rs441364	chr6:145853662	G/C	cg05220968	chr6:146057943	EPM2A	-0.28	-4.81	-0.3	2.72e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6570726	0.791	rs383841	chr6:145888329	G/T	cg05347473	chr6:146136440	FBXO30	-0.51	-6.89	-0.41	5.2e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6964587	1.000	rs12537846	chr7:91721581	C/T	cg17063962	chr7:91808500	NA	-0.96	-16.1	-0.73	1.01e-39	Breast cancer;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg21331461	chr12:21927773	KCNJ8	0.5	6.29	0.38	1.57e-9	Lung adenocarcinoma;
SARC	cis	rs9916302	0.904	rs3964723	chr17:37403979	C/T	cg07936489	chr17:37558343	FBXL20	-0.69	-9.15	-0.51	2.92e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs921968	0.509	rs72963905	chr2:219547027	T/G	cg02176678	chr2:219576539	TTLL4	-0.52	-7.87	-0.46	1.37e-13	Mean corpuscular hemoglobin concentration;
SARC	cis	rs4975616	0.869	rs370348	chr5:1331219	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.55	-7.53	-0.44	1.12e-12	Lung cancer;
SARC	cis	rs734999	0.545	rs10797441	chr1:2551660	T/G	cg18854424	chr1:2615690	NA	0.31	4.87	0.3	2.09e-6	Ulcerative colitis;
SARC	cis	rs668210	0.793	rs540584	chr11:65765866	C/G	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.66	-6.62	-0.4	2.41e-10	Cerebrospinal fluid biomarker levels;
SARC	cis	rs79149102	0.579	rs61166993	chr15:75306644	C/A	cg09165964	chr15:75287851	SCAMP5	-0.96	-9.03	-0.51	6.67e-17	Lung cancer;
SARC	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg00149659	chr3:10157352	C3orf10	0.69	6.44	0.39	6.6e-10	Alzheimer's disease;
SARC	cis	rs12142240	0.738	rs17361749	chr1:46806480	C/T	cg00530320	chr1:46809349	NSUN4	0.55	6.69	0.4	1.61e-10	Menopause (age at onset);
SARC	trans	rs9325144	0.600	rs7965877	chr12:38743697	G/T	cg23762105	chr12:34175262	ALG10	-0.55	-7.16	-0.42	1.07e-11	Morning vs. evening chronotype;
SARC	cis	rs9462027	0.628	rs2296360	chr6:34803558	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-6.11	-0.37	4.25e-9	Systemic lupus erythematosus;
SARC	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg11766577	chr21:47581405	C21orf56	0.43	5.05	0.31	8.77e-7	Testicular germ cell tumor;
SARC	cis	rs4144743	1.000	rs11871447	chr17:45331618	C/G	cg18085866	chr17:45331354	ITGB3	-0.72	-7.26	-0.43	5.77e-12	Body mass index;
SARC	cis	rs7223966	1.000	rs61360320	chr17:61800392	C/T	cg00588841	chr17:61851480	DDX42;CCDC47	-0.68	-7.6	-0.45	7.42e-13	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7614311	0.555	rs58676857	chr3:63903883	G/A	cg22134162	chr3:63841271	THOC7	-0.42	-4.82	-0.3	2.59e-6	Lung function (FVC);Lung function (FEV1);
SARC	cis	rs9916302	0.861	rs8079590	chr17:37426201	T/C	cg00129232	chr17:37814104	STARD3	-0.59	-7.33	-0.43	3.69e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs244731	0.919	rs12652509	chr5:176626441	A/G	cg17509989	chr5:176798049	RGS14	-0.68	-8.46	-0.48	3.06e-15	Urate levels in lean individuals;
SARC	cis	rs3091242	0.933	rs9645452	chr1:25668326	C/T	cg23205692	chr1:25664452	TMEM50A	-0.47	-5.72	-0.35	3.31e-8	Erythrocyte sedimentation rate;
SARC	cis	rs995000	0.931	rs6678483	chr1:63074442	C/A	cg06896770	chr1:63153194	DOCK7	0.89	13.21	0.65	4.23e-30	Triglyceride levels;
SARC	cis	rs460214	0.528	rs4817954	chr21:40023857	C/T	cg12884169	chr21:40033163	ERG	-0.35	-5.05	-0.31	8.83e-7	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg21724239	chr8:58056113	NA	0.66	6.2	0.38	2.55e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg22805491	chr14:51172404	NA	-0.51	-6.6	-0.4	2.7e-10	Height;
SARC	cis	rs17155006	0.664	rs401487	chr7:107743409	A/G	cg05962710	chr7:107745446	LAMB4	-0.35	-4.76	-0.3	3.4e-6	Pneumococcal bacteremia;
SARC	cis	rs2204008	0.577	rs11520050	chr12:38051839	G/A	cg26384229	chr12:38710491	ALG10B	0.89	13.14	0.65	6.99e-30	Bladder cancer;
SARC	cis	rs16854884	0.657	rs4611822	chr3:143735544	C/T	cg06585982	chr3:143692056	C3orf58	0.67	9.14	0.51	3.13e-17	Economic and political preferences (feminism/equality);
SARC	cis	rs2652834	1.000	rs2729833	chr15:63397044	G/A	cg05507819	chr15:63340323	TPM1	0.54	5.29	0.33	2.75e-7	HDL cholesterol;
SARC	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.22	0.38	2.3e-9	Electroencephalogram traits;
SARC	cis	rs4689388	0.816	rs13147655	chr4:6293474	A/G	cg14416269	chr4:6271139	WFS1	0.32	4.92	0.31	1.61e-6	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg15556689	chr8:8085844	FLJ10661	0.46	5.65	0.35	4.77e-8	Mood instability;
SARC	cis	rs1153858	1.000	rs4775937	chr15:45678614	C/A	cg21132104	chr15:45694354	SPATA5L1	0.78	11.01	0.59	5.55e-23	Homoarginine levels;
SARC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.11	0.37	4.11e-9	Prudent dietary pattern;
SARC	cis	rs965469	0.625	rs1043159	chr20:3232031	C/T	cg25506879	chr20:3388711	C20orf194	-0.51	-5.96	-0.36	9.13e-9	IFN-related cytopenia;
SARC	trans	rs61931739	0.517	rs12815556	chr12:34319670	G/A	cg26384229	chr12:38710491	ALG10B	0.84	12.0	0.62	3.8e-26	Morning vs. evening chronotype;
SARC	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg06713675	chr4:122721982	EXOSC9	-0.52	-7.35	-0.43	3.4e-12	Type 2 diabetes;
SARC	cis	rs8141529	0.748	rs132531	chr22:29297365	C/T	cg02153584	chr22:29168773	CCDC117	-0.78	-11.26	-0.59	9.4e-24	Lymphocyte counts;
SARC	cis	rs3767633	0.858	rs10753645	chr1:161815364	T/C	cg09175582	chr1:161736000	ATF6	0.68	5.88	0.36	1.38e-8	IgG glycosylation;
SARC	cis	rs7220711	1.000	rs9902329	chr17:41787573	A/G	cg26893861	chr17:41843967	DUSP3	0.4	5.06	0.31	8.37e-7	Bone mineral density (spine);Bone mineral density (hip);
SARC	cis	rs7264396	0.790	rs3787168	chr20:34233278	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.56	5.85	0.36	1.66e-8	Total cholesterol levels;
SARC	cis	rs67133203	0.606	rs11169731	chr12:51561573	G/A	cg15029631	chr12:52078762	SCN8A	-0.42	-4.72	-0.3	3.98e-6	Urinary tract infection frequency;
SARC	cis	rs3845702	0.736	rs72960701	chr2:180851202	A/T	cg01881094	chr2:180872142	CWC22	1.13	9.17	0.51	2.57e-17	Schizophrenia;
SARC	cis	rs4689388	0.856	rs10016157	chr4:6294414	T/C	cg25554036	chr4:6271136	WFS1	0.39	6.42	0.39	7.48e-10	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg00933542	chr6:150070202	PCMT1	0.31	5.16	0.32	5.33e-7	Lung cancer;
SARC	cis	rs2425143	1.000	rs7267759	chr20:34257284	G/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.13	0.32	6.04e-7	Blood protein levels;
SARC	cis	rs12142240	0.698	rs56909107	chr1:46808224	A/C	cg00530320	chr1:46809349	NSUN4	0.58	7.07	0.42	1.74e-11	Menopause (age at onset);
SARC	cis	rs17253792	0.822	rs9323289	chr14:56106784	G/C	cg01858014	chr14:56050164	KTN1	-0.69	-5.41	-0.33	1.53e-7	Putamen volume;
SARC	cis	rs10911232	0.507	rs3934697	chr1:183027512	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.12	0.55	3.44e-20	Hypertriglyceridemia;
SARC	cis	rs7824557	0.602	rs11784458	chr8:11204184	G/A	cg21775007	chr8:11205619	TDH	0.67	8.62	0.49	1.02e-15	Retinal vascular caliber;
SARC	cis	rs1707322	0.686	rs61784833	chr1:46233772	T/C	cg06784218	chr1:46089804	CCDC17	0.37	6.54	0.39	3.92e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs17376456	0.825	rs17314825	chr5:93234937	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.65	5.78	0.35	2.36e-8	Diabetic retinopathy;
SARC	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg01238044	chr22:24384105	GSTT1	0.67	7.14	0.42	1.15e-11	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs11190604	1.000	rs10883493	chr10:102208188	A/T	cg07080220	chr10:102295463	HIF1AN	0.78	9.58	0.53	1.56e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs1153858	0.621	rs2413769	chr15:45561868	A/C	cg15395560	chr15:45543142	SLC28A2	-0.27	-4.82	-0.3	2.64e-6	Homoarginine levels;
SARC	cis	rs72945132	0.882	rs66627443	chr11:70199036	C/G	cg00319359	chr11:70116639	PPFIA1	0.67	6.21	0.38	2.36e-9	Coronary artery disease;
SARC	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg12016809	chr21:47604291	C21orf56	0.43	5.2	0.32	4.33e-7	Testicular germ cell tumor;
SARC	cis	rs2180341	0.781	rs7742161	chr6:127571676	T/C	cg24812749	chr6:127587940	RNF146	0.86	11.6	0.61	7.28e-25	Breast cancer;
SARC	cis	rs6500602	0.727	rs2160567	chr16:4535557	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.33	5.55	0.34	7.56e-8	Schizophrenia;
SARC	cis	rs858239	0.601	rs929507	chr7:23166664	G/C	cg23682824	chr7:23144976	KLHL7	0.74	10.09	0.55	4.18e-20	Cerebrospinal fluid biomarker levels;
SARC	cis	rs8141529	0.719	rs5762880	chr22:29287816	T/G	cg15103426	chr22:29168792	CCDC117	0.63	8.2	0.47	1.63e-14	Lymphocyte counts;
SARC	cis	rs4761669	0.876	rs9634181	chr12:95231062	G/C	cg21533806	chr12:95267307	NA	0.43	5.29	0.33	2.88e-7	Common carotid intima-media thickness in HIV infection;
SARC	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg11062466	chr8:58055876	NA	0.54	5.49	0.34	1.04e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7223966	1.000	rs7209435	chr17:61712964	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.32	0.38	1.33e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg00684032	chr4:1343700	KIAA1530	0.37	5.36	0.33	1.99e-7	Obesity-related traits;
SARC	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg01341218	chr17:43662625	NA	-0.85	-9.63	-0.53	1.11e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9611519	0.964	rs2179744	chr22:41621714	G/A	cg17376030	chr22:41985996	PMM1	0.48	5.82	0.36	1.95e-8	Neuroticism;
SARC	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg02891314	chr5:179741120	GFPT2	-0.53	-6.61	-0.4	2.66e-10	Height;
SARC	cis	rs6580649	0.941	rs4760683	chr12:48516296	T/C	cg24011408	chr12:48396354	COL2A1	-0.51	-5.82	-0.36	1.93e-8	Lung cancer;
SARC	cis	rs3126085	0.877	rs868304	chr1:152178568	G/A	cg03465714	chr1:152285911	FLG	-0.46	-5.51	-0.34	9.24e-8	Atopic dermatitis;
SARC	cis	rs10504073	0.669	rs55948643	chr8:50026403	C/G	cg00325661	chr8:49890786	NA	0.5	6.84	0.41	6.92e-11	Blood metabolite ratios;
SARC	cis	rs12701220	0.689	rs6973645	chr7:1112246	C/T	cg02733842	chr7:1102375	C7orf50	-0.58	-6.68	-0.4	1.71e-10	Bronchopulmonary dysplasia;
SARC	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg24675658	chr1:53192096	ZYG11B	-0.6	-8.01	-0.46	5.64e-14	Monocyte count;
SARC	cis	rs7833986	0.501	rs72653981	chr8:57027814	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.73	7.47	0.44	1.56e-12	Height;
SARC	cis	rs11690935	0.569	rs62183770	chr2:172838117	C/G	cg13550731	chr2:172543902	DYNC1I2	0.55	7.26	0.43	5.91e-12	Schizophrenia;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg24344221	chr1:35658281	SFPQ	-0.5	-6.49	-0.39	4.98e-10	Electrocardiographic conduction measures;
SARC	cis	rs11203032	0.634	rs3802658	chr10:90965691	C/T	cg16672925	chr10:90967113	CH25H	-0.67	-6.87	-0.41	5.89e-11	Heart failure;
SARC	cis	rs4713118	0.513	rs149959	chr6:28013854	T/C	cg17221315	chr6:27791827	HIST1H4J	0.44	4.73	0.3	3.9e-6	Parkinson's disease;
SARC	cis	rs1729951	0.575	rs1682356	chr3:136692037	T/C	cg15507776	chr3:136538369	TMEM22	0.5	5.6	0.34	6.04e-8	Neuroticism;
SARC	cis	rs4792901	0.802	rs56357945	chr17:41613691	G/T	cg22562494	chr17:41607896	ETV4	-0.34	-5.28	-0.33	3.02e-7	Dupuytren's disease;
SARC	cis	rs6728642	0.572	rs13387563	chr2:97600916	C/A	cg26665480	chr2:98280029	ACTR1B	-0.7	-7.5	-0.44	1.33e-12	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs4555082	0.915	rs79048296	chr14:105754944	G/A	cg13114125	chr14:105738426	BRF1	-0.8	-11.27	-0.59	8.46e-24	Mean platelet volume;Platelet distribution width;
SARC	cis	rs10927875	0.864	rs6674071	chr1:16144855	G/C	cg21385522	chr1:16154831	NA	-0.92	-10.93	-0.58	1.01e-22	Dilated cardiomyopathy;
SARC	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg21724239	chr8:58056113	NA	-0.59	-5.86	-0.36	1.6e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2985684	1.000	rs2985687	chr14:50100386	T/C	cg04989706	chr14:50066350	PPIL5	-0.53	-5.66	-0.35	4.54e-8	Carotid intima media thickness;
SARC	trans	rs208515	0.560	rs207084	chr6:66776966	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.09	-20.69	-0.8	1.12e-54	Exhaled nitric oxide levels;
SARC	cis	rs2731664	0.792	rs466256	chr5:176875956	C/A	cg23176889	chr5:176863531	GRK6	-0.55	-8.06	-0.47	4.08e-14	Intelligence (multi-trait analysis);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg15991546	chr1:98386723	DPYD	-0.76	-6.54	-0.39	3.88e-10	Autism spectrum disorder or schizophrenia;
SARC	trans	rs1493916	0.721	rs4471760	chr18:31374233	G/A	cg27147174	chr7:100797783	AP1S1	-0.55	-6.79	-0.41	9.28e-11	Life satisfaction;
SARC	cis	rs4660306	0.961	rs12145526	chr1:45969036	G/C	cg24296786	chr1:45957014	TESK2	0.56	6.57	0.4	3.21e-10	Homocysteine levels;
SARC	cis	rs6964587	1.000	rs733957	chr7:91707197	C/T	cg17063962	chr7:91808500	NA	0.96	16.16	0.73	6.46e-40	Breast cancer;
SARC	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg04772025	chr11:68637568	NA	0.53	6.67	0.4	1.83e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs4975616	0.869	rs452384	chr5:1330840	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.58	-8.61	-0.49	1.11e-15	Lung cancer;
SARC	cis	rs644799	0.610	rs1255179	chr11:95472097	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.58	7.37	0.43	3e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9322193	0.607	rs7764677	chr6:150227333	C/T	cg01145232	chr6:150245071	RAET1G	0.43	4.93	0.31	1.57e-6	Lung cancer;
SARC	cis	rs7568458	0.837	rs6547624	chr2:85802134	A/T	cg23752985	chr2:85803571	VAMP8	0.34	4.9	0.31	1.76e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs10464366	0.544	rs4723824	chr7:39153698	T/C	cg18850127	chr7:39170497	POU6F2	0.45	5.9	0.36	1.24e-8	IgG glycosylation;
SARC	cis	rs6582630	0.537	rs35336822	chr12:38346251	T/C	cg13010199	chr12:38710504	ALG10B	0.79	10.87	0.58	1.61e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs66887589	0.777	rs1814815	chr4:120258091	C/T	cg09307838	chr4:120376055	NA	0.53	7.16	0.42	1.03e-11	Diastolic blood pressure;
SARC	cis	rs748404	0.697	rs501884	chr15:43553982	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	5.63	0.35	5.04e-8	Lung cancer;
SARC	cis	rs1865760	0.532	rs2794719	chr6:26088890	T/G	cg17691542	chr6:26056736	HIST1H1C	0.54	6.61	0.4	2.54e-10	Height;
SARC	cis	rs11668609	0.505	rs114268224	chr19:24061855	G/A	cg27517351	chr19:23941871	ZNF681	-0.54	-4.73	-0.3	3.86e-6	Response to taxane treatment (docetaxel);
SARC	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg09699651	chr6:150184138	LRP11	0.5	6.43	0.39	7.1e-10	Testicular germ cell tumor;
SARC	cis	rs11225247	0.764	rs78166284	chr11:102252087	A/G	cg11690896	chr11:102217788	BIRC2	0.77	5.37	0.33	1.93e-7	Vein graft stenosis in coronary artery bypass grafting;
SARC	cis	rs854765	0.583	rs7214002	chr17:17852104	G/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.41	5.09	0.32	7.31e-7	Total body bone mineral density;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg02655739	chr5:87956517	LOC645323	-0.47	-6.31	-0.38	1.38e-9	Chemerin levels;
SARC	cis	rs405956	0.818	rs6571218	chr6:105583605	T/G	cg08749305	chr6:106441987	NA	0.5	5.0	0.31	1.12e-6	QT interval;
SARC	cis	rs4336470	0.547	rs9499924	chr6:105142638	C/G	cg02098413	chr6:105308735	HACE1	-0.38	-5.74	-0.35	2.96e-8	Neuroblastoma;
SARC	cis	rs7264396	1.000	rs6060479	chr20:34165723	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	0.46	5.21	0.32	4.23e-7	Total cholesterol levels;
SARC	trans	rs3808502	0.605	rs11784572	chr8:11174484	C/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.47	-0.39	5.67e-10	Neuroticism;
SARC	cis	rs11098499	0.954	rs878373	chr4:120237484	A/T	cg09160332	chr4:120329925	NA	-0.35	-4.96	-0.31	1.38e-6	Corneal astigmatism;
SARC	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg03517284	chr6:25882590	NA	-0.49	-6.51	-0.39	4.63e-10	Blood metabolite levels;
SARC	cis	rs12709013	0.636	rs12325516	chr16:58783803	T/C	cg04273148	chr16:57808038	KIFC3	0.32	4.72	0.3	4.08e-6	Blood metabolite ratios;
SARC	cis	rs7808935	0.768	rs739704	chr7:27989768	G/A	cg05786569	chr7:27702416	HIBADH	0.53	5.51	0.34	9.68e-8	Prostate cancer;
SARC	cis	rs13256369	0.802	rs13256404	chr8:8562974	T/C	cg17143192	chr8:8559678	CLDN23	0.51	5.67	0.35	4.18e-8	Obesity-related traits;
SARC	cis	rs8067545	0.750	rs4924805	chr17:19997205	C/G	cg13482628	chr17:19912719	NA	0.52	7.04	0.42	2.14e-11	Schizophrenia;
SARC	cis	rs9843304	0.585	rs9842139	chr3:149207517	T/C	cg08667024	chr3:149219783	TM4SF4	0.45	6.79	0.41	9.35e-11	Gallstone disease;
SARC	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg19223190	chr17:80058835	NA	0.45	6.11	0.37	4.24e-9	Life satisfaction;
SARC	cis	rs7937682	0.558	rs7113067	chr11:111692182	G/A	cg09085632	chr11:111637200	PPP2R1B	0.8	10.68	0.57	6.08e-22	Primary sclerosing cholangitis;
SARC	cis	rs17376456	0.877	rs10059230	chr5:93450347	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	6.14	0.37	3.45e-9	Diabetic retinopathy;
SARC	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg02487422	chr3:49467188	NICN1	0.5	6.66	0.4	1.9e-10	Resting heart rate;
SARC	cis	rs6693567	0.565	rs834225	chr1:150300727	T/C	cg09579323	chr1:150459698	TARS2	0.44	5.5	0.34	1.01e-7	Migraine;
SARC	cis	rs4664304	0.739	rs2162500	chr2:160708645	C/G	cg02280532	chr2:160761244	LY75	0.33	5.15	0.32	5.66e-7	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs6088813	1.000	rs4911178	chr20:33952620	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	-0.44	-5.23	-0.32	3.69e-7	Height;
SARC	cis	rs6570726	0.846	rs4896824	chr6:145927048	C/T	cg23711669	chr6:146136114	FBXO30	0.79	12.38	0.63	2.22e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9916302	0.904	rs8079355	chr17:37473018	G/A	cg20243544	chr17:37824526	PNMT	-0.55	-6.64	-0.4	2.19e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs9788682	0.947	rs12439240	chr15:78829091	T/C	cg06917634	chr15:78832804	PSMA4	-0.59	-6.68	-0.4	1.77e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs9916302	0.605	rs12938099	chr17:37612910	T/G	cg20243544	chr17:37824526	PNMT	0.52	5.34	0.33	2.19e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg25894440	chr7:65020034	NA	-0.75	-5.59	-0.34	6.48e-8	Diabetic kidney disease;
SARC	trans	rs56279505	0.690	rs62305762	chr4:100287247	T/C	cg21156590	chr1:3420848	MEGF6	-0.78	-6.26	-0.38	1.79e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7300001	0.667	rs7302198	chr12:110506280	T/C	cg08946844	chr12:110511112	NA	0.66	4.83	0.3	2.45e-6	Headache;
SARC	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg02574844	chr11:5959923	NA	-0.37	-5.24	-0.32	3.55e-7	DNA methylation (variation);
SARC	cis	rs9326248	0.539	rs10892065	chr11:116897024	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.68	8.53	0.49	1.91e-15	Blood protein levels;
SARC	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg11644478	chr21:40555479	PSMG1	0.87	11.09	0.59	3.23e-23	Cognitive function;
SARC	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-9.17	-0.51	2.59e-17	Alzheimer's disease;
SARC	cis	rs67311347	0.544	rs67533651	chr3:40338367	T/A	cg24209194	chr3:40518798	ZNF619	0.49	6.6	0.4	2.72e-10	Renal cell carcinoma;
SARC	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg11987759	chr7:65425863	GUSB	0.58	7.93	0.46	9.38e-14	Calcium levels;
SARC	cis	rs7130144	0.541	rs7936386	chr11:130462505	T/C	cg26307797	chr11:130446613	NA	-0.68	-5.72	-0.35	3.31e-8	Urate levels in lean individuals;
SARC	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs12458462	0.892	rs2242174	chr18:77458037	T/C	cg11879182	chr18:77439856	CTDP1	0.87	12.61	0.64	3.99e-28	Monocyte count;
SARC	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg15847926	chr7:2749597	AMZ1	-0.3	-4.95	-0.31	1.41e-6	Height;
SARC	cis	rs3812831	0.695	rs6560936	chr13:114945972	C/T	cg06611532	chr13:114900021	NA	-0.35	-6.0	-0.37	7.62e-9	Schizophrenia;
SARC	cis	rs6570726	0.935	rs9390329	chr6:145828026	T/C	cg05347473	chr6:146136440	FBXO30	0.48	6.45	0.39	6.38e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs514406	0.861	rs7518390	chr1:53233374	A/G	cg16325326	chr1:53192061	ZYG11B	-0.83	-13.39	-0.66	1.08e-30	Monocyte count;
SARC	cis	rs601339	1.000	rs11059384	chr12:123170301	C/A	cg18578876	chr12:123200353	GPR109B	0.43	4.87	0.3	2.08e-6	Adiponectin levels;
SARC	cis	rs7772486	0.754	rs6937661	chr6:146113299	T/C	cg23711669	chr6:146136114	FBXO30	-0.87	-14.81	-0.7	2.09e-35	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9420	0.925	rs10896636	chr11:57448032	C/G	cg19752551	chr11:57585705	CTNND1	-0.51	-6.93	-0.41	3.99e-11	Schizophrenia;
SARC	cis	rs11710088	0.626	rs6803863	chr3:149225718	A/G	cg08667024	chr3:149219783	TM4SF4	0.32	4.72	0.3	4.08e-6	QRS duration;
SARC	cis	rs858239	0.636	rs7808488	chr7:23221870	T/C	cg23682824	chr7:23144976	KLHL7	0.63	8.05	0.47	4.3e-14	Cerebrospinal fluid biomarker levels;
SARC	cis	rs1144333	0.655	rs77244403	chr1:76304872	A/G	cg03433033	chr1:76189801	ACADM	0.61	5.03	0.31	9.78e-7	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg16405210	chr4:1374714	KIAA1530	-0.46	-5.55	-0.34	7.64e-8	Longevity;
SARC	cis	rs7216064	0.684	rs8182243	chr17:66018505	T/C	cg12091567	chr17:66097778	LOC651250	0.91	11.6	0.6	7.56e-25	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg21226059	chr5:178986404	RUFY1	-0.36	-5.07	-0.31	8.28e-7	Lung cancer;
SARC	cis	rs4780401	0.655	rs17606098	chr16:11789190	C/T	cg01061890	chr16:11836724	TXNDC11	-0.44	-5.73	-0.35	3.08e-8	Rheumatoid arthritis;
SARC	cis	rs929354	0.742	rs2051877	chr7:157008813	A/T	cg05182265	chr7:156933206	UBE3C	-0.31	-4.72	-0.3	4.07e-6	Body mass index;
SARC	cis	rs561341	1.000	rs576985	chr17:30323323	C/T	cg00745463	chr17:30367425	LRRC37B	-0.69	-5.53	-0.34	8.77e-8	Hip circumference adjusted for BMI;
SARC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.72	7.45	0.44	1.79e-12	Platelet count;
SARC	cis	rs7772486	0.651	rs1292338	chr6:145967471	A/C	cg05347473	chr6:146136440	FBXO30	-0.51	-7.1	-0.42	1.52e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9916302	0.904	rs11078898	chr17:37536480	A/G	cg20243544	chr17:37824526	PNMT	-0.56	-6.77	-0.41	1.06e-10	Glomerular filtration rate (creatinine);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg05240795	chr11:561364	RASSF7;C11orf35	0.5	6.7	0.4	1.56e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg22857025	chr5:266934	NA	-1.06	-11.8	-0.61	1.74e-25	Breast cancer;
SARC	trans	rs9325144	0.647	rs35254764	chr12:39102928	T/C	cg23762105	chr12:34175262	ALG10	0.49	6.25	0.38	1.96e-9	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg08677398	chr8:58056175	NA	0.43	5.19	0.32	4.67e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg01833398	chr12:53894760	TARBP2;MAP3K12	0.52	6.57	0.4	3.22e-10	Height;
SARC	cis	rs10504229	0.679	rs16921683	chr8:58053270	T/C	cg08219700	chr8:58056026	NA	0.59	5.98	0.36	8.5e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7412746	0.658	rs12097963	chr1:150870450	T/C	cg15448220	chr1:150897856	SETDB1	0.51	6.65	0.4	2.02e-10	Melanoma;
SARC	cis	rs244731	0.959	rs9313752	chr5:176645435	G/T	cg17509989	chr5:176798049	RGS14	-0.68	-8.63	-0.49	9.71e-16	Urate levels in lean individuals;
SARC	cis	rs62158211	0.565	rs2121243	chr2:114099346	C/T	cg17784749	chr2:114082611	LOC440839	0.45	5.2	0.32	4.39e-7	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
SARC	cis	rs6665290	0.904	rs6677602	chr1:227187838	G/T	cg14016676	chr1:227182615	CDC42BPA	0.35	5.09	0.32	7.39e-7	Myeloid white cell count;
SARC	cis	rs963731	0.649	rs10779924	chr2:39208057	G/T	cg04010122	chr2:39346883	SOS1	-0.93	-5.35	-0.33	2.14e-7	Corticobasal degeneration;
SARC	cis	rs9868809	0.505	rs73080312	chr3:48737847	C/T	cg00383909	chr3:49044727	WDR6	0.76	5.74	0.35	2.93e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs9914544	0.564	rs12451220	chr17:18778421	C/T	cg25390199	chr17:18761479	PRPSAP2	0.47	6.14	0.37	3.58e-9	Educational attainment (years of education);
SARC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg11203670	chr7:100026453	MEPCE;ZCWPW1	0.49	4.83	0.3	2.48e-6	Platelet count;
SARC	cis	rs6060717	0.702	rs6060756	chr20:34608479	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.44	4.72	0.3	4.09e-6	Hip circumference adjusted for BMI;
SARC	cis	rs7937682	0.889	rs2850247	chr11:111637202	C/A	cg22437258	chr11:111473054	SIK2	-0.72	-9.44	-0.53	3.92e-18	Primary sclerosing cholangitis;
SARC	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg03351412	chr1:154909251	PMVK	0.62	8.24	0.47	1.27e-14	Prostate cancer;
SARC	cis	rs6687430	0.526	rs6688558	chr1:10611403	A/G	cg17425144	chr1:10567563	PEX14	0.41	6.15	0.37	3.31e-9	Hand grip strength;
SARC	cis	rs9916302	0.861	rs3889368	chr17:37683231	C/T	cg00129232	chr17:37814104	STARD3	-0.64	-7.95	-0.46	8.02e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs66569888	0.754	rs6719028	chr2:106895212	T/C	cg16099169	chr2:106886729	NA	0.65	7.8	0.45	2.08e-13	Facial morphology (factor 23);
SARC	cis	rs11098499	0.865	rs28753180	chr4:120405367	A/T	cg09307838	chr4:120376055	NA	0.93	12.75	0.64	1.39e-28	Corneal astigmatism;
SARC	cis	rs637571	0.522	rs606978	chr11:65711517	A/C	cg26695010	chr11:65641043	EFEMP2	-0.5	-6.41	-0.39	7.8e-10	Eosinophil percentage of white cells;
SARC	cis	rs6910061	0.830	rs7753943	chr6:11133496	T/G	cg27233058	chr6:11094804	LOC221710	0.59	5.46	0.34	1.23e-7	Diabetic kidney disease;
SARC	cis	rs1420338	0.967	rs10807873	chr7:34171276	C/T	cg01275685	chr7:34179230	BMPER	-0.4	-4.89	-0.31	1.88e-6	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
SARC	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9715521	0.900	rs62301182	chr4:59834267	A/G	cg11281224	chr4:60001000	NA	-0.39	-5.02	-0.31	1.01e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs11722228	0.964	rs10939614	chr4:9926613	T/C	cg11266682	chr4:10021025	SLC2A9	-0.32	-5.37	-0.33	1.89e-7	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs854765	0.647	rs8066764	chr17:17974668	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.42	5.22	0.32	4.02e-7	Total body bone mineral density;
SARC	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg18252515	chr7:66147081	NA	-0.49	-5.24	-0.32	3.64e-7	Aortic root size;
SARC	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg16325326	chr1:53192061	ZYG11B	0.78	12.11	0.62	1.67e-26	Monocyte count;
SARC	cis	rs7659604	0.540	rs4833775	chr4:122716826	T/C	cg19671926	chr4:122722719	EXOSC9	0.67	8.58	0.49	1.37e-15	Type 2 diabetes;
SARC	cis	rs7264396	0.790	rs2425083	chr20:34300456	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-8.51	-0.49	2.11e-15	Total cholesterol levels;
SARC	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg08859206	chr1:53392774	SCP2	0.43	6.17	0.37	2.96e-9	Monocyte count;
SARC	cis	rs7159888	0.577	rs1269068	chr14:65767333	A/G	cg15999311	chr14:65749247	NA	-0.35	-5.72	-0.35	3.23e-8	IgG glycosylation;N-glycan levels;
SARC	cis	rs6120849	0.754	rs13433216	chr20:33616301	T/C	cg06115741	chr20:33292138	TP53INP2	0.54	5.16	0.32	5.3e-7	Protein C levels;
SARC	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg15049968	chr18:44337910	ST8SIA5	0.36	5.62	0.35	5.46e-8	Personality dimensions;
SARC	cis	rs72634258	0.520	rs12078018	chr1:7857309	G/A	cg26816564	chr1:7831052	VAMP3	0.55	4.98	0.31	1.25e-6	Inflammatory bowel disease;
SARC	cis	rs5744897	0.708	rs5744769	chr12:133250734	C/G	cg16945633	chr12:133170342	NA	0.6	6.07	0.37	5.14e-9	Urate levels in overweight individuals;
SARC	cis	rs12586317	0.586	rs74243591	chr14:35520917	C/T	cg16230307	chr14:35515116	FAM177A1	1.03	11.98	0.62	4.51e-26	Psoriasis;
SARC	cis	rs4555082	0.834	rs2735819	chr14:105713449	C/T	cg10792982	chr14:105748885	BRF1	0.54	7.94	0.46	8.59e-14	Mean platelet volume;Platelet distribution width;
SARC	cis	rs59112743	0.588	rs2743873	chr6:15678228	G/C	cg06375068	chr6:15849678	NA	0.54	4.82	0.3	2.54e-6	Multiple keratinocyte cancers;
SARC	cis	rs6893300	0.560	rs1019443	chr5:179207547	A/G	cg14593053	chr5:179126677	CANX	-0.47	-6.68	-0.4	1.74e-10	Resting heart rate;
SARC	cis	rs1018836	0.923	rs756569	chr8:91610957	G/A	cg16814680	chr8:91681699	NA	-0.82	-13.0	-0.65	2.08e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg12311346	chr5:56204834	C5orf35	-0.53	-5.42	-0.33	1.5e-7	Initial pursuit acceleration;
SARC	cis	rs763121	0.853	rs4821810	chr22:39072098	C/G	cg21395723	chr22:39101663	GTPBP1	0.57	6.94	0.41	3.74e-11	Menopause (age at onset);
SARC	cis	rs9303401	0.527	rs12939313	chr17:56755616	A/T	cg25039879	chr17:56429692	SUPT4H1	0.69	6.15	0.37	3.29e-9	Cognitive test performance;
SARC	cis	rs981844	0.712	rs2405208	chr4:154755774	T/C	cg14289246	chr4:154710475	SFRP2	-0.47	-5.49	-0.34	1.04e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs11785400	0.731	rs4294163	chr8:143730830	G/T	cg10596483	chr8:143751796	JRK	0.57	7.39	0.44	2.61e-12	Schizophrenia;
SARC	cis	rs2710247	1	rs2710247	chr2:219467508	A/G	cg02176678	chr2:219576539	TTLL4	0.36	5.17	0.32	5.11e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9549260	0.564	rs9549279	chr13:41315582	C/G	cg21288729	chr13:41239152	FOXO1	-0.5	-6.09	-0.37	4.71e-9	Red blood cell count;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg15231902	chr12:56618064	OBFC2B	-0.5	-6.35	-0.38	1.09e-9	Schizophrenia;
SARC	cis	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg23616842	chr20:4129483	SMOX	0.39	5.32	0.33	2.38e-7	Immature fraction of reticulocytes;
SARC	cis	rs6910061	0.830	rs28360554	chr6:11136570	A/G	cg27233058	chr6:11094804	LOC221710	0.63	5.63	0.35	5.03e-8	Diabetic kidney disease;
SARC	cis	rs798554	0.686	rs7777484	chr7:2814271	A/G	cg13628971	chr7:2884303	GNA12	0.43	5.24	0.32	3.56e-7	Height;
SARC	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-9.15	-0.51	2.85e-17	Alzheimer's disease;
SARC	cis	rs9309473	1.000	rs11901272	chr2:73720444	A/G	cg20560298	chr2:73613845	ALMS1	-0.5	-6.01	-0.37	7.25e-9	Metabolite levels;
SARC	cis	rs6933660	0.512	rs13202634	chr6:151800630	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.64	5.67	0.35	4.18e-8	Menarche (age at onset);
SARC	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg15448220	chr1:150897856	SETDB1	0.47	6.25	0.38	1.94e-9	Tonsillectomy;
SARC	cis	rs9948	1.000	rs72811629	chr2:97519901	T/G	cg01990225	chr2:97406019	LMAN2L	-0.87	-5.8	-0.36	2.1e-8	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs12142240	0.698	rs6683192	chr1:46830257	C/T	cg00530320	chr1:46809349	NSUN4	0.58	7.07	0.42	1.78e-11	Menopause (age at onset);
SARC	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg18876405	chr7:65276391	NA	0.47	5.45	0.34	1.27e-7	Aortic root size;
SARC	cis	rs10276381	1.000	rs10260837	chr7:28181129	C/T	cg23620719	chr7:28220237	JAZF1	0.71	5.85	0.36	1.63e-8	Crohn's disease;
SARC	cis	rs9818758	0.607	rs66991555	chr3:49228643	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.73	-6.42	-0.39	7.71e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs17376456	0.877	rs13165147	chr5:93422214	G/A	cg25358565	chr5:93447407	FAM172A	1.32	14.94	0.7	7.42e-36	Diabetic retinopathy;
SARC	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	5.33	0.33	2.34e-7	Bipolar disorder;
SARC	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg18404041	chr3:52824283	ITIH1	-0.38	-5.73	-0.35	3.13e-8	Bipolar disorder;
SARC	cis	rs7264396	0.528	rs6058370	chr20:34518592	C/T	cg12579300	chr20:34535607	PHF20	-0.47	-5.18	-0.32	4.69e-7	Total cholesterol levels;
SARC	cis	rs7829975	0.510	rs332037	chr8:8722675	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	7.19	0.43	8.72e-12	Mood instability;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg18333152	chr14:24025304	THTPA	0.47	6.39	0.39	8.91e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs9300255	0.508	rs1716176	chr12:123655467	T/G	cg05973401	chr12:123451056	ABCB9	0.54	5.78	0.35	2.44e-8	Neutrophil percentage of white cells;
SARC	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	12.27	0.63	4.95e-27	Platelet count;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg06790860	chr16:69760301	NQO1	0.49	6.28	0.38	1.61e-9	Lung adenocarcinoma;
SARC	cis	rs2282802	0.711	rs1864970	chr5:139633042	T/C	cg26211634	chr5:139558579	C5orf32	0.37	4.75	0.3	3.56e-6	Intelligence (multi-trait analysis);
SARC	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	16.23	0.73	3.75e-40	Height;
SARC	cis	rs5753618	0.561	rs9606830	chr22:31717799	T/G	cg02404636	chr22:31891804	SFI1	0.47	4.94	0.31	1.48e-6	Colorectal cancer;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg04550941	chr4:177241289	SPCS3	0.52	6.74	0.4	1.2e-10	Lung adenocarcinoma;
SARC	cis	rs526231	0.511	rs3776861	chr5:102349662	A/C	cg23492399	chr5:102201601	PAM	-0.46	-5.15	-0.32	5.44e-7	Primary biliary cholangitis;
SARC	trans	rs116095464	0.558	rs9654453	chr5:299621	T/C	cg00938859	chr5:1591904	SDHAP3	0.77	6.37	0.39	1.01e-9	Breast cancer;
SARC	trans	rs3945119	0.838	rs12121989	chr1:91156882	G/A	cg01730148	chr2:3698421	NA	0.34	6.31	0.38	1.41e-9	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg21724239	chr8:58056113	NA	0.61	5.93	0.36	1.1e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg12923728	chr3:195709715	SDHAP1	-0.68	-8.28	-0.48	9.55e-15	Pancreatic cancer;
SARC	cis	rs2235544	0.542	rs679801	chr1:54470757	T/C	cg10336722	chr1:54665764	CYB5RL;MRPL37	-0.38	-4.71	-0.3	4.17e-6	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
SARC	cis	rs7412746	0.611	rs72704679	chr1:150897477	C/T	cg13175981	chr1:150552382	MCL1	-0.52	-6.43	-0.39	7.28e-10	Melanoma;
SARC	cis	rs2276314	1.000	rs2276314	chr18:33557466	C/T	cg19628046	chr18:33552617	C18orf21	-0.58	-6.2	-0.38	2.5e-9	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg23758822	chr17:41437982	NA	0.89	11.37	0.6	3.91e-24	Menopause (age at onset);
SARC	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg05890377	chr2:74357713	NA	0.58	7.23	0.43	6.96e-12	Gestational age at birth (maternal effect);
SARC	cis	rs7818345	0.967	rs4433156	chr8:19284247	A/C	cg11303988	chr8:19266685	CSGALNACT1	0.42	5.73	0.35	3.06e-8	Language performance in older adults (adjusted for episodic memory);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg09333812	chr10:99052472	ARHGAP19	0.64	8.47	0.49	2.78e-15	Breast cancer;
SARC	cis	rs72781680	1.000	rs72798408	chr2:24181845	G/C	cg06627628	chr2:24431161	ITSN2	-0.75	-7.03	-0.42	2.31e-11	Lymphocyte counts;
SARC	cis	rs9400467	0.506	rs74529244	chr6:111775358	C/T	cg15721981	chr6:111408429	SLC16A10	0.65	5.67	0.35	4.31e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs9733	0.650	rs61820165	chr1:150555987	C/T	cg18016565	chr1:150552671	MCL1	-0.39	-5.41	-0.33	1.56e-7	Tonsillectomy;
SARC	cis	rs9660992	0.710	rs7367930	chr1:205235512	A/G	cg07972983	chr1:205091412	RBBP5	0.56	6.71	0.4	1.48e-10	Mean corpuscular volume;Mean platelet volume;
SARC	trans	rs7937682	0.921	rs4616071	chr11:111440865	C/G	cg18187862	chr3:45730750	SACM1L	-0.53	-6.41	-0.39	7.89e-10	Primary sclerosing cholangitis;
SARC	cis	rs9527	0.567	rs11191573	chr10:104896816	T/C	cg04362960	chr10:104952993	NT5C2	0.44	5.15	0.32	5.58e-7	Arsenic metabolism;
SARC	cis	rs9911578	0.967	rs302842	chr17:56728102	C/G	cg05425664	chr17:57184151	TRIM37	-0.68	-8.49	-0.49	2.48e-15	Intelligence (multi-trait analysis);
SARC	cis	rs12291225	0.839	rs4757244	chr11:14258655	A/G	cg19336497	chr11:14380999	RRAS2	0.29	4.93	0.31	1.59e-6	Sense of smell;
SARC	cis	rs9398803	0.687	rs1417572	chr6:126958727	T/C	cg20229609	chr6:126660872	C6orf173	0.37	5.28	0.33	2.99e-7	Male-pattern baldness;
SARC	cis	rs2071303	0.502	rs9393686	chr6:26106601	C/A	cg21479132	chr6:26055353	NA	0.65	6.61	0.4	2.64e-10	Intelligence (multi-trait analysis);
SARC	cis	rs986417	0.901	rs4901987	chr14:60987529	C/T	cg27398547	chr14:60952738	C14orf39	0.96	8.88	0.5	1.87e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs9300255	0.537	rs1619561	chr12:123620268	G/C	cg05973401	chr12:123451056	ABCB9	0.51	5.64	0.35	4.8e-8	Neutrophil percentage of white cells;
SARC	cis	rs708547	0.735	rs1277280	chr4:57866872	T/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.54	-6.39	-0.39	9.12e-10	Response to bleomycin (chromatid breaks);
SARC	cis	rs1697139	0.583	rs1428475	chr5:66543954	G/T	cg11553311	chr5:66541588	NA	0.3	4.8	0.3	2.84e-6	Breast cancer;
SARC	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.85	-9.22	-0.52	1.79e-17	Mean platelet volume;
SARC	cis	rs9302635	0.513	rs7184169	chr16:72152933	C/T	cg01557791	chr16:72042693	DHODH	-0.57	-6.24	-0.38	2.07e-9	Blood protein levels;
SARC	cis	rs9896933	0.830	rs607544	chr17:80768760	C/G	cg20578329	chr17:80767326	TBCD	-0.64	-7.77	-0.45	2.56e-13	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
SARC	cis	rs2933343	0.661	rs2630259	chr3:128606322	C/T	cg25356066	chr3:128598488	ACAD9	0.73	9.65	0.53	9.44e-19	IgG glycosylation;
SARC	cis	rs6450176	0.909	rs80213371	chr5:53300874	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.66	-7.57	-0.44	8.49e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs7819412	0.522	rs11776603	chr8:11020313	G/T	cg21775007	chr8:11205619	TDH	-0.48	-6.05	-0.37	5.65e-9	Triglycerides;
SARC	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg25072359	chr17:41440525	NA	0.49	5.8	0.36	2.15e-8	Menopause (age at onset);
SARC	cis	rs617791	0.508	rs1047464	chr11:65769456	A/T	cg09462587	chr11:65769444	EIF1AD;BANF1	0.41	4.84	0.3	2.4e-6	Breast cancer;
SARC	cis	rs62432291	0.681	rs2932988	chr6:159655402	A/G	cg14500486	chr6:159655392	FNDC1	-0.62	-6.03	-0.37	6.44e-9	Joint mobility (Beighton score);
SARC	cis	rs554111	0.891	rs646786	chr1:21054726	A/G	cg08890418	chr1:21044141	KIF17	0.52	7.19	0.43	8.76e-12	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs7666738	0.830	rs13110903	chr4:98946373	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs3091242	0.933	rs61775167	chr1:25780893	A/G	cg27572855	chr1:25598939	RHD	-0.53	-9.08	-0.51	4.77e-17	Erythrocyte sedimentation rate;
SARC	cis	rs10752881	1.000	rs10911191	chr1:182984524	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.79	0.58	2.82e-22	Colorectal cancer;
SARC	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.93	-13.91	-0.67	2e-32	Chronic sinus infection;
SARC	cis	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg19223190	chr17:80058835	NA	-0.36	-4.94	-0.31	1.48e-6	Life satisfaction;
SARC	cis	rs76419734	1.000	rs72671878	chr4:106662692	G/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.84	5.56	0.34	7.44e-8	Post bronchodilator FEV1;
SARC	cis	rs4481887	1.000	rs4244174	chr1:248467956	A/G	cg13385794	chr1:248469461	NA	0.36	5.59	0.34	6.44e-8	Common traits (Other);
SARC	cis	rs8044868	0.530	rs12918956	chr16:72224335	A/G	cg16558253	chr16:72132732	DHX38	0.45	6.76	0.4	1.1e-10	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
SARC	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg03033257	chr22:50311977	ALG12;CRELD2	0.61	5.8	0.36	2.1e-8	Schizophrenia;
SARC	cis	rs2594989	0.943	rs2454493	chr3:11506458	A/G	cg00170343	chr3:11313890	ATG7	0.54	5.33	0.33	2.37e-7	Circulating chemerin levels;
SARC	cis	rs2115536	0.704	rs2163005	chr15:80194480	A/G	cg00225070	chr15:80189496	MTHFS	0.47	5.78	0.35	2.38e-8	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
SARC	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg21724239	chr8:58056113	NA	0.61	5.93	0.36	1.1e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs870825	0.616	rs4437299	chr4:185643223	T/A	cg04058563	chr4:185651563	MLF1IP	0.81	11.52	0.6	1.31e-24	Blood protein levels;
SARC	cis	rs6904897	0.563	rs6569976	chr6:135224753	A/C	cg12549451	chr6:135224345	NA	0.43	5.86	0.36	1.55e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs13088645	0.532	rs7623580	chr3:134164345	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.45	5.58	0.34	6.61e-8	Coronary artery disease;
SARC	cis	rs4555082	0.874	rs56263609	chr14:105756944	C/T	cg13114125	chr14:105738426	BRF1	-0.79	-11.34	-0.6	5.21e-24	Mean platelet volume;Platelet distribution width;
SARC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.99	11.2	0.59	1.46e-23	Platelet count;
SARC	cis	rs12594515	0.967	rs11857628	chr15:45998206	C/T	cg14863074	chr15:45997064	NA	0.34	5.13	0.32	6.03e-7	Waist circumference;Weight;
SARC	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg21782813	chr7:2030301	MAD1L1	0.45	7.04	0.42	2.08e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg02018176	chr4:1364513	KIAA1530	0.61	9.01	0.51	7.62e-17	Longevity;
SARC	trans	rs2727020	0.567	rs1164687	chr11:49290669	G/A	cg15704280	chr7:45808275	SEPT13	0.78	10.68	0.57	6.21e-22	Coronary artery disease;
SARC	cis	rs920590	0.527	rs79929516	chr8:19650050	G/C	cg17834443	chr8:19674713	INTS10	0.6	6.3	0.38	1.5e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs240764	0.764	rs13201976	chr6:100933185	T/A	cg21058520	chr6:100914733	NA	0.31	4.81	0.3	2.76e-6	Neuroticism;
SARC	cis	rs4535497	0.525	rs4975639	chr5:1108250	A/G	cg18655438	chr5:1077845	SLC12A7	0.35	4.76	0.3	3.43e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs4690686	0.509	rs61482060	chr4:177264465	A/G	cg17059388	chr4:177262070	NA	0.36	4.78	0.3	3.09e-6	Essential tremor;
SARC	cis	rs7647973	0.626	rs9835157	chr3:49797769	G/A	cg03060546	chr3:49711283	APEH	-0.63	-6.63	-0.4	2.28e-10	Menarche (age at onset);
SARC	cis	rs5753037	0.653	rs140102	chr22:30128443	T/C	cg01021169	chr22:30184971	ASCC2	-0.42	-5.66	-0.35	4.44e-8	Type 1 diabetes;
SARC	cis	rs67311347	1.000	rs4974017	chr3:40473519	C/T	cg09455208	chr3:40491958	NA	0.42	6.66	0.4	1.92e-10	Renal cell carcinoma;
SARC	trans	rs9325144	0.510	rs6582599	chr12:38715965	T/G	cg23762105	chr12:34175262	ALG10	-0.53	-6.95	-0.41	3.65e-11	Morning vs. evening chronotype;
SARC	cis	rs1707322	0.721	rs4330955	chr1:46217485	G/C	cg06784218	chr1:46089804	CCDC17	0.36	6.22	0.38	2.26e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.63	-6.57	-0.4	3.29e-10	Platelet count;
SARC	cis	rs1023500	0.573	rs8135801	chr22:42475568	A/G	cg15557168	chr22:42548783	NA	0.35	4.8	0.3	2.85e-6	Schizophrenia;
SARC	cis	rs2576037	0.796	rs2576039	chr18:44582148	C/T	cg15049968	chr18:44337910	ST8SIA5	0.31	5.01	0.31	1.05e-6	Personality dimensions;
SARC	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg23758822	chr17:41437982	NA	0.88	11.31	0.6	6.44e-24	Menopause (age at onset);
SARC	trans	rs3929778	1.000	rs3929778	chr20:6460290	C/T	cg00270625	chr22:51017019	CPT1B;CHKB-CPT1B	-0.59	-6.58	-0.4	3.04e-10	QRS complex (Cornell);
SARC	cis	rs4253772	0.530	rs9615362	chr22:46795141	A/C	cg24881330	chr22:46731750	TRMU	-0.71	-6.28	-0.38	1.6e-9	LDL cholesterol;Cholesterol, total;
SARC	cis	rs981844	0.921	rs2606336	chr4:154656792	C/T	cg14289246	chr4:154710475	SFRP2	0.58	6.64	0.4	2.14e-10	Response to statins (LDL cholesterol change);
SARC	trans	rs11098499	0.863	rs1010739	chr4:120463471	C/T	cg25214090	chr10:38739885	LOC399744	0.52	6.68	0.4	1.78e-10	Corneal astigmatism;
SARC	cis	rs4595586	0.525	rs6580891	chr12:39370127	C/T	cg13010199	chr12:38710504	ALG10B	0.4	4.75	0.3	3.57e-6	Morning vs. evening chronotype;
SARC	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg13628971	chr7:2884303	GNA12	0.65	7.38	0.44	2.72e-12	Height;
SARC	cis	rs240764	0.658	rs35967345	chr6:101187858	T/G	cg09795085	chr6:101329169	ASCC3	-0.49	-6.42	-0.39	7.54e-10	Neuroticism;
SARC	cis	rs3106136	0.814	rs6532481	chr4:95277311	T/G	cg11021082	chr4:95130006	SMARCAD1	0.35	5.42	0.33	1.5e-7	Capecitabine sensitivity;
SARC	trans	rs13240504	0.557	rs12706735	chr7:126180384	A/G	cg14121234	chr10:696332	DIP2C;C10orf108	0.61	6.24	0.38	2.06e-9	Anti-saccade response;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg09574498	chr17:48944758	NA	-0.51	-6.32	-0.38	1.29e-9	Height;
SARC	cis	rs11676348	0.967	rs4672873	chr2:219005210	A/G	cg00012203	chr2:219082015	ARPC2	-0.44	-5.75	-0.35	2.75e-8	Ulcerative colitis;
SARC	cis	rs17376456	0.877	rs67066109	chr5:93494101	G/C	cg21475434	chr5:93447410	FAM172A	0.91	7.74	0.45	3e-13	Diabetic retinopathy;
SARC	cis	rs17666538	0.792	rs1979174	chr8:592274	C/A	cg07234876	chr8:600039	NA	0.87	7.02	0.42	2.36e-11	IgG glycosylation;
SARC	cis	rs2425143	0.818	rs73902932	chr20:34489009	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	4.76	0.3	3.48e-6	Blood protein levels;
SARC	cis	rs6963495	0.818	rs6973263	chr7:105170293	A/G	cg13798780	chr7:105162888	PUS7	0.6	5.55	0.34	7.84e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg25703541	chr22:24373054	LOC391322	0.96	16.08	0.73	1.21e-39	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	7.41	0.44	2.28e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs950169	0.580	rs62021208	chr15:85196244	G/A	cg17507749	chr15:85114479	UBE2QP1	0.59	6.85	0.41	6.41e-11	Schizophrenia;
SARC	cis	rs13166103	0.628	rs11740846	chr5:57722340	T/A	cg10487770	chr5:57879443	RAB3C	0.53	5.46	0.34	1.24e-7	Type 2 diabetes (age of onset);
SARC	trans	rs17685	0.753	rs1637039	chr7:75693009	C/T	cg19862616	chr7:65841803	NCRNA00174	0.63	7.89	0.46	1.17e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs1348850	0.914	rs3902850	chr2:178315899	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.71	9.12	0.51	3.66e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	trans	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg17712092	chr4:129076599	LARP1B	0.71	9.73	0.54	5.35e-19	Eosinophil percentage of white cells;
SARC	cis	rs2153535	0.580	rs1932276	chr6:8442593	G/A	cg21535247	chr6:8435926	SLC35B3	0.56	7.01	0.42	2.6e-11	Motion sickness;
SARC	cis	rs7635838	0.617	rs2606731	chr3:11291615	A/C	cg00170343	chr3:11313890	ATG7	0.69	9.14	0.51	3.23e-17	HDL cholesterol;
SARC	cis	rs9359856	0.662	rs1179904	chr6:90322573	A/G	cg13799429	chr6:90582589	CASP8AP2	0.5	4.84	0.3	2.41e-6	Bipolar disorder;
SARC	cis	rs6772849	0.830	rs7633674	chr3:128355026	G/A	cg01163369	chr3:128370232	RPN1	-0.34	-4.94	-0.31	1.51e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs12477438	0.765	rs2309454	chr2:99595418	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-8.16	-0.47	2.11e-14	Chronic sinus infection;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg07580718	chr14:32543373	NA	-0.48	-6.24	-0.38	2.04e-9	Electrocardiographic conduction measures;
SARC	cis	rs950169	0.614	rs765524	chr15:84681782	G/T	cg17507749	chr15:85114479	UBE2QP1	0.69	8.03	0.47	4.7e-14	Schizophrenia;
SARC	cis	rs10892173	0.935	rs7108548	chr11:117674072	A/T	cg21640587	chr11:117668038	DSCAML1	0.49	6.85	0.41	6.45e-11	Myopia;
SARC	cis	rs72945132	0.882	rs56770826	chr11:70128874	A/G	cg00319359	chr11:70116639	PPFIA1	0.68	6.37	0.39	1.01e-9	Coronary artery disease;
SARC	cis	rs1046896	0.594	rs8070403	chr17:80865404	A/G	cg02711726	chr17:80685570	FN3KRP	-0.52	-6.22	-0.38	2.24e-9	Glycated hemoglobin levels;
SARC	trans	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg22717607	chr5:10353969	MARCH6	0.46	6.31	0.38	1.39e-9	Immature fraction of reticulocytes;
SARC	cis	rs910316	0.839	rs35977276	chr14:75637359	A/C	cg08847533	chr14:75593920	NEK9	-0.92	-14.01	-0.68	9.49e-33	Height;
SARC	cis	rs854765	0.618	rs8068820	chr17:17834119	A/G	cg04398451	chr17:18023971	MYO15A	-0.39	-5.56	-0.34	7.34e-8	Total body bone mineral density;
SARC	cis	rs1450679	0.891	rs3758292	chr9:106854205	C/T	cg21169611	chr9:106856078	SMC2	0.58	5.1	0.32	7.06e-7	Response to cytadine analogues (cytosine arabinoside);
SARC	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.67	6.71	0.4	1.47e-10	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-4.93	-0.31	1.59e-6	Total body bone mineral density;
SARC	cis	rs10752881	1.000	rs10797813	chr1:182989366	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.69	0.57	6.02e-22	Colorectal cancer;
SARC	cis	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg00409905	chr10:38381863	ZNF37A	-0.53	-7.47	-0.44	1.6e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg15049968	chr18:44337910	ST8SIA5	-0.33	-5.24	-0.32	3.58e-7	Personality dimensions;
SARC	cis	rs4742903	0.935	rs1889284	chr9:106926980	C/T	cg14250997	chr9:106856677	SMC2	0.44	5.47	0.34	1.17e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs6752107	0.967	rs3792111	chr2:234179690	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.44	5.94	0.36	1.04e-8	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs172166	0.694	rs203892	chr6:28067196	T/C	cg16479474	chr6:28041457	NA	0.33	5.09	0.32	7.48e-7	Cardiac Troponin-T levels;
SARC	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg09165964	chr15:75287851	SCAMP5	0.52	6.92	0.41	4.24e-11	Breast cancer;
SARC	cis	rs1865760	0.663	rs9348704	chr6:26000393	A/C	cg17691542	chr6:26056736	HIST1H1C	0.5	6.41	0.39	8.09e-10	Height;
SARC	cis	rs4481887	0.861	rs4497248	chr1:248450525	T/C	cg13385794	chr1:248469461	NA	0.31	4.72	0.3	4.08e-6	Common traits (Other);
SARC	cis	rs6901004	0.716	rs35312643	chr6:111574536	C/A	cg15721981	chr6:111408429	SLC16A10	0.46	5.52	0.34	8.88e-8	Blood metabolite levels;
SARC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg11494091	chr17:61959527	GH2	-0.51	-7.62	-0.45	6.37e-13	Prudent dietary pattern;
SARC	cis	rs2559856	1.000	rs2695282	chr12:102089502	A/G	cg12924262	chr12:102091054	CHPT1	-0.56	-7.73	-0.45	3.2e-13	Blood protein levels;
SARC	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs829883	0.573	rs73136486	chr12:98913727	T/A	cg25150519	chr12:98850993	NA	-0.66	-8.18	-0.47	1.79e-14	Colorectal adenoma (advanced);
SARC	cis	rs9638182	1.000	rs9638180	chr7:72998952	A/G	cg07467649	chr7:72856462	BAZ1B	0.46	4.77	0.3	3.25e-6	Triglycerides;
SARC	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg18252515	chr7:66147081	NA	1.29	11.12	0.59	2.48e-23	Diabetic kidney disease;
SARC	cis	rs12477438	1.000	rs6732980	chr2:99921613	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-8.08	-0.47	3.55e-14	Chronic sinus infection;
SARC	cis	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg06558623	chr16:89946397	TCF25	0.93	6.44	0.39	6.63e-10	Skin colour saturation;
SARC	cis	rs8114671	0.562	rs6119536	chr20:33450041	A/G	cg24642439	chr20:33292090	TP53INP2	-0.4	-4.76	-0.3	3.36e-6	Height;
SARC	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg13628971	chr7:2884303	GNA12	0.58	6.79	0.41	9.4e-11	Height;
SARC	cis	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg15556689	chr8:8085844	FLJ10661	0.53	6.77	0.41	1.06e-10	Mood instability;
SARC	cis	rs9868809	0.881	rs7631574	chr3:48663046	A/G	cg06212747	chr3:49208901	KLHDC8B	0.53	4.9	0.31	1.78e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs2153535	0.580	rs1414345	chr6:8471537	T/G	cg07606381	chr6:8435919	SLC35B3	0.76	10.81	0.58	2.43e-22	Motion sickness;
SARC	cis	rs796364	0.760	rs56225698	chr2:200910653	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-6.47	-0.39	5.62e-10	Schizophrenia;
SARC	cis	rs7568458	0.846	rs6738645	chr2:85783128	T/G	cg17127132	chr2:85788382	GGCX	0.47	6.43	0.39	7.23e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs291671	0.718	rs76771178	chr20:32130651	G/C	cg05840533	chr20:31755943	C20orf70	-0.82	-5.27	-0.33	3.04e-7	Hair color;
SARC	cis	rs858239	0.539	rs2141305	chr7:23191899	T/C	cg23682824	chr7:23144976	KLHL7	0.74	9.66	0.53	8.86e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs27434	0.583	rs28129	chr5:96155518	G/A	cg16492584	chr5:96139282	ERAP1	-0.56	-7.02	-0.42	2.43e-11	Ankylosing spondylitis;
SARC	cis	rs78545713	1.000	rs78661760	chr6:26250033	A/T	cg13736514	chr6:26305472	NA	-0.6	-5.06	-0.31	8.67e-7	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg11764359	chr7:65958608	NA	0.88	12.58	0.64	4.89e-28	Aortic root size;
SARC	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.89	12.64	0.64	3.1e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7208859	0.524	rs28760584	chr17:29141017	G/A	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	trans	rs17783634	0.509	rs11775489	chr8:11036843	T/C	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.42	-0.39	7.68e-10	Subjective well-being;
SARC	cis	rs9303542	0.694	rs4793854	chr17:46572133	A/G	cg04904318	chr17:46607828	HOXB1	0.4	4.93	0.31	1.53e-6	Ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs2370759	1.000	rs11599044	chr10:32615445	A/G	cg01819863	chr10:32635814	EPC1	1.02	10.15	0.55	2.83e-20	Sexual dysfunction (female);
SARC	cis	rs5758511	0.633	rs5758690	chr22:42668295	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.44	6.56	0.39	3.53e-10	Birth weight;
SARC	cis	rs9815354	1.000	rs2272006	chr3:41997059	C/T	cg03022575	chr3:42003672	ULK4	-0.59	-5.67	-0.35	4.22e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9398803	0.687	rs1262552	chr6:127078752	C/T	cg19875578	chr6:126661172	C6orf173	-0.6	-8.29	-0.48	8.89e-15	Male-pattern baldness;
SARC	cis	rs9786986	0.908	rs10925824	chr1:235645079	T/C	cg26050004	chr1:235667680	B3GALNT2	0.59	5.34	0.33	2.24e-7	Body mass index;
SARC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg11987759	chr7:65425863	GUSB	-0.43	-5.72	-0.35	3.17e-8	Calcium levels;
SARC	cis	rs698833	0.780	rs2005203	chr2:44541725	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.64	8.27	0.48	1.06e-14	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	trans	rs17685	0.672	rs1639618	chr7:75701987	T/C	cg19862616	chr7:65841803	NCRNA00174	0.63	7.77	0.45	2.42e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs35306767	0.903	rs12763396	chr10:927357	C/A	cg20503657	chr10:835505	NA	0.88	8.48	0.49	2.64e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs7474896	0.537	rs2749586	chr10:38270214	G/C	cg25427524	chr10:38739819	LOC399744	0.44	5.54	0.34	8.21e-8	Obesity (extreme);
SARC	cis	rs4713118	0.955	rs9468204	chr6:27688809	C/T	cg17221315	chr6:27791827	HIST1H4J	0.47	4.82	0.3	2.63e-6	Parkinson's disease;
SARC	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg10018233	chr7:150070692	REPIN1	0.72	9.37	0.52	6.39e-18	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs9291683	0.530	rs10939620	chr4:9946132	C/T	cg00071950	chr4:10020882	SLC2A9	-0.41	-6.61	-0.4	2.53e-10	Bone mineral density;
SARC	cis	rs73001065	0.818	rs73004975	chr19:19727152	A/G	cg03709012	chr19:19516395	GATAD2A	0.87	5.67	0.35	4.23e-8	LDL cholesterol;
SARC	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg25072359	chr17:41440525	NA	0.5	5.41	0.33	1.53e-7	Menopause (age at onset);
SARC	cis	rs2120019	1.000	rs35577967	chr15:75354621	G/A	cg00629941	chr15:75287862	SCAMP5	-0.65	-7.55	-0.44	9.64e-13	Blood trace element (Zn levels);
SARC	cis	rs10504229	0.679	rs2317991	chr8:58035080	C/T	cg20607798	chr8:58055168	NA	-0.52	-4.91	-0.31	1.69e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs2832191	0.716	rs1888440	chr21:30454484	C/T	cg24692254	chr21:30365293	RNF160	1.03	18.09	0.76	2.8e-46	Dental caries;
SARC	cis	rs4319547	0.656	rs28730465	chr12:122863864	A/C	cg05707623	chr12:122985044	ZCCHC8	0.57	6.41	0.39	7.89e-10	Body mass index;
SARC	cis	rs722599	0.748	rs61978948	chr14:75363369	G/A	cg08847533	chr14:75593920	NEK9	-0.45	-5.26	-0.33	3.29e-7	IgG glycosylation;
SARC	cis	rs12545912	0.863	rs10112821	chr8:9461883	A/G	cg21625330	chr8:9911636	MSRA	-0.52	-4.96	-0.31	1.38e-6	Multiple myeloma (hyperdiploidy);
SARC	cis	rs2522056	1.000	rs2706381	chr5:131810619	C/T	cg24060327	chr5:131705240	SLC22A5	0.55	5.77	0.35	2.57e-8	Lymphocyte counts;Fibrinogen;
SARC	cis	rs11792861	0.781	rs17729408	chr9:111740860	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.73	-8.72	-0.5	5.52e-16	Menarche (age at onset);
SARC	cis	rs34779708	0.966	rs1545757	chr10:35445588	A/T	cg03585969	chr10:35415529	CREM	0.39	4.86	0.3	2.14e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs72781680	0.716	rs2712068	chr2:23984000	A/G	cg06627628	chr2:24431161	ITSN2	-0.51	-5.46	-0.34	1.21e-7	Lymphocyte counts;
SARC	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-4.91	-0.31	1.71e-6	Total body bone mineral density;
SARC	cis	rs2204008	0.623	rs1315348	chr12:38163044	G/A	cg13010199	chr12:38710504	ALG10B	-0.61	-7.74	-0.45	3.09e-13	Bladder cancer;
SARC	cis	rs2769264	0.505	rs11801791	chr1:151387508	C/T	cg18801370	chr1:151430492	POGZ	0.83	8.96	0.51	1.05e-16	Blood trace element (Cu levels);
SARC	cis	rs113835537	0.808	rs10896128	chr11:66324529	G/A	cg24851651	chr11:66362959	CCS	0.44	4.74	0.3	3.73e-6	Airway imaging phenotypes;
SARC	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.41	-5.55	-0.34	7.6e-8	Personality dimensions;
SARC	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg18135555	chr8:22132992	PIWIL2	0.4	5.96	0.36	9.11e-9	Hypertriglyceridemia;
SARC	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg07701084	chr6:150067640	NUP43	0.4	5.3	0.33	2.67e-7	Lung cancer;
SARC	cis	rs1318878	0.565	rs11056438	chr12:15500176	T/C	cg08258403	chr12:15378311	NA	0.51	7.08	0.42	1.68e-11	Intelligence (multi-trait analysis);
SARC	cis	rs6570726	0.935	rs400968	chr6:145819718	A/G	cg23711669	chr6:146136114	FBXO30	0.76	11.37	0.6	3.96e-24	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.44	-0.39	6.58e-10	Joint mobility (Beighton score);
SARC	cis	rs360798	0.512	rs2710637	chr2:63173450	G/A	cg17519650	chr2:63277830	OTX1	0.39	5.03	0.31	9.69e-7	Coronary artery disease;
SARC	cis	rs611744	0.967	rs584555	chr8:109218612	C/G	cg21045802	chr8:109455806	TTC35	0.48	5.74	0.35	2.89e-8	Dupuytren's disease;
SARC	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg11764359	chr7:65958608	NA	0.64	7.54	0.44	1.06e-12	Aortic root size;
SARC	cis	rs2742234	0.590	rs2075912	chr10:43622217	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.38	-4.74	-0.3	3.68e-6	Hirschsprung disease;
SARC	cis	rs2075371	1.000	rs2075373	chr7:133984683	A/C	cg20476274	chr7:133979776	SLC35B4	0.62	8.49	0.49	2.43e-15	Mean platelet volume;
SARC	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg06420487	chr17:61919686	SMARCD2	0.47	5.03	0.31	9.65e-7	Height;
SARC	cis	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg20965017	chr5:231967	SDHA	-0.55	-5.26	-0.33	3.23e-7	Breast cancer;
SARC	cis	rs763121	0.853	rs138704	chr22:39133410	A/G	cg06022373	chr22:39101656	GTPBP1	0.89	12.69	0.64	2.15e-28	Menopause (age at onset);
SARC	cis	rs6456156	0.819	rs9457273	chr6:167520749	A/T	cg07741184	chr6:167504864	NA	-0.32	-5.8	-0.36	2.11e-8	Primary biliary cholangitis;
SARC	cis	rs1008375	0.966	rs2302393	chr4:17654341	G/A	cg16339924	chr4:17578868	LAP3	0.66	8.78	0.5	3.5e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7312933	0.703	rs10880259	chr12:42558003	T/C	cg19980929	chr12:42632907	YAF2	0.44	5.99	0.37	7.71e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs2061333	0.557	rs8104573	chr19:44603385	A/G	cg18700516	chr19:44507157	ZNF230	-0.53	-4.97	-0.31	1.3e-6	Alzheimer's disease;
SARC	cis	rs7666738	0.753	rs4699604	chr4:99056353	T/C	cg05340658	chr4:99064831	C4orf37	0.63	8.34	0.48	6.64e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6121246	0.529	rs6058196	chr20:30194714	A/T	cg13852791	chr20:30311386	BCL2L1	0.68	5.91	0.36	1.2e-8	Mean corpuscular hemoglobin;
SARC	cis	rs933688	1.000	rs2059208	chr5:90732065	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.94	12.01	0.62	3.5e-26	Smoking behavior;
SARC	cis	rs2204008	0.777	rs11179774	chr12:38219559	A/C	cg26384229	chr12:38710491	ALG10B	0.88	12.86	0.64	5.78e-29	Bladder cancer;
SARC	cis	rs17376456	1.000	rs13163610	chr5:93548877	A/C	cg25358565	chr5:93447407	FAM172A	1.35	14.25	0.68	1.48e-33	Diabetic retinopathy;
SARC	cis	rs561341	1.000	rs498391	chr17:30328704	G/A	cg12193833	chr17:30244370	NA	-0.43	-4.82	-0.3	2.6e-6	Hip circumference adjusted for BMI;
SARC	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-6.36	-0.38	1.03e-9	Personality dimensions;
SARC	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg23758822	chr17:41437982	NA	0.89	11.37	0.6	3.91e-24	Menopause (age at onset);
SARC	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg05368731	chr17:41323189	NBR1	0.79	9.53	0.53	2.09e-18	Menopause (age at onset);
SARC	cis	rs9388451	0.536	rs34725880	chr6:126155237	A/G	cg05901451	chr6:126070800	HEY2	-0.5	-6.04	-0.37	5.89e-9	Brugada syndrome;
SARC	cis	rs910316	0.967	rs4899545	chr14:75568138	A/G	cg06637938	chr14:75390232	RPS6KL1	0.52	7.35	0.43	3.42e-12	Height;
SARC	cis	rs7659604	0.702	rs6815790	chr4:122695385	A/C	cg06713675	chr4:122721982	EXOSC9	-0.49	-6.79	-0.41	9.11e-11	Type 2 diabetes;
SARC	cis	rs12200560	0.505	rs211179	chr6:97074103	A/G	cg06623918	chr6:96969491	KIAA0776	0.45	5.11	0.32	6.85e-7	Coronary heart disease;
SARC	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg22535103	chr8:58192502	C8orf71	-0.82	-9.32	-0.52	9.15e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs9513627	0.915	rs73556182	chr13:100122107	A/G	cg25919922	chr13:100150906	NA	-0.69	-5.22	-0.32	3.92e-7	Obesity-related traits;
SARC	cis	rs1401999	1.000	rs1533684	chr3:183635815	A/G	cg01324343	chr3:183735012	ABCC5	0.68	13.9	0.67	2.12e-32	Anterior chamber depth;
SARC	cis	rs8064299	0.967	rs878906	chr17:72769334	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.54	6.73	0.4	1.28e-10	Monocyte count;
SARC	cis	rs9325144	0.624	rs10506126	chr12:39123244	G/A	cg13010199	chr12:38710504	ALG10B	-0.5	-6.25	-0.38	1.91e-9	Morning vs. evening chronotype;
SARC	cis	rs16858210	0.520	rs35586421	chr3:183544607	G/A	cg03417191	chr3:183542750	MAP6D1	-0.63	-6.13	-0.37	3.71e-9	Menopause (age at onset);
SARC	cis	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg20965017	chr5:231967	SDHA	-0.51	-4.88	-0.3	1.94e-6	Breast cancer;
SARC	cis	rs9300255	0.602	rs1402274	chr12:123686224	T/C	cg05973401	chr12:123451056	ABCB9	0.52	5.89	0.36	1.34e-8	Neutrophil percentage of white cells;
SARC	cis	rs9611565	0.921	rs2235846	chr22:41741042	G/C	cg03806693	chr22:41940476	POLR3H	-0.69	-9.52	-0.53	2.32e-18	Vitiligo;
SARC	trans	rs6894249	1.000	rs6894249	chr5:131797547	A/G	cg04278597	chr1:63154320	DOCK7	0.51	6.28	0.38	1.66e-9	Asthma;
SARC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg24101359	chr6:42928495	GNMT	0.46	6.22	0.38	2.32e-9	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs12142240	0.698	rs17357683	chr1:46815378	C/T	cg10495392	chr1:46806563	NSUN4	0.65	6.83	0.41	7.25e-11	Menopause (age at onset);
SARC	cis	rs6582630	0.519	rs9738104	chr12:38338459	A/C	cg13010199	chr12:38710504	ALG10B	0.82	11.08	0.59	3.34e-23	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg05552183	chr6:42928497	GNMT	0.51	6.86	0.41	6.04e-11	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg26695010	chr11:65641043	EFEMP2	-0.55	-7.22	-0.43	7.33e-12	Breast cancer;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg17227355	chr12:4430526	C12orf5	0.5	6.46	0.39	5.91e-10	Lung adenocarcinoma;
SARC	cis	rs2988277	0.737	rs2949668	chr1:167434721	T/C	cg09179987	chr1:167433047	CD247	0.36	5.55	0.34	7.91e-8	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs2549003	1.000	rs6873426	chr5:131818631	G/T	cg21138405	chr5:131827807	IRF1	0.28	5.59	0.34	6.22e-8	Asthma (sex interaction);
SARC	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg26335602	chr6:28129616	ZNF389	-0.5	-5.69	-0.35	3.84e-8	Depression;
SARC	cis	rs7607369	0.536	rs7600248	chr2:219665963	C/T	cg02176678	chr2:219576539	TTLL4	-0.4	-6.16	-0.37	3.1e-9	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs2153535	0.580	rs4365970	chr6:8453813	C/T	cg07606381	chr6:8435919	SLC35B3	-0.78	-11.0	-0.58	6.2e-23	Motion sickness;
SARC	cis	rs7918232	0.941	rs4749230	chr10:27441218	C/T	cg14240646	chr10:27532245	ACBD5	-0.53	-5.08	-0.32	7.82e-7	Breast cancer;
SARC	cis	rs709400	0.659	rs3825566	chr14:103852725	C/T	cg26031613	chr14:104095156	KLC1	-0.81	-11.42	-0.6	2.82e-24	Body mass index;
SARC	cis	rs9473924	0.505	rs9463664	chr6:50902570	T/A	cg14470998	chr6:50812995	TFAP2B	0.76	7.13	0.42	1.27e-11	Body mass index;
SARC	cis	rs2204008	0.643	rs1315347	chr12:38162494	C/T	cg13010199	chr12:38710504	ALG10B	-0.63	-7.89	-0.46	1.16e-13	Bladder cancer;
SARC	cis	rs16976116	0.901	rs8030981	chr15:55499442	A/G	cg11288833	chr15:55489084	RSL24D1	0.62	6.02	0.37	6.78e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs11098499	0.865	rs9994730	chr4:120381564	A/C	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs4253772	0.591	rs6008545	chr22:46686375	C/T	cg24881330	chr22:46731750	TRMU	0.67	6.97	0.42	3.27e-11	LDL cholesterol;Cholesterol, total;
SARC	cis	rs9325144	0.555	rs11183215	chr12:38693127	G/A	cg26384229	chr12:38710491	ALG10B	-0.64	-8.57	-0.49	1.47e-15	Morning vs. evening chronotype;
SARC	cis	rs6570726	0.791	rs6570692	chr6:145904401	T/A	cg05347473	chr6:146136440	FBXO30	0.52	7.31	0.43	4.32e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs8180040	0.726	rs1869871	chr3:47023948	C/T	cg02527881	chr3:46936655	PTH1R	-0.32	-4.92	-0.31	1.64e-6	Colorectal cancer;
SARC	cis	rs965469	1.000	rs6051702	chr20:3251924	A/C	cg25506879	chr20:3388711	C20orf194	-0.5	-5.11	-0.32	6.73e-7	IFN-related cytopenia;
SARC	trans	rs36093844	0.800	rs112468922	chr11:85576694	A/G	cg15359163	chr5:122429178	PRDM6	-0.54	-6.6	-0.4	2.7e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs13256369	0.950	rs12548792	chr8:8568031	T/C	cg18904891	chr8:8559673	CLDN23	0.48	5.54	0.34	8.31e-8	Obesity-related traits;
SARC	cis	rs3087591	1.000	rs6505234	chr17:29688299	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.5	-6.06	-0.37	5.34e-9	Hip circumference;
SARC	trans	rs2055729	0.528	rs11987861	chr8:9742206	A/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-6.29	-0.38	1.53e-9	Multiple myeloma (hyperdiploidy);
SARC	cis	rs7312933	0.566	rs11181454	chr12:42746486	T/C	cg19980929	chr12:42632907	YAF2	-0.44	-6.52	-0.39	4.29e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs72781680	0.898	rs10490751	chr2:24001356	A/G	cg08917208	chr2:24149416	ATAD2B	0.75	7.09	0.42	1.56e-11	Lymphocyte counts;
SARC	trans	rs11098499	0.738	rs10026493	chr4:120384194	C/G	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	cis	rs9303401	0.659	rs62081316	chr17:56781499	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	11.87	0.61	9.72e-26	Cognitive test performance;
SARC	cis	rs5753618	0.539	rs2106294	chr22:31645759	C/T	cg13145458	chr22:31556086	RNF185	0.48	5.21	0.32	4.21e-7	Colorectal cancer;
SARC	cis	rs7766436	0.885	rs13220769	chr6:22596464	T/A	cg13666174	chr6:22585274	NA	-0.61	-8.0	-0.46	5.87e-14	Coronary artery disease;
SARC	cis	rs3768617	0.510	rs3768621	chr1:183090057	C/T	cg13390022	chr1:182993471	LAMC1	0.32	4.83	0.3	2.44e-6	Fuchs's corneal dystrophy;
SARC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg21248554	chr2:27665150	KRTCAP3	-0.32	-4.77	-0.3	3.26e-6	Total body bone mineral density;
SARC	cis	rs763121	0.889	rs9610971	chr22:38910810	C/T	cg06022373	chr22:39101656	GTPBP1	0.92	11.51	0.6	1.47e-24	Menopause (age at onset);
SARC	cis	rs1008375	1.000	rs6818639	chr4:17633049	A/G	cg27347728	chr4:17578864	LAP3	0.47	5.88	0.36	1.42e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10752881	1.000	rs10737235	chr1:182971816	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.84	0.58	2.03e-22	Colorectal cancer;
SARC	cis	rs79976124	0.837	rs12194087	chr6:66644399	T/A	cg07460842	chr6:66804631	NA	0.59	6.43	0.39	7.17e-10	Type 2 diabetes;
SARC	cis	rs3772130	0.583	rs34051021	chr3:121433005	C/A	cg20356878	chr3:121714668	ILDR1	0.39	6.16	0.37	3.21e-9	Cognitive performance;
SARC	cis	rs1983170	0.668	rs77687738	chr1:92016191	C/G	cg25838465	chr1:92012736	NA	0.59	5.63	0.35	5.1e-8	Eosinophil percentage of white cells;
SARC	cis	rs721399	1.000	rs1390360	chr8:18261493	G/A	cg18736775	chr8:18248649	NAT2	0.43	5.66	0.35	4.53e-8	Blood metabolite levels;
SARC	cis	rs787274	1.000	rs787294	chr9:115540424	T/C	cg13803584	chr9:115635662	SNX30	-0.83	-5.06	-0.31	8.49e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.47	5.33	0.33	2.32e-7	Renal function-related traits (BUN);
SARC	cis	rs17376456	0.877	rs17374627	chr5:93296306	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.62	5.64	0.35	4.86e-8	Diabetic retinopathy;
SARC	cis	rs7681440	0.967	rs1372517	chr4:90755909	G/A	cg06632027	chr4:90757378	SNCA	0.41	5.83	0.36	1.8e-8	Dementia with Lewy bodies;
SARC	cis	rs2304069	0.826	rs245076	chr5:149350648	C/T	cg12661370	chr5:149340060	SLC26A2	0.64	7.33	0.43	3.68e-12	HIV-1 control;
SARC	cis	rs6696846	0.515	rs12136320	chr1:205110946	T/C	cg21643547	chr1:205240462	TMCC2	-0.48	-5.93	-0.36	1.09e-8	Red blood cell count;
SARC	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg03433033	chr1:76189801	ACADM	0.53	7.63	0.45	6.08e-13	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9303401	0.659	rs11079358	chr17:56920949	G/T	cg25039879	chr17:56429692	SUPT4H1	0.65	6.13	0.37	3.77e-9	Cognitive test performance;
SARC	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg12463550	chr7:65579703	CRCP	0.48	5.24	0.32	3.65e-7	Aortic root size;
SARC	cis	rs17666538	1.000	rs59631161	chr8:587808	G/T	cg02524346	chr8:600233	NA	-0.82	-6.5	-0.39	4.95e-10	IgG glycosylation;
SARC	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg16028171	chr13:111560076	ANKRD10	0.69	5.09	0.32	7.3e-7	Obesity-related traits;
SARC	cis	rs2243480	1.000	rs709607	chr7:65449541	C/G	cg18252515	chr7:66147081	NA	1.14	9.55	0.53	1.95e-18	Diabetic kidney disease;
SARC	cis	rs11190604	1.000	rs12355721	chr10:102244911	C/T	cg07080220	chr10:102295463	HIF1AN	0.75	8.65	0.49	8.27e-16	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs9467711	0.720	rs3857546	chr6:26157762	C/T	cg21479132	chr6:26055353	NA	0.62	4.82	0.3	2.62e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9911578	1.000	rs304270	chr17:56802141	A/G	cg12560992	chr17:57184187	TRIM37	-0.84	-11.38	-0.6	3.71e-24	Intelligence (multi-trait analysis);
SARC	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg04317338	chr11:64019027	PLCB3	0.81	8.68	0.49	6.79e-16	Mean platelet volume;
SARC	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg18357526	chr6:26021779	HIST1H4A	-0.46	-5.74	-0.35	2.91e-8	Blood metabolite levels;
SARC	cis	rs6570726	1.000	rs436066	chr6:145847127	C/T	cg05347473	chr6:146136440	FBXO30	0.48	6.48	0.39	5.45e-10	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg11292385	chr22:29138453	CHEK2;HSCB	-0.6	-6.76	-0.4	1.1e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs710216	0.912	rs11537640	chr1:43424519	T/G	cg22176566	chr1:43424700	SLC2A1	0.51	5.08	0.32	7.72e-7	Red cell distribution width;
SARC	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg11644478	chr21:40555479	PSMG1	1.02	14.34	0.68	7.23e-34	Cognitive function;
SARC	cis	rs7605378	0.752	rs769960	chr2:200710706	G/T	cg23649088	chr2:200775458	C2orf69	-0.7	-9.36	-0.52	7.17e-18	Osteoporosis;
SARC	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg18404041	chr3:52824283	ITIH1	-0.43	-6.39	-0.39	8.92e-10	Bipolar disorder;
SARC	cis	rs6141769	0.542	rs28548407	chr20:31301495	T/C	cg17884169	chr20:31446444	EFCAB8	-0.44	-4.77	-0.3	3.19e-6	Subjective well-being;
SARC	cis	rs8017423	0.967	rs3825662	chr14:90723152	A/G	cg20276874	chr14:90721474	PSMC1	-0.39	-5.49	-0.34	1.06e-7	Mortality in heart failure;
SARC	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg05368731	chr17:41323189	NBR1	0.81	9.84	0.54	2.49e-19	Menopause (age at onset);
SARC	cis	rs7208859	0.673	rs3764421	chr17:29167653	A/C	cg13385521	chr17:29058706	SUZ12P	0.86	7.34	0.43	3.52e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs2273669	0.667	rs117941557	chr6:109298135	G/A	cg05315195	chr6:109294784	ARMC2	-0.59	-5.37	-0.33	1.93e-7	Prostate cancer;
SARC	cis	rs9815354	1.000	rs76471037	chr3:41799414	T/C	cg03022575	chr3:42003672	ULK4	0.6	5.81	0.36	2.07e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs10911232	0.507	rs28477876	chr1:183019882	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.1	0.55	4.11e-20	Hypertriglyceridemia;
SARC	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg18876405	chr7:65276391	NA	-0.72	-9.06	-0.51	5.37e-17	Aortic root size;
SARC	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg11987759	chr7:65425863	GUSB	0.47	5.58	0.34	6.68e-8	Aortic root size;
SARC	cis	rs67311347	1.000	rs7636719	chr3:40432084	C/T	cg24209194	chr3:40518798	ZNF619	0.6	7.59	0.45	7.87e-13	Renal cell carcinoma;
SARC	cis	rs1568889	0.838	rs11030185	chr11:28041904	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	14.68	0.69	5.6e-35	Bipolar disorder;
SARC	cis	rs3099143	1.000	rs3102709	chr15:77072260	C/T	cg21673338	chr15:77095150	SCAPER	-0.6	-5.06	-0.31	8.57e-7	Recalcitrant atopic dermatitis;
SARC	cis	rs72945132	0.598	rs61887432	chr11:70239065	A/C	cg05964544	chr11:70165517	PPFIA1	-0.66	-6.64	-0.4	2.14e-10	Coronary artery disease;
SARC	cis	rs7666738	0.830	rs7657982	chr4:99044015	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.86	0.5	2.07e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg00800038	chr16:89945340	TCF25	-0.79	-5.47	-0.34	1.19e-7	Skin colour saturation;
SARC	cis	rs4481887	1.000	rs9660769	chr1:248484558	C/G	cg00666640	chr1:248458726	OR2T12	-0.41	-6.37	-0.38	1.01e-9	Common traits (Other);
SARC	cis	rs870825	0.616	rs6814278	chr4:185644417	G/C	cg04058563	chr4:185651563	MLF1IP	0.8	11.35	0.6	4.56e-24	Blood protein levels;
SARC	trans	rs17685	0.712	rs10952842	chr7:75780413	G/A	cg19862616	chr7:65841803	NCRNA00174	0.6	7.38	0.44	2.77e-12	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs282587	0.569	rs432522	chr13:113400015	A/G	cg02820901	chr13:113351484	ATP11A	-0.48	-4.77	-0.3	3.21e-6	Glycated hemoglobin levels;
SARC	cis	rs12458462	1.000	rs12458462	chr18:77472436	C/A	cg23301140	chr18:77439876	CTDP1	0.61	7.83	0.46	1.74e-13	Monocyte count;
SARC	cis	rs1801251	0.929	rs10933409	chr2:233629386	A/G	cg25237894	chr2:233734115	C2orf82	0.37	4.8	0.3	2.81e-6	Coronary artery disease;
SARC	cis	rs765787	0.530	rs2554454	chr15:45521536	A/G	cg25801113	chr15:45476975	SHF	0.28	4.75	0.3	3.59e-6	Uric acid levels;
SARC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	19.74	0.79	1.22e-51	Prudent dietary pattern;
SARC	cis	rs453301	0.631	rs17700611	chr8:8793654	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.45	-0.39	6.55e-10	Joint mobility (Beighton score);
SARC	cis	rs6674176	0.597	rs4031031	chr1:44393533	C/T	cg13606994	chr1:44402422	ARTN	-0.32	-5.23	-0.32	3.81e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs9951602	0.850	rs56367211	chr18:76677563	G/T	cg00806245	chr18:76673096	NA	0.4	5.15	0.32	5.44e-7	Obesity-related traits;
SARC	cis	rs7927771	0.801	rs12798028	chr11:47604639	C/T	cg05585544	chr11:47624801	NA	-0.33	-4.77	-0.3	3.29e-6	Subjective well-being;
SARC	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg13902645	chr11:5959945	NA	-0.42	-5.44	-0.34	1.36e-7	DNA methylation (variation);
SARC	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg05368731	chr17:41323189	NBR1	-0.73	-8.75	-0.5	4.39e-16	Menopause (age at onset);
SARC	cis	rs2806561	0.704	rs674386	chr1:23521835	G/A	cg12483005	chr1:23474871	LUZP1	0.47	6.11	0.37	4.15e-9	Height;
SARC	cis	rs2486288	0.656	rs2413772	chr15:45549862	G/A	cg15395560	chr15:45543142	SLC28A2	0.29	5.7	0.35	3.7e-8	Glomerular filtration rate;
SARC	cis	rs151234	0.676	rs151320	chr16:28568678	A/G	cg01378222	chr16:28622494	SULT1A1	0.47	5.49	0.34	1.04e-7	Platelet distribution width;
SARC	cis	rs2559856	0.904	rs2695283	chr12:102089391	G/C	cg12924262	chr12:102091054	CHPT1	0.57	7.86	0.46	1.44e-13	Blood protein levels;
SARC	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg12311346	chr5:56204834	C5orf35	0.55	5.7	0.35	3.68e-8	Initial pursuit acceleration;
SARC	cis	rs796364	0.813	rs7565417	chr2:201057491	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.52	5.16	0.32	5.21e-7	Schizophrenia;
SARC	trans	rs1865760	0.929	rs9461224	chr6:25936402	G/T	cg02410754	chr1:32410520	NA	-0.53	-6.26	-0.38	1.8e-9	Height;
SARC	cis	rs41271473	0.526	rs12094319	chr1:228717836	G/C	cg16512390	chr1:228756714	NA	0.63	5.7	0.35	3.52e-8	Chronic lymphocytic leukemia;
SARC	cis	rs12586317	0.547	rs2254990	chr14:35465565	T/C	cg16230307	chr14:35515116	FAM177A1	1.02	11.85	0.61	1.18e-25	Psoriasis;
SARC	trans	rs877282	0.755	rs2486579	chr10:785647	G/A	cg22713356	chr15:30763199	NA	0.93	9.61	0.53	1.26e-18	Uric acid levels;
SARC	cis	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg06212747	chr3:49208901	KLHDC8B	0.5	6.29	0.38	1.56e-9	Resting heart rate;
SARC	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg23262073	chr20:60523788	NA	-0.38	-5.36	-0.33	2.02e-7	Body mass index;
SARC	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg03354898	chr7:1950403	MAD1L1	-0.37	-5.02	-0.31	1.02e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs1707322	1.000	rs10890372	chr1:46391020	T/G	cg03146154	chr1:46216737	IPP	0.46	5.54	0.34	7.97e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6582630	0.519	rs11495724	chr12:38337507	T/C	cg26384229	chr12:38710491	ALG10B	0.87	12.56	0.64	5.69e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs806795	0.605	rs809871	chr6:26256526	C/G	cg05868516	chr6:26286170	HIST1H4H	-0.45	-4.98	-0.31	1.23e-6	Mosquito bite size;
SARC	cis	rs7223966	1.000	rs55674647	chr17:61794195	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.49	-4.87	-0.3	2.06e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg14234805	chr20:37101345	RALGAPB	0.47	6.33	0.38	1.27e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs1153858	1.000	rs1049503	chr15:45653707	T/C	cg14582100	chr15:45693742	SPATA5L1	0.35	4.82	0.3	2.64e-6	Homoarginine levels;
SARC	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg05332525	chr7:65337924	VKORC1L1	-0.45	-5.02	-0.31	1.04e-6	Aortic root size;
SARC	cis	rs9911578	1.000	rs999431	chr17:56854441	A/G	cg05425664	chr17:57184151	TRIM37	-0.67	-8.13	-0.47	2.58e-14	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg08677398	chr8:58056175	NA	0.48	4.78	0.3	3.07e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs4481887	0.927	rs4916121	chr1:248432003	C/T	cg00666640	chr1:248458726	OR2T12	0.36	5.75	0.35	2.76e-8	Common traits (Other);
SARC	cis	rs1865760	0.963	rs1540273	chr6:25924158	T/C	cg10373733	chr6:25993375	NA	0.42	5.02	0.31	1.04e-6	Height;
SARC	cis	rs826838	0.967	rs1352123	chr12:39130992	T/C	cg26384229	chr12:38710491	ALG10B	-0.76	-11.59	-0.6	7.97e-25	Heart rate;
SARC	cis	rs6121246	0.657	rs74392247	chr20:30241737	C/T	cg13852791	chr20:30311386	BCL2L1	0.85	8.04	0.47	4.44e-14	Mean corpuscular hemoglobin;
SARC	cis	rs1008375	1.000	rs2872959	chr4:17677163	G/A	cg27347728	chr4:17578864	LAP3	-0.49	-6.06	-0.37	5.54e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs7844647	0.530	rs2959330	chr8:34164000	C/T	cg26394233	chr7:157444480	PTPRN2	0.44	6.61	0.4	2.6e-10	Body mass index;
SARC	cis	rs11574514	1.000	rs112526325	chr16:67761917	T/C	cg01866162	chr16:67596514	CTCF	0.97	5.75	0.35	2.76e-8	Crohn's disease;
SARC	cis	rs57506017	0.585	rs3800841	chr7:12272568	A/T	cg23422036	chr7:12250390	TMEM106B	0.46	5.96	0.36	9.38e-9	Neuroticism;
SARC	cis	rs9894429	0.646	rs7406522	chr17:79615396	G/T	cg18240062	chr17:79603768	NPLOC4	0.59	7.3	0.43	4.39e-12	Eye color traits;
SARC	cis	rs9914544	0.545	rs3803835	chr17:18793061	C/T	cg25390199	chr17:18761479	PRPSAP2	0.46	6.05	0.37	5.66e-9	Educational attainment (years of education);
SARC	cis	rs72781680	0.716	rs2551326	chr2:23982378	T/C	cg08917208	chr2:24149416	ATAD2B	0.54	5.64	0.35	4.93e-8	Lymphocyte counts;
SARC	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg11987759	chr7:65425863	GUSB	0.49	5.98	0.36	8.43e-9	Aortic root size;
SARC	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg23982607	chr1:1823379	GNB1	0.5	7.83	0.46	1.71e-13	Body mass index;
SARC	cis	rs950776	0.695	rs8025188	chr15:78912278	C/G	cg22563815	chr15:78856949	CHRNA5	-0.37	-6.22	-0.38	2.29e-9	Sudden cardiac arrest;
SARC	cis	rs8114671	0.562	rs7266550	chr20:33495510	C/T	cg24642439	chr20:33292090	TP53INP2	0.5	6.11	0.37	4.08e-9	Height;
SARC	trans	rs877282	1.000	rs112522746	chr10:772288	T/C	cg22713356	chr15:30763199	NA	1.03	9.92	0.54	1.45e-19	Uric acid levels;
SARC	cis	rs9467773	0.596	rs2494693	chr6:26619226	T/C	cg11502198	chr6:26597334	ABT1	0.62	8.48	0.49	2.55e-15	Intelligence (multi-trait analysis);
SARC	cis	rs7647973	0.961	rs11130186	chr3:49275828	A/G	cg07636037	chr3:49044803	WDR6	0.78	8.96	0.51	1.08e-16	Menarche (age at onset);
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg03723506	chr5:38557143	LIFR	0.51	6.74	0.4	1.23e-10	Lung adenocarcinoma;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg22256960	chr15:77711686	NA	-0.64	-7.37	-0.43	3.02e-12	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg00933542	chr6:150070202	PCMT1	-0.33	-5.51	-0.34	9.3e-8	Lung cancer;
SARC	cis	rs9814567	0.762	rs13075332	chr3:134329836	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.51	5.55	0.34	7.93e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs10276381	0.786	rs73300665	chr7:28227024	G/A	cg23620719	chr7:28220237	JAZF1	0.74	5.55	0.34	7.62e-8	Crohn's disease;
SARC	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg25072359	chr17:41440525	NA	0.51	6.05	0.37	5.78e-9	Menopause (age at onset);
SARC	cis	rs62244186	0.566	rs2135531	chr3:44881158	C/G	cg15687855	chr3:44754131	ZNF502	-0.33	-4.88	-0.3	1.95e-6	Depressive symptoms;
SARC	cis	rs5753618	0.504	rs7284622	chr22:31907985	G/A	cg02404636	chr22:31891804	SFI1	0.52	5.72	0.35	3.29e-8	Colorectal cancer;
SARC	cis	rs2908197	0.737	rs10230188	chr7:75980872	A/G	cg24580635	chr7:76178542	LOC100133091	-0.42	-4.86	-0.3	2.19e-6	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.73	6.7	0.4	1.57e-10	Platelet count;
SARC	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg03806693	chr22:41940476	POLR3H	-0.96	-12.23	-0.63	6.72e-27	Vitiligo;
SARC	cis	rs9467773	1.000	rs4871	chr6:26545632	G/A	cg11502198	chr6:26597334	ABT1	0.46	5.61	0.34	5.83e-8	Intelligence (multi-trait analysis);
SARC	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg25072359	chr17:41440525	NA	0.53	6.25	0.38	1.98e-9	Menopause (age at onset);
SARC	cis	rs865483	0.764	rs113593735	chr17:35755546	A/G	cg06561646	chr17:35873369	DUSP14	0.47	5.99	0.37	7.91e-9	Monocyte count;
SARC	cis	rs4969178	0.895	rs2292640	chr17:76396610	G/A	cg20026190	chr17:76395443	PGS1	0.4	5.37	0.33	1.94e-7	HDL cholesterol levels;
SARC	trans	rs61931739	0.534	rs11052984	chr12:34045904	T/C	cg26384229	chr12:38710491	ALG10B	0.75	10.68	0.57	6.46e-22	Morning vs. evening chronotype;
SARC	cis	rs865483	0.895	rs6607275	chr17:35833208	T/C	cg06561646	chr17:35873369	DUSP14	-0.49	-6.55	-0.39	3.6e-10	Monocyte count;
SARC	cis	rs737337	0.623	rs12463177	chr19:11341680	G/C	cg00586551	chr19:11347513	LOC55908;DOCK6	0.57	5.93	0.36	1.1e-8	HDL cholesterol;HDL cholesterol levels;
SARC	cis	rs1957429	0.808	rs1957436	chr14:65348207	T/G	cg23373153	chr14:65346875	NA	1.07	11.5	0.6	1.53e-24	Pediatric areal bone mineral density (radius);
SARC	trans	rs9650657	0.513	rs4841459	chr8:10782442	A/C	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.62	-0.45	6.47e-13	Neuroticism;
SARC	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-9.59	-0.53	1.43e-18	Chronic sinus infection;
SARC	cis	rs240764	0.782	rs239231	chr6:101105022	G/A	cg09795085	chr6:101329169	ASCC3	0.44	5.71	0.35	3.39e-8	Neuroticism;
SARC	trans	rs12310956	0.510	rs10772109	chr12:33839548	A/C	cg26384229	chr12:38710491	ALG10B	-0.64	-8.64	-0.49	9.36e-16	Morning vs. evening chronotype;
SARC	cis	rs11785693	0.862	rs17435605	chr8:4987302	A/G	cg26367366	chr8:4980734	NA	0.7	6.35	0.38	1.11e-9	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs3796352	1.000	rs13078971	chr3:53103645	G/C	cg07884673	chr3:53033167	SFMBT1	0.79	5.03	0.31	9.74e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-7.19	-0.43	8.82e-12	Gut microbiome composition (summer);
SARC	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg18252515	chr7:66147081	NA	1.29	11.21	0.59	1.32e-23	Diabetic kidney disease;
SARC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg05025164	chr4:1340916	KIAA1530	0.84	11.09	0.59	3.21e-23	Longevity;
SARC	cis	rs3741404	0.620	rs882147	chr11:63976689	T/A	cg04317338	chr11:64019027	PLCB3	0.41	4.95	0.31	1.43e-6	Platelet count;
SARC	cis	rs4588572	0.686	rs4703756	chr5:77683490	T/C	cg11547950	chr5:77652471	NA	0.4	4.87	0.3	2.11e-6	Triglycerides;
SARC	cis	rs796364	0.806	rs10931889	chr2:201101900	G/T	cg23649088	chr2:200775458	C2orf69	-0.67	-5.91	-0.36	1.23e-8	Schizophrenia;
SARC	cis	rs3931020	0.616	rs277380	chr1:75263088	T/C	cg10128416	chr1:75198403	TYW3;CRYZ	-0.48	-4.92	-0.31	1.62e-6	Resistin levels;
SARC	cis	rs11581859	0.613	rs3813786	chr1:99224250	T/G	cg20286094	chr1:99190917	SNX7	-0.43	-5.05	-0.31	8.81e-7	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs834603	0.575	rs1620852	chr7:47481786	A/T	cg23694490	chr7:47445681	TNS3	-0.32	-5.86	-0.36	1.58e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	trans	rs2540051	1.000	rs2540051	chr2:201571143	C/T	cg03403686	chr16:1254199	CACNA1H	0.46	6.46	0.39	6.17e-10	Intelligence;
SARC	cis	rs6840360	0.550	rs4696269	chr4:152481704	T/A	cg22705602	chr4:152727874	NA	-0.43	-6.64	-0.4	2.24e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7666738	0.830	rs10012271	chr4:99065154	A/C	cg05340658	chr4:99064831	C4orf37	0.65	8.7	0.5	6.15e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs673253	0.556	rs517191	chr1:44116466	G/A	cg19824710	chr1:43995379	PTPRF	0.39	4.81	0.3	2.71e-6	Intelligence (multi-trait analysis);
SARC	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg21782813	chr7:2030301	MAD1L1	0.34	5.32	0.33	2.45e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs7582180	0.629	rs6757754	chr2:100951273	C/T	cg14675211	chr2:100938903	LONRF2	-0.5	-7.47	-0.44	1.61e-12	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.97e-8	Aortic root size;
SARC	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.78	-0.5	3.56e-16	Alzheimer's disease;
SARC	cis	rs344364	0.511	rs1657132	chr16:1949924	C/T	cg26617929	chr16:1858877	NA	-0.71	-6.06	-0.37	5.5e-9	Glomerular filtration rate in chronic kidney disease;
SARC	cis	rs2576037	0.899	rs7233515	chr18:44585955	A/G	cg19077165	chr18:44547161	KATNAL2	-0.49	-6.62	-0.4	2.5e-10	Personality dimensions;
SARC	trans	rs9329221	0.686	rs35406700	chr8:10244593	A/G	cg08975724	chr8:8085496	FLJ10661	0.51	6.24	0.38	1.99e-9	Neuroticism;
SARC	cis	rs425277	1.000	rs262667	chr1:2082722	T/C	cg24578937	chr1:2090814	PRKCZ	0.3	5.84	0.36	1.76e-8	Height;
SARC	cis	rs523522	0.962	rs4766966	chr12:120942911	G/C	cg27279351	chr12:120934652	DYNLL1	0.71	8.85	0.5	2.22e-16	High light scatter reticulocyte count;
SARC	cis	rs2120019	0.938	rs35911108	chr15:75322179	G/A	cg12414181	chr15:75287860	SCAMP5	-0.48	-5.53	-0.34	8.36e-8	Blood trace element (Zn levels);
SARC	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg00933542	chr6:150070202	PCMT1	0.34	5.92	0.36	1.17e-8	Lung cancer;
SARC	cis	rs8523	0.901	rs2295602	chr6:11005842	A/G	cg13562911	chr6:11044106	ELOVL2	0.37	4.84	0.3	2.39e-6	Red blood cell fatty acid levels;
SARC	cis	rs11608355	0.521	rs1119271	chr12:109819727	A/T	cg19025524	chr12:109796872	NA	-0.42	-6.24	-0.38	2.04e-9	Neuroticism;
SARC	cis	rs950776	0.531	rs12915652	chr15:78831928	G/A	cg17108064	chr15:78857060	CHRNA5	0.29	4.9	0.31	1.76e-6	Sudden cardiac arrest;
SARC	cis	rs12474201	0.832	rs11695058	chr2:46978349	A/G	cg06386533	chr2:46925753	SOCS5	0.88	13.24	0.66	3.37e-30	Height;
SARC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.19	0.8	4.45e-53	Prudent dietary pattern;
SARC	cis	rs12142240	0.698	rs77185326	chr1:46818417	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-5.46	-0.34	1.22e-7	Menopause (age at onset);
SARC	cis	rs2204008	0.774	rs11495721	chr12:38337224	A/C	cg13010199	chr12:38710504	ALG10B	0.78	10.85	0.58	1.8e-22	Bladder cancer;
SARC	cis	rs6570726	0.811	rs375873	chr6:145812371	G/T	cg23711669	chr6:146136114	FBXO30	0.76	11.39	0.6	3.59e-24	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg23221052	chr5:179740743	GFPT2	-0.55	-6.79	-0.41	9.22e-11	Height;
SARC	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.12	0.37	3.93e-9	Height;
SARC	cis	rs6137287	0.668	rs6082329	chr20:21100138	G/T	cg22058250	chr20:21685842	PAX1	0.38	4.75	0.3	3.55e-6	Height;
SARC	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg12310025	chr6:25882481	NA	-0.46	-6.07	-0.37	5.11e-9	Intelligence (multi-trait analysis);
SARC	cis	rs3820928	0.692	rs17416354	chr2:227770844	A/G	cg11843606	chr2:227700838	RHBDD1	-0.56	-7.83	-0.46	1.68e-13	Pulmonary function;
SARC	cis	rs17608059	0.518	rs4792436	chr17:13972307	T/A	cg27005118	chr17:13972210	COX10	0.59	9.44	0.53	4.17e-18	Temperament;
SARC	cis	rs2997447	0.655	rs12059101	chr1:26384013	A/G	cg19633962	chr1:26362018	EXTL1	-0.81	-7.73	-0.45	3.26e-13	QRS complex (12-leadsum);
SARC	cis	rs524281	0.861	rs535395	chr11:65906534	A/G	cg14036092	chr11:66035641	RAB1B	0.51	5.49	0.34	1.06e-7	Electroencephalogram traits;
SARC	cis	rs870825	0.616	rs28497285	chr4:185629169	G/A	cg04058563	chr4:185651563	MLF1IP	0.81	11.25	0.59	9.68e-24	Blood protein levels;
SARC	cis	rs2425143	1.000	rs11699690	chr20:34271774	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-5.75	-0.35	2.78e-8	Blood protein levels;
SARC	cis	rs7917772	0.636	rs7911747	chr10:104528890	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-6.35	-0.38	1.1e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	trans	rs3780486	1.000	rs12342831	chr9:33124872	A/G	cg20290983	chr6:43655470	MRPS18A	1.0	13.78	0.67	5.34e-32	IgG glycosylation;
SARC	cis	rs11785400	0.753	rs9694286	chr8:143737157	G/T	cg10596483	chr8:143751796	JRK	0.55	6.92	0.41	4.38e-11	Schizophrenia;
SARC	cis	rs986417	0.818	rs10139251	chr14:60959958	A/C	cg27398547	chr14:60952738	C14orf39	0.88	8.66	0.49	7.84e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs2933343	0.951	rs789218	chr3:128592670	G/A	cg25356066	chr3:128598488	ACAD9	0.58	6.6	0.4	2.79e-10	IgG glycosylation;
SARC	cis	rs2028299	0.919	rs8026131	chr15:90417999	C/G	cg19708238	chr15:90437601	AP3S2	0.44	4.96	0.31	1.35e-6	Type 2 diabetes;
SARC	cis	rs995000	0.899	rs1168027	chr1:62970184	T/C	cg06896770	chr1:63153194	DOCK7	-0.89	-12.89	-0.65	4.52e-29	Triglyceride levels;
SARC	cis	rs1949733	0.523	rs16842560	chr4:8544238	G/A	cg11789530	chr4:8429930	ACOX3	-0.7	-7.82	-0.46	1.81e-13	Response to antineoplastic agents;
SARC	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg12564285	chr5:131593104	PDLIM4	0.46	6.48	0.39	5.31e-10	Blood metabolite levels;
SARC	cis	rs11105298	0.891	rs10858894	chr12:89914261	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-5.43	-0.34	1.39e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs17030434	0.834	rs28658020	chr4:154759048	C/T	cg14289246	chr4:154710475	SFRP2	-0.62	-7.14	-0.42	1.16e-11	Electrocardiographic conduction measures;
SARC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg09373136	chr17:61933544	TCAM1	-0.45	-6.09	-0.37	4.56e-9	Prudent dietary pattern;
SARC	cis	rs6570726	0.791	rs400329	chr6:145879442	A/T	cg23711669	chr6:146136114	FBXO30	0.83	13.68	0.67	1.11e-31	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2242116	0.932	rs4683301	chr3:46931478	A/T	cg02527881	chr3:46936655	PTH1R	0.43	7.31	0.43	4.14e-12	Birth weight;
SARC	cis	rs9436747	0.605	rs2025805	chr1:65949878	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.4	5.0	0.31	1.12e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs7927592	0.913	rs67947146	chr11:68314980	C/T	cg01657329	chr11:68192670	LRP5	-0.41	-4.82	-0.3	2.55e-6	Total body bone mineral density;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24452366	chr12:42719850	PPHLN1;ZCRB1	-0.58	-7.61	-0.45	6.68e-13	Smoking initiation;
SARC	cis	rs6963495	0.818	rs73190151	chr7:105152887	C/T	cg13798780	chr7:105162888	PUS7	0.6	5.5	0.34	9.98e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs1729951	0.575	rs16844362	chr3:136704008	T/C	cg15507776	chr3:136538369	TMEM22	0.49	5.34	0.33	2.18e-7	Neuroticism;
SARC	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg13206674	chr6:150067644	NUP43	0.43	5.51	0.34	9.63e-8	Lung cancer;
SARC	cis	rs2933343	1.000	rs789237	chr3:128636961	A/C	cg24203234	chr3:128598194	ACAD9	0.54	6.12	0.37	3.83e-9	IgG glycosylation;
SARC	cis	rs6909752	0.629	rs4712695	chr6:22556680	C/T	cg13666174	chr6:22585274	NA	0.41	5.57	0.34	7.14e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
SARC	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg03433033	chr1:76189801	ACADM	0.52	7.44	0.44	1.89e-12	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg00262122	chr8:11665843	FDFT1	-0.43	-5.2	-0.32	4.31e-7	Neuroticism;
SARC	trans	rs7937682	0.883	rs517982	chr11:111462687	T/C	cg18187862	chr3:45730750	SACM1L	0.53	6.28	0.38	1.69e-9	Primary sclerosing cholangitis;
SARC	cis	rs11122272	0.668	rs2749712	chr1:231537751	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.09	-0.55	4.24e-20	Hemoglobin concentration;
SARC	cis	rs10911232	0.507	rs10797816	chr1:182998486	A/T	cg13390022	chr1:182993471	LAMC1	0.32	4.82	0.3	2.61e-6	Hypertriglyceridemia;
SARC	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg05863683	chr7:1912471	MAD1L1	0.34	5.1	0.32	7.17e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs9640161	0.750	rs4395803	chr7:150025367	A/C	cg21361702	chr7:150065534	REPIN1	0.5	5.12	0.32	6.3e-7	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs7220711	1.000	rs7220711	chr17:41789965	C/T	cg26893861	chr17:41843967	DUSP3	-0.42	-5.3	-0.33	2.7e-7	Bone mineral density (spine);Bone mineral density (hip);
SARC	cis	rs2230307	0.656	rs11166389	chr1:100466279	G/A	cg24955406	chr1:100503596	HIAT1	0.7	5.87	0.36	1.49e-8	Carotid intima media thickness;
SARC	cis	rs55692411	0.537	rs35375092	chr3:50065274	G/A	cg14019146	chr3:50243930	SLC38A3	-0.36	-5.16	-0.32	5.27e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7666738	0.830	rs7663661	chr4:99014761	A/G	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs13161895	1.000	rs12654148	chr5:179438920	T/A	cg02702477	chr5:179499311	RNF130	-0.65	-6.46	-0.39	5.92e-10	LDL cholesterol;
SARC	cis	rs514024	0.656	rs537881	chr9:130485618	C/T	cg13643465	chr9:130375613	STXBP1	0.41	5.14	0.32	5.69e-7	Eating disorders (purging via substances);
SARC	cis	rs6835098	0.961	rs28709762	chr4:174099149	T/C	cg08422745	chr4:174089978	GALNT7	-0.73	-9.4	-0.52	5.41e-18	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs7412746	0.611	rs11204726	chr1:150743492	T/C	cg13175981	chr1:150552382	MCL1	-0.54	-6.57	-0.4	3.32e-10	Melanoma;
SARC	cis	rs193541	0.632	rs415417	chr5:122322884	G/A	cg19412675	chr5:122181750	SNX24	-0.49	-6.27	-0.38	1.75e-9	Glucose homeostasis traits;
SARC	cis	rs4561483	0.832	rs33645	chr16:11985201	T/C	cg08843971	chr16:11963173	GSPT1	-0.42	-5.11	-0.32	6.78e-7	Testicular germ cell tumor;
SARC	cis	rs28386778	0.700	rs12452767	chr17:62010503	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.93	-13.37	-0.66	1.2e-30	Prudent dietary pattern;
SARC	cis	rs6003958	1	rs6003958	chr22:24264089	T/G	cg04234412	chr22:24373322	LOC391322	0.59	6.52	0.39	4.44e-10	S-phenylmercapturic acid levels in smokers;
SARC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg04234412	chr22:24373322	LOC391322	-0.73	-10.46	-0.57	3.15e-21	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9326248	0.581	rs12225187	chr11:116793231	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.59	7.5	0.44	1.31e-12	Blood protein levels;
SARC	cis	rs6788895	1.000	rs6805481	chr3:150506351	A/C	cg09723797	chr3:150481914	SIAH2	0.89	5.49	0.34	1.06e-7	Breast cancer;
SARC	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg11987759	chr7:65425863	GUSB	0.5	6.22	0.38	2.29e-9	Aortic root size;
SARC	cis	rs2153535	0.580	rs2184585	chr6:8474168	G/A	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	cis	rs2204008	0.570	rs1315664	chr12:38138274	A/G	cg14851346	chr12:38532713	NA	-0.44	-5.16	-0.32	5.3e-7	Bladder cancer;
SARC	cis	rs9381040	0.626	rs2272986	chr6:41037778	C/T	cg02167203	chr6:41068553	NFYA;LOC221442	-0.41	-4.73	-0.3	3.81e-6	Alzheimer's disease (late onset);
SARC	cis	rs9916302	0.706	rs2879259	chr17:37410892	C/G	cg20243544	chr17:37824526	PNMT	0.57	6.2	0.38	2.6e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs2976388	0.692	rs2978983	chr8:143765842	A/G	cg06565975	chr8:143823917	SLURP1	0.3	5.1	0.32	7.07e-7	Urinary tract infection frequency;
SARC	cis	rs3008870	0.583	rs11208978	chr1:67442210	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.83	-8.83	-0.5	2.64e-16	Lymphocyte percentage of white cells;
SARC	cis	rs6912958	0.515	rs381782	chr6:88040649	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.37	6.38	0.39	9.58e-10	Monocyte percentage of white cells;
SARC	trans	rs62103177	0.810	rs62103197	chr18:77632923	G/A	cg05926928	chr17:57297772	GDPD1	1.14	9.58	0.53	1.57e-18	Opioid sensitivity;
SARC	cis	rs1341267	0.529	rs6492721	chr13:95258944	A/G	cg11661263	chr13:95253900	GPR180	-0.38	-4.79	-0.3	2.9e-6	Triglyceride levels;
SARC	cis	rs4711336	0.712	rs942641	chr6:33687007	G/A	cg15676125	chr6:33679581	C6orf125	0.44	5.38	0.33	1.78e-7	Height;
SARC	cis	rs4727027	0.870	rs1105261	chr7:148794442	T/G	cg23583168	chr7:148888333	NA	-0.73	-9.88	-0.54	1.91e-19	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs1691799	0.867	rs961049	chr12:66762591	A/C	cg16791601	chr12:66731901	HELB	0.68	9.9	0.54	1.65e-19	White blood cell count (basophil);
SARC	cis	rs7520050	0.833	rs1085242	chr1:46544224	T/A	cg06784218	chr1:46089804	CCDC17	-0.26	-4.82	-0.3	2.57e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs9611565	0.569	rs6002328	chr22:41710034	T/C	cg17376030	chr22:41985996	PMM1	0.52	6.43	0.39	7.34e-10	Vitiligo;
SARC	trans	rs9650657	0.836	rs11250067	chr8:10606954	T/C	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.63	-0.4	2.28e-10	Neuroticism;
SARC	cis	rs2997447	0.846	rs61775419	chr1:26395539	C/T	cg19633962	chr1:26362018	EXTL1	-0.67	-5.47	-0.34	1.18e-7	QRS complex (12-leadsum);
SARC	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg06634786	chr22:41940651	POLR3H	-0.51	-6.07	-0.37	5.04e-9	Vitiligo;
SARC	trans	rs1814175	0.645	rs1851853	chr11:49953434	C/T	cg15704280	chr7:45808275	SEPT13	-0.89	-14.17	-0.68	2.8e-33	Height;
SARC	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg06634786	chr22:41940651	POLR3H	0.56	6.55	0.39	3.63e-10	Vitiligo;
SARC	cis	rs6061231	0.755	rs11699160	chr20:60958651	T/C	cg23531748	chr20:60969906	CABLES2	0.45	5.41	0.33	1.56e-7	Colorectal cancer;
SARC	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg07636037	chr3:49044803	WDR6	1.0	18.01	0.76	5.23e-46	Parkinson's disease;
SARC	cis	rs155076	0.938	rs536209	chr13:21847714	C/T	cg14456004	chr13:21872349	NA	-1.0	-12.77	-0.64	1.13e-28	White matter hyperintensity burden;
SARC	cis	rs4642101	0.855	rs9836128	chr3:12845426	G/C	cg05775895	chr3:12838266	CAND2	0.74	12.08	0.62	2.01e-26	QRS complex (12-leadsum);
SARC	cis	rs35213789	0.853	rs34221396	chr7:69312104	A/G	cg10619644	chr7:69149951	AUTS2	0.37	4.73	0.3	3.85e-6	Childhood ear infection;
SARC	cis	rs8102137	1.000	rs7247779	chr19:30297919	G/C	cg27475126	chr19:30303651	CCNE1	-0.42	-5.9	-0.36	1.25e-8	Bladder cancer;
SARC	cis	rs7944584	0.545	rs7118178	chr11:47659135	G/A	cg20307385	chr11:47447363	PSMC3	0.73	9.54	0.53	1.98e-18	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs6570726	0.967	rs9403707	chr6:145800010	A/G	cg05347473	chr6:146136440	FBXO30	0.45	6.05	0.37	5.62e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg27286337	chr10:134555280	INPP5A	0.68	7.93	0.46	9.33e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs1008375	0.932	rs11941874	chr4:17666416	C/T	cg16339924	chr4:17578868	LAP3	-0.61	-7.62	-0.45	6.35e-13	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs3110496	0.650	rs563976	chr17:27905673	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.45	4.75	0.3	3.62e-6	Height;
SARC	cis	rs1729951	0.575	rs361237	chr3:136702414	A/G	cg15507776	chr3:136538369	TMEM22	0.45	4.91	0.31	1.7e-6	Neuroticism;
SARC	cis	rs826838	1.000	rs10506122	chr12:38699232	A/G	cg26384229	chr12:38710491	ALG10B	0.96	15.54	0.71	7.79e-38	Heart rate;
SARC	cis	rs6963495	0.818	rs114865717	chr7:105158526	C/T	cg13798780	chr7:105162888	PUS7	0.6	5.45	0.34	1.31e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs4868243	0.500	rs255318	chr5:172616029	C/T	cg18319967	chr5:173416427	C5orf47	0.76	5.14	0.32	5.74e-7	Resting heart rate;
SARC	cis	rs6540556	0.723	rs12116437	chr1:209897027	G/A	cg05527609	chr1:210001259	C1orf107	-0.64	-5.96	-0.36	9.19e-9	Red blood cell count;
SARC	cis	rs4713675	0.584	rs9380375	chr6:33682391	G/A	cg15676125	chr6:33679581	C6orf125	0.52	6.37	0.39	9.8e-10	Plateletcrit;
SARC	cis	rs72781680	1.000	rs72781632	chr2:24198342	A/C	cg08917208	chr2:24149416	ATAD2B	0.95	9.11	0.51	3.82e-17	Lymphocyte counts;
SARC	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg22920501	chr2:26401640	FAM59B	0.61	8.19	0.47	1.71e-14	Gut microbiome composition (summer);
SARC	cis	rs9814567	1.000	rs7433663	chr3:134235790	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-7.06	-0.42	1.93e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.79	10.24	0.56	1.45e-20	Prudent dietary pattern;
SARC	cis	rs4478037	0.822	rs9826234	chr3:33123832	A/C	cg19404215	chr3:33155277	CRTAP	0.53	4.74	0.3	3.69e-6	Major depressive disorder;
SARC	cis	rs9309473	1.000	rs2056486	chr2:73717567	G/T	cg20560298	chr2:73613845	ALMS1	-0.5	-6.04	-0.37	6.04e-9	Metabolite levels;
SARC	cis	rs634534	0.622	rs552130	chr11:65732800	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.56	8.66	0.49	7.86e-16	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs9400467	0.537	rs12191266	chr6:111528041	T/C	cg15721981	chr6:111408429	SLC16A10	0.69	5.76	0.35	2.67e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg18404041	chr3:52824283	ITIH1	-0.36	-5.45	-0.34	1.3e-7	Bipolar disorder;
SARC	cis	rs4642101	0.560	rs4535210	chr3:12839617	T/G	cg05775895	chr3:12838266	CAND2	0.69	10.08	0.55	4.65e-20	QRS complex (12-leadsum);
SARC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg07308232	chr7:1071921	C7orf50	-0.46	-5.67	-0.35	4.11e-8	Longevity;Endometriosis;
SARC	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg12310025	chr6:25882481	NA	-0.38	-4.96	-0.31	1.33e-6	Intelligence (multi-trait analysis);
SARC	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg09455208	chr3:40491958	NA	0.38	5.47	0.34	1.14e-7	Renal cell carcinoma;
SARC	cis	rs4144743	0.938	rs55677902	chr17:45322572	G/T	cg18085866	chr17:45331354	ITGB3	-0.7	-7.15	-0.42	1.11e-11	Body mass index;
SARC	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg11062466	chr8:58055876	NA	0.53	5.53	0.34	8.39e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs12926788	0.689	rs1862450	chr16:24856775	A/G	cg04756594	chr16:24857601	SLC5A11	-0.4	-5.34	-0.33	2.25e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	trans	rs6600671	1.000	rs1986111	chr1:121204788	C/T	cg00646200	chr1:148855367	NA	0.51	7.09	0.42	1.62e-11	Hip geometry;
SARC	cis	rs721399	0.962	rs1495746	chr8:18262842	C/T	cg18736775	chr8:18248649	NAT2	0.39	4.91	0.31	1.71e-6	Blood metabolite levels;
SARC	cis	rs1056053	0.514	rs3127334	chr6:166574246	G/A	cg11088901	chr6:166572345	T	-0.4	-5.27	-0.33	3.07e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg18107960	chr5:76787392	WDR41	-0.49	-6.65	-0.4	2.1e-10	Thyroid stimulating hormone;
SARC	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg08280861	chr8:58055591	NA	0.6	5.28	0.33	2.92e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs916888	0.610	rs199444	chr17:44818276	T/C	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.52	6.12	0.37	3.84e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg11987759	chr7:65425863	GUSB	0.48	5.88	0.36	1.42e-8	Aortic root size;
SARC	cis	rs10870270	0.830	rs10781571	chr10:133774316	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.84	-10.21	-0.56	1.77e-20	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs33912345	0.695	rs1313245	chr14:60878544	A/T	cg27398547	chr14:60952738	C14orf39	-0.39	-4.73	-0.3	3.85e-6	Glaucoma (high intraocular pressure);
SARC	cis	rs4727027	1.000	rs4727027	chr7:148869277	C/T	cg23583168	chr7:148888333	NA	-0.73	-11.26	-0.59	9.2e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	trans	rs1814175	0.935	rs6485999	chr11:49658986	G/C	cg15704280	chr7:45808275	SEPT13	-0.92	-15.93	-0.72	3.71e-39	Height;
SARC	cis	rs761746	0.960	rs5753680	chr22:31930972	A/G	cg15162869	chr22:32027605	PISD	0.42	5.65	0.35	4.66e-8	Intelligence;
SARC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg26338869	chr17:61819248	STRADA	0.62	8.23	0.47	1.35e-14	Prudent dietary pattern;
SARC	cis	rs17270561	0.609	rs9379785	chr6:25726213	G/A	cg17691542	chr6:26056736	HIST1H1C	0.58	7.09	0.42	1.59e-11	Iron status biomarkers;
SARC	cis	rs1497406	0.744	rs6677710	chr1:16507618	A/G	cg20430773	chr1:16534157	ARHGEF19	0.51	7.69	0.45	4.05e-13	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg19077165	chr18:44547161	KATNAL2	-0.52	-7.11	-0.42	1.38e-11	Personality dimensions;
SARC	cis	rs7607369	0.791	rs12468043	chr2:219354197	C/A	cg02176678	chr2:219576539	TTLL4	0.46	7.12	0.42	1.33e-11	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs1448094	0.512	rs6539931	chr12:86247473	C/T	cg02569458	chr12:86230093	RASSF9	0.38	5.39	0.33	1.71e-7	Major depressive disorder;
SARC	cis	rs5762813	0.566	rs28360615	chr22:29338656	G/C	cg02153584	chr22:29168773	CCDC117	0.65	6.82	0.41	7.55e-11	Hematocrit;Hemoglobin concentration;
SARC	cis	rs11711311	1.000	rs891574	chr3:113537639	C/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.69	8.61	0.49	1.12e-15	IgG glycosylation;
SARC	cis	rs2273669	0.504	rs75555274	chr6:109478385	G/A	cg05315195	chr6:109294784	ARMC2	-0.6	-5.01	-0.31	1.08e-6	Prostate cancer;
SARC	cis	rs4566357	0.615	rs12618793	chr2:227909552	T/C	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.86	-0.36	1.61e-8	Coronary artery disease;
SARC	cis	rs1401999	1.000	rs13317532	chr3:183641669	G/C	cg01324343	chr3:183735012	ABCC5	0.67	13.84	0.67	3.53e-32	Anterior chamber depth;
SARC	cis	rs1707322	0.752	rs11211168	chr1:46163647	C/T	cg03146154	chr1:46216737	IPP	0.52	6.23	0.38	2.12e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1348850	0.914	rs1453370	chr2:178327727	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.71	9.08	0.51	4.77e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs5771069	0.931	rs5771222	chr22:50445704	C/T	cg03721641	chr22:50451245	IL17REL	-0.31	-4.93	-0.31	1.55e-6	Ulcerative colitis;
SARC	cis	rs7828089	0.967	rs7828414	chr8:22264585	T/C	cg12081754	chr8:22256438	SLC39A14	0.44	5.71	0.35	3.39e-8	Verbal declarative memory;
SARC	cis	rs344364	0.529	rs186941	chr16:1930088	T/C	cg26617929	chr16:1858877	NA	0.71	6.13	0.37	3.67e-9	Glomerular filtration rate in chronic kidney disease;
SARC	cis	rs734999	0.545	rs4648356	chr1:2709164	C/A	cg00980319	chr1:2560884	MMEL1	-0.34	-4.91	-0.31	1.73e-6	Ulcerative colitis;
SARC	cis	rs12142240	0.698	rs6695043	chr1:46844530	A/G	cg14993813	chr1:46806288	NSUN4	0.52	5.5	0.34	1.02e-7	Menopause (age at onset);
SARC	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg02841227	chr6:26021843	HIST1H4A	0.5	5.54	0.34	8.24e-8	Intelligence (multi-trait analysis);
SARC	cis	rs10870270	0.956	rs7904594	chr10:133734671	C/T	cg26149184	chr10:133730230	NA	0.47	5.39	0.33	1.68e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs2637266	1.000	rs2637266	chr10:78331318	C/T	cg24693376	chr10:77541764	C10orf11	0.34	4.98	0.31	1.26e-6	Pulmonary function;
SARC	cis	rs6754311	0.564	rs1960171	chr2:136815388	C/T	cg07169764	chr2:136633963	MCM6	0.43	5.38	0.33	1.84e-7	Mosquito bite size;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg00586367	chr8:74790437	UBE2W	-0.6	-6.88	-0.41	5.4e-11	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs9392918	0.935	rs9392919	chr6:7711052	A/G	cg23089261	chr6:7723385	NA	0.39	5.07	0.32	8.01e-7	Height;
SARC	trans	rs9354308	0.933	rs2022856	chr6:66568235	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.58	6.82	0.41	7.77e-11	Metabolite levels;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg25808101	chr3:48282816	ZNF589	0.47	6.5	0.39	4.88e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs3796352	1.000	rs2336541	chr3:52974630	G/C	cg27565382	chr3:53032988	SFMBT1	0.83	5.57	0.34	7.16e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs9309473	0.607	rs2421489	chr2:73593448	A/G	cg20560298	chr2:73613845	ALMS1	-0.58	-7.1	-0.42	1.46e-11	Metabolite levels;
SARC	cis	rs7927771	0.690	rs35496532	chr11:47450338	C/T	cg20307385	chr11:47447363	PSMC3	-0.58	-7.33	-0.43	3.86e-12	Subjective well-being;
SARC	cis	rs9818758	0.556	rs9814987	chr3:49207849	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.71	-6.41	-0.39	8.01e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs12421382	0.659	rs11604254	chr11:109392413	G/A	cg16359550	chr11:109292809	C11orf87	0.37	5.45	0.34	1.31e-7	Schizophrenia;
SARC	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg22535103	chr8:58192502	C8orf71	-0.59	-6.27	-0.38	1.69e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4141404	0.851	rs8135417	chr22:31559255	G/A	cg13145458	chr22:31556086	RNF185	0.53	6.48	0.39	5.52e-10	Paclitaxel-induced neuropathy;
SARC	cis	rs35110281	0.712	rs1454648	chr21:45053815	C/T	cg21573476	chr21:45109991	RRP1B	-0.53	-7.78	-0.45	2.29e-13	Mean corpuscular volume;
SARC	cis	rs2153535	0.580	rs7341201	chr6:8470270	T/C	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	trans	rs61931739	0.534	rs11052973	chr12:34029708	A/G	cg26384229	chr12:38710491	ALG10B	0.86	12.5	0.63	9.09e-28	Morning vs. evening chronotype;
SARC	cis	rs9916302	0.904	rs1619021	chr17:37739274	G/A	cg00129232	chr17:37814104	STARD3	-0.67	-7.92	-0.46	9.86e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg05368731	chr17:41323189	NBR1	0.79	9.83	0.54	2.62e-19	Menopause (age at onset);
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23794323	chr6:116937974	RSPH4A	-0.51	-6.26	-0.38	1.85e-9	Fibrinogen levels;
SARC	cis	rs9902453	0.845	rs58575982	chr17:28221776	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	6.89	0.41	5.12e-11	Coffee consumption (cups per day);
SARC	cis	rs2228479	0.850	rs1800355	chr16:89813194	C/T	cg26513180	chr16:89883248	FANCA	0.72	4.75	0.3	3.53e-6	Skin colour saturation;
SARC	cis	rs11676348	1.000	rs11676348	chr2:219010146	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.43	-5.57	-0.34	7.03e-8	Ulcerative colitis;
SARC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg26338869	chr17:61819248	STRADA	-0.77	-10.22	-0.56	1.69e-20	Prudent dietary pattern;
SARC	cis	rs17826219	0.561	rs4085382	chr17:29071202	T/C	cg13385521	chr17:29058706	SUZ12P	0.84	7.72	0.45	3.43e-13	Body mass index;
SARC	cis	rs6484504	0.576	rs441975	chr11:31233351	C/T	cg26647111	chr11:31128758	NA	-0.4	-5.23	-0.32	3.72e-7	Red blood cell count;
SARC	cis	rs34783982	0.881	rs36116028	chr15:89500629	A/G	cg26213453	chr15:89455860	MFGE8	0.27	4.78	0.3	3.14e-6	Squamous cell lung carcinoma;
SARC	cis	rs3008870	1.000	rs2815370	chr1:67503727	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.89	-10.78	-0.58	3.12e-22	Lymphocyte percentage of white cells;
SARC	cis	rs765787	0.530	rs1648287	chr15:45516956	T/C	cg24006582	chr15:45444508	DUOX1	-0.56	-7.42	-0.44	2.14e-12	Uric acid levels;
SARC	cis	rs644799	0.562	rs669973	chr11:95571839	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.49	5.93	0.36	1.06e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs12950390	0.853	rs17773010	chr17:45858297	C/T	cg24803719	chr17:45855879	NA	-0.47	-7.63	-0.45	6.05e-13	IgG glycosylation;
SARC	cis	rs73198271	0.740	rs10112989	chr8:8647334	A/C	cg06636001	chr8:8085503	FLJ10661	-0.47	-5.0	-0.31	1.15e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs2425143	0.818	rs11167280	chr20:34560526	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-5.4	-0.33	1.62e-7	Blood protein levels;
SARC	cis	rs826838	0.935	rs1719855	chr12:39127242	C/T	cg13010199	chr12:38710504	ALG10B	-0.63	-8.88	-0.5	1.87e-16	Heart rate;
SARC	cis	rs4555082	0.872	rs7153832	chr14:105730563	G/T	cg10792982	chr14:105748885	BRF1	0.53	7.9	0.46	1.1e-13	Mean platelet volume;Platelet distribution width;
SARC	cis	rs9303401	0.580	rs12603808	chr17:56578508	T/G	cg25039879	chr17:56429692	SUPT4H1	0.67	6.04	0.37	5.9e-9	Cognitive test performance;
SARC	cis	rs2153535	0.601	rs9505451	chr6:8469950	C/T	cg23788917	chr6:8435910	SLC35B3	0.64	8.39	0.48	4.57e-15	Motion sickness;
SARC	cis	rs7726839	0.561	rs11955068	chr5:582324	C/T	cg09021430	chr5:549028	NA	-0.48	-6.36	-0.38	1.08e-9	Obesity-related traits;
SARC	cis	rs4466137	0.953	rs7735476	chr5:83015140	G/C	cg16102102	chr5:83017553	HAPLN1	-0.75	-9.27	-0.52	1.27e-17	Prostate cancer;
SARC	trans	rs2347867	0.771	rs9479143	chr6:152245465	G/A	cg12042060	chr8:4846849	CSMD1	-0.4	-6.3	-0.38	1.49e-9	Age at first birth;
SARC	cis	rs7412746	0.646	rs10399947	chr1:150861960	G/A	cg13175981	chr1:150552382	MCL1	-0.5	-6.04	-0.37	5.98e-9	Melanoma;
SARC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.97	10.66	0.57	7.33e-22	Platelet count;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg17177017	chr17:74668252	NA	0.74	6.26	0.38	1.78e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2228479	1.000	rs11642267	chr16:89957635	T/C	cg00800038	chr16:89945340	TCF25	-0.75	-5.23	-0.32	3.82e-7	Skin colour saturation;
SARC	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg25072359	chr17:41440525	NA	0.51	6.11	0.37	4.18e-9	Menopause (age at onset);
SARC	cis	rs12497850	0.931	rs7616815	chr3:48779715	C/T	cg03060546	chr3:49711283	APEH	0.38	4.78	0.3	3.11e-6	Parkinson's disease;
SARC	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg05255149	chr17:80675120	FN3KRP	0.45	5.0	0.31	1.1e-6	Glycated hemoglobin levels;
SARC	cis	rs1784581	0.546	rs1954917	chr6:162447490	C/T	cg17173639	chr6:162384350	PARK2	0.5	6.38	0.39	9.35e-10	Itch intensity from mosquito bite;
SARC	cis	rs911555	0.755	rs12436729	chr14:103929889	G/C	cg12935359	chr14:103987150	CKB	0.38	5.25	0.33	3.39e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9902453	0.689	rs56788338	chr17:28186557	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	7.57	0.44	8.93e-13	Coffee consumption (cups per day);
SARC	trans	rs10519937	1.000	rs6595764	chr5:126724157	C/T	cg26526953	chr19:1921199	SCAMP4	0.63	6.39	0.39	9.11e-10	IgG glycosylation;
SARC	cis	rs1003719	0.613	rs9978998	chr21:38535848	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.48	-0.53	3.11e-18	Eye color traits;
SARC	cis	rs4132509	0.553	rs12140414	chr1:243674387	A/G	cg21452805	chr1:244014465	NA	0.51	5.37	0.33	1.89e-7	RR interval (heart rate);
SARC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.34	5.06	0.31	8.43e-7	Bipolar disorder;
SARC	cis	rs10465746	0.746	rs6699501	chr1:84389993	A/G	cg10977910	chr1:84465055	TTLL7	0.43	5.15	0.32	5.49e-7	Obesity-related traits;
SARC	cis	rs11122272	0.735	rs2486740	chr1:231517552	T/C	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs634534	0.562	rs642293	chr11:65730217	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.4	5.07	0.32	8.19e-7	Sum eosinophil basophil counts;Eosinophil counts;
SARC	trans	rs11098499	0.909	rs35165976	chr4:120325630	G/A	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	cis	rs4727027	0.933	rs62505074	chr7:148834780	C/T	cg23583168	chr7:148888333	NA	-0.74	-11.01	-0.59	5.64e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.5	5.78	0.35	2.4e-8	Prudent dietary pattern;
SARC	cis	rs11509153	0.648	rs1019308	chr7:12251726	G/C	cg23422036	chr7:12250390	TMEM106B	0.48	6.21	0.38	2.36e-9	Residual cognition;
SARC	cis	rs12142240	0.698	rs56063031	chr1:46825433	C/T	cg10495392	chr1:46806563	NSUN4	0.65	6.8	0.41	8.89e-11	Menopause (age at onset);
SARC	cis	rs35213789	0.722	rs41858	chr7:69007901	G/A	cg10619644	chr7:69149951	AUTS2	0.4	5.26	0.33	3.27e-7	Childhood ear infection;
SARC	cis	rs13202913	0.518	rs13205543	chr6:151813779	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.63	5.43	0.34	1.43e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	trans	rs1814175	0.817	rs4881648	chr11:49812901	A/G	cg03929089	chr4:120376271	NA	-0.9	-14.66	-0.69	6.51e-35	Height;
SARC	cis	rs9513627	1.000	rs73556178	chr13:100121947	T/C	cg25919922	chr13:100150906	NA	-0.69	-5.22	-0.32	3.92e-7	Obesity-related traits;
SARC	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg13012494	chr21:47604986	C21orf56	-0.56	-6.69	-0.4	1.62e-10	Testicular germ cell tumor;
SARC	cis	rs3762637	1.000	rs9879508	chr3:122136480	A/G	cg24169773	chr3:122142474	KPNA1	-0.54	-5.52	-0.34	8.94e-8	LDL cholesterol levels;
SARC	cis	rs9916302	0.808	rs6503515	chr17:37606433	G/T	cg07936489	chr17:37558343	FBXL20	-0.69	-9.02	-0.51	7.32e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg08219700	chr8:58056026	NA	0.59	6.26	0.38	1.8e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs34172651	0.502	rs12930727	chr16:24838497	G/T	cg00339695	chr16:24857497	SLC5A11	-0.33	-5.08	-0.32	7.56e-7	Intelligence (multi-trait analysis);
SARC	trans	rs11722228	0.522	rs1109472	chr4:10134448	C/G	cg26043149	chr18:55253948	FECH	0.66	7.82	0.46	1.78e-13	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs7712401	0.601	rs30058	chr5:122297703	A/G	cg19412675	chr5:122181750	SNX24	0.4	5.13	0.32	5.98e-7	Mean platelet volume;
SARC	cis	rs950169	0.922	rs6603022	chr15:84830170	T/C	cg17507749	chr15:85114479	UBE2QP1	-0.76	-8.67	-0.49	7.34e-16	Schizophrenia;
SARC	cis	rs9660992	0.573	rs12140703	chr1:205182865	G/C	cg21545522	chr1:205238299	TMCC2	0.4	5.39	0.33	1.73e-7	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs710216	0.917	rs1681859	chr1:43411829	G/A	cg22176566	chr1:43424700	SLC2A1	0.54	5.28	0.33	2.92e-7	Red cell distribution width;
SARC	cis	rs41271473	0.526	rs1925720	chr1:228728377	G/C	cg10167378	chr1:228756711	NA	0.6	5.3	0.33	2.69e-7	Chronic lymphocytic leukemia;
SARC	cis	rs7714584	1.000	rs17800987	chr5:150323428	A/G	cg22134413	chr5:150180641	NA	0.77	6.65	0.4	2.09e-10	Crohn's disease;
SARC	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg12463550	chr7:65579703	CRCP	0.48	5.24	0.32	3.65e-7	Aortic root size;
SARC	cis	rs870825	0.616	rs7682505	chr4:185640648	C/T	cg04058563	chr4:185651563	MLF1IP	0.81	11.48	0.6	1.8e-24	Blood protein levels;
SARC	cis	rs11687170	0.882	rs11688634	chr2:237058905	T/C	cg19324714	chr2:237145437	ASB18	0.49	4.89	0.31	1.89e-6	Educational attainment;Educational attainment (years of education);
SARC	cis	rs11920354	0.642	rs9812878	chr3:47182787	T/C	cg27129171	chr3:47204927	SETD2	0.66	8.79	0.5	3.45e-16	Granulocyte count;Sum neutrophil eosinophil counts;
SARC	cis	rs4509693	0.765	rs10786604	chr10:102495302	C/G	cg11654490	chr10:102505349	PAX2	0.52	4.83	0.3	2.51e-6	Alzheimer's disease;
SARC	cis	rs17345786	1.000	rs55641278	chr3:101290577	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.47	5.19	0.32	4.5e-7	Colonoscopy-negative controls vs population controls;
SARC	cis	rs13095912	0.962	rs1568664	chr3:185312231	T/C	cg11274856	chr3:185301563	NA	0.34	4.75	0.3	3.56e-6	Systolic blood pressure;
SARC	cis	rs9309473	0.950	rs6726694	chr2:73847230	A/G	cg20560298	chr2:73613845	ALMS1	-0.43	-5.27	-0.33	3.04e-7	Metabolite levels;
SARC	cis	rs6940638	0.688	rs6921388	chr6:27080205	A/G	cg12826209	chr6:26865740	GUSBL1	0.55	6.03	0.37	6.46e-9	Intelligence (multi-trait analysis);
SARC	cis	rs55823223	0.648	rs11867560	chr17:73857206	A/G	cg10935138	chr17:73851978	WBP2	0.52	5.62	0.35	5.51e-8	Psoriasis;
SARC	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs941408	1.000	rs941406	chr19:2803623	A/G	cg00079169	chr19:2811669	THOP1	0.48	5.29	0.33	2.85e-7	Total cholesterol levels;
SARC	cis	rs13191362	1.000	rs36042757	chr6:163004744	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.56	5.41	0.33	1.53e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs13191362	0.507	rs2849525	chr6:163126652	A/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.44	-4.76	-0.3	3.43e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg12000995	chr2:27665139	KRTCAP3	-0.3	-4.77	-0.3	3.24e-6	Total body bone mineral density;
SARC	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg25894440	chr7:65020034	NA	0.79	5.95	0.36	9.65e-9	Diabetic kidney disease;
SARC	cis	rs2777491	0.915	rs9302109	chr15:41612180	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.74	-10.89	-0.58	1.32e-22	Ulcerative colitis;
SARC	cis	rs6831352	0.918	rs2851253	chr4:100043505	G/T	cg12011299	chr4:100065546	ADH4	-0.33	-5.46	-0.34	1.21e-7	Alcohol dependence;
SARC	cis	rs3857536	0.813	rs1029401	chr6:66952268	A/G	cg07460842	chr6:66804631	NA	-0.45	-5.07	-0.32	8.17e-7	Blood trace element (Cu levels);
SARC	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg10435706	chr6:150039699	LATS1	0.36	4.8	0.3	2.88e-6	Lung cancer;
SARC	cis	rs2439831	0.850	rs12442297	chr15:44168470	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.95	7.97	0.46	7e-14	Lung cancer in ever smokers;
SARC	cis	rs524281	0.861	rs485857	chr11:65959519	A/G	cg14036092	chr11:66035641	RAB1B	-0.49	-5.4	-0.33	1.62e-7	Electroencephalogram traits;
SARC	cis	rs2180341	0.920	rs6916990	chr6:127698759	G/A	cg27446573	chr6:127587934	RNF146	1.06	14.34	0.68	7.2e-34	Breast cancer;
SARC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.59	7.79	0.45	2.16e-13	Lymphocyte counts;
SARC	cis	rs9810259	0.648	rs35939242	chr3:12301893	A/C	cg04748988	chr3:12329223	PPARG	-0.38	-4.85	-0.3	2.26e-6	Platelet count;
SARC	cis	rs13256369	0.802	rs2280560	chr8:8560602	C/T	cg18904891	chr8:8559673	CLDN23	0.48	5.38	0.33	1.79e-7	Obesity-related traits;
SARC	cis	rs6807306	1.000	rs9839570	chr3:167349983	T/C	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.49	4.78	0.3	3.15e-6	Mean platelet volume;
SARC	cis	rs9325144	0.560	rs10785573	chr12:38654166	G/A	cg13010199	chr12:38710504	ALG10B	-0.56	-6.97	-0.42	3.3e-11	Morning vs. evening chronotype;
SARC	cis	rs1670533	1.000	rs2045066	chr4:1052401	C/T	cg27284194	chr4:1044797	NA	0.45	4.94	0.31	1.52e-6	Recombination rate (females);
SARC	cis	rs2576037	0.796	rs2576038	chr18:44582200	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.69	-10.16	-0.55	2.54e-20	Personality dimensions;
SARC	cis	rs1707322	1.000	rs10890353	chr1:46298383	G/T	cg03146154	chr1:46216737	IPP	0.47	5.65	0.35	4.76e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9309473	0.500	rs2421664	chr2:73858881	C/T	cg20560298	chr2:73613845	ALMS1	0.49	6.55	0.39	3.57e-10	Metabolite levels;
SARC	cis	rs9911578	1.000	rs11079365	chr17:56945430	T/C	cg12560992	chr17:57184187	TRIM37	0.86	11.82	0.61	1.41e-25	Intelligence (multi-trait analysis);
SARC	cis	rs1707322	1.000	rs10890378	chr1:46410657	A/G	cg06784218	chr1:46089804	CCDC17	-0.34	-5.88	-0.36	1.39e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9916302	0.851	rs6503502	chr17:37501855	A/G	cg15445000	chr17:37608096	MED1	-0.45	-5.48	-0.34	1.1e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs7546668	0.640	rs6675825	chr1:15811346	C/T	cg21858823	chr1:15850916	CASP9	0.44	5.43	0.33	1.44e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs17376456	0.877	rs13156865	chr5:93390908	C/A	cg21475434	chr5:93447410	FAM172A	0.87	7.91	0.46	1.06e-13	Diabetic retinopathy;
SARC	cis	rs7937682	0.883	rs490492	chr11:111465150	C/T	cg22437258	chr11:111473054	SIK2	0.76	9.87	0.54	2.07e-19	Primary sclerosing cholangitis;
SARC	cis	rs9733	0.744	rs12758227	chr1:150844583	C/A	cg15448220	chr1:150897856	SETDB1	-0.39	-5.17	-0.32	4.95e-7	Tonsillectomy;
SARC	cis	rs644799	0.965	rs566877	chr11:95528045	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	15.35	0.71	3.21e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs4253772	0.744	rs1134224	chr22:46633371	A/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.46	5.1	0.32	6.91e-7	LDL cholesterol;Cholesterol, total;
SARC	cis	rs2228479	0.572	rs62054252	chr16:89896834	G/A	cg06558623	chr16:89946397	TCF25	0.91	6.5	0.39	4.78e-10	Skin colour saturation;
SARC	cis	rs17270561	0.609	rs4712968	chr6:25760344	T/C	cg17691542	chr6:26056736	HIST1H1C	0.57	7.0	0.42	2.78e-11	Iron status biomarkers;
SARC	cis	rs7666738	0.830	rs13108871	chr4:98803872	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.61	0.49	1.1e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg03806693	chr22:41940476	POLR3H	-0.99	-13.49	-0.66	4.78e-31	Vitiligo;
SARC	cis	rs4423214	0.840	rs1790341	chr11:71177578	T/C	cg05163923	chr11:71159392	DHCR7	-0.61	-7.39	-0.44	2.64e-12	Vitamin D levels;
SARC	cis	rs5758659	0.652	rs133330	chr22:42409456	G/A	cg04733989	chr22:42467013	NAGA	0.5	6.7	0.4	1.52e-10	Cognitive function;
SARC	cis	rs17401966	0.838	rs7553228	chr1:10350438	G/C	cg15208524	chr1:10270712	KIF1B	0.45	5.31	0.33	2.53e-7	Hepatocellular carcinoma;
SARC	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg06108461	chr20:60628389	TAF4	-0.95	-13.02	-0.65	1.7e-29	Body mass index;
SARC	cis	rs7326068	0.610	rs9552275	chr13:21337389	G/A	cg16922012	chr13:21400325	XPO4	-0.44	-6.09	-0.37	4.5e-9	Schizophrenia, bipolar disorder and depression (combined);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg05424782	chr22:42017079	XRCC6;PPPDE2	-0.53	-6.44	-0.39	6.6e-10	Height;
SARC	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg24549020	chr5:56110836	MAP3K1	0.64	6.02	0.37	6.63e-9	Initial pursuit acceleration;
SARC	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg20607798	chr8:58055168	NA	0.61	5.41	0.33	1.57e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2948294	0.588	rs7011221	chr8:8114246	C/T	cg06636001	chr8:8085503	FLJ10661	0.63	7.42	0.44	2.13e-12	Red cell distribution width;
SARC	cis	rs4253772	0.550	rs6008615	chr22:46707928	G/A	cg24881330	chr22:46731750	TRMU	0.73	6.12	0.37	3.87e-9	LDL cholesterol;Cholesterol, total;
SARC	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	15.35	0.71	3.17e-37	Chronic sinus infection;
SARC	trans	rs61931739	0.534	rs11053029	chr12:34131766	G/T	cg26384229	chr12:38710491	ALG10B	0.87	12.6	0.64	4.2e-28	Morning vs. evening chronotype;
SARC	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	7.77	0.45	2.56e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs614226	1.000	rs614226	chr12:120974510	C/T	cg01236616	chr12:121019343	POP5	-1.26	-17.58	-0.76	1.27e-44	Type 1 diabetes nephropathy;
SARC	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg27347728	chr4:17578864	LAP3	0.49	6.13	0.37	3.8e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6570726	0.818	rs437147	chr6:145875423	A/T	cg23711669	chr6:146136114	FBXO30	0.86	14.47	0.69	2.67e-34	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg07167872	chr1:205819463	PM20D1	0.42	4.92	0.31	1.65e-6	Parkinson's disease;
SARC	cis	rs1348850	0.526	rs2293475	chr2:178407897	C/T	cg23306229	chr2:178417860	TTC30B	-0.76	-6.93	-0.41	4.05e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.33	-5.0	-0.31	1.11e-6	Total body bone mineral density;
SARC	cis	rs72781680	0.948	rs72781652	chr2:24213754	G/A	cg06627628	chr2:24431161	ITSN2	-0.7	-6.78	-0.41	9.98e-11	Lymphocyte counts;
SARC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg21724239	chr8:58056113	NA	0.61	6.43	0.39	7.16e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9341808	0.690	rs9448909	chr6:80909031	G/A	cg08355045	chr6:80787529	NA	0.33	5.33	0.33	2.26e-7	Sitting height ratio;
SARC	cis	rs2933343	0.672	rs1872545	chr3:128645039	G/C	cg24203234	chr3:128598194	ACAD9	0.64	8.08	0.47	3.49e-14	IgG glycosylation;
SARC	cis	rs9462027	0.628	rs6899938	chr6:34749113	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.85	-0.36	1.69e-8	Systemic lupus erythematosus;
SARC	cis	rs2273669	0.667	rs12196024	chr6:109302258	C/T	cg05315195	chr6:109294784	ARMC2	-0.56	-5.1	-0.32	7.09e-7	Prostate cancer;
SARC	cis	rs440932	0.565	rs330930	chr8:9008908	A/C	cg06636001	chr8:8085503	FLJ10661	0.42	4.97	0.31	1.31e-6	High light scatter reticulocyte percentage of red cells;
SARC	cis	rs34779708	0.931	rs72789690	chr10:35382817	T/C	cg03585969	chr10:35415529	CREM	0.41	4.98	0.31	1.21e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs58785573	0.504	rs62294474	chr4:38628725	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.4	5.1	0.32	7.13e-7	Lymphocyte percentage of white cells;
SARC	cis	rs735396	1.000	rs2464195	chr12:121435475	G/A	cg02403541	chr12:121454288	C12orf43	0.72	9.5	0.53	2.6e-18	N-glycan levels;
SARC	cis	rs3796352	1.000	rs11720191	chr3:53013839	T/C	cg15956490	chr3:53032818	SFMBT1	0.75	4.99	0.31	1.2e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs7555523	0.887	rs2814471	chr1:165739598	C/T	cg24409356	chr1:165738333	TMCO1	0.8	6.89	0.41	5.07e-11	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	cis	rs9341808	0.529	rs9350851	chr6:81059188	A/G	cg08355045	chr6:80787529	NA	0.32	4.94	0.31	1.5e-6	Sitting height ratio;
SARC	cis	rs2486288	0.586	rs12909883	chr15:45572054	G/C	cg26924012	chr15:45694286	SPATA5L1	-0.53	-6.65	-0.4	2.03e-10	Glomerular filtration rate;
SARC	cis	rs2153535	0.580	rs1855769	chr6:8473095	A/G	cg07606381	chr6:8435919	SLC35B3	0.76	10.59	0.57	1.21e-21	Motion sickness;
SARC	cis	rs6450176	0.587	rs10471884	chr5:53344135	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.6	-7.08	-0.42	1.72e-11	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs367615	0.704	rs72802966	chr5:108846754	T/G	cg17395555	chr5:108820864	NA	0.47	6.86	0.41	6.08e-11	Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg02788857	chr8:22132959	PIWIL2	0.36	5.18	0.32	4.71e-7	Hypertriglyceridemia;
SARC	cis	rs55883249	0.957	rs62119432	chr2:9753939	C/T	cg23886495	chr2:9695866	ADAM17	0.69	6.87	0.41	5.75e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs2075230	0.705	rs1641525	chr17:7549211	A/G	cg05737601	chr17:7551277	NA	-0.51	-5.48	-0.34	1.1e-7	Hormone measurements;
SARC	cis	rs9436747	0.680	rs2154381	chr1:65995701	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.5	-5.39	-0.33	1.74e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	trans	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-6.73	-0.4	1.27e-10	Intelligence (multi-trait analysis);
SARC	cis	rs9462027	0.883	rs6941110	chr6:34791334	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.8	-0.36	2.13e-8	Systemic lupus erythematosus;
SARC	cis	rs2486288	0.656	rs1719232	chr15:45572072	A/G	cg15395560	chr15:45543142	SLC28A2	0.31	5.95	0.36	9.57e-9	Glomerular filtration rate;
SARC	cis	rs1538970	0.962	rs9429158	chr1:45821393	A/G	cg05343316	chr1:45956843	TESK2	0.63	7.33	0.43	3.72e-12	Platelet count;
SARC	cis	rs7833986	0.877	rs35399547	chr8:57075473	A/C	cg26371346	chr8:56986568	SNORD54;RPS20	0.72	5.15	0.32	5.67e-7	Height;
SARC	cis	rs11112613	0.713	rs12307351	chr12:105955634	T/A	cg03607813	chr12:105948248	NA	0.54	7.35	0.43	3.23e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.8	12.0	0.62	3.85e-26	Total body bone mineral density;
SARC	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg21248554	chr2:27665150	KRTCAP3	0.32	4.9	0.31	1.81e-6	Total body bone mineral density;
SARC	cis	rs9807841	0.545	rs4804514	chr19:10764203	G/T	cg17710535	chr19:10819994	QTRT1	0.4	4.86	0.3	2.15e-6	Inflammatory skin disease;
SARC	cis	rs6815814	0.861	rs10034903	chr4:38784678	C/G	cg06935464	chr4:38784597	TLR10	0.49	5.62	0.35	5.43e-8	Breast cancer;
SARC	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg03575189	chr17:44344142	NA	0.6	5.68	0.35	4.04e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	trans	rs9329221	0.619	rs591346	chr8:9818065	C/T	cg06636001	chr8:8085503	FLJ10661	-0.71	-9.8	-0.54	3.35e-19	Neuroticism;
SARC	cis	rs78487399	0.808	rs7559842	chr2:43673442	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.14	-0.32	5.7e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	trans	rs9329221	0.650	rs657913	chr8:9882575	G/T	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.82	-0.41	7.61e-11	Neuroticism;
SARC	cis	rs7615952	0.641	rs4422257	chr3:125774363	A/G	cg05084668	chr3:125655381	ALG1L	-0.48	-4.99	-0.31	1.2e-6	Blood pressure (smoking interaction);
SARC	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg08280861	chr8:58055591	NA	0.59	5.2	0.32	4.28e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg10307600	chr1:33430314	RNF19B	0.57	7.64	0.45	5.47e-13	Attention deficit hyperactivity disorder and conduct disorder;
SARC	trans	rs61931739	0.534	rs12371021	chr12:34062252	T/C	cg13010199	chr12:38710504	ALG10B	0.77	10.36	0.56	6.42e-21	Morning vs. evening chronotype;
SARC	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg00149659	chr3:10157352	C3orf10	0.69	6.4	0.39	8.64e-10	Alzheimer's disease;
SARC	cis	rs2483519	0.584	rs11196864	chr10:116437083	T/C	cg03647239	chr10:116582469	FAM160B1	0.41	4.78	0.3	3.08e-6	Paclitaxel disposition in epithelial ovarian cancer;
SARC	cis	rs9393692	0.905	rs9379838	chr6:26277133	C/T	cg13736514	chr6:26305472	NA	-0.6	-8.38	-0.48	5.15e-15	Educational attainment;
SARC	cis	rs7584330	0.780	rs937395	chr2:238378749	T/C	cg11271282	chr2:238384023	NA	0.42	4.85	0.3	2.22e-6	Prostate cancer;
SARC	cis	rs7666738	0.830	rs13110410	chr4:98920018	T/C	cg05340658	chr4:99064831	C4orf37	0.68	9.2	0.52	2.08e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6582630	0.512	rs11181007	chr12:38266700	C/T	cg04568710	chr12:38710424	ALG10B	-0.4	-4.71	-0.3	4.19e-6	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg07241146	chr10:134145514	LRRC27	-0.79	-6.64	-0.4	2.13e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs4975616	0.836	rs13178866	chr5:1323212	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.54	-7.49	-0.44	1.45e-12	Lung cancer;
SARC	cis	rs921968	0.612	rs2384950	chr2:219499719	T/C	cg02176678	chr2:219576539	TTLL4	0.45	6.86	0.41	6.18e-11	Mean corpuscular hemoglobin concentration;
SARC	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg11644478	chr21:40555479	PSMG1	1.02	14.15	0.68	3.11e-33	Cognitive function;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg07327202	chr20:5107451	CDS2;PCNA	0.54	6.73	0.4	1.32e-10	Breast cancer;
SARC	cis	rs981844	0.712	rs921882	chr4:154752878	A/C	cg14289246	chr4:154710475	SFRP2	-0.45	-5.36	-0.33	1.96e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.14	0.8	6.21e-53	Prudent dietary pattern;
SARC	cis	rs2933343	0.621	rs789242	chr3:128585707	T/C	cg25356066	chr3:128598488	ACAD9	0.71	9.44	0.53	3.93e-18	IgG glycosylation;
SARC	cis	rs9309473	0.660	rs10496192	chr2:73679866	T/C	cg20560298	chr2:73613845	ALMS1	-0.54	-5.25	-0.33	3.47e-7	Metabolite levels;
SARC	cis	rs8141529	0.748	rs2064261	chr22:29287730	C/T	cg02153584	chr22:29168773	CCDC117	0.76	11.12	0.59	2.48e-23	Lymphocyte counts;
SARC	cis	rs6963495	0.818	rs73192141	chr7:105201129	T/G	cg19920283	chr7:105172520	RINT1	0.68	5.75	0.35	2.84e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg22535103	chr8:58192502	C8orf71	-0.58	-5.84	-0.36	1.72e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9796	0.621	rs2918462	chr15:41481254	A/G	cg18705301	chr15:41695430	NDUFAF1	0.55	7.92	0.46	9.59e-14	Menopause (age at onset);
SARC	trans	rs1114504	0.860	rs12361527	chr11:79229431	A/G	cg14484681	chr9:135158694	SETX	-0.57	-6.35	-0.38	1.1e-9	Diastolic blood pressure;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg24396566	chr4:52904500	SGCB	-0.56	-7.34	-0.43	3.6e-12	Gallstone disease;
SARC	cis	rs17125944	0.615	rs8019585	chr14:53374843	G/A	cg00686598	chr14:53173677	PSMC6	0.79	5.69	0.35	3.87e-8	Alzheimer's disease (late onset);
SARC	cis	rs2276314	1.000	rs9956938	chr18:33567061	A/G	cg05985134	chr18:33552581	C18orf21	0.62	6.47	0.39	5.64e-10	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs7772486	0.720	rs9403757	chr6:146261271	C/T	cg05347473	chr6:146136440	FBXO30	-0.48	-6.53	-0.39	4.01e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg17221315	chr6:27791827	HIST1H4J	-0.47	-4.94	-0.31	1.48e-6	Depression;
SARC	cis	rs7178572	0.568	rs12908262	chr15:77493256	G/A	cg22256960	chr15:77711686	NA	-0.5	-5.53	-0.34	8.67e-8	Type 2 diabetes;
SARC	cis	rs10782582	0.593	rs12132750	chr1:76136222	A/G	cg10523679	chr1:76189770	ACADM	-0.44	-5.29	-0.33	2.8e-7	Daytime sleep phenotypes;
SARC	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg20607798	chr8:58055168	NA	0.61	5.4	0.33	1.67e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg12564285	chr5:131593104	PDLIM4	0.41	5.96	0.36	9.22e-9	Acylcarnitine levels;
SARC	cis	rs6582630	0.502	rs4309219	chr12:38293584	A/G	cg13010199	chr12:38710504	ALG10B	0.76	10.41	0.56	4.5e-21	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg14820908	chr5:178986412	RUFY1	0.37	5.09	0.32	7.24e-7	Lung cancer;
SARC	cis	rs72781680	0.800	rs56398785	chr2:24091515	T/A	cg06627628	chr2:24431161	ITSN2	-0.69	-6.62	-0.4	2.46e-10	Lymphocyte counts;
SARC	cis	rs10513788	0.813	rs72622592	chr3:182037901	C/T	cg05977900	chr3:182512126	ATP11B	0.46	4.75	0.3	3.56e-6	Cognitive function;
SARC	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg13939156	chr17:80058883	NA	0.39	5.96	0.36	9.1e-9	Life satisfaction;
SARC	cis	rs546131	0.928	rs516228	chr11:34838823	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.56	7.41	0.44	2.29e-12	Lung disease severity in cystic fibrosis;
SARC	cis	rs6570726	0.846	rs7773939	chr6:145927384	C/T	cg05347473	chr6:146136440	FBXO30	-0.48	-6.41	-0.39	7.86e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7264396	0.563	rs2425114	chr20:34322346	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	5.68	0.35	4.03e-8	Total cholesterol levels;
SARC	cis	rs35995292	0.534	rs10274968	chr7:38939254	C/T	cg19327137	chr7:38886074	VPS41	0.54	8.25	0.48	1.15e-14	Subjective well-being (multi-trait analysis);
SARC	cis	rs1510510	0.757	rs907109	chr2:239566309	C/T	cg18131467	chr2:239335373	ASB1	-0.51	-4.8	-0.3	2.89e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs7914558	1.000	rs2275271	chr10:104814162	T/C	cg04362960	chr10:104952993	NT5C2	0.42	5.08	0.32	7.7300000000000005e-07	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs4919087	0.590	rs7915926	chr10:99054052	C/T	cg25902810	chr10:99078978	FRAT1	-0.58	-6.51	-0.39	4.47e-10	Monocyte count;
SARC	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg04772025	chr11:68637568	NA	-0.5	-6.32	-0.38	1.32e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs2860975	0.501	rs602941	chr10:96961184	G/A	cg09036531	chr10:96991505	NA	-0.62	-8.57	-0.49	1.41e-15	Immune response to smallpox vaccine (IL-6);
SARC	cis	rs7424096	0.582	rs12105781	chr2:37221567	T/C	cg14987922	chr2:37194071	STRN	0.58	6.73	0.4	1.33e-10	High light scatter reticulocyte percentage of red cells;
SARC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg25703541	chr22:24373054	LOC391322	-0.76	-9.64	-0.53	1.04e-18	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs826838	0.616	rs1601746	chr12:38626195	G/T	cg13010199	chr12:38710504	ALG10B	-0.52	-6.68	-0.4	1.7e-10	Heart rate;
SARC	cis	rs3741404	0.609	rs635139	chr11:63872210	A/G	cg04317338	chr11:64019027	PLCB3	0.48	5.52	0.34	9.17e-8	Platelet count;
SARC	cis	rs4561483	0.801	rs33643	chr16:11986149	A/G	cg08843971	chr16:11963173	GSPT1	-0.41	-5.04	-0.31	9.24e-7	Testicular germ cell tumor;
SARC	cis	rs1865760	0.625	rs9393681	chr6:26008260	A/G	cg17691542	chr6:26056736	HIST1H1C	0.48	6.03	0.37	6.39e-9	Height;
SARC	trans	rs13098911	0.540	rs34718164	chr3:46098526	C/G	cg03842258	chr15:67135396	NA	0.78	6.27	0.38	1.74e-9	Celiac disease;
SARC	cis	rs11098499	0.866	rs10518329	chr4:120401835	A/G	cg09307838	chr4:120376055	NA	0.82	11.82	0.61	1.4e-25	Corneal astigmatism;
SARC	cis	rs6062302	0.522	rs4809312	chr20:62234240	C/T	cg09650180	chr20:62225654	GMEB2	-0.47	-5.69	-0.35	3.72e-8	Glioblastoma;
SARC	cis	rs6424115	0.767	rs11591202	chr1:24102080	A/C	cg15997130	chr1:24165203	NA	-0.45	-5.56	-0.34	7.46e-8	Immature fraction of reticulocytes;
SARC	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg10207240	chr12:122356781	WDR66	0.3	5.03	0.31	1e-6	Mean corpuscular volume;
SARC	cis	rs6732160	0.845	rs6752507	chr2:73385158	C/G	cg01422370	chr2:73384389	NA	0.32	5.41	0.33	1.53e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9527	0.590	rs10883829	chr10:104840635	T/C	cg04362960	chr10:104952993	NT5C2	0.42	4.92	0.31	1.65e-6	Arsenic metabolism;
SARC	cis	rs2153535	0.601	rs9505474	chr6:8539794	C/G	cg07606381	chr6:8435919	SLC35B3	0.76	10.69	0.57	5.72e-22	Motion sickness;
SARC	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg15352829	chr14:105391018	PLD4	-0.33	-6.37	-0.38	1.02e-9	Rheumatoid arthritis;
SARC	cis	rs1018836	0.923	rs9643298	chr8:91552502	G/A	cg16814680	chr8:91681699	NA	-0.77	-12.42	-0.63	1.61e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs9467711	0.591	rs13192365	chr6:25993968	T/C	cg21479132	chr6:26055353	NA	0.93	6.17	0.37	2.93e-9	Autism spectrum disorder or schizophrenia;
SARC	trans	rs11039798	0.511	rs2047812	chr11:48162042	A/G	cg15704280	chr7:45808275	SEPT13	-0.63	-6.57	-0.4	3.34e-10	Axial length;
SARC	cis	rs4771122	0.740	rs1006353	chr13:28047269	A/G	cg22138327	chr13:27999177	GTF3A	-0.47	-5.61	-0.34	5.83e-8	Body mass index;
SARC	cis	rs6087990	0.735	rs4911260	chr20:31376490	T/C	cg13636640	chr20:31349939	DNMT3B	0.8	12.77	0.64	1.15e-28	Ulcerative colitis;
SARC	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs3741404	0.560	rs2875748	chr11:63915537	G/A	cg05555928	chr11:63887634	MACROD1	0.36	5.65	0.35	4.62e-8	Platelet count;
SARC	trans	rs61931739	0.817	rs592857	chr12:34197673	T/G	cg26384229	chr12:38710491	ALG10B	0.63	8.25	0.48	1.14e-14	Morning vs. evening chronotype;
SARC	cis	rs6912958	1.000	rs6937823	chr6:88160386	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-5.8	-0.36	2.12e-8	Monocyte percentage of white cells;
SARC	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg18252515	chr7:66147081	NA	0.56	6.02	0.37	6.63e-9	Aortic root size;
SARC	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg02931644	chr1:25747376	RHCE	0.46	7.86	0.46	1.44e-13	Erythrocyte sedimentation rate;
SARC	cis	rs25645	0.830	rs4072639	chr17:38189049	G/A	cg17467752	chr17:38218738	THRA	-0.41	-5.2	-0.32	4.38e-7	Myeloid white cell count;
SARC	cis	rs2177596	0.595	rs1917124	chr2:227937611	C/T	cg11843606	chr2:227700838	RHBDD1	-0.46	-5.02	-0.31	1.03e-6	Body mass index;
SARC	cis	rs4792901	0.918	rs76798487	chr17:41633391	A/G	cg22562494	chr17:41607896	ETV4	-0.32	-4.97	-0.31	1.3e-6	Dupuytren's disease;
SARC	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg04277193	chr17:41438351	NA	0.46	4.98	0.31	1.25e-6	Menopause (age at onset);
SARC	cis	rs1982346	1.000	rs2544424	chr4:106718316	A/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.64	4.76	0.3	3.33e-6	Lung function (FEV1);
SARC	cis	rs77633900	0.614	rs279999	chr15:76945466	C/T	cg21673338	chr15:77095150	SCAPER	-0.76	-6.36	-0.38	1.07e-9	Non-glioblastoma glioma;Glioma;
SARC	cis	rs13401104	0.796	rs11887905	chr2:237114756	C/T	cg19324714	chr2:237145437	ASB18	0.56	5.83	0.36	1.87e-8	Educational attainment;
SARC	cis	rs8114671	0.562	rs3746450	chr20:33508588	G/T	cg24642439	chr20:33292090	TP53INP2	0.49	5.94	0.36	1e-8	Height;
SARC	cis	rs7681440	0.904	rs7672979	chr4:90767873	A/G	cg06632027	chr4:90757378	SNCA	0.39	5.66	0.35	4.49e-8	Dementia with Lewy bodies;
SARC	cis	rs8054556	0.787	rs11642612	chr16:30030195	A/C	cg06015834	chr16:30021696	DOC2A	-0.37	-4.98	-0.31	1.26e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg08280861	chr8:58055591	NA	0.61	5.96	0.36	9.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7953249	0.514	rs1169312	chr12:121441461	G/T	cg02403541	chr12:121454288	C12orf43	0.72	9.48	0.53	2.96e-18	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs7264396	0.563	rs56941405	chr20:34313426	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-7.17	-0.43	9.99e-12	Total cholesterol levels;
SARC	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg10207240	chr12:122356781	WDR66	-0.29	-4.94	-0.31	1.47e-6	Mean corpuscular volume;
SARC	cis	rs7824557	0.767	rs2164272	chr8:11162496	A/C	cg21775007	chr8:11205619	TDH	0.52	6.27	0.38	1.77e-9	Retinal vascular caliber;
SARC	cis	rs9400467	0.506	rs12203093	chr6:111585382	T/C	cg15721981	chr6:111408429	SLC16A10	0.67	5.65	0.35	4.63e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg16479474	chr6:28041457	NA	0.37	5.48	0.34	1.11e-7	Depression;
SARC	cis	rs3784262	0.669	rs3742960	chr15:58248088	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.34	-5.09	-0.32	7.36e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg11062466	chr8:58055876	NA	0.55	5.32	0.33	2.48e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg21724239	chr8:58056113	NA	0.6	6.37	0.38	1.03e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs17376456	0.809	rs10476602	chr5:93445255	T/C	cg21475434	chr5:93447410	FAM172A	0.88	8.11	0.47	2.81e-14	Diabetic retinopathy;
SARC	cis	rs561341	0.528	rs11650908	chr17:30195425	T/C	cg13647721	chr17:30228624	UTP6	-0.66	-7.67	-0.45	4.61e-13	Hip circumference adjusted for BMI;
SARC	cis	rs7917772	0.636	rs7079231	chr10:104527341	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	6.34	0.38	1.21e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	trans	rs7819412	0.623	rs7833435	chr8:10801137	A/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-7.79	-0.45	2.19e-13	Triglycerides;
SARC	cis	rs9611519	0.579	rs8136274	chr22:41415311	T/C	cg03806693	chr22:41940476	POLR3H	-0.59	-7.95	-0.46	8.04e-14	Neuroticism;
SARC	cis	rs2180341	0.960	rs9401952	chr6:127677027	A/C	cg27446573	chr6:127587934	RNF146	1.05	14.54	0.69	1.63e-34	Breast cancer;
SARC	trans	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg09070846	chr13:69559039	NA	0.39	6.36	0.38	1.03e-9	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg17294928	chr15:75287854	SCAMP5	0.48	6.06	0.37	5.52e-9	Breast cancer;
SARC	cis	rs1448094	0.842	rs7978562	chr12:86451478	A/G	cg02569458	chr12:86230093	RASSF9	0.41	6.14	0.37	3.51e-9	Major depressive disorder;
SARC	cis	rs6964587	0.692	rs7807490	chr7:91773359	A/G	cg17063962	chr7:91808500	NA	0.79	12.09	0.62	1.89e-26	Breast cancer;
SARC	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg05368731	chr17:41323189	NBR1	0.67	8.27	0.48	1.01e-14	Menopause (age at onset);
SARC	cis	rs10883723	0.518	rs10786679	chr10:104315667	C/T	cg22532475	chr10:104410764	TRIM8	-0.24	-4.74	-0.3	3.67e-6	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg26695010	chr11:65641043	EFEMP2	-0.52	-6.73	-0.4	1.32e-10	Eosinophil percentage of white cells;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg11213199	chr7:43909298	MRPS24	0.46	6.23	0.38	2.13e-9	Chemerin levels;
SARC	cis	rs34172651	0.917	rs200539	chr16:24735178	T/C	cg00339695	chr16:24857497	SLC5A11	-0.32	-5.0	-0.31	1.13e-6	Intelligence (multi-trait analysis);
SARC	cis	rs10189230	0.967	rs7573758	chr2:222357326	G/T	cg14652038	chr2:222343519	EPHA4	0.46	6.15	0.37	3.43e-9	Urate levels in lean individuals;
SARC	cis	rs1538970	0.781	rs10890330	chr1:45920406	G/A	cg05343316	chr1:45956843	TESK2	0.79	8.77	0.5	3.84e-16	Platelet count;
SARC	cis	rs10463316	0.894	rs10476980	chr5:150764157	A/G	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.28	-0.33	2.89e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs7931462	0.655	rs6483208	chr11:92705844	A/C	cg13528726	chr11:93495850	C11orf54	-0.59	-4.89	-0.3	1.91e-6	DNA methylation (parent-of-origin);
SARC	cis	rs6991838	0.584	rs7836349	chr8:66503563	A/G	cg13398993	chr8:66546079	ARMC1	-0.62	-8.36	-0.48	5.8e-15	Intelligence (multi-trait analysis);
SARC	cis	rs7584330	0.554	rs6740722	chr2:238393288	T/C	cg08992911	chr2:238395768	MLPH	0.68	5.74	0.35	2.89e-8	Prostate cancer;
SARC	cis	rs2760061	0.583	rs708121	chr1:228208257	A/G	cg01200585	chr1:228362443	C1orf69	0.44	5.51	0.34	9.46e-8	Diastolic blood pressure;
SARC	cis	rs7818688	0.697	rs78802294	chr8:95977974	G/A	cg13393036	chr8:95962371	TP53INP1	0.4	4.85	0.3	2.27e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs10791097	0.690	rs12286234	chr11:130730528	T/C	cg12179176	chr11:130786555	SNX19	0.65	9.0	0.51	8.36e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs76419734	1.000	rs76694233	chr4:106681036	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.76	4.95	0.31	1.4e-6	Post bronchodilator FEV1;
SARC	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg07701084	chr6:150067640	NUP43	0.41	5.4	0.33	1.62e-7	Lung cancer;
SARC	cis	rs26232	0.520	rs26432	chr5:102365710	T/A	cg23492399	chr5:102201601	PAM	0.45	5.02	0.31	1.03e-6	Rheumatoid arthritis;
SARC	cis	rs7223966	0.883	rs2727317	chr17:61961302	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	7.13	0.42	1.25e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs35110281	0.627	rs1436291	chr21:44965485	T/C	cg21573476	chr21:45109991	RRP1B	-0.41	-5.87	-0.36	1.48e-8	Mean corpuscular volume;
SARC	cis	rs992157	0.710	rs13026485	chr2:219057984	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.64	-8.82	-0.5	2.68e-16	Colorectal cancer;
SARC	cis	rs57221529	0.664	rs72704802	chr5:554211	C/T	cg09021430	chr5:549028	NA	-0.41	-5.2	-0.32	4.33e-7	Lung disease severity in cystic fibrosis;
SARC	trans	rs1814175	0.817	rs6486046	chr11:49997017	T/C	cg03929089	chr4:120376271	NA	-0.89	-14.59	-0.69	1.1e-34	Height;
SARC	cis	rs709400	1.000	rs55885592	chr14:104126024	C/T	cg12935359	chr14:103987150	CKB	-0.33	-4.97	-0.31	1.28e-6	Body mass index;
SARC	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg16606324	chr3:10149918	C3orf24	0.48	4.75	0.3	3.56e-6	Alzheimer's disease;
SARC	cis	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg14541582	chr5:601475	NA	-0.39	-4.93	-0.31	1.59e-6	Obesity-related traits;
SARC	cis	rs66887589	0.934	rs7672519	chr4:120544112	C/T	cg09307838	chr4:120376055	NA	-0.54	-7.45	-0.44	1.81e-12	Diastolic blood pressure;
SARC	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg22535103	chr8:58192502	C8orf71	-0.6	-6.15	-0.37	3.42e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1008375	0.966	rs1860591	chr4:17577329	A/G	cg27347728	chr4:17578864	LAP3	0.46	5.65	0.35	4.6e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs8114671	0.527	rs2295352	chr20:33320055	C/G	cg24642439	chr20:33292090	TP53INP2	-0.55	-6.82	-0.41	7.62e-11	Height;
SARC	cis	rs9398803	0.723	rs1262546	chr6:127075491	T/C	cg20229609	chr6:126660872	C6orf173	-0.34	-4.79	-0.3	3.02e-6	Male-pattern baldness;
SARC	cis	rs3845702	1.000	rs3845697	chr2:180798553	C/T	cg01881094	chr2:180872142	CWC22	0.68	6.24	0.38	2e-9	Schizophrenia;
SARC	cis	rs9612	1.000	rs61002661	chr19:44269032	T/A	cg07522664	chr19:44259120	C19orf61	0.5	5.73	0.35	3.06e-8	Exhaled nitric oxide output;
SARC	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.69	6.81	0.41	8.16e-11	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs4372836	0.729	rs10166861	chr2:29061111	A/G	cg09522027	chr2:28974177	PPP1CB	0.35	4.71	0.3	4.19e-6	Body mass index;
SARC	cis	rs7000551	0.751	rs2461482	chr8:22382898	C/T	cg12081754	chr8:22256438	SLC39A14	0.57	7.98	0.46	6.83e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg27266027	chr21:40555129	PSMG1	0.51	5.73	0.35	3.05e-8	Cognitive function;
SARC	cis	rs9303401	0.614	rs2333409	chr17:57139134	G/A	cg25039879	chr17:56429692	SUPT4H1	0.59	5.25	0.33	3.46e-7	Cognitive test performance;
SARC	cis	rs2361710	0.668	rs2304855	chr17:78118266	T/A	cg06718696	chr17:78121285	EIF4A3	0.39	4.81	0.3	2.67e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
SARC	cis	rs7027203	0.797	rs3996254	chr9:96591239	A/G	cg14598338	chr9:96623480	NA	-0.54	-7.65	-0.45	5.18e-13	DNA methylation (variation);
SARC	cis	rs4689388	0.782	rs4262051	chr4:6281775	G/A	cg14416269	chr4:6271139	WFS1	0.37	5.49	0.34	1.03e-7	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs7223966	1.000	rs112143304	chr17:61822401	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.48	4.97	0.31	1.31e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9467773	1.000	rs10946835	chr6:26533757	C/T	cg12292205	chr6:26970375	C6orf41	0.45	5.43	0.34	1.41e-7	Intelligence (multi-trait analysis);
SARC	cis	rs4689388	0.853	rs6446479	chr4:6291737	G/C	cg00701064	chr4:6280414	WFS1	0.55	8.62	0.49	1.07e-15	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg18305652	chr10:134549665	INPP5A	0.38	5.85	0.36	1.64e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs477692	0.549	rs7079744	chr10:131454790	G/A	cg05714579	chr10:131428358	MGMT	-0.39	-4.96	-0.31	1.37e-6	Response to temozolomide;
SARC	cis	rs6570726	0.738	rs6917199	chr6:145918320	G/A	cg05347473	chr6:146136440	FBXO30	0.54	7.32	0.43	4.05e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11758351	0.929	rs6906367	chr6:26187125	C/T	cg00631329	chr6:26305371	NA	-0.51	-5.5	-0.34	1e-7	Gout;Renal underexcretion gout;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg12114820	chr12:76953697	OSBPL8	-0.78	-6.28	-0.38	1.63e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.03	12.03	0.62	3.06e-26	Alzheimer's disease;
SARC	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4668356	0.773	rs11883894	chr2:172034974	G/C	cg13882835	chr2:172017928	TLK1	0.66	5.86	0.36	1.61e-8	Cognitive performance;
SARC	cis	rs1707322	0.721	rs11211178	chr1:46227566	G/T	cg06784218	chr1:46089804	CCDC17	0.39	6.81	0.41	8.12e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6912958	0.712	rs2754260	chr6:88397666	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.27	-0.33	3.18e-7	Monocyte percentage of white cells;
SARC	cis	rs6963495	0.745	rs75805443	chr7:105162828	A/G	cg13798780	chr7:105162888	PUS7	0.6	5.45	0.34	1.31e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs526821	0.595	rs624478	chr11:55340778	C/G	cg04317927	chr11:55418816	OR4S2	0.41	6.14	0.37	3.62e-9	Pediatric bone mineral density (spine);
SARC	cis	rs1008375	0.931	rs979823	chr4:17700176	G/A	cg16339924	chr4:17578868	LAP3	0.55	7.04	0.42	2.16e-11	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg20607798	chr8:58055168	NA	0.61	5.41	0.33	1.57e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7402982	0.934	rs8027457	chr15:99204101	A/G	cg03437748	chr15:99193247	IGF1R	0.89	12.61	0.64	3.99e-28	Birth weight;
SARC	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg04267008	chr7:1944627	MAD1L1	-0.5	-5.62	-0.35	5.57e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs75246769	1.000	rs1523723	chr7:145439365	A/T	cg00210271	chr12:54088934	NA	-0.47	-6.25	-0.38	1.93e-9	Facial morphology (factor 10, width of nasal floor);
SARC	cis	rs9314323	0.862	rs3808580	chr8:26250296	C/T	cg11498726	chr8:26250323	BNIP3L	0.62	8.24	0.47	1.28e-14	Red cell distribution width;
SARC	cis	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg08045932	chr20:61659980	NA	0.5	6.84	0.41	7.06e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs2404602	0.647	rs10851892	chr15:77176491	T/C	cg15268244	chr15:77196840	NA	0.45	5.18	0.32	4.76e-7	Blood metabolite levels;
SARC	cis	rs910316	0.687	rs175059	chr14:75490667	T/C	cg08847533	chr14:75593920	NEK9	-0.82	-11.67	-0.61	4.39e-25	Height;
SARC	cis	rs6977660	0.652	rs58559474	chr7:19751569	C/T	cg05791153	chr7:19748676	TWISTNB	0.95	7.43	0.44	2.09e-12	Thyroid stimulating hormone;
SARC	cis	rs11112613	0.818	rs73184093	chr12:106010066	G/C	cg03607813	chr12:105948248	NA	0.51	5.37	0.33	1.89e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs1153858	1.000	rs4775906	chr15:45638294	C/T	cg26924012	chr15:45694286	SPATA5L1	0.75	10.34	0.56	7.46e-21	Homoarginine levels;
SARC	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg22920501	chr2:26401640	FAM59B	-0.57	-7.45	-0.44	1.82e-12	Gut microbiome composition (summer);
SARC	trans	rs561341	0.883	rs6505274	chr17:30344581	G/T	cg20587970	chr11:113659929	NA	-0.96	-9.96	-0.55	1.1e-19	Hip circumference adjusted for BMI;
SARC	trans	rs61931739	0.500	rs11053260	chr12:34530215	T/G	cg26384229	chr12:38710491	ALG10B	0.85	12.62	0.64	3.51e-28	Morning vs. evening chronotype;
SARC	cis	rs9303401	0.615	rs35288118	chr17:56600748	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.06	11.34	0.6	5.04e-24	Cognitive test performance;
SARC	cis	rs2439831	0.850	rs2228368	chr15:44102010	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.93	8.14	0.47	2.39e-14	Lung cancer in ever smokers;
SARC	cis	rs2204008	0.805	rs11514348	chr12:38243427	T/C	cg13010199	chr12:38710504	ALG10B	0.81	11.31	0.6	6.33e-24	Bladder cancer;
SARC	cis	rs2425143	1.000	rs78421482	chr20:34376486	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-5.85	-0.36	1.62e-8	Blood protein levels;
SARC	trans	rs208515	0.525	rs10944870	chr6:66687757	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.99	11.54	0.6	1.13e-24	Exhaled nitric oxide levels;
SARC	trans	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.11	-0.42	1.41e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs4803468	1.000	rs1043413	chr19:41939297	C/G	cg14132834	chr19:41945861	ATP5SL	0.6	8.03	0.47	4.83e-14	Height;
SARC	cis	rs282587	0.569	rs282600	chr13:113391602	G/A	cg02820901	chr13:113351484	ATP11A	-0.51	-4.92	-0.31	1.61e-6	Glycated hemoglobin levels;
SARC	cis	rs3768617	0.510	rs4651140	chr1:183096952	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.82e-21	Fuchs's corneal dystrophy;
SARC	cis	rs1448094	0.813	rs6539942	chr12:86452969	T/C	cg02569458	chr12:86230093	RASSF9	-0.39	-5.69	-0.35	3.82e-8	Major depressive disorder;
SARC	cis	rs16976116	0.901	rs28714578	chr15:55491121	G/A	cg11288833	chr15:55489084	RSL24D1	0.63	6.09	0.37	4.66e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6582630	0.572	rs1969363	chr12:38514872	A/G	cg04568710	chr12:38710424	ALG10B	0.41	5.02	0.31	1.05e-6	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs17685	0.753	rs12531559	chr7:75631697	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.6	-7.47	-0.44	1.61e-12	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs910316	1.000	rs4903289	chr14:75623988	C/T	cg08847533	chr14:75593920	NEK9	-0.91	-15.55	-0.71	7e-38	Height;
SARC	cis	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg11995313	chr8:8860691	ERI1	-0.4	-4.91	-0.31	1.7e-6	Joint mobility (Beighton score);
SARC	cis	rs7044106	0.791	rs735110	chr9:123488940	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.7	0.54	6.57e-19	Hip circumference adjusted for BMI;
SARC	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg19223190	chr17:80058835	NA	0.45	6.32	0.38	1.33e-9	Life satisfaction;
SARC	cis	rs524281	1.000	rs475805	chr11:65848738	G/A	cg14036092	chr11:66035641	RAB1B	0.51	5.8	0.36	2.14e-8	Electroencephalogram traits;
SARC	cis	rs13034020	0.522	rs12988616	chr2:61244663	A/C	cg18625361	chr2:61244694	PEX13;PUS10	0.63	5.88	0.36	1.38e-8	Hodgkin's lymphoma;
SARC	trans	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.75	10.78	0.58	3.03e-22	Intelligence (multi-trait analysis);
SARC	cis	rs9896052	0.649	rs6501801	chr17:73447030	A/G	cg04121983	chr17:73511085	CASKIN2	-0.42	-4.94	-0.31	1.51e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs4073582	0.964	rs801742	chr11:65914766	C/A	cg14036092	chr11:66035641	RAB1B	0.54	6.47	0.39	5.67e-10	Gout;
SARC	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg02018176	chr4:1364513	KIAA1530	0.33	4.94	0.31	1.52e-6	Longevity;
SARC	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg22920501	chr2:26401640	FAM59B	-0.58	-8.16	-0.47	2.04e-14	Gut microbiome composition (summer);
SARC	cis	rs1707322	1.000	rs4298677	chr1:46306619	G/A	cg03146154	chr1:46216737	IPP	0.46	5.54	0.34	8.14e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs12999616	1.000	rs12999616	chr2:98324381	C/T	cg26665480	chr2:98280029	ACTR1B	0.51	4.72	0.3	4.01e-6	Colorectal cancer;
SARC	cis	rs7592578	0.679	rs62181020	chr2:191325601	A/C	cg27211696	chr2:191398769	TMEM194B	-0.49	-5.33	-0.33	2.32e-7	Diastolic blood pressure;
SARC	cis	rs7772486	0.790	rs9386141	chr6:146268623	T/A	cg05347473	chr6:146136440	FBXO30	-0.46	-6.31	-0.38	1.4e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9814567	0.752	rs4605591	chr3:134328361	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.51	-6.66	-0.4	1.95e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs854765	0.623	rs9893690	chr17:17753846	A/T	cg04398451	chr17:18023971	MYO15A	0.43	6.29	0.38	1.52e-9	Total body bone mineral density;
SARC	cis	rs10870270	0.956	rs10430618	chr10:133748996	C/T	cg26149184	chr10:133730230	NA	0.46	5.18	0.32	4.84e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg08975724	chr8:8085496	FLJ10661	0.49	6.02	0.37	6.57e-9	Mood instability;
SARC	cis	rs4642101	0.824	rs9835677	chr3:12845158	G/A	cg05775895	chr3:12838266	CAND2	0.74	12.08	0.62	2.01e-26	QRS complex (12-leadsum);
SARC	cis	rs3099143	0.901	rs76036665	chr15:77232720	A/G	cg21673338	chr15:77095150	SCAPER	-0.74	-5.6	-0.34	5.87e-8	Recalcitrant atopic dermatitis;
SARC	cis	rs11648796	0.757	rs6600231	chr16:766485	A/G	cg27144592	chr16:783916	NARFL	-0.46	-6.79	-0.41	9.49e-11	Height;
SARC	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg22920501	chr2:26401640	FAM59B	-0.56	-7.63	-0.45	6e-13	Gut microbiome composition (summer);
SARC	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.99	11.36	0.6	4.27e-24	Platelet count;
SARC	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg11644478	chr21:40555479	PSMG1	-0.55	-6.63	-0.4	2.27e-10	Menarche (age at onset);
SARC	cis	rs13191362	1.000	rs66529337	chr6:163005662	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.56	5.41	0.33	1.53e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs514024	0.700	rs557749	chr9:130492039	G/A	cg13643465	chr9:130375613	STXBP1	0.42	5.16	0.32	5.21e-7	Eating disorders (purging via substances);
SARC	cis	rs763121	0.853	rs6001204	chr22:39100239	T/C	cg21395723	chr22:39101663	GTPBP1	0.56	6.68	0.4	1.74e-10	Menopause (age at onset);
SARC	cis	rs7481584	0.581	rs105686	chr11:3062467	G/A	cg05729581	chr11:3078854	CARS	0.52	6.82	0.41	7.73e-11	Calcium levels;
SARC	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.12	24.57	0.85	1.28e-66	Chronic sinus infection;
SARC	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg11987759	chr7:65425863	GUSB	0.48	5.78	0.35	2.39e-8	Aortic root size;
SARC	cis	rs7785360	0.800	rs6953075	chr7:69731497	A/G	cg10619644	chr7:69149951	AUTS2	0.42	4.9	0.31	1.77e-6	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
SARC	cis	rs11098499	0.863	rs34868248	chr4:120442430	A/G	cg24375607	chr4:120327624	NA	0.42	4.9	0.31	1.76e-6	Corneal astigmatism;
SARC	cis	rs910316	0.737	rs175424	chr14:75626257	T/C	cg11812906	chr14:75593930	NEK9	-0.74	-9.71	-0.54	6.21e-19	Height;
SARC	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg06108461	chr20:60628389	TAF4	0.54	5.59	0.34	6.25e-8	Obesity-related traits;
SARC	cis	rs6582630	0.537	rs7310749	chr12:38400472	C/T	cg13010199	chr12:38710504	ALG10B	0.76	10.37	0.56	5.67e-21	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs16976116	0.803	rs9920136	chr15:55504102	A/G	cg11288833	chr15:55489084	RSL24D1	0.6	5.77	0.35	2.46e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4268898	1.000	rs6707781	chr2:24441883	T/G	cg06627628	chr2:24431161	ITSN2	0.59	8.23	0.47	1.32e-14	Asthma;
SARC	cis	rs7932354	0.528	rs1965952	chr11:47181040	G/A	cg03339077	chr11:47165057	C11orf49	0.4	5.36	0.33	2.04e-7	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs13314892	0.728	rs55808455	chr3:69861423	G/A	cg17445875	chr3:69859618	MITF	-0.49	-5.14	-0.32	5.68e-7	QRS complex (12-leadsum);
SARC	cis	rs6582630	0.502	rs1115515	chr12:38279830	C/T	cg26384229	chr12:38710491	ALG10B	0.91	13.79	0.67	4.83e-32	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs4775413	1.000	rs4775413	chr15:61840103	C/T	cg09972561	chr15:62353371	VPS13C	0.37	5.01	0.31	1.08e-6	Schizophrenia;
SARC	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg22974920	chr21:40686053	BRWD1	0.44	4.95	0.31	1.44e-6	Cognitive function;
SARC	cis	rs9790314	0.871	rs466626	chr3:161103629	A/C	cg04691961	chr3:161091175	C3orf57	-0.74	-10.42	-0.56	4.04e-21	Morning vs. evening chronotype;
SARC	cis	rs1348850	0.914	rs7587604	chr2:178309848	T/A	cg23306229	chr2:178417860	TTC30B	0.51	6.09	0.37	4.6e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2043112	0.867	rs13168966	chr5:39044831	C/A	cg04869206	chr5:39074266	RICTOR	0.48	5.7	0.35	3.53e-8	Obesity-related traits;
SARC	trans	rs9329221	0.712	rs1962073	chr8:10260553	A/G	cg00262122	chr8:11665843	FDFT1	-0.52	-6.27	-0.38	1.69e-9	Neuroticism;
SARC	cis	rs698833	0.962	rs1067386	chr2:44644257	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.68	8.69	0.49	6.72e-16	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs79247733	0.786	rs2286442	chr22:30772686	C/T	cg00101453	chr22:30685584	GATSL3	0.63	5.3	0.33	2.66e-7	Tonsillectomy;
SARC	cis	rs765787	0.530	rs4442750	chr15:45535328	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.67e-7	Uric acid levels;
SARC	cis	rs9467773	0.620	rs2130657	chr6:26650826	C/T	cg12292205	chr6:26970375	C6orf41	0.4	4.9	0.31	1.77e-6	Intelligence (multi-trait analysis);
SARC	cis	rs6570726	0.791	rs435671	chr6:145881215	A/G	cg23711669	chr6:146136114	FBXO30	0.83	13.68	0.67	1.11e-31	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs765787	0.530	rs28756676	chr15:45540360	G/A	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.51e-10	Uric acid levels;
SARC	cis	rs2797685	0.853	rs707462	chr1:7849880	A/G	cg00864860	chr1:7907996	UTS2	-0.34	-4.92	-0.31	1.66e-6	Crohn's disease;
SARC	cis	rs13314892	0.692	rs62252239	chr3:69893971	G/T	cg17445875	chr3:69859618	MITF	-0.51	-5.24	-0.32	3.51e-7	QRS complex (12-leadsum);
SARC	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg25894440	chr7:65020034	NA	0.79	5.96	0.36	9.49e-9	Diabetic kidney disease;
SARC	trans	rs561341	0.700	rs6505266	chr17:30225813	G/A	cg20587970	chr11:113659929	NA	-0.58	-6.76	-0.4	1.12e-10	Hip circumference adjusted for BMI;
SARC	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg13939156	chr17:80058883	NA	-0.42	-6.52	-0.39	4.23e-10	Life satisfaction;
SARC	cis	rs6570726	0.967	rs6903252	chr6:145922777	A/G	cg23711669	chr6:146136114	FBXO30	0.77	11.83	0.61	1.31e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs8180040	0.805	rs17410853	chr3:47363971	G/T	cg27129171	chr3:47204927	SETD2	-0.65	-8.61	-0.49	1.11e-15	Colorectal cancer;
SARC	cis	rs6570726	0.791	rs2096201	chr6:145934273	C/T	cg05347473	chr6:146136440	FBXO30	0.54	7.46	0.44	1.67e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6963495	0.818	rs55825845	chr7:105166713	A/G	cg13798780	chr7:105162888	PUS7	0.6	5.55	0.34	7.64e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg26335602	chr6:28129616	ZNF389	0.52	5.78	0.35	2.41e-8	Depression;
SARC	cis	rs6815814	1.000	rs11722836	chr4:38811529	T/A	cg02016764	chr4:38805732	TLR1	-0.41	-4.86	-0.3	2.18e-6	Breast cancer;
SARC	cis	rs965469	0.846	rs7271575	chr20:3333877	C/T	cg25506879	chr20:3388711	C20orf194	-0.51	-5.21	-0.32	4.1e-7	IFN-related cytopenia;
SARC	cis	rs748404	0.660	rs509306	chr15:43715171	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.41	4.86	0.3	2.17e-6	Lung cancer;
SARC	cis	rs12545109	0.765	rs1960727	chr8:57411368	G/A	cg19413350	chr8:57351067	NA	-0.43	-4.83	-0.3	2.45e-6	Obesity-related traits;
SARC	cis	rs2730245	1.000	rs2730241	chr7:158723014	T/C	cg24397884	chr7:158709396	WDR60	-1.05	-15.21	-0.71	9.2e-37	Height;
SARC	cis	rs2072499	0.932	rs2540183	chr1:156164885	C/G	cg25208724	chr1:156163844	SLC25A44	0.9	11.17	0.59	1.77e-23	Testicular germ cell tumor;
SARC	cis	rs1044826	0.642	rs2071388	chr3:139236683	C/T	cg15131784	chr3:139108705	COPB2	-0.39	-4.99	-0.31	1.2e-6	Obesity-related traits;
SARC	trans	rs10510776	0.875	rs11710973	chr3:55217512	C/T	cg21837372	chr12:104234663	NT5DC3	-0.74	-6.26	-0.38	1.81e-9	Cancer;
SARC	cis	rs796364	0.806	rs1605900	chr2:200870197	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.71	6.06	0.37	5.43e-9	Schizophrenia;
SARC	cis	rs829883	0.966	rs249815	chr12:98893709	A/G	cg25150519	chr12:98850993	NA	0.71	9.49	0.53	2.82e-18	Colorectal adenoma (advanced);
SARC	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg11764359	chr7:65958608	NA	0.76	8.78	0.5	3.62e-16	Aortic root size;
SARC	cis	rs7551222	0.752	rs2369244	chr1:204515299	C/G	cg20240347	chr1:204465584	NA	0.34	6.12	0.37	4.03e-9	Schizophrenia;
SARC	cis	rs6696846	0.715	rs12139373	chr1:205054879	A/C	cg00857998	chr1:205179979	DSTYK	0.48	6.16	0.37	3.15e-9	Red blood cell count;
SARC	cis	rs7769051	0.522	rs17061975	chr6:133240019	T/A	cg07930552	chr6:133119739	C6orf192	0.9	5.08	0.32	7.61e-7	Type 2 diabetes nephropathy;
SARC	cis	rs921968	0.565	rs4674328	chr2:219593203	T/C	cg02176678	chr2:219576539	TTLL4	-0.34	-5.13	-0.32	6.05e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs4727027	0.870	rs1534196	chr7:148790591	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.47	5.61	0.35	5.67e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs1580019	0.587	rs7804457	chr7:32557981	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.62	8.17	0.47	1.92e-14	Cognitive ability;
SARC	trans	rs3779273	0.722	rs4730115	chr7:77833976	A/G	cg05596911	chr5:118502651	DMXL1	-0.5	-6.35	-0.38	1.11e-9	Body mass index;
SARC	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg20965017	chr5:231967	SDHA	-0.58	-5.52	-0.34	8.82e-8	Breast cancer;
SARC	cis	rs2652834	1.000	rs7181141	chr15:63398552	A/G	cg05507819	chr15:63340323	TPM1	0.54	5.34	0.33	2.23e-7	HDL cholesterol;
SARC	cis	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg20965017	chr5:231967	SDHA	-0.58	-5.57	-0.34	7.06e-8	Breast cancer;
SARC	cis	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg24110177	chr3:50126178	RBM5	-0.59	-7.57	-0.44	8.76e-13	Body mass index;
SARC	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg25894440	chr7:65020034	NA	0.76	5.68	0.35	3.95e-8	Diabetic kidney disease;
SARC	trans	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-7.11	-0.42	1.4e-11	Intelligence (multi-trait analysis);
SARC	cis	rs2439831	0.681	rs3742969	chr15:43621947	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	8.94	0.51	1.19e-16	Lung cancer in ever smokers;
SARC	cis	rs6815814	0.950	rs5743565	chr4:38805983	T/C	cg06935464	chr4:38784597	TLR10	0.63	6.25	0.38	1.95e-9	Breast cancer;
SARC	cis	rs9486715	0.790	rs2971602	chr6:97022468	C/T	cg06623918	chr6:96969491	KIAA0776	-0.94	-14.49	-0.69	2.36e-34	Headache;
SARC	cis	rs2760061	0.603	rs697761	chr1:228192397	G/A	cg02753203	chr1:228287806	NA	0.81	11.43	0.6	2.62e-24	Diastolic blood pressure;
SARC	cis	rs7246657	0.943	rs2303131	chr19:37936025	G/A	cg23950597	chr19:37808831	NA	-0.63	-6.04	-0.37	6.1e-9	Coronary artery calcification;
SARC	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9325144	0.581	rs2730929	chr12:38942739	T/C	cg26384229	chr12:38710491	ALG10B	-0.68	-9.37	-0.52	6.66e-18	Morning vs. evening chronotype;
SARC	cis	rs7647973	1.000	rs11710434	chr3:49346130	T/C	cg06212747	chr3:49208901	KLHDC8B	0.54	5.85	0.36	1.61e-8	Menarche (age at onset);
SARC	cis	rs9733	0.818	rs6694531	chr1:150683512	C/A	cg13175981	chr1:150552382	MCL1	0.64	8.91	0.5	1.51e-16	Tonsillectomy;
SARC	cis	rs2315504	0.626	rs2957100	chr17:39004145	A/G	cg05063374	chr17:38953512	KRT28	0.28	4.86	0.3	2.13e-6	Height;
SARC	cis	rs11764590	0.724	rs55789728	chr7:2107649	A/G	cg21782813	chr7:2030301	MAD1L1	-0.38	-5.41	-0.33	1.56e-7	Neuroticism;
SARC	cis	rs11690462	0.926	rs12467721	chr2:26558489	T/G	cg26119090	chr2:26468346	HADHA;HADHB	0.4	5.06	0.31	8.39e-7	Coronary artery disease;
SARC	cis	rs9911578	0.967	rs6416932	chr17:57148991	G/A	cg12560992	chr17:57184187	TRIM37	0.87	12.52	0.63	7.77e-28	Intelligence (multi-trait analysis);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg06149212	chr13:93932639	GPC6	0.49	6.73	0.4	1.32e-10	Thyroid stimulating hormone;
SARC	cis	rs2797160	0.651	rs1343121	chr6:126036184	C/T	cg05901451	chr6:126070800	HEY2	0.43	5.16	0.32	5.33e-7	Endometrial cancer;
SARC	cis	rs9640161	0.830	rs7800196	chr7:150061534	C/G	cg17279839	chr7:150038598	RARRES2	0.38	5.75	0.35	2.82e-8	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs1348850	0.632	rs12471621	chr2:178502353	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.51	5.84	0.36	1.77e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg08859206	chr1:53392774	SCP2	-0.38	-5.38	-0.33	1.79e-7	Monocyte count;
SARC	cis	rs7772486	0.754	rs9373476	chr6:146139741	C/G	cg23711669	chr6:146136114	FBXO30	0.86	14.73	0.69	3.83e-35	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9902453	0.791	rs57719820	chr17:28335088	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.52	-6.74	-0.4	1.21e-10	Coffee consumption (cups per day);
SARC	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg07636037	chr3:49044803	WDR6	0.97	16.8	0.74	4.97e-42	Parkinson's disease;
SARC	cis	rs7945705	0.747	rs1123936	chr11:9003306	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.5	-7.27	-0.43	5.53e-12	Hemoglobin concentration;
SARC	cis	rs17533156	0.729	rs12603490	chr17:75122581	T/C	cg18815765	chr17:75136729	SEC14L1	0.48	4.86	0.3	2.12e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs7766436	0.885	rs4712699	chr6:22592884	C/A	cg13666174	chr6:22585274	NA	-0.61	-7.98	-0.46	6.78e-14	Coronary artery disease;
SARC	cis	rs933688	0.532	rs28637141	chr5:90538743	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.51	-5.72	-0.35	3.2e-8	Smoking behavior;
SARC	cis	rs6991838	0.530	rs35038843	chr8:66522498	T/A	cg13398993	chr8:66546079	ARMC1	-0.62	-8.19	-0.47	1.72e-14	Intelligence (multi-trait analysis);
SARC	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	-0.39	-4.75	-0.3	3.58e-6	Tonsillectomy;
SARC	cis	rs11122272	0.735	rs2474633	chr1:231486989	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-9.95	-0.55	1.14e-19	Hemoglobin concentration;
SARC	cis	rs9329221	0.527	rs7833781	chr8:10333477	A/G	cg21775007	chr8:11205619	TDH	0.39	5.11	0.32	6.62e-7	Neuroticism;
SARC	cis	rs7520050	0.966	rs61783220	chr1:46335312	G/A	cg24296786	chr1:45957014	TESK2	0.39	4.92	0.31	1.63e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs4268898	0.662	rs2891382	chr2:24511491	C/G	cg26838691	chr2:24397539	C2orf84	-0.49	-5.69	-0.35	3.78e-8	Asthma;
SARC	cis	rs477692	0.875	rs7091540	chr10:131420276	C/T	cg05714579	chr10:131428358	MGMT	-0.58	-7.77	-0.45	2.46e-13	Response to temozolomide;
SARC	cis	rs7617773	0.539	rs2017858	chr3:48382282	G/T	cg11946769	chr3:48343235	NME6	0.55	6.76	0.4	1.11e-10	Coronary artery disease;
SARC	cis	rs6456156	0.773	rs6456159	chr6:167529272	T/A	cg07741184	chr6:167504864	NA	-0.28	-5.29	-0.33	2.76e-7	Primary biliary cholangitis;
SARC	cis	rs1008375	0.646	rs4235387	chr4:17569327	T/G	cg02297831	chr4:17616191	MED28	0.42	4.92	0.31	1.61e-6	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs17030434	0.911	rs115948674	chr4:154742052	G/T	cg14289246	chr4:154710475	SFRP2	-0.76	-7.91	-0.46	1.03e-13	Electrocardiographic conduction measures;
SARC	cis	rs2153535	0.580	rs1577471	chr6:8485905	T/A	cg21535247	chr6:8435926	SLC35B3	0.55	6.88	0.41	5.45e-11	Motion sickness;
SARC	cis	rs4481887	0.610	rs28763387	chr1:248559244	T/C	cg00666640	chr1:248458726	OR2T12	0.32	5.77	0.35	2.57e-8	Common traits (Other);
SARC	cis	rs3106136	0.546	rs2276910	chr4:95129238	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.45	-6.47	-0.39	5.78e-10	Capecitabine sensitivity;
SARC	cis	rs9906944	0.641	rs11655587	chr17:47140794	C/T	cg16584676	chr17:46985605	UBE2Z	-0.41	-4.89	-0.31	1.84e-6	Intelligence (multi-trait analysis);Body fat percentage;
SARC	cis	rs7528419	0.617	rs4970834	chr1:109814880	C/T	cg00908766	chr1:109817496	CELSR2	-0.42	-4.88	-0.3	1.98e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
SARC	cis	rs6963495	0.818	rs17343556	chr7:105151272	C/T	cg13798780	chr7:105162888	PUS7	0.58	5.28	0.33	2.95e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs112591243	0.685	rs73379602	chr21:48027317	G/A	cg10657630	chr21:48055338	PRMT2	0.85	6.2	0.38	2.55e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	trans	rs10242455	0.571	rs28365067	chr7:99272310	G/A	cg20468253	chr7:106685977	PRKAR2B	-1.06	-6.34	-0.38	1.18e-9	Blood metabolite levels;
SARC	cis	rs2197308	0.610	rs10880837	chr12:37864924	C/T	cg26384229	chr12:38710491	ALG10B	0.9	13.46	0.66	5.96e-31	Morning vs. evening chronotype;
SARC	cis	rs7647973	0.626	rs62262672	chr3:49655927	T/A	cg13072238	chr3:49761600	GMPPB	0.68	6.56	0.39	3.49e-10	Menarche (age at onset);
SARC	cis	rs1448094	0.512	rs61930137	chr12:86242930	C/T	cg02569458	chr12:86230093	RASSF9	0.39	5.44	0.34	1.34e-7	Major depressive disorder;
SARC	cis	rs62158211	0.565	rs57611236	chr2:114103804	A/T	cg17784749	chr2:114082611	LOC440839	0.47	5.7	0.35	3.62e-8	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
SARC	cis	rs4690686	0.500	rs4690429	chr4:177263983	G/A	cg17059388	chr4:177262070	NA	0.36	4.78	0.3	3.09e-6	Essential tremor;
SARC	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg14517863	chr17:44321492	NA	0.4	5.96	0.36	9.13e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9388451	0.839	rs3799709	chr6:126078361	A/G	cg06289844	chr6:126071538	HEY2	0.37	6.14	0.37	3.45e-9	Brugada syndrome;
SARC	cis	rs2153535	0.580	rs9406159	chr6:8464859	C/G	cg07606381	chr6:8435919	SLC35B3	0.77	10.83	0.58	2.14e-22	Motion sickness;
SARC	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg11062466	chr8:58055876	NA	0.54	4.99	0.31	1.17e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs56235845	0.694	rs4976643	chr5:176760227	A/C	cg16006841	chr5:176797999	RGS14	0.52	7.0	0.42	2.7e-11	Hemoglobin concentration;Hematocrit;
SARC	cis	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg00745463	chr17:30367425	LRRC37B	-0.65	-5.13	-0.32	6.19e-7	Hip circumference adjusted for BMI;
SARC	cis	rs4481887	1.000	rs7513161	chr1:248453422	A/T	cg13385794	chr1:248469461	NA	0.34	5.15	0.32	5.62e-7	Common traits (Other);
SARC	cis	rs7769051	0.521	rs9321367	chr6:133084359	G/T	cg22852734	chr6:133119734	C6orf192	1.01	6.16	0.37	3.22e-9	Type 2 diabetes nephropathy;
SARC	cis	rs2760061	0.569	rs621631	chr1:228114728	A/G	cg02753203	chr1:228287806	NA	-0.54	-7.44	-0.44	1.96e-12	Diastolic blood pressure;
SARC	cis	rs2043112	0.929	rs13160161	chr5:39058356	A/G	cg04869206	chr5:39074266	RICTOR	-0.52	-6.27	-0.38	1.71e-9	Obesity-related traits;
SARC	cis	rs854765	0.547	rs2955355	chr17:17948475	G/A	cg23370820	chr17:17987590	NA	0.24	4.73	0.3	3.95e-6	Total body bone mineral density;
SARC	cis	rs11622475	1.000	rs7143682	chr14:104413455	C/T	cg20488157	chr14:104394430	TDRD9	0.37	4.9	0.31	1.78e-6	Bipolar disorder;
SARC	cis	rs35160687	0.901	rs10200186	chr2:86527423	C/T	cg10973622	chr2:86423274	IMMT	0.38	4.89	0.31	1.86e-6	Night sleep phenotypes;
SARC	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg07234876	chr8:600039	NA	0.98	7.66	0.45	4.82e-13	IgG glycosylation;
SARC	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.78	7.78	0.45	2.27e-13	Platelet count;
SARC	trans	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg21659725	chr3:3221576	CRBN	-0.8	-12.22	-0.62	7.09e-27	Intelligence (multi-trait analysis);
SARC	cis	rs7582720	0.945	rs72934601	chr2:204031137	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	7.85	0.46	1.5e-13	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs600231	0.623	rs3015966	chr11:65217589	T/C	cg17120908	chr11:65337727	SSSCA1	-0.41	-5.12	-0.32	6.44e-7	Bone mineral density;
SARC	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg11941060	chr3:133502564	NA	-0.4	-5.66	-0.35	4.32e-8	Iron status biomarkers;
SARC	cis	rs7481584	0.624	rs440130	chr11:3051476	A/G	cg08508325	chr11:3079039	CARS	0.23	5.15	0.32	5.5e-7	Calcium levels;
SARC	cis	rs950776	0.616	rs647041	chr15:78880481	T/C	cg17108064	chr15:78857060	CHRNA5	-0.34	-5.78	-0.35	2.35e-8	Sudden cardiac arrest;
SARC	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg11062466	chr8:58055876	NA	0.52	5.11	0.32	6.81e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs11122272	0.735	rs2486743	chr1:231506928	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-9.85	-0.54	2.37e-19	Hemoglobin concentration;
SARC	cis	rs7829975	0.606	rs7819827	chr8:8797055	G/C	cg08975724	chr8:8085496	FLJ10661	-0.39	-4.78	-0.3	3.16e-6	Mood instability;
SARC	cis	rs3093024	0.595	rs4412174	chr6:167476066	A/G	cg07741184	chr6:167504864	NA	0.38	7.32	0.43	3.92e-12	Rheumatoid arthritis;
SARC	cis	rs514406	0.505	rs427319	chr1:53178807	T/G	cg08859206	chr1:53392774	SCP2	-0.35	-5.02	-0.31	1.01e-6	Monocyte count;
SARC	cis	rs10876993	0.890	rs12302351	chr12:58062590	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.48	-6.12	-0.37	4.02e-9	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs3820928	0.874	rs1114562	chr2:227788592	T/C	cg05526886	chr2:227700861	RHBDD1	-0.53	-6.52	-0.39	4.25e-10	Pulmonary function;
SARC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg07332563	chr6:291687	DUSP22	-0.6	-8.2	-0.47	1.63e-14	Menopause (age at onset);
SARC	cis	rs992157	0.835	rs12987180	chr2:219144089	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.7	-10.25	-0.56	1.35e-20	Colorectal cancer;
SARC	cis	rs3741151	0.687	rs56857598	chr11:73234173	G/A	cg17517138	chr11:73019481	ARHGEF17	0.92	6.86	0.41	6.15e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs10504229	0.593	rs113184543	chr8:58042950	A/G	cg20607798	chr8:58055168	NA	0.54	4.95	0.31	1.44e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs7666738	0.830	rs13108705	chr4:99044438	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs798554	0.660	rs2527694	chr7:2858240	T/C	cg13628971	chr7:2884303	GNA12	0.46	5.77	0.35	2.54e-8	Height;
SARC	cis	rs9467711	0.516	rs1165163	chr6:25863487	G/C	cg21479132	chr6:26055353	NA	0.64	5.0	0.31	1.15e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs4268898	0.931	rs34504814	chr2:24503766	C/T	cg26838691	chr2:24397539	C2orf84	-0.37	-4.88	-0.3	1.93e-6	Asthma;
SARC	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg19223190	chr17:80058835	NA	-0.43	-6.02	-0.37	6.57e-9	Life satisfaction;
SARC	cis	rs2153904	0.590	rs823106	chr1:205656453	G/C	cg11965913	chr1:205819406	PM20D1	0.59	5.3	0.33	2.7e-7	Prostate-specific antigen levels;
SARC	cis	rs9815354	0.812	rs73071343	chr3:41826877	G/C	cg03022575	chr3:42003672	ULK4	0.71	5.89	0.36	1.34e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs7937682	0.562	rs12275761	chr11:111367083	T/A	cg22437258	chr11:111473054	SIK2	-0.4	-4.78	-0.3	3.17e-6	Primary sclerosing cholangitis;
SARC	cis	rs58688157	0.739	rs56333810	chr11:575408	C/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.51	-6.18	-0.38	2.88e-9	Systemic lupus erythematosus;
SARC	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg22920501	chr2:26401640	FAM59B	-0.61	-8.19	-0.47	1.71e-14	Gut microbiome composition (summer);
SARC	cis	rs7223966	1.000	rs9909992	chr17:61731931	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.56	-5.97	-0.36	8.65e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs10791097	0.694	rs10791100	chr11:130738946	T/A	cg12179176	chr11:130786555	SNX19	0.73	10.92	0.58	1.08e-22	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs738322	0.753	rs5756968	chr22:38595240	C/T	cg25457927	chr22:38595422	NA	0.37	8.24	0.48	1.23e-14	Cutaneous nevi;
SARC	cis	rs654950	0.806	rs10749832	chr1:42041806	C/T	cg06885757	chr1:42089581	HIVEP3	0.39	5.65	0.35	4.64e-8	Airway imaging phenotypes;
SARC	cis	rs67311347	1.000	rs4973898	chr3:40459532	A/G	cg09455208	chr3:40491958	NA	-0.4	-6.27	-0.38	1.72e-9	Renal cell carcinoma;
SARC	cis	rs35110281	0.693	rs2838344	chr21:45089877	C/T	cg21573476	chr21:45109991	RRP1B	-0.56	-7.94	-0.46	8.51e-14	Mean corpuscular volume;
SARC	cis	rs897080	0.552	rs1067405	chr2:44674861	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	6.37	0.38	1.02e-9	Height;
SARC	cis	rs4423214	1.000	rs12419334	chr11:71139472	T/C	cg24826892	chr11:71159390	DHCR7	0.45	5.4	0.33	1.66e-7	Vitamin D levels;
SARC	cis	rs6141769	0.542	rs2064934	chr20:31314757	C/G	cg13636640	chr20:31349939	DNMT3B	-0.45	-4.78	-0.3	3.08e-6	Subjective well-being;
SARC	cis	rs12421382	0.811	rs11602639	chr11:109472829	C/T	cg15948088	chr11:109293068	C11orf87	0.39	5.06	0.31	8.64e-7	Schizophrenia;
SARC	cis	rs2230307	0.536	rs611421	chr1:100540289	A/G	cg24955406	chr1:100503596	HIAT1	0.63	6.2	0.38	2.48e-9	Carotid intima media thickness;
SARC	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg04772025	chr11:68637568	NA	0.55	7.0	0.42	2.72e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9457247	1.000	rs2769354	chr6:167379771	G/T	cg23791538	chr6:167370224	RNASET2	0.63	8.74	0.5	4.81e-16	Crohn's disease;
SARC	cis	rs2645694	0.626	rs2645704	chr4:77830805	T/C	cg03477792	chr4:77819574	ANKRD56	0.41	6.1	0.37	4.45e-9	Emphysema distribution in smoking;
SARC	cis	rs2859741	1.000	rs543121	chr1:37497098	T/C	cg09363841	chr1:37513479	NA	-0.28	-4.98	-0.31	1.21e-6	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
SARC	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg11890956	chr21:40555474	PSMG1	-1.17	-18.51	-0.77	1.14e-47	Cognitive function;
SARC	cis	rs9810259	0.554	rs13088728	chr3:12338450	C/A	cg23514324	chr3:12329213	PPARG	-0.38	-4.89	-0.31	1.84e-6	Platelet count;
SARC	cis	rs981844	1.000	rs62325105	chr4:154673846	T/C	cg14289246	chr4:154710475	SFRP2	0.59	6.62	0.4	2.43e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs6546550	0.901	rs3771531	chr2:70164034	T/C	cg02498382	chr2:70120550	SNRNP27	-0.35	-5.63	-0.35	5.04e-8	Prevalent atrial fibrillation;
SARC	cis	rs7178572	1.000	rs965480	chr15:77781926	A/G	cg22256960	chr15:77711686	NA	-0.56	-6.59	-0.4	2.99e-10	Type 2 diabetes;
SARC	cis	rs4319547	0.695	rs10773103	chr12:122856532	A/G	cg05707623	chr12:122985044	ZCCHC8	0.57	6.43	0.39	6.96e-10	Body mass index;
SARC	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg22535103	chr8:58192502	C8orf71	-0.64	-6.67	-0.4	1.84e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs17376456	0.569	rs2045021	chr5:93224222	G/A	cg25358565	chr5:93447407	FAM172A	-0.96	-11.33	-0.6	5.62e-24	Diabetic retinopathy;
SARC	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.9	-0.5	1.61e-16	Alzheimer's disease;
SARC	cis	rs2760061	0.626	rs2313118	chr1:228118084	T/C	cg02753203	chr1:228287806	NA	-0.54	-7.45	-0.44	1.79e-12	Diastolic blood pressure;
SARC	cis	rs2228479	0.850	rs11642010	chr16:89845111	T/C	cg00800038	chr16:89945340	TCF25	-0.81	-5.46	-0.34	1.21e-7	Skin colour saturation;
SARC	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg00684032	chr4:1343700	KIAA1530	0.37	5.34	0.33	2.23e-7	Obesity-related traits;
SARC	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.38	0.44	2.71e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.06	17.7	0.76	5.38e-45	Height;
SARC	cis	rs870825	0.616	rs7674952	chr4:185622327	A/C	cg04058563	chr4:185651563	MLF1IP	0.81	11.32	0.6	5.66e-24	Blood protein levels;
SARC	cis	rs694739	0.726	rs516124	chr11:64128423	G/T	cg23796481	chr11:64053134	BAD;GPR137	0.67	7.66	0.45	4.92e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs1059312	1.000	rs7135854	chr12:129279988	G/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.5	7.08	0.42	1.69e-11	Systemic lupus erythematosus;
SARC	cis	rs2838344	0.776	rs2298561	chr21:45085234	A/G	cg21573476	chr21:45109991	RRP1B	-0.59	-8.5	-0.49	2.35e-15	Coronary artery disease;
SARC	cis	rs17376456	0.778	rs10476604	chr5:93461838	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.5	5.53	0.34	8.52e-8	Diabetic retinopathy;
SARC	cis	rs6570726	0.934	rs430003	chr6:145819506	C/T	cg05220968	chr6:146057943	EPM2A	-0.29	-4.83	-0.3	2.44e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10870270	0.956	rs7915388	chr10:133734972	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.8	-10.37	-0.56	5.78e-21	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs9902453	0.833	rs7216631	chr17:28495112	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	7.0	0.42	2.73e-11	Coffee consumption (cups per day);
SARC	cis	rs6500602	0.964	rs2304633	chr16:4496973	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.37	6.11	0.37	4.2e-9	Schizophrenia;
SARC	cis	rs35306767	0.953	rs11253520	chr10:975961	C/G	cg09063859	chr10:1086904	IDI1;C10orf110	0.4	5.1	0.32	7.13e-7	Eosinophil percentage of granulocytes;
SARC	cis	rs6500395	0.962	rs9936883	chr16:48676443	G/A	cg04672837	chr16:48644449	N4BP1	0.46	6.28	0.38	1.65e-9	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg20607798	chr8:58055168	NA	0.56	5.25	0.33	3.4e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	trans	rs10887741	0.646	rs11202502	chr10:89437933	C/T	cg10339481	chr11:33850452	NA	0.37	6.37	0.39	1.02e-9	Exercise (leisure time);
SARC	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	11.57	0.6	9.31e-25	Platelet count;
SARC	cis	rs10782582	0.609	rs5745553	chr1:76379135	A/T	cg10523679	chr1:76189770	ACADM	-0.39	-4.73	-0.3	3.86e-6	Daytime sleep phenotypes;
SARC	cis	rs2204008	0.777	rs114096617	chr12:38342557	A/C	cg26384229	chr12:38710491	ALG10B	0.88	12.61	0.64	3.88e-28	Bladder cancer;
SARC	cis	rs7223966	0.960	rs7212379	chr17:61706122	G/A	cg26338869	chr17:61819248	STRADA	0.44	4.88	0.3	1.95e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs3857536	0.706	rs2157963	chr6:66945449	A/T	cg07460842	chr6:66804631	NA	-0.45	-5.19	-0.32	4.5e-7	Blood trace element (Cu levels);
SARC	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg19346786	chr7:2764209	NA	0.39	5.89	0.36	1.35e-8	Height;
SARC	cis	rs3733585	0.673	rs7378340	chr4:9955198	C/T	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.89	-0.36	1.37e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs57920188	0.535	rs58051771	chr1:4092146	T/C	cg20703997	chr1:4087676	NA	0.5	5.37	0.33	1.86e-7	Interleukin-17 levels;
SARC	cis	rs7659604	1.000	rs28618203	chr4:122663935	T/C	cg19748678	chr4:122722346	EXOSC9	0.43	5.37	0.33	1.9e-7	Type 2 diabetes;
SARC	cis	rs9372253	0.678	rs9372251	chr6:110700656	A/G	cg00083206	chr6:110721305	DDO	-0.4	-5.26	-0.33	3.26e-7	Platelet distribution width;
SARC	cis	rs12188164	1.000	rs34453673	chr5:434722	G/C	cg26850624	chr5:429559	AHRR	-0.32	-4.98	-0.31	1.26e-6	Cystic fibrosis severity;
SARC	cis	rs9916302	0.821	rs1966915	chr17:37425262	A/C	cg15445000	chr17:37608096	MED1	0.42	5.16	0.32	5.18e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs7824557	0.564	rs2572404	chr8:11199584	A/G	cg21775007	chr8:11205619	TDH	0.66	8.64	0.49	9.36e-16	Retinal vascular caliber;
SARC	cis	rs7829975	0.846	rs11779061	chr8:8549432	G/A	cg06636001	chr8:8085503	FLJ10661	-0.64	-8.4	-0.48	4.55e-15	Mood instability;
SARC	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg02733842	chr7:1102375	C7orf50	-0.62	-7.48	-0.44	1.49e-12	Bronchopulmonary dysplasia;
SARC	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg13628971	chr7:2884303	GNA12	0.65	7.82	0.46	1.85e-13	Height;
SARC	cis	rs7005380	0.581	rs9987165	chr8:120933873	T/C	cg21744203	chr8:120868354	DSCC1	0.44	5.15	0.32	5.65e-7	Interstitial lung disease;
SARC	cis	rs870825	0.616	rs4623060	chr4:185642943	A/G	cg04058563	chr4:185651563	MLF1IP	0.83	11.73	0.61	2.78e-25	Blood protein levels;
SARC	cis	rs7615952	0.932	rs13321217	chr3:125631771	G/A	cg05084668	chr3:125655381	ALG1L	-0.59	-5.93	-0.36	1.07e-8	Blood pressure (smoking interaction);
SARC	cis	rs3820928	1.000	rs978909	chr2:227771389	A/C	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.88	-0.36	1.41e-8	Pulmonary function;
SARC	cis	rs611744	0.967	rs635624	chr8:109197799	G/C	cg21045802	chr8:109455806	TTC35	0.44	5.15	0.32	5.6e-7	Dupuytren's disease;
SARC	cis	rs11997175	0.583	rs34540455	chr8:33799300	C/T	ch.8.33884649F	chr8:33765107	NA	0.5	6.49	0.39	4.99e-10	Body mass index;
SARC	cis	rs9398803	0.678	rs9401892	chr6:126895368	G/A	cg20229609	chr6:126660872	C6orf173	0.35	5.07	0.31	8.26e-7	Male-pattern baldness;
SARC	cis	rs2239547	0.563	rs9876403	chr3:52916916	C/T	cg18404041	chr3:52824283	ITIH1	-0.4	-4.9	-0.31	1.77e-6	Schizophrenia;
SARC	cis	rs644799	1.000	rs560854	chr11:95584905	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.69	9.41	0.52	4.97e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs6500602	0.727	rs4786516	chr16:4578641	C/T	cg08645402	chr16:4508243	NA	0.42	5.37	0.33	1.86e-7	Schizophrenia;
SARC	cis	rs2504916	0.955	rs2457014	chr6:160824145	C/T	cg20340146	chr6:160172821	WTAP	0.47	4.73	0.3	3.93e-6	Response to hepatitis C treatment;
SARC	cis	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.41	5.1	0.32	6.88e-7	Eosinophil percentage of white cells;
SARC	cis	rs6831352	0.918	rs17218141	chr4:100055908	T/C	cg12011299	chr4:100065546	ADH4	-0.34	-5.74	-0.35	2.95e-8	Alcohol dependence;
SARC	cis	rs9818758	0.607	rs5030795	chr3:49141116	C/T	cg01304814	chr3:48885189	PRKAR2A	0.64	5.57	0.34	6.99e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg08677398	chr8:58056175	NA	0.44	5.27	0.33	3.14e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7712401	0.601	rs13155907	chr5:122334633	C/T	cg19412675	chr5:122181750	SNX24	-0.43	-5.43	-0.34	1.41e-7	Mean platelet volume;
SARC	cis	rs9322193	0.566	rs3922947	chr6:150245992	G/A	cg05036130	chr6:150231994	NA	-0.3	-4.88	-0.3	1.98e-6	Lung cancer;
SARC	cis	rs644799	0.932	rs523934	chr11:95641775	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.63	8.19	0.47	1.75e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7011049	1.000	rs78977297	chr8:53858902	T/C	cg26025543	chr8:53854495	NA	0.61	5.37	0.33	1.87e-7	Systolic blood pressure;
SARC	cis	rs950776	0.518	rs12906284	chr15:78825105	C/T	cg06917634	chr15:78832804	PSMA4	0.91	14.24	0.68	1.6e-33	Sudden cardiac arrest;
SARC	cis	rs806795	0.605	rs6935954	chr6:26255451	A/G	cg05868516	chr6:26286170	HIST1H4H	0.47	5.16	0.32	5.31e-7	Mosquito bite size;
SARC	cis	rs7666738	0.791	rs6828752	chr4:99063382	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.7	0.5	6.15e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg04772025	chr11:68637568	NA	0.52	6.55	0.39	3.56e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs10782582	0.609	rs72979226	chr1:76302222	C/A	cg10523679	chr1:76189770	ACADM	-0.43	-5.29	-0.33	2.77e-7	Daytime sleep phenotypes;
SARC	cis	rs1981331	0.609	rs57896262	chr21:48028188	C/T	cg17243659	chr21:48055224	PRMT2	1.03	5.9	0.36	1.26e-8	Cerebrospinal fluid t-tau:AB1-42 ratio;
SARC	cis	rs9916302	0.821	rs1966915	chr17:37425262	A/C	cg20243544	chr17:37824526	PNMT	0.56	6.87	0.41	5.87e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.46	5.77	0.35	2.54e-8	Gut microbiome composition (summer);
SARC	cis	rs1320333	0.772	rs17786120	chr2:700580	A/T	cg03444855	chr2:621920	NA	-0.47	-4.93	-0.31	1.53e-6	Obesity-related traits;
SARC	cis	rs950776	0.593	rs680244	chr15:78871288	T/C	cg17108064	chr15:78857060	CHRNA5	-0.29	-4.97	-0.31	1.32e-6	Sudden cardiac arrest;
SARC	cis	rs6912958	0.728	rs6923230	chr6:88213949	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.28	-0.33	2.89e-7	Monocyte percentage of white cells;
SARC	cis	rs6964587	0.692	rs2299233	chr7:91626953	C/T	cg17063962	chr7:91808500	NA	-0.82	-12.53	-0.63	7.27e-28	Breast cancer;
SARC	cis	rs9457247	0.515	rs1951459	chr6:167402536	G/A	cg23791538	chr6:167370224	RNASET2	0.65	9.32	0.52	8.95e-18	Crohn's disease;
SARC	cis	rs7089973	0.872	rs34064819	chr10:116621154	C/A	cg08188268	chr10:116634841	FAM160B1	0.37	5.89	0.36	1.33e-8	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg11301795	chr4:187892539	NA	-0.69	-10.25	-0.56	1.41e-20	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4713675	0.565	rs4713665	chr6:33674419	T/G	cg15676125	chr6:33679581	C6orf125	0.52	6.36	0.38	1.03e-9	Plateletcrit;
SARC	cis	rs7216064	0.953	rs12450907	chr17:65870644	T/G	cg12091567	chr17:66097778	LOC651250	-0.64	-6.45	-0.39	6.56e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs10752881	0.775	rs2147585	chr1:183074875	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.17	0.55	2.42e-20	Colorectal cancer;
SARC	cis	rs4619890	0.528	rs28558196	chr4:7880360	T/A	cg18538662	chr4:7941764	AFAP1	-0.37	-4.76	-0.3	3.39e-6	Glaucoma (primary open-angle);
SARC	cis	rs17209837	1.000	rs45502492	chr7:87089898	C/T	cg00919237	chr7:87102261	ABCB4	-0.47	-4.96	-0.31	1.38e-6	Gallbladder cancer;
SARC	cis	rs7264396	0.747	rs2425151	chr20:34394541	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	5.2	0.32	4.36e-7	Total cholesterol levels;
SARC	cis	rs999943	0.810	rs62407648	chr6:33622436	C/G	cg14003231	chr6:33640908	ITPR3	0.6	9.56	0.53	1.81e-18	Obesity (extreme);
SARC	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4242434	0.854	rs13258100	chr8:22451116	A/T	cg03733263	chr8:22462867	KIAA1967	0.92	13.65	0.67	1.42e-31	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg24642844	chr7:1081250	C7orf50	-0.38	-5.24	-0.32	3.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs17376456	0.569	rs7729807	chr5:93104089	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.55	5.72	0.35	3.26e-8	Diabetic retinopathy;
SARC	cis	rs6815814	1.000	rs11722836	chr4:38811529	T/A	cg06935464	chr4:38784597	TLR10	0.63	6.34	0.38	1.16e-9	Breast cancer;
SARC	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg11062466	chr8:58055876	NA	0.56	5.69	0.35	3.79e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7769051	1.000	rs73554431	chr6:133129922	T/G	cg07930552	chr6:133119739	C6orf192	0.9	8.35	0.48	6.1e-15	Type 2 diabetes nephropathy;
SARC	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg12311346	chr5:56204834	C5orf35	-0.55	-5.68	-0.35	4.08e-8	Initial pursuit acceleration;
SARC	cis	rs9487051	0.652	rs13210424	chr6:109598737	G/A	cg01475377	chr6:109611718	NA	-0.36	-5.23	-0.32	3.86e-7	Reticulocyte fraction of red cells;
SARC	cis	rs892961	0.720	rs103458	chr17:75416031	A/G	cg05865280	chr17:75406074	SEPT9	0.54	7.85	0.46	1.5e-13	Airflow obstruction;
SARC	cis	rs796364	1.000	rs166845	chr2:200823360	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.75	7.03	0.42	2.27e-11	Schizophrenia;
SARC	trans	rs208520	0.526	rs6455072	chr6:66797215	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-21.67	-0.82	9.44e-58	Exhaled nitric oxide output;
SARC	cis	rs67311347	1.000	rs12638199	chr3:40475285	A/G	cg24209194	chr3:40518798	ZNF619	0.62	8.09	0.47	3.31e-14	Renal cell carcinoma;
SARC	cis	rs9309473	0.950	rs6711001	chr2:73850820	C/G	cg20560298	chr2:73613845	ALMS1	-0.45	-5.48	-0.34	1.08e-7	Metabolite levels;
SARC	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg21724239	chr8:58056113	NA	0.6	6.37	0.39	9.97e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg03517284	chr6:25882590	NA	0.48	6.38	0.39	9.58e-10	Blood metabolite levels;
SARC	trans	rs35833281	1.000	rs9464203	chr6:55037124	G/A	cg19977494	chr7:128431264	CCDC136	-0.75	-6.98	-0.42	3.11e-11	Morning vs. evening chronotype;
SARC	cis	rs10493773	0.609	rs12058974	chr1:86192235	T/A	cg17807903	chr1:86174739	ZNHIT6	-0.59	-9.62	-0.53	1.17e-18	Urate levels in overweight individuals;
SARC	cis	rs1904096	0.506	rs8336	chr4:95211610	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.5	-7.51	-0.44	1.22e-12	Type 2 diabetes;
SARC	cis	rs6580649	0.943	rs1990029	chr12:48407987	C/T	cg24011408	chr12:48396354	COL2A1	0.53	5.61	0.34	5.71e-8	Lung cancer;
SARC	cis	rs2033732	0.706	rs1370420	chr8:85068234	G/T	cg05716166	chr8:85095498	RALYL	0.47	5.62	0.35	5.51e-8	Body mass index;
SARC	cis	rs7246657	0.943	rs9304566	chr19:37845504	T/C	cg23950597	chr19:37808831	NA	-0.6	-5.85	-0.36	1.67e-8	Coronary artery calcification;
SARC	cis	rs9807989	0.773	rs72823661	chr2:102968716	G/A	cg09003973	chr2:102972529	NA	0.41	5.6	0.34	6.11e-8	Asthma;
SARC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.76	9.95	0.55	1.12e-19	Prudent dietary pattern;
SARC	cis	rs986417	0.818	rs10144990	chr14:60927816	T/C	cg27398547	chr14:60952738	C14orf39	1.01	9.11	0.51	3.86e-17	Gut microbiota (bacterial taxa);
SARC	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg11764359	chr7:65958608	NA	0.77	9.76	0.54	4.51e-19	Aortic root size;
SARC	cis	rs7953249	0.502	rs1169294	chr12:121426594	G/A	cg25281562	chr12:121454272	C12orf43	0.52	6.35	0.38	1.12e-9	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg11062466	chr8:58055876	NA	0.51	5.26	0.33	3.22e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs11098499	0.954	rs10008392	chr4:120318839	G/A	cg09307838	chr4:120376055	NA	0.9	12.12	0.62	1.58e-26	Corneal astigmatism;
SARC	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.68	6.53	0.39	4.09e-10	Platelet count;
SARC	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg12696929	chr3:195401817	SDHAP2	0.39	5.26	0.33	3.33e-7	Pancreatic cancer;
SARC	cis	rs9393692	0.645	rs2179152	chr6:26325888	T/C	cg13736514	chr6:26305472	NA	-0.72	-9.27	-0.52	1.3e-17	Educational attainment;
SARC	cis	rs4974559	1.000	rs10006789	chr4:1330333	T/C	cg02980000	chr4:1222292	CTBP1	0.61	5.86	0.36	1.54e-8	Systolic blood pressure;
SARC	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-7.96	-0.46	7.49e-14	Chronic sinus infection;
SARC	cis	rs2361718	0.900	rs8081698	chr17:78104212	G/A	cg27427491	chr17:78079615	GAA	-0.33	-5.41	-0.33	1.59e-7	Yeast infection;
SARC	cis	rs950169	1.000	rs11638297	chr15:84782417	A/C	cg17507749	chr15:85114479	UBE2QP1	0.77	9.58	0.53	1.52e-18	Schizophrenia;
SARC	cis	rs654950	0.653	rs2810568	chr1:42054247	A/G	cg06885757	chr1:42089581	HIVEP3	-0.41	-6.05	-0.37	5.72e-9	Airway imaging phenotypes;
SARC	cis	rs546131	0.890	rs485845	chr11:34830389	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-5.85	-0.36	1.69e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs4509693	0.765	rs10786604	chr10:102495302	C/G	cg15234845	chr10:102496500	NA	0.33	4.82	0.3	2.63e-6	Alzheimer's disease;
SARC	cis	rs9916302	0.904	rs10221223	chr17:37489100	T/G	cg07936489	chr17:37558343	FBXL20	0.68	9.2	0.52	2.14e-17	Glomerular filtration rate (creatinine);
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg16677885	chr7:150778122	FASTK	0.5	6.52	0.39	4.38e-10	Lung adenocarcinoma;
SARC	cis	rs7223966	0.921	rs6504186	chr17:61863932	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.53	-5.68	-0.35	4.01e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs4803468	1.000	rs284656	chr19:41929251	T/C	cg14132834	chr19:41945861	ATP5SL	-0.57	-7.49	-0.44	1.39e-12	Height;
SARC	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.92	9.25	0.52	1.46e-17	Platelet count;
SARC	cis	rs943466	1.000	rs61394483	chr6:33751945	G/A	cg04676172	chr6:33757040	LEMD2	0.47	4.91	0.31	1.75e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
SARC	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg16479474	chr6:28041457	NA	0.36	5.18	0.32	4.71e-7	Parkinson's disease;
SARC	cis	rs3796352	1.000	rs11707780	chr3:53084326	A/G	cg07884673	chr3:53033167	SFMBT1	-0.62	-4.74	-0.3	3.8e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs6963495	0.818	rs6956234	chr7:105149707	A/G	cg19920283	chr7:105172520	RINT1	0.67	5.8	0.36	2.14e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7216064	1.000	rs6504548	chr17:65886048	T/C	cg12091567	chr17:66097778	LOC651250	-0.71	-7.84	-0.46	1.6e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs67311347	0.911	rs6773917	chr3:40469254	G/T	cg24209194	chr3:40518798	ZNF619	0.61	7.88	0.46	1.24e-13	Renal cell carcinoma;
SARC	cis	rs11122272	0.735	rs2739509	chr1:231526765	C/T	cg06096015	chr1:231504339	EGLN1	0.4	5.89	0.36	1.33e-8	Hemoglobin concentration;
SARC	cis	rs67460515	0.892	rs11711695	chr3:161057593	A/G	cg17135325	chr3:160939158	NMD3	0.62	7.93	0.46	8.88e-14	Parkinson's disease;
SARC	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.4	-4.83	-0.3	2.44e-6	Lymphocyte counts;
SARC	cis	rs9549260	0.534	rs4943810	chr13:41297405	C/A	cg21288729	chr13:41239152	FOXO1	0.54	4.91	0.31	1.69e-6	Red blood cell count;
SARC	cis	rs74181299	1.000	rs74181299	chr2:65283972	T/C	cg20592124	chr2:65290738	CEP68	0.5	7.39	0.44	2.64e-12	Pulse pressure;
SARC	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg22535103	chr8:58192502	C8orf71	-0.59	-6.21	-0.38	2.35e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6942407	0.546	rs2190424	chr7:86841971	T/C	cg02420886	chr7:86849541	C7orf23	0.71	6.17	0.37	2.99e-9	Food allergy;
SARC	cis	rs7681440	0.804	rs1442135	chr4:90819093	C/T	cg01966878	chr4:90757139	SNCA	0.38	4.86	0.3	2.13e-6	Dementia with Lewy bodies;
SARC	cis	rs6456042	1.000	rs4709098	chr6:166534145	G/A	cg11088901	chr6:166572345	T	-0.32	-4.74	-0.3	3.8e-6	Asthma;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg24721157	chr3:193311006	OPA1	0.6	7.53	0.44	1.08e-12	Breast cancer;
SARC	cis	rs8523	0.744	rs57896541	chr6:11075017	T/C	cg13562911	chr6:11044106	ELOVL2	0.41	5.39	0.33	1.69e-7	Red blood cell fatty acid levels;
SARC	cis	rs9796	0.621	rs9972349	chr15:41491656	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.54	-7.81	-0.46	1.88e-13	Menopause (age at onset);
SARC	cis	rs77633900	0.614	rs2468123	chr15:76931345	T/C	cg21673338	chr15:77095150	SCAPER	-0.6	-5.06	-0.31	8.63e-7	Non-glioblastoma glioma;Glioma;
SARC	cis	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg08564027	chr20:61660810	NA	0.76	11.75	0.61	2.46e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs1712517	1.000	rs1163084	chr10:105039048	T/C	cg05636881	chr10:105038444	INA	0.33	4.81	0.3	2.77e-6	Migraine;
SARC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg11494091	chr17:61959527	GH2	0.54	8.26	0.48	1.08e-14	Prudent dietary pattern;
SARC	trans	rs208520	1.000	rs208521	chr6:66953625	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.82	-8.98	-0.51	9.32e-17	Exhaled nitric oxide output;
SARC	trans	rs11098499	0.697	rs4560394	chr4:120313435	T/G	cg25214090	chr10:38739885	LOC399744	0.55	7.14	0.42	1.15e-11	Corneal astigmatism;
SARC	cis	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg05623727	chr3:50126028	RBM5	-0.35	-5.15	-0.32	5.59e-7	Body mass index;
SARC	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.31	-0.38	1.36e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7582720	0.943	rs72934550	chr2:203983940	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	7.8	0.45	2.11e-13	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs12142240	0.660	rs6679080	chr1:46819779	A/T	cg10495392	chr1:46806563	NSUN4	0.65	6.83	0.41	7.25e-11	Menopause (age at onset);
SARC	cis	rs6570726	0.577	rs399502	chr6:145805874	A/G	cg05347473	chr6:146136440	FBXO30	0.7	9.49	0.53	2.94e-18	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs897080	0.515	rs1067400	chr2:44677647	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	5.62	0.35	5.55e-8	Height;
SARC	cis	rs4253772	0.575	rs9615983	chr22:46793314	G/A	cg24881330	chr22:46731750	TRMU	0.73	5.89	0.36	1.34e-8	LDL cholesterol;Cholesterol, total;
SARC	cis	rs7520050	0.807	rs28844317	chr1:46209207	T/C	cg06784218	chr1:46089804	CCDC17	0.26	4.82	0.3	2.6e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs4268898	0.662	rs74470633	chr2:24438712	A/G	cg26838691	chr2:24397539	C2orf84	-0.53	-6.14	-0.37	3.56e-9	Asthma;
SARC	cis	rs6686643	1.000	rs6686643	chr1:165616588	T/C	cg19407955	chr1:165599744	MGST3	-0.58	-5.98	-0.36	8.23e-9	Total ventricular volume;
SARC	cis	rs288326	0.561	rs77496277	chr2:183761706	C/T	cg09997497	chr2:183902928	NCKAP1	0.72	4.83	0.3	2.43e-6	Blood protein levels;
SARC	cis	rs344364	0.511	rs2982449	chr16:1947878	C/G	cg26617929	chr16:1858877	NA	-0.71	-6.06	-0.37	5.5e-9	Glomerular filtration rate in chronic kidney disease;
SARC	cis	rs7084402	0.967	rs1649092	chr10:60289389	A/T	cg07615347	chr10:60278583	BICC1	0.6	8.57	0.49	1.41e-15	Refractive error;
SARC	cis	rs559928	0.606	rs11605856	chr11:63925528	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	5.07	0.32	8.03e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs7617773	0.963	rs9822496	chr3:48181333	T/C	cg11946769	chr3:48343235	NME6	0.49	5.93	0.36	1.1e-8	Coronary artery disease;
SARC	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.45	-5.48	-0.34	1.08e-7	Tonsillectomy;
SARC	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg07308232	chr7:1071921	C7orf50	-0.6	-7.67	-0.45	4.79e-13	Longevity;Endometriosis;
SARC	cis	rs5015933	0.736	rs10125995	chr9:128145942	C/T	cg14078157	chr9:128172775	NA	-0.32	-4.79	-0.3	2.93e-6	Body mass index;
SARC	cis	rs67460515	0.529	rs11712713	chr3:160852471	A/G	cg17135325	chr3:160939158	NMD3	0.59	7.25	0.43	5.97e-12	Parkinson's disease;
SARC	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	7.34	0.43	3.43e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2011503	0.941	rs17751061	chr19:19413092	C/T	cg03709012	chr19:19516395	GATAD2A	0.69	6.05	0.37	5.86e-9	Bipolar disorder;
SARC	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg21782813	chr7:2030301	MAD1L1	0.37	5.59	0.34	6.24e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs2075371	1.000	rs2598296	chr7:133992985	C/T	cg00033643	chr7:134001901	SLC35B4	0.42	5.15	0.32	5.59e-7	Mean platelet volume;
SARC	cis	rs12479064	0.724	rs11885942	chr2:100004165	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.45	-5.16	-0.32	5.23e-7	Chronic sinus infection;
SARC	cis	rs7829975	0.846	rs11779061	chr8:8549432	G/A	cg08975724	chr8:8085496	FLJ10661	-0.45	-5.53	-0.34	8.68e-8	Mood instability;
SARC	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg24110177	chr3:50126178	RBM5	-0.39	-5.01	-0.31	1.08e-6	Intelligence (multi-trait analysis);
SARC	trans	rs66573146	0.831	rs56031152	chr4:6973832	C/A	cg07817883	chr1:32538562	TMEM39B	1.32	8.67	0.49	7.41e-16	Granulocyte percentage of myeloid white cells;
SARC	cis	rs7666738	0.791	rs11729596	chr4:99045461	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1055129	0.560	rs56248937	chr17:73915153	T/A	cg06969265	chr17:73775802	H3F3B	0.46	5.54	0.34	8.01e-8	White matter hyperintensity burden;
SARC	cis	rs2304069	0.954	rs10045945	chr5:149419297	C/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.67	6.62	0.4	2.48e-10	HIV-1 control;
SARC	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg11890956	chr21:40555474	PSMG1	1.13	18.53	0.77	9.93e-48	Cognitive function;
SARC	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg06636001	chr8:8085503	FLJ10661	0.85	12.75	0.64	1.3e-28	Neuroticism;
SARC	cis	rs10911232	0.507	rs3934578	chr1:183027216	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.12	0.55	3.44e-20	Hypertriglyceridemia;
SARC	cis	rs2075371	0.932	rs2241333	chr7:133970750	C/T	cg11752832	chr7:134001865	SLC35B4	0.57	7.5	0.44	1.34e-12	Mean platelet volume;
SARC	cis	rs6546550	0.935	rs2305523	chr2:70039677	G/T	cg02498382	chr2:70120550	SNRNP27	0.37	6.15	0.37	3.4e-9	Prevalent atrial fibrillation;
SARC	cis	rs7824557	0.767	rs7003241	chr8:11169075	A/G	cg21775007	chr8:11205619	TDH	0.5	5.89	0.36	1.35e-8	Retinal vascular caliber;
SARC	cis	rs4727027	0.901	rs4727018	chr7:148822247	G/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	5.85	0.36	1.61e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	trans	rs9354308	0.838	rs9445595	chr6:66537559	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.56	-6.63	-0.4	2.26e-10	Metabolite levels;
SARC	cis	rs76419734	1.000	rs11732629	chr4:106754347	C/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.77	5.19	0.32	4.53e-7	Post bronchodilator FEV1;
SARC	cis	rs12477438	0.765	rs17708262	chr2:99696313	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-7.6	-0.45	7.03e-13	Chronic sinus infection;
SARC	cis	rs2228479	0.850	rs62056091	chr16:89930414	G/A	cg06558623	chr16:89946397	TCF25	0.94	6.66	0.4	2e-10	Skin colour saturation;
SARC	cis	rs10504073	0.584	rs1511368	chr8:49949523	A/T	cg00325661	chr8:49890786	NA	0.51	6.78	0.41	9.76e-11	Blood metabolite ratios;
SARC	cis	rs8072100	0.840	rs11079774	chr17:45479706	C/G	cg08085267	chr17:45401833	C17orf57	-0.42	-5.02	-0.31	1.05e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs9467711	0.651	rs13192713	chr6:25943234	C/A	cg21479132	chr6:26055353	NA	0.84	5.2	0.32	4.46e-7	Autism spectrum disorder or schizophrenia;
SARC	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg08859206	chr1:53392774	SCP2	-0.41	-5.96	-0.36	9.04e-9	Monocyte count;
SARC	trans	rs637571	0.512	rs660118	chr11:65735174	G/C	cg17712092	chr4:129076599	LARP1B	0.72	9.75	0.54	4.81e-19	Eosinophil percentage of white cells;
SARC	cis	rs11676348	0.755	rs6436026	chr2:218951738	T/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.49	-6.44	-0.39	6.62e-10	Ulcerative colitis;
SARC	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.44	5.01	0.31	1.06e-6	Renal function-related traits (BUN);
SARC	cis	rs2559856	1.000	rs2695298	chr12:102082589	G/A	cg12924262	chr12:102091054	CHPT1	0.58	7.73	0.45	3.2e-13	Blood protein levels;
SARC	cis	rs35110281	0.667	rs7282405	chr21:45123611	C/G	cg21573476	chr21:45109991	RRP1B	-0.58	-8.06	-0.47	4e-14	Mean corpuscular volume;
SARC	cis	rs929354	0.713	rs6459733	chr7:156930550	G/C	cg05182265	chr7:156933206	UBE3C	-0.33	-4.96	-0.31	1.37e-6	Body mass index;
SARC	cis	rs7824557	0.564	rs34389419	chr8:11229319	C/G	cg21775007	chr8:11205619	TDH	-0.64	-8.55	-0.49	1.65e-15	Retinal vascular caliber;
SARC	cis	rs2153535	0.601	rs6906170	chr6:8543128	T/A	cg21535247	chr6:8435926	SLC35B3	0.55	6.96	0.41	3.48e-11	Motion sickness;
SARC	cis	rs7429990	0.965	rs9854454	chr3:48012797	A/G	cg11946769	chr3:48343235	NME6	-0.46	-5.47	-0.34	1.18e-7	Educational attainment (years of education);
SARC	cis	rs10911232	0.507	rs10797817	chr1:182999136	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.67	0.57	6.63e-22	Hypertriglyceridemia;
SARC	cis	rs887829	0.570	rs7608175	chr2:234599089	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.31	4.73	0.3	3.85e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
SARC	cis	rs7520050	0.966	rs12405451	chr1:46384326	T/A	cg06784218	chr1:46089804	CCDC17	-0.26	-4.75	-0.3	3.57e-6	Red blood cell count;Reticulocyte count;
SARC	trans	rs208520	1.000	rs72884033	chr6:66995747	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	9.32	0.52	9.16e-18	Exhaled nitric oxide output;
SARC	trans	rs3780486	0.505	rs959749	chr9:33147858	T/C	cg04842962	chr6:43655489	MRPS18A	0.84	11.76	0.61	2.23e-25	IgG glycosylation;
SARC	cis	rs11731606	0.508	rs28501313	chr4:95281023	G/A	cg20625393	chr4:95128694	SMARCAD1	0.59	5.62	0.35	5.5e-8	Mean platelet volume;
SARC	cis	rs9916302	0.904	rs7221875	chr17:37543328	G/A	cg07936489	chr17:37558343	FBXL20	0.67	8.85	0.5	2.18e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs80178925	0.803	rs76191032	chr18:70772145	A/C	cg26966630	chr18:70211916	CBLN2	-0.77	-4.71	-0.3	4.17e-6	Pursuit maintenance gain;
SARC	cis	rs9400467	0.537	rs73528982	chr6:111431638	T/G	cg15721981	chr6:111408429	SLC16A10	0.65	5.67	0.35	4.23e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs9325144	0.647	rs870431	chr12:38953073	T/C	cg26384229	chr12:38710491	ALG10B	-0.61	-7.94	-0.46	8.55e-14	Morning vs. evening chronotype;
SARC	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg18225595	chr11:63971243	STIP1	0.43	5.15	0.32	5.43e-7	Mean platelet volume;
SARC	cis	rs9326248	0.798	rs10892079	chr11:117016824	T/G	cg01368799	chr11:117014884	PAFAH1B2	0.55	6.23	0.38	2.13e-9	Blood protein levels;
SARC	cis	rs72627123	0.867	rs57731447	chr14:74487521	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.74	5.84	0.36	1.78e-8	Morning vs. evening chronotype;
SARC	cis	rs17270561	0.609	rs7450798	chr6:25719280	T/A	cg16482183	chr6:26056742	HIST1H1C	0.43	5.11	0.32	6.67e-7	Iron status biomarkers;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg26425730	chr6:153304295	FBXO5	0.59	8.28	0.48	9.7e-15	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs1018836	0.828	rs12548806	chr8:91564256	C/T	cg16814680	chr8:91681699	NA	-0.74	-11.52	-0.6	1.37e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg04980793	chr14:35451984	SRP54	0.5	6.67	0.4	1.85e-10	Chemerin levels;
SARC	cis	rs11676348	0.873	rs10210012	chr2:219013334	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.45	-5.9	-0.36	1.29e-8	Ulcerative colitis;
SARC	trans	rs981844	0.683	rs4696191	chr4:154740668	G/A	cg25721732	chr2:74602550	DCTN1	-0.51	-6.28	-0.38	1.63e-9	Response to statins (LDL cholesterol change);
SARC	cis	rs9398803	0.865	rs4895808	chr6:126781434	C/T	cg20229609	chr6:126660872	C6orf173	0.4	5.82	0.36	1.96e-8	Male-pattern baldness;
SARC	cis	rs514406	0.505	rs387436	chr1:53179376	C/T	cg08859206	chr1:53392774	SCP2	0.36	5.14	0.32	5.79e-7	Monocyte count;
SARC	cis	rs7264396	1.000	rs224434	chr20:34153856	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-5.49	-0.34	1.07e-7	Total cholesterol levels;
SARC	trans	rs1814175	0.509	rs60698301	chr11:49877672	G/A	cg15704280	chr7:45808275	SEPT13	-0.88	-13.91	-0.67	1.97e-32	Height;
SARC	cis	rs4141404	0.787	rs4820042	chr22:31589056	T/C	cg00478049	chr22:31556069	RNF185	0.44	4.74	0.3	3.65e-6	Paclitaxel-induced neuropathy;
SARC	cis	rs9487051	1.000	rs9487048	chr6:109615603	G/T	cg01475377	chr6:109611718	NA	-0.4	-5.66	-0.35	4.54e-8	Reticulocyte fraction of red cells;
SARC	cis	rs2213920	0.679	rs4979536	chr9:118213738	C/T	cg13918206	chr9:118159781	DEC1	0.93	7.46	0.44	1.71e-12	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs9303280	0.806	rs4795395	chr17:37962987	T/A	cg20243544	chr17:37824526	PNMT	0.41	5.46	0.34	1.21e-7	Self-reported allergy;
SARC	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.46	-5.83	-0.36	1.83e-8	Personality dimensions;
SARC	cis	rs2882877	0.648	rs17271134	chr2:190389803	A/G	cg21926118	chr2:190387206	NA	0.41	4.88	0.3	1.95e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs765787	0.530	rs28526629	chr15:45540462	C/T	cg25801113	chr15:45476975	SHF	0.3	4.89	0.31	1.84e-6	Uric acid levels;
SARC	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg20607798	chr8:58055168	NA	0.55	5.2	0.32	4.33e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2486288	0.656	rs12911861	chr15:45566718	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.54	-6.92	-0.41	4.29e-11	Glomerular filtration rate;
SARC	cis	rs9814567	1.000	rs6766897	chr3:134191303	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-6.66	-0.4	1.94e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs2439831	1.000	rs28666488	chr15:43741090	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	10.66	0.57	7.41e-22	Lung cancer in ever smokers;
SARC	cis	rs10782582	0.609	rs2029682	chr1:76341619	T/C	cg03433033	chr1:76189801	ACADM	-0.37	-4.85	-0.3	2.22e-6	Daytime sleep phenotypes;
SARC	trans	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg06437703	chr8:37914619	EIF4EBP1	-0.63	-8.39	-0.48	4.78e-15	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs4234284	0.556	rs34147515	chr3:126965137	G/C	cg27326032	chr3:127006922	NA	-0.5	-5.88	-0.36	1.44e-8	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
SARC	cis	rs7582720	1.000	rs75166090	chr2:203692760	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.71	7.33	0.43	3.68e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs79149102	0.579	rs58068887	chr15:75286140	G/A	cg00629941	chr15:75287862	SCAMP5	-0.65	-5.22	-0.32	3.93e-7	Lung cancer;
SARC	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg21782813	chr7:2030301	MAD1L1	0.46	7.46	0.44	1.67e-12	Bipolar disorder and schizophrenia;
SARC	cis	rs35079168	0.661	rs3118529	chr9:137304915	C/T	cg00753924	chr9:137298813	RXRA	-0.39	-4.91	-0.31	1.71e-6	Intelligence;
SARC	cis	rs2295359	0.724	rs10489630	chr1:67662622	G/T	cg12940439	chr1:67600707	NA	-0.37	-5.75	-0.35	2.78e-8	Psoriasis;
SARC	cis	rs17079247	0.908	rs9575809	chr13:85756961	T/C	ch.13.84760847R	chr13:85862846	NA	-0.56	-4.73	-0.3	3.93e-6	Bipolar disorder (mania);
SARC	cis	rs6693567	0.565	rs1260457	chr1:150347374	G/A	cg09579323	chr1:150459698	TARS2	0.44	5.64	0.35	4.85e-8	Migraine;
SARC	cis	rs2180341	0.960	rs7756884	chr6:127684018	A/G	cg24812749	chr6:127587940	RNF146	1.03	13.58	0.66	2.54e-31	Breast cancer;
SARC	cis	rs8028182	0.636	rs62027209	chr15:75871626	A/G	cg20655648	chr15:75932815	IMP3	0.61	7.42	0.44	2.2e-12	Sudden cardiac arrest;
SARC	cis	rs3741151	1.000	rs79038783	chr11:73038746	C/G	cg17517138	chr11:73019481	ARHGEF17	1.01	7.6	0.45	7.09e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs6840360	0.571	rs62327277	chr4:152555905	C/T	cg22705602	chr4:152727874	NA	-0.42	-6.57	-0.4	3.24e-10	Intelligence (multi-trait analysis);
SARC	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg01316550	chr5:56110833	MAP3K1	0.51	4.77	0.3	3.3e-6	Initial pursuit acceleration;
SARC	cis	rs72781680	0.898	rs72798049	chr2:23958002	C/G	cg08917208	chr2:24149416	ATAD2B	0.75	7.34	0.43	3.6e-12	Lymphocyte counts;
SARC	cis	rs12048904	0.595	rs10493937	chr1:101342650	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.6	-8.0	-0.46	5.89e-14	Multiple sclerosis;
SARC	cis	rs7666738	0.962	rs17550217	chr4:98999699	T/A	cg05340658	chr4:99064831	C4orf37	0.57	7.14	0.42	1.17e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg27170947	chr2:26402098	FAM59B	-0.37	-4.77	-0.3	3.19e-6	Gut microbiome composition (summer);
SARC	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg26335602	chr6:28129616	ZNF389	0.52	5.84	0.36	1.75e-8	Depression;
SARC	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	8.08	0.47	3.49e-14	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs9549260	0.753	rs9532563	chr13:41160270	T/C	cg21288729	chr13:41239152	FOXO1	0.54	5.36	0.33	2.02e-7	Red blood cell count;
SARC	cis	rs7666738	0.830	rs17026973	chr4:98680041	T/A	cg05340658	chr4:99064831	C4orf37	0.64	8.33	0.48	7.14e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs11122272	0.735	rs2244994	chr1:231537127	C/G	cg06096015	chr1:231504339	EGLN1	0.38	5.7	0.35	3.54e-8	Hemoglobin concentration;
SARC	trans	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.56	-6.73	-0.4	1.29e-10	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg02725872	chr8:58115012	NA	-0.27	-4.77	-0.3	3.27e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs12802200	0.561	rs7937217	chr11:571967	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.39	-4.77	-0.3	3.2e-6	Systemic lupus erythematosus;
SARC	cis	rs12912251	1.000	rs12912251	chr15:38986368	G/T	cg01338139	chr15:38987640	C15orf53	-0.44	-5.03	-0.31	9.68e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
SARC	cis	rs5753618	0.555	rs5749291	chr22:31907523	C/G	cg07713946	chr22:31675144	LIMK2	0.37	5.19	0.32	4.56e-7	Colorectal cancer;
SARC	cis	rs17270561	0.585	rs9393663	chr6:25741033	A/T	cg16482183	chr6:26056742	HIST1H1C	0.42	5.03	0.31	9.83e-7	Iron status biomarkers;
SARC	cis	rs7568458	0.527	rs35416445	chr2:85773659	A/G	cg02493740	chr2:85810744	VAMP5	-0.41	-5.1	-0.32	6.93e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs7833790	0.724	rs6473309	chr8:82707880	A/G	cg17211192	chr8:82754475	SNX16	-0.5	-6.3	-0.38	1.48e-9	Diastolic blood pressure;
SARC	cis	rs854765	0.583	rs66531105	chr17:17809001	C/T	cg04398451	chr17:18023971	MYO15A	-0.39	-5.5	-0.34	9.94e-8	Total body bone mineral density;
SARC	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.52	-5.26	-0.33	3.22e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs9815354	1.000	rs9865780	chr3:41895802	A/G	cg03022575	chr3:42003672	ULK4	0.56	5.29	0.33	2.81e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2645694	0.533	rs2645681	chr4:77820949	G/A	cg18351406	chr4:77819688	ANKRD56	0.45	6.31	0.38	1.37e-9	Emphysema distribution in smoking;
SARC	cis	rs12421382	0.811	rs11602639	chr11:109472829	C/T	cg11473876	chr11:109292803	C11orf87	0.4	5.15	0.32	5.44e-7	Schizophrenia;
SARC	cis	rs11785400	0.793	rs4371985	chr8:143737279	C/T	cg24634471	chr8:143751801	JRK	0.56	7.04	0.42	2.19e-11	Schizophrenia;
SARC	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg22920501	chr2:26401640	FAM59B	-0.56	-7.27	-0.43	5.49e-12	Gut microbiome composition (summer);
SARC	cis	rs6912958	1.000	rs6454630	chr6:88171357	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.58	7.99	0.46	6.03e-14	Monocyte percentage of white cells;
SARC	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg04277193	chr17:41438351	NA	0.48	5.2	0.32	4.35e-7	Menopause (age at onset);
SARC	cis	rs6840360	1.000	rs12331037	chr4:152663971	G/A	cg22705602	chr4:152727874	NA	-0.37	-6.51	-0.39	4.54e-10	Intelligence (multi-trait analysis);
SARC	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg04772025	chr11:68637568	NA	0.5	6.27	0.38	1.76e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs34779708	0.931	rs11597483	chr10:35285117	A/G	cg03585969	chr10:35415529	CREM	0.42	5.14	0.32	5.83e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg07061783	chr6:25882402	NA	0.4	4.74	0.3	3.66e-6	Blood metabolite levels;
SARC	cis	rs6088580	0.624	rs6120645	chr20:33025171	C/T	cg24642439	chr20:33292090	TP53INP2	0.67	8.56	0.49	1.55e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg11890956	chr21:40555474	PSMG1	-0.68	-9.01	-0.51	7.44e-17	Menarche (age at onset);
SARC	cis	rs36051895	0.659	rs1575285	chr9:5267440	A/G	cg02405213	chr9:5042618	JAK2	-0.43	-5.08	-0.32	7.81e-7	Pediatric autoimmune diseases;
SARC	cis	rs9843304	0.528	rs1317213	chr3:149191150	C/T	cg08667024	chr3:149219783	TM4SF4	0.43	6.69	0.4	1.65e-10	Gallstone disease;
SARC	cis	rs6930083	0.510	rs4713994	chr6:36621533	A/G	cg08179530	chr6:36648295	CDKN1A	-0.73	-9.89	-0.54	1.69e-19	Coronary artery disease;
SARC	cis	rs1943345	0.830	rs571055	chr11:82898829	G/C	cg07047830	chr11:82868014	PCF11	0.52	5.95	0.36	9.72e-9	Obesity-related traits;
SARC	cis	rs2228479	0.850	rs12597299	chr16:89822364	C/A	cg26513180	chr16:89883248	FANCA	0.72	4.79	0.3	2.99e-6	Skin colour saturation;
SARC	cis	rs9733	0.650	rs1971378	chr1:150597261	C/T	cg13175981	chr1:150552382	MCL1	0.68	9.39	0.52	5.83e-18	Tonsillectomy;
SARC	cis	rs992157	0.798	rs10193383	chr2:219157692	C/T	cg00012203	chr2:219082015	ARPC2	0.65	9.23	0.52	1.74e-17	Colorectal cancer;
SARC	cis	rs1865760	0.827	rs9295681	chr6:25944117	T/G	cg10373733	chr6:25993375	NA	0.39	4.76	0.3	3.34e-6	Height;
SARC	cis	rs477895	1.000	rs34292685	chr11:64049021	C/T	cg04317338	chr11:64019027	PLCB3	0.68	5.93	0.36	1.07e-8	Mean platelet volume;
SARC	cis	rs3820928	0.874	rs4423583	chr2:227874957	A/G	cg11843606	chr2:227700838	RHBDD1	0.52	6.51	0.39	4.52e-10	Pulmonary function;
SARC	trans	rs7815944	1.000	rs4637784	chr8:129388451	C/G	cg17342469	chr22:46473074	NA	0.71	6.67	0.4	1.82e-10	Atopic dermatitis;
SARC	cis	rs9911578	0.967	rs6503893	chr17:57149695	G/A	cg20303301	chr17:57937339	TUBD1	-0.34	-4.95	-0.31	1.42e-6	Intelligence (multi-trait analysis);
SARC	cis	rs57994353	0.600	rs10870163	chr9:139315594	G/A	cg14169450	chr9:139327907	INPP5E	0.45	5.57	0.34	7.17e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs4481887	0.772	rs4916127	chr1:248466615	A/G	cg13385794	chr1:248469461	NA	0.36	5.57	0.34	7.1e-8	Common traits (Other);
SARC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg09033563	chr22:24373618	LOC391322	-0.5	-5.95	-0.36	9.53e-9	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7326068	0.610	rs9552265	chr13:21311695	C/T	cg16922012	chr13:21400325	XPO4	-0.46	-6.49	-0.39	5.18e-10	Schizophrenia, bipolar disorder and depression (combined);
SARC	cis	rs1707322	0.785	rs10890348	chr1:46242423	G/T	cg06784218	chr1:46089804	CCDC17	0.35	6.31	0.38	1.42e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6580649	0.941	rs57380031	chr12:48452237	C/T	cg24011408	chr12:48396354	COL2A1	-0.48	-5.31	-0.33	2.56e-7	Lung cancer;
SARC	cis	rs2439831	0.850	rs28696802	chr15:44140395	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.76	7.53	0.44	1.14e-12	Lung cancer in ever smokers;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg10741399	chr3:113251979	SIDT1	0.47	6.35	0.38	1.09e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs7959452	0.640	rs4274230	chr12:69700772	T/G	cg14784868	chr12:69753453	YEATS4	0.39	5.15	0.32	5.47e-7	Blood protein levels;
SARC	cis	rs9612	1.000	rs9612	chr19:44235517	A/G	cg08581076	chr19:44259116	C19orf61	0.72	9.12	0.51	3.7e-17	Exhaled nitric oxide output;
SARC	cis	rs7264396	0.563	rs2425138	chr20:34345710	G/A	cg01084648	chr20:34329383	RBM39	0.62	5.11	0.32	6.73e-7	Total cholesterol levels;
SARC	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg05025164	chr4:1340916	KIAA1530	0.88	11.32	0.6	5.87e-24	Longevity;
SARC	cis	rs72781680	0.898	rs72796171	chr2:23942667	G/C	cg08917208	chr2:24149416	ATAD2B	0.75	7.07	0.42	1.78e-11	Lymphocyte counts;
SARC	cis	rs6088580	0.609	rs6058029	chr20:32969643	T/C	cg08999081	chr20:33150536	PIGU	-0.44	-6.65	-0.4	2.07e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs3126085	1.000	rs1858482	chr1:152306921	A/G	cg03465714	chr1:152285911	FLG	-0.42	-4.8	-0.3	2.79e-6	Atopic dermatitis;
SARC	cis	rs7792596	0.861	rs57900160	chr7:93986265	C/G	cg20814616	chr7:94014465	NA	-0.47	-5.37	-0.33	1.91e-7	Intelligence;
SARC	trans	rs3774749	0.565	rs2188151	chr3:50201924	A/C	cg21659725	chr3:3221576	CRBN	-0.49	-6.33	-0.38	1.24e-9	Intelligence (multi-trait analysis);
SARC	cis	rs12464483	0.524	rs1901906	chr2:30884576	A/G	cg12454169	chr2:30669597	LCLAT1	-0.55	-5.94	-0.36	1.04e-8	Pre-treatment pain in head and neck squamous cell carcinoma;
SARC	cis	rs17376456	0.597	rs7728825	chr5:93384594	T/C	cg21475434	chr5:93447410	FAM172A	-0.6	-6.27	-0.38	1.73e-9	Diabetic retinopathy;
SARC	cis	rs13256369	1.000	rs883648	chr8:8569521	A/G	cg17143192	chr8:8559678	CLDN23	0.52	6.0	0.37	7.31e-9	Obesity-related traits;
SARC	cis	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg14541582	chr5:601475	NA	-0.41	-5.0	-0.31	1.15e-6	Obesity-related traits;
SARC	cis	rs11098499	0.722	rs28713555	chr4:120251995	C/T	cg09307838	chr4:120376055	NA	0.81	11.03	0.59	4.84e-23	Corneal astigmatism;
SARC	cis	rs73206853	0.841	rs74728497	chr12:111020179	T/C	cg10860002	chr12:110842031	ANAPC7	0.61	5.15	0.32	5.58e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs765787	0.556	rs10851422	chr15:45513738	T/C	cg21132104	chr15:45694354	SPATA5L1	0.4	4.89	0.31	1.85e-6	Uric acid levels;
SARC	cis	rs9733	0.519	rs11204717	chr1:150709129	T/A	cg13175981	chr1:150552382	MCL1	-0.48	-5.93	-0.36	1.09e-8	Tonsillectomy;
SARC	cis	rs9790314	1.000	rs1478565	chr3:161027464	C/T	cg03342759	chr3:160939853	NMD3	-0.59	-7.36	-0.43	3.23e-12	Morning vs. evening chronotype;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg14309307	chr6:105750523	PREP	0.45	6.3	0.38	1.5e-9	Thyroid stimulating hormone;
SARC	cis	rs910316	1.000	rs3742773	chr14:75579643	A/G	cg11812906	chr14:75593930	NEK9	0.88	13.58	0.66	2.41e-31	Height;
SARC	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg16049864	chr8:95962084	TP53INP1	-0.55	-8.88	-0.5	1.89e-16	Type 2 diabetes;
SARC	cis	rs910316	0.737	rs175084	chr14:75519175	C/T	cg08847533	chr14:75593920	NEK9	-0.81	-11.8	-0.61	1.65e-25	Height;
SARC	cis	rs6088813	0.961	rs3795159	chr20:33896262	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.43	5.04	0.31	9.24e-7	Height;
SARC	cis	rs2645694	0.626	rs2645684	chr4:77819892	A/C	cg06046430	chr4:77819534	ANKRD56	0.53	7.52	0.44	1.16e-12	Emphysema distribution in smoking;
SARC	cis	rs9399135	0.967	rs11754783	chr6:135347661	T/A	cg24558204	chr6:135376177	HBS1L	0.45	6.07	0.37	5.25e-9	Red blood cell count;
SARC	cis	rs826838	0.651	rs1843892	chr12:38616965	A/G	cg13010199	chr12:38710504	ALG10B	0.7	9.21	0.52	2.01e-17	Heart rate;
SARC	cis	rs28829049	0.597	rs71645438	chr1:19502349	G/A	cg13387374	chr1:19411106	UBR4	0.43	5.05	0.31	8.85e-7	QRS duration in Tripanosoma cruzi seropositivity;
SARC	cis	rs614226	1.000	rs541126	chr12:120972396	C/T	cg01236616	chr12:121019343	POP5	-1.26	-17.58	-0.76	1.33e-44	Type 1 diabetes nephropathy;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg14617448	chr9:138852499	UBAC1	-0.51	-6.33	-0.38	1.26e-9	Schizophrenia;
SARC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.03	12.47	0.63	1.08e-27	Platelet count;
SARC	cis	rs11608355	0.545	rs12822891	chr12:109896002	A/G	cg05360138	chr12:110035743	NA	0.92	9.61	0.53	1.27e-18	Neuroticism;
SARC	cis	rs9896052	0.591	rs11077790	chr17:73464718	G/A	cg27037648	chr17:73511087	CASKIN2	0.39	5.2	0.32	4.46e-7	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs1957429	0.614	rs73279834	chr14:65352544	G/A	cg23373153	chr14:65346875	NA	-0.96	-7.36	-0.43	3.09e-12	Pediatric areal bone mineral density (radius);
SARC	trans	rs61931739	0.635	rs10743836	chr12:33961680	C/T	cg13010199	chr12:38710504	ALG10B	0.5	6.42	0.39	7.45e-10	Morning vs. evening chronotype;
SARC	cis	rs7666738	0.830	rs10050008	chr4:99025313	T/G	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg11890956	chr21:40555474	PSMG1	-0.7	-9.2	-0.52	2.12e-17	Menarche (age at onset);
SARC	cis	rs288326	0.561	rs74869113	chr2:183858306	C/T	cg09997497	chr2:183902928	NCKAP1	0.74	5.1	0.32	6.97e-7	Blood protein levels;
SARC	cis	rs3762637	1.000	rs9842736	chr3:122161101	C/T	cg24169773	chr3:122142474	KPNA1	-0.56	-5.67	-0.35	4.18e-8	LDL cholesterol levels;
SARC	trans	rs208520	1.000	rs12191403	chr6:66978137	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.83	9.35	0.52	7.46e-18	Exhaled nitric oxide output;
SARC	cis	rs6790105	1	rs6790105	chr3:49393409	C/T	cg07636037	chr3:49044803	WDR6	0.8	8.72	0.5	5.3e-16	Childhood ear infection;
SARC	trans	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg20587970	chr11:113659929	NA	1.0	9.39	0.52	5.65e-18	Hip circumference adjusted for BMI;
SARC	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.58	0.34	6.55e-8	Bipolar disorder;
SARC	trans	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg21659725	chr3:3221576	CRBN	-0.54	-7.01	-0.42	2.57e-11	Intelligence (multi-trait analysis);
SARC	cis	rs12220238	1.000	rs11000912	chr10:75948477	A/C	cg19889307	chr10:75911429	ADK;AP3M1	0.59	5.9	0.36	1.3e-8	Soluble interleukin-2 receptor subunit alpha;
SARC	cis	rs709400	0.633	rs10141433	chr14:103962559	A/G	cg12935359	chr14:103987150	CKB	-0.39	-5.74	-0.35	2.98e-8	Body mass index;
SARC	cis	rs77633900	0.614	rs279997	chr15:76949262	T/C	cg21673338	chr15:77095150	SCAPER	-0.61	-5.12	-0.32	6.42e-7	Non-glioblastoma glioma;Glioma;
SARC	cis	rs2916247	0.954	rs1443558	chr8:92986385	G/A	cg10183463	chr8:93005414	RUNX1T1	0.46	4.74	0.3	3.75e-6	Intelligence (multi-trait analysis);
SARC	cis	rs77106637	1.000	rs3862791	chr11:72501002	C/T	cg03713592	chr11:72463424	ARAP1	1.03	9.86	0.54	2.2e-19	Type 2 diabetes;
SARC	cis	rs858239	0.899	rs28458177	chr7:23294872	G/A	cg23682824	chr7:23144976	KLHL7	0.58	7.41	0.44	2.32e-12	Cerebrospinal fluid biomarker levels;
SARC	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg11987759	chr7:65425863	GUSB	0.45	6.04	0.37	5.94e-9	Aortic root size;
SARC	cis	rs12497850	1.000	rs10865952	chr3:48744484	A/G	cg03060546	chr3:49711283	APEH	0.41	5.22	0.32	4.05e-7	Parkinson's disease;
SARC	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg02297831	chr4:17616191	MED28	0.51	6.6	0.4	2.78e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs295137	0.836	rs1217429	chr2:201094151	G/T	cg23649088	chr2:200775458	C2orf69	0.49	6.83	0.41	7.37e-11	Asthma (bronchodilator response);
SARC	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-8.45	-0.48	3.14e-15	Chronic sinus infection;
SARC	cis	rs918629	0.724	rs55841351	chr5:95278019	A/G	cg16656078	chr5:95278638	ELL2	-0.65	-7.82	-0.46	1.87e-13	IgG glycosylation;
SARC	cis	rs5762813	0.566	rs5762818	chr22:29211435	C/T	cg02153584	chr22:29168773	CCDC117	0.65	6.65	0.4	2.02e-10	Hematocrit;Hemoglobin concentration;
SARC	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg11062466	chr8:58055876	NA	0.56	5.69	0.35	3.79e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg10351095	chr21:47802916	PCNT	-0.44	-5.19	-0.32	4.53e-7	Testicular germ cell tumor;
SARC	cis	rs6450176	0.638	rs1542167	chr5:53305742	T/G	ch.5.1024479R	chr5:53302184	ARL15	-1.1	-12.8	-0.64	9.42e-29	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg22834771	chr12:69754056	YEATS4	-0.44	-5.78	-0.35	2.42e-8	Blood protein levels;
SARC	cis	rs67460515	0.500	rs1868105	chr3:160645335	A/G	cg03342759	chr3:160939853	NMD3	-0.55	-6.03	-0.37	6.4e-9	Parkinson's disease;
SARC	cis	rs7772486	0.790	rs6924159	chr6:146267873	A/G	cg05347473	chr6:146136440	FBXO30	-0.48	-6.54	-0.39	3.87e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs478304	0.654	rs10896029	chr11:65452952	C/T	cg27068330	chr11:65405492	SIPA1	-0.41	-4.84	-0.3	2.32e-6	Acne (severe);
SARC	cis	rs7727544	0.660	rs274563	chr5:131717859	C/A	cg24060327	chr5:131705240	SLC22A5	0.72	9.38	0.52	6.29e-18	Blood metabolite levels;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg19734201	chr4:39699603	UBE2K	0.46	6.37	0.39	9.76e-10	Thyroid stimulating hormone;
SARC	cis	rs5753618	0.561	rs2283879	chr22:31638448	G/A	cg07713946	chr22:31675144	LIMK2	-0.37	-5.19	-0.32	4.64e-7	Colorectal cancer;
SARC	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg18876405	chr7:65276391	NA	0.52	6.54	0.39	3.76e-10	Calcium levels;
SARC	cis	rs2380220	0.872	rs2613529	chr6:95945036	C/T	cg23517279	chr6:96025343	MANEA	-0.54	-5.39	-0.33	1.76e-7	Behavioural disinhibition (generation interaction);
SARC	cis	rs6424115	0.931	rs2982390	chr1:24147830	G/C	cg15997130	chr1:24165203	NA	0.46	6.17	0.37	2.93e-9	Immature fraction of reticulocytes;
SARC	cis	rs7605378	0.964	rs2689763	chr2:200689555	G/A	cg23649088	chr2:200775458	C2orf69	0.52	6.02	0.37	6.55e-9	Osteoporosis;
SARC	cis	rs1580019	0.587	rs6951955	chr7:32548761	A/T	cg14728415	chr7:32535168	LSM5;AVL9	0.54	6.95	0.41	3.56e-11	Cognitive ability;
SARC	trans	rs1635	0.655	rs16893973	chr6:28302113	C/T	cg08080395	chr15:65488966	CILP	0.66	6.45	0.39	6.46e-10	Schizophrenia;
SARC	cis	rs9790314	0.560	rs1450521	chr3:161091237	C/A	cg17135325	chr3:160939158	NMD3	0.53	6.59	0.4	2.91e-10	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs148734725	1	rs148734725	chr3:49406708	G/A	cg07274523	chr3:49395745	GPX1	0.53	6.26	0.38	1.8e-9	Educational attainment (college completion);
SARC	cis	rs7927771	0.896	rs12794570	chr11:47658314	C/T	cg05585544	chr11:47624801	NA	-0.39	-5.14	-0.32	5.72e-7	Subjective well-being;
SARC	cis	rs710216	0.843	rs710220	chr1:43415346	G/T	cg03128534	chr1:43423976	SLC2A1	0.65	7.03	0.42	2.25e-11	Red cell distribution width;
SARC	cis	rs7914558	0.966	rs2065977	chr10:104729415	C/T	cg04362960	chr10:104952993	NT5C2	0.41	5.0	0.31	1.14e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs5758659	0.967	rs5751250	chr22:42639645	T/G	cg15128208	chr22:42549153	NA	-0.37	-5.35	-0.33	2.12e-7	Cognitive function;
SARC	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg24110177	chr3:50126178	RBM5	-0.67	-9.23	-0.52	1.76e-17	Body mass index;
SARC	trans	rs61931739	0.517	rs11053067	chr12:34191391	T/C	cg26384229	chr12:38710491	ALG10B	0.85	12.17	0.62	1.07e-26	Morning vs. evening chronotype;
SARC	trans	rs7395662	0.500	rs7951327	chr11:48925359	C/T	cg15704280	chr7:45808275	SEPT13	-0.55	-7.45	-0.44	1.8e-12	HDL cholesterol;
SARC	cis	rs6088813	1.000	rs6142358	chr20:33960308	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.43	5.19	0.32	4.68e-7	Height;
SARC	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg16049864	chr8:95962084	TP53INP1	-0.49	-7.94	-0.46	8.43e-14	Type 2 diabetes;
SARC	cis	rs9325144	0.560	rs7971313	chr12:38653413	A/G	cg13010199	chr12:38710504	ALG10B	-0.57	-7.44	-0.44	1.87e-12	Morning vs. evening chronotype;
SARC	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg11247378	chr22:39784982	NA	-0.31	-4.87	-0.3	2.11e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-5.68	-0.35	3.93e-8	Bipolar disorder;
SARC	cis	rs10463554	0.963	rs6883113	chr5:102377889	C/T	cg23492399	chr5:102201601	PAM	-0.52	-5.71	-0.35	3.34e-8	Parkinson's disease;
SARC	cis	rs1348850	0.651	rs4893821	chr2:178229352	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.6	-7.81	-0.46	1.98e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2204008	0.683	rs7305703	chr12:38138381	T/C	cg26384229	chr12:38710491	ALG10B	0.86	12.33	0.63	3.12e-27	Bladder cancer;
SARC	cis	rs17376456	0.877	rs10476601	chr5:93402522	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.86	0.36	1.59e-8	Diabetic retinopathy;
SARC	cis	rs6964587	1.000	rs2157747	chr7:91750578	A/G	cg17063962	chr7:91808500	NA	0.93	15.61	0.72	4.29e-38	Breast cancer;
SARC	cis	rs2576037	0.899	rs7233515	chr18:44585955	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.68	9.29	0.52	1.14e-17	Personality dimensions;
SARC	cis	rs533123	0.877	rs482692	chr1:29154255	T/C	cg08366446	chr1:29138936	OPRD1	0.92	7.65	0.45	5.3e-13	Schizophrenia;
SARC	cis	rs2204008	0.683	rs11522927	chr12:38137537	C/T	cg26384229	chr12:38710491	ALG10B	0.88	12.62	0.64	3.61e-28	Bladder cancer;
SARC	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg04772025	chr11:68637568	NA	0.47	5.76	0.35	2.61e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg13206674	chr6:150067644	NUP43	0.48	6.17	0.37	3.03e-9	Lung cancer;
SARC	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg19346786	chr7:2764209	NA	-0.39	-5.72	-0.35	3.26e-8	Height;
SARC	cis	rs2576037	0.899	rs2576035	chr18:44587654	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.36	-4.89	-0.3	1.9e-6	Personality dimensions;
SARC	cis	rs7666738	0.830	rs13148913	chr4:99009732	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	trans	rs1814175	0.676	rs11040647	chr11:49935947	A/C	cg03929089	chr4:120376271	NA	-0.81	-11.69	-0.61	3.89e-25	Height;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg13184539	chr1:241683111	FH	-0.53	-6.58	-0.4	2.99e-10	Height;
SARC	trans	rs11165623	0.765	rs12749081	chr1:96970371	A/C	cg10631902	chr5:14652156	NA	-0.45	-7.38	-0.44	2.72e-12	Hip circumference;Waist circumference;
SARC	cis	rs6500395	1.000	rs3743779	chr16:48574040	T/G	cg04672837	chr16:48644449	N4BP1	0.46	6.0	0.37	7.56e-9	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs7923452	0.507	rs612802	chr10:30756441	G/A	cg25182066	chr10:30743637	MAP3K8	0.45	6.47	0.39	5.83e-10	Itch intensity from mosquito bite;
SARC	cis	rs11098499	0.954	rs878373	chr4:120237484	A/T	cg09307838	chr4:120376055	NA	0.9	12.43	0.63	1.54e-27	Corneal astigmatism;
SARC	cis	rs12887734	0.524	rs4900599	chr14:104283444	G/T	cg26031613	chr14:104095156	KLC1	-0.44	-5.17	-0.32	5.06e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	cis	rs2645694	0.626	rs2703136	chr4:77828957	T/A	cg06046430	chr4:77819534	ANKRD56	0.52	7.4	0.44	2.43e-12	Emphysema distribution in smoking;
SARC	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.45	0.44	1.86e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs28829049	0.597	rs34215816	chr1:19433953	G/A	cg13387374	chr1:19411106	UBR4	0.47	5.53	0.34	8.61e-8	QRS duration in Tripanosoma cruzi seropositivity;
SARC	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg06634786	chr22:41940651	POLR3H	-0.48	-5.93	-0.36	1.1e-8	Vitiligo;
SARC	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg11764359	chr7:65958608	NA	-0.66	-7.79	-0.45	2.25e-13	Aortic root size;
SARC	cis	rs2204008	0.754	rs11181244	chr12:38302454	T/C	cg26384229	chr12:38710491	ALG10B	0.87	12.74	0.64	1.45e-28	Bladder cancer;
SARC	cis	rs7246760	0.867	rs7259075	chr19:9778776	G/A	cg16876255	chr19:9731953	ZNF561	0.82	5.05	0.31	8.72e-7	Pursuit maintenance gain;
SARC	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.47	5.17	0.32	5.14e-7	Renal function-related traits (BUN);
SARC	cis	rs10875746	0.903	rs989144	chr12:48483973	T/C	cg26205652	chr12:48591994	NA	0.56	6.1	0.37	4.37e-9	Longevity (90 years and older);
SARC	cis	rs2652834	0.808	rs11071723	chr15:63355275	A/T	cg05507819	chr15:63340323	TPM1	0.64	6.52	0.39	4.42e-10	HDL cholesterol;
SARC	cis	rs524281	1.000	rs524281	chr11:65886662	C/A	cg14036092	chr11:66035641	RAB1B	0.52	5.8	0.36	2.12e-8	Electroencephalogram traits;
SARC	cis	rs1691799	0.899	rs1168310	chr12:66726355	A/G	cg16791601	chr12:66731901	HELB	0.71	10.44	0.56	3.58e-21	White blood cell count (basophil);
SARC	cis	rs4268898	0.662	rs72793213	chr2:24524725	A/G	cg26838691	chr2:24397539	C2orf84	-0.49	-5.67	-0.35	4.28e-8	Asthma;
SARC	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg13607699	chr17:42295918	UBTF	-0.5	-6.09	-0.37	4.67e-9	Total body bone mineral density;
SARC	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg20607798	chr8:58055168	NA	-0.58	-5.0	-0.31	1.11e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs12762955	0.507	rs7070724	chr10:1040138	C/T	cg18964960	chr10:1102726	WDR37	-0.62	-7.51	-0.44	1.29e-12	Response to angiotensin II receptor blocker therapy;
SARC	trans	rs12310956	0.532	rs10844715	chr12:33968444	A/G	cg13010199	chr12:38710504	ALG10B	0.65	8.62	0.49	1.04e-15	Morning vs. evening chronotype;
SARC	cis	rs17376456	0.569	rs6556839	chr5:93206292	T/C	cg21475434	chr5:93447410	FAM172A	-0.64	-6.37	-0.39	9.72e-10	Diabetic retinopathy;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg16535062	chr11:14521425	COPB1	0.53	6.74	0.4	1.26e-10	Lung adenocarcinoma;
SARC	cis	rs4727027	0.804	rs13231262	chr7:148886058	C/T	cg23583168	chr7:148888333	NA	-0.78	-10.89	-0.58	1.31e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs7011049	0.908	rs72640860	chr8:53840500	G/A	cg26025543	chr8:53854495	NA	0.6	5.43	0.34	1.42e-7	Systolic blood pressure;
SARC	cis	rs739401	0.527	rs423236	chr11:3065916	C/T	cg08508325	chr11:3079039	CARS	-0.32	-7.76	-0.45	2.67e-13	Longevity;
SARC	cis	rs11764590	0.694	rs6977161	chr7:2099361	T/C	cg23043544	chr7:2124092	MAD1L1	-0.35	-4.85	-0.3	2.27e-6	Neuroticism;
SARC	cis	rs3733585	0.604	rs73215003	chr4:10126317	C/G	cg00071950	chr4:10020882	SLC2A9	-0.39	-5.93	-0.36	1.08e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs6866344	0.570	rs11740283	chr5:178136440	T/C	cg03877680	chr5:178157825	ZNF354A	1.03	14.42	0.69	3.96e-34	Neutrophil percentage of white cells;
SARC	cis	rs10752881	0.935	rs12082051	chr1:183051614	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.35	0.56	6.82e-21	Colorectal cancer;
SARC	cis	rs763121	0.853	rs2205802	chr22:39046327	T/C	cg06022373	chr22:39101656	GTPBP1	0.9	11.56	0.6	9.96e-25	Menopause (age at onset);
SARC	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg18876405	chr7:65276391	NA	0.75	9.57	0.53	1.62e-18	Aortic root size;
SARC	cis	rs11785400	0.928	rs10100287	chr8:143734836	C/T	cg24634471	chr8:143751801	JRK	0.67	8.88	0.5	1.88e-16	Schizophrenia;
SARC	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg13902645	chr11:5959945	NA	-0.45	-6.22	-0.38	2.31e-9	DNA methylation (variation);
SARC	cis	rs6840360	0.571	rs4696276	chr4:152532682	G/A	cg22705602	chr4:152727874	NA	-0.43	-6.74	-0.4	1.22e-10	Intelligence (multi-trait analysis);
SARC	cis	rs4481887	0.962	rs10749653	chr1:248481384	C/G	cg00666640	chr1:248458726	OR2T12	0.39	6.45	0.39	6.29e-10	Common traits (Other);
SARC	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	11.4	0.6	3.34e-24	Alzheimer's disease;
SARC	cis	rs2652822	0.584	rs1017546	chr15:63566702	G/T	cg02713581	chr15:63449717	RPS27L	-0.57	-6.63	-0.4	2.32e-10	Metabolic traits;
SARC	cis	rs4601821	1.000	rs877138	chr11:113256508	A/G	cg14159747	chr11:113255604	NA	-0.37	-4.98	-0.31	1.21e-6	Alcoholic chronic pancreatitis;
SARC	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg22800045	chr5:56110881	MAP3K1	0.74	7.83	0.46	1.74e-13	Initial pursuit acceleration;
SARC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg07157834	chr1:205819609	PM20D1	0.71	11.18	0.59	1.64e-23	Menarche (age at onset);
SARC	cis	rs11574514	1.000	rs117705890	chr16:67714211	G/A	cg01866162	chr16:67596514	CTCF	1.13	6.68	0.4	1.7e-10	Crohn's disease;
SARC	cis	rs4742903	0.967	rs10820600	chr9:106856692	T/C	cg14250997	chr9:106856677	SMC2	0.52	6.86	0.41	6.13e-11	High-grade serous ovarian cancer;Breast cancer;
SARC	trans	rs2018683	0.707	rs4722877	chr7:28972906	A/G	cg19402173	chr7:128379420	CALU	-0.5	-6.37	-0.39	9.91e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	6.0	0.37	7.37e-9	Prudent dietary pattern;
SARC	cis	rs2463822	0.583	rs72917377	chr11:62025930	A/G	cg06239285	chr11:62104954	ASRGL1	-0.88	-7.97	-0.46	7.26e-14	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.62	7.66	0.45	4.97e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg24642844	chr7:1081250	C7orf50	-0.59	-6.25	-0.38	1.98e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg24503407	chr1:205819492	PM20D1	0.43	4.91	0.31	1.72e-6	Parkinson's disease;
SARC	cis	rs7666738	0.830	rs13111977	chr4:98953813	G/A	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs13256369	1.000	rs7820159	chr8:8576215	T/C	cg18904891	chr8:8559673	CLDN23	0.48	5.29	0.33	2.88e-7	Obesity-related traits;
SARC	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.44	6.57	0.4	3.3e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs7412746	0.611	rs10888395	chr1:150762171	C/T	cg10589385	chr1:150898437	SETDB1	0.41	5.34	0.33	2.17e-7	Melanoma;
SARC	cis	rs60871478	0.853	rs62432864	chr7:808405	T/G	cg19087971	chr7:751233	PRKAR1B	-0.44	-5.02	-0.31	1.01e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs1568889	1.000	rs35343234	chr11:28034379	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.73	9.53	0.53	2.16e-18	Bipolar disorder;
SARC	cis	rs12950390	0.853	rs4794107	chr17:45843159	T/G	cg24803719	chr17:45855879	NA	-0.49	-7.98	-0.46	6.41e-14	IgG glycosylation;
SARC	cis	rs910187	0.605	rs6018320	chr20:45804412	A/G	cg27589058	chr20:45804311	EYA2	-0.3	-4.96	-0.31	1.36e-6	Migraine;
SARC	trans	rs208515	0.525	rs10498841	chr6:66663706	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.01	11.85	0.61	1.13e-25	Exhaled nitric oxide levels;
SARC	cis	rs2180341	0.722	rs9388555	chr6:127576363	G/A	cg27446573	chr6:127587934	RNF146	0.94	13.28	0.66	2.37e-30	Breast cancer;
SARC	cis	rs11105298	0.891	rs10858854	chr12:89835728	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.49	-4.87	-0.3	2.02e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	trans	rs1814175	0.817	rs28679516	chr11:50055998	G/A	cg03929089	chr4:120376271	NA	-0.88	-14.35	-0.68	6.73e-34	Height;
SARC	trans	rs7830939	0.553	rs11997346	chr8:9324448	A/C	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.32	-0.38	1.31e-9	Neuroticism;
SARC	cis	rs10463316	0.817	rs10476770	chr5:150777720	G/C	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.34	-0.33	2.19e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs6582630	0.532	rs1589394	chr12:38419700	A/C	cg26384229	chr12:38710491	ALG10B	0.67	8.55	0.49	1.59e-15	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs7815944	1.000	rs74623761	chr8:129363670	A/G	cg25487405	chr22:46473039	NA	0.64	6.37	0.39	9.82e-10	Atopic dermatitis;
SARC	cis	rs4805272	0.512	rs7260055	chr19:29341599	G/A	cg12756686	chr19:29218302	NA	0.51	5.53	0.34	8.45e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs9926296	0.744	rs164746	chr16:89709019	C/T	cg04287289	chr16:89883240	FANCA	-0.45	-5.52	-0.34	9.03e-8	Vitiligo;
SARC	cis	rs17376456	0.877	rs10476598	chr5:93367281	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.62	-5.37	-0.33	1.86e-7	Diabetic retinopathy;
SARC	cis	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg24110177	chr3:50126178	RBM5	0.4	5.07	0.32	8e-7	Intelligence (multi-trait analysis);
SARC	cis	rs4969178	0.965	rs16971107	chr17:76394042	C/T	cg20026190	chr17:76395443	PGS1	0.39	5.31	0.33	2.61e-7	HDL cholesterol levels;
SARC	cis	rs7615952	0.512	rs2922175	chr3:125361360	T/C	cg21696256	chr3:125484277	NA	-0.35	-5.05	-0.31	8.97e-7	Blood pressure (smoking interaction);
SARC	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg07636037	chr3:49044803	WDR6	1.01	17.84	0.76	1.85e-45	Parkinson's disease;
SARC	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg11764359	chr7:65958608	NA	0.86	12.33	0.63	3.29e-27	Aortic root size;
SARC	cis	rs1153858	1.000	rs11070457	chr15:45686943	A/C	cg15395560	chr15:45543142	SLC28A2	-0.27	-4.91	-0.31	1.74e-6	Homoarginine levels;
SARC	cis	rs2439831	0.681	rs3742969	chr15:43621947	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.09	12.69	0.64	2.16e-28	Lung cancer in ever smokers;
SARC	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg00933542	chr6:150070202	PCMT1	0.3	5.14	0.32	5.92e-7	Lung cancer;
SARC	cis	rs1124769	0.827	rs77725238	chr15:51099645	G/A	cg21246271	chr15:51200259	AP4E1	-0.6	-5.54	-0.34	8.14e-8	Cognitive performance;
SARC	cis	rs28374715	0.617	rs16971735	chr15:41563970	C/G	cg01768344	chr15:41576519	LOC729082	0.45	4.8	0.3	2.87e-6	Ulcerative colitis;
SARC	cis	rs6582630	0.555	rs10785443	chr12:38463792	A/C	cg26384229	chr12:38710491	ALG10B	0.84	12.06	0.62	2.42e-26	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg11987759	chr7:65425863	GUSB	0.48	6.12	0.37	3.95e-9	Aortic root size;
SARC	trans	rs9650657	0.769	rs1968400	chr8:10615431	G/C	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.73	-0.4	1.27e-10	Neuroticism;
SARC	cis	rs10078	0.559	rs2037077	chr5:447226	A/G	cg26072250	chr5:443457	EXOC3;C5orf55	0.74	6.32	0.38	1.32e-9	Fat distribution (HIV);
SARC	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg17971929	chr21:40555470	PSMG1	-0.6	-7.62	-0.45	6.24e-13	Menarche (age at onset);
SARC	cis	rs3126085	0.935	rs11204934	chr1:152176848	C/A	cg03465714	chr1:152285911	FLG	0.49	5.72	0.35	3.28e-8	Atopic dermatitis;
SARC	cis	rs9840812	0.623	rs6794351	chr3:136292279	C/T	cg15507776	chr3:136538369	TMEM22	0.45	4.86	0.3	2.14e-6	Fibrinogen levels;
SARC	cis	rs858239	0.633	rs858300	chr7:23244631	A/G	cg23682824	chr7:23144976	KLHL7	0.64	8.09	0.47	3.33e-14	Cerebrospinal fluid biomarker levels;
SARC	trans	rs11039798	0.588	rs7116858	chr11:48543920	C/A	cg15704280	chr7:45808275	SEPT13	0.63	6.42	0.39	7.76e-10	Axial length;
SARC	cis	rs9354308	1.000	rs9354308	chr6:66565353	A/G	cg07460842	chr6:66804631	NA	0.45	5.15	0.32	5.56e-7	Metabolite levels;
SARC	cis	rs6570726	0.935	rs449377	chr6:145852437	C/G	cg05347473	chr6:146136440	FBXO30	0.5	6.79	0.41	9.1e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9611565	0.559	rs1006407	chr22:41972032	T/C	cg06634786	chr22:41940651	POLR3H	-0.6	-6.55	-0.39	3.7e-10	Vitiligo;
SARC	cis	rs4727027	0.704	rs13221837	chr7:148903597	C/T	cg23583168	chr7:148888333	NA	-0.83	-13.99	-0.68	1.06e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg17376030	chr22:41985996	PMM1	0.73	9.01	0.51	7.6e-17	Vitiligo;
SARC	cis	rs9398803	0.678	rs4380768	chr6:126867351	G/C	cg20229609	chr6:126660872	C6orf173	0.37	5.29	0.33	2.81e-7	Male-pattern baldness;
SARC	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	11.03	0.59	4.93e-23	Alzheimer's disease;
SARC	cis	rs12579753	0.871	rs35801863	chr12:82238818	A/T	cg07988820	chr12:82153109	PPFIA2	-0.52	-6.07	-0.37	5.24e-9	Resting heart rate;
SARC	cis	rs4792901	0.802	rs2242598	chr17:41610398	C/T	cg22562494	chr17:41607896	ETV4	-0.35	-5.38	-0.33	1.84e-7	Dupuytren's disease;
SARC	cis	rs7615952	0.932	rs3811679	chr3:125648283	A/G	cg05084668	chr3:125655381	ALG1L	-0.68	-6.76	-0.41	1.08e-10	Blood pressure (smoking interaction);
SARC	cis	rs7208859	0.623	rs11656844	chr17:29060597	G/T	cg13385521	chr17:29058706	SUZ12P	0.84	7.31	0.43	4.29e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg09674502	chr1:92953279	GFI1	0.45	6.35	0.38	1.12e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs6963495	0.818	rs118134111	chr7:105161229	A/C	cg19920283	chr7:105172520	RINT1	0.65	5.48	0.34	1.09e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs28655083	0.785	rs7404856	chr16:77130339	A/C	cg01504555	chr16:77246968	SYCE1L	0.38	4.91	0.31	1.69e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs72781680	0.716	rs17045975	chr2:24099611	A/T	cg06627628	chr2:24431161	ITSN2	0.51	5.44	0.34	1.38e-7	Lymphocyte counts;
SARC	cis	rs8077889	0.871	rs16940243	chr17:41900003	C/G	cg26893861	chr17:41843967	DUSP3	0.85	10.61	0.57	1.03e-21	Triglycerides;
SARC	trans	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg17712092	chr4:129076599	LARP1B	0.73	10.08	0.55	4.52e-20	Eosinophil percentage of white cells;
SARC	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.56	-0.39	3.45e-10	Total body bone mineral density;
SARC	cis	rs1881797	1.000	rs1881797	chr1:247689532	A/G	cg05639522	chr1:247681581	NA	0.49	5.37	0.33	1.95e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs79349575	0.691	rs28528789	chr17:46986616	C/T	cg16584676	chr17:46985605	UBE2Z	-0.54	-6.89	-0.41	5.05e-11	Type 2 diabetes;
SARC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg20007245	chr22:24372913	LOC391322	-0.79	-11.3	-0.6	6.54e-24	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-8.67	-0.49	7.67e-16	Chronic sinus infection;
SARC	cis	rs79839061	0.610	rs78590562	chr4:869715	C/T	cg07828340	chr4:882639	GAK	0.77	5.87	0.36	1.52e-8	Intelligence (multi-trait analysis);
SARC	trans	rs629535	0.734	rs542288	chr8:70057149	G/T	cg21567404	chr3:27674614	NA	-1.06	-13.52	-0.66	3.87e-31	Dupuytren's disease;
SARC	cis	rs10791323	0.660	rs2156681	chr11:133731644	G/T	cg14349672	chr11:133703707	NA	-0.32	-4.92	-0.31	1.63e-6	Childhood ear infection;
SARC	trans	rs11098499	0.697	rs11941899	chr4:120382758	C/A	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	cis	rs17384381	1.000	rs12140170	chr1:85849723	G/A	cg16011679	chr1:85725395	C1orf52	0.64	5.93	0.36	1.06e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6598955	0.515	rs61776655	chr1:26541430	T/C	cg04990556	chr1:26633338	UBXN11	-0.61	-8.41	-0.48	4.02e-15	Obesity-related traits;
SARC	cis	rs6088590	1.000	rs11698977	chr20:33449691	C/T	cg24642439	chr20:33292090	TP53INP2	0.78	10.73	0.58	4.2e-22	Coronary artery disease;
SARC	cis	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg13072238	chr3:49761600	GMPPB	-0.42	-5.54	-0.34	8.33e-8	Intelligence (multi-trait analysis);
SARC	trans	rs208520	0.690	rs10455595	chr6:66738034	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	13.86	0.67	2.98e-32	Exhaled nitric oxide output;
SARC	cis	rs11190604	1.000	rs11190613	chr10:102313997	C/T	cg14256752	chr10:102295592	HIF1AN	-0.43	-4.99	-0.31	1.21e-6	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs897080	0.515	rs698791	chr2:44683168	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	5.75	0.35	2.76e-8	Height;
SARC	cis	rs7644634	0.634	rs3772527	chr3:105441542	T/C	cg23051926	chr3:105466016	CBLB	0.43	5.45	0.34	1.3e-7	Itch intensity from mosquito bite;
SARC	cis	rs763121	0.853	rs6001182	chr22:39047443	A/G	cg06022373	chr22:39101656	GTPBP1	0.9	11.56	0.6	9.96e-25	Menopause (age at onset);
SARC	cis	rs17376456	0.825	rs13361613	chr5:93272176	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	5.84	0.36	1.75e-8	Diabetic retinopathy;
SARC	trans	rs1814175	0.645	rs1963215	chr11:49931486	G/A	cg15704280	chr7:45808275	SEPT13	-0.88	-14.0	-0.68	1.02e-32	Height;
SARC	cis	rs10504229	0.679	rs60869047	chr8:58053221	G/A	cg08280861	chr8:58055591	NA	0.56	5.14	0.32	5.9e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2153535	0.580	rs962590	chr6:8450899	A/G	cg07606381	chr6:8435919	SLC35B3	0.78	11.11	0.59	2.68e-23	Motion sickness;
SARC	cis	rs6542838	0.583	rs12712040	chr2:99513416	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-5.74	-0.35	2.95e-8	Fear of minor pain;
SARC	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg16405210	chr4:1374714	KIAA1530	-0.57	-6.89	-0.41	5.29e-11	Obesity-related traits;
SARC	cis	rs2832191	0.791	rs2832187	chr21:30485543	T/C	cg24692254	chr21:30365293	RNF160	-0.95	-14.51	-0.69	2.02e-34	Dental caries;
SARC	cis	rs11098499	0.863	rs6858777	chr4:120475966	A/G	cg24375607	chr4:120327624	NA	0.42	4.92	0.31	1.64e-6	Corneal astigmatism;
SARC	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg05861140	chr6:150128134	PCMT1	-0.42	-5.44	-0.34	1.32e-7	Lung cancer;
SARC	cis	rs76917914	0.820	rs4743158	chr9:100821275	T/C	cg03040243	chr9:100819229	NANS	0.71	7.81	0.46	1.93e-13	Immature fraction of reticulocytes;
SARC	trans	rs17685	0.753	rs1806885	chr7:75785612	T/G	cg19862616	chr7:65841803	NCRNA00174	0.63	7.95	0.46	8.05e-14	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.5	0.34	9.76e-8	Bipolar disorder;
SARC	cis	rs748404	0.587	rs690276	chr15:43704558	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	5.8	0.36	2.11e-8	Lung cancer;
SARC	cis	rs7729447	0.813	rs4867121	chr5:32692548	T/C	cg16267343	chr5:32710456	NPR3	0.63	8.36	0.48	5.74e-15	Blood pressure;
SARC	trans	rs61931739	0.534	rs10844729	chr12:34022919	A/G	cg13010199	chr12:38710504	ALG10B	0.72	9.64	0.53	9.88e-19	Morning vs. evening chronotype;
SARC	cis	rs3126085	1.000	rs72698906	chr1:152307184	G/A	cg26876637	chr1:152193138	HRNR	-0.49	-5.17	-0.32	5.09e-7	Atopic dermatitis;
SARC	cis	rs3087591	0.959	rs8076441	chr17:29405878	C/T	cg24425628	chr17:29625626	OMG;NF1	-0.54	-6.23	-0.38	2.17e-9	Hip circumference;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg01194519	chr13:26760793	NA	-0.77	-6.29	-0.38	1.52e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7264396	0.563	rs2425090	chr20:34304783	C/A	cg01084648	chr20:34329383	RBM39	0.57	4.95	0.31	1.45e-6	Total cholesterol levels;
SARC	cis	rs367943	0.901	rs348951	chr5:112822017	G/C	cg12552261	chr5:112820674	MCC	-0.46	-5.27	-0.33	3.05e-7	Type 2 diabetes;
SARC	cis	rs735396	1.000	rs1169309	chr12:121439192	G/T	cg02403541	chr12:121454288	C12orf43	0.72	9.48	0.53	2.97e-18	N-glycan levels;
SARC	cis	rs12142240	0.698	rs6659228	chr1:46811027	C/G	cg14993813	chr1:46806288	NSUN4	-0.48	-5.0	-0.31	1.1e-6	Menopause (age at onset);
SARC	cis	rs7681440	0.606	rs2583980	chr4:90751109	T/G	cg06632027	chr4:90757378	SNCA	-0.42	-5.25	-0.33	3.35e-7	Dementia with Lewy bodies;
SARC	cis	rs4803455	0.565	rs2241713	chr19:41869468	C/G	cg09537434	chr19:41945824	ATP5SL	0.69	9.49	0.53	2.95e-18	Migraine;Coronary artery disease;
SARC	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg23758822	chr17:41437982	NA	0.89	11.37	0.6	3.91e-24	Menopause (age at onset);
SARC	cis	rs3796352	1.000	rs34121720	chr3:53072167	C/T	cg15956490	chr3:53032818	SFMBT1	0.76	5.35	0.33	2.05e-7	Immune reponse to smallpox (secreted IL-2);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg19723775	chr5:179050963	HNRNPH1	0.51	6.5	0.39	4.73e-10	Breast cancer;
SARC	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg24675658	chr1:53192096	ZYG11B	0.74	11.28	0.59	7.72e-24	Monocyte count;
SARC	cis	rs9911578	1.000	rs6503866	chr17:56619581	C/T	cg12560992	chr17:57184187	TRIM37	-0.81	-10.81	-0.58	2.45e-22	Intelligence (multi-trait analysis);
SARC	cis	rs7647973	0.593	rs62262730	chr3:49808274	T/G	cg07636037	chr3:49044803	WDR6	-0.59	-5.63	-0.35	5.09e-8	Menarche (age at onset);
SARC	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg18357526	chr6:26021779	HIST1H4A	0.85	11.69	0.61	3.91e-25	Intelligence (multi-trait analysis);
SARC	cis	rs10927875	0.722	rs1763606	chr1:16338282	A/G	cg21385522	chr1:16154831	NA	0.71	9.12	0.51	3.56e-17	Dilated cardiomyopathy;
SARC	cis	rs78487399	0.808	rs75934770	chr2:43659694	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-5.69	-0.35	3.88e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs8016982	0.674	rs1957549	chr14:81706179	G/A	cg01989461	chr14:81687754	GTF2A1	0.74	11.26	0.59	8.89e-24	Schizophrenia;
SARC	cis	rs73001065	0.792	rs17216588	chr19:19664077	C/T	cg03709012	chr19:19516395	GATAD2A	0.91	5.39	0.33	1.75e-7	LDL cholesterol;
SARC	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.48	5.93	0.36	1.09e-8	Tonsillectomy;
SARC	cis	rs2235642	0.826	rs8053605	chr16:1594158	G/A	cg09065629	chr16:1709722	CRAMP1L	0.35	4.97	0.31	1.27e-6	Coronary artery disease;
SARC	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6908034	0.607	rs77753186	chr6:19812980	G/C	cg02682789	chr6:19804855	NA	0.69	5.56	0.34	7.3900000000000007e-08	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	trans	rs8020941	0.585	rs7149193	chr14:97505099	C/T	cg05136476	chr3:53190709	NA	-0.61	-6.29	-0.38	1.58e-9	Diabetic kidney disease;
SARC	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg05863683	chr7:1912471	MAD1L1	0.31	4.75	0.3	3.64e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs9640161	0.789	rs3735174	chr7:150020489	T/C	cg10018233	chr7:150070692	REPIN1	0.71	9.71	0.54	6.07e-19	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.66	6.15	0.37	3.26e-9	Platelet count;
SARC	cis	rs847851	0.798	rs10947536	chr6:34975993	A/G	cg04594399	chr6:34941065	ANKS1A	-0.41	-4.98	-0.31	1.22e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2562456	0.917	rs2681376	chr19:21715525	T/G	cg00806126	chr19:22604979	ZNF98	0.49	5.05	0.31	9.09e-7	Pain;
SARC	cis	rs7089973	0.836	rs1046492	chr10:116624067	C/T	cg08188268	chr10:116634841	FAM160B1	0.37	5.89	0.36	1.33e-8	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs79349575	0.715	rs4793997	chr17:47019672	C/A	cg16584676	chr17:46985605	UBE2Z	0.55	6.66	0.4	1.91e-10	Type 2 diabetes;
SARC	cis	rs9486719	0.843	rs3860230	chr6:97036560	T/A	cg06623918	chr6:96969491	KIAA0776	-0.77	-9.37	-0.52	6.76e-18	Migraine;Coronary artery disease;
SARC	cis	rs1691799	0.899	rs1168321	chr12:66744517	C/G	cg16791601	chr12:66731901	HELB	0.71	10.65	0.57	7.95e-22	White blood cell count (basophil);
SARC	cis	rs7666738	0.830	rs11932942	chr4:98998939	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs16976116	0.901	rs28535372	chr15:55500602	T/C	cg11288833	chr15:55489084	RSL24D1	0.63	6.13	0.37	3.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs950776	0.593	rs588765	chr15:78865425	T/C	cg06917634	chr15:78832804	PSMA4	-0.84	-12.81	-0.64	8.79e-29	Sudden cardiac arrest;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21217345	chr7:134855774	C7orf49	-0.53	-6.69	-0.4	1.63e-10	Smoking initiation;
SARC	cis	rs9473924	0.542	rs9473922	chr6:50831792	C/T	cg14470998	chr6:50812995	TFAP2B	0.75	6.83	0.41	7.45e-11	Body mass index;
SARC	cis	rs9372253	0.967	rs1055301	chr6:110713042	A/G	cg19196401	chr6:110721138	DDO	-0.37	-4.76	-0.3	3.34e-6	Platelet distribution width;
SARC	cis	rs16854884	0.526	rs7643341	chr3:143726980	C/T	cg06585982	chr3:143692056	C3orf58	0.51	6.96	0.41	3.41e-11	Economic and political preferences (feminism/equality);
SARC	cis	rs8044995	0.517	rs61593058	chr16:68384496	T/C	cg09835421	chr16:68378352	PRMT7	-0.43	-4.89	-0.3	1.91e-6	Schizophrenia;
SARC	cis	rs2832077	0.943	rs2832099	chr21:30173460	A/G	cg03476357	chr21:30257390	N6AMT1	-0.63	-5.98	-0.36	8.3e-9	Cognitive test performance;
SARC	cis	rs865483	0.895	rs853192	chr17:35821931	C/G	cg06561646	chr17:35873369	DUSP14	-0.46	-6.15	-0.37	3.31e-9	Monocyte count;
SARC	cis	rs12145833	0.920	rs12354170	chr1:243457776	G/T	cg02356786	chr1:243265016	LOC731275	0.7	5.98	0.36	8.34e-9	Obesity (early onset extreme);
SARC	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg23758822	chr17:41437982	NA	0.87	10.68	0.57	6.2e-22	Menopause (age at onset);
SARC	cis	rs7772486	0.806	rs4075696	chr6:146250947	T/C	cg05347473	chr6:146136440	FBXO30	-0.46	-6.13	-0.37	3.8e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11098499	0.738	rs28408407	chr4:120376030	C/G	cg09160332	chr4:120329925	NA	-0.33	-4.74	-0.3	3.75e-6	Corneal astigmatism;
SARC	trans	rs8020941	0.585	rs2024663	chr14:97492568	C/G	cg05136476	chr3:53190709	NA	0.61	6.28	0.38	1.66e-9	Diabetic kidney disease;
SARC	cis	rs883565	0.792	rs813669	chr3:39181723	C/T	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.51	-5.72	-0.35	3.32e-8	Handedness;
SARC	cis	rs2013441	1.000	rs4924809	chr17:20044673	C/T	cg13482628	chr17:19912719	NA	0.47	6.13	0.37	3.67e-9	Obesity-related traits;
SARC	cis	rs55882075	1.000	rs55882075	chr5:179210115	C/G	cg14593053	chr5:179126677	CANX	0.42	5.39	0.33	1.7e-7	Monocyte percentage of white cells;
SARC	cis	rs76419734	0.614	rs17035951	chr4:106527613	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.65	5.95	0.36	9.85e-9	Post bronchodilator FEV1;
SARC	cis	rs7223966	1.000	rs8075273	chr17:61728881	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.56	-5.44	-0.34	1.33e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.85	12.69	0.64	2.2e-28	Eosinophil percentage of white cells;
SARC	cis	rs477692	0.569	rs10764886	chr10:131310680	C/T	cg05714579	chr10:131428358	MGMT	0.56	7.69	0.45	4.09e-13	Response to temozolomide;
SARC	cis	rs1003719	0.713	rs2835594	chr21:38466064	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.63	9.05	0.51	5.67e-17	Eye color traits;
SARC	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	7.39	0.44	2.59e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg21747090	chr2:27597821	SNX17	-0.54	-7.58	-0.44	8.33e-13	Total body bone mineral density;
SARC	cis	rs7833986	0.501	rs2719259	chr8:56941630	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.73	7.27	0.43	5.52e-12	Height;
SARC	cis	rs4253772	0.591	rs6008545	chr22:46686375	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.66	6.72	0.4	1.39e-10	LDL cholesterol;Cholesterol, total;
SARC	cis	rs4974559	0.790	rs5019560	chr4:1324793	G/A	cg02980000	chr4:1222292	CTBP1	0.63	6.14	0.37	3.48e-9	Systolic blood pressure;
SARC	trans	rs9650657	0.655	rs10093774	chr8:10703293	C/T	cg08975724	chr8:8085496	FLJ10661	0.49	6.3	0.38	1.48e-9	Neuroticism;
SARC	trans	rs61931739	0.929	rs10844748	chr12:34092930	G/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.05	-0.42	2.07e-11	Morning vs. evening chronotype;
SARC	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg16405210	chr4:1374714	KIAA1530	-0.5	-5.79	-0.35	2.29e-8	Obesity-related traits;
SARC	cis	rs9462027	0.628	rs9462030	chr6:34831280	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-6.01	-0.37	6.99e-9	Systemic lupus erythematosus;
SARC	cis	rs6087990	0.806	rs910084	chr20:31379665	C/T	cg13636640	chr20:31349939	DNMT3B	0.8	13.03	0.65	1.67e-29	Ulcerative colitis;
SARC	cis	rs9303401	0.614	rs12948536	chr17:56580413	G/T	cg25039879	chr17:56429692	SUPT4H1	0.63	5.81	0.36	2.03e-8	Cognitive test performance;
SARC	cis	rs6963495	0.818	rs73190184	chr7:105163736	C/T	cg19920283	chr7:105172520	RINT1	0.65	5.48	0.34	1.09e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs6570726	0.526	rs72994723	chr6:145722948	G/A	cg23711669	chr6:146136114	FBXO30	-0.63	-8.17	-0.47	1.96e-14	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg08365438	chr10:21683093	NA	-0.84	-6.97	-0.42	3.14e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7223966	1.000	rs11658329	chr17:61763031	C/G	cg00588841	chr17:61851480	DDX42;CCDC47	0.59	6.86	0.41	5.99e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs986417	0.748	rs10145546	chr14:61100892	A/G	cg27398547	chr14:60952738	C14orf39	0.76	7.3	0.43	4.54e-12	Gut microbiota (bacterial taxa);
SARC	cis	rs72781680	0.898	rs55761273	chr2:23957849	A/G	cg06627628	chr2:24431161	ITSN2	-0.63	-6.18	-0.38	2.86e-9	Lymphocyte counts;
SARC	cis	rs11690935	0.531	rs4280428	chr2:172813219	G/A	cg13550731	chr2:172543902	DYNC1I2	0.55	7.22	0.43	7.52e-12	Schizophrenia;
SARC	cis	rs2066819	1.000	rs2371494	chr12:56728000	G/A	cg26734620	chr12:56694298	CS	0.86	6.37	0.39	1.01e-9	Psoriasis vulgaris;
SARC	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg13770153	chr20:60521292	NA	-0.46	-6.38	-0.39	9.39e-10	Body mass index;
SARC	cis	rs9303401	0.659	rs11079357	chr17:56902778	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	11.58	0.6	8.42e-25	Cognitive test performance;
SARC	cis	rs7264396	0.563	rs11698796	chr20:34248134	T/C	cg01084648	chr20:34329383	RBM39	0.63	5.25	0.33	3.48e-7	Total cholesterol levels;
SARC	cis	rs995000	0.868	rs1168029	chr1:62969402	G/A	cg06896770	chr1:63153194	DOCK7	-0.89	-12.99	-0.65	2.12e-29	Triglyceride levels;
SARC	cis	rs13392177	0.684	rs6720449	chr2:219080978	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.56	-7.17	-0.43	9.82e-12	Pyoderma gangrenosum in inflammatory bowel disease;
SARC	cis	rs916888	0.531	rs183211	chr17:44788310	G/A	cg15921436	chr17:44337874	NA	0.48	5.43	0.33	1.45e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg14541582	chr5:601475	NA	-0.43	-5.19	-0.32	4.48e-7	Obesity-related traits;
SARC	cis	rs1707322	0.752	rs6658700	chr1:46160260	C/T	cg03146154	chr1:46216737	IPP	0.52	6.28	0.38	1.6e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2730245	0.959	rs2527201	chr7:158738611	G/T	cg24397884	chr7:158709396	WDR60	-1.05	-15.87	-0.72	6.01e-39	Height;
SARC	cis	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg13072238	chr3:49761600	GMPPB	-0.58	-5.82	-0.36	1.9e-8	Menarche (age at onset);
SARC	cis	rs503341	0.756	rs626333	chr11:63591861	C/T	cg04362095	chr11:63592001	C11orf84	-0.56	-7.61	-0.45	6.63e-13	Pulse pressure;
SARC	trans	rs1814175	0.616	rs4881723	chr11:49788566	G/T	cg03929089	chr4:120376271	NA	-0.84	-12.3	-0.63	4.13e-27	Height;
SARC	cis	rs9430161	0.579	rs7542158	chr1:11040193	G/A	cg02454025	chr1:11042201	C1orf127	0.85	12.51	0.63	8.47e-28	Ewing sarcoma;
SARC	cis	rs77956314	0.515	rs4767473	chr12:117365506	C/T	cg02017074	chr12:117425053	FBXW8	0.56	6.9	0.41	4.78e-11	Subcortical brain region volumes;Hippocampal volume;
SARC	cis	rs6141769	0.542	rs4425162	chr20:31312916	A/G	cg13636640	chr20:31349939	DNMT3B	-0.45	-4.78	-0.3	3.08e-6	Subjective well-being;
SARC	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	11.97	0.62	4.67e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs854765	0.583	rs8073001	chr17:17831716	A/C	cg05444541	chr17:17804740	TOM1L2	0.31	5.31	0.33	2.49e-7	Total body bone mineral density;
SARC	cis	rs644799	0.932	rs480079	chr11:95643777	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.84	-12.14	-0.62	1.37e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9811216	0.876	rs10936600	chr3:169514585	A/T	cg14222479	chr3:169487675	ARPM1	0.45	5.32	0.33	2.39e-7	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs8077889	0.703	rs231543	chr17:41940360	G/T	cg26893861	chr17:41843967	DUSP3	-0.71	-7.05	-0.42	2.04e-11	Triglycerides;
SARC	cis	rs13191362	1.000	rs13214516	chr6:163121583	A/T	cg18825119	chr6:163149453	PACRG;PARK2	0.4	5.08	0.32	7.89e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg15556689	chr8:8085844	FLJ10661	0.44	5.73	0.35	3.07e-8	Joint mobility (Beighton score);
SARC	cis	rs2721811	0.528	rs2237312	chr7:24760039	A/G	cg17569154	chr7:24781545	DFNA5	0.49	7.01	0.42	2.49e-11	Depressive symptoms (multi-trait analysis);
SARC	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg18876405	chr7:65276391	NA	-0.44	-4.92	-0.31	1.62e-6	Aortic root size;
SARC	cis	rs9902453	0.904	rs7213076	chr17:28419428	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.08	-0.42	1.73e-11	Coffee consumption (cups per day);
SARC	cis	rs2377585	0.653	rs10770955	chr12:8842752	C/T	cg03761649	chr12:8850719	RIMKLB	0.46	4.81	0.3	2.73e-6	Reticulocyte fraction of red cells;
SARC	cis	rs73198271	0.740	rs10113326	chr8:8647630	A/T	cg06636001	chr8:8085503	FLJ10661	-0.47	-5.0	-0.31	1.13e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg06713675	chr4:122721982	EXOSC9	-0.5	-6.62	-0.4	2.41e-10	Type 2 diabetes;
SARC	cis	rs9818758	0.607	rs11719220	chr3:49245201	A/G	cg03060546	chr3:49711283	APEH	-0.54	-4.73	-0.3	3.87e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg02592271	chr2:27665507	KRTCAP3	-0.42	-6.36	-0.38	1.04e-9	Total body bone mineral density;
SARC	cis	rs7726839	0.555	rs7720419	chr5:589343	A/T	cg09021430	chr5:549028	NA	-0.56	-11.46	-0.6	2.06e-24	Obesity-related traits;
SARC	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	10.83	0.58	2.15e-22	Alzheimer's disease;
SARC	cis	rs477692	0.544	rs7894836	chr10:131442595	T/A	cg05714579	chr10:131428358	MGMT	-0.67	-8.71	-0.5	5.63e-16	Response to temozolomide;
SARC	trans	rs7937682	0.883	rs1784775	chr11:111472460	T/C	cg18187862	chr3:45730750	SACM1L	0.51	6.31	0.38	1.37e-9	Primary sclerosing cholangitis;
SARC	cis	rs262150	0.714	rs2657397	chr7:158785095	C/T	cg19418458	chr7:158789849	NA	-0.48	-6.53	-0.39	4.19e-10	Facial morphology (factor 20);
SARC	cis	rs4646312	0.555	rs2078748	chr22:19925414	A/G	cg07194846	chr22:19930177	COMT;TXNRD2	0.5	6.46	0.39	5.94e-10	Schizophrenia;
SARC	cis	rs7005606	1.000	rs7834206	chr8:32406148	C/A	cg14488905	chr8:32406789	NRG1	0.45	6.31	0.38	1.42e-9	Hirschsprung disease;
SARC	cis	rs13191362	0.935	rs34603926	chr6:163266793	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.63	6.06	0.37	5.5e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs7522061	0.565	rs6695840	chr1:157645696	C/G	cg18268488	chr1:157545234	FCRL4	0.26	4.86	0.3	2.18e-6	Blood protein levels;
SARC	cis	rs7178572	1.000	rs952471	chr15:77776498	C/G	cg22256960	chr15:77711686	NA	-0.56	-6.64	-0.4	2.2e-10	Type 2 diabetes;
SARC	cis	rs526821	0.595	rs4938937	chr11:55305507	T/A	cg04317927	chr11:55418816	OR4S2	0.39	5.61	0.34	5.74e-8	Pediatric bone mineral density (spine);
SARC	cis	rs7264396	0.513	rs2425092	chr20:34306815	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-7.17	-0.43	9.99e-12	Total cholesterol levels;
SARC	cis	rs9420	0.961	rs527528	chr11:57433327	C/T	cg23127183	chr11:57508653	C11orf31	-0.52	-6.05	-0.37	5.64e-9	Schizophrenia;
SARC	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg16414030	chr3:133502952	NA	-0.41	-5.52	-0.34	8.98e-8	Iron status biomarkers;
SARC	cis	rs7644634	0.649	rs9657915	chr3:105374814	A/G	cg23051926	chr3:105466016	CBLB	0.48	5.96	0.36	9.37e-9	Itch intensity from mosquito bite;
SARC	cis	rs9325144	0.647	rs34311455	chr12:39060889	C/T	cg26384229	chr12:38710491	ALG10B	-0.61	-7.9	-0.46	1.09e-13	Morning vs. evening chronotype;
SARC	trans	rs11710567	0.734	rs9849219	chr3:57897582	C/T	cg01127878	chr19:42811035	PRR19	-0.43	-6.43	-0.39	7.18e-10	Granulocyte percentage of myeloid white cells;
SARC	cis	rs7274811	0.681	rs291707	chr20:31964256	G/A	cg21523528	chr20:32077966	CBFA2T2	-0.41	-4.88	-0.3	2e-6	Height;
SARC	cis	rs2731664	0.792	rs2630765	chr5:176876825	T/C	cg23176889	chr5:176863531	GRK6	-0.54	-8.05	-0.47	4.15e-14	Intelligence (multi-trait analysis);
SARC	cis	rs698833	0.962	rs698829	chr2:44730846	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.66	7.98	0.46	6.73e-14	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs41271473	0.526	rs12136157	chr1:228703236	T/C	cg10167378	chr1:228756711	NA	0.58	5.29	0.33	2.87e-7	Chronic lymphocytic leukemia;
SARC	cis	rs9325144	0.600	rs6582634	chr12:38748041	G/A	cg13010199	chr12:38710504	ALG10B	0.55	7.03	0.42	2.21e-11	Morning vs. evening chronotype;
SARC	cis	rs7666738	0.753	rs1830230	chr4:99026186	G/C	cg05340658	chr4:99064831	C4orf37	0.65	8.86	0.5	2.05e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs3008870	0.755	rs1024229	chr1:67512903	G/T	cg02640540	chr1:67518911	SLC35D1	0.61	7.69	0.45	4.01e-13	Lymphocyte percentage of white cells;
SARC	cis	rs13082711	0.554	rs66854845	chr3:27387008	C/T	cg02860705	chr3:27208620	NA	0.65	8.03	0.47	4.7e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs1865760	0.508	rs9379820	chr6:26049924	T/C	cg16482183	chr6:26056742	HIST1H1C	0.5	6.38	0.39	9.53e-10	Height;
SARC	trans	rs8020941	0.585	rs77608728	chr14:97519423	G/A	cg05136476	chr3:53190709	NA	-0.7	-6.97	-0.42	3.14e-11	Diabetic kidney disease;
SARC	trans	rs10519937	0.935	rs59745967	chr5:126740052	C/T	cg26526953	chr19:1921199	SCAMP4	0.6	6.26	0.38	1.79e-9	IgG glycosylation;
SARC	cis	rs9399135	0.967	rs9399129	chr6:135285148	C/A	cg24558204	chr6:135376177	HBS1L	0.44	6.02	0.37	6.61e-9	Red blood cell count;
SARC	cis	rs16933812	0.510	rs7854114	chr9:36989004	T/C	cg14294708	chr9:37120828	ZCCHC7	-0.41	-4.74	-0.3	3.64e-6	Obesity-related traits;
SARC	cis	rs3820928	0.874	rs10178731	chr2:227874232	C/T	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.69	-0.35	3.77e-8	Pulmonary function;
SARC	cis	rs2486288	0.656	rs9921035	chr15:45546660	C/T	cg15395560	chr15:45543142	SLC28A2	0.29	5.55	0.34	7.67e-8	Glomerular filtration rate;
SARC	cis	rs1318878	0.589	rs10846167	chr12:15515945	C/T	cg08258403	chr12:15378311	NA	0.36	5.36	0.33	1.98e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7119	0.717	rs35268067	chr15:77753688	C/G	cg17802220	chr15:77601643	NA	-0.44	-5.71	-0.35	3.44e-8	Type 2 diabetes;
SARC	cis	rs1949733	0.958	rs2631731	chr4:8429817	A/G	cg13073564	chr4:8508604	NA	-0.43	-6.67	-0.4	1.8e-10	Response to antineoplastic agents;
SARC	cis	rs1059312	0.522	rs3825181	chr12:129279264	G/A	cg09035930	chr12:129282057	SLC15A4	-0.44	-5.4	-0.33	1.67e-7	Systemic lupus erythematosus;
SARC	cis	rs10089	0.552	rs1351141	chr5:127550055	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.62	-7.09	-0.42	1.6e-11	Ileal carcinoids;
SARC	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg20607798	chr8:58055168	NA	-0.61	-5.55	-0.34	7.94e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg24110177	chr3:50126178	RBM5	0.38	4.87	0.3	2.11e-6	Intelligence (multi-trait analysis);
SARC	cis	rs4243830	0.571	rs60256927	chr1:6614747	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	0.99	9.28	0.52	1.23e-17	Body mass index;
SARC	cis	rs8180040	0.764	rs4082155	chr3:47125385	G/A	cg27129171	chr3:47204927	SETD2	0.66	9.25	0.52	1.51e-17	Colorectal cancer;
SARC	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg18876405	chr7:65276391	NA	-0.69	-8.81	-0.5	2.95e-16	Aortic root size;
SARC	cis	rs2361718	0.500	rs4889818	chr17:78085228	A/G	cg23534315	chr17:78082725	GAA	0.45	5.32	0.33	2.42e-7	Yeast infection;
SARC	cis	rs17023223	0.537	rs17023174	chr1:119593301	T/C	cg05756136	chr1:119680316	WARS2	-0.45	-5.44	-0.34	1.35e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg27266027	chr21:40555129	PSMG1	-0.41	-4.72	-0.3	4.01e-6	Menarche (age at onset);
SARC	cis	rs875971	0.830	rs427973	chr7:65526648	C/A	cg18876405	chr7:65276391	NA	0.5	6.24	0.38	2.06e-9	Aortic root size;
SARC	cis	rs1355223	0.902	rs1539251	chr11:34742772	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.34	-0.33	2.21e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs61861422	0.516	rs12412216	chr10:134393338	C/T	cg27286337	chr10:134555280	INPP5A	0.5	5.17	0.32	5.02e-7	Primary sclerosing cholangitis;
SARC	cis	rs6570726	0.791	rs392612	chr6:145881586	C/G	cg23711669	chr6:146136114	FBXO30	-0.85	-14.0	-0.68	1.03e-32	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg02018176	chr4:1364513	KIAA1530	-0.46	-6.56	-0.4	3.36e-10	Obesity-related traits;
SARC	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg07701084	chr6:150067640	NUP43	0.4	5.2	0.32	4.31e-7	Lung cancer;
SARC	cis	rs12579753	0.917	rs2401003	chr12:82215192	G/A	cg07988820	chr12:82153109	PPFIA2	-0.49	-5.48	-0.34	1.12e-7	Resting heart rate;
SARC	cis	rs4242434	0.927	rs34027561	chr8:22465385	T/C	cg03733263	chr8:22462867	KIAA1967	1.05	18.05	0.76	3.87e-46	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs780094	0.585	rs7586601	chr2:27584666	A/G	cg22903471	chr2:27725779	GCKR	-0.38	-5.34	-0.33	2.2e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs2204008	0.685	rs4556621	chr12:38187236	C/A	cg26384229	chr12:38710491	ALG10B	0.88	12.94	0.65	3.26e-29	Bladder cancer;
SARC	cis	rs6669919	0.553	rs12733443	chr1:211667751	C/T	cg10512769	chr1:211675356	NA	-0.36	-5.78	-0.35	2.38e-8	Intelligence (multi-trait analysis);
SARC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg10295955	chr4:187884368	NA	-1.05	-17.53	-0.75	1.93e-44	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg02841227	chr6:26021843	HIST1H4A	0.49	5.88	0.36	1.42e-8	Intelligence (multi-trait analysis);
SARC	cis	rs10927875	0.632	rs1122068	chr1:16127480	G/C	cg07117364	chr1:16154769	NA	-0.42	-4.89	-0.31	1.86e-6	Dilated cardiomyopathy;
SARC	cis	rs4975616	0.836	rs460073	chr5:1336459	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.56	-7.74	-0.45	3.07e-13	Lung cancer;
SARC	cis	rs6088580	0.660	rs6059893	chr20:33105897	T/G	cg24642439	chr20:33292090	TP53INP2	0.66	8.58	0.49	1.39e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg24110177	chr3:50126178	RBM5	0.64	8.48	0.49	2.53e-15	Body mass index;
SARC	cis	rs1318878	0.565	rs11056422	chr12:15461785	A/G	cg08258403	chr12:15378311	NA	0.49	6.81	0.41	8.07e-11	Intelligence (multi-trait analysis);
SARC	cis	rs6582630	0.638	rs10880644	chr12:38554959	G/A	cg26384229	chr12:38710491	ALG10B	0.58	7.36	0.43	3.22e-12	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.41	4.98	0.31	1.21e-6	Lymphocyte counts;
SARC	cis	rs2204008	0.837	rs2127955	chr12:37969194	A/G	cg26384229	chr12:38710491	ALG10B	0.78	11.28	0.59	7.97e-24	Bladder cancer;
SARC	cis	rs4803468	1.000	rs3810175	chr19:41904396	C/T	cg09537434	chr19:41945824	ATP5SL	0.94	16.14	0.73	7.78e-40	Height;
SARC	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg15921436	chr17:44337874	NA	0.52	5.28	0.33	2.98e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs4919694	1.000	rs77827514	chr10:104822009	C/T	cg04362960	chr10:104952993	NT5C2	0.65	5.49	0.34	1.03e-7	Arsenic metabolism;
SARC	cis	rs7000551	0.751	rs2443494	chr8:22372262	C/G	cg12081754	chr8:22256438	SLC39A14	0.57	8.11	0.47	2.8e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs17666538	1.000	rs61064968	chr8:587933	T/C	cg07685180	chr8:600429	NA	-0.73	-5.89	-0.36	1.37e-8	IgG glycosylation;
SARC	cis	rs9398803	0.865	rs2184967	chr6:126773487	C/T	cg19875578	chr6:126661172	C6orf173	0.63	8.6	0.49	1.17e-15	Male-pattern baldness;
SARC	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg07153921	chr17:41440717	NA	-0.4	-4.77	-0.3	3.29e-6	Menopause (age at onset);
SARC	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg11764359	chr7:65958608	NA	-0.88	-12.72	-0.64	1.65e-28	Aortic root size;
SARC	cis	rs920590	0.758	rs7011322	chr8:19661937	C/T	cg17834443	chr8:19674713	INTS10	0.58	7.0	0.42	2.74e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9549367	0.713	rs2146750	chr13:113822530	A/G	cg18105134	chr13:113819100	PROZ	0.38	5.41	0.33	1.54e-7	Platelet distribution width;
SARC	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg24633833	chr3:10029261	TMEM111	-0.52	-4.82	-0.3	2.54e-6	Alzheimer's disease;
SARC	cis	rs2070677	1.000	rs1410897	chr10:135349537	G/A	cg20169779	chr10:135381914	SYCE1	0.46	5.95	0.36	9.87e-9	Gout;
SARC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg11965913	chr1:205819406	PM20D1	0.6	7.94	0.46	8.36e-14	Menarche (age at onset);
SARC	cis	rs9443189	0.570	rs775072	chr6:76377998	G/A	cg01950844	chr6:76311363	SENP6	-0.86	-8.19	-0.47	1.68e-14	Prostate cancer;
SARC	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs71636778	0.722	rs34928032	chr1:27139229	A/G	cg04852280	chr1:26496234	ZNF593	0.57	5.12	0.32	6.35e-7	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs2486288	0.656	rs12911861	chr15:45566718	T/C	cg15395560	chr15:45543142	SLC28A2	0.31	6.0	0.37	7.54e-9	Glomerular filtration rate;
SARC	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	13.84	0.67	3.51e-32	Chronic sinus infection;
SARC	cis	rs3087591	0.960	rs2952995	chr17:29541061	T/C	cg24425628	chr17:29625626	OMG;NF1	0.5	6.22	0.38	2.32e-9	Hip circumference;
SARC	cis	rs3749237	0.595	rs7621003	chr3:49411404	T/C	cg03060546	chr3:49711283	APEH	0.75	10.72	0.57	4.68e-22	Resting heart rate;
SARC	trans	rs1814175	0.616	rs1794131	chr11:49904194	A/G	cg15704280	chr7:45808275	SEPT13	-0.88	-13.97	-0.68	1.24e-32	Height;
SARC	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg01341218	chr17:43662625	NA	1.01	11.8	0.61	1.73e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs765787	0.530	rs28414644	chr15:45536721	G/C	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.51e-10	Uric acid levels;
SARC	cis	rs2481665	0.742	rs6670849	chr1:62542717	C/T	cg18591186	chr1:62594603	INADL	-0.47	-6.25	-0.38	1.89e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs11645898	0.935	rs28419077	chr16:72196776	A/G	cg14768367	chr16:72042858	DHODH	-0.55	-5.19	-0.32	4.54e-7	Blood protein levels;
SARC	cis	rs9300255	0.602	rs2695478	chr12:123689521	C/T	cg00376283	chr12:123451042	ABCB9	0.57	5.54	0.34	8.1e-8	Neutrophil percentage of white cells;
SARC	cis	rs7552404	0.920	rs2788654	chr1:76219569	C/T	cg03433033	chr1:76189801	ACADM	0.48	6.89	0.41	5.18e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs35160687	0.901	rs13020869	chr2:86523360	C/T	cg10973622	chr2:86423274	IMMT	0.38	4.92	0.31	1.67e-6	Night sleep phenotypes;
SARC	cis	rs5753618	0.607	rs5753621	chr22:31847647	T/C	cg02404636	chr22:31891804	SFI1	0.49	5.35	0.33	2.1e-7	Colorectal cancer;
SARC	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg08859206	chr1:53392774	SCP2	0.43	6.13	0.37	3.76e-9	Monocyte count;
SARC	cis	rs1008375	1.000	rs1860597	chr4:17657650	C/T	cg02297831	chr4:17616191	MED28	0.49	6.31	0.38	1.39e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs1814175	0.817	rs7927373	chr11:49957640	A/C	cg03929089	chr4:120376271	NA	-0.89	-14.59	-0.69	1.1e-34	Height;
SARC	cis	rs3733585	0.699	rs62294332	chr4:9959989	T/C	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.55	-0.34	7.65e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg11062466	chr8:58055876	NA	0.67	6.2	0.38	2.57e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	9.01	0.51	7.42e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg03637622	chr5:179334771	TBC1D9B	0.53	6.37	0.39	1e-9	Blood pressure;
SARC	cis	rs4742903	0.935	rs10739885	chr9:106912892	G/A	cg14250997	chr9:106856677	SMC2	0.47	6.08	0.37	4.81e-9	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg03517284	chr6:25882590	NA	-0.45	-5.92	-0.36	1.15e-8	Blood metabolite levels;
SARC	cis	rs9435341	0.896	rs1730850	chr1:107597988	C/T	cg09367891	chr1:107599246	PRMT6	-0.74	-9.01	-0.51	7.88e-17	Facial morphology (factor 21, depth of nasal alae);
SARC	cis	rs6693567	0.526	rs834239	chr1:150375458	C/A	cg09579323	chr1:150459698	TARS2	0.46	5.84	0.36	1.74e-8	Migraine;
SARC	cis	rs11098499	0.866	rs12510451	chr4:120289143	C/T	cg09307838	chr4:120376055	NA	0.83	11.82	0.61	1.46e-25	Corneal astigmatism;
SARC	cis	rs7481584	0.624	rs438384	chr11:3045651	A/G	cg05729581	chr11:3078854	CARS	0.48	5.67	0.35	4.28e-8	Calcium levels;
SARC	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.44	5.61	0.34	5.81e-8	Personality dimensions;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg26389465	chr11:112097071	PTS	0.48	6.34	0.38	1.18e-9	Chemerin levels;
SARC	cis	rs898097	0.528	rs2243523	chr17:80680449	G/T	cg20578329	chr17:80767326	TBCD	-0.4	-5.69	-0.35	3.77e-8	Breast cancer;
SARC	cis	rs10463316	0.817	rs7701271	chr5:150776708	A/G	cg03212797	chr5:150827313	SLC36A1	0.44	5.24	0.32	3.53e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs2594989	0.887	rs7643330	chr3:11442093	A/G	cg00170343	chr3:11313890	ATG7	0.6	5.92	0.36	1.13e-8	Circulating chemerin levels;
SARC	cis	rs2439831	0.867	rs2243434	chr15:43689867	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.78	8.26	0.48	1.12e-14	Lung cancer in ever smokers;
SARC	cis	rs1707322	0.506	rs2991983	chr1:46079391	T/C	cg06784218	chr1:46089804	CCDC17	-0.38	-6.68	-0.4	1.79e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6426558	0.514	rs3754418	chr1:227348473	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.41	-4.78	-0.3	3.09e-6	Neutrophil percentage of white cells;
SARC	cis	rs4803468	1.000	rs284655	chr19:41928765	C/T	cg09537434	chr19:41945824	ATP5SL	-0.98	-17.28	-0.75	1.27e-43	Height;
SARC	cis	rs9322817	0.503	rs6571205	chr6:105208813	A/C	cg02098413	chr6:105308735	HACE1	-0.37	-5.7	-0.35	3.65e-8	Thyroid stimulating hormone;
SARC	cis	rs2180341	0.782	rs6912196	chr6:127722732	C/G	cg27446573	chr6:127587934	RNF146	0.8	10.99	0.58	6.72e-23	Breast cancer;
SARC	cis	rs2576037	0.796	rs2571031	chr18:44577063	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.67	-9.83	-0.54	2.77e-19	Personality dimensions;
SARC	cis	rs2479724	0.805	rs11756454	chr6:41798578	T/A	cg17623882	chr6:41773611	USP49	0.48	6.32	0.38	1.28e-9	Menarche (age at onset);
SARC	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg24549020	chr5:56110836	MAP3K1	0.81	8.4	0.48	4.52e-15	Initial pursuit acceleration;
SARC	cis	rs9486719	0.895	rs3798294	chr6:97049587	G/A	cg06623918	chr6:96969491	KIAA0776	-0.79	-8.93	-0.51	1.3e-16	Migraine;Coronary artery disease;
SARC	cis	rs6912958	0.712	rs2814712	chr6:88396322	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.3	5.1	0.32	7.16e-7	Monocyte percentage of white cells;
SARC	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg18252515	chr7:66147081	NA	-1.3	-11.5	-0.6	1.59e-24	Diabetic kidney disease;
SARC	cis	rs6940638	0.513	rs4424065	chr6:27036456	C/T	cg12292205	chr6:26970375	C6orf41	-0.43	-5.03	-0.31	9.71e-7	Intelligence (multi-trait analysis);
SARC	cis	rs3126085	0.935	rs10888466	chr1:152166223	A/C	cg03465714	chr1:152285911	FLG	0.44	5.28	0.33	2.99e-7	Atopic dermatitis;
SARC	cis	rs765787	0.530	rs4775837	chr15:45537684	G/T	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.51e-10	Uric acid levels;
SARC	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg19223190	chr17:80058835	NA	0.44	6.19	0.38	2.67e-9	Life satisfaction;
SARC	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-14.67	-0.69	5.84e-35	Chronic sinus infection;
SARC	cis	rs6991838	0.584	rs60023200	chr8:66486782	C/T	cg13398993	chr8:66546079	ARMC1	-0.62	-8.36	-0.48	5.88e-15	Intelligence (multi-trait analysis);
SARC	cis	rs6831352	0.918	rs29001194	chr4:100054844	A/G	cg13256891	chr4:100009986	ADH5	-0.64	-8.0	-0.46	5.7e-14	Alcohol dependence;
SARC	cis	rs644799	0.544	rs1527450	chr11:95467777	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.67	8.48	0.49	2.62e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs1559088	0.847	rs8110181	chr19:33605939	G/A	cg17764715	chr19:33622953	WDR88	0.49	6.66	0.4	1.99e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs6500395	0.584	rs9922553	chr16:48739059	A/G	cg04672837	chr16:48644449	N4BP1	0.41	4.72	0.3	4.07e-6	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs600231	0.708	rs1784100	chr11:65249227	T/C	cg17120908	chr11:65337727	SSSCA1	-0.42	-5.44	-0.34	1.38e-7	Bone mineral density;
SARC	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg00933542	chr6:150070202	PCMT1	0.32	5.46	0.34	1.23e-7	Lung cancer;
SARC	cis	rs1865760	0.929	rs9467646	chr6:25957408	A/G	cg10373733	chr6:25993375	NA	0.44	5.35	0.33	2.09e-7	Height;
SARC	cis	rs79349575	0.749	rs8182364	chr17:47018025	A/G	cg07967210	chr17:47022446	SNF8	0.38	4.77	0.3	3.2e-6	Type 2 diabetes;
SARC	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg07636037	chr3:49044803	WDR6	1.0	17.66	0.76	6.92e-45	Parkinson's disease;
SARC	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg24531977	chr5:56204891	C5orf35	-0.54	-5.45	-0.34	1.26e-7	Initial pursuit acceleration;
SARC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg06873352	chr17:61820015	STRADA	0.53	6.88	0.41	5.32e-11	Prudent dietary pattern;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg12037538	chr1:25664880	TMEM50A	0.52	6.48	0.39	5.34e-10	Breast cancer;
SARC	cis	rs6089584	0.627	rs13045575	chr20:60565596	G/A	cg13770153	chr20:60521292	NA	-0.45	-6.59	-0.4	2.93e-10	Body mass index;
SARC	cis	rs78487399	0.808	rs6544668	chr2:43732488	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-4.94	-0.31	1.52e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg14298792	chr15:30685198	CHRFAM7A	0.52	5.68	0.35	4.02e-8	Huntington's disease progression;
SARC	cis	rs1966248	0.656	rs11154745	chr6:134123832	G/A	cg25632230	chr6:134101081	NA	-0.52	-6.99	-0.42	2.83e-11	Coronary artery disease;
SARC	cis	rs1008375	0.898	rs7670500	chr4:17586957	A/G	cg16339924	chr4:17578868	LAP3	0.69	9.17	0.51	2.59e-17	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg14541582	chr5:601475	NA	-0.39	-4.85	-0.3	2.3e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.44	-5.28	-0.33	2.96e-7	Renal function-related traits (BUN);
SARC	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg18404041	chr3:52824283	ITIH1	0.39	5.78	0.35	2.36e-8	Bipolar disorder;
SARC	cis	rs3099143	1.000	rs1398241	chr15:77153386	C/T	cg21673338	chr15:77095150	SCAPER	-0.6	-5.02	-0.31	1.01e-6	Recalcitrant atopic dermatitis;
SARC	cis	rs9527	0.615	rs11191489	chr10:104740568	C/A	cg04362960	chr10:104952993	NT5C2	0.42	4.93	0.31	1.6e-6	Arsenic metabolism;
SARC	cis	rs17376456	0.504	rs6898507	chr5:93082343	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.56	5.82	0.36	1.96e-8	Diabetic retinopathy;
SARC	cis	rs2032447	0.530	rs9356996	chr6:26008487	C/A	cg12310025	chr6:25882481	NA	-0.38	-5.31	-0.33	2.58e-7	Intelligence (multi-trait analysis);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg14655858	chr8:37978472	ASH2L	0.55	7.66	0.45	5e-13	Thyroid stimulating hormone;
SARC	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg11764359	chr7:65958608	NA	0.65	7.6	0.45	7.08e-13	Aortic root size;
SARC	cis	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg22857025	chr5:266934	NA	-1.06	-11.62	-0.61	6.2e-25	Breast cancer;
SARC	cis	rs11645898	0.935	rs72787078	chr16:72158493	C/T	cg14768367	chr16:72042858	DHODH	-0.69	-6.2	-0.38	2.5e-9	Blood protein levels;
SARC	cis	rs12973672	1.000	rs10405246	chr19:35768949	A/G	cg12095397	chr19:35769544	USF2	0.38	4.79	0.3	2.9e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs963731	0.649	rs2060989	chr2:39293530	G/A	cg04010122	chr2:39346883	SOS1	-0.74	-4.87	-0.3	2.03e-6	Corticobasal degeneration;
SARC	cis	rs6977660	0.507	rs72591448	chr7:19775298	C/T	cg05791153	chr7:19748676	TWISTNB	0.89	7.44	0.44	1.87e-12	Thyroid stimulating hormone;
SARC	cis	rs918629	0.679	rs56002885	chr5:95269602	A/G	cg16656078	chr5:95278638	ELL2	-0.73	-8.04	-0.47	4.44e-14	IgG glycosylation;
SARC	cis	rs16973500	0.808	rs112452788	chr16:71911198	C/T	cg09427745	chr16:71932006	KIAA0174	-0.55	-5.33	-0.33	2.27e-7	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs7940866	0.903	rs2324316	chr11:130872353	G/T	cg12179176	chr11:130786555	SNX19	0.62	8.42	0.48	3.94e-15	Schizophrenia;
SARC	cis	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg08045932	chr20:61659980	NA	0.49	6.67	0.4	1.84e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg06420487	chr17:61919686	SMARCD2	0.48	5.47	0.34	1.16e-7	Height;
SARC	cis	rs523522	0.962	rs4767902	chr12:120910004	C/T	cg27279351	chr12:120934652	DYNLL1	0.7	8.44	0.48	3.44e-15	High light scatter reticulocyte count;
SARC	cis	rs9815354	0.812	rs58442057	chr3:41827209	G/A	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg16565063	chr17:77770460	CBX8	-0.68	-7.14	-0.42	1.17e-11	Lung cancer in ever smokers;
SARC	cis	rs3126085	0.544	rs3126074	chr1:152279841	G/C	cg03465714	chr1:152285911	FLG	0.48	5.57	0.34	6.86e-8	Atopic dermatitis;
SARC	cis	rs2242116	0.796	rs2290546	chr3:46965197	C/G	cg27129171	chr3:47204927	SETD2	0.62	8.19	0.47	1.77e-14	Birth weight;
SARC	cis	rs2933343	0.700	rs1680788	chr3:128625318	C/T	cg25356066	chr3:128598488	ACAD9	0.69	9.2	0.52	2.15e-17	IgG glycosylation;
SARC	cis	rs16976116	0.901	rs28630909	chr15:55500102	G/A	cg11288833	chr15:55489084	RSL24D1	0.63	6.13	0.37	3.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2635047	0.967	rs2684843	chr18:44726260	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.52	6.92	0.41	4.27e-11	Educational attainment;
SARC	cis	rs6484504	0.576	rs2616792	chr11:31324298	T/G	cg02090638	chr11:31391270	DNAJC24;DCDC1	0.41	5.08	0.32	7.71e-7	Red blood cell count;
SARC	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg18404041	chr3:52824283	ITIH1	-0.43	-6.47	-0.39	5.81e-10	Bipolar disorder;
SARC	cis	rs6429082	0.871	rs6675944	chr1:235572669	C/T	cg26050004	chr1:235667680	B3GALNT2	0.42	5.41	0.33	1.56e-7	Adiposity;
SARC	trans	rs1814175	0.676	rs1851859	chr11:49860405	A/T	cg03929089	chr4:120376271	NA	-0.83	-12.21	-0.62	7.87e-27	Height;
SARC	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg20607798	chr8:58055168	NA	0.65	5.61	0.35	5.68e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2228479	0.850	rs117880578	chr16:89910230	C/G	cg06558623	chr16:89946397	TCF25	0.93	6.61	0.4	2.59e-10	Skin colour saturation;
SARC	cis	rs4780401	0.728	rs6498239	chr16:11780774	T/C	cg01061890	chr16:11836724	TXNDC11	-0.5	-6.53	-0.39	4.05e-10	Rheumatoid arthritis;
SARC	cis	rs6582630	0.502	rs2204008	chr12:38439203	C/T	cg13010199	chr12:38710504	ALG10B	0.74	9.38	0.52	6.11e-18	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9911578	0.842	rs12450766	chr17:56832965	G/C	cg12560992	chr17:57184187	TRIM37	-0.84	-10.46	-0.57	2.96e-21	Intelligence (multi-trait analysis);
SARC	cis	rs8180040	0.932	rs12490058	chr3:47529063	T/C	cg27129171	chr3:47204927	SETD2	0.67	9.29	0.52	1.1e-17	Colorectal cancer;
SARC	cis	rs9788682	0.624	rs518425	chr15:78883813	A/G	cg24631222	chr15:78858424	CHRNA5	0.63	8.49	0.49	2.46e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-6.38	-0.39	9.39e-10	Personality dimensions;
SARC	cis	rs6120849	0.707	rs6120798	chr20:33610822	T/G	cg06115741	chr20:33292138	TP53INP2	0.55	5.31	0.33	2.58e-7	Protein C levels;
SARC	cis	rs7246657	0.943	rs7252325	chr19:37930645	A/G	cg23950597	chr19:37808831	NA	-0.57	-5.78	-0.35	2.37e-8	Coronary artery calcification;
SARC	cis	rs763121	0.853	rs5757200	chr22:39043491	T/G	cg06022373	chr22:39101656	GTPBP1	0.9	11.56	0.6	9.96e-25	Menopause (age at onset);
SARC	cis	rs6674176	0.660	rs11210936	chr1:44391438	A/T	cg13606994	chr1:44402422	ARTN	-0.34	-5.71	-0.35	3.44e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs9811216	1.000	rs2141595	chr3:169503432	C/T	cg14222479	chr3:169487675	ARPM1	0.4	5.01	0.31	1.07e-6	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs9486719	1.000	rs3798289	chr6:97023632	T/C	cg06623918	chr6:96969491	KIAA0776	-0.79	-8.83	-0.5	2.51e-16	Migraine;Coronary artery disease;
SARC	cis	rs17376456	0.825	rs74825443	chr5:93254973	T/C	cg25358565	chr5:93447407	FAM172A	1.29	14.23	0.68	1.68e-33	Diabetic retinopathy;
SARC	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg07636037	chr3:49044803	WDR6	0.91	15.5	0.71	1.03e-37	Menarche (age at onset);
SARC	cis	rs11608355	0.618	rs4486687	chr12:109790741	T/A	cg19025524	chr12:109796872	NA	-0.49	-7.06	-0.42	1.93e-11	Neuroticism;
SARC	cis	rs72945132	0.882	rs7121012	chr11:70214421	A/T	cg05964544	chr11:70165517	PPFIA1	-0.58	-5.86	-0.36	1.6e-8	Coronary artery disease;
SARC	cis	rs2213920	1.000	rs9299227	chr9:118263508	A/G	cg13918206	chr9:118159781	DEC1	0.65	5.33	0.33	2.33e-7	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs896854	0.548	rs574183	chr8:95973816	A/G	cg09323728	chr8:95962352	TP53INP1	0.31	4.86	0.3	2.13e-6	Type 2 diabetes;
SARC	cis	rs838147	0.844	rs12611203	chr19:49248295	G/A	cg13540341	chr19:49222985	MAMSTR	0.28	4.73	0.3	3.83e-6	Dietary macronutrient intake;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg01473472	chr12:42680699	NA	0.55	6.37	0.39	9.92e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs865483	0.965	rs853199	chr17:35850225	T/C	cg06561646	chr17:35873369	DUSP14	-0.48	-6.33	-0.38	1.21e-9	Monocyte count;
SARC	cis	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg25427524	chr10:38739819	LOC399744	-0.52	-8.25	-0.48	1.17e-14	Extrinsic epigenetic age acceleration;
SARC	cis	rs7666738	0.753	rs17483788	chr4:98985623	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6504663	0.558	rs2412325	chr17:48546232	G/C	cg03611598	chr17:48586076	MYCBPAP	0.47	5.39	0.33	1.73e-7	Visceral fat;
SARC	cis	rs9303401	0.659	rs35797125	chr17:56736547	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.09	12.1	0.62	1.73e-26	Cognitive test performance;
SARC	cis	rs8028182	0.636	rs28783769	chr15:75849009	C/A	cg20655648	chr15:75932815	IMP3	0.64	7.35	0.43	3.33e-12	Sudden cardiac arrest;
SARC	trans	rs61931739	0.927	rs12315970	chr12:34038535	A/G	cg26384229	chr12:38710491	ALG10B	-0.56	-7.11	-0.42	1.44e-11	Morning vs. evening chronotype;
SARC	trans	rs3857536	0.673	rs7759888	chr6:66891922	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.6	-7.14	-0.42	1.19e-11	Blood trace element (Cu levels);
SARC	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg11890956	chr21:40555474	PSMG1	1.18	19.31	0.78	2.97e-50	Cognitive function;
SARC	cis	rs7084402	0.967	rs1621227	chr10:60327734	C/G	cg07615347	chr10:60278583	BICC1	0.58	8.58	0.49	1.36e-15	Refractive error;
SARC	cis	rs79839061	0.610	rs3775122	chr4:893287	A/G	cg07828340	chr4:882639	GAK	-0.8	-6.37	-0.38	1.02e-9	Intelligence (multi-trait analysis);
SARC	cis	rs912057	0.671	rs1294420	chr6:6742752	C/T	cg06612196	chr6:6737390	NA	0.62	9.67	0.53	8.42e-19	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs96067	0.805	rs2231317	chr1:36603290	C/T	cg24686825	chr1:36642396	MAP7D1	-0.43	-4.83	-0.3	2.43e-6	Corneal structure;
SARC	cis	rs67460515	0.852	rs2404341	chr3:161092405	T/C	cg04691961	chr3:161091175	C3orf57	-0.51	-6.4	-0.39	8.68e-10	Parkinson's disease;
SARC	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg16049864	chr8:95962084	TP53INP1	-0.45	-7.23	-0.43	6.88e-12	Type 2 diabetes;
SARC	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg11987759	chr7:65425863	GUSB	-0.47	-6.27	-0.38	1.7e-9	Aortic root size;
SARC	cis	rs2242116	0.796	rs9852082	chr3:46972377	T/C	cg27129171	chr3:47204927	SETD2	0.64	8.36	0.48	5.87e-15	Birth weight;
SARC	cis	rs9790314	0.936	rs7629987	chr3:161002023	A/C	cg04691961	chr3:161091175	C3orf57	-0.79	-11.72	-0.61	3.09e-25	Morning vs. evening chronotype;
SARC	cis	rs57221529	0.608	rs11749927	chr5:668842	C/T	cg07777115	chr5:623756	CEP72	-0.53	-4.96	-0.31	1.33e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs2204008	0.619	rs8189576	chr12:38307275	G/A	cg14851346	chr12:38532713	NA	-0.45	-5.3	-0.33	2.66e-7	Bladder cancer;
SARC	cis	rs4664308	0.967	rs34248629	chr2:160902497	C/T	cg03641300	chr2:160917029	PLA2R1	-0.65	-8.52	-0.49	1.95e-15	Idiopathic membranous nephropathy;
SARC	cis	rs6582630	0.622	rs11831595	chr12:38511489	C/A	cg26384229	chr12:38710491	ALG10B	-0.56	-7.11	-0.42	1.39e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs79149102	0.579	rs58294763	chr15:75299768	G/A	cg09165964	chr15:75287851	SCAMP5	-0.99	-8.93	-0.51	1.27e-16	Lung cancer;
SARC	cis	rs9314323	0.767	rs1865305	chr8:26233325	G/A	cg11498726	chr8:26250323	BNIP3L	-0.6	-7.67	-0.45	4.64e-13	Red cell distribution width;
SARC	cis	rs2658782	0.704	rs2658766	chr11:93232229	G/A	cg15737290	chr11:93063684	CCDC67	0.74	8.68	0.49	7.18e-16	Pulmonary function decline;
SARC	cis	rs9399135	0.967	rs11755229	chr6:135369913	A/G	cg24558204	chr6:135376177	HBS1L	0.46	6.18	0.38	2.88e-9	Red blood cell count;
SARC	cis	rs6866344	0.697	rs6873150	chr5:178125704	G/A	cg03877680	chr5:178157825	ZNF354A	1.03	12.65	0.64	2.88e-28	Neutrophil percentage of white cells;
SARC	cis	rs2073300	0.609	rs1936011	chr20:23341912	G/C	cg12062639	chr20:23401060	NAPB	1.01	6.97	0.42	3.31e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs9467773	0.869	rs742090	chr6:26415637	A/C	cg11502198	chr6:26597334	ABT1	-0.48	-5.9	-0.36	1.26e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7566780	0.596	rs1991584	chr2:16647050	T/C	cg09580478	chr2:16689509	NA	0.48	5.67	0.35	4.26e-8	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs637571	0.522	rs528736	chr11:65705108	A/G	cg26695010	chr11:65641043	EFEMP2	-0.51	-6.42	-0.39	7.72e-10	Eosinophil percentage of white cells;
SARC	cis	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.75	-0.45	2.87e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg18876405	chr7:65276391	NA	0.69	9.05	0.51	5.93e-17	Calcium levels;
SARC	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg00933542	chr6:150070202	PCMT1	0.3	5.1	0.32	7.09e-7	Lung cancer;
SARC	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg18252515	chr7:66147081	NA	-1.3	-11.5	-0.6	1.59e-24	Diabetic kidney disease;
SARC	cis	rs9303280	0.719	rs56750287	chr17:38062944	A/C	cg20243544	chr17:37824526	PNMT	0.44	5.77	0.35	2.56e-8	Self-reported allergy;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg19078334	chr9:113019254	TXN	0.52	6.55	0.39	3.57e-10	Breast cancer;
SARC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg20007245	chr22:24372913	LOC391322	-0.74	-9.97	-0.55	1.01e-19	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs72781680	0.821	rs2176265	chr2:24158638	C/G	cg08917208	chr2:24149416	ATAD2B	0.57	5.85	0.36	1.65e-8	Lymphocyte counts;
SARC	cis	rs3859192	0.599	rs2227319	chr17:38170845	G/A	cg17467752	chr17:38218738	THRA	-0.38	-4.87	-0.3	2.11e-6	White blood cell count;
SARC	cis	rs11235843	1.000	rs4944852	chr11:73372107	A/C	cg18195628	chr11:73498948	MRPL48	0.67	4.86	0.3	2.13e-6	Hand grip strength;
SARC	cis	rs2836633	0.929	rs62217518	chr21:40033189	T/G	cg12884169	chr21:40033163	ERG	0.48	8.79	0.5	3.33e-16	Coronary artery disease;
SARC	cis	rs6570726	0.526	rs7755237	chr6:145731852	T/C	cg05347473	chr6:146136440	FBXO30	-0.42	-5.35	-0.33	2.1e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs67311347	0.822	rs9826847	chr3:40345312	A/T	cg09455208	chr3:40491958	NA	0.36	5.76	0.35	2.67e-8	Renal cell carcinoma;
SARC	cis	rs910316	0.712	rs175015	chr14:75457075	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.5	-6.48	-0.39	5.51e-10	Height;
SARC	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg22875332	chr1:76189707	ACADM	0.47	6.44	0.39	6.83e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9914544	0.545	rs35911764	chr17:18782582	C/T	cg25390199	chr17:18761479	PRPSAP2	0.46	6.05	0.37	5.66e-9	Educational attainment (years of education);
SARC	trans	rs2727020	0.930	rs1164686	chr11:49291822	C/T	cg15704280	chr7:45808275	SEPT13	0.78	10.59	0.57	1.19e-21	Coronary artery disease;
SARC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg09373136	chr17:61933544	TCAM1	-0.45	-6.23	-0.38	2.18e-9	Prudent dietary pattern;
SARC	cis	rs11098499	0.954	rs9993199	chr4:120392873	A/G	cg09307838	chr4:120376055	NA	-0.89	-12.34	-0.63	2.93e-27	Corneal astigmatism;
SARC	cis	rs4742903	0.935	rs3818626	chr9:106856633	C/T	cg21169611	chr9:106856078	SMC2	0.39	4.73	0.3	3.94e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg16325326	chr1:53192061	ZYG11B	0.65	8.33	0.48	7.06e-15	Monocyte count;
SARC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.28	0.8	2.29e-53	Prudent dietary pattern;
SARC	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg13770153	chr20:60521292	NA	-0.72	-10.57	-0.57	1.38e-21	Obesity-related traits;
SARC	cis	rs9815354	0.680	rs73071354	chr3:41829186	C/A	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg05084668	chr3:125655381	ALG1L	0.49	5.22	0.32	3.98e-7	Blood pressure (smoking interaction);
SARC	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9486719	0.857	rs4486027	chr6:96911886	T/C	cg06623918	chr6:96969491	KIAA0776	-0.72	-8.22	-0.47	1.44e-14	Migraine;Coronary artery disease;
SARC	cis	rs6141769	0.542	rs6057628	chr20:31308684	C/T	cg17884169	chr20:31446444	EFCAB8	-0.43	-4.76	-0.3	3.37e-6	Subjective well-being;
SARC	cis	rs11227306	0.902	rs625652	chr11:65641931	T/A	cg00576331	chr11:65640516	EFEMP2	0.5	6.43	0.39	7.23e-10	DNA methylation (variation);
SARC	cis	rs763121	0.853	rs5750633	chr22:38993467	A/G	cg06022373	chr22:39101656	GTPBP1	0.9	12.24	0.63	6.39e-27	Menopause (age at onset);
SARC	cis	rs79976124	0.842	rs1548154	chr6:66624910	G/A	cg07460842	chr6:66804631	NA	0.64	7.07	0.42	1.84e-11	Type 2 diabetes;
SARC	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.02	0.37	6.61e-9	Height;
SARC	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg21724239	chr8:58056113	NA	0.61	5.93	0.36	1.1e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs80130819	0.748	rs7953726	chr12:48611757	A/G	cg24011408	chr12:48396354	COL2A1	0.53	5.97	0.36	8.96e-9	Prostate cancer;
SARC	cis	rs854765	0.547	rs28537385	chr17:17902135	G/A	cg05444541	chr17:17804740	TOM1L2	-0.3	-4.83	-0.3	2.51e-6	Total body bone mineral density;
SARC	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg05368731	chr17:41323189	NBR1	0.78	9.34	0.52	7.99e-18	Menopause (age at onset);
SARC	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg18876405	chr7:65276391	NA	-0.7	-8.47	-0.49	2.81e-15	Aortic root size;
SARC	cis	rs9916302	0.706	rs8078599	chr17:37518660	C/T	cg00129232	chr17:37814104	STARD3	0.52	5.41	0.33	1.54e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs861020	0.606	rs657844	chr1:210006873	T/G	cg05527609	chr1:210001259	C1orf107	0.78	10.12	0.55	3.37e-20	Orofacial clefts;
SARC	cis	rs1008375	0.900	rs6812675	chr4:17597549	A/G	cg27347728	chr4:17578864	LAP3	0.47	5.62	0.35	5.52e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2562456	1.000	rs2562456	chr19:21666210	A/G	cg00806126	chr19:22604979	ZNF98	-0.48	-5.24	-0.32	3.51e-7	Pain;
SARC	cis	rs71636778	0.596	rs2095637	chr1:27232845	A/G	cg12203394	chr1:27248618	NUDC	0.55	4.8	0.3	2.87e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs854765	0.583	rs7214002	chr17:17852104	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.69	10.04	0.55	6.06e-20	Total body bone mineral density;
SARC	cis	rs55665837	0.524	rs2882128	chr11:14414634	A/C	cg19336497	chr11:14380999	RRAS2	-0.33	-5.69	-0.35	3.82e-8	Vitamin D levels;
SARC	cis	rs11785400	0.793	rs10956992	chr8:143736235	A/C	cg10596483	chr8:143751796	JRK	0.58	7.68	0.45	4.43e-13	Schizophrenia;
SARC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.33	5.07	0.32	8.17e-7	Bipolar disorder;
SARC	cis	rs10504229	0.679	rs6474100	chr8:58031161	G/A	cg08280861	chr8:58055591	NA	0.54	4.97	0.31	1.28e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg20965017	chr5:231967	SDHA	-0.54	-5.21	-0.32	4.22e-7	Breast cancer;
SARC	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg01475735	chr3:40494733	NA	0.49	5.68	0.35	3.97e-8	Renal cell carcinoma;
SARC	cis	rs8180040	0.764	rs13084117	chr3:47183239	C/A	cg27129171	chr3:47204927	SETD2	0.67	9.51	0.53	2.43e-18	Colorectal cancer;
SARC	cis	rs7762018	0.607	rs79355059	chr6:170062157	T/C	cg13015042	chr6:170102002	WDR27;C6orf120	0.7	4.9	0.31	1.83e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs6831352	0.918	rs13129488	chr4:100053025	G/T	cg12011299	chr4:100065546	ADH4	-0.34	-5.74	-0.35	2.95e-8	Alcohol dependence;
SARC	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg11168104	chr5:1857477	NA	-0.36	-5.1	-0.32	7.12e-7	Cardiovascular disease risk factors;
SARC	cis	rs1920116	0.778	rs12489230	chr3:169558821	C/T	cg14222479	chr3:169487675	ARPM1	0.41	4.75	0.3	3.56e-6	Glioma (high-grade);
SARC	cis	rs1153858	1.000	rs12591058	chr15:45640172	T/C	cg14582100	chr15:45693742	SPATA5L1	0.37	5.06	0.31	8.45e-7	Homoarginine levels;
SARC	cis	rs965469	1.000	rs6037583	chr20:3360632	G/A	cg25506879	chr20:3388711	C20orf194	-0.48	-4.87	-0.3	2.04e-6	IFN-related cytopenia;
SARC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg25703541	chr22:24373054	LOC391322	-0.77	-9.65	-0.53	9.67e-19	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9660992	0.762	rs1172130	chr1:205244953	G/A	cg21643547	chr1:205240462	TMCC2	-0.57	-7.29	-0.43	4.73e-12	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs10088262	0.629	rs7015861	chr8:124795613	C/T	cg20713898	chr8:124780851	FAM91A1	-0.62	-7.05	-0.42	2.04e-11	Pancreatic cancer;
SARC	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg18252515	chr7:66147081	NA	0.51	5.5	0.34	9.8e-8	Aortic root size;
SARC	cis	rs2204008	0.728	rs11495375	chr12:38282631	G/A	cg26384229	chr12:38710491	ALG10B	0.91	13.64	0.67	1.61e-31	Bladder cancer;
SARC	cis	rs1267303	0.675	rs2476164	chr1:46985274	T/C	cg25110126	chr1:46999211	NA	-0.69	-7.8	-0.45	2.08e-13	Monobrow;
SARC	cis	rs1113500	0.897	rs55980437	chr1:108639498	G/A	cg06207961	chr1:108661230	NA	0.44	5.92	0.36	1.13e-8	Growth-regulated protein alpha levels;
SARC	cis	rs9420	0.784	rs12798206	chr11:57668479	T/G	cg19752551	chr11:57585705	CTNND1	-0.47	-5.47	-0.34	1.16e-7	Schizophrenia;
SARC	trans	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.73	10.55	0.57	1.63e-21	Intelligence (multi-trait analysis);
SARC	cis	rs7635838	0.785	rs2606738	chr3:11396562	T/C	cg00170343	chr3:11313890	ATG7	0.57	7.62	0.45	6.48e-13	HDL cholesterol;
SARC	cis	rs8014204	0.533	rs12434646	chr14:75178693	C/T	cg06637938	chr14:75390232	RPS6KL1	0.61	9.03	0.51	6.76e-17	Caffeine consumption;
SARC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg06873352	chr17:61820015	STRADA	0.53	6.89	0.41	5.29e-11	Prudent dietary pattern;
SARC	cis	rs2153535	0.580	rs9379216	chr6:8481235	G/A	cg07606381	chr6:8435919	SLC35B3	0.78	11.13	0.59	2.44e-23	Motion sickness;
SARC	cis	rs11613048	0.897	rs1485413	chr12:30331700	C/T	cg12718339	chr12:29936407	TMTC1	-0.35	-4.78	-0.3	3.07e-6	Major depressive disorder;
SARC	cis	rs17608059	0.524	rs9897978	chr17:13900256	G/T	cg11395062	chr17:14139857	CDRT15	-0.48	-6.21	-0.38	2.44e-9	Temperament;
SARC	cis	rs2115630	0.764	rs11073716	chr15:85335774	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.42	-4.77	-0.3	3.3e-6	P wave terminal force;
SARC	cis	rs2985684	1.000	rs8014170	chr14:50071694	C/G	cg04989706	chr14:50066350	PPIL5	-0.54	-5.91	-0.36	1.19e-8	Carotid intima media thickness;
SARC	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg22683308	chr4:1340831	KIAA1530	-0.43	-4.81	-0.3	2.71e-6	Obesity-related traits;
SARC	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-13.51	-0.66	4.13e-31	Chronic sinus infection;
SARC	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg24531977	chr5:56204891	C5orf35	-0.54	-5.51	-0.34	9.41e-8	Initial pursuit acceleration;
SARC	cis	rs1865760	0.865	rs1436306	chr6:25948421	A/G	cg16482183	chr6:26056742	HIST1H1C	0.51	6.47	0.39	5.56e-10	Height;
SARC	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg11764359	chr7:65958608	NA	-0.67	-7.97	-0.46	7.26e-14	Aortic root size;
SARC	cis	rs7808935	0.789	rs2040668	chr7:27958773	G/T	cg05786569	chr7:27702416	HIBADH	-0.59	-6.47	-0.39	5.58e-10	Prostate cancer;
SARC	cis	rs1008375	0.966	rs3775927	chr4:17599894	G/T	cg27347728	chr4:17578864	LAP3	0.45	5.4	0.33	1.62e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.4	-4.83	-0.3	2.44e-6	Lymphocyte counts;
SARC	cis	rs2576037	0.899	rs7233515	chr18:44585955	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.56	-7.1	-0.42	1.5e-11	Personality dimensions;
SARC	cis	rs4713118	0.868	rs2893928	chr6:27738430	C/A	cg17221315	chr6:27791827	HIST1H4J	0.55	5.58	0.34	6.79e-8	Parkinson's disease;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg20591167	chr15:99602178	NA	0.53	6.83	0.41	7.2e-11	Lung adenocarcinoma;
SARC	cis	rs2204008	0.687	rs11181339	chr12:38322271	G/T	cg13010199	chr12:38710504	ALG10B	0.71	9.49	0.53	2.89e-18	Bladder cancer;
SARC	cis	rs7772486	0.806	rs2253648	chr6:146199296	G/A	cg23711669	chr6:146136114	FBXO30	0.81	13.08	0.65	1.1e-29	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs17739167	0.569	rs11638621	chr15:42228226	C/T	cg20935245	chr15:42234343	EHD4	0.48	6.36	0.38	1.03e-9	Monocyte count;
SARC	cis	rs9840812	0.592	rs900048	chr3:136218930	C/T	cg15507776	chr3:136538369	TMEM22	0.46	5.1	0.32	7.09e-7	Fibrinogen levels;
SARC	cis	rs6431644	0.640	rs2286430	chr2:234761225	A/G	cg23688111	chr2:234825859	TRPM8	-0.35	-5.21	-0.32	4.24e-7	Left atrial antero-posterior diameter;
SARC	cis	rs2075371	0.644	rs1643041	chr7:134012211	C/T	cg00033643	chr7:134001901	SLC35B4	0.5	6.15	0.37	3.38e-9	Mean platelet volume;
SARC	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg15052019	chr19:19431593	KIAA0892;SF4	0.39	4.77	0.3	3.28e-6	Tonsillectomy;
SARC	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	trans	rs1814175	0.935	rs11040438	chr11:49622521	G/A	cg15704280	chr7:45808275	SEPT13	-0.91	-16.05	-0.72	1.56e-39	Height;
SARC	cis	rs818427	0.858	rs698405	chr5:112243527	C/T	cg07820702	chr5:112228657	REEP5	-0.49	-5.39	-0.33	1.69e-7	Total body bone mineral density;
SARC	cis	rs35955747	0.902	rs5997938	chr22:31676992	A/G	cg13145458	chr22:31556086	RNF185	0.41	5.1	0.32	6.93e-7	Neutrophil count;Sum basophil neutrophil counts;
SARC	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	trans	rs61931739	0.500	rs11053261	chr12:34530810	C/T	cg26384229	chr12:38710491	ALG10B	0.91	13.78	0.67	5.4e-32	Morning vs. evening chronotype;
SARC	cis	rs7553864	1.000	rs4551571	chr1:87614244	C/G	cg18153957	chr1:87613403	LOC339524	-0.51	-6.08	-0.37	4.84e-9	Smoking behavior;
SARC	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg22974920	chr21:40686053	BRWD1	-0.44	-4.83	-0.3	2.46e-6	Cognitive function;
SARC	cis	rs7223966	1.000	rs9747164	chr17:61864787	T/C	cg26338869	chr17:61819248	STRADA	0.49	5.06	0.31	8.38e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2933343	0.729	rs813945	chr3:128660937	A/G	cg24203234	chr3:128598194	ACAD9	0.62	7.66	0.45	5.01e-13	IgG glycosylation;
SARC	cis	rs3008870	1.000	rs3008870	chr1:67418027	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.92	11.37	0.6	3.93e-24	Lymphocyte percentage of white cells;
SARC	cis	rs769267	0.864	rs7245983	chr19:19657632	A/C	cg03709012	chr19:19516395	GATAD2A	0.98	16.12	0.73	9.07e-40	Tonsillectomy;
SARC	cis	rs11718455	0.960	rs17076255	chr3:44002093	C/T	cg21419209	chr3:44054225	NA	-0.42	-5.04	-0.31	9.45e-7	Coronary artery disease;
SARC	cis	rs7647973	0.626	rs4855833	chr3:49657441	A/G	cg13072238	chr3:49761600	GMPPB	-0.62	-6.18	-0.38	2.9e-9	Menarche (age at onset);
SARC	cis	rs11235843	0.565	rs1723840	chr11:73473885	T/A	cg18195628	chr11:73498948	MRPL48	0.58	5.56	0.34	7.19e-8	Hand grip strength;
SARC	cis	rs2295359	1.000	rs4655524	chr1:67629469	G/A	cg12940439	chr1:67600707	NA	0.43	6.6	0.4	2.73e-10	Psoriasis;
SARC	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg02725872	chr8:58115012	NA	-0.37	-6.55	-0.39	3.71e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs11690935	0.885	rs6752812	chr2:172851502	C/A	cg13550731	chr2:172543902	DYNC1I2	-0.95	-14.21	-0.68	1.97e-33	Schizophrenia;
SARC	cis	rs2295359	1.000	rs10889661	chr1:67625309	T/A	cg08029281	chr1:67600428	NA	0.36	5.02	0.31	1.01e-6	Psoriasis;
SARC	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg19671926	chr4:122722719	EXOSC9	-0.56	-6.22	-0.38	2.22e-9	Type 2 diabetes;
SARC	cis	rs34486957	0.625	rs17255933	chr14:60042939	A/T	cg03950873	chr14:60045040	C14orf38	0.28	4.8	0.3	2.87e-6	Initial pursuit acceleration in psychotic disorders;
SARC	cis	rs7945705	0.692	rs2742470	chr11:9004002	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.5	-7.27	-0.43	5.53e-12	Hemoglobin concentration;
SARC	cis	rs898097	0.625	rs7406464	chr17:80891460	A/G	cg15664640	chr17:80829946	TBCD	-0.36	-5.69	-0.35	3.73e-8	Breast cancer;
SARC	trans	rs17221829	0.733	rs11018668	chr11:89356178	C/T	cg08339719	chr10:103347733	POLL;RP11-529I10.4	-0.47	-6.32	-0.38	1.34e-9	Anxiety in major depressive disorder;
SARC	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg18876405	chr7:65276391	NA	0.49	6.04	0.37	6e-9	Aortic root size;
SARC	cis	rs1008375	0.966	rs4515155	chr4:17696477	G/T	cg16339924	chr4:17578868	LAP3	0.52	6.64	0.4	2.24e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs10506458	0.834	rs55966529	chr12:63384114	A/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.77	-6.85	-0.41	6.36e-11	Hemostatic factors and hematological phenotypes;
SARC	trans	rs7937682	0.889	rs559482	chr11:111497902	G/A	cg18187862	chr3:45730750	SACM1L	0.57	7.11	0.42	1.45e-11	Primary sclerosing cholangitis;
SARC	cis	rs9457247	0.637	rs9459846	chr6:167441023	T/G	cg07741184	chr6:167504864	NA	0.37	7.22	0.43	7.5e-12	Crohn's disease;
SARC	cis	rs6058796	0.892	rs6141782	chr20:31263507	A/G	cg13636640	chr20:31349939	DNMT3B	0.53	4.87	0.3	2.06e-6	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs9858542	0.953	rs35115732	chr3:49475155	T/C	cg07274523	chr3:49395745	GPX1	0.53	6.11	0.37	4.1e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs3008870	0.583	rs3008892	chr1:67373558	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.72	7.79	0.45	2.19e-13	Lymphocyte percentage of white cells;
SARC	cis	rs1023500	0.505	rs134889	chr22:42674350	A/T	cg04733989	chr22:42467013	NAGA	0.52	6.59	0.4	2.83e-10	Schizophrenia;
SARC	cis	rs7264396	0.570	rs6060717	chr20:34544647	T/C	cg12579300	chr20:34535607	PHF20	-0.41	-4.8	-0.3	2.84e-6	Total cholesterol levels;
SARC	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg17691542	chr6:26056736	HIST1H1C	0.38	4.75	0.3	3.63e-6	Blood metabolite levels;
SARC	cis	rs35110281	0.667	rs4819288	chr21:45120173	C/G	cg01579765	chr21:45077557	HSF2BP	-0.34	-5.32	-0.33	2.38e-7	Mean corpuscular volume;
SARC	cis	rs3008870	1.000	rs912797	chr1:67413478	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.92	11.4	0.6	3.22e-24	Lymphocyte percentage of white cells;
SARC	cis	rs4660306	0.961	rs1337902	chr1:45952066	G/A	cg24296786	chr1:45957014	TESK2	0.58	6.72	0.4	1.35e-10	Homocysteine levels;
SARC	cis	rs7592578	0.766	rs62182865	chr2:191434180	T/C	cg27211696	chr2:191398769	TMEM194B	-0.56	-5.78	-0.35	2.44e-8	Diastolic blood pressure;
SARC	cis	rs8141529	0.702	rs469991	chr22:29307859	G/C	cg02153584	chr22:29168773	CCDC117	-0.79	-11.51	-0.6	1.4e-24	Lymphocyte counts;
SARC	cis	rs12908161	0.960	rs62019463	chr15:85288087	G/A	cg17507749	chr15:85114479	UBE2QP1	0.55	6.22	0.38	2.33e-9	Schizophrenia;
SARC	cis	rs79349575	0.783	rs62078372	chr17:47028989	T/C	cg16584676	chr17:46985605	UBE2Z	0.55	6.58	0.4	3.01e-10	Type 2 diabetes;
SARC	cis	rs36051895	0.695	rs10815147	chr9:5016145	C/T	cg02405213	chr9:5042618	JAK2	-0.51	-5.75	-0.35	2.78e-8	Pediatric autoimmune diseases;
SARC	cis	rs611744	0.967	rs666821	chr8:109204313	T/A	cg21045802	chr8:109455806	TTC35	0.44	5.23	0.32	3.81e-7	Dupuytren's disease;
SARC	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg16606324	chr3:10149918	C3orf24	0.5	5.01	0.31	1.08e-6	Alzheimer's disease;
SARC	trans	rs9388451	0.839	rs11154331	chr6:126111429	A/T	cg05039488	chr6:79577232	IRAK1BP1	-0.59	-7.73	-0.45	3.15e-13	Brugada syndrome;
SARC	cis	rs11098699	0.821	rs11935129	chr4:124207106	T/A	cg09941581	chr4:124220074	SPATA5	0.39	4.73	0.3	3.98e-6	Mosquito bite size;
SARC	cis	rs6988636	0.792	rs62521807	chr8:124163621	T/C	cg23067535	chr8:124195133	FAM83A	-0.68	-4.87	-0.3	2.01e-6	Urinary uromodulin levels;
SARC	cis	rs11098499	0.821	rs10032151	chr4:120391628	C/T	cg09307838	chr4:120376055	NA	0.9	12.45	0.63	1.34e-27	Corneal astigmatism;
SARC	cis	rs1707322	0.963	rs1768815	chr1:46528603	G/A	cg06784218	chr1:46089804	CCDC17	-0.37	-6.4	-0.39	8.26e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6493487	0.546	rs12904155	chr15:51356728	C/T	cg02338191	chr15:51200825	AP4E1	-0.52	-4.86	-0.3	2.18e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	trans	rs6600671	0.899	rs11249432	chr1:121283476	T/A	cg00646200	chr1:148855367	NA	0.52	7.2	0.43	8.11e-12	Hip geometry;
SARC	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg27170947	chr2:26402098	FAM59B	0.39	4.98	0.31	1.22e-6	Gut microbiome composition (summer);
SARC	cis	rs3087591	0.960	rs9896041	chr17:29571326	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.51	-6.31	-0.38	1.4e-9	Hip circumference;
SARC	cis	rs1580019	0.563	rs10486509	chr7:32585443	C/G	cg14728415	chr7:32535168	LSM5;AVL9	-0.47	-5.85	-0.36	1.7e-8	Cognitive ability;
SARC	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	4.86	0.3	2.13e-6	Personality dimensions;
SARC	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7264396	0.563	rs2425132	chr20:34338390	A/G	cg01084648	chr20:34329383	RBM39	0.54	4.8	0.3	2.83e-6	Total cholesterol levels;
SARC	cis	rs9902453	0.933	rs7224199	chr17:28523726	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.49	6.31	0.38	1.41e-9	Coffee consumption (cups per day);
SARC	cis	rs7937682	0.889	rs1789359	chr11:111475995	T/A	cg22437258	chr11:111473054	SIK2	0.76	10.68	0.57	6.13e-22	Primary sclerosing cholangitis;
SARC	cis	rs4711336	0.935	rs3818525	chr6:33660779	A/G	cg15676125	chr6:33679581	C6orf125	0.56	6.88	0.41	5.51e-11	Height;
SARC	cis	rs1448094	0.872	rs12322940	chr12:86406708	G/C	cg02569458	chr12:86230093	RASSF9	0.38	5.66	0.35	4.41e-8	Major depressive disorder;
SARC	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg12463550	chr7:65579703	CRCP	0.67	5.06	0.31	8.43e-7	Diabetic kidney disease;
SARC	cis	rs2797160	0.651	rs9491503	chr6:126031682	G/A	cg05901451	chr6:126070800	HEY2	0.43	5.13	0.32	6.19e-7	Endometrial cancer;
SARC	cis	rs6867032	1.000	rs4975802	chr5:2019750	T/C	cg26168224	chr5:2018326	NA	0.93	15.39	0.71	2.47e-37	Gut microbiome composition (winter);
SARC	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg12311346	chr5:56204834	C5orf35	-0.58	-6.01	-0.37	7.24e-9	Initial pursuit acceleration;
SARC	cis	rs8031584	0.918	rs11639169	chr15:31255438	C/T	cg08109568	chr15:31115862	NA	-0.48	-5.75	-0.35	2.79e-8	Huntington's disease progression;
SARC	cis	rs9790314	0.639	rs6769642	chr3:160763469	C/A	cg03342759	chr3:160939853	NMD3	-0.42	-5.06	-0.31	8.46e-7	Morning vs. evening chronotype;
SARC	cis	rs9527	0.590	rs10883820	chr10:104764661	A/C	cg04362960	chr10:104952993	NT5C2	-0.44	-5.31	-0.33	2.5e-7	Arsenic metabolism;
SARC	trans	rs10085978	0.604	rs11167128	chr8:143225883	A/G	cg16838729	chr4:43901032	NA	0.38	6.32	0.38	1.29e-9	Mosquito bite size;
SARC	cis	rs7666738	0.791	rs2865953	chr4:99040319	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg03709012	chr19:19516395	GATAD2A	1.0	17.09	0.75	5.28e-43	Tonsillectomy;
SARC	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg14784868	chr12:69753453	YEATS4	-0.62	-8.74	-0.5	4.64e-16	Cerebrospinal fluid biomarker levels;
SARC	cis	rs963731	0.522	rs297128	chr2:39298403	C/G	cg04010122	chr2:39346883	SOS1	-0.95	-5.84	-0.36	1.79e-8	Corticobasal degeneration;
SARC	cis	rs1865760	0.532	rs9295687	chr6:26082710	T/C	cg16482183	chr6:26056742	HIST1H1C	0.47	5.91	0.36	1.22e-8	Height;
SARC	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	20.82	0.81	4.4e-55	Chronic sinus infection;
SARC	cis	rs9896933	0.623	rs77166830	chr17:80833525	T/C	cg20578329	chr17:80767326	TBCD	-0.74	-8.28	-0.48	9.55e-15	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
SARC	cis	rs748404	0.697	rs475227	chr15:43546446	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	5.83	0.36	1.83e-8	Lung cancer;
SARC	cis	rs11690935	1.000	rs2138348	chr2:172558172	A/C	cg13550731	chr2:172543902	DYNC1I2	0.98	14.68	0.69	5.5800000000000005e-35	Schizophrenia;
SARC	cis	rs10754283	0.967	rs7513928	chr1:90104834	A/G	cg21401794	chr1:90099060	LRRC8C	0.59	8.13	0.47	2.59e-14	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs10791097	0.694	rs4436551	chr11:130755739	A/G	cg09137382	chr11:130731461	NA	-0.33	-5.14	-0.32	5.92e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs1003719	0.680	rs2835629	chr21:38521660	A/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.27	-0.52	1.32e-17	Eye color traits;
SARC	cis	rs4555082	0.874	rs28625632	chr14:105748849	G/T	cg06808227	chr14:105710500	BRF1	-0.52	-6.54	-0.39	3.77e-10	Mean platelet volume;Platelet distribution width;
SARC	cis	rs7587476	0.531	rs35933323	chr2:215674090	T/G	cg04004882	chr2:215674386	BARD1	-0.59	-6.74	-0.4	1.25e-10	Neuroblastoma;
SARC	cis	rs7592578	0.766	rs12472081	chr2:191398545	G/A	cg25963032	chr2:191064776	C2orf88	-0.49	-5.23	-0.32	3.86e-7	Diastolic blood pressure;
SARC	cis	rs6598955	0.724	rs10902737	chr1:26635716	G/A	cg04990556	chr1:26633338	UBXN11	-0.61	-8.31	-0.48	7.94e-15	Obesity-related traits;
SARC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.33	-5.0	-0.31	1.11e-6	Total body bone mineral density;
SARC	cis	rs910316	0.967	rs1071989	chr14:75564659	G/T	cg06637938	chr14:75390232	RPS6KL1	0.54	7.69	0.45	4.04e-13	Height;
SARC	cis	rs13082711	0.863	rs77135084	chr3:27423549	A/C	cg02860705	chr3:27208620	NA	0.49	6.4	0.39	8.22e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs7766436	0.610	rs13195654	chr6:22601416	C/G	cg13666174	chr6:22585274	NA	-0.53	-7.03	-0.42	2.23e-11	Coronary artery disease;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg05394294	chr10:3160926	PFKP	0.46	6.35	0.38	1.12e-9	Schizophrenia;
SARC	cis	rs4699052	0.928	rs2126473	chr4:104141533	G/C	cg16532752	chr4:104119610	CENPE	-0.42	-5.01	-0.31	1.09e-6	Testicular germ cell tumor;
SARC	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg26335602	chr6:28129616	ZNF389	0.53	5.88	0.36	1.43e-8	Depression;
SARC	cis	rs28829049	0.861	rs10492996	chr1:19365552	C/T	cg13387374	chr1:19411106	UBR4	0.4	4.8	0.3	2.79e-6	QRS duration in Tripanosoma cruzi seropositivity;
SARC	cis	rs41278232	0.557	rs1093457	chr20:62604816	T/C	cg24354818	chr20:62328094	TNFRSF6B	0.35	4.83	0.3	2.43e-6	Tonsillectomy;
SARC	cis	rs2273669	0.915	rs6568554	chr6:109290319	C/A	cg05315195	chr6:109294784	ARMC2	-0.49	-4.79	-0.3	2.91e-6	Prostate cancer;
SARC	cis	rs9911578	1.000	rs12453049	chr17:56611372	C/T	cg05425664	chr17:57184151	TRIM37	0.65	7.98	0.46	6.49e-14	Intelligence (multi-trait analysis);
SARC	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg07701084	chr6:150067640	NUP43	0.42	5.56	0.34	7.3900000000000007e-08	Lung cancer;
SARC	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg12311346	chr5:56204834	C5orf35	-0.53	-5.42	-0.33	1.5e-7	Initial pursuit acceleration;
SARC	cis	rs9398803	0.650	rs10499135	chr6:126626333	A/G	cg19875578	chr6:126661172	C6orf173	0.5	6.75	0.4	1.16e-10	Male-pattern baldness;
SARC	cis	rs3008870	0.755	rs2815368	chr1:67500778	C/T	cg02640540	chr1:67518911	SLC35D1	0.46	5.22	0.32	4.03e-7	Lymphocyte percentage of white cells;
SARC	cis	rs4975616	0.869	rs380286	chr5:1320247	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.58	-8.61	-0.49	1.13e-15	Lung cancer;
SARC	cis	rs1062177	0.950	rs59580263	chr5:151269577	T/A	cg00977110	chr5:151150581	G3BP1	0.51	4.98	0.31	1.22e-6	Preschool internalizing problems;
SARC	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg05861140	chr6:150128134	PCMT1	-0.36	-4.79	-0.3	2.99e-6	Lung cancer;
SARC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	9.57	0.53	1.59e-18	Platelet count;
SARC	cis	rs13191362	1.000	rs67747005	chr6:163150845	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.28	0.33	3e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs870825	0.616	rs28444118	chr4:185621692	T/C	cg04058563	chr4:185651563	MLF1IP	0.82	11.42	0.6	2.8e-24	Blood protein levels;
SARC	cis	rs7296418	0.922	rs12425009	chr12:123502044	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.43	-5.81	-0.36	2e-8	Platelet count;
SARC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	11.15	0.59	2.1e-23	Platelet count;
SARC	cis	rs5753618	0.607	rs5753621	chr22:31847647	T/C	cg13145458	chr22:31556086	RNF185	-0.47	-5.03	-0.31	9.96e-7	Colorectal cancer;
SARC	cis	rs8031584	0.958	rs35256769	chr15:31237776	G/A	cg14298792	chr15:30685198	CHRFAM7A	-0.45	-4.93	-0.31	1.57e-6	Huntington's disease progression;
SARC	cis	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg11812906	chr14:75593930	NEK9	0.78	9.21	0.52	1.99e-17	Height;
SARC	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg14983838	chr19:29218262	NA	0.77	10.53	0.57	1.83e-21	Methadone dose in opioid dependence;
SARC	cis	rs1005277	0.522	rs7072977	chr10:37940440	C/A	cg00409905	chr10:38381863	ZNF37A	-0.53	-7.23	-0.43	6.71e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs7666738	0.753	rs6826709	chr4:98714553	C/G	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9303401	0.614	rs34678056	chr17:57177549	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.98	10.26	0.56	1.25e-20	Cognitive test performance;
SARC	trans	rs9929218	0.859	rs9936682	chr16:68748223	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.65	-8.33	-0.48	6.83e-15	Colorectal cancer;
SARC	cis	rs7662987	0.517	rs4235436	chr4:100039620	G/A	cg12011299	chr4:100065546	ADH4	0.33	5.47	0.34	1.13e-7	Smoking initiation;
SARC	cis	rs12594711	1	rs12594711	chr15:78793921	C/T	cg24631222	chr15:78858424	CHRNA5	-0.45	-5.78	-0.35	2.33e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg00339695	chr16:24857497	SLC5A11	-0.42	-6.11	-0.37	4.26e-9	Intelligence (multi-trait analysis);
SARC	cis	rs9786986	0.908	rs11803123	chr1:235658857	A/T	cg26050004	chr1:235667680	B3GALNT2	0.59	5.43	0.33	1.44e-7	Body mass index;
SARC	cis	rs9388451	0.537	rs1739383	chr6:126098915	G/T	cg05901451	chr6:126070800	HEY2	-0.49	-6.22	-0.38	2.22e-9	Brugada syndrome;
SARC	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg13939156	chr17:80058883	NA	-0.41	-6.37	-0.38	1.01e-9	Life satisfaction;
SARC	cis	rs10140922	0.864	rs72666622	chr14:35820138	T/A	cg26967526	chr14:35346199	BAZ1A	-0.38	-4.75	-0.3	3.62e-6	Hip circumference adjusted for BMI;
SARC	cis	rs7914558	0.966	rs10748835	chr10:104660256	C/T	cg15744005	chr10:104629667	AS3MT	-0.28	-4.82	-0.3	2.6e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs712039	0.652	rs2680719	chr17:35811453	C/T	cg16670864	chr17:35848621	DUSP14	0.44	4.84	0.3	2.41e-6	Tuberculosis;
SARC	cis	rs793571	0.590	rs347115	chr15:59082959	C/T	cg05156742	chr15:59063176	FAM63B	0.75	10.77	0.58	3.24e-22	Schizophrenia;
SARC	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.48	5.92	0.36	1.17e-8	Tonsillectomy;
SARC	cis	rs9916302	0.706	rs11655972	chr17:37407072	C/T	cg20243544	chr17:37824526	PNMT	0.55	5.89	0.36	1.35e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs3825932	0.736	rs1036939	chr15:79237324	C/A	cg25744700	chr15:79237217	CTSH	0.37	4.96	0.31	1.33e-6	Type 1 diabetes;
SARC	cis	rs1348850	0.750	rs12997716	chr2:178494629	G/A	cg22681709	chr2:178499509	PDE11A	-0.37	-4.89	-0.31	1.85e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs11608355	0.521	rs6606706	chr12:109830173	C/T	cg19025524	chr12:109796872	NA	-0.42	-6.34	-0.38	1.18e-9	Neuroticism;
SARC	cis	rs6582630	0.555	rs10880520	chr12:38464111	C/T	cg26384229	chr12:38710491	ALG10B	0.84	12.0	0.62	3.64e-26	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg05861140	chr6:150128134	PCMT1	-0.41	-5.18	-0.32	4.71e-7	Lung cancer;
SARC	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.49	7.16	0.42	1.05e-11	Systemic lupus erythematosus;
SARC	cis	rs6750795	0.569	rs1667305	chr2:232403829	A/G	cg18877969	chr2:232395326	NMUR1	-0.33	-4.89	-0.31	1.88e-6	Height;
SARC	cis	rs2235642	0.701	rs2281230	chr16:1601767	T/C	cg09065629	chr16:1709722	CRAMP1L	0.36	4.77	0.3	3.2e-6	Coronary artery disease;
SARC	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg00800038	chr16:89945340	TCF25	-0.66	-5.63	-0.35	5.07e-8	Skin colour saturation;
SARC	cis	rs11112613	0.762	rs73184077	chr12:105949999	G/A	cg03607813	chr12:105948248	NA	0.56	7.54	0.44	1.06e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs3815700	1.000	rs10406750	chr19:33097144	C/T	cg02997394	chr19:33096574	ANKRD27	0.77	8.29	0.48	9.02e-15	Eosinophilic esophagitis;
SARC	cis	rs1865760	0.865	rs9467648	chr6:25957933	T/A	cg16482183	chr6:26056742	HIST1H1C	0.52	6.68	0.4	1.69e-10	Height;
SARC	cis	rs9527	0.590	rs12415199	chr10:104895536	T/C	cg04362960	chr10:104952993	NT5C2	0.44	5.15	0.32	5.58e-7	Arsenic metabolism;
SARC	cis	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg03060546	chr3:49711283	APEH	0.77	11.26	0.59	8.94e-24	Resting heart rate;
SARC	cis	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg05623727	chr3:50126028	RBM5	0.32	4.87	0.3	2.06e-6	Intelligence (multi-trait analysis);
SARC	cis	rs282587	0.569	rs914012	chr13:113386715	C/T	cg02820901	chr13:113351484	ATP11A	-0.5	-4.76	-0.3	3.41e-6	Glycated hemoglobin levels;
SARC	trans	rs877282	1.000	rs11253362	chr10:770979	G/T	cg22713356	chr15:30763199	NA	1.08	10.56	0.57	1.45e-21	Uric acid levels;
SARC	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg03351412	chr1:154909251	PMVK	0.65	8.39	0.48	4.69e-15	Prostate cancer;
SARC	cis	rs9840812	0.623	rs4678433	chr3:136265682	C/T	cg15507776	chr3:136538369	TMEM22	0.5	5.54	0.34	8.1e-8	Fibrinogen levels;
SARC	cis	rs2070997	0.607	rs11244148	chr9:133677970	A/G	cg11464064	chr9:133710261	ABL1	0.57	5.01	0.31	1.09e-6	Response to amphetamines;
SARC	cis	rs17253792	0.822	rs10483643	chr14:56089931	G/C	cg01858014	chr14:56050164	KTN1	-0.67	-5.11	-0.32	6.86e-7	Putamen volume;
SARC	cis	rs11583043	0.958	rs12730160	chr1:101438791	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	6.01	0.37	7.19e-9	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg11494091	chr17:61959527	GH2	0.36	5.14	0.32	5.83e-7	Height;
SARC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg07414643	chr4:187882934	NA	-0.44	-6.07	-0.37	5.21e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6456042	1.000	rs6924688	chr6:166534443	T/G	cg11088901	chr6:166572345	T	-0.32	-4.74	-0.3	3.8e-6	Asthma;
SARC	cis	rs644799	0.862	rs1150361	chr11:95633805	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	13.46	0.66	6.03e-31	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs7980799	0.618	rs1482983	chr12:33690326	A/C	cg13010199	chr12:38710504	ALG10B	0.57	6.6	0.4	2.77e-10	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs7945705	0.935	rs1883098	chr11:8890594	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.46	-6.62	-0.4	2.51e-10	Hemoglobin concentration;
SARC	trans	rs561341	1.000	rs576985	chr17:30323323	C/T	cg20587970	chr11:113659929	NA	-1.34	-13.79	-0.67	4.87e-32	Hip circumference adjusted for BMI;
SARC	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg05861140	chr6:150128134	PCMT1	-0.41	-5.15	-0.32	5.56e-7	Lung cancer;
SARC	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg16606324	chr3:10149918	C3orf24	0.5	4.82	0.3	2.62e-6	Alzheimer's disease;
SARC	cis	rs11264799	0.539	rs12125930	chr1:157577086	A/G	cg18268488	chr1:157545234	FCRL4	0.3	5.41	0.33	1.57e-7	IgA nephropathy;
SARC	trans	rs3942852	0.774	rs10838812	chr11:48186924	T/C	cg03929089	chr4:120376271	NA	-0.6	-6.75	-0.4	1.13e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9815354	0.638	rs56194645	chr3:41843593	T/C	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg17971929	chr21:40555470	PSMG1	1.0	14.01	0.68	9.02e-33	Cognitive function;
SARC	cis	rs2439831	1.000	rs2245908	chr15:43731454	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.07	10.94	0.58	9.59e-23	Lung cancer in ever smokers;
SARC	cis	rs35213789	0.762	rs210600	chr7:69238281	G/A	cg10619644	chr7:69149951	AUTS2	0.43	5.49	0.34	1.02e-7	Childhood ear infection;
SARC	cis	rs9300255	0.602	rs2682431	chr12:123703226	T/A	cg00376283	chr12:123451042	ABCB9	0.55	6.53	0.39	4.09e-10	Neutrophil percentage of white cells;
SARC	cis	rs9467773	0.620	rs2494701	chr6:26634432	C/T	cg11502198	chr6:26597334	ABT1	0.63	8.63	0.49	9.91e-16	Intelligence (multi-trait analysis);
SARC	cis	rs17270561	0.609	rs6924782	chr6:25735816	C/G	cg16482183	chr6:26056742	HIST1H1C	0.43	5.22	0.32	3.92e-7	Iron status biomarkers;
SARC	cis	rs3857536	0.813	rs6903411	chr6:66938288	T/C	cg07460842	chr6:66804631	NA	-0.51	-5.83	-0.36	1.86e-8	Blood trace element (Cu levels);
SARC	cis	rs477692	0.673	rs10764889	chr10:131341521	G/A	cg14263093	chr10:131365266	MGMT	0.37	5.31	0.33	2.62e-7	Response to temozolomide;
SARC	cis	rs17030434	0.953	rs10010787	chr4:154692059	G/A	cg14289246	chr4:154710475	SFRP2	-0.8	-7.96	-0.46	7.38e-14	Electrocardiographic conduction measures;
SARC	trans	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.56	-7.41	-0.44	2.25e-12	Intelligence (multi-trait analysis);
SARC	cis	rs7681440	0.904	rs35424815	chr4:90767877	C/T	cg06632027	chr4:90757378	SNCA	0.39	5.66	0.35	4.49e-8	Dementia with Lewy bodies;
SARC	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg11062466	chr8:58055876	NA	0.56	5.69	0.35	3.79e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs8051517	1.000	rs35245000	chr16:68378040	T/G	cg01866162	chr16:67596514	CTCF	0.85	5.31	0.33	2.56e-7	Blood protein levels;
SARC	cis	rs2832191	0.935	rs11910316	chr21:30519729	G/A	cg08807101	chr21:30365312	RNF160	-0.74	-10.16	-0.55	2.51e-20	Dental caries;
SARC	cis	rs2354432	0.505	rs3737845	chr1:146724408	A/G	cg25205988	chr1:146714368	CHD1L	1.02	7.73	0.45	3.15e-13	Mitochondrial DNA levels;
SARC	cis	rs13096760	1	rs13096760	chr3:49476806	T/C	cg07636037	chr3:49044803	WDR6	0.63	8.37	0.48	5.44e-15	Intelligence (multi-trait analysis);
SARC	cis	rs1003719	0.788	rs2006941	chr21:38467616	C/A	cg10648535	chr21:38446584	PIGP;TTC3	0.63	9.05	0.51	5.67e-17	Eye color traits;
SARC	cis	rs2075371	0.932	rs1035328	chr7:133978419	T/C	cg00033643	chr7:134001901	SLC35B4	0.42	5.13	0.32	5.95e-7	Mean platelet volume;
SARC	cis	rs4851254	0.920	rs4850920	chr2:100757308	C/A	cg17356467	chr2:100759845	AFF3	0.29	4.85	0.3	2.27e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2072499	0.932	rs3001790	chr1:156165290	T/G	cg25208724	chr1:156163844	SLC25A44	0.93	12.69	0.64	2.13e-28	Testicular germ cell tumor;
SARC	cis	rs7772486	0.719	rs4391282	chr6:146276780	A/T	cg05347473	chr6:146136440	FBXO30	-0.46	-6.31	-0.38	1.39e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs910316	1.000	rs12897094	chr14:75579416	C/T	cg23033748	chr14:75592666	NEK9	0.38	5.38	0.33	1.84e-7	Height;
SARC	cis	rs3011225	0.683	rs4660753	chr1:44321044	G/A	cg13606994	chr1:44402422	ARTN	-0.29	-4.77	-0.3	3.3e-6	Amyotrophic lateral sclerosis (age of onset);
SARC	cis	rs9381040	0.655	rs2268192	chr6:41024626	T/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.41	-4.85	-0.3	2.31e-6	Alzheimer's disease (late onset);
SARC	cis	rs4319547	0.915	rs7966094	chr12:123115771	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.64	-7.39	-0.44	2.55e-12	Body mass index;
SARC	cis	rs449789	0.857	rs9346784	chr6:159703757	G/T	cg14500486	chr6:159655392	FNDC1	-0.44	-5.02	-0.31	1.01e-6	Pulse pressure;
SARC	cis	rs12709013	0.591	rs30834	chr16:58749298	T/C	cg04273148	chr16:57808038	KIFC3	0.39	5.33	0.33	2.35e-7	Blood metabolite ratios;
SARC	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg10311833	chr22:26908351	TFIP11	-0.5	-6.43	-0.39	7.21e-10	Thyroid cancer;
SARC	cis	rs72781680	1.000	rs72796358	chr2:24160132	T/A	cg06627628	chr2:24431161	ITSN2	-0.68	-6.32	-0.38	1.35e-9	Lymphocyte counts;
SARC	cis	rs7833790	0.724	rs72603871	chr8:82754460	C/G	cg27398817	chr8:82754497	SNX16	0.43	5.37	0.33	1.9e-7	Diastolic blood pressure;
SARC	cis	rs72781680	0.898	rs72782117	chr2:24026921	G/A	cg06627628	chr2:24431161	ITSN2	-0.7	-6.44	-0.39	6.77e-10	Lymphocyte counts;
SARC	cis	rs1153858	0.943	rs11070454	chr15:45680252	C/T	cg26924012	chr15:45694286	SPATA5L1	0.79	11.28	0.59	7.91e-24	Homoarginine levels;
SARC	cis	rs9457247	0.765	rs9459849	chr6:167444160	G/T	cg07741184	chr6:167504864	NA	0.38	7.49	0.44	1.39e-12	Crohn's disease;
SARC	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg08219700	chr8:58056026	NA	-0.62	-6.64	-0.4	2.19e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs748404	0.578	rs552701	chr15:43613810	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	5.7	0.35	3.65e-8	Lung cancer;
SARC	cis	rs2239547	0.522	rs6771610	chr3:53026104	T/C	cg11645453	chr3:52864694	ITIH4	0.3	4.89	0.31	1.84e-6	Schizophrenia;
SARC	cis	rs9341808	0.905	rs9343977	chr6:80967001	C/T	cg08355045	chr6:80787529	NA	0.35	5.81	0.36	2e-8	Sitting height ratio;
SARC	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg05861140	chr6:150128134	PCMT1	-0.38	-4.91	-0.31	1.72e-6	Lung cancer;
SARC	cis	rs7666738	0.712	rs11731393	chr4:98859070	G/C	cg05340658	chr4:99064831	C4orf37	0.5	5.45	0.34	1.27e-7	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1448094	0.645	rs8181635	chr12:86465136	C/T	cg02569458	chr12:86230093	RASSF9	-0.34	-4.86	-0.3	2.13e-6	Major depressive disorder;
SARC	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg14159672	chr1:205819179	PM20D1	-0.5	-6.35	-0.38	1.12e-9	Menarche (age at onset);
SARC	cis	rs651907	0.557	rs11914318	chr3:101453858	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	6.39	0.39	8.85e-10	Colorectal cancer;
SARC	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg26335602	chr6:28129616	ZNF389	0.53	5.8	0.35	2.19e-8	Depression;
SARC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg09373136	chr17:61933544	TCAM1	-0.46	-6.25	-0.38	1.99e-9	Prudent dietary pattern;
SARC	cis	rs7582720	1.000	rs72932777	chr2:203689914	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.71	7.33	0.43	3.68e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg00933542	chr6:150070202	PCMT1	0.33	5.74	0.35	2.93e-8	Lung cancer;
SARC	cis	rs734999	0.588	rs2764842	chr1:2529192	A/G	cg18854424	chr1:2615690	NA	-0.33	-5.28	-0.33	3.03e-7	Ulcerative colitis;
SARC	cis	rs2050392	0.624	rs303436	chr10:30731893	G/T	cg25182066	chr10:30743637	MAP3K8	0.39	5.51	0.34	9.25e-8	Inflammatory bowel disease;
SARC	cis	rs826838	1.000	rs7299124	chr12:39002661	T/C	cg26384229	chr12:38710491	ALG10B	0.92	14.49	0.69	2.32e-34	Heart rate;
SARC	cis	rs9398803	0.865	rs4559102	chr6:126773580	G/A	cg20229609	chr6:126660872	C6orf173	0.4	5.73	0.35	3.09e-8	Male-pattern baldness;
SARC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg18404041	chr3:52824283	ITIH1	-0.39	-5.87	-0.36	1.52e-8	Bipolar disorder;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg11203551	chr1:52610547	ZFYVE9	0.45	6.43	0.39	7.19e-10	Thyroid stimulating hormone;
SARC	cis	rs7520050	0.966	rs6668284	chr1:46354510	G/A	cg06784218	chr1:46089804	CCDC17	-0.26	-4.79	-0.3	3.01e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs11638352	0.661	rs2706492	chr15:44423846	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.76	-5.91	-0.36	1.23e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	cis	rs7103648	1.000	rs10838709	chr11:47447346	C/T	cg10504702	chr11:47789108	FNBP4	0.58	7.51	0.44	1.28e-12	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs523522	0.962	rs3742052	chr12:120966921	A/G	cg27279351	chr12:120934652	DYNLL1	0.73	9.05	0.51	5.73e-17	High light scatter reticulocyte count;
SARC	cis	rs2204008	0.837	rs73112346	chr12:38357606	C/T	cg26384229	chr12:38710491	ALG10B	0.91	13.46	0.66	6.11e-31	Bladder cancer;
SARC	cis	rs6429082	0.585	rs7524848	chr1:235711688	G/C	cg26050004	chr1:235667680	B3GALNT2	-0.54	-6.28	-0.38	1.69e-9	Adiposity;
SARC	cis	rs17021463	0.902	rs13102926	chr4:95245527	C/T	cg11021082	chr4:95130006	SMARCAD1	0.43	6.46	0.39	5.89e-10	Testicular germ cell tumor;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg23366762	chr2:128991292	NA	0.78	6.41	0.39	7.95e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs12479064	0.703	rs28382977	chr2:100018304	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.46	-5.22	-0.32	3.96e-7	Chronic sinus infection;
SARC	cis	rs965469	1.000	rs6037579	chr20:3347980	G/A	cg25506879	chr20:3388711	C20orf194	-0.49	-4.93	-0.31	1.55e-6	IFN-related cytopenia;
SARC	cis	rs9303401	0.538	rs2240259	chr17:56458129	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.99	9.92	0.55	1.38e-19	Cognitive test performance;
SARC	cis	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg14541582	chr5:601475	NA	-0.39	-4.76	-0.3	3.39e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs11098499	0.820	rs6534140	chr4:120455311	C/T	cg09307838	chr4:120376055	NA	0.91	12.31	0.63	3.63e-27	Corneal astigmatism;
SARC	cis	rs943466	0.911	rs73746509	chr6:33729825	C/T	cg04676172	chr6:33757040	LEMD2	0.47	4.78	0.3	3.1e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
SARC	cis	rs826838	0.967	rs1719852	chr12:39128531	A/G	cg26384229	chr12:38710491	ALG10B	-0.75	-11.21	-0.59	1.27e-23	Heart rate;
SARC	cis	rs9354308	0.899	rs2802055	chr6:66545756	T/C	cg07460842	chr6:66804631	NA	0.48	5.48	0.34	1.12e-7	Metabolite levels;
SARC	cis	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg25894440	chr7:65020034	NA	-0.78	-6.04	-0.37	6.1e-9	Diabetic kidney disease;
SARC	cis	rs9640161	0.830	rs3757424	chr7:150067679	C/A	cg17279839	chr7:150038598	RARRES2	0.34	5.32	0.33	2.41e-7	Blood protein levels;Circulating chemerin levels;
SARC	trans	rs17685	0.725	rs1044483	chr7:75659815	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.6	-7.6	-0.45	7.35e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.93	12.61	0.64	3.98e-28	Platelet count;
SARC	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg13770153	chr20:60521292	NA	-0.53	-7.29	-0.43	4.91e-12	Body mass index;
SARC	cis	rs9399135	1.000	rs9399135	chr6:135368314	G/A	cg24558204	chr6:135376177	HBS1L	0.46	6.06	0.37	5.3e-9	Red blood cell count;
SARC	cis	rs3857536	0.785	rs1935895	chr6:66936606	T/G	cg07460842	chr6:66804631	NA	-0.51	-5.83	-0.36	1.86e-8	Blood trace element (Cu levels);
SARC	cis	rs2645694	0.626	rs2645684	chr4:77819892	A/C	cg03477792	chr4:77819574	ANKRD56	0.5	7.36	0.43	3.09e-12	Emphysema distribution in smoking;
SARC	cis	rs1707322	1.000	rs6677777	chr1:46475836	A/G	cg03146154	chr1:46216737	IPP	0.52	6.03	0.37	6.25e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4803468	0.967	rs4605279	chr19:41888131	C/G	cg09537434	chr19:41945824	ATP5SL	-0.93	-16.68	-0.74	1.26e-41	Height;
SARC	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg22920501	chr2:26401640	FAM59B	-0.55	-7.14	-0.42	1.18e-11	Gut microbiome composition (summer);
SARC	cis	rs7617773	0.780	rs35297395	chr3:48342882	C/T	cg11946769	chr3:48343235	NME6	0.76	9.7	0.54	6.55e-19	Coronary artery disease;
SARC	cis	rs2197308	0.667	rs61920838	chr12:37856814	T/C	cg04568710	chr12:38710424	ALG10B	-0.4	-4.88	-0.3	1.98e-6	Morning vs. evening chronotype;
SARC	cis	rs9457247	0.756	rs2345572	chr6:167403441	A/T	cg07741184	chr6:167504864	NA	0.32	6.05	0.37	5.77e-9	Crohn's disease;
SARC	cis	rs3758785	0.586	rs637114	chr11:94070685	C/G	cg13023536	chr11:94226537	MRE11A;ANKRD49	-0.41	-5.1	-0.32	7.15e-7	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
SARC	cis	rs7566780	0.548	rs11889461	chr2:16700727	A/G	cg09580478	chr2:16689509	NA	0.51	6.32	0.38	1.35e-9	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg03806693	chr22:41940476	POLR3H	0.83	10.89	0.58	1.36e-22	Vitiligo;
SARC	cis	rs72781680	0.898	rs72798064	chr2:23982832	T/C	cg06627628	chr2:24431161	ITSN2	-0.68	-6.49	-0.39	5.15e-10	Lymphocyte counts;
SARC	cis	rs870825	0.549	rs7656993	chr4:185635159	T/C	cg04058563	chr4:185651563	MLF1IP	0.84	11.31	0.6	6.15e-24	Blood protein levels;
SARC	cis	rs2635047	0.542	rs1512236	chr18:44768493	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.43	-5.31	-0.33	2.51e-7	Educational attainment;
SARC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg24503407	chr1:205819492	PM20D1	0.81	12.89	0.65	4.82e-29	Menarche (age at onset);
SARC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg09373136	chr17:61933544	TCAM1	-0.45	-6.23	-0.38	2.18e-9	Prudent dietary pattern;
SARC	trans	rs9987353	0.830	rs2126267	chr8:9107951	C/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.29	-0.38	1.59e-9	Recombination measurement;
SARC	cis	rs9486719	1.000	rs35487471	chr6:96879715	C/T	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.01	-0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs6933660	0.646	rs6915598	chr6:151778664	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.66	7.82	0.46	1.86e-13	Menarche (age at onset);
SARC	cis	rs3741151	0.656	rs12290785	chr11:73259012	G/T	cg17517138	chr11:73019481	ARHGEF17	0.82	6.28	0.38	1.65e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg02034447	chr16:89574710	SPG7	-0.48	-6.52	-0.39	4.24e-10	Multiple myeloma (IgH translocation);
SARC	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg24531977	chr5:56204891	C5orf35	-0.53	-5.36	-0.33	2.02e-7	Initial pursuit acceleration;
SARC	cis	rs11792861	0.926	rs77567374	chr9:111835034	T/C	cg13535736	chr9:111863775	C9orf5	-0.41	-5.05	-0.31	8.81e-7	Menarche (age at onset);
SARC	cis	rs9395865	0.520	rs6903708	chr6:53332940	A/G	cg25020846	chr6:53659618	LRRC1	-0.42	-4.95	-0.31	1.41e-6	Electroencephalographic traits in alcoholism;
SARC	cis	rs765787	0.530	rs55920042	chr15:45541577	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.67e-7	Uric acid levels;
SARC	cis	rs2997447	0.669	rs61776584	chr1:26438455	T/C	cg19633962	chr1:26362018	EXTL1	-0.57	-5.22	-0.32	4e-7	QRS complex (12-leadsum);
SARC	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg12463550	chr7:65579703	CRCP	-0.47	-5.16	-0.32	5.3e-7	Aortic root size;
SARC	cis	rs9296092	0.538	rs76589475	chr6:33519517	G/C	cg13560919	chr6:33536144	NA	-0.51	-6.24	-0.38	2.08e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs17270561	0.609	rs9358879	chr6:25742918	C/G	cg16482183	chr6:26056742	HIST1H1C	0.43	5.08	0.32	7.76e-7	Iron status biomarkers;
SARC	cis	rs11997175	0.550	rs7464954	chr8:33832202	A/G	ch.8.33884649F	chr8:33765107	NA	0.46	5.86	0.36	1.59e-8	Body mass index;
SARC	cis	rs7584330	0.744	rs10929235	chr2:238380272	A/G	cg11271282	chr2:238384023	NA	0.53	5.39	0.33	1.76e-7	Prostate cancer;
SARC	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg18252515	chr7:66147081	NA	0.45	4.85	0.3	2.27e-6	Aortic root size;
SARC	cis	rs6060717	0.536	rs6060704	chr20:34530270	A/G	cg01084648	chr20:34329383	RBM39	0.62	4.72	0.3	4.09e-6	Hip circumference adjusted for BMI;
SARC	cis	rs113835537	0.529	rs57207756	chr11:66270360	C/T	cg24851651	chr11:66362959	CCS	0.38	4.72	0.3	4.02e-6	Airway imaging phenotypes;
SARC	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs4713118	0.869	rs9461405	chr6:27719375	G/T	cg17221315	chr6:27791827	HIST1H4J	0.47	5.12	0.32	6.46e-7	Parkinson's disease;
SARC	cis	rs9457247	0.561	rs916331	chr6:167470559	T/G	cg07741184	chr6:167504864	NA	0.38	7.32	0.43	3.92e-12	Crohn's disease;
SARC	cis	rs3768617	0.706	rs6678517	chr1:183002639	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.65	9.26	0.52	1.38e-17	Fuchs's corneal dystrophy;
SARC	cis	rs4423214	1.000	rs4423214	chr11:71173254	C/T	cg24826892	chr11:71159390	DHCR7	0.48	6.19	0.38	2.73e-9	Vitamin D levels;
SARC	cis	rs3820928	0.647	rs2115597	chr2:227791218	T/C	cg11843606	chr2:227700838	RHBDD1	-0.57	-7.33	-0.43	3.81e-12	Pulmonary function;
SARC	cis	rs834603	0.965	rs834601	chr7:47445812	T/C	cg23694490	chr7:47445681	TNS3	-0.4	-7.42	-0.44	2.17e-12	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs74181299	0.591	rs1894875	chr2:65363579	G/A	cg20592124	chr2:65290738	CEP68	-0.38	-4.99	-0.31	1.18e-6	Pulse pressure;
SARC	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg01341218	chr17:43662625	NA	0.69	8.14	0.47	2.41e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs10911232	0.524	rs4487994	chr1:182982173	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.72	10.87	0.58	1.6e-22	Hypertriglyceridemia;
SARC	cis	rs636291	0.517	rs673254	chr1:10550352	C/T	cg07384165	chr1:10488281	NA	-0.45	-6.2	-0.38	2.49e-9	Prostate cancer;
SARC	cis	rs2304069	0.545	rs7728248	chr5:149394965	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.6	7.02	0.42	2.37e-11	HIV-1 control;
SARC	cis	rs1790761	0.658	rs684928	chr11:67329742	G/A	cg00290607	chr11:67383545	NA	0.39	5.24	0.32	3.56e-7	Mean corpuscular volume;
SARC	cis	rs9916302	0.571	rs28799952	chr17:37533056	C/T	cg20243544	chr17:37824526	PNMT	-0.55	-5.86	-0.36	1.56e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7617773	0.780	rs35297486	chr3:48378147	T/A	cg11946769	chr3:48343235	NME6	0.76	9.63	0.53	1.08e-18	Coronary artery disease;
SARC	cis	rs13314892	0.692	rs62252240	chr3:69894042	C/T	cg17445875	chr3:69859618	MITF	-0.51	-5.24	-0.32	3.51e-7	QRS complex (12-leadsum);
SARC	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg04317338	chr11:64019027	PLCB3	-0.57	-6.76	-0.4	1.1e-10	Platelet count;
SARC	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg16325326	chr1:53192061	ZYG11B	0.78	12.14	0.62	1.29e-26	Monocyte count;
SARC	cis	rs72781680	0.898	rs72782113	chr2:24024952	G/C	cg06627628	chr2:24431161	ITSN2	-0.66	-6.27	-0.38	1.69e-9	Lymphocyte counts;
SARC	cis	rs453301	0.579	rs10096850	chr8:8798222	A/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.47	-0.39	5.83e-10	Joint mobility (Beighton score);
SARC	cis	rs7555523	0.887	rs2814471	chr1:165739598	C/T	cg19769164	chr1:165738335	TMCO1	0.6	5.15	0.32	5.5e-7	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg22875332	chr1:76189707	ACADM	0.47	5.81	0.36	2.01e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg25072359	chr17:41440525	NA	0.51	6.03	0.37	6.43e-9	Menopause (age at onset);
SARC	cis	rs72781680	0.821	rs1022346	chr2:24127849	T/C	cg08917208	chr2:24149416	ATAD2B	0.61	6.31	0.38	1.38e-9	Lymphocyte counts;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg14331404	chr2:97482184	CNNM3	-0.52	-6.48	-0.39	5.51e-10	Schizophrenia;
SARC	cis	rs11997175	0.624	rs7001604	chr8:33680979	T/C	ch.8.33884649F	chr8:33765107	NA	0.61	8.17	0.47	1.98e-14	Body mass index;
SARC	cis	rs2243480	1.000	rs160643	chr7:65558222	C/T	cg12463550	chr7:65579703	CRCP	0.64	4.96	0.31	1.35e-6	Diabetic kidney disease;
SARC	cis	rs9303401	0.659	rs7225896	chr17:56637337	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.05	11.09	0.59	3.14e-23	Cognitive test performance;
SARC	cis	rs6977660	0.598	rs10239147	chr7:19787459	T/C	cg07541023	chr7:19748670	TWISTNB	0.77	6.83	0.41	7.53e-11	Thyroid stimulating hormone;
SARC	cis	rs950776	0.593	rs601079	chr15:78869579	T/A	cg22563815	chr15:78856949	CHRNA5	-0.38	-6.44	-0.39	6.68e-10	Sudden cardiac arrest;
SARC	cis	rs7512552	0.724	rs7002	chr1:150445819	A/G	cg15654264	chr1:150340011	RPRD2	0.39	4.96	0.31	1.34e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs651907	0.557	rs35117343	chr3:101445126	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	6.39	0.39	8.85e-10	Colorectal cancer;
SARC	cis	rs9467773	1.000	rs767471	chr6:26557854	C/T	cg11502198	chr6:26597334	ABT1	0.5	6.09	0.37	4.53e-9	Intelligence (multi-trait analysis);
SARC	cis	rs59918340	0.738	rs3739235	chr8:142229145	A/G	cg16341495	chr8:142228727	SLC45A4	-0.37	-5.14	-0.32	5.84e-7	Immature fraction of reticulocytes;
SARC	cis	rs933688	1.000	rs12651840	chr5:90729592	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.04	13.24	0.66	3.34e-30	Smoking behavior;
SARC	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg05025164	chr4:1340916	KIAA1530	0.64	7.93	0.46	9.01e-14	Longevity;
SARC	cis	rs16976116	0.619	rs7169407	chr15:55465652	T/C	cg17854078	chr15:55489399	RSL24D1	0.61	5.26	0.33	3.3e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg04756594	chr16:24857601	SLC5A11	0.44	5.65	0.35	4.63e-8	Intelligence (multi-trait analysis);
SARC	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg13395646	chr4:1353034	KIAA1530	-0.47	-5.64	-0.35	4.87e-8	Obesity-related traits;
SARC	cis	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg07777115	chr5:623756	CEP72	-0.64	-5.61	-0.34	5.84e-8	Obesity-related traits;
SARC	cis	rs796364	0.951	rs7565005	chr2:201013277	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.57	-5.74	-0.35	3.01e-8	Schizophrenia;
SARC	cis	rs3771570	1.000	rs60604866	chr2:242352257	A/G	cg21155796	chr2:242212141	HDLBP	0.7	6.27	0.38	1.74e-9	Prostate cancer;
SARC	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg08219700	chr8:58056026	NA	0.62	6.52	0.39	4.28e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9948	0.655	rs62156228	chr2:97420335	A/G	cg01990225	chr2:97406019	LMAN2L	-0.96	-6.77	-0.41	1.04e-10	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs9394841	0.692	rs9394834	chr6:41806793	G/A	cg08135965	chr6:41755394	TOMM6	0.6	6.42	0.39	7.49e-10	Mean corpuscular hemoglobin;Red cell distribution width;
SARC	cis	rs7595412	1.000	rs10183584	chr2:199069965	T/A	cg00208931	chr2:198669586	PLCL1	-0.69	-4.95	-0.31	1.43e-6	Hip bone size;
SARC	cis	rs8067545	0.641	rs203481	chr17:19828728	C/T	cg04132472	chr17:19861366	AKAP10	0.38	5.08	0.32	7.88e-7	Schizophrenia;
SARC	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg08859206	chr1:53392774	SCP2	-0.44	-6.3	-0.38	1.46e-9	Monocyte count;
SARC	cis	rs769267	0.792	rs4808961	chr19:19577215	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.41	4.95	0.31	1.41e-6	Tonsillectomy;
SARC	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg16405210	chr4:1374714	KIAA1530	0.52	6.36	0.38	1.03e-9	Obesity-related traits;
SARC	cis	rs12134245	0.747	rs11164912	chr1:92005191	A/T	cg25838465	chr1:92012736	NA	-0.69	-10.1	-0.55	4.07e-20	Breast cancer;
SARC	cis	rs7843479	1.000	rs17615788	chr8:21814739	C/T	cg17168535	chr8:21777572	XPO7	0.61	7.78	0.45	2.27e-13	Mean corpuscular volume;
SARC	cis	rs13191362	0.507	rs2849524	chr6:163127070	C/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.48	-5.3	-0.33	2.66e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs6456042	0.965	rs6920259	chr6:166534490	A/G	cg11088901	chr6:166572345	T	-0.32	-4.74	-0.3	3.8e-6	Asthma;
SARC	cis	rs35110281	0.806	rs1454649	chr21:45032982	C/T	cg21573476	chr21:45109991	RRP1B	-0.56	-8.23	-0.47	1.3e-14	Mean corpuscular volume;
SARC	cis	rs1949733	1.000	rs868105	chr4:8501030	G/T	cg11789530	chr4:8429930	ACOX3	-0.83	-11.23	-0.59	1.15e-23	Response to antineoplastic agents;
SARC	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.97e-8	Aortic root size;
SARC	cis	rs2273669	0.667	rs11757168	chr6:109301091	A/G	cg05315195	chr6:109294784	ARMC2	-0.58	-5.25	-0.33	3.37e-7	Prostate cancer;
SARC	cis	rs1008375	1.000	rs10805357	chr4:17652352	G/A	cg16339924	chr4:17578868	LAP3	0.66	8.83	0.5	2.57e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2070488	0.695	rs6599201	chr3:38476614	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.81	12.58	0.64	4.83e-28	Electrocardiographic conduction measures;
SARC	cis	rs4951018	0.821	rs7529037	chr1:205637501	C/G	cg07157834	chr1:205819609	PM20D1	-0.39	-5.43	-0.34	1.4e-7	Prostate-specific antigen levels;
SARC	cis	rs644799	0.648	rs1255181	chr11:95472148	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.54	6.75	0.4	1.2e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs4711350	0.765	rs2182658	chr6:33748831	G/T	cg18005901	chr6:33739558	LEMD2	0.44	5.16	0.32	5.21e-7	Schizophrenia;
SARC	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-9.01	-0.51	7.77e-17	Alzheimer's disease;
SARC	cis	rs13191362	1.000	rs13199223	chr6:163001083	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.57	5.38	0.33	1.85e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs798554	0.660	rs2644274	chr7:2854380	A/T	cg04166393	chr7:2884313	GNA12	0.42	5.19	0.32	4.53e-7	Height;
SARC	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg10374962	chr7:1011985	COX19	-0.44	-5.13	-0.32	6.24e-7	Bronchopulmonary dysplasia;
SARC	trans	rs2814331	0.544	rs10788487	chr10:88030550	A/G	cg24630164	chr12:111158279	PPP1CC	-0.45	-6.31	-0.38	1.39e-9	Balding;
SARC	cis	rs3857536	0.740	rs9360191	chr6:66942454	A/T	cg07460842	chr6:66804631	NA	-0.51	-5.83	-0.36	1.86e-8	Blood trace element (Cu levels);
SARC	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg18876405	chr7:65276391	NA	-0.61	-7.7	-0.45	3.75e-13	Calcium levels;
SARC	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.63e-10	Life satisfaction;
SARC	cis	rs3126085	0.935	rs3120661	chr1:152294402	A/G	cg26876637	chr1:152193138	HRNR	-0.47	-5.32	-0.33	2.46e-7	Atopic dermatitis;
SARC	cis	rs7044106	0.762	rs10491783	chr9:123450155	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	5.44	0.34	1.32e-7	Hip circumference adjusted for BMI;
SARC	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	9.89	0.54	1.77e-19	Alzheimer's disease;
SARC	cis	rs753778	1.000	rs753778	chr8:142228909	G/A	cg18755752	chr8:142205143	DENND3	-0.48	-5.78	-0.35	2.45e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs17376456	0.569	rs7702348	chr5:93065683	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.62	-6.64	-0.4	2.17e-10	Diabetic retinopathy;
SARC	cis	rs1538970	0.924	rs7531253	chr1:45890183	T/C	cg05343316	chr1:45956843	TESK2	0.77	8.82	0.5	2.75e-16	Platelet count;
SARC	cis	rs35110281	0.715	rs2838320	chr21:44995037	A/G	cg21573476	chr21:45109991	RRP1B	-0.52	-7.58	-0.44	8.03e-13	Mean corpuscular volume;
SARC	cis	rs7647973	1.000	rs6785045	chr3:49435243	G/C	cg07636037	chr3:49044803	WDR6	-0.75	-8.18	-0.47	1.88e-14	Menarche (age at onset);
SARC	trans	rs28595532	0.557	rs4359977	chr4:119314055	T/C	cg26518628	chr1:97050305	NA	-0.8	-6.57	-0.4	3.26e-10	Cannabis dependence symptom count;
SARC	cis	rs2933343	0.729	rs6767104	chr3:128648117	G/T	cg24203234	chr3:128598194	ACAD9	-0.6	-7.22	-0.43	7.29e-12	IgG glycosylation;
SARC	cis	rs870825	0.616	rs6552805	chr4:185637894	C/A	cg04058563	chr4:185651563	MLF1IP	0.84	11.36	0.6	4.49e-24	Blood protein levels;
SARC	cis	rs3862030	0.720	rs11593583	chr10:104228149	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.48	6.26	0.38	1.88e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
SARC	cis	rs6424115	1.000	rs4649115	chr1:24155731	A/G	cg15997130	chr1:24165203	NA	-0.49	-6.59	-0.4	2.91e-10	Immature fraction of reticulocytes;
SARC	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg22535103	chr8:58192502	C8orf71	-0.6	-6.15	-0.37	3.42e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg18876405	chr7:65276391	NA	0.49	6.04	0.37	6e-9	Aortic root size;
SARC	cis	rs6942407	0.592	rs757961	chr7:86849510	T/C	cg02420886	chr7:86849541	C7orf23	0.71	6.17	0.37	2.99e-9	Food allergy;
SARC	cis	rs668210	0.793	rs645571	chr11:65752852	A/T	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.61	-5.89	-0.36	1.35e-8	Cerebrospinal fluid biomarker levels;
SARC	cis	rs734999	0.566	rs10797435	chr1:2534801	G/C	cg20673091	chr1:2541236	MMEL1	0.34	5.24	0.32	3.53e-7	Ulcerative colitis;
SARC	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg17221315	chr6:27791827	HIST1H4J	0.46	5.28	0.33	3.02e-7	Depression;
SARC	cis	rs16866061	0.962	rs72972361	chr2:225341550	G/A	cg12698349	chr2:225449008	CUL3	0.71	10.27	0.56	1.22e-20	Acute graft versus host disease in bone marrow transplantation (recipient effect);
SARC	cis	rs11122272	0.735	rs2256908	chr1:231506557	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-9.93	-0.55	1.3e-19	Hemoglobin concentration;
SARC	cis	rs10416265	0.502	rs7245411	chr19:33543029	A/T	cg17764715	chr19:33622953	WDR88	0.6	8.18	0.47	1.89e-14	Bone properties (heel);
SARC	cis	rs7208859	0.614	rs9914534	chr17:29202664	G/A	cg13385521	chr17:29058706	SUZ12P	0.86	7.34	0.43	3.54e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs34779708	0.931	rs4934533	chr10:35359619	A/G	cg03585969	chr10:35415529	CREM	0.38	4.79	0.3	3e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs400736	0.729	rs9434948	chr1:8004963	A/C	cg25007680	chr1:8021821	PARK7	-0.42	-5.4	-0.33	1.66e-7	Response to antidepressants and depression;
SARC	cis	rs6733011	0.500	rs2280142	chr2:99434872	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.4	-4.73	-0.3	3.83e-6	Bipolar disorder;
SARC	cis	rs881375	0.967	rs7034492	chr9:123687211	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.44	5.22	0.32	3.91e-7	Rheumatoid arthritis;
SARC	cis	rs34891900	0.507	rs12167771	chr22:18124332	G/A	cg19898043	chr22:18121309	BCL2L13	0.66	7.37	0.43	2.93e-12	Sum neutrophil eosinophil counts;
SARC	cis	rs7824557	0.602	rs35807737	chr8:11204411	C/G	cg21775007	chr8:11205619	TDH	0.67	8.62	0.49	1.02e-15	Retinal vascular caliber;
SARC	cis	rs7103648	0.864	rs10769264	chr11:47423340	C/T	cg20307385	chr11:47447363	PSMC3	0.87	14.65	0.69	6.94e-35	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs4851254	0.920	rs11686599	chr2:100753475	A/G	cg04109781	chr2:100722022	AFF3	0.33	4.86	0.3	2.18e-6	Intelligence (multi-trait analysis);
SARC	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg20007245	chr22:24372913	LOC391322	0.59	7.08	0.42	1.71e-11	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs2486288	0.656	rs62026703	chr15:45569929	G/T	cg21132104	chr15:45694354	SPATA5L1	-0.54	-6.81	-0.41	8.2e-11	Glomerular filtration rate;
SARC	cis	rs2712184	0.935	rs2541387	chr2:217666174	A/C	cg05032264	chr2:217675019	NA	-0.61	-8.42	-0.48	3.95e-15	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
SARC	cis	rs4619890	0.528	rs28600706	chr4:7876410	T/C	cg18538662	chr4:7941764	AFAP1	-0.41	-5.28	-0.33	2.95e-7	Glaucoma (primary open-angle);
SARC	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg04267008	chr7:1944627	MAD1L1	0.5	5.82	0.36	1.91e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg03433033	chr1:76189801	ACADM	0.48	6.17	0.37	3.02e-9	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs561341	0.882	rs16967101	chr17:30377162	A/G	cg13647721	chr17:30228624	UTP6	0.55	4.92	0.31	1.66e-6	Hip circumference adjusted for BMI;
SARC	cis	rs2073300	0.609	rs6137948	chr20:23416845	G/A	cg12062639	chr20:23401060	NAPB	0.98	6.61	0.4	2.57e-10	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg10659447	chr19:51535231	KLK12	-0.67	-6.38	-0.39	9.51e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	9.07	0.51	5.2e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs300703	0.816	rs449725	chr2:202993	C/G	cg21211680	chr2:198530	NA	-0.53	-5.34	-0.33	2.22e-7	Blood protein levels;
SARC	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg20607798	chr8:58055168	NA	0.58	5.57	0.34	6.9e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4926611	0.762	rs2950250	chr1:54042714	T/G	cg08927728	chr1:54059983	GLIS1	-0.28	-4.84	-0.3	2.35e-6	Hand grip strength;
SARC	cis	rs1707322	1.000	rs10890377	chr1:46406594	G/A	cg06784218	chr1:46089804	CCDC17	0.34	5.97	0.36	8.98e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2011503	1.000	rs2060275	chr19:19536208	G/C	cg15839431	chr19:19639596	YJEFN3	-0.49	-4.85	-0.3	2.28e-6	Bipolar disorder;
SARC	cis	rs6120849	0.754	rs7268266	chr20:33581889	T/C	cg06115741	chr20:33292138	TP53INP2	0.56	5.35	0.33	2.1e-7	Protein C levels;
SARC	cis	rs11711311	0.866	rs13313893	chr3:113400856	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	8.15	0.47	2.29e-14	IgG glycosylation;
SARC	cis	rs10782582	0.609	rs78776851	chr1:76424845	T/C	cg03433033	chr1:76189801	ACADM	-0.39	-5.13	-0.32	6e-7	Daytime sleep phenotypes;
SARC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	12.4	0.63	1.87e-27	Platelet count;
SARC	cis	rs9291683	0.510	rs4318649	chr4:10016815	T/C	cg11266682	chr4:10021025	SLC2A9	0.39	6.79	0.41	9.41e-11	Bone mineral density;
SARC	cis	rs7666738	0.546	rs6827131	chr4:98744810	C/G	cg05340658	chr4:99064831	C4orf37	0.6	7.3	0.43	4.4e-12	Colonoscopy-negative controls vs population controls;
SARC	cis	rs72781680	0.898	rs72788302	chr2:24107246	C/T	cg06627628	chr2:24431161	ITSN2	-0.71	-6.74	-0.4	1.23e-10	Lymphocyte counts;
SARC	cis	rs950169	0.580	rs2271431	chr15:85189464	A/C	cg17507749	chr15:85114479	UBE2QP1	0.58	6.72	0.4	1.4e-10	Schizophrenia;
SARC	cis	rs10911232	0.507	rs4652772	chr1:183023696	C/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.68	-9.67	-0.54	8.38e-19	Hypertriglyceridemia;
SARC	cis	rs4481887	1.000	rs6659039	chr1:248465689	C/T	cg01631408	chr1:248437212	OR2T33	-0.44	-5.62	-0.35	5.3e-8	Common traits (Other);
SARC	cis	rs7223966	1.000	rs7209758	chr17:61913621	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	7.51	0.44	1.28e-12	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs651907	0.514	rs11706494	chr3:101509475	A/T	cg12386194	chr3:101231763	SENP7	0.48	5.54	0.34	7.97e-8	Colorectal cancer;
SARC	cis	rs910316	0.967	rs119076	chr14:75572419	G/T	cg11812906	chr14:75593930	NEK9	-0.81	-12.06	-0.62	2.38e-26	Height;
SARC	cis	rs7582180	0.764	rs11693424	chr2:100925439	G/A	cg14675211	chr2:100938903	LONRF2	0.54	7.84	0.46	1.61e-13	Intelligence (multi-trait analysis);
SARC	cis	rs13191362	1.000	rs35593345	chr6:163174981	G/C	cg06582575	chr6:163149167	PACRG;PARK2	0.72	6.1	0.37	4.46e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs9341808	0.718	rs9448886	chr6:80825901	C/T	cg08355045	chr6:80787529	NA	0.34	5.5	0.34	1.02e-7	Sitting height ratio;
SARC	cis	rs9341808	1.000	rs9341808	chr6:80953257	C/A	cg08355045	chr6:80787529	NA	0.37	6.28	0.38	1.69e-9	Sitting height ratio;
SARC	cis	rs568617	0.767	rs2231884	chr11:65656564	C/T	cg00576331	chr11:65640516	EFEMP2	-0.48	-4.98	-0.31	1.23e-6	Crohn's disease;
SARC	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg06420487	chr17:61919686	SMARCD2	-0.45	-5.07	-0.32	8.09e-7	Height;
SARC	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg04772025	chr11:68637568	NA	0.48	6.0	0.37	7.65e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7766436	0.767	rs7764914	chr6:22601548	T/G	cg13666174	chr6:22585274	NA	-0.51	-7.1	-0.42	1.46e-11	Coronary artery disease;
SARC	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg11890956	chr21:40555474	PSMG1	-1.06	-15.79	-0.72	1.08e-38	Cognitive function;
SARC	cis	rs763121	0.853	rs5757234	chr22:39072686	C/T	cg21395723	chr22:39101663	GTPBP1	0.56	6.74	0.4	1.26e-10	Menopause (age at onset);
SARC	cis	rs1018836	0.608	rs2142146	chr8:91464808	T/C	cg16814680	chr8:91681699	NA	-0.69	-9.95	-0.55	1.14e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs7264396	0.635	rs6060675	chr20:34493614	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-7.65	-0.45	5.39e-13	Total cholesterol levels;
SARC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg09373136	chr17:61933544	TCAM1	-0.46	-6.23	-0.38	2.19e-9	Prudent dietary pattern;
SARC	trans	rs11634851	0.933	rs7171632	chr15:81003816	G/C	cg04669574	chr12:50297945	FAIM2	0.47	6.26	0.38	1.88e-9	Systolic blood pressure;
SARC	cis	rs818427	0.896	rs712671	chr5:112211786	T/C	cg07820702	chr5:112228657	REEP5	0.47	5.46	0.34	1.22e-7	Total body bone mineral density;
SARC	cis	rs7940866	0.801	rs2113929	chr11:130835974	G/A	cg12179176	chr11:130786555	SNX19	0.64	8.62	0.49	1.06e-15	Schizophrenia;
SARC	cis	rs909341	0.537	rs13041528	chr20:62385446	C/G	cg14758556	chr20:62440591	NA	-0.51	-5.06	-0.31	8.36e-7	Atopic dermatitis;
SARC	cis	rs7824557	1.000	rs2736371	chr8:11105529	A/G	cg21775007	chr8:11205619	TDH	-0.44	-5.15	-0.32	5.53e-7	Retinal vascular caliber;
SARC	cis	rs12079745	0.793	rs78483993	chr1:169410428	G/A	cg09363564	chr1:169337483	NME7;BLZF1	-0.79	-5.05	-0.31	8.86e-7	QT interval;
SARC	cis	rs8044995	0.563	rs3785113	chr16:68369213	T/C	cg09835421	chr16:68378352	PRMT7	-0.62	-5.62	-0.35	5.55e-8	Schizophrenia;
SARC	trans	rs11165623	0.564	rs6669908	chr1:96998261	G/A	cg10631902	chr5:14652156	NA	-0.43	-6.51	-0.39	4.61e-10	Hip circumference;Waist circumference;
SARC	cis	rs7474896	0.559	rs2753880	chr10:38173338	G/A	cg25427524	chr10:38739819	LOC399744	0.52	6.36	0.38	1.04e-9	Obesity (extreme);
SARC	cis	rs6089829	0.692	rs6122349	chr20:61664096	T/C	cg08564027	chr20:61660810	NA	0.66	8.44	0.48	3.4e-15	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs644148	0.836	rs2686770	chr19:44998773	A/G	cg15540054	chr19:45004280	ZNF180	-0.44	-4.98	-0.31	1.22e-6	Personality dimensions;
SARC	cis	rs2153535	0.580	rs7341206	chr6:8470489	T/G	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	cis	rs1881797	1.000	rs7527856	chr1:247688139	C/T	cg18198730	chr1:247681584	NA	0.47	5.22	0.32	4.02e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs11871801	0.517	rs668799	chr17:40716235	C/T	cg14558262	chr17:40713999	COASY	0.49	5.47	0.34	1.16e-7	Crohn's disease;
SARC	cis	rs12586317	0.514	rs61100068	chr14:35400232	A/T	cg26967526	chr14:35346199	BAZ1A	-0.7	-6.67	-0.4	1.89e-10	Psoriasis;
SARC	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg18404041	chr3:52824283	ITIH1	-0.39	-5.79	-0.35	2.27e-8	Bipolar disorder;
SARC	cis	rs12079745	0.793	rs78566263	chr1:169316011	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.98	-5.75	-0.35	2.79e-8	QT interval;
SARC	cis	rs9640161	0.789	rs4554381	chr7:150025567	G/A	cg21361702	chr7:150065534	REPIN1	0.49	5.28	0.33	2.96e-7	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs1008375	0.932	rs4698626	chr4:17605821	G/C	cg02297831	chr4:17616191	MED28	0.51	6.45	0.39	6.53e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.85	12.39	0.63	2.02e-27	Chronic sinus infection;
SARC	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg10523679	chr1:76189770	ACADM	-0.43	-5.28	-0.33	2.94e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs56176327	0.600	rs7628207	chr3:49754970	T/C	cg03060546	chr3:49711283	APEH	0.61	6.47	0.39	5.6e-10	Intelligence (multi-trait analysis);
SARC	trans	rs1109861	0.663	rs658469	chr10:11221366	C/T	cg25382472	chr1:47779932	STIL	-0.49	-6.32	-0.38	1.33e-9	Urinary albumin-to-creatinine ratio;
SARC	cis	rs10463554	0.963	rs34773	chr5:102450576	C/G	cg23492399	chr5:102201601	PAM	-0.47	-5.2	-0.32	4.43e-7	Parkinson's disease;
SARC	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg16606324	chr3:10149918	C3orf24	0.52	4.96	0.31	1.34e-6	Alzheimer's disease;
SARC	cis	rs7312933	0.702	rs10785333	chr12:42586470	A/G	cg19980929	chr12:42632907	YAF2	-0.43	-5.8	-0.36	2.11e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg20607798	chr8:58055168	NA	0.53	5.13	0.32	6.12e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg06873352	chr17:61820015	STRADA	0.56	7.27	0.43	5.51e-12	Prudent dietary pattern;
SARC	cis	rs41271473	0.898	rs3738073	chr1:228871693	C/T	cg16512390	chr1:228756714	NA	0.5	4.95	0.31	1.43e-6	Chronic lymphocytic leukemia;
SARC	cis	rs9291683	0.507	rs6845554	chr4:10013173	T/G	cg00071950	chr4:10020882	SLC2A9	0.32	4.89	0.31	1.86e-6	Bone mineral density;
SARC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.44	0.53	4.06e-18	Prudent dietary pattern;
SARC	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.29	0.38	1.55e-9	Bipolar disorder;
SARC	cis	rs2576037	0.899	rs2246877	chr18:44577005	A/G	cg19077165	chr18:44547161	KATNAL2	0.51	6.85	0.41	6.54e-11	Personality dimensions;
SARC	cis	rs2011503	0.941	rs55822665	chr19:19383298	C/T	cg03709012	chr19:19516395	GATAD2A	0.59	5.26	0.33	3.26e-7	Bipolar disorder;
SARC	cis	rs1008375	0.933	rs4698637	chr4:17632843	A/T	cg16339924	chr4:17578868	LAP3	0.65	8.41	0.48	4.19e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg15049968	chr18:44337910	ST8SIA5	-0.33	-5.16	-0.32	5.31e-7	Personality dimensions;
SARC	cis	rs7833790	0.963	rs28823280	chr8:82777716	G/A	cg17211192	chr8:82754475	SNX16	0.57	6.26	0.38	1.8e-9	Diastolic blood pressure;
SARC	cis	rs4243830	0.737	rs4908923	chr1:6614535	G/A	cg04093404	chr1:6614507	TAS1R1;NOL9	0.62	5.2	0.32	4.39e-7	Body mass index;
SARC	cis	rs8064299	0.636	rs9915279	chr17:72772848	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.82	11.0	0.58	6.09e-23	Monocyte count;
SARC	cis	rs483180	0.855	rs562038	chr1:120254545	G/C	cg19096424	chr1:120255104	PHGDH	0.84	10.17	0.55	2.48e-20	Macular telangiectasia type 2;
SARC	cis	rs4481887	0.741	rs28468416	chr1:248564451	G/T	cg13385794	chr1:248469461	NA	0.32	5.14	0.32	5.95e-7	Common traits (Other);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg10302505	chr8:128748092	MYC	0.48	6.3	0.38	1.49e-9	Thyroid stimulating hormone;
SARC	cis	rs6545883	0.965	rs3771261	chr2:61762161	A/G	cg15711740	chr2:61764176	XPO1	-0.43	-5.29	-0.33	2.77e-7	Tuberculosis;
SARC	trans	rs1814175	0.935	rs7479914	chr11:49661351	T/C	cg03929089	chr4:120376271	NA	-0.85	-13.36	-0.66	1.31e-30	Height;
SARC	cis	rs1707322	0.686	rs11211179	chr1:46228082	A/C	cg03146154	chr1:46216737	IPP	0.48	5.71	0.35	3.45e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg05368731	chr17:41323189	NBR1	0.77	9.47	0.53	3.29e-18	Menopause (age at onset);
SARC	cis	rs2635047	0.565	rs2668759	chr18:44693711	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	6.41	0.39	8.1e-10	Educational attainment;
SARC	cis	rs13191362	1.000	rs66594243	chr6:163169024	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.75	6.38	0.39	9.54e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs6088590	0.687	rs6088580	chr20:33285053	G/C	cg24642439	chr20:33292090	TP53INP2	0.75	10.14	0.55	2.93e-20	Coronary artery disease;
SARC	cis	rs2439831	0.681	rs498837	chr15:43608024	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.05	12.09	0.62	1.9e-26	Lung cancer in ever smokers;
SARC	cis	rs6570726	0.791	rs9390336	chr6:145896823	A/T	cg23711669	chr6:146136114	FBXO30	0.83	13.94	0.67	1.53e-32	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9486715	0.758	rs2971610	chr6:97027380	C/T	cg18709589	chr6:96969512	KIAA0776	-0.59	-7.44	-0.44	1.88e-12	Headache;
SARC	cis	rs11098499	0.955	rs6815725	chr4:120158410	C/A	cg09307838	chr4:120376055	NA	0.85	11.68	0.61	3.97e-25	Corneal astigmatism;
SARC	cis	rs11711311	1.000	rs7622515	chr3:113472538	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	8.23	0.47	1.32e-14	IgG glycosylation;
SARC	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg03060546	chr3:49711283	APEH	0.42	5.24	0.32	3.51e-7	Parkinson's disease;
SARC	cis	rs9462027	0.628	rs9462009	chr6:34716330	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.4	-5.7	-0.35	3.69e-8	Systemic lupus erythematosus;
SARC	cis	rs735396	0.770	rs2264782	chr12:121432603	C/T	cg15155738	chr12:121454335	C12orf43	0.5	5.99	0.37	7.74e-9	N-glycan levels;
SARC	cis	rs9902453	0.967	rs61240589	chr17:28449035	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	6.53	0.39	4.13e-10	Coffee consumption (cups per day);
SARC	trans	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg23043438	chr9:103115132	TEX10	0.45	6.37	0.39	9.8e-10	Immature fraction of reticulocytes;
SARC	cis	rs950027	0.620	rs1145076	chr15:45684508	G/T	cg21132104	chr15:45694354	SPATA5L1	0.53	6.75	0.4	1.19e-10	Response to fenofibrate (adiponectin levels);
SARC	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg05368731	chr17:41323189	NBR1	-0.8	-9.88	-0.54	1.84e-19	Menopause (age at onset);
SARC	cis	rs4642101	0.793	rs56082700	chr3:12833833	T/C	cg24848339	chr3:12840334	CAND2	0.33	4.99	0.31	1.19e-6	QRS complex (12-leadsum);
SARC	cis	rs6456156	0.586	rs12198816	chr6:167483546	G/A	cg23791538	chr6:167370224	RNASET2	-0.56	-7.3	-0.43	4.38e-12	Primary biliary cholangitis;
SARC	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg07061783	chr6:25882402	NA	-0.41	-4.99	-0.31	1.16e-6	Intelligence (multi-trait analysis);
SARC	cis	rs3812831	0.695	rs7983872	chr13:114944781	T/G	cg08824895	chr13:115047677	UPF3A	0.51	6.78	0.41	9.68e-11	Schizophrenia;
SARC	cis	rs6999452	0.967	rs1552108	chr8:106377021	C/T	cg12032713	chr8:106369363	ZFPM2	-0.32	-5.11	-0.32	6.86e-7	Gut microbiome composition (summer);
SARC	cis	rs853679	0.760	rs9295768	chr6:28209102	G/A	cg26450541	chr6:28235208	ZNF187	0.59	5.21	0.32	4.25e-7	Depression;
SARC	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-9.6	-0.53	1.3e-18	Chronic sinus infection;
SARC	cis	rs4128725	1.000	rs12144843	chr1:159388183	C/A	cg25076881	chr1:159409836	OR10J1	0.4	4.78	0.3	3.16e-6	Select biomarker traits;
SARC	cis	rs2624839	0.704	rs2624838	chr3:50205642	C/G	cg19755318	chr3:50243323	SLC38A3	-0.27	-4.72	-0.3	4.01e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg11890956	chr21:40555474	PSMG1	1.17	19.24	0.78	4.84e-50	Cognitive function;
SARC	cis	rs7197653	0.667	rs16957831	chr16:68378341	C/T	cg05110241	chr16:68378359	PRMT7	-0.65	-6.3	-0.38	1.44e-9	Magnesium levels;
SARC	cis	rs722599	0.562	rs2193597	chr14:75234329	G/A	cg06637938	chr14:75390232	RPS6KL1	0.42	5.2	0.32	4.32e-7	IgG glycosylation;
SARC	cis	rs1008375	0.931	rs2098151	chr4:17577490	T/C	cg16339924	chr4:17578868	LAP3	0.68	8.84	0.5	2.4e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2486288	0.656	rs8039352	chr15:45551790	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.56	-7.33	-0.43	3.7e-12	Glomerular filtration rate;
SARC	cis	rs10992471	0.597	rs11789163	chr9:95234973	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.76	-0.35	2.69e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs6580649	0.771	rs1034762	chr12:48389643	G/T	cg05342945	chr12:48394962	COL2A1	0.52	5.66	0.35	4.32e-8	Lung cancer;
SARC	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs5762813	0.566	rs16987027	chr22:29215703	G/A	cg02153584	chr22:29168773	CCDC117	0.67	6.92	0.41	4.38e-11	Hematocrit;Hemoglobin concentration;
SARC	cis	rs9486719	1.000	rs11153018	chr6:96956137	G/A	cg06623918	chr6:96969491	KIAA0776	-0.74	-8.09	-0.47	3.37e-14	Migraine;Coronary artery disease;
SARC	cis	rs7647973	0.593	rs9870755	chr3:49809841	A/G	cg03060546	chr3:49711283	APEH	0.57	6.04	0.37	6.2e-9	Menarche (age at onset);
SARC	cis	rs35110281	0.774	rs1003280	chr21:44997322	A/G	cg01579765	chr21:45077557	HSF2BP	-0.31	-5.24	-0.32	3.67e-7	Mean corpuscular volume;
SARC	cis	rs8114671	0.527	rs6060112	chr20:33489276	A/T	cg24642439	chr20:33292090	TP53INP2	0.49	5.87	0.36	1.51e-8	Height;
SARC	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg11062466	chr8:58055876	NA	0.53	4.98	0.31	1.25e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs7539409	0.651	rs969724	chr1:84300712	T/G	cg10977910	chr1:84465055	TTLL7	0.63	5.99	0.37	7.82e-9	Alzheimer's disease;
SARC	cis	rs30380	0.632	rs26500	chr5:96133712	A/C	cg16492584	chr5:96139282	ERAP1	-0.48	-5.5	-0.34	1.01e-7	Cerebrospinal fluid biomarker levels;
SARC	cis	rs16976116	0.901	rs28864456	chr15:55503092	T/C	cg17854078	chr15:55489399	RSL24D1	0.66	6.53	0.39	4.18e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs11676348	0.811	rs4674255	chr2:218987325	C/T	cg00012203	chr2:219082015	ARPC2	-0.54	-7.33	-0.43	3.78e-12	Ulcerative colitis;
SARC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg14159672	chr1:205819179	PM20D1	0.68	10.36	0.56	6.17e-21	Menarche (age at onset);
SARC	cis	rs6121246	0.909	rs6060929	chr20:30345914	C/T	cg13852791	chr20:30311386	BCL2L1	0.85	9.18	0.52	2.48e-17	Mean corpuscular hemoglobin;
SARC	cis	rs8031584	0.958	rs34294266	chr15:31246840	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.44	-4.85	-0.3	2.27e-6	Huntington's disease progression;
SARC	cis	rs11997175	0.625	rs4268088	chr8:33599343	A/T	ch.8.33884649F	chr8:33765107	NA	0.48	6.05	0.37	5.66e-9	Body mass index;
SARC	cis	rs6087990	0.735	rs2424920	chr20:31385452	T/C	cg13636640	chr20:31349939	DNMT3B	0.78	12.03	0.62	3.06e-26	Ulcerative colitis;
SARC	cis	rs787274	0.764	rs4979157	chr9:115571791	T/C	cg13803584	chr9:115635662	SNX30	-0.83	-5.06	-0.31	8.34e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs2075371	1.000	rs2544210	chr7:133971535	C/T	cg00033643	chr7:134001901	SLC35B4	0.4	4.97	0.31	1.3e-6	Mean platelet volume;
SARC	trans	rs11098499	0.863	rs7699064	chr4:120428309	A/G	cg25214090	chr10:38739885	LOC399744	-0.55	-6.86	-0.41	6.26e-11	Corneal astigmatism;
SARC	cis	rs6952809	0.516	rs6952959	chr7:2440722	C/T	cg05083358	chr7:2394359	EIF3B	-0.57	-5.24	-0.32	3.57e-7	Multiple sclerosis;
SARC	cis	rs9549260	0.753	rs4943794	chr13:41173408	G/C	cg21288729	chr13:41239152	FOXO1	0.57	5.53	0.34	8.54e-8	Red blood cell count;
SARC	cis	rs7607369	0.580	rs7594289	chr2:219652286	A/G	cg02176678	chr2:219576539	TTLL4	-0.51	-8.32	-0.48	7.33e-15	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs7647973	1.000	rs3870339	chr3:49536863	T/A	cg07636037	chr3:49044803	WDR6	0.8	9.36	0.52	6.83e-18	Menarche (age at onset);
SARC	cis	rs7945705	0.869	rs11042154	chr11:9029700	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.45	-6.16	-0.37	3.15e-9	Hemoglobin concentration;
SARC	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg07701084	chr6:150067640	NUP43	0.41	5.5	0.34	9.85e-8	Lung cancer;
SARC	cis	rs12950390	0.814	rs11659069	chr17:45834275	G/T	cg24803719	chr17:45855879	NA	-0.49	-7.98	-0.46	6.41e-14	IgG glycosylation;
SARC	cis	rs2204008	0.678	rs61929520	chr12:38446800	T/C	cg26384229	chr12:38710491	ALG10B	-0.55	-6.9	-0.41	4.81e-11	Bladder cancer;
SARC	cis	rs2153535	0.580	rs7747306	chr6:8453663	C/G	cg23788917	chr6:8435910	SLC35B3	-0.65	-8.61	-0.49	1.13e-15	Motion sickness;
SARC	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg08859206	chr1:53392774	SCP2	-0.42	-6.0	-0.37	7.63e-9	Monocyte count;
SARC	cis	rs1336900	0.513	rs56253522	chr1:150614869	C/A	cg13175981	chr1:150552382	MCL1	-0.46	-5.58	-0.34	6.59e-8	Blood protein levels;
SARC	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg03060546	chr3:49711283	APEH	0.44	5.55	0.34	7.66e-8	Parkinson's disease;
SARC	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg26335602	chr6:28129616	ZNF389	0.53	5.95	0.36	9.59e-9	Depression;
SARC	trans	rs9329221	0.741	rs9650622	chr8:9804292	G/T	cg06636001	chr8:8085503	FLJ10661	-0.69	-9.29	-0.52	1.13e-17	Neuroticism;
SARC	cis	rs9398803	0.865	rs7738135	chr6:126829981	G/A	cg19875578	chr6:126661172	C6orf173	0.63	8.53	0.49	1.82e-15	Male-pattern baldness;
SARC	trans	rs11098499	0.909	rs28884220	chr4:120307211	A/G	cg25214090	chr10:38739885	LOC399744	0.54	7.08	0.42	1.66e-11	Corneal astigmatism;
SARC	cis	rs926392	0.896	rs742276	chr20:37679849	C/T	cg16355469	chr20:37678765	NA	0.57	7.35	0.43	3.33e-12	Dialysis-related mortality;
SARC	cis	rs11758351	1.000	rs74363821	chr6:26189524	G/C	cg23601095	chr6:26197514	HIST1H3D	0.62	5.42	0.33	1.45e-7	Gout;Renal underexcretion gout;
SARC	cis	rs7011049	0.908	rs113206545	chr8:53858648	A/G	cg26025543	chr8:53854495	NA	0.61	5.37	0.33	1.87e-7	Systolic blood pressure;
SARC	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	7.3	0.43	4.48e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9815354	0.672	rs12107296	chr3:41892503	C/G	cg03022575	chr3:42003672	ULK4	0.56	5.29	0.33	2.86e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.69	8.88	0.5	1.86e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1018836	0.632	rs6995399	chr8:91481629	T/C	cg16814680	chr8:91681699	NA	-0.69	-10.45	-0.56	3.21e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs36051895	0.625	rs11792531	chr9:5152203	T/C	cg02405213	chr9:5042618	JAK2	-0.45	-5.07	-0.32	7.93e-7	Pediatric autoimmune diseases;
SARC	cis	rs10911232	0.507	rs4651137	chr1:182994300	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.57	0.57	1.37e-21	Hypertriglyceridemia;
SARC	cis	rs7937682	0.889	rs490199	chr11:111487890	A/G	cg22437258	chr11:111473054	SIK2	0.75	10.19	0.56	2.17e-20	Primary sclerosing cholangitis;
SARC	cis	rs1042058	0.565	rs650110	chr10:30753132	A/G	cg25182066	chr10:30743637	MAP3K8	0.45	6.4	0.39	8.3e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs11098499	0.865	rs9994730	chr4:120381564	A/C	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	cis	rs2070488	0.662	rs6599203	chr3:38487802	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.64	8.26	0.48	1.09e-14	Electrocardiographic conduction measures;
SARC	cis	rs9790314	0.846	rs7636941	chr3:160993928	A/G	cg04691961	chr3:161091175	C3orf57	-0.64	-8.7	-0.5	6.2e-16	Morning vs. evening chronotype;
SARC	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg06074448	chr4:187884817	NA	0.4	5.48	0.34	1.09e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7769051	0.803	rs59740783	chr6:133231711	G/A	cg22852734	chr6:133119734	C6orf192	0.88	7.51	0.44	1.23e-12	Type 2 diabetes nephropathy;
SARC	cis	rs9905704	0.647	rs2286299	chr17:57043367	T/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.39	-4.77	-0.3	3.23e-6	Testicular germ cell tumor;
SARC	cis	rs6815814	0.950	rs5743794	chr4:38832727	C/T	cg06935464	chr4:38784597	TLR10	0.51	4.91	0.31	1.73e-6	Breast cancer;
SARC	cis	rs7336332	0.598	rs74183666	chr13:28007765	A/T	cg01674679	chr13:27998804	GTF3A	-0.57	-5.3	-0.33	2.71e-7	Weight;
SARC	cis	rs9868809	0.505	rs73080312	chr3:48737847	C/T	cg07636037	chr3:49044803	WDR6	-0.7	-5.23	-0.32	3.73e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs11792861	0.926	rs1044905	chr9:111781495	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.69	7.8	0.46	2.04e-13	Menarche (age at onset);
SARC	cis	rs986417	0.892	rs11628559	chr14:61038153	G/C	cg27398547	chr14:60952738	C14orf39	0.87	8.04	0.47	4.42e-14	Gut microbiota (bacterial taxa);
SARC	cis	rs57920188	0.535	rs10915664	chr1:4093700	G/A	cg20703997	chr1:4087676	NA	0.51	5.35	0.33	2.09e-7	Interleukin-17 levels;
SARC	cis	rs981844	0.712	rs1012029	chr4:154749233	C/T	cg14289246	chr4:154710475	SFRP2	-0.45	-5.36	-0.33	1.96e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg00933542	chr6:150070202	PCMT1	0.33	5.74	0.35	2.95e-8	Lung cancer;
SARC	cis	rs1983170	0.673	rs11164934	chr1:92015267	C/T	cg25838465	chr1:92012736	NA	0.53	5.0	0.31	1.14e-6	Eosinophil percentage of white cells;
SARC	cis	rs4268898	0.662	rs2303291	chr2:24431184	C/T	cg06627628	chr2:24431161	ITSN2	-0.84	-10.13	-0.55	3.29e-20	Asthma;
SARC	cis	rs6500395	1.000	rs8052073	chr16:48682696	T/C	cg04672837	chr16:48644449	N4BP1	0.46	6.28	0.38	1.65e-9	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs17270561	0.609	rs4712965	chr6:25742022	G/T	cg17691542	chr6:26056736	HIST1H1C	0.61	7.36	0.43	3.06e-12	Iron status biomarkers;
SARC	cis	rs73242632	1.000	rs73242623	chr4:57840543	C/T	cg20415529	chr4:57845134	POLR2B;C4orf14	1.06	6.44	0.39	6.67e-10	Congenital heart disease (maternal effect);
SARC	cis	rs9398803	0.616	rs6909149	chr6:126631091	A/T	cg19875578	chr6:126661172	C6orf173	0.47	6.37	0.39	1e-9	Male-pattern baldness;
SARC	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.71	6.87	0.41	5.8200000000000003e-11	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs1568889	1.000	rs12808162	chr11:28067027	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	10.33	0.56	7.9e-21	Bipolar disorder;
SARC	cis	rs10463554	0.927	rs34776	chr5:102451794	C/G	cg23492399	chr5:102201601	PAM	-0.52	-5.72	-0.35	3.2e-8	Parkinson's disease;
SARC	cis	rs7927771	0.929	rs66749409	chr11:47568074	C/T	cg05585544	chr11:47624801	NA	-0.36	-4.85	-0.3	2.27e-6	Subjective well-being;
SARC	cis	rs10504229	0.520	rs55967509	chr8:57992448	A/G	cg08280861	chr8:58055591	NA	0.57	4.89	0.31	1.84e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs698813	0.604	rs768007	chr2:44487486	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.68	0.35	4.07e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs6708331	1.000	rs6708331	chr2:70368923	C/T	cg16435808	chr2:70475954	TIA1	0.49	5.23	0.32	3.74e-7	Obesity-related traits;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg12603043	chr19:48216450	EHD2	0.51	6.34	0.38	1.17e-9	Breast cancer;
SARC	cis	rs11792861	0.591	rs10979632	chr9:111732140	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.76	9.74	0.54	4.86e-19	Menarche (age at onset);
SARC	cis	rs17381785	0.545	rs1494947	chr4:14969983	T/G	cg12377275	chr4:15005593	CPEB2	0.86	12.63	0.64	3.23e-28	Urate levels in overweight individuals;
SARC	cis	rs12995849	0.905	rs6712210	chr2:106449251	G/A	cg16077055	chr2:106428750	NCK2	0.26	4.76	0.3	3.41e-6	Addiction;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg19289870	chr15:77154861	SCAPER	0.5	7.37	0.43	3e-12	Thyroid stimulating hormone;
SARC	cis	rs9902453	1.000	rs4465649	chr17:28394747	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.53	-6.91	-0.41	4.72e-11	Coffee consumption (cups per day);
SARC	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg02018176	chr4:1364513	KIAA1530	0.61	9.38	0.52	6.02e-18	Longevity;
SARC	cis	rs11719291	0.584	rs13080725	chr3:49076092	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.68	-5.76	-0.35	2.62e-8	Cognitive function;
SARC	cis	rs193541	0.632	rs152038	chr5:122195846	G/A	cg19412675	chr5:122181750	SNX24	0.51	6.63	0.4	2.27e-10	Glucose homeostasis traits;
SARC	cis	rs7818345	0.935	rs12542575	chr8:19286558	A/T	cg11303988	chr8:19266685	CSGALNACT1	0.42	5.71	0.35	3.44e-8	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs854765	0.575	rs2955357	chr17:17946401	T/C	cg05444541	chr17:17804740	TOM1L2	0.29	4.75	0.3	3.62e-6	Total body bone mineral density;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg23059689	chr13:111288257	CARKD	-0.71	-5.62	-0.35	5.54e-8	Obesity-related traits;
SARC	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-8.11	-0.47	2.87e-14	Chronic sinus infection;
SARC	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg12564285	chr5:131593104	PDLIM4	0.4	5.88	0.36	1.43e-8	Acylcarnitine levels;
SARC	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	11.64	0.61	5.7e-25	Alzheimer's disease;
SARC	cis	rs950169	0.881	rs150965	chr15:85080527	T/G	cg24253500	chr15:84953950	NA	0.38	5.43	0.34	1.42e-7	Schizophrenia;
SARC	cis	rs709400	0.628	rs72708854	chr14:103864885	T/C	cg26031613	chr14:104095156	KLC1	0.81	11.65	0.61	5.24e-25	Body mass index;
SARC	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg11987759	chr7:65425863	GUSB	-0.48	-6.54	-0.39	3.9e-10	Aortic root size;
SARC	cis	rs9487051	0.872	rs6924815	chr6:109612344	A/G	cg01475377	chr6:109611718	NA	-0.41	-5.9	-0.36	1.25e-8	Reticulocyte fraction of red cells;
SARC	cis	rs7662987	0.517	rs2602883	chr4:100040914	A/T	cg13256891	chr4:100009986	ADH5	0.68	8.6	0.49	1.22e-15	Smoking initiation;
SARC	cis	rs9303280	0.868	rs11650661	chr17:38026286	A/T	cg20243544	chr17:37824526	PNMT	0.44	5.89	0.36	1.35e-8	Self-reported allergy;
SARC	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg25036284	chr2:26402008	FAM59B	0.46	5.57	0.34	6.86e-8	Gut microbiome composition (summer);
SARC	cis	rs9513627	0.920	rs7334943	chr13:100121287	C/G	cg25919922	chr13:100150906	NA	0.63	4.73	0.3	3.86e-6	Obesity-related traits;
SARC	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg24829409	chr8:58192753	C8orf71	-0.64	-5.98	-0.36	8.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs459571	0.839	rs10993895	chr9:136887726	C/T	cg13789015	chr9:136890014	NCRNA00094	-0.62	-9.02	-0.51	7.03e-17	Platelet distribution width;
SARC	cis	rs240764	0.697	rs9485411	chr6:101261352	A/C	cg09795085	chr6:101329169	ASCC3	0.39	4.84	0.3	2.36e-6	Neuroticism;
SARC	cis	rs372883	0.530	rs2832305	chr21:30752964	G/A	cg08807101	chr21:30365312	RNF160	0.57	7.09	0.42	1.61e-11	Pancreatic cancer;
SARC	cis	rs1062177	1.000	rs41494545	chr5:151235094	A/G	cg00977110	chr5:151150581	G3BP1	-0.57	-5.57	-0.34	6.91e-8	Preschool internalizing problems;
SARC	cis	rs735539	0.593	rs4463942	chr13:21367434	C/T	cg16922012	chr13:21400325	XPO4	-0.39	-5.56	-0.34	7.31e-8	Dental caries;
SARC	cis	rs7666738	0.830	rs6831588	chr4:98977356	T/G	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs60871478	0.588	rs73043546	chr7:857513	C/G	cg05535760	chr7:792225	HEATR2	-0.8	-7.34	-0.43	3.54e-12	Cerebrospinal P-tau181p levels;
SARC	cis	rs282587	0.597	rs1756075	chr13:113396211	T/C	cg02820901	chr13:113351484	ATP11A	-0.53	-5.08	-0.32	7.67e-7	Glycated hemoglobin levels;
SARC	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg05890377	chr2:74357713	NA	0.61	7.08	0.42	1.7e-11	Gestational age at birth (maternal effect);
SARC	cis	rs7712401	0.601	rs246315	chr5:122266438	C/T	cg19412675	chr5:122181750	SNX24	0.4	5.19	0.32	4.65e-7	Mean platelet volume;
SARC	cis	rs10870270	1.000	rs10159746	chr10:133742677	C/T	cg26149184	chr10:133730230	NA	0.47	5.39	0.33	1.68e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs1318878	0.565	rs11831965	chr12:15491823	T/G	cg08258403	chr12:15378311	NA	0.48	6.65	0.4	2.05e-10	Intelligence (multi-trait analysis);
SARC	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg11764359	chr7:65958608	NA	0.88	12.63	0.64	3.42e-28	Aortic root size;
SARC	cis	rs2120019	1.000	rs8036197	chr15:75370232	T/C	cg00629941	chr15:75287862	SCAMP5	-0.6	-7.27	-0.43	5.46e-12	Blood trace element (Zn levels);
SARC	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg06212747	chr3:49208901	KLHDC8B	0.68	8.89	0.5	1.74e-16	Parkinson's disease;
SARC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg09373136	chr17:61933544	TCAM1	-0.43	-5.96	-0.36	9.44e-9	Prudent dietary pattern;
SARC	trans	rs10838798	0.504	rs11039632	chr11:48297280	C/T	cg15704280	chr7:45808275	SEPT13	-0.48	-6.56	-0.39	3.45e-10	Height;
SARC	cis	rs2916247	0.954	rs1484564	chr8:93122508	G/A	cg10183463	chr8:93005414	RUNX1T1	0.55	5.86	0.36	1.56e-8	Intelligence (multi-trait analysis);
SARC	cis	rs55883249	1.000	rs56372340	chr2:9741536	A/G	cg23886495	chr2:9695866	ADAM17	0.66	6.73	0.4	1.33e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg04274916	chr22:41252959	ST13;XPNPEP3	0.52	6.4	0.39	8.23e-10	Lung adenocarcinoma;
SARC	cis	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg07636037	chr3:49044803	WDR6	0.63	8.4	0.48	4.49e-15	Resting heart rate;
SARC	cis	rs7818345	0.967	rs11787230	chr8:19280982	C/G	cg11303988	chr8:19266685	CSGALNACT1	0.42	5.57	0.34	6.97e-8	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.48	-6.06	-0.37	5.38e-9	Lymphocyte counts;
SARC	cis	rs2191566	0.576	rs396786	chr19:44494351	A/G	cg20607764	chr19:44506953	ZNF230	0.48	5.4	0.33	1.66e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs7106204	0.748	rs2403888	chr11:24208071	C/G	ch.11.24196551F	chr11:24239977	NA	-0.55	-5.77	-0.35	2.48e-8	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs2463822	0.583	rs72919477	chr11:62042403	G/C	cg06239285	chr11:62104954	ASRGL1	-0.85	-7.9	-0.46	1.08e-13	Chronic obstructive pulmonary disease-related biomarkers;
SARC	trans	rs13098911	0.540	rs35516580	chr3:46107498	A/G	cg03842258	chr15:67135396	NA	0.79	6.41	0.39	8.07e-10	Celiac disease;
SARC	cis	rs477692	0.699	rs509017	chr10:131367174	T/G	cg05714579	chr10:131428358	MGMT	0.56	7.31	0.43	4.19e-12	Response to temozolomide;
SARC	cis	rs11098499	0.954	rs4309825	chr4:120314881	C/T	cg09307838	chr4:120376055	NA	-0.93	-12.79	-0.64	9.92e-29	Corneal astigmatism;
SARC	cis	rs501120	0.925	rs494045	chr10:44773498	C/T	cg09554077	chr10:44749378	NA	0.4	5.03	0.31	1e-6	Coronary artery disease;Coronary heart disease;
SARC	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg22535103	chr8:58192502	C8orf71	-0.73	-7.26	-0.43	5.73e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg16405210	chr4:1374714	KIAA1530	0.48	5.73	0.35	3.08e-8	Obesity-related traits;
SARC	cis	rs1697139	0.583	rs11739587	chr5:66540481	A/C	cg11553311	chr5:66541588	NA	-0.31	-4.99	-0.31	1.2e-6	Breast cancer;
SARC	cis	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg03060546	chr3:49711283	APEH	0.75	11.17	0.59	1.7e-23	Resting heart rate;
SARC	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-15.51	-0.71	9.76e-38	Chronic sinus infection;
SARC	cis	rs6674176	0.660	rs3791112	chr1:44379248	T/G	cg12908607	chr1:44402522	ARTN	-0.42	-7.35	-0.43	3.41e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg21782813	chr7:2030301	MAD1L1	0.39	6.14	0.37	3.58e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs6963495	0.719	rs73190172	chr7:105161210	T/C	cg13798780	chr7:105162888	PUS7	0.6	5.45	0.34	1.31e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs11644362	1.000	rs11644362	chr16:12994097	T/C	cg06890432	chr16:12997467	SHISA9	-0.54	-7.05	-0.42	1.97e-11	Positive affect;Subjective well-being;
SARC	cis	rs2652834	0.851	rs11071721	chr15:63350218	T/C	cg05507819	chr15:63340323	TPM1	0.6	6.06	0.37	5.49e-9	HDL cholesterol;
SARC	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg11952622	chr19:58962976	ZNF324B	0.53	6.65	0.4	2.05e-10	Uric acid clearance;
SARC	cis	rs7818688	0.697	rs57890591	chr8:95983130	G/A	cg13393036	chr8:95962371	TP53INP1	0.42	5.1	0.32	7.06e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	trans	rs9693857	1.000	rs9693857	chr8:9267117	C/T	cg06636001	chr8:8085503	FLJ10661	-0.6	-7.63	-0.45	5.89e-13	Systolic blood pressure;
SARC	cis	rs7223966	1.000	rs55868506	chr17:61851686	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-5.76	-0.35	2.6e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1451375	0.572	rs896309	chr7:50545022	A/G	cg14593290	chr7:50529359	DDC	-0.44	-4.84	-0.3	2.36e-6	Malaria;
SARC	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg08219700	chr8:58056026	NA	0.62	6.52	0.39	4.28e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg00684032	chr4:1343700	KIAA1530	0.39	5.76	0.35	2.71e-8	Obesity-related traits;
SARC	trans	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.73	10.46	0.57	2.95e-21	Intelligence (multi-trait analysis);
SARC	cis	rs2153535	0.580	rs7763190	chr6:8484197	G/A	cg21535247	chr6:8435926	SLC35B3	0.55	6.88	0.41	5.45e-11	Motion sickness;
SARC	cis	rs367943	1.000	rs348960	chr5:112820651	C/A	cg12552261	chr5:112820674	MCC	0.45	5.19	0.32	4.65e-7	Type 2 diabetes;
SARC	trans	rs1814175	0.765	rs1721990	chr11:49912154	G/C	cg15704280	chr7:45808275	SEPT13	-0.98	-18.28	-0.77	6.55e-47	Height;
SARC	cis	rs10752881	0.935	rs10911197	chr1:182995399	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.57	0.57	1.37e-21	Colorectal cancer;
SARC	cis	rs9818758	0.607	rs9847839	chr3:49289003	T/C	cg00383909	chr3:49044727	WDR6	0.67	5.91	0.36	1.24e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs9612	1.000	rs61002661	chr19:44269032	T/A	cg08581076	chr19:44259116	C19orf61	0.69	8.46	0.48	3e-15	Exhaled nitric oxide output;
SARC	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg05368731	chr17:41323189	NBR1	0.77	9.24	0.52	1.58e-17	Menopause (age at onset);
SARC	cis	rs2439831	1.000	rs1814538	chr15:43759774	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.77	-8.34	-0.48	6.63e-15	Lung cancer in ever smokers;
SARC	cis	rs7552404	0.961	rs211710	chr1:76109038	G/A	cg22875332	chr1:76189707	ACADM	-0.44	-5.89	-0.36	1.32e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs11711311	1.000	rs9855613	chr3:113448455	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	8.38	0.48	5.09e-15	IgG glycosylation;
SARC	cis	rs9303401	0.659	rs35103007	chr17:56900738	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	11.58	0.6	8.42e-25	Cognitive test performance;
SARC	cis	rs950776	0.752	rs62010328	chr15:78894971	C/T	cg17108064	chr15:78857060	CHRNA5	0.3	4.9	0.31	1.81e-6	Sudden cardiac arrest;
SARC	cis	rs2073300	0.609	rs6137927	chr20:23372513	A/G	cg12062639	chr20:23401060	NAPB	0.95	6.5	0.39	4.74e-10	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs751728	1.000	rs4713682	chr6:33757047	G/C	cg25922239	chr6:33757077	LEMD2	0.78	10.49	0.57	2.5e-21	Crohn's disease;
SARC	cis	rs35110281	0.633	rs4818860	chr21:45119617	C/T	cg04455712	chr21:45112962	RRP1B	0.33	4.76	0.3	3.35e-6	Mean corpuscular volume;
SARC	cis	rs4243830	0.850	rs2063806	chr1:6610382	C/T	cg04093404	chr1:6614507	TAS1R1;NOL9	0.62	5.23	0.32	3.76e-7	Body mass index;
SARC	cis	rs12586317	0.547	rs4982236	chr14:35468046	C/G	cg26967526	chr14:35346199	BAZ1A	-0.57	-5.71	-0.35	3.4e-8	Psoriasis;
SARC	cis	rs2370759	1.000	rs75984055	chr10:32591276	T/C	cg18270830	chr10:32634957	EPC1	0.6	5.37	0.33	1.88e-7	Sexual dysfunction (female);
SARC	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg24209194	chr3:40518798	ZNF619	0.66	8.45	0.48	3.17e-15	Renal cell carcinoma;
SARC	cis	rs13040088	0.580	rs11905041	chr20:61563408	C/T	cg23096297	chr20:61557774	DIDO1	0.64	6.95	0.41	3.59e-11	Menopause (age at onset);
SARC	cis	rs730775	0.505	rs324137	chr6:44273546	G/T	cg21130236	chr6:44246755	TMEM151B	0.25	4.73	0.3	3.92e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg01238044	chr22:24384105	GSTT1	0.64	7.06	0.42	1.92e-11	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs453301	0.686	rs1045527	chr8:8890041	A/G	cg08975724	chr8:8085496	FLJ10661	-0.47	-6.11	-0.37	4.23e-9	Joint mobility (Beighton score);
SARC	cis	rs6604026	0.656	rs2811589	chr1:93367643	C/T	cg17283838	chr1:93427260	FAM69A	-0.42	-4.75	-0.3	3.59e-6	Multiple sclerosis;
SARC	cis	rs17401966	0.838	rs4333852	chr1:10387704	A/T	cg15208524	chr1:10270712	KIF1B	-0.46	-5.45	-0.34	1.3e-7	Hepatocellular carcinoma;
SARC	cis	rs7223966	1.000	rs9747164	chr17:61864787	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.47	4.82	0.3	2.54e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7766436	0.961	rs6922960	chr6:22570189	T/C	cg13666174	chr6:22585274	NA	-0.56	-7.09	-0.42	1.55e-11	Coronary artery disease;
SARC	cis	rs4595586	0.545	rs1607042	chr12:39368028	A/G	cg13010199	chr12:38710504	ALG10B	0.4	4.75	0.3	3.57e-6	Morning vs. evening chronotype;
SARC	cis	rs9790314	0.740	rs4856767	chr3:161004379	C/T	cg04691961	chr3:161091175	C3orf57	-0.65	-8.8	-0.5	3.1e-16	Morning vs. evening chronotype;
SARC	cis	rs12579753	1.000	rs17748942	chr12:82170478	G/A	cg07988820	chr12:82153109	PPFIA2	-0.58	-6.74	-0.4	1.26e-10	Resting heart rate;
SARC	cis	rs8031584	0.918	rs61997139	chr15:31273602	C/G	cg19680485	chr15:31195859	MTMR15	-0.51	-5.97	-0.36	8.87e-9	Huntington's disease progression;
SARC	cis	rs9487051	0.714	rs6930733	chr6:109631587	T/C	cg01475377	chr6:109611718	NA	-0.37	-5.35	-0.33	2.1e-7	Reticulocyte fraction of red cells;
SARC	cis	rs7044106	0.791	rs4837793	chr9:123483621	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.37	0.52	6.57e-18	Hip circumference adjusted for BMI;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg14430886	chr7:44646103	OGDH	-0.51	-6.51	-0.39	4.55e-10	Schizophrenia;
SARC	cis	rs12477438	0.765	rs10181422	chr2:99558970	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-9.7	-0.54	6.85e-19	Chronic sinus infection;
SARC	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg13393036	chr8:95962371	TP53INP1	-0.32	-5.55	-0.34	7.7e-8	Type 2 diabetes;
SARC	cis	rs986417	0.901	rs12886086	chr14:61042091	A/G	cg27398547	chr14:60952738	C14orf39	0.89	8.2	0.47	1.59e-14	Gut microbiota (bacterial taxa);
SARC	cis	rs72772090	0.634	rs72773906	chr5:96092274	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.62	-5.16	-0.32	5.27e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs6582630	0.503	rs4882293	chr12:38388200	G/C	cg14851346	chr12:38532713	NA	-0.48	-5.78	-0.35	2.36e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs13064447	0.967	rs9861125	chr3:12765012	G/A	cg05775895	chr3:12838266	CAND2	0.39	5.11	0.32	6.87e-7	Major depression and alcohol dependence;
SARC	cis	rs7223966	1.000	rs8069687	chr17:61883023	C/T	cg00588841	chr17:61851480	DDX42;CCDC47	0.64	6.94	0.41	3.93e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs10851411	0.738	rs60569090	chr15:42746801	T/G	cg21293051	chr15:42870591	STARD9	0.45	5.03	0.31	9.61e-7	Glucose homeostasis traits;
SARC	cis	rs11997175	0.624	rs4733179	chr8:33692223	T/G	ch.8.33884649F	chr8:33765107	NA	0.63	8.57	0.49	1.4e-15	Body mass index;
SARC	cis	rs735396	0.595	rs2258287	chr12:121454313	G/T	cg15155738	chr12:121454335	C12orf43	0.52	6.83	0.41	7.16e-11	N-glycan levels;
SARC	cis	rs748404	0.578	rs552701	chr15:43613810	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	6.87	0.41	5.71e-11	Lung cancer;
SARC	cis	rs734999	0.545	rs41300092	chr1:2537838	C/T	cg20673091	chr1:2541236	MMEL1	0.34	5.13	0.32	6.15e-7	Ulcerative colitis;
SARC	cis	rs3820928	0.874	rs13423046	chr2:227901805	G/T	cg05526886	chr2:227700861	RHBDD1	-0.5	-5.95	-0.36	9.58e-9	Pulmonary function;
SARC	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg20607798	chr8:58055168	NA	0.6	5.33	0.33	2.29e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7264396	0.563	rs2425119	chr20:34324216	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-7.01	-0.42	2.5e-11	Total cholesterol levels;
SARC	cis	rs4561483	0.801	rs33631	chr16:11995387	G/C	cg08843971	chr16:11963173	GSPT1	-0.41	-4.99	-0.31	1.17e-6	Testicular germ cell tumor;
SARC	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg12463550	chr7:65579703	CRCP	0.66	5.06	0.31	8.64e-7	Diabetic kidney disease;
SARC	cis	rs7582180	0.652	rs11678158	chr2:100932297	T/C	cg14675211	chr2:100938903	LONRF2	0.51	7.58	0.44	7.91e-13	Intelligence (multi-trait analysis);
SARC	cis	rs17376456	0.825	rs13182631	chr5:93115701	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.7	6.39	0.39	8.96e-10	Diabetic retinopathy;
SARC	cis	rs7772486	0.790	rs2254257	chr6:146203724	C/T	cg05347473	chr6:146136440	FBXO30	0.49	6.76	0.4	1.12e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1018836	0.923	rs2105965	chr8:91537690	T/C	cg16814680	chr8:91681699	NA	-0.78	-12.42	-0.63	1.56e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs1045529	0.524	rs34251783	chr8:8891376	T/C	cg11608241	chr8:8085544	FLJ10661	-0.44	-5.53	-0.34	8.73e-8	Myopia;Myopia (pathological);
SARC	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg24250549	chr1:154909240	PMVK	0.75	10.12	0.55	3.55e-20	Prostate cancer;
SARC	cis	rs9326248	0.559	rs10892052	chr11:116834313	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.6	7.72	0.45	3.52e-13	Blood protein levels;
SARC	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg12463550	chr7:65579703	CRCP	-0.5	-5.56	-0.34	7.28e-8	Aortic root size;
SARC	cis	rs12579753	1.000	rs2400979	chr12:82197353	T/C	cg07988820	chr12:82153109	PPFIA2	-0.55	-6.43	-0.39	7e-10	Resting heart rate;
SARC	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg20965017	chr5:231967	SDHA	-0.55	-5.26	-0.33	3.23e-7	Breast cancer;
SARC	cis	rs12682352	0.579	rs7006589	chr8:8668486	A/G	cg06636001	chr8:8085503	FLJ10661	0.55	7.19	0.43	8.62e-12	Neuroticism;
SARC	cis	rs2120243	0.539	rs6441126	chr3:157095016	C/T	cg24825693	chr3:157122686	VEPH1	-0.45	-6.11	-0.37	4.09e-9	Hepatocellular carcinoma in hepatitis B infection;
SARC	trans	rs12310956	0.532	rs1589902	chr12:33989289	G/A	cg13010199	chr12:38710504	ALG10B	0.65	8.68	0.49	7.12e-16	Morning vs. evening chronotype;
SARC	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg03433033	chr1:76189801	ACADM	0.49	6.14	0.37	3.56e-9	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6815814	0.950	rs56408159	chr4:38812116	T/A	cg09316306	chr4:38807337	TLR1	0.5	5.22	0.32	3.93e-7	Breast cancer;
SARC	cis	rs6089584	0.566	rs6061401	chr20:60607482	G/A	cg13770153	chr20:60521292	NA	-0.39	-5.63	-0.35	5.06e-8	Body mass index;
SARC	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg13628971	chr7:2884303	GNA12	0.41	5.02	0.31	1.03e-6	Height;
SARC	cis	rs2072499	0.966	rs2842869	chr1:156160696	A/G	cg24450063	chr1:156163899	SLC25A44	1.18	21.59	0.82	1.66e-57	Testicular germ cell tumor;
SARC	cis	rs2073300	0.609	rs6137951	chr20:23429459	T/C	cg12062639	chr20:23401060	NAPB	0.9	5.6	0.34	5.98e-8	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs1580019	0.563	rs13225132	chr7:32800975	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.5	6.2	0.38	2.52e-9	Cognitive ability;
SARC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg12419862	chr22:24373484	LOC391322	-0.82	-11.63	-0.61	5.94e-25	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9309711	0.737	rs9284795	chr2:3492065	G/A	cg10845886	chr2:3471009	TTC15	-0.53	-6.46	-0.39	6.02e-10	Neurofibrillary tangles;
SARC	cis	rs10754283	0.840	rs6428560	chr1:90102462	A/T	cg21401794	chr1:90099060	LRRC8C	0.62	8.57	0.49	1.45e-15	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs787274	0.850	rs10739376	chr9:115616775	A/T	cg13803584	chr9:115635662	SNX30	-0.83	-5.23	-0.32	3.76e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs7786808	0.741	rs4909222	chr7:158228095	C/T	cg09998033	chr7:158218633	PTPRN2	0.34	5.48	0.34	1.09e-7	Obesity-related traits;
SARC	cis	rs367615	0.679	rs10070786	chr5:108815081	T/G	cg17395555	chr5:108820864	NA	0.5	7.1	0.42	1.49e-11	Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs9916302	0.904	rs10432031	chr17:37397852	G/A	cg07936489	chr17:37558343	FBXL20	-0.68	-8.97	-0.51	1.02e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.7	6.78	0.41	9.97e-11	Platelet count;
SARC	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg04317338	chr11:64019027	PLCB3	0.58	6.6	0.4	2.68e-10	Platelet count;
SARC	cis	rs4660306	0.672	rs534534	chr1:46024701	G/A	cg24296786	chr1:45957014	TESK2	0.42	4.89	0.31	1.86e-6	Homocysteine levels;
SARC	cis	rs939574	1.000	rs908196	chr2:220088248	A/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.56	-5.3	-0.33	2.69e-7	Platelet distribution width;
SARC	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg11890956	chr21:40555474	PSMG1	1.17	19.28	0.78	3.57e-50	Cognitive function;
SARC	cis	rs9815354	0.638	rs76276404	chr3:41931770	A/G	cg03022575	chr3:42003672	ULK4	0.7	5.7	0.35	3.66e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg03709012	chr19:19516395	GATAD2A	0.96	14.88	0.7	1.18e-35	Tonsillectomy;
SARC	cis	rs9902453	0.933	rs9898353	chr17:28451865	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	6.57	0.4	3.22e-10	Coffee consumption (cups per day);
SARC	cis	rs7762018	1.000	rs6923339	chr6:170128033	T/A	cg13891659	chr6:170190454	C6orf122;C6orf208	0.53	4.92	0.31	1.63e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg00745463	chr17:30367425	LRRC37B	-0.63	-5.02	-0.31	1.05e-6	Hip circumference adjusted for BMI;
SARC	cis	rs4891159	0.790	rs4891018	chr18:74127082	A/T	cg24786174	chr18:74118243	ZNF516	-0.65	-9.42	-0.53	4.67e-18	Longevity;
SARC	trans	rs629535	0.814	rs545720	chr8:70063370	T/C	cg21567404	chr3:27674614	NA	1.06	13.5	0.66	4.52e-31	Dupuytren's disease;
SARC	cis	rs651907	0.557	rs56291106	chr3:101377474	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	6.18	0.38	2.83e-9	Colorectal cancer;
SARC	cis	rs2304069	0.733	rs216138	chr5:149437190	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.68	7.26	0.43	5.9e-12	HIV-1 control;
SARC	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.71	10.32	0.56	8.13e-21	Age at first birth;
SARC	cis	rs4713118	0.868	rs35069907	chr6:27746692	T/C	cg26335602	chr6:28129616	ZNF389	0.47	4.89	0.3	1.91e-6	Parkinson's disease;
SARC	cis	rs2573652	0.755	rs1469830	chr15:100517403	G/T	cg09918751	chr15:100517450	ADAMTS17	0.42	5.7	0.35	3.52e-8	Height;
SARC	cis	rs2013441	0.932	rs2526479	chr17:20130221	T/G	cg13482628	chr17:19912719	NA	-0.47	-6.24	-0.38	2.02e-9	Obesity-related traits;
SARC	cis	rs7843479	0.965	rs2291317	chr8:21827162	C/T	cg17168535	chr8:21777572	XPO7	0.65	8.61	0.49	1.14e-15	Mean corpuscular volume;
SARC	cis	rs11249608	0.636	rs6888539	chr5:178449010	T/A	cg21905437	chr5:178450457	ZNF879	0.57	7.66	0.45	5.07e-13	Pubertal anthropometrics;
SARC	cis	rs4319547	0.656	rs7294559	chr12:122837564	C/A	cg05707623	chr12:122985044	ZCCHC8	-0.57	-6.67	-0.4	1.84e-10	Body mass index;
SARC	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg25427524	chr10:38739819	LOC399744	-0.63	-10.05	-0.55	5.66e-20	Extrinsic epigenetic age acceleration;
SARC	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg20607798	chr8:58055168	NA	0.56	5.19	0.32	4.68e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs3812049	0.737	rs1112956	chr5:127433798	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.89	-9.79	-0.54	3.51e-19	Lymphocyte counts;Red cell distribution width;
SARC	cis	rs2013441	0.965	rs8068720	chr17:20214171	G/T	cg13482628	chr17:19912719	NA	-0.48	-6.16	-0.37	3.23e-9	Obesity-related traits;
SARC	cis	rs6088580	0.524	rs6088569	chr20:33268199	G/A	cg08999081	chr20:33150536	PIGU	-0.34	-4.96	-0.31	1.35e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs7264396	0.623	rs6060504	chr20:34197619	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	5.39	0.33	1.76e-7	Total cholesterol levels;
SARC	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg12463550	chr7:65579703	CRCP	0.69	5.25	0.33	3.37e-7	Diabetic kidney disease;
SARC	cis	rs6815814	0.950	rs67206233	chr4:38807853	T/C	cg02016764	chr4:38805732	TLR1	-0.42	-4.89	-0.31	1.89e-6	Breast cancer;
SARC	cis	rs9325144	0.555	rs7977200	chr12:38713745	C/T	cg13010199	chr12:38710504	ALG10B	0.56	7.43	0.44	1.98e-12	Morning vs. evening chronotype;
SARC	cis	rs72781680	0.799	rs2712084	chr2:24003051	A/G	cg06627628	chr2:24431161	ITSN2	-0.54	-5.49	-0.34	1.04e-7	Lymphocyte counts;
SARC	cis	rs911263	0.603	rs11628954	chr14:68782604	C/T	cg18825221	chr14:68749962	RAD51L1	0.41	7.28	0.43	5.24e-12	Primary biliary cholangitis;
SARC	cis	rs2075371	0.966	rs1646676	chr7:133999267	G/A	cg00033643	chr7:134001901	SLC35B4	0.42	5.06	0.31	8.4e-7	Mean platelet volume;
SARC	cis	rs2282802	0.685	rs13359519	chr5:139654664	G/A	cg26211634	chr5:139558579	C5orf32	0.37	4.84	0.3	2.38e-6	Intelligence (multi-trait analysis);
SARC	cis	rs17401966	0.838	rs12120042	chr1:10345325	A/T	cg15208524	chr1:10270712	KIF1B	0.46	5.43	0.34	1.42e-7	Hepatocellular carcinoma;
SARC	cis	rs9840812	0.728	rs12635723	chr3:136300732	A/G	cg15507776	chr3:136538369	TMEM22	0.48	5.33	0.33	2.31e-7	Fibrinogen levels;
SARC	cis	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-5.43	-0.34	1.41e-7	Mood instability;
SARC	cis	rs6964587	0.967	rs10280620	chr7:91582183	C/G	cg17063962	chr7:91808500	NA	-0.94	-15.25	-0.71	6.82e-37	Breast cancer;
SARC	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg24209194	chr3:40518798	ZNF619	0.66	8.18	0.47	1.82e-14	Renal cell carcinoma;
SARC	cis	rs2387326	0.761	rs2857028	chr10:129903465	A/G	cg16087940	chr10:129947807	NA	-0.46	-6.02	-0.37	6.63e-9	Select biomarker traits;
SARC	cis	rs6665290	0.935	rs11588904	chr1:227196211	T/C	cg14016676	chr1:227182615	CDC42BPA	0.39	5.59	0.34	6.27e-8	Myeloid white cell count;
SARC	cis	rs11651000	0.857	rs16947078	chr17:45825500	A/G	cg03474202	chr17:45855739	NA	-0.43	-6.06	-0.37	5.53e-9	IgG glycosylation;
SARC	cis	rs7927771	0.965	rs12787112	chr11:47687147	A/G	cg20307385	chr11:47447363	PSMC3	-0.5	-6.06	-0.37	5.32e-9	Subjective well-being;
SARC	cis	rs6701037	0.555	rs10912898	chr1:175120469	A/G	cg00321850	chr1:175162397	KIAA0040	-0.41	-6.29	-0.38	1.52e-9	Alcohol dependence;
SARC	cis	rs8028182	0.577	rs8023268	chr15:75814672	A/T	cg20655648	chr15:75932815	IMP3	0.64	7.41	0.44	2.38e-12	Sudden cardiac arrest;
SARC	cis	rs2228479	0.850	rs62056065	chr16:89905115	C/G	cg00800038	chr16:89945340	TCF25	-0.82	-5.77	-0.35	2.46e-8	Skin colour saturation;
SARC	cis	rs7769051	0.522	rs10457596	chr6:133169974	T/G	cg07930552	chr6:133119739	C6orf192	0.81	5.61	0.35	5.63e-8	Type 2 diabetes nephropathy;
SARC	cis	rs7959452	0.868	rs10784774	chr12:69737879	C/T	cg20891283	chr12:69753455	YEATS4	-0.45	-5.97	-0.36	8.66e-9	Blood protein levels;
SARC	cis	rs1950500	1.000	rs12590407	chr14:24835115	A/G	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.49	-5.5	-0.34	9.98e-8	Height;
SARC	trans	rs10746997	0.630	rs35823552	chr9:78844111	A/C	cg22374213	chr18:67136976	DOK6	-0.39	-6.32	-0.38	1.34e-9	Response to fenofibrate (adiponectin levels);
SARC	cis	rs7833986	0.941	rs13249175	chr8:57058706	T/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.64	5.3	0.33	2.69e-7	Height;
SARC	cis	rs2290720	0.930	rs1379486	chr12:101699347	T/C	cg22051763	chr12:101673672	UTP20	-0.45	-5.44	-0.34	1.32e-7	Brain structure (hippocampal volume);
SARC	cis	rs6670533	0.571	rs11799673	chr1:24861471	G/A	cg07475527	chr1:24864545	NA	-1.0	-5.65	-0.35	4.76e-8	Fasting blood insulin (BMI interaction);
SARC	cis	rs6964587	0.610	rs2888850	chr7:91430027	T/C	cg17063962	chr7:91808500	NA	0.69	10.14	0.55	3.1e-20	Breast cancer;
SARC	trans	rs3734266	0.702	rs6900426	chr6:34624148	A/G	cg08157914	chr7:2646478	IQCE	-0.52	-6.5	-0.39	4.95e-10	Systemic lupus erythematosus;
SARC	cis	rs796364	0.806	rs11688168	chr2:200916004	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-6.61	-0.4	2.63e-10	Schizophrenia;
SARC	cis	rs910316	1.000	rs4903275	chr14:75512509	C/T	cg23033748	chr14:75592666	NEK9	0.36	4.97	0.31	1.3e-6	Height;
SARC	cis	rs2985684	1.000	rs3007031	chr14:50102269	G/C	cg04989706	chr14:50066350	PPIL5	-0.52	-5.49	-0.34	1.03e-7	Carotid intima media thickness;
SARC	cis	rs7666738	0.716	rs114187620	chr4:98819534	T/A	cg05340658	chr4:99064831	C4orf37	0.66	8.68	0.49	7.14e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs926938	0.765	rs2268701	chr1:115233046	C/T	cg12756093	chr1:115239321	AMPD1	-0.37	-4.88	-0.3	2e-6	Autism;
SARC	cis	rs6991838	0.584	rs7823840	chr8:66519001	A/G	cg13398993	chr8:66546079	ARMC1	-0.63	-8.49	-0.49	2.44e-15	Intelligence (multi-trait analysis);
SARC	cis	rs7927771	1.000	rs4752873	chr11:47857520	C/T	cg05585544	chr11:47624801	NA	-0.36	-4.86	-0.3	2.11e-6	Subjective well-being;
SARC	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg16132339	chr22:24313637	DDTL;DDT	-0.41	-5.22	-0.32	3.92e-7	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs854765	0.654	rs11078400	chr17:17757728	A/G	cg05444541	chr17:17804740	TOM1L2	0.31	5.16	0.32	5.27e-7	Total body bone mineral density;
SARC	cis	rs10411936	0.712	rs3810198	chr19:16601194	C/T	cg10248733	chr19:16607483	C19orf44;CALR3	0.62	7.37	0.44	2.87e-12	White blood cell count;Multiple sclerosis;
SARC	cis	rs1580019	0.522	rs10951340	chr7:32562408	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.99	17.98	0.76	6.16e-46	Cognitive ability;
SARC	cis	rs989128	0.572	rs6504674	chr17:48630814	T/C	cg20467136	chr17:48638190	CACNA1G	0.46	5.36	0.33	2e-7	Type 2 diabetes;
SARC	cis	rs854765	0.583	rs62064158	chr17:17826935	T/C	cg04398451	chr17:18023971	MYO15A	-0.39	-5.48	-0.34	1.12e-7	Total body bone mineral density;
SARC	cis	rs10958369	0.541	rs1477955	chr8:54435226	T/C	cg12485204	chr8:54507357	NA	0.45	6.23	0.38	2.13e-9	Response to antineoplastic agents;
SARC	cis	rs7729447	0.776	rs17540155	chr5:32694033	C/T	cg16267343	chr5:32710456	NPR3	0.65	8.59	0.49	1.24e-15	Blood pressure;
SARC	cis	rs1728785	1.000	rs1182968	chr16:68573945	C/T	cg02972257	chr16:68554789	NA	-0.43	-5.07	-0.32	8.03e-7	Ulcerative colitis;
SARC	trans	rs3808502	0.526	rs36048422	chr8:11417144	T/C	cg06636001	chr8:8085503	FLJ10661	-0.66	-9.22	-0.52	1.83e-17	Neuroticism;
SARC	cis	rs8078723	1.000	rs7214085	chr17:38169095	T/C	cg17467752	chr17:38218738	THRA	0.47	5.94	0.36	1.01e-8	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs7647973	0.626	rs12715437	chr3:49751856	T/C	cg03060546	chr3:49711283	APEH	0.63	6.63	0.4	2.32e-10	Menarche (age at onset);
SARC	cis	rs5753618	0.504	rs9609329	chr22:31966313	A/C	cg07713946	chr22:31675144	LIMK2	0.35	4.91	0.31	1.73e-6	Colorectal cancer;
SARC	cis	rs2777491	0.915	rs7178634	chr15:41634587	A/G	cg01768344	chr15:41576519	LOC729082	0.45	4.97	0.31	1.31e-6	Ulcerative colitis;
SARC	cis	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg07636037	chr3:49044803	WDR6	0.65	8.6	0.49	1.19e-15	Resting heart rate;
SARC	cis	rs2250402	0.510	rs7535	chr15:40328575	G/C	cg16127683	chr15:40268777	EIF2AK4	-0.58	-5.01	-0.31	1.07e-6	Corneal curvature;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg18055230	chr19:16296654	FAM32A	-0.53	-6.66	-0.4	1.9e-10	Breast cancer;
SARC	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg04772025	chr11:68637568	NA	0.51	6.19	0.38	2.72e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs2011503	1.000	rs756999	chr19:19448200	A/G	cg03709012	chr19:19516395	GATAD2A	-0.64	-5.78	-0.35	2.38e-8	Bipolar disorder;
SARC	cis	rs3784262	1.000	rs4646627	chr15:58255305	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.38	-5.56	-0.34	7.36e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs17270561	0.609	rs4711097	chr6:25732314	C/T	cg17691542	chr6:26056736	HIST1H1C	0.58	7.09	0.42	1.59e-11	Iron status biomarkers;
SARC	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	7.7	0.45	3.9e-13	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg19223190	chr17:80058835	NA	0.46	6.26	0.38	1.85e-9	Life satisfaction;
SARC	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg13770153	chr20:60521292	NA	-0.52	-7.5	-0.44	1.33e-12	Body mass index;
SARC	cis	rs1007738	0.507	rs4752969	chr11:47185510	A/G	cg03339077	chr11:47165057	C11orf49	0.42	5.15	0.32	5.44e-7	Bone mineral density (hip);
SARC	cis	rs2153535	0.580	rs7741456	chr6:8452424	G/A	cg07606381	chr6:8435919	SLC35B3	0.78	11.13	0.59	2.34e-23	Motion sickness;
SARC	cis	rs2635047	0.811	rs12957869	chr18:44786869	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.54	6.93	0.41	4e-11	Educational attainment;
SARC	cis	rs1983546	0.547	rs1517748	chr1:169337853	G/A	cg02837999	chr1:169338281	NME7;BLZF1	0.51	5.7	0.35	3.51e-8	QT interval;
SARC	cis	rs986417	0.818	rs1950315	chr14:61000031	A/C	cg27398547	chr14:60952738	C14orf39	0.96	8.88	0.5	1.87e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs79976124	0.797	rs78317899	chr6:66652896	C/A	cg07460842	chr6:66804631	NA	0.63	6.8	0.41	8.51e-11	Type 2 diabetes;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg15560884	chr1:710097	NA	-0.44	-6.99	-0.42	2.8e-11	Chemerin levels;
SARC	cis	rs12477438	0.834	rs1563107	chr2:99701276	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.75	9.78	0.54	3.78e-19	Chronic sinus infection;
SARC	cis	rs9393692	0.905	rs34916901	chr6:26286149	G/T	cg13736514	chr6:26305472	NA	-0.62	-8.6	-0.49	1.16e-15	Educational attainment;
SARC	cis	rs12682352	0.652	rs3789843	chr8:8724257	C/T	cg06636001	chr8:8085503	FLJ10661	0.52	6.56	0.4	3.37e-10	Neuroticism;
SARC	cis	rs12188164	0.561	rs2721010	chr5:456915	A/G	cg16584290	chr5:462447	EXOC3	0.43	6.57	0.4	3.34e-10	Cystic fibrosis severity;
SARC	cis	rs2130392	1.000	rs11132254	chr4:185611592	G/T	cg04058563	chr4:185651563	MLF1IP	0.41	5.81	0.36	2.02e-8	Kawasaki disease;
SARC	cis	rs2016266	0.819	rs10747662	chr12:53669821	A/T	cg26875137	chr12:53738046	NA	0.41	5.33	0.33	2.33e-7	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs11770686	0.666	rs2269884	chr7:75308252	G/A	cg17787366	chr7:75369077	HIP1	0.39	5.03	0.31	9.98e-7	Essential tremor;
SARC	cis	rs73198271	0.740	rs1039911	chr8:8648206	G/A	cg06636001	chr8:8085503	FLJ10661	-0.48	-5.25	-0.33	3.46e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs9611519	0.507	rs12484525	chr22:41443877	G/C	cg17376030	chr22:41985996	PMM1	0.42	5.31	0.33	2.61e-7	Neuroticism;
SARC	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg08645402	chr16:4508243	NA	0.44	5.65	0.35	4.67e-8	Schizophrenia;
SARC	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg00149659	chr3:10157352	C3orf10	0.64	5.91	0.36	1.22e-8	Alzheimer's disease;
SARC	cis	rs7635838	0.617	rs346085	chr3:11282724	T/C	cg00170343	chr3:11313890	ATG7	0.74	9.88	0.54	1.85e-19	HDL cholesterol;
SARC	cis	rs1113500	0.787	rs473704	chr1:108637310	T/C	cg06207961	chr1:108661230	NA	-0.38	-4.96	-0.31	1.34e-6	Growth-regulated protein alpha levels;
SARC	cis	rs4268898	0.662	rs12052954	chr2:24425620	C/T	cg26838691	chr2:24397539	C2orf84	0.53	6.41	0.39	8.13e-10	Asthma;
SARC	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg11987759	chr7:65425863	GUSB	-0.48	-6.38	-0.39	9.64e-10	Aortic root size;
SARC	cis	rs9902453	1.000	rs6505158	chr17:28403348	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.53	-6.94	-0.41	3.85e-11	Coffee consumption (cups per day);
SARC	cis	rs9325144	0.577	rs10876008	chr12:39126750	T/C	cg26384229	chr12:38710491	ALG10B	-0.57	-7.25	-0.43	5.95e-12	Morning vs. evening chronotype;
SARC	trans	rs61931739	0.534	rs7310499	chr12:34212112	G/A	cg13010199	chr12:38710504	ALG10B	0.73	9.95	0.55	1.13e-19	Morning vs. evening chronotype;
SARC	cis	rs2839627	0.561	rs4148970	chr21:44313293	A/G	cg03543861	chr21:44258195	NA	0.44	4.85	0.3	2.26e-6	Information processing speed;
SARC	cis	rs2916247	0.908	rs993790	chr8:93160730	G/A	cg10183463	chr8:93005414	RUNX1T1	0.5	5.13	0.32	6.11e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9309473	0.615	rs11680965	chr2:73725916	G/T	cg20560298	chr2:73613845	ALMS1	-0.55	-5.35	-0.33	2.08e-7	Metabolite levels;
SARC	cis	rs9733	0.621	rs12746899	chr1:150579678	A/T	cg17724175	chr1:150552817	MCL1	-0.39	-5.07	-0.32	7.99e-7	Tonsillectomy;
SARC	cis	rs12142240	0.660	rs72890715	chr1:46852077	A/G	cg10495392	chr1:46806563	NSUN4	0.65	6.88	0.41	5.6e-11	Menopause (age at onset);
SARC	cis	rs9788682	1.000	rs2036534	chr15:78826948	T/C	cg06917634	chr15:78832804	PSMA4	-0.58	-6.59	-0.4	2.95e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs7927771	0.698	rs34467936	chr11:47915299	A/G	cg20307385	chr11:47447363	PSMC3	-0.47	-5.54	-0.34	7.97e-8	Subjective well-being;
SARC	cis	rs6502050	0.761	rs62078754	chr17:80058666	C/T	cg13939156	chr17:80058883	NA	0.43	6.83	0.41	7.5e-11	Life satisfaction;
SARC	cis	rs7568458	0.846	rs10179195	chr2:85762761	A/G	cg02493740	chr2:85810744	VAMP5	-0.37	-5.46	-0.34	1.22e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs735539	0.521	rs9315905	chr13:21404969	A/G	cg16922012	chr13:21400325	XPO4	0.43	5.97	0.36	8.76e-9	Dental caries;
SARC	cis	rs501120	1.000	rs665855	chr10:44757751	T/C	cg09554077	chr10:44749378	NA	0.48	6.49	0.39	5.12e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs820218	0.886	rs1093993	chr17:73614726	C/T	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.58	7.3	0.43	4.61e-12	Rotator cuff tears;
SARC	cis	rs11758351	1.000	rs79868973	chr6:26189312	C/G	cg23601095	chr6:26197514	HIST1H3D	0.66	5.58	0.34	6.53e-8	Gout;Renal underexcretion gout;
SARC	cis	rs9462027	0.628	rs9469857	chr6:34719793	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.39	-5.5	-0.34	9.74e-8	Systemic lupus erythematosus;
SARC	cis	rs9916302	0.555	rs12940193	chr17:37652178	T/G	cg15445000	chr17:37608096	MED1	0.42	5.01	0.31	1.08e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg00933542	chr6:150070202	PCMT1	0.32	5.25	0.33	3.4e-7	Lung cancer;
SARC	cis	rs6060717	0.536	rs2425104	chr20:34312346	C/A	cg01084648	chr20:34329383	RBM39	0.62	4.74	0.3	3.79e-6	Hip circumference adjusted for BMI;
SARC	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg09060608	chr5:178986726	RUFY1	0.34	5.01	0.31	1.06e-6	Lung cancer;
SARC	cis	rs9436747	0.641	rs6691282	chr1:66046505	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.48	4.94	0.31	1.48e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs6912958	0.559	rs242287	chr6:88071825	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.76	11.03	0.59	5.03e-23	Monocyte percentage of white cells;
SARC	cis	rs2467099	0.504	rs2608881	chr17:73936653	C/G	cg23806715	chr17:73775811	H3F3B	0.52	5.98	0.36	8.18e-9	Systolic blood pressure;
SARC	cis	rs981844	0.740	rs12644642	chr4:154686550	G/C	cg14289246	chr4:154710475	SFRP2	-0.61	-7.22	-0.43	7.26e-12	Response to statins (LDL cholesterol change);
SARC	cis	rs763121	0.889	rs1043402	chr22:38879688	G/A	cg06022373	chr22:39101656	GTPBP1	0.91	11.48	0.6	1.78e-24	Menopause (age at onset);
SARC	cis	rs7674212	0.541	rs2623064	chr4:104030792	C/A	cg16532752	chr4:104119610	CENPE	-0.48	-5.9	-0.36	1.3e-8	Type 2 diabetes;
SARC	cis	rs4561483	0.798	rs33629	chr16:11997490	G/A	cg08843971	chr16:11963173	GSPT1	-0.42	-4.8	-0.3	2.9e-6	Testicular germ cell tumor;
SARC	cis	rs7005606	1.000	rs12548687	chr8:32408820	A/G	cg14488905	chr8:32406789	NRG1	0.45	6.31	0.38	1.42e-9	Hirschsprung disease;
SARC	cis	rs2777491	0.872	rs7163649	chr15:41586798	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.72	-10.59	-0.57	1.2e-21	Ulcerative colitis;
SARC	cis	rs13161895	1.000	rs17079968	chr5:179443423	C/T	cg04265672	chr5:179402240	RNF130	-0.5	-4.93	-0.31	1.58e-6	LDL cholesterol;
SARC	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.58	-7.34	-0.43	3.57e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6568686	0.679	rs6913489	chr6:111845573	A/C	cg15721981	chr6:111408429	SLC16A10	-0.61	-5.07	-0.32	8.09e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg09033563	chr22:24373618	LOC391322	-0.43	-4.84	-0.3	2.32e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs290268	1.000	rs290271	chr9:93551619	G/A	cg02608019	chr9:93564028	SYK	0.35	4.91	0.31	1.75e-6	Platelet count;
SARC	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg18876405	chr7:65276391	NA	-0.43	-4.97	-0.31	1.3e-6	Aortic root size;
SARC	cis	rs9467773	1.000	rs10484442	chr6:26555879	A/G	cg12292205	chr6:26970375	C6orf41	0.44	5.25	0.32	3.5e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6807306	1.000	rs9848373	chr3:167403273	A/C	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.52	5.22	0.32	3.87e-7	Mean platelet volume;
SARC	cis	rs7647973	1.000	rs1009051	chr3:49521549	G/A	cg06212747	chr3:49208901	KLHDC8B	0.57	6.19	0.38	2.71e-9	Menarche (age at onset);
SARC	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg02951883	chr7:2050386	MAD1L1	-0.53	-6.92	-0.41	4.45e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs7647973	0.626	rs9870858	chr3:49769071	C/T	cg03060546	chr3:49711283	APEH	0.61	6.48	0.39	5.48e-10	Menarche (age at onset);
SARC	cis	rs2425143	1.000	rs74785978	chr20:34373234	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.67	5.32	0.33	2.38e-7	Blood protein levels;
SARC	cis	rs981844	1.000	rs17299041	chr4:154673127	T/C	cg14289246	chr4:154710475	SFRP2	0.59	6.62	0.4	2.43e-10	Response to statins (LDL cholesterol change);
SARC	trans	rs208520	0.802	rs208516	chr6:66946119	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.9	-10.42	-0.56	4.04e-21	Exhaled nitric oxide output;
SARC	cis	rs2288912	0.807	rs7251501	chr19:45455706	C/T	cg20090143	chr19:45452003	APOC2	0.31	4.99	0.31	1.18e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg17376030	chr22:41985996	PMM1	-0.8	-10.14	-0.55	2.93e-20	Vitiligo;
SARC	cis	rs2985684	0.948	rs12897941	chr14:50016701	G/C	cg04989706	chr14:50066350	PPIL5	-0.51	-5.54	-0.34	8.19e-8	Carotid intima media thickness;
SARC	cis	rs10927875	0.757	rs4661679	chr1:16321010	C/T	cg21385522	chr1:16154831	NA	0.46	5.98	0.36	8.2e-9	Dilated cardiomyopathy;
SARC	cis	rs965469	0.779	rs6051752	chr20:3310452	C/T	cg25506879	chr20:3388711	C20orf194	-0.45	-4.96	-0.31	1.37e-6	IFN-related cytopenia;
SARC	cis	rs3126085	0.935	rs10888475	chr1:152226012	C/T	cg26876637	chr1:152193138	HRNR	0.45	5.28	0.33	2.97e-7	Atopic dermatitis;
SARC	cis	rs13202913	0.837	rs9383901	chr6:151788059	T/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.64	5.22	0.32	4.03e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs3796352	1.000	rs11712653	chr3:53070875	A/C	cg12962167	chr3:53033115	SFMBT1	-0.68	-4.88	-0.3	1.94e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs1018836	0.923	rs13254212	chr8:91582355	T/C	cg16814680	chr8:91681699	NA	-0.81	-12.9	-0.65	4.19e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs2288073	0.965	rs13395596	chr2:24410738	T/C	cg26838691	chr2:24397539	C2orf84	-0.55	-6.84	-0.41	6.85e-11	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs9916302	0.706	rs4516267	chr17:37471482	G/T	cg15445000	chr17:37608096	MED1	-0.45	-4.92	-0.31	1.62e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs7918232	0.574	rs10458708	chr10:27455605	C/T	cg14240646	chr10:27532245	ACBD5	-0.71	-9.77	-0.54	3.94e-19	Breast cancer;
SARC	cis	rs910316	0.763	rs175047	chr14:75479039	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.42	-5.54	-0.34	8.04e-8	Height;
SARC	cis	rs698833	0.859	rs17580340	chr2:44602554	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.68	8.53	0.49	1.92e-15	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg25072359	chr17:41440525	NA	0.5	5.96	0.36	9.44e-9	Menopause (age at onset);
SARC	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg22535103	chr8:58192502	C8orf71	-0.59	-5.59	-0.34	6.17e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs61823972	0.547	rs12048743	chr1:205114873	C/G	cg07972983	chr1:205091412	RBBP5	0.51	6.63	0.4	2.26e-10	Immature fraction of reticulocytes;Mean corpuscular volume;Mean corpuscular hemoglobin;Mean corpuscular hemoglobin concentration;High light scatter reticulocyte count;
SARC	cis	rs881375	0.967	rs7864019	chr9:123692868	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	5.44	0.34	1.33e-7	Rheumatoid arthritis;
SARC	cis	rs9420	0.961	rs12805841	chr11:57443842	G/A	cg23127183	chr11:57508653	C11orf31	-0.56	-6.43	-0.39	7.29e-10	Schizophrenia;
SARC	cis	rs7659604	1.000	rs28433617	chr4:122664138	C/A	cg20573242	chr4:122745356	CCNA2	0.43	5.67	0.35	4.13e-8	Type 2 diabetes;
SARC	cis	rs4706831	0.647	rs627240	chr6:80985885	C/A	cg08355045	chr6:80787529	NA	-0.31	-4.92	-0.31	1.61e-6	Joint mobility (Beighton score);
SARC	cis	rs6831352	0.879	rs29001215	chr4:100051722	T/C	cg12011299	chr4:100065546	ADH4	-0.34	-5.67	-0.35	4.13e-8	Alcohol dependence;
SARC	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg12463550	chr7:65579703	CRCP	0.5	5.9	0.36	1.27e-8	Aortic root size;
SARC	cis	rs6912958	1.000	rs2223880	chr6:88167897	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.62	-8.54	-0.49	1.74e-15	Monocyte percentage of white cells;
SARC	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg01368799	chr11:117014884	PAFAH1B2	-0.44	-4.96	-0.31	1.39e-6	Blood protein levels;
SARC	cis	rs9682041	0.696	rs16855034	chr3:170097842	C/G	cg11886554	chr3:170076028	SKIL	0.83	7.66	0.45	4.97e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs3796352	0.892	rs11718388	chr3:53076415	G/A	cg15956490	chr3:53032818	SFMBT1	0.76	5.35	0.33	2.05e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs72781680	0.611	rs72781695	chr2:24266744	T/C	cg08917208	chr2:24149416	ATAD2B	0.66	6.39	0.39	8.72e-10	Lymphocyte counts;
SARC	cis	rs7633770	0.710	rs11710586	chr3:46693457	A/G	cg11219411	chr3:46661640	NA	-0.43	-6.74	-0.4	1.26e-10	Coronary artery disease;
SARC	trans	rs12310956	0.532	rs11608842	chr12:33951121	C/T	cg26384229	chr12:38710491	ALG10B	0.78	10.62	0.57	9.96e-22	Morning vs. evening chronotype;
SARC	cis	rs761746	0.960	rs9621279	chr22:31949800	T/A	cg15162869	chr22:32027605	PISD	-0.34	-4.78	-0.3	3.09e-6	Intelligence;
SARC	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg11062466	chr8:58055876	NA	0.51	5.28	0.33	2.95e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg25072359	chr17:41440525	NA	0.48	5.62	0.35	5.43e-8	Menopause (age at onset);
SARC	cis	rs8180040	0.966	rs878659	chr3:47500662	G/A	cg27129171	chr3:47204927	SETD2	0.67	9.29	0.52	1.1e-17	Colorectal cancer;
SARC	trans	rs36093844	0.752	rs56396016	chr11:85596390	C/A	cg15359163	chr5:122429178	PRDM6	-0.55	-6.78	-0.41	9.54e-11	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs9815354	0.638	rs73071259	chr3:42001847	G/A	cg03022575	chr3:42003672	ULK4	0.71	6.03	0.37	6.5e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg08975724	chr8:8085496	FLJ10661	-0.56	-6.44	-0.39	6.61e-10	Mood instability;
SARC	cis	rs6840360	0.571	rs62327270	chr4:152533618	C/T	cg22705602	chr4:152727874	NA	-0.43	-6.74	-0.4	1.22e-10	Intelligence (multi-trait analysis);
SARC	cis	rs6580649	0.943	rs3803183	chr12:48398080	T/A	cg24011408	chr12:48396354	COL2A1	0.55	6.31	0.38	1.4e-9	Lung cancer;
SARC	cis	rs6456156	1.000	rs9457274	chr6:167520865	G/T	cg07741184	chr6:167504864	NA	0.31	5.73	0.35	3.06e-8	Primary biliary cholangitis;
SARC	cis	rs1568889	0.887	rs2062269	chr11:28116537	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.87	14.91	0.7	9.4e-36	Bipolar disorder;
SARC	cis	rs950169	1.000	rs35297609	chr15:84772896	A/G	cg24253500	chr15:84953950	NA	0.37	5.4	0.33	1.67e-7	Schizophrenia;
SARC	cis	rs2197308	0.765	rs117216293	chr12:37882982	T/C	cg13010199	chr12:38710504	ALG10B	-0.68	-9.06	-0.51	5.6e-17	Morning vs. evening chronotype;
SARC	cis	rs10752881	1.000	rs10797808	chr1:182979623	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.76	0.58	3.38e-22	Colorectal cancer;
SARC	cis	rs1215050	0.874	rs2167893	chr4:99048464	A/T	cg05340658	chr4:99064831	C4orf37	0.45	5.67	0.35	4.21e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs1048238	0.506	rs598371	chr1:16212739	G/A	cg21385522	chr1:16154831	NA	-0.45	-5.47	-0.34	1.15e-7	Systolic blood pressure;
SARC	cis	rs12348691	0.503	rs7847259	chr9:100600712	A/G	cg13688889	chr9:100608707	NA	-0.45	-4.87	-0.3	2.03e-6	Alopecia areata;
SARC	cis	rs11764590	0.694	rs6972969	chr7:2099331	A/G	cg23043544	chr7:2124092	MAD1L1	-0.35	-4.85	-0.3	2.27e-6	Neuroticism;
SARC	cis	rs6942407	0.546	rs3789252	chr7:86793362	G/C	cg02420886	chr7:86849541	C7orf23	0.72	6.32	0.38	1.3e-9	Food allergy;
SARC	cis	rs4689388	0.926	rs4689391	chr4:6280449	G/A	cg00701064	chr4:6280414	WFS1	0.57	9.32	0.52	9e-18	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs10490913	0.777	rs11198393	chr10:120168873	G/T	cg23160142	chr10:120154512	NA	0.36	5.45	0.34	1.27e-7	Cancer;
SARC	cis	rs1153858	1.000	rs12595087	chr15:45655232	A/G	cg03999130	chr15:45571217	NA	0.39	5.06	0.31	8.55e-7	Homoarginine levels;
SARC	cis	rs611744	0.647	rs2594357	chr8:109255989	A/G	cg21045802	chr8:109455806	TTC35	0.6	7.65	0.45	5.26e-13	Dupuytren's disease;
SARC	cis	rs709400	0.663	rs72708893	chr14:103929535	G/A	cg26031613	chr14:104095156	KLC1	0.83	12.13	0.62	1.39e-26	Body mass index;
SARC	cis	rs1707322	0.686	rs2991986	chr1:46081282	A/G	cg03146154	chr1:46216737	IPP	-0.51	-6.16	-0.37	3.15e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7555523	0.887	rs12691499	chr1:165687665	A/C	cg24409356	chr1:165738333	TMCO1	0.69	5.64	0.35	5e-8	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15077012	chr10:99400394	PI4K2A	-0.53	-6.38	-0.39	9.41e-10	Fibrinogen levels;
SARC	cis	rs735396	0.595	rs1169279	chr12:121455873	C/T	cg04422896	chr12:121454269	C12orf43	0.47	6.04	0.37	6.12e-9	N-glycan levels;
SARC	cis	rs9807989	0.524	rs4851576	chr2:103028895	C/T	cg03938978	chr2:103052716	IL18RAP	0.31	4.96	0.31	1.34e-6	Asthma;
SARC	cis	rs11673344	0.583	rs10421436	chr19:37885503	T/C	cg14683738	chr19:37701593	ZNF585B	0.47	5.7	0.35	3.54e-8	Obesity-related traits;
SARC	cis	rs7113874	0.578	rs1026021	chr11:8564778	C/T	cg09828998	chr11:8703972	RPL27A	-0.48	-4.87	-0.3	2.07e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2594989	0.790	rs2443716	chr3:11523670	A/G	cg00170343	chr3:11313890	ATG7	0.46	5.08	0.32	7.6e-7	Circulating chemerin levels;
SARC	cis	rs6045173	0.524	rs62207130	chr20:18027748	A/C	ch.20.378824F	chr20:17967508	C20orf72	-0.42	-5.13	-0.32	6.12e-7	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs7674212	0.570	rs12501621	chr4:104095505	T/G	cg16532752	chr4:104119610	CENPE	-0.48	-6.04	-0.37	5.89e-9	Type 2 diabetes;
SARC	cis	rs11690935	0.632	rs35854151	chr2:172657439	G/A	cg13550731	chr2:172543902	DYNC1I2	0.66	9.6	0.53	1.32e-18	Schizophrenia;
SARC	cis	rs10823500	0.748	rs7072230	chr10:71978144	A/G	cg04118878	chr10:71993077	PPA1	0.59	6.55	0.39	3.67e-10	Blood protein levels;
SARC	cis	rs3784262	0.565	rs12914603	chr15:58350896	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.32	-4.75	-0.3	3.59e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs17401966	0.931	rs912961	chr1:10356848	A/G	cg15208524	chr1:10270712	KIF1B	0.51	6.06	0.37	5.3300000000000004e-09	Hepatocellular carcinoma;
SARC	cis	rs7223966	1.000	rs6504168	chr17:61697469	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.51	-5.3	-0.33	2.64e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs876084	0.505	rs11985173	chr8:121107511	G/A	cg06265175	chr8:121136014	COL14A1	0.58	7.56	0.44	9.46e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs1729951	0.575	rs361242	chr3:136698330	C/G	cg15507776	chr3:136538369	TMEM22	0.49	5.39	0.33	1.69e-7	Neuroticism;
SARC	cis	rs7429990	0.965	rs2053767	chr3:47999674	A/G	cg11946769	chr3:48343235	NME6	0.46	5.39	0.33	1.75e-7	Educational attainment (years of education);
SARC	cis	rs9914544	0.545	rs7222893	chr17:18811702	A/G	cg25390199	chr17:18761479	PRPSAP2	0.45	5.96	0.36	9.34e-9	Educational attainment (years of education);
SARC	cis	rs7223966	1.000	rs7216798	chr17:61740963	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.73	0.4	1.32e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs72634258	0.838	rs10489450	chr1:8079301	C/T	cg00042356	chr1:8021962	PARK7	0.82	7.5	0.44	1.3e-12	Inflammatory bowel disease;
SARC	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-4.89	-0.31	1.86e-6	Total body bone mineral density;
SARC	cis	rs9916302	0.851	rs11657899	chr17:37626963	G/A	cg20243544	chr17:37824526	PNMT	0.56	6.58	0.4	3.13e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs2180341	1.000	rs9398838	chr6:127635285	C/T	cg27446573	chr6:127587934	RNF146	1.03	14.58	0.69	1.15e-34	Breast cancer;
SARC	cis	rs73206853	0.764	rs73206857	chr12:110767721	T/A	cg10860002	chr12:110842031	ANAPC7	0.62	4.99	0.31	1.17e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs7717697	0.830	rs7711932	chr5:82752394	C/T	cg19814134	chr5:82768288	VCAN	0.44	5.15	0.32	5.55e-7	Vertical cup-disc ratio;
SARC	cis	rs10927875	0.541	rs1763596	chr1:16343835	C/T	cg21385522	chr1:16154831	NA	0.53	6.36	0.38	1.03e-9	Dilated cardiomyopathy;
SARC	cis	rs7714584	1.000	rs75774363	chr5:150223722	C/T	cg22134413	chr5:150180641	NA	0.79	6.54	0.39	3.91e-10	Crohn's disease;
SARC	cis	rs7659604	0.540	rs11724322	chr4:122697850	A/T	cg19748678	chr4:122722346	EXOSC9	-0.42	-5.26	-0.33	3.21e-7	Type 2 diabetes;
SARC	cis	rs7681440	0.606	rs2736996	chr4:90754691	A/G	cg06632027	chr4:90757378	SNCA	-0.44	-5.44	-0.34	1.32e-7	Dementia with Lewy bodies;
SARC	trans	rs9951602	0.512	rs1599636	chr18:76643916	G/A	cg02800362	chr5:177631904	HNRNPAB	0.68	8.61	0.49	1.13e-15	Obesity-related traits;
SARC	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.86	-12.46	-0.63	1.2100000000000001e-27	Chronic sinus infection;
SARC	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg22800045	chr5:56110881	MAP3K1	0.77	8.18	0.47	1.84e-14	Initial pursuit acceleration;
SARC	trans	rs36093844	0.706	rs1445503	chr11:85585011	G/A	cg15359163	chr5:122429178	PRDM6	-0.53	-6.33	-0.38	1.28e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs16976116	0.901	rs7172108	chr15:55501551	C/G	cg11288833	chr15:55489084	RSL24D1	0.63	6.13	0.37	3.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs700651	0.789	rs5007118	chr2:198909738	G/C	cg00792783	chr2:198669748	PLCL1	0.44	4.81	0.3	2.68e-6	Intracranial aneurysm;
SARC	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg27170947	chr2:26402098	FAM59B	0.37	4.8	0.3	2.79e-6	Gut microbiome composition (summer);
SARC	cis	rs7113850	0.541	rs7107667	chr11:24224091	T/A	ch.11.24196551F	chr11:24239977	NA	0.75	5.95	0.36	9.77e-9	Bone fracture in osteoporosis;
SARC	cis	rs965469	1.000	rs2236122	chr20:3305240	C/T	cg25506879	chr20:3388711	C20orf194	-0.52	-5.24	-0.32	3.52e-7	IFN-related cytopenia;
SARC	cis	rs8028182	0.636	rs28623700	chr15:75849714	T/A	cg20655648	chr15:75932815	IMP3	0.62	7.18	0.43	9.2e-12	Sudden cardiac arrest;
SARC	cis	rs10791097	0.739	rs4936120	chr11:130723452	G/A	cg09137382	chr11:130731461	NA	0.33	5.15	0.32	5.52e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs8077889	0.917	rs8081646	chr17:41893360	T/C	cg26893861	chr17:41843967	DUSP3	0.88	11.03	0.59	4.85e-23	Triglycerides;
SARC	cis	rs9297145	0.958	rs11975761	chr7:98766688	G/A	cg05967295	chr7:98741636	SMURF1	-0.86	-10.4	-0.56	4.72e-21	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
SARC	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg18876405	chr7:65276391	NA	0.65	7.97	0.46	7.16e-14	Aortic root size;
SARC	cis	rs2153535	0.601	rs9393030	chr6:8516489	C/G	cg21535247	chr6:8435926	SLC35B3	0.57	7.21	0.43	7.67e-12	Motion sickness;
SARC	cis	rs76419734	0.510	rs12504088	chr4:106662004	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	9.37	0.52	6.36e-18	Post bronchodilator FEV1;
SARC	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs8141529	0.748	rs1318026	chr22:29283518	A/G	cg02153584	chr22:29168773	CCDC117	0.77	11.31	0.6	6.33e-24	Lymphocyte counts;
SARC	cis	rs9300255	0.602	rs1790095	chr12:123681222	G/A	cg05973401	chr12:123451056	ABCB9	0.52	5.89	0.36	1.34e-8	Neutrophil percentage of white cells;
SARC	cis	rs1707322	0.821	rs11211182	chr1:46240170	G/A	cg03146154	chr1:46216737	IPP	0.51	6.23	0.38	2.13e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs72634258	0.554	rs34020118	chr1:7895015	C/T	cg05338066	chr1:7812865	CAMTA1	0.62	5.0	0.31	1.13e-6	Inflammatory bowel disease;
SARC	cis	rs1153858	1.000	rs8032904	chr15:45651309	C/T	cg14582100	chr15:45693742	SPATA5L1	0.35	4.83	0.3	2.49e-6	Homoarginine levels;
SARC	cis	rs4888262	0.526	rs7193423	chr16:74626340	A/C	cg02853019	chr16:75273486	BCAR1	0.36	4.86	0.3	2.18e-6	Testicular germ cell tumor;
SARC	cis	rs17376456	0.569	rs13186432	chr5:93336940	G/A	cg21475434	chr5:93447410	FAM172A	-0.63	-6.64	-0.4	2.22e-10	Diabetic retinopathy;
SARC	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg08859206	chr1:53392774	SCP2	0.35	5.05	0.31	8.74e-7	Monocyte count;
SARC	cis	rs72627123	0.737	rs61475846	chr14:74485781	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.76	5.99	0.37	7.73e-9	Morning vs. evening chronotype;
SARC	trans	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg00938859	chr5:1591904	SDHAP3	0.79	7.66	0.45	5.1e-13	Breast cancer;
SARC	cis	rs7412746	0.611	rs2228099	chr1:150808889	C/G	cg15448220	chr1:150897856	SETDB1	0.48	6.39	0.39	8.99e-10	Melanoma;
SARC	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg26335602	chr6:28129616	ZNF389	0.52	5.84	0.36	1.75e-8	Depression;
SARC	cis	rs7843479	0.965	rs13269198	chr8:21823025	G/A	cg17168535	chr8:21777572	XPO7	0.61	7.83	0.46	1.69e-13	Mean corpuscular volume;
SARC	cis	rs7647973	0.710	rs12637313	chr3:49645458	A/G	cg03060546	chr3:49711283	APEH	0.72	6.73	0.4	1.34e-10	Menarche (age at onset);
SARC	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg05368731	chr17:41323189	NBR1	0.66	7.92	0.46	9.4e-14	Menopause (age at onset);
SARC	cis	rs11098499	0.863	rs3775844	chr4:120428033	G/A	cg09307838	chr4:120376055	NA	0.9	11.6	0.61	7.15e-25	Corneal astigmatism;
SARC	cis	rs4233949	0.897	rs6752877	chr2:54661569	A/C	cg24760922	chr2:54683707	SPTBN1	-0.39	-4.73	-0.3	3.86e-6	Bone mineral density;
SARC	trans	rs8073060	0.586	rs8064895	chr17:34001121	T/C	cg19694781	chr19:47549865	TMEM160	-0.71	-6.97	-0.42	3.32e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs4481887	0.893	rs1339990	chr1:248509495	C/T	cg00666640	chr1:248458726	OR2T12	-0.32	-5.55	-0.34	7.77e-8	Common traits (Other);
SARC	cis	rs9868809	0.505	rs9877685	chr3:48748588	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.57	-5.28	-0.33	2.94e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs2228479	0.850	rs62056103	chr16:89942781	G/A	cg06558623	chr16:89946397	TCF25	0.89	6.23	0.38	2.17e-9	Skin colour saturation;
SARC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg06873352	chr17:61820015	STRADA	-0.54	-7.1	-0.42	1.51e-11	Prudent dietary pattern;
SARC	cis	rs6088580	0.634	rs6059868	chr20:33079460	A/G	cg24642439	chr20:33292090	TP53INP2	0.65	8.48	0.49	2.54e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs6060717	0.536	rs11696912	chr20:34497660	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.62	-5.08	-0.32	7.6e-7	Hip circumference adjusted for BMI;
SARC	cis	rs709400	0.520	rs28583452	chr14:103938664	C/A	cg12935359	chr14:103987150	CKB	-0.39	-5.79	-0.35	2.22e-8	Body mass index;
SARC	cis	rs10875746	0.855	rs17122620	chr12:48464475	A/G	cg26205652	chr12:48591994	NA	0.56	6.05	0.37	5.72e-9	Longevity (90 years and older);
SARC	cis	rs8103278	0.793	rs59093775	chr19:46374037	G/A	cg14061069	chr19:46274453	DMPK	-0.38	-5.26	-0.33	3.22e-7	Coronary artery disease;
SARC	cis	rs12950390	0.853	rs12450729	chr17:45855363	A/G	cg24803719	chr17:45855879	NA	-0.46	-7.55	-0.44	9.68e-13	IgG glycosylation;
SARC	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg16405210	chr4:1374714	KIAA1530	-0.53	-6.5	-0.39	4.88e-10	Obesity-related traits;
SARC	cis	rs6570726	0.791	rs436498	chr6:145876347	G/A	cg23711669	chr6:146136114	FBXO30	0.88	14.91	0.7	9.65e-36	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs9329221	0.621	rs12156350	chr8:10268516	T/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.98	-0.42	3.01e-11	Neuroticism;
SARC	cis	rs66887589	0.967	rs1480933	chr4:120433248	C/T	cg09307838	chr4:120376055	NA	0.52	7.22	0.43	7.12e-12	Diastolic blood pressure;
SARC	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.42	-4.94	-0.31	1.51e-6	Renal function-related traits (BUN);
SARC	cis	rs425277	1.000	rs262654	chr1:2089526	G/A	cg21442419	chr1:2182373	SKI	-0.52	-6.62	-0.4	2.44e-10	Height;
SARC	cis	rs710216	0.917	rs4660691	chr1:43417150	T/G	cg22176566	chr1:43424700	SLC2A1	-0.52	-5.23	-0.32	3.76e-7	Red cell distribution width;
SARC	cis	rs7917772	0.536	rs4919667	chr10:104426011	A/G	ch.10.2196322F	chr10:104248062	ACTR1A	-0.51	-6.34	-0.38	1.18e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs12586317	0.547	rs76770287	chr14:35487210	C/A	cg16230307	chr14:35515116	FAM177A1	1.02	11.85	0.61	1.18e-25	Psoriasis;
SARC	cis	rs12142240	0.698	rs56344958	chr1:46814518	G/A	cg10495392	chr1:46806563	NSUN4	0.65	6.83	0.41	7.25e-11	Menopause (age at onset);
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg06183820	chr6:2972097	SERPINB6	-0.5	-6.63	-0.4	2.25e-10	Neuroticism;
SARC	cis	rs6484504	0.576	rs208090	chr11:31190992	T/C	cg26647111	chr11:31128758	NA	-0.39	-5.19	-0.32	4.67e-7	Red blood cell count;
SARC	cis	rs1008375	1.000	rs10027755	chr4:17615954	G/C	cg02297831	chr4:17616191	MED28	0.47	5.91	0.36	1.23e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2251381	0.515	rs2832299	chr21:30749237	G/C	cg24692254	chr21:30365293	RNF160	0.54	6.71	0.4	1.47e-10	Selective IgA deficiency;
SARC	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg26335602	chr6:28129616	ZNF389	-0.52	-5.94	-0.36	1.03e-8	Depression;
SARC	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7520050	0.771	rs4660882	chr1:46116292	C/T	cg06784218	chr1:46089804	CCDC17	0.27	4.94	0.31	1.47e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs10174077	0.874	rs11892439	chr2:152469858	T/A	cg19508488	chr2:152266495	RIF1	0.5	5.78	0.35	2.44e-8	Squamous cell lung carcinoma;
SARC	cis	rs62432291	0.614	rs370434	chr6:159654551	C/G	cg14500486	chr6:159655392	FNDC1	-0.62	-6.03	-0.37	6.44e-9	Joint mobility (Beighton score);
SARC	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg00149659	chr3:10157352	C3orf10	0.64	6.01	0.37	7.21e-9	Alzheimer's disease;
SARC	cis	rs10927875	1.000	rs4307563	chr1:16313788	C/T	cg21385522	chr1:16154831	NA	-0.79	-10.07	-0.55	4.76e-20	Dilated cardiomyopathy;
SARC	cis	rs35110281	0.782	rs4818856	chr21:45043495	A/G	cg21573476	chr21:45109991	RRP1B	-0.55	-8.3	-0.48	8.51e-15	Mean corpuscular volume;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg17243582	chr15:59969081	BNIP2	0.54	6.71	0.4	1.48e-10	Breast cancer;
SARC	cis	rs763121	0.962	rs5757135	chr22:38952573	C/T	cg06022373	chr22:39101656	GTPBP1	0.77	10.01	0.55	7.76e-20	Menopause (age at onset);
SARC	cis	rs9398803	0.865	rs4895808	chr6:126781434	C/T	cg19875578	chr6:126661172	C6orf173	0.63	8.55	0.49	1.64e-15	Male-pattern baldness;
SARC	cis	rs9314323	0.767	rs10866848	chr8:26208209	G/C	cg11498726	chr8:26250323	BNIP3L	-0.61	-7.76	-0.45	2.73e-13	Red cell distribution width;
SARC	cis	rs7246657	0.508	rs1644702	chr19:37491907	C/T	cg23950597	chr19:37808831	NA	-0.54	-4.85	-0.3	2.24e-6	Coronary artery calcification;
SARC	cis	rs3808502	0.526	rs7822958	chr8:11422442	C/A	cg21775007	chr8:11205619	TDH	-0.46	-5.86	-0.36	1.54e-8	Neuroticism;
SARC	cis	rs67311347	0.866	rs9826419	chr3:40352051	G/A	cg24209194	chr3:40518798	ZNF619	0.56	6.99	0.42	2.9e-11	Renal cell carcinoma;
SARC	cis	rs10782582	0.609	rs5745410	chr1:76314356	C/A	cg10523679	chr1:76189770	ACADM	-0.44	-5.39	-0.33	1.72e-7	Daytime sleep phenotypes;
SARC	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg08280861	chr8:58055591	NA	0.61	5.67	0.35	4.27e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7223966	1.000	rs113134232	chr17:61715461	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.53	-5.41	-0.33	1.58e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg00933542	chr6:150070202	PCMT1	0.34	5.52	0.34	9.04e-8	Lung cancer;
SARC	cis	rs12586317	0.547	rs45531432	chr14:35484423	C/T	cg26967526	chr14:35346199	BAZ1A	-0.57	-5.71	-0.35	3.4e-8	Psoriasis;
SARC	cis	rs4253772	0.591	rs6519994	chr22:46656805	A/G	cg24881330	chr22:46731750	TRMU	-0.62	-7.12	-0.42	1.31e-11	LDL cholesterol;Cholesterol, total;
SARC	cis	rs10435719	0.902	rs4840599	chr8:11805380	C/T	cg12395012	chr8:11607386	GATA4	0.3	4.99	0.31	1.2e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
SARC	cis	rs9354308	0.933	rs12194424	chr6:66574007	T/C	cg07460842	chr6:66804631	NA	0.49	5.59	0.34	6.34e-8	Metabolite levels;
SARC	cis	rs9911578	0.967	rs2567892	chr17:56668929	T/C	cg12560992	chr17:57184187	TRIM37	0.82	11.2	0.59	1.36e-23	Intelligence (multi-trait analysis);
SARC	cis	rs4803468	1.000	rs11670668	chr19:41920454	G/C	cg14132834	chr19:41945861	ATP5SL	-0.55	-7.19	-0.43	8.79e-12	Height;
SARC	cis	rs11190604	1.000	rs9420782	chr10:102235015	G/A	cg07080220	chr10:102295463	HIF1AN	0.71	8.52	0.49	2.06e-15	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs5758511	0.680	rs5758684	chr22:42649509	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.46	6.9	0.41	4.87e-11	Birth weight;
SARC	trans	rs8073060	0.544	rs8071584	chr17:33999435	G/A	cg19694781	chr19:47549865	TMEM160	-0.71	-6.97	-0.42	3.32e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs7264396	0.790	rs2207889	chr20:34224898	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.56	5.84	0.36	1.72e-8	Total cholesterol levels;
SARC	trans	rs61931739	0.500	rs11053277	chr12:34553835	T/A	cg26384229	chr12:38710491	ALG10B	0.85	12.64	0.64	3.01e-28	Morning vs. evening chronotype;
SARC	cis	rs8078723	0.738	rs4065321	chr17:38143548	C/T	cg17467752	chr17:38218738	THRA	-0.38	-4.91	-0.31	1.69e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg17971929	chr21:40555470	PSMG1	0.95	11.46	0.6	2.01e-24	Cognitive function;
SARC	cis	rs3733585	0.699	rs28613263	chr4:9964880	C/T	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.31	-0.33	2.55e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs8062405	0.824	rs4788084	chr16:28539848	C/T	cg08761264	chr16:28874980	SH2B1	-0.42	-4.78	-0.3	3.04e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg14755054	chr2:201940010	NDUFB3	0.48	6.8	0.41	8.5e-11	Thyroid stimulating hormone;
SARC	cis	rs1401999	1.000	rs939338	chr3:183704068	A/G	cg01324343	chr3:183735012	ABCC5	-0.65	-12.95	-0.65	2.98e-29	Anterior chamber depth;
SARC	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg02725872	chr8:58115012	NA	-0.37	-6.55	-0.39	3.71e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7828089	0.542	rs7332050	chr8:22265294	G/T	cg12081754	chr8:22256438	SLC39A14	0.54	7.01	0.42	2.61e-11	Verbal declarative memory;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg07432643	chr22:50247581	ZBED4	0.46	6.25	0.38	1.89e-9	Tetralogy of Fallot;
SARC	trans	rs61931739	0.534	rs11053047	chr12:34161084	C/T	cg26384229	chr12:38710491	ALG10B	0.83	12.09	0.62	1.93e-26	Morning vs. evening chronotype;
SARC	cis	rs7583236	0.500	rs6728352	chr2:70343432	G/A	cg19638749	chr2:70312615	NA	0.66	5.95	0.36	1e-8	Obesity-related traits;
SARC	cis	rs644799	0.930	rs2186782	chr11:95649543	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.82	11.46	0.6	2.04e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs911555	0.723	rs6575991	chr14:103908433	C/T	cg24130564	chr14:104152367	KLC1	0.49	5.75	0.35	2.83e-8	Intelligence (multi-trait analysis);
SARC	cis	rs35110281	0.511	rs2298562	chr21:45085236	A/G	cg21573476	chr21:45109991	RRP1B	-0.55	-7.83	-0.46	1.74e-13	Mean corpuscular volume;
SARC	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg25952890	chr19:58913133	NA	-0.4	-5.7	-0.35	3.62e-8	Uric acid clearance;
SARC	cis	rs9303401	0.659	rs7224276	chr17:56897827	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	11.5	0.6	1.52e-24	Cognitive test performance;
SARC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg04234412	chr22:24373322	LOC391322	-0.64	-8.48	-0.49	2.6e-15	Liver enzyme levels (gamma-glutamyl transferase);
SARC	trans	rs561341	0.843	rs4795666	chr17:30241409	A/G	cg20587970	chr11:113659929	NA	-0.87	-8.69	-0.49	6.43e-16	Hip circumference adjusted for BMI;
SARC	cis	rs546131	0.928	rs552171	chr11:34830709	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.48	5.99	0.37	7.73e-9	Lung disease severity in cystic fibrosis;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg23963136	chr19:8372973	CD320	-0.5	-6.54	-0.39	3.82e-10	Gallstone disease;
SARC	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg09455208	chr3:40491958	NA	0.39	5.85	0.36	1.66e-8	Renal cell carcinoma;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg21828898	chr3:132379245	UBA5;ACAD11	-0.79	-6.68	-0.4	1.7e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1346751	0.619	rs6531129	chr2:16629315	C/A	cg09580478	chr2:16689509	NA	0.52	5.92	0.36	1.13e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
SARC	cis	rs8072100	0.777	rs9914653	chr17:45537395	T/C	cg08085267	chr17:45401833	C17orf57	-0.39	-4.72	-0.3	4.15e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg03351412	chr1:154909251	PMVK	0.4	4.88	0.3	1.98e-6	Prostate cancer;
SARC	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.58	7.16	0.42	1.04e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7312933	0.584	rs7974654	chr12:42630466	C/A	cg17420585	chr12:42539391	GXYLT1	-0.33	-4.76	-0.3	3.46e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.42	-6.87	-0.41	5.71e-11	Total body bone mineral density;
SARC	cis	rs9796	0.621	rs2899013	chr15:41492283	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.54	-7.81	-0.46	1.88e-13	Menopause (age at onset);
SARC	cis	rs4742903	0.545	rs111944779	chr9:106953205	A/C	cg14250997	chr9:106856677	SMC2	0.39	4.85	0.3	2.3e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg09338965	chr19:6361957	CLPP	-0.52	-6.63	-0.4	2.31e-10	Schizophrenia;
SARC	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg12564285	chr5:131593104	PDLIM4	-0.4	-6.04	-0.37	6.06e-9	Acylcarnitine levels;
SARC	cis	rs763121	0.962	rs6001159	chr22:38966487	A/G	cg06022373	chr22:39101656	GTPBP1	0.78	10.34	0.56	7.31e-21	Menopause (age at onset);
SARC	cis	rs79149102	0.737	rs7163332	chr15:75193623	C/T	cg09165964	chr15:75287851	SCAMP5	-1.0	-7.42	-0.44	2.15e-12	Lung cancer;
SARC	cis	rs7666738	0.791	rs62318907	chr4:99037120	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.88	0.5	1.85e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs172166	0.637	rs1233691	chr6:28153897	T/G	cg16479474	chr6:28041457	NA	0.31	5.11	0.32	6.74e-7	Cardiac Troponin-T levels;
SARC	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.94	9.83	0.54	2.7e-19	Platelet count;
SARC	cis	rs10782582	0.522	rs12125933	chr1:76130920	C/T	cg10523679	chr1:76189770	ACADM	-0.44	-5.38	-0.33	1.85e-7	Daytime sleep phenotypes;
SARC	cis	rs7647973	1.000	rs11719762	chr3:49409002	G/C	cg06212747	chr3:49208901	KLHDC8B	0.58	6.05	0.37	5.65e-9	Menarche (age at onset);
SARC	cis	rs3020736	0.500	rs2413672	chr22:42513261	C/T	cg04733989	chr22:42467013	NAGA	-0.76	-10.57	-0.57	1.4e-21	Autism spectrum disorder or schizophrenia;
SARC	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg21433313	chr16:3507492	NAT15	0.33	4.74	0.3	3.65e-6	Tuberculosis;
SARC	cis	rs7772486	0.714	rs1883365	chr6:146076749	C/T	cg05347473	chr6:146136440	FBXO30	-0.52	-7.25	-0.43	6.22e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4727443	0.932	rs7803714	chr7:99585150	G/T	cg22004693	chr7:99632812	ZKSCAN1	0.61	7.96	0.46	7.48e-14	Interstitial lung disease;
SARC	cis	rs10504229	0.679	rs6474100	chr8:58031161	G/A	cg20607798	chr8:58055168	NA	0.57	5.29	0.33	2.84e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs807669	0.934	rs1780643	chr22:19191725	T/C	cg02655711	chr22:19163373	SLC25A1	0.53	7.23	0.43	6.82e-12	Metabolite levels;
SARC	cis	rs6089584	0.586	rs2296087	chr20:60584328	T/A	cg06108461	chr20:60628389	TAF4	-0.64	-8.04	-0.47	4.46e-14	Body mass index;
SARC	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg18252515	chr7:66147081	NA	0.6	6.36	0.38	1.07e-9	Aortic root size;
SARC	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg20607798	chr8:58055168	NA	0.57	4.85	0.3	2.31e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs7005380	0.581	rs9987297	chr8:120933689	G/A	cg21744203	chr8:120868354	DSCC1	0.44	5.14	0.32	5.72e-7	Interstitial lung disease;
SARC	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg06221963	chr1:154839813	KCNN3	-0.53	-8.61	-0.49	1.11e-15	Prostate cancer;
SARC	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg04546413	chr19:29218101	NA	0.63	8.52	0.49	2.01e-15	Methadone dose in opioid dependence;
SARC	cis	rs995000	0.931	rs11207984	chr1:63013396	C/T	cg06896770	chr1:63153194	DOCK7	-0.9	-13.26	-0.66	2.87e-30	Triglyceride levels;
SARC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg02353165	chr6:42928485	GNMT	0.62	8.58	0.49	1.38e-15	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs7589342	0.895	rs2033008	chr2:106502585	T/A	cg14210321	chr2:106509881	NCK2	-0.52	-6.02	-0.37	6.88e-9	Addiction;
SARC	cis	rs1348850	0.561	rs57986285	chr2:178468663	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	5.52	0.34	8.82e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs10463554	0.892	rs1560040	chr5:102300067	C/A	cg23492399	chr5:102201601	PAM	-0.47	-5.67	-0.35	4.26e-8	Parkinson's disease;
SARC	trans	rs17685	0.712	rs10275521	chr7:75770972	T/C	cg19862616	chr7:65841803	NCRNA00174	0.62	7.72	0.45	3.44e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg17971929	chr21:40555470	PSMG1	-0.88	-11.56	-0.6	9.86e-25	Cognitive function;
SARC	cis	rs4481887	1.000	rs6663817	chr1:248495613	A/G	cg00666640	chr1:248458726	OR2T12	0.4	6.6	0.4	2.8e-10	Common traits (Other);
SARC	cis	rs78487399	0.614	rs77389971	chr2:43718084	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-5.02	-0.31	1.04e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs36051895	0.559	rs12342390	chr9:5211297	G/A	cg02405213	chr9:5042618	JAK2	-0.43	-5.03	-0.31	9.65e-7	Pediatric autoimmune diseases;
SARC	cis	rs6912958	0.781	rs9444522	chr6:88309705	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.66	-0.4	1.96e-10	Monocyte percentage of white cells;
SARC	cis	rs9309473	0.607	rs7573719	chr2:73582986	G/A	cg20560298	chr2:73613845	ALMS1	-0.59	-7.42	-0.44	2.2e-12	Metabolite levels;
SARC	cis	rs147858478	1	rs147858478	chr5:131682785	CCTGAGTT/C	cg07395648	chr5:131743802	NA	-0.42	-4.92	-0.31	1.63e-6	High light scatter reticulocyte percentage of red cells;
SARC	cis	rs6807306	1.000	rs7641659	chr3:167362358	A/G	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.5	5.05	0.31	8.99e-7	Mean platelet volume;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg14410395	chr5:134879818	NA	0.46	6.28	0.38	1.68e-9	Breast cancer;
SARC	trans	rs9818941	0.744	rs13098886	chr3:157613783	C/T	cg04041942	chr8:28747613	INTS9;HMBOX1	0.55	6.51	0.39	4.51e-10	Height;
SARC	cis	rs72720396	0.789	rs12048450	chr1:91199660	G/A	cg24453699	chr1:91190891	NA	0.38	4.95	0.31	1.43e-6	Morning vs. evening chronotype;Chronotype;
SARC	cis	rs1559088	0.948	rs12610071	chr19:33582687	A/C	cg17764715	chr19:33622953	WDR88	0.5	6.69	0.4	1.68e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs2991971	0.729	rs10890328	chr1:45905383	G/T	cg05343316	chr1:45956843	TESK2	0.39	4.85	0.3	2.27e-6	High light scatter reticulocyte count;
SARC	cis	rs2303745	0.544	rs12710308	chr19:17395879	T/A	cg04248312	chr19:17393744	ANKLE1	-0.6	-7.96	-0.46	7.52e-14	Systemic lupus erythematosus;
SARC	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg06558623	chr16:89946397	TCF25	0.98	8.13	0.47	2.6e-14	Skin colour saturation;
SARC	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.96	11.84	0.61	1.21e-25	Platelet count;
SARC	cis	rs1707322	1.000	rs4660334	chr1:46462126	A/C	cg06784218	chr1:46089804	CCDC17	0.35	6.0	0.37	7.6e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7824557	0.564	rs2736295	chr8:11234780	C/G	cg21775007	chr8:11205619	TDH	0.63	8.46	0.48	2.95e-15	Retinal vascular caliber;
SARC	cis	rs16854884	0.657	rs6791078	chr3:143736876	A/G	cg06585982	chr3:143692056	C3orf58	0.67	9.14	0.51	3.13e-17	Economic and political preferences (feminism/equality);
SARC	cis	rs16976116	0.851	rs28393427	chr15:55490981	A/G	cg11288833	chr15:55489084	RSL24D1	0.63	6.09	0.37	4.66e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs35110281	0.744	rs230646	chr21:44918788	A/G	cg21573476	chr21:45109991	RRP1B	-0.5	-7.37	-0.43	2.92e-12	Mean corpuscular volume;
SARC	cis	rs734999	0.588	rs745367	chr1:2524457	T/C	cg20673091	chr1:2541236	MMEL1	0.33	5.13	0.32	6.14e-7	Ulcerative colitis;
SARC	cis	rs16854884	0.837	rs7644767	chr3:143803092	C/G	cg06585982	chr3:143692056	C3orf58	0.6	7.88	0.46	1.21e-13	Economic and political preferences (feminism/equality);
SARC	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	-0.38	-4.74	-0.3	3.77e-6	Tonsillectomy;
SARC	cis	rs2153535	0.580	rs1932281	chr6:8473765	A/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs4975616	0.686	rs37008	chr5:1351538	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.41	-6.0	-0.37	7.58e-9	Lung cancer;
SARC	cis	rs10876993	0.928	rs1628552	chr12:58082142	C/T	cg18357645	chr12:58087776	OS9	0.48	6.4	0.39	8.59e-10	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg20814179	chr4:940893	TMEM175	0.36	5.22	0.32	4.04e-7	Sjögren's syndrome;
SARC	cis	rs3017493	0.685	rs61885467	chr11:70649857	C/T	cg23696210	chr11:69928942	ANO1	0.65	5.41	0.33	1.56e-7	Renal transplant outcome;
SARC	cis	rs1401999	0.668	rs6806313	chr3:183642152	G/C	cg01324343	chr3:183735012	ABCC5	0.59	10.81	0.58	2.41e-22	Anterior chamber depth;
SARC	cis	rs9788721	0.934	rs55676755	chr15:78898932	C/G	cg06917634	chr15:78832804	PSMA4	-0.56	-5.92	-0.36	1.15e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg09699651	chr6:150184138	LRP11	0.4	4.92	0.31	1.63e-6	Lung cancer;
SARC	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	10.04	0.55	6.13e-20	Platelet count;
SARC	cis	rs7772486	0.686	rs2328708	chr6:146095739	G/A	cg05347473	chr6:146136440	FBXO30	-0.51	-7.13	-0.42	1.24e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg25036284	chr2:26402008	FAM59B	0.46	5.7	0.35	3.59e-8	Gut microbiome composition (summer);
SARC	cis	rs8060686	0.545	rs17688076	chr16:68286427	C/A	cg27539214	chr16:67997921	SLC12A4	-0.59	-5.76	-0.35	2.68e-8	HDL cholesterol;Metabolic syndrome;
SARC	cis	rs11997175	0.756	rs4739435	chr8:33818818	A/G	ch.8.33884649F	chr8:33765107	NA	0.48	6.28	0.38	1.68e-9	Body mass index;
SARC	cis	rs1008375	0.932	rs9283698	chr4:17662471	T/C	cg16339924	chr4:17578868	LAP3	0.65	8.28	0.48	9.62e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg03452623	chr4:187889614	NA	-0.76	-11.77	-0.61	2.03e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs8114671	0.967	rs2093058	chr20:33791281	C/T	cg24642439	chr20:33292090	TP53INP2	-0.49	-5.63	-0.35	5.13e-8	Height;
SARC	cis	rs9398803	0.865	rs1578060	chr6:126712247	G/C	cg19875578	chr6:126661172	C6orf173	0.61	8.17	0.47	1.95e-14	Male-pattern baldness;
SARC	cis	rs3020736	0.500	rs764481	chr22:42518426	G/A	cg04733989	chr22:42467013	NAGA	-0.75	-10.52	-0.57	2e-21	Autism spectrum disorder or schizophrenia;
SARC	cis	rs977987	0.872	rs4888422	chr16:75470576	A/G	cg03315344	chr16:75512273	CHST6	0.33	5.68	0.35	4.02e-8	Dupuytren's disease;
SARC	cis	rs5167	0.504	rs7248162	chr19:45454686	T/C	cg13119609	chr19:45449297	APOC2	0.5	8.44	0.48	3.42e-15	Blood protein levels;
SARC	cis	rs10908458	0.808	rs10908456	chr1:155086148	A/G	cg22049894	chr1:155113146	DPM3	-0.4	-5.15	-0.32	5.62e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs73086581	1.000	rs73086597	chr20:3983571	G/A	cg02187196	chr20:3869020	PANK2	0.63	5.82	0.36	1.97e-8	Response to antidepressants in depression;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg13411879	chr7:30068273	PLEKHA8	0.47	6.29	0.38	1.58e-9	Chemerin levels;
SARC	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg11764359	chr7:65958608	NA	0.65	7.59	0.45	7.45e-13	Aortic root size;
SARC	cis	rs7208859	0.623	rs11657777	chr17:29091785	T/C	cg13385521	chr17:29058706	SUZ12P	0.9	7.81	0.46	1.96e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs55728055	0.661	rs9619215	chr22:32042732	A/G	cg01338084	chr22:32026380	PISD	0.93	6.01	0.37	7.03e-9	Age-related hearing impairment;
SARC	cis	rs2153535	0.505	rs1335629	chr6:8491863	C/T	cg21535247	chr6:8435926	SLC35B3	0.56	6.96	0.41	3.41e-11	Motion sickness;
SARC	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg05234568	chr11:5960015	NA	-0.42	-5.78	-0.35	2.41e-8	DNA methylation (variation);
SARC	cis	rs12681288	0.862	rs4735981	chr8:1018437	A/C	cg15309053	chr8:964076	NA	0.41	6.87	0.41	5.78e-11	Schizophrenia;
SARC	cis	rs763121	0.853	rs4821811	chr22:39075145	C/T	cg06022373	chr22:39101656	GTPBP1	0.85	10.41	0.56	4.3e-21	Menopause (age at onset);
SARC	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg06634786	chr22:41940651	POLR3H	-0.57	-6.71	-0.4	1.45e-10	Vitiligo;
SARC	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg03433033	chr1:76189801	ACADM	0.55	7.76	0.45	2.61e-13	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs981844	0.714	rs6822142	chr4:154683524	C/T	cg14289246	chr4:154710475	SFRP2	-0.61	-7.18	-0.43	9.42e-12	Response to statins (LDL cholesterol change);
SARC	cis	rs7914558	1.000	rs4917380	chr10:104775335	C/G	cg04362960	chr10:104952993	NT5C2	0.45	5.6	0.34	5.97e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs9467711	0.651	rs35069699	chr6:25957282	C/T	cg21479132	chr6:26055353	NA	0.83	5.06	0.31	8.49e-7	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9435341	1.000	rs1762484	chr1:107613923	A/C	cg09367891	chr1:107599246	PRMT6	-0.71	-8.45	-0.48	3.22e-15	Facial morphology (factor 21, depth of nasal alae);
SARC	cis	rs1790761	0.520	rs1551884	chr11:67399601	C/G	cg00864171	chr11:67383662	NA	-0.45	-5.91	-0.36	1.22e-8	Mean corpuscular volume;
SARC	cis	rs9467773	1.000	rs6933176	chr6:26540178	G/A	cg11502198	chr6:26597334	ABT1	0.46	5.61	0.34	5.83e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2652834	0.851	rs2652819	chr15:63431175	A/G	cg02713581	chr15:63449717	RPS27L	0.48	4.75	0.3	3.6e-6	HDL cholesterol;
SARC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.69	9.31	0.52	1e-17	Lymphocyte counts;
SARC	cis	rs7481584	0.926	rs10833024	chr11:3010390	C/T	cg05729581	chr11:3078854	CARS	0.44	5.5	0.34	1.01e-7	Calcium levels;
SARC	cis	rs4234284	0.556	rs13072737	chr3:126948835	C/T	cg27326032	chr3:127006922	NA	-0.5	-5.59	-0.34	6.24e-8	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
SARC	cis	rs473651	0.935	rs474478	chr2:239335473	C/T	cg00800569	chr2:239229395	TRAF3IP1	0.4	4.79	0.3	3.03e-6	Multiple system atrophy;
SARC	cis	rs7568458	0.709	rs762684	chr2:85782023	G/A	cg02493740	chr2:85810744	VAMP5	-0.41	-5.1	-0.32	6.93e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg08859206	chr1:53392774	SCP2	0.39	5.65	0.35	4.74e-8	Monocyte count;
SARC	cis	rs6933660	0.744	rs3800279	chr6:151766162	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.48	6.02	0.37	6.6e-9	Menarche (age at onset);
SARC	cis	rs6815814	0.898	rs6848423	chr4:38887933	C/T	cg06935464	chr4:38784597	TLR10	0.53	5.25	0.32	3.5e-7	Breast cancer;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg08208899	chr2:181931215	NA	-0.52	-6.5	-0.39	4.91e-10	Alcohol dependence;
SARC	cis	rs6910061	1.000	rs28542236	chr6:11106966	T/C	cg27233058	chr6:11094804	LOC221710	0.56	5.32	0.33	2.43e-7	Diabetic kidney disease;
SARC	cis	rs4689388	0.926	rs4234730	chr4:6296343	A/G	cg25554036	chr4:6271136	WFS1	0.38	5.9	0.36	1.28e-8	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs2361710	0.668	rs4889830	chr17:78114528	G/A	cg06718696	chr17:78121285	EIF4A3	0.4	4.93	0.31	1.56e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
SARC	cis	rs2730245	0.505	rs1188956	chr7:158690576	G/A	cg11945929	chr7:158750384	NA	0.35	5.47	0.34	1.18e-7	Height;
SARC	cis	rs2204008	0.774	rs9669565	chr12:38294428	C/A	cg26384229	chr12:38710491	ALG10B	0.87	12.86	0.64	6.01e-29	Bladder cancer;
SARC	cis	rs9761603	0.774	rs9685307	chr4:138411527	C/G	cg12033966	chr4:138453416	PCDH18	0.56	7.46	0.44	1.71e-12	Diastolic blood pressure;
SARC	cis	rs9911578	1.000	rs12936058	chr17:57017420	T/C	cg12560992	chr17:57184187	TRIM37	0.85	11.72	0.61	3.03e-25	Intelligence (multi-trait analysis);
SARC	cis	rs6540556	0.859	rs11119340	chr1:209940560	A/T	cg23920097	chr1:209922102	NA	0.5	5.1	0.32	7.04e-7	Red blood cell count;
SARC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg11494091	chr17:61959527	GH2	0.53	7.95	0.46	7.84e-14	Prudent dietary pattern;
SARC	cis	rs3617	0.652	rs7630552	chr3:52891570	G/C	cg18404041	chr3:52824283	ITIH1	0.38	5.42	0.33	1.51e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs5997397	0.967	rs5752791	chr22:29153547	A/G	cg15103426	chr22:29168792	CCDC117	-0.52	-6.93	-0.41	4.09e-11	Red cell distribution width;
SARC	cis	rs6570726	0.935	rs369214	chr6:145856709	G/A	cg05347473	chr6:146136440	FBXO30	0.49	6.58	0.4	3.04e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2070488	0.965	rs6599209	chr3:38558197	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.81	-12.82	-0.64	8e-29	Electrocardiographic conduction measures;
SARC	cis	rs4561483	0.831	rs2075158	chr16:11945231	T/C	cg08843971	chr16:11963173	GSPT1	0.45	5.04	0.31	9.39e-7	Testicular germ cell tumor;
SARC	cis	rs9462027	0.540	rs9366863	chr6:34688946	T/C	cg07306190	chr6:34760872	UHRF1BP1	0.42	5.91	0.36	1.19e-8	Systemic lupus erythematosus;
SARC	cis	rs9291683	0.588	rs17246745	chr4:9994583	T/C	cg11266682	chr4:10021025	SLC2A9	0.44	7.91	0.46	1.06e-13	Bone mineral density;
SARC	cis	rs7586879	0.598	rs6545806	chr2:25124348	G/A	cg04586622	chr2:25135609	ADCY3	0.32	5.35	0.33	2.13e-7	Body mass index;
SARC	cis	rs7772486	0.754	rs9399561	chr6:145955687	C/G	cg23711669	chr6:146136114	FBXO30	0.88	15.02	0.7	4.22e-36	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4642101	0.737	rs4299468	chr3:12825559	G/A	cg12400702	chr3:12838781	CAND2	-0.26	-5.27	-0.33	3.08e-7	QRS complex (12-leadsum);
SARC	cis	rs6582630	0.555	rs10880613	chr12:38509553	C/T	cg13010199	chr12:38710504	ALG10B	0.79	10.89	0.58	1.35e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6674176	0.628	rs2240447	chr1:44415415	C/T	cg13606994	chr1:44402422	ARTN	-0.33	-5.35	-0.33	2.13e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	trans	rs9329221	0.537	rs6995859	chr8:9975709	T/A	cg06636001	chr8:8085503	FLJ10661	0.53	7.11	0.42	1.44e-11	Neuroticism;
SARC	trans	rs2980436	1	rs2980436	chr8:8092025	A/G	cg16141378	chr3:129829833	LOC729375	0.53	6.47	0.39	5.82e-10	Schizophrenia;
SARC	cis	rs12579753	0.871	rs10862364	chr12:82201280	C/T	cg07988820	chr12:82153109	PPFIA2	-0.52	-6.11	-0.37	4.18e-9	Resting heart rate;
SARC	cis	rs858239	0.600	rs9691762	chr7:23125922	G/C	cg23682824	chr7:23144976	KLHL7	0.72	9.79	0.54	3.42e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs36715	0.951	rs36698	chr5:127549749	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.61	6.82	0.41	7.84e-11	Breast cancer;
SARC	cis	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg15145296	chr3:125709740	NA	-0.5	-4.93	-0.31	1.59e-6	Blood pressure (smoking interaction);
SARC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg05552183	chr6:42928497	GNMT	0.59	7.93	0.46	8.88e-14	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs6582630	0.519	rs12372510	chr12:38293074	T/C	cg26384229	chr12:38710491	ALG10B	0.87	13.0	0.65	2.03e-29	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2439831	0.850	rs28858500	chr15:44156942	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	7.86	0.46	1.43e-13	Lung cancer in ever smokers;
SARC	cis	rs9527	0.569	rs78193706	chr10:104780564	T/C	cg04362960	chr10:104952993	NT5C2	0.45	5.49	0.34	1.05e-7	Arsenic metabolism;
SARC	cis	rs7000551	0.725	rs2449349	chr8:22383284	A/G	cg12081754	chr8:22256438	SLC39A14	0.56	7.87	0.46	1.33e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs7122257	0.563	rs2403460	chr11:11146438	A/G	cg22322375	chr11:11978034	USP47	0.37	4.93	0.31	1.54e-6	Cerebrospinal fluid biomarker levels;
SARC	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg09455208	chr3:40491958	NA	-0.36	-5.35	-0.33	2.05e-7	Renal cell carcinoma;
SARC	cis	rs8067545	0.611	rs2526465	chr17:20167611	T/C	cg13482628	chr17:19912719	NA	-0.57	-7.56	-0.44	9.1e-13	Schizophrenia;
SARC	cis	rs67478160	0.584	rs12433009	chr14:104196405	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.39	-5.56	-0.34	7.23e-8	Schizophrenia;
SARC	cis	rs9815354	1.000	rs9840037	chr3:41827522	C/T	cg03022575	chr3:42003672	ULK4	0.57	5.51	0.34	9.66e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs7429990	0.965	rs4599334	chr3:48066400	A/C	cg11946769	chr3:48343235	NME6	-0.47	-5.51	-0.34	9.37e-8	Educational attainment (years of education);
SARC	cis	rs7667	0.959	rs3790762	chr1:19702078	G/A	cg15311933	chr1:19638897	PQLC2;AKR7A2	-0.47	-5.41	-0.33	1.54e-7	Crohn's disease and psoriasis;
SARC	cis	rs6570726	0.935	rs452552	chr6:145820781	G/A	cg05220968	chr6:146057943	EPM2A	-0.29	-4.83	-0.3	2.44e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3091242	0.933	rs9645452	chr1:25668326	C/T	cg27572855	chr1:25598939	RHD	-0.58	-9.96	-0.55	1.05e-19	Erythrocyte sedimentation rate;
SARC	cis	rs17384381	0.859	rs12724823	chr1:85906385	G/T	cg16011679	chr1:85725395	C1orf52	0.52	5.1	0.32	6.89e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs17253792	0.822	rs8018142	chr14:56173288	C/T	cg01858014	chr14:56050164	KTN1	-0.66	-5.33	-0.33	2.27e-7	Putamen volume;
SARC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg25405998	chr7:65216604	CCT6P1	-0.51	-6.14	-0.37	3.45e-9	Calcium levels;
SARC	cis	rs6952808	0.964	rs10950407	chr7:1895666	T/G	cg13880726	chr7:1868755	MAD1L1	0.53	6.23	0.38	2.19e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg03806693	chr22:41940476	POLR3H	-0.93	-12.83	-0.64	7.61e-29	Vitiligo;
SARC	cis	rs34172651	0.917	rs35283675	chr16:24820393	A/G	cg00339695	chr16:24857497	SLC5A11	0.31	4.88	0.3	1.93e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg07701084	chr6:150067640	NUP43	0.4	5.43	0.34	1.43e-7	Lung cancer;
SARC	cis	rs6940638	0.688	rs9348750	chr6:27057945	T/G	cg12826209	chr6:26865740	GUSBL1	0.54	5.87	0.36	1.46e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9467773	0.620	rs2130657	chr6:26650826	C/T	cg11502198	chr6:26597334	ABT1	0.63	8.48	0.49	2.58e-15	Intelligence (multi-trait analysis);
SARC	cis	rs3126085	0.673	rs3126089	chr1:152306187	T/A	cg26876637	chr1:152193138	HRNR	-0.44	-4.76	-0.3	3.46e-6	Atopic dermatitis;
SARC	cis	rs593982	0.920	rs4930298	chr11:65448108	T/A	cg08755490	chr11:65554678	OVOL1	-0.9	-8.55	-0.49	1.7e-15	Atopic dermatitis;
SARC	cis	rs986417	1.000	rs10130267	chr14:60944527	A/G	cg27398547	chr14:60952738	C14orf39	0.98	8.85	0.5	2.24e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg05863683	chr7:1912471	MAD1L1	0.31	4.73	0.3	3.85e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs4144743	1.000	rs2317384	chr17:45329770	G/A	cg18085866	chr17:45331354	ITGB3	-0.73	-7.41	-0.44	2.29e-12	Body mass index;
SARC	cis	rs6582630	0.502	rs10880092	chr12:38262965	A/T	cg13010199	chr12:38710504	ALG10B	0.81	11.31	0.6	6.33e-24	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2370759	1.000	rs11599044	chr10:32615445	A/G	cg18270830	chr10:32634957	EPC1	0.69	6.25	0.38	1.91e-9	Sexual dysfunction (female);
SARC	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg18876405	chr7:65276391	NA	-0.69	-8.95	-0.51	1.15e-16	Calcium levels;
SARC	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg04772025	chr11:68637568	NA	0.49	6.14	0.37	3.49e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs3008870	1.000	rs2985811	chr1:67377722	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.93	11.27	0.59	8.55e-24	Lymphocyte percentage of white cells;
SARC	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.59e-6	Depression;
SARC	trans	rs6964833	0.872	rs4717903	chr7:74068167	T/C	cg07504079	chr7:72649617	NCF1B	-0.6	-6.51	-0.39	4.51e-10	Menarche (age at onset);
SARC	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-6.07	-0.37	5.11e-9	Personality dimensions;
SARC	cis	rs611744	0.967	rs651814	chr8:109196571	A/G	cg21045802	chr8:109455806	TTC35	0.44	5.3	0.33	2.63e-7	Dupuytren's disease;
SARC	cis	rs9611519	0.929	rs73174657	chr22:41434158	G/A	cg03806693	chr22:41940476	POLR3H	-0.61	-7.52	-0.44	1.2e-12	Neuroticism;
SARC	cis	rs9398803	0.865	rs2326451	chr6:126811928	A/T	cg19875578	chr6:126661172	C6orf173	0.63	8.66	0.49	8.1e-16	Male-pattern baldness;
SARC	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg12064134	chr16:90016061	DEF8	-0.56	-4.83	-0.3	2.51e-6	Skin colour saturation;
SARC	cis	rs193541	0.632	rs30023	chr5:122285299	T/G	cg19412675	chr5:122181750	SNX24	0.49	6.2	0.38	2.56e-9	Glucose homeostasis traits;
SARC	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.4	6.39	0.39	8.7e-10	Schizophrenia;
SARC	cis	rs2439831	0.850	rs8032649	chr15:44134922	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.81	-7.67	-0.45	4.77e-13	Lung cancer in ever smokers;
SARC	cis	rs12681288	0.645	rs2600509	chr8:989022	C/G	cg04851639	chr8:1020857	NA	0.28	4.79	0.3	3.01e-6	Schizophrenia;
SARC	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg05872129	chr22:39784769	NA	-0.43	-5.89	-0.36	1.37e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	trans	rs1814175	0.781	rs2866734	chr11:49886338	A/G	cg15704280	chr7:45808275	SEPT13	-0.97	-18.12	-0.76	2.26e-46	Height;
SARC	cis	rs2832191	0.716	rs2249028	chr21:30365322	G/A	cg08807101	chr21:30365312	RNF160	0.89	13.95	0.67	1.42e-32	Dental caries;
SARC	cis	rs9916302	0.904	rs4795357	chr17:37569551	T/C	cg00129232	chr17:37814104	STARD3	-0.62	-7.59	-0.45	7.62e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs9457247	0.935	rs401260	chr6:167405888	T/C	cg07741184	chr6:167504864	NA	0.29	5.55	0.34	7.72e-8	Crohn's disease;
SARC	cis	rs72949976	0.934	rs1441172	chr2:214037703	C/T	cg08319019	chr2:214017104	IKZF2	-0.46	-5.97	-0.36	8.67e-9	Lung cancer;Squamous cell lung carcinoma;
SARC	cis	rs9467711	0.591	rs56195001	chr6:25976165	C/T	cg21479132	chr6:26055353	NA	0.94	6.2	0.38	2.55e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2797160	0.651	rs1268067	chr6:126036621	T/C	cg06289844	chr6:126071538	HEY2	-0.32	-4.88	-0.3	1.98e-6	Endometrial cancer;
SARC	cis	rs13161895	1.000	rs248318	chr5:179430530	C/T	cg04265672	chr5:179402240	RNF130	-0.52	-5.15	-0.32	5.48e-7	LDL cholesterol;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg23811096	chr1:33502772	AK2	-0.65	-6.82	-0.41	7.59e-11	Lung cancer in ever smokers;
SARC	cis	rs34779708	0.931	rs35317849	chr10:35285721	C/A	cg03585969	chr10:35415529	CREM	0.42	5.14	0.32	5.83e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs2898681	0.618	rs79471207	chr4:53738524	C/T	cg00338735	chr4:53728038	RASL11B	0.47	4.84	0.3	2.38e-6	Optic nerve measurement (cup area);
SARC	cis	rs2635047	0.624	rs2289036	chr18:44595809	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.55	-7.21	-0.43	7.7e-12	Educational attainment;
SARC	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	11.03	0.59	4.93e-23	Alzheimer's disease;
SARC	cis	rs4901847	0.562	rs4901849	chr14:58614471	G/A	cg15908186	chr14:58618357	C14orf37	0.58	7.49	0.44	1.4e-12	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs477895	1.000	rs1047206	chr11:64089216	C/G	cg04317338	chr11:64019027	PLCB3	0.67	5.53	0.34	8.45e-8	Mean platelet volume;
SARC	cis	rs35110281	0.667	rs2155722	chr21:45096206	A/G	cg04455712	chr21:45112962	RRP1B	-0.33	-4.74	-0.3	3.7e-6	Mean corpuscular volume;
SARC	cis	rs7555523	0.887	rs6696454	chr1:165707923	T/C	cg24409356	chr1:165738333	TMCO1	0.8	6.67	0.4	1.88e-10	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	cis	rs2153535	0.580	rs9406170	chr6:8514153	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	8.28	0.48	9.37e-15	Motion sickness;
SARC	cis	rs9486719	1.000	rs11152969	chr6:96908712	A/C	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.01	-0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs17030434	0.728	rs2124641	chr4:154645810	T/C	cg14289246	chr4:154710475	SFRP2	0.57	5.54	0.34	8.23e-8	Electrocardiographic conduction measures;
SARC	trans	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.72	-0.4	1.42e-10	Triglycerides;
SARC	cis	rs6930083	0.527	rs9368950	chr6:36627872	T/C	cg08179530	chr6:36648295	CDKN1A	-0.75	-10.36	-0.56	6.44e-21	Coronary artery disease;
SARC	cis	rs6088813	0.961	rs1886691	chr20:33986271	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	-0.44	-5.29	-0.33	2.78e-7	Height;
SARC	cis	rs12586317	0.620	rs8020370	chr14:35581432	G/A	cg05294307	chr14:35346193	BAZ1A	-0.48	-4.93	-0.31	1.59e-6	Psoriasis;
SARC	trans	rs1814175	0.645	rs7103554	chr11:50027612	G/A	cg15704280	chr7:45808275	SEPT13	-0.91	-14.68	-0.69	5.63e-35	Height;
SARC	cis	rs6831352	0.918	rs4699714	chr4:100060538	A/G	cg12011299	chr4:100065546	ADH4	-0.35	-5.75	-0.35	2.8e-8	Alcohol dependence;
SARC	cis	rs1538970	0.962	rs2153607	chr1:45813820	G/A	cg05343316	chr1:45956843	TESK2	0.66	7.93	0.46	9.31e-14	Platelet count;
SARC	cis	rs9309473	0.898	rs9807961	chr2:73694043	A/G	cg20560298	chr2:73613845	ALMS1	-0.49	-5.97	-0.36	8.77e-9	Metabolite levels;
SARC	cis	rs9325144	0.602	rs10785590	chr12:38694145	C/T	cg04568710	chr12:38710424	ALG10B	0.38	4.74	0.3	3.69e-6	Morning vs. evening chronotype;
SARC	cis	rs17600642	0.855	rs750431	chr10:72474117	G/A	cg19779893	chr10:72451501	ADAMTS14	-0.44	-6.65	-0.4	2.11e-10	Bipolar disorder;
SARC	cis	rs6456156	0.586	rs4710176	chr6:167491639	T/C	cg23791538	chr6:167370224	RNASET2	-0.56	-7.28	-0.43	4.95e-12	Primary biliary cholangitis;
SARC	cis	rs1348850	0.608	rs10176632	chr2:178225934	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.63	7.6	0.45	7.28e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1055129	0.655	rs7216615	chr17:73833910	T/C	cg14829360	chr17:73884958	NA	-0.45	-6.15	-0.37	3.36e-9	White matter hyperintensity burden;
SARC	cis	rs72945132	0.882	rs17160777	chr11:70163723	T/C	cg05964544	chr11:70165517	PPFIA1	-0.61	-5.87	-0.36	1.5e-8	Coronary artery disease;
SARC	cis	rs17376456	1.000	rs13174700	chr5:93554644	G/A	cg25358565	chr5:93447407	FAM172A	1.35	14.25	0.68	1.48e-33	Diabetic retinopathy;
SARC	cis	rs4128725	1.000	rs12145616	chr1:159409479	G/T	cg25076881	chr1:159409836	OR10J1	-0.4	-4.84	-0.3	2.41e-6	Select biomarker traits;
SARC	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.73	-7.15	-0.42	1.11e-11	Platelet count;
SARC	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs950027	0.620	rs1153860	chr15:45636584	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.56	-7.16	-0.42	1.03e-11	Response to fenofibrate (adiponectin levels);
SARC	cis	rs9815354	0.812	rs73081370	chr3:41916258	G/C	cg03022575	chr3:42003672	ULK4	0.69	5.65	0.35	4.69e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs7223966	1.000	rs28463311	chr17:61919643	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.5	5.14	0.32	5.85e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg16325326	chr1:53192061	ZYG11B	-0.81	-12.99	-0.65	2.14e-29	Monocyte count;
SARC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg06873352	chr17:61820015	STRADA	0.53	6.92	0.41	4.3e-11	Prudent dietary pattern;
SARC	cis	rs2204008	0.606	rs1581358	chr12:38391582	G/T	cg26384229	chr12:38710491	ALG10B	0.93	12.93	0.65	3.57e-29	Bladder cancer;
SARC	cis	rs7843479	0.965	rs11135742	chr8:21802910	A/T	cg17168535	chr8:21777572	XPO7	0.61	7.9	0.46	1.08e-13	Mean corpuscular volume;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg10119313	chr21:46962548	SLC19A1	-0.52	-6.39	-0.39	8.7e-10	Schizophrenia;
SARC	cis	rs9843304	0.546	rs9858201	chr3:149219668	C/T	cg08667024	chr3:149219783	TM4SF4	0.48	7.28	0.43	4.97e-12	Gallstone disease;
SARC	cis	rs7264396	0.528	rs7273880	chr20:34551507	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-6.92	-0.41	4.41e-11	Total cholesterol levels;
SARC	cis	rs6831352	0.729	rs4699718	chr4:100067791	G/A	cg13256891	chr4:100009986	ADH5	-0.65	-7.8	-0.45	2.07e-13	Alcohol dependence;
SARC	cis	rs9487051	0.872	rs9398197	chr6:109609988	C/A	cg01475377	chr6:109611718	NA	-0.42	-5.94	-0.36	1.01e-8	Reticulocyte fraction of red cells;
SARC	cis	rs854765	0.522	rs63721860	chr17:17829576	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.68	10.09	0.55	4.39e-20	Total body bone mineral density;
SARC	cis	rs7666738	0.887	rs34509663	chr4:98982531	C/T	cg05340658	chr4:99064831	C4orf37	0.57	7.15	0.42	1.12e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6088813	1.000	rs6087698	chr20:33948919	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.44	-5.35	-0.33	2.07e-7	Height;
SARC	cis	rs2180341	0.920	rs6906717	chr6:127596782	C/A	cg24812749	chr6:127587940	RNF146	0.96	12.68	0.64	2.3e-28	Breast cancer;
SARC	cis	rs1881797	0.872	rs2141544	chr1:247690800	A/G	cg18198730	chr1:247681584	NA	0.54	6.5	0.39	4.73e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg11890956	chr21:40555474	PSMG1	-0.68	-9.01	-0.51	7.44e-17	Menarche (age at onset);
SARC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg07167872	chr1:205819463	PM20D1	0.75	11.59	0.6	8.04e-25	Menarche (age at onset);
SARC	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg06634786	chr22:41940651	POLR3H	0.5	6.02	0.37	6.73e-9	Cannabis dependence symptom count;
SARC	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.44	-5.48	-0.34	1.12e-7	Intelligence (multi-trait analysis);
SARC	cis	rs4319547	0.695	rs10773152	chr12:122910180	T/C	cg23029597	chr12:123009494	RSRC2	-0.42	-5.21	-0.32	4.06e-7	Body mass index;
SARC	cis	rs9612	0.718	rs346535	chr19:44251425	C/T	cg08581076	chr19:44259116	C19orf61	0.59	7.54	0.44	1.06e-12	Exhaled nitric oxide output;
SARC	cis	rs12950390	0.512	rs11651000	chr17:45835278	G/A	cg24803719	chr17:45855879	NA	-0.42	-5.31	-0.33	2.55e-7	IgG glycosylation;
SARC	cis	rs10876993	0.928	rs1678532	chr12:58055197	T/G	cg18357645	chr12:58087776	OS9	0.46	5.91	0.36	1.2e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs9325144	0.600	rs12297194	chr12:38735803	A/G	cg13010199	chr12:38710504	ALG10B	-0.53	-6.71	-0.4	1.44e-10	Morning vs. evening chronotype;
SARC	cis	rs8180040	0.966	rs60369822	chr3:47479735	A/C	cg27129171	chr3:47204927	SETD2	-0.69	-9.67	-0.54	8.06e-19	Colorectal cancer;
SARC	cis	rs9840812	0.769	rs534944	chr3:135961031	T/G	cg15507776	chr3:136538369	TMEM22	0.49	5.19	0.32	4.65e-7	Fibrinogen levels;
SARC	cis	rs1153858	1.000	rs1980288	chr15:45620612	T/C	cg03999130	chr15:45571217	NA	0.41	5.11	0.32	6.78e-7	Homoarginine levels;
SARC	cis	rs9398803	0.652	rs853961	chr6:127003464	G/T	cg19875578	chr6:126661172	C6orf173	-0.62	-8.6	-0.49	1.21e-15	Male-pattern baldness;
SARC	trans	rs1814175	0.817	rs11493756	chr11:50017885	T/C	cg15704280	chr7:45808275	SEPT13	-0.98	-18.94	-0.78	4.51e-49	Height;
SARC	cis	rs787274	0.867	rs787279	chr9:115539514	T/C	cg13803584	chr9:115635662	SNX30	-0.79	-6.14	-0.37	3.47e-9	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg25036284	chr2:26402008	FAM59B	0.47	5.76	0.35	2.7e-8	Gut microbiome composition (summer);
SARC	trans	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg20587970	chr11:113659929	NA	-1.29	-13.65	-0.67	1.47e-31	Hip circumference adjusted for BMI;
SARC	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg11952622	chr19:58962976	ZNF324B	0.54	7.09	0.42	1.55e-11	Uric acid clearance;
SARC	cis	rs1707322	0.721	rs11211157	chr1:46132844	T/C	cg03146154	chr1:46216737	IPP	0.52	6.32	0.38	1.33e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs10791323	0.604	rs2723598	chr11:133711652	G/A	cg14349672	chr11:133703707	NA	-0.38	-5.42	-0.33	1.47e-7	Childhood ear infection;
SARC	cis	rs6582630	0.599	rs12824838	chr12:38373584	G/T	cg13010199	chr12:38710504	ALG10B	-0.47	-5.83	-0.36	1.84e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2712184	0.756	rs2541393	chr2:217651230	G/C	cg05032264	chr2:217675019	NA	-0.52	-6.92	-0.41	4.26e-11	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
SARC	cis	rs3540	0.533	rs1869179	chr15:90895564	A/C	cg22089800	chr15:90895588	ZNF774	0.76	10.35	0.56	6.76e-21	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg11941060	chr3:133502564	NA	-0.41	-5.7	-0.35	3.56e-8	Iron status biomarkers;
SARC	cis	rs6871536	1.000	rs2252775	chr5:131918444	T/G	cg11797159	chr5:131991491	NA	0.38	4.78	0.3	3.13e-6	Asthma (childhood onset);
SARC	cis	rs2011013	1.000	rs12148239	chr15:84641018	G/T	cg17507749	chr15:85114479	UBE2QP1	0.45	4.75	0.3	3.62e-6	Sitting height ratio;
SARC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.3	-4.89	-0.31	1.85e-6	Total body bone mineral density;
SARC	cis	rs503734	0.502	rs2660803	chr3:100914035	A/G	cg27318481	chr3:100970896	IMPG2	-0.5	-6.04	-0.37	5.97e-9	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs138880	0.505	rs56248708	chr22:50306969	G/A	cg03033257	chr22:50311977	ALG12;CRELD2	0.64	4.85	0.3	2.26e-6	Schizophrenia;
SARC	cis	rs2425143	1.000	rs7264414	chr20:34446826	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-5.96	-0.36	9.2e-9	Blood protein levels;
SARC	cis	rs514024	0.700	rs505268	chr9:130493724	C/T	cg13643465	chr9:130375613	STXBP1	0.39	4.74	0.3	3.66e-6	Eating disorders (purging via substances);
SARC	cis	rs2070488	0.775	rs11926767	chr3:38527913	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.78	-11.23	-0.59	1.14e-23	Electrocardiographic conduction measures;
SARC	cis	rs1322639	0.614	rs6940913	chr6:169563666	G/A	cg03254818	chr6:169586852	NA	0.7	7.01	0.42	2.62e-11	Pulse pressure;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg23398173	chr7:135662345	MTPN;LUZP6	-0.51	-6.76	-0.4	1.12e-10	Thyroid stimulating hormone;
SARC	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg11987759	chr7:65425863	GUSB	0.48	5.91	0.36	1.22e-8	Aortic root size;
SARC	cis	rs6580649	0.941	rs6580651	chr12:48429933	A/T	cg24011408	chr12:48396354	COL2A1	-0.47	-5.15	-0.32	5.45e-7	Lung cancer;
SARC	cis	rs78487399	0.808	rs17030818	chr2:43680318	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-5.01	-0.31	1.08e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs933688	1.000	rs6867219	chr5:90718008	T/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.02	12.84	0.64	6.81e-29	Smoking behavior;
SARC	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg05332525	chr7:65337924	VKORC1L1	0.43	4.83	0.3	2.44e-6	Aortic root size;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg21272473	chr15:75128881	ULK3	-0.46	-6.24	-0.38	2.02e-9	Chemerin levels;
SARC	cis	rs6545883	0.931	rs12713438	chr2:61725501	G/A	cg15711740	chr2:61764176	XPO1	-0.42	-5.16	-0.32	5.23e-7	Tuberculosis;
SARC	cis	rs145445141	1	rs145445141	chr1:67489169	ATT/A	cg08660285	chr1:67390436	MIER1;WDR78	0.91	9.23	0.52	1.67e-17	Neutrophil percentage of white cells;
SARC	cis	rs981844	0.961	rs17299034	chr4:154671396	A/G	cg14289246	chr4:154710475	SFRP2	0.59	6.62	0.4	2.43e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs7700895	0.737	rs10035477	chr5:95227507	C/T	cg16656078	chr5:95278638	ELL2	0.59	7.31	0.43	4.28e-12	IgG glycosylation;
SARC	cis	rs9398803	0.723	rs1022573	chr6:127054914	C/A	cg19875578	chr6:126661172	C6orf173	-0.63	-8.78	-0.5	3.64e-16	Male-pattern baldness;
SARC	cis	rs8141529	0.748	rs6519766	chr22:29269991	A/G	cg15103426	chr22:29168792	CCDC117	-0.66	-8.63	-0.49	9.72e-16	Lymphocyte counts;
SARC	cis	rs6840360	0.615	rs58977077	chr4:152470239	T/G	cg22705602	chr4:152727874	NA	-0.4	-6.25	-0.38	1.92e-9	Intelligence (multi-trait analysis);
SARC	cis	rs6089584	0.566	rs6061964	chr20:60607536	G/A	cg13770153	chr20:60521292	NA	-0.39	-5.65	-0.35	4.77e-8	Body mass index;
SARC	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg19729930	chr2:74357872	NA	0.74	10.84	0.58	2e-22	Gestational age at birth (maternal effect);
SARC	cis	rs8067354	0.789	rs1292068	chr17:57929319	T/C	cg13753209	chr17:57696993	CLTC	0.49	6.02	0.37	6.78e-9	Hemoglobin concentration;
SARC	cis	rs6815814	0.950	rs5743566	chr4:38805942	G/C	cg02016764	chr4:38805732	TLR1	-0.42	-4.89	-0.31	1.89e-6	Breast cancer;
SARC	cis	rs2204008	0.577	rs2623049	chr12:38018831	G/A	cg13010199	chr12:38710504	ALG10B	-0.66	-8.85	-0.5	2.18e-16	Bladder cancer;
SARC	cis	rs77972916	0.536	rs62137421	chr2:43594091	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.5	-5.05	-0.31	8.8e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg25703541	chr22:24373054	LOC391322	-0.68	-8.21	-0.47	1.52e-14	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2635047	0.542	rs2684853	chr18:44793532	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.4	4.88	0.3	1.96e-6	Educational attainment;
SARC	cis	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg25427524	chr10:38739819	LOC399744	-0.61	-9.58	-0.53	1.5e-18	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs3126085	0.935	rs72696975	chr1:152206090	A/G	cg26876637	chr1:152193138	HRNR	-0.48	-5.02	-0.31	1.02e-6	Atopic dermatitis;
SARC	cis	rs965469	0.947	rs6037529	chr20:3261006	C/T	cg25506879	chr20:3388711	C20orf194	-0.48	-4.87	-0.3	2.04e-6	IFN-related cytopenia;
SARC	cis	rs4642101	0.737	rs9877165	chr3:12828497	C/T	cg05775895	chr3:12838266	CAND2	0.75	12.16	0.62	1.17e-26	QRS complex (12-leadsum);
SARC	cis	rs910316	1.000	rs3742773	chr14:75579643	A/G	cg23033748	chr14:75592666	NEK9	0.37	5.07	0.32	8.22e-7	Height;
SARC	cis	rs3126085	0.825	rs4845428	chr1:152225261	T/C	cg03465714	chr1:152285911	FLG	-0.44	-5.34	-0.33	2.26e-7	Atopic dermatitis;
SARC	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg11062466	chr8:58055876	NA	0.53	5.53	0.34	8.39e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs116095464	1.000	rs55671190	chr5:287422	G/A	cg20965017	chr5:231967	SDHA	-0.72	-5.54	-0.34	8.13e-8	Breast cancer;
SARC	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.95	-15.47	-0.71	1.34e-37	Chronic sinus infection;
SARC	cis	rs10992471	0.631	rs2296667	chr9:95274338	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.93	-0.36	1.1e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs921968	0.541	rs523305	chr2:219402691	T/C	cg02176678	chr2:219576539	TTLL4	0.47	7.16	0.42	1.06e-11	Mean corpuscular hemoglobin concentration;
SARC	cis	rs262150	0.842	rs2657398	chr7:158784911	T/C	cg09640425	chr7:158790006	NA	-0.38	-5.09	-0.32	7.49e-7	Facial morphology (factor 20);
SARC	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg16680214	chr1:154839983	KCNN3	-0.37	-5.85	-0.36	1.69e-8	Prostate cancer;
SARC	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs10490913	0.806	rs1932549	chr10:120171113	C/T	cg23160142	chr10:120154512	NA	0.38	5.77	0.35	2.45e-8	Cancer;
SARC	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg05368731	chr17:41323189	NBR1	0.8	9.59	0.53	1.43e-18	Menopause (age at onset);
SARC	cis	rs992157	0.732	rs10932771	chr2:219170236	A/T	cg20019365	chr2:219134978	PNKD;AAMP	0.63	8.93	0.51	1.29e-16	Colorectal cancer;
SARC	cis	rs2573652	0.755	rs6598286	chr15:100515985	G/T	cg09918751	chr15:100517450	ADAMTS17	-0.42	-5.47	-0.34	1.16e-7	Height;
SARC	cis	rs7412746	0.611	rs12085336	chr1:150775780	A/T	cg10589385	chr1:150898437	SETDB1	0.39	5.25	0.33	3.46e-7	Melanoma;
SARC	cis	rs453301	0.686	rs6987107	chr8:8893581	A/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-8.22	-0.47	1.45e-14	Joint mobility (Beighton score);
SARC	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.39	5.31	0.33	2.56e-7	Obesity-related traits;
SARC	cis	rs6912958	0.559	rs445434	chr6:88041849	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.37	6.3	0.38	1.47e-9	Monocyte percentage of white cells;
SARC	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg05025164	chr4:1340916	KIAA1530	0.51	6.41	0.39	7.95e-10	Longevity;
SARC	cis	rs6060717	0.536	rs11697851	chr20:34524494	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-5.77	-0.35	2.54e-8	Hip circumference adjusted for BMI;
SARC	cis	rs9325144	0.560	rs11182952	chr12:38636278	C/A	cg26384229	chr12:38710491	ALG10B	-0.62	-7.98	-0.46	6.51e-14	Morning vs. evening chronotype;
SARC	cis	rs3768617	0.510	rs6666259	chr1:183102855	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.68	9.88	0.54	1.95e-19	Fuchs's corneal dystrophy;
SARC	cis	rs7208859	0.623	rs9911490	chr17:29073013	C/T	cg13385521	chr17:29058706	SUZ12P	0.88	7.94	0.46	8.37e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs11264799	0.603	rs12733062	chr1:157585932	C/A	cg18268488	chr1:157545234	FCRL4	0.35	5.96	0.36	9.2e-9	IgA nephropathy;
SARC	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg05861140	chr6:150128134	PCMT1	-0.39	-4.81	-0.3	2.74e-6	Lung cancer;
SARC	cis	rs5753037	0.676	rs737945	chr22:30202774	G/C	cg01021169	chr22:30184971	ASCC2	-0.39	-5.18	-0.32	4.86e-7	Type 1 diabetes;
SARC	cis	rs5167	0.525	rs10402642	chr19:45453878	G/A	cg10169327	chr19:45448959	APOC2	0.31	5.11	0.32	6.81e-7	Blood protein levels;
SARC	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg04772025	chr11:68637568	NA	0.52	6.33	0.38	1.22e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs73206853	0.764	rs61227741	chr12:110598319	G/T	cg10860002	chr12:110842031	ANAPC7	0.67	5.29	0.33	2.82e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs2361718	0.568	rs1042397	chr17:78092063	G/A	cg27427491	chr17:78079615	GAA	-0.3	-4.73	-0.3	3.83e-6	Yeast infection;
SARC	cis	rs4253772	0.626	rs12169526	chr22:46763846	C/T	cg18190219	chr22:46762943	CELSR1	-0.63	-4.81	-0.3	2.75e-6	LDL cholesterol;Cholesterol, total;
SARC	cis	rs56104184	0.830	rs73061617	chr19:49350984	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.95	-9.45	-0.53	3.75e-18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs17209837	1.000	rs45447097	chr7:87086144	G/A	cg00919237	chr7:87102261	ABCB4	-0.5	-5.47	-0.34	1.14e-7	Gallbladder cancer;
SARC	cis	rs9486715	0.867	rs2223238	chr6:96871855	G/A	cg18709589	chr6:96969512	KIAA0776	0.59	7.33	0.43	3.83e-12	Headache;
SARC	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg22974920	chr21:40686053	BRWD1	0.45	4.88	0.3	1.94e-6	Cognitive function;
SARC	cis	rs2549003	0.966	rs10213701	chr5:131824064	T/A	cg21138405	chr5:131827807	IRF1	0.27	5.17	0.32	5.15e-7	Asthma (sex interaction);
SARC	cis	rs6582630	0.502	rs10880388	chr12:38401341	A/T	cg13010199	chr12:38710504	ALG10B	0.77	10.42	0.56	4.05e-21	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg07777115	chr5:623756	CEP72	-0.6	-5.47	-0.34	1.17e-7	Obesity-related traits;
SARC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg20887711	chr4:1340912	KIAA1530	0.82	10.33	0.56	7.55e-21	Longevity;
SARC	cis	rs9796	0.621	rs28737302	chr15:41469943	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.54	-7.86	-0.46	1.44e-13	Menopause (age at onset);
SARC	cis	rs7584330	0.737	rs6758246	chr2:238359891	G/C	cg14458575	chr2:238380390	NA	0.44	5.41	0.33	1.59e-7	Prostate cancer;
SARC	cis	rs9640161	0.750	rs11769348	chr7:150026753	C/T	cg21361702	chr7:150065534	REPIN1	-0.52	-5.33	-0.33	2.27e-7	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs7772486	0.641	rs2253757	chr6:146199686	C/T	cg23711669	chr6:146136114	FBXO30	0.83	12.06	0.62	2.43e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg12311346	chr5:56204834	C5orf35	-0.58	-6.14	-0.37	3.46e-9	Initial pursuit acceleration;
SARC	cis	rs1348850	0.958	rs4893941	chr2:178269531	A/T	cg23306229	chr2:178417860	TTC30B	0.52	6.0	0.37	7.66e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2153535	0.580	rs2225766	chr6:8481833	G/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.49	0.6	1.71e-24	Motion sickness;
SARC	cis	rs807669	0.868	rs762529	chr22:19170205	C/G	cg02655711	chr22:19163373	SLC25A1	0.56	7.96	0.46	7.73e-14	Metabolite levels;
SARC	cis	rs11583043	1.000	rs17123612	chr1:101476814	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	5.68	0.35	4.01e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs2997447	0.846	rs2997446	chr1:26388241	C/G	cg19633962	chr1:26362018	EXTL1	-0.59	-5.09	-0.32	7.48e-7	QRS complex (12-leadsum);
SARC	cis	rs9393692	0.905	rs6908328	chr6:26292855	C/A	cg13736514	chr6:26305472	NA	-0.65	-9.06	-0.51	5.33e-17	Educational attainment;
SARC	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg05861140	chr6:150128134	PCMT1	-0.4	-5.23	-0.32	3.75e-7	Lung cancer;
SARC	trans	rs1635	0.655	rs73742539	chr6:28305471	C/T	cg08080395	chr15:65488966	CILP	0.62	6.26	0.38	1.88e-9	Schizophrenia;
SARC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.63	-0.4	2.28e-10	Total body bone mineral density;
SARC	cis	rs1190552	0.639	rs3742446	chr14:102975572	C/T	cg10241871	chr14:102965420	TECPR2	-0.43	-4.88	-0.3	1.98e-6	Blood protein levels;
SARC	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg16006841	chr5:176797999	RGS14	-0.67	-9.27	-0.52	1.27e-17	Urinary electrolytes (magnesium/calcium ratio);
SARC	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg10435706	chr6:150039699	LATS1	0.36	4.77	0.3	3.2e-6	Lung cancer;
SARC	trans	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg21659725	chr3:3221576	CRBN	0.79	11.35	0.6	4.7e-24	Intelligence (multi-trait analysis);
SARC	cis	rs858239	0.738	rs7807879	chr7:23260588	G/T	cg23682824	chr7:23144976	KLHL7	0.6	7.6	0.45	7.36e-13	Cerebrospinal fluid biomarker levels;
SARC	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg00825309	chr19:58991885	ZNF446	-0.55	-7.61	-0.45	6.74e-13	Uric acid clearance;
SARC	cis	rs1878931	0.531	rs9635548	chr16:3417156	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.74	9.51	0.53	2.48e-18	Body mass index (adult);
SARC	cis	rs7264396	0.635	rs6060709	chr20:34536022	A/G	cg12579300	chr20:34535607	PHF20	-0.42	-4.93	-0.31	1.58e-6	Total cholesterol levels;
SARC	cis	rs554111	0.858	rs10916855	chr1:21056382	T/C	cg08890418	chr1:21044141	KIF17	0.51	6.94	0.41	3.77e-11	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs796364	0.806	rs79156935	chr2:200913822	T/G	cg23649088	chr2:200775458	C2orf69	-0.6	-5.31	-0.33	2.51e-7	Schizophrenia;
SARC	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg18252515	chr7:66147081	NA	1.35	12.11	0.62	1.7e-26	Diabetic kidney disease;
SARC	cis	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg07777115	chr5:623756	CEP72	-0.55	-4.98	-0.31	1.25e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg08280861	chr8:58055591	NA	0.6	5.28	0.33	2.92e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2303759	0.709	rs2278405	chr19:49812403	A/C	cg22307029	chr19:49891270	CCDC155	-0.58	-6.58	-0.4	3.1e-10	Multiple sclerosis;
SARC	cis	rs9304742	0.962	rs1044467	chr19:53452769	A/G	cg24044776	chr19:53454761	ZNF816A	-0.38	-5.31	-0.33	2.5e-7	Psoriasis;
SARC	cis	rs6835098	0.961	rs17322893	chr4:174122556	A/G	cg08422745	chr4:174089978	GALNT7	0.75	9.58	0.53	1.53e-18	Dementia and core Alzheimer's disease neuropathologic changes;
SARC	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.44	5.43	0.34	1.38e-7	Tonsillectomy;
SARC	cis	rs8072100	0.713	rs8075058	chr17:45482857	A/G	cg08085267	chr17:45401833	C17orf57	-0.44	-5.18	-0.32	4.76e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs829661	0.532	rs11127276	chr2:30794215	C/T	cg17749961	chr2:30669863	LCLAT1	-0.4	-4.89	-0.31	1.84e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
SARC	cis	rs4563143	0.514	rs73029079	chr19:29294903	A/G	cg12756686	chr19:29218302	NA	0.59	6.77	0.41	1.03e-10	Methadone dose in opioid dependence;
SARC	cis	rs1355223	0.934	rs5010670	chr11:34766649	A/C	cg18508148	chr11:34937573	PDHX;APIP	-0.42	-5.32	-0.33	2.46e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.08	0.37	4.83e-9	Prudent dietary pattern;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg19012475	chr9:32552486	TOPORS	0.52	6.32	0.38	1.34e-9	Breast cancer;
SARC	cis	rs67311347	1.000	rs10510708	chr3:40404770	A/G	cg09455208	chr3:40491958	NA	0.41	6.26	0.38	1.88e-9	Renal cell carcinoma;
SARC	cis	rs7566780	0.568	rs1965731	chr2:16687183	A/G	cg09580478	chr2:16689509	NA	0.57	6.88	0.41	5.32e-11	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs35110281	0.805	rs162402	chr21:44963418	G/C	cg01579765	chr21:45077557	HSF2BP	-0.32	-5.42	-0.33	1.46e-7	Mean corpuscular volume;
SARC	cis	rs2153535	0.580	rs1414346	chr6:8471574	A/G	cg21535247	chr6:8435926	SLC35B3	0.54	6.79	0.41	9.19e-11	Motion sickness;
SARC	cis	rs6964587	0.626	rs10225241	chr7:91524940	A/G	cg17063962	chr7:91808500	NA	-0.78	-11.46	-0.6	2.11e-24	Breast cancer;
SARC	cis	rs72781680	0.898	rs79023848	chr2:24038174	C/A	cg08917208	chr2:24149416	ATAD2B	0.95	9.02	0.51	7.19e-17	Lymphocyte counts;
SARC	trans	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg06636001	chr8:8085503	FLJ10661	-0.68	-8.62	-0.49	1.03e-15	Neuroticism;
SARC	cis	rs3857067	0.773	rs10023115	chr4:95095502	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.34	-4.98	-0.31	1.26e-6	QT interval;
SARC	cis	rs7588746	0.621	rs11691757	chr2:201148951	C/T	cg23649088	chr2:200775458	C2orf69	-0.5	-5.95	-0.36	9.95e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs2439831	1.000	rs2444029	chr15:43737484	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	8.11	0.47	2.95e-14	Lung cancer in ever smokers;
SARC	cis	rs611744	0.870	rs638905	chr8:109203406	A/G	cg21045802	chr8:109455806	TTC35	0.44	5.23	0.32	3.81e-7	Dupuytren's disease;
SARC	cis	rs6141769	0.542	rs28456308	chr20:31273747	C/T	cg17884169	chr20:31446444	EFCAB8	-0.45	-4.83	-0.3	2.46e-6	Subjective well-being;
SARC	cis	rs3761847	0.500	rs7037673	chr9:123740484	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.39	4.84	0.3	2.37e-6	Rheumatoid arthritis;
SARC	cis	rs4243830	0.522	rs10157142	chr1:6618785	A/T	cg04093404	chr1:6614507	TAS1R1;NOL9	0.65	5.17	0.32	4.98e-7	Body mass index;
SARC	cis	rs35306767	0.903	rs10904577	chr10:922077	A/G	cg20503657	chr10:835505	NA	0.88	8.25	0.48	1.18e-14	Eosinophil percentage of granulocytes;
SARC	trans	rs3942852	0.806	rs10769316	chr11:48119745	C/G	cg15704280	chr7:45808275	SEPT13	-0.57	-6.64	-0.4	2.2e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs8180040	0.620	rs2278963	chr3:47054869	G/T	cg27129171	chr3:47204927	SETD2	-0.73	-9.66	-0.53	9.08e-19	Colorectal cancer;
SARC	cis	rs709400	0.628	rs10141120	chr14:103923008	T/C	cg12935359	chr14:103987150	CKB	-0.4	-5.87	-0.36	1.51e-8	Body mass index;
SARC	cis	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg25894440	chr7:65020034	NA	-0.74	-5.72	-0.35	3.18e-8	Diabetic kidney disease;
SARC	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg18252515	chr7:66147081	NA	-0.58	-6.24	-0.38	2.01e-9	Aortic root size;
SARC	cis	rs2997447	0.894	rs55722280	chr1:26412684	T/C	cg19633962	chr1:26362018	EXTL1	-0.58	-5.39	-0.33	1.72e-7	QRS complex (12-leadsum);
SARC	cis	rs147649347	1	rs147649347	chr2:24210076	GATAA/G	cg06627628	chr2:24431161	ITSN2	-0.73	-7.04	-0.42	2.17e-11	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22720560	chr5:65222058	ERBB2IP	-0.57	-7.36	-0.43	3.2e-12	Smoking initiation;
SARC	cis	rs11581859	0.613	rs6683801	chr1:99184056	A/G	cg20286094	chr1:99190917	SNX7	-0.41	-4.88	-0.3	1.97e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs6831352	0.819	rs1230155	chr4:99989259	C/T	cg13256891	chr4:100009986	ADH5	0.61	8.29	0.48	9.15e-15	Alcohol dependence;
SARC	cis	rs7264396	0.563	rs6058312	chr20:34324484	A/C	cg01084648	chr20:34329383	RBM39	0.58	5.03	0.31	9.74e-7	Total cholesterol levels;
SARC	cis	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg03060546	chr3:49711283	APEH	0.75	11.17	0.59	1.7e-23	Resting heart rate;
SARC	cis	rs11122272	0.735	rs2491405	chr1:231513431	C/A	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg12016809	chr21:47604291	C21orf56	-0.47	-5.63	-0.35	5.2e-8	Testicular germ cell tumor;
SARC	cis	rs7264396	0.563	rs2425121	chr20:34326186	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-7.01	-0.42	2.5e-11	Total cholesterol levels;
SARC	cis	rs13256369	0.901	rs12681327	chr8:8566414	G/T	cg18904891	chr8:8559673	CLDN23	0.5	5.73	0.35	3.14e-8	Obesity-related traits;
SARC	cis	rs10927875	0.929	rs10927879	chr1:16320028	G/A	cg21385522	chr1:16154831	NA	-0.72	-9.32	-0.52	8.97e-18	Dilated cardiomyopathy;
SARC	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg11890956	chr21:40555474	PSMG1	1.15	18.49	0.77	1.33e-47	Cognitive function;
SARC	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg18876405	chr7:65276391	NA	0.7	9.04	0.51	6.05e-17	Aortic root size;
SARC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg24503407	chr1:205819492	PM20D1	0.75	12.18	0.62	9.52e-27	Monocyte percentage of white cells;
SARC	cis	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.62	-0.45	6.36e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs950169	0.579	rs11633088	chr15:84672181	A/T	cg17507749	chr15:85114479	UBE2QP1	-0.71	-7.81	-0.46	1.98e-13	Schizophrenia;
SARC	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg00684032	chr4:1343700	KIAA1530	0.42	6.29	0.38	1.58e-9	Obesity-related traits;
SARC	cis	rs13256369	0.802	rs11249883	chr8:8561537	G/A	cg17143192	chr8:8559678	CLDN23	0.52	5.74	0.35	2.9e-8	Obesity-related traits;
SARC	cis	rs10752881	1.000	rs10911185	chr1:182971747	G/C	cg13390022	chr1:182993471	LAMC1	0.33	5.06	0.31	8.52e-7	Colorectal cancer;
SARC	cis	rs12477438	0.666	rs10179910	chr2:99658503	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-9.68	-0.54	7.43e-19	Chronic sinus infection;
SARC	cis	rs116095464	0.614	rs10059220	chr5:242813	C/T	cg22496380	chr5:211416	CCDC127	-0.96	-8.86	-0.5	2.03e-16	Breast cancer;
SARC	cis	rs7945705	0.870	rs10840142	chr11:8906078	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.41	5.64	0.35	4.96e-8	Hemoglobin concentration;
SARC	cis	rs67311347	1.000	rs4246666	chr3:40407670	C/T	cg09455208	chr3:40491958	NA	0.4	6.31	0.38	1.36e-9	Renal cell carcinoma;
SARC	cis	rs7617480	0.648	rs9284885	chr3:48883100	A/C	cg06212747	chr3:49208901	KLHDC8B	0.5	5.08	0.32	7.91e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs1707322	0.717	rs2991989	chr1:46082965	C/T	cg06784218	chr1:46089804	CCDC17	-0.39	-6.88	-0.41	5.34e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04798523	chr4:103749125	UBE2D3	-0.56	-7.1	-0.42	1.52e-11	Smoking initiation;
SARC	cis	rs6088590	1.000	rs2076668	chr20:33437621	G/A	cg06115741	chr20:33292138	TP53INP2	0.57	6.72	0.4	1.38e-10	Coronary artery disease;
SARC	cis	rs2120243	0.565	rs1500919	chr3:157079048	C/T	cg24825693	chr3:157122686	VEPH1	-0.45	-6.04	-0.37	6.03e-9	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs4319547	0.774	rs7307233	chr12:123124301	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.54	-6.35	-0.38	1.12e-9	Body mass index;
SARC	cis	rs6815814	0.950	rs56289835	chr4:38811845	G/C	cg09316306	chr4:38807337	TLR1	0.5	5.22	0.32	3.93e-7	Breast cancer;
SARC	cis	rs2361718	0.933	rs8066452	chr17:78104080	A/G	cg14949292	chr17:78079608	GAA	-0.29	-4.73	-0.3	3.85e-6	Yeast infection;
SARC	cis	rs36051895	0.659	rs61284219	chr9:5062816	C/A	cg02405213	chr9:5042618	JAK2	-0.46	-5.29	-0.33	2.83e-7	Pediatric autoimmune diseases;
SARC	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg18252515	chr7:66147081	NA	0.45	4.91	0.31	1.7e-6	Aortic root size;
SARC	cis	rs9911578	0.805	rs1811202	chr17:56454435	T/G	cg05425664	chr17:57184151	TRIM37	0.67	7.81	0.46	1.95e-13	Intelligence (multi-trait analysis);
SARC	cis	rs7274811	0.681	rs210074	chr20:31949756	A/T	cg21523528	chr20:32077966	CBFA2T2	-0.42	-4.92	-0.31	1.64e-6	Height;
SARC	trans	rs2898290	0.622	rs1382567	chr8:11350899	T/C	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.08	-0.42	1.65e-11	Systolic blood pressure;
SARC	cis	rs6088580	0.634	rs6087580	chr20:32992592	A/G	cg24642439	chr20:33292090	TP53INP2	-0.64	-8.04	-0.47	4.47e-14	Glomerular filtration rate (creatinine);
SARC	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg16479474	chr6:28041457	NA	0.37	5.44	0.34	1.37e-7	Depression;
SARC	cis	rs911555	0.723	rs12436956	chr14:103852607	G/T	cg24130564	chr14:104152367	KLC1	0.49	5.48	0.34	1.12e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2070488	1.000	rs34258593	chr3:38464565	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	14.49	0.69	2.36e-34	Electrocardiographic conduction measures;
SARC	cis	rs11724804	0.532	rs7657611	chr4:880558	G/C	cg20814179	chr4:940893	TMEM175	0.38	4.86	0.3	2.17e-6	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
SARC	cis	rs240764	0.853	rs10457809	chr6:100984400	C/T	cg09795085	chr6:101329169	ASCC3	-0.46	-6.06	-0.37	5.45e-9	Neuroticism;
SARC	cis	rs933688	1.000	rs7720132	chr5:90745105	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	13.03	0.65	1.61e-29	Smoking behavior;
SARC	cis	rs7772486	0.754	rs9497419	chr6:146142609	T/C	cg23711669	chr6:146136114	FBXO30	0.82	13.68	0.67	1.19e-31	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7712401	0.601	rs415534	chr5:122325301	C/T	cg19412675	chr5:122181750	SNX24	-0.43	-5.43	-0.34	1.41e-7	Mean platelet volume;
SARC	cis	rs4253772	0.637	rs7284687	chr22:46690321	T/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.68	5.56	0.34	7.33e-8	LDL cholesterol;Cholesterol, total;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg08828868	chr10:70715731	DDX21	-0.55	-6.49	-0.39	5.03e-10	Blood pressure;
SARC	cis	rs7223966	1.000	rs15637	chr17:61772050	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.48	-5.35	-0.33	2.07e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg10826053	chr4:108641834	PAPSS1	-0.59	-6.28	-0.38	1.65e-9	Lung cancer in ever smokers;
SARC	cis	rs13191362	1.000	rs34637087	chr6:163004064	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.49	0.34	1.04e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs11718455	0.960	rs17076255	chr3:44002093	C/T	cg08738300	chr3:44038990	NA	0.54	5.97	0.36	8.73e-9	Coronary artery disease;
SARC	cis	rs2749592	0.550	rs7081464	chr10:37883937	C/T	cg25427524	chr10:38739819	LOC399744	0.45	6.55	0.39	3.69e-10	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs7264396	0.836	rs6058275	chr20:34186331	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-6.18	-0.38	2.9e-9	Total cholesterol levels;
SARC	cis	rs2115630	0.967	rs7171167	chr15:85239123	A/T	cg17507749	chr15:85114479	UBE2QP1	-0.47	-5.6	-0.34	6.12e-8	P wave terminal force;
SARC	cis	rs2043112	0.691	rs7729041	chr5:39090696	C/G	cg04869206	chr5:39074266	RICTOR	0.52	6.37	0.39	9.99e-10	Obesity-related traits;
SARC	cis	rs1348850	0.561	rs4893956	chr2:178373452	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	5.87	0.36	1.5e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs6087771	0.642	rs6060403	chr20:30221104	C/A	cg13852791	chr20:30311386	BCL2L1	0.66	6.62	0.4	2.43e-10	Subcortical brain region volumes;Putamen volume;
SARC	cis	rs7937682	0.602	rs4936804	chr11:111743851	A/C	cg09085632	chr11:111637200	PPP2R1B	0.78	10.3	0.56	9.89e-21	Primary sclerosing cholangitis;
SARC	cis	rs72781680	0.664	rs2712076	chr2:23993366	T/C	cg08917208	chr2:24149416	ATAD2B	0.59	5.95	0.36	9.52e-9	Lymphocyte counts;
SARC	trans	rs2736337	0.530	rs11782375	chr8:11294934	C/T	cg06636001	chr8:8085503	FLJ10661	0.54	6.38	0.39	9.34e-10	Rheumatoid arthritis;
SARC	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg24549020	chr5:56110836	MAP3K1	0.52	5.74	0.35	2.91e-8	Initial pursuit acceleration;
SARC	cis	rs2933343	0.700	rs1683777	chr3:128624880	T/G	cg24203234	chr3:128598194	ACAD9	0.63	8.03	0.47	4.8e-14	IgG glycosylation;
SARC	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg17294928	chr15:75287854	SCAMP5	0.48	6.25	0.38	1.92e-9	Breast cancer;
SARC	cis	rs2075371	0.764	rs1643034	chr7:134006176	A/G	cg11752832	chr7:134001865	SLC35B4	0.6	7.95	0.46	8.08e-14	Mean platelet volume;
SARC	trans	rs1493916	0.870	rs7235698	chr18:31382486	A/G	cg27147174	chr7:100797783	AP1S1	-0.57	-7.26	-0.43	5.59e-12	Life satisfaction;
SARC	cis	rs6733011	0.519	rs11900176	chr2:99463536	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.44	5.39	0.33	1.75e-7	Bipolar disorder;
SARC	cis	rs1348850	0.526	rs6723063	chr2:178491398	C/T	cg23306229	chr2:178417860	TTC30B	0.77	6.9	0.41	4.83e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.7	-9.86	-0.54	2.09e-19	Menarche (age at onset);
SARC	cis	rs7766436	0.767	rs6909574	chr6:22606773	A/G	cg13666174	chr6:22585274	NA	-0.51	-7.04	-0.42	2.14e-11	Coronary artery disease;
SARC	cis	rs9291683	0.655	rs35750364	chr4:10049049	T/C	cg11266682	chr4:10021025	SLC2A9	0.4	7.27	0.43	5.35e-12	Bone mineral density;
SARC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg03395511	chr6:291903	DUSP22	-0.53	-6.64	-0.4	2.2e-10	Menopause (age at onset);
SARC	cis	rs34421088	0.560	rs2618434	chr8:11398865	A/G	cg21775007	chr8:11205619	TDH	-0.38	-4.73	-0.3	3.97e-6	Neuroticism;
SARC	cis	rs6690583	0.512	rs7547224	chr1:85456902	T/C	cg22153463	chr1:85462885	MCOLN2	0.75	6.45	0.39	6.42e-10	Serum sulfate level;
SARC	cis	rs854765	0.647	rs854769	chr17:18019011	A/G	cg04398451	chr17:18023971	MYO15A	0.55	8.16	0.47	2.13e-14	Total body bone mineral density;
SARC	cis	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg09021430	chr5:549028	NA	-0.44	-5.69	-0.35	3.85e-8	Obesity-related traits;
SARC	cis	rs372883	0.600	rs2832293	chr21:30738872	C/G	cg24692254	chr21:30365293	RNF160	0.65	8.31	0.48	7.81e-15	Pancreatic cancer;
SARC	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg05368731	chr17:41323189	NBR1	-0.68	-8.11	-0.47	2.89e-14	Menopause (age at onset);
SARC	cis	rs3820928	0.874	rs10210997	chr2:227859108	C/T	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.23	-0.32	3.85e-7	Pulmonary function;
SARC	cis	rs9300255	0.544	rs1790130	chr12:123701270	A/C	cg05973401	chr12:123451056	ABCB9	0.52	5.89	0.36	1.34e-8	Neutrophil percentage of white cells;
SARC	cis	rs7412746	0.658	rs7528773	chr1:150915875	G/A	cg10589385	chr1:150898437	SETDB1	0.42	5.64	0.35	4.91e-8	Melanoma;
SARC	cis	rs11098499	0.863	rs11723090	chr4:120490592	T/C	cg09307838	chr4:120376055	NA	0.91	12.25	0.63	5.66e-27	Corneal astigmatism;
SARC	cis	rs9381040	0.610	rs9394758	chr6:41017821	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.41	-4.8	-0.3	2.9e-6	Alzheimer's disease (late onset);
SARC	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.8	-8.05	-0.47	4.36e-14	Platelet count;
SARC	cis	rs6815814	0.950	rs11722788	chr4:38810738	C/G	cg02016764	chr4:38805732	TLR1	-0.41	-4.86	-0.3	2.18e-6	Breast cancer;
SARC	cis	rs453301	0.631	rs17700611	chr8:8793654	A/G	cg15556689	chr8:8085844	FLJ10661	-0.41	-5.0	-0.31	1.15e-6	Joint mobility (Beighton score);
SARC	cis	rs4481887	0.927	rs12044126	chr1:248481952	T/C	cg01631408	chr1:248437212	OR2T33	-0.37	-4.73	-0.3	3.98e-6	Common traits (Other);
SARC	cis	rs1003719	0.680	rs7275984	chr21:38505696	C/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-9.13	-0.51	3.35e-17	Eye color traits;
SARC	cis	rs7635838	0.859	rs9826803	chr3:11461863	G/A	cg00170343	chr3:11313890	ATG7	0.56	7.3	0.43	4.38e-12	HDL cholesterol;
SARC	cis	rs9916302	0.706	rs7208487	chr17:37543449	T/G	cg20243544	chr17:37824526	PNMT	-0.55	-5.81	-0.36	2.08e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs11718455	0.960	rs3843372	chr3:43997666	C/T	cg08738300	chr3:44038990	NA	0.54	6.03	0.37	6.53e-9	Coronary artery disease;
SARC	cis	rs11997175	0.545	rs66584807	chr8:33667609	A/G	ch.8.33884649F	chr8:33765107	NA	0.49	6.17	0.37	2.95e-9	Body mass index;
SARC	cis	rs2439831	0.681	rs1549523	chr15:43624189	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	8.94	0.51	1.19e-16	Lung cancer in ever smokers;
SARC	cis	rs7819412	0.765	rs17783634	chr8:11054097	C/A	cg14752069	chr8:11977206	FAM66D	-0.29	-4.82	-0.3	2.62e-6	Triglycerides;
SARC	cis	rs425277	1.000	rs262654	chr1:2089526	G/A	cg24578937	chr1:2090814	PRKCZ	0.32	5.97	0.36	8.76e-9	Height;
SARC	cis	rs16854884	0.586	rs6796460	chr3:143756367	G/A	cg06585982	chr3:143692056	C3orf58	0.7	9.83	0.54	2.77e-19	Economic and political preferences (feminism/equality);
SARC	cis	rs55871839	0.559	rs2326268	chr8:59841217	C/T	cg07426533	chr8:59803705	TOX	0.47	5.32	0.33	2.39e-7	Pneumonia;
SARC	cis	rs2635047	0.530	rs4986228	chr18:44595259	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.55	6.91	0.41	4.66e-11	Educational attainment;
SARC	cis	rs56235845	0.694	rs36102285	chr5:176774018	C/T	cg16006841	chr5:176797999	RGS14	0.55	7.35	0.43	3.43e-12	Hemoglobin concentration;Hematocrit;
SARC	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg22857025	chr5:266934	NA	-1.06	-11.8	-0.61	1.74e-25	Breast cancer;
SARC	cis	rs6598163	0.517	rs10902453	chr12:132297091	G/T	cg15284433	chr12:132323321	MMP17	0.38	5.04	0.31	9.31e-7	Migraine;
SARC	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg01475735	chr3:40494733	NA	-0.47	-5.15	-0.32	5.48e-7	Renal cell carcinoma;
SARC	cis	rs9291683	0.597	rs11722989	chr4:10126139	A/G	cg00071950	chr4:10020882	SLC2A9	-0.32	-5.08	-0.32	7.72e-7	Bone mineral density;
SARC	cis	rs7264396	0.733	rs6058305	chr20:34310757	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-8.49	-0.49	2.46e-15	Total cholesterol levels;
SARC	cis	rs995000	0.965	rs10889333	chr1:62957030	G/A	cg06896770	chr1:63153194	DOCK7	0.98	14.97	0.7	5.81e-36	Triglyceride levels;
SARC	cis	rs986417	1.000	rs1254286	chr14:60858300	T/C	cg27398547	chr14:60952738	C14orf39	-0.97	-8.69	-0.49	6.36e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs1008375	0.966	rs10939755	chr4:17693755	T/C	cg02297831	chr4:17616191	MED28	0.39	4.87	0.3	2.03e-6	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9902453	0.845	rs7221516	chr17:28232506	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	7.1	0.42	1.52e-11	Coffee consumption (cups per day);
SARC	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg08219700	chr8:58056026	NA	0.57	5.51	0.34	9.69e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6570726	0.846	rs6919684	chr6:145883801	A/G	cg05347473	chr6:146136440	FBXO30	0.51	7.18	0.43	9.15e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs67460515	0.563	rs4521287	chr3:160812752	C/T	cg04691961	chr3:161091175	C3orf57	-0.41	-4.76	-0.3	3.48e-6	Parkinson's disease;
SARC	cis	rs2290159	0.615	rs7610956	chr3:12677158	A/G	cg23032965	chr3:12705835	RAF1	0.76	8.24	0.47	1.27e-14	Cholesterol, total;
SARC	cis	rs9436747	0.807	rs1186075	chr1:66000437	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	-0.53	-5.19	-0.32	4.49e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs668210	0.793	rs619701	chr11:65772080	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.66	-6.46	-0.39	5.96e-10	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9430161	0.564	rs12081176	chr1:11034145	T/C	cg27631724	chr1:11040367	C1orf127	0.33	4.71	0.3	4.2e-6	Ewing sarcoma;
SARC	cis	rs9896052	0.614	rs4789201	chr17:73440579	A/G	cg04121983	chr17:73511085	CASKIN2	0.43	5.08	0.32	7.75e-7	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	trans	rs10771431	0.782	rs10771415	chr12:9358223	C/T	cg27600084	chr12:12264075	NA	0.53	7.04	0.42	2.14e-11	Breast size;
SARC	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg08645402	chr16:4508243	NA	0.52	6.05	0.37	5.7e-9	Schizophrenia;
SARC	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg18876405	chr7:65276391	NA	-0.66	-8.24	-0.48	1.21e-14	Aortic root size;
SARC	trans	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg02425709	chr6:133135492	RPS12;SNORD101	-0.51	-6.28	-0.38	1.65e-9	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9815354	0.904	rs73081347	chr3:41903582	T/C	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs921968	0.541	rs549026	chr2:219339283	T/C	cg02176678	chr2:219576539	TTLL4	0.47	7.22	0.43	7.15e-12	Mean corpuscular hemoglobin concentration;
SARC	cis	rs9640161	0.750	rs1983440	chr7:150023941	G/C	cg10018233	chr7:150070692	REPIN1	0.71	9.29	0.52	1.16e-17	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs116095464	1.000	rs56235400	chr5:312625	G/A	cg22857025	chr5:266934	NA	-1.04	-8.51	-0.49	2.12e-15	Breast cancer;
SARC	cis	rs3820928	0.839	rs12151848	chr2:227859326	G/A	cg05526886	chr2:227700861	RHBDD1	-0.49	-5.87	-0.36	1.5e-8	Pulmonary function;
SARC	cis	rs1697139	0.583	rs11739603	chr5:66540687	C/T	cg11553311	chr5:66541588	NA	0.31	4.96	0.31	1.33e-6	Breast cancer;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg20940459	chr1:173793922	CENPL;DARS2	-0.55	-6.24	-0.38	2.07e-9	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs9296095	1.000	rs9296095	chr6:33542523	A/G	cg14003231	chr6:33640908	ITPR3	0.35	5.72	0.35	3.32e-8	Platelet count;
SARC	cis	rs11190604	1.000	rs7085439	chr10:102210100	C/T	cg07080220	chr10:102295463	HIF1AN	0.78	9.58	0.53	1.56e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg03433033	chr1:76189801	ACADM	0.55	7.76	0.45	2.61e-13	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg25894440	chr7:65020034	NA	-0.81	-6.15	-0.37	3.34e-9	Diabetic kidney disease;
SARC	cis	rs2749592	0.505	rs7915670	chr10:37870212	T/C	cg00409905	chr10:38381863	ZNF37A	0.54	7.21	0.43	7.55e-12	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs11608355	1.000	rs2075439	chr12:109859374	A/G	cg05360138	chr12:110035743	NA	0.43	4.76	0.3	3.4e-6	Neuroticism;
SARC	trans	rs3942852	0.806	rs4752808	chr11:48141252	G/A	cg15704280	chr7:45808275	SEPT13	-0.57	-6.61	-0.4	2.55e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs709400	0.633	rs10143247	chr14:103920927	G/A	cg12935359	chr14:103987150	CKB	-0.4	-5.9	-0.36	1.24e-8	Body mass index;
SARC	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg17221315	chr6:27791827	HIST1H4J	0.46	4.83	0.3	2.53e-6	Depression;
SARC	cis	rs1163251	0.902	rs514491	chr1:120216743	C/T	cg19096424	chr1:120255104	PHGDH	0.53	6.2	0.38	2.58e-9	Blood metabolite levels;
SARC	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg00933542	chr6:150070202	PCMT1	0.3	5.08	0.32	7.66e-7	Lung cancer;
SARC	cis	rs6762477	0.748	rs9831967	chr3:50217234	C/T	cg24110177	chr3:50126178	RBM5	0.57	7.59	0.45	7.5e-13	Menarche (age at onset);
SARC	cis	rs9297145	0.761	rs62473015	chr7:98763301	G/A	cg05967295	chr7:98741636	SMURF1	0.76	7.8	0.46	2.04e-13	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
SARC	cis	rs6582630	0.519	rs4002440	chr12:38485012	A/G	cg13010199	chr12:38710504	ALG10B	0.75	10.21	0.56	1.79e-20	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg21830066	chr3:125239063	SNX4	0.52	6.74	0.4	1.25e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg20607798	chr8:58055168	NA	0.61	5.41	0.33	1.57e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9660992	0.674	rs12122105	chr1:205256818	C/T	cg21643547	chr1:205240462	TMCC2	-0.56	-6.98	-0.42	3.04e-11	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg09373136	chr17:61933544	TCAM1	-0.45	-6.1	-0.37	4.27e-9	Prudent dietary pattern;
SARC	cis	rs599083	0.829	rs314751	chr11:68179560	C/T	cg01657329	chr11:68192670	LRP5	0.42	5.94	0.36	1.04e-8	Bone mineral density (spine);
SARC	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	15.01	0.7	4.27e-36	Chronic sinus infection;
SARC	cis	rs3126085	0.778	rs10788828	chr1:152191879	G/A	cg26876637	chr1:152193138	HRNR	0.49	5.65	0.35	4.63e-8	Atopic dermatitis;
SARC	cis	rs1448094	0.512	rs12314274	chr12:86249196	A/G	cg02569458	chr12:86230093	RASSF9	0.35	4.91	0.31	1.72e-6	Major depressive disorder;
SARC	cis	rs8078723	0.866	rs11078934	chr17:38189793	C/T	cg17467752	chr17:38218738	THRA	0.55	7.37	0.43	3.03e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs12711979	0.509	rs12711972	chr2:3823786	T/C	cg17052675	chr2:3827356	NA	-0.51	-7.54	-0.44	1.07e-12	Itch intensity from mosquito bite adjusted by bite size;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08194979	chr14:62229171	SNAPC1	0.51	6.5	0.39	4.79e-10	Smoking initiation;
SARC	cis	rs9911578	1.000	rs2611782	chr17:56717956	T/C	cg12560992	chr17:57184187	TRIM37	0.83	11.32	0.6	5.91e-24	Intelligence (multi-trait analysis);
SARC	cis	rs7605378	0.528	rs281787	chr2:200784238	C/T	cg23649088	chr2:200775458	C2orf69	-0.82	-11.92	-0.62	6.89e-26	Osteoporosis;
SARC	cis	rs2153904	0.793	rs12132270	chr1:205660940	C/T	cg17178900	chr1:205818956	PM20D1	-0.55	-5.0	-0.31	1.15e-6	Prostate-specific antigen levels;
SARC	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg03806693	chr22:41940476	POLR3H	-0.94	-13.31	-0.66	1.99e-30	Vitiligo;
SARC	cis	rs910316	1.000	rs4903279	chr14:75546583	C/T	cg06637938	chr14:75390232	RPS6KL1	0.54	7.7	0.45	3.98e-13	Height;
SARC	cis	rs1355223	1.000	rs12792532	chr11:34765782	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.13	-0.37	3.69e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs7681440	0.606	rs2619353	chr4:90747975	G/C	cg06632027	chr4:90757378	SNCA	-0.42	-5.25	-0.33	3.41e-7	Dementia with Lewy bodies;
SARC	cis	rs1018836	0.923	rs13277387	chr8:91633713	C/G	cg16814680	chr8:91681699	NA	-0.81	-13.33	-0.66	1.7e-30	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs4930561	0.765	rs10896304	chr11:67981714	T/G	cg16338278	chr11:67432957	ALDH3B2	0.35	5.61	0.35	5.6e-8	Breast cancer in childhood cancer survivors;IgG glycosylation;
SARC	cis	rs55986470	0.763	rs6713788	chr2:239456932	T/A	cg21699342	chr2:239360505	ASB1	-0.44	-4.79	-0.3	2.92e-6	Chronotype;
SARC	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	7.33	0.43	3.82e-12	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	cis	rs2836633	0.895	rs2212606	chr21:40044940	A/C	cg12884169	chr21:40033163	ERG	0.48	8.51	0.49	2.2e-15	Coronary artery disease;
SARC	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-8.09	-0.47	3.32e-14	Chronic sinus infection;
SARC	cis	rs4253772	0.550	rs9615913	chr22:46668515	A/T	cg24881330	chr22:46731750	TRMU	-0.63	-6.39	-0.39	8.73e-10	LDL cholesterol;Cholesterol, total;
SARC	cis	rs7539542	0.516	rs10732291	chr1:202891168	G/A	cg08940984	chr1:202857613	RABIF	0.36	4.9	0.31	1.77e-6	Mean platelet volume;
SARC	cis	rs17600642	0.694	rs56055213	chr10:72445307	T/C	cg19779893	chr10:72451501	ADAMTS14	-0.35	-5.53	-0.34	8.53e-8	Bipolar disorder;
SARC	cis	rs7223966	1.000	rs2874121	chr17:61731024	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.56	-6.03	-0.37	6.33e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs9523762	0.577	rs9516124	chr13:93354797	A/G	cg04405926	chr1:150208726	ANP32E	0.47	6.42	0.39	7.53e-10	Multiple sclerosis;
SARC	cis	rs2832077	1.000	rs2832077	chr21:30141021	G/A	cg03476357	chr21:30257390	N6AMT1	-0.62	-5.81	-0.36	2.05e-8	Cognitive test performance;
SARC	cis	rs7666738	0.546	rs13141117	chr4:98892798	G/A	cg05340658	chr4:99064831	C4orf37	0.58	7.16	0.42	1.02e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.51	6.5	0.39	4.93e-10	Lymphocyte counts;
SARC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg25934064	chr3:52569026	NT5DC2	0.31	4.75	0.3	3.56e-6	Bipolar disorder;
SARC	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg04772025	chr11:68637568	NA	0.5	6.12	0.37	3.95e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs17376456	0.825	rs7715562	chr5:93222034	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.6	-5.38	-0.33	1.85e-7	Diabetic retinopathy;
SARC	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg13628971	chr7:2884303	GNA12	0.67	8.3	0.48	8.72e-15	Height;
SARC	trans	rs629535	0.911	rs490165	chr8:70014976	A/G	cg21567404	chr3:27674614	NA	-1.07	-14.6	-0.69	1.01e-34	Dupuytren's disease;
SARC	cis	rs3796352	1.000	rs35174175	chr3:53041509	T/C	cg27565382	chr3:53032988	SFMBT1	1.04	7.27	0.43	5.28e-12	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg06221963	chr1:154839813	KCNN3	-0.47	-7.2	-0.43	8.4e-12	Prostate cancer;
SARC	cis	rs6542838	0.641	rs4553869	chr2:99505940	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-5.94	-0.36	1.02e-8	Fear of minor pain;
SARC	cis	rs8067545	0.750	rs7208365	chr17:19998017	T/G	cg13482628	chr17:19912719	NA	0.52	7.09	0.42	1.6e-11	Schizophrenia;
SARC	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg05368731	chr17:41323189	NBR1	0.77	9.18	0.52	2.34e-17	Menopause (age at onset);
SARC	cis	rs7595412	0.877	rs1434293	chr2:199048138	A/C	cg00208931	chr2:198669586	PLCL1	-0.72	-5.15	-0.32	5.53e-7	Hip bone size;
SARC	cis	rs2276314	1.000	rs9304153	chr18:33562150	T/C	cg19628046	chr18:33552617	C18orf21	0.57	5.96	0.36	9.43e-9	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs73198271	0.531	rs17154756	chr8:8652394	C/T	cg01851573	chr8:8652454	MFHAS1	0.39	4.81	0.3	2.69e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	trans	rs3942852	0.774	rs1039481	chr11:48182237	G/A	cg15704280	chr7:45808275	SEPT13	-0.61	-7.11	-0.42	1.42e-11	Acute lymphoblastic leukemia (childhood);
SARC	trans	rs9329221	0.657	rs17694485	chr8:10114458	A/T	cg06636001	chr8:8085503	FLJ10661	0.54	7.26	0.43	5.7e-12	Neuroticism;
SARC	cis	rs7084402	0.967	rs1649059	chr10:60312599	T/C	cg07615347	chr10:60278583	BICC1	0.59	8.65	0.49	8.48e-16	Refractive error;
SARC	cis	rs72945132	0.882	rs7941933	chr11:70123351	G/A	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.58	-0.34	6.78e-8	Coronary artery disease;
SARC	cis	rs2404602	0.716	rs1946650	chr15:76848463	T/C	cg22467129	chr15:76604101	ETFA	-0.36	-4.78	-0.3	3.11e-6	Blood metabolite levels;
SARC	cis	rs6495122	0.699	rs1378940	chr15:75083494	C/A	cg09165964	chr15:75287851	SCAMP5	0.4	4.71	0.3	4.17e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	cis	rs807669	0.903	rs1771540	chr22:19173933	T/A	cg02655711	chr22:19163373	SLC25A1	0.55	7.49	0.44	1.44e-12	Metabolite levels;
SARC	cis	rs9911578	0.967	rs11079368	chr17:57086473	C/T	cg05425664	chr17:57184151	TRIM37	0.63	8.0	0.46	5.74e-14	Intelligence (multi-trait analysis);
SARC	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg03185022	chr7:2884158	GNA12	0.43	4.73	0.3	3.82e-6	Height;
SARC	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.31	-4.76	-0.3	3.39e-6	Total body bone mineral density;
SARC	cis	rs7927592	0.913	rs7104345	chr11:68316772	G/A	cg01657329	chr11:68192670	LRP5	-0.41	-4.82	-0.3	2.55e-6	Total body bone mineral density;
SARC	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg16479474	chr6:28041457	NA	0.37	5.44	0.34	1.37e-7	Depression;
SARC	trans	rs11098499	0.954	rs10017371	chr4:120293776	A/G	cg25214090	chr10:38739885	LOC399744	0.56	7.24	0.43	6.38e-12	Corneal astigmatism;
SARC	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg12667521	chr19:29218732	NA	0.4	5.3	0.33	2.7e-7	Methadone dose in opioid dependence;
SARC	cis	rs7216064	0.655	rs8078543	chr17:66037251	G/T	cg12091567	chr17:66097778	LOC651250	0.92	11.89	0.61	8.31e-26	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs7264396	0.690	rs2425171	chr20:34443173	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-7.07	-0.42	1.76e-11	Total cholesterol levels;
SARC	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg21782813	chr7:2030301	MAD1L1	0.47	7.41	0.44	2.33e-12	Bipolar disorder and schizophrenia;
SARC	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg18404041	chr3:52824283	ITIH1	-0.44	-6.7	-0.4	1.58e-10	Bipolar disorder;
SARC	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg16405210	chr4:1374714	KIAA1530	-0.5	-5.92	-0.36	1.12e-8	Obesity-related traits;
SARC	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg11062466	chr8:58055876	NA	0.54	4.84	0.3	2.33e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs931812	0.757	rs4734015	chr8:101909258	C/G	cg07585502	chr8:101912084	NA	-0.37	-4.72	-0.3	4.05e-6	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs10193935	0.901	rs222471	chr2:42638057	C/T	cg27598129	chr2:42591480	NA	0.37	4.88	0.3	1.99e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg24549020	chr5:56110836	MAP3K1	-0.65	-7.44	-0.44	1.94e-12	Type 2 diabetes;
SARC	cis	rs2734839	0.537	rs10891549	chr11:113278447	T/C	cg14159747	chr11:113255604	NA	0.33	4.78	0.3	3.11e-6	Information processing speed;
SARC	cis	rs7927592	0.956	rs10896341	chr11:68313180	G/A	cg01657329	chr11:68192670	LRP5	-0.41	-4.82	-0.3	2.55e-6	Total body bone mineral density;
SARC	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg06420487	chr17:61919686	SMARCD2	0.46	5.09	0.32	7.48e-7	Height;
SARC	cis	rs2153535	0.580	rs9378551	chr6:8463744	A/G	cg21535247	chr6:8435926	SLC35B3	0.54	6.78	0.41	1e-10	Motion sickness;
SARC	cis	rs763121	0.819	rs5750658	chr22:39060917	C/T	cg21395723	chr22:39101663	GTPBP1	0.58	6.43	0.39	7.23e-10	Menopause (age at onset);
SARC	cis	rs2033732	0.706	rs10102194	chr8:85075662	T/G	cg05716166	chr8:85095498	RALYL	0.49	5.65	0.35	4.59e-8	Body mass index;
SARC	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg09699651	chr6:150184138	LRP11	0.43	5.07	0.31	8.28e-7	Lung cancer;
SARC	cis	rs854765	0.547	rs2955370	chr17:17966945	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.41	-5.06	-0.31	8.66e-7	Total body bone mineral density;
SARC	cis	rs4921915	0.519	rs35583283	chr8:18254509	G/C	cg18736775	chr8:18248649	NAT2	-0.63	-6.68	-0.4	1.72e-10	Iron status biomarkers (transferrin levels);
SARC	cis	rs3923518	1.000	rs11915204	chr3:38908127	A/G	cg15678707	chr3:39149194	GORASP1;TTC21A	-0.48	-5.2	-0.32	4.32e-7	Migraine;
SARC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg06074448	chr4:187884817	NA	0.46	6.0	0.37	7.62e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7412746	0.658	rs17660092	chr1:150797748	T/C	cg15448220	chr1:150897856	SETDB1	0.48	6.3	0.38	1.5e-9	Melanoma;
SARC	cis	rs9911578	1.000	rs9911578	chr17:56953147	C/T	cg05425664	chr17:57184151	TRIM37	-0.65	-8.0	-0.46	5.84e-14	Intelligence (multi-trait analysis);
SARC	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg06713675	chr4:122721982	EXOSC9	-0.49	-6.51	-0.39	4.59e-10	Type 2 diabetes;
SARC	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg03060546	chr3:49711283	APEH	0.42	5.27	0.33	3.17e-7	Parkinson's disease;
SARC	cis	rs708547	0.836	rs1625691	chr4:57845740	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.76	10.08	0.55	4.61e-20	Response to bleomycin (chromatid breaks);
SARC	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg13939156	chr17:80058883	NA	-0.44	-6.79	-0.41	9.27e-11	Life satisfaction;
SARC	cis	rs2933343	0.951	rs9871612	chr3:128570402	C/T	cg25356066	chr3:128598488	ACAD9	0.47	5.04	0.31	9.23e-7	IgG glycosylation;
SARC	cis	rs17826219	0.568	rs7213925	chr17:29121634	A/G	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Body mass index;
SARC	cis	rs854765	0.547	rs8075189	chr17:17901946	C/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.46	6.01	0.37	7.21e-9	Total body bone mineral density;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg03469202	chr8:71520450	TRAM1	-0.6	-6.8	-0.41	8.47e-11	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs57502260	0.704	rs72936599	chr11:68320405	G/A	cg20283391	chr11:68216788	NA	-0.54	-4.74	-0.3	3.69e-6	Total body bone mineral density (age 45-60);
SARC	cis	rs12348691	0.503	rs907576	chr9:100615359	C/T	cg13688889	chr9:100608707	NA	-0.47	-5.0	-0.31	1.15e-6	Alopecia areata;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg25976786	chr12:53662079	ESPL1	-0.56	-6.43	-0.39	7.04e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs6963495	0.745	rs2392749	chr7:105182605	A/G	cg19920283	chr7:105172520	RINT1	0.72	7.15	0.42	1.13e-11	Bipolar disorder (body mass index interaction);
SARC	cis	rs17854409	0.881	rs68091818	chr20:61479882	A/C	cg05147244	chr20:61493195	TCFL5	0.97	7.01	0.42	2.49e-11	Obesity-related traits;
SARC	cis	rs9790314	0.846	rs9815222	chr3:160994897	C/T	cg03342759	chr3:160939853	NMD3	-0.73	-9.93	-0.55	1.29e-19	Morning vs. evening chronotype;
SARC	cis	rs7089973	0.604	rs11196943	chr10:116598865	T/C	cg08188268	chr10:116634841	FAM160B1	0.28	4.86	0.3	2.13e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs73198271	0.531	rs17154758	chr8:8653343	G/A	cg01851573	chr8:8652454	MFHAS1	0.39	4.81	0.3	2.69e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg11764359	chr7:65958608	NA	0.61	7.23	0.43	6.7e-12	Aortic root size;
SARC	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg19223190	chr17:80058835	NA	0.46	6.25	0.38	1.92e-9	Life satisfaction;
SARC	cis	rs4595586	0.545	rs11615718	chr12:39395335	A/G	cg26384229	chr12:38710491	ALG10B	0.5	6.12	0.37	3.98e-9	Morning vs. evening chronotype;
SARC	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg06028808	chr11:68637592	NA	0.46	5.76	0.35	2.68e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg14019146	chr3:50243930	SLC38A3	-0.32	-5.04	-0.31	9.29e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg08975724	chr8:8085496	FLJ10661	0.48	6.07	0.37	5.25e-9	Mood instability;
SARC	cis	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg05623727	chr3:50126028	RBM5	0.34	5.19	0.32	4.52e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6570726	0.905	rs377143	chr6:145834220	C/T	cg23711669	chr6:146136114	FBXO30	0.75	11.25	0.59	9.44e-24	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	11.03	0.59	4.93e-23	Alzheimer's disease;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg07080607	chr2:10712018	NOL10	0.46	6.62	0.4	2.5e-10	Thyroid stimulating hormone;
SARC	cis	rs7208859	0.673	rs60020217	chr17:29185054	G/A	cg13385521	chr17:29058706	SUZ12P	0.86	7.34	0.43	3.54e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs4481887	1.000	rs4244176	chr1:248468231	G/A	cg00666640	chr1:248458726	OR2T12	0.38	6.42	0.39	7.43e-10	Common traits (Other);
SARC	cis	rs427394	0.632	rs2279656	chr5:6737576	G/A	cg10857441	chr5:6722123	POLS	-0.35	-5.1	-0.32	7.11e-7	Menopause (age at onset);
SARC	cis	rs7264396	0.563	rs2425079	chr20:34298191	T/C	cg01084648	chr20:34329383	RBM39	0.56	4.93	0.31	1.57e-6	Total cholesterol levels;
SARC	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg07701084	chr6:150067640	NUP43	0.41	5.42	0.33	1.5e-7	Lung cancer;
SARC	cis	rs9467711	0.651	rs34116162	chr6:25937652	G/A	cg21479132	chr6:26055353	NA	0.83	5.14	0.32	5.94e-7	Autism spectrum disorder or schizophrenia;
SARC	cis	rs4742903	0.935	rs10991166	chr9:106974096	T/C	cg14250997	chr9:106856677	SMC2	0.4	5.05	0.31	8.76e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs3126085	0.935	rs3126046	chr1:152256925	G/A	cg03465714	chr1:152285911	FLG	0.46	5.55	0.34	7.61e-8	Atopic dermatitis;
SARC	cis	rs7224737	1.000	rs2240010	chr17:40278081	T/A	cg20291162	chr17:40259547	DHX58	-0.33	-4.87	-0.3	2.08e-6	Fibrinogen levels;
SARC	cis	rs7927592	0.513	rs607887	chr11:68196961	C/T	cg01657329	chr11:68192670	LRP5	-0.4	-5.49	-0.34	1.07e-7	Total body bone mineral density;
SARC	cis	rs10992471	0.639	rs10125587	chr9:95499882	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.43	-4.9	-0.31	1.82e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs6952808	0.609	rs34967784	chr7:1949507	T/G	cg04267008	chr7:1944627	MAD1L1	-0.48	-5.48	-0.34	1.1e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs12586317	0.620	rs79832710	chr14:35547434	G/T	cg26967526	chr14:35346199	BAZ1A	-0.62	-6.32	-0.38	1.31e-9	Psoriasis;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg24047689	chr1:6614587	TAS1R1;NOL9	0.47	6.43	0.39	7.13e-10	Tetralogy of Fallot;
SARC	cis	rs17376456	0.809	rs10476602	chr5:93445255	T/C	cg25358565	chr5:93447407	FAM172A	1.31	15.17	0.7	1.33e-36	Diabetic retinopathy;
SARC	cis	rs4588572	0.644	rs2115435	chr5:77723700	A/C	cg18281939	chr5:77783895	LHFPL2	0.36	5.16	0.32	5.32e-7	Triglycerides;
SARC	cis	rs8044868	0.861	rs7192848	chr16:72206955	A/G	cg16558253	chr16:72132732	DHX38	-0.37	-5.26	-0.33	3.29e-7	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
SARC	cis	rs7592578	0.599	rs62180992	chr2:191285732	A/G	cg25963032	chr2:191064776	C2orf88	-0.47	-5.36	-0.33	2.05e-7	Diastolic blood pressure;
SARC	cis	rs4713675	0.709	rs542441	chr6:33675851	A/C	cg15676125	chr6:33679581	C6orf125	-0.42	-5.02	-0.31	1.01e-6	Plateletcrit;
SARC	cis	rs9486719	1.000	rs12208011	chr6:96991105	G/A	cg06623918	chr6:96969491	KIAA0776	-0.79	-8.63	-0.49	9.42e-16	Migraine;Coronary artery disease;
SARC	cis	rs2236918	1.000	rs1776137	chr1:242027045	A/G	cg17736920	chr1:242011382	EXO1	0.77	10.59	0.57	1.16e-21	Menopause (age at onset);
SARC	cis	rs3760982	0.585	rs10422108	chr19:44294868	C/T	cg11993925	chr19:44307056	LYPD5	0.3	4.76	0.3	3.37e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
SARC	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg22535103	chr8:58192502	C8orf71	-0.8	-9.2	-0.52	2.12e-17	Developmental language disorder (linguistic errors);
SARC	cis	rs9790314	0.690	rs6441354	chr3:160826404	A/G	cg03342759	chr3:160939853	NMD3	-0.52	-6.57	-0.4	3.24e-10	Morning vs. evening chronotype;
SARC	cis	rs7824557	0.591	rs2060457	chr8:11213250	C/T	cg21775007	chr8:11205619	TDH	0.72	9.58	0.53	1.49e-18	Retinal vascular caliber;
SARC	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg17499041	chr6:35310257	PPARD	0.46	6.37	0.39	9.79e-10	Cancer;
SARC	cis	rs5758659	0.904	rs134877	chr22:42662371	C/T	cg15128208	chr22:42549153	NA	-0.34	-4.87	-0.3	2.09e-6	Cognitive function;
SARC	cis	rs908922	0.676	rs1337340	chr1:152508260	T/C	cg09873164	chr1:152488093	CRCT1	0.66	8.62	0.49	1.03e-15	Hair morphology;
SARC	cis	rs6570726	0.902	rs406979	chr6:145838983	G/T	cg05347473	chr6:146136440	FBXO30	0.48	6.45	0.39	6.38e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9399135	0.636	rs4646871	chr6:135265617	A/G	cg24558204	chr6:135376177	HBS1L	-0.45	-6.02	-0.37	6.59e-9	Red blood cell count;
SARC	cis	rs6991838	0.584	rs11985628	chr8:66542739	T/C	cg13398993	chr8:66546079	ARMC1	0.62	8.19	0.47	1.72e-14	Intelligence (multi-trait analysis);
SARC	cis	rs709400	0.663	rs17617941	chr14:103953032	T/C	cg26031613	chr14:104095156	KLC1	0.83	12.13	0.62	1.39e-26	Body mass index;
SARC	cis	rs644799	1.000	rs11021319	chr11:95523123	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.94	15.6	0.71	4.77e-38	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg24110177	chr3:50126178	RBM5	-0.4	-5.07	-0.32	7.98e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9400467	0.506	rs12215049	chr6:111618384	A/G	cg15721981	chr6:111408429	SLC16A10	0.69	5.85	0.36	1.67e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs9616064	0.506	rs6008944	chr22:47060976	C/T	cg05621596	chr22:47072043	GRAMD4	-0.5	-7.18	-0.43	9.36e-12	Urate levels in obese individuals;
SARC	cis	rs9818758	0.607	rs67060340	chr3:48915321	C/T	cg07636037	chr3:49044803	WDR6	-0.74	-6.49	-0.39	5.12e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs208520	0.802	rs4710315	chr6:66887594	A/G	cg07460842	chr6:66804631	NA	-1.06	-13.61	-0.67	1.99e-31	Exhaled nitric oxide output;
SARC	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg10374962	chr7:1011985	COX19	-0.44	-5.13	-0.32	6.24e-7	Bronchopulmonary dysplasia;
SARC	cis	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg13072238	chr3:49761600	GMPPB	-0.43	-5.6	-0.34	5.96e-8	Intelligence (multi-trait analysis);
SARC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg27588902	chr6:42928151	GNMT	-0.37	-5.59	-0.34	6.29e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs78487399	0.710	rs6544665	chr2:43729212	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-4.84	-0.3	2.37e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs12142240	0.698	rs72677593	chr1:46824363	T/C	cg14993813	chr1:46806288	NSUN4	-0.51	-5.34	-0.33	2.19e-7	Menopause (age at onset);
SARC	cis	rs112591243	0.685	rs78463142	chr21:47964481	A/G	cg26904215	chr21:47823096	PCNT	-0.82	-5.33	-0.33	2.26e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg11764359	chr7:65958608	NA	0.69	8.18	0.47	1.88e-14	Aortic root size;
SARC	cis	rs9420	0.961	rs1647405	chr11:57477889	C/T	cg19752551	chr11:57585705	CTNND1	-0.4	-5.48	-0.34	1.11e-7	Schizophrenia;
SARC	cis	rs1448094	0.817	rs11117115	chr12:86331021	A/G	cg02569458	chr12:86230093	RASSF9	0.41	5.84	0.36	1.73e-8	Major depressive disorder;
SARC	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg23131131	chr22:24373011	LOC391322	-0.47	-5.32	-0.33	2.4e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6429082	0.660	rs10737818	chr1:235542023	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.6	-6.91	-0.41	4.68e-11	Adiposity;
SARC	cis	rs2075371	1.000	rs2544218	chr7:133992315	C/A	cg20476274	chr7:133979776	SLC35B4	0.62	8.41	0.48	4.18e-15	Mean platelet volume;
SARC	cis	rs7667	0.812	rs12042004	chr1:19764040	C/G	cg15311933	chr1:19638897	PQLC2;AKR7A2	-0.44	-5.01	-0.31	1.06e-6	Crohn's disease and psoriasis;
SARC	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg18876405	chr7:65276391	NA	-0.73	-9.17	-0.51	2.64e-17	Aortic root size;
SARC	cis	rs2444217	0.542	rs11649287	chr16:4039968	A/G	cg09300795	chr16:4042428	ADCY9	-0.35	-4.87	-0.3	2.09e-6	Body mass index;
SARC	cis	rs6450176	0.625	rs11747281	chr5:53289047	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.86	-10.05	-0.55	5.8e-20	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs3812831	0.695	rs422149	chr13:114931086	T/G	cg06611532	chr13:114900021	NA	0.35	5.79	0.35	2.28e-8	Schizophrenia;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg06530742	chr19:41223047	ITPKC;ADCK4	0.76	6.44	0.39	6.79e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg12373951	chr3:133503437	NA	0.36	5.28	0.33	3e-7	Iron status biomarkers;
SARC	cis	rs6690583	0.623	rs7522239	chr1:85484366	C/T	cg22153463	chr1:85462885	MCOLN2	0.7	6.45	0.39	6.31e-10	Serum sulfate level;
SARC	cis	rs12311304	1.000	rs12303992	chr12:15386448	A/G	cg08258403	chr12:15378311	NA	0.49	7.35	0.43	3.4e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg22800045	chr5:56110881	MAP3K1	0.75	7.94	0.46	8.65e-14	Initial pursuit acceleration;
SARC	cis	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg13647721	chr17:30228624	UTP6	-0.69	-5.88	-0.36	1.4e-8	Hip circumference adjusted for BMI;
SARC	cis	rs1401999	0.690	rs6773408	chr3:183716609	G/T	cg01324343	chr3:183735012	ABCC5	0.6	11.58	0.6	8.38e-25	Anterior chamber depth;
SARC	trans	rs61931739	0.500	rs3934517	chr12:34451396	T/C	cg26384229	chr12:38710491	ALG10B	0.84	12.56	0.64	5.71e-28	Morning vs. evening chronotype;
SARC	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-6.33	-0.38	1.22e-9	Personality dimensions;
SARC	cis	rs72781680	0.848	rs56021814	chr2:24073437	T/A	cg08917208	chr2:24149416	ATAD2B	0.79	7.6	0.45	7.14e-13	Lymphocyte counts;
SARC	cis	rs10752881	0.740	rs1889307	chr1:183049389	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.67	9.71	0.54	6.39e-19	Colorectal cancer;
SARC	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg03060546	chr3:49711283	APEH	0.4	5.08	0.32	7.86e-7	Parkinson's disease;
SARC	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg03806693	chr22:41940476	POLR3H	-0.96	-13.6	-0.67	2.21e-31	Vitiligo;
SARC	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg24250549	chr1:154909240	PMVK	0.83	11.95	0.62	5.56e-26	Prostate cancer;
SARC	cis	rs7824557	0.564	rs2736288	chr8:11228100	G/A	cg21775007	chr8:11205619	TDH	-0.6	-7.84	-0.46	1.61e-13	Retinal vascular caliber;
SARC	cis	rs7084402	0.934	rs1658453	chr10:60309602	T/C	cg07615347	chr10:60278583	BICC1	0.59	8.61	0.49	1.12e-15	Refractive error;
SARC	cis	rs4689388	0.824	rs6446482	chr4:6295693	C/G	cg14416269	chr4:6271139	WFS1	0.32	4.81	0.3	2.66e-6	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs66573146	0.831	rs67315413	chr4:6987910	T/C	cg00086871	chr4:6988644	TBC1D14	0.9	5.39	0.33	1.72e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs12421382	0.592	rs2029297	chr11:109465968	A/G	cg27471124	chr11:109292789	C11orf87	0.37	5.14	0.32	5.83e-7	Schizophrenia;
SARC	cis	rs6496667	0.533	rs7173201	chr15:90991195	A/T	cg22089800	chr15:90895588	ZNF774	0.43	4.92	0.31	1.65e-6	Rheumatoid arthritis;
SARC	trans	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg07211511	chr3:129823064	LOC729375	-0.61	-6.56	-0.39	3.4e-10	Blood pressure (smoking interaction);
SARC	cis	rs11578119	0.933	rs115701628	chr1:170421735	C/T	cg09767346	chr1:170501363	GORAB	0.44	5.23	0.32	3.78e-7	Male-pattern baldness;
SARC	trans	rs17685	0.558	rs60787921	chr7:75792844	C/A	cg19862616	chr7:65841803	NCRNA00174	0.64	8.01	0.46	5.5e-14	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs1865760	1.000	rs1865760	chr6:25916979	C/T	cg10373733	chr6:25993375	NA	0.41	4.83	0.3	2.42e-6	Height;
SARC	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg11301795	chr4:187892539	NA	-0.72	-10.48	-0.57	2.68e-21	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg07701084	chr6:150067640	NUP43	0.43	5.72	0.35	3.29e-8	Lung cancer;
SARC	trans	rs6445525	0.935	rs6806075	chr3:66000650	G/T	cg07396746	chr8:23162295	LOXL2	-0.37	-6.27	-0.38	1.74e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs1003719	0.715	rs2835659	chr21:38567902	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-8.99	-0.51	8.94e-17	Eye color traits;
SARC	cis	rs7617773	0.963	rs6766754	chr3:48182589	T/C	cg11946769	chr3:48343235	NME6	-0.52	-6.38	-0.39	9.29e-10	Coronary artery disease;
SARC	cis	rs7412746	0.658	rs8444	chr1:150938571	G/A	cg13175981	chr1:150552382	MCL1	-0.48	-5.7	-0.35	3.56e-8	Melanoma;
SARC	cis	rs11997175	0.583	rs56045827	chr8:33787015	G/A	ch.8.33884649F	chr8:33765107	NA	0.46	5.87	0.36	1.51e-8	Body mass index;
SARC	cis	rs17533156	0.612	rs62078287	chr17:75128493	C/T	cg18815765	chr17:75136729	SEC14L1	0.52	5.06	0.31	8.44e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs7223966	1.000	rs11658329	chr17:61763031	C/G	cg26338869	chr17:61819248	STRADA	-0.43	-4.92	-0.31	1.63e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9715521	0.900	rs72634620	chr4:59822396	C/T	cg11281224	chr4:60001000	NA	-0.37	-4.73	-0.3	3.83e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs262150	0.574	rs2730272	chr7:158798622	G/C	cg04111992	chr7:158790115	NA	-0.35	-4.93	-0.31	1.58e-6	Facial morphology (factor 20);
SARC	cis	rs2282802	0.685	rs67813630	chr5:139623592	C/A	cg26211634	chr5:139558579	C5orf32	0.38	4.88	0.3	2.01e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2273669	0.667	rs12201821	chr6:109340291	C/T	cg05315195	chr6:109294784	ARMC2	-0.63	-5.73	-0.35	3.16e-8	Prostate cancer;
SARC	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg22683308	chr4:1340831	KIAA1530	0.43	5.15	0.32	5.51e-7	Longevity;
SARC	cis	rs651907	0.640	rs771573	chr3:101620896	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.43	-4.88	-0.3	1.98e-6	Colorectal cancer;
SARC	cis	rs9467773	1.000	rs9467797	chr6:26568473	A/T	cg12292205	chr6:26970375	C6orf41	0.45	5.43	0.33	1.45e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7395581	0.918	rs10742799	chr11:47293702	T/C	cg25783544	chr11:47291846	MADD	0.5	5.64	0.35	4.98e-8	HDL cholesterol;
SARC	cis	rs2033732	0.642	rs1370417	chr8:85056283	A/G	cg05716166	chr8:85095498	RALYL	0.47	5.63	0.35	5.1e-8	Body mass index;
SARC	cis	rs4889855	0.530	rs12451459	chr17:78589668	G/A	cg17956530	chr17:78667699	RPTOR	0.43	4.88	0.3	2.01e-6	Fractional excretion of uric acid;
SARC	cis	rs9381040	0.610	rs4140580	chr6:41041742	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.45	-5.16	-0.32	5.17e-7	Alzheimer's disease (late onset);
SARC	cis	rs6772849	0.930	rs13434160	chr3:128374770	T/C	cg08795948	chr3:128337044	NA	0.55	7.82	0.46	1.85e-13	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg01017244	chr2:74357527	NA	0.54	6.68	0.4	1.75e-10	Gestational age at birth (maternal effect);
SARC	cis	rs6504663	0.525	rs557	chr17:48563234	C/T	cg00901687	chr17:48585270	MYCBPAP	0.47	5.45	0.34	1.25e-7	Visceral fat;
SARC	cis	rs11690935	1.000	rs34542126	chr2:172542705	C/T	cg13550731	chr2:172543902	DYNC1I2	0.99	15.22	0.71	8.98e-37	Schizophrenia;
SARC	cis	rs2204008	0.630	rs7314669	chr12:38203602	G/A	cg14851346	chr12:38532713	NA	-0.44	-5.09	-0.32	7.21e-7	Bladder cancer;
SARC	cis	rs634534	0.622	rs624273	chr11:65712413	A/G	cg26695010	chr11:65641043	EFEMP2	-0.59	-7.76	-0.45	2.58e-13	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg24642844	chr7:1081250	C7orf50	-0.59	-6.25	-0.38	1.98e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	trans	rs2727020	0.894	rs2866361	chr11:49372481	A/G	cg15704280	chr7:45808275	SEPT13	-0.74	-9.66	-0.53	8.92e-19	Coronary artery disease;
SARC	cis	rs2354432	0.607	rs10453880	chr1:146693689	T/C	cg25205988	chr1:146714368	CHD1L	1.08	9.02	0.51	7.36e-17	Mitochondrial DNA levels;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg24060954	chr7:123197996	NDUFA5	0.49	6.29	0.38	1.55e-9	Lung adenocarcinoma;
SARC	trans	rs7927370	0.717	rs61898411	chr11:55027609	G/A	cg07162727	chr16:4848039	ROGDI	0.8	6.25	0.38	1.98e-9	Systemic lupus erythematosus;
SARC	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg22920501	chr2:26401640	FAM59B	-0.53	-6.57	-0.4	3.17e-10	Gut microbiome composition (summer);
SARC	cis	rs12421382	0.659	rs1439518	chr11:109382921	T/G	cg16359550	chr11:109292809	C11orf87	0.35	5.1	0.32	7.02e-7	Schizophrenia;
SARC	cis	rs3741404	0.620	rs2236647	chr11:63964605	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.64	-8.38	-0.48	5.14e-15	Platelet count;
SARC	cis	rs1707322	1.000	rs10890375	chr1:46406581	G/A	cg06784218	chr1:46089804	CCDC17	0.34	5.97	0.36	8.98e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg11843238	chr5:131593191	PDLIM4	-0.43	-5.96	-0.36	9.14e-9	Acylcarnitine levels;
SARC	trans	rs61931739	0.534	rs1826144	chr12:34094272	A/G	cg26384229	chr12:38710491	ALG10B	0.87	12.44	0.63	1.37e-27	Morning vs. evening chronotype;
SARC	cis	rs12200560	0.505	rs59296768	chr6:97075535	C/T	cg06623918	chr6:96969491	KIAA0776	0.45	5.13	0.32	6.14e-7	Coronary heart disease;
SARC	cis	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg22857025	chr5:266934	NA	-1.07	-11.72	-0.61	2.97e-25	Breast cancer;
SARC	cis	rs9322193	0.566	rs9397070	chr6:150243209	T/C	cg01145232	chr6:150245071	RAET1G	-0.44	-5.12	-0.32	6.28e-7	Lung cancer;
SARC	cis	rs9916302	0.752	rs12150047	chr17:37601755	A/G	cg00129232	chr17:37814104	STARD3	-0.55	-5.83	-0.36	1.82e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs782590	0.935	rs782606	chr2:55886602	T/C	cg18811423	chr2:55921094	PNPT1	0.68	10.28	0.56	1.14e-20	Metabolic syndrome;
SARC	cis	rs7264396	0.563	rs2425086	chr20:34302873	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-7.21	-0.43	7.81e-12	Total cholesterol levels;
SARC	cis	rs1185460	0.967	rs11217133	chr11:118928249	G/A	cg23280166	chr11:118938394	VPS11	0.74	10.38	0.56	5.34e-21	Coronary artery disease;
SARC	cis	rs7223966	1.000	rs78172786	chr17:61847114	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	7.13	0.42	1.22e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs911555	0.755	rs17841064	chr14:103900609	A/G	cg12935359	chr14:103987150	CKB	-0.42	-5.75	-0.35	2.79e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7264396	0.511	rs2425102	chr20:34312303	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-6.98	-0.42	3.04e-11	Total cholesterol levels;
SARC	cis	rs10791097	0.694	rs4937581	chr11:130740335	T/C	cg12179176	chr11:130786555	SNX19	0.73	10.92	0.58	1.08e-22	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs13161895	0.591	rs12655422	chr5:179480825	C/A	cg02702477	chr5:179499311	RNF130	0.74	6.76	0.41	1.08e-10	LDL cholesterol;
SARC	cis	rs7666738	0.830	rs7691864	chr4:98971376	G/C	cg05340658	chr4:99064831	C4orf37	0.64	8.6	0.49	1.18e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2120243	0.539	rs7629293	chr3:157114462	C/T	cg24825693	chr3:157122686	VEPH1	-0.46	-6.39	-0.39	9e-10	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.52	6.64	0.4	2.13e-10	Lymphocyte counts;
SARC	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg14820908	chr5:178986412	RUFY1	0.33	4.73	0.3	3.84e-6	Lung cancer;
SARC	cis	rs240764	0.658	rs4571568	chr6:101223955	T/A	cg09795085	chr6:101329169	ASCC3	-0.49	-6.57	-0.4	3.29e-10	Neuroticism;
SARC	cis	rs7635838	0.684	rs2606757	chr3:11358163	T/A	cg00170343	chr3:11313890	ATG7	0.64	8.83	0.5	2.64e-16	HDL cholesterol;
SARC	cis	rs425277	1.000	rs262651	chr1:2091397	A/G	cg24578937	chr1:2090814	PRKCZ	0.32	5.97	0.36	8.76e-9	Height;
SARC	cis	rs13191362	1.000	rs35044651	chr6:163004142	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.57	5.38	0.33	1.85e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg06618935	chr21:46677482	NA	0.42	5.49	0.34	1.06e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	19.47	0.79	8.91e-51	Prudent dietary pattern;
SARC	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg24503407	chr1:205819492	PM20D1	0.44	5.69	0.35	3.83e-8	Menarche (age at onset);
SARC	trans	rs79976124	0.797	rs79522358	chr6:66641140	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	7.86	0.46	1.41e-13	Type 2 diabetes;
SARC	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg01475735	chr3:40494733	NA	-0.47	-5.14	-0.32	5.91e-7	Renal cell carcinoma;
SARC	cis	rs13191362	1.000	rs35911566	chr6:162994154	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.59	0.34	6.28e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg00149659	chr3:10157352	C3orf10	0.69	6.96	0.42	3.37e-11	Alzheimer's disease;
SARC	cis	rs2721195	0.626	rs59464125	chr8:145857786	G/A	cg15320075	chr8:145703422	NA	-0.54	-6.83	-0.41	7.32e-11	Age at first birth;
SARC	cis	rs4144743	0.528	rs11868894	chr17:45353189	T/C	cg18085866	chr17:45331354	ITGB3	-0.53	-5.11	-0.32	6.81e-7	Body mass index;
SARC	cis	rs9296092	0.538	rs62405943	chr6:33517359	A/G	cg13560919	chr6:33536144	NA	-0.51	-6.21	-0.38	2.4e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg19223190	chr17:80058835	NA	-0.42	-5.77	-0.35	2.46e-8	Life satisfaction;
SARC	cis	rs9359856	0.636	rs3748085	chr6:90315789	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.52	-4.78	-0.3	3.07e-6	Bipolar disorder;
SARC	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg13939156	chr17:80058883	NA	0.4	6.25	0.38	1.92e-9	Life satisfaction;
SARC	cis	rs703842	1.000	rs11172344	chr12:58193448	T/C	cg00677455	chr12:58241039	CTDSP2	0.53	6.94	0.41	3.93e-11	Multiple sclerosis;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg00636639	chr9:125027249	RBM18;MRRF	0.55	6.91	0.41	4.56e-11	Breast cancer;
SARC	cis	rs1568889	1.000	rs7945367	chr11:28166272	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	9.83	0.54	2.63e-19	Bipolar disorder;
SARC	cis	rs2576037	0.796	rs2576041	chr18:44580919	C/T	cg15049968	chr18:44337910	ST8SIA5	0.31	4.95	0.31	1.46e-6	Personality dimensions;
SARC	cis	rs3796352	0.764	rs11714902	chr3:53101544	G/C	cg27565382	chr3:53032988	SFMBT1	0.97	6.96	0.42	3.37e-11	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs526231	0.511	rs3910557	chr5:102350471	T/A	cg23492399	chr5:102201601	PAM	-0.51	-5.77	-0.35	2.47e-8	Primary biliary cholangitis;
SARC	cis	rs4319547	0.688	rs6489158	chr12:123110365	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.5	-6.51	-0.39	4.55e-10	Body mass index;
SARC	cis	rs7005380	0.538	rs7000488	chr8:120923299	A/G	cg21744203	chr8:120868354	DSCC1	-0.47	-5.52	-0.34	9.18e-8	Interstitial lung disease;
SARC	cis	rs986417	0.818	rs1955702	chr14:61074301	T/A	cg27398547	chr14:60952738	C14orf39	0.77	7.2	0.43	8.17e-12	Gut microbiota (bacterial taxa);
SARC	cis	rs11722228	1.000	rs6823877	chr4:9921931	T/C	cg00071950	chr4:10020882	SLC2A9	-0.32	-4.91	-0.31	1.71e-6	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs7481584	1.000	rs12786344	chr11:3021392	G/A	cg08508325	chr11:3079039	CARS	0.22	4.76	0.3	3.44e-6	Calcium levels;
SARC	cis	rs694739	0.796	rs479777	chr11:64107477	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.62	7.79	0.45	2.26e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs6088813	1.000	rs6142370	chr20:33973378	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	-0.43	-5.24	-0.32	3.67e-7	Height;
SARC	cis	rs17376456	0.877	rs10064520	chr5:93427358	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.54	0.34	8.18e-8	Diabetic retinopathy;
SARC	trans	rs6716963	0.585	rs11687224	chr2:194568323	A/G	cg27662611	chr22:38598981	MAFF	0.55	6.65	0.4	2.06e-10	Schizophrenia;
SARC	trans	rs61931739	0.963	rs1817759	chr12:34101521	G/A	cg13010199	chr12:38710504	ALG10B	-0.56	-6.74	-0.4	1.26e-10	Morning vs. evening chronotype;
SARC	cis	rs9916302	0.904	rs620686	chr17:37453617	A/G	cg07936489	chr17:37558343	FBXL20	0.68	9.06	0.51	5.39e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.28	0.8	2.29e-53	Prudent dietary pattern;
SARC	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	8.71	0.5	5.56e-16	Alzheimer's disease;
SARC	cis	rs9467711	0.559	rs3799383	chr6:26510748	C/T	cg12826209	chr6:26865740	GUSBL1	0.7	5.01	0.31	1.06e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9916302	0.904	rs9894500	chr17:37515735	G/C	cg00129232	chr17:37814104	STARD3	0.58	7.24	0.43	6.36e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg21724239	chr8:58056113	NA	0.6	5.84	0.36	1.72e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7255436	0.830	rs4350678	chr19:8447366	A/G	cg10174797	chr19:8464628	RAB11B	0.45	6.5	0.39	4.91e-10	HDL cholesterol;
SARC	cis	rs7274811	0.681	rs291674	chr20:31954890	C/G	cg21523528	chr20:32077966	CBFA2T2	-0.41	-4.85	-0.3	2.3e-6	Height;
SARC	cis	rs9399135	0.967	rs6915770	chr6:135369214	G/A	cg24558204	chr6:135376177	HBS1L	0.46	6.24	0.38	2.09e-9	Red blood cell count;
SARC	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-5.69	-0.35	3.87e-8	Bipolar disorder;
SARC	cis	rs1707322	0.963	rs6666763	chr1:46436451	C/A	cg03146154	chr1:46216737	IPP	0.45	5.41	0.33	1.57e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg22496380	chr5:211416	CCDC127	-0.88	-9.59	-0.53	1.47e-18	Breast cancer;
SARC	cis	rs7937682	0.587	rs571594	chr11:111359334	A/G	cg09085632	chr11:111637200	PPP2R1B	0.55	6.7	0.4	1.52e-10	Primary sclerosing cholangitis;
SARC	cis	rs7223966	1.000	rs6504173	chr17:61735056	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.32	0.38	1.34e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg11987759	chr7:65425863	GUSB	0.48	5.7	0.35	3.52e-8	Aortic root size;
SARC	cis	rs4242434	0.819	rs7826059	chr8:22512068	T/C	cg03733263	chr8:22462867	KIAA1967	-0.89	-13.83	-0.67	3.63e-32	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs11864453	0.762	rs6416742	chr16:72149061	C/T	cg01557791	chr16:72042693	DHODH	-0.64	-8.53	-0.49	1.85e-15	Fibrinogen levels;
SARC	cis	rs17376456	0.877	rs34184666	chr5:93444584	T/C	cg25358565	chr5:93447407	FAM172A	1.32	14.94	0.7	7.42e-36	Diabetic retinopathy;
SARC	cis	rs9486715	0.758	rs9386528	chr6:96928514	G/A	cg18709589	chr6:96969512	KIAA0776	-0.48	-5.71	-0.35	3.35e-8	Headache;
SARC	cis	rs7208859	0.524	rs8069400	chr17:29075967	G/T	cg13385521	chr17:29058706	SUZ12P	0.87	7.69	0.45	4.21e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs920590	0.758	rs17091534	chr8:19670651	C/T	cg17834443	chr8:19674713	INTS10	0.63	7.86	0.46	1.41e-13	Acute lymphoblastic leukemia (childhood);
SARC	trans	rs9325144	0.602	rs10785590	chr12:38694145	C/T	cg23762105	chr12:34175262	ALG10	-0.53	-7.07	-0.42	1.81e-11	Morning vs. evening chronotype;
SARC	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg15049968	chr18:44337910	ST8SIA5	-0.35	-5.65	-0.35	4.75e-8	Personality dimensions;
SARC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg06873352	chr17:61820015	STRADA	0.52	6.83	0.41	7.29e-11	Prudent dietary pattern;
SARC	cis	rs7828089	1.000	rs7823832	chr8:22264426	A/G	cg12081754	chr8:22256438	SLC39A14	0.44	5.71	0.35	3.4e-8	Verbal declarative memory;
SARC	cis	rs526231	0.578	rs2112886	chr5:102251382	C/T	cg23492399	chr5:102201601	PAM	0.47	5.57	0.34	7.05e-8	Primary biliary cholangitis;
SARC	cis	rs9625935	0.518	rs245008	chr22:30315736	T/C	cg01021169	chr22:30184971	ASCC2	-0.41	-5.47	-0.34	1.17e-7	Tonsillectomy;
SARC	cis	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg08564027	chr20:61660810	NA	0.78	11.75	0.61	2.44e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg03452623	chr4:187889614	NA	-0.82	-13.91	-0.67	2.01e-32	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.86	-13.48	-0.66	5.28e-31	Personality dimensions;
SARC	cis	rs3812111	0.510	rs1569825	chr6:116590807	T/G	cg18828861	chr6:116576566	TSPYL4	0.33	4.85	0.3	2.21e-6	Age-related macular degeneration;
SARC	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg17971929	chr21:40555470	PSMG1	0.97	12.05	0.62	2.62e-26	Cognitive function;
SARC	cis	rs950776	0.518	rs12902493	chr15:78819275	C/G	cg22563815	chr15:78856949	CHRNA5	0.38	6.17	0.37	3.06e-9	Sudden cardiac arrest;
SARC	cis	rs1941023	0.503	rs10750936	chr11:60144180	G/A	cg08716584	chr11:60157161	MS4A7	-0.4	-6.38	-0.39	9.68e-10	Congenital heart disease (maternal effect);
SARC	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg05896524	chr21:47604654	C21orf56	-0.53	-6.49	-0.39	5.03e-10	Testicular germ cell tumor;
SARC	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg05313129	chr8:58192883	C8orf71	-0.62	-6.25	-0.38	1.94e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs3812565	0.506	rs4259518	chr9:139322503	T/C	cg14169450	chr9:139327907	INPP5E	0.43	5.74	0.35	2.87e-8	Granulocyte percentage of myeloid white cells;
SARC	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg06558623	chr16:89946397	TCF25	0.98	7.65	0.45	5.42e-13	Skin colour saturation;
SARC	cis	rs72634258	0.554	rs17374292	chr1:7881234	C/T	cg26816564	chr1:7831052	VAMP3	0.53	4.87	0.3	2.09e-6	Inflammatory bowel disease;
SARC	cis	rs874628	0.686	rs56252442	chr19:18229208	G/T	cg00493341	chr19:18228948	MAST3	0.49	5.21	0.32	4.25e-7	Multiple sclerosis;
SARC	cis	rs7927771	0.896	rs12794570	chr11:47658314	C/T	cg20307385	chr11:47447363	PSMC3	-0.53	-6.48	-0.39	5.32e-10	Subjective well-being;
SARC	cis	rs4243830	0.850	rs10864612	chr1:6593830	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.9	-9.22	-0.52	1.77e-17	Body mass index;
SARC	trans	rs877282	0.583	rs11253424	chr10:813426	C/T	cg22713356	chr15:30763199	NA	0.86	9.04	0.51	6.19e-17	Uric acid levels;
SARC	cis	rs910316	0.967	rs175432	chr14:75615246	C/G	cg08847533	chr14:75593920	NEK9	-0.86	-13.34	-0.66	1.56e-30	Height;
SARC	cis	rs959260	0.614	rs9914731	chr17:73408824	T/G	cg00200289	chr17:73401734	GRB2	-0.61	-5.62	-0.35	5.55e-8	Systemic lupus erythematosus;
SARC	cis	rs11792861	0.816	rs17792434	chr9:111667319	C/T	cg13535736	chr9:111863775	C9orf5	-0.38	-4.72	-0.3	4.04e-6	Menarche (age at onset);
SARC	cis	rs12477438	0.501	rs11123770	chr2:99825102	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.7	9.46	0.53	3.47e-18	Chronic sinus infection;
SARC	cis	rs6121246	0.529	rs41310803	chr20:30452709	A/G	cg09796376	chr20:30640595	HCK	0.53	4.81	0.3	2.68e-6	Mean corpuscular hemoglobin;
SARC	cis	rs11785693	0.862	rs17351027	chr8:4987098	A/G	cg26367366	chr8:4980734	NA	-0.74	-6.58	-0.4	3.12e-10	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs2153535	0.601	rs9379224	chr6:8538413	A/G	cg21535247	chr6:8435926	SLC35B3	0.54	6.58	0.4	3.07e-10	Motion sickness;
SARC	cis	rs3768617	0.510	rs10911254	chr1:183088627	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.1	0.55	4.11e-20	Fuchs's corneal dystrophy;
SARC	cis	rs9650657	0.812	rs4240669	chr8:10629987	C/T	cg21775007	chr8:11205619	TDH	-0.37	-4.75	-0.3	3.54e-6	Neuroticism;
SARC	trans	rs116095464	0.558	rs6866632	chr5:264429	C/G	cg00938859	chr5:1591904	SDHAP3	0.77	7.03	0.42	2.28e-11	Breast cancer;
SARC	cis	rs1580019	0.961	rs4320456	chr7:32496003	T/C	cg14728415	chr7:32535168	LSM5;AVL9	0.43	5.04	0.31	9.3e-7	Cognitive ability;
SARC	cis	rs16854884	1.000	rs17668478	chr3:143794370	G/A	cg06585982	chr3:143692056	C3orf58	0.56	6.85	0.41	6.58e-11	Economic and political preferences (feminism/equality);
SARC	cis	rs9486715	0.867	rs4598081	chr6:96975227	A/G	cg18709589	chr6:96969512	KIAA0776	0.62	7.79	0.45	2.18e-13	Headache;
SARC	cis	rs7959452	0.684	rs11177615	chr12:69754189	G/A	cg22834771	chr12:69754056	YEATS4	-0.45	-5.91	-0.36	1.21e-8	Blood protein levels;
SARC	cis	rs7106204	0.534	rs76997388	chr11:24272878	C/G	ch.11.24196551F	chr11:24239977	NA	0.65	4.8	0.3	2.88e-6	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg05623727	chr3:50126028	RBM5	0.36	5.15	0.32	5.45e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.61	8.08	0.47	3.46e-14	Lymphocyte counts;
SARC	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg11766577	chr21:47581405	C21orf56	0.43	5.05	0.31	8.77e-7	Testicular germ cell tumor;
SARC	cis	rs2916247	1.000	rs2011093	chr8:92982608	A/G	cg10183463	chr8:93005414	RUNX1T1	0.61	5.8	0.36	2.15e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9398803	0.698	rs853970	chr6:127063983	A/G	cg19875578	chr6:126661172	C6orf173	-0.6	-8.29	-0.48	8.89e-15	Male-pattern baldness;
SARC	cis	rs13077101	0.800	rs322456	chr3:120517010	C/T	cg24332942	chr3:120408071	RABL3	-0.41	-5.09	-0.32	7.53e-7	Obesity-related traits;
SARC	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg13628971	chr7:2884303	GNA12	0.44	5.46	0.34	1.24e-7	Height;
SARC	cis	rs7223966	1.000	rs7209758	chr17:61913621	C/T	cg00588841	chr17:61851480	DDX42;CCDC47	-0.61	-6.56	-0.39	3.4e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs778371	1.000	rs778371	chr2:233743109	A/G	cg16596103	chr2:233749413	NGEF	0.35	4.99	0.31	1.18e-6	Schizophrenia;
SARC	cis	rs9807989	0.507	rs6710034	chr2:103023678	G/A	cg03938978	chr2:103052716	IL18RAP	0.31	4.91	0.31	1.72e-6	Asthma;
SARC	cis	rs4819052	0.679	rs2838860	chr21:46684904	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	6.65	0.4	2.02e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7647973	0.588	rs4855848	chr3:49653457	C/T	cg03060546	chr3:49711283	APEH	0.67	7.1	0.42	1.54e-11	Menarche (age at onset);
SARC	cis	rs7412746	0.658	rs4970988	chr1:150950062	A/G	cg13175981	chr1:150552382	MCL1	0.48	5.75	0.35	2.82e-8	Melanoma;
SARC	cis	rs10875746	0.859	rs12305511	chr12:48582716	C/T	cg26205652	chr12:48591994	NA	-0.5	-5.88	-0.36	1.43e-8	Longevity (90 years and older);
SARC	cis	rs7937682	0.883	rs631490	chr11:111452040	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.87	-13.38	-0.66	1.14e-30	Primary sclerosing cholangitis;
SARC	cis	rs721399	0.719	rs12674710	chr8:18263663	A/C	cg18736775	chr8:18248649	NAT2	-0.64	-6.82	-0.41	7.79e-11	Blood metabolite levels;
SARC	cis	rs918629	0.798	rs10052503	chr5:95283658	A/C	cg16656078	chr5:95278638	ELL2	-0.63	-7.66	-0.45	5.03e-13	IgG glycosylation;
SARC	cis	rs6089584	0.566	rs55881457	chr20:60608424	G/A	cg06108461	chr20:60628389	TAF4	-0.72	-9.53	-0.53	2.22e-18	Body mass index;
SARC	cis	rs9354308	0.901	rs12197136	chr6:66590953	T/C	cg07460842	chr6:66804631	NA	0.49	5.59	0.34	6.34e-8	Metabolite levels;
SARC	cis	rs7647973	0.626	rs11720705	chr3:49753788	A/G	cg06212747	chr3:49208901	KLHDC8B	0.55	5.52	0.34	9.13e-8	Menarche (age at onset);
SARC	cis	rs11719291	0.915	rs1048940	chr3:48725707	C/T	cg07636037	chr3:49044803	WDR6	-0.73	-5.42	-0.33	1.48e-7	Cognitive function;
SARC	cis	rs12956009	0.518	rs4574017	chr18:44891703	A/T	cg15049968	chr18:44337910	ST8SIA5	-0.31	-4.74	-0.3	3.67e-6	Educational attainment (years of education);
SARC	cis	rs11098499	0.863	rs2127823	chr4:120485670	G/T	cg09307838	chr4:120376055	NA	0.91	12.58	0.64	4.84e-28	Corneal astigmatism;
SARC	cis	rs4919694	1.000	rs4919694	chr10:104698978	T/C	cg04362960	chr10:104952993	NT5C2	0.64	5.46	0.34	1.2e-7	Arsenic metabolism;
SARC	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg23758822	chr17:41437982	NA	0.9	12.17	0.62	1.04e-26	Menopause (age at onset);
SARC	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg03650068	chr1:25596491	NA	0.32	4.98	0.31	1.23e-6	Plateletcrit;Mean corpuscular volume;
SARC	cis	rs854765	0.583	rs6502627	chr17:17849671	C/T	cg05444541	chr17:17804740	TOM1L2	-0.29	-4.82	-0.3	2.56e-6	Total body bone mineral density;
SARC	cis	rs7714584	1.000	rs1428555	chr5:150257391	A/G	cg22134413	chr5:150180641	NA	-0.8	-6.98	-0.42	3.06e-11	Crohn's disease;
SARC	cis	rs6963495	0.745	rs73192151	chr7:105211876	A/G	cg13798780	chr7:105162888	PUS7	0.57	5.19	0.32	4.5e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs7937682	0.921	rs34584980	chr11:111441537	G/A	cg22437258	chr11:111473054	SIK2	-0.68	-8.49	-0.49	2.39e-15	Primary sclerosing cholangitis;
SARC	cis	rs66887589	0.560	rs9684327	chr4:120365441	A/G	cg09307838	chr4:120376055	NA	0.54	7.39	0.44	2.63e-12	Diastolic blood pressure;
SARC	cis	rs858239	0.665	rs858306	chr7:23242754	A/T	cg23682824	chr7:23144976	KLHL7	0.64	8.1	0.47	3.07e-14	Cerebrospinal fluid biomarker levels;
SARC	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.76	11.12	0.59	2.51e-23	Personality dimensions;
SARC	trans	rs11098499	0.954	rs10008459	chr4:120394231	T/C	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	cis	rs1348850	0.914	rs1975544	chr2:178465423	G/A	cg23306229	chr2:178417860	TTC30B	0.54	5.77	0.35	2.48e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs6772849	0.804	rs9832430	chr3:128412897	C/T	cg01163369	chr3:128370232	RPN1	-0.35	-4.89	-0.31	1.86e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs5753037	0.653	rs131273	chr22:30153721	T/C	cg01021169	chr22:30184971	ASCC2	-0.45	-6.33	-0.38	1.27e-9	Type 1 diabetes;
SARC	cis	rs6089584	0.606	rs6089599	chr20:60576992	A/G	cg23262073	chr20:60523788	NA	0.37	5.65	0.35	4.73e-8	Body mass index;
SARC	cis	rs10504229	0.724	rs72649117	chr8:58037639	A/G	cg08219700	chr8:58056026	NA	0.58	6.0	0.37	7.52e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg08045932	chr20:61659980	NA	0.5	6.84	0.41	7.06e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg19723775	chr5:179050963	HNRNPH1	-0.45	-5.87	-0.36	1.52e-8	Lung cancer;
SARC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg06877462	chr1:205807181	PM20D1	0.33	4.78	0.3	3.07e-6	Menarche (age at onset);
SARC	cis	rs2806561	0.765	rs2806565	chr1:23507068	A/G	cg12483005	chr1:23474871	LUZP1	0.44	5.73	0.35	3.05e-8	Height;
SARC	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs155076	0.702	rs482731	chr13:21846075	G/A	cg11317459	chr13:21872234	NA	-0.98	-12.36	-0.63	2.52e-27	White matter hyperintensity burden;
SARC	cis	rs9467773	0.620	rs1490488	chr6:26614808	T/C	cg11502198	chr6:26597334	ABT1	0.62	8.29	0.48	8.89e-15	Intelligence (multi-trait analysis);
SARC	cis	rs17376456	0.877	rs10052428	chr5:93476530	T/C	cg25358565	chr5:93447407	FAM172A	1.36	14.41	0.69	4.32e-34	Diabetic retinopathy;
SARC	cis	rs57502260	0.790	rs7129320	chr11:68388220	G/A	cg01657329	chr11:68192670	LRP5	-0.52	-5.34	-0.33	2.25e-7	Total body bone mineral density (age 45-60);
SARC	cis	rs7264396	0.690	rs2425175	chr20:34445563	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.47	-0.44	1.58e-12	Total cholesterol levels;
SARC	cis	rs7833986	1.000	rs7833986	chr8:57100149	C/T	cg26371346	chr8:56986568	SNORD54;RPS20	0.52	4.99	0.31	1.18e-6	Height;
SARC	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg24829409	chr8:58192753	C8orf71	-0.6	-6.23	-0.38	2.13e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs8114671	0.562	rs6088655	chr20:33527838	A/G	cg24642439	chr20:33292090	TP53INP2	0.51	6.14	0.37	3.54e-9	Height;
SARC	trans	rs1814175	0.587	rs7948538	chr11:50021353	A/C	cg03929089	chr4:120376271	NA	-0.84	-12.08	-0.62	2.02e-26	Height;
SARC	cis	rs7523050	0.908	rs17621621	chr1:109398917	G/T	cg08274380	chr1:109419600	GPSM2	0.79	6.61	0.4	2.55e-10	Fat distribution (HIV);
SARC	cis	rs7666738	0.830	rs28618180	chr4:98912184	A/C	cg05340658	chr4:99064831	C4orf37	0.65	8.64	0.49	9.2e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1505368	0.567	rs2054617	chr2:213355890	T/C	cg20637307	chr2:213403960	ERBB4	0.5	6.58	0.4	3.06e-10	Symmetrical dimethylarginine levels;
SARC	cis	rs2072499	0.722	rs61462713	chr1:156161682	C/T	cg24450063	chr1:156163899	SLC25A44	1.09	14.4	0.69	4.79e-34	Testicular germ cell tumor;
SARC	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	12.74	0.64	1.44e-28	Platelet count;
SARC	cis	rs910316	1.000	rs8017642	chr14:75590822	G/A	cg23033748	chr14:75592666	NEK9	0.36	5.06	0.31	8.64e-7	Height;
SARC	cis	rs1559088	0.600	rs10421769	chr19:33605312	T/C	cg17764715	chr19:33622953	WDR88	0.57	7.82	0.46	1.85e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs6582630	0.599	rs12824838	chr12:38373584	G/T	cg26384229	chr12:38710491	ALG10B	-0.56	-7.09	-0.42	1.6e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs3020736	0.500	rs8143153	chr22:42515637	G/C	cg04733989	chr22:42467013	NAGA	-0.77	-10.79	-0.58	2.84e-22	Autism spectrum disorder or schizophrenia;
SARC	cis	rs4481887	0.893	rs4529743	chr1:248473683	G/C	cg01631408	chr1:248437212	OR2T33	-0.39	-5.04	-0.31	9.2e-7	Common traits (Other);
SARC	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg26818010	chr10:134567672	INPP5A	-0.62	-6.49	-0.39	5.08e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs7833986	0.501	rs17812659	chr8:56889862	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.55	5.16	0.32	5.22e-7	Height;
SARC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	20.2	0.8	4.16e-53	Prudent dietary pattern;
SARC	cis	rs7264396	0.563	rs6060570	chr20:34291166	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	5.69	0.35	3.71e-8	Total cholesterol levels;
SARC	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg20891283	chr12:69753455	YEATS4	0.68	9.72	0.54	5.85e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9381040	0.655	rs9381032	chr6:41044986	A/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.45	-5.27	-0.33	3.04e-7	Alzheimer's disease (late onset);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg22914762	chr4:117220908	MIR1973	-0.78	-7.29	-0.43	4.77e-12	Autism spectrum disorder or schizophrenia;
SARC	cis	rs4233949	0.868	rs7607093	chr2:54659174	G/T	cg24760922	chr2:54683707	SPTBN1	-0.39	-4.73	-0.3	3.85e-6	Bone mineral density;
SARC	cis	rs79149102	0.649	rs3803568	chr15:75108636	G/A	cg09165964	chr15:75287851	SCAMP5	-1.06	-5.96	-0.36	9.5e-9	Lung cancer;
SARC	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg13175981	chr1:150552382	MCL1	-0.54	-6.82	-0.41	7.54e-11	Tonsillectomy;
SARC	cis	rs9926296	0.715	rs2115401	chr16:89740609	A/G	cg03605463	chr16:89740564	NA	-0.49	-6.83	-0.41	7.23e-11	Vitiligo;
SARC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg07167872	chr1:205819463	PM20D1	0.75	11.64	0.61	5.48e-25	Menarche (age at onset);
SARC	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg04317338	chr11:64019027	PLCB3	0.83	8.49	0.49	2.43e-15	Mean platelet volume;
SARC	cis	rs2116941	1.000	rs8104426	chr19:10338676	G/T	cg01850179	chr19:10340795	S1PR2	0.65	8.37	0.48	5.34e-15	Pulse pressure;
SARC	cis	rs55728055	0.661	rs55673702	chr22:32035518	G/A	cg01338084	chr22:32026380	PISD	1.01	6.07	0.37	5.2e-9	Age-related hearing impairment;
SARC	cis	rs9303401	1.000	rs6503882	chr17:56915761	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.69	8.19	0.47	1.67e-14	Cognitive test performance;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg13542817	chr10:104154499	NFKB2	0.53	6.56	0.39	3.45e-10	Breast cancer;
SARC	cis	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg22496380	chr5:211416	CCDC127	-0.86	-9.02	-0.51	6.97e-17	Breast cancer;
SARC	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg24642844	chr7:1081250	C7orf50	-0.58	-6.12	-0.37	3.86e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	trans	rs1814175	0.817	rs4405313	chr11:50013636	G/A	cg15704280	chr7:45808275	SEPT13	-0.97	-18.31	-0.77	5.28e-47	Height;
SARC	cis	rs1144333	0.655	rs1438175	chr1:76474728	T/C	cg03433033	chr1:76189801	ACADM	0.62	4.94	0.31	1.51e-6	Attention function in attention deficit hyperactive disorder;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg25157874	chr6:163835117	QKI	-0.5	-6.87	-0.41	5.78e-11	Thyroid stimulating hormone;
SARC	trans	rs208520	1.000	rs12216109	chr6:66987488	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.83	9.35	0.52	7.46e-18	Exhaled nitric oxide output;
SARC	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg13175981	chr1:150552382	MCL1	-0.48	-5.79	-0.35	2.24e-8	Melanoma;
SARC	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	6.41	0.39	8.11e-10	Platelet count;
SARC	cis	rs4713118	0.513	rs156739	chr6:28013410	C/A	cg26335602	chr6:28129616	ZNF389	0.46	5.32	0.33	2.41e-7	Parkinson's disease;
SARC	cis	rs9788682	0.747	rs28511883	chr15:78783683	C/T	cg06917634	chr15:78832804	PSMA4	-0.53	-5.5	-0.34	1.01e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.41	-6.76	-0.4	1.1e-10	Total body bone mineral density;
SARC	cis	rs12887734	0.546	rs4900597	chr14:104266664	A/G	cg26031613	chr14:104095156	KLC1	0.45	5.29	0.33	2.85e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
SARC	trans	rs637571	0.584	rs659824	chr11:65636509	A/G	cg17712092	chr4:129076599	LARP1B	-0.54	-7.17	-0.43	9.99e-12	Eosinophil percentage of white cells;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg24947615	chr21:44515479	U2AF1	-0.51	-6.31	-0.38	1.4e-9	Height;
SARC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	6.02	0.37	6.63e-9	Prudent dietary pattern;
SARC	cis	rs2439831	0.850	rs60883262	chr15:44076503	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.81	7.69	0.45	4.23e-13	Lung cancer in ever smokers;
SARC	cis	rs60871478	1.000	rs62432242	chr7:797715	G/A	cg05535760	chr7:792225	HEATR2	0.77	8.07	0.47	3.66e-14	Cerebrospinal P-tau181p levels;
SARC	cis	rs13166103	0.723	rs11958495	chr5:57736718	C/G	cg10487770	chr5:57879443	RAB3C	0.51	5.45	0.34	1.29e-7	Type 2 diabetes (age of onset);
SARC	cis	rs7584330	0.780	rs7582828	chr2:238378476	A/C	cg11271282	chr2:238384023	NA	-0.46	-5.16	-0.32	5.3e-7	Prostate cancer;
SARC	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.5	-5.5	-0.34	1.02e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs77633900	0.614	rs2439982	chr15:76925071	T/G	cg21673338	chr15:77095150	SCAPER	-0.62	-5.15	-0.32	5.56e-7	Non-glioblastoma glioma;Glioma;
SARC	cis	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg25427524	chr10:38739819	LOC399744	-0.55	-8.75	-0.5	4.44e-16	Extrinsic epigenetic age acceleration;
SARC	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg01475735	chr3:40494733	NA	-0.49	-5.38	-0.33	1.82e-7	Renal cell carcinoma;
SARC	cis	rs4713675	0.546	rs10947435	chr6:33718075	G/A	cg15676125	chr6:33679581	C6orf125	0.58	7.13	0.42	1.22e-11	Plateletcrit;
SARC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg26338869	chr17:61819248	STRADA	0.8	10.8	0.58	2.52e-22	Prudent dietary pattern;
SARC	cis	rs2594989	0.779	rs2443701	chr3:11588773	C/T	cg00170343	chr3:11313890	ATG7	-0.57	-6.02	-0.37	6.55e-9	Circulating chemerin levels;
SARC	cis	rs7712401	0.601	rs418562	chr5:122340262	A/G	cg19412675	chr5:122181750	SNX24	-0.42	-5.35	-0.33	2.07e-7	Mean platelet volume;
SARC	cis	rs6963495	0.818	rs55740553	chr7:105159551	A/G	cg19920283	chr7:105172520	RINT1	0.65	5.48	0.34	1.09e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs9896052	0.614	rs11077791	chr17:73474629	T/G	cg27037648	chr17:73511087	CASKIN2	0.41	4.73	0.3	3.94e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg11366901	chr6:160182831	ACAT2	0.95	9.86	0.54	2.2e-19	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs2204008	0.560	rs4129033	chr12:38301897	A/T	cg13010199	chr12:38710504	ALG10B	-0.53	-6.37	-0.39	9.86e-10	Bladder cancer;
SARC	cis	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg12395012	chr8:11607386	GATA4	0.29	4.86	0.3	2.18e-6	Neuroticism;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg00194681	chr8:124428640	WDYHV1	0.78	6.4	0.39	8.35e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs995000	0.895	rs10889348	chr1:63078222	A/T	cg06896770	chr1:63153194	DOCK7	0.98	14.63	0.69	8.05e-35	Triglyceride levels;
SARC	cis	rs2730245	1.000	rs2527199	chr7:158737113	G/A	cg24397884	chr7:158709396	WDR60	-1.05	-15.92	-0.72	4e-39	Height;
SARC	trans	rs17685	0.753	rs4573217	chr7:75733946	G/A	cg19862616	chr7:65841803	NCRNA00174	0.63	7.83	0.46	1.68e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	trans	rs7937682	0.924	rs7938360	chr11:111539875	A/G	cg18187862	chr3:45730750	SACM1L	0.53	6.71	0.4	1.47e-10	Primary sclerosing cholangitis;
SARC	cis	rs6912958	0.754	rs6918909	chr6:88247251	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.32	-0.33	2.49e-7	Monocyte percentage of white cells;
SARC	cis	rs10779751	0.734	rs1194820	chr1:11129259	A/C	cg08854313	chr1:11322531	MTOR	0.87	12.08	0.62	2.12e-26	Body mass index;
SARC	cis	rs4853036	1.000	rs6718012	chr2:70078258	T/C	cg02498382	chr2:70120550	SNRNP27	-0.39	-5.23	-0.32	3.72e-7	Colorectal or endometrial cancer;
SARC	cis	rs9291683	0.588	rs35438220	chr4:9999398	C/T	cg11266682	chr4:10021025	SLC2A9	0.42	7.52	0.44	1.19e-12	Bone mineral density;
SARC	cis	rs7772486	0.840	rs854144	chr6:146360880	G/T	cg05347473	chr6:146136440	FBXO30	-0.49	-6.24	-0.38	2e-9	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg15231902	chr12:56618064	OBFC2B	0.51	6.52	0.39	4.23e-10	Height;
SARC	cis	rs11997175	1.000	rs10453046	chr8:33773179	T/C	ch.8.33884649F	chr8:33765107	NA	0.57	7.93	0.46	9.31e-14	Body mass index;
SARC	cis	rs6831352	0.918	rs29001199	chr4:100053891	A/G	cg12011299	chr4:100065546	ADH4	-0.34	-5.72	-0.35	3.33e-8	Alcohol dependence;
SARC	cis	rs738322	0.555	rs5750549	chr22:38547172	C/T	cg25457927	chr22:38595422	NA	-0.26	-4.94	-0.31	1.5e-6	Cutaneous nevi;
SARC	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg11987759	chr7:65425863	GUSB	-0.6	-7.96	-0.46	7.64e-14	Aortic root size;
SARC	cis	rs9467773	0.620	rs1027204	chr6:26639613	T/C	cg11502198	chr6:26597334	ABT1	0.63	8.63	0.49	9.91e-16	Intelligence (multi-trait analysis);
SARC	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg25894440	chr7:65020034	NA	0.79	5.96	0.36	9.49e-9	Diabetic kidney disease;
SARC	cis	rs4268898	0.931	rs60716082	chr2:24526265	T/A	cg26838691	chr2:24397539	C2orf84	-0.4	-5.4	-0.33	1.64e-7	Asthma;
SARC	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg04944784	chr2:26401820	FAM59B	-0.48	-6.05	-0.37	5.59e-9	Gut microbiome composition (summer);
SARC	cis	rs56011263	0.687	rs4690186	chr4:703607	G/A	cg20735989	chr4:730612	PCGF3	-0.46	-5.22	-0.32	3.96e-7	White blood cell count;
SARC	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg14983838	chr19:29218262	NA	0.68	7.89	0.46	1.19e-13	Methadone dose in opioid dependence;
SARC	cis	rs3126085	0.877	rs10888472	chr1:152206896	C/G	cg09127314	chr1:152161683	NA	-0.46	-5.05	-0.31	8.73e-7	Atopic dermatitis;
SARC	cis	rs7917772	0.636	rs7911747	chr10:104528890	A/G	ch.10.2196322F	chr10:104248062	ACTR1A	-0.47	-5.57	-0.34	6.9e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs36051895	0.632	rs10974982	chr9:5149382	G/C	cg02405213	chr9:5042618	JAK2	-0.47	-5.62	-0.35	5.56e-8	Pediatric autoimmune diseases;
SARC	cis	rs8141529	0.509	rs6005927	chr22:29255884	A/G	cg15103426	chr22:29168792	CCDC117	0.64	7.89	0.46	1.15e-13	Lymphocyte counts;
SARC	cis	rs9916302	0.904	rs11655531	chr17:37697959	T/C	cg20243544	chr17:37824526	PNMT	0.55	6.41	0.39	7.87e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs6089584	0.526	rs6089619	chr20:60610916	C/T	cg23262073	chr20:60523788	NA	-0.36	-5.54	-0.34	8.04e-8	Body mass index;
SARC	trans	rs12155874	0.774	rs13252664	chr8:13971870	C/T	cg13917004	chr19:42462874	RABAC1	0.61	6.29	0.38	1.56e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg07636037	chr3:49044803	WDR6	0.93	15.22	0.71	9.04e-37	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs11249608	0.789	rs7700958	chr5:178436617	G/A	cg01312482	chr5:178451176	ZNF879	-0.36	-4.89	-0.31	1.88e-6	Pubertal anthropometrics;
SARC	cis	rs9473924	0.505	rs7746581	chr6:50853479	T/C	cg14470998	chr6:50812995	TFAP2B	0.76	7.14	0.42	1.19e-11	Body mass index;
SARC	cis	rs7927771	1.000	rs11605774	chr11:47832793	G/A	cg20307385	chr11:47447363	PSMC3	-0.48	-5.64	-0.35	5.01e-8	Subjective well-being;
SARC	cis	rs2070433	0.539	rs2070432	chr21:47957332	G/A	cg12379764	chr21:47803548	PCNT	0.55	5.96	0.36	9.46e-9	Lymphocyte counts;
SARC	trans	rs12546673	0.628	rs17737459	chr8:24275679	T/C	cg13641198	chr9:16044344	NA	-0.47	-6.24	-0.38	2e-9	Scarlet fever;
SARC	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg03060546	chr3:49711283	APEH	0.53	6.94	0.41	3.93e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg24549020	chr5:56110836	MAP3K1	0.79	8.36	0.48	5.64e-15	Initial pursuit acceleration;
SARC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg03452623	chr4:187889614	NA	-0.76	-11.77	-0.61	2.03e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7264396	0.623	rs2425123	chr20:34329547	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-6.82	-0.41	7.98e-11	Total cholesterol levels;
SARC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg12419862	chr22:24373484	LOC391322	-0.69	-8.27	-0.48	1.01e-14	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs4900538	0.821	rs2009575	chr14:102820787	C/T	cg18135206	chr14:102964638	TECPR2	-0.56	-7.12	-0.42	1.33e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg11764359	chr7:65958608	NA	0.88	12.58	0.64	4.89e-28	Aortic root size;
SARC	cis	rs897080	0.515	rs4953088	chr2:44564518	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.64	-7.38	-0.44	2.83e-12	Height;
SARC	cis	rs4423214	1.000	rs4944958	chr11:71168073	A/G	cg05163923	chr11:71159392	DHCR7	0.65	9.08	0.51	4.88e-17	Vitamin D levels;
SARC	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg11644478	chr21:40555479	PSMG1	-0.59	-7.29	-0.43	4.77e-12	Menarche (age at onset);
SARC	cis	rs787274	1.000	rs2796027	chr9:115529404	A/T	cg13803584	chr9:115635662	SNX30	-0.82	-5.01	-0.31	1.07e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs7223966	1.000	rs16947005	chr17:61702989	C/T	cg00588841	chr17:61851480	DDX42;CCDC47	0.62	7.07	0.42	1.75e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs6960319	0.885	rs851827	chr7:147236664	A/G	cg03084652	chr4:7638050	SORCS2	0.52	6.28	0.38	1.64e-9	Body mass index;
SARC	cis	rs4268898	0.610	rs55860688	chr2:24451534	T/C	cg06627628	chr2:24431161	ITSN2	-0.8	-9.46	-0.53	3.41e-18	Asthma;
SARC	cis	rs2380220	0.574	rs7766765	chr6:95997362	G/A	cg04719120	chr6:96025338	MANEA	0.53	5.99	0.37	7.78e-9	Behavioural disinhibition (generation interaction);
SARC	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg09455208	chr3:40491958	NA	0.4	5.81	0.36	2.01e-8	Renal cell carcinoma;
SARC	cis	rs16854884	0.657	rs16854819	chr3:143736126	C/T	cg06585982	chr3:143692056	C3orf58	-0.66	-8.88	-0.5	1.79e-16	Economic and political preferences (feminism/equality);
SARC	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg13880726	chr7:1868755	MAD1L1	0.49	5.99	0.37	7.75e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs13082711	0.516	rs13084067	chr3:27358935	A/T	cg02860705	chr3:27208620	NA	0.54	6.62	0.4	2.44e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs7582180	0.629	rs13031508	chr2:100952757	A/G	cg14675211	chr2:100938903	LONRF2	0.49	7.15	0.42	1.12e-11	Intelligence (multi-trait analysis);
SARC	cis	rs270601	0.866	rs460271	chr5:131630062	C/G	cg04518342	chr5:131593106	PDLIM4	0.4	4.94	0.31	1.5e-6	Acylcarnitine levels;
SARC	cis	rs2832191	0.716	rs1888440	chr21:30454484	C/T	cg08807101	chr21:30365312	RNF160	0.89	13.47	0.66	5.67e-31	Dental caries;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg26879696	chr10:114206778	VTI1A;ZDHHC6	-0.58	-8.1	-0.47	3.04e-14	Thyroid stimulating hormone;
SARC	cis	rs2645694	0.626	rs2645704	chr4:77830805	T/C	cg06046430	chr4:77819534	ANKRD56	0.48	6.76	0.41	1.07e-10	Emphysema distribution in smoking;
SARC	cis	rs854765	0.583	rs7214536	chr17:17852446	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.43	5.52	0.34	9.04e-8	Total body bone mineral density;
SARC	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	11.03	0.59	4.93e-23	Alzheimer's disease;
SARC	cis	rs46522	0.585	rs79049364	chr17:47014991	T/A	cg16584676	chr17:46985605	UBE2Z	0.55	6.58	0.4	3.12e-10	Coronary heart disease;
SARC	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg25072359	chr17:41440525	NA	0.49	5.8	0.36	2.15e-8	Menopause (age at onset);
SARC	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg11987759	chr7:65425863	GUSB	-0.6	-8.13	-0.47	2.6e-14	Aortic root size;
SARC	cis	rs2732480	0.517	rs2634676	chr12:48738236	A/G	cg21466736	chr12:48725269	NA	-0.34	-5.31	-0.33	2.54e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs2976388	0.647	rs2164307	chr8:143788831	A/T	cg06565975	chr8:143823917	SLURP1	0.32	5.53	0.34	8.39e-8	Urinary tract infection frequency;
SARC	cis	rs12711979	0.509	rs10181286	chr2:3824567	G/A	cg17052675	chr2:3827356	NA	-0.53	-7.74	-0.45	2.97e-13	Itch intensity from mosquito bite adjusted by bite size;
SARC	cis	rs763121	0.853	rs5750633	chr22:38993467	A/G	cg21395723	chr22:39101663	GTPBP1	0.58	6.81	0.41	8.44e-11	Menopause (age at onset);
SARC	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.85	12.39	0.63	2.02e-27	Chronic sinus infection;
SARC	cis	rs7666738	0.830	rs7664340	chr4:99037820	C/T	cg05340658	chr4:99064831	C4orf37	0.64	8.6	0.49	1.18e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9309473	1.000	rs7594511	chr2:73681639	A/G	cg20560298	chr2:73613845	ALMS1	-0.53	-6.32	-0.38	1.28e-9	Metabolite levels;
SARC	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg13385521	chr17:29058706	SUZ12P	0.68	6.65	0.4	2.03e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs908922	0.676	rs908927	chr1:152513338	C/G	cg09873164	chr1:152488093	CRCT1	0.63	8.2	0.47	1.6e-14	Hair morphology;
SARC	cis	rs9987353	0.566	rs34491841	chr8:9065510	C/A	cg15556689	chr8:8085844	FLJ10661	-0.46	-5.63	-0.35	5.07e-8	Recombination measurement;
SARC	cis	rs9916302	0.706	rs2302073	chr17:37457342	A/G	cg07936489	chr17:37558343	FBXL20	0.75	8.92	0.5	1.37e-16	Glomerular filtration rate (creatinine);
SARC	trans	rs10085978	0.604	rs13265336	chr8:143220373	G/T	cg12891252	chr10:43902500	HNRNPF	0.52	6.41	0.39	7.91e-10	Mosquito bite size;
SARC	cis	rs739401	0.572	rs7111857	chr11:3068106	A/G	cg20651018	chr11:3035856	CARS	0.45	6.84	0.41	6.76e-11	Longevity;
SARC	cis	rs12586317	0.547	rs114371385	chr14:35503724	G/A	cg26967526	chr14:35346199	BAZ1A	-0.57	-5.64	-0.35	4.92e-8	Psoriasis;
SARC	cis	rs10875746	0.951	rs8804	chr12:48541757	A/G	cg26205652	chr12:48591994	NA	0.6	6.14	0.37	3.45e-9	Longevity (90 years and older);
SARC	cis	rs3820928	0.874	rs1054413	chr2:227867719	A/G	cg11843606	chr2:227700838	RHBDD1	0.51	6.43	0.39	7.11e-10	Pulmonary function;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg05808815	chr1:54666250	CYB5RL;MRPL37	0.47	6.28	0.38	1.66e-9	Chemerin levels;
SARC	cis	rs2486288	0.656	rs7167146	chr15:45571386	A/G	cg19305227	chr15:45544335	SLC28A2	-0.31	-5.45	-0.34	1.3e-7	Glomerular filtration rate;
SARC	cis	rs11809207	0.855	rs17257155	chr1:26526439	C/T	cg04990556	chr1:26633338	UBXN11	0.51	5.02	0.31	1.01e-6	Height;
SARC	cis	rs6815814	0.950	rs11722813	chr4:38810769	C/T	cg09316306	chr4:38807337	TLR1	0.48	5.02	0.31	1.04e-6	Breast cancer;
SARC	cis	rs449303	1	rs449303	chr14:60605788	A/G	cg08229199	chr14:59932289	GPR135	0.49	4.81	0.3	2.68e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	trans	rs10771431	0.738	rs11049697	chr12:9385339	T/C	cg27600084	chr12:12264075	NA	0.55	7.07	0.42	1.83e-11	Breast size;
SARC	cis	rs7223966	1.000	rs55674647	chr17:61794195	T/C	cg00588841	chr17:61851480	DDX42;CCDC47	-0.67	-7.12	-0.42	1.33e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2916247	0.954	rs72671436	chr8:93077986	T/A	cg10183463	chr8:93005414	RUNX1T1	-0.64	-6.54	-0.39	3.91e-10	Intelligence (multi-trait analysis);
SARC	cis	rs155076	0.711	rs4770131	chr13:21897468	A/G	cg11317459	chr13:21872234	NA	1.14	15.81	0.72	9.44e-39	White matter hyperintensity burden;
SARC	cis	rs6570726	0.935	rs451349	chr6:145820894	A/G	cg05220968	chr6:146057943	EPM2A	-0.29	-4.83	-0.3	2.44e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg04756594	chr16:24857601	SLC5A11	0.41	5.5	0.34	9.76e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs6867032	1.000	rs4975796	chr5:2015520	A/T	cg26168224	chr5:2018326	NA	-0.93	-15.14	-0.7	1.64e-36	Gut microbiome composition (winter);
SARC	cis	rs76419734	0.702	rs77988914	chr4:106682436	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.8	5.36	0.33	2.02e-7	Post bronchodilator FEV1;
SARC	cis	rs2576037	0.796	rs2571033	chr18:44578552	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.67	-9.83	-0.54	2.77e-19	Personality dimensions;
SARC	cis	rs9816226	0.793	rs869400	chr3:185826740	T/G	cg00760338	chr3:185826511	ETV5	0.9	9.82	0.54	2.88e-19	Obesity;Body mass index;
SARC	cis	rs4148883	0.651	rs4147547	chr4:100127311	G/T	cg12011299	chr4:100065546	ADH4	0.31	5.56	0.34	7.33e-8	Alcohol dependence;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg05316006	chr10:114879619	TCF7L2	0.47	6.36	0.38	1.04e-9	Thyroid stimulating hormone;
SARC	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg21782813	chr7:2030301	MAD1L1	0.45	7.11	0.42	1.44e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs523522	0.962	rs7136951	chr12:120941927	C/T	cg27279351	chr12:120934652	DYNLL1	0.71	8.85	0.5	2.22e-16	High light scatter reticulocyte count;
SARC	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg22903471	chr2:27725779	GCKR	-0.49	-7.33	-0.43	3.78e-12	Total body bone mineral density;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg01166994	chr20:58515340	PPP1R3D;C20orf177	0.65	6.58	0.4	2.99e-10	Lung cancer in ever smokers;
SARC	cis	rs1322639	0.575	rs9294966	chr6:169565318	G/T	cg04662567	chr6:169592167	NA	-0.49	-4.89	-0.3	1.89e-6	Pulse pressure;
SARC	cis	rs11249608	0.636	rs6868893	chr5:178449826	C/A	cg01312482	chr5:178451176	ZNF879	-0.37	-4.79	-0.3	3.02e-6	Pubertal anthropometrics;
SARC	cis	rs11122272	0.668	rs2808616	chr1:231554993	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.62	9.01	0.51	7.66e-17	Hemoglobin concentration;
SARC	cis	rs933688	0.527	rs1511344	chr5:90582914	G/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.51	-4.88	-0.3	1.98e-6	Smoking behavior;
SARC	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.43	6.4	0.39	8.27e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs10504229	0.679	rs2317991	chr8:58035080	C/T	cg21724239	chr8:58056113	NA	-0.59	-6.28	-0.38	1.63e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs477692	0.699	rs509017	chr10:131367174	T/G	cg14263093	chr10:131365266	MGMT	0.36	5.04	0.31	9.54e-7	Response to temozolomide;
SARC	cis	rs11731606	0.508	rs56943028	chr4:95285813	T/C	cg20625393	chr4:95128694	SMARCAD1	0.57	5.6	0.34	6.12e-8	Mean platelet volume;
SARC	cis	rs3820928	1.000	rs4673173	chr2:227769493	A/C	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.89	-0.36	1.36e-8	Pulmonary function;
SARC	cis	rs8114671	0.562	rs3818273	chr20:33509275	G/A	cg24642439	chr20:33292090	TP53INP2	0.5	6.12	0.37	3.89e-9	Height;
SARC	cis	rs9309473	0.607	rs1522926	chr2:73591241	T/C	cg20560298	chr2:73613845	ALMS1	-0.54	-6.87	-0.41	5.76e-11	Metabolite levels;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg14128259	chr12:27848523	REP15	0.49	6.68	0.4	1.74e-10	Thyroid stimulating hormone;
SARC	cis	rs7786808	0.504	rs10949725	chr7:158196003	C/T	cg01191920	chr7:158217561	PTPRN2	0.34	5.85	0.36	1.62e-8	Obesity-related traits;
SARC	cis	rs1878931	0.517	rs17685105	chr16:3413749	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.81	-11.8	-0.61	1.63e-25	Body mass index (adult);
SARC	trans	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg00938859	chr5:1591904	SDHAP3	0.79	7.66	0.45	5.1e-13	Breast cancer;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg16829450	chr12:96184020	NTN4	0.52	6.56	0.39	3.5e-10	Breast cancer;
SARC	cis	rs10504229	0.636	rs114725691	chr8:58054292	C/T	cg08280861	chr8:58055591	NA	0.57	5.23	0.32	3.72e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs4718428	0.705	rs12536410	chr7:66254290	G/A	cg18252515	chr7:66147081	NA	-0.56	-6.14	-0.37	3.61e-9	Corneal structure;
SARC	cis	rs7264396	0.563	rs2425120	chr20:34324456	A/T	cg01084648	chr20:34329383	RBM39	0.58	5.03	0.31	9.74e-7	Total cholesterol levels;
SARC	cis	rs9843304	0.651	rs9842794	chr3:149210942	G/T	cg08667024	chr3:149219783	TM4SF4	0.43	6.78	0.41	9.67e-11	Gallstone disease;
SARC	cis	rs8180040	0.767	rs11920853	chr3:47308183	G/A	cg27129171	chr3:47204927	SETD2	-0.72	-9.53	-0.53	2.16e-18	Colorectal cancer;
SARC	cis	rs17345786	0.861	rs17402964	chr3:101067945	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.45	-4.75	-0.3	3.57e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg01181863	chr3:195395398	SDHAP2	-0.74	-8.39	-0.48	4.67e-15	Pancreatic cancer;
SARC	cis	rs10504073	0.647	rs9643395	chr8:50014500	A/C	cg00325661	chr8:49890786	NA	0.53	7.33	0.43	3.72e-12	Blood metabolite ratios;
SARC	cis	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg07636037	chr3:49044803	WDR6	0.63	8.37	0.48	5.44e-15	Resting heart rate;
SARC	cis	rs12472274	0.646	rs2305171	chr2:239097140	G/A	cg17459225	chr2:239074497	NA	0.6	6.19	0.38	2.69e-9	Phospholipid levels (plasma);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg06745955	chr17:27038470	PROCA1	0.47	6.24	0.38	2.03e-9	Height;
SARC	cis	rs735396	1.000	rs1169310	chr12:121439433	G/A	cg15155738	chr12:121454335	C12orf43	0.5	6.09	0.37	4.73e-9	N-glycan levels;
SARC	trans	rs2018683	0.899	rs10269454	chr7:28978400	C/T	cg19402173	chr7:128379420	CALU	-0.68	-8.87	-0.5	1.99e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs611744	0.752	rs609197	chr8:109234035	G/A	cg21045802	chr8:109455806	TTC35	0.46	5.43	0.34	1.38e-7	Dupuytren's disease;
SARC	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg12463550	chr7:65579703	CRCP	-0.71	-5.4	-0.33	1.61e-7	Diabetic kidney disease;
SARC	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg03806693	chr22:41940476	POLR3H	0.88	11.72	0.61	2.96e-25	Vitiligo;
SARC	cis	rs9549367	0.789	rs2302757	chr13:113909339	A/G	cg18105134	chr13:113819100	PROZ	-0.38	-5.69	-0.35	3.81e-8	Platelet distribution width;
SARC	cis	rs1008375	0.966	rs7658240	chr4:17588950	A/G	cg02297831	chr4:17616191	MED28	-0.47	-5.88	-0.36	1.41e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10927875	0.541	rs1763599	chr1:16342602	C/T	cg21385522	chr1:16154831	NA	0.55	6.58	0.4	3.05e-10	Dilated cardiomyopathy;
SARC	cis	rs1707322	0.686	rs3014236	chr1:46091305	T/C	cg06784218	chr1:46089804	CCDC17	-0.38	-6.57	-0.4	3.31e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2204008	0.837	rs12146734	chr12:38237079	A/G	cg13010199	chr12:38710504	ALG10B	0.81	11.19	0.59	1.48e-23	Bladder cancer;
SARC	cis	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg00071950	chr4:10020882	SLC2A9	0.41	6.57	0.4	3.2e-10	Bone mineral density;
SARC	cis	rs713477	1.000	rs12888234	chr14:55911352	T/A	cg13175173	chr14:55914753	NA	-0.3	-4.75	-0.3	3.63e-6	Pediatric bone mineral content (femoral neck);
SARC	cis	rs7551222	0.721	rs4951080	chr1:204533284	A/G	cg20240347	chr1:204465584	NA	-0.33	-5.76	-0.35	2.6e-8	Schizophrenia;
SARC	cis	rs3793683	1.000	rs3793683	chr10:134568387	G/T	cg01276201	chr10:134613136	NA	-0.27	-5.04	-0.31	9.25e-7	Migraine;
SARC	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg22857025	chr5:266934	NA	-1.06	-11.69	-0.61	3.74e-25	Breast cancer;
SARC	cis	rs875971	0.545	rs73378304	chr7:65640747	G/A	cg25894440	chr7:65020034	NA	0.5	4.81	0.3	2.7e-6	Aortic root size;
SARC	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg12463550	chr7:65579703	CRCP	-0.48	-5.58	-0.34	6.74e-8	Aortic root size;
SARC	cis	rs11871801	0.517	rs35635959	chr17:40772288	T/C	cg14558262	chr17:40713999	COASY	0.5	5.57	0.34	6.9e-8	Crohn's disease;
SARC	cis	rs7726839	0.540	rs61731455	chr5:665295	A/G	cg07777115	chr5:623756	CEP72	-0.57	-4.86	-0.3	2.2e-6	Obesity-related traits;
SARC	cis	rs3106136	0.527	rs10016806	chr4:95158495	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.47	-7.05	-0.42	2.06e-11	Capecitabine sensitivity;
SARC	cis	rs11105298	0.891	rs10858881	chr12:89891474	T/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.53	-5.32	-0.33	2.4e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs10876993	0.890	rs7963927	chr12:58046272	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.46	-5.88	-0.36	1.38e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs35995292	0.500	rs28369620	chr7:38921872	C/T	cg19327137	chr7:38886074	VPS41	0.5	7.3	0.43	4.4e-12	Subjective well-being (multi-trait analysis);
SARC	cis	rs17401966	0.838	rs4475756	chr1:10387788	A/G	cg15208524	chr1:10270712	KIF1B	0.44	5.11	0.32	6.79e-7	Hepatocellular carcinoma;
SARC	cis	rs6831352	0.959	rs6532796	chr4:100042242	C/T	cg13256891	chr4:100009986	ADH5	-0.68	-9.09	-0.51	4.4e-17	Alcohol dependence;
SARC	trans	rs11098499	0.820	rs11737395	chr4:120520704	C/G	cg25214090	chr10:38739885	LOC399744	0.57	7.2	0.43	8.42e-12	Corneal astigmatism;
SARC	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg12463550	chr7:65579703	CRCP	0.5	5.82	0.36	1.98e-8	Aortic root size;
SARC	cis	rs72781680	0.716	rs2551343	chr2:24027002	C/G	cg06627628	chr2:24431161	ITSN2	-0.53	-5.56	-0.34	7.38e-8	Lymphocyte counts;
SARC	cis	rs28374715	0.733	rs7167706	chr15:41569644	C/A	cg18705301	chr15:41695430	NDUFAF1	-1.12	-16.71	-0.74	9.98e-42	Ulcerative colitis;
SARC	cis	rs1468333	0.514	rs10515498	chr5:137586330	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.63	6.48	0.39	5.42e-10	Resting heart rate;
SARC	cis	rs965469	1.000	rs77763497	chr20:3250007	A/G	cg25506879	chr20:3388711	C20orf194	-0.57	-5.57	-0.34	7.16e-8	IFN-related cytopenia;
SARC	cis	rs9436747	0.641	rs11208676	chr1:66048123	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.48	4.98	0.31	1.26e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs372883	0.638	rs117213	chr21:30720536	G/A	cg08807101	chr21:30365312	RNF160	-0.54	-6.67	-0.4	1.85e-10	Pancreatic cancer;
SARC	cis	rs5769765	0.773	rs7410291	chr22:50300078	A/G	cg03033257	chr22:50311977	ALG12;CRELD2	0.52	5.4	0.33	1.65e-7	Schizophrenia;
SARC	cis	rs62158211	0.565	rs62158212	chr2:114106326	A/G	cg17784749	chr2:114082611	LOC440839	0.47	5.66	0.35	4.36e-8	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
SARC	cis	rs7044106	0.537	rs10739573	chr9:123489818	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	5.26	0.33	3.3e-7	Hip circumference adjusted for BMI;
SARC	cis	rs3126085	0.935	rs10888483	chr1:152252789	T/A	cg26876637	chr1:152193138	HRNR	-0.5	-5.14	-0.32	5.95e-7	Atopic dermatitis;
SARC	cis	rs6912958	0.754	rs1051131	chr6:88221546	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.52	-7.03	-0.42	2.22e-11	Monocyte percentage of white cells;
SARC	cis	rs4851254	1.000	rs4851254	chr2:100762937	C/G	cg17356467	chr2:100759845	AFF3	0.29	4.81	0.3	2.75e-6	Intelligence (multi-trait analysis);
SARC	cis	rs6429082	0.818	rs704722	chr1:235669988	G/A	cg26050004	chr1:235667680	B3GALNT2	0.66	7.59	0.45	7.48e-13	Adiposity;
SARC	cis	rs7582180	0.614	rs3748930	chr2:101010082	G/C	cg14675211	chr2:100938903	LONRF2	0.53	8.03	0.47	4.93e-14	Intelligence (multi-trait analysis);
SARC	cis	rs2197308	0.765	rs11182481	chr12:37926019	T/C	cg13010199	chr12:38710504	ALG10B	0.77	10.27	0.56	1.23e-20	Morning vs. evening chronotype;
SARC	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg18252515	chr7:66147081	NA	-0.63	-6.76	-0.41	1.07e-10	Aortic root size;
SARC	cis	rs9486719	0.948	rs11153059	chr6:97014537	T/A	cg06623918	chr6:96969491	KIAA0776	-0.79	-8.83	-0.5	2.51e-16	Migraine;Coronary artery disease;
SARC	cis	rs9479482	1.000	rs9479482	chr6:150358012	T/C	cg03788504	chr6:150331562	NA	-0.33	-5.34	-0.33	2.21e-7	Alopecia areata;
SARC	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg25072359	chr17:41440525	NA	0.52	6.13	0.37	3.75e-9	Menopause (age at onset);
SARC	cis	rs1044826	0.642	rs7624321	chr3:139220159	C/A	cg15131784	chr3:139108705	COPB2	0.4	5.06	0.31	8.66e-7	Obesity-related traits;
SARC	cis	rs240764	0.658	rs1336244	chr6:101197953	C/T	cg09795085	chr6:101329169	ASCC3	-0.49	-6.42	-0.39	7.72e-10	Neuroticism;
SARC	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg13628971	chr7:2884303	GNA12	0.54	6.39	0.39	8.97e-10	Height;
SARC	cis	rs7264396	0.563	rs3827029	chr20:34332784	G/T	cg23207816	chr20:34252616	CPNE1;RBM12	-0.56	-5.29	-0.33	2.84e-7	Total cholesterol levels;
SARC	cis	rs9818758	0.545	rs11717978	chr3:48969036	T/A	cg01304814	chr3:48885189	PRKAR2A	0.62	5.12	0.32	6.46e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs9467773	0.620	rs2504565	chr6:26656890	G/A	cg11502198	chr6:26597334	ABT1	0.63	8.43	0.48	3.64e-15	Intelligence (multi-trait analysis);
SARC	cis	rs2479724	0.792	rs7739064	chr6:41834037	C/A	cg08135965	chr6:41755394	TOMM6	0.4	4.74	0.3	3.71e-6	Menarche (age at onset);
SARC	cis	rs7727544	0.660	rs272886	chr5:131665840	T/C	cg24060327	chr5:131705240	SLC22A5	-0.68	-8.8	-0.5	3.11e-16	Blood metabolite levels;
SARC	cis	rs854765	0.583	rs10048206	chr17:17866897	A/G	cg05444541	chr17:17804740	TOM1L2	-0.29	-4.82	-0.3	2.56e-6	Total body bone mineral density;
SARC	cis	rs2120019	1.000	rs34237279	chr15:75361121	A/G	cg17294928	chr15:75287854	SCAMP5	-0.94	-13.59	-0.67	2.25e-31	Blood trace element (Zn levels);
SARC	trans	rs1814175	0.817	rs1851860	chr11:49861310	A/C	cg03929089	chr4:120376271	NA	-0.9	-15.22	-0.71	9.01e-37	Height;
SARC	cis	rs9302635	0.550	rs35959677	chr16:72200801	G/T	cg01557791	chr16:72042693	DHODH	-0.58	-6.09	-0.37	4.54e-9	Blood protein levels;
SARC	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg00825309	chr19:58991885	ZNF446	-0.57	-7.93	-0.46	9e-14	Uric acid clearance;
SARC	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.68	8.61	0.49	1.1e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2153535	0.584	rs9502721	chr6:8541379	G/A	cg21535247	chr6:8435926	SLC35B3	0.53	6.56	0.39	3.47e-10	Motion sickness;
SARC	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg00933542	chr6:150070202	PCMT1	0.3	4.83	0.3	2.5e-6	Lung cancer;
SARC	cis	rs10463554	0.963	rs158254	chr5:102394883	G/A	cg23492399	chr5:102201601	PAM	-0.52	-5.73	-0.35	3.13e-8	Parkinson's disease;
SARC	cis	rs9790314	1.000	rs336569	chr3:161072346	T/G	cg04691961	chr3:161091175	C3orf57	-0.81	-12.41	-0.63	1.74e-27	Morning vs. evening chronotype;
SARC	cis	rs60871478	1.000	rs62432252	chr7:802886	C/G	cg05535760	chr7:792225	HEATR2	0.78	8.11	0.47	2.97e-14	Cerebrospinal P-tau181p levels;
SARC	cis	rs4595586	0.545	rs61939641	chr12:39378001	T/C	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	cis	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg00745463	chr17:30367425	LRRC37B	-0.69	-5.28	-0.33	2.96e-7	Hip circumference adjusted for BMI;
SARC	cis	rs72781680	0.644	rs72783627	chr2:24315685	A/C	cg06627628	chr2:24431161	ITSN2	-0.5	-5.32	-0.33	2.4e-7	Lymphocyte counts;
SARC	cis	rs568617	1.000	rs656980	chr11:65656282	G/A	cg00576331	chr11:65640516	EFEMP2	-0.46	-5.41	-0.33	1.53e-7	Crohn's disease;
SARC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg11494091	chr17:61959527	GH2	0.54	7.97	0.46	7.07e-14	Prudent dietary pattern;
SARC	cis	rs7223966	0.655	rs7209961	chr17:61633705	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.47	-4.73	-0.3	3.96e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1008375	0.932	rs12500947	chr4:17603424	C/T	cg02297831	chr4:17616191	MED28	0.51	6.48	0.39	5.36e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg01475735	chr3:40494733	NA	-0.46	-5.07	-0.31	8.3e-7	Renal cell carcinoma;
SARC	cis	rs9902453	0.619	rs1038088	chr17:28074563	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.25	-0.43	6.15e-12	Coffee consumption (cups per day);
SARC	cis	rs7246657	0.943	rs4803347	chr19:37848017	G/A	cg23950597	chr19:37808831	NA	-0.53	-5.27	-0.33	3.05e-7	Coronary artery calcification;
SARC	cis	rs6121246	0.567	rs7361893	chr20:30200751	C/T	cg21427119	chr20:30132790	HM13	-0.44	-4.93	-0.31	1.58e-6	Mean corpuscular hemoglobin;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg07314148	chr10:129924922	MKI67	-0.48	-6.45	-0.39	6.46e-10	Neuroticism;
SARC	cis	rs7766436	0.621	rs6903615	chr6:22602569	T/C	cg13666174	chr6:22585274	NA	-0.48	-6.59	-0.4	2.98e-10	Coronary artery disease;
SARC	cis	rs7772486	0.790	rs6926076	chr6:146232804	C/T	cg05347473	chr6:146136440	FBXO30	-0.48	-6.55	-0.39	3.63e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6088590	1.000	rs12626122	chr20:33425800	A/G	cg24642439	chr20:33292090	TP53INP2	0.78	10.21	0.56	1.8e-20	Coronary artery disease;
SARC	trans	rs9354308	0.868	rs9363456	chr6:66548343	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.56	-6.64	-0.4	2.19e-10	Metabolite levels;
SARC	cis	rs787274	1.000	rs947609	chr9:115516562	A/G	cg13803584	chr9:115635662	SNX30	-0.83	-4.9	-0.31	1.79e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs6700896	0.832	rs11208693	chr1:66108063	C/T	cg04111102	chr1:66153794	NA	0.35	5.52	0.34	9.17e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs17376456	0.825	rs28534784	chr5:93063332	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	7.01	0.42	2.61e-11	Diabetic retinopathy;
SARC	cis	rs7216064	0.734	rs11653507	chr17:65892064	A/T	cg12091567	chr17:66097778	LOC651250	-0.56	-6.14	-0.37	3.45e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs12824058	0.831	rs11060826	chr12:130809931	G/C	cg24838063	chr12:130822603	PIWIL1	0.63	8.94	0.51	1.25e-16	Menopause (age at onset);
SARC	cis	rs36051895	0.522	rs12341844	chr9:5177872	C/T	cg02405213	chr9:5042618	JAK2	-0.45	-5.31	-0.33	2.62e-7	Pediatric autoimmune diseases;
SARC	cis	rs17376456	0.877	rs10476601	chr5:93402522	G/A	cg21475434	chr5:93447410	FAM172A	0.85	7.56	0.44	9.4e-13	Diabetic retinopathy;
SARC	cis	rs6714710	0.603	rs717417	chr2:98416850	T/G	cg26665480	chr2:98280029	ACTR1B	0.55	7.42	0.44	2.2e-12	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs6582630	0.519	rs8189549	chr12:38245752	A/G	cg13010199	chr12:38710504	ALG10B	0.81	11.31	0.6	6.33e-24	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6120849	0.754	rs6119560	chr20:33606977	G/C	cg24642439	chr20:33292090	TP53INP2	0.57	5.48	0.34	1.1e-7	Protein C levels;
SARC	cis	rs2286885	0.896	rs62578061	chr9:129248219	C/T	cg14319473	chr9:129242481	FAM125B	0.38	4.87	0.3	2.04e-6	Intraocular pressure;
SARC	cis	rs9513627	1.000	rs73556181	chr13:100122092	G/A	cg25919922	chr13:100150906	NA	-0.69	-5.22	-0.32	3.92e-7	Obesity-related traits;
SARC	cis	rs9479482	0.967	rs3860823	chr6:150356526	A/G	cg03788504	chr6:150331562	NA	-0.32	-5.18	-0.32	4.75e-7	Alopecia areata;
SARC	cis	rs138249	1.000	rs138209	chr22:50539413	T/C	cg24864161	chr22:50528282	MOV10L1	0.31	4.98	0.31	1.21e-6	Gestational age at birth in labor-initiated deliveries (child effect);
SARC	cis	rs7681440	0.904	rs7672979	chr4:90767873	A/G	cg02192967	chr4:90758406	SNCA	0.36	5.13	0.32	6.11e-7	Dementia with Lewy bodies;
SARC	cis	rs9926296	0.744	rs164746	chr16:89709019	C/T	cg03605463	chr16:89740564	NA	0.49	6.27	0.38	1.7e-9	Vitiligo;
SARC	cis	rs240764	0.817	rs239219	chr6:101116146	C/T	cg09795085	chr6:101329169	ASCC3	0.44	5.72	0.35	3.32e-8	Neuroticism;
SARC	cis	rs2985684	0.789	rs1957979	chr14:50063332	A/G	cg04989706	chr14:50066350	PPIL5	-0.56	-6.28	-0.38	1.65e-9	Carotid intima media thickness;
SARC	cis	rs818427	0.783	rs57721139	chr5:112223870	G/A	cg07820702	chr5:112228657	REEP5	-0.46	-5.2	-0.32	4.45e-7	Total body bone mineral density;
SARC	cis	rs854765	0.547	rs9913277	chr17:17919749	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.61	8.85	0.5	2.29e-16	Total body bone mineral density;
SARC	cis	rs4803468	1.000	rs11883104	chr19:41923799	T/C	cg08477640	chr19:41863820	B9D2	0.45	5.82	0.36	1.94e-8	Height;
SARC	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg18252515	chr7:66147081	NA	-1.33	-11.96	-0.62	5.03e-26	Diabetic kidney disease;
SARC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg22535103	chr8:58192502	C8orf71	-0.72	-6.61	-0.4	2.6e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9894429	0.646	rs7210026	chr17:79612382	T/C	cg18240062	chr17:79603768	NPLOC4	0.58	7.04	0.42	2.14e-11	Eye color traits;
SARC	cis	rs10870270	1.000	rs10870292	chr10:133770782	G/C	cg26149184	chr10:133730230	NA	0.48	5.22	0.32	3.99e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	trans	rs9325144	0.600	rs6582630	chr12:38743508	A/G	cg23762105	chr12:34175262	ALG10	0.54	7.07	0.42	1.74e-11	Morning vs. evening chronotype;
SARC	cis	rs1153858	0.943	rs7402632	chr15:45701913	A/T	cg21132104	chr15:45694354	SPATA5L1	0.78	10.33	0.56	7.8e-21	Homoarginine levels;
SARC	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg27266027	chr21:40555129	PSMG1	0.5	5.64	0.35	5.01e-8	Cognitive function;
SARC	cis	rs4853036	0.904	rs7578366	chr2:70135695	C/T	cg02498382	chr2:70120550	SNRNP27	-0.38	-5.12	-0.32	6.27e-7	Colorectal or endometrial cancer;
SARC	cis	rs9916302	0.706	rs4488484	chr17:37717377	A/T	cg07936489	chr17:37558343	FBXL20	0.77	8.76	0.5	4.12e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.82	12.64	0.64	3.01e-28	Personality dimensions;
SARC	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg24250549	chr1:154909240	PMVK	0.77	10.54	0.57	1.73e-21	Prostate cancer;
SARC	cis	rs6088580	0.634	rs6088475	chr20:32964987	T/C	cg08999081	chr20:33150536	PIGU	-0.43	-6.58	-0.4	3.15e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs826838	0.967	rs6580726	chr12:39108623	T/C	cg13010199	chr12:38710504	ALG10B	-0.65	-9.37	-0.52	6.39e-18	Heart rate;
SARC	trans	rs208520	0.874	rs208514	chr6:66945520	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.84	-9.8	-0.54	3.23e-19	Exhaled nitric oxide output;
SARC	cis	rs448720	0.806	rs47713	chr15:68173855	C/T	cg05925327	chr15:68127851	NA	0.34	4.88	0.3	2.01e-6	Cognitive performance;
SARC	cis	rs1008375	1.000	rs1860597	chr4:17657650	C/T	cg27347728	chr4:17578864	LAP3	0.47	5.88	0.36	1.42e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2242116	0.932	rs4683301	chr3:46931478	A/T	cg23352942	chr3:46931381	PTH1R	0.34	5.14	0.32	5.87e-7	Birth weight;
SARC	cis	rs11122272	0.735	rs2790880	chr1:231534259	C/T	cg06096015	chr1:231504339	EGLN1	0.36	5.36	0.33	2.01e-7	Hemoglobin concentration;
SARC	cis	rs2070488	0.775	rs2186457	chr3:38553965	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.71	10.7	0.57	5.49e-22	Electrocardiographic conduction measures;
SARC	cis	rs854765	0.583	rs66531105	chr17:17809001	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.66	9.77	0.54	3.98e-19	Total body bone mineral density;
SARC	cis	rs11685299	1	rs11685299	chr2:225391296	C/A	cg12698349	chr2:225449008	CUL3	0.73	10.53	0.57	1.89e-21	Schizophrenia;
SARC	cis	rs9472414	0.546	rs35565233	chr6:45349497	C/T	cg11115867	chr6:45345767	RUNX2;SUPT3H	0.56	5.17	0.32	4.93e-7	Height;
SARC	cis	rs820218	0.926	rs8074319	chr17:73652060	C/A	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.69	9.5	0.53	2.62e-18	Rotator cuff tears;
SARC	cis	rs4689388	0.926	rs28420833	chr4:6279504	G/A	cg14416269	chr4:6271139	WFS1	0.35	5.49	0.34	1.04e-7	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs2153535	0.580	rs6912374	chr6:8456423	T/C	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.04e-14	Motion sickness;
SARC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.62	-6.59	-0.4	2.82e-10	Platelet count;
SARC	cis	rs13082711	0.834	rs2840088	chr3:27428371	G/A	cg02860705	chr3:27208620	NA	0.48	6.3	0.38	1.51e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs826838	0.967	rs2892410	chr12:38990282	A/G	cg26384229	chr12:38710491	ALG10B	-0.92	-14.48	-0.69	2.64e-34	Heart rate;
SARC	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg20891283	chr12:69753455	YEATS4	0.55	7.56	0.44	9.09e-13	Blood protein levels;
SARC	trans	rs9951602	0.512	rs1599633	chr18:76643526	T/C	cg02800362	chr5:177631904	HNRNPAB	0.68	8.61	0.49	1.13e-15	Obesity-related traits;
SARC	cis	rs35110281	0.807	rs9976441	chr21:45046591	G/A	cg01579765	chr21:45077557	HSF2BP	-0.33	-5.68	-0.35	3.94e-8	Mean corpuscular volume;
SARC	trans	rs7944735	0.507	rs7114598	chr11:48101766	C/T	cg15704280	chr7:45808275	SEPT13	0.58	6.75	0.4	1.17e-10	Intraocular pressure;
SARC	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg14343924	chr8:8086146	FLJ10661	-0.41	-5.01	-0.31	1.09e-6	Mood instability;
SARC	cis	rs897984	0.520	rs4889614	chr16:30862135	G/A	cg02466173	chr16:30829666	NA	0.42	5.28	0.33	2.96e-7	Dementia with Lewy bodies;
SARC	cis	rs2033732	0.673	rs10808858	chr8:85070841	C/T	cg05716166	chr8:85095498	RALYL	0.48	5.65	0.35	4.56e-8	Body mass index;
SARC	cis	rs854765	0.583	rs4925126	chr17:17798633	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.44	5.59	0.34	6.25e-8	Total body bone mineral density;
SARC	cis	rs10484885	0.878	rs1328018	chr6:90297847	A/G	cg13799429	chr6:90582589	CASP8AP2	0.67	5.26	0.33	3.33e-7	QRS interval (sulfonylurea treatment interaction);
SARC	cis	rs1348850	0.793	rs13020788	chr2:178480714	C/A	cg23306229	chr2:178417860	TTC30B	0.53	5.83	0.36	1.88e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs34330	0.562	rs12229100	chr12:12865836	A/G	cg04607235	chr12:12878440	APOLD1	0.56	5.43	0.33	1.45e-7	Systemic lupus erythematosus;
SARC	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	5.67	0.35	4.13e-8	Bipolar disorder;
SARC	cis	rs858239	1.000	rs858240	chr7:23284237	A/G	cg23682824	chr7:23144976	KLHL7	0.62	7.61	0.45	6.78e-13	Cerebrospinal fluid biomarker levels;
SARC	cis	rs11122272	0.735	rs2295420	chr1:231485640	C/T	cg06096015	chr1:231504339	EGLN1	0.38	5.71	0.35	3.45e-8	Hemoglobin concentration;
SARC	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg18357526	chr6:26021779	HIST1H4A	0.74	9.15	0.51	2.95e-17	Intelligence (multi-trait analysis);
SARC	cis	rs9467773	0.620	rs2451737	chr6:26619041	T/C	cg11502198	chr6:26597334	ABT1	0.62	8.48	0.49	2.55e-15	Intelligence (multi-trait analysis);
SARC	cis	rs2204008	0.720	rs11181343	chr12:38323616	G/T	cg26384229	chr12:38710491	ALG10B	0.87	12.51	0.63	8.19e-28	Bladder cancer;
SARC	cis	rs911555	0.755	rs2756132	chr14:103967820	C/G	cg12935359	chr14:103987150	CKB	0.41	5.62	0.35	5.48e-8	Intelligence (multi-trait analysis);
SARC	trans	rs7615952	0.673	rs16834637	chr3:125605471	C/T	cg07211511	chr3:129823064	LOC729375	-0.83	-8.29	-0.48	9.31e-15	Blood pressure (smoking interaction);
SARC	cis	rs864537	0.618	rs2988277	chr1:167431352	A/G	cg09179987	chr1:167433047	CD247	-0.41	-6.78	-0.41	9.63e-11	Celiac disease or Rheumatoid arthritis;Celiac disease;
SARC	cis	rs8114671	0.562	rs6087653	chr20:33522054	T/C	cg08999081	chr20:33150536	PIGU	0.33	4.89	0.3	1.89e-6	Height;
SARC	trans	rs9650657	0.501	rs3021500	chr8:11023997	G/C	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.76	-0.5	3.96e-16	Neuroticism;
SARC	cis	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.4	-4.87	-0.3	2.06e-6	Eosinophil percentage of white cells;
SARC	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg26681399	chr22:41777847	TEF	0.43	4.92	0.31	1.67e-6	Vitiligo;
SARC	cis	rs12135062	0.755	rs1553287	chr1:3101277	G/A	cg25382214	chr1:3105252	PRDM16	-0.35	-5.08	-0.32	7.8e-7	Migraine;
SARC	cis	rs10504229	0.679	rs60869047	chr8:58053221	G/A	cg11062466	chr8:58055876	NA	0.51	5.02	0.31	1.01e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg16479474	chr6:28041457	NA	0.36	5.36	0.33	1.97e-7	Depression;
SARC	cis	rs6964587	0.869	rs34791781	chr7:91532720	C/T	cg17063962	chr7:91808500	NA	-0.91	-14.0	-0.68	9.98e-33	Breast cancer;
SARC	cis	rs959260	0.502	rs11658023	chr17:73308722	C/T	cg14668889	chr17:73230827	NUP85	-0.54	-6.98	-0.42	3.13e-11	Systemic lupus erythematosus;
SARC	cis	rs425277	0.539	rs3128338	chr1:2046786	G/A	cg21442419	chr1:2182373	SKI	0.45	5.82	0.36	1.9e-8	Height;
SARC	cis	rs9660992	0.674	rs1151784	chr1:205232447	C/T	cg00857998	chr1:205179979	DSTYK	0.52	6.33	0.38	1.28e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.89	12.64	0.64	3.1e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9911578	1.000	rs302854	chr17:56683612	G/A	cg05425664	chr17:57184151	TRIM37	-0.69	-8.6	-0.49	1.16e-15	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs3087591	1.000	rs2905870	chr17:29521833	G/A	cg24425628	chr17:29625626	OMG;NF1	0.49	5.99	0.37	7.8e-9	Hip circumference;
SARC	cis	rs992157	0.710	rs56364928	chr2:219059058	G/A	cg00012203	chr2:219082015	ARPC2	0.83	13.59	0.66	2.32e-31	Colorectal cancer;
SARC	cis	rs11098699	0.784	rs7684146	chr4:124207309	C/A	cg09941581	chr4:124220074	SPATA5	0.39	4.75	0.3	3.5e-6	Mosquito bite size;
SARC	cis	rs7481584	1.000	rs756693	chr11:3027889	A/G	cg05729581	chr11:3078854	CARS	0.48	5.84	0.36	1.73e-8	Calcium levels;
SARC	cis	rs7647973	0.593	rs9870755	chr3:49809841	A/G	cg06212747	chr3:49208901	KLHDC8B	0.55	5.61	0.34	5.72e-8	Menarche (age at onset);
SARC	cis	rs3008870	0.755	rs2815363	chr1:67497221	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.6	-7.53	-0.44	1.13e-12	Lymphocyte percentage of white cells;
SARC	cis	rs17376456	0.569	rs10057664	chr5:93182274	C/T	cg21475434	chr5:93447410	FAM172A	-0.65	-6.46	-0.39	6.18e-10	Diabetic retinopathy;
SARC	cis	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg07777115	chr5:623756	CEP72	0.63	5.9	0.36	1.25e-8	Obesity-related traits;
SARC	cis	rs10088262	0.629	rs7833650	chr8:124822969	C/T	cg20713898	chr8:124780851	FAM91A1	-0.64	-7.12	-0.42	1.34e-11	Pancreatic cancer;
SARC	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-4.82	-0.3	2.59e-6	Total body bone mineral density;
SARC	cis	rs432925	0.600	rs385862	chr16:344659	A/G	cg06233593	chr16:337645	AXIN1	0.35	4.72	0.3	4.11e-6	Morning vs. evening chronotype;
SARC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg22105103	chr4:187893119	NA	0.51	6.69	0.4	1.66e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7385804	0.761	rs576236	chr7:100316975	C/T	cg20848291	chr7:100343083	ZAN	0.4	4.92	0.31	1.66e-6	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
SARC	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg16049864	chr8:95962084	TP53INP1	-0.47	-7.69	-0.45	4.13e-13	Type 2 diabetes;
SARC	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg17971929	chr21:40555470	PSMG1	0.99	14.16	0.68	2.89e-33	Cognitive function;
SARC	trans	rs9354308	1.000	rs9342503	chr6:66565436	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.55	-6.55	-0.39	3.62e-10	Metabolite levels;
SARC	cis	rs3768617	0.510	rs2296291	chr1:183079509	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.8e-21	Fuchs's corneal dystrophy;
SARC	cis	rs2180341	1.000	rs6904520	chr6:127629802	T/C	cg17762328	chr6:126965162	NA	-0.46	-5.24	-0.32	3.55e-7	Breast cancer;
SARC	cis	rs8067545	0.611	rs11653869	chr17:20197586	T/G	cg13482628	chr17:19912719	NA	-0.58	-7.72	-0.45	3.32e-13	Schizophrenia;
SARC	cis	rs2072499	0.750	rs7534339	chr1:156156219	A/G	cg24450063	chr1:156163899	SLC25A44	1.11	14.31	0.68	9.55e-34	Testicular germ cell tumor;
SARC	cis	rs9948	0.529	rs2139406	chr2:97366779	A/G	cg01990225	chr2:97406019	LMAN2L	-0.79	-6.45	-0.39	6.33e-10	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs807669	0.903	rs756651	chr22:19179367	T/C	cg02655711	chr22:19163373	SLC25A1	0.55	7.51	0.44	1.27e-12	Metabolite levels;
SARC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg02353165	chr6:42928485	GNMT	0.65	8.88	0.5	1.87e-16	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs12950390	0.893	rs4794110	chr17:45847230	A/G	cg03474202	chr17:45855739	NA	-0.41	-6.63	-0.4	2.27e-10	IgG glycosylation;
SARC	trans	rs79976124	0.879	rs12213669	chr6:66627704	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	8.0	0.46	5.76e-14	Type 2 diabetes;
SARC	cis	rs1023500	0.505	rs134888	chr22:42674281	C/T	cg15557168	chr22:42548783	NA	-0.41	-5.76	-0.35	2.71e-8	Schizophrenia;
SARC	cis	rs9660992	0.710	rs7367930	chr1:205235512	A/G	cg00857998	chr1:205179979	DSTYK	0.52	6.31	0.38	1.41e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs17376456	0.597	rs10866760	chr5:93338335	G/A	cg21475434	chr5:93447410	FAM172A	-0.62	-6.56	-0.39	3.5e-10	Diabetic retinopathy;
SARC	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg22875332	chr1:76189707	ACADM	0.43	5.48	0.34	1.13e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs4141404	0.740	rs9609301	chr22:31895940	C/T	cg02404636	chr22:31891804	SFI1	0.5	5.18	0.32	4.82e-7	Paclitaxel-induced neuropathy;
SARC	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg17971929	chr21:40555470	PSMG1	0.98	13.57	0.66	2.65e-31	Cognitive function;
SARC	cis	rs7216064	1.000	rs3206817	chr17:65892834	A/G	cg12091567	chr17:66097778	LOC651250	-0.69	-7.05	-0.42	1.99e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg24209194	chr3:40518798	ZNF619	-0.65	-8.08	-0.47	3.47e-14	Renal cell carcinoma;
SARC	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg20120463	chr17:44301886	NA	0.32	5.03	0.31	9.89e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7659604	1.000	rs6816071	chr4:122665185	G/A	cg20573242	chr4:122745356	CCNA2	0.44	5.73	0.35	3.13e-8	Type 2 diabetes;
SARC	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.63e-10	Life satisfaction;
SARC	cis	rs3758785	0.641	rs4753600	chr11:94101345	G/A	cg13023536	chr11:94226537	MRE11A;ANKRD49	-0.44	-5.72	-0.35	3.2e-8	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
SARC	cis	rs7582180	0.614	rs2241809	chr2:101014363	C/T	cg14675211	chr2:100938903	LONRF2	0.52	7.63	0.45	6.09e-13	Intelligence (multi-trait analysis);
SARC	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg13206674	chr6:150067644	NUP43	0.41	5.36	0.33	1.98e-7	Lung cancer;
SARC	cis	rs240764	0.658	rs2132169	chr6:101177663	C/A	cg09795085	chr6:101329169	ASCC3	-0.51	-6.74	-0.4	1.25e-10	Neuroticism;
SARC	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.46	0.39	6.12e-10	Bipolar disorder;
SARC	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg22683308	chr4:1340831	KIAA1530	-0.42	-4.76	-0.3	3.47e-6	Obesity-related traits;
SARC	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg08280861	chr8:58055591	NA	0.67	5.84	0.36	1.76e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7615952	0.673	rs34209763	chr3:125599595	G/A	cg05084668	chr3:125655381	ALG1L	-0.78	-7.64	-0.45	5.74e-13	Blood pressure (smoking interaction);
SARC	cis	rs9790314	0.967	rs336586	chr3:161081347	G/A	cg03342759	chr3:160939853	NMD3	-0.59	-7.33	-0.43	3.83e-12	Morning vs. evening chronotype;
SARC	cis	rs9788682	0.747	rs7174190	chr15:78763617	C/T	cg24631222	chr15:78858424	CHRNA5	0.74	9.03	0.51	6.53e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs3762637	1.000	rs9843165	chr3:122131111	G/C	cg24169773	chr3:122142474	KPNA1	-0.55	-5.62	-0.35	5.4e-8	LDL cholesterol levels;
SARC	cis	rs17213078	0.510	rs17032713	chr2:106886839	T/C	cg16099169	chr2:106886729	NA	-0.57	-7.56	-0.44	9.32e-13	Facial morphology (factor 23);
SARC	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg01316550	chr5:56110833	MAP3K1	0.54	4.92	0.31	1.62e-6	Initial pursuit acceleration;
SARC	cis	rs897080	0.515	rs786617	chr2:44593158	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.65	7.79	0.45	2.2e-13	Height;
SARC	cis	rs9462027	0.606	rs2814984	chr6:34597513	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-6.07	-0.37	5.26e-9	Systemic lupus erythematosus;
SARC	cis	rs4808199	0.895	rs10419672	chr19:19471241	T/C	cg03709012	chr19:19516395	GATAD2A	1.08	11.39	0.6	3.41e-24	Nonalcoholic fatty liver disease;
SARC	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg24549020	chr5:56110836	MAP3K1	0.54	5.99	0.37	7.7e-9	Coronary artery disease;
SARC	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7772486	0.764	rs2247211	chr6:146216379	G/A	cg23711669	chr6:146136114	FBXO30	0.76	11.9	0.61	8.07e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs599083	0.829	rs23691	chr11:68178668	G/A	cg24974729	chr11:67764320	UNC93B1	-0.32	-4.77	-0.3	3.2e-6	Bone mineral density (spine);
SARC	cis	rs6540556	0.769	rs10157973	chr1:209924425	C/T	cg05527609	chr1:210001259	C1orf107	-0.52	-5.25	-0.33	3.45e-7	Red blood cell count;
SARC	cis	rs4073582	0.595	rs708472	chr11:65930990	A/G	cg14036092	chr11:66035641	RAB1B	0.59	8.36	0.48	5.75e-15	Gout;
SARC	cis	rs11122272	0.735	rs1076804	chr1:231498460	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.98	-0.55	9.29e-20	Hemoglobin concentration;
SARC	cis	rs7647973	0.771	rs9865051	chr3:49166069	C/T	cg06212747	chr3:49208901	KLHDC8B	0.51	4.94	0.31	1.49e-6	Menarche (age at onset);
SARC	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.34	-5.15	-0.32	5.42e-7	Longevity;Endometriosis;
SARC	cis	rs10484885	0.824	rs72919976	chr6:90526686	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.59	-4.91	-0.31	1.73e-6	QRS interval (sulfonylurea treatment interaction);
SARC	cis	rs7113874	0.612	rs11517715	chr11:8511888	G/C	cg09828998	chr11:8703972	RPL27A	0.5	5.41	0.33	1.56e-7	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9291683	0.620	rs7699512	chr4:10125808	C/T	cg11266682	chr4:10021025	SLC2A9	-0.37	-6.66	-0.4	1.93e-10	Bone mineral density;
SARC	cis	rs17030434	0.784	rs4696486	chr4:154651354	T/C	cg14289246	chr4:154710475	SFRP2	-0.47	-5.41	-0.33	1.59e-7	Electrocardiographic conduction measures;
SARC	trans	rs2727020	1.000	rs2727020	chr11:49111407	C/G	cg03929089	chr4:120376271	NA	0.72	9.02	0.51	7.29e-17	Coronary artery disease;
SARC	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg06074448	chr4:187884817	NA	0.39	5.36	0.33	2.03e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs950776	0.593	rs680244	chr15:78871288	T/C	cg06917634	chr15:78832804	PSMA4	-0.84	-12.6	-0.64	4.24e-28	Sudden cardiac arrest;
SARC	cis	rs4889855	0.505	rs6565467	chr17:78610113	A/G	cg17956530	chr17:78667699	RPTOR	-0.45	-5.29	-0.33	2.81e-7	Fractional excretion of uric acid;
SARC	cis	rs10979	1.000	rs9376763	chr6:143887386	C/T	cg25407410	chr6:143891975	LOC285740	-0.62	-8.34	-0.48	6.73e-15	Hypospadias;
SARC	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg04317338	chr11:64019027	PLCB3	0.6	6.95	0.41	3.69e-11	Platelet count;
SARC	cis	rs3857536	0.706	rs7749120	chr6:66889832	T/G	cg07460842	chr6:66804631	NA	-0.6	-7.16	-0.42	1.02e-11	Blood trace element (Cu levels);
SARC	cis	rs3771570	0.901	rs869943	chr2:242431585	C/G	cg21155796	chr2:242212141	HDLBP	0.64	6.0	0.37	7.52e-9	Prostate cancer;
SARC	cis	rs36051895	0.658	rs7030260	chr9:5008070	C/A	cg02405213	chr9:5042618	JAK2	-0.56	-6.53	-0.39	4.19e-10	Pediatric autoimmune diseases;
SARC	cis	rs6141769	0.542	rs6058813	chr20:31270861	C/T	cg17884169	chr20:31446444	EFCAB8	-0.45	-4.77	-0.3	3.27e-6	Subjective well-being;
SARC	cis	rs2635047	0.615	rs2571007	chr18:44645610	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	5.82	0.36	1.98e-8	Educational attainment;
SARC	cis	rs9916302	0.861	rs644173	chr17:37430519	T/C	cg07936489	chr17:37558343	FBXL20	-0.69	-9.23	-0.52	1.71e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs6570726	0.818	rs412350	chr6:145852409	T/C	cg05347473	chr6:146136440	FBXO30	0.53	7.41	0.44	2.31e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs950776	0.518	rs2869055	chr15:78822388	G/C	cg17108064	chr15:78857060	CHRNA5	-0.29	-5.01	-0.31	1.09e-6	Sudden cardiac arrest;
SARC	cis	rs2153535	0.580	rs7341381	chr6:8470537	A/G	cg23788917	chr6:8435910	SLC35B3	0.64	8.63	0.49	9.85e-16	Motion sickness;
SARC	trans	rs7819412	0.740	rs11250119	chr8:11037034	C/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.18	-0.43	9.13e-12	Triglycerides;
SARC	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg02725872	chr8:58115012	NA	-0.37	-6.55	-0.39	3.71e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs11190604	0.767	rs7076606	chr10:102192267	T/C	cg07080220	chr10:102295463	HIF1AN	0.71	8.15	0.47	2.29e-14	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs2908197	0.699	rs2860469	chr7:75960506	A/C	cg24580635	chr7:76178542	LOC100133091	-0.42	-4.88	-0.3	1.98e-6	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg05623727	chr3:50126028	RBM5	0.32	4.78	0.3	3.17e-6	Intelligence (multi-trait analysis);
SARC	cis	rs526231	0.511	rs11951374	chr5:102355798	C/A	cg23492399	chr5:102201601	PAM	-0.46	-5.15	-0.32	5.44e-7	Primary biliary cholangitis;
SARC	cis	rs9420	0.754	rs631791	chr11:57675410	A/G	cg23127183	chr11:57508653	C11orf31	0.55	5.45	0.34	1.26e-7	Schizophrenia;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg26364903	chr2:67624840	ETAA1	-0.86	-7.13	-0.42	1.27e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.75	-7.82	-0.46	1.79e-13	Platelet count;
SARC	cis	rs9916302	0.706	rs28482878	chr17:37497100	A/G	cg15445000	chr17:37608096	MED1	-0.47	-5.08	-0.32	7.63e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs7589342	0.801	rs13411829	chr2:106466101	G/C	cg14210321	chr2:106509881	NCK2	-0.47	-5.37	-0.33	1.87e-7	Addiction;
SARC	cis	rs7615952	0.512	rs2979351	chr3:125363599	C/T	cg21696256	chr3:125484277	NA	-0.35	-5.01	-0.31	1.08e-6	Blood pressure (smoking interaction);
SARC	cis	rs34779708	0.931	rs7908573	chr10:35309513	T/C	cg03585969	chr10:35415529	CREM	0.4	5.0	0.31	1.11e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs1865760	0.929	rs9358896	chr6:25943197	C/A	cg17691542	chr6:26056736	HIST1H1C	0.6	7.66	0.45	5.05e-13	Height;
SARC	cis	rs826838	1.000	rs851934	chr12:39104453	G/T	cg13010199	chr12:38710504	ALG10B	-0.65	-9.27	-0.52	1.3e-17	Heart rate;
SARC	cis	rs4642101	0.512	rs12629892	chr3:12818920	A/G	cg05775895	chr3:12838266	CAND2	0.79	13.77	0.67	5.6e-32	QRS complex (12-leadsum);
SARC	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg13012494	chr21:47604986	C21orf56	-0.57	-6.7	-0.4	1.52e-10	Testicular germ cell tumor;
SARC	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg01475735	chr3:40494733	NA	-0.46	-5.1	-0.32	7.12e-7	Renal cell carcinoma;
SARC	cis	rs8114671	0.869	rs6060199	chr20:33654773	A/G	cg24642439	chr20:33292090	TP53INP2	-0.51	-5.96	-0.36	9.12e-9	Height;
SARC	cis	rs7666738	0.753	rs11097607	chr4:99011640	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9398803	0.723	rs1262546	chr6:127075491	T/C	cg19875578	chr6:126661172	C6orf173	-0.62	-8.6	-0.49	1.17e-15	Male-pattern baldness;
SARC	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg11890956	chr21:40555474	PSMG1	-1.06	-16.06	-0.72	1.39e-39	Cognitive function;
SARC	cis	rs208515	0.525	rs10944868	chr6:66687508	A/G	cg07460842	chr6:66804631	NA	0.86	9.87	0.54	2.02e-19	Exhaled nitric oxide levels;
SARC	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg05025164	chr4:1340916	KIAA1530	-0.43	-4.91	-0.31	1.71e-6	Obesity-related traits;
SARC	cis	rs3750965	1.000	rs7937006	chr11:68843932	C/T	cg06818126	chr11:68850279	TPCN2	-0.43	-4.92	-0.31	1.64e-6	Hair color;
SARC	cis	rs10789491	0.953	rs1866770	chr1:47182468	G/T	cg15501359	chr1:47185051	KIAA0494	0.78	8.26	0.48	1.08e-14	Response to hepatitis C treatment;
SARC	cis	rs11718455	0.960	rs11720974	chr3:43999111	G/C	cg08738300	chr3:44038990	NA	0.55	6.18	0.38	2.89e-9	Coronary artery disease;
SARC	cis	rs1023500	0.505	rs134891	chr22:42675882	T/C	cg04733989	chr22:42467013	NAGA	0.52	6.71	0.4	1.44e-10	Schizophrenia;
SARC	cis	rs2382817	0.580	rs6756265	chr2:219095554	G/A	cg00012203	chr2:219082015	ARPC2	-0.73	-10.74	-0.58	3.92e-22	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg17221315	chr6:27791827	HIST1H4J	0.47	5.14	0.32	5.95e-7	Parkinson's disease;
SARC	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg15921436	chr17:44337874	NA	0.48	4.74	0.3	3.74e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg00635944	chr16:29827205	C16orf53	-0.66	-6.91	-0.41	4.66e-11	Lung cancer in ever smokers;
SARC	cis	rs897080	0.515	rs698813	chr2:44705615	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.58	5.89	0.36	1.32e-8	Height;
SARC	trans	rs2727020	0.553	rs4980447	chr11:49591662	T/C	cg15704280	chr7:45808275	SEPT13	-0.72	-8.25	-0.48	1.18e-14	Coronary artery disease;
SARC	cis	rs240764	0.717	rs151640	chr6:101111521	A/C	cg09795085	chr6:101329169	ASCC3	0.42	5.31	0.33	2.58e-7	Neuroticism;
SARC	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg04267008	chr7:1944627	MAD1L1	-0.51	-6.16	-0.37	3.23e-9	Bipolar disorder and schizophrenia;
SARC	trans	rs629535	0.725	rs639127	chr8:70073251	A/G	cg21567404	chr3:27674614	NA	1.04	13.3	0.66	2.13e-30	Dupuytren's disease;
SARC	cis	rs11864453	0.826	rs12448315	chr16:72147242	G/T	cg01557791	chr16:72042693	DHODH	-0.64	-8.87	-0.5	1.95e-16	Fibrinogen levels;
SARC	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.53	6.0	0.37	7.32e-9	Renal function-related traits (BUN);
SARC	trans	rs7815944	1.000	rs74623761	chr8:129363670	A/G	cg17342469	chr22:46473074	NA	0.72	6.83	0.41	7.2e-11	Atopic dermatitis;
SARC	cis	rs897080	0.515	rs1085450	chr2:44650698	A/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	6.41	0.39	8.17e-10	Height;
SARC	cis	rs9815354	0.812	rs73081321	chr3:41890231	G/A	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6016377	0.737	rs6016380	chr20:39179975	A/G	cg06424997	chr20:39929561	ZHX3	0.39	5.04	0.31	9.4e-7	Birth weight;
SARC	cis	rs1153858	0.621	rs1719237	chr15:45579822	G/A	cg26924012	chr15:45694286	SPATA5L1	0.69	8.77	0.5	3.82e-16	Homoarginine levels;
SARC	cis	rs854765	0.693	rs8079321	chr17:17760789	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.43	5.41	0.33	1.54e-7	Total body bone mineral density;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg00597055	chr15:41523239	CHP;EXD1	-0.78	-6.87	-0.41	5.8200000000000003e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6570726	0.935	rs408768	chr6:145871735	A/G	cg23711669	chr6:146136114	FBXO30	0.78	11.99	0.62	4.06e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg11764359	chr7:65958608	NA	-0.72	-8.42	-0.48	3.9e-15	Aortic root size;
SARC	cis	rs1957429	0.901	rs1957432	chr14:65352796	A/G	cg23373153	chr14:65346875	NA	0.99	10.56	0.57	1.46e-21	Pediatric areal bone mineral density (radius);
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg19963728	chr2:44588792	PREPL;C2orf34	-0.56	-7.28	-0.43	5.19e-12	Neuroticism;
SARC	cis	rs554111	0.634	rs10799673	chr1:21274671	T/G	cg04902671	chr1:21058625	SH2D5	0.45	5.52	0.34	8.89e-8	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs6484504	0.600	rs2761593	chr11:31326752	G/T	cg02090638	chr11:31391270	DNAJC24;DCDC1	0.43	5.32	0.33	2.43e-7	Red blood cell count;
SARC	cis	rs478304	0.651	rs11600918	chr11:65511965	A/G	cg27068330	chr11:65405492	SIPA1	-0.39	-4.79	-0.3	2.94e-6	Acne (severe);
SARC	cis	rs6834538	0.894	rs34712587	chr4:113485894	A/T	cg05166686	chr4:113558556	LARP7;C4orf21	0.44	5.1	0.32	7.03e-7	Free thyroxine concentration;
SARC	cis	rs17600642	0.724	rs17528468	chr10:72459184	A/C	cg18679544	chr10:72432482	ADAMTS14	0.46	4.77	0.3	3.26e-6	Bipolar disorder;
SARC	cis	rs4595586	0.525	rs1878227	chr12:39355719	A/T	cg26384229	chr12:38710491	ALG10B	0.52	6.08	0.37	4.97e-9	Morning vs. evening chronotype;
SARC	cis	rs4718428	0.705	rs12536410	chr7:66254290	G/A	cg12165864	chr7:66369176	NA	-0.43	-4.75	-0.3	3.51e-6	Corneal structure;
SARC	cis	rs611744	0.967	rs650968	chr8:109211055	C/G	cg21045802	chr8:109455806	TTC35	0.45	5.32	0.33	2.41e-7	Dupuytren's disease;
SARC	cis	rs4803468	1.000	rs284655	chr19:41928765	C/T	cg14132834	chr19:41945861	ATP5SL	-0.57	-7.49	-0.44	1.39e-12	Height;
SARC	cis	rs7914558	0.933	rs10883814	chr10:104737404	T/C	cg04362960	chr10:104952993	NT5C2	0.41	5.02	0.31	1.04e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs7223966	1.000	rs12325866	chr17:61755974	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.53	-5.79	-0.35	2.31e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	5.09	0.32	7.24e-7	Personality dimensions;
SARC	cis	rs4563143	0.592	rs12151001	chr19:29283386	C/G	cg03161606	chr19:29218774	NA	0.47	6.57	0.4	3.17e-10	Methadone dose in opioid dependence;
SARC	cis	rs1707322	1.000	rs4073847	chr1:46463012	A/C	cg03146154	chr1:46216737	IPP	-0.45	-5.37	-0.33	1.87e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg07701084	chr6:150067640	NUP43	0.41	5.41	0.33	1.57e-7	Lung cancer;
SARC	cis	rs9400467	0.506	rs12215189	chr6:111646002	G/C	cg15721981	chr6:111408429	SLC16A10	0.69	5.86	0.36	1.6e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg09988129	chr7:74988866	PMS2L2;STAG3L1	0.59	7.52	0.44	1.15e-12	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs7843479	0.898	rs4311656	chr8:21802276	T/G	cg17168535	chr8:21777572	XPO7	0.62	7.96	0.46	7.33e-14	Mean corpuscular volume;
SARC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg02592271	chr2:27665507	KRTCAP3	-0.42	-6.42	-0.39	7.6e-10	Total body bone mineral density;
SARC	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs698761	0.519	rs10427177	chr2:44510179	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.7	7.41	0.44	2.26e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs3796352	1.000	rs11710292	chr3:53117798	T/C	cg12962167	chr3:53033115	SFMBT1	0.76	4.96	0.31	1.37e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs6696846	0.749	rs7553876	chr1:205079915	A/G	cg00857998	chr1:205179979	DSTYK	0.41	4.87	0.3	2.08e-6	Red blood cell count;
SARC	cis	rs2153535	0.580	rs1832100	chr6:8446956	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	8.38	0.48	5.16e-15	Motion sickness;
SARC	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-6.82	-0.41	7.59e-11	Personality dimensions;
SARC	cis	rs10979	0.597	rs9496691	chr6:143910970	T/C	cg25407410	chr6:143891975	LOC285740	-0.5	-5.83	-0.36	1.81e-8	Hypospadias;
SARC	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg13206674	chr6:150067644	NUP43	0.45	5.75	0.35	2.76e-8	Lung cancer;
SARC	cis	rs427394	0.802	rs274720	chr5:6719933	A/G	cg10857441	chr5:6722123	POLS	-0.33	-5.04	-0.31	9.56e-7	Menopause (age at onset);
SARC	cis	rs7246657	0.941	rs12982333	chr19:37794724	A/G	cg14683738	chr19:37701593	ZNF585B	0.6	5.51	0.34	9.46e-8	Coronary artery calcification;
SARC	cis	rs3858526	0.883	rs4758183	chr11:5925178	C/G	cg13902645	chr11:5959945	NA	-0.42	-4.9	-0.31	1.78e-6	DNA methylation (variation);
SARC	cis	rs6831352	0.744	rs2602847	chr4:100025963	T/C	cg12011299	chr4:100065546	ADH4	0.32	5.26	0.33	3.23e-7	Alcohol dependence;
SARC	cis	rs477692	1.000	rs565974	chr10:131423274	C/T	cg05714579	chr10:131428358	MGMT	0.55	7.13	0.42	1.23e-11	Response to temozolomide;
SARC	cis	rs9916302	0.904	rs11654018	chr17:37703740	C/T	cg00129232	chr17:37814104	STARD3	0.63	7.52	0.44	1.21e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs1580019	0.587	rs7805311	chr7:32558302	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.96	-15.84	-0.72	7.44e-39	Cognitive ability;
SARC	cis	rs4481887	0.962	rs10749653	chr1:248481384	C/G	cg01631408	chr1:248437212	OR2T33	-0.42	-5.25	-0.33	3.39e-7	Common traits (Other);
SARC	cis	rs17401966	0.931	rs4240911	chr1:10307453	A/G	cg15208524	chr1:10270712	KIF1B	0.47	5.42	0.33	1.52e-7	Hepatocellular carcinoma;
SARC	cis	rs8070128	0.534	rs2955350	chr17:17953548	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.41	-5.13	-0.32	6.16e-7	Total body bone mineral density;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg01324437	chr2:98206175	ANKRD36B	-0.74	-6.23	-0.38	2.12e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs4718428	0.705	rs4718422	chr7:66359269	A/G	cg18252515	chr7:66147081	NA	-0.56	-6.17	-0.37	3.06e-9	Corneal structure;
SARC	trans	rs9354308	0.933	rs2802064	chr6:66564352	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.57	6.71	0.4	1.42e-10	Metabolite levels;
SARC	cis	rs6141769	0.569	rs6119935	chr20:31270570	C/A	cg13636640	chr20:31349939	DNMT3B	-0.46	-4.79	-0.3	3e-6	Subjective well-being;
SARC	cis	rs920590	0.704	rs3866469	chr8:19658534	T/C	cg17834443	chr8:19674713	INTS10	0.4	5.09	0.32	7.26e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs8077889	0.956	rs116979403	chr17:41849105	G/A	cg26893861	chr17:41843967	DUSP3	0.88	10.19	0.56	2.15e-20	Triglycerides;
SARC	cis	rs4588572	0.643	rs13155648	chr5:77755343	A/G	cg11547950	chr5:77652471	NA	-0.41	-5.13	-0.32	6.15e-7	Triglycerides;
SARC	cis	rs262150	0.501	rs2730206	chr7:158815173	G/C	cg04111992	chr7:158790115	NA	-0.36	-5.12	-0.32	6.46e-7	Facial morphology (factor 20);
SARC	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg00684032	chr4:1343700	KIAA1530	0.37	5.33	0.33	2.28e-7	Obesity-related traits;
SARC	cis	rs709400	0.628	rs6575983	chr14:103869849	C/G	cg12935359	chr14:103987150	CKB	-0.39	-5.94	-0.36	1.03e-8	Body mass index;
SARC	cis	rs9547692	0.938	rs7333607	chr13:37462010	A/G	cg01493522	chr13:37497338	NA	-0.42	-4.79	-0.3	3e-6	Coronary artery disease;
SARC	trans	rs61931739	0.929	rs2389274	chr12:34075149	T/C	cg26384229	chr12:38710491	ALG10B	-0.52	-7.07	-0.42	1.84e-11	Morning vs. evening chronotype;
SARC	cis	rs798554	0.660	rs2644274	chr7:2854380	A/T	cg13628971	chr7:2884303	GNA12	0.46	5.66	0.35	4.39e-8	Height;
SARC	cis	rs12142240	0.738	rs41293277	chr1:46806550	C/T	cg10495392	chr1:46806563	NSUN4	0.65	6.9	0.41	4.99e-11	Menopause (age at onset);
SARC	cis	rs11676348	0.710	rs11894169	chr2:219046846	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.45	5.63	0.35	5.12e-8	Ulcerative colitis;
SARC	cis	rs77972916	0.561	rs13411485	chr2:43575984	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.58	5.65	0.35	4.68e-8	Granulocyte percentage of myeloid white cells;
SARC	cis	rs1707322	1.000	rs12403666	chr1:46431621	G/A	cg06784218	chr1:46089804	CCDC17	0.34	5.98	0.36	8.31e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg00094256	chr4:25378438	ANAPC4	-0.53	-7.03	-0.42	2.28e-11	Thyroid stimulating hormone;
SARC	cis	rs9309473	1.000	rs10190219	chr2:73658331	C/T	cg20560298	chr2:73613845	ALMS1	-0.52	-6.22	-0.38	2.34e-9	Metabolite levels;
SARC	cis	rs2075371	1.000	rs2075373	chr7:133984683	A/C	cg11752832	chr7:134001865	SLC35B4	0.56	7.26	0.43	5.74e-12	Mean platelet volume;
SARC	cis	rs9815354	1.000	rs1717024	chr3:41984888	G/T	cg03022575	chr3:42003672	ULK4	-0.56	-5.44	-0.34	1.36e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs12142240	0.738	rs10489769	chr1:46806703	A/G	cg00530320	chr1:46809349	NSUN4	0.55	6.72	0.4	1.35e-10	Menopause (age at onset);
SARC	cis	rs929354	0.742	rs3808316	chr7:156944787	C/G	cg05182265	chr7:156933206	UBE3C	-0.32	-4.88	-0.3	1.97e-6	Body mass index;
SARC	cis	rs7929679	0.551	rs10836302	chr11:34791897	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.36	4.76	0.3	3.47e-6	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
SARC	cis	rs2498796	0.647	rs7149551	chr14:105210759	G/A	cg07523784	chr14:105186699	NA	-0.36	-5.15	-0.32	5.59e-7	Endometrial cancer;Endometrial endometrioid carcinoma;
SARC	cis	rs9916302	0.660	rs4795379	chr17:37674683	T/G	cg07936489	chr17:37558343	FBXL20	-0.75	-8.71	-0.5	5.74e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs11191193	0.662	rs12359517	chr10:103714782	C/T	cg15320455	chr10:103880129	LDB1	0.56	5.99	0.37	8.07e-9	Educational attainment;
SARC	cis	rs9398803	0.687	rs853962	chr6:127027650	G/T	cg19875578	chr6:126661172	C6orf173	-0.64	-8.9	-0.5	1.56e-16	Male-pattern baldness;
SARC	cis	rs7772486	0.743	rs9390344	chr6:146012755	C/G	cg23711669	chr6:146136114	FBXO30	-0.8	-12.54	-0.63	6.41e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9810259	0.706	rs13070844	chr3:12275286	G/A	cg04748988	chr3:12329223	PPARG	-0.38	-4.74	-0.3	3.74e-6	Platelet count;
SARC	cis	rs9291683	0.588	rs4697705	chr4:10108127	G/A	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.28	-0.33	2.93e-7	Bone mineral density;
SARC	trans	rs11165623	0.792	rs6701031	chr1:96975515	C/T	cg10631902	chr5:14652156	NA	-0.46	-7.52	-0.44	1.16e-12	Hip circumference;Waist circumference;
SARC	cis	rs6121246	0.909	rs7272062	chr20:30259145	A/G	cg13852791	chr20:30311386	BCL2L1	0.87	9.27	0.52	1.33e-17	Mean corpuscular hemoglobin;
SARC	cis	rs151349	1.000	rs151344	chr20:57585301	A/G	cg23907860	chr20:57583709	CTSZ	-0.31	-4.76	-0.3	3.41e-6	Platelet distribution width;
SARC	cis	rs11190604	1.000	rs7090431	chr10:102261753	A/G	cg07080220	chr10:102295463	HIF1AN	0.8	9.91	0.54	1.53e-19	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg09373136	chr17:61933544	TCAM1	-0.45	-6.1	-0.37	4.27e-9	Prudent dietary pattern;
SARC	cis	rs2075371	0.501	rs1421469	chr7:134028260	C/G	cg11752832	chr7:134001865	SLC35B4	0.45	5.71	0.35	3.46e-8	Mean platelet volume;
SARC	cis	rs2153535	0.580	rs9505450	chr6:8469902	C/T	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	cis	rs11770686	0.766	rs4731887	chr7:75339335	G/A	cg17787366	chr7:75369077	HIP1	0.43	5.39	0.33	1.75e-7	Essential tremor;
SARC	cis	rs9916302	0.904	rs11869109	chr17:37518205	G/T	cg15445000	chr17:37608096	MED1	-0.45	-5.48	-0.34	1.1e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs9818758	0.556	rs9872660	chr3:49378832	G/T	cg00383909	chr3:49044727	WDR6	0.53	5.23	0.32	3.72e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg15847926	chr7:2749597	AMZ1	-0.29	-4.73	-0.3	3.9e-6	Height;
SARC	cis	rs1728785	0.901	rs933713	chr16:68581378	C/A	cg02972257	chr16:68554789	NA	-0.43	-5.01	-0.31	1.08e-6	Ulcerative colitis;
SARC	cis	rs453301	0.506	rs476845	chr8:8622877	A/G	cg15556689	chr8:8085844	FLJ10661	-0.38	-4.86	-0.3	2.13e-6	Joint mobility (Beighton score);
SARC	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg11987759	chr7:65425863	GUSB	-0.47	-6.27	-0.38	1.7e-9	Aortic root size;
SARC	cis	rs9329289	0.926	rs9329290	chr10:2542751	G/T	cg15501526	chr10:2543763	NA	0.52	8.28	0.48	9.69e-15	Age-related hearing impairment;
SARC	cis	rs4141404	0.787	rs4820042	chr22:31589056	T/C	cg02404636	chr22:31891804	SFI1	-0.48	-5.05	-0.31	8.88e-7	Paclitaxel-induced neuropathy;
SARC	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.52	-5.99	-0.37	7.95e-9	Systemic lupus erythematosus;
SARC	cis	rs9818758	0.607	rs11719220	chr3:49245201	A/G	cg07636037	chr3:49044803	WDR6	-0.79	-6.99	-0.42	2.83e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg25952890	chr19:58913133	NA	0.35	4.94	0.31	1.5e-6	Uric acid clearance;
SARC	cis	rs694739	1.000	rs646153	chr11:64089588	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.68	8.69	0.49	6.59e-16	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs1153858	0.943	rs28605551	chr15:45641720	C/T	cg14582100	chr15:45693742	SPATA5L1	0.37	5.06	0.31	8.45e-7	Homoarginine levels;
SARC	cis	rs4253772	0.530	rs9627387	chr22:46684678	A/G	cg24881330	chr22:46731750	TRMU	0.71	7.26	0.43	5.66e-12	LDL cholesterol;Cholesterol, total;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg04526987	chr8:131370329	ASAP1	0.5	6.45	0.39	6.44e-10	Breast cancer;
SARC	cis	rs6840360	0.571	rs11729136	chr4:152529227	C/A	cg22705602	chr4:152727874	NA	-0.44	-6.81	-0.41	8.04e-11	Intelligence (multi-trait analysis);
SARC	cis	rs8062405	0.789	rs2106480	chr16:28537971	T/C	cg08761264	chr16:28874980	SH2B1	-0.42	-4.76	-0.3	3.33e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg00800038	chr16:89945340	TCF25	-0.74	-5.08	-0.32	7.86e-7	Skin colour saturation;
SARC	cis	rs10046574	0.731	rs6961685	chr7:135115985	T/C	cg27474649	chr7:135195673	CNOT4	0.87	7.13	0.42	1.27e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs11098499	0.874	rs17839089	chr4:120111069	A/G	cg09307838	chr4:120376055	NA	0.82	11.06	0.59	3.96e-23	Corneal astigmatism;
SARC	cis	rs9399135	0.527	rs61738492	chr6:135282771	G/A	cg22676075	chr6:135203613	NA	0.38	4.96	0.31	1.34e-6	Red blood cell count;
SARC	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg24250549	chr1:154909240	PMVK	0.84	12.21	0.62	8.01e-27	Prostate cancer;
SARC	cis	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg21573476	chr21:45109991	RRP1B	-0.55	-8.3	-0.48	8.51e-15	Mean corpuscular volume;
SARC	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg27170947	chr2:26402098	FAM59B	0.37	4.8	0.3	2.79e-6	Gut microbiome composition (summer);
SARC	cis	rs7659604	0.521	rs4833773	chr4:122689245	C/T	cg19748678	chr4:122722346	EXOSC9	-0.43	-5.34	-0.33	2.24e-7	Type 2 diabetes;
SARC	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg13939156	chr17:80058883	NA	-0.42	-6.48	-0.39	5.51e-10	Life satisfaction;
SARC	cis	rs3087591	0.683	rs7502556	chr17:29642430	T/C	cg24425628	chr17:29625626	OMG;NF1	0.43	5.65	0.35	4.71e-8	Hip circumference;
SARC	cis	rs2070997	0.702	rs2227985	chr9:133755528	A/G	cg13390441	chr9:132962957	FREQ	0.47	4.75	0.3	3.6e-6	Response to amphetamines;
SARC	cis	rs240110	0.548	rs12190574	chr6:101173842	T/G	cg09795085	chr6:101329169	ASCC3	-0.41	-5.17	-0.32	5.13e-7	Neuroticism;
SARC	cis	rs10504229	0.593	rs2317990	chr8:58024168	G/T	cg20607798	chr8:58055168	NA	0.62	5.51	0.34	9.38e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg19077165	chr18:44547161	KATNAL2	-0.52	-7.29	-0.43	4.74e-12	Personality dimensions;
SARC	cis	rs2043112	1.000	rs35831082	chr5:38963532	A/G	cg04869206	chr5:39074266	RICTOR	0.52	6.41	0.39	7.98e-10	Obesity-related traits;
SARC	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg22105103	chr4:187893119	NA	0.45	6.03	0.37	6.35e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg15448220	chr1:150897856	SETDB1	0.48	6.38	0.39	9.29e-10	Tonsillectomy;
SARC	cis	rs13082711	0.911	rs7644466	chr3:27515271	C/G	cg02860705	chr3:27208620	NA	0.41	5.36	0.33	2.01e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs4481887	1.000	rs10888352	chr1:248451965	G/A	cg01631408	chr1:248437212	OR2T33	-0.43	-5.43	-0.34	1.39e-7	Common traits (Other);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg24830314	chr6:83775579	UBE2CBP	0.48	6.3	0.38	1.44e-9	Chemerin levels;
SARC	cis	rs9612	1.000	rs346526	chr19:44259565	A/G	cg08581076	chr19:44259116	C19orf61	0.65	7.93	0.46	9.08e-14	Exhaled nitric oxide output;
SARC	cis	rs826838	0.651	rs12367384	chr12:38618460	G/T	cg26384229	chr12:38710491	ALG10B	0.75	10.03	0.55	6.41e-20	Heart rate;
SARC	cis	rs35110281	0.666	rs2838348	chr21:45107285	C/G	cg21573476	chr21:45109991	RRP1B	0.6	8.5	0.49	2.28e-15	Mean corpuscular volume;
SARC	cis	rs7824557	0.707	rs3808519	chr8:11142970	C/G	cg21775007	chr8:11205619	TDH	0.56	6.58	0.4	3.16e-10	Retinal vascular caliber;
SARC	cis	rs11098499	0.954	rs10014845	chr4:120301077	T/G	cg09160332	chr4:120329925	NA	-0.33	-4.77	-0.3	3.27e-6	Corneal astigmatism;
SARC	cis	rs9640161	0.659	rs7806429	chr7:150013393	A/G	cg10018233	chr7:150070692	REPIN1	0.62	8.71	0.5	5.65e-16	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs5753618	0.509	rs5753500	chr22:31578879	A/G	cg07713946	chr22:31675144	LIMK2	-0.38	-5.53	-0.34	8.54e-8	Colorectal cancer;
SARC	cis	rs13082711	0.522	rs515402	chr3:27331022	G/T	cg02860705	chr3:27208620	NA	0.47	6.26	0.38	1.86e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs7666738	0.512	rs165251	chr4:98758490	C/G	cg05340658	chr4:99064831	C4orf37	0.42	5.63	0.35	5.17e-8	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.78	-0.5	3.56e-16	Alzheimer's disease;
SARC	cis	rs9549367	0.789	rs2302754	chr13:113898385	C/T	cg18105134	chr13:113819100	PROZ	0.35	5.25	0.33	3.45e-7	Platelet distribution width;
SARC	cis	rs2180341	1.000	rs3798852	chr6:127636733	A/G	cg27446573	chr6:127587934	RNF146	1.02	14.19	0.68	2.31e-33	Breast cancer;
SARC	cis	rs10493773	0.775	rs12756013	chr1:86153532	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.54	-8.51	-0.49	2.16e-15	Urate levels in overweight individuals;
SARC	cis	rs7818688	0.697	rs17665714	chr8:95982542	T/C	cg13393036	chr8:95962371	TP53INP1	0.4	4.85	0.3	2.27e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs9291683	0.597	rs11722989	chr4:10126139	A/G	cg11266682	chr4:10021025	SLC2A9	-0.37	-6.55	-0.39	3.6e-10	Bone mineral density;
SARC	cis	rs13064447	0.967	rs113886525	chr3:12762356	A/G	cg05775895	chr3:12838266	CAND2	0.39	5.11	0.32	6.87e-7	Major depression and alcohol dependence;
SARC	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg02018176	chr4:1364513	KIAA1530	0.44	6.53	0.39	3.97e-10	Longevity;
SARC	cis	rs644799	1.000	rs509720	chr11:95562771	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	14.89	0.7	1.07e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs11785400	0.793	rs35985277	chr8:143736137	C/T	cg10596483	chr8:143751796	JRK	0.56	7.21	0.43	7.54e-12	Schizophrenia;
SARC	cis	rs11098499	0.863	rs36040693	chr4:120477616	A/G	cg24375607	chr4:120327624	NA	0.42	4.92	0.31	1.64e-6	Corneal astigmatism;
SARC	trans	rs7922314	0.571	rs61865717	chr10:64739190	G/A	cg25304107	chr2:177017331	HOXD4	-0.83	-6.46	-0.39	5.88e-10	Cutaneous psoriasis;
SARC	cis	rs17376456	0.825	rs10078941	chr5:93279029	C/T	cg25358565	chr5:93447407	FAM172A	1.29	14.27	0.68	1.27e-33	Diabetic retinopathy;
SARC	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg03264133	chr6:25882463	NA	-0.55	-7.14	-0.42	1.2e-11	Intelligence (multi-trait analysis);
SARC	cis	rs2242194	0.816	rs11264296	chr1:154994750	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.37	6.34	0.38	1.18e-9	Schizophrenia;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg22603542	chr1:166945234	ILDR2	-0.62	-6.51	-0.39	4.49e-10	Lung cancer in ever smokers;
SARC	cis	rs4835937	0.670	rs10064559	chr5:127329683	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	5.61	0.34	5.84e-8	Cancer;
SARC	cis	rs2228479	0.702	rs2074903	chr16:89811663	T/C	cg06558623	chr16:89946397	TCF25	0.91	6.37	0.38	1.03e-9	Skin colour saturation;
SARC	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg03999130	chr15:45571217	NA	0.39	5.09	0.32	7.55e-7	Homoarginine levels;
SARC	cis	rs1881797	1.000	rs66845073	chr1:247688010	C/T	cg18198730	chr1:247681584	NA	0.48	5.29	0.33	2.85e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9457247	0.967	rs1794696	chr6:167396174	T/C	cg07741184	chr6:167504864	NA	0.3	5.68	0.35	4.05e-8	Crohn's disease;
SARC	cis	rs116095464	1.000	rs2015774	chr5:312958	G/T	cg20965017	chr5:231967	SDHA	-0.7	-5.52	-0.34	9.22e-8	Breast cancer;
SARC	cis	rs9467773	1.000	rs2393670	chr6:26535541	A/G	cg11502198	chr6:26597334	ABT1	0.46	5.53	0.34	8.38e-8	Intelligence (multi-trait analysis);
SARC	cis	rs6133127	0.580	rs297743	chr20:4471298	A/G	cg14606382	chr20:4573199	NA	-0.46	-4.84	-0.3	2.4e-6	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
SARC	cis	rs2742234	0.590	rs2257767	chr10:43657811	T/G	cg15436174	chr10:43711423	RASGEF1A	-0.41	-4.87	-0.3	2.05e-6	Hirschsprung disease;
SARC	cis	rs7712401	0.601	rs246303	chr5:122251717	C/G	cg19412675	chr5:122181750	SNX24	0.42	5.35	0.33	2.14e-7	Mean platelet volume;
SARC	cis	rs7772486	0.720	rs7752286	chr6:146072662	C/T	cg05347473	chr6:146136440	FBXO30	-0.55	-7.72	-0.45	3.51e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg22920501	chr2:26401640	FAM59B	0.53	6.56	0.4	3.37e-10	Gut microbiome composition (summer);
SARC	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg11987759	chr7:65425863	GUSB	-0.5	-5.97	-0.36	8.76e-9	Aortic root size;
SARC	trans	rs800082	0.698	rs800073	chr3:144347599	G/A	cg24215973	chr2:240111563	HDAC4	-0.52	-6.33	-0.38	1.26e-9	Smoking behavior;
SARC	cis	rs12497850	1.000	rs10865952	chr3:48744484	A/G	cg06212747	chr3:49208901	KLHDC8B	0.66	8.79	0.5	3.35e-16	Parkinson's disease;
SARC	cis	rs2916247	1.000	rs894754	chr8:93012369	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.59	-6.26	-0.38	1.81e-9	Intelligence (multi-trait analysis);
SARC	cis	rs616402	0.527	rs11121581	chr1:10577740	A/G	cg07384165	chr1:10488281	NA	-0.4	-5.17	-0.32	5.05e-7	Breast size;
SARC	cis	rs17376456	0.877	rs34595581	chr5:93369422	G/A	cg21475434	chr5:93447410	FAM172A	0.85	7.56	0.44	9.4e-13	Diabetic retinopathy;
SARC	cis	rs2153535	0.542	rs1120393	chr6:8486890	G/A	cg21535247	chr6:8435926	SLC35B3	0.56	6.93	0.41	3.98e-11	Motion sickness;
SARC	cis	rs9487051	0.676	rs1608044	chr6:109594076	T/C	cg01475377	chr6:109611718	NA	-0.35	-5.09	-0.32	7.21e-7	Reticulocyte fraction of red cells;
SARC	cis	rs7599312	1.000	rs7599312	chr2:213413231	C/T	cg20637307	chr2:213403960	ERBB4	0.47	5.1	0.32	7.06e-7	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2273669	0.915	rs6941125	chr6:109287209	T/A	cg05315195	chr6:109294784	ARMC2	-0.49	-4.88	-0.3	1.94e-6	Prostate cancer;
SARC	cis	rs9513627	0.915	rs73556177	chr13:100121840	G/A	cg25919922	chr13:100150906	NA	-0.7	-5.26	-0.33	3.26e-7	Obesity-related traits;
SARC	cis	rs72781680	0.821	rs72796378	chr2:24167385	G/A	cg06627628	chr2:24431161	ITSN2	-0.57	-6.05	-0.37	5.69e-9	Lymphocyte counts;
SARC	cis	rs6540556	0.769	rs7521461	chr1:209926207	C/G	cg23920097	chr1:209922102	NA	-0.6	-6.87	-0.41	5.79e-11	Red blood cell count;
SARC	cis	rs826838	1.000	rs11610522	chr12:38687575	C/T	cg26384229	chr12:38710491	ALG10B	0.95	15.37	0.71	2.69e-37	Heart rate;
SARC	cis	rs2204008	0.540	rs1283306	chr12:38153778	C/A	cg26384229	chr12:38710491	ALG10B	-0.68	-8.74	-0.5	4.76e-16	Bladder cancer;
SARC	cis	rs9858542	0.953	rs71324979	chr3:49619651	T/C	cg03060546	chr3:49711283	APEH	-0.62	-7.88	-0.46	1.28e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs2075371	1.000	rs2075372	chr7:133984432	C/T	cg11752832	chr7:134001865	SLC35B4	0.57	7.43	0.44	1.99e-12	Mean platelet volume;
SARC	trans	rs11098499	0.738	rs28408407	chr4:120376030	C/G	cg25214090	chr10:38739885	LOC399744	0.54	7.11	0.42	1.38e-11	Corneal astigmatism;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg01011614	chr20:44600351	ZNF335	-0.63	-8.5	-0.49	2.33e-15	Gallstone disease;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg18393173	chr6:34856135	ANKS1A;TAF11	0.49	6.3	0.38	1.45e-9	Electrocardiographic conduction measures;
SARC	cis	rs79349575	0.870	rs12941262	chr17:46967037	T/A	cg16584676	chr17:46985605	UBE2Z	0.54	6.43	0.39	7.1e-10	Type 2 diabetes;
SARC	cis	rs2153535	0.580	rs2327053	chr6:8443127	A/G	cg07606381	chr6:8435919	SLC35B3	0.82	11.62	0.61	6.34e-25	Motion sickness;
SARC	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg18876405	chr7:65276391	NA	0.47	5.5	0.34	1e-7	Aortic root size;
SARC	cis	rs28493229	0.522	rs2287692	chr19:41289756	G/A	cg07297178	chr19:42193084	CEACAM7	0.41	5.11	0.32	6.71e-7	Kawasaki disease;
SARC	cis	rs2531992	0.686	rs2041247	chr16:4032581	A/G	cg05927578	chr16:4029543	ADCY9	0.5	6.08	0.37	4.9e-9	Waist circumference;
SARC	cis	rs5758659	0.657	rs5758587	chr22:42517636	C/G	cg15128208	chr22:42549153	NA	0.36	5.0	0.31	1.15e-6	Cognitive function;
SARC	cis	rs17401966	0.867	rs10492973	chr1:10398985	T/C	cg15208524	chr1:10270712	KIF1B	0.46	5.46	0.34	1.22e-7	Hepatocellular carcinoma;
SARC	cis	rs77372450	0.636	rs6879751	chr5:157007406	T/C	cg23851860	chr5:157002805	ADAM19	0.51	4.91	0.31	1.72e-6	Bipolar disorder (body mass index interaction);
SARC	trans	rs2736345	0.516	rs7844858	chr8:11392659	T/A	cg06636001	chr8:8085503	FLJ10661	0.57	7.61	0.45	6.66e-13	Sjögren's syndrome;Systemic lupus erythematosus;
SARC	cis	rs7819412	0.740	rs28633434	chr8:11053922	G/A	cg21775007	chr8:11205619	TDH	-0.41	-5.09	-0.32	7.29e-7	Triglycerides;
SARC	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg11644478	chr21:40555479	PSMG1	-0.55	-6.84	-0.41	6.95e-11	Menarche (age at onset);
SARC	cis	rs6582630	0.679	rs10785514	chr12:38573689	T/C	cg26384229	chr12:38710491	ALG10B	0.6	7.81	0.46	1.96e-13	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs4711336	0.935	rs754404	chr6:33664730	T/C	cg15676125	chr6:33679581	C6orf125	0.51	6.43	0.39	7.24e-10	Height;
SARC	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg19077165	chr18:44547161	KATNAL2	-0.52	-7.14	-0.42	1.21e-11	Personality dimensions;
SARC	cis	rs10463554	0.895	rs3756583	chr5:102334044	A/C	cg23492399	chr5:102201601	PAM	-0.4	-4.78	-0.3	3.13e-6	Parkinson's disease;
SARC	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	4.86	0.3	2.16e-6	Personality dimensions;
SARC	cis	rs9435341	0.965	rs1730864	chr1:107607810	C/T	cg09367891	chr1:107599246	PRMT6	-0.7	-8.38	-0.48	4.9e-15	Facial morphology (factor 21, depth of nasal alae);
SARC	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg04277193	chr17:41438351	NA	0.45	4.93	0.31	1.59e-6	Menopause (age at onset);
SARC	cis	rs72627509	0.857	rs55762216	chr4:57765731	G/C	cg26694713	chr4:57773883	REST	0.63	6.21	0.38	2.47e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg21132104	chr15:45694354	SPATA5L1	0.77	10.98	0.58	6.87e-23	Homoarginine levels;
SARC	cis	rs2777491	0.957	rs2015781	chr15:41648967	C/G	cg01768344	chr15:41576519	LOC729082	0.46	5.09	0.32	7.54e-7	Ulcerative colitis;
SARC	cis	rs6493487	0.512	rs12902196	chr15:51160796	C/G	cg02338191	chr15:51200825	AP4E1	0.52	5.0	0.31	1.13e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs9329221	0.905	rs4841329	chr8:10253098	A/G	cg21775007	chr8:11205619	TDH	-0.41	-4.98	-0.31	1.23e-6	Neuroticism;
SARC	cis	rs9796	0.621	rs557864	chr15:41471358	T/C	cg18705301	chr15:41695430	NDUFAF1	0.56	8.07	0.47	3.82e-14	Menopause (age at onset);
SARC	cis	rs9910055	0.529	rs408282	chr17:42182267	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.47	-5.48	-0.34	1.13e-7	Total body bone mineral density;
SARC	cis	rs1559088	0.847	rs10416218	chr19:33599127	T/C	cg17764715	chr19:33622953	WDR88	0.5	6.91	0.41	4.61e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs12142240	0.698	rs55670684	chr1:46835139	C/T	cg14993813	chr1:46806288	NSUN4	-0.5	-5.13	-0.32	6.01e-7	Menopause (age at onset);
SARC	cis	rs4803468	0.967	rs7259900	chr19:41889429	A/T	cg14132834	chr19:41945861	ATP5SL	-0.55	-7.29	-0.43	4.7e-12	Height;
SARC	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg00446065	chr7:2154175	MAD1L1	0.39	5.01	0.31	1.06e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs11585357	0.947	rs72646795	chr1:17612120	C/T	cg08277548	chr1:17600880	PADI3	-0.47	-5.36	-0.33	2.01e-7	Hair shape;
SARC	cis	rs72792276	1.000	rs72792279	chr5:127374404	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.7	5.75	0.35	2.73e-8	Red cell distribution width;
SARC	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.55	6.35	0.38	1.13e-9	Renal function-related traits (BUN);
SARC	cis	rs2213920	0.516	rs34302658	chr9:118168158	T/A	cg13918206	chr9:118159781	DEC1	-0.84	-6.88	-0.41	5.36e-11	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs8114671	0.562	rs6088646	chr20:33505937	T/C	cg24642439	chr20:33292090	TP53INP2	0.49	5.94	0.36	1e-8	Height;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg18323984	chr6:45386802	RUNX2	0.47	6.71	0.4	1.48e-10	Thyroid stimulating hormone;
SARC	cis	rs78456975	1.000	rs6744743	chr2:1558161	C/T	cg01028140	chr2:1542097	TPO	0.5	5.36	0.33	1.98e-7	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg25894440	chr7:65020034	NA	0.73	5.51	0.34	9.25e-8	Diabetic kidney disease;
SARC	cis	rs2204008	0.702	rs3849999	chr12:38483498	G/A	cg14851346	chr12:38532713	NA	-0.46	-5.58	-0.34	6.64e-8	Bladder cancer;
SARC	cis	rs7659604	0.540	rs67150579	chr4:122704331	T/A	cg19748678	chr4:122722346	EXOSC9	-0.42	-5.15	-0.32	5.55e-7	Type 2 diabetes;
SARC	cis	rs7772486	0.790	rs2265472	chr6:146220758	G/C	cg05347473	chr6:146136440	FBXO30	0.49	6.62	0.4	2.39e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7953249	0.791	rs10774579	chr12:121405210	T/C	cg02403541	chr12:121454288	C12orf43	-0.44	-5.37	-0.33	1.9e-7	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs9303401	0.659	rs61291849	chr17:56909867	T/C	cg25039879	chr17:56429692	SUPT4H1	0.65	6.13	0.37	3.77e-9	Cognitive test performance;
SARC	cis	rs2467099	0.679	rs59867239	chr17:73931787	G/A	cg06969265	chr17:73775802	H3F3B	0.64	6.66	0.4	1.92e-10	Systolic blood pressure;
SARC	cis	rs2204008	0.774	rs10400552	chr12:38393577	C/G	cg26384229	chr12:38710491	ALG10B	0.84	11.8	0.61	1.67e-25	Bladder cancer;
SARC	cis	rs3859192	0.599	rs34933056	chr17:38162983	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.39	7.23	0.43	6.79e-12	White blood cell count;
SARC	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	5.73	0.35	3.02e-8	Bipolar disorder;
SARC	cis	rs1707322	0.752	rs61784798	chr1:46173481	C/T	cg03146154	chr1:46216737	IPP	0.52	6.28	0.38	1.6e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg25894440	chr7:65020034	NA	0.79	5.96	0.36	9.49e-9	Diabetic kidney disease;
SARC	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.74	-9.15	-0.51	2.91e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs344364	0.511	rs1742460	chr16:1945441	G/C	cg26617929	chr16:1858877	NA	-0.79	-6.59	-0.4	2.98e-10	Glomerular filtration rate in chronic kidney disease;
SARC	cis	rs244731	0.919	rs12652509	chr5:176626441	A/G	cg16006841	chr5:176797999	RGS14	-0.57	-6.79	-0.41	9.23e-11	Urate levels in lean individuals;
SARC	cis	rs2075371	1.000	rs1862050	chr7:133980999	T/C	cg00033643	chr7:134001901	SLC35B4	0.4	4.83	0.3	2.46e-6	Mean platelet volume;
SARC	cis	rs7843479	0.601	rs1058486	chr8:21862551	A/G	cg17168535	chr8:21777572	XPO7	0.87	13.33	0.66	1.72e-30	Mean corpuscular volume;
SARC	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg02733842	chr7:1102375	C7orf50	0.42	5.28	0.33	2.98e-7	Bronchopulmonary dysplasia;
SARC	cis	rs12142240	0.698	rs41294458	chr1:46810304	T/C	cg00530320	chr1:46809349	NSUN4	0.58	7.07	0.42	1.74e-11	Menopause (age at onset);
SARC	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg00431813	chr7:1051703	C7orf50	-0.34	-5.06	-0.31	8.5e-7	Longevity;Endometriosis;
SARC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.33	-4.99	-0.31	1.18e-6	Total body bone mineral density;
SARC	cis	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg22496380	chr5:211416	CCDC127	-0.88	-9.35	-0.52	7.72e-18	Breast cancer;
SARC	cis	rs7700895	0.729	rs3777182	chr5:95263752	T/A	cg16656078	chr5:95278638	ELL2	-0.55	-6.58	-0.4	3.16e-10	IgG glycosylation;
SARC	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg04267008	chr7:1944627	MAD1L1	-0.51	-5.78	-0.35	2.36e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs6815814	0.851	rs9715769	chr4:38774489	A/C	cg09316306	chr4:38807337	TLR1	0.53	5.28	0.33	3e-7	Breast cancer;
SARC	cis	rs870825	0.655	rs2310104	chr4:185619967	A/G	cg04058563	chr4:185651563	MLF1IP	0.82	11.42	0.6	2.8e-24	Blood protein levels;
SARC	cis	rs7772486	0.641	rs2748489	chr6:146331287	T/G	cg05347473	chr6:146136440	FBXO30	0.68	9.31	0.52	1.01e-17	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2832077	0.943	rs2832091	chr21:30162855	C/T	cg03476357	chr21:30257390	N6AMT1	-0.61	-5.56	-0.34	7.2e-8	Cognitive test performance;
SARC	cis	rs11098499	0.913	rs67073020	chr4:120152557	C/T	cg09307838	chr4:120376055	NA	0.82	10.47	0.57	2.86e-21	Corneal astigmatism;
SARC	cis	rs7647973	0.626	rs11130217	chr3:49737323	A/G	cg07636037	chr3:49044803	WDR6	0.62	6.3	0.38	1.44e-9	Menarche (age at onset);
SARC	cis	rs7727544	0.684	rs272893	chr5:131663062	T/C	cg24060327	chr5:131705240	SLC22A5	-0.71	-9.2	-0.52	2.14e-17	Blood metabolite levels;
SARC	cis	rs189798	0.807	rs330905	chr8:8993551	A/T	cg06636001	chr8:8085503	FLJ10661	0.41	4.79	0.3	2.97e-6	Myopia (pathological);
SARC	cis	rs933688	1.000	rs12651840	chr5:90729592	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.09	13.76	0.67	6.21e-32	Smoking behavior;
SARC	cis	rs10489202	0.612	rs3820401	chr1:168074753	T/C	cg24449463	chr1:168025552	DCAF6	-0.6	-7.82	-0.46	1.81e-13	Schizophrenia;
SARC	cis	rs10493773	0.775	rs11161662	chr1:86185040	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.53	-8.12	-0.47	2.76e-14	Urate levels in overweight individuals;
SARC	trans	rs561341	1.000	rs72821952	chr17:30248133	T/A	cg20587970	chr11:113659929	NA	-1.37	-13.21	-0.65	4.12e-30	Hip circumference adjusted for BMI;
SARC	cis	rs8078723	1.000	rs3213762	chr17:38178627	A/G	cg17467752	chr17:38218738	THRA	0.47	6.04	0.37	6.01e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs3820928	1.000	rs1346618	chr2:227771988	C/T	cg05526886	chr2:227700861	RHBDD1	0.5	6.13	0.37	3.66e-9	Pulmonary function;
SARC	cis	rs12912251	1.000	rs12916379	chr15:38991520	A/G	cg01338139	chr15:38987640	C15orf53	-0.49	-5.57	-0.34	6.92e-8	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
SARC	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg23758822	chr17:41437982	NA	0.87	10.64	0.57	8.54e-22	Menopause (age at onset);
SARC	cis	rs2180341	0.594	rs7738385	chr6:127777516	T/C	cg24812749	chr6:127587940	RNF146	0.67	7.93	0.46	9.04e-14	Breast cancer;
SARC	cis	rs7945705	0.935	rs2653593	chr11:8877317	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-6.88	-0.41	5.52e-11	Hemoglobin concentration;
SARC	cis	rs4481887	0.962	rs4369256	chr1:248492274	G/A	cg00666640	chr1:248458726	OR2T12	0.4	6.64	0.4	2.15e-10	Common traits (Other);
SARC	cis	rs6831352	0.918	rs29001201	chr4:100053861	T/C	cg12011299	chr4:100065546	ADH4	-0.34	-5.72	-0.35	3.33e-8	Alcohol dependence;
SARC	cis	rs1008375	1.000	rs4698649	chr4:17692782	A/G	cg27347728	chr4:17578864	LAP3	0.46	5.74	0.35	2.94e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs3092073	0.624	rs34293711	chr20:44587186	C/T	cg10662479	chr20:44420225	WFDC3;DNTTIP1	0.47	6.09	0.37	4.57e-9	Intelligence (multi-trait analysis);
SARC	cis	rs9747201	1.000	rs58119191	chr17:80155329	T/C	cg17462356	chr17:80056334	FASN	-0.47	-5.24	-0.32	3.56e-7	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg12463550	chr7:65579703	CRCP	-0.49	-5.3	-0.33	2.64e-7	Aortic root size;
SARC	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg12564285	chr5:131593104	PDLIM4	-0.46	-6.22	-0.38	2.24e-9	Breast cancer;
SARC	cis	rs4689388	0.856	rs4308430	chr4:6294095	A/G	cg00701064	chr4:6280414	WFS1	0.53	8.41	0.48	4.24e-15	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs6696846	0.749	rs7553876	chr1:205079915	A/G	cg07972983	chr1:205091412	RBBP5	0.57	7.07	0.42	1.83e-11	Red blood cell count;
SARC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg05552183	chr6:42928497	GNMT	0.51	6.9	0.41	4.85e-11	Alzheimer's disease in APOE e4+ carriers;
SARC	trans	rs61931739	0.500	rs9669027	chr12:34583528	C/T	cg26384229	chr12:38710491	ALG10B	-0.85	-12.8	-0.64	9.59e-29	Morning vs. evening chronotype;
SARC	cis	rs11676348	0.935	rs2230054	chr2:219000310	C/T	cg00012203	chr2:219082015	ARPC2	-0.47	-6.18	-0.38	2.81e-9	Ulcerative colitis;
SARC	cis	rs4443100	0.792	rs9612223	chr22:23389142	T/G	cg14186256	chr22:23484241	RTDR1	0.49	5.08	0.32	7.85e-7	Serum parathyroid hormone levels;
SARC	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-4.89	-0.3	1.92e-6	Menopause (age at onset);
SARC	cis	rs2576037	0.521	rs4986227	chr18:44595031	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.45	-5.4	-0.33	1.67e-7	Personality dimensions;
SARC	cis	rs6665290	0.836	rs56029302	chr1:227203390	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.06	-23.08	-0.83	3.96e-62	Myeloid white cell count;
SARC	cis	rs2153535	0.541	rs9392222	chr6:8467649	G/A	cg07606381	chr6:8435919	SLC35B3	0.77	10.83	0.58	2.14e-22	Motion sickness;
SARC	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg20607798	chr8:58055168	NA	0.49	4.83	0.3	2.43e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs66573146	0.831	rs67702333	chr4:6983040	C/G	cg00086871	chr4:6988644	TBC1D14	0.89	5.29	0.33	2.88e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs7223966	1.000	rs2013288	chr17:61785904	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.52	-5.69	-0.35	3.83e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs297755	0.675	rs169867	chr20:4483512	C/T	cg14606382	chr20:4573199	NA	0.49	5.82	0.36	1.91e-8	Current cigarettes per day in chronic obstructive pulmonary disease;
SARC	cis	rs7412746	0.611	rs11204747	chr1:150927152	A/G	cg15448220	chr1:150897856	SETDB1	-0.51	-6.57	-0.4	3.17e-10	Melanoma;
SARC	cis	rs11155671	0.530	rs9322228	chr6:150209309	C/G	cg05036130	chr6:150231994	NA	0.28	4.87	0.3	2.04e-6	Testicular germ cell tumor;
SARC	cis	rs4642101	0.561	rs9812144	chr3:12805910	G/A	cg24848339	chr3:12840334	CAND2	0.35	5.33	0.33	2.29e-7	QRS complex (12-leadsum);
SARC	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg05368731	chr17:41323189	NBR1	0.79	9.6	0.53	1.34e-18	Menopause (age at onset);
SARC	cis	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg06212747	chr3:49208901	KLHDC8B	0.72	6.46	0.39	6.03e-10	Menarche (age at onset);
SARC	cis	rs2073300	0.609	rs6132610	chr20:23403987	C/T	cg16736954	chr20:23401023	NAPB	0.77	4.76	0.3	3.39e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg27421308	chr10:70092824	PBLD;HNRNPH3	-0.47	-6.32	-0.38	1.29e-9	Neuroticism;
SARC	cis	rs3126085	0.877	rs4415568	chr1:152181207	G/A	cg03465714	chr1:152285911	FLG	-0.46	-5.51	-0.34	9.24e-8	Atopic dermatitis;
SARC	cis	rs6088590	1.000	rs6120747	chr20:33449769	T/C	cg24642439	chr20:33292090	TP53INP2	0.8	10.98	0.58	7.29e-23	Coronary artery disease;
SARC	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	10.84	0.58	1.98e-22	Platelet count;
SARC	trans	rs2018683	0.745	rs917217	chr7:28975025	G/T	cg19402173	chr7:128379420	CALU	0.59	7.8	0.46	2.04e-13	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg12064134	chr16:90016061	DEF8	-0.49	-5.16	-0.32	5.36e-7	Skin colour saturation;
SARC	cis	rs10927875	0.541	rs1763601	chr1:16340460	G/T	cg21385522	chr1:16154831	NA	0.55	6.64	0.4	2.24e-10	Dilated cardiomyopathy;
SARC	cis	rs7932354	0.528	rs7121418	chr11:47165106	G/A	cg03339077	chr11:47165057	C11orf49	-0.47	-6.66	-0.4	1.94e-10	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg00933542	chr6:150070202	PCMT1	0.33	5.22	0.32	3.89e-7	Lung cancer;
SARC	cis	rs79149102	0.579	rs12591175	chr15:75356073	C/T	cg09165964	chr15:75287851	SCAMP5	-1.08	-9.29	-0.52	1.12e-17	Lung cancer;
SARC	cis	rs607987	0.871	rs1782508	chr11:30243795	C/G	cg06241208	chr11:30344200	C11orf46	-0.4	-4.98	-0.31	1.23e-6	Body mass index;
SARC	cis	rs2153535	0.580	rs9392223	chr6:8468650	G/A	cg07606381	chr6:8435919	SLC35B3	0.73	10.14	0.55	3.07e-20	Motion sickness;
SARC	cis	rs2832077	0.527	rs2832116	chr21:30228368	C/A	cg03476357	chr21:30257390	N6AMT1	-0.56	-6.24	-0.38	2.03e-9	Cognitive test performance;
SARC	cis	rs4742903	0.875	rs4543600	chr9:106939884	A/G	cg14250997	chr9:106856677	SMC2	0.44	5.47	0.34	1.17e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs2235544	0.565	rs928441	chr1:54473368	C/A	cg10336722	chr1:54665764	CYB5RL;MRPL37	0.39	4.79	0.3	2.98e-6	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
SARC	cis	rs722599	0.562	rs2287400	chr14:75182937	G/A	cg06637938	chr14:75390232	RPS6KL1	0.45	5.63	0.35	5.19e-8	IgG glycosylation;
SARC	cis	rs651907	0.557	rs7651406	chr3:101393296	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	6.47	0.39	5.82e-10	Colorectal cancer;
SARC	trans	rs11098499	0.954	rs9998585	chr4:120396802	T/A	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	cis	rs2075371	1.000	rs2598292	chr7:133988584	C/G	cg00033643	chr7:134001901	SLC35B4	0.4	4.85	0.3	2.25e-6	Mean platelet volume;
SARC	cis	rs2916247	1.000	rs2916247	chr8:93013666	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.58	-6.04	-0.37	5.91e-9	Intelligence (multi-trait analysis);
SARC	cis	rs9916302	0.706	rs9944459	chr17:37484185	T/C	cg15445000	chr17:37608096	MED1	-0.46	-5.04	-0.31	9.46e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg03433033	chr1:76189801	ACADM	0.54	7.42	0.44	2.19e-12	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs829883	0.966	rs249818	chr12:98896994	A/C	cg25150519	chr12:98850993	NA	0.71	9.49	0.53	2.82e-18	Colorectal adenoma (advanced);
SARC	cis	rs10791323	0.598	rs10750550	chr11:133736083	A/G	cg15485101	chr11:133734466	NA	0.33	5.3	0.33	2.72e-7	Childhood ear infection;
SARC	cis	rs929354	0.772	rs2301916	chr7:156974127	G/T	cg05182265	chr7:156933206	UBE3C	-0.33	-5.01	-0.31	1.08e-6	Body mass index;
SARC	cis	rs9486719	0.895	rs34051754	chr6:97007754	A/T	cg06623918	chr6:96969491	KIAA0776	-0.8	-8.93	-0.5	1.31e-16	Migraine;Coronary artery disease;
SARC	cis	rs9916302	0.904	rs7223438	chr17:37521355	T/C	cg00129232	chr17:37814104	STARD3	0.59	7.34	0.43	3.46e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs6088580	0.602	rs6059840	chr20:33030405	G/A	cg08999081	chr20:33150536	PIGU	0.44	6.58	0.4	3.05e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs8028182	0.525	rs9920028	chr15:75927717	G/A	cg20655648	chr15:75932815	IMP3	0.62	7.45	0.44	1.78e-12	Sudden cardiac arrest;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg23752923	chr1:85513892	MCOLN3	0.45	6.24	0.38	2.03e-9	Thyroid stimulating hormone;
SARC	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	5.42	0.33	1.46e-7	Bipolar disorder;
SARC	trans	rs1994135	0.715	rs10844624	chr12:33691010	A/G	cg26384229	chr12:38710491	ALG10B	0.78	9.72	0.54	5.85e-19	Resting heart rate;
SARC	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg11987759	chr7:65425863	GUSB	-0.64	-8.39	-0.48	4.86e-15	Aortic root size;
SARC	cis	rs2952156	0.834	rs903503	chr17:37829571	C/A	cg00129232	chr17:37814104	STARD3	-0.7	-9.9	-0.54	1.66e-19	Asthma;
SARC	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg17294928	chr15:75287854	SCAMP5	0.48	6.06	0.37	5.47e-9	Breast cancer;
SARC	cis	rs986417	1.000	rs6573316	chr14:61058029	C/A	cg27398547	chr14:60952738	C14orf39	0.86	7.67	0.45	4.72e-13	Gut microbiota (bacterial taxa);
SARC	cis	rs9325144	0.555	rs11183215	chr12:38693127	G/A	cg04568710	chr12:38710424	ALG10B	-0.4	-4.92	-0.31	1.66e-6	Morning vs. evening chronotype;
SARC	cis	rs4805272	0.539	rs11883172	chr19:29318536	C/T	cg14983838	chr19:29218262	NA	0.66	7.41	0.44	2.26e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs11997175	0.509	rs67427312	chr8:33674377	A/G	ch.8.33884649F	chr8:33765107	NA	0.54	6.84	0.41	7.08e-11	Body mass index;
SARC	cis	rs8005677	1.000	rs4981449	chr14:23388871	C/G	cg01529538	chr14:23388837	RBM23	0.46	5.72	0.35	3.25e-8	Cognitive ability (multi-trait analysis);
SARC	cis	rs72945132	0.769	rs3781645	chr11:70190374	T/C	cg05964544	chr11:70165517	PPFIA1	-0.58	-5.65	-0.35	4.56e-8	Coronary artery disease;
SARC	cis	rs9389248	0.690	rs728030	chr6:135246294	G/T	cg24558204	chr6:135376177	HBS1L	-0.5	-6.22	-0.38	2.24e-9	High light scatter reticulocyte percentage of red cells;
SARC	cis	rs7659604	1.000	rs72678650	chr4:122666000	A/G	cg20573242	chr4:122745356	CCNA2	0.44	5.74	0.35	3e-8	Type 2 diabetes;
SARC	cis	rs739401	0.572	rs404629	chr11:3077025	A/G	cg20651018	chr11:3035856	CARS	-0.44	-6.93	-0.41	4.07e-11	Longevity;
SARC	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-8.66	-0.49	7.91e-16	Chronic sinus infection;
SARC	cis	rs72781680	0.848	rs2339926	chr2:24045734	C/G	cg06627628	chr2:24431161	ITSN2	-0.67	-6.37	-0.38	1.02e-9	Lymphocyte counts;
SARC	cis	rs1153858	1.000	rs8032904	chr15:45651309	C/T	cg03999130	chr15:45571217	NA	0.39	5.01	0.31	1.09e-6	Homoarginine levels;
SARC	cis	rs4919087	0.705	rs701812	chr10:98975413	A/G	cg25902810	chr10:99078978	FRAT1	-0.54	-6.11	-0.37	4.04e-9	Monocyte count;
SARC	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.19	-0.47	1.67e-14	Alzheimer's disease;
SARC	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg11987759	chr7:65425863	GUSB	0.62	8.25	0.48	1.17e-14	Aortic root size;
SARC	cis	rs2836974	0.549	rs34160989	chr21:40554118	C/G	cg17971929	chr21:40555470	PSMG1	0.69	5.91	0.36	1.22e-8	Cognitive function;
SARC	cis	rs9916302	0.706	rs9646419	chr17:37597185	A/G	cg07936489	chr17:37558343	FBXL20	-0.77	-9.06	-0.51	5.48e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs12956009	0.583	rs12327454	chr18:44863964	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.57	7.2	0.43	8.44e-12	Educational attainment (years of education);
SARC	cis	rs6089584	0.566	rs2181589	chr20:60622817	C/T	cg13770153	chr20:60521292	NA	0.38	5.61	0.35	5.65e-8	Body mass index;
SARC	trans	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg21659725	chr3:3221576	CRBN	0.52	6.71	0.4	1.46e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg05623727	chr3:50126028	RBM5	-0.34	-4.96	-0.31	1.34e-6	Body mass index;
SARC	cis	rs425277	0.958	rs262688	chr1:2113565	T/G	cg24578937	chr1:2090814	PRKCZ	0.3	5.55	0.34	7.71e-8	Height;
SARC	cis	rs1691799	0.899	rs1168299	chr12:66736074	C/G	cg16791601	chr12:66731901	HELB	-0.71	-10.6	-0.57	1.09e-21	White blood cell count (basophil);
SARC	cis	rs72781680	0.898	rs7569424	chr2:24036222	A/G	cg06627628	chr2:24431161	ITSN2	-0.67	-6.31	-0.38	1.39e-9	Lymphocyte counts;
SARC	cis	rs9399137	0.507	rs28384513	chr6:135376209	T/G	cg24558204	chr6:135376177	HBS1L	0.63	8.13	0.47	2.59e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs4595586	0.545	rs12810822	chr12:39391807	T/A	cg26384229	chr12:38710491	ALG10B	0.5	6.12	0.37	3.98e-9	Morning vs. evening chronotype;
SARC	cis	rs6912958	0.559	rs2985039	chr6:88041757	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.37	6.39	0.39	8.91e-10	Monocyte percentage of white cells;
SARC	cis	rs9916302	0.904	rs9892055	chr17:37510402	C/T	cg20243544	chr17:37824526	PNMT	-0.53	-6.37	-0.39	9.76e-10	Glomerular filtration rate (creatinine);
SARC	trans	rs61931739	0.635	rs1486884	chr12:33908876	A/T	cg26384229	chr12:38710491	ALG10B	-0.63	-8.59	-0.49	1.22e-15	Morning vs. evening chronotype;
SARC	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg18252515	chr7:66147081	NA	1.29	11.21	0.59	1.32e-23	Diabetic kidney disease;
SARC	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg20102877	chr2:27665638	KRTCAP3	-0.38	-5.37	-0.33	1.88e-7	Total body bone mineral density;
SARC	cis	rs1865760	0.713	rs6928951	chr6:25995554	C/T	cg16482183	chr6:26056742	HIST1H1C	0.5	6.68	0.4	1.75e-10	Height;
SARC	cis	rs501120	0.810	rs683297	chr10:44746140	A/G	cg09554077	chr10:44749378	NA	0.47	6.48	0.39	5.32e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs34172651	0.583	rs4787649	chr16:24700215	C/T	cg00152838	chr16:24741724	TNRC6A	0.51	5.3	0.33	2.75e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7582720	1.000	rs72932781	chr2:203697278	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	7.5	0.44	1.36e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs634534	0.622	rs593525	chr11:65727799	T/C	cg26695010	chr11:65641043	EFEMP2	-0.57	-7.46	-0.44	1.69e-12	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs7772486	0.654	rs6928007	chr6:146074941	G/A	cg23711669	chr6:146136114	FBXO30	-0.8	-13.1	-0.65	9.33e-30	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs611744	0.967	rs597649	chr8:109187718	T/G	cg21045802	chr8:109455806	TTC35	0.44	5.3	0.33	2.64e-7	Dupuytren's disease;
SARC	cis	rs2050392	0.517	rs2489847	chr10:30743673	G/A	cg25182066	chr10:30743637	MAP3K8	0.57	8.22	0.47	1.45e-14	Inflammatory bowel disease;
SARC	cis	rs742614	0.533	rs6059498	chr20:32447282	T/C	cg06304546	chr20:32448765	NA	-0.58	-7.6	-0.45	7.01e-13	Stearic acid (18:0) levels;
SARC	cis	rs10979	0.679	rs2275345	chr6:143872960	G/A	cg25407410	chr6:143891975	LOC285740	-0.58	-7.0	-0.42	2.66e-11	Hypospadias;
SARC	cis	rs7412746	0.611	rs7532045	chr1:150821847	G/A	cg15448220	chr1:150897856	SETDB1	0.52	6.75	0.4	1.17e-10	Melanoma;
SARC	cis	rs7246657	0.508	rs1628959	chr19:37490376	G/A	cg14683738	chr19:37701593	ZNF585B	0.56	4.9	0.31	1.79e-6	Coronary artery calcification;
SARC	cis	rs35110281	0.774	rs2838327	chr21:45018566	A/C	cg01579765	chr21:45077557	HSF2BP	-0.34	-5.82	-0.36	1.89e-8	Mean corpuscular volume;
SARC	trans	rs208520	0.690	rs12202805	chr6:66703903	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.04	-14.14	-0.68	3.38e-33	Exhaled nitric oxide output;
SARC	cis	rs11910985	0.546	rs9978916	chr21:48080492	A/C	cg17243659	chr21:48055224	PRMT2	1.04	5.93	0.36	1.1e-8	Cerebrospinal fluid t-tau:AB1-42 ratio;
SARC	trans	rs459571	0.959	rs392134	chr9:136909008	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.6	-6.83	-0.41	7.26e-11	Platelet distribution width;
SARC	cis	rs920590	0.510	rs4922101	chr8:19648895	A/G	cg17834443	chr8:19674713	INTS10	0.6	6.3	0.38	1.5e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9388451	0.839	rs3966775	chr6:126067655	C/A	cg06289844	chr6:126071538	HEY2	0.39	6.37	0.39	9.76e-10	Brugada syndrome;
SARC	cis	rs17376456	0.877	rs66696214	chr5:93424533	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.54	0.34	8.18e-8	Diabetic retinopathy;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg15035459	chr3:51430541	RBM15B	-0.7	-6.26	-0.38	1.8e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6540556	0.608	rs2884090	chr1:209884059	C/T	cg23920097	chr1:209922102	NA	-0.45	-4.99	-0.31	1.2e-6	Red blood cell count;
SARC	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg13175981	chr1:150552382	MCL1	-0.54	-6.9	-0.41	4.97e-11	Tonsillectomy;
SARC	cis	rs5758659	1.000	rs134882	chr22:42670965	A/G	cg15128208	chr22:42549153	NA	-0.33	-4.78	-0.3	3.13e-6	Cognitive function;
SARC	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg04267008	chr7:1944627	MAD1L1	-0.51	-5.92	-0.36	1.17e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs11190604	0.767	rs872290	chr10:102198879	G/A	cg07080220	chr10:102295463	HIF1AN	0.7	8.06	0.47	3.87e-14	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs3733585	0.648	rs13103497	chr4:9979262	A/G	cg00071950	chr4:10020882	SLC2A9	0.38	5.8	0.36	2.12e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7552404	0.691	rs1770890	chr1:76401117	A/G	cg22875332	chr1:76189707	ACADM	-0.4	-4.97	-0.31	1.32e-6	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9487051	0.872	rs7773331	chr6:109609208	C/T	cg01475377	chr6:109611718	NA	-0.41	-5.92	-0.36	1.13e-8	Reticulocyte fraction of red cells;
SARC	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg13393036	chr8:95962371	TP53INP1	-0.36	-6.21	-0.38	2.45e-9	Type 2 diabetes;
SARC	cis	rs2576037	0.796	rs2576043	chr18:44573476	C/G	cg15049968	chr18:44337910	ST8SIA5	0.34	5.53	0.34	8.74e-8	Personality dimensions;
SARC	cis	rs11587400	0.572	rs2268699	chr1:115227896	G/T	cg12756093	chr1:115239321	AMPD1	0.38	4.83	0.3	2.51e-6	Autism;
SARC	cis	rs910316	1.000	rs4903284	chr14:75592483	G/C	cg06637938	chr14:75390232	RPS6KL1	0.5	7.13	0.42	1.25e-11	Height;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg10146780	chr14:52897968	TXNDC16	0.48	6.51	0.39	4.52e-10	Thyroid stimulating hormone;
SARC	cis	rs763121	0.853	rs2281021	chr22:39064667	T/C	cg06022373	chr22:39101656	GTPBP1	0.87	10.87	0.58	1.61e-22	Menopause (age at onset);
SARC	cis	rs79349575	0.783	rs17708633	chr17:47011620	C/G	cg16584676	chr17:46985605	UBE2Z	0.55	6.66	0.4	1.91e-10	Type 2 diabetes;
SARC	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-5.45	-0.34	1.28e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg01238044	chr22:24384105	GSTT1	-0.58	-6.49	-0.39	4.98e-10	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs8067545	0.611	rs2703795	chr17:20077141	C/A	cg13482628	chr17:19912719	NA	-0.53	-6.88	-0.41	5.39e-11	Schizophrenia;
SARC	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.41	-6.84	-0.41	6.94e-11	Total body bone mineral density;
SARC	cis	rs950027	0.620	rs1719246	chr15:45625479	T/A	cg26924012	chr15:45694286	SPATA5L1	0.52	6.5	0.39	4.79e-10	Response to fenofibrate (adiponectin levels);
SARC	cis	rs7927592	0.701	rs12226585	chr11:68257861	A/T	cg01657329	chr11:68192670	LRP5	0.38	5.31	0.33	2.61e-7	Total body bone mineral density;
SARC	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg25894440	chr7:65020034	NA	0.79	5.95	0.36	9.65e-9	Diabetic kidney disease;
SARC	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg20607798	chr8:58055168	NA	0.56	5.27	0.33	3.12e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg09699651	chr6:150184138	LRP11	0.48	5.87	0.36	1.52e-8	Lung cancer;
SARC	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.65	-6.99	-0.42	2.9100000000000002e-11	Platelet count;
SARC	cis	rs7296418	0.630	rs11057238	chr12:123767971	C/A	cg00376283	chr12:123451042	ABCB9	0.56	6.88	0.41	5.55e-11	Platelet count;
SARC	cis	rs12142240	0.692	rs7532149	chr1:46824932	A/C	cg14993813	chr1:46806288	NSUN4	-0.51	-5.34	-0.33	2.19e-7	Menopause (age at onset);
SARC	cis	rs6732160	0.845	rs10203718	chr2:73361515	G/C	cg01422370	chr2:73384389	NA	0.33	5.44	0.34	1.36e-7	Intelligence (multi-trait analysis);
SARC	cis	rs507506	0.771	rs929229	chr17:7105399	C/T	cg13768953	chr17:7114967	DLG4	-0.37	-6.08	-0.37	4.95e-9	Adiponectin levels;
SARC	trans	rs11098499	0.954	rs7687843	chr4:120421211	C/T	cg25214090	chr10:38739885	LOC399744	0.58	7.47	0.44	1.63e-12	Corneal astigmatism;
SARC	cis	rs13034020	0.522	rs12464096	chr2:61239332	G/C	cg18625361	chr2:61244694	PEX13;PUS10	0.71	6.13	0.37	3.79e-9	Hodgkin's lymphoma;
SARC	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg27347728	chr4:17578864	LAP3	0.48	6.1	0.37	4.5e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg07701084	chr6:150067640	NUP43	0.43	5.5	0.34	9.92e-8	Lung cancer;
SARC	cis	rs13191362	0.935	rs35378894	chr6:163123933	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.71	6.21	0.38	2.47e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs10876993	0.890	rs774887	chr12:58034835	A/G	cg18357645	chr12:58087776	OS9	0.44	5.66	0.35	4.44e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs4132509	0.843	rs6671475	chr1:243789342	A/G	cg21452805	chr1:244014465	NA	0.48	5.45	0.34	1.28e-7	RR interval (heart rate);
SARC	cis	rs2880765	0.631	rs55767890	chr15:86004142	C/G	cg19183879	chr15:85880815	NA	-0.3	-4.86	-0.3	2.19e-6	Coronary artery disease;
SARC	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg11247378	chr22:39784982	NA	-0.3	-4.86	-0.3	2.15e-6	Intelligence (multi-trait analysis);
SARC	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg18305652	chr10:134549665	INPP5A	0.36	5.15	0.32	5.46e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs9296092	0.538	rs9461880	chr6:33518714	C/T	cg13560919	chr6:33536144	NA	-0.49	-5.92	-0.36	1.16e-8	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs7584330	0.737	rs1497128	chr2:238369211	A/G	cg14458575	chr2:238380390	NA	0.43	5.25	0.33	3.48e-7	Prostate cancer;
SARC	trans	rs1814175	0.781	rs28681334	chr11:50051177	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-18.68	-0.77	3.33e-48	Height;
SARC	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	8.95	0.51	1.11e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs56235845	0.694	rs11748912	chr5:176765395	G/A	cg06060754	chr5:176797920	RGS14	0.45	5.94	0.36	1.01e-8	Hemoglobin concentration;Hematocrit;
SARC	trans	rs10771431	0.597	rs10771412	chr12:9354353	A/C	cg27600084	chr12:12264075	NA	0.52	6.87	0.41	5.96e-11	Breast size;
SARC	cis	rs3796352	1.000	rs13069006	chr3:52973305	G/C	cg12962167	chr3:53033115	SFMBT1	0.83	5.32	0.33	2.41e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs7223966	1.000	rs11871767	chr17:61698723	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.52	-5.6	-0.34	5.92e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs3820928	0.874	rs2276593	chr2:227898434	A/G	cg05526886	chr2:227700861	RHBDD1	0.47	5.38	0.33	1.77e-7	Pulmonary function;
SARC	cis	rs1355223	0.506	rs1828299	chr11:34870418	T/C	cg11622362	chr11:34938112	PDHX;APIP	0.46	6.07	0.37	5.27e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs1371867	0.846	rs1788194	chr8:101277916	T/C	cg11906718	chr8:101322791	RNF19A	0.73	9.41	0.52	4.96e-18	Atrioventricular conduction;
SARC	cis	rs6815814	0.950	rs55830619	chr4:38807364	G/A	cg09316306	chr4:38807337	TLR1	0.5	5.16	0.32	5.23e-7	Breast cancer;
SARC	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg00933542	chr6:150070202	PCMT1	0.31	5.32	0.33	2.44e-7	Lung cancer;
SARC	cis	rs9815354	0.812	rs57209010	chr3:41854743	A/T	cg03022575	chr3:42003672	ULK4	0.7	5.79	0.35	2.3e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs7523050	0.643	rs12729998	chr1:109405505	T/C	cg08274380	chr1:109419600	GPSM2	1.06	8.03	0.47	4.73e-14	Fat distribution (HIV);
SARC	cis	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg24110177	chr3:50126178	RBM5	-0.39	-5.04	-0.31	9.46e-7	Intelligence (multi-trait analysis);
SARC	cis	rs4481887	0.927	rs6587444	chr1:248438452	C/T	cg13385794	chr1:248469461	NA	-0.38	-5.11	-0.32	6.72e-7	Common traits (Other);
SARC	cis	rs7561149	1.000	rs12469367	chr2:179691670	T/C	cg17765952	chr2:179737173	CCDC141	-0.39	-5.17	-0.32	4.99e-7	QT interval;
SARC	cis	rs9473924	0.542	rs9473939	chr6:50877477	T/G	cg14470998	chr6:50812995	TFAP2B	0.71	6.74	0.4	1.2e-10	Body mass index;
SARC	cis	rs13082711	0.555	rs7627508	chr3:27252495	A/C	cg02860705	chr3:27208620	NA	0.6	7.93	0.46	9.24e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg18252515	chr7:66147081	NA	0.45	4.97	0.31	1.3e-6	Aortic root size;
SARC	cis	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg26513180	chr16:89883248	FANCA	0.72	4.79	0.3	2.94e-6	Skin colour saturation;
SARC	cis	rs6088590	1.000	rs6087623	chr20:33317662	C/G	cg08999081	chr20:33150536	PIGU	0.34	4.92	0.31	1.63e-6	Coronary artery disease;
SARC	cis	rs116979167	0.630	rs56230603	chr7:105165268	A/G	cg13798780	chr7:105162888	PUS7	0.61	5.61	0.34	5.84e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg15556689	chr8:8085844	FLJ10661	-0.4	-5.05	-0.31	9.04e-7	Mood instability;
SARC	cis	rs17376456	0.877	rs55832164	chr5:93436579	C/T	cg21475434	chr5:93447410	FAM172A	0.86	7.77	0.45	2.57e-13	Diabetic retinopathy;
SARC	cis	rs61409971	0.961	rs10137524	chr14:93017149	C/T	cg04718702	chr14:93020195	RIN3	-0.36	-4.76	-0.3	3.47e-6	Lymphocyte percentage of white cells;
SARC	cis	rs9309473	0.607	rs1522927	chr2:73556155	T/G	cg20560298	chr2:73613845	ALMS1	-0.57	-6.79	-0.41	8.97e-11	Metabolite levels;
SARC	cis	rs7927592	0.830	rs7120635	chr11:68261293	A/G	cg01657329	chr11:68192670	LRP5	-0.39	-5.1	-0.32	7.15e-7	Total body bone mineral density;
SARC	cis	rs1355223	0.573	rs1361646	chr11:34746360	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-4.84	-0.3	2.33e-6	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs4481887	0.830	rs4474289	chr1:248474972	T/A	cg13385794	chr1:248469461	NA	0.36	5.43	0.34	1.4e-7	Common traits (Other);
SARC	cis	rs9457247	1.000	rs386548	chr6:167385533	A/T	cg23791538	chr6:167370224	RNASET2	0.62	8.61	0.49	1.09e-15	Crohn's disease;
SARC	cis	rs4268898	0.636	rs72787383	chr2:24583861	G/A	cg26838691	chr2:24397539	C2orf84	-0.54	-6.18	-0.38	2.78e-9	Asthma;
SARC	cis	rs9611519	0.929	rs12484971	chr22:41439304	A/T	cg03806693	chr22:41940476	POLR3H	-0.6	-7.69	-0.45	4.15e-13	Neuroticism;
SARC	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg00339695	chr16:24857497	SLC5A11	0.4	5.46	0.34	1.22e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs6772849	0.930	rs4857914	chr3:128350684	C/T	cg01163369	chr3:128370232	RPN1	-0.35	-5.06	-0.31	8.59e-7	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg13607699	chr17:42295918	UBTF	0.57	6.88	0.41	5.56e-11	Total body bone mineral density;
SARC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg10295955	chr4:187884368	NA	-1.09	-21.34	-0.81	9.83e-57	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6456156	0.774	rs6456158	chr6:167528032	A/C	cg07741184	chr6:167504864	NA	0.27	5.15	0.32	5.56e-7	Primary biliary cholangitis;
SARC	cis	rs4891159	0.548	rs10782013	chr18:74128348	C/T	cg24786174	chr18:74118243	ZNF516	0.72	12.17	0.62	1.09e-26	Longevity;
SARC	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg15448220	chr1:150897856	SETDB1	0.47	6.25	0.38	1.94e-9	Tonsillectomy;
SARC	cis	rs7772486	0.790	rs2814880	chr6:146208937	T/G	cg05347473	chr6:146136440	FBXO30	0.49	6.66	0.4	1.96e-10	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg22968622	chr17:43663579	NA	-1.13	-15.28	-0.71	5.37e-37	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7953249	0.807	rs2393775	chr12:121424574	G/A	cg02403541	chr12:121454288	C12orf43	-0.58	-7.33	-0.43	3.75e-12	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs11098499	0.739	rs2203039	chr4:120132347	T/C	cg09307838	chr4:120376055	NA	-0.77	-10.47	-0.57	2.93e-21	Corneal astigmatism;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg24232869	chr12:48478849	SENP1	-0.49	-6.28	-0.38	1.62e-9	Height;
SARC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg03452623	chr4:187889614	NA	-0.76	-11.77	-0.61	2.03e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs35306767	0.903	rs11816064	chr10:931176	A/C	cg20503657	chr10:835505	NA	0.88	8.48	0.49	2.64e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs5997397	0.967	rs5762777	chr22:29150044	T/C	cg02153584	chr22:29168773	CCDC117	0.54	7.33	0.43	3.71e-12	Red cell distribution width;
SARC	cis	rs72945132	0.825	rs57871058	chr11:70192344	T/C	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.7	-0.35	3.57e-8	Coronary artery disease;
SARC	cis	rs7615952	0.932	rs6438948	chr3:125650045	A/T	cg05084668	chr3:125655381	ALG1L	0.69	7.24	0.43	6.65e-12	Blood pressure (smoking interaction);
SARC	cis	rs10504229	0.679	rs16921623	chr8:58039473	G/C	cg08219700	chr8:58056026	NA	0.62	6.19	0.38	2.68e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2073499	0.872	rs41291724	chr3:50294066	C/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.52	4.74	0.3	3.71e-6	Schizophrenia;
SARC	cis	rs698813	0.674	rs4952707	chr2:44500683	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	6.32	0.38	1.31e-9	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs6665290	0.904	rs2297416	chr1:227172935	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.08	-25.73	-0.86	5.05e-70	Myeloid white cell count;
SARC	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg16479474	chr6:28041457	NA	0.37	5.48	0.34	1.11e-7	Depression;
SARC	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg03517284	chr6:25882590	NA	-0.46	-5.81	-0.36	2.04e-8	Intelligence (multi-trait analysis);
SARC	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.5	4.97	0.31	1.32e-6	Lung function (FEV1/FVC);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg27303959	chr7:35076959	DPY19L1	0.49	6.43	0.39	7.19e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs4713118	0.869	rs2056925	chr6:27690905	A/G	cg17221315	chr6:27791827	HIST1H4J	0.5	5.41	0.33	1.57e-7	Parkinson's disease;
SARC	cis	rs3768617	0.510	rs20558	chr1:183094547	T/C	cg13390022	chr1:182993471	LAMC1	0.31	4.79	0.3	3.01e-6	Fuchs's corneal dystrophy;
SARC	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6752107	1.000	rs2289472	chr2:234182240	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.46	6.24	0.38	1.99e-9	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg08280861	chr8:58055591	NA	0.61	5.94	0.36	1.01e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7766436	0.885	rs1418312	chr6:22589704	C/T	cg13666174	chr6:22585274	NA	-0.61	-7.86	-0.46	1.37e-13	Coronary artery disease;
SARC	cis	rs7264396	0.563	rs11906854	chr20:34383634	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.41	-0.39	7.88e-10	Total cholesterol levels;
SARC	cis	rs1550582	1.000	rs76091740	chr8:135514419	C/T	cg17885191	chr8:135476712	NA	0.59	6.12	0.37	3.93e-9	Educational attainment;
SARC	cis	rs9462027	0.628	rs6906759	chr6:34742990	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.84	-0.36	1.71e-8	Systemic lupus erythematosus;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg10455704	chr8:9413697	TNKS	0.52	6.32	0.38	1.3e-9	Breast cancer;
SARC	cis	rs936229	0.813	rs1378938	chr15:75096443	T/C	cg14664628	chr15:75095509	CSK	-1.04	-14.59	-0.69	1.1e-34	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs7113874	0.625	rs10743073	chr11:8504619	C/T	cg09828998	chr11:8703972	RPL27A	-0.46	-4.8	-0.3	2.83e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7568458	0.846	rs6705839	chr2:85761279	A/T	cg02493740	chr2:85810744	VAMP5	-0.36	-5.45	-0.34	1.27e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg22496380	chr5:211416	CCDC127	-0.81	-8.38	-0.48	5.13e-15	Breast cancer;
SARC	trans	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg20587970	chr11:113659929	NA	-1.31	-13.7	-0.67	9.62e-32	Hip circumference adjusted for BMI;
SARC	cis	rs7712401	0.584	rs30037	chr5:122277990	T/C	cg19412675	chr5:122181750	SNX24	0.39	4.95	0.31	1.45e-6	Mean platelet volume;
SARC	cis	rs644799	0.735	rs10831432	chr11:95516040	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	13.58	0.66	2.42e-31	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs34421088	0.559	rs12386974	chr8:11400628	C/G	cg06636001	chr8:8085503	FLJ10661	0.69	9.89	0.54	1.79e-19	Neuroticism;
SARC	cis	rs2635047	0.967	rs2247784	chr18:44746997	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	7.55	0.44	9.75e-13	Educational attainment;
SARC	cis	rs7940866	0.845	rs1433976	chr11:130875123	C/T	cg12179176	chr11:130786555	SNX19	-0.67	-8.86	-0.5	2.05e-16	Schizophrenia;
SARC	cis	rs1153858	1.000	rs1820518	chr15:45694579	C/T	cg26924012	chr15:45694286	SPATA5L1	0.78	10.68	0.57	6.18e-22	Homoarginine levels;
SARC	cis	rs763121	0.853	rs5757226	chr22:39070550	T/C	cg14440974	chr22:39074834	NA	-0.33	-4.8	-0.3	2.84e-6	Menopause (age at onset);
SARC	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg03060546	chr3:49711283	APEH	0.43	5.33	0.33	2.31e-7	Parkinson's disease;
SARC	cis	rs10504229	0.906	rs28447218	chr8:58170813	T/G	cg24829409	chr8:58192753	C8orf71	-0.51	-5.61	-0.34	5.77e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9828933	0.752	rs832192	chr3:63853423	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	0.87	7.03	0.42	2.33e-11	Type 2 diabetes;
SARC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg24101359	chr6:42928495	GNMT	0.43	5.8	0.36	2.16e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg01579765	chr21:45077557	HSF2BP	-0.3	-5.02	-0.31	1.04e-6	Mean corpuscular volume;
SARC	cis	rs3741404	0.594	rs11231704	chr11:63898182	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.57	-7.5	-0.44	1.31e-12	Platelet count;
SARC	trans	rs13325613	0.915	rs34677490	chr3:46270748	G/T	cg12387106	chr12:133178249	NA	0.85	6.5	0.39	4.85e-10	Monocyte count;
SARC	cis	rs73086581	0.945	rs6052222	chr20:3972793	G/A	cg02187196	chr20:3869020	PANK2	0.58	5.45	0.34	1.28e-7	Response to antidepressants in depression;
SARC	cis	rs6908034	0.607	rs79842087	chr6:19821316	G/A	cg02682789	chr6:19804855	NA	0.68	5.23	0.32	3.79e-7	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs3796352	1.000	rs3806692	chr3:53080987	C/G	cg27565382	chr3:53032988	SFMBT1	0.76	5.7	0.35	3.58e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs7772486	0.686	rs7739735	chr6:146123536	G/A	cg23711669	chr6:146136114	FBXO30	0.79	12.69	0.64	2.16e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2191566	0.960	rs56171514	chr19:44506110	G/C	cg20607764	chr19:44506953	ZNF230	-0.53	-6.22	-0.38	2.3e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs3749237	0.595	rs1568661	chr3:49520958	A/G	cg06212747	chr3:49208901	KLHDC8B	0.5	6.16	0.37	3.19e-9	Resting heart rate;
SARC	cis	rs6840360	0.530	rs12645029	chr4:152650032	T/C	cg22705602	chr4:152727874	NA	-0.45	-6.99	-0.42	2.82e-11	Intelligence (multi-trait analysis);
SARC	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg08975724	chr8:8085496	FLJ10661	-0.68	-9.36	-0.52	7.11e-18	Neuroticism;
SARC	cis	rs4481887	1.000	rs6697735	chr1:248465315	G/C	cg00666640	chr1:248458726	OR2T12	0.36	6.13	0.37	3.71e-9	Common traits (Other);
SARC	cis	rs1580019	0.961	rs1580022	chr7:32497712	C/A	cg06627557	chr7:32535165	LSM5;AVL9	0.73	9.78	0.54	3.93e-19	Cognitive ability;
SARC	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg09699651	chr6:150184138	LRP11	0.46	5.58	0.34	6.79e-8	Lung cancer;
SARC	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg05872129	chr22:39784769	NA	-0.42	-6.12	-0.37	4.03e-9	Intelligence (multi-trait analysis);
SARC	cis	rs763121	0.853	rs5995610	chr22:39064681	C/T	cg14440974	chr22:39074834	NA	-0.34	-5.07	-0.32	8.19e-7	Menopause (age at onset);
SARC	cis	rs9467773	0.967	rs6924865	chr6:26521353	A/G	cg11502198	chr6:26597334	ABT1	0.47	5.93	0.36	1.1e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7927771	0.931	rs12361256	chr11:47910823	A/C	cg20307385	chr11:47447363	PSMC3	-0.46	-5.75	-0.35	2.73e-8	Subjective well-being;
SARC	cis	rs17600642	0.724	rs56114443	chr10:72453821	C/T	cg19779893	chr10:72451501	ADAMTS14	-0.38	-5.86	-0.36	1.59e-8	Bipolar disorder;
SARC	cis	rs34891900	0.507	rs2535707	chr22:18181869	C/T	cg19898043	chr22:18121309	BCL2L13	-0.66	-7.65	-0.45	5.42e-13	Sum neutrophil eosinophil counts;
SARC	cis	rs367615	0.506	rs2914680	chr5:108787146	A/G	cg17395555	chr5:108820864	NA	-0.43	-6.26	-0.38	1.84e-9	Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs1476670	0.683	rs813642	chr1:44506420	A/C	cg09470012	chr1:44509516	NA	0.44	5.6	0.34	5.92e-8	Eotaxin levels;
SARC	cis	rs7246657	0.941	rs67293224	chr19:37803248	C/T	cg23950597	chr19:37808831	NA	-0.57	-5.1	-0.32	6.99e-7	Coronary artery calcification;
SARC	cis	rs4555082	0.915	rs66527719	chr14:105750523	C/G	cg10792982	chr14:105748885	BRF1	0.54	8.16	0.47	2.12e-14	Mean platelet volume;Platelet distribution width;
SARC	cis	rs73206853	0.534	rs13313219	chr12:110509461	G/A	cg08946844	chr12:110511112	NA	0.63	5.02	0.31	1.03e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs11687170	0.882	rs55830725	chr2:237056854	T/A	cg19324714	chr2:237145437	ASB18	0.49	4.87	0.3	2.09e-6	Educational attainment;Educational attainment (years of education);
SARC	cis	rs9814567	0.896	rs11915964	chr3:134348930	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.49	6.2	0.38	2.59e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs6831352	0.918	rs7670060	chr4:100059568	G/T	cg12011299	chr4:100065546	ADH4	-0.34	-5.74	-0.35	2.95e-8	Alcohol dependence;
SARC	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg24399712	chr22:39784796	NA	0.45	5.96	0.36	9.29e-9	Intelligence (multi-trait analysis);
SARC	cis	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg18252515	chr7:66147081	NA	-1.3	-11.63	-0.61	5.98e-25	Diabetic kidney disease;
SARC	cis	rs356220	0.632	rs2572324	chr4:90678798	G/A	cg06632027	chr4:90757378	SNCA	0.4	5.03	0.31	9.77e-7	Parkinson's disease;
SARC	cis	rs12594515	1.000	rs12595137	chr15:45986105	G/T	cg14863074	chr15:45997064	NA	0.34	5.19	0.32	4.48e-7	Waist circumference;Weight;
SARC	cis	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg08564027	chr20:61660810	NA	0.76	11.8	0.61	1.69e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.61e-6	Parkinson's disease;
SARC	cis	rs9788682	0.895	rs3813570	chr15:78832832	T/C	cg24631222	chr15:78858424	CHRNA5	0.76	10.11	0.55	3.7799999999999997e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.6	0.53	1.33e-18	Prudent dietary pattern;
SARC	cis	rs9457247	1.000	rs408080	chr6:167392522	T/C	cg07741184	chr6:167504864	NA	0.3	5.62	0.35	5.47e-8	Crohn's disease;
SARC	cis	rs8114671	0.869	rs2038503	chr20:33675900	G/A	cg24642439	chr20:33292090	TP53INP2	-0.49	-5.59	-0.34	6.23e-8	Height;
SARC	cis	rs3106136	0.681	rs11097420	chr4:95301035	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.33	-4.91	-0.31	1.73e-6	Capecitabine sensitivity;
SARC	cis	rs8114671	0.967	rs2378337	chr20:33771435	G/A	cg24642439	chr20:33292090	TP53INP2	0.51	5.9	0.36	1.26e-8	Height;
SARC	trans	rs61931739	0.817	rs11053125	chr12:34265417	C/T	cg13010199	chr12:38710504	ALG10B	0.56	7.15	0.42	1.1e-11	Morning vs. evening chronotype;
SARC	cis	rs427394	0.802	rs200841	chr5:6737134	A/G	cg10857441	chr5:6722123	POLS	-0.34	-5.17	-0.32	5.13e-7	Menopause (age at onset);
SARC	cis	rs708547	0.578	rs781665	chr4:57831461	G/A	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.41	-4.83	-0.3	2.44e-6	Response to bleomycin (chromatid breaks);
SARC	cis	rs7113850	0.541	rs11819948	chr11:24231257	A/C	ch.11.24196551F	chr11:24239977	NA	0.73	5.37	0.33	1.91e-7	Bone fracture in osteoporosis;
SARC	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg21782813	chr7:2030301	MAD1L1	0.48	7.75	0.45	2.91e-13	Bipolar disorder and schizophrenia;
SARC	cis	rs7020830	0.931	rs6476613	chr9:37084340	A/G	cg14294708	chr9:37120828	ZCCHC7	1.14	20.94	0.81	1.86e-55	Schizophrenia;
SARC	cis	rs7223966	1.000	rs16947005	chr17:61702989	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.49	5.42	0.33	1.51e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9457247	0.765	rs6900701	chr6:167434112	A/G	cg07741184	chr6:167504864	NA	0.35	7.03	0.42	2.31e-11	Crohn's disease;
SARC	cis	rs782590	0.559	rs12617719	chr2:55915826	G/C	cg18811423	chr2:55921094	PNPT1	-0.71	-9.27	-0.52	1.29e-17	Metabolic syndrome;
SARC	cis	rs28795989	0.761	rs1320075	chr4:7903244	C/A	cg18538662	chr4:7941764	AFAP1	-0.41	-5.29	-0.33	2.83e-7	Intraocular pressure;
SARC	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg05313129	chr8:58192883	C8orf71	-0.62	-6.34	-0.38	1.18e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7712401	0.601	rs154496	chr5:122221731	A/G	cg19412675	chr5:122181750	SNX24	0.42	5.33	0.33	2.36e-7	Mean platelet volume;
SARC	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg27121462	chr16:89883253	FANCA	-0.62	-8.18	-0.47	1.85e-14	Vitiligo;
SARC	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg19077165	chr18:44547161	KATNAL2	-0.53	-7.39	-0.44	2.66e-12	Personality dimensions;
SARC	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.5	-0.44	1.37e-12	Gut microbiome composition (summer);
SARC	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg12463550	chr7:65579703	CRCP	0.5	5.9	0.36	1.27e-8	Aortic root size;
SARC	cis	rs7927771	0.864	rs11604680	chr11:47457539	A/G	cg20307385	chr11:47447363	PSMC3	-0.59	-7.35	-0.43	3.39e-12	Subjective well-being;
SARC	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.5	-5.58	-0.34	6.52e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	trans	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg00938859	chr5:1591904	SDHAP3	0.74	7.18	0.43	9.17e-12	Breast cancer;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg07263984	chr5:115177777	ATG12;AP3S1	-0.76	-6.25	-0.38	1.91e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs17376456	0.569	rs2045020	chr5:93224466	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.47	-4.92	-0.31	1.64e-6	Diabetic retinopathy;
SARC	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg16405210	chr4:1374714	KIAA1530	-0.48	-5.72	-0.35	3.29e-8	Obesity-related traits;
SARC	cis	rs9487051	0.872	rs9400271	chr6:109607556	G/A	cg01475377	chr6:109611718	NA	-0.42	-5.98	-0.36	8.27e-9	Reticulocyte fraction of red cells;
SARC	trans	rs11098499	0.604	rs34278750	chr4:120571136	G/A	cg25214090	chr10:38739885	LOC399744	0.51	6.61	0.4	2.56e-10	Corneal astigmatism;
SARC	cis	rs7772486	0.790	rs4075694	chr6:146251108	G/C	cg05347473	chr6:146136440	FBXO30	-0.48	-6.53	-0.39	4.1e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg09165964	chr15:75287851	SCAMP5	-0.52	-7.15	-0.42	1.08e-11	Breast cancer;
SARC	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg25703541	chr22:24373054	LOC391322	-0.78	-9.76	-0.54	4.26e-19	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs5769765	0.955	rs8139758	chr22:50261123	G/T	cg03033257	chr22:50311977	ALG12;CRELD2	-0.54	-5.64	-0.35	4.81e-8	Schizophrenia;
SARC	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg18252515	chr7:66147081	NA	-0.62	-6.64	-0.4	2.2e-10	Aortic root size;
SARC	trans	rs66573146	0.634	rs55633489	chr4:6988745	C/A	cg07817883	chr1:32538562	TMEM39B	1.26	8.27	0.48	1.04e-14	Granulocyte percentage of myeloid white cells;
SARC	cis	rs7539542	0.556	rs1539357	chr1:202878454	T/A	cg08940984	chr1:202857613	RABIF	0.39	5.25	0.33	3.41e-7	Mean platelet volume;
SARC	trans	rs1957429	0.520	rs72625642	chr14:65338884	G/T	cg10286983	chr6:24494717	ALDH5A1	-0.71	-6.29	-0.38	1.52e-9	Pediatric areal bone mineral density (radius);
SARC	cis	rs7666738	0.927	rs11736876	chr4:98987206	A/G	cg05340658	chr4:99064831	C4orf37	0.57	7.15	0.42	1.12e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2997447	0.761	rs17163588	chr1:26450009	C/T	cg19633962	chr1:26362018	EXTL1	-0.57	-5.17	-0.32	5.07e-7	QRS complex (12-leadsum);
SARC	cis	rs7659604	1.000	rs10016433	chr4:122664771	A/G	cg19748678	chr4:122722346	EXOSC9	0.42	5.19	0.32	4.59e-7	Type 2 diabetes;
SARC	cis	rs2289583	0.544	rs6495132	chr15:75255322	C/T	cg14664628	chr15:75095509	CSK	0.46	5.04	0.31	9.46e-7	Systemic lupus erythematosus;
SARC	cis	rs11122272	0.735	rs2491403	chr1:231511185	C/T	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs6430585	0.528	rs79826902	chr2:136670419	G/A	cg07169764	chr2:136633963	MCM6	1.05	13.66	0.67	1.29e-31	Corneal structure;
SARC	cis	rs11633958	1	rs11633958	chr15:78862064	C/T	cg18825076	chr15:78729989	IREB2	-0.43	-5.02	-0.31	1.01e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	trans	rs641862	1	rs641862	chr13:110790232	C/T	cg12796743	chr13:113510312	ATP11A	0.88	6.4	0.39	8.29e-10	Obesity-related traits;
SARC	cis	rs67366981	1.000	rs17105594	chr14:77713146	C/T	cg06779847	chr14:77687015	TMEM63C	-0.46	-5.15	-0.32	5.51e-7	Obsessive-compulsive symptoms;
SARC	cis	rs9788682	0.642	rs2568483	chr15:78752343	A/G	cg24631222	chr15:78858424	CHRNA5	0.74	9.23	0.52	1.74e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs6942407	0.545	rs6465101	chr7:86859065	C/G	cg02420886	chr7:86849541	C7orf23	0.66	5.81	0.36	2e-8	Food allergy;
SARC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.33	4.9	0.31	1.78e-6	Electroencephalogram traits;
SARC	cis	rs3126085	0.935	rs11204941	chr1:152203343	A/G	cg03465714	chr1:152285911	FLG	-0.46	-5.64	-0.35	4.94e-8	Atopic dermatitis;
SARC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg24503407	chr1:205819492	PM20D1	0.53	6.96	0.41	3.43e-11	Menarche (age at onset);
SARC	cis	rs2073499	1.000	rs2071802	chr3:50412945	A/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.56	5.07	0.32	8.21e-7	Schizophrenia;
SARC	cis	rs2816062	0.760	rs2244192	chr1:18890939	A/T	cg18795169	chr1:18902165	NA	-0.8	-12.68	-0.64	2.32e-28	Urate levels in lean individuals;
SARC	cis	rs9896933	0.775	rs79299098	chr17:80830944	G/A	cg20578329	chr17:80767326	TBCD	-0.74	-8.21	-0.47	1.51e-14	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
SARC	cis	rs6120849	0.615	rs11167248	chr20:33538721	G/T	cg24642439	chr20:33292090	TP53INP2	0.6	5.92	0.36	1.12e-8	Protein C levels;
SARC	cis	rs6580649	1.000	rs6580649	chr12:48410517	A/G	cg24011408	chr12:48396354	COL2A1	0.48	5.47	0.34	1.13e-7	Lung cancer;
SARC	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg17221315	chr6:27791827	HIST1H4J	0.47	5.07	0.32	8.18e-7	Parkinson's disease;
SARC	cis	rs9397240	0.789	rs9371880	chr6:155601125	A/C	cg07943832	chr6:155568918	TIAM2	-0.6	-5.77	-0.35	2.54e-8	Life satisfaction;
SARC	cis	rs9818758	0.607	rs9837625	chr3:49215966	C/T	cg07636037	chr3:49044803	WDR6	-0.78	-6.86	-0.41	6.17e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs2011503	1.000	rs11671253	chr19:19604206	C/T	cg03709012	chr19:19516395	GATAD2A	0.61	5.36	0.33	1.95e-7	Bipolar disorder;
SARC	cis	rs11155671	0.530	rs9322228	chr6:150209309	C/G	cg09699651	chr6:150184138	LRP11	0.52	6.59	0.4	2.86e-10	Testicular germ cell tumor;
SARC	cis	rs72949976	0.606	rs2178756	chr2:214031423	A/G	cg08319019	chr2:214017104	IKZF2	0.47	6.31	0.38	1.39e-9	Lung cancer;Squamous cell lung carcinoma;
SARC	trans	rs208515	0.525	rs10944859	chr6:66665197	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.01	11.59	0.6	7.98e-25	Exhaled nitric oxide levels;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg17942371	chr19:796826	PTBP1	0.5	6.9	0.41	4.78e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs9916302	0.904	rs9898773	chr17:37532507	C/G	cg20243544	chr17:37824526	PNMT	-0.56	-6.74	-0.4	1.22e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs7927592	0.546	rs554734	chr11:68192518	T/G	cg01657329	chr11:68192670	LRP5	-0.41	-5.5	-0.34	9.88e-8	Total body bone mineral density;
SARC	cis	rs12995491	0.933	rs34029976	chr2:88537797	T/C	cg07952391	chr2:88470173	THNSL2	-0.35	-4.71	-0.3	4.19e-6	Response to metformin (IC50);
SARC	cis	rs1215050	0.740	rs783932	chr4:98973936	C/G	cg05340658	chr4:99064831	C4orf37	-0.46	-6.22	-0.38	2.26e-9	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs5753618	0.561	rs9609264	chr22:31746719	C/G	cg13145458	chr22:31556086	RNF185	-0.49	-5.27	-0.33	3.12e-7	Colorectal cancer;
SARC	cis	rs1003719	0.715	rs2835640	chr21:38537380	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.48	-0.53	3.11e-18	Eye color traits;
SARC	cis	rs453301	0.624	rs6987558	chr8:8862521	C/G	cg15556689	chr8:8085844	FLJ10661	0.39	4.94	0.31	1.46e-6	Joint mobility (Beighton score);
SARC	cis	rs561341	0.700	rs79272796	chr17:30226974	T/C	cg13647721	chr17:30228624	UTP6	0.74	8.74	0.5	4.54e-16	Hip circumference adjusted for BMI;
SARC	cis	rs995000	0.931	rs6690733	chr1:63060311	A/C	cg06896770	chr1:63153194	DOCK7	0.9	13.28	0.66	2.38e-30	Triglyceride levels;
SARC	cis	rs1355223	0.573	rs947501	chr11:34753375	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-4.87	-0.3	2.02e-6	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs12579753	0.957	rs35001833	chr12:82188510	C/G	cg07988820	chr12:82153109	PPFIA2	-0.57	-6.51	-0.39	4.54e-10	Resting heart rate;
SARC	cis	rs6598163	0.520	rs12813376	chr12:132302324	C/T	cg07389463	chr12:132296394	NA	0.4	6.13	0.37	3.7e-9	Migraine;
SARC	cis	rs7666738	0.830	rs116103936	chr4:98954531	T/C	cg05340658	chr4:99064831	C4orf37	0.66	9.0	0.51	8.07e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg11644478	chr21:40555479	PSMG1	1.02	14.38	0.69	5.5e-34	Cognitive function;
SARC	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg21016266	chr12:122356598	WDR66	0.42	6.5	0.39	4.91e-10	Mean corpuscular volume;
SARC	cis	rs2594989	0.733	rs9811482	chr3:11578591	C/T	cg00170343	chr3:11313890	ATG7	-0.56	-6.12	-0.37	3.89e-9	Circulating chemerin levels;
SARC	cis	rs4253772	0.550	rs6007823	chr22:46706249	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.58	4.9	0.31	1.77e-6	LDL cholesterol;Cholesterol, total;
SARC	cis	rs9902453	0.934	rs7223645	chr17:28491029	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	6.77	0.41	1.05e-10	Coffee consumption (cups per day);
SARC	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg22974920	chr21:40686053	BRWD1	0.45	4.79	0.3	3e-6	Cognitive function;
SARC	cis	rs1707322	1.000	rs4454479	chr1:46423555	G/A	cg06784218	chr1:46089804	CCDC17	0.34	5.98	0.36	8.31e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9398803	0.713	rs3861455	chr6:126897969	A/C	cg20229609	chr6:126660872	C6orf173	0.37	5.39	0.33	1.74e-7	Male-pattern baldness;
SARC	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg25894440	chr7:65020034	NA	-0.72	-5.46	-0.34	1.2e-7	Diabetic kidney disease;
SARC	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg13206674	chr6:150067644	NUP43	0.42	5.47	0.34	1.17e-7	Lung cancer;
SARC	cis	rs7020830	0.898	rs13284651	chr9:37222681	G/T	cg14294708	chr9:37120828	ZCCHC7	-1.13	-19.48	-0.79	8.48e-51	Schizophrenia;
SARC	cis	rs651907	0.514	rs11706494	chr3:101509475	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	5.91	0.36	1.22e-8	Colorectal cancer;
SARC	cis	rs9393777	0.513	rs7754159	chr6:26620312	G/A	cg12826209	chr6:26865740	GUSBL1	0.69	6.15	0.37	3.39e-9	Intelligence (multi-trait analysis);
SARC	cis	rs6570726	0.935	rs366621	chr6:145861275	A/G	cg23711669	chr6:146136114	FBXO30	0.74	11.05	0.59	4.32e-23	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs699371	0.507	rs10149787	chr14:74925452	A/C	cg16374328	chr14:74960395	NPC2;ISCA2	-0.47	-6.2	-0.38	2.53e-9	Height;
SARC	cis	rs7523050	0.908	rs12404382	chr1:109397129	G/A	cg08274380	chr1:109419600	GPSM2	0.7	6.1	0.37	4.3e-9	Fat distribution (HIV);
SARC	cis	rs2797160	0.651	rs1268067	chr6:126036621	T/C	cg05901451	chr6:126070800	HEY2	0.46	5.52	0.34	8.97e-8	Endometrial cancer;
SARC	cis	rs17384381	1.000	rs12138852	chr1:85878208	C/T	cg16011679	chr1:85725395	C1orf52	0.6	5.63	0.35	5.18e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11574514	1.000	rs74645730	chr16:67749378	G/T	cg01866162	chr16:67596514	CTCF	1.13	6.68	0.4	1.7e-10	Crohn's disease;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg08479976	chr1:90286333	LRRC8D	0.54	6.87	0.41	5.8200000000000003e-11	Breast cancer;
SARC	cis	rs6831352	0.918	rs29001211	chr4:100051941	C/T	cg13256891	chr4:100009986	ADH5	-0.65	-8.09	-0.47	3.18e-14	Alcohol dependence;
SARC	cis	rs1062177	1.000	rs892006	chr5:151180890	G/T	cg00977110	chr5:151150581	G3BP1	0.57	5.67	0.35	4.24e-8	Preschool internalizing problems;
SARC	cis	rs933688	0.532	rs28637141	chr5:90538743	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.43	-4.8	-0.3	2.81e-6	Smoking behavior;
SARC	cis	rs35306767	0.623	rs36062650	chr10:1142571	T/C	cg18964960	chr10:1102726	WDR37	0.54	5.53	0.34	8.58e-8	Eosinophil percentage of granulocytes;
SARC	cis	rs7633770	0.931	rs12637421	chr3:46695074	T/C	cg11219411	chr3:46661640	NA	0.4	6.29	0.38	1.59e-9	Coronary artery disease;
SARC	cis	rs2832191	0.671	rs2832213	chr21:30512914	A/G	cg08807101	chr21:30365312	RNF160	-0.7	-8.59	-0.49	1.29e-15	Dental caries;
SARC	cis	rs3126085	0.935	rs991231	chr1:152211898	T/G	cg03465714	chr1:152285911	FLG	0.49	5.78	0.35	2.41e-8	Atopic dermatitis;
SARC	cis	rs9911578	0.967	rs4598970	chr17:57076893	T/A	cg12560992	chr17:57184187	TRIM37	-0.86	-11.9	-0.61	7.75e-26	Intelligence (multi-trait analysis);
SARC	cis	rs2197308	0.765	rs11182434	chr12:37923968	C/A	cg13010199	chr12:38710504	ALG10B	0.8	11.02	0.59	5.3e-23	Morning vs. evening chronotype;
SARC	cis	rs3820928	0.904	rs10933161	chr2:227764872	A/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-6.55	-0.39	3.67e-10	Pulmonary function;
SARC	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg00149659	chr3:10157352	C3orf10	0.6	5.45	0.34	1.27e-7	Alzheimer's disease;
SARC	cis	rs55962025	0.587	rs2857935	chr4:3075691	G/C	cg06533319	chr4:3265114	C4orf44	0.37	5.45	0.34	1.28e-7	Parental longevity (mother's age at death);
SARC	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg22535103	chr8:58192502	C8orf71	-0.8	-9.15	-0.51	2.94e-17	Developmental language disorder (linguistic errors);
SARC	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg14829155	chr15:31115871	NA	-0.49	-6.29	-0.38	1.59e-9	Huntington's disease progression;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg08417804	chr9:133588801	ABL1	0.54	6.89	0.41	5.06e-11	Breast cancer;
SARC	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6912958	0.514	rs1980792	chr6:87889917	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.75	-11.58	-0.6	8.82e-25	Monocyte percentage of white cells;
SARC	cis	rs13202913	0.733	rs13215869	chr6:151803659	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.65	5.59	0.34	6.36e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs709400	0.659	rs7160366	chr14:103944137	C/T	cg26031613	chr14:104095156	KLC1	0.83	11.96	0.62	5.03e-26	Body mass index;
SARC	cis	rs7264396	0.623	rs78949029	chr20:34384964	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-6.05	-0.37	5.6e-9	Total cholesterol levels;
SARC	cis	rs3733585	0.673	rs4235348	chr4:9951968	T/C	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.94	-0.36	1.06e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs4132509	0.516	rs10927031	chr1:243685760	G/C	cg21452805	chr1:244014465	NA	0.52	5.42	0.33	1.52e-7	RR interval (heart rate);
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00736283	chr19:14247601	ASF1B	-0.58	-7.11	-0.42	1.43e-11	Fibrinogen levels;
SARC	cis	rs9341808	0.754	rs3805907	chr6:80973665	A/G	cg08355045	chr6:80787529	NA	-0.34	-5.58	-0.34	6.74e-8	Sitting height ratio;
SARC	trans	rs10085978	0.604	rs10087298	chr8:143235004	A/G	cg12891252	chr10:43902500	HNRNPF	0.53	6.44	0.39	6.65e-10	Mosquito bite size;
SARC	trans	rs6076960	0.684	rs3844461	chr20:6253115	G/A	cg21095983	chr6:86352623	SYNCRIP	0.47	6.76	0.4	1.07e-10	Smooth-surface caries;
SARC	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg22618164	chr12:122356400	WDR66	0.42	6.7	0.4	1.55e-10	Mean corpuscular volume;
SARC	cis	rs17401966	0.838	rs946503	chr1:10308631	C/G	cg15208524	chr1:10270712	KIF1B	-0.44	-5.12	-0.32	6.34e-7	Hepatocellular carcinoma;
SARC	cis	rs35110281	0.626	rs162368	chr21:44934767	G/A	cg01579765	chr21:45077557	HSF2BP	-0.3	-5.16	-0.32	5.17e-7	Mean corpuscular volume;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg09690219	chr13:37396509	RFXAP	0.46	6.43	0.39	6.98e-10	Thyroid stimulating hormone;
SARC	cis	rs6772849	1.000	rs6798431	chr3:128303373	C/T	cg08795948	chr3:128337044	NA	0.38	4.98	0.31	1.27e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs1784581	1.000	rs1615717	chr6:162400612	C/T	cg17173639	chr6:162384350	PARK2	-0.8	-11.03	-0.59	4.95e-23	Itch intensity from mosquito bite;
SARC	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg16606324	chr3:10149918	C3orf24	0.49	5.04	0.31	9.35e-7	Alzheimer's disease;
SARC	cis	rs6061231	1.000	rs13043313	chr20:60958269	A/G	cg24112000	chr20:60950667	NA	-0.38	-5.99	-0.37	7.88e-9	Colorectal cancer;
SARC	cis	rs9303401	0.659	rs16943326	chr17:57050365	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	11.42	0.6	2.79e-24	Cognitive test performance;
SARC	cis	rs5769765	0.646	rs9627789	chr22:50300562	A/G	cg03033257	chr22:50311977	ALG12;CRELD2	0.51	4.87	0.3	2.04e-6	Schizophrenia;
SARC	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-10.55	-0.57	1.63e-21	Intelligence (multi-trait analysis);
SARC	cis	rs9902453	0.904	rs12948898	chr17:28410324	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.56	-7.3	-0.43	4.39e-12	Coffee consumption (cups per day);
SARC	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.85	9.32	0.52	9.01e-18	Alzheimer's disease;
SARC	cis	rs75804782	0.641	rs77448526	chr2:239353487	A/C	cg21699342	chr2:239360505	ASB1	-0.58	-4.79	-0.3	2.96e-6	Morning vs. evening chronotype;Chronotype;
SARC	cis	rs155076	1.000	rs58519241	chr13:21845006	C/A	cg25811766	chr13:21894605	NA	-0.51	-5.5	-0.34	9.92e-8	White matter hyperintensity burden;
SARC	cis	rs9815354	0.812	rs73077360	chr3:41850054	C/T	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg08859206	chr1:53392774	SCP2	-0.41	-5.83	-0.36	1.82e-8	Monocyte count;
SARC	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg11890956	chr21:40555474	PSMG1	1.16	19.69	0.79	1.79e-51	Cognitive function;
SARC	cis	rs9814567	0.896	rs7653807	chr3:134345724	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.5	-6.36	-0.38	1.03e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg13206674	chr6:150067644	NUP43	0.44	5.69	0.35	3.84e-8	Lung cancer;
SARC	cis	rs3847687	1.000	rs11061291	chr12:131518875	C/T	cg25772418	chr12:131519998	GPR133	-0.31	-4.88	-0.3	1.95e-6	Longevity;
SARC	cis	rs6088580	0.634	rs6059897	chr20:33113224	A/G	cg08999081	chr20:33150536	PIGU	0.43	6.69	0.4	1.68e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs2204008	0.677	rs1581356	chr12:38391467	T/C	cg26384229	chr12:38710491	ALG10B	0.89	12.52	0.63	7.92e-28	Bladder cancer;
SARC	cis	rs372883	0.507	rs8132992	chr21:30750561	T/C	cg24692254	chr21:30365293	RNF160	0.54	6.71	0.4	1.47e-10	Pancreatic cancer;
SARC	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg11168104	chr5:1857477	NA	-0.34	-4.79	-0.3	2.96e-6	Cardiovascular disease risk factors;
SARC	cis	rs7178572	0.568	rs7177533	chr15:77387923	C/T	cg22256960	chr15:77711686	NA	-0.51	-5.36	-0.33	1.99e-7	Type 2 diabetes;
SARC	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg12463550	chr7:65579703	CRCP	-0.69	-5.23	-0.32	3.73e-7	Diabetic kidney disease;
SARC	trans	rs6810798	0.672	rs4399964	chr4:148084305	C/T	cg17278401	chr5:66462662	MAST4	-0.44	-6.38	-0.39	9.44e-10	Coronary artery disease;
SARC	cis	rs16937	0.597	rs3862949	chr1:205103070	A/T	cg21643547	chr1:205240462	TMCC2	-0.45	-5.56	-0.34	7.32e-8	Schizophrenia;
SARC	cis	rs2236918	0.643	rs3121389	chr1:242020264	C/T	cg17736920	chr1:242011382	EXO1	0.65	8.96	0.51	1.08e-16	Menopause (age at onset);
SARC	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg03351412	chr1:154909251	PMVK	0.64	8.15	0.47	2.17e-14	Prostate cancer;
SARC	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg24829409	chr8:58192753	C8orf71	-0.68	-6.28	-0.38	1.63e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg13395646	chr4:1353034	KIAA1530	-0.47	-5.64	-0.35	4.87e-8	Obesity-related traits;
SARC	cis	rs2180341	1.000	rs6569486	chr6:127708424	A/C	cg27446573	chr6:127587934	RNF146	1.06	14.34	0.68	7.2e-34	Breast cancer;
SARC	cis	rs6545883	0.929	rs3821222	chr2:61713526	C/G	cg15711740	chr2:61764176	XPO1	-0.44	-5.28	-0.33	2.89e-7	Tuberculosis;
SARC	cis	rs2180341	0.680	rs9388554	chr6:127576234	C/G	cg27446573	chr6:127587934	RNF146	0.89	12.75	0.64	1.4e-28	Breast cancer;
SARC	cis	rs1941023	0.606	rs3825020	chr11:60184191	G/A	cg08716584	chr11:60157161	MS4A7	-0.32	-5.12	-0.32	6.29e-7	Congenital heart disease (maternal effect);
SARC	cis	rs17253792	0.822	rs17683656	chr14:56053361	C/T	cg01858014	chr14:56050164	KTN1	0.71	5.03	0.31	1e-6	Putamen volume;
SARC	cis	rs9309473	0.519	rs12618600	chr2:73890682	T/C	cg20560298	chr2:73613845	ALMS1	0.52	7.14	0.42	1.21e-11	Metabolite levels;
SARC	cis	rs8180040	0.903	rs12487736	chr3:47459679	C/T	cg27129171	chr3:47204927	SETD2	0.66	9.05	0.51	5.92e-17	Colorectal cancer;
SARC	cis	rs4975709	0.569	rs931509	chr5:1858821	A/T	cg12288994	chr5:1860383	NA	0.41	6.53	0.39	4.03e-10	Cardiovascular disease risk factors;
SARC	cis	rs7927592	0.546	rs683978	chr11:68192421	T/C	cg01657329	chr11:68192670	LRP5	-0.41	-5.5	-0.34	9.88e-8	Total body bone mineral density;
SARC	cis	rs2153535	0.580	rs6902001	chr6:8477055	T/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs523522	0.962	rs687873	chr12:121019634	G/A	cg12219531	chr12:120966889	COQ5	0.82	11.01	0.59	5.52e-23	High light scatter reticulocyte count;
SARC	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg15049968	chr18:44337910	ST8SIA5	-0.39	-6.27	-0.38	1.74e-9	Personality dimensions;
SARC	cis	rs1348850	0.598	rs1405717	chr2:178500101	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.51	5.89	0.36	1.35e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7666738	0.581	rs34205844	chr4:98887494	C/A	cg05340658	chr4:99064831	C4orf37	0.65	8.56	0.49	1.59e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4780401	0.728	rs8191288	chr16:11765614	G/A	cg01061890	chr16:11836724	TXNDC11	-0.44	-5.53	-0.34	8.59e-8	Rheumatoid arthritis;
SARC	cis	rs559928	0.606	rs11231726	chr11:63987339	C/T	cg05555928	chr11:63887634	MACROD1	-0.48	-4.72	-0.3	4.1e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs11785400	1.000	rs3735994	chr8:143742683	C/T	cg10596483	chr8:143751796	JRK	0.64	8.65	0.49	8.4e-16	Schizophrenia;
SARC	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9916302	0.706	rs6503521	chr17:37715551	A/C	cg07936489	chr17:37558343	FBXL20	0.72	7.82	0.46	1.84e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs7666738	0.962	rs2865986	chr4:99067907	A/G	cg05340658	chr4:99064831	C4orf37	0.56	6.81	0.41	8.11e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.66	-7.0	-0.42	2.67e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9486719	1.000	rs12208124	chr6:97027942	C/T	cg06623918	chr6:96969491	KIAA0776	-0.79	-8.83	-0.5	2.51e-16	Migraine;Coronary artery disease;
SARC	cis	rs17030434	0.871	rs78151744	chr4:154730266	C/T	cg14289246	chr4:154710475	SFRP2	-0.6	-6.85	-0.41	6.65e-11	Electrocardiographic conduction measures;
SARC	cis	rs1395	0.813	rs11685326	chr2:27453679	A/G	cg21747090	chr2:27597821	SNX17	-0.48	-5.78	-0.35	2.43e-8	Blood metabolite levels;
SARC	cis	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg24110177	chr3:50126178	RBM5	-0.42	-5.28	-0.33	3.02e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7615952	0.608	rs35668111	chr3:125544635	C/T	cg05084668	chr3:125655381	ALG1L	-0.49	-5.17	-0.32	5.02e-7	Blood pressure (smoking interaction);
SARC	cis	rs3817198	0.927	rs112907808	chr11:1907610	T/C	cg23636072	chr11:1216443	NA	0.4	5.37	0.33	1.95e-7	Breast cancer;Mammographic density (dense area);
SARC	cis	rs763121	0.853	rs2413546	chr22:39107001	G/A	cg21395723	chr22:39101663	GTPBP1	0.54	6.08	0.37	4.86e-9	Menopause (age at onset);
SARC	cis	rs11578119	0.933	rs12116910	chr1:170465981	A/T	cg09767346	chr1:170501363	GORAB	0.44	5.15	0.32	5.49e-7	Male-pattern baldness;
SARC	cis	rs2153535	0.541	rs9405386	chr6:8458067	C/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.04e-14	Motion sickness;
SARC	cis	rs9916302	0.904	rs8076546	chr17:37555403	G/A	cg07936489	chr17:37558343	FBXL20	0.67	8.85	0.5	2.27e-16	Glomerular filtration rate (creatinine);
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg24071500	chr4:114683176	CAMK2D	0.49	6.36	0.38	1.03e-9	Lung adenocarcinoma;
SARC	cis	rs11098499	0.754	rs10212714	chr4:120254302	T/C	cg09307838	chr4:120376055	NA	0.79	10.17	0.55	2.43e-20	Corneal astigmatism;
SARC	cis	rs2303759	0.709	rs10422677	chr19:49824290	C/T	cg22590775	chr19:49891494	CCDC155	0.48	5.33	0.33	2.37e-7	Multiple sclerosis;
SARC	cis	rs11098499	0.738	rs72918577	chr4:120326701	G/A	cg09307838	chr4:120376055	NA	0.92	13.13	0.65	7.44e-30	Corneal astigmatism;
SARC	cis	rs9807989	0.839	rs4851565	chr2:102971481	C/A	cg09003973	chr2:102972529	NA	0.41	5.6	0.34	6.11e-8	Asthma;
SARC	cis	rs9910055	0.529	rs425038	chr17:42182028	T/C	cg19774624	chr17:42201019	HDAC5	0.54	6.54	0.39	3.75e-10	Total body bone mineral density;
SARC	cis	rs11690462	0.963	rs12471804	chr2:26559717	C/G	cg26119090	chr2:26468346	HADHA;HADHB	0.42	5.35	0.33	2.13e-7	Coronary artery disease;
SARC	cis	rs1983891	0.673	rs9369296	chr6:41570251	A/G	cg15051332	chr6:41514432	FOXP4	0.51	5.62	0.35	5.41e-8	Prostate cancer;
SARC	cis	rs2635047	0.967	rs2684820	chr18:44664304	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.53	7.16	0.42	1.04e-11	Educational attainment;
SARC	cis	rs1983891	0.954	rs4714481	chr6:41521110	T/C	cg15051332	chr6:41514432	FOXP4	0.57	6.21	0.38	2.36e-9	Prostate cancer;
SARC	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg21354621	chr12:46384284	SFRS2IP	0.59	6.29	0.38	1.58e-9	Bilirubin levels;
SARC	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9914988	0.943	rs4795465	chr17:27151498	A/G	cg20469991	chr17:27169893	C17orf63	0.51	5.43	0.34	1.39e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg14895029	chr7:2775587	GNA12	-0.38	-5.0	-0.31	1.12e-6	Height;
SARC	cis	rs372883	0.600	rs2832298	chr21:30743863	C/G	cg08807101	chr21:30365312	RNF160	0.54	7.02	0.42	2.34e-11	Pancreatic cancer;
SARC	cis	rs10982256	0.817	rs10817632	chr9:117270853	T/C	cg21159778	chr9:117266918	DFNB31	0.4	5.65	0.35	4.54e-8	Bipolar disorder;
SARC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg12419862	chr22:24373484	LOC391322	-0.75	-9.19	-0.52	2.23e-17	Liver enzyme levels (gamma-glutamyl transferase);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg16519495	chr1:225782482	ENAH	0.44	6.24	0.38	2e-9	Thyroid stimulating hormone;
SARC	cis	rs611744	0.967	rs681099	chr8:109218892	T/C	cg21045802	chr8:109455806	TTC35	0.46	5.44	0.34	1.34e-7	Dupuytren's disease;
SARC	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.5	5.96	0.36	9.48e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	trans	rs208515	0.525	rs12193034	chr6:66677866	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.99	11.54	0.6	1.13e-24	Exhaled nitric oxide levels;
SARC	cis	rs2073300	0.609	rs77673953	chr20:23398794	G/C	cg12062639	chr20:23401060	NAPB	1.03	7.0	0.42	2.64e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg08859206	chr1:53392774	SCP2	-0.41	-5.96	-0.36	9.14e-9	Monocyte count;
SARC	cis	rs8014131	0.689	rs6574825	chr14:85979157	T/C	cg10406690	chr14:85995726	FLRT2	0.4	5.18	0.32	4.69e-7	Menarche (age at onset);
SARC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg11494091	chr17:61959527	GH2	0.55	8.31	0.48	7.99e-15	Prudent dietary pattern;
SARC	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.42	-6.36	-0.38	1.04e-9	Total body bone mineral density;
SARC	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.43	5.39	0.33	1.72e-7	Lymphocyte counts;
SARC	cis	rs11668609	0.505	rs115387740	chr19:24062507	A/G	cg27517351	chr19:23941871	ZNF681	-0.56	-4.77	-0.3	3.22e-6	Response to taxane treatment (docetaxel);
SARC	cis	rs883565	0.569	rs784514	chr3:39164622	A/G	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.44	-5.12	-0.32	6.37e-7	Handedness;
SARC	cis	rs79349575	0.685	rs1124829	chr17:46967797	C/A	cg16584676	chr17:46985605	UBE2Z	0.54	6.45	0.39	6.25e-10	Type 2 diabetes;
SARC	cis	rs10911232	0.507	rs12037585	chr1:183000041	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.67	0.57	6.63e-22	Hypertriglyceridemia;
SARC	cis	rs2479724	0.935	rs1887718	chr6:41857691	C/T	cg17623882	chr6:41773611	USP49	-0.45	-5.56	-0.34	7.42e-8	Menarche (age at onset);
SARC	cis	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg25427524	chr10:38739819	LOC399744	-0.53	-8.46	-0.48	2.95e-15	Extrinsic epigenetic age acceleration;
SARC	cis	rs4481887	0.636	rs10788761	chr1:248410663	C/T	cg13385794	chr1:248469461	NA	0.38	5.19	0.32	4.48e-7	Common traits (Other);
SARC	cis	rs11252926	0.801	rs11252332	chr10:467318	A/T	cg08603382	chr10:743973	NA	0.42	5.24	0.32	3.6e-7	Psychosis in Alzheimer's disease;
SARC	cis	rs2204008	0.805	rs7296063	chr12:37964775	T/G	cg13010199	chr12:38710504	ALG10B	0.79	11.0	0.58	6.02e-23	Bladder cancer;
SARC	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg24549020	chr5:56110836	MAP3K1	0.83	8.56	0.49	1.54e-15	Type 2 diabetes;
SARC	cis	rs9462027	0.628	rs7756405	chr6:34722659	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.81	-0.36	2.03e-8	Systemic lupus erythematosus;
SARC	cis	rs10782582	0.593	rs11163915	chr1:76130199	C/T	cg10523679	chr1:76189770	ACADM	-0.43	-5.28	-0.33	2.91e-7	Daytime sleep phenotypes;
SARC	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.76	9.64	0.53	9.91e-19	Height;
SARC	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.82	-11.5	-0.6	1.59e-24	Chronic sinus infection;
SARC	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg02725872	chr8:58115012	NA	-0.36	-5.47	-0.34	1.16e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs796364	1.000	rs1704186	chr2:200769539	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.73	6.76	0.4	1.12e-10	Schizophrenia;
SARC	trans	rs7937682	0.924	rs1784782	chr11:111525764	A/C	cg18187862	chr3:45730750	SACM1L	0.55	6.96	0.41	3.46e-11	Primary sclerosing cholangitis;
SARC	cis	rs2075371	0.829	rs11770521	chr7:133936251	A/C	cg20476274	chr7:133979776	SLC35B4	0.55	6.93	0.41	4.18e-11	Mean platelet volume;
SARC	cis	rs7587476	0.601	rs13021937	chr2:215673937	C/T	cg04530015	chr2:215796436	ABCA12	0.45	7.45	0.44	1.84e-12	Neuroblastoma;
SARC	cis	rs10463554	0.963	rs40322	chr5:102446957	A/G	cg23492399	chr5:102201601	PAM	-0.47	-5.19	-0.32	4.6e-7	Parkinson's disease;
SARC	cis	rs360798	0.553	rs11682530	chr2:63073194	C/T	cg17519650	chr2:63277830	OTX1	-0.42	-5.33	-0.33	2.34e-7	Coronary artery disease;
SARC	cis	rs7589342	0.929	rs6725519	chr2:106445209	A/G	cg16077055	chr2:106428750	NCK2	-0.39	-7.28	-0.43	5.16e-12	Addiction;
SARC	cis	rs1348850	0.918	rs12463893	chr2:178448559	G/T	cg23306229	chr2:178417860	TTC30B	0.58	6.96	0.41	3.42e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1580019	0.587	rs6968990	chr7:32552159	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.96	-16.58	-0.74	2.63e-41	Cognitive ability;
SARC	cis	rs2120243	0.598	rs1500916	chr3:157088042	C/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.4	5.01	0.31	1.07e-6	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg20965017	chr5:231967	SDHA	-0.55	-5.26	-0.33	3.23e-7	Breast cancer;
SARC	cis	rs72781680	0.898	rs72798064	chr2:23982832	T/C	cg08917208	chr2:24149416	ATAD2B	0.76	7.16	0.42	1.08e-11	Lymphocyte counts;
SARC	cis	rs12594515	1.000	rs11070464	chr15:45984776	C/A	cg14863074	chr15:45997064	NA	0.34	5.18	0.32	4.74e-7	Waist circumference;Weight;
SARC	cis	rs7666738	0.785	rs11097614	chr4:99092175	G/C	cg05340658	chr4:99064831	C4orf37	0.45	4.96	0.31	1.37e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9300255	0.739	rs11057210	chr12:123733799	A/G	cg05973401	chr12:123451056	ABCB9	0.47	5.18	0.32	4.77e-7	Neutrophil percentage of white cells;
SARC	cis	rs4642101	0.694	rs12631514	chr3:12838293	G/C	cg24848339	chr3:12840334	CAND2	0.36	5.67	0.35	4.19e-8	QRS complex (12-leadsum);
SARC	cis	rs6840360	0.571	rs11931934	chr4:152552082	A/G	cg22705602	chr4:152727874	NA	-0.43	-6.69	-0.4	1.66e-10	Intelligence (multi-trait analysis);
SARC	cis	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg00409905	chr10:38381863	ZNF37A	-0.55	-7.89	-0.46	1.19e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.76	10.88	0.58	1.52e-22	Personality dimensions;
SARC	cis	rs67460515	0.563	rs11922959	chr3:160828871	A/G	cg03342759	chr3:160939853	NMD3	-0.63	-7.65	-0.45	5.18e-13	Parkinson's disease;
SARC	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg16049864	chr8:95962084	TP53INP1	0.47	7.48	0.44	1.48e-12	Type 2 diabetes;
SARC	cis	rs1395	0.922	rs13404446	chr2:27519254	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.34	-5.13	-0.32	6e-7	Blood metabolite levels;
SARC	cis	rs4891159	0.548	rs617823	chr18:74120233	A/G	cg24786174	chr18:74118243	ZNF516	0.76	12.81	0.64	8.31e-29	Longevity;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg03121168	chr20:61558123	DIDO1	0.47	6.23	0.38	2.12e-9	Chemerin levels;
SARC	cis	rs2070433	0.615	rs2073379	chr21:47863025	C/T	cg12379764	chr21:47803548	PCNT	0.6	5.28	0.33	2.91e-7	Lymphocyte counts;
SARC	trans	rs2727020	0.823	rs7102374	chr11:49261795	G/A	cg03929089	chr4:120376271	NA	0.75	9.85	0.54	2.38e-19	Coronary artery disease;
SARC	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg16479474	chr6:28041457	NA	0.36	5.45	0.34	1.25e-7	Depression;
SARC	cis	rs3768617	0.510	rs4651139	chr1:183091963	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.68	10.11	0.55	3.67e-20	Fuchs's corneal dystrophy;
SARC	cis	rs941408	0.928	rs2260414	chr19:2796316	G/A	cg06609049	chr19:2785107	THOP1	0.75	9.52	0.53	2.37e-18	Total cholesterol levels;
SARC	cis	rs7582720	1.000	rs72936842	chr2:203773686	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.31	0.43	4.24e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs2204008	0.805	rs11180825	chr12:38242916	G/T	cg13010199	chr12:38710504	ALG10B	0.81	11.31	0.6	6.33e-24	Bladder cancer;
SARC	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg19748678	chr4:122722346	EXOSC9	0.79	10.21	0.56	1.85e-20	Type 2 diabetes;
SARC	trans	rs2727020	0.595	rs11040416	chr11:49566429	C/T	cg15704280	chr7:45808275	SEPT13	-0.86	-14.37	-0.69	6.01e-34	Coronary artery disease;
SARC	trans	rs61931739	0.500	rs12809868	chr12:34464905	C/T	cg13010199	chr12:38710504	ALG10B	0.81	11.23	0.59	1.12e-23	Morning vs. evening chronotype;
SARC	cis	rs9291683	0.546	rs13129453	chr4:10044784	T/C	cg00071950	chr4:10020882	SLC2A9	0.33	4.98	0.31	1.26e-6	Bone mineral density;
SARC	cis	rs11880706	0.667	rs10425506	chr19:6110911	G/T	cg18109231	chr19:6110877	RFX2	0.86	5.3	0.33	2.72e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg26039829	chr8:22132926	PIWIL2	0.48	6.79	0.41	9.09e-11	Hypertriglyceridemia;
SARC	cis	rs10751667	1.000	rs7927156	chr11:970607	A/G	cg06064525	chr11:970664	AP2A2	-0.22	-4.74	-0.3	3.69e-6	Alzheimer's disease (late onset);
SARC	cis	rs4268898	0.722	rs11680491	chr2:24416292	T/A	cg26838691	chr2:24397539	C2orf84	0.4	5.38	0.33	1.79e-7	Asthma;
SARC	cis	rs7149242	0.796	rs12588718	chr14:101149605	G/C	cg18089426	chr14:101175970	NA	-0.34	-4.75	-0.3	3.52e-6	Platelet count;
SARC	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg00450029	chr8:599525	NA	0.6	4.97	0.31	1.31e-6	IgG glycosylation;
SARC	cis	rs12973672	1.000	rs34832786	chr19:35769518	T/C	cg12095397	chr19:35769544	USF2	0.38	4.79	0.3	2.9e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs66573146	0.572	rs55740475	chr4:6954092	C/G	cg26116260	chr4:7069785	GRPEL1	-0.68	-5.05	-0.31	8.76e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs7772486	0.686	rs9386131	chr6:146121608	G/A	cg23711669	chr6:146136114	FBXO30	0.79	12.69	0.64	2.16e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9815354	0.767	rs73077390	chr3:41860255	T/C	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2180341	0.889	rs9321074	chr6:127618019	G/A	cg17762328	chr6:126965162	NA	-0.46	-5.24	-0.32	3.55e-7	Breast cancer;
SARC	cis	rs10046574	1.000	rs10046574	chr7:135170470	C/T	cg27474649	chr7:135195673	CNOT4	0.87	7.13	0.42	1.27e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs2239547	0.657	rs7638524	chr3:52874861	G/A	cg18404041	chr3:52824283	ITIH1	-0.42	-5.26	-0.33	3.31e-7	Schizophrenia;
SARC	cis	rs6570726	0.738	rs7746330	chr6:145899257	A/C	cg23711669	chr6:146136114	FBXO30	0.89	14.72	0.69	3.93e-35	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg26513180	chr16:89883248	FANCA	0.72	4.81	0.3	2.66e-6	Skin colour saturation;
SARC	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg20891283	chr12:69753455	YEATS4	0.66	9.45	0.53	3.79e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg09699651	chr6:150184138	LRP11	0.4	4.93	0.31	1.58e-6	Lung cancer;
SARC	cis	rs13401104	0.716	rs6750934	chr2:237125551	G/C	cg19324714	chr2:237145437	ASB18	0.54	5.48	0.34	1.09e-7	Educational attainment;
SARC	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg05025164	chr4:1340916	KIAA1530	0.62	7.69	0.45	4.05e-13	Longevity;
SARC	trans	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg16273366	chr3:25426563	NA	0.61	6.36	0.38	1.07e-9	Cutaneous psoriasis;
SARC	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg24060327	chr5:131705240	SLC22A5	-0.72	-8.75	-0.5	4.31e-16	Breast cancer;
SARC	cis	rs6714710	0.603	rs17489984	chr2:98421364	A/G	cg26665480	chr2:98280029	ACTR1B	0.49	6.59	0.4	2.96e-10	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs3126085	0.935	rs3126048	chr1:152260165	T/C	cg26876637	chr1:152193138	HRNR	-0.47	-5.44	-0.34	1.36e-7	Atopic dermatitis;
SARC	cis	rs9611519	0.732	rs1883826	chr22:41703428	G/A	cg17376030	chr22:41985996	PMM1	0.58	7.18	0.43	9.3e-12	Neuroticism;
SARC	cis	rs3126085	0.877	rs1552992	chr1:152171625	C/G	cg26876637	chr1:152193138	HRNR	0.47	5.33	0.33	2.33e-7	Atopic dermatitis;
SARC	trans	rs9929218	0.817	rs3114404	chr16:68722096	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.7	-9.05	-0.51	5.91e-17	Colorectal cancer;
SARC	cis	rs1008375	1.000	rs7671752	chr4:17661398	C/T	cg27347728	chr4:17578864	LAP3	0.43	5.36	0.33	1.98e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs3768617	1.000	rs3768617	chr1:183092500	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.56	7.3	0.43	4.63e-12	Fuchs's corneal dystrophy;
SARC	cis	rs7208859	0.778	rs6505219	chr17:29265621	A/C	cg13385521	chr17:29058706	SUZ12P	0.61	6.01	0.37	7.07e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs4713118	0.868	rs9468220	chr6:27732976	A/G	cg17221315	chr6:27791827	HIST1H4J	-0.53	-5.59	-0.34	6.42e-8	Parkinson's disease;
SARC	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg01570182	chr17:44337453	NA	0.85	9.67	0.54	8.2e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs2072499	0.750	rs57056972	chr1:156159064	C/A	cg25208724	chr1:156163844	SLC25A44	0.86	9.9	0.54	1.67e-19	Testicular germ cell tumor;
SARC	cis	rs1864400	0.690	rs2565200	chr10:43622933	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.4	-4.8	-0.3	2.84e-6	Hirschsprung disease;
SARC	cis	rs59918340	0.764	rs2304282	chr8:142229543	A/G	cg16341495	chr8:142228727	SLC45A4	-0.36	-5.06	-0.31	8.63e-7	Immature fraction of reticulocytes;
SARC	cis	rs6831352	0.918	rs17218162	chr4:100056060	G/A	cg12011299	chr4:100065546	ADH4	-0.34	-5.74	-0.35	3e-8	Alcohol dependence;
SARC	cis	rs12291225	0.585	rs11023197	chr11:14380998	G/A	cg19336497	chr11:14380999	RRAS2	-0.46	-8.14	-0.47	2.32e-14	Sense of smell;
SARC	cis	rs3733585	0.673	rs7434391	chr4:9967682	C/G	cg11266682	chr4:10021025	SLC2A9	-0.37	-6.48	-0.39	5.28e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg22535103	chr8:58192502	C8orf71	-0.6	-6.15	-0.37	3.42e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7654585	0.962	rs2309289	chr4:25947094	T/A	cg10409131	chr4:25915609	C4orf52	0.5	6.17	0.37	3.04e-9	Obesity-related traits;
SARC	cis	rs17253792	0.822	rs77197405	chr14:56159662	T/A	cg01858014	chr14:56050164	KTN1	-0.62	-4.78	-0.3	3.12e-6	Putamen volume;
SARC	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg11764359	chr7:65958608	NA	0.79	9.88	0.54	1.93e-19	Aortic root size;
SARC	cis	rs12971120	0.891	rs3794953	chr18:72180519	C/T	cg25817165	chr18:72167213	CNDP2	-0.51	-6.95	-0.41	3.72e-11	Refractive error;
SARC	cis	rs10782582	0.609	rs1630302	chr1:76412090	A/T	cg03433033	chr1:76189801	ACADM	-0.42	-5.37	-0.33	1.94e-7	Daytime sleep phenotypes;
SARC	cis	rs9814567	0.752	rs4318591	chr3:134328333	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.51	-6.61	-0.4	2.53e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs6456156	0.774	rs1012657	chr6:167525142	A/C	cg07741184	chr6:167504864	NA	-0.29	-5.42	-0.33	1.52e-7	Primary biliary cholangitis;
SARC	cis	rs2191566	0.960	rs12232810	chr19:44525122	A/G	cg20607764	chr19:44506953	ZNF230	-0.49	-5.66	-0.35	4.34e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9393692	0.875	rs2142703	chr6:26289605	A/G	cg05868516	chr6:26286170	HIST1H4H	0.58	7.66	0.45	4.96e-13	Educational attainment;
SARC	cis	rs7264396	0.635	rs6088971	chr20:34535373	A/G	cg12579300	chr20:34535607	PHF20	-0.43	-5.02	-0.31	1.02e-6	Total cholesterol levels;
SARC	cis	rs2204008	0.660	rs2320745	chr12:38239101	T/C	cg13010199	chr12:38710504	ALG10B	0.78	10.36	0.56	6.22e-21	Bladder cancer;
SARC	cis	rs1167827	0.680	rs1167796	chr7:75173180	C/T	cg09988129	chr7:74988866	PMS2L2;STAG3L1	-0.58	-7.05	-0.42	2.07e-11	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs12421382	0.511	rs2212430	chr11:109289538	C/T	cg06719900	chr11:109292894	C11orf87	0.34	4.88	0.3	1.95e-6	Schizophrenia;
SARC	cis	rs5758659	0.652	rs5758553	chr22:42431429	G/A	cg04733989	chr22:42467013	NAGA	0.54	7.13	0.42	1.27e-11	Cognitive function;
SARC	cis	rs9400467	0.506	rs12198788	chr6:111686791	C/G	cg15721981	chr6:111408429	SLC16A10	0.65	5.65	0.35	4.61e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs4561483	0.832	rs171656	chr16:11953167	C/T	cg08843971	chr16:11963173	GSPT1	-0.44	-5.55	-0.34	7.85e-8	Testicular germ cell tumor;
SARC	cis	rs6963495	0.818	rs73190200	chr7:105165856	T/C	cg13798780	chr7:105162888	PUS7	0.6	5.56	0.34	7.22e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs6546550	0.901	rs6721891	chr2:70146121	A/G	cg02498382	chr2:70120550	SNRNP27	-0.32	-5.22	-0.32	3.9e-7	Prevalent atrial fibrillation;
SARC	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg13628971	chr7:2884303	GNA12	0.48	5.97	0.36	8.63e-9	Height;
SARC	trans	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg00938859	chr5:1591904	SDHAP3	0.79	7.61	0.45	6.69e-13	Breast cancer;
SARC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.37	0.52	6.7e-18	Prudent dietary pattern;
SARC	cis	rs7666738	0.830	rs11935078	chr4:99010476	T/A	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg20932348	chr4:26862197	STIM2	0.59	7.33	0.43	3.73e-12	Breast cancer;
SARC	cis	rs9660992	0.649	rs72745216	chr1:205261016	G/A	cg21545522	chr1:205238299	TMCC2	0.46	6.07	0.37	5.05e-9	Mean corpuscular volume;Mean platelet volume;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg12538597	chr11:85906334	NA	-0.52	-6.63	-0.4	2.35e-10	Height;
SARC	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg17747265	chr1:1875780	NA	-0.33	-4.78	-0.3	3.18e-6	Body mass index;
SARC	cis	rs11608355	1.000	rs11066591	chr12:109880523	G/A	cg05360138	chr12:110035743	NA	0.44	4.96	0.31	1.36e-6	Neuroticism;
SARC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg06873352	chr17:61820015	STRADA	0.53	6.88	0.41	5.34e-11	Prudent dietary pattern;
SARC	cis	rs2077654	0.822	rs1805036	chr11:17434284	G/A	cg25308976	chr11:17434268	ABCC8	0.53	6.52	0.39	4.41e-10	Gout;
SARC	cis	rs9462027	0.651	rs7769820	chr6:34760228	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.85	-0.36	1.63e-8	Systemic lupus erythematosus;
SARC	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg22535103	chr8:58192502	C8orf71	-0.78	-9.12	-0.51	3.63e-17	Developmental language disorder (linguistic errors);
SARC	cis	rs2221894	0.632	rs11785025	chr8:28845999	G/A	cg07962641	chr8:28805897	HMBOX1	-0.46	-5.26	-0.33	3.3e-7	Obesity-related traits;
SARC	cis	rs17253792	0.822	rs75351812	chr14:56082192	G/A	cg01858014	chr14:56050164	KTN1	-0.67	-5.17	-0.32	5.01e-7	Putamen volume;
SARC	cis	rs2908197	0.713	rs2961038	chr7:75952070	G/C	cg24580635	chr7:76178542	LOC100133091	-0.41	-4.77	-0.3	3.23e-6	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs10849605	0.737	rs7300039	chr12:1068178	A/T	cg02055889	chr12:1059459	RAD52	0.44	6.13	0.37	3.81e-9	Lung cancer;
SARC	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg25952890	chr19:58913133	NA	0.36	5.14	0.32	5.74e-7	Uric acid clearance;
SARC	cis	rs10782582	0.609	rs1796827	chr1:76391536	A/T	cg03433033	chr1:76189801	ACADM	-0.4	-5.14	-0.32	5.68e-7	Daytime sleep phenotypes;
SARC	cis	rs734999	0.588	rs2764842	chr1:2529192	A/G	cg20673091	chr1:2541236	MMEL1	-0.33	-5.0	-0.31	1.13e-6	Ulcerative colitis;
SARC	cis	rs427394	0.802	rs274718	chr5:6720988	G/T	cg10857441	chr5:6722123	POLS	-0.33	-5.09	-0.32	7.46e-7	Menopause (age at onset);
SARC	cis	rs2075555	0.679	rs12939159	chr17:48244531	C/G	cg06769994	chr17:48288538	NA	0.53	5.37	0.33	1.94e-7	Breast cancer;
SARC	cis	rs11792861	0.781	rs11793272	chr9:111762102	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.73	8.54	0.49	1.78e-15	Menarche (age at onset);
SARC	cis	rs4481887	1.000	rs10888360	chr1:248479282	G/A	cg00666640	chr1:248458726	OR2T12	0.39	6.55	0.39	3.71e-10	Common traits (Other);
SARC	cis	rs4319547	0.695	rs4758648	chr12:122900460	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.5	-5.98	-0.36	8.44e-9	Body mass index;
SARC	cis	rs644799	0.710	rs1852535	chr11:95501241	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.94	16.24	0.73	3.62e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg09877947	chr5:131593287	PDLIM4	0.42	5.02	0.31	1.04e-6	Blood metabolite levels;
SARC	cis	rs7959452	0.535	rs2305641	chr12:69646914	C/T	cg14784868	chr12:69753453	YEATS4	0.38	4.97	0.31	1.3e-6	Blood protein levels;
SARC	cis	rs4901847	0.967	rs12433260	chr14:58552893	T/C	cg15908186	chr14:58618357	C14orf37	0.45	5.18	0.32	4.8e-7	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg22920501	chr2:26401640	FAM59B	-0.5	-6.32	-0.38	1.3e-9	Gut microbiome composition (summer);
SARC	cis	rs1729951	0.575	rs168635	chr3:136699078	A/G	cg15507776	chr3:136538369	TMEM22	0.5	5.56	0.34	7.32e-8	Neuroticism;
SARC	cis	rs7523050	0.643	rs17621851	chr1:109400835	C/T	cg08274380	chr1:109419600	GPSM2	1.07	8.3	0.48	8.22e-15	Fat distribution (HIV);
SARC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg09373136	chr17:61933544	TCAM1	-0.45	-6.24	-0.38	2.04e-9	Prudent dietary pattern;
SARC	cis	rs7937682	0.632	rs2070894	chr11:111780837	G/A	cg22437258	chr11:111473054	SIK2	-0.49	-5.66	-0.35	4.48e-8	Primary sclerosing cholangitis;
SARC	cis	rs2635047	0.777	rs9944807	chr18:44788908	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.51	6.49	0.39	5.11e-10	Educational attainment;
SARC	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.56	-0.39	3.45e-10	Menopause (age at onset);
SARC	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg23982607	chr1:1823379	GNB1	-0.64	-10.65	-0.57	7.88e-22	Body mass index;
SARC	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg22920501	chr2:26401640	FAM59B	-0.42	-5.7	-0.35	3.55e-8	Gut microbiome composition (summer);
SARC	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2652834	1.000	rs8032104	chr15:63400584	A/G	cg05507819	chr15:63340323	TPM1	0.54	5.37	0.33	1.94e-7	HDL cholesterol;
SARC	cis	rs12142240	0.659	rs67547686	chr1:46832229	G/C	cg10495392	chr1:46806563	NSUN4	0.64	6.83	0.41	7.39e-11	Menopause (age at onset);
SARC	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2213920	0.679	rs6415819	chr9:118212492	A/C	cg13918206	chr9:118159781	DEC1	0.79	6.33	0.38	1.24e-9	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg11890956	chr21:40555474	PSMG1	-1.15	-19.52	-0.79	6.1e-51	Cognitive function;
SARC	cis	rs709400	0.663	rs2273703	chr14:103918029	C/G	cg26031613	chr14:104095156	KLC1	0.84	12.44	0.63	1.35e-27	Body mass index;
SARC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg02725872	chr8:58115012	NA	-0.37	-6.47	-0.39	5.76e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9300255	0.506	rs11057251	chr12:123791227	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.4	5.38	0.33	1.82e-7	Neutrophil percentage of white cells;
SARC	cis	rs782590	0.837	rs782584	chr2:55921116	C/G	cg18811423	chr2:55921094	PNPT1	-0.8	-12.93	-0.65	3.57e-29	Metabolic syndrome;
SARC	cis	rs754466	0.580	rs10824575	chr10:79549047	A/G	cg17075019	chr10:79541650	NA	-0.84	-13.29	-0.66	2.26e-30	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6831352	0.842	rs1230156	chr4:99989626	C/T	cg13256891	chr4:100009986	ADH5	0.66	8.44	0.48	3.38e-15	Alcohol dependence;
SARC	cis	rs910316	0.726	rs175040	chr14:75469555	A/G	cg11812906	chr14:75593930	NEK9	-0.79	-11.12	-0.59	2.62e-23	Height;
SARC	cis	rs1480597	1.000	rs11591579	chr10:45203117	C/G	cg23694080	chr10:45486418	RASSF4	-0.45	-4.73	-0.3	3.88e-6	Parkinson's disease;
SARC	cis	rs1691799	0.867	rs1183274	chr12:66732057	C/G	cg16791601	chr12:66731901	HELB	-0.72	-10.65	-0.57	7.69e-22	White blood cell count (basophil);
SARC	cis	rs12824058	0.767	rs4759654	chr12:130815559	A/G	cg24838063	chr12:130822603	PIWIL1	0.64	9.26	0.52	1.42e-17	Menopause (age at onset);
SARC	cis	rs910316	0.763	rs13712	chr14:75483812	T/C	cg23033748	chr14:75592666	NEK9	0.38	5.18	0.32	4.8e-7	Height;
SARC	cis	rs6121246	0.559	rs6060915	chr20:30330306	A/G	cg13852791	chr20:30311386	BCL2L1	0.86	10.88	0.58	1.49e-22	Mean corpuscular hemoglobin;
SARC	cis	rs7089973	0.872	rs7075888	chr10:116627117	C/T	cg08188268	chr10:116634841	FAM160B1	0.37	5.89	0.36	1.33e-8	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	trans	rs1814175	0.791	rs10839395	chr11:49846274	G/T	cg15704280	chr7:45808275	SEPT13	-0.97	-18.3	-0.77	5.86e-47	Height;
SARC	cis	rs1348850	0.872	rs12991272	chr2:178457339	T/C	cg23306229	chr2:178417860	TTC30B	0.56	6.22	0.38	2.32e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs526821	0.595	rs485555	chr11:55323570	A/G	cg04317927	chr11:55418816	OR4S2	-0.4	-5.83	-0.36	1.83e-8	Pediatric bone mineral density (spine);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg26956263	chr7:140624468	BRAF	0.53	6.42	0.39	7.67e-10	Breast cancer;
SARC	cis	rs208520	0.742	rs208454	chr6:66907783	T/C	cg07460842	chr6:66804631	NA	-0.96	-11.34	-0.6	5.21e-24	Exhaled nitric oxide output;
SARC	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg01570182	chr17:44337453	NA	-0.82	-9.75	-0.54	4.71e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	trans	rs61931739	0.517	rs1486882	chr12:34025896	A/G	cg26384229	chr12:38710491	ALG10B	0.87	12.5	0.63	8.77e-28	Morning vs. evening chronotype;
SARC	cis	rs757110	0.866	rs5213	chr11:17408404	C/T	cg03864215	chr11:17408437	KCNJ11	-0.3	-4.85	-0.3	2.23e-6	Type 2 diabetes;
SARC	cis	rs10911251	0.528	rs10911266	chr1:183115097	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.67	9.66	0.53	8.88e-19	Colorectal cancer;
SARC	cis	rs1355223	0.902	rs2185700	chr11:34724204	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-5.31	-0.33	2.57e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs76419734	1.000	rs10050159	chr4:106765915	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.73	5.35	0.33	2.06e-7	Post bronchodilator FEV1;
SARC	cis	rs6696846	0.765	rs11577406	chr1:205065733	G/T	cg21643547	chr1:205240462	TMCC2	-0.57	-7.66	-0.45	5.01e-13	Red blood cell count;
SARC	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg13080626	chr1:110753717	KCNC4	0.5	6.7	0.4	1.58e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs400736	0.729	rs2493215	chr1:8007716	C/T	cg25007680	chr1:8021821	PARK7	0.44	5.77	0.35	2.5e-8	Response to antidepressants and depression;
SARC	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg01341218	chr17:43662625	NA	-0.85	-9.63	-0.53	1.11e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs8114671	0.562	rs4911450	chr20:33512406	C/T	cg07148914	chr20:33460835	GGT7	0.46	5.67	0.35	4.22e-8	Height;
SARC	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	22.95	0.83	9.94e-62	Chronic sinus infection;
SARC	cis	rs7647973	0.626	rs7637711	chr3:49829653	A/G	cg03060546	chr3:49711283	APEH	-0.69	-7.6	-0.45	7.31e-13	Menarche (age at onset);
SARC	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg24829409	chr8:58192753	C8orf71	-0.63	-5.96	-0.36	9.37e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg17830980	chr10:43048298	ZNF37B	-0.49	-6.74	-0.4	1.24e-10	Extrinsic epigenetic age acceleration;
SARC	cis	rs6089584	1.000	rs6089585	chr20:60564395	G/A	cg23262073	chr20:60523788	NA	-0.45	-6.4	-0.39	8.3e-10	Body mass index;
SARC	cis	rs17666538	1.000	rs61122136	chr8:585027	G/C	cg26554054	chr8:600488	NA	-0.62	-4.96	-0.31	1.35e-6	IgG glycosylation;
SARC	cis	rs6578185	0.782	rs10109519	chr8:142453669	T/C	cg07762003	chr8:142452454	FLJ43860	-0.33	-5.78	-0.35	2.42e-8	Endometriosis;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg20554397	chr5:303564	PDCD6;AHRR	0.53	6.6	0.4	2.67e-10	Breast cancer;
SARC	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg09455208	chr3:40491958	NA	0.4	5.82	0.36	1.89e-8	Renal cell carcinoma;
SARC	cis	rs2221894	0.600	rs76071566	chr8:28785985	A/T	cg07962641	chr8:28805897	HMBOX1	-0.45	-5.21	-0.32	4.17e-7	Obesity-related traits;
SARC	cis	rs6582630	0.548	rs8189608	chr12:38327775	T/G	cg13010199	chr12:38710504	ALG10B	-0.51	-6.05	-0.37	5.69e-9	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs4713675	0.584	rs2966	chr6:33689520	C/T	cg15676125	chr6:33679581	C6orf125	0.51	6.22	0.38	2.27e-9	Plateletcrit;
SARC	cis	rs10463554	0.963	rs154355	chr5:102498881	G/T	cg23492399	chr5:102201601	PAM	-0.48	-5.28	-0.33	2.9e-7	Parkinson's disease;
SARC	cis	rs920590	0.643	rs7012694	chr8:19662732	C/T	cg17834443	chr8:19674713	INTS10	0.49	6.08	0.37	4.88e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs826838	1.000	rs11610522	chr12:38687575	C/T	cg13010199	chr12:38710504	ALG10B	0.83	12.03	0.62	3.1e-26	Heart rate;
SARC	cis	rs865483	0.895	rs4795203	chr17:35828972	T/C	cg06561646	chr17:35873369	DUSP14	-0.49	-6.58	-0.4	3.11e-10	Monocyte count;
SARC	cis	rs4737010	0.570	rs6474364	chr8:41646997	T/G	cg08923054	chr8:41654455	ANK1	0.7	8.38	0.48	4.92e-15	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
SARC	cis	rs838147	0.844	rs8102032	chr19:49249795	C/T	cg13540341	chr19:49222985	MAMSTR	0.28	4.84	0.3	2.32e-6	Dietary macronutrient intake;
SARC	cis	rs2439831	0.850	rs28509275	chr15:44098105	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.93	7.8	0.45	2.11e-13	Lung cancer in ever smokers;
SARC	cis	rs3796352	1.000	rs35163227	chr3:53127876	A/G	cg15956490	chr3:53032818	SFMBT1	0.9	5.83	0.36	1.81e-8	Immune reponse to smallpox (secreted IL-2);
SARC	trans	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg01943983	chr11:78387190	ODZ4	0.41	6.45	0.39	6.28e-10	Colonoscopy-negative controls vs population controls;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg17609731	chr7:77325533	RSBN1L	0.51	6.79	0.41	9.08e-11	Chemerin levels;
SARC	cis	rs7089973	0.604	rs3758603	chr10:116605368	T/C	cg08188268	chr10:116634841	FAM160B1	0.28	4.79	0.3	3.02e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	trans	rs7824557	0.564	rs2736304	chr8:11236964	C/T	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.84	-0.41	7.03e-11	Retinal vascular caliber;
SARC	cis	rs9790314	0.521	rs13084731	chr3:161086020	G/A	cg04691961	chr3:161091175	C3orf57	-0.58	-7.67	-0.45	4.63e-13	Morning vs. evening chronotype;
SARC	cis	rs478304	0.627	rs11227254	chr11:65454000	A/G	cg27068330	chr11:65405492	SIPA1	-0.41	-4.84	-0.3	2.32e-6	Acne (severe);
SARC	cis	rs7481584	0.669	rs12421922	chr11:3035070	A/G	cg20651018	chr11:3035856	CARS	0.41	6.26	0.38	1.87e-9	Calcium levels;
SARC	cis	rs9611519	0.780	rs9611542	chr22:41677317	C/T	cg17376030	chr22:41985996	PMM1	0.58	7.3	0.43	4.54e-12	Neuroticism;
SARC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg26338869	chr17:61819248	STRADA	0.8	10.82	0.58	2.2e-22	Prudent dietary pattern;
SARC	cis	rs826838	0.904	rs1554550	chr12:39208889	G/A	cg26384229	chr12:38710491	ALG10B	0.86	11.67	0.61	4.34e-25	Heart rate;
SARC	cis	rs11697848	0.881	rs75950318	chr20:48547448	A/G	cg17849948	chr20:48532315	SPATA2	0.87	5.2	0.32	4.3e-7	Systemic lupus erythematosus;
SARC	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg06028605	chr16:24865363	SLC5A11	0.37	5.87	0.36	1.49e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9611519	0.580	rs8138349	chr22:41412723	C/T	cg17376030	chr22:41985996	PMM1	0.39	4.85	0.3	2.29e-6	Neuroticism;
SARC	cis	rs17376456	0.866	rs13356088	chr5:93423479	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	4.87	0.3	2.05e-6	Diabetic retinopathy;
SARC	cis	rs4689388	0.929	rs1046320	chr4:6304344	C/T	cg25554036	chr4:6271136	WFS1	0.34	5.48	0.34	1.11e-7	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg00684032	chr4:1343700	KIAA1530	0.38	5.55	0.34	7.9e-8	Obesity-related traits;
SARC	cis	rs6893300	0.542	rs3797774	chr5:179193970	C/T	cg14593053	chr5:179126677	CANX	0.51	7.37	0.44	2.87e-12	Resting heart rate;
SARC	cis	rs9640161	0.830	rs35840727	chr7:150063204	A/G	cg10018233	chr7:150070692	REPIN1	0.7	9.98	0.55	9.32e-20	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs3106136	0.967	rs61004493	chr4:95163317	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.39	-6.05	-0.37	5.83e-9	Capecitabine sensitivity;
SARC	cis	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg15145296	chr3:125709740	NA	-0.51	-4.95	-0.31	1.44e-6	Blood pressure (smoking interaction);
SARC	cis	rs7474896	0.583	rs7071147	chr10:38003376	T/C	cg25427524	chr10:38739819	LOC399744	-0.48	-5.86	-0.36	1.56e-8	Obesity (extreme);
SARC	cis	rs72781680	0.948	rs72796385	chr2:24170360	T/A	cg08917208	chr2:24149416	ATAD2B	0.79	7.54	0.44	1.05e-12	Lymphocyte counts;
SARC	cis	rs950169	0.922	rs12906983	chr15:84931022	G/A	cg17507749	chr15:85114479	UBE2QP1	0.79	9.69	0.54	7.1e-19	Schizophrenia;
SARC	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg09323728	chr8:95962352	TP53INP1	-0.29	-4.96	-0.31	1.35e-6	Type 2 diabetes;
SARC	cis	rs10744422	1.000	rs897386	chr12:123341289	A/C	cg25930673	chr12:123319894	HIP1R	-0.65	-5.0	-0.31	1.14e-6	Schizophrenia;
SARC	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg12000995	chr2:27665139	KRTCAP3	-0.31	-4.86	-0.3	2.17e-6	Total body bone mineral density;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg19144769	chr2:39298958	SOS1	0.49	7.06	0.42	1.89e-11	Thyroid stimulating hormone;
SARC	cis	rs4595586	0.756	rs1400283	chr12:39364596	G/C	cg26384229	chr12:38710491	ALG10B	0.49	6.28	0.38	1.63e-9	Morning vs. evening chronotype;
SARC	cis	rs9858213	1	rs9858213	chr3:49731861	G/T	cg07274523	chr3:49395745	GPX1	0.52	5.8	0.36	2.14e-8	Educational attainment;
SARC	cis	rs6772849	0.830	rs7633674	chr3:128355026	G/A	cg08795948	chr3:128337044	NA	0.54	7.44	0.44	1.96e-12	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg11494091	chr17:61959527	GH2	0.55	8.26	0.48	1.11e-14	Prudent dietary pattern;
SARC	cis	rs7937682	0.889	rs567859	chr11:111486738	A/G	cg22437258	chr11:111473054	SIK2	0.74	10.24	0.56	1.44e-20	Primary sclerosing cholangitis;
SARC	cis	rs986417	0.901	rs1955697	chr14:61028435	T/C	cg27398547	chr14:60952738	C14orf39	0.97	8.82	0.5	2.73e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs6665290	0.835	rs7549586	chr1:227214566	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.06	-22.79	-0.83	3.13e-61	Myeloid white cell count;
SARC	cis	rs6456156	0.586	rs12529876	chr6:167461501	G/A	cg07741184	chr6:167504864	NA	0.35	6.83	0.41	7.46e-11	Primary biliary cholangitis;
SARC	cis	rs1562975	0.609	rs60290218	chr4:109409501	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.45	5.85	0.36	1.61e-8	Height;
SARC	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg08280861	chr8:58055591	NA	0.66	5.63	0.35	5.09e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4481887	1.000	rs10888351	chr1:248451608	G/A	cg00666640	chr1:248458726	OR2T12	0.33	5.48	0.34	1.12e-7	Common traits (Other);
SARC	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg16819604	chr20:47836038	DDX27	0.55	6.67	0.4	1.86e-10	Brain structure;
SARC	cis	rs3770081	1.000	rs12620810	chr2:86391481	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.76	-4.73	-0.3	3.92e-6	Facial emotion recognition (sad faces);
SARC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg06873352	chr17:61820015	STRADA	0.5	6.49	0.39	5.1e-10	Prudent dietary pattern;
SARC	cis	rs11098699	0.821	rs904712	chr4:124225337	T/C	cg09941581	chr4:124220074	SPATA5	0.38	4.77	0.3	3.3e-6	Mosquito bite size;
SARC	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg10207240	chr12:122356781	WDR66	-0.29	-4.9	-0.31	1.8e-6	Mean corpuscular volume;
SARC	cis	rs11608355	0.515	rs12822282	chr12:109923207	G/A	cg05360138	chr12:110035743	NA	0.93	9.49	0.53	2.87e-18	Neuroticism;
SARC	cis	rs7824557	0.564	rs2572389	chr8:11236392	T/C	cg21775007	chr8:11205619	TDH	-0.65	-8.62	-0.49	1.01e-15	Retinal vascular caliber;
SARC	cis	rs2153535	0.584	rs9502723	chr6:8541504	G/A	cg07606381	chr6:8435919	SLC35B3	0.76	10.73	0.58	4.41e-22	Motion sickness;
SARC	cis	rs240764	0.658	rs11155635	chr6:101199367	C/T	cg09795085	chr6:101329169	ASCC3	-0.49	-6.42	-0.39	7.72e-10	Neuroticism;
SARC	cis	rs1957429	0.520	rs72625646	chr14:65343809	C/A	cg23373153	chr14:65346875	NA	-0.82	-5.63	-0.35	5.25e-8	Pediatric areal bone mineral density (radius);
SARC	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg05279229	chr7:1896384	MAD1L1	-0.36	-4.86	-0.3	2.11e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg04317338	chr11:64019027	PLCB3	0.81	8.68	0.49	6.79e-16	Mean platelet volume;
SARC	cis	rs796364	1.000	rs281759	chr2:200787719	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.75	6.87	0.41	5.72e-11	Schizophrenia;
SARC	trans	rs7824557	0.628	rs17797894	chr8:11212081	A/G	cg06636001	chr8:8085503	FLJ10661	0.52	6.31	0.38	1.41e-9	Retinal vascular caliber;
SARC	cis	rs477692	0.629	rs945231	chr10:131294827	A/G	cg05714579	chr10:131428358	MGMT	0.58	7.4	0.44	2.5e-12	Response to temozolomide;
SARC	cis	rs4820539	1.000	rs4822357	chr22:23473231	A/G	cg14186256	chr22:23484241	RTDR1	0.84	12.89	0.65	4.83e-29	Bone mineral density;
SARC	cis	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg25427524	chr10:38739819	LOC399744	-0.56	-8.56	-0.49	1.58e-15	Extrinsic epigenetic age acceleration;
SARC	cis	rs1153858	1.000	rs12595087	chr15:45655232	A/G	cg21132104	chr15:45694354	SPATA5L1	0.78	11.07	0.59	3.59e-23	Homoarginine levels;
SARC	cis	rs617791	0.530	rs7952056	chr11:65744597	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.58	7.0	0.42	2.71e-11	Breast cancer;
SARC	cis	rs7633857	0.595	rs7640874	chr3:160672617	T/A	cg03342759	chr3:160939853	NMD3	-0.5	-6.09	-0.37	4.62e-9	Educational attainment (years of education);
SARC	cis	rs7681440	0.606	rs2583981	chr4:90752582	A/T	cg06632027	chr4:90757378	SNCA	-0.41	-5.2	-0.32	4.3e-7	Dementia with Lewy bodies;
SARC	trans	rs2727020	0.521	rs1909220	chr11:49572109	T/C	cg15704280	chr7:45808275	SEPT13	-0.72	-8.3	-0.48	8.48e-15	Coronary artery disease;
SARC	cis	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg12463550	chr7:65579703	CRCP	0.66	5.08	0.32	7.79e-7	Diabetic kidney disease;
SARC	cis	rs6604026	0.656	rs34389767	chr1:93373780	T/G	cg17283838	chr1:93427260	FAM69A	0.42	4.75	0.3	3.59e-6	Multiple sclerosis;
SARC	cis	rs965469	1.000	rs6051810	chr20:3355384	A/G	cg25506879	chr20:3388711	C20orf194	-0.48	-4.87	-0.3	2.04e-6	IFN-related cytopenia;
SARC	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg12667521	chr19:29218732	NA	0.39	5.26	0.33	3.3e-7	Methadone dose in opioid dependence;
SARC	trans	rs9987353	0.876	rs329993	chr8:9123438	T/C	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.47	-0.39	5.84e-10	Recombination measurement;
SARC	cis	rs6580649	0.769	rs60629297	chr12:48438290	T/A	cg05342945	chr12:48394962	COL2A1	0.54	5.76	0.35	2.6e-8	Lung cancer;
SARC	cis	rs9816226	0.591	rs10513801	chr3:185822353	T/G	cg00760338	chr3:185826511	ETV5	-0.88	-8.56	-0.49	1.57e-15	Obesity;Body mass index;
SARC	cis	rs6813479	0.594	rs1031711	chr4:137737358	A/C	cg16185213	chr4:137733633	NA	0.44	6.3	0.38	1.46e-9	Longevity;
SARC	cis	rs7727544	0.709	rs441969	chr5:131702120	G/A	cg07395648	chr5:131743802	NA	-0.42	-4.92	-0.31	1.65e-6	Blood metabolite levels;
SARC	cis	rs4253772	0.530	rs6008774	chr22:46755298	C/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.74	6.86	0.41	6.24e-11	LDL cholesterol;Cholesterol, total;
SARC	cis	rs10461617	0.541	rs7715822	chr5:56043600	G/T	cg12311346	chr5:56204834	C5orf35	-0.54	-4.99	-0.31	1.21e-6	Type 2 diabetes;
SARC	cis	rs6088580	0.609	rs6059844	chr20:33036482	A/G	cg08999081	chr20:33150536	PIGU	0.41	6.37	0.39	9.77e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg01316550	chr5:56110833	MAP3K1	-0.53	-4.96	-0.31	1.39e-6	Initial pursuit acceleration;
SARC	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	9.15	0.51	3.02e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7586879	0.681	rs28836469	chr2:25117215	A/G	cg04586622	chr2:25135609	ADCY3	0.33	5.67	0.35	4.12e-8	Body mass index;
SARC	cis	rs7247513	0.964	rs8105902	chr19:12718351	G/A	cg01871581	chr19:12707946	ZNF490	-0.86	-12.08	-0.62	2.02e-26	Bipolar disorder;
SARC	cis	rs7818345	1.000	rs7835461	chr8:19307051	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.37	5.01	0.31	1.08e-6	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs2200578	1.000	rs2200578	chr2:99876244	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.62	5.88	0.36	1.38e-8	IgG glycosylation;
SARC	cis	rs9322193	0.504	rs7771014	chr6:150205446	T/A	cg05036130	chr6:150231994	NA	0.3	5.06	0.31	8.6e-7	Lung cancer;
SARC	cis	rs11764590	0.666	rs7787359	chr7:2090849	A/G	cg21782813	chr7:2030301	MAD1L1	-0.31	-4.82	-0.3	2.54e-6	Neuroticism;
SARC	trans	rs11098499	0.954	rs10006877	chr4:120242793	C/T	cg25214090	chr10:38739885	LOC399744	0.55	7.17	0.43	9.85e-12	Corneal astigmatism;
SARC	cis	rs870825	0.655	rs28726376	chr4:185638954	A/G	cg04058563	chr4:185651563	MLF1IP	0.81	11.3	0.6	6.58e-24	Blood protein levels;
SARC	cis	rs2243480	0.522	rs73150635	chr7:65972490	C/T	cg18252515	chr7:66147081	NA	-1.15	-7.71	-0.45	3.6e-13	Diabetic kidney disease;
SARC	cis	rs644799	0.965	rs549695	chr11:95617788	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.89	12.91	0.65	3.95e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs1707322	0.721	rs7519900	chr1:46234947	C/T	cg06784218	chr1:46089804	CCDC17	0.37	6.54	0.39	3.92e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7766436	0.885	rs12111199	chr6:22578106	C/T	cg13666174	chr6:22585274	NA	-0.59	-7.66	-0.45	5.07e-13	Coronary artery disease;
SARC	cis	rs11098499	0.954	rs34858317	chr4:120387110	A/C	cg09307838	chr4:120376055	NA	0.9	12.47	0.63	1.13e-27	Corneal astigmatism;
SARC	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg08017634	chr8:144659831	NAPRT1	-0.6	-5.6	-0.34	5.98e-8	Attention deficit hyperactivity disorder;
SARC	cis	rs936229	0.626	rs3765066	chr15:75140854	G/A	cg10253484	chr15:75165896	SCAMP2	-0.43	-4.74	-0.3	3.72e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs208520	0.909	rs58958359	chr6:67021381	A/C	cg07460842	chr6:66804631	NA	0.84	8.59	0.49	1.29e-15	Exhaled nitric oxide output;
SARC	cis	rs9811216	0.917	rs2293607	chr3:169482335	T/C	cg14222479	chr3:169487675	ARPM1	0.47	5.26	0.33	3.23e-7	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs2273669	0.915	rs4992382	chr6:109292826	T/A	cg01304950	chr6:109416612	SESN1;C6orf182	0.55	4.81	0.3	2.66e-6	Prostate cancer;
SARC	trans	rs1814175	0.935	rs10839329	chr11:49694206	G/A	cg15704280	chr7:45808275	SEPT13	-0.94	-16.94	-0.74	1.71e-42	Height;
SARC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg17178900	chr1:205818956	PM20D1	0.67	9.97	0.55	1.01e-19	Menarche (age at onset);
SARC	cis	rs4975616	0.843	rs4975615	chr5:1315343	C/T	cg26373071	chr5:1325741	CLPTM1L	-0.29	-4.8	-0.3	2.84e-6	Lung cancer;
SARC	cis	rs2732480	0.538	rs1387260	chr12:48703091	A/C	cg24011408	chr12:48396354	COL2A1	0.45	5.3	0.33	2.74e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs12545912	0.821	rs4372006	chr8:9457345	A/G	cg21625330	chr8:9911636	MSRA	-0.53	-4.96	-0.31	1.37e-6	Multiple myeloma (hyperdiploidy);
SARC	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-9.19	-0.52	2.22e-17	Alzheimer's disease;
SARC	trans	rs3780486	0.881	rs10738906	chr9:33135634	T/C	cg04842962	chr6:43655489	MRPS18A	1.09	19.93	0.79	2.97e-52	IgG glycosylation;
SARC	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg11987759	chr7:65425863	GUSB	-0.62	-8.26	-0.48	1.11e-14	Aortic root size;
SARC	cis	rs1580019	0.587	rs7806941	chr7:32553319	G/T	cg07520158	chr7:32535189	LSM5;AVL9	0.61	8.1	0.47	3.04e-14	Cognitive ability;
SARC	cis	rs3758785	0.596	rs7933335	chr11:94111627	G/C	cg13023536	chr11:94226537	MRE11A;ANKRD49	-0.42	-5.45	-0.34	1.27e-7	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
SARC	cis	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg12463550	chr7:65579703	CRCP	-0.7	-5.31	-0.33	2.54e-7	Diabetic kidney disease;
SARC	cis	rs881375	0.900	rs2241003	chr9:123666777	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	5.89	0.36	1.32e-8	Rheumatoid arthritis;
SARC	cis	rs747650	0.926	rs10838659	chr11:47148210	C/T	cg03339077	chr11:47165057	C11orf49	-0.47	-6.64	-0.4	2.16e-10	Acne (severe);
SARC	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg22974920	chr21:40686053	BRWD1	-0.44	-4.82	-0.3	2.54e-6	Cognitive function;
SARC	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg04944784	chr2:26401820	FAM59B	0.57	7.21	0.43	7.73e-12	Gut microbiome composition (summer);
SARC	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg05793240	chr7:2802953	GNA12	-0.36	-5.32	-0.33	2.45e-7	Height;
SARC	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.48	5.61	0.35	5.62e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7236492	0.872	rs78226032	chr18:77230822	G/A	cg15644404	chr18:77186268	NFATC1	-0.58	-5.21	-0.32	4.21e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs11249608	0.548	rs11951738	chr5:178491228	G/A	cg01312482	chr5:178451176	ZNF879	-0.4	-5.01	-0.31	1.08e-6	Pubertal anthropometrics;
SARC	cis	rs11871801	0.517	rs665268	chr17:40722029	A/G	cg14558262	chr17:40713999	COASY	0.51	5.76	0.35	2.62e-8	Crohn's disease;
SARC	cis	rs72781680	1.000	rs72796328	chr2:24141343	A/G	cg08917208	chr2:24149416	ATAD2B	0.93	8.69	0.49	6.38e-16	Lymphocyte counts;
SARC	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg13877915	chr19:58951672	ZNF132	0.67	10.19	0.56	2.08e-20	Uric acid clearance;
SARC	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.79	-11.84	-0.61	1.26e-25	Personality dimensions;
SARC	cis	rs1707322	1.000	rs3922886	chr1:46473902	A/T	cg06784218	chr1:46089804	CCDC17	0.34	5.94	0.36	1.03e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6708331	0.540	rs11890701	chr2:70360457	T/A	cg16435808	chr2:70475954	TIA1	0.4	4.87	0.3	2.02e-6	Obesity-related traits;
SARC	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-8.48	-0.49	2.66e-15	Alzheimer's disease;
SARC	cis	rs829883	0.659	rs10860342	chr12:98941223	C/T	cg25150519	chr12:98850993	NA	0.6	7.26	0.43	5.74e-12	Colorectal adenoma (advanced);
SARC	cis	rs2072499	1.000	rs2072499	chr1:156169610	A/G	cg25208724	chr1:156163844	SLC25A44	0.87	11.58	0.6	8.59e-25	Testicular germ cell tumor;
SARC	cis	rs910316	1.000	rs1047418	chr14:75605792	A/G	cg08847533	chr14:75593920	NEK9	0.91	15.38	0.71	2.65e-37	Height;
SARC	cis	rs796364	1.000	rs4263095	chr2:200830137	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.79	-7.67	-0.45	4.7e-13	Schizophrenia;
SARC	cis	rs3091242	0.933	rs61775174	chr1:25787313	G/A	cg02931644	chr1:25747376	RHCE	-0.44	-7.27	-0.43	5.5e-12	Erythrocyte sedimentation rate;
SARC	cis	rs9549260	0.753	rs1986649	chr13:41178824	C/T	cg21288729	chr13:41239152	FOXO1	0.55	5.28	0.33	2.95e-7	Red blood cell count;
SARC	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg08219700	chr8:58056026	NA	0.58	6.2	0.38	2.48e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg22143209	chr7:4254977	SDK1	-0.42	-6.61	-0.4	2.59e-10	Height;
SARC	cis	rs7712401	0.601	rs13164134	chr5:122337941	T/A	cg19412675	chr5:122181750	SNX24	-0.43	-5.43	-0.34	1.41e-7	Mean platelet volume;
SARC	cis	rs9325144	0.505	rs7138977	chr12:38642109	G/A	cg13010199	chr12:38710504	ALG10B	0.71	9.59	0.53	1.39e-18	Morning vs. evening chronotype;
SARC	cis	rs918629	1.000	rs918629	chr5:95301463	G/A	cg16656078	chr5:95278638	ELL2	-0.51	-6.32	-0.38	1.29e-9	IgG glycosylation;
SARC	cis	rs7914558	0.966	rs10786721	chr10:104654383	C/A	cg15744005	chr10:104629667	AS3MT	-0.27	-4.9	-0.31	1.79e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs6733011	0.560	rs7579189	chr2:99464718	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.4	-5.03	-0.31	9.71e-7	Bipolar disorder;
SARC	cis	rs926938	0.618	rs6693491	chr1:115371061	A/G	cg12756093	chr1:115239321	AMPD1	-0.37	-4.79	-0.3	2.93e-6	Autism;
SARC	cis	rs2153535	0.601	rs9406160	chr6:8464907	A/C	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs6570726	0.791	rs401561	chr6:145835917	G/T	cg23711669	chr6:146136114	FBXO30	0.87	14.58	0.69	1.18e-34	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11997175	0.653	rs7817167	chr8:33633088	A/C	ch.8.33884649F	chr8:33765107	NA	0.52	6.78	0.41	1e-10	Body mass index;
SARC	cis	rs7945705	0.875	rs2653616	chr11:8885892	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.46	-6.51	-0.39	4.59e-10	Hemoglobin concentration;
SARC	cis	rs9300255	0.602	rs2851450	chr12:123703501	C/T	cg00376283	chr12:123451042	ABCB9	0.55	6.53	0.39	4.09e-10	Neutrophil percentage of white cells;
SARC	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg03185022	chr7:2884158	GNA12	0.45	5.03	0.31	9.66e-7	Height;
SARC	cis	rs7769051	1.000	rs9493454	chr6:133144629	G/T	cg22852734	chr6:133119734	C6orf192	-1.04	-10.6	-0.57	1.09e-21	Type 2 diabetes nephropathy;
SARC	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg10435706	chr6:150039699	LATS1	0.36	4.8	0.3	2.88e-6	Lung cancer;
SARC	trans	rs7980799	0.649	rs2389218	chr12:33680929	C/A	cg26384229	chr12:38710491	ALG10B	0.65	7.72	0.45	3.33e-13	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs4986172	0.700	rs71373536	chr17:43221808	G/A	cg27395066	chr17:43221220	ACBD4	0.39	5.09	0.32	7.43e-7	Height;
SARC	cis	rs4423214	0.840	rs4435028	chr11:71183690	C/A	cg05163923	chr11:71159392	DHCR7	-0.6	-7.21	-0.43	7.58e-12	Vitamin D levels;
SARC	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg11502198	chr6:26597334	ABT1	0.65	8.87	0.5	1.95e-16	Intelligence (multi-trait analysis);
SARC	cis	rs4561483	0.734	rs33655	chr16:11970381	C/T	cg08843971	chr16:11963173	GSPT1	-0.43	-5.23	-0.32	3.81e-7	Testicular germ cell tumor;
SARC	cis	rs4642101	0.765	rs9870269	chr3:12853450	T/G	cg24848339	chr3:12840334	CAND2	0.34	4.99	0.31	1.17e-6	QRS complex (12-leadsum);
SARC	cis	rs477692	0.692	rs12265758	chr10:131445144	A/G	cg05714579	chr10:131428358	MGMT	-0.59	-7.69	-0.45	4.22e-13	Response to temozolomide;
SARC	cis	rs11786130	1.000	rs4733812	chr8:128999640	C/T	cg17583432	chr8:129005567	PVT1	-0.37	-6.4	-0.39	8.59e-10	Eosinophil counts;Sum eosinophil basophil counts;
SARC	cis	rs8005677	1.000	rs8014936	chr14:23375145	A/G	cg01529538	chr14:23388837	RBM23	0.46	5.77	0.35	2.53e-8	Cognitive ability (multi-trait analysis);
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg10654737	chr15:25655057	UBE3A	0.48	6.71	0.4	1.49e-10	Tetralogy of Fallot;
SARC	cis	rs6141769	0.542	rs2064933	chr20:31314625	A/G	cg13636640	chr20:31349939	DNMT3B	-0.45	-4.78	-0.3	3.08e-6	Subjective well-being;
SARC	cis	rs910316	1.000	rs11845639	chr14:75570293	C/T	cg08847533	chr14:75593920	NEK9	0.93	15.76	0.72	1.36e-38	Height;
SARC	cis	rs950169	0.920	rs12915390	chr15:84792069	T/C	cg17507749	chr15:85114479	UBE2QP1	0.76	9.35	0.52	7.67e-18	Schizophrenia;
SARC	cis	rs3806933	0.522	rs12521169	chr5:110448313	G/A	cg04022379	chr5:110408740	TSLP	0.69	8.85	0.5	2.22e-16	Eosinophilic esophagitis;
SARC	cis	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg06558623	chr16:89946397	TCF25	0.88	6.21	0.38	2.39e-9	Skin colour saturation;
SARC	cis	rs870825	0.616	rs28607131	chr4:185651617	A/G	cg04058563	chr4:185651563	MLF1IP	0.8	11.37	0.6	3.9e-24	Blood protein levels;
SARC	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg04267008	chr7:1944627	MAD1L1	-0.6	-6.85	-0.41	6.46e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs910316	1.000	rs175449	chr14:75590846	A/T	cg11812906	chr14:75593930	NEK9	-0.83	-12.38	-0.63	2.16e-27	Height;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg17025142	chr5:99871651	FAM174A	-0.74	-6.39	-0.39	8.91e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs112591243	0.570	rs4819254	chr21:47887462	T/A	cg26904215	chr21:47823096	PCNT	-0.75	-4.86	-0.3	2.15e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs1003719	0.788	rs1543750	chr21:38446918	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.67	9.98	0.55	9.49e-20	Eye color traits;
SARC	cis	rs2429369	0.528	rs2526376	chr17:56427142	A/C	cg05425664	chr17:57184151	TRIM37	-0.56	-6.48	-0.39	5.35e-10	Cognitive function;
SARC	cis	rs7043114	0.507	rs7856204	chr9:95173814	G/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.81	-0.36	2.07e-8	Height;
SARC	cis	rs13191362	1.000	rs34619021	chr6:163029767	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.57	5.48	0.34	1.09e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs6570726	0.764	rs9399553	chr6:145873664	A/T	cg05347473	chr6:146136440	FBXO30	0.54	7.43	0.44	2.05e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9341808	0.667	rs2322632	chr6:80845608	G/A	cg08355045	chr6:80787529	NA	0.36	5.67	0.35	4.22e-8	Sitting height ratio;
SARC	cis	rs9303401	0.538	rs2240258	chr17:56458183	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	9.8	0.54	3.38e-19	Cognitive test performance;
SARC	cis	rs13256369	1.000	rs13256369	chr8:8577379	T/C	cg17143192	chr8:8559678	CLDN23	0.5	5.72	0.35	3.23e-8	Obesity-related traits;
SARC	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg04546413	chr19:29218101	NA	0.63	8.71	0.5	5.81e-16	Methadone dose in opioid dependence;
SARC	cis	rs73195822	0.667	rs60184376	chr12:111229975	T/C	cg10860002	chr12:110842031	ANAPC7	0.58	4.77	0.3	3.29e-6	Itch intensity from mosquito bite;
SARC	cis	rs2013441	1.000	rs2526460	chr17:20086352	G/A	cg13482628	chr17:19912719	NA	-0.48	-6.16	-0.37	3.1e-9	Obesity-related traits;
SARC	cis	rs12142240	0.698	rs12385695	chr1:46819021	A/G	cg00530320	chr1:46809349	NSUN4	0.57	6.92	0.41	4.4e-11	Menopause (age at onset);
SARC	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg26335602	chr6:28129616	ZNF389	-0.49	-5.46	-0.34	1.2e-7	Depression;
SARC	cis	rs2153535	0.580	rs2143354	chr6:8517907	G/A	cg21535247	chr6:8435926	SLC35B3	0.57	7.21	0.43	7.67e-12	Motion sickness;
SARC	cis	rs2228479	0.541	rs9806913	chr16:89953773	A/G	cg06558623	chr16:89946397	TCF25	0.77	6.74	0.4	1.25e-10	Skin colour saturation;
SARC	cis	rs7617773	0.539	rs2017859	chr3:48382261	G/A	cg11946769	chr3:48343235	NME6	0.55	6.76	0.4	1.11e-10	Coronary artery disease;
SARC	cis	rs6450176	1.000	rs4588541	chr5:53300640	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.68	-7.82	-0.46	1.84e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs651907	0.535	rs36060163	chr3:101360963	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	6.46	0.39	6.1e-10	Colorectal cancer;
SARC	trans	rs7937682	0.883	rs510388	chr11:111451869	G/T	cg18187862	chr3:45730750	SACM1L	-0.51	-6.46	-0.39	6.1e-10	Primary sclerosing cholangitis;
SARC	cis	rs11785400	0.793	rs7007891	chr8:143749228	C/T	cg24634471	chr8:143751801	JRK	-0.59	-7.43	-0.44	2.07e-12	Schizophrenia;
SARC	cis	rs6456156	0.806	rs11967165	chr6:167529936	T/C	cg07741184	chr6:167504864	NA	-0.29	-5.41	-0.33	1.53e-7	Primary biliary cholangitis;
SARC	trans	rs2018683	0.739	rs10233884	chr7:28972307	A/G	cg19402173	chr7:128379420	CALU	-0.5	-6.42	-0.39	7.71e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs722599	0.715	rs8008785	chr14:75307600	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.42	-5.38	-0.33	1.82e-7	IgG glycosylation;
SARC	cis	rs6582630	0.519	rs11514372	chr12:38308613	T/G	cg13010199	chr12:38710504	ALG10B	0.78	10.82	0.58	2.18e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2070997	0.756	rs3134875	chr9:133710072	G/C	cg03924115	chr9:133768966	QRFP	0.49	4.87	0.3	2.1e-6	Response to amphetamines;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg03063453	chr19:52693134	PPP2R1A	0.47	6.23	0.38	2.15e-9	Chemerin levels;
SARC	cis	rs3733585	0.631	rs4697924	chr4:10124239	A/G	cg11266682	chr4:10021025	SLC2A9	-0.4	-6.58	-0.4	3.09e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg11644478	chr21:40555479	PSMG1	-0.88	-11.57	-0.6	9.56e-25	Cognitive function;
SARC	cis	rs986417	1.000	rs4901994	chr14:61090202	C/T	cg27398547	chr14:60952738	C14orf39	0.87	7.45	0.44	1.84e-12	Gut microbiota (bacterial taxa);
SARC	cis	rs607987	0.841	rs11031028	chr11:30302923	G/A	cg06241208	chr11:30344200	C11orf46	0.42	5.13	0.32	5.96e-7	Body mass index;
SARC	cis	rs4319547	0.956	rs7397990	chr12:123119472	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.57	-6.71	-0.4	1.49e-10	Body mass index;
SARC	cis	rs826838	0.967	rs1719853	chr12:39128515	A/G	cg26384229	chr12:38710491	ALG10B	-0.75	-11.21	-0.59	1.27e-23	Heart rate;
SARC	cis	rs883565	0.569	rs1274972	chr3:39161456	G/A	cg26331595	chr3:39149181	GORASP1;TTC21A	0.43	5.04	0.31	9.47e-7	Handedness;
SARC	cis	rs7005606	1.000	rs4541858	chr8:32410309	A/G	cg14488905	chr8:32406789	NRG1	0.45	6.23	0.38	2.21e-9	Hirschsprung disease;
SARC	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg10792982	chr14:105748885	BRF1	0.49	7.45	0.44	1.81e-12	Mean platelet volume;Platelet distribution width;
SARC	cis	rs8014204	0.604	rs11625594	chr14:75389833	G/A	cg06637938	chr14:75390232	RPS6KL1	0.92	14.98	0.7	5.46e-36	Caffeine consumption;
SARC	cis	rs7662987	0.517	rs1311618	chr4:100012612	A/G	cg12011299	chr4:100065546	ADH4	0.32	5.24	0.32	3.6e-7	Smoking initiation;
SARC	cis	rs1348850	0.874	rs4893822	chr2:178285727	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.68	8.07	0.47	3.71e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7412746	0.658	rs4537557	chr1:150734436	A/G	cg13175981	chr1:150552382	MCL1	-0.46	-5.51	-0.34	9.58e-8	Melanoma;
SARC	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	cis	rs7117932	0.507	rs12797048	chr11:128438323	A/G	cg23774988	chr11:128419199	ETS1	-0.33	-4.8	-0.3	2.78e-6	Obesity-related traits;
SARC	cis	rs1966248	0.656	rs6569906	chr6:134132333	T/A	cg25632230	chr6:134101081	NA	-0.55	-7.3	-0.43	4.56e-12	Coronary artery disease;
SARC	cis	rs11098499	0.954	rs17005535	chr4:120411562	C/T	cg09307838	chr4:120376055	NA	0.93	12.73	0.64	1.6e-28	Corneal astigmatism;
SARC	cis	rs2070677	0.935	rs11101885	chr10:135417088	T/C	cg20169779	chr10:135381914	SYCE1	-0.42	-5.29	-0.33	2.75e-7	Gout;
SARC	cis	rs546131	0.928	rs572690	chr11:34833614	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.59	7.71	0.45	3.59e-13	Lung disease severity in cystic fibrosis;
SARC	cis	rs734999	0.505	rs10910108	chr1:2539532	A/G	cg20673091	chr1:2541236	MMEL1	0.33	5.11	0.32	6.61e-7	Ulcerative colitis;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg11316592	chr17:63556608	AXIN2	0.5	6.26	0.38	1.83e-9	Breast cancer;
SARC	cis	rs6448317	0.556	rs4481227	chr4:24906858	C/T	cg21108841	chr4:24914750	CCDC149	0.49	4.79	0.3	3.04e-6	Heschl's gyrus morphology;
SARC	cis	rs9911578	0.835	rs3744093	chr17:56492800	T/C	cg12560992	chr17:57184187	TRIM37	-0.74	-9.19	-0.52	2.18e-17	Intelligence (multi-trait analysis);
SARC	cis	rs72653721	0.730	rs9468303	chr6:11042029	A/T	cg13562911	chr6:11044106	ELOVL2	0.49	5.64	0.35	4.86e-8	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.93	9.72	0.54	5.77e-19	Platelet count;
SARC	cis	rs9611565	0.506	rs4822020	chr22:41700203	C/T	cg17376030	chr22:41985996	PMM1	0.57	7.14	0.42	1.15e-11	Vitiligo;
SARC	cis	rs7818345	0.845	rs17407039	chr8:19268056	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.39	4.93	0.31	1.58e-6	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs76419734	1.000	rs12374256	chr4:106617361	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.81	4.91	0.31	1.73e-6	Post bronchodilator FEV1;
SARC	cis	rs116979167	0.545	rs1706914	chr7:105196445	A/T	cg19920283	chr7:105172520	RINT1	0.55	5.64	0.35	4.99e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg01316550	chr5:56110833	MAP3K1	0.53	4.8	0.3	2.86e-6	Initial pursuit acceleration;
SARC	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg11965913	chr1:205819406	PM20D1	-0.51	-6.34	-0.38	1.19e-9	Menarche (age at onset);
SARC	cis	rs7546	0.504	rs2015319	chr16:4936280	C/G	cg08329684	chr16:4932620	PPL	-0.42	-6.72	-0.4	1.38e-10	Cancer;
SARC	cis	rs1008375	1.000	rs28497813	chr4:17685503	A/G	cg27347728	chr4:17578864	LAP3	0.45	5.54	0.34	8.14e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg15049968	chr18:44337910	ST8SIA5	-0.39	-6.05	-0.37	5.76e-9	Personality dimensions;
SARC	cis	rs9300255	0.602	rs1727315	chr12:123638930	A/G	cg00376283	chr12:123451042	ABCB9	-0.56	-6.5	-0.39	4.76e-10	Neutrophil percentage of white cells;
SARC	cis	rs1371867	0.875	rs1788169	chr8:101326314	C/T	cg11906718	chr8:101322791	RNF19A	0.71	9.12	0.51	3.68e-17	Atrioventricular conduction;
SARC	cis	rs6733011	0.559	rs6711022	chr2:99449536	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.38	-4.74	-0.3	3.67e-6	Bipolar disorder;
SARC	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg01341218	chr17:43662625	NA	-0.85	-9.63	-0.53	1.11e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg17755581	chr20:56964015	VAPB	-0.5	-6.77	-0.41	1.05e-10	Neuroticism;
SARC	cis	rs1448094	0.967	rs11117116	chr12:86331087	A/T	cg02569458	chr12:86230093	RASSF9	0.4	5.81	0.36	2.07e-8	Major depressive disorder;
SARC	trans	rs3942852	0.806	rs1503188	chr11:48117478	C/T	cg15704280	chr7:45808275	SEPT13	-0.58	-6.58	-0.4	3.15e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs11097912	0.632	rs77408017	chr4:107268488	C/A	cg09646026	chr4:107269030	AIMP1	-0.45	-4.73	-0.3	3.84e-6	Airflow obstruction;
SARC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg20887711	chr4:1340912	KIAA1530	0.78	9.27	0.52	1.34e-17	Longevity;
SARC	cis	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg15556689	chr8:8085844	FLJ10661	0.49	6.01	0.37	7.06e-9	Systolic blood pressure;
SARC	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg18876405	chr7:65276391	NA	0.42	4.87	0.3	2.07e-6	Aortic root size;
SARC	cis	rs1320333	0.772	rs17786111	chr2:700562	C/T	cg03444855	chr2:621920	NA	-0.49	-5.14	-0.32	5.92e-7	Obesity-related traits;
SARC	cis	rs12477438	0.765	rs7591992	chr2:99668954	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-9.6	-0.53	1.3e-18	Chronic sinus infection;
SARC	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg22535103	chr8:58192502	C8orf71	-0.78	-9.12	-0.51	3.6e-17	Developmental language disorder (linguistic errors);
SARC	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg23758822	chr17:41437982	NA	0.83	11.06	0.59	4.02e-23	Menopause (age at onset);
SARC	cis	rs7666738	0.753	rs7659724	chr4:98944063	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs634534	0.622	rs593525	chr11:65727799	T/C	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.42	-5.13	-0.32	6e-7	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs9818758	0.607	rs67831908	chr3:49313513	T/G	cg06212747	chr3:49208901	KLHDC8B	-0.7	-5.94	-0.36	1.05e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs7220711	1.000	rs9896582	chr17:41787209	G/C	cg26893861	chr17:41843967	DUSP3	0.4	5.06	0.31	8.37e-7	Bone mineral density (spine);Bone mineral density (hip);
SARC	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg20965017	chr5:231967	SDHA	-0.58	-5.51	-0.34	9.25e-8	Breast cancer;
SARC	cis	rs2213920	0.569	rs6478170	chr9:118246331	G/A	cg13918206	chr9:118159781	DEC1	0.77	6.27	0.38	1.75e-9	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg00864171	chr11:67383662	NA	0.46	6.38	0.39	9.57e-10	Mean corpuscular volume;
SARC	trans	rs61931739	0.534	rs11052986	chr12:34052578	T/C	cg26384229	chr12:38710491	ALG10B	0.74	10.63	0.57	8.92e-22	Morning vs. evening chronotype;
SARC	cis	rs6493487	0.512	rs71471587	chr15:51281623	G/T	cg02338191	chr15:51200825	AP4E1	0.55	5.09	0.32	7.21e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs2011503	0.891	rs2965186	chr19:19497195	T/G	cg03709012	chr19:19516395	GATAD2A	-0.65	-5.63	-0.35	5.07e-8	Bipolar disorder;
SARC	cis	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg14019146	chr3:50243930	SLC38A3	0.31	4.82	0.3	2.62e-6	Body mass index;
SARC	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg22618164	chr12:122356400	WDR66	0.42	6.54	0.39	3.8e-10	Mean corpuscular volume;
SARC	cis	rs11190604	1.000	rs2273695	chr10:102259568	A/G	cg07080220	chr10:102295463	HIF1AN	0.83	8.95	0.51	1.18e-16	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs4737010	0.644	rs777870	chr8:41610234	G/A	cg08923054	chr8:41654455	ANK1	-0.4	-4.86	-0.3	2.16e-6	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
SARC	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg11764359	chr7:65958608	NA	0.76	8.71	0.5	5.53e-16	Aortic root size;
SARC	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg04317338	chr11:64019027	PLCB3	0.83	8.49	0.49	2.43e-15	Mean platelet volume;
SARC	cis	rs9311474	0.598	rs1010554	chr3:52542919	T/C	cg05564831	chr3:52568323	NT5DC2	-0.3	-5.29	-0.33	2.85e-7	Electroencephalogram traits;
SARC	cis	rs796364	0.806	rs112486506	chr2:201073947	C/T	cg23649088	chr2:200775458	C2orf69	-0.64	-5.39	-0.33	1.7e-7	Schizophrenia;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg09754991	chr13:107220236	ARGLU1	0.59	7.58	0.44	8.04e-13	Breast cancer;
SARC	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg22974920	chr21:40686053	BRWD1	-0.47	-5.06	-0.31	8.41e-7	Cognitive function;
SARC	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg11987759	chr7:65425863	GUSB	0.48	5.94	0.36	1.06e-8	Aortic root size;
SARC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg10295955	chr4:187884368	NA	-1.07	-20.18	-0.8	4.55e-53	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9894429	0.550	rs6565617	chr17:79612333	G/A	cg18240062	chr17:79603768	NPLOC4	0.58	7.04	0.42	2.14e-11	Eye color traits;
SARC	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	8.76	0.5	4.1e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs10078	0.571	rs2721014	chr5:463539	G/A	cg24955955	chr5:415729	AHRR	0.73	6.66	0.4	1.93e-10	Fat distribution (HIV);
SARC	cis	rs35213789	0.802	rs2865805	chr7:69318195	A/C	cg10619644	chr7:69149951	AUTS2	0.39	4.83	0.3	2.42e-6	Childhood ear infection;
SARC	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg02725872	chr8:58115012	NA	-0.36	-6.32	-0.38	1.35e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg18876405	chr7:65276391	NA	-0.41	-4.77	-0.3	3.31e-6	Aortic root size;
SARC	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg26513180	chr16:89883248	FANCA	-0.9	-16.18	-0.73	5.77e-40	Vitiligo;
SARC	cis	rs11098499	0.954	rs35091806	chr4:120325529	G/A	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs3617	0.591	rs11918800	chr3:52868145	G/A	cg18404041	chr3:52824283	ITIH1	0.37	5.42	0.33	1.5e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs11650494	0.516	rs2233660	chr17:47492366	C/T	cg08112188	chr17:47440006	ZNF652	-0.74	-6.72	-0.4	1.38e-10	Prostate cancer;
SARC	cis	rs62344088	0.590	rs7700533	chr5:180646	C/T	cg22857025	chr5:266934	NA	-0.77	-5.36	-0.33	1.95e-7	Asthma (childhood onset);
SARC	cis	rs7666738	0.753	rs11932536	chr4:98930105	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs67311347	0.866	rs2371183	chr3:40334247	C/T	cg09455208	chr3:40491958	NA	-0.37	-6.0	-0.37	7.44e-9	Renal cell carcinoma;
SARC	cis	rs10782582	0.593	rs11802717	chr1:76124648	C/T	cg03433033	chr1:76189801	ACADM	-0.4	-5.23	-0.32	3.85e-7	Daytime sleep phenotypes;
SARC	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg09699651	chr6:150184138	LRP11	0.46	5.41	0.33	1.55e-7	Lung cancer;
SARC	cis	rs9487051	0.714	rs6927569	chr6:109621494	T/C	cg21918786	chr6:109611834	NA	-0.34	-4.75	-0.3	3.55e-6	Reticulocyte fraction of red cells;
SARC	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg16479474	chr6:28041457	NA	-0.36	-5.65	-0.35	4.57e-8	Depression;
SARC	cis	rs12594515	0.967	rs71405295	chr15:45988921	T/C	cg14863074	chr15:45997064	NA	0.34	5.24	0.32	3.57e-7	Waist circumference;Weight;
SARC	cis	rs4953404	0.613	rs4355163	chr2:46909817	G/C	cg09399716	chr2:46890238	NA	-0.25	-5.0	-0.31	1.12e-6	Pulse pressure (alcohol consumption interaction);
SARC	cis	rs9815354	0.830	rs1624519	chr3:41984800	G/A	cg03022575	chr3:42003672	ULK4	-0.56	-5.41	-0.33	1.55e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs654950	0.806	rs941971	chr1:42040893	T/C	cg06885757	chr1:42089581	HIVEP3	-0.43	-6.11	-0.37	4.19e-9	Airway imaging phenotypes;
SARC	cis	rs870825	0.587	rs7682995	chr4:185640684	G/A	cg04058563	chr4:185651563	MLF1IP	0.81	11.48	0.6	1.8e-24	Blood protein levels;
SARC	cis	rs17376456	0.932	rs3940842	chr5:93534858	C/A	cg25358565	chr5:93447407	FAM172A	1.35	14.06	0.68	6.12e-33	Diabetic retinopathy;
SARC	cis	rs7551222	0.752	rs1380576	chr1:204488278	G/C	cg20240347	chr1:204465584	NA	-0.33	-5.89	-0.36	1.36e-8	Schizophrenia;
SARC	cis	rs9911578	0.967	rs7502208	chr17:57165097	G/A	cg12560992	chr17:57184187	TRIM37	0.86	12.22	0.63	7.21e-27	Intelligence (multi-trait analysis);
SARC	cis	rs7216064	0.532	rs8065296	chr17:66018562	T/A	cg12091567	chr17:66097778	LOC651250	0.91	11.48	0.6	1.78e-24	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs911263	0.560	rs12896939	chr14:68812662	T/C	cg18825221	chr14:68749962	RAD51L1	0.42	7.48	0.44	1.53e-12	Primary biliary cholangitis;
SARC	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg08280861	chr8:58055591	NA	0.58	5.74	0.35	2.88e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs916888	0.610	rs199536	chr17:44820425	T/C	cg15921436	chr17:44337874	NA	-0.5	-5.76	-0.35	2.67e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs3768617	0.811	rs6674729	chr1:183059143	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.61	8.28	0.48	9.66e-15	Fuchs's corneal dystrophy;
SARC	cis	rs7659604	0.967	rs28529384	chr4:122664215	T/C	cg19671926	chr4:122722719	EXOSC9	-0.48	-5.91	-0.36	1.24e-8	Type 2 diabetes;
SARC	trans	rs629535	0.814	rs56326813	chr8:70107736	T/A	cg21567404	chr3:27674614	NA	-1.08	-14.03	-0.68	8.18e-33	Dupuytren's disease;
SARC	cis	rs4423214	0.959	rs12794668	chr11:71168715	C/T	cg24826892	chr11:71159390	DHCR7	0.46	5.76	0.35	2.69e-8	Vitamin D levels;
SARC	cis	rs11786130	0.901	rs4733817	chr8:129005584	G/A	cg01765152	chr8:129005526	PVT1	-0.46	-7.72	-0.45	3.48e-13	Eosinophil counts;Sum eosinophil basophil counts;
SARC	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg06074448	chr4:187884817	NA	-0.41	-5.4	-0.33	1.62e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg13175981	chr1:150552382	MCL1	-0.53	-6.81	-0.41	8.15e-11	Tonsillectomy;
SARC	cis	rs34779708	0.897	rs4934527	chr10:35281118	T/A	cg03585969	chr10:35415529	CREM	0.4	5.12	0.32	6.35e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs72781680	0.848	rs56371415	chr2:23932603	C/G	cg08917208	chr2:24149416	ATAD2B	0.93	8.58	0.49	1.32e-15	Lymphocyte counts;
SARC	cis	rs7666738	0.546	rs10010088	chr4:98655945	C/T	cg05340658	chr4:99064831	C4orf37	0.59	7.1	0.42	1.47e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg08975724	chr8:8085496	FLJ10661	0.48	6.09	0.37	4.7e-9	Mood instability;
SARC	cis	rs9814567	1.000	rs6766818	chr3:134226159	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-7.0	-0.42	2.75e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg12756686	chr19:29218302	NA	0.68	9.11	0.51	4e-17	Methadone dose in opioid dependence;
SARC	cis	rs9325144	0.671	rs35817541	chr12:38975001	T/C	cg26384229	chr12:38710491	ALG10B	-0.6	-7.88	-0.46	1.22e-13	Morning vs. evening chronotype;
SARC	cis	rs3126085	0.696	rs41266112	chr1:152185762	C/G	cg26876637	chr1:152193138	HRNR	0.47	5.37	0.33	1.87e-7	Atopic dermatitis;
SARC	cis	rs1915146	0.967	rs7086481	chr10:126844523	A/T	cg23000734	chr10:126850823	CTBP2	-0.32	-5.74	-0.35	2.89e-8	Menarche (age at onset);
SARC	cis	rs2439831	0.850	rs16950562	chr15:44036364	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.75	7.34	0.43	3.55e-12	Lung cancer in ever smokers;
SARC	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg11890956	chr21:40555474	PSMG1	1.14	18.51	0.77	1.18e-47	Cognitive function;
SARC	cis	rs546131	0.642	rs2915186	chr11:34851183	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.45	5.11	0.32	6.76e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs4727027	0.866	rs7778766	chr7:148806729	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.48	5.64	0.35	4.84e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs7786808	0.707	rs11770299	chr7:158228822	G/A	cg09998033	chr7:158218633	PTPRN2	-0.33	-5.27	-0.33	3.06e-7	Obesity-related traits;
SARC	trans	rs11098499	0.863	rs10019674	chr4:120443489	C/T	cg25214090	chr10:38739885	LOC399744	-0.56	-7.24	-0.43	6.35e-12	Corneal astigmatism;
SARC	cis	rs787274	0.543	rs4979177	chr9:115644266	G/A	cg13803584	chr9:115635662	SNX30	-0.71	-5.69	-0.35	3.76e-8	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg05872129	chr22:39784769	NA	-0.44	-6.38	-0.39	9.48e-10	Intelligence (multi-trait analysis);
SARC	cis	rs72945132	0.882	rs72945194	chr11:70138621	A/G	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.59	-0.34	6.41e-8	Coronary artery disease;
SARC	cis	rs1941023	0.584	rs10897057	chr11:60172273	A/T	cg08716584	chr11:60157161	MS4A7	-0.41	-6.65	-0.4	2.09e-10	Congenital heart disease (maternal effect);
SARC	trans	rs1635	0.655	rs1416919	chr6:28302884	T/G	cg08080395	chr15:65488966	CILP	0.66	6.47	0.39	5.71e-10	Schizophrenia;
SARC	cis	rs2712184	0.729	rs2541397	chr2:217646693	G/A	cg05032264	chr2:217675019	NA	-0.53	-7.04	-0.42	2.19e-11	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
SARC	cis	rs2204008	0.745	rs8189516	chr12:38239084	C/T	cg13010199	chr12:38710504	ALG10B	0.81	11.3	0.59	6.91e-24	Bladder cancer;
SARC	cis	rs11168187	0.891	rs757284	chr12:48128119	C/G	cg12761788	chr12:48120090	P11	-0.41	-5.32	-0.33	2.49e-7	Vertical cup-disc ratio;
SARC	trans	rs2018683	0.707	rs1021689	chr7:28974223	G/T	cg19402173	chr7:128379420	CALU	-0.5	-6.4	-0.39	8.28e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
SARC	cis	rs9747201	0.962	rs62078313	chr17:80116708	A/C	cg09264619	chr17:80180166	NA	0.5	5.87	0.36	1.5e-8	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs13401104	0.796	rs72620806	chr2:237113736	C/T	cg19324714	chr2:237145437	ASB18	0.57	5.91	0.36	1.22e-8	Educational attainment;
SARC	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.49	5.63	0.35	5.2e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs453301	0.631	rs11780774	chr8:8799111	C/A	cg11608241	chr8:8085544	FLJ10661	-0.42	-5.05	-0.31	8.79e-7	Joint mobility (Beighton score);
SARC	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.63e-10	Life satisfaction;
SARC	cis	rs644799	0.526	rs693172	chr11:95636618	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	10.43	0.56	3.74e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs11098499	0.754	rs34425882	chr4:120253177	G/A	cg09307838	chr4:120376055	NA	0.81	11.03	0.59	4.84e-23	Corneal astigmatism;
SARC	cis	rs1957429	0.614	rs76809238	chr14:65380579	C/T	cg23373153	chr14:65346875	NA	-1.03	-6.42	-0.39	7.58e-10	Pediatric areal bone mineral density (radius);
SARC	cis	rs7582720	1.000	rs6738618	chr2:203749439	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.31	0.43	4.24e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs7043114	0.525	rs7847929	chr9:95154244	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.49	-0.34	1.03e-7	Height;
SARC	cis	rs7481584	0.624	rs516443	chr11:3047294	A/G	cg20651018	chr11:3035856	CARS	0.41	6.08	0.37	4.91e-9	Calcium levels;
SARC	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.56	5.24	0.32	3.52e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs6011674	1.000	rs11908424	chr20:61863955	C/T	cg06763829	chr20:61885236	FLJ16779;NKAIN4	0.63	4.85	0.3	2.26e-6	Response to cytadine analogues (cytosine arabinoside);
SARC	cis	rs9868809	0.505	rs13316551	chr3:48745167	A/C	cg03060546	chr3:49711283	APEH	-0.51	-4.74	-0.3	3.73e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs7084402	0.967	rs1658462	chr10:60298284	A/C	cg07615347	chr10:60278583	BICC1	0.59	8.77	0.5	3.93e-16	Refractive error;
SARC	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg22800045	chr5:56110881	MAP3K1	0.76	8.19	0.47	1.68e-14	Initial pursuit acceleration;
SARC	cis	rs472402	0.507	rs8192139	chr5:6636973	C/G	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.41	-5.13	-0.32	6.08e-7	Response to amphetamines;
SARC	cis	rs6840360	0.868	rs6823462	chr4:152708740	G/A	cg22705602	chr4:152727874	NA	-0.37	-6.52	-0.39	4.39e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7659604	0.643	rs6839054	chr4:122663628	C/T	cg19748678	chr4:122722346	EXOSC9	0.47	5.52	0.34	9.15e-8	Type 2 diabetes;
SARC	cis	rs10782582	0.593	rs11802717	chr1:76124648	C/T	cg10523679	chr1:76189770	ACADM	-0.41	-5.1	-0.32	6.96e-7	Daytime sleep phenotypes;
SARC	cis	rs12142240	0.731	rs6681857	chr1:46850124	T/C	cg10495392	chr1:46806563	NSUN4	0.61	6.15	0.37	3.41e-9	Menopause (age at onset);
SARC	cis	rs950776	0.518	rs12915428	chr15:78823368	G/A	cg17108064	chr15:78857060	CHRNA5	0.29	4.93	0.31	1.56e-6	Sudden cardiac arrest;
SARC	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg19223190	chr17:80058835	NA	0.45	6.29	0.38	1.57e-9	Life satisfaction;
SARC	cis	rs2075671	0.903	rs4727459	chr7:100276821	T/C	cg03098644	chr7:100410630	EPHB4	0.45	4.91	0.31	1.74e-6	Other erythrocyte phenotypes;
SARC	cis	rs2933343	0.700	rs789233	chr3:128603150	G/T	cg24203234	chr3:128598194	ACAD9	0.64	8.27	0.48	1.03e-14	IgG glycosylation;
SARC	cis	rs10979	0.931	rs9484771	chr6:143896897	T/A	cg25407410	chr6:143891975	LOC285740	-0.64	-8.78	-0.5	3.67e-16	Hypospadias;
SARC	cis	rs11203032	1.000	rs11203031	chr10:90964395	G/T	cg16672925	chr10:90967113	CH25H	0.67	7.3	0.43	4.43e-12	Heart failure;
SARC	cis	rs7529073	0.545	rs1431985	chr1:214148246	C/T	cg24083324	chr1:214162604	PROX1	-0.39	-5.46	-0.34	1.23e-7	Schizophrenia;
SARC	cis	rs11997175	0.766	rs4273817	chr8:33702686	C/T	ch.8.33884649F	chr8:33765107	NA	0.57	7.72	0.45	3.31e-13	Body mass index;
SARC	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	9.59	0.53	1.45e-18	Platelet count;
SARC	cis	rs10905065	0.862	rs9423948	chr10:5742491	G/A	cg09072322	chr10:5726702	C10orf18	-0.39	-4.83	-0.3	2.5e-6	Menopause (age at onset);
SARC	trans	rs13240504	0.557	rs12154383	chr7:126176966	T/C	cg12155036	chr3:194015171	NA	-0.55	-6.46	-0.39	6.17e-10	Anti-saccade response;
SARC	cis	rs11997175	0.600	rs4739590	chr8:33802686	A/G	ch.8.33884649F	chr8:33765107	NA	0.4	5.15	0.32	5.49e-7	Body mass index;
SARC	cis	rs7927771	1.000	rs4752873	chr11:47857520	C/T	cg20307385	chr11:47447363	PSMC3	-0.48	-5.7	-0.35	3.6e-8	Subjective well-being;
SARC	cis	rs2115630	1.000	rs8037423	chr15:85355494	C/T	cg12501888	chr15:85177176	SCAND2	-0.46	-5.64	-0.35	4.97e-8	P wave terminal force;
SARC	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-7.83	-0.46	1.71e-13	Alzheimer's disease;
SARC	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg08219700	chr8:58056026	NA	0.6	5.82	0.36	1.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1832871	0.672	rs9457345	chr6:158743098	A/G	cg07165851	chr6:158734300	TULP4	0.58	6.77	0.41	1.05e-10	Height;
SARC	cis	rs7766436	0.583	rs62389420	chr6:22557720	G/A	cg13666174	chr6:22585274	NA	-0.59	-6.07	-0.37	5.23e-9	Coronary artery disease;
SARC	cis	rs2624839	0.704	rs12637671	chr3:50224562	G/A	cg24110177	chr3:50126178	RBM5	0.57	7.17	0.43	9.57e-12	Intelligence (multi-trait analysis);
SARC	trans	rs61931739	0.500	rs56056630	chr12:34543465	T/C	cg13010199	chr12:38710504	ALG10B	0.78	11.07	0.59	3.68e-23	Morning vs. evening chronotype;
SARC	cis	rs2228479	0.702	rs11649501	chr16:89850957	A/T	cg12064134	chr16:90016061	DEF8	-0.59	-5.06	-0.31	8.56e-7	Skin colour saturation;
SARC	cis	rs2933343	0.621	rs728838	chr3:128589013	A/G	cg25356066	chr3:128598488	ACAD9	0.7	9.3	0.52	1.07e-17	IgG glycosylation;
SARC	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg05896524	chr21:47604654	C21orf56	0.4	4.75	0.3	3.6e-6	Testicular germ cell tumor;
SARC	cis	rs7726839	0.561	rs6555357	chr5:560923	A/G	cg07777115	chr5:623756	CEP72	-0.59	-5.46	-0.34	1.19e-7	Obesity-related traits;
SARC	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg21442419	chr1:2182373	SKI	0.37	4.78	0.3	3.15e-6	Height;
SARC	cis	rs193541	0.586	rs11241662	chr5:122181975	A/G	cg19412675	chr5:122181750	SNX24	-0.47	-6.1	-0.37	4.38e-9	Glucose homeostasis traits;
SARC	cis	rs3820928	0.935	rs113195824	chr2:227769139	A/G	cg05526886	chr2:227700861	RHBDD1	-0.49	-5.92	-0.36	1.13e-8	Pulmonary function;
SARC	cis	rs76419734	0.850	rs72673805	chr4:106700822	C/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.8	5.36	0.33	2.02e-7	Post bronchodilator FEV1;
SARC	cis	rs7568458	0.709	rs2043675	chr2:85769975	C/T	cg23752985	chr2:85803571	VAMP8	-0.4	-5.05	-0.31	9.03e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	trans	rs3808502	0.526	rs36048422	chr8:11417144	T/C	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.76	-0.4	1.08e-10	Neuroticism;
SARC	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg22535103	chr8:58192502	C8orf71	-0.71	-6.82	-0.41	7.73e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs8044995	0.563	rs56220628	chr16:68384837	G/A	cg09835421	chr16:68378352	PRMT7	-0.66	-6.27	-0.38	1.7e-9	Schizophrenia;
SARC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg26338869	chr17:61819248	STRADA	0.81	10.92	0.58	1.13e-22	Prudent dietary pattern;
SARC	cis	rs7130144	0.541	rs73572219	chr11:130459830	C/T	cg26307797	chr11:130446613	NA	-0.7	-5.81	-0.36	2.02e-8	Urate levels in lean individuals;
SARC	cis	rs9611519	1.000	rs9611520	chr22:41613303	C/T	cg17376030	chr22:41985996	PMM1	0.5	6.07	0.37	5.23e-9	Neuroticism;
SARC	cis	rs870825	0.616	rs12512839	chr4:185610347	G/A	cg04058563	chr4:185651563	MLF1IP	0.86	11.47	0.6	1.97e-24	Blood protein levels;
SARC	cis	rs7833986	0.501	rs2719258	chr8:56941389	C/T	cg26371346	chr8:56986568	SNORD54;RPS20	0.73	7.27	0.43	5.52e-12	Height;
SARC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg09373136	chr17:61933544	TCAM1	-0.44	-5.99	-0.37	7.94e-9	Prudent dietary pattern;
SARC	cis	rs870825	0.616	rs28608669	chr4:185632890	T/C	cg04058563	chr4:185651563	MLF1IP	0.85	11.37	0.6	4.03e-24	Blood protein levels;
SARC	cis	rs10046574	0.519	rs17403948	chr7:135215169	C/T	cg27474649	chr7:135195673	CNOT4	-0.79	-7.57	-0.44	8.67e-13	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs270601	0.913	rs273899	chr5:131695178	G/A	cg04518342	chr5:131593106	PDLIM4	0.44	5.57	0.34	7.06e-8	Acylcarnitine levels;
SARC	cis	rs8114671	0.804	rs6060139	chr20:33566499	T/C	cg24642439	chr20:33292090	TP53INP2	0.49	5.64	0.35	4.78e-8	Height;
SARC	cis	rs10876993	0.784	rs10083154	chr12:58020933	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.46	5.6	0.34	5.88e-8	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs67460515	0.563	rs6441362	chr3:160877613	G/A	cg17135325	chr3:160939158	NMD3	0.65	8.22	0.47	1.45e-14	Parkinson's disease;
SARC	cis	rs4619890	0.528	rs28622214	chr4:7879440	C/T	cg18538662	chr4:7941764	AFAP1	-0.37	-4.76	-0.3	3.39e-6	Glaucoma (primary open-angle);
SARC	cis	rs5753618	0.509	rs5997913	chr22:31593959	C/A	cg07713946	chr22:31675144	LIMK2	-0.38	-5.29	-0.33	2.76e-7	Colorectal cancer;
SARC	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg27286337	chr10:134555280	INPP5A	0.67	7.89	0.46	1.15e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs36051895	0.664	rs17425819	chr9:5114773	C/T	cg02405213	chr9:5042618	JAK2	-0.41	-4.92	-0.31	1.63e-6	Pediatric autoimmune diseases;
SARC	cis	rs7223966	1.000	rs8081612	chr17:61724695	A/G	cg26338869	chr17:61819248	STRADA	-0.46	-5.28	-0.33	2.95e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg16132339	chr22:24313637	DDTL;DDT	0.42	5.54	0.34	8.35e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9400467	0.506	rs78051065	chr6:111600406	A/G	cg15721981	chr6:111408429	SLC16A10	0.67	5.77	0.35	2.55e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg12311346	chr5:56204834	C5orf35	-0.54	-5.58	-0.34	6.53e-8	Initial pursuit acceleration;
SARC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg09373136	chr17:61933544	TCAM1	-0.44	-6.07	-0.37	5.18e-9	Prudent dietary pattern;
SARC	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg22800045	chr5:56110881	MAP3K1	-0.69	-7.39	-0.44	2.57e-12	Initial pursuit acceleration;
SARC	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg08280861	chr8:58055591	NA	-0.58	-5.08	-0.32	7.87e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg16405210	chr4:1374714	KIAA1530	-0.51	-6.07	-0.37	5.28e-9	Obesity-related traits;
SARC	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.35	4.81	0.3	2.73e-6	Personality dimensions;
SARC	cis	rs2204008	0.571	rs8175738	chr12:38311234	C/T	cg26384229	chr12:38710491	ALG10B	-0.59	-7.31	-0.43	4.14e-12	Bladder cancer;
SARC	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg01448562	chr3:133502909	NA	-0.46	-6.7	-0.4	1.58e-10	Iron status biomarkers;
SARC	cis	rs10493773	0.862	rs12075929	chr1:86248138	A/C	cg17807903	chr1:86174739	ZNHIT6	0.48	7.01	0.42	2.59e-11	Urate levels in overweight individuals;
SARC	cis	rs12447804	0.863	rs12929002	chr16:58085882	A/G	cg03859792	chr16:58121049	NA	-0.38	-5.29	-0.33	2.77e-7	Pulmonary function;Pulmonary function (smoking interaction);
SARC	cis	rs9858542	0.537	rs9874474	chr3:49326178	A/G	cg00383909	chr3:49044727	WDR6	0.49	5.11	0.32	6.6e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg02462569	chr6:150064036	NUP43	-0.37	-4.8	-0.3	2.85e-6	Lung cancer;
SARC	cis	rs8114671	0.933	rs2103971	chr20:33786256	T/C	cg24642439	chr20:33292090	TP53INP2	-0.48	-5.44	-0.34	1.36e-7	Height;
SARC	cis	rs607987	0.776	rs11031032	chr11:30304726	G/C	cg06241208	chr11:30344200	C11orf46	0.42	5.14	0.32	5.9e-7	Body mass index;
SARC	cis	rs116095464	0.558	rs7356535	chr5:284117	G/T	cg22496380	chr5:211416	CCDC127	-0.96	-8.83	-0.5	2.59e-16	Breast cancer;
SARC	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg22535103	chr8:58192502	C8orf71	-0.8	-7.83	-0.46	1.69e-13	Developmental language disorder (linguistic errors);
SARC	cis	rs35110281	0.807	rs9976441	chr21:45046591	G/A	cg21573476	chr21:45109991	RRP1B	-0.5	-7.44	-0.44	1.94e-12	Mean corpuscular volume;
SARC	trans	rs56279505	0.690	rs56109716	chr4:100284798	A/G	cg21156590	chr1:3420848	MEGF6	-0.83	-6.49	-0.39	5.01e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg17545662	chr6:170176663	C6orf70	0.43	5.87	0.36	1.46e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs9807989	0.839	rs4988956	chr2:102968007	G/A	cg09003973	chr2:102972529	NA	0.41	5.6	0.34	6.11e-8	Asthma;
SARC	cis	rs3741798	1.000	rs61922028	chr12:12487096	A/C	cg08615371	chr12:12503544	MANSC1	0.84	6.58	0.4	3.05e-10	Cerebrospinal fluid biomarker levels;
SARC	cis	rs2916247	0.955	rs2976501	chr8:92976563	T/G	cg10183463	chr8:93005414	RUNX1T1	0.5	5.12	0.32	6.34e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2228479	0.850	rs9282681	chr16:89805914	T/C	cg00800038	chr16:89945340	TCF25	-0.74	-5.03	-0.31	9.61e-7	Skin colour saturation;
SARC	trans	rs61931739	0.517	rs10844802	chr12:34231001	C/A	cg13010199	chr12:38710504	ALG10B	0.74	9.99	0.55	8.5e-20	Morning vs. evening chronotype;
SARC	cis	rs10078	0.571	rs2671890	chr5:456457	A/G	cg24955955	chr5:415729	AHRR	0.72	6.54	0.39	3.84e-10	Fat distribution (HIV);
SARC	cis	rs10927875	0.619	rs28537253	chr1:16148600	A/C	cg21385522	chr1:16154831	NA	-0.61	-8.24	-0.47	1.25e-14	Dilated cardiomyopathy;
SARC	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg09455208	chr3:40491958	NA	0.39	5.66	0.35	4.41e-8	Renal cell carcinoma;
SARC	cis	rs9875589	0.509	rs6770928	chr3:14077189	G/C	cg19554555	chr3:13937349	NA	-0.38	-4.87	-0.3	2.08e-6	Ovarian reserve;
SARC	cis	rs2635047	0.638	rs9956809	chr18:44655843	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	6.5	0.39	4.81e-10	Educational attainment;
SARC	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg07636037	chr3:49044803	WDR6	0.99	17.48	0.75	2.73e-44	Parkinson's disease;
SARC	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs240764	0.746	rs240156	chr6:101063149	C/G	cg09795085	chr6:101329169	ASCC3	0.46	5.74	0.35	2.98e-8	Neuroticism;
SARC	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg11987759	chr7:65425863	GUSB	0.48	5.91	0.36	1.22e-8	Aortic root size;
SARC	cis	rs6582630	0.547	rs1589388	chr12:38416025	C/T	cg14851346	chr12:38532713	NA	-0.47	-5.67	-0.35	4.25e-8	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs2736345	0.788	rs998683	chr8:11353000	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.29	-0.38	1.54e-9	Sjögren's syndrome;Systemic lupus erythematosus;
SARC	cis	rs5760092	0.755	rs6003959	chr22:24264395	C/T	cg20007245	chr22:24372913	LOC391322	0.68	7.63	0.45	5.82e-13	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs73086581	1.000	rs2326289	chr20:3952300	T/C	cg02187196	chr20:3869020	PANK2	0.67	6.4	0.39	8.3e-10	Response to antidepressants in depression;
SARC	cis	rs449789	0.857	rs2451988	chr6:159714390	G/A	cg14500486	chr6:159655392	FNDC1	-0.44	-5.02	-0.31	1.01e-6	Pulse pressure;
SARC	cis	rs76419734	1.000	rs35370743	chr4:106604190	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.81	4.88	0.3	1.96e-6	Post bronchodilator FEV1;
SARC	cis	rs477692	0.789	rs506915	chr10:131398005	A/G	cg14263093	chr10:131365266	MGMT	0.35	5.06	0.31	8.65e-7	Response to temozolomide;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg23018707	chr12:32145672	C12orf35	0.5	6.88	0.41	5.46e-11	Thyroid stimulating hormone;
SARC	cis	rs7945705	0.935	rs2568061	chr11:8886260	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.46	-6.46	-0.39	5.97e-10	Hemoglobin concentration;
SARC	cis	rs208520	1.000	rs12190773	chr6:66968194	T/C	cg07460842	chr6:66804631	NA	0.86	9.56	0.53	1.79e-18	Exhaled nitric oxide output;
SARC	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-10.05	-0.55	5.49e-20	Chronic sinus infection;
SARC	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg13271783	chr10:134563150	INPP5A	-0.38	-4.97	-0.31	1.27e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs3784262	0.692	rs1822205	chr15:58284657	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.35	-5.25	-0.33	3.48e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs7617773	1.000	rs9832957	chr3:48185266	A/G	cg11946769	chr3:48343235	NME6	-0.53	-6.25	-0.38	1.95e-9	Coronary artery disease;
SARC	cis	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg20965017	chr5:231967	SDHA	-0.55	-5.26	-0.33	3.23e-7	Breast cancer;
SARC	cis	rs3126085	1.000	rs2011331	chr1:152286002	T/C	cg26876637	chr1:152193138	HRNR	-0.47	-5.19	-0.32	4.65e-7	Atopic dermatitis;
SARC	cis	rs3758785	0.537	rs622647	chr11:94069719	T/C	cg13023536	chr11:94226537	MRE11A;ANKRD49	-0.44	-5.64	-0.35	4.92e-8	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
SARC	cis	rs9388451	0.839	rs4897155	chr6:126095144	C/A	cg06289844	chr6:126071538	HEY2	0.35	5.67	0.35	4.18e-8	Brugada syndrome;
SARC	cis	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg18252515	chr7:66147081	NA	-1.42	-13.08	-0.65	1.15e-29	Diabetic kidney disease;
SARC	cis	rs1568889	1.000	rs11826837	chr11:28322566	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.72	-9.88	-0.54	1.82e-19	Bipolar disorder;
SARC	cis	rs3820928	0.904	rs59135978	chr2:227857763	T/C	cg11843606	chr2:227700838	RHBDD1	-0.49	-5.95	-0.36	9.92e-9	Pulmonary function;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg23508591	chr15:75871807	PTPN9	0.51	6.3	0.38	1.47e-9	Height;
SARC	trans	rs36093844	0.800	rs76663264	chr11:85578455	C/G	cg27065003	chr5:122429449	PRDM6	-0.54	-6.42	-0.39	7.74e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs2832191	0.692	rs2245517	chr21:30357968	C/T	cg08807101	chr21:30365312	RNF160	0.91	14.5	0.69	2.12e-34	Dental caries;
SARC	cis	rs7296418	0.699	rs11608297	chr12:123826642	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-5.07	-0.31	8.3e-7	Platelet count;
SARC	cis	rs912057	0.585	rs1745341	chr6:6744990	T/C	cg06612196	chr6:6737390	NA	0.63	9.53	0.53	2.18e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.9	14.49	0.69	2.32e-34	Subjective well-being;
SARC	trans	rs9329221	0.905	rs17709397	chr8:10249861	G/A	cg06636001	chr8:8085503	FLJ10661	-0.68	-9.26	-0.52	1.42e-17	Neuroticism;
SARC	trans	rs877282	0.583	rs12358255	chr10:828626	C/T	cg22713356	chr15:30763199	NA	0.92	9.03	0.51	6.59e-17	Uric acid levels;
SARC	cis	rs8060686	0.920	rs2271293	chr16:67902070	A/G	cg27539214	chr16:67997921	SLC12A4	0.56	4.76	0.3	3.4e-6	HDL cholesterol;Metabolic syndrome;
SARC	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg20203357	chr6:166919577	RPS6KA2	-0.43	-6.24	-0.38	2.05e-9	Body mass index;
SARC	cis	rs11122272	0.735	rs2808604	chr1:231538916	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.04	-0.55	6e-20	Hemoglobin concentration;
SARC	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg16405210	chr4:1374714	KIAA1530	0.53	6.47	0.39	5.64e-10	Obesity-related traits;
SARC	cis	rs9462027	0.628	rs2814971	chr6:34714209	A/T	cg07306190	chr6:34760872	UHRF1BP1	0.41	5.86	0.36	1.59e-8	Systemic lupus erythematosus;
SARC	cis	rs2806561	0.514	rs7519093	chr1:23541078	A/T	cg12483005	chr1:23474871	LUZP1	0.39	4.96	0.31	1.33e-6	Height;
SARC	cis	rs1185460	0.967	rs1784459	chr11:118938388	C/A	cg01677386	chr11:118938358	VPS11	-0.39	-4.72	-0.3	4.08e-6	Coronary artery disease;
SARC	cis	rs3733585	0.673	rs4455410	chr4:9953297	C/T	cg00071950	chr4:10020882	SLC2A9	0.37	5.61	0.35	5.57e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg17221315	chr6:27791827	HIST1H4J	0.45	4.75	0.3	3.57e-6	Depression;
SARC	cis	rs17826219	0.636	rs7221463	chr17:29080551	A/C	cg13385521	chr17:29058706	SUZ12P	0.88	7.75	0.45	2.9e-13	Body mass index;
SARC	cis	rs2549003	1.000	rs10068129	chr5:131821246	A/G	cg21138405	chr5:131827807	IRF1	-0.28	-5.55	-0.34	7.89e-8	Asthma (sex interaction);
SARC	cis	rs2370759	1.000	rs79487858	chr10:32616405	T/C	cg01819863	chr10:32635814	EPC1	1.02	10.19	0.56	2.06e-20	Sexual dysfunction (female);
SARC	cis	rs9611565	0.918	rs2281333	chr22:41749630	T/C	cg17376030	chr22:41985996	PMM1	0.56	7.06	0.42	1.91e-11	Vitiligo;
SARC	cis	rs9291683	0.546	rs13120348	chr4:10053155	C/G	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.24	-0.43	6.67e-12	Bone mineral density;
SARC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.8	10.38	0.56	5.49e-21	Prudent dietary pattern;
SARC	cis	rs16976116	0.643	rs7183255	chr15:55513601	A/T	cg17854078	chr15:55489399	RSL24D1	-0.52	-5.24	-0.32	3.65e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs11690935	0.589	rs62183782	chr2:172865009	T/A	cg13550731	chr2:172543902	DYNC1I2	0.51	6.53	0.39	4.03e-10	Schizophrenia;
SARC	cis	rs3812831	0.635	rs6560937	chr13:114945991	C/G	cg06611532	chr13:114900021	NA	0.36	6.17	0.37	3.03e-9	Schizophrenia;
SARC	cis	rs11718455	0.960	rs13060222	chr3:44005046	A/T	cg08738300	chr3:44038990	NA	0.54	5.94	0.36	1.01e-8	Coronary artery disease;
SARC	cis	rs8114671	0.967	rs4911476	chr20:33780768	A/C	cg24642439	chr20:33292090	TP53INP2	-0.5	-5.75	-0.35	2.84e-8	Height;
SARC	trans	rs56279505	0.629	rs78346552	chr4:100247609	A/G	cg18024358	chr1:3420815	MEGF6	-0.84	-6.43	-0.39	7.04e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6142102	0.961	rs1883524	chr20:32626107	G/A	cg24642439	chr20:33292090	TP53INP2	0.44	4.81	0.3	2.67e-6	Skin pigmentation;
SARC	cis	rs9733	0.818	rs6694531	chr1:150683512	C/A	cg15448220	chr1:150897856	SETDB1	-0.36	-4.73	-0.3	3.86e-6	Tonsillectomy;
SARC	cis	rs240764	0.658	rs9322183	chr6:101225121	G/A	cg09795085	chr6:101329169	ASCC3	-0.43	-5.53	-0.34	8.64e-8	Neuroticism;
SARC	cis	rs1538970	0.962	rs2153608	chr1:45813941	C/T	cg05343316	chr1:45956843	TESK2	-0.66	-7.94	-0.46	8.5e-14	Platelet count;
SARC	cis	rs3020736	0.500	rs6002603	chr22:42492362	C/G	cg15557168	chr22:42548783	NA	0.36	4.92	0.31	1.61e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs3126085	0.935	rs12742573	chr1:152260103	A/C	cg09127314	chr1:152161683	NA	-0.46	-5.01	-0.31	1.09e-6	Atopic dermatitis;
SARC	trans	rs12310956	0.510	rs10844693	chr12:33865197	A/G	cg26384229	chr12:38710491	ALG10B	-0.64	-8.58	-0.49	1.35e-15	Morning vs. evening chronotype;
SARC	trans	rs656319	0.638	rs670044	chr8:9892529	G/T	cg15556689	chr8:8085844	FLJ10661	0.53	6.31	0.38	1.37e-9	Myopia (pathological);
SARC	cis	rs72781680	1.000	rs115861480	chr2:24129464	T/A	cg06627628	chr2:24431161	ITSN2	-0.75	-6.86	-0.41	6.31e-11	Lymphocyte counts;
SARC	cis	rs7084402	0.967	rs1658446	chr10:60314183	A/C	cg07615347	chr10:60278583	BICC1	0.59	8.65	0.49	8.56e-16	Refractive error;
SARC	trans	rs208520	0.545	rs10944874	chr6:66752080	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-19.49	-0.79	7.5e-51	Exhaled nitric oxide output;
SARC	cis	rs10861342	1.000	rs11112394	chr12:105551570	C/T	cg23923672	chr12:105501055	KIAA1033	-0.71	-5.19	-0.32	4.59e-7	IgG glycosylation;
SARC	cis	rs7568458	0.709	rs11895401	chr2:85753847	C/T	cg23752985	chr2:85803571	VAMP8	0.4	5.28	0.33	3.02e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs9430161	0.645	rs12081186	chr1:11034195	T/C	cg27631724	chr1:11040367	C1orf127	0.33	4.71	0.3	4.2e-6	Ewing sarcoma;
SARC	cis	rs9916302	0.752	rs9901219	chr17:37558369	T/G	cg00129232	chr17:37814104	STARD3	0.54	6.12	0.37	3.95e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs7937682	0.562	rs630002	chr11:111377758	G/A	cg22437258	chr11:111473054	SIK2	0.43	5.19	0.32	4.48e-7	Primary sclerosing cholangitis;
SARC	cis	rs1983891	0.955	rs9381076	chr6:41517564	G/A	cg15051332	chr6:41514432	FOXP4	0.53	5.76	0.35	2.62e-8	Prostate cancer;
SARC	cis	rs7264396	0.676	rs6060723	chr20:34549947	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-6.92	-0.41	4.41e-11	Total cholesterol levels;
SARC	cis	rs7872515	0.775	rs1970121	chr9:94870152	A/C	cg01248375	chr9:94877805	SPTLC1	-0.67	-6.06	-0.37	5.51e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs73198271	0.530	rs113160067	chr8:8654521	A/C	cg01851573	chr8:8652454	MFHAS1	0.38	4.72	0.3	4.08e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs8141529	0.778	rs5762795	chr22:29182500	C/A	cg15103426	chr22:29168792	CCDC117	0.69	9.43	0.53	4.44e-18	Lymphocyte counts;
SARC	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg11764359	chr7:65958608	NA	-0.83	-10.8	-0.58	2.67e-22	Aortic root size;
SARC	cis	rs2236918	0.901	rs1776135	chr1:242025530	A/G	cg17736920	chr1:242011382	EXO1	0.77	10.82	0.58	2.24e-22	Menopause (age at onset);
SARC	cis	rs7223966	1.000	rs7209435	chr17:61712964	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.47	-5.12	-0.32	6.5e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg14773178	chr5:1868261	NA	0.34	5.31	0.33	2.56e-7	Cardiovascular disease risk factors;
SARC	cis	rs7945705	0.902	rs10769980	chr11:9014180	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.44	6.13	0.37	3.71e-9	Hemoglobin concentration;
SARC	cis	rs3741151	0.881	rs73542929	chr11:73094539	G/T	cg17517138	chr11:73019481	ARHGEF17	0.89	6.47	0.39	5.75e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.97	10.28	0.56	1.11e-20	Platelet count;
SARC	trans	rs11098499	0.779	rs7356491	chr4:120381974	C/T	cg25214090	chr10:38739885	LOC399744	0.54	7.11	0.42	1.38e-11	Corneal astigmatism;
SARC	cis	rs2197308	0.740	rs10880619	chr12:37922720	T/C	cg13010199	chr12:38710504	ALG10B	0.8	11.02	0.59	5.3e-23	Morning vs. evening chronotype;
SARC	cis	rs9372253	0.645	rs7753212	chr6:110700229	T/C	cg00083206	chr6:110721305	DDO	-0.38	-5.1	-0.32	6.88e-7	Platelet distribution width;
SARC	cis	rs957448	1.000	rs12678305	chr8:95521139	T/C	cg26464482	chr8:95565502	KIAA1429	0.43	4.74	0.3	3.73e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg00933542	chr6:150070202	PCMT1	0.33	5.69	0.35	3.81e-8	Lung cancer;
SARC	cis	rs3858526	0.959	rs1840179	chr11:5949148	A/G	cg05234568	chr11:5960015	NA	-0.42	-4.87	-0.3	2.07e-6	DNA methylation (variation);
SARC	cis	rs2276314	0.857	rs62101394	chr18:33592299	C/T	cg19628046	chr18:33552617	C18orf21	0.58	5.87	0.36	1.51e-8	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs6860806	0.507	rs270614	chr5:131640813	G/A	cg11843238	chr5:131593191	PDLIM4	0.39	4.81	0.3	2.66e-6	Breast cancer;
SARC	cis	rs1450679	0.891	rs3758291	chr9:106854122	C/T	cg21169611	chr9:106856078	SMC2	0.58	5.1	0.32	7.06e-7	Response to cytadine analogues (cytosine arabinoside);
SARC	cis	rs7833986	0.501	rs72653967	chr8:56999432	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.73	7.47	0.44	1.56e-12	Height;
SARC	cis	rs6120849	0.754	rs1885117	chr20:33600740	C/T	cg24642439	chr20:33292090	TP53INP2	0.56	5.38	0.33	1.78e-7	Protein C levels;
SARC	cis	rs76419734	1.000	rs11727500	chr4:106745948	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	5.33	0.33	2.37e-7	Post bronchodilator FEV1;
SARC	cis	rs6424115	0.800	rs4649123	chr1:24197696	A/G	cg09473613	chr1:24152604	HMGCL	0.35	5.07	0.32	7.95e-7	Immature fraction of reticulocytes;
SARC	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg00149659	chr3:10157352	C3orf10	0.64	5.91	0.36	1.22e-8	Alzheimer's disease;
SARC	cis	rs240764	0.507	rs17794439	chr6:101177456	G/A	cg09795085	chr6:101329169	ASCC3	0.41	4.94	0.31	1.48e-6	Neuroticism;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg09638070	chr5:10583443	ANKRD33B	0.49	6.26	0.38	1.83e-9	Schizophrenia;
SARC	cis	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg15726785	chr20:3827665	MAVS	0.42	5.63	0.35	5.13e-8	Immature fraction of reticulocytes;
SARC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	19.35	0.79	2.25e-50	Prudent dietary pattern;
SARC	cis	rs72627123	0.867	rs8019192	chr14:74471267	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.79	5.88	0.36	1.38e-8	Morning vs. evening chronotype;
SARC	cis	rs7712401	0.601	rs39819	chr5:122301676	G/A	cg19412675	chr5:122181750	SNX24	0.4	5.13	0.32	5.98e-7	Mean platelet volume;
SARC	cis	rs453301	0.605	rs7843024	chr8:8799976	G/A	cg11608241	chr8:8085544	FLJ10661	-0.41	-4.88	-0.3	1.95e-6	Joint mobility (Beighton score);
SARC	cis	rs2204008	0.776	rs8186824	chr12:38316537	A/C	cg13010199	chr12:38710504	ALG10B	0.75	10.16	0.55	2.68e-20	Bladder cancer;
SARC	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg09517075	chr8:22133004	PIWIL2	0.35	4.84	0.3	2.34e-6	Hypertriglyceridemia;
SARC	cis	rs7179456	0.547	rs653765	chr15:59042012	T/C	cg05156742	chr15:59063176	FAM63B	0.66	8.6	0.49	1.16e-15	Asperger disorder;
SARC	cis	rs1355223	0.902	rs836466	chr11:34737366	G/T	cg18508148	chr11:34937573	PDHX;APIP	-0.38	-4.83	-0.3	2.46e-6	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg16049864	chr8:95962084	TP53INP1	-0.46	-7.52	-0.44	1.18e-12	Type 2 diabetes;
SARC	cis	rs9291683	0.669	rs887733	chr4:10183108	T/C	cg11266682	chr4:10021025	SLC2A9	-0.32	-5.32	-0.33	2.42e-7	Bone mineral density;
SARC	cis	rs3126085	0.932	rs11587676	chr1:152159961	C/T	cg26876637	chr1:152193138	HRNR	-0.53	-5.83	-0.36	1.88e-8	Atopic dermatitis;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg07452098	chr3:173457176	NLGN1	0.5	7.9	0.46	1.11e-13	Thyroid stimulating hormone;
SARC	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg25894440	chr7:65020034	NA	0.73	5.51	0.34	9.25e-8	Diabetic kidney disease;
SARC	cis	rs12579753	1.000	rs7306395	chr12:82175867	A/G	cg07988820	chr12:82153109	PPFIA2	-0.56	-6.58	-0.4	3.08e-10	Resting heart rate;
SARC	cis	rs35110281	0.807	rs2838325	chr21:45014284	A/T	cg21573476	chr21:45109991	RRP1B	0.51	7.64	0.45	5.63e-13	Mean corpuscular volume;
SARC	cis	rs10504229	0.520	rs55967509	chr8:57992448	A/G	cg20607798	chr8:58055168	NA	0.58	5.02	0.31	1.04e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs9790314	0.715	rs9290065	chr3:160776964	A/G	cg03342759	chr3:160939853	NMD3	0.44	5.3	0.33	2.63e-7	Morning vs. evening chronotype;
SARC	cis	rs77106637	0.932	rs17244499	chr11:72629946	C/T	cg03713592	chr11:72463424	ARAP1	-0.86	-8.22	-0.47	1.42e-14	Type 2 diabetes;
SARC	cis	rs826838	0.904	rs11612004	chr12:39204282	G/A	cg26384229	chr12:38710491	ALG10B	0.87	12.37	0.63	2.35e-27	Heart rate;
SARC	cis	rs2760061	0.819	rs708111	chr1:228191365	G/A	cg02753203	chr1:228287806	NA	0.58	8.12	0.47	2.71e-14	Diastolic blood pressure;
SARC	cis	rs3008870	0.755	rs2815360	chr1:67494458	C/T	cg02640540	chr1:67518911	SLC35D1	0.46	5.25	0.33	3.48e-7	Lymphocyte percentage of white cells;
SARC	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg22857025	chr5:266934	NA	-1.06	-11.6	-0.61	7.2e-25	Breast cancer;
SARC	cis	rs2228479	0.850	rs17233448	chr16:89816424	G/T	cg00800038	chr16:89945340	TCF25	-0.74	-5.14	-0.32	5.75e-7	Skin colour saturation;
SARC	cis	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg05666828	chr4:146403874	SMAD1	-0.42	-4.82	-0.3	2.58e-6	Hip circumference;
SARC	cis	rs11112613	0.818	rs2374507	chr12:106009570	A/C	cg03607813	chr12:105948248	NA	0.52	5.72	0.35	3.17e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.68	-8.75	-0.5	4.34e-16	Chronic sinus infection;
SARC	cis	rs7223966	0.960	rs7212379	chr17:61706122	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	6.75	0.4	1.13e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7223966	0.921	rs6504186	chr17:61863932	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.51	-5.33	-0.33	2.31e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2594989	0.831	rs7651886	chr3:11572728	A/G	cg00170343	chr3:11313890	ATG7	0.51	5.21	0.32	4.11e-7	Circulating chemerin levels;
SARC	cis	rs9325144	0.560	rs11183046	chr12:38655270	A/T	cg26384229	chr12:38710491	ALG10B	-0.63	-8.12	-0.47	2.64e-14	Morning vs. evening chronotype;
SARC	cis	rs9814567	1.000	rs9864439	chr3:134298671	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-6.93	-0.41	4.18e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs10988449	0.891	rs10988452	chr9:132376859	C/T	cg18327994	chr9:132372705	NA	-0.46	-4.82	-0.3	2.57e-6	Response to anti-depressant treatment in major depressive disorder;
SARC	cis	rs2273669	0.585	rs6900472	chr6:109372120	G/A	cg05315195	chr6:109294784	ARMC2	-0.62	-5.63	-0.35	5.06e-8	Prostate cancer;
SARC	cis	rs10911232	0.507	rs10797832	chr1:183044034	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.1	0.55	3.88e-20	Hypertriglyceridemia;
SARC	cis	rs41278232	0.557	rs817338	chr20:62604201	T/C	cg24354818	chr20:62328094	TNFRSF6B	0.35	4.83	0.3	2.43e-6	Tonsillectomy;
SARC	cis	rs3106136	0.843	rs17021507	chr4:95274671	G/A	cg11021082	chr4:95130006	SMARCAD1	0.35	5.43	0.34	1.38e-7	Capecitabine sensitivity;
SARC	cis	rs1568889	0.838	rs6484347	chr11:28040969	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.87	-14.66	-0.69	6.61e-35	Bipolar disorder;
SARC	cis	rs8180040	0.966	rs17476234	chr3:47326298	G/A	cg27129171	chr3:47204927	SETD2	-0.69	-9.6	-0.53	1.3e-18	Colorectal cancer;
SARC	cis	rs9612	0.950	rs11351	chr19:44271066	A/C	cg08581076	chr19:44259116	C19orf61	0.61	7.43	0.44	2.02e-12	Exhaled nitric oxide output;
SARC	cis	rs2120019	0.935	rs12591119	chr15:75355944	A/G	cg09165964	chr15:75287851	SCAMP5	-0.93	-13.7	-0.67	1.01e-31	Blood trace element (Zn levels);
SARC	cis	rs4481887	0.927	rs4916121	chr1:248432003	C/T	cg13385794	chr1:248469461	NA	0.35	5.13	0.32	6.01e-7	Common traits (Other);
SARC	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg03647317	chr4:187891568	NA	-0.35	-4.98	-0.31	1.21e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs820218	0.576	rs820172	chr17:73730483	C/T	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.61	7.09	0.42	1.61e-11	Rotator cuff tears;
SARC	cis	rs12477438	0.871	rs13396584	chr2:99611768	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.89	11.37	0.6	4.17e-24	Chronic sinus infection;
SARC	cis	rs1707322	1.000	rs4660318	chr1:46334876	A/G	cg06784218	chr1:46089804	CCDC17	0.33	5.78	0.35	2.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs10911232	0.507	rs4369195	chr1:182996291	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.7	0.57	5.5e-22	Hypertriglyceridemia;
SARC	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg12463550	chr7:65579703	CRCP	0.47	5.16	0.32	5.3e-7	Aortic root size;
SARC	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg27266027	chr21:40555129	PSMG1	0.51	5.53	0.34	8.5e-8	Cognitive function;
SARC	cis	rs2985684	0.894	rs4900927	chr14:50018741	G/T	cg04989706	chr14:50066350	PPIL5	-0.53	-5.88	-0.36	1.41e-8	Carotid intima media thickness;
SARC	cis	rs933688	0.938	rs12110065	chr5:90718474	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.08	13.96	0.67	1.33e-32	Smoking behavior;
SARC	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg24675658	chr1:53192096	ZYG11B	-0.66	-9.87	-0.54	2e-19	Monocyte count;
SARC	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg19077165	chr18:44547161	KATNAL2	-0.52	-7.3	-0.43	4.41e-12	Personality dimensions;
SARC	cis	rs7818345	0.967	rs35029660	chr8:19308126	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.37	4.92	0.31	1.62e-6	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs6570726	0.791	rs9403730	chr6:145907233	C/T	cg05347473	chr6:146136440	FBXO30	0.52	7.31	0.43	4.32e-12	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs890100	0.673	rs1117258	chr2:56667438	A/G	cg26233084	chr5:15510258	FBXL7	-0.31	-6.33	-0.38	1.21e-9	Gut microbiome composition (summer);
SARC	cis	rs7561528	0.501	rs61308109	chr2:127891326	G/A	cg12632573	chr2:127783243	NA	0.64	5.8	0.36	2.11e-8	Alzheimer's disease;Alzheimer's disease (late onset);
SARC	cis	rs7833986	0.501	rs2976012	chr8:56974343	T/C	cg26371346	chr8:56986568	SNORD54;RPS20	0.72	7.24	0.43	6.48e-12	Height;
SARC	cis	rs7236492	0.688	rs9709477	chr18:77202786	C/A	cg15644404	chr18:77186268	NFATC1	-0.66	-6.68	-0.4	1.77e-10	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs17125944	0.556	rs12588482	chr14:53311552	G/A	cg00686598	chr14:53173677	PSMC6	-0.67	-5.05	-0.31	8.9e-7	Alzheimer's disease (late onset);
SARC	cis	rs73206853	0.563	rs73194026	chr12:111140219	G/T	cg10860002	chr12:110842031	ANAPC7	0.61	5.19	0.32	4.67e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	trans	rs7815944	0.744	rs16902889	chr8:129424715	G/C	cg17342469	chr22:46473074	NA	0.71	6.7	0.4	1.58e-10	Atopic dermatitis;
SARC	trans	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg21775007	chr8:11205619	TDH	-0.52	-6.42	-0.39	7.58e-10	Joint mobility (Beighton score);
SARC	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg19678392	chr7:94953810	PON1	-0.44	-6.31	-0.38	1.4e-9	Paraoxonase activity;
SARC	cis	rs6058796	1.000	rs6141333	chr20:31263324	C/A	cg13636640	chr20:31349939	DNMT3B	0.58	5.18	0.32	4.89e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs9462027	0.606	rs1201874	chr6:34549810	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-6.09	-0.37	4.53e-9	Systemic lupus erythematosus;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	ch.6.2893423F	chr6:150056792	NUP43	0.49	6.26	0.38	1.84e-9	Electrocardiographic conduction measures;
SARC	cis	rs2153535	0.580	rs2143357	chr6:8497196	A/G	cg21535247	chr6:8435926	SLC35B3	0.6	7.39	0.44	2.59e-12	Motion sickness;
SARC	trans	rs561341	0.739	rs1978116	chr17:30220978	A/C	cg20587970	chr11:113659929	NA	-0.69	-7.27	-0.43	5.4e-12	Hip circumference adjusted for BMI;
SARC	cis	rs9612	0.950	rs7256472	chr19:44246970	C/T	cg07522664	chr19:44259120	C19orf61	0.48	5.41	0.33	1.56e-7	Exhaled nitric oxide output;
SARC	cis	rs11718455	0.960	rs35277738	chr3:44006732	T/C	cg21419209	chr3:44054225	NA	-0.42	-5.18	-0.32	4.74e-7	Coronary artery disease;
SARC	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.41	-5.0	-0.31	1.11e-6	Renal function-related traits (BUN);
SARC	cis	rs5753618	0.555	rs9609304	chr22:31897795	T/C	cg02404636	chr22:31891804	SFI1	0.49	5.1	0.32	7.1e-7	Colorectal cancer;
SARC	trans	rs7937682	0.924	rs12791699	chr11:111505880	T/C	cg18187862	chr3:45730750	SACM1L	0.55	6.96	0.41	3.46e-11	Primary sclerosing cholangitis;
SARC	cis	rs8067545	0.641	rs4925060	chr17:19863258	C/G	cg13482628	chr17:19912719	NA	0.52	6.54	0.39	3.85e-10	Schizophrenia;
SARC	cis	rs10823500	0.748	rs12355080	chr10:71963608	G/A	cg04118878	chr10:71993077	PPA1	0.55	6.19	0.38	2.68e-9	Blood protein levels;
SARC	cis	rs11792861	0.926	rs72607169	chr9:111832471	A/T	cg13535736	chr9:111863775	C9orf5	-0.41	-5.05	-0.31	8.81e-7	Menarche (age at onset);
SARC	cis	rs796364	0.760	rs56285751	chr2:200919836	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.67	-5.68	-0.35	4.06e-8	Schizophrenia;
SARC	cis	rs2845885	0.793	rs3751120	chr11:63884453	C/T	cg24431193	chr11:63883947	FLRT1;MACROD1	0.69	6.51	0.39	4.63e-10	Body mass index;
SARC	cis	rs11098499	0.863	rs13149407	chr4:120437825	A/G	cg09307838	chr4:120376055	NA	0.91	12.31	0.63	3.63e-27	Corneal astigmatism;
SARC	cis	rs2153535	0.553	rs2984099	chr6:8637274	C/T	cg23788917	chr6:8435910	SLC35B3	-0.73	-9.22	-0.52	1.85e-17	Motion sickness;
SARC	cis	rs820218	0.717	rs729778	chr17:73642281	C/T	cg01592526	chr17:73663357	RECQL5;SAP30BP	-0.6	-7.84	-0.46	1.6e-13	Rotator cuff tears;
SARC	cis	rs7615952	0.546	rs11717632	chr3:125321130	G/C	cg21696256	chr3:125484277	NA	-0.4	-4.76	-0.3	3.34e-6	Blood pressure (smoking interaction);
SARC	cis	rs2295359	0.892	rs11209004	chr1:67613932	G/A	cg11235152	chr1:67600687	NA	0.51	7.11	0.42	1.41e-11	Psoriasis;
SARC	cis	rs4765905	0.549	rs2239026	chr12:2312291	C/T	cg10668781	chr12:2307325	CACNA1C	-0.3	-4.75	-0.3	3.56e-6	Schizophrenia;
SARC	cis	rs6860806	0.507	rs270614	chr5:131640813	G/A	cg12564285	chr5:131593104	PDLIM4	0.45	6.04	0.37	5.99e-9	Breast cancer;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg20684973	chr10:105127632	TAF5	-0.59	-6.75	-0.4	1.13e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs9916302	0.706	rs7208252	chr17:37584368	A/G	cg07936489	chr17:37558343	FBXL20	-0.77	-9.06	-0.51	5.48e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs9814567	1.000	rs6800862	chr3:134228628	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-7.09	-0.42	1.61e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs763121	0.853	rs9610986	chr22:39025277	T/C	cg21395723	chr22:39101663	GTPBP1	0.57	6.46	0.39	5.9e-10	Menopause (age at onset);
SARC	cis	rs17666538	0.792	rs1979174	chr8:592274	C/A	cg00450029	chr8:599525	NA	0.64	5.23	0.32	3.74e-7	IgG glycosylation;
SARC	cis	rs1270639	0.778	rs1638021	chr7:157438037	A/G	cg13357408	chr7:157437802	PTPRN2	0.44	4.83	0.3	2.48e-6	Colorectal cancer;
SARC	cis	rs1008375	0.932	rs3846356	chr4:17614176	C/T	cg16339924	chr4:17578868	LAP3	0.63	8.11	0.47	2.83e-14	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg07701084	chr6:150067640	NUP43	-0.42	-5.52	-0.34	8.97e-8	Lung cancer;
SARC	cis	rs2832191	0.646	rs2832210	chr21:30508723	T/G	cg24692254	chr21:30365293	RNF160	-0.68	-8.18	-0.47	1.85e-14	Dental caries;
SARC	cis	rs4727027	0.901	rs7794500	chr7:148819519	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.48	-5.7	-0.35	3.54e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs9911578	0.765	rs66954617	chr17:56999427	A/G	cg12560992	chr17:57184187	TRIM37	0.85	11.7	0.61	3.63e-25	Intelligence (multi-trait analysis);
SARC	cis	rs2504916	0.779	rs2504925	chr6:160876394	A/G	cg20340146	chr6:160172821	WTAP	0.46	4.89	0.31	1.87e-6	Response to hepatitis C treatment;
SARC	cis	rs1559088	0.948	rs7259333	chr19:33579128	T/C	cg27124370	chr19:33622961	WDR88	0.43	5.65	0.35	4.58e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs9916302	0.904	rs11655531	chr17:37697959	T/C	cg15445000	chr17:37608096	MED1	0.41	4.85	0.3	2.29e-6	Glomerular filtration rate (creatinine);
SARC	trans	rs1814175	0.817	rs1615305	chr11:49895222	T/A	cg15704280	chr7:45808275	SEPT13	-0.97	-18.17	-0.77	1.53e-46	Height;
SARC	cis	rs7666738	0.830	rs10000573	chr4:99048785	G/C	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7296418	0.922	rs1790134	chr12:123697898	T/C	cg05973401	chr12:123451056	ABCB9	0.57	6.63	0.4	2.26e-10	Platelet count;
SARC	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg11062466	chr8:58055876	NA	0.56	5.69	0.35	3.79e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs57244997	0.652	rs78477696	chr6:162428316	C/T	cg17173639	chr6:162384350	PARK2	-0.51	-5.2	-0.32	4.28e-7	Mosquito bite size;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg23197559	chr2:232573080	PTMA	0.49	6.39	0.39	8.7e-10	Tetralogy of Fallot;
SARC	cis	rs6669543	0.883	rs6676438	chr1:161983089	A/G	cg10810183	chr1:161993987	OLFML2B	0.49	5.72	0.35	3.18e-8	QT interval;
SARC	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg06212747	chr3:49208901	KLHDC8B	0.72	9.85	0.54	2.27e-19	Parkinson's disease;
SARC	cis	rs2073300	0.609	rs3827086	chr20:23357331	C/T	cg16736954	chr20:23401023	NAPB	0.79	4.95	0.31	1.44e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs870825	0.616	rs6552807	chr4:185640531	A/G	cg04058563	chr4:185651563	MLF1IP	0.83	11.69	0.61	3.86e-25	Blood protein levels;
SARC	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg00339695	chr16:24857497	SLC5A11	0.42	5.67	0.35	4.31e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7833986	0.501	rs2719226	chr8:57044066	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.74	7.37	0.43	2.94e-12	Height;
SARC	cis	rs17376456	0.597	rs10866760	chr5:93338335	G/A	cg25358565	chr5:93447407	FAM172A	-0.85	-9.87	-0.54	1.97e-19	Diabetic retinopathy;
SARC	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg06212747	chr3:49208901	KLHDC8B	0.66	8.79	0.5	3.35e-16	Parkinson's disease;
SARC	cis	rs12922317	0.535	rs8051349	chr16:12105523	T/A	cg09319797	chr16:12061715	TNFRSF17	-0.33	-5.01	-0.31	1.07e-6	Schizophrenia;
SARC	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg04518342	chr5:131593106	PDLIM4	0.35	5.06	0.31	8.48e-7	Breast cancer;
SARC	cis	rs9916302	0.861	rs2338801	chr17:37490780	G/T	cg00129232	chr17:37814104	STARD3	0.6	7.28	0.43	5.12e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs34779708	0.897	rs4934529	chr10:35302376	T/A	cg03585969	chr10:35415529	CREM	0.41	5.04	0.31	9.27e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs4555082	0.915	rs28594491	chr14:105758018	G/A	cg10792982	chr14:105748885	BRF1	0.54	7.8	0.45	2.1e-13	Mean platelet volume;Platelet distribution width;
SARC	cis	rs12579753	1.000	rs11115047	chr12:82232773	C/G	cg07988820	chr12:82153109	PPFIA2	-0.54	-6.22	-0.38	2.22e-9	Resting heart rate;
SARC	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.43	0.44	2.1e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs10782582	0.586	rs5745383	chr1:76288590	G/C	cg10523679	chr1:76189770	ACADM	-0.43	-5.29	-0.33	2.77e-7	Daytime sleep phenotypes;
SARC	cis	rs67460515	0.563	rs1585481	chr3:160901481	C/T	cg04691961	chr3:161091175	C3orf57	-0.41	-4.94	-0.31	1.52e-6	Parkinson's disease;
SARC	cis	rs631288	0.557	rs4534444	chr1:146679283	T/C	cg25205988	chr1:146714368	CHD1L	1.08	6.4	0.39	8.34e-10	PR interval in Tripanosoma cruzi seropositivity;
SARC	cis	rs2295359	1.000	rs4655682	chr1:67610967	C/T	cg08029281	chr1:67600428	NA	0.38	5.54	0.34	8.12e-8	Psoriasis;
SARC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg01238044	chr22:24384105	GSTT1	-0.61	-6.87	-0.41	5.8200000000000003e-11	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs644799	1.000	rs1944074	chr11:95511445	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.68	9.44	0.53	3.97e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs1578862	0.966	rs41268345	chr1:247486213	G/A	cg22704608	chr1:247479546	ZNF496	-0.33	-4.73	-0.3	3.96e-6	Monocyte percentage of white cells;
SARC	cis	rs17376456	0.825	rs13357713	chr5:93145423	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.71	6.43	0.39	7.19e-10	Diabetic retinopathy;
SARC	cis	rs3733585	0.699	rs6449177	chr4:9968050	T/C	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.96	-0.36	9.19e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs34172651	0.837	rs12596793	chr16:24823667	C/G	cg04756594	chr16:24857601	SLC5A11	0.33	5.21	0.32	4.08e-7	Intelligence (multi-trait analysis);
SARC	cis	rs13256369	1.000	rs10088439	chr8:8576699	T/G	cg17143192	chr8:8559678	CLDN23	0.52	5.99	0.37	7.84e-9	Obesity-related traits;
SARC	cis	rs6448317	0.906	rs6448313	chr4:24905088	G/A	cg21108841	chr4:24914750	CCDC149	0.55	6.24	0.38	2e-9	Heschl's gyrus morphology;
SARC	cis	rs7937682	0.889	rs493810	chr11:111491888	G/T	cg22437258	chr11:111473054	SIK2	0.74	10.24	0.56	1.44e-20	Primary sclerosing cholangitis;
SARC	cis	rs12971120	0.891	rs11151960	chr18:72177232	G/A	cg26446133	chr18:72167187	CNDP2	-0.47	-6.32	-0.38	1.32e-9	Refractive error;
SARC	cis	rs1559088	0.739	rs9304845	chr19:33592794	A/G	cg27124370	chr19:33622961	WDR88	0.44	5.86	0.36	1.6e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs7829975	1.000	rs7829975	chr8:8548117	T/A	cg08975724	chr8:8085496	FLJ10661	-0.49	-5.85	-0.36	1.65e-8	Mood instability;
SARC	cis	rs734999	0.524	rs4648448	chr1:2695687	C/T	cg18854424	chr1:2615690	NA	0.32	4.97	0.31	1.28e-6	Ulcerative colitis;
SARC	cis	rs820218	0.926	rs820135	chr17:73674977	T/C	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.68	9.26	0.52	1.38e-17	Rotator cuff tears;
SARC	cis	rs8067545	0.611	rs6587219	chr17:20034531	T/G	cg13482628	chr17:19912719	NA	0.53	7.08	0.42	1.7e-11	Schizophrenia;
SARC	cis	rs912057	0.932	rs1294404	chr6:6735022	G/A	cg06612196	chr6:6737390	NA	0.6	8.67	0.49	7.65e-16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs6963495	0.818	rs17343556	chr7:105151272	C/T	cg19920283	chr7:105172520	RINT1	0.63	5.3	0.33	2.75e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs1873147	1.000	rs7179658	chr15:63312695	T/C	cg05507819	chr15:63340323	TPM1	-0.48	-5.25	-0.33	3.36e-7	Orofacial clefts;
SARC	cis	rs11098499	0.570	rs6832740	chr4:120546136	T/C	cg09307838	chr4:120376055	NA	0.77	10.48	0.57	2.73e-21	Corneal astigmatism;
SARC	trans	rs2637266	1.000	rs2637266	chr10:78331318	C/T	cg21154426	chr3:53161967	RFT1	0.4	6.38	0.39	9.58e-10	Pulmonary function;
SARC	cis	rs2306786	0.558	rs61740133	chr15:59500255	C/T	cg23054309	chr15:59226205	SLTM	0.76	5.0	0.31	1.14e-6	Metabolite levels;
SARC	cis	rs2115630	0.905	rs6496401	chr15:85297793	A/T	cg12501888	chr15:85177176	SCAND2	-0.5	-5.99	-0.37	8.08e-9	P wave terminal force;
SARC	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg00149659	chr3:10157352	C3orf10	0.69	6.9	0.41	4.76e-11	Alzheimer's disease;
SARC	cis	rs7586879	0.681	rs6723803	chr2:25120713	G/C	cg04586622	chr2:25135609	ADCY3	0.33	5.67	0.35	4.19e-8	Body mass index;
SARC	cis	rs2282802	0.685	rs6889283	chr5:139653439	G/T	cg26211634	chr5:139558579	C5orf32	0.39	4.98	0.31	1.24e-6	Intelligence (multi-trait analysis);
SARC	cis	rs57506017	0.540	rs7808568	chr7:12271252	T/C	cg23422036	chr7:12250390	TMEM106B	0.46	5.97	0.36	9e-9	Neuroticism;
SARC	trans	rs8020941	0.585	rs77418493	chr14:97502221	G/A	cg05136476	chr3:53190709	NA	-0.64	-6.44	-0.39	6.89e-10	Diabetic kidney disease;
SARC	cis	rs9768139	0.708	rs921615	chr7:158117935	A/G	cg25566285	chr7:158114605	PTPRN2	0.31	5.19	0.32	4.66e-7	Calcium levels;
SARC	cis	rs1185460	1.000	rs1614264	chr11:118942638	A/C	cg23280166	chr11:118938394	VPS11	0.77	10.95	0.58	8.51e-23	Coronary artery disease;
SARC	trans	rs9650657	0.812	rs11250074	chr8:10632259	A/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.32	-0.38	1.29e-9	Neuroticism;
SARC	cis	rs7264396	1.000	rs224418	chr20:34142527	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-4.94	-0.31	1.47e-6	Total cholesterol levels;
SARC	cis	rs9486715	0.964	rs6921480	chr6:97066329	C/G	cg06623918	chr6:96969491	KIAA0776	-0.81	-11.12	-0.59	2.56e-23	Headache;
SARC	cis	rs7626444	0.625	rs843531	chr3:196481771	T/C	cg12930392	chr3:196481615	PAK2	0.25	4.9	0.31	1.79e-6	Monocyte count;
SARC	cis	rs12893668	0.703	rs2274267	chr14:104029449	G/A	cg26031613	chr14:104095156	KLC1	-0.51	-5.36	-0.33	1.97e-7	Reticulocyte count;
SARC	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg08109568	chr15:31115862	NA	0.53	6.81	0.41	8.4e-11	Huntington's disease progression;
SARC	cis	rs17376456	0.569	rs1026279	chr5:93209581	C/A	cg25358565	chr5:93447407	FAM172A	-0.96	-10.91	-0.58	1.14e-22	Diabetic retinopathy;
SARC	trans	rs7824557	0.527	rs2572447	chr8:11239510	G/A	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.72	-0.45	3.43e-13	Retinal vascular caliber;
SARC	cis	rs7772486	0.719	rs4391282	chr6:146276780	A/T	cg23711669	chr6:146136114	FBXO30	-0.76	-11.76	-0.61	2.21e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9549260	0.755	rs7986407	chr13:41179798	A/G	cg21288729	chr13:41239152	FOXO1	0.6	7.76	0.45	2.62e-13	Red blood cell count;
SARC	cis	rs6011002	0.872	rs6010987	chr20:62277675	G/A	cg23957118	chr20:62200850	PRIC285	0.64	4.84	0.3	2.41e-6	Dental caries;
SARC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg05165339	chr4:1420672	NA	-0.24	-5.19	-0.32	4.68e-7	Longevity;
SARC	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg18225595	chr11:63971243	STIP1	0.44	5.36	0.33	1.97e-7	Mean platelet volume;
SARC	cis	rs2180341	0.694	rs2875972	chr6:127585522	T/C	cg24812749	chr6:127587940	RNF146	0.9	12.12	0.62	1.58e-26	Breast cancer;
SARC	cis	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg06636001	chr8:8085503	FLJ10661	0.65	8.79	0.5	3.38e-16	Mood instability;
SARC	cis	rs3820928	0.605	rs6718767	chr2:227800776	A/G	cg05526886	chr2:227700861	RHBDD1	-0.49	-6.1	-0.37	4.4e-9	Pulmonary function;
SARC	cis	rs7681440	0.583	rs2619364	chr4:90759887	A/G	cg06632027	chr4:90757378	SNCA	-0.44	-5.61	-0.35	5.66e-8	Dementia with Lewy bodies;
SARC	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg11764359	chr7:65958608	NA	-0.72	-8.42	-0.48	3.77e-15	Aortic root size;
SARC	cis	rs4803468	0.967	rs4803461	chr19:41908871	G/A	cg09537434	chr19:41945824	ATP5SL	-0.95	-16.56	-0.74	3.03e-41	Height;
SARC	cis	rs4689388	0.890	rs11732208	chr4:6292716	G/C	cg00701064	chr4:6280414	WFS1	0.53	8.46	0.48	2.95e-15	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs6456156	0.586	rs720325	chr6:167467349	G/T	cg07741184	chr6:167504864	NA	0.35	6.88	0.41	5.51e-11	Primary biliary cholangitis;
SARC	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg24675658	chr1:53192096	ZYG11B	-0.66	-9.45	-0.53	3.74e-18	Monocyte count;
SARC	cis	rs6772849	0.965	rs67790930	chr3:128310036	C/T	cg08795948	chr3:128337044	NA	0.37	4.88	0.3	1.96e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs7264396	0.790	rs6060516	chr20:34214368	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-7.35	-0.43	3.4e-12	Total cholesterol levels;
SARC	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg22903657	chr4:1355424	KIAA1530	-0.36	-4.86	-0.3	2.14e-6	Obesity-related traits;
SARC	cis	rs7412746	0.658	rs4970987	chr1:150949682	T/C	cg13175981	chr1:150552382	MCL1	-0.47	-5.47	-0.34	1.18e-7	Melanoma;
SARC	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.91	12.41	0.63	1.81e-27	Platelet count;
SARC	cis	rs7084402	0.967	rs1427223	chr10:60290966	T/C	cg07615347	chr10:60278583	BICC1	0.61	9.02	0.51	7.31e-17	Refractive error;
SARC	cis	rs2997447	0.761	rs56078964	chr1:26442600	C/A	cg19633962	chr1:26362018	EXTL1	-0.56	-5.06	-0.31	8.55e-7	QRS complex (12-leadsum);
SARC	cis	rs7043114	0.525	rs4744134	chr9:95246833	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.44	5.25	0.33	3.35e-7	Height;
SARC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg11965913	chr1:205819406	PM20D1	0.9	15.03	0.7	3.78e-36	Menarche (age at onset);
SARC	cis	rs8067545	0.641	rs203460	chr17:19815286	G/C	cg04132472	chr17:19861366	AKAP10	0.39	5.1	0.32	7.18e-7	Schizophrenia;
SARC	trans	rs16964211	0.826	rs17647719	chr15:51568204	C/T	cg09074755	chr12:29650711	OVCH1	1.01	6.23	0.38	2.16e-9	Height;
SARC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg24101359	chr6:42928495	GNMT	0.42	5.78	0.35	2.44e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg24209194	chr3:40518798	ZNF619	0.65	7.99	0.46	6.21e-14	Renal cell carcinoma;
SARC	cis	rs4243830	0.579	rs10779794	chr1:6612651	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.88	-8.45	-0.48	3.08e-15	Body mass index;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg00260889	chr4:80869858	ANTXR2	0.5	6.68	0.4	1.78e-10	Thyroid stimulating hormone;
SARC	cis	rs2306786	0.558	rs3825936	chr15:59500405	T/C	cg23054309	chr15:59226205	SLTM	0.76	5.0	0.31	1.14e-6	Metabolite levels;
SARC	cis	rs8028182	0.609	rs10220738	chr15:75666546	A/T	cg20655648	chr15:75932815	IMP3	-0.64	-7.32	-0.43	4.05e-12	Sudden cardiac arrest;
SARC	cis	rs17376456	0.778	rs10476604	chr5:93461838	C/T	cg21475434	chr5:93447410	FAM172A	0.6	6.32	0.38	1.3e-9	Diabetic retinopathy;
SARC	cis	rs2204008	0.560	rs1315354	chr12:38165716	A/G	cg26384229	chr12:38710491	ALG10B	-0.68	-8.8	-0.5	3.1e-16	Bladder cancer;
SARC	cis	rs883565	0.792	rs784501	chr3:39183895	A/G	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.56	-5.99	-0.37	7.82e-9	Handedness;
SARC	cis	rs13401104	0.796	rs11677552	chr2:237110230	T/C	cg19324714	chr2:237145437	ASB18	0.57	5.6	0.34	5.92e-8	Educational attainment;
SARC	cis	rs7561149	0.966	rs12471428	chr2:179687519	A/G	cg17765952	chr2:179737173	CCDC141	0.39	5.21	0.32	4.25e-7	QT interval;
SARC	cis	rs73198271	0.740	rs1039912	chr8:8648229	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-5.49	-0.34	1.03e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg15242686	chr22:24348715	GSTTP1	0.43	5.17	0.32	5.03e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs2645694	0.626	rs2703121	chr4:77822328	C/G	cg10057126	chr4:77819792	ANKRD56	0.44	6.58	0.4	3.1e-10	Emphysema distribution in smoking;
SARC	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg11987759	chr7:65425863	GUSB	0.46	5.69	0.35	3.87e-8	Aortic root size;
SARC	cis	rs13191362	0.810	rs13200053	chr6:163011443	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.56	5.35	0.33	2.07e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg12311346	chr5:56204834	C5orf35	-0.58	-6.01	-0.37	7.24e-9	Initial pursuit acceleration;
SARC	cis	rs7312774	0.881	rs60941459	chr12:107318583	T/C	cg16260113	chr12:107380972	MTERFD3	0.68	5.78	0.35	2.38e-8	Severe influenza A (H1N1) infection;
SARC	cis	rs9916302	0.904	rs612194	chr17:37442707	T/A	cg00129232	chr17:37814104	STARD3	0.59	7.39	0.44	2.69e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs9733	0.621	rs6669122	chr1:150591732	A/G	cg13175981	chr1:150552382	MCL1	0.69	9.28	0.52	1.19e-17	Tonsillectomy;
SARC	cis	rs11098499	0.754	rs1849457	chr4:120254355	A/G	cg09307838	chr4:120376055	NA	0.79	10.17	0.55	2.43e-20	Corneal astigmatism;
SARC	cis	rs6450176	1.000	rs3776702	chr5:53305419	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.68	-7.87	-0.46	1.29e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs763121	0.626	rs5757236	chr22:39073824	T/C	cg21395723	chr22:39101663	GTPBP1	0.52	5.8	0.36	2.17e-8	Menopause (age at onset);
SARC	cis	rs2290159	0.800	rs5746191	chr3:12658774	G/A	cg23032965	chr3:12705835	RAF1	0.77	8.46	0.48	2.96e-15	Cholesterol, total;
SARC	cis	rs9868809	0.772	rs9877794	chr3:48718388	G/C	cg07636037	chr3:49044803	WDR6	-0.71	-6.62	-0.4	2.39e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg13206674	chr6:150067644	NUP43	0.46	6.1	0.37	4.29e-9	Lung cancer;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg22046830	chr8:145133508	EXOSC4	0.47	6.25	0.38	1.93e-9	Chemerin levels;
SARC	cis	rs9916302	0.904	rs9898170	chr17:37510092	T/C	cg15445000	chr17:37608096	MED1	-0.46	-5.69	-0.35	3.78e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg09699651	chr6:150184138	LRP11	0.39	4.85	0.3	2.29e-6	Lung cancer;
SARC	cis	rs12950390	0.512	rs11655306	chr17:45858744	C/T	cg03474202	chr17:45855739	NA	-0.42	-5.12	-0.32	6.35e-7	IgG glycosylation;
SARC	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg13206674	chr6:150067644	NUP43	0.41	5.37	0.33	1.95e-7	Lung cancer;
SARC	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg03433033	chr1:76189801	ACADM	-0.43	-5.64	-0.35	4.81e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg18876405	chr7:65276391	NA	0.47	5.45	0.34	1.27e-7	Aortic root size;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg06547017	chr7:105514694	ATXN7L1	0.46	6.28	0.38	1.66e-9	Thyroid stimulating hormone;
SARC	cis	rs2645694	0.626	rs12502590	chr4:77823642	G/A	cg06046430	chr4:77819534	ANKRD56	0.54	7.98	0.46	6.82e-14	Emphysema distribution in smoking;
SARC	cis	rs10751667	0.600	rs6597948	chr11:1005308	C/T	cg20946044	chr11:1010712	AP2A2	-0.38	-5.73	-0.35	3.04e-8	Alzheimer's disease (late onset);
SARC	cis	rs9309473	0.687	rs6546827	chr2:73606493	C/T	cg20560298	chr2:73613845	ALMS1	-0.52	-6.75	-0.4	1.15e-10	Metabolite levels;
SARC	cis	rs2952156	0.920	rs9675194	chr17:37833805	A/G	cg20243544	chr17:37824526	PNMT	0.57	7.31	0.43	4.2e-12	Asthma;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg09315469	chr11:101762317	ANGPTL5	0.45	6.57	0.4	3.31e-10	Thyroid stimulating hormone;
SARC	cis	rs477692	1.000	rs569235	chr10:131411620	T/C	cg05714579	chr10:131428358	MGMT	0.59	7.66	0.45	5.07e-13	Response to temozolomide;
SARC	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg04166393	chr7:2884313	GNA12	0.67	7.97	0.46	6.95e-14	Height;
SARC	cis	rs6089584	0.821	rs4925332	chr20:60604639	C/T	cg13770153	chr20:60521292	NA	-0.49	-6.87	-0.41	5.84e-11	Body mass index;
SARC	cis	rs3768617	0.510	rs1886500	chr1:183095048	G/A	cg13390022	chr1:182993471	LAMC1	0.31	4.79	0.3	3.01e-6	Fuchs's corneal dystrophy;
SARC	cis	rs2115630	0.902	rs8023276	chr15:85219638	C/T	cg12501888	chr15:85177176	SCAND2	-0.44	-5.37	-0.33	1.94e-7	P wave terminal force;
SARC	cis	rs7246657	0.891	rs7257495	chr19:37823876	C/G	cg23950597	chr19:37808831	NA	-0.54	-5.46	-0.34	1.24e-7	Coronary artery calcification;
SARC	cis	rs611744	0.647	rs674391	chr8:109242803	A/T	cg21045802	chr8:109455806	TTC35	0.6	7.78	0.45	2.28e-13	Dupuytren's disease;
SARC	cis	rs1691799	0.899	rs1168301	chr12:66736771	C/T	cg16791601	chr12:66731901	HELB	-0.72	-10.72	-0.57	4.65e-22	White blood cell count (basophil);
SARC	cis	rs3733585	0.699	rs28837683	chr4:9959808	C/T	cg11266682	chr4:10021025	SLC2A9	-0.34	-5.85	-0.36	1.62e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7005380	0.581	rs7007672	chr8:120919221	G/A	cg21744203	chr8:120868354	DSCC1	-0.47	-5.46	-0.34	1.23e-7	Interstitial lung disease;
SARC	cis	rs9611519	0.603	rs8142276	chr22:41471447	T/C	cg03806693	chr22:41940476	POLR3H	-0.53	-6.77	-0.41	1.03e-10	Neuroticism;
SARC	cis	rs12048904	0.512	rs932798	chr1:101249355	G/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.73	-9.25	-0.52	1.51e-17	Multiple sclerosis;
SARC	cis	rs73206853	0.543	rs7972256	chr12:110575444	G/A	cg10860002	chr12:110842031	ANAPC7	0.66	5.21	0.32	4.14e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs9314323	0.693	rs13264882	chr8:26224240	G/T	cg11498726	chr8:26250323	BNIP3L	-0.58	-7.47	-0.44	1.58e-12	Red cell distribution width;
SARC	trans	rs61931739	0.817	rs592857	chr12:34197673	T/G	cg13010199	chr12:38710504	ALG10B	0.59	7.64	0.45	5.47e-13	Morning vs. evening chronotype;
SARC	cis	rs1371867	0.839	rs1660313	chr8:101332712	G/A	cg11906718	chr8:101322791	RNF19A	0.71	9.13	0.51	3.37e-17	Atrioventricular conduction;
SARC	cis	rs765787	0.530	rs4775834	chr15:45537511	C/T	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.51e-10	Uric acid levels;
SARC	trans	rs2898290	0.622	rs11250140	chr8:11346592	A/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.49	-0.44	1.43e-12	Systolic blood pressure;
SARC	cis	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg00800038	chr16:89945340	TCF25	-0.79	-5.45	-0.34	1.26e-7	Skin colour saturation;
SARC	cis	rs7766436	0.614	rs2066335	chr6:22566590	C/T	cg13666174	chr6:22585274	NA	-0.56	-5.86	-0.36	1.59e-8	Coronary artery disease;
SARC	cis	rs35164067	1.000	rs73923215	chr19:10514842	A/C	cg21868191	chr19:10515988	NA	-0.41	-5.18	-0.32	4.79e-7	Inflammatory bowel disease;
SARC	cis	rs4919087	0.683	rs1687371	chr10:98978183	T/A	cg25902810	chr10:99078978	FRAT1	-0.55	-6.22	-0.38	2.25e-9	Monocyte count;
SARC	cis	rs2204008	0.807	rs4123933	chr12:37973539	G/A	cg26384229	chr12:38710491	ALG10B	0.89	13.46	0.66	6.13e-31	Bladder cancer;
SARC	cis	rs9398803	0.865	rs1572569	chr6:126771687	G/A	cg19875578	chr6:126661172	C6orf173	0.6	8.15	0.47	2.22e-14	Male-pattern baldness;
SARC	cis	rs10782582	0.593	rs11163904	chr1:76121208	A/G	cg03433033	chr1:76189801	ACADM	0.4	5.3	0.33	2.68e-7	Daytime sleep phenotypes;
SARC	cis	rs9322193	1.000	rs58189451	chr6:149921388	G/A	cg07701084	chr6:150067640	NUP43	0.4	5.2	0.32	4.43e-7	Lung cancer;
SARC	cis	rs17376456	0.877	rs10070390	chr5:93452345	G/A	cg25358565	chr5:93447407	FAM172A	1.31	15.17	0.7	1.33e-36	Diabetic retinopathy;
SARC	cis	rs6570726	0.935	rs372378	chr6:145816227	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.48	0.39	5.27e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1008375	0.933	rs10939757	chr4:17694125	T/C	cg02297831	chr4:17616191	MED28	0.39	4.8	0.3	2.78e-6	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs8028182	0.636	rs12708520	chr15:75830539	C/T	cg20655648	chr15:75932815	IMP3	0.61	7.17	0.43	9.98e-12	Sudden cardiac arrest;
SARC	cis	rs11997175	0.653	rs7005254	chr8:33641781	A/T	ch.8.33884649F	chr8:33765107	NA	0.51	6.69	0.4	1.64e-10	Body mass index;
SARC	cis	rs7927592	0.913	rs7127948	chr11:68363062	G/A	cg01657329	chr11:68192670	LRP5	-0.43	-5.11	-0.32	6.59e-7	Total body bone mineral density;
SARC	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg11859384	chr17:80120422	CCDC57	-0.43	-5.31	-0.33	2.53e-7	Life satisfaction;
SARC	cis	rs9814567	1.000	rs6790466	chr3:134197740	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-7.08	-0.42	1.68e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs34779708	0.966	rs10827493	chr10:35454976	C/T	cg03585969	chr10:35415529	CREM	0.38	4.84	0.3	2.39e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs74181299	0.964	rs2540951	chr2:65276736	A/G	cg20592124	chr2:65290738	CEP68	0.46	6.82	0.41	7.96e-11	Pulse pressure;
SARC	cis	rs3806933	0.522	rs12522383	chr5:110455266	C/T	cg04022379	chr5:110408740	TSLP	0.72	9.44	0.53	3.92e-18	Eosinophilic esophagitis;
SARC	cis	rs1023500	0.551	rs133355	chr22:42440285	G/A	cg04733989	chr22:42467013	NAGA	0.74	10.55	0.57	1.65e-21	Schizophrenia;
SARC	cis	rs6912958	0.712	rs4706294	chr6:88317675	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.61	-0.4	2.63e-10	Monocyte percentage of white cells;
SARC	cis	rs986417	0.551	rs1956553	chr14:60952298	T/A	cg27398547	chr14:60952738	C14orf39	1.03	9.89	0.54	1.74e-19	Gut microbiota (bacterial taxa);
SARC	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.94	9.51	0.53	2.52e-18	Platelet count;
SARC	cis	rs1448094	0.717	rs7137122	chr12:86290702	T/C	cg02569458	chr12:86230093	RASSF9	0.39	5.12	0.32	6.5e-7	Major depressive disorder;
SARC	cis	rs3106136	0.901	rs17623135	chr4:95213091	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.39	-6.06	-0.37	5.47e-9	Capecitabine sensitivity;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg12615137	chr3:87040286	VGLL3	0.54	6.93	0.41	4.02e-11	Breast cancer;
SARC	cis	rs9291683	0.620	rs7699512	chr4:10125808	C/T	cg00071950	chr4:10020882	SLC2A9	-0.32	-5.04	-0.31	9.41e-7	Bone mineral density;
SARC	cis	rs4481887	0.927	rs4453080	chr1:248474671	T/C	cg13385794	chr1:248469461	NA	0.35	5.45	0.34	1.29e-7	Common traits (Other);
SARC	cis	rs7020830	0.825	rs7036132	chr9:37317241	A/G	cg14294708	chr9:37120828	ZCCHC7	1.14	20.04	0.8	1.28e-52	Schizophrenia;
SARC	trans	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg17830980	chr10:43048298	ZNF37B	-0.51	-6.71	-0.4	1.5e-10	Extrinsic epigenetic age acceleration;
SARC	cis	rs1008375	0.966	rs758483	chr4:17703614	G/T	cg27347728	chr4:17578864	LAP3	-0.49	-6.16	-0.37	3.12e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10504073	0.527	rs118032023	chr8:49926296	A/T	cg00325661	chr8:49890786	NA	0.49	6.66	0.4	2e-10	Blood metabolite ratios;
SARC	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.67	6.58	0.4	3.01e-10	Platelet count;
SARC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg10862848	chr6:42927986	GNMT	-0.4	-6.23	-0.38	2.13e-9	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs9902453	0.933	rs9908901	chr17:28469713	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	6.64	0.4	2.23e-10	Coffee consumption (cups per day);
SARC	cis	rs1707322	0.721	rs6429574	chr1:46134054	A/G	cg03146154	chr1:46216737	IPP	0.49	5.96	0.36	9.12e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs73198271	0.640	rs7838012	chr8:8656630	A/G	cg06636001	chr8:8085503	FLJ10661	-0.41	-4.83	-0.3	2.52e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs4601821	0.522	rs754672	chr11:113249136	C/T	cg14159747	chr11:113255604	NA	0.34	4.97	0.31	1.3e-6	Alcoholic chronic pancreatitis;
SARC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg06873352	chr17:61820015	STRADA	0.53	6.81	0.41	8.2e-11	Prudent dietary pattern;
SARC	cis	rs568617	1.000	rs568617	chr11:65653242	C/T	cg00576331	chr11:65640516	EFEMP2	-0.46	-5.41	-0.33	1.53e-7	Crohn's disease;
SARC	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg03452623	chr4:187889614	NA	-0.79	-12.37	-0.63	2.34e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11025559	0.812	rs10766679	chr11:20509190	T/C	cg19653624	chr11:20408972	PRMT3	-0.56	-6.16	-0.37	3.2e-9	Pursuit maintenance gain;
SARC	cis	rs950027	0.620	rs1153862	chr15:45631868	A/G	cg21132104	chr15:45694354	SPATA5L1	0.55	7.05	0.42	1.99e-11	Response to fenofibrate (adiponectin levels);
SARC	cis	rs6696846	0.905	rs11240349	chr1:205041015	G/A	cg07972983	chr1:205091412	RBBP5	0.46	5.77	0.35	2.53e-8	Red blood cell count;
SARC	cis	rs1451375	0.572	rs4948205	chr7:50557774	G/A	cg14593290	chr7:50529359	DDC	-0.43	-4.75	-0.3	3.6e-6	Malaria;
SARC	cis	rs35213789	0.920	rs6963101	chr7:69344357	A/G	cg10619644	chr7:69149951	AUTS2	0.48	5.89	0.36	1.35e-8	Childhood ear infection;
SARC	cis	rs933688	1.000	rs6867091	chr5:90734333	C/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.94	12.17	0.62	1.09e-26	Smoking behavior;
SARC	cis	rs6582630	0.537	rs1949611	chr12:38373092	C/T	cg14851346	chr12:38532713	NA	-0.39	-4.76	-0.3	3.34e-6	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1865760	0.663	rs9379815	chr6:25980116	T/A	cg18357526	chr6:26021779	HIST1H4A	0.38	4.8	0.3	2.84e-6	Height;
SARC	cis	rs11098499	0.863	rs3775847	chr4:120447642	A/C	cg24375607	chr4:120327624	NA	0.42	4.9	0.31	1.76e-6	Corneal astigmatism;
SARC	cis	rs6938	0.618	rs11072514	chr15:75221865	T/A	cg17294928	chr15:75287854	SCAMP5	0.53	6.7	0.4	1.56e-10	Breast cancer;
SARC	cis	rs7178572	0.568	rs1125617	chr15:77532711	A/G	cg22256960	chr15:77711686	NA	-0.51	-5.58	-0.34	6.56e-8	Type 2 diabetes;
SARC	trans	rs8073060	0.586	rs7213804	chr17:34010931	T/G	cg19694781	chr19:47549865	TMEM160	-0.71	-6.94	-0.41	3.88e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs9828933	1.000	rs9828933	chr3:64002897	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	-0.64	-5.65	-0.35	4.59e-8	Type 2 diabetes;
SARC	cis	rs7315438	0.557	rs11067596	chr12:115873887	C/T	cg00387115	chr12:115889598	NA	-0.36	-4.85	-0.3	2.3e-6	Colorectal cancer;
SARC	cis	rs11098499	0.863	rs3736115	chr4:120488703	A/G	cg24375607	chr4:120327624	NA	-0.41	-5.04	-0.31	9.32e-7	Corneal astigmatism;
SARC	cis	rs9943753	0.508	rs2075433	chr12:109833920	A/G	cg19025524	chr12:109796872	NA	-0.39	-5.78	-0.35	2.39e-8	HDL cholesterol;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg11249241	chr19:13107045	NFIX	-0.47	-6.48	-0.39	5.28e-10	Chemerin levels;
SARC	cis	rs12912251	0.948	rs34141940	chr15:38989657	G/A	cg01338139	chr15:38987640	C15orf53	-0.45	-5.29	-0.33	2.79e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
SARC	cis	rs3126085	1.000	rs11204971	chr1:152259078	A/G	cg26876637	chr1:152193138	HRNR	-0.5	-5.14	-0.32	5.95e-7	Atopic dermatitis;
SARC	trans	rs9302817	0.891	rs9302818	chr16:6164306	C/G	cg20068074	chr3:48672407	SLC26A6	-0.71	-6.57	-0.4	3.2e-10	Body mass index;
SARC	cis	rs11585357	0.947	rs6684387	chr1:17611519	T/C	cg08277548	chr1:17600880	PADI3	0.46	5.32	0.33	2.47e-7	Hair shape;
SARC	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg19077165	chr18:44547161	KATNAL2	-0.53	-7.39	-0.44	2.66e-12	Personality dimensions;
SARC	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg22535103	chr8:58192502	C8orf71	-0.7	-7.12	-0.42	1.31e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs13161895	0.941	rs12519642	chr5:179438626	T/G	cg04265672	chr5:179402240	RNF130	0.52	5.15	0.32	5.48e-7	LDL cholesterol;
SARC	cis	rs8014204	0.836	rs7153700	chr14:75268544	C/T	cg17347104	chr14:75034677	LTBP2	-0.44	-5.52	-0.34	9.13e-8	Caffeine consumption;
SARC	cis	rs4237845	0.844	rs4630335	chr12:58302258	A/G	cg00677455	chr12:58241039	CTDSP2	0.41	5.64	0.35	4.88e-8	Intelligence (multi-trait analysis);
SARC	cis	rs11697848	1.000	rs117045038	chr20:48572284	C/T	cg17849948	chr20:48532315	SPATA2	0.87	5.2	0.32	4.3e-7	Systemic lupus erythematosus;
SARC	cis	rs754466	0.606	rs56402185	chr10:79585848	G/A	cg17075019	chr10:79541650	NA	-0.81	-12.84	-0.64	6.84e-29	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7089973	0.604	rs7915943	chr10:116618077	G/A	cg03647239	chr10:116582469	FAM160B1	0.49	6.21	0.38	2.39e-9	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs9916302	0.861	rs2338801	chr17:37490780	G/T	cg15445000	chr17:37608096	MED1	-0.41	-4.95	-0.31	1.45e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs6840360	1.000	rs10007167	chr4:152603655	C/T	cg22705602	chr4:152727874	NA	-0.3	-4.75	-0.3	3.55e-6	Intelligence (multi-trait analysis);
SARC	cis	rs910316	0.737	rs108622	chr14:75481908	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.45	-5.93	-0.36	1.09e-8	Height;
SARC	cis	rs9393692	0.557	rs9366648	chr6:26306282	T/C	cg13736514	chr6:26305472	NA	-0.4	-4.96	-0.31	1.35e-6	Educational attainment;
SARC	trans	rs1853207	1.000	rs9332092	chr10:96696529	T/C	cg02737782	chr1:8014393	NA	-0.91	-6.52	-0.39	4.4e-10	Blood metabolite levels;
SARC	cis	rs7223966	0.961	rs112709843	chr17:61836936	T/A	cg00588841	chr17:61851480	DDX42;CCDC47	-0.64	-7.11	-0.42	1.39e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs668210	0.739	rs543952	chr11:65744275	T/C	cg02202077	chr11:65769826	EIF1AD;BANF1	0.68	7.13	0.42	1.26e-11	Cerebrospinal fluid biomarker levels;
SARC	cis	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg21775007	chr8:11205619	TDH	-0.5	-6.26	-0.38	1.82e-9	Retinal vascular caliber;
SARC	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg26681399	chr22:41777847	TEF	0.41	4.77	0.3	3.18e-6	Vitiligo;
SARC	cis	rs4074493	0.963	rs6541251	chr1:231173596	T/C	cg22172038	chr1:231176991	FAM89A	0.35	5.08	0.32	7.86e-7	Carotid plaque burden (smoking interaction);
SARC	cis	rs1950500	0.545	rs1950501	chr14:24806800	C/G	cg16194253	chr14:24768981	DHRS1;C14orf21	0.59	7.39	0.44	2.68e-12	Height;
SARC	cis	rs6912958	0.781	rs4334949	chr6:88290150	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-5.43	-0.34	1.42e-7	Monocyte percentage of white cells;
SARC	cis	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg18252515	chr7:66147081	NA	-1.27	-11.31	-0.6	6.26e-24	Diabetic kidney disease;
SARC	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg07636037	chr3:49044803	WDR6	1.03	18.4	0.77	2.65e-47	Parkinson's disease;
SARC	cis	rs2115630	1.000	rs55646601	chr15:85323568	G/T	cg17507749	chr15:85114479	UBE2QP1	-0.46	-5.45	-0.34	1.31e-7	P wave terminal force;
SARC	trans	rs561341	0.700	rs8079471	chr17:30218317	A/G	cg20587970	chr11:113659929	NA	-0.6	-6.55	-0.39	3.6e-10	Hip circumference adjusted for BMI;
SARC	trans	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg21659725	chr3:3221576	CRBN	-0.66	-6.57	-0.4	3.2e-10	Menarche (age at onset);
SARC	cis	rs7223966	1.000	rs7214312	chr17:61870863	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.5	-5.18	-0.32	4.77e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs4742903	0.935	rs7026246	chr9:106955686	A/C	cg14250997	chr9:106856677	SMC2	0.44	5.52	0.34	9.08e-8	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs6087990	0.899	rs4911107	chr20:31374991	G/A	cg13636640	chr20:31349939	DNMT3B	0.8	12.61	0.64	4.02e-28	Ulcerative colitis;
SARC	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg27266027	chr21:40555129	PSMG1	0.46	4.84	0.3	2.36e-6	Cognitive function;
SARC	cis	rs9790314	1.000	rs2218803	chr3:161047973	T/G	cg04691961	chr3:161091175	C3orf57	-0.8	-11.81	-0.61	1.59e-25	Morning vs. evening chronotype;
SARC	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg16479474	chr6:28041457	NA	0.34	5.17	0.32	5.12e-7	Cardiac Troponin-T levels;
SARC	cis	rs9399135	0.967	rs10872427	chr6:135353452	T/C	cg24558204	chr6:135376177	HBS1L	0.45	6.15	0.37	3.33e-9	Red blood cell count;
SARC	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.78	-11.57	-0.6	9.52e-25	Menarche (age at onset);
SARC	cis	rs1008375	1.000	rs10939749	chr4:17692319	A/C	cg16339924	chr4:17578868	LAP3	0.56	7.03	0.42	2.24e-11	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg04550941	chr4:177241289	SPCS3	0.52	6.43	0.39	7.19e-10	Breast cancer;
SARC	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	trans	rs9325144	0.555	rs7301258	chr12:38706942	C/T	cg23762105	chr12:34175262	ALG10	-0.52	-6.67	-0.4	1.83e-10	Morning vs. evening chronotype;
SARC	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg22875332	chr1:76189707	ACADM	-0.42	-5.53	-0.34	8.5e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	trans	rs7824557	0.614	rs10503421	chr8:11221313	C/T	cg06636001	chr8:8085503	FLJ10661	0.6	7.85	0.46	1.54e-13	Retinal vascular caliber;
SARC	cis	rs7647973	1.000	rs9871024	chr3:49554241	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.57	-6.06	-0.37	5.34e-9	Menarche (age at onset);
SARC	cis	rs4555082	1.000	rs4277291	chr14:105759009	A/G	cg13114125	chr14:105738426	BRF1	-0.8	-11.76	-0.61	2.32e-25	Mean platelet volume;Platelet distribution width;
SARC	cis	rs2273669	0.915	rs1887414	chr6:109292736	C/T	cg05315195	chr6:109294784	ARMC2	0.51	5.3	0.33	2.66e-7	Prostate cancer;
SARC	cis	rs116095464	0.558	rs9312957	chr5:202194	C/T	cg22496380	chr5:211416	CCDC127	-0.89	-7.84	-0.46	1.6e-13	Breast cancer;
SARC	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg01276201	chr10:134613136	NA	0.31	5.01	0.31	1.06e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs2153535	0.580	rs9379213	chr6:8474945	G/A	cg07606381	chr6:8435919	SLC35B3	0.77	10.83	0.58	2.14e-22	Motion sickness;
SARC	cis	rs239198	0.602	rs9377236	chr6:101289960	A/G	cg09795085	chr6:101329169	ASCC3	0.47	5.97	0.36	9e-9	Menarche (age at onset);
SARC	cis	rs796364	0.813	rs7565417	chr2:201057491	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.57	5.88	0.36	1.4e-8	Schizophrenia;
SARC	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg18252515	chr7:66147081	NA	0.55	5.9	0.36	1.3e-8	Aortic root size;
SARC	cis	rs35995292	0.927	rs4720308	chr7:38914285	A/C	cg19327137	chr7:38886074	VPS41	0.36	5.24	0.32	3.57e-7	Subjective well-being (multi-trait analysis);
SARC	trans	rs11098499	0.909	rs11723757	chr4:120299669	C/T	cg25214090	chr10:38739885	LOC399744	0.54	7.06	0.42	1.84e-11	Corneal astigmatism;
SARC	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg07061783	chr6:25882402	NA	-0.5	-5.85	-0.36	1.66e-8	Intelligence (multi-trait analysis);
SARC	cis	rs210142	1.000	rs210142	chr6:33546837	T/C	cg24505687	chr6:33548425	BAK1	0.36	4.86	0.3	2.13e-6	Platelet count;Plateletcrit;Chronic lymphocytic leukemia;
SARC	cis	rs7666738	0.830	rs13328042	chr4:99055406	A/G	cg05340658	chr4:99064831	C4orf37	0.65	8.85	0.5	2.24e-16	Colonoscopy-negative controls vs population controls;
SARC	trans	rs7615952	0.688	rs12638224	chr3:125541320	C/T	cg07211511	chr3:129823064	LOC729375	-0.75	-8.65	-0.49	8.5e-16	Blood pressure (smoking interaction);
SARC	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg11366901	chr6:160182831	ACAT2	1.05	10.45	0.56	3.29e-21	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6582630	0.502	rs4379906	chr12:38295673	G/A	cg13010199	chr12:38710504	ALG10B	0.75	10.18	0.56	2.19e-20	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs12311304	1.000	rs11056410	chr12:15382815	T/C	cg08258403	chr12:15378311	NA	0.49	7.35	0.43	3.4e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs10463554	0.892	rs72783890	chr5:102274540	A/C	cg23492399	chr5:102201601	PAM	-0.45	-5.38	-0.33	1.84e-7	Parkinson's disease;
SARC	cis	rs826838	1.000	rs10880914	chr12:38720543	C/T	cg13010199	chr12:38710504	ALG10B	0.82	11.86	0.61	1.11e-25	Heart rate;
SARC	trans	rs79976124	0.719	rs34488909	chr6:66637850	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	7.98	0.46	6.52e-14	Type 2 diabetes;
SARC	cis	rs7113850	0.541	rs77054343	chr11:24215636	A/G	ch.11.24196551F	chr11:24239977	NA	0.69	4.98	0.31	1.26e-6	Bone fracture in osteoporosis;
SARC	cis	rs8114671	0.586	rs734111	chr20:33533736	A/C	cg07148914	chr20:33460835	GGT7	0.47	5.68	0.35	3.9e-8	Height;
SARC	cis	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg06070291	chr15:44828899	EIF3J	0.56	5.67	0.35	4.28e-8	Lung cancer in ever smokers;
SARC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg18110333	chr6:292329	DUSP22	-0.65	-8.32	-0.48	7.33e-15	Menopause (age at onset);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg15544402	chr2:24299646	SF3B14	-0.49	-6.44	-0.39	6.59e-10	Breast cancer;
SARC	cis	rs35995292	1.000	rs56098802	chr7:38913730	T/C	cg19327137	chr7:38886074	VPS41	0.36	5.24	0.32	3.57e-7	Subjective well-being (multi-trait analysis);
SARC	cis	rs782590	0.935	rs782652	chr2:55862775	C/A	cg18811423	chr2:55921094	PNPT1	0.7	10.64	0.57	8.61e-22	Metabolic syndrome;
SARC	cis	rs1580019	0.844	rs1376290	chr7:32486922	C/T	cg14728415	chr7:32535168	LSM5;AVL9	0.45	5.43	0.33	1.44e-7	Cognitive ability;
SARC	cis	rs910316	0.935	rs2268620	chr14:75640403	G/A	cg08847533	chr14:75593920	NEK9	-0.89	-13.82	-0.67	4e-32	Height;
SARC	cis	rs9790314	1.000	rs4597724	chr3:160963110	A/G	cg04691961	chr3:161091175	C3orf57	-0.78	-11.65	-0.61	5.03e-25	Morning vs. evening chronotype;
SARC	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg00684032	chr4:1343700	KIAA1530	0.39	5.52	0.34	8.95e-8	Obesity-related traits;
SARC	cis	rs2635047	0.601	rs2635052	chr18:44650607	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	6.48	0.39	5.46e-10	Educational attainment;
SARC	cis	rs16854884	0.586	rs4561830	chr3:143735572	C/T	cg06585982	chr3:143692056	C3orf58	0.7	9.83	0.54	2.77e-19	Economic and political preferences (feminism/equality);
SARC	cis	rs4803468	1.000	rs8105833	chr19:41896145	G/A	cg08477640	chr19:41863820	B9D2	0.44	5.57	0.34	6.98e-8	Height;
SARC	cis	rs7589342	0.536	rs55830542	chr2:106387206	C/T	cg16077055	chr2:106428750	NCK2	0.31	6.07	0.37	5.12e-9	Addiction;
SARC	cis	rs11098499	0.863	rs34308924	chr4:120481431	T/C	cg09307838	chr4:120376055	NA	0.91	12.25	0.63	5.66e-27	Corneal astigmatism;
SARC	cis	rs11997175	0.646	rs4609158	chr8:33693420	A/G	ch.8.33884649F	chr8:33765107	NA	0.63	8.6	0.49	1.21e-15	Body mass index;
SARC	trans	rs877282	0.945	rs71491303	chr10:772884	G/T	cg22713356	chr15:30763199	NA	1.04	10.32	0.56	8.5e-21	Uric acid levels;
SARC	cis	rs3008870	0.755	rs1024229	chr1:67512903	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.38	4.75	0.3	3.51e-6	Lymphocyte percentage of white cells;
SARC	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.03	11.11	0.59	2.83e-23	Platelet count;
SARC	cis	rs12200560	0.505	rs211174	chr6:97071120	C/T	cg06623918	chr6:96969491	KIAA0776	0.44	5.02	0.31	1e-6	Coronary heart disease;
SARC	cis	rs644799	1.000	rs527899	chr11:95529242	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	15.35	0.71	3.21e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg20891558	chr2:74357851	NA	0.7	9.54	0.53	1.95e-18	Gestational age at birth (maternal effect);
SARC	cis	rs62344088	0.590	rs2115276	chr5:169829	C/G	cg22857025	chr5:266934	NA	-0.81	-5.31	-0.33	2.61e-7	Asthma (childhood onset);
SARC	cis	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg07777115	chr5:623756	CEP72	-0.65	-6.02	-0.37	6.6e-9	Obesity-related traits;
SARC	cis	rs9398803	0.687	rs3905044	chr6:126972883	A/G	cg19875578	chr6:126661172	C6orf173	0.63	8.7	0.5	5.9e-16	Male-pattern baldness;
SARC	cis	rs6696846	0.515	rs12739846	chr1:205096895	T/C	cg00857998	chr1:205179979	DSTYK	0.4	4.73	0.3	3.93e-6	Red blood cell count;
SARC	cis	rs2361718	0.500	rs4889818	chr17:78085228	A/G	cg14949292	chr17:78079608	GAA	-0.35	-4.82	-0.3	2.54e-6	Yeast infection;
SARC	cis	rs9902453	0.845	rs7222842	chr17:28246943	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	6.95	0.41	3.65e-11	Coffee consumption (cups per day);
SARC	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg12042659	chr19:58951599	ZNF132	0.41	5.43	0.34	1.43e-7	Uric acid clearance;
SARC	cis	rs9399137	0.507	rs13064	chr6:135287533	A/G	cg24558204	chr6:135376177	HBS1L	0.62	7.98	0.46	6.83e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs1580019	0.562	rs4720064	chr7:32559638	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.99	18.06	0.76	3.58e-46	Cognitive ability;
SARC	cis	rs9916302	0.752	rs676882	chr17:37433424	A/T	cg00129232	chr17:37814104	STARD3	0.58	5.75	0.35	2.85e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg16325326	chr1:53192061	ZYG11B	0.68	9.92	0.54	1.43e-19	Monocyte count;
SARC	cis	rs2933343	0.729	rs6767104	chr3:128648117	G/T	cg25356066	chr3:128598488	ACAD9	-0.72	-9.28	-0.52	1.23e-17	IgG glycosylation;
SARC	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.82	8.39	0.48	4.76e-15	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs11122272	0.735	rs2486737	chr1:231520523	T/C	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs6912958	0.728	rs6923230	chr6:88213949	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.51	-6.82	-0.41	7.71e-11	Monocyte percentage of white cells;
SARC	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg22433210	chr17:43662623	NA	1.03	12.12	0.62	1.58e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg18252515	chr7:66147081	NA	-1.3	-11.5	-0.6	1.59e-24	Diabetic kidney disease;
SARC	cis	rs1371867	0.846	rs1788206	chr8:101306966	A/G	cg11906718	chr8:101322791	RNF19A	0.7	8.98	0.51	9.31e-17	Atrioventricular conduction;
SARC	cis	rs11608355	0.521	rs7978210	chr12:109835990	A/G	cg19025524	chr12:109796872	NA	-0.42	-6.25	-0.38	1.97e-9	Neuroticism;
SARC	cis	rs10845606	1.000	rs10845607	chr12:12835228	C/T	cg09462578	chr12:12878428	APOLD1	-0.52	-5.08	-0.32	7.65e-7	Systemic lupus erythematosus;
SARC	cis	rs2153535	0.580	rs7755284	chr6:8457479	T/C	cg21535247	chr6:8435926	SLC35B3	0.52	6.55	0.39	3.66e-10	Motion sickness;
SARC	cis	rs79349575	0.783	rs12453394	chr17:46994970	G/A	cg16584676	chr17:46985605	UBE2Z	0.53	6.38	0.39	9.28e-10	Type 2 diabetes;
SARC	cis	rs10870270	0.830	rs10781571	chr10:133774316	G/C	cg26149184	chr10:133730230	NA	0.48	5.22	0.32	3.99e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs11098499	0.644	rs3986377	chr4:120260270	G/A	cg09307838	chr4:120376055	NA	0.75	10.4	0.56	4.7e-21	Corneal astigmatism;
SARC	cis	rs3099143	1.000	rs111908804	chr15:77123773	C/G	cg21673338	chr15:77095150	SCAPER	-0.75	-5.76	-0.35	2.58e-8	Recalcitrant atopic dermatitis;
SARC	cis	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg15145296	chr3:125709740	NA	-0.49	-4.88	-0.3	1.98e-6	Blood pressure (smoking interaction);
SARC	cis	rs11731606	0.508	rs17376943	chr4:95277117	G/A	cg20625393	chr4:95128694	SMARCAD1	0.58	5.6	0.34	5.97e-8	Mean platelet volume;
SARC	cis	rs644799	0.932	rs10831447	chr11:95663017	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	-0.47	-5.59	-0.34	6.4e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2243480	1.000	rs958550	chr7:65635679	C/T	cg18252515	chr7:66147081	NA	1.1	9.07	0.51	5.19e-17	Diabetic kidney disease;
SARC	cis	rs1707322	0.716	rs28375469	chr1:46195375	T/C	cg03146154	chr1:46216737	IPP	0.52	6.3	0.38	1.44e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg24675658	chr1:53192096	ZYG11B	0.65	9.21	0.52	1.91e-17	Monocyte count;
SARC	cis	rs965469	1.000	rs6051792	chr20:3343519	T/C	cg25506879	chr20:3388711	C20orf194	-0.47	-4.74	-0.3	3.66e-6	IFN-related cytopenia;
SARC	cis	rs10861342	1.000	rs11112373	chr12:105503708	G/A	cg23923672	chr12:105501055	KIAA1033	0.73	5.37	0.33	1.91e-7	IgG glycosylation;
SARC	cis	rs921968	0.565	rs3821035	chr2:219620223	T/G	cg02176678	chr2:219576539	TTLL4	-0.32	-4.88	-0.3	1.93e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.54	8.14	0.47	2.46e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs11581859	0.613	rs6656354	chr1:99200416	A/G	cg20286094	chr1:99190917	SNX7	-0.42	-4.94	-0.31	1.47e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs4727027	0.866	rs35599790	chr7:148806012	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.48	5.63	0.35	5.09e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs2153535	0.580	rs9393033	chr6:8521446	G/A	cg07606381	chr6:8435919	SLC35B3	0.76	11.08	0.59	3.38e-23	Motion sickness;
SARC	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.66	-6.89	-0.41	5.03e-11	Platelet count;
SARC	cis	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg00031303	chr3:195681400	NA	0.66	7.51	0.44	1.25e-12	Pancreatic cancer;
SARC	cis	rs6582630	0.555	rs2197308	chr12:38281261	A/G	cg14851346	chr12:38532713	NA	-0.45	-5.39	-0.33	1.71e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs870825	0.616	rs4264873	chr4:185624336	C/T	cg04058563	chr4:185651563	MLF1IP	0.82	11.42	0.6	2.8e-24	Blood protein levels;
SARC	cis	rs13191362	0.688	rs73035006	chr6:162997083	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.57	5.38	0.33	1.85e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs6500602	0.702	rs1051308	chr16:4560301	A/G	cg08645402	chr16:4508243	NA	-0.44	-5.9	-0.36	1.26e-8	Schizophrenia;
SARC	cis	rs752010	0.714	rs6600384	chr1:42085141	A/G	cg06885757	chr1:42089581	HIVEP3	-0.36	-5.5	-0.34	9.87e-8	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs9660992	0.686	rs1668870	chr1:205239031	C/G	cg07972983	chr1:205091412	RBBP5	0.56	6.71	0.4	1.48e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs7582180	0.613	rs12988464	chr2:100946285	A/G	cg14675211	chr2:100938903	LONRF2	0.5	7.44	0.44	1.93e-12	Intelligence (multi-trait analysis);
SARC	cis	rs2046867	0.818	rs62251647	chr3:72805789	G/A	cg25664220	chr3:72788482	NA	-0.29	-4.81	-0.3	2.66e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
SARC	cis	rs2380220	0.606	rs7754906	chr6:95992429	C/T	cg15832292	chr6:96025679	MANEA	0.49	5.45	0.34	1.27e-7	Behavioural disinhibition (generation interaction);
SARC	cis	rs7113874	0.659	rs2166470	chr11:8523172	A/T	cg09828998	chr11:8703972	RPL27A	-0.52	-5.47	-0.34	1.15e-7	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2120243	0.539	rs9878474	chr3:157123147	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	-0.38	-4.95	-0.31	1.44e-6	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs57506017	0.585	rs10234805	chr7:12253543	T/C	cg23422036	chr7:12250390	TMEM106B	0.51	6.88	0.41	5.42e-11	Neuroticism;
SARC	cis	rs290268	0.585	rs290992	chr9:93561309	C/T	cg02608019	chr9:93564028	SYK	-0.34	-4.93	-0.31	1.54e-6	Platelet count;
SARC	cis	rs780094	0.606	rs6729709	chr2:27583156	G/A	cg21747090	chr2:27597821	SNX17	-0.48	-6.31	-0.38	1.42e-9	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg13175981	chr1:150552382	MCL1	-0.48	-5.91	-0.36	1.23e-8	Melanoma;
SARC	trans	rs61931739	0.500	rs7965421	chr12:34523624	G/T	cg26384229	chr12:38710491	ALG10B	0.91	13.78	0.67	5.4e-32	Morning vs. evening chronotype;
SARC	cis	rs950776	0.720	rs11633223	chr15:78935476	T/C	cg06917634	chr15:78832804	PSMA4	0.61	7.81	0.46	1.9e-13	Sudden cardiac arrest;
SARC	cis	rs1843834	0.539	rs6749402	chr2:225443901	T/G	cg12698349	chr2:225449008	CUL3	0.7	9.17	0.52	2.5e-17	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs4073582	0.595	rs801739	chr11:65922589	A/G	cg14036092	chr11:66035641	RAB1B	0.62	8.36	0.48	5.57e-15	Gout;
SARC	cis	rs208520	0.874	rs208473	chr6:66917265	G/C	cg07460842	chr6:66804631	NA	-0.99	-12.1	-0.62	1.73e-26	Exhaled nitric oxide output;
SARC	cis	rs8067545	0.750	rs35003563	chr17:19989218	G/A	cg13482628	chr17:19912719	NA	0.55	7.17	0.43	9.9e-12	Schizophrenia;
SARC	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg12288994	chr5:1860383	NA	0.37	6.06	0.37	5.47e-9	Cardiovascular disease risk factors;
SARC	cis	rs35306767	0.903	rs11812523	chr10:915638	C/T	cg20503657	chr10:835505	NA	0.89	8.26	0.48	1.08e-14	Eosinophil percentage of granulocytes;
SARC	trans	rs66573146	1.000	rs9942188	chr4:6984181	C/T	cg07817883	chr1:32538562	TMEM39B	1.52	9.1	0.51	4.22e-17	Granulocyte percentage of myeloid white cells;
SARC	cis	rs12142240	0.698	rs56358525	chr1:46849520	C/T	cg10495392	chr1:46806563	NSUN4	0.65	6.93	0.41	4.14e-11	Menopause (age at onset);
SARC	cis	rs11098499	0.863	rs3733525	chr4:120447048	A/G	cg24375607	chr4:120327624	NA	0.42	4.9	0.31	1.76e-6	Corneal astigmatism;
SARC	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg16606324	chr3:10149918	C3orf24	0.51	5.19	0.32	4.53e-7	Alzheimer's disease;
SARC	cis	rs1153858	1.000	rs67744121	chr15:45677237	C/G	cg03999130	chr15:45571217	NA	0.39	4.98	0.31	1.25e-6	Homoarginine levels;
SARC	cis	rs910316	1.000	rs876402	chr14:75601862	C/T	cg08847533	chr14:75593920	NEK9	-0.92	-15.42	-0.71	1.84e-37	Height;
SARC	cis	rs1113500	0.897	rs11185263	chr1:108639804	C/G	cg06207961	chr1:108661230	NA	0.46	6.12	0.37	3.86e-9	Growth-regulated protein alpha levels;
SARC	cis	rs854765	0.583	rs4413022	chr17:17858280	G/C	cg04398451	chr17:18023971	MYO15A	-0.4	-5.51	-0.34	9.71e-8	Total body bone mineral density;
SARC	cis	rs12780845	0.505	rs10795462	chr10:17245119	A/C	cg11116878	chr10:17243438	TRDMT1	0.37	4.75	0.3	3.58e-6	Homocysteine levels;
SARC	cis	rs6582630	0.555	rs10785443	chr12:38463792	A/C	cg13010199	chr12:38710504	ALG10B	0.74	10.08	0.55	4.42e-20	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6963495	0.818	rs73192107	chr7:105168095	G/A	cg13798780	chr7:105162888	PUS7	0.6	5.54	0.34	8.27e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs6912958	0.781	rs7750207	chr6:88303967	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.66	-0.4	1.96e-10	Monocyte percentage of white cells;
SARC	cis	rs6484504	0.625	rs6484501	chr11:31373100	G/T	cg02090638	chr11:31391270	DNAJC24;DCDC1	0.4	5.09	0.32	7.49e-7	Red blood cell count;
SARC	cis	rs9462027	0.628	rs11759151	chr6:34747603	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.84	-0.36	1.71e-8	Systemic lupus erythematosus;
SARC	cis	rs9650657	0.530	rs6982381	chr8:10952500	A/T	cg16664915	chr8:10907788	XKR6	-0.35	-4.82	-0.3	2.57e-6	Neuroticism;
SARC	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg24060327	chr5:131705240	SLC22A5	-0.43	-5.11	-0.32	6.75e-7	Blood metabolite levels;
SARC	cis	rs6690583	0.623	rs74761855	chr1:85432947	A/C	cg22153463	chr1:85462885	MCOLN2	0.7	6.73	0.4	1.29e-10	Serum sulfate level;
SARC	cis	rs2180341	0.960	rs7751865	chr6:127683040	G/A	cg17762328	chr6:126965162	NA	-0.43	-4.77	-0.3	3.22e-6	Breast cancer;
SARC	cis	rs2562456	0.917	rs2681377	chr19:21716520	T/C	cg00806126	chr19:22604979	ZNF98	0.47	4.83	0.3	2.46e-6	Pain;
SARC	cis	rs3749237	0.595	rs4855877	chr3:49448527	T/C	cg02487422	chr3:49467188	NICN1	0.49	6.46	0.39	6.02e-10	Resting heart rate;
SARC	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg18252515	chr7:66147081	NA	-1.34	-11.85	-0.61	1.15e-25	Diabetic kidney disease;
SARC	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg24399712	chr22:39784796	NA	-0.44	-5.89	-0.36	1.35e-8	Intelligence (multi-trait analysis);
SARC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg11494091	chr17:61959527	GH2	0.54	8.07	0.47	3.82e-14	Prudent dietary pattern;
SARC	cis	rs1113500	0.933	rs4593854	chr1:108638519	A/G	cg06207961	chr1:108661230	NA	0.45	6.02	0.37	6.81e-9	Growth-regulated protein alpha levels;
SARC	cis	rs72945132	0.882	rs67822447	chr11:70230972	G/T	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.88	-0.36	1.41e-8	Coronary artery disease;
SARC	cis	rs9436747	0.641	rs12239395	chr1:66046013	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.48	4.97	0.31	1.29e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs9303401	0.538	rs2240258	chr17:56458183	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.0	9.7	0.54	6.85e-19	Cognitive test performance;
SARC	cis	rs12142240	0.698	rs17413701	chr1:46818452	A/G	cg00530320	chr1:46809349	NSUN4	0.57	6.92	0.41	4.4e-11	Menopause (age at onset);
SARC	cis	rs16976116	0.851	rs13380400	chr15:55490518	A/G	cg17854078	chr15:55489399	RSL24D1	0.66	6.46	0.39	6.14e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg24675658	chr1:53192096	ZYG11B	0.6	8.35	0.48	6.02e-15	Monocyte count;
SARC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.67	0.54	8.17e-19	Prudent dietary pattern;
SARC	cis	rs710216	0.843	rs10890232	chr1:43416514	C/T	cg03128534	chr1:43423976	SLC2A1	0.62	6.92	0.41	4.38e-11	Red cell distribution width;
SARC	cis	rs1550582	0.548	rs7828645	chr8:135497385	A/G	cg17885191	chr8:135476712	NA	-0.83	-8.25	-0.48	1.14e-14	Educational attainment;
SARC	cis	rs992157	0.798	rs4674284	chr2:219161241	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.64	-8.95	-0.51	1.11e-16	Colorectal cancer;
SARC	cis	rs6088580	0.524	rs2889855	chr20:33276853	A/G	cg08999081	chr20:33150536	PIGU	-0.32	-4.75	-0.3	3.5e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs4601821	0.823	rs4938015	chr11:113264644	C/T	cg14159747	chr11:113255604	NA	-0.36	-4.81	-0.3	2.68e-6	Alcoholic chronic pancreatitis;
SARC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg06873352	chr17:61820015	STRADA	-0.4	-5.11	-0.32	6.78e-7	Prudent dietary pattern;
SARC	cis	rs820218	0.576	rs820170	chr17:73729172	A/T	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.6	6.73	0.4	1.28e-10	Rotator cuff tears;
SARC	cis	rs2242116	0.796	rs4587	chr3:46963502	T/C	cg27129171	chr3:47204927	SETD2	0.62	8.19	0.47	1.74e-14	Birth weight;
SARC	cis	rs2013441	0.901	rs2526474	chr17:20137134	C/T	cg13482628	chr17:19912719	NA	-0.47	-6.2	-0.38	2.57e-9	Obesity-related traits;
SARC	cis	rs1448094	0.556	rs11614513	chr12:86167756	G/C	cg00310523	chr12:86230176	RASSF9	0.32	4.96	0.31	1.38e-6	Major depressive disorder;
SARC	cis	rs910316	0.934	rs4903278	chr14:75535019	C/A	cg06637938	chr14:75390232	RPS6KL1	0.59	8.61	0.49	1.1e-15	Height;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg08719467	chr1:146714230	CHD1L	0.65	6.85	0.41	6.37e-11	Lung cancer in ever smokers;
SARC	cis	rs11077998	0.935	rs12185276	chr17:80498997	T/C	cg10255544	chr17:80519551	FOXK2	0.44	6.45	0.39	6.37e-10	Reticulocyte fraction of red cells;
SARC	cis	rs796364	1.000	rs281794	chr2:200846666	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.78	7.31	0.43	4.37e-12	Schizophrenia;
SARC	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg00684032	chr4:1343700	KIAA1530	0.37	5.36	0.33	1.99e-7	Obesity-related traits;
SARC	cis	rs1784581	0.775	rs7755404	chr6:162427731	T/C	cg17173639	chr6:162384350	PARK2	0.65	8.89	0.5	1.66e-16	Itch intensity from mosquito bite;
SARC	cis	rs6582630	0.572	rs1969363	chr12:38514872	A/G	cg13010199	chr12:38710504	ALG10B	0.68	9.04	0.51	6.32e-17	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs79349575	0.811	rs60708039	chr17:46999373	C/G	cg16584676	chr17:46985605	UBE2Z	0.53	6.38	0.39	9.28e-10	Type 2 diabetes;
SARC	trans	rs3942852	0.726	rs10742836	chr11:48175831	G/A	cg15704280	chr7:45808275	SEPT13	-0.61	-7.11	-0.42	1.42e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs3784262	0.935	rs4646636	chr15:58251034	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.39	-6.0	-0.37	7.37e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg26769984	chr7:1090371	C7orf50	-0.47	-5.26	-0.33	3.21e-7	Bronchopulmonary dysplasia;
SARC	cis	rs1881797	1.000	rs1881796	chr1:247688931	G/A	cg18198730	chr1:247681584	NA	0.5	5.31	0.33	2.6e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs607987	0.871	rs7924960	chr11:30280075	C/T	cg06241208	chr11:30344200	C11orf46	0.42	5.06	0.31	8.31e-7	Body mass index;
SARC	cis	rs900145	0.773	rs11022753	chr11:13310854	A/G	cg10435282	chr11:13303971	ARNTL	0.35	4.81	0.3	2.76e-6	Menarche (age at onset);
SARC	cis	rs9815354	1.000	rs9842261	chr3:41822708	A/G	cg03022575	chr3:42003672	ULK4	-0.6	-5.81	-0.36	2.01e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs11122272	0.735	rs11122281	chr1:231519842	A/G	cg06096015	chr1:231504339	EGLN1	0.4	5.85	0.36	1.64e-8	Hemoglobin concentration;
SARC	cis	rs11122272	0.735	rs973253	chr1:231520874	C/T	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs10911232	0.507	rs10911194	chr1:182993025	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.64	0.57	8.13e-22	Hypertriglyceridemia;
SARC	cis	rs6570726	0.902	rs406979	chr6:145838983	G/T	cg05220968	chr6:146057943	EPM2A	-0.29	-4.86	-0.3	2.17e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6604026	0.656	rs11578986	chr1:93402823	G/T	cg17283838	chr1:93427260	FAM69A	0.41	4.76	0.3	3.35e-6	Multiple sclerosis;
SARC	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg04944784	chr2:26401820	FAM59B	-0.5	-6.37	-0.39	1.01e-9	Gut microbiome composition (summer);
SARC	cis	rs883565	0.525	rs9833327	chr3:39029631	A/G	cg01426195	chr3:39028469	NA	-0.39	-5.74	-0.35	3e-8	Handedness;
SARC	cis	rs1559088	0.546	rs11881543	chr19:33559372	T/G	cg17764715	chr19:33622953	WDR88	0.58	7.68	0.45	4.46e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs7937890	0.684	rs12799007	chr11:14426484	T/A	cg19336497	chr11:14380999	RRAS2	-0.28	-4.79	-0.3	3.02e-6	Mitochondrial DNA levels;
SARC	cis	rs11792861	1.000	rs11792861	chr9:111809295	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.67	7.59	0.45	7.47e-13	Menarche (age at onset);
SARC	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg13401987	chr15:63569418	APH1B	-0.48	-6.3	-0.38	1.45e-9	Parental extreme longevity (95 years and older);
SARC	cis	rs765787	0.530	rs1706835	chr15:45517884	G/A	cg24006582	chr15:45444508	DUOX1	-0.5	-6.57	-0.4	3.24e-10	Uric acid levels;
SARC	cis	rs425277	0.917	rs78395918	chr1:2045876	G/A	cg24578937	chr1:2090814	PRKCZ	0.32	6.01	0.37	7.22e-9	Height;
SARC	cis	rs763121	0.853	rs6001173	chr22:39015302	A/G	cg21395723	chr22:39101663	GTPBP1	0.56	6.52	0.39	4.4e-10	Menopause (age at onset);
SARC	cis	rs875971	0.502	rs6460311	chr7:66111873	C/T	cg11764359	chr7:65958608	NA	-0.6	-5.77	-0.35	2.45e-8	Aortic root size;
SARC	trans	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg00938859	chr5:1591904	SDHAP3	0.69	6.36	0.38	1.03e-9	Breast cancer;
SARC	cis	rs9814567	1.000	rs7648990	chr3:134244390	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.1	-0.42	1.49e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6456042	1.000	rs3099291	chr6:166528913	A/G	cg11088901	chr6:166572345	T	0.34	4.97	0.31	1.29e-6	Asthma;
SARC	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg22800045	chr5:56110881	MAP3K1	0.72	7.66	0.45	4.94e-13	Initial pursuit acceleration;
SARC	cis	rs72653721	0.838	rs3798710	chr6:11002783	C/G	cg13562911	chr6:11044106	ELOVL2	0.54	6.27	0.38	1.75e-9	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	cis	rs17376456	0.741	rs10036829	chr5:93309897	G/C	cg25358565	chr5:93447407	FAM172A	1.29	14.58	0.69	1.2e-34	Diabetic retinopathy;
SARC	cis	rs7647973	0.667	rs9869256	chr3:49624095	T/G	cg03060546	chr3:49711283	APEH	0.68	5.77	0.35	2.51e-8	Menarche (age at onset);
SARC	cis	rs9911578	0.967	rs11079368	chr17:57086473	C/T	cg20303301	chr17:57937339	TUBD1	0.34	4.92	0.31	1.64e-6	Intelligence (multi-trait analysis);
SARC	cis	rs3733585	0.781	rs13103879	chr4:9972879	T/C	cg00071950	chr4:10020882	SLC2A9	-0.38	-6.07	-0.37	5.24e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7223966	0.655	rs9906924	chr17:61634538	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.51	5.2	0.32	4.29e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.4	-4.86	-0.3	2.11e-6	Total body bone mineral density;
SARC	cis	rs6500602	0.727	rs2058811	chr16:4575162	C/T	cg08645402	chr16:4508243	NA	0.42	5.32	0.33	2.47e-7	Schizophrenia;
SARC	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.22	0.38	2.3e-9	Electroencephalogram traits;
SARC	cis	rs1003719	0.788	rs8133549	chr21:38447489	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.67	9.98	0.55	9.34e-20	Eye color traits;
SARC	trans	rs9329221	0.686	rs60755617	chr8:10243327	T/G	cg06636001	chr8:8085503	FLJ10661	0.57	6.94	0.41	3.84e-11	Neuroticism;
SARC	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7264396	0.790	rs2295355	chr20:34252654	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-8.22	-0.47	1.46e-14	Total cholesterol levels;
SARC	cis	rs8114671	0.562	rs6087644	chr20:33480917	G/C	cg07148914	chr20:33460835	GGT7	0.44	5.18	0.32	4.7e-7	Height;
SARC	cis	rs6831352	0.734	rs1311620	chr4:100013091	C/T	cg13256891	chr4:100009986	ADH5	0.58	7.68	0.45	4.26e-13	Alcohol dependence;
SARC	trans	rs56279505	0.690	rs2165670	chr4:100286085	G/A	cg18024358	chr1:3420815	MEGF6	-0.79	-6.28	-0.38	1.61e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs877282	0.853	rs7069720	chr10:754487	A/G	cg22713356	chr15:30763199	NA	0.99	9.88	0.54	1.92e-19	Uric acid levels;
SARC	cis	rs2645694	0.626	rs2645705	chr4:77830434	G/A	cg18351406	chr4:77819688	ANKRD56	0.37	5.14	0.32	5.77e-7	Emphysema distribution in smoking;
SARC	cis	rs968567	0.501	rs174553	chr11:61575158	A/G	cg19610905	chr11:61596333	FADS2	-0.4	-4.79	-0.3	3.03e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
SARC	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-15.51	-0.71	9.76e-38	Chronic sinus infection;
SARC	cis	rs62244186	0.659	rs4682745	chr3:44508967	T/C	cg15225532	chr3:44803084	KIF15;KIAA1143	0.46	5.75	0.35	2.84e-8	Depressive symptoms;
SARC	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg12463550	chr7:65579703	CRCP	0.71	5.37	0.33	1.9e-7	Diabetic kidney disease;
SARC	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.68	-8.8	-0.5	3.09e-16	Intelligence (multi-trait analysis);
SARC	cis	rs748404	0.697	rs567357	chr15:43571390	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	6.53	0.39	4.02e-10	Lung cancer;
SARC	cis	rs9948	0.655	rs62156228	chr2:97420335	A/G	cg15007626	chr2:97405879	LMAN2L	0.74	4.91	0.31	1.74e-6	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs4481887	0.800	rs10788780	chr1:248483598	G/A	cg01631408	chr1:248437212	OR2T33	-0.39	-4.87	-0.3	2.04e-6	Common traits (Other);
SARC	cis	rs3820928	0.804	rs4675125	chr2:227802499	T/C	cg11843606	chr2:227700838	RHBDD1	-0.56	-7.12	-0.42	1.33e-11	Pulmonary function;
SARC	cis	rs17345786	0.906	rs11708616	chr3:101231731	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.45	-4.92	-0.31	1.62e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7914558	1.000	rs10786740	chr10:104935593	G/C	cg04362960	chr10:104952993	NT5C2	0.4	4.8	0.3	2.83e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs8017423	0.967	rs59006192	chr14:90706456	C/T	cg20276874	chr14:90721474	PSMC1	-0.36	-5.03	-0.31	9.98e-7	Mortality in heart failure;
SARC	cis	rs1113500	0.933	rs10494089	chr1:108626695	T/G	cg06207961	chr1:108661230	NA	0.45	5.92	0.36	1.13e-8	Growth-regulated protein alpha levels;
SARC	cis	rs7044106	0.762	rs10984974	chr9:123421556	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.71	9.05	0.51	5.78e-17	Hip circumference adjusted for BMI;
SARC	cis	rs634534	0.562	rs661335	chr11:65754061	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.45	-5.58	-0.34	6.51e-8	Sum eosinophil basophil counts;Eosinophil counts;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg13357455	chr5:134240501	PCBD2	0.78	6.48	0.39	5.38e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs17376456	1.000	rs12187701	chr5:93522290	A/G	cg25358565	chr5:93447407	FAM172A	1.35	14.06	0.68	6.12e-33	Diabetic retinopathy;
SARC	cis	rs78487399	0.808	rs12105399	chr2:43676939	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-5.01	-0.31	1.08e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs12908161	1.000	rs35630683	chr15:85349231	T/C	cg17507749	chr15:85114479	UBE2QP1	0.56	6.43	0.39	6.96e-10	Schizophrenia;
SARC	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg12463550	chr7:65579703	CRCP	-0.5	-5.48	-0.34	1.09e-7	Aortic root size;
SARC	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg26335602	chr6:28129616	ZNF389	0.53	5.88	0.36	1.43e-8	Depression;
SARC	cis	rs7264396	0.563	rs2425116	chr20:34323553	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	5.68	0.35	4.03e-8	Total cholesterol levels;
SARC	cis	rs73206853	0.841	rs73191836	chr12:110966177	G/T	cg08946844	chr12:110511112	NA	0.59	4.74	0.3	3.75e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs3126085	0.935	rs4845741	chr1:152183474	A/G	cg26876637	chr1:152193138	HRNR	0.47	5.44	0.34	1.36e-7	Atopic dermatitis;
SARC	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg24549020	chr5:56110836	MAP3K1	-0.53	-5.84	-0.36	1.78e-8	Initial pursuit acceleration;
SARC	cis	rs3741151	0.656	rs10501411	chr11:73292085	A/C	cg17517138	chr11:73019481	ARHGEF17	0.82	6.09	0.37	4.68e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs3008870	0.755	rs4655662	chr1:67416432	T/C	cg02640540	chr1:67518911	SLC35D1	0.45	5.22	0.32	3.94e-7	Lymphocyte percentage of white cells;
SARC	cis	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg24110177	chr3:50126178	RBM5	-0.38	-4.87	-0.3	2.11e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg15049968	chr18:44337910	ST8SIA5	-0.32	-5.04	-0.31	9.43e-7	Personality dimensions;
SARC	cis	rs28386778	0.703	rs2286565	chr17:62010232	G/T	cg06873352	chr17:61820015	STRADA	-0.43	-5.41	-0.33	1.56e-7	Prudent dietary pattern;
SARC	trans	rs11098499	0.954	rs2306455	chr4:120421969	G/A	cg25214090	chr10:38739885	LOC399744	0.58	7.47	0.44	1.63e-12	Corneal astigmatism;
SARC	cis	rs78487399	0.808	rs116451849	chr2:43662911	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-5.69	-0.35	3.88e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg25894440	chr7:65020034	NA	-0.79	-5.99	-0.37	8.04e-9	Diabetic kidney disease;
SARC	trans	rs17685	0.753	rs869806	chr7:75688623	C/T	cg19862616	chr7:65841803	NCRNA00174	0.61	7.7	0.45	3.98e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs910316	0.763	rs175047	chr14:75479039	C/G	cg11812906	chr14:75593930	NEK9	-0.78	-10.75	-0.58	3.68e-22	Height;
SARC	cis	rs7560272	0.723	rs2421548	chr2:73641240	A/G	cg20560298	chr2:73613845	ALMS1	0.52	7.14	0.42	1.19e-11	Schizophrenia;
SARC	cis	rs9916302	0.707	rs11078903	chr17:37631924	G/A	cg15445000	chr17:37608096	MED1	0.42	4.86	0.3	2.15e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs17376456	0.757	rs6859757	chr5:93206042	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.69	6.08	0.37	4.82e-9	Diabetic retinopathy;
SARC	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg21132104	chr15:45694354	SPATA5L1	0.77	10.98	0.58	6.87e-23	Homoarginine levels;
SARC	cis	rs2070488	1.000	rs13074160	chr3:38455650	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	14.45	0.69	3.18e-34	Electrocardiographic conduction measures;
SARC	cis	rs7103648	0.695	rs11039290	chr11:47572279	G/A	cg20307385	chr11:47447363	PSMC3	0.77	11.05	0.59	4.16e-23	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs10927875	0.518	rs1763597	chr1:16343297	C/T	cg21385522	chr1:16154831	NA	0.55	6.64	0.4	2.24e-10	Dilated cardiomyopathy;
SARC	cis	rs28374715	0.662	rs11852419	chr15:41456374	A/T	cg18705301	chr15:41695430	NDUFAF1	0.97	13.53	0.66	3.63e-31	Ulcerative colitis;
SARC	trans	rs61931739	0.517	rs1843738	chr12:34056935	C/T	cg13010199	chr12:38710504	ALG10B	0.77	10.46	0.57	2.95e-21	Morning vs. evening chronotype;
SARC	cis	rs9911578	0.967	rs9894274	chr17:56977919	G/A	cg05425664	chr17:57184151	TRIM37	-0.67	-8.33	-0.48	7.15e-15	Intelligence (multi-trait analysis);
SARC	cis	rs2658782	1.000	rs2658782	chr11:93166731	T/G	cg15737290	chr11:93063684	CCDC67	0.73	7.67	0.45	4.53e-13	Pulmonary function decline;
SARC	cis	rs7772486	0.686	rs9403746	chr6:146103768	C/A	cg23711669	chr6:146136114	FBXO30	-0.81	-13.15	-0.65	6.52e-30	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs3780486	0.846	rs2209948	chr9:33138247	G/A	cg20290983	chr6:43655470	MRPS18A	1.15	22.06	0.82	5.4e-59	IgG glycosylation;
SARC	cis	rs4481887	0.962	rs10788768	chr1:248456027	G/A	cg00666640	chr1:248458726	OR2T12	0.36	5.95	0.36	9.69e-9	Common traits (Other);
SARC	cis	rs6484504	0.576	rs58702363	chr11:31246397	C/A	cg26647111	chr11:31128758	NA	-0.4	-5.2	-0.32	4.32e-7	Red blood cell count;
SARC	cis	rs6831352	0.918	rs29001201	chr4:100053861	T/C	cg13256891	chr4:100009986	ADH5	-0.63	-7.87	-0.46	1.31e-13	Alcohol dependence;
SARC	cis	rs11711311	1.000	rs12736	chr3:113530211	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	8.6	0.49	1.21e-15	IgG glycosylation;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg13135637	chr7:117056487	ASZ1	0.52	7.5	0.44	1.32e-12	Thyroid stimulating hormone;
SARC	cis	rs4319547	1.000	rs7309390	chr12:123110422	A/G	cg23029597	chr12:123009494	RSRC2	-0.4	-5.18	-0.32	4.79e-7	Body mass index;
SARC	trans	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.74	10.52	0.57	1.96e-21	Intelligence (multi-trait analysis);
SARC	cis	rs763121	0.853	rs2072794	chr22:39150543	G/T	cg06022373	chr22:39101656	GTPBP1	0.89	11.4	0.6	3.29e-24	Menopause (age at onset);
SARC	cis	rs28374715	0.681	rs28687846	chr15:41599902	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.14	-18.31	-0.77	5.15e-47	Ulcerative colitis;
SARC	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg17294928	chr15:75287854	SCAMP5	0.57	7.26	0.43	5.83e-12	Breast cancer;
SARC	cis	rs854765	0.583	rs8075965	chr17:17853180	A/T	cg05444541	chr17:17804740	TOM1L2	-0.29	-4.82	-0.3	2.56e-6	Total body bone mineral density;
SARC	trans	rs7824557	0.933	rs6601576	chr8:11100275	A/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.27	-0.38	1.7e-9	Retinal vascular caliber;
SARC	cis	rs11676348	0.712	rs12694426	chr2:218942351	T/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.42	-5.37	-0.33	1.93e-7	Ulcerative colitis;
SARC	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg05861140	chr6:150128134	PCMT1	-0.39	-4.81	-0.3	2.72e-6	Lung cancer;
SARC	cis	rs7772486	0.754	rs9386134	chr6:146145508	G/A	cg23711669	chr6:146136114	FBXO30	0.9	15.69	0.72	2.36e-38	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3099143	1.000	rs7174048	chr15:77165416	T/C	cg21673338	chr15:77095150	SCAPER	0.6	5.09	0.32	7.43e-7	Recalcitrant atopic dermatitis;
SARC	cis	rs11864453	1.000	rs7185407	chr16:72034957	A/T	cg16558253	chr16:72132732	DHX38	0.53	7.15	0.42	1.1e-11	Fibrinogen levels;
SARC	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg22800045	chr5:56110881	MAP3K1	0.76	7.99	0.46	6.06e-14	Initial pursuit acceleration;
SARC	cis	rs12702595	0.818	rs7791957	chr7:7270034	T/C	cg04827551	chr7:7268805	C1GALT1	0.44	5.4	0.33	1.61e-7	Serum dimethylarginine levels (asymmetric/symetric ratio);Symmetrical dimethylarginine levels;
SARC	cis	rs11098499	0.863	rs2306457	chr4:120472839	T/A	cg09307838	chr4:120376055	NA	0.91	12.11	0.62	1.67e-26	Corneal astigmatism;
SARC	cis	rs9325144	0.555	rs4882284	chr12:38710459	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-8.38	-0.48	5.17e-15	Morning vs. evening chronotype;
SARC	cis	rs9325144	0.532	rs12812406	chr12:38719802	G/A	cg04568710	chr12:38710424	ALG10B	-0.39	-4.75	-0.3	3.56e-6	Morning vs. evening chronotype;
SARC	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	10.28	0.56	1.08e-20	Platelet count;
SARC	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.59e-6	Depression;
SARC	trans	rs11722228	0.549	rs73212828	chr4:10078756	C/T	cg26043149	chr18:55253948	FECH	0.68	7.6	0.45	7.08e-13	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs6793245	0.845	rs4073796	chr3:38590849	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.46	-5.35	-0.33	2.06e-7	QT interval;
SARC	cis	rs4925386	0.802	rs6142735	chr20:60918087	G/C	cg24112000	chr20:60950667	NA	-0.37	-5.55	-0.34	7.91e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs72843506	1.000	rs7223910	chr17:19982768	G/A	cg13482628	chr17:19912719	NA	0.58	5.6	0.34	6.15e-8	Schizophrenia;
SARC	cis	rs9616064	0.889	rs5767287	chr22:46996179	G/A	cg05621596	chr22:47072043	GRAMD4	-0.42	-5.79	-0.35	2.31e-8	Urate levels in obese individuals;
SARC	cis	rs1570884	0.556	rs2146146	chr13:50170368	C/T	cg03651054	chr13:50194643	NA	0.32	5.21	0.32	4.22e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg10523679	chr1:76189770	ACADM	0.54	7.38	0.44	2.73e-12	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs17023223	0.537	rs61806983	chr1:119731524	G/C	cg05756136	chr1:119680316	WARS2	-0.49	-5.62	-0.35	5.47e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg03060546	chr3:49711283	APEH	0.42	5.23	0.32	3.86e-7	Parkinson's disease;
SARC	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg01017244	chr2:74357527	NA	0.56	7.15	0.42	1.12e-11	Gestational age at birth (maternal effect);
SARC	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg19671926	chr4:122722719	EXOSC9	-0.58	-6.56	-0.4	3.36e-10	Type 2 diabetes;
SARC	cis	rs13392177	0.672	rs4674270	chr2:219053141	G/T	cg00012203	chr2:219082015	ARPC2	-0.69	-9.36	-0.52	6.97e-18	Pyoderma gangrenosum in inflammatory bowel disease;
SARC	cis	rs1059312	0.772	rs11609637	chr12:129300202	T/G	cg09035930	chr12:129282057	SLC15A4	0.55	7.82	0.46	1.81e-13	Systemic lupus erythematosus;
SARC	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg21782813	chr7:2030301	MAD1L1	0.39	5.9	0.36	1.26e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs748404	0.578	rs573615	chr15:43614281	C/T	cg08831455	chr15:43942014	CATSPER2	-0.4	-4.74	-0.3	3.79e-6	Lung cancer;
SARC	cis	rs262150	0.731	rs2657388	chr7:158763428	A/G	cg19418458	chr7:158789849	NA	0.4	5.3	0.33	2.68e-7	Facial morphology (factor 20);
SARC	cis	rs9807989	0.839	rs9308857	chr2:102979624	G/A	cg09003973	chr2:102972529	NA	0.41	5.64	0.35	4.86e-8	Asthma;
SARC	cis	rs9303401	0.704	rs740605	chr17:56604811	C/T	cg12560992	chr17:57184187	TRIM37	0.5	6.13	0.37	3.69e-9	Cognitive test performance;
SARC	cis	rs2072499	0.868	rs2758600	chr1:156195205	C/T	cg25208724	chr1:156163844	SLC25A44	0.8	9.49	0.53	2.82e-18	Testicular germ cell tumor;
SARC	cis	rs9858542	0.953	rs9858280	chr3:49597737	T/C	cg07274523	chr3:49395745	GPX1	0.51	6.0	0.37	7.32e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs11122272	0.735	rs2486728	chr1:231535883	T/G	cg06096015	chr1:231504339	EGLN1	0.38	5.7	0.35	3.54e-8	Hemoglobin concentration;
SARC	cis	rs11690935	0.959	rs11904009	chr2:172627343	T/G	cg13550731	chr2:172543902	DYNC1I2	-1.0	-15.76	-0.72	1.36e-38	Schizophrenia;
SARC	cis	rs17376456	0.825	rs12188163	chr5:93250608	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.64	-5.85	-0.36	1.65e-8	Diabetic retinopathy;
SARC	cis	rs921968	0.613	rs6436066	chr2:219578361	T/G	cg02176678	chr2:219576539	TTLL4	-0.34	-5.09	-0.32	7.51e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs6540556	0.769	rs627670	chr1:209929299	G/A	cg23920097	chr1:209922102	NA	0.61	7.06	0.42	1.86e-11	Red blood cell count;
SARC	cis	rs12190007	0.508	rs6605538	chr6:169731432	G/A	cg16388071	chr6:169726476	NA	0.55	7.47	0.44	1.63e-12	Obesity-related traits;
SARC	cis	rs4128725	1.000	rs12131860	chr1:159386592	A/C	cg25076881	chr1:159409836	OR10J1	0.4	4.78	0.3	3.16e-6	Select biomarker traits;
SARC	trans	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg06437703	chr8:37914619	EIF4EBP1	-0.56	-6.97	-0.42	3.21e-11	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs35213789	0.708	rs2851515	chr7:69142936	C/A	cg10619644	chr7:69149951	AUTS2	-0.35	-4.82	-0.3	2.57e-6	Childhood ear infection;
SARC	cis	rs9291683	0.588	rs12507330	chr4:10002195	G/A	cg00071950	chr4:10020882	SLC2A9	0.4	6.48	0.39	5.4e-10	Bone mineral density;
SARC	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg25072359	chr17:41440525	NA	0.52	6.37	0.38	1.03e-9	Menopause (age at onset);
SARC	cis	rs7659604	0.521	rs4833235	chr4:122695136	C/A	cg19748678	chr4:122722346	EXOSC9	-0.41	-5.06	-0.31	8.41e-7	Type 2 diabetes;
SARC	cis	rs72945132	0.882	rs12274436	chr11:70132204	T/C	cg00319359	chr11:70116639	PPFIA1	0.68	6.35	0.38	1.14e-9	Coronary artery disease;
SARC	trans	rs3780486	0.718	rs73645257	chr9:33132354	C/T	cg20290983	chr6:43655470	MRPS18A	0.95	11.56	0.6	1.03e-24	IgG glycosylation;
SARC	cis	rs7512552	0.839	rs11581351	chr1:150440200	G/C	cg15654264	chr1:150340011	RPRD2	0.39	5.13	0.32	6.09e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs2463822	0.764	rs7125402	chr11:62097259	C/T	cg06239285	chr11:62104954	ASRGL1	0.9	9.65	0.53	9.5e-19	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs6450176	0.909	rs2448	chr5:53302354	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.66	-7.57	-0.44	8.49e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs6088580	0.602	rs6058064	chr20:33086622	A/G	cg08999081	chr20:33150536	PIGU	0.45	6.89	0.41	5.28e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs7447927	0.950	rs13181561	chr5:138850905	A/G	cg26929925	chr5:138714136	SLC23A1	-0.37	-5.13	-0.32	6.24e-7	Esophageal squamous cell carcinoma;
SARC	cis	rs3008870	0.755	rs2755254	chr1:67470855	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.59	7.57	0.44	8.73e-13	Lymphocyte percentage of white cells;
SARC	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg13395646	chr4:1353034	KIAA1530	-0.43	-5.29	-0.33	2.8e-7	Longevity;
SARC	cis	rs4969178	0.965	rs11077362	chr17:76397219	A/T	cg20026190	chr17:76395443	PGS1	0.4	5.37	0.33	1.94e-7	HDL cholesterol levels;
SARC	cis	rs11785400	0.731	rs4644221	chr8:143736984	C/T	cg10596483	chr8:143751796	JRK	-0.54	-7.09	-0.42	1.61e-11	Schizophrenia;
SARC	cis	rs2760061	0.819	rs708112	chr1:228192452	G/A	cg02753203	chr1:228287806	NA	0.58	8.12	0.47	2.71e-14	Diastolic blood pressure;
SARC	cis	rs763121	0.962	rs1980455	chr22:38925719	A/C	cg21395723	chr22:39101663	GTPBP1	0.47	5.7	0.35	3.67e-8	Menopause (age at onset);
SARC	cis	rs9640161	0.830	rs3757424	chr7:150067679	C/A	cg10018233	chr7:150070692	REPIN1	0.73	11.92	0.62	6.76e-26	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs9322193	0.607	rs3798763	chr6:150211100	T/C	cg05036130	chr6:150231994	NA	0.32	4.84	0.3	2.41e-6	Lung cancer;
SARC	cis	rs17376456	0.877	rs10062711	chr5:93348659	G/A	cg21475434	chr5:93447410	FAM172A	0.85	7.56	0.44	9.4e-13	Diabetic retinopathy;
SARC	cis	rs9303401	0.659	rs12150264	chr17:56939927	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.05	11.76	0.61	2.3e-25	Cognitive test performance;
SARC	cis	rs12681366	0.708	rs2515099	chr8:95379658	C/T	cg26464482	chr8:95565502	KIAA1429	-0.43	-5.26	-0.33	3.26e-7	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs79149102	0.522	rs1030888	chr15:74843323	G/C	cg09165964	chr15:75287851	SCAMP5	-0.71	-5.16	-0.32	5.31e-7	Lung cancer;
SARC	cis	rs4481887	0.893	rs4275482	chr1:248473506	T/C	cg00666640	chr1:248458726	OR2T12	0.32	5.45	0.34	1.25e-7	Common traits (Other);
SARC	cis	rs6121246	0.609	rs6087783	chr20:30421224	T/G	cg13852791	chr20:30311386	BCL2L1	0.81	10.0	0.55	8.24e-20	Mean corpuscular hemoglobin;
SARC	cis	rs1355223	0.506	rs11032898	chr11:34870111	C/G	cg11622362	chr11:34938112	PDHX;APIP	0.46	6.07	0.37	5.27e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	trans	rs3780486	0.505	rs10758188	chr9:33123386	C/T	cg04842962	chr6:43655489	MRPS18A	-0.88	-13.24	-0.66	3.34e-30	IgG glycosylation;
SARC	cis	rs7524258	0.868	rs1304711	chr1:7270320	G/T	cg07173049	chr1:7289937	CAMTA1	-0.34	-6.48	-0.39	5.44e-10	Tourette's syndrome or obsessive-compulsive disorder;
SARC	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg17376030	chr22:41985996	PMM1	0.64	7.52	0.44	1.15e-12	Vitiligo;
SARC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg11494091	chr17:61959527	GH2	0.54	8.22	0.47	1.45e-14	Prudent dietary pattern;
SARC	cis	rs9788682	0.948	rs59133824	chr15:78833450	C/A	cg06917634	chr15:78832804	PSMA4	-0.6	-6.56	-0.39	3.48e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs1559088	1.000	rs12979164	chr19:33553228	G/C	cg27124370	chr19:33622961	WDR88	0.42	5.25	0.33	3.38e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg04267008	chr7:1944627	MAD1L1	-0.45	-5.05	-0.31	8.78e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs8077889	0.917	rs60335331	chr17:41907509	A/G	cg26893861	chr17:41843967	DUSP3	0.86	10.74	0.58	4.09e-22	Triglycerides;
SARC	cis	rs6840360	0.837	rs13137669	chr4:152710943	A/G	cg22705602	chr4:152727874	NA	-0.37	-6.44	-0.39	6.79e-10	Intelligence (multi-trait analysis);
SARC	trans	rs7615952	1.000	rs7616044	chr3:125649354	G/C	cg07211511	chr3:129823064	LOC729375	-0.95	-10.99	-0.58	6.6e-23	Blood pressure (smoking interaction);
SARC	cis	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg24110177	chr3:50126178	RBM5	0.54	7.4	0.44	2.43e-12	Intelligence (multi-trait analysis);
SARC	cis	rs3008870	0.959	rs3008852	chr1:67383416	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.93	11.27	0.59	8.55e-24	Lymphocyte percentage of white cells;
SARC	cis	rs503734	0.502	rs348885	chr3:100976219	C/G	cg27318481	chr3:100970896	IMPG2	-0.46	-5.45	-0.34	1.31e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs7255045	0.788	rs4804737	chr19:12947938	C/T	cg21491176	chr19:12958399	MAST1	0.35	5.16	0.32	5.29e-7	Mean corpuscular volume;
SARC	cis	rs10504229	0.679	rs16921623	chr8:58039473	G/C	cg21724239	chr8:58056113	NA	0.61	6.15	0.37	3.34e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2066819	1.000	rs773664	chr12:56702176	C/T	cg26316697	chr12:56727976	PAN2	-0.9	-6.37	-0.39	9.89e-10	Psoriasis vulgaris;
SARC	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6570726	0.791	rs9373466	chr6:145912016	T/C	cg05347473	chr6:146136440	FBXO30	0.51	7.13	0.42	1.29e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg22903471	chr2:27725779	GCKR	-0.52	-7.74	-0.45	2.92e-13	Menopause (age at onset);
SARC	cis	rs4906332	1.000	rs35344594	chr14:103955792	A/G	cg26031613	chr14:104095156	KLC1	-0.49	-5.76	-0.35	2.64e-8	Coronary artery disease;
SARC	cis	rs6087771	0.747	rs6058261	chr20:30235470	C/A	cg13852791	chr20:30311386	BCL2L1	0.8	9.61	0.53	1.22e-18	Subcortical brain region volumes;Putamen volume;
SARC	cis	rs9916302	0.904	rs8070695	chr17:37478062	C/T	cg20243544	chr17:37824526	PNMT	-0.56	-6.46	-0.39	5.98e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs7412746	0.611	rs4970984	chr1:150887377	T/C	cg15448220	chr1:150897856	SETDB1	0.52	6.89	0.41	5.17e-11	Melanoma;
SARC	trans	rs3942852	0.774	rs2270990	chr11:48184983	G/T	cg03929089	chr4:120376271	NA	-0.61	-6.92	-0.41	4.3e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs616402	0.527	rs10779737	chr1:10580275	C/G	cg07384165	chr1:10488281	NA	-0.41	-5.38	-0.33	1.78e-7	Breast size;
SARC	cis	rs11098499	0.954	rs7436506	chr4:120393769	T/C	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs79349575	0.783	rs903567	chr17:46980318	C/T	cg16584676	chr17:46985605	UBE2Z	0.54	6.58	0.4	3.1e-10	Type 2 diabetes;
SARC	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg15448220	chr1:150897856	SETDB1	0.48	6.38	0.39	9.29e-10	Tonsillectomy;
SARC	cis	rs9322817	0.691	rs4460239	chr6:105325562	C/T	cg02098413	chr6:105308735	HACE1	0.38	5.92	0.36	1.13e-8	Thyroid stimulating hormone;
SARC	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	11.04	0.59	4.42e-23	Platelet count;
SARC	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg11247378	chr22:39784982	NA	-0.33	-5.35	-0.33	2.15e-7	Intelligence (multi-trait analysis);
SARC	cis	rs8067545	0.750	rs11871651	chr17:19997425	T/C	cg13482628	chr17:19912719	NA	0.56	7.56	0.44	9.06e-13	Schizophrenia;
SARC	cis	rs6121246	0.909	rs8126355	chr20:30332660	C/T	cg13852791	chr20:30311386	BCL2L1	0.85	9.18	0.52	2.48e-17	Mean corpuscular hemoglobin;
SARC	cis	rs1448094	0.534	rs11613070	chr12:86167544	T/A	cg02569458	chr12:86230093	RASSF9	0.37	5.03	0.31	9.77e-7	Major depressive disorder;
SARC	cis	rs7843479	0.965	rs733543	chr8:21835465	A/G	cg17168535	chr8:21777572	XPO7	0.62	7.95	0.46	7.95e-14	Mean corpuscular volume;
SARC	cis	rs10791097	0.667	rs4937585	chr11:130741940	A/G	cg09137382	chr11:130731461	NA	0.31	4.78	0.3	3.15e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs7674212	0.541	rs2623070	chr4:104037388	A/G	cg16532752	chr4:104119610	CENPE	0.48	5.73	0.35	3.16e-8	Type 2 diabetes;
SARC	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg13126279	chr21:47581558	C21orf56	-0.46	-5.68	-0.35	4.03e-8	Testicular germ cell tumor;
SARC	cis	rs8077889	0.763	rs4792913	chr17:41854497	T/C	cg26893861	chr17:41843967	DUSP3	0.98	15.59	0.71	5.36e-38	Triglycerides;
SARC	cis	rs4660306	1.000	rs2356559	chr1:45981512	A/G	cg24296786	chr1:45957014	TESK2	0.55	6.34	0.38	1.2e-9	Homocysteine levels;
SARC	trans	rs11098499	0.908	rs28499576	chr4:120386677	G/A	cg25214090	chr10:38739885	LOC399744	0.54	7.11	0.42	1.38e-11	Corneal astigmatism;
SARC	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg16479474	chr6:28041457	NA	0.37	5.44	0.34	1.37e-7	Depression;
SARC	cis	rs12142240	0.698	rs66847432	chr1:46832013	G/A	cg00530320	chr1:46809349	NSUN4	0.58	7.07	0.42	1.78e-11	Menopause (age at onset);
SARC	cis	rs8017423	0.935	rs11624295	chr14:90695612	T/G	cg20276874	chr14:90721474	PSMC1	-0.35	-4.83	-0.3	2.53e-6	Mortality in heart failure;
SARC	cis	rs8038734	0.688	rs4777512	chr15:72785701	G/C	cg10943348	chr15:72668568	HEXA;C15orf34	0.62	4.8	0.3	2.81e-6	Posterior cortical atrophy and Alzheimer's disease;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg18493069	chr6:108582623	SNX3	-0.55	-6.31	-0.38	1.39e-9	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs9486715	1.000	rs3798297	chr6:97062835	C/T	cg06623918	chr6:96969491	KIAA0776	-0.82	-11.37	-0.6	4.07e-24	Headache;
SARC	cis	rs10128251	0.746	rs9424194	chr10:5724073	A/G	cg09234995	chr10:5726438	C10orf18	0.44	5.39	0.33	1.75e-7	Childhood ear infection;
SARC	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg00290607	chr11:67383545	NA	0.56	7.82	0.46	1.82e-13	Mean corpuscular volume;
SARC	cis	rs796364	0.806	rs77853713	chr2:201006880	A/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-5.12	-0.32	6.43e-7	Schizophrenia;
SARC	cis	rs6685188	0.920	rs6593964	chr1:205662337	G/T	cg14893161	chr1:205819251	PM20D1	0.52	5.67	0.35	4.12e-8	White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs8017423	0.967	rs11623275	chr14:90721335	C/T	cg20276874	chr14:90721474	PSMC1	-0.38	-5.32	-0.33	2.41e-7	Mortality in heart failure;
SARC	cis	rs748404	0.697	rs1814323	chr15:43563237	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.55	-6.57	-0.4	3.22e-10	Lung cancer;
SARC	cis	rs1318878	0.565	rs56354312	chr12:15476069	T/C	cg08258403	chr12:15378311	NA	0.51	7.05	0.42	2.01e-11	Intelligence (multi-trait analysis);
SARC	trans	rs61931739	0.500	rs35030191	chr12:34548865	C/T	cg13010199	chr12:38710504	ALG10B	0.83	11.77	0.61	2.09e-25	Morning vs. evening chronotype;
SARC	cis	rs7824557	0.564	rs2736300	chr8:11235579	T/G	cg21775007	chr8:11205619	TDH	-0.65	-8.61	-0.49	1.12e-15	Retinal vascular caliber;
SARC	cis	rs7219021	0.705	rs9904288	chr17:47031973	T/C	cg16584676	chr17:46985605	UBE2Z	-0.51	-5.91	-0.36	1.2e-8	Schizophrenia or bipolar disorder;
SARC	cis	rs710216	0.843	rs10890232	chr1:43416514	C/T	cg22176566	chr1:43424700	SLC2A1	0.48	5.19	0.32	4.54e-7	Red cell distribution width;
SARC	cis	rs208520	0.690	rs851458	chr6:66813279	T/G	cg07460842	chr6:66804631	NA	-1.07	-14.98	-0.7	5.39e-36	Exhaled nitric oxide output;
SARC	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg07701084	chr6:150067640	NUP43	0.41	5.39	0.33	1.75e-7	Lung cancer;
SARC	cis	rs7223966	1.000	rs2013288	chr17:61785904	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.48	-5.14	-0.32	5.86e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7568458	0.846	rs6705971	chr2:85761417	G/T	cg02493740	chr2:85810744	VAMP5	0.34	5.02	0.31	1.02e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs8028182	0.549	rs7402844	chr15:75637396	C/G	cg20655648	chr15:75932815	IMP3	-0.66	-7.55	-0.44	9.59e-13	Sudden cardiac arrest;
SARC	cis	rs826838	0.967	rs1684415	chr12:39130099	T/C	cg13010199	chr12:38710504	ALG10B	-0.63	-8.88	-0.5	1.87e-16	Heart rate;
SARC	cis	rs3782089	1.000	rs11602375	chr11:65296540	C/T	cg21890820	chr11:65308645	LTBP3	0.88	5.45	0.34	1.27e-7	Height;
SARC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg02475777	chr4:1388615	CRIPAK	0.65	7.6	0.45	7.37e-13	Longevity;
SARC	cis	rs7520050	1.000	rs785473	chr1:46516863	T/C	cg06784218	chr1:46089804	CCDC17	-0.28	-5.08	-0.32	7.58e-7	Red blood cell count;Reticulocyte count;
SARC	cis	rs10411936	0.720	rs7252649	chr19:16582785	G/T	cg10248733	chr19:16607483	C19orf44;CALR3	0.58	7.03	0.42	2.32e-11	White blood cell count;Multiple sclerosis;
SARC	cis	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg05623727	chr3:50126028	RBM5	0.35	5.16	0.32	5.22e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2658782	0.826	rs1975820	chr11:93081815	G/A	cg15737290	chr11:93063684	CCDC67	0.7	7.17	0.42	1.02e-11	Pulmonary function decline;
SARC	cis	rs7106204	0.534	rs75297923	chr11:24253530	A/G	ch.11.24196551F	chr11:24239977	NA	0.73	6.26	0.38	1.84e-9	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs4243830	0.826	rs12565181	chr1:6620545	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	0.95	8.4	0.48	4.36e-15	Body mass index;
SARC	cis	rs8070128	0.601	rs8080602	chr17:17954728	G/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.41	-5.13	-0.32	6.16e-7	Total body bone mineral density;
SARC	cis	rs12701220	0.503	rs12702024	chr7:1129820	G/C	cg10374962	chr7:1011985	COX19	-0.45	-4.83	-0.3	2.5e-6	Bronchopulmonary dysplasia;
SARC	cis	rs9462027	0.628	rs10947532	chr6:34780315	G/T	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.91	-0.36	1.22e-8	Systemic lupus erythematosus;
SARC	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg16606324	chr3:10149918	C3orf24	0.49	4.82	0.3	2.56e-6	Alzheimer's disease;
SARC	cis	rs7044106	0.762	rs10739570	chr9:123381222	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	9.01	0.51	7.73e-17	Hip circumference adjusted for BMI;
SARC	cis	rs926392	0.965	rs6124106	chr20:37693042	G/A	cg16355469	chr20:37678765	NA	0.53	6.88	0.41	5.45e-11	Dialysis-related mortality;
SARC	cis	rs858239	0.537	rs2286272	chr7:23224367	T/C	cg23682824	chr7:23144976	KLHL7	0.67	8.58	0.49	1.36e-15	Cerebrospinal fluid biomarker levels;
SARC	cis	rs7614311	0.681	rs73117083	chr3:63948455	G/C	cg22134162	chr3:63841271	THOC7	-0.44	-4.78	-0.3	3.07e-6	Lung function (FVC);Lung function (FEV1);
SARC	cis	rs9467773	0.901	rs1407045	chr6:26476155	A/G	cg11502198	chr6:26597334	ABT1	0.46	5.42	0.33	1.52e-7	Intelligence (multi-trait analysis);
SARC	cis	rs60871478	1.000	rs12531530	chr7:827366	T/C	cg09839136	chr7:766187	HEATR2;PRKAR1B	0.58	4.95	0.31	1.4e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs4423214	1.000	rs12278461	chr11:71182185	C/T	cg24826892	chr11:71159390	DHCR7	0.48	6.03	0.37	6.32e-9	Vitamin D levels;
SARC	cis	rs9486719	0.901	rs760619	chr6:96857431	A/G	cg18709589	chr6:96969512	KIAA0776	0.48	4.78	0.3	3.1e-6	Migraine;Coronary artery disease;
SARC	cis	rs4774830	0.744	rs62045232	chr15:56284419	A/G	cg24530489	chr15:56299380	NA	-0.83	-5.14	-0.32	5.76e-7	Delta-5 desaturase activity;
SARC	cis	rs4836694	0.574	rs3780712	chr9:132943082	A/G	cg05251000	chr9:132935664	FREQ	0.38	4.96	0.31	1.38e-6	Alzheimer's disease (cognitive decline);
SARC	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg12311346	chr5:56204834	C5orf35	-0.55	-5.64	-0.35	4.88e-8	Initial pursuit acceleration;
SARC	cis	rs9399135	0.967	rs4896121	chr6:135293645	T/C	cg24558204	chr6:135376177	HBS1L	0.45	6.11	0.37	4.06e-9	Red blood cell count;
SARC	cis	rs936229	0.654	rs762551	chr15:75041917	C/A	cg14664628	chr15:75095509	CSK	-0.99	-12.37	-0.63	2.32e-27	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs2033732	0.706	rs7830484	chr8:85068154	C/G	cg05716166	chr8:85095498	RALYL	0.47	5.62	0.35	5.51e-8	Body mass index;
SARC	cis	rs8016982	0.674	rs3815953	chr14:81685482	G/A	cg01989461	chr14:81687754	GTF2A1	0.74	11.38	0.6	3.67e-24	Schizophrenia;
SARC	cis	rs561341	0.941	rs4625780	chr17:30249214	A/C	cg13647721	chr17:30228624	UTP6	0.59	5.14	0.32	5.82e-7	Hip circumference adjusted for BMI;
SARC	cis	rs9398803	0.588	rs970403	chr6:126645966	G/A	cg19875578	chr6:126661172	C6orf173	0.5	6.69	0.4	1.6e-10	Male-pattern baldness;
SARC	trans	rs208515	0.556	rs12201658	chr6:66678457	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.9	10.58	0.57	1.26e-21	Exhaled nitric oxide levels;
SARC	cis	rs7084402	0.817	rs7099496	chr10:60265242	G/A	cg07615347	chr10:60278583	BICC1	-0.59	-8.2	-0.47	1.58e-14	Refractive error;
SARC	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.33	-5.26	-0.33	3.27e-7	Longevity;Endometriosis;
SARC	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg25072359	chr17:41440525	NA	0.48	5.55	0.34	7.82e-8	Menopause (age at onset);
SARC	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg04277193	chr17:41438351	NA	0.44	4.86	0.3	2.18e-6	Menopause (age at onset);
SARC	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-8.94	-0.51	1.21e-16	Alzheimer's disease;
SARC	cis	rs6582630	0.555	rs34145279	chr12:38405588	T/C	cg13010199	chr12:38710504	ALG10B	0.78	10.51	0.57	2.15e-21	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6912958	1.000	rs2207144	chr6:88150816	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.46	-0.34	1.2e-7	Monocyte percentage of white cells;
SARC	trans	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg06636001	chr8:8085503	FLJ10661	-0.62	-8.93	-0.5	1.34e-16	Neuroticism;
SARC	cis	rs12950390	1.000	rs12950390	chr17:45830948	A/G	cg24803719	chr17:45855879	NA	-0.39	-5.69	-0.35	3.71e-8	IgG glycosylation;
SARC	cis	rs2072499	0.778	rs2842868	chr1:156196407	A/C	cg24450063	chr1:156163899	SLC25A44	0.97	12.97	0.65	2.54e-29	Testicular germ cell tumor;
SARC	cis	rs7843479	0.601	rs11785043	chr8:21810377	C/T	cg17168535	chr8:21777572	XPO7	0.87	13.57	0.66	2.77e-31	Mean corpuscular volume;
SARC	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg09455208	chr3:40491958	NA	0.39	5.67	0.35	4.15e-8	Renal cell carcinoma;
SARC	cis	rs7786808	0.505	rs67537656	chr7:158192646	C/T	cg01191920	chr7:158217561	PTPRN2	0.35	5.96	0.36	9.32e-9	Obesity-related traits;
SARC	cis	rs1345301	0.518	rs1558623	chr2:102862402	T/A	cg12451869	chr2:102867685	NA	0.4	5.45	0.34	1.3e-7	Waist circumference;
SARC	cis	rs9858542	0.953	rs11713474	chr3:49611457	A/G	cg03060546	chr3:49711283	APEH	-0.61	-7.75	-0.45	2.75e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs881375	0.967	rs1008381	chr9:123681116	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	4.85	0.3	2.24e-6	Rheumatoid arthritis;
SARC	cis	rs853679	0.550	rs1225598	chr6:28160799	T/G	cg26335602	chr6:28129616	ZNF389	0.46	5.35	0.33	2.14e-7	Depression;
SARC	cis	rs9948	0.655	rs7568206	chr2:97393108	A/C	cg01990225	chr2:97406019	LMAN2L	-0.81	-6.22	-0.38	2.25e-9	Erectile dysfunction and prostate cancer treatment;
SARC	trans	rs7395662	0.611	rs4882089	chr11:48515612	A/T	cg15704280	chr7:45808275	SEPT13	-0.5	-6.77	-0.41	1.04e-10	HDL cholesterol;
SARC	cis	rs9420	0.884	rs644883	chr11:57663522	C/G	cg19752551	chr11:57585705	CTNND1	0.46	6.08	0.37	4.88e-9	Schizophrenia;
SARC	cis	rs9457247	0.638	rs239933	chr6:167413230	A/G	cg23791538	chr6:167370224	RNASET2	-0.5	-6.69	-0.4	1.63e-10	Crohn's disease;
SARC	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg11890956	chr21:40555474	PSMG1	1.17	19.56	0.79	4.67e-51	Cognitive function;
SARC	cis	rs8031584	0.958	rs7168641	chr15:31235452	G/A	cg19680485	chr15:31195859	MTMR15	-0.51	-5.92	-0.36	1.16e-8	Huntington's disease progression;
SARC	cis	rs4242434	0.597	rs1877675	chr8:22533947	C/T	cg03733263	chr8:22462867	KIAA1967	-0.83	-12.74	-0.64	1.41e-28	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs2882667	0.824	rs13189485	chr5:138475401	C/T	cg04439458	chr5:138467593	SIL1	-0.3	-5.04	-0.31	9.46e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs67311347	0.713	rs9861194	chr3:40309225	C/T	cg09455208	chr3:40491958	NA	0.34	5.15	0.32	5.61e-7	Renal cell carcinoma;
SARC	trans	rs61931739	0.534	rs814669	chr12:34102459	C/T	cg26384229	chr12:38710491	ALG10B	0.74	10.17	0.55	2.5e-20	Morning vs. evening chronotype;
SARC	cis	rs3857536	0.904	rs1578765	chr6:66883550	G/A	cg07460842	chr6:66804631	NA	-0.46	-5.35	-0.33	2.11e-7	Blood trace element (Cu levels);
SARC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg09373136	chr17:61933544	TCAM1	-0.43	-5.96	-0.36	9.44e-9	Prudent dietary pattern;
SARC	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg24209194	chr3:40518798	ZNF619	0.68	8.29	0.48	8.84e-15	Renal cell carcinoma;
SARC	cis	rs425277	1.000	rs262670	chr1:2082458	C/T	cg21442419	chr1:2182373	SKI	-0.52	-6.68	-0.4	1.76e-10	Height;
SARC	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg03806693	chr22:41940476	POLR3H	-0.9	-12.22	-0.62	7.49e-27	Vitiligo;
SARC	cis	rs4588572	0.643	rs10044028	chr5:77794750	C/T	cg11547950	chr5:77652471	NA	0.38	4.78	0.3	3.12e-6	Triglycerides;
SARC	cis	rs34779708	0.931	rs7079205	chr10:35324619	C/T	cg03585969	chr10:35415529	CREM	0.43	5.43	0.34	1.42e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs2635047	0.638	rs16954999	chr18:44610718	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	6.41	0.39	8.05e-10	Educational attainment;
SARC	cis	rs11249608	0.548	rs62393072	chr5:178450056	C/T	cg01312482	chr5:178451176	ZNF879	-0.37	-4.82	-0.3	2.62e-6	Pubertal anthropometrics;
SARC	cis	rs4642101	0.883	rs6810325	chr3:12840934	T/C	cg05775895	chr3:12838266	CAND2	0.65	8.89	0.5	1.74e-16	QRS complex (12-leadsum);
SARC	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg06636001	chr8:8085503	FLJ10661	-0.61	-8.18	-0.47	1.9e-14	Mood instability;
SARC	trans	rs1973993	0.669	rs510552	chr1:96891671	A/G	cg10631902	chr5:14652156	NA	0.51	8.81	0.5	2.87e-16	Weight;
SARC	cis	rs2832191	0.716	rs1888439	chr21:30454457	A/G	cg24692254	chr21:30365293	RNF160	1.04	17.74	0.76	3.9e-45	Dental caries;
SARC	cis	rs13191362	0.507	rs2849511	chr6:163139050	C/G	cg21926612	chr6:163149169	PACRG;PARK2	-0.5	-5.37	-0.33	1.94e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs7555523	0.887	rs4656461	chr1:165687205	G/A	cg24409356	chr1:165738333	TMCO1	0.7	5.75	0.35	2.75e-8	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	cis	rs7959452	0.535	rs11615712	chr12:69619736	A/T	cg22834771	chr12:69754056	YEATS4	0.4	5.33	0.33	2.35e-7	Blood protein levels;
SARC	cis	rs34779708	0.931	rs34815241	chr10:35296676	T/C	cg03585969	chr10:35415529	CREM	0.38	4.78	0.3	3.14e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg26643937	chr20:3869678	PANK2	0.35	4.71	0.3	4.2e-6	Immature fraction of reticulocytes;
SARC	cis	rs7772486	0.790	rs2256998	chr6:146207657	A/C	cg05347473	chr6:146136440	FBXO30	0.49	6.67	0.4	1.79e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg04267008	chr7:1944627	MAD1L1	-0.57	-6.46	-0.39	6.17e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs2251381	0.565	rs2832279	chr21:30613466	G/T	cg08807101	chr21:30365312	RNF160	0.59	7.47	0.44	1.61e-12	Selective IgA deficiency;
SARC	cis	rs7539409	0.604	rs6689821	chr1:84316605	A/G	cg10977910	chr1:84465055	TTLL7	0.65	6.18	0.38	2.84e-9	Alzheimer's disease;
SARC	cis	rs2075371	1.000	rs7486	chr7:133975183	A/G	cg00033643	chr7:134001901	SLC35B4	0.41	4.98	0.31	1.25e-6	Mean platelet volume;
SARC	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg16325326	chr1:53192061	ZYG11B	-0.95	-17.79	-0.76	2.78e-45	Monocyte count;
SARC	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg12463550	chr7:65579703	CRCP	-0.71	-5.4	-0.33	1.61e-7	Diabetic kidney disease;
SARC	cis	rs4132509	1.000	rs7534117	chr1:243964902	A/C	cg21452805	chr1:244014465	NA	-0.52	-5.85	-0.36	1.66e-8	RR interval (heart rate);
SARC	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	8.91	0.5	1.45e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs5758511	0.680	rs1033460	chr22:42619308	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.46	7.01	0.42	2.52e-11	Birth weight;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg01893322	chr3:173113110	NA	-0.72	-6.23	-0.38	2.15e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9814567	1.000	rs6439487	chr3:134260860	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.1	-0.42	1.49e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	trans	rs208515	0.525	rs1484577	chr6:66688397	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.92	11.01	0.58	5.49e-23	Exhaled nitric oxide levels;
SARC	cis	rs10463316	0.855	rs352701	chr5:150736474	A/G	cg03212797	chr5:150827313	SLC36A1	-0.49	-6.1	-0.37	4.31e-9	Metabolite levels (Pyroglutamine);
SARC	trans	rs1814175	0.565	rs4881721	chr11:49761851	G/A	cg15704280	chr7:45808275	SEPT13	-0.8	-12.93	-0.65	3.5e-29	Height;
SARC	cis	rs9916302	0.768	rs62077464	chr17:37656056	C/G	cg20243544	chr17:37824526	PNMT	0.56	6.67	0.4	1.87e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs13314892	0.692	rs2014255	chr3:69895022	G/A	cg17445875	chr3:69859618	MITF	-0.52	-5.39	-0.33	1.75e-7	QRS complex (12-leadsum);
SARC	cis	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.72	-0.45	3.34e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs262150	0.659	rs2657340	chr7:158796968	C/T	cg09640425	chr7:158790006	NA	0.4	5.74	0.35	2.95e-8	Facial morphology (factor 20);
SARC	cis	rs1023500	0.573	rs133378	chr22:42467695	G/C	cg15557168	chr22:42548783	NA	-0.35	-4.8	-0.3	2.83e-6	Schizophrenia;
SARC	cis	rs12586317	0.547	rs115019197	chr14:35503764	G/A	cg16230307	chr14:35515116	FAM177A1	1.03	11.88	0.61	9.41e-26	Psoriasis;
SARC	cis	rs2342371	0.883	rs11185542	chr3:196187927	G/C	cg15048948	chr3:196158458	UBXN7	-0.5	-5.96	-0.36	9.17e-9	Fat distribution (HIV);
SARC	cis	rs11668609	0.505	rs114822678	chr19:24061884	A/G	cg27517351	chr19:23941871	ZNF681	-0.56	-4.87	-0.3	2.04e-6	Response to taxane treatment (docetaxel);
SARC	cis	rs240764	0.635	rs7773043	chr6:100921115	G/A	cg09795085	chr6:101329169	ASCC3	-0.39	-4.94	-0.31	1.52e-6	Neuroticism;
SARC	cis	rs793571	0.714	rs972801	chr15:58921198	C/T	cg05156742	chr15:59063176	FAM63B	-0.65	-8.35	-0.48	6.13e-15	Schizophrenia;
SARC	cis	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg13859212	chr4:99580143	TSPAN5	0.39	5.17	0.32	4.92e-7	Colonoscopy-negative controls vs population controls;
SARC	cis	rs3781913	0.874	rs11235557	chr11:72373637	C/T	cg03713592	chr11:72463424	ARAP1	-0.41	-5.07	-0.32	8.11e-7	Rheumatoid arthritis;
SARC	cis	rs12451471	0.620	rs11150846	chr17:78098520	C/T	cg24585782	chr17:78113791	EIF4A3	-0.59	-6.96	-0.41	3.51e-11	Plateletcrit;Mean corpuscular hemoglobin concentration;
SARC	cis	rs2072499	1.000	rs2241108	chr1:156181007	C/G	cg25208724	chr1:156163844	SLC25A44	0.85	11.26	0.59	9.26e-24	Testicular germ cell tumor;
SARC	cis	rs6484504	0.532	rs7121949	chr11:31288160	G/T	cg26647111	chr11:31128758	NA	-0.36	-4.83	-0.3	2.46e-6	Red blood cell count;
SARC	cis	rs8141529	0.748	rs5762881	chr22:29289346	C/A	cg02153584	chr22:29168773	CCDC117	0.77	11.31	0.6	6.33e-24	Lymphocyte counts;
SARC	cis	rs7481584	0.624	rs428726	chr11:3046201	G/A	cg25174290	chr11:3078921	CARS	-0.6	-8.31	-0.48	8e-15	Calcium levels;
SARC	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg26335602	chr6:28129616	ZNF389	0.53	5.92	0.36	1.12e-8	Depression;
SARC	cis	rs11673344	0.566	rs2385181	chr19:37886330	C/A	cg14683738	chr19:37701593	ZNF585B	0.46	5.49	0.34	1.04e-7	Obesity-related traits;
SARC	cis	rs1707322	0.752	rs7541962	chr1:46235117	G/A	cg03146154	chr1:46216737	IPP	0.51	6.11	0.37	4.14e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs35079168	0.701	rs3132296	chr9:137302631	C/T	cg00753924	chr9:137298813	RXRA	-0.41	-5.08	-0.32	7.74e-7	Intelligence;
SARC	cis	rs9815354	0.767	rs73081341	chr3:41900335	A/T	cg03022575	chr3:42003672	ULK4	0.67	5.73	0.35	3.13e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs875971	0.545	rs7811204	chr7:65852200	G/A	cg11764359	chr7:65958608	NA	0.67	6.66	0.4	1.97e-10	Aortic root size;
SARC	cis	rs9768139	0.733	rs13309408	chr7:158122261	C/T	cg25566285	chr7:158114605	PTPRN2	0.32	5.24	0.32	3.63e-7	Calcium levels;
SARC	cis	rs751728	0.626	rs57150921	chr6:33737518	T/C	cg25922239	chr6:33757077	LEMD2	0.6	7.83	0.46	1.73e-13	Crohn's disease;
SARC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg26338869	chr17:61819248	STRADA	-0.8	-10.99	-0.58	6.65e-23	Prudent dietary pattern;
SARC	cis	rs3768617	0.811	rs12120747	chr1:183042531	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.6	8.0	0.46	5.99e-14	Fuchs's corneal dystrophy;
SARC	cis	rs7223966	1.000	rs11079509	chr17:61762148	G/T	cg00588841	chr17:61851480	DDX42;CCDC47	-0.66	-6.92	-0.41	4.43e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9818758	0.556	rs9835439	chr3:49220330	G/C	cg00383909	chr3:49044727	WDR6	0.69	6.0	0.37	7.65e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs965469	1.000	rs6051753	chr20:3315513	G/A	cg25506879	chr20:3388711	C20orf194	-0.53	-5.43	-0.34	1.41e-7	IFN-related cytopenia;
SARC	cis	rs9517320	0.534	rs9554478	chr13:99187792	G/A	cg07423050	chr13:99094983	FARP1	-0.43	-5.54	-0.34	8.09e-8	Longevity;
SARC	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg24642844	chr7:1081250	C7orf50	-0.38	-5.24	-0.32	3.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs660899	0.578	rs72678674	chr1:44224688	G/A	cg19824710	chr1:43995379	PTPRF	0.46	5.1	0.32	7.17e-7	Hypertension risk in short sleep duration;
SARC	cis	rs10982256	0.789	rs1535964	chr9:117272439	C/G	cg21159778	chr9:117266918	DFNB31	-0.39	-5.49	-0.34	1.03e-7	Bipolar disorder;
SARC	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg22920501	chr2:26401640	FAM59B	-0.53	-6.68	-0.4	1.78e-10	Gut microbiome composition (summer);
SARC	cis	rs12824058	0.831	rs12831363	chr12:130814013	C/T	cg23887609	chr12:130822674	PIWIL1	-0.38	-5.3	-0.33	2.7e-7	Menopause (age at onset);
SARC	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	13.05	0.65	1.41e-29	Chronic sinus infection;
SARC	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	12.42	0.63	1.59e-27	Personality dimensions;
SARC	cis	rs17376456	0.569	rs7701114	chr5:93096028	T/C	cg25358565	chr5:93447407	FAM172A	0.94	10.54	0.57	1.68e-21	Diabetic retinopathy;
SARC	cis	rs2115630	1.000	rs4633690	chr15:85361960	C/T	cg12501888	chr15:85177176	SCAND2	-0.47	-5.91	-0.36	1.22e-8	P wave terminal force;
SARC	cis	rs10193935	1.000	rs13419669	chr2:42387254	T/C	cg27598129	chr2:42591480	NA	-0.36	-5.0	-0.31	1.13e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs883565	0.792	rs784490	chr3:39173530	C/T	cg26331595	chr3:39149181	GORASP1;TTC21A	0.5	5.82	0.36	1.9e-8	Handedness;
SARC	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg18404041	chr3:52824283	ITIH1	-0.43	-6.4	-0.39	8.51e-10	Bipolar disorder;
SARC	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg08280861	chr8:58055591	NA	0.61	5.81	0.36	2.02e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7937682	0.632	rs3944619	chr11:111774743	A/G	cg22437258	chr11:111473054	SIK2	-0.49	-5.61	-0.34	5.78e-8	Primary sclerosing cholangitis;
SARC	cis	rs4555082	0.834	rs2735819	chr14:105713449	C/T	cg06808227	chr14:105710500	BRF1	-0.52	-6.52	-0.39	4.38e-10	Mean platelet volume;Platelet distribution width;
SARC	cis	rs8180040	0.845	rs295441	chr3:47333295	T/A	cg27129171	chr3:47204927	SETD2	0.67	9.24	0.52	1.54e-17	Colorectal cancer;
SARC	cis	rs6456156	0.586	rs6456150	chr6:167468922	A/G	cg23791538	chr6:167370224	RNASET2	-0.52	-6.81	-0.41	8.22e-11	Primary biliary cholangitis;
SARC	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg15049968	chr18:44337910	ST8SIA5	-0.33	-5.19	-0.32	4.58e-7	Personality dimensions;
SARC	cis	rs918629	0.530	rs3815768	chr5:95236459	C/T	cg16656078	chr5:95278638	ELL2	-0.57	-6.96	-0.41	3.51e-11	IgG glycosylation;
SARC	cis	rs13082711	0.519	rs13091109	chr3:27229125	G/A	cg02860705	chr3:27208620	NA	0.59	7.74	0.45	3.09e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg01341218	chr17:43662625	NA	-0.72	-8.55	-0.49	1.69e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs12681288	0.823	rs2701908	chr8:1003250	T/C	cg15309053	chr8:964076	NA	0.4	6.72	0.4	1.35e-10	Schizophrenia;
SARC	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.39	-4.97	-0.31	1.28e-6	Blood metabolite levels;
SARC	cis	rs11874712	0.965	rs28694780	chr18:43665338	C/T	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.46	5.5	0.34	1.02e-7	Migraine - clinic-based;
SARC	cis	rs6696846	0.515	rs12739846	chr1:205096895	T/C	cg21643547	chr1:205240462	TMCC2	-0.45	-5.56	-0.34	7.27e-8	Red blood cell count;
SARC	cis	rs6138458	0.626	rs6138473	chr20:25012155	A/G	cg26195577	chr20:24973756	C20orf3	-0.72	-9.4	-0.52	5.42e-18	Blood protein levels;
SARC	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg12463550	chr7:65579703	CRCP	0.49	5.81	0.36	2.09e-8	Aortic root size;
SARC	cis	rs6545883	0.894	rs6545867	chr2:61651027	C/T	cg15711740	chr2:61764176	XPO1	0.43	5.22	0.32	3.94e-7	Tuberculosis;
SARC	cis	rs6456156	0.774	rs968333	chr6:167526198	A/T	cg07741184	chr6:167504864	NA	0.3	5.57	0.34	6.99e-8	Primary biliary cholangitis;
SARC	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg20607798	chr8:58055168	NA	0.58	5.57	0.34	6.9e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2075371	0.933	rs1868785	chr7:133945855	G/C	cg20476274	chr7:133979776	SLC35B4	0.6	8.18	0.47	1.85e-14	Mean platelet volume;
SARC	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg15556689	chr8:8085844	FLJ10661	0.55	6.94	0.41	3.96e-11	Neuroticism;
SARC	cis	rs1448094	0.717	rs60713909	chr12:86294469	C/G	cg02569458	chr12:86230093	RASSF9	0.36	4.79	0.3	2.92e-6	Major depressive disorder;
SARC	cis	rs7666738	0.791	rs10033211	chr4:98995624	T/A	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	trans	rs365060	0.630	rs260705	chr2:109571440	A/G	cg04287289	chr16:89883240	FANCA	-0.59	-6.27	-0.38	1.69e-9	Beard thickness;
SARC	cis	rs898097	0.528	rs2243523	chr17:80680449	G/T	cg05255149	chr17:80675120	FN3KRP	-0.39	-5.02	-0.31	1.04e-6	Breast cancer;
SARC	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg21171335	chr12:122356390	WDR66	0.37	5.5	0.34	1.01e-7	Mean corpuscular volume;
SARC	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg05890377	chr2:74357713	NA	0.59	7.22	0.43	7.17e-12	Gestational age at birth (maternal effect);
SARC	cis	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg26513180	chr16:89883248	FANCA	0.72	4.79	0.3	2.92e-6	Skin colour saturation;
SARC	trans	rs61931739	0.749	rs7315233	chr12:34271975	G/T	cg13010199	chr12:38710504	ALG10B	0.55	7.15	0.42	1.08e-11	Morning vs. evening chronotype;
SARC	cis	rs3204270	0.639	rs11867543	chr17:79655046	C/T	cg26965718	chr17:79658957	HGS	-0.61	-4.93	-0.31	1.6e-6	Dental caries;
SARC	cis	rs1046896	0.562	rs2380172	chr17:80887719	C/A	cg02711726	chr17:80685570	FN3KRP	-0.53	-6.07	-0.37	5.12e-9	Glycated hemoglobin levels;
SARC	cis	rs9906944	0.707	rs9899931	chr17:47108282	G/A	cg16584676	chr17:46985605	UBE2Z	-0.43	-5.24	-0.32	3.62e-7	Intelligence (multi-trait analysis);Body fat percentage;
SARC	cis	rs7412746	0.658	rs1546376	chr1:150937661	A/G	cg15448220	chr1:150897856	SETDB1	0.52	6.67	0.4	1.85e-10	Melanoma;
SARC	cis	rs992157	0.835	rs34353396	chr2:219153982	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.69	-10.01	-0.55	7.42e-20	Colorectal cancer;
SARC	cis	rs9916302	0.731	rs11868030	chr17:37650332	A/G	cg15445000	chr17:37608096	MED1	0.4	4.75	0.3	3.6e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg07701084	chr6:150067640	NUP43	0.41	5.39	0.33	1.68e-7	Lung cancer;
SARC	cis	rs2290159	0.800	rs5746214	chr3:12644753	A/G	cg23032965	chr3:12705835	RAF1	0.77	8.56	0.49	1.52e-15	Cholesterol, total;
SARC	cis	rs765787	0.530	rs4774542	chr15:45526026	A/C	cg25801113	chr15:45476975	SHF	-0.29	-4.85	-0.3	2.21e-6	Uric acid levels;
SARC	cis	rs3820928	0.874	rs10176882	chr2:227896432	A/T	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.1	-0.32	7.03e-7	Pulmonary function;
SARC	cis	rs35110281	0.805	rs2838330	chr21:45023876	T/A	cg21573476	chr21:45109991	RRP1B	-0.51	-7.45	-0.44	1.84e-12	Mean corpuscular volume;
SARC	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	8.69	0.49	6.64e-16	Alzheimer's disease;
SARC	cis	rs1538970	0.816	rs4633317	chr1:45985157	T/C	cg05343316	chr1:45956843	TESK2	0.82	9.01	0.51	7.85e-17	Platelet count;
SARC	cis	rs503341	0.756	rs11231591	chr11:63587986	G/T	cg04362095	chr11:63592001	C11orf84	-0.56	-7.62	-0.45	6.53e-13	Pulse pressure;
SARC	cis	rs1971762	0.527	rs7311902	chr12:54015236	A/G	cg06632207	chr12:54070931	ATP5G2	0.57	7.93	0.46	8.95e-14	Height;
SARC	cis	rs11098499	0.954	rs10024844	chr4:120311528	A/G	cg09307838	chr4:120376055	NA	0.91	12.88	0.65	4.9e-29	Corneal astigmatism;
SARC	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg22920501	chr2:26401640	FAM59B	-0.57	-7.45	-0.44	1.82e-12	Gut microbiome composition (summer);
SARC	cis	rs7223966	1.000	rs6504168	chr17:61697469	G/T	cg00588841	chr17:61851480	DDX42;CCDC47	-0.67	-7.26	-0.43	5.62e-12	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs35522438	1	rs35522438	chr7:91872872	A/AT	cg17063962	chr7:91808500	NA	0.98	17.0	0.74	1.05e-42	Breast cancer;
SARC	cis	rs2963155	0.518	rs2963151	chr5:142734151	T/C	cg17617527	chr5:142782415	NR3C1	0.87	6.62	0.4	2.4e-10	Breast cancer;
SARC	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg16479474	chr6:28041457	NA	0.34	5.14	0.32	5.75e-7	Parkinson's disease;
SARC	cis	rs7712401	0.592	rs154515	chr5:122191145	G/T	cg19412675	chr5:122181750	SNX24	0.38	5.01	0.31	1.08e-6	Mean platelet volume;
SARC	cis	rs6570726	0.935	rs367643	chr6:145859602	A/C	cg05347473	chr6:146136440	FBXO30	0.49	6.58	0.4	3.04e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg18357526	chr6:26021779	HIST1H4A	0.84	11.61	0.61	6.98e-25	Intelligence (multi-trait analysis);
SARC	cis	rs9341808	0.718	rs910266	chr6:80921170	A/T	cg08355045	chr6:80787529	NA	0.33	5.33	0.33	2.35e-7	Sitting height ratio;
SARC	cis	rs6864727	1.000	rs2349556	chr5:137248721	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.53	5.86	0.36	1.6e-8	Atrial fibrillation;
SARC	cis	rs9916302	0.861	rs3889368	chr17:37683231	C/T	cg07936489	chr17:37558343	FBXL20	-0.66	-8.46	-0.48	2.89e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs8013055	0.846	rs12893999	chr14:105970842	C/G	cg19700328	chr14:106028568	NA	-0.62	-8.61	-0.49	1.11e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
SARC	cis	rs3767633	0.858	rs2341468	chr1:161862312	G/A	cg09175582	chr1:161736000	ATF6	0.68	5.88	0.36	1.38e-8	IgG glycosylation;
SARC	cis	rs62432291	0.681	rs402388	chr6:159654994	A/C	cg14500486	chr6:159655392	FNDC1	-0.62	-6.03	-0.37	6.44e-9	Joint mobility (Beighton score);
SARC	cis	rs35213789	1.000	rs7456463	chr7:69304093	G/A	cg10619644	chr7:69149951	AUTS2	0.45	5.67	0.35	4.17e-8	Childhood ear infection;
SARC	cis	rs6456156	0.904	rs2021033	chr6:167524239	C/T	cg07741184	chr6:167504864	NA	-0.3	-5.67	-0.35	4.11e-8	Primary biliary cholangitis;
SARC	cis	rs8133932	0.859	rs74681567	chr21:47054985	T/C	cg11214348	chr21:47283868	PCBP3	-0.44	-4.83	-0.3	2.53e-6	Schizophrenia;
SARC	cis	rs9457247	0.846	rs2757052	chr6:167380174	T/C	cg07741184	chr6:167504864	NA	-0.3	-5.61	-0.35	5.69e-8	Crohn's disease;
SARC	cis	rs4906332	0.811	rs2296487	chr14:103996205	T/C	cg19000871	chr14:103996768	TRMT61A	-0.4	-4.97	-0.31	1.32e-6	Coronary artery disease;
SARC	trans	rs2986971	0.564	rs4376805	chr10:30094198	A/G	cg12849484	chr7:103083817	SLC26A5	-0.33	-6.3	-0.38	1.46e-9	Non-alcoholic fatty liver disease histology (lobular);
SARC	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg05890377	chr2:74357713	NA	0.61	7.31	0.43	4.29e-12	Gestational age at birth (maternal effect);
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg15605888	chr2:109403293	CCDC138	-0.62	-6.26	-0.38	1.83e-9	Lung cancer in ever smokers;
SARC	cis	rs1153858	1.000	rs12440038	chr15:45706739	A/G	cg15395560	chr15:45543142	SLC28A2	-0.27	-4.87	-0.3	2.05e-6	Homoarginine levels;
SARC	cis	rs9325144	0.555	rs10748433	chr12:38696352	C/G	cg26384229	chr12:38710491	ALG10B	0.6	8.03	0.47	4.66e-14	Morning vs. evening chronotype;
SARC	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg17971929	chr21:40555470	PSMG1	-0.58	-7.36	-0.43	3.08e-12	Menarche (age at onset);
SARC	cis	rs6582630	0.555	rs11181657	chr12:38381858	T/C	cg14851346	chr12:38532713	NA	-0.4	-4.89	-0.31	1.85e-6	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs899997	0.953	rs11633519	chr15:78999552	A/G	cg04896959	chr15:78267971	NA	0.49	5.71	0.35	3.51e-8	Coronary artery disease or large artery stroke;
SARC	cis	rs9914988	0.832	rs34267753	chr17:27157586	T/C	cg20469991	chr17:27169893	C17orf63	-0.52	-5.39	-0.33	1.74e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs7561273	0.609	rs2080727	chr2:24350907	A/G	cg07265300	chr2:24346000	PFN4;LOC375190	-0.42	-4.77	-0.3	3.2e-6	Quantitative traits;
SARC	cis	rs6500395	0.735	rs74017013	chr16:48664120	G/A	cg04672837	chr16:48644449	N4BP1	0.41	5.63	0.35	5.04e-8	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg24642844	chr7:1081250	C7orf50	-0.54	-5.91	-0.36	1.21e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs10927875	1.000	rs10927875	chr1:16299312	A/G	cg21385522	chr1:16154831	NA	0.72	9.2	0.52	2.06e-17	Dilated cardiomyopathy;
SARC	cis	rs8014204	0.836	rs12888998	chr14:75292662	G/T	cg17347104	chr14:75034677	LTBP2	-0.42	-5.23	-0.32	3.78e-7	Caffeine consumption;
SARC	cis	rs854765	0.583	rs6502622	chr17:17834691	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.43	5.58	0.34	6.59e-8	Total body bone mineral density;
SARC	cis	rs6546324	0.625	rs1430789	chr2:67866370	T/C	cg18237512	chr2:67827392	NA	-0.56	-6.71	-0.4	1.49e-10	Endometriosis;
SARC	cis	rs3768617	0.510	rs10911247	chr1:183076993	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.66	9.51	0.53	2.41e-18	Fuchs's corneal dystrophy;
SARC	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg05025164	chr4:1340916	KIAA1530	0.59	7.31	0.43	4.29e-12	Longevity;
SARC	cis	rs9894429	0.646	rs7405937	chr17:79597811	G/A	cg10661904	chr17:79619235	PDE6G	-0.45	-6.33	-0.38	1.22e-9	Eye color traits;
SARC	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg26335602	chr6:28129616	ZNF389	0.48	5.43	0.34	1.39e-7	Parkinson's disease;
SARC	trans	rs9395865	0.501	rs2067833	chr6:53330356	A/G	cg01831166	chr2:198570100	MARS2	-0.51	-6.3	-0.38	1.5e-9	Electroencephalographic traits in alcoholism;
SARC	cis	rs6456156	0.846	rs7774396	chr6:167519786	G/A	cg23791538	chr6:167370224	RNASET2	-0.38	-4.79	-0.3	2.92e-6	Primary biliary cholangitis;
SARC	cis	rs6582630	0.555	rs11182429	chr12:38526679	A/C	cg26384229	chr12:38710491	ALG10B	0.84	12.57	0.64	5.06e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1062177	1.000	rs2347596	chr5:151179199	T/C	cg00977110	chr5:151150581	G3BP1	0.57	5.84	0.36	1.79e-8	Preschool internalizing problems;
SARC	cis	rs9815354	0.761	rs17280777	chr3:41806167	C/T	cg03022575	chr3:42003672	ULK4	0.72	5.99	0.37	7.83e-9	Pulse pressure;Diastolic blood pressure;
SARC	trans	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg07020846	chr15:70390363	TLE3	-0.49	-6.68	-0.4	1.78e-10	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2153535	0.580	rs9328484	chr6:8524843	A/T	cg23788917	chr6:8435910	SLC35B3	0.64	8.54	0.49	1.76e-15	Motion sickness;
SARC	cis	rs508618	0.731	rs12033229	chr1:231545703	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.54	6.43	0.39	6.97e-10	Red blood cell count;
SARC	cis	rs7811142	1.000	rs6972167	chr7:100080013	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.92	10.19	0.56	2.06e-20	Platelet count;
SARC	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg18404041	chr3:52824283	ITIH1	-0.43	-6.54	-0.39	3.78e-10	Bipolar disorder;
SARC	cis	rs9815354	1.000	rs6796210	chr3:41851718	T/C	cg03022575	chr3:42003672	ULK4	0.57	5.37	0.33	1.87e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-8.62	-0.49	1.01e-15	Gut microbiome composition (summer);
SARC	cis	rs611744	0.647	rs589347	chr8:109253929	T/A	cg21045802	chr8:109455806	TTC35	0.61	7.7	0.45	3.89e-13	Dupuytren's disease;
SARC	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg22920501	chr2:26401640	FAM59B	0.61	8.19	0.47	1.71e-14	Gut microbiome composition (summer);
SARC	cis	rs9902453	0.817	rs7217961	chr17:28403112	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.23	-0.43	7.03e-12	Coffee consumption (cups per day);
SARC	cis	rs6690583	0.623	rs12033900	chr1:85478559	T/C	cg22488158	chr1:85528044	WDR63	0.63	5.01	0.31	1.09e-6	Serum sulfate level;
SARC	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	5.96	0.36	9.28e-9	Tonsillectomy;
SARC	cis	rs10078	0.515	rs6872510	chr5:481610	T/C	cg08916839	chr5:415575	AHRR	0.79	7.2	0.43	8.1e-12	Fat distribution (HIV);
SARC	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg02018176	chr4:1364513	KIAA1530	0.44	6.64	0.4	2.18e-10	Longevity;
SARC	cis	rs34375054	0.525	rs7133614	chr12:125605957	C/T	cg25124228	chr12:125621409	AACS	-0.62	-7.74	-0.45	3.03e-13	Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs1865760	1.000	rs3799372	chr6:25922311	A/G	cg16482183	chr6:26056742	HIST1H1C	0.5	6.21	0.38	2.37e-9	Height;
SARC	cis	rs7633770	0.841	rs6442010	chr3:46669500	A/T	cg11219411	chr3:46661640	NA	0.48	8.2	0.47	1.63e-14	Coronary artery disease;
SARC	cis	rs2304069	0.954	rs216127	chr5:149428890	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.86	9.2	0.52	2.11e-17	HIV-1 control;
SARC	cis	rs11574514	1.000	rs28668419	chr16:68010195	C/G	cg01866162	chr16:67596514	CTCF	0.92	5.56	0.34	7.47e-8	Crohn's disease;
SARC	cis	rs2599510	0.811	rs2243844	chr2:32775984	G/T	cg02381751	chr2:32503542	YIPF4	0.48	6.01	0.37	7.02e-9	Interleukin-18 levels;
SARC	cis	rs9611519	0.964	rs20551	chr22:41548008	A/G	cg17376030	chr22:41985996	PMM1	0.45	4.98	0.31	1.22e-6	Neuroticism;
SARC	cis	rs709400	0.628	rs2273699	chr14:103923475	A/G	cg12935359	chr14:103987150	CKB	-0.4	-5.86	-0.36	1.54e-8	Body mass index;
SARC	cis	rs1008375	0.900	rs13101742	chr4:17701297	G/A	cg16339924	chr4:17578868	LAP3	-0.6	-7.66	-0.45	5.01e-13	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs61931739	0.929	rs10844748	chr12:34092930	G/T	cg13010199	chr12:38710504	ALG10B	-0.5	-6.68	-0.4	1.7e-10	Morning vs. evening chronotype;
SARC	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg26681399	chr22:41777847	TEF	-0.44	-4.79	-0.3	2.92e-6	Vitiligo;
SARC	cis	rs11770686	0.747	rs2705781	chr7:75312231	G/A	cg17787366	chr7:75369077	HIP1	0.42	5.23	0.32	3.74e-7	Essential tremor;
SARC	trans	rs61931739	0.500	rs34061369	chr12:34519283	C/T	cg13010199	chr12:38710504	ALG10B	0.83	11.73	0.61	2.89e-25	Morning vs. evening chronotype;
SARC	trans	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	6.88	0.41	5.53e-11	Intelligence (multi-trait analysis);
SARC	cis	rs11098499	1.000	rs11726229	chr4:120211580	C/T	cg09307838	chr4:120376055	NA	0.83	11.36	0.6	4.4e-24	Corneal astigmatism;
SARC	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-9.63	-0.53	1.1e-18	Chronic sinus infection;
SARC	cis	rs6456156	0.583	rs7748224	chr6:167456860	C/T	cg07741184	chr6:167504864	NA	0.35	6.69	0.4	1.64e-10	Primary biliary cholangitis;
SARC	cis	rs10876993	0.928	rs10877001	chr12:58083077	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.42	5.32	0.33	2.4e-7	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs9914988	0.943	rs34693224	chr17:27079555	C/T	cg20469991	chr17:27169893	C17orf63	-0.5	-5.32	-0.33	2.38e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg09699651	chr6:150184138	LRP11	0.5	6.43	0.39	7.1e-10	Testicular germ cell tumor;
SARC	trans	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg00938859	chr5:1591904	SDHAP3	0.81	7.78	0.45	2.27e-13	Breast cancer;
SARC	cis	rs6991952	0.676	rs12679260	chr8:25690787	T/G	cg21775463	chr8:25538546	NA	0.27	4.73	0.3	3.89e-6	Inguinal hernia;
SARC	cis	rs17666538	0.636	rs10107345	chr8:603700	G/T	cg00450029	chr8:599525	NA	0.59	5.15	0.32	5.5e-7	IgG glycosylation;
SARC	cis	rs526821	0.595	rs517627	chr11:55356489	C/T	cg04317927	chr11:55418816	OR4S2	0.41	6.13	0.37	3.62e-9	Pediatric bone mineral density (spine);
SARC	cis	rs6502050	0.761	rs62078747	chr17:80055206	C/G	cg19223190	chr17:80058835	NA	-0.42	-6.06	-0.37	5.42e-9	Life satisfaction;
SARC	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg12463550	chr7:65579703	CRCP	0.52	5.81	0.36	2.06e-8	Aortic root size;
SARC	cis	rs12311304	1.000	rs11056409	chr12:15382567	T/C	cg08258403	chr12:15378311	NA	0.47	7.36	0.43	3.23e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs2153904	0.590	rs823106	chr1:205656453	G/C	cg24503407	chr1:205819492	PM20D1	0.57	5.21	0.32	4.16e-7	Prostate-specific antigen levels;
SARC	cis	rs9325144	0.624	rs12231544	chr12:38901956	C/T	cg13010199	chr12:38710504	ALG10B	-0.46	-5.89	-0.36	1.33e-8	Morning vs. evening chronotype;
SARC	cis	rs995000	0.931	rs7548877	chr1:63005950	T/C	cg06896770	chr1:63153194	DOCK7	-0.9	-13.49	-0.66	5.08e-31	Triglyceride levels;
SARC	cis	rs6582630	0.555	rs11180986	chr12:38264486	G/A	cg14851346	chr12:38532713	NA	-0.46	-5.54	-0.34	8.07e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9815354	0.909	rs1716975	chr3:41960006	T/C	cg03022575	chr3:42003672	ULK4	-0.55	-5.22	-0.32	4.01e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg16405210	chr4:1374714	KIAA1530	0.89	12.48	0.63	1e-27	Longevity;
SARC	cis	rs7084402	0.967	rs1649076	chr10:60294061	A/T	cg07615347	chr10:60278583	BICC1	0.6	8.91	0.5	1.45e-16	Refractive error;
SARC	cis	rs11690935	0.885	rs6727017	chr2:172766847	T/A	cg13550731	chr2:172543902	DYNC1I2	-0.93	-13.48	-0.66	5.44e-31	Schizophrenia;
SARC	cis	rs995000	0.931	rs1748197	chr1:63056112	G/A	cg06896770	chr1:63153194	DOCK7	0.89	13.35	0.66	1.4e-30	Triglyceride levels;
SARC	cis	rs3820928	0.874	rs10194663	chr2:227875369	T/A	cg05526886	chr2:227700861	RHBDD1	-0.49	-5.91	-0.36	1.24e-8	Pulmonary function;
SARC	cis	rs7914558	0.966	rs12571568	chr10:104891396	C/G	cg04362960	chr10:104952993	NT5C2	0.42	4.99	0.31	1.16e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs853679	0.760	rs967005	chr6:28210688	C/T	cg26450541	chr6:28235208	ZNF187	0.59	5.21	0.32	4.25e-7	Depression;
SARC	cis	rs7659604	0.702	rs58649165	chr4:122693752	C/A	cg19671926	chr4:122722719	EXOSC9	-0.51	-5.91	-0.36	1.24e-8	Type 2 diabetes;
SARC	cis	rs950027	0.596	rs2467853	chr15:45698793	T/G	cg21132104	chr15:45694354	SPATA5L1	0.54	6.71	0.4	1.47e-10	Response to fenofibrate (adiponectin levels);
SARC	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	10.84	0.58	2.01e-22	Alzheimer's disease;
SARC	cis	rs1448094	0.512	rs6539926	chr12:86244460	G/A	cg02569458	chr12:86230093	RASSF9	0.38	5.39	0.33	1.71e-7	Major depressive disorder;
SARC	cis	rs734999	0.545	rs10797441	chr1:2551660	T/G	cg00980319	chr1:2560884	MMEL1	-0.35	-4.94	-0.31	1.47e-6	Ulcerative colitis;
SARC	cis	rs55794721	0.509	rs6699896	chr1:25762902	A/T	cg02931644	chr1:25747376	RHCE	0.44	7.13	0.42	1.27e-11	Plateletcrit;Mean corpuscular volume;
SARC	trans	rs17685	0.753	rs1637051	chr7:75730659	G/A	cg19862616	chr7:65841803	NCRNA00174	0.63	7.83	0.46	1.68e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs921968	0.643	rs2303561	chr2:219527005	C/T	cg02176678	chr2:219576539	TTLL4	-0.35	-5.27	-0.33	3.13e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs9398803	0.865	rs1361108	chr6:126767600	C/T	cg20229609	chr6:126660872	C6orf173	0.4	5.73	0.35	3.09e-8	Male-pattern baldness;
SARC	cis	rs6545883	0.894	rs2694642	chr2:61596180	A/G	cg15711740	chr2:61764176	XPO1	0.4	4.81	0.3	2.76e-6	Tuberculosis;
SARC	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg20607798	chr8:58055168	NA	0.52	4.93	0.31	1.54e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg16414030	chr3:133502952	NA	-0.4	-5.44	-0.34	1.32e-7	Iron status biomarkers;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg21377712	chr21:45526957	PWP2	0.51	6.49	0.39	5.04e-10	Breast cancer;
SARC	cis	rs12447804	0.645	rs12920639	chr16:58114140	G/T	cg03859792	chr16:58121049	NA	-0.36	-5.0	-0.31	1.1e-6	Pulmonary function;Pulmonary function (smoking interaction);
SARC	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg11764359	chr7:65958608	NA	0.8	11.25	0.59	9.96e-24	Aortic root size;
SARC	cis	rs8068544	0.748	rs75881902	chr17:40156612	C/A	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.06	-8.41	-0.48	4.15e-15	Reticulocyte fraction of red cells;Reticulocyte count;
SARC	cis	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg18252515	chr7:66147081	NA	-1.38	-12.57	-0.64	5.19e-28	Diabetic kidney disease;
SARC	cis	rs10089	0.953	rs758180	chr5:127354423	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	9.81	0.54	3e-19	Ileal carcinoids;
SARC	cis	rs2070677	0.736	rs7099806	chr10:135414896	C/T	cg20169779	chr10:135381914	SYCE1	-0.5	-5.32	-0.33	2.47e-7	Gout;
SARC	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.94	11.83	0.61	1.3e-25	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs12973672	1.000	rs10410675	chr19:35768828	T/C	cg12095397	chr19:35769544	USF2	0.38	4.79	0.3	2.9e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs2070488	0.965	rs7372386	chr3:38484175	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.86	14.41	0.69	4.2e-34	Electrocardiographic conduction measures;
SARC	cis	rs208520	0.526	rs7775830	chr6:66755249	A/G	cg07460842	chr6:66804631	NA	1.08	20.76	0.81	6.76e-55	Exhaled nitric oxide output;
SARC	cis	rs7843479	0.965	rs3816786	chr8:21860425	A/T	cg17168535	chr8:21777572	XPO7	0.6	7.57	0.44	8.73e-13	Mean corpuscular volume;
SARC	cis	rs11105298	0.838	rs4842488	chr12:89881564	C/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.55	-5.5	-0.34	9.86e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs9398803	0.687	rs1826189	chr6:126922214	C/T	cg19875578	chr6:126661172	C6orf173	0.63	8.7	0.5	5.9e-16	Male-pattern baldness;
SARC	trans	rs56279505	0.629	rs78346552	chr4:100247609	A/G	cg21156590	chr1:3420848	MEGF6	-0.83	-6.43	-0.39	7.07e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10861342	1.000	rs10861354	chr12:105524294	T/C	cg23923672	chr12:105501055	KIAA1033	0.75	6.09	0.37	4.65e-9	IgG glycosylation;
SARC	cis	rs2997447	0.706	rs61776622	chr1:26469035	A/G	cg19633962	chr1:26362018	EXTL1	-0.56	-4.88	-0.3	2.01e-6	QRS complex (12-leadsum);
SARC	cis	rs2043112	0.691	rs6866518	chr5:39086454	C/T	cg04869206	chr5:39074266	RICTOR	0.51	6.4	0.39	8.33e-10	Obesity-related traits;
SARC	cis	rs7769051	0.614	rs76404165	chr6:133235936	T/G	cg22852734	chr6:133119734	C6orf192	0.94	5.82	0.36	1.94e-8	Type 2 diabetes nephropathy;
SARC	cis	rs854765	0.647	rs8066764	chr17:17974668	C/T	cg05444541	chr17:17804740	TOM1L2	-0.31	-5.02	-0.31	1.04e-6	Total body bone mineral density;
SARC	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg02018176	chr4:1364513	KIAA1530	-0.46	-6.56	-0.4	3.36e-10	Obesity-related traits;
SARC	cis	rs4073582	0.595	rs801731	chr11:65938446	G/C	cg14036092	chr11:66035641	RAB1B	0.6	8.48	0.49	2.64e-15	Gout;
SARC	cis	rs6696846	0.777	rs9651228	chr1:205049383	A/G	cg07972983	chr1:205091412	RBBP5	0.46	5.81	0.36	2.07e-8	Red blood cell count;
SARC	cis	rs778371	0.723	rs1022329	chr2:233591239	T/C	cg16596103	chr2:233749413	NGEF	-0.37	-5.79	-0.35	2.24e-8	Schizophrenia;
SARC	cis	rs6691722	0.506	rs1016209	chr1:24745615	A/G	cg18323236	chr1:24743029	NIPAL3	-0.36	-5.12	-0.32	6.41e-7	Response to interferon beta in multiple sclerosis;
SARC	cis	rs67460515	0.500	rs9822435	chr3:160748068	A/T	cg04691961	chr3:161091175	C3orf57	-0.41	-4.85	-0.3	2.28e-6	Parkinson's disease;
SARC	cis	rs2303759	0.918	rs10405465	chr19:49869298	C/T	cg22307029	chr19:49891270	CCDC155	0.55	6.4	0.39	8.27e-10	Multiple sclerosis;
SARC	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg16405210	chr4:1374714	KIAA1530	-0.49	-5.85	-0.36	1.67e-8	Obesity-related traits;
SARC	cis	rs10493773	0.609	rs12097932	chr1:86182216	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.61	-9.85	-0.54	2.39e-19	Urate levels in overweight individuals;
SARC	cis	rs7027203	0.595	rs4308796	chr9:96570165	G/A	cg14598338	chr9:96623480	NA	0.36	4.91	0.31	1.68e-6	DNA methylation (variation);
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg15159880	chr19:7459989	ARHGEF18	-0.53	-6.72	-0.4	1.34e-10	Schizophrenia;
SARC	cis	rs7223966	1.000	rs28463311	chr17:61919643	C/T	cg00588841	chr17:61851480	DDX42;CCDC47	-0.62	-6.4	-0.39	8.37e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9612	0.948	rs12609056	chr19:44258702	G/T	cg08581076	chr19:44259116	C19orf61	0.7	8.73	0.5	5.1e-16	Exhaled nitric oxide output;
SARC	cis	rs13191362	0.938	rs13213746	chr6:163167777	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.25	0.33	3.44e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg18876405	chr7:65276391	NA	0.49	6.04	0.37	6e-9	Aortic root size;
SARC	cis	rs17270561	0.609	rs1165156	chr6:25792978	T/C	cg17691542	chr6:26056736	HIST1H1C	0.45	5.49	0.34	1.05e-7	Iron status biomarkers;
SARC	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-6.01	-0.37	7.13e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg03060546	chr3:49711283	APEH	0.43	5.39	0.33	1.74e-7	Parkinson's disease;
SARC	cis	rs12612619	0.695	rs10207670	chr2:27243001	C/T	cg17611932	chr2:27505586	TRIM54	0.27	4.78	0.3	3.04e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
SARC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg24503407	chr1:205819492	PM20D1	0.82	13.08	0.65	1.14e-29	Menarche (age at onset);
SARC	cis	rs9473924	0.505	rs9473938	chr6:50874050	C/T	cg14470998	chr6:50812995	TFAP2B	0.76	7.07	0.42	1.79e-11	Body mass index;
SARC	cis	rs593982	0.925	rs3953806	chr11:65505153	C/T	cg08755490	chr11:65554678	OVOL1	-0.91	-9.66	-0.53	8.59e-19	Atopic dermatitis;
SARC	cis	rs600231	0.708	rs602838	chr11:65253247	T/G	cg17120908	chr11:65337727	SSSCA1	-0.42	-5.49	-0.34	1.07e-7	Bone mineral density;
SARC	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg12463550	chr7:65579703	CRCP	-0.71	-5.42	-0.33	1.47e-7	Diabetic kidney disease;
SARC	cis	rs6582630	0.622	rs11182005	chr12:38441292	G/A	cg13010199	chr12:38710504	ALG10B	-0.46	-5.63	-0.35	5.19e-8	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg13413755	chr9:94186957	NFIL3	-0.77	-6.33	-0.38	1.26e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg27347728	chr4:17578864	LAP3	0.48	6.1	0.37	4.5e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6942407	0.546	rs2373387	chr7:86745948	T/G	cg02420886	chr7:86849541	C7orf23	0.7	6.22	0.38	2.24e-9	Food allergy;
SARC	cis	rs2204008	0.806	rs11525001	chr12:38234397	A/G	cg13010199	chr12:38710504	ALG10B	0.78	10.44	0.56	3.64e-21	Bladder cancer;
SARC	cis	rs208520	0.690	rs10455194	chr6:66743356	A/G	cg07460842	chr6:66804631	NA	1.04	13.8	0.67	4.75e-32	Exhaled nitric oxide output;
SARC	cis	rs950027	0.787	rs2433616	chr15:45728599	A/G	cg21132104	chr15:45694354	SPATA5L1	0.53	6.45	0.39	6.4e-10	Response to fenofibrate (adiponectin levels);
SARC	cis	rs2404602	0.684	rs157759	chr15:76846990	T/A	cg15268244	chr15:77196840	NA	-0.4	-4.86	-0.3	2.17e-6	Blood metabolite levels;
SARC	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg04944784	chr2:26401820	FAM59B	0.63	8.03	0.47	4.74e-14	Gut microbiome composition (summer);
SARC	cis	rs7223966	1.000	rs8073373	chr17:61703320	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.82	0.41	7.9e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9790314	0.747	rs9990115	chr3:160838412	C/G	cg04691961	chr3:161091175	C3orf57	-0.68	-9.55	-0.53	1.9e-18	Morning vs. evening chronotype;
SARC	cis	rs79976124	0.877	rs79507557	chr6:66640908	C/A	cg07460842	chr6:66804631	NA	0.62	6.73	0.4	1.27e-10	Type 2 diabetes;
SARC	cis	rs3741404	0.560	rs17699798	chr11:63898806	C/G	cg05555928	chr11:63887634	MACROD1	0.35	5.4	0.33	1.63e-7	Platelet count;
SARC	cis	rs427394	0.802	rs274692	chr5:6734625	C/T	cg10857441	chr5:6722123	POLS	-0.34	-5.1	-0.32	7.2e-7	Menopause (age at onset);
SARC	cis	rs7312933	0.737	rs10880261	chr12:42573822	T/C	cg19980929	chr12:42632907	YAF2	0.43	5.89	0.36	1.32e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg08936487	chr6:3224596	TUBB2B	0.49	6.69	0.4	1.67e-10	Thyroid stimulating hormone;
SARC	cis	rs9790314	1.000	rs6765269	chr3:160948542	T/C	cg04691961	chr3:161091175	C3orf57	-0.78	-11.47	-0.6	1.96e-24	Morning vs. evening chronotype;
SARC	cis	rs4800452	0.826	rs28589524	chr18:20746829	G/A	cg13313047	chr18:20735648	CABLES1	-0.39	-4.79	-0.3	2.99e-6	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
SARC	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg22920501	chr2:26401640	FAM59B	-0.61	-8.19	-0.47	1.71e-14	Gut microbiome composition (summer);
SARC	cis	rs17376456	0.569	rs2045019	chr5:93201971	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.56	-5.83	-0.36	1.87e-8	Diabetic retinopathy;
SARC	cis	rs9807989	0.839	rs10206753	chr2:102968362	T/C	cg09003973	chr2:102972529	NA	0.41	5.6	0.34	6.11e-8	Asthma;
SARC	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg10374962	chr7:1011985	COX19	-0.42	-4.82	-0.3	2.6e-6	Bronchopulmonary dysplasia;
SARC	cis	rs9660992	0.710	rs1668869	chr1:205239779	G/C	cg21545522	chr1:205238299	TMCC2	0.49	6.8	0.41	8.94e-11	Mean corpuscular volume;Mean platelet volume;
SARC	trans	rs1814175	0.645	rs847635	chr11:49923323	G/A	cg15704280	chr7:45808275	SEPT13	-0.88	-14.0	-0.68	1.02e-32	Height;
SARC	cis	rs12142240	0.698	rs17361915	chr1:46847321	C/T	cg10495392	chr1:46806563	NSUN4	0.65	6.88	0.41	5.6e-11	Menopause (age at onset);
SARC	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg13939156	chr17:80058883	NA	-0.43	-6.66	-0.4	1.95e-10	Life satisfaction;
SARC	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg24060327	chr5:131705240	SLC22A5	-0.48	-5.95	-0.36	9.84e-9	Blood metabolite levels;
SARC	cis	rs9303401	0.614	rs66480139	chr17:57101538	G/A	cg25039879	chr17:56429692	SUPT4H1	0.56	5.03	0.31	9.58e-7	Cognitive test performance;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg10812733	chr19:49014889	LMTK3	0.51	6.97	0.42	3.16e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg04772025	chr11:68637568	NA	0.55	7.0	0.42	2.72e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9902453	0.791	rs9904051	chr17:28244122	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	7.1	0.42	1.52e-11	Coffee consumption (cups per day);
SARC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg09373136	chr17:61933544	TCAM1	-0.45	-6.14	-0.37	3.58e-9	Prudent dietary pattern;
SARC	cis	rs2228479	0.850	rs11649510	chr16:89851004	A/G	cg12064134	chr16:90016061	DEF8	-0.59	-5.06	-0.31	8.56e-7	Skin colour saturation;
SARC	cis	rs12145833	0.748	rs11807162	chr1:243454680	C/T	cg02356786	chr1:243265016	LOC731275	0.57	5.1	0.32	7.15e-7	Obesity (early onset extreme);
SARC	cis	rs6570726	0.935	rs434298	chr6:145846873	G/A	cg05347473	chr6:146136440	FBXO30	0.49	6.58	0.4	3.04e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-6.82	-0.41	7.86e-11	Personality dimensions;
SARC	cis	rs11574514	0.661	rs8058310	chr16:67893839	G/A	cg01866162	chr16:67596514	CTCF	0.81	5.39	0.33	1.76e-7	Crohn's disease;
SARC	cis	rs1023500	0.573	rs133377	chr22:42466950	C/T	cg04733989	chr22:42467013	NAGA	0.79	11.04	0.59	4.62e-23	Schizophrenia;
SARC	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg01276201	chr10:134613136	NA	0.29	5.09	0.32	7.23e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs8044995	0.568	rs55675218	chr16:68323647	G/C	cg05110241	chr16:68378359	PRMT7	-0.66	-5.67	-0.35	4.18e-8	Schizophrenia;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg19791277	chr8:136469780	KHDRBS3	-0.51	-6.82	-0.41	7.74e-11	Electrocardiographic conduction measures;
SARC	cis	rs6733011	0.508	rs12712041	chr2:99522059	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-6.29	-0.38	1.56e-9	Bipolar disorder;
SARC	cis	rs8111500	0.793	rs2892233	chr19:49160255	G/A	cg07051648	chr19:49177693	NTN5;SEC1	0.44	4.76	0.3	3.4e-6	Elevated serum carcinoembryonic antigen levels;
SARC	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg21782813	chr7:2030301	MAD1L1	0.41	6.57	0.4	3.31e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs1707322	0.752	rs4660313	chr1:46110841	A/G	cg03146154	chr1:46216737	IPP	-0.5	-6.08	-0.37	4.75e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg24642844	chr7:1081250	C7orf50	-0.57	-6.05	-0.37	5.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs9309473	0.607	rs6546826	chr2:73599808	A/G	cg20560298	chr2:73613845	ALMS1	0.52	6.72	0.4	1.41e-10	Metabolite levels;
SARC	cis	rs3126085	0.867	rs12027899	chr1:152253954	C/A	cg26876637	chr1:152193138	HRNR	0.45	5.13	0.32	6.04e-7	Atopic dermatitis;
SARC	cis	rs76419734	1.000	rs72673824	chr4:106724464	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.75	5.1	0.32	7.18e-7	Post bronchodilator FEV1;
SARC	cis	rs1059312	0.966	rs2291349	chr12:129284248	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.5	-6.13	-0.37	3.69e-9	Systemic lupus erythematosus;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg16655754	chr17:27920371	ANKRD13B	0.48	6.44	0.39	6.73e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	trans	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg23109134	chr10:7830051	ATP5C1;KIN	-0.55	-7.11	-0.42	1.43e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs73001065	0.818	rs12610185	chr19:19721722	G/A	cg03709012	chr19:19516395	GATAD2A	0.87	5.94	0.36	1.05e-8	LDL cholesterol;
SARC	cis	rs986417	1.000	rs1955686	chr14:61093560	C/T	cg27398547	chr14:60952738	C14orf39	0.87	7.55	0.44	9.83e-13	Gut microbiota (bacterial taxa);
SARC	cis	rs8141529	0.778	rs763073	chr22:29215542	G/A	cg15103426	chr22:29168792	CCDC117	0.68	9.01	0.51	7.63e-17	Lymphocyte counts;
SARC	cis	rs11764590	0.694	rs10241537	chr7:2083358	A/G	cg21782813	chr7:2030301	MAD1L1	-0.32	-4.88	-0.3	1.97e-6	Neuroticism;
SARC	cis	rs6582630	0.537	rs12823925	chr12:38409323	C/T	cg13010199	chr12:38710504	ALG10B	0.75	10.21	0.56	1.86e-20	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1475911	0.708	rs66994219	chr21:43521647	G/A	cg19766460	chr21:43528205	UMODL1;C21orf128	0.6	7.3	0.43	4.61e-12	IgG glycosylation;
SARC	cis	rs7552404	0.727	rs6683437	chr1:76316619	G/A	cg22875332	chr1:76189707	ACADM	0.44	5.53	0.34	8.47e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs13256369	1.000	rs1109619	chr8:8571616	G/T	cg17143192	chr8:8559678	CLDN23	0.53	6.19	0.38	2.69e-9	Obesity-related traits;
SARC	cis	rs477895	1.000	rs66968227	chr11:64070930	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.66	5.34	0.33	2.24e-7	Mean platelet volume;
SARC	cis	rs2197308	0.728	rs7304305	chr12:37932990	T/C	cg13010199	chr12:38710504	ALG10B	-0.68	-9.06	-0.51	5.6e-17	Morning vs. evening chronotype;
SARC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg19318889	chr4:1322082	MAEA	0.45	5.51	0.34	9.64e-8	Longevity;
SARC	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg21782813	chr7:2030301	MAD1L1	0.45	7.19	0.43	8.83e-12	Bipolar disorder and schizophrenia;
SARC	cis	rs11122272	0.766	rs2486732	chr1:231531476	A/C	cg06096015	chr1:231504339	EGLN1	0.35	5.14	0.32	5.72e-7	Hemoglobin concentration;
SARC	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg21644426	chr2:191273491	MFSD6	0.52	7.03	0.42	2.21e-11	Pulse pressure;
SARC	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg23172400	chr8:95962367	TP53INP1	-0.3	-5.28	-0.33	3.02e-7	Type 2 diabetes;
SARC	cis	rs2735413	0.918	rs1922621	chr16:78075015	A/G	cg04733911	chr16:78082701	NA	-0.31	-5.61	-0.34	5.78e-8	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs11623869	0.711	rs2403173	chr14:103909289	T/C	cg26031613	chr14:104095156	KLC1	0.8	11.45	0.6	2.26e-24	Bone mineral density;
SARC	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg06618935	chr21:46677482	NA	-0.36	-4.83	-0.3	2.42e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs12347191	0.500	rs925486	chr9:100619733	C/T	cg13688889	chr9:100608707	NA	-0.48	-5.07	-0.32	8.16e-7	Orofacial clefts;
SARC	cis	rs8141529	0.529	rs28458474	chr22:29213034	A/G	cg15103426	chr22:29168792	CCDC117	0.61	5.94	0.36	1.03e-8	Lymphocyte counts;
SARC	cis	rs7589342	0.501	rs7602971	chr2:106440675	G/A	cg16077055	chr2:106428750	NCK2	0.26	4.9	0.31	1.83e-6	Addiction;
SARC	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg03999130	chr15:45571217	NA	0.39	5.09	0.32	7.55e-7	Homoarginine levels;
SARC	cis	rs9814567	0.752	rs1534030	chr3:134330083	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.51	-6.61	-0.4	2.53e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs4481887	1.000	rs4916125	chr1:248466583	A/T	cg01631408	chr1:248437212	OR2T33	-0.44	-5.66	-0.35	4.35e-8	Common traits (Other);
SARC	cis	rs240764	0.579	rs6937520	chr6:101173735	C/T	cg09795085	chr6:101329169	ASCC3	-0.4	-4.98	-0.31	1.21e-6	Neuroticism;
SARC	cis	rs11770686	0.967	rs13231091	chr7:75343738	C/T	cg17787366	chr7:75369077	HIP1	0.43	5.29	0.33	2.88e-7	Essential tremor;
SARC	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-9.9	-0.54	1.66e-19	Chronic sinus infection;
SARC	cis	rs7100689	0.646	rs10749579	chr10:82140959	C/T	cg01528321	chr10:82214614	TSPAN14	0.74	10.24	0.56	1.51e-20	Post bronchodilator FEV1;
SARC	cis	rs10504073	0.647	rs4873098	chr8:50021041	T/C	cg00325661	chr8:49890786	NA	0.5	6.82	0.41	7.84e-11	Blood metabolite ratios;
SARC	trans	rs12310956	0.510	rs4931759	chr12:33871969	T/C	cg13010199	chr12:38710504	ALG10B	0.58	7.48	0.44	1.49e-12	Morning vs. evening chronotype;
SARC	cis	rs926938	0.618	rs904292	chr1:115358421	C/T	cg12756093	chr1:115239321	AMPD1	0.39	5.09	0.32	7.22e-7	Autism;
SARC	cis	rs4926611	0.796	rs6588482	chr1:54054618	T/A	cg08927728	chr1:54059983	GLIS1	0.29	4.78	0.3	3.1e-6	Hand grip strength;
SARC	cis	rs7819412	0.522	rs3021495	chr8:10994743	C/G	cg21775007	chr8:11205619	TDH	-0.44	-5.13	-0.32	6.09e-7	Triglycerides;
SARC	cis	rs910316	0.673	rs2012627	chr14:75443103	C/T	cg23033748	chr14:75592666	NEK9	0.38	5.11	0.32	6.68e-7	Height;
SARC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg21782813	chr7:2030301	MAD1L1	0.43	6.67	0.4	1.8e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs11969893	0.655	rs67724651	chr6:101417004	T/G	cg12253828	chr6:101329408	ASCC3	1.03	6.17	0.37	2.96e-9	Economic and political preferences (immigration/crime);
SARC	cis	rs763121	0.962	rs5757130	chr22:38937794	G/A	cg21395723	chr22:39101663	GTPBP1	0.49	5.79	0.35	2.21e-8	Menopause (age at onset);
SARC	cis	rs9790314	1.000	rs2218803	chr3:161047973	T/G	cg03342759	chr3:160939853	NMD3	-0.55	-6.84	-0.41	6.98e-11	Morning vs. evening chronotype;
SARC	cis	rs9394841	0.667	rs12661667	chr6:41792545	C/T	cg08135965	chr6:41755394	TOMM6	0.65	7.11	0.42	1.41e-11	Mean corpuscular hemoglobin;Red cell distribution width;
SARC	cis	rs9393692	0.905	rs6916289	chr6:26289122	A/T	cg05868516	chr6:26286170	HIST1H4H	0.52	6.69	0.4	1.62e-10	Educational attainment;
SARC	cis	rs9818758	0.607	rs11706189	chr3:49210833	C/A	cg01304814	chr3:48885189	PRKAR2A	0.61	5.12	0.32	6.42e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs6977660	0.507	rs4721822	chr7:19771693	T/C	cg07541023	chr7:19748670	TWISTNB	0.92	8.02	0.47	5.06e-14	Thyroid stimulating hormone;
SARC	trans	rs11098499	0.954	rs6822679	chr4:120402702	A/C	cg25214090	chr10:38739885	LOC399744	0.57	7.33	0.43	3.83e-12	Corneal astigmatism;
SARC	cis	rs240764	0.604	rs705583	chr6:101261408	C/A	cg09795085	chr6:101329169	ASCC3	0.49	6.46	0.39	5.88e-10	Neuroticism;
SARC	cis	rs7208859	0.524	rs57670615	chr17:29069498	A/G	cg13385521	chr17:29058706	SUZ12P	0.84	7.31	0.43	4.29e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg17383024	chr4:87797556	C4orf36	0.53	6.54	0.39	3.8e-10	Breast cancer;
SARC	cis	rs12893668	0.703	rs35498576	chr14:104025893	T/C	cg26031613	chr14:104095156	KLC1	-0.49	-5.3	-0.33	2.65e-7	Reticulocyte count;
SARC	cis	rs9786986	0.665	rs1874129	chr1:235700023	T/G	cg08848088	chr1:235714526	GNG4	0.51	4.9	0.31	1.81e-6	Body mass index;
SARC	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg11987759	chr7:65425863	GUSB	0.47	5.77	0.35	2.51e-8	Aortic root size;
SARC	cis	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg24110177	chr3:50126178	RBM5	0.64	8.59	0.49	1.24e-15	Body mass index;
SARC	cis	rs17376456	0.757	rs1031424	chr5:93139706	G/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.7	6.56	0.39	3.42e-10	Diabetic retinopathy;
SARC	cis	rs7216064	1.000	rs7209675	chr17:65831258	A/T	cg12091567	chr17:66097778	LOC651250	-0.72	-8.06	-0.47	4e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs13191362	1.000	rs35424047	chr6:163029715	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.55	5.32	0.33	2.48e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs3126085	0.935	rs2152862	chr1:152259742	T/C	cg03465714	chr1:152285911	FLG	0.45	5.45	0.34	1.25e-7	Atopic dermatitis;
SARC	cis	rs568617	1.000	rs656980	chr11:65656282	G/A	cg26695010	chr11:65641043	EFEMP2	-0.49	-5.75	-0.35	2.82e-8	Crohn's disease;
SARC	cis	rs4660306	0.884	rs7543076	chr1:45964238	T/C	cg24296786	chr1:45957014	TESK2	0.56	6.54	0.39	3.8e-10	Homocysteine levels;
SARC	trans	rs10209086	0.736	rs1584436	chr2:138298878	A/G	cg16247290	chr7:36429691	ANLN;KIAA0895	-0.49	-6.28	-0.38	1.62e-9	Multiple system atrophy;
SARC	cis	rs239198	0.555	rs9399695	chr6:101290415	A/C	cg09795085	chr6:101329169	ASCC3	0.47	5.82	0.36	1.93e-8	Menarche (age at onset);
SARC	cis	rs2066819	1.000	rs2643626	chr12:56726518	C/T	cg26316697	chr12:56727976	PAN2	-0.88	-6.05	-0.37	5.67e-9	Psoriasis vulgaris;
SARC	cis	rs17376456	0.877	rs9314101	chr5:93461593	A/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	6.14	0.37	3.45e-9	Diabetic retinopathy;
SARC	cis	rs7937682	1.000	rs11608149	chr11:111535102	G/A	cg09085632	chr11:111637200	PPP2R1B	0.99	16.4	0.73	1.01e-40	Primary sclerosing cholangitis;
SARC	cis	rs17376456	1.000	rs67150649	chr5:93292377	A/G	cg25358565	chr5:93447407	FAM172A	1.3	14.47	0.69	2.7200000000000002e-34	Diabetic retinopathy;
SARC	cis	rs7772486	0.727	rs4896843	chr6:146063451	T/C	cg23711669	chr6:146136114	FBXO30	-0.89	-15.13	-0.7	1.78e-36	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10193935	1.000	rs13399869	chr2:42386041	C/G	cg27598129	chr2:42591480	NA	-0.36	-5.0	-0.31	1.13e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2486288	0.656	rs8039354	chr15:45551756	A/G	cg15395560	chr15:45543142	SLC28A2	-0.28	-5.32	-0.33	2.43e-7	Glomerular filtration rate;
SARC	cis	rs796364	1.000	rs11680723	chr2:200810957	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.76	-6.19	-0.38	2.63e-9	Schizophrenia;
SARC	cis	rs7712401	0.601	rs34707663	chr5:122320463	A/G	cg19412675	chr5:122181750	SNX24	-0.43	-5.47	-0.34	1.15e-7	Mean platelet volume;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg14700821	chr5:64777802	ADAMTS6	0.46	6.4	0.39	8.56e-10	Lung adenocarcinoma;
SARC	cis	rs3768617	0.510	rs3768620	chr1:183092237	G/A	cg13390022	chr1:182993471	LAMC1	0.31	4.73	0.3	3.89e-6	Fuchs's corneal dystrophy;
SARC	cis	rs4595586	0.505	rs12823590	chr12:39399750	A/T	cg26384229	chr12:38710491	ALG10B	0.51	6.09	0.37	4.54e-9	Morning vs. evening chronotype;
SARC	cis	rs7762018	0.607	rs79355059	chr6:170062157	T/C	cg19338460	chr6:170058176	WDR27	-0.83	-5.85	-0.36	1.68e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg04277193	chr17:41438351	NA	0.44	4.73	0.3	3.83e-6	Menopause (age at onset);
SARC	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg14582100	chr15:45693742	SPATA5L1	0.35	4.91	0.31	1.69e-6	Homoarginine levels;
SARC	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.46	-5.83	-0.36	1.83e-8	Personality dimensions;
SARC	cis	rs72627509	0.857	rs781658	chr4:57779567	G/A	cg26694713	chr4:57773883	REST	0.64	6.54	0.39	3.87e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs9911578	1.000	rs654778	chr17:56736473	A/C	cg12560992	chr17:57184187	TRIM37	0.81	11.0	0.58	6.1e-23	Intelligence (multi-trait analysis);
SARC	cis	rs35110281	0.807	rs28840140	chr21:45039163	T/C	cg01579765	chr21:45077557	HSF2BP	-0.33	-5.68	-0.35	3.94e-8	Mean corpuscular volume;
SARC	cis	rs7644634	0.559	rs2301040	chr3:105430090	A/C	cg23051926	chr3:105466016	CBLB	0.47	5.27	0.33	3.18e-7	Itch intensity from mosquito bite;
SARC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.63	-0.4	2.28e-10	Total body bone mineral density;
SARC	cis	rs992157	0.798	rs10193383	chr2:219157692	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.62	8.62	0.49	1.03e-15	Colorectal cancer;
SARC	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg10435706	chr6:150039699	LATS1	0.36	4.8	0.3	2.88e-6	Lung cancer;
SARC	cis	rs3845702	0.736	rs259810	chr2:180787821	T/C	cg01881094	chr2:180872142	CWC22	-1.05	-8.41	-0.48	4.22e-15	Schizophrenia;
SARC	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.52	-5.4	-0.33	1.68e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	trans	rs4644046	0.620	rs9381975	chr6:51366221	A/G	cg21235075	chr6:170500610	NA	-0.36	-6.27	-0.38	1.74e-9	Coronary artery disease;
SARC	cis	rs6947395	0.521	rs6943309	chr7:69335516	A/C	cg10619644	chr7:69149951	AUTS2	0.39	4.83	0.3	2.49e-6	Body mass index;
SARC	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	8.39	0.48	4.78e-15	Mean platelet volume;
SARC	cis	rs4880487	1.000	rs4880487	chr10:1246883	C/T	cg03183215	chr10:1252341	ADARB2	-0.34	-5.8	-0.36	2.14e-8	Migraine;
SARC	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.82	12.1	0.62	1.79e-26	Personality dimensions;
SARC	cis	rs477692	0.663	rs491929	chr10:131368111	G/A	cg05714579	chr10:131428358	MGMT	0.57	7.37	0.43	3e-12	Response to temozolomide;
SARC	cis	rs995000	0.931	rs10889349	chr1:63081919	A/G	cg06896770	chr1:63153194	DOCK7	0.89	13.21	0.65	4.23e-30	Triglyceride levels;
SARC	cis	rs2425143	1.000	rs2425142	chr20:34350346	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	5.25	0.33	3.49e-7	Blood protein levels;
SARC	cis	rs1941023	0.568	rs1373064	chr11:60168200	C/T	cg08716584	chr11:60157161	MS4A7	-0.41	-6.65	-0.4	2.09e-10	Congenital heart disease (maternal effect);
SARC	cis	rs6582618	1	rs6582618	chr12:38726137	A/G	cg26384229	chr12:38710491	ALG10B	0.56	7.23	0.43	6.82e-12	Morning vs. evening chronotype;
SARC	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg11644478	chr21:40555479	PSMG1	-0.88	-11.6	-0.6	7.56e-25	Cognitive function;
SARC	cis	rs2832191	0.740	rs13048618	chr21:30458684	A/G	cg24692254	chr21:30365293	RNF160	1.04	18.46	0.77	1.65e-47	Dental caries;
SARC	cis	rs6570726	0.935	rs422540	chr6:145837815	G/T	cg23711669	chr6:146136114	FBXO30	0.78	11.86	0.61	1.04e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg26335602	chr6:28129616	ZNF389	0.53	5.95	0.36	9.59e-9	Depression;
SARC	cis	rs3126085	0.877	rs6662450	chr1:152191709	C/G	cg09127314	chr1:152161683	NA	0.41	4.79	0.3	2.93e-6	Atopic dermatitis;
SARC	cis	rs798554	0.679	rs2644300	chr7:2883071	G/A	cg13628971	chr7:2884303	GNA12	0.67	8.17	0.47	1.92e-14	Height;
SARC	cis	rs7713065	0.531	rs2522051	chr5:131797578	C/T	cg09877947	chr5:131593287	PDLIM4	0.4	4.89	0.3	1.92e-6	Lung function (FEV1/FVC);
SARC	cis	rs2290159	0.571	rs7637392	chr3:12696433	A/G	cg23032965	chr3:12705835	RAF1	0.74	7.87	0.46	1.35e-13	Cholesterol, total;
SARC	cis	rs7555523	0.887	rs4657475	chr1:165687175	T/C	cg24409356	chr1:165738333	TMCO1	0.7	5.74	0.35	2.98e-8	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg22974920	chr21:40686053	BRWD1	-0.45	-4.97	-0.31	1.28e-6	Cognitive function;
SARC	cis	rs72781680	0.611	rs2303289	chr2:24342242	C/G	cg06627628	chr2:24431161	ITSN2	0.58	6.25	0.38	1.91e-9	Lymphocyte counts;
SARC	cis	rs933688	0.941	rs2887007	chr5:90740531	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.99	12.79	0.64	1e-28	Smoking behavior;
SARC	cis	rs9297145	0.761	rs62473005	chr7:98742510	G/C	cg05967295	chr7:98741636	SMURF1	0.78	8.02	0.47	5.04e-14	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
SARC	cis	rs9815354	1.000	rs1717009	chr3:41946308	T/C	cg03022575	chr3:42003672	ULK4	-0.55	-5.21	-0.32	4.11e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs10512697	0.803	rs13161713	chr5:3575234	C/G	cg19473799	chr5:3511975	NA	-0.65	-4.79	-0.3	3.03e-6	Immune response to smallpox vaccine (IL-6);
SARC	cis	rs2251381	0.750	rs2255055	chr21:30537045	C/T	cg08807101	chr21:30365312	RNF160	0.77	10.96	0.58	7.93e-23	Selective IgA deficiency;
SARC	cis	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg03060546	chr3:49711283	APEH	0.59	7.33	0.43	3.8e-12	Resting heart rate;
SARC	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg06558623	chr16:89946397	TCF25	0.96	7.37	0.43	2.89e-12	Skin colour saturation;
SARC	cis	rs11756659	0.653	rs185635	chr6:25957109	G/A	cg00631329	chr6:26305371	NA	-0.49	-5.23	-0.32	3.8e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;Red cell distribution width;
SARC	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg00800038	chr16:89945340	TCF25	-0.6	-4.92	-0.31	1.65e-6	Skin colour saturation;
SARC	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg11062466	chr8:58055876	NA	-0.54	-5.53	-0.34	8.68e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4713675	0.510	rs1014933	chr6:33677235	A/G	cg15676125	chr6:33679581	C6orf125	0.53	6.43	0.39	7.32e-10	Plateletcrit;
SARC	cis	rs3126085	0.935	rs11204952	chr1:152227321	G/A	cg03465714	chr1:152285911	FLG	-0.44	-5.37	-0.33	1.88e-7	Atopic dermatitis;
SARC	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg11859384	chr17:80120422	CCDC57	-0.41	-4.93	-0.31	1.57e-6	Life satisfaction;
SARC	trans	rs67900830	0.602	rs11701620	chr21:44601373	C/G	cg04875614	chr4:2008706	WHSC2	-0.57	-6.25	-0.38	1.95e-9	Schizophrenia;
SARC	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg11764359	chr7:65958608	NA	0.66	7.62	0.45	6.4e-13	Aortic root size;
SARC	cis	rs9920506	0.536	rs12441998	chr15:78929372	G/A	cg24631222	chr15:78858424	CHRNA5	-0.51	-5.88	-0.36	1.38e-8	Post bronchodilator FEV1;
SARC	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	10.56	0.57	1.49e-21	Alzheimer's disease;
SARC	cis	rs10463316	0.817	rs6895187	chr5:150775909	G/A	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.37	-0.33	1.86e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs748404	0.697	rs493444	chr15:43566470	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	6.56	0.39	3.51e-10	Lung cancer;
SARC	cis	rs10463554	0.892	rs2195272	chr5:102295504	G/T	cg23492399	chr5:102201601	PAM	-0.45	-5.52	-0.34	9.23e-8	Parkinson's disease;
SARC	cis	rs4901847	0.562	rs7142336	chr14:58612539	C/G	cg15908186	chr14:58618357	C14orf37	0.59	7.64	0.45	5.67e-13	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs9581943	0.967	rs7995917	chr13:28472724	T/C	cg17352152	chr13:28491409	NA	0.39	5.15	0.32	5.59e-7	Pancreatic cancer;
SARC	cis	rs4243830	0.850	rs10779787	chr1:6599755	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.01	-9.9	-0.54	1.61e-19	Body mass index;
SARC	trans	rs7824557	0.564	rs2736300	chr8:11235579	T/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-6.99	-0.42	2.9e-11	Retinal vascular caliber;
SARC	cis	rs9436747	0.626	rs17412368	chr1:65939158	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	-0.42	-5.36	-0.33	2.01e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs7481584	0.962	rs12805426	chr11:3020580	C/T	cg25174290	chr11:3078921	CARS	-0.5	-6.49	-0.39	5.03e-10	Calcium levels;
SARC	cis	rs11764590	0.694	rs2056477	chr7:2079744	G/C	cg21782813	chr7:2030301	MAD1L1	-0.37	-5.06	-0.31	8.4e-7	Neuroticism;
SARC	cis	rs1800562	1	rs1800562	chr6:26093141	C/T	cg17691542	chr6:26056736	HIST1H1C	0.98	5.63	0.35	5.16e-8	Hematocrit;Iron status biomarkers (transferrin levels);Diastolic blood pressure;Hemoglobin;Red blood cell count;Cholesterol, total;Hematology traits;Alcohol consumption (transferrin glycosylation);Iron status biomarkers (ferritin levels);LDL cholesterol;Iron status biomarkers;Mean corpuscular hemoglobin;Iron status biomarkers (transferrin saturation);Mean corpuscular volume;Iron status biomarkers (iron levels);Red blood cell traits;Iron status biomarkers (total iron binding capacity);Glycated hemoglobin levels;Hematological parameters;Hepcidin levels;Cardiovascular disease risk factors;
SARC	cis	rs6598955	0.724	rs12068388	chr1:26621596	G/A	cg21300267	chr1:26547059	NA	-0.25	-4.85	-0.3	2.23e-6	Obesity-related traits;
SARC	cis	rs6120849	0.707	rs752075	chr20:33591591	C/A	cg06115741	chr20:33292138	TP53INP2	0.54	5.24	0.32	3.64e-7	Protein C levels;
SARC	cis	rs644799	0.672	rs61902245	chr11:95517737	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.83	13.41	0.66	9.14e-31	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg21919877	chr17:30362448	LRRC37B	0.46	6.43	0.39	7e-10	Thyroid stimulating hormone;
SARC	cis	rs1448094	0.648	rs10863093	chr12:86285792	T/G	cg02569458	chr12:86230093	RASSF9	0.42	5.62	0.35	5.52e-8	Major depressive disorder;
SARC	cis	rs72634258	0.786	rs9434992	chr1:8179392	G/T	cg00042356	chr1:8021962	PARK7	0.59	5.52	0.34	9.08e-8	Inflammatory bowel disease;
SARC	cis	rs6912958	0.631	rs9450704	chr6:88182704	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.3	-4.99	-0.31	1.2e-6	Monocyte percentage of white cells;
SARC	cis	rs2963155	0.518	rs33389	chr5:142700499	C/T	cg17617527	chr5:142782415	NR3C1	0.84	6.4	0.39	8.26e-10	Breast cancer;
SARC	cis	rs11997175	0.603	rs7464053	chr8:33786938	C/A	ch.8.33884649F	chr8:33765107	NA	0.43	5.54	0.34	8.07e-8	Body mass index;
SARC	cis	rs6088590	1.000	rs6119530	chr20:33403930	A/G	cg24642439	chr20:33292090	TP53INP2	0.86	12.29	0.63	4.4e-27	Coronary artery disease;
SARC	cis	rs453301	0.658	rs9650616	chr8:8869199	T/G	cg11995313	chr8:8860691	ERI1	0.47	5.85	0.36	1.69e-8	Joint mobility (Beighton score);
SARC	cis	rs7927771	0.524	rs4752865	chr11:47759841	G/A	cg20307385	chr11:47447363	PSMC3	-0.49	-6.63	-0.4	2.36e-10	Subjective well-being;
SARC	cis	rs35110281	0.774	rs141521	chr21:44963686	G/A	cg01579765	chr21:45077557	HSF2BP	-0.32	-5.38	-0.33	1.79e-7	Mean corpuscular volume;
SARC	cis	rs8114671	0.527	rs2253484	chr20:33405263	A/T	cg08999081	chr20:33150536	PIGU	-0.32	-4.71	-0.3	4.2e-6	Height;
SARC	cis	rs9473924	0.542	rs2857482	chr6:50790642	C/T	cg14470998	chr6:50812995	TFAP2B	0.66	5.55	0.34	7.86e-8	Body mass index;
SARC	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg04166393	chr7:2884313	GNA12	0.57	6.59	0.4	2.9e-10	Height;
SARC	trans	rs1814175	0.645	rs1721997	chr11:49916653	T/C	cg15704280	chr7:45808275	SEPT13	-0.88	-14.0	-0.68	1.02e-32	Height;
SARC	cis	rs4319547	0.656	rs4997380	chr12:122838956	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.54	-6.25	-0.38	1.93e-9	Body mass index;
SARC	cis	rs2013441	0.965	rs6587063	chr17:20193940	T/C	cg13482628	chr17:19912719	NA	-0.5	-6.47	-0.39	5.83e-10	Obesity-related traits;
SARC	cis	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg05623727	chr3:50126028	RBM5	0.33	4.94	0.31	1.46e-6	Intelligence (multi-trait analysis);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg26952205	chr17:42404036	NA	0.47	6.52	0.39	4.43e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs10791323	0.546	rs55801927	chr11:133713094	A/C	cg14349672	chr11:133703707	NA	-0.37	-5.42	-0.33	1.5e-7	Childhood ear infection;
SARC	cis	rs920590	0.758	rs7010174	chr8:19661930	G/C	cg17834443	chr8:19674713	INTS10	0.58	7.0	0.42	2.74e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs11574514	1.000	rs116886316	chr16:68286291	T/C	cg01866162	chr16:67596514	CTCF	1.12	6.52	0.39	4.27e-10	Crohn's disease;
SARC	cis	rs986417	1.000	rs6573313	chr14:60961299	A/G	cg27398547	chr14:60952738	C14orf39	1.02	9.17	0.51	2.58e-17	Gut microbiota (bacterial taxa);
SARC	cis	rs365132	1.000	rs2055619	chr5:176415964	A/G	cg16309518	chr5:176445507	NA	-0.47	-6.07	-0.37	5.09e-9	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs7714584	1.000	rs4958843	chr5:150224924	T/C	cg22134413	chr5:150180641	NA	0.78	6.56	0.39	3.42e-10	Crohn's disease;
SARC	cis	rs11731606	0.508	rs17376943	chr4:95277117	G/A	cg00507259	chr4:95128692	SMARCAD1	0.57	5.48	0.34	1.11e-7	Mean platelet volume;
SARC	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg02951883	chr7:2050386	MAD1L1	-0.47	-6.06	-0.37	5.51e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs11578119	0.933	rs35227427	chr1:170468472	G/A	cg09767346	chr1:170501363	GORAB	0.4	4.74	0.3	3.8e-6	Male-pattern baldness;
SARC	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg18402987	chr7:1209562	NA	0.54	5.29	0.33	2.88e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs36051895	0.603	rs10123980	chr9:5130363	T/C	cg02405213	chr9:5042618	JAK2	-0.45	-5.46	-0.34	1.19e-7	Pediatric autoimmune diseases;
SARC	cis	rs7208859	0.623	rs56325146	chr17:29151024	T/C	cg13385521	chr17:29058706	SUZ12P	0.9	8.01	0.46	5.57e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg21724239	chr8:58056113	NA	-0.56	-5.31	-0.33	2.58e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg13323047	chr6:7261517	NA	0.54	7.08	0.42	1.68e-11	Breast cancer;
SARC	cis	rs1008375	1.000	rs4235388	chr4:17682030	G/A	cg02297831	chr4:17616191	MED28	0.44	5.5	0.34	1.01e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg09404381	chr10:28869285	WAC	0.46	6.37	0.39	9.83e-10	Thyroid stimulating hormone;
SARC	cis	rs9916302	0.904	rs10491128	chr17:37551988	G/A	cg07936489	chr17:37558343	FBXL20	0.7	9.35	0.52	7.68e-18	Glomerular filtration rate (creatinine);
SARC	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg19680485	chr15:31195859	MTMR15	-0.58	-6.88	-0.41	5.42e-11	Huntington's disease progression;
SARC	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg13395646	chr4:1353034	KIAA1530	-0.4	-4.82	-0.3	2.61e-6	Longevity;
SARC	cis	rs13191362	1.000	rs66789102	chr6:163104432	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.76	6.61	0.4	2.6e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs6831352	0.918	rs7669636	chr4:100059312	G/A	cg13256891	chr4:100009986	ADH5	-0.64	-7.95	-0.46	8.13e-14	Alcohol dependence;
SARC	cis	rs6759839	0.698	rs11096574	chr2:16644988	A/C	cg09580478	chr2:16689509	NA	0.44	5.75	0.35	2.75e-8	Mean platelet volume;
SARC	cis	rs80130819	0.515	rs72644846	chr12:48508283	A/G	cg24011408	chr12:48396354	COL2A1	-0.47	-5.28	-0.33	2.92e-7	Prostate cancer;
SARC	cis	rs7772486	0.742	rs4896851	chr6:146278959	T/C	cg23711669	chr6:146136114	FBXO30	-0.73	-10.9	-0.58	1.3e-22	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs8013055	0.846	rs12717698	chr14:105979015	G/A	cg19700328	chr14:106028568	NA	-0.6	-8.33	-0.48	6.8e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
SARC	cis	rs1707322	1.000	rs785469	chr1:46521091	C/T	cg03146154	chr1:46216737	IPP	-0.48	-5.73	-0.35	3.14e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg04066115	chr4:140374523	RAB33B	-0.78	-8.35	-0.48	6.28e-15	Lung cancer in ever smokers;
SARC	trans	rs61931739	0.569	rs1872746	chr12:33985843	T/C	cg26384229	chr12:38710491	ALG10B	0.65	8.88	0.5	1.78e-16	Morning vs. evening chronotype;
SARC	cis	rs6545883	0.965	rs7591345	chr2:61729641	T/A	cg15711740	chr2:61764176	XPO1	-0.41	-5.12	-0.32	6.42e-7	Tuberculosis;
SARC	cis	rs7587476	0.822	rs6726763	chr2:215681580	T/G	cg04004882	chr2:215674386	BARD1	0.58	6.68	0.4	1.73e-10	Neuroblastoma;
SARC	cis	rs4930103	0.619	rs10769945	chr11:1985127	C/T	cg23202291	chr11:1979235	NA	0.38	4.78	0.3	3.13e-6	DNA methylation (parent-of-origin);DNA methylation (variation);
SARC	cis	rs13082711	0.911	rs923940	chr3:27459341	C/G	cg02860705	chr3:27208620	NA	0.44	5.65	0.35	4.57e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs10911232	0.507	rs10797817	chr1:182999136	G/T	cg13390022	chr1:182993471	LAMC1	0.33	4.97	0.31	1.31e-6	Hypertriglyceridemia;
SARC	cis	rs17376456	0.877	rs2085960	chr5:93399934	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.86	0.36	1.59e-8	Diabetic retinopathy;
SARC	cis	rs9303401	0.612	rs2526370	chr17:56487636	G/C	cg12560992	chr17:57184187	TRIM37	0.49	5.97	0.36	8.74e-9	Cognitive test performance;
SARC	cis	rs6540556	0.954	rs6696463	chr1:209933757	G/C	cg23920097	chr1:209922102	NA	-0.63	-7.33	-0.43	3.65e-12	Red blood cell count;
SARC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg10862848	chr6:42927986	GNMT	-0.45	-7.44	-0.44	1.93e-12	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs6570726	0.791	rs365869	chr6:145884751	C/T	cg05347473	chr6:146136440	FBXO30	0.54	7.51	0.44	1.24e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs228769	0.562	rs228779	chr17:42091213	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.48	-5.02	-0.31	1.03e-6	Bone mineral density (hip);Bone mineral density (spine);
SARC	cis	rs317689	0.918	rs581911	chr12:69738293	C/T	cg20891283	chr12:69753455	YEATS4	0.46	5.08	0.32	7.57e-7	Response to diuretic therapy;
SARC	cis	rs2370759	1.000	rs76998371	chr10:32631785	A/G	cg05361325	chr10:32636312	EPC1	-0.76	-6.75	-0.4	1.15e-10	Sexual dysfunction (female);
SARC	cis	rs2439831	0.867	rs3213990	chr15:43670226	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.76	7.92	0.46	9.46e-14	Lung cancer in ever smokers;
SARC	cis	rs2191566	0.761	rs446016	chr19:44501518	A/G	cg03039196	chr19:44506973	ZNF230	0.48	5.4	0.33	1.6e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs2273669	0.588	rs79465564	chr6:109350290	C/T	cg05315195	chr6:109294784	ARMC2	-0.64	-5.7	-0.35	3.68e-8	Prostate cancer;
SARC	cis	rs1008375	1.000	rs10939742	chr4:17659936	G/T	cg16339924	chr4:17578868	LAP3	0.66	8.83	0.5	2.61e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1018836	0.608	rs10094978	chr8:91509054	C/T	cg16814680	chr8:91681699	NA	-0.67	-9.65	-0.53	9.24e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs4819052	0.788	rs2236449	chr21:46702506	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.65	7.58	0.44	8.13e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs7824557	0.564	rs2572395	chr8:11235360	A/C	cg15556689	chr8:8085844	FLJ10661	-0.55	-6.99	-0.42	2.9e-11	Retinal vascular caliber;
SARC	cis	rs9290065	0.519	rs2376475	chr3:160708942	C/T	cg03342759	chr3:160939853	NMD3	-0.49	-6.02	-0.37	6.72e-9	Kawasaki disease;
SARC	cis	rs7760949	0.888	rs9296853	chr6:13893945	T/A	cg27413430	chr6:13925136	RNF182	0.41	4.95	0.31	1.44e-6	Mean corpuscular hemoglobin concentration;
SARC	trans	rs561341	0.710	rs9900031	chr17:30199537	T/C	cg20587970	chr11:113659929	NA	0.88	8.12	0.47	2.79e-14	Hip circumference adjusted for BMI;
SARC	cis	rs2075371	0.835	rs1646724	chr7:134001875	T/G	cg11752832	chr7:134001865	SLC35B4	0.66	8.62	0.49	1.02e-15	Mean platelet volume;
SARC	cis	rs5750830	0.594	rs6001568	chr22:39775786	G/A	cg05872129	chr22:39784769	NA	-0.43	-6.13	-0.37	3.68e-9	Intelligence (multi-trait analysis);
SARC	cis	rs10791323	0.569	rs11533204	chr11:133743644	A/G	cg15485101	chr11:133734466	NA	0.32	5.14	0.32	5.92e-7	Childhood ear infection;
SARC	cis	rs778371	0.723	rs12619195	chr2:233678326	G/A	cg20388707	chr2:233749442	NGEF	0.33	4.76	0.3	3.46e-6	Schizophrenia;
SARC	cis	rs2439831	0.850	rs28707214	chr15:44131623	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	7.59	0.45	7.57e-13	Lung cancer in ever smokers;
SARC	cis	rs2832191	0.740	rs2853830	chr21:30416824	A/G	cg24692254	chr21:30365293	RNF160	1.01	16.93	0.74	1.79e-42	Dental caries;
SARC	cis	rs15676	0.783	rs10988134	chr9:131595407	C/T	cg00228799	chr9:131580591	ENDOG	-0.59	-7.19	-0.43	8.54e-12	Blood metabolite levels;
SARC	cis	rs57221529	0.766	rs28563961	chr5:554498	C/G	cg07777115	chr5:623756	CEP72	-0.55	-4.76	-0.3	3.42e-6	Lung disease severity in cystic fibrosis;
SARC	trans	rs62103177	0.759	rs7227794	chr18:77610925	C/T	cg05926928	chr17:57297772	GDPD1	1.03	9.83	0.54	2.61e-19	Opioid sensitivity;
SARC	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg16006841	chr5:176797999	RGS14	0.65	8.32	0.48	7.47e-15	Urinary electrolytes (magnesium/calcium ratio);
SARC	trans	rs9329221	0.510	rs6995837	chr8:9975675	T/C	cg06636001	chr8:8085503	FLJ10661	0.53	7.11	0.42	1.44e-11	Neuroticism;
SARC	cis	rs7551222	0.681	rs2926533	chr1:204480742	T/A	cg20240347	chr1:204465584	NA	0.31	5.17	0.32	4.97e-7	Schizophrenia;
SARC	cis	rs17209837	1.000	rs45607141	chr7:87087025	A/G	cg00919237	chr7:87102261	ABCB4	-0.5	-5.47	-0.34	1.14e-7	Gallbladder cancer;
SARC	cis	rs10992471	0.756	rs7027595	chr9:95131553	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.55	-6.69	-0.4	1.67e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg22004693	chr7:99632812	ZKSCAN1	0.54	5.53	0.34	8.46e-8	Lung function (FEV1/FVC);
SARC	cis	rs73635312	0.850	rs76718063	chr10:8934780	G/T	cg24467326	chr10:9646929	NA	0.76	5.97	0.36	8.74e-9	Basal cell carcinoma;
SARC	cis	rs734999	0.588	rs2260976	chr1:2527678	A/G	cg20673091	chr1:2541236	MMEL1	-0.33	-5.13	-0.32	5.98e-7	Ulcerative colitis;
SARC	cis	rs9807989	0.524	rs2110662	chr2:103020139	A/T	cg03938978	chr2:103052716	IL18RAP	0.31	4.91	0.31	1.72e-6	Asthma;
SARC	cis	rs477692	0.569	rs7087541	chr10:131309979	A/C	cg05714579	chr10:131428358	MGMT	0.56	7.69	0.45	4.14e-13	Response to temozolomide;
SARC	cis	rs926938	0.618	rs360624	chr1:115409476	A/C	cg12756093	chr1:115239321	AMPD1	0.38	4.89	0.3	1.9e-6	Autism;
SARC	cis	rs6772849	0.896	rs35535737	chr3:128383406	G/A	cg08795948	chr3:128337044	NA	0.53	7.37	0.43	3.04e-12	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs8014204	0.743	rs35809608	chr14:75254762	A/G	cg17347104	chr14:75034677	LTBP2	-0.43	-5.33	-0.33	2.33e-7	Caffeine consumption;
SARC	cis	rs8072100	0.701	rs6503807	chr17:45772932	T/C	cg08085267	chr17:45401833	C17orf57	-0.44	-5.15	-0.32	5.55e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs11098499	0.863	rs3775849	chr4:120450908	G/C	cg24375607	chr4:120327624	NA	0.42	4.9	0.31	1.76e-6	Corneal astigmatism;
SARC	cis	rs10897473	0.554	rs7115071	chr11:63851633	G/T	cg04317338	chr11:64019027	PLCB3	0.4	4.76	0.3	3.38e-6	Immature fraction of reticulocytes;
SARC	cis	rs4481887	1.000	rs10736378	chr1:248455769	T/G	cg00666640	chr1:248458726	OR2T12	0.35	5.72	0.35	3.2e-8	Common traits (Other);
SARC	cis	rs981844	1.000	rs2606327	chr4:154653629	C/T	cg14289246	chr4:154710475	SFRP2	0.51	5.91	0.36	1.22e-8	Response to statins (LDL cholesterol change);
SARC	cis	rs11785400	0.793	rs4736366	chr8:143742413	C/T	cg10596483	chr8:143751796	JRK	0.56	7.05	0.42	2.06e-11	Schizophrenia;
SARC	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg15966229	chr18:44337664	ST8SIA5	-0.37	-4.81	-0.3	2.68e-6	Personality dimensions;
SARC	cis	rs11690935	1.000	rs35549875	chr2:172532392	A/G	cg13550731	chr2:172543902	DYNC1I2	1.01	15.03	0.7	3.72e-36	Schizophrenia;
SARC	cis	rs7762018	1.000	rs6923339	chr6:170128033	T/A	cg00262263	chr6:170184901	NA	0.39	4.75	0.3	3.51e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg07636037	chr3:49044803	WDR6	0.81	7.47	0.44	1.64e-12	Menarche (age at onset);
SARC	cis	rs8114671	0.562	rs6060064	chr20:33406339	C/G	cg07148914	chr20:33460835	GGT7	-0.41	-5.2	-0.32	4.42e-7	Height;
SARC	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg16405210	chr4:1374714	KIAA1530	-0.51	-6.17	-0.37	3.05e-9	Obesity-related traits;
SARC	cis	rs2439831	0.867	rs4075674	chr15:43650230	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.05	11.01	0.58	5.67e-23	Lung cancer in ever smokers;
SARC	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	11.82	0.61	1.42e-25	Chronic sinus infection;
SARC	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg08280861	chr8:58055591	NA	0.6	5.83	0.36	1.8e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs826838	0.809	rs11169666	chr12:39211300	T/C	cg26384229	chr12:38710491	ALG10B	0.87	12.37	0.63	2.35e-27	Heart rate;
SARC	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg05368731	chr17:41323189	NBR1	0.8	9.65	0.53	9.38e-19	Menopause (age at onset);
SARC	cis	rs56011263	0.687	rs4690187	chr4:703813	C/T	cg17689763	chr4:710664	PCGF3	-0.66	-9.2	-0.52	2.08e-17	White blood cell count;
SARC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg09373136	chr17:61933544	TCAM1	-0.42	-5.61	-0.34	5.86e-8	Prudent dietary pattern;
SARC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.55	-7.08	-0.42	1.66e-11	Lymphocyte counts;
SARC	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg03517284	chr6:25882590	NA	-0.34	-4.74	-0.3	3.74e-6	Blood metabolite levels;
SARC	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg10295955	chr4:187884368	NA	1.03	17.14	0.75	3.67e-43	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs793571	0.590	rs17190727	chr15:59073790	C/A	cg05156742	chr15:59063176	FAM63B	0.76	10.61	0.57	1.06e-21	Schizophrenia;
SARC	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg18876405	chr7:65276391	NA	-0.41	-4.77	-0.3	3.31e-6	Aortic root size;
SARC	cis	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg02574844	chr11:5959923	NA	-0.42	-5.2	-0.32	4.46e-7	DNA methylation (variation);
SARC	cis	rs72687362	0.581	rs12544947	chr8:143345477	A/T	cg10761372	chr8:143398763	TSNARE1	-0.38	-5.0	-0.31	1.14e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	9.01	0.51	7.55e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs17384381	1.000	rs79695640	chr1:85836073	T/C	cg16011679	chr1:85725395	C1orf52	0.67	6.02	0.37	6.59e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9486719	0.895	rs12190520	chr6:96928620	A/C	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.01	-0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	trans	rs61931739	0.963	rs12310956	chr12:33970682	A/G	cg26384229	chr12:38710491	ALG10B	-0.52	-6.3	-0.38	1.43e-9	Morning vs. evening chronotype;
SARC	trans	rs17685	0.712	rs7785025	chr7:75628101	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.59	-7.27	-0.43	5.28e-12	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs11722228	1.000	rs6825187	chr4:9915325	T/C	cg25986240	chr4:9926439	SLC2A9	0.31	5.14	0.32	5.89e-7	Gout;Urate levels;Serum uric acid levels;
SARC	trans	rs34421088	0.560	rs2248325	chr8:11396874	A/G	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.5	-0.39	4.96e-10	Neuroticism;
SARC	cis	rs193541	0.632	rs2910135	chr5:122229790	C/T	cg19412675	chr5:122181750	SNX24	0.48	6.16	0.37	3.09e-9	Glucose homeostasis traits;
SARC	cis	rs7918232	1.000	rs6482595	chr10:27380261	A/G	cg14442939	chr10:27389572	ANKRD26	-0.63	-6.53	-0.39	4.05e-10	Breast cancer;
SARC	cis	rs4319547	1.000	rs9705654	chr12:123083508	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.6	-7.2	-0.43	8.23e-12	Body mass index;
SARC	cis	rs2710642	0.777	rs2539987	chr2:63142864	A/G	cg17519650	chr2:63277830	OTX1	0.43	5.52	0.34	8.85e-8	LDL cholesterol levels;LDL cholesterol;
SARC	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg05313129	chr8:58192883	C8orf71	-0.51	-4.79	-0.3	2.93e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs933688	0.536	rs332537	chr5:90794973	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.67	-5.89	-0.36	1.35e-8	Smoking behavior;
SARC	trans	rs2727020	0.638	rs1164668	chr11:49330627	A/C	cg15704280	chr7:45808275	SEPT13	0.83	13.5	0.66	4.69e-31	Coronary artery disease;
SARC	cis	rs2180341	1.000	rs2144742	chr6:127595786	C/A	cg27446573	chr6:127587934	RNF146	1.01	14.18	0.68	2.45e-33	Breast cancer;
SARC	cis	rs2075064	0.500	rs34341106	chr9:126815471	T/C	cg14112217	chr9:126806003	NA	0.33	4.95	0.31	1.43e-6	Waist circumference;
SARC	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg26335602	chr6:28129616	ZNF389	-0.55	-6.14	-0.37	3.57e-9	Parkinson's disease;
SARC	cis	rs317689	0.513	rs317659	chr12:69686132	T/A	cg22834771	chr12:69754056	YEATS4	-0.49	-6.23	-0.38	2.12e-9	Response to diuretic therapy;
SARC	cis	rs10197940	0.624	rs6731486	chr2:152410732	C/T	cg19508488	chr2:152266495	RIF1	-0.53	-6.22	-0.38	2.26e-9	Lung cancer;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg21568731	chr6:80714280	TTK	-0.94	-8.12	-0.47	2.69e-14	Autism spectrum disorder or schizophrenia;
SARC	trans	rs34421088	0.560	rs1478898	chr8:11395079	G/A	cg08975724	chr8:8085496	FLJ10661	-0.48	-6.31	-0.38	1.38e-9	Neuroticism;
SARC	cis	rs6456156	0.586	rs2017338	chr6:167471714	G/A	cg07741184	chr6:167504864	NA	0.36	7.09	0.42	1.62e-11	Primary biliary cholangitis;
SARC	cis	rs9818758	0.556	rs13086240	chr3:49001409	G/A	cg01304814	chr3:48885189	PRKAR2A	0.62	5.12	0.32	6.46e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg05896524	chr21:47604654	C21orf56	0.41	4.85	0.3	2.29e-6	Testicular germ cell tumor;
SARC	cis	rs9611565	0.506	rs7364221	chr22:41650190	C/A	cg03806693	chr22:41940476	POLR3H	-0.74	-9.82	-0.54	2.85e-19	Vitiligo;
SARC	cis	rs7582720	1.000	rs75869289	chr2:203806724	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs559928	0.606	rs56207008	chr11:63883215	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	5.26	0.33	3.29e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
SARC	cis	rs6424115	1.000	rs12031592	chr1:24127864	A/C	cg15997130	chr1:24165203	NA	0.52	7.08	0.42	1.69e-11	Immature fraction of reticulocytes;
SARC	cis	rs6456156	0.565	rs2181058	chr6:167465330	A/T	cg23791538	chr6:167370224	RNASET2	-0.52	-6.79	-0.41	9.49e-11	Primary biliary cholangitis;
SARC	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.58	-7.61	-0.45	6.65e-13	Mean platelet volume;
SARC	cis	rs1046896	0.553	rs1044661	chr17:80901020	G/A	cg03160526	chr17:80928410	B3GNTL1	0.35	4.83	0.3	2.51e-6	Glycated hemoglobin levels;
SARC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg25818813	chr2:112656629	MERTK	0.5	6.54	0.39	3.75e-10	Myopia (pathological);
SARC	cis	rs78366141	0.536	rs78517451	chr4:89650437	C/A	cg01026744	chr4:89619053	NAP1L5;HERC3	0.9	4.72	0.3	4.03e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
SARC	cis	rs2836950	0.805	rs2836961	chr21:40627020	A/C	cg11890956	chr21:40555474	PSMG1	-0.56	-6.93	-0.41	4.16e-11	Menarche (age at onset);
SARC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.75	-9.78	-0.54	3.88e-19	Prudent dietary pattern;
SARC	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg00101154	chr16:420108	MRPL28	-0.4	-6.13	-0.37	3.79e-9	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs7412746	0.658	rs11204739	chr1:150865760	A/G	cg10589385	chr1:150898437	SETDB1	0.42	5.64	0.35	4.91e-8	Melanoma;
SARC	cis	rs3741151	0.773	rs73542990	chr11:73134398	C/T	cg17517138	chr11:73019481	ARHGEF17	0.91	6.77	0.41	1.04e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs1865760	1.000	rs7770139	chr6:25925823	A/G	cg16482183	chr6:26056742	HIST1H1C	0.5	6.22	0.38	2.32e-9	Height;
SARC	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg18252515	chr7:66147081	NA	0.56	5.9	0.36	1.27e-8	Aortic root size;
SARC	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg22433210	chr17:43662623	NA	1.08	12.98	0.65	2.45e-29	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs1048238	0.506	rs848212	chr1:16263452	A/G	cg21385522	chr1:16154831	NA	-0.47	-5.72	-0.35	3.32e-8	Systolic blood pressure;
SARC	cis	rs9467711	0.651	rs67554133	chr6:25866232	T/A	cg21479132	chr6:26055353	NA	0.77	4.79	0.3	3.02e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg02951883	chr7:2050386	MAD1L1	-0.5	-6.47	-0.39	5.74e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg06618935	chr21:46677482	NA	0.38	5.12	0.32	6.46e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg11987759	chr7:65425863	GUSB	0.53	6.89	0.41	5.12e-11	Aortic root size;
SARC	cis	rs981844	0.712	rs4696507	chr4:154753702	G/A	cg14289246	chr4:154710475	SFRP2	-0.45	-5.36	-0.33	1.96e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg03033257	chr22:50311977	ALG12;CRELD2	0.59	5.67	0.35	4.29e-8	Schizophrenia;
SARC	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	5.45	0.34	1.26e-7	Bipolar disorder;
SARC	cis	rs477692	0.905	rs485579	chr10:131425492	T/G	cg05714579	chr10:131428358	MGMT	0.57	7.57	0.44	8.6e-13	Response to temozolomide;
SARC	cis	rs1355223	0.583	rs1828298	chr11:34870439	A/G	cg18508148	chr11:34937573	PDHX;APIP	0.49	6.36	0.38	1.08e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs13256369	0.950	rs1522839	chr8:8580453	C/T	cg17143192	chr8:8559678	CLDN23	0.47	5.29	0.33	2.85e-7	Obesity-related traits;
SARC	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.5	-5.35	-0.33	2.06e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs7044106	0.615	rs10818470	chr9:123359204	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.67	8.46	0.48	2.93e-15	Hip circumference adjusted for BMI;
SARC	cis	rs6120849	0.707	rs6088694	chr20:33652371	G/A	cg06115741	chr20:33292138	TP53INP2	0.56	5.28	0.33	2.9e-7	Protein C levels;
SARC	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg24642844	chr7:1081250	C7orf50	-0.6	-6.11	-0.37	4.06e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg11941060	chr3:133502564	NA	-0.4	-5.68	-0.35	3.91e-8	Iron status biomarkers;
SARC	cis	rs1059312	0.771	rs11059922	chr12:129290418	C/T	cg09035930	chr12:129282057	SLC15A4	0.56	7.99	0.46	6.12e-14	Systemic lupus erythematosus;
SARC	cis	rs2921073	0.510	rs2976945	chr8:8270871	G/T	cg15556689	chr8:8085844	FLJ10661	0.52	6.14	0.37	3.5e-9	Parkinson's disease;
SARC	cis	rs6988636	1.000	rs57165742	chr8:124184559	G/A	cg23067535	chr8:124195133	FAM83A	-0.65	-4.97	-0.31	1.29e-6	Urinary uromodulin levels;
SARC	cis	rs2120019	0.938	rs59094290	chr15:75308561	G/T	cg00629941	chr15:75287862	SCAMP5	-0.71	-8.19	-0.47	1.71e-14	Blood trace element (Zn levels);
SARC	cis	rs1580019	0.961	rs11768506	chr7:32494788	A/C	cg14728415	chr7:32535168	LSM5;AVL9	0.43	5.04	0.31	9.3e-7	Cognitive ability;
SARC	cis	rs782590	1.000	rs782594	chr2:55844445	T/C	cg18811423	chr2:55921094	PNPT1	0.68	10.55	0.57	1.65e-21	Metabolic syndrome;
SARC	cis	rs79149102	0.579	rs3812946	chr15:75288610	G/C	cg17294928	chr15:75287854	SCAMP5	-1.11	-8.85	-0.5	2.24e-16	Lung cancer;
SARC	cis	rs6693567	0.565	rs1313569	chr1:150344171	G/A	cg09579323	chr1:150459698	TARS2	0.46	5.86	0.36	1.55e-8	Migraine;
SARC	cis	rs11871801	0.517	rs34855406	chr17:40731411	G/C	cg24808754	chr17:40851514	CNTNAP1	0.36	4.84	0.3	2.4e-6	Crohn's disease;
SARC	trans	rs988958	0.883	rs7595778	chr2:42304150	G/C	cg02435573	chr1:94712239	NA	-0.51	-6.72	-0.4	1.4e-10	Hypospadias;
SARC	cis	rs16937	0.711	rs6675633	chr1:205100480	G/A	cg21643547	chr1:205240462	TMCC2	-0.45	-5.57	-0.34	7.17e-8	Schizophrenia;
SARC	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg22800045	chr5:56110881	MAP3K1	-0.66	-6.12	-0.37	3.96e-9	Initial pursuit acceleration;
SARC	cis	rs7937890	1.000	rs2970334	chr11:14329355	C/T	cg02886208	chr11:14281011	SPON1	0.38	5.24	0.32	3.52e-7	Mitochondrial DNA levels;
SARC	cis	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg11995313	chr8:8860691	ERI1	0.39	5.16	0.32	5.36e-7	Joint mobility (Beighton score);
SARC	cis	rs3093024	1.000	rs3093023	chr6:167534290	A/G	cg07741184	chr6:167504864	NA	-0.33	-6.24	-0.38	2e-9	Rheumatoid arthritis;
SARC	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg07701084	chr6:150067640	NUP43	0.39	5.14	0.32	5.83e-7	Lung cancer;
SARC	cis	rs4780401	0.728	rs8057398	chr16:11780629	G/T	cg01061890	chr16:11836724	TXNDC11	-0.48	-6.15	-0.37	3.3e-9	Rheumatoid arthritis;
SARC	cis	rs7833790	0.724	rs1054078	chr8:82712153	A/G	cg06027949	chr8:82754900	SNX16	-0.49	-6.14	-0.37	3.46e-9	Diastolic blood pressure;
SARC	cis	rs5769765	0.542	rs1033666	chr22:50252783	T/C	cg03033257	chr22:50311977	ALG12;CRELD2	-0.54	-4.75	-0.3	3.58e-6	Schizophrenia;
SARC	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg26513180	chr16:89883248	FANCA	0.89	16.31	0.73	2.1e-40	Vitiligo;
SARC	cis	rs7124681	0.584	rs4752792	chr11:47815702	G/A	cg10504702	chr11:47789108	FNBP4	-0.43	-5.62	-0.35	5.52e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
SARC	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg19077165	chr18:44547161	KATNAL2	-0.51	-6.97	-0.42	3.14e-11	Personality dimensions;
SARC	cis	rs7819412	0.811	rs2409691	chr8:10943276	C/T	cg21775007	chr8:11205619	TDH	-0.44	-5.83	-0.36	1.87e-8	Triglycerides;
SARC	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg03264133	chr6:25882463	NA	0.48	6.18	0.38	2.87e-9	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6991838	0.771	rs13282323	chr8:66472792	G/A	cg13398993	chr8:66546079	ARMC1	0.48	6.39	0.39	8.89e-10	Intelligence (multi-trait analysis);
SARC	cis	rs738322	0.719	rs34066050	chr22:38612604	G/A	cg25457927	chr22:38595422	NA	0.34	6.95	0.41	3.71e-11	Cutaneous nevi;
SARC	cis	rs2985684	0.841	rs12894785	chr14:50049755	G/C	cg04989706	chr14:50066350	PPIL5	-0.56	-6.24	-0.38	2.09e-9	Carotid intima media thickness;
SARC	cis	rs7833790	0.553	rs9693128	chr8:82706128	A/G	cg17211192	chr8:82754475	SNX16	-0.51	-6.59	-0.4	2.96e-10	Diastolic blood pressure;
SARC	cis	rs9790314	1.000	rs7653233	chr3:160992033	G/A	cg03342759	chr3:160939853	NMD3	-0.63	-8.03	-0.47	4.77e-14	Morning vs. evening chronotype;
SARC	cis	rs3126085	0.935	rs7550106	chr1:152197202	C/T	cg26876637	chr1:152193138	HRNR	-0.45	-5.32	-0.33	2.39e-7	Atopic dermatitis;
SARC	cis	rs2204008	0.715	rs3899385	chr12:38169880	C/G	cg26384229	chr12:38710491	ALG10B	0.89	13.09	0.65	1.03e-29	Bladder cancer;
SARC	cis	rs73206853	0.841	rs73206886	chr12:110851190	T/G	cg10860002	chr12:110842031	ANAPC7	0.63	5.08	0.32	7.81e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg05605921	chr1:225998232	EPHX1	0.63	6.65	0.4	2.04e-10	Lung cancer in ever smokers;
SARC	cis	rs828999	0.583	rs12047398	chr1:108693305	C/G	cg06207961	chr1:108661230	NA	0.37	5.08	0.32	7.81e-7	Monocyte percentage of white cells;
SARC	cis	rs4727027	0.933	rs28767030	chr7:148825918	T/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.47	5.7	0.35	3.52e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg12016809	chr21:47604291	C21orf56	-0.47	-5.63	-0.35	5.2e-8	Testicular germ cell tumor;
SARC	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg00990874	chr7:1149470	C7orf50	-0.55	-5.75	-0.35	2.78e-8	Bronchopulmonary dysplasia;
SARC	cis	rs9457247	0.508	rs6941355	chr6:167506238	A/G	cg07741184	chr6:167504864	NA	0.32	5.98	0.36	8.44e-9	Crohn's disease;
SARC	cis	rs2153535	0.560	rs9379214	chr6:8480870	T/C	cg23788917	chr6:8435910	SLC35B3	0.64	8.36	0.48	5.74e-15	Motion sickness;
SARC	cis	rs9527	0.614	rs2153774	chr10:104881035	T/C	cg04362960	chr10:104952993	NT5C2	0.43	4.94	0.31	1.47e-6	Arsenic metabolism;
SARC	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg15049968	chr18:44337910	ST8SIA5	0.36	5.74	0.35	2.92e-8	Personality dimensions;
SARC	cis	rs7312774	0.867	rs10492213	chr12:107295841	A/T	cg16260113	chr12:107380972	MTERFD3	-0.76	-6.5	-0.39	4.71e-10	Severe influenza A (H1N1) infection;
SARC	cis	rs9457247	0.663	rs9457257	chr6:167440736	G/A	cg23791538	chr6:167370224	RNASET2	-0.53	-7.06	-0.42	1.89e-11	Crohn's disease;
SARC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.51	6.5	0.39	4.93e-10	Lymphocyte counts;
SARC	cis	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg12591125	chr7:1885375	MAD1L1	0.48	5.0	0.31	1.12e-6	Bipolar disorder;
SARC	cis	rs11122272	0.705	rs2486731	chr1:231532511	C/T	cg06096015	chr1:231504339	EGLN1	-0.35	-5.27	-0.33	3.04e-7	Hemoglobin concentration;
SARC	cis	rs910316	0.763	rs1548807	chr14:75479582	T/G	cg11812906	chr14:75593930	NEK9	0.82	11.78	0.61	1.94e-25	Height;
SARC	cis	rs11711311	0.955	rs9830102	chr3:113408302	C/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	8.13	0.47	2.59e-14	IgG glycosylation;
SARC	cis	rs796364	0.901	rs4673762	chr2:201065171	C/G	cg05691004	chr2:201170426	SPATS2L	-0.44	-4.76	-0.3	3.35e-6	Schizophrenia;
SARC	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg12042659	chr19:58951599	ZNF132	-0.44	-5.85	-0.36	1.68e-8	Uric acid clearance;
SARC	cis	rs7712401	0.755	rs27740	chr5:122204772	A/T	cg19412675	chr5:122181750	SNX24	-0.41	-5.51	-0.34	9.38e-8	Mean platelet volume;
SARC	cis	rs854765	0.520	rs7219324	chr17:17909775	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.68	-9.41	-0.52	5.12e-18	Total body bone mineral density;
SARC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg06873352	chr17:61820015	STRADA	0.53	6.9	0.41	4.95e-11	Prudent dietary pattern;
SARC	cis	rs7666738	0.830	rs4699600	chr4:99019429	C/G	cg05340658	chr4:99064831	C4orf37	0.66	9.04	0.51	6.35e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2916247	1.000	rs2979856	chr8:92980145	A/T	cg10183463	chr8:93005414	RUNX1T1	0.61	5.93	0.36	1.1e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg11905131	chr22:24372483	LOC391322	-0.42	-4.84	-0.3	2.38e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs17376456	0.542	rs1453003	chr5:93151611	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.56	-5.8	-0.36	2.13e-8	Diabetic retinopathy;
SARC	cis	rs7647973	0.710	rs12637313	chr3:49645458	A/G	cg07636037	chr3:49044803	WDR6	0.76	6.92	0.41	4.44e-11	Menarche (age at onset);
SARC	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg02931644	chr1:25747376	RHCE	0.45	7.6	0.45	7.18e-13	Erythrocyte sedimentation rate;
SARC	cis	rs911555	0.713	rs10162425	chr14:103931621	C/T	cg24130564	chr14:104152367	KLC1	-0.5	-5.94	-0.36	1.01e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg10523679	chr1:76189770	ACADM	-0.5	-6.72	-0.4	1.36e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs10892173	0.566	rs10892175	chr11:117674355	G/A	cg07621104	chr11:117668040	DSCAML1	0.6	7.74	0.45	2.93e-13	Myopia;
SARC	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg22903657	chr4:1355424	KIAA1530	-0.36	-5.24	-0.32	3.65e-7	Longevity;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg17315873	chr14:83226240	NA	0.46	6.8	0.41	8.76e-11	Thyroid stimulating hormone;
SARC	cis	rs7766436	0.583	rs6938995	chr6:22556935	G/T	cg13666174	chr6:22585274	NA	-0.58	-5.94	-0.36	1.04e-8	Coronary artery disease;
SARC	cis	rs17376456	0.877	rs9314101	chr5:93461593	A/T	cg21475434	chr5:93447410	FAM172A	0.88	8.11	0.47	2.81e-14	Diabetic retinopathy;
SARC	cis	rs11719291	0.667	rs9877542	chr3:48748545	C/T	cg07636037	chr3:49044803	WDR6	-0.7	-6.73	-0.4	1.27e-10	Cognitive function;
SARC	cis	rs11676348	0.808	rs61700947	chr2:219046171	C/G	cg20019365	chr2:219134978	PNKD;AAMP	0.45	5.81	0.36	2.09e-8	Ulcerative colitis;
SARC	cis	rs4742903	0.935	rs9942894	chr9:106914905	A/G	cg14250997	chr9:106856677	SMC2	0.46	5.83	0.36	1.87e-8	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg03060546	chr3:49711283	APEH	0.45	5.78	0.35	2.44e-8	Parkinson's disease;
SARC	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg03452623	chr4:187889614	NA	-0.78	-11.72	-0.61	2.97e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.69	-8.79	-0.5	3.29e-16	Prudent dietary pattern;
SARC	cis	rs11122272	0.735	rs2474633	chr1:231486989	A/C	cg06096015	chr1:231504339	EGLN1	0.38	5.63	0.35	5.19e-8	Hemoglobin concentration;
SARC	cis	rs7793919	0.726	rs10261971	chr7:4776547	A/G	cg09789173	chr7:4769017	FOXK1	0.51	6.75	0.4	1.15e-10	Mosquito bite size;
SARC	cis	rs17030434	1.000	rs17030434	chr4:154703596	A/G	cg14289246	chr4:154710475	SFRP2	-0.83	-8.47	-0.49	2.77e-15	Electrocardiographic conduction measures;
SARC	cis	rs637571	0.544	rs617791	chr11:65702523	C/G	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.4	-4.84	-0.3	2.34e-6	Eosinophil percentage of white cells;
SARC	cis	rs733175	0.855	rs10023068	chr4:10004832	C/T	cg25986240	chr4:9926439	SLC2A9	0.3	4.72	0.3	3.99e-6	Psychosis and Alzheimer's disease;
SARC	cis	rs17030434	0.906	rs4145339	chr4:154710481	C/T	cg14289246	chr4:154710475	SFRP2	-0.81	-7.75	-0.45	2.91e-13	Electrocardiographic conduction measures;
SARC	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.72	8.69	0.49	6.62e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9486715	1.000	rs9373985	chr6:97063522	C/G	cg18709589	chr6:96969512	KIAA0776	-0.55	-6.75	-0.4	1.18e-10	Headache;
SARC	cis	rs2273669	0.667	rs12374597	chr6:109346184	A/G	cg05315195	chr6:109294784	ARMC2	-0.63	-5.7	-0.35	3.6e-8	Prostate cancer;
SARC	cis	rs2066819	1.000	rs773664	chr12:56702176	C/T	cg26734620	chr12:56694298	CS	-0.86	-6.37	-0.39	1.01e-9	Psoriasis vulgaris;
SARC	cis	rs6484504	0.512	rs7940020	chr11:31366453	T/G	cg02090638	chr11:31391270	DNAJC24;DCDC1	0.4	5.02	0.31	1.03e-6	Red blood cell count;
SARC	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg03060546	chr3:49711283	APEH	0.48	6.19	0.38	2.74e-9	Menarche (age at onset);
SARC	cis	rs7635838	0.785	rs2606735	chr3:11400714	A/C	cg00170343	chr3:11313890	ATG7	0.56	7.64	0.45	5.7e-13	HDL cholesterol;
SARC	cis	rs79149102	0.579	rs59303424	chr15:75370014	G/A	cg09165964	chr15:75287851	SCAMP5	-0.87	-8.2	-0.47	1.65e-14	Lung cancer;
SARC	cis	rs10870270	0.957	rs3829156	chr10:133789386	C/G	cg17892150	chr10:133769511	PPP2R2D	-0.78	-9.56	-0.53	1.81e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs9902453	0.584	rs3809790	chr17:27955540	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.46	-5.66	-0.35	4.41e-8	Coffee consumption (cups per day);
SARC	cis	rs12681288	0.676	rs2701910	chr8:1001246	G/T	cg15309053	chr8:964076	NA	0.44	7.23	0.43	7.03e-12	Schizophrenia;
SARC	cis	rs9487051	0.676	rs6929438	chr6:109595506	C/T	cg01475377	chr6:109611718	NA	-0.35	-5.12	-0.32	6.44e-7	Reticulocyte fraction of red cells;
SARC	cis	rs6594499	0.872	rs6594498	chr5:110458351	G/A	cg04022379	chr5:110408740	TSLP	0.47	6.06	0.37	5.3e-9	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs6582630	0.502	rs11520276	chr12:38359216	C/T	cg13010199	chr12:38710504	ALG10B	0.78	10.77	0.58	3.24e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs4690686	0.500	rs12498752	chr4:177265451	T/C	cg17059388	chr4:177262070	NA	0.36	4.78	0.3	3.09e-6	Essential tremor;
SARC	cis	rs11676348	0.967	rs4672873	chr2:219005210	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.47	-6.23	-0.38	2.15e-9	Ulcerative colitis;
SARC	cis	rs7553864	0.614	rs4559475	chr1:87614236	T/C	cg17420885	chr1:87600446	LOC339524	-0.35	-4.95	-0.31	1.45e-6	Smoking behavior;
SARC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg21782813	chr7:2030301	MAD1L1	0.43	6.66	0.4	1.95e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs12478296	1.000	rs73007129	chr2:243000555	T/C	cg18898632	chr2:242989856	NA	-0.63	-4.86	-0.3	2.15e-6	Obesity-related traits;
SARC	cis	rs9790314	0.586	rs35713426	chr3:161131271	A/G	cg03342759	chr3:160939853	NMD3	-0.57	-7.19	-0.43	8.96e-12	Morning vs. evening chronotype;
SARC	cis	rs526231	0.511	rs73179850	chr5:102348577	T/A	cg23492399	chr5:102201601	PAM	-0.49	-5.47	-0.34	1.14e-7	Primary biliary cholangitis;
SARC	cis	rs6582630	0.519	rs11181998	chr12:38439970	C/A	cg26384229	chr12:38710491	ALG10B	0.84	12.04	0.62	2.79e-26	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs921968	0.613	rs556497	chr2:219446477	G/A	cg02176678	chr2:219576539	TTLL4	0.35	5.34	0.33	2.2e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs17376456	0.757	rs6859757	chr5:93206042	C/T	cg25358565	chr5:93447407	FAM172A	1.22	12.21	0.62	7.87e-27	Diabetic retinopathy;
SARC	cis	rs892961	0.932	rs9916143	chr17:75409282	C/G	cg05865280	chr17:75406074	SEPT9	-0.55	-8.42	-0.48	3.93e-15	Airflow obstruction;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg22707130	chr10:17659395	PTPLA	0.49	6.44	0.39	6.94e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs10782582	0.593	rs4638068	chr1:76161663	G/A	cg10523679	chr1:76189770	ACADM	-0.42	-5.18	-0.32	4.75e-7	Daytime sleep phenotypes;
SARC	cis	rs7296418	0.816	rs1790096	chr12:123710364	C/T	cg00376283	chr12:123451042	ABCB9	0.61	7.56	0.44	9.45e-13	Platelet count;
SARC	cis	rs3820928	0.874	rs10169717	chr2:227796911	T/G	cg11843606	chr2:227700838	RHBDD1	-0.56	-7.12	-0.42	1.33e-11	Pulmonary function;
SARC	cis	rs2197308	0.667	rs11181073	chr12:37898543	A/G	cg13010199	chr12:38710504	ALG10B	0.77	10.27	0.56	1.16e-20	Morning vs. evening chronotype;
SARC	cis	rs2658782	0.724	rs2658770	chr11:93261886	A/G	cg15737290	chr11:93063684	CCDC67	0.72	8.14	0.47	2.39e-14	Pulmonary function decline;
SARC	cis	rs12478296	0.818	rs57194240	chr2:243011545	A/G	cg06360820	chr2:242988706	NA	-0.61	-5.68	-0.35	4.04e-8	Obesity-related traits;
SARC	cis	rs41307935	0.722	rs12724052	chr1:27234682	G/A	cg12203394	chr1:27248618	NUDC	0.55	4.8	0.3	2.87e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg06028808	chr11:68637592	NA	0.44	5.64	0.35	5.01e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs3126085	0.935	rs877776	chr1:152178018	C/G	cg09127314	chr1:152161683	NA	0.43	5.16	0.32	5.34e-7	Atopic dermatitis;
SARC	cis	rs4713118	0.629	rs149899	chr6:28019979	C/T	cg16479474	chr6:28041457	NA	0.36	5.07	0.31	8.29e-7	Parkinson's disease;
SARC	cis	rs2235642	0.891	rs2281231	chr16:1601879	A/G	cg09065629	chr16:1709722	CRAMP1L	0.34	4.91	0.31	1.71e-6	Coronary artery disease;
SARC	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg16680214	chr1:154839983	KCNN3	-0.35	-5.38	-0.33	1.78e-7	Prostate cancer;
SARC	cis	rs11785400	1.000	rs7459630	chr8:143738585	A/C	cg24634471	chr8:143751801	JRK	0.65	8.62	0.49	1.02e-15	Schizophrenia;
SARC	cis	rs208515	0.525	rs10455593	chr6:66691341	C/T	cg07460842	chr6:66804631	NA	0.96	11.03	0.59	4.77e-23	Exhaled nitric oxide levels;
SARC	cis	rs11098499	0.657	rs7664458	chr4:120371967	A/G	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	trans	rs3942852	0.568	rs1039484	chr11:48097948	A/G	cg15704280	chr7:45808275	SEPT13	-0.66	-8.7	-0.5	6.08e-16	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs11098499	0.863	rs12502389	chr4:120454191	A/G	cg09307838	chr4:120376055	NA	0.91	12.31	0.63	3.63e-27	Corneal astigmatism;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg23811837	chr6:10694962	C6orf52;PAK1IP1	-0.6	-7.09	-0.42	1.58e-11	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs1707322	1.000	rs4460583	chr1:46449918	C/G	cg03146154	chr1:46216737	IPP	0.45	5.41	0.33	1.57e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg16479474	chr6:28041457	NA	0.34	4.8	0.3	2.86e-6	Parkinson's disease;
SARC	cis	rs6545883	0.929	rs6707830	chr2:61749472	G/A	cg15711740	chr2:61764176	XPO1	-0.43	-5.38	-0.33	1.8e-7	Tuberculosis;
SARC	cis	rs6693567	0.565	rs698917	chr1:150319884	G/A	cg09579323	chr1:150459698	TARS2	0.44	5.5	0.34	1.01e-7	Migraine;
SARC	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-14.89	-0.7	1.1e-35	Chronic sinus infection;
SARC	cis	rs17826219	0.706	rs73271850	chr17:29142140	A/G	cg13385521	chr17:29058706	SUZ12P	0.9	7.58	0.44	7.91e-13	Body mass index;
SARC	cis	rs709400	0.930	rs57447494	chr14:104034569	G/A	cg26031613	chr14:104095156	KLC1	1.03	20.38	0.8	1.06e-53	Body mass index;
SARC	cis	rs2380220	1.000	rs9400318	chr6:95972381	T/A	cg07718321	chr6:96025334	MANEA	0.5	5.14	0.32	5.74e-7	Behavioural disinhibition (generation interaction);
SARC	cis	rs986417	0.636	rs8020587	chr14:60952612	A/G	cg27398547	chr14:60952738	C14orf39	1.03	9.89	0.54	1.74e-19	Gut microbiota (bacterial taxa);
SARC	cis	rs898097	0.585	rs9892342	chr17:80893029	C/T	cg15664640	chr17:80829946	TBCD	0.34	5.29	0.33	2.86e-7	Breast cancer;
SARC	cis	rs7178572	0.568	rs10152181	chr15:77678346	A/G	cg22256960	chr15:77711686	NA	-0.51	-5.59	-0.34	6.36e-8	Type 2 diabetes;
SARC	cis	rs9948	0.655	rs62152771	chr2:97447121	C/G	cg15007626	chr2:97405879	LMAN2L	0.73	4.86	0.3	2.14e-6	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs2115630	1.000	rs8037423	chr15:85355494	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.49	-5.88	-0.36	1.41e-8	P wave terminal force;
SARC	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg18404041	chr3:52824283	ITIH1	-0.43	-6.53	-0.39	4.04e-10	Bipolar disorder;
SARC	cis	rs709400	0.628	rs1989565	chr14:103862193	G/A	cg12935359	chr14:103987150	CKB	0.39	5.75	0.35	2.8e-8	Body mass index;
SARC	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg24209194	chr3:40518798	ZNF619	-0.64	-8.06	-0.47	4.1e-14	Renal cell carcinoma;
SARC	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg14343924	chr8:8086146	FLJ10661	0.41	4.91	0.31	1.72e-6	Systolic blood pressure;
SARC	trans	rs61931739	0.635	rs1486883	chr12:33908740	C/T	cg13010199	chr12:38710504	ALG10B	0.51	6.45	0.39	6.22e-10	Morning vs. evening chronotype;
SARC	cis	rs2760061	0.626	rs2527614	chr1:228126470	A/G	cg02753203	chr1:228287806	NA	-0.56	-7.63	-0.45	5.85e-13	Diastolic blood pressure;
SARC	trans	rs11098499	0.863	rs11736416	chr4:120431661	C/T	cg25214090	chr10:38739885	LOC399744	0.58	7.35	0.43	3.33e-12	Corneal astigmatism;
SARC	cis	rs709400	0.604	rs7158144	chr14:103887615	A/G	cg26031613	chr14:104095156	KLC1	0.81	11.42	0.6	2.88e-24	Body mass index;
SARC	cis	rs950776	0.518	rs12906951	chr15:78825562	C/T	cg22563815	chr15:78856949	CHRNA5	0.41	6.82	0.41	7.56e-11	Sudden cardiac arrest;
SARC	cis	rs11608355	0.545	rs33997929	chr12:109912064	C/T	cg05360138	chr12:110035743	NA	0.93	9.74	0.54	4.9e-19	Neuroticism;
SARC	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg14456004	chr13:21872349	NA	1.12	16.91	0.74	2.18e-42	White matter hyperintensity burden;
SARC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg26338869	chr17:61819248	STRADA	-0.8	-10.66	-0.57	7.29e-22	Prudent dietary pattern;
SARC	cis	rs8180040	0.783	rs11710121	chr3:47351501	T/G	cg27129171	chr3:47204927	SETD2	-0.66	-8.51	-0.49	2.16e-15	Colorectal cancer;
SARC	cis	rs2204008	0.837	rs11612125	chr12:38213212	C/T	cg26384229	chr12:38710491	ALG10B	0.88	12.94	0.65	3.26e-29	Bladder cancer;
SARC	trans	rs2637266	1.000	rs2637266	chr10:78331318	C/T	cg26480675	chr16:66461075	BEAN	0.48	6.35	0.38	1.14e-9	Pulmonary function;
SARC	cis	rs7647973	1.000	rs3905330	chr3:49550774	A/G	cg06212747	chr3:49208901	KLHDC8B	0.58	6.17	0.37	2.98e-9	Menarche (age at onset);
SARC	cis	rs208520	0.690	rs207096	chr6:66797287	T/C	cg07460842	chr6:66804631	NA	-1.08	-14.98	-0.7	5.37e-36	Exhaled nitric oxide output;
SARC	cis	rs11608355	0.545	rs1073779	chr12:109894721	C/T	cg05360138	chr12:110035743	NA	0.92	9.61	0.53	1.27e-18	Neuroticism;
SARC	cis	rs7666738	0.830	rs17027216	chr4:99009152	G/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs12142240	0.698	rs79490411	chr1:46813568	G/A	cg10495392	chr1:46806563	NSUN4	0.67	6.89	0.41	5.17e-11	Menopause (age at onset);
SARC	cis	rs7769051	0.522	rs7762248	chr6:133105303	A/C	cg07930552	chr6:133119739	C6orf192	0.89	5.28	0.33	2.91e-7	Type 2 diabetes nephropathy;
SARC	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.43	5.31	0.33	2.6e-7	Intelligence (multi-trait analysis);
SARC	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg21747090	chr2:27597821	SNX17	-0.54	-7.72	-0.45	3.44e-13	Total body bone mineral density;
SARC	cis	rs71403859	0.502	rs35394108	chr16:71540639	T/C	cg08717414	chr16:71523259	ZNF19	-0.45	-4.72	-0.3	4e-6	Post bronchodilator FEV1;
SARC	cis	rs6964587	0.610	rs6465338	chr7:91450624	T/C	cg17063962	chr7:91808500	NA	0.69	9.83	0.54	2.67e-19	Breast cancer;
SARC	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg00149659	chr3:10157352	C3orf10	0.69	6.9	0.41	4.76e-11	Alzheimer's disease;
SARC	cis	rs4319547	0.620	rs12372756	chr12:122815130	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.6	-7.03	-0.42	2.27e-11	Body mass index;
SARC	trans	rs10085978	0.604	rs11167128	chr8:143225883	A/G	cg09404256	chr19:35759233	USF2	0.48	6.33	0.38	1.25e-9	Mosquito bite size;
SARC	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg04166393	chr7:2884313	GNA12	0.56	6.47	0.39	5.74e-10	Height;
SARC	cis	rs362296	0.661	rs3095078	chr4:3265479	C/T	cg06533319	chr4:3265114	C4orf44	0.34	5.58	0.34	6.73e-8	Parental longevity (mother's age at death);
SARC	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg19346786	chr7:2764209	NA	-0.35	-4.97	-0.31	1.3e-6	Height;
SARC	cis	rs4443100	0.916	rs2330335	chr22:23382362	G/A	cg14186256	chr22:23484241	RTDR1	0.49	5.16	0.32	5.21e-7	Serum parathyroid hormone levels;
SARC	cis	rs7568458	0.837	rs3731827	chr2:85806068	T/C	cg17127132	chr2:85788382	GGCX	0.43	5.77	0.35	2.54e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6831352	0.918	rs17817958	chr4:100061245	A/C	cg13256891	chr4:100009986	ADH5	0.7	7.96	0.46	7.32e-14	Alcohol dependence;
SARC	cis	rs16854884	0.657	rs35788195	chr3:143739311	C/T	cg06585982	chr3:143692056	C3orf58	0.63	8.44	0.48	3.36e-15	Economic and political preferences (feminism/equality);
SARC	cis	rs6429082	0.818	rs167092	chr1:235642359	A/G	cg26050004	chr1:235667680	B3GALNT2	0.67	8.33	0.48	7.13e-15	Adiposity;
SARC	cis	rs6496667	0.609	rs7183707	chr15:90883733	G/T	cg22089800	chr15:90895588	ZNF774	0.47	5.3	0.33	2.71e-7	Rheumatoid arthritis;
SARC	cis	rs6696846	0.715	rs61822659	chr1:205142847	G/A	cg21643547	chr1:205240462	TMCC2	-0.58	-7.37	-0.43	2.93e-12	Red blood cell count;
SARC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg12000995	chr2:27665139	KRTCAP3	-0.3	-4.77	-0.3	3.24e-6	Total body bone mineral density;
SARC	cis	rs9300255	0.739	rs4759371	chr12:123742563	T/C	cg00376283	chr12:123451042	ABCB9	0.49	5.53	0.34	8.36e-8	Neutrophil percentage of white cells;
SARC	cis	rs2834188	0.889	rs1467849	chr21:34682069	G/T	cg14352951	chr21:34696688	IFNAR1	0.45	5.54	0.34	7.98e-8	Narcolepsy;
SARC	cis	rs9611565	0.570	rs12159188	chr22:42121125	A/T	cg03806693	chr22:41940476	POLR3H	0.75	10.34	0.56	7.44e-21	Vitiligo;
SARC	cis	rs1878931	0.624	rs1149492	chr16:3445239	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.7	-7.82	-0.46	1.83e-13	Body mass index (adult);
SARC	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-4.93	-0.31	1.58e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs17826219	0.636	rs2449770	chr17:29101064	G/T	cg13385521	chr17:29058706	SUZ12P	0.84	7.05	0.42	2e-11	Body mass index;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg00287711	chr11:85338379	TMEM126B;DLG2	0.49	6.36	0.38	1.05e-9	Electrocardiographic conduction measures;
SARC	cis	rs870825	0.655	rs7683556	chr4:185632019	T/A	cg04058563	chr4:185651563	MLF1IP	0.82	11.08	0.59	3.31e-23	Blood protein levels;
SARC	cis	rs9473924	0.542	rs9463650	chr6:50822081	C/T	cg14470998	chr6:50812995	TFAP2B	0.73	6.63	0.4	2.26e-10	Body mass index;
SARC	cis	rs11249608	0.548	rs6867208	chr5:178455575	G/A	cg21905437	chr5:178450457	ZNF879	0.59	8.22	0.47	1.45e-14	Pubertal anthropometrics;
SARC	cis	rs372883	0.509	rs1999322	chr21:30533959	A/T	cg24692254	chr21:30365293	RNF160	0.4	4.95	0.31	1.41e-6	Pancreatic cancer;
SARC	cis	rs1707322	0.964	rs6675259	chr1:46502295	G/A	cg06784218	chr1:46089804	CCDC17	-0.37	-6.56	-0.39	3.52e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2075371	0.863	rs12707139	chr7:133954153	A/G	cg20476274	chr7:133979776	SLC35B4	0.57	7.41	0.44	2.28e-12	Mean platelet volume;
SARC	cis	rs874628	0.851	rs55973594	chr19:18330668	A/G	cg13670957	chr19:18329801	PDE4C	0.5	5.78	0.35	2.34e-8	Multiple sclerosis;
SARC	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg19774624	chr17:42201019	HDAC5	0.8	11.6	0.6	7.63e-25	Total body bone mineral density;
SARC	cis	rs3020736	0.500	rs6002604	chr22:42493081	A/T	cg15557168	chr22:42548783	NA	0.35	4.8	0.3	2.85e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1691799	0.867	rs1168348	chr12:66757168	G/A	cg16791601	chr12:66731901	HELB	-0.72	-10.83	-0.58	2.06e-22	White blood cell count (basophil);
SARC	cis	rs2885056	0.800	rs8105074	chr19:10708692	A/G	cg04833646	chr19:10679720	CDKN2D	0.77	8.54	0.49	1.71e-15	Red cell distribution width;
SARC	cis	rs1564271	0.553	rs9334138	chr10:26978929	G/A	cg13837822	chr10:26931731	LOC731789	0.4	5.88	0.36	1.39e-8	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
SARC	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg06618935	chr21:46677482	NA	-0.41	-5.37	-0.33	1.92e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg01475735	chr3:40494733	NA	0.46	5.2	0.32	4.46e-7	Renal cell carcinoma;
SARC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg26668828	chr6:292823	DUSP22	-0.6	-7.82	-0.46	1.78e-13	Menopause (age at onset);
SARC	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg23758822	chr17:41437982	NA	0.86	10.56	0.57	1.52e-21	Menopause (age at onset);
SARC	trans	rs9329221	0.905	rs4433149	chr8:10249268	A/T	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.66	-0.4	1.99e-10	Neuroticism;
SARC	cis	rs7223966	1.000	rs11871767	chr17:61698723	A/G	cg00588841	chr17:61851480	DDX42;CCDC47	-0.65	-7.29	-0.43	4.86e-12	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg25703541	chr22:24373054	LOC391322	-0.84	-12.22	-0.62	7.23e-27	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg11764359	chr7:65958608	NA	-0.78	-9.41	-0.52	4.93e-18	Aortic root size;
SARC	cis	rs933688	1.000	rs12654787	chr5:90713259	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.03	13.23	0.65	3.53e-30	Smoking behavior;
SARC	cis	rs9398803	0.865	rs9401882	chr6:126755055	A/G	cg20229609	chr6:126660872	C6orf173	0.4	5.85	0.36	1.67e-8	Male-pattern baldness;
SARC	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg00149659	chr3:10157352	C3orf10	0.68	6.38	0.39	9.46e-10	Alzheimer's disease;
SARC	cis	rs76419734	0.850	rs72671810	chr4:106613753	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.81	4.9	0.31	1.76e-6	Post bronchodilator FEV1;
SARC	cis	rs3796352	1.000	rs75217232	chr3:53132373	A/C	cg27565382	chr3:53032988	SFMBT1	0.79	5.56	0.34	7.32e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg08045932	chr20:61659980	NA	0.49	6.67	0.4	1.84e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs2933343	0.729	rs6790091	chr3:128608751	G/C	cg25356066	chr3:128598488	ACAD9	0.73	9.65	0.53	9.44e-19	IgG glycosylation;
SARC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg15242686	chr22:24348715	GSTTP1	0.4	4.87	0.3	2.08e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs367943	0.644	rs348942	chr5:112824039	T/C	cg12552261	chr5:112820674	MCC	-0.45	-5.1	-0.32	7.19e-7	Type 2 diabetes;
SARC	cis	rs3859192	0.537	rs12309	chr17:38175462	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.4	7.35	0.43	3.33e-12	White blood cell count;
SARC	cis	rs6570726	0.935	rs408723	chr6:145838535	A/G	cg05347473	chr6:146136440	FBXO30	0.48	6.42	0.39	7.51e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11098499	0.954	rs4309825	chr4:120314881	C/T	cg09160332	chr4:120329925	NA	0.36	5.0	0.31	1.12e-6	Corneal astigmatism;
SARC	cis	rs11718455	0.960	rs11921995	chr3:44017301	C/A	cg08738300	chr3:44038990	NA	0.53	5.75	0.35	2.77e-8	Coronary artery disease;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg23944480	chr2:120734864	PTPN4	0.52	7.29	0.43	4.66e-12	Thyroid stimulating hormone;
SARC	cis	rs8180040	0.690	rs7640397	chr3:46989828	C/T	cg27129171	chr3:47204927	SETD2	0.65	8.94	0.51	1.2e-16	Colorectal cancer;
SARC	cis	rs7520050	0.966	rs10890361	chr1:46346234	A/T	cg24296786	chr1:45957014	TESK2	0.4	5.17	0.32	4.93e-7	Red blood cell count;Reticulocyte count;
SARC	cis	rs4975616	0.804	rs457130	chr5:1336178	A/T	cg06550200	chr5:1325588	CLPTM1L	-0.5	-7.09	-0.42	1.57e-11	Lung cancer;
SARC	cis	rs7647973	0.593	rs55997059	chr3:49858661	A/T	cg03060546	chr3:49711283	APEH	-0.64	-6.75	-0.4	1.2e-10	Menarche (age at onset);
SARC	cis	rs3796352	1.000	rs11707780	chr3:53084326	A/G	cg27565382	chr3:53032988	SFMBT1	-0.71	-5.79	-0.35	2.27e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs7520050	0.743	rs61789988	chr1:46085242	G/C	cg06784218	chr1:46089804	CCDC17	-0.28	-5.15	-0.32	5.44e-7	Red blood cell count;Reticulocyte count;
SARC	cis	rs6732160	0.588	rs62151795	chr2:73376840	G/A	cg01422370	chr2:73384389	NA	0.38	5.69	0.35	3.79e-8	Intelligence (multi-trait analysis);
SARC	cis	rs1008375	1.000	rs10009541	chr4:17682218	C/T	cg02297831	chr4:17616191	MED28	-0.45	-5.52	-0.34	9.16e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg19721680	chr1:244816665	PPPDE1	-0.78	-6.54	-0.39	3.89e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs13191362	0.507	rs2849525	chr6:163126652	A/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.48	-5.3	-0.33	2.66e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs4280164	0.551	rs3212260	chr14:24804088	A/T	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.55	-5.51	-0.34	9.63e-8	Parent of origin effect on language impairment (paternal);
SARC	cis	rs796364	0.951	rs1105964	chr2:201000776	T/A	cg23649088	chr2:200775458	C2orf69	-0.58	-5.78	-0.35	2.39e-8	Schizophrenia;
SARC	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg26335602	chr6:28129616	ZNF389	0.5	5.46	0.34	1.22e-7	Depression;
SARC	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.53	4.72	0.3	4.15e-6	Lung function (FEV1/FVC);
SARC	cis	rs9303401	0.659	rs62081315	chr17:56781468	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	12.31	0.63	3.57e-27	Cognitive test performance;
SARC	cis	rs523522	0.847	rs11065132	chr12:120908459	C/T	cg12219531	chr12:120966889	COQ5	0.81	10.4	0.56	4.74e-21	High light scatter reticulocyte count;
SARC	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg02592271	chr2:27665507	KRTCAP3	-0.41	-6.15	-0.37	3.34e-9	Total body bone mineral density;
SARC	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg22857025	chr5:266934	NA	-1.08	-11.87	-0.61	1.02e-25	Breast cancer;
SARC	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg06212747	chr3:49208901	KLHDC8B	0.66	8.8	0.5	3.19e-16	Parkinson's disease;
SARC	cis	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg15556689	chr8:8085844	FLJ10661	0.43	5.35	0.33	2.11e-7	Mood instability;
SARC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.79	9.97	0.55	9.68e-20	Prudent dietary pattern;
SARC	cis	rs1003719	0.708	rs8126491	chr21:38551219	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.25	-0.52	1.49e-17	Eye color traits;
SARC	cis	rs6540556	0.954	rs7548219	chr1:209936466	A/G	cg23920097	chr1:209922102	NA	-0.62	-6.92	-0.41	4.38e-11	Red blood cell count;
SARC	cis	rs9324022	0.929	rs9635184	chr14:101173056	C/T	cg18089426	chr14:101175970	NA	0.54	4.91	0.31	1.69e-6	Plateletcrit;
SARC	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.9	13.48	0.66	5.36e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs12956009	0.583	rs4331415	chr18:44885048	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.58	7.49	0.44	1.44e-12	Educational attainment (years of education);
SARC	cis	rs2486288	0.656	rs7162022	chr15:45565253	C/T	cg15395560	chr15:45543142	SLC28A2	0.3	5.61	0.35	5.64e-8	Glomerular filtration rate;
SARC	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg04772025	chr11:68637568	NA	0.47	5.76	0.35	2.61e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs4648845	0.777	rs2477686	chr1:2392648	C/G	cg02275930	chr1:2372054	NA	-0.29	-5.66	-0.35	4.34e-8	Schizophrenia;
SARC	cis	rs11718455	0.960	rs6781618	chr3:44001933	C/T	cg21419209	chr3:44054225	NA	-0.42	-5.04	-0.31	9.45e-7	Coronary artery disease;
SARC	trans	rs61931739	0.500	rs7955247	chr12:34126580	G/A	cg26384229	chr12:38710491	ALG10B	0.87	12.58	0.64	4.75e-28	Morning vs. evening chronotype;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg01897796	chr15:59225903	SLTM	-0.89	-7.63	-0.45	6.05e-13	Autism spectrum disorder or schizophrenia;
SARC	cis	rs17854409	1.000	rs16983290	chr20:61478894	A/G	cg05147244	chr20:61493195	TCFL5	-0.93	-6.57	-0.4	3.19e-10	Obesity-related traits;
SARC	cis	rs739401	0.595	rs6578305	chr11:3001120	C/T	cg08508325	chr11:3079039	CARS	-0.32	-7.95	-0.46	8.12e-14	Longevity;
SARC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg26338869	chr17:61819248	STRADA	0.8	10.68	0.57	6.2e-22	Prudent dietary pattern;
SARC	cis	rs9290065	0.519	rs6441345	chr3:160696867	C/T	cg03342759	chr3:160939853	NMD3	-0.49	-6.13	-0.37	3.62e-9	Kawasaki disease;
SARC	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	-0.86	-10.17	-0.55	2.41e-20	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs504918	0.584	rs4420813	chr3:123990232	A/G	cg05766129	chr3:123988013	KALRN	-0.32	-5.3	-0.33	2.7e-7	Schizophrenia;
SARC	cis	rs9296095	0.796	rs3846855	chr6:33555877	G/A	cg14003231	chr6:33640908	ITPR3	0.44	6.73	0.4	1.27e-10	Platelet count;
SARC	cis	rs751728	0.664	rs4711349	chr6:33740592	C/T	cg15252951	chr6:33757062	LEMD2	0.42	5.01	0.31	1.09e-6	Crohn's disease;
SARC	cis	rs826838	0.967	rs1684414	chr12:39129553	A/G	cg26384229	chr12:38710491	ALG10B	-0.76	-11.59	-0.6	7.97e-25	Heart rate;
SARC	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg14298792	chr15:30685198	CHRFAM7A	-0.48	-5.48	-0.34	1.12e-7	Huntington's disease progression;
SARC	cis	rs12479064	0.694	rs11896520	chr2:99995517	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.52	-5.83	-0.36	1.82e-8	Chronic sinus infection;
SARC	cis	rs644799	0.965	rs502521	chr11:95533557	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.9	14.0	0.68	1.01e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs61931739	0.890	rs1705750	chr12:34142648	C/T	cg26384229	chr12:38710491	ALG10B	0.6	7.85	0.46	1.53e-13	Morning vs. evening chronotype;
SARC	cis	rs4919087	1.000	rs4919089	chr10:99087905	G/A	cg25902810	chr10:99078978	FRAT1	-0.46	-5.75	-0.35	2.72e-8	Monocyte count;
SARC	cis	rs709400	1.000	rs709400	chr14:104149475	A/G	cg12935359	chr14:103987150	CKB	-0.35	-5.18	-0.32	4.82e-7	Body mass index;
SARC	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg06873352	chr17:61820015	STRADA	-0.45	-5.73	-0.35	3.13e-8	Prudent dietary pattern;
SARC	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.55	-0.39	3.7e-10	Total body bone mineral density;
SARC	cis	rs1355223	0.902	rs1453380	chr11:34703682	C/G	cg18508148	chr11:34937573	PDHX;APIP	-0.36	-4.73	-0.3	3.92e-6	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs4689388	0.782	rs4262051	chr4:6281775	G/A	cg25554036	chr4:6271136	WFS1	0.42	6.51	0.39	4.69e-10	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs7647973	0.961	rs4955417	chr3:49298205	T/C	cg07636037	chr3:49044803	WDR6	0.79	9.28	0.52	1.19e-17	Menarche (age at onset);
SARC	cis	rs7914558	0.966	rs12569617	chr10:104729996	T/C	cg04362960	chr10:104952993	NT5C2	0.41	5.0	0.31	1.14e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs35213789	0.887	rs720056	chr7:69094079	A/G	cg10619644	chr7:69149951	AUTS2	-0.43	-5.77	-0.35	2.54e-8	Childhood ear infection;
SARC	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.38	-4.98	-0.31	1.21e-6	Intelligence (multi-trait analysis);
SARC	cis	rs208520	0.955	rs17644076	chr6:67004973	A/G	cg07460842	chr6:66804631	NA	-0.86	-9.68	-0.54	7.78e-19	Exhaled nitric oxide output;
SARC	cis	rs13082711	0.871	rs34209332	chr3:27434061	A/T	cg02860705	chr3:27208620	NA	0.47	6.19	0.38	2.7e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs4803468	0.934	rs8103531	chr19:41891974	C/T	cg09537434	chr19:41945824	ATP5SL	-0.95	-16.38	-0.73	1.18e-40	Height;
SARC	cis	rs2652834	0.898	rs10162675	chr15:63370358	T/C	cg05507819	chr15:63340323	TPM1	-0.58	-5.75	-0.35	2.72e-8	HDL cholesterol;
SARC	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg13271783	chr10:134563150	INPP5A	0.4	5.2	0.32	4.35e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs9858542	0.953	rs35169793	chr3:49423274	A/G	cg03060546	chr3:49711283	APEH	-0.57	-7.14	-0.42	1.19e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg11935053	chr6:118973021	C6orf204	-0.83	-7.11	-0.42	1.39e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs34375054	0.525	rs10846829	chr12:125595058	G/C	cg25124228	chr12:125621409	AACS	-0.63	-7.81	-0.46	1.95e-13	Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg11764359	chr7:65958608	NA	-0.79	-9.77	-0.54	4.17e-19	Aortic root size;
SARC	cis	rs710865	0.519	rs3748759	chr1:19487656	C/T	cg13387374	chr1:19411106	UBR4	-0.53	-7.41	-0.44	2.34e-12	Brain structure;
SARC	cis	rs9381040	0.748	rs9357348	chr6:41154232	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.39	-4.73	-0.3	3.91e-6	Alzheimer's disease (late onset);
SARC	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg22920501	chr2:26401640	FAM59B	-0.53	-6.56	-0.4	3.37e-10	Gut microbiome composition (summer);
SARC	cis	rs1008375	0.932	rs11938710	chr4:17670664	G/C	cg27347728	chr4:17578864	LAP3	-0.46	-5.65	-0.35	4.65e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7312933	0.558	rs4768402	chr12:42755576	A/G	cg19980929	chr12:42632907	YAF2	-0.45	-6.65	-0.4	2.08e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs13082711	0.911	rs2370995	chr3:27428216	C/T	cg02860705	chr3:27208620	NA	0.46	6.03	0.37	6.37e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg08219700	chr8:58056026	NA	0.6	5.71	0.35	3.49e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs17221829	0.733	rs11018668	chr11:89356178	C/T	cg22485059	chr12:12764594	CREBL2	-0.48	-6.5	-0.39	4.89e-10	Anxiety in major depressive disorder;
SARC	cis	rs807669	0.557	rs712958	chr22:19167409	T/C	cg02655711	chr22:19163373	SLC25A1	0.5	7.07	0.42	1.75e-11	Metabolite levels;
SARC	cis	rs72627123	0.867	rs3815331	chr14:74482948	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	5.51	0.34	9.28e-8	Morning vs. evening chronotype;
SARC	cis	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg15145296	chr3:125709740	NA	-0.5	-4.96	-0.31	1.36e-6	Blood pressure (smoking interaction);
SARC	cis	rs2153535	0.542	rs9505465	chr6:8510846	C/T	cg23788917	chr6:8435910	SLC35B3	0.64	8.3	0.48	8.65e-15	Motion sickness;
SARC	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg11764359	chr7:65958608	NA	-0.67	-7.97	-0.46	7.24e-14	Aortic root size;
SARC	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg18876405	chr7:65276391	NA	0.48	5.47	0.34	1.14e-7	Aortic root size;
SARC	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg03354898	chr7:1950403	MAD1L1	-0.36	-4.89	-0.3	1.9e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg20607798	chr8:58055168	NA	0.48	4.74	0.3	3.75e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg24531977	chr5:56204891	C5orf35	0.65	6.11	0.37	4.04e-9	Initial pursuit acceleration;
SARC	cis	rs6582630	0.555	rs7294313	chr12:38323603	G/A	cg14851346	chr12:38532713	NA	-0.44	-5.15	-0.32	5.55e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9920	0.585	rs75396674	chr7:116145937	T/A	cg24770985	chr7:116166421	CAV1	0.81	5.59	0.34	6.29e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Immature fraction of reticulocytes;QT interval;
SARC	cis	rs7927771	1.000	rs2290850	chr11:47807774	T/C	cg20307385	chr11:47447363	PSMC3	-0.48	-5.71	-0.35	3.46e-8	Subjective well-being;
SARC	cis	rs78456975	0.941	rs11886649	chr2:1567757	A/G	cg26248373	chr2:1572462	NA	-0.63	-6.69	-0.4	1.64e-10	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs73206853	0.841	rs55634798	chr12:110833748	G/T	cg10860002	chr12:110842031	ANAPC7	0.64	5.02	0.31	1.04e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.45	-5.07	-0.32	7.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs7247513	0.790	rs17476839	chr19:12762783	C/T	cg01871581	chr19:12707946	ZNF490	0.68	8.81	0.5	2.94e-16	Bipolar disorder;
SARC	cis	rs3796352	1.000	rs71301814	chr3:53117663	G/A	cg15956490	chr3:53032818	SFMBT1	0.9	5.96	0.36	9.12e-9	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs5753618	0.539	rs4820962	chr22:31689951	A/G	cg07713946	chr22:31675144	LIMK2	-0.37	-4.96	-0.31	1.37e-6	Colorectal cancer;
SARC	cis	rs838147	0.844	rs12611201	chr19:49248255	G/A	cg13540341	chr19:49222985	MAMSTR	0.28	4.73	0.3	3.83e-6	Dietary macronutrient intake;
SARC	cis	rs6484504	0.532	rs2150212	chr11:31255935	G/A	cg26647111	chr11:31128758	NA	-0.39	-5.1	-0.32	6.91e-7	Red blood cell count;
SARC	cis	rs6831352	0.918	rs2602891	chr4:100043284	C/T	cg12011299	chr4:100065546	ADH4	0.34	5.71	0.35	3.43e-8	Alcohol dependence;
SARC	cis	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg06636001	chr8:8085503	FLJ10661	-0.69	-9.43	-0.53	4.37e-18	Joint mobility (Beighton score);
SARC	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg25072359	chr17:41440525	NA	0.56	7.03	0.42	2.23e-11	Menopause (age at onset);
SARC	cis	rs9457247	0.967	rs2149084	chr6:167370988	G/C	cg23791538	chr6:167370224	RNASET2	0.63	8.61	0.49	1.13e-15	Crohn's disease;
SARC	cis	rs9393692	0.645	rs11756673	chr6:26323505	A/G	cg00631329	chr6:26305371	NA	-0.61	-7.88	-0.46	1.25e-13	Educational attainment;
SARC	cis	rs782590	0.837	rs782585	chr2:55922930	C/T	cg18811423	chr2:55921094	PNPT1	0.8	12.28	0.63	4.72e-27	Metabolic syndrome;
SARC	cis	rs9660992	0.626	rs61823972	chr1:205201325	A/C	cg21545522	chr1:205238299	TMCC2	0.38	5.26	0.33	3.32e-7	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs2742234	0.590	rs2505506	chr10:43645854	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.39	-5.03	-0.31	9.73e-7	Hirschsprung disease;
SARC	cis	rs8077889	0.917	rs4793038	chr17:41916761	A/T	cg26893861	chr17:41843967	DUSP3	0.82	10.18	0.55	2.28e-20	Triglycerides;
SARC	cis	rs2486288	0.656	rs12899058	chr15:45547324	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.45	-5.55	-0.34	7.66e-8	Glomerular filtration rate;
SARC	cis	rs2933343	0.621	rs789241	chr3:128585752	G/A	cg24203234	chr3:128598194	ACAD9	0.63	8.15	0.47	2.18e-14	IgG glycosylation;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg05572930	chr6:125404126	RNF217	0.47	6.6	0.4	2.7e-10	Thyroid stimulating hormone;
SARC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg07157834	chr1:205819609	PM20D1	0.71	11.21	0.59	1.34e-23	Menarche (age at onset);
SARC	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg19223190	chr17:80058835	NA	0.45	6.26	0.38	1.84e-9	Life satisfaction;
SARC	cis	rs3126085	0.800	rs55650366	chr1:152279920	A/G	cg03465714	chr1:152285911	FLG	0.48	5.59	0.34	6.32e-8	Atopic dermatitis;
SARC	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg08219700	chr8:58056026	NA	0.6	5.71	0.35	3.49e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg04267008	chr7:1944627	MAD1L1	-0.49	-5.35	-0.33	2.06e-7	Bipolar disorder and schizophrenia;
SARC	trans	rs629535	0.590	rs56200825	chr8:70123450	G/A	cg21567404	chr3:27674614	NA	-0.97	-10.7	-0.57	5.22e-22	Dupuytren's disease;
SARC	cis	rs9902453	0.704	rs2617874	chr17:28085172	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	7.15	0.42	1.12e-11	Coffee consumption (cups per day);
SARC	cis	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg13072238	chr3:49761600	GMPPB	0.43	5.57	0.34	6.87e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9354308	0.866	rs2802054	chr6:66544766	G/C	cg07460842	chr6:66804631	NA	0.48	5.48	0.34	1.12e-7	Metabolite levels;
SARC	cis	rs4253772	0.591	rs6007726	chr22:46650858	A/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.64	6.81	0.41	8.27e-11	LDL cholesterol;Cholesterol, total;
SARC	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.36	-4.86	-0.3	2.15e-6	Personality dimensions;
SARC	cis	rs2153535	0.541	rs9328471	chr6:8468842	T/C	cg23788917	chr6:8435910	SLC35B3	0.64	8.39	0.48	4.57e-15	Motion sickness;
SARC	cis	rs11122272	0.735	rs2011357	chr1:231480208	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-10.37	-0.56	5.72e-21	Hemoglobin concentration;
SARC	cis	rs6582630	0.638	rs11182428	chr12:38526387	T/C	cg13010199	chr12:38710504	ALG10B	-0.56	-6.97	-0.42	3.28e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs3106136	0.967	rs2129595	chr4:95224454	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.39	-6.05	-0.37	5.71e-9	Capecitabine sensitivity;
SARC	trans	rs10506458	1.000	rs12425932	chr12:63410497	C/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.71	-6.35	-0.38	1.12e-9	Hemostatic factors and hematological phenotypes;
SARC	trans	rs208520	0.690	rs1100981	chr6:66852052	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-13.87	-0.67	2.61e-32	Exhaled nitric oxide output;
SARC	cis	rs12479064	0.724	rs2309618	chr2:99974473	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.56	-6.46	-0.39	6.06e-10	Chronic sinus infection;
SARC	cis	rs9398803	0.687	rs9482757	chr6:126923877	A/C	cg20229609	chr6:126660872	C6orf173	0.35	5.07	0.31	8.26e-7	Male-pattern baldness;
SARC	cis	rs9486719	1.000	rs2472897	chr6:96870569	G/T	cg18709589	chr6:96969512	KIAA0776	0.54	5.34	0.33	2.19e-7	Migraine;Coronary artery disease;
SARC	trans	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg21659725	chr3:3221576	CRBN	0.56	6.55	0.39	3.57e-10	Resting heart rate;
SARC	cis	rs13191362	1.000	rs13210412	chr6:163019478	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.54	5.29	0.33	2.82e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2439831	0.702	rs28699233	chr15:44122866	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	7.51	0.44	1.22e-12	Lung cancer in ever smokers;
SARC	cis	rs763121	0.853	rs2072795	chr22:39064209	A/G	cg06022373	chr22:39101656	GTPBP1	-0.86	-10.76	-0.58	3.57e-22	Menopause (age at onset);
SARC	cis	rs892961	0.932	rs11650011	chr17:75412334	A/G	cg05865280	chr17:75406074	SEPT9	0.54	8.11	0.47	2.85e-14	Airflow obstruction;
SARC	cis	rs3820928	0.839	rs10197773	chr2:227824835	G/A	cg11843606	chr2:227700838	RHBDD1	-0.55	-6.87	-0.41	5.7e-11	Pulmonary function;
SARC	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	10.09	0.55	4.39e-20	Alzheimer's disease;
SARC	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg03709012	chr19:19516395	GATAD2A	0.94	14.51	0.69	1.97e-34	Tonsillectomy;
SARC	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	7.77	0.45	2.56e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs3741151	0.773	rs61345051	chr11:73112305	T/C	cg17517138	chr11:73019481	ARHGEF17	0.9	6.7	0.4	1.59e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg08048268	chr3:133502702	NA	0.45	6.1	0.37	4.27e-9	Iron status biomarkers;
SARC	cis	rs7264396	0.623	rs78949029	chr20:34384964	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.46	0.34	1.23e-7	Total cholesterol levels;
SARC	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg12463550	chr7:65579703	CRCP	0.47	5.16	0.32	5.3e-7	Aortic root size;
SARC	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg22484793	chr3:52261325	TLR9	0.29	4.76	0.3	3.34e-6	Bipolar disorder;
SARC	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg04166393	chr7:2884313	GNA12	0.65	7.83	0.46	1.71e-13	Height;
SARC	cis	rs918629	0.567	rs3777194	chr5:95245384	C/T	cg16656078	chr5:95278638	ELL2	-0.49	-6.45	-0.39	6.28e-10	IgG glycosylation;
SARC	cis	rs6088580	0.505	rs6142219	chr20:33256345	G/A	cg24642439	chr20:33292090	TP53INP2	-0.54	-6.65	-0.4	2.07e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs8084125	0.832	rs62105173	chr18:74947147	A/G	cg05528293	chr18:74961138	GALR1	0.5	5.58	0.34	6.66e-8	Obesity-related traits;
SARC	cis	rs3733585	0.699	rs6449178	chr4:9968684	A/G	cg11266682	chr4:10021025	SLC2A9	0.38	6.55	0.39	3.64e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs9388451	0.839	rs3757217	chr6:126069636	G/C	cg05901451	chr6:126070800	HEY2	-0.69	-9.57	-0.53	1.59e-18	Brugada syndrome;
SARC	trans	rs10829156	0.732	rs10828834	chr10:18812434	T/C	cg21448875	chr7:44104584	PGAM2	0.43	6.39	0.39	9.14e-10	Sudden cardiac arrest;
SARC	cis	rs981844	0.775	rs921884	chr4:154753059	G/A	cg14289246	chr4:154710475	SFRP2	-0.47	-5.49	-0.34	1.02e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs11764590	0.756	rs17132130	chr7:2108036	G/C	cg21782813	chr7:2030301	MAD1L1	-0.38	-5.39	-0.33	1.75e-7	Neuroticism;
SARC	cis	rs4713118	0.699	rs200978	chr6:27853168	C/G	cg17221315	chr6:27791827	HIST1H4J	0.52	5.15	0.32	5.54e-7	Parkinson's disease;
SARC	cis	rs9640161	0.711	rs3800781	chr7:150027324	T/A	cg17279839	chr7:150038598	RARRES2	0.5	6.97	0.42	3.17e-11	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg11965913	chr1:205819406	PM20D1	1.02	19.95	0.79	2.63e-52	Menarche (age at onset);
SARC	cis	rs2011503	1.000	rs8110250	chr19:19559989	G/A	cg03709012	chr19:19516395	GATAD2A	0.64	5.69	0.35	3.77e-8	Bipolar disorder;
SARC	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg12463550	chr7:65579703	CRCP	0.44	4.9	0.31	1.79e-6	Aortic root size;
SARC	cis	rs12479064	0.724	rs3792143	chr2:100057020	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.47	-5.33	-0.33	2.32e-7	Chronic sinus infection;
SARC	cis	rs55871839	0.559	rs4737526	chr8:59823372	A/G	cg07426533	chr8:59803705	TOX	0.47	5.4	0.33	1.63e-7	Pneumonia;
SARC	cis	rs1008375	0.932	rs6449317	chr4:17631253	T/C	cg16339924	chr4:17578868	LAP3	0.66	8.65	0.49	8.66e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs763121	0.853	rs2281020	chr22:39064406	A/G	cg06022373	chr22:39101656	GTPBP1	0.87	10.87	0.58	1.61e-22	Menopause (age at onset);
SARC	cis	rs16933812	0.510	rs7850976	chr9:36988851	C/T	cg14294708	chr9:37120828	ZCCHC7	0.41	4.78	0.3	3.17e-6	Obesity-related traits;
SARC	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg09359103	chr1:154839909	KCNN3	-0.48	-8.12	-0.47	2.73e-14	Prostate cancer;
SARC	cis	rs733592	0.929	rs4760678	chr12:48461581	T/C	cg05342945	chr12:48394962	COL2A1	0.39	4.76	0.3	3.47e-6	Plateletcrit;
SARC	cis	rs1843834	0.505	rs2140508	chr2:225355839	G/T	cg22455342	chr2:225449267	CUL3	0.64	7.97	0.46	6.98e-14	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs55883249	0.957	rs10495572	chr2:9734859	C/G	cg23886495	chr2:9695866	ADAM17	-0.67	-7.14	-0.42	1.17e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg06873352	chr17:61820015	STRADA	0.53	6.91	0.41	4.63e-11	Prudent dietary pattern;
SARC	cis	rs73086581	1.000	rs56141565	chr20:3998603	G/A	cg02187196	chr20:3869020	PANK2	0.58	5.4	0.33	1.68e-7	Response to antidepressants in depression;
SARC	cis	rs10927875	0.619	rs2013019	chr1:16129320	T/C	cg21385522	chr1:16154831	NA	-0.61	-8.17	-0.47	1.9e-14	Dilated cardiomyopathy;
SARC	cis	rs910316	0.967	rs10142770	chr14:75525449	G/A	cg08847533	chr14:75593920	NEK9	0.92	15.46	0.71	1.4e-37	Height;
SARC	cis	rs7223966	1.000	rs13380863	chr17:61780793	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.49	-4.97	-0.31	1.29e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg05896524	chr21:47604654	C21orf56	0.41	4.84	0.3	2.4e-6	Testicular germ cell tumor;
SARC	cis	rs9868809	0.505	rs35064573	chr3:48740280	C/A	cg00383909	chr3:49044727	WDR6	0.65	6.21	0.38	2.36e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg12538597	chr11:85906334	NA	-0.77	-6.51	-0.39	4.59e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1018836	0.923	rs7833025	chr8:91568470	G/C	cg16814680	chr8:91681699	NA	-0.82	-12.94	-0.65	3.26e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs2354432	0.556	rs11239964	chr1:146753902	G/C	cg25205988	chr1:146714368	CHD1L	-1.0	-7.56	-0.44	9.4e-13	Mitochondrial DNA levels;
SARC	cis	rs8180040	0.701	rs34103310	chr3:47073266	C/T	cg27129171	chr3:47204927	SETD2	0.66	9.23	0.52	1.66e-17	Colorectal cancer;
SARC	cis	rs80130819	0.748	rs2732474	chr12:48700817	A/T	cg05342945	chr12:48394962	COL2A1	-0.54	-5.9	-0.36	1.3e-8	Prostate cancer;
SARC	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg08219700	chr8:58056026	NA	0.62	6.53	0.39	4.08e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs921968	0.643	rs3932856	chr2:219320207	C/A	cg02176678	chr2:219576539	TTLL4	0.36	5.51	0.34	9.71e-8	Mean corpuscular hemoglobin concentration;
SARC	cis	rs9443189	0.570	rs661229	chr6:76293793	G/A	cg01950844	chr6:76311363	SENP6	0.85	7.74	0.45	3.02e-13	Prostate cancer;
SARC	cis	rs3857536	0.740	rs7763555	chr6:66889930	C/T	cg07460842	chr6:66804631	NA	-0.6	-7.16	-0.42	1.02e-11	Blood trace element (Cu levels);
SARC	cis	rs9790314	0.818	rs6797066	chr3:161008725	T/A	cg04691961	chr3:161091175	C3orf57	-0.65	-8.8	-0.5	3.1e-16	Morning vs. evening chronotype;
SARC	cis	rs992157	0.710	rs12694432	chr2:219082330	A/G	cg00012203	chr2:219082015	ARPC2	0.85	13.87	0.67	2.76e-32	Colorectal cancer;
SARC	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg15049968	chr18:44337910	ST8SIA5	-0.32	-5.04	-0.31	9.43e-7	Personality dimensions;
SARC	cis	rs9660992	0.710	rs4951184	chr1:205240659	A/T	cg07972983	chr1:205091412	RBBP5	0.54	6.83	0.41	7.44e-11	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs1707322	1.000	rs11211228	chr1:46399840	G/A	cg06784218	chr1:46089804	CCDC17	0.34	5.97	0.36	8.98e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7959452	0.868	rs10784774	chr12:69737879	C/T	cg14784868	chr12:69753453	YEATS4	-0.4	-5.11	-0.32	6.75e-7	Blood protein levels;
SARC	cis	rs193541	0.632	rs62377425	chr5:122332625	C/G	cg19412675	chr5:122181750	SNX24	-0.49	-6.27	-0.38	1.75e-9	Glucose homeostasis traits;
SARC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg05025164	chr4:1340916	KIAA1530	0.89	11.62	0.61	6.29e-25	Longevity;
SARC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg01171360	chr6:293285	DUSP22	-0.54	-6.93	-0.41	3.98e-11	Menopause (age at onset);
SARC	cis	rs4481887	0.927	rs4460676	chr1:248431781	G/A	cg01631408	chr1:248437212	OR2T33	-0.46	-5.7	-0.35	3.65e-8	Common traits (Other);
SARC	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg04944784	chr2:26401820	FAM59B	-0.48	-5.99	-0.37	7.95e-9	Gut microbiome composition (summer);
SARC	cis	rs4481887	0.893	rs1339992	chr1:248509182	G/A	cg00666640	chr1:248458726	OR2T12	0.33	5.67	0.35	4.17e-8	Common traits (Other);
SARC	cis	rs7223966	1.000	rs7216798	chr17:61740963	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.57	-6.67	-0.4	1.87e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7633857	0.512	rs7611005	chr3:160698549	A/T	cg04691961	chr3:161091175	C3orf57	-0.46	-5.88	-0.36	1.43e-8	Educational attainment (years of education);
SARC	cis	rs17376456	0.877	rs10059630	chr5:93459807	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	6.14	0.37	3.45e-9	Diabetic retinopathy;
SARC	cis	rs453301	0.658	rs3855900	chr8:8901921	A/G	cg11608241	chr8:8085544	FLJ10661	-0.44	-5.49	-0.34	1.07e-7	Joint mobility (Beighton score);
SARC	trans	rs7824557	0.564	rs2572386	chr8:11236975	A/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.75	-0.5	4.27e-16	Retinal vascular caliber;
SARC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.54	6.14	0.37	3.48e-9	Prudent dietary pattern;
SARC	cis	rs3733585	0.673	rs116046986	chr4:9957794	A/G	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.55	-0.34	7.65e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7726839	0.561	rs4957050	chr5:579066	A/C	cg07777115	chr5:623756	CEP72	-0.61	-5.53	-0.34	8.61e-8	Obesity-related traits;
SARC	cis	rs2204008	0.782	rs117824012	chr12:38215517	T/C	cg26384229	chr12:38710491	ALG10B	0.88	12.94	0.65	3.26e-29	Bladder cancer;
SARC	cis	rs7566780	0.549	rs13412159	chr2:16679208	T/A	cg09580478	chr2:16689509	NA	0.54	6.67	0.4	1.79e-10	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.63e-10	Life satisfaction;
SARC	cis	rs763121	0.962	rs138703	chr22:39132748	C/T	cg06022373	chr22:39101656	GTPBP1	0.71	8.89	0.5	1.69e-16	Menopause (age at onset);
SARC	cis	rs2239547	0.522	rs4519686	chr3:52997871	C/T	cg22484793	chr3:52261325	TLR9	0.35	4.96	0.31	1.36e-6	Schizophrenia;
SARC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg22105103	chr4:187893119	NA	-0.47	-5.9	-0.36	1.29e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6570726	0.935	rs385134	chr6:145851005	C/T	cg05347473	chr6:146136440	FBXO30	0.49	6.55	0.39	3.56e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6580649	0.941	rs11612970	chr12:48451009	T/C	cg24011408	chr12:48396354	COL2A1	-0.48	-5.31	-0.33	2.56e-7	Lung cancer;
SARC	cis	rs10752881	1.000	rs10797811	chr1:182984432	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.72	10.86	0.58	1.73e-22	Colorectal cancer;
SARC	cis	rs17376456	0.877	rs10061080	chr5:93420559	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.6	5.63	0.35	5.07e-8	Diabetic retinopathy;
SARC	cis	rs7819412	0.505	rs17782554	chr8:11022106	C/G	cg21775007	chr8:11205619	TDH	-0.46	-5.9	-0.36	1.25e-8	Triglycerides;
SARC	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg14773178	chr5:1868261	NA	0.37	5.77	0.35	2.51e-8	Cardiovascular disease risk factors;
SARC	cis	rs1008375	1.000	rs1860596	chr4:17660082	C/T	cg02297831	chr4:17616191	MED28	0.52	6.72	0.4	1.37e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg18876405	chr7:65276391	NA	0.69	9.05	0.51	5.93e-17	Calcium levels;
SARC	cis	rs7592578	0.771	rs75579212	chr2:191376575	C/T	cg10560079	chr2:191398806	TMEM194B	-0.78	-8.61	-0.49	1.09e-15	Diastolic blood pressure;
SARC	cis	rs11874712	0.527	rs7359798	chr18:43648999	A/C	cg26436583	chr18:43649176	PSTPIP2	0.43	5.6	0.34	5.88e-8	Migraine - clinic-based;
SARC	cis	rs7618915	0.773	rs10510760	chr3:52650348	G/A	cg22484793	chr3:52261325	TLR9	0.33	5.13	0.32	6.07e-7	Bipolar disorder;
SARC	cis	rs2718798	1	rs2718798	chr3:133492088	A/C	cg12373951	chr3:133503437	NA	0.31	4.78	0.3	3.07e-6	Ankle injury;
SARC	cis	rs1728785	1.000	rs1170445	chr16:68573064	G/T	cg02972257	chr16:68554789	NA	-0.44	-5.15	-0.32	5.43e-7	Ulcerative colitis;
SARC	cis	rs10927875	0.632	rs6699394	chr1:16145143	C/A	cg21385522	chr1:16154831	NA	-0.91	-13.06	-0.65	1.25e-29	Dilated cardiomyopathy;
SARC	cis	rs10504229	0.679	rs72649107	chr8:58030453	C/A	cg11062466	chr8:58055876	NA	0.53	5.25	0.33	3.36e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg26818010	chr10:134567672	INPP5A	-0.62	-6.49	-0.39	5.08e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs9303401	0.659	rs7224276	chr17:56897827	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.06	12.03	0.62	3.09e-26	Cognitive test performance;
SARC	cis	rs1153858	1.000	rs3759899	chr15:45655903	T/C	cg21132104	chr15:45694354	SPATA5L1	0.78	11.07	0.59	3.59e-23	Homoarginine levels;
SARC	cis	rs9291683	0.530	rs11723591	chr4:9985398	T/A	cg00071950	chr4:10020882	SLC2A9	0.42	6.69	0.4	1.6e-10	Bone mineral density;
SARC	cis	rs826838	1.000	rs826892	chr12:39100790	T/C	cg26384229	chr12:38710491	ALG10B	-0.77	-12.0	-0.62	3.9e-26	Heart rate;
SARC	cis	rs11756659	0.653	rs199738	chr6:25963456	A/G	cg00631329	chr6:26305371	NA	-0.47	-5.06	-0.31	8.63e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;Red cell distribution width;
SARC	cis	rs7786808	0.741	rs11769149	chr7:158227127	A/G	cg01191920	chr7:158217561	PTPRN2	0.41	7.66	0.45	4.87e-13	Obesity-related traits;
SARC	cis	rs9467711	0.591	rs34525648	chr6:25914853	G/A	cg21479132	chr6:26055353	NA	0.75	4.75	0.3	3.62e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9394841	0.692	rs9381097	chr6:41847800	A/G	cg08135965	chr6:41755394	TOMM6	-0.6	-6.31	-0.38	1.4e-9	Mean corpuscular hemoglobin;Red cell distribution width;
SARC	cis	rs2857078	0.654	rs4793083	chr17:42312973	C/T	cg13607699	chr17:42295918	UBTF	-0.83	-12.88	-0.64	4.97e-29	Red cell distribution width;Reticulocyte count;
SARC	cis	rs208520	0.874	rs208517	chr6:66947040	G/T	cg07460842	chr6:66804631	NA	-0.92	-10.86	-0.58	1.66e-22	Exhaled nitric oxide output;
SARC	cis	rs655720	1	rs655720	chr3:136103267	C/T	cg15507776	chr3:136538369	TMEM22	0.47	5.22	0.32	3.96e-7	Coronary artery disease;
SARC	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg11764359	chr7:65958608	NA	-0.7	-8.06	-0.47	3.94e-14	Aortic root size;
SARC	cis	rs7927592	0.913	rs66752716	chr11:68273626	C/T	cg01657329	chr11:68192670	LRP5	-0.41	-5.01	-0.31	1.08e-6	Total body bone mineral density;
SARC	trans	rs3780486	0.846	rs7864705	chr9:33140352	A/C	cg04842962	chr6:43655489	MRPS18A	1.09	20.57	0.8	2.6e-54	IgG glycosylation;
SARC	cis	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg06636001	chr8:8085503	FLJ10661	0.61	8.25	0.48	1.18e-14	Mood instability;
SARC	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg06618935	chr21:46677482	NA	-0.39	-5.14	-0.32	5.72e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1059312	0.545	rs7312683	chr12:129280105	T/C	cg09035930	chr12:129282057	SLC15A4	0.5	5.99	0.37	7.93e-9	Systemic lupus erythematosus;
SARC	cis	rs4803468	1.000	rs11880539	chr19:41918949	A/C	cg14132834	chr19:41945861	ATP5SL	0.54	7.3	0.43	4.58e-12	Height;
SARC	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg01174269	chr3:195385542	SDHAP2	0.51	6.24	0.38	2e-9	Myopia (pathological);
SARC	cis	rs796364	0.951	rs11897245	chr2:201063644	A/G	cg05691004	chr2:201170426	SPATS2L	-0.44	-4.99	-0.31	1.2e-6	Schizophrenia;
SARC	trans	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg22413388	chr22:46367617	WNT7B	-0.68	-6.58	-0.4	3.03e-10	Cutaneous psoriasis;
SARC	cis	rs3741404	0.609	rs641430	chr11:63869531	C/T	cg04317338	chr11:64019027	PLCB3	-0.47	-5.44	-0.34	1.38e-7	Platelet count;
SARC	cis	rs2197308	0.692	rs1904964	chr12:37933241	T/A	cg26384229	chr12:38710491	ALG10B	0.89	13.36	0.66	1.32e-30	Morning vs. evening chronotype;
SARC	cis	rs7208859	0.623	rs3752020	chr17:29111125	T/G	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs2976388	0.609	rs2585152	chr8:143786214	A/T	cg06565975	chr8:143823917	SLURP1	0.32	5.68	0.35	3.91e-8	Urinary tract infection frequency;
SARC	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg13770153	chr20:60521292	NA	-0.44	-6.06	-0.37	5.56e-9	Body mass index;
SARC	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.41	-6.76	-0.4	1.1e-10	Total body bone mineral density;
SARC	cis	rs9326248	0.954	rs4938349	chr11:117021923	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.57	6.22	0.38	2.34e-9	Blood protein levels;
SARC	cis	rs4588572	0.643	rs1159929	chr5:77768820	A/G	cg11547950	chr5:77652471	NA	0.41	5.05	0.31	9.08e-7	Triglycerides;
SARC	cis	rs11581859	0.587	rs55962916	chr1:99187784	C/T	cg20286094	chr1:99190917	SNX7	-0.42	-4.99	-0.31	1.2e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs6121246	0.559	rs6060932	chr20:30350545	A/G	cg13852791	chr20:30311386	BCL2L1	0.88	11.01	0.58	5.71e-23	Mean corpuscular hemoglobin;
SARC	cis	rs3820928	0.874	rs4461255	chr2:227846524	C/T	cg11843606	chr2:227700838	RHBDD1	0.56	6.82	0.41	7.77e-11	Pulmonary function;
SARC	cis	rs2712184	0.935	rs2712169	chr2:217671349	G/A	cg05032264	chr2:217675019	NA	-0.62	-8.45	-0.48	3.12e-15	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
SARC	cis	rs7717697	0.797	rs10058141	chr5:82741694	C/T	cg19814134	chr5:82768288	VCAN	0.44	5.03	0.31	9.94e-7	Vertical cup-disc ratio;
SARC	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg11952622	chr19:58962976	ZNF324B	0.54	7.05	0.42	1.97e-11	Uric acid clearance;
SARC	cis	rs1865760	0.865	rs9467652	chr6:25959127	A/G	cg16482183	chr6:26056742	HIST1H1C	0.52	6.68	0.4	1.69e-10	Height;
SARC	trans	rs904095	0.583	rs1693435	chr4:100246711	G/T	cg01588345	chr2:120023921	NA	0.44	6.24	0.38	2.03e-9	Alcohol dependence;
SARC	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.59e-6	Depression;
SARC	cis	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg08564027	chr20:61660810	NA	0.76	11.8	0.61	1.69e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs9815354	0.812	rs73071212	chr3:41981856	C/A	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg11644478	chr21:40555479	PSMG1	1.03	14.36	0.69	6.38e-34	Cognitive function;
SARC	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg05863683	chr7:1912471	MAD1L1	0.34	4.86	0.3	2.16e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs4646312	0.555	rs2020917	chr22:19928884	C/T	cg07194846	chr22:19930177	COMT;TXNRD2	0.52	6.8	0.41	8.56e-11	Schizophrenia;
SARC	cis	rs9581857	0.685	rs9319372	chr13:28042796	C/T	cg01674679	chr13:27998804	GTF3A	0.69	5.11	0.32	6.74e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	cis	rs910316	0.967	rs2010678	chr14:75567178	C/T	cg11812906	chr14:75593930	NEK9	0.89	14.1	0.68	4.63e-33	Height;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg26737766	chr1:24127303	GALE	0.53	6.78	0.41	9.8e-11	Breast cancer;
SARC	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg16482183	chr6:26056742	HIST1H1C	0.41	4.77	0.3	3.21e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9787249	0.957	rs10888958	chr1:40211737	T/C	cg19912559	chr1:40204330	PPIE	0.4	4.77	0.3	3.26e-6	Blood protein levels;
SARC	cis	rs6714710	0.603	rs1875699	chr2:98580724	G/T	cg26665480	chr2:98280029	ACTR1B	0.5	6.77	0.41	1.04e-10	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg03351412	chr1:154909251	PMVK	-0.58	-7.31	-0.43	4.3e-12	Prostate cancer;
SARC	cis	rs11718455	0.960	rs13082990	chr3:44005172	T/C	cg21419209	chr3:44054225	NA	-0.41	-4.95	-0.31	1.41e-6	Coronary artery disease;
SARC	cis	rs4423214	0.840	rs1540127	chr11:71179038	G/A	cg05163923	chr11:71159392	DHCR7	-0.61	-7.39	-0.44	2.64e-12	Vitamin D levels;
SARC	cis	rs11718455	1.000	rs9854785	chr3:44031295	A/G	cg08738300	chr3:44038990	NA	0.51	5.66	0.35	4.49e-8	Coronary artery disease;
SARC	cis	rs6752107	0.935	rs11688431	chr2:234147175	T/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.46	6.24	0.38	2.08e-9	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs2953145	0.545	rs2975755	chr2:241524919	G/A	cg07929629	chr2:241523174	NA	0.36	4.78	0.3	3.17e-6	Bipolar disorder;
SARC	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.54	0.34	8.14e-8	Bipolar disorder;
SARC	cis	rs17381785	0.531	rs34479500	chr4:14939389	G/A	cg18497811	chr4:14860861	NA	0.47	4.91	0.31	1.68e-6	Urate levels in overweight individuals;
SARC	cis	rs11697848	1.000	rs56327845	chr20:48532306	C/T	cg17849948	chr20:48532315	SPATA2	0.87	5.2	0.32	4.3e-7	Systemic lupus erythematosus;
SARC	cis	rs796364	0.951	rs281776	chr2:200834282	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.79	7.39	0.44	2.55e-12	Schizophrenia;
SARC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg14893161	chr1:205819251	PM20D1	0.94	16.56	0.74	3.11e-41	Menarche (age at onset);
SARC	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.53	4.88	0.3	1.93e-6	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs67311347	0.955	rs4974068	chr3:40376929	T/C	cg09455208	chr3:40491958	NA	0.4	6.24	0.38	2.01e-9	Renal cell carcinoma;
SARC	cis	rs7123876	0.830	rs59311588	chr11:72435996	A/G	cg03713592	chr11:72463424	ARAP1	0.69	7.74	0.45	3.06e-13	Body mass index;
SARC	cis	rs7179456	0.654	rs12905056	chr15:59249956	G/C	cg05156742	chr15:59063176	FAM63B	0.57	7.31	0.43	4.31e-12	Asperger disorder;
SARC	cis	rs3858526	0.959	rs11039540	chr11:5928334	C/T	cg13902645	chr11:5959945	NA	-0.45	-5.23	-0.32	3.7e-7	DNA methylation (variation);
SARC	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg24633833	chr3:10029261	TMEM111	0.52	5.25	0.33	3.43e-7	Alzheimer's disease;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg15971836	chr2:55647419	CCDC88A	-0.48	-6.31	-0.38	1.42e-9	Schizophrenia;
SARC	cis	rs193541	0.632	rs154503	chr5:122204499	G/A	cg19412675	chr5:122181750	SNX24	0.51	6.71	0.4	1.47e-10	Glucose homeostasis traits;
SARC	cis	rs796364	0.906	rs281789	chr2:200780698	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.73	6.8	0.41	8.64e-11	Schizophrenia;
SARC	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg09165964	chr15:75287851	SCAMP5	0.58	7.86	0.46	1.38e-13	Breast cancer;
SARC	cis	rs12997796	0.556	rs35594332	chr2:86982651	G/A	cg25203885	chr2:87302643	LOC285074	-0.6	-5.11	-0.32	6.7e-7	Schizophrenia;
SARC	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg22968622	chr17:43663579	NA	-0.87	-11.07	-0.59	3.65e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9303401	0.573	rs34717648	chr17:56886624	T/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.06	12.01	0.62	3.46e-26	Cognitive test performance;
SARC	cis	rs12824058	0.831	rs7310433	chr12:130809289	C/T	cg24838063	chr12:130822603	PIWIL1	0.63	8.94	0.51	1.25e-16	Menopause (age at onset);
SARC	cis	rs7246657	0.943	rs10405407	chr19:37839164	C/T	cg14683738	chr19:37701593	ZNF585B	0.51	4.99	0.31	1.16e-6	Coronary artery calcification;
SARC	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg21724239	chr8:58056113	NA	0.63	6.1	0.37	4.33e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg21782813	chr7:2030301	MAD1L1	0.31	4.8	0.3	2.87e-6	Schizophrenia;
SARC	cis	rs568617	0.953	rs645900	chr11:65648135	G/A	cg26695010	chr11:65641043	EFEMP2	0.5	5.78	0.35	2.36e-8	Crohn's disease;
SARC	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg08280861	chr8:58055591	NA	0.6	5.28	0.33	2.92e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg06437703	chr8:37914619	EIF4EBP1	-0.75	-10.84	-0.58	2e-22	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9457247	0.602	rs12208359	chr6:167458455	G/A	cg23791538	chr6:167370224	RNASET2	-0.53	-6.97	-0.42	3.27e-11	Crohn's disease;
SARC	cis	rs6901004	0.803	rs193282	chr6:111543067	G/A	cg15721981	chr6:111408429	SLC16A10	-0.43	-5.23	-0.32	3.7e-7	Blood metabolite levels;
SARC	cis	rs7666738	0.830	rs3846444	chr4:99032888	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs3018712	0.532	rs61889616	chr11:68412006	G/T	cg01657329	chr11:68192670	LRP5	0.62	5.46	0.34	1.24e-7	Total body bone mineral density;
SARC	cis	rs6909279	0.678	rs9479056	chr6:151848899	C/A	cg14262678	chr6:151773367	RMND1;C6orf211	-0.48	-5.92	-0.36	1.17e-8	Bone mineral density;
SARC	cis	rs6141769	0.542	rs28536730	chr20:31301954	A/C	cg17884169	chr20:31446444	EFCAB8	-0.44	-4.78	-0.3	3.09e-6	Subjective well-being;
SARC	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg07701084	chr6:150067640	NUP43	0.41	5.4	0.33	1.62e-7	Lung cancer;
SARC	cis	rs4481887	0.927	rs4472779	chr1:248474603	G/A	cg01631408	chr1:248437212	OR2T33	-0.39	-5.06	-0.31	8.56e-7	Common traits (Other);
SARC	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg06618935	chr21:46677482	NA	-0.36	-4.83	-0.3	2.42e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2916247	1.000	rs2976512	chr8:93013459	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.58	-6.04	-0.37	5.91e-9	Intelligence (multi-trait analysis);
SARC	cis	rs889312	0.500	rs832570	chr5:56156408	G/A	cg14703610	chr5:56206110	C5orf35	0.51	6.35	0.38	1.1e-9	Breast cancer;Breast cancer (early onset);
SARC	cis	rs8064024	0.620	rs8048709	chr16:4913761	A/C	cg08329684	chr16:4932620	PPL	0.35	5.55	0.34	7.84e-8	Cancer;
SARC	cis	rs763121	0.925	rs9835	chr22:39130971	A/G	cg06022373	chr22:39101656	GTPBP1	0.75	9.53	0.53	2.21e-18	Menopause (age at onset);
SARC	cis	rs7945705	0.840	rs10840136	chr11:8885024	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.45	-6.44	-0.39	6.8e-10	Hemoglobin concentration;
SARC	cis	rs9303280	0.719	rs56750287	chr17:38062944	A/C	cg00129232	chr17:37814104	STARD3	-0.37	-4.83	-0.3	2.51e-6	Self-reported allergy;
SARC	cis	rs1568889	1.000	rs16917687	chr11:28062614	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	10.33	0.56	7.9e-21	Bipolar disorder;
SARC	trans	rs66573146	0.561	rs67245546	chr4:6947164	T/C	cg07817883	chr1:32538562	TMEM39B	1.12	8.18	0.47	1.86e-14	Granulocyte percentage of myeloid white cells;
SARC	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg22903657	chr4:1355424	KIAA1530	-0.36	-4.86	-0.3	2.14e-6	Obesity-related traits;
SARC	cis	rs240764	0.781	rs12212736	chr6:101151410	C/T	cg09795085	chr6:101329169	ASCC3	-0.45	-5.91	-0.36	1.21e-8	Neuroticism;
SARC	trans	rs3942852	0.688	rs10742834	chr11:48169717	G/A	cg03929089	chr4:120376271	NA	-0.6	-6.75	-0.4	1.13e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs2153535	0.580	rs1034272	chr6:8469335	G/C	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	trans	rs1656966	1.000	rs1656966	chr3:186466252	C/T	cg21735344	chr14:102553260	HSP90AA1	0.56	6.42	0.39	7.76e-10	Myopia (pathological);
SARC	cis	rs9905704	0.846	rs304267	chr17:56799380	A/G	cg12560992	chr17:57184187	TRIM37	0.43	4.93	0.31	1.58e-6	Testicular germ cell tumor;
SARC	cis	rs17376456	1.000	rs17323433	chr5:93551028	G/A	cg25358565	chr5:93447407	FAM172A	1.35	14.25	0.68	1.48e-33	Diabetic retinopathy;
SARC	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg18404041	chr3:52824283	ITIH1	-0.44	-6.7	-0.4	1.58e-10	Bipolar disorder;
SARC	cis	rs10463554	0.927	rs464702	chr5:102406884	C/T	cg23492399	chr5:102201601	PAM	-0.45	-4.99	-0.31	1.21e-6	Parkinson's disease;
SARC	cis	rs11792861	0.926	rs2271878	chr9:111868885	G/A	cg13535736	chr9:111863775	C9orf5	-0.4	-4.89	-0.31	1.87e-6	Menarche (age at onset);
SARC	cis	rs13056815	1	rs13056815	chr22:31668250	G/A	cg13145458	chr22:31556086	RNF185	0.38	4.72	0.3	4e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs78487399	0.808	rs10189235	chr2:43745520	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.58	-4.82	-0.3	2.63e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs57502260	0.749	rs67446678	chr11:68227466	C/T	cg01657329	chr11:68192670	LRP5	-0.48	-4.78	-0.3	3.13e-6	Total body bone mineral density (age 45-60);
SARC	cis	rs2439831	0.681	rs484029	chr15:43619560	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	8.56	0.49	1.5e-15	Lung cancer in ever smokers;
SARC	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7681440	0.606	rs13142587	chr4:90750169	G/T	cg06632027	chr4:90757378	SNCA	-0.42	-5.25	-0.33	3.35e-7	Dementia with Lewy bodies;
SARC	cis	rs3767633	0.925	rs4656339	chr1:161915387	A/T	cg09175582	chr1:161736000	ATF6	0.64	5.6	0.34	6.13e-8	IgG glycosylation;
SARC	cis	rs9916302	0.904	rs55660616	chr17:37684990	C/A	cg07936489	chr17:37558343	FBXL20	-0.68	-8.81	-0.5	2.97e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs6815814	0.950	rs56289835	chr4:38811845	G/C	cg06935464	chr4:38784597	TLR10	0.63	6.34	0.38	1.16e-9	Breast cancer;
SARC	cis	rs17666538	0.636	rs62486234	chr8:589157	G/T	cg02524346	chr8:600233	NA	-0.59	-5.18	-0.32	4.82e-7	IgG glycosylation;
SARC	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg18357526	chr6:26021779	HIST1H4A	0.49	6.14	0.37	3.61e-9	Blood metabolite levels;
SARC	cis	rs796364	0.951	rs7608668	chr2:201000017	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.56	-5.78	-0.35	2.41e-8	Schizophrenia;
SARC	trans	rs2052678	0.568	rs10843487	chr12:29841066	C/G	cg09015146	chr3:127308803	TPRA1	0.61	6.28	0.38	1.66e-9	Colorectal or endometrial cancer;
SARC	cis	rs2180341	0.883	rs6904630	chr6:127696869	A/G	cg24812749	chr6:127587940	RNF146	1.02	13.05	0.65	1.41e-29	Breast cancer;
SARC	cis	rs56011263	0.687	rs4690292	chr4:703712	A/G	cg20735989	chr4:730612	PCGF3	-0.46	-5.22	-0.32	3.96e-7	White blood cell count;
SARC	cis	rs10465746	0.725	rs10127737	chr1:84368642	G/A	cg10977910	chr1:84465055	TTLL7	0.42	5.2	0.32	4.37e-7	Obesity-related traits;
SARC	cis	rs7607369	0.617	rs12987009	chr2:219658170	A/T	cg02176678	chr2:219576539	TTLL4	-0.51	-8.27	-0.48	1.05e-14	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg09021430	chr5:549028	NA	-0.43	-5.68	-0.35	3.92e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs9457247	1.000	rs364283	chr6:167383750	C/T	cg23791538	chr6:167370224	RNASET2	-0.63	-8.73	-0.5	4.98e-16	Crohn's disease;
SARC	cis	rs3126085	0.877	rs10888472	chr1:152206896	C/G	cg26876637	chr1:152193138	HRNR	-0.51	-5.54	-0.34	8.33e-8	Atopic dermatitis;
SARC	cis	rs6604026	0.656	rs2255723	chr1:93368309	A/C	cg17283838	chr1:93427260	FAM69A	0.43	4.81	0.3	2.74e-6	Multiple sclerosis;
SARC	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.5	5.62	0.35	5.47e-8	Renal function-related traits (BUN);
SARC	cis	rs151234	0.741	rs56236750	chr16:28594711	C/T	cg01378222	chr16:28622494	SULT1A1	-0.52	-6.01	-0.37	7.16e-9	Platelet distribution width;
SARC	cis	rs7615952	0.611	rs72979452	chr3:125756178	C/T	cg05084668	chr3:125655381	ALG1L	-0.95	-7.6	-0.45	7.23e-13	Blood pressure (smoking interaction);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg10783774	chr12:58176443	TSFM	0.49	6.58	0.4	2.99e-10	Chemerin levels;
SARC	cis	rs9486715	0.867	rs9373833	chr6:96904998	A/G	cg06623918	chr6:96969491	KIAA0776	-0.87	-12.54	-0.63	6.52e-28	Headache;
SARC	cis	rs4742903	0.527	rs7037376	chr9:106940114	T/A	cg14250997	chr9:106856677	SMC2	0.42	5.16	0.32	5.37e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs12711979	0.509	rs10200764	chr2:3827772	C/G	cg17052675	chr2:3827356	NA	-0.56	-8.35	-0.48	6.02e-15	Itch intensity from mosquito bite adjusted by bite size;
SARC	cis	rs9911578	0.935	rs6503878	chr17:56884581	T/G	cg12560992	chr17:57184187	TRIM37	0.89	12.39	0.63	2.03e-27	Intelligence (multi-trait analysis);
SARC	cis	rs11190604	0.767	rs77769532	chr10:102193646	T/C	cg07080220	chr10:102295463	HIF1AN	0.71	8.15	0.47	2.29e-14	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg25894440	chr7:65020034	NA	-0.73	-5.48	-0.34	1.09e-7	Diabetic kidney disease;
SARC	cis	rs2749592	0.550	rs9733309	chr10:37882405	G/A	cg00409905	chr10:38381863	ZNF37A	0.54	7.46	0.44	1.73e-12	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs16854884	0.632	rs35362423	chr3:143687441	C/A	cg06585982	chr3:143692056	C3orf58	0.65	8.46	0.48	2.99e-15	Economic and political preferences (feminism/equality);
SARC	cis	rs763121	0.889	rs6001209	chr22:39121252	C/T	cg21395723	chr22:39101663	GTPBP1	-0.57	-6.65	-0.4	2.01e-10	Menopause (age at onset);
SARC	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg16325326	chr1:53192061	ZYG11B	-0.82	-13.46	-0.66	6.13e-31	Monocyte count;
SARC	cis	rs5758659	0.714	rs6002607	chr22:42496506	C/T	cg15128208	chr22:42549153	NA	0.37	5.23	0.32	3.8e-7	Cognitive function;
SARC	cis	rs7429990	0.932	rs9862913	chr3:48016172	T/C	cg11946769	chr3:48343235	NME6	0.46	5.41	0.33	1.58e-7	Educational attainment (years of education);
SARC	trans	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg21659725	chr3:3221576	CRBN	-0.79	-11.79	-0.61	1.76e-25	Intelligence (multi-trait analysis);
SARC	cis	rs4919694	0.611	rs77328741	chr10:105066314	T/C	cg04362960	chr10:104952993	NT5C2	0.64	4.92	0.31	1.65e-6	Arsenic metabolism;
SARC	cis	rs6449957	0.832	rs960383	chr5:67450986	A/G	cg23036683	chr5:67512108	NA	0.52	6.0	0.37	7.34e-9	Cleft lip with or without cleft palate;
SARC	cis	rs6582630	0.599	rs1589392	chr12:38418535	G/C	cg13010199	chr12:38710504	ALG10B	-0.47	-5.69	-0.35	3.83e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1865760	0.963	rs3846838	chr6:25911775	T/C	cg17691542	chr6:26056736	HIST1H1C	0.58	7.18	0.43	9.15e-12	Height;
SARC	cis	rs10883723	0.810	rs13287	chr10:104240438	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.63	7.92	0.46	9.67e-14	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs1832871	0.672	rs9457344	chr6:158742043	C/T	cg07165851	chr6:158734300	TULP4	0.58	6.77	0.41	1.05e-10	Height;
SARC	cis	rs757978	0.929	rs111943976	chr2:242378905	T/C	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.81	-7.18	-0.43	9.44e-12	Chronic lymphocytic leukemia;
SARC	cis	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg15145296	chr3:125709740	NA	-0.51	-5.01	-0.31	1.09e-6	Blood pressure (smoking interaction);
SARC	trans	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.72	10.44	0.56	3.55e-21	Intelligence (multi-trait analysis);
SARC	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg27266027	chr21:40555129	PSMG1	-0.42	-4.87	-0.3	2.08e-6	Menarche (age at onset);
SARC	cis	rs4803468	0.967	rs4605279	chr19:41888131	C/G	cg08477640	chr19:41863820	B9D2	0.4	5.16	0.32	5.35e-7	Height;
SARC	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg14298792	chr15:30685198	CHRFAM7A	0.46	5.1	0.32	6.93e-7	Huntington's disease progression;
SARC	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg13628971	chr7:2884303	GNA12	0.57	6.79	0.41	8.97e-11	Height;
SARC	cis	rs778371	0.723	rs10210953	chr2:233698830	G/A	cg16596103	chr2:233749413	NGEF	0.35	5.39	0.33	1.74e-7	Schizophrenia;
SARC	cis	rs7647973	1.000	rs10865956	chr3:49581559	C/A	cg06212747	chr3:49208901	KLHDC8B	0.57	5.94	0.36	1.06e-8	Menarche (age at onset);
SARC	cis	rs9547692	1.000	rs9547691	chr13:37468588	T/C	cg01493522	chr13:37497338	NA	-0.45	-5.01	-0.31	1.08e-6	Coronary artery disease;
SARC	cis	rs2834188	1.000	rs2096464	chr21:34686049	G/T	cg14352951	chr21:34696688	IFNAR1	-0.45	-5.49	-0.34	1.05e-7	Narcolepsy;
SARC	cis	rs9916302	0.904	rs4794814	chr17:37696852	G/A	cg15445000	chr17:37608096	MED1	0.43	5.01	0.31	1.08e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg05861140	chr6:150128134	PCMT1	-0.41	-5.28	-0.33	2.98e-7	Lung cancer;
SARC	cis	rs11203032	1.000	rs11203033	chr10:90964731	C/G	cg16672925	chr10:90967113	CH25H	-0.75	-7.81	-0.46	1.96e-13	Heart failure;
SARC	cis	rs34779708	0.931	rs11597392	chr10:35288575	T/C	cg03585969	chr10:35415529	CREM	0.41	5.06	0.31	8.68e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs4794202	0.836	rs62066132	chr17:45937923	T/C	cg23391107	chr17:45924227	SP6	-0.52	-4.79	-0.3	3e-6	Alzheimer's disease (cognitive decline);
SARC	cis	rs6952809	0.504	rs1978169	chr7:2434522	G/A	cg23289794	chr7:2394357	EIF3B	-0.6	-5.9	-0.36	1.29e-8	Multiple sclerosis;
SARC	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg20891283	chr12:69753455	YEATS4	0.66	9.54	0.53	2e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9911578	1.000	rs12449365	chr17:56600660	C/G	cg05425664	chr17:57184151	TRIM37	0.65	8.02	0.46	5.23e-14	Intelligence (multi-trait analysis);
SARC	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg08109568	chr15:31115862	NA	-0.52	-6.71	-0.4	1.46e-10	Huntington's disease progression;
SARC	cis	rs4308124	0.708	rs28871990	chr2:111962441	G/A	cg04571233	chr2:111982156	NA	-0.48	-5.59	-0.34	6.46e-8	Vitiligo;
SARC	cis	rs9733	0.650	rs4970923	chr1:150608300	A/G	cg18016565	chr1:150552671	MCL1	-0.38	-5.19	-0.32	4.51e-7	Tonsillectomy;
SARC	cis	rs8014204	1.000	rs10483863	chr14:75322327	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.64	-9.56	-0.53	1.74e-18	Caffeine consumption;
SARC	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg22496380	chr5:211416	CCDC127	-0.88	-9.59	-0.53	1.47e-18	Breast cancer;
SARC	cis	rs8058578	1.000	rs7187359	chr16:30703155	G/A	cg00531865	chr16:30841666	NA	-0.49	-5.6	-0.34	5.87e-8	Multiple myeloma;
SARC	cis	rs9843304	0.509	rs6798061	chr3:149218470	G/T	cg08667024	chr3:149219783	TM4SF4	0.47	7.15	0.42	1.1e-11	Gallstone disease;
SARC	cis	rs9790314	0.905	rs1154701	chr3:161008025	T/A	cg04691961	chr3:161091175	C3orf57	-0.75	-10.77	-0.58	3.23e-22	Morning vs. evening chronotype;
SARC	trans	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg20587970	chr11:113659929	NA	-1.31	-13.7	-0.67	9.62e-32	Hip circumference adjusted for BMI;
SARC	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg01238044	chr22:24384105	GSTT1	0.59	6.77	0.41	1.02e-10	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	trans	rs61931739	0.782	rs1197569	chr12:34186733	A/T	cg26384229	chr12:38710491	ALG10B	0.61	8.27	0.48	1.06e-14	Morning vs. evening chronotype;
SARC	cis	rs933688	1.000	rs35712350	chr5:90679519	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.08	13.84	0.67	3.38e-32	Smoking behavior;
SARC	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg03060546	chr3:49711283	APEH	0.42	5.23	0.32	3.68e-7	Parkinson's disease;
SARC	cis	rs7113850	0.541	rs77227176	chr11:24208375	T/C	ch.11.24196551F	chr11:24239977	NA	0.77	6.01	0.37	7.03e-9	Bone fracture in osteoporosis;
SARC	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	8.04	0.47	4.39e-14	Alzheimer's disease;
SARC	cis	rs240764	0.631	rs12195369	chr6:101204106	G/A	cg09795085	chr6:101329169	ASCC3	-0.49	-6.55	-0.39	3.59e-10	Neuroticism;
SARC	cis	rs7223966	1.000	rs8077265	chr17:61732727	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.59	-6.71	-0.4	1.46e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg03264133	chr6:25882463	NA	0.36	4.73	0.3	3.91e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7524258	0.900	rs7544004	chr1:7314529	A/C	cg07173049	chr1:7289937	CAMTA1	0.34	6.67	0.4	1.83e-10	Tourette's syndrome or obsessive-compulsive disorder;
SARC	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg02733842	chr7:1102375	C7orf50	-0.62	-7.23	-0.43	6.98e-12	Bronchopulmonary dysplasia;
SARC	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg05234568	chr11:5960015	NA	-0.43	-5.99	-0.37	8.03e-9	DNA methylation (variation);
SARC	trans	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg00255811	chr16:22217330	EEF2K	-0.51	-6.54	-0.39	3.92e-10	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg25072359	chr17:41440525	NA	0.49	5.69	0.35	3.8e-8	Menopause (age at onset);
SARC	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg26335602	chr6:28129616	ZNF389	0.48	5.53	0.34	8.67e-8	Parkinson's disease;
SARC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg20007245	chr22:24372913	LOC391322	0.69	8.25	0.48	1.21e-14	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6448317	0.556	rs4697495	chr4:24907501	A/G	cg21108841	chr4:24914750	CCDC149	0.49	4.79	0.3	3.04e-6	Heschl's gyrus morphology;
SARC	cis	rs3020736	0.500	rs6002614	chr22:42501802	G/A	cg04733989	chr22:42467013	NAGA	-0.76	-10.57	-0.57	1.4e-21	Autism spectrum disorder or schizophrenia;
SARC	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg13395646	chr4:1353034	KIAA1530	-0.45	-5.65	-0.35	4.64e-8	Longevity;
SARC	cis	rs10791097	0.690	rs12284540	chr11:130729772	T/C	cg09137382	chr11:130731461	NA	0.34	5.26	0.33	3.27e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs9398803	0.865	rs4565329	chr6:126752798	A/G	cg19875578	chr6:126661172	C6orf173	-0.59	-8.04	-0.47	4.55e-14	Male-pattern baldness;
SARC	cis	rs950776	0.593	rs588765	chr15:78865425	T/C	cg22563815	chr15:78856949	CHRNA5	-0.39	-6.56	-0.4	3.37e-10	Sudden cardiac arrest;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg03877919	chr17:3572250	TMEM93;TAX1BP3	0.63	6.49	0.39	5.02e-10	Lung cancer in ever smokers;
SARC	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg11987759	chr7:65425863	GUSB	-0.49	-5.89	-0.36	1.36e-8	Aortic root size;
SARC	cis	rs7106204	0.609	rs12791360	chr11:24286239	T/G	ch.11.24196551F	chr11:24239977	NA	0.57	4.81	0.3	2.71e-6	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs9436747	0.777	rs1751484	chr1:66019891	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.52	-5.1	-0.32	7.17e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	-0.4	-4.83	-0.3	2.51e-6	Tonsillectomy;
SARC	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.66	-8.19	-0.47	1.72e-14	Parkinson's disease;
SARC	cis	rs763121	0.853	rs2284073	chr22:39105948	T/C	cg06022373	chr22:39101656	GTPBP1	0.9	12.69	0.64	2.12e-28	Menopause (age at onset);
SARC	cis	rs6540556	0.954	rs6540555	chr1:209936571	A/G	cg05527609	chr1:210001259	C1orf107	-0.62	-6.26	-0.38	1.78e-9	Red blood cell count;
SARC	cis	rs10911251	0.528	rs2147584	chr1:183074764	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.17	0.55	2.42e-20	Colorectal cancer;
SARC	cis	rs7552404	0.545	rs12748741	chr1:76351193	A/G	cg22875332	chr1:76189707	ACADM	-0.42	-5.45	-0.34	1.29e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg26752003	chr8:145688521	CYHR1	0.45	5.81	0.36	2.09e-8	Age at first birth;
SARC	cis	rs7927771	0.864	rs3781626	chr11:47442893	A/T	cg20135002	chr11:47629003	NA	-0.29	-4.72	-0.3	4e-6	Subjective well-being;
SARC	cis	rs2228479	0.850	rs17227057	chr16:89816333	C/T	cg26513180	chr16:89883248	FANCA	0.72	4.79	0.3	2.99e-6	Skin colour saturation;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg12633985	chr6:26056540	HIST1H1C	0.49	6.34	0.38	1.17e-9	Chemerin levels;
SARC	cis	rs9733	0.536	rs10888385	chr1:150574302	T/C	cg18016565	chr1:150552671	MCL1	-0.38	-5.14	-0.32	5.89e-7	Tonsillectomy;
SARC	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg23958373	chr8:599963	NA	0.72	5.89	0.36	1.36e-8	IgG glycosylation;
SARC	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	8.51	0.49	2.13e-15	Mean platelet volume;
SARC	cis	rs7927771	0.965	rs12364432	chr11:47902883	G/A	cg05585544	chr11:47624801	NA	-0.36	-4.73	-0.3	3.98e-6	Subjective well-being;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg13184539	chr1:241683111	FH	0.52	6.59	0.4	2.91e-10	Breast cancer;
SARC	cis	rs240764	0.817	rs240146	chr6:101078718	G/A	cg09795085	chr6:101329169	ASCC3	0.45	5.77	0.35	2.55e-8	Neuroticism;
SARC	cis	rs9325144	0.600	rs7312522	chr12:38730423	A/G	cg10518543	chr12:38710700	ALG10B	0.38	4.78	0.3	3.1e-6	Morning vs. evening chronotype;
SARC	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg26335602	chr6:28129616	ZNF389	0.48	5.48	0.34	1.08e-7	Parkinson's disease;
SARC	cis	rs2439831	0.702	rs3784275	chr15:44091386	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	7.66	0.45	4.91e-13	Lung cancer in ever smokers;
SARC	cis	rs2075371	0.611	rs13235296	chr7:134019192	A/G	cg00033643	chr7:134001901	SLC35B4	-0.47	-5.71	-0.35	3.49e-8	Mean platelet volume;
SARC	cis	rs12545109	0.800	rs1467126	chr8:57418452	C/T	cg21220214	chr8:57350948	NA	-0.4	-4.84	-0.3	2.37e-6	Obesity-related traits;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg12812760	chr12:53645951	MFSD5	0.55	7.48	0.44	1.48e-12	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg16325326	chr1:53192061	ZYG11B	-0.83	-13.35	-0.66	1.47e-30	Monocyte count;
SARC	cis	rs712039	0.652	rs1102920	chr17:35760940	A/G	cg16670864	chr17:35848621	DUSP14	0.49	5.38	0.33	1.82e-7	Tuberculosis;
SARC	cis	rs2479724	0.905	rs2274578	chr6:41888827	C/G	cg17623882	chr6:41773611	USP49	-0.48	-6.04	-0.37	5.97e-9	Menarche (age at onset);
SARC	cis	rs3796352	1.000	rs34244302	chr3:53102236	C/G	cg07884673	chr3:53033167	SFMBT1	0.79	5.04	0.31	9.33e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs6840360	0.593	rs1877185	chr4:152690348	C/T	cg22705602	chr4:152727874	NA	-0.47	-8.08	-0.47	3.4e-14	Intelligence (multi-trait analysis);
SARC	cis	rs9790314	0.589	rs9790132	chr3:160627289	A/T	cg04691961	chr3:161091175	C3orf57	0.54	7.23	0.43	7.05e-12	Morning vs. evening chronotype;
SARC	cis	rs9314323	0.964	rs3808576	chr8:26266834	G/A	cg11498726	chr8:26250323	BNIP3L	-0.61	-7.92	-0.46	9.67e-14	Red cell distribution width;
SARC	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg14403583	chr14:105418241	AHNAK2	-0.61	-7.78	-0.45	2.38e-13	Rheumatoid arthritis;
SARC	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg11987759	chr7:65425863	GUSB	-0.62	-7.89	-0.46	1.15e-13	Aortic root size;
SARC	cis	rs13082711	0.834	rs2172297	chr3:27428423	C/T	cg02860705	chr3:27208620	NA	0.48	6.16	0.37	3.12e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs1448094	0.511	rs59668915	chr12:86197170	C/T	cg00310523	chr12:86230176	RASSF9	0.31	4.86	0.3	2.12e-6	Major depressive disorder;
SARC	cis	rs9660992	0.789	rs1768584	chr1:205240145	A/G	cg07972983	chr1:205091412	RBBP5	0.56	7.08	0.42	1.71e-11	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs2997447	0.846	rs3008233	chr1:26403991	C/T	cg19633962	chr1:26362018	EXTL1	-0.59	-5.34	-0.33	2.17e-7	QRS complex (12-leadsum);
SARC	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	8.4	0.48	4.36e-15	Mean platelet volume;
SARC	cis	rs17209837	0.607	rs2888611	chr7:87103670	C/G	cg00919237	chr7:87102261	ABCB4	0.41	4.85	0.3	2.3e-6	Gallbladder cancer;
SARC	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg22549504	chr19:17448937	GTPBP3	0.48	4.88	0.3	1.94e-6	Systemic lupus erythematosus;
SARC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg11494091	chr17:61959527	GH2	0.53	7.86	0.46	1.4e-13	Prudent dietary pattern;
SARC	cis	rs2303759	0.918	rs9749416	chr19:49885005	G/A	cg24324837	chr19:49891574	CCDC155	0.43	5.41	0.33	1.56e-7	Multiple sclerosis;
SARC	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg21724239	chr8:58056113	NA	0.57	6.08	0.37	4.82e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9486719	0.857	rs9285393	chr6:97020917	C/A	cg06623918	chr6:96969491	KIAA0776	-0.74	-8.65	-0.49	8.6e-16	Migraine;Coronary artery disease;
SARC	cis	rs13256369	0.951	rs12679360	chr8:8566269	G/T	cg17143192	chr8:8559678	CLDN23	-0.51	-5.92	-0.36	1.15e-8	Obesity-related traits;
SARC	cis	rs950776	0.518	rs4243083	chr15:78833830	C/G	cg17108064	chr15:78857060	CHRNA5	-0.29	-4.98	-0.31	1.24e-6	Sudden cardiac arrest;
SARC	cis	rs9388451	0.559	rs1777210	chr6:126098916	T/G	cg05901451	chr6:126070800	HEY2	-0.49	-6.22	-0.38	2.22e-9	Brugada syndrome;
SARC	cis	rs9341808	0.754	rs978814	chr6:80959912	G/T	cg08355045	chr6:80787529	NA	0.36	5.83	0.36	1.83e-8	Sitting height ratio;
SARC	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg04944784	chr2:26401820	FAM59B	-0.5	-6.37	-0.39	1.01e-9	Gut microbiome composition (summer);
SARC	cis	rs8014204	1.000	rs4553560	chr14:75334199	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.74	-10.77	-0.58	3.27e-22	Caffeine consumption;
SARC	cis	rs7712401	0.580	rs185008	chr5:122274734	T/C	cg19412675	chr5:122181750	SNX24	0.4	5.09	0.32	7.55e-7	Mean platelet volume;
SARC	cis	rs2235642	0.928	rs9932984	chr16:1605051	A/G	cg26528668	chr16:1614120	IFT140	0.37	4.79	0.3	3.03e-6	Coronary artery disease;
SARC	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg27541892	chr1:1571801	CDK11B	0.4	5.42	0.33	1.5e-7	Body mass index;
SARC	cis	rs1008375	1.000	rs3846357	chr4:17635887	A/T	cg27347728	chr4:17578864	LAP3	0.47	5.88	0.36	1.42e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7223966	0.921	rs2727300	chr17:61965398	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.52	-5.37	-0.33	1.86e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs12600121	0.600	rs12051517	chr16:72022866	A/G	cg01557791	chr16:72042693	DHODH	0.43	5.38	0.33	1.81e-7	Intelligence (multi-trait analysis);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg23064501	chr12:42680748	NA	-0.77	-6.5	-0.39	4.77e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs12586317	0.547	rs10146699	chr14:35483577	G/A	cg16230307	chr14:35515116	FAM177A1	1.02	11.85	0.61	1.18e-25	Psoriasis;
SARC	cis	rs2952156	0.959	rs907087	chr17:37828787	G/A	cg00129232	chr17:37814104	STARD3	-0.7	-9.37	-0.52	6.65e-18	Asthma;
SARC	cis	rs11651000	0.841	rs11650451	chr17:45809822	G/A	cg03474202	chr17:45855739	NA	-0.44	-5.06	-0.31	8.38e-7	IgG glycosylation;
SARC	cis	rs7020830	0.861	rs2291589	chr9:37079661	T/G	cg14294708	chr9:37120828	ZCCHC7	1.15	21.76	0.82	4.67e-58	Schizophrenia;
SARC	cis	rs826838	0.967	rs826856	chr12:39115434	G/A	cg13010199	chr12:38710504	ALG10B	-0.69	-9.65	-0.53	9.18e-19	Heart rate;
SARC	cis	rs2444217	0.872	rs2531977	chr16:4043701	C/G	cg09300795	chr16:4042428	ADCY9	0.52	8.32	0.48	7.25e-15	Body mass index;
SARC	cis	rs3008870	0.755	rs10789219	chr1:67417742	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.59	7.5	0.44	1.36e-12	Lymphocyte percentage of white cells;
SARC	cis	rs875971	0.964	rs160635	chr7:65528918	T/C	cg11987759	chr7:65425863	GUSB	-0.44	-5.82	-0.36	1.95e-8	Aortic root size;
SARC	cis	rs33912345	0.695	rs1254315	chr14:60896779	C/T	cg27398547	chr14:60952738	C14orf39	-0.39	-4.78	-0.3	3.16e-6	Glaucoma (high intraocular pressure);
SARC	trans	rs294883	0.963	rs294890	chr6:159677498	A/G	cg05258123	chr7:101813842	CUX1	-0.42	-6.56	-0.39	3.46e-10	Coronary artery disease;
SARC	cis	rs8031584	0.918	rs61997140	chr15:31277312	A/G	cg14829155	chr15:31115871	NA	-0.43	-5.37	-0.33	1.86e-7	Huntington's disease progression;
SARC	cis	rs15676	0.783	rs11515530	chr9:131576367	C/T	cg00228799	chr9:131580591	ENDOG	-0.59	-7.4	-0.44	2.46e-12	Blood metabolite levels;
SARC	cis	rs11190604	0.767	rs7078070	chr10:102166415	A/C	cg07080220	chr10:102295463	HIF1AN	0.69	7.39	0.44	2.64e-12	Palmitoleic acid (16:1n-7) levels;
SARC	trans	rs7824557	0.527	rs2572446	chr8:11239565	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.39	-0.39	8.91e-10	Retinal vascular caliber;
SARC	cis	rs6582630	0.502	rs11495393	chr12:38341194	T/C	cg26384229	chr12:38710491	ALG10B	0.88	12.71	0.64	1.78e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg21747090	chr2:27597821	SNX17	-0.55	-7.62	-0.45	6.44e-13	Total body bone mineral density;
SARC	cis	rs533581	0.866	rs561795	chr16:88970818	A/G	cg16701003	chr16:89028210	CBFA2T3	0.35	5.47	0.34	1.15e-7	Social autistic-like traits;
SARC	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg26335602	chr6:28129616	ZNF389	-0.5	-5.71	-0.35	3.34e-8	Depression;
SARC	cis	rs9858542	0.953	rs6766581	chr3:49539401	T/C	cg07274523	chr3:49395745	GPX1	0.53	6.1	0.37	4.27e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	trans	rs7844647	0.530	rs2978843	chr8:34166099	T/C	cg26394233	chr7:157444480	PTPRN2	0.44	6.61	0.4	2.6e-10	Body mass index;
SARC	cis	rs2645694	0.626	rs2703118	chr4:77823672	A/G	cg03477792	chr4:77819574	ANKRD56	0.5	7.62	0.45	6.49e-13	Emphysema distribution in smoking;
SARC	cis	rs9916302	0.851	rs2338795	chr17:37399364	T/G	cg00129232	chr17:37814104	STARD3	-0.61	-7.49	-0.44	1.38e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs7727544	0.735	rs274568	chr5:131713578	C/T	cg24060327	chr5:131705240	SLC22A5	0.68	8.59	0.49	1.26e-15	Blood metabolite levels;
SARC	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg22535103	chr8:58192502	C8orf71	-0.59	-6.06	-0.37	5.57e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs362272	0.524	rs13150241	chr4:3367281	A/G	cg08741688	chr4:3415352	RGS12	-0.51	-6.51	-0.39	4.66e-10	Serum sulfate level;
SARC	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg07298985	chr8:22133076	PIWIL2	0.35	4.71	0.3	4.18e-6	Hypertriglyceridemia;
SARC	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg24324837	chr19:49891574	CCDC155	0.43	5.45	0.34	1.31e-7	Multiple sclerosis;
SARC	cis	rs76419734	1.000	rs17036105	chr4:106603272	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.81	4.88	0.3	1.96e-6	Post bronchodilator FEV1;
SARC	cis	rs4742903	0.509	rs1004358	chr9:106966367	C/T	cg14250997	chr9:106856677	SMC2	0.39	4.8	0.3	2.77e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs9786986	0.908	rs9787165	chr1:235652028	A/G	cg26050004	chr1:235667680	B3GALNT2	0.57	5.18	0.32	4.69e-7	Body mass index;
SARC	cis	rs425277	1.000	rs381664	chr1:2088104	A/G	cg21442419	chr1:2182373	SKI	-0.53	-6.71	-0.4	1.44e-10	Height;
SARC	cis	rs123509	0.863	rs339662	chr3:42752093	T/C	cg12982090	chr3:42733453	KBTBD5	0.53	6.29	0.38	1.55e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2624839	0.704	rs12637671	chr3:50224562	G/A	cg14019146	chr3:50243930	SLC38A3	0.45	7.3	0.43	4.56e-12	Intelligence (multi-trait analysis);
SARC	cis	rs7681440	0.874	rs1372525	chr4:90776165	G/A	cg06632027	chr4:90757378	SNCA	0.4	5.68	0.35	3.91e-8	Dementia with Lewy bodies;
SARC	cis	rs3816788	0.620	rs11783414	chr8:21773384	A/G	cg17168535	chr8:21777572	XPO7	-0.72	-9.83	-0.54	2.61e-19	Lung cancer in ever smokers;
SARC	cis	rs6582630	0.555	rs35186318	chr12:38295822	C/T	cg13010199	chr12:38710504	ALG10B	-0.55	-6.73	-0.4	1.3e-10	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs981844	0.712	rs10009854	chr4:154741785	C/T	cg25721732	chr2:74602550	DCTN1	-0.51	-6.28	-0.38	1.63e-9	Response to statins (LDL cholesterol change);
SARC	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	9.15	0.51	3.02e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2304069	0.954	rs6861548	chr5:149384680	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.89	9.34	0.52	8.2e-18	HIV-1 control;
SARC	cis	rs4555082	0.834	rs28489970	chr14:105748862	T/C	cg06808227	chr14:105710500	BRF1	-0.52	-6.54	-0.39	3.77e-10	Mean platelet volume;Platelet distribution width;
SARC	cis	rs910316	0.763	rs12588981	chr14:75460561	A/G	cg08847533	chr14:75593920	NEK9	0.9	13.73	0.67	7.96e-32	Height;
SARC	trans	rs7819412	0.595	rs10503416	chr8:10987553	C/T	cg06636001	chr8:8085503	FLJ10661	0.58	7.8	0.46	2.07e-13	Triglycerides;
SARC	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg04944784	chr2:26401820	FAM59B	-0.48	-6.01	-0.37	7.08e-9	Gut microbiome composition (summer);
SARC	cis	rs7666738	0.791	rs10013680	chr4:99023030	G/C	cg05340658	chr4:99064831	C4orf37	0.66	9.02	0.51	7.15e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg26681399	chr22:41777847	TEF	-0.5	-5.53	-0.34	8.77e-8	Vitiligo;
SARC	cis	rs17376456	0.877	rs10062711	chr5:93348659	G/A	cg25358565	chr5:93447407	FAM172A	1.3	14.56	0.69	1.43e-34	Diabetic retinopathy;
SARC	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-5.56	-0.34	7.23e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs11673344	0.583	rs7247090	chr19:38013411	T/A	cg14683738	chr19:37701593	ZNF585B	-0.42	-4.93	-0.31	1.54e-6	Obesity-related traits;
SARC	cis	rs1003719	0.751	rs56268364	chr21:38542765	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.38	-0.52	5.99e-18	Eye color traits;
SARC	cis	rs7647973	1.000	rs3870339	chr3:49536863	T/A	cg06212747	chr3:49208901	KLHDC8B	0.57	6.19	0.38	2.71e-9	Menarche (age at onset);
SARC	cis	rs8067354	0.645	rs28516945	chr17:57816578	T/C	cg02344993	chr17:57696989	CLTC	0.65	6.69	0.4	1.61e-10	Hemoglobin concentration;
SARC	cis	rs739401	0.572	rs384490	chr11:3078885	A/C	cg05729581	chr11:3078854	CARS	-0.51	-6.74	-0.4	1.24e-10	Longevity;
SARC	cis	rs858239	0.509	rs6975524	chr7:23186452	T/C	cg23682824	chr7:23144976	KLHL7	0.72	9.28	0.52	1.22e-17	Cerebrospinal fluid biomarker levels;
SARC	trans	rs61931739	0.534	rs11052960	chr12:33997754	A/T	cg26384229	chr12:38710491	ALG10B	0.86	12.43	0.63	1.52e-27	Morning vs. evening chronotype;
SARC	cis	rs11190604	1.000	rs10883500	chr10:102238324	T/G	cg07080220	chr10:102295463	HIF1AN	0.76	8.87	0.5	1.92e-16	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg22903471	chr2:27725779	GCKR	-0.49	-7.42	-0.44	2.21e-12	Total body bone mineral density;
SARC	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg02725872	chr8:58115012	NA	-0.37	-6.55	-0.39	3.71e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9818758	0.607	rs80170003	chr3:48951640	T/C	cg07636037	chr3:49044803	WDR6	-0.79	-6.78	-0.41	9.62e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg11843238	chr5:131593191	PDLIM4	0.38	5.37	0.33	1.92e-7	Breast cancer;
SARC	trans	rs7824557	0.583	rs4448232	chr8:11231354	G/T	cg15556689	chr8:8085844	FLJ10661	0.5	6.28	0.38	1.61e-9	Retinal vascular caliber;
SARC	cis	rs4722166	0.597	rs2069845	chr7:22770149	G/A	cg26061582	chr7:22766209	IL6	0.5	5.74	0.35	2.99e-8	Lung cancer;
SARC	cis	rs7937682	0.924	rs7938360	chr11:111539875	A/G	cg22437258	chr11:111473054	SIK2	0.74	10.41	0.56	4.36e-21	Primary sclerosing cholangitis;
SARC	cis	rs651907	0.557	rs59596156	chr3:101394217	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	6.33	0.38	1.26e-9	Colorectal cancer;
SARC	cis	rs752010	0.715	rs11807117	chr1:42101206	C/T	cg06885757	chr1:42089581	HIVEP3	0.54	7.78	0.45	2.35e-13	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg05863683	chr7:1912471	MAD1L1	0.35	5.29	0.33	2.77e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg11366901	chr6:160182831	ACAT2	0.64	6.65	0.4	2.1e-10	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs9393777	0.513	rs6936555	chr6:26640886	C/T	cg12826209	chr6:26865740	GUSBL1	0.69	6.13	0.37	3.64e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7624766	0.743	rs7643513	chr3:160479592	T/C	cg22637730	chr3:160473554	PPM1L	0.43	5.61	0.35	5.58e-8	Response to methotrexate in rheumatoid arthritis;
SARC	cis	rs11098499	0.955	rs1511015	chr4:120170473	A/C	cg09307838	chr4:120376055	NA	0.85	11.65	0.61	4.92e-25	Corneal astigmatism;
SARC	cis	rs7659604	0.628	rs3828485	chr4:122722368	G/A	cg20573242	chr4:122745356	CCNA2	0.59	7.4	0.44	2.53e-12	Type 2 diabetes;
SARC	cis	rs7717697	0.797	rs12188947	chr5:82742118	A/C	cg19814134	chr5:82768288	VCAN	0.41	4.85	0.3	2.27e-6	Vertical cup-disc ratio;
SARC	cis	rs10911251	0.546	rs944971	chr1:183112505	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	9.86	0.54	2.11e-19	Colorectal cancer;
SARC	cis	rs2228479	0.867	rs12930606	chr16:89946682	A/G	cg00800038	chr16:89945340	TCF25	-0.72	-5.75	-0.35	2.8e-8	Skin colour saturation;
SARC	cis	rs6456156	0.742	rs3093026	chr6:167532690	A/G	cg07741184	chr6:167504864	NA	0.3	5.9	0.36	1.28e-8	Primary biliary cholangitis;
SARC	cis	rs72945132	0.882	rs7114200	chr11:70186099	C/A	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.58	-0.34	6.81e-8	Coronary artery disease;
SARC	cis	rs4243830	0.522	rs10864614	chr1:6596008	G/A	cg04093404	chr1:6614507	TAS1R1;NOL9	0.56	4.9	0.31	1.77e-6	Body mass index;
SARC	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg04267008	chr7:1944627	MAD1L1	-0.6	-6.91	-0.41	4.51e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg22875332	chr1:76189707	ACADM	-0.39	-5.63	-0.35	5.18e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9814567	0.896	rs6794258	chr3:134344505	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.5	-6.4	-0.39	8.24e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg22920501	chr2:26401640	FAM59B	0.61	8.19	0.47	1.71e-14	Gut microbiome composition (summer);
SARC	trans	rs6934651	0.786	rs9450206	chr6:85957119	G/A	cg04848555	chr14:53975804	NA	0.67	6.48	0.39	5.45e-10	Breast cancer;
SARC	cis	rs9388451	0.874	rs3734634	chr6:126111800	G/A	cg05901451	chr6:126070800	HEY2	-0.7	-9.67	-0.54	8.01e-19	Brugada syndrome;
SARC	cis	rs9916302	0.752	rs11078895	chr17:37401051	A/G	cg00129232	chr17:37814104	STARD3	-0.52	-5.5	-0.34	1.02e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs1468333	0.538	rs13153017	chr5:137750669	C/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.65	7.95	0.46	8.14e-14	Resting heart rate;
SARC	cis	rs8078723	1.000	rs1042658	chr17:38173902	C/T	cg17467752	chr17:38218738	THRA	0.47	5.96	0.36	9.44e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
SARC	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg13395646	chr4:1353034	KIAA1530	-0.58	-6.87	-0.41	5.71e-11	Obesity-related traits;
SARC	cis	rs453301	0.686	rs10217044	chr8:8894752	A/G	cg08975724	chr8:8085496	FLJ10661	-0.47	-6.12	-0.37	3.93e-9	Joint mobility (Beighton score);
SARC	trans	rs208520	0.526	rs9351542	chr6:66788571	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.11	-22.05	-0.82	5.76e-59	Exhaled nitric oxide output;
SARC	cis	rs926938	0.812	rs11102832	chr1:115244253	G/C	cg12756093	chr1:115239321	AMPD1	-0.37	-4.92	-0.31	1.65e-6	Autism;
SARC	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg03806693	chr22:41940476	POLR3H	-0.94	-13.14	-0.65	7.11e-30	Vitiligo;
SARC	cis	rs7000551	0.725	rs2443496	chr8:22365788	G/A	cg12081754	chr8:22256438	SLC39A14	0.53	7.49	0.44	1.46e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs4748857	0.853	rs7095016	chr10:23610272	C/G	cg12804278	chr10:23633326	C10orf67	-0.41	-4.94	-0.31	1.47e-6	Systemic lupus erythematosus;
SARC	cis	rs2933343	0.729	rs789224	chr3:128598231	A/C	cg24203234	chr3:128598194	ACAD9	0.63	8.11	0.47	2.89e-14	IgG glycosylation;
SARC	cis	rs751728	0.664	rs4711349	chr6:33740592	C/T	cg25922239	chr6:33757077	LEMD2	0.61	7.93	0.46	9.01e-14	Crohn's disease;
SARC	cis	rs6504663	0.586	rs60117965	chr17:48569755	G/A	cg03611598	chr17:48586076	MYCBPAP	0.48	5.25	0.33	3.47e-7	Visceral fat;
SARC	cis	rs2116941	0.523	rs8104608	chr19:10370133	G/A	cg01850179	chr19:10340795	S1PR2	0.51	5.82	0.36	1.89e-8	Pulse pressure;
SARC	cis	rs72945132	0.678	rs7113595	chr11:70236819	T/C	cg00319359	chr11:70116639	PPFIA1	0.56	5.16	0.32	5.22e-7	Coronary artery disease;
SARC	cis	rs7762018	1.000	rs73242927	chr6:170129573	T/A	cg17545662	chr6:170176663	C6orf70	0.41	4.73	0.3	3.96e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs8067545	0.641	rs1638525	chr17:19848594	G/C	cg04132472	chr17:19861366	AKAP10	0.4	5.14	0.32	5.88e-7	Schizophrenia;
SARC	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg03806693	chr22:41940476	POLR3H	0.89	11.95	0.62	5.29e-26	Vitiligo;
SARC	cis	rs4975709	0.610	rs6886669	chr5:1867830	T/C	cg15595755	chr5:1867978	NA	0.48	6.56	0.4	3.36e-10	Cardiovascular disease risk factors;
SARC	cis	rs9309473	1.000	rs7558944	chr2:73810909	T/G	cg20560298	chr2:73613845	ALMS1	-0.48	-5.89	-0.36	1.32e-8	Metabolite levels;
SARC	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg13628971	chr7:2884303	GNA12	0.56	6.49	0.39	4.99e-10	Height;
SARC	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.5	-4.91	-0.31	1.7e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9625935	0.518	rs5752972	chr22:30250312	A/T	cg01021169	chr22:30184971	ASCC2	0.39	5.25	0.33	3.4e-7	Tonsillectomy;
SARC	cis	rs9400467	0.537	rs12211045	chr6:111498116	C/T	cg15721981	chr6:111408429	SLC16A10	0.62	4.98	0.31	1.22e-6	Blood metabolite levels;Amino acid levels;
SARC	cis	rs710216	0.763	rs9438964	chr1:43443742	C/T	cg03128534	chr1:43423976	SLC2A1	0.53	5.18	0.32	4.72e-7	Red cell distribution width;
SARC	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg00149659	chr3:10157352	C3orf10	0.81	7.87	0.46	1.36e-13	Alzheimer's disease;
SARC	cis	rs7408868	0.764	rs62113791	chr19:15277009	C/T	cg14696996	chr19:15285081	NOTCH3	1.02	8.7	0.5	6e-16	Pulse pressure;
SARC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg12419862	chr22:24373484	LOC391322	0.72	8.63	0.49	9.73e-16	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg07636037	chr3:49044803	WDR6	0.46	5.38	0.33	1.82e-7	Resting heart rate;
SARC	cis	rs1728785	0.818	rs1645984	chr16:68628850	T/C	cg02972257	chr16:68554789	NA	-0.45	-5.19	-0.32	4.62e-7	Ulcerative colitis;
SARC	cis	rs9660992	0.547	rs748012	chr1:205216573	C/T	cg21545522	chr1:205238299	TMCC2	0.37	5.07	0.32	8.21e-7	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.31	-4.79	-0.3	2.97e-6	Total body bone mineral density;
SARC	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg22857025	chr5:266934	NA	-1.08	-11.86	-0.61	1.06e-25	Breast cancer;
SARC	cis	rs7932354	0.528	rs12224096	chr11:47174361	C/T	cg03339077	chr11:47165057	C11orf49	0.45	6.12	0.37	3.93e-9	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs6728642	0.908	rs17842456	chr2:98014319	C/T	cg26665480	chr2:98280029	ACTR1B	0.66	5.99	0.37	7.73e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs2153535	0.580	rs6941771	chr6:8494452	T/G	cg21535247	chr6:8435926	SLC35B3	0.57	7.27	0.43	5.44e-12	Motion sickness;
SARC	cis	rs17023223	0.537	rs2645305	chr1:119561365	A/G	cg05756136	chr1:119680316	WARS2	-0.49	-5.79	-0.35	2.3e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs698833	0.852	rs4953089	chr2:44565024	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.72	9.15	0.51	2.9e-17	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs509477	0.718	rs273363	chr18:32594703	A/G	cg23791764	chr18:32556832	MAPRE2	0.43	5.31	0.33	2.6e-7	Cerebrospinal fluid AB1-42 levels;
SARC	cis	rs17376456	0.825	rs17372615	chr5:93124768	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.73	6.78	0.41	1.01e-10	Diabetic retinopathy;
SARC	cis	rs9486715	0.867	rs9384602	chr6:96919561	G/A	cg18709589	chr6:96969512	KIAA0776	0.54	6.65	0.4	2.04e-10	Headache;
SARC	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	11.5	0.6	1.53e-24	Platelet count;
SARC	cis	rs780096	0.778	rs780094	chr2:27741237	C/T	cg12648201	chr2:27665141	KRTCAP3	0.31	4.94	0.31	1.51e-6	Total body bone mineral density;
SARC	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg21171335	chr12:122356390	WDR66	0.39	5.84	0.36	1.74e-8	Mean corpuscular volume;
SARC	cis	rs920590	0.758	rs62496731	chr8:19659543	C/G	cg17834443	chr8:19674713	INTS10	0.6	7.31	0.43	4.21e-12	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs4737010	0.644	rs522407	chr8:41610969	G/A	cg08923054	chr8:41654455	ANK1	-0.39	-4.8	-0.3	2.81e-6	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
SARC	trans	rs7824557	0.510	rs1435274	chr8:11235910	G/A	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.81	-0.41	8.4e-11	Retinal vascular caliber;
SARC	cis	rs7633770	0.769	rs2385858	chr3:46660436	T/C	cg11219411	chr3:46661640	NA	0.5	8.6	0.49	1.17e-15	Coronary artery disease;
SARC	cis	rs72945132	0.882	rs12278741	chr11:70135742	A/G	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.78	-0.35	2.39e-8	Coronary artery disease;
SARC	cis	rs9309473	1.000	rs2421555	chr2:73816955	G/A	cg07208825	chr2:73871855	ALMS1P	0.33	4.84	0.3	2.4e-6	Metabolite levels;
SARC	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.14	-26.09	-0.86	4.36e-71	Chronic sinus infection;
SARC	cis	rs13166103	0.657	rs11749794	chr5:57722326	A/C	cg10487770	chr5:57879443	RAB3C	-0.52	-5.38	-0.33	1.83e-7	Type 2 diabetes (age of onset);
SARC	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg12373951	chr3:133503437	NA	0.41	5.88	0.36	1.43e-8	Iron status biomarkers;
SARC	cis	rs4764124	0.646	rs11610238	chr12:14975721	C/T	cg19759883	chr12:14956454	WBP11;C12orf60	0.72	10.38	0.56	5.4e-21	Pubertal anthropometrics;
SARC	cis	rs9790314	0.686	rs2306061	chr3:160787502	C/T	cg03342759	chr3:160939853	NMD3	-0.48	-5.85	-0.36	1.61e-8	Morning vs. evening chronotype;
SARC	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg17221315	chr6:27791827	HIST1H4J	0.45	4.84	0.3	2.41e-6	Cardiac Troponin-T levels;
SARC	cis	rs1865760	0.865	rs9467641	chr6:25947236	T/C	cg18357526	chr6:26021779	HIST1H4A	0.38	4.72	0.3	3.99e-6	Height;
SARC	cis	rs1153858	1.000	rs8042786	chr15:45703539	T/C	cg15395560	chr15:45543142	SLC28A2	-0.27	-4.87	-0.3	2.05e-6	Homoarginine levels;
SARC	trans	rs3734266	0.639	rs11968972	chr6:34741094	G/A	cg08157914	chr7:2646478	IQCE	0.52	6.24	0.38	2.1e-9	Systemic lupus erythematosus;
SARC	cis	rs9902453	0.967	rs4473252	chr17:28454423	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	6.53	0.39	4.03e-10	Coffee consumption (cups per day);
SARC	cis	rs1843834	0.539	rs6713629	chr2:225410973	A/T	cg22509189	chr2:225307070	NA	-0.7	-8.91	-0.5	1.53e-16	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg05623727	chr3:50126028	RBM5	-0.33	-5.03	-0.31	9.84e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg21782813	chr7:2030301	MAD1L1	0.38	6.26	0.38	1.86e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs9902453	0.709	rs6505162	chr17:28444183	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.49	6.33	0.38	1.22e-9	Coffee consumption (cups per day);
SARC	cis	rs7633770	0.786	rs1520488	chr3:46677459	C/T	cg11219411	chr3:46661640	NA	0.41	6.61	0.4	2.59e-10	Coronary artery disease;
SARC	cis	rs6088580	0.634	rs3746455	chr20:32957216	G/A	cg24642439	chr20:33292090	TP53INP2	-0.67	-8.62	-0.49	1.02e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs2576037	1.000	rs2576037	chr18:44585420	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.68	-9.53	-0.53	2.12e-18	Personality dimensions;
SARC	cis	rs12541335	0.615	rs4872464	chr8:22153381	G/A	cg02463440	chr8:22132932	PIWIL2	0.46	6.39	0.39	9.06e-10	Hypertriglyceridemia;
SARC	cis	rs6459804	1.000	rs58278053	chr7:157512934	A/T	cg05731713	chr7:157510257	PTPRN2	0.3	5.62	0.35	5.29e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs807669	0.903	rs807667	chr22:19161327	A/G	cg02655711	chr22:19163373	SLC25A1	-0.55	-7.76	-0.45	2.68e-13	Metabolite levels;
SARC	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg00908189	chr16:619842	PIGQ	0.83	12.03	0.62	2.92e-26	Height;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg23979677	chr14:67981515	TMEM229B	-0.49	-6.32	-0.38	1.33e-9	Height;
SARC	cis	rs1008375	0.800	rs35463363	chr4:17613423	G/T	cg02297831	chr4:17616191	MED28	0.48	6.0	0.37	7.35e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2486288	0.656	rs11639349	chr15:45568260	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.57	-7.27	-0.43	5.5e-12	Glomerular filtration rate;
SARC	cis	rs11608355	0.573	rs7970666	chr12:109793495	T/G	cg19025524	chr12:109796872	NA	-0.47	-6.63	-0.4	2.27e-10	Neuroticism;
SARC	cis	rs17376456	0.877	rs10057605	chr5:93443950	T/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.54	0.34	8.18e-8	Diabetic retinopathy;
SARC	cis	rs9894429	0.966	rs6565605	chr17:79589359	C/T	cg18240062	chr17:79603768	NPLOC4	0.71	9.58	0.53	1.48e-18	Eye color traits;
SARC	cis	rs9290065	0.519	rs9857743	chr3:160677732	G/A	cg17135325	chr3:160939158	NMD3	0.4	4.85	0.3	2.25e-6	Kawasaki disease;
SARC	cis	rs9916302	0.706	rs7503081	chr17:37482673	A/G	cg07936489	chr17:37558343	FBXL20	0.76	9.22	0.52	1.85e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs2735413	0.875	rs12923229	chr16:78080302	C/A	cg04733911	chr16:78082701	NA	-0.3	-5.47	-0.34	1.14e-7	Systolic blood pressure (alcohol consumption interaction);
SARC	cis	rs12142240	0.698	rs1053628	chr1:46827769	C/T	cg14993813	chr1:46806288	NSUN4	-0.53	-5.62	-0.35	5.48e-8	Menopause (age at onset);
SARC	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg24675658	chr1:53192096	ZYG11B	-0.58	-7.94	-0.46	8.57e-14	Monocyte count;
SARC	cis	rs2522056	0.808	rs17771891	chr5:131744202	A/G	cg24060327	chr5:131705240	SLC22A5	-0.64	-6.66	-0.4	2e-10	Lymphocyte counts;Fibrinogen;
SARC	cis	rs17376456	0.569	rs2045019	chr5:93201971	C/T	cg21475434	chr5:93447410	FAM172A	-0.66	-6.55	-0.39	3.65e-10	Diabetic retinopathy;
SARC	cis	rs6912958	1.000	rs9294379	chr6:88152535	C/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.62	-8.71	-0.5	5.53e-16	Monocyte percentage of white cells;
SARC	trans	rs6981523	0.532	rs1987190	chr8:11053514	T/A	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.49	-0.39	5.18e-10	Neuroticism;
SARC	cis	rs853679	0.699	rs9468318	chr6:28209531	T/A	cg26450541	chr6:28235208	ZNF187	0.59	5.21	0.32	4.25e-7	Depression;
SARC	cis	rs7647973	0.593	rs9870755	chr3:49809841	A/G	cg07636037	chr3:49044803	WDR6	0.59	5.99	0.37	7.94e-9	Menarche (age at onset);
SARC	cis	rs79149102	0.649	rs3743486	chr15:75113958	C/G	cg09165964	chr15:75287851	SCAMP5	-0.94	-5.98	-0.36	8.22e-9	Lung cancer;
SARC	cis	rs6952808	0.929	rs12699483	chr7:1975624	C/G	cg04267008	chr7:1944627	MAD1L1	-0.65	-7.39	-0.44	2.54e-12	Bipolar disorder and schizophrenia;
SARC	trans	rs561341	0.843	rs879944	chr17:30242803	A/G	cg20587970	chr11:113659929	NA	-0.9	-9.0	-0.51	8.31e-17	Hip circumference adjusted for BMI;
SARC	cis	rs67311347	1.000	rs67311347	chr3:40533243	G/A	cg24209194	chr3:40518798	ZNF619	0.61	7.77	0.45	2.54e-13	Renal cell carcinoma;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg06853599	chr11:46413816	NA	0.47	6.29	0.38	1.58e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs3008870	0.677	rs2815354	chr1:67483642	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.86	9.09	0.51	4.53e-17	Lymphocyte percentage of white cells;
SARC	cis	rs944802	0.929	rs10965266	chr9:22161494	G/T	cg00491127	chr9:22154101	NA	0.5	5.34	0.33	2.19e-7	White blood cell count;
SARC	cis	rs2594989	0.943	rs1391903	chr3:11423271	C/G	cg00170343	chr3:11313890	ATG7	-0.56	-5.39	-0.33	1.71e-7	Circulating chemerin levels;
SARC	cis	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg20034785	chr20:44440976	UBE2C	0.51	5.43	0.34	1.39e-7	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
SARC	cis	rs939574	1.000	rs1024131	chr2:220117458	G/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.63	5.01	0.31	1.09e-6	Platelet distribution width;
SARC	cis	rs950776	0.714	rs3743074	chr15:78909480	G/A	cg24631222	chr15:78858424	CHRNA5	0.37	4.72	0.3	3.99e-6	Sudden cardiac arrest;
SARC	cis	rs2933343	0.601	rs1680759	chr3:128594896	C/G	cg25356066	chr3:128598488	ACAD9	0.71	9.53	0.53	2.1e-18	IgG glycosylation;
SARC	cis	rs9316337	0.872	rs9580094	chr13:21951162	C/A	cg18095732	chr13:22033692	ZDHHC20	0.38	4.88	0.3	1.95e-6	Schizophrenia;
SARC	cis	rs7098414	0.511	rs7899513	chr10:82150559	G/A	cg01528321	chr10:82214614	TSPAN14	0.57	7.98	0.46	6.5e-14	Post bronchodilator FEV1;
SARC	cis	rs698813	0.604	rs7606004	chr2:44479983	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.8	0.36	2.1e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9467711	0.538	rs7750960	chr6:25887217	A/C	cg21479132	chr6:26055353	NA	0.74	4.83	0.3	2.44e-6	Autism spectrum disorder or schizophrenia;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg02085815	chr4:128802010	PLK4	0.57	6.52	0.39	4.31e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs9814567	1.000	rs7428326	chr3:134251184	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.1	-0.42	1.49e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs12188164	0.543	rs2672757	chr5:454732	A/G	cg16584290	chr5:462447	EXOC3	0.46	7.27	0.43	5.46e-12	Cystic fibrosis severity;
SARC	cis	rs8067545	0.750	rs9897246	chr17:19965702	T/G	cg13482628	chr17:19912719	NA	0.54	7.2	0.43	8.22e-12	Schizophrenia;
SARC	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	cis	rs3126085	0.778	rs10788828	chr1:152191879	G/A	cg03465714	chr1:152285911	FLG	-0.47	-5.62	-0.35	5.41e-8	Atopic dermatitis;
SARC	cis	rs769267	0.629	rs7245672	chr19:19699963	T/C	cg03709012	chr19:19516395	GATAD2A	-0.74	-9.69	-0.54	7.14e-19	Tonsillectomy;
SARC	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg21644426	chr2:191273491	MFSD6	-0.49	-6.57	-0.4	3.23e-10	Pulse pressure;
SARC	cis	rs9814567	1.000	rs9968172	chr3:134231251	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.55	6.87	0.41	5.92e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs4481887	0.927	rs4558008	chr1:248477641	C/T	cg00666640	chr1:248458726	OR2T12	0.35	5.8	0.36	2.16e-8	Common traits (Other);
SARC	cis	rs7092929	0.941	rs1890583	chr10:3590269	T/C	cg14308648	chr10:3568949	NA	0.5	5.05	0.31	8.93e-7	Coronary artery calcification;
SARC	cis	rs3768617	0.510	rs6424885	chr1:183066254	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.59	0.57	1.23e-21	Fuchs's corneal dystrophy;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg24382680	chr15:80351977	ZFAND6	-0.52	-6.67	-0.4	1.81e-10	Schizophrenia;
SARC	cis	rs6120849	0.754	rs3818253	chr20:33596876	C/T	cg24642439	chr20:33292090	TP53INP2	0.58	5.54	0.34	8.09e-8	Protein C levels;
SARC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg11494091	chr17:61959527	GH2	0.53	8.08	0.47	3.55e-14	Prudent dietary pattern;
SARC	cis	rs412000	0.560	rs4793583	chr17:56451407	A/C	cg05425664	chr17:57184151	TRIM37	0.65	7.78	0.45	2.4e-13	Primary tooth development (time to first tooth eruption);
SARC	cis	rs7904368	0.707	rs12253979	chr10:16853415	T/C	cg23933602	chr10:16859644	RSU1	0.62	6.18	0.38	2.91e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	trans	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.75	10.38	0.56	5.47e-21	Intelligence (multi-trait analysis);
SARC	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	16.1	0.73	1.06e-39	Chronic sinus infection;
SARC	cis	rs2153535	0.580	rs1577468	chr6:8444266	C/A	cg23788917	chr6:8435910	SLC35B3	0.63	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs9788682	0.747	rs12910984	chr15:78891627	G/A	cg24631222	chr15:78858424	CHRNA5	-0.72	-9.74	-0.54	4.96e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.27	0.43	5.52e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs908922	0.676	rs12116609	chr1:152497685	C/T	cg09873164	chr1:152488093	CRCT1	0.63	8.06	0.47	4.07e-14	Hair morphology;
SARC	cis	rs6138458	1.000	rs11906373	chr20:24938832	A/G	cg26195577	chr20:24973756	C20orf3	0.89	9.28	0.52	1.19e-17	Blood protein levels;
SARC	cis	rs2204008	0.811	rs12368410	chr12:38305705	C/T	cg26384229	chr12:38710491	ALG10B	0.91	13.52	0.66	3.87e-31	Bladder cancer;
SARC	cis	rs7216064	1.000	rs7224923	chr17:65842265	T/G	cg12091567	chr17:66097778	LOC651250	-0.69	-6.99	-0.42	2.89e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg11987759	chr7:65425863	GUSB	-0.47	-6.27	-0.38	1.7e-9	Aortic root size;
SARC	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-9.74	-0.54	4.9e-19	Chronic sinus infection;
SARC	cis	rs6690583	0.943	rs1837329	chr1:85469614	G/A	cg22153463	chr1:85462885	MCOLN2	-0.65	-6.63	-0.4	2.36e-10	Serum sulfate level;
SARC	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.38	-5.18	-0.32	4.69e-7	Personality dimensions;
SARC	cis	rs9457247	1.000	rs2149090	chr6:167372764	T/C	cg07741184	chr6:167504864	NA	-0.3	-5.61	-0.34	5.78e-8	Crohn's disease;
SARC	cis	rs920590	0.642	rs6993525	chr8:19671104	A/G	cg03894339	chr8:19674705	INTS10	-0.64	-7.34	-0.43	3.63e-12	Acute lymphoblastic leukemia (childhood);
SARC	trans	rs1422110	0.543	rs888804	chr5:85411181	G/A	cg01787110	chr1:109008453	NBPF6	0.44	6.33	0.38	1.25e-9	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs6570726	0.935	rs416987	chr6:145847005	G/C	cg23711669	chr6:146136114	FBXO30	0.78	12.08	0.62	2.13e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1969363	0.509	rs8189633	chr12:38065155	C/G	cg26384229	chr12:38710491	ALG10B	0.89	13.14	0.65	6.99e-30	Morning vs. evening chronotype;
SARC	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg27347728	chr4:17578864	LAP3	0.48	6.1	0.37	4.5e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs61931739	0.500	rs1843736	chr12:34012080	C/G	cg13010199	chr12:38710504	ALG10B	0.75	10.07	0.55	4.77e-20	Morning vs. evening chronotype;
SARC	cis	rs3812831	0.669	rs382913	chr13:114928255	G/T	cg08824895	chr13:115047677	UPF3A	0.53	7.0	0.42	2.75e-11	Schizophrenia;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg07967114	chr12:94915694	NA	-0.52	-7.09	-0.42	1.59e-11	Height;
SARC	cis	rs6933660	0.512	rs13198669	chr6:151799924	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	-0.66	-5.52	-0.34	8.86e-8	Menarche (age at onset);
SARC	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg22974920	chr21:40686053	BRWD1	-0.46	-4.98	-0.31	1.23e-6	Cognitive function;
SARC	cis	rs10789491	1.000	rs35861275	chr1:47171909	A/C	cg15501359	chr1:47185051	KIAA0494	-0.73	-7.62	-0.45	6.43e-13	Response to hepatitis C treatment;
SARC	cis	rs9296092	0.517	rs6911036	chr6:33471652	C/G	cg13560919	chr6:33536144	NA	-0.44	-5.07	-0.32	8.23e-7	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg21782813	chr7:2030301	MAD1L1	0.4	6.22	0.38	2.26e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs7560272	0.695	rs780394	chr2:73700930	A/G	cg20560298	chr2:73613845	ALMS1	0.54	7.28	0.43	5.19e-12	Schizophrenia;
SARC	cis	rs17345786	0.798	rs1609159	chr3:101275902	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.43	4.93	0.31	1.53e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg00933542	chr6:150070202	PCMT1	0.31	5.03	0.31	9.61e-7	Testicular germ cell tumor;
SARC	cis	rs7223966	1.000	rs16947005	chr17:61702989	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.58	-6.71	-0.4	1.45e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs4713675	0.584	rs9394163	chr6:33682414	A/G	cg15676125	chr6:33679581	C6orf125	0.51	6.06	0.37	5.37e-9	Plateletcrit;
SARC	cis	rs752010	0.967	rs6675999	chr1:42099024	T/G	cg06885757	chr1:42089581	HIVEP3	0.35	5.57	0.34	6.92e-8	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs1580019	0.563	rs34319173	chr7:32585904	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.61	7.96	0.46	7.76e-14	Cognitive ability;
SARC	cis	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg21775007	chr8:11205619	TDH	0.38	4.74	0.3	3.71e-6	Neuroticism;
SARC	cis	rs2230307	0.536	rs554742	chr1:100512568	G/A	cg24955406	chr1:100503596	HIAT1	0.69	6.41	0.39	7.81e-10	Carotid intima media thickness;
SARC	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg27170947	chr2:26402098	FAM59B	0.37	4.79	0.3	2.91e-6	Gut microbiome composition (summer);
SARC	cis	rs7552404	0.731	rs61770552	chr1:76373050	T/C	cg03433033	chr1:76189801	ACADM	0.46	5.61	0.34	5.79e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9309711	0.623	rs7569694	chr2:3483390	T/G	cg08493051	chr2:3487164	NA	-0.4	-5.06	-0.31	8.4e-7	Neurofibrillary tangles;
SARC	cis	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg12257692	chr3:49977190	RBM6	0.28	4.98	0.31	1.25e-6	Body mass index;
SARC	cis	rs7927592	0.672	rs10501398	chr11:68331715	C/G	cg01657329	chr11:68192670	LRP5	0.35	4.84	0.3	2.4e-6	Total body bone mineral density;
SARC	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg02725872	chr8:58115012	NA	-0.36	-6.12	-0.37	3.91e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg10862848	chr6:42927986	GNMT	0.41	6.76	0.4	1.11e-10	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg20120463	chr17:44301886	NA	-0.35	-5.39	-0.33	1.7e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg17376030	chr22:41985996	PMM1	0.71	8.39	0.48	4.61e-15	Vitiligo;
SARC	cis	rs888194	0.966	rs7313797	chr12:109896165	A/G	cg13986417	chr12:110012484	MVK;MMAB	-0.34	-5.21	-0.32	4.2e-7	Neuroticism;
SARC	cis	rs6121246	0.697	rs45557936	chr20:30226690	G/A	cg13852791	chr20:30311386	BCL2L1	0.8	8.64	0.49	9.21e-16	Mean corpuscular hemoglobin;
SARC	cis	rs10131894	0.611	rs174994	chr14:75434102	A/G	cg08847533	chr14:75593920	NEK9	-0.77	-10.54	-0.57	1.73e-21	Coronary artery disease;
SARC	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg17554472	chr22:41940697	POLR3H	-0.45	-4.87	-0.3	2.05e-6	Vitiligo;
SARC	cis	rs7447927	0.950	rs13181561	chr5:138850905	A/G	cg11459648	chr5:138714337	SLC23A1	-0.39	-5.46	-0.34	1.23e-7	Esophageal squamous cell carcinoma;
SARC	cis	rs1401999	0.966	rs2313216	chr3:183637251	C/T	cg01324343	chr3:183735012	ABCC5	0.67	13.46	0.66	6.18e-31	Anterior chamber depth;
SARC	cis	rs9611519	1.000	rs4820433	chr22:41607065	C/G	cg03806693	chr22:41940476	POLR3H	-0.52	-6.55	-0.39	3.65e-10	Neuroticism;
SARC	cis	rs8180040	0.966	rs6792488	chr3:47503349	C/T	cg27129171	chr3:47204927	SETD2	-0.68	-9.56	-0.53	1.8e-18	Colorectal cancer;
SARC	cis	rs4268898	0.636	rs72787383	chr2:24583861	G/A	cg06627628	chr2:24431161	ITSN2	-0.83	-10.03	-0.55	6.44e-20	Asthma;
SARC	cis	rs12681288	0.823	rs12681230	chr8:994422	G/A	cg15309053	chr8:964076	NA	0.42	7.02	0.42	2.43e-11	Schizophrenia;
SARC	cis	rs526231	0.543	rs32851	chr5:102468671	A/G	cg23492399	chr5:102201601	PAM	-0.51	-5.55	-0.34	7.77e-8	Primary biliary cholangitis;
SARC	cis	rs1580019	1.000	rs1580019	chr7:32493169	A/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.63	-8.48	-0.49	2.7e-15	Cognitive ability;
SARC	cis	rs10465746	0.682	rs55693838	chr1:84359081	G/A	cg10977910	chr1:84465055	TTLL7	0.41	4.89	0.3	1.9e-6	Obesity-related traits;
SARC	cis	rs4803455	0.565	rs1800470	chr19:41858921	G/A	cg08477640	chr19:41863820	B9D2	0.65	8.74	0.5	4.57e-16	Migraine;Coronary artery disease;
SARC	cis	rs11690935	0.851	rs10174055	chr2:172858214	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.96	-14.09	-0.68	5.15e-33	Schizophrenia;
SARC	cis	rs9788682	0.694	rs10851906	chr15:78774676	A/G	cg24631222	chr15:78858424	CHRNA5	0.74	9.03	0.51	6.82e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.75	10.79	0.58	2.75e-22	Menarche (age at onset);
SARC	cis	rs11697848	1.000	rs56309244	chr20:48491207	G/A	cg17849948	chr20:48532315	SPATA2	0.8	4.86	0.3	2.15e-6	Systemic lupus erythematosus;
SARC	cis	rs865483	0.646	rs1034686	chr17:35899141	T/A	cg06561646	chr17:35873369	DUSP14	-0.49	-6.38	-0.39	9.35e-10	Monocyte count;
SARC	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.58	0.34	6.8e-8	Bipolar disorder;
SARC	cis	rs3733585	0.699	rs6449179	chr4:9969117	G/A	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.65	-0.35	4.69e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	trans	rs459571	0.804	rs448918	chr9:136885979	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.6	-6.81	-0.41	8.21e-11	Platelet distribution width;
SARC	cis	rs11601602	0.531	rs35031414	chr11:28545563	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.66	6.93	0.41	4.13e-11	Obesity-related traits;
SARC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg11494091	chr17:61959527	GH2	0.55	8.26	0.48	1.11e-14	Prudent dietary pattern;
SARC	cis	rs2276314	0.857	rs62101379	chr18:33584902	G/A	cg05985134	chr18:33552581	C18orf21	0.67	6.78	0.41	9.61e-11	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs2916247	0.865	rs7813262	chr8:93157419	C/T	cg10183463	chr8:93005414	RUNX1T1	0.5	5.34	0.33	2.26e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-6.45	-0.39	6.31e-10	Personality dimensions;
SARC	cis	rs9796	0.576	rs13329511	chr15:41299121	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.52	-7.09	-0.42	1.6e-11	Menopause (age at onset);
SARC	cis	rs644799	0.932	rs480079	chr11:95643777	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.9	-14.08	-0.68	5.65e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs208520	0.690	rs12213581	chr6:66735818	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	13.86	0.67	2.98e-32	Exhaled nitric oxide output;
SARC	trans	rs36093844	0.605	rs79719453	chr11:85582217	C/A	cg15359163	chr5:122429178	PRDM6	-0.53	-6.33	-0.38	1.28e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs6089584	0.566	rs2181589	chr20:60622817	C/T	cg06108461	chr20:60628389	TAF4	0.71	9.63	0.53	1.09e-18	Body mass index;
SARC	cis	rs6674176	0.628	rs12145999	chr1:44428632	C/T	cg13606994	chr1:44402422	ARTN	-0.33	-5.4	-0.33	1.63e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs7927771	0.894	rs12798346	chr11:47583121	C/T	cg20307385	chr11:47447363	PSMC3	-0.51	-6.31	-0.38	1.37e-9	Subjective well-being;
SARC	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg23758822	chr17:41437982	NA	0.88	11.32	0.6	6.01e-24	Menopause (age at onset);
SARC	cis	rs601339	1.000	rs630408	chr12:123172822	C/T	cg18578876	chr12:123200353	GPR109B	0.43	4.91	0.31	1.68e-6	Adiponectin levels;
SARC	cis	rs1707322	1.000	rs34446427	chr1:46417655	A/C	cg03146154	chr1:46216737	IPP	0.46	5.5	0.34	9.8e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs8180040	0.726	rs34344887	chr3:47042161	A/G	cg27129171	chr3:47204927	SETD2	0.67	9.15	0.51	2.92e-17	Colorectal cancer;
SARC	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg06634786	chr22:41940651	POLR3H	0.5	6.08	0.37	4.99e-9	Vitiligo;
SARC	cis	rs7089973	0.604	rs7904188	chr10:116610271	G/C	cg03647239	chr10:116582469	FAM160B1	0.5	6.49	0.39	5.19e-10	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs2016266	0.787	rs4520636	chr12:53752133	G/T	cg26875137	chr12:53738046	NA	0.41	4.93	0.31	1.55e-6	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg02951883	chr7:2050386	MAD1L1	-0.4	-5.11	-0.32	6.72e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs67311347	1.000	rs2305522	chr3:40429358	A/G	cg24209194	chr3:40518798	ZNF619	0.6	7.59	0.45	7.87e-13	Renal cell carcinoma;
SARC	cis	rs11690935	1.000	rs6433311	chr2:172549248	A/G	cg13550731	chr2:172543902	DYNC1I2	0.98	15.15	0.7	1.45e-36	Schizophrenia;
SARC	trans	rs629535	0.814	rs78813708	chr8:70073977	A/G	cg21567404	chr3:27674614	NA	1.03	13.0	0.65	1.98e-29	Dupuytren's disease;
SARC	cis	rs9858542	0.537	rs56038006	chr3:49362369	C/T	cg00383909	chr3:49044727	WDR6	0.55	5.67	0.35	4.21e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs1018836	0.828	rs10956730	chr8:91597428	T/G	cg16814680	chr8:91681699	NA	-0.77	-12.08	-0.62	2.1e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs4742903	0.846	rs7022158	chr9:106924872	A/G	cg14250997	chr9:106856677	SMC2	0.44	5.5	0.34	9.91e-8	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs6714710	0.580	rs17489915	chr2:98420431	T/C	cg26665480	chr2:98280029	ACTR1B	0.51	6.84	0.41	6.93e-11	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs12545109	0.879	rs7845180	chr8:57324431	C/T	cg19413350	chr8:57351067	NA	0.4	4.85	0.3	2.3e-6	Obesity-related traits;
SARC	cis	rs7552404	0.924	rs1146588	chr1:76229787	C/G	cg03433033	chr1:76189801	ACADM	0.48	6.83	0.41	7.47e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9916302	0.904	rs2168785	chr17:37407135	C/T	cg20243544	chr17:37824526	PNMT	0.53	6.39	0.39	8.84e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs2832077	1.000	rs2832065	chr21:30135362	C/T	cg03476357	chr21:30257390	N6AMT1	-0.6	-5.72	-0.35	3.25e-8	Cognitive test performance;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg09677007	chr2:236648916	AGAP1	0.49	6.24	0.38	2.1e-9	Schizophrenia;
SARC	cis	rs11785400	0.731	rs4736363	chr8:143742112	C/A	cg24634471	chr8:143751801	JRK	0.62	8.02	0.46	5.27e-14	Schizophrenia;
SARC	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg25427524	chr10:38739819	LOC399744	-0.62	-9.58	-0.53	1.5e-18	Extrinsic epigenetic age acceleration;
SARC	cis	rs155076	1.000	rs261432	chr13:21865915	G/C	cg06138931	chr13:21896616	NA	-0.39	-5.07	-0.31	8.3e-7	White matter hyperintensity burden;
SARC	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg24250549	chr1:154909240	PMVK	0.83	11.96	0.62	4.97e-26	Prostate cancer;
SARC	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.31	-4.99	-0.31	1.2e-6	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs2230307	0.536	rs684519	chr1:100604715	T/G	cg24955406	chr1:100503596	HIAT1	-0.67	-6.64	-0.4	2.19e-10	Carotid intima media thickness;
SARC	cis	rs12912251	1.000	rs7163869	chr15:38988391	G/C	cg01338139	chr15:38987640	C15orf53	-0.46	-5.42	-0.33	1.52e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
SARC	cis	rs7772486	0.597	rs9386136	chr6:146158300	A/T	cg05347473	chr6:146136440	FBXO30	0.69	9.58	0.53	1.54e-18	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9815354	0.767	rs73079350	chr3:41876310	C/T	cg03022575	chr3:42003672	ULK4	0.71	5.8	0.36	2.14e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9650657	0.515	rs7820860	chr8:10950396	C/G	cg00262122	chr8:11665843	FDFT1	-0.4	-4.81	-0.3	2.75e-6	Neuroticism;
SARC	cis	rs4566357	0.615	rs10190621	chr2:227914484	A/G	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.71	-0.35	3.43e-8	Coronary artery disease;
SARC	cis	rs8067545	0.641	rs203457	chr17:19818338	A/C	cg13482628	chr17:19912719	NA	-0.49	-6.05	-0.37	5.78e-9	Schizophrenia;
SARC	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg24642844	chr7:1081250	C7orf50	-0.5	-5.57	-0.34	6.94e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg10862848	chr6:42927986	GNMT	-0.43	-7.24	-0.43	6.53e-12	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs526821	0.595	rs629948	chr11:55356448	G/A	cg04317927	chr11:55418816	OR4S2	0.41	6.14	0.37	3.62e-9	Pediatric bone mineral density (spine);
SARC	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg22509189	chr2:225307070	NA	0.63	7.92	0.46	9.69e-14	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs79387448	0.745	rs17027442	chr2:103164948	A/G	cg09003973	chr2:102972529	NA	-0.62	-6.0	-0.37	7.34e-9	Gut microbiota (bacterial taxa);
SARC	trans	rs61931739	0.500	rs11053194	chr12:34440841	A/G	cg26384229	chr12:38710491	ALG10B	0.83	12.55	0.64	5.92e-28	Morning vs. evening chronotype;
SARC	cis	rs1570884	0.516	rs9316463	chr13:50176844	G/A	cg03651054	chr13:50194643	NA	0.3	4.88	0.3	1.95e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg17221315	chr6:27791827	HIST1H4J	0.49	5.01	0.31	1.08e-6	Depression;
SARC	cis	rs4132509	0.947	rs10927039	chr1:243721726	C/T	cg21452805	chr1:244014465	NA	-0.56	-6.3	-0.38	1.46e-9	RR interval (heart rate);
SARC	cis	rs4803468	1.000	rs4803468	chr19:41922352	A/G	cg09537434	chr19:41945824	ATP5SL	-0.98	-17.39	-0.75	5.41e-44	Height;
SARC	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg14664628	chr15:75095509	CSK	-0.42	-5.07	-0.32	7.94e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	cis	rs6089584	0.606	rs2144674	chr20:60576579	G/A	cg23262073	chr20:60523788	NA	-0.39	-5.85	-0.36	1.62e-8	Body mass index;
SARC	cis	rs1355223	0.506	rs11032894	chr11:34865544	T/C	cg11622362	chr11:34938112	PDHX;APIP	0.46	6.04	0.37	5.98e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs17376456	0.542	rs1982439	chr5:93160560	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.55	-5.68	-0.35	4.03e-8	Diabetic retinopathy;
SARC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg10295955	chr4:187884368	NA	-1.08	-20.57	-0.8	2.68e-54	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4319547	0.695	rs113841747	chr12:122886088	G/T	cg05707623	chr12:122985044	ZCCHC8	0.55	6.16	0.37	3.2e-9	Body mass index;
SARC	cis	rs67460515	0.563	rs4494975	chr3:160866768	C/T	cg17135325	chr3:160939158	NMD3	0.65	8.1	0.47	2.99e-14	Parkinson's disease;
SARC	cis	rs6580649	1.000	rs3825404	chr12:48399931	A/G	cg24011408	chr12:48396354	COL2A1	0.52	6.0	0.37	7.53e-9	Lung cancer;
SARC	cis	rs4148883	0.651	rs4147547	chr4:100127311	G/T	cg13256891	chr4:100009986	ADH5	0.55	7.21	0.43	7.6e-12	Alcohol dependence;
SARC	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg03264133	chr6:25882463	NA	-0.63	-8.57	-0.49	1.49e-15	Uric acid levels;
SARC	cis	rs9400467	0.506	rs56381513	chr6:111429685	C/G	cg15721981	chr6:111408429	SLC16A10	0.69	5.84	0.36	1.7e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs1728785	0.892	rs1170427	chr16:68603852	G/T	cg02972257	chr16:68554789	NA	-0.47	-5.56	-0.34	7.2e-8	Ulcerative colitis;
SARC	cis	rs6120849	0.518	rs11696652	chr20:33637060	T/G	cg24642439	chr20:33292090	TP53INP2	0.57	5.48	0.34	1.1e-7	Protein C levels;
SARC	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg25036284	chr2:26402008	FAM59B	-0.43	-5.42	-0.33	1.52e-7	Gut microbiome composition (summer);
SARC	cis	rs453301	0.686	rs11785634	chr8:8892597	G/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.77	-0.41	1.03e-10	Joint mobility (Beighton score);
SARC	cis	rs11122272	0.603	rs2998427	chr1:231528112	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.15	-0.55	2.79e-20	Hemoglobin concentration;
SARC	cis	rs11098499	0.908	rs11729050	chr4:120300066	T/C	cg09160332	chr4:120329925	NA	-0.33	-4.77	-0.3	3.27e-6	Corneal astigmatism;
SARC	cis	rs4819052	0.655	rs2330102	chr21:46690968	C/G	cg06618935	chr21:46677482	NA	-0.35	-4.82	-0.3	2.61e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4805272	0.512	rs17772319	chr19:29343064	T/A	cg12756686	chr19:29218302	NA	0.49	5.26	0.33	3.23e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs3771570	1.000	rs62190367	chr2:242376276	G/A	cg21155796	chr2:242212141	HDLBP	0.7	6.4	0.39	8.59e-10	Prostate cancer;
SARC	cis	rs763121	0.853	rs11704021	chr22:39074716	G/A	cg14440974	chr22:39074834	NA	-0.33	-4.77	-0.3	3.24e-6	Menopause (age at onset);
SARC	cis	rs2204008	0.658	rs11495742	chr12:38395688	C/A	cg13010199	chr12:38710504	ALG10B	0.78	10.49	0.57	2.41e-21	Bladder cancer;
SARC	cis	rs10870270	1.000	rs9971066	chr10:133788233	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.43	-4.77	-0.3	3.26e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs314370	1.000	rs314370	chr7:100453208	T/C	cg10426581	chr7:100472382	SRRT	0.6	6.25	0.38	1.94e-9	Resting heart rate;
SARC	cis	rs6429082	0.683	rs2131920	chr1:235579912	T/A	cg26050004	chr1:235667680	B3GALNT2	-0.58	-7.55	-0.44	9.58e-13	Adiposity;
SARC	cis	rs12545912	0.818	rs7462102	chr8:9461368	T/C	cg21625330	chr8:9911636	MSRA	-0.51	-4.93	-0.31	1.57e-6	Multiple myeloma (hyperdiploidy);
SARC	cis	rs34779708	0.966	rs12774834	chr10:35400070	A/T	cg03585969	chr10:35415529	CREM	0.42	5.17	0.32	5.03e-7	Inflammatory bowel disease;Crohn's disease;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg24983605	chr2:180487919	ZNF385B	0.45	6.39	0.39	8.95e-10	Thyroid stimulating hormone;
SARC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.68	-6.9	-0.41	4.89e-11	Platelet count;
SARC	cis	rs7647973	1.000	rs6446275	chr3:49466871	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.56	-5.94	-0.36	1.03e-8	Menarche (age at onset);
SARC	trans	rs7615952	0.736	rs9866347	chr3:125669925	C/T	cg07211511	chr3:129823064	LOC729375	-0.91	-8.46	-0.48	3.06e-15	Blood pressure (smoking interaction);
SARC	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg06420487	chr17:61919686	SMARCD2	0.43	4.78	0.3	3.11e-6	Height;
SARC	cis	rs76419734	0.850	rs115599607	chr4:106590294	T/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.76	4.76	0.3	3.46e-6	Post bronchodilator FEV1;
SARC	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg17294928	chr15:75287854	SCAMP5	0.5	6.38	0.39	9.25e-10	Breast cancer;
SARC	cis	rs6089829	0.962	rs1116450	chr20:61658210	T/C	cg08564027	chr20:61660810	NA	0.78	11.74	0.61	2.61e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs4803468	1.000	rs3816037	chr19:41918009	C/T	cg14132834	chr19:41945861	ATP5SL	-0.56	-7.37	-0.43	2.9e-12	Height;
SARC	cis	rs55692411	0.537	rs35012435	chr3:50031840	C/T	cg24110177	chr3:50126178	RBM5	-0.49	-5.37	-0.33	1.91e-7	Intelligence (multi-trait analysis);
SARC	cis	rs5167	0.743	rs57204168	chr19:45496776	A/G	cg10169327	chr19:45448959	APOC2	0.31	4.84	0.3	2.36e-6	Blood protein levels;
SARC	cis	rs2013441	1.000	rs4924810	chr17:20071819	T/C	cg13482628	chr17:19912719	NA	0.48	6.15	0.37	3.36e-9	Obesity-related traits;
SARC	cis	rs317865	0.609	rs73234660	chr4:16221047	G/C	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.63	4.83	0.3	2.46e-6	Kidney disease (early stage) in type 1 diabetes;
SARC	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg03060546	chr3:49711283	APEH	0.48	6.19	0.38	2.71e-9	Menarche (age at onset);
SARC	cis	rs7917772	0.502	rs2296584	chr10:104244323	T/A	ch.10.2196322F	chr10:104248062	ACTR1A	0.56	7.31	0.43	4.14e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs7769051	0.522	rs73554461	chr6:133139087	T/G	cg07930552	chr6:133119739	C6orf192	1.0	6.01	0.37	7.02e-9	Type 2 diabetes nephropathy;
SARC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.76	0.54	4.42e-19	Prudent dietary pattern;
SARC	cis	rs1008375	0.931	rs10939733	chr4:17570658	T/C	cg02297831	chr4:17616191	MED28	0.46	5.7	0.35	3.62e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg11814155	chr7:99998594	ZCWPW1	0.44	4.79	0.3	3e-6	Platelet count;
SARC	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.62	7.52	0.44	1.14e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs1814175	0.616	rs847641	chr11:49919261	T/C	cg15704280	chr7:45808275	SEPT13	-0.88	-14.0	-0.68	1.02e-32	Height;
SARC	cis	rs6504663	1.000	rs6504661	chr17:48580126	A/T	cg11440486	chr17:48585216	MYCBPAP	-0.4	-4.95	-0.31	1.43e-6	Visceral fat;
SARC	cis	rs10771431	0.935	rs1117735	chr12:9372728	G/A	cg08997352	chr12:9597637	DDX12	-0.55	-7.77	-0.45	2.49e-13	Breast size;
SARC	cis	rs9400467	0.506	rs12192147	chr6:111648057	G/C	cg15721981	chr6:111408429	SLC16A10	0.66	5.7	0.35	3.57e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs722599	0.748	rs55707505	chr14:75362552	T/C	cg11812906	chr14:75593930	NEK9	-0.44	-5.0	-0.31	1.15e-6	IgG glycosylation;
SARC	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg02725872	chr8:58115012	NA	-0.33	-5.0	-0.31	1.13e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs9640161	0.789	rs10282458	chr7:150045302	C/T	cg10018233	chr7:150070692	REPIN1	0.63	8.57	0.49	1.46e-15	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs3540	0.960	rs12440447	chr15:91022694	C/G	cg22089800	chr15:90895588	ZNF774	0.49	5.56	0.34	7.34e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs57221529	0.655	rs11948381	chr5:568413	A/T	cg07777115	chr5:623756	CEP72	-0.58	-5.28	-0.33	2.95e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.42	5.21	0.32	4.18e-7	Eosinophil percentage of white cells;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg01024009	chr3:145968696	PLSCR4	0.55	7.18	0.43	9.17e-12	Tetralogy of Fallot;
SARC	trans	rs1853207	1.000	rs28371676	chr10:96702363	T/C	cg02737782	chr1:8014393	NA	-0.94	-6.48	-0.39	5.26e-10	Blood metabolite levels;
SARC	cis	rs13082711	0.522	rs537674	chr3:27361901	G/T	cg02860705	chr3:27208620	NA	0.45	5.97	0.36	8.66e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs6542838	0.611	rs6742047	chr2:99531460	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.52	-6.74	-0.4	1.22e-10	Fear of minor pain;
SARC	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg25036284	chr2:26402008	FAM59B	-0.43	-5.42	-0.33	1.52e-7	Gut microbiome composition (summer);
SARC	cis	rs75804782	0.641	rs60841092	chr2:239349640	G/A	cg21699342	chr2:239360505	ASB1	-0.58	-4.81	-0.3	2.68e-6	Morning vs. evening chronotype;Chronotype;
SARC	cis	rs2976388	1.000	rs2585179	chr8:143774193	G/A	cg06565975	chr8:143823917	SLURP1	-0.28	-4.78	-0.3	3.05e-6	Urinary tract infection frequency;
SARC	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg04518342	chr5:131593106	PDLIM4	0.35	5.01	0.31	1.07e-6	Breast cancer;
SARC	cis	rs3784262	0.740	rs4646596	chr15:58300895	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.34	-4.98	-0.31	1.23e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	trans	rs11098499	0.604	rs2389882	chr4:120566733	A/C	cg25214090	chr10:38739885	LOC399744	0.5	6.49	0.39	5.25e-10	Corneal astigmatism;
SARC	cis	rs3018712	0.532	rs4930589	chr11:68415257	G/A	cg01657329	chr11:68192670	LRP5	0.59	5.38	0.33	1.81e-7	Total body bone mineral density;
SARC	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg25072359	chr17:41440525	NA	0.49	5.3	0.33	2.68e-7	Menopause (age at onset);
SARC	cis	rs4891159	0.584	rs690397	chr18:74117767	C/T	cg24786174	chr18:74118243	ZNF516	0.77	13.31	0.66	1.92e-30	Longevity;
SARC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg26338869	chr17:61819248	STRADA	0.8	10.64	0.57	8.58e-22	Prudent dietary pattern;
SARC	trans	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg00938859	chr5:1591904	SDHAP3	0.79	7.66	0.45	5.1e-13	Breast cancer;
SARC	cis	rs12421382	0.511	rs2212430	chr11:109289538	C/T	cg27471124	chr11:109292789	C11orf87	0.53	7.59	0.45	7.85e-13	Schizophrenia;
SARC	cis	rs734999	0.545	rs10910105	chr1:2538209	G/A	cg20673091	chr1:2541236	MMEL1	0.34	5.13	0.32	6.15e-7	Ulcerative colitis;
SARC	cis	rs4481887	0.861	rs4295906	chr1:248429861	C/T	cg00666640	chr1:248458726	OR2T12	0.36	5.81	0.36	2.03e-8	Common traits (Other);
SARC	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg17294928	chr15:75287854	SCAMP5	0.46	5.92	0.36	1.15e-8	Breast cancer;
SARC	cis	rs10870270	1.000	rs10159746	chr10:133742677	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.8	-10.37	-0.56	5.78e-21	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs11997175	0.713	rs4327826	chr8:33654807	T/G	ch.8.33884649F	chr8:33765107	NA	0.5	6.69	0.4	1.67e-10	Body mass index;
SARC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg06873352	chr17:61820015	STRADA	0.51	6.58	0.4	3.04e-10	Prudent dietary pattern;
SARC	cis	rs9303401	0.614	rs34843288	chr17:57103140	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.04	10.16	0.55	2.59e-20	Cognitive test performance;
SARC	cis	rs12545109	1.000	rs2217957	chr8:57313360	T/C	cg09654669	chr8:57350985	NA	-0.41	-5.08	-0.32	7.75e-7	Obesity-related traits;
SARC	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg02725872	chr8:58115012	NA	-0.36	-5.52	-0.34	8.99e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10861342	0.579	rs77585712	chr12:105482251	T/C	cg23923672	chr12:105501055	KIAA1033	0.73	5.3	0.33	2.74e-7	IgG glycosylation;
SARC	cis	rs7818345	0.845	rs4256608	chr8:19267560	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.38	4.79	0.3	2.93e-6	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs765787	0.530	rs4444275	chr15:45535347	T/C	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.51e-10	Uric acid levels;
SARC	cis	rs1707322	0.928	rs6681068	chr1:46398382	G/A	cg03146154	chr1:46216737	IPP	0.46	5.53	0.34	8.66e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7584330	0.737	rs61212490	chr2:238365230	T/C	cg14458575	chr2:238380390	NA	0.45	5.56	0.34	7.38e-8	Prostate cancer;
SARC	cis	rs765787	0.530	rs28396110	chr15:45536909	A/G	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.51e-10	Uric acid levels;
SARC	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg08280861	chr8:58055591	NA	0.6	5.28	0.33	2.92e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6964587	0.967	rs2040499	chr7:91809657	C/G	cg17063962	chr7:91808500	NA	-0.94	-15.45	-0.71	1.46e-37	Breast cancer;
SARC	cis	rs739401	0.572	rs404629	chr11:3077025	A/G	cg08508325	chr11:3079039	CARS	-0.31	-7.45	-0.44	1.83e-12	Longevity;
SARC	cis	rs7481584	0.581	rs105686	chr11:3062467	G/A	cg20651018	chr11:3035856	CARS	0.39	5.8	0.36	2.13e-8	Calcium levels;
SARC	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg10351095	chr21:47802916	PCNT	0.42	4.9	0.31	1.76e-6	Testicular germ cell tumor;
SARC	cis	rs6484504	0.576	rs169623	chr11:31184157	T/C	cg02090638	chr11:31391270	DNAJC24;DCDC1	-0.38	-4.86	-0.3	2.15e-6	Red blood cell count;
SARC	cis	rs933688	0.536	rs332537	chr5:90794973	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.77	-6.78	-0.41	9.92e-11	Smoking behavior;
SARC	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg19774624	chr17:42201019	HDAC5	0.79	11.5	0.6	1.54e-24	Total body bone mineral density;
SARC	cis	rs270601	0.837	rs367805	chr5:131701279	T/C	cg12564285	chr5:131593104	PDLIM4	0.41	5.77	0.35	2.45e-8	Acylcarnitine levels;
SARC	cis	rs4660306	1.000	rs2077808	chr1:45988115	G/A	cg24296786	chr1:45957014	TESK2	0.58	6.79	0.41	9.22e-11	Homocysteine levels;
SARC	trans	rs7824557	0.603	rs2246606	chr8:11219334	G/A	cg15556689	chr8:8085844	FLJ10661	0.51	6.26	0.38	1.85e-9	Retinal vascular caliber;
SARC	cis	rs4319547	0.695	rs7969429	chr12:122875606	A/G	cg23029597	chr12:123009494	RSRC2	-0.43	-5.29	-0.33	2.85e-7	Body mass index;
SARC	cis	rs7666738	0.830	rs13125930	chr4:98654695	G/A	cg05340658	chr4:99064831	C4orf37	0.64	8.27	0.48	1.04e-14	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.75	-0.45	2.87e-13	Extrinsic epigenetic age acceleration;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg20986655	chr6:170151393	TCTE3;C6orf70	-0.49	-6.53	-0.39	4.03e-10	Thyroid stimulating hormone;
SARC	cis	rs7566780	0.568	rs4832447	chr2:16629534	A/G	cg09580478	chr2:16689509	NA	0.53	6.16	0.37	3.12e-9	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs2177596	0.549	rs4592846	chr2:227948866	G/A	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.61	-0.34	5.73e-8	Body mass index;
SARC	cis	rs3812831	0.599	rs428636	chr13:114927133	T/C	cg06611532	chr13:114900021	NA	0.35	5.75	0.35	2.77e-8	Schizophrenia;
SARC	cis	rs912057	1.000	rs1294407	chr6:6738103	C/G	cg06612196	chr6:6737390	NA	0.65	9.49	0.53	2.85e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
SARC	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg11987759	chr7:65425863	GUSB	0.44	5.69	0.35	3.76e-8	Aortic root size;
SARC	cis	rs3859192	0.599	rs34342173	chr17:38161507	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.39	7.23	0.43	6.79e-12	White blood cell count;
SARC	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6669543	0.637	rs7514121	chr1:162000432	C/T	cg11795308	chr1:161133984	USP21	-0.42	-4.8	-0.3	2.77e-6	QT interval;
SARC	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg11764359	chr7:65958608	NA	0.63	7.29	0.43	4.8e-12	Aortic root size;
SARC	cis	rs3768617	0.510	rs10752895	chr1:183068505	C/G	cg13390022	chr1:182993471	LAMC1	0.32	4.83	0.3	2.48e-6	Fuchs's corneal dystrophy;
SARC	cis	rs796364	1.000	rs769949	chr2:200729558	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.8	7.11	0.42	1.4e-11	Schizophrenia;
SARC	cis	rs2839186	0.605	rs2839173	chr21:47676711	G/A	cg03841560	chr21:47649172	MCM3APAS;LSS	0.36	4.78	0.3	3.18e-6	Testicular germ cell tumor;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg20127207	chr2:160625571	CD302	0.46	6.53	0.39	4.15e-10	Thyroid stimulating hormone;
SARC	cis	rs9309711	0.666	rs6767	chr2:3483205	C/T	cg15541040	chr2:3486749	NA	-0.43	-5.76	-0.35	2.6e-8	Neurofibrillary tangles;
SARC	cis	rs734999	0.505	rs10797438	chr1:2540262	C/T	cg18854424	chr1:2615690	NA	0.33	5.16	0.32	5.25e-7	Ulcerative colitis;
SARC	cis	rs3106136	0.807	rs6851128	chr4:95259455	A/G	cg11021082	chr4:95130006	SMARCAD1	0.35	5.34	0.33	2.23e-7	Capecitabine sensitivity;
SARC	cis	rs13040088	1.000	rs6090155	chr20:61527378	G/A	cg23096297	chr20:61557774	DIDO1	0.92	9.87	0.54	2.02e-19	Menopause (age at onset);
SARC	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.61	5.25	0.33	3.47e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs644799	1.000	rs623191	chr11:95548359	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	14.15	0.68	3.08e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs6582630	0.502	rs3902522	chr12:38271203	T/C	cg13010199	chr12:38710504	ALG10B	0.78	10.65	0.57	7.82e-22	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs61931739	0.517	rs7958755	chr12:34294699	T/C	cg26384229	chr12:38710491	ALG10B	0.84	11.77	0.61	2.04e-25	Morning vs. evening chronotype;
SARC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	20.42	0.8	8.2e-54	Prudent dietary pattern;
SARC	cis	rs9790314	0.846	rs4560315	chr3:160982132	G/T	cg03342759	chr3:160939853	NMD3	-0.73	-9.94	-0.55	1.26e-19	Morning vs. evening chronotype;
SARC	cis	rs2153904	0.793	rs12118655	chr1:205663478	A/G	cg26354017	chr1:205819088	PM20D1	-0.58	-4.85	-0.3	2.31e-6	Prostate-specific antigen levels;
SARC	cis	rs1355223	0.506	rs7131229	chr11:34869328	A/G	cg11622362	chr11:34938112	PDHX;APIP	-0.46	-6.03	-0.37	6.23e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs9900497	0.569	rs2072327	chr17:19651482	G/T	cg22552966	chr17:19620595	SLC47A2	-0.3	-5.47	-0.34	1.13e-7	Response to paliperidone in schizophrenia (CGI-S score);
SARC	cis	rs611744	0.967	rs684093	chr8:109199355	G/C	cg21045802	chr8:109455806	TTC35	0.44	5.23	0.32	3.81e-7	Dupuytren's disease;
SARC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg26338869	chr17:61819248	STRADA	0.81	10.89	0.58	1.38e-22	Prudent dietary pattern;
SARC	cis	rs838147	0.508	rs507711	chr19:49208564	C/T	cg07051648	chr19:49177693	NTN5;SEC1	-0.41	-5.3	-0.33	2.68e-7	Dietary macronutrient intake;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg23956036	chr11:16627172	NA	-0.53	-6.79	-0.41	9.35e-11	Lung adenocarcinoma;
SARC	cis	rs1729951	0.575	rs747843	chr3:136703130	G/C	cg15507776	chr3:136538369	TMEM22	0.49	5.34	0.33	2.17e-7	Neuroticism;
SARC	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg22535103	chr8:58192502	C8orf71	-0.59	-6.27	-0.38	1.69e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7465272	1.000	rs13259747	chr8:143683567	A/C	cg24634471	chr8:143751801	JRK	0.61	6.6	0.4	2.74e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs9513627	0.749	rs73556149	chr13:100117012	G/A	cg25919922	chr13:100150906	NA	-0.76	-5.44	-0.34	1.33e-7	Obesity-related traits;
SARC	cis	rs3820928	1.000	rs10167422	chr2:227777554	G/A	cg05526886	chr2:227700861	RHBDD1	-0.5	-6.14	-0.37	3.52e-9	Pulmonary function;
SARC	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg18758796	chr5:131593413	PDLIM4	-0.37	-4.93	-0.31	1.59e-6	Acylcarnitine levels;
SARC	cis	rs7818688	0.697	rs80217195	chr8:95986853	T/C	cg13393036	chr8:95962371	TP53INP1	0.39	4.77	0.3	3.24e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs2816062	0.721	rs2816047	chr1:18893728	A/C	cg10574377	chr1:18908098	NA	0.37	5.34	0.33	2.23e-7	Urate levels in lean individuals;
SARC	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg00149659	chr3:10157352	C3orf10	0.64	5.91	0.36	1.22e-8	Alzheimer's disease;
SARC	cis	rs2985684	0.894	rs6572585	chr14:50021075	A/G	cg04989706	chr14:50066350	PPIL5	-0.54	-6.2	-0.38	2.56e-9	Carotid intima media thickness;
SARC	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg13939156	chr17:80058883	NA	0.36	5.57	0.34	7.17e-8	Life satisfaction;
SARC	cis	rs7223966	1.000	rs9899788	chr17:61756384	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.57	-6.67	-0.4	1.87e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs708547	0.836	rs1718882	chr4:57859533	C/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.55	-6.84	-0.41	7.06e-11	Response to bleomycin (chromatid breaks);
SARC	cis	rs10463554	0.892	rs72783889	chr5:102274539	A/G	cg23492399	chr5:102201601	PAM	-0.45	-5.38	-0.33	1.84e-7	Parkinson's disease;
SARC	cis	rs12579753	0.917	rs12366599	chr12:82212112	C/T	cg07988820	chr12:82153109	PPFIA2	-0.6	-6.96	-0.41	3.39e-11	Resting heart rate;
SARC	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg24829409	chr8:58192753	C8orf71	-0.58	-5.24	-0.32	3.55e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2898290	0.617	rs13273172	chr8:11461111	A/G	cg21775007	chr8:11205619	TDH	-0.46	-5.79	-0.35	2.26e-8	Systolic blood pressure;
SARC	cis	rs477692	0.967	rs488143	chr10:131407369	A/C	cg05714579	chr10:131428358	MGMT	0.57	7.83	0.46	1.66e-13	Response to temozolomide;
SARC	cis	rs7811528	0.656	rs7782028	chr7:2706478	T/C	cg11411865	chr7:2701802	TTYH3	0.54	5.23	0.32	3.7e-7	Schizophrenia;
SARC	cis	rs12971120	0.891	rs12608037	chr18:72169395	A/G	cg25817165	chr18:72167213	CNDP2	-0.53	-7.55	-0.44	1.01e-12	Refractive error;
SARC	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg11941060	chr3:133502564	NA	0.36	5.2	0.32	4.27e-7	Iron status biomarkers;
SARC	cis	rs1691799	0.867	rs1168330	chr12:66763167	C/T	cg16791601	chr12:66731901	HELB	0.69	10.59	0.57	1.18e-21	White blood cell count (basophil);
SARC	cis	rs4722166	0.603	rs7801406	chr7:22788274	A/G	cg26061582	chr7:22766209	IL6	0.56	6.2	0.38	2.54e-9	Lung cancer;
SARC	cis	rs2635047	0.638	rs2668762	chr18:44667871	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.41	-4.86	-0.3	2.18e-6	Educational attainment;
SARC	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg00864171	chr11:67383662	NA	0.49	6.91	0.41	4.67e-11	Mean corpuscular volume;
SARC	cis	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg25894440	chr7:65020034	NA	-0.73	-5.51	-0.34	9.48e-8	Diabetic kidney disease;
SARC	trans	rs11098499	0.954	rs11940028	chr4:120411907	T/C	cg25214090	chr10:38739885	LOC399744	0.58	7.47	0.44	1.63e-12	Corneal astigmatism;
SARC	cis	rs72781680	0.821	rs72796325	chr2:24134537	G/A	cg08917208	chr2:24149416	ATAD2B	0.6	6.22	0.38	2.27e-9	Lymphocyte counts;
SARC	cis	rs9910055	0.530	rs2269905	chr17:42294462	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.46	6.14	0.37	3.44e-9	Total body bone mineral density;
SARC	cis	rs10463554	0.927	rs34820	chr5:102436868	A/G	cg23492399	chr5:102201601	PAM	-0.46	-5.05	-0.31	9.13e-7	Parkinson's disease;
SARC	cis	rs11690935	0.632	rs2292816	chr2:172586714	G/C	cg13550731	chr2:172543902	DYNC1I2	0.67	9.77	0.54	4e-19	Schizophrenia;
SARC	cis	rs6815814	0.950	rs5743565	chr4:38805983	T/C	cg02016764	chr4:38805732	TLR1	-0.42	-4.89	-0.31	1.87e-6	Breast cancer;
SARC	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg25952890	chr19:58913133	NA	0.36	5.1	0.32	6.95e-7	Uric acid clearance;
SARC	cis	rs10927875	0.691	rs1048302	chr1:16340879	T/G	cg21385522	chr1:16154831	NA	0.72	9.16	0.51	2.81e-17	Dilated cardiomyopathy;
SARC	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.46	-5.77	-0.35	2.54e-8	Gut microbiome composition (summer);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg18589478	chr6:26159120	HIST1H2BD	-0.5	-6.6	-0.4	2.7e-10	Thyroid stimulating hormone;
SARC	cis	rs13006833	0.703	rs291459	chr2:191181527	T/C	cg25963032	chr2:191064776	C2orf88	0.36	4.99	0.31	1.16e-6	Urinary metabolites;
SARC	cis	rs6840360	0.615	rs6535816	chr4:152614264	T/C	cg22705602	chr4:152727874	NA	-0.51	-8.66	-0.49	8.03e-16	Intelligence (multi-trait analysis);
SARC	cis	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg25894440	chr7:65020034	NA	0.75	5.62	0.35	5.53e-8	Diabetic kidney disease;
SARC	cis	rs757110	0.745	rs2074311	chr11:17421860	A/G	cg04705435	chr11:17411270	KCNJ11	0.33	4.89	0.31	1.87e-6	Type 2 diabetes;
SARC	cis	rs918629	0.798	rs3777163	chr5:95293316	C/G	cg16656078	chr5:95278638	ELL2	-0.64	-7.69	-0.45	4.21e-13	IgG glycosylation;
SARC	cis	rs15676	0.947	rs6478854	chr9:131588888	G/C	cg00228799	chr9:131580591	ENDOG	-0.57	-7.19	-0.43	8.92e-12	Blood metabolite levels;
SARC	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg13175981	chr1:150552382	MCL1	-0.48	-5.93	-0.36	1.09e-8	Tonsillectomy;
SARC	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg00990874	chr7:1149470	C7orf50	-0.6	-6.28	-0.38	1.65e-9	Bronchopulmonary dysplasia;
SARC	cis	rs9381040	0.610	rs2235678	chr6:41020510	G/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.41	-4.88	-0.3	1.95e-6	Alzheimer's disease (late onset);
SARC	cis	rs7681440	0.606	rs2619358	chr4:90752670	A/C	cg06632027	chr4:90757378	SNCA	-0.42	-5.25	-0.33	3.35e-7	Dementia with Lewy bodies;
SARC	trans	rs877282	1.000	rs11253370	chr10:773712	G/A	cg22713356	chr15:30763199	NA	1.02	10.4	0.56	4.63e-21	Uric acid levels;
SARC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg06074448	chr4:187884817	NA	-0.38	-5.18	-0.32	4.69e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs8031584	0.918	rs61997138	chr15:31270776	C/T	cg08109568	chr15:31115862	NA	-0.47	-5.85	-0.36	1.69e-8	Huntington's disease progression;
SARC	cis	rs73001065	0.901	rs73004951	chr19:19695228	C/T	cg03709012	chr19:19516395	GATAD2A	0.86	5.49	0.34	1.05e-7	LDL cholesterol;
SARC	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg11890956	chr21:40555474	PSMG1	1.1	17.42	0.75	4.56e-44	Cognitive function;
SARC	cis	rs1355223	0.525	rs55796371	chr11:34872769	T/C	cg11622362	chr11:34938112	PDHX;APIP	0.45	5.88	0.36	1.42e-8	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs17095355	1.000	rs6584962	chr10:111689904	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.41	-4.84	-0.3	2.38e-6	Biliary atresia;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg00342743	chr10:76970673	VDAC2	0.53	6.96	0.41	3.34e-11	Tetralogy of Fallot;
SARC	trans	rs6934651	1.000	rs6934651	chr6:85920475	T/C	cg04848555	chr14:53975804	NA	0.67	6.45	0.39	6.33e-10	Breast cancer;
SARC	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.46	0.39	6.12e-10	Bipolar disorder;
SARC	cis	rs3099143	1.000	rs4886832	chr15:77121196	G/A	cg21673338	chr15:77095150	SCAPER	0.61	5.16	0.32	5.16e-7	Recalcitrant atopic dermatitis;
SARC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg03452623	chr4:187889614	NA	0.81	13.58	0.66	2.57e-31	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7659604	1.000	rs6814995	chr4:122664963	A/T	cg20573242	chr4:122745356	CCNA2	-0.46	-5.98	-0.36	8.15e-9	Type 2 diabetes;
SARC	cis	rs12586317	0.620	rs8020370	chr14:35581432	G/A	cg26967526	chr14:35346199	BAZ1A	-0.64	-6.96	-0.41	3.45e-11	Psoriasis;
SARC	cis	rs2236918	0.710	rs1776159	chr1:242018583	C/G	cg17736920	chr1:242011382	EXO1	0.66	9.04	0.51	6.24e-17	Menopause (age at onset);
SARC	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg08859206	chr1:53392774	SCP2	0.38	5.43	0.34	1.43e-7	Monocyte count;
SARC	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg23758822	chr17:41437982	NA	-0.91	-12.25	-0.63	5.93e-27	Menopause (age at onset);
SARC	cis	rs6690583	0.623	rs111687161	chr1:85443533	A/G	cg22153463	chr1:85462885	MCOLN2	0.72	6.85	0.41	6.56e-11	Serum sulfate level;
SARC	cis	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg22496380	chr5:211416	CCDC127	-0.85	-9.44	-0.53	4.07e-18	Breast cancer;
SARC	cis	rs965469	0.652	rs6051837	chr20:3388994	G/T	cg25506879	chr20:3388711	C20orf194	-0.51	-5.9	-0.36	1.26e-8	IFN-related cytopenia;
SARC	trans	rs3942852	0.568	rs6485807	chr11:48102867	G/A	cg15704280	chr7:45808275	SEPT13	-0.66	-8.67	-0.49	7.4e-16	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs12200560	0.505	rs984520	chr6:97076454	A/G	cg06623918	chr6:96969491	KIAA0776	-0.46	-5.21	-0.32	4.16e-7	Coronary heart disease;
SARC	cis	rs17376456	0.877	rs17316137	chr5:93456577	C/T	cg21475434	chr5:93447410	FAM172A	0.86	7.87	0.46	1.33e-13	Diabetic retinopathy;
SARC	cis	rs6738485	0.552	rs62146770	chr2:106854277	C/T	cg16099169	chr2:106886729	NA	-0.39	-5.02	-0.31	1.03e-6	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
SARC	cis	rs6910061	1.000	rs6910061	chr6:11101918	A/T	cg27233058	chr6:11094804	LOC221710	-0.61	-5.91	-0.36	1.19e-8	Diabetic kidney disease;
SARC	trans	rs11098499	0.690	rs34818745	chr4:120257055	T/C	cg25214090	chr10:38739885	LOC399744	0.49	6.24	0.38	2.1e-9	Corneal astigmatism;
SARC	cis	rs11997175	0.603	rs4291230	chr8:33674570	A/C	ch.8.33884649F	chr8:33765107	NA	-0.54	-6.93	-0.41	4.05e-11	Body mass index;
SARC	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg06618935	chr21:46677482	NA	-0.35	-4.81	-0.3	2.73e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1008375	0.932	rs13134570	chr4:17692863	C/T	cg02297831	chr4:17616191	MED28	-0.43	-5.27	-0.33	3.08e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1018697	0.518	rs2790914	chr10:104568018	C/T	cg04362960	chr10:104952993	NT5C2	-0.58	-5.81	-0.36	2.06e-8	Colorectal adenoma (advanced);
SARC	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg00908189	chr16:619842	PIGQ	0.85	12.44	0.63	1.38e-27	Height;
SARC	cis	rs8042680	0.522	rs10775251	chr15:91554425	T/G	cg08919649	chr15:91565780	VPS33B	0.42	5.0	0.31	1.14e-6	Type 2 diabetes;
SARC	cis	rs5753618	0.504	rs5753669	chr22:31905819	T/G	cg07713946	chr22:31675144	LIMK2	0.37	5.19	0.32	4.56e-7	Colorectal cancer;
SARC	cis	rs13394619	0.744	rs10929759	chr2:11722012	C/G	cg07314298	chr2:11723111	GREB1	0.37	5.03	0.31	9.85e-7	Endometriosis;
SARC	cis	rs7312774	0.618	rs73385161	chr12:107300164	G/A	cg16260113	chr12:107380972	MTERFD3	0.76	6.55	0.39	3.63e-10	Severe influenza A (H1N1) infection;
SARC	cis	rs4595586	0.525	rs12812749	chr12:39363254	C/T	cg13010199	chr12:38710504	ALG10B	0.41	4.76	0.3	3.46e-6	Morning vs. evening chronotype;
SARC	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg13206674	chr6:150067644	NUP43	0.41	5.19	0.32	4.51e-7	Lung cancer;
SARC	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg00149659	chr3:10157352	C3orf10	0.71	6.61	0.4	2.56e-10	Alzheimer's disease;
SARC	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg22105103	chr4:187893119	NA	-0.47	-6.24	-0.38	2.03e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg19346786	chr7:2764209	NA	-0.41	-6.06	-0.37	5.52e-9	Height;
SARC	cis	rs1185460	0.967	rs1168568	chr11:118949799	G/A	cg01677386	chr11:118938358	VPS11	-0.4	-4.78	-0.3	3.14e-6	Coronary artery disease;
SARC	cis	rs9611519	0.558	rs8137906	chr22:41442566	A/G	cg03806693	chr22:41940476	POLR3H	-0.6	-7.97	-0.46	6.92e-14	Neuroticism;
SARC	cis	rs2011503	0.941	rs56044734	chr19:19366927	G/A	cg03709012	chr19:19516395	GATAD2A	0.59	5.33	0.33	2.33e-7	Bipolar disorder;
SARC	cis	rs908922	0.676	rs2282296	chr1:152487979	C/T	cg09873164	chr1:152488093	CRCT1	0.65	8.42	0.48	3.98e-15	Hair morphology;
SARC	cis	rs12912251	0.591	rs10520103	chr15:39006243	C/G	cg10631289	chr15:39006617	NA	0.4	4.71	0.3	4.18e-6	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
SARC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg25703541	chr22:24373054	LOC391322	-0.77	-9.65	-0.53	9.67e-19	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs17376456	0.825	rs10052662	chr5:93271385	A/G	cg25358565	chr5:93447407	FAM172A	1.3	14.32	0.68	8.73e-34	Diabetic retinopathy;
SARC	cis	rs4642101	0.560	rs4535210	chr3:12839617	T/G	cg24848339	chr3:12840334	CAND2	0.38	5.68	0.35	4.01e-8	QRS complex (12-leadsum);
SARC	cis	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg04055107	chr11:65626734	MUS81;CFL1	0.45	5.68	0.35	4.01e-8	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs7223966	1.000	rs11657120	chr17:61857218	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.52	-5.44	-0.34	1.35e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2985684	0.846	rs11157693	chr14:50048426	T/C	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.45	4.94	0.31	1.49e-6	Carotid intima media thickness;
SARC	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg03650068	chr1:25596491	NA	-0.3	-4.83	-0.3	2.47e-6	Erythrocyte sedimentation rate;
SARC	cis	rs4595586	0.525	rs1400279	chr12:39343825	T/A	cg26384229	chr12:38710491	ALG10B	0.52	6.09	0.37	4.58e-9	Morning vs. evening chronotype;
SARC	cis	rs2120019	0.938	rs8028632	chr15:75321262	T/C	cg09165964	chr15:75287851	SCAMP5	-0.95	-14.5	-0.69	2.24e-34	Blood trace element (Zn levels);
SARC	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg27266027	chr21:40555129	PSMG1	0.51	5.57	0.34	6.84e-8	Cognitive function;
SARC	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg16049864	chr8:95962084	TP53INP1	-0.54	-8.82	-0.5	2.69e-16	Type 2 diabetes;
SARC	cis	rs3771570	1.000	rs55634485	chr2:242268994	T/C	cg21155796	chr2:242212141	HDLBP	0.67	5.74	0.35	2.99e-8	Prostate cancer;
SARC	cis	rs10876993	0.890	rs4760165	chr12:58063801	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.48	-6.11	-0.37	4.15e-9	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs9916302	0.904	rs55660616	chr17:37684990	C/A	cg00129232	chr17:37814104	STARD3	-0.63	-7.73	-0.45	3.25e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs17001868	0.568	rs74424549	chr22:40736938	A/C	cg07138101	chr22:40742427	ADSL	0.54	5.94	0.36	1.01e-8	Mammographic density (dense area);
SARC	cis	rs7524258	0.900	rs12035586	chr1:7273020	C/T	cg07173049	chr1:7289937	CAMTA1	-0.32	-6.24	-0.38	2.07e-9	Tourette's syndrome or obsessive-compulsive disorder;
SARC	cis	rs7666738	0.791	rs1830231	chr4:99026185	A/C	cg05340658	chr4:99064831	C4orf37	0.65	8.86	0.5	2.05e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg05861140	chr6:150128134	PCMT1	-0.39	-5.05	-0.31	9.06e-7	Lung cancer;
SARC	cis	rs10504073	0.647	rs10435612	chr8:49993696	A/T	cg00325661	chr8:49890786	NA	0.54	7.22	0.43	7.43e-12	Blood metabolite ratios;
SARC	cis	rs738322	0.806	rs2235264	chr22:38609950	G/A	cg25457927	chr22:38595422	NA	0.34	6.94	0.41	3.91e-11	Cutaneous nevi;
SARC	cis	rs1728785	1.000	rs1728785	chr16:68591230	G/T	cg02972257	chr16:68554789	NA	0.46	5.16	0.32	5.37e-7	Ulcerative colitis;
SARC	cis	rs35110281	0.666	rs9977076	chr21:45085829	G/A	cg01579765	chr21:45077557	HSF2BP	-0.37	-5.84	-0.36	1.79e-8	Mean corpuscular volume;
SARC	cis	rs4481887	1.000	rs4244172	chr1:248466838	A/G	cg00666640	chr1:248458726	OR2T12	0.36	5.93	0.36	1.06e-8	Common traits (Other);
SARC	cis	rs2228479	0.619	rs78001663	chr16:89896331	C/A	cg06558623	chr16:89946397	TCF25	0.91	6.5	0.39	4.78e-10	Skin colour saturation;
SARC	trans	rs10506458	0.915	rs17763441	chr12:63418335	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.73	-6.78	-0.41	9.97e-11	Hemostatic factors and hematological phenotypes;
SARC	cis	rs854765	0.583	rs28428991	chr17:17827649	C/T	cg04398451	chr17:18023971	MYO15A	-0.39	-5.53	-0.34	8.65e-8	Total body bone mineral density;
SARC	cis	rs7296418	0.675	rs1879379	chr12:123727443	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-5.06	-0.31	8.32e-7	Platelet count;
SARC	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg03060546	chr3:49711283	APEH	0.42	5.19	0.32	4.47e-7	Parkinson's disease;
SARC	cis	rs883565	0.528	rs35946914	chr3:38992107	A/G	cg26331595	chr3:39149181	GORASP1;TTC21A	0.44	5.31	0.33	2.61e-7	Handedness;
SARC	cis	rs7555523	0.887	rs2251768	chr1:165738311	A/T	cg19769164	chr1:165738335	TMCO1	0.6	5.15	0.32	5.5e-7	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	trans	rs208520	0.874	rs208469	chr6:66915891	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-11.15	-0.59	2.01e-23	Exhaled nitric oxide output;
SARC	cis	rs9467711	0.559	rs9393727	chr6:26500011	C/G	cg12826209	chr6:26865740	GUSBL1	0.7	5.01	0.31	1.06e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs3796352	1.000	rs35576914	chr3:53092270	G/A	cg15956490	chr3:53032818	SFMBT1	0.89	6.02	0.37	6.61e-9	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs1707322	0.758	rs10789474	chr1:46250040	G/T	cg03146154	chr1:46216737	IPP	0.51	6.28	0.38	1.68e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs698833	0.859	rs786612	chr2:44600819	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.66	8.34	0.48	6.37e-15	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg12205742	chr18:68097929	NA	0.52	7.0	0.42	2.74e-11	Breast cancer;
SARC	cis	rs7250872	0.606	rs12985022	chr19:1825401	A/G	cg18850929	chr19:1828978	REXO1	0.43	5.05	0.31	8.81e-7	Bipolar disorder;
SARC	cis	rs7666738	0.830	rs35865860	chr4:98968822	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9486719	0.857	rs11751075	chr6:97065751	G/A	cg06623918	chr6:96969491	KIAA0776	-0.69	-7.52	-0.44	1.15e-12	Migraine;Coronary artery disease;
SARC	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	14.13	0.68	3.83e-33	Chronic sinus infection;
SARC	cis	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg05623727	chr3:50126028	RBM5	0.33	5.0	0.31	1.15e-6	Intelligence (multi-trait analysis);
SARC	cis	rs1348850	0.914	rs12616443	chr2:178315751	A/G	cg23306229	chr2:178417860	TTC30B	0.53	6.26	0.38	1.81e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs4969178	0.965	rs16971107	chr17:76394042	C/T	cg02836325	chr17:76403955	PGS1	0.33	5.06	0.31	8.32e-7	HDL cholesterol levels;
SARC	cis	rs796364	0.806	rs203769	chr2:200900866	C/T	cg23649088	chr2:200775458	C2orf69	-0.66	-5.76	-0.35	2.68e-8	Schizophrenia;
SARC	trans	rs28425639	1.000	rs28425639	chr2:100552512	T/A	cg08602190	chr10:128076260	ADAM12	-0.67	-6.26	-0.38	1.82e-9	Response to paliperidone in schizophrenia (negative Marder score);
SARC	cis	rs6690583	0.623	rs6679539	chr1:85479457	G/T	cg22153463	chr1:85462885	MCOLN2	-0.67	-6.05	-0.37	5.58e-9	Serum sulfate level;
SARC	cis	rs4642101	0.662	rs9840766	chr3:12821870	G/A	cg05775895	chr3:12838266	CAND2	0.83	15.35	0.71	3.19e-37	QRS complex (12-leadsum);
SARC	cis	rs9814567	1.000	rs1863913	chr3:134200205	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.1	-0.42	1.49e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs4803468	1.000	rs284649	chr19:41926838	C/T	cg14132834	chr19:41945861	ATP5SL	-0.57	-7.45	-0.44	1.85e-12	Height;
SARC	cis	rs8017423	0.967	rs57793584	chr14:90714833	G/A	cg20276874	chr14:90721474	PSMC1	-0.36	-5.0	-0.31	1.13e-6	Mortality in heart failure;
SARC	cis	rs7428	0.545	rs17026212	chr2:85551696	T/G	cg03728395	chr2:85555865	TGOLN2	-0.46	-6.39	-0.39	9.01e-10	Ear protrusion;
SARC	cis	rs3008870	1.000	rs3008858	chr1:67390416	G/C	cg08660285	chr1:67390436	MIER1;WDR78	0.93	11.48	0.6	1.77e-24	Lymphocyte percentage of white cells;
SARC	cis	rs7647973	0.626	rs11709734	chr3:49745235	G/A	cg06212747	chr3:49208901	KLHDC8B	0.55	5.52	0.34	9.13e-8	Menarche (age at onset);
SARC	cis	rs79349575	0.783	rs4399576	chr17:47009835	G/A	cg07967210	chr17:47022446	SNF8	0.38	4.77	0.3	3.2e-6	Type 2 diabetes;
SARC	cis	rs1580019	0.547	rs56981934	chr7:32535202	C/G	cg06627557	chr7:32535165	LSM5;AVL9	1.01	19.24	0.78	4.82e-50	Cognitive ability;
SARC	cis	rs10791097	0.667	rs4937584	chr11:130741761	A/G	cg12179176	chr11:130786555	SNX19	0.73	10.91	0.58	1.19e-22	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs1348850	0.632	rs11682717	chr2:178499240	C/G	cg23306229	chr2:178417860	TTC30B	0.51	5.73	0.35	3.03e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg12373951	chr3:133503437	NA	0.36	5.3	0.33	2.62e-7	Iron status biomarkers;
SARC	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg03060546	chr3:49711283	APEH	0.76	11.08	0.59	3.49e-23	Resting heart rate;
SARC	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg18404041	chr3:52824283	ITIH1	-0.43	-6.53	-0.39	4.04e-10	Bipolar disorder;
SARC	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg11062466	chr8:58055876	NA	0.56	5.69	0.35	3.79e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2652834	0.904	rs34786874	chr15:63397504	A/G	cg05507819	chr15:63340323	TPM1	0.54	5.36	0.33	2e-7	HDL cholesterol;
SARC	cis	rs6753739	0.784	rs6730783	chr2:219922835	A/G	cg24212621	chr2:219920517	IHH	0.35	4.82	0.3	2.62e-6	Height;
SARC	cis	rs739401	0.967	rs451041	chr11:3060725	C/T	cg20651018	chr11:3035856	CARS	-0.41	-6.3	-0.38	1.48e-9	Longevity;
SARC	cis	rs7666738	0.830	rs7687315	chr4:98900613	A/G	cg05340658	chr4:99064831	C4orf37	0.64	8.46	0.48	3.06e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs13191362	1.000	rs67747005	chr6:163150845	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.36	4.75	0.3	3.6e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs13191362	0.573	rs1877769	chr6:163252315	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.44	4.96	0.31	1.39e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs11097912	0.632	rs74285705	chr4:107251278	C/T	cg09646026	chr4:107269030	AIMP1	-0.46	-4.94	-0.31	1.52e-6	Airflow obstruction;
SARC	cis	rs8064024	0.680	rs3747613	chr16:4908504	C/G	cg08329684	chr16:4932620	PPL	-0.34	-5.37	-0.33	1.92e-7	Cancer;
SARC	cis	rs705471	0.932	rs11251979	chr10:3673153	C/T	cg14308648	chr10:3568949	NA	0.47	6.18	0.38	2.83e-9	Capecitabine sensitivity;
SARC	cis	rs9486719	1.000	rs13210597	chr6:96969694	C/A	cg18709589	chr6:96969512	KIAA0776	-0.49	-5.04	-0.31	9.5e-7	Migraine;Coronary artery disease;
SARC	cis	rs6752107	0.936	rs6431660	chr2:234167234	A/G	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.5	6.72	0.4	1.35e-10	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs10791323	0.604	rs2257010	chr11:133712348	G/A	cg15485101	chr11:133734466	NA	0.34	5.13	0.32	6.22e-7	Childhood ear infection;
SARC	cis	rs11719291	0.833	rs11713694	chr3:48833615	G/T	cg00383909	chr3:49044727	WDR6	0.76	6.79	0.41	9.41e-11	Cognitive function;
SARC	cis	rs30380	0.632	rs149189	chr5:96137804	A/G	cg16492584	chr5:96139282	ERAP1	-0.48	-5.5	-0.34	1.01e-7	Cerebrospinal fluid biomarker levels;
SARC	trans	rs11722228	0.522	rs73212880	chr4:10115692	T/A	cg26043149	chr18:55253948	FECH	0.73	8.5	0.49	2.32e-15	Gout;Urate levels;Serum uric acid levels;
SARC	cis	rs12347191	0.500	rs907580	chr9:100622597	T/C	cg13688889	chr9:100608707	NA	-0.48	-5.01	-0.31	1.08e-6	Orofacial clefts;
SARC	cis	rs11098499	0.863	rs1383533	chr4:120434576	G/A	cg09307838	chr4:120376055	NA	0.91	12.31	0.63	3.63e-27	Corneal astigmatism;
SARC	cis	rs137603	0.966	rs126228	chr22:39681436	A/G	cg01093212	chr22:39715156	SNORD43;RPL3	0.41	4.98	0.31	1.22e-6	Primary biliary cholangitis;
SARC	cis	rs2354432	0.556	rs57388899	chr1:146773422	T/C	cg25205988	chr1:146714368	CHD1L	-0.97	-9.27	-0.52	1.26e-17	Mitochondrial DNA levels;
SARC	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg18357526	chr6:26021779	HIST1H4A	0.46	5.85	0.36	1.64e-8	Blood metabolite levels;
SARC	cis	rs7123876	0.587	rs11604034	chr11:72364147	G/C	cg03713592	chr11:72463424	ARAP1	0.56	5.06	0.31	8.43e-7	Body mass index;
SARC	cis	rs17376456	1.000	rs17376456	chr5:93557702	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.61	-5.3	-0.33	2.65e-7	Diabetic retinopathy;
SARC	cis	rs6963495	0.538	rs55967123	chr7:105163678	C/A	cg19920283	chr7:105172520	RINT1	0.65	5.48	0.34	1.09e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs13256369	0.802	rs1060106	chr8:8561452	A/G	cg18904891	chr8:8559673	CLDN23	0.47	5.32	0.33	2.45e-7	Obesity-related traits;
SARC	cis	rs10916814	0.632	rs6701759	chr1:20898400	G/T	cg24502330	chr1:20914028	CDA	-0.3	-5.27	-0.33	3.16e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	trans	rs2727020	0.521	rs7930855	chr11:49521660	C/T	cg15704280	chr7:45808275	SEPT13	0.7	8.11	0.47	2.96e-14	Coronary artery disease;
SARC	cis	rs1040555	0.516	rs242547	chr20:31418581	T/C	cg13636640	chr20:31349939	DNMT3B	0.64	8.63	0.49	9.46e-16	Lymphocyte percentage of white cells;
SARC	trans	rs3780486	0.505	rs10117038	chr9:33122626	T/C	cg04842962	chr6:43655489	MRPS18A	0.88	13.15	0.65	6.38e-30	IgG glycosylation;
SARC	cis	rs7727544	0.735	rs272867	chr5:131681057	G/A	cg07395648	chr5:131743802	NA	-0.42	-4.9	-0.31	1.77e-6	Blood metabolite levels;
SARC	cis	rs9660992	0.674	rs17345816	chr1:205262868	A/T	cg07972983	chr1:205091412	RBBP5	-0.51	-5.98	-0.36	8.52e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs2486288	0.656	rs7165039	chr15:45570413	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.54	-6.88	-0.41	5.51e-11	Glomerular filtration rate;
SARC	cis	rs2594989	1.000	rs346077	chr3:11326102	A/C	cg00170343	chr3:11313890	ATG7	0.54	5.2	0.32	4.45e-7	Circulating chemerin levels;
SARC	cis	rs4689388	0.929	rs1046320	chr4:6304344	C/T	cg00701064	chr4:6280414	WFS1	0.54	8.63	0.49	9.63e-16	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs17253792	0.822	rs75991559	chr14:56092419	A/T	cg01858014	chr14:56050164	KTN1	-0.67	-5.11	-0.32	6.86e-7	Putamen volume;
SARC	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg23758822	chr17:41437982	NA	0.9	11.46	0.6	2.14e-24	Menopause (age at onset);
SARC	cis	rs2204008	0.805	rs3863360	chr12:37966432	C/T	cg13010199	chr12:38710504	ALG10B	0.74	9.85	0.54	2.39e-19	Bladder cancer;
SARC	cis	rs9868809	0.881	rs2276852	chr3:48666923	A/G	cg07636037	chr3:49044803	WDR6	-0.68	-6.5	-0.39	4.81e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	trans	rs1853207	1.000	rs78919131	chr10:96638446	T/C	cg02737782	chr1:8014393	NA	-0.97	-6.42	-0.39	7.44e-10	Blood metabolite levels;
SARC	cis	rs77372450	0.636	rs55699399	chr5:157028363	C/A	cg23851860	chr5:157002805	ADAM19	0.5	4.85	0.3	2.27e-6	Bipolar disorder (body mass index interaction);
SARC	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg06634786	chr22:41940651	POLR3H	0.55	6.45	0.39	6.23e-10	Vitiligo;
SARC	cis	rs7904368	0.806	rs4612698	chr10:16855070	C/A	cg14835575	chr10:16859367	RSU1	0.78	7.79	0.45	2.21e-13	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs9831754	0.704	rs1512491	chr3:78470954	T/C	cg06138941	chr3:78371609	NA	0.54	6.45	0.39	6.22e-10	Calcium levels;
SARC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg20102877	chr2:27665638	KRTCAP3	-0.37	-5.25	-0.33	3.44e-7	Total body bone mineral density;
SARC	cis	rs28830936	0.510	rs11858843	chr15:42092915	C/A	cg17847044	chr15:42102381	MAPKBP1	-0.47	-7.56	-0.44	9.4e-13	Diastolic blood pressure;
SARC	cis	rs9309473	0.606	rs62149777	chr2:73795364	G/A	cg20560298	chr2:73613845	ALMS1	-0.5	-4.98	-0.31	1.26e-6	Metabolite levels;
SARC	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg13206674	chr6:150067644	NUP43	0.46	6.07	0.37	5.05e-9	Lung cancer;
SARC	cis	rs4711350	0.765	rs2395446	chr6:33743264	C/T	cg07979401	chr6:33739406	LEMD2	-0.38	-4.82	-0.3	2.61e-6	Schizophrenia;
SARC	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs858239	0.796	rs433395	chr7:23401955	G/T	cg23682824	chr7:23144976	KLHL7	0.54	6.86	0.41	6.15e-11	Cerebrospinal fluid biomarker levels;
SARC	cis	rs2239547	0.603	rs12489490	chr3:53064022	C/A	cg11645453	chr3:52864694	ITIH4	0.34	5.14	0.32	5.86e-7	Schizophrenia;
SARC	cis	rs9341808	0.754	rs9341811	chr6:80982701	G/A	cg08355045	chr6:80787529	NA	0.35	5.58	0.34	6.59e-8	Sitting height ratio;
SARC	cis	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg05623727	chr3:50126028	RBM5	-0.34	-5.19	-0.32	4.68e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9916302	0.706	rs12950186	chr17:37393395	A/C	cg20243544	chr17:37824526	PNMT	0.53	5.56	0.34	7.32e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.63	7.52	0.44	1.18e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs61931739	0.613	rs1525898	chr12:33904445	G/T	cg13010199	chr12:38710504	ALG10B	0.51	6.42	0.39	7.52e-10	Morning vs. evening chronotype;
SARC	cis	rs13082711	0.554	rs1494423	chr3:27375345	A/G	cg02860705	chr3:27208620	NA	-0.53	-6.69	-0.4	1.67e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs1008375	1.000	rs28501187	chr4:17643620	G/A	cg27347728	chr4:17578864	LAP3	0.47	5.94	0.36	1.01e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg03213289	chr20:61660250	NA	0.47	6.47	0.39	5.68e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs9815354	0.904	rs62258655	chr3:41932330	G/A	cg03022575	chr3:42003672	ULK4	-0.6	-5.67	-0.35	4.23e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs865483	0.929	rs8064314	chr17:35858392	A/G	cg06561646	chr17:35873369	DUSP14	-0.48	-6.46	-0.39	6.12e-10	Monocyte count;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg04530460	chr6:42858550	C6orf226	-0.57	-6.46	-0.39	5.88e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg18225595	chr11:63971243	STIP1	0.44	5.36	0.33	1.97e-7	Mean platelet volume;
SARC	cis	rs2985684	1.000	rs56098064	chr14:50105849	T/C	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.47	4.85	0.3	2.24e-6	Carotid intima media thickness;
SARC	cis	rs6912958	0.781	rs2300906	chr6:88207155	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.52	-6.75	-0.4	1.18e-10	Monocyte percentage of white cells;
SARC	cis	rs11785400	0.762	rs7007349	chr8:143722673	T/C	cg24634471	chr8:143751801	JRK	0.6	7.8	0.46	2.03e-13	Schizophrenia;
SARC	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg03806693	chr22:41940476	POLR3H	-0.82	-10.81	-0.58	2.45e-22	Vitiligo;
SARC	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs11608355	1.000	rs10850134	chr12:109861454	G/C	cg19025524	chr12:109796872	NA	-0.4	-5.06	-0.31	8.4e-7	Neuroticism;
SARC	cis	rs9910055	0.530	rs7222349	chr17:42304644	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.44	5.87	0.36	1.46e-8	Total body bone mineral density;
SARC	cis	rs4430311	0.723	rs1870272	chr1:243924743	T/A	cg21452805	chr1:244014465	NA	-0.38	-4.96	-0.31	1.34e-6	Post-traumatic stress disorder (asjusted for relatedness);
SARC	trans	rs8073060	0.586	rs226084	chr17:34019582	T/A	cg19694781	chr19:47549865	TMEM160	-0.71	-6.94	-0.41	3.88e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs6121246	0.567	rs6060263	chr20:30193110	T/C	cg13852791	chr20:30311386	BCL2L1	0.68	5.91	0.36	1.2e-8	Mean corpuscular hemoglobin;
SARC	cis	rs2439831	1.000	rs2251538	chr15:43767209	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	8.42	0.48	3.97e-15	Lung cancer in ever smokers;
SARC	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg10589385	chr1:150898437	SETDB1	0.42	5.61	0.34	5.7e-8	Melanoma;
SARC	cis	rs950169	0.922	rs62029585	chr15:84951874	C/G	cg24253500	chr15:84953950	NA	0.35	4.94	0.31	1.51e-6	Schizophrenia;
SARC	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg06634786	chr22:41940651	POLR3H	-0.58	-6.95	-0.41	3.64e-11	Vitiligo;
SARC	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg16479474	chr6:28041457	NA	0.4	5.71	0.35	3.46e-8	Depression;
SARC	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg11987759	chr7:65425863	GUSB	-0.59	-7.75	-0.45	2.88e-13	Aortic root size;
SARC	cis	rs7666738	0.753	rs10033138	chr4:98981922	A/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs72781680	1.000	rs72798417	chr2:24188656	C/T	cg08917208	chr2:24149416	ATAD2B	0.79	7.55	0.44	9.78e-13	Lymphocyte counts;
SARC	cis	rs7712401	0.601	rs246306	chr5:122279218	G/C	cg19412675	chr5:122181750	SNX24	0.39	4.95	0.31	1.45e-6	Mean platelet volume;
SARC	cis	rs6546550	0.901	rs10205487	chr2:70151471	C/T	cg02498382	chr2:70120550	SNRNP27	0.34	5.47	0.34	1.16e-7	Prevalent atrial fibrillation;
SARC	cis	rs611744	0.967	rs596245	chr8:109240822	G/A	cg21045802	chr8:109455806	TTC35	0.46	5.43	0.34	1.41e-7	Dupuytren's disease;
SARC	cis	rs2486288	0.656	rs62026703	chr15:45569929	G/T	cg19305227	chr15:45544335	SLC28A2	0.31	5.75	0.35	2.86e-8	Glomerular filtration rate;
SARC	cis	rs28829049	0.597	rs12740975	chr1:19437923	G/A	cg13387374	chr1:19411106	UBR4	0.47	5.58	0.34	6.82e-8	QRS duration in Tripanosoma cruzi seropositivity;
SARC	cis	rs9430161	0.611	rs34032547	chr1:11034374	C/G	cg27631724	chr1:11040367	C1orf127	0.33	4.71	0.3	4.2e-6	Ewing sarcoma;
SARC	cis	rs1707322	0.752	rs4660880	chr1:46111040	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.26	0.38	1.8e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg13206674	chr6:150067644	NUP43	0.46	6.1	0.37	4.29e-9	Lung cancer;
SARC	cis	rs453301	0.686	rs11787026	chr8:8902371	A/T	cg08975724	chr8:8085496	FLJ10661	0.49	6.35	0.38	1.11e-9	Joint mobility (Beighton score);
SARC	cis	rs9467711	0.651	rs13191776	chr6:25955741	C/T	cg21479132	chr6:26055353	NA	0.83	4.81	0.3	2.69e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1008375	1.000	rs2159583	chr4:17658838	T/C	cg02297831	chr4:17616191	MED28	0.49	6.32	0.38	1.34e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs11711311	1.000	rs13061150	chr3:113506734	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	8.61	0.49	1.12e-15	IgG glycosylation;
SARC	cis	rs9868809	0.881	rs7631574	chr3:48663046	A/G	cg07636037	chr3:49044803	WDR6	0.7	6.86	0.41	6.13e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs35110281	0.693	rs3819161	chr21:45092653	A/G	cg01579765	chr21:45077557	HSF2BP	-0.4	-6.22	-0.38	2.28e-9	Mean corpuscular volume;
SARC	cis	rs7940866	0.903	rs7940465	chr11:130861339	C/T	cg12179176	chr11:130786555	SNX19	0.64	8.5	0.49	2.32e-15	Schizophrenia;
SARC	cis	rs1062177	1.000	rs2964576	chr5:151150602	T/G	cg00977110	chr5:151150581	G3BP1	0.62	6.23	0.38	2.19e-9	Preschool internalizing problems;
SARC	cis	rs2153535	0.580	rs7450817	chr6:8481421	G/A	cg21535247	chr6:8435926	SLC35B3	0.55	6.97	0.42	3.17e-11	Motion sickness;
SARC	cis	rs208520	0.837	rs208488	chr6:66926902	C/T	cg07460842	chr6:66804631	NA	-1.0	-11.88	-0.61	9.23e-26	Exhaled nitric oxide output;
SARC	cis	rs2273669	0.667	rs11153150	chr6:109316652	C/G	cg05315195	chr6:109294784	ARMC2	-0.59	-5.45	-0.34	1.28e-7	Prostate cancer;
SARC	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg09455208	chr3:40491958	NA	0.39	5.78	0.35	2.35e-8	Renal cell carcinoma;
SARC	cis	rs9341808	0.667	rs3828753	chr6:80912746	C/T	cg08355045	chr6:80787529	NA	0.36	5.69	0.35	3.75e-8	Sitting height ratio;
SARC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.1	0.37	4.28e-9	Prudent dietary pattern;
SARC	cis	rs920590	0.642	rs6993525	chr8:19671104	A/G	cg17834443	chr8:19674713	INTS10	-0.61	-7.06	-0.42	1.87e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs8180040	0.726	rs2385867	chr3:47059323	C/T	cg02527881	chr3:46936655	PTH1R	-0.31	-4.83	-0.3	2.48e-6	Colorectal cancer;
SARC	cis	rs734999	0.545	rs9970196	chr1:2574078	T/C	cg18854424	chr1:2615690	NA	-0.31	-4.81	-0.3	2.71e-6	Ulcerative colitis;
SARC	cis	rs9768139	0.708	rs896782	chr7:158114115	G/A	cg06219351	chr7:158114137	PTPRN2	-0.29	-4.86	-0.3	2.2e-6	Calcium levels;
SARC	cis	rs614226	0.935	rs2235222	chr12:120892193	G/C	cg01236616	chr12:121019343	POP5	-1.17	-16.98	-0.74	1.28e-42	Type 1 diabetes nephropathy;
SARC	cis	rs4481887	1.000	rs4916128	chr1:248466706	G/A	cg13385794	chr1:248469461	NA	0.36	5.57	0.34	7.1e-8	Common traits (Other);
SARC	cis	rs6138458	1.000	rs6138458	chr20:24973769	C/T	cg26195577	chr20:24973756	C20orf3	0.89	9.87	0.54	1.97e-19	Blood protein levels;
SARC	cis	rs35995292	0.517	rs6948026	chr7:38920854	A/G	cg19327137	chr7:38886074	VPS41	0.5	7.3	0.43	4.4e-12	Subjective well-being (multi-trait analysis);
SARC	cis	rs11209002	0.915	rs6588240	chr1:67577367	A/T	cg02640540	chr1:67518911	SLC35D1	0.47	4.77	0.3	3.19e-6	Crohn's disease;
SARC	cis	rs6674176	0.628	rs3791116	chr1:44414156	T/A	cg12908607	chr1:44402522	ARTN	-0.38	-6.54	-0.39	3.79e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs1957429	0.803	rs10873177	chr14:65318228	G/C	cg23373153	chr14:65346875	NA	0.85	8.92	0.5	1.39e-16	Pediatric areal bone mineral density (radius);
SARC	cis	rs7224737	0.750	rs731151	chr17:40279903	G/A	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-0.57	-5.02	-0.31	1.02e-6	Fibrinogen levels;
SARC	cis	rs525592	1	rs525592	chr11:68195104	C/T	cg01657329	chr11:68192670	LRP5	-0.38	-5.09	-0.32	7.35e-7	Bone mineral density;
SARC	cis	rs3796352	1.000	rs3097417	chr3:53088601	C/G	cg27565382	chr3:53032988	SFMBT1	-0.79	-6.03	-0.37	6.36e-9	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs360798	0.512	rs17027429	chr2:63079983	C/T	cg17519650	chr2:63277830	OTX1	0.38	4.83	0.3	2.5e-6	Coronary artery disease;
SARC	cis	rs6089584	0.528	rs4925334	chr20:60626769	C/T	cg06108461	chr20:60628389	TAF4	-0.72	-9.38	-0.52	5.95e-18	Body mass index;
SARC	cis	rs826838	0.616	rs11182893	chr12:38627715	C/G	cg14851346	chr12:38532713	NA	-0.43	-5.2	-0.32	4.3e-7	Heart rate;
SARC	trans	rs2468186	0.710	rs1485292	chr8:120092974	C/T	cg09688763	chr10:114206798	VTI1A;ZDHHC6	-0.56	-6.76	-0.4	1.09e-10	Osteoprotegerin levels;
SARC	cis	rs11645898	1.000	rs72791115	chr16:72207315	T/C	cg14768367	chr16:72042858	DHODH	-0.55	-5.1	-0.32	7.14e-7	Blood protein levels;
SARC	cis	rs3781913	0.874	rs3781916	chr11:72368986	T/G	cg03713592	chr11:72463424	ARAP1	-0.47	-5.71	-0.35	3.42e-8	Rheumatoid arthritis;
SARC	cis	rs7223966	1.000	rs8075061	chr17:61804723	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.53	-5.55	-0.34	7.66e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs854765	0.547	rs9896837	chr17:17924868	A/G	cg04398451	chr17:18023971	MYO15A	-0.45	-6.19	-0.38	2.64e-9	Total body bone mineral density;
SARC	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg10591111	chr5:226296	SDHA	-0.51	-4.79	-0.3	3e-6	Breast cancer;
SARC	cis	rs35213789	0.762	rs2851516	chr7:69141592	C/G	cg10619644	chr7:69149951	AUTS2	-0.35	-4.82	-0.3	2.57e-6	Childhood ear infection;
SARC	cis	rs7560272	0.723	rs7562047	chr2:73725168	G/T	cg20560298	chr2:73613845	ALMS1	-0.52	-7.07	-0.42	1.79e-11	Schizophrenia;
SARC	cis	rs926938	0.584	rs1286558	chr1:115357587	C/T	cg12756093	chr1:115239321	AMPD1	0.37	4.95	0.31	1.41e-6	Autism;
SARC	cis	rs1865760	0.827	rs9295681	chr6:25944117	T/G	cg16482183	chr6:26056742	HIST1H1C	0.51	6.53	0.39	3.99e-10	Height;
SARC	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg05313129	chr8:58192883	C8orf71	-0.5	-5.87	-0.36	1.49e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs796364	0.906	rs6740981	chr2:201060216	T/C	cg05691004	chr2:201170426	SPATS2L	-0.46	-5.11	-0.32	6.8e-7	Schizophrenia;
SARC	cis	rs9660992	0.736	rs1180734	chr1:205255438	A/G	cg00857998	chr1:205179979	DSTYK	0.45	5.62	0.35	5.48e-8	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs4719841	0.662	rs9639523	chr7:25991977	A/C	cg24254488	chr7:25991654	NA	0.3	5.26	0.33	3.21e-7	Triglyceride levels;
SARC	cis	rs2197308	0.765	rs2387436	chr12:37935337	C/T	cg13010199	chr12:38710504	ALG10B	-0.69	-9.28	-0.52	1.23e-17	Morning vs. evening chronotype;
SARC	cis	rs6964587	1.000	rs4644173	chr7:91759597	A/G	cg17063962	chr7:91808500	NA	0.97	16.93	0.74	1.8e-42	Breast cancer;
SARC	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg03185022	chr7:2884158	GNA12	0.45	4.99	0.31	1.19e-6	Height;
SARC	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg16405210	chr4:1374714	KIAA1530	-0.51	-5.92	-0.36	1.13e-8	Obesity-related traits;
SARC	cis	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.54	-0.39	3.81e-10	Joint mobility (Beighton score);
SARC	trans	rs17685	0.753	rs10245584	chr7:75745866	C/T	cg19862616	chr7:65841803	NCRNA00174	0.63	7.77	0.45	2.42e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs11785400	1.000	rs9720653	chr8:143731939	T/G	cg10596483	chr8:143751796	JRK	0.64	8.53	0.49	1.94e-15	Schizophrenia;
SARC	cis	rs7216064	1.000	rs62084214	chr17:65843325	C/G	cg12091567	chr17:66097778	LOC651250	-0.68	-6.87	-0.41	5.8200000000000003e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs427394	1.000	rs182135	chr5:6747453	G/A	cg10857441	chr5:6722123	POLS	-0.32	-4.96	-0.31	1.38e-6	Menopause (age at onset);
SARC	cis	rs11122272	0.705	rs2808599	chr1:231533482	T/C	cg06096015	chr1:231504339	EGLN1	0.38	5.64	0.35	4.92e-8	Hemoglobin concentration;
SARC	cis	rs67460515	0.892	rs13059340	chr3:161062631	T/C	cg04691961	chr3:161091175	C3orf57	-0.52	-6.57	-0.4	3.32e-10	Parkinson's disease;
SARC	cis	rs2486288	0.656	rs9920290	chr15:45548035	G/A	cg15395560	chr15:45543142	SLC28A2	0.29	5.59	0.34	6.44e-8	Glomerular filtration rate;
SARC	cis	rs9291683	0.530	rs882223	chr4:9981625	A/C	cg00071950	chr4:10020882	SLC2A9	0.4	6.43	0.39	7.09e-10	Bone mineral density;
SARC	cis	rs1355223	0.583	rs2116085	chr11:34884001	C/A	cg11058730	chr11:34937778	PDHX;APIP	0.8	11.59	0.6	7.94e-25	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg03452623	chr4:187889614	NA	-0.76	-11.88	-0.61	9e-26	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg07564645	chr13:45915210	TPT1;LOC100190939	0.51	6.5	0.39	4.91e-10	Lung adenocarcinoma;
SARC	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg20102877	chr2:27665638	KRTCAP3	-0.36	-5.14	-0.32	5.87e-7	Total body bone mineral density;
SARC	cis	rs1185460	0.967	rs1177563	chr11:118949083	C/T	cg23280166	chr11:118938394	VPS11	0.79	11.82	0.61	1.42e-25	Coronary artery disease;
SARC	cis	rs8020289	0.560	rs4903491	chr14:77263609	A/G	cg23436960	chr14:77239540	VASH1	-0.33	-4.97	-0.31	1.3e-6	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);
SARC	cis	rs7932354	0.528	rs747650	chr11:47176005	C/T	cg03339077	chr11:47165057	C11orf49	0.44	6.14	0.37	3.57e-9	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg22974920	chr21:40686053	BRWD1	-0.43	-4.74	-0.3	3.78e-6	Cognitive function;
SARC	cis	rs858239	0.539	rs6976957	chr7:23187333	T/A	cg23682824	chr7:23144976	KLHL7	0.72	9.28	0.52	1.22e-17	Cerebrospinal fluid biomarker levels;
SARC	cis	rs10876993	0.855	rs1689601	chr12:58049557	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.49	-6.12	-0.37	3.87e-9	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs10791323	0.604	rs2853115	chr11:133707908	C/T	cg13461336	chr11:133711254	SPATA19	0.28	4.89	0.31	1.88e-6	Childhood ear infection;
SARC	cis	rs7607369	0.559	rs4674341	chr2:219659911	A/G	cg02176678	chr2:219576539	TTLL4	-0.37	-5.73	-0.35	3.02e-8	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs3733585	0.699	rs6449176	chr4:9967843	G/A	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.65	-0.35	4.69e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs3845702	0.736	rs6733426	chr2:180830958	A/G	cg01881094	chr2:180872142	CWC22	-1.12	-9.33	-0.52	8.63e-18	Schizophrenia;
SARC	cis	rs6087990	0.842	rs4911253	chr20:31352585	A/G	cg13636640	chr20:31349939	DNMT3B	0.8	12.48	0.63	1.07e-27	Ulcerative colitis;
SARC	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg11764359	chr7:65958608	NA	-0.78	-9.63	-0.53	1.11e-18	Aortic root size;
SARC	cis	rs7666738	0.546	rs10025064	chr4:98914060	A/G	cg05340658	chr4:99064831	C4orf37	0.59	7.19	0.43	8.82e-12	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	8.71	0.5	5.56e-16	Alzheimer's disease;
SARC	trans	rs7815944	1.000	rs80294477	chr8:129424138	G/A	cg17342469	chr22:46473074	NA	0.71	6.7	0.4	1.58e-10	Atopic dermatitis;
SARC	trans	rs4834272	0.580	rs9884299	chr4:113302950	A/G	cg19336959	chr7:150497703	TMEM176B;TMEM176A	-0.43	-6.29	-0.38	1.59e-9	Body mass index;
SARC	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg11764359	chr7:65958608	NA	-0.71	-8.42	-0.48	3.97e-15	Aortic root size;
SARC	cis	rs72781680	0.756	rs2712059	chr2:24020539	T/C	cg06627628	chr2:24431161	ITSN2	-0.52	-5.44	-0.34	1.38e-7	Lymphocyte counts;
SARC	cis	rs72949976	0.606	rs11898263	chr2:214030649	A/G	cg08319019	chr2:214017104	IKZF2	0.48	6.39	0.39	8.75e-10	Lung cancer;Squamous cell lung carcinoma;
SARC	cis	rs2230307	0.656	rs6699449	chr1:100542638	G/A	cg24955406	chr1:100503596	HIAT1	0.66	5.09	0.32	7.51e-7	Carotid intima media thickness;
SARC	cis	rs17384381	0.863	rs12140272	chr1:85789757	G/A	cg16011679	chr1:85725395	C1orf52	0.53	4.82	0.3	2.56e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11252926	0.537	rs4881255	chr10:453638	T/C	cg08603382	chr10:743973	NA	0.39	5.1	0.32	7.13e-7	Psychosis in Alzheimer's disease;
SARC	cis	rs1580019	0.961	rs4357201	chr7:32496333	T/C	cg14728415	chr7:32535168	LSM5;AVL9	0.43	5.04	0.31	9.3e-7	Cognitive ability;
SARC	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	12.76	0.64	1.22e-28	Platelet count;
SARC	cis	rs1044826	0.642	rs4683464	chr3:139196961	C/T	cg15131784	chr3:139108705	COPB2	0.39	4.79	0.3	2.96e-6	Obesity-related traits;
SARC	cis	rs193541	0.632	rs2407402	chr5:122107105	G/C	cg19412675	chr5:122181750	SNX24	0.46	6.15	0.37	3.39e-9	Glucose homeostasis traits;
SARC	cis	rs9487051	0.872	rs9386789	chr6:109603218	A/G	cg01475377	chr6:109611718	NA	-0.4	-5.77	-0.35	2.57e-8	Reticulocyte fraction of red cells;
SARC	cis	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg13072238	chr3:49761600	GMPPB	-0.61	-6.13	-0.37	3.64e-9	Menarche (age at onset);
SARC	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg24846343	chr22:24311635	DDTL	-0.39	-5.12	-0.32	6.5e-7	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg06618935	chr21:46677482	NA	-0.36	-4.82	-0.3	2.55e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs3126085	0.825	rs10788830	chr1:152206898	A/C	cg26876637	chr1:152193138	HRNR	0.48	5.6	0.34	6.08e-8	Atopic dermatitis;
SARC	cis	rs7089973	0.604	rs17663670	chr10:116596269	A/C	cg03647239	chr10:116582469	FAM160B1	-0.52	-6.6	-0.4	2.72e-10	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs10992471	0.533	rs331381	chr9:95249859	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.44	5.28	0.33	2.93e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs6831352	0.918	rs13133647	chr4:100058727	C/T	cg12011299	chr4:100065546	ADH4	-0.34	-5.74	-0.35	2.95e-8	Alcohol dependence;
SARC	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg02951883	chr7:2050386	MAD1L1	-0.51	-6.76	-0.4	1.11e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg13628971	chr7:2884303	GNA12	-0.54	-6.4	-0.39	8.52e-10	Height;
SARC	trans	rs61931739	1.000	rs12304768	chr12:34000986	T/G	cg26384229	chr12:38710491	ALG10B	-0.56	-7.1	-0.42	1.46e-11	Morning vs. evening chronotype;
SARC	cis	rs2273669	0.915	rs2038542	chr6:109295293	T/C	cg01304950	chr6:109416612	SESN1;C6orf182	0.54	4.79	0.3	3e-6	Prostate cancer;
SARC	cis	rs644799	0.710	rs11021309	chr11:95501898	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.94	16.24	0.73	3.62e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg03060546	chr3:49711283	APEH	-0.66	-8.29	-0.48	9.28e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs9868809	0.772	rs13070798	chr3:48705934	C/T	cg07636037	chr3:49044803	WDR6	0.6	6.06	0.37	5.46e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs7647973	1.000	rs6783003	chr3:49524778	G/C	cg06212747	chr3:49208901	KLHDC8B	-0.57	-5.74	-0.35	2.88e-8	Menarche (age at onset);
SARC	cis	rs7766436	0.553	rs62391069	chr6:22610835	C/T	cg13666174	chr6:22585274	NA	-0.59	-6.0	-0.37	7.61e-9	Coronary artery disease;
SARC	cis	rs832540	0.656	rs832567	chr5:56152416	C/A	cg22800045	chr5:56110881	MAP3K1	0.42	5.08	0.32	7.63e-7	Coronary artery disease;
SARC	cis	rs3767633	0.925	rs6427633	chr1:161849569	C/T	cg09175582	chr1:161736000	ATF6	0.65	5.5	0.34	9.86e-8	IgG glycosylation;
SARC	cis	rs9486715	0.838	rs7452350	chr6:96883326	C/A	cg18709589	chr6:96969512	KIAA0776	0.58	7.27	0.43	5.5e-12	Headache;
SARC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.47	-7.53	-0.44	1.11e-12	Longevity;Endometriosis;
SARC	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg12463550	chr7:65579703	CRCP	-0.48	-5.68	-0.35	4.06e-8	Aortic root size;
SARC	trans	rs9523762	0.577	rs9516124	chr13:93354797	A/G	cg12065285	chr1:155946346	ARHGEF2	0.46	6.45	0.39	6.29e-10	Multiple sclerosis;
SARC	cis	rs2486288	0.656	rs12899058	chr15:45547324	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.5	-6.29	-0.38	1.57e-9	Glomerular filtration rate;
SARC	cis	rs9303280	0.806	rs9907088	chr17:38035116	G/A	cg17467752	chr17:38218738	THRA	-0.37	-4.76	-0.3	3.34e-6	Self-reported allergy;
SARC	cis	rs12142240	0.738	rs67545510	chr1:46806242	G/T	cg00530320	chr1:46809349	NSUN4	0.55	6.72	0.4	1.35e-10	Menopause (age at onset);
SARC	cis	rs10754283	0.967	rs6428561	chr1:90102619	G/A	cg21401794	chr1:90099060	LRRC8C	0.6	8.43	0.48	3.54e-15	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs10078	0.528	rs2434697	chr5:466811	T/C	cg07599136	chr5:415885	AHRR	0.67	5.93	0.36	1.08e-8	Fat distribution (HIV);
SARC	cis	rs796364	0.951	rs59695400	chr2:201021325	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.56	-5.71	-0.35	3.35e-8	Schizophrenia;
SARC	cis	rs9300255	0.602	rs1727316	chr12:123618603	C/T	cg05973401	chr12:123451056	ABCB9	0.52	5.98	0.36	8.42e-9	Neutrophil percentage of white cells;
SARC	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg16049864	chr8:95962084	TP53INP1	-0.47	-7.7	-0.45	3.91e-13	Type 2 diabetes;
SARC	cis	rs561341	1.000	rs542132	chr17:30307193	A/T	cg00745463	chr17:30367425	LRRC37B	-0.67	-5.36	-0.33	2.03e-7	Hip circumference adjusted for BMI;
SARC	cis	rs11122272	0.735	rs2486734	chr1:231531392	A/G	cg06096015	chr1:231504339	EGLN1	0.38	5.7	0.35	3.54e-8	Hemoglobin concentration;
SARC	cis	rs2180341	1.000	rs9385419	chr6:127597591	A/G	cg17762328	chr6:126965162	NA	-0.46	-5.28	-0.33	3.01e-7	Breast cancer;
SARC	cis	rs4975616	0.804	rs459961	chr5:1337106	T/A	cg26373071	chr5:1325741	CLPTM1L	0.3	4.9	0.31	1.83e-6	Lung cancer;
SARC	cis	rs6693567	0.516	rs3850844	chr1:150413940	G/T	cg09579323	chr1:150459698	TARS2	0.44	5.58	0.34	6.5e-8	Migraine;
SARC	cis	rs2153535	0.580	rs4365970	chr6:8453813	C/T	cg23788917	chr6:8435910	SLC35B3	-0.64	-8.44	-0.48	3.39e-15	Motion sickness;
SARC	cis	rs10805346	1.000	rs10805346	chr4:9920347	T/C	cg25986240	chr4:9926439	SLC2A9	0.3	5.4	0.33	1.62e-7	Urate levels in overweight individuals;Urate levels in obese individuals;
SARC	cis	rs7236492	0.748	rs79548165	chr18:77183529	C/T	cg15644404	chr18:77186268	NFATC1	-0.66	-6.53	-0.39	4.15e-10	Inflammatory bowel disease;Crohn's disease;
SARC	trans	rs9929218	0.911	rs1075959	chr16:68832750	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.5	-6.31	-0.38	1.43e-9	Colorectal cancer;
SARC	cis	rs10992471	0.580	rs7847534	chr9:95282653	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.38	-0.33	1.78e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs6665290	0.935	rs12409755	chr1:227196949	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.09	-25.37	-0.86	5.39e-69	Myeloid white cell count;
SARC	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	9.06	0.51	5.34e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7769051	0.522	rs6934155	chr6:133124021	C/T	cg22852734	chr6:133119734	C6orf192	1.21	7.73	0.45	3.24e-13	Type 2 diabetes nephropathy;
SARC	cis	rs4555082	0.957	rs2816622	chr14:105733114	T/C	cg13114125	chr14:105738426	BRF1	-0.8	-11.92	-0.62	6.63e-26	Mean platelet volume;Platelet distribution width;
SARC	cis	rs2230307	0.656	rs6662945	chr1:100584746	A/C	cg24955406	chr1:100503596	HIAT1	0.68	5.44	0.34	1.37e-7	Carotid intima media thickness;
SARC	cis	rs7618915	1.000	rs3852063	chr3:52349204	A/G	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.38	5.09	0.32	7.26e-7	Bipolar disorder;
SARC	cis	rs11105298	0.891	rs10858899	chr12:89923811	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.53	-5.36	-0.33	2.01e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs4481887	1.000	rs4244172	chr1:248466838	A/G	cg13385794	chr1:248469461	NA	0.35	5.27	0.33	3.17e-7	Common traits (Other);
SARC	cis	rs4713675	0.546	rs791903	chr6:33702645	G/C	cg15676125	chr6:33679581	C6orf125	-0.49	-5.76	-0.35	2.61e-8	Plateletcrit;
SARC	cis	rs9790314	1.000	rs459697	chr3:161093420	G/A	cg03342759	chr3:160939853	NMD3	-0.58	-7.25	-0.43	6.09e-12	Morning vs. evening chronotype;
SARC	cis	rs12142240	0.698	rs1053628	chr1:46827769	C/T	cg10495392	chr1:46806563	NSUN4	0.64	6.83	0.41	7.39e-11	Menopause (age at onset);
SARC	cis	rs9858542	0.903	rs17080528	chr3:49389842	C/T	cg07274523	chr3:49395745	GPX1	0.54	6.35	0.38	1.12e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg14343924	chr8:8086146	FLJ10661	-0.4	-4.74	-0.3	3.69e-6	Joint mobility (Beighton score);
SARC	cis	rs9790314	0.589	rs1447618	chr3:160610438	C/T	cg04691961	chr3:161091175	C3orf57	0.53	7.16	0.42	1.06e-11	Morning vs. evening chronotype;
SARC	cis	rs9894429	0.966	rs6565604	chr17:79589242	G/A	cg18240062	chr17:79603768	NPLOC4	0.72	9.85	0.54	2.38e-19	Eye color traits;
SARC	cis	rs1965732	0.588	rs13385033	chr2:3715071	C/T	cg15327641	chr2:3715039	ALLC	0.29	4.8	0.3	2.86e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
SARC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	9.8	0.54	3.29e-19	Platelet count;
SARC	cis	rs3126085	1.000	rs12567463	chr1:152180128	T/A	cg03465714	chr1:152285911	FLG	0.48	5.64	0.35	4.99e-8	Atopic dermatitis;
SARC	cis	rs7740797	0.791	rs4870312	chr6:155120819	T/A	cg02865717	chr6:155053990	RBM16	-0.34	-4.82	-0.3	2.63e-6	Colorectal or endometrial cancer;
SARC	trans	rs1814175	0.817	rs28679516	chr11:50055998	G/A	cg15704280	chr7:45808275	SEPT13	-0.96	-18.23	-0.77	9.55e-47	Height;
SARC	cis	rs262150	0.837	rs2657404	chr7:158783155	C/T	cg09640425	chr7:158790006	NA	-0.41	-5.45	-0.34	1.3e-7	Facial morphology (factor 20);
SARC	cis	rs2731664	0.792	rs652242	chr5:176873010	C/G	cg23176889	chr5:176863531	GRK6	-0.57	-8.64	-0.49	9.19e-16	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg08280861	chr8:58055591	NA	0.7	5.74	0.35	2.91e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6120849	0.707	rs6088694	chr20:33652371	G/A	cg24642439	chr20:33292090	TP53INP2	0.57	5.44	0.34	1.33e-7	Protein C levels;
SARC	cis	rs1003719	0.737	rs9974374	chr21:38479885	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.62	8.7	0.5	5.92e-16	Eye color traits;
SARC	cis	rs8141529	0.509	rs5762853	chr22:29245231	T/G	cg02153584	chr22:29168773	CCDC117	0.66	8.8	0.5	3.12e-16	Lymphocyte counts;
SARC	cis	rs6834538	1.000	rs7665050	chr4:113521476	G/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.46	5.54	0.34	8.08e-8	Free thyroxine concentration;
SARC	cis	rs13095912	1.000	rs6762208	chr3:185331165	A/C	cg11274856	chr3:185301563	NA	-0.36	-4.99	-0.31	1.17e-6	Systolic blood pressure;
SARC	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg21782813	chr7:2030301	MAD1L1	0.4	6.05	0.37	5.81e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs12048904	1.000	rs12048904	chr1:101331536	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.39	-4.79	-0.3	2.97e-6	Multiple sclerosis;
SARC	cis	rs4819052	0.679	rs2236450	chr21:46702553	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	6.39	0.39	8.91e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs765787	0.556	rs10851422	chr15:45513738	T/C	cg24006582	chr15:45444508	DUOX1	0.42	5.45	0.34	1.31e-7	Uric acid levels;
SARC	cis	rs9388451	0.903	rs9388446	chr6:126064920	T/A	cg05901451	chr6:126070800	HEY2	-0.67	-9.18	-0.52	2.42e-17	Brugada syndrome;
SARC	cis	rs4841097	0.876	rs6601288	chr8:8943430	A/T	cg06636001	chr8:8085503	FLJ10661	0.45	5.47	0.34	1.16e-7	Platelet distribution width;
SARC	cis	rs3857536	0.642	rs7755840	chr6:66891913	A/G	cg07460842	chr6:66804631	NA	-0.6	-7.16	-0.42	1.04e-11	Blood trace element (Cu levels);
SARC	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg01448562	chr3:133502909	NA	-0.49	-7.48	-0.44	1.47e-12	Iron status biomarkers;
SARC	cis	rs1153858	0.621	rs12913645	chr15:45555066	G/A	cg15395560	chr15:45543142	SLC28A2	0.26	4.77	0.3	3.22e-6	Homoarginine levels;
SARC	cis	rs3733589	0.744	rs3756234	chr4:10022474	C/T	cg16430538	chr4:10459836	ZNF518B	0.61	4.92	0.31	1.62e-6	Renal overload gout;
SARC	cis	rs7599312	0.553	rs6710653	chr2:213404893	A/G	cg16329650	chr2:213403929	ERBB4	0.7	10.61	0.57	1.03e-21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs1971762	0.527	rs7972401	chr12:53940046	T/C	cg06632207	chr12:54070931	ATP5G2	0.57	7.89	0.46	1.14e-13	Height;
SARC	cis	rs12079745	0.793	rs114369903	chr1:169251394	T/C	cg09363564	chr1:169337483	NME7;BLZF1	-0.87	-5.2	-0.32	4.27e-7	QT interval;
SARC	cis	rs7223966	1.000	rs72848797	chr17:61934664	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-4.84	-0.3	2.4e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs858239	0.698	rs858295	chr7:23245569	A/G	cg23682824	chr7:23144976	KLHL7	0.64	8.14	0.47	2.44e-14	Cerebrospinal fluid biomarker levels;
SARC	cis	rs7681440	0.583	rs2583988	chr4:90760828	C/T	cg06632027	chr4:90757378	SNCA	-0.44	-5.61	-0.35	5.66e-8	Dementia with Lewy bodies;
SARC	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9436747	0.680	rs1171268	chr1:65996166	G/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.47	-5.03	-0.31	9.77e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs858239	0.600	rs7788821	chr7:23133645	A/T	cg23682824	chr7:23144976	KLHL7	0.71	9.42	0.53	4.53e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs62244186	0.541	rs62244226	chr3:44831831	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.56	7.3	0.43	4.39e-12	Depressive symptoms;
SARC	cis	rs644799	0.965	rs549695	chr11:95617788	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.67	8.45	0.48	3.16e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs1018836	0.798	rs28568272	chr8:91652958	A/G	cg16814680	chr8:91681699	NA	-0.95	-17.42	-0.75	4.46e-44	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs1691799	0.867	rs1168343	chr12:66758581	C/T	cg16791601	chr12:66731901	HELB	-0.72	-10.83	-0.58	2.06e-22	White blood cell count (basophil);
SARC	cis	rs2153535	0.580	rs6920779	chr6:8437624	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	8.08	0.47	3.6e-14	Motion sickness;
SARC	cis	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg25894440	chr7:65020034	NA	-0.77	-5.74	-0.35	2.92e-8	Diabetic kidney disease;
SARC	cis	rs8031584	0.541	rs2959037	chr15:31218164	T/C	cg08109568	chr15:31115862	NA	0.45	5.96	0.36	9.12e-9	Huntington's disease progression;
SARC	cis	rs17376456	0.877	rs12374463	chr5:93483569	C/G	cg25358565	chr5:93447407	FAM172A	1.36	14.18	0.68	2.63e-33	Diabetic retinopathy;
SARC	cis	rs17608059	0.504	rs11656981	chr17:13978777	A/G	cg11395062	chr17:14139857	CDRT15	0.52	7.12	0.42	1.32e-11	Temperament;
SARC	cis	rs7264396	0.676	rs6060729	chr20:34557004	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-6.92	-0.41	4.41e-11	Total cholesterol levels;
SARC	cis	rs6964587	1.000	rs12530646	chr7:91588036	A/G	cg17063962	chr7:91808500	NA	-0.95	-15.95	-0.72	3.35e-39	Breast cancer;
SARC	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg20891283	chr12:69753455	YEATS4	0.55	7.56	0.44	9.09e-13	Blood protein levels;
SARC	cis	rs9388451	0.626	rs3799708	chr6:126078530	C/T	cg05901451	chr6:126070800	HEY2	-0.5	-6.5	-0.39	4.93e-10	Brugada syndrome;
SARC	cis	rs6772849	0.830	rs4857917	chr3:128376178	C/T	cg08795948	chr3:128337044	NA	0.54	7.48	0.44	1.51e-12	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs13401104	0.796	rs10929174	chr2:237116829	A/G	cg19324714	chr2:237145437	ASB18	0.58	5.83	0.36	1.87e-8	Educational attainment;
SARC	cis	rs11225247	0.772	rs11501343	chr11:102227214	A/C	cg11690896	chr11:102217788	BIRC2	0.72	5.19	0.32	4.65e-7	Vein graft stenosis in coronary artery bypass grafting;
SARC	cis	rs2425143	1.000	rs7273668	chr20:34442731	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	4.84	0.3	2.35e-6	Blood protein levels;
SARC	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg11644478	chr21:40555479	PSMG1	0.98	11.79	0.61	1.77e-25	Cognitive function;
SARC	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg13699009	chr12:122356056	WDR66	0.59	9.17	0.52	2.5e-17	Mean corpuscular volume;
SARC	cis	rs72627509	0.951	rs72627508	chr4:57831564	C/G	cg26694713	chr4:57773883	REST	0.67	6.52	0.39	4.23e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg03264133	chr6:25882463	NA	-0.5	-6.8	-0.41	8.67e-11	Intelligence (multi-trait analysis);
SARC	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	5.62	0.35	5.51e-8	Bipolar disorder;
SARC	trans	rs561341	1.000	rs521919	chr17:30298039	G/T	cg20587970	chr11:113659929	NA	-1.23	-12.04	-0.62	2.88e-26	Hip circumference adjusted for BMI;
SARC	cis	rs6867032	0.958	rs4975798	chr5:2015580	G/A	cg26168224	chr5:2018326	NA	0.92	14.86	0.7	1.4e-35	Gut microbiome composition (winter);
SARC	cis	rs6696846	1.000	rs6696846	chr1:205041952	C/T	cg07972983	chr1:205091412	RBBP5	0.45	5.68	0.35	3.96e-8	Red blood cell count;
SARC	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg01475735	chr3:40494733	NA	-0.49	-5.36	-0.33	1.97e-7	Renal cell carcinoma;
SARC	cis	rs9815354	1.000	rs1716661	chr3:41962818	C/T	cg03022575	chr3:42003672	ULK4	-0.57	-5.4	-0.33	1.68e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg19346786	chr7:2764209	NA	-0.4	-5.96	-0.36	9.33e-9	Height;
SARC	cis	rs3812831	0.599	rs428637	chr13:114927139	T/G	cg06611532	chr13:114900021	NA	0.35	5.77	0.35	2.5e-8	Schizophrenia;
SARC	cis	rs8060686	0.545	rs78229587	chr16:68165243	T/C	cg27539214	chr16:67997921	SLC12A4	-0.51	-4.86	-0.3	2.14e-6	HDL cholesterol;Metabolic syndrome;
SARC	cis	rs12545109	0.800	rs1440762	chr8:57410708	C/T	cg21220214	chr8:57350948	NA	-0.4	-4.72	-0.3	4.12e-6	Obesity-related traits;
SARC	cis	rs9916302	0.800	rs9892675	chr17:37549200	C/T	cg07936489	chr17:37558343	FBXL20	0.78	10.14	0.55	2.93e-20	Glomerular filtration rate (creatinine);
SARC	cis	rs933688	1.000	rs7720132	chr5:90745105	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	12.57	0.64	5.35e-28	Smoking behavior;
SARC	cis	rs7672847	0.547	rs10084942	chr4:170352819	T/C	cg00846720	chr4:170533756	NEK1	-0.59	-4.86	-0.3	2.15e-6	Subjective well-being;
SARC	cis	rs4689388	0.824	rs114669221	chr4:6301459	G/A	cg25554036	chr4:6271136	WFS1	0.37	5.81	0.36	2.04e-8	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs35110281	0.720	rs162394	chr21:44943550	C/G	cg21573476	chr21:45109991	RRP1B	0.52	7.76	0.45	2.7e-13	Mean corpuscular volume;
SARC	cis	rs12477438	0.871	rs13396584	chr2:99611768	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.7	8.02	0.47	5e-14	Chronic sinus infection;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg22280406	chr17:78582647	RPTOR	0.49	6.26	0.38	1.8e-9	Schizophrenia;
SARC	cis	rs9796	0.621	rs58109657	chr15:41471750	A/G	cg18705301	chr15:41695430	NDUFAF1	0.56	8.2	0.47	1.62e-14	Menopause (age at onset);
SARC	cis	rs9916302	0.904	rs4795359	chr17:37573146	C/T	cg20243544	chr17:37824526	PNMT	0.55	6.56	0.39	3.39e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs397969	0.569	rs62066351	chr17:19900994	A/G	cg13482628	chr17:19912719	NA	0.43	4.73	0.3	3.97e-6	Platelet count;
SARC	cis	rs7223966	0.921	rs2006123	chr17:61958669	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-5.91	-0.36	1.23e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1256061	0.603	rs1256044	chr14:64734027	G/A	cg23250157	chr14:64679961	SYNE2	0.48	6.62	0.4	2.49e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs17250963	0.797	rs153926	chr5:14745357	A/G	cg12465520	chr5:14733886	ANKH	0.5	4.8	0.3	2.79e-6	Homeostasis model assessment of insulin resistance (dietary factor interaction);
SARC	cis	rs26232	0.521	rs3776856	chr5:102358806	T/C	cg23492399	chr5:102201601	PAM	-0.51	-5.6	-0.34	6.07e-8	Rheumatoid arthritis;
SARC	cis	rs6665290	0.904	rs1343744	chr1:227183022	C/T	cg14016676	chr1:227182615	CDC42BPA	0.36	5.09	0.32	7.23e-7	Myeloid white cell count;
SARC	cis	rs9911578	1.000	rs2270097	chr17:56572070	G/A	cg05425664	chr17:57184151	TRIM37	0.64	7.86	0.46	1.41e-13	Intelligence (multi-trait analysis);
SARC	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg09517075	chr8:22133004	PIWIL2	0.36	4.95	0.31	1.43e-6	Hypertriglyceridemia;
SARC	cis	rs71191701	1.000	rs71191701	chr9:139322257	G/C	cg13611204	chr9:139324423	INPP5E	-0.29	-4.96	-0.31	1.36e-6	Myeloid white cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
SARC	cis	rs36051895	0.553	rs12338854	chr9:5057568	G/C	cg02405213	chr9:5042618	JAK2	-0.48	-5.55	-0.34	7.92e-8	Pediatric autoimmune diseases;
SARC	cis	rs9470361	0.506	rs4568449	chr6:36621143	A/G	cg08179530	chr6:36648295	CDKN1A	0.53	6.47	0.39	5.82e-10	QRS complex (Cornell);QRS duration;Left ventricular fractional shortening;
SARC	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg06420487	chr17:61919686	SMARCD2	0.48	5.48	0.34	1.1e-7	Height;
SARC	cis	rs523522	1.000	rs1563333	chr12:120934407	C/T	cg12219531	chr12:120966889	COQ5	0.82	11.15	0.59	1.99e-23	High light scatter reticulocyte count;
SARC	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg23758822	chr17:41437982	NA	0.87	10.64	0.57	8.54e-22	Menopause (age at onset);
SARC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg02592271	chr2:27665507	KRTCAP3	-0.42	-6.42	-0.39	7.6e-10	Total body bone mineral density;
SARC	cis	rs9303401	0.704	rs7359501	chr17:56641200	C/T	cg12560992	chr17:57184187	TRIM37	0.48	5.89	0.36	1.32e-8	Cognitive test performance;
SARC	cis	rs6942407	0.542	rs744136	chr7:86747081	T/C	cg02420886	chr7:86849541	C7orf23	0.59	5.41	0.33	1.55e-7	Food allergy;
SARC	cis	rs2273669	0.667	rs117412830	chr6:109336617	A/G	cg05315195	chr6:109294784	ARMC2	-0.64	-5.7	-0.35	3.68e-8	Prostate cancer;
SARC	cis	rs79149102	0.737	rs12593975	chr15:75189591	G/A	cg17294928	chr15:75287854	SCAMP5	-0.94	-5.77	-0.35	2.54e-8	Lung cancer;
SARC	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-9.42	-0.53	4.61e-18	Chronic sinus infection;
SARC	cis	rs12980942	0.810	rs8103839	chr19:41781493	C/G	cg25627403	chr19:41769009	HNRNPUL1	0.6	4.88	0.3	2.01e-6	Coronary artery disease;
SARC	cis	rs13161895	0.702	rs74507840	chr5:179487430	G/A	cg02702477	chr5:179499311	RNF130	0.77	7.14	0.42	1.17e-11	LDL cholesterol;
SARC	cis	rs611744	0.870	rs596703	chr8:109160146	A/G	cg21045802	chr8:109455806	TTC35	-0.49	-6.27	-0.38	1.73e-9	Dupuytren's disease;
SARC	cis	rs66573146	0.831	rs67315413	chr4:6987910	T/C	cg15105060	chr4:7024189	TBC1D14	-0.69	-4.96	-0.31	1.35e-6	Granulocyte percentage of myeloid white cells;
SARC	cis	rs763121	0.853	rs5757203	chr22:39044152	G/C	cg06022373	chr22:39101656	GTPBP1	0.9	11.56	0.6	9.96e-25	Menopause (age at onset);
SARC	cis	rs17376456	0.877	rs9885329	chr5:93380278	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.51	0.34	9.53e-8	Diabetic retinopathy;
SARC	cis	rs3820928	0.933	rs1429267	chr2:227767593	G/C	cg11843606	chr2:227700838	RHBDD1	-0.53	-6.68	-0.4	1.72e-10	Pulmonary function;
SARC	trans	rs288326	0.561	rs57018234	chr2:183708256	G/T	cg05855065	chr22:43623455	SCUBE1	-0.71	-6.26	-0.38	1.81e-9	Blood protein levels;
SARC	cis	rs11105298	0.891	rs10858852	chr12:89833338	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.5	-5.01	-0.31	1.1e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg12648201	chr2:27665141	KRTCAP3	-0.33	-5.0	-0.31	1.11e-6	Total body bone mineral density;
SARC	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg26681399	chr22:41777847	TEF	0.43	4.92	0.31	1.67e-6	Vitiligo;
SARC	cis	rs3733585	0.699	rs13328050	chr4:9951120	G/T	cg00071950	chr4:10020882	SLC2A9	-0.38	-5.89	-0.36	1.37e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs9796	0.553	rs1869908	chr15:41257224	C/A	cg18705301	chr15:41695430	NDUFAF1	0.51	6.72	0.4	1.41e-10	Menopause (age at onset);
SARC	cis	rs13040088	1.000	rs2295000	chr20:61536938	A/G	cg23096297	chr20:61557774	DIDO1	-0.95	-10.92	-0.58	1.12e-22	Menopause (age at onset);
SARC	cis	rs9816226	0.645	rs16860471	chr3:185847441	G/T	cg00760338	chr3:185826511	ETV5	-0.78	-7.6	-0.45	7.28e-13	Obesity;Body mass index;
SARC	cis	rs372883	0.967	rs2832290	chr21:30728863	C/T	cg24692254	chr21:30365293	RNF160	-0.43	-5.21	-0.32	4.11e-7	Pancreatic cancer;
SARC	cis	rs11583043	0.708	rs1060481	chr1:101546699	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.45	4.91	0.31	1.75e-6	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs818427	0.927	rs2909904	chr5:112207007	G/C	cg07820702	chr5:112228657	REEP5	0.44	4.89	0.3	1.89e-6	Total body bone mineral density;
SARC	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg08280861	chr8:58055591	NA	0.63	5.43	0.34	1.42e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs67460515	0.531	rs13060601	chr3:160823159	G/A	cg03342759	chr3:160939853	NMD3	-0.67	-8.02	-0.47	5.16e-14	Parkinson's disease;
SARC	cis	rs9916302	0.706	rs649180	chr17:37464959	A/C	cg20243544	chr17:37824526	PNMT	-0.54	-5.61	-0.35	5.6e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs7909074	0.798	rs914699	chr10:45377066	A/C	cg04218760	chr10:45406644	TMEM72	-0.25	-4.85	-0.3	2.22e-6	Mean corpuscular volume;
SARC	cis	rs9843304	0.568	rs71304473	chr3:149217190	G/A	cg08667024	chr3:149219783	TM4SF4	-0.34	-4.92	-0.31	1.65e-6	Gallstone disease;
SARC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg07157834	chr1:205819609	PM20D1	0.82	14.62	0.69	8.73e-35	Menarche (age at onset);
SARC	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg03060546	chr3:49711283	APEH	0.44	5.55	0.34	7.66e-8	Parkinson's disease;
SARC	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	8.93	0.5	1.34e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs11122272	0.735	rs973252	chr1:231520802	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs13161895	0.818	rs78282770	chr5:179483686	T/A	cg06664874	chr5:179499304	RNF130	0.6	5.48	0.34	1.13e-7	LDL cholesterol;
SARC	cis	rs4853036	0.951	rs6738783	chr2:70120608	A/G	cg02498382	chr2:70120550	SNRNP27	-0.38	-4.96	-0.31	1.36e-6	Colorectal or endometrial cancer;
SARC	cis	rs10411936	0.962	rs10404046	chr19:16477255	G/C	cg10248733	chr19:16607483	C19orf44;CALR3	0.45	5.12	0.32	6.4e-7	White blood cell count;Multiple sclerosis;
SARC	cis	rs3796352	1.000	rs11710292	chr3:53117798	T/C	cg15956490	chr3:53032818	SFMBT1	0.9	5.96	0.36	9.12e-9	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg24250549	chr1:154909240	PMVK	0.83	12.38	0.63	2.18e-27	Prostate cancer;
SARC	cis	rs60871478	1.000	rs62432250	chr7:801792	C/G	cg19087971	chr7:751233	PRKAR1B	-0.43	-4.96	-0.31	1.38e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs2204008	0.658	rs11181310	chr12:38315963	C/A	cg13010199	chr12:38710504	ALG10B	0.76	10.35	0.56	6.76e-21	Bladder cancer;
SARC	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg04267008	chr7:1944627	MAD1L1	-0.49	-5.55	-0.34	7.83e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs898097	0.841	rs9896263	chr17:80902741	A/G	cg15369054	chr17:80825471	TBCD	-0.48	-6.99	-0.42	2.87e-11	Breast cancer;
SARC	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg27266027	chr21:40555129	PSMG1	-0.5	-5.42	-0.33	1.5e-7	Cognitive function;
SARC	cis	rs1448094	0.802	rs56391398	chr12:86424114	C/T	cg02569458	chr12:86230093	RASSF9	0.4	5.76	0.35	2.68e-8	Major depressive disorder;
SARC	cis	rs9398803	0.687	rs1538956	chr6:126964026	G/T	cg20229609	chr6:126660872	C6orf173	0.37	5.39	0.33	1.74e-7	Male-pattern baldness;
SARC	cis	rs6964587	0.869	rs6979024	chr7:91481512	T/C	cg17063962	chr7:91808500	NA	-0.92	-13.22	-0.65	3.97e-30	Breast cancer;
SARC	cis	rs17023223	0.537	rs2645292	chr1:119573194	C/T	cg05756136	chr1:119680316	WARS2	-0.45	-5.44	-0.34	1.35e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs4268898	0.527	rs72789910	chr2:24388609	T/G	cg06627628	chr2:24431161	ITSN2	-0.81	-9.48	-0.53	3.14e-18	Asthma;
SARC	cis	rs780094	0.606	rs6729709	chr2:27583156	G/A	cg22903471	chr2:27725779	GCKR	-0.38	-5.34	-0.33	2.2e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs6570726	0.967	rs374728	chr6:145854598	T/A	cg05220968	chr6:146057943	EPM2A	-0.3	-5.08	-0.32	7.76e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2412459	0.611	rs4924402	chr15:40245754	C/T	cg25407064	chr15:40226267	EIF2AK4	-0.5	-4.72	-0.3	4.04e-6	Response to haloperidol in psychosis;
SARC	cis	rs735539	0.521	rs2585895	chr13:21396967	A/T	cg16922012	chr13:21400325	XPO4	-0.41	-5.62	-0.35	5.45e-8	Dental caries;
SARC	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg04944784	chr2:26401820	FAM59B	0.64	8.27	0.48	1.03e-14	Gut microbiome composition (summer);
SARC	cis	rs2153535	0.580	rs1414351	chr6:8476634	T/C	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs2070997	0.607	rs4740204	chr9:133676052	T/G	cg11464064	chr9:133710261	ABL1	0.63	5.96	0.36	9.17e-9	Response to amphetamines;
SARC	cis	rs7945705	0.902	rs11042152	chr11:9020987	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.44	6.12	0.37	3.88e-9	Hemoglobin concentration;
SARC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.57	0.57	1.43e-21	Prudent dietary pattern;
SARC	cis	rs10489202	0.632	rs149912	chr1:167957803	A/T	cg24449463	chr1:168025552	DCAF6	-0.66	-8.67	-0.49	7.54e-16	Schizophrenia;
SARC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.83	0.81	3.93e-55	Prudent dietary pattern;
SARC	cis	rs9309473	0.898	rs10209517	chr2:73845392	C/G	cg07208825	chr2:73871855	ALMS1P	0.32	4.85	0.3	2.25e-6	Metabolite levels;
SARC	cis	rs2153535	0.580	rs4140586	chr6:8503192	A/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.09	0.59	3.11e-23	Motion sickness;
SARC	cis	rs2486288	0.656	rs12440356	chr15:45567529	T/C	cg19305227	chr15:45544335	SLC28A2	-0.31	-5.78	-0.35	2.35e-8	Glomerular filtration rate;
SARC	cis	rs3824867	1.000	rs3824867	chr11:47468569	A/G	cg20307385	chr11:47447363	PSMC3	0.49	5.43	0.34	1.42e-7	Mean corpuscular hemoglobin;
SARC	cis	rs1448094	0.512	rs1900701	chr12:86236231	T/C	cg00310523	chr12:86230176	RASSF9	0.3	4.89	0.3	1.92e-6	Major depressive disorder;
SARC	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	13.6	0.67	2.11e-31	Chronic sinus infection;
SARC	cis	rs7726839	0.561	rs11955068	chr5:582324	C/T	cg07777115	chr5:623756	CEP72	-0.61	-5.53	-0.34	8.43e-8	Obesity-related traits;
SARC	cis	rs4423214	1.000	rs7928249	chr11:71161063	A/G	cg05163923	chr11:71159392	DHCR7	0.67	9.13	0.51	3.46e-17	Vitamin D levels;
SARC	cis	rs10876993	0.928	rs1678540	chr12:58065002	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.48	-6.15	-0.37	3.36e-9	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.4	5.13	0.32	6.12e-7	Lymphocyte counts;
SARC	cis	rs875971	0.545	rs2460427	chr7:65619205	T/C	cg11764359	chr7:65958608	NA	-0.67	-6.6	-0.4	2.73e-10	Aortic root size;
SARC	cis	rs34172651	0.917	rs6497760	chr16:24806535	G/A	cg00339695	chr16:24857497	SLC5A11	0.31	4.98	0.31	1.24e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg25703541	chr22:24373054	LOC391322	-0.69	-9.34	-0.52	8.21e-18	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg00071950	chr4:10020882	SLC2A9	0.4	6.4	0.39	8.66e-10	Bone mineral density;
SARC	cis	rs9814567	0.806	rs55835132	chr3:134325256	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.5	-6.55	-0.39	3.6e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs9443189	0.526	rs6902898	chr6:76201856	G/A	cg01950844	chr6:76311363	SENP6	0.87	7.08	0.42	1.65e-11	Prostate cancer;
SARC	cis	rs5167	0.566	rs60876330	chr19:45488133	C/T	cg10169327	chr19:45448959	APOC2	0.33	4.86	0.3	2.18e-6	Blood protein levels;
SARC	cis	rs11122272	0.735	rs2486736	chr1:231521478	A/G	cg06096015	chr1:231504339	EGLN1	-0.38	-5.73	-0.35	3.13e-8	Hemoglobin concentration;
SARC	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg13175981	chr1:150552382	MCL1	-0.54	-6.84	-0.41	6.75e-11	Tonsillectomy;
SARC	cis	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg06289844	chr6:126071538	HEY2	-0.34	-5.65	-0.35	4.68e-8	Brugada syndrome;
SARC	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg26818010	chr10:134567672	INPP5A	-0.5	-5.56	-0.34	7.45e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs7766436	0.885	rs12524244	chr6:22585287	T/C	cg13666174	chr6:22585274	NA	-0.6	-7.74	-0.45	3.04e-13	Coronary artery disease;
SARC	cis	rs2120019	1.000	rs8033837	chr15:75353975	A/C	cg00629941	chr15:75287862	SCAMP5	-0.67	-8.0	-0.46	5.81e-14	Blood trace element (Zn levels);
SARC	cis	rs262147	0.610	rs2657363	chr7:158684273	C/T	cg24397884	chr7:158709396	WDR60	1.07	7.04	0.42	2.17e-11	Hippocampal volume;
SARC	cis	rs17376456	0.877	rs2290937	chr5:93356515	A/T	cg25358565	chr5:93447407	FAM172A	1.31	14.47	0.69	2.86e-34	Diabetic retinopathy;
SARC	cis	rs734999	0.588	rs3748819	chr1:2524966	C/T	cg20673091	chr1:2541236	MMEL1	0.34	5.23	0.32	3.7e-7	Ulcerative colitis;
SARC	cis	rs208520	1.000	rs72882102	chr6:66983408	C/A	cg07460842	chr6:66804631	NA	0.9	10.32	0.56	8.16e-21	Exhaled nitric oxide output;
SARC	cis	rs910316	1.000	rs876403	chr14:75602834	A/T	cg06637938	chr14:75390232	RPS6KL1	0.51	7.3	0.43	4.64e-12	Height;
SARC	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.23e-9	Life satisfaction;
SARC	cis	rs6840360	1.000	rs9998462	chr4:152646548	T/A	cg22705602	chr4:152727874	NA	-0.38	-6.64	-0.4	2.25e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7927771	0.524	rs7122182	chr11:47843133	A/C	cg10504702	chr11:47789108	FNBP4	-0.43	-5.62	-0.35	5.52e-8	Subjective well-being;
SARC	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	0.38	4.71	0.3	4.2e-6	Tonsillectomy;
SARC	cis	rs360798	0.512	rs1420018	chr2:63112500	A/G	cg17519650	chr2:63277830	OTX1	0.4	4.99	0.31	1.17e-6	Coronary artery disease;
SARC	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs7727544	0.735	rs272884	chr5:131668654	G/C	cg24060327	chr5:131705240	SLC22A5	-0.68	-8.77	-0.5	3.9e-16	Blood metabolite levels;
SARC	cis	rs1562975	0.609	rs62316329	chr4:109419399	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.46	6.03	0.37	6.34e-9	Height;
SARC	cis	rs12586317	0.620	rs8021414	chr14:35581480	T/A	cg16230307	chr14:35515116	FAM177A1	0.92	10.85	0.58	1.78e-22	Psoriasis;
SARC	cis	rs6540556	0.723	rs7539852	chr1:209898539	A/G	cg05527609	chr1:210001259	C1orf107	-0.62	-5.57	-0.34	6.86e-8	Red blood cell count;
SARC	cis	rs7044106	0.708	rs920745	chr9:123429943	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	8.99	0.51	9.01e-17	Hip circumference adjusted for BMI;
SARC	cis	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg14343924	chr8:8086146	FLJ10661	0.39	4.84	0.3	2.34e-6	Mood instability;
SARC	cis	rs9814567	1.000	rs9864346	chr3:134312352	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-6.93	-0.41	4.14e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs1348850	0.645	rs4893963	chr2:178430747	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.51	-5.44	-0.34	1.32e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs6940638	0.688	rs9393790	chr6:27114052	A/C	cg12826209	chr6:26865740	GUSBL1	-0.51	-5.29	-0.33	2.77e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6121246	0.609	rs6060983	chr20:30420924	T/C	cg13852791	chr20:30311386	BCL2L1	0.81	9.77	0.54	4e-19	Mean corpuscular hemoglobin;
SARC	cis	rs7107356	1	rs7107356	chr11:47676170	A/G	cg20307385	chr11:47447363	PSMC3	0.61	8.83	0.5	2.55e-16	Neuroticism;Neuroticism (multi-trait analysis);
SARC	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg08219700	chr8:58056026	NA	0.61	6.36	0.38	1.05e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs208520	0.661	rs207090	chr6:66783963	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.06	-14.41	-0.69	4.36e-34	Exhaled nitric oxide output;
SARC	cis	rs2276314	0.857	rs28396546	chr18:33639024	T/C	cg19628046	chr18:33552617	C18orf21	0.55	5.83	0.36	1.84e-8	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs1448094	0.512	rs7960130	chr12:86243191	T/C	cg02569458	chr12:86230093	RASSF9	0.39	5.44	0.34	1.34e-7	Major depressive disorder;
SARC	cis	rs2204008	0.744	rs1115514	chr12:38280140	C/T	cg13010199	chr12:38710504	ALG10B	0.78	10.65	0.57	7.82e-22	Bladder cancer;
SARC	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg22903471	chr2:27725779	GCKR	-0.46	-6.82	-0.41	7.89e-11	Total body bone mineral density;
SARC	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg18876405	chr7:65276391	NA	0.45	4.92	0.31	1.62e-6	Aortic root size;
SARC	cis	rs2204008	0.840	rs7136347	chr12:38453531	G/A	cg13010199	chr12:38710504	ALG10B	0.77	10.35	0.56	6.77e-21	Bladder cancer;
SARC	cis	rs753778	0.667	rs10092439	chr8:142210881	C/T	cg18755752	chr8:142205143	DENND3	-0.54	-8.06	-0.47	3.9e-14	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-8.85	-0.5	2.28e-16	Alzheimer's disease;
SARC	cis	rs7786808	0.712	rs2335170	chr7:158207101	G/A	cg01191920	chr7:158217561	PTPRN2	-0.33	-5.63	-0.35	5.1e-8	Obesity-related traits;
SARC	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg08280861	chr8:58055591	NA	0.57	5.13	0.32	6.16e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2304069	0.526	rs6863283	chr5:149402448	C/A	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.46	5.19	0.32	4.51e-7	HIV-1 control;
SARC	cis	rs6580649	0.941	rs7959755	chr12:48446318	T/A	cg24011408	chr12:48396354	COL2A1	-0.48	-5.38	-0.33	1.78e-7	Lung cancer;
SARC	cis	rs1018836	0.923	rs1858674	chr8:91580665	G/T	cg16814680	chr8:91681699	NA	-0.78	-12.19	-0.62	9.3e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs7829975	0.846	rs6601724	chr8:8544872	C/T	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.55	-0.49	1.69e-15	Mood instability;
SARC	cis	rs2933343	0.601	rs1680758	chr3:128594897	T/C	cg25356066	chr3:128598488	ACAD9	0.71	9.53	0.53	2.1e-18	IgG glycosylation;
SARC	cis	rs11078597	0.731	rs4790285	chr17:1651697	C/T	cg18436246	chr17:1640651	WDR81	-0.61	-7.51	-0.44	1.26e-12	Serum albumin level;
SARC	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg08493051	chr2:3487164	NA	-0.4	-5.04	-0.31	9.2e-7	Neurofibrillary tangles;
SARC	cis	rs6570726	0.818	rs437978	chr6:145809134	A/G	cg05220968	chr6:146057943	EPM2A	-0.29	-5.0	-0.31	1.1e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7474896	0.537	rs2505255	chr10:38359642	C/A	cg25427524	chr10:38739819	LOC399744	-0.53	-6.55	-0.39	3.57e-10	Obesity (extreme);
SARC	cis	rs9300255	0.543	rs1260294	chr12:123560289	T/C	cg00376283	chr12:123451042	ABCB9	-0.53	-5.06	-0.31	8.61e-7	Neutrophil percentage of white cells;
SARC	cis	rs4690686	0.500	rs7657249	chr4:177275198	A/G	cg17059388	chr4:177262070	NA	0.39	5.16	0.32	5.37e-7	Essential tremor;
SARC	trans	rs61931739	0.500	rs11053208	chr12:34460029	A/G	cg13010199	chr12:38710504	ALG10B	0.75	10.56	0.57	1.45e-21	Morning vs. evening chronotype;
SARC	cis	rs6591341	0.515	rs599301	chr11:68189945	G/C	cg01657329	chr11:68192670	LRP5	-0.4	-5.48	-0.34	1.11e-7	Lean body mass;
SARC	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.43	-0.44	2.03e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs10465746	0.780	rs11163865	chr1:84366917	C/T	cg10977910	chr1:84465055	TTLL7	0.4	4.82	0.3	2.6e-6	Obesity-related traits;
SARC	cis	rs7589342	0.899	rs11885225	chr2:106486548	T/C	cg14210321	chr2:106509881	NCK2	-0.51	-5.94	-0.36	1.04e-8	Addiction;
SARC	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg26681399	chr22:41777847	TEF	-0.46	-4.95	-0.31	1.39e-6	Vitiligo;
SARC	cis	rs7617773	0.925	rs7374376	chr3:48172687	T/C	cg11946769	chr3:48343235	NME6	-0.47	-5.67	-0.35	4.31e-8	Coronary artery disease;
SARC	cis	rs580438	1.000	rs580438	chr3:13345450	C/T	cg05446471	chr3:13522740	HDAC11	0.32	5.01	0.31	1.06e-6	Myringotomy;
SARC	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg12463550	chr7:65579703	CRCP	0.48	5.79	0.35	2.23e-8	Aortic root size;
SARC	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.88	12.77	0.64	1.16e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs3812049	0.532	rs251389	chr5:127541877	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.7	7.55	0.44	9.69e-13	Lymphocyte counts;Red cell distribution width;
SARC	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg03575189	chr17:44344142	NA	0.61	5.97	0.36	8.61e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs473651	0.935	rs483166	chr2:239346641	C/T	cg21699342	chr2:239360505	ASB1	-0.43	-6.26	-0.38	1.83e-9	Multiple system atrophy;
SARC	cis	rs826838	0.586	rs10880753	chr12:38628147	C/A	cg26384229	chr12:38710491	ALG10B	-0.6	-7.64	-0.45	5.47e-13	Heart rate;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg11532054	chr1:173021195	TNFSF18	0.45	6.73	0.4	1.3100000000000001e-10	Thyroid stimulating hormone;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg12065272	chr1:245028125	HNRNPU	-0.48	-6.29	-0.38	1.58e-9	Schizophrenia;
SARC	cis	rs72766638	1.000	rs72766638	chr9:136931778	C/A	cg13789015	chr9:136890014	NCRNA00094	0.62	6.69	0.4	1.64e-10	Mosquito bite size;
SARC	cis	rs992157	0.710	rs12996912	chr2:219110555	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.68	9.52	0.53	2.34e-18	Colorectal cancer;
SARC	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg07701084	chr6:150067640	NUP43	0.4	5.37	0.33	1.93e-7	Lung cancer;
SARC	cis	rs607987	0.871	rs11031025	chr11:30292350	G/A	cg06241208	chr11:30344200	C11orf46	0.42	5.03	0.31	9.7e-7	Body mass index;
SARC	cis	rs3733585	0.699	rs4621431	chr4:9947590	C/T	cg00071950	chr4:10020882	SLC2A9	-0.38	-5.78	-0.35	2.33e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs2562456	0.917	rs2650825	chr19:21699225	A/G	cg00806126	chr19:22604979	ZNF98	-0.5	-4.92	-0.31	1.65e-6	Pain;
SARC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg26338869	chr17:61819248	STRADA	0.77	10.1	0.55	3.96e-20	Prudent dietary pattern;
SARC	cis	rs7932354	0.710	rs10838621	chr11:46851459	C/T	cg03339077	chr11:47165057	C11orf49	-0.37	-4.91	-0.31	1.7e-6	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs1594829	0.500	rs2046223	chr8:26210178	C/T	cg11498726	chr8:26250323	BNIP3L	0.47	6.13	0.37	3.8e-9	Height;
SARC	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg11987759	chr7:65425863	GUSB	-0.39	-4.96	-0.31	1.39e-6	Calcium levels;
SARC	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2865126	0.779	rs4796905	chr18:10755251	T/C	cg21165219	chr18:10698044	FAM38B	-0.5	-5.04	-0.31	9.28e-7	Metabolite levels (5-HIAA/ MHPG Ratio);
SARC	cis	rs3126085	0.877	rs3126045	chr1:152256794	A/G	cg26876637	chr1:152193138	HRNR	0.45	5.21	0.32	4.07e-7	Atopic dermatitis;
SARC	cis	rs6733011	0.519	rs12990579	chr2:99457447	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-5.16	-0.32	5.33e-7	Bipolar disorder;
SARC	cis	rs6963495	0.510	rs56353563	chr7:105226698	G/C	cg19920283	chr7:105172520	RINT1	0.58	4.77	0.3	3.27e-6	Bipolar disorder (body mass index interaction);
SARC	trans	rs6934651	0.655	rs55975352	chr6:85909990	A/C	cg04848555	chr14:53975804	NA	0.67	6.45	0.39	6.33e-10	Breast cancer;
SARC	cis	rs7044106	0.791	rs7036196	chr9:123479457	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	6.08	0.37	4.78e-9	Hip circumference adjusted for BMI;
SARC	cis	rs7762018	0.607	rs75010113	chr6:170057441	C/T	cg14662283	chr6:170068385	WDR27	-0.64	-4.73	-0.3	3.85e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs2933343	0.553	rs35979399	chr3:128697313	G/A	cg25356066	chr3:128598488	ACAD9	0.62	7.63	0.45	6.12e-13	IgG glycosylation;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg08847991	chr17:27717924	TAOK1	-0.52	-6.39	-0.39	8.76e-10	Height;
SARC	cis	rs748404	0.723	rs565658	chr15:43556307	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.41	5.09	0.32	7.44e-7	Lung cancer;
SARC	cis	rs2033732	0.789	rs7821259	chr8:85081619	T/G	cg05716166	chr8:85095498	RALYL	0.55	7.16	0.42	1.02e-11	Body mass index;
SARC	cis	rs4742903	0.967	rs3739737	chr9:106858192	A/G	cg14250997	chr9:106856677	SMC2	0.52	6.86	0.41	6.13e-11	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs3820928	1.000	rs9288617	chr2:227762815	G/C	cg11843606	chr2:227700838	RHBDD1	-0.52	-6.53	-0.39	4.09e-10	Pulmonary function;
SARC	cis	rs7512552	0.809	rs9436108	chr1:150360930	A/G	cg15654264	chr1:150340011	RPRD2	0.38	4.81	0.3	2.7e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs7412746	0.611	rs10888391	chr1:150729983	G/A	cg15448220	chr1:150897856	SETDB1	0.48	6.23	0.38	2.15e-9	Melanoma;
SARC	cis	rs67311347	1.000	rs7617989	chr3:40512463	A/G	cg09455208	chr3:40491958	NA	-0.42	-6.55	-0.39	3.67e-10	Renal cell carcinoma;
SARC	cis	rs6752107	0.935	rs10929322	chr2:234149702	A/G	cg23050873	chr2:234184376	ATG16L1;SCARNA5	-0.48	-6.7	-0.4	1.57e-10	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg00933542	chr6:150070202	PCMT1	0.33	5.51	0.34	9.62e-8	Lung cancer;
SARC	cis	rs12791968	0.765	rs12794846	chr11:44998943	C/T	cg11846598	chr11:44996168	LOC221122	0.35	5.15	0.32	5.42e-7	Inhibitory control;
SARC	cis	rs16854884	0.739	rs1898265	chr3:143776096	A/G	cg06585982	chr3:143692056	C3orf58	-0.67	-8.81	-0.5	2.97e-16	Economic and political preferences (feminism/equality);
SARC	cis	rs79349575	0.749	rs2270574	chr17:47022270	C/T	cg16584676	chr17:46985605	UBE2Z	0.55	6.66	0.4	1.91e-10	Type 2 diabetes;
SARC	cis	rs7824557	0.628	rs7005469	chr8:11194457	G/A	cg21775007	chr8:11205619	TDH	0.65	8.33	0.48	7.04e-15	Retinal vascular caliber;
SARC	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	7.38	0.44	2.71e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.32	4.79	0.3	2.98e-6	Bipolar disorder;
SARC	cis	rs17376456	0.877	rs10035340	chr5:93490465	C/T	cg21475434	chr5:93447410	FAM172A	0.89	7.4	0.44	2.4e-12	Diabetic retinopathy;
SARC	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg06634786	chr22:41940651	POLR3H	-0.56	-6.65	-0.4	2.06e-10	Vitiligo;
SARC	trans	rs61931739	0.793	rs609886	chr12:34138160	T/G	cg13010199	chr12:38710504	ALG10B	0.59	7.77	0.45	2.5e-13	Morning vs. evening chronotype;
SARC	cis	rs12586317	0.620	rs12588810	chr14:35554484	C/T	cg16230307	chr14:35515116	FAM177A1	0.99	11.5	0.6	1.52e-24	Psoriasis;
SARC	cis	rs16976116	0.951	rs6493768	chr15:55484294	T/A	cg17854078	chr15:55489399	RSL24D1	0.66	6.52	0.39	4.27e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs921968	0.678	rs689116	chr2:219433888	C/A	cg02176678	chr2:219576539	TTLL4	0.37	5.49	0.34	1.02e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg24209194	chr3:40518798	ZNF619	0.65	7.97	0.46	7.13e-14	Renal cell carcinoma;
SARC	cis	rs765787	0.505	rs1648302	chr15:45494238	A/G	cg24006582	chr15:45444508	DUOX1	-0.55	-7.4	-0.44	2.4e-12	Uric acid levels;
SARC	cis	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg06212747	chr3:49208901	KLHDC8B	0.58	5.74	0.35	2.88e-8	Menarche (age at onset);
SARC	cis	rs13095912	1.000	rs13072061	chr3:185326023	G/T	cg11274856	chr3:185301563	NA	0.36	4.98	0.31	1.24e-6	Systolic blood pressure;
SARC	cis	rs2361718	0.967	rs12942941	chr17:78103013	C/T	cg27427491	chr17:78079615	GAA	-0.35	-5.88	-0.36	1.39e-8	Yeast infection;
SARC	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg11987759	chr7:65425863	GUSB	0.5	6.22	0.38	2.3e-9	Aortic root size;
SARC	cis	rs6696846	0.691	rs11240370	chr1:205118336	T/G	cg07972983	chr1:205091412	RBBP5	0.57	7.38	0.44	2.72e-12	Red blood cell count;
SARC	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.33	-4.93	-0.31	1.54e-6	Menopause (age at onset);
SARC	cis	rs826838	1.000	rs11168505	chr12:38939057	A/T	cg13010199	chr12:38710504	ALG10B	-0.78	-10.77	-0.58	3.36e-22	Heart rate;
SARC	trans	rs17221829	0.733	rs11018668	chr11:89356178	C/T	cg20665002	chr13:25946220	ATP8A2	-0.51	-7.45	-0.44	1.81e-12	Anxiety in major depressive disorder;
SARC	cis	rs73206853	0.764	rs76044375	chr12:110901339	C/T	cg10860002	chr12:110842031	ANAPC7	0.63	4.98	0.31	1.22e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs4423214	0.879	rs1792264	chr11:71150247	C/T	cg05163923	chr11:71159392	DHCR7	-0.61	-7.15	-0.42	1.14e-11	Vitamin D levels;
SARC	cis	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg07777115	chr5:623756	CEP72	-0.62	-5.56	-0.34	7.5e-8	Obesity-related traits;
SARC	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg26335602	chr6:28129616	ZNF389	0.53	5.95	0.36	9.59e-9	Depression;
SARC	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg24642844	chr7:1081250	C7orf50	-0.59	-5.98	-0.36	8.18e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs1144333	0.655	rs17097695	chr1:76387258	A/C	cg03433033	chr1:76189801	ACADM	0.64	5.23	0.32	3.73e-7	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs7605378	1.000	rs2346662	chr2:200679158	C/T	cg23649088	chr2:200775458	C2orf69	0.49	5.32	0.33	2.42e-7	Osteoporosis;
SARC	cis	rs734999	0.588	rs3748817	chr1:2525665	T/C	cg00980319	chr1:2560884	MMEL1	-0.35	-4.91	-0.31	1.69e-6	Ulcerative colitis;
SARC	cis	rs1008375	1.000	rs28480159	chr4:17685707	A/C	cg16339924	chr4:17578868	LAP3	0.62	8.1	0.47	3.05e-14	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs3779273	0.740	rs4727630	chr7:77834201	A/G	cg05596911	chr5:118502651	DMXL1	-0.52	-6.55	-0.39	3.67e-10	Body mass index;
SARC	cis	rs77633900	0.614	rs2439991	chr15:76877227	A/G	cg21673338	chr15:77095150	SCAPER	-0.77	-6.35	-0.38	1.15e-9	Non-glioblastoma glioma;Glioma;
SARC	cis	rs2839627	0.561	rs9977774	chr21:44342476	G/C	cg03543861	chr21:44258195	NA	0.47	4.95	0.31	1.44e-6	Information processing speed;
SARC	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	5.45	0.34	1.3e-7	Bipolar disorder;
SARC	cis	rs8024058	0.919	rs3826039	chr15:89173136	G/T	cg00367546	chr15:89165046	AEN	-0.46	-4.93	-0.31	1.57e-6	Night sleep phenotypes;
SARC	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg00684032	chr4:1343700	KIAA1530	0.48	6.91	0.41	4.49e-11	Obesity-related traits;
SARC	trans	rs7824557	0.778	rs3808502	chr8:11179458	G/T	cg06636001	chr8:8085503	FLJ10661	0.67	9.08	0.51	4.8e-17	Retinal vascular caliber;
SARC	cis	rs17376456	0.877	rs67066109	chr5:93494101	G/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.62	5.37	0.33	1.89e-7	Diabetic retinopathy;
SARC	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg16479474	chr6:28041457	NA	0.37	5.48	0.34	1.11e-7	Depression;
SARC	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg26752003	chr8:145688521	CYHR1	-0.57	-7.68	-0.45	4.25e-13	Age at first birth;
SARC	cis	rs2204008	0.869	rs34438288	chr12:38211582	G/T	cg13010199	chr12:38710504	ALG10B	0.78	10.64	0.57	8.61e-22	Bladder cancer;
SARC	cis	rs9843304	0.900	rs6774253	chr3:149211897	G/C	cg08667024	chr3:149219783	TM4SF4	0.39	6.05	0.37	5.83e-9	Gallstone disease;
SARC	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg25072359	chr17:41440525	NA	0.52	6.17	0.37	3.06e-9	Menopause (age at onset);
SARC	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg03709012	chr19:19516395	GATAD2A	-0.95	-15.25	-0.71	7.23e-37	Tonsillectomy;
SARC	cis	rs9902453	0.726	rs3115092	chr17:28036350	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	7.06	0.42	1.9e-11	Coffee consumption (cups per day);
SARC	cis	rs141518190	1	rs141518190	chr15:78900647	A/G	cg06917634	chr15:78832804	PSMA4	-0.55	-5.87	-0.36	1.47e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs3733585	0.806	rs7375599	chr4:9954918	C/T	cg11266682	chr4:10021025	SLC2A9	0.4	7.17	0.43	9.65e-12	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs754466	0.580	rs1866437	chr10:79526766	A/G	cg17075019	chr10:79541650	NA	-0.82	-12.67	-0.64	2.49e-28	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg00149659	chr3:10157352	C3orf10	1.09	10.0	0.55	7.87e-20	Alzheimer's disease;
SARC	cis	rs72781680	0.611	rs56113233	chr2:24341085	A/C	cg06627628	chr2:24431161	ITSN2	-0.55	-5.77	-0.35	2.5e-8	Lymphocyte counts;
SARC	cis	rs75804782	0.641	rs3769124	chr2:239349362	G/A	cg21699342	chr2:239360505	ASB1	-0.58	-4.81	-0.3	2.68e-6	Morning vs. evening chronotype;Chronotype;
SARC	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.46	0.39	6.12e-10	Bipolar disorder;
SARC	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg15847926	chr7:2749597	AMZ1	-0.3	-4.88	-0.3	1.98e-6	Height;
SARC	cis	rs7589342	0.839	rs11895235	chr2:106432355	C/G	cg16077055	chr2:106428750	NCK2	0.34	6.14	0.37	3.6e-9	Addiction;
SARC	cis	rs1568889	0.592	rs11828877	chr11:28384030	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.72	8.05	0.47	4.2e-14	Bipolar disorder;
SARC	cis	rs986417	0.901	rs1884098	chr14:61038944	A/T	cg27398547	chr14:60952738	C14orf39	0.89	8.44	0.48	3.37e-15	Gut microbiota (bacterial taxa);
SARC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg11494091	chr17:61959527	GH2	0.53	7.94	0.46	8.72e-14	Prudent dietary pattern;
SARC	cis	rs5758511	0.680	rs5758687	chr22:42656588	A/T	cg00645731	chr22:42541494	CYP2D7P1	0.44	6.47	0.39	5.59e-10	Birth weight;
SARC	cis	rs1707322	0.927	rs6690386	chr1:46253011	C/T	cg03146154	chr1:46216737	IPP	0.48	5.82	0.36	1.94e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs10493773	0.775	rs11161649	chr1:86165446	A/C	cg17807903	chr1:86174739	ZNHIT6	-0.54	-8.51	-0.49	2.16e-15	Urate levels in overweight individuals;
SARC	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg15556689	chr8:8085844	FLJ10661	-0.43	-5.37	-0.33	1.87e-7	Mood instability;
SARC	cis	rs7666738	0.830	rs1967980	chr4:98966426	C/G	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs228769	1.000	rs12937692	chr17:42256430	G/A	cg10896456	chr17:42255109	ASB16;C17orf65	0.37	4.75	0.3	3.48e-6	Bone mineral density (hip);Bone mineral density (spine);
SARC	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg21724239	chr8:58056113	NA	0.58	6.14	0.37	3.49e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7772486	0.790	rs9791313	chr6:146266172	T/C	cg05347473	chr6:146136440	FBXO30	-0.46	-6.31	-0.38	1.4e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2694528	0.764	rs112511311	chr5:59872002	G/A	cg11474532	chr5:59995715	DEPDC1B	0.94	6.5	0.39	4.76e-10	Parkinson's disease;
SARC	cis	rs910316	0.967	rs4384542	chr14:75658013	A/C	cg11812906	chr14:75593930	NEK9	-0.83	-12.37	-0.63	2.4e-27	Height;
SARC	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs35213789	0.878	rs735060	chr7:69546617	T/C	cg10619644	chr7:69149951	AUTS2	0.42	5.24	0.32	3.6e-7	Childhood ear infection;
SARC	cis	rs873946	0.689	rs2803993	chr10:134550606	T/C	cg27286337	chr10:134555280	INPP5A	0.68	8.76	0.5	3.99e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs7811142	1.000	rs6953107	chr7:100095664	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.73	7.35	0.43	3.32e-12	Platelet count;
SARC	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg00933542	chr6:150070202	PCMT1	-0.31	-5.28	-0.33	3e-7	Lung cancer;
SARC	cis	rs6456156	0.742	rs6456157	chr6:167527818	C/A	cg07741184	chr6:167504864	NA	-0.28	-5.44	-0.34	1.37e-7	Primary biliary cholangitis;
SARC	cis	rs561341	0.739	rs9906455	chr17:30215669	G/A	cg12000587	chr17:30186630	C17orf79	0.38	4.98	0.31	1.21e-6	Hip circumference adjusted for BMI;
SARC	cis	rs526231	0.543	rs34766	chr5:102510923	T/C	cg23492399	chr5:102201601	PAM	-0.53	-5.63	-0.35	5.27e-8	Primary biliary cholangitis;
SARC	cis	rs9916302	0.904	rs4511574	chr17:37532916	A/G	cg00129232	chr17:37814104	STARD3	-0.52	-5.94	-0.36	1.05e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs911263	0.540	rs7158493	chr14:68812330	C/G	cg18825221	chr14:68749962	RAD51L1	0.42	7.42	0.44	2.2e-12	Primary biliary cholangitis;
SARC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.42	-6.42	-0.39	7.6e-10	Total body bone mineral density;
SARC	cis	rs28374715	0.578	rs17730589	chr15:41600878	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.16	-18.54	-0.77	9.63e-48	Ulcerative colitis;
SARC	cis	rs950027	0.620	rs1145080	chr15:45681338	C/T	cg26924012	chr15:45694286	SPATA5L1	0.53	6.79	0.41	9.23e-11	Response to fenofibrate (adiponectin levels);
SARC	trans	rs208520	0.955	rs12204033	chr6:67001525	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.83	9.29	0.52	1.12e-17	Exhaled nitric oxide output;
SARC	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg09263875	chr16:632152	PIGQ	0.55	8.32	0.48	7.43e-15	Height;
SARC	trans	rs561341	0.609	rs7209493	chr17:30197323	A/G	cg20587970	chr11:113659929	NA	0.67	6.8	0.41	8.57e-11	Hip circumference adjusted for BMI;
SARC	cis	rs1419980	0.673	rs10772553	chr12:7768089	G/A	cg10578777	chr12:7781093	NA	-0.51	-5.47	-0.34	1.16e-7	HDL cholesterol levels;
SARC	cis	rs6598955	0.724	rs7526545	chr1:26569990	C/A	cg04990556	chr1:26633338	UBXN11	-0.6	-8.32	-0.48	7.57e-15	Obesity-related traits;
SARC	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg27211696	chr2:191398769	TMEM194B	0.49	6.77	0.41	1.06e-10	Pulse pressure;
SARC	cis	rs12586317	0.534	rs2273157	chr14:35438836	A/G	cg26967526	chr14:35346199	BAZ1A	-0.57	-6.72	-0.4	1.38e-10	Psoriasis;
SARC	cis	rs6088580	0.524	rs6088564	chr20:33249444	A/G	cg07148914	chr20:33460835	GGT7	-0.42	-5.16	-0.32	5.4e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg05552183	chr6:42928497	GNMT	0.52	7.2	0.43	8.42e-12	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs3733585	0.631	rs4697925	chr4:10124330	G/C	cg00071950	chr4:10020882	SLC2A9	-0.41	-6.21	-0.38	2.42e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7666738	0.761	rs28758886	chr4:99059704	C/T	cg05340658	chr4:99064831	C4orf37	0.64	8.66	0.49	7.7e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7980687	0.638	rs7299943	chr12:123593485	A/T	cg05973401	chr12:123451056	ABCB9	0.49	5.36	0.33	2.05e-7	Height;Educational attainment;Head circumference (infant);
SARC	cis	rs2916247	1.000	rs10100101	chr8:93041761	T/A	cg10183463	chr8:93005414	RUNX1T1	-0.58	-6.03	-0.37	6.49e-9	Intelligence (multi-trait analysis);
SARC	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg26116260	chr4:7069785	GRPEL1	0.88	10.7	0.57	5.31e-22	Monocyte percentage of white cells;
SARC	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg22508957	chr16:3507546	NAT15	0.36	5.34	0.33	2.26e-7	Tuberculosis;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg08823554	chr21:46269191	NA	0.48	6.32	0.38	1.33e-9	Schizophrenia;
SARC	cis	rs1468333	0.537	rs13184188	chr5:137789519	C/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.54	6.46	0.39	6.16e-10	Resting heart rate;
SARC	cis	rs2645694	0.911	rs2703147	chr4:77831307	C/T	cg03477792	chr4:77819574	ANKRD56	0.37	5.32	0.33	2.42e-7	Emphysema distribution in smoking;
SARC	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg24209194	chr3:40518798	ZNF619	0.66	8.03	0.47	4.73e-14	Renal cell carcinoma;
SARC	cis	rs4919087	0.590	rs701821	chr10:99038562	G/A	cg25902810	chr10:99078978	FRAT1	-0.55	-6.03	-0.37	6.32e-9	Monocyte count;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg20702802	chr19:10823868	QTRT1	0.47	6.23	0.38	2.15e-9	Schizophrenia;
SARC	trans	rs11098499	0.954	rs2892848	chr4:120381341	C/T	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg01524091	chr6:44281032	AARS2	0.48	6.25	0.38	1.9e-9	Chemerin levels;
SARC	cis	rs9326248	0.530	rs6589589	chr11:116932428	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.58	4.8	0.3	2.9e-6	Blood protein levels;
SARC	cis	rs3020736	0.500	rs5996111	chr22:42493902	C/T	cg15557168	chr22:42548783	NA	0.37	4.96	0.31	1.36e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg22800045	chr5:56110881	MAP3K1	0.77	8.18	0.47	1.86e-14	Initial pursuit acceleration;
SARC	cis	rs911555	0.755	rs2273702	chr14:103918182	C/G	cg24130564	chr14:104152367	KLC1	0.49	5.81	0.36	2e-8	Intelligence (multi-trait analysis);
SARC	trans	rs13325613	0.915	rs35613615	chr3:46265243	T/C	cg12387106	chr12:133178249	NA	0.84	6.57	0.4	3.25e-10	Monocyte count;
SARC	cis	rs1008375	1.000	rs2286771	chr4:17643848	G/A	cg02297831	chr4:17616191	MED28	0.5	6.47	0.39	5.62e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2315504	0.626	rs2469823	chr17:39006842	A/G	cg05063374	chr17:38953512	KRT28	0.28	4.86	0.3	2.13e-6	Height;
SARC	cis	rs6598955	0.640	rs1577507	chr1:26547179	C/T	cg04990556	chr1:26633338	UBXN11	-0.61	-8.56	-0.49	1.5e-15	Obesity-related traits;
SARC	trans	rs1994135	0.647	rs11052745	chr12:33695999	G/T	cg26384229	chr12:38710491	ALG10B	0.69	8.28	0.48	9.47e-15	Resting heart rate;
SARC	cis	rs9325144	0.600	rs10880934	chr12:38730455	C/T	cg26384229	chr12:38710491	ALG10B	-0.63	-8.32	-0.48	7.25e-15	Morning vs. evening chronotype;
SARC	cis	rs8060686	0.545	rs75229939	chr16:68164949	G/A	cg09117114	chr16:67998030	SLC12A4	-0.49	-4.71	-0.3	4.2e-6	HDL cholesterol;Metabolic syndrome;
SARC	cis	rs6665290	0.904	rs6684821	chr1:227190233	G/A	cg14016676	chr1:227182615	CDC42BPA	0.37	5.28	0.33	3e-7	Myeloid white cell count;
SARC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg15242686	chr22:24348715	GSTTP1	0.43	5.17	0.32	5.03e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs892961	0.932	rs2170863	chr17:75415037	C/T	cg05865280	chr17:75406074	SEPT9	0.54	7.77	0.45	2.49e-13	Airflow obstruction;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg06162264	chr12:49628356	NA	0.82	6.87	0.41	5.68e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9814567	0.752	rs7649910	chr3:134241310	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-7.11	-0.42	1.39e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs3857536	0.834	rs2351881	chr6:66873635	G/A	cg07460842	chr6:66804631	NA	-0.51	-5.96	-0.36	9.32e-9	Blood trace element (Cu levels);
SARC	cis	rs11630290	0.592	rs1039817	chr15:64155367	T/A	cg12036633	chr15:63758958	NA	0.47	4.99	0.31	1.17e-6	Iris characteristics;
SARC	cis	rs67460515	0.892	rs34016896	chr3:160992864	C/T	cg03342759	chr3:160939853	NMD3	-0.71	-9.05	-0.51	5.73e-17	Parkinson's disease;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg11789864	chr1:229694784	ABCB10	0.48	6.32	0.38	1.35e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.67	-8.0	-0.46	5.69e-14	Gut microbiome composition (summer);
SARC	cis	rs13343954	0.825	rs12462077	chr19:33529231	C/G	cg17764715	chr19:33622953	WDR88	0.49	5.32	0.33	2.43e-7	Colorectal cancer;
SARC	cis	rs6089584	0.586	rs1079755	chr20:60615262	G/A	cg23262073	chr20:60523788	NA	-0.36	-5.54	-0.34	8.04e-8	Body mass index;
SARC	cis	rs12995849	0.905	rs7565757	chr2:106452408	T/A	cg16077055	chr2:106428750	NCK2	0.26	4.76	0.3	3.41e-6	Addiction;
SARC	cis	rs9858542	0.953	rs6809216	chr3:49412559	G/A	cg07274523	chr3:49395745	GPX1	0.53	6.26	0.38	1.8e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs1215050	0.791	rs7688942	chr4:98832048	T/C	cg05340658	chr4:99064831	C4orf37	0.43	5.71	0.35	3.37e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg20891558	chr2:74357851	NA	0.7	9.65	0.53	9.4e-19	Gestational age at birth (maternal effect);
SARC	cis	rs3091242	0.933	rs11249250	chr1:25767609	G/A	cg27572855	chr1:25598939	RHD	0.54	9.3	0.52	1.03e-17	Erythrocyte sedimentation rate;
SARC	cis	rs2011503	1.000	rs2060275	chr19:19536208	G/C	cg03709012	chr19:19516395	GATAD2A	0.67	5.85	0.36	1.66e-8	Bipolar disorder;
SARC	cis	rs2235642	0.685	rs2667681	chr16:1653206	C/T	cg03715980	chr16:1756201	MAPK8IP3	0.42	5.09	0.32	7.4e-7	Coronary artery disease;
SARC	cis	rs8523	0.671	rs60376022	chr6:11027949	A/C	cg13562911	chr6:11044106	ELOVL2	0.38	5.09	0.32	7.22e-7	Red blood cell fatty acid levels;
SARC	trans	rs2727020	0.704	rs2988340	chr11:49176057	C/T	cg15704280	chr7:45808275	SEPT13	-0.63	-8.8	-0.5	3.18e-16	Coronary artery disease;
SARC	cis	rs9911578	0.934	rs58092632	chr17:57111101	T/C	cg20303301	chr17:57937339	TUBD1	0.34	4.95	0.31	1.42e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2644899	0.859	rs2644898	chr19:41299015	G/A	cg24958765	chr19:41283667	RAB4B	-0.59	-6.47	-0.39	5.69e-10	Post bronchodilator FEV1/FVC ratio;
SARC	trans	rs17685	0.672	rs6465011	chr7:75811297	T/C	cg19862616	chr7:65841803	NCRNA00174	0.61	7.59	0.45	7.5e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg11764359	chr7:65958608	NA	0.57	6.54	0.39	3.89e-10	Aortic root size;
SARC	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg09699651	chr6:150184138	LRP11	0.44	5.36	0.33	1.99e-7	Lung cancer;
SARC	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg24549020	chr5:56110836	MAP3K1	0.81	8.46	0.48	3.01e-15	Initial pursuit acceleration;
SARC	trans	rs9395865	0.520	rs6903708	chr6:53332940	A/G	cg00120998	chr16:67881473	CENPT;NUTF2	-0.52	-6.52	-0.39	4.22e-10	Electroencephalographic traits in alcoholism;
SARC	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg00933542	chr6:150070202	PCMT1	0.3	5.2	0.32	4.45e-7	Lung cancer;
SARC	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg07701084	chr6:150067640	NUP43	0.4	5.32	0.33	2.4e-7	Lung cancer;
SARC	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.72	-7.24	-0.43	6.52e-12	Platelet count;
SARC	cis	rs2000999	0.515	rs2854956	chr16:72115238	A/T	cg01557791	chr16:72042693	DHODH	-0.66	-9.09	-0.51	4.53e-17	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
SARC	cis	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg22496380	chr5:211416	CCDC127	-0.88	-9.35	-0.52	7.72e-18	Breast cancer;
SARC	cis	rs4642101	0.561	rs7638333	chr3:12806142	T/C	cg24848339	chr3:12840334	CAND2	0.34	5.26	0.33	3.21e-7	QRS complex (12-leadsum);
SARC	cis	rs1008375	0.931	rs2315558	chr4:17674558	C/A	cg27347728	chr4:17578864	LAP3	0.44	5.55	0.34	7.92e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs3733585	0.673	rs4407505	chr4:9953367	T/G	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.39	-0.33	1.76e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs4664308	0.967	rs17831329	chr2:160915819	T/C	cg03641300	chr2:160917029	PLA2R1	-0.68	-9.22	-0.52	1.82e-17	Idiopathic membranous nephropathy;
SARC	cis	rs9790314	0.659	rs13066683	chr3:160847410	A/G	cg03342759	chr3:160939853	NMD3	-0.49	-6.02	-0.37	6.64e-9	Morning vs. evening chronotype;
SARC	cis	rs6815814	0.861	rs7658651	chr4:38786002	A/C	cg06935464	chr4:38784597	TLR10	0.5	5.69	0.35	3.82e-8	Breast cancer;
SARC	cis	rs16976116	0.851	rs13380400	chr15:55490518	A/G	cg11288833	chr15:55489084	RSL24D1	0.63	6.09	0.37	4.66e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg05025164	chr4:1340916	KIAA1530	-0.68	-8.1	-0.47	3.08e-14	Obesity-related traits;
SARC	cis	rs17173637	1.000	rs17173637	chr7:150529449	T/C	cg26935020	chr7:151217007	RHEB	-0.75	-5.1	-0.32	7.1e-7	HDL cholesterol;HDL cholesterol levels;
SARC	cis	rs861020	0.771	rs674804	chr1:210014603	C/G	cg23166289	chr1:210001082	C1orf107	0.52	5.53	0.34	8.46e-8	Orofacial clefts;
SARC	cis	rs7216064	1.000	rs6504543	chr17:65837659	T/C	cg12091567	chr17:66097778	LOC651250	-0.76	-8.43	-0.48	3.68e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs9457247	0.555	rs2247325	chr6:167369992	A/G	cg23791538	chr6:167370224	RNASET2	0.7	10.13	0.55	3.28e-20	Crohn's disease;
SARC	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg16850897	chr7:100343110	ZAN	-0.64	-6.86	-0.41	5.97e-11	Other erythrocyte phenotypes;
SARC	cis	rs995000	0.965	rs11208004	chr1:63145439	G/A	cg06896770	chr1:63153194	DOCK7	0.98	15.49	0.71	1.14e-37	Triglyceride levels;
SARC	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg05861140	chr6:150128134	PCMT1	-0.38	-4.98	-0.31	1.23e-6	Lung cancer;
SARC	cis	rs4805272	0.512	rs8105613	chr19:29339151	C/T	cg04546413	chr19:29218101	NA	0.45	5.08	0.32	7.92e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	trans	rs4332037	0.805	rs10278591	chr7:1921362	A/G	cg11693508	chr17:37793320	STARD3	-0.59	-6.29	-0.38	1.56e-9	Bipolar disorder;
SARC	cis	rs765787	0.530	rs2413785	chr15:45530381	T/C	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.51e-10	Uric acid levels;
SARC	cis	rs1355223	0.902	rs1773908	chr11:34743380	A/G	cg18508148	chr11:34937573	PDHX;APIP	-0.38	-4.83	-0.3	2.46e-6	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs6963495	0.818	rs56055535	chr7:105163574	C/A	cg13798780	chr7:105162888	PUS7	0.6	5.45	0.34	1.31e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs10463554	0.927	rs469094	chr5:102423579	A/C	cg23492399	chr5:102201601	PAM	-0.54	-5.89	-0.36	1.31e-8	Parkinson's disease;
SARC	cis	rs798554	0.549	rs1623138	chr7:2899410	A/G	cg04166393	chr7:2884313	GNA12	0.51	6.07	0.37	5.12e-9	Height;
SARC	cis	rs897080	0.515	rs1067337	chr2:44624859	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.62	0.4	2.41e-10	Height;
SARC	cis	rs4642101	1.000	rs4642101	chr3:12842223	T/G	cg05775895	chr3:12838266	CAND2	0.67	9.56	0.53	1.81e-18	QRS complex (12-leadsum);
SARC	cis	rs751728	0.664	rs943475	chr6:33749978	C/T	cg25922239	chr6:33757077	LEMD2	-0.57	-7.43	-0.44	2.04e-12	Crohn's disease;
SARC	cis	rs709400	0.663	rs62007719	chr14:103943130	G/T	cg12935359	chr14:103987150	CKB	-0.39	-5.65	-0.35	4.62e-8	Body mass index;
SARC	cis	rs67460515	0.892	rs1478566	chr3:161030335	A/T	cg17135325	chr3:160939158	NMD3	0.63	7.93	0.46	9.03e-14	Parkinson's disease;
SARC	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg26681399	chr22:41777847	TEF	-0.45	-4.95	-0.31	1.45e-6	Vitiligo;
SARC	cis	rs9399135	0.967	rs45544135	chr6:135324051	T/C	cg24558204	chr6:135376177	HBS1L	0.45	6.04	0.37	6.16e-9	Red blood cell count;
SARC	cis	rs6831352	0.918	rs17218108	chr4:100055755	T/C	cg13256891	chr4:100009986	ADH5	-0.64	-8.0	-0.46	5.7e-14	Alcohol dependence;
SARC	cis	rs35306767	0.953	rs1539174	chr10:974870	C/G	cg26597838	chr10:835615	NA	0.62	7.12	0.42	1.33e-11	Eosinophil percentage of granulocytes;
SARC	cis	rs10958369	0.588	rs1904072	chr8:54439902	A/T	cg12485204	chr8:54507357	NA	0.48	6.73	0.4	1.28e-10	Response to antineoplastic agents;
SARC	cis	rs7666738	0.791	rs10010438	chr4:99022177	C/T	cg05340658	chr4:99064831	C4orf37	0.66	9.04	0.51	6.35e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-15.42	-0.71	1.91e-37	Chronic sinus infection;
SARC	cis	rs1056053	0.514	rs3099268	chr6:166572826	T/C	cg11088901	chr6:166572345	T	-0.42	-5.49	-0.34	1.04e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs4889855	0.530	rs62068346	chr17:78608052	A/G	cg17956530	chr17:78667699	RPTOR	-0.47	-5.31	-0.33	2.55e-7	Fractional excretion of uric acid;
SARC	cis	rs3796352	1.000	rs71301808	chr3:53085577	C/G	cg12962167	chr3:53033115	SFMBT1	0.81	5.48	0.34	1.11e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2652834	0.904	rs8032506	chr15:63371644	G/A	cg05507819	chr15:63340323	TPM1	-0.59	-5.9	-0.36	1.29e-8	HDL cholesterol;
SARC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.45	0.56	3.22e-21	Prudent dietary pattern;
SARC	cis	rs7481584	0.624	rs1077335	chr11:3030524	A/G	cg20651018	chr11:3035856	CARS	0.39	5.69	0.35	3.74e-8	Calcium levels;
SARC	cis	rs950169	0.922	rs4842941	chr15:84831312	G/C	cg24253500	chr15:84953950	NA	-0.36	-5.07	-0.32	8e-7	Schizophrenia;
SARC	trans	rs11039798	0.588	rs584899	chr11:48431408	T/C	cg15704280	chr7:45808275	SEPT13	-0.61	-6.38	-0.39	9.51e-10	Axial length;
SARC	cis	rs4555082	0.957	rs2816622	chr14:105733114	T/C	cg06808227	chr14:105710500	BRF1	-0.48	-6.18	-0.38	2.89e-9	Mean platelet volume;Platelet distribution width;
SARC	trans	rs877282	0.898	rs11253340	chr10:764786	G/T	cg22713356	chr15:30763199	NA	1.04	10.06	0.55	5.37e-20	Uric acid levels;
SARC	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg05368731	chr17:41323189	NBR1	0.64	7.66	0.45	5.02e-13	Menopause (age at onset);
SARC	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg24829409	chr8:58192753	C8orf71	-0.55	-6.17	-0.37	2.94e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs61931739	0.517	rs10844815	chr12:34245150	G/A	cg26384229	chr12:38710491	ALG10B	0.83	12.05	0.62	2.56e-26	Morning vs. evening chronotype;
SARC	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg24399712	chr22:39784796	NA	0.38	5.04	0.31	9.35e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs8072100	0.656	rs2610367	chr17:45569815	A/G	cg08085267	chr17:45401833	C17orf57	-0.45	-5.42	-0.33	1.49e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs7582180	0.591	rs11674569	chr2:101010860	G/A	cg14675211	chr2:100938903	LONRF2	0.53	7.93	0.46	8.91e-14	Intelligence (multi-trait analysis);
SARC	cis	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg24110177	chr3:50126178	RBM5	0.39	5.04	0.31	9.18e-7	Intelligence (multi-trait analysis);
SARC	cis	rs62244186	1.000	rs62244186	chr3:44739783	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.48	5.95	0.36	9.69e-9	Depressive symptoms;
SARC	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg22535103	chr8:58192502	C8orf71	-0.59	-6.21	-0.38	2.35e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9549260	0.564	rs9646110	chr13:41308301	A/T	cg21288729	chr13:41239152	FOXO1	-0.43	-5.16	-0.32	5.27e-7	Red blood cell count;
SARC	trans	rs61931739	0.500	rs6488222	chr12:34526289	G/A	cg13010199	chr12:38710504	ALG10B	0.83	11.73	0.61	2.89e-25	Morning vs. evening chronotype;
SARC	cis	rs9398803	0.723	rs2793052	chr6:127064917	T/A	cg19875578	chr6:126661172	C6orf173	-0.6	-8.29	-0.48	8.89e-15	Male-pattern baldness;
SARC	cis	rs4727027	0.865	rs12154368	chr7:148862041	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	5.63	0.35	5.08e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs7937682	0.889	rs516263	chr11:111484719	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.89	-14.14	-0.68	3.36e-33	Primary sclerosing cholangitis;
SARC	cis	rs3767633	0.925	rs10737502	chr1:161792321	G/A	cg09175582	chr1:161736000	ATF6	0.65	5.35	0.33	2.05e-7	IgG glycosylation;
SARC	cis	rs6570726	0.935	rs380433	chr6:145859601	A/T	cg23711669	chr6:146136114	FBXO30	0.78	12.0	0.62	3.86e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs947211	0.800	rs1341249	chr1:205759876	T/C	cg14159672	chr1:205819179	PM20D1	0.45	4.72	0.3	4.15e-6	Parkinson's disease;
SARC	cis	rs7726839	0.561	rs3915384	chr5:573395	G/T	cg09021430	chr5:549028	NA	-0.4	-5.31	-0.33	2.5e-7	Obesity-related traits;
SARC	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg22920501	chr2:26401640	FAM59B	-0.56	-7.32	-0.43	4.02e-12	Gut microbiome composition (summer);
SARC	cis	rs654950	0.776	rs2759254	chr1:42035683	G/C	cg06885757	chr1:42089581	HIVEP3	-0.45	-6.42	-0.39	7.77e-10	Airway imaging phenotypes;
SARC	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg07701084	chr6:150067640	NUP43	-0.4	-5.16	-0.32	5.17e-7	Lung cancer;
SARC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg12648201	chr2:27665141	KRTCAP3	-0.33	-5.0	-0.31	1.11e-6	Total body bone mineral density;
SARC	cis	rs36051895	0.659	rs3780365	chr9:5068520	T/C	cg02405213	chr9:5042618	JAK2	-0.47	-5.46	-0.34	1.21e-7	Pediatric autoimmune diseases;
SARC	cis	rs7223966	0.883	rs2955250	chr17:61959740	C/T	cg26338869	chr17:61819248	STRADA	0.5	5.64	0.35	4.88e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs34779708	0.931	rs7923217	chr10:35309589	A/G	cg03585969	chr10:35415529	CREM	0.39	4.91	0.31	1.72e-6	Inflammatory bowel disease;Crohn's disease;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg02267838	chr4:26862852	STIM2	0.57	6.44	0.39	6.71e-10	Brain volume in infants (cerebrospinal fluid);
SARC	trans	rs12310956	0.532	rs11494810	chr12:33952881	C/A	cg13010199	chr12:38710504	ALG10B	0.64	8.45	0.48	3.11e-15	Morning vs. evening chronotype;
SARC	cis	rs10927875	0.864	rs12744578	chr1:16173110	A/T	cg21385522	chr1:16154831	NA	-0.91	-11.36	-0.6	4.38e-24	Dilated cardiomyopathy;
SARC	cis	rs751728	1.000	rs11752297	chr6:33735154	G/C	cg15252951	chr6:33757062	LEMD2	0.59	7.01	0.42	2.51e-11	Crohn's disease;
SARC	cis	rs9388451	0.868	rs10457467	chr6:126045148	T/A	cg05901451	chr6:126070800	HEY2	-0.66	-9.0	-0.51	8.04e-17	Brugada syndrome;
SARC	cis	rs2952156	0.920	rs12940986	chr17:37836581	A/G	cg00129232	chr17:37814104	STARD3	0.71	10.05	0.55	5.63e-20	Asthma;
SARC	trans	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg17830980	chr10:43048298	ZNF37B	-0.54	-7.22	-0.43	7.23e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs9815354	1.000	rs1716696	chr3:41935811	C/T	cg03022575	chr3:42003672	ULK4	-0.56	-5.45	-0.34	1.29e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6570726	0.791	rs9373466	chr6:145912016	T/C	cg23711669	chr6:146136114	FBXO30	0.84	14.12	0.68	3.87e-33	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9296092	0.517	rs7743445	chr6:33470600	G/T	cg13560919	chr6:33536144	NA	-0.44	-5.07	-0.32	8.23e-7	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs9818758	0.607	rs12715434	chr3:49295025	G/C	cg00383909	chr3:49044727	WDR6	0.72	6.26	0.38	1.86e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs16854884	0.770	rs13091882	chr3:143818661	C/T	cg06585982	chr3:143692056	C3orf58	0.61	8.2	0.47	1.62e-14	Economic and political preferences (feminism/equality);
SARC	trans	rs56279505	0.630	rs78744403	chr4:100276771	G/A	cg18024358	chr1:3420815	MEGF6	-0.83	-6.4	-0.39	8.29e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6582630	0.555	rs4601853	chr12:38435569	G/A	cg26384229	chr12:38710491	ALG10B	0.84	12.04	0.62	2.79e-26	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg08125733	chr17:73851984	WBP2	0.6	6.63	0.4	2.28e-10	Psoriasis;
SARC	cis	rs11578119	0.872	rs114909548	chr1:170542820	G/A	cg09767346	chr1:170501363	GORAB	0.44	5.19	0.32	4.61e-7	Male-pattern baldness;
SARC	cis	rs2439831	0.850	rs12441984	chr15:44126285	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	8.16	0.47	2.04e-14	Lung cancer in ever smokers;
SARC	trans	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg06636001	chr8:8085503	FLJ10661	-0.72	-10.39	-0.56	5.1e-21	Neuroticism;
SARC	cis	rs79349575	0.783	rs318095	chr17:46974734	T/C	cg07967210	chr17:47022446	SNF8	0.38	4.79	0.3	2.91e-6	Type 2 diabetes;
SARC	cis	rs17023223	0.537	rs11487668	chr1:119726796	T/C	cg05756136	chr1:119680316	WARS2	-0.49	-5.62	-0.35	5.47e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg07636037	chr3:49044803	WDR6	1.0	17.66	0.76	6.92e-45	Parkinson's disease;
SARC	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg11878867	chr6:150167359	LRP11	-0.34	-4.8	-0.3	2.89e-6	Lung cancer;
SARC	cis	rs2011503	1.000	rs2916070	chr19:19524105	C/T	cg15839431	chr19:19639596	YJEFN3	-0.51	-5.02	-0.31	1.04e-6	Bipolar disorder;
SARC	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg21747090	chr2:27597821	SNX17	-0.5	-6.9	-0.41	4.76e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg17554472	chr22:41940697	POLR3H	-0.45	-4.79	-0.3	3.04e-6	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs9393777	0.557	rs6933999	chr6:27074929	G/A	cg12826209	chr6:26865740	GUSBL1	0.64	6.25	0.38	1.9e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7223966	1.000	rs7223966	chr17:61893398	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.46	4.88	0.3	1.92e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1699337	0.930	rs1373640	chr3:12402601	A/G	cg04748988	chr3:12329223	PPARG	0.39	5.09	0.32	7.27e-7	Cholesterol, total;
SARC	cis	rs637571	0.522	rs538954	chr11:65756808	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.39	4.99	0.31	1.2e-6	Eosinophil percentage of white cells;
SARC	cis	rs72949976	0.934	rs13406406	chr2:214034826	C/T	cg08319019	chr2:214017104	IKZF2	-0.5	-6.82	-0.41	7.94e-11	Lung cancer;Squamous cell lung carcinoma;
SARC	trans	rs12310956	0.510	rs10129020	chr12:33858936	T/G	cg26384229	chr12:38710491	ALG10B	0.64	8.26	0.48	1.07e-14	Morning vs. evening chronotype;
SARC	cis	rs7264396	0.790	rs2425160	chr20:34425968	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.52	5.15	0.32	5.59e-7	Total cholesterol levels;
SARC	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg18876405	chr7:65276391	NA	0.47	5.74	0.35	2.97e-8	Aortic root size;
SARC	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.48	7.48	0.44	1.52e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs9611519	1.000	rs9611520	chr22:41613303	C/T	cg03806693	chr22:41940476	POLR3H	-0.57	-6.86	-0.41	6.28e-11	Neuroticism;
SARC	cis	rs6866344	0.697	rs62392832	chr5:178134395	T/C	cg10224037	chr5:178157518	ZNF354A	1.0	12.57	0.64	5.41e-28	Neutrophil percentage of white cells;
SARC	cis	rs11764590	0.694	rs10276536	chr7:2086960	C/T	cg21782813	chr7:2030301	MAD1L1	-0.31	-4.79	-0.3	2.96e-6	Neuroticism;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg10091662	chr10:22609897	BMI1	-0.5	-6.45	-0.39	6.57e-10	Chemerin levels;
SARC	cis	rs7027203	0.828	rs3996239	chr9:96611290	T/A	cg14598338	chr9:96623480	NA	-0.56	-8.1	-0.47	3.1e-14	DNA methylation (variation);
SARC	cis	rs10782582	0.593	rs17585530	chr1:76134990	G/A	cg10523679	chr1:76189770	ACADM	-0.44	-5.24	-0.32	3.55e-7	Daytime sleep phenotypes;
SARC	cis	rs17125944	0.615	rs12586707	chr14:53298277	A/G	cg00686598	chr14:53173677	PSMC6	-0.76	-5.9	-0.36	1.3e-8	Alzheimer's disease (late onset);
SARC	cis	rs7615952	0.599	rs7631268	chr3:125755664	T/A	cg05084668	chr3:125655381	ALG1L	-0.49	-5.15	-0.32	5.64e-7	Blood pressure (smoking interaction);
SARC	cis	rs7044106	0.791	rs735109	chr9:123488879	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	6.24	0.38	2.03e-9	Hip circumference adjusted for BMI;
SARC	cis	rs865483	0.828	rs1016680	chr17:35874385	G/T	cg06561646	chr17:35873369	DUSP14	0.51	6.61	0.4	2.64e-10	Monocyte count;
SARC	cis	rs2050392	0.517	rs2480299	chr10:30743197	G/A	cg25182066	chr10:30743637	MAP3K8	0.56	8.14	0.47	2.35e-14	Inflammatory bowel disease;
SARC	cis	rs1322639	0.614	rs6903921	chr6:169563957	C/T	cg03254818	chr6:169586852	NA	0.7	6.78	0.41	9.91e-11	Pulse pressure;
SARC	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg21724239	chr8:58056113	NA	0.66	6.28	0.38	1.66e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6964587	1.000	rs61244255	chr7:91751662	C/T	cg17063962	chr7:91808500	NA	0.96	15.46	0.71	1.38e-37	Breast cancer;
SARC	cis	rs9916302	0.904	rs4795359	chr17:37573146	C/T	cg07936489	chr17:37558343	FBXL20	-0.7	-9.15	-0.51	2.94e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs4906332	1.000	rs4906327	chr14:103929039	C/T	cg26031613	chr14:104095156	KLC1	-0.49	-5.74	-0.35	2.88e-8	Coronary artery disease;
SARC	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.7	6.55	0.39	3.61e-10	Platelet count;
SARC	cis	rs36051895	0.632	rs11791350	chr9:5172907	G/T	cg02405213	chr9:5042618	JAK2	-0.44	-4.98	-0.31	1.26e-6	Pediatric autoimmune diseases;
SARC	cis	rs7264396	0.563	rs2425137	chr20:34345396	G/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.6	5.39	0.33	1.74e-7	Total cholesterol levels;
SARC	cis	rs854765	0.547	rs2955384	chr17:17939573	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.68	9.91	0.54	1.51e-19	Total body bone mineral density;
SARC	cis	rs12142240	0.698	rs1135460	chr1:46815970	T/C	cg00530320	chr1:46809349	NSUN4	0.57	6.92	0.41	4.4e-11	Menopause (age at onset);
SARC	cis	rs826838	0.967	rs7963716	chr12:38876090	C/T	cg13010199	chr12:38710504	ALG10B	0.74	9.74	0.54	4.9e-19	Heart rate;
SARC	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg11247378	chr22:39784982	NA	-0.33	-5.29	-0.33	2.82e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1468333	0.667	rs113260319	chr5:137742713	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.71	8.55	0.49	1.7e-15	Resting heart rate;
SARC	cis	rs2295359	0.892	rs72676069	chr1:67658954	T/C	cg11235152	chr1:67600687	NA	0.5	7.03	0.42	2.23e-11	Psoriasis;
SARC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg18099408	chr3:52552593	STAB1	-0.39	-5.2	-0.32	4.31e-7	Electroencephalogram traits;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg24109975	chr19:59055787	TRIM28	-0.52	-6.27	-0.38	1.7e-9	Fibrinogen levels;
SARC	cis	rs911555	0.755	rs9671414	chr14:103967299	C/T	cg12935359	chr14:103987150	CKB	0.39	5.32	0.33	2.46e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1568889	0.838	rs7127069	chr11:28325412	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	14.17	0.68	2.71e-33	Bipolar disorder;
SARC	cis	rs8141529	0.732	rs5762815	chr22:29205076	A/G	cg02153584	chr22:29168773	CCDC117	0.79	11.6	0.61	7.18e-25	Lymphocyte counts;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg21918026	chr16:68344902	SLC7A6OS;PRMT7	0.53	6.55	0.39	3.58e-10	Breast cancer;
SARC	cis	rs13082711	0.555	rs73149363	chr3:27265394	C/A	cg02860705	chr3:27208620	NA	0.61	7.92	0.46	9.82e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	trans	rs9427116	0.502	rs12125166	chr1:154582129	A/G	cg19057882	chr20:37101373	RALGAPB	-0.52	-6.48	-0.39	5.28e-10	Blood protein levels;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg13378886	chr1:26232871	STMN1	0.5	6.55	0.39	3.59e-10	Lung adenocarcinoma;
SARC	cis	rs73635312	0.850	rs75375842	chr10:8951029	C/A	cg24467326	chr10:9646929	NA	0.61	5.05	0.31	8.74e-7	Basal cell carcinoma;
SARC	cis	rs4474742	1	rs4474742	chr17:28065578	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.29	-0.43	4.68e-12	Monocyte count;
SARC	cis	rs3733585	0.699	rs7435196	chr4:9967556	A/C	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.45	-0.34	1.25e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg10836716	chr7:73868151	GTF2IRD1	0.55	6.76	0.4	1.11e-10	Breast cancer;
SARC	trans	rs877282	1.000	rs12773872	chr10:771939	T/C	cg22713356	chr15:30763199	NA	1.04	10.16	0.55	2.56e-20	Uric acid levels;
SARC	cis	rs344364	0.511	rs2982453	chr16:1949520	G/A	cg26617929	chr16:1858877	NA	-0.71	-6.06	-0.37	5.5e-9	Glomerular filtration rate in chronic kidney disease;
SARC	cis	rs908922	0.651	rs10888493	chr1:152503913	G/A	cg09873164	chr1:152488093	CRCT1	0.63	7.96	0.46	7.31e-14	Hair morphology;
SARC	cis	rs7089973	0.604	rs7914792	chr10:116591391	T/C	cg03647239	chr10:116582469	FAM160B1	0.49	6.3	0.38	1.48e-9	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs7555523	0.887	rs10800155	chr1:165723770	A/G	cg19769164	chr1:165738335	TMCO1	0.56	4.71	0.3	4.19e-6	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	cis	rs4481887	0.927	rs4558008	chr1:248477641	C/T	cg01631408	chr1:248437212	OR2T33	-0.38	-4.81	-0.3	2.73e-6	Common traits (Other);
SARC	cis	rs3764563	1.000	rs2031061	chr19:15721961	T/C	cg20725493	chr19:15740067	CYP4F8	-0.65	-4.75	-0.3	3.49e-6	Inflammatory biomarkers;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg20749916	chr13:111767003	ARHGEF7	-0.66	-5.04	-0.31	9.49e-7	Obesity-related traits;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg23354014	chr12:118498668	WSB2	-0.59	-7.2	-0.43	8.44e-12	Fibrinogen levels;
SARC	cis	rs17331151	0.541	rs11709430	chr3:52862055	G/A	cg04865290	chr3:52927548	TMEM110	-0.54	-5.09	-0.32	7.34e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2885056	0.783	rs12459941	chr19:10666112	A/G	cg04833646	chr19:10679720	CDKN2D	-0.88	-10.63	-0.57	8.72e-22	Red cell distribution width;
SARC	cis	rs6831352	0.879	rs35146617	chr4:100066686	C/T	cg13256891	chr4:100009986	ADH5	-0.63	-7.44	-0.44	1.98e-12	Alcohol dependence;
SARC	cis	rs796364	1.000	rs281785	chr2:200749566	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.72	6.36	0.38	1.06e-9	Schizophrenia;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg27328408	chr15:75615005	NA	0.5	6.61	0.4	2.6e-10	Breast cancer;
SARC	cis	rs57994353	0.659	rs76259794	chr9:139377405	C/A	cg14169450	chr9:139327907	INPP5E	0.42	5.38	0.33	1.79e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs11676348	0.751	rs6715591	chr2:219019871	T/C	cg00012203	chr2:219082015	ARPC2	-0.42	-5.51	-0.34	9.38e-8	Ulcerative colitis;
SARC	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg06634786	chr22:41940651	POLR3H	0.54	6.39	0.39	8.97e-10	Vitiligo;
SARC	cis	rs1865760	0.827	rs9295680	chr6:25944103	T/C	cg17691542	chr6:26056736	HIST1H1C	0.57	7.18	0.43	9.29e-12	Height;
SARC	cis	rs698813	0.805	rs804877	chr2:44702751	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.18	0.32	4.73e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg11247378	chr22:39784982	NA	-0.29	-4.87	-0.3	2.08e-6	Intelligence (multi-trait analysis);
SARC	cis	rs10927875	0.691	rs2017583	chr1:16350028	A/G	cg21385522	chr1:16154831	NA	0.72	9.1	0.51	4.19e-17	Dilated cardiomyopathy;
SARC	cis	rs3087591	0.960	rs2905872	chr17:29525027	C/A	cg24425628	chr17:29625626	OMG;NF1	0.48	5.9	0.36	1.29e-8	Hip circumference;
SARC	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg02841227	chr6:26021843	HIST1H4A	0.68	8.21	0.47	1.54e-14	Intelligence (multi-trait analysis);
SARC	cis	rs7103648	0.618	rs11039284	chr11:47564785	A/G	cg10504702	chr11:47789108	FNBP4	0.64	7.62	0.45	6.22e-13	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs9840812	0.598	rs1145101	chr3:136069286	T/C	cg15507776	chr3:136538369	TMEM22	0.63	6.29	0.38	1.52e-9	Fibrinogen levels;
SARC	cis	rs950169	0.922	rs4842939	chr15:84827966	C/T	cg24253500	chr15:84953950	NA	-0.33	-4.81	-0.3	2.74e-6	Schizophrenia;
SARC	cis	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg12395012	chr8:11607386	GATA4	-0.31	-5.13	-0.32	6.07e-7	Triglycerides;
SARC	cis	rs3106136	0.618	rs6853674	chr4:95309190	T/C	cg11021082	chr4:95130006	SMARCAD1	0.32	4.88	0.3	1.97e-6	Capecitabine sensitivity;
SARC	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg12463550	chr7:65579703	CRCP	0.55	5.86	0.36	1.54e-8	Aortic root size;
SARC	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg02733842	chr7:1102375	C7orf50	-0.53	-6.65	-0.4	2.05e-10	Bronchopulmonary dysplasia;
SARC	trans	rs7395662	0.534	rs12418219	chr11:48988091	G/T	cg00717180	chr2:96193071	NA	-0.38	-6.29	-0.38	1.53e-9	HDL cholesterol;
SARC	cis	rs7412746	0.658	rs59988025	chr1:150940358	C/T	cg10589385	chr1:150898437	SETDB1	0.41	5.46	0.34	1.2e-7	Melanoma;
SARC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg02018176	chr4:1364513	KIAA1530	-0.64	-9.96	-0.55	1.09e-19	Longevity;
SARC	cis	rs1008375	0.898	rs9998130	chr4:17593905	A/G	cg16339924	chr4:17578868	LAP3	0.7	8.96	0.51	1.06e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs17376456	0.877	rs12153501	chr5:93360866	T/G	cg25358565	chr5:93447407	FAM172A	1.3	14.78	0.7	2.47e-35	Diabetic retinopathy;
SARC	trans	rs804280	0.509	rs12719915	chr8:11786255	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.82	-0.41	7.86e-11	Myopia (pathological);
SARC	cis	rs2115630	0.691	rs61322921	chr15:85163638	T/C	cg17507749	chr15:85114479	UBE2QP1	-0.56	-6.55	-0.39	3.55e-10	P wave terminal force;
SARC	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg23758822	chr17:41437982	NA	0.84	10.47	0.57	2.81e-21	Menopause (age at onset);
SARC	cis	rs9325144	0.560	rs11183090	chr12:38662293	G/C	cg13010199	chr12:38710504	ALG10B	-0.57	-7.44	-0.44	1.87e-12	Morning vs. evening chronotype;
SARC	cis	rs2153535	0.580	rs965706	chr6:8464708	G/A	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	cis	rs78487399	0.908	rs17031088	chr2:43807090	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.51	-4.9	-0.31	1.78e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs9527	0.590	rs2281877	chr10:104866062	C/T	cg04362960	chr10:104952993	NT5C2	0.43	4.94	0.31	1.47e-6	Arsenic metabolism;
SARC	cis	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg05623727	chr3:50126028	RBM5	-0.34	-5.18	-0.32	4.79e-7	Intelligence (multi-trait analysis);
SARC	cis	rs6952808	0.931	rs12537479	chr7:1868995	A/G	cg04267008	chr7:1944627	MAD1L1	0.49	5.54	0.34	8.24e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs143283559	1	rs143283559	chr18:77567761	T/G	cg24058013	chr18:77568902	NA	-0.37	-4.76	-0.3	3.33e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7223966	1.000	rs2854223	chr17:61939014	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	7.21	0.43	7.77e-12	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs27434	0.583	rs34762	chr5:96153966	A/G	cg16492584	chr5:96139282	ERAP1	-0.56	-6.96	-0.42	3.35e-11	Ankylosing spondylitis;
SARC	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg12311346	chr5:56204834	C5orf35	-0.72	-7.01	-0.42	2.59e-11	Initial pursuit acceleration;
SARC	cis	rs208520	0.690	rs851464	chr6:66839802	C/T	cg07460842	chr6:66804631	NA	-1.04	-14.38	-0.69	5.61e-34	Exhaled nitric oxide output;
SARC	cis	rs7937682	0.593	rs4598705	chr11:111345840	G/A	cg09085632	chr11:111637200	PPP2R1B	0.42	4.95	0.31	1.41e-6	Primary sclerosing cholangitis;
SARC	cis	rs4713675	0.565	rs6904816	chr6:33676156	G/A	cg15676125	chr6:33679581	C6orf125	0.52	6.36	0.38	1.03e-9	Plateletcrit;
SARC	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg18404041	chr3:52824283	ITIH1	-0.42	-6.29	-0.38	1.56e-9	Bipolar disorder;
SARC	trans	rs9329221	0.678	rs560638	chr8:9882767	A/G	cg21775007	chr8:11205619	TDH	-0.51	-6.64	-0.4	2.23e-10	Neuroticism;
SARC	cis	rs989128	0.600	rs916978	chr17:48630452	T/C	cg20467136	chr17:48638190	CACNA1G	0.46	5.36	0.33	2e-7	Type 2 diabetes;
SARC	cis	rs1865760	0.566	rs3752419	chr6:26027433	C/T	cg16482183	chr6:26056742	HIST1H1C	0.45	5.59	0.34	6.48e-8	Height;
SARC	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg01341218	chr17:43662625	NA	0.96	10.77	0.58	3.24e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs523522	0.962	rs670568	chr12:121021206	C/T	cg27279351	chr12:120934652	DYNLL1	0.71	8.75	0.5	4.4e-16	High light scatter reticulocyte count;
SARC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.8	10.33	0.56	7.67e-21	Prudent dietary pattern;
SARC	cis	rs7914558	1.000	rs4917996	chr10:104925829	A/C	cg04362960	chr10:104952993	NT5C2	0.4	4.8	0.3	2.83e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	trans	rs17685	0.697	rs2302437	chr7:75677016	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.59	-7.56	-0.44	9.02e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs34779708	0.931	rs12771399	chr10:35452377	C/T	cg03585969	chr10:35415529	CREM	0.39	4.82	0.3	2.62e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg08048268	chr3:133502702	NA	-0.49	-6.5	-0.39	4.85e-10	Iron status biomarkers;
SARC	cis	rs17376456	0.877	rs10476598	chr5:93367281	C/T	cg25358565	chr5:93447407	FAM172A	-1.34	-14.52	-0.69	1.89e-34	Diabetic retinopathy;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg23551132	chr14:32030686	NUBPL	0.49	6.45	0.39	6.48e-10	Lung adenocarcinoma;
SARC	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg22800045	chr5:56110881	MAP3K1	-0.73	-7.72	-0.45	3.44e-13	Initial pursuit acceleration;
SARC	cis	rs11098499	0.955	rs56386062	chr4:120155135	T/C	cg09307838	chr4:120376055	NA	0.85	11.51	0.6	1.4e-24	Corneal astigmatism;
SARC	cis	rs6815814	0.904	rs3924113	chr4:38796255	G/T	cg09316306	chr4:38807337	TLR1	0.51	5.02	0.31	1.03e-6	Breast cancer;
SARC	cis	rs763121	0.925	rs5750654	chr22:39051428	T/C	cg06022373	chr22:39101656	GTPBP1	0.85	11.21	0.59	1.34e-23	Menopause (age at onset);
SARC	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.76	9.5	0.53	2.75e-18	Height;
SARC	cis	rs818427	0.964	rs419632	chr5:112216389	C/T	cg07820702	chr5:112228657	REEP5	-0.45	-4.98	-0.31	1.22e-6	Total body bone mineral density;
SARC	cis	rs11098499	0.909	rs17046118	chr4:120387496	T/G	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs72781680	0.611	rs7602797	chr2:24318148	C/T	cg08917208	chr2:24149416	ATAD2B	0.58	6.08	0.37	4.89e-9	Lymphocyte counts;
SARC	cis	rs11696501	0.637	rs2093090	chr20:44205464	C/T	cg11783356	chr20:44313418	WFDC10B	-0.45	-4.8	-0.3	2.86e-6	Brain structure;
SARC	cis	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg07636037	chr3:49044803	WDR6	0.46	5.38	0.33	1.82e-7	Resting heart rate;
SARC	cis	rs11690935	0.632	rs62183783	chr2:172865775	A/G	cg13550731	chr2:172543902	DYNC1I2	0.55	7.02	0.42	2.39e-11	Schizophrenia;
SARC	cis	rs9457247	1.000	rs429083	chr6:167383972	T/C	cg07741184	chr6:167504864	NA	0.3	5.6	0.34	5.86e-8	Crohn's disease;
SARC	cis	rs2304069	1.000	rs10072275	chr5:149401596	T/C	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.67	6.8	0.41	8.83e-11	HIV-1 control;
SARC	cis	rs2204008	0.837	rs11495722	chr12:38337245	G/A	cg26384229	chr12:38710491	ALG10B	0.91	13.3	0.66	2.07e-30	Bladder cancer;
SARC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg06873352	chr17:61820015	STRADA	0.53	6.92	0.41	4.3e-11	Prudent dietary pattern;
SARC	cis	rs7639513	0.545	rs9874557	chr3:12720967	A/G	cg23032965	chr3:12705835	RAF1	0.7	7.75	0.45	2.88e-13	Itch intensity from mosquito bite;
SARC	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.75	10.78	0.58	3.05e-22	Personality dimensions;
SARC	cis	rs79349575	0.721	rs1008834	chr17:46968008	G/C	cg16584676	chr17:46985605	UBE2Z	0.54	6.45	0.39	6.25e-10	Type 2 diabetes;
SARC	cis	rs1559088	1.000	rs7260051	chr19:33550111	C/A	cg27124370	chr19:33622961	WDR88	0.42	5.25	0.33	3.44e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs763121	0.819	rs5750629	chr22:38985065	T/C	cg21395723	chr22:39101663	GTPBP1	0.58	6.81	0.41	8.44e-11	Menopause (age at onset);
SARC	cis	rs9462027	0.561	rs2262245	chr6:34567694	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.99	-0.37	7.88e-9	Systemic lupus erythematosus;
SARC	cis	rs11098499	0.691	rs28396837	chr4:120271541	G/A	cg09307838	chr4:120376055	NA	0.74	10.26	0.56	1.27e-20	Corneal astigmatism;
SARC	cis	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg15145296	chr3:125709740	NA	-0.45	-4.78	-0.3	3.06e-6	Blood pressure (smoking interaction);
SARC	cis	rs113835537	0.529	rs2298806	chr11:66282095	G/A	cg24851651	chr11:66362959	CCS	0.37	4.76	0.3	3.36e-6	Airway imaging phenotypes;
SARC	cis	rs9916302	0.904	rs4511574	chr17:37532916	A/G	cg20243544	chr17:37824526	PNMT	0.49	5.56	0.34	7.28e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs8014204	0.604	rs2159906	chr14:75390912	G/T	cg06637938	chr14:75390232	RPS6KL1	0.91	15.43	0.71	1.75e-37	Caffeine consumption;
SARC	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg18876405	chr7:65276391	NA	-0.65	-8.11	-0.47	2.97e-14	Aortic root size;
SARC	trans	rs10519937	1.000	rs10519938	chr5:126723321	T/G	cg26526953	chr19:1921199	SCAMP4	0.63	6.39	0.39	9.11e-10	IgG glycosylation;
SARC	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg05861140	chr6:150128134	PCMT1	-0.4	-4.85	-0.3	2.23e-6	Lung cancer;
SARC	cis	rs7944584	0.879	rs11039182	chr11:47346723	T/C	cg20307385	chr11:47447363	PSMC3	0.59	7.1	0.42	1.49e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs449789	0.857	rs578714	chr6:159715118	G/T	cg14500486	chr6:159655392	FNDC1	-0.44	-5.02	-0.31	1.01e-6	Pulse pressure;
SARC	trans	rs9929218	0.551	rs8051095	chr16:68722049	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.88	15.42	0.71	1.9e-37	Colorectal cancer;
SARC	cis	rs7219021	0.705	rs7207087	chr17:46917953	C/G	cg16584676	chr17:46985605	UBE2Z	0.48	5.82	0.36	1.98e-8	Schizophrenia or bipolar disorder;
SARC	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg16606324	chr3:10149918	C3orf24	0.46	4.8	0.3	2.79e-6	Alzheimer's disease;
SARC	cis	rs13191362	0.935	rs7769048	chr6:163010040	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.56	5.35	0.33	2.07e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs4974559	0.739	rs35571200	chr4:1268129	G/A	cg02980000	chr4:1222292	CTBP1	-0.68	-5.54	-0.34	8e-8	Systolic blood pressure;
SARC	cis	rs2290720	0.930	rs7296094	chr12:101689959	A/G	cg22051763	chr12:101673672	UTP20	-0.43	-5.36	-0.33	2.02e-7	Brain structure (hippocampal volume);
SARC	trans	rs61931739	0.853	rs10844751	chr12:34099651	T/G	cg26384229	chr12:38710491	ALG10B	-0.57	-7.62	-0.45	6.21e-13	Morning vs. evening chronotype;
SARC	cis	rs4713118	0.662	rs149901	chr6:27965503	C/T	cg16479474	chr6:28041457	NA	0.35	5.03	0.31	9.78e-7	Parkinson's disease;
SARC	trans	rs1493916	0.721	rs4799723	chr18:31367050	T/G	cg27147174	chr7:100797783	AP1S1	-0.56	-6.95	-0.41	3.56e-11	Life satisfaction;
SARC	cis	rs6504663	0.586	rs60117965	chr17:48569755	G/A	cg00901687	chr17:48585270	MYCBPAP	0.48	5.45	0.34	1.31e-7	Visceral fat;
SARC	cis	rs11719291	0.915	rs1048940	chr3:48725707	C/T	cg01304814	chr3:48885189	PRKAR2A	0.81	5.86	0.36	1.6e-8	Cognitive function;
SARC	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg11764359	chr7:65958608	NA	-0.67	-7.84	-0.46	1.5700000000000001e-13	Aortic root size;
SARC	cis	rs7223966	1.000	rs8078462	chr17:61857937	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.49	-4.92	-0.31	1.61e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2180341	0.618	rs11961994	chr6:127649350	A/G	cg24812749	chr6:127587940	RNF146	-0.55	-6.7	-0.4	1.52e-10	Breast cancer;
SARC	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.69	-7.67	-0.45	4.55e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg13395646	chr4:1353034	KIAA1530	-0.49	-5.93	-0.36	1.1e-8	Obesity-related traits;
SARC	cis	rs2221894	0.506	rs78814308	chr8:28847683	T/C	cg07962641	chr8:28805897	HMBOX1	-0.78	-7.69	-0.45	4.02e-13	Obesity-related traits;
SARC	cis	rs9796	0.621	rs1659227	chr15:41472398	G/A	cg18705301	chr15:41695430	NDUFAF1	0.56	8.03	0.47	4.86e-14	Menopause (age at onset);
SARC	cis	rs9790314	0.613	rs1447620	chr3:160616211	T/C	cg04691961	chr3:161091175	C3orf57	0.52	7.07	0.42	1.79e-11	Morning vs. evening chronotype;
SARC	cis	rs7582720	1.000	rs7582720	chr2:203753072	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.31	0.43	4.24e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs561341	1.000	rs8064843	chr17:30245744	A/G	cg00745463	chr17:30367425	LRRC37B	-0.56	-4.79	-0.3	2.95e-6	Hip circumference adjusted for BMI;
SARC	cis	rs9303401	0.527	rs2116450	chr17:56745561	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	11.88	0.61	9.47e-26	Cognitive test performance;
SARC	cis	rs897984	0.537	rs8045637	chr16:30818662	C/T	cg02466173	chr16:30829666	NA	-0.55	-7.99	-0.46	6.36e-14	Dementia with Lewy bodies;
SARC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg26338869	chr17:61819248	STRADA	0.81	10.89	0.58	1.38e-22	Prudent dietary pattern;
SARC	cis	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg20965017	chr5:231967	SDHA	-0.52	-5.0	-0.31	1.12e-6	Breast cancer;
SARC	cis	rs2762353	0.526	rs6456693	chr6:25710087	C/G	cg17691542	chr6:26056736	HIST1H1C	-0.41	-5.17	-0.32	4.95e-7	Blood metabolite levels;
SARC	cis	rs854765	0.583	rs28428991	chr17:17827649	C/T	cg05444541	chr17:17804740	TOM1L2	-0.3	-5.05	-0.31	9.06e-7	Total body bone mineral density;
SARC	trans	rs61931739	0.534	rs2667447	chr12:34133468	C/A	cg13010199	chr12:38710504	ALG10B	0.7	9.6	0.53	1.32e-18	Morning vs. evening chronotype;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg17401635	chr5:176944162	DDX41	0.5	6.73	0.4	1.3100000000000001e-10	Chemerin levels;
SARC	cis	rs1048257	0.682	rs2582514	chr14:105413204	G/T	cg15352829	chr14:105391018	PLD4	-0.32	-5.93	-0.36	1.08e-8	Systemic lupus erythematosus;
SARC	cis	rs6700896	0.931	rs4655585	chr1:66155627	T/C	cg04111102	chr1:66153794	NA	0.36	5.5	0.34	1e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs7178572	0.568	rs11853460	chr15:77515319	C/T	cg22256960	chr15:77711686	NA	-0.5	-5.52	-0.34	8.84e-8	Type 2 diabetes;
SARC	trans	rs7937682	0.889	rs490199	chr11:111487890	A/G	cg18187862	chr3:45730750	SACM1L	0.56	6.93	0.41	3.99e-11	Primary sclerosing cholangitis;
SARC	cis	rs7659604	0.728	rs3924987	chr4:122689784	G/T	cg06713675	chr4:122721982	EXOSC9	-0.45	-6.13	-0.37	3.67e-9	Type 2 diabetes;
SARC	cis	rs17376456	0.877	rs10078194	chr5:93364310	A/C	cg21475434	chr5:93447410	FAM172A	0.87	7.91	0.46	1.06e-13	Diabetic retinopathy;
SARC	cis	rs9916302	0.904	rs6503506	chr17:37524653	C/A	cg00129232	chr17:37814104	STARD3	0.61	7.44	0.44	1.87e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs7927592	0.913	rs3740629	chr11:68343593	C/T	cg01657329	chr11:68192670	LRP5	-0.43	-5.11	-0.32	6.59e-7	Total body bone mineral density;
SARC	cis	rs2425143	0.598	rs2425118	chr20:34324098	G/A	cg01084648	chr20:34329383	RBM39	0.58	5.03	0.31	9.74e-7	Blood protein levels;
SARC	cis	rs10870270	0.956	rs10430618	chr10:133748996	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.47	-5.58	-0.34	6.64e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs9818758	0.556	rs11716614	chr3:49017208	C/G	cg00383909	chr3:49044727	WDR6	0.8	6.51	0.39	4.65e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	trans	rs1459104	0.636	rs559362	chr11:55275456	T/G	cg15704280	chr7:45808275	SEPT13	0.61	6.35	0.38	1.14e-9	Body mass index;
SARC	cis	rs9875589	0.509	rs12330714	chr3:14040342	A/T	cg19554555	chr3:13937349	NA	-0.4	-5.22	-0.32	4.03e-7	Ovarian reserve;
SARC	cis	rs9814567	1.000	rs2373865	chr3:134291556	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	7.01	0.42	2.54e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs2380220	0.720	rs9400397	chr6:95980623	C/A	cg04719120	chr6:96025338	MANEA	0.55	6.18	0.38	2.83e-9	Behavioural disinhibition (generation interaction);
SARC	cis	rs6582630	0.537	rs6582500	chr12:38534206	G/A	cg13010199	chr12:38710504	ALG10B	0.77	10.7	0.57	5.25e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs17539620	0.628	rs11541340	chr6:154831572	C/G	cg20019720	chr6:154832845	CNKSR3	0.41	4.82	0.3	2.6e-6	Lipoprotein (a) levels;
SARC	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs922107	0.713	rs10922663	chr1:90032893	C/A	cg15422784	chr1:90023713	LRRC8B	-0.32	-4.75	-0.3	3.56e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
SARC	cis	rs8114671	0.562	rs6087643	chr20:33474462	C/T	cg07148914	chr20:33460835	GGT7	0.42	5.06	0.31	8.36e-7	Height;
SARC	cis	rs501120	0.810	rs474281	chr10:44749120	T/C	cg09554077	chr10:44749378	NA	0.43	5.79	0.35	2.24e-8	Coronary artery disease;Coronary heart disease;
SARC	cis	rs17376456	0.825	rs34592268	chr5:93232751	G/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.74	0.35	3.01e-8	Diabetic retinopathy;
SARC	cis	rs6089584	0.507	rs28545731	chr20:60634102	C/T	cg13770153	chr20:60521292	NA	-0.34	-4.81	-0.3	2.69e-6	Body mass index;
SARC	cis	rs9547692	1.000	rs527929	chr13:37478506	C/T	cg01493522	chr13:37497338	NA	-0.45	-4.97	-0.31	1.29e-6	Coronary artery disease;
SARC	cis	rs1018836	0.828	rs10091275	chr8:91559751	A/G	cg16814680	chr8:91681699	NA	-0.74	-11.56	-0.6	9.89e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs7662987	0.517	rs1311615	chr4:100012261	G/A	cg12011299	chr4:100065546	ADH4	0.32	5.24	0.32	3.6e-7	Smoking initiation;
SARC	cis	rs2408955	0.521	rs7301003	chr12:48550227	A/G	cg24011408	chr12:48396354	COL2A1	0.42	5.15	0.32	5.59e-7	Glycated hemoglobin levels;
SARC	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg20887711	chr4:1340912	KIAA1530	0.43	5.39	0.33	1.69e-7	Longevity;
SARC	cis	rs7044106	0.762	rs7849566	chr9:123460769	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	4.94	0.31	1.47e-6	Hip circumference adjusted for BMI;
SARC	cis	rs7089973	0.872	rs41284358	chr10:116622339	A/G	cg08188268	chr10:116634841	FAM160B1	0.37	5.89	0.36	1.33e-8	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg11148483	chr3:28393736	NA	0.46	6.24	0.38	2.07e-9	Chemerin levels;
SARC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg11494091	chr17:61959527	GH2	0.54	8.07	0.47	3.81e-14	Prudent dietary pattern;
SARC	cis	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg05623727	chr3:50126028	RBM5	0.33	4.91	0.31	1.69e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7617773	0.780	rs3731550	chr3:48206583	A/C	cg11946769	chr3:48343235	NME6	0.72	9.38	0.52	6.07e-18	Coronary artery disease;
SARC	cis	rs2033732	0.955	rs2033731	chr8:85079720	T/G	cg05716166	chr8:85095498	RALYL	0.54	6.24	0.38	2.06e-9	Body mass index;
SARC	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg06713675	chr4:122721982	EXOSC9	-0.5	-6.59	-0.4	2.96e-10	Type 2 diabetes;
SARC	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg27121462	chr16:89883253	FANCA	-0.45	-6.24	-0.38	2.1e-9	Vitiligo;
SARC	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.46	5.25	0.33	3.37e-7	Renal function-related traits (BUN);
SARC	trans	rs61931739	0.517	rs4931748	chr12:34140827	C/T	cg26384229	chr12:38710491	ALG10B	0.85	12.17	0.62	1.05e-26	Morning vs. evening chronotype;
SARC	cis	rs7481584	1.000	rs7481584	chr11:3029089	G/A	cg05729581	chr11:3078854	CARS	0.48	5.83	0.36	1.87e-8	Calcium levels;
SARC	cis	rs3741404	0.672	rs4980524	chr11:63959259	A/C	cg18225595	chr11:63971243	STIP1	0.47	7.32	0.43	3.9e-12	Platelet count;
SARC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.54	0.57	1.68e-21	Prudent dietary pattern;
SARC	cis	rs694739	0.930	rs574087	chr11:64102948	A/G	cg23796481	chr11:64053134	BAD;GPR137	0.76	10.28	0.56	1.14e-20	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs751728	0.597	rs767895	chr6:33791463	C/G	cg25922239	chr6:33757077	LEMD2	0.54	5.95	0.36	9.76e-9	Crohn's disease;
SARC	cis	rs6138458	1.000	rs227631	chr20:24913653	A/G	cg26195577	chr20:24973756	C20orf3	0.88	9.9	0.54	1.69e-19	Blood protein levels;
SARC	cis	rs77372450	0.636	rs60855017	chr5:157012717	G/A	cg23851860	chr5:157002805	ADAM19	0.51	4.91	0.31	1.72e-6	Bipolar disorder (body mass index interaction);
SARC	cis	rs76419734	1.000	rs11724884	chr4:106677384	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.76	4.98	0.31	1.23e-6	Post bronchodilator FEV1;
SARC	cis	rs2137920	0.730	rs2255360	chr10:50219089	C/T	cg09419352	chr10:50604330	NA	0.42	4.85	0.3	2.24e-6	Migraine with aura;
SARC	trans	rs10838801	1	rs10838801	chr11:48098280	G/A	cg03929089	chr4:120376271	NA	-0.56	-6.75	-0.4	1.14e-10	Height;
SARC	cis	rs240764	0.658	rs11155659	chr6:101222568	A/G	cg09795085	chr6:101329169	ASCC3	-0.5	-6.68	-0.4	1.74e-10	Neuroticism;
SARC	cis	rs34421088	0.560	rs2467520	chr8:11398953	T/C	cg21775007	chr8:11205619	TDH	-0.38	-4.74	-0.3	3.78e-6	Neuroticism;
SARC	trans	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg06756369	chr1:231762664	TSNAX-DISC1;DISC1	0.45	6.29	0.38	1.56e-9	Immature fraction of reticulocytes;
SARC	cis	rs11098499	1.000	rs11098500	chr4:120219239	T/A	cg24375607	chr4:120327624	NA	0.39	4.72	0.3	4.12e-6	Corneal astigmatism;
SARC	cis	rs193541	0.530	rs2125857	chr5:122083156	G/A	cg19412675	chr5:122181750	SNX24	0.48	6.42	0.39	7.41e-10	Glucose homeostasis traits;
SARC	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg08219700	chr8:58056026	NA	-0.58	-5.67	-0.35	4.29e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10046574	0.561	rs7789858	chr7:135212285	A/G	cg27474649	chr7:135195673	CNOT4	0.81	7.74	0.45	3e-13	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs73086581	1.000	rs113812453	chr20:3963193	T/C	cg02187196	chr20:3869020	PANK2	0.67	6.4	0.39	8.3e-10	Response to antidepressants in depression;
SARC	cis	rs62244186	0.566	rs55852922	chr3:44826188	A/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.56	7.3	0.43	4.39e-12	Depressive symptoms;
SARC	cis	rs2180341	0.960	rs1964130	chr6:127677391	C/G	cg24812749	chr6:127587940	RNF146	1.01	12.72	0.64	1.7e-28	Breast cancer;
SARC	trans	rs3808502	0.605	rs11784572	chr8:11174484	C/G	cg06636001	chr8:8085503	FLJ10661	-0.6	-7.71	-0.45	3.66e-13	Neuroticism;
SARC	cis	rs3099143	1.000	rs4583202	chr15:77161676	G/A	cg21673338	chr15:77095150	SCAPER	0.73	6.15	0.37	3.32e-9	Recalcitrant atopic dermatitis;
SARC	cis	rs12474201	0.507	rs6714451	chr2:47017743	G/C	cg06386533	chr2:46925753	SOCS5	0.56	7.6	0.45	6.98e-13	Height;
SARC	cis	rs228437	0.913	rs1535117	chr6:134911816	G/A	cg24504307	chr6:134963096	NA	0.43	4.89	0.31	1.85e-6	Melanoma;
SARC	trans	rs11098499	0.865	rs10032158	chr4:120391632	C/T	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.47e-12	Corneal astigmatism;
SARC	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.89	-13.64	-0.67	1.61e-31	Chronic sinus infection;
SARC	cis	rs4820539	0.641	rs5759602	chr22:23489362	C/T	cg14186256	chr22:23484241	RTDR1	-0.72	-10.2	-0.56	1.9e-20	Bone mineral density;
SARC	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-5.62	-0.35	5.3e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg17376030	chr22:41985996	PMM1	-0.78	-9.96	-0.55	1.04e-19	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	8.88	0.5	1.84e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs3733585	0.699	rs6852441	chr4:9973744	C/T	cg00071950	chr4:10020882	SLC2A9	-0.38	-5.86	-0.36	1.54e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs17376456	0.877	rs10044066	chr5:93437580	T/C	cg21475434	chr5:93447410	FAM172A	0.88	8.11	0.47	2.81e-14	Diabetic retinopathy;
SARC	cis	rs1387259	0.839	rs7487682	chr12:48579665	A/C	cg24011408	chr12:48396354	COL2A1	-0.39	-4.9	-0.31	1.83e-6	Obstructive sleep apnea trait (apnea hypopnea index);
SARC	cis	rs7429990	0.965	rs4858871	chr3:47953405	A/C	cg11946769	chr3:48343235	NME6	0.45	5.16	0.32	5.26e-7	Educational attainment (years of education);
SARC	trans	rs61931739	0.817	rs7297799	chr12:34260142	T/C	cg26384229	chr12:38710491	ALG10B	0.61	8.01	0.46	5.55e-14	Morning vs. evening chronotype;
SARC	cis	rs11644362	1.000	rs35325771	chr16:12985138	A/C	cg06890432	chr16:12997467	SHISA9	-0.55	-7.31	-0.43	4.12e-12	Positive affect;Subjective well-being;
SARC	cis	rs4820539	1.000	rs2267003	chr22:23457098	A/G	cg14186256	chr22:23484241	RTDR1	0.84	13.34	0.66	1.5e-30	Bone mineral density;
SARC	cis	rs854765	0.505	rs4506969	chr17:17899839	A/G	cg04398451	chr17:18023971	MYO15A	-0.47	-6.62	-0.4	2.51e-10	Total body bone mineral density;
SARC	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg22168489	chr12:122356033	WDR66	0.74	11.71	0.61	3.35e-25	Mean corpuscular volume;
SARC	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-5.61	-0.35	5.58e-8	Bipolar disorder;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg02249930	chr10:70166207	RUFY2	-0.64	-7.23	-0.43	6.97e-12	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs7005380	0.531	rs4871010	chr8:120907639	C/G	cg21744203	chr8:120868354	DSCC1	0.46	4.86	0.3	2.2e-6	Interstitial lung disease;
SARC	cis	rs7599312	0.534	rs7607363	chr2:213402705	A/G	cg20637307	chr2:213403960	ERBB4	0.8	12.5	0.63	8.9e-28	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs963731	0.579	rs1454226	chr2:39246862	A/G	cg04010122	chr2:39346883	SOS1	-0.89	-5.12	-0.32	6.33e-7	Corticobasal degeneration;
SARC	cis	rs763121	0.853	rs5750626	chr22:38977890	G/C	cg21395723	chr22:39101663	GTPBP1	0.56	6.31	0.38	1.4e-9	Menopause (age at onset);
SARC	cis	rs7312774	0.618	rs7304621	chr12:107325888	C/T	cg16260113	chr12:107380972	MTERFD3	0.82	6.82	0.41	7.94e-11	Severe influenza A (H1N1) infection;
SARC	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg17971929	chr21:40555470	PSMG1	0.98	13.73	0.67	7.71e-32	Cognitive function;
SARC	cis	rs11690935	0.959	rs10497374	chr2:172640623	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.99	-15.89	-0.72	5.21e-39	Schizophrenia;
SARC	cis	rs601339	0.878	rs7956284	chr12:123183017	G/A	cg18578876	chr12:123200353	GPR109B	0.43	4.84	0.3	2.42e-6	Adiponectin levels;
SARC	cis	rs11697848	0.867	rs77083750	chr20:48548465	C/T	cg17849948	chr20:48532315	SPATA2	0.87	5.2	0.32	4.3e-7	Systemic lupus erythematosus;
SARC	cis	rs9916302	0.718	rs7219909	chr17:37706243	C/T	cg20243544	chr17:37824526	PNMT	0.52	6.12	0.37	3.86e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs11688816	0.967	rs6714241	chr2:63069112	G/T	cg17519650	chr2:63277830	OTX1	0.38	4.72	0.3	3.98e-6	Body mass index;
SARC	trans	rs1814175	0.645	rs10839382	chr11:49823172	C/T	cg15704280	chr7:45808275	SEPT13	-0.87	-13.69	-0.67	1.06e-31	Height;
SARC	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg11764359	chr7:65958608	NA	-0.67	-7.97	-0.46	7.26e-14	Aortic root size;
SARC	cis	rs17102884	0.506	rs4899540	chr14:75403408	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.41	-5.45	-0.34	1.25e-7	Neuroticism;
SARC	trans	rs3942852	0.594	rs10769311	chr11:48094009	T/C	cg03929089	chr4:120376271	NA	-0.56	-6.87	-0.41	5.73e-11	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs35213789	0.878	rs12698850	chr7:69570345	G/A	cg10619644	chr7:69149951	AUTS2	0.42	5.17	0.32	4.92e-7	Childhood ear infection;
SARC	cis	rs6540556	0.643	rs2282739	chr1:209883001	C/T	cg23920097	chr1:209922102	NA	-0.45	-5.06	-0.31	8.32e-7	Red blood cell count;
SARC	cis	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg12463550	chr7:65579703	CRCP	0.69	5.29	0.33	2.86e-7	Diabetic kidney disease;
SARC	trans	rs931812	0.825	rs55818461	chr8:101899229	T/C	cg20993868	chr7:22813445	NA	0.47	6.52	0.39	4.29e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg18252515	chr7:66147081	NA	-1.34	-11.74	-0.61	2.62e-25	Diabetic kidney disease;
SARC	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.12	24.35	0.85	5.74e-66	Chronic sinus infection;
SARC	cis	rs524281	0.861	rs471484	chr11:65955144	A/G	cg14036092	chr11:66035641	RAB1B	-0.51	-5.71	-0.35	3.46e-8	Electroencephalogram traits;
SARC	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.73	7.63	0.45	6.01e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7666738	0.861	rs10018654	chr4:99002226	A/G	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg00933542	chr6:150070202	PCMT1	0.3	5.05	0.31	8.91e-7	Lung cancer;
SARC	cis	rs208520	0.837	rs208471	chr6:66916749	A/C	cg07460842	chr6:66804631	NA	-0.99	-12.1	-0.62	1.73e-26	Exhaled nitric oxide output;
SARC	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg13877915	chr19:58951672	ZNF132	0.67	10.19	0.56	2.08e-20	Uric acid clearance;
SARC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg18402987	chr7:1209562	NA	0.41	5.46	0.34	1.24e-7	Longevity;Endometriosis;
SARC	cis	rs9660992	0.710	rs1668864	chr1:205248799	T/C	cg21545522	chr1:205238299	TMCC2	0.49	6.61	0.4	2.58e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg23221052	chr5:179740743	GFPT2	-0.55	-6.95	-0.41	3.59e-11	Height;
SARC	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg21724239	chr8:58056113	NA	0.58	5.69	0.35	3.74e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2221894	0.506	rs17526904	chr8:28947843	C/T	cg07962641	chr8:28805897	HMBOX1	-0.76	-7.63	-0.45	6.05e-13	Obesity-related traits;
SARC	cis	rs1003719	0.788	rs2835588	chr21:38462716	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.63	9.05	0.51	5.67e-17	Eye color traits;
SARC	cis	rs634534	0.562	rs661335	chr11:65754061	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.59	9.16	0.51	2.73e-17	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs1395	0.778	rs60631624	chr2:27497815	T/G	cg22903471	chr2:27725779	GCKR	-0.39	-4.78	-0.3	3.14e-6	Blood metabolite levels;
SARC	cis	rs365132	0.875	rs2940521	chr5:176339209	A/C	cg16309518	chr5:176445507	NA	-0.48	-6.24	-0.38	2.01e-9	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs523522	0.962	rs2168319	chr12:120933217	C/T	cg27279351	chr12:120934652	DYNLL1	0.71	8.85	0.5	2.22e-16	High light scatter reticulocyte count;
SARC	cis	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg25894440	chr7:65020034	NA	-0.74	-5.55	-0.34	7.85e-8	Diabetic kidney disease;
SARC	cis	rs13088645	0.729	rs7620040	chr3:134163082	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.39	-4.82	-0.3	2.56e-6	Coronary artery disease;
SARC	cis	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg15556689	chr8:8085844	FLJ10661	0.42	5.19	0.32	4.58e-7	Mood instability;
SARC	cis	rs8067545	0.750	rs28637614	chr17:19985108	G/T	cg13482628	chr17:19912719	NA	0.53	7.12	0.42	1.35e-11	Schizophrenia;
SARC	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.54	4.88	0.3	2e-6	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs12681366	0.708	rs2515100	chr8:95380956	A/T	cg26464482	chr8:95565502	KIAA1429	0.44	5.54	0.34	8.19e-8	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg13939156	chr17:80058883	NA	-0.42	-6.39	-0.39	8.97e-10	Life satisfaction;
SARC	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg01570182	chr17:44337453	NA	-0.82	-9.63	-0.53	1.06e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs1957429	0.901	rs1467569	chr14:65347986	T/C	cg23373153	chr14:65346875	NA	1.07	11.5	0.6	1.53e-24	Pediatric areal bone mineral density (radius);
SARC	cis	rs5753618	0.561	rs5749265	chr22:31796897	A/C	cg02404636	chr22:31891804	SFI1	0.49	5.17	0.32	4.93e-7	Colorectal cancer;
SARC	cis	rs1729951	0.575	rs1654926	chr3:136709924	G/A	cg15507776	chr3:136538369	TMEM22	0.5	5.55	0.34	7.93e-8	Neuroticism;
SARC	cis	rs9443189	0.950	rs276698	chr6:76473071	T/C	cg01950844	chr6:76311363	SENP6	0.77	6.56	0.39	3.53e-10	Prostate cancer;
SARC	cis	rs7927771	0.524	rs2290851	chr11:47753370	C/T	cg10504702	chr11:47789108	FNBP4	-0.44	-5.65	-0.35	4.55e-8	Subjective well-being;
SARC	cis	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg05084668	chr3:125655381	ALG1L	-0.48	-4.93	-0.31	1.54e-6	Blood pressure (smoking interaction);
SARC	cis	rs796364	1.000	rs1658807	chr2:200767512	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.77	7.03	0.42	2.27e-11	Schizophrenia;
SARC	cis	rs2180341	1.000	rs7756336	chr6:127650299	T/C	cg27446573	chr6:127587934	RNF146	1.04	14.77	0.7	2.87e-35	Breast cancer;
SARC	cis	rs2425143	1.000	rs60646509	chr20:34303409	T/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.68	5.52	0.34	9.15e-8	Blood protein levels;
SARC	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg12463550	chr7:65579703	CRCP	-0.49	-5.34	-0.33	2.15e-7	Aortic root size;
SARC	cis	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg03060546	chr3:49711283	APEH	0.75	11.19	0.59	1.56e-23	Resting heart rate;
SARC	cis	rs9393692	0.905	rs9393694	chr6:26279296	T/C	cg13736514	chr6:26305472	NA	-0.6	-8.38	-0.48	5.15e-15	Educational attainment;
SARC	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg18758796	chr5:131593413	PDLIM4	0.38	4.93	0.31	1.55e-6	Acylcarnitine levels;
SARC	trans	rs877282	0.898	rs11253347	chr10:765769	A/G	cg22713356	chr15:30763199	NA	1.04	10.06	0.55	5.37e-20	Uric acid levels;
SARC	cis	rs9916302	0.851	rs11868029	chr17:37650304	A/G	cg07936489	chr17:37558343	FBXL20	-0.69	-9.12	-0.51	3.72e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg11890956	chr21:40555474	PSMG1	1.18	16.58	0.74	2.61e-41	Cognitive function;
SARC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg23034840	chr1:205782522	SLC41A1	0.63	8.14	0.47	2.36e-14	Menarche (age at onset);
SARC	cis	rs67311347	1.000	rs2305522	chr3:40429358	A/G	cg09455208	chr3:40491958	NA	0.41	6.33	0.38	1.27e-9	Renal cell carcinoma;
SARC	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg15966229	chr18:44337664	ST8SIA5	-0.37	-4.86	-0.3	2.15e-6	Personality dimensions;
SARC	cis	rs7760949	0.852	rs9464423	chr6:13931851	A/G	cg27413430	chr6:13925136	RNF182	0.42	4.88	0.3	1.97e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs4595586	0.545	rs3914596	chr12:39388538	T/C	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	cis	rs17345786	0.861	rs79181492	chr3:101216021	G/A	cg12386194	chr3:101231763	SENP7	0.81	9.54	0.53	2e-18	Colonoscopy-negative controls vs population controls;
SARC	cis	rs11770686	0.666	rs2253020	chr7:75312037	A/G	cg17787366	chr7:75369077	HIP1	-0.4	-4.95	-0.31	1.44e-6	Essential tremor;
SARC	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7246657	0.943	rs10403613	chr19:37844306	C/T	cg23950597	chr19:37808831	NA	-0.6	-5.85	-0.36	1.67e-8	Coronary artery calcification;
SARC	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg24829409	chr8:58192753	C8orf71	-0.63	-5.96	-0.36	9.37e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg04519421	chr11:819128	PNPLA2	0.52	6.64	0.4	2.19e-10	Lung adenocarcinoma;
SARC	cis	rs4889855	0.556	rs4508465	chr17:78543368	G/A	cg17956530	chr17:78667699	RPTOR	0.42	4.78	0.3	3.13e-6	Fractional excretion of uric acid;
SARC	cis	rs7264396	0.635	rs6060719	chr20:34546013	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	4.92	0.31	1.67e-6	Total cholesterol levels;
SARC	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg14582100	chr15:45693742	SPATA5L1	0.35	4.91	0.31	1.69e-6	Homoarginine levels;
SARC	cis	rs2486288	0.656	rs2413771	chr15:45553140	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.55	-7.2	-0.43	8.32e-12	Glomerular filtration rate;
SARC	cis	rs4689388	0.926	rs3889821	chr4:6282596	C/T	cg00701064	chr4:6280414	WFS1	0.57	9.23	0.52	1.67e-17	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs76419734	0.558	rs11730825	chr4:106527568	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.65	5.95	0.36	9.85e-9	Post bronchodilator FEV1;
SARC	cis	rs986417	1.000	rs1313243	chr14:60876398	C/T	cg27398547	chr14:60952738	C14orf39	-0.99	-8.88	-0.5	1.89e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg24110177	chr3:50126178	RBM5	-0.6	-7.89	-0.46	1.18e-13	Body mass index;
SARC	cis	rs11718455	1.000	rs17076273	chr3:44020113	A/G	cg08738300	chr3:44038990	NA	0.52	5.68	0.35	4.07e-8	Coronary artery disease;
SARC	cis	rs2732480	0.577	rs2634680	chr12:48734564	T/C	cg24011408	chr12:48396354	COL2A1	0.43	5.07	0.32	8.19e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg01448562	chr3:133502909	NA	-0.51	-7.76	-0.45	2.65e-13	Iron status biomarkers;
SARC	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg15049968	chr18:44337910	ST8SIA5	0.34	5.23	0.32	3.81e-7	Personality dimensions;
SARC	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg01273672	chr2:206336536	PARD3B	0.46	6.53	0.39	4.05e-10	Thyroid stimulating hormone;
SARC	cis	rs7666738	0.830	rs17027058	chr4:98864671	G/A	cg05340658	chr4:99064831	C4orf37	0.66	8.78	0.5	3.5e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs8014204	0.836	rs8021280	chr14:75290018	C/G	cg17347104	chr14:75034677	LTBP2	-0.45	-5.7	-0.35	3.6e-8	Caffeine consumption;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg07805240	chr7:8008383	GLCCI1	0.53	6.75	0.4	1.14e-10	Height;
SARC	cis	rs7089973	0.604	rs11196952	chr10:116607592	G/A	cg03647239	chr10:116582469	FAM160B1	0.5	6.49	0.39	5.19e-10	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs9467773	0.620	rs2504540	chr6:26641626	A/G	cg11502198	chr6:26597334	ABT1	0.63	8.48	0.49	2.58e-15	Intelligence (multi-trait analysis);
SARC	cis	rs7772486	0.754	rs697054	chr6:146003770	C/T	cg23711669	chr6:146136114	FBXO30	0.9	15.3	0.71	4.6e-37	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs17666538	0.591	rs1669716	chr8:593707	C/T	cg23958373	chr8:599963	NA	0.64	5.68	0.35	3.94e-8	IgG glycosylation;
SARC	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.74	10.88	0.58	1.51e-22	Personality dimensions;
SARC	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.74	-7.74	-0.45	2.99e-13	Platelet count;
SARC	cis	rs858239	0.665	rs6964665	chr7:23211352	G/A	cg23682824	chr7:23144976	KLHL7	0.69	8.87	0.5	2.01e-16	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9916302	0.706	rs12947506	chr17:37707592	A/G	cg00129232	chr17:37814104	STARD3	-0.57	-6.04	-0.37	6.17e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs870825	0.616	rs2141257	chr4:185609463	C/T	cg04058563	chr4:185651563	MLF1IP	-0.75	-10.06	-0.55	5.34e-20	Blood protein levels;
SARC	cis	rs3820928	0.839	rs4675123	chr2:227800205	T/C	cg11843606	chr2:227700838	RHBDD1	-0.54	-6.85	-0.41	6.68e-11	Pulmonary function;
SARC	cis	rs6540556	0.723	rs6702301	chr1:209923154	C/T	cg23920097	chr1:209922102	NA	-0.59	-6.95	-0.41	3.61e-11	Red blood cell count;
SARC	trans	rs61931739	0.500	rs6488221	chr12:34525671	A/G	cg26384229	chr12:38710491	ALG10B	0.85	12.62	0.64	3.51e-28	Morning vs. evening chronotype;
SARC	cis	rs12545109	0.800	rs1561224	chr8:57419922	T/C	cg09654669	chr8:57350985	NA	-0.39	-4.98	-0.31	1.26e-6	Obesity-related traits;
SARC	cis	rs1448094	0.737	rs10863135	chr12:86382657	C/T	cg02569458	chr12:86230093	RASSF9	0.4	5.99	0.37	7.92e-9	Major depressive disorder;
SARC	cis	rs8180040	0.726	rs4078466	chr3:47126543	C/T	cg02527881	chr3:46936655	PTH1R	-0.32	-4.94	-0.31	1.47e-6	Colorectal cancer;
SARC	cis	rs7826238	0.601	rs2979206	chr8:8345581	G/C	cg15556689	chr8:8085844	FLJ10661	0.39	4.94	0.31	1.49e-6	Systolic blood pressure;
SARC	cis	rs7223966	0.921	rs67018565	chr17:61928055	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	7.48	0.44	1.5e-12	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg22875332	chr1:76189707	ACADM	0.48	6.71	0.4	1.5e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs881375	0.867	rs10818484	chr9:123661194	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.41	4.95	0.31	1.4e-6	Rheumatoid arthritis;
SARC	trans	rs1814175	0.645	rs10444311	chr11:49986906	A/G	cg15704280	chr7:45808275	SEPT13	-0.89	-14.17	-0.68	2.8e-33	Height;
SARC	cis	rs1348850	0.597	rs13014417	chr2:178417835	T/G	cg23306229	chr2:178417860	TTC30B	0.77	8.62	0.49	1.07e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg01448562	chr3:133502909	NA	-0.49	-7.49	-0.44	1.44e-12	Iron status biomarkers;
SARC	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg02574844	chr11:5959923	NA	-0.38	-5.41	-0.33	1.53e-7	DNA methylation (variation);
SARC	cis	rs2502731	0.539	rs3003615	chr9:130997892	C/T	cg09976142	chr9:130955436	CIZ1	0.36	4.83	0.3	2.45e-6	Attention deficit hyperactivity disorder;
SARC	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg06138931	chr13:21896616	NA	0.35	5.28	0.33	2.94e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg11941060	chr3:133502564	NA	-0.34	-4.84	-0.3	2.36e-6	Iron status biomarkers;
SARC	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg26560785	chr8:103251167	RRM2B	0.52	6.43	0.39	7.02e-10	Migraine with aura;
SARC	cis	rs9948	0.786	rs62152775	chr2:97448474	G/T	cg01990225	chr2:97406019	LMAN2L	-0.96	-6.95	-0.41	3.73e-11	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg21280719	chr6:42927975	GNMT	0.46	8.04	0.47	4.62e-14	Alzheimer's disease in APOE e4+ carriers;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg13135637	chr7:117056487	ASZ1	0.46	6.45	0.39	6.49e-10	Tetralogy of Fallot;
SARC	cis	rs17270561	0.636	rs1165216	chr6:25797971	G/A	cg17691542	chr6:26056736	HIST1H1C	0.45	5.49	0.34	1.05e-7	Iron status biomarkers;
SARC	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg05340658	chr4:99064831	C4orf37	0.56	6.84	0.41	7.09e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs17270561	0.609	rs4132072	chr6:25717843	C/T	cg17691542	chr6:26056736	HIST1H1C	0.56	6.85	0.41	6.68e-11	Iron status biomarkers;
SARC	cis	rs9296095	0.950	rs5745587	chr6:33545125	A/G	cg14003231	chr6:33640908	ITPR3	0.36	5.71	0.35	3.41e-8	Platelet count;
SARC	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg09323728	chr8:95962352	TP53INP1	-0.29	-4.91	-0.31	1.72e-6	Type 2 diabetes;
SARC	cis	rs2153535	0.580	rs9505454	chr6:8478532	T/G	cg07606381	chr6:8435919	SLC35B3	0.79	11.49	0.6	1.71e-24	Motion sickness;
SARC	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.77	-11.3	-0.6	6.64e-24	Age at first birth;
SARC	cis	rs35995292	0.534	rs7793692	chr7:38940580	G/C	cg19327137	chr7:38886074	VPS41	0.53	7.94	0.46	8.43e-14	Subjective well-being (multi-trait analysis);
SARC	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg06074448	chr4:187884817	NA	0.4	5.43	0.33	1.44e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg22974920	chr21:40686053	BRWD1	-0.44	-4.83	-0.3	2.45e-6	Cognitive function;
SARC	cis	rs3767633	0.925	rs4657103	chr1:161740483	G/T	cg09175582	chr1:161736000	ATF6	0.67	5.53	0.34	8.68e-8	IgG glycosylation;
SARC	cis	rs7959452	0.535	rs11177577	chr12:69671791	C/T	cg20891283	chr12:69753455	YEATS4	0.41	5.44	0.34	1.33e-7	Blood protein levels;
SARC	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg17376030	chr22:41985996	PMM1	-0.68	-8.73	-0.5	5.08e-16	Vitiligo;
SARC	cis	rs8017423	0.967	rs11159956	chr14:90715890	C/T	cg20276874	chr14:90721474	PSMC1	0.38	5.36	0.33	2.04e-7	Mortality in heart failure;
SARC	cis	rs9486719	0.895	rs12527021	chr6:97025496	C/T	cg06623918	chr6:96969491	KIAA0776	-0.79	-8.83	-0.5	2.51e-16	Migraine;Coronary artery disease;
SARC	cis	rs6988636	1.000	rs28513831	chr8:124189208	T/C	cg23067535	chr8:124195133	FAM83A	-0.69	-5.46	-0.34	1.24e-7	Urinary uromodulin levels;
SARC	cis	rs9470366	0.816	rs7742159	chr6:36619452	A/C	cg08179530	chr6:36648295	CDKN1A	0.57	6.27	0.38	1.75e-9	QRS duration;
SARC	cis	rs7084402	0.967	rs1649033	chr10:60279634	T/C	cg07615347	chr10:60278583	BICC1	-0.6	-8.82	-0.5	2.78e-16	Refractive error;
SARC	cis	rs3733585	0.578	rs4466042	chr4:9955367	T/C	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.39	-0.33	1.73e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs854765	0.594	rs8066560	chr17:17728043	A/G	cg04398451	chr17:18023971	MYO15A	0.41	5.88	0.36	1.42e-8	Total body bone mineral density;
SARC	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg19680485	chr15:31195859	MTMR15	-0.53	-6.08	-0.37	4.89e-9	Huntington's disease progression;
SARC	cis	rs1050631	1.000	rs1785914	chr18:33700796	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	-0.45	-5.42	-0.33	1.45e-7	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs4951018	0.821	rs7529037	chr1:205637501	C/G	cg14893161	chr1:205819251	PM20D1	-0.41	-5.32	-0.33	2.49e-7	Prostate-specific antigen levels;
SARC	cis	rs9916302	0.706	rs9906612	chr17:37547631	A/C	cg07936489	chr17:37558343	FBXL20	0.77	9.13	0.51	3.36e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs16854884	0.657	rs7610378	chr3:143711298	G/A	cg06585982	chr3:143692056	C3orf58	0.68	9.21	0.52	1.9e-17	Economic and political preferences (feminism/equality);
SARC	cis	rs9398803	0.835	rs4897182	chr6:126755642	A/C	cg19875578	chr6:126661172	C6orf173	0.59	7.97	0.46	7.1e-14	Male-pattern baldness;
SARC	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg03433033	chr1:76189801	ACADM	0.48	6.15	0.37	3.28e-9	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6964587	0.867	rs12704637	chr7:91874686	C/T	cg17063962	chr7:91808500	NA	0.92	13.89	0.67	2.38e-32	Breast cancer;
SARC	cis	rs36051895	0.695	rs10974915	chr9:5016818	A/G	cg02405213	chr9:5042618	JAK2	-0.49	-5.8	-0.36	2.11e-8	Pediatric autoimmune diseases;
SARC	cis	rs11098499	0.874	rs13123591	chr4:120105990	T/G	cg09307838	chr4:120376055	NA	0.82	11.06	0.59	3.96e-23	Corneal astigmatism;
SARC	cis	rs17270561	0.609	rs9379783	chr6:25725207	C/T	cg16482183	chr6:26056742	HIST1H1C	0.41	4.89	0.31	1.87e-6	Iron status biomarkers;
SARC	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs713477	0.967	rs12431542	chr14:55913078	T/C	cg13175173	chr14:55914753	NA	-0.3	-4.72	-0.3	3.99e-6	Pediatric bone mineral content (femoral neck);
SARC	cis	rs9467773	0.967	rs9358954	chr6:26531178	A/G	cg12292205	chr6:26970375	C6orf41	0.45	5.43	0.34	1.41e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9902453	0.967	rs4294864	chr17:28440138	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	6.5	0.39	4.8e-10	Coffee consumption (cups per day);
SARC	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg07636037	chr3:49044803	WDR6	1.0	17.53	0.75	1.89e-44	Parkinson's disease;
SARC	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.56	6.75	0.4	1.15e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg05465498	chr17:4871300	CAMTA2;SPAG7	0.5	6.4	0.39	8.49e-10	Lung adenocarcinoma;
SARC	cis	rs6696846	0.729	rs72757512	chr1:205079203	G/A	cg07972983	chr1:205091412	RBBP5	0.58	7.53	0.44	1.14e-12	Red blood cell count;
SARC	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg05368731	chr17:41323189	NBR1	0.68	7.94	0.46	8.46e-14	Menopause (age at onset);
SARC	cis	rs6088590	0.813	rs1884668	chr20:33285514	A/G	cg24642439	chr20:33292090	TP53INP2	0.75	10.14	0.55	2.93e-20	Coronary artery disease;
SARC	cis	rs523522	0.962	rs10849757	chr12:120964014	G/A	cg27279351	chr12:120934652	DYNLL1	0.73	9.05	0.51	5.73e-17	High light scatter reticulocyte count;
SARC	cis	rs1568889	0.838	rs7131379	chr11:28085789	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.87	14.89	0.7	1.06e-35	Bipolar disorder;
SARC	cis	rs11190604	1.000	rs4244338	chr10:102272802	A/G	cg07080220	chr10:102295463	HIF1AN	0.77	9.1	0.51	4.22e-17	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs3815700	1.000	rs8109885	chr19:33095557	A/G	cg02997394	chr19:33096574	ANKRD27	0.79	8.19	0.47	1.69e-14	Eosinophilic esophagitis;
SARC	cis	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg25894440	chr7:65020034	NA	-0.73	-5.55	-0.34	7.84e-8	Diabetic kidney disease;
SARC	cis	rs11097912	0.632	rs6816698	chr4:107225541	A/G	cg09646026	chr4:107269030	AIMP1	-0.45	-4.86	-0.3	2.14e-6	Airflow obstruction;
SARC	cis	rs193541	0.632	rs10037044	chr5:122123299	A/G	cg19412675	chr5:122181750	SNX24	-0.5	-6.57	-0.4	3.28e-10	Glucose homeostasis traits;
SARC	cis	rs2180341	1.000	rs9398837	chr6:127635217	G/A	cg17762328	chr6:126965162	NA	-0.46	-5.29	-0.33	2.88e-7	Breast cancer;
SARC	cis	rs1144333	0.826	rs1146645	chr1:76265056	T/C	cg03433033	chr1:76189801	ACADM	-0.58	-4.75	-0.3	3.54e-6	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg22535103	chr8:58192502	C8orf71	-0.59	-6.06	-0.37	5.57e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4689388	0.926	rs9998519	chr4:6292909	C/T	cg00701064	chr4:6280414	WFS1	0.54	8.61	0.49	1.14e-15	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs8038465	0.662	rs57771618	chr15:73967578	T/C	cg15420318	chr15:73925796	NPTN	0.48	5.51	0.34	9.47e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg25072359	chr17:41440525	NA	-0.48	-5.83	-0.36	1.85e-8	Menopause (age at onset);
SARC	cis	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg03060546	chr3:49711283	APEH	-0.65	-8.12	-0.47	2.71e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg00071950	chr4:10020882	SLC2A9	0.39	6.31	0.38	1.4e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs3126085	0.935	rs1858480	chr1:152301735	A/G	cg26876637	chr1:152193138	HRNR	-0.48	-5.56	-0.34	7.35e-8	Atopic dermatitis;
SARC	cis	rs1008375	0.932	rs11934968	chr4:17667766	A/G	cg27347728	chr4:17578864	LAP3	0.46	5.62	0.35	5.33e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7208859	0.673	rs7211776	chr17:29120196	T/G	cg13385521	chr17:29058706	SUZ12P	0.83	7.55	0.44	9.72e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs6840360	0.615	rs72728173	chr4:152469373	C/T	cg22705602	chr4:152727874	NA	-0.42	-6.55	-0.39	3.67e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7216064	1.000	rs8072225	chr17:65912960	A/G	cg12091567	chr17:66097778	LOC651250	-0.74	-8.23	-0.47	1.32e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	trans	rs61931739	0.500	rs11053260	chr12:34530215	T/G	cg13010199	chr12:38710504	ALG10B	0.78	11.07	0.59	3.76e-23	Morning vs. evening chronotype;
SARC	cis	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg11246071	chr9:23826065	ELAVL2	-0.44	-6.25	-0.38	1.92e-9	Neuroticism;
SARC	cis	rs5753618	0.529	rs5749298	chr22:31941032	C/T	cg02404636	chr22:31891804	SFI1	0.54	5.98	0.37	8.13e-9	Colorectal cancer;
SARC	cis	rs4727027	0.933	rs1058059	chr7:148879134	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.48	5.81	0.36	2e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	5.48	0.34	1.07e-7	Personality dimensions;
SARC	cis	rs9611565	0.921	rs2235846	chr22:41741042	G/C	cg17376030	chr22:41985996	PMM1	0.52	6.66	0.4	1.99e-10	Vitiligo;
SARC	cis	rs6831352	0.704	rs1800759	chr4:100065509	T/G	cg12011299	chr4:100065546	ADH4	0.38	7.07	0.42	1.83e-11	Alcohol dependence;
SARC	cis	rs3540	0.618	rs11636089	chr15:91039527	C/T	cg22089800	chr15:90895588	ZNF774	0.62	8.04	0.47	4.39e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs798554	0.704	rs709282	chr7:2769921	G/A	cg04166393	chr7:2884313	GNA12	0.46	5.65	0.35	4.67e-8	Height;
SARC	cis	rs7208859	0.623	rs9911997	chr17:29124648	A/G	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs6952808	0.929	rs4721217	chr7:1973579	C/T	cg21782813	chr7:2030301	MAD1L1	0.41	6.33	0.38	1.21e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs3733346	0.529	rs6842493	chr4:914638	T/C	cg23939001	chr4:940644	TMEM175	0.5	7.63	0.45	5.86e-13	Sjögren's syndrome;
SARC	cis	rs5762813	0.560	rs5762823	chr22:29220758	C/G	cg02153584	chr22:29168773	CCDC117	0.65	6.65	0.4	2.02e-10	Hematocrit;Hemoglobin concentration;
SARC	trans	rs9929218	0.861	rs8056206	chr16:68802072	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.53	-6.72	-0.4	1.41e-10	Colorectal cancer;
SARC	cis	rs6570726	0.935	rs380883	chr6:145822992	A/G	cg23711669	chr6:146136114	FBXO30	0.78	11.41	0.6	3e-24	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs72781680	0.581	rs116520786	chr2:24272645	C/T	cg08917208	chr2:24149416	ATAD2B	0.66	6.39	0.39	8.72e-10	Lymphocyte counts;
SARC	cis	rs12824058	0.831	rs12829373	chr12:130814114	G/C	cg24838063	chr12:130822603	PIWIL1	0.63	9.04	0.51	6.29e-17	Menopause (age at onset);
SARC	cis	rs10416265	0.516	rs1270252	chr19:33623604	G/A	cg17764715	chr19:33622953	WDR88	-0.45	-4.78	-0.3	3.11e-6	Bone properties (heel);
SARC	cis	rs2842992	0.747	rs4709378	chr6:160227435	G/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	7.56	0.44	9.24e-13	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs3091242	0.933	rs35403885	chr1:25784551	G/A	cg02931644	chr1:25747376	RHCE	-0.45	-7.45	-0.44	1.78e-12	Erythrocyte sedimentation rate;
SARC	cis	rs9840812	0.637	rs667920	chr3:136069472	G/T	cg15507776	chr3:136538369	TMEM22	0.53	5.83	0.36	1.84e-8	Fibrinogen levels;
SARC	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg08280861	chr8:58055591	NA	0.61	5.81	0.36	2.02e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg03060546	chr3:49711283	APEH	0.59	7.29	0.43	4.7e-12	Resting heart rate;
SARC	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg16049864	chr8:95962084	TP53INP1	-0.47	-7.69	-0.45	4.13e-13	Type 2 diabetes;
SARC	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg05863683	chr7:1912471	MAD1L1	0.34	4.98	0.31	1.25e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg18252515	chr7:66147081	NA	-1.33	-11.84	-0.61	1.22e-25	Diabetic kidney disease;
SARC	cis	rs13144136	0.664	rs4296670	chr4:10651160	C/T	cg10242279	chr4:10666415	CLNK	-0.41	-6.54	-0.39	3.81e-10	Resistance to antihypertensive treatment in hypertension;
SARC	cis	rs1790761	0.667	rs591434	chr11:67337814	C/T	cg00290607	chr11:67383545	NA	0.39	5.38	0.33	1.84e-7	Mean corpuscular volume;
SARC	cis	rs6424115	1.000	rs34477640	chr1:24154067	T/C	cg15997130	chr1:24165203	NA	-0.46	-6.21	-0.38	2.43e-9	Immature fraction of reticulocytes;
SARC	trans	rs7824557	0.564	rs2736301	chr8:11236413	C/T	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.72	-0.5	5.49e-16	Retinal vascular caliber;
SARC	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg13770153	chr20:60521292	NA	-0.45	-6.31	-0.38	1.39e-9	Body mass index;
SARC	cis	rs34172651	0.917	rs11074651	chr16:24778409	A/G	cg06028605	chr16:24865363	SLC5A11	0.26	4.75	0.3	3.52e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg15448220	chr1:150897856	SETDB1	0.46	6.02	0.37	6.8e-9	Melanoma;
SARC	cis	rs2070677	0.935	rs12242613	chr10:135419831	C/T	cg20169779	chr10:135381914	SYCE1	-0.52	-6.46	-0.39	6e-10	Gout;
SARC	cis	rs17376456	0.877	rs13170509	chr5:93378564	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.63	5.7	0.35	3.55e-8	Diabetic retinopathy;
SARC	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg23758822	chr17:41437982	NA	0.92	11.65	0.61	5.02e-25	Menopause (age at onset);
SARC	cis	rs6088580	0.634	rs6059850	chr20:33044784	C/G	cg08999081	chr20:33150536	PIGU	0.44	6.63	0.4	2.28e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs6604026	0.656	rs7550347	chr1:93401157	G/C	cg17283838	chr1:93427260	FAM69A	0.41	4.77	0.3	3.25e-6	Multiple sclerosis;
SARC	cis	rs6060717	0.536	rs8125393	chr20:34496162	G/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	4.92	0.31	1.62e-6	Hip circumference adjusted for BMI;
SARC	cis	rs8017423	0.967	rs12589808	chr14:90719236	C/T	cg20276874	chr14:90721474	PSMC1	0.36	4.95	0.31	1.45e-6	Mortality in heart failure;
SARC	cis	rs599083	0.793	rs471966	chr11:68173861	C/T	cg24974729	chr11:67764320	UNC93B1	-0.32	-4.74	-0.3	3.69e-6	Bone mineral density (spine);
SARC	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg03185022	chr7:2884158	GNA12	0.44	4.74	0.3	3.77e-6	Height;
SARC	cis	rs941408	1.000	rs2260416	chr19:2796355	G/A	cg00079169	chr19:2811669	THOP1	0.49	5.32	0.33	2.44e-7	Total cholesterol levels;
SARC	cis	rs7223966	1.000	rs9747164	chr17:61864787	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.52	-5.24	-0.32	3.64e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs12956009	0.518	rs10164267	chr18:44820032	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.55	-7.21	-0.43	7.55e-12	Educational attainment (years of education);
SARC	cis	rs526231	0.543	rs3776863	chr5:102327869	G/C	cg23492399	chr5:102201601	PAM	-0.52	-6.36	-0.38	1.03e-9	Primary biliary cholangitis;
SARC	cis	rs9457247	0.967	rs86755	chr6:167403108	T/C	cg23791538	chr6:167370224	RNASET2	-0.63	-8.73	-0.5	4.84e-16	Crohn's disease;
SARC	cis	rs7819412	0.691	rs73198970	chr8:11040216	T/C	cg12395012	chr8:11607386	GATA4	0.28	4.87	0.3	2.09e-6	Triglycerides;
SARC	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg11890956	chr21:40555474	PSMG1	1.16	19.69	0.79	1.79e-51	Cognitive function;
SARC	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg11062466	chr8:58055876	NA	0.54	5.56	0.34	7.55e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs950776	0.518	rs11636131	chr15:78821606	C/T	cg17108064	chr15:78857060	CHRNA5	0.29	4.93	0.31	1.56e-6	Sudden cardiac arrest;
SARC	cis	rs73635312	0.850	rs76407406	chr10:8944052	A/G	cg24467326	chr10:9646929	NA	0.64	5.23	0.32	3.73e-7	Basal cell carcinoma;
SARC	cis	rs2204008	0.665	rs11179830	chr12:38220966	T/C	cg26384229	chr12:38710491	ALG10B	0.86	12.31	0.63	3.57e-27	Bladder cancer;
SARC	cis	rs7726839	0.561	rs72703044	chr5:579737	G/A	cg09021430	chr5:549028	NA	-0.48	-6.35	-0.38	1.12e-9	Obesity-related traits;
SARC	cis	rs3105593	0.547	rs3131559	chr15:50780214	C/A	cg05456662	chr15:50716270	USP8	0.42	5.1	0.32	7.18e-7	QT interval;
SARC	cis	rs11190604	1.000	rs2295780	chr10:102305965	A/G	cg07080220	chr10:102295463	HIF1AN	0.79	9.04	0.51	6.1e-17	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs1468333	0.930	rs2269954	chr5:137501003	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.74	9.39	0.52	5.69e-18	Resting heart rate;
SARC	cis	rs4689388	0.926	rs11725494	chr4:6293855	C/T	cg25554036	chr4:6271136	WFS1	0.42	7.01	0.42	2.49e-11	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs651907	0.535	rs13059470	chr3:101424800	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.54	-6.74	-0.4	1.25e-10	Colorectal cancer;
SARC	cis	rs929354	0.713	rs10085650	chr7:156993413	T/C	cg05182265	chr7:156933206	UBE3C	-0.33	-5.02	-0.31	1.03e-6	Body mass index;
SARC	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg14517863	chr17:44321492	NA	0.4	6.05	0.37	5.77e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs2120243	0.641	rs7639254	chr3:157141041	A/G	cg24825693	chr3:157122686	VEPH1	-0.49	-6.91	-0.41	4.58e-11	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs9393777	0.623	rs9358948	chr6:26483806	G/A	cg12826209	chr6:26865740	GUSBL1	0.81	7.39	0.44	2.59e-12	Intelligence (multi-trait analysis);
SARC	cis	rs7659604	1.000	rs35249024	chr4:122664538	C/A	cg19671926	chr4:122722719	EXOSC9	-0.49	-6.04	-0.37	5.99e-9	Type 2 diabetes;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg18987026	chr7:107297715	LOC286002	0.48	6.64	0.4	2.18e-10	Thyroid stimulating hormone;
SARC	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg26119090	chr2:26468346	HADHA;HADHB	0.95	13.96	0.67	1.32e-32	Gut microbiome composition (summer);
SARC	cis	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg02487422	chr3:49467188	NICN1	0.5	6.83	0.41	7.5e-11	Resting heart rate;
SARC	cis	rs2153535	0.541	rs9405386	chr6:8458067	C/G	cg07606381	chr6:8435919	SLC35B3	0.75	10.66	0.57	7.43e-22	Motion sickness;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg22754179	chr19:42901115	NA	-0.47	-6.27	-0.38	1.7e-9	Chemerin levels;
SARC	cis	rs76917914	0.820	rs2281732	chr9:100845007	A/G	cg03040243	chr9:100819229	NANS	0.67	7.22	0.43	7.29e-12	Immature fraction of reticulocytes;
SARC	cis	rs4268898	1.000	rs4268898	chr2:24490413	C/T	cg06627628	chr2:24431161	ITSN2	0.6	8.42	0.48	3.91e-15	Asthma;
SARC	cis	rs950776	0.518	rs12916999	chr15:78826912	C/T	cg17108064	chr15:78857060	CHRNA5	0.29	4.93	0.31	1.56e-6	Sudden cardiac arrest;
SARC	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg22105103	chr4:187893119	NA	0.45	5.9	0.36	1.26e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs933688	1.000	rs60513756	chr5:90727692	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.09	13.62	0.67	1.87e-31	Smoking behavior;
SARC	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs1814175	0.715	rs1722007	chr11:49897319	T/C	cg03929089	chr4:120376271	NA	-0.89	-14.63	-0.69	8.1e-35	Height;
SARC	cis	rs4889855	0.556	rs4278795	chr17:78533189	A/T	cg17956530	chr17:78667699	RPTOR	0.42	4.85	0.3	2.22e-6	Fractional excretion of uric acid;
SARC	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg00149659	chr3:10157352	C3orf10	0.71	6.68	0.4	1.75e-10	Alzheimer's disease;
SARC	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg18252515	chr7:66147081	NA	0.56	6.15	0.37	3.26e-9	Aortic root size;
SARC	cis	rs67460515	0.892	rs2054710	chr3:161090616	C/T	cg03342759	chr3:160939853	NMD3	-0.65	-8.06	-0.47	3.98e-14	Parkinson's disease;
SARC	cis	rs9868809	0.505	rs11706203	chr3:48746239	T/A	cg07636037	chr3:49044803	WDR6	-0.69	-6.55	-0.39	3.7e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	trans	rs6600671	0.967	rs11249349	chr1:121179169	G/C	cg00646200	chr1:148855367	NA	0.49	6.93	0.41	4.12e-11	Hip geometry;
SARC	cis	rs1707322	1.000	rs9803784	chr1:46401907	T/C	cg03146154	chr1:46216737	IPP	0.46	5.53	0.34	8.66e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs13144136	0.687	rs61796835	chr4:10656807	C/A	cg10242279	chr4:10666415	CLNK	-0.42	-6.88	-0.41	5.36e-11	Resistance to antihypertensive treatment in hypertension;
SARC	cis	rs7615952	0.515	rs4267608	chr3:125680500	C/T	cg05084668	chr3:125655381	ALG1L	-0.63	-6.45	-0.39	6.4e-10	Blood pressure (smoking interaction);
SARC	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg24675658	chr1:53192096	ZYG11B	-0.65	-9.49	-0.53	2.85e-18	Monocyte count;
SARC	cis	rs9549260	0.753	rs9549254	chr13:41234763	G/A	cg21288729	chr13:41239152	FOXO1	0.6	6.18	0.38	2.78e-9	Red blood cell count;
SARC	cis	rs2769264	0.649	rs9436029	chr1:151367378	C/T	cg18801370	chr1:151430492	POGZ	-0.76	-5.03	-0.31	9.83e-7	Blood trace element (Cu levels);
SARC	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg24829409	chr8:58192753	C8orf71	-0.65	-6.19	-0.38	2.73e-9	Developmental language disorder (linguistic errors);
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27498304	chr1:28415137	EYA3	-0.51	-6.34	-0.38	1.2e-9	Smoking initiation;
SARC	cis	rs8180040	0.764	rs11716539	chr3:47186503	G/T	cg27129171	chr3:47204927	SETD2	0.68	9.67	0.54	7.94e-19	Colorectal cancer;
SARC	cis	rs9326248	0.954	rs10790177	chr11:117048417	A/G	cg10130564	chr11:117069849	TAGLN	0.24	5.08	0.32	7.74e-7	Blood protein levels;
SARC	cis	rs3858526	0.959	rs61876224	chr11:5952859	G/A	cg05234568	chr11:5960015	NA	-0.42	-4.99	-0.31	1.2e-6	DNA methylation (variation);
SARC	cis	rs35213789	0.887	rs2851488	chr7:69146789	A/T	cg10619644	chr7:69149951	AUTS2	0.43	5.85	0.36	1.68e-8	Childhood ear infection;
SARC	cis	rs17376456	0.825	rs17374166	chr5:93238655	T/C	cg21475434	chr5:93447410	FAM172A	0.83	7.35	0.43	3.37e-12	Diabetic retinopathy;
SARC	cis	rs57994353	0.897	rs66477686	chr9:139372224	T/C	cg14169450	chr9:139327907	INPP5E	0.4	5.05	0.31	8.82e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs6456156	0.586	rs7761977	chr6:167485678	A/G	cg23791538	chr6:167370224	RNASET2	-0.53	-6.99	-0.42	2.86e-11	Primary biliary cholangitis;
SARC	cis	rs2033711	0.654	rs734380	chr19:58898963	A/C	cg12042659	chr19:58951599	ZNF132	0.42	5.47	0.34	1.16e-7	Uric acid clearance;
SARC	cis	rs995000	0.929	rs2029763	chr1:63013134	A/G	cg06896770	chr1:63153194	DOCK7	1.0	15.5	0.71	1.02e-37	Triglyceride levels;
SARC	cis	rs7005606	0.870	rs2466076	chr8:32432796	G/T	cg14488905	chr8:32406789	NRG1	-0.44	-6.05	-0.37	5.87e-9	Hirschsprung disease;
SARC	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg20887711	chr4:1340912	KIAA1530	0.4	4.78	0.3	3.07e-6	Longevity;
SARC	cis	rs7429990	0.965	rs2631721	chr3:47923297	G/T	cg11946769	chr3:48343235	NME6	0.45	5.16	0.32	5.26e-7	Educational attainment (years of education);
SARC	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg18876405	chr7:65276391	NA	0.74	9.42	0.53	4.63e-18	Aortic root size;
SARC	cis	rs1008375	0.902	rs7654332	chr4:17691778	A/T	cg16339924	chr4:17578868	LAP3	0.56	7.03	0.42	2.24e-11	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg03650068	chr1:25596491	NA	0.33	5.1	0.32	6.99e-7	Erythrocyte sedimentation rate;
SARC	cis	rs2242194	0.816	rs6671688	chr1:154994265	T/C	cg09359103	chr1:154839909	KCNN3	-0.33	-5.28	-0.33	3e-7	Schizophrenia;
SARC	cis	rs9467773	1.000	rs9461271	chr6:26554968	G/A	cg12292205	chr6:26970375	C6orf41	0.46	5.51	0.34	9.65e-8	Intelligence (multi-trait analysis);
SARC	cis	rs365132	1.000	rs353468	chr5:176445494	A/T	cg16309518	chr5:176445507	NA	-0.46	-5.89	-0.36	1.32e-8	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg23982607	chr1:1823379	GNB1	-0.65	-11.07	-0.59	3.61e-23	Body mass index;
SARC	cis	rs12153160	1.000	rs12520758	chr5:152956017	A/G	cg16532600	chr5:153857824	HAND1	0.51	4.8	0.3	2.85e-6	Middle childhood and early adolescence aggressive behavior;
SARC	cis	rs765787	0.530	rs12915027	chr15:45512626	G/A	cg26924012	chr15:45694286	SPATA5L1	0.43	5.23	0.32	3.86e-7	Uric acid levels;
SARC	cis	rs7666738	0.715	rs3857216	chr4:99032129	G/T	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg03709012	chr19:19516395	GATAD2A	1.01	17.59	0.76	1.21e-44	Tonsillectomy;
SARC	cis	rs10958369	0.613	rs7829521	chr8:54433888	C/T	cg12485204	chr8:54507357	NA	0.45	6.4	0.39	8.66e-10	Response to antineoplastic agents;
SARC	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg08859206	chr1:53392774	SCP2	0.39	5.68	0.35	3.99e-8	Monocyte count;
SARC	cis	rs7223966	1.000	rs11079511	chr17:61858537	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	7.54	0.44	1.07e-12	Hip circumference adjusted for BMI;Body mass index;
SARC	trans	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-10.55	-0.57	1.63e-21	Intelligence (multi-trait analysis);
SARC	cis	rs950169	1.000	rs11638297	chr15:84782417	A/C	cg24253500	chr15:84953950	NA	0.36	5.31	0.33	2.52e-7	Schizophrenia;
SARC	cis	rs78545713	0.502	rs57145038	chr6:26311510	A/C	cg00631329	chr6:26305371	NA	-0.67	-6.66	-0.4	1.96e-10	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs12579753	0.879	rs12829053	chr12:82161926	T/A	cg07988820	chr12:82153109	PPFIA2	-0.59	-7.04	-0.42	2.1e-11	Resting heart rate;
SARC	cis	rs765787	0.530	rs11636367	chr15:45535862	A/G	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.51e-10	Uric acid levels;
SARC	cis	rs2276314	1.000	rs4799832	chr18:33559646	T/C	cg05985134	chr18:33552581	C18orf21	0.71	7.71	0.45	3.59e-13	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs4713118	0.911	rs9295746	chr6:27730064	T/C	cg17221315	chr6:27791827	HIST1H4J	0.51	5.35	0.33	2.05e-7	Parkinson's disease;
SARC	trans	rs56279505	0.629	rs34774688	chr4:100274464	A/T	cg21156590	chr1:3420848	MEGF6	-0.83	-6.41	-0.39	8.04e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9392918	0.935	rs1885486	chr6:7695973	G/A	cg23089261	chr6:7723385	NA	0.37	4.79	0.3	2.93e-6	Height;
SARC	cis	rs950027	0.620	rs1049518	chr15:45653367	G/A	cg15395560	chr15:45543142	SLC28A2	-0.27	-5.21	-0.32	4.22e-7	Response to fenofibrate (adiponectin levels);
SARC	cis	rs6867032	0.695	rs3902820	chr5:2000330	T/A	cg26168224	chr5:2018326	NA	-0.71	-9.17	-0.52	2.5e-17	Gut microbiome composition (winter);
SARC	cis	rs2204008	0.774	rs11616004	chr12:38278822	G/A	cg26384229	chr12:38710491	ALG10B	0.91	13.64	0.67	1.61e-31	Bladder cancer;
SARC	cis	rs1044826	1.000	rs34742758	chr3:139218378	C/G	cg15131784	chr3:139108705	COPB2	0.47	5.32	0.33	2.4e-7	Obesity-related traits;
SARC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg11965913	chr1:205819406	PM20D1	-0.79	-12.92	-0.65	3.69e-29	Monocyte percentage of white cells;
SARC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.33	-5.0	-0.31	1.11e-6	Total body bone mineral density;
SARC	cis	rs372883	0.506	rs2832301	chr21:30749712	G/A	cg24692254	chr21:30365293	RNF160	0.55	6.91	0.41	4.66e-11	Pancreatic cancer;
SARC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg02018176	chr4:1364513	KIAA1530	-0.56	-8.42	-0.48	3.96e-15	Longevity;
SARC	cis	rs11143230	1.000	rs17628494	chr9:74889167	C/T	cg07476130	chr9:74525250	C9orf85;FAM108B1	-0.47	-5.06	-0.31	8.7e-7	Suicidal ideation;
SARC	cis	rs6815814	0.950	rs73236615	chr4:38786869	G/T	cg09316306	chr4:38807337	TLR1	0.48	4.96	0.31	1.35e-6	Breast cancer;
SARC	cis	rs7681440	0.606	rs2583976	chr4:90750173	T/C	cg06632027	chr4:90757378	SNCA	-0.42	-5.25	-0.33	3.35e-7	Dementia with Lewy bodies;
SARC	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg03433033	chr1:76189801	ACADM	-0.72	-11.92	-0.62	6.68e-26	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7927771	1.000	rs35624992	chr11:47615798	G/C	cg20307385	chr11:47447363	PSMC3	-0.51	-6.31	-0.38	1.37e-9	Subjective well-being;
SARC	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg03735888	chr19:58951602	ZNF132	0.42	5.46	0.34	1.19e-7	Uric acid clearance;
SARC	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg01341218	chr17:43662625	NA	-0.85	-9.63	-0.53	1.11e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs77956314	0.515	rs10850733	chr12:117380961	G/A	cg16111737	chr12:117408163	FBXW8	-0.5	-6.62	-0.4	2.42e-10	Subcortical brain region volumes;Hippocampal volume;
SARC	cis	rs12973672	1.000	rs28365136	chr19:35769561	T/G	cg12095397	chr19:35769544	USF2	0.38	4.79	0.3	2.9e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs7223966	0.960	rs7212379	chr17:61706122	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.53	-5.63	-0.35	5.03e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1801251	0.778	rs2250654	chr2:233752376	A/T	cg25237894	chr2:233734115	C2orf82	-0.35	-4.97	-0.31	1.31e-6	Coronary artery disease;
SARC	cis	rs10782582	0.609	rs1796810	chr1:76403305	C/T	cg03433033	chr1:76189801	ACADM	-0.42	-5.37	-0.33	1.94e-7	Daytime sleep phenotypes;
SARC	cis	rs9894429	0.646	rs7220310	chr17:79606056	C/A	cg18240062	chr17:79603768	NPLOC4	0.59	7.2	0.43	8.16e-12	Eye color traits;
SARC	cis	rs11190604	1.000	rs11190552	chr10:102206607	G/A	cg07080220	chr10:102295463	HIF1AN	0.78	9.58	0.53	1.56e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs4481887	0.927	rs6587444	chr1:248438452	C/T	cg01631408	chr1:248437212	OR2T33	0.48	5.45	0.34	1.27e-7	Common traits (Other);
SARC	cis	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg09021430	chr5:549028	NA	-0.44	-5.69	-0.35	3.85e-8	Obesity-related traits;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg23551132	chr14:32030686	NUBPL	-0.89	-7.69	-0.45	4.06e-13	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7792596	1.000	rs2027983	chr7:94004513	A/T	cg20814616	chr7:94014465	NA	-0.42	-5.25	-0.32	3.5e-7	Intelligence;
SARC	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg11062466	chr8:58055876	NA	0.69	6.08	0.37	4.94e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg24846343	chr22:24311635	DDTL	0.51	6.78	0.41	9.78e-11	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs12545109	0.800	rs2670026	chr8:57424338	G/T	cg09654669	chr8:57350985	NA	-0.4	-5.15	-0.32	5.61e-7	Obesity-related traits;
SARC	cis	rs4481887	0.893	rs4512685	chr1:248446246	C/T	cg01631408	chr1:248437212	OR2T33	-0.43	-5.4	-0.33	1.61e-7	Common traits (Other);
SARC	cis	rs765787	0.530	rs2433228	chr15:45515371	A/C	cg24006582	chr15:45444508	DUOX1	-0.49	-6.47	-0.39	5.7e-10	Uric acid levels;
SARC	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg20891558	chr2:74357851	NA	0.69	9.48	0.53	2.98e-18	Gestational age at birth (maternal effect);
SARC	cis	rs7216064	0.953	rs8073510	chr17:65839210	A/G	cg12091567	chr17:66097778	LOC651250	-0.69	-6.99	-0.42	2.89e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs2070677	0.799	rs11101854	chr10:135394430	G/A	cg20169779	chr10:135381914	SYCE1	-0.55	-6.67	-0.4	1.8e-10	Gout;
SARC	cis	rs1023500	0.505	rs134887	chr22:42674239	A/G	cg15557168	chr22:42548783	NA	-0.38	-5.42	-0.33	1.52e-7	Schizophrenia;
SARC	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.12	24.2	0.85	1.59e-65	Chronic sinus infection;
SARC	cis	rs274567	0.602	rs272853	chr5:131688561	A/G	cg24060327	chr5:131705240	SLC22A5	-0.7	-8.79	-0.5	3.43e-16	Blood metabolite levels;
SARC	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.5	-6.22	-0.38	2.27e-9	Lymphocyte counts;
SARC	cis	rs938554	0.744	rs7675964	chr4:9941434	C/T	cg25986240	chr4:9926439	SLC2A9	0.3	4.99	0.31	1.16e-6	Blood metabolite levels;
SARC	cis	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg08045932	chr20:61659980	NA	0.52	6.91	0.41	4.6e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs6542838	0.641	rs4850890	chr2:99535426	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.53	-6.98	-0.42	3.01e-11	Fear of minor pain;
SARC	cis	rs7119	0.717	rs11636412	chr15:77767291	C/T	cg17802220	chr15:77601643	NA	-0.43	-5.6	-0.34	5.92e-8	Type 2 diabetes;
SARC	cis	rs6733011	0.518	rs12992214	chr2:99466337	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.45	-5.67	-0.35	4.23e-8	Bipolar disorder;
SARC	cis	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg24110177	chr3:50126178	RBM5	-0.38	-4.87	-0.3	2.11e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9611519	1.000	rs5758264	chr22:41616284	T/G	cg17376030	chr22:41985996	PMM1	0.48	5.82	0.36	1.9e-8	Neuroticism;
SARC	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9910055	0.529	rs400460	chr17:42182770	A/G	cg19774624	chr17:42201019	HDAC5	0.55	6.79	0.41	9.01e-11	Total body bone mineral density;
SARC	cis	rs72945132	0.882	rs947812	chr11:70209169	C/T	cg00319359	chr11:70116639	PPFIA1	0.68	6.1	0.37	4.34e-9	Coronary artery disease;
SARC	cis	rs10791097	0.694	rs2155750	chr11:130751261	A/C	cg09137382	chr11:130731461	NA	0.32	4.99	0.31	1.18e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg24829409	chr8:58192753	C8orf71	-0.64	-5.95	-0.36	9.52e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1580019	0.844	rs1901202	chr7:32503724	A/T	cg14728415	chr7:32535168	LSM5;AVL9	0.46	5.57	0.34	6.97e-8	Cognitive ability;
SARC	cis	rs7599312	0.534	rs10182996	chr2:213404834	T/C	cg16329650	chr2:213403929	ERBB4	0.7	10.61	0.57	1.03e-21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	trans	rs208520	0.690	rs1318604	chr6:66825278	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-13.6	-0.67	2.17e-31	Exhaled nitric oxide output;
SARC	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg11062466	chr8:58055876	NA	0.65	5.83	0.36	1.79e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg03033257	chr22:50311977	ALG12;CRELD2	0.61	5.8	0.36	2.1e-8	Schizophrenia;
SARC	cis	rs12142240	0.698	rs67142569	chr1:46828460	C/T	cg10495392	chr1:46806563	NSUN4	0.64	6.83	0.41	7.39e-11	Menopause (age at onset);
SARC	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg16325326	chr1:53192061	ZYG11B	0.83	13.21	0.65	4.25e-30	Monocyte count;
SARC	cis	rs1448094	0.512	rs6539928	chr12:86244920	G/A	cg02569458	chr12:86230093	RASSF9	0.38	5.4	0.33	1.64e-7	Major depressive disorder;
SARC	cis	rs6772849	0.930	rs4857916	chr3:128376014	C/G	cg01163369	chr3:128370232	RPN1	-0.34	-4.94	-0.31	1.47e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs11098499	0.697	rs28458294	chr4:120238924	T/C	cg09307838	chr4:120376055	NA	0.84	11.54	0.6	1.15e-24	Corneal astigmatism;
SARC	cis	rs35110281	0.720	rs162393	chr21:44942692	G/A	cg01579765	chr21:45077557	HSF2BP	-0.35	-5.95	-0.36	9.67e-9	Mean corpuscular volume;
SARC	cis	rs9815354	0.767	rs111708447	chr3:41809583	G/A	cg03022575	chr3:42003672	ULK4	0.72	5.99	0.37	7.83e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs1144333	0.655	rs76612182	chr1:76451889	C/T	cg03433033	chr1:76189801	ACADM	0.57	4.74	0.3	3.65e-6	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg04267008	chr7:1944627	MAD1L1	-0.51	-5.86	-0.36	1.55e-8	Bipolar disorder and schizophrenia;
SARC	trans	rs61931739	0.929	rs1825358	chr12:34011895	C/T	cg26384229	chr12:38710491	ALG10B	-0.57	-7.17	-0.43	9.66e-12	Morning vs. evening chronotype;
SARC	cis	rs11719291	0.667	rs9877542	chr3:48748545	C/T	cg00383909	chr3:49044727	WDR6	0.63	5.94	0.36	1.02e-8	Cognitive function;
SARC	cis	rs2180341	0.521	rs12203812	chr6:127617816	A/T	cg27446573	chr6:127587934	RNF146	0.53	6.46	0.39	5.95e-10	Breast cancer;
SARC	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.61e-6	Depression;
SARC	cis	rs1044826	1.000	rs17336869	chr3:139194247	T/C	cg15131784	chr3:139108705	COPB2	0.45	5.19	0.32	4.69e-7	Obesity-related traits;
SARC	cis	rs11785400	0.963	rs6990126	chr8:143728387	T/C	cg24634471	chr8:143751801	JRK	0.67	8.92	0.5	1.42e-16	Schizophrenia;
SARC	cis	rs11792861	0.781	rs11789252	chr9:111762010	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.73	8.54	0.49	1.78e-15	Menarche (age at onset);
SARC	cis	rs11676348	0.774	rs13397673	chr2:219047782	A/G	cg00012203	chr2:219082015	ARPC2	-0.42	-5.5	-0.34	9.94e-8	Ulcerative colitis;
SARC	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg17221315	chr6:27791827	HIST1H4J	0.45	4.75	0.3	3.57e-6	Depression;
SARC	trans	rs11098499	0.954	rs10031483	chr4:120422636	T/C	cg25214090	chr10:38739885	LOC399744	0.58	7.47	0.44	1.63e-12	Corneal astigmatism;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg03762505	chr1:171750926	METTL13	-0.56	-6.29	-0.38	1.6e-9	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs9341808	0.935	rs9448894	chr6:80837253	G/T	cg08355045	chr6:80787529	NA	0.36	5.91	0.36	1.19e-8	Sitting height ratio;
SARC	cis	rs9487051	0.676	rs6925716	chr6:109597641	T/C	cg01475377	chr6:109611718	NA	-0.35	-5.08	-0.32	7.8e-7	Reticulocyte fraction of red cells;
SARC	cis	rs637571	0.522	rs503524	chr11:65751764	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.86	13.0	0.65	2.06e-29	Eosinophil percentage of white cells;
SARC	trans	rs7615952	0.673	rs35001498	chr3:125628644	A/G	cg07211511	chr3:129823064	LOC729375	-0.84	-7.72	-0.45	3.42e-13	Blood pressure (smoking interaction);
SARC	cis	rs67311347	0.544	rs4974047	chr3:40339653	G/T	cg09455208	chr3:40491958	NA	0.3	4.99	0.31	1.17e-6	Renal cell carcinoma;
SARC	cis	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg15556689	chr8:8085844	FLJ10661	-0.41	-4.96	-0.31	1.35e-6	Mood instability;
SARC	cis	rs4481887	0.830	rs4474289	chr1:248474972	T/A	cg00666640	chr1:248458726	OR2T12	0.36	5.91	0.36	1.21e-8	Common traits (Other);
SARC	cis	rs9435341	0.762	rs72697623	chr1:107554269	G/A	cg09367891	chr1:107599246	PRMT6	0.69	7.92	0.46	9.8e-14	Facial morphology (factor 21, depth of nasal alae);
SARC	cis	rs11997175	0.583	rs7464599	chr8:33817572	G/A	ch.8.33884649F	chr8:33765107	NA	0.48	6.09	0.37	4.6e-9	Body mass index;
SARC	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg11062466	chr8:58055876	NA	0.7	6.11	0.37	4.13e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs12762955	0.519	rs7094331	chr10:1022816	T/C	cg18964960	chr10:1102726	WDR37	-0.49	-5.66	-0.35	4.48e-8	Response to angiotensin II receptor blocker therapy;
SARC	trans	rs7927370	0.702	rs61894903	chr11:55042468	G/C	cg07162727	chr16:4848039	ROGDI	0.8	6.25	0.38	1.98e-9	Systemic lupus erythematosus;
SARC	cis	rs208515	0.525	rs10944863	chr6:66676238	C/T	cg07460842	chr6:66804631	NA	0.86	9.87	0.54	2.02e-19	Exhaled nitric oxide levels;
SARC	trans	rs7824557	0.679	rs10110008	chr8:11133736	G/T	cg06636001	chr8:8085503	FLJ10661	-0.62	-7.61	-0.45	6.6e-13	Retinal vascular caliber;
SARC	cis	rs778371	0.723	rs283470	chr2:233656918	G/A	cg20388707	chr2:233749442	NGEF	-0.38	-5.72	-0.35	3.29e-8	Schizophrenia;
SARC	cis	rs9790314	0.718	rs6774635	chr3:160847908	A/G	cg04691961	chr3:161091175	C3orf57	-0.68	-9.55	-0.53	1.9e-18	Morning vs. evening chronotype;
SARC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.62	-6.59	-0.4	2.82e-10	Platelet count;
SARC	cis	rs4727027	0.866	rs10435245	chr7:148816081	C/G	cg23583168	chr7:148888333	NA	-0.75	-10.83	-0.58	2.11e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.39	5.34	0.33	2.25e-7	Personality dimensions;
SARC	cis	rs12142240	0.730	rs56030283	chr1:46823093	C/G	cg10495392	chr1:46806563	NSUN4	0.65	6.8	0.41	8.89e-11	Menopause (age at onset);
SARC	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg26335602	chr6:28129616	ZNF389	0.47	5.37	0.33	1.88e-7	Cardiac Troponin-T levels;
SARC	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg19223190	chr17:80058835	NA	0.44	6.19	0.38	2.67e-9	Life satisfaction;
SARC	cis	rs9303280	0.806	rs9909593	chr17:37970149	C/T	cg19468946	chr17:37922297	IKZF3	0.31	5.16	0.32	5.27e-7	Self-reported allergy;
SARC	cis	rs3768617	0.510	rs3818417	chr1:183079376	G/A	cg13390022	chr1:182993471	LAMC1	0.32	4.88	0.3	1.95e-6	Fuchs's corneal dystrophy;
SARC	trans	rs61931739	0.534	rs10844774	chr12:34166764	C/T	cg26384229	chr12:38710491	ALG10B	0.85	12.35	0.63	2.69e-27	Morning vs. evening chronotype;
SARC	cis	rs9911578	0.867	rs4793941	chr17:56472366	G/A	cg12560992	chr17:57184187	TRIM37	-0.74	-9.55	-0.53	1.83e-18	Intelligence (multi-trait analysis);
SARC	cis	rs131777	0.575	rs963980	chr22:51022117	C/A	cg25309564	chr22:51001381	C22orf41	0.53	6.67	0.4	1.89e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs10754283	0.967	rs12058749	chr1:90105604	C/T	cg21401794	chr1:90099060	LRRC8C	0.55	7.56	0.44	9.3e-13	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs9916302	0.904	rs602282	chr17:37433021	C/T	cg15445000	chr17:37608096	MED1	0.42	5.16	0.32	5.18e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg11062466	chr8:58055876	NA	0.61	7.6	0.45	7.13e-13	Developmental language disorder (linguistic errors);
SARC	cis	rs288326	0.561	rs75139715	chr2:183890660	T/A	cg09997497	chr2:183902928	NCKAP1	0.74	5.1	0.32	6.97e-7	Blood protein levels;
SARC	cis	rs8067354	0.645	rs9899611	chr17:57832190	A/G	cg13753209	chr17:57696993	CLTC	0.67	7.22	0.43	7.37e-12	Hemoglobin concentration;
SARC	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg20607798	chr8:58055168	NA	0.68	5.8	0.36	2.17e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.59	5.52	0.34	9.05e-8	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs7818345	0.967	rs6990357	chr8:19276681	C/G	cg11303988	chr8:19266685	CSGALNACT1	0.43	5.73	0.35	3.14e-8	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs1218582	0.741	rs705094	chr1:154917314	G/A	cg06221963	chr1:154839813	KCNN3	-0.48	-7.52	-0.44	1.14e-12	Prostate cancer;
SARC	cis	rs9303401	1.000	rs1390006	chr17:56890663	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.69	-8.19	-0.47	1.74e-14	Cognitive test performance;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg27587223	chr3:113822217	NA	-0.46	-6.32	-0.38	1.29e-9	Height;
SARC	cis	rs1008375	0.932	rs10009933	chr4:17670107	A/C	cg27347728	chr4:17578864	LAP3	0.46	5.68	0.35	3.9e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs854765	0.547	rs28537385	chr17:17902135	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.66	9.52	0.53	2.38e-18	Total body bone mineral density;
SARC	cis	rs9788682	1.000	rs35212593	chr15:78831826	G/A	cg06917634	chr15:78832804	PSMA4	-0.58	-6.51	-0.39	4.48e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs9457247	0.663	rs9457257	chr6:167440736	G/A	cg07741184	chr6:167504864	NA	0.37	7.22	0.43	7.5e-12	Crohn's disease;
SARC	cis	rs875971	0.545	rs73376394	chr7:65637681	C/T	cg11764359	chr7:65958608	NA	0.61	6.11	0.37	4.21e-9	Aortic root size;
SARC	cis	rs13161895	1.000	rs17079968	chr5:179443423	C/T	cg06664874	chr5:179499304	RNF130	0.49	4.86	0.3	2.11e-6	LDL cholesterol;
SARC	cis	rs11579220	1	rs11579220	chr1:205144363	G/T	cg00857998	chr1:205179979	DSTYK	0.51	6.24	0.38	2.04e-9	White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs10979	1.000	rs1416205	chr6:143889397	T/C	cg25407410	chr6:143891975	LOC285740	-0.64	-8.68	-0.49	6.88e-16	Hypospadias;
SARC	cis	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg07636037	chr3:49044803	WDR6	0.63	8.4	0.48	4.49e-15	Resting heart rate;
SARC	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg26874164	chr19:58962979	ZNF324B	0.88	11.71	0.61	3.24e-25	Mean platelet volume;
SARC	cis	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg08045932	chr20:61659980	NA	0.5	6.84	0.41	7.06e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs2204008	0.744	rs11514073	chr12:38399553	A/C	cg26384229	chr12:38710491	ALG10B	0.88	12.36	0.63	2.48e-27	Bladder cancer;
SARC	cis	rs2204008	0.652	rs11520002	chr12:38022179	G/T	cg13010199	chr12:38710504	ALG10B	0.78	10.69	0.57	5.8e-22	Bladder cancer;
SARC	cis	rs7709909	0.755	rs2035256	chr5:79996632	A/G	cg04186980	chr5:79953697	MSH3	0.36	4.79	0.3	2.99e-6	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
SARC	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg05313129	chr8:58192883	C8orf71	-0.51	-4.81	-0.3	2.65e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs7089973	0.604	rs11196929	chr10:116582080	G/C	cg03647239	chr10:116582469	FAM160B1	0.5	6.29	0.38	1.55e-9	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs4713118	0.513	rs149897	chr6:28006650	A/G	cg26335602	chr6:28129616	ZNF389	0.45	5.25	0.33	3.39e-7	Parkinson's disease;
SARC	cis	rs11225247	0.772	rs11501344	chr11:102228252	A/G	cg11690896	chr11:102217788	BIRC2	0.72	5.19	0.32	4.65e-7	Vein graft stenosis in coronary artery bypass grafting;
SARC	cis	rs2380220	0.872	rs66723559	chr6:95956338	T/C	cg23517279	chr6:96025343	MANEA	-0.54	-5.39	-0.33	1.76e-7	Behavioural disinhibition (generation interaction);
SARC	cis	rs7551222	0.721	rs4252717	chr1:204512100	T/C	cg20240347	chr1:204465584	NA	-0.34	-5.98	-0.36	8.35e-9	Schizophrenia;
SARC	cis	rs9398803	0.698	rs1262553	chr6:127078785	T/C	cg20229609	chr6:126660872	C6orf173	-0.34	-4.79	-0.3	3.02e-6	Male-pattern baldness;
SARC	cis	rs7216064	1.000	rs4271626	chr17:65930133	G/A	cg12091567	chr17:66097778	LOC651250	-0.7	-7.28	-0.43	4.96e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg14773178	chr5:1868261	NA	0.3	4.76	0.3	3.45e-6	Cardiovascular disease risk factors;
SARC	cis	rs12579753	1.000	rs2401004	chr12:82214822	T/C	cg07988820	chr12:82153109	PPFIA2	-0.54	-6.07	-0.37	5.24e-9	Resting heart rate;
SARC	cis	rs644799	1.000	rs3748256	chr11:95521953	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.7	9.61	0.53	1.25e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs6582630	0.519	rs12582285	chr12:38298753	C/T	cg26384229	chr12:38710491	ALG10B	0.85	12.48	0.63	1.01e-27	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.43	6.46	0.39	5.89e-10	Schizophrenia;
SARC	cis	rs3820928	0.605	rs7560867	chr2:227780945	C/A	cg05526886	chr2:227700861	RHBDD1	-0.5	-6.18	-0.38	2.79e-9	Pulmonary function;
SARC	cis	rs7551222	0.663	rs1563828	chr1:204516577	A/G	cg07972458	chr1:204535000	NA	0.35	4.72	0.3	4.14e-6	Schizophrenia;
SARC	cis	rs9733	0.650	rs11204680	chr1:150587140	T/G	cg17724175	chr1:150552817	MCL1	-0.39	-5.07	-0.32	8.05e-7	Tonsillectomy;
SARC	cis	rs9902453	0.845	rs3115099	chr17:28019293	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	7.08	0.42	1.73e-11	Coffee consumption (cups per day);
SARC	cis	rs79839061	0.610	rs11732965	chr4:869359	C/A	cg07828340	chr4:882639	GAK	0.77	5.84	0.36	1.75e-8	Intelligence (multi-trait analysis);
SARC	cis	rs992157	0.687	rs10206984	chr2:219066980	C/T	cg00012203	chr2:219082015	ARPC2	0.84	13.95	0.67	1.51e-32	Colorectal cancer;
SARC	cis	rs45430	0.928	rs398206	chr21:42742036	C/A	cg06102954	chr21:42741788	MX2	0.38	5.17	0.32	4.97e-7	Melanoma;
SARC	cis	rs9818758	0.556	rs13086240	chr3:49001409	G/A	cg07636037	chr3:49044803	WDR6	-0.74	-6.49	-0.39	5.12e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg02725872	chr8:58115012	NA	-0.37	-6.28	-0.38	1.66e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9309473	1.000	rs6705489	chr2:73648811	G/T	cg20560298	chr2:73613845	ALMS1	-0.47	-5.78	-0.35	2.34e-8	Metabolite levels;
SARC	cis	rs1355223	0.583	rs2915178	chr11:34878051	C/T	cg18508148	chr11:34937573	PDHX;APIP	0.5	6.26	0.38	1.82e-9	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg21724239	chr8:58056113	NA	0.62	5.81	0.36	2.09e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1707322	1.000	rs6429588	chr1:46454058	T/G	cg03146154	chr1:46216737	IPP	0.46	5.59	0.34	6.25e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs870825	0.860	rs2705895	chr4:185598404	C/T	cg04058563	chr4:185651563	MLF1IP	-0.72	-9.09	-0.51	4.54e-17	Blood protein levels;
SARC	cis	rs13161895	1.000	rs4389651	chr5:179460968	T/A	cg06664874	chr5:179499304	RNF130	0.5	4.85	0.3	2.26e-6	LDL cholesterol;
SARC	trans	rs2736345	0.788	rs13277113	chr8:11349186	G/A	cg06636001	chr8:8085503	FLJ10661	0.56	6.27	0.38	1.76e-9	Sjögren's syndrome;Systemic lupus erythematosus;
SARC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg11494091	chr17:61959527	GH2	0.45	6.6	0.4	2.81e-10	Prudent dietary pattern;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg19774488	chr17:6554971	C17orf100;MED31	0.48	6.38	0.39	9.56e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs7949030	0.653	rs2516634	chr11:62367186	G/A	cg02375832	chr11:62437615	C11orf48	0.3	4.82	0.3	2.56e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs265548	0.646	rs36692	chr19:17906839	C/T	cg21960279	chr19:17905606	B3GNT3	0.35	4.78	0.3	3.11e-6	Tumor biomarkers;
SARC	cis	rs1150668	0.796	rs2247002	chr6:28397951	G/C	cg13525197	chr6:28411240	ZSCAN23	-0.43	-5.25	-0.33	3.44e-7	Pubertal anthropometrics;
SARC	cis	rs6546550	0.901	rs10496174	chr2:70153436	T/G	cg02498382	chr2:70120550	SNRNP27	-0.33	-5.41	-0.33	1.56e-7	Prevalent atrial fibrillation;
SARC	cis	rs751728	0.664	rs2296744	chr6:33740382	G/A	cg25922239	chr6:33757077	LEMD2	0.6	7.7	0.45	3.97e-13	Crohn's disease;
SARC	cis	rs8114671	0.967	rs6142324	chr20:33789043	C/T	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.45	-0.34	1.28e-7	Height;
SARC	cis	rs7937682	0.575	rs7114617	chr11:111768173	A/T	cg22437258	chr11:111473054	SIK2	-0.48	-5.54	-0.34	8.16e-8	Primary sclerosing cholangitis;
SARC	cis	rs1003719	0.586	rs2298685	chr21:38533390	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-9.48	-0.53	3.11e-18	Eye color traits;
SARC	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg02725872	chr8:58115012	NA	-0.36	-6.12	-0.37	3.91e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9815354	0.767	rs17280980	chr3:41810949	A/T	cg03022575	chr3:42003672	ULK4	0.72	5.99	0.37	7.83e-9	Pulse pressure;Diastolic blood pressure;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg04094633	chr10:60154907	TFAM	0.46	6.33	0.38	1.22e-9	Thyroid stimulating hormone;
SARC	cis	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg08045932	chr20:61659980	NA	0.5	6.84	0.41	7.06e-11	Prostate cancer (SNP x SNP interaction);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg06775001	chr6:101325415	ASCC3	0.55	7.92	0.46	9.46e-14	Thyroid stimulating hormone;
SARC	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg05368731	chr17:41323189	NBR1	-0.72	-8.78	-0.5	3.64e-16	Menopause (age at onset);
SARC	cis	rs13166103	0.657	rs17709263	chr5:57700479	A/C	cg10487770	chr5:57879443	RAB3C	-0.52	-5.71	-0.35	3.44e-8	Type 2 diabetes (age of onset);
SARC	cis	rs1448094	0.512	rs7313035	chr12:86250100	C/G	cg02569458	chr12:86230093	RASSF9	0.37	5.15	0.32	5.54e-7	Major depressive disorder;
SARC	cis	rs2506889	0.553	rs11580264	chr1:10605796	C/A	cg17425144	chr1:10567563	PEX14	0.43	6.94	0.41	3.93e-11	Breast cancer;
SARC	trans	rs36093844	0.747	rs17817314	chr11:85594972	T/C	cg15359163	chr5:122429178	PRDM6	-0.54	-6.62	-0.4	2.4e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs9303401	0.659	rs12602808	chr17:56698420	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	12.63	0.64	3.28e-28	Cognitive test performance;
SARC	cis	rs13095912	1.000	rs35497918	chr3:185310312	C/T	cg11274856	chr3:185301563	NA	0.35	4.81	0.3	2.76e-6	Systolic blood pressure;
SARC	cis	rs899997	1.000	rs11072793	chr15:79006442	C/T	cg04896959	chr15:78267971	NA	0.51	6.08	0.37	4.81e-9	Coronary artery disease or large artery stroke;
SARC	trans	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.71	-0.4	1.48e-10	Triglycerides;
SARC	cis	rs425277	1.000	rs262657	chr1:2088577	G/A	cg24578937	chr1:2090814	PRKCZ	0.32	5.97	0.36	8.76e-9	Height;
SARC	cis	rs4803468	1.000	rs6508977	chr19:41909346	A/G	cg08477640	chr19:41863820	B9D2	0.48	6.12	0.37	3.89e-9	Height;
SARC	cis	rs17030434	0.784	rs6835960	chr4:154650460	G/A	cg14289246	chr4:154710475	SFRP2	-0.49	-5.61	-0.35	5.57e-8	Electrocardiographic conduction measures;
SARC	cis	rs9815354	1.000	rs6801343	chr3:41767234	C/T	cg03022575	chr3:42003672	ULK4	0.57	5.34	0.33	2.2e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs72781680	0.716	rs2551334	chr2:24000396	G/A	cg08917208	chr2:24149416	ATAD2B	0.6	6.13	0.37	3.65e-9	Lymphocyte counts;
SARC	cis	rs4481887	0.676	rs1538704	chr1:248523554	C/T	cg01631408	chr1:248437212	OR2T33	-0.34	-4.86	-0.3	2.17e-6	Common traits (Other);
SARC	trans	rs1994135	0.617	rs12821909	chr12:33723466	T/C	cg26384229	chr12:38710491	ALG10B	0.85	10.53	0.57	1.81e-21	Resting heart rate;
SARC	cis	rs67311347	1.000	rs897117	chr3:40437294	C/T	cg24209194	chr3:40518798	ZNF619	-0.62	-8.01	-0.46	5.35e-14	Renal cell carcinoma;
SARC	trans	rs9388451	0.626	rs3799712	chr6:126075103	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.63	-8.17	-0.47	1.96e-14	Brugada syndrome;
SARC	cis	rs3857536	0.813	rs6455083	chr6:66935406	T/C	cg07460842	chr6:66804631	NA	-0.51	-5.83	-0.36	1.86e-8	Blood trace element (Cu levels);
SARC	cis	rs2766692	0.788	rs2281892	chr14:100769938	G/A	cg14866419	chr14:100704911	YY1	0.51	5.73	0.35	3.13e-8	Electroencephalographic traits in alcoholism;
SARC	cis	rs8077889	0.703	rs231532	chr17:41945769	C/T	cg26893861	chr17:41843967	DUSP3	-0.69	-6.87	-0.41	5.92e-11	Triglycerides;
SARC	cis	rs79349575	0.721	rs4794004	chr17:47038471	C/T	cg16584676	chr17:46985605	UBE2Z	0.49	5.78	0.35	2.39e-8	Type 2 diabetes;
SARC	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg22484793	chr3:52261325	TLR9	0.29	4.8	0.3	2.81e-6	Bipolar disorder;
SARC	cis	rs2439831	0.867	rs3213991	chr15:43670280	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	8.32	0.48	7.2e-15	Lung cancer in ever smokers;
SARC	cis	rs10088262	0.591	rs13270541	chr8:124794849	G/A	cg20713898	chr8:124780851	FAM91A1	-0.64	-7.14	-0.42	1.16e-11	Pancreatic cancer;
SARC	cis	rs365132	1.000	rs7718874	chr5:176358065	A/G	cg16309518	chr5:176445507	NA	-0.46	-6.0	-0.37	7.33e-9	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs6696846	0.765	rs3738155	chr1:205074424	C/T	cg21643547	chr1:205240462	TMCC2	-0.57	-7.72	-0.45	3.47e-13	Red blood cell count;
SARC	cis	rs4803468	1.000	rs1473248	chr19:41923314	C/T	cg08477640	chr19:41863820	B9D2	-0.46	-5.89	-0.36	1.33e-8	Height;
SARC	trans	rs1814175	0.817	rs3974439	chr11:50022607	G/A	cg15704280	chr7:45808275	SEPT13	-0.97	-18.31	-0.77	5.28e-47	Height;
SARC	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg04277193	chr17:41438351	NA	0.46	4.98	0.31	1.23e-6	Menopause (age at onset);
SARC	cis	rs3106136	1.000	rs2664871	chr4:95146281	A/G	cg11021082	chr4:95130006	SMARCAD1	0.39	5.98	0.36	8.31e-9	Capecitabine sensitivity;
SARC	cis	rs9325144	0.560	rs11183150	chr12:38674698	A/G	cg26384229	chr12:38710491	ALG10B	-0.63	-8.11	-0.47	2.91e-14	Morning vs. evening chronotype;
SARC	trans	rs17685	0.753	rs9691174	chr7:75790405	T/C	cg19862616	chr7:65841803	NCRNA00174	0.64	8.01	0.46	5.5e-14	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs17023223	0.537	rs56708249	chr1:119593205	C/G	cg05756136	chr1:119680316	WARS2	-0.45	-5.44	-0.34	1.35e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
SARC	cis	rs7666738	0.830	rs28444709	chr4:99028496	A/T	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.09	13.14	0.65	7.15e-30	Platelet count;
SARC	cis	rs72627123	0.737	rs77361581	chr14:74465290	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.79	5.97	0.36	8.61e-9	Morning vs. evening chronotype;
SARC	cis	rs9467603	0.925	rs6456701	chr6:25774130	C/T	cg21479132	chr6:26055353	NA	-0.75	-4.75	-0.3	3.55e-6	Intelligence (multi-trait analysis);
SARC	cis	rs4808199	0.895	rs2163805	chr19:19575945	G/A	cg03709012	chr19:19516395	GATAD2A	1.2	13.19	0.65	4.79e-30	Nonalcoholic fatty liver disease;
SARC	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg22920501	chr2:26401640	FAM59B	-0.52	-6.58	-0.4	3e-10	Gut microbiome composition (summer);
SARC	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	trans	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg16141378	chr3:129829833	LOC729375	-0.54	-6.26	-0.38	1.86e-9	Systolic blood pressure;
SARC	cis	rs17376456	0.877	rs34673483	chr5:93315079	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.54	0.34	8.17e-8	Diabetic retinopathy;
SARC	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.56	-5.46	-0.34	1.2e-7	Body mass index;
SARC	cis	rs3857536	0.740	rs9354390	chr6:66890162	C/T	cg07460842	chr6:66804631	NA	0.6	7.11	0.42	1.41e-11	Blood trace element (Cu levels);
SARC	cis	rs7772486	0.625	rs2050027	chr6:146116113	C/G	cg23711669	chr6:146136114	FBXO30	-0.8	-13.15	-0.65	6.6e-30	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs929354	0.713	rs7798816	chr7:156940574	A/G	cg05182265	chr7:156933206	UBE3C	-0.34	-5.19	-0.32	4.49e-7	Body mass index;
SARC	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg03161606	chr19:29218774	NA	0.47	6.61	0.4	2.65e-10	Methadone dose in opioid dependence;
SARC	cis	rs6930083	0.713	rs1321308	chr6:36638691	A/C	cg08179530	chr6:36648295	CDKN1A	-0.83	-11.65	-0.61	5.13e-25	Coronary artery disease;
SARC	trans	rs3808502	0.526	rs7823100	chr8:11422491	C/A	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.37	-0.39	9.81e-10	Neuroticism;
SARC	cis	rs9302635	0.513	rs3902135	chr16:72175820	C/T	cg16558253	chr16:72132732	DHX38	-0.55	-6.7	-0.4	1.57e-10	Blood protein levels;
SARC	cis	rs72781680	0.904	rs72796340	chr2:24143622	T/A	cg08917208	chr2:24149416	ATAD2B	0.77	7.18	0.43	9.09e-12	Lymphocyte counts;
SARC	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	10.7	0.57	5.58e-22	Platelet count;
SARC	cis	rs8067545	0.516	rs11869258	chr17:20206898	G/A	cg13482628	chr17:19912719	NA	-0.58	-7.72	-0.45	3.32e-13	Schizophrenia;
SARC	cis	rs6867032	1.000	rs4246753	chr5:2014721	G/A	cg26168224	chr5:2018326	NA	0.92	15.65	0.72	3.23e-38	Gut microbiome composition (winter);
SARC	cis	rs7666738	0.830	rs7662199	chr4:99019766	G/A	cg05340658	chr4:99064831	C4orf37	0.64	8.71	0.5	5.83e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2425143	0.730	rs7263640	chr20:34314725	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.68	5.51	0.34	9.25e-8	Blood protein levels;
SARC	cis	rs13166103	0.723	rs13168895	chr5:57742282	G/A	cg10487770	chr5:57879443	RAB3C	0.51	5.47	0.34	1.17e-7	Type 2 diabetes (age of onset);
SARC	cis	rs9467160	1.000	rs12198188	chr6:24442482	A/G	cg16211469	chr6:24423932	MRS2	0.38	4.79	0.3	2.95e-6	Liver enzyme levels;
SARC	cis	rs2290159	0.948	rs11711270	chr3:12639596	C/T	cg23032965	chr3:12705835	RAF1	0.67	7.15	0.42	1.09e-11	Cholesterol, total;
SARC	cis	rs2180341	0.538	rs4392733	chr6:127712603	T/C	cg27446573	chr6:127587934	RNF146	0.5	6.28	0.38	1.67e-9	Breast cancer;
SARC	cis	rs3087591	0.960	rs12945157	chr17:29603631	G/A	cg24425628	chr17:29625626	OMG;NF1	0.55	6.84	0.41	6.8e-11	Hip circumference;
SARC	cis	rs2273669	0.667	rs12208578	chr6:109369745	T/C	cg05315195	chr6:109294784	ARMC2	-0.64	-5.7	-0.35	3.68e-8	Prostate cancer;
SARC	cis	rs370915	0.542	rs1895844	chr4:187833759	C/T	cg10295955	chr4:187884368	NA	-0.44	-5.25	-0.33	3.36e-7	Gout;
SARC	cis	rs2204008	0.748	rs7312204	chr12:38334909	T/C	cg13010199	chr12:38710504	ALG10B	0.77	10.2	0.56	1.95e-20	Bladder cancer;
SARC	cis	rs826838	0.967	rs11168985	chr12:39045983	A/C	cg13010199	chr12:38710504	ALG10B	-0.76	-10.27	-0.56	1.18e-20	Heart rate;
SARC	cis	rs7633770	0.664	rs34000414	chr3:46689958	G/A	cg11219411	chr3:46661640	NA	-0.41	-6.24	-0.38	2.06e-9	Coronary artery disease;
SARC	cis	rs72945132	0.882	rs17160039	chr11:70145489	A/G	cg00319359	chr11:70116639	PPFIA1	0.67	6.08	0.37	4.85e-9	Coronary artery disease;
SARC	cis	rs3008870	0.959	rs2985810	chr1:67376162	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.93	11.27	0.59	8.55e-24	Lymphocyte percentage of white cells;
SARC	trans	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg21659725	chr3:3221576	CRBN	0.57	6.51	0.39	4.57e-10	Resting heart rate;
SARC	cis	rs7568458	0.905	rs6714709	chr2:85756375	C/G	cg17127132	chr2:85788382	GGCX	0.42	5.53	0.34	8.6e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs3762637	1.000	rs7645862	chr3:122221139	C/T	cg24169773	chr3:122142474	KPNA1	-0.52	-5.31	-0.33	2.5e-7	LDL cholesterol levels;
SARC	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg05368731	chr17:41323189	NBR1	0.81	9.96	0.55	1.06e-19	Menopause (age at onset);
SARC	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg11890956	chr21:40555474	PSMG1	1.17	18.84	0.78	9.66e-49	Cognitive function;
SARC	cis	rs10089	0.904	rs3087889	chr5:127524944	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	9.22	0.52	1.81e-17	Ileal carcinoids;
SARC	cis	rs9420	0.961	rs11229131	chr11:57562525	G/A	cg19752551	chr11:57585705	CTNND1	-0.53	-7.23	-0.43	6.92e-12	Schizophrenia;
SARC	cis	rs7959452	0.640	rs10878957	chr12:69699638	G/C	cg14784868	chr12:69753453	YEATS4	0.39	5.15	0.32	5.47e-7	Blood protein levels;
SARC	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg24399712	chr22:39784796	NA	-0.42	-5.36	-0.33	1.99e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs9457247	0.740	rs10946204	chr6:167451129	T/C	cg07741184	chr6:167504864	NA	0.39	7.4	0.44	2.42e-12	Crohn's disease;
SARC	cis	rs7084402	0.967	rs1658421	chr10:60331928	A/T	cg07615347	chr10:60278583	BICC1	0.58	8.44	0.48	3.3e-15	Refractive error;
SARC	cis	rs35110281	0.744	rs162373	chr21:44927107	C/A	cg01579765	chr21:45077557	HSF2BP	0.32	5.54	0.34	8.33e-8	Mean corpuscular volume;
SARC	cis	rs9486719	1.000	rs12190507	chr6:96898265	T/G	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.01	-0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs35160687	0.901	rs10520415	chr2:86498738	C/T	cg10973622	chr2:86423274	IMMT	-0.39	-4.96	-0.31	1.33e-6	Night sleep phenotypes;
SARC	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg22920501	chr2:26401640	FAM59B	-0.58	-8.34	-0.48	6.5e-15	Gut microbiome composition (summer);
SARC	cis	rs10782582	0.593	rs12131493	chr1:76139172	G/A	cg10523679	chr1:76189770	ACADM	-0.43	-5.22	-0.32	3.95e-7	Daytime sleep phenotypes;
SARC	cis	rs1707322	1.000	rs4524994	chr1:46370263	A/G	cg06784218	chr1:46089804	CCDC17	0.33	5.69	0.35	3.84e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg24642844	chr7:1081250	C7orf50	-0.39	-5.42	-0.33	1.48e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs6570726	0.791	rs7765687	chr6:145915100	A/C	cg23711669	chr6:146136114	FBXO30	0.79	12.63	0.64	3.37e-28	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg02836479	chr16:21964489	UQCRC2	-0.78	-6.38	-0.39	9.58e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1448094	0.556	rs11610789	chr12:86169541	A/G	cg00310523	chr12:86230176	RASSF9	0.32	5.02	0.31	1.04e-6	Major depressive disorder;
SARC	cis	rs3812831	0.695	rs10467349	chr13:114939441	A/G	cg06611532	chr13:114900021	NA	0.34	5.9	0.36	1.28e-8	Schizophrenia;
SARC	cis	rs2832077	0.943	rs11701445	chr21:30160807	C/T	cg24692254	chr21:30365293	RNF160	-0.52	-4.83	-0.3	2.43e-6	Cognitive test performance;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg10966500	chr12:110338339	TCHP	0.48	6.32	0.38	1.31e-9	Tetralogy of Fallot;
SARC	cis	rs13144136	0.664	rs17267821	chr4:10653402	A/G	cg10242279	chr4:10666415	CLNK	-0.42	-6.82	-0.41	7.86e-11	Resistance to antihypertensive treatment in hypertension;
SARC	cis	rs765787	0.530	rs28733848	chr15:45516047	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.43	-5.39	-0.33	1.73e-7	Uric acid levels;
SARC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.08	0.37	4.77e-9	Prudent dietary pattern;
SARC	cis	rs2933343	0.679	rs789254	chr3:128574593	A/G	cg25356066	chr3:128598488	ACAD9	0.7	9.31	0.52	9.55e-18	IgG glycosylation;
SARC	cis	rs9815354	0.909	rs11717540	chr3:41932938	G/A	cg03022575	chr3:42003672	ULK4	-0.56	-5.45	-0.34	1.28e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6546550	0.868	rs12713682	chr2:70154134	G/A	cg02498382	chr2:70120550	SNRNP27	-0.32	-5.24	-0.32	3.6e-7	Prevalent atrial fibrillation;
SARC	cis	rs3733585	0.699	rs7686538	chr4:9948077	C/T	cg00071950	chr4:10020882	SLC2A9	-0.39	-5.99	-0.37	7.76e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7089973	0.526	rs1045657	chr10:116736985	A/T	cg08188268	chr10:116634841	FAM160B1	0.4	5.17	0.32	5.02e-7	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg02487422	chr3:49467188	NICN1	0.5	6.83	0.41	7.5e-11	Resting heart rate;
SARC	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg06028808	chr11:68637592	NA	0.45	5.53	0.34	8.7e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs2153535	0.541	rs1414347	chr6:8471831	T/C	cg21535247	chr6:8435926	SLC35B3	0.53	6.7	0.4	1.55e-10	Motion sickness;
SARC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg26338869	chr17:61819248	STRADA	0.76	9.85	0.54	2.37e-19	Prudent dietary pattern;
SARC	cis	rs7666738	0.830	rs35491210	chr4:99003364	T/C	cg05340658	chr4:99064831	C4orf37	0.64	8.59	0.49	1.22e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg25036284	chr2:26402008	FAM59B	-0.41	-4.89	-0.31	1.88e-6	Gut microbiome composition (summer);
SARC	cis	rs17057640	1.000	rs17057625	chr6:130015764	G/A	cg08633085	chr6:130031345	ARHGAP18	-0.66	-5.15	-0.32	5.56e-7	Cognitive function;
SARC	cis	rs796364	0.662	rs11688415	chr2:201143409	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.72	5.85	0.36	1.64e-8	Schizophrenia;
SARC	cis	rs2153535	0.580	rs9379206	chr6:8458021	C/A	cg21535247	chr6:8435926	SLC35B3	0.52	6.55	0.39	3.66e-10	Motion sickness;
SARC	cis	rs709400	0.663	rs8015918	chr14:103942991	A/G	cg12935359	chr14:103987150	CKB	-0.39	-5.74	-0.35	2.92e-8	Body mass index;
SARC	cis	rs7296418	0.754	rs1619283	chr12:123717362	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-5.31	-0.33	2.52e-7	Platelet count;
SARC	cis	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg24110177	chr3:50126178	RBM5	-0.67	-9.12	-0.51	3.67e-17	Body mass index;
SARC	cis	rs7248779	0.512	rs7250002	chr19:2413188	A/G	cg22729335	chr19:2427816	TIMM13	1.06	17.1	0.75	5.2e-43	Cortisol levels (saliva);
SARC	cis	rs4803468	1.000	rs3810174	chr19:41904165	C/T	cg08477640	chr19:41863820	B9D2	0.48	6.27	0.38	1.77e-9	Height;
SARC	cis	rs995000	0.931	rs1781195	chr1:62988972	T/C	cg06896770	chr1:63153194	DOCK7	-0.88	-12.57	-0.64	5.16e-28	Triglyceride levels;
SARC	cis	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg08564027	chr20:61660810	NA	0.76	11.8	0.61	1.69e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg09359103	chr1:154839909	KCNN3	-0.46	-7.62	-0.45	6.16e-13	Prostate cancer;
SARC	cis	rs9467711	0.651	rs13197334	chr6:26122648	G/C	cg21479132	chr6:26055353	NA	0.93	6.78	0.41	1e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2576037	0.796	rs2247021	chr18:44578794	A/C	cg19077165	chr18:44547161	KATNAL2	-0.43	-5.94	-0.36	1.02e-8	Personality dimensions;
SARC	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg12667521	chr19:29218732	NA	0.36	4.76	0.3	3.44e-6	Methadone dose in opioid dependence;
SARC	cis	rs2933343	0.700	rs2630257	chr3:128644015	T/C	cg25356066	chr3:128598488	ACAD9	0.71	9.47	0.53	3.18e-18	IgG glycosylation;
SARC	cis	rs2273669	0.667	rs76430494	chr6:109350128	C/A	cg05315195	chr6:109294784	ARMC2	-0.63	-5.7	-0.35	3.6e-8	Prostate cancer;
SARC	cis	rs3784262	0.669	rs4646554	chr15:58355437	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.35	-5.19	-0.32	4.66e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs4742903	0.904	rs1333941	chr9:106996386	C/G	cg14250997	chr9:106856677	SMC2	0.38	4.86	0.3	2.17e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs6963495	0.818	rs73190166	chr7:105159955	G/A	cg13798780	chr7:105162888	PUS7	0.6	5.45	0.34	1.26e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs6582630	0.599	rs4882313	chr12:38454011	G/A	cg14851346	chr12:38532713	NA	-0.47	-5.76	-0.35	2.63e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6912958	0.514	rs1980792	chr6:87889917	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.36	-6.33	-0.38	1.22e-9	Monocyte percentage of white cells;
SARC	cis	rs9640161	0.742	rs2108854	chr7:150017408	C/T	cg17279839	chr7:150038598	RARRES2	-0.46	-6.81	-0.41	8.25e-11	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.35	4.81	0.3	2.73e-6	Personality dimensions;
SARC	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg05793240	chr7:2802953	GNA12	-0.35	-5.02	-0.31	1.01e-6	Height;
SARC	cis	rs2354432	0.607	rs72692962	chr1:146802674	C/A	cg25205988	chr1:146714368	CHD1L	-1.06	-7.79	-0.45	2.22e-13	Mitochondrial DNA levels;
SARC	cis	rs6495122	0.501	rs12904227	chr15:75387048	A/C	cg17294928	chr15:75287854	SCAMP5	-0.49	-6.41	-0.39	8.01e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg06028808	chr11:68637592	NA	0.47	6.11	0.37	4.22e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg19223190	chr17:80058835	NA	0.43	6.04	0.37	6.11e-9	Life satisfaction;
SARC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.28	0.8	2.29e-53	Prudent dietary pattern;
SARC	cis	rs72781680	0.948	rs72790326	chr2:24126153	C/T	cg06627628	chr2:24431161	ITSN2	-0.65	-6.25	-0.38	1.93e-9	Lymphocyte counts;
SARC	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg22974920	chr21:40686053	BRWD1	-0.45	-5.09	-0.32	7.31e-7	Cognitive function;
SARC	cis	rs9323205	0.765	rs2999390	chr14:51654944	C/G	cg23942311	chr14:51606299	NA	-0.28	-4.73	-0.3	3.95e-6	Cancer;
SARC	cis	rs1448094	1.000	rs10083080	chr12:86348579	G/C	cg02569458	chr12:86230093	RASSF9	0.43	6.16	0.37	3.08e-9	Major depressive disorder;
SARC	cis	rs4242434	0.892	rs34269854	chr8:22465160	G/C	cg03733263	chr8:22462867	KIAA1967	1.02	17.73	0.76	4.38e-45	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs2295359	1.000	rs4655524	chr1:67629469	G/A	cg08029281	chr1:67600428	NA	0.38	5.41	0.33	1.53e-7	Psoriasis;
SARC	cis	rs6582630	0.519	rs4405392	chr12:38293661	A/C	cg26384229	chr12:38710491	ALG10B	0.87	12.86	0.64	6.01e-29	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2120019	0.935	rs12591119	chr15:75355944	A/G	cg12414181	chr15:75287860	SCAMP5	-0.45	-5.06	-0.31	8.48e-7	Blood trace element (Zn levels);
SARC	cis	rs9486719	0.948	rs2472904	chr6:96874962	T/G	cg06623918	chr6:96969491	KIAA0776	0.73	8.01	0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs1707322	1.000	rs10890350	chr1:46262378	G/A	cg06784218	chr1:46089804	CCDC17	0.36	6.34	0.38	1.17e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7666738	0.830	rs11097606	chr4:99011486	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.81	0.5	2.95e-16	Colonoscopy-negative controls vs population controls;
SARC	trans	rs66573146	0.808	rs55942328	chr4:6990960	T/G	cg07817883	chr1:32538562	TMEM39B	1.25	8.25	0.48	1.19e-14	Granulocyte percentage of myeloid white cells;
SARC	trans	rs12310956	0.532	rs7979535	chr12:33947450	A/C	cg13010199	chr12:38710504	ALG10B	-0.74	-9.99	-0.55	8.61e-20	Morning vs. evening chronotype;
SARC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg25703541	chr22:24373054	LOC391322	-0.89	-13.08	-0.65	1.11e-29	Liver enzyme levels (gamma-glutamyl transferase);
SARC	trans	rs1910358	0.554	rs10057796	chr5:23759746	C/T	cg14234680	chr8:57905925	IMPAD1	0.56	6.38	0.39	9.54e-10	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs2645694	0.626	rs2645709	chr4:77824474	G/A	cg06046430	chr4:77819534	ANKRD56	0.54	8.03	0.47	4.8e-14	Emphysema distribution in smoking;
SARC	cis	rs240764	0.578	rs1414734	chr6:101201823	T/C	cg09795085	chr6:101329169	ASCC3	0.5	6.48	0.39	5.46e-10	Neuroticism;
SARC	cis	rs8031584	0.958	rs11293	chr15:31234981	G/A	cg08109568	chr15:31115862	NA	-0.46	-5.69	-0.35	3.85e-8	Huntington's disease progression;
SARC	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg26874164	chr19:58962979	ZNF324B	0.52	6.71	0.4	1.45e-10	Uric acid clearance;
SARC	cis	rs35306767	0.714	rs10508206	chr10:1075777	A/C	cg26597838	chr10:835615	NA	0.42	4.75	0.3	3.5e-6	Eosinophil percentage of granulocytes;
SARC	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg00990874	chr7:1149470	C7orf50	0.53	5.75	0.35	2.78e-8	Bronchopulmonary dysplasia;
SARC	cis	rs2153535	0.580	rs9379215	chr6:8481225	G/A	cg21535247	chr6:8435926	SLC35B3	0.58	7.33	0.43	3.7e-12	Motion sickness;
SARC	trans	rs3118867	0.695	rs6560011	chr9:90256637	A/G	cg19404215	chr3:33155277	CRTAP	0.53	6.49	0.39	5.04e-10	Blood pressure;
SARC	cis	rs1942	0.837	rs12440045	chr15:41782684	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.46	-6.31	-0.38	1.36e-9	Eosinophil percentage of granulocytes;
SARC	cis	rs739401	0.595	rs2237903	chr11:2967901	C/T	cg08508325	chr11:3079039	CARS	-0.29	-6.9	-0.41	4.73e-11	Longevity;
SARC	cis	rs72949976	0.646	rs4673731	chr2:214028544	C/T	cg08319019	chr2:214017104	IKZF2	0.49	6.51	0.39	4.6e-10	Lung cancer;Squamous cell lung carcinoma;
SARC	cis	rs2834188	1.000	rs2026254	chr21:34688032	C/T	cg14352951	chr21:34696688	IFNAR1	0.46	5.57	0.34	7.03e-8	Narcolepsy;
SARC	cis	rs3796352	0.527	rs11715498	chr3:52943551	G/C	cg04865290	chr3:52927548	TMEM110	-0.58	-5.31	-0.33	2.61e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs1497406	0.802	rs11588341	chr1:16498048	A/G	cg06365898	chr1:16533907	ARHGEF19	0.35	4.85	0.3	2.27e-6	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9309473	0.607	rs1851546	chr2:73591127	C/A	cg20560298	chr2:73613845	ALMS1	-0.57	-7.12	-0.42	1.29e-11	Metabolite levels;
SARC	cis	rs7474896	0.526	rs1742235	chr10:38052256	T/C	cg25427524	chr10:38739819	LOC399744	-0.5	-6.07	-0.37	5.19e-9	Obesity (extreme);
SARC	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg13395646	chr4:1353034	KIAA1530	-0.48	-5.76	-0.35	2.68e-8	Obesity-related traits;
SARC	cis	rs1003719	0.680	rs2835664	chr21:38573429	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-8.88	-0.5	1.88e-16	Eye color traits;
SARC	cis	rs1008375	0.932	rs13127157	chr4:17618049	A/G	cg27347728	chr4:17578864	LAP3	-0.49	-6.06	-0.37	5.51e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs3796352	1.000	rs71301809	chr3:53090312	C/T	cg12962167	chr3:53033115	SFMBT1	0.81	5.46	0.34	1.22e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs12451471	0.559	rs1042396	chr17:78084769	G/A	cg06718696	chr17:78121285	EIF4A3	0.88	10.13	0.55	3.31e-20	Plateletcrit;Mean corpuscular hemoglobin concentration;
SARC	cis	rs12142240	0.698	rs13374893	chr1:46843800	A/G	cg00530320	chr1:46809349	NSUN4	0.57	7.0	0.42	2.74e-11	Menopause (age at onset);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg00429618	chr9:99962350	ZNF322B	-0.75	-6.7	-0.4	1.59e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9677476	0.516	rs6755467	chr2:232044684	G/T	cg23338755	chr2:231921595	PSMD1	-0.43	-5.23	-0.32	3.82e-7	Food antigen IgG levels;
SARC	cis	rs9868809	0.772	rs9809222	chr3:48714411	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.61	-5.49	-0.34	1.05e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg22903657	chr4:1355424	KIAA1530	-0.35	-4.75	-0.3	3.63e-6	Obesity-related traits;
SARC	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg25894440	chr7:65020034	NA	-0.73	-5.48	-0.34	1.09e-7	Diabetic kidney disease;
SARC	cis	rs2522056	1.000	rs2706395	chr5:131796803	A/T	cg24060327	chr5:131705240	SLC22A5	0.48	4.76	0.3	3.38e-6	Lymphocyte counts;Fibrinogen;
SARC	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	7.3	0.43	4.48e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9611565	0.921	rs4822021	chr22:41726053	G/A	cg17376030	chr22:41985996	PMM1	0.58	7.27	0.43	5.54e-12	Vitiligo;
SARC	cis	rs7659604	0.502	rs28435300	chr4:122709412	T/C	cg19748678	chr4:122722346	EXOSC9	-0.41	-5.02	-0.31	1e-6	Type 2 diabetes;
SARC	cis	rs7589342	0.929	rs12053259	chr2:106428720	G/A	cg14210321	chr2:106509881	NCK2	-0.46	-5.39	-0.33	1.76e-7	Addiction;
SARC	cis	rs9322817	0.583	rs6941988	chr6:105146656	C/T	cg02098413	chr6:105308735	HACE1	0.36	5.53	0.34	8.36e-8	Thyroid stimulating hormone;
SARC	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg19223190	chr17:80058835	NA	0.44	6.19	0.38	2.67e-9	Life satisfaction;
SARC	cis	rs9398803	0.678	rs9372841	chr6:126898541	A/G	cg20229609	chr6:126660872	C6orf173	0.37	5.39	0.33	1.74e-7	Male-pattern baldness;
SARC	cis	rs9322817	0.902	rs4336470	chr6:105180785	C/T	cg02098413	chr6:105308735	HACE1	-0.33	-4.76	-0.3	3.45e-6	Thyroid stimulating hormone;
SARC	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg14517863	chr17:44321492	NA	-0.32	-4.75	-0.3	3.53e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.85	-11.78	-0.61	1.91e-25	Chronic sinus infection;
SARC	cis	rs6582630	0.555	rs10748382	chr12:38504529	C/T	cg26384229	chr12:38710491	ALG10B	0.85	12.58	0.64	5.02e-28	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg09455208	chr3:40491958	NA	-0.34	-5.25	-0.33	3.48e-7	Renal cell carcinoma;
SARC	cis	rs854765	0.583	rs8065416	chr17:17851162	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.43	5.52	0.34	9.04e-8	Total body bone mineral density;
SARC	cis	rs9818758	0.607	rs113186424	chr3:49272726	T/C	cg03060546	chr3:49711283	APEH	-0.54	-4.73	-0.3	3.9e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs2370759	1.000	rs79806114	chr10:32618022	T/C	cg18270830	chr10:32634957	EPC1	0.69	6.26	0.38	1.85e-9	Sexual dysfunction (female);
SARC	cis	rs9341808	0.667	rs3805913	chr6:80927322	A/G	cg08355045	chr6:80787529	NA	0.38	5.95	0.36	9.66e-9	Sitting height ratio;
SARC	cis	rs9323205	0.765	rs2999388	chr14:51654157	A/G	cg23942311	chr14:51606299	NA	0.3	5.02	0.31	1.02e-6	Cancer;
SARC	cis	rs6570726	0.791	rs1509214	chr6:145784606	A/C	cg23711669	chr6:146136114	FBXO30	-0.85	-13.81	-0.67	4.15e-32	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs8070624	0.574	rs9914127	chr17:17875836	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	10.75	0.58	3.66e-22	Total body bone mineral density;
SARC	cis	rs13077101	0.927	rs386759	chr3:120511582	T/G	cg24332942	chr3:120408071	RABL3	-0.38	-4.77	-0.3	3.18e-6	Obesity-related traits;
SARC	cis	rs7914558	0.966	rs11191518	chr10:104782853	C/G	cg04362960	chr10:104952993	NT5C2	0.45	5.62	0.35	5.49e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs12142240	0.698	rs45517837	chr1:46859225	A/G	cg00530320	chr1:46809349	NSUN4	0.57	7.0	0.42	2.74e-11	Menopause (age at onset);
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg21749275	chr4:110460898	SEC24B	-0.53	-6.46	-0.39	6.05e-10	Alcohol dependence;
SARC	cis	rs12497850	1.000	rs4858798	chr3:48727112	C/T	cg07636037	chr3:49044803	WDR6	0.92	14.81	0.7	1.99e-35	Parkinson's disease;
SARC	cis	rs501120	1.000	rs479596	chr10:44760473	C/T	cg09554077	chr10:44749378	NA	0.5	6.67	0.4	1.81e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs2645694	0.651	rs2703144	chr4:77830505	C/G	cg06046430	chr4:77819534	ANKRD56	0.48	6.77	0.41	1.03e-10	Emphysema distribution in smoking;
SARC	cis	rs1728785	1.000	rs1170433	chr16:68606081	A/G	cg02972257	chr16:68554789	NA	-0.47	-5.56	-0.34	7.2e-8	Ulcerative colitis;
SARC	cis	rs11687170	0.882	rs73131621	chr2:237059064	C/T	cg19324714	chr2:237145437	ASB18	0.49	4.89	0.31	1.89e-6	Educational attainment;Educational attainment (years of education);
SARC	cis	rs9828933	0.752	rs13434089	chr3:63948566	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.85	7.29	0.43	4.88e-12	Type 2 diabetes;
SARC	cis	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg25427524	chr10:38739819	LOC399744	-0.55	-8.75	-0.5	4.45e-16	Extrinsic epigenetic age acceleration;
SARC	cis	rs1975974	0.935	rs41361749	chr17:21732693	A/G	cg18423549	chr17:21743878	NA	0.45	5.24	0.32	3.68e-7	Psoriasis;
SARC	cis	rs7208859	0.623	rs28627615	chr17:29145817	G/C	cg13385521	chr17:29058706	SUZ12P	0.9	7.58	0.44	7.91e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs2197308	0.606	rs2218397	chr12:38278307	C/T	cg26384229	chr12:38710491	ALG10B	-0.61	-7.62	-0.45	6.2800000000000005e-13	Morning vs. evening chronotype;
SARC	cis	rs883565	0.528	rs4504116	chr3:38953768	A/G	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.45	-5.44	-0.34	1.35e-7	Handedness;
SARC	cis	rs651907	0.557	rs7629753	chr3:101371922	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.51	-6.13	-0.37	3.68e-9	Colorectal cancer;
SARC	cis	rs2729354	0.953	rs2649650	chr11:57327567	C/T	cg02958346	chr11:57425731	CLP1	0.49	4.9	0.31	1.76e-6	Blood protein levels;
SARC	cis	rs7843479	0.965	rs11785657	chr8:21859485	G/A	cg17168535	chr8:21777572	XPO7	0.62	7.91	0.46	1.04e-13	Mean corpuscular volume;
SARC	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	13.88	0.67	2.59e-32	Chronic sinus infection;
SARC	cis	rs1580019	0.961	rs11765387	chr7:32494790	T/C	cg14728415	chr7:32535168	LSM5;AVL9	0.43	5.04	0.31	9.3e-7	Cognitive ability;
SARC	cis	rs1144333	0.655	rs931506	chr1:76401349	T/C	cg03433033	chr1:76189801	ACADM	0.66	5.31	0.33	2.55e-7	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs7904368	0.568	rs7075036	chr10:16864810	C/T	cg14835575	chr10:16859367	RSU1	0.49	5.36	0.33	2.03e-7	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs1865760	0.865	rs1115920	chr6:25954027	A/G	cg17691542	chr6:26056736	HIST1H1C	0.58	7.28	0.43	5.19e-12	Height;
SARC	cis	rs2834188	0.889	rs2040108	chr21:34676158	T/C	cg14352951	chr21:34696688	IFNAR1	0.44	5.36	0.33	2e-7	Narcolepsy;
SARC	cis	rs4481887	0.962	rs12037921	chr1:248454167	T/G	cg13385794	chr1:248469461	NA	0.32	4.92	0.31	1.67e-6	Common traits (Other);
SARC	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg16606324	chr3:10149918	C3orf24	0.5	5.01	0.31	1.08e-6	Alzheimer's disease;
SARC	cis	rs7681440	0.606	rs2583984	chr4:90754153	C/T	cg06632027	chr4:90757378	SNCA	0.46	5.76	0.35	2.6e-8	Dementia with Lewy bodies;
SARC	cis	rs1570884	0.516	rs9526580	chr13:50164023	C/G	cg03651054	chr13:50194643	NA	-0.32	-5.16	-0.32	5.19e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg09021430	chr5:549028	NA	-0.42	-5.83	-0.36	1.86e-8	Obesity-related traits;
SARC	cis	rs7092929	0.883	rs705458	chr10:3611415	C/T	cg14308648	chr10:3568949	NA	-0.54	-5.3	-0.33	2.62e-7	Coronary artery calcification;
SARC	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg09699651	chr6:150184138	LRP11	0.39	4.87	0.3	2.04e-6	Lung cancer;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg24706213	chr1:109633347	TMEM167B	0.5	6.64	0.4	2.19e-10	Tetralogy of Fallot;
SARC	trans	rs7824557	0.564	rs2572392	chr8:11235605	T/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.71	-0.5	5.7e-16	Retinal vascular caliber;
SARC	cis	rs372883	0.648	rs1153292	chr21:30689195	G/T	cg08807101	chr21:30365312	RNF160	-0.59	-7.51	-0.44	1.27e-12	Pancreatic cancer;
SARC	cis	rs3892630	0.878	rs114224536	chr19:33211232	A/G	cg22980127	chr19:33182716	NUDT19	1.02	8.83	0.5	2.53e-16	Red blood cell traits;
SARC	cis	rs17666538	0.585	rs6559064	chr8:623061	G/A	cg00450029	chr8:599525	NA	0.6	5.1	0.32	7.13e-7	IgG glycosylation;
SARC	cis	rs1008375	1.000	rs28480159	chr4:17685707	A/C	cg02297831	chr4:17616191	MED28	0.43	5.43	0.33	1.44e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs12310956	0.510	rs4931759	chr12:33871969	T/C	cg26384229	chr12:38710491	ALG10B	0.62	8.13	0.47	2.48e-14	Morning vs. evening chronotype;
SARC	cis	rs11785400	1.000	rs4484678	chr8:143730796	A/G	cg10596483	chr8:143751796	JRK	0.64	8.46	0.48	2.97e-15	Schizophrenia;
SARC	cis	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg13147721	chr7:65941812	NA	-0.52	-4.79	-0.3	3.03e-6	Diabetic kidney disease;
SARC	cis	rs3008870	1.000	rs3008873	chr1:67425770	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.92	11.37	0.6	3.93e-24	Lymphocyte percentage of white cells;
SARC	cis	rs7644634	0.649	rs2301051	chr3:105401406	A/T	cg23051926	chr3:105466016	CBLB	0.48	6.03	0.37	6.23e-9	Itch intensity from mosquito bite;
SARC	trans	rs1814175	0.617	rs6486020	chr11:49769149	T/G	cg15704280	chr7:45808275	SEPT13	-0.88	-13.89	-0.67	2.29e-32	Height;
SARC	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg25036284	chr2:26402008	FAM59B	-0.46	-5.63	-0.35	5.16e-8	Gut microbiome composition (summer);
SARC	cis	rs4128725	0.925	rs11265206	chr1:159449083	A/G	cg25076881	chr1:159409836	OR10J1	0.4	4.84	0.3	2.32e-6	Select biomarker traits;
SARC	cis	rs6988636	0.710	rs59229243	chr8:124155673	G/A	cg23067535	chr8:124195133	FAM83A	-0.64	-4.75	-0.3	3.54e-6	Urinary uromodulin levels;
SARC	cis	rs11638352	1.000	rs1820485	chr15:44430332	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	-0.76	-5.91	-0.36	1.23e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	cis	rs3126085	0.935	rs6587647	chr1:152192631	C/T	cg09127314	chr1:152161683	NA	0.41	4.76	0.3	3.39e-6	Atopic dermatitis;
SARC	cis	rs9399137	0.507	rs4895437	chr6:135317354	G/A	cg22676075	chr6:135203613	NA	0.38	4.84	0.3	2.32e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs3768617	0.510	rs10797851	chr1:183098001	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.82e-21	Fuchs's corneal dystrophy;
SARC	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	11.64	0.61	5.7e-25	Alzheimer's disease;
SARC	cis	rs9640161	0.830	rs12703061	chr7:150062545	T/C	cg17279839	chr7:150038598	RARRES2	0.36	5.45	0.34	1.27e-7	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg22857025	chr5:266934	NA	-1.06	-11.8	-0.61	1.74e-25	Breast cancer;
SARC	cis	rs12311304	1.000	rs12578517	chr12:15407185	C/T	cg08258403	chr12:15378311	NA	-0.49	-7.17	-0.43	9.63e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs9916302	0.706	rs1054488	chr17:37687968	A/G	cg07936489	chr17:37558343	FBXL20	-0.73	-8.44	-0.48	3.45e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs4555082	0.874	rs2816606	chr14:105716034	C/T	cg06808227	chr14:105710500	BRF1	-0.52	-6.47	-0.39	5.56e-10	Mean platelet volume;Platelet distribution width;
SARC	cis	rs11190604	1.000	rs3750720	chr10:102248884	C/T	cg07080220	chr10:102295463	HIF1AN	0.77	8.59	0.49	1.3e-15	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs1707322	0.721	rs28501477	chr1:46199084	A/G	cg03146154	chr1:46216737	IPP	0.53	6.39	0.39	8.82e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9399137	0.561	rs11753985	chr6:135280438	C/T	cg22676075	chr6:135203613	NA	0.4	5.16	0.32	5.35e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs826838	0.900	rs9739128	chr12:38948960	A/T	cg26384229	chr12:38710491	ALG10B	0.92	14.21	0.68	1.95e-33	Heart rate;
SARC	cis	rs7560272	0.538	rs6732812	chr2:73922475	T/C	cg20560298	chr2:73613845	ALMS1	0.48	6.35	0.38	1.09e-9	Schizophrenia;
SARC	cis	rs2549003	1.000	rs2548999	chr5:131831058	G/T	cg21138405	chr5:131827807	IRF1	-0.27	-5.56	-0.34	7.32e-8	Asthma (sex interaction);
SARC	cis	rs3741404	0.609	rs687581	chr11:63871533	G/T	cg18225595	chr11:63971243	STIP1	-0.4	-5.54	-0.34	8.15e-8	Platelet count;
SARC	cis	rs1322639	0.657	rs9355135	chr6:169573006	C/T	cg03254818	chr6:169586852	NA	0.72	7.22	0.43	7.25e-12	Pulse pressure;
SARC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.71	-7.54	-0.44	1.04e-12	Platelet count;
SARC	cis	rs7236492	0.572	rs112024357	chr18:77175610	T/C	cg15644404	chr18:77186268	NFATC1	-0.64	-5.01	-0.31	1.09e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs7615952	0.641	rs4490307	chr3:125712676	T/G	cg15145296	chr3:125709740	NA	-0.46	-4.89	-0.31	1.85e-6	Blood pressure (smoking interaction);
SARC	cis	rs11608355	0.545	rs6606724	chr12:109905179	T/C	cg05360138	chr12:110035743	NA	0.92	9.68	0.54	7.88e-19	Neuroticism;
SARC	cis	rs6088590	1.000	rs6120750	chr20:33465289	A/C	cg24642439	chr20:33292090	TP53INP2	0.79	10.75	0.58	3.87e-22	Coronary artery disease;
SARC	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg13770153	chr20:60521292	NA	-0.48	-6.45	-0.39	6.27e-10	Body mass index;
SARC	trans	rs1814175	0.904	rs7924371	chr11:49620595	C/T	cg15704280	chr7:45808275	SEPT13	-0.91	-16.05	-0.72	1.56e-39	Height;
SARC	trans	rs9951602	0.512	rs12607561	chr18:76644284	G/A	cg02800362	chr5:177631904	HNRNPAB	0.68	8.61	0.49	1.13e-15	Obesity-related traits;
SARC	cis	rs35110281	0.682	rs162379	chr21:44925334	A/G	cg21573476	chr21:45109991	RRP1B	0.45	6.72	0.4	1.37e-10	Mean corpuscular volume;
SARC	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg21782813	chr7:2030301	MAD1L1	0.4	6.2	0.38	2.48e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs7937682	0.632	rs11214028	chr11:111761149	T/C	cg09085632	chr11:111637200	PPP2R1B	0.77	10.11	0.55	3.75e-20	Primary sclerosing cholangitis;
SARC	cis	rs2115630	0.905	rs6496401	chr15:85297793	A/T	cg17507749	chr15:85114479	UBE2QP1	-0.45	-5.3	-0.33	2.7e-7	P wave terminal force;
SARC	cis	rs8017423	0.967	rs2401875	chr14:90688451	A/G	cg20276874	chr14:90721474	PSMC1	-0.34	-4.75	-0.3	3.56e-6	Mortality in heart failure;
SARC	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg04772025	chr11:68637568	NA	0.5	6.02	0.37	6.72e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs1018836	0.923	rs13255452	chr8:91582988	A/G	cg16814680	chr8:91681699	NA	-0.8	-12.44	-0.63	1.41e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs7772486	0.754	rs9399561	chr6:145955687	C/G	cg05347473	chr6:146136440	FBXO30	0.54	7.56	0.44	9e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs72781680	0.716	rs2712071	chr2:23990419	A/G	cg06627628	chr2:24431161	ITSN2	-0.52	-5.14	-0.32	5.75e-7	Lymphocyte counts;
SARC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.33	-4.81	-0.3	2.77e-6	Lymphocyte counts;
SARC	trans	rs1945213	0.694	rs7106894	chr11:55877315	T/C	cg15704280	chr7:45808275	SEPT13	0.64	6.7	0.4	1.51e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs7246657	0.943	rs2891699	chr19:37920237	A/G	cg23950597	chr19:37808831	NA	-0.57	-5.67	-0.35	4.24e-8	Coronary artery calcification;
SARC	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.43	-5.08	-0.32	7.71e-7	Bipolar disorder;
SARC	cis	rs2070997	0.818	rs9696884	chr9:133660521	G/A	cg11464064	chr9:133710261	ABL1	0.66	4.95	0.31	1.43e-6	Response to amphetamines;
SARC	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg08677398	chr8:58056175	NA	0.44	5.25	0.33	3.38e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs36051895	0.632	rs1328919	chr9:5166548	C/T	cg02405213	chr9:5042618	JAK2	-0.54	-6.37	-0.39	9.88e-10	Pediatric autoimmune diseases;
SARC	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg17971929	chr21:40555470	PSMG1	-0.86	-11.1	-0.59	2.97e-23	Cognitive function;
SARC	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg22800045	chr5:56110881	MAP3K1	-0.63	-5.84	-0.36	1.73e-8	Initial pursuit acceleration;
SARC	cis	rs918629	0.798	rs57595413	chr5:95277776	C/T	cg16656078	chr5:95278638	ELL2	-0.62	-7.52	-0.44	1.18e-12	IgG glycosylation;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg11644349	chr3:184661427	VPS8	0.47	6.55	0.39	3.56e-10	Thyroid stimulating hormone;
SARC	cis	rs6570726	0.577	rs399502	chr6:145805874	A/G	cg23711669	chr6:146136114	FBXO30	0.81	11.41	0.6	2.97e-24	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4555082	1.000	rs4334224	chr14:105759198	C/T	cg10792982	chr14:105748885	BRF1	0.52	7.71	0.45	3.67e-13	Mean platelet volume;Platelet distribution width;
SARC	cis	rs7937682	0.562	rs7938620	chr11:111366844	G/A	cg09085632	chr11:111637200	PPP2R1B	0.56	7.24	0.43	6.52e-12	Primary sclerosing cholangitis;
SARC	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg22433210	chr17:43662623	NA	1.06	12.89	0.65	4.57e-29	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs709400	0.663	rs62007687	chr14:103903763	G/T	cg12935359	chr14:103987150	CKB	-0.4	-5.76	-0.35	2.61e-8	Body mass index;
SARC	cis	rs2120019	1.000	rs8036197	chr15:75370232	T/C	cg12414181	chr15:75287860	SCAMP5	-0.42	-4.89	-0.31	1.87e-6	Blood trace element (Zn levels);
SARC	cis	rs1957429	0.520	rs12433757	chr14:65296598	T/C	cg23373153	chr14:65346875	NA	-0.73	-5.51	-0.34	9.29e-8	Pediatric areal bone mineral density (radius);
SARC	cis	rs10461617	0.617	rs6874733	chr5:56069600	A/G	cg24549020	chr5:56110836	MAP3K1	0.64	6.97	0.42	3.2e-11	Type 2 diabetes;
SARC	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg12463550	chr7:65579703	CRCP	-0.5	-5.56	-0.34	7.28e-8	Aortic root size;
SARC	cis	rs11718455	0.960	rs13082990	chr3:44005172	T/C	cg08738300	chr3:44038990	NA	0.54	5.86	0.36	1.53e-8	Coronary artery disease;
SARC	cis	rs2228479	0.702	rs62056100	chr16:89939753	C/T	cg00800038	chr16:89945340	TCF25	-0.75	-5.25	-0.32	3.5e-7	Skin colour saturation;
SARC	cis	rs4746059	0.545	rs7081273	chr10:72457038	C/G	cg18679544	chr10:72432482	ADAMTS14	0.43	5.45	0.34	1.3e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4141404	0.851	rs5749248	chr22:31683711	C/A	cg07713946	chr22:31675144	LIMK2	-0.38	-4.75	-0.3	3.57e-6	Paclitaxel-induced neuropathy;
SARC	cis	rs875971	0.545	rs73136346	chr7:65566082	A/G	cg11764359	chr7:65958608	NA	-0.63	-6.14	-0.37	3.47e-9	Aortic root size;
SARC	cis	rs9462027	0.606	rs2744941	chr6:34646917	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-5.98	-0.36	8.35e-9	Systemic lupus erythematosus;
SARC	cis	rs4481887	0.861	rs4309013	chr1:248480768	C/T	cg13385794	chr1:248469461	NA	0.33	5.08	0.32	7.75e-7	Common traits (Other);
SARC	cis	rs9487051	0.676	rs1521905	chr6:109594515	T/C	cg01475377	chr6:109611718	NA	-0.35	-5.08	-0.32	7.66e-7	Reticulocyte fraction of red cells;
SARC	cis	rs7599312	0.534	rs7355673	chr2:213404389	T/C	cg16329650	chr2:213403929	ERBB4	0.7	10.61	0.57	1.03e-21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2882877	0.621	rs17198934	chr2:190378371	C/G	cg21926118	chr2:190387206	NA	-0.4	-4.9	-0.31	1.81e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs870825	0.616	rs28375770	chr4:185647395	C/T	cg04058563	chr4:185651563	MLF1IP	0.8	11.35	0.6	4.56e-24	Blood protein levels;
SARC	cis	rs12142240	0.698	rs72677596	chr1:46833930	C/T	cg00530320	chr1:46809349	NSUN4	0.58	6.91	0.41	4.52e-11	Menopause (age at onset);
SARC	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg02725872	chr8:58115012	NA	-0.36	-6.32	-0.38	1.35e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7208859	0.623	rs55938328	chr17:29117010	T/C	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg20607798	chr8:58055168	NA	0.57	5.54	0.34	8.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9790314	0.936	rs7629987	chr3:161002023	A/C	cg03342759	chr3:160939853	NMD3	-0.61	-7.73	-0.45	3.22e-13	Morning vs. evening chronotype;
SARC	cis	rs2732480	0.538	rs2468943	chr12:48747249	G/T	cg21466736	chr12:48725269	NA	0.36	5.44	0.34	1.33e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs8014204	0.804	rs2287403	chr14:75259140	C/T	cg17347104	chr14:75034677	LTBP2	-0.43	-5.3	-0.33	2.66e-7	Caffeine consumption;
SARC	cis	rs151234	0.741	rs151229	chr16:28584937	G/A	cg01378222	chr16:28622494	SULT1A1	-0.51	-5.81	-0.36	2.04e-8	Platelet distribution width;
SARC	cis	rs7264396	0.790	rs6058293	chr20:34248891	T/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	5.91	0.36	1.21e-8	Total cholesterol levels;
SARC	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg16680214	chr1:154839983	KCNN3	-0.38	-5.98	-0.36	8.29e-9	Prostate cancer;
SARC	cis	rs7561149	1.000	rs12992014	chr2:179691285	G/A	cg17765952	chr2:179737173	CCDC141	-0.39	-5.15	-0.32	5.62e-7	QT interval;
SARC	cis	rs4927850	0.794	rs2019472	chr3:195735371	T/C	cg00031303	chr3:195681400	NA	0.71	7.78	0.45	2.29e-13	Pancreatic cancer;
SARC	cis	rs12824058	0.737	rs11060829	chr12:130814996	G/T	cg24838063	chr12:130822603	PIWIL1	0.64	9.26	0.52	1.42e-17	Menopause (age at onset);
SARC	cis	rs1113500	0.933	rs11185255	chr1:108633191	T/A	cg06207961	chr1:108661230	NA	0.45	5.92	0.36	1.12e-8	Growth-regulated protein alpha levels;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg15874048	chr14:45369753	C14orf28	0.55	7.52	0.44	1.21e-12	Thyroid stimulating hormone;
SARC	cis	rs8067545	0.611	rs9902032	chr17:20015178	G/C	cg13482628	chr17:19912719	NA	0.57	7.33	0.43	3.87e-12	Schizophrenia;
SARC	cis	rs2046867	0.908	rs62251636	chr3:72792650	A/G	cg25664220	chr3:72788482	NA	-0.29	-4.85	-0.3	2.24e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
SARC	cis	rs11711311	1.000	rs12497716	chr3:113453258	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	8.48	0.49	2.62e-15	IgG glycosylation;
SARC	cis	rs7644634	0.688	rs6773661	chr3:105487849	T/C	cg23051926	chr3:105466016	CBLB	0.46	5.75	0.35	2.83e-8	Itch intensity from mosquito bite;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg14618681	chr20:32273893	E2F1	0.48	6.47	0.39	5.59e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs9399137	0.507	rs7745289	chr6:135380327	A/G	cg24558204	chr6:135376177	HBS1L	0.64	8.17	0.47	1.9e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg11494091	chr17:61959527	GH2	0.36	5.14	0.32	5.83e-7	Height;
SARC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.28	0.8	2.29e-53	Prudent dietary pattern;
SARC	trans	rs629535	0.862	rs662725	chr8:70029616	C/T	cg21567404	chr3:27674614	NA	1.05	14.23	0.68	1.78e-33	Dupuytren's disease;
SARC	cis	rs926392	0.547	rs6129161	chr20:37678327	T/G	cg16355469	chr20:37678765	NA	0.76	9.77	0.54	3.94e-19	Dialysis-related mortality;
SARC	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg26681399	chr22:41777847	TEF	0.48	5.3	0.33	2.65e-7	Vitiligo;
SARC	cis	rs11098499	0.863	rs1010740	chr4:120463409	C/T	cg09307838	chr4:120376055	NA	-0.91	-12.48	-0.63	1.06e-27	Corneal astigmatism;
SARC	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.36	-4.95	-0.31	1.45e-6	Total body bone mineral density;
SARC	cis	rs11690935	0.527	rs7586556	chr2:172901887	G/C	cg13550731	chr2:172543902	DYNC1I2	0.58	7.8	0.45	2.08e-13	Schizophrenia;
SARC	cis	rs1153858	0.943	rs12439575	chr15:45684816	T/G	cg26924012	chr15:45694286	SPATA5L1	0.79	11.28	0.59	7.79e-24	Homoarginine levels;
SARC	cis	rs3762637	1.000	rs6777596	chr3:122133321	C/T	cg24169773	chr3:122142474	KPNA1	-0.54	-5.44	-0.34	1.33e-7	LDL cholesterol levels;
SARC	cis	rs12421382	0.811	rs11602639	chr11:109472829	C/T	cg16359550	chr11:109292809	C11orf87	0.46	6.29	0.38	1.54e-9	Schizophrenia;
SARC	cis	rs710216	0.917	rs900837	chr1:43412793	A/G	cg03128534	chr1:43423976	SLC2A1	-0.66	-6.84	-0.41	6.75e-11	Red cell distribution width;
SARC	cis	rs9788682	0.747	rs938682	chr15:78896547	A/G	cg24631222	chr15:78858424	CHRNA5	0.71	9.72	0.54	5.87e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	trans	rs7615952	0.932	rs3811679	chr3:125648283	A/G	cg07211511	chr3:129823064	LOC729375	-0.96	-10.77	-0.58	3.15e-22	Blood pressure (smoking interaction);
SARC	cis	rs2075371	0.933	rs1421482	chr7:133964383	A/G	cg11752832	chr7:134001865	SLC35B4	0.54	6.92	0.41	4.35e-11	Mean platelet volume;
SARC	cis	rs2832191	0.511	rs7278227	chr21:30482707	C/T	cg08807101	chr21:30365312	RNF160	-0.56	-6.29	-0.38	1.56e-9	Dental caries;
SARC	cis	rs2120243	0.534	rs35004310	chr3:157113800	C/T	cg24825693	chr3:157122686	VEPH1	-0.46	-6.41	-0.39	8.16e-10	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg11764359	chr7:65958608	NA	0.88	12.58	0.64	4.89e-28	Aortic root size;
SARC	cis	rs10931896	0.531	rs295117	chr2:201146828	C/T	cg17644776	chr2:200775616	C2orf69	0.44	5.97	0.36	8.68e-9	Systolic blood pressure;
SARC	cis	rs8067545	0.611	rs1992561	chr17:20219119	G/A	cg13482628	chr17:19912719	NA	-0.56	-7.38	-0.44	2.79e-12	Schizophrenia;
SARC	cis	rs896854	0.517	rs1011795	chr8:95951073	G/A	cg16049864	chr8:95962084	TP53INP1	-0.34	-5.01	-0.31	1.06e-6	Type 2 diabetes;
SARC	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg20965017	chr5:231967	SDHA	-0.58	-5.73	-0.35	3.14e-8	Breast cancer;
SARC	cis	rs13191362	0.507	rs13212746	chr6:163203092	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.47	5.16	0.32	5.26e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2963155	0.518	rs853178	chr5:142634799	C/T	cg17617527	chr5:142782415	NR3C1	0.81	5.67	0.35	4.31e-8	Breast cancer;
SARC	cis	rs7264396	0.635	rs2425166	chr20:34439391	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.51	5.08	0.32	7.84e-7	Total cholesterol levels;
SARC	cis	rs7394190	0.748	rs4082339	chr10:75539812	C/T	cg07699608	chr10:75541558	CHCHD1	-0.91	-8.55	-0.49	1.66e-15	Incident atrial fibrillation;
SARC	cis	rs12142240	0.698	rs1475389	chr1:46816429	T/C	cg10495392	chr1:46806563	NSUN4	0.65	6.83	0.41	7.25e-11	Menopause (age at onset);
SARC	cis	rs9303401	0.659	rs34275691	chr17:56736640	A/T	cg25039879	chr17:56429692	SUPT4H1	0.66	6.1	0.37	4.28e-9	Cognitive test performance;
SARC	cis	rs4319547	0.915	rs10734924	chr12:123018894	T/G	cg23029597	chr12:123009494	RSRC2	-0.41	-5.2	-0.32	4.4e-7	Body mass index;
SARC	cis	rs995000	0.868	rs10889357	chr1:63160282	C/T	cg06896770	chr1:63153194	DOCK7	0.93	14.05	0.68	7.05e-33	Triglyceride levels;
SARC	trans	rs9325144	0.555	rs4882279	chr12:38688918	C/A	cg23762105	chr12:34175262	ALG10	-0.52	-6.97	-0.42	3.32e-11	Morning vs. evening chronotype;
SARC	cis	rs9902453	0.900	rs9910970	chr17:28478329	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	6.92	0.41	4.36e-11	Coffee consumption (cups per day);
SARC	cis	rs3768617	0.565	rs2027080	chr1:183074415	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.67	9.71	0.54	6.11e-19	Fuchs's corneal dystrophy;
SARC	cis	rs950776	1.000	rs950776	chr15:78926018	A/G	cg24631222	chr15:78858424	CHRNA5	-0.37	-4.77	-0.3	3.3e-6	Sudden cardiac arrest;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg19732469	chr14:96968481	PAPOLA	0.75	6.65	0.4	2.04e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2197308	0.765	rs2387436	chr12:37935337	C/T	cg26384229	chr12:38710491	ALG10B	-0.81	-11.63	-0.61	6.08e-25	Morning vs. evening chronotype;
SARC	cis	rs698813	0.674	rs6544752	chr2:44499049	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	6.17	0.37	3.03e-9	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs116979167	0.630	rs56230603	chr7:105165268	A/G	cg19920283	chr7:105172520	RINT1	0.66	5.66	0.35	4.47e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs6570726	0.935	rs453609	chr6:145812332	T/C	cg05220968	chr6:146057943	EPM2A	-0.29	-4.83	-0.3	2.44e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs554111	0.660	rs658851	chr1:21079425	T/C	cg04902671	chr1:21058625	SH2D5	-0.49	-5.97	-0.36	8.83e-9	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs7208859	0.614	rs73265646	chr17:29244023	C/T	cg13385521	chr17:29058706	SUZ12P	0.85	6.58	0.4	3.08e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs7584330	0.666	rs72620817	chr2:238353661	C/T	cg14458575	chr2:238380390	NA	0.59	6.5	0.39	4.78e-10	Prostate cancer;
SARC	cis	rs2239547	0.618	rs2071041	chr3:52864693	T/G	cg11645453	chr3:52864694	ITIH4	0.32	5.08	0.32	7.61e-7	Schizophrenia;
SARC	cis	rs17739167	0.550	rs1426890	chr15:42226125	G/A	cg20935245	chr15:42234343	EHD4	0.46	5.99	0.37	7.93e-9	Monocyte count;
SARC	cis	rs6088580	0.524	rs7269596	chr20:33229063	T/C	cg07148914	chr20:33460835	GGT7	-0.42	-5.11	-0.32	6.81e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs7216064	1.000	rs35243555	chr17:65876477	G/C	cg12091567	chr17:66097778	LOC651250	-0.64	-6.45	-0.39	6.56e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs10512697	0.803	rs34134373	chr5:3574462	C/A	cg19473799	chr5:3511975	NA	-0.65	-4.77	-0.3	3.27e-6	Immune response to smallpox vaccine (IL-6);
SARC	trans	rs66573146	0.656	rs66517061	chr4:6935163	C/G	cg07817883	chr1:32538562	TMEM39B	1.13	7.91	0.46	1.05e-13	Granulocyte percentage of myeloid white cells;
SARC	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg22535103	chr8:58192502	C8orf71	-0.73	-7.24	-0.43	6.52e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs11651000	0.817	rs7502875	chr17:45823227	A/C	cg03474202	chr17:45855739	NA	-0.4	-5.74	-0.35	2.93e-8	IgG glycosylation;
SARC	cis	rs10791323	0.628	rs2853117	chr11:133705266	T/G	cg13461336	chr11:133711254	SPATA19	-0.28	-4.84	-0.3	2.41e-6	Childhood ear infection;
SARC	cis	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg05623727	chr3:50126028	RBM5	-0.33	-4.99	-0.31	1.19e-6	Intelligence (multi-trait analysis);
SARC	cis	rs3126085	0.877	rs7537633	chr1:152223333	T/G	cg26876637	chr1:152193138	HRNR	0.45	5.34	0.33	2.24e-7	Atopic dermatitis;
SARC	cis	rs6807306	1.000	rs3804610	chr3:167413168	T/C	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.52	5.06	0.31	8.51e-7	Mean platelet volume;
SARC	cis	rs3749237	0.595	rs6797765	chr3:49423976	A/G	cg02487422	chr3:49467188	NICN1	0.48	6.39	0.39	8.9e-10	Resting heart rate;
SARC	cis	rs10464366	0.560	rs11763728	chr7:39145862	C/T	cg15212455	chr7:39170539	POU6F2	0.35	4.84	0.3	2.41e-6	IgG glycosylation;
SARC	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.44	4.71	0.3	4.18e-6	Renal function-related traits (BUN);
SARC	cis	rs7772486	0.719	rs702307	chr6:145993454	C/G	cg23711669	chr6:146136114	FBXO30	-0.89	-15.38	-0.71	2.56e-37	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7208859	0.623	rs59447372	chr17:29057585	C/T	cg13385521	chr17:29058706	SUZ12P	0.85	7.36	0.43	3.19e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg03709012	chr19:19516395	GATAD2A	1.01	17.45	0.75	3.42e-44	Tonsillectomy;
SARC	cis	rs13082711	0.522	rs569960	chr3:27329540	C/T	cg02860705	chr3:27208620	NA	0.46	6.2	0.38	2.61e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs7937682	0.847	rs583032	chr11:111432757	C/T	cg22437258	chr11:111473054	SIK2	0.77	10.23	0.56	1.53e-20	Primary sclerosing cholangitis;
SARC	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg22433210	chr17:43662623	NA	-0.95	-11.34	-0.6	4.92e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs11785400	0.793	rs4301430	chr8:143737416	A/G	cg24634471	chr8:143751801	JRK	0.59	7.63	0.45	6.14e-13	Schizophrenia;
SARC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	5.98	0.36	8.19e-9	Prudent dietary pattern;
SARC	cis	rs72653721	0.793	rs4713100	chr6:10968216	T/C	cg13562911	chr6:11044106	ELOVL2	0.57	6.18	0.38	2.85e-9	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	cis	rs1707322	0.752	rs61784793	chr1:46149285	G/A	cg06784218	chr1:46089804	CCDC17	0.36	6.25	0.38	1.89e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg18357526	chr6:26021779	HIST1H4A	0.57	6.84	0.41	7.03e-11	Intelligence (multi-trait analysis);
SARC	cis	rs7520050	0.966	rs6675946	chr1:46371774	G/T	cg06784218	chr1:46089804	CCDC17	-0.26	-4.79	-0.3	2.97e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs10895275	0.510	rs1942683	chr11:102044647	C/T	cg00496961	chr11:102638706	NA	0.34	5.05	0.31	8.94e-7	Migraine;
SARC	cis	rs2481665	0.902	rs1013293	chr1:62570321	G/A	cg18591186	chr1:62594603	INADL	-0.64	-9.08	-0.51	4.72e-17	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs1018836	0.828	rs12547016	chr8:91563847	T/C	cg16814680	chr8:91681699	NA	-0.74	-11.48	-0.6	1.84e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	trans	rs9329221	0.537	rs13264586	chr8:9979385	T/C	cg06636001	chr8:8085503	FLJ10661	0.53	7.25	0.43	6.07e-12	Neuroticism;
SARC	cis	rs9843304	0.616	rs4681174	chr3:149201626	G/A	cg08667024	chr3:149219783	TM4SF4	-0.36	-5.12	-0.32	6.44e-7	Gallstone disease;
SARC	cis	rs7539409	0.604	rs910183	chr1:84297285	A/G	cg10977910	chr1:84465055	TTLL7	0.59	5.43	0.34	1.41e-7	Alzheimer's disease;
SARC	cis	rs9902453	0.765	rs9890747	chr17:28007442	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	7.15	0.42	1.11e-11	Coffee consumption (cups per day);
SARC	cis	rs7100689	0.577	rs2282367	chr10:82040346	A/G	cg01528321	chr10:82214614	TSPAN14	0.69	8.91	0.5	1.45e-16	Post bronchodilator FEV1;
SARC	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.44	-5.64	-0.35	4.97e-8	Personality dimensions;
SARC	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg20607798	chr8:58055168	NA	0.6	5.34	0.33	2.19e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs4243830	0.850	rs1114661	chr1:6596871	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.9	-9.19	-0.52	2.23e-17	Body mass index;
SARC	cis	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg05623727	chr3:50126028	RBM5	-0.34	-5.27	-0.33	3.18e-7	Intelligence (multi-trait analysis);
SARC	cis	rs8077889	0.871	rs7212648	chr17:41917962	A/C	cg26893861	chr17:41843967	DUSP3	0.82	10.24	0.56	1.44e-20	Triglycerides;
SARC	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg09699651	chr6:150184138	LRP11	0.46	5.53	0.34	8.63e-8	Lung cancer;
SARC	cis	rs1153858	1.000	rs7163720	chr15:45639374	G/A	cg14582100	chr15:45693742	SPATA5L1	0.37	5.03	0.31	9.67e-7	Homoarginine levels;
SARC	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg07061783	chr6:25882402	NA	-0.51	-5.74	-0.35	2.87e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9457247	1.000	rs2149090	chr6:167372764	T/C	cg23791538	chr6:167370224	RNASET2	0.63	8.74	0.5	4.74e-16	Crohn's disease;
SARC	cis	rs10791097	0.592	rs7116068	chr11:130732739	A/C	cg12179176	chr11:130786555	SNX19	-0.68	-9.84	-0.54	2.54e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs12148488	0.816	rs11854975	chr15:75363876	C/T	cg09165964	chr15:75287851	SCAMP5	0.53	7.02	0.42	2.37e-11	Caffeine consumption;
SARC	cis	rs832540	0.931	rs832529	chr5:56229288	C/T	cg14703610	chr5:56206110	C5orf35	0.52	6.61	0.4	2.63e-10	Coronary artery disease;
SARC	cis	rs11098499	0.909	rs28714195	chr4:120316950	A/T	cg09307838	chr4:120376055	NA	0.91	12.88	0.65	4.9e-29	Corneal astigmatism;
SARC	cis	rs911555	0.692	rs60235428	chr14:103904350	T/C	cg24130564	chr14:104152367	KLC1	0.49	5.75	0.35	2.83e-8	Intelligence (multi-trait analysis);
SARC	cis	rs4969178	0.930	rs11077363	chr17:76397309	C/T	cg02836325	chr17:76403955	PGS1	0.33	5.01	0.31	1.07e-6	HDL cholesterol levels;
SARC	cis	rs2075371	1.000	rs2075372	chr7:133984432	C/T	cg20476274	chr7:133979776	SLC35B4	0.62	8.41	0.48	4.18e-15	Mean platelet volume;
SARC	cis	rs6570726	0.791	rs408443	chr6:145874643	T/C	cg23711669	chr6:146136114	FBXO30	0.87	14.67	0.69	5.76e-35	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs753778	0.628	rs1045248	chr8:142204326	C/G	cg18755752	chr8:142205143	DENND3	-0.55	-7.98	-0.46	6.75e-14	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs9486715	0.867	rs1127175	chr6:96999725	C/T	cg06623918	chr6:96969491	KIAA0776	-0.87	-12.25	-0.63	5.76e-27	Headache;
SARC	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg13939156	chr17:80058883	NA	-0.42	-6.48	-0.39	5.51e-10	Life satisfaction;
SARC	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg06634786	chr22:41940651	POLR3H	0.49	6.09	0.37	4.68e-9	Vitiligo;
SARC	cis	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.44	-0.39	6.9e-10	Joint mobility (Beighton score);
SARC	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg08859206	chr1:53392774	SCP2	-0.42	-6.1	-0.37	4.37e-9	Monocyte count;
SARC	cis	rs10927875	0.541	rs1763607	chr1:16337509	G/A	cg21385522	chr1:16154831	NA	0.53	6.39	0.39	8.97e-10	Dilated cardiomyopathy;
SARC	cis	rs10861342	1.000	rs11112403	chr12:105586649	A/G	cg23923672	chr12:105501055	KIAA1033	0.65	5.03	0.31	9.67e-7	IgG glycosylation;
SARC	cis	rs1865760	0.516	rs9379819	chr6:26049819	A/C	cg02841227	chr6:26021843	HIST1H4A	0.39	4.82	0.3	2.53e-6	Height;
SARC	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg11843238	chr5:131593191	PDLIM4	-0.42	-5.6	-0.34	6.08e-8	Acylcarnitine levels;
SARC	cis	rs7829975	0.533	rs1039917	chr8:8718850	C/T	cg06636001	chr8:8085503	FLJ10661	0.65	8.44	0.48	3.42e-15	Mood instability;
SARC	cis	rs11786130	0.544	rs10087240	chr8:129012574	C/T	cg01765152	chr8:129005526	PVT1	0.39	6.07	0.37	5.15e-9	Eosinophil counts;Sum eosinophil basophil counts;
SARC	cis	rs477692	0.663	rs491929	chr10:131368111	G/A	cg14263093	chr10:131365266	MGMT	0.35	4.86	0.3	2.19e-6	Response to temozolomide;
SARC	cis	rs7224737	1.000	rs1122326	chr17:40274873	A/C	cg20291162	chr17:40259547	DHX58	-0.33	-4.77	-0.3	3.29e-6	Fibrinogen levels;
SARC	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg13395646	chr4:1353034	KIAA1530	-0.48	-5.68	-0.35	4.08e-8	Obesity-related traits;
SARC	cis	rs11098499	0.863	rs11731756	chr4:120478696	T/G	cg09307838	chr4:120376055	NA	0.91	12.25	0.63	5.66e-27	Corneal astigmatism;
SARC	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6500602	0.893	rs4785962	chr16:4484328	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.31	4.82	0.3	2.54e-6	Schizophrenia;
SARC	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg02931644	chr1:25747376	RHCE	-0.41	-7.11	-0.42	1.37e-11	Erythrocyte sedimentation rate;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg00765254	chr10:103815936	C10orf76	0.75	6.44	0.39	6.58e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs11668609	0.515	rs61308481	chr19:24065347	C/T	cg27517351	chr19:23941871	ZNF681	0.54	4.76	0.3	3.43e-6	Response to taxane treatment (docetaxel);
SARC	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg23758822	chr17:41437982	NA	0.9	11.42	0.6	2.87e-24	Menopause (age at onset);
SARC	cis	rs6908034	0.607	rs76245225	chr6:19813188	T/G	cg02682789	chr6:19804855	NA	0.69	5.56	0.34	7.3900000000000007e-08	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs6570726	0.516	rs9322025	chr6:145729196	C/T	cg23711669	chr6:146136114	FBXO30	0.56	7.72	0.45	3.43e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9322817	0.902	rs9322812	chr6:105194651	A/G	cg02098413	chr6:105308735	HACE1	-0.33	-4.78	-0.3	3.16e-6	Thyroid stimulating hormone;
SARC	cis	rs644799	0.965	rs11021305	chr11:95498269	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	14.53	0.69	1.75e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs12824058	0.831	rs4759450	chr12:130812732	G/A	cg23887609	chr12:130822674	PIWIL1	0.37	5.15	0.32	5.52e-7	Menopause (age at onset);
SARC	cis	rs10504229	0.679	rs2218271	chr8:58052446	T/A	cg08219700	chr8:58056026	NA	0.6	6.01	0.37	6.93e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg00431813	chr7:1051703	C7orf50	-0.33	-4.97	-0.31	1.3e-6	Longevity;Endometriosis;
SARC	cis	rs2439831	0.850	rs28718261	chr15:44043793	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	7.55	0.44	1.01e-12	Lung cancer in ever smokers;
SARC	cis	rs12048904	0.930	rs11166529	chr1:101333733	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.43	5.34	0.33	2.22e-7	Multiple sclerosis;
SARC	cis	rs9486715	0.867	rs6568428	chr6:96903604	A/G	cg06623918	chr6:96969491	KIAA0776	0.84	11.84	0.61	1.24e-25	Headache;
SARC	cis	rs12701220	0.553	rs13245507	chr7:1163694	C/T	cg00990874	chr7:1149470	C7orf50	-0.45	-4.75	-0.3	3.61e-6	Bronchopulmonary dysplasia;
SARC	cis	rs1843834	0.539	rs1494109	chr2:225441833	G/A	cg12698349	chr2:225449008	CUL3	0.7	9.17	0.52	2.5e-17	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg05793240	chr7:2802953	GNA12	-0.35	-5.1	-0.32	7.15e-7	Height;
SARC	cis	rs892961	0.932	rs747481	chr17:75412143	A/G	cg05865280	chr17:75406074	SEPT9	0.57	8.47	0.49	2.71e-15	Airflow obstruction;
SARC	cis	rs6714710	0.603	rs2044459	chr2:98447004	T/C	cg26665480	chr2:98280029	ACTR1B	0.49	6.59	0.4	2.96e-10	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs11785400	0.762	rs7017931	chr8:143726728	A/G	cg24634471	chr8:143751801	JRK	0.6	7.74	0.45	2.98e-13	Schizophrenia;
SARC	trans	rs61931739	0.500	rs11053223	chr12:34481947	T/A	cg26384229	chr12:38710491	ALG10B	0.91	13.6	0.67	2.08e-31	Morning vs. evening chronotype;
SARC	cis	rs9611519	1.000	rs9611505	chr22:41540279	T/C	cg03806693	chr22:41940476	POLR3H	-0.55	-6.23	-0.38	2.19e-9	Neuroticism;
SARC	cis	rs72792276	1.000	rs72794370	chr5:127444907	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	6.19	0.38	2.7e-9	Red cell distribution width;
SARC	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg06028808	chr11:68637592	NA	0.47	5.96	0.36	9.37e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs1348850	0.914	rs10170546	chr2:178248790	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.72	9.23	0.52	1.72e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs611744	0.967	rs602384	chr8:109188185	G/C	cg21045802	chr8:109455806	TTC35	0.44	5.3	0.33	2.64e-7	Dupuytren's disease;
SARC	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg07701084	chr6:150067640	NUP43	0.39	5.08	0.32	7.86e-7	Lung cancer;
SARC	cis	rs1005277	1.000	rs1005277	chr10:38218259	A/C	cg25427524	chr10:38739819	LOC399744	0.39	5.26	0.33	3.25e-7	Extrinsic epigenetic age acceleration;
SARC	trans	rs10771431	0.713	rs17794353	chr12:9361783	C/T	cg27600084	chr12:12264075	NA	-0.57	-7.44	-0.44	1.89e-12	Breast size;
SARC	cis	rs2276314	1.000	rs16967317	chr18:33573400	A/G	cg05985134	chr18:33552581	C18orf21	0.73	7.55	0.44	9.55e-13	Endometriosis;Drug-induced torsades de pointes;
SARC	trans	rs7824557	0.564	rs2043508	chr8:11227406	G/A	cg06636001	chr8:8085503	FLJ10661	-0.6	-7.88	-0.46	1.23e-13	Retinal vascular caliber;
SARC	cis	rs6964587	1.000	rs7805077	chr7:91644553	A/G	cg17063962	chr7:91808500	NA	0.93	15.71	0.72	2.06e-38	Breast cancer;
SARC	cis	rs875971	0.571	rs160647	chr7:65554352	C/T	cg11764359	chr7:65958608	NA	-0.63	-6.12	-0.37	3.9e-9	Aortic root size;
SARC	cis	rs734999	0.549	rs2764845	chr1:2528999	G/T	cg00980319	chr1:2560884	MMEL1	0.34	4.91	0.31	1.7e-6	Ulcerative colitis;
SARC	cis	rs10463316	0.894	rs6875014	chr5:150754345	C/T	cg03212797	chr5:150827313	SLC36A1	-0.43	-5.2	-0.32	4.41e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs2836974	0.653	rs8130556	chr21:40516872	C/T	cg17971929	chr21:40555470	PSMG1	0.98	13.17	0.65	5.44e-30	Cognitive function;
SARC	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg03185022	chr7:2884158	GNA12	0.46	5.15	0.32	5.63e-7	Height;
SARC	cis	rs4742903	0.901	rs10122512	chr9:106898410	C/T	cg14250997	chr9:106856677	SMC2	0.5	6.56	0.39	3.46e-10	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg11764359	chr7:65958608	NA	-0.66	-7.79	-0.45	2.25e-13	Aortic root size;
SARC	cis	rs7772486	0.790	rs4314514	chr6:146260010	A/G	cg23711669	chr6:146136114	FBXO30	-0.8	-12.47	-0.63	1.13e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg11764359	chr7:65958608	NA	0.59	6.91	0.41	4.63e-11	Calcium levels;
SARC	cis	rs12618769	0.597	rs17031905	chr2:99070902	A/G	cg14361474	chr2:99058762	NA	-0.31	-4.72	-0.3	4.14e-6	Bipolar disorder;
SARC	cis	rs11785400	1.000	rs9720653	chr8:143731939	T/G	cg24634471	chr8:143751801	JRK	0.66	8.76	0.5	4.01e-16	Schizophrenia;
SARC	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-5.45	-0.34	1.28e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs965469	0.947	rs6037578	chr20:3345911	T/C	cg25506879	chr20:3388711	C20orf194	-0.47	-4.74	-0.3	3.66e-6	IFN-related cytopenia;
SARC	cis	rs1707322	1.000	rs4660328	chr1:46444831	G/T	cg03146154	chr1:46216737	IPP	0.45	5.41	0.33	1.57e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg23795623	chr13:111268031	CARKD	0.69	4.76	0.3	3.36e-6	Obesity-related traits;
SARC	cis	rs11039131	0.629	rs67871383	chr11:47335838	T/C	cg20307385	chr11:47447363	PSMC3	-0.44	-5.2	-0.32	4.4e-7	Schizophrenia;
SARC	cis	rs1865760	0.613	rs9379805	chr6:25938764	T/A	cg16482183	chr6:26056742	HIST1H1C	0.45	5.64	0.35	4.98e-8	Height;
SARC	cis	rs73635312	0.706	rs79282820	chr10:8942796	T/G	cg24467326	chr10:9646929	NA	0.56	4.88	0.3	1.95e-6	Basal cell carcinoma;
SARC	cis	rs9300255	0.602	rs1727306	chr12:123665695	A/G	cg00376283	chr12:123451042	ABCB9	0.55	6.53	0.39	4.09e-10	Neutrophil percentage of white cells;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg04221387	chr4:113276997	ALPK1	0.52	6.67	0.4	1.89e-10	Schizophrenia;
SARC	cis	rs17125944	0.686	rs7141335	chr14:53336934	C/T	cg00686598	chr14:53173677	PSMC6	-0.65	-4.91	-0.31	1.7e-6	Alzheimer's disease (late onset);
SARC	cis	rs7712401	0.755	rs13172043	chr5:122184759	G/A	cg19412675	chr5:122181750	SNX24	0.41	5.44	0.34	1.35e-7	Mean platelet volume;
SARC	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg17221315	chr6:27791827	HIST1H4J	0.45	4.75	0.3	3.57e-6	Parkinson's disease;
SARC	cis	rs1215050	0.740	rs783949	chr4:99001933	A/G	cg05340658	chr4:99064831	C4orf37	-0.47	-6.34	-0.38	1.17e-9	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs7666738	0.791	rs1405766	chr4:98965389	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg20607798	chr8:58055168	NA	0.58	5.57	0.34	6.9e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs8067354	0.645	rs2173120	chr17:57892640	A/T	cg13753209	chr17:57696993	CLTC	0.62	6.28	0.38	1.62e-9	Hemoglobin concentration;
SARC	cis	rs1448094	0.556	rs2061686	chr12:86170951	C/T	cg00310523	chr12:86230176	RASSF9	-0.36	-5.67	-0.35	4.14e-8	Major depressive disorder;
SARC	cis	rs17079773	1.000	rs17079773	chr13:24598384	A/G	cg14700609	chr13:24463713	PCOTH;MIPEP	-0.54	-4.9	-0.31	1.8e-6	Inattentive symptoms;
SARC	cis	rs8072100	0.790	rs1962307	chr17:45707871	A/G	cg08085267	chr17:45401833	C17orf57	-0.45	-5.33	-0.33	2.3e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs1153858	1.000	rs67744121	chr15:45677237	C/G	cg21132104	chr15:45694354	SPATA5L1	0.78	11.01	0.59	5.55e-23	Homoarginine levels;
SARC	cis	rs2230307	0.572	rs2810419	chr1:100643968	C/A	cg24955406	chr1:100503596	HIAT1	-0.63	-6.08	-0.37	4.96e-9	Carotid intima media thickness;
SARC	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg24531977	chr5:56204891	C5orf35	-0.54	-5.45	-0.34	1.26e-7	Initial pursuit acceleration;
SARC	cis	rs6121246	0.954	rs73241710	chr20:30424956	G/A	cg13852791	chr20:30311386	BCL2L1	0.85	9.16	0.51	2.77e-17	Mean corpuscular hemoglobin;
SARC	cis	rs6674176	0.597	rs12127737	chr1:44402565	G/A	cg12908607	chr1:44402522	ARTN	-0.4	-7.1	-0.42	1.53e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs1348850	0.519	rs10201883	chr2:178471407	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.59	5.35	0.33	2.14e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs4803468	0.967	rs67047091	chr19:41938684	C/T	cg08477640	chr19:41863820	B9D2	-0.43	-5.39	-0.33	1.71e-7	Height;
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg03982820	chr1:40723960	ZMPSTE24	0.51	6.76	0.4	1.08e-10	Tetralogy of Fallot;
SARC	cis	rs2236918	1.000	rs2526701	chr1:242018427	T/C	cg17736920	chr1:242011382	EXO1	0.79	11.16	0.59	1.87e-23	Menopause (age at onset);
SARC	cis	rs3784262	1.000	rs7495968	chr15:58244103	C/G	cg12031962	chr15:58353849	ALDH1A2	0.42	6.47	0.39	5.58e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs7829975	0.511	rs2976902	chr8:8341105	T/G	cg06636001	chr8:8085503	FLJ10661	0.62	8.79	0.5	3.44e-16	Mood instability;
SARC	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg24633833	chr3:10029261	TMEM111	0.52	5.25	0.33	3.43e-7	Alzheimer's disease;
SARC	cis	rs6570726	0.935	rs436212	chr6:145849400	G/A	cg05220968	chr6:146057943	EPM2A	-0.29	-5.04	-0.31	9.48e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2073300	0.609	rs56094936	chr20:23401586	G/A	cg12062639	chr20:23401060	NAPB	0.99	6.67	0.4	1.81e-10	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg05313129	chr8:58192883	C8orf71	-0.58	-6.5	-0.39	4.83e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6121246	0.559	rs6060950	chr20:30378031	T/C	cg13852791	chr20:30311386	BCL2L1	0.89	10.96	0.58	8.41e-23	Mean corpuscular hemoglobin;
SARC	cis	rs2242194	0.816	rs11264296	chr1:154994750	T/C	cg16680214	chr1:154839983	KCNN3	-0.33	-5.14	-0.32	5.72e-7	Schizophrenia;
SARC	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg10523679	chr1:76189770	ACADM	-0.44	-5.26	-0.33	3.32e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg22920501	chr2:26401640	FAM59B	0.58	7.77	0.45	2.55e-13	Gut microbiome composition (summer);
SARC	cis	rs6570726	0.818	rs9390338	chr6:145908265	A/G	cg05347473	chr6:146136440	FBXO30	0.51	7.13	0.42	1.29e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6121246	0.909	rs4518038	chr20:30419051	A/G	cg13852791	chr20:30311386	BCL2L1	0.89	8.64	0.49	9.18e-16	Mean corpuscular hemoglobin;
SARC	cis	rs1920116	0.778	rs6785618	chr3:169562797	G/A	cg14222479	chr3:169487675	ARPM1	0.45	5.2	0.32	4.33e-7	Glioma (high-grade);
SARC	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	10.82	0.58	2.34e-22	Alzheimer's disease;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg10515953	chr10:61666281	CCDC6	0.51	6.83	0.41	7.41e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs9660992	0.710	rs1768586	chr1:205238275	A/G	cg21643547	chr1:205240462	TMCC2	-0.66	-8.83	-0.5	2.63e-16	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs9948	0.867	rs17119598	chr2:97486315	A/G	cg01990225	chr2:97406019	LMAN2L	0.9	6.26	0.38	1.81e-9	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs758129	0.722	rs150295	chr15:89929934	T/C	cg03745604	chr15:89905304	NA	0.39	5.16	0.32	5.32e-7	Schizophrenia;
SARC	cis	rs2204008	0.560	rs4129033	chr12:38301897	A/T	cg14851346	chr12:38532713	NA	-0.45	-5.3	-0.33	2.66e-7	Bladder cancer;
SARC	cis	rs8141529	0.778	rs7287806	chr22:29213011	G/A	cg15103426	chr22:29168792	CCDC117	0.68	9.01	0.51	7.63e-17	Lymphocyte counts;
SARC	cis	rs17376456	0.866	rs13356088	chr5:93423479	C/T	cg25358565	chr5:93447407	FAM172A	1.33	12.68	0.64	2.29e-28	Diabetic retinopathy;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg00237586	chr2:33107130	LOC285045	0.51	7.45	0.44	1.85e-12	Thyroid stimulating hormone;
SARC	cis	rs7666738	0.830	rs6831925	chr4:98947401	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.96	0.51	1.06e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs12477438	0.953	rs3851334	chr2:99794704	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-6.68	-0.4	1.71e-10	Chronic sinus infection;
SARC	cis	rs2985684	0.901	rs7146248	chr14:50112067	C/T	cg23336454	chr14:50234671	KLHDC2	-0.45	-4.74	-0.3	3.73e-6	Carotid intima media thickness;
SARC	cis	rs3768617	0.528	rs4652778	chr1:183097420	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.2	0.56	1.95e-20	Fuchs's corneal dystrophy;
SARC	cis	rs8067545	0.516	rs4925086	chr17:20013459	A/T	cg13482628	chr17:19912719	NA	0.54	7.12	0.42	1.35e-11	Schizophrenia;
SARC	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	10.12	0.55	3.42e-20	Platelet count;
SARC	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg18876405	chr7:65276391	NA	-0.69	-8.95	-0.51	1.15e-16	Calcium levels;
SARC	cis	rs7223966	1.000	rs55868506	chr17:61851686	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.52	-5.44	-0.34	1.35e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg12311346	chr5:56204834	C5orf35	-0.54	-5.58	-0.34	6.53e-8	Initial pursuit acceleration;
SARC	cis	rs4423214	1.000	rs2040323	chr11:71172783	A/C	cg05163923	chr11:71159392	DHCR7	0.67	9.26	0.52	1.38e-17	Vitamin D levels;
SARC	cis	rs4128725	0.929	rs12042314	chr1:159390129	G/C	cg25076881	chr1:159409836	OR10J1	0.4	4.78	0.3	3.16e-6	Select biomarker traits;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg01783706	chr12:49739991	DNAJC22	0.46	6.28	0.38	1.64e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	trans	rs12310956	0.531	rs10772110	chr12:33841755	A/G	cg13010199	chr12:38710504	ALG10B	0.54	6.36	0.38	1.06e-9	Morning vs. evening chronotype;
SARC	cis	rs870825	0.860	rs34985821	chr4:185599489	G/A	cg04058563	chr4:185651563	MLF1IP	0.79	9.69	0.54	7.16e-19	Blood protein levels;
SARC	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg05368731	chr17:41323189	NBR1	0.64	6.71	0.4	1.5e-10	Menopause (age at onset);
SARC	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg06713675	chr4:122721982	EXOSC9	-0.51	-6.61	-0.4	2.54e-10	Type 2 diabetes;
SARC	cis	rs7113850	0.541	rs78652241	chr11:24234956	A/T	ch.11.24196551F	chr11:24239977	NA	0.72	5.41	0.33	1.6e-7	Bone fracture in osteoporosis;
SARC	cis	rs1707322	0.964	rs785509	chr1:46527300	G/A	cg03146154	chr1:46216737	IPP	-0.48	-5.65	-0.35	4.78e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs826838	0.754	rs2387920	chr12:38626351	A/G	cg26384229	chr12:38710491	ALG10B	0.9	13.74	0.67	7.52e-32	Heart rate;
SARC	cis	rs4481887	1.000	rs6697735	chr1:248465315	G/C	cg13385794	chr1:248469461	NA	0.35	5.34	0.33	2.17e-7	Common traits (Other);
SARC	cis	rs9400467	0.506	rs12196873	chr6:111598058	G/T	cg15721981	chr6:111408429	SLC16A10	-0.65	-5.81	-0.36	2.09e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs4660306	0.677	rs781062	chr1:45932738	T/A	cg24296786	chr1:45957014	TESK2	-0.51	-4.84	-0.3	2.37e-6	Homocysteine levels;
SARC	cis	rs854765	0.724	rs62072049	chr17:17906520	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.59	8.63	0.49	9.41e-16	Total body bone mineral density;
SARC	cis	rs524281	0.773	rs4393319	chr11:66001878	A/T	cg14036092	chr11:66035641	RAB1B	-0.59	-6.28	-0.38	1.67e-9	Electroencephalogram traits;
SARC	cis	rs11122272	0.667	rs2244992	chr1:231537220	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.08	-0.55	4.68e-20	Hemoglobin concentration;
SARC	cis	rs4699052	0.927	rs1870888	chr4:104169326	G/C	cg16532752	chr4:104119610	CENPE	-0.41	-4.73	-0.3	3.81e-6	Testicular germ cell tumor;
SARC	trans	rs9388451	0.874	rs1159974	chr6:126090277	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.59	7.72	0.45	3.34e-13	Brugada syndrome;
SARC	cis	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg26695010	chr11:65641043	EFEMP2	-0.57	-7.46	-0.44	1.69e-12	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg27266027	chr21:40555129	PSMG1	-0.48	-5.11	-0.32	6.69e-7	Cognitive function;
SARC	cis	rs12579753	1.000	rs12830268	chr12:82233627	A/C	cg07988820	chr12:82153109	PPFIA2	-0.52	-6.07	-0.37	5.24e-9	Resting heart rate;
SARC	cis	rs611744	0.647	rs615233	chr8:109254262	C/T	cg21045802	chr8:109455806	TTC35	0.61	7.7	0.45	3.89e-13	Dupuytren's disease;
SARC	cis	rs11668609	0.506	rs8113480	chr19:24061019	G/T	cg27517351	chr19:23941871	ZNF681	-0.54	-4.74	-0.3	3.77e-6	Response to taxane treatment (docetaxel);
SARC	cis	rs9487051	0.872	rs1111863	chr6:109611206	C/T	cg01475377	chr6:109611718	NA	0.39	5.48	0.34	1.09e-7	Reticulocyte fraction of red cells;
SARC	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg22800045	chr5:56110881	MAP3K1	0.66	6.37	0.39	9.95e-10	Type 2 diabetes;
SARC	trans	rs9329221	0.527	rs4841351	chr8:10327367	G/A	cg06636001	chr8:8085503	FLJ10661	-0.62	-9.09	-0.51	4.41e-17	Neuroticism;
SARC	cis	rs7291412	1.000	rs7291412	chr22:46459132	G/T	cg23691090	chr22:46449981	C22orf26;LOC150381	0.33	4.85	0.3	2.23e-6	Dupuytren's disease;Subjective well-being;
SARC	cis	rs10876993	0.784	rs1871417	chr12:58018979	C/T	cg18357645	chr12:58087776	OS9	-0.41	-5.23	-0.32	3.73e-7	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs6570726	0.791	rs400329	chr6:145879442	A/T	cg05347473	chr6:146136440	FBXO30	0.54	7.54	0.44	1.05e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4481887	0.927	rs4558008	chr1:248477641	C/T	cg13385794	chr1:248469461	NA	0.34	5.22	0.32	4e-7	Common traits (Other);
SARC	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg04944784	chr2:26401820	FAM59B	-0.59	-7.88	-0.46	1.25e-13	Gut microbiome composition (summer);
SARC	cis	rs35110281	0.659	rs2236667	chr21:45112939	A/G	cg21573476	chr21:45109991	RRP1B	-0.6	-8.76	-0.5	4.16e-16	Mean corpuscular volume;
SARC	trans	rs2727020	0.521	rs937430	chr11:49542457	A/G	cg03929089	chr4:120376271	NA	0.7	7.9	0.46	1.11e-13	Coronary artery disease;
SARC	cis	rs6568686	0.577	rs174394	chr6:111918999	T/G	cg15721981	chr6:111408429	SLC16A10	0.6	5.07	0.32	8.05e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs12447804	0.645	rs35033732	chr16:58108191	G/A	cg03859792	chr16:58121049	NA	0.38	4.77	0.3	3.24e-6	Pulmonary function;Pulmonary function (smoking interaction);
SARC	cis	rs3733585	0.673	rs6850143	chr4:9958924	T/C	cg11266682	chr4:10021025	SLC2A9	-0.35	-6.03	-0.37	6.35e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs1018836	0.892	rs2187981	chr8:91549629	T/C	cg16814680	chr8:91681699	NA	-0.72	-11.28	-0.59	7.73e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg11987759	chr7:65425863	GUSB	0.58	7.64	0.45	5.63e-13	Aortic root size;
SARC	cis	rs12044355	0.927	rs12043433	chr1:231843591	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.53	6.97	0.42	3.21e-11	Alzheimer's disease;
SARC	cis	rs11690935	0.959	rs6705200	chr2:172637600	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.01	-16.42	-0.73	9.16e-41	Schizophrenia;
SARC	trans	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg15573879	chr1:36851774	STK40	-0.68	-6.27	-0.38	1.69e-9	Cutaneous psoriasis;
SARC	cis	rs79349575	0.783	rs17635252	chr17:47006950	T/C	cg16584676	chr17:46985605	UBE2Z	0.54	6.53	0.39	4.09e-10	Type 2 diabetes;
SARC	cis	rs10883723	0.775	rs2296579	chr10:104241375	A/G	ch.10.2196322F	chr10:104248062	ACTR1A	0.57	7.42	0.44	2.21e-12	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs459482	0.504	rs469390	chr21:42817930	A/G	cg14166395	chr21:42792516	MX1	0.42	4.86	0.3	2.18e-6	IgG glycosylation;
SARC	cis	rs617219	0.613	rs10043008	chr5:78586914	G/T	cg24856658	chr5:78533917	JMY	0.3	4.75	0.3	3.55e-6	Betaine levels in individuals undergoing cardiac evaluation;
SARC	cis	rs8114671	0.586	rs6087634	chr20:33413809	G/A	cg24642439	chr20:33292090	TP53INP2	0.54	6.66	0.4	1.9e-10	Height;
SARC	cis	rs9916302	0.652	rs9903269	chr17:37742383	A/T	cg07936489	chr17:37558343	FBXL20	-0.63	-7.02	-0.42	2.43e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs2733201	1.000	rs2042741	chr15:44390286	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.75	-5.73	-0.35	3.08e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	cis	rs6088590	0.561	rs6059926	chr20:33164804	C/T	cg24642439	chr20:33292090	TP53INP2	0.66	8.51	0.49	2.12e-15	Coronary artery disease;
SARC	cis	rs7666738	0.791	rs10033994	chr4:98969582	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2898290	0.540	rs12677146	chr8:11450737	C/G	cg21775007	chr8:11205619	TDH	-0.39	-4.99	-0.31	1.17e-6	Systolic blood pressure;
SARC	cis	rs7552404	0.727	rs11161626	chr1:76260837	C/T	cg10523679	chr1:76189770	ACADM	0.45	5.36	0.33	2e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7681440	0.935	rs3756059	chr4:90757272	G/A	cg06632027	chr4:90757378	SNCA	0.4	5.72	0.35	3.24e-8	Dementia with Lewy bodies;
SARC	cis	rs7582720	1.000	rs72926796	chr2:203827480	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs11098499	0.863	rs3775854	chr4:120471971	C/T	cg09307838	chr4:120376055	NA	0.91	12.25	0.63	5.66e-27	Corneal astigmatism;
SARC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg22903471	chr2:27725779	GCKR	-0.48	-7.29	-0.43	4.87e-12	Total body bone mineral density;
SARC	cis	rs1865760	0.865	rs6929805	chr6:25950834	T/A	cg18357526	chr6:26021779	HIST1H4A	0.39	4.72	0.3	4.1e-6	Height;
SARC	cis	rs6696846	0.749	rs11578293	chr1:205070178	T/C	cg00857998	chr1:205179979	DSTYK	0.41	4.92	0.31	1.61e-6	Red blood cell count;
SARC	cis	rs67478160	0.634	rs7141928	chr14:104219949	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.35	-4.86	-0.3	2.17e-6	Schizophrenia;
SARC	cis	rs6963495	0.818	rs1355614	chr7:105179176	A/G	cg19920283	chr7:105172520	RINT1	0.74	7.42	0.44	2.16e-12	Bipolar disorder (body mass index interaction);
SARC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg22105103	chr4:187893119	NA	0.5	6.86	0.41	6.16e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg12564285	chr5:131593104	PDLIM4	0.35	5.25	0.33	3.46e-7	Breast cancer;
SARC	cis	rs7666738	0.830	rs62321597	chr4:99014221	C/A	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs858239	0.600	rs2072369	chr7:23146189	A/G	cg23682824	chr7:23144976	KLHL7	0.69	9.42	0.53	4.67e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs8031584	0.958	rs8034856	chr15:31240957	T/C	cg19680485	chr15:31195859	MTMR15	-0.52	-5.95	-0.36	9.62e-9	Huntington's disease progression;
SARC	cis	rs995000	0.931	rs12074528	chr1:63010871	T/C	cg06896770	chr1:63153194	DOCK7	-0.89	-13.16	-0.65	6e-30	Triglyceride levels;
SARC	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg05368731	chr17:41323189	NBR1	0.69	8.39	0.48	4.62e-15	Menopause (age at onset);
SARC	cis	rs8028182	0.636	rs6495182	chr15:75814388	C/T	cg20655648	chr15:75932815	IMP3	0.64	7.38	0.44	2.83e-12	Sudden cardiac arrest;
SARC	cis	rs9596270	0.772	rs11842790	chr13:50924448	A/G	cg06342072	chr13:50985639	NA	-0.36	-4.82	-0.3	2.6e-6	Multiple sclerosis;
SARC	cis	rs9303401	0.538	rs12603174	chr17:56489279	T/C	cg25039879	chr17:56429692	SUPT4H1	0.62	5.48	0.34	1.1e-7	Cognitive test performance;
SARC	cis	rs861020	0.630	rs585627	chr1:210004199	C/G	cg05527609	chr1:210001259	C1orf107	0.79	10.25	0.56	1.36e-20	Orofacial clefts;
SARC	cis	rs883565	0.569	rs7613766	chr3:39152248	C/G	cg26331595	chr3:39149181	GORASP1;TTC21A	0.44	5.11	0.32	6.63e-7	Handedness;
SARC	cis	rs6840360	1.000	rs4696285	chr4:152605449	A/G	cg22705602	chr4:152727874	NA	-0.38	-6.52	-0.39	4.37e-10	Intelligence (multi-trait analysis);
SARC	cis	rs2204008	0.683	rs7305703	chr12:38138381	T/C	cg13010199	chr12:38710504	ALG10B	0.74	9.72	0.54	5.71e-19	Bladder cancer;
SARC	cis	rs3857536	0.813	rs9360189	chr6:66933424	A/C	cg07460842	chr6:66804631	NA	-0.51	-5.8	-0.36	2.14e-8	Blood trace element (Cu levels);
SARC	cis	rs911186	1.000	rs911186	chr6:27150599	A/G	cg12826209	chr6:26865740	GUSBL1	0.66	5.89	0.36	1.33e-8	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7647973	1.000	rs3870341	chr3:49584745	A/G	cg07636037	chr3:49044803	WDR6	0.78	8.9	0.5	1.65e-16	Menarche (age at onset);
SARC	cis	rs9916302	0.904	rs11078898	chr17:37536480	A/G	cg07936489	chr17:37558343	FBXL20	0.69	9.21	0.52	2e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs7772486	0.686	rs9497380	chr6:145955305	T/C	cg23711669	chr6:146136114	FBXO30	0.77	12.21	0.62	7.64e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs12600121	0.622	rs12600132	chr16:72022534	C/T	cg01557791	chr16:72042693	DHODH	0.38	4.76	0.3	3.35e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9462027	0.628	rs6924898	chr6:34811199	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-6.09	-0.37	4.69e-9	Systemic lupus erythematosus;
SARC	trans	rs12310956	0.532	rs11052952	chr12:33988048	G/A	cg13010199	chr12:38710504	ALG10B	0.75	10.16	0.55	2.58e-20	Morning vs. evening chronotype;
SARC	cis	rs1707322	1.000	rs9803784	chr1:46401907	T/C	cg06784218	chr1:46089804	CCDC17	0.34	5.97	0.36	8.98e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs8064299	0.597	rs6501736	chr17:72775358	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.81	11.01	0.58	5.72e-23	Monocyte count;
SARC	cis	rs1966248	0.570	rs12204363	chr6:134098184	T/C	cg25632230	chr6:134101081	NA	-0.54	-7.19	-0.43	8.89e-12	Coronary artery disease;
SARC	cis	rs3771570	1.000	rs16843590	chr2:242298228	G/A	cg21155796	chr2:242212141	HDLBP	0.68	6.1	0.37	4.3e-9	Prostate cancer;
SARC	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.83	8.49	0.49	2.52e-15	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg10935138	chr17:73851978	WBP2	0.48	5.1	0.32	7.08e-7	Psoriasis;
SARC	cis	rs11249608	0.548	rs6601007	chr5:178455796	G/C	cg21905437	chr5:178450457	ZNF879	0.57	7.79	0.45	2.21e-13	Pubertal anthropometrics;
SARC	cis	rs2412208	0.816	rs7525119	chr1:7061430	C/T	cg20434152	chr1:7120926	CAMTA1	-0.33	-4.98	-0.31	1.25e-6	Survival in sporadic amyotrophic lateral sclerosis;
SARC	cis	rs8114671	0.836	rs6142284	chr20:33641367	G/A	cg24642439	chr20:33292090	TP53INP2	-0.51	-5.96	-0.36	9.41e-9	Height;
SARC	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg19077165	chr18:44547161	KATNAL2	-0.53	-7.33	-0.43	3.7e-12	Personality dimensions;
SARC	cis	rs6570726	0.935	rs1883406	chr6:145823205	A/G	cg05347473	chr6:146136440	FBXO30	0.48	6.42	0.39	7.51e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	10.66	0.57	7.14e-22	Platelet count;
SARC	trans	rs11039798	0.511	rs717896	chr11:48375335	G/T	cg15704280	chr7:45808275	SEPT13	-0.62	-6.35	-0.38	1.15e-9	Axial length;
SARC	cis	rs17125944	0.686	rs4901305	chr14:53364271	C/T	cg00686598	chr14:53173677	PSMC6	-0.66	-4.99	-0.31	1.2e-6	Alzheimer's disease (late onset);
SARC	cis	rs2952156	0.883	rs907089	chr17:37833600	C/T	cg07936489	chr17:37558343	FBXL20	-0.43	-5.65	-0.35	4.67e-8	Asthma;
SARC	cis	rs425277	0.958	rs262652	chr1:2090816	T/C	cg21442419	chr1:2182373	SKI	-0.52	-6.62	-0.4	2.44e-10	Height;
SARC	cis	rs116095464	1.000	rs6555160	chr5:311669	A/G	cg22857025	chr5:266934	NA	0.89	7.24	0.43	6.58e-12	Breast cancer;
SARC	cis	rs7264396	0.563	rs11906854	chr20:34383634	A/G	cg01084648	chr20:34329383	RBM39	0.63	5.03	0.31	9.66e-7	Total cholesterol levels;
SARC	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg19223190	chr17:80058835	NA	-0.43	-6.02	-0.37	6.57e-9	Life satisfaction;
SARC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg17178900	chr1:205818956	PM20D1	0.65	9.31	0.52	9.88e-18	Menarche (age at onset);
SARC	cis	rs41271473	1.000	rs11587994	chr1:228860072	A/C	cg16512390	chr1:228756714	NA	0.49	4.74	0.3	3.65e-6	Chronic lymphocytic leukemia;
SARC	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.72	-7.24	-0.43	6.52e-12	Platelet count;
SARC	cis	rs282587	0.502	rs408476	chr13:113400056	A/C	cg02820901	chr13:113351484	ATP11A	-0.48	-4.77	-0.3	3.21e-6	Glycated hemoglobin levels;
SARC	cis	rs11969893	0.737	rs9498439	chr6:101404768	A/T	cg12253828	chr6:101329408	ASCC3	0.91	6.2	0.38	2.55e-9	Economic and political preferences (immigration/crime);
SARC	cis	rs1729951	0.575	rs1654904	chr3:136681149	T/C	cg15507776	chr3:136538369	TMEM22	0.51	5.73	0.35	3.12e-8	Neuroticism;
SARC	cis	rs7249142	0.549	rs539	chr19:19287802	A/G	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.23	4.82	0.3	2.57e-6	IgG glycosylation;
SARC	cis	rs1728785	1.000	rs1170429	chr16:68604126	A/G	cg02972257	chr16:68554789	NA	-0.47	-5.56	-0.34	7.2e-8	Ulcerative colitis;
SARC	cis	rs11792861	0.781	rs17729408	chr9:111740860	A/G	cg13535736	chr9:111863775	C9orf5	0.39	4.81	0.3	2.69e-6	Menarche (age at onset);
SARC	cis	rs11785693	0.774	rs62489516	chr8:4946015	T/C	cg26367366	chr8:4980734	NA	0.67	5.62	0.35	5.34e-8	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.45	0.53	3.79e-18	Prudent dietary pattern;
SARC	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg10128416	chr1:75198403	TYW3;CRYZ	0.43	5.53	0.34	8.63e-8	Resistin levels;
SARC	cis	rs8067545	0.562	rs2526481	chr17:20127018	T/C	cg13482628	chr17:19912719	NA	-0.51	-6.59	-0.4	2.95e-10	Schizophrenia;
SARC	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg04944784	chr2:26401820	FAM59B	-0.48	-5.8	-0.36	2.14e-8	Gut microbiome composition (summer);
SARC	cis	rs2576037	0.796	rs2571031	chr18:44577063	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.49	6.48	0.39	5.32e-10	Personality dimensions;
SARC	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg15847926	chr7:2749597	AMZ1	-0.3	-4.86	-0.3	2.2e-6	Height;
SARC	cis	rs6071524	0.592	rs6124090	chr20:37455588	A/T	cg24229276	chr20:36931287	BPI	-0.31	-4.87	-0.3	2.1e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7582180	0.629	rs12989897	chr2:100940998	A/G	cg14675211	chr2:100938903	LONRF2	0.51	7.59	0.45	7.54e-13	Intelligence (multi-trait analysis);
SARC	cis	rs10791323	0.569	rs2156680	chr11:133742292	T/G	cg15485101	chr11:133734466	NA	0.32	5.14	0.32	5.92e-7	Childhood ear infection;
SARC	cis	rs2304069	0.601	rs216143	chr5:149444147	A/G	cg12661370	chr5:149340060	SLC26A2	0.48	4.92	0.31	1.61e-6	HIV-1 control;
SARC	cis	rs7772486	0.686	rs1292337	chr6:145967807	A/G	cg05347473	chr6:146136440	FBXO30	-0.51	-7.1	-0.42	1.46e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9487051	0.872	rs1521908	chr6:109613986	T/C	cg01475377	chr6:109611718	NA	-0.41	-5.88	-0.36	1.39e-8	Reticulocyte fraction of red cells;
SARC	cis	rs2075371	1.000	rs2075371	chr7:133984127	A/G	cg00033643	chr7:134001901	SLC35B4	0.39	4.77	0.3	3.25e-6	Mean platelet volume;
SARC	trans	rs9388451	0.839	rs9401845	chr6:126104118	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.57	-7.38	-0.44	2.73e-12	Brugada syndrome;
SARC	cis	rs9916302	0.904	rs2024073	chr17:37471330	T/G	cg15445000	chr17:37608096	MED1	-0.44	-5.31	-0.33	2.6e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg12373951	chr3:133503437	NA	0.42	6.02	0.37	6.68e-9	Iron status biomarkers;
SARC	cis	rs80130819	0.688	rs1387256	chr12:48643738	G/A	cg05342945	chr12:48394962	COL2A1	-0.49	-5.29	-0.33	2.81e-7	Prostate cancer;
SARC	cis	rs4242434	0.757	rs4872531	chr8:22529695	A/G	cg03733263	chr8:22462867	KIAA1967	-0.9	-14.32	-0.68	8.71e-34	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs4727443	0.691	rs6975827	chr7:99585798	C/G	cg22004693	chr7:99632812	ZKSCAN1	-0.59	-7.39	-0.44	2.62e-12	Interstitial lung disease;
SARC	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg25811766	chr13:21894605	NA	0.67	8.73	0.5	5.16e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs4853036	0.904	rs12713683	chr2:70156321	G/A	cg02498382	chr2:70120550	SNRNP27	-0.39	-5.42	-0.33	1.46e-7	Colorectal or endometrial cancer;
SARC	cis	rs644799	0.509	rs561635	chr11:95634232	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.73	-8.38	-0.48	4.98e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg03433033	chr1:76189801	ACADM	0.56	7.77	0.45	2.56e-13	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg06873352	chr17:61820015	STRADA	0.43	5.69	0.35	3.81e-8	Prudent dietary pattern;
SARC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg25703541	chr22:24373054	LOC391322	0.81	10.21	0.56	1.77e-20	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1008375	1.000	rs10939744	chr4:17664473	G/T	cg27347728	chr4:17578864	LAP3	0.45	5.54	0.34	8.25e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9341808	0.718	rs9443734	chr6:80820293	C/T	cg08355045	chr6:80787529	NA	0.34	5.48	0.34	1.09e-7	Sitting height ratio;
SARC	cis	rs2718058	0.589	rs1986618	chr7:37800116	C/G	cg24998770	chr7:37888106	TXNDC3	0.35	4.99	0.31	1.18e-6	Alzheimer's disease (late onset);
SARC	cis	rs7224737	0.956	rs8081900	chr17:40289875	G/A	cg20291162	chr17:40259547	DHX58	-0.33	-4.85	-0.3	2.24e-6	Fibrinogen levels;
SARC	trans	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg00938859	chr5:1591904	SDHAP3	0.76	7.39	0.44	2.55e-12	Breast cancer;
SARC	cis	rs2204008	0.837	rs4312131	chr12:38181087	G/T	cg13010199	chr12:38710504	ALG10B	0.78	10.64	0.57	8.61e-22	Bladder cancer;
SARC	cis	rs7772486	0.686	rs1292336	chr6:145967818	T/C	cg05347473	chr6:146136440	FBXO30	-0.5	-6.83	-0.41	7.41e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11209002	1.000	rs2863202	chr1:67584335	T/C	cg02640540	chr1:67518911	SLC35D1	0.49	5.0	0.31	1.12e-6	Crohn's disease;
SARC	cis	rs9902453	0.933	rs7225462	chr17:28321226	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	7.02	0.42	2.42e-11	Coffee consumption (cups per day);
SARC	cis	rs995000	0.899	rs4495740	chr1:63124465	T/G	cg06896770	chr1:63153194	DOCK7	0.99	15.67	0.72	2.76e-38	Triglyceride levels;
SARC	cis	rs13082711	0.911	rs2887926	chr3:27494475	T/C	cg02860705	chr3:27208620	NA	0.46	5.89	0.36	1.33e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs62064224	0.902	rs35830939	chr17:30627564	A/C	cg18200150	chr17:30822561	MYO1D	0.35	5.26	0.33	3.26e-7	Schizophrenia;
SARC	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg09323728	chr8:95962352	TP53INP1	-0.29	-4.95	-0.31	1.41e-6	Type 2 diabetes;
SARC	cis	rs4566357	0.615	rs10178098	chr2:227914425	C/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.62	-0.35	5.48e-8	Coronary artery disease;
SARC	cis	rs950776	0.518	rs12900783	chr15:78815523	G/A	cg06917634	chr15:78832804	PSMA4	0.9	13.8	0.67	4.79e-32	Sudden cardiac arrest;
SARC	cis	rs17376456	0.877	rs10066791	chr5:93350255	G/T	cg25358565	chr5:93447407	FAM172A	1.3	14.56	0.69	1.43e-34	Diabetic retinopathy;
SARC	cis	rs4481887	0.741	rs4360554	chr1:248553206	C/T	cg00666640	chr1:248458726	OR2T12	0.32	5.81	0.36	2.08e-8	Common traits (Other);
SARC	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg06074448	chr4:187884817	NA	-0.41	-5.39	-0.33	1.76e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7727544	0.606	rs11950562	chr5:131652529	A/C	cg24060327	chr5:131705240	SLC22A5	-0.41	-4.89	-0.31	1.84e-6	Blood metabolite levels;
SARC	cis	rs765787	0.530	rs2413780	chr15:45538866	A/G	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.81e-6	Uric acid levels;
SARC	cis	rs12586317	0.620	rs28404080	chr14:35539418	G/T	cg26967526	chr14:35346199	BAZ1A	-0.63	-6.66	-0.4	1.99e-10	Psoriasis;
SARC	cis	rs1355223	0.902	rs1453387	chr11:34707898	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-5.55	-0.34	7.86e-8	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs12464559	0.522	rs12472627	chr2:152633114	C/T	cg01189475	chr2:152685088	ARL5A	0.61	4.98	0.31	1.22e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	trans	rs9329221	0.905	rs28507213	chr8:10250849	C/T	cg06636001	chr8:8085503	FLJ10661	-0.68	-9.31	-0.52	1.01e-17	Neuroticism;
SARC	cis	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg08975724	chr8:8085496	FLJ10661	0.56	7.15	0.42	1.11e-11	Systolic blood pressure;
SARC	cis	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg20965017	chr5:231967	SDHA	-0.54	-5.21	-0.32	4.22e-7	Breast cancer;
SARC	cis	rs72781680	0.898	rs72786298	chr2:24083011	C/T	cg08917208	chr2:24149416	ATAD2B	0.91	8.96	0.51	1.08e-16	Lymphocyte counts;
SARC	cis	rs78545713	1.000	rs16891484	chr6:26242930	G/A	cg00631329	chr6:26305371	NA	-0.7	-6.33	-0.38	1.22e-9	Iron status biomarkers (total iron binding capacity);
SARC	trans	rs10506458	0.915	rs79133015	chr12:63396838	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.74	-6.26	-0.38	1.81e-9	Hemostatic factors and hematological phenotypes;
SARC	cis	rs698833	0.892	rs698801	chr2:44691662	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.66	8.42	0.48	3.75e-15	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs4720575	1.000	rs1859522	chr7:47096901	G/A	cg00036614	chr7:47093842	NA	-0.44	-6.23	-0.38	2.17e-9	Angiotensin-converting enzyme inhibitor intolerance;
SARC	cis	rs9487051	0.676	rs7773213	chr6:109601885	C/T	cg01475377	chr6:109611718	NA	-0.36	-5.26	-0.33	3.22e-7	Reticulocyte fraction of red cells;
SARC	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg00800038	chr16:89945340	TCF25	0.6	5.46	0.34	1.19e-7	Skin colour saturation;
SARC	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg12311346	chr5:56204834	C5orf35	0.69	6.63	0.4	2.25e-10	Initial pursuit acceleration;
SARC	cis	rs2180341	0.920	rs7756880	chr6:127683999	A/T	cg24812749	chr6:127587940	RNF146	1.03	13.58	0.66	2.54e-31	Breast cancer;
SARC	cis	rs7786877	0.508	rs11765509	chr7:100310990	T/G	cg20848291	chr7:100343083	ZAN	-0.69	-7.71	-0.45	3.57e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg23131131	chr22:24373011	LOC391322	-0.49	-5.35	-0.33	2.15e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6484504	0.625	rs7940420	chr11:31366700	T/A	cg19308365	chr11:31391254	DNAJC24;DCDC1	0.38	4.8	0.3	2.86e-6	Red blood cell count;
SARC	cis	rs6696846	0.729	rs72757512	chr1:205079203	G/A	cg21545522	chr1:205238299	TMCC2	0.34	4.75	0.3	3.61e-6	Red blood cell count;
SARC	cis	rs796364	0.756	rs2949006	chr2:200715388	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.73	6.37	0.38	1.02e-9	Schizophrenia;
SARC	cis	rs116095464	1.000	rs56095714	chr5:311256	C/T	cg22857025	chr5:266934	NA	-1.06	-6.98	-0.42	3.02e-11	Breast cancer;
SARC	cis	rs2749592	0.550	rs10764135	chr10:37866845	C/T	cg25427524	chr10:38739819	LOC399744	0.44	6.33	0.38	1.27e-9	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs4588572	0.643	rs10474555	chr5:77799193	A/G	cg11547950	chr5:77652471	NA	0.39	4.78	0.3	3.17e-6	Triglycerides;
SARC	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg18876405	chr7:65276391	NA	0.46	5.11	0.32	6.58e-7	Aortic root size;
SARC	cis	rs1371867	0.846	rs1788197	chr8:101290928	T/C	cg11906718	chr8:101322791	RNF19A	0.66	8.78	0.5	3.67e-16	Atrioventricular conduction;
SARC	cis	rs9660992	0.736	rs72745207	chr1:205251991	C/G	cg21545522	chr1:205238299	TMCC2	0.49	6.61	0.4	2.58e-10	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs9916302	0.707	rs11078903	chr17:37631924	G/A	cg07936489	chr17:37558343	FBXL20	-0.7	-8.97	-0.51	9.88e-17	Glomerular filtration rate (creatinine);
SARC	trans	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg00938859	chr5:1591904	SDHAP3	0.7	6.97	0.42	3.18e-11	Breast cancer;
SARC	cis	rs1371867	0.846	rs1788204	chr8:101303936	C/T	cg11906718	chr8:101322791	RNF19A	0.7	8.98	0.51	9.31e-17	Atrioventricular conduction;
SARC	trans	rs11098499	0.954	rs17009122	chr4:120362403	G/A	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg08925066	chr14:39572669	SEC23A	-0.55	-6.9	-0.41	4.97e-11	Schizophrenia;
SARC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.55	-9.59	-0.53	1.39e-18	Longevity;Endometriosis;
SARC	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.57	7.0	0.42	2.69e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6696846	0.716	rs6593921	chr1:205062861	A/G	cg21545522	chr1:205238299	TMCC2	0.41	5.59	0.34	6.21e-8	Red blood cell count;
SARC	cis	rs4481887	1.000	rs4916125	chr1:248466583	A/T	cg13385794	chr1:248469461	NA	0.36	5.57	0.34	7.1e-8	Common traits (Other);
SARC	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg22496380	chr5:211416	CCDC127	-0.84	-8.6	-0.49	1.19e-15	Breast cancer;
SARC	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg22920501	chr2:26401640	FAM59B	-0.55	-7.06	-0.42	1.92e-11	Gut microbiome composition (summer);
SARC	cis	rs4803468	0.905	rs284662	chr19:41932275	T/C	cg08477640	chr19:41863820	B9D2	0.43	5.42	0.33	1.48e-7	Height;
SARC	cis	rs3820928	0.967	rs12622456	chr2:227768868	G/A	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.91	-0.36	1.22e-8	Pulmonary function;
SARC	cis	rs72653721	0.730	rs17764682	chr6:11058815	A/C	cg13562911	chr6:11044106	ELOVL2	0.52	5.83	0.36	1.85e-8	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg11987759	chr7:65425863	GUSB	0.62	8.25	0.48	1.17e-14	Aortic root size;
SARC	cis	rs832540	0.864	rs832576	chr5:56163255	C/A	cg24549020	chr5:56110836	MAP3K1	0.4	4.88	0.3	2.01e-6	Coronary artery disease;
SARC	cis	rs17376456	0.825	rs10038831	chr5:93124115	C/T	cg21475434	chr5:93447410	FAM172A	0.72	6.25	0.38	1.92e-9	Diabetic retinopathy;
SARC	cis	rs9660992	0.674	rs17345816	chr1:205262868	A/T	cg21643547	chr1:205240462	TMCC2	0.61	7.55	0.44	1.01e-12	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.96	10.15	0.55	2.8e-20	Platelet count;
SARC	cis	rs60871478	1.000	rs62432861	chr7:807649	G/A	cg19087971	chr7:751233	PRKAR1B	-0.43	-4.85	-0.3	2.23e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs709400	0.663	rs62007718	chr14:103940436	G/A	cg26031613	chr14:104095156	KLC1	0.83	12.18	0.62	9.84e-27	Body mass index;
SARC	cis	rs7264396	0.635	rs6058363	chr20:34505054	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	5.1	0.32	7.06e-7	Total cholesterol levels;
SARC	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg16049864	chr8:95962084	TP53INP1	-0.5	-8.01	-0.46	5.38e-14	Type 2 diabetes;
SARC	cis	rs9457247	0.534	rs7750593	chr6:167387359	C/G	cg23791538	chr6:167370224	RNASET2	0.65	9.23	0.52	1.73e-17	Crohn's disease;
SARC	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg12311346	chr5:56204834	C5orf35	-0.58	-6.01	-0.37	7.24e-9	Initial pursuit acceleration;
SARC	cis	rs6570726	0.967	rs373704	chr6:145860618	C/A	cg05347473	chr6:146136440	FBXO30	0.48	6.43	0.39	7.24e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs929354	0.713	rs3802129	chr7:156965297	G/A	cg05182265	chr7:156933206	UBE3C	-0.33	-5.07	-0.32	8.04e-7	Body mass index;
SARC	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg21724239	chr8:58056113	NA	0.6	6.37	0.38	1.03e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7829975	0.606	rs6422352	chr8:8794193	A/G	cg08975724	chr8:8085496	FLJ10661	-0.42	-5.23	-0.32	3.71e-7	Mood instability;
SARC	cis	rs734999	0.588	rs10910099	chr1:2533552	G/T	cg20673091	chr1:2541236	MMEL1	-0.31	-4.81	-0.3	2.68e-6	Ulcerative colitis;
SARC	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg04166393	chr7:2884313	GNA12	0.52	5.95	0.36	9.59e-9	Height;
SARC	cis	rs9660992	0.710	rs1180721	chr1:205232696	T/C	cg07972983	chr1:205091412	RBBP5	0.55	6.87	0.41	5.84e-11	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs7512552	0.809	rs1694377	chr1:150293153	A/G	cg15654264	chr1:150340011	RPRD2	0.38	4.83	0.3	2.45e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs4891159	0.790	rs9950025	chr18:74113596	C/G	cg24786174	chr18:74118243	ZNF516	0.68	9.82	0.54	2.85e-19	Longevity;
SARC	cis	rs2204008	0.837	rs11514225	chr12:38076270	G/A	cg26384229	chr12:38710491	ALG10B	0.88	12.95	0.65	2.86e-29	Bladder cancer;
SARC	cis	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg25894440	chr7:65020034	NA	0.52	4.8	0.3	2.79e-6	Aortic root size;
SARC	trans	rs629535	0.773	rs681534	chr8:70056964	A/C	cg21567404	chr3:27674614	NA	1.05	13.73	0.67	7.76e-32	Dupuytren's disease;
SARC	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg18252515	chr7:66147081	NA	0.44	4.74	0.3	3.79e-6	Aortic root size;
SARC	cis	rs734999	0.505	rs4648659	chr1:2560903	T/G	cg18854424	chr1:2615690	NA	-0.31	-4.91	-0.31	1.73e-6	Ulcerative colitis;
SARC	cis	rs7561528	0.501	rs72838226	chr2:127882342	T/C	cg12632573	chr2:127783243	NA	0.67	6.1	0.37	4.44e-9	Alzheimer's disease;Alzheimer's disease (late onset);
SARC	cis	rs2180341	1.000	rs6569482	chr6:127631371	C/T	cg17762328	chr6:126965162	NA	-0.46	-5.24	-0.32	3.55e-7	Breast cancer;
SARC	cis	rs9322817	0.691	rs1933804	chr6:105341969	G/C	cg02098413	chr6:105308735	HACE1	0.39	6.11	0.37	4.17e-9	Thyroid stimulating hormone;
SARC	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg16486109	chr11:613632	IRF7	0.44	5.61	0.34	5.73e-8	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs12477438	0.765	rs7571390	chr2:99626593	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.31	-0.48	7.7e-15	Chronic sinus infection;
SARC	cis	rs17600642	0.950	rs56165139	chr10:72465978	G/A	cg19779893	chr10:72451501	ADAMTS14	-0.47	-7.0	-0.42	2.73e-11	Bipolar disorder;
SARC	cis	rs921968	0.565	rs6761437	chr2:219598092	G/A	cg02176678	chr2:219576539	TTLL4	-0.34	-5.14	-0.32	5.86e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs3815700	0.844	rs444089	chr19:33106991	G/C	cg02997394	chr19:33096574	ANKRD27	0.81	8.2	0.47	1.57e-14	Eosinophilic esophagitis;
SARC	cis	rs1784581	0.588	rs6455789	chr6:162417948	C/T	cg17173639	chr6:162384350	PARK2	0.51	6.5	0.39	4.82e-10	Itch intensity from mosquito bite;
SARC	cis	rs9921222	1.000	rs9921222	chr16:375782	A/G	cg00101154	chr16:420108	MRPL28	0.49	7.78	0.45	2.33e-13	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg06636001	chr8:8085503	FLJ10661	0.67	8.98	0.51	9.1e-17	Mood instability;
SARC	cis	rs7429990	0.901	rs7433678	chr3:48037078	G/A	cg11946769	chr3:48343235	NME6	-0.45	-5.27	-0.33	3.07e-7	Educational attainment (years of education);
SARC	cis	rs2204008	0.678	rs61929520	chr12:38446800	T/C	cg14851346	chr12:38532713	NA	-0.48	-5.94	-0.36	1.04e-8	Bladder cancer;
SARC	cis	rs3820928	1.000	rs10197757	chr2:227763244	A/C	cg05526886	chr2:227700861	RHBDD1	-0.47	-5.69	-0.35	3.72e-8	Pulmonary function;
SARC	cis	rs7481584	0.624	rs375579	chr11:3065300	G/C	cg20651018	chr11:3035856	CARS	0.4	5.88	0.36	1.38e-8	Calcium levels;
SARC	cis	rs1878931	0.582	rs27239	chr16:3442140	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.66	-7.2	-0.43	8.14e-12	Body mass index (adult);
SARC	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg22903471	chr2:27725779	GCKR	-0.5	-7.57	-0.44	8.61e-13	Total body bone mineral density;
SARC	cis	rs12311304	1.000	rs1479407	chr12:15391524	G/T	cg08258403	chr12:15378311	NA	0.5	7.57	0.44	8.42e-13	Behavioural disinhibition (generation interaction);
SARC	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg06618935	chr21:46677482	NA	-0.38	-4.97	-0.31	1.27e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg20587970	chr11:113659929	NA	-1.24	-12.35	-0.63	2.73e-27	Hip circumference adjusted for BMI;
SARC	cis	rs9790314	0.586	rs11710916	chr3:161130070	A/G	cg04691961	chr3:161091175	C3orf57	-0.48	-5.9	-0.36	1.25e-8	Morning vs. evening chronotype;
SARC	trans	rs61931739	0.534	rs7310499	chr12:34212112	G/A	cg26384229	chr12:38710491	ALG10B	0.83	11.93	0.62	6.14e-26	Morning vs. evening chronotype;
SARC	cis	rs2075371	1.000	rs1421485	chr7:133985181	C/T	cg00033643	chr7:134001901	SLC35B4	0.39	4.77	0.3	3.25e-6	Mean platelet volume;
SARC	cis	rs9611565	0.921	rs5751077	chr22:41720728	G/C	cg03806693	chr22:41940476	POLR3H	-0.68	-9.32	-0.52	9.09e-18	Vitiligo;
SARC	cis	rs76419734	1.000	rs11733287	chr4:106705339	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.81	5.48	0.34	1.08e-7	Post bronchodilator FEV1;
SARC	cis	rs995000	0.931	rs1168009	chr1:62943954	G/A	cg06896770	chr1:63153194	DOCK7	-0.9	-13.43	-0.66	7.67e-31	Triglyceride levels;
SARC	cis	rs7264396	0.635	rs6060710	chr20:34536055	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	5.27	0.33	3.1e-7	Total cholesterol levels;
SARC	cis	rs8070624	0.543	rs11078409	chr17:17876296	C/G	cg04398451	chr17:18023971	MYO15A	-0.46	-6.24	-0.38	2e-9	Total body bone mineral density;
SARC	cis	rs7223966	0.921	rs67018565	chr17:61928055	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.5	-5.23	-0.32	3.77e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs941408	0.515	rs4624312	chr19:2774460	T/C	cg00079169	chr19:2811669	THOP1	0.44	4.77	0.3	3.19e-6	Total cholesterol levels;
SARC	cis	rs8044995	0.563	rs73615919	chr16:68398862	C/T	cg09835421	chr16:68378352	PRMT7	-0.64	-6.04	-0.37	6.1e-9	Schizophrenia;
SARC	cis	rs6667605	0.506	rs10797440	chr1:2541269	A/G	cg18854424	chr1:2615690	NA	0.33	5.16	0.32	5.25e-7	Inflammatory bowel disease;Ulcerative colitis;
SARC	cis	rs28374715	0.532	rs7164211	chr15:41705041	A/T	cg18705301	chr15:41695430	NDUFAF1	-1.15	-19.26	-0.78	4.21e-50	Ulcerative colitis;
SARC	cis	rs7523050	0.643	rs35860016	chr1:109404639	C/T	cg08274380	chr1:109419600	GPSM2	0.99	7.56	0.44	9.38e-13	Fat distribution (HIV);
SARC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg20607798	chr8:58055168	NA	0.58	5.55	0.34	7.69e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg13072238	chr3:49761600	GMPPB	0.42	5.54	0.34	8.33e-8	Intelligence (multi-trait analysis);
SARC	cis	rs41271473	1.000	rs11583565	chr1:228880135	C/T	cg16512390	chr1:228756714	NA	0.5	5.15	0.32	5.61e-7	Chronic lymphocytic leukemia;
SARC	cis	rs8141529	0.871	rs5762877	chr22:29277555	G/A	cg15103426	chr22:29168792	CCDC117	0.68	8.64	0.49	8.89e-16	Lymphocyte counts;
SARC	cis	rs16976116	0.572	rs16976015	chr15:55447050	C/T	cg17854078	chr15:55489399	RSL24D1	0.65	5.71	0.35	3.51e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg18373279	chr13:48668852	MED4	-0.85	-7.25	-0.43	5.95e-12	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg13944838	chr5:179740914	GFPT2	-0.59	-7.45	-0.44	1.86e-12	Height;
SARC	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.55	5.09	0.32	7.45e-7	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs7927592	0.763	rs10896327	chr11:68235275	G/C	cg01657329	chr11:68192670	LRP5	-0.36	-5.03	-0.31	9.95e-7	Total body bone mineral density;
SARC	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg20607798	chr8:58055168	NA	0.72	5.85	0.36	1.63e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs3091242	0.933	rs35530120	chr1:25785451	A/G	cg02931644	chr1:25747376	RHCE	-0.45	-7.45	-0.44	1.78e-12	Erythrocyte sedimentation rate;
SARC	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg12756686	chr19:29218302	NA	0.69	9.02	0.51	7.08e-17	Methadone dose in opioid dependence;
SARC	cis	rs1559088	1.000	rs1974783	chr19:33551507	C/G	cg27124370	chr19:33622961	WDR88	0.41	5.22	0.32	3.87e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs9303401	0.646	rs7217845	chr17:57236900	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.6	7.17	0.43	9.69e-12	Cognitive test performance;
SARC	cis	rs3771570	1.000	rs41266959	chr2:242275579	G/A	cg21155796	chr2:242212141	HDLBP	0.67	5.74	0.35	2.99e-8	Prostate cancer;
SARC	cis	rs796364	0.616	rs2689762	chr2:200687204	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.55	4.74	0.3	3.76e-6	Schizophrenia;
SARC	cis	rs6558174	0.965	rs7831119	chr8:22489678	C/T	cg03733263	chr8:22462867	KIAA1967	-0.52	-6.13	-0.37	3.75e-9	Breast cancer;
SARC	cis	rs1200821	0.535	rs1208784	chr10:37768433	A/G	cg00409905	chr10:38381863	ZNF37A	-0.45	-6.11	-0.37	4.14e-9	Hemostatic factors and hematological phenotypes;
SARC	cis	rs10791097	0.694	rs4936123	chr11:130740967	G/A	cg09137382	chr11:130731461	NA	0.32	4.93	0.31	1.55e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	14.0	0.68	9.94e-33	Chronic sinus infection;
SARC	cis	rs1865760	0.566	rs3752420	chr6:26027135	G/A	cg17691542	chr6:26056736	HIST1H1C	0.54	6.67	0.4	1.83e-10	Height;
SARC	cis	rs787274	1.000	rs2153837	chr9:115463001	A/T	cg13803584	chr9:115635662	SNX30	0.82	5.56	0.34	7.31e-8	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs2985684	0.948	rs12897941	chr14:50016701	G/C	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.49	5.32	0.33	2.48e-7	Carotid intima media thickness;
SARC	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg26335602	chr6:28129616	ZNF389	0.52	5.69	0.35	3.74e-8	Parkinson's disease;
SARC	cis	rs58653258	1.000	rs58653258	chr1:234990900	T/C	cg14037484	chr1:235490207	ARID4B	-0.64	-4.74	-0.3	3.64e-6	Granulocyte percentage of myeloid white cells;
SARC	cis	rs40363	0.680	rs4010628	chr16:3529779	G/A	cg22508957	chr16:3507546	NAT15	0.56	5.01	0.31	1.09e-6	Tuberculosis;
SARC	cis	rs1865760	0.865	rs9467641	chr6:25947236	T/C	cg16482183	chr6:26056742	HIST1H1C	0.51	6.49	0.39	4.98e-10	Height;
SARC	cis	rs10782582	0.586	rs11161902	chr1:76392498	C/G	cg03433033	chr1:76189801	ACADM	-0.38	-4.77	-0.3	3.26e-6	Daytime sleep phenotypes;
SARC	cis	rs7020830	0.823	rs7019699	chr9:37125081	C/A	cg14294708	chr9:37120828	ZCCHC7	1.15	21.16	0.81	3.55e-56	Schizophrenia;
SARC	cis	rs950776	0.714	rs472054	chr15:78887994	A/G	cg17108064	chr15:78857060	CHRNA5	-0.3	-4.99	-0.31	1.2e-6	Sudden cardiac arrest;
SARC	cis	rs1568889	1.000	rs7934085	chr11:28369660	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	9.88	0.54	1.89e-19	Bipolar disorder;
SARC	cis	rs72781680	0.716	rs78332127	chr2:24150163	C/G	cg08917208	chr2:24149416	ATAD2B	0.58	5.89	0.36	1.34e-8	Lymphocyte counts;
SARC	cis	rs151234	0.800	rs231974	chr16:28540322	A/T	cg01378222	chr16:28622494	SULT1A1	-0.46	-5.41	-0.33	1.59e-7	Platelet distribution width;
SARC	cis	rs74181299	0.750	rs13421845	chr2:65336033	G/A	cg20592124	chr2:65290738	CEP68	-0.39	-5.6	-0.34	6.11e-8	Pulse pressure;
SARC	cis	rs6582630	0.519	rs4002440	chr12:38485012	A/G	cg26384229	chr12:38710491	ALG10B	0.84	12.0	0.62	3.64e-26	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs877282	0.583	rs10904566	chr10:821662	C/G	cg22713356	chr15:30763199	NA	0.93	8.8	0.5	3.09e-16	Uric acid levels;
SARC	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg02841227	chr6:26021843	HIST1H4A	-0.47	-5.64	-0.35	4.9e-8	Intelligence (multi-trait analysis);
SARC	cis	rs3099143	1.000	rs4541044	chr15:77173193	C/T	cg21673338	chr15:77095150	SCAPER	0.6	5.09	0.32	7.43e-7	Recalcitrant atopic dermatitis;
SARC	cis	rs17376456	0.597	rs7708175	chr5:93381182	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.48	-5.22	-0.32	3.93e-7	Diabetic retinopathy;
SARC	cis	rs7089973	0.604	rs11196952	chr10:116607592	G/A	cg08188268	chr10:116634841	FAM160B1	0.28	4.79	0.3	3.02e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg11644478	chr21:40555479	PSMG1	1.05	14.79	0.7	2.43e-35	Cognitive function;
SARC	cis	rs3733585	0.673	rs4697914	chr4:9952266	G/A	cg00071950	chr4:10020882	SLC2A9	-0.35	-5.39	-0.33	1.76e-7	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7595412	1.000	rs4850820	chr2:198982211	C/G	cg00208931	chr2:198669586	PLCL1	-0.72	-5.9	-0.36	1.26e-8	Hip bone size;
SARC	cis	rs7223966	1.000	rs8075257	chr17:61728750	G/C	cg00588841	chr17:61851480	DDX42;CCDC47	-0.64	-7.13	-0.42	1.28e-11	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs1322639	0.614	rs9689800	chr6:169572945	T/A	cg04662567	chr6:169592167	NA	0.41	5.46	0.34	1.22e-7	Pulse pressure;
SARC	cis	rs9911578	1.000	rs302848	chr17:56686454	C/T	cg12560992	chr17:57184187	TRIM37	0.85	11.44	0.6	2.48e-24	Intelligence (multi-trait analysis);
SARC	cis	rs9787249	0.957	rs56064244	chr1:40213890	C/T	cg02773041	chr1:40204384	PPIE	0.53	6.46	0.39	6.11e-10	Blood protein levels;
SARC	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg03188948	chr7:1209495	NA	0.59	5.05	0.31	8.95e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs12824058	0.844	rs7956408	chr12:130807547	A/T	cg26677194	chr12:130822605	PIWIL1	-0.45	-6.31	-0.38	1.36e-9	Menopause (age at onset);
SARC	cis	rs763121	0.853	rs5757166	chr22:38995385	G/T	cg21395723	chr22:39101663	GTPBP1	0.58	6.78	0.41	9.85e-11	Menopause (age at onset);
SARC	cis	rs796364	0.950	rs56155997	chr2:200768491	C/T	cg23649088	chr2:200775458	C2orf69	-0.59	-5.1	-0.32	7.18e-7	Schizophrenia;
SARC	cis	rs35306767	0.668	rs12784928	chr10:1083617	A/C	cg18964960	chr10:1102726	WDR37	0.48	4.8	0.3	2.83e-6	Eosinophil percentage of granulocytes;
SARC	cis	rs7223966	1.000	rs8080211	chr17:61729882	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	6.24	0.38	2.08e-9	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs72634258	0.554	rs10462018	chr1:7879627	C/T	cg05338066	chr1:7812865	CAMTA1	0.63	5.52	0.34	8.93e-8	Inflammatory bowel disease;
SARC	cis	rs6121246	0.821	rs7265413	chr20:30317923	G/A	cg13852791	chr20:30311386	BCL2L1	0.85	9.18	0.52	2.48e-17	Mean corpuscular hemoglobin;
SARC	cis	rs7589728	1.000	rs2363731	chr2:88521793	C/T	cg04511125	chr2:88470314	THNSL2	0.64	5.79	0.35	2.29e-8	Plasma clusterin levels;
SARC	cis	rs2658782	0.694	rs3019221	chr11:93079700	C/G	cg15737290	chr11:93063684	CCDC67	0.73	7.94	0.46	8.57e-14	Pulmonary function decline;
SARC	cis	rs7412746	0.658	rs10305711	chr1:150802996	T/C	cg15448220	chr1:150897856	SETDB1	0.49	6.32	0.38	1.31e-9	Melanoma;
SARC	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg23758822	chr17:41437982	NA	0.89	11.4	0.6	3.3e-24	Menopause (age at onset);
SARC	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg24675658	chr1:53192096	ZYG11B	-0.4	-4.74	-0.3	3.7e-6	Monocyte count;
SARC	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs1707322	0.789	rs10789473	chr1:46248131	C/T	cg03146154	chr1:46216737	IPP	0.51	6.25	0.38	1.98e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs12586317	0.547	rs116499019	chr14:35441931	T/C	cg26967526	chr14:35346199	BAZ1A	-0.57	-5.7	-0.35	3.53e-8	Psoriasis;
SARC	cis	rs12142240	0.659	rs67547686	chr1:46832229	G/C	cg14993813	chr1:46806288	NSUN4	-0.53	-5.62	-0.35	5.48e-8	Menopause (age at onset);
SARC	cis	rs4128725	0.925	rs11265218	chr1:159486640	T/C	cg25076881	chr1:159409836	OR10J1	0.46	5.49	0.34	1.04e-7	Select biomarker traits;
SARC	cis	rs4642101	0.561	rs7641959	chr3:12810755	G/C	cg24848339	chr3:12840334	CAND2	0.34	5.16	0.32	5.35e-7	QRS complex (12-leadsum);
SARC	cis	rs9815354	0.812	rs55788971	chr3:41843965	T/A	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs854765	0.647	rs721669	chr17:18005073	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.63	8.7	0.5	5.99e-16	Total body bone mineral density;
SARC	cis	rs72781680	0.611	rs55905755	chr2:24330264	T/C	cg08917208	chr2:24149416	ATAD2B	0.62	6.34	0.38	1.19e-9	Lymphocyte counts;
SARC	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg01238044	chr22:24384105	GSTT1	-0.59	-6.82	-0.41	7.55e-11	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg21016266	chr12:122356598	WDR66	-0.32	-5.1	-0.32	6.97e-7	Mean corpuscular volume;
SARC	cis	rs1008375	1.000	rs10805359	chr4:17684886	A/G	cg16339924	chr4:17578868	LAP3	0.62	8.08	0.47	3.54e-14	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1865760	0.865	rs1115920	chr6:25954027	A/G	cg18357526	chr6:26021779	HIST1H4A	0.4	4.87	0.3	2.07e-6	Height;
SARC	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg24531977	chr5:56204891	C5orf35	-0.51	-5.16	-0.32	5.21e-7	Initial pursuit acceleration;
SARC	cis	rs9309473	0.519	rs4852950	chr2:73864670	C/T	cg20560298	chr2:73613845	ALMS1	0.48	6.45	0.39	6.38e-10	Metabolite levels;
SARC	cis	rs2985684	1.000	rs11157696	chr14:50105746	C/G	cg04989706	chr14:50066350	PPIL5	0.56	5.88	0.36	1.39e-8	Carotid intima media thickness;
SARC	cis	rs501120	0.810	rs684196	chr10:44745950	A/T	cg09554077	chr10:44749378	NA	0.47	6.48	0.39	5.32e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs2180341	0.842	rs9375492	chr6:127545492	C/T	cg24812749	chr6:127587940	RNF146	-0.94	-10.88	-0.58	1.5e-22	Breast cancer;
SARC	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg02018176	chr4:1364513	KIAA1530	0.41	6.19	0.38	2.74e-9	Longevity;
SARC	cis	rs6963495	0.818	rs117887993	chr7:105193837	T/G	cg19920283	chr7:105172520	RINT1	0.67	5.72	0.35	3.33e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs11583043	0.957	rs6667932	chr1:101503755	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.49	5.8	0.36	2.12e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs501120	0.925	rs492152	chr10:44757677	C/T	cg09554077	chr10:44749378	NA	0.48	6.52	0.39	4.38e-10	Coronary artery disease;Coronary heart disease;
SARC	cis	rs2072499	0.778	rs2247476	chr1:156190280	C/A	cg24450063	chr1:156163899	SLC25A44	1.02	12.86	0.64	5.94e-29	Testicular germ cell tumor;
SARC	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg02733842	chr7:1102375	C7orf50	-0.52	-6.42	-0.39	7.72e-10	Bronchopulmonary dysplasia;
SARC	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg14582100	chr15:45693742	SPATA5L1	0.35	4.91	0.31	1.69e-6	Homoarginine levels;
SARC	cis	rs9400467	0.568	rs12204075	chr6:111489059	G/T	cg15721981	chr6:111408429	SLC16A10	0.68	5.85	0.36	1.63e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs73206853	0.698	rs56327628	chr12:111117931	A/C	cg10860002	chr12:110842031	ANAPC7	0.58	4.94	0.31	1.49e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs2439831	0.850	rs28595038	chr15:44044859	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	7.55	0.44	1.01e-12	Lung cancer in ever smokers;
SARC	cis	rs12912251	0.500	rs2643204	chr15:39007171	C/T	cg01338139	chr15:38987640	C15orf53	0.51	4.72	0.3	4.01e-6	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
SARC	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs870825	0.655	rs7675046	chr4:185652201	G/A	cg04058563	chr4:185651563	MLF1IP	-0.79	-11.11	-0.59	2.8e-23	Blood protein levels;
SARC	cis	rs9916302	0.861	rs752314	chr17:37410700	C/T	cg00129232	chr17:37814104	STARD3	-0.59	-7.35	-0.43	3.37e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs7247513	0.964	rs4804202	chr19:12718619	T/C	cg01871581	chr19:12707946	ZNF490	-0.85	-12.4	-0.63	1.92e-27	Bipolar disorder;
SARC	cis	rs6088580	0.524	rs6088568	chr20:33265971	A/C	cg07148914	chr20:33460835	GGT7	-0.42	-5.16	-0.32	5.4e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs10870270	1.000	rs10159943	chr10:133744744	T/C	cg26149184	chr10:133730230	NA	0.46	5.27	0.33	3.11e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs4242434	0.927	rs2291234	chr8:22464390	T/C	cg03733263	chr8:22462867	KIAA1967	1.04	18.24	0.77	8.95e-47	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg23262073	chr20:60523788	NA	0.59	8.38	0.48	4.97e-15	Obesity-related traits;
SARC	cis	rs116095464	0.558	rs7714335	chr5:263513	T/C	cg20965017	chr5:231967	SDHA	-0.53	-5.03	-0.31	9.79e-7	Breast cancer;
SARC	cis	rs7819412	0.540	rs2409726	chr8:11043138	T/C	cg12395012	chr8:11607386	GATA4	0.32	5.46	0.34	1.24e-7	Triglycerides;
SARC	cis	rs526821	0.595	rs2926309	chr11:55314219	G/A	cg04317927	chr11:55418816	OR4S2	0.39	5.7	0.35	3.69e-8	Pediatric bone mineral density (spine);
SARC	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg25952890	chr19:58913133	NA	0.37	5.12	0.32	6.48e-7	Uric acid clearance;
SARC	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg09699651	chr6:150184138	LRP11	0.39	4.89	0.3	1.89e-6	Lung cancer;
SARC	trans	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg16178998	chr1:231762459	TSNAX-DISC1;DISC1	0.45	6.26	0.38	1.88e-9	Immature fraction of reticulocytes;
SARC	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.39	-5.32	-0.33	2.4e-7	Personality dimensions;
SARC	cis	rs9814567	1.000	rs7374325	chr3:134275601	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-6.99	-0.42	2.88e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs9612	0.718	rs173202	chr19:44253588	C/T	cg08581076	chr19:44259116	C19orf61	0.61	7.7	0.45	3.84e-13	Exhaled nitric oxide output;
SARC	cis	rs6813479	0.523	rs2926564	chr4:137744172	C/T	cg16185213	chr4:137733633	NA	0.39	5.41	0.33	1.58e-7	Longevity;
SARC	cis	rs8180040	1.000	rs807810	chr3:47403892	G/A	cg27129171	chr3:47204927	SETD2	-0.68	-9.55	-0.53	1.85e-18	Colorectal cancer;
SARC	cis	rs9300255	0.602	rs1716177	chr12:123655457	C/T	cg05973401	chr12:123451056	ABCB9	0.54	5.78	0.35	2.44e-8	Neutrophil percentage of white cells;
SARC	cis	rs981844	1.000	rs56232929	chr4:154665700	A/G	cg14289246	chr4:154710475	SFRP2	0.57	6.43	0.39	7.08e-10	Response to statins (LDL cholesterol change);
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg22830590	chr2:175260396	CIR1;SCRN3	-0.49	-6.58	-0.4	3.08e-10	Neuroticism;
SARC	cis	rs11097912	0.603	rs77562460	chr4:107207415	C/A	cg09646026	chr4:107269030	AIMP1	-0.45	-4.86	-0.3	2.2e-6	Airflow obstruction;
SARC	cis	rs765787	0.530	rs4514617	chr15:45535439	A/G	cg24006582	chr15:45444508	DUOX1	-0.54	-7.16	-0.42	1.08e-11	Uric acid levels;
SARC	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	5.92	0.36	1.14e-8	Electroencephalogram traits;
SARC	cis	rs17376456	0.504	rs6898507	chr5:93082343	C/T	cg25358565	chr5:93447407	FAM172A	0.94	10.43	0.56	3.7e-21	Diabetic retinopathy;
SARC	cis	rs8180040	0.932	rs1038394	chr3:47464122	A/G	cg27129171	chr3:47204927	SETD2	0.65	9.11	0.51	3.86e-17	Colorectal cancer;
SARC	cis	rs10875746	0.951	rs10875756	chr12:48562304	C/T	cg26205652	chr12:48591994	NA	0.54	6.12	0.37	4.04e-9	Longevity (90 years and older);
SARC	cis	rs6991838	0.557	rs67046768	chr8:66489721	A/G	cg13398993	chr8:66546079	ARMC1	-0.62	-8.36	-0.48	5.88e-15	Intelligence (multi-trait analysis);
SARC	cis	rs6570726	0.764	rs4896821	chr6:145896181	G/A	cg05347473	chr6:146136440	FBXO30	0.51	7.09	0.42	1.56e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg06634786	chr22:41940651	POLR3H	-0.57	-6.69	-0.4	1.64e-10	Vitiligo;
SARC	cis	rs9902453	0.765	rs34585141	chr17:28336432	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.54	-6.95	-0.41	3.57e-11	Coffee consumption (cups per day);
SARC	cis	rs807669	0.807	rs712948	chr22:19206499	A/G	cg02655711	chr22:19163373	SLC25A1	0.56	7.65	0.45	5.41e-13	Metabolite levels;
SARC	cis	rs11608355	1.000	rs10850134	chr12:109861454	G/C	cg05360138	chr12:110035743	NA	0.43	4.8	0.3	2.86e-6	Neuroticism;
SARC	cis	rs8070624	0.574	rs11078408	chr17:17876011	A/G	cg05444541	chr17:17804740	TOM1L2	-0.32	-5.22	-0.32	3.88e-7	Total body bone mineral density;
SARC	cis	rs4803468	1.000	rs4803463	chr19:41911040	C/G	cg08477640	chr19:41863820	B9D2	0.47	6.01	0.37	7.01e-9	Height;
SARC	cis	rs1348850	0.872	rs4893825	chr2:178298687	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.7	8.38	0.48	5.09e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs826838	1.000	rs11183469	chr12:38752311	G/A	cg13010199	chr12:38710504	ALG10B	0.81	11.63	0.61	6.07e-25	Heart rate;
SARC	trans	rs208515	0.525	rs10944868	chr6:66687508	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.9	10.58	0.57	1.26e-21	Exhaled nitric oxide levels;
SARC	cis	rs9443189	0.723	rs2748947	chr6:76437921	C/T	cg01950844	chr6:76311363	SENP6	-0.81	-7.73	-0.45	3.18e-13	Prostate cancer;
SARC	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg07701084	chr6:150067640	NUP43	0.43	5.55	0.34	7.7e-8	Lung cancer;
SARC	cis	rs10876993	0.890	rs2640630	chr12:58067267	T/C	cg18357645	chr12:58087776	OS9	0.46	5.98	0.37	8.13e-9	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs796364	0.951	rs1105964	chr2:201000776	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.61	-5.7	-0.35	3.59e-8	Schizophrenia;
SARC	cis	rs2997447	0.723	rs2802338	chr1:26475257	G/A	cg19633962	chr1:26362018	EXTL1	-0.55	-5.0	-0.31	1.12e-6	QRS complex (12-leadsum);
SARC	cis	rs3106136	0.681	rs7658390	chr4:95304083	C/T	cg11021082	chr4:95130006	SMARCAD1	0.33	4.91	0.31	1.73e-6	Capecitabine sensitivity;
SARC	cis	rs1062177	0.826	rs2915879	chr5:151147442	A/G	cg00977110	chr5:151150581	G3BP1	0.65	6.53	0.39	4.16e-10	Preschool internalizing problems;
SARC	cis	rs472402	0.580	rs3736316	chr5:6656210	G/A	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.43	-5.14	-0.32	5.69e-7	Response to amphetamines;
SARC	cis	rs1865760	0.566	rs9467663	chr6:26021456	C/G	cg18357526	chr6:26021779	HIST1H4A	0.46	5.75	0.35	2.85e-8	Height;
SARC	cis	rs787274	1.000	rs7859381	chr9:115546649	C/T	cg13803584	chr9:115635662	SNX30	-0.76	-5.4	-0.33	1.65e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs5758659	0.569	rs133294	chr22:42382805	C/T	cg04733989	chr22:42467013	NAGA	0.53	6.94	0.41	3.75e-11	Cognitive function;
SARC	cis	rs17376456	1.000	rs17323433	chr5:93551028	G/A	cg21475434	chr5:93447410	FAM172A	0.95	8.25	0.48	1.16e-14	Diabetic retinopathy;
SARC	cis	rs459571	0.959	rs392134	chr9:136909008	G/A	cg13789015	chr9:136890014	NCRNA00094	0.63	8.63	0.49	9.46e-16	Platelet distribution width;
SARC	cis	rs11122272	0.735	rs2749699	chr1:231520279	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	trans	rs7824557	0.527	rs2736296	chr8:11234844	G/A	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.02	-0.42	2.36e-11	Retinal vascular caliber;
SARC	cis	rs7223966	1.000	rs8066719	chr17:61825764	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.52	-5.31	-0.33	2.51e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg13770153	chr20:60521292	NA	-0.45	-6.29	-0.38	1.55e-9	Body mass index;
SARC	cis	rs10464366	0.571	rs13233049	chr7:39187536	C/T	cg18850127	chr7:39170497	POU6F2	0.38	5.04	0.31	9.28e-7	IgG glycosylation;
SARC	cis	rs12594515	0.967	rs11854477	chr15:45998345	A/C	cg14863074	chr15:45997064	NA	0.34	5.13	0.32	6.03e-7	Waist circumference;Weight;
SARC	cis	rs10934753	0.560	rs73859048	chr3:125931603	G/A	cg01346077	chr3:125931526	NA	0.43	6.02	0.37	6.71e-9	Plasma homocysteine levels (post-methionine load test);
SARC	cis	rs2153535	0.580	rs915352	chr6:8442766	G/A	cg07606381	chr6:8435919	SLC35B3	0.78	11.09	0.59	3.11e-23	Motion sickness;
SARC	cis	rs11190604	1.000	rs3750633	chr10:102308214	C/T	cg14256752	chr10:102295592	HIF1AN	0.44	4.95	0.31	1.44e-6	Palmitoleic acid (16:1n-7) levels;
SARC	trans	rs12310956	0.510	rs7965329	chr12:33868199	C/A	cg13010199	chr12:38710504	ALG10B	0.57	7.5	0.44	1.32e-12	Morning vs. evening chronotype;
SARC	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg17971929	chr21:40555470	PSMG1	0.99	13.74	0.67	7.45e-32	Cognitive function;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg21076211	chr12:108908879	FICD	0.63	6.29	0.38	1.54e-9	Lung cancer in ever smokers;
SARC	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	22.91	0.83	1.28e-61	Chronic sinus infection;
SARC	cis	rs17376456	0.825	rs13156202	chr5:93157721	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.71	-6.38	-0.39	9.56e-10	Diabetic retinopathy;
SARC	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg12310025	chr6:25882481	NA	-0.4	-4.91	-0.31	1.7e-6	Intelligence (multi-trait analysis);
SARC	cis	rs2439831	0.681	rs2444036	chr15:43694108	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.75	7.82	0.46	1.88e-13	Lung cancer in ever smokers;
SARC	cis	rs7523050	0.908	rs12405585	chr1:109397229	C/A	cg08274380	chr1:109419600	GPSM2	0.7	6.1	0.37	4.3e-9	Fat distribution (HIV);
SARC	trans	rs9951602	0.512	rs8085719	chr18:76649111	A/G	cg02800362	chr5:177631904	HNRNPAB	0.72	9.1	0.51	4.14e-17	Obesity-related traits;
SARC	cis	rs2342371	0.756	rs12637868	chr3:196106754	G/A	cg15048948	chr3:196158458	UBXN7	0.63	7.62	0.45	6.4e-13	Fat distribution (HIV);
SARC	trans	rs17038463	1.000	rs17038174	chr3:1400993	T/G	cg18003583	chr5:176819624	SLC34A1	0.99	6.29	0.38	1.56e-9	Neurocognitive impairment in HIV-1 infection (continuous);
SARC	cis	rs78320035	0.609	rs115670366	chr1:168155816	G/T	cg17113809	chr1:168148080	TIPRL	1.29	6.84	0.41	6.96e-11	Red cell distribution width;
SARC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.03	0.37	6.27e-9	Prudent dietary pattern;
SARC	cis	rs11711311	0.955	rs10934241	chr3:113394705	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	8.19	0.47	1.72e-14	IgG glycosylation;
SARC	cis	rs6545883	0.965	rs1992765	chr2:61751333	A/G	cg15711740	chr2:61764176	XPO1	-0.42	-5.21	-0.32	4.16e-7	Tuberculosis;
SARC	trans	rs61931739	0.612	rs1906136	chr12:33905293	C/T	cg26384229	chr12:38710491	ALG10B	0.59	7.53	0.44	1.14e-12	Morning vs. evening chronotype;
SARC	cis	rs1957429	0.901	rs59876171	chr14:65384429	C/T	cg23373153	chr14:65346875	NA	-1.01	-10.28	-0.56	1.07e-20	Pediatric areal bone mineral density (radius);
SARC	cis	rs7551222	0.752	rs16853865	chr1:204465659	A/G	cg20240347	chr1:204465584	NA	-0.35	-6.11	-0.37	4.22e-9	Schizophrenia;
SARC	cis	rs7560272	0.501	rs10191988	chr2:73947787	A/G	cg20560298	chr2:73613845	ALMS1	0.45	5.99	0.37	7.95e-9	Schizophrenia;
SARC	cis	rs10046574	0.731	rs10458299	chr7:135052348	C/T	cg27474649	chr7:135195673	CNOT4	0.86	6.44	0.39	6.61e-10	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs9868809	0.772	rs9877794	chr3:48718388	G/C	cg03060546	chr3:49711283	APEH	-0.54	-4.97	-0.31	1.31e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs965604	1.000	rs12916801	chr15:78769130	A/G	cg24631222	chr15:78858424	CHRNA5	-0.45	-5.85	-0.36	1.68e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs9399135	0.967	rs7763836	chr6:135362378	T/C	cg24558204	chr6:135376177	HBS1L	0.46	6.2	0.38	2.52e-9	Red blood cell count;
SARC	cis	rs459571	0.715	rs401826	chr9:136890591	C/T	cg13789015	chr9:136890014	NCRNA00094	0.64	8.77	0.5	3.8e-16	Platelet distribution width;
SARC	cis	rs9486715	0.867	rs4131519	chr6:96964939	G/A	cg06623918	chr6:96969491	KIAA0776	0.84	11.82	0.61	1.4e-25	Headache;
SARC	cis	rs7552404	0.731	rs10732723	chr1:76392437	C/T	cg22875332	chr1:76189707	ACADM	-0.42	-5.19	-0.32	4.68e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9640161	0.789	rs6964110	chr7:150041836	A/C	cg21361702	chr7:150065534	REPIN1	0.48	5.27	0.33	3.15e-7	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs4268898	0.965	rs4665673	chr2:24459737	A/T	cg06627628	chr2:24431161	ITSN2	0.61	8.56	0.49	1.53e-15	Asthma;
SARC	cis	rs1030877	0.515	rs17030766	chr2:105911905	G/A	cg02079111	chr2:105885981	TGFBRAP1	-0.49	-5.6	-0.34	5.96e-8	Obesity-related traits;
SARC	cis	rs2075371	0.830	rs1421478	chr7:133922793	T/A	cg11752832	chr7:134001865	SLC35B4	0.5	6.11	0.37	4.17e-9	Mean platelet volume;
SARC	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg22535103	chr8:58192502	C8orf71	-0.7	-6.64	-0.4	2.17e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs240764	0.658	rs12194255	chr6:101168439	G/A	cg09795085	chr6:101329169	ASCC3	-0.46	-5.76	-0.35	2.58e-8	Neuroticism;
SARC	cis	rs5760092	0.755	rs6003959	chr22:24264395	C/T	cg25703541	chr22:24373054	LOC391322	0.78	9.02	0.51	7.06e-17	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs1050631	0.592	rs1785930	chr18:33723718	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.56	6.5	0.39	4.8e-10	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs7681440	0.746	rs1442134	chr4:90819154	A/G	cg06632027	chr4:90757378	SNCA	0.41	5.51	0.34	9.38e-8	Dementia with Lewy bodies;
SARC	cis	rs796364	0.951	rs11675980	chr2:201051150	A/G	cg23649088	chr2:200775458	C2orf69	-0.62	-6.66	-0.4	1.97e-10	Schizophrenia;
SARC	trans	rs9650657	0.571	rs11783247	chr8:10788875	C/T	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.59	-0.45	7.43e-13	Neuroticism;
SARC	cis	rs6669919	0.553	rs7527603	chr1:211668090	G/A	cg10512769	chr1:211675356	NA	-0.36	-5.72	-0.35	3.21e-8	Intelligence (multi-trait analysis);
SARC	cis	rs4481887	1.000	rs10788782	chr1:248496132	C/A	cg13385794	chr1:248469461	NA	0.36	5.35	0.33	2.06e-7	Common traits (Other);
SARC	cis	rs78366141	0.649	rs6813481	chr4:89739174	G/A	cg01026744	chr4:89619053	NAP1L5;HERC3	0.76	4.79	0.3	2.95e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
SARC	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg06697600	chr4:7070879	GRPEL1	-0.37	-4.82	-0.3	2.62e-6	Monocyte percentage of white cells;
SARC	cis	rs950169	0.922	rs4586394	chr15:84822385	G/A	cg17507749	chr15:85114479	UBE2QP1	-0.75	-8.58	-0.49	1.33e-15	Schizophrenia;
SARC	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs4481887	1.000	rs10888358	chr1:248471467	C/A	cg00666640	chr1:248458726	OR2T12	0.37	6.18	0.38	2.86e-9	Common traits (Other);
SARC	cis	rs9916302	0.706	rs12937013	chr17:37665571	G/A	cg07936489	chr17:37558343	FBXL20	-0.75	-8.71	-0.5	5.74e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs3617	0.573	rs9850563	chr3:52912214	G/A	cg18404041	chr3:52824283	ITIH1	0.32	4.77	0.3	3.24e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs9398803	0.678	rs4621655	chr6:126896107	G/A	cg20229609	chr6:126660872	C6orf173	0.35	5.07	0.31	8.26e-7	Male-pattern baldness;
SARC	cis	rs2273669	0.915	rs6935782	chr6:109289881	A/G	cg01304950	chr6:109416612	SESN1;C6orf182	0.57	4.79	0.3	2.94e-6	Prostate cancer;
SARC	cis	rs6782228	0.606	rs2811500	chr3:128366256	C/T	cg08795948	chr3:128337044	NA	0.37	5.11	0.32	6.73e-7	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
SARC	cis	rs7644634	0.635	rs6796643	chr3:105484620	C/T	cg23051926	chr3:105466016	CBLB	0.46	5.78	0.35	2.39e-8	Itch intensity from mosquito bite;
SARC	cis	rs67460515	0.563	rs4679672	chr3:160901020	G/A	cg04691961	chr3:161091175	C3orf57	-0.41	-4.94	-0.31	1.52e-6	Parkinson's disease;
SARC	cis	rs9400467	0.506	rs11153281	chr6:111594594	C/T	cg15721981	chr6:111408429	SLC16A10	0.68	5.85	0.36	1.66e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg11644478	chr21:40555479	PSMG1	-0.89	-11.46	-0.6	2.09e-24	Cognitive function;
SARC	cis	rs9911578	0.967	rs4132925	chr17:56938016	C/G	cg05425664	chr17:57184151	TRIM37	0.69	8.43	0.48	3.63e-15	Intelligence (multi-trait analysis);
SARC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	5.88	0.36	1.4e-8	Prudent dietary pattern;
SARC	cis	rs7772486	0.590	rs1890170	chr6:146071839	G/C	cg05347473	chr6:146136440	FBXO30	-0.72	-10.05	-0.55	5.74e-20	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7772486	0.603	rs2223411	chr6:146028767	T/C	cg23711669	chr6:146136114	FBXO30	-0.81	-11.88	-0.61	8.96e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs57221529	0.563	rs4957057	chr5:569230	C/G	cg07777115	chr5:623756	CEP72	-0.61	-5.43	-0.33	1.44e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs7296418	0.699	rs11057254	chr12:123794581	A/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-5.12	-0.32	6.32e-7	Platelet count;
SARC	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.43	-0.56	3.88e-21	Chronic sinus infection;
SARC	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg24060327	chr5:131705240	SLC22A5	0.71	8.52	0.49	1.96e-15	Blood metabolite levels;
SARC	cis	rs9399137	0.507	rs4451150	chr6:135279063	T/G	cg22676075	chr6:135203613	NA	0.42	5.36	0.33	1.98e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg13939156	chr17:80058883	NA	-0.43	-6.48	-0.39	5.55e-10	Life satisfaction;
SARC	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg05872129	chr22:39784769	NA	-0.44	-6.14	-0.37	3.56e-9	Intelligence (multi-trait analysis);
SARC	cis	rs10870270	0.957	rs3753008	chr10:133785129	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.47	-5.47	-0.34	1.18e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg08859206	chr1:53392774	SCP2	0.42	5.86	0.36	1.57e-8	Monocyte count;
SARC	cis	rs2153535	0.580	rs9406143	chr6:8444583	C/T	cg21535247	chr6:8435926	SLC35B3	0.56	7.01	0.42	2.6e-11	Motion sickness;
SARC	cis	rs2361718	0.933	rs8066452	chr17:78104080	A/G	cg06718696	chr17:78121285	EIF4A3	0.49	5.6	0.34	6e-8	Yeast infection;
SARC	cis	rs2832191	0.729	rs2832201	chr21:30499841	A/G	cg24692254	chr21:30365293	RNF160	-0.96	-16.05	-0.72	1.52e-39	Dental caries;
SARC	cis	rs875971	0.545	rs67688847	chr7:65626051	G/A	cg11764359	chr7:65958608	NA	0.67	6.65	0.4	2.03e-10	Aortic root size;
SARC	cis	rs6500602	0.627	rs863501	chr16:4588394	G/C	cg09269891	chr16:3843415	CREBBP	0.4	4.8	0.3	2.82e-6	Schizophrenia;
SARC	trans	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg00938859	chr5:1591904	SDHAP3	0.78	7.37	0.43	3.02e-12	Breast cancer;
SARC	cis	rs1448094	0.511	rs34885805	chr12:86155180	A/T	cg02569458	chr12:86230093	RASSF9	0.36	4.77	0.3	3.26e-6	Major depressive disorder;
SARC	trans	rs8073060	0.586	rs4796100	chr17:33997657	G/T	cg19694781	chr19:47549865	TMEM160	0.71	6.83	0.41	7.41e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	trans	rs61931739	0.500	rs11053222	chr12:34481100	C/A	cg26384229	chr12:38710491	ALG10B	0.91	13.67	0.67	1.28e-31	Morning vs. evening chronotype;
SARC	cis	rs9818758	0.556	rs116432667	chr3:48947589	C/T	cg01304814	chr3:48885189	PRKAR2A	0.62	5.12	0.32	6.46e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs10782582	0.609	rs56159153	chr1:76353498	T/G	cg10523679	chr1:76189770	ACADM	-0.4	-4.93	-0.31	1.57e-6	Daytime sleep phenotypes;
SARC	cis	rs3092073	0.617	rs3893276	chr20:44591089	G/C	cg27529037	chr20:44575021	PCIF1	-0.34	-5.04	-0.31	9.4e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9470366	0.527	rs733590	chr6:36645203	A/G	cg08179530	chr6:36648295	CDKN1A	0.68	8.97	0.51	9.91e-17	QRS duration;
SARC	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs651907	0.514	rs34301719	chr3:101417993	C/T	cg12386194	chr3:101231763	SENP7	0.47	5.49	0.34	1.05e-7	Colorectal cancer;
SARC	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg18252515	chr7:66147081	NA	0.56	6.02	0.37	6.73e-9	Aortic root size;
SARC	cis	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg09021430	chr5:549028	NA	-0.45	-5.81	-0.36	2.03e-8	Obesity-related traits;
SARC	cis	rs367615	0.704	rs7704824	chr5:108850278	A/G	cg17395555	chr5:108820864	NA	0.41	5.94	0.36	1.05e-8	Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg11062466	chr8:58055876	NA	0.61	5.75	0.35	2.74e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs611744	0.967	rs627604	chr8:109189819	C/G	cg21045802	chr8:109455806	TTC35	0.44	5.3	0.33	2.64e-7	Dupuytren's disease;
SARC	trans	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg24592846	chr11:129873229	NCRNA00167;PRDM10	0.46	6.31	0.38	1.39e-9	Immature fraction of reticulocytes;
SARC	cis	rs2832191	1.000	rs2832184	chr21:30483265	C/T	cg24692254	chr21:30365293	RNF160	-0.77	-10.73	-0.58	4.22e-22	Dental caries;
SARC	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg07701084	chr6:150067640	NUP43	0.43	5.51	0.34	9.4e-8	Lung cancer;
SARC	cis	rs6540556	0.723	rs6540551	chr1:209925295	C/T	cg23920097	chr1:209922102	NA	-0.61	-7.02	-0.42	2.4e-11	Red blood cell count;
SARC	cis	rs2180341	0.680	rs9388554	chr6:127576234	C/G	cg24812749	chr6:127587940	RNF146	0.85	11.55	0.6	1.08e-24	Breast cancer;
SARC	cis	rs9393692	0.875	rs12526215	chr6:26262916	T/C	cg05868516	chr6:26286170	HIST1H4H	0.58	7.68	0.45	4.32e-13	Educational attainment;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg17041101	chr6:105259926	HACE1	0.49	6.87	0.41	5.69e-11	Thyroid stimulating hormone;
SARC	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg02463440	chr8:22132932	PIWIL2	0.45	6.23	0.38	2.11e-9	Hypertriglyceridemia;
SARC	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.97	-15.81	-0.72	9.26e-39	Chronic sinus infection;
SARC	cis	rs709400	1.000	rs56660916	chr14:104126137	G/T	cg12935359	chr14:103987150	CKB	-0.33	-4.97	-0.31	1.28e-6	Body mass index;
SARC	cis	rs7586879	0.616	rs876186	chr2:25125585	C/T	cg04586622	chr2:25135609	ADCY3	0.32	5.41	0.33	1.57e-7	Body mass index;
SARC	cis	rs2073499	0.935	rs57842657	chr3:50227787	T/A	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.56	4.86	0.3	2.2e-6	Schizophrenia;
SARC	cis	rs4423214	1.000	rs12790558	chr11:71170905	T/C	cg05163923	chr11:71159392	DHCR7	0.64	8.92	0.5	1.44e-16	Vitamin D levels;
SARC	cis	rs2072499	0.778	rs2842868	chr1:156196407	A/C	cg25208724	chr1:156163844	SLC25A44	0.69	7.96	0.46	7.57e-14	Testicular germ cell tumor;
SARC	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg21171335	chr12:122356390	WDR66	0.42	6.66	0.4	1.99e-10	Mean corpuscular volume;
SARC	cis	rs2380220	0.606	rs4571572	chr6:96004823	T/C	cg23517279	chr6:96025343	MANEA	0.53	6.09	0.37	4.7e-9	Behavioural disinhibition (generation interaction);
SARC	cis	rs35306767	0.903	rs35567307	chr10:915804	G/C	cg20503657	chr10:835505	NA	0.89	8.26	0.48	1.08e-14	Eosinophil percentage of granulocytes;
SARC	cis	rs9300255	0.602	rs1790095	chr12:123681222	G/A	cg00376283	chr12:123451042	ABCB9	0.55	6.53	0.39	4.09e-10	Neutrophil percentage of white cells;
SARC	cis	rs6964587	0.967	rs4626516	chr7:91807153	G/C	cg17063962	chr7:91808500	NA	0.96	15.87	0.72	6.19e-39	Breast cancer;
SARC	cis	rs2273669	0.667	rs76367548	chr6:109356589	C/T	cg05315195	chr6:109294784	ARMC2	-0.63	-5.7	-0.35	3.6e-8	Prostate cancer;
SARC	cis	rs17539620	0.628	rs62432728	chr6:154829511	G/C	cg20019720	chr6:154832845	CNKSR3	0.41	4.91	0.31	1.75e-6	Lipoprotein (a) levels;
SARC	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.32	-4.79	-0.3	2.97e-6	Total body bone mineral density;
SARC	cis	rs5753618	0.509	rs5997902	chr22:31583007	A/G	cg13145458	chr22:31556086	RNF185	0.44	4.74	0.3	3.76e-6	Colorectal cancer;
SARC	cis	rs2153535	0.580	rs9379222	chr6:8514788	T/C	cg21535247	chr6:8435926	SLC35B3	0.58	7.25	0.43	6.2e-12	Motion sickness;
SARC	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg00149659	chr3:10157352	C3orf10	0.64	5.91	0.36	1.22e-8	Alzheimer's disease;
SARC	trans	rs17221829	0.733	rs11018668	chr11:89356178	C/T	cg07393057	chr1:89149638	PKN2	-0.49	-6.71	-0.4	1.46e-10	Anxiety in major depressive disorder;
SARC	cis	rs147120681	1	rs147120681	chr1:101239293	CT/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.44	-5.54	-0.34	8.23e-8	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
SARC	cis	rs7264396	0.616	rs6142476	chr20:34581216	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-6.12	-0.37	4.03e-9	Total cholesterol levels;
SARC	cis	rs2012796	0.661	rs59969857	chr14:81841579	A/G	cg02996355	chr14:81879375	NA	0.51	5.67	0.35	4.12e-8	Night sleep phenotypes;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg02897042	chr10:95720710	PIPSL	0.48	6.4	0.39	8.57e-10	Thyroid stimulating hormone;
SARC	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.53	-6.22	-0.38	2.31e-9	Intelligence (multi-trait analysis);
SARC	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg27266027	chr21:40555129	PSMG1	0.5	5.46	0.34	1.21e-7	Cognitive function;
SARC	cis	rs6952808	0.609	rs34967784	chr7:1949507	T/G	cg13880726	chr7:1868755	MAD1L1	0.43	4.97	0.31	1.33e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.55	6.52	0.39	4.37e-10	Prudent dietary pattern;
SARC	cis	rs7264396	0.690	rs2425180	chr20:34447160	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	5.52	0.34	8.89e-8	Total cholesterol levels;
SARC	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg02018176	chr4:1364513	KIAA1530	0.44	6.28	0.38	1.64e-9	Longevity;
SARC	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg13206674	chr6:150067644	NUP43	0.39	5.04	0.31	9.17e-7	Lung cancer;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16605745	chr12:48099745	RPAP3	0.52	6.83	0.41	7.32e-11	Smoking initiation;
SARC	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.94	10.04	0.55	5.91e-20	Platelet count;
SARC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg07157834	chr1:205819609	PM20D1	0.69	11.0	0.58	5.98e-23	Menarche (age at onset);
SARC	cis	rs9814567	1.000	rs7429866	chr3:134236306	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	7.03	0.42	2.24e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs9814567	0.502	rs12634127	chr3:134256159	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.4	-5.03	-0.31	9.84e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-6.05	-0.37	5.68e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4509693	0.891	rs10748797	chr10:102502173	A/C	cg15234845	chr10:102496500	NA	0.32	4.86	0.3	2.13e-6	Alzheimer's disease;
SARC	cis	rs2120243	0.539	rs1869859	chr3:157107762	G/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.4	5.12	0.32	6.53e-7	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs13191362	0.938	rs35395472	chr6:163008493	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.5	0.34	1.01e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs10791323	0.604	rs2723607	chr11:133711018	C/G	cg14349672	chr11:133703707	NA	-0.38	-5.42	-0.33	1.47e-7	Childhood ear infection;
SARC	cis	rs113835537	0.529	rs17496250	chr11:66270774	C/G	cg24851651	chr11:66362959	CCS	0.38	4.72	0.3	4.02e-6	Airway imaging phenotypes;
SARC	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg24633833	chr3:10029261	TMEM111	0.51	5.09	0.32	7.27e-7	Alzheimer's disease;
SARC	cis	rs950776	0.752	rs7182583	chr15:78899210	G/C	cg24631222	chr15:78858424	CHRNA5	-0.38	-4.78	-0.3	3.05e-6	Sudden cardiac arrest;
SARC	cis	rs3784262	0.669	rs17820990	chr15:58349568	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.33	-4.98	-0.31	1.24e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs425277	0.958	rs626479	chr1:2110260	A/G	cg21442419	chr1:2182373	SKI	0.53	6.71	0.4	1.46e-10	Height;
SARC	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg11878867	chr6:150167359	LRP11	0.35	4.8	0.3	2.78e-6	Lung cancer;
SARC	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg02725872	chr8:58115012	NA	-0.37	-6.54	-0.39	3.94e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs8084125	0.832	rs62105180	chr18:74951197	C/G	cg19705131	chr18:74961163	GALR1	0.42	4.75	0.3	3.55e-6	Obesity-related traits;
SARC	cis	rs10883723	0.810	rs2281879	chr10:104268877	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	9.33	0.52	8.61e-18	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs7712401	0.580	rs42536	chr5:122276423	T/C	cg19412675	chr5:122181750	SNX24	0.4	5.09	0.32	7.55e-7	Mean platelet volume;
SARC	cis	rs7089973	0.604	rs11196937	chr10:116589500	G/C	cg03647239	chr10:116582469	FAM160B1	0.49	6.3	0.38	1.48e-9	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs9660992	0.674	rs56198325	chr1:205265450	G/A	cg21545522	chr1:205238299	TMCC2	0.45	6.03	0.37	6.35e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg24549020	chr5:56110836	MAP3K1	0.44	5.16	0.32	5.16e-7	Coronary artery disease;
SARC	cis	rs55823223	0.564	rs9894009	chr17:73850414	C/T	cg14829360	chr17:73884958	NA	-0.59	-7.95	-0.46	8.15e-14	Psoriasis;
SARC	cis	rs7769051	0.522	rs7761207	chr6:133110430	G/A	cg07930552	chr6:133119739	C6orf192	0.93	5.74	0.35	2.86e-8	Type 2 diabetes nephropathy;
SARC	cis	rs76917914	0.820	rs7041811	chr9:100821028	C/T	cg03040243	chr9:100819229	NANS	0.72	7.98	0.46	6.45e-14	Immature fraction of reticulocytes;
SARC	cis	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg07777115	chr5:623756	CEP72	-0.56	-4.78	-0.3	3.11e-6	Obesity-related traits;
SARC	cis	rs73206853	0.764	rs68087637	chr12:110619797	T/C	cg10860002	chr12:110842031	ANAPC7	0.64	5.27	0.33	3.06e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs3857536	0.813	rs7771716	chr6:66946769	C/T	cg07460842	chr6:66804631	NA	-0.45	-5.19	-0.32	4.5e-7	Blood trace element (Cu levels);
SARC	cis	rs807669	1.000	rs807669	chr22:19154522	T/C	cg02655711	chr22:19163373	SLC25A1	0.58	8.05	0.47	4.34e-14	Metabolite levels;
SARC	cis	rs7223966	1.000	rs6504170	chr17:61709168	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	5.92	0.36	1.15e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg14298792	chr15:30685198	CHRFAM7A	-0.48	-5.43	-0.34	1.42e-7	Huntington's disease progression;
SARC	cis	rs2439831	1.000	rs689647	chr15:43762196	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	8.35	0.48	6.17e-15	Lung cancer in ever smokers;
SARC	cis	rs6088590	1.000	rs6119516	chr20:33328024	C/T	cg08999081	chr20:33150536	PIGU	0.33	4.74	0.3	3.79e-6	Coronary artery disease;
SARC	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.74	8.5	0.49	2.3e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs17270561	0.609	rs1317816	chr6:25765390	T/C	cg16482183	chr6:26056742	HIST1H1C	0.48	5.95	0.36	9.58e-9	Iron status biomarkers;
SARC	cis	rs2268241	0.938	rs17878783	chr21:34779185	G/A	cg14850771	chr21:34775459	IFNGR2	0.97	9.33	0.52	8.64e-18	Obesity-related traits;
SARC	cis	rs2204008	0.537	rs11170128	chr12:38006632	G/A	cg26384229	chr12:38710491	ALG10B	0.89	13.14	0.65	6.99e-30	Bladder cancer;
SARC	cis	rs11190604	1.000	rs11190569	chr10:102227409	C/T	cg07080220	chr10:102295463	HIF1AN	0.78	9.47	0.53	3.33e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs9302635	0.513	rs8061282	chr16:72155938	C/T	cg16558253	chr16:72132732	DHX38	-0.53	-6.83	-0.41	7.18e-11	Blood protein levels;
SARC	cis	rs1472147	0.696	rs1532222	chr7:128516945	A/C	cg00260937	chr7:128520193	KCP	-0.45	-5.11	-0.32	6.58e-7	Calcium levels;
SARC	cis	rs1008375	0.931	rs4479701	chr4:17571496	G/A	cg02297831	chr4:17616191	MED28	0.46	5.7	0.35	3.52e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9911578	0.900	rs7214335	chr17:57158840	G/A	cg12560992	chr17:57184187	TRIM37	0.79	10.85	0.58	1.8e-22	Intelligence (multi-trait analysis);
SARC	cis	rs2236918	0.710	rs1635507	chr1:242028358	G/T	cg17736920	chr1:242011382	EXO1	0.78	10.75	0.58	3.79e-22	Menopause (age at onset);
SARC	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg10523679	chr1:76189770	ACADM	-0.47	-5.81	-0.36	2.04e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	trans	rs629535	0.735	rs525610	chr8:70074535	A/G	cg21567404	chr3:27674614	NA	1.04	13.3	0.66	2.13e-30	Dupuytren's disease;
SARC	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg11062466	chr8:58055876	NA	0.54	5.56	0.34	7.55e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg08280861	chr8:58055591	NA	0.6	5.28	0.33	2.92e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	11.07	0.59	3.59e-23	Alzheimer's disease;
SARC	cis	rs6665290	0.566	rs1513617	chr1:227447213	C/T	cg10327440	chr1:227177885	CDC42BPA	0.92	14.33	0.68	7.8e-34	Myeloid white cell count;
SARC	cis	rs7614311	1.000	rs2087704	chr3:63820493	A/C	cg16258503	chr3:63850278	ATXN7;THOC7	-0.47	-4.94	-0.31	1.46e-6	Lung function (FVC);Lung function (FEV1);
SARC	cis	rs2486288	0.656	rs6493143	chr15:45570781	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.54	-6.88	-0.41	5.51e-11	Glomerular filtration rate;
SARC	cis	rs1050631	0.592	rs1785903	chr18:33711642	G/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.57	6.88	0.41	5.59e-11	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg11987759	chr7:65425863	GUSB	-0.63	-8.24	-0.48	1.22e-14	Aortic root size;
SARC	cis	rs7772486	0.790	rs9485024	chr6:146142487	A/G	cg05347473	chr6:146136440	FBXO30	-0.5	-6.91	-0.41	4.5e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs34172651	0.876	rs964782	chr16:24811740	T/C	cg00152838	chr16:24741724	TNRC6A	-0.49	-5.88	-0.36	1.41e-8	Intelligence (multi-trait analysis);
SARC	cis	rs765787	0.530	rs1706764	chr15:45524256	T/A	cg24006582	chr15:45444508	DUOX1	-0.49	-6.49	-0.39	5.13e-10	Uric acid levels;
SARC	cis	rs12545109	0.842	rs2670050	chr8:57402914	T/G	cg19413350	chr8:57351067	NA	-0.43	-4.88	-0.3	2e-6	Obesity-related traits;
SARC	cis	rs6088813	0.922	rs6088800	chr20:33934437	T/A	cg23207816	chr20:34252616	CPNE1;RBM12	-0.44	-5.35	-0.33	2.07e-7	Height;
SARC	cis	rs7566780	0.549	rs6746795	chr2:16682166	A/G	cg09580478	chr2:16689509	NA	0.56	7.01	0.42	2.56e-11	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg06969125	chr15:64648580	CSNK1G1	-0.52	-7.01	-0.42	2.53e-11	Neuroticism;
SARC	trans	rs7615952	0.736	rs11921945	chr3:125643719	A/G	cg07211511	chr3:129823064	LOC729375	-0.95	-11.08	-0.59	3.33e-23	Blood pressure (smoking interaction);
SARC	cis	rs7666738	0.830	rs34870112	chr4:99045815	T/G	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7833790	0.963	rs2400473	chr8:82703403	C/T	cg17211192	chr8:82754475	SNX16	-0.58	-6.29	-0.38	1.59e-9	Diastolic blood pressure;
SARC	cis	rs17401966	0.931	rs10864448	chr1:10277497	A/T	cg15208524	chr1:10270712	KIF1B	0.52	6.15	0.37	3.42e-9	Hepatocellular carcinoma;
SARC	cis	rs2180341	0.521	rs12189967	chr6:127718058	G/A	cg24812749	chr6:127587940	RNF146	0.44	5.4	0.33	1.63e-7	Breast cancer;
SARC	cis	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg24110177	chr3:50126178	RBM5	0.58	7.97	0.46	7.25e-14	Intelligence (multi-trait analysis);
SARC	cis	rs9911578	0.967	rs7503190	chr17:57184162	A/C	cg05425664	chr17:57184151	TRIM37	-0.63	-7.9	-0.46	1.07e-13	Intelligence (multi-trait analysis);
SARC	cis	rs864537	0.584	rs7523907	chr1:167427247	A/G	cg09179987	chr1:167433047	CD247	0.36	5.82	0.36	1.95e-8	Celiac disease or Rheumatoid arthritis;Celiac disease;
SARC	cis	rs10744422	1.000	rs4759387	chr12:123377569	C/T	cg25930673	chr12:123319894	HIP1R	-0.65	-4.81	-0.3	2.66e-6	Schizophrenia;
SARC	trans	rs4076764	0.958	rs6688181	chr1:163384193	C/T	cg25157874	chr6:163835117	QKI	0.48	6.43	0.39	7.13e-10	Motion sickness;
SARC	cis	rs17783634	0.509	rs11775489	chr8:11036843	T/C	cg21775007	chr8:11205619	TDH	-0.46	-5.94	-0.36	1.04e-8	Subjective well-being;
SARC	cis	rs950027	0.620	rs1719246	chr15:45625479	T/A	cg21132104	chr15:45694354	SPATA5L1	0.58	7.37	0.44	2.87e-12	Response to fenofibrate (adiponectin levels);
SARC	trans	rs6894249	1.000	rs6894249	chr5:131797547	A/G	cg00892999	chr4:892055	GAK	-0.46	-6.25	-0.38	1.95e-9	Asthma;
SARC	cis	rs7940866	0.809	rs11222410	chr11:130833994	A/G	cg12179176	chr11:130786555	SNX19	0.67	9.25	0.52	1.47e-17	Schizophrenia;
SARC	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg09455208	chr3:40491958	NA	0.38	5.45	0.34	1.31e-7	Renal cell carcinoma;
SARC	trans	rs1493916	0.905	rs4799727	chr18:31393095	T/G	cg27147174	chr7:100797783	AP1S1	-0.58	-7.27	-0.43	5.3e-12	Life satisfaction;
SARC	cis	rs9788721	0.806	rs4887056	chr15:78734585	A/G	cg06917634	chr15:78832804	PSMA4	-0.54	-5.98	-0.36	8.51e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs708547	0.647	rs4864609	chr4:57878141	T/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.57	7.18	0.43	9.05e-12	Response to bleomycin (chromatid breaks);
SARC	cis	rs2635047	0.967	rs12960378	chr18:44614090	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	7.65	0.45	5.16e-13	Educational attainment;
SARC	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg08048268	chr3:133502702	NA	-0.42	-5.66	-0.35	4.53e-8	Iron status biomarkers;
SARC	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg01316550	chr5:56110833	MAP3K1	0.53	4.89	0.31	1.85e-6	Initial pursuit acceleration;
SARC	cis	rs11191205	0.954	rs11191191	chr10:103800979	G/A	cg15320455	chr10:103880129	LDB1	0.84	8.11	0.47	2.92e-14	Intelligence (multi-trait analysis);
SARC	cis	rs8027181	0.839	rs998021	chr15:72999825	T/C	cg25996835	chr15:72978165	BBS4;HIGD2B	0.4	5.27	0.33	3.06e-7	Triglyceride levels;
SARC	cis	rs155076	1.000	rs261432	chr13:21865915	G/C	cg25811766	chr13:21894605	NA	-0.53	-5.69	-0.35	3.78e-8	White matter hyperintensity burden;
SARC	cis	rs6807306	1.000	rs2420031	chr3:167382194	C/T	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.51	4.83	0.3	2.45e-6	Mean platelet volume;
SARC	cis	rs11644362	0.966	rs35678048	chr16:12989235	A/G	cg06890432	chr16:12997467	SHISA9	-0.51	-6.64	-0.4	2.15e-10	Positive affect;Subjective well-being;
SARC	cis	rs4906332	0.966	rs12588705	chr14:103865477	T/A	cg26031613	chr14:104095156	KLC1	-0.53	-6.2	-0.38	2.6e-9	Coronary artery disease;
SARC	cis	rs950027	0.620	rs1153862	chr15:45631868	A/G	cg15395560	chr15:45543142	SLC28A2	-0.27	-5.06	-0.31	8.37e-7	Response to fenofibrate (adiponectin levels);
SARC	cis	rs25645	0.771	rs10445310	chr17:38205396	C/A	cg17344932	chr17:38183730	MED24;SNORD124	0.38	6.94	0.41	3.75e-11	Myeloid white cell count;
SARC	cis	rs13166103	0.571	rs62366397	chr5:57763182	C/T	cg10487770	chr5:57879443	RAB3C	0.53	5.38	0.33	1.85e-7	Type 2 diabetes (age of onset);
SARC	cis	rs34779708	0.897	rs16935880	chr10:35415468	C/G	cg03585969	chr10:35415529	CREM	0.43	5.24	0.32	3.63e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs4481887	0.927	rs4350233	chr1:248489994	G/A	cg01631408	chr1:248437212	OR2T33	-0.38	-4.74	-0.3	3.75e-6	Common traits (Other);
SARC	cis	rs9309473	0.950	rs6546853	chr2:73833739	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-5.4	-0.33	1.64e-7	Metabolite levels;
SARC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg18402987	chr7:1209562	NA	0.41	5.3	0.33	2.71e-7	Longevity;Endometriosis;
SARC	cis	rs698833	0.669	rs1584885	chr2:44647038	A/C	cg00619915	chr2:44497795	NA	0.39	5.0	0.31	1.14e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs9300255	0.568	rs1627724	chr12:123638580	T/A	cg05973401	chr12:123451056	ABCB9	0.54	6.17	0.37	2.97e-9	Neutrophil percentage of white cells;
SARC	cis	rs9309473	0.607	rs7604588	chr2:73571417	C/T	cg20560298	chr2:73613845	ALMS1	-0.52	-6.68	-0.4	1.72e-10	Metabolite levels;
SARC	cis	rs9948	0.748	rs62156223	chr2:97412167	T/C	cg01990225	chr2:97406019	LMAN2L	-0.9	-6.09	-0.37	4.56e-9	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs72781680	0.898	rs17462433	chr2:24012758	T/C	cg08917208	chr2:24149416	ATAD2B	0.75	7.09	0.42	1.56e-11	Lymphocyte counts;
SARC	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg21782813	chr7:2030301	MAD1L1	0.34	5.34	0.33	2.21e-7	Bipolar disorder and schizophrenia;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg03950009	chr9:102669115	STX17	0.48	6.28	0.38	1.6e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs4722166	0.568	rs1880241	chr7:22759469	A/G	cg26061582	chr7:22766209	IL6	0.46	5.95	0.36	9.59e-9	Lung cancer;
SARC	cis	rs6089584	0.586	rs1079755	chr20:60615262	G/A	cg06108461	chr20:60628389	TAF4	-0.65	-8.35	-0.48	5.93e-15	Body mass index;
SARC	cis	rs1552244	0.706	rs279545	chr3:9972493	A/G	cg00149659	chr3:10157352	C3orf10	0.63	6.63	0.4	2.33e-10	Alzheimer's disease;
SARC	cis	rs910316	1.000	rs28626045	chr14:75589195	G/C	cg11812906	chr14:75593930	NEK9	0.87	13.87	0.67	2.61e-32	Height;
SARC	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.73	6.7	0.4	1.57e-10	Platelet count;
SARC	trans	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg21659725	chr3:3221576	CRBN	0.53	6.8	0.41	8.54e-11	Intelligence (multi-trait analysis);
SARC	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg02951883	chr7:2050386	MAD1L1	-0.42	-5.31	-0.33	2.51e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg22117014	chr7:120662793	C7orf58	0.47	6.38	0.39	9.63e-10	Thyroid stimulating hormone;
SARC	cis	rs1707322	1.000	rs11211190	chr1:46266255	C/T	cg06784218	chr1:46089804	CCDC17	0.33	5.76	0.35	2.66e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs709400	0.663	rs62007719	chr14:103943130	G/T	cg26031613	chr14:104095156	KLC1	0.83	12.18	0.62	9.84e-27	Body mass index;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg24043861	chr14:73396628	DCAF4	-0.86	-7.33	-0.43	3.84e-12	Autism spectrum disorder or schizophrenia;
SARC	cis	rs910316	1.000	rs8003506	chr14:75586288	A/C	cg23033748	chr14:75592666	NEK9	-0.36	-4.97	-0.31	1.29e-6	Height;
SARC	cis	rs10484885	0.878	rs72921937	chr6:90579863	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.61	-5.23	-0.32	3.71e-7	QRS interval (sulfonylurea treatment interaction);
SARC	cis	rs12022452	0.506	rs61779163	chr1:41015423	T/C	cg25568243	chr1:40974465	DEM1	0.54	5.27	0.33	3.08e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg03188948	chr7:1209495	NA	0.42	5.5	0.34	1.01e-7	Longevity;Endometriosis;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg15409931	chr19:34973341	WTIP	0.47	6.36	0.38	1.06e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs2032447	0.530	rs9356996	chr6:26008487	C/A	cg02841227	chr6:26021843	HIST1H4A	0.43	5.48	0.34	1.13e-7	Intelligence (multi-trait analysis);
SARC	cis	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg06637938	chr14:75390232	RPS6KL1	0.42	4.88	0.3	2.01e-6	Height;
SARC	cis	rs1983891	0.706	rs3800285	chr6:41558443	C/T	cg15051332	chr6:41514432	FOXP4	-0.47	-5.11	-0.32	6.59e-7	Prostate cancer;
SARC	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.42	-5.18	-0.32	4.79e-7	Tonsillectomy;
SARC	cis	rs10791097	0.690	rs12284487	chr11:130729705	T/C	cg09137382	chr11:130731461	NA	0.34	5.26	0.33	3.27e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs1865760	0.566	rs2051544	chr6:26071093	C/T	cg17691542	chr6:26056736	HIST1H1C	0.52	6.39	0.39	8.96e-10	Height;
SARC	cis	rs72634258	0.842	rs7545677	chr1:8165619	C/T	cg00042356	chr1:8021962	PARK7	0.55	5.14	0.32	5.73e-7	Inflammatory bowel disease;
SARC	cis	rs2952156	0.883	rs12150603	chr17:37834715	G/A	cg07936489	chr17:37558343	FBXL20	-0.42	-5.43	-0.34	1.4e-7	Asthma;
SARC	cis	rs933688	0.526	rs9293565	chr5:90609736	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.64	5.68	0.35	3.91e-8	Smoking behavior;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg01893322	chr3:173113110	NA	0.49	6.39	0.39	8.94e-10	Breast cancer;
SARC	cis	rs4713118	0.866	rs9468217	chr6:27726467	G/A	cg17221315	chr6:27791827	HIST1H4J	0.51	5.35	0.33	2.05e-7	Parkinson's disease;
SARC	cis	rs751728	1.000	rs943477	chr6:33750931	T/C	cg25922239	chr6:33757077	LEMD2	0.77	10.25	0.56	1.35e-20	Crohn's disease;
SARC	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg05368731	chr17:41323189	NBR1	0.73	8.7	0.5	6.12e-16	Menopause (age at onset);
SARC	cis	rs2204008	0.714	rs11520135	chr12:38114863	C/T	cg26384229	chr12:38710491	ALG10B	0.91	13.39	0.66	1.08e-30	Bladder cancer;
SARC	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg18225595	chr11:63971243	STIP1	0.42	5.86	0.36	1.55e-8	Platelet count;
SARC	cis	rs4253772	0.550	rs12165597	chr22:46705584	A/G	cg24881330	chr22:46731750	TRMU	0.67	5.7	0.35	3.53e-8	LDL cholesterol;Cholesterol, total;
SARC	cis	rs2559856	1.000	rs2559860	chr12:102087636	C/T	cg12924262	chr12:102091054	CHPT1	0.57	7.89	0.46	1.19e-13	Blood protein levels;
SARC	cis	rs5753618	0.561	rs737887	chr22:31696615	A/G	cg07713946	chr22:31675144	LIMK2	-0.38	-5.32	-0.33	2.48e-7	Colorectal cancer;
SARC	cis	rs7582720	0.945	rs2351524	chr2:203880992	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	-0.69	-7.05	-0.42	1.97e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs17376456	0.877	rs10061080	chr5:93420559	A/G	cg21475434	chr5:93447410	FAM172A	0.83	7.68	0.45	4.29e-13	Diabetic retinopathy;
SARC	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6450176	0.564	rs391470	chr5:53332338	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.55	-6.23	-0.38	2.21e-9	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs2439831	0.850	rs16963953	chr15:44081719	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	7.7	0.45	3.96e-13	Lung cancer in ever smokers;
SARC	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg05368731	chr17:41323189	NBR1	0.79	9.75	0.54	4.8e-19	Menopause (age at onset);
SARC	cis	rs7647973	0.925	rs4955421	chr3:49218888	G/A	cg06212747	chr3:49208901	KLHDC8B	0.6	6.42	0.39	7.37e-10	Menarche (age at onset);
SARC	cis	rs7666738	0.830	rs62321587	chr4:98997958	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1153858	1.000	rs1980288	chr15:45620612	T/C	cg26924012	chr15:45694286	SPATA5L1	0.77	10.57	0.57	1.33e-21	Homoarginine levels;
SARC	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.36	5.31	0.33	2.61e-7	Electroencephalogram traits;
SARC	cis	rs9818758	0.607	rs56004653	chr3:49072228	T/C	cg07636037	chr3:49044803	WDR6	-0.69	-5.46	-0.34	1.23e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs523522	0.962	rs7136951	chr12:120941927	C/T	cg12219531	chr12:120966889	COQ5	0.82	11.15	0.59	1.99e-23	High light scatter reticulocyte count;
SARC	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg08859206	chr1:53392774	SCP2	-0.38	-5.37	-0.33	1.86e-7	Monocyte count;
SARC	cis	rs9473924	0.505	rs7745565	chr6:50860083	A/G	cg14470998	chr6:50812995	TFAP2B	0.73	7.06	0.42	1.95e-11	Body mass index;
SARC	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg11764359	chr7:65958608	NA	0.65	7.59	0.45	7.45e-13	Aortic root size;
SARC	cis	rs4481887	0.927	rs6587445	chr1:248440915	A/G	cg01631408	chr1:248437212	OR2T33	-0.42	-5.3	-0.33	2.73e-7	Common traits (Other);
SARC	cis	rs9747201	1.000	rs56051385	chr17:80126712	T/C	cg09264619	chr17:80180166	NA	0.5	5.87	0.36	1.51e-8	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg11494091	chr17:61959527	GH2	0.53	7.94	0.46	8.67e-14	Prudent dietary pattern;
SARC	cis	rs1707322	0.717	rs1547925	chr1:46085356	C/T	cg06784218	chr1:46089804	CCDC17	-0.4	-7.0	-0.42	2.63e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9815354	1.000	rs9855965	chr3:41860508	C/T	cg03022575	chr3:42003672	ULK4	0.58	5.41	0.33	1.59e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg17971929	chr21:40555470	PSMG1	0.6	7.29	0.43	4.86e-12	Cognitive function;
SARC	cis	rs6011674	1.000	rs41282998	chr20:61875513	A/G	cg06763829	chr20:61885236	FLJ16779;NKAIN4	0.7	5.17	0.32	5.04e-7	Response to cytadine analogues (cytosine arabinoside);
SARC	cis	rs8114671	0.967	rs34515766	chr20:33785221	C/G	cg24642439	chr20:33292090	TP53INP2	-0.49	-5.66	-0.35	4.42e-8	Height;
SARC	cis	rs793571	0.523	rs12439457	chr15:58982390	T/C	cg05156742	chr15:59063176	FAM63B	0.71	9.59	0.53	1.43e-18	Schizophrenia;
SARC	cis	rs8114671	0.562	rs7266550	chr20:33495510	C/T	cg08999081	chr20:33150536	PIGU	0.33	4.91	0.31	1.72e-6	Height;
SARC	cis	rs67460515	0.563	rs1599388	chr3:160846866	A/G	cg17135325	chr3:160939158	NMD3	0.62	7.68	0.45	4.46e-13	Parkinson's disease;
SARC	cis	rs11874712	1.000	rs11082510	chr18:43656620	T/A	cg25174615	chr18:43684699	ATP5A1;HAUS1	0.4	4.75	0.3	3.52e-6	Migraine - clinic-based;
SARC	cis	rs644799	1.000	rs12786522	chr11:95522858	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.9	14.04	0.68	7.48e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg26752003	chr8:145688521	CYHR1	0.64	8.85	0.5	2.3e-16	Age at first birth;
SARC	cis	rs7666738	0.830	rs6854594	chr4:99065312	A/T	cg05340658	chr4:99064831	C4orf37	0.65	8.7	0.5	6.15e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9341808	0.617	rs9294170	chr6:80814080	A/G	cg08355045	chr6:80787529	NA	0.37	5.94	0.36	1.03e-8	Sitting height ratio;
SARC	cis	rs2486288	0.656	rs8041702	chr15:45547093	C/T	cg15395560	chr15:45543142	SLC28A2	0.3	5.91	0.36	1.19e-8	Glomerular filtration rate;
SARC	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg04234412	chr22:24373322	LOC391322	-0.53	-6.18	-0.38	2.78e-9	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs77972916	0.536	rs6751209	chr2:43588302	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.47	-5.18	-0.32	4.9e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs10779751	0.960	rs12739368	chr1:11288247	T/C	cg08854313	chr1:11322531	MTOR	0.8	11.4	0.6	3.16e-24	Body mass index;
SARC	cis	rs2836633	0.859	rs8132069	chr21:40032611	T/C	cg12884169	chr21:40033163	ERG	0.45	8.43	0.48	3.58e-15	Coronary artery disease;
SARC	cis	rs11758351	0.789	rs4496782	chr6:26184617	T/C	cg23601095	chr6:26197514	HIST1H3D	0.48	4.9	0.31	1.78e-6	Gout;Renal underexcretion gout;
SARC	cis	rs10932679	0.901	rs6435954	chr2:217658580	T/C	cg05032264	chr2:217675019	NA	0.6	5.75	0.35	2.72e-8	Pulse pressure;
SARC	cis	rs17376456	0.825	rs10052662	chr5:93271385	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.85	0.36	1.65e-8	Diabetic retinopathy;
SARC	cis	rs16976116	0.855	rs11856010	chr15:55495008	A/G	cg17854078	chr15:55489399	RSL24D1	0.66	6.53	0.39	4.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2120243	0.504	rs114107407	chr3:157062635	G/A	cg01018701	chr3:157155998	VEPH1;PTX3	0.41	5.4	0.33	1.64e-7	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs9398803	0.931	rs1361262	chr6:126701967	T/C	cg19875578	chr6:126661172	C6orf173	0.6	8.17	0.47	1.95e-14	Male-pattern baldness;
SARC	cis	rs9486715	0.867	rs2499774	chr6:97006581	C/G	cg06623918	chr6:96969491	KIAA0776	-0.94	-14.56	-0.69	1.37e-34	Headache;
SARC	cis	rs9715521	0.746	rs57464801	chr4:59851169	C/G	cg11281224	chr4:60001000	NA	-0.39	-4.93	-0.31	1.56e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	trans	rs11098499	0.820	rs28394116	chr4:120524283	T/G	cg25214090	chr10:38739885	LOC399744	0.51	6.69	0.4	1.61e-10	Corneal astigmatism;
SARC	cis	rs9969804	0.502	rs3858096	chr9:94941278	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.42	-5.12	-0.32	6.44e-7	Height;
SARC	cis	rs9814567	0.731	rs34797591	chr3:134192516	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.48	5.01	0.31	1.08e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs3768617	0.528	rs4651144	chr1:183097421	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.2	0.56	1.95e-20	Fuchs's corneal dystrophy;
SARC	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg11644478	chr21:40555479	PSMG1	1.04	14.58	0.69	1.17e-34	Cognitive function;
SARC	cis	rs897080	0.552	rs1067323	chr2:44630018	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.7	0.4	1.59e-10	Height;
SARC	cis	rs6964587	0.626	rs4422709	chr7:91510968	A/G	cg17063962	chr7:91808500	NA	-0.78	-11.55	-0.6	1.06e-24	Breast cancer;
SARC	cis	rs3087591	0.960	rs8080679	chr17:29602610	A/G	cg24425628	chr17:29625626	OMG;NF1	0.55	6.78	0.41	1e-10	Hip circumference;
SARC	cis	rs1318878	0.565	rs11836121	chr12:15495470	G/A	cg08258403	chr12:15378311	NA	0.48	6.78	0.41	9.62e-11	Intelligence (multi-trait analysis);
SARC	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg02592271	chr2:27665507	KRTCAP3	-0.41	-6.16	-0.37	3.2e-9	Total body bone mineral density;
SARC	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg00149659	chr3:10157352	C3orf10	1.02	8.65	0.49	8.4e-16	Alzheimer's disease;
SARC	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg11644478	chr21:40555479	PSMG1	1.04	14.58	0.69	1.17e-34	Cognitive function;
SARC	cis	rs959260	1.000	rs4788891	chr17:73391145	A/G	cg14668889	chr17:73230827	NUP85	-0.43	-4.74	-0.3	3.7e-6	Systemic lupus erythematosus;
SARC	cis	rs10463554	0.963	rs12655592	chr5:102379419	A/G	cg23492399	chr5:102201601	PAM	-0.51	-5.65	-0.35	4.78e-8	Parkinson's disease;
SARC	cis	rs11229030	0.722	rs7948027	chr11:57184964	C/T	cg17237962	chr11:57479805	MED19;TMX2	0.42	4.94	0.31	1.46e-6	Crohn's disease;
SARC	cis	rs6665290	0.935	rs17600669	chr1:227201871	A/G	cg14016676	chr1:227182615	CDC42BPA	0.37	5.29	0.33	2.77e-7	Myeloid white cell count;
SARC	cis	rs7786808	0.564	rs10267128	chr7:158198490	G/A	cg01191920	chr7:158217561	PTPRN2	0.36	6.1	0.37	4.28e-9	Obesity-related traits;
SARC	cis	rs1843834	0.505	rs2140508	chr2:225355839	G/T	cg12698349	chr2:225449008	CUL3	0.6	7.71	0.45	3.63e-13	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs921943	0.957	rs6860801	chr5:78310914	C/G	cg26802063	chr5:78281964	ARSB	0.46	5.06	0.31	8.56e-7	Blood and toenail selenium levels;Blood trace element (Se levels);
SARC	cis	rs7103648	0.897	rs2278890	chr11:47399602	G/A	cg10504702	chr11:47789108	FNBP4	0.54	6.53	0.39	4.1e-10	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.45	6.11	0.37	4.19e-9	Personality dimensions;
SARC	cis	rs9640161	0.871	rs56156367	chr7:150047201	A/T	cg17279839	chr7:150038598	RARRES2	0.39	5.55	0.34	7.87e-8	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs240764	0.658	rs13196803	chr6:101188052	A/T	cg09795085	chr6:101329169	ASCC3	-0.5	-6.59	-0.4	2.98e-10	Neuroticism;
SARC	cis	rs6815814	0.950	rs11727978	chr4:38811051	T/A	cg09316306	chr4:38807337	TLR1	0.5	5.22	0.32	3.93e-7	Breast cancer;
SARC	cis	rs78456975	1.000	rs10177095	chr2:1570976	C/A	cg26248373	chr2:1572462	NA	-0.62	-6.45	-0.39	6.46e-10	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs72945132	0.882	rs67093918	chr11:70198999	C/A	cg00319359	chr11:70116639	PPFIA1	0.67	6.21	0.38	2.36e-9	Coronary artery disease;
SARC	cis	rs10752881	0.967	rs4652757	chr1:182974750	T/A	cg13390022	chr1:182993471	LAMC1	0.33	5.06	0.31	8.36e-7	Colorectal cancer;
SARC	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg13393036	chr8:95962371	TP53INP1	-0.37	-6.24	-0.38	2.03e-9	Type 2 diabetes;
SARC	trans	rs2727020	0.658	rs4980431	chr11:49350071	G/T	cg15704280	chr7:45808275	SEPT13	-0.81	-13.02	-0.65	1.73e-29	Coronary artery disease;
SARC	cis	rs9462027	0.628	rs9296129	chr6:34774414	C/G	cg07306190	chr6:34760872	UHRF1BP1	0.43	6.19	0.38	2.64e-9	Systemic lupus erythematosus;
SARC	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg23205692	chr1:25664452	TMEM50A	0.41	4.98	0.31	1.21e-6	Erythrocyte sedimentation rate;
SARC	cis	rs13256369	0.774	rs13248423	chr8:8577602	C/G	cg17143192	chr8:8559678	CLDN23	0.44	5.03	0.31	1e-6	Obesity-related traits;
SARC	trans	rs1814175	0.765	rs1722003	chr11:49895896	G/A	cg03929089	chr4:120376271	NA	-0.9	-14.56	-0.69	1.39e-34	Height;
SARC	cis	rs6752107	1.000	rs6738490	chr2:234161583	T/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.48	6.62	0.4	2.48e-10	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs7429990	0.965	rs35012836	chr3:47711490	G/A	cg11946769	chr3:48343235	NME6	0.67	6.82	0.41	7.63e-11	Educational attainment (years of education);
SARC	cis	rs6840360	0.571	rs4696271	chr4:152509118	G/A	cg22705602	chr4:152727874	NA	-0.43	-6.66	-0.4	1.91e-10	Intelligence (multi-trait analysis);
SARC	cis	rs2276314	0.857	rs3737474	chr18:33613595	T/C	cg05985134	chr18:33552581	C18orf21	0.66	6.73	0.4	1.3e-10	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs11240408	1	rs11240408	chr1:205264536	A/T	cg00857998	chr1:205179979	DSTYK	-0.43	-5.11	-0.32	6.85e-7	Platelet count;
SARC	cis	rs11676348	0.873	rs10210012	chr2:219013334	G/A	cg00012203	chr2:219082015	ARPC2	-0.41	-5.39	-0.33	1.7e-7	Ulcerative colitis;
SARC	cis	rs2769264	0.546	rs12047617	chr1:151392597	G/A	cg18801370	chr1:151430492	POGZ	0.83	8.96	0.51	1.05e-16	Blood trace element (Cu levels);
SARC	cis	rs10513788	0.665	rs16832987	chr3:181993707	A/G	cg05977900	chr3:182512126	ATP11B	-0.46	-4.82	-0.3	2.61e-6	Cognitive function;
SARC	cis	rs11785693	0.865	rs11784227	chr8:4970485	A/C	cg26367366	chr8:4980734	NA	0.71	6.31	0.38	1.36e-9	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs2120243	0.539	rs1840673	chr3:157117977	A/G	cg24825693	chr3:157122686	VEPH1	-0.46	-6.42	-0.39	7.36e-10	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs77741769	0.529	rs525425	chr12:121195625	A/G	cg02403541	chr12:121454288	C12orf43	0.42	4.91	0.31	1.69e-6	Mean corpuscular volume;
SARC	trans	rs7824557	0.736	rs35392635	chr8:11164349	G/C	cg06636001	chr8:8085503	FLJ10661	0.57	6.98	0.42	3.02e-11	Retinal vascular caliber;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg23334298	chr4:78692537	CNOT6L	0.49	7.23	0.43	6.77e-12	Thyroid stimulating hormone;
SARC	cis	rs9290065	0.519	rs7613316	chr3:160674533	A/G	cg17135325	chr3:160939158	NMD3	0.42	5.04	0.31	9.28e-7	Kawasaki disease;
SARC	cis	rs1832871	0.672	rs9456295	chr6:158772078	G/A	cg07165851	chr6:158734300	TULP4	0.53	6.34	0.38	1.16e-9	Height;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg00393435	chr22:39052596	LOC646851;CBY1	0.49	6.56	0.39	3.41e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg03046325	chr10:93558661	TNKS2	0.51	6.29	0.38	1.59e-9	Height;
SARC	cis	rs77956314	0.515	rs9804817	chr12:117440220	G/A	cg02017074	chr12:117425053	FBXW8	-0.59	-7.22	-0.43	7.11e-12	Subcortical brain region volumes;Hippocampal volume;
SARC	cis	rs9660180	0.967	rs12040325	chr1:1702436	G/A	cg23982607	chr1:1823379	GNB1	-0.64	-10.65	-0.57	7.88e-22	Body mass index;
SARC	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg12310025	chr6:25882481	NA	-0.48	-6.33	-0.38	1.24e-9	Intelligence (multi-trait analysis);
SARC	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg04267008	chr7:1944627	MAD1L1	-0.51	-5.92	-0.36	1.17e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg12288994	chr5:1860383	NA	0.4	6.57	0.4	3.2e-10	Cardiovascular disease risk factors;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg01985852	chr16:88772985	CTU2;RNF166	0.47	6.25	0.38	1.97e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg11764359	chr7:65958608	NA	0.88	12.63	0.64	3.25e-28	Aortic root size;
SARC	trans	rs3780486	0.846	rs10113903	chr9:33122645	C/G	cg04842962	chr6:43655489	MRPS18A	-1.04	-18.99	-0.78	3.11e-49	IgG glycosylation;
SARC	cis	rs7607369	0.536	rs4674344	chr2:219669875	A/T	cg02176678	chr2:219576539	TTLL4	-0.38	-5.67	-0.35	4.2e-8	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs9747201	0.962	rs6502062	chr17:80086177	T/G	cg09264619	chr17:80180166	NA	0.49	5.67	0.35	4.29e-8	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.66	-7.13	-0.42	1.27e-11	Platelet count;
SARC	cis	rs7113874	0.545	rs72855149	chr11:8607707	T/C	cg09828998	chr11:8703972	RPL27A	0.48	4.76	0.3	3.39e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9398803	0.713	rs1490385	chr6:126875521	C/T	cg20229609	chr6:126660872	C6orf173	0.35	5.04	0.31	9.23e-7	Male-pattern baldness;
SARC	cis	rs1318878	0.565	rs73057218	chr12:15474585	T/C	cg08258403	chr12:15378311	NA	0.49	6.85	0.41	6.46e-11	Intelligence (multi-trait analysis);
SARC	cis	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg08975724	chr8:8085496	FLJ10661	0.74	9.82	0.54	2.79e-19	Systolic blood pressure;
SARC	cis	rs2832191	0.716	rs2297252	chr21:30377104	G/A	cg24692254	chr21:30365293	RNF160	1.03	18.85	0.78	8.94e-49	Dental caries;
SARC	cis	rs116248771	0.549	rs1548013	chr3:158431070	C/T	cg16708174	chr3:158430962	RARRES1	0.48	4.8	0.3	2.81e-6	diarrhoeal disease at age 2;
SARC	cis	rs35306767	0.953	rs11253517	chr10:970524	A/G	cg26597838	chr10:835615	NA	-0.49	-5.55	-0.34	7.65e-8	Eosinophil percentage of granulocytes;
SARC	cis	rs6088580	0.634	rs6058073	chr20:33116483	T/C	cg08999081	chr20:33150536	PIGU	0.45	6.92	0.41	4.39e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs2180341	0.961	rs3798857	chr6:127659473	A/T	cg17762328	chr6:126965162	NA	-0.45	-5.11	-0.32	6.78e-7	Breast cancer;
SARC	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg21747090	chr2:27597821	SNX17	-0.55	-7.62	-0.45	6.44e-13	Total body bone mineral density;
SARC	cis	rs7927771	0.524	rs10742820	chr11:47781057	C/T	cg10504702	chr11:47789108	FNBP4	-0.43	-5.62	-0.35	5.45e-8	Subjective well-being;
SARC	cis	rs2425143	1.000	rs79035779	chr20:34343004	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.68	5.73	0.35	3.16e-8	Blood protein levels;
SARC	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg06108461	chr20:60628389	TAF4	-0.92	-12.7	-0.64	1.92e-28	Body mass index;
SARC	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg16479474	chr6:28041457	NA	0.38	5.58	0.34	6.78e-8	Depression;
SARC	cis	rs950027	0.549	rs1719250	chr15:45609773	A/G	cg15395560	chr15:45543142	SLC28A2	-0.31	-6.02	-0.37	6.72e-9	Response to fenofibrate (adiponectin levels);
SARC	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg00800038	chr16:89945340	TCF25	-0.76	-5.06	-0.31	8.3e-7	Skin colour saturation;
SARC	cis	rs1059312	0.500	rs12303338	chr12:129276641	C/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	-0.45	-5.75	-0.35	2.81e-8	Systemic lupus erythematosus;
SARC	cis	rs10911251	0.546	rs7473	chr1:183114634	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	9.87	0.54	2.03e-19	Colorectal cancer;
SARC	cis	rs4930561	0.739	rs12225316	chr11:67976003	T/C	cg16338278	chr11:67432957	ALDH3B2	0.33	5.37	0.33	1.87e-7	Breast cancer in childhood cancer survivors;IgG glycosylation;
SARC	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg18252515	chr7:66147081	NA	-0.57	-6.2	-0.38	2.51e-9	Aortic root size;
SARC	cis	rs4969178	0.965	rs8072632	chr17:76397830	T/C	cg20026190	chr17:76395443	PGS1	0.4	5.34	0.33	2.19e-7	HDL cholesterol levels;
SARC	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg25072359	chr17:41440525	NA	0.48	5.62	0.35	5.43e-8	Menopause (age at onset);
SARC	cis	rs3784262	1.000	rs4646629	chr15:58255215	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.38	-5.56	-0.34	7.36e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs7520050	0.966	rs6675946	chr1:46371774	G/T	cg24296786	chr1:45957014	TESK2	0.38	4.82	0.3	2.54e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs7089973	0.641	rs12772737	chr10:116741501	C/G	cg08188268	chr10:116634841	FAM160B1	0.39	5.06	0.31	8.37e-7	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs950169	0.810	rs62029594	chr15:84955252	T/C	cg24253500	chr15:84953950	NA	0.36	5.21	0.32	4.19e-7	Schizophrenia;
SARC	cis	rs561341	0.843	rs4795666	chr17:30241409	A/G	cg13647721	chr17:30228624	UTP6	0.67	6.21	0.38	2.42e-9	Hip circumference adjusted for BMI;
SARC	cis	rs1865063	1.000	rs737338	chr19:11347657	C/T	cg00586551	chr19:11347513	LOC55908;DOCK6	0.83	7.31	0.43	4.13e-12	HDL cholesterol levels;
SARC	cis	rs72781680	0.898	rs72788212	chr2:24087385	G/A	cg06627628	chr2:24431161	ITSN2	-0.65	-6.37	-0.39	9.72e-10	Lymphocyte counts;
SARC	cis	rs950776	0.518	rs952216	chr15:78819202	C/T	cg06917634	chr15:78832804	PSMA4	0.9	13.92	0.67	1.88e-32	Sudden cardiac arrest;
SARC	cis	rs1865760	0.663	rs9379815	chr6:25980116	T/A	cg17691542	chr6:26056736	HIST1H1C	0.5	6.48	0.39	5.44e-10	Height;
SARC	cis	rs7615952	0.576	rs2276726	chr3:125826287	C/G	cg05084668	chr3:125655381	ALG1L	-0.48	-5.08	-0.32	7.57e-7	Blood pressure (smoking interaction);
SARC	cis	rs4800452	0.826	rs28625207	chr18:20746672	A/G	cg13313047	chr18:20735648	CABLES1	-0.48	-5.51	-0.34	9.66e-8	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
SARC	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-9.22	-0.52	1.78e-17	Alzheimer's disease;
SARC	cis	rs9916302	0.904	rs8065879	chr17:37515978	G/A	cg20243544	chr17:37824526	PNMT	-0.53	-6.45	-0.39	6.43e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs2115630	0.967	rs11073702	chr15:85310071	G/A	cg12501888	chr15:85177176	SCAND2	-0.49	-5.92	-0.36	1.15e-8	P wave terminal force;
SARC	cis	rs7481584	0.626	rs2071103	chr11:3040087	C/T	cg20651018	chr11:3035856	CARS	0.4	5.9	0.36	1.28e-8	Calcium levels;
SARC	cis	rs950776	0.518	rs12903129	chr15:78819606	C/T	cg22563815	chr15:78856949	CHRNA5	0.41	6.83	0.41	7.14e-11	Sudden cardiac arrest;
SARC	cis	rs7712401	0.715	rs395981	chr5:122347911	C/T	cg19412675	chr5:122181750	SNX24	-0.41	-5.26	-0.33	3.18e-7	Mean platelet volume;
SARC	cis	rs4780401	0.588	rs7205167	chr16:11791057	A/T	cg01061890	chr16:11836724	TXNDC11	-0.38	-4.79	-0.3	2.95e-6	Rheumatoid arthritis;
SARC	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg20607798	chr8:58055168	NA	0.6	5.34	0.33	2.19e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2204008	0.702	rs3849999	chr12:38483498	G/A	cg26384229	chr12:38710491	ALG10B	-0.56	-7.06	-0.42	1.89e-11	Bladder cancer;
SARC	cis	rs17122278	0.858	rs12289253	chr11:118405068	A/G	cg06090739	chr11:118230722	UBE4A	0.61	4.78	0.3	3.17e-6	Total cholesterol levels;
SARC	cis	rs9788721	0.933	rs72738786	chr15:78828086	G/T	cg06917634	chr15:78832804	PSMA4	-0.5	-5.34	-0.33	2.24e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs7829975	0.511	rs2955578	chr8:8137083	T/C	cg06636001	chr8:8085503	FLJ10661	0.77	10.97	0.58	7.36e-23	Mood instability;
SARC	cis	rs274567	0.501	rs272855	chr5:131687175	C/T	cg12564285	chr5:131593104	PDLIM4	0.44	5.89	0.36	1.36e-8	Blood metabolite levels;
SARC	cis	rs7633857	0.537	rs1580253	chr3:160767150	T/C	cg03342759	chr3:160939853	NMD3	-0.57	-6.86	-0.41	6.31e-11	Educational attainment (years of education);
SARC	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg16405210	chr4:1374714	KIAA1530	0.5	6.12	0.37	3.93e-9	Obesity-related traits;
SARC	cis	rs9291683	0.509	rs998676	chr4:9948564	T/C	cg11266682	chr4:10021025	SLC2A9	-0.4	-7.1	-0.42	1.46e-11	Bone mineral density;
SARC	cis	rs7953249	0.542	rs1169284	chr12:121419926	T/C	cg25281562	chr12:121454272	C12orf43	0.5	6.18	0.38	2.86e-9	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs3820928	0.605	rs10186145	chr2:227781150	A/G	cg05526886	chr2:227700861	RHBDD1	-0.48	-6.11	-0.37	4.19e-9	Pulmonary function;
SARC	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg16049864	chr8:95962084	TP53INP1	-0.52	-8.51	-0.49	2.09e-15	Type 2 diabetes;
SARC	cis	rs11608355	0.515	rs12826754	chr12:109923244	A/G	cg05360138	chr12:110035743	NA	0.93	9.49	0.53	2.87e-18	Neuroticism;
SARC	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg18876405	chr7:65276391	NA	0.55	6.97	0.42	3.15e-11	Calcium levels;
SARC	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg08677398	chr8:58056175	NA	0.44	5.25	0.33	3.38e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg27266027	chr21:40555129	PSMG1	-0.48	-5.17	-0.32	5.03e-7	Cognitive function;
SARC	trans	rs61931739	0.500	rs11053246	chr12:34516620	C/T	cg26384229	chr12:38710491	ALG10B	0.91	13.63	0.67	1.63e-31	Morning vs. evening chronotype;
SARC	cis	rs6540556	0.723	rs11487866	chr1:209892046	G/A	cg23920097	chr1:209922102	NA	-0.51	-5.25	-0.33	3.43e-7	Red blood cell count;
SARC	cis	rs7937682	1.000	rs9734135	chr11:111536190	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.97	-16.26	-0.73	3.06e-40	Primary sclerosing cholangitis;
SARC	trans	rs1853207	1.000	rs17110317	chr10:96634735	C/T	cg02737782	chr1:8014393	NA	-0.97	-6.42	-0.39	7.44e-10	Blood metabolite levels;
SARC	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg04511125	chr2:88470314	THNSL2	0.81	7.27	0.43	5.44e-12	Plasma clusterin levels;
SARC	cis	rs6088580	0.634	rs6059892	chr20:33105766	A/G	cg08999081	chr20:33150536	PIGU	0.45	6.91	0.41	4.59e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs2463822	0.514	rs10750972	chr11:62053687	A/G	cg06239285	chr11:62104954	ASRGL1	0.57	6.48	0.39	5.4e-10	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs7712401	0.765	rs4349713	chr5:122391626	A/G	cg19412675	chr5:122181750	SNX24	0.43	5.58	0.34	6.78e-8	Mean platelet volume;
SARC	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg18252515	chr7:66147081	NA	0.53	5.7	0.35	3.55e-8	Aortic root size;
SARC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg23131131	chr22:24373011	LOC391322	-0.46	-4.99	-0.31	1.19e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs920590	0.758	rs1826420	chr8:19664878	G/T	cg17834443	chr8:19674713	INTS10	0.61	7.46	0.44	1.67e-12	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs4481887	1.000	rs4489592	chr1:248470697	A/T	cg00666640	chr1:248458726	OR2T12	0.37	6.18	0.38	2.86e-9	Common traits (Other);
SARC	cis	rs798554	0.679	rs2644300	chr7:2883071	G/A	cg03185022	chr7:2884158	GNA12	0.44	4.82	0.3	2.55e-6	Height;
SARC	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg14829155	chr15:31115871	NA	-0.38	-4.78	-0.3	3.08e-6	Huntington's disease progression;
SARC	cis	rs1801251	0.963	rs7591176	chr2:233581803	C/A	cg25237894	chr2:233734115	C2orf82	0.39	5.15	0.32	5.42e-7	Coronary artery disease;
SARC	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg00149659	chr3:10157352	C3orf10	0.69	6.38	0.39	9.6e-10	Alzheimer's disease;
SARC	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg10792982	chr14:105748885	BRF1	0.54	8.0	0.46	5.67e-14	Mean platelet volume;Platelet distribution width;
SARC	cis	rs2290159	0.800	rs9817675	chr3:12676113	C/T	cg23032965	chr3:12705835	RAF1	0.74	8.1	0.47	3.1e-14	Cholesterol, total;
SARC	cis	rs9457247	0.935	rs2757046	chr6:167374353	C/T	cg07741184	chr6:167504864	NA	-0.3	-5.61	-0.35	5.69e-8	Crohn's disease;
SARC	cis	rs2070997	0.607	rs13294646	chr9:133715206	C/G	cg11464064	chr9:133710261	ABL1	0.63	6.1	0.37	4.44e-9	Response to amphetamines;
SARC	cis	rs6674970	0.966	rs2091219	chr1:151012060	A/G	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.44	-5.0	-0.31	1.14e-6	Childhood ear infection;
SARC	trans	rs3780486	0.505	rs10813958	chr9:33165985	A/G	cg20290983	chr6:43655470	MRPS18A	0.94	13.7	0.67	1.02e-31	IgG glycosylation;
SARC	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.62	0.45	6.48e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs12142240	0.698	rs17361936	chr1:46862893	C/T	cg00530320	chr1:46809349	NSUN4	0.57	7.0	0.42	2.74e-11	Menopause (age at onset);
SARC	cis	rs2997447	0.653	rs2802329	chr1:26466189	T/C	cg19633962	chr1:26362018	EXTL1	-0.6	-5.46	-0.34	1.19e-7	QRS complex (12-leadsum);
SARC	cis	rs12142240	0.698	rs56909107	chr1:46808224	A/C	cg14993813	chr1:46806288	NSUN4	-0.52	-5.45	-0.34	1.28e-7	Menopause (age at onset);
SARC	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg27266027	chr21:40555129	PSMG1	-0.46	-4.96	-0.31	1.36e-6	Cognitive function;
SARC	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg12463550	chr7:65579703	CRCP	-0.7	-5.34	-0.33	2.21e-7	Diabetic kidney disease;
SARC	cis	rs10892173	0.935	rs7108548	chr11:117674072	A/T	cg07621104	chr11:117668040	DSCAML1	0.38	5.01	0.31	1.08e-6	Myopia;
SARC	cis	rs9467773	1.000	rs10214634	chr6:26564582	T/A	cg11502198	chr6:26597334	ABT1	0.51	6.28	0.38	1.68e-9	Intelligence (multi-trait analysis);
SARC	cis	rs3741151	0.656	rs56884659	chr11:73252947	C/G	cg17517138	chr11:73019481	ARHGEF17	0.93	6.88	0.41	5.4e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs7772486	0.686	rs9373473	chr6:146082282	A/G	cg05347473	chr6:146136440	FBXO30	0.5	6.84	0.41	6.78e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11209002	1.000	rs10732838	chr1:67577955	C/T	cg02640540	chr1:67518911	SLC35D1	0.47	4.77	0.3	3.19e-6	Crohn's disease;
SARC	cis	rs9300255	0.602	rs2682431	chr12:123703226	T/A	cg05973401	chr12:123451056	ABCB9	0.52	5.89	0.36	1.34e-8	Neutrophil percentage of white cells;
SARC	cis	rs7084402	0.967	rs1658460	chr10:60299151	T/G	cg07615347	chr10:60278583	BICC1	0.6	8.92	0.5	1.43e-16	Refractive error;
SARC	trans	rs61931739	0.500	rs7971957	chr12:34477558	C/T	cg26384229	chr12:38710491	ALG10B	0.84	12.42	0.63	1.59e-27	Morning vs. evening chronotype;
SARC	cis	rs910316	0.967	rs8013444	chr14:75661981	A/G	cg11812906	chr14:75593930	NEK9	-0.83	-12.26	-0.63	5.24e-27	Height;
SARC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg14893161	chr1:205819251	PM20D1	0.94	16.07	0.72	1.34e-39	Menarche (age at onset);
SARC	cis	rs2836950	0.545	rs2836922	chr21:40516308	C/T	cg17971929	chr21:40555470	PSMG1	-0.56	-6.78	-0.41	9.53e-11	Menarche (age at onset);
SARC	cis	rs11098499	0.754	rs1980025	chr4:120252806	A/G	cg24375607	chr4:120327624	NA	-0.38	-4.74	-0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg01448562	chr3:133502909	NA	-0.5	-7.63	-0.45	5.8e-13	Iron status biomarkers;
SARC	cis	rs9814567	1.000	rs9289471	chr3:134230811	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-6.9	-0.41	4.95e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs17376456	0.825	rs10079708	chr5:93261796	G/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.67	6.14	0.37	3.48e-9	Diabetic retinopathy;
SARC	cis	rs71636778	1.000	rs71636778	chr1:27104612	T/C	cg04852280	chr1:26496234	ZNF593	0.57	5.13	0.32	6.01e-7	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs838147	0.507	rs1704773	chr19:49209566	A/G	cg07051648	chr19:49177693	NTN5;SEC1	-0.4	-5.19	-0.32	4.68e-7	Dietary macronutrient intake;
SARC	cis	rs9389248	0.690	rs1028314	chr6:135255710	A/C	cg22676075	chr6:135203613	NA	-0.43	-5.56	-0.34	7.3900000000000007e-08	High light scatter reticulocyte percentage of red cells;
SARC	cis	rs589448	0.535	rs12423794	chr12:69713018	G/A	cg20891283	chr12:69753455	YEATS4	0.5	6.62	0.4	2.48e-10	Cerebrospinal fluid biomarker levels;
SARC	cis	rs7587476	0.505	rs777323	chr2:215738485	A/G	cg04004882	chr2:215674386	BARD1	-0.53	-6.26	-0.38	1.81e-9	Neuroblastoma;
SARC	cis	rs829883	0.659	rs11109510	chr12:98911382	A/G	cg25150519	chr12:98850993	NA	-0.66	-8.18	-0.47	1.79e-14	Colorectal adenoma (advanced);
SARC	cis	rs7223966	1.000	rs55868506	chr17:61851686	T/G	cg00588841	chr17:61851480	DDX42;CCDC47	-0.67	-7.46	-0.44	1.69e-12	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs765787	0.530	rs2554456	chr15:45521138	A/C	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.55e-10	Uric acid levels;
SARC	cis	rs7511006	1.000	rs5771109	chr22:50678571	T/C	cg15134628	chr22:50699649	MAPK12	0.41	4.93	0.31	1.54e-6	Obesity-related traits;
SARC	cis	rs72627123	0.867	rs77321049	chr14:74455219	G/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	5.52	0.34	8.92e-8	Morning vs. evening chronotype;
SARC	cis	rs9985766	0.883	rs28665284	chr4:151053905	C/T	cg05926478	chr4:151174724	DCLK2	-0.49	-4.76	-0.3	3.41e-6	Coronary artery disease;Myocardial infarction;
SARC	cis	rs9911578	0.967	rs405684	chr17:56777148	T/C	cg05425664	chr17:57184151	TRIM37	-0.65	-8.12	-0.47	2.72e-14	Intelligence (multi-trait analysis);
SARC	trans	rs4295623	0.816	rs35558975	chr8:11584476	C/G	cg08975724	chr8:8085496	FLJ10661	-0.54	-6.46	-0.39	5.99e-10	Morning vs. evening chronotype;
SARC	cis	rs2991971	0.967	rs644915	chr1:46007002	T/C	cg24296786	chr1:45957014	TESK2	0.67	9.54	0.53	2.04e-18	High light scatter reticulocyte count;
SARC	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg11764359	chr7:65958608	NA	0.73	8.72	0.5	5.25e-16	Aortic root size;
SARC	cis	rs3812831	0.662	rs418027	chr13:114929344	A/C	cg08824895	chr13:115047677	UPF3A	0.47	6.05	0.37	5.58e-9	Schizophrenia;
SARC	cis	rs7103648	0.618	rs11039284	chr11:47564785	A/G	cg20307385	chr11:47447363	PSMC3	0.72	9.13	0.51	3.34e-17	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs2361718	0.527	rs7211994	chr17:78152514	A/G	cg06718696	chr17:78121285	EIF4A3	-0.47	-5.9	-0.36	1.29e-8	Yeast infection;
SARC	cis	rs2832191	0.740	rs6516890	chr21:30476812	T/A	cg24692254	chr21:30365293	RNF160	0.93	13.66	0.67	1.32e-31	Dental caries;
SARC	cis	rs7027203	1.000	rs34624092	chr9:96523092	G/A	cg14598338	chr9:96623480	NA	0.51	6.85	0.41	6.52e-11	DNA methylation (variation);
SARC	cis	rs6831352	0.918	rs1126672	chr4:100047812	G/A	cg12011299	chr4:100065546	ADH4	-0.34	-5.66	-0.35	4.44e-8	Alcohol dependence;
SARC	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg13607699	chr17:42295918	UBTF	0.59	7.17	0.43	9.66e-12	Total body bone mineral density;
SARC	trans	rs34421088	0.560	rs1478898	chr8:11395079	G/A	cg06636001	chr8:8085503	FLJ10661	-0.65	-9.17	-0.51	2.51e-17	Neuroticism;
SARC	cis	rs4853036	0.540	rs4853013	chr2:70004302	T/C	cg02498382	chr2:70120550	SNRNP27	-0.35	-4.8	-0.3	2.86e-6	Colorectal or endometrial cancer;
SARC	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg22968622	chr17:43663579	NA	-0.8	-9.75	-0.54	4.72e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs2404602	0.716	rs7164060	chr15:76707694	T/C	cg22467129	chr15:76604101	ETFA	-0.36	-4.86	-0.3	2.15e-6	Blood metabolite levels;
SARC	cis	rs11105298	0.891	rs4842664	chr12:89938030	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.55	-5.53	-0.34	8.4e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs2276314	0.857	rs9960670	chr18:33577712	A/G	cg19628046	chr18:33552617	C18orf21	0.61	6.08	0.37	4.95e-9	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs1707322	0.721	rs6699418	chr1:46100181	G/A	cg03146154	chr1:46216737	IPP	0.49	5.82	0.36	1.9e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1215050	0.791	rs2865942	chr4:98737709	G/C	cg05340658	chr4:99064831	C4orf37	0.44	5.81	0.36	2.02e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs2486288	0.656	rs12911186	chr15:45551423	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.45	-5.57	-0.34	7.07e-8	Glomerular filtration rate;
SARC	cis	rs1865721	0.771	rs7236311	chr18:73137450	A/G	cg26385618	chr18:73139727	C18orf62	-0.41	-5.68	-0.35	3.93e-8	Intelligence;
SARC	cis	rs3756766	0.500	rs6596428	chr5:137642030	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.53	6.43	0.39	7.17e-10	Schizophrenia;
SARC	cis	rs72627509	0.951	rs72606404	chr4:57841213	G/C	cg26694713	chr4:57773883	REST	0.7	6.98	0.42	2.98e-11	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg06212747	chr3:49208901	KLHDC8B	0.72	9.86	0.54	2.17e-19	Parkinson's disease;
SARC	cis	rs2070433	0.539	rs721131	chr21:47957767	T/C	cg12379764	chr21:47803548	PCNT	0.52	5.64	0.35	4.98e-8	Lymphocyte counts;
SARC	cis	rs3820928	0.874	rs10195072	chr2:227794452	G/A	cg05526886	chr2:227700861	RHBDD1	-0.55	-6.65	-0.4	2.05e-10	Pulmonary function;
SARC	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg05863683	chr7:1912471	MAD1L1	0.36	5.4	0.33	1.63e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs698833	0.828	rs2165421	chr2:44526010	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.65	8.47	0.49	2.7e-15	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs1018836	0.828	rs4734250	chr8:91591239	C/G	cg16814680	chr8:91681699	NA	0.72	11.26	0.59	9.31e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs35213789	0.534	rs41847	chr7:69018885	A/G	cg10619644	chr7:69149951	AUTS2	0.34	4.77	0.3	3.22e-6	Childhood ear infection;
SARC	cis	rs6750795	0.569	rs1667313	chr2:232408018	A/C	cg19187155	chr2:232395269	NMUR1	0.73	10.98	0.58	7.26e-23	Height;
SARC	cis	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg12463550	chr7:65579703	CRCP	-0.66	-5.19	-0.32	4.67e-7	Diabetic kidney disease;
SARC	cis	rs4713118	0.629	rs172165	chr6:28020814	T/G	cg16479474	chr6:28041457	NA	0.36	5.07	0.31	8.29e-7	Parkinson's disease;
SARC	cis	rs6759839	0.761	rs6753768	chr2:16620437	G/T	cg09580478	chr2:16689509	NA	0.44	5.78	0.35	2.4e-8	Mean platelet volume;
SARC	cis	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg20965017	chr5:231967	SDHA	-0.55	-5.24	-0.32	3.56e-7	Breast cancer;
SARC	cis	rs526231	0.543	rs32849	chr5:102470043	C/T	cg23492399	chr5:102201601	PAM	-0.52	-5.58	-0.34	6.67e-8	Primary biliary cholangitis;
SARC	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg11062466	chr8:58055876	NA	0.7	6.14	0.37	3.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10876993	0.928	rs1678530	chr12:58054076	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.49	-6.22	-0.38	2.3e-9	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs1707322	1.000	rs4460583	chr1:46449918	C/G	cg06784218	chr1:46089804	CCDC17	0.34	5.95	0.36	9.76e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg25427524	chr10:38739819	LOC399744	-0.53	-8.46	-0.48	2.95e-15	Extrinsic epigenetic age acceleration;
SARC	cis	rs1008375	1.000	rs9991307	chr4:17662408	A/G	cg16339924	chr4:17578868	LAP3	0.62	8.03	0.47	4.8e-14	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2733201	1.000	rs2623019	chr15:44399628	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	-0.75	-5.73	-0.35	3.08e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	cis	rs34779708	0.931	rs7920095	chr10:35303334	G/A	cg03585969	chr10:35415529	CREM	0.41	5.04	0.31	9.27e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs9309473	0.797	rs6723247	chr2:73846749	A/G	cg07208825	chr2:73871855	ALMS1P	0.32	4.83	0.3	2.51e-6	Metabolite levels;
SARC	cis	rs1034435	0.575	rs5768673	chr22:48883905	T/A	cg05992904	chr22:48892994	FAM19A5	-0.41	-5.11	-0.32	6.78e-7	Late-onset Alzheimer's disease;
SARC	cis	rs12142240	0.667	rs66990604	chr1:46822073	G/A	cg10495392	chr1:46806563	NSUN4	0.65	6.8	0.41	8.89e-11	Menopause (age at onset);
SARC	cis	rs2742234	0.541	rs871763	chr10:43734188	C/T	cg15436174	chr10:43711423	RASGEF1A	0.41	4.97	0.31	1.28e-6	Hirschsprung disease;
SARC	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg12564285	chr5:131593104	PDLIM4	-0.45	-5.93	-0.36	1.06e-8	Breast cancer;
SARC	cis	rs4319547	0.737	rs10846920	chr12:122943231	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.54	-6.36	-0.38	1.05e-9	Body mass index;
SARC	cis	rs10189230	0.967	rs1864460	chr2:222347655	A/C	cg14652038	chr2:222343519	EPHA4	0.44	5.8	0.36	2.1e-8	Urate levels in lean individuals;
SARC	trans	rs3857536	0.611	rs6927407	chr6:66870010	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.7	-8.57	-0.49	1.45e-15	Blood trace element (Cu levels);
SARC	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-9.39	-0.52	5.75e-18	Alzheimer's disease;
SARC	cis	rs17376456	1.000	rs13185608	chr5:93509688	T/G	cg25358565	chr5:93447407	FAM172A	1.36	14.03	0.68	8.03e-33	Diabetic retinopathy;
SARC	cis	rs710216	0.827	rs841850	chr1:43402054	T/C	cg03128534	chr1:43423976	SLC2A1	0.59	5.64	0.35	5e-8	Red cell distribution width;
SARC	cis	rs4555082	0.874	rs2142190	chr14:105719306	G/A	cg06808227	chr14:105710500	BRF1	-0.51	-6.39	-0.39	9.15e-10	Mean platelet volume;Platelet distribution width;
SARC	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	10.62	0.57	9.57e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs11098699	0.821	rs13120866	chr4:124199293	A/G	cg09941581	chr4:124220074	SPATA5	0.39	4.81	0.3	2.68e-6	Mosquito bite size;
SARC	cis	rs12545109	0.800	rs1440763	chr8:57410481	C/A	cg19413350	chr8:57351067	NA	-0.43	-4.77	-0.3	3.18e-6	Obesity-related traits;
SARC	cis	rs4595586	0.525	rs4768531	chr12:39417754	T/A	cg26384229	chr12:38710491	ALG10B	0.55	6.14	0.37	3.48e-9	Morning vs. evening chronotype;
SARC	cis	rs1943345	0.519	rs11233504	chr11:82886525	A/G	cg07047830	chr11:82868014	PCF11	0.7	9.89	0.54	1.81e-19	Obesity-related traits;
SARC	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg20007245	chr22:24372913	LOC391322	0.58	6.83	0.41	7.29e-11	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs2408955	0.521	rs10875749	chr12:48531917	T/A	cg24011408	chr12:48396354	COL2A1	-0.41	-5.09	-0.32	7.39e-7	Glycated hemoglobin levels;
SARC	cis	rs778371	0.723	rs1022329	chr2:233591239	T/C	cg20388707	chr2:233749442	NGEF	-0.35	-5.16	-0.32	5.3e-7	Schizophrenia;
SARC	cis	rs17376456	0.877	rs10065056	chr5:93380123	G/T	cg25358565	chr5:93447407	FAM172A	1.3	14.78	0.7	2.47e-35	Diabetic retinopathy;
SARC	cis	rs1568889	0.877	rs7933326	chr11:28288416	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	10.21	0.56	1.77e-20	Bipolar disorder;
SARC	cis	rs1318878	0.726	rs55867853	chr12:15523367	A/T	cg08258403	chr12:15378311	NA	0.52	6.84	0.41	6.82e-11	Intelligence (multi-trait analysis);
SARC	cis	rs950169	0.922	rs11633075	chr15:85113972	C/A	cg24253500	chr15:84953950	NA	0.37	5.34	0.33	2.24e-7	Schizophrenia;
SARC	cis	rs3796352	0.571	rs71301816	chr3:53142071	G/A	cg15956490	chr3:53032818	SFMBT1	0.92	5.92	0.36	1.12e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs6815814	0.731	rs4504265	chr4:38773865	G/T	cg06935464	chr4:38784597	TLR10	0.5	5.19	0.32	4.66e-7	Breast cancer;
SARC	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg23958373	chr8:599963	NA	0.73	5.79	0.35	2.32e-8	IgG glycosylation;
SARC	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.66	0.35	4.44e-8	Bipolar disorder;
SARC	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg22974920	chr21:40686053	BRWD1	0.46	4.95	0.31	1.43e-6	Cognitive function;
SARC	cis	rs9394159	0.583	rs6457738	chr6:33617464	C/T	cg14003231	chr6:33640908	ITPR3	-0.34	-5.96	-0.36	9.18e-9	Graves' disease;
SARC	cis	rs9611565	0.921	rs5751081	chr22:41742788	A/T	cg17376030	chr22:41985996	PMM1	0.52	6.66	0.4	1.99e-10	Vitiligo;
SARC	cis	rs3812831	0.695	rs7983872	chr13:114944781	T/G	cg06611532	chr13:114900021	NA	0.36	6.11	0.37	4.15e-9	Schizophrenia;
SARC	cis	rs4268898	0.722	rs11691212	chr2:24404733	A/G	cg26838691	chr2:24397539	C2orf84	0.41	5.65	0.35	4.58e-8	Asthma;
SARC	trans	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg09983370	chr4:42658444	ATP8A1	-0.48	-6.62	-0.4	2.48e-10	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1568889	1.000	rs11604085	chr11:28141002	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.71	9.16	0.51	2.71e-17	Bipolar disorder;
SARC	cis	rs6667605	0.527	rs12046118	chr1:2540343	A/C	cg18854424	chr1:2615690	NA	0.33	5.16	0.32	5.25e-7	Inflammatory bowel disease;Ulcerative colitis;
SARC	cis	rs1044826	0.642	rs7652860	chr3:139205818	T/A	cg15131784	chr3:139108705	COPB2	0.39	4.93	0.31	1.54e-6	Obesity-related traits;
SARC	cis	rs4711350	1.000	rs10947436	chr6:33739960	A/G	cg18005901	chr6:33739558	LEMD2	-0.45	-4.9	-0.31	1.76e-6	Schizophrenia;
SARC	cis	rs17376456	0.825	rs10072232	chr5:93398890	G/A	cg25358565	chr5:93447407	FAM172A	1.3	14.56	0.69	1.43e-34	Diabetic retinopathy;
SARC	cis	rs11785693	0.862	rs11780705	chr8:4988221	G/A	cg26367366	chr8:4980734	NA	0.69	6.15	0.37	3.4e-9	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg19678392	chr7:94953810	PON1	-0.45	-6.82	-0.41	7.83e-11	Paraoxonase activity;
SARC	cis	rs2153535	0.580	rs1932285	chr6:8477719	T/G	cg21535247	chr6:8435926	SLC35B3	0.55	6.9	0.41	4.81e-11	Motion sickness;
SARC	cis	rs3087591	0.708	rs9894648	chr17:29653293	T/C	cg24425628	chr17:29625626	OMG;NF1	0.46	5.95	0.36	1e-8	Hip circumference;
SARC	cis	rs7772486	0.790	rs6923545	chr6:146244743	A/G	cg23711669	chr6:146136114	FBXO30	-0.81	-12.93	-0.65	3.43e-29	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs523522	0.962	rs55848094	chr12:120966659	G/A	cg12219531	chr12:120966889	COQ5	0.84	11.36	0.6	4.3e-24	High light scatter reticulocyte count;
SARC	cis	rs7647973	0.626	rs1078341	chr3:49685592	A/G	cg13072238	chr3:49761600	GMPPB	-0.57	-5.84	-0.36	1.75e-8	Menarche (age at onset);
SARC	cis	rs9291683	0.588	rs13121211	chr4:9999539	A/G	cg00071950	chr4:10020882	SLC2A9	0.4	6.3	0.38	1.5e-9	Bone mineral density;
SARC	cis	rs3008870	1.000	rs12041926	chr1:67434602	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.87	10.21	0.56	1.77e-20	Lymphocyte percentage of white cells;
SARC	cis	rs9916302	0.851	rs4390625	chr17:37620347	A/G	cg15445000	chr17:37608096	MED1	0.41	4.91	0.31	1.68e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg23758822	chr17:41437982	NA	0.89	11.4	0.6	3.2e-24	Menopause (age at onset);
SARC	cis	rs9399135	0.967	rs6909975	chr6:135315570	C/T	cg24558204	chr6:135376177	HBS1L	0.44	5.95	0.36	9.55e-9	Red blood cell count;
SARC	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg26335602	chr6:28129616	ZNF389	0.55	5.95	0.36	9.89e-9	Parkinson's disease;
SARC	cis	rs10875746	0.669	rs2279464	chr12:48690409	C/T	cg26205652	chr12:48591994	NA	0.45	4.73	0.3	3.96e-6	Longevity (90 years and older);
SARC	cis	rs7940866	0.838	rs12790299	chr11:130803634	A/G	cg12179176	chr11:130786555	SNX19	0.66	9.34	0.52	8.24e-18	Schizophrenia;
SARC	cis	rs561341	1.000	rs527256	chr17:30321293	C/G	cg00745463	chr17:30367425	LRRC37B	-0.69	-5.53	-0.34	8.77e-8	Hip circumference adjusted for BMI;
SARC	cis	rs4851254	0.695	rs12712069	chr2:100766354	C/G	cg04109781	chr2:100722022	AFF3	0.34	4.85	0.3	2.31e-6	Intelligence (multi-trait analysis);
SARC	cis	rs1865760	0.516	rs9358903	chr6:26061949	A/C	cg02841227	chr6:26021843	HIST1H4A	0.39	4.88	0.3	2.01e-6	Height;
SARC	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg22168489	chr12:122356033	WDR66	0.63	9.75	0.54	4.56e-19	Mean corpuscular volume;
SARC	cis	rs193541	0.632	rs34714850	chr5:122332695	A/G	cg19412675	chr5:122181750	SNX24	-0.49	-6.27	-0.38	1.75e-9	Glucose homeostasis traits;
SARC	cis	rs7959452	0.640	rs4761154	chr12:69705362	A/G	cg22834771	chr12:69754056	YEATS4	0.41	5.34	0.33	2.25e-7	Blood protein levels;
SARC	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg08280861	chr8:58055591	NA	0.58	5.3	0.33	2.67e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6062509	1.000	rs6011066	chr20:62364180	G/A	cg27236539	chr20:62289627	RTEL1	0.52	5.87	0.36	1.47e-8	Prostate cancer;
SARC	cis	rs11969893	0.850	rs9498409	chr6:101299966	G/A	cg12253828	chr6:101329408	ASCC3	1.25	7.83	0.46	1.71e-13	Economic and political preferences (immigration/crime);
SARC	cis	rs2075371	1.000	rs2544218	chr7:133992315	C/A	cg11752832	chr7:134001865	SLC35B4	0.57	7.43	0.44	1.99e-12	Mean platelet volume;
SARC	cis	rs8077889	0.956	rs4792910	chr17:41840229	T/C	cg26893861	chr17:41843967	DUSP3	0.9	10.63	0.57	8.74e-22	Triglycerides;
SARC	cis	rs1878931	0.501	rs28735976	chr16:3418419	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.74	9.48	0.53	2.99e-18	Body mass index (adult);
SARC	cis	rs2721195	0.845	rs3757966	chr8:145744618	G/A	cg15857475	chr8:145742913	RECQL4;LRRC14	0.87	13.7	0.67	9.62e-32	Age at first birth;
SARC	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg18404041	chr3:52824283	ITIH1	-0.42	-6.25	-0.38	1.96e-9	Bipolar disorder;
SARC	cis	rs7833790	0.685	rs13255262	chr8:82728024	T/G	cg06027949	chr8:82754900	SNX16	-0.49	-6.14	-0.37	3.46e-9	Diastolic blood pressure;
SARC	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg13944838	chr5:179740914	GFPT2	-0.58	-7.37	-0.43	2.96e-12	Height;
SARC	cis	rs694739	0.796	rs479777	chr11:64107477	A/G	cg23796481	chr11:64053134	BAD;GPR137	0.69	9.14	0.51	3.19e-17	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs7474896	0.559	rs1779075	chr10:38167530	C/G	cg00409905	chr10:38381863	ZNF37A	0.46	5.18	0.32	4.72e-7	Obesity (extreme);
SARC	cis	rs6901004	0.803	rs354539	chr6:111517829	T/C	cg15721981	chr6:111408429	SLC16A10	-0.46	-5.62	-0.35	5.38e-8	Blood metabolite levels;
SARC	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg18876405	chr7:65276391	NA	0.7	8.68	0.49	6.76e-16	Aortic root size;
SARC	cis	rs317689	0.581	rs315132	chr12:69761996	G/C	cg14784868	chr12:69753453	YEATS4	0.49	6.0	0.37	7.3e-9	Response to diuretic therapy;
SARC	cis	rs4689388	0.926	rs11732178	chr4:6292643	G/C	cg25554036	chr4:6271136	WFS1	0.42	7.01	0.42	2.49e-11	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-8.39	-0.48	4.7e-15	Alzheimer's disease;
SARC	cis	rs524281	0.817	rs10791859	chr11:65978453	C/T	cg14036092	chr11:66035641	RAB1B	-0.52	-5.44	-0.34	1.33e-7	Electroencephalogram traits;
SARC	cis	rs9341808	0.690	rs2322634	chr6:80874014	A/C	cg08355045	chr6:80787529	NA	0.34	5.48	0.34	1.08e-7	Sitting height ratio;
SARC	cis	rs6964587	0.935	rs28412174	chr7:91577245	T/G	cg17063962	chr7:91808500	NA	-0.92	-14.15	-0.68	3.27e-33	Breast cancer;
SARC	cis	rs1568889	1.000	rs12794100	chr11:28332785	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.73	9.63	0.53	1.06e-18	Bipolar disorder;
SARC	cis	rs35306767	0.903	rs12769873	chr10:936526	G/T	cg20503657	chr10:835505	NA	0.82	7.81	0.46	1.89e-13	Eosinophil percentage of granulocytes;
SARC	cis	rs735396	0.770	rs2264782	chr12:121432603	C/T	cg25281562	chr12:121454272	C12orf43	0.49	5.84	0.36	1.74e-8	N-glycan levels;
SARC	cis	rs644799	1.000	rs617999	chr11:95589935	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.68	8.73	0.5	4.89e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs9951602	0.573	rs78623099	chr18:76646228	G/T	cg02800362	chr5:177631904	HNRNPAB	0.68	8.44	0.48	3.37e-15	Obesity-related traits;
SARC	cis	rs666930	0.519	rs662602	chr1:120266903	C/G	cg19096424	chr1:120255104	PHGDH	0.85	10.14	0.55	2.91e-20	Breast cancer;
SARC	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-7.06	-0.42	1.87e-11	Gut microbiome composition (summer);
SARC	cis	rs11509153	0.696	rs5011433	chr7:12268695	T/A	cg23422036	chr7:12250390	TMEM106B	0.46	5.82	0.36	1.9e-8	Residual cognition;
SARC	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg04518342	chr5:131593106	PDLIM4	0.43	5.52	0.34	9.21e-8	Breast cancer;
SARC	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg13206674	chr6:150067644	NUP43	0.44	5.77	0.35	2.54e-8	Lung cancer;
SARC	cis	rs7587476	0.861	rs3768716	chr2:215635794	T/C	cg04530015	chr2:215796436	ABCA12	-0.36	-5.29	-0.33	2.86e-7	Neuroblastoma;
SARC	cis	rs12594515	0.904	rs8032875	chr15:45998010	A/C	cg14863074	chr15:45997064	NA	0.34	5.2	0.32	4.34e-7	Waist circumference;Weight;
SARC	cis	rs2980439	0.525	rs1850511	chr8:8170329	T/A	cg06636001	chr8:8085503	FLJ10661	0.61	8.16	0.47	2.06e-14	Neuroticism;
SARC	cis	rs6582630	0.519	rs10880629	chr12:38533611	T/G	cg13010199	chr12:38710504	ALG10B	0.76	10.6	0.57	1.08e-21	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg24675658	chr1:53192096	ZYG11B	-0.57	-7.94	-0.46	8.69e-14	Monocyte count;
SARC	cis	rs1865760	0.566	rs9295688	chr6:26084217	G/A	cg18357526	chr6:26021779	HIST1H4A	0.41	4.98	0.31	1.23e-6	Height;
SARC	cis	rs763014	0.838	rs4984670	chr16:641044	A/G	cg09263875	chr16:632152	PIGQ	0.52	7.94	0.46	8.8e-14	Height;
SARC	cis	rs763121	0.853	rs5757187	chr22:39021522	A/G	cg21395723	chr22:39101663	GTPBP1	-0.59	-6.67	-0.4	1.87e-10	Menopause (age at onset);
SARC	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg24675658	chr1:53192096	ZYG11B	0.59	8.35	0.48	6.18e-15	Monocyte count;
SARC	cis	rs796364	0.760	rs2881594	chr2:201026183	T/A	cg23649088	chr2:200775458	C2orf69	-0.64	-5.65	-0.35	4.56e-8	Schizophrenia;
SARC	cis	rs9309473	0.514	rs62149659	chr2:73585196	C/T	cg20560298	chr2:73613845	ALMS1	-0.55	-5.45	-0.34	1.25e-7	Metabolite levels;
SARC	cis	rs654950	0.774	rs941972	chr1:42040740	T/C	cg06885757	chr1:42089581	HIVEP3	-0.42	-6.0	-0.37	7.45e-9	Airway imaging phenotypes;
SARC	cis	rs9457247	0.508	rs6918286	chr6:167505829	C/T	cg07741184	chr6:167504864	NA	0.33	6.14	0.37	3.48e-9	Crohn's disease;
SARC	cis	rs7178572	0.568	rs12906708	chr15:77681444	A/G	cg22256960	chr15:77711686	NA	-0.51	-5.59	-0.34	6.36e-8	Type 2 diabetes;
SARC	cis	rs981844	1.000	rs55722886	chr4:154668335	A/G	cg14289246	chr4:154710475	SFRP2	0.57	6.43	0.39	7.08e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs13191362	1.000	rs35583420	chr6:163214327	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.71	6.11	0.37	4.19e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg24110177	chr3:50126178	RBM5	-0.65	-8.73	-0.5	5.13e-16	Body mass index;
SARC	cis	rs9916302	0.784	rs34473775	chr17:37396201	G/T	cg00129232	chr17:37814104	STARD3	-0.61	-7.49	-0.44	1.38e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs72634258	0.945	rs4908724	chr1:8119251	G/T	cg00042356	chr1:8021962	PARK7	0.91	8.35	0.48	6.28e-15	Inflammatory bowel disease;
SARC	cis	rs11098499	0.954	rs2389802	chr4:120325732	C/A	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg07636037	chr3:49044803	WDR6	0.95	16.38	0.73	1.26e-40	Menarche (age at onset);
SARC	trans	rs7824557	0.564	rs4631424	chr8:11236809	T/C	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.0	-0.42	2.66e-11	Retinal vascular caliber;
SARC	cis	rs8141529	0.529	rs5752803	chr22:29205004	G/A	cg15103426	chr22:29168792	CCDC117	0.61	5.94	0.36	1.03e-8	Lymphocyte counts;
SARC	cis	rs1865721	0.771	rs4410169	chr18:73138840	A/G	cg26385618	chr18:73139727	C18orf62	-0.4	-5.64	-0.35	4.85e-8	Intelligence;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg12543821	chr10:18964622	ARL5B	0.45	6.42	0.39	7.44e-10	Thyroid stimulating hormone;
SARC	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg13939156	chr17:80058883	NA	-0.43	-6.53	-0.39	4.12e-10	Life satisfaction;
SARC	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-8.7	-0.5	6.21e-16	Alzheimer's disease;
SARC	cis	rs6565180	0.926	rs12446288	chr16:30388709	A/G	cg17640201	chr16:30407289	ZNF48	1.01	17.97	0.76	6.81e-46	Tonsillectomy;
SARC	cis	rs6121246	0.697	rs6088864	chr20:30228157	G/A	cg13852791	chr20:30311386	BCL2L1	0.79	8.49	0.49	2.49e-15	Mean corpuscular hemoglobin;
SARC	cis	rs6545883	0.894	rs778157	chr2:61554289	C/G	cg15711740	chr2:61764176	XPO1	-0.4	-4.73	-0.3	3.84e-6	Tuberculosis;
SARC	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg26513180	chr16:89883248	FANCA	0.75	4.84	0.3	2.35e-6	Skin colour saturation;
SARC	cis	rs9303401	0.659	rs62083410	chr17:56964386	T/C	cg25039879	chr17:56429692	SUPT4H1	0.62	5.77	0.35	2.46e-8	Cognitive test performance;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg24901679	chr4:26364116	RBPJ	0.48	6.39	0.39	8.84e-10	Thyroid stimulating hormone;
SARC	cis	rs12142240	0.698	rs6659228	chr1:46811027	C/G	cg10495392	chr1:46806563	NSUN4	0.63	6.55	0.39	3.68e-10	Menopause (age at onset);
SARC	cis	rs9303401	0.614	rs35057477	chr17:57097064	G/A	cg25039879	chr17:56429692	SUPT4H1	0.61	5.44	0.34	1.35e-7	Cognitive test performance;
SARC	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg02931644	chr1:25747376	RHCE	0.42	6.92	0.41	4.45e-11	Erythrocyte sedimentation rate;
SARC	cis	rs35110281	0.506	rs13051661	chr21:45111518	A/T	cg04455712	chr21:45112962	RRP1B	0.34	4.89	0.31	1.84e-6	Mean corpuscular volume;
SARC	cis	rs763121	0.651	rs738249	chr22:39037979	T/C	cg21395723	chr22:39101663	GTPBP1	0.57	6.49	0.39	5.17e-10	Menopause (age at onset);
SARC	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.82	12.55	0.64	5.95e-28	Personality dimensions;
SARC	cis	rs3741151	0.773	rs73544783	chr11:73221256	C/G	cg17517138	chr11:73019481	ARHGEF17	0.97	7.67	0.45	4.69e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs9715521	0.718	rs7441564	chr4:59845405	A/T	cg11281224	chr4:60001000	NA	-0.4	-5.12	-0.32	6.5e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	trans	rs6003958	1	rs6003958	chr22:24264089	T/G	cg06437703	chr8:37914619	EIF4EBP1	0.68	7.86	0.46	1.45e-13	S-phenylmercapturic acid levels in smokers;
SARC	cis	rs634534	0.562	rs661335	chr11:65754061	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.83	12.28	0.63	4.65e-27	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg02725872	chr8:58115012	NA	-0.37	-6.54	-0.39	3.81e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs8114671	0.562	rs2076667	chr20:33506964	G/A	cg08999081	chr20:33150536	PIGU	0.33	4.91	0.31	1.72e-6	Height;
SARC	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg20573242	chr4:122745356	CCNA2	0.66	8.32	0.48	7.52e-15	Type 2 diabetes;
SARC	cis	rs7520050	0.807	rs28647556	chr1:46206399	G/A	cg24296786	chr1:45957014	TESK2	-0.44	-5.69	-0.35	3.89e-8	Red blood cell count;Reticulocyte count;
SARC	cis	rs6456156	0.586	rs13208636	chr6:167461965	T/G	cg07741184	chr6:167504864	NA	0.35	6.83	0.41	7.46e-11	Primary biliary cholangitis;
SARC	cis	rs11758351	1.000	rs79264785	chr6:26194121	C/T	cg23601095	chr6:26197514	HIST1H3D	0.62	5.39	0.33	1.68e-7	Gout;Renal underexcretion gout;
SARC	cis	rs1420338	0.869	rs1362452	chr7:34170519	G/A	cg01275685	chr7:34179230	BMPER	-0.43	-5.37	-0.33	1.91e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
SARC	cis	rs7666738	0.761	rs13136913	chr4:98998031	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg18404041	chr3:52824283	ITIH1	-0.33	-5.05	-0.31	9.1e-7	Electroencephalogram traits;
SARC	cis	rs6003958	1	rs6003958	chr22:24264089	T/G	cg12419862	chr22:24373484	LOC391322	0.76	8.71	0.5	5.86e-16	S-phenylmercapturic acid levels in smokers;
SARC	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg11890956	chr21:40555474	PSMG1	-1.03	-15.71	-0.72	1.99e-38	Cognitive function;
SARC	cis	rs6570726	0.935	rs379164	chr6:145829093	A/T	cg05347473	chr6:146136440	FBXO30	0.48	6.42	0.39	7.51e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs60871478	1.000	rs62432253	chr7:802928	A/G	cg19087971	chr7:751233	PRKAR1B	-0.44	-4.81	-0.3	2.75e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs911263	0.603	rs12878627	chr14:68795149	G/A	cg18825221	chr14:68749962	RAD51L1	0.4	7.14	0.42	1.21e-11	Primary biliary cholangitis;
SARC	cis	rs9398803	0.678	rs1844593	chr6:126897827	G/A	cg19875578	chr6:126661172	C6orf173	0.6	8.22	0.47	1.39e-14	Male-pattern baldness;
SARC	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.47	-5.82	-0.36	1.93e-8	Tonsillectomy;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg09813817	chr1:249152821	ZNF692	-0.48	-6.35	-0.38	1.14e-9	Schizophrenia;
SARC	cis	rs12995491	0.731	rs56188884	chr2:88508657	G/A	cg04511125	chr2:88470314	THNSL2	-0.39	-5.95	-0.36	9.57e-9	Response to metformin (IC50);
SARC	cis	rs2180341	0.960	rs9375503	chr6:127677071	T/C	cg27446573	chr6:127587934	RNF146	1.06	14.67	0.69	5.76e-35	Breast cancer;
SARC	cis	rs11997175	0.574	rs4520125	chr8:33648628	C/T	ch.8.33884649F	chr8:33765107	NA	0.5	6.63	0.4	2.28e-10	Body mass index;
SARC	cis	rs6456156	0.755	rs4710182	chr6:167514061	G/A	cg07741184	chr6:167504864	NA	0.37	7.32	0.43	4.11e-12	Primary biliary cholangitis;
SARC	cis	rs7246657	0.943	rs4452075	chr19:37879589	A/G	cg14683738	chr19:37701593	ZNF585B	0.5	4.88	0.3	1.99e-6	Coronary artery calcification;
SARC	cis	rs459571	0.959	rs416390	chr9:136908549	C/G	cg01294253	chr9:136912663	BRD3	-0.42	-5.27	-0.33	3.12e-7	Platelet distribution width;
SARC	cis	rs9987353	0.566	rs34491841	chr8:9065510	C/A	cg06636001	chr8:8085503	FLJ10661	-0.62	-8.06	-0.47	3.88e-14	Recombination measurement;
SARC	cis	rs6089584	0.606	rs7270469	chr20:60577258	G/A	cg06108461	chr20:60628389	TAF4	-0.66	-8.24	-0.48	1.22e-14	Body mass index;
SARC	cis	rs1348850	0.668	rs4893971	chr2:178495743	T/C	cg23306229	chr2:178417860	TTC30B	0.59	6.28	0.38	1.64e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1448094	0.533	rs2169572	chr12:86170370	G/T	cg00310523	chr12:86230176	RASSF9	-0.34	-5.47	-0.34	1.15e-7	Major depressive disorder;
SARC	cis	rs2115630	0.653	rs61394864	chr15:85170174	T/C	cg12501888	chr15:85177176	SCAND2	-0.52	-6.35	-0.38	1.09e-9	P wave terminal force;
SARC	cis	rs933688	1.000	rs889213	chr5:90682151	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.02	12.69	0.64	2.13e-28	Smoking behavior;
SARC	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg22834771	chr12:69754056	YEATS4	-0.44	-5.78	-0.35	2.43e-8	Blood protein levels;
SARC	cis	rs16976116	0.572	rs28802062	chr15:55452308	G/C	cg11288833	chr15:55489084	RSL24D1	0.63	5.52	0.34	9.21e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs3780486	0.718	rs3818593	chr9:33120706	A/G	cg04842962	chr6:43655489	MRPS18A	0.86	10.42	0.56	4.19e-21	IgG glycosylation;
SARC	cis	rs7607369	0.609	rs13391398	chr2:219282429	A/G	cg02176678	chr2:219576539	TTLL4	0.42	6.4	0.39	8.62e-10	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs9921222	0.502	rs28461430	chr16:369562	G/A	cg00101154	chr16:420108	MRPL28	-0.45	-6.24	-0.38	2.02e-9	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs12586317	0.547	rs3759548	chr14:35450333	C/T	cg16230307	chr14:35515116	FAM177A1	1.01	11.35	0.6	4.59e-24	Psoriasis;
SARC	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg05861140	chr6:150128134	PCMT1	-0.42	-5.44	-0.34	1.32e-7	Lung cancer;
SARC	cis	rs10875746	0.807	rs12313300	chr12:48470717	G/A	cg26205652	chr12:48591994	NA	0.56	6.1	0.37	4.38e-9	Longevity (90 years and older);
SARC	cis	rs11785400	0.793	rs11785012	chr8:143748355	G/A	cg10596483	chr8:143751796	JRK	0.54	6.82	0.41	7.87e-11	Schizophrenia;
SARC	trans	rs1814175	0.817	rs28594987	chr11:50045181	C/T	cg03929089	chr4:120376271	NA	-0.89	-14.58	-0.69	1.16e-34	Height;
SARC	cis	rs80282103	0.618	rs11250252	chr10:1124939	G/C	cg08668510	chr10:1095578	IDI1	0.74	5.0	0.31	1.11e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	5.97	0.36	8.78e-9	Prudent dietary pattern;
SARC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg05025164	chr4:1340916	KIAA1530	0.9	11.73	0.61	2.86e-25	Longevity;
SARC	cis	rs295140	1.000	rs10931899	chr2:201176901	A/G	cg05691004	chr2:201170426	SPATS2L	-0.34	-4.93	-0.31	1.59e-6	QT interval;
SARC	cis	rs62244186	0.659	rs9835270	chr3:44553722	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.43	5.27	0.33	3.17e-7	Depressive symptoms;
SARC	cis	rs11578119	0.933	rs12405323	chr1:170418964	G/A	cg09767346	chr1:170501363	GORAB	0.41	4.84	0.3	2.41e-6	Male-pattern baldness;
SARC	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg21442419	chr1:2182373	SKI	0.5	6.67	0.4	1.8e-10	Height;
SARC	cis	rs11098499	0.863	rs3775848	chr4:120447724	C/T	cg24375607	chr4:120327624	NA	0.42	4.9	0.31	1.76e-6	Corneal astigmatism;
SARC	cis	rs9814567	1.000	rs4535272	chr3:134299916	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.56	6.93	0.41	4.1e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg04267008	chr7:1944627	MAD1L1	-0.56	-6.39	-0.39	8.75e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs920590	0.684	rs59565447	chr8:19668430	A/T	cg01411142	chr8:19674711	INTS10	0.53	6.0	0.37	7.45e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs992157	0.835	rs2271543	chr2:219142491	C/T	cg00012203	chr2:219082015	ARPC2	-0.64	-9.27	-0.52	1.34e-17	Colorectal cancer;
SARC	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg22903471	chr2:27725779	GCKR	-0.5	-7.53	-0.44	1.11e-12	Total body bone mineral density;
SARC	cis	rs1355223	0.872	rs12802798	chr11:34747434	T/G	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-5.9	-0.36	1.3e-8	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs651907	0.535	rs34743741	chr3:101532448	C/T	cg12386194	chr3:101231763	SENP7	0.48	5.38	0.33	1.79e-7	Colorectal cancer;
SARC	cis	rs1348850	0.750	rs55792594	chr2:178496468	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.5	5.67	0.35	4.11e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	trans	rs4430311	0.964	rs2953331	chr1:244024268	A/G	cg02897366	chr1:201425990	NA	0.45	6.27	0.38	1.71e-9	Post-traumatic stress disorder (asjusted for relatedness);
SARC	cis	rs11690935	0.632	rs6737308	chr2:172872042	G/A	cg13550731	chr2:172543902	DYNC1I2	0.55	7.05	0.42	2e-11	Schizophrenia;
SARC	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.49	6.18	0.38	2.82e-9	Lymphocyte counts;
SARC	cis	rs6860806	0.507	rs272854	chr5:131688017	C/T	cg24060327	chr5:131705240	SLC22A5	-0.7	-8.39	-0.48	4.63e-15	Breast cancer;
SARC	cis	rs7937682	0.961	rs7106104	chr11:111635655	T/C	cg09085632	chr11:111637200	PPP2R1B	1.08	19.87	0.79	4.72e-52	Primary sclerosing cholangitis;
SARC	cis	rs1580019	0.844	rs1584615	chr7:32503258	G/C	cg07520158	chr7:32535189	LSM5;AVL9	0.43	5.01	0.31	1.08e-6	Cognitive ability;
SARC	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg01448562	chr3:133502909	NA	-0.5	-7.55	-0.44	9.6e-13	Iron status biomarkers;
SARC	cis	rs10191773	0.589	rs11676628	chr2:112953355	A/G	cg07905836	chr2:113190072	RGPD8;RGPD5	-0.8	-6.82	-0.41	7.71e-11	Yeast infection;
SARC	cis	rs8058578	1.000	rs6565197	chr16:30706477	T/C	cg02466173	chr16:30829666	NA	-0.39	-5.18	-0.32	4.74e-7	Multiple myeloma;
SARC	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg09263875	chr16:632152	PIGQ	0.52	7.98	0.46	6.48e-14	Height;
SARC	cis	rs7623687	0.892	rs73088122	chr3:49432404	C/T	cg19401529	chr3:49056140	DALRD3	0.63	5.47	0.34	1.17e-7	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
SARC	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs76419734	0.510	rs2216515	chr4:106750214	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	-0.73	-7.38	-0.44	2.7e-12	Post bronchodilator FEV1;
SARC	cis	rs6582630	0.555	rs10880613	chr12:38509553	C/T	cg26384229	chr12:38710491	ALG10B	0.89	13.22	0.65	3.76e-30	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg03806693	chr22:41940476	POLR3H	-0.93	-12.83	-0.64	7.61e-29	Vitiligo;
SARC	cis	rs986417	1.000	rs10148202	chr14:61055940	C/T	cg27398547	chr14:60952738	C14orf39	-0.85	-7.69	-0.45	4.14e-13	Gut microbiota (bacterial taxa);
SARC	cis	rs9394841	0.646	rs9369313	chr6:41847065	C/T	cg08135965	chr6:41755394	TOMM6	0.63	6.7	0.4	1.53e-10	Mean corpuscular hemoglobin;Red cell distribution width;
SARC	cis	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg05623727	chr3:50126028	RBM5	0.4	5.86	0.36	1.56e-8	Intelligence (multi-trait analysis);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg08688551	chr12:21927971	KCNJ8	-0.45	-6.23	-0.38	2.14e-9	Thyroid stimulating hormone;
SARC	cis	rs9487051	0.700	rs9400266	chr6:109596193	T/A	cg01475377	chr6:109611718	NA	-0.35	-5.08	-0.32	7.8e-7	Reticulocyte fraction of red cells;
SARC	trans	rs1853207	1.000	rs28399511	chr10:96580140	T/G	cg02737782	chr1:8014393	NA	-0.95	-6.37	-0.39	1.01e-9	Blood metabolite levels;
SARC	cis	rs637571	0.512	rs660118	chr11:65735174	G/C	cg04055107	chr11:65626734	MUS81;CFL1	0.42	5.22	0.32	3.95e-7	Eosinophil percentage of white cells;
SARC	trans	rs11098499	1.000	rs11098499	chr4:120187611	C/T	cg25214090	chr10:38739885	LOC399744	0.53	7.04	0.42	2.18e-11	Corneal astigmatism;
SARC	cis	rs12579753	0.719	rs12369450	chr12:82266940	A/G	cg07988820	chr12:82153109	PPFIA2	-0.45	-5.47	-0.34	1.14e-7	Resting heart rate;
SARC	cis	rs11997175	0.624	rs12677772	chr8:33772521	T/C	ch.8.33884649F	chr8:33765107	NA	0.64	8.78	0.5	3.68e-16	Body mass index;
SARC	cis	rs7615952	0.515	rs4441610	chr3:125681307	C/G	cg05084668	chr3:125655381	ALG1L	-0.55	-5.99	-0.37	8.1e-9	Blood pressure (smoking interaction);
SARC	cis	rs76025697	1	rs76025697	chr5:179184488	G/A	cg14593053	chr5:179126677	CANX	0.41	5.14	0.32	5.85e-7	Granulocyte percentage of myeloid white cells;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Granulocyte count;
SARC	cis	rs8067545	0.720	rs11204419	chr17:19888997	A/G	cg13482628	chr17:19912719	NA	0.56	6.89	0.41	5.1e-11	Schizophrenia;
SARC	cis	rs60871478	0.898	rs62432225	chr7:789433	G/A	cg19087971	chr7:751233	PRKAR1B	-0.44	-4.79	-0.3	3e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs7624766	0.518	rs9815499	chr3:160491722	T/A	cg22637730	chr3:160473554	PPM1L	0.38	4.9	0.31	1.82e-6	Response to methotrexate in rheumatoid arthritis;
SARC	cis	rs561341	0.883	rs886224	chr17:30229902	T/C	cg25833597	chr17:30823145	MYO1D	-0.54	-5.01	-0.31	1.07e-6	Hip circumference adjusted for BMI;
SARC	cis	rs2180341	1.000	rs4897207	chr6:127605898	C/T	cg24812749	chr6:127587940	RNF146	0.97	12.76	0.64	1.23e-28	Breast cancer;
SARC	cis	rs477692	0.647	rs524804	chr10:131430686	G/A	cg05714579	chr10:131428358	MGMT	-0.58	-7.47	-0.44	1.63e-12	Response to temozolomide;
SARC	cis	rs9398803	0.713	rs9401891	chr6:126894135	G/T	cg19875578	chr6:126661172	C6orf173	0.63	8.7	0.5	6.13e-16	Male-pattern baldness;
SARC	cis	rs870825	0.616	rs6552804	chr4:185637699	A/G	cg04058563	chr4:185651563	MLF1IP	0.84	11.36	0.6	4.49e-24	Blood protein levels;
SARC	cis	rs6546324	1.000	rs1430787	chr2:67868498	A/T	cg18237512	chr2:67827392	NA	-0.44	-5.62	-0.35	5.5e-8	Endometriosis;
SARC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg05025164	chr4:1340916	KIAA1530	-0.83	-10.96	-0.58	7.99e-23	Longevity;
SARC	cis	rs2439831	1.000	rs2439841	chr15:43734749	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.04	10.37	0.56	5.65e-21	Lung cancer in ever smokers;
SARC	cis	rs11945232	1.000	rs11945232	chr4:88342369	A/G	cg23841344	chr4:88312519	HSD17B11	-0.55	-7.16	-0.42	1.05e-11	Intelligence (multi-trait analysis);
SARC	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg12648201	chr2:27665141	KRTCAP3	-0.32	-4.84	-0.3	2.36e-6	Total body bone mineral density;
SARC	cis	rs6918586	0.658	rs198843	chr6:26110314	A/T	cg18357526	chr6:26021779	HIST1H4A	-0.46	-5.93	-0.36	1.09e-8	Schizophrenia;
SARC	cis	rs2120243	0.874	rs1840680	chr3:157156029	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.7	10.09	0.55	4.37e-20	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs11122272	0.735	rs2739513	chr1:231515201	C/T	cg06096015	chr1:231504339	EGLN1	0.4	5.92	0.36	1.15e-8	Hemoglobin concentration;
SARC	cis	rs2486288	0.586	rs12909625	chr15:45572053	C/A	cg15395560	chr15:45543142	SLC28A2	0.3	5.78	0.35	2.41e-8	Glomerular filtration rate;
SARC	cis	rs1707322	1.000	rs785510	chr1:46528618	T/C	cg06784218	chr1:46089804	CCDC17	-0.37	-6.45	-0.39	6.55e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9640161	0.830	rs3757423	chr7:150067714	A/G	cg21361702	chr7:150065534	REPIN1	-0.57	-7.33	-0.43	3.82e-12	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs67460515	0.892	rs2100238	chr3:161058055	T/A	cg04691961	chr3:161091175	C3orf57	-0.5	-6.24	-0.38	2.06e-9	Parkinson's disease;
SARC	cis	rs1355223	0.872	rs1258466	chr11:34730066	T/A	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.32	-0.33	2.4e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg07701084	chr6:150067640	NUP43	0.41	5.39	0.33	1.75e-7	Lung cancer;
SARC	cis	rs41271473	0.519	rs9660783	chr1:228886880	C/T	cg16512390	chr1:228756714	NA	0.42	5.38	0.33	1.81e-7	Chronic lymphocytic leukemia;
SARC	cis	rs9527	0.590	rs943039	chr10:104825132	C/T	cg04362960	chr10:104952993	NT5C2	0.43	5.0	0.31	1.11e-6	Arsenic metabolism;
SARC	cis	rs921968	0.643	rs535830	chr2:219372233	C/G	cg02176678	chr2:219576539	TTLL4	0.37	5.52	0.34	8.97e-8	Mean corpuscular hemoglobin concentration;
SARC	trans	rs330048	0.644	rs10102807	chr8:9104590	C/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.47	-0.39	5.84e-10	Systemic lupus erythematosus;
SARC	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg00908189	chr16:619842	PIGQ	0.85	12.47	0.63	1.13e-27	Height;
SARC	cis	rs7481584	0.624	rs421196	chr11:3048582	T/G	cg08508325	chr11:3079039	CARS	0.23	5.15	0.32	5.5e-7	Calcium levels;
SARC	cis	rs1559088	0.847	rs7254758	chr19:33608047	T/A	cg17764715	chr19:33622953	WDR88	0.49	6.65	0.4	2.03e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs793571	0.523	rs7161889	chr15:58983425	C/G	cg05156742	chr15:59063176	FAM63B	0.7	9.79	0.54	3.53e-19	Schizophrenia;
SARC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg21724239	chr8:58056113	NA	0.61	6.43	0.39	7.16e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7178572	0.568	rs11854193	chr15:77458136	C/A	cg22256960	chr15:77711686	NA	-0.5	-5.56	-0.34	7.45e-8	Type 2 diabetes;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg00053086	chr1:233119296	NA	0.48	6.34	0.38	1.19e-9	Schizophrenia;
SARC	cis	rs9733	1.000	rs9733	chr1:150618961	A/C	cg13175981	chr1:150552382	MCL1	0.49	6.08	0.37	4.97e-9	Tonsillectomy;
SARC	cis	rs5753037	0.543	rs131267	chr22:30147861	A/G	cg01021169	chr22:30184971	ASCC2	-0.5	-6.77	-0.41	1.05e-10	Type 1 diabetes;
SARC	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg02725872	chr8:58115012	NA	-0.37	-6.58	-0.4	3.02e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs3845702	0.736	rs6433818	chr2:180810264	A/T	cg01881094	chr2:180872142	CWC22	-1.12	-9.33	-0.52	8.56e-18	Schizophrenia;
SARC	cis	rs6665290	0.904	rs3795449	chr1:227181838	T/G	cg14016676	chr1:227182615	CDC42BPA	0.34	4.97	0.31	1.33e-6	Myeloid white cell count;
SARC	cis	rs793571	0.544	rs1427282	chr15:58914326	C/T	cg05156742	chr15:59063176	FAM63B	0.74	10.32	0.56	8.26e-21	Schizophrenia;
SARC	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.37	0.33	1.86e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs7264396	0.635	rs6060720	chr20:34548336	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-6.92	-0.41	4.41e-11	Total cholesterol levels;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg26663469	chr17:26662463	TNFAIP1;IFT20	0.52	6.49	0.39	5.05e-10	Breast cancer;
SARC	cis	rs8114671	0.935	rs35193912	chr20:33785050	C/T	cg24642439	chr20:33292090	TP53INP2	-0.49	-5.66	-0.35	4.42e-8	Height;
SARC	cis	rs8054556	0.733	rs35467921	chr16:30048553	C/T	cg06015834	chr16:30021696	DOC2A	-0.35	-4.75	-0.3	3.5e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg11644478	chr21:40555479	PSMG1	0.61	7.68	0.45	4.34e-13	Menarche (age at onset);
SARC	cis	rs8017423	0.967	rs2149655	chr14:90707246	T/C	cg20276874	chr14:90721474	PSMC1	-0.36	-5.03	-0.31	9.98e-7	Mortality in heart failure;
SARC	cis	rs2239547	0.607	rs9836178	chr3:52925403	T/C	cg18404041	chr3:52824283	ITIH1	0.44	5.41	0.33	1.54e-7	Schizophrenia;
SARC	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg20965017	chr5:231967	SDHA	-0.58	-5.73	-0.35	3.14e-8	Breast cancer;
SARC	cis	rs17401966	0.931	rs2276100	chr1:10394536	C/G	cg15208524	chr1:10270712	KIF1B	0.51	6.01	0.37	7.13e-9	Hepatocellular carcinoma;
SARC	cis	rs3126085	0.935	rs10888467	chr1:152171707	C/T	cg09127314	chr1:152161683	NA	0.41	4.84	0.3	2.36e-6	Atopic dermatitis;
SARC	cis	rs7264396	0.563	rs2425117	chr20:34323776	C/T	cg01084648	chr20:34329383	RBM39	0.59	4.96	0.31	1.37e-6	Total cholesterol levels;
SARC	cis	rs12472274	0.941	rs12616232	chr2:239080093	C/T	cg17459225	chr2:239074497	NA	0.6	6.96	0.41	3.53e-11	Phospholipid levels (plasma);
SARC	cis	rs12893668	0.572	rs1606	chr14:104161281	G/A	cg26031613	chr14:104095156	KLC1	-0.54	-5.97	-0.36	8.7e-9	Reticulocyte count;
SARC	cis	rs9420	0.961	rs11229148	chr11:57621460	A/T	cg23127183	chr11:57508653	C11orf31	-0.58	-6.76	-0.4	1.09e-10	Schizophrenia;
SARC	cis	rs2354432	0.599	rs6693667	chr1:146817245	A/T	cg25205988	chr1:146714368	CHD1L	0.87	8.14	0.47	2.38e-14	Mitochondrial DNA levels;
SARC	cis	rs9815354	0.812	rs73073234	chr3:42012071	C/T	cg03022575	chr3:42003672	ULK4	0.71	6.03	0.37	6.5e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6570726	0.935	rs407721	chr6:145871354	A/C	cg05220968	chr6:146057943	EPM2A	-0.3	-5.08	-0.32	7.72e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs733592	0.894	rs886589	chr12:48477197	C/T	cg24011408	chr12:48396354	COL2A1	-0.47	-6.19	-0.38	2.72e-9	Plateletcrit;
SARC	trans	rs11039798	0.557	rs4441015	chr11:49027070	A/G	cg15704280	chr7:45808275	SEPT13	0.69	7.05	0.42	2.06e-11	Axial length;
SARC	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	11.07	0.59	3.59e-23	Alzheimer's disease;
SARC	cis	rs1957429	0.901	rs60979440	chr14:65390231	A/G	cg23373153	chr14:65346875	NA	-1.01	-10.18	-0.55	2.21e-20	Pediatric areal bone mineral density (radius);
SARC	cis	rs10492096	0.947	rs11064227	chr12:6598043	A/G	cg13857086	chr12:6580257	VAMP1	0.7	6.77	0.41	1.02e-10	Hip geometry;
SARC	cis	rs7553035	0.850	rs2120671	chr1:211690993	A/C	cg01575408	chr1:211752895	SLC30A1	0.58	4.95	0.31	1.42e-6	Retinopathy in non-diabetics;
SARC	cis	rs4561483	0.801	rs33623	chr16:12007435	A/G	cg08843971	chr16:11963173	GSPT1	0.44	5.53	0.34	8.39e-8	Testicular germ cell tumor;
SARC	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg26874164	chr19:58962979	ZNF324B	0.51	6.75	0.4	1.14e-10	Uric acid clearance;
SARC	cis	rs910316	1.000	rs8003506	chr14:75586288	A/C	cg11812906	chr14:75593930	NEK9	-0.88	-13.45	-0.66	6.63e-31	Height;
SARC	cis	rs7959452	0.570	rs10878964	chr12:69720691	T/G	cg20891283	chr12:69753455	YEATS4	0.43	5.73	0.35	3.04e-8	Blood protein levels;
SARC	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg16405210	chr4:1374714	KIAA1530	-0.44	-5.3	-0.33	2.62e-7	Longevity;
SARC	cis	rs12586317	0.620	rs8020370	chr14:35581432	G/A	cg16230307	chr14:35515116	FAM177A1	0.92	10.85	0.58	1.78e-22	Psoriasis;
SARC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.58	0.57	1.3e-21	Prudent dietary pattern;
SARC	cis	rs6570726	0.935	rs409121	chr6:145839793	G/A	cg05220968	chr6:146057943	EPM2A	-0.29	-4.99	-0.31	1.19e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9790314	0.905	rs6441370	chr3:160993754	C/T	cg04691961	chr3:161091175	C3orf57	-0.76	-10.99	-0.58	6.62e-23	Morning vs. evening chronotype;
SARC	cis	rs8070624	0.574	rs11078408	chr17:17876011	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	10.75	0.58	3.66e-22	Total body bone mineral density;
SARC	cis	rs9810089	0.900	rs480162	chr3:136068695	A/T	cg15507776	chr3:136538369	TMEM22	0.44	5.0	0.31	1.15e-6	Gestational age at birth (child effect);
SARC	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.7	5.17	0.32	4.95e-7	Initial pursuit acceleration;
SARC	trans	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg00938859	chr5:1591904	SDHAP3	0.69	6.36	0.38	1.03e-9	Breast cancer;
SARC	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg24399712	chr22:39784796	NA	-0.44	-5.75	-0.35	2.74e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs17600642	0.694	rs72814530	chr10:72444745	A/G	cg19779893	chr10:72451501	ADAMTS14	-0.35	-5.5	-0.34	1.02e-7	Bipolar disorder;
SARC	cis	rs7312774	0.618	rs3759317	chr12:107370252	T/C	cg16260113	chr12:107380972	MTERFD3	1.0	8.21	0.47	1.5e-14	Severe influenza A (H1N1) infection;
SARC	cis	rs2777491	0.574	rs72739644	chr15:41719706	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.16	-17.91	-0.76	1.05e-45	Ulcerative colitis;
SARC	cis	rs2354432	1.000	rs6680778	chr1:146747153	T/C	cg25205988	chr1:146714368	CHD1L	1.11	14.18	0.68	2.46e-33	Mitochondrial DNA levels;
SARC	cis	rs3099143	1.000	rs1913001	chr15:77179408	A/C	cg21673338	chr15:77095150	SCAPER	0.73	6.15	0.37	3.32e-9	Recalcitrant atopic dermatitis;
SARC	cis	rs67311347	1.000	rs4974017	chr3:40473519	C/T	cg24209194	chr3:40518798	ZNF619	0.63	8.24	0.48	1.22e-14	Renal cell carcinoma;
SARC	cis	rs2180341	1.000	rs3798850	chr6:127613966	C/T	cg27446573	chr6:127587934	RNF146	1.02	14.46	0.69	2.89e-34	Breast cancer;
SARC	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg07636037	chr3:49044803	WDR6	0.63	8.4	0.48	4.49e-15	Resting heart rate;
SARC	cis	rs796364	0.760	rs55906940	chr2:201049386	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-5.29	-0.33	2.86e-7	Schizophrenia;
SARC	cis	rs616402	0.527	rs11584327	chr1:10578791	T/C	cg17425144	chr1:10567563	PEX14	0.46	7.34	0.43	3.59e-12	Breast size;
SARC	cis	rs9818758	0.607	rs3923475	chr3:49055788	G/T	cg06212747	chr3:49208901	KLHDC8B	-0.69	-5.8	-0.36	2.17e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs1707322	0.686	rs2991987	chr1:46081422	C/G	cg03146154	chr1:46216737	IPP	-0.52	-6.24	-0.38	2e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs13082711	0.596	rs479404	chr3:27363064	T/C	cg02860705	chr3:27208620	NA	0.44	5.68	0.35	4.05e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs2594989	0.943	rs7349536	chr3:11442503	C/T	cg00170343	chr3:11313890	ATG7	-0.57	-5.59	-0.34	6.47e-8	Circulating chemerin levels;
SARC	cis	rs10788972	0.620	rs34764952	chr1:54483694	C/T	cg10336722	chr1:54665764	CYB5RL;MRPL37	0.41	5.04	0.31	9.26e-7	Parkinson disease and lewy body pathology;
SARC	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg27572855	chr1:25598939	RHD	-0.53	-9.15	-0.51	3.03e-17	Erythrocyte sedimentation rate;
SARC	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	7.58	0.44	8.22e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6910061	0.830	rs9468408	chr6:11093745	C/T	cg27233058	chr6:11094804	LOC221710	0.6	5.51	0.34	9.49e-8	Diabetic kidney disease;
SARC	cis	rs55823223	0.646	rs55868394	chr17:73851113	C/A	cg23806715	chr17:73775811	H3F3B	1.02	9.24	0.52	1.62e-17	Psoriasis;
SARC	cis	rs4654899	0.897	rs12121807	chr1:21069129	A/C	cg04902671	chr1:21058625	SH2D5	-0.41	-4.97	-0.31	1.27e-6	Superior frontal gyrus grey matter volume;
SARC	cis	rs916888	0.647	rs199523	chr17:44848517	C/A	cg15921436	chr17:44337874	NA	-0.5	-5.43	-0.34	1.42e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9325144	0.624	rs10783329	chr12:39113951	C/T	cg13010199	chr12:38710504	ALG10B	-0.51	-6.29	-0.38	1.59e-9	Morning vs. evening chronotype;
SARC	cis	rs501120	0.810	rs513391	chr10:44749708	A/C	cg09554077	chr10:44749378	NA	0.46	6.33	0.38	1.25e-9	Coronary artery disease;Coronary heart disease;
SARC	cis	rs3809863	0.602	rs11650072	chr17:45393665	A/G	cg08085267	chr17:45401833	C17orf57	-0.47	-5.81	-0.36	2.05e-8	Glaucoma (primary open-angle);
SARC	cis	rs72781680	1.000	rs7578969	chr2:24168620	T/C	cg08917208	chr2:24149416	ATAD2B	0.79	7.54	0.44	1.05e-12	Lymphocyte counts;
SARC	cis	rs12044355	0.827	rs11583715	chr1:231829039	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-8.29	-0.48	8.98e-15	Alzheimer's disease;
SARC	cis	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg03060546	chr3:49711283	APEH	0.77	11.26	0.59	8.94e-24	Resting heart rate;
SARC	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg00933542	chr6:150070202	PCMT1	0.31	5.25	0.33	3.38e-7	Lung cancer;
SARC	trans	rs11098499	0.863	rs34308924	chr4:120481431	T/C	cg25214090	chr10:38739885	LOC399744	0.57	7.25	0.43	6.27e-12	Corneal astigmatism;
SARC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg21782813	chr7:2030301	MAD1L1	0.43	6.83	0.41	7.41e-11	Bipolar disorder and schizophrenia;
SARC	cis	rs7659604	1.000	rs10005932	chr4:122664782	T/C	cg19748678	chr4:122722346	EXOSC9	0.42	5.19	0.32	4.59e-7	Type 2 diabetes;
SARC	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg17971929	chr21:40555470	PSMG1	-0.86	-11.03	-0.59	4.8e-23	Cognitive function;
SARC	cis	rs13161895	1.000	rs394616	chr5:179418134	T/G	cg04265672	chr5:179402240	RNF130	-0.53	-5.07	-0.32	8.22e-7	LDL cholesterol;
SARC	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg11890956	chr21:40555474	PSMG1	-1.04	-15.35	-0.71	3.27e-37	Cognitive function;
SARC	cis	rs11785400	0.753	rs9694286	chr8:143737157	G/T	cg24634471	chr8:143751801	JRK	0.58	7.37	0.43	3.02e-12	Schizophrenia;
SARC	cis	rs6456156	0.586	rs13195158	chr6:167481392	G/A	cg07741184	chr6:167504864	NA	0.36	6.99	0.42	2.83e-11	Primary biliary cholangitis;
SARC	cis	rs6570726	0.755	rs2092297	chr6:145893765	A/G	cg05347473	chr6:146136440	FBXO30	0.51	7.17	0.43	9.59e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg12756686	chr19:29218302	NA	0.68	9.11	0.51	4e-17	Methadone dose in opioid dependence;
SARC	cis	rs7005606	0.967	rs11991474	chr8:32413310	C/T	cg14488905	chr8:32406789	NRG1	0.47	6.6	0.4	2.68e-10	Hirschsprung disease;
SARC	cis	rs950169	0.922	rs11638445	chr15:85137694	C/A	cg17507749	chr15:85114479	UBE2QP1	0.77	9.32	0.52	9.27e-18	Schizophrenia;
SARC	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg13206674	chr6:150067644	NUP43	0.46	5.91	0.36	1.22e-8	Lung cancer;
SARC	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg11366901	chr6:160182831	ACAT2	1.03	10.98	0.58	7.22e-23	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	11.03	0.59	4.93e-23	Alzheimer's disease;
SARC	cis	rs72945132	0.607	rs67767222	chr11:70121610	T/A	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.78	-0.35	2.39e-8	Coronary artery disease;
SARC	cis	rs76419734	1.000	rs11723225	chr4:106746065	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	5.33	0.33	2.37e-7	Post bronchodilator FEV1;
SARC	cis	rs1878931	0.520	rs2015640	chr16:3465018	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.65	-6.93	-0.41	3.99e-11	Body mass index (adult);
SARC	cis	rs6058796	0.901	rs6087966	chr20:31255035	C/G	cg13636640	chr20:31349939	DNMT3B	0.56	4.94	0.31	1.48e-6	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
SARC	trans	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.1	-0.42	1.51e-11	Extrinsic epigenetic age acceleration;
SARC	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg22433210	chr17:43662623	NA	-0.95	-11.34	-0.6	4.92e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7824557	0.593	rs11774673	chr8:11191537	T/C	cg21775007	chr8:11205619	TDH	0.66	8.45	0.48	3.16e-15	Retinal vascular caliber;
SARC	cis	rs10512697	0.803	rs11745378	chr5:3579723	G/A	cg19473799	chr5:3511975	NA	-0.63	-4.8	-0.3	2.84e-6	Immune response to smallpox vaccine (IL-6);
SARC	cis	rs17270561	0.609	rs1892255	chr6:25750354	G/A	cg16482183	chr6:26056742	HIST1H1C	0.43	5.14	0.32	5.72e-7	Iron status biomarkers;
SARC	cis	rs6594499	0.872	rs6881147	chr5:110451936	G/C	cg04022379	chr5:110408740	TSLP	0.48	6.06	0.37	5.48e-9	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg11266682	chr4:10021025	SLC2A9	0.43	7.81	0.46	1.91e-13	Bone mineral density;
SARC	cis	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg14019146	chr3:50243930	SLC38A3	-0.32	-5.04	-0.31	9.14e-7	Intelligence (multi-trait analysis);
SARC	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg01475735	chr3:40494733	NA	-0.48	-5.12	-0.32	6.33e-7	Renal cell carcinoma;
SARC	cis	rs10782582	0.609	rs1630587	chr1:76399787	T/C	cg03433033	chr1:76189801	ACADM	-0.4	-5.22	-0.32	3.99e-7	Daytime sleep phenotypes;
SARC	cis	rs3126085	0.877	rs12065368	chr1:152253497	C/T	cg26876637	chr1:152193138	HRNR	0.45	5.21	0.32	4.07e-7	Atopic dermatitis;
SARC	trans	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg21659725	chr3:3221576	CRBN	0.81	12.44	0.63	1.38e-27	Intelligence (multi-trait analysis);
SARC	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg02733842	chr7:1102375	C7orf50	-0.62	-7.23	-0.43	6.98e-12	Bronchopulmonary dysplasia;
SARC	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg21782813	chr7:2030301	MAD1L1	0.33	5.1	0.32	6.88e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs2304069	0.545	rs12153714	chr5:149395254	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.6	7.02	0.42	2.37e-11	HIV-1 control;
SARC	cis	rs35110281	0.744	rs162396	chr21:44947807	T/C	cg21573476	chr21:45109991	RRP1B	-0.47	-6.96	-0.41	3.47e-11	Mean corpuscular volume;
SARC	cis	rs7223966	1.000	rs7222060	chr17:61868279	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.45	4.82	0.3	2.6e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg00031303	chr3:195681400	NA	0.48	5.42	0.33	1.48e-7	Pancreatic cancer;
SARC	cis	rs9326248	1.000	rs585849	chr11:117069061	A/G	cg10130564	chr11:117069849	TAGLN	0.22	4.89	0.31	1.88e-6	Blood protein levels;
SARC	cis	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg18252515	chr7:66147081	NA	-1.41	-12.93	-0.65	3.5e-29	Diabetic kidney disease;
SARC	cis	rs7552404	0.889	rs1250874	chr1:76190978	A/G	cg10523679	chr1:76189770	ACADM	0.46	6.39	0.39	9.07e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs10088262	0.629	rs7833650	chr8:124822969	C/T	cg15047889	chr8:124780837	FAM91A1	-0.66	-7.27	-0.43	5.31e-12	Pancreatic cancer;
SARC	cis	rs9921222	0.521	rs757460	chr16:367174	G/C	cg00101154	chr16:420108	MRPL28	-0.41	-5.67	-0.35	4.16e-8	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs11098499	0.754	rs2036860	chr4:120248934	A/G	cg09307838	chr4:120376055	NA	0.82	11.13	0.59	2.31e-23	Corneal astigmatism;
SARC	cis	rs735539	0.521	rs2818994	chr13:21418410	G/A	cg16922012	chr13:21400325	XPO4	-0.44	-6.08	-0.37	4.98e-9	Dental caries;
SARC	cis	rs3820928	0.845	rs13419076	chr2:227873028	A/G	cg11843606	chr2:227700838	RHBDD1	-0.55	-7.0	-0.42	2.78e-11	Pulmonary function;
SARC	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg18876405	chr7:65276391	NA	-0.45	-4.92	-0.31	1.64e-6	Aortic root size;
SARC	cis	rs4253772	0.550	rs6007819	chr22:46704916	C/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.61	5.07	0.32	8.23e-7	LDL cholesterol;Cholesterol, total;
SARC	cis	rs2120019	1.000	rs67544533	chr15:75361539	A/G	cg17294928	chr15:75287854	SCAMP5	-0.94	-13.51	-0.66	4.31e-31	Blood trace element (Zn levels);
SARC	cis	rs1008375	0.932	rs2302391	chr4:17660237	T/C	cg16339924	chr4:17578868	LAP3	0.63	8.3	0.48	8.67e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-5.58	-0.34	6.81e-8	Bipolar disorder;
SARC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg09373136	chr17:61933544	TCAM1	-0.43	-5.91	-0.36	1.22e-8	Prudent dietary pattern;
SARC	cis	rs986417	1.000	rs1313249	chr14:60881997	C/G	cg27398547	chr14:60952738	C14orf39	-0.99	-8.88	-0.5	1.89e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs34333482	1	rs34333482	chr6:116855952	A/AG	cg03003256	chr6:116849557	FAM26D;BET3L	0.33	5.13	0.32	6.23e-7	Pelvic organ prolapse (moderate/severe);
SARC	cis	rs2115630	0.645	rs6496284	chr15:85178270	A/G	cg12501888	chr15:85177176	SCAND2	-0.5	-6.01	-0.37	7.25e-9	P wave terminal force;
SARC	cis	rs896854	0.738	rs527234	chr8:95963798	C/G	cg16049864	chr8:95962084	TP53INP1	0.4	6.24	0.38	2.01e-9	Type 2 diabetes;
SARC	cis	rs12477438	0.765	rs2309454	chr2:99595418	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-9.87	-0.54	1.98e-19	Chronic sinus infection;
SARC	cis	rs10875746	0.624	rs11168498	chr12:48655088	A/G	cg26205652	chr12:48591994	NA	0.45	4.75	0.3	3.53e-6	Longevity (90 years and older);
SARC	cis	rs7561273	0.609	rs2339945	chr2:24348096	G/A	cg07265300	chr2:24346000	PFN4;LOC375190	-0.42	-4.77	-0.3	3.26e-6	Quantitative traits;
SARC	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg18252515	chr7:66147081	NA	1.29	11.21	0.59	1.32e-23	Diabetic kidney disease;
SARC	cis	rs3820928	0.874	rs4675134	chr2:227843489	C/T	cg05526886	chr2:227700861	RHBDD1	-0.56	-6.84	-0.41	6.73e-11	Pulmonary function;
SARC	cis	rs35213789	0.800	rs35317642	chr7:69547616	A/G	cg10619644	chr7:69149951	AUTS2	0.42	5.18	0.32	4.89e-7	Childhood ear infection;
SARC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg23131131	chr22:24373011	LOC391322	-0.46	-5.08	-0.32	7.78e-7	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg10295955	chr4:187884368	NA	-1.04	-18.48	-0.77	1.44e-47	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2032447	0.530	rs9356996	chr6:26008487	C/A	cg18357526	chr6:26021779	HIST1H4A	0.63	8.72	0.5	5.25e-16	Intelligence (multi-trait analysis);
SARC	cis	rs4664308	0.710	rs13001911	chr2:161020703	G/C	cg03641300	chr2:160917029	PLA2R1	-0.56	-7.36	-0.43	3.19e-12	Idiopathic membranous nephropathy;
SARC	cis	rs6701037	1.000	rs6701037	chr1:175120079	G/T	cg17845761	chr1:175162550	KIAA0040	0.28	4.8	0.3	2.79e-6	Alcohol dependence;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg17712120	chr10:62150630	ANK3	0.46	6.32	0.38	1.35e-9	Thyroid stimulating hormone;
SARC	cis	rs7438	0.550	rs62334472	chr4:170357792	G/A	cg07701716	chr4:170533879	NEK1	0.4	4.72	0.3	4.06e-6	Schizophrenia;
SARC	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg21724239	chr8:58056113	NA	0.61	5.93	0.36	1.1e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7659604	1.000	rs7689714	chr4:122665943	T/A	cg19671926	chr4:122722719	EXOSC9	-0.51	-6.14	-0.37	3.44e-9	Type 2 diabetes;
SARC	cis	rs9911578	0.967	rs2567892	chr17:56668929	T/C	cg05425664	chr17:57184151	TRIM37	-0.66	-8.29	-0.48	8.87e-15	Intelligence (multi-trait analysis);
SARC	cis	rs6693567	0.565	rs832621	chr1:150392909	G/C	cg09579323	chr1:150459698	TARS2	0.45	5.84	0.36	1.74e-8	Migraine;
SARC	cis	rs981844	1.000	rs2606342	chr4:154659980	C/A	cg14289246	chr4:154710475	SFRP2	0.58	6.64	0.4	2.14e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg10523679	chr1:76189770	ACADM	-0.5	-6.71	-0.4	1.5e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2243123	0.602	rs6441283	chr3:159717900	G/A	cg20712415	chr3:159570903	SCHIP1	0.34	5.25	0.33	3.44e-7	Multiple sclerosis;
SARC	cis	rs4919087	0.962	rs10748691	chr10:98983955	C/T	cg25902810	chr10:99078978	FRAT1	0.45	5.29	0.33	2.77e-7	Monocyte count;
SARC	trans	rs2727020	0.617	rs7102702	chr11:49401125	T/G	cg03929089	chr4:120376271	NA	-0.73	-8.96	-0.51	1.04e-16	Coronary artery disease;
SARC	cis	rs765787	0.530	rs11070444	chr15:45513121	T/C	cg21132104	chr15:45694354	SPATA5L1	0.4	4.84	0.3	2.33e-6	Uric acid levels;
SARC	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg12042659	chr19:58951599	ZNF132	0.4	5.34	0.33	2.2e-7	Uric acid clearance;
SARC	cis	rs76917914	0.820	rs7034147	chr9:100821691	T/G	cg03040243	chr9:100819229	NANS	0.71	7.65	0.45	5.35e-13	Immature fraction of reticulocytes;
SARC	cis	rs7904368	0.806	rs7900527	chr10:16857992	C/G	cg23933602	chr10:16859644	RSU1	0.6	6.17	0.37	3.02e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs12134245	0.742	rs17501381	chr1:92003919	A/G	cg25838465	chr1:92012736	NA	-0.69	-9.79	-0.54	3.53e-19	Breast cancer;
SARC	cis	rs2832077	0.943	rs2832084	chr21:30154798	A/G	cg24692254	chr21:30365293	RNF160	-0.53	-4.82	-0.3	2.54e-6	Cognitive test performance;
SARC	cis	rs11676348	0.901	rs7562334	chr2:219003360	G/A	cg00012203	chr2:219082015	ARPC2	-0.44	-5.75	-0.35	2.75e-8	Ulcerative colitis;
SARC	cis	rs9868809	0.542	rs9873726	chr3:48712367	C/T	cg03060546	chr3:49711283	APEH	-0.54	-4.97	-0.31	1.31e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs2916247	1.000	rs6986430	chr8:93048104	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.58	-6.03	-0.37	6.49e-9	Intelligence (multi-trait analysis);
SARC	cis	rs634534	0.622	rs531612	chr11:65705432	C/T	cg26695010	chr11:65641043	EFEMP2	0.52	6.66	0.4	1.94e-10	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs10463554	0.892	rs464591	chr5:102447304	T/C	cg23492399	chr5:102201601	PAM	-0.52	-5.72	-0.35	3.2e-8	Parkinson's disease;
SARC	cis	rs9388451	0.807	rs1268065	chr6:126042783	G/A	cg05901451	chr6:126070800	HEY2	0.61	8.35	0.48	6.06e-15	Brugada syndrome;
SARC	cis	rs36051895	0.603	rs11795305	chr9:5179920	G/C	cg02405213	chr9:5042618	JAK2	-0.45	-5.04	-0.31	9.49e-7	Pediatric autoimmune diseases;
SARC	cis	rs1801251	1.000	rs2675971	chr2:233726154	A/G	cg25237894	chr2:233734115	C2orf82	-0.38	-5.07	-0.32	8.13e-7	Coronary artery disease;
SARC	cis	rs2742234	0.554	rs1254963	chr10:43696086	C/T	cg15436174	chr10:43711423	RASGEF1A	0.41	4.81	0.3	2.7e-6	Hirschsprung disease;
SARC	cis	rs7216064	0.861	rs73352810	chr17:65875184	G/A	cg12091567	chr17:66097778	LOC651250	-0.7	-7.64	-0.45	5.5e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg20607798	chr8:58055168	NA	0.68	5.88	0.36	1.43e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs61935443	1.000	rs4761691	chr12:95248171	C/G	cg21533806	chr12:95267307	NA	0.62	7.7	0.45	3.97e-13	Schizophrenia;
SARC	cis	rs798554	0.610	rs1182173	chr7:2878016	C/G	cg04166393	chr7:2884313	GNA12	0.41	5.02	0.31	1.01e-6	Height;
SARC	cis	rs933688	1.000	rs4382199	chr5:90744228	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	12.57	0.64	5.35e-28	Smoking behavior;
SARC	cis	rs950169	0.922	rs11633534	chr15:85124642	C/T	cg24253500	chr15:84953950	NA	0.39	5.55	0.34	7.67e-8	Schizophrenia;
SARC	cis	rs1215050	0.765	rs588851	chr4:98678247	C/T	cg05340658	chr4:99064831	C4orf37	0.44	5.78	0.35	2.38e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg17971929	chr21:40555470	PSMG1	-0.59	-7.36	-0.43	3.22e-12	Menarche (age at onset);
SARC	cis	rs10489202	1.000	rs4657727	chr1:167965241	T/C	cg24449463	chr1:168025552	DCAF6	-0.64	-6.96	-0.41	3.42e-11	Schizophrenia;
SARC	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg14820908	chr5:178986412	RUFY1	0.34	4.72	0.3	4.08e-6	Lung cancer;
SARC	cis	rs33912345	0.695	rs1313244	chr14:60877348	C/G	cg27398547	chr14:60952738	C14orf39	-0.39	-4.73	-0.3	3.85e-6	Glaucoma (high intraocular pressure);
SARC	cis	rs7937682	0.883	rs566647	chr11:111466607	A/G	cg09085632	chr11:111637200	PPP2R1B	0.91	13.27	0.66	2.61e-30	Primary sclerosing cholangitis;
SARC	cis	rs2486288	0.656	rs1706770	chr15:45575062	T/C	cg19305227	chr15:45544335	SLC28A2	0.32	5.81	0.36	2.03e-8	Glomerular filtration rate;
SARC	cis	rs703842	1.000	rs10783848	chr12:58196528	G/A	cg00677455	chr12:58241039	CTDSP2	0.53	6.94	0.41	3.93e-11	Multiple sclerosis;
SARC	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg07414643	chr4:187882934	NA	0.51	7.58	0.44	8.37e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6738485	0.601	rs13011900	chr2:106845059	G/C	cg16099169	chr2:106886729	NA	-0.4	-5.16	-0.32	5.23e-7	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
SARC	cis	rs2304069	0.545	rs1864998	chr5:149389465	C/T	cg12661370	chr5:149340060	SLC26A2	0.56	6.54	0.39	3.93e-10	HIV-1 control;
SARC	cis	rs7829975	0.533	rs1039917	chr8:8718850	C/T	cg08975724	chr8:8085496	FLJ10661	0.47	5.73	0.35	3.11e-8	Mood instability;
SARC	cis	rs365132	0.967	rs353471	chr5:176363429	T/C	cg16309518	chr5:176445507	NA	-0.46	-6.01	-0.37	7.17e-9	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs17376456	0.757	rs10066431	chr5:93198204	A/G	cg25358565	chr5:93447407	FAM172A	1.23	12.61	0.64	3.94e-28	Diabetic retinopathy;
SARC	cis	rs344364	0.511	rs337286	chr16:1965719	C/T	cg26617929	chr16:1858877	NA	-0.6	-5.03	-0.31	9.73e-7	Glomerular filtration rate in chronic kidney disease;
SARC	trans	rs8002861	0.935	rs7318147	chr13:44445153	C/G	cg17145862	chr1:211918768	LPGAT1	-0.55	-6.91	-0.41	4.63e-11	Leprosy;
SARC	cis	rs910316	0.967	rs7146523	chr14:75659880	T/C	cg08847533	chr14:75593920	NEK9	-0.87	-13.56	-0.66	2.91e-31	Height;
SARC	cis	rs6582630	0.537	rs2204006	chr12:38407098	A/G	cg26384229	chr12:38710491	ALG10B	0.84	12.16	0.62	1.14e-26	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs4268898	0.662	rs17733015	chr2:24509370	A/G	cg26838691	chr2:24397539	C2orf84	-0.51	-5.96	-0.36	9.47e-9	Asthma;
SARC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.43	5.25	0.33	3.38e-7	Bipolar disorder;
SARC	cis	rs1018836	0.608	rs2205150	chr8:91483232	G/A	cg16814680	chr8:91681699	NA	-0.65	-9.3	-0.52	1.09e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs7520050	0.966	rs9429183	chr1:46524582	G/A	cg06784218	chr1:46089804	CCDC17	-0.27	-4.93	-0.31	1.58e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs13256369	0.755	rs12550057	chr8:8562268	G/A	cg18904891	chr8:8559673	CLDN23	0.49	5.53	0.34	8.66e-8	Obesity-related traits;
SARC	cis	rs1050631	0.592	rs1785932	chr18:33719434	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.56	6.5	0.39	4.8e-10	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.58	0.34	6.8e-8	Bipolar disorder;
SARC	cis	rs7555523	0.887	rs2790053	chr1:165737704	C/G	cg19769164	chr1:165738335	TMCO1	0.6	5.14	0.32	5.76e-7	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg02097667	chr5:60751658	ZSWIM6	-0.51	-6.96	-0.41	3.35e-11	Alcohol dependence;
SARC	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs5753618	0.561	rs1858821	chr22:31676454	T/C	cg00478049	chr22:31556069	RNF185	0.44	4.81	0.3	2.71e-6	Colorectal cancer;
SARC	cis	rs3018712	0.532	rs2513282	chr11:68418311	A/C	cg01657329	chr11:68192670	LRP5	0.59	5.38	0.33	1.81e-7	Total body bone mineral density;
SARC	cis	rs11098499	0.909	rs7659501	chr4:120371552	G/T	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	cis	rs67460515	0.563	rs11922959	chr3:160828871	A/G	cg17135325	chr3:160939158	NMD3	0.63	7.74	0.45	3.01e-13	Parkinson's disease;
SARC	cis	rs995000	0.868	rs1168102	chr1:63127705	C/T	cg06896770	chr1:63153194	DOCK7	-0.89	-13.48	-0.66	5.3e-31	Triglyceride levels;
SARC	cis	rs72945132	0.660	rs12292191	chr11:70122426	T/C	cg05964544	chr11:70165517	PPFIA1	-0.6	-5.85	-0.36	1.66e-8	Coronary artery disease;
SARC	cis	rs8114671	0.562	rs4911447	chr20:33479445	T/A	cg07148914	chr20:33460835	GGT7	0.43	5.37	0.33	1.93e-7	Height;
SARC	cis	rs75920871	0.588	rs1940626	chr11:116828121	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.47	-4.89	-0.31	1.88e-6	Subjective well-being;
SARC	cis	rs4969178	0.965	rs11077362	chr17:76397219	A/T	cg02836325	chr17:76403955	PGS1	0.33	5.01	0.31	1.07e-6	HDL cholesterol levels;
SARC	cis	rs2425143	1.000	rs6060642	chr20:34449840	G/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.67	5.43	0.34	1.42e-7	Blood protein levels;
SARC	cis	rs2425143	1.000	rs2425093	chr20:34306875	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.61	5.69	0.35	3.71e-8	Blood protein levels;
SARC	cis	rs6840360	1.000	rs10019048	chr4:152603615	A/G	cg22705602	chr4:152727874	NA	-0.38	-6.48	-0.39	5.35e-10	Intelligence (multi-trait analysis);
SARC	cis	rs7666738	0.830	rs13124689	chr4:98961182	A/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2466076	0.503	rs11783353	chr8:32436785	T/C	cg14488905	chr8:32406789	NRG1	0.44	4.78	0.3	3.16e-6	Thyroid cancer;
SARC	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.61e-6	Depression;
SARC	cis	rs7647973	1.000	rs10155014	chr3:49432321	C/T	cg07636037	chr3:49044803	WDR6	0.76	8.55	0.49	1.69e-15	Menarche (age at onset);
SARC	cis	rs12586317	0.547	rs28589276	chr14:35478865	A/G	cg26967526	chr14:35346199	BAZ1A	-0.57	-5.71	-0.35	3.4e-8	Psoriasis;
SARC	cis	rs17030434	0.769	rs11727144	chr4:154645181	G/C	cg14289246	chr4:154710475	SFRP2	-0.65	-6.17	-0.37	3.07e-9	Electrocardiographic conduction measures;
SARC	cis	rs6540556	0.723	rs12034758	chr1:209920545	G/A	cg05527609	chr1:210001259	C1orf107	-0.66	-6.2	-0.38	2.57e-9	Red blood cell count;
SARC	cis	rs10883723	0.810	rs1056857	chr10:104240003	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	7.72	0.45	3.39e-13	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs9325144	0.505	rs1906262	chr12:38653605	A/G	cg13010199	chr12:38710504	ALG10B	0.71	9.54	0.53	1.98e-18	Morning vs. evening chronotype;
SARC	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg06420487	chr17:61919686	SMARCD2	0.43	4.73	0.3	3.94e-6	Height;
SARC	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg06221963	chr1:154839813	KCNN3	0.49	7.89	0.46	1.16e-13	Prostate cancer;
SARC	cis	rs35110281	0.774	rs1378080	chr21:45011315	T/A	cg01579765	chr21:45077557	HSF2BP	-0.32	-5.49	-0.34	1.05e-7	Mean corpuscular volume;
SARC	cis	rs13390159	1.000	rs1377451	chr2:237155599	A/G	cg19324714	chr2:237145437	ASB18	-0.51	-5.4	-0.33	1.67e-7	Response to statin therapy;
SARC	cis	rs10191773	0.522	rs6747639	chr2:112967458	C/T	cg07905836	chr2:113190072	RGPD8;RGPD5	0.94	8.34	0.48	6.42e-15	Yeast infection;
SARC	cis	rs7582180	0.629	rs7597615	chr2:100954828	T/C	cg14675211	chr2:100938903	LONRF2	0.51	7.5	0.44	1.37e-12	Intelligence (multi-trait analysis);
SARC	cis	rs7481584	0.624	rs80871	chr11:3049843	A/C	cg25174290	chr11:3078921	CARS	-0.6	-8.35	-0.48	6.26e-15	Calcium levels;
SARC	cis	rs1355223	0.525	rs7129517	chr11:34872236	A/C	cg11622362	chr11:34938112	PDHX;APIP	0.42	5.39	0.33	1.72e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs12421382	0.659	rs56410856	chr11:109382455	T/G	cg27471124	chr11:109292789	C11orf87	0.38	5.1	0.32	7.01e-7	Schizophrenia;
SARC	cis	rs137603	0.602	rs137654	chr22:39732413	C/T	cg01093212	chr22:39715156	SNORD43;RPL3	-0.58	-7.01	-0.42	2.56e-11	Primary biliary cholangitis;
SARC	cis	rs644799	0.672	rs11021347	chr11:95653494	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	6.49	0.39	5.09e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs4969178	0.965	rs938351	chr17:76399404	C/T	cg20026190	chr17:76395443	PGS1	0.39	5.32	0.33	2.44e-7	HDL cholesterol levels;
SARC	cis	rs989128	0.517	rs1809284	chr17:48632310	A/G	cg20467136	chr17:48638190	CACNA1G	0.46	5.34	0.33	2.19e-7	Type 2 diabetes;
SARC	cis	rs910316	0.870	rs7147712	chr14:75670707	C/G	cg11812906	chr14:75593930	NEK9	-0.74	-10.32	-0.56	8.04e-21	Height;
SARC	trans	rs208520	0.526	rs1385219	chr6:66754476	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	19.32	0.78	2.81e-50	Exhaled nitric oxide output;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg00832928	chr3:150329458	SELT	-0.49	-6.24	-0.38	2.09e-9	Height;
SARC	cis	rs1018836	0.631	rs2205158	chr8:91472515	C/T	cg16814680	chr8:91681699	NA	-0.68	-9.79	-0.54	3.5e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs7208859	0.524	rs11653605	chr17:29088385	T/G	cg13385521	chr17:29058706	SUZ12P	0.9	7.81	0.46	1.96e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs11583043	1.000	rs2391573	chr1:101489698	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.49	5.72	0.35	3.19e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	trans	rs7819412	0.775	rs2898257	chr8:10935368	A/C	cg15556689	chr8:8085844	FLJ10661	-0.54	-7.03	-0.42	2.3e-11	Triglycerides;
SARC	cis	rs3617	0.573	rs9810807	chr3:52924227	C/T	cg05564831	chr3:52568323	NT5DC2	-0.28	-4.78	-0.3	3.04e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs17376456	0.877	rs10057605	chr5:93443950	T/G	cg25358565	chr5:93447407	FAM172A	1.32	14.75	0.69	3.21e-35	Diabetic retinopathy;
SARC	cis	rs6912958	0.558	rs9444530	chr6:88343318	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.3	5.3	0.33	2.64e-7	Monocyte percentage of white cells;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg02782889	chr17:47074637	IGF2BP1	-0.48	-6.29	-0.38	1.52e-9	Chemerin levels;
SARC	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg02931644	chr1:25747376	RHCE	0.47	7.88	0.46	1.28e-13	Erythrocyte sedimentation rate;
SARC	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg08677398	chr8:58056175	NA	0.44	5.25	0.33	3.38e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7599312	0.534	rs6435711	chr2:213410065	G/A	cg20637307	chr2:213403960	ERBB4	0.79	12.11	0.62	1.7e-26	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs1497406	0.802	rs28629977	chr1:16497272	G/C	cg06365898	chr1:16533907	ARHGEF19	0.36	4.9	0.31	1.8e-6	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs4689388	0.853	rs11729672	chr4:6293838	A/G	cg14416269	chr4:6271139	WFS1	0.32	4.92	0.31	1.61e-6	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs757647	0.540	rs4457069	chr5:137619591	A/G	cg27119451	chr5:137514611	BRD8;KIF20A	-0.47	-4.83	-0.3	2.47e-6	Menarche (age at onset);
SARC	cis	rs1008375	0.966	rs12503517	chr4:17698725	G/A	cg16339924	chr4:17578868	LAP3	0.52	6.67	0.4	1.8e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9868809	0.505	rs28567949	chr3:48744560	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.55	-5.05	-0.31	8.91e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs9899728	0.539	rs12938889	chr17:73039929	A/C	cg27626185	chr17:73056755	KCTD2	0.94	7.27	0.43	5.33e-12	Alzheimer's disease or small vessel stroke;
SARC	cis	rs787274	1.000	rs4979165	chr9:115609539	T/C	cg13803584	chr9:115635662	SNX30	-0.82	-4.94	-0.31	1.48e-6	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg17221315	chr6:27791827	HIST1H4J	-0.45	-5.17	-0.32	5e-7	Depression;
SARC	cis	rs7937682	0.681	rs7107378	chr11:111401840	C/A	cg22437258	chr11:111473054	SIK2	-0.4	-4.87	-0.3	2.05e-6	Primary sclerosing cholangitis;
SARC	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg06063517	chr11:575810	LOC143666;PHRF1	0.49	4.91	0.31	1.72e-6	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs1878931	0.858	rs3760083	chr16:3450052	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.91	-15.59	-0.71	5.01e-38	Body mass index (adult);
SARC	trans	rs17038463	1.000	rs17038181	chr3:1401203	G/C	cg18003583	chr5:176819624	SLC34A1	0.99	6.29	0.38	1.56e-9	Neurocognitive impairment in HIV-1 infection (continuous);
SARC	cis	rs4713675	0.584	rs7739505	chr6:33670370	G/A	cg15676125	chr6:33679581	C6orf125	0.52	6.41	0.39	7.82e-10	Plateletcrit;
SARC	cis	rs1008375	0.932	rs13127157	chr4:17618049	A/G	cg02297831	chr4:17616191	MED28	-0.45	-5.57	-0.34	7.14e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9916302	0.904	rs55689507	chr17:37404436	G/C	cg07936489	chr17:37558343	FBXL20	-0.67	-8.87	-0.5	1.96e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs9818758	0.607	rs35108630	chr3:49088356	T/A	cg06212747	chr3:49208901	KLHDC8B	-0.68	-5.76	-0.35	2.62e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.54	6.81	0.41	8.11e-11	Lymphocyte counts;
SARC	cis	rs1048238	0.525	rs848214	chr1:16265422	A/G	cg21385522	chr1:16154831	NA	-0.47	-5.72	-0.35	3.32e-8	Systolic blood pressure;
SARC	cis	rs1008375	0.966	rs3796813	chr4:17591648	A/G	cg02297831	chr4:17616191	MED28	0.49	6.25	0.38	1.95e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg05165339	chr4:1420672	NA	-0.27	-5.77	-0.35	2.45e-8	Longevity;
SARC	cis	rs10504229	0.679	rs7840100	chr8:58036662	T/G	cg11062466	chr8:58055876	NA	0.49	4.93	0.31	1.56e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs1355223	0.545	rs12278318	chr11:34876507	C/G	cg11622362	chr11:34938112	PDHX;APIP	0.45	5.88	0.36	1.42e-8	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs2290416	0.892	rs34178175	chr8:144664687	G/A	cg10810860	chr8:144639591	GSDMD	-0.7	-5.02	-0.31	1.02e-6	Attention deficit hyperactivity disorder;
SARC	cis	rs35110281	0.626	rs162368	chr21:44934767	G/A	cg21573476	chr21:45109991	RRP1B	-0.45	-6.48	-0.39	5.48e-10	Mean corpuscular volume;
SARC	cis	rs9473924	0.505	rs4111288	chr6:50908094	G/A	cg14470998	chr6:50812995	TFAP2B	0.75	7.03	0.42	2.26e-11	Body mass index;
SARC	cis	rs17376456	0.877	rs10060160	chr5:93387879	G/A	cg21475434	chr5:93447410	FAM172A	0.85	7.5	0.44	1.34e-12	Diabetic retinopathy;
SARC	cis	rs7712401	0.601	rs30029	chr5:122283170	A/C	cg19412675	chr5:122181750	SNX24	-0.41	-5.21	-0.32	4.16e-7	Mean platelet volume;
SARC	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg02018176	chr4:1364513	KIAA1530	0.39	5.67	0.35	4.23e-8	Obesity-related traits;
SARC	cis	rs72781680	1.000	rs55982282	chr2:24188128	G/A	cg06627628	chr2:24431161	ITSN2	-0.73	-6.97	-0.42	3.24e-11	Lymphocyte counts;
SARC	cis	rs34333482	1	rs34333482	chr6:116855952	A/AG	cg23085344	chr6:116937351	RSPH4A	-0.47	-5.84	-0.36	1.74e-8	Pelvic organ prolapse (moderate/severe);
SARC	trans	rs561341	0.941	rs4795664	chr17:30233467	C/T	cg20587970	chr11:113659929	NA	-1.03	-9.65	-0.53	9.56e-19	Hip circumference adjusted for BMI;
SARC	cis	rs9790314	0.638	rs6441339	chr3:160619683	T/G	cg04691961	chr3:161091175	C3orf57	0.53	7.2	0.43	8.32e-12	Morning vs. evening chronotype;
SARC	cis	rs7712401	0.818	rs13166350	chr5:122153569	C/T	cg19412675	chr5:122181750	SNX24	0.37	5.0	0.31	1.15e-6	Mean platelet volume;
SARC	cis	rs6815814	0.950	rs67206233	chr4:38807853	T/C	cg06935464	chr4:38784597	TLR10	0.63	6.31	0.38	1.41e-9	Breast cancer;
SARC	cis	rs34172651	0.606	rs7194189	chr16:24703484	G/T	cg00152838	chr16:24741724	TNRC6A	0.52	5.27	0.33	3.08e-7	Intelligence (multi-trait analysis);
SARC	cis	rs12142240	0.660	rs72890715	chr1:46852077	A/G	cg00530320	chr1:46809349	NSUN4	0.57	7.0	0.42	2.74e-11	Menopause (age at onset);
SARC	cis	rs7247513	0.964	rs35235213	chr19:12713156	C/T	cg01871581	chr19:12707946	ZNF490	-0.92	-13.36	-0.66	1.33e-30	Bipolar disorder;
SARC	cis	rs7520050	0.966	rs1707321	chr1:46505309	A/G	cg24296786	chr1:45957014	TESK2	0.39	4.98	0.31	1.25e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg08280861	chr8:58055591	NA	0.59	5.16	0.32	5.2e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2273669	0.915	rs10872027	chr6:109289540	T/C	cg05315195	chr6:109294784	ARMC2	-0.48	-4.76	-0.3	3.42e-6	Prostate cancer;
SARC	cis	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg03213289	chr20:61660250	NA	0.46	6.43	0.39	7.22e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs28795989	0.795	rs4696746	chr4:7904945	G/T	cg18538662	chr4:7941764	AFAP1	-0.42	-5.42	-0.33	1.5e-7	Intraocular pressure;
SARC	cis	rs950169	0.800	rs4099846	chr15:84956894	C/G	cg17507749	chr15:85114479	UBE2QP1	0.77	9.42	0.53	4.67e-18	Schizophrenia;
SARC	cis	rs7520050	0.807	rs28378621	chr1:46189554	T/C	cg24296786	chr1:45957014	TESK2	-0.43	-5.62	-0.35	5.44e-8	Red blood cell count;Reticulocyte count;
SARC	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg11965913	chr1:205819406	PM20D1	0.43	4.92	0.31	1.67e-6	Parkinson's disease;
SARC	cis	rs698833	0.926	rs1085449	chr2:44653432	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.65	8.54	0.49	1.78e-15	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs2814982	0.605	rs114672114	chr6:34480065	A/G	cg14254433	chr6:34482411	PACSIN1	-0.5	-4.81	-0.3	2.71e-6	Cholesterol, total;Total cholesterol levels;
SARC	cis	rs7666738	0.791	rs1527516	chr4:98967937	A/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	trans	rs3808502	0.526	rs11985709	chr8:11423083	A/C	cg06636001	chr8:8085503	FLJ10661	-0.65	-9.02	-0.51	7.33e-17	Neuroticism;
SARC	cis	rs7666738	0.830	rs1593569	chr4:99017485	C/G	cg05340658	chr4:99064831	C4orf37	0.63	8.56	0.49	1.51e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg07777115	chr5:623756	CEP72	-0.65	-5.82	-0.36	1.89e-8	Obesity-related traits;
SARC	cis	rs7208859	0.623	rs55961983	chr17:29119286	G/A	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs3733585	0.725	rs6449201	chr4:9973894	C/T	cg00071950	chr4:10020882	SLC2A9	-0.38	-5.86	-0.36	1.54e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs2230307	0.536	rs11166384	chr1:100439890	C/T	cg24955406	chr1:100503596	HIAT1	0.7	7.09	0.42	1.59e-11	Carotid intima media thickness;
SARC	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg17971929	chr21:40555470	PSMG1	0.99	13.99	0.68	1.05e-32	Cognitive function;
SARC	cis	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg09021430	chr5:549028	NA	-0.45	-5.7	-0.35	3.69e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg23758822	chr17:41437982	NA	0.89	11.4	0.6	3.2e-24	Menopause (age at onset);
SARC	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.43	-6.85	-0.41	6.33e-11	Total body bone mineral density;
SARC	cis	rs1580019	0.922	rs59938271	chr7:32484844	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.8	11.31	0.6	6.22e-24	Cognitive ability;
SARC	cis	rs17376456	0.825	rs10054903	chr5:93281491	C/A	cg21475434	chr5:93447410	FAM172A	0.86	7.67	0.45	4.52e-13	Diabetic retinopathy;
SARC	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg20573242	chr4:122745356	CCNA2	0.65	8.29	0.48	8.76e-15	Type 2 diabetes;
SARC	cis	rs920590	0.643	rs2083640	chr8:19660212	T/C	cg17834443	chr8:19674713	INTS10	0.49	6.05	0.37	5.74e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs367943	1.000	rs168366	chr5:112818587	C/T	cg12552261	chr5:112820674	MCC	0.45	5.21	0.32	4.24e-7	Type 2 diabetes;
SARC	cis	rs7084402	1.000	rs717452	chr10:60268270	A/G	cg07615347	chr10:60278583	BICC1	0.56	8.17	0.47	1.99e-14	Refractive error;
SARC	cis	rs2204008	0.774	rs8189620	chr12:38241621	A/G	cg26384229	chr12:38710491	ALG10B	0.91	13.63	0.67	1.66e-31	Bladder cancer;
SARC	cis	rs10463554	0.963	rs61418746	chr5:102379618	T/A	cg23492399	chr5:102201601	PAM	-0.46	-5.05	-0.31	8.78e-7	Parkinson's disease;
SARC	cis	rs826838	0.616	rs2387921	chr12:38624767	T/C	cg13010199	chr12:38710504	ALG10B	-0.52	-6.43	-0.39	7.32e-10	Heart rate;
SARC	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg16606324	chr3:10149918	C3orf24	0.51	5.19	0.32	4.53e-7	Alzheimer's disease;
SARC	cis	rs112591243	0.570	rs4819254	chr21:47887462	T/A	cg10657630	chr21:48055338	PRMT2	0.77	4.82	0.3	2.55e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	cis	rs13161895	0.887	rs863231	chr5:179409613	C/T	cg02702477	chr5:179499311	RNF130	0.5	5.11	0.32	6.75e-7	LDL cholesterol;
SARC	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg19077165	chr18:44547161	KATNAL2	-0.47	-6.41	-0.39	8.09e-10	Personality dimensions;
SARC	cis	rs1153858	1.000	rs8042786	chr15:45703539	T/C	cg21132104	chr15:45694354	SPATA5L1	0.78	10.53	0.57	1.86e-21	Homoarginine levels;
SARC	cis	rs2439831	1.000	rs537115	chr15:43729948	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.08	11.12	0.59	2.58e-23	Lung cancer in ever smokers;
SARC	trans	rs11098499	0.863	rs3736115	chr4:120488703	A/G	cg25214090	chr10:38739885	LOC399744	-0.52	-6.72	-0.4	1.41e-10	Corneal astigmatism;
SARC	cis	rs9790314	0.581	rs6772578	chr3:160760851	T/A	cg03342759	chr3:160939853	NMD3	-0.42	-5.07	-0.32	8.21e-7	Morning vs. evening chronotype;
SARC	cis	rs1483890	0.723	rs13061189	chr3:69411453	T/C	cg22125112	chr3:69402811	FRMD4B	0.29	4.78	0.3	3.12e-6	Resting heart rate;
SARC	cis	rs4253772	0.513	rs9615345	chr22:46713631	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.74	7.24	0.43	6.46e-12	LDL cholesterol;Cholesterol, total;
SARC	cis	rs9329289	0.510	rs12359941	chr10:2547015	G/A	cg15501526	chr10:2543763	NA	0.37	5.68	0.35	4.03e-8	Age-related hearing impairment;
SARC	cis	rs910316	1.000	rs10136948	chr14:75511075	C/T	cg23033748	chr14:75592666	NEK9	0.35	4.79	0.3	3.03e-6	Height;
SARC	cis	rs2120019	0.938	rs13056	chr15:75312187	A/G	cg12414181	chr15:75287860	SCAMP5	-0.48	-5.53	-0.34	8.36e-8	Blood trace element (Zn levels);
SARC	cis	rs10504229	0.679	rs6474100	chr8:58031161	G/A	cg08219700	chr8:58056026	NA	0.59	5.99	0.37	7.69e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs11098499	0.619	rs28502463	chr4:120257023	T/C	cg09307838	chr4:120376055	NA	0.81	11.03	0.59	4.84e-23	Corneal astigmatism;
SARC	cis	rs992157	0.560	rs7578940	chr2:219083318	G/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.59	-7.89	-0.46	1.16e-13	Colorectal cancer;
SARC	cis	rs2235642	0.750	rs2859310	chr16:1656765	C/T	cg09065629	chr16:1709722	CRAMP1L	-0.34	-4.77	-0.3	3.27e-6	Coronary artery disease;
SARC	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg24250549	chr1:154909240	PMVK	-0.49	-6.19	-0.38	2.68e-9	Schizophrenia;
SARC	trans	rs10771431	0.810	rs10771418	chr12:9358995	A/G	cg27600084	chr12:12264075	NA	0.56	7.56	0.44	9.31e-13	Breast size;
SARC	cis	rs798554	0.610	rs1182173	chr7:2878016	C/G	cg13628971	chr7:2884303	GNA12	0.44	5.45	0.34	1.31e-7	Height;
SARC	cis	rs8067545	0.586	rs11657161	chr17:20180715	A/G	cg13482628	chr17:19912719	NA	-0.56	-7.47	-0.44	1.62e-12	Schizophrenia;
SARC	cis	rs79149102	0.579	rs28394281	chr15:75326754	C/G	cg09165964	chr15:75287851	SCAMP5	-1.03	-9.14	-0.51	3.19e-17	Lung cancer;
SARC	cis	rs10782582	0.593	rs11589276	chr1:76105545	G/A	cg10523679	chr1:76189770	ACADM	-0.4	-5.04	-0.31	9.43e-7	Daytime sleep phenotypes;
SARC	cis	rs2075371	1.000	rs2244694	chr7:133987093	C/T	cg00033643	chr7:134001901	SLC35B4	0.39	4.77	0.3	3.25e-6	Mean platelet volume;
SARC	cis	rs2777491	0.872	rs61037359	chr15:41585926	T/C	cg01768344	chr15:41576519	LOC729082	0.44	4.96	0.31	1.36e-6	Ulcerative colitis;
SARC	cis	rs10791323	0.592	rs2851115	chr11:133705381	C/A	cg14349672	chr11:133703707	NA	-0.4	-5.81	-0.36	2.01e-8	Childhood ear infection;
SARC	cis	rs11190604	1.000	rs2489037	chr10:102319918	A/G	cg07080220	chr10:102295463	HIF1AN	-0.88	-9.23	-0.52	1.68e-17	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs2425143	0.512	rs2425126	chr20:34331730	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-6.82	-0.41	7.56e-11	Blood protein levels;
SARC	cis	rs6582630	0.516	rs12814528	chr12:38296111	G/A	cg26384229	chr12:38710491	ALG10B	-0.62	-7.76	-0.45	2.61e-13	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1215050	0.791	rs1506438	chr4:98789542	C/T	cg05340658	chr4:99064831	C4orf37	0.45	6.03	0.37	6.53e-9	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs7959452	0.640	rs4761154	chr12:69705362	A/G	cg14784868	chr12:69753453	YEATS4	-0.44	-5.74	-0.35	2.96e-8	Blood protein levels;
SARC	cis	rs3099143	0.901	rs1813479	chr15:77168646	T/C	cg21673338	chr15:77095150	SCAPER	0.6	5.09	0.32	7.43e-7	Recalcitrant atopic dermatitis;
SARC	cis	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg03213289	chr20:61660250	NA	0.46	6.37	0.39	9.75e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs2486288	0.586	rs12909625	chr15:45572053	C/A	cg19305227	chr15:45544335	SLC28A2	0.3	5.63	0.35	5.06e-8	Glomerular filtration rate;
SARC	cis	rs10189230	1.000	rs10189230	chr2:222357961	T/A	cg14652038	chr2:222343519	EPHA4	0.44	5.74	0.35	2.89e-8	Urate levels in lean individuals;
SARC	cis	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg08045932	chr20:61659980	NA	0.5	6.84	0.41	7.06e-11	Prostate cancer (SNP x SNP interaction);
SARC	trans	rs9929218	0.748	rs34592833	chr16:68739125	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.65	-8.19	-0.47	1.77e-14	Colorectal cancer;
SARC	cis	rs7000551	0.751	rs2461490	chr8:22370115	G/C	cg12081754	chr8:22256438	SLC39A14	0.55	7.77	0.45	2.47e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs2290720	0.930	rs10778112	chr12:101713020	T/C	cg22051763	chr12:101673672	UTP20	-0.42	-5.05	-0.31	9.05e-7	Brain structure (hippocampal volume);
SARC	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg14582100	chr15:45693742	SPATA5L1	0.35	4.91	0.31	1.69e-6	Homoarginine levels;
SARC	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg03213289	chr20:61660250	NA	0.44	6.21	0.38	2.43e-9	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs9911578	1.000	rs2333332	chr17:56631054	A/G	cg05425664	chr17:57184151	TRIM37	0.66	8.19	0.47	1.68e-14	Intelligence (multi-trait analysis);
SARC	cis	rs7772486	0.686	rs2142983	chr6:146069701	G/C	cg05347473	chr6:146136440	FBXO30	-0.52	-7.24	-0.43	6.47e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs599083	0.530	rs2508834	chr11:68175354	C/T	cg01657329	chr11:68192670	LRP5	0.46	6.24	0.38	2.09e-9	Bone mineral density (spine);
SARC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	0.32	4.89	0.31	1.85e-6	Total body bone mineral density;
SARC	cis	rs2729354	0.514	rs1967179	chr11:57348483	C/T	cg02147041	chr11:57308142	SMTNL1	0.31	4.9	0.31	1.8e-6	Blood protein levels;
SARC	cis	rs7681440	0.904	rs1822217	chr4:90765052	C/T	cg06632027	chr4:90757378	SNCA	0.39	5.66	0.35	4.49e-8	Dementia with Lewy bodies;
SARC	cis	rs10256972	0.626	rs62433138	chr7:1050877	T/C	cg07308232	chr7:1071921	C7orf50	-0.44	-5.32	-0.33	2.49e-7	Longevity;Endometriosis;
SARC	cis	rs3740540	0.530	rs2362505	chr10:126290739	T/G	cg04949429	chr10:126290192	LHPP	0.42	5.92	0.36	1.16e-8	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9790314	1.000	rs464766	chr3:161087592	C/G	cg03342759	chr3:160939853	NMD3	-0.58	-7.44	-0.44	1.97e-12	Morning vs. evening chronotype;
SARC	cis	rs12142240	0.698	rs67487250	chr1:46811333	T/C	cg10495392	chr1:46806563	NSUN4	0.65	6.8	0.41	8.47e-11	Menopause (age at onset);
SARC	cis	rs651907	0.535	rs61396602	chr3:101509046	T/C	cg12386194	chr3:101231763	SENP7	0.49	5.59	0.34	6.28e-8	Colorectal cancer;
SARC	cis	rs4718428	0.672	rs13241598	chr7:66300652	A/G	cg18252515	chr7:66147081	NA	-0.58	-6.36	-0.38	1.06e-9	Corneal structure;
SARC	cis	rs523522	0.962	rs11065145	chr12:120947419	A/G	cg12219531	chr12:120966889	COQ5	0.84	11.36	0.6	4.3e-24	High light scatter reticulocyte count;
SARC	cis	rs6062302	0.522	rs11696202	chr20:62246292	G/C	cg09650180	chr20:62225654	GMEB2	-0.45	-5.55	-0.34	7.75e-8	Glioblastoma;
SARC	cis	rs875971	0.545	rs10950036	chr7:65818228	G/T	cg25894440	chr7:65020034	NA	0.53	4.97	0.31	1.31e-6	Aortic root size;
SARC	cis	rs12155623	0.619	rs11775403	chr8:49877323	A/T	cg01449144	chr8:49782592	NA	0.31	5.11	0.32	6.57e-7	Sudden cardiac arrest;
SARC	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg21724239	chr8:58056113	NA	0.65	5.93	0.36	1.1e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs734999	0.545	rs4474198	chr1:2553758	C/T	cg18854424	chr1:2615690	NA	0.3	4.77	0.3	3.3e-6	Ulcerative colitis;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg16294570	chr8:16858909	FGF20	-0.51	-7.07	-0.42	1.82e-11	Thyroid stimulating hormone;
SARC	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg17509989	chr5:176798049	RGS14	-0.82	-11.71	-0.61	3.17e-25	Hemoglobin concentration;Hematocrit;
SARC	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg02524346	chr8:600233	NA	0.83	6.29	0.38	1.57e-9	IgG glycosylation;
SARC	trans	rs11098499	0.954	rs6857105	chr4:120222298	C/G	cg25214090	chr10:38739885	LOC399744	0.55	7.1	0.42	1.48e-11	Corneal astigmatism;
SARC	cis	rs2075371	0.932	rs2544215	chr7:133987896	T/C	cg11752832	chr7:134001865	SLC35B4	0.57	7.44	0.44	1.98e-12	Mean platelet volume;
SARC	cis	rs1008375	0.863	rs2058336	chr4:17608299	T/C	cg02297831	chr4:17616191	MED28	0.51	6.46	0.39	6.19e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7588746	0.868	rs12104649	chr2:201128832	C/T	cg23649088	chr2:200775458	C2orf69	-0.66	-7.56	-0.44	9.17e-13	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg00409905	chr10:38381863	ZNF37A	-0.49	-6.53	-0.39	4.01e-10	Extrinsic epigenetic age acceleration;
SARC	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.92	-10.05	-0.55	5.82e-20	Alzheimer's disease;
SARC	cis	rs7553864	1.000	rs4514217	chr1:87614094	G/A	cg17420885	chr1:87600446	LOC339524	-0.32	-4.74	-0.3	3.76e-6	Smoking behavior;
SARC	cis	rs796364	0.951	rs281793	chr2:200847990	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.78	7.31	0.43	4.37e-12	Schizophrenia;
SARC	cis	rs5167	0.534	rs56803710	chr19:45481884	C/T	cg13119609	chr19:45449297	APOC2	0.39	5.53	0.34	8.77e-8	Blood protein levels;
SARC	cis	rs921968	0.565	rs12694439	chr2:219590871	A/G	cg02176678	chr2:219576539	TTLL4	-0.33	-5.07	-0.32	8.2e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs9581857	0.685	rs17808758	chr13:28036412	C/T	cg01674679	chr13:27998804	GTF3A	-0.61	-4.76	-0.3	3.4e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	cis	rs67478160	0.619	rs11623546	chr14:104269098	A/G	cg26031613	chr14:104095156	KLC1	-0.4	-4.79	-0.3	3e-6	Schizophrenia;
SARC	trans	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg06437703	chr8:37914619	EIF4EBP1	-0.57	-7.61	-0.45	6.72e-13	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs1023500	0.505	rs134901	chr22:42683520	C/T	cg15557168	chr22:42548783	NA	-0.4	-5.59	-0.34	6.44e-8	Schizophrenia;
SARC	cis	rs1355223	0.545	rs7106831	chr11:34879542	T/C	cg11622362	chr11:34938112	PDHX;APIP	0.46	5.93	0.36	1.1e-8	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs6782228	0.606	rs1127030	chr3:128338953	T/C	cg08795948	chr3:128337044	NA	0.36	4.82	0.3	2.55e-6	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
SARC	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg22618164	chr12:122356400	WDR66	0.43	6.81	0.41	8.3e-11	Mean corpuscular volume;
SARC	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	8.71	0.5	5.56e-16	Alzheimer's disease;
SARC	cis	rs356220	0.656	rs356217	chr4:90636803	G/T	cg06632027	chr4:90757378	SNCA	0.39	5.0	0.31	1.13e-6	Parkinson's disease;
SARC	cis	rs897080	0.515	rs1067331	chr2:44627626	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.62	7.48	0.44	1.52e-12	Height;
SARC	cis	rs13392177	0.647	rs10932761	chr2:219064391	T/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.56	-6.98	-0.42	2.98e-11	Pyoderma gangrenosum in inflammatory bowel disease;
SARC	cis	rs7178572	0.568	rs12913233	chr15:77543297	C/T	cg22256960	chr15:77711686	NA	-0.51	-5.54	-0.34	8.16e-8	Type 2 diabetes;
SARC	trans	rs7824557	0.688	rs2572397	chr8:11176403	G/A	cg15556689	chr8:8085844	FLJ10661	0.54	6.86	0.41	6.28e-11	Retinal vascular caliber;
SARC	cis	rs10791323	0.572	rs1114367	chr11:133737304	G/T	cg15485101	chr11:133734466	NA	0.32	5.05	0.31	9.07e-7	Childhood ear infection;
SARC	cis	rs473651	0.740	rs502349	chr2:239318389	C/T	cg18131467	chr2:239335373	ASB1	0.85	13.3	0.66	2.04e-30	Multiple system atrophy;
SARC	cis	rs35213789	0.708	rs2533443	chr7:69099111	A/T	cg10619644	chr7:69149951	AUTS2	-0.37	-4.94	-0.31	1.48e-6	Childhood ear infection;
SARC	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg11965913	chr1:205819406	PM20D1	-0.51	-5.55	-0.34	7.76e-8	White blood cell count (basophil);Basophil percentage of white cells;
SARC	cis	rs240764	0.853	rs12660725	chr6:100978570	C/T	cg09795085	chr6:101329169	ASCC3	-0.46	-6.04	-0.37	5.97e-9	Neuroticism;
SARC	cis	rs1580019	0.563	rs896137	chr7:32579345	G/T	cg07520158	chr7:32535189	LSM5;AVL9	0.6	7.66	0.45	4.81e-13	Cognitive ability;
SARC	cis	rs2153535	0.580	rs9328488	chr6:8529411	G/C	cg23788917	chr6:8435910	SLC35B3	0.61	8.19	0.47	1.75e-14	Motion sickness;
SARC	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	10.83	0.58	2.15e-22	Platelet count;
SARC	cis	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg15556689	chr8:8085844	FLJ10661	0.58	7.38	0.44	2.83e-12	Joint mobility (Beighton score);
SARC	cis	rs425277	0.958	rs262688	chr1:2113565	T/G	cg21442419	chr1:2182373	SKI	-0.53	-6.79	-0.41	9.33e-11	Height;
SARC	cis	rs6909279	0.678	rs11155795	chr6:151851339	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.48	5.96	0.36	9.34e-9	Bone mineral density;
SARC	cis	rs356220	0.656	rs356208	chr4:90635453	A/T	cg06632027	chr4:90757378	SNCA	0.39	5.0	0.31	1.13e-6	Parkinson's disease;
SARC	cis	rs12451471	0.637	rs12950757	chr17:78096800	T/G	cg24585782	chr17:78113791	EIF4A3	-0.55	-6.1	-0.37	4.48e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
SARC	cis	rs9325144	0.555	rs4882359	chr12:38726679	T/C	cg13010199	chr12:38710504	ALG10B	0.55	7.05	0.42	2.04e-11	Morning vs. evening chronotype;
SARC	cis	rs9398803	0.605	rs112166936	chr6:126733140	A/C	cg19875578	chr6:126661172	C6orf173	0.58	7.78	0.45	2.37e-13	Male-pattern baldness;
SARC	cis	rs9814567	1.000	rs12490835	chr3:134223730	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-7.08	-0.42	1.7e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs3092073	0.617	rs56324610	chr20:44564030	G/C	cg00981651	chr20:44574847	PCIF1	-0.32	-5.05	-0.31	9.12e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2404602	0.647	rs36114653	chr15:77025393	G/A	cg15268244	chr15:77196840	NA	0.45	5.23	0.32	3.85e-7	Blood metabolite levels;
SARC	cis	rs965469	0.779	rs6051740	chr20:3301165	T/C	cg25506879	chr20:3388711	C20orf194	-0.45	-4.96	-0.31	1.37e-6	IFN-related cytopenia;
SARC	cis	rs2032447	0.613	rs6456708	chr6:26032847	G/C	cg02841227	chr6:26021843	HIST1H4A	0.48	6.19	0.38	2.62e-9	Intelligence (multi-trait analysis);
SARC	cis	rs6912958	0.781	rs6916732	chr6:88259225	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.52	-7.08	-0.42	1.66e-11	Monocyte percentage of white cells;
SARC	cis	rs1707322	1.000	rs4298677	chr1:46306619	G/A	cg06784218	chr1:46089804	CCDC17	0.33	5.76	0.35	2.69e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9381107	0.505	rs9394957	chr6:9484928	C/G	cg14735645	chr6:9486422	NA	-0.49	-5.77	-0.35	2.49e-8	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs2153535	0.580	rs718503	chr6:8527463	A/T	cg07606381	chr6:8435919	SLC35B3	0.74	10.6	0.57	1.12e-21	Motion sickness;
SARC	cis	rs7949030	1.000	rs10897289	chr11:62400016	T/C	cg22862634	chr11:62369728	EML3;MTA2	0.46	6.66	0.4	2e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs11098499	0.774	rs73842616	chr4:120290683	G/A	cg09307838	chr4:120376055	NA	0.83	11.82	0.61	1.46e-25	Corneal astigmatism;
SARC	cis	rs1348850	0.634	rs1534304	chr2:178489264	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.52	5.38	0.33	1.85e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	trans	rs9427116	0.502	rs12125166	chr1:154582129	A/G	cg01630567	chr9:26892919	C9orf82	-0.53	-6.63	-0.4	2.28e-10	Blood protein levels;
SARC	cis	rs11122272	0.701	rs2790887	chr1:231523724	G/C	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs6912958	0.712	rs6908386	chr6:88354746	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-6.42	-0.39	7.39e-10	Monocyte percentage of white cells;
SARC	cis	rs7605378	1.000	rs796363	chr2:200693668	T/C	cg23649088	chr2:200775458	C2orf69	0.53	6.16	0.37	3.13e-9	Osteoporosis;
SARC	cis	rs4242434	0.672	rs900267	chr8:22485258	T/C	cg03733263	chr8:22462867	KIAA1967	0.88	14.02	0.68	8.81e-33	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs7829975	0.511	rs1543238	chr8:8134809	A/G	cg11608241	chr8:8085544	FLJ10661	0.43	5.33	0.33	2.31e-7	Mood instability;
SARC	cis	rs7027203	0.557	rs2487015	chr9:96521240	T/G	cg14598338	chr9:96623480	NA	-0.34	-4.76	-0.3	3.43e-6	DNA methylation (variation);
SARC	cis	rs921968	0.643	rs471846	chr2:219432237	C/T	cg02176678	chr2:219576539	TTLL4	0.37	5.49	0.34	1.02e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg16405210	chr4:1374714	KIAA1530	0.85	11.57	0.6	9.42e-25	Longevity;
SARC	cis	rs35213789	0.513	rs9647925	chr7:68965029	G/A	cg10619644	chr7:69149951	AUTS2	0.34	4.72	0.3	4.02e-6	Childhood ear infection;
SARC	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.43	5.16	0.32	5.38e-7	Bipolar disorder;
SARC	cis	rs7084402	0.967	rs7921371	chr10:60330531	G/C	cg07615347	chr10:60278583	BICC1	-0.51	-7.33	-0.43	3.88e-12	Refractive error;
SARC	cis	rs72653721	0.938	rs12529809	chr6:10980639	C/T	cg13562911	chr6:11044106	ELOVL2	0.53	5.79	0.35	2.21e-8	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	trans	rs36093844	0.706	rs79814326	chr11:85585573	A/G	cg27065003	chr5:122429449	PRDM6	-0.55	-6.54	-0.39	3.91e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs6456156	0.586	rs9459862	chr6:167487011	A/G	cg23791538	chr6:167370224	RNASET2	0.5	6.66	0.4	1.96e-10	Primary biliary cholangitis;
SARC	cis	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg14541582	chr5:601475	NA	-0.44	-5.22	-0.32	3.96e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs6815814	0.950	rs66922907	chr4:38812537	A/G	cg06935464	chr4:38784597	TLR10	0.61	5.97	0.36	8.8e-9	Breast cancer;
SARC	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg16325326	chr1:53192061	ZYG11B	-0.83	-13.35	-0.66	1.47e-30	Monocyte count;
SARC	cis	rs10089	0.953	rs4835940	chr5:127406596	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.85	10.23	0.56	1.55e-20	Ileal carcinoids;
SARC	cis	rs526231	0.543	rs26525	chr5:102464923	G/C	cg23492399	chr5:102201601	PAM	-0.51	-5.55	-0.34	7.77e-8	Primary biliary cholangitis;
SARC	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg20891283	chr12:69753455	YEATS4	0.54	7.43	0.44	2.04e-12	Blood protein levels;
SARC	cis	rs4481887	0.927	rs4345830	chr1:248474845	G/C	cg13385794	chr1:248469461	NA	0.35	5.45	0.34	1.29e-7	Common traits (Other);
SARC	cis	rs11190604	1.000	rs11292	chr10:102313607	A/G	cg07080220	chr10:102295463	HIF1AN	0.82	9.52	0.53	2.38e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg05368731	chr17:41323189	NBR1	0.74	9.0	0.51	8.38e-17	Menopause (age at onset);
SARC	cis	rs7666738	0.576	rs7660951	chr4:98651581	T/A	cg05340658	chr4:99064831	C4orf37	0.58	7.03	0.42	2.24e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7927592	0.763	rs624003	chr11:68231240	C/T	cg01657329	chr11:68192670	LRP5	-0.35	-4.82	-0.3	2.55e-6	Total body bone mineral density;
SARC	cis	rs7223966	1.000	rs8066719	chr17:61825764	C/T	cg26338869	chr17:61819248	STRADA	0.47	5.0	0.31	1.13e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs17095355	1.000	rs12247564	chr10:111721400	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.42	-4.81	-0.3	2.65e-6	Biliary atresia;
SARC	cis	rs7615952	0.688	rs7624806	chr3:125599074	G/A	cg05084668	chr3:125655381	ALG1L	-0.57	-5.8	-0.36	2.17e-8	Blood pressure (smoking interaction);
SARC	cis	rs6060717	0.536	rs11697851	chr20:34524494	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.62	4.95	0.31	1.44e-6	Hip circumference adjusted for BMI;
SARC	cis	rs3126085	1.000	rs11204971	chr1:152259078	A/G	cg03465714	chr1:152285911	FLG	0.46	4.84	0.3	2.31e-6	Atopic dermatitis;
SARC	cis	rs2153535	0.580	rs9406161	chr6:8466144	G/T	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	cis	rs9547692	1.000	rs2147167	chr13:37467404	G/A	cg01493522	chr13:37497338	NA	-0.43	-4.81	-0.3	2.68e-6	Coronary artery disease;
SARC	cis	rs34779708	0.931	rs4934723	chr10:35381763	A/G	cg03585969	chr10:35415529	CREM	0.41	4.98	0.31	1.21e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs13191362	0.810	rs35509380	chr6:163053028	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.64	5.59	0.34	6.38e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs9503598	0.636	rs7745968	chr6:3467745	G/T	cg00476032	chr6:3446245	SLC22A23	0.39	6.14	0.37	3.47e-9	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
SARC	cis	rs3091242	0.809	rs660129	chr1:25727438	C/T	cg03650068	chr1:25596491	NA	0.34	5.24	0.32	3.62e-7	Erythrocyte sedimentation rate;
SARC	cis	rs2425143	1.000	rs12480408	chr20:34234800	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-5.55	-0.34	7.91e-8	Blood protein levels;
SARC	cis	rs9462027	0.628	rs11757370	chr6:34760736	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.85	-0.36	1.63e-8	Systemic lupus erythematosus;
SARC	cis	rs9640161	0.830	rs7800196	chr7:150061534	C/G	cg10018233	chr7:150070692	REPIN1	0.7	10.51	0.57	2.2e-21	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg06108461	chr20:60628389	TAF4	-0.92	-12.7	-0.64	1.92e-28	Body mass index;
SARC	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg18252515	chr7:66147081	NA	0.49	5.2	0.32	4.43e-7	Aortic root size;
SARC	cis	rs2997447	0.846	rs61775416	chr1:26393329	C/T	cg19633962	chr1:26362018	EXTL1	-0.7	-5.51	-0.34	9.68e-8	QRS complex (12-leadsum);
SARC	cis	rs10875746	0.669	rs11168459	chr12:48596241	A/G	cg26205652	chr12:48591994	NA	0.47	5.19	0.32	4.47e-7	Longevity (90 years and older);
SARC	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg19671926	chr4:122722719	EXOSC9	-0.57	-6.44	-0.39	6.6e-10	Type 2 diabetes;
SARC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.44	0.53	3.96e-18	Prudent dietary pattern;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg27228074	chr10:104678015	CNNM2	-0.79	-6.33	-0.38	1.24e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7666738	0.861	rs28829607	chr4:98964325	G/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2180341	0.924	rs9285459	chr6:127631113	T/C	cg24812749	chr6:127587940	RNF146	0.97	12.89	0.65	4.63e-29	Breast cancer;
SARC	cis	rs611744	0.647	rs631775	chr8:109252746	T/C	cg21045802	chr8:109455806	TTC35	0.6	7.56	0.44	8.95e-13	Dupuytren's disease;
SARC	cis	rs1059312	1.000	rs7970815	chr12:129288366	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.5	-6.05	-0.37	5.87e-9	Systemic lupus erythematosus;
SARC	cis	rs6882046	0.513	rs42850	chr5:88019474	G/A	cg22951263	chr5:87985283	NA	-0.36	-4.78	-0.3	3.16e-6	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
SARC	cis	rs2425143	0.632	rs7270009	chr20:34433561	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-5.17	-0.32	5.07e-7	Blood protein levels;
SARC	cis	rs7296418	0.961	rs12425850	chr12:123501972	T/C	cg00376283	chr12:123451042	ABCB9	0.67	8.64	0.49	9.3e-16	Platelet count;
SARC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg07414643	chr4:187882934	NA	0.48	6.95	0.41	3.61e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.73	8.51	0.49	2.1e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9902453	1.000	rs4581755	chr17:28427898	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	6.71	0.4	1.5e-10	Coffee consumption (cups per day);
SARC	cis	rs796364	0.906	rs281784	chr2:200749749	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.74	6.53	0.39	4.05e-10	Schizophrenia;
SARC	cis	rs6991838	0.557	rs13266834	chr8:66543538	C/A	cg13398993	chr8:66546079	ARMC1	0.62	8.19	0.47	1.72e-14	Intelligence (multi-trait analysis);
SARC	cis	rs9916302	0.904	rs7503705	chr17:37669704	A/G	cg15445000	chr17:37608096	MED1	0.4	4.74	0.3	3.8e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs2072499	0.838	rs2758619	chr1:156162559	A/G	cg25208724	chr1:156163844	SLC25A44	0.92	12.68	0.64	2.29e-28	Testicular germ cell tumor;
SARC	cis	rs8114671	0.836	rs62213676	chr20:33612676	T/A	cg24642439	chr20:33292090	TP53INP2	-0.51	-5.97	-0.36	8.85e-9	Height;
SARC	cis	rs28530618	0.580	rs11167174	chr20:31248879	G/A	cg13636640	chr20:31349939	DNMT3B	-0.43	-4.96	-0.31	1.35e-6	Birth weight;
SARC	cis	rs17376456	0.542	rs17083380	chr5:93170476	C/G	cg25358565	chr5:93447407	FAM172A	-0.76	-8.46	-0.48	2.91e-15	Diabetic retinopathy;
SARC	cis	rs7599312	0.534	rs6735626	chr2:213403972	G/A	cg16329650	chr2:213403929	ERBB4	0.7	10.61	0.57	1.03e-21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg22903471	chr2:27725779	GCKR	-0.49	-7.45	-0.44	1.81e-12	Total body bone mineral density;
SARC	trans	rs2816316	0.583	rs1323295	chr1:192537686	A/G	cg02079908	chr2:42411760	EML4	-0.5	-6.28	-0.38	1.68e-9	Celiac disease;
SARC	cis	rs3204955	0.918	rs4614259	chr1:116244298	C/A	cg20810993	chr1:116250018	CASQ2	-0.52	-5.4	-0.33	1.66e-7	Itch intensity from mosquito bite adjusted by bite size;
SARC	cis	rs1153858	0.723	rs1719238	chr15:45594766	C/T	cg15395560	chr15:45543142	SLC28A2	0.29	5.19	0.32	4.6e-7	Homoarginine levels;
SARC	cis	rs4443100	0.958	rs5996455	chr22:23379255	G/A	cg14186256	chr22:23484241	RTDR1	0.48	4.99	0.31	1.19e-6	Serum parathyroid hormone levels;
SARC	cis	rs5167	0.566	rs934427	chr19:45478816	T/G	cg13119609	chr19:45449297	APOC2	0.38	5.49	0.34	1.06e-7	Blood protein levels;
SARC	cis	rs7904368	0.806	rs7899853	chr10:16857603	A/T	cg14835575	chr10:16859367	RSU1	0.88	9.3	0.52	1.08e-17	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg08564027	chr20:61660810	NA	0.76	11.8	0.61	1.69e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs797680	0.598	rs3754186	chr1:93711782	T/A	cg01538778	chr1:93646459	TMED5;CCDC18	0.4	4.81	0.3	2.72e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;
SARC	cis	rs11264799	0.520	rs2777965	chr1:157550417	A/C	cg18268488	chr1:157545234	FCRL4	0.32	5.81	0.36	2.01e-8	IgA nephropathy;
SARC	cis	rs4742903	1.000	rs4742906	chr9:106857078	A/G	cg14250997	chr9:106856677	SMC2	0.52	6.86	0.41	6.13e-11	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs17376456	1.000	rs12188453	chr5:93560807	G/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.59	-5.22	-0.32	3.94e-7	Diabetic retinopathy;
SARC	cis	rs10861342	1.000	rs11112390	chr12:105542200	A/C	cg23923672	chr12:105501055	KIAA1033	0.71	5.61	0.34	5.77e-8	IgG glycosylation;
SARC	cis	rs2153535	0.580	rs6921964	chr6:8446395	A/G	cg21535247	chr6:8435926	SLC35B3	0.57	7.04	0.42	2.19e-11	Motion sickness;
SARC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.53	6.8	0.41	8.51e-11	Lymphocyte counts;
SARC	cis	rs11169225	0.724	rs7305290	chr12:50341465	A/G	cg23855989	chr12:50355821	AQP5	0.36	4.95	0.31	1.45e-6	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs72945132	0.882	rs55738915	chr11:70190019	C/T	cg00319359	chr11:70116639	PPFIA1	0.69	6.25	0.38	1.92e-9	Coronary artery disease;
SARC	cis	rs1451375	0.617	rs2876829	chr7:50566762	A/G	cg18232548	chr7:50535776	DDC	0.46	4.78	0.3	3.17e-6	Malaria;
SARC	cis	rs7829975	0.509	rs2945269	chr8:8115578	G/C	cg15556689	chr8:8085844	FLJ10661	0.59	7.18	0.43	9.09e-12	Mood instability;
SARC	cis	rs9487051	0.872	rs9374079	chr6:109609619	A/G	cg01475377	chr6:109611718	NA	-0.41	-5.92	-0.36	1.13e-8	Reticulocyte fraction of red cells;
SARC	cis	rs9393777	0.588	rs9467772	chr6:26496578	A/T	cg12826209	chr6:26865740	GUSBL1	0.82	8.25	0.48	1.13e-14	Intelligence (multi-trait analysis);
SARC	cis	rs11098499	0.866	rs9995136	chr4:120286845	A/G	cg09307838	chr4:120376055	NA	0.83	11.82	0.61	1.46e-25	Corneal astigmatism;
SARC	cis	rs3741151	0.656	rs11544311	chr11:73106237	A/C	cg17517138	chr11:73019481	ARHGEF17	0.9	6.7	0.4	1.59e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs4713118	0.513	rs149959	chr6:28013854	T/C	cg26335602	chr6:28129616	ZNF389	0.46	5.24	0.32	3.62e-7	Parkinson's disease;
SARC	cis	rs778371	0.697	rs6717048	chr2:233586427	T/C	cg16596103	chr2:233749413	NGEF	-0.37	-5.74	-0.35	3e-8	Schizophrenia;
SARC	cis	rs7666738	0.830	rs4443293	chr4:99063120	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.7	0.5	6.15e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs12348691	0.503	rs894672	chr9:100612185	C/T	cg13688889	chr9:100608707	NA	-0.47	-4.96	-0.31	1.36e-6	Alopecia areata;
SARC	cis	rs9896052	0.608	rs61264861	chr17:73459278	T/C	cg27037648	chr17:73511087	CASKIN2	0.4	4.74	0.3	3.67e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs477692	1.000	rs473771	chr10:131408155	A/C	cg05714579	chr10:131428358	MGMT	0.58	7.64	0.45	5.79e-13	Response to temozolomide;
SARC	cis	rs9858542	0.953	rs35115732	chr3:49475155	T/C	cg03060546	chr3:49711283	APEH	-0.58	-7.1	-0.42	1.49e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs6696846	0.905	rs12117194	chr1:205040943	C/G	cg21643547	chr1:205240462	TMCC2	0.45	5.87	0.36	1.47e-8	Red blood cell count;
SARC	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg10792982	chr14:105748885	BRF1	0.49	7.57	0.44	8.67e-13	Mean platelet volume;Platelet distribution width;
SARC	cis	rs9916302	0.808	rs12943928	chr17:37611330	G/A	cg20243544	chr17:37824526	PNMT	0.56	6.73	0.4	1.32e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg20607798	chr8:58055168	NA	0.53	5.01	0.31	1.09e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs5760092	0.755	rs6003959	chr22:24264395	C/T	cg01238044	chr22:24384105	GSTT1	0.68	7.29	0.43	4.68e-12	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg05313129	chr8:58192883	C8orf71	-0.65	-6.45	-0.39	6.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg16479474	chr6:28041457	NA	-0.37	-5.87	-0.36	1.46e-8	Depression;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg19698099	chr2:189897254	COL5A2	0.5	7.01	0.42	2.55e-11	Thyroid stimulating hormone;
SARC	cis	rs2816062	0.760	rs2745319	chr1:18895078	G/A	cg10574377	chr1:18908098	NA	0.35	4.94	0.31	1.51e-6	Urate levels in lean individuals;
SARC	trans	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg21659725	chr3:3221576	CRBN	0.54	6.26	0.38	1.79e-9	Resting heart rate;
SARC	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg11843238	chr5:131593191	PDLIM4	0.41	5.08	0.32	7.81e-7	Breast cancer;
SARC	cis	rs11608355	0.597	rs2304548	chr12:109795166	T/G	cg19025524	chr12:109796872	NA	-0.48	-6.85	-0.41	6.57e-11	Neuroticism;
SARC	cis	rs533581	0.866	rs475796	chr16:88970776	C/G	cg16701003	chr16:89028210	CBFA2T3	0.4	5.97	0.36	8.92e-9	Social autistic-like traits;
SARC	cis	rs9747201	0.962	rs34016823	chr17:80095428	G/T	cg09264619	chr17:80180166	NA	0.49	5.76	0.35	2.64e-8	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs17021463	0.844	rs17311008	chr4:95274653	A/G	cg11021082	chr4:95130006	SMARCAD1	0.41	5.86	0.36	1.58e-8	Testicular germ cell tumor;
SARC	cis	rs765787	0.530	rs10851423	chr15:45515950	G/A	cg24006582	chr15:45444508	DUOX1	0.44	5.49	0.34	1.04e-7	Uric acid levels;
SARC	cis	rs11758351	1.000	rs16891401	chr6:26202337	G/A	cg23601095	chr6:26197514	HIST1H3D	0.62	5.34	0.33	2.24e-7	Gout;Renal underexcretion gout;
SARC	cis	rs13392177	0.684	rs6720105	chr2:219080718	G/A	cg00012203	chr2:219082015	ARPC2	-0.69	-9.47	-0.53	3.19e-18	Pyoderma gangrenosum in inflammatory bowel disease;
SARC	cis	rs7255436	0.965	rs11668346	chr19:8450854	A/T	cg10174797	chr19:8464628	RAB11B	0.45	6.44	0.39	6.84e-10	HDL cholesterol;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg13828592	chr12:122751068	VPS33A	0.62	6.34	0.38	1.16e-9	Lung cancer in ever smokers;
SARC	cis	rs17270561	0.609	rs4132072	chr6:25717843	C/T	cg16482183	chr6:26056742	HIST1H1C	0.42	5.1	0.32	6.96e-7	Iron status biomarkers;
SARC	cis	rs796364	1.000	rs281760	chr2:200787804	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.76	6.9	0.41	4.82e-11	Schizophrenia;
SARC	cis	rs926938	0.608	rs360612	chr1:115394747	G/A	cg12756093	chr1:115239321	AMPD1	0.39	5.12	0.32	6.42e-7	Autism;
SARC	cis	rs4423214	1.000	rs28364617	chr11:71159764	T/G	cg24826892	chr11:71159390	DHCR7	0.46	5.56	0.34	7.31e-8	Vitamin D levels;
SARC	cis	rs1008375	0.966	rs4235392	chr4:17696422	A/G	cg16339924	chr4:17578868	LAP3	0.52	6.67	0.4	1.8e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs910316	1.000	rs175426	chr14:75624134	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.52	-7.28	-0.43	5e-12	Height;
SARC	trans	rs12310956	0.532	rs11052920	chr12:33955891	T/G	cg26384229	chr12:38710491	ALG10B	0.73	10.21	0.56	1.84e-20	Morning vs. evening chronotype;
SARC	cis	rs897080	0.794	rs2341456	chr2:44759941	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.43	4.99	0.31	1.2e-6	Height;
SARC	cis	rs11098499	0.954	rs7654587	chr4:120388406	C/T	cg09307838	chr4:120376055	NA	0.9	12.52	0.63	7.73e-28	Corneal astigmatism;
SARC	cis	rs7666738	0.830	rs1426667	chr4:98949772	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4944092	0.855	rs596339	chr11:75916507	T/C	cg04588336	chr11:75916460	WNT11	-0.47	-6.33	-0.38	1.24e-9	PR interval;
SARC	cis	rs2273669	0.667	rs75263286	chr6:109350489	G/C	cg05315195	chr6:109294784	ARMC2	-0.64	-5.7	-0.35	3.68e-8	Prostate cancer;
SARC	cis	rs910316	0.935	rs11159119	chr14:75636967	C/T	cg11812906	chr14:75593930	NEK9	-0.87	-12.65	-0.64	2.91e-28	Height;
SARC	cis	rs1949733	0.701	rs2688222	chr4:8473735	C/A	cg11789530	chr4:8429930	ACOX3	0.74	8.69	0.49	6.59e-16	Response to antineoplastic agents;
SARC	cis	rs4356932	1.000	rs8878	chr4:76942300	C/T	cg24176760	chr4:76958061	ART3;CXCL11	0.29	4.82	0.3	2.61e-6	Blood protein levels;
SARC	trans	rs61931739	0.517	rs1197562	chr12:34122037	G/A	cg13010199	chr12:38710504	ALG10B	0.7	9.63	0.53	1.12e-18	Morning vs. evening chronotype;
SARC	cis	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg06558623	chr16:89946397	TCF25	0.89	6.23	0.38	2.14e-9	Skin colour saturation;
SARC	cis	rs763121	0.853	rs6001184	chr22:39052116	C/T	cg21395723	chr22:39101663	GTPBP1	0.58	6.67	0.4	1.85e-10	Menopause (age at onset);
SARC	cis	rs3733346	0.529	rs6842493	chr4:914638	T/C	cg04824913	chr4:887549	GAK	0.41	5.09	0.32	7.31e-7	Sjögren's syndrome;
SARC	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg09323728	chr8:95962352	TP53INP1	-0.31	-5.21	-0.32	4.2e-7	Type 2 diabetes;
SARC	cis	rs56235845	0.694	rs9313758	chr5:176773091	T/G	cg06060754	chr5:176797920	RGS14	0.49	6.44	0.39	6.68e-10	Hemoglobin concentration;Hematocrit;
SARC	cis	rs262150	0.672	rs2730230	chr7:158788529	A/G	cg07977927	chr7:158815555	LOC154822	0.25	4.95	0.31	1.41e-6	Facial morphology (factor 20);
SARC	cis	rs67478160	0.619	rs3742365	chr14:104198251	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.34	-4.83	-0.3	2.53e-6	Schizophrenia;
SARC	cis	rs6910061	0.750	rs16870965	chr6:11123550	G/A	cg27233058	chr6:11094804	LOC221710	0.61	5.52	0.34	8.83e-8	Diabetic kidney disease;
SARC	cis	rs6840360	0.593	rs2175409	chr4:152701656	A/G	cg22705602	chr4:152727874	NA	-0.48	-8.68	-0.49	7.07e-16	Intelligence (multi-trait analysis);
SARC	cis	rs9640161	0.636	rs56190213	chr7:150025720	T/C	cg10018233	chr7:150070692	REPIN1	0.69	8.57	0.49	1.41e-15	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	6.98	0.42	3.08e-11	Platelet count;
SARC	cis	rs752010	0.631	rs7515066	chr1:42076915	A/G	cg06885757	chr1:42089581	HIVEP3	-0.56	-7.91	-0.46	1.03e-13	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2013441	1.000	rs34712254	chr17:20049308	C/T	cg13482628	chr17:19912719	NA	0.48	6.2	0.38	2.58e-9	Obesity-related traits;
SARC	cis	rs4132509	0.744	rs12021907	chr1:243995640	A/G	cg21452805	chr1:244014465	NA	-0.6	-6.32	-0.38	1.33e-9	RR interval (heart rate);
SARC	trans	rs7824557	0.836	rs765731	chr8:11121498	T/A	cg06636001	chr8:8085503	FLJ10661	-0.58	-6.94	-0.41	3.74e-11	Retinal vascular caliber;
SARC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg06074448	chr4:187884817	NA	-0.37	-5.07	-0.32	8.2e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2228479	0.850	rs17233567	chr16:89813821	G/A	cg26513180	chr16:89883248	FANCA	0.72	4.75	0.3	3.53e-6	Skin colour saturation;
SARC	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg02018176	chr4:1364513	KIAA1530	0.37	5.51	0.34	9.39e-8	Longevity;
SARC	cis	rs765787	0.530	rs2413784	chr15:45530516	A/C	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.67e-7	Uric acid levels;
SARC	cis	rs6840360	0.571	rs72728182	chr4:152487027	T/C	cg22705602	chr4:152727874	NA	-0.43	-6.66	-0.4	1.91e-10	Intelligence (multi-trait analysis);
SARC	cis	rs9398803	0.713	rs9401888	chr6:126877523	A/G	cg20229609	chr6:126660872	C6orf173	0.35	5.08	0.32	7.67e-7	Male-pattern baldness;
SARC	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg11764359	chr7:65958608	NA	-0.69	-8.18	-0.47	1.88e-14	Aortic root size;
SARC	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.71	-6.92	-0.41	4.32e-11	Platelet count;
SARC	cis	rs503734	0.502	rs348880	chr3:100981426	A/G	cg27318481	chr3:100970896	IMPG2	-0.48	-5.73	-0.35	3.12e-8	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs7614311	1.000	rs7614311	chr3:63813654	A/C	cg16258503	chr3:63850278	ATXN7;THOC7	0.47	4.77	0.3	3.22e-6	Lung function (FVC);Lung function (FEV1);
SARC	cis	rs7412746	0.621	rs7518156	chr1:150945794	A/C	cg15448220	chr1:150897856	SETDB1	0.52	6.65	0.4	2.01e-10	Melanoma;
SARC	cis	rs6570726	0.846	rs441575	chr6:145849205	A/C	cg05220968	chr6:146057943	EPM2A	-0.29	-5.04	-0.31	9.48e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2013441	1.000	rs1992562	chr17:20218793	A/C	cg13482628	chr17:19912719	NA	-0.42	-5.6	-0.34	6.13e-8	Obesity-related traits;
SARC	cis	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg18252515	chr7:66147081	NA	-1.35	-11.9	-0.61	7.81e-26	Diabetic kidney disease;
SARC	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg21724239	chr8:58056113	NA	0.63	5.99	0.37	7.96e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2014572	0.904	rs10412465	chr19:57753931	T/C	cg24459738	chr19:57751996	ZNF805	-0.49	-5.91	-0.36	1.22e-8	Hyperactive-impulsive symptoms;
SARC	cis	rs13166103	0.571	rs62366400	chr5:57765808	G/A	cg10487770	chr5:57879443	RAB3C	0.53	5.58	0.34	6.73e-8	Type 2 diabetes (age of onset);
SARC	cis	rs6582630	0.513	rs1596446	chr12:38282160	C/T	cg13010199	chr12:38710504	ALG10B	-0.76	-10.65	-0.57	7.64e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs17376456	0.877	rs7728736	chr5:93404277	C/T	cg25358565	chr5:93447407	FAM172A	1.3	14.78	0.7	2.47e-35	Diabetic retinopathy;
SARC	cis	rs425277	1.000	rs262667	chr1:2082722	T/C	cg21442419	chr1:2182373	SKI	-0.52	-6.73	-0.4	1.32e-10	Height;
SARC	cis	rs926392	0.572	rs6129157	chr20:37672247	G/T	cg16355469	chr20:37678765	NA	0.75	9.28	0.52	1.19e-17	Dialysis-related mortality;
SARC	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs13401104	0.796	rs10929169	chr2:237115532	C/T	cg19324714	chr2:237145437	ASB18	0.56	5.44	0.34	1.36e-7	Educational attainment;
SARC	cis	rs9916302	0.595	rs4795371	chr17:37636695	T/G	cg15445000	chr17:37608096	MED1	0.42	4.8	0.3	2.8e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg17376030	chr22:41985996	PMM1	0.75	9.22	0.52	1.79e-17	Vitiligo;
SARC	cis	rs6964587	1.000	rs6946356	chr7:91727385	G/A	cg17063962	chr7:91808500	NA	0.96	16.21	0.73	4.62e-40	Breast cancer;
SARC	cis	rs4742903	0.870	rs1354894	chr9:106975237	G/A	cg14250997	chr9:106856677	SMC2	0.42	5.21	0.32	4.06e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs3733585	0.805	rs882222	chr4:9981294	G/A	cg00071950	chr4:10020882	SLC2A9	0.4	6.43	0.39	7.09e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg10862848	chr6:42927986	GNMT	0.41	6.7	0.4	1.52e-10	Alzheimer's disease in APOE e4+ carriers;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg22110492	chr9:136283026	ADAMTS13;REXO4	-0.52	-6.49	-0.39	5.11e-10	Height;
SARC	cis	rs989128	0.600	rs9913430	chr17:48628470	A/T	cg20467136	chr17:48638190	CACNA1G	0.47	5.58	0.34	6.69e-8	Type 2 diabetes;
SARC	cis	rs4803468	0.967	rs4802116	chr19:41905540	C/T	cg09537434	chr19:41945824	ATP5SL	-0.93	-15.79	-0.72	1.15e-38	Height;
SARC	cis	rs7712401	0.601	rs36099390	chr5:122317719	G/A	cg19412675	chr5:122181750	SNX24	-0.43	-5.47	-0.34	1.15e-7	Mean platelet volume;
SARC	cis	rs11690935	0.851	rs6731562	chr2:172798262	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.77	-10.71	-0.57	4.89e-22	Schizophrenia;
SARC	cis	rs17376456	0.542	rs10070350	chr5:93103753	C/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.51	5.17	0.32	5.14e-7	Diabetic retinopathy;
SARC	trans	rs1994135	0.654	rs11052759	chr12:33724126	G/A	cg26384229	chr12:38710491	ALG10B	0.85	10.48	0.57	2.72e-21	Resting heart rate;
SARC	cis	rs763121	0.853	rs3747170	chr22:39067331	G/A	cg14440974	chr22:39074834	NA	-0.34	-5.01	-0.31	1.08e-6	Menopause (age at onset);
SARC	cis	rs9291683	0.585	rs12648479	chr4:10104571	G/A	cg00071950	chr4:10020882	SLC2A9	-0.34	-5.28	-0.33	2.95e-7	Bone mineral density;
SARC	cis	rs3931020	0.688	rs277375	chr1:75204143	A/G	cg10128416	chr1:75198403	TYW3;CRYZ	0.5	5.3	0.33	2.74e-7	Resistin levels;
SARC	cis	rs1707322	1.000	rs10890377	chr1:46406594	G/A	cg03146154	chr1:46216737	IPP	0.46	5.53	0.34	8.66e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6582630	0.547	rs1589388	chr12:38416025	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-6.89	-0.41	5.04e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs8044868	0.861	rs9936642	chr16:72209519	A/G	cg16558253	chr16:72132732	DHX38	0.34	4.87	0.3	2.1e-6	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
SARC	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg11843238	chr5:131593191	PDLIM4	0.39	5.38	0.33	1.78e-7	Breast cancer;
SARC	cis	rs2304069	0.545	rs4705404	chr5:149381952	A/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.57	6.67	0.4	1.82e-10	HIV-1 control;
SARC	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg12016809	chr21:47604291	C21orf56	0.42	5.02	0.31	1.05e-6	Testicular germ cell tumor;
SARC	cis	rs208515	0.525	rs12204452	chr6:66680325	C/T	cg07460842	chr6:66804631	NA	0.96	11.01	0.59	5.47e-23	Exhaled nitric oxide levels;
SARC	cis	rs1467026	0.563	rs12629928	chr3:12811796	C/T	cg05775895	chr3:12838266	CAND2	0.62	9.08	0.51	4.69e-17	P wave duration;
SARC	cis	rs2068229	0.958	rs4683637	chr3:141587740	C/G	cg15223831	chr3:141585169	NA	-0.38	-4.74	-0.3	3.66e-6	Red cell distribution width;
SARC	cis	rs16976116	0.901	rs28864456	chr15:55503092	T/C	cg11288833	chr15:55489084	RSL24D1	0.63	6.08	0.37	4.81e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7917772	0.636	rs7894154	chr10:104524647	G/A	ch.10.2196322F	chr10:104248062	ACTR1A	-0.46	-5.4	-0.33	1.61e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs6088580	0.561	rs3761147	chr20:32996689	G/T	cg24642439	chr20:33292090	TP53INP2	-0.68	-8.73	-0.5	4.96e-16	Glomerular filtration rate (creatinine);
SARC	trans	rs11039798	0.588	rs589834	chr11:48419382	C/G	cg15704280	chr7:45808275	SEPT13	-0.61	-6.38	-0.39	9.51e-10	Axial length;
SARC	cis	rs17376456	0.825	rs10072232	chr5:93398890	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	5.68	0.35	3.93e-8	Diabetic retinopathy;
SARC	cis	rs9911578	0.900	rs717828	chr17:56535932	A/G	cg05425664	chr17:57184151	TRIM37	-0.65	-7.91	-0.46	1.06e-13	Intelligence (multi-trait analysis);
SARC	cis	rs12701220	0.504	rs12702092	chr7:1145868	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.39	-4.84	-0.3	2.39e-6	Bronchopulmonary dysplasia;
SARC	cis	rs6546550	0.935	rs1531025	chr2:70055505	G/T	cg02498382	chr2:70120550	SNRNP27	-0.39	-6.53	-0.39	3.97e-10	Prevalent atrial fibrillation;
SARC	cis	rs79149102	0.579	rs9788648	chr15:75300284	A/G	cg17294928	chr15:75287854	SCAMP5	-1.01	-9.17	-0.52	2.56e-17	Lung cancer;
SARC	cis	rs4742903	0.935	rs12351370	chr9:106928940	G/A	cg14250997	chr9:106856677	SMC2	0.44	5.5	0.34	1.01e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs6738485	0.507	rs66569888	chr2:106886967	G/A	cg15412446	chr2:106886593	NA	-0.59	-6.51	-0.39	4.61e-10	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
SARC	cis	rs11731606	0.508	rs6828270	chr4:95309212	G/A	cg00507259	chr4:95128692	SMARCAD1	0.49	4.75	0.3	3.56e-6	Mean platelet volume;
SARC	cis	rs561341	0.700	rs2074101	chr17:30228656	G/A	cg13647721	chr17:30228624	UTP6	0.72	8.41	0.48	4.23e-15	Hip circumference adjusted for BMI;
SARC	cis	rs78456975	1.000	rs7584264	chr2:1565555	A/G	cg26248373	chr2:1572462	NA	-0.56	-6.28	-0.38	1.68e-9	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg26839252	chr6:160211577	TCP1;MRPL18	-0.67	-7.23	-0.43	6.83e-12	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs611744	0.967	rs591792	chr8:109200446	T/C	cg21045802	chr8:109455806	TTC35	0.44	5.23	0.32	3.81e-7	Dupuytren's disease;
SARC	cis	rs9914988	0.613	rs7214938	chr17:27280226	A/G	cg10538030	chr17:27276405	PHF12	-0.62	-5.07	-0.32	8.01e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs7712401	0.584	rs4836382	chr5:122376641	G/A	cg19412675	chr5:122181750	SNX24	0.44	5.82	0.36	1.96e-8	Mean platelet volume;
SARC	cis	rs12155623	0.619	rs17641604	chr8:49842784	C/T	cg22283653	chr8:49824208	NA	0.35	5.07	0.32	8.13e-7	Sudden cardiac arrest;
SARC	cis	rs501120	0.584	rs11238891	chr10:44670992	A/C	cg09554077	chr10:44749378	NA	-0.44	-4.72	-0.3	4.03e-6	Coronary artery disease;Coronary heart disease;
SARC	cis	rs10979	0.964	rs9321922	chr6:143895231	A/G	cg25407410	chr6:143891975	LOC285740	-0.64	-8.78	-0.5	3.67e-16	Hypospadias;
SARC	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg05313129	chr8:58192883	C8orf71	-0.57	-6.54	-0.39	3.75e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg12463550	chr7:65579703	CRCP	0.67	5.15	0.32	5.59e-7	Diabetic kidney disease;
SARC	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg23982607	chr1:1823379	GNB1	-0.64	-10.9	-0.58	1.26e-22	Body mass index;
SARC	cis	rs9388451	0.505	rs9372828	chr6:126175185	A/T	cg05901451	chr6:126070800	HEY2	-0.48	-5.85	-0.36	1.67e-8	Brugada syndrome;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg24026757	chr18:12407806	SLMO1	0.53	6.54	0.39	3.95e-10	Breast cancer;
SARC	cis	rs34172651	0.917	rs2343606	chr16:24793741	C/T	cg00339695	chr16:24857497	SLC5A11	0.31	4.94	0.31	1.47e-6	Intelligence (multi-trait analysis);
SARC	cis	rs367943	1.000	rs348958	chr5:112821137	G/A	cg12552261	chr5:112820674	MCC	-0.45	-5.19	-0.32	4.65e-7	Type 2 diabetes;
SARC	cis	rs7615952	0.599	rs67575510	chr3:125742355	C/G	cg15145296	chr3:125709740	NA	-0.5	-4.97	-0.31	1.28e-6	Blood pressure (smoking interaction);
SARC	cis	rs17125944	0.506	rs7151491	chr14:53313711	C/G	cg00686598	chr14:53173677	PSMC6	-0.67	-4.99	-0.31	1.16e-6	Alzheimer's disease (late onset);
SARC	cis	rs10791097	0.748	rs2282579	chr11:130735482	C/T	cg09137382	chr11:130731461	NA	0.32	5.02	0.31	1.05e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs6580649	0.941	rs7310579	chr12:48427523	G/A	cg05342945	chr12:48394962	COL2A1	0.57	5.92	0.36	1.17e-8	Lung cancer;
SARC	cis	rs17253792	0.822	rs79618862	chr14:56093971	C/T	cg01858014	chr14:56050164	KTN1	-0.67	-5.26	-0.33	3.19e-7	Putamen volume;
SARC	trans	rs61931739	0.534	rs2625897	chr12:34064295	G/A	cg13010199	chr12:38710504	ALG10B	0.66	8.79	0.5	3.28e-16	Morning vs. evening chronotype;
SARC	cis	rs1920116	0.744	rs12492658	chr3:169562083	C/T	cg14222479	chr3:169487675	ARPM1	0.44	5.14	0.32	5.7e-7	Glioma (high-grade);
SARC	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg04248312	chr19:17393744	ANKLE1	-0.61	-8.03	-0.47	4.94e-14	Systemic lupus erythematosus;
SARC	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg21782813	chr7:2030301	MAD1L1	-0.33	-5.05	-0.31	9.02e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs12477438	0.520	rs2632276	chr2:99779655	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.91	13.88	0.67	2.51e-32	Chronic sinus infection;
SARC	cis	rs2120019	0.938	rs8033925	chr15:75311959	A/G	cg17294928	chr15:75287854	SCAMP5	-1.01	-15.27	-0.71	6.03e-37	Blood trace element (Zn levels);
SARC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg20102877	chr2:27665638	KRTCAP3	-0.37	-5.25	-0.33	3.44e-7	Total body bone mineral density;
SARC	cis	rs35110281	0.591	rs230642	chr21:44915533	A/C	cg01579765	chr21:45077557	HSF2BP	0.32	5.37	0.33	1.94e-7	Mean corpuscular volume;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg19075208	chr5:94890810	ARSK;TTC37	-0.46	-6.25	-0.38	1.89e-9	Chemerin levels;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg09920145	chr3:69100714	TMF1	-0.75	-6.38	-0.39	9.24e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7666738	0.830	rs13149346	chr4:99009933	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	trans	rs11250098	0.547	rs2409764	chr8:11281273	C/T	cg06636001	chr8:8085503	FLJ10661	0.56	7.61	0.45	6.95e-13	Morning vs. evening chronotype;
SARC	cis	rs3858526	0.959	rs1840179	chr11:5949148	A/G	cg13902645	chr11:5959945	NA	-0.45	-5.13	-0.32	5.99e-7	DNA methylation (variation);
SARC	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg17747265	chr1:1875780	NA	-0.33	-4.73	-0.3	3.94e-6	Body mass index;
SARC	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg11987759	chr7:65425863	GUSB	-0.48	-6.54	-0.39	3.9e-10	Aortic root size;
SARC	trans	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg17830980	chr10:43048298	ZNF37B	-0.51	-7.02	-0.42	2.42e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs5753618	0.504	rs9609303	chr22:31896309	C/T	cg02404636	chr22:31891804	SFI1	0.5	5.18	0.32	4.82e-7	Colorectal cancer;
SARC	cis	rs12200560	0.505	rs4839848	chr6:97076577	G/A	cg06623918	chr6:96969491	KIAA0776	0.46	5.29	0.33	2.82e-7	Coronary heart disease;
SARC	cis	rs4660306	1.000	rs4660870	chr1:45995231	T/A	cg24296786	chr1:45957014	TESK2	0.55	6.46	0.39	6.07e-10	Homocysteine levels;
SARC	cis	rs7587476	0.784	rs13008641	chr2:215698033	T/C	cg04004882	chr2:215674386	BARD1	0.57	6.53	0.39	4.09e-10	Neuroblastoma;
SARC	cis	rs910316	0.763	rs2080201	chr14:75629972	C/T	cg08847533	chr14:75593920	NEK9	-0.76	-10.31	-0.56	8.72e-21	Height;
SARC	cis	rs2463822	1.000	rs7481995	chr11:62129312	G/C	cg06239285	chr11:62104954	ASRGL1	0.89	9.16	0.51	2.79e-17	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs6582630	0.638	rs35864536	chr12:38472255	T/A	cg13010199	chr12:38710504	ALG10B	-0.48	-5.91	-0.36	1.2e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg24209194	chr3:40518798	ZNF619	0.65	7.83	0.46	1.76e-13	Renal cell carcinoma;
SARC	cis	rs2997447	0.655	rs2275949	chr1:26385150	C/G	cg19633962	chr1:26362018	EXTL1	-0.76	-7.37	-0.43	2.93e-12	QRS complex (12-leadsum);
SARC	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg08859206	chr1:53392774	SCP2	0.38	5.43	0.34	1.39e-7	Monocyte count;
SARC	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	9.89	0.54	1.77e-19	Alzheimer's disease;
SARC	cis	rs2013441	1.000	rs2243732	chr17:20088589	C/G	cg13482628	chr17:19912719	NA	-0.48	-6.16	-0.37	3.1e-9	Obesity-related traits;
SARC	cis	rs10465746	0.570	rs11163885	chr1:84472956	A/G	cg04407776	chr1:84465009	TTLL7	-0.42	-5.06	-0.31	8.62e-7	Obesity-related traits;
SARC	cis	rs4481887	0.962	rs5009868	chr1:248474495	A/G	cg00666640	chr1:248458726	OR2T12	0.37	6.15	0.37	3.35e-9	Common traits (Other);
SARC	cis	rs1983170	0.808	rs10782962	chr1:92016210	C/A	cg25838465	chr1:92012736	NA	0.51	5.89	0.36	1.35e-8	Eosinophil percentage of white cells;
SARC	cis	rs7726839	0.526	rs11960159	chr5:568685	C/T	cg09021430	chr5:549028	NA	-0.41	-5.86	-0.36	1.58e-8	Obesity-related traits;
SARC	cis	rs7223966	0.621	rs9906747	chr17:61639694	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.47	-5.3	-0.33	2.72e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs644799	0.544	rs687559	chr11:95598629	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.69	-8.94	-0.51	1.2e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs5750830	0.594	rs9611165	chr22:39775250	A/G	cg24399712	chr22:39784796	NA	-0.44	-6.11	-0.37	4.14e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7666738	0.830	rs3846443	chr4:99032666	G/A	cg05340658	chr4:99064831	C4orf37	0.66	8.96	0.51	1.08e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2250402	0.510	rs6492926	chr15:40325829	T/G	cg16127683	chr15:40268777	EIF2AK4	-0.6	-5.11	-0.32	6.8e-7	Corneal curvature;
SARC	cis	rs921968	0.643	rs832799	chr2:219490111	C/A	cg02176678	chr2:219576539	TTLL4	0.4	6.05	0.37	5.79e-9	Mean corpuscular hemoglobin concentration;
SARC	cis	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.57	8.94	0.51	1.24e-16	Eosinophil percentage of white cells;
SARC	cis	rs9790314	0.875	rs7615592	chr3:160981548	A/C	cg04691961	chr3:161091175	C3orf57	-0.79	-11.42	-0.6	2.89e-24	Morning vs. evening chronotype;
SARC	cis	rs4481887	0.927	rs4581306	chr1:248476158	C/A	cg00666640	chr1:248458726	OR2T12	0.34	5.7	0.35	3.65e-8	Common traits (Other);
SARC	cis	rs8114671	0.562	rs6120758	chr20:33492523	C/T	cg07148914	chr20:33460835	GGT7	0.42	5.12	0.32	6.3e-7	Height;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg05414835	chr15:59225898	SLTM	-0.52	-6.6	-0.4	2.7e-10	Height;
SARC	cis	rs7829975	0.572	rs7005000	chr8:8796602	A/G	cg08975724	chr8:8085496	FLJ10661	-0.41	-5.1	-0.32	7.02e-7	Mood instability;
SARC	cis	rs5995756	0.666	rs926231	chr22:40006986	C/G	cg10455938	chr22:40058150	CACNA1I	0.43	5.08	0.32	7.79e-7	Autism spectrum disorder or schizophrenia;
SARC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg12000995	chr2:27665139	KRTCAP3	-0.3	-4.77	-0.3	3.24e-6	Total body bone mineral density;
SARC	cis	rs7481584	1.000	rs12804412	chr11:3020782	G/A	cg08508325	chr11:3079039	CARS	0.22	4.76	0.3	3.44e-6	Calcium levels;
SARC	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-9.31	-0.52	9.88e-18	Alzheimer's disease;
SARC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.28	0.8	2.29e-53	Prudent dietary pattern;
SARC	cis	rs7584330	0.737	rs7568588	chr2:238364342	G/T	cg11271282	chr2:238384023	NA	0.42	4.77	0.3	3.2e-6	Prostate cancer;
SARC	trans	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg06437703	chr8:37914619	EIF4EBP1	-0.6	-7.17	-0.43	9.7e-12	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs883565	0.528	rs6599271	chr3:38970730	A/G	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.44	-5.22	-0.32	3.92e-7	Handedness;
SARC	cis	rs11122272	0.525	rs2739517	chr1:231537914	C/A	cg06096015	chr1:231504339	EGLN1	0.38	5.71	0.35	3.4e-8	Hemoglobin concentration;
SARC	cis	rs8084125	1.000	rs72978665	chr18:74953641	A/G	cg19705131	chr18:74961163	GALR1	0.42	4.74	0.3	3.68e-6	Obesity-related traits;
SARC	cis	rs7568458	0.870	rs1058588	chr2:85808871	A/G	cg17127132	chr2:85788382	GGCX	-0.38	-4.96	-0.31	1.36e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs7772486	0.641	rs2777485	chr6:146334377	G/A	cg23711669	chr6:146136114	FBXO30	0.76	10.36	0.56	6.45e-21	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs734999	0.545	rs12749591	chr1:2563250	G/T	cg00980319	chr1:2560884	MMEL1	0.33	4.74	0.3	3.73e-6	Ulcerative colitis;
SARC	cis	rs2486288	0.539	rs2433601	chr15:45716425	T/C	cg15395560	chr15:45543142	SLC28A2	-0.28	-5.37	-0.33	1.89e-7	Glomerular filtration rate;
SARC	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.12	26.45	0.87	3.92e-72	Chronic sinus infection;
SARC	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg24642844	chr7:1081250	C7orf50	-0.52	-5.75	-0.35	2.79e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs7264396	0.635	rs6060688	chr20:34516731	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.68	7.6	0.45	7.2e-13	Total cholesterol levels;
SARC	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.99	11.73	0.61	2.89e-25	Platelet count;
SARC	cis	rs2120019	0.567	rs8037152	chr15:75156996	A/T	cg12414181	chr15:75287860	SCAMP5	-0.5	-4.8	-0.3	2.84e-6	Blood trace element (Zn levels);
SARC	cis	rs1790761	0.520	rs4930461	chr11:67394895	A/G	cg00290607	chr11:67383545	NA	0.44	5.62	0.35	5.42e-8	Mean corpuscular volume;
SARC	cis	rs9473924	0.542	rs9473946	chr6:50892950	G/A	cg14470998	chr6:50812995	TFAP2B	0.71	6.74	0.4	1.2e-10	Body mass index;
SARC	cis	rs9325144	0.555	rs6582576	chr12:38701230	C/T	cg26384229	chr12:38710491	ALG10B	-0.57	-7.24	-0.43	6.5e-12	Morning vs. evening chronotype;
SARC	trans	rs1814175	0.645	rs10742953	chr11:49807491	C/G	cg03929089	chr4:120376271	NA	0.79	11.07	0.59	3.78e-23	Height;
SARC	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg18404041	chr3:52824283	ITIH1	-0.47	-7.15	-0.42	1.1e-11	Bipolar disorder;
SARC	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg24633833	chr3:10029261	TMEM111	0.51	5.09	0.32	7.27e-7	Alzheimer's disease;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg01711272	chr12:56122120	CD63	-0.58	-6.58	-0.4	3.11e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs17401966	0.838	rs12141246	chr1:10327407	A/T	cg15208524	chr1:10270712	KIF1B	0.43	5.08	0.32	7.83e-7	Hepatocellular carcinoma;
SARC	cis	rs155076	1.000	rs261407	chr13:21855213	C/A	cg06138931	chr13:21896616	NA	-0.39	-5.06	-0.31	8.68e-7	White matter hyperintensity burden;
SARC	cis	rs13191362	0.935	rs34009353	chr6:163007668	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.57	5.51	0.34	9.61e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs11758351	1.000	rs75921373	chr6:26191843	C/T	cg23601095	chr6:26197514	HIST1H3D	0.64	5.51	0.34	9.33e-8	Gout;Renal underexcretion gout;
SARC	cis	rs4713675	0.565	rs4711340	chr6:33681131	C/T	cg15676125	chr6:33679581	C6orf125	0.52	6.43	0.39	7.17e-10	Plateletcrit;
SARC	cis	rs1153858	1.000	rs4775906	chr15:45638294	C/T	cg14582100	chr15:45693742	SPATA5L1	0.37	5.03	0.31	9.67e-7	Homoarginine levels;
SARC	cis	rs3820928	0.869	rs2396436	chr2:227795464	G/A	cg05526886	chr2:227700861	RHBDD1	-0.54	-6.65	-0.4	2.04e-10	Pulmonary function;
SARC	cis	rs911555	0.723	rs6575986	chr14:103886671	G/A	cg12935359	chr14:103987150	CKB	-0.38	-5.24	-0.32	3.57e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1050631	1.000	rs1785919	chr18:33691964	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.43	5.23	0.32	3.77e-7	Esophageal squamous cell cancer (length of survival);
SARC	trans	rs11098499	0.863	rs3775848	chr4:120447724	C/T	cg25214090	chr10:38739885	LOC399744	0.57	7.35	0.43	3.31e-12	Corneal astigmatism;
SARC	cis	rs6688363	0.887	rs6695366	chr1:160097666	G/A	cg22802111	chr1:160068614	IGSF8	0.52	4.81	0.3	2.72e-6	Response to antipsychotic treatment;
SARC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg10963375	chr1:205815865	PM20D1	0.33	5.03	0.31	9.96e-7	Menarche (age at onset);
SARC	cis	rs10782582	0.609	rs5745545	chr1:76377356	A/G	cg03433033	chr1:76189801	ACADM	-0.4	-5.15	-0.32	5.55e-7	Daytime sleep phenotypes;
SARC	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg22968622	chr17:43663579	NA	1.25	16.95	0.74	1.61e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg09021430	chr5:549028	NA	-0.44	-5.69	-0.35	3.85e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs13191362	1.000	rs55847707	chr6:163003414	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.57	5.38	0.33	1.85e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs8141529	0.748	rs7287918	chr22:29281710	G/A	cg02153584	chr22:29168773	CCDC117	0.76	10.97	0.58	7.54e-23	Lymphocyte counts;
SARC	cis	rs6456156	0.586	rs6456150	chr6:167468922	A/G	cg07741184	chr6:167504864	NA	0.36	7.11	0.42	1.42e-11	Primary biliary cholangitis;
SARC	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg12292205	chr6:26970375	C6orf41	-0.41	-4.99	-0.31	1.19e-6	Intelligence (multi-trait analysis);
SARC	cis	rs11785400	0.928	rs2280878	chr8:143722366	G/A	cg10596483	chr8:143751796	JRK	0.61	7.83	0.46	1.74e-13	Schizophrenia;
SARC	cis	rs735396	0.770	rs1169300	chr12:121431225	G/A	cg15155738	chr12:121454335	C12orf43	0.52	6.39	0.39	8.97e-10	N-glycan levels;
SARC	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg13939156	chr17:80058883	NA	-0.42	-6.48	-0.39	5.51e-10	Life satisfaction;
SARC	cis	rs10791097	0.642	rs7107568	chr11:130779668	T/C	cg12179176	chr11:130786555	SNX19	0.82	13.08	0.65	1.12e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs7084402	0.967	rs10826198	chr10:60274182	C/T	cg07615347	chr10:60278583	BICC1	-0.58	-8.45	-0.48	3.16e-15	Refractive error;
SARC	cis	rs62344088	1.000	rs73022563	chr5:140813	G/T	cg22496380	chr5:211416	CCDC127	-0.85	-4.81	-0.3	2.72e-6	Asthma (childhood onset);
SARC	trans	rs561341	1.000	rs757009	chr17:30243937	A/G	cg20587970	chr11:113659929	NA	-0.94	-9.26	-0.52	1.35e-17	Hip circumference adjusted for BMI;
SARC	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg16434002	chr17:42200994	HDAC5	0.39	4.81	0.3	2.67e-6	Total body bone mineral density;
SARC	cis	rs16944613	0.588	rs6416553	chr15:91135411	A/G	cg26821196	chr15:91095069	CRTC3	-0.55	-5.76	-0.35	2.63e-8	Colorectal cancer;
SARC	cis	rs12545109	0.879	rs1513317	chr8:57372966	C/G	cg19413350	chr8:57351067	NA	-0.45	-4.92	-0.31	1.61e-6	Obesity-related traits;
SARC	cis	rs6834538	1.000	rs1486864	chr4:113465766	G/T	cg05166686	chr4:113558556	LARP7;C4orf21	0.41	5.01	0.31	1.07e-6	Free thyroxine concentration;
SARC	cis	rs7772486	0.754	rs1415746	chr6:146077107	A/G	cg05347473	chr6:146136440	FBXO30	-0.56	-7.8	-0.46	2.05e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg08219700	chr8:58056026	NA	0.63	6.15	0.37	3.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9916302	0.904	rs6503503	chr17:37514373	G/A	cg07936489	chr17:37558343	FBXL20	0.68	9.2	0.52	2.14e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs1950500	0.509	rs12895424	chr14:24823186	G/T	cg16194253	chr14:24768981	DHRS1;C14orf21	0.6	7.53	0.44	1.08e-12	Height;
SARC	cis	rs2204008	0.744	rs8186814	chr12:38335169	C/T	cg26384229	chr12:38710491	ALG10B	0.87	12.6	0.64	4.2e-28	Bladder cancer;
SARC	cis	rs2370759	1.000	rs77165999	chr10:32577131	T/C	cg05361325	chr10:32636312	EPC1	-0.74	-6.51	-0.39	4.62e-10	Sexual dysfunction (female);
SARC	cis	rs796364	0.951	rs12620298	chr2:201047184	C/T	cg23649088	chr2:200775458	C2orf69	-0.62	-6.68	-0.4	1.71e-10	Schizophrenia;
SARC	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg12463550	chr7:65579703	CRCP	-0.44	-5.05	-0.31	8.91e-7	Aortic root size;
SARC	cis	rs7568458	1.000	rs7568458	chr2:85788175	T/A	cg02493740	chr2:85810744	VAMP5	-0.37	-5.41	-0.33	1.54e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs2463822	0.920	rs28678254	chr11:62151875	G/C	cg06239285	chr11:62104954	ASRGL1	-0.86	-8.36	-0.48	5.71e-15	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs17666538	1.000	rs61122136	chr8:585027	G/C	cg07685180	chr8:600429	NA	-0.8	-6.13	-0.37	3.67e-9	IgG glycosylation;
SARC	cis	rs7940866	0.678	rs61909201	chr11:130839547	C/T	cg12179176	chr11:130786555	SNX19	0.55	7.05	0.42	1.99e-11	Schizophrenia;
SARC	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg11987759	chr7:65425863	GUSB	-0.5	-6.52	-0.39	4.3e-10	Aortic root size;
SARC	cis	rs7772486	0.686	rs1011596	chr6:146076433	A/G	cg23711669	chr6:146136114	FBXO30	0.82	13.53	0.66	3.7e-31	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs782590	0.764	rs2054728	chr2:55818419	C/T	cg18811423	chr2:55921094	PNPT1	0.57	8.16	0.47	2.14e-14	Metabolic syndrome;
SARC	cis	rs5758659	0.652	rs133300	chr22:42389839	A/G	cg04733989	chr22:42467013	NAGA	0.52	6.98	0.42	3.05e-11	Cognitive function;
SARC	cis	rs694739	0.628	rs617051	chr11:64133638	C/A	cg02228329	chr11:64053129	BAD;GPR137	0.52	5.61	0.35	5.69e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs6912958	0.514	rs7767449	chr6:87887985	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.36	-6.33	-0.38	1.22e-9	Monocyte percentage of white cells;
SARC	cis	rs2380220	0.606	rs7754906	chr6:95992429	C/T	cg23517279	chr6:96025343	MANEA	0.51	5.91	0.36	1.19e-8	Behavioural disinhibition (generation interaction);
SARC	cis	rs9916302	0.706	rs9891892	chr17:37479856	A/C	cg20243544	chr17:37824526	PNMT	-0.54	-5.76	-0.35	2.67e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs2239547	0.603	rs2276825	chr3:52886605	T/C	cg18404041	chr3:52824283	ITIH1	-0.41	-5.07	-0.32	7.92e-7	Schizophrenia;
SARC	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg08219700	chr8:58056026	NA	0.63	6.61	0.4	2.59e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs9790314	0.718	rs6774635	chr3:160847908	A/G	cg03342759	chr3:160939853	NMD3	-0.46	-5.67	-0.35	4.11e-8	Morning vs. evening chronotype;
SARC	trans	rs1910358	0.554	rs10057796	chr5:23759746	C/T	cg07985704	chr6:108395859	OSTM1	0.56	6.36	0.38	1.07e-9	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs4742903	0.967	rs10820599	chr9:106856691	T/G	cg14250997	chr9:106856677	SMC2	0.52	6.86	0.41	6.13e-11	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg12419862	chr22:24373484	LOC391322	-0.67	-8.05	-0.47	4.21e-14	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs5753618	0.583	rs5753612	chr22:31821479	T/C	cg07713946	chr22:31675144	LIMK2	0.36	4.91	0.31	1.73e-6	Colorectal cancer;
SARC	trans	rs3960554	0.660	rs55671363	chr7:75793405	T/C	cg19862616	chr7:65841803	NCRNA00174	0.62	7.28	0.43	5.04e-12	Eotaxin levels;
SARC	cis	rs3106136	0.967	rs12645192	chr4:95181525	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.39	-6.05	-0.37	5.83e-9	Capecitabine sensitivity;
SARC	cis	rs911555	0.755	rs4906329	chr14:103942669	A/G	cg24130564	chr14:104152367	KLC1	0.5	5.96	0.36	9.3e-9	Intelligence (multi-trait analysis);
SARC	cis	rs76419734	1.000	rs116034011	chr4:106735622	A/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.79	5.34	0.33	2.23e-7	Post bronchodilator FEV1;
SARC	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.35	-0.43	3.34e-12	Gut microbiome composition (summer);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg00013410	chr17:60142592	MED13	0.54	6.63	0.4	2.35e-10	Breast cancer;
SARC	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg03354898	chr7:1950403	MAD1L1	-0.37	-5.07	-0.32	8.12e-7	Bipolar disorder and schizophrenia;
SARC	trans	rs208520	1.000	rs72882079	chr6:66973878	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	9.16	0.51	2.69e-17	Exhaled nitric oxide output;
SARC	cis	rs7659604	0.967	rs28529384	chr4:122664215	T/C	cg19748678	chr4:122722346	EXOSC9	0.44	5.49	0.34	1.06e-7	Type 2 diabetes;
SARC	cis	rs9467711	0.651	rs72832596	chr6:25962951	C/A	cg21479132	chr6:26055353	NA	0.84	5.13	0.32	6.01e-7	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7819412	0.595	rs2409712	chr8:10986837	A/C	cg21775007	chr8:11205619	TDH	-0.44	-5.5	-0.34	9.83e-8	Triglycerides;
SARC	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg26513180	chr16:89883248	FANCA	-0.6	-8.42	-0.48	3.93e-15	Vitiligo;
SARC	trans	rs1814175	0.791	rs10839395	chr11:49846274	G/T	cg03929089	chr4:120376271	NA	-0.91	-15.27	-0.71	6.12e-37	Height;
SARC	trans	rs61931739	0.534	rs4547187	chr12:34041259	T/C	cg26384229	chr12:38710491	ALG10B	0.75	10.82	0.58	2.31e-22	Morning vs. evening chronotype;
SARC	cis	rs17854409	0.536	rs3765464	chr20:61485236	T/C	cg07645718	chr20:61493192	TCFL5	0.79	5.19	0.32	4.6e-7	Obesity-related traits;
SARC	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg08280861	chr8:58055591	NA	0.61	5.81	0.36	2.02e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9916302	0.851	rs11870631	chr17:37645129	C/T	cg15445000	chr17:37608096	MED1	0.4	4.73	0.3	3.86e-6	Glomerular filtration rate (creatinine);
SARC	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg01341218	chr17:43662625	NA	-0.66	-7.53	-0.44	1.14e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7570971	0.617	rs1869829	chr2:135877562	C/T	cg07169764	chr2:136633963	MCM6	-0.51	-6.72	-0.4	1.36e-10	Blood metabolite levels;Body mass index;Cholesterol, total;
SARC	trans	rs890100	0.673	rs10174257	chr2:56677556	T/C	cg26233084	chr5:15510258	FBXL7	-0.32	-6.55	-0.39	3.61e-10	Gut microbiome composition (summer);
SARC	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg18404041	chr3:52824283	ITIH1	-0.48	-7.35	-0.43	3.36e-12	Bipolar disorder;
SARC	cis	rs2075371	0.932	rs1862052	chr7:133981227	G/A	cg11752832	chr7:134001865	SLC35B4	0.52	6.54	0.39	3.82e-10	Mean platelet volume;
SARC	cis	rs9398803	0.865	rs9375446	chr6:126835015	G/A	cg19875578	chr6:126661172	C6orf173	0.63	8.53	0.49	1.82e-15	Male-pattern baldness;
SARC	cis	rs6539267	0.847	rs12831519	chr12:106682917	A/G	cg00173435	chr12:106696525	TCP11L2	0.64	6.22	0.38	2.23e-9	Tourette syndrome;
SARC	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.76	11.16	0.59	1.95e-23	Personality dimensions;
SARC	cis	rs2153535	0.580	rs9393021	chr6:8466123	A/G	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9788721	0.630	rs77681598	chr15:78906103	C/A	cg22563815	chr15:78856949	CHRNA5	-0.36	-6.07	-0.37	5.21e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs6570726	0.837	rs636894	chr6:145864122	T/C	cg05347473	chr6:146136440	FBXO30	0.48	6.55	0.39	3.57e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3857536	0.834	rs4710575	chr6:66890782	C/T	cg07460842	chr6:66804631	NA	-0.44	-5.22	-0.32	3.92e-7	Blood trace element (Cu levels);
SARC	cis	rs77372450	0.636	rs6889910	chr5:157014912	A/T	cg23851860	chr5:157002805	ADAM19	0.51	4.91	0.31	1.72e-6	Bipolar disorder (body mass index interaction);
SARC	cis	rs7568458	0.527	rs35416445	chr2:85773659	A/G	cg23752985	chr2:85803571	VAMP8	0.45	5.75	0.35	2.78e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg07701084	chr6:150067640	NUP43	0.41	5.33	0.33	2.33e-7	Lung cancer;
SARC	cis	rs826838	0.616	rs7966266	chr12:38626138	G/A	cg14851346	chr12:38532713	NA	-0.44	-5.32	-0.33	2.39e-7	Heart rate;
SARC	cis	rs73086581	1.000	rs6107391	chr20:3983083	A/G	cg02187196	chr20:3869020	PANK2	0.63	5.87	0.36	1.51e-8	Response to antidepressants in depression;
SARC	cis	rs12824058	0.831	rs11608406	chr12:130805866	G/C	cg24838063	chr12:130822603	PIWIL1	0.61	8.57	0.49	1.49e-15	Menopause (age at onset);
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07916071	chr1:151227225	PSMD4	0.51	6.92	0.41	4.22e-11	Smoking initiation;
SARC	cis	rs7914558	1.000	rs1926030	chr10:104855656	T/C	cg04362960	chr10:104952993	NT5C2	0.42	5.0	0.31	1.12e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs6728642	0.908	rs9973669	chr2:97679094	T/C	cg26665480	chr2:98280029	ACTR1B	-0.69	-6.45	-0.39	6.3e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs854765	0.547	rs4459604	chr17:17888549	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.62	9.13	0.51	3.36e-17	Total body bone mineral density;
SARC	cis	rs4727027	0.804	rs13231262	chr7:148886058	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	5.89	0.36	1.37e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs7659604	0.840	rs6821305	chr4:122713863	A/C	cg19671926	chr4:122722719	EXOSC9	-0.63	-7.52	-0.44	1.16e-12	Type 2 diabetes;
SARC	cis	rs10464366	0.544	rs34866559	chr7:39166071	G/A	cg18850127	chr7:39170497	POU6F2	0.41	5.45	0.34	1.28e-7	IgG glycosylation;
SARC	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg04166393	chr7:2884313	GNA12	0.56	6.46	0.39	5.93e-10	Height;
SARC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg03452623	chr4:187889614	NA	-0.75	-11.79	-0.61	1.83e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6866344	0.697	rs11743893	chr5:178125194	C/T	cg10224037	chr5:178157518	ZNF354A	0.97	11.98	0.62	4.46e-26	Neutrophil percentage of white cells;
SARC	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg13206674	chr6:150067644	NUP43	0.42	5.53	0.34	8.42e-8	Lung cancer;
SARC	cis	rs2290720	0.896	rs1350351	chr12:101713590	G/A	cg22051763	chr12:101673672	UTP20	-0.42	-4.97	-0.31	1.27e-6	Brain structure (hippocampal volume);
SARC	cis	rs1878931	0.582	rs10048083	chr16:3417465	A/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.69	7.86	0.46	1.38e-13	Body mass index (adult);
SARC	cis	rs9325144	0.555	rs4550281	chr12:38689937	A/G	cg10518543	chr12:38710700	ALG10B	0.39	4.94	0.31	1.5e-6	Morning vs. evening chronotype;
SARC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.19	0.8	4.45e-53	Prudent dietary pattern;
SARC	cis	rs3733585	0.605	rs4235355	chr4:10123078	C/A	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.61	-0.35	5.57e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs11097912	0.632	rs6831665	chr4:107222086	C/T	cg09646026	chr4:107269030	AIMP1	-0.45	-4.86	-0.3	2.13e-6	Airflow obstruction;
SARC	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg24642844	chr7:1081250	C7orf50	-0.5	-5.58	-0.34	6.65e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs7264396	0.563	rs73902913	chr20:34432784	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-6.14	-0.37	3.49e-9	Total cholesterol levels;
SARC	cis	rs751728	1.000	rs3806108	chr6:33767579	C/G	cg15252951	chr6:33757062	LEMD2	0.58	6.58	0.4	3.02e-10	Crohn's disease;
SARC	cis	rs11969893	0.850	rs9498414	chr6:101322976	C/T	cg12253828	chr6:101329408	ASCC3	1.08	6.92	0.41	4.34e-11	Economic and political preferences (immigration/crime);
SARC	cis	rs34779708	0.966	rs2126984	chr10:35410291	A/G	cg03585969	chr10:35415529	CREM	0.42	5.22	0.32	4e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs12586317	0.620	rs17103042	chr14:35575428	T/C	cg16230307	chr14:35515116	FAM177A1	0.92	10.85	0.58	1.78e-22	Psoriasis;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg02287630	chr1:101361426	SLC30A7;EXTL2	0.81	6.55	0.39	3.56e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7772486	0.625	rs9390355	chr6:146112942	C/T	cg23711669	chr6:146136114	FBXO30	-0.8	-13.15	-0.65	6.6e-30	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs36051895	0.659	rs7046077	chr9:5045328	C/G	cg02405213	chr9:5042618	JAK2	-0.53	-6.22	-0.38	2.22e-9	Pediatric autoimmune diseases;
SARC	cis	rs3784262	0.512	rs4646571	chr15:58343137	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.33	-4.99	-0.31	1.18e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	trans	rs12310956	0.532	rs1906134	chr12:33957135	A/C	cg13010199	chr12:38710504	ALG10B	0.73	9.92	0.54	1.4e-19	Morning vs. evening chronotype;
SARC	cis	rs72772090	0.710	rs10515244	chr5:96078337	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.57	-4.88	-0.3	1.95e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2718058	0.519	rs2598071	chr7:37875347	G/A	cg24998770	chr7:37888106	TXNDC3	0.45	6.67	0.4	1.81e-10	Alzheimer's disease (late onset);
SARC	cis	rs6540556	0.723	rs12120361	chr1:209913473	A/C	cg05527609	chr1:210001259	C1orf107	-0.56	-5.51	-0.34	9.39e-8	Red blood cell count;
SARC	cis	rs4792901	0.879	rs12600482	chr17:41630597	T/G	cg22562494	chr17:41607896	ETV4	-0.34	-5.4	-0.33	1.68e-7	Dupuytren's disease;
SARC	cis	rs2228479	0.850	rs62056068	chr16:89909737	C/T	cg06558623	chr16:89946397	TCF25	0.93	6.61	0.4	2.59e-10	Skin colour saturation;
SARC	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg18876405	chr7:65276391	NA	-0.44	-5.43	-0.34	1.4e-7	Aortic root size;
SARC	trans	rs11098499	0.955	rs11931312	chr4:120159023	T/C	cg25214090	chr10:38739885	LOC399744	0.52	6.86	0.41	6.19e-11	Corneal astigmatism;
SARC	cis	rs7568458	0.870	rs1058588	chr2:85808871	A/G	cg23752985	chr2:85803571	VAMP8	-0.34	-5.06	-0.31	8.7e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs1030877	0.960	rs3792047	chr2:105901553	A/G	cg02079111	chr2:105885981	TGFBRAP1	-0.53	-7.54	-0.44	1.04e-12	Obesity-related traits;
SARC	cis	rs17270561	0.636	rs7754814	chr6:25745243	A/T	cg16482183	chr6:26056742	HIST1H1C	0.43	5.08	0.32	7.76e-7	Iron status biomarkers;
SARC	cis	rs7659604	0.502	rs13106764	chr4:122699630	C/G	cg20573242	chr4:122745356	CCNA2	-0.36	-4.74	-0.3	3.65e-6	Type 2 diabetes;
SARC	cis	rs78487399	0.808	rs7564886	chr2:43733028	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-4.87	-0.3	2.07e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs6088580	0.634	rs6088475	chr20:32964987	T/C	cg24642439	chr20:33292090	TP53INP2	-0.66	-8.63	-0.49	9.96e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs1218582	0.741	rs705094	chr1:154917314	G/A	cg24250549	chr1:154909240	PMVK	0.82	11.68	0.61	4.07e-25	Prostate cancer;
SARC	cis	rs10463554	0.890	rs26428	chr5:102366484	C/T	cg23492399	chr5:102201601	PAM	0.43	4.74	0.3	3.75e-6	Parkinson's disease;
SARC	cis	rs12594515	1.000	rs12906442	chr15:45985254	C/A	cg14863074	chr15:45997064	NA	0.34	5.25	0.33	3.39e-7	Waist circumference;Weight;
SARC	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg16482183	chr6:26056742	HIST1H1C	0.41	4.74	0.3	3.79e-6	Intelligence (multi-trait analysis);
SARC	cis	rs79839061	0.563	rs55728587	chr4:843674	G/A	cg07828340	chr4:882639	GAK	0.75	5.5	0.34	1.01e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.71	-9.86	-0.54	2.14e-19	Menarche (age at onset);
SARC	cis	rs62432291	0.681	rs447637	chr6:159658726	A/G	cg14500486	chr6:159655392	FNDC1	-0.64	-6.37	-0.39	9.75e-10	Joint mobility (Beighton score);
SARC	cis	rs477692	0.673	rs579325	chr10:131363688	C/T	cg14263093	chr10:131365266	MGMT	0.37	5.22	0.32	3.97e-7	Response to temozolomide;
SARC	cis	rs2180341	0.855	rs9385422	chr6:127716457	C/T	cg24812749	chr6:127587940	RNF146	0.78	10.09	0.55	4.29e-20	Breast cancer;
SARC	cis	rs1153858	1.000	rs12591058	chr15:45640172	T/C	cg03999130	chr15:45571217	NA	0.39	4.99	0.31	1.16e-6	Homoarginine levels;
SARC	cis	rs644799	0.672	rs11021307	chr11:95501407	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.87	14.28	0.68	1.16e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs10046574	0.517	rs7782727	chr7:135200299	A/G	cg27474649	chr7:135195673	CNOT4	0.84	7.94	0.46	8.38e-14	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs9818758	0.607	rs34823813	chr3:49749976	G/A	cg00383909	chr3:49044727	WDR6	0.76	6.57	0.4	3.31e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs7208859	0.623	rs55814012	chr17:29077697	T/A	cg13385521	chr17:29058706	SUZ12P	0.88	7.75	0.45	2.9e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs3768617	0.510	rs12095664	chr1:183101686	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.66e-21	Fuchs's corneal dystrophy;
SARC	trans	rs7980799	0.682	rs10161491	chr12:33623806	T/C	cg26384229	chr12:38710491	ALG10B	-0.63	-7.84	-0.46	1.59e-13	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg06558623	chr16:89946397	TCF25	0.98	8.13	0.47	2.6e-14	Skin colour saturation;
SARC	cis	rs155076	1.000	rs9509638	chr13:21860193	G/A	cg14456004	chr13:21872349	NA	-0.98	-12.34	-0.63	3.01e-27	White matter hyperintensity burden;
SARC	cis	rs7395581	0.918	rs1055510	chr11:47292237	A/G	cg25783544	chr11:47291846	MADD	0.5	5.63	0.35	5.08e-8	HDL cholesterol;
SARC	cis	rs11675119	0.517	rs12619851	chr2:3492747	T/C	cg15506890	chr2:3487001	NA	-0.46	-5.82	-0.36	1.91e-8	Neurofibrillary tangles;
SARC	cis	rs929354	0.651	rs6951298	chr7:156949149	T/C	cg05182265	chr7:156933206	UBE3C	-0.34	-5.19	-0.32	4.49e-7	Body mass index;
SARC	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg20916646	chr4:852691	GAK	0.46	6.58	0.4	3.11e-10	Sjögren's syndrome;
SARC	cis	rs875971	0.545	rs6460276	chr7:65647277	G/A	cg25894440	chr7:65020034	NA	0.51	4.76	0.3	3.33e-6	Aortic root size;
SARC	trans	rs61931739	0.517	rs7958856	chr12:34294737	T/C	cg13010199	chr12:38710504	ALG10B	0.75	10.04	0.55	6.11e-20	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg02725872	chr8:58115012	NA	-0.32	-4.82	-0.3	2.64e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs1008375	1.000	rs3815414	chr4:17606659	A/G	cg02297831	chr4:17616191	MED28	-0.5	-6.27	-0.38	1.77e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs920590	0.684	rs59259846	chr8:19669468	C/G	cg03894339	chr8:19674705	INTS10	0.63	7.33	0.43	3.72e-12	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs13191362	1.000	rs67042566	chr6:163006541	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.49	0.34	1.04e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	trans	rs2727020	0.729	rs1917325	chr11:49370004	G/A	cg03929089	chr4:120376271	NA	-0.76	-11.22	-0.59	1.25e-23	Coronary artery disease;
SARC	cis	rs739401	0.611	rs572373	chr11:3055361	T/C	cg05729581	chr11:3078854	CARS	-0.5	-6.6	-0.4	2.67e-10	Longevity;
SARC	cis	rs7659604	0.935	rs73844280	chr4:122664687	G/A	cg19748678	chr4:122722346	EXOSC9	0.42	5.17	0.32	5.01e-7	Type 2 diabetes;
SARC	cis	rs3733585	0.699	rs6449176	chr4:9967843	G/A	cg11266682	chr4:10021025	SLC2A9	-0.37	-6.48	-0.39	5.28e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs9640161	0.742	rs2108853	chr7:150017589	A/C	cg10018233	chr7:150070692	REPIN1	0.69	9.06	0.51	5.35e-17	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs3796352	1.000	rs71301809	chr3:53090312	C/T	cg07884673	chr3:53033167	SFMBT1	0.86	5.68	0.35	3.95e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg11890956	chr21:40555474	PSMG1	-0.69	-8.96	-0.51	1.04e-16	Menarche (age at onset);
SARC	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg24549020	chr5:56110836	MAP3K1	-0.51	-5.66	-0.35	4.38e-8	Initial pursuit acceleration;
SARC	trans	rs7980799	0.649	rs12819439	chr12:33684509	A/C	cg26384229	chr12:38710491	ALG10B	0.65	7.68	0.45	4.47e-13	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.62	7.44	0.44	1.87e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs11098499	0.909	rs11098530	chr4:120413154	C/T	cg24375607	chr4:120327624	NA	0.41	4.86	0.3	2.12e-6	Corneal astigmatism;
SARC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.14	0.8	6.21e-53	Prudent dietary pattern;
SARC	cis	rs10789491	1.000	rs618505	chr1:47144532	T/C	cg15501359	chr1:47185051	KIAA0494	0.73	7.91	0.46	1.01e-13	Response to hepatitis C treatment;
SARC	trans	rs3779273	0.776	rs4727631	chr7:77834209	G/A	cg05596911	chr5:118502651	DMXL1	-0.52	-6.55	-0.39	3.67e-10	Body mass index;
SARC	cis	rs17376456	0.825	rs13164315	chr5:93147421	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.7	6.26	0.38	1.82e-9	Diabetic retinopathy;
SARC	cis	rs9914988	0.943	rs9898892	chr17:27150750	T/C	cg20469991	chr17:27169893	C17orf63	-0.52	-5.39	-0.33	1.74e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs2204008	0.774	rs2387811	chr12:38369794	C/A	cg13010199	chr12:38710504	ALG10B	0.8	11.03	0.59	4.88e-23	Bladder cancer;
SARC	cis	rs950169	1.000	rs34751999	chr15:84758419	T/C	cg24253500	chr15:84953950	NA	0.36	5.24	0.32	3.66e-7	Schizophrenia;
SARC	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg18225595	chr11:63971243	STIP1	0.44	5.19	0.32	4.59e-7	Mean platelet volume;
SARC	cis	rs3796352	1.000	rs34313969	chr3:52995166	A/G	cg12962167	chr3:53033115	SFMBT1	0.75	4.9	0.31	1.8e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs1801251	0.963	rs283481	chr2:233648091	A/G	cg25237894	chr2:233734115	C2orf82	0.37	4.79	0.3	3.02e-6	Coronary artery disease;
SARC	cis	rs240764	0.736	rs9968897	chr6:100945858	G/A	cg21058520	chr6:100914733	NA	0.32	4.89	0.31	1.88e-6	Neuroticism;
SARC	cis	rs6060717	0.536	rs6060699	chr20:34523833	C/T	cg01084648	chr20:34329383	RBM39	0.6	4.76	0.3	3.37e-6	Hip circumference adjusted for BMI;
SARC	cis	rs10911232	0.507	rs6668980	chr1:183018857	T/C	cg13390022	chr1:182993471	LAMC1	0.36	5.42	0.33	1.46e-7	Hypertriglyceridemia;
SARC	cis	rs13191362	0.935	rs67368176	chr6:162968436	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.53	4.76	0.3	3.4e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg22903657	chr4:1355424	KIAA1530	-0.37	-5.06	-0.31	8.33e-7	Obesity-related traits;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg18812130	chr14:75179894	FCF1;KIAA0317	0.49	6.35	0.38	1.12e-9	Chemerin levels;
SARC	cis	rs78487399	0.710	rs74469180	chr2:43603367	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-4.85	-0.3	2.26e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs7818688	0.697	rs77055525	chr8:95980583	G/A	cg13393036	chr8:95962371	TP53INP1	0.4	4.85	0.3	2.27e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs7542091	0.579	rs34638782	chr1:210032055	C/G	cg05527609	chr1:210001259	C1orf107	-0.57	-7.25	-0.43	6.07e-12	Monobrow;
SARC	cis	rs4144743	1.000	rs7208170	chr17:45330759	G/A	cg18085866	chr17:45331354	ITGB3	-0.73	-7.41	-0.44	2.29e-12	Body mass index;
SARC	cis	rs58688157	0.883	rs34793529	chr11:575800	T/G	cg16486109	chr11:613632	IRF7	0.4	5.48	0.34	1.11e-7	Systemic lupus erythematosus;
SARC	cis	rs10875746	0.855	rs73102065	chr12:48492607	T/C	cg26205652	chr12:48591994	NA	0.56	6.05	0.37	5.72e-9	Longevity (90 years and older);
SARC	trans	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg16141378	chr3:129829833	LOC729375	-0.55	-6.65	-0.4	2.12e-10	Systolic blood pressure;
SARC	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	11.07	0.59	3.6e-23	Alzheimer's disease;
SARC	cis	rs2075371	1.000	rs2244694	chr7:133987093	C/T	cg20476274	chr7:133979776	SLC35B4	0.62	8.49	0.49	2.43e-15	Mean platelet volume;
SARC	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-7.93	-0.46	8.96e-14	Chronic sinus infection;
SARC	cis	rs2425143	1.000	rs11700256	chr20:34372941	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.67	5.32	0.33	2.38e-7	Blood protein levels;
SARC	cis	rs10513432	0.826	rs16864613	chr3:152555452	C/G	cg04845053	chr3:152552877	P2RY1	0.88	4.86	0.3	2.14e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs4690686	0.500	rs4690688	chr4:177264192	G/C	cg17059388	chr4:177262070	NA	0.36	4.78	0.3	3.09e-6	Essential tremor;
SARC	cis	rs67366981	1.000	rs59262654	chr14:77712261	A/G	cg06779847	chr14:77687015	TMEM63C	-0.47	-5.22	-0.32	3.93e-7	Obsessive-compulsive symptoms;
SARC	cis	rs9814567	1.000	rs13071551	chr3:134310867	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	6.89	0.41	5.31e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs2153535	0.580	rs7743418	chr6:8438128	A/C	cg07606381	chr6:8435919	SLC35B3	0.79	11.13	0.59	2.34e-23	Motion sickness;
SARC	cis	rs7084402	1.000	rs1863664	chr10:60266839	A/G	cg07615347	chr10:60278583	BICC1	-0.58	-8.27	-0.48	1.04e-14	Refractive error;
SARC	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg06618935	chr21:46677482	NA	-0.37	-4.89	-0.31	1.85e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9394841	0.692	rs9381094	chr6:41800629	T/C	cg08135965	chr6:41755394	TOMM6	0.64	6.91	0.41	4.54e-11	Mean corpuscular hemoglobin;Red cell distribution width;
SARC	cis	rs10465746	0.725	rs12070578	chr1:84349607	A/G	cg10977910	chr1:84465055	TTLL7	0.42	5.09	0.32	7.37e-7	Obesity-related traits;
SARC	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs13082711	0.522	rs533175	chr3:27361432	A/G	cg02860705	chr3:27208620	NA	-0.41	-5.46	-0.34	1.19e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs4642101	0.561	rs9812144	chr3:12805910	G/A	cg05775895	chr3:12838266	CAND2	0.54	7.58	0.44	8.3e-13	QRS complex (12-leadsum);
SARC	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg21724239	chr8:58056113	NA	0.62	5.81	0.36	2.09e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg18436758	chr1:21113190	HP1BP3	0.5	6.26	0.38	1.82e-9	Height;
SARC	cis	rs9916302	0.653	rs4239223	chr17:37717004	T/C	cg07936489	chr17:37558343	FBXL20	-0.75	-8.82	-0.5	2.71e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs1348850	0.914	rs7604673	chr2:178392346	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.71	8.82	0.5	2.78e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs2985684	0.895	rs3007033	chr14:50103816	T/C	cg04989706	chr14:50066350	PPIL5	-0.53	-5.55	-0.34	7.76e-8	Carotid intima media thickness;
SARC	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg20090690	chr10:134436459	INPP5A	0.43	4.78	0.3	3.13e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs7582720	0.887	rs72934589	chr2:204017937	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.76	7.84	0.46	1.65e-13	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs3126085	0.935	rs7540844	chr1:152230586	A/T	cg26876637	chr1:152193138	HRNR	0.45	5.14	0.32	5.9e-7	Atopic dermatitis;
SARC	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg03806693	chr22:41940476	POLR3H	0.91	12.22	0.63	7.07e-27	Vitiligo;
SARC	cis	rs9443189	0.762	rs2748944	chr6:76436106	A/G	cg01950844	chr6:76311363	SENP6	0.82	7.75	0.45	2.8e-13	Prostate cancer;
SARC	cis	rs17666538	0.710	rs1703941	chr8:658447	G/A	cg23958373	chr8:599963	NA	0.87	6.73	0.4	1.3e-10	IgG glycosylation;
SARC	cis	rs950169	0.580	rs11630887	chr15:85193015	A/T	cg17507749	chr15:85114479	UBE2QP1	0.58	6.8	0.41	8.76e-11	Schizophrenia;
SARC	cis	rs4970988	0.787	rs1532770	chr1:150725335	G/T	cg10589385	chr1:150898437	SETDB1	0.39	5.09	0.32	7.52e-7	Urate levels;
SARC	cis	rs7819412	0.740	rs28633434	chr8:11053922	G/A	cg14752069	chr8:11977206	FAM66D	-0.3	-4.81	-0.3	2.7e-6	Triglycerides;
SARC	cis	rs7635838	0.892	rs9310384	chr3:11491980	A/G	cg00170343	chr3:11313890	ATG7	0.61	8.21	0.47	1.53e-14	HDL cholesterol;
SARC	trans	rs1563304	1	rs1563304	chr17:44874453	C/T	cg22968622	chr17:43663579	NA	0.72	6.5	0.39	4.91e-10	Neuroticism;
SARC	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg17376030	chr22:41985996	PMM1	0.77	9.57	0.53	1.66e-18	Vitiligo;
SARC	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.1	21.57	0.82	1.82e-57	Chronic sinus infection;
SARC	cis	rs7586879	0.616	rs11900505	chr2:25131986	A/C	cg04586622	chr2:25135609	ADCY3	0.3	5.11	0.32	6.64e-7	Body mass index;
SARC	cis	rs1707322	0.752	rs4586014	chr1:46150443	A/G	cg06784218	chr1:46089804	CCDC17	0.36	6.25	0.38	1.89e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	6.02	0.37	6.81e-9	Prudent dietary pattern;
SARC	cis	rs2228479	0.718	rs11645376	chr16:89912281	G/C	cg12064134	chr16:90016061	DEF8	-0.56	-4.83	-0.3	2.47e-6	Skin colour saturation;
SARC	trans	rs2727020	0.729	rs34647977	chr11:49195543	G/A	cg03929089	chr4:120376271	NA	-0.72	-9.96	-0.55	1.04e-19	Coronary artery disease;
SARC	cis	rs10089	0.953	rs114881127	chr5:127369661	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.87	10.36	0.56	6.04e-21	Ileal carcinoids;
SARC	cis	rs2908197	0.713	rs2961037	chr7:75952212	G/T	cg24580635	chr7:76178542	LOC100133091	-0.42	-4.85	-0.3	2.23e-6	3-hydroxypropylmercapturic acid levels in smokers;
SARC	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg01341218	chr17:43662625	NA	-0.86	-9.61	-0.53	1.28e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs2304069	0.954	rs216125	chr5:149428395	C/G	cg12661370	chr5:149340060	SLC26A2	0.57	5.61	0.35	5.64e-8	HIV-1 control;
SARC	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg05368731	chr17:41323189	NBR1	0.77	9.18	0.52	2.34e-17	Menopause (age at onset);
SARC	cis	rs9436747	0.528	rs9436748	chr1:65911672	G/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.41	-4.92	-0.31	1.62e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg04518342	chr5:131593106	PDLIM4	0.39	5.3	0.33	2.7e-7	Blood metabolite levels;
SARC	cis	rs9398803	0.741	rs9388501	chr6:126903011	T/C	cg20229609	chr6:126660872	C6orf173	0.35	5.07	0.31	8.26e-7	Male-pattern baldness;
SARC	cis	rs2841277	0.509	rs11850949	chr14:105408827	A/C	cg14403583	chr14:105418241	AHNAK2	-0.58	-7.79	-0.45	2.22e-13	Rheumatoid arthritis;
SARC	cis	rs6991838	0.778	rs7843697	chr8:66462768	G/A	cg13398993	chr8:66546079	ARMC1	0.42	5.22	0.32	4.03e-7	Intelligence (multi-trait analysis);
SARC	cis	rs11608355	0.545	rs4766604	chr12:109892179	T/C	cg05360138	chr12:110035743	NA	0.92	9.61	0.53	1.27e-18	Neuroticism;
SARC	cis	rs11098499	0.691	rs10028773	chr4:120265259	C/G	cg09307838	chr4:120376055	NA	-0.7	-9.53	-0.53	2.24e-18	Corneal astigmatism;
SARC	cis	rs12044355	0.929	rs6696914	chr1:231853480	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.53	7.08	0.42	1.73e-11	Alzheimer's disease;
SARC	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs425277	1.000	rs1401138	chr1:2063149	C/T	cg21442419	chr1:2182373	SKI	-0.49	-6.06	-0.37	5.3300000000000004e-09	Height;
SARC	cis	rs2153535	0.601	rs1855768	chr6:8472969	T/G	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	cis	rs16976116	0.901	rs9920219	chr15:55503964	T/C	cg17854078	chr15:55489399	RSL24D1	0.64	6.27	0.38	1.74e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs10988449	1.000	rs10988449	chr9:132370360	C/T	cg18327994	chr9:132372705	NA	-0.48	-5.0	-0.31	1.14e-6	Response to anti-depressant treatment in major depressive disorder;
SARC	trans	rs61931739	0.513	rs1608906	chr12:33894986	T/C	cg26384229	chr12:38710491	ALG10B	0.62	8.19	0.47	1.73e-14	Morning vs. evening chronotype;
SARC	cis	rs735396	0.694	rs2264750	chr12:121450165	C/T	cg25281562	chr12:121454272	C12orf43	0.57	7.14	0.42	1.15e-11	N-glycan levels;
SARC	cis	rs3796352	1.000	rs35720014	chr3:52982110	A/C	cg12962167	chr3:53033115	SFMBT1	0.82	5.27	0.33	3.14e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs6060717	0.536	rs6058364	chr20:34507890	G/C	cg01084648	chr20:34329383	RBM39	0.62	4.73	0.3	3.89e-6	Hip circumference adjusted for BMI;
SARC	cis	rs12824058	0.831	rs12314111	chr12:130813663	G/T	cg24838063	chr12:130822603	PIWIL1	0.63	8.91	0.5	1.52e-16	Menopause (age at onset);
SARC	trans	rs5760092	0.755	rs6003959	chr22:24264395	C/T	cg06437703	chr8:37914619	EIF4EBP1	0.68	7.86	0.46	1.45e-13	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs6121246	0.567	rs6060249	chr20:30190944	G/A	cg21427119	chr20:30132790	HM13	-0.48	-5.29	-0.33	2.84e-7	Mean corpuscular hemoglobin;
SARC	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg04277193	chr17:41438351	NA	0.44	4.78	0.3	3.04e-6	Menopause (age at onset);
SARC	cis	rs910316	1.000	rs175443	chr14:75601963	C/T	cg11812906	chr14:75593930	NEK9	-0.83	-12.34	-0.63	2.86e-27	Height;
SARC	cis	rs7949030	0.653	rs2516634	chr11:62367186	G/A	cg22862634	chr11:62369728	EML3;MTA2	-0.54	-8.6	-0.49	1.21e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg15556689	chr8:8085844	FLJ10661	0.48	6.26	0.38	1.81e-9	Mood instability;
SARC	cis	rs6696846	0.765	rs11240360	chr1:205083865	T/C	cg00857998	chr1:205179979	DSTYK	0.49	6.13	0.37	3.73e-9	Red blood cell count;
SARC	cis	rs554111	0.593	rs7540023	chr1:21310092	T/C	cg08890418	chr1:21044141	KIF17	-0.36	-4.97	-0.31	1.29e-6	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg26335602	chr6:28129616	ZNF389	0.55	6.12	0.37	3.99e-9	Parkinson's disease;
SARC	cis	rs12701220	0.553	rs13245507	chr7:1163694	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.36	-4.76	-0.3	3.35e-6	Bronchopulmonary dysplasia;
SARC	cis	rs7937682	0.632	rs10891297	chr11:111770150	C/T	cg09085632	chr11:111637200	PPP2R1B	0.82	10.92	0.58	1.09e-22	Primary sclerosing cholangitis;
SARC	cis	rs7772486	0.754	rs6570718	chr6:146088443	T/G	cg05347473	chr6:146136440	FBXO30	-0.55	-7.7	-0.45	3.97e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2439831	0.850	rs28413881	chr15:44174099	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	7.65	0.45	5.13e-13	Lung cancer in ever smokers;
SARC	cis	rs7582180	0.629	rs11688285	chr2:100948054	A/C	cg14675211	chr2:100938903	LONRF2	0.5	7.47	0.44	1.63e-12	Intelligence (multi-trait analysis);
SARC	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	10.54	0.57	1.68e-21	Platelet count;
SARC	cis	rs2227564	0.729	rs2633304	chr10:75650650	T/C	cg16540259	chr10:75572220	NDST2	0.35	4.97	0.31	1.29e-6	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs11997175	0.624	rs79944133	chr8:33730588	A/G	ch.8.33884649F	chr8:33765107	NA	0.57	7.32	0.43	4.08e-12	Body mass index;
SARC	cis	rs10752881	1.000	rs4233193	chr1:182970865	C/T	cg13390022	chr1:182993471	LAMC1	0.34	5.15	0.32	5.59e-7	Colorectal cancer;
SARC	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg04518342	chr5:131593106	PDLIM4	-0.44	-5.74	-0.35	2.98e-8	Breast cancer;
SARC	cis	rs2120243	0.508	rs12492874	chr3:157113227	C/A	cg24825693	chr3:157122686	VEPH1	-0.46	-6.42	-0.39	7.47e-10	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs9325144	0.555	rs7301258	chr12:38706942	C/T	cg13010199	chr12:38710504	ALG10B	0.53	6.83	0.41	7.38e-11	Morning vs. evening chronotype;
SARC	cis	rs453301	0.631	rs7843789	chr8:8800561	G/C	cg08975724	chr8:8085496	FLJ10661	-0.42	-5.08	-0.32	7.64e-7	Joint mobility (Beighton score);
SARC	cis	rs9640161	0.789	rs11767409	chr7:150058043	C/T	cg21361702	chr7:150065534	REPIN1	0.58	6.13	0.37	3.63e-9	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs9902453	0.934	rs34433787	chr17:28496780	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	6.77	0.41	1.07e-10	Coffee consumption (cups per day);
SARC	cis	rs1348850	0.567	rs880897	chr2:178532503	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.4	4.79	0.3	3e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg17691542	chr6:26056736	HIST1H1C	0.47	5.77	0.35	2.55e-8	Height;
SARC	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg22857025	chr5:266934	NA	-1.08	-11.86	-0.61	1.06e-25	Breast cancer;
SARC	cis	rs2239547	0.562	rs6794389	chr3:53096394	A/G	cg11645453	chr3:52864694	ITIH4	0.32	5.09	0.32	7.43e-7	Schizophrenia;
SARC	cis	rs7264396	0.635	rs6058365	chr20:34508092	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	5.34	0.33	2.21e-7	Total cholesterol levels;
SARC	cis	rs4805272	0.539	rs7256211	chr19:29333063	C/G	cg12756686	chr19:29218302	NA	0.51	5.77	0.35	2.56e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
SARC	cis	rs2180341	0.842	rs9375492	chr6:127545492	C/T	cg27446573	chr6:127587934	RNF146	-1.03	-12.68	-0.64	2.37e-28	Breast cancer;
SARC	cis	rs1904096	0.506	rs11097408	chr4:95165662	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.48	-7.29	-0.43	4.93e-12	Type 2 diabetes;
SARC	cis	rs9346455	1.000	rs9342828	chr6:71993657	T/C	cg27238071	chr6:71998145	OGFRL1	0.58	4.81	0.3	2.73e-6	Antipsychotic drug-induced weight gain (time interaction);Antipsychotic drug-induced weight gain;
SARC	cis	rs6701037	0.875	rs6929	chr1:175126721	A/G	cg00321850	chr1:175162397	KIAA0040	-0.32	-5.04	-0.31	9.45e-7	Alcohol dependence;
SARC	cis	rs10490913	0.806	rs10886237	chr10:120170492	C/T	cg23160142	chr10:120154512	NA	0.4	6.05	0.37	5.86e-9	Cancer;
SARC	cis	rs11190604	0.767	rs35508946	chr10:102191156	A/G	cg07080220	chr10:102295463	HIF1AN	0.71	8.15	0.47	2.29e-14	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs614226	0.872	rs12307148	chr12:120903179	T/C	cg01236616	chr12:121019343	POP5	-1.15	-16.1	-0.73	1.02e-39	Type 1 diabetes nephropathy;
SARC	cis	rs9398803	0.678	rs9375448	chr6:126896782	A/T	cg20229609	chr6:126660872	C6orf173	0.37	5.39	0.33	1.74e-7	Male-pattern baldness;
SARC	cis	rs12291225	0.585	rs34171876	chr11:14353957	G/C	cg19336497	chr11:14380999	RRAS2	-0.45	-7.98	-0.46	6.58e-14	Sense of smell;
SARC	cis	rs7520050	0.966	rs10890363	chr1:46356148	C/T	cg24296786	chr1:45957014	TESK2	-0.38	-4.82	-0.3	2.55e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg00290607	chr11:67383545	NA	0.59	8.47	0.49	2.79e-15	Mean corpuscular volume;
SARC	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg06558623	chr16:89946397	TCF25	0.83	6.88	0.41	5.39e-11	Skin colour saturation;
SARC	cis	rs1865760	0.508	rs9379820	chr6:26049924	T/C	cg18357526	chr6:26021779	HIST1H4A	0.43	5.32	0.33	2.42e-7	Height;
SARC	cis	rs7772486	0.776	rs2265467	chr6:146218339	T/A	cg05347473	chr6:146136440	FBXO30	0.46	6.15	0.37	3.41e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg13072238	chr3:49761600	GMPPB	0.42	5.54	0.34	8.33e-8	Intelligence (multi-trait analysis);
SARC	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	cis	rs9914544	0.545	rs4924945	chr17:18813160	A/G	cg25390199	chr17:18761479	PRPSAP2	0.45	5.97	0.36	8.57e-9	Educational attainment (years of education);
SARC	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg26335602	chr6:28129616	ZNF389	0.45	5.12	0.32	6.53e-7	Cardiac Troponin-T levels;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg17823230	chr13:111141841	COL4A2	0.73	5.37	0.33	1.93e-7	Obesity-related traits;
SARC	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg13770153	chr20:60521292	NA	-0.72	-10.37	-0.56	5.61e-21	Obesity-related traits;
SARC	cis	rs2075371	0.966	rs1619682	chr7:133996703	T/G	cg00033643	chr7:134001901	SLC35B4	0.42	5.06	0.31	8.41e-7	Mean platelet volume;
SARC	cis	rs995000	0.931	rs1168036	chr1:62962734	A/G	cg06896770	chr1:63153194	DOCK7	-0.89	-12.89	-0.65	4.52e-29	Triglyceride levels;
SARC	cis	rs7089973	0.872	rs7909566	chr10:116629136	A/G	cg08188268	chr10:116634841	FAM160B1	0.37	5.89	0.36	1.33e-8	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs7872515	0.838	rs6479403	chr9:94829156	A/G	cg01248375	chr9:94877805	SPTLC1	0.56	5.33	0.33	2.35e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs6546324	0.959	rs11126143	chr2:67865408	A/G	cg18237512	chr2:67827392	NA	0.41	5.29	0.33	2.88e-7	Endometriosis;
SARC	cis	rs17376456	0.569	rs17083377	chr5:93164870	C/G	cg25358565	chr5:93447407	FAM172A	0.9	10.12	0.55	3.49e-20	Diabetic retinopathy;
SARC	cis	rs3796352	1.000	rs35507120	chr3:53053924	C/T	cg27565382	chr3:53032988	SFMBT1	1.05	7.3	0.43	4.42e-12	Immune reponse to smallpox (secreted IL-2);
SARC	trans	rs61931739	0.534	rs10844774	chr12:34166764	C/T	cg13010199	chr12:38710504	ALG10B	0.73	9.84	0.54	2.42e-19	Morning vs. evening chronotype;
SARC	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.45	-5.72	-0.35	3.33e-8	Blood metabolite levels;
SARC	cis	rs9911578	0.967	rs686425	chr17:56776730	A/G	cg12560992	chr17:57184187	TRIM37	0.83	11.24	0.59	1.02e-23	Intelligence (multi-trait analysis);
SARC	cis	rs9457247	1.000	rs10946198	chr6:167404432	C/T	cg23791538	chr6:167370224	RNASET2	-0.63	-8.74	-0.5	4.69e-16	Crohn's disease;
SARC	trans	rs8020941	0.585	rs78311053	chr14:97497543	A/G	cg05136476	chr3:53190709	NA	-0.63	-6.39	-0.39	8.99e-10	Diabetic kidney disease;
SARC	cis	rs10078	0.515	rs890984	chr5:479540	A/G	cg07599136	chr5:415885	AHRR	0.66	5.93	0.36	1.09e-8	Fat distribution (HIV);
SARC	cis	rs365132	0.875	rs4490607	chr5:176349386	T/C	cg16309518	chr5:176445507	NA	-0.48	-6.24	-0.38	2.01e-9	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs6831352	0.918	rs13107558	chr4:100050200	C/A	cg12011299	chr4:100065546	ADH4	-0.3	-5.11	-0.32	6.65e-7	Alcohol dependence;
SARC	cis	rs11055008	0.935	rs10845601	chr12:12820134	A/G	cg04607235	chr12:12878440	APOLD1	0.44	5.2	0.32	4.39e-7	Pulse pressure;
SARC	cis	rs9398803	0.865	rs9375441	chr6:126778600	G/A	cg19875578	chr6:126661172	C6orf173	0.63	8.6	0.49	1.17e-15	Male-pattern baldness;
SARC	cis	rs1419980	0.673	rs7296837	chr12:7757832	A/G	cg10578777	chr12:7781093	NA	0.56	6.01	0.37	6.92e-9	HDL cholesterol levels;
SARC	cis	rs367615	0.660	rs4632850	chr5:108832883	C/G	cg17395555	chr5:108820864	NA	0.47	6.59	0.4	2.98e-10	Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs611744	0.647	rs4735053	chr8:109260776	A/G	cg21045802	chr8:109455806	TTC35	0.6	7.71	0.45	3.55e-13	Dupuytren's disease;
SARC	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg11905131	chr22:24372483	LOC391322	-0.42	-4.89	-0.31	1.84e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6580649	0.941	rs4760683	chr12:48516296	T/C	cg05342945	chr12:48394962	COL2A1	0.45	4.84	0.3	2.38e-6	Lung cancer;
SARC	cis	rs2486288	0.656	rs7166580	chr15:45571209	C/G	cg15395560	chr15:45543142	SLC28A2	0.31	6.0	0.37	7.43e-9	Glomerular filtration rate;
SARC	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg04166393	chr7:2884313	GNA12	0.49	5.39	0.33	1.75e-7	Height;
SARC	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg08677398	chr8:58056175	NA	0.43	5.0	0.31	1.13e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs9910055	0.529	rs228748	chr17:42174390	G/A	cg19774624	chr17:42201019	HDAC5	0.53	6.43	0.39	7.02e-10	Total body bone mineral density;
SARC	cis	rs10752881	0.967	rs4652758	chr1:182975100	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.76	0.58	3.38e-22	Colorectal cancer;
SARC	cis	rs1371867	0.846	rs1660323	chr8:101278724	T/A	cg11906718	chr8:101322791	RNF19A	0.73	9.41	0.52	4.96e-18	Atrioventricular conduction;
SARC	cis	rs7727544	0.684	rs272849	chr5:131690241	A/G	cg24060327	chr5:131705240	SLC22A5	-0.69	-8.81	-0.5	2.95e-16	Blood metabolite levels;
SARC	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.57	-0.4	3.25e-10	Total body bone mineral density;
SARC	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg00933542	chr6:150070202	PCMT1	0.33	5.49	0.34	1.04e-7	Lung cancer;
SARC	cis	rs1949733	0.582	rs61258495	chr4:8534017	G/A	cg11789530	chr4:8429930	ACOX3	-0.5	-5.83	-0.36	1.85e-8	Response to antineoplastic agents;
SARC	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg16606324	chr3:10149918	C3orf24	0.5	5.01	0.31	1.08e-6	Alzheimer's disease;
SARC	cis	rs6582630	0.555	rs7294313	chr12:38323603	G/A	cg26384229	chr12:38710491	ALG10B	-0.57	-6.93	-0.41	4.11e-11	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6570726	0.764	rs367065	chr6:145882309	T/G	cg23711669	chr6:146136114	FBXO30	0.83	13.68	0.67	1.11e-31	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg11644478	chr21:40555479	PSMG1	1.06	15.22	0.71	9e-37	Cognitive function;
SARC	trans	rs12310956	0.510	rs10844694	chr12:33865682	A/C	cg13010199	chr12:38710504	ALG10B	0.56	7.32	0.43	3.98e-12	Morning vs. evening chronotype;
SARC	cis	rs8180040	0.966	rs7628631	chr3:47560863	C/T	cg27129171	chr3:47204927	SETD2	-0.68	-9.14	-0.51	3.07e-17	Colorectal cancer;
SARC	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg11644478	chr21:40555479	PSMG1	1.02	14.57	0.69	1.3e-34	Cognitive function;
SARC	cis	rs870825	0.616	rs6552801	chr4:185620623	G/A	cg04058563	chr4:185651563	MLF1IP	0.82	11.42	0.6	2.8e-24	Blood protein levels;
SARC	cis	rs9916302	0.706	rs4795358	chr17:37573065	A/C	cg15445000	chr17:37608096	MED1	0.46	4.89	0.3	1.91e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs4589502	0.502	rs2169460	chr15:67197240	A/G	cg18595228	chr15:67193261	NA	-0.56	-6.02	-0.37	6.74e-9	Lung cancer (smoking interaction);
SARC	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-8.94	-0.51	1.25e-16	Alzheimer's disease;
SARC	cis	rs9920	0.585	rs62468993	chr7:116140764	G/A	cg24770985	chr7:116166421	CAV1	0.87	5.67	0.35	4.26e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Immature fraction of reticulocytes;QT interval;
SARC	cis	rs35213789	0.887	rs4717521	chr7:69206930	A/G	cg10619644	chr7:69149951	AUTS2	-0.43	-5.82	-0.36	1.89e-8	Childhood ear infection;
SARC	cis	rs11122272	0.735	rs2808585	chr1:231514218	C/T	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	trans	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.59	6.99	0.42	2.83e-11	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6570726	0.791	rs440477	chr6:145854188	C/T	cg23711669	chr6:146136114	FBXO30	0.87	14.71	0.69	4.26e-35	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg01475735	chr3:40494733	NA	0.46	5.22	0.32	4.04e-7	Renal cell carcinoma;
SARC	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg12564285	chr5:131593104	PDLIM4	0.45	6.11	0.37	4.12e-9	Breast cancer;
SARC	cis	rs11581859	0.613	rs28545337	chr1:99191143	C/T	cg20286094	chr1:99190917	SNX7	-0.42	-4.93	-0.31	1.55e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg09699651	chr6:150184138	LRP11	0.38	4.76	0.3	3.37e-6	Lung cancer;
SARC	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg03709012	chr19:19516395	GATAD2A	1.01	17.49	0.75	2.65e-44	Tonsillectomy;
SARC	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg21644426	chr2:191273491	MFSD6	0.52	7.0	0.42	2.66e-11	Pulse pressure;
SARC	cis	rs2075371	0.932	rs34664116	chr7:133984878	G/A	cg11752832	chr7:134001865	SLC35B4	0.52	6.52	0.39	4.39e-10	Mean platelet volume;
SARC	cis	rs11249608	0.636	rs6888567	chr5:178449074	C/T	cg21905437	chr5:178450457	ZNF879	-0.59	-7.9	-0.46	1.08e-13	Pubertal anthropometrics;
SARC	cis	rs7666738	0.830	rs11727653	chr4:99001774	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2153535	0.580	rs2327057	chr6:8443319	G/A	cg21535247	chr6:8435926	SLC35B3	0.57	7.07	0.42	1.77e-11	Motion sickness;
SARC	cis	rs422249	0.512	rs174554	chr11:61579463	A/G	cg19610905	chr11:61596333	FADS2	-0.4	-4.79	-0.3	3.03e-6	Trans fatty acid levels;
SARC	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg22535103	chr8:58192502	C8orf71	-0.73	-7.25	-0.43	5.96e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs2153535	0.580	rs6937186	chr6:8494493	A/C	cg23788917	chr6:8435910	SLC35B3	0.64	8.41	0.48	4.24e-15	Motion sickness;
SARC	cis	rs2777491	0.915	rs8032838	chr15:41605632	G/A	cg01768344	chr15:41576519	LOC729082	0.44	4.9	0.31	1.76e-6	Ulcerative colitis;
SARC	cis	rs1707322	0.752	rs11211146	chr1:46109794	T/C	cg03146154	chr1:46216737	IPP	0.51	6.03	0.37	6.22e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs910316	1.000	rs12897094	chr14:75579416	C/T	cg11812906	chr14:75593930	NEK9	0.87	13.55	0.66	3.08e-31	Height;
SARC	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.71	-7.47	-0.44	1.63e-12	Platelet count;
SARC	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg11062466	chr8:58055876	NA	0.54	5.56	0.34	7.55e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2486288	0.656	rs11632651	chr15:45550838	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.45	-5.57	-0.34	7.07e-8	Glomerular filtration rate;
SARC	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg24642844	chr7:1081250	C7orf50	-0.6	-6.12	-0.37	3.83e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs910316	1.000	rs3742780	chr14:75505008	G/C	cg23033748	chr14:75592666	NEK9	0.35	4.77	0.3	3.22e-6	Height;
SARC	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.98	-16.12	-0.73	9.07e-40	Chronic sinus infection;
SARC	cis	rs1267303	0.600	rs57100184	chr1:47004710	A/C	cg25110126	chr1:46999211	NA	0.89	9.25	0.52	1.51e-17	Monobrow;
SARC	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg20607798	chr8:58055168	NA	0.65	5.61	0.35	5.68e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg12463550	chr7:65579703	CRCP	0.48	5.79	0.35	2.23e-8	Aortic root size;
SARC	cis	rs4319547	0.728	rs61954974	chr12:123074169	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.66	-7.98	-0.46	6.73e-14	Body mass index;
SARC	cis	rs11122272	0.735	rs2247124	chr1:231493687	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-9.88	-0.54	1.83e-19	Hemoglobin concentration;
SARC	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg00933542	chr6:150070202	PCMT1	0.3	5.08	0.32	7.56e-7	Lung cancer;
SARC	cis	rs992157	0.767	rs2014615	chr2:219171191	A/G	cg00012203	chr2:219082015	ARPC2	0.63	9.26	0.52	1.4e-17	Colorectal cancer;
SARC	cis	rs3820928	0.874	rs2177594	chr2:227836239	C/G	cg11843606	chr2:227700838	RHBDD1	-0.56	-6.88	-0.41	5.63e-11	Pulmonary function;
SARC	cis	rs2832191	0.935	rs11910316	chr21:30519729	G/A	cg24692254	chr21:30365293	RNF160	-0.79	-11.12	-0.59	2.53e-23	Dental caries;
SARC	cis	rs4803468	1.000	rs284658	chr19:41929988	G/A	cg08477640	chr19:41863820	B9D2	0.41	5.11	0.32	6.7e-7	Height;
SARC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg05165339	chr4:1420672	NA	-0.25	-5.46	-0.34	1.24e-7	Longevity;
SARC	cis	rs2120019	0.517	rs872263	chr15:75136444	C/T	cg12414181	chr15:75287860	SCAMP5	-0.56	-4.92	-0.31	1.65e-6	Blood trace element (Zn levels);
SARC	cis	rs933688	1.000	rs7720132	chr5:90745105	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.0	12.52	0.63	7.66e-28	Smoking behavior;
SARC	trans	rs2388896	1.000	rs1854013	chr10:8951670	A/T	cg14153061	chr9:102669613	STX17	0.45	6.27	0.38	1.71e-9	Tetralogy of Fallot;
SARC	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg09359103	chr1:154839909	KCNN3	-0.44	-7.39	-0.44	2.58e-12	Prostate cancer;
SARC	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg05793240	chr7:2802953	GNA12	-0.37	-5.33	-0.33	2.36e-7	Height;
SARC	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg02462569	chr6:150064036	NUP43	-0.37	-4.8	-0.3	2.85e-6	Lung cancer;
SARC	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg18135555	chr8:22132992	PIWIL2	0.39	5.81	0.36	2.01e-8	Hypertriglyceridemia;
SARC	cis	rs11997175	0.819	rs6415400	chr8:33783714	C/T	ch.8.33884649F	chr8:33765107	NA	0.52	7.13	0.42	1.24e-11	Body mass index;
SARC	cis	rs7937682	0.632	rs11214009	chr11:111683142	T/C	cg09085632	chr11:111637200	PPP2R1B	0.8	10.69	0.57	5.93e-22	Primary sclerosing cholangitis;
SARC	cis	rs2412208	0.509	rs7546792	chr1:7124346	C/T	cg20434152	chr1:7120926	CAMTA1	-0.31	-5.23	-0.32	3.71e-7	Survival in sporadic amyotrophic lateral sclerosis;
SARC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.58	0.57	1.3e-21	Prudent dietary pattern;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg26726589	chr20:306364	SOX12	0.49	6.33	0.38	1.27e-9	Chemerin levels;
SARC	cis	rs72634258	0.740	rs6665452	chr1:8172492	A/T	cg00042356	chr1:8021962	PARK7	-0.64	-5.98	-0.36	8.19e-9	Inflammatory bowel disease;
SARC	cis	rs11190604	0.666	rs7084768	chr10:102200497	T/C	cg07080220	chr10:102295463	HIF1AN	-0.68	-8.23	-0.47	1.35e-14	Palmitoleic acid (16:1n-7) levels;
SARC	trans	rs1161098	0.723	rs1178001	chr12:67825798	G/A	cg14535245	chr2:47283713	TTC7A	-0.64	-6.29	-0.38	1.55e-9	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs3796352	1.000	rs116616340	chr3:53132371	C/G	cg15956490	chr3:53032818	SFMBT1	0.77	5.29	0.33	2.88e-7	Immune reponse to smallpox (secreted IL-2);
SARC	trans	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg21659725	chr3:3221576	CRBN	0.81	12.44	0.63	1.38e-27	Intelligence (multi-trait analysis);
SARC	cis	rs1215050	0.846	rs783923	chr4:98968686	C/T	cg05340658	chr4:99064831	C4orf37	-0.42	-5.39	-0.33	1.72e-7	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs12421382	0.543	rs11213094	chr11:109357926	G/A	cg11473876	chr11:109292803	C11orf87	0.42	5.36	0.33	1.96e-7	Schizophrenia;
SARC	cis	rs6450176	1.000	rs1445887	chr5:53299376	A/T	ch.5.1024479R	chr5:53302184	ARL15	-0.67	-7.78	-0.45	2.32e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg03647317	chr4:187891568	NA	-0.4	-5.73	-0.35	3.03e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9815354	0.812	rs4264702	chr3:41952539	T/A	cg03022575	chr3:42003672	ULK4	0.7	5.7	0.35	3.66e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs3617	0.625	rs11719137	chr3:52876389	G/T	cg04865290	chr3:52927548	TMEM110	0.35	5.02	0.31	1.02e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs6542838	0.702	rs6739176	chr2:99536846	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.45	-5.83	-0.36	1.88e-8	Fear of minor pain;
SARC	cis	rs3756766	0.500	rs4835676	chr5:137648417	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.53	6.42	0.39	7.52e-10	Schizophrenia;
SARC	cis	rs3540	0.960	rs8025842	chr15:90995471	C/T	cg22089800	chr15:90895588	ZNF774	0.54	6.27	0.38	1.72e-9	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs7666738	0.830	rs34892904	chr4:98938097	T/C	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg11062466	chr8:58055876	NA	0.55	5.07	0.32	8.25e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg24829409	chr8:58192753	C8orf71	-0.58	-5.24	-0.32	3.55e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-4.75	-0.3	3.61e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs561341	1.000	rs501312	chr17:30329066	A/G	cg00745463	chr17:30367425	LRRC37B	-0.62	-5.04	-0.31	9.23e-7	Hip circumference adjusted for BMI;
SARC	trans	rs1814175	0.817	rs10839401	chr11:49876144	C/T	cg15704280	chr7:45808275	SEPT13	-0.96	-18.05	-0.76	3.72e-46	Height;
SARC	cis	rs2439831	0.702	rs2788	chr15:44064886	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	8.62	0.49	1.07e-15	Lung cancer in ever smokers;
SARC	cis	rs12956009	0.583	rs1115360	chr18:44894550	C/G	cg15049968	chr18:44337910	ST8SIA5	-0.31	-4.72	-0.3	4.11e-6	Educational attainment (years of education);
SARC	cis	rs72781680	1.000	rs7581107	chr2:24173565	C/T	cg06627628	chr2:24431161	ITSN2	-0.7	-6.69	-0.4	1.64e-10	Lymphocyte counts;
SARC	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg13448127	chr9:109622908	NA	-0.46	-6.24	-0.38	2.09e-9	Thyroid cancer;
SARC	cis	rs4853036	0.857	rs12613717	chr2:70039263	T/G	cg02498382	chr2:70120550	SNRNP27	-0.36	-4.75	-0.3	3.48e-6	Colorectal or endometrial cancer;
SARC	cis	rs7247513	0.639	rs12984441	chr19:12760287	A/C	cg01871581	chr19:12707946	ZNF490	-0.77	-11.32	-0.6	5.99e-24	Bipolar disorder;
SARC	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.7	6.55	0.39	3.61e-10	Platelet count;
SARC	cis	rs9916302	0.904	rs8076494	chr17:37516722	A/G	cg20243544	chr17:37824526	PNMT	-0.57	-6.42	-0.39	7.39e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs9815354	0.951	rs1716679	chr3:41905339	T/C	cg03022575	chr3:42003672	ULK4	0.56	5.29	0.33	2.81e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs193541	0.593	rs154499	chr5:122219666	A/C	cg19412675	chr5:122181750	SNX24	0.48	6.27	0.38	1.73e-9	Glucose homeostasis traits;
SARC	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg08280861	chr8:58055591	NA	0.57	5.47	0.34	1.14e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs546131	0.642	rs1897203	chr11:34821988	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-4.99	-0.31	1.19e-6	Lung disease severity in cystic fibrosis;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg26670626	chr7:99613244	ZKSCAN1	0.52	6.45	0.39	6.39e-10	Breast cancer;
SARC	cis	rs7624766	0.903	rs9838392	chr3:160432549	A/G	cg22637730	chr3:160473554	PPM1L	0.38	4.96	0.31	1.34e-6	Response to methotrexate in rheumatoid arthritis;
SARC	cis	rs17376456	0.866	rs13356088	chr5:93423479	C/T	cg21475434	chr5:93447410	FAM172A	0.84	6.72	0.4	1.4e-10	Diabetic retinopathy;
SARC	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg18252515	chr7:66147081	NA	0.45	4.97	0.31	1.3e-6	Aortic root size;
SARC	cis	rs10504229	0.679	rs16921687	chr8:58053514	T/C	cg11062466	chr8:58055876	NA	0.51	5.05	0.31	8.85e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg08109568	chr15:31115862	NA	-0.52	-6.69	-0.4	1.63e-10	Huntington's disease progression;
SARC	cis	rs472402	0.623	rs8192135	chr5:6636757	T/A	cg27314116	chr5:6583850	LOC255167	0.31	4.9	0.31	1.75e-6	Response to amphetamines;
SARC	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.57	5.28	0.33	2.98e-7	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg06618935	chr21:46677482	NA	-0.4	-5.25	-0.33	3.5e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs208520	0.690	rs4618506	chr6:66756889	A/C	cg07460842	chr6:66804631	NA	-1.04	-14.11	-0.68	4.38e-33	Exhaled nitric oxide output;
SARC	cis	rs6964587	0.869	rs6964050	chr7:91482418	C/T	cg17063962	chr7:91808500	NA	-0.91	-13.69	-0.67	1.08e-31	Breast cancer;
SARC	cis	rs9303542	0.559	rs2229302	chr17:46620402	G/A	cg04904318	chr17:46607828	HOXB1	-0.44	-4.88	-0.3	1.93e-6	Ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs796364	0.806	rs11694236	chr2:200916230	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-6.61	-0.4	2.63e-10	Schizophrenia;
SARC	cis	rs67460515	0.630	rs7638370	chr3:160921793	G/T	cg17135325	chr3:160939158	NMD3	0.68	8.66	0.49	7.95e-16	Parkinson's disease;
SARC	cis	rs2425143	1.000	rs6060572	chr20:34294015	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-6.78	-0.41	9.68e-11	Blood protein levels;
SARC	cis	rs35110281	0.840	rs2838331	chr21:45026728	A/G	cg21573476	chr21:45109991	RRP1B	0.55	7.89	0.46	1.19e-13	Mean corpuscular volume;
SARC	cis	rs9790314	0.747	rs7650703	chr3:160851639	T/C	cg04691961	chr3:161091175	C3orf57	-0.68	-9.61	-0.53	1.27e-18	Morning vs. evening chronotype;
SARC	cis	rs6991838	0.612	rs7832407	chr8:66533306	C/T	cg13398993	chr8:66546079	ARMC1	0.62	8.19	0.47	1.72e-14	Intelligence (multi-trait analysis);
SARC	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg04518342	chr5:131593106	PDLIM4	0.36	5.01	0.31	1.07e-6	Breast cancer;
SARC	cis	rs6594499	0.872	rs1379300	chr5:110441439	A/G	cg04022379	chr5:110408740	TSLP	0.41	5.1	0.32	6.87e-7	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs8014204	0.762	rs10138360	chr14:75293386	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.55	-7.77	-0.45	2.46e-13	Caffeine consumption;
SARC	cis	rs3087591	0.708	rs2854307	chr17:29652147	G/A	cg24425628	chr17:29625626	OMG;NF1	0.42	5.38	0.33	1.8e-7	Hip circumference;
SARC	cis	rs992157	0.798	rs10206064	chr2:219157959	T/C	cg00012203	chr2:219082015	ARPC2	0.65	9.23	0.52	1.74e-17	Colorectal cancer;
SARC	cis	rs6088590	1.000	rs12626122	chr20:33425800	A/G	cg06115741	chr20:33292138	TP53INP2	0.45	5.19	0.32	4.53e-7	Coronary artery disease;
SARC	cis	rs6964587	1.000	rs13230588	chr7:91615427	C/A	cg17063962	chr7:91808500	NA	0.93	15.5	0.71	9.99e-38	Breast cancer;
SARC	cis	rs2073300	0.609	rs6137929	chr20:23376357	G/A	cg12062639	chr20:23401060	NAPB	0.95	6.5	0.39	4.74e-10	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg07414643	chr4:187882934	NA	0.46	6.66	0.4	1.92e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9815354	1.000	rs1717020	chr3:41981490	A/C	cg03022575	chr3:42003672	ULK4	0.57	5.54	0.34	8.13e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.46	-5.87	-0.36	1.47e-8	Tonsillectomy;
SARC	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg11890956	chr21:40555474	PSMG1	-1.04	-14.62	-0.69	8.91e-35	Cognitive function;
SARC	cis	rs11083475	0.681	rs62121377	chr19:39257296	G/A	cg07905965	chr19:39260460	NA	0.48	7.9	0.46	1.1e-13	Heart rate;
SARC	cis	rs2816062	0.775	rs2816046	chr1:18893708	A/G	cg18795169	chr1:18902165	NA	-0.76	-11.79	-0.61	1.76e-25	Urate levels in lean individuals;
SARC	cis	rs4803468	1.000	rs1473248	chr19:41923314	C/T	cg14132834	chr19:41945861	ATP5SL	0.57	7.67	0.45	4.69e-13	Height;
SARC	cis	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg11266682	chr4:10021025	SLC2A9	0.41	7.29	0.43	4.75e-12	Bone mineral density;
SARC	cis	rs11997175	0.624	rs10435522	chr8:33698608	G/A	ch.8.33884649F	chr8:33765107	NA	0.56	7.24	0.43	6.38e-12	Body mass index;
SARC	cis	rs2908197	0.762	rs2908192	chr7:75949617	C/T	cg22830091	chr7:75961684	YWHAG	-0.33	-4.93	-0.31	1.53e-6	3-hydroxypropylmercapturic acid levels in smokers;
SARC	cis	rs889312	0.924	rs4700485	chr5:56034207	A/G	cg14703610	chr5:56206110	C5orf35	0.42	5.05	0.31	9.11e-7	Breast cancer;Breast cancer (early onset);
SARC	cis	rs4242434	0.927	rs11136093	chr8:22479988	C/G	cg03733263	chr8:22462867	KIAA1967	1.03	15.75	0.72	1.48e-38	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs7786808	0.608	rs6978352	chr7:158209802	T/C	cg01191920	chr7:158217561	PTPRN2	0.35	5.98	0.36	8.26e-9	Obesity-related traits;
SARC	cis	rs73206853	0.764	rs7312469	chr12:110889072	A/G	cg10860002	chr12:110842031	ANAPC7	0.63	4.98	0.31	1.22e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs6580649	0.941	rs12580764	chr12:48453882	G/A	cg05342945	chr12:48394962	COL2A1	0.57	6.15	0.37	3.42e-9	Lung cancer;
SARC	trans	rs3779273	1.000	rs1829990	chr7:77829312	A/G	cg05596911	chr5:118502651	DMXL1	-0.54	-6.86	-0.41	6.06e-11	Body mass index;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg16538507	chr16:21513691	LOC100271836	0.5	6.44	0.39	6.82e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs986417	1.000	rs1254292	chr14:60863636	T/C	cg27398547	chr14:60952738	C14orf39	-0.99	-9.29	-0.52	1.17e-17	Gut microbiota (bacterial taxa);
SARC	cis	rs911555	0.755	rs8014013	chr14:103937372	A/G	cg24130564	chr14:104152367	KLC1	0.52	6.14	0.37	3.51e-9	Intelligence (multi-trait analysis);
SARC	cis	rs6430585	1.000	rs6430585	chr2:136506927	A/C	cg07169764	chr2:136633963	MCM6	-0.71	-9.51	-0.53	2.51e-18	Corneal structure;
SARC	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg17971929	chr21:40555470	PSMG1	0.98	13.77	0.67	5.73e-32	Cognitive function;
SARC	cis	rs748404	0.660	rs690512	chr15:43717678	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	5.75	0.35	2.76e-8	Lung cancer;
SARC	cis	rs2153535	0.601	rs1855768	chr6:8472969	T/G	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	cis	rs6570726	0.935	rs408768	chr6:145871735	A/G	cg05220968	chr6:146057943	EPM2A	-0.3	-5.08	-0.32	7.72e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs875971	1.000	rs1144894	chr7:65542894	A/G	cg11987759	chr7:65425863	GUSB	0.43	5.69	0.35	3.81e-8	Aortic root size;
SARC	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg06618935	chr21:46677482	NA	-0.4	-5.33	-0.33	2.35e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs3796352	0.881	rs35384050	chr3:53008769	G/T	cg12962167	chr3:53033115	SFMBT1	0.73	4.8	0.3	2.82e-6	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs6912958	0.667	rs7746545	chr6:88090225	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.35	6.04	0.37	6.09e-9	Monocyte percentage of white cells;
SARC	cis	rs2839627	0.561	rs1107830	chr21:44275097	G/A	cg03543861	chr21:44258195	NA	0.46	5.1	0.32	7.04e-7	Information processing speed;
SARC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	19.69	0.79	1.74e-51	Prudent dietary pattern;
SARC	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-15.02	-0.7	4.13e-36	Chronic sinus infection;
SARC	cis	rs262150	0.501	rs2730206	chr7:158815173	G/C	cg19418458	chr7:158789849	NA	-0.42	-6.01	-0.37	6.98e-9	Facial morphology (factor 20);
SARC	cis	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg12463550	chr7:65579703	CRCP	0.69	5.29	0.33	2.86e-7	Diabetic kidney disease;
SARC	cis	rs2204008	0.837	rs55962152	chr12:38234281	G/A	cg26384229	chr12:38710491	ALG10B	0.92	13.59	0.66	2.33e-31	Bladder cancer;
SARC	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg22834771	chr12:69754056	YEATS4	-0.42	-5.57	-0.34	7.17e-8	Blood protein levels;
SARC	cis	rs1003719	0.715	rs1981432	chr21:38541356	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-9.11	-0.51	3.81e-17	Eye color traits;
SARC	cis	rs2276314	1.000	rs2298715	chr18:33552425	T/C	cg05985134	chr18:33552581	C18orf21	0.74	7.88	0.46	1.28e-13	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.43	0.44	2.1e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7084402	0.967	rs1427198	chr10:60274970	T/G	cg07615347	chr10:60278583	BICC1	-0.57	-8.4	-0.48	4.36e-15	Refractive error;
SARC	cis	rs2439831	0.850	rs28684672	chr15:44107662	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.95	8.35	0.48	5.93e-15	Lung cancer in ever smokers;
SARC	cis	rs796364	1.000	rs769950	chr2:200730028	A/G	cg23649088	chr2:200775458	C2orf69	0.59	5.34	0.33	2.23e-7	Schizophrenia;
SARC	cis	rs7208859	0.623	rs8075163	chr17:29106310	A/G	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs72781680	0.898	rs72780118	chr2:23994431	G/A	cg08917208	chr2:24149416	ATAD2B	0.77	7.29	0.43	4.79e-12	Lymphocyte counts;
SARC	cis	rs7326068	0.610	rs2314719	chr13:21313282	G/A	cg16922012	chr13:21400325	XPO4	-0.42	-5.72	-0.35	3.18e-8	Schizophrenia, bipolar disorder and depression (combined);
SARC	cis	rs651907	0.535	rs13059470	chr3:101424800	A/G	cg12386194	chr3:101231763	SENP7	-0.49	-5.84	-0.36	1.79e-8	Colorectal cancer;
SARC	cis	rs4319547	0.656	rs7135419	chr12:122911861	T/A	cg23029597	chr12:123009494	RSRC2	-0.42	-5.21	-0.32	4.06e-7	Body mass index;
SARC	cis	rs1318878	1.000	rs11056456	chr12:15543758	T/C	cg08258403	chr12:15378311	NA	0.47	6.05	0.37	5.63e-9	Intelligence (multi-trait analysis);
SARC	cis	rs11098499	0.913	rs56122576	chr4:120129336	A/G	cg09307838	chr4:120376055	NA	0.82	11.05	0.59	4.35e-23	Corneal astigmatism;
SARC	cis	rs473651	0.904	rs501333	chr2:239336045	G/A	cg21699342	chr2:239360505	ASB1	0.49	7.29	0.43	4.68e-12	Multiple system atrophy;
SARC	cis	rs7644634	0.559	rs726444	chr3:105438538	C/T	cg23051926	chr3:105466016	CBLB	0.47	5.27	0.33	3.18e-7	Itch intensity from mosquito bite;
SARC	cis	rs17376456	0.542	rs10061069	chr5:93071630	G/C	cg25358565	chr5:93447407	FAM172A	0.82	9.18	0.52	2.41e-17	Diabetic retinopathy;
SARC	cis	rs11098499	0.779	rs28495013	chr4:120375831	A/C	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs6867032	0.527	rs13162781	chr5:2012235	C/T	cg26168224	chr5:2018326	NA	0.68	9.61	0.53	1.21e-18	Gut microbiome composition (winter);
SARC	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg06618935	chr21:46677482	NA	-0.39	-5.23	-0.32	3.69e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg09699651	chr6:150184138	LRP11	0.41	5.11	0.32	6.6e-7	Lung cancer;
SARC	cis	rs8067545	0.611	rs1859407	chr17:20078137	T/C	cg13482628	chr17:19912719	NA	-0.55	-7.18	-0.43	9.03e-12	Schizophrenia;
SARC	cis	rs7481584	0.624	rs1077335	chr11:3030524	A/G	cg08508325	chr11:3079039	CARS	0.23	5.27	0.33	3.08e-7	Calcium levels;
SARC	cis	rs2046867	0.862	rs62251645	chr3:72805733	T/C	cg25664220	chr3:72788482	NA	-0.29	-4.81	-0.3	2.66e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
SARC	cis	rs6991838	0.584	rs7842085	chr8:66549022	T/A	cg13398993	chr8:66546079	ARMC1	0.57	7.16	0.42	1.07e-11	Intelligence (multi-trait analysis);
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg04735594	chr11:72853087	FCHSD2	-0.52	-6.56	-0.39	3.51e-10	Schizophrenia;
SARC	cis	rs7589342	0.628	rs12996286	chr2:106399667	A/G	cg16077055	chr2:106428750	NCK2	0.35	6.11	0.37	4.09e-9	Addiction;
SARC	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg25072359	chr17:41440525	NA	0.48	5.57	0.34	6.86e-8	Menopause (age at onset);
SARC	cis	rs1008375	1.000	rs2058339	chr4:17678456	C/T	cg27347728	chr4:17578864	LAP3	0.45	5.64	0.35	4.94e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg11764359	chr7:65958608	NA	-0.67	-7.97	-0.46	7.26e-14	Aortic root size;
SARC	cis	rs79149102	0.737	rs113915655	chr15:75219722	T/C	cg17294928	chr15:75287854	SCAMP5	-0.94	-5.55	-0.34	7.73e-8	Lung cancer;
SARC	cis	rs9747201	0.963	rs4789729	chr17:80146089	G/A	cg17462356	chr17:80056334	FASN	-0.47	-5.31	-0.33	2.6e-7	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs2769264	1.000	rs6684085	chr1:151357333	C/T	cg18801370	chr1:151430492	POGZ	-0.66	-6.62	-0.4	2.42e-10	Blood trace element (Cu levels);
SARC	cis	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg10591111	chr5:226296	SDHA	-0.53	-4.84	-0.3	2.38e-6	Breast cancer;
SARC	trans	rs9325144	0.600	rs6582634	chr12:38748041	G/A	cg23762105	chr12:34175262	ALG10	-0.55	-7.19	-0.43	8.49e-12	Morning vs. evening chronotype;
SARC	cis	rs4423214	1.000	rs7935125	chr11:71184190	C/A	cg05163923	chr11:71159392	DHCR7	0.65	9.03	0.51	6.47e-17	Vitamin D levels;
SARC	cis	rs1355223	0.902	rs1258470	chr11:34729265	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.39	5.02	0.31	1e-6	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs1003719	0.742	rs8129231	chr21:38501034	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-9.12	-0.51	3.7e-17	Eye color traits;
SARC	cis	rs2072499	1.000	rs2072499	chr1:156169610	A/G	cg24450063	chr1:156163899	SLC25A44	1.15	19.89	0.79	3.86e-52	Testicular germ cell tumor;
SARC	cis	rs7555523	0.887	rs4269750	chr1:165711510	C/T	cg24409356	chr1:165738333	TMCO1	0.8	6.67	0.4	1.88e-10	Intraocular pressure;Glaucoma (high intraocular pressure);
SARC	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg01448562	chr3:133502909	NA	-0.49	-7.53	-0.44	1.09e-12	Iron status biomarkers;
SARC	cis	rs2276314	0.857	rs28791905	chr18:33602213	G/A	cg19628046	chr18:33552617	C18orf21	0.61	6.4	0.39	8.25e-10	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs33912345	0.695	rs1254313	chr14:60895686	A/T	cg27398547	chr14:60952738	C14orf39	-0.39	-4.82	-0.3	2.62e-6	Glaucoma (high intraocular pressure);
SARC	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg01570182	chr17:44337453	NA	0.83	9.46	0.53	3.42e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs6963495	0.615	rs2697021	chr7:105151029	A/C	cg19920283	chr7:105172520	RINT1	0.54	5.49	0.34	1.06e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs1008375	0.932	rs11935124	chr4:17668200	G/A	cg27347728	chr4:17578864	LAP3	-0.46	-5.64	-0.35	4.8e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9430161	0.579	rs7542158	chr1:11040193	G/A	cg27631724	chr1:11040367	C1orf127	0.39	5.88	0.36	1.44e-8	Ewing sarcoma;
SARC	cis	rs4727027	0.899	rs6464942	chr7:148826368	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.47	5.7	0.35	3.52e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs2370759	0.891	rs77706860	chr10:32628537	C/T	cg01819863	chr10:32635814	EPC1	0.95	7.06	0.42	1.94e-11	Sexual dysfunction (female);
SARC	cis	rs9916302	0.904	rs801426	chr17:37441109	C/T	cg00129232	chr17:37814104	STARD3	0.59	7.22	0.43	7.28e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs7927771	0.524	rs7116346	chr11:47883880	G/A	cg10504702	chr11:47789108	FNBP4	-0.43	-5.62	-0.35	5.38e-8	Subjective well-being;
SARC	cis	rs1728785	0.818	rs11648503	chr16:68598938	G/A	cg02972257	chr16:68554789	NA	-0.48	-5.63	-0.35	5.29e-8	Ulcerative colitis;
SARC	cis	rs12155623	0.619	rs870397	chr8:49861225	C/T	cg06076277	chr8:49783056	NA	0.3	5.16	0.32	5.36e-7	Sudden cardiac arrest;
SARC	cis	rs4718428	0.705	rs12698547	chr7:66278258	T/C	cg18252515	chr7:66147081	NA	-0.57	-6.2	-0.38	2.61e-9	Corneal structure;
SARC	cis	rs2425143	0.687	rs6119649	chr20:34369596	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.74	6.35	0.38	1.1e-9	Blood protein levels;
SARC	cis	rs13161895	0.941	rs3797764	chr5:179439345	A/G	cg06664874	chr5:179499304	RNF130	-0.49	-4.78	-0.3	3.14e-6	LDL cholesterol;
SARC	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg23958373	chr8:599963	NA	0.74	6.25	0.38	1.93e-9	IgG glycosylation;
SARC	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg19671926	chr4:122722719	EXOSC9	-0.53	-6.09	-0.37	4.64e-9	Type 2 diabetes;
SARC	cis	rs796364	0.806	rs112305133	chr2:201010380	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.66	-6.39	-0.39	8.99e-10	Schizophrenia;
SARC	cis	rs778371	0.723	rs12105766	chr2:233617647	A/G	cg16596103	chr2:233749413	NGEF	-0.34	-4.79	-0.3	2.98e-6	Schizophrenia;
SARC	cis	rs7568458	0.684	rs7608074	chr2:85809703	T/G	cg23752985	chr2:85803571	VAMP8	0.47	5.96	0.36	9.41e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	trans	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg21659725	chr3:3221576	CRBN	-0.55	-7.19	-0.43	8.59e-12	Intelligence (multi-trait analysis);
SARC	cis	rs9457247	1.000	rs393727	chr6:167398632	T/A	cg23791538	chr6:167370224	RNASET2	-0.63	-8.73	-0.5	4.84e-16	Crohn's disease;
SARC	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg21747090	chr2:27597821	SNX17	-0.56	-7.58	-0.44	8.12e-13	Total body bone mineral density;
SARC	cis	rs1562975	0.567	rs7654972	chr4:109407499	C/T	cg16022748	chr4:109541635	LOC285456;RPL34	0.4	4.83	0.3	2.5e-6	Height;
SARC	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg03709012	chr19:19516395	GATAD2A	1.02	17.93	0.76	9.26e-46	Tonsillectomy;
SARC	cis	rs12908161	1.000	rs17601029	chr15:85347709	A/G	cg17507749	chr15:85114479	UBE2QP1	0.55	6.3	0.38	1.48e-9	Schizophrenia;
SARC	cis	rs12022452	0.591	rs16827359	chr1:41001438	C/G	cg25568243	chr1:40974465	DEM1	-0.51	-5.19	-0.32	4.67e-7	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs9611519	0.780	rs1535048	chr22:41684093	C/T	cg03806693	chr22:41940476	POLR3H	-0.73	-9.87	-0.54	1.98e-19	Neuroticism;
SARC	cis	rs10911251	0.546	rs1062044	chr1:183112412	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	9.86	0.54	2.11e-19	Colorectal cancer;
SARC	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.08	23.05	0.83	4.89e-62	Chronic sinus infection;
SARC	cis	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg21775007	chr8:11205619	TDH	-0.48	-6.06	-0.37	5.38e-9	Triglycerides;
SARC	cis	rs9858542	1.000	rs11130213	chr3:49712297	C/T	cg03060546	chr3:49711283	APEH	-0.65	-8.01	-0.46	5.35e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs698813	0.604	rs12712916	chr2:44482099	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	6.06	0.37	5.47e-9	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs7589728	0.858	rs79992736	chr2:88530575	A/C	cg04511125	chr2:88470314	THNSL2	0.69	6.83	0.41	7.28e-11	Plasma clusterin levels;
SARC	cis	rs13191362	0.507	rs2849524	chr6:163127070	C/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.44	-4.76	-0.3	3.43e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg24503407	chr1:205819492	PM20D1	0.81	12.82	0.64	7.82e-29	Menarche (age at onset);
SARC	cis	rs7481584	0.624	rs693687	chr11:3052494	A/G	cg20651018	chr11:3035856	CARS	0.41	6.13	0.37	3.73e-9	Calcium levels;
SARC	cis	rs7772486	0.686	rs2072911	chr6:146056801	G/A	cg23711669	chr6:146136114	FBXO30	-0.82	-13.23	-0.66	3.43e-30	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg12000995	chr2:27665139	KRTCAP3	-0.31	-4.76	-0.3	3.39e-6	Total body bone mineral density;
SARC	cis	rs587080	0.559	rs12364730	chr11:65228278	C/T	cg17120908	chr11:65337727	SSSCA1	-0.46	-5.12	-0.32	6.25e-7	Plateletcrit;
SARC	cis	rs2933343	0.729	rs789230	chr3:128602558	G/A	cg24203234	chr3:128598194	ACAD9	0.62	7.77	0.45	2.49e-13	IgG glycosylation;
SARC	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg00149659	chr3:10157352	C3orf10	0.69	6.38	0.39	9.6e-10	Alzheimer's disease;
SARC	cis	rs4595586	0.545	rs12812750	chr12:39363258	C/T	cg26384229	chr12:38710491	ALG10B	0.52	6.22	0.38	2.28e-9	Morning vs. evening chronotype;
SARC	cis	rs1545257	0.560	rs7561752	chr2:24643834	A/G	cg06627628	chr2:24431161	ITSN2	0.56	7.28	0.43	5.04e-12	Sjögren's syndrome;
SARC	cis	rs1348850	0.914	rs1348849	chr2:178358072	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.71	9.15	0.51	2.86e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.03	0.37	6.27e-9	Prudent dietary pattern;
SARC	cis	rs4819052	0.766	rs4819035	chr21:46645715	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.51	5.26	0.33	3.27e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-8.89	-0.5	1.75e-16	Alzheimer's disease;
SARC	cis	rs2304069	0.817	rs216132	chr5:149431259	C/T	cg12661370	chr5:149340060	SLC26A2	-0.57	-5.95	-0.36	9.86e-9	HIV-1 control;
SARC	cis	rs9814567	0.929	rs13088413	chr3:134309977	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	6.89	0.41	5.31e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs240764	0.817	rs239230	chr6:101105862	C/A	cg09795085	chr6:101329169	ASCC3	0.44	5.71	0.35	3.39e-8	Neuroticism;
SARC	cis	rs7766436	0.767	rs6456496	chr6:22599386	G/C	cg13666174	chr6:22585274	NA	-0.52	-7.14	-0.42	1.2e-11	Coronary artery disease;
SARC	cis	rs2288073	0.562	rs112892911	chr2:24590800	G/A	cg06627628	chr2:24431161	ITSN2	-0.8	-9.78	-0.54	3.71e-19	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs6543140	0.601	rs78178597	chr2:103023596	G/T	cg09003973	chr2:102972529	NA	0.53	6.4	0.39	8.29e-10	Blood protein levels;
SARC	cis	rs9398803	0.965	rs2027299	chr6:126685827	G/C	cg20229609	chr6:126660872	C6orf173	0.4	5.76	0.35	2.62e-8	Male-pattern baldness;
SARC	cis	rs2439831	0.850	rs28564774	chr15:44125475	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	7.59	0.45	7.57e-13	Lung cancer in ever smokers;
SARC	cis	rs17376456	0.877	rs12374470	chr5:93481046	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.62	5.28	0.33	3.02e-7	Diabetic retinopathy;
SARC	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg00933542	chr6:150070202	PCMT1	0.33	5.72	0.35	3.32e-8	Lung cancer;
SARC	trans	rs1814175	0.645	rs1851853	chr11:49953434	C/T	cg03929089	chr4:120376271	NA	-0.82	-11.88	-0.61	9.2e-26	Height;
SARC	cis	rs2016266	0.859	rs10747668	chr12:53737461	C/T	cg26875137	chr12:53738046	NA	0.42	5.23	0.32	3.7e-7	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs920590	0.721	rs61180388	chr8:19670214	G/C	cg17834443	chr8:19674713	INTS10	0.64	7.74	0.45	3.1e-13	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs936229	0.690	rs2472299	chr15:75033400	C/T	cg14664628	chr15:75095509	CSK	0.97	12.56	0.64	5.61e-28	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	9.31	0.52	9.95e-18	Prudent dietary pattern;
SARC	cis	rs72781680	0.898	rs55761273	chr2:23957849	A/G	cg08917208	chr2:24149416	ATAD2B	0.75	7.34	0.43	3.6e-12	Lymphocyte counts;
SARC	cis	rs9290065	0.519	rs7613316	chr3:160674533	A/G	cg04691961	chr3:161091175	C3orf57	-0.51	-6.5	-0.39	4.84e-10	Kawasaki disease;
SARC	cis	rs7597155	0.935	rs7577493	chr2:69980174	T/G	cg02498382	chr2:70120550	SNRNP27	-0.31	-5.26	-0.33	3.23e-7	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg19346786	chr7:2764209	NA	0.35	5.22	0.32	3.9e-7	Height;
SARC	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg27284194	chr4:1044797	NA	-0.59	-8.5	-0.49	2.3e-15	Recombination rate (males);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg16640633	chr6:83073819	TPBG	-0.75	-6.44	-0.39	6.88e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.8	12.23	0.63	6.76e-27	Total body bone mineral density;
SARC	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg05861140	chr6:150128134	PCMT1	-0.4	-4.83	-0.3	2.42e-6	Lung cancer;
SARC	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg25894440	chr7:65020034	NA	0.41	4.74	0.3	3.7e-6	Calcium levels;
SARC	cis	rs453301	0.686	rs11785634	chr8:8892597	G/T	cg08975724	chr8:8085496	FLJ10661	-0.47	-6.05	-0.37	5.67e-9	Joint mobility (Beighton score);
SARC	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg12373951	chr3:133503437	NA	0.36	5.28	0.33	2.97e-7	Iron status biomarkers;
SARC	cis	rs7528684	0.546	rs10908584	chr1:157641758	A/T	cg18268488	chr1:157545234	FCRL4	0.27	5.15	0.32	5.61e-7	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;
SARC	cis	rs7647973	0.807	rs4955416	chr3:49108428	T/C	cg07636037	chr3:49044803	WDR6	0.9	10.65	0.57	7.83e-22	Menarche (age at onset);
SARC	cis	rs2228479	0.850	rs62054601	chr16:89811751	C/G	cg00800038	chr16:89945340	TCF25	-0.74	-5.1	-0.32	7.08e-7	Skin colour saturation;
SARC	cis	rs929354	0.806	rs28446734	chr7:156996775	T/C	cg05182265	chr7:156933206	UBE3C	-0.33	-5.01	-0.31	1.08e-6	Body mass index;
SARC	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg06634786	chr22:41940651	POLR3H	0.5	6.16	0.37	3.11e-9	Vitiligo;
SARC	cis	rs2486288	0.656	rs7171312	chr15:45570225	C/G	cg15395560	chr15:45543142	SLC28A2	0.32	6.17	0.37	2.98e-9	Glomerular filtration rate;
SARC	cis	rs7223966	0.618	rs9906903	chr17:61634508	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.49	-5.0	-0.31	1.1e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs6570726	0.755	rs2103633	chr6:145894021	C/T	cg05347473	chr6:146136440	FBXO30	0.51	7.17	0.43	9.59e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs524281	0.817	rs10896097	chr11:65967953	A/C	cg14036092	chr11:66035641	RAB1B	-0.49	-5.36	-0.33	2.04e-7	Electroencephalogram traits;
SARC	cis	rs7666738	0.830	rs11729753	chr4:98803267	T/A	cg05340658	chr4:99064831	C4orf37	0.65	8.44	0.48	3.43e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg04166393	chr7:2884313	GNA12	0.66	7.62	0.45	6.4e-13	Height;
SARC	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg24549020	chr5:56110836	MAP3K1	-0.53	-5.84	-0.36	1.78e-8	Initial pursuit acceleration;
SARC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg01238044	chr22:24384105	GSTT1	-0.67	-8.34	-0.48	6.43e-15	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg03213289	chr20:61660250	NA	0.46	6.43	0.39	7.22e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg24110177	chr3:50126178	RBM5	0.54	7.12	0.42	1.31e-11	Intelligence (multi-trait analysis);
SARC	cis	rs739401	0.611	rs417957	chr11:3046231	A/G	cg20651018	chr11:3035856	CARS	-0.49	-7.97	-0.46	6.84e-14	Longevity;
SARC	cis	rs986417	1.000	rs2093212	chr14:60843322	G/A	cg27398547	chr14:60952738	C14orf39	-1.0	-8.65	-0.49	8.38e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs10791097	0.694	rs2155749	chr11:130751094	G/T	cg12179176	chr11:130786555	SNX19	0.75	11.23	0.59	1.09e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	trans	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg06636001	chr8:8085503	FLJ10661	-0.65	-9.21	-0.52	1.99e-17	Neuroticism;
SARC	cis	rs11098499	0.818	rs10008791	chr4:120431469	A/C	cg09307838	chr4:120376055	NA	0.9	11.88	0.61	9.34e-26	Corneal astigmatism;
SARC	cis	rs897080	0.552	rs698799	chr2:44690618	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.58	6.6	0.4	2.72e-10	Height;
SARC	cis	rs2011503	1.000	rs113527843	chr19:19643343	A/T	cg15839431	chr19:19639596	YJEFN3	-0.48	-4.77	-0.3	3.32e-6	Bipolar disorder;
SARC	cis	rs4619890	0.510	rs13130704	chr4:7882614	C/T	cg18538662	chr4:7941764	AFAP1	-0.37	-4.76	-0.3	3.36e-6	Glaucoma (primary open-angle);
SARC	cis	rs6670533	0.571	rs11801547	chr1:24861399	A/G	cg07475527	chr1:24864545	NA	-1.0	-5.65	-0.35	4.76e-8	Fasting blood insulin (BMI interaction);
SARC	cis	rs9916302	0.904	rs8065963	chr17:37681332	C/T	cg07936489	chr17:37558343	FBXL20	-0.68	-8.78	-0.5	3.5e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs72781680	1.000	rs7578969	chr2:24168620	T/C	cg06627628	chr2:24431161	ITSN2	-0.7	-6.69	-0.4	1.64e-10	Lymphocyte counts;
SARC	cis	rs950776	0.518	rs12910289	chr15:78822065	T/G	cg17108064	chr15:78857060	CHRNA5	0.29	4.93	0.31	1.56e-6	Sudden cardiac arrest;
SARC	cis	rs9814567	0.806	rs6806810	chr3:134323522	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.5	-6.55	-0.39	3.6e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs8067545	0.641	rs203466	chr17:19809953	C/G	cg13482628	chr17:19912719	NA	-0.55	-6.77	-0.41	1.04e-10	Schizophrenia;
SARC	cis	rs9916302	0.660	rs4795367	chr17:37608843	G/C	cg00129232	chr17:37814104	STARD3	-0.56	-5.98	-0.36	8.3e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs9581857	0.615	rs79793528	chr13:28007823	G/A	cg01674679	chr13:27998804	GTF3A	-0.68	-5.31	-0.33	2.5e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg18225595	chr11:63971243	STIP1	0.42	5.02	0.31	1.03e-6	Mean platelet volume;
SARC	cis	rs907683	0.584	rs12920	chr2:220285666	C/G	cg15015639	chr2:220282977	DES	0.36	5.66	0.35	4.53e-8	Resting heart rate;
SARC	cis	rs933688	0.532	rs28693622	chr5:90538722	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.51	-5.72	-0.35	3.2e-8	Smoking behavior;
SARC	trans	rs61931739	0.635	rs1601627	chr12:33962420	G/A	cg26384229	chr12:38710491	ALG10B	0.57	7.37	0.43	2.93e-12	Morning vs. evening chronotype;
SARC	cis	rs67311347	0.955	rs60554147	chr3:40472503	T/C	cg24209194	chr3:40518798	ZNF619	0.6	7.81	0.46	1.91e-13	Renal cell carcinoma;
SARC	cis	rs1059312	0.545	rs12303387	chr12:129276733	C/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	-0.48	-6.28	-0.38	1.68e-9	Systemic lupus erythematosus;
SARC	cis	rs911263	0.603	rs12892777	chr14:68778913	T/G	cg18825221	chr14:68749962	RAD51L1	0.44	7.92	0.46	9.72e-14	Primary biliary cholangitis;
SARC	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg24531977	chr5:56204891	C5orf35	-0.55	-5.53	-0.34	8.64e-8	Initial pursuit acceleration;
SARC	cis	rs11122272	0.525	rs2749713	chr1:231537921	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.94	-0.55	1.26e-19	Hemoglobin concentration;
SARC	cis	rs9325144	0.505	rs7955162	chr12:38711658	G/A	cg26384229	chr12:38710491	ALG10B	0.83	12.4	0.63	1.87e-27	Morning vs. evening chronotype;
SARC	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.77	8.72	0.5	5.3e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs10088262	0.591	rs13270541	chr8:124794849	G/A	cg02993010	chr8:124780839	FAM91A1	-0.79	-9.25	-0.52	1.45e-17	Pancreatic cancer;
SARC	cis	rs67311347	0.635	rs73071706	chr3:40288190	C/A	cg24209194	chr3:40518798	ZNF619	0.53	6.26	0.38	1.79e-9	Renal cell carcinoma;
SARC	cis	rs2832077	0.527	rs2142375	chr21:30223742	G/A	cg24692254	chr21:30365293	RNF160	-0.65	-7.62	-0.45	6.52e-13	Cognitive test performance;
SARC	cis	rs6121246	0.567	rs6060297	chr20:30198560	A/G	cg21427119	chr20:30132790	HM13	-0.48	-5.29	-0.33	2.84e-7	Mean corpuscular hemoglobin;
SARC	cis	rs9948	0.786	rs62156226	chr2:97417108	G/A	cg01990225	chr2:97406019	LMAN2L	-0.97	-6.96	-0.42	3.35e-11	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs11122272	0.735	rs2244986	chr1:231537452	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-10.08	-0.55	4.55e-20	Hemoglobin concentration;
SARC	cis	rs7264396	0.561	rs2050930	chr20:34579397	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-5.45	-0.34	1.31e-7	Total cholesterol levels;
SARC	cis	rs2354432	0.607	rs6677679	chr1:146803630	C/T	cg25205988	chr1:146714368	CHD1L	-1.06	-7.79	-0.45	2.22e-13	Mitochondrial DNA levels;
SARC	cis	rs17376456	0.569	rs10476520	chr5:93058290	A/C	cg25358565	chr5:93447407	FAM172A	0.94	10.59	0.57	1.17e-21	Diabetic retinopathy;
SARC	cis	rs79349575	0.715	rs999474	chr17:46987665	G/A	cg16584676	chr17:46985605	UBE2Z	-0.54	-6.89	-0.41	5.05e-11	Type 2 diabetes;
SARC	cis	rs6772849	0.965	rs4286447	chr3:128310589	G/T	cg08795948	chr3:128337044	NA	0.37	4.88	0.3	1.96e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs2280018	0.526	rs2941257	chr16:15166445	T/C	cg07549590	chr16:15018862	NA	-0.53	-6.87	-0.41	5.85e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs8114671	0.562	rs6087651	chr20:33518353	C/T	cg08999081	chr20:33150536	PIGU	0.33	4.89	0.3	1.89e-6	Height;
SARC	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs561341	0.941	rs2428338	chr17:30299629	T/C	cg13647721	chr17:30228624	UTP6	0.6	4.77	0.3	3.21e-6	Hip circumference adjusted for BMI;
SARC	trans	rs9888736	0.501	rs2164370	chr15:47900379	A/G	cg01357263	chr12:122459509	BCL7A	-0.49	-6.25	-0.38	1.92e-9	Body mass index;
SARC	cis	rs617791	0.508	rs2276132	chr11:65770545	G/A	cg26695010	chr11:65641043	EFEMP2	0.56	6.89	0.41	5.22e-11	Breast cancer;
SARC	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	24.35	0.85	5.64e-66	Chronic sinus infection;
SARC	cis	rs753778	0.570	rs6985866	chr8:142210336	C/T	cg16341495	chr8:142228727	SLC45A4	0.44	6.24	0.38	2e-9	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg18404041	chr3:52824283	ITIH1	-0.42	-5.92	-0.36	1.16e-8	Bipolar disorder;
SARC	cis	rs12950390	0.853	rs4794107	chr17:45843159	T/G	cg03474202	chr17:45855739	NA	-0.46	-7.26	-0.43	5.71e-12	IgG glycosylation;
SARC	cis	rs9682041	0.696	rs6774380	chr3:170091644	T/A	cg11886554	chr3:170076028	SKIL	0.83	7.75	0.45	2.91e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs6860806	0.507	rs272854	chr5:131688017	C/T	cg11843238	chr5:131593191	PDLIM4	0.39	4.83	0.3	2.44e-6	Breast cancer;
SARC	cis	rs72387598	1	rs72387598	chr1:45922977	CAT/C	cg05343316	chr1:45956843	TESK2	0.79	8.77	0.5	3.84e-16	Platelet distribution width;
SARC	cis	rs2858942	0.602	rs1211375	chr16:240280	G/T	cg08400316	chr16:204221	HBZ	-0.54	-7.01	-0.42	2.49e-11	Mean corpuscular hemoglobin;
SARC	cis	rs950776	0.518	rs12916999	chr15:78826912	C/T	cg06917634	chr15:78832804	PSMA4	0.91	14.24	0.68	1.6e-33	Sudden cardiac arrest;
SARC	cis	rs2997447	0.761	rs61776620	chr1:26457980	T/C	cg19633962	chr1:26362018	EXTL1	-0.57	-4.93	-0.31	1.54e-6	QRS complex (12-leadsum);
SARC	cis	rs12497850	0.863	rs4974084	chr3:48939080	G/A	cg06212747	chr3:49208901	KLHDC8B	0.68	9.02	0.51	7.27e-17	Parkinson's disease;
SARC	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg21442419	chr1:2182373	SKI	-0.46	-5.97	-0.36	8.84e-9	Height;
SARC	cis	rs6580649	0.941	rs11613485	chr12:48462455	T/C	cg05342945	chr12:48394962	COL2A1	0.56	6.03	0.37	6.35e-9	Lung cancer;
SARC	cis	rs35306767	0.903	rs12244355	chr10:944465	T/C	cg26597838	chr10:835615	NA	0.73	7.44	0.44	1.95e-12	Eosinophil percentage of granulocytes;
SARC	cis	rs9818758	0.607	rs9850917	chr3:49286983	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.69	-6.0	-0.37	7.4e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs7589342	0.839	rs1465639	chr2:106439181	T/C	cg16077055	chr2:106428750	NCK2	0.33	5.96	0.36	9.24e-9	Addiction;
SARC	cis	rs524281	0.731	rs11227433	chr11:66004693	G/A	cg14036092	chr11:66035641	RAB1B	-0.59	-6.28	-0.38	1.67e-9	Electroencephalogram traits;
SARC	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg11987759	chr7:65425863	GUSB	-0.48	-5.87	-0.36	1.51e-8	Aortic root size;
SARC	cis	rs7647973	0.667	rs4241405	chr3:49642027	C/T	cg13072238	chr3:49761600	GMPPB	-0.61	-5.32	-0.33	2.38e-7	Menarche (age at onset);
SARC	cis	rs694739	1.000	rs1783521	chr11:64106291	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.67	8.58	0.49	1.38e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs6088590	0.965	rs6120730	chr20:33385102	G/C	cg24642439	chr20:33292090	TP53INP2	0.88	12.41	0.63	1.76e-27	Coronary artery disease;
SARC	cis	rs950776	0.593	rs6495306	chr15:78865893	C/T	cg06917634	chr15:78832804	PSMA4	-0.84	-12.33	-0.63	3.08e-27	Sudden cardiac arrest;
SARC	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg22903471	chr2:27725779	GCKR	-0.51	-7.68	-0.45	4.26e-13	Total body bone mineral density;
SARC	cis	rs6456156	0.792	rs4710178	chr6:167513532	G/A	cg23791538	chr6:167370224	RNASET2	-0.41	-5.24	-0.32	3.66e-7	Primary biliary cholangitis;
SARC	cis	rs7429990	0.965	rs319684	chr3:47932274	C/T	cg11946769	chr3:48343235	NME6	0.45	5.16	0.32	5.26e-7	Educational attainment (years of education);
SARC	cis	rs6570726	0.526	rs9403699	chr6:145730685	G/T	cg05347473	chr6:146136440	FBXO30	0.44	5.32	0.33	2.38e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9682041	0.877	rs9682908	chr3:170072010	C/T	cg11886554	chr3:170076028	SKIL	0.65	6.43	0.39	7.09e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg15448220	chr1:150897856	SETDB1	0.48	6.38	0.39	9.29e-10	Tonsillectomy;
SARC	cis	rs6456156	0.586	rs6456154	chr6:167472256	C/T	cg07741184	chr6:167504864	NA	0.36	7.09	0.42	1.62e-11	Primary biliary cholangitis;
SARC	trans	rs7465272	1.000	rs13258638	chr8:143683582	C/T	cg16922340	chr20:33873526	FAM83C;EIF6	0.47	6.24	0.38	2.03e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs7084402	0.967	rs1658438	chr10:60326583	A/G	cg07615347	chr10:60278583	BICC1	-0.58	-8.55	-0.49	1.7e-15	Refractive error;
SARC	cis	rs4481887	0.927	rs4551626	chr1:248489128	G/T	cg01631408	chr1:248437212	OR2T33	-0.38	-4.74	-0.3	3.75e-6	Common traits (Other);
SARC	cis	rs7572733	0.534	rs58374969	chr2:198764363	C/T	cg00792783	chr2:198669748	PLCL1	0.43	4.73	0.3	3.84e-6	Dermatomyositis;
SARC	cis	rs9916302	0.851	rs7225096	chr17:37664443	T/C	cg15445000	chr17:37608096	MED1	0.4	4.75	0.3	3.6e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs644799	0.965	rs11021310	chr11:95502106	A/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	15.68	0.72	2.64e-38	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs1451375	0.617	rs880029	chr7:50569927	G/C	cg18232548	chr7:50535776	DDC	-0.49	-5.05	-0.31	8.79e-7	Malaria;
SARC	cis	rs17376456	0.569	rs68122392	chr5:93077807	A/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.51	5.08	0.32	7.91e-7	Diabetic retinopathy;
SARC	cis	rs6121246	0.908	rs17093657	chr20:30428894	G/A	cg13852791	chr20:30311386	BCL2L1	0.85	9.16	0.51	2.77e-17	Mean corpuscular hemoglobin;
SARC	cis	rs933688	1.000	rs12655973	chr5:90736537	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.98	12.75	0.64	1.33e-28	Smoking behavior;
SARC	trans	rs11098499	0.820	rs28578366	chr4:120536905	A/G	cg25214090	chr10:38739885	LOC399744	-0.5	-6.61	-0.4	2.6e-10	Corneal astigmatism;
SARC	cis	rs6901004	0.835	rs1150079	chr6:111471425	A/T	cg15721981	chr6:111408429	SLC16A10	-0.43	-5.24	-0.32	3.53e-7	Blood metabolite levels;
SARC	cis	rs72949976	0.707	rs62186571	chr2:214038673	C/G	cg08319019	chr2:214017104	IKZF2	-0.44	-5.33	-0.33	2.36e-7	Lung cancer;Squamous cell lung carcinoma;
SARC	cis	rs6546550	0.901	rs11126251	chr2:70163434	A/C	cg02498382	chr2:70120550	SNRNP27	-0.36	-5.98	-0.36	8.27e-9	Prevalent atrial fibrillation;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg25396643	chr4:83956648	COPS4	0.52	6.7	0.4	1.58e-10	Lung adenocarcinoma;
SARC	cis	rs9300255	0.602	rs1727317	chr12:123618942	T/C	cg00376283	chr12:123451042	ABCB9	0.55	5.3	0.33	2.66e-7	Neutrophil percentage of white cells;
SARC	cis	rs4851254	0.660	rs59447631	chr2:100691493	T/C	cg17356467	chr2:100759845	AFF3	0.32	4.82	0.3	2.59e-6	Intelligence (multi-trait analysis);
SARC	trans	rs9650657	0.740	rs11250077	chr8:10656437	T/C	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.53	-0.39	3.99e-10	Neuroticism;
SARC	cis	rs8058578	0.943	rs3747486	chr16:30786927	C/T	cg02466173	chr16:30829666	NA	-0.43	-5.52	-0.34	8.88e-8	Multiple myeloma;
SARC	cis	rs17270561	0.609	rs7754733	chr6:25745049	C/G	cg17691542	chr6:26056736	HIST1H1C	0.61	7.36	0.43	3.06e-12	Iron status biomarkers;
SARC	cis	rs1018836	0.851	rs12548741	chr8:91628878	G/A	cg16814680	chr8:91681699	NA	-0.85	-13.93	-0.67	1.75e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg06221963	chr1:154839813	KCNN3	-0.52	-8.14	-0.47	2.38e-14	Prostate cancer;
SARC	cis	rs7666738	0.830	rs7684646	chr4:99071062	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.92	0.5	1.37e-16	Colonoscopy-negative controls vs population controls;
SARC	trans	rs79976124	0.879	rs17432710	chr6:66621744	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.69	7.47	0.44	1.61e-12	Type 2 diabetes;
SARC	cis	rs4727027	0.631	rs62507511	chr7:148796080	C/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.47	5.53	0.34	8.58e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs796364	0.806	rs34381014	chr2:200916403	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-6.61	-0.4	2.63e-10	Schizophrenia;
SARC	cis	rs617219	0.574	rs1870057	chr5:78593204	T/C	cg24856658	chr5:78533917	JMY	0.3	4.78	0.3	3.15e-6	Betaine levels in individuals undergoing cardiac evaluation;
SARC	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg03517284	chr6:25882590	NA	-0.43	-5.56	-0.34	7.26e-8	Intelligence (multi-trait analysis);
SARC	trans	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.07	-0.42	1.77e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs981844	1.000	rs2405430	chr4:154658391	A/G	cg14289246	chr4:154710475	SFRP2	0.58	6.64	0.4	2.14e-10	Response to statins (LDL cholesterol change);
SARC	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg06028808	chr11:68637592	NA	0.42	5.4	0.33	1.62e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg11766577	chr21:47581405	C21orf56	-0.47	-5.39	-0.33	1.72e-7	Testicular germ cell tumor;
SARC	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg12667521	chr19:29218732	NA	0.39	5.26	0.33	3.27e-7	Methadone dose in opioid dependence;
SARC	cis	rs72781680	1.000	rs72781658	chr2:24220141	A/G	cg06627628	chr2:24431161	ITSN2	-0.73	-6.93	-0.41	4.14e-11	Lymphocyte counts;
SARC	cis	rs10209086	0.736	rs1584436	chr2:138298878	A/G	cg13451882	chr2:139256702	NA	0.38	5.35	0.33	2.14e-7	Multiple system atrophy;
SARC	cis	rs9660992	0.674	rs1151785	chr1:205232299	C/T	cg21643547	chr1:205240462	TMCC2	-0.64	-8.25	-0.48	1.2e-14	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs826838	0.616	rs7966266	chr12:38626138	G/A	cg26384229	chr12:38710491	ALG10B	-0.59	-7.54	-0.44	1.04e-12	Heart rate;
SARC	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg17376030	chr22:41985996	PMM1	-0.78	-9.83	-0.54	2.67e-19	Vitiligo;
SARC	cis	rs854765	0.587	rs4077828	chr17:17833644	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	9.75	0.54	4.62e-19	Total body bone mineral density;
SARC	cis	rs72627123	0.867	rs73301477	chr14:74463560	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.78	6.14	0.37	3.47e-9	Morning vs. evening chronotype;
SARC	cis	rs611744	0.806	rs374810	chr8:109096029	G/A	cg21045802	chr8:109455806	TTC35	0.47	5.47	0.34	1.17e-7	Dupuytren's disease;
SARC	cis	rs12142240	0.698	rs7515284	chr1:46809419	A/G	cg00530320	chr1:46809349	NSUN4	0.58	7.07	0.42	1.74e-11	Menopause (age at onset);
SARC	cis	rs477895	1.000	rs2276014	chr11:64081445	G/A	cg04317338	chr11:64019027	PLCB3	0.63	5.15	0.32	5.45e-7	Mean platelet volume;
SARC	cis	rs3768617	0.510	rs1886499	chr1:183095024	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.31	0.56	8.82e-21	Fuchs's corneal dystrophy;
SARC	cis	rs9325144	0.647	rs12227834	chr12:38849246	G/C	cg26384229	chr12:38710491	ALG10B	-0.56	-7.3	-0.43	4.44e-12	Morning vs. evening chronotype;
SARC	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	24.35	0.85	5.64e-66	Chronic sinus infection;
SARC	cis	rs17376456	0.825	rs10036024	chr5:93074804	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.69	5.77	0.35	2.51e-8	Diabetic retinopathy;
SARC	cis	rs9322817	0.653	rs9399896	chr6:105216969	A/G	cg02098413	chr6:105308735	HACE1	-0.39	-6.13	-0.37	3.8e-9	Thyroid stimulating hormone;
SARC	cis	rs7818688	0.697	rs74633235	chr8:95981476	A/G	cg13393036	chr8:95962371	TP53INP1	0.4	4.85	0.3	2.27e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs9905704	0.846	rs304298	chr17:56839689	G/A	cg12560992	chr17:57184187	TRIM37	0.45	5.24	0.32	3.56e-7	Testicular germ cell tumor;
SARC	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg00152838	chr16:24741724	TNRC6A	0.59	5.74	0.35	2.98e-8	Intelligence (multi-trait analysis);
SARC	cis	rs7662987	0.540	rs2851257	chr4:100039499	G/C	cg13256891	chr4:100009986	ADH5	0.68	8.61	0.49	1.13e-15	Smoking initiation;
SARC	trans	rs12310956	0.532	rs11052920	chr12:33955891	T/G	cg13010199	chr12:38710504	ALG10B	0.65	8.64	0.49	8.85e-16	Morning vs. evening chronotype;
SARC	cis	rs9604529	0.532	rs41291213	chr13:114774991	C/T	cg24241305	chr13:114826075	RASA3	-0.37	-4.84	-0.3	2.35e-6	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs7582720	0.832	rs115194657	chr2:203829284	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs11785693	0.862	rs11782556	chr8:5002389	C/G	cg26367366	chr8:4980734	NA	0.6	5.36	0.33	1.97e-7	Neuroticism (multi-trait analysis);Neuroticism;
SARC	cis	rs8027181	0.804	rs34661924	chr15:72994564	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	0.38	5.04	0.31	9.24e-7	Triglyceride levels;
SARC	cis	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.8	-0.46	2.01e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs2645694	0.533	rs2645674	chr4:77818202	T/C	cg06046430	chr4:77819534	ANKRD56	0.52	7.34	0.43	3.64e-12	Emphysema distribution in smoking;
SARC	cis	rs12130219	0.500	rs1552991	chr1:152165878	C/T	cg17718321	chr1:152188247	HRNR	-0.34	-4.83	-0.3	2.47e-6	Inflammatory skin disease;
SARC	cis	rs735539	0.521	rs2818990	chr13:21388724	A/G	cg08585351	chr13:22178326	EFHA1	0.43	4.79	0.3	3.01e-6	Dental caries;
SARC	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg17971929	chr21:40555470	PSMG1	0.96	13.39	0.66	1.04e-30	Cognitive function;
SARC	cis	rs13191362	0.938	rs28360532	chr6:162997477	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.57	5.38	0.33	1.85e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs5753618	1.000	rs5753618	chr22:31838518	C/T	cg02404636	chr22:31891804	SFI1	0.55	5.74	0.35	2.93e-8	Colorectal cancer;
SARC	cis	rs796364	0.806	rs10931890	chr2:201102055	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-6.38	-0.39	9.34e-10	Schizophrenia;
SARC	cis	rs7412746	0.658	rs72704685	chr1:150897687	C/G	cg15448220	chr1:150897856	SETDB1	0.51	6.65	0.4	2.02e-10	Melanoma;
SARC	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg07636037	chr3:49044803	WDR6	1.0	17.66	0.76	6.92e-45	Parkinson's disease;
SARC	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg12373951	chr3:133503437	NA	0.41	5.87	0.36	1.49e-8	Iron status biomarkers;
SARC	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg11366901	chr6:160182831	ACAT2	0.64	6.65	0.4	2.1e-10	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs453301	0.658	rs13271797	chr8:8885954	G/A	cg11995313	chr8:8860691	ERI1	0.4	5.18	0.32	4.75e-7	Joint mobility (Beighton score);
SARC	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg09263875	chr16:632152	PIGQ	0.55	8.32	0.48	7.43e-15	Height;
SARC	cis	rs78487399	0.808	rs72865267	chr2:43726328	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-4.84	-0.3	2.37e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs11719291	0.833	rs13074318	chr3:48816725	C/T	cg07636037	chr3:49044803	WDR6	-0.74	-6.5	-0.39	4.93e-10	Cognitive function;
SARC	cis	rs1920116	0.778	rs12492588	chr3:169558711	T/A	cg14222479	chr3:169487675	ARPM1	0.43	5.03	0.31	9.72e-7	Glioma (high-grade);
SARC	cis	rs2153535	0.563	rs1737586	chr6:8535897	C/T	cg07606381	chr6:8435919	SLC35B3	0.77	10.77	0.58	3.24e-22	Motion sickness;
SARC	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg11987759	chr7:65425863	GUSB	-0.48	-6.54	-0.39	3.9e-10	Aortic root size;
SARC	cis	rs2354432	0.607	rs894471	chr1:146687913	A/G	cg25205988	chr1:146714368	CHD1L	-1.01	-8.83	-0.5	2.6e-16	Mitochondrial DNA levels;
SARC	cis	rs1044826	1.000	rs13083195	chr3:139067890	A/G	cg15131784	chr3:139108705	COPB2	0.43	4.9	0.31	1.81e-6	Obesity-related traits;
SARC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg21548813	chr6:291882	DUSP22	-0.6	-7.76	-0.45	2.7e-13	Menopause (age at onset);
SARC	cis	rs3733585	0.673	rs4292332	chr4:9953830	C/A	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.94	-0.36	1.06e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs10493773	0.674	rs414618	chr1:86220418	G/A	cg17807903	chr1:86174739	ZNHIT6	0.45	6.78	0.41	9.86e-11	Urate levels in overweight individuals;
SARC	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg03709012	chr19:19516395	GATAD2A	1.0	17.34	0.75	7.93e-44	Tonsillectomy;
SARC	cis	rs3741404	0.584	rs645461	chr11:63893694	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.72	-9.46	-0.53	3.45e-18	Platelet count;
SARC	trans	rs7980799	0.682	rs10844611	chr12:33603544	T/C	cg26384229	chr12:38710491	ALG10B	-0.61	-7.5	-0.44	1.34e-12	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg20891283	chr12:69753455	YEATS4	0.68	9.8	0.54	3.26e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs11122272	0.735	rs2790889	chr1:231520240	C/A	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg22535103	chr8:58192502	C8orf71	-0.59	-6.21	-0.38	2.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg11764359	chr7:65958608	NA	-0.54	-6.19	-0.38	2.72e-9	Aortic root size;
SARC	cis	rs2230307	0.656	rs571697	chr1:100478755	T/C	cg24955406	chr1:100503596	HIAT1	0.69	5.59	0.34	6.48e-8	Carotid intima media thickness;
SARC	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg07701084	chr6:150067640	NUP43	0.44	5.64	0.35	4.79e-8	Lung cancer;
SARC	cis	rs12579753	0.879	rs11115008	chr12:82164859	C/T	cg07988820	chr12:82153109	PPFIA2	-0.58	-6.87	-0.41	5.86e-11	Resting heart rate;
SARC	cis	rs2425143	1.000	rs6060572	chr20:34294015	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.6	5.11	0.32	6.74e-7	Blood protein levels;
SARC	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	5.99	0.37	8.05e-9	Bipolar disorder;
SARC	cis	rs7712401	0.601	rs385547	chr5:122321833	C/T	cg19412675	chr5:122181750	SNX24	-0.43	-5.47	-0.34	1.15e-7	Mean platelet volume;
SARC	cis	rs9303401	0.592	rs66583824	chr17:56639853	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.06	11.65	0.61	5.15e-25	Cognitive test performance;
SARC	cis	rs9303280	0.806	rs35736272	chr17:38032680	T/C	cg20243544	chr17:37824526	PNMT	0.42	5.52	0.34	9.01e-8	Self-reported allergy;
SARC	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg04944784	chr2:26401820	FAM59B	-0.49	-5.92	-0.36	1.16e-8	Gut microbiome composition (summer);
SARC	cis	rs748404	0.697	rs530188	chr15:43545314	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	6.61	0.4	2.61e-10	Lung cancer;
SARC	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.78	-11.99	-0.62	4.16e-26	Personality dimensions;
SARC	cis	rs7829975	0.509	rs7838674	chr8:8797073	A/T	cg08975724	chr8:8085496	FLJ10661	-0.39	-4.77	-0.3	3.19e-6	Mood instability;
SARC	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg17376030	chr22:41985996	PMM1	0.68	8.2	0.47	1.62e-14	Vitiligo;
SARC	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg24209194	chr3:40518798	ZNF619	-0.66	-8.47	-0.49	2.81e-15	Renal cell carcinoma;
SARC	cis	rs4595586	0.545	rs2218761	chr12:39393593	A/G	cg26384229	chr12:38710491	ALG10B	0.5	6.12	0.37	3.98e-9	Morning vs. evening chronotype;
SARC	cis	rs9341808	0.718	rs9294171	chr6:80839815	C/T	cg08355045	chr6:80787529	NA	0.33	5.31	0.33	2.56e-7	Sitting height ratio;
SARC	cis	rs11719291	0.833	rs11709246	chr3:48859498	G/A	cg00383909	chr3:49044727	WDR6	0.76	6.79	0.41	9.41e-11	Cognitive function;
SARC	cis	rs2120019	0.938	rs1867150	chr15:75321139	T/C	cg09165964	chr15:75287851	SCAMP5	-0.95	-14.5	-0.69	2.24e-34	Blood trace element (Zn levels);
SARC	cis	rs9913156	0.707	rs9902000	chr17:4582426	A/C	cg00122941	chr17:4613640	ARRB2	-0.7	-7.89	-0.46	1.18e-13	Lymphocyte counts;
SARC	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg18357526	chr6:26021779	HIST1H4A	0.9	12.5	0.63	8.9e-28	Intelligence (multi-trait analysis);
SARC	trans	rs1814175	0.519	rs3913237	chr11:49551828	G/A	cg15704280	chr7:45808275	SEPT13	0.7	8.11	0.47	2.85e-14	Height;
SARC	cis	rs453301	0.631	rs28572014	chr8:8793607	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.42	-0.39	7.56e-10	Joint mobility (Beighton score);
SARC	cis	rs9814567	0.752	rs1534029	chr3:134330213	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.51	-6.66	-0.4	1.95e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg18876405	chr7:65276391	NA	0.46	5.11	0.32	6.58e-7	Aortic root size;
SARC	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg18876405	chr7:65276391	NA	-0.46	-5.15	-0.32	5.63e-7	Aortic root size;
SARC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg05863683	chr7:1912471	MAD1L1	0.34	5.25	0.33	3.4e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs17376456	0.877	rs10057605	chr5:93443950	T/G	cg21475434	chr5:93447410	FAM172A	0.86	7.71	0.45	3.65e-13	Diabetic retinopathy;
SARC	cis	rs6456156	0.586	rs9457261	chr6:167467679	A/G	cg07741184	chr6:167504864	NA	0.36	7.09	0.42	1.62e-11	Primary biliary cholangitis;
SARC	cis	rs9581857	0.556	rs9579085	chr13:28041039	G/A	cg22138327	chr13:27999177	GTF3A	0.54	5.62	0.35	5.52e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	cis	rs4737010	0.501	rs34342524	chr8:41633857	G/A	cg08923054	chr8:41654455	ANK1	-0.56	-6.4	-0.39	8.34e-10	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
SARC	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg22535103	chr8:58192502	C8orf71	-0.74	-8.66	-0.49	8.13e-16	Developmental language disorder (linguistic errors);
SARC	cis	rs950169	0.922	rs17531523	chr15:85132449	C/G	cg03959625	chr15:84868606	LOC388152	0.36	4.9	0.31	1.76e-6	Schizophrenia;
SARC	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.56	7.26	0.43	5.58e-12	Menarche (age at onset);
SARC	cis	rs9790314	0.967	rs1382427	chr3:161032576	T/C	cg03342759	chr3:160939853	NMD3	-0.59	-7.41	-0.44	2.26e-12	Morning vs. evening chronotype;
SARC	cis	rs72627123	0.867	rs17093884	chr14:74482039	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.76	5.99	0.37	7.73e-9	Morning vs. evening chronotype;
SARC	cis	rs561341	0.700	rs79272796	chr17:30226974	T/C	cg12000587	chr17:30186630	C17orf79	-0.33	-4.96	-0.31	1.36e-6	Hip circumference adjusted for BMI;
SARC	cis	rs2832191	0.967	rs2832216	chr21:30521921	C/T	cg08807101	chr21:30365312	RNF160	0.73	9.96	0.55	1.1e-19	Dental caries;
SARC	trans	rs2727020	0.702	rs609054	chr11:49219725	C/G	cg15704280	chr7:45808275	SEPT13	0.87	13.44	0.66	7.46e-31	Coronary artery disease;
SARC	cis	rs3857067	0.806	rs6825522	chr4:95108140	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.07	-0.32	8.15e-7	QT interval;
SARC	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg00409905	chr10:38381863	ZNF37A	-0.49	-6.74	-0.4	1.22e-10	Extrinsic epigenetic age acceleration;
SARC	cis	rs7607369	0.714	rs4674332	chr2:219604326	C/T	cg02176678	chr2:219576539	TTLL4	0.48	7.41	0.44	2.28e-12	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs7772486	0.719	rs2206141	chr6:146086192	A/G	cg05347473	chr6:146136440	FBXO30	-0.55	-7.7	-0.45	3.97e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7672847	0.547	rs6553436	chr4:170336962	C/T	cg00846720	chr4:170533756	NEK1	0.6	4.99	0.31	1.16e-6	Subjective well-being;
SARC	cis	rs6964587	0.839	rs13229273	chr7:91444472	G/A	cg17063962	chr7:91808500	NA	0.84	11.84	0.61	1.26e-25	Breast cancer;
SARC	cis	rs4141404	0.748	rs2232176	chr22:31536133	A/C	cg07713946	chr22:31675144	LIMK2	-0.41	-5.33	-0.33	2.37e-7	Paclitaxel-induced neuropathy;
SARC	cis	rs155076	1.000	rs261427	chr13:21860998	G/A	cg06138931	chr13:21896616	NA	-0.39	-5.11	-0.32	6.83e-7	White matter hyperintensity burden;
SARC	cis	rs7524258	0.868	rs7538921	chr1:7267007	T/C	cg07173049	chr1:7289937	CAMTA1	0.4	7.63	0.45	6.02e-13	Tourette's syndrome or obsessive-compulsive disorder;
SARC	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg06212747	chr3:49208901	KLHDC8B	0.71	9.75	0.54	4.8e-19	Parkinson's disease;
SARC	cis	rs10088262	0.629	rs1367829	chr8:124797135	A/G	cg02993010	chr8:124780839	FAM91A1	-0.77	-9.15	-0.51	2.98e-17	Pancreatic cancer;
SARC	cis	rs9816226	0.591	rs6809651	chr3:185814642	G/A	cg00760338	chr3:185826511	ETV5	-0.82	-8.09	-0.47	3.21e-14	Obesity;Body mass index;
SARC	cis	rs2658782	0.724	rs2658769	chr11:93252030	T/C	cg15737290	chr11:93063684	CCDC67	0.77	8.54	0.49	1.74e-15	Pulmonary function decline;
SARC	cis	rs7684253	0.526	rs34112167	chr4:57719549	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.41	-4.99	-0.31	1.16e-6	Migraine;
SARC	cis	rs1468333	0.697	rs35931944	chr5:137629132	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.73	8.68	0.49	7.09e-16	Resting heart rate;
SARC	cis	rs798554	0.704	rs798503	chr7:2789704	G/A	cg04166393	chr7:2884313	GNA12	0.41	5.04	0.31	9.44e-7	Height;
SARC	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg26119090	chr2:26468346	HADHA;HADHB	0.95	13.49	0.66	4.97e-31	Gut microbiome composition (summer);
SARC	cis	rs2014572	0.901	rs35658377	chr19:57755627	T/G	cg24459738	chr19:57751996	ZNF805	-0.47	-5.62	-0.35	5.46e-8	Hyperactive-impulsive symptoms;
SARC	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg02487422	chr3:49467188	NICN1	0.52	6.96	0.42	3.34e-11	Resting heart rate;
SARC	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg06808227	chr14:105710500	BRF1	-0.55	-7.48	-0.44	1.5e-12	Mean platelet volume;Platelet distribution width;
SARC	cis	rs2075371	0.674	rs11771785	chr7:134013249	A/G	cg11752832	chr7:134001865	SLC35B4	-0.49	-6.11	-0.37	4.23e-9	Mean platelet volume;
SARC	cis	rs2221894	0.506	rs77417969	chr8:28844934	C/T	cg07962641	chr8:28805897	HMBOX1	-0.78	-7.69	-0.45	4.02e-13	Obesity-related traits;
SARC	cis	rs7666738	0.830	rs115712871	chr4:98954535	A/T	cg05340658	chr4:99064831	C4orf37	0.66	9.0	0.51	8.07e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs826838	1.000	rs4768328	chr12:39129315	C/T	cg26384229	chr12:38710491	ALG10B	-0.76	-11.59	-0.6	7.97e-25	Heart rate;
SARC	cis	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg08975724	chr8:8085496	FLJ10661	0.49	6.17	0.37	3.07e-9	Mood instability;
SARC	cis	rs854765	0.583	rs7214002	chr17:17852104	G/C	cg04398451	chr17:18023971	MYO15A	-0.43	-6.0	-0.37	7.33e-9	Total body bone mineral density;
SARC	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg13175981	chr1:150552382	MCL1	-0.54	-6.84	-0.41	6.75e-11	Tonsillectomy;
SARC	cis	rs9322817	0.691	rs12203954	chr6:105295647	C/T	cg02098413	chr6:105308735	HACE1	0.38	5.91	0.36	1.18e-8	Thyroid stimulating hormone;
SARC	cis	rs9951602	0.703	rs2959407	chr18:76682915	A/G	cg00806245	chr18:76673096	NA	-0.39	-5.25	-0.33	3.4e-7	Obesity-related traits;
SARC	cis	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg07636037	chr3:49044803	WDR6	0.48	5.62	0.35	5.42e-8	Resting heart rate;
SARC	cis	rs367615	0.506	rs2963013	chr5:108775811	C/T	cg17395555	chr5:108820864	NA	-0.41	-6.02	-0.37	6.62e-9	Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs3733585	0.673	rs4311316	chr4:9955971	A/C	cg11266682	chr4:10021025	SLC2A9	0.4	6.86	0.41	6.33e-11	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs7296418	0.630	rs28419092	chr12:123812629	G/C	cg05973401	chr12:123451056	ABCB9	0.5	5.74	0.35	3e-8	Platelet count;
SARC	cis	rs2635047	0.967	rs7242978	chr18:44633424	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.55	-7.42	-0.44	2.14e-12	Educational attainment;
SARC	cis	rs4132509	0.895	rs7556516	chr1:243782009	G/A	cg21452805	chr1:244014465	NA	0.49	5.37	0.33	1.91e-7	RR interval (heart rate);
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg26550873	chr12:49629119	NA	0.51	6.69	0.4	1.6e-10	Electrocardiographic conduction measures;
SARC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.58	0.57	1.3e-21	Prudent dietary pattern;
SARC	cis	rs9325144	0.600	rs2171405	chr12:38741030	G/T	cg26384229	chr12:38710491	ALG10B	-0.63	-8.26	-0.48	1.12e-14	Morning vs. evening chronotype;
SARC	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg21433313	chr16:3507492	NAT15	0.33	4.73	0.3	3.88e-6	Tuberculosis;
SARC	cis	rs4423214	1.000	rs12789751	chr11:71164471	G/A	cg24826892	chr11:71159390	DHCR7	0.43	5.24	0.32	3.64e-7	Vitamin D levels;
SARC	cis	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg06212747	chr3:49208901	KLHDC8B	0.72	6.46	0.39	6.03e-10	Menarche (age at onset);
SARC	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg26681399	chr22:41777847	TEF	0.47	5.14	0.32	5.91e-7	Vitiligo;
SARC	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	7.88	0.46	1.28e-13	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg07636037	chr3:49044803	WDR6	1.0	17.31	0.75	1.05e-43	Parkinson's disease;
SARC	cis	rs7772486	0.712	rs6570726	chr6:146159460	T/C	cg05347473	chr6:146136440	FBXO30	0.48	6.33	0.38	1.24e-9	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs72781680	0.848	rs6754694	chr2:24155448	T/C	cg06627628	chr2:24431161	ITSN2	-0.68	-6.49	-0.39	4.99e-10	Lymphocyte counts;
SARC	cis	rs8077889	0.917	rs4793037	chr17:41914826	C/T	cg26893861	chr17:41843967	DUSP3	0.85	10.6	0.57	1.12e-21	Triglycerides;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg06618957	chr4:52883909	LRRC66	0.49	6.59	0.4	2.92e-10	Thyroid stimulating hormone;
SARC	cis	rs9911578	0.935	rs7218105	chr17:57041119	A/G	cg05425664	chr17:57184151	TRIM37	-0.65	-8.04	-0.47	4.55e-14	Intelligence (multi-trait analysis);
SARC	cis	rs6670533	0.571	rs114121573	chr1:24859035	G/T	cg07475527	chr1:24864545	NA	-0.97	-5.41	-0.33	1.58e-7	Fasting blood insulin (BMI interaction);
SARC	cis	rs7927592	0.871	rs55953412	chr11:68328283	C/T	cg01657329	chr11:68192670	LRP5	-0.43	-5.11	-0.32	6.57e-7	Total body bone mineral density;
SARC	cis	rs2742234	0.590	rs2435338	chr10:43642115	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.4	-4.93	-0.31	1.56e-6	Hirschsprung disease;
SARC	cis	rs7513165	0.660	rs12040249	chr1:204158228	C/T	cg23788856	chr1:204159729	KISS1	-0.3	-4.95	-0.31	1.4e-6	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
SARC	cis	rs6088590	1.000	rs6088590	chr20:33313566	T/C	cg24642439	chr20:33292090	TP53INP2	0.89	12.72	0.64	1.66e-28	Coronary artery disease;
SARC	cis	rs10752881	0.935	rs4652771	chr1:183023503	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.09	0.55	4.29e-20	Colorectal cancer;
SARC	cis	rs7659604	0.540	rs4455438	chr4:122669550	G/A	cg19671926	chr4:122722719	EXOSC9	0.54	6.81	0.41	8.14e-11	Type 2 diabetes;
SARC	cis	rs41271473	1.000	rs11580020	chr1:228880466	A/G	cg10167378	chr1:228756711	NA	-0.49	-5.05	-0.31	9.04e-7	Chronic lymphocytic leukemia;
SARC	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg19077165	chr18:44547161	KATNAL2	-0.47	-6.56	-0.39	3.42e-10	Personality dimensions;
SARC	cis	rs7106204	0.748	rs6484031	chr11:24237115	A/C	ch.11.24196551F	chr11:24239977	NA	0.55	5.69	0.35	3.81e-8	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.09	0.37	4.51e-9	Height;
SARC	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg26335602	chr6:28129616	ZNF389	0.53	5.92	0.36	1.12e-8	Depression;
SARC	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg26597838	chr10:835615	NA	1.05	10.26	0.56	1.24e-20	Eosinophil percentage of granulocytes;
SARC	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg15556689	chr8:8085844	FLJ10661	-0.63	-8.31	-0.48	8.15e-15	Schizophrenia;
SARC	cis	rs12681288	0.862	rs2701899	chr8:1019581	G/A	cg15309053	chr8:964076	NA	0.44	7.41	0.44	2.25e-12	Schizophrenia;
SARC	cis	rs73635312	0.850	rs77249403	chr10:8989198	G/A	cg24467326	chr10:9646929	NA	0.59	5.07	0.32	8.19e-7	Basal cell carcinoma;
SARC	cis	rs9787249	0.957	rs12086750	chr1:40210468	G/C	cg19912559	chr1:40204330	PPIE	0.4	4.77	0.3	3.24e-6	Blood protein levels;
SARC	cis	rs9916302	0.904	rs13341996	chr17:37536862	C/T	cg00129232	chr17:37814104	STARD3	0.6	7.49	0.44	1.39e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs11719291	0.833	rs73080361	chr3:48832146	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.64	-4.98	-0.31	1.25e-6	Cognitive function;
SARC	cis	rs2425143	0.818	rs11700299	chr20:34548865	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-5.4	-0.33	1.62e-7	Blood protein levels;
SARC	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg15038512	chr6:170123185	PHF10	0.59	6.95	0.41	3.64e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs7927592	0.956	rs7944870	chr11:68309108	C/G	cg01657329	chr11:68192670	LRP5	-0.46	-5.5	-0.34	9.94e-8	Total body bone mineral density;
SARC	cis	rs12042938	1.000	rs11122319	chr1:231808282	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-7.25	-0.43	6.24e-12	Neuranatomic and neurocognitive phenotypes;
SARC	trans	rs3945119	0.808	rs7552235	chr1:91152416	A/G	cg01730148	chr2:3698421	NA	0.34	6.26	0.38	1.79e-9	Intelligence (multi-trait analysis);
SARC	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	21.47	0.82	3.89e-57	Chronic sinus infection;
SARC	cis	rs4148883	0.651	rs2851301	chr4:100010127	C/T	cg13256891	chr4:100009986	ADH5	0.61	8.2	0.47	1.61e-14	Alcohol dependence;
SARC	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.74	6.62	0.4	2.48e-10	Platelet count;
SARC	cis	rs910316	0.870	rs7147712	chr14:75670707	C/G	cg08847533	chr14:75593920	NEK9	-0.79	-11.72	-0.61	2.98e-25	Height;
SARC	cis	rs12586317	1.000	rs12586317	chr14:35682172	T/C	cg26967526	chr14:35346199	BAZ1A	-0.54	-5.79	-0.35	2.26e-8	Psoriasis;
SARC	cis	rs765787	0.505	rs1648302	chr15:45494238	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.39	-4.8	-0.3	2.88e-6	Uric acid levels;
SARC	trans	rs1814175	0.791	rs10769625	chr11:49869887	G/A	cg15704280	chr7:45808275	SEPT13	-0.97	-18.12	-0.76	2.26e-46	Height;
SARC	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg05165339	chr4:1420672	NA	-0.22	-4.94	-0.31	1.51e-6	Longevity;
SARC	cis	rs10992471	0.729	rs2181585	chr9:95551830	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-5.84	-0.36	1.77e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs9815354	1.000	rs9865127	chr3:41807448	C/T	cg03022575	chr3:42003672	ULK4	0.59	5.64	0.35	4.85e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs7917772	0.582	rs10786684	chr10:104323028	A/C	ch.10.2196322F	chr10:104248062	ACTR1A	-0.48	-6.58	-0.4	3.11e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs11608355	1.000	rs7970482	chr12:109862335	G/A	cg19025524	chr12:109796872	NA	-0.39	-5.0	-0.31	1.11e-6	Neuroticism;
SARC	cis	rs7917772	0.636	rs4919676	chr10:104524352	C/T	ch.10.2196322F	chr10:104248062	ACTR1A	-0.46	-5.4	-0.33	1.61e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs56011263	0.687	rs4690186	chr4:703607	G/A	cg14024328	chr4:719362	PCGF3	-0.42	-5.62	-0.35	5.33e-8	White blood cell count;
SARC	cis	rs7599312	0.534	rs6751692	chr2:213408120	C/T	cg20637307	chr2:213403960	ERBB4	0.8	12.22	0.62	7.34e-27	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg00149659	chr3:10157352	C3orf10	0.64	5.91	0.36	1.22e-8	Alzheimer's disease;
SARC	trans	rs7927370	1.000	rs76463468	chr11:55327996	G/T	cg00957901	chr4:41614842	LIMCH1	0.62	6.26	0.38	1.84e-9	Systemic lupus erythematosus;
SARC	cis	rs6831352	0.589	rs1133483	chr4:100023923	G/C	cg13256891	chr4:100009986	ADH5	0.71	11.03	0.59	4.8e-23	Alcohol dependence;
SARC	cis	rs2594989	0.943	rs2606748	chr3:11373989	T/C	cg00170343	chr3:11313890	ATG7	0.54	5.28	0.33	3e-7	Circulating chemerin levels;
SARC	cis	rs7566780	0.700	rs1430052	chr2:16667742	C/G	cg09580478	chr2:16689509	NA	0.49	5.68	0.35	4.09e-8	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg21280719	chr6:42927975	GNMT	-0.44	-7.46	-0.44	1.75e-12	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs72653721	0.838	rs958712	chr6:11026161	T/C	cg13562911	chr6:11044106	ELOVL2	0.49	5.63	0.35	5.03e-8	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs367943	1.000	rs348956	chr5:112821464	C/T	cg12552261	chr5:112820674	MCC	0.45	5.19	0.32	4.65e-7	Type 2 diabetes;
SARC	cis	rs1018836	0.923	rs34126139	chr8:91572045	T/G	cg16814680	chr8:91681699	NA	-0.84	-13.56	-0.66	2.92e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs7713065	0.531	rs2522051	chr5:131797578	C/T	cg12564285	chr5:131593104	PDLIM4	0.33	4.84	0.3	2.4e-6	Lung function (FEV1/FVC);
SARC	cis	rs7666738	0.715	rs116787789	chr4:98718720	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.54	0.49	1.76e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs634534	0.561	rs14157	chr11:65769780	T/G	cg26695010	chr11:65641043	EFEMP2	-0.53	-6.79	-0.41	9.11e-11	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg04055107	chr11:65626734	MUS81;CFL1	0.42	5.26	0.33	3.31e-7	Eosinophil percentage of white cells;
SARC	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg22484793	chr3:52261325	TLR9	0.29	4.78	0.3	3.13e-6	Bipolar disorder;
SARC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.77	9.92	0.54	1.42e-19	Prudent dietary pattern;
SARC	cis	rs3820928	1.000	rs3820927	chr2:227779191	C/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-6.64	-0.4	2.19e-10	Pulmonary function;
SARC	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg11644478	chr21:40555479	PSMG1	1.05	14.79	0.7	2.43e-35	Cognitive function;
SARC	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg15966229	chr18:44337664	ST8SIA5	-0.37	-4.86	-0.3	2.15e-6	Personality dimensions;
SARC	cis	rs2070488	0.775	rs7374458	chr3:38531211	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	11.79	0.61	1.76e-25	Electrocardiographic conduction measures;
SARC	cis	rs2120019	1.000	rs12185102	chr15:75352201	G/A	cg00629941	chr15:75287862	SCAMP5	-0.67	-8.0	-0.46	5.81e-14	Blood trace element (Zn levels);
SARC	cis	rs4588572	0.643	rs6861678	chr5:77764613	G/C	cg11547950	chr5:77652471	NA	-0.41	-5.03	-0.31	9.75e-7	Triglycerides;
SARC	cis	rs11122272	0.766	rs2808614	chr1:231550168	A/G	cg06096015	chr1:231504339	EGLN1	-0.38	-5.71	-0.35	3.37e-8	Hemoglobin concentration;
SARC	cis	rs1448094	0.511	rs59668915	chr12:86197170	C/T	cg02569458	chr12:86230093	RASSF9	0.39	5.34	0.33	2.17e-7	Major depressive disorder;
SARC	cis	rs9815354	1.000	rs1717006	chr3:41940448	A/C	cg03022575	chr3:42003672	ULK4	0.58	5.7	0.35	3.54e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs1215050	0.791	rs2695472	chr4:98855127	T/C	cg05340658	chr4:99064831	C4orf37	-0.44	-5.89	-0.36	1.37e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg12292205	chr6:26970375	C6orf41	-0.56	-6.17	-0.37	2.96e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs11690935	0.550	rs62183784	chr2:172866696	A/G	cg13550731	chr2:172543902	DYNC1I2	0.51	6.53	0.39	4.03e-10	Schizophrenia;
SARC	cis	rs1355223	0.872	rs7116409	chr11:34751007	T/G	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-5.81	-0.36	2.02e-8	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg18252515	chr7:66147081	NA	-1.29	-11.2	-0.59	1.41e-23	Diabetic kidney disease;
SARC	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg05393297	chr12:53359155	NA	-0.53	-7.08	-0.42	1.73e-11	Cancer (pleiotropy);
SARC	cis	rs8114671	0.967	rs6142323	chr20:33788983	A/G	cg24642439	chr20:33292090	TP53INP2	-0.48	-5.51	-0.34	9.63e-8	Height;
SARC	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg07701084	chr6:150067640	NUP43	0.42	5.59	0.34	6.35e-8	Lung cancer;
SARC	trans	rs1973993	0.689	rs67544133	chr1:96971241	G/A	cg10631902	chr5:14652156	NA	-0.42	-6.66	-0.4	1.96e-10	Weight;
SARC	cis	rs780096	0.778	rs780094	chr2:27741237	C/T	cg11618577	chr2:27665543	KRTCAP3	0.31	5.08	0.32	7.66e-7	Total body bone mineral density;
SARC	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg25894440	chr7:65020034	NA	0.73	5.51	0.34	9.25e-8	Diabetic kidney disease;
SARC	cis	rs2439831	0.850	rs7179388	chr15:44123945	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	7.5	0.44	1.33e-12	Lung cancer in ever smokers;
SARC	cis	rs1153858	1.000	rs56806728	chr15:45637814	A/G	cg03999130	chr15:45571217	NA	0.4	5.21	0.32	4.21e-7	Homoarginine levels;
SARC	cis	rs79149102	0.522	rs12441794	chr15:74764149	C/T	cg09165964	chr15:75287851	SCAMP5	-0.65	-5.14	-0.32	5.91e-7	Lung cancer;
SARC	cis	rs995000	0.931	rs10889331	chr1:62943007	G/T	cg06896770	chr1:63153194	DOCK7	-0.9	-13.43	-0.66	7.67e-31	Triglyceride levels;
SARC	cis	rs17030434	1.000	rs12646758	chr4:154731625	A/G	cg14289246	chr4:154710475	SFRP2	-0.78	-7.87	-0.46	1.29e-13	Electrocardiographic conduction measures;
SARC	cis	rs9302635	0.513	rs9923575	chr16:72230112	C/T	cg01557791	chr16:72042693	DHODH	-0.57	-5.64	-0.35	4.88e-8	Blood protein levels;
SARC	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg15052019	chr19:19431593	KIAA0892;SF4	-0.39	-4.75	-0.3	3.58e-6	Tonsillectomy;
SARC	trans	rs7937682	1.000	rs11213973	chr11:111538903	A/T	cg18187862	chr3:45730750	SACM1L	0.58	7.21	0.43	7.85e-12	Primary sclerosing cholangitis;
SARC	cis	rs6964587	0.839	rs6949881	chr7:91433827	C/T	cg17063962	chr7:91808500	NA	0.81	11.36	0.6	4.44e-24	Breast cancer;
SARC	cis	rs2075371	0.863	rs1646638	chr7:134008706	T/C	cg11752832	chr7:134001865	SLC35B4	0.64	8.5	0.49	2.36e-15	Mean platelet volume;
SARC	cis	rs11122272	0.735	rs2790886	chr1:231529491	A/C	cg06096015	chr1:231504339	EGLN1	0.39	5.81	0.36	1.99e-8	Hemoglobin concentration;
SARC	cis	rs832540	0.519	rs1445998	chr5:56268205	A/G	cg14703610	chr5:56206110	C5orf35	0.46	5.6	0.34	5.89e-8	Coronary artery disease;
SARC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.53	-6.09	-0.37	4.52e-9	Prudent dietary pattern;
SARC	cis	rs35272691	1	rs35272691	chr17:38157841	T/C	cg17467752	chr17:38218738	THRA	-0.4	-5.0	-0.31	1.11e-6	White blood cell count (neutrophil);
SARC	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.47	5.94	0.36	1.04e-8	Lymphocyte counts;
SARC	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.98	11.82	0.61	1.49e-25	Platelet count;
SARC	cis	rs17376456	0.825	rs28534784	chr5:93063332	C/A	cg25358565	chr5:93447407	FAM172A	1.19	12.26	0.63	5.27e-27	Diabetic retinopathy;
SARC	cis	rs7312774	0.748	rs10492211	chr12:107298213	T/C	cg16260113	chr12:107380972	MTERFD3	0.76	6.55	0.39	3.63e-10	Severe influenza A (H1N1) infection;
SARC	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg11644478	chr21:40555479	PSMG1	-0.89	-11.13	-0.59	2.41e-23	Cognitive function;
SARC	cis	rs9457247	0.565	rs2239823	chr6:167512131	T/C	cg07741184	chr6:167504864	NA	0.37	7.08	0.42	1.73e-11	Crohn's disease;
SARC	cis	rs7666738	0.609	rs35214820	chr4:98864692	G/A	cg05340658	chr4:99064831	C4orf37	0.58	7.09	0.42	1.54e-11	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg05896524	chr21:47604654	C21orf56	0.46	5.46	0.34	1.24e-7	Testicular germ cell tumor;
SARC	cis	rs7561273	0.586	rs11902756	chr2:24300932	A/G	cg08917208	chr2:24149416	ATAD2B	0.44	4.82	0.3	2.63e-6	Quantitative traits;
SARC	cis	rs3617	0.625	rs7612624	chr3:52893426	T/C	cg18404041	chr3:52824283	ITIH1	0.38	5.45	0.34	1.25e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	trans	rs7980799	0.711	rs1482993	chr12:33594515	G/A	cg26384229	chr12:38710491	ALG10B	-0.63	-7.62	-0.45	6.25e-13	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg11987759	chr7:65425863	GUSB	-0.58	-7.96	-0.46	7.3e-14	Aortic root size;
SARC	cis	rs61935443	0.501	rs10745698	chr12:95204072	C/T	cg21533806	chr12:95267307	NA	0.37	4.86	0.3	2.18e-6	Schizophrenia;
SARC	cis	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg06212747	chr3:49208901	KLHDC8B	0.52	6.42	0.39	7.41e-10	Resting heart rate;
SARC	cis	rs16976116	0.572	rs28802062	chr15:55452308	G/C	cg17854078	chr15:55489399	RSL24D1	0.65	5.75	0.35	2.74e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6701037	0.512	rs2285216	chr1:175133012	C/T	cg08873628	chr1:175162347	KIAA0040	0.34	4.85	0.3	2.26e-6	Alcohol dependence;
SARC	trans	rs1994135	0.549	rs2218650	chr12:33734783	A/G	cg13010199	chr12:38710504	ALG10B	0.54	6.39	0.39	9.09e-10	Resting heart rate;
SARC	cis	rs6964587	1.000	rs55745934	chr7:91670998	T/C	cg17063962	chr7:91808500	NA	0.95	15.13	0.7	1.69e-36	Breast cancer;
SARC	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.78	7.31	0.43	4.3e-12	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs9640161	0.789	rs2098053	chr7:150043205	G/A	cg17279839	chr7:150038598	RARRES2	0.41	5.4	0.33	1.66e-7	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs4253772	0.550	rs6007761	chr22:46670394	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.66	-6.96	-0.41	3.44e-11	LDL cholesterol;Cholesterol, total;
SARC	cis	rs7647973	1.000	rs11720542	chr3:49357427	A/G	cg06212747	chr3:49208901	KLHDC8B	0.54	5.8	0.36	2.1e-8	Menarche (age at onset);
SARC	cis	rs2730245	0.550	rs2709860	chr7:158651156	A/T	cg14689365	chr7:158441557	NCAPG2	0.41	5.01	0.31	1.06e-6	Height;
SARC	cis	rs1420338	0.933	rs6462533	chr7:34168028	G/A	cg01275685	chr7:34179230	BMPER	-0.41	-5.05	-0.31	8.98e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
SARC	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.7	6.55	0.39	3.61e-10	Platelet count;
SARC	cis	rs7647973	0.626	rs62260723	chr3:49872124	T/C	cg13072238	chr3:49761600	GMPPB	0.59	5.9	0.36	1.25e-8	Menarche (age at onset);
SARC	cis	rs1865760	0.534	rs72834629	chr6:26023032	C/T	cg16482183	chr6:26056742	HIST1H1C	0.49	5.6	0.34	5.96e-8	Height;
SARC	cis	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg12463550	chr7:65579703	CRCP	0.66	5.06	0.31	8.64e-7	Diabetic kidney disease;
SARC	cis	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg12064134	chr16:90016061	DEF8	-0.56	-4.83	-0.3	2.51e-6	Skin colour saturation;
SARC	cis	rs6540556	0.608	rs3817821	chr1:209918503	A/T	cg23920097	chr1:209922102	NA	-0.61	-7.23	-0.43	6.83e-12	Red blood cell count;
SARC	cis	rs751728	0.965	rs4713681	chr6:33754817	T/C	cg25922239	chr6:33757077	LEMD2	0.78	10.39	0.56	5.11e-21	Crohn's disease;
SARC	cis	rs2991971	0.810	rs12119202	chr1:45925931	A/T	cg24296786	chr1:45957014	TESK2	-0.6	-8.14	-0.47	2.36e-14	High light scatter reticulocyte count;
SARC	cis	rs8103278	0.826	rs11669442	chr19:46374557	A/G	cg11657440	chr19:46296263	DMWD	-0.65	-8.05	-0.47	4.28e-14	Coronary artery disease;
SARC	cis	rs9430161	0.645	rs6675082	chr1:11033797	T/C	cg02454025	chr1:11042201	C1orf127	0.85	12.06	0.62	2.33e-26	Ewing sarcoma;
SARC	cis	rs9399137	0.507	rs13196486	chr6:135283874	C/G	cg24558204	chr6:135376177	HBS1L	0.62	7.98	0.46	6.83e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs2050392	0.517	rs619864	chr10:30750950	A/G	cg25182066	chr10:30743637	MAP3K8	-0.47	-7.02	-0.42	2.43e-11	Inflammatory bowel disease;
SARC	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	13.98	0.68	1.21e-32	Chronic sinus infection;
SARC	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	11.69	0.61	3.89e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs4253772	0.575	rs6008684	chr22:46719100	C/G	cg24881330	chr22:46731750	TRMU	0.72	5.67	0.35	4.16e-8	LDL cholesterol;Cholesterol, total;
SARC	cis	rs17539620	0.624	rs62432740	chr6:154836054	C/T	cg20019720	chr6:154832845	CNKSR3	0.41	4.84	0.3	2.39e-6	Lipoprotein (a) levels;
SARC	cis	rs1448094	0.817	rs73176252	chr12:86347649	T/A	cg02569458	chr12:86230093	RASSF9	0.43	6.21	0.38	2.43e-9	Major depressive disorder;
SARC	cis	rs17376456	0.877	rs17083455	chr5:93446380	A/C	cg25358565	chr5:93447407	FAM172A	1.31	15.17	0.7	1.33e-36	Diabetic retinopathy;
SARC	cis	rs9467773	0.967	rs9461267	chr6:26525455	T/G	cg12292205	chr6:26970375	C6orf41	0.44	5.46	0.34	1.24e-7	Intelligence (multi-trait analysis);
SARC	cis	rs10861342	1.000	rs34705618	chr12:105518611	C/G	cg23923672	chr12:105501055	KIAA1033	0.69	5.1	0.32	6.95e-7	IgG glycosylation;
SARC	cis	rs7513165	1.000	rs7513165	chr1:204147186	C/T	cg23788856	chr1:204159729	KISS1	0.34	5.36	0.33	2.04e-7	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
SARC	cis	rs3857536	0.719	rs9363555	chr6:66930332	T/C	cg07460842	chr6:66804631	NA	-0.51	-5.77	-0.35	2.47e-8	Blood trace element (Cu levels);
SARC	cis	rs7216064	0.954	rs9907491	chr17:65949993	G/A	cg12091567	chr17:66097778	LOC651250	0.77	8.57	0.49	1.42e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs6840258	1.000	rs56395939	chr4:87963633	T/G	cg11209507	chr4:87813803	C4orf36	0.45	4.85	0.3	2.26e-6	Mean corpuscular volume;Basophil percentage of granulocytes;
SARC	cis	rs861020	0.630	rs599649	chr1:210003402	T/C	cg05527609	chr1:210001259	C1orf107	0.79	10.18	0.55	2.29e-20	Orofacial clefts;
SARC	cis	rs2084898	0.527	rs605374	chr11:120005633	A/C	cg07435449	chr11:120005650	TRIM29	0.4	6.44	0.39	6.77e-10	Stroke (pediatric);
SARC	cis	rs73242632	1.000	rs10026915	chr4:57857771	G/T	cg20415529	chr4:57845134	POLR2B;C4orf14	1.07	6.6	0.4	2.74e-10	Congenital heart disease (maternal effect);
SARC	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg25894440	chr7:65020034	NA	-0.77	-5.85	-0.36	1.67e-8	Diabetic kidney disease;
SARC	cis	rs11155671	0.530	rs9397398	chr6:150193603	G/A	cg05036130	chr6:150231994	NA	0.33	5.49	0.34	1.02e-7	Testicular germ cell tumor;
SARC	cis	rs910187	0.678	rs1046659	chr20:45817068	G/A	cg27589058	chr20:45804311	EYA2	-0.3	-4.78	-0.3	3.13e-6	Migraine;
SARC	cis	rs576982	1	rs576982	chr15:78870803	C/T	cg06917634	chr15:78832804	PSMA4	-0.5	-5.61	-0.35	5.63e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs7729447	0.813	rs4867470	chr5:32692536	C/A	cg16267343	chr5:32710456	NPR3	0.64	8.54	0.49	1.75e-15	Blood pressure;
SARC	cis	rs2011503	1.000	rs4808951	chr19:19550306	C/G	cg03709012	chr19:19516395	GATAD2A	0.67	5.8	0.36	2.16e-8	Bipolar disorder;
SARC	cis	rs472402	0.905	rs540212	chr5:6656003	G/A	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.4	-5.06	-0.31	8.41e-7	Response to amphetamines;
SARC	cis	rs2576037	0.901	rs2571021	chr18:44583498	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.49	6.41	0.39	7.78e-10	Personality dimensions;
SARC	cis	rs7208859	0.673	rs73277964	chr17:29179201	A/T	cg13385521	chr17:29058706	SUZ12P	0.86	7.34	0.43	3.54e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs1707322	1.000	rs6657720	chr1:46386269	G/A	cg06784218	chr1:46089804	CCDC17	0.34	5.97	0.36	8.8e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs7980799	0.682	rs1447873	chr12:33615236	A/G	cg26384229	chr12:38710491	ALG10B	-0.62	-7.62	-0.45	6.26e-13	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs11574514	1.000	rs28679372	chr16:67882932	C/T	cg01866162	chr16:67596514	CTCF	-1.02	-5.82	-0.36	1.89e-8	Crohn's disease;
SARC	cis	rs35213789	0.887	rs611052	chr7:69157267	A/G	cg10619644	chr7:69149951	AUTS2	0.44	5.98	0.36	8.49e-9	Childhood ear infection;
SARC	cis	rs73198271	0.562	rs964772	chr8:8651306	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-4.78	-0.3	3.09e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs1348850	0.526	rs10497504	chr2:178370040	T/C	cg23306229	chr2:178417860	TTC30B	0.84	7.66	0.45	4.88e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs11112613	0.653	rs59504344	chr12:105950837	C/T	cg03607813	chr12:105948248	NA	0.55	7.79	0.45	2.16e-13	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs6912958	0.547	rs451089	chr6:88041859	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	11.05	0.59	4.11e-23	Monocyte percentage of white cells;
SARC	cis	rs2377585	0.653	rs7299203	chr12:8849161	G/A	cg03761649	chr12:8850719	RIMKLB	0.43	4.74	0.3	3.8e-6	Reticulocyte fraction of red cells;
SARC	cis	rs9902453	0.967	rs4356528	chr17:28489670	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	6.66	0.4	1.91e-10	Coffee consumption (cups per day);
SARC	cis	rs6502050	0.723	rs8077209	chr17:80163221	A/G	cg19223190	chr17:80058835	NA	0.51	7.23	0.43	6.74e-12	Life satisfaction;
SARC	cis	rs9814567	0.806	rs2293294	chr3:134322814	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.52	6.73	0.4	1.32e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs2153535	0.580	rs9378556	chr6:8514695	A/G	cg07606381	chr6:8435919	SLC35B3	0.77	10.9	0.58	1.28e-22	Motion sickness;
SARC	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg20607798	chr8:58055168	NA	-0.52	-4.76	-0.3	3.42e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs753778	0.570	rs6985866	chr8:142210336	C/T	cg18755752	chr8:142205143	DENND3	0.42	5.95	0.36	9.6e-9	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs17376456	0.825	rs6877030	chr5:93201841	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.7	6.29	0.38	1.52e-9	Diabetic retinopathy;
SARC	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg04772025	chr11:68637568	NA	0.46	5.66	0.35	4.46e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7769051	0.522	rs9493449	chr6:133126179	T/A	cg07930552	chr6:133119739	C6orf192	0.98	5.85	0.36	1.62e-8	Type 2 diabetes nephropathy;
SARC	cis	rs2033732	0.706	rs7821182	chr8:85060586	C/T	cg05716166	chr8:85095498	RALYL	0.47	5.62	0.35	5.51e-8	Body mass index;
SARC	cis	rs80282103	0.867	rs7099063	chr10:1078547	C/G	cg08668510	chr10:1095578	IDI1	0.65	4.72	0.3	4.16e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs6493487	0.512	rs28366661	chr15:51258315	A/G	cg02338191	chr15:51200825	AP4E1	0.54	5.05	0.31	8.73e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs7000551	0.505	rs13258195	chr8:22227271	A/G	cg12081754	chr8:22256438	SLC39A14	-0.78	-10.64	-0.57	8.43e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs4481887	0.888	rs4525076	chr1:248456876	T/G	cg01631408	chr1:248437212	OR2T33	-0.43	-5.43	-0.34	1.39e-7	Common traits (Other);
SARC	cis	rs17539620	0.624	rs62432738	chr6:154835674	T/C	cg17771515	chr6:154831774	CNKSR3	0.53	5.07	0.32	8.2e-7	Lipoprotein (a) levels;
SARC	cis	rs73086581	1.000	rs11906274	chr20:3945536	G/A	cg02187196	chr20:3869020	PANK2	0.67	6.46	0.39	6.21e-10	Response to antidepressants in depression;
SARC	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9486719	0.947	rs11755945	chr6:96908038	G/C	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.01	-0.46	5.62e-14	Migraine;Coronary artery disease;
SARC	cis	rs651907	0.557	rs3094295	chr3:101401995	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	6.51	0.39	4.57e-10	Colorectal cancer;
SARC	cis	rs9790314	0.812	rs2004862	chr3:161135638	C/T	cg04691961	chr3:161091175	C3orf57	-0.66	-9.1	-0.51	4.17e-17	Morning vs. evening chronotype;
SARC	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs763121	0.853	rs6001185	chr22:39052155	G/A	cg06022373	chr22:39101656	GTPBP1	0.9	11.56	0.6	9.96e-25	Menopause (age at onset);
SARC	cis	rs6088580	0.634	rs6088508	chr20:33060081	A/G	cg24642439	chr20:33292090	TP53INP2	0.69	8.88	0.5	1.85e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs7481584	0.581	rs406598	chr11:3076285	G/A	cg20651018	chr11:3035856	CARS	0.39	5.84	0.36	1.77e-8	Calcium levels;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg21619547	chr3:93780328	DHFRL1	0.49	7.11	0.42	1.4e-11	Thyroid stimulating hormone;
SARC	cis	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg09021430	chr5:549028	NA	-0.45	-5.7	-0.35	3.69e-8	Lung disease severity in cystic fibrosis;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg11562466	chr6:13328824	TBC1D7	0.49	6.47	0.39	5.87e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	trans	rs629535	0.814	rs674429	chr8:70069942	G/A	cg21567404	chr3:27674614	NA	1.04	13.3	0.66	2.13e-30	Dupuytren's disease;
SARC	cis	rs2832077	0.506	rs2832085	chr21:30155258	G/T	cg08807101	chr21:30365312	RNF160	-0.51	-5.5	-0.34	1.01e-7	Cognitive test performance;
SARC	cis	rs453301	0.598	rs2921383	chr8:8892221	C/T	cg06636001	chr8:8085503	FLJ10661	0.49	6.48	0.39	5.26e-10	Joint mobility (Beighton score);
SARC	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg08280861	chr8:58055591	NA	0.59	5.22	0.32	4.02e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs3762637	0.941	rs60222267	chr3:122179632	G/T	cg24169773	chr3:122142474	KPNA1	-0.56	-5.73	-0.35	3.07e-8	LDL cholesterol levels;
SARC	cis	rs11785400	0.762	rs7007349	chr8:143722673	T/C	cg10596483	chr8:143751796	JRK	0.58	7.5	0.44	1.29e-12	Schizophrenia;
SARC	cis	rs453301	0.686	rs3895823	chr8:8873646	T/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.23	-0.43	6.77e-12	Joint mobility (Beighton score);
SARC	cis	rs796364	0.951	rs2881593	chr2:201000347	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.51	-5.14	-0.32	5.82e-7	Schizophrenia;
SARC	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg24503407	chr1:205819492	PM20D1	0.44	5.01	0.31	1.07e-6	Parkinson's disease;
SARC	cis	rs9902453	0.619	rs2244585	chr17:28072176	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-7.25	-0.43	6.15e-12	Coffee consumption (cups per day);
SARC	cis	rs9486715	1.000	rs11153082	chr6:97059666	A/G	cg06623918	chr6:96969491	KIAA0776	-0.84	-11.41	-0.6	3.02e-24	Headache;
SARC	cis	rs11098499	0.908	rs9995234	chr4:120321827	A/G	cg09307838	chr4:120376055	NA	0.91	12.7	0.64	2.03e-28	Corneal astigmatism;
SARC	cis	rs5995756	0.761	rs6001638	chr22:40003267	T/C	cg10455938	chr22:40058150	CACNA1I	-0.48	-6.25	-0.38	1.98e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs425277	1.000	rs196128	chr1:2078444	T/G	cg24578937	chr1:2090814	PRKCZ	0.31	5.85	0.36	1.63e-8	Height;
SARC	cis	rs12142240	0.698	rs1475390	chr1:46816340	A/G	cg10495392	chr1:46806563	NSUN4	0.65	6.83	0.41	7.25e-11	Menopause (age at onset);
SARC	cis	rs7084402	0.967	rs1623568	chr10:60320446	T/C	cg07615347	chr10:60278583	BICC1	0.59	8.39	0.48	4.59e-15	Refractive error;
SARC	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-8.78	-0.5	3.56e-16	Alzheimer's disease;
SARC	cis	rs992157	0.560	rs6436048	chr2:219109033	C/T	cg00012203	chr2:219082015	ARPC2	0.77	11.49	0.6	1.73e-24	Colorectal cancer;
SARC	trans	rs1994135	0.715	rs11052742	chr12:33692290	A/C	cg13010199	chr12:38710504	ALG10B	0.61	7.26	0.43	5.87e-12	Resting heart rate;
SARC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.95	0.81	1.72e-55	Prudent dietary pattern;
SARC	cis	rs7249142	0.549	rs7260127	chr19:19280499	C/T	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	-0.23	-4.83	-0.3	2.45e-6	IgG glycosylation;
SARC	cis	rs3764563	1.000	rs4646530	chr19:15735238	A/T	cg20725493	chr19:15740067	CYP4F8	0.73	6.0	0.37	7.59e-9	Inflammatory biomarkers;
SARC	cis	rs7786877	0.508	rs11765509	chr7:100310990	T/G	cg16850897	chr7:100343110	ZAN	-0.66	-7.1	-0.42	1.51e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs2115536	1.000	rs2115536	chr15:80194247	C/T	cg00225070	chr15:80189496	MTHFS	0.63	8.8	0.5	3.16e-16	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg25405821	chr13:111531992	ANKRD10	0.75	5.35	0.33	2.14e-7	Obesity-related traits;
SARC	trans	rs3780486	0.846	rs10813950	chr9:33127640	A/G	cg20290983	chr6:43655470	MRPS18A	-1.06	-17.75	-0.76	3.59e-45	IgG glycosylation;
SARC	cis	rs7923609	0.756	rs6479908	chr10:65333648	C/G	cg01631684	chr10:65280961	REEP3	0.36	4.72	0.3	4e-6	Educational attainment;Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg18357526	chr6:26021779	HIST1H4A	0.4	5.12	0.32	6.48e-7	Blood metabolite levels;
SARC	cis	rs11098499	0.954	rs11734241	chr4:120416872	A/G	cg09307838	chr4:120376055	NA	0.93	12.73	0.64	1.6e-28	Corneal astigmatism;
SARC	cis	rs2276314	0.857	rs62101376	chr18:33582955	T/C	cg19628046	chr18:33552617	C18orf21	0.61	6.2	0.38	2.52e-9	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs6598955	0.670	rs10794525	chr1:26537193	C/A	cg04990556	chr1:26633338	UBXN11	-0.6	-8.41	-0.48	4.25e-15	Obesity-related traits;
SARC	trans	rs7937682	0.855	rs490897	chr11:111487914	A/G	cg18187862	chr3:45730750	SACM1L	0.56	6.93	0.41	3.99e-11	Primary sclerosing cholangitis;
SARC	cis	rs17253792	0.822	rs75115817	chr14:56069537	G/A	cg01858014	chr14:56050164	KTN1	-0.67	-5.16	-0.32	5.38e-7	Putamen volume;
SARC	cis	rs13191362	1.000	rs35449999	chr6:163023465	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.55	5.25	0.33	3.46e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs10876993	0.928	rs813854	chr12:58071347	A/G	cg18357645	chr12:58087776	OS9	0.46	6.05	0.37	5.82e-9	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs9920	0.541	rs62468984	chr7:116136882	G/A	cg24770985	chr7:116166421	CAV1	0.93	6.19	0.38	2.64e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Immature fraction of reticulocytes;QT interval;
SARC	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg20891558	chr2:74357851	NA	0.7	9.67	0.54	8.18e-19	Gestational age at birth (maternal effect);
SARC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg26354017	chr1:205819088	PM20D1	0.56	7.34	0.43	3.6e-12	Menarche (age at onset);
SARC	cis	rs9322817	0.691	rs2499659	chr6:105286124	A/T	cg02098413	chr6:105308735	HACE1	0.38	5.91	0.36	1.18e-8	Thyroid stimulating hormone;
SARC	cis	rs1568889	0.838	rs1483858	chr11:28189639	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	14.84	0.7	1.63e-35	Bipolar disorder;
SARC	cis	rs11105298	0.786	rs10777186	chr12:89921277	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-5.43	-0.34	1.39e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg06873352	chr17:61820015	STRADA	0.54	6.99	0.42	2.8e-11	Prudent dietary pattern;
SARC	cis	rs4727027	0.769	rs10952797	chr7:148816722	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	5.45	0.34	1.26e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs12311304	0.965	rs56148413	chr12:15391157	G/A	cg08258403	chr12:15378311	NA	0.46	7.1	0.42	1.47e-11	Behavioural disinhibition (generation interaction);
SARC	cis	rs7712401	0.791	rs6595409	chr5:122113756	G/A	cg19412675	chr5:122181750	SNX24	0.37	4.87	0.3	2.04e-6	Mean platelet volume;
SARC	cis	rs2933343	0.649	rs728839	chr3:128589359	A/G	cg25356066	chr3:128598488	ACAD9	0.7	9.35	0.52	7.52e-18	IgG glycosylation;
SARC	cis	rs7666738	0.830	rs79075162	chr4:98960674	A/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs8062405	0.824	rs28698667	chr16:28533071	C/T	cg08761264	chr16:28874980	SH2B1	-0.42	-4.78	-0.3	3.11e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
SARC	cis	rs7772486	0.686	rs9390357	chr6:146129347	A/G	cg23711669	chr6:146136114	FBXO30	0.79	12.71	0.64	1.83e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs425277	0.916	rs414777	chr1:2101687	G/A	cg24578937	chr1:2090814	PRKCZ	0.32	5.97	0.36	8.7e-9	Height;
SARC	cis	rs4253772	0.575	rs9615364	chr22:46797503	G/A	cg24881330	chr22:46731750	TRMU	0.7	5.77	0.35	2.51e-8	LDL cholesterol;Cholesterol, total;
SARC	cis	rs9931543	0.504	rs4784651	chr16:56311774	A/G	cg02433656	chr16:56322654	GNAO1	-0.39	-6.28	-0.38	1.62e-9	Subjective well-being;
SARC	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg07061783	chr6:25882402	NA	0.41	4.97	0.31	1.27e-6	Intelligence (multi-trait analysis);
SARC	cis	rs11697848	1.000	rs74837988	chr20:48541193	G/A	cg17849948	chr20:48532315	SPATA2	0.87	5.2	0.32	4.3e-7	Systemic lupus erythematosus;
SARC	cis	rs7617480	0.558	rs12715430	chr3:48942855	A/C	cg07636037	chr3:49044803	WDR6	0.86	9.26	0.52	1.39e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs1008375	0.966	rs3775925	chr4:17588437	A/G	cg16339924	chr4:17578868	LAP3	0.69	9.1	0.51	4.12e-17	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9303401	0.734	rs8073316	chr17:57211381	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.67	-7.97	-0.46	6.89e-14	Cognitive test performance;
SARC	cis	rs7044106	0.708	rs1324472	chr9:123375110	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	5.34	0.33	2.19e-7	Hip circumference adjusted for BMI;
SARC	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg24250549	chr1:154909240	PMVK	-0.84	-12.44	-0.63	1.35e-27	Prostate cancer;
SARC	cis	rs10089	0.953	rs6879970	chr5:127387178	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	9.72	0.54	5.8e-19	Ileal carcinoids;
SARC	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.44	5.1	0.32	7.14e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9916302	0.904	rs585961	chr17:37444036	G/A	cg07936489	chr17:37558343	FBXL20	0.7	9.26	0.52	1.41e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs7731783	1	rs7731783	chr5:177060312	T/C	cg26673648	chr5:177209285	NA	0.44	5.26	0.33	3.26e-7	Methadone dose in opioid dependence;
SARC	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg11062466	chr8:58055876	NA	0.61	5.75	0.35	2.74e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7005380	0.581	rs10099088	chr8:120939658	C/T	cg21744203	chr8:120868354	DSCC1	-0.43	-5.03	-0.31	9.61e-7	Interstitial lung disease;
SARC	trans	rs2898290	0.622	rs1478890	chr8:11355602	C/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.47	-0.44	1.62e-12	Systolic blood pressure;
SARC	cis	rs4974559	0.947	rs28418481	chr4:1330975	C/G	cg02980000	chr4:1222292	CTBP1	0.59	5.82	0.36	1.89e-8	Systolic blood pressure;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg03140190	chr16:3812613	CREBBP	-0.5	-6.25	-0.38	1.96e-9	Height;
SARC	cis	rs1153858	1.000	rs7181167	chr15:45686236	C/G	cg21132104	chr15:45694354	SPATA5L1	0.78	10.53	0.57	1.9e-21	Homoarginine levels;
SARC	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg09839136	chr7:766187	HEATR2;PRKAR1B	0.56	4.8	0.3	2.89e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs9303280	0.806	rs12941333	chr17:38040534	C/T	cg20243544	chr17:37824526	PNMT	0.43	5.74	0.35	2.99e-8	Self-reported allergy;
SARC	trans	rs1814175	0.645	rs1721996	chr11:49915527	G/A	cg03929089	chr4:120376271	NA	-0.81	-11.69	-0.61	3.89e-25	Height;
SARC	cis	rs10504073	0.584	rs7818507	chr8:49918423	G/T	cg00325661	chr8:49890786	NA	0.49	6.66	0.4	2e-10	Blood metabolite ratios;
SARC	cis	rs77106637	0.860	rs75896506	chr11:72429579	G/A	cg03713592	chr11:72463424	ARAP1	1.09	10.4	0.56	4.77e-21	Type 2 diabetes;
SARC	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg05368731	chr17:41323189	NBR1	0.81	9.93	0.55	1.35e-19	Menopause (age at onset);
SARC	cis	rs10752881	1.000	rs10797810	chr1:182980950	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.76	0.58	3.38e-22	Colorectal cancer;
SARC	cis	rs11638352	1.000	rs8038096	chr15:44367290	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.81	-5.72	-0.35	3.3e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
SARC	cis	rs11227306	0.934	rs7102454	chr11:65594820	C/T	cg00576331	chr11:65640516	EFEMP2	0.47	5.89	0.36	1.32e-8	DNA methylation (variation);
SARC	cis	rs3018712	0.590	rs4930236	chr11:68414000	C/A	cg01657329	chr11:68192670	LRP5	0.6	5.46	0.34	1.2e-7	Total body bone mineral density;
SARC	cis	rs1568889	1.000	rs11602768	chr11:28351786	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	9.53	0.53	2.2e-18	Bipolar disorder;
SARC	cis	rs7568458	0.684	rs7579147	chr2:85805654	G/A	cg02493740	chr2:85810744	VAMP5	-0.42	-5.26	-0.33	3.18e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs6582630	0.584	rs12832156	chr12:38419435	C/T	cg14851346	chr12:38532713	NA	-0.45	-5.31	-0.33	2.52e-7	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00003784	chr17:62503072	CCDC45;DDX5	-0.55	-6.91	-0.41	4.71e-11	Smoking initiation;
SARC	cis	rs780094	0.585	rs3739095	chr2:27556721	C/T	cg22903471	chr2:27725779	GCKR	-0.4	-5.85	-0.36	1.68e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
SARC	cis	rs34779708	0.897	rs12830	chr10:35302705	C/T	cg03585969	chr10:35415529	CREM	0.41	5.05	0.31	8.91e-7	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs9815354	0.556	rs113213296	chr3:41873097	G/A	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs7589342	0.839	rs12995333	chr2:106436366	A/C	cg16077055	chr2:106428750	NCK2	-0.34	-6.03	-0.37	6.21e-9	Addiction;
SARC	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7760949	0.889	rs9475787	chr6:13926102	G/C	cg27413430	chr6:13925136	RNF182	0.43	4.99	0.31	1.2e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs920590	0.704	rs6586867	chr8:19653050	A/G	cg03894339	chr8:19674705	INTS10	0.39	4.78	0.3	3.06e-6	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs2880765	0.835	rs7180923	chr15:86050890	A/T	cg10818794	chr15:86012489	AKAP13	-0.39	-4.98	-0.31	1.25e-6	Coronary artery disease;
SARC	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg14784868	chr12:69753453	YEATS4	0.63	8.8	0.5	3.09e-16	Cerebrospinal fluid biomarker levels;
SARC	cis	rs17376456	0.877	rs13156865	chr5:93390908	C/A	cg25358565	chr5:93447407	FAM172A	1.3	14.78	0.7	2.47e-35	Diabetic retinopathy;
SARC	cis	rs11676348	0.772	rs6738953	chr2:218950036	C/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.45	-5.73	-0.35	3.15e-8	Ulcerative colitis;
SARC	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg10591111	chr5:226296	SDHA	-0.57	-5.16	-0.32	5.32e-7	Breast cancer;
SARC	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg00149659	chr3:10157352	C3orf10	0.64	6.01	0.37	7.21e-9	Alzheimer's disease;
SARC	cis	rs4481887	0.893	rs10888347	chr1:248448566	T/C	cg13385794	chr1:248469461	NA	0.32	4.79	0.3	2.96e-6	Common traits (Other);
SARC	trans	rs61931739	0.517	rs12367881	chr12:34175508	T/C	cg26384229	chr12:38710491	ALG10B	0.85	12.24	0.63	6.32e-27	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg02725872	chr8:58115012	NA	-0.34	-5.48	-0.34	1.1e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg27266027	chr21:40555129	PSMG1	0.49	5.4	0.33	1.62e-7	Cognitive function;
SARC	cis	rs9818758	0.545	rs9853352	chr3:49813258	C/T	cg07636037	chr3:49044803	WDR6	0.73	6.61	0.4	2.64e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs3796352	1.000	rs13072818	chr3:53074263	C/T	cg07884673	chr3:53033167	SFMBT1	0.77	5.33	0.33	2.35e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs6570726	0.935	rs408723	chr6:145838535	A/G	cg23711669	chr6:146136114	FBXO30	0.78	11.86	0.61	1.04e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2180341	0.883	rs6904630	chr6:127696869	A/G	cg27446573	chr6:127587934	RNF146	1.05	14.03	0.68	7.79e-33	Breast cancer;
SARC	trans	rs7922314	1.000	rs10995337	chr10:64626026	A/G	cg10578696	chr1:65532742	NA	-0.68	-6.46	-0.39	6.19e-10	Cutaneous psoriasis;
SARC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg16132339	chr22:24313637	DDTL;DDT	0.42	5.78	0.35	2.41e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg19729930	chr2:74357872	NA	0.55	7.25	0.43	6.17e-12	Gestational age at birth (maternal effect);
SARC	cis	rs7296418	0.699	rs11608297	chr12:123826642	T/C	cg05973401	chr12:123451056	ABCB9	0.48	5.61	0.35	5.69e-8	Platelet count;
SARC	cis	rs7264396	0.635	rs6058375	chr20:34531997	T/A	cg12579300	chr20:34535607	PHF20	-0.44	-5.14	-0.32	5.69e-7	Total cholesterol levels;
SARC	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs7666738	0.830	rs13102369	chr4:99045912	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9611519	0.929	rs71327107	chr22:41418229	T/G	cg03806693	chr22:41940476	POLR3H	-0.56	-6.56	-0.39	3.54e-10	Neuroticism;
SARC	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg11987759	chr7:65425863	GUSB	-0.47	-6.27	-0.38	1.7e-9	Aortic root size;
SARC	cis	rs67311347	0.544	rs12054197	chr3:40337562	C/T	cg24209194	chr3:40518798	ZNF619	0.48	6.42	0.39	7.46e-10	Renal cell carcinoma;
SARC	cis	rs12824058	0.831	rs1390849	chr12:130811547	A/G	cg24838063	chr12:130822603	PIWIL1	0.63	8.94	0.51	1.25e-16	Menopause (age at onset);
SARC	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg00684032	chr4:1343700	KIAA1530	0.38	5.6	0.34	5.93e-8	Obesity-related traits;
SARC	cis	rs16976116	0.901	rs2899581	chr15:55491643	T/C	cg17854078	chr15:55489399	RSL24D1	0.66	6.46	0.39	6.14e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs12142240	0.698	rs66575205	chr1:46814092	T/G	cg00530320	chr1:46809349	NSUN4	0.57	6.92	0.41	4.4e-11	Menopause (age at onset);
SARC	cis	rs297755	0.675	rs2208206	chr20:4487030	G/A	cg14606382	chr20:4573199	NA	0.52	6.14	0.37	3.49e-9	Current cigarettes per day in chronic obstructive pulmonary disease;
SARC	cis	rs2439831	1.000	rs689596	chr15:43761717	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	8.35	0.48	6.17e-15	Lung cancer in ever smokers;
SARC	cis	rs12791968	1.000	rs10838397	chr11:45009133	A/G	cg11846598	chr11:44996168	LOC221122	0.38	5.82	0.36	1.96e-8	Inhibitory control;
SARC	cis	rs1971762	0.527	rs784562	chr12:53919700	A/C	cg06632207	chr12:54070931	ATP5G2	-0.59	-8.04	-0.47	4.66e-14	Height;
SARC	trans	rs1910358	0.554	rs10057796	chr5:23759746	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.58	6.64	0.4	2.18e-10	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs11608355	0.597	rs9943699	chr12:109840876	G/C	cg05360138	chr12:110035743	NA	0.41	5.02	0.31	1.02e-6	Neuroticism;
SARC	cis	rs896854	0.517	rs9643353	chr8:95957063	A/G	cg16049864	chr8:95962084	TP53INP1	0.35	5.28	0.33	2.99e-7	Type 2 diabetes;
SARC	cis	rs7659604	1.000	rs35249024	chr4:122664538	C/A	cg20573242	chr4:122745356	CCNA2	0.44	5.8	0.36	2.16e-8	Type 2 diabetes;
SARC	cis	rs9948	1.000	rs62152794	chr2:97485110	T/C	cg01990225	chr2:97406019	LMAN2L	-0.66	-5.14	-0.32	5.95e-7	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg22535103	chr8:58192502	C8orf71	-0.59	-6.2	-0.38	2.48e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4808199	0.901	rs12973258	chr19:19488718	T/C	cg03709012	chr19:19516395	GATAD2A	1.17	13.08	0.65	1.09e-29	Nonalcoholic fatty liver disease;
SARC	cis	rs4481887	0.800	rs4514268	chr1:248444600	T/G	cg00666640	chr1:248458726	OR2T12	0.29	4.77	0.3	3.23e-6	Common traits (Other);
SARC	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.08	22.41	0.83	4.65e-60	Chronic sinus infection;
SARC	cis	rs453301	0.686	rs4840389	chr8:8884503	G/C	cg06636001	chr8:8085503	FLJ10661	-0.62	-8.56	-0.49	1.59e-15	Joint mobility (Beighton score);
SARC	cis	rs6546550	0.901	rs11893500	chr2:70154187	T/C	cg02498382	chr2:70120550	SNRNP27	-0.32	-5.24	-0.32	3.6e-7	Prevalent atrial fibrillation;
SARC	cis	rs9815354	0.857	rs9816772	chr3:41872877	C/T	cg03022575	chr3:42003672	ULK4	0.57	5.32	0.33	2.38e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg11764359	chr7:65958608	NA	-0.79	-9.84	-0.54	2.42e-19	Aortic root size;
SARC	cis	rs6570726	0.818	rs399516	chr6:145810849	C/A	cg05220968	chr6:146057943	EPM2A	-0.28	-4.86	-0.3	2.12e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9457247	0.967	rs1590257	chr6:167377782	G/T	cg07741184	chr6:167504864	NA	-0.3	-5.61	-0.35	5.69e-8	Crohn's disease;
SARC	cis	rs2228479	1.000	rs4257207	chr16:89947861	T/A	cg12064134	chr16:90016061	DEF8	-0.55	-4.75	-0.3	3.59e-6	Skin colour saturation;
SARC	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg07701084	chr6:150067640	NUP43	0.38	5.13	0.32	6.14e-7	Lung cancer;
SARC	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg04944784	chr2:26401820	FAM59B	-0.54	-6.85	-0.41	6.43e-11	Gut microbiome composition (summer);
SARC	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg11843238	chr5:131593191	PDLIM4	0.43	5.86	0.36	1.6e-8	Acylcarnitine levels;
SARC	cis	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg03060546	chr3:49711283	APEH	0.75	11.1	0.59	2.98e-23	Resting heart rate;
SARC	cis	rs6963495	0.818	rs73190155	chr7:105153535	T/A	cg19920283	chr7:105172520	RINT1	0.65	5.53	0.34	8.62e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg07701084	chr6:150067640	NUP43	0.42	5.46	0.34	1.23e-7	Lung cancer;
SARC	cis	rs73195822	0.614	rs11834902	chr12:111219809	C/A	cg10860002	chr12:110842031	ANAPC7	0.58	5.05	0.31	8.94e-7	Itch intensity from mosquito bite;
SARC	cis	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg08564027	chr20:61660810	NA	0.78	11.75	0.61	2.44e-25	Prostate cancer (SNP x SNP interaction);
SARC	trans	rs9650657	0.515	rs6601560	chr8:10950866	T/C	cg06636001	chr8:8085503	FLJ10661	-0.73	-10.4	-0.56	4.55e-21	Neuroticism;
SARC	cis	rs644799	0.932	rs523934	chr11:95641775	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	12.22	0.62	7.35e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs72720396	0.789	rs12022460	chr1:91202257	A/G	cg13456504	chr1:91191583	NA	-0.33	-4.85	-0.3	2.3e-6	Morning vs. evening chronotype;Chronotype;
SARC	cis	rs6834538	0.597	rs9307383	chr4:113529834	C/T	cg05166686	chr4:113558556	LARP7;C4orf21	0.56	7.5	0.44	1.34e-12	Free thyroxine concentration;
SARC	cis	rs2290405	0.527	rs6829987	chr4:932974	C/G	cg04824913	chr4:887549	GAK	-0.59	-7.14	-0.42	1.19e-11	Systemic sclerosis;
SARC	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg27266027	chr21:40555129	PSMG1	0.51	5.13	0.32	6.09e-7	Cognitive function;
SARC	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg20814179	chr4:940893	TMEM175	0.44	6.28	0.38	1.64e-9	Sjögren's syndrome;
SARC	cis	rs11608355	0.846	rs4766471	chr12:109853462	G/A	cg05360138	chr12:110035743	NA	0.59	6.3	0.38	1.46e-9	Neuroticism;
SARC	cis	rs73086581	0.945	rs6037715	chr20:3972166	A/T	cg02187196	chr20:3869020	PANK2	0.57	5.56	0.34	7.21e-8	Response to antidepressants in depression;
SARC	cis	rs6484504	0.576	rs158146	chr11:31210433	G/A	cg26647111	chr11:31128758	NA	-0.39	-5.11	-0.32	6.59e-7	Red blood cell count;
SARC	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg17221315	chr6:27791827	HIST1H4J	0.46	4.82	0.3	2.54e-6	Depression;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg22983760	chr13:111214246	RAB20	0.77	5.41	0.33	1.53e-7	Obesity-related traits;
SARC	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg11366901	chr6:160182831	ACAT2	0.64	6.65	0.4	2.1e-10	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs72781680	0.898	rs10490752	chr2:24025132	C/T	cg08917208	chr2:24149416	ATAD2B	0.76	7.11	0.42	1.4e-11	Lymphocyte counts;
SARC	cis	rs9316337	0.933	rs9509670	chr13:21953885	T/G	cg21080246	chr13:22033151	ZDHHC20	0.38	4.71	0.3	4.18e-6	Schizophrenia;
SARC	cis	rs17739167	0.550	rs2665213	chr15:42234265	T/G	cg20935245	chr15:42234343	EHD4	-0.46	-6.03	-0.37	6.41e-9	Monocyte count;
SARC	cis	rs62064224	1.000	rs62064224	chr17:30635115	G/A	cg25809561	chr17:30822961	MYO1D	0.37	5.35	0.33	2.06e-7	Schizophrenia;
SARC	cis	rs11785400	0.793	rs2280879	chr8:143722228	T/C	cg10596483	chr8:143751796	JRK	0.58	7.53	0.44	1.08e-12	Schizophrenia;
SARC	cis	rs3087591	1.000	rs2854331	chr17:29711728	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.53	-6.4	-0.39	8.27e-10	Hip circumference;
SARC	cis	rs3008870	0.920	rs2755253	chr1:67470843	C/T	cg02640540	chr1:67518911	SLC35D1	0.49	5.15	0.32	5.62e-7	Lymphocyte percentage of white cells;
SARC	cis	rs6121246	0.567	rs6120937	chr20:30219721	C/T	cg13852791	chr20:30311386	BCL2L1	0.64	5.64	0.35	4.79e-8	Mean corpuscular hemoglobin;
SARC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.74	-9.44	-0.53	4.08e-18	Prudent dietary pattern;
SARC	cis	rs4481887	0.741	rs4360554	chr1:248553206	C/T	cg13385794	chr1:248469461	NA	0.32	5.29	0.33	2.81e-7	Common traits (Other);
SARC	cis	rs9393692	0.905	rs989134	chr6:26336224	A/C	cg00631329	chr6:26305371	NA	-0.63	-9.12	-0.51	3.62e-17	Educational attainment;
SARC	cis	rs10464366	0.544	rs1525799	chr7:39153131	C/G	cg18850127	chr7:39170497	POU6F2	-0.42	-5.51	-0.34	9.51e-8	IgG glycosylation;
SARC	cis	rs2342371	1.000	rs13094241	chr3:196190893	G/T	cg15048948	chr3:196158458	UBXN7	0.41	5.0	0.31	1.12e-6	Fat distribution (HIV);
SARC	cis	rs61869271	0.777	rs12764662	chr10:116722834	G/T	cg08188268	chr10:116634841	FAM160B1	0.44	5.9	0.36	1.28e-8	Tonsillectomy;
SARC	cis	rs8058578	1.000	rs7198250	chr16:30746822	C/A	cg00531865	chr16:30841666	NA	-0.54	-6.13	-0.37	3.63e-9	Multiple myeloma;
SARC	cis	rs11583043	1.000	rs34915449	chr1:101476786	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	5.68	0.35	4.01e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs6582630	0.576	rs2222345	chr12:38356020	G/A	cg13010199	chr12:38710504	ALG10B	-0.5	-6.0	-0.37	7.41e-9	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7520050	0.807	rs6429576	chr1:46216575	T/C	cg06784218	chr1:46089804	CCDC17	0.26	4.82	0.3	2.6e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs7727544	0.709	rs272852	chr5:131688767	G/A	cg24060327	chr5:131705240	SLC22A5	-0.66	-8.35	-0.48	6.23e-15	Blood metabolite levels;
SARC	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg08280861	chr8:58055591	NA	0.6	5.71	0.35	3.4e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg05313129	chr8:58192883	C8orf71	-0.62	-6.34	-0.38	1.18e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg16405210	chr4:1374714	KIAA1530	0.51	6.09	0.37	4.65e-9	Obesity-related traits;
SARC	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg06618935	chr21:46677482	NA	-0.41	-5.46	-0.34	1.2e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg18404041	chr3:52824283	ITIH1	-0.4	-6.11	-0.37	4.08e-9	Electroencephalogram traits;
SARC	cis	rs80130819	0.515	rs6580656	chr12:48570604	C/T	cg05342945	chr12:48394962	COL2A1	-0.49	-5.23	-0.32	3.75e-7	Prostate cancer;
SARC	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg16049864	chr8:95962084	TP53INP1	-0.47	-7.69	-0.45	4.13e-13	Type 2 diabetes;
SARC	cis	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg11608241	chr8:8085544	FLJ10661	0.41	5.03	0.31	9.85e-7	Neuroticism;
SARC	cis	rs367615	0.704	rs7726991	chr5:108847434	C/T	cg17395555	chr5:108820864	NA	0.47	6.86	0.41	6.08e-11	Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs57561814	0.655	rs58879058	chr7:22741822	T/C	cg01770232	chr7:22766155	IL6	0.63	5.04	0.31	9.29e-7	Tonsillectomy;
SARC	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg08677398	chr8:58056175	NA	0.43	5.08	0.32	7.68e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9296092	0.538	rs62405941	chr6:33517297	G/A	cg13560919	chr6:33536144	NA	-0.5	-5.91	-0.36	1.22e-8	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg11843238	chr5:131593191	PDLIM4	0.38	4.77	0.3	3.27e-6	Breast cancer;
SARC	cis	rs11574514	1.000	rs115391623	chr16:68276064	C/T	cg01866162	chr16:67596514	CTCF	1.12	6.52	0.39	4.27e-10	Crohn's disease;
SARC	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg11987759	chr7:65425863	GUSB	0.47	5.71	0.35	3.48e-8	Aortic root size;
SARC	cis	rs10979	0.597	rs10782290	chr6:143906340	T/C	cg25407410	chr6:143891975	LOC285740	-0.53	-6.22	-0.38	2.26e-9	Hypospadias;
SARC	cis	rs4761669	0.876	rs12368595	chr12:95215057	G/A	cg21533806	chr12:95267307	NA	0.42	5.14	0.32	5.77e-7	Common carotid intima-media thickness in HIV infection;
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg25910466	chr20:21283998	XRN2	-0.57	-6.5	-0.39	4.72e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs2013441	1.000	rs8079701	chr17:20216565	G/A	cg13482628	chr17:19912719	NA	-0.48	-6.16	-0.37	3.24e-9	Obesity-related traits;
SARC	cis	rs7772486	0.790	rs6923545	chr6:146244743	A/G	cg05347473	chr6:146136440	FBXO30	-0.48	-6.53	-0.39	4.1e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6570726	1.000	rs374464	chr6:145846679	A/C	cg23711669	chr6:146136114	FBXO30	0.75	11.27	0.59	8.17e-24	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs35306767	0.903	rs1341741	chr10:888073	A/G	cg20503657	chr10:835505	NA	0.8	7.94	0.46	8.64e-14	Eosinophil percentage of granulocytes;
SARC	cis	rs10870270	0.913	rs115236491	chr10:133766855	T/G	cg26149184	chr10:133730230	NA	0.48	5.28	0.33	2.99e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs921968	0.643	rs539451	chr2:219426972	T/C	cg02176678	chr2:219576539	TTLL4	0.36	5.43	0.34	1.38e-7	Mean corpuscular hemoglobin concentration;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg22913584	chr5:81046758	SSBP2	-0.54	-7.23	-0.43	6.95e-12	Electrocardiographic conduction measures;
SARC	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.74	7.03	0.42	2.32e-11	Platelet count;
SARC	cis	rs7599312	0.534	rs10207878	chr2:213409337	A/G	cg20637307	chr2:213403960	ERBB4	0.8	12.2	0.62	8.29e-27	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs10504229	0.679	rs16921606	chr8:58034477	A/C	cg21724239	chr8:58056113	NA	0.56	5.88	0.36	1.45e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9790314	0.690	rs4679930	chr3:160842875	C/G	cg03342759	chr3:160939853	NMD3	-0.57	-7.22	-0.43	7.36e-12	Morning vs. evening chronotype;
SARC	cis	rs10189230	0.935	rs1864461	chr2:222347615	A/G	cg14652038	chr2:222343519	EPHA4	0.44	5.8	0.36	2.1e-8	Urate levels in lean individuals;
SARC	cis	rs6580649	1.000	rs7305954	chr12:48403530	C/T	cg05342945	chr12:48394962	COL2A1	-0.46	-4.98	-0.31	1.24e-6	Lung cancer;
SARC	cis	rs35306767	0.855	rs11253459	chr10:886402	C/T	cg20503657	chr10:835505	NA	0.8	8.0	0.46	5.71e-14	Eosinophil percentage of granulocytes;
SARC	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7582180	0.681	rs6754176	chr2:100995691	C/T	cg14675211	chr2:100938903	LONRF2	0.53	7.86	0.46	1.46e-13	Intelligence (multi-trait analysis);
SARC	cis	rs11676348	0.846	rs3890158	chr2:218990292	G/A	cg00012203	chr2:219082015	ARPC2	-0.54	-7.33	-0.43	3.78e-12	Ulcerative colitis;
SARC	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg03709012	chr19:19516395	GATAD2A	-0.93	-14.98	-0.7	5.39e-36	Tonsillectomy;
SARC	cis	rs6964587	1.000	rs7802668	chr7:91648939	A/G	cg17063962	chr7:91808500	NA	0.94	15.73	0.72	1.82e-38	Breast cancer;
SARC	cis	rs6570726	0.599	rs426371	chr6:145886469	A/G	cg23711669	chr6:146136114	FBXO30	-0.81	-11.08	-0.59	3.38e-23	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs208515	0.592	rs10944862	chr6:66674215	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.99	11.64	0.61	5.43e-25	Exhaled nitric oxide levels;
SARC	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg20607798	chr8:58055168	NA	0.58	5.57	0.34	6.9e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9902453	0.904	rs11080115	chr17:28408070	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.57	-7.44	-0.44	1.91e-12	Coffee consumption (cups per day);
SARC	trans	rs7815944	1.000	rs4637784	chr8:129388451	C/G	cg25487405	chr22:46473039	NA	0.64	6.32	0.38	1.3e-9	Atopic dermatitis;
SARC	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg12463550	chr7:65579703	CRCP	0.47	5.16	0.32	5.3e-7	Aortic root size;
SARC	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg11890956	chr21:40555474	PSMG1	-0.72	-9.61	-0.53	1.25e-18	Menarche (age at onset);
SARC	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg12463550	chr7:65579703	CRCP	0.69	5.26	0.33	3.2e-7	Diabetic kidney disease;
SARC	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg11987759	chr7:65425863	GUSB	0.51	6.55	0.39	3.69e-10	Aortic root size;
SARC	cis	rs73206853	0.841	rs56017468	chr12:110653857	T/C	cg10860002	chr12:110842031	ANAPC7	0.65	5.13	0.32	5.97e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs2439831	0.850	rs16950562	chr15:44036364	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	8.5	0.49	2.24e-15	Lung cancer in ever smokers;
SARC	cis	rs7312933	0.576	rs11181364	chr12:42567800	C/T	cg19980929	chr12:42632907	YAF2	0.44	6.06	0.37	5.43e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs617219	0.613	rs12520803	chr5:78628629	T/A	cg24856658	chr5:78533917	JMY	0.3	4.73	0.3	3.97e-6	Betaine levels in individuals undergoing cardiac evaluation;
SARC	cis	rs7086627	0.515	rs10887900	chr10:82210265	A/G	cg00277334	chr10:82204260	NA	-0.59	-8.98	-0.51	9.59e-17	Post bronchodilator FEV1;
SARC	cis	rs7927771	1.000	rs10838757	chr11:47763016	T/C	cg20307385	chr11:47447363	PSMC3	-0.47	-5.58	-0.34	6.66e-8	Subjective well-being;
SARC	cis	rs6450176	1.000	rs3776705	chr5:53304955	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-7.97	-0.46	6.84e-14	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs4243830	0.737	rs11122091	chr1:6609559	C/A	cg04093404	chr1:6614507	TAS1R1;NOL9	0.55	4.76	0.3	3.45e-6	Body mass index;
SARC	cis	rs9381040	0.610	rs4140580	chr6:41041742	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.42	-4.79	-0.3	2.96e-6	Alzheimer's disease (late onset);
SARC	trans	rs17150703	0.630	rs12545481	chr8:9747377	G/A	cg06636001	chr8:8085503	FLJ10661	0.59	6.55	0.39	3.73e-10	Obesity (early onset extreme);
SARC	cis	rs3008870	1.000	rs2755240	chr1:67477339	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.91	11.06	0.59	3.94e-23	Lymphocyte percentage of white cells;
SARC	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg13206674	chr6:150067644	NUP43	0.46	6.05	0.37	5.69e-9	Lung cancer;
SARC	trans	rs1814175	0.645	rs7952104	chr11:49964180	C/T	cg03929089	chr4:120376271	NA	-0.82	-11.87	-0.61	1.01e-25	Height;
SARC	cis	rs6582630	0.519	rs1607882	chr12:38361657	G/A	cg26384229	chr12:38710491	ALG10B	0.85	12.17	0.62	1.02e-26	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs4481887	0.741	rs6587467	chr1:248550976	T/G	cg13385794	chr1:248469461	NA	0.32	5.29	0.33	2.81e-7	Common traits (Other);
SARC	cis	rs60871478	1.000	rs9195	chr7:825786	C/T	cg05535760	chr7:792225	HEATR2	-0.73	-7.91	-0.46	1.06e-13	Cerebrospinal P-tau181p levels;
SARC	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg05861140	chr6:150128134	PCMT1	-0.36	-4.75	-0.3	3.51e-6	Lung cancer;
SARC	cis	rs4851254	0.961	rs13028981	chr2:100795783	C/T	cg17356467	chr2:100759845	AFF3	0.28	4.73	0.3	3.9e-6	Intelligence (multi-trait analysis);
SARC	cis	rs7647973	0.626	rs11130217	chr3:49737323	A/G	cg06212747	chr3:49208901	KLHDC8B	0.58	5.8	0.36	2.11e-8	Menarche (age at onset);
SARC	cis	rs9611519	0.780	rs5751072	chr22:41656509	C/T	cg03806693	chr22:41940476	POLR3H	-0.67	-9.07	-0.51	5.23e-17	Neuroticism;
SARC	cis	rs34779708	0.771	rs12098283	chr10:35478115	G/T	cg03585969	chr10:35415529	CREM	0.4	4.84	0.3	2.42e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs9611519	0.929	rs12484477	chr22:41429084	G/A	cg03806693	chr22:41940476	POLR3H	-0.61	-7.54	-0.44	1.03e-12	Neuroticism;
SARC	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg20573242	chr4:122745356	CCNA2	0.64	8.11	0.47	2.93e-14	Type 2 diabetes;
SARC	trans	rs79976124	0.837	rs11751994	chr6:66644028	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	7.86	0.46	1.41e-13	Type 2 diabetes;
SARC	cis	rs2594989	0.943	rs2595004	chr3:11406721	C/T	cg00170343	chr3:11313890	ATG7	0.57	5.16	0.32	5.37e-7	Circulating chemerin levels;
SARC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-5.58	-0.34	6.69e-8	Prudent dietary pattern;
SARC	cis	rs2073300	0.609	rs6137941	chr20:23400848	G/A	cg12062639	chr20:23401060	NAPB	1.01	6.99	0.42	2.92e-11	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs10782582	0.609	rs111914775	chr1:76319036	C/T	cg10523679	chr1:76189770	ACADM	-0.42	-5.17	-0.32	5.07e-7	Daytime sleep phenotypes;
SARC	cis	rs9902453	0.845	rs3102556	chr17:28042542	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	7.08	0.42	1.69e-11	Coffee consumption (cups per day);
SARC	cis	rs765787	0.530	rs11070445	chr15:45513163	T/A	cg24006582	chr15:45444508	DUOX1	0.43	5.53	0.34	8.48e-8	Uric acid levels;
SARC	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg18252515	chr7:66147081	NA	1.34	12.06	0.62	2.34e-26	Diabetic kidney disease;
SARC	cis	rs61935443	0.525	rs11107744	chr12:95226811	G/T	cg21533806	chr12:95267307	NA	0.42	5.18	0.32	4.81e-7	Schizophrenia;
SARC	cis	rs2370759	1.000	rs2370759	chr10:32634972	G/A	cg05361325	chr10:32636312	EPC1	-0.76	-6.75	-0.4	1.15e-10	Sexual dysfunction (female);
SARC	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg24829409	chr8:58192753	C8orf71	-0.62	-6.29	-0.38	1.54e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6141769	0.542	rs6058821	chr20:31304713	C/T	cg17884169	chr20:31446444	EFCAB8	-0.44	-4.78	-0.3	3.09e-6	Subjective well-being;
SARC	cis	rs2072499	0.931	rs1052053	chr1:156202173	A/G	cg25208724	chr1:156163844	SLC25A44	0.79	9.94	0.55	1.23e-19	Testicular germ cell tumor;
SARC	cis	rs2153535	0.580	rs6597332	chr6:8504748	C/G	cg21535247	chr6:8435926	SLC35B3	0.59	7.33	0.43	3.84e-12	Motion sickness;
SARC	trans	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg21659725	chr3:3221576	CRBN	-0.79	-11.94	-0.62	5.9e-26	Intelligence (multi-trait analysis);
SARC	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg12463550	chr7:65579703	CRCP	0.41	4.85	0.3	2.21e-6	Aortic root size;
SARC	cis	rs875971	1.000	rs1167612	chr7:65567976	C/A	cg11987759	chr7:65425863	GUSB	0.46	6.01	0.37	7.26e-9	Aortic root size;
SARC	cis	rs11770686	0.967	rs12216544	chr7:75327544	T/C	cg17787366	chr7:75369077	HIP1	0.43	5.32	0.33	2.48e-7	Essential tremor;
SARC	cis	rs854765	0.547	rs2955355	chr17:17948475	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.64	-9.48	-0.53	3.17e-18	Total body bone mineral density;
SARC	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg03060546	chr3:49711283	APEH	0.48	6.19	0.38	2.71e-9	Menarche (age at onset);
SARC	cis	rs10875746	0.903	rs61918774	chr12:48448134	C/G	cg26205652	chr12:48591994	NA	0.56	6.05	0.37	5.72e-9	Longevity (90 years and older);
SARC	cis	rs6565180	1.000	rs8049108	chr16:30376486	A/G	cg17640201	chr16:30407289	ZNF48	-0.96	-15.99	-0.72	2.45e-39	Tonsillectomy;
SARC	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg06808227	chr14:105710500	BRF1	-0.59	-8.02	-0.47	5e-14	Mean platelet volume;Platelet distribution width;
SARC	cis	rs72945132	0.882	rs12289915	chr11:70131956	G/C	cg05964544	chr11:70165517	PPFIA1	-0.59	-5.78	-0.35	2.39e-8	Coronary artery disease;
SARC	cis	rs7766436	0.885	rs13202434	chr6:22583694	G/C	cg13666174	chr6:22585274	NA	-0.6	-7.74	-0.45	3.04e-13	Coronary artery disease;
SARC	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	9.68	0.54	7.66e-19	Platelet count;
SARC	trans	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg00938859	chr5:1591904	SDHAP3	0.79	7.61	0.45	6.61e-13	Breast cancer;
SARC	cis	rs2712184	0.756	rs2712164	chr2:217659916	G/A	cg05032264	chr2:217675019	NA	-0.52	-6.77	-0.41	1.03e-10	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
SARC	cis	rs8014204	0.935	rs8010840	chr14:75355203	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.78	-11.9	-0.61	7.78e-26	Caffeine consumption;
SARC	cis	rs7000551	0.606	rs13256933	chr8:22267199	T/G	cg12081754	chr8:22256438	SLC39A14	0.87	12.5	0.63	8.56e-28	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs2066819	1.000	rs2643623	chr12:56689725	G/C	cg26734620	chr12:56694298	CS	-0.86	-6.37	-0.39	1.01e-9	Psoriasis vulgaris;
SARC	cis	rs9910055	0.529	rs228766	chr17:42186813	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.49	-5.78	-0.35	2.34e-8	Total body bone mineral density;
SARC	cis	rs2070997	0.756	rs3824400	chr9:133734075	A/G	cg11464064	chr9:133710261	ABL1	-0.57	-4.91	-0.31	1.68e-6	Response to amphetamines;
SARC	cis	rs6456156	0.565	rs12529959	chr6:167469292	T/C	cg23791538	chr6:167370224	RNASET2	-0.52	-6.81	-0.41	8.22e-11	Primary biliary cholangitis;
SARC	cis	rs832540	0.898	rs702680	chr5:56220382	T/C	cg14703610	chr5:56206110	C5orf35	0.53	6.7	0.4	1.54e-10	Coronary artery disease;
SARC	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg13012494	chr21:47604986	C21orf56	-0.43	-5.08	-0.32	7.62e-7	Testicular germ cell tumor;
SARC	cis	rs6733011	0.628	rs6713991	chr2:99464384	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.4	-5.0	-0.31	1.12e-6	Bipolar disorder;
SARC	cis	rs7918232	0.882	rs10829190	chr10:27409555	C/T	cg14240646	chr10:27532245	ACBD5	-0.55	-5.2	-0.32	4.39e-7	Breast cancer;
SARC	cis	rs9790314	0.663	rs778657	chr3:160719577	C/A	cg04691961	chr3:161091175	C3orf57	-0.58	-8.09	-0.47	3.19e-14	Morning vs. evening chronotype;
SARC	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg11764359	chr7:65958608	NA	-0.53	-6.13	-0.37	3.78e-9	Aortic root size;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg15423853	chr12:11323943	PRR4;PRH1	-0.53	-6.34	-0.38	1.2e-9	Fibrinogen levels;
SARC	cis	rs10504229	0.679	rs12375445	chr8:58040082	A/G	cg22535103	chr8:58192502	C8orf71	-0.53	-5.3	-0.33	2.73e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg22484793	chr3:52261325	TLR9	0.29	4.77	0.3	3.31e-6	Bipolar disorder;
SARC	cis	rs7223966	1.000	rs7217982	chr17:61832150	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-5.85	-0.36	1.69e-8	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg11168104	chr5:1857477	NA	-0.34	-4.93	-0.31	1.54e-6	Cardiovascular disease risk factors;
SARC	cis	rs6867032	0.527	rs13153217	chr5:2012788	G/T	cg26168224	chr5:2018326	NA	-0.56	-8.13	-0.47	2.57e-14	Gut microbiome composition (winter);
SARC	cis	rs6759839	0.621	rs4417714	chr2:16684465	C/T	cg09580478	chr2:16689509	NA	0.44	6.01	0.37	7.09e-9	Mean platelet volume;
SARC	cis	rs1957429	0.901	rs6573583	chr14:65351211	G/T	cg23373153	chr14:65346875	NA	1.1	11.91	0.62	7.39e-26	Pediatric areal bone mineral density (radius);
SARC	cis	rs910316	1.000	rs4899544	chr14:75546556	C/T	cg06637938	chr14:75390232	RPS6KL1	0.54	7.7	0.45	3.98e-13	Height;
SARC	cis	rs9583531	0.891	rs61969072	chr13:111380701	T/G	cg15841412	chr13:111365552	ING1	-0.5	-5.02	-0.31	1.04e-6	Coronary artery disease;
SARC	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.4	-5.43	-0.34	1.4e-7	Personality dimensions;
SARC	cis	rs826838	1.000	rs11168218	chr12:38884466	A/G	cg26384229	chr12:38710491	ALG10B	0.92	14.37	0.69	6.03e-34	Heart rate;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg13883939	chr12:118541731	VSIG10	0.51	6.38	0.39	9.42e-10	Breast cancer;
SARC	cis	rs8014204	0.935	rs4903267	chr14:75360419	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.79	-11.92	-0.62	6.79e-26	Caffeine consumption;
SARC	cis	rs9911578	0.967	rs8182277	chr17:57144367	C/T	cg05425664	chr17:57184151	TRIM37	-0.64	-8.01	-0.46	5.41e-14	Intelligence (multi-trait analysis);
SARC	cis	rs910316	0.935	rs175448	chr14:75591071	G/A	cg11812906	chr14:75593930	NEK9	-0.83	-12.38	-0.63	2.16e-27	Height;
SARC	cis	rs6964587	1.000	rs2075881	chr7:91734552	T/C	cg17063962	chr7:91808500	NA	0.96	16.59	0.74	2.42e-41	Breast cancer;
SARC	cis	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg08564027	chr20:61660810	NA	0.76	11.8	0.61	1.69e-25	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs6484504	0.532	rs7116443	chr11:31283170	T/C	cg02090638	chr11:31391270	DNAJC24;DCDC1	-0.43	-5.43	-0.34	1.38e-7	Red blood cell count;
SARC	cis	rs3733585	0.605	rs56178126	chr4:10123581	C/T	cg11266682	chr4:10021025	SLC2A9	-0.38	-6.18	-0.38	2.89e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg11764359	chr7:65958608	NA	0.88	12.58	0.64	4.89e-28	Aortic root size;
SARC	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.45	-5.46	-0.34	1.22e-7	Renal function-related traits (BUN);
SARC	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg18876405	chr7:65276391	NA	-0.71	-9.08	-0.51	4.78e-17	Cotinine glucuronidation;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15988843	chr1:1092940	NA	0.49	6.45	0.39	6.45e-10	Smoking initiation;
SARC	cis	rs2204008	0.837	rs1842599	chr12:37986081	G/A	cg13010199	chr12:38710504	ALG10B	-0.66	-8.9	-0.5	1.64e-16	Bladder cancer;
SARC	cis	rs6439153	0.933	rs6769662	chr3:128721310	A/C	cg25356066	chr3:128598488	ACAD9	0.46	5.51	0.34	9.37e-8	Pneumococcal bacteremia;
SARC	cis	rs1448094	0.717	rs7305873	chr12:86290831	G/C	cg02569458	chr12:86230093	RASSF9	0.39	5.12	0.32	6.5e-7	Major depressive disorder;
SARC	cis	rs7633770	0.769	rs3796371	chr3:46667224	C/T	cg11219411	chr3:46661640	NA	0.48	8.2	0.47	1.63e-14	Coronary artery disease;
SARC	cis	rs2197308	0.740	rs1842595	chr12:37906223	G/A	cg26384229	chr12:38710491	ALG10B	-0.79	-11.38	-0.6	3.64e-24	Morning vs. evening chronotype;
SARC	cis	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg12257692	chr3:49977190	RBM6	-0.27	-4.86	-0.3	2.21e-6	Body mass index;
SARC	cis	rs3820928	0.874	rs7562776	chr2:227806550	G/A	cg11843606	chr2:227700838	RHBDD1	-0.56	-7.12	-0.42	1.33e-11	Pulmonary function;
SARC	cis	rs1322639	0.697	rs12661910	chr6:169584388	A/G	cg04662567	chr6:169592167	NA	-0.49	-5.05	-0.31	9.12e-7	Pulse pressure;
SARC	cis	rs2370759	0.945	rs3740237	chr10:32557592	G/C	cg01819863	chr10:32635814	EPC1	0.97	7.29	0.43	4.66e-12	Sexual dysfunction (female);
SARC	cis	rs7772486	0.625	rs9390355	chr6:146112942	C/T	cg05220968	chr6:146057943	EPM2A	0.28	4.87	0.3	2.03e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs17125944	0.686	rs3818453	chr14:53326454	C/A	cg00686598	chr14:53173677	PSMC6	-0.64	-5.0	-0.31	1.13e-6	Alzheimer's disease (late onset);
SARC	cis	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg05084668	chr3:125655381	ALG1L	-0.5	-5.27	-0.33	3.12e-7	Blood pressure (smoking interaction);
SARC	cis	rs7666738	0.830	rs2015828	chr4:98984594	A/G	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2072499	0.695	rs112223391	chr1:156156094	G/A	cg25208724	chr1:156163844	SLC25A44	0.86	9.68	0.54	7.66e-19	Testicular germ cell tumor;
SARC	cis	rs921968	0.528	rs35695178	chr2:219589164	C/T	cg02176678	chr2:219576539	TTLL4	-0.33	-5.07	-0.32	8.2e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	8.85	0.5	2.17e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs67366981	1.000	rs8006117	chr14:77713279	G/A	cg06779847	chr14:77687015	TMEM63C	-0.46	-5.15	-0.32	5.51e-7	Obsessive-compulsive symptoms;
SARC	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg17221315	chr6:27791827	HIST1H4J	0.51	5.28	0.33	2.97e-7	Parkinson's disease;
SARC	cis	rs72781680	0.848	rs56218741	chr2:23977377	A/C	cg06627628	chr2:24431161	ITSN2	-0.68	-6.49	-0.39	5.15e-10	Lymphocyte counts;
SARC	cis	rs617791	0.530	rs7934543	chr11:65752508	G/T	cg26695010	chr11:65641043	EFEMP2	0.58	7.13	0.42	1.25e-11	Breast cancer;
SARC	cis	rs3845702	0.733	rs12693217	chr2:180841914	T/G	cg01881094	chr2:180872142	CWC22	-1.12	-9.3	-0.52	1.07e-17	Schizophrenia;
SARC	cis	rs240764	0.554	rs723742	chr6:101237174	T/A	cg09795085	chr6:101329169	ASCC3	0.45	5.66	0.35	4.42e-8	Neuroticism;
SARC	cis	rs950169	1.000	rs1848093	chr15:84755527	G/C	cg17507749	chr15:85114479	UBE2QP1	0.75	9.12	0.51	3.59e-17	Schizophrenia;
SARC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg02353165	chr6:42928485	GNMT	0.65	8.88	0.5	1.87e-16	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs13256369	0.802	rs11249884	chr8:8561552	C/T	cg17143192	chr8:8559678	CLDN23	-0.5	-5.59	-0.34	6.3e-8	Obesity-related traits;
SARC	cis	rs35213789	0.735	rs611573	chr7:69157105	G/T	cg10619644	chr7:69149951	AUTS2	-0.45	-5.78	-0.35	2.36e-8	Childhood ear infection;
SARC	cis	rs6733011	0.518	rs12712033	chr2:99457973	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.39	-4.78	-0.3	3.05e-6	Bipolar disorder;
SARC	cis	rs6582630	0.638	rs10880620	chr12:38517467	A/G	cg26384229	chr12:38710491	ALG10B	-0.61	-7.82	-0.46	1.87e-13	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs3857536	0.740	rs7769722	chr6:66891363	C/T	cg07460842	chr6:66804631	NA	-0.6	-7.16	-0.42	1.04e-11	Blood trace element (Cu levels);
SARC	cis	rs995000	0.899	rs11207985	chr1:63013786	A/G	cg06896770	chr1:63153194	DOCK7	-0.9	-13.26	-0.66	2.87e-30	Triglyceride levels;
SARC	cis	rs703842	0.575	rs701006	chr12:58106836	C/T	cg18357645	chr12:58087776	OS9	-0.39	-5.28	-0.33	3.02e-7	Multiple sclerosis;
SARC	cis	rs1387259	0.929	rs2956703	chr12:48670294	C/T	cg24011408	chr12:48396354	COL2A1	0.46	5.44	0.34	1.32e-7	Obstructive sleep apnea trait (apnea hypopnea index);
SARC	cis	rs7568458	0.811	rs3755014	chr2:85764006	C/T	cg02493740	chr2:85810744	VAMP5	-0.38	-5.58	-0.34	6.57e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs7647973	0.626	rs4855882	chr3:49715354	G/T	cg13072238	chr3:49761600	GMPPB	-0.71	-7.02	-0.42	2.42e-11	Menarche (age at onset);
SARC	cis	rs9393692	0.905	rs6916289	chr6:26289122	A/T	cg13736514	chr6:26305472	NA	-0.61	-8.46	-0.48	2.91e-15	Educational attainment;
SARC	cis	rs925228	0.504	rs6755030	chr2:24318343	C/T	cg01493198	chr2:24299560	SF3B14	0.79	4.75	0.3	3.62e-6	Reticulocyte fraction of red cells;Reticulocyte count;
SARC	trans	rs36093844	0.800	rs79276445	chr11:85587827	G/T	cg27065003	chr5:122429449	PRDM6	-0.55	-6.54	-0.39	3.91e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs7818688	0.697	rs77402106	chr8:95970484	C/T	cg23172400	chr8:95962367	TP53INP1	0.39	4.72	0.3	4.01e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg08219700	chr8:58056026	NA	0.66	6.64	0.4	2.23e-10	Developmental language disorder (linguistic errors);
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg24987806	chr2:209130885	PIKFYVE	0.49	6.59	0.4	2.91e-10	Chemerin levels;
SARC	cis	rs7000551	0.725	rs2469757	chr8:22360938	C/T	cg12081754	chr8:22256438	SLC39A14	0.52	7.33	0.43	3.81e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs611744	0.647	rs1609472	chr8:109269232	T/G	cg21045802	chr8:109455806	TTC35	0.57	7.1	0.42	1.45e-11	Dupuytren's disease;
SARC	cis	rs7843479	0.524	rs1031884	chr8:21788984	C/T	cg17168535	chr8:21777572	XPO7	0.89	13.68	0.67	1.11e-31	Mean corpuscular volume;
SARC	cis	rs11105298	0.838	rs10858862	chr12:89842053	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.5	-5.01	-0.31	1.1e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs9790314	1.000	rs975323	chr3:161021322	A/G	cg04691961	chr3:161091175	C3orf57	-0.79	-11.53	-0.6	1.27e-24	Morning vs. evening chronotype;
SARC	cis	rs10752881	1.000	rs10911191	chr1:182984524	A/G	cg13390022	chr1:182993471	LAMC1	0.33	5.04	0.31	9.53e-7	Colorectal cancer;
SARC	cis	rs3768617	0.811	rs61808068	chr1:182979377	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.64	8.73	0.5	4.89e-16	Fuchs's corneal dystrophy;
SARC	cis	rs9660992	0.762	rs1172130	chr1:205244953	G/A	cg00857998	chr1:205179979	DSTYK	0.47	5.74	0.35	2.96e-8	Mean corpuscular volume;Mean platelet volume;
SARC	trans	rs2929451	0.566	rs17658270	chr8:9153619	C/G	cg06636001	chr8:8085503	FLJ10661	0.6	7.87	0.46	1.3e-13	Nose size;
SARC	cis	rs6815814	0.950	rs55830619	chr4:38807364	G/A	cg06935464	chr4:38784597	TLR10	0.63	6.31	0.38	1.41e-9	Breast cancer;
SARC	cis	rs273218	1.000	rs274366	chr5:53374636	C/G	ch.5.1024479R	chr5:53302184	ARL15	0.68	7.35	0.43	3.25e-12	Migraine;
SARC	cis	rs11690935	0.959	rs10184866	chr2:172608956	T/G	cg13550731	chr2:172543902	DYNC1I2	-1.01	-16.42	-0.73	9.16e-41	Schizophrenia;
SARC	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg18357526	chr6:26021779	HIST1H4A	0.45	5.64	0.35	5.01e-8	Blood metabolite levels;
SARC	cis	rs4803468	0.967	rs3826713	chr19:41892269	C/T	cg09537434	chr19:41945824	ATP5SL	-0.93	-16.21	-0.73	4.56e-40	Height;
SARC	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg16325326	chr1:53192061	ZYG11B	-0.85	-14.04	-0.68	7.45e-33	Monocyte count;
SARC	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	5.91	0.36	1.21e-8	Electroencephalogram traits;
SARC	cis	rs1003719	0.667	rs13050226	chr21:38457708	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.55	7.61	0.45	6.63e-13	Eye color traits;
SARC	cis	rs7223966	1.000	rs8076717	chr17:61850301	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.49	5.03	0.31	9.6e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs763121	0.853	rs138706	chr22:39137834	C/G	cg06022373	chr22:39101656	GTPBP1	0.87	11.9	0.61	7.72e-26	Menopause (age at onset);
SARC	cis	rs4803468	0.967	rs11083619	chr19:41913267	A/C	cg14132834	chr19:41945861	ATP5SL	-0.56	-7.32	-0.43	4.06e-12	Height;
SARC	cis	rs41278232	0.557	rs1093456	chr20:62604361	G/A	cg07620230	chr20:62328084	TNFRSF6B	0.33	4.72	0.3	4.13e-6	Tonsillectomy;
SARC	cis	rs6831352	0.918	rs13107558	chr4:100050200	C/A	cg13256891	chr4:100009986	ADH5	-0.6	-7.64	-0.45	5.59e-13	Alcohol dependence;
SARC	cis	rs34172651	0.917	rs6497760	chr16:24806535	G/A	cg04756594	chr16:24857601	SLC5A11	0.38	5.9	0.36	1.29e-8	Intelligence (multi-trait analysis);
SARC	cis	rs10791097	0.694	rs10894273	chr11:130742155	G/T	cg12179176	chr11:130786555	SNX19	0.73	10.91	0.58	1.19e-22	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	trans	rs656319	0.559	rs17689289	chr8:9977980	C/G	cg06636001	chr8:8085503	FLJ10661	0.6	8.14	0.47	2.37e-14	Myopia (pathological);
SARC	cis	rs7829975	0.511	rs2921028	chr8:8340477	T/C	cg15556689	chr8:8085844	FLJ10661	0.39	4.98	0.31	1.26e-6	Mood instability;
SARC	cis	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg18252515	chr7:66147081	NA	-1.29	-11.49	-0.6	1.7e-24	Diabetic kidney disease;
SARC	cis	rs9399135	0.967	rs9373122	chr6:135373534	G/A	cg24558204	chr6:135376177	HBS1L	0.46	6.22	0.38	2.22e-9	Red blood cell count;
SARC	cis	rs3136516	0.772	rs7947747	chr11:46852839	A/G	cg03339077	chr11:47165057	C11orf49	-0.34	-4.77	-0.3	3.28e-6	Venous thromboembolism;
SARC	cis	rs7584330	0.910	rs6737914	chr2:238393434	A/G	cg11271282	chr2:238384023	NA	0.44	5.22	0.32	3.91e-7	Prostate cancer;
SARC	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg13939156	chr17:80058883	NA	-0.43	-6.67	-0.4	1.85e-10	Life satisfaction;
SARC	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	11.64	0.61	5.7e-25	Alzheimer's disease;
SARC	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg22875332	chr1:76189707	ACADM	-0.46	-6.42	-0.39	7.54e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	6.14	0.37	3.59e-9	Height;
SARC	trans	rs11250098	0.503	rs7821826	chr8:10769439	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.62	-0.4	2.5e-10	Morning vs. evening chronotype;
SARC	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.74	-7.74	-0.45	2.99e-13	Platelet count;
SARC	cis	rs8067354	0.645	rs2132715	chr17:57858374	A/T	cg02344993	chr17:57696989	CLTC	0.62	6.0	0.37	7.47e-9	Hemoglobin concentration;
SARC	cis	rs2204008	0.580	rs11520047	chr12:38051778	T/A	cg13010199	chr12:38710504	ALG10B	0.78	10.73	0.57	4.45e-22	Bladder cancer;
SARC	trans	rs3799977	0.531	rs62436031	chr6:44722203	A/G	cg03948781	chr1:205179583	DSTYK	0.39	6.26	0.38	1.83e-9	Attention deficit hyperactivity disorder;
SARC	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg18404041	chr3:52824283	ITIH1	-0.37	-5.55	-0.34	7.65e-8	Electroencephalogram traits;
SARC	cis	rs4568518	0.803	rs12699938	chr7:18034520	C/A	cg00911873	chr7:18067463	PRPS1L1	-0.33	-4.73	-0.3	3.89e-6	Measles;
SARC	cis	rs34779708	0.931	rs4934720	chr10:35376800	T/C	cg03585969	chr10:35415529	CREM	0.39	4.86	0.3	2.17e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs1008375	0.932	rs9884565	chr4:17655096	A/G	cg02297831	chr4:17616191	MED28	0.49	6.36	0.38	1.04e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9303401	0.659	rs34170300	chr17:56789905	G/C	cg25039879	chr17:56429692	SUPT4H1	0.68	6.4	0.39	8.57e-10	Cognitive test performance;
SARC	cis	rs6772849	0.662	rs12494372	chr3:128401693	A/C	cg01163369	chr3:128370232	RPN1	-0.35	-4.74	-0.3	3.74e-6	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs12545109	0.800	rs1467125	chr8:57418638	C/T	cg19413350	chr8:57351067	NA	-0.43	-4.88	-0.3	1.95e-6	Obesity-related traits;
SARC	cis	rs7772486	0.686	rs6570705	chr6:145961201	C/T	cg05347473	chr6:146136440	FBXO30	0.51	7.11	0.42	1.4e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2204008	0.818	rs7313608	chr12:38383428	C/A	cg26384229	chr12:38710491	ALG10B	-0.83	-12.16	-0.62	1.11e-26	Bladder cancer;
SARC	trans	rs8073060	0.586	rs8074800	chr17:33979148	A/G	cg19694781	chr19:47549865	TMEM160	0.69	7.23	0.43	6.88e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg22903471	chr2:27725779	GCKR	-0.46	-6.78	-0.41	1.01e-10	Total body bone mineral density;
SARC	cis	rs861020	0.677	rs2049998	chr1:210031154	C/T	cg05527609	chr1:210001259	C1orf107	-0.92	-9.9	-0.54	1.6e-19	Orofacial clefts;
SARC	cis	rs6598955	0.724	rs6656716	chr1:26563105	G/A	cg04990556	chr1:26633338	UBXN11	-0.62	-8.65	-0.49	8.57e-16	Obesity-related traits;
SARC	cis	rs79839061	0.610	rs3736089	chr4:870118	G/A	cg07828340	chr4:882639	GAK	0.77	5.84	0.36	1.75e-8	Intelligence (multi-trait analysis);
SARC	cis	rs6121246	0.567	rs6120879	chr20:30202961	T/C	cg21427119	chr20:30132790	HM13	-0.48	-5.19	-0.32	4.57e-7	Mean corpuscular hemoglobin;
SARC	cis	rs501120	0.925	rs684521	chr10:44752523	G/A	cg09554077	chr10:44749378	NA	0.44	5.98	0.36	8.31e-9	Coronary artery disease;Coronary heart disease;
SARC	cis	rs10078	0.559	rs2037077	chr5:447226	A/G	cg08916839	chr5:415575	AHRR	0.8	7.59	0.45	7.54e-13	Fat distribution (HIV);
SARC	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg03351412	chr1:154909251	PMVK	0.62	7.87	0.46	1.34e-13	Prostate cancer;
SARC	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg17971929	chr21:40555470	PSMG1	0.67	8.77	0.5	3.91e-16	Cognitive function;
SARC	cis	rs2070488	0.804	rs2276541	chr3:38512779	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	12.56	0.64	5.73e-28	Electrocardiographic conduction measures;
SARC	cis	rs1008375	1.000	rs2058338	chr4:17678600	A/G	cg27347728	chr4:17578864	LAP3	-0.44	-5.44	-0.34	1.32e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg11644478	chr21:40555479	PSMG1	-0.57	-6.99	-0.42	2.95e-11	Menarche (age at onset);
SARC	cis	rs6424115	1.000	rs7514394	chr1:24100223	A/G	cg15997130	chr1:24165203	NA	-0.46	-6.08	-0.37	4.88e-9	Immature fraction of reticulocytes;
SARC	cis	rs708547	0.874	rs1718868	chr4:57881215	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.68	7.99	0.46	6.22e-14	Response to bleomycin (chromatid breaks);
SARC	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg17376030	chr22:41985996	PMM1	0.65	7.83	0.46	1.74e-13	Vitiligo;
SARC	cis	rs12711979	0.509	rs10195488	chr2:3824135	T/C	cg17052675	chr2:3827356	NA	-0.52	-7.58	-0.44	8e-13	Itch intensity from mosquito bite adjusted by bite size;
SARC	cis	rs9316337	0.933	rs3759472	chr13:21948988	C/T	cg18095732	chr13:22033692	ZDHHC20	0.39	4.98	0.31	1.26e-6	Schizophrenia;
SARC	cis	rs10504229	0.679	rs4738574	chr8:58033771	T/C	cg08280861	chr8:58055591	NA	0.54	4.97	0.31	1.28e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs9815354	1.000	rs9882329	chr3:41767154	T/C	cg03022575	chr3:42003672	ULK4	0.57	5.36	0.33	2.01e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs11098499	0.754	rs10006259	chr4:120242145	C/T	cg09307838	chr4:120376055	NA	0.81	11.15	0.59	2.11e-23	Corneal astigmatism;
SARC	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg04166393	chr7:2884313	GNA12	0.67	8.33	0.48	6.83e-15	Height;
SARC	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg07308232	chr7:1071921	C7orf50	-0.47	-5.7	-0.35	3.65e-8	Longevity;Endometriosis;
SARC	cis	rs6568686	0.627	rs174377	chr6:111908646	C/A	cg15721981	chr6:111408429	SLC16A10	0.59	5.08	0.32	7.6e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs17125944	0.686	rs8003683	chr14:53366605	G/T	cg00686598	chr14:53173677	PSMC6	0.76	5.59	0.34	6.17e-8	Alzheimer's disease (late onset);
SARC	cis	rs3099143	1.000	rs3099142	chr15:77104909	C/T	cg21673338	chr15:77095150	SCAPER	-0.76	-6.25	-0.38	1.93e-9	Recalcitrant atopic dermatitis;
SARC	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg18451016	chr1:38461880	NA	0.32	5.32	0.33	2.43e-7	Coronary artery disease;
SARC	cis	rs2273669	0.915	rs6935782	chr6:109289881	A/G	cg05315195	chr6:109294784	ARMC2	-0.51	-4.81	-0.3	2.66e-6	Prostate cancer;
SARC	cis	rs13191362	1.000	rs35583420	chr6:163214327	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.72	6.22	0.38	2.26e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs4689388	0.853	rs1079214	chr4:6282157	T/C	cg00701064	chr4:6280414	WFS1	0.56	8.5	0.49	2.32e-15	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	trans	rs9951602	0.512	rs4798994	chr18:76654327	T/G	cg02800362	chr5:177631904	HNRNPAB	0.7	8.92	0.5	1.4e-16	Obesity-related traits;
SARC	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg10523679	chr1:76189770	ACADM	0.51	6.81	0.41	8.23e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6546550	0.935	rs6546551	chr2:70073703	C/T	cg02498382	chr2:70120550	SNRNP27	-0.4	-6.66	-0.4	1.96e-10	Prevalent atrial fibrillation;
SARC	cis	rs28374715	0.681	rs7165396	chr15:41586947	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.12	-18.44	-0.77	1.99e-47	Ulcerative colitis;
SARC	cis	rs453301	0.605	rs7843024	chr8:8799976	G/A	cg15556689	chr8:8085844	FLJ10661	-0.45	-5.47	-0.34	1.19e-7	Joint mobility (Beighton score);
SARC	cis	rs12893668	0.703	rs55751606	chr14:104028806	G/A	cg26031613	chr14:104095156	KLC1	-0.47	-4.95	-0.31	1.42e-6	Reticulocyte count;
SARC	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg08280861	chr8:58055591	NA	0.71	6.16	0.37	3.23e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg01276201	chr10:134613136	NA	0.31	5.34	0.33	2.25e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs9326248	0.861	rs4938352	chr11:117027481	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.59	5.91	0.36	1.18e-8	Blood protein levels;
SARC	cis	rs9435341	0.965	rs1730859	chr1:107617707	A/G	cg09367891	chr1:107599246	PRMT6	0.72	8.52	0.49	1.97e-15	Facial morphology (factor 21, depth of nasal alae);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg03745386	chr12:29534188	ERGIC2	-0.6	-6.74	-0.4	1.25e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs6570726	0.791	rs365747	chr6:145866784	C/T	cg05347473	chr6:146136440	FBXO30	0.54	7.45	0.44	1.82e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7104764	0.673	rs3782118	chr11:222620	T/C	cg03958208	chr11:236908	PSMD13;SIRT3	0.41	4.74	0.3	3.69e-6	Menarche (age at onset);
SARC	cis	rs3762637	1.000	rs16845530	chr3:122142447	T/C	cg24169773	chr3:122142474	KPNA1	-0.56	-5.7	-0.35	3.6e-8	LDL cholesterol levels;
SARC	cis	rs1348850	0.526	rs59972556	chr2:178399561	A/G	cg23306229	chr2:178417860	TTC30B	0.77	7.56	0.44	8.96e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs6540556	0.678	rs11119330	chr1:209889659	A/G	cg05527609	chr1:210001259	C1orf107	-0.55	-4.93	-0.31	1.55e-6	Red blood cell count;
SARC	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg12923728	chr3:195709715	SDHAP1	-0.67	-8.23	-0.47	1.3e-14	Pancreatic cancer;
SARC	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg03161606	chr19:29218774	NA	0.48	6.84	0.41	6.76e-11	Methadone dose in opioid dependence;
SARC	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg25072359	chr17:41440525	NA	0.48	5.62	0.35	5.43e-8	Menopause (age at onset);
SARC	cis	rs28795989	0.862	rs28631205	chr4:7889631	A/G	cg18538662	chr4:7941764	AFAP1	-0.37	-4.73	-0.3	3.83e-6	Intraocular pressure;
SARC	cis	rs2652834	1.000	rs2729785	chr15:63402574	G/A	cg05507819	chr15:63340323	TPM1	0.55	5.44	0.34	1.38e-7	HDL cholesterol;
SARC	cis	rs6834538	0.862	rs7659503	chr4:113425304	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	-0.43	-5.32	-0.33	2.47e-7	Free thyroxine concentration;
SARC	cis	rs2425143	0.730	rs6060626	chr20:34415073	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-6.36	-0.38	1.06e-9	Blood protein levels;
SARC	cis	rs35110281	0.511	rs2298562	chr21:45085236	A/G	cg01579765	chr21:45077557	HSF2BP	-0.34	-5.59	-0.34	6.34e-8	Mean corpuscular volume;
SARC	cis	rs9309473	0.848	rs17009159	chr2:73797762	A/T	cg20560298	chr2:73613845	ALMS1	-0.48	-5.92	-0.36	1.14e-8	Metabolite levels;
SARC	cis	rs2396442	1.000	rs2256819	chr6:45418402	A/G	cg18323984	chr6:45386802	RUNX2	-0.46	-5.47	-0.34	1.17e-7	Left ventricle wall thickness;
SARC	trans	rs7824557	0.564	rs2572379	chr8:11237480	A/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-8.14	-0.47	2.44e-14	Retinal vascular caliber;
SARC	cis	rs7828089	0.715	rs11136029	chr8:22253485	A/G	cg12081754	chr8:22256438	SLC39A14	-0.61	-8.68	-0.49	6.98e-16	Verbal declarative memory;
SARC	cis	rs76419734	0.558	rs10032269	chr4:106525703	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.66	5.87	0.36	1.51e-8	Post bronchodilator FEV1;
SARC	cis	rs7824557	0.628	rs7008205	chr8:11197323	T/G	cg21775007	chr8:11205619	TDH	0.66	8.52	0.49	2e-15	Retinal vascular caliber;
SARC	cis	rs2153535	0.580	rs9406162	chr6:8466196	C/T	cg21535247	chr6:8435926	SLC35B3	0.54	6.79	0.41	9.19e-11	Motion sickness;
SARC	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg04518342	chr5:131593106	PDLIM4	0.42	5.31	0.33	2.6e-7	Breast cancer;
SARC	cis	rs4727027	0.769	rs10952797	chr7:148816722	A/T	cg23583168	chr7:148888333	NA	-0.75	-11.2	-0.59	1.39e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg05617927	chr15:83654886	FAM103A1	0.48	6.26	0.38	1.83e-9	Lung adenocarcinoma;
SARC	cis	rs9309473	1.000	rs6710438	chr2:73820108	C/G	cg20560298	chr2:73613845	ALMS1	0.45	5.35	0.33	2.07e-7	Metabolite levels;
SARC	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg00290607	chr11:67383545	NA	0.38	5.2	0.32	4.39e-7	Mean corpuscular volume;
SARC	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg11247378	chr22:39784982	NA	-0.32	-5.2	-0.32	4.3e-7	Intelligence (multi-trait analysis);
SARC	cis	rs17854409	0.881	rs12625401	chr20:61472939	A/T	cg05147244	chr20:61493195	TCFL5	0.9	5.88	0.36	1.39e-8	Obesity-related traits;
SARC	cis	rs10782582	0.609	rs2881785	chr1:76318096	T/C	cg03433033	chr1:76189801	ACADM	-0.38	-4.87	-0.3	2.09e-6	Daytime sleep phenotypes;
SARC	cis	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg00409905	chr10:38381863	ZNF37A	-0.53	-7.41	-0.44	2.26e-12	Extrinsic epigenetic age acceleration;
SARC	trans	rs10810790	0.651	rs1583986	chr9:17422922	A/T	cg09054412	chr2:173941167	ZAK	0.75	6.27	0.38	1.75e-9	Response to amphetamines;
SARC	cis	rs1784581	0.802	rs9365359	chr6:162423945	C/A	cg17173639	chr6:162384350	PARK2	0.64	8.75	0.5	4.48e-16	Itch intensity from mosquito bite;
SARC	cis	rs7584330	0.737	rs10445707	chr2:238368751	A/G	cg14458575	chr2:238380390	NA	0.43	5.39	0.33	1.71e-7	Prostate cancer;
SARC	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.79	-11.56	-0.6	1.01e-24	Personality dimensions;
SARC	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg19774624	chr17:42201019	HDAC5	-0.81	-11.78	-0.61	1.99e-25	Total body bone mineral density;
SARC	cis	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg05623727	chr3:50126028	RBM5	0.34	5.19	0.32	4.52e-7	Intelligence (multi-trait analysis);
SARC	cis	rs11190604	0.767	rs10883481	chr10:102165021	G/A	cg07080220	chr10:102295463	HIF1AN	0.73	7.84	0.46	1.61e-13	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs7113850	0.541	rs75347910	chr11:24213815	G/A	ch.11.24196551F	chr11:24239977	NA	0.78	6.06	0.37	5.36e-9	Bone fracture in osteoporosis;
SARC	cis	rs17376456	1.000	rs12187701	chr5:93522290	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.14	0.32	5.94e-7	Diabetic retinopathy;
SARC	cis	rs826838	0.967	rs826876	chr12:39123843	T/C	cg26384229	chr12:38710491	ALG10B	-0.76	-11.6	-0.61	7.32e-25	Heart rate;
SARC	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg05313129	chr8:58192883	C8orf71	0.63	6.6	0.4	2.78e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs11098499	0.954	rs59394118	chr4:120295551	A/G	cg09307838	chr4:120376055	NA	0.9	12.7	0.64	2.01e-28	Corneal astigmatism;
SARC	cis	rs2072499	0.966	rs2842857	chr1:156168736	T/C	cg24450063	chr1:156163899	SLC25A44	1.18	21.33	0.81	1.1e-56	Testicular germ cell tumor;
SARC	cis	rs2624839	0.679	rs2624835	chr3:50209049	G/A	cg19755318	chr3:50243323	SLC38A3	-0.31	-5.19	-0.32	4.63e-7	Intelligence (multi-trait analysis);
SARC	cis	rs10861342	0.786	rs11112393	chr12:105548053	C/T	cg23923672	chr12:105501055	KIAA1033	0.73	6.21	0.38	2.47e-9	IgG glycosylation;
SARC	cis	rs7659604	0.540	rs11724322	chr4:122697850	A/T	cg19671926	chr4:122722719	EXOSC9	0.66	8.77	0.5	3.77e-16	Type 2 diabetes;
SARC	cis	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg06558623	chr16:89946397	TCF25	0.94	6.59	0.4	2.87e-10	Skin colour saturation;
SARC	cis	rs17539620	0.628	rs11541340	chr6:154831572	C/G	cg17771515	chr6:154831774	CNKSR3	0.54	5.14	0.32	5.76e-7	Lipoprotein (a) levels;
SARC	cis	rs8180040	1.000	rs2302278	chr3:47361082	G/T	cg27129171	chr3:47204927	SETD2	-0.68	-9.6	-0.53	1.38e-18	Colorectal cancer;
SARC	cis	rs2204008	0.777	rs114096617	chr12:38342557	A/C	cg13010199	chr12:38710504	ALG10B	0.79	10.86	0.58	1.65e-22	Bladder cancer;
SARC	cis	rs832540	0.864	rs252908	chr5:56120686	T/C	cg14703610	chr5:56206110	C5orf35	0.51	6.29	0.38	1.52e-9	Coronary artery disease;
SARC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg02018176	chr4:1364513	KIAA1530	0.63	9.53	0.53	2.22e-18	Longevity;
SARC	cis	rs10782582	0.609	rs112205173	chr1:76310100	C/T	cg10523679	chr1:76189770	ACADM	-0.41	-4.97	-0.31	1.3e-6	Daytime sleep phenotypes;
SARC	cis	rs10416265	0.527	rs7508599	chr19:33546512	A/T	cg27124370	chr19:33622961	WDR88	0.48	6.24	0.38	2.05e-9	Bone properties (heel);
SARC	cis	rs7712401	0.601	rs4555798	chr5:122332114	C/T	cg19412675	chr5:122181750	SNX24	-0.43	-5.43	-0.34	1.41e-7	Mean platelet volume;
SARC	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-14.27	-0.68	1.26e-33	Chronic sinus infection;
SARC	cis	rs6582630	0.599	rs12309369	chr12:38419683	C/G	cg13010199	chr12:38710504	ALG10B	-0.49	-5.93	-0.36	1.11e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7582180	0.652	rs11694700	chr2:100936637	C/T	cg14675211	chr2:100938903	LONRF2	0.51	7.65	0.45	5.19e-13	Intelligence (multi-trait analysis);
SARC	cis	rs3812049	0.826	rs2409110	chr5:127433047	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.89	9.76	0.54	4.3e-19	Lymphocyte counts;Red cell distribution width;
SARC	cis	rs1559088	0.847	rs3786933	chr19:33602881	C/T	cg17764715	chr19:33622953	WDR88	0.49	6.66	0.4	1.99e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg18876405	chr7:65276391	NA	0.46	5.25	0.33	3.41e-7	Aortic root size;
SARC	cis	rs734999	0.545	rs41300092	chr1:2537838	C/T	cg18854424	chr1:2615690	NA	0.32	5.04	0.31	9.14e-7	Ulcerative colitis;
SARC	cis	rs10779751	1.000	rs12730522	chr1:11284091	G/A	cg08854313	chr1:11322531	MTOR	0.9	14.21	0.68	1.99e-33	Body mass index;
SARC	cis	rs7614311	0.681	rs73117036	chr3:63892725	G/C	cg22134162	chr3:63841271	THOC7	-0.45	-4.86	-0.3	2.15e-6	Lung function (FVC);Lung function (FEV1);
SARC	cis	rs13191362	0.935	rs34934114	chr6:163082480	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.72	6.38	0.39	9.33e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	trans	rs561341	0.941	rs112569713	chr17:30271738	C/T	cg20587970	chr11:113659929	NA	-1.26	-12.41	-0.63	1.72e-27	Hip circumference adjusted for BMI;
SARC	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg17971929	chr21:40555470	PSMG1	-0.83	-11.14	-0.59	2.22e-23	Cognitive function;
SARC	cis	rs148387471	1	rs148387471	chr3:127057551	ATAG/A	cg20920097	chr3:127057149	NA	-0.39	-4.97	-0.31	1.3e-6	Interleukin-10 levels;Interleukin-13 levels;
SARC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg05279229	chr7:1896384	MAD1L1	0.34	4.72	0.3	4.03e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg27266027	chr21:40555129	PSMG1	0.46	4.85	0.3	2.3e-6	Cognitive function;
SARC	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg18876405	chr7:65276391	NA	-0.46	-5.23	-0.32	3.79e-7	Aortic root size;
SARC	cis	rs607987	0.871	rs1782507	chr11:30243868	G/T	cg06241208	chr11:30344200	C11orf46	-0.39	-4.77	-0.3	3.27e-6	Body mass index;
SARC	cis	rs55823223	0.648	rs11867582	chr17:73857306	A/G	cg10935138	chr17:73851978	WBP2	0.52	5.62	0.35	5.51e-8	Psoriasis;
SARC	cis	rs9611519	0.780	rs2235850	chr22:41657626	C/T	cg03806693	chr22:41940476	POLR3H	-0.68	-8.89	-0.5	1.66e-16	Neuroticism;
SARC	cis	rs9300255	0.602	rs10846486	chr12:123709927	G/A	cg00376283	chr12:123451042	ABCB9	0.53	6.21	0.38	2.45e-9	Neutrophil percentage of white cells;
SARC	cis	rs739401	0.572	rs739400	chr11:3016520	G/A	cg20651018	chr11:3035856	CARS	-0.48	-7.61	-0.45	6.57e-13	Longevity;
SARC	cis	rs8180040	1.000	rs295442	chr3:47335881	A/C	cg27129171	chr3:47204927	SETD2	0.64	8.99	0.51	9e-17	Colorectal cancer;
SARC	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg03517284	chr6:25882590	NA	-0.39	-5.08	-0.32	7.87e-7	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.679	rs11783557	chr8:58030644	A/G	cg22535103	chr8:58192502	C8orf71	-0.54	-5.48	-0.34	1.08e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs9911578	0.933	rs74370218	chr17:57095212	C/T	cg20303301	chr17:57937339	TUBD1	0.34	4.95	0.31	1.42e-6	Intelligence (multi-trait analysis);
SARC	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg13939156	chr17:80058883	NA	-0.4	-6.27	-0.38	1.77e-9	Life satisfaction;
SARC	cis	rs1707322	1.000	rs11211204	chr1:46317864	A/G	cg06784218	chr1:46089804	CCDC17	0.33	5.77	0.35	2.45e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs6831352	0.918	rs29001231	chr4:100046680	T/C	cg13256891	chr4:100009986	ADH5	-0.66	-8.4	-0.48	4.51e-15	Alcohol dependence;
SARC	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg06074448	chr4:187884817	NA	-0.39	-5.41	-0.33	1.58e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs8028182	0.537	rs4371118	chr15:75898890	C/G	cg20655648	chr15:75932815	IMP3	0.64	7.67	0.45	4.53e-13	Sudden cardiac arrest;
SARC	cis	rs9303401	0.659	rs34426768	chr17:56683385	C/T	cg25039879	chr17:56429692	SUPT4H1	0.72	6.77	0.41	1.02e-10	Cognitive test performance;
SARC	cis	rs9420	0.961	rs11605731	chr11:57524089	C/G	cg19752551	chr11:57585705	CTNND1	-0.52	-7.19	-0.43	8.7e-12	Schizophrenia;
SARC	cis	rs2486288	0.656	rs8039138	chr15:45551592	C/T	cg15395560	chr15:45543142	SLC28A2	0.29	5.63	0.35	5.17e-8	Glomerular filtration rate;
SARC	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg23262073	chr20:60523788	NA	-0.45	-6.57	-0.4	3.3e-10	Body mass index;
SARC	trans	rs56279505	0.690	rs78234152	chr4:100279889	G/A	cg18024358	chr1:3420815	MEGF6	-0.82	-6.42	-0.39	7.63e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs372883	0.532	rs425989	chr21:30715275	T/C	cg24692254	chr21:30365293	RNF160	-0.5	-6.22	-0.38	2.28e-9	Pancreatic cancer;
SARC	cis	rs9902453	0.817	rs3115089	chr17:28031881	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	7.15	0.42	1.11e-11	Coffee consumption (cups per day);
SARC	cis	rs11264799	0.603	rs12133056	chr1:157585751	G/T	cg18268488	chr1:157545234	FCRL4	0.34	5.84	0.36	1.75e-8	IgA nephropathy;
SARC	cis	rs12145833	1.000	rs10926984	chr1:243462153	T/G	cg02356786	chr1:243265016	LOC731275	0.68	6.0	0.37	7.48e-9	Obesity (early onset extreme);
SARC	cis	rs17376456	0.877	rs12716457	chr5:93397627	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.64	5.86	0.36	1.59e-8	Diabetic retinopathy;
SARC	cis	rs9303280	0.901	rs2952140	chr17:37928059	C/T	cg20243544	chr17:37824526	PNMT	-0.45	-6.05	-0.37	5.81e-9	Self-reported allergy;
SARC	cis	rs7216064	1.000	rs58122682	chr17:65876915	T/C	cg12091567	chr17:66097778	LOC651250	-0.64	-6.4	-0.39	8.26e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs9828933	0.882	rs3816156	chr3:63999712	A/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.52	-4.79	-0.3	2.94e-6	Type 2 diabetes;
SARC	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.23e-9	Life satisfaction;
SARC	cis	rs4319547	0.728	rs61954974	chr12:123074169	T/C	cg23029597	chr12:123009494	RSRC2	-0.41	-5.17	-0.32	5.05e-7	Body mass index;
SARC	cis	rs6964587	0.869	rs7812219	chr7:91545727	C/T	cg17063962	chr7:91808500	NA	-0.91	-13.85	-0.67	3.28e-32	Breast cancer;
SARC	cis	rs1215050	0.791	rs2865943	chr4:98778449	C/T	cg05340658	chr4:99064831	C4orf37	0.47	6.16	0.37	3.09e-9	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg03213289	chr20:61660250	NA	0.46	6.43	0.39	7.22e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg03517284	chr6:25882590	NA	0.47	6.27	0.38	1.78e-9	Blood metabolite levels;
SARC	cis	rs12048904	0.505	rs11166511	chr1:101240686	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.71	-8.1	-0.47	3.1e-14	Multiple sclerosis;
SARC	cis	rs2115630	0.641	rs11073613	chr15:85185893	G/A	cg12501888	chr15:85177176	SCAND2	-0.45	-5.43	-0.34	1.39e-7	P wave terminal force;
SARC	cis	rs1707322	1.000	rs4660332	chr1:46461418	T/A	cg06784218	chr1:46089804	CCDC17	0.36	6.49	0.39	5.22e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs56279505	0.629	rs11499828	chr4:100277558	T/C	cg21156590	chr1:3420848	MEGF6	-0.83	-6.41	-0.39	8.04e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	trans	rs11710567	0.734	rs1053711	chr3:57743246	C/T	cg01127878	chr19:42811035	PRR19	-0.44	-6.55	-0.39	3.54e-10	Granulocyte percentage of myeloid white cells;
SARC	cis	rs2404602	0.536	rs1587381	chr15:76769620	G/A	cg22467129	chr15:76604101	ETFA	-0.37	-4.81	-0.3	2.69e-6	Blood metabolite levels;
SARC	cis	rs11249608	0.548	rs34054398	chr5:178458371	A/G	cg01312482	chr5:178451176	ZNF879	-0.38	-5.06	-0.31	8.65e-7	Pubertal anthropometrics;
SARC	cis	rs1865760	0.929	rs12195653	chr6:25958621	A/G	cg17691542	chr6:26056736	HIST1H1C	0.6	7.63	0.45	5.82e-13	Height;
SARC	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg03351412	chr1:154909251	PMVK	-0.64	-8.5	-0.49	2.24e-15	Prostate cancer;
SARC	cis	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg20965017	chr5:231967	SDHA	-0.55	-5.26	-0.33	3.23e-7	Breast cancer;
SARC	cis	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg08975724	chr8:8085496	FLJ10661	0.55	7.02	0.42	2.38e-11	Systolic blood pressure;
SARC	cis	rs778371	0.723	rs11689851	chr2:233567342	A/G	cg16596103	chr2:233749413	NGEF	-0.37	-5.52	-0.34	8.92e-8	Schizophrenia;
SARC	cis	rs765787	0.530	rs4442750	chr15:45535328	G/T	cg25801113	chr15:45476975	SHF	0.29	4.8	0.3	2.81e-6	Uric acid levels;
SARC	cis	rs41271473	0.898	rs55730631	chr1:228865663	C/A	cg16512390	chr1:228756714	NA	0.5	4.95	0.31	1.43e-6	Chronic lymphocytic leukemia;
SARC	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg12288994	chr5:1860383	NA	0.39	6.26	0.38	1.78e-9	Cardiovascular disease risk factors;
SARC	cis	rs5167	0.566	rs2075620	chr19:45480037	C/T	cg09555818	chr19:45449301	APOC2	-0.36	-4.81	-0.3	2.73e-6	Blood protein levels;
SARC	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg13939156	chr17:80058883	NA	0.4	5.98	0.36	8.33e-9	Life satisfaction;
SARC	cis	rs12142240	0.698	rs61519400	chr1:46855298	A/G	cg10495392	chr1:46806563	NSUN4	0.65	6.88	0.41	5.6e-11	Menopause (age at onset);
SARC	cis	rs6088580	0.634	rs6119497	chr20:33012529	T/A	cg08999081	chr20:33150536	PIGU	0.44	6.59	0.4	2.93e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs17376456	0.825	rs13182631	chr5:93115701	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.73	6.78	0.41	1.01e-10	Diabetic retinopathy;
SARC	cis	rs208520	0.837	rs208509	chr6:66941706	A/G	cg07460842	chr6:66804631	NA	-0.89	-10.43	-0.56	3.83e-21	Exhaled nitric oxide output;
SARC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.79	10.24	0.56	1.45e-20	Prudent dietary pattern;
SARC	cis	rs8072100	0.817	rs9905581	chr17:45547185	C/T	cg08085267	chr17:45401833	C17orf57	-0.49	-6.04	-0.37	6.17e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs6456156	0.586	rs12213801	chr6:167474084	T/A	cg07741184	chr6:167504864	NA	0.35	6.87	0.41	5.87e-11	Primary biliary cholangitis;
SARC	cis	rs2228479	0.850	rs34033205	chr16:89922959	G/T	cg12064134	chr16:90016061	DEF8	-0.56	-4.83	-0.3	2.47e-6	Skin colour saturation;
SARC	cis	rs2204008	0.744	rs11181635	chr12:38378420	C/T	cg13010199	chr12:38710504	ALG10B	0.8	11.05	0.59	4.21e-23	Bladder cancer;
SARC	trans	rs208520	0.690	rs207112	chr6:66792092	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.06	-14.41	-0.69	4.36e-34	Exhaled nitric oxide output;
SARC	cis	rs17376456	0.877	rs10055340	chr5:93317644	T/C	cg25358565	chr5:93447407	FAM172A	1.28	14.54	0.69	1.6e-34	Diabetic retinopathy;
SARC	trans	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg20587970	chr11:113659929	NA	-1.33	-13.84	-0.67	3.43e-32	Hip circumference adjusted for BMI;
SARC	cis	rs72634258	0.503	rs707457	chr1:7831064	C/A	cg26816564	chr1:7831052	VAMP3	0.6	5.23	0.32	3.76e-7	Inflammatory bowel disease;
SARC	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg11843238	chr5:131593191	PDLIM4	0.4	5.11	0.32	6.77e-7	Breast cancer;
SARC	cis	rs6087771	0.642	rs6060411	chr20:30222139	T/C	cg13852791	chr20:30311386	BCL2L1	0.66	6.62	0.4	2.43e-10	Subcortical brain region volumes;Putamen volume;
SARC	cis	rs13082711	0.513	rs66472045	chr3:27242887	G/A	cg02860705	chr3:27208620	NA	0.57	7.55	0.44	9.67e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs2075671	0.810	rs12531792	chr7:100280624	G/A	cg16850897	chr7:100343110	ZAN	-0.65	-7.01	-0.42	2.53e-11	Other erythrocyte phenotypes;
SARC	trans	rs62103177	0.535	rs4799109	chr18:77675188	A/T	cg05926928	chr17:57297772	GDPD1	0.84	7.81	0.46	1.99e-13	Opioid sensitivity;
SARC	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg02841227	chr6:26021843	HIST1H4A	0.6	7.26	0.43	5.89e-12	Intelligence (multi-trait analysis);
SARC	trans	rs459571	0.959	rs465535	chr9:136910905	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.61	-7.08	-0.42	1.64e-11	Platelet distribution width;
SARC	cis	rs9457247	1.000	rs932644	chr6:167404187	A/C	cg23791538	chr6:167370224	RNASET2	-0.63	-8.74	-0.5	4.69e-16	Crohn's disease;
SARC	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg13175981	chr1:150552382	MCL1	-0.48	-5.93	-0.36	1.09e-8	Tonsillectomy;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg22682031	chr1:151585010	SNX27	0.47	6.28	0.38	1.62e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs12612619	0.627	rs13391244	chr2:27287609	T/C	cg17611932	chr2:27505586	TRIM54	0.27	4.87	0.3	2.08e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
SARC	cis	rs876084	0.505	rs9969584	chr8:121104786	G/A	cg06265175	chr8:121136014	COL14A1	0.58	7.52	0.44	1.2e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	trans	rs34421088	0.560	rs2245250	chr8:11400680	G/A	cg06636001	chr8:8085503	FLJ10661	-0.66	-9.08	-0.51	4.76e-17	Neuroticism;
SARC	cis	rs6088590	0.610	rs6120663	chr20:33081906	A/C	cg24642439	chr20:33292090	TP53INP2	-0.71	-9.22	-0.52	1.89e-17	Coronary artery disease;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg15270851	chr13:111358291	CARS2	0.77	5.59	0.34	6.26e-8	Obesity-related traits;
SARC	cis	rs9325144	0.560	rs11183189	chr12:38683770	T/A	cg10518543	chr12:38710700	ALG10B	0.4	4.91	0.31	1.7e-6	Morning vs. evening chronotype;
SARC	cis	rs6540556	0.723	rs11487867	chr1:209892070	G/T	cg05527609	chr1:210001259	C1orf107	-0.56	-4.96	-0.31	1.33e-6	Red blood cell count;
SARC	cis	rs1570884	0.536	rs1359541	chr13:50158939	A/G	cg08779649	chr13:50194554	NA	0.36	6.26	0.38	1.79e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
SARC	cis	rs3087591	1.000	rs1800845	chr17:29703438	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.55	-6.79	-0.41	9.19e-11	Hip circumference;
SARC	cis	rs35213789	0.839	rs6970670	chr7:69509271	A/G	cg10619644	chr7:69149951	AUTS2	0.41	5.09	0.32	7.26e-7	Childhood ear infection;
SARC	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg01341218	chr17:43662625	NA	0.95	11.08	0.59	3.29e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs2197308	0.659	rs11181327	chr12:37903171	C/T	cg26384229	chr12:38710491	ALG10B	-0.79	-11.38	-0.6	3.64e-24	Morning vs. evening chronotype;
SARC	cis	rs10791323	0.511	rs4937837	chr11:133731134	T/C	cg13461336	chr11:133711254	SPATA19	-0.27	-4.75	-0.3	3.63e-6	Childhood ear infection;
SARC	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg25036284	chr2:26402008	FAM59B	0.46	5.7	0.35	3.59e-8	Gut microbiome composition (summer);
SARC	cis	rs1865760	0.713	rs1130000	chr6:25985396	A/G	cg17691542	chr6:26056736	HIST1H1C	0.52	6.65	0.4	2.12e-10	Height;
SARC	cis	rs504918	0.525	rs920894	chr3:123987216	G/A	cg05766129	chr3:123988013	KALRN	0.31	5.1	0.32	7.07e-7	Schizophrenia;
SARC	cis	rs10870270	0.784	rs10430614	chr10:133748640	C/T	cg17892150	chr10:133769511	PPP2R2D	0.76	9.98	0.55	9.52e-20	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs3784262	0.679	rs4238326	chr15:58336000	C/T	cg12031962	chr15:58353849	ALDH1A2	0.36	5.25	0.33	3.48e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs6542838	0.641	rs6704682	chr2:99499602	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-5.88	-0.36	1.43e-8	Fear of minor pain;
SARC	cis	rs6976053	0.518	rs314344	chr7:100395003	G/C	cg03098644	chr7:100410630	EPHB4	-0.42	-5.85	-0.36	1.62e-8	Plasminogen activator inhibitor type 1 levels (PAI-1);
SARC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg12419862	chr22:24373484	LOC391322	-0.71	-8.7	-0.5	6.04e-16	Liver enzyme levels (gamma-glutamyl transferase);
SARC	trans	rs6499100	1.000	rs1833196	chr16:52821090	A/G	cg15997635	chr19:6737431	GPR108	0.46	6.34	0.38	1.18e-9	Tetralogy of Fallot;
SARC	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg08280861	chr8:58055591	NA	0.6	5.28	0.33	2.92e-7	Developmental language disorder (linguistic errors);
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg01418856	chr12:49658425	TUBA1C	0.47	6.33	0.38	1.26e-9	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs6909279	0.678	rs11753987	chr6:151851428	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	-0.49	-6.17	-0.38	2.92e-9	Bone mineral density;
SARC	cis	rs1059312	0.808	rs4760537	chr12:129301299	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.46	-5.65	-0.35	4.67e-8	Systemic lupus erythematosus;
SARC	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg19077165	chr18:44547161	KATNAL2	-0.5	-6.94	-0.41	3.92e-11	Personality dimensions;
SARC	cis	rs10791323	0.569	rs329664	chr11:133754975	G/T	cg15485101	chr11:133734466	NA	0.32	5.17	0.32	5.1e-7	Childhood ear infection;
SARC	cis	rs1008375	0.932	rs9884565	chr4:17655096	A/G	cg27347728	chr4:17578864	LAP3	0.47	5.86	0.36	1.57e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs17428076	0.793	rs12622772	chr2:172625737	T/C	cg13550731	chr2:172543902	DYNC1I2	0.44	4.85	0.3	2.22e-6	Myopia;
SARC	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg21017887	chr14:105400489	NA	0.53	7.5	0.44	1.3e-12	Rheumatoid arthritis;
SARC	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg04267008	chr7:1944627	MAD1L1	-0.49	-5.55	-0.34	7.83e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs6459804	0.935	rs72505543	chr7:157508867	G/A	cg05731713	chr7:157510257	PTPRN2	0.29	5.65	0.35	4.64e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs1322639	0.614	rs6925950	chr6:169563958	A/G	cg04662567	chr6:169592167	NA	-0.57	-5.64	-0.35	4.88e-8	Pulse pressure;
SARC	cis	rs11690935	0.959	rs6709156	chr2:172591944	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.99	-15.89	-0.72	5.28e-39	Schizophrenia;
SARC	cis	rs9457247	1.000	rs408040	chr6:167398903	A/T	cg07741184	chr6:167504864	NA	0.29	5.55	0.34	7.59e-8	Crohn's disease;
SARC	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg12751644	chr20:60527061	NA	-0.42	-5.52	-0.34	9.22e-8	Obesity-related traits;
SARC	cis	rs3780378	0.875	rs7869668	chr9:5069837	G/A	cg02405213	chr9:5042618	JAK2	-0.39	-4.89	-0.31	1.86e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
SARC	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.45	-5.57	-0.34	6.97e-8	Lymphocyte counts;
SARC	cis	rs7524258	0.868	rs4908448	chr1:7269283	A/G	cg07173049	chr1:7289937	CAMTA1	-0.33	-6.56	-0.4	3.36e-10	Tourette's syndrome or obsessive-compulsive disorder;
SARC	cis	rs3764563	1.000	rs11673070	chr19:15746095	A/G	cg20725493	chr19:15740067	CYP4F8	-0.76	-5.93	-0.36	1.06e-8	Inflammatory biomarkers;
SARC	cis	rs7659604	0.539	rs72680779	chr4:122797263	C/T	cg19748678	chr4:122722346	EXOSC9	0.8	9.78	0.54	3.88e-19	Type 2 diabetes;
SARC	cis	rs2073300	0.609	rs6137919	chr20:23363163	T/C	cg16736954	chr20:23401023	NAPB	0.79	4.95	0.31	1.44e-6	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs1707322	1.000	rs785506	chr1:46540652	C/T	cg06784218	chr1:46089804	CCDC17	-0.36	-6.28	-0.38	1.64e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7932354	0.655	rs6485690	chr11:46798631	A/G	cg03339077	chr11:47165057	C11orf49	-0.39	-5.31	-0.33	2.61e-7	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs11785400	0.793	rs11785376	chr8:143730412	C/T	cg24634471	chr8:143751801	JRK	0.6	7.74	0.45	2.98e-13	Schizophrenia;
SARC	cis	rs921968	0.565	rs7605055	chr2:219627050	G/C	cg02176678	chr2:219576539	TTLL4	-0.32	-4.95	-0.31	1.41e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs1348850	0.872	rs2084233	chr2:178331206	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.72	9.24	0.52	1.64e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7216064	0.906	rs7223643	chr17:65830282	A/G	cg12091567	chr17:66097778	LOC651250	-0.72	-7.67	-0.45	4.61e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs2421770	0.530	rs2421764	chr11:35364578	A/T	cg13971030	chr11:35366721	SLC1A2	-0.33	-4.99	-0.31	1.18e-6	Staphylococcus aureus nasal carriage (persistent);
SARC	cis	rs2180341	0.782	rs6912552	chr6:127722946	C/G	cg27446573	chr6:127587934	RNF146	-0.82	-10.95	-0.58	8.73e-23	Breast cancer;
SARC	cis	rs1355223	1.000	rs1355221	chr11:34758609	G/A	cg18508148	chr11:34937573	PDHX;APIP	-0.44	-5.67	-0.35	4.26e-8	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs6570726	0.875	rs368744	chr6:145812622	A/G	cg05347473	chr6:146136440	FBXO30	0.48	6.45	0.39	6.29e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9815354	0.812	rs111967505	chr3:41873157	C/T	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs72949976	0.646	rs1441169	chr2:214033530	A/G	cg08319019	chr2:214017104	IKZF2	0.45	5.95	0.36	9.75e-9	Lung cancer;Squamous cell lung carcinoma;
SARC	cis	rs11209002	0.614	rs6670381	chr1:67562106	G/T	cg02640540	chr1:67518911	SLC35D1	0.54	6.34	0.38	1.19e-9	Crohn's disease;
SARC	cis	rs5753618	0.561	rs2078803	chr22:31652852	G/A	cg07713946	chr22:31675144	LIMK2	-0.37	-5.24	-0.32	3.63e-7	Colorectal cancer;
SARC	cis	rs7833986	0.501	rs17814658	chr8:56989130	T/C	cg26371346	chr8:56986568	SNORD54;RPS20	0.73	7.37	0.43	2.98e-12	Height;
SARC	cis	rs7264396	0.635	rs6058355	chr20:34491343	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	5.36	0.33	2.04e-7	Total cholesterol levels;
SARC	cis	rs6707600	1.000	rs2702040	chr2:24541561	A/G	cg18984486	chr2:23609845	KLHL29	0.7	5.48	0.34	1.1e-7	Response to antipsychotic treatment in schizophrenia (working memory);
SARC	cis	rs7822058	0.722	rs4873682	chr8:53699486	T/C	cg26025543	chr8:53854495	NA	0.42	4.72	0.3	4.1e-6	Obesity-related traits;
SARC	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg09359103	chr1:154839909	KCNN3	-0.46	-8.06	-0.47	4.07e-14	Prostate cancer;
SARC	cis	rs2014572	0.967	rs10412975	chr19:57770554	C/A	cg24459738	chr19:57751996	ZNF805	-0.42	-4.88	-0.3	1.97e-6	Hyperactive-impulsive symptoms;
SARC	cis	rs12044355	0.929	rs11122323	chr1:231848933	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.52	7.04	0.42	2.1e-11	Alzheimer's disease;
SARC	cis	rs56313388	0.521	rs62039274	chr16:56328813	G/T	cg02433656	chr16:56322654	GNAO1	0.4	5.91	0.36	1.24e-8	Pulse pressure;
SARC	cis	rs4919044	0.599	rs11187206	chr10:94659515	C/G	cg05127821	chr10:94822908	CYP26C1	-0.56	-4.86	-0.3	2.13e-6	Coronary artery disease;
SARC	cis	rs9393692	0.905	rs9358919	chr6:26287862	C/T	cg05868516	chr6:26286170	HIST1H4H	0.54	7.14	0.42	1.15e-11	Educational attainment;
SARC	trans	rs1814175	0.754	rs28663627	chr11:50048829	C/T	cg15704280	chr7:45808275	SEPT13	-0.96	-17.89	-0.76	1.25e-45	Height;
SARC	cis	rs7944584	0.837	rs11039149	chr11:47276675	A/G	cg10504702	chr11:47789108	FNBP4	0.44	4.83	0.3	2.44e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs9815354	1.000	rs6599178	chr3:41842129	C/T	cg03022575	chr3:42003672	ULK4	0.57	5.44	0.34	1.36e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg07234876	chr8:600039	NA	0.88	6.64	0.4	2.19e-10	IgG glycosylation;
SARC	cis	rs440932	0.757	rs330943	chr8:9021026	G/A	cg06636001	chr8:8085503	FLJ10661	0.44	5.15	0.32	5.63e-7	High light scatter reticulocyte percentage of red cells;
SARC	cis	rs56176327	0.583	rs7613603	chr3:49812866	C/T	cg03060546	chr3:49711283	APEH	-0.63	-6.63	-0.4	2.28e-10	Intelligence (multi-trait analysis);
SARC	cis	rs765787	0.530	rs28524974	chr15:45543528	C/T	cg25801113	chr15:45476975	SHF	0.3	4.92	0.31	1.62e-6	Uric acid levels;
SARC	cis	rs9462027	0.727	rs3798352	chr6:34734809	T/A	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-5.85	-0.36	1.69e-8	Systemic lupus erythematosus;
SARC	cis	rs1729951	0.575	rs1654925	chr3:136690391	C/T	cg15507776	chr3:136538369	TMEM22	-0.5	-5.68	-0.35	4.09e-8	Neuroticism;
SARC	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg13607699	chr17:42295918	UBTF	0.5	6.03	0.37	6.22e-9	Total body bone mineral density;
SARC	cis	rs9302635	0.626	rs34508528	chr16:72215115	C/T	cg01557791	chr16:72042693	DHODH	-0.61	-6.16	-0.37	3.19e-9	Blood protein levels;
SARC	cis	rs9549260	0.755	rs9532571	chr13:41218670	C/T	cg21288729	chr13:41239152	FOXO1	0.69	9.06	0.51	5.47e-17	Red blood cell count;
SARC	cis	rs12594515	1.000	rs8031128	chr15:45988528	C/G	cg14863074	chr15:45997064	NA	0.34	5.24	0.32	3.57e-7	Waist circumference;Weight;
SARC	cis	rs7223966	1.000	rs9909992	chr17:61731931	G/A	cg00588841	chr17:61851480	DDX42;CCDC47	-0.62	-6.66	-0.4	1.91e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs67311347	0.544	rs1902073	chr3:40333497	C/T	cg24209194	chr3:40518798	ZNF619	0.49	6.54	0.39	3.91e-10	Renal cell carcinoma;
SARC	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg12463550	chr7:65579703	CRCP	-0.48	-5.51	-0.34	9.61e-8	Aortic root size;
SARC	cis	rs12042938	0.622	rs61707606	chr1:231813446	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.59	7.56	0.44	9.18e-13	Neuranatomic and neurocognitive phenotypes;
SARC	trans	rs4332037	0.851	rs1403175	chr7:1964357	A/T	cg11693508	chr17:37793320	STARD3	-0.74	-6.98	-0.42	3.11e-11	Bipolar disorder;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg19053929	chr7:91502092	MTERF	0.46	6.32	0.38	1.34e-9	Thyroid stimulating hormone;
SARC	cis	rs4689388	0.926	rs9998519	chr4:6292909	C/T	cg25554036	chr4:6271136	WFS1	0.39	6.26	0.38	1.79e-9	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs708547	0.871	rs2687238	chr4:57880474	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.46	-5.02	-0.31	1.04e-6	Response to bleomycin (chromatid breaks);
SARC	cis	rs7633857	0.532	rs9858335	chr3:160760146	A/G	cg04691961	chr3:161091175	C3orf57	-0.46	-5.96	-0.36	9.41e-9	Educational attainment (years of education);
SARC	cis	rs2066819	1.000	rs2695788	chr12:56697110	G/A	cg26734620	chr12:56694298	CS	-0.86	-6.39	-0.39	8.78e-10	Psoriasis vulgaris;
SARC	cis	rs763121	0.853	rs4821798	chr22:39021165	T/C	cg06022373	chr22:39101656	GTPBP1	0.92	12.78	0.64	1.11e-28	Menopause (age at onset);
SARC	cis	rs35110281	0.743	rs2329443	chr21:45059431	C/T	cg01579765	chr21:45077557	HSF2BP	-0.38	-6.31	-0.38	1.4e-9	Mean corpuscular volume;
SARC	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg07930192	chr7:1003750	NA	0.44	5.87	0.36	1.51e-8	Longevity;Endometriosis;
SARC	cis	rs2991971	0.967	rs12743512	chr1:45954033	A/G	cg24296786	chr1:45957014	TESK2	-0.67	-9.62	-0.53	1.15e-18	High light scatter reticulocyte count;
SARC	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg08048268	chr3:133502702	NA	-0.49	-6.5	-0.39	4.85e-10	Iron status biomarkers;
SARC	cis	rs6088813	0.925	rs1540928	chr20:33961845	C/A	cg23207816	chr20:34252616	CPNE1;RBM12	-0.43	-5.24	-0.32	3.67e-7	Height;
SARC	trans	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg21659725	chr3:3221576	CRBN	-0.53	-6.84	-0.41	6.96e-11	Intelligence (multi-trait analysis);
SARC	cis	rs7766436	0.553	rs6939284	chr6:22556885	C/G	cg13666174	chr6:22585274	NA	0.58	5.88	0.36	1.45e-8	Coronary artery disease;
SARC	cis	rs7917772	0.582	rs10786680	chr10:104317192	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.47	6.15	0.37	3.38e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs614226	1.000	rs1167727	chr12:120965508	C/A	cg01236616	chr12:121019343	POP5	1.27	18.35	0.77	4.03e-47	Type 1 diabetes nephropathy;
SARC	cis	rs12545109	0.879	rs893234	chr8:57363885	G/A	cg19413350	chr8:57351067	NA	-0.45	-4.95	-0.31	1.41e-6	Obesity-related traits;
SARC	cis	rs7520050	0.966	rs4660317	chr1:46326226	G/A	cg24296786	chr1:45957014	TESK2	0.39	4.92	0.31	1.63e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs6582630	0.559	rs12318620	chr12:38522340	T/C	cg13010199	chr12:38710504	ALG10B	-0.52	-6.46	-0.39	5.98e-10	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs761746	0.960	rs738656	chr22:31935347	G/A	cg15162869	chr22:32027605	PISD	0.44	5.82	0.36	1.9e-8	Intelligence;
SARC	cis	rs546131	0.642	rs7946980	chr11:34820438	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.44	4.95	0.31	1.45e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg14829155	chr15:31115871	NA	0.5	6.45	0.39	6.22e-10	Huntington's disease progression;
SARC	cis	rs17376456	1.000	rs10514382	chr5:93566534	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	5.31	0.33	2.58e-7	Diabetic retinopathy;
SARC	trans	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg21659725	chr3:3221576	CRBN	0.52	6.71	0.4	1.46e-10	Intelligence (multi-trait analysis);
SARC	cis	rs2228479	0.850	rs3785281	chr16:89824263	G/C	cg00800038	chr16:89945340	TCF25	-0.74	-5.14	-0.32	5.75e-7	Skin colour saturation;
SARC	cis	rs9916302	0.706	rs4488484	chr17:37717377	A/T	cg00129232	chr17:37814104	STARD3	0.61	6.31	0.38	1.41e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs2991971	0.967	rs11211130	chr1:45986852	G/C	cg24296786	chr1:45957014	TESK2	0.64	9.17	0.51	2.57e-17	High light scatter reticulocyte count;
SARC	cis	rs16854884	0.739	rs56196484	chr3:143786160	G/T	cg06585982	chr3:143692056	C3orf58	0.67	9.07	0.51	5.21e-17	Economic and political preferences (feminism/equality);
SARC	cis	rs8141529	0.702	rs8137262	chr22:29292135	C/T	cg15103426	chr22:29168792	CCDC117	0.63	8.19	0.47	1.77e-14	Lymphocyte counts;
SARC	cis	rs7635838	0.654	rs164101	chr3:11281082	G/A	cg00170343	chr3:11313890	ATG7	0.63	7.83	0.46	1.74e-13	HDL cholesterol;
SARC	cis	rs6121246	0.909	rs6119720	chr20:30347568	T/G	cg13852791	chr20:30311386	BCL2L1	0.85	9.18	0.52	2.48e-17	Mean corpuscular hemoglobin;
SARC	cis	rs1218582	0.741	rs705094	chr1:154917314	G/A	cg09359103	chr1:154839909	KCNN3	-0.43	-7.12	-0.42	1.31e-11	Prostate cancer;
SARC	cis	rs920590	0.876	rs3907477	chr8:19657744	C/T	cg01411142	chr8:19674711	INTS10	0.43	5.19	0.32	4.48e-7	Acute lymphoblastic leukemia (childhood);
SARC	trans	rs61931739	0.500	rs11053251	chr12:34520743	A/G	cg26384229	chr12:38710491	ALG10B	0.85	12.62	0.64	3.51e-28	Morning vs. evening chronotype;
SARC	cis	rs55728055	0.661	rs12165609	chr22:32036332	T/C	cg01338084	chr22:32026380	PISD	1.01	6.07	0.37	5.2e-9	Age-related hearing impairment;
SARC	trans	rs3780486	0.846	rs913214	chr9:33135085	G/A	cg20290983	chr6:43655470	MRPS18A	1.13	21.43	0.81	5.28e-57	IgG glycosylation;
SARC	cis	rs12579753	1.000	rs12367791	chr12:82237278	C/T	cg07988820	chr12:82153109	PPFIA2	-0.52	-6.07	-0.37	5.24e-9	Resting heart rate;
SARC	cis	rs2439831	0.702	rs7171750	chr15:44025858	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	7.63	0.45	6.02e-13	Lung cancer in ever smokers;
SARC	cis	rs12142240	0.698	rs1475388	chr1:46816465	G/A	cg14993813	chr1:46806288	NSUN4	-0.52	-5.46	-0.34	1.22e-7	Menopause (age at onset);
SARC	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	11.64	0.61	5.7e-25	Alzheimer's disease;
SARC	cis	rs8102137	1.000	rs17513752	chr19:30290811	C/T	cg27475126	chr19:30303651	CCNE1	0.38	5.32	0.33	2.39e-7	Bladder cancer;
SARC	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg16339924	chr4:17578868	LAP3	0.66	8.76	0.5	4e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1448094	0.802	rs7487591	chr12:86434112	T/C	cg02569458	chr12:86230093	RASSF9	0.38	5.55	0.34	7.59e-8	Major depressive disorder;
SARC	cis	rs9916302	0.706	rs11655972	chr17:37407072	C/T	cg07936489	chr17:37558343	FBXL20	-0.75	-9.02	-0.51	7.13e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs9894429	0.538	rs9747080	chr17:79606704	A/G	cg18240062	chr17:79603768	NPLOC4	0.74	9.9	0.54	1.66e-19	Eye color traits;
SARC	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg16325326	chr1:53192061	ZYG11B	0.97	18.85	0.78	8.88e-49	Monocyte count;
SARC	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg18364779	chr6:26104403	HIST1H4C	0.44	5.25	0.33	3.37e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg03433033	chr1:76189801	ACADM	0.57	7.88	0.46	1.22e-13	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6121246	0.512	rs6060941	chr20:30367383	C/T	cg13852791	chr20:30311386	BCL2L1	0.89	11.0	0.58	6.1e-23	Mean corpuscular hemoglobin;
SARC	cis	rs11758351	1.000	rs77961951	chr6:26186075	A/G	cg23601095	chr6:26197514	HIST1H3D	0.63	5.18	0.32	4.72e-7	Gout;Renal underexcretion gout;
SARC	cis	rs6831352	0.879	rs7434491	chr4:100069847	G/C	cg13256891	chr4:100009986	ADH5	-0.65	-7.8	-0.45	2.07e-13	Alcohol dependence;
SARC	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg19774624	chr17:42201019	HDAC5	0.78	11.1	0.59	2.87e-23	Total body bone mineral density;
SARC	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-6.5	-0.39	4.93e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs10128251	0.962	rs4748018	chr10:5711507	T/A	cg09234995	chr10:5726438	C10orf18	0.39	4.8	0.3	2.83e-6	Childhood ear infection;
SARC	cis	rs2153535	0.580	rs9505457	chr6:8479142	C/T	cg07606381	chr6:8435919	SLC35B3	0.79	11.16	0.59	1.88e-23	Motion sickness;
SARC	cis	rs13191362	0.810	rs34714603	chr6:163008078	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.56	5.39	0.33	1.71e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg22875332	chr1:76189707	ACADM	0.47	6.52	0.39	4.35e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg07701084	chr6:150067640	NUP43	0.41	5.38	0.33	1.81e-7	Lung cancer;
SARC	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg00933542	chr6:150070202	PCMT1	0.33	5.5	0.34	9.75e-8	Lung cancer;
SARC	cis	rs2985684	1.000	rs11157696	chr14:50105746	C/G	cg15316458	chr14:50087796	RPL36AL;MGAT2	-0.46	-4.71	-0.3	4.2e-6	Carotid intima media thickness;
SARC	cis	rs6570726	0.935	rs387965	chr6:145869366	A/G	cg05220968	chr6:146057943	EPM2A	-0.29	-5.0	-0.31	1.15e-6	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs8051517	1.000	rs12934542	chr16:68371084	G/A	cg01866162	chr16:67596514	CTCF	0.85	5.31	0.33	2.56e-7	Blood protein levels;
SARC	cis	rs6495122	0.651	rs11636952	chr15:75114322	T/C	cg14664628	chr15:75095509	CSK	-0.82	-10.87	-0.58	1.54e-22	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg11644478	chr21:40555479	PSMG1	-0.89	-11.39	-0.6	3.4e-24	Cognitive function;
SARC	cis	rs4642101	0.737	rs4447735	chr3:12825513	C/T	cg05775895	chr3:12838266	CAND2	0.73	11.73	0.61	2.86e-25	QRS complex (12-leadsum);
SARC	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg03517284	chr6:25882590	NA	-0.43	-5.62	-0.35	5.42e-8	Intelligence (multi-trait analysis);
SARC	cis	rs1059312	1.000	rs12814773	chr12:129280786	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.48	-5.86	-0.36	1.56e-8	Systemic lupus erythematosus;
SARC	cis	rs9948	1.000	rs9948	chr2:97500800	C/G	cg01990225	chr2:97406019	LMAN2L	0.66	5.16	0.32	5.26e-7	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg22903471	chr2:27725779	GCKR	-0.49	-7.46	-0.44	1.71e-12	Total body bone mineral density;
SARC	cis	rs13256369	0.802	rs11995449	chr8:8559898	G/A	cg18904891	chr8:8559673	CLDN23	0.47	5.23	0.32	3.74e-7	Obesity-related traits;
SARC	cis	rs4906332	1.000	rs12879663	chr14:103874215	A/G	cg26031613	chr14:104095156	KLC1	-0.52	-6.04	-0.37	6.13e-9	Coronary artery disease;
SARC	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg05025164	chr4:1340916	KIAA1530	0.6	7.43	0.44	2.1e-12	Longevity;
SARC	cis	rs7681440	0.606	rs2619342	chr4:90744170	A/T	cg06632027	chr4:90757378	SNCA	-0.42	-5.23	-0.32	3.81e-7	Dementia with Lewy bodies;
SARC	cis	rs892961	0.932	rs55661113	chr17:75408386	A/C	cg05865280	chr17:75406074	SEPT9	0.51	7.33	0.43	3.71e-12	Airflow obstruction;
SARC	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg07701084	chr6:150067640	NUP43	0.44	5.66	0.35	4.53e-8	Lung cancer;
SARC	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg26681399	chr22:41777847	TEF	0.48	5.27	0.33	3.16e-7	Vitiligo;
SARC	cis	rs4319547	0.656	rs1553179	chr12:122831073	A/G	cg23029597	chr12:123009494	RSRC2	-0.42	-5.4	-0.33	1.68e-7	Body mass index;
SARC	cis	rs1018836	0.608	rs1033347	chr8:91464137	G/A	cg16814680	chr8:91681699	NA	-0.69	-10.0	-0.55	7.82e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs2153535	0.580	rs1319169	chr6:8464456	G/A	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg17376030	chr22:41985996	PMM1	-0.64	-8.25	-0.48	1.19e-14	Vitiligo;
SARC	cis	rs858239	1.000	rs199357	chr7:23288309	A/G	cg23682824	chr7:23144976	KLHL7	-0.57	-6.68	-0.4	1.73e-10	Cerebrospinal fluid biomarker levels;
SARC	cis	rs11098499	0.954	rs6849171	chr4:120409549	G/A	cg09160332	chr4:120329925	NA	-0.34	-4.84	-0.3	2.32e-6	Corneal astigmatism;
SARC	trans	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg21659725	chr3:3221576	CRBN	0.52	6.72	0.4	1.35e-10	Intelligence (multi-trait analysis);
SARC	cis	rs2153535	0.601	rs9502719	chr6:8541032	A/G	cg07606381	chr6:8435919	SLC35B3	0.77	11.04	0.59	4.62e-23	Motion sickness;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg23319546	chr10:75173760	ANXA7	-0.49	-6.52	-0.39	4.22e-10	Electrocardiographic conduction measures;
SARC	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg01316550	chr5:56110833	MAP3K1	0.54	4.92	0.31	1.62e-6	Initial pursuit acceleration;
SARC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg12419862	chr22:24373484	LOC391322	-0.71	-8.67	-0.49	7.39e-16	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs4803468	1.000	rs10422956	chr19:41901261	C/T	cg08477640	chr19:41863820	B9D2	0.46	5.93	0.36	1.09e-8	Height;
SARC	cis	rs2180341	0.889	rs2000909	chr6:127711173	G/A	cg24812749	chr6:127587940	RNF146	0.78	10.05	0.55	5.57e-20	Breast cancer;
SARC	cis	rs4737010	0.536	rs6474365	chr8:41662940	G/T	cg08923054	chr8:41654455	ANK1	0.7	8.2	0.47	1.62e-14	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
SARC	cis	rs7772486	0.790	rs9376968	chr6:146180364	T/C	cg05347473	chr6:146136440	FBXO30	0.51	7.3	0.43	4.63e-12	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs4332037	1.000	rs62442899	chr7:1948454	C/T	cg11693508	chr17:37793320	STARD3	0.72	6.49	0.39	5.25e-10	Bipolar disorder;
SARC	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs986417	1.000	rs10130255	chr14:60944435	C/T	cg27398547	chr14:60952738	C14orf39	1.02	9.71	0.54	6e-19	Gut microbiota (bacterial taxa);
SARC	trans	rs9329221	0.741	rs534523	chr8:9884999	C/G	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.65	-0.4	2.11e-10	Neuroticism;
SARC	trans	rs11098499	0.954	rs10518331	chr4:120323595	C/T	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	cis	rs3818285	0.544	rs9787456	chr10:111711822	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.57	-7.74	-0.45	2.95e-13	Superior crus of antihelix expression;
SARC	trans	rs629535	0.814	rs62513376	chr8:70086881	C/T	cg21567404	chr3:27674614	NA	-1.06	-13.6	-0.67	2.14e-31	Dupuytren's disease;
SARC	cis	rs3204270	0.639	rs7215738	chr17:79659847	C/T	cg26965718	chr17:79658957	HGS	-0.63	-5.16	-0.32	5.23e-7	Dental caries;
SARC	cis	rs2479724	0.901	rs33954419	chr6:41786136	A/G	cg17623882	chr6:41773611	USP49	-0.45	-5.62	-0.35	5.35e-8	Menarche (age at onset);
SARC	cis	rs3820928	0.874	rs10166456	chr2:227900113	G/A	cg11843606	chr2:227700838	RHBDD1	-0.55	-6.87	-0.41	5.92e-11	Pulmonary function;
SARC	cis	rs10465746	0.658	rs980418	chr1:84365653	T/G	cg10977910	chr1:84465055	TTLL7	0.45	5.53	0.34	8.42e-8	Obesity-related traits;
SARC	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg05890377	chr2:74357713	NA	0.62	7.42	0.44	2.13e-12	Gestational age at birth (maternal effect);
SARC	cis	rs3099143	1.000	rs4243043	chr15:77178540	A/G	cg21673338	chr15:77095150	SCAPER	0.6	5.22	0.32	4.03e-7	Recalcitrant atopic dermatitis;
SARC	cis	rs425277	0.959	rs77665022	chr1:2065958	C/T	cg21442419	chr1:2182373	SKI	-0.52	-6.5	-0.39	4.9e-10	Height;
SARC	cis	rs17376456	0.877	rs13153245	chr5:93374891	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	6.12	0.37	3.99e-9	Diabetic retinopathy;
SARC	cis	rs13144136	0.748	rs12502077	chr4:10667802	A/C	cg10242279	chr4:10666415	CLNK	-0.34	-5.33	-0.33	2.35e-7	Resistance to antihypertensive treatment in hypertension;
SARC	cis	rs9650657	0.524	rs2163379	chr8:10732050	G/T	cg21775007	chr8:11205619	TDH	0.45	5.27	0.33	3.11e-7	Neuroticism;
SARC	cis	rs9393692	0.905	rs34916901	chr6:26286149	G/T	cg00631329	chr6:26305371	NA	-0.62	-9.05	-0.51	5.63e-17	Educational attainment;
SARC	cis	rs2985684	0.625	rs4900931	chr14:50022793	A/T	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.44	4.91	0.31	1.72e-6	Carotid intima media thickness;
SARC	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg07701084	chr6:150067640	NUP43	0.39	5.02	0.31	1.01e-6	Lung cancer;
SARC	cis	rs920590	0.684	rs59259846	chr8:19669468	C/G	cg01411142	chr8:19674711	INTS10	0.54	6.08	0.37	4.97e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg07701084	chr6:150067640	NUP43	0.37	4.91	0.31	1.7e-6	Lung cancer;
SARC	cis	rs9303401	0.614	rs34058624	chr17:57118121	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.99	10.1	0.55	3.91e-20	Cognitive test performance;
SARC	trans	rs1741314	0.575	rs1741319	chr20:4158400	C/G	cg14669919	chr11:65340482	FAM89B	0.49	6.65	0.4	2.01e-10	Immature fraction of reticulocytes;
SARC	trans	rs9325144	0.647	rs11169258	chr12:39113040	C/T	cg23762105	chr12:34175262	ALG10	0.5	6.35	0.38	1.09e-9	Morning vs. evening chronotype;
SARC	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg06634786	chr22:41940651	POLR3H	-0.52	-6.15	-0.37	3.38e-9	Vitiligo;
SARC	cis	rs1728785	1.000	rs1624718	chr16:68580385	A/G	cg02972257	chr16:68554789	NA	-0.43	-5.01	-0.31	1.08e-6	Ulcerative colitis;
SARC	cis	rs155076	1.000	rs261431	chr13:21865738	A/G	cg11317459	chr13:21872234	NA	0.89	11.18	0.59	1.66e-23	White matter hyperintensity burden;
SARC	cis	rs11098499	1.000	rs3749591	chr4:120214030	T/G	cg24375607	chr4:120327624	NA	0.4	4.89	0.3	1.91e-6	Corneal astigmatism;
SARC	cis	rs6864727	0.855	rs529526	chr5:137443486	A/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.5	5.54	0.34	8.01e-8	Atrial fibrillation;
SARC	cis	rs13401104	0.796	rs11894483	chr2:237114619	T/C	cg19324714	chr2:237145437	ASB18	0.57	5.91	0.36	1.22e-8	Educational attainment;
SARC	cis	rs4144743	1.000	rs7223003	chr17:45324293	G/A	cg18085866	chr17:45331354	ITGB3	-0.71	-7.35	-0.43	3.36e-12	Body mass index;
SARC	cis	rs6732160	0.588	rs13394018	chr2:73372605	C/T	cg01422370	chr2:73384389	NA	0.38	5.63	0.35	5.16e-8	Intelligence (multi-trait analysis);
SARC	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg05861140	chr6:150128134	PCMT1	-0.44	-5.72	-0.35	3.18e-8	Lung cancer;
SARC	cis	rs11105298	0.891	rs12369685	chr12:89928905	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.56	-5.65	-0.35	4.71e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg04267008	chr7:1944627	MAD1L1	-0.58	-6.58	-0.4	3.14e-10	Bipolar disorder and schizophrenia;
SARC	cis	rs793571	0.523	rs7163162	chr15:58983588	T/A	cg05156742	chr15:59063176	FAM63B	0.7	9.69	0.54	7.31e-19	Schizophrenia;
SARC	cis	rs7592578	0.639	rs61709084	chr2:191287685	A/C	cg27211696	chr2:191398769	TMEM194B	-0.48	-5.2	-0.32	4.39e-7	Diastolic blood pressure;
SARC	cis	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg00409905	chr10:38381863	ZNF37A	-0.55	-7.97	-0.46	6.91e-14	Extrinsic epigenetic age acceleration;
SARC	cis	rs7674212	0.539	rs6533056	chr4:104120997	T/C	cg16532752	chr4:104119610	CENPE	-0.49	-6.08	-0.37	4.81e-9	Type 2 diabetes;
SARC	cis	rs6089584	1.000	rs6089587	chr20:60564829	C/T	cg23262073	chr20:60523788	NA	-0.44	-6.42	-0.39	7.39e-10	Body mass index;
SARC	cis	rs11608355	0.573	rs7970666	chr12:109793495	T/G	cg05360138	chr12:110035743	NA	0.43	5.12	0.32	6.33e-7	Neuroticism;
SARC	cis	rs473651	0.935	rs541013	chr2:239336492	G/A	cg21699342	chr2:239360505	ASB1	0.48	7.13	0.42	1.22e-11	Multiple system atrophy;
SARC	cis	rs2439831	0.867	rs8039638	chr15:43634405	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	8.32	0.48	7.2e-15	Lung cancer in ever smokers;
SARC	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg13206674	chr6:150067644	NUP43	0.46	6.03	0.37	6.45e-9	Lung cancer;
SARC	cis	rs3820928	0.839	rs13398103	chr2:227859693	T/G	cg11843606	chr2:227700838	RHBDD1	-0.5	-5.61	-0.34	5.79e-8	Pulmonary function;
SARC	cis	rs2153535	0.580	rs7766852	chr6:8472417	C/T	cg21535247	chr6:8435926	SLC35B3	0.55	6.91	0.41	4.47e-11	Motion sickness;
SARC	cis	rs76419734	1.000	rs80245547	chr4:106628955	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.81	4.97	0.31	1.27e-6	Post bronchodilator FEV1;
SARC	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg04944784	chr2:26401820	FAM59B	-0.47	-5.76	-0.35	2.66e-8	Gut microbiome composition (summer);
SARC	cis	rs826838	0.654	rs7977738	chr12:38722460	G/A	cg26384229	chr12:38710491	ALG10B	0.61	7.96	0.46	7.72e-14	Heart rate;
SARC	cis	rs36051895	0.658	rs10815145	chr9:5013309	G/A	cg02405213	chr9:5042618	JAK2	-0.5	-5.87	-0.36	1.51e-8	Pediatric autoimmune diseases;
SARC	cis	rs7005606	1.000	rs2466095	chr8:32430849	C/T	cg14488905	chr8:32406789	NRG1	-0.42	-5.75	-0.35	2.82e-8	Hirschsprung disease;
SARC	cis	rs1865760	0.865	rs9467647	chr6:25957642	A/G	cg10373733	chr6:25993375	NA	0.4	4.81	0.3	2.74e-6	Height;
SARC	cis	rs3126085	0.799	rs11589532	chr1:152176539	G/A	cg09127314	chr1:152161683	NA	-0.43	-4.77	-0.3	3.19e-6	Atopic dermatitis;
SARC	cis	rs9457247	1.000	rs436707	chr6:167388843	T/C	cg07741184	chr6:167504864	NA	0.29	5.49	0.34	1.04e-7	Crohn's disease;
SARC	cis	rs2721811	0.593	rs2521768	chr7:24784403	C/T	cg17569154	chr7:24781545	DFNA5	0.35	4.74	0.3	3.71e-6	Depressive symptoms (multi-trait analysis);
SARC	cis	rs453301	0.686	rs6601280	chr8:8909236	A/T	cg11995313	chr8:8860691	ERI1	-0.46	-5.93	-0.36	1.07e-8	Joint mobility (Beighton score);
SARC	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg03060546	chr3:49711283	APEH	0.41	5.15	0.32	5.49e-7	Parkinson's disease;
SARC	cis	rs79349575	0.783	rs28409394	chr17:46998118	T/C	cg16584676	chr17:46985605	UBE2Z	0.53	6.46	0.39	6.07e-10	Type 2 diabetes;
SARC	cis	rs10782582	0.609	rs1796815	chr1:76396793	T/G	cg03433033	chr1:76189801	ACADM	-0.38	-4.77	-0.3	3.26e-6	Daytime sleep phenotypes;
SARC	cis	rs72949976	0.864	rs13389834	chr2:214025112	G/A	cg08319019	chr2:214017104	IKZF2	-0.53	-7.34	-0.43	3.51e-12	Lung cancer;Squamous cell lung carcinoma;
SARC	trans	rs75804782	0.641	rs60841092	chr2:239349640	G/A	cg01134436	chr17:81009848	B3GNTL1	0.86	6.23	0.38	2.11e-9	Morning vs. evening chronotype;Chronotype;
SARC	cis	rs986417	0.818	rs1010051	chr14:61002988	G/C	cg27398547	chr14:60952738	C14orf39	0.96	8.75	0.5	4.38e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs4820539	0.966	rs5751587	chr22:23470090	G/A	cg14186256	chr22:23484241	RTDR1	0.9	14.69	0.69	4.95e-35	Bone mineral density;
SARC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg11905131	chr22:24372483	LOC391322	-0.51	-5.69	-0.35	3.81e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs142483589	1	rs142483589	chr9:139320323	CCG/C	cg13611204	chr9:139324423	INPP5E	-0.29	-5.03	-0.31	9.87e-7	White blood cell count;
SARC	cis	rs1733410	0.504	rs11181874	chr12:37912890	C/A	cg26384229	chr12:38710491	ALG10B	-0.79	-11.38	-0.6	3.64e-24	Morning vs. evening chronotype;
SARC	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg21724239	chr8:58056113	NA	0.58	6.2	0.38	2.61e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs875971	0.830	rs427973	chr7:65526648	C/A	cg11987759	chr7:65425863	GUSB	-0.47	-6.32	-0.38	1.29e-9	Aortic root size;
SARC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.99	12.8	0.64	9.54e-29	Platelet count;
SARC	trans	rs17025548	1.000	rs17025548	chr1:216056348	A/G	cg16540442	chr5:140053369	DND1	0.51	6.23	0.38	2.16e-9	IgG glycosylation;
SARC	cis	rs8031584	0.560	rs1056118	chr15:31203786	G/A	cg14829155	chr15:31115871	NA	0.4	5.39	0.33	1.73e-7	Huntington's disease progression;
SARC	cis	rs4242434	0.747	rs6986550	chr8:22467870	T/A	cg03733263	chr8:22462867	KIAA1967	0.94	15.49	0.71	1.11e-37	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
SARC	cis	rs9398803	1.000	rs9398803	chr6:126683594	A/G	cg19875578	chr6:126661172	C6orf173	0.59	7.96	0.46	7.62e-14	Male-pattern baldness;
SARC	cis	rs8038465	0.615	rs6495076	chr15:73982965	G/A	cg15420318	chr15:73925796	NPTN	0.52	6.19	0.38	2.67e-9	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9398803	0.723	rs2793051	chr6:127064918	C/T	cg19875578	chr6:126661172	C6orf173	-0.6	-8.29	-0.48	8.89e-15	Male-pattern baldness;
SARC	cis	rs6500395	0.775	rs8050844	chr16:48665696	A/G	cg04672837	chr16:48644449	N4BP1	0.41	5.63	0.35	5.04e-8	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs8077889	1.000	rs2079005	chr17:41865627	T/G	cg26893861	chr17:41843967	DUSP3	0.9	10.81	0.58	2.48e-22	Triglycerides;
SARC	cis	rs72945132	0.882	rs3781648	chr11:70190058	T/C	cg05964544	chr11:70165517	PPFIA1	-0.58	-5.6	-0.34	5.95e-8	Coronary artery disease;
SARC	cis	rs2303745	0.589	rs10401700	chr19:17397700	A/C	cg04248312	chr19:17393744	ANKLE1	-0.61	-7.98	-0.46	6.47e-14	Systemic lupus erythematosus;
SARC	cis	rs1153858	1.000	rs4775895	chr15:45617957	T/A	cg15395560	chr15:45543142	SLC28A2	-0.27	-4.9	-0.31	1.78e-6	Homoarginine levels;
SARC	cis	rs9916302	0.904	rs12452509	chr17:37574722	G/A	cg00129232	chr17:37814104	STARD3	-0.62	-7.61	-0.45	6.89e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg25072359	chr17:41440525	NA	0.51	6.03	0.37	6.43e-9	Menopause (age at onset);
SARC	cis	rs7818688	0.697	rs10504939	chr8:95983354	C/G	cg13393036	chr8:95962371	TP53INP1	0.4	4.85	0.3	2.27e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
SARC	cis	rs478304	0.654	rs6591187	chr11:65460086	C/G	cg27068330	chr11:65405492	SIPA1	-0.42	-4.87	-0.3	2.06e-6	Acne (severe);
SARC	cis	rs4481887	1.000	rs4508046	chr1:248488988	T/C	cg00666640	chr1:248458726	OR2T12	0.41	6.68	0.4	1.75e-10	Common traits (Other);
SARC	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg15448220	chr1:150897856	SETDB1	-0.42	-5.3	-0.33	2.74e-7	Urate levels;
SARC	cis	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg25894440	chr7:65020034	NA	-0.77	-5.9	-0.36	1.24e-8	Diabetic kidney disease;
SARC	cis	rs1153858	1.000	rs1365610	chr15:45694610	C/T	cg21132104	chr15:45694354	SPATA5L1	0.79	10.68	0.57	6.03e-22	Homoarginine levels;
SARC	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg13628971	chr7:2884303	GNA12	0.53	6.33	0.38	1.24e-9	Height;
SARC	cis	rs79349575	0.715	rs9894220	chr17:46989154	C/T	cg16584676	chr17:46985605	UBE2Z	0.55	7.04	0.42	2.16e-11	Type 2 diabetes;
SARC	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg25405998	chr7:65216604	CCT6P1	0.47	5.6	0.34	5.92e-8	Calcium levels;
SARC	cis	rs3812831	0.695	rs6560935	chr13:114945867	G/A	cg08824895	chr13:115047677	UPF3A	0.48	6.49	0.39	5.25e-10	Schizophrenia;
SARC	trans	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg08975724	chr8:8085496	FLJ10661	-0.59	-7.78	-0.45	2.37e-13	Neuroticism;
SARC	cis	rs611744	0.967	rs685690	chr8:109192145	A/G	cg21045802	chr8:109455806	TTC35	0.44	5.3	0.33	2.63e-7	Dupuytren's disease;
SARC	cis	rs957448	1.000	rs55897841	chr8:95577270	C/T	cg26464482	chr8:95565502	KIAA1429	0.44	4.85	0.3	2.23e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.92	13.88	0.67	2.57e-32	Chronic sinus infection;
SARC	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg05793240	chr7:2802953	GNA12	-0.36	-5.09	-0.32	7.25e-7	Height;
SARC	cis	rs6665290	0.904	rs7541033	chr1:227188371	C/A	cg14016676	chr1:227182615	CDC42BPA	0.37	5.31	0.33	2.5e-7	Myeloid white cell count;
SARC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.6	7.86	0.46	1.39e-13	Lymphocyte counts;
SARC	cis	rs763121	0.853	rs2072798	chr22:39148483	G/A	cg21395723	chr22:39101663	GTPBP1	0.55	6.23	0.38	2.13e-9	Menopause (age at onset);
SARC	cis	rs7772486	0.875	rs10872583	chr6:146396699	G/T	cg05347473	chr6:146136440	FBXO30	-0.49	-6.82	-0.41	7.54e-11	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg07308232	chr7:1071921	C7orf50	-0.49	-5.69	-0.35	3.73e-8	Longevity;Endometriosis;
SARC	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg02931644	chr1:25747376	RHCE	0.46	7.65	0.45	5.44e-13	Erythrocyte sedimentation rate;
SARC	cis	rs829883	0.604	rs249841	chr12:98871743	A/G	cg25150519	chr12:98850993	NA	0.41	5.25	0.33	3.39e-7	Colorectal adenoma (advanced);
SARC	cis	rs12545109	0.800	rs1913278	chr8:57403725	T/C	cg19413350	chr8:57351067	NA	-0.42	-4.72	-0.3	4.04e-6	Obesity-related traits;
SARC	cis	rs2439831	0.867	rs12324572	chr15:43636200	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.08	11.58	0.6	8.71e-25	Lung cancer in ever smokers;
SARC	cis	rs2236918	0.664	rs1776146	chr1:242040577	A/T	cg17736920	chr1:242011382	EXO1	0.57	7.18	0.43	9.09e-12	Menopause (age at onset);
SARC	cis	rs17376456	1.000	rs34068652	chr5:93563319	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.6	5.35	0.33	2.13e-7	Diabetic retinopathy;
SARC	cis	rs9916302	0.851	rs4390625	chr17:37620347	A/G	cg00129232	chr17:37814104	STARD3	-0.63	-7.8	-0.46	2.06e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs7208859	0.673	rs9899349	chr17:29200122	C/T	cg13385521	chr17:29058706	SUZ12P	0.86	7.34	0.43	3.54e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9297145	0.565	rs12705030	chr7:98765041	A/G	cg05967295	chr7:98741636	SMURF1	-0.52	-5.76	-0.35	2.68e-8	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
SARC	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	10.31	0.56	8.8e-21	Platelet count;
SARC	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg11764359	chr7:65958608	NA	0.77	9.41	0.52	5.12e-18	Aortic root size;
SARC	trans	rs11098499	0.954	rs7437420	chr4:120312903	A/G	cg25214090	chr10:38739885	LOC399744	0.55	7.14	0.42	1.15e-11	Corneal astigmatism;
SARC	cis	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg05623727	chr3:50126028	RBM5	-0.33	-5.15	-0.32	5.66e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1059312	0.966	rs35907548	chr12:129282180	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.5	-6.13	-0.37	3.69e-9	Systemic lupus erythematosus;
SARC	cis	rs7659604	1.000	rs28532673	chr4:122664323	A/G	cg20573242	chr4:122745356	CCNA2	-0.46	-6.03	-0.37	6.51e-9	Type 2 diabetes;
SARC	cis	rs11711311	1.000	rs2566963	chr3:113531849	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.65	-7.86	-0.46	1.45e-13	IgG glycosylation;
SARC	cis	rs8067354	0.872	rs1292060	chr17:57913849	A/G	cg13753209	chr17:57696993	CLTC	0.53	6.53	0.39	3.97e-10	Hemoglobin concentration;
SARC	trans	rs7819412	0.775	rs2898257	chr8:10935368	A/C	cg08975724	chr8:8085496	FLJ10661	-0.59	-7.79	-0.45	2.22e-13	Triglycerides;
SARC	cis	rs748404	0.578	rs478028	chr15:43610772	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	6.87	0.41	5.71e-11	Lung cancer;
SARC	cis	rs67311347	0.544	rs6599088	chr3:40329288	T/C	cg09455208	chr3:40491958	NA	0.3	4.93	0.31	1.56e-6	Renal cell carcinoma;
SARC	trans	rs1814175	0.619	rs847644	chr11:49918418	G/A	cg15704280	chr7:45808275	SEPT13	-0.88	-14.0	-0.68	1.02e-32	Height;
SARC	cis	rs12479064	0.671	rs62155807	chr2:100076579	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.43	-4.76	-0.3	3.43e-6	Chronic sinus infection;
SARC	cis	rs9325144	0.560	rs10506127	chr12:39126686	C/G	cg13010199	chr12:38710504	ALG10B	-0.55	-7.3	-0.43	4.38e-12	Morning vs. evening chronotype;
SARC	cis	rs7617773	0.780	rs13079728	chr3:48339360	A/G	cg11946769	chr3:48343235	NME6	0.76	9.72	0.54	5.94e-19	Coronary artery disease;
SARC	cis	rs751728	0.664	rs2296744	chr6:33740382	G/A	cg15252951	chr6:33757062	LEMD2	0.41	4.89	0.3	1.92e-6	Crohn's disease;
SARC	cis	rs1198872	0.563	rs2005011	chr2:10963925	C/T	cg15705551	chr2:10952987	PDIA6	0.47	5.98	0.36	8.18e-9	Cardiac Troponin-T levels;
SARC	trans	rs1814175	0.588	rs10466497	chr11:49864381	A/T	cg03929089	chr4:120376271	NA	-0.83	-12.24	-0.63	6.14e-27	Height;
SARC	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs4780401	0.527	rs4780402	chr16:11839809	C/T	cg01061890	chr16:11836724	TXNDC11	-0.51	-6.62	-0.4	2.39e-10	Rheumatoid arthritis;
SARC	cis	rs2742234	0.911	rs3004214	chr10:43631698	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.41	-5.11	-0.32	6.86e-7	Hirschsprung disease;
SARC	trans	rs61931739	0.500	rs12367292	chr12:33998075	T/C	cg26384229	chr12:38710491	ALG10B	0.86	12.43	0.63	1.52e-27	Morning vs. evening chronotype;
SARC	cis	rs78456975	1.000	rs11884854	chr2:1566154	A/G	cg26248373	chr2:1572462	NA	-0.59	-6.32	-0.38	1.31e-9	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg24110177	chr3:50126178	RBM5	-0.62	-8.02	-0.46	5.28e-14	Intelligence (multi-trait analysis);
SARC	cis	rs829883	0.872	rs1641637	chr12:98890564	G/A	cg25150519	chr12:98850993	NA	0.7	9.54	0.53	1.99e-18	Colorectal adenoma (advanced);
SARC	cis	rs273218	1.000	rs156438	chr5:53374120	A/G	ch.5.1024479R	chr5:53302184	ARL15	0.68	7.49	0.44	1.44e-12	Migraine;
SARC	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg09455208	chr3:40491958	NA	0.36	5.43	0.33	1.45e-7	Renal cell carcinoma;
SARC	cis	rs9457247	0.663	rs2282860	chr6:167440244	T/C	cg23791538	chr6:167370224	RNASET2	-0.52	-7.03	-0.42	2.23e-11	Crohn's disease;
SARC	cis	rs10464366	0.544	rs4723824	chr7:39153698	T/C	cg15212455	chr7:39170539	POU6F2	0.44	5.57	0.34	7.06e-8	IgG glycosylation;
SARC	cis	rs11874712	1.000	rs9945606	chr18:43673325	A/G	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.46	5.49	0.34	1.06e-7	Migraine - clinic-based;
SARC	cis	rs4319547	1.000	rs7295397	chr12:123116209	C/T	cg23029597	chr12:123009494	RSRC2	-0.45	-5.71	-0.35	3.36e-8	Body mass index;
SARC	cis	rs137603	0.644	rs94852	chr22:39712334	T/C	cg01093212	chr22:39715156	SNORD43;RPL3	-0.51	-5.92	-0.36	1.14e-8	Primary biliary cholangitis;
SARC	cis	rs2635047	0.710	rs36095873	chr18:44603199	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.53	6.85	0.41	6.54e-11	Educational attainment;
SARC	cis	rs4713118	0.868	rs760587	chr6:27740300	C/A	cg17221315	chr6:27791827	HIST1H4J	0.56	5.75	0.35	2.84e-8	Parkinson's disease;
SARC	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	10.25	0.56	1.33e-20	Platelet count;
SARC	cis	rs7833790	0.660	rs67666182	chr8:82772037	A/G	cg06027949	chr8:82754900	SNX16	0.47	5.94	0.36	1.01e-8	Diastolic blood pressure;
SARC	cis	rs11997175	0.546	rs11778519	chr8:33615873	G/A	ch.8.33884649F	chr8:33765107	NA	0.51	6.49	0.39	5.05e-10	Body mass index;
SARC	cis	rs6450176	0.909	rs67199213	chr5:53290648	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.63	-7.13	-0.42	1.25e-11	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
SARC	cis	rs1707322	0.721	rs10749856	chr1:46164846	A/T	cg03146154	chr1:46216737	IPP	0.53	6.35	0.38	1.12e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2635047	0.783	rs8084241	chr18:44798139	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.54	6.81	0.41	8.31e-11	Educational attainment;
SARC	cis	rs5753037	0.653	rs131286	chr22:30158351	C/T	cg01021169	chr22:30184971	ASCC2	-0.45	-6.19	-0.38	2.72e-9	Type 1 diabetes;
SARC	cis	rs13256369	0.851	rs11786125	chr8:8564570	T/G	cg17143192	chr8:8559678	CLDN23	0.52	5.83	0.36	1.82e-8	Obesity-related traits;
SARC	trans	rs561341	0.714	rs473535	chr17:30312365	A/G	cg20587970	chr11:113659929	NA	-1.33	-13.65	-0.67	1.51e-31	Hip circumference adjusted for BMI;
SARC	cis	rs2153535	0.580	rs2184584	chr6:8468407	T/C	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs910316	1.000	rs12897094	chr14:75579416	C/T	cg08847533	chr14:75593920	NEK9	0.92	15.54	0.71	7.54e-38	Height;
SARC	cis	rs11574514	0.661	rs76160073	chr16:67820246	A/T	cg01866162	chr16:67596514	CTCF	1.12	6.6	0.4	2.74e-10	Crohn's disease;
SARC	cis	rs72653721	0.730	rs9468304	chr6:11042165	A/G	cg13562911	chr6:11044106	ELOVL2	-0.49	-5.63	-0.35	5.29e-8	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	cis	rs9815354	0.812	rs73071325	chr3:41809989	T/G	cg03022575	chr3:42003672	ULK4	0.72	5.99	0.37	7.83e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs752010	0.619	rs1123483	chr1:42114198	C/T	cg06885757	chr1:42089581	HIVEP3	-0.47	-6.6	-0.4	2.67e-10	Lupus nephritis in systemic lupus erythematosus;
SARC	trans	rs17685	0.753	rs6953665	chr7:75769049	C/T	cg19862616	chr7:65841803	NCRNA00174	0.62	7.72	0.45	3.44e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs2916247	0.954	rs12056584	chr8:93141987	T/C	cg10183463	chr8:93005414	RUNX1T1	0.53	5.75	0.35	2.72e-8	Intelligence (multi-trait analysis);
SARC	cis	rs10766496	1.000	rs4341511	chr11:18736627	C/T	cg10955973	chr11:19366714	NA	0.45	4.75	0.3	3.6e-6	Diabetic kidney disease;
SARC	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg02733842	chr7:1102375	C7orf50	-0.47	-6.35	-0.38	1.14e-9	Bronchopulmonary dysplasia;
SARC	cis	rs2066819	0.901	rs773665	chr12:56717466	C/T	cg26316697	chr12:56727976	PAN2	-0.9	-6.37	-0.39	9.89e-10	Psoriasis vulgaris;
SARC	cis	rs6665290	0.904	rs3738729	chr1:227191227	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.1	-25.46	-0.86	3.01e-69	Myeloid white cell count;
SARC	cis	rs365302	0.716	rs452441	chr6:159610622	C/T	cg14500486	chr6:159655392	FNDC1	0.41	5.03	0.31	9.65e-7	Coronary heart disease;
SARC	cis	rs1865760	0.713	rs7766342	chr6:25990674	C/A	cg17691542	chr6:26056736	HIST1H1C	0.51	6.58	0.4	3e-10	Height;
SARC	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg11843238	chr5:131593191	PDLIM4	0.43	5.82	0.36	1.93e-8	Acylcarnitine levels;
SARC	cis	rs4889855	0.505	rs4890057	chr17:78591679	A/G	cg17956530	chr17:78667699	RPTOR	-0.47	-5.41	-0.33	1.56e-7	Fractional excretion of uric acid;
SARC	cis	rs7220711	0.967	rs4793022	chr17:41798855	C/G	cg26893861	chr17:41843967	DUSP3	0.4	5.07	0.32	7.98e-7	Bone mineral density (spine);Bone mineral density (hip);
SARC	cis	rs8114671	0.562	rs6087653	chr20:33522054	T/C	cg24642439	chr20:33292090	TP53INP2	0.51	6.17	0.37	3.06e-9	Height;
SARC	cis	rs2075064	0.500	rs10986190	chr9:126818818	A/G	cg14112217	chr9:126806003	NA	0.33	5.09	0.32	7.52e-7	Waist circumference;
SARC	cis	rs11190604	1.000	rs2489035	chr10:102319395	C/T	cg07080220	chr10:102295463	HIF1AN	0.83	8.82	0.5	2.8e-16	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs2832191	0.755	rs55671430	chr21:30492421	G/C	cg08807101	chr21:30365312	RNF160	-0.82	-11.26	-0.59	9.12e-24	Dental caries;
SARC	cis	rs72781680	0.528	rs56258075	chr2:24104256	C/G	cg06627628	chr2:24431161	ITSN2	-0.67	-6.59	-0.4	2.95e-10	Lymphocyte counts;
SARC	cis	rs6545883	0.791	rs4672445	chr2:61655008	T/C	cg15711740	chr2:61764176	XPO1	0.42	5.14	0.32	5.83e-7	Tuberculosis;
SARC	cis	rs7714584	1.000	rs13361189	chr5:150223387	A/G	cg22134413	chr5:150180641	NA	0.77	6.38	0.39	9.69e-10	Crohn's disease;
SARC	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg05863683	chr7:1912471	MAD1L1	0.33	4.89	0.31	1.86e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs6964587	0.869	rs13237856	chr7:91551788	G/A	cg17063962	chr7:91808500	NA	-0.9	-13.54	-0.66	3.31e-31	Breast cancer;
SARC	cis	rs2273669	0.667	rs11752532	chr6:109335969	C/G	cg05315195	chr6:109294784	ARMC2	-0.63	-5.7	-0.35	3.6e-8	Prostate cancer;
SARC	cis	rs2228479	0.850	rs1108063	chr16:89893983	A/G	cg12064134	chr16:90016061	DEF8	-0.55	-4.78	-0.3	3.16e-6	Skin colour saturation;
SARC	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.54	0.44	1.04e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9815354	0.812	rs73077386	chr3:41857652	A/G	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2288073	0.965	rs13387930	chr2:24414400	A/G	cg06627628	chr2:24431161	ITSN2	-0.66	-7.99	-0.46	6.4e-14	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs7246657	0.943	rs4452075	chr19:37879589	A/G	cg23950597	chr19:37808831	NA	-0.56	-5.67	-0.35	4.18e-8	Coronary artery calcification;
SARC	cis	rs11792861	0.851	rs17552292	chr9:111891954	C/T	cg13535736	chr9:111863775	C9orf5	-0.4	-4.84	-0.3	2.39e-6	Menarche (age at onset);
SARC	cis	rs4319547	0.585	rs7952868	chr12:122846949	A/G	cg23029597	chr12:123009494	RSRC2	-0.46	-5.68	-0.35	3.93e-8	Body mass index;
SARC	cis	rs2153535	0.546	rs1335640	chr6:8485325	A/C	cg23788917	chr6:8435910	SLC35B3	0.62	8.05	0.47	4.27e-14	Motion sickness;
SARC	cis	rs9650657	0.572	rs4841465	chr8:10819854	C/T	cg21775007	chr8:11205619	TDH	-0.42	-5.17	-0.32	5.04e-7	Neuroticism;
SARC	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg17376030	chr22:41985996	PMM1	-0.75	-9.38	-0.52	6.19e-18	Vitiligo;
SARC	cis	rs62244186	0.748	rs13319803	chr3:44635461	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.44	5.58	0.34	6.6e-8	Depressive symptoms;
SARC	cis	rs10791097	0.678	rs10894272	chr11:130731081	A/G	cg12179176	chr11:130786555	SNX19	0.64	9.11	0.51	4e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs17539620	0.624	rs871069	chr6:154837578	A/C	cg17771515	chr6:154831774	CNKSR3	0.53	5.07	0.32	8.2e-7	Lipoprotein (a) levels;
SARC	cis	rs941408	0.963	rs2537855	chr19:2806574	A/G	cg00079169	chr19:2811669	THOP1	0.48	5.01	0.31	1.06e-6	Total cholesterol levels;
SARC	cis	rs2228479	0.850	rs62054610	chr16:89816920	G/A	cg00800038	chr16:89945340	TCF25	-0.74	-5.14	-0.32	5.75e-7	Skin colour saturation;
SARC	cis	rs2153535	0.580	rs4960433	chr6:8523697	A/G	cg23788917	chr6:8435910	SLC35B3	0.64	8.69	0.49	6.72e-16	Motion sickness;
SARC	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg22974920	chr21:40686053	BRWD1	-0.45	-4.91	-0.31	1.73e-6	Cognitive function;
SARC	cis	rs2120019	0.508	rs8030528	chr15:75171825	C/T	cg09165964	chr15:75287851	SCAMP5	-0.94	-10.66	-0.57	7.17e-22	Blood trace element (Zn levels);
SARC	cis	rs7635838	0.892	rs3942925	chr3:11442921	T/C	cg00170343	chr3:11313890	ATG7	0.61	8.23	0.47	1.33e-14	HDL cholesterol;
SARC	cis	rs11098499	0.648	rs2002047	chr4:120257228	A/G	cg09307838	chr4:120376055	NA	0.81	11.03	0.59	4.84e-23	Corneal astigmatism;
SARC	cis	rs1256061	0.603	rs10148269	chr14:64736924	A/G	cg23250157	chr14:64679961	SYNE2	0.48	6.62	0.4	2.49e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs854765	0.693	rs8080061	chr17:17776389	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.45	-5.85	-0.36	1.62e-8	Total body bone mineral density;
SARC	cis	rs34375054	0.525	rs7133864	chr12:125606180	C/T	cg25124228	chr12:125621409	AACS	-0.63	-7.93	-0.46	9.35e-14	Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs6540556	0.608	rs12129718	chr1:209912540	C/T	cg05527609	chr1:210001259	C1orf107	-0.58	-5.69	-0.35	3.73e-8	Red blood cell count;
SARC	cis	rs3857067	0.530	rs72663744	chr4:94998544	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.34	-4.81	-0.3	2.65e-6	QT interval;
SARC	cis	rs9948	0.655	rs2280356	chr2:97366324	C/T	cg01990225	chr2:97406019	LMAN2L	0.83	6.72	0.4	1.35e-10	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg22834771	chr12:69754056	YEATS4	-0.44	-5.78	-0.35	2.42e-8	Blood protein levels;
SARC	cis	rs9309473	0.660	rs11679594	chr2:73779507	G/A	cg20560298	chr2:73613845	ALMS1	-0.5	-5.0	-0.31	1.14e-6	Metabolite levels;
SARC	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg17554472	chr22:41940697	POLR3H	-0.45	-4.97	-0.31	1.32e-6	Vitiligo;
SARC	cis	rs2952156	1.000	rs1810132	chr17:37866005	C/T	cg00129232	chr17:37814104	STARD3	-0.67	-8.57	-0.49	1.43e-15	Asthma;
SARC	cis	rs58804349	0.605	rs117540287	chr10:43512040	G/T	cg08461752	chr10:43522343	NA	-0.43	-4.78	-0.3	3.08e-6	Pediatric bone mineral content (radius);
SARC	cis	rs7712401	0.692	rs9327273	chr5:122073550	T/G	cg19412675	chr5:122181750	SNX24	0.41	5.78	0.35	2.45e-8	Mean platelet volume;
SARC	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg24675658	chr1:53192096	ZYG11B	0.73	11.22	0.59	1.25e-23	Monocyte count;
SARC	cis	rs743757	0.938	rs2236959	chr3:50441627	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.55	5.12	0.32	6.26e-7	Diastolic blood pressure;
SARC	cis	rs4481887	0.861	rs10888345	chr1:248447533	A/G	cg00666640	chr1:248458726	OR2T12	0.35	5.85	0.36	1.62e-8	Common traits (Other);
SARC	trans	rs61931739	0.635	rs1486884	chr12:33908876	A/T	cg13010199	chr12:38710504	ALG10B	-0.57	-7.51	-0.44	1.23e-12	Morning vs. evening chronotype;
SARC	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg13866156	chr1:1669148	SLC35E2	-0.62	-9.22	-0.52	1.82e-17	Body mass index;
SARC	cis	rs4280164	0.945	rs4981503	chr14:24786293	T/G	cg16194253	chr14:24768981	DHRS1;C14orf21	0.52	4.91	0.31	1.72e-6	Parent of origin effect on language impairment (paternal);
SARC	cis	rs4481887	1.000	rs4916124	chr1:248466495	T/C	cg00666640	chr1:248458726	OR2T12	0.37	6.3	0.38	1.43e-9	Common traits (Other);
SARC	cis	rs986417	0.786	rs76632048	chr14:60846934	G/A	cg27398547	chr14:60952738	C14orf39	-1.01	-8.72	-0.5	5.17e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs4642101	0.686	rs9822382	chr3:12828828	T/G	cg24848339	chr3:12840334	CAND2	0.32	4.8	0.3	2.82e-6	QRS complex (12-leadsum);
SARC	cis	rs11097912	0.632	rs7662395	chr4:107185855	C/T	cg09646026	chr4:107269030	AIMP1	-0.45	-5.06	-0.31	8.51e-7	Airflow obstruction;
SARC	cis	rs4253772	0.530	rs9615961	chr22:46754993	T/C	cg24881330	chr22:46731750	TRMU	0.68	4.76	0.3	3.33e-6	LDL cholesterol;Cholesterol, total;
SARC	trans	rs12097821	0.627	rs4914979	chr1:107118046	G/A	cg24684357	chr21:43188367	RIPK4	0.64	6.31	0.38	1.35e-9	Non-obstructive azoospermia;
SARC	cis	rs76419734	1.000	rs72673831	chr4:106733380	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.79	5.34	0.33	2.23e-7	Post bronchodilator FEV1;
SARC	cis	rs3768617	0.782	rs10911211	chr1:183022299	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	7.98	0.46	6.5e-14	Fuchs's corneal dystrophy;
SARC	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg18404041	chr3:52824283	ITIH1	-0.42	-6.23	-0.38	2.13e-9	Bipolar disorder;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg24196566	chr3:97596840	CRYBG3	0.46	6.71	0.4	1.44e-10	Thyroid stimulating hormone;
SARC	trans	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-10.59	-0.57	1.18e-21	Intelligence (multi-trait analysis);
SARC	cis	rs17376456	0.569	rs12653528	chr5:93212833	T/C	cg21475434	chr5:93447410	FAM172A	-0.65	-6.47	-0.39	5.77e-10	Diabetic retinopathy;
SARC	cis	rs7103648	0.695	rs6485758	chr11:47530024	G/A	cg10504702	chr11:47789108	FNBP4	0.7	9.26	0.52	1.36e-17	Diastolic blood pressure;Systolic blood pressure;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg01742680	chr3:152879841	RAP2B	0.75	6.37	0.39	9.8e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs11105298	0.891	rs10777185	chr12:89921275	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.53	-5.33	-0.33	2.3e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg11062466	chr8:58055876	NA	0.58	4.74	0.3	3.74e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs11098499	0.697	rs11941899	chr4:120382758	C/A	cg24375607	chr4:120327624	NA	0.39	4.74	0.3	3.7e-6	Corneal astigmatism;
SARC	cis	rs7666738	0.830	rs6823718	chr4:99063202	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.7	0.5	6.15e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg18876405	chr7:65276391	NA	0.46	5.25	0.33	3.41e-7	Aortic root size;
SARC	cis	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg15556689	chr8:8085844	FLJ10661	0.41	5.25	0.33	3.37e-7	Mood instability;
SARC	cis	rs524281	0.954	rs549187	chr11:65898631	C/T	cg14036092	chr11:66035641	RAB1B	-0.53	-5.98	-0.36	8.25e-9	Electroencephalogram traits;
SARC	cis	rs9875589	0.509	rs1386932	chr3:14061369	G/A	cg19554555	chr3:13937349	NA	-0.4	-5.22	-0.32	4.03e-7	Ovarian reserve;
SARC	cis	rs6570726	0.791	rs6915094	chr6:145883540	C/G	cg23711669	chr6:146136114	FBXO30	0.87	14.69	0.69	4.99e-35	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2180341	0.960	rs6900074	chr6:127685893	A/G	cg24812749	chr6:127587940	RNF146	1.02	13.36	0.66	1.31e-30	Breast cancer;
SARC	cis	rs3762637	1.000	rs3762637	chr3:122145324	C/T	cg24169773	chr3:122142474	KPNA1	-0.56	-5.7	-0.35	3.6e-8	LDL cholesterol levels;
SARC	cis	rs72653721	0.756	rs116642513	chr6:11059211	A/G	cg13562911	chr6:11044106	ELOVL2	0.44	4.95	0.31	1.43e-6	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	cis	rs7208859	0.623	rs58908911	chr17:29244558	C/T	cg13385521	chr17:29058706	SUZ12P	0.9	7.34	0.43	3.55e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs7927592	0.956	rs7116899	chr11:68385535	G/T	cg01657329	chr11:68192670	LRP5	-0.4	-4.96	-0.31	1.37e-6	Total body bone mineral density;
SARC	cis	rs1401999	0.934	rs1132776	chr3:183696402	A/G	cg01324343	chr3:183735012	ABCC5	0.66	13.23	0.65	3.66e-30	Anterior chamber depth;
SARC	cis	rs2153535	0.580	rs1932279	chr6:8473653	T/C	cg21535247	chr6:8435926	SLC35B3	0.54	6.79	0.41	9.19e-11	Motion sickness;
SARC	cis	rs4481887	0.821	rs7515408	chr1:248425738	C/T	cg00666640	chr1:248458726	OR2T12	0.34	5.45	0.34	1.25e-7	Common traits (Other);
SARC	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg02034447	chr16:89574710	SPG7	-0.48	-6.49	-0.39	5.22e-10	Multiple myeloma (IgH translocation);
SARC	cis	rs7772486	0.719	rs702317	chr6:146005010	C/T	cg05347473	chr6:146136440	FBXO30	-0.55	-7.76	-0.45	2.64e-13	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7666738	0.819	rs13120307	chr4:99036100	A/C	cg05340658	chr4:99064831	C4orf37	0.66	8.81	0.5	2.97e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6815814	1.000	rs11722836	chr4:38811529	T/A	cg09316306	chr4:38807337	TLR1	0.5	5.22	0.32	3.93e-7	Breast cancer;
SARC	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg16325326	chr1:53192061	ZYG11B	0.73	10.85	0.58	1.77e-22	Monocyte count;
SARC	cis	rs7000551	0.689	rs10110254	chr8:22309551	G/T	cg12081754	chr8:22256438	SLC39A14	0.61	8.5	0.49	2.27e-15	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
SARC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg21747090	chr2:27597821	SNX17	-0.55	-7.68	-0.45	4.44e-13	Total body bone mineral density;
SARC	cis	rs1059312	0.808	rs2170989	chr12:129291317	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.45	5.58	0.34	6.7e-8	Systemic lupus erythematosus;
SARC	cis	rs6430585	0.528	rs309161	chr2:136688749	A/G	cg07169764	chr2:136633963	MCM6	-0.93	-11.94	-0.62	5.72e-26	Corneal structure;
SARC	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg12463550	chr7:65579703	CRCP	-0.49	-5.3	-0.33	2.64e-7	Aortic root size;
SARC	cis	rs55871839	0.708	rs4738732	chr8:59809943	A/G	cg07426533	chr8:59803705	TOX	0.41	5.41	0.33	1.6e-7	Pneumonia;
SARC	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg07701084	chr6:150067640	NUP43	0.4	5.38	0.33	1.78e-7	Lung cancer;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg21348526	chr15:38647056	SPRED1	0.5	6.53	0.39	4.11e-10	Thyroid stimulating hormone;
SARC	cis	rs7914558	0.966	rs10748836	chr10:104693917	G/A	cg04362960	chr10:104952993	NT5C2	0.41	4.95	0.31	1.43e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg09021430	chr5:549028	NA	-0.45	-5.7	-0.35	3.69e-8	Lung disease severity in cystic fibrosis;
SARC	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg20965017	chr5:231967	SDHA	-0.55	-5.26	-0.33	3.23e-7	Breast cancer;
SARC	cis	rs9398803	0.723	rs853975	chr6:127070234	C/T	cg19875578	chr6:126661172	C6orf173	-0.6	-8.27	-0.48	1.04e-14	Male-pattern baldness;
SARC	cis	rs6690583	0.623	rs12047435	chr1:85452927	T/G	cg22153463	chr1:85462885	MCOLN2	0.72	6.84	0.41	6.88e-11	Serum sulfate level;
SARC	cis	rs11190604	1.000	rs7071271	chr10:102264824	G/A	cg07080220	chr10:102295463	HIF1AN	0.78	9.5	0.53	2.76e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs9948	0.786	rs62152783	chr2:97457389	T/A	cg01990225	chr2:97406019	LMAN2L	-1.0	-7.3	-0.43	4.63e-12	Erectile dysfunction and prostate cancer treatment;
SARC	cis	rs4481887	0.861	rs4575112	chr1:248473534	A/G	cg01631408	chr1:248437212	OR2T33	-0.39	-5.06	-0.31	8.56e-7	Common traits (Other);
SARC	cis	rs9430161	0.579	rs10864486	chr1:11040979	A/G	cg27631724	chr1:11040367	C1orf127	0.4	5.93	0.36	1.06e-8	Ewing sarcoma;
SARC	cis	rs11971779	0.715	rs10265	chr7:139026152	T/G	cg23387468	chr7:139079360	LUC7L2	0.33	4.74	0.3	3.79e-6	Diisocyanate-induced asthma;
SARC	cis	rs2251381	0.515	rs2832299	chr21:30749237	G/C	cg08807101	chr21:30365312	RNF160	0.53	6.62	0.4	2.43e-10	Selective IgA deficiency;
SARC	cis	rs2153535	0.623	rs2152346	chr6:8454652	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	10.67	0.57	6.5600000000000005e-22	Motion sickness;
SARC	cis	rs13191362	0.938	rs13192618	chr6:163132822	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.53	5.42	0.33	1.48e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	trans	rs6600671	1.000	rs12145080	chr1:121185531	C/T	cg00646200	chr1:148855367	NA	-0.51	-7.09	-0.42	1.62e-11	Hip geometry;
SARC	cis	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg00800038	chr16:89945340	TCF25	-0.78	-5.4	-0.33	1.6e-7	Skin colour saturation;
SARC	cis	rs6952809	0.532	rs2057840	chr7:2432797	C/G	cg05083358	chr7:2394359	EIF3B	-0.48	-4.72	-0.3	4.06e-6	Multiple sclerosis;
SARC	cis	rs3768617	0.528	rs10911240	chr1:183062948	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.65	0.57	7.77e-22	Fuchs's corneal dystrophy;
SARC	cis	rs9911578	0.935	rs2567912	chr17:56731270	T/C	cg12560992	chr17:57184187	TRIM37	0.83	11.29	0.59	7.52e-24	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg20607798	chr8:58055168	NA	0.6	5.35	0.33	2.05e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7829975	0.509	rs2945269	chr8:8115578	G/C	cg14343924	chr8:8086146	FLJ10661	0.44	5.07	0.31	8.28e-7	Mood instability;
SARC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.63	-6.57	-0.4	3.29e-10	Platelet count;
SARC	cis	rs17376456	1.000	rs13154249	chr5:93550508	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.61	5.17	0.32	5e-7	Diabetic retinopathy;
SARC	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg15448220	chr1:150897856	SETDB1	0.46	6.02	0.37	6.66e-9	Tonsillectomy;
SARC	cis	rs2070488	0.965	rs2051215	chr3:38560345	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.82	-13.55	-0.66	3.11e-31	Electrocardiographic conduction measures;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg02544571	chr7:139187165	NA	-0.81	-7.02	-0.42	2.47e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6908034	0.607	rs73376680	chr6:19808099	G/A	cg02682789	chr6:19804855	NA	0.72	5.71	0.35	3.37e-8	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs2153535	0.580	rs9393022	chr6:8466588	T/C	cg23788917	chr6:8435910	SLC35B3	0.64	8.39	0.48	4.57e-15	Motion sickness;
SARC	cis	rs926938	0.560	rs360610	chr1:115393915	T/C	cg12756093	chr1:115239321	AMPD1	0.38	5.07	0.32	8.11e-7	Autism;
SARC	cis	rs11190604	1.000	rs2489053	chr10:102353341	A/G	cg07080220	chr10:102295463	HIF1AN	0.74	8.26	0.48	1.08e-14	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs228437	0.770	rs376192	chr6:134904524	A/G	cg24504307	chr6:134963096	NA	-0.42	-4.75	-0.3	3.52e-6	Melanoma;
SARC	cis	rs11190604	1.000	rs10883496	chr10:102221931	T/C	cg07080220	chr10:102295463	HIF1AN	0.76	9.5	0.53	2.59e-18	Palmitoleic acid (16:1n-7) levels;
SARC	trans	rs10771431	0.967	rs7137443	chr12:9372029	C/T	cg27600084	chr12:12264075	NA	0.56	7.8	0.46	2.08e-13	Breast size;
SARC	cis	rs10992471	0.603	rs10761163	chr9:95313287	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.45	-0.34	1.25e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs7312933	0.558	rs2178753	chr12:42732804	T/C	cg19980929	chr12:42632907	YAF2	-0.44	-6.42	-0.39	7.61e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg05368731	chr17:41323189	NBR1	0.65	7.83	0.46	1.71e-13	Menopause (age at onset);
SARC	cis	rs8014131	0.615	rs34929848	chr14:85987969	T/C	cg10406690	chr14:85995726	FLRT2	0.41	5.26	0.33	3.29e-7	Menarche (age at onset);
SARC	cis	rs910316	0.763	rs175044	chr14:75472109	G/A	cg08847533	chr14:75593920	NEK9	-0.82	-11.31	-0.6	6.25e-24	Height;
SARC	cis	rs6448317	0.520	rs13116411	chr4:24928949	G/A	cg21108841	chr4:24914750	CCDC149	-0.6	-7.59	-0.45	7.75e-13	Heschl's gyrus morphology;
SARC	trans	rs7824557	0.527	rs57629785	chr8:11235150	C/A	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.7	-0.5	6e-16	Retinal vascular caliber;
SARC	cis	rs10504229	0.679	rs72649107	chr8:58030453	C/A	cg08280861	chr8:58055591	NA	0.57	5.28	0.33	3.01e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs6456156	0.565	rs6921588	chr6:167494397	G/T	cg07741184	chr6:167504864	NA	0.33	6.15	0.37	3.33e-9	Primary biliary cholangitis;
SARC	cis	rs6582630	0.638	rs12423236	chr12:38548162	G/A	cg13010199	chr12:38710504	ALG10B	-0.52	-6.44	-0.39	6.84e-10	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg08564027	chr20:61660810	NA	0.75	11.24	0.59	1.09e-23	Prostate cancer (SNP x SNP interaction);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg05310613	chr6:139456890	HECA	0.51	6.39	0.39	8.85e-10	Height;
SARC	cis	rs698813	0.674	rs713447	chr2:44505185	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.26	0.38	1.85e-9	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
SARC	cis	rs1538970	0.962	rs2185549	chr1:45814103	C/T	cg05343316	chr1:45956843	TESK2	-0.7	-8.23	-0.47	1.36e-14	Platelet count;
SARC	cis	rs6831352	0.918	rs13140423	chr4:100050400	T/C	cg12011299	chr4:100065546	ADH4	-0.34	-5.74	-0.35	2.97e-8	Alcohol dependence;
SARC	trans	rs1814175	0.527	rs7110797	chr11:49644096	T/C	cg15704280	chr7:45808275	SEPT13	-0.72	-8.44	-0.48	3.35e-15	Height;
SARC	cis	rs4803468	1.000	rs166925	chr19:41926098	T/C	cg14132834	chr19:41945861	ATP5SL	-0.57	-7.5	-0.44	1.34e-12	Height;
SARC	cis	rs11190604	1.000	rs3750626	chr10:102266316	C/T	cg07080220	chr10:102295463	HIF1AN	0.78	9.5	0.53	2.76e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs4642101	0.662	rs57411588	chr3:12820384	C/G	cg05775895	chr3:12838266	CAND2	0.84	15.68	0.72	2.67e-38	QRS complex (12-leadsum);
SARC	cis	rs1044826	1.000	rs9848241	chr3:139129631	C/G	cg15131784	chr3:139108705	COPB2	0.45	5.2	0.32	4.31e-7	Obesity-related traits;
SARC	cis	rs2239815	0.515	rs9625591	chr22:29232564	A/G	cg15103426	chr22:29168792	CCDC117	0.61	6.33	0.38	1.25e-9	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
SARC	cis	rs929354	0.772	rs2051876	chr7:157009037	A/G	cg05182265	chr7:156933206	UBE3C	0.33	4.98	0.31	1.21e-6	Body mass index;
SARC	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.33	-4.93	-0.31	1.54e-6	Total body bone mineral density;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg21344215	chr2:27851972	GPN1;CCDC121	0.59	8.14	0.47	2.38e-14	Thyroid stimulating hormone;
SARC	cis	rs6999452	1.000	rs1021066	chr8:106368050	T/G	cg12032713	chr8:106369363	ZFPM2	-0.3	-4.89	-0.31	1.85e-6	Gut microbiome composition (summer);
SARC	cis	rs6121246	0.523	rs6060286	chr20:30197663	C/A	cg21427119	chr20:30132790	HM13	-0.48	-5.29	-0.33	2.84e-7	Mean corpuscular hemoglobin;
SARC	cis	rs826838	1.000	rs11183214	chr12:38692938	C/T	cg13010199	chr12:38710504	ALG10B	0.82	11.91	0.62	7.24e-26	Heart rate;
SARC	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg11890956	chr21:40555474	PSMG1	-0.69	-9.03	-0.51	6.64e-17	Menarche (age at onset);
SARC	cis	rs1784581	0.588	rs7765624	chr6:162427462	C/A	cg17173639	chr6:162384350	PARK2	0.52	6.66	0.4	1.93e-10	Itch intensity from mosquito bite;
SARC	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-6.41	-0.39	7.99e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs1008375	0.932	rs9291660	chr4:17663414	A/G	cg16339924	chr4:17578868	LAP3	0.65	8.28	0.48	9.62e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7027203	0.797	rs4744294	chr9:96612114	C/G	cg14598338	chr9:96623480	NA	-0.54	-7.62	-0.45	6.39e-13	DNA methylation (variation);
SARC	cis	rs73198271	0.530	rs11778326	chr8:8651566	T/G	cg01851573	chr8:8652454	MFHAS1	0.39	4.72	0.3	3.99e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg11644478	chr21:40555479	PSMG1	-0.56	-6.72	-0.4	1.38e-10	Menarche (age at onset);
SARC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg11494091	chr17:61959527	GH2	0.52	7.7	0.45	3.81e-13	Prudent dietary pattern;
SARC	cis	rs2425143	1.000	rs13038622	chr20:34319343	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.67	5.47	0.34	1.15e-7	Blood protein levels;
SARC	cis	rs2594989	0.779	rs2437686	chr3:11588989	C/T	cg00170343	chr3:11313890	ATG7	0.55	5.86	0.36	1.54e-8	Circulating chemerin levels;
SARC	cis	rs911263	0.603	rs60593979	chr14:68773298	C/G	cg18825221	chr14:68749962	RAD51L1	0.41	7.36	0.43	3.06e-12	Primary biliary cholangitis;
SARC	cis	rs2439831	0.867	rs2242068	chr15:43699304	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	7.84	0.46	1.61e-13	Lung cancer in ever smokers;
SARC	trans	rs36093844	0.615	rs77258124	chr11:85578081	G/A	cg27065003	chr5:122429449	PRDM6	-0.54	-6.42	-0.39	7.74e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
SARC	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg14784868	chr12:69753453	YEATS4	0.63	8.8	0.5	3.15e-16	Cerebrospinal fluid biomarker levels;
SARC	cis	rs427394	1.000	rs427394	chr5:6745875	A/G	cg10857441	chr5:6722123	POLS	-0.34	-5.32	-0.33	2.37e-7	Menopause (age at onset);
SARC	cis	rs2425143	0.915	rs6060597	chr20:34370100	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.74	6.35	0.38	1.1e-9	Blood protein levels;
SARC	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg20607798	chr8:58055168	NA	0.56	5.51	0.34	9.64e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7587476	0.601	rs13021937	chr2:215673937	C/T	cg04004882	chr2:215674386	BARD1	-0.59	-6.74	-0.4	1.25e-10	Neuroblastoma;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg01074347	chr1:93427451	FAM69A	0.5	6.63	0.4	2.27e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	trans	rs1814175	0.645	rs1874969	chr11:49826700	G/A	cg15704280	chr7:45808275	SEPT13	-0.88	-13.93	-0.67	1.69e-32	Height;
SARC	cis	rs6060717	0.654	rs6058347	chr20:34483781	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-6.74	-0.4	1.26e-10	Hip circumference adjusted for BMI;
SARC	cis	rs959260	0.614	rs930296	chr17:73404168	C/T	cg00200289	chr17:73401734	GRB2	0.53	4.88	0.3	2.01e-6	Systemic lupus erythematosus;
SARC	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg11062466	chr8:58055876	NA	0.59	5.74	0.35	2.95e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.66	0.35	4.44e-8	Bipolar disorder;
SARC	cis	rs644799	0.526	rs693172	chr11:95636618	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	6.07	0.37	5.2e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs1801251	0.963	rs13011298	chr2:233612996	A/G	cg25237894	chr2:233734115	C2orf82	0.38	5.03	0.31	9.71e-7	Coronary artery disease;
SARC	cis	rs10489202	0.954	rs12403023	chr1:168086999	A/G	cg17859187	chr1:168147929	TIPRL	0.44	4.79	0.3	2.91e-6	Schizophrenia;
SARC	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg18252515	chr7:66147081	NA	-1.3	-11.62	-0.61	6.33e-25	Diabetic kidney disease;
SARC	cis	rs7824557	0.606	rs1047950	chr8:11185096	G/C	cg21775007	chr8:11205619	TDH	0.67	9.02	0.51	7.03e-17	Retinal vascular caliber;
SARC	cis	rs2282802	0.685	rs7730245	chr5:139628163	C/A	cg26211634	chr5:139558579	C5orf32	0.41	5.28	0.33	2.96e-7	Intelligence (multi-trait analysis);
SARC	cis	rs8072100	0.701	rs4794053	chr17:45769551	G/A	cg08085267	chr17:45401833	C17orf57	-0.42	-4.95	-0.31	1.42e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs10504073	0.647	rs10105794	chr8:50012793	G/C	cg00325661	chr8:49890786	NA	0.5	6.82	0.41	7.84e-11	Blood metabolite ratios;
SARC	cis	rs9388451	0.872	rs2008027	chr6:126052359	A/G	cg05901451	chr6:126070800	HEY2	-0.67	-9.17	-0.51	2.58e-17	Brugada syndrome;
SARC	cis	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg14541582	chr5:601475	NA	-0.4	-4.98	-0.31	1.24e-6	Obesity-related traits;
SARC	cis	rs734999	0.588	rs2260976	chr1:2527678	A/G	cg18854424	chr1:2615690	NA	-0.32	-5.03	-0.31	9.77e-7	Ulcerative colitis;
SARC	cis	rs1594829	0.553	rs1564577	chr8:26164723	G/A	cg11498726	chr8:26250323	BNIP3L	-0.4	-5.27	-0.33	3.09e-7	Height;
SARC	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg24675658	chr1:53192096	ZYG11B	0.57	8.08	0.47	3.54e-14	Monocyte count;
SARC	cis	rs698833	0.819	rs1372078	chr2:44543389	A/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.59	-7.27	-0.43	5.34e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs10789491	0.951	rs35050319	chr1:47103886	C/A	cg15501359	chr1:47185051	KIAA0494	-0.69	-6.98	-0.42	3.13e-11	Response to hepatitis C treatment;
SARC	cis	rs2180341	1.000	rs9398838	chr6:127635285	C/T	cg17762328	chr6:126965162	NA	-0.46	-5.29	-0.33	2.88e-7	Breast cancer;
SARC	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg19671926	chr4:122722719	EXOSC9	-0.57	-6.44	-0.39	6.6e-10	Type 2 diabetes;
SARC	cis	rs1008375	0.966	rs28750296	chr4:17685826	A/T	cg02297831	chr4:17616191	MED28	0.43	5.43	0.33	1.44e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs12701220	0.689	rs12536282	chr7:1115650	C/T	cg02733842	chr7:1102375	C7orf50	-0.58	-6.73	-0.4	1.34e-10	Bronchopulmonary dysplasia;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg06506128	chr11:95565688	CEP57	0.44	6.33	0.38	1.24e-9	Thyroid stimulating hormone;
SARC	cis	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg18252515	chr7:66147081	NA	-1.43	-12.98	-0.65	2.35e-29	Gout;
SARC	cis	rs13401104	0.754	rs11902623	chr2:237117624	G/A	cg19324714	chr2:237145437	ASB18	0.57	5.66	0.35	4.32e-8	Educational attainment;
SARC	cis	rs6446601	1	rs6446601	chr4:4300410	A/C	cg14436098	chr4:4690634	NA	0.62	4.94	0.31	1.49e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7089973	0.604	rs11196942	chr10:116596872	G/A	cg03647239	chr10:116582469	FAM160B1	0.51	6.61	0.4	2.57e-10	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs2486288	0.656	rs1719236	chr15:45577783	G/T	cg15395560	chr15:45543142	SLC28A2	0.28	5.15	0.32	5.41e-7	Glomerular filtration rate;
SARC	cis	rs76419734	1.000	rs79571438	chr4:106616198	C/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.81	4.9	0.31	1.76e-6	Post bronchodilator FEV1;
SARC	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg25894440	chr7:65020034	NA	-0.77	-5.85	-0.36	1.67e-8	Diabetic kidney disease;
SARC	cis	rs1215050	0.765	rs1530905	chr4:98805705	A/G	cg05340658	chr4:99064831	C4orf37	0.44	5.85	0.36	1.62e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs826838	0.684	rs12367400	chr12:38618673	G/T	cg26384229	chr12:38710491	ALG10B	0.9	13.74	0.67	7.52e-32	Heart rate;
SARC	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg17376030	chr22:41985996	PMM1	-0.64	-8.25	-0.48	1.17e-14	Vitiligo;
SARC	cis	rs9814567	0.752	rs4955544	chr3:134332776	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.51	-6.73	-0.4	1.29e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs10992471	0.528	rs1924244	chr9:95224952	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.43	-4.84	-0.3	2.37e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg02711726	chr17:80685570	FN3KRP	-0.55	-6.84	-0.41	7.05e-11	Glycated hemoglobin levels;
SARC	cis	rs9398803	0.723	rs853971	chr6:127066190	T/C	cg20229609	chr6:126660872	C6orf173	-0.33	-4.78	-0.3	3.1e-6	Male-pattern baldness;
SARC	cis	rs921968	0.565	rs13408305	chr2:219628183	G/A	cg02176678	chr2:219576539	TTLL4	-0.32	-4.95	-0.31	1.41e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.6	-6.31	-0.38	1.42e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs7833986	0.501	rs2976038	chr8:57028864	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.73	7.47	0.44	1.56e-12	Height;
SARC	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg00149659	chr3:10157352	C3orf10	0.7	6.89	0.41	5.14e-11	Alzheimer's disease;
SARC	cis	rs9818758	0.607	rs9837237	chr3:49215583	G/T	cg07636037	chr3:49044803	WDR6	-0.78	-6.86	-0.41	6.17e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg17376030	chr22:41985996	PMM1	0.64	7.79	0.45	2.15e-13	Vitiligo;
SARC	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg08219700	chr8:58056026	NA	0.6	5.71	0.35	3.49e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2204008	0.547	rs12318267	chr12:38250905	T/G	cg14851346	chr12:38532713	NA	-0.45	-5.39	-0.33	1.71e-7	Bladder cancer;
SARC	cis	rs9916302	0.800	rs8081220	chr17:37473157	A/C	cg15445000	chr17:37608096	MED1	-0.46	-5.65	-0.35	4.66e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs8180040	1.000	rs11130127	chr3:47398793	C/G	cg27129171	chr3:47204927	SETD2	-0.7	-9.89	-0.54	1.77e-19	Colorectal cancer;
SARC	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg22800045	chr5:56110881	MAP3K1	-0.71	-7.58	-0.44	8.27e-13	Initial pursuit acceleration;
SARC	trans	rs61931739	0.517	rs11052964	chr12:34010996	G/C	cg26384229	chr12:38710491	ALG10B	0.86	12.21	0.62	7.79e-27	Morning vs. evening chronotype;
SARC	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg13206674	chr6:150067644	NUP43	0.46	6.03	0.37	6.45e-9	Lung cancer;
SARC	cis	rs2290159	0.509	rs6763925	chr3:12515602	T/C	cg23032965	chr3:12705835	RAF1	0.45	5.0	0.31	1.14e-6	Cholesterol, total;
SARC	cis	rs78545713	0.536	rs11755618	chr6:26215802	C/T	cg00631329	chr6:26305371	NA	0.72	4.99	0.31	1.18e-6	Iron status biomarkers (total iron binding capacity);
SARC	cis	rs1008375	1.000	rs2109522	chr4:17658645	T/A	cg02297831	chr4:17616191	MED28	0.49	6.31	0.38	1.39e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs3733589	1.000	rs13106922	chr4:10021759	A/G	cg16430538	chr4:10459836	ZNF518B	0.61	4.92	0.31	1.62e-6	Renal overload gout;
SARC	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.38	5.13	0.32	6.11e-7	Total body bone mineral density;
SARC	cis	rs1113500	0.636	rs3853493	chr1:108637193	G/A	cg06207961	chr1:108661230	NA	0.38	4.99	0.31	1.2e-6	Growth-regulated protein alpha levels;
SARC	cis	rs7614311	0.731	rs3774721	chr3:63954649	A/G	cg22134162	chr3:63841271	THOC7	-0.46	-4.98	-0.31	1.22e-6	Lung function (FVC);Lung function (FEV1);
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg09928813	chr16:30794679	ZNF629	0.48	6.26	0.38	1.81e-9	Schizophrenia;
SARC	cis	rs76419734	0.702	rs72673822	chr4:106719192	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.75	4.95	0.31	1.43e-6	Post bronchodilator FEV1;
SARC	cis	rs4891159	0.824	rs17059362	chr18:74144307	G/A	cg24786174	chr18:74118243	ZNF516	-0.64	-8.97	-0.51	9.84e-17	Longevity;
SARC	cis	rs10504073	0.584	rs4873307	chr8:49950417	C/T	cg00325661	chr8:49890786	NA	0.51	6.87	0.41	5.95e-11	Blood metabolite ratios;
SARC	cis	rs9916302	0.706	rs667193	chr17:37448835	T/C	cg07936489	chr17:37558343	FBXL20	0.75	8.92	0.5	1.37e-16	Glomerular filtration rate (creatinine);
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg10591475	chr6:28109693	ZNF192	0.52	6.71	0.4	1.51e-10	Lung adenocarcinoma;
SARC	cis	rs708547	0.874	rs73242624	chr4:57847420	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.69	8.18	0.47	1.82e-14	Response to bleomycin (chromatid breaks);
SARC	trans	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg21659725	chr3:3221576	CRBN	0.81	12.44	0.63	1.38e-27	Intelligence (multi-trait analysis);
SARC	trans	rs9388451	0.587	rs1739385	chr6:126099939	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.59	-7.62	-0.45	6.23e-13	Brugada syndrome;
SARC	cis	rs2425143	1.000	rs73902914	chr20:34432882	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.6	4.77	0.3	3.27e-6	Blood protein levels;
SARC	cis	rs1865760	0.566	rs2032443	chr6:26046802	A/G	cg10373733	chr6:25993375	NA	0.41	5.06	0.31	8.65e-7	Height;
SARC	cis	rs453301	0.686	rs3895823	chr8:8873646	T/C	cg11608241	chr8:8085544	FLJ10661	-0.45	-5.64	-0.35	4.89e-8	Joint mobility (Beighton score);
SARC	cis	rs367943	1.000	rs367943	chr5:112809728	C/T	cg12552261	chr5:112820674	MCC	0.46	5.25	0.33	3.35e-7	Type 2 diabetes;
SARC	cis	rs6570726	0.846	rs1935616	chr6:145943512	C/T	cg23711669	chr6:146136114	FBXO30	0.77	12.35	0.63	2.82e-27	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg16141378	chr3:129829833	LOC729375	0.56	6.93	0.41	4.1e-11	Neuroticism;
SARC	cis	rs875971	1.000	rs1183245	chr7:65541185	C/T	cg12463550	chr7:65579703	CRCP	-0.48	-5.67	-0.35	4.28e-8	Aortic root size;
SARC	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg05896524	chr21:47604654	C21orf56	0.4	4.75	0.3	3.6e-6	Testicular germ cell tumor;
SARC	cis	rs722599	0.748	rs929579	chr14:75330697	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.45	-5.65	-0.35	4.71e-8	IgG glycosylation;
SARC	cis	rs57994353	0.568	rs10870171	chr9:139318530	C/T	cg14169450	chr9:139327907	INPP5E	0.38	4.73	0.3	3.87e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.42	5.1	0.32	6.99e-7	Electroencephalogram traits;
SARC	cis	rs9457247	0.967	rs433191	chr6:167409662	T/A	cg07741184	chr6:167504864	NA	0.3	5.59	0.34	6.38e-8	Crohn's disease;
SARC	cis	rs911555	0.755	rs10144051	chr14:103885931	A/C	cg24130564	chr14:104152367	KLC1	-0.5	-5.8	-0.36	2.12e-8	Intelligence (multi-trait analysis);
SARC	cis	rs78456975	1.000	rs10177095	chr2:1570976	C/A	cg01028140	chr2:1542097	TPO	-0.47	-4.88	-0.3	1.98e-6	Placebo response in major depressive disorder (% change in symptom score);
SARC	cis	rs3741798	1.000	rs61922047	chr12:12496471	C/A	cg08615371	chr12:12503544	MANSC1	0.68	5.43	0.34	1.43e-7	Cerebrospinal fluid biomarker levels;
SARC	cis	rs644799	0.562	rs1254989	chr11:95508121	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.54	6.76	0.4	1.09e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs796364	0.951	rs3098341	chr2:200792498	G/T	cg23649088	chr2:200775458	C2orf69	0.64	6.06	0.37	5.52e-9	Schizophrenia;
SARC	cis	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg15556689	chr8:8085844	FLJ10661	0.5	6.29	0.38	1.57e-9	Neuroticism;
SARC	cis	rs4253772	0.591	rs6008546	chr22:46686377	T/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.68	6.14	0.37	3.44e-9	LDL cholesterol;Cholesterol, total;
SARC	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg12648201	chr2:27665141	KRTCAP3	-0.32	-4.86	-0.3	2.17e-6	Total body bone mineral density;
SARC	cis	rs3733585	0.762	rs6449217	chr4:10009151	T/A	cg11266682	chr4:10021025	SLC2A9	0.37	6.41	0.39	8.1e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs73198271	0.737	rs535094	chr8:8633928	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.35	-0.38	1.13e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs75920871	0.588	rs10892055	chr11:116868371	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.48	-4.95	-0.31	1.39e-6	Subjective well-being;
SARC	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg11843238	chr5:131593191	PDLIM4	0.43	5.82	0.36	1.93e-8	Acylcarnitine levels;
SARC	cis	rs1018836	0.608	rs6986165	chr8:91477062	C/G	cg16814680	chr8:91681699	NA	-0.65	-9.25	-0.52	1.48e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	trans	rs1814175	0.616	rs1722020	chr11:49904189	G/A	cg15704280	chr7:45808275	SEPT13	-0.88	-13.85	-0.67	3.16e-32	Height;
SARC	cis	rs561341	1.000	rs473356	chr17:30321762	G/C	cg00745463	chr17:30367425	LRRC37B	-0.69	-5.53	-0.34	8.77e-8	Hip circumference adjusted for BMI;
SARC	cis	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg22857025	chr5:266934	NA	-1.05	-11.52	-0.6	1.36e-24	Breast cancer;
SARC	cis	rs7412746	0.658	rs12090215	chr1:150893660	C/A	cg10589385	chr1:150898437	SETDB1	0.42	5.64	0.35	4.91e-8	Melanoma;
SARC	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg17221315	chr6:27791827	HIST1H4J	0.48	4.93	0.31	1.55e-6	Depression;
SARC	cis	rs60871478	0.947	rs62432862	chr7:807719	G/C	cg05535760	chr7:792225	HEATR2	0.78	8.06	0.47	3.86e-14	Cerebrospinal P-tau181p levels;
SARC	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg24642844	chr7:1081250	C7orf50	-0.59	-6.21	-0.38	2.41e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs2997447	0.739	rs3008223	chr1:26389633	T/C	cg19633962	chr1:26362018	EXTL1	-0.59	-5.09	-0.32	7.48e-7	QRS complex (12-leadsum);
SARC	cis	rs2153535	0.580	rs7769020	chr6:8457724	G/A	cg23788917	chr6:8435910	SLC35B3	0.62	8.27	0.48	1.04e-14	Motion sickness;
SARC	cis	rs56011263	0.687	rs73221103	chr4:706740	T/C	cg20735989	chr4:730612	PCGF3	-0.48	-5.53	-0.34	8.69e-8	White blood cell count;
SARC	cis	rs7647973	0.961	rs6778080	chr3:49317338	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.58	-6.26	-0.38	1.83e-9	Menarche (age at onset);
SARC	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg27572855	chr1:25598939	RHD	0.54	9.4	0.52	5.29e-18	Erythrocyte sedimentation rate;
SARC	cis	rs7772486	0.743	rs1292339	chr6:145967086	C/T	cg23711669	chr6:146136114	FBXO30	-0.78	-12.19	-0.62	9.44e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.74	8.74	0.5	4.58e-16	Height;
SARC	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg24399712	chr22:39784796	NA	-0.43	-5.71	-0.35	3.49e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2425143	1.000	rs6060578	chr20:34305445	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-5.92	-0.36	1.12e-8	Blood protein levels;
SARC	cis	rs10791323	0.569	rs10791328	chr11:133713730	A/G	cg14349672	chr11:133703707	NA	-0.38	-5.51	-0.34	9.27e-8	Childhood ear infection;
SARC	cis	rs79149102	0.579	rs76900720	chr15:75348895	A/T	cg09165964	chr15:75287851	SCAMP5	-1.04	-9.05	-0.51	5.99e-17	Lung cancer;
SARC	cis	rs9420	0.961	rs11604333	chr11:57467035	C/G	cg23127183	chr11:57508653	C11orf31	-0.56	-6.36	-0.38	1.08e-9	Schizophrenia;
SARC	cis	rs4727027	0.933	rs4725800	chr7:148862516	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.52	6.28	0.38	1.6e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs748404	0.660	rs2249952	chr15:43720533	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	5.75	0.35	2.76e-8	Lung cancer;
SARC	cis	rs7582720	1.000	rs114395475	chr2:203769112	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.31	0.43	4.24e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs2070488	1.000	rs4147025	chr3:38456531	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	14.38	0.69	5.41e-34	Electrocardiographic conduction measures;
SARC	cis	rs4319547	0.695	rs113841747	chr12:122886088	G/T	cg23029597	chr12:123009494	RSRC2	0.43	5.34	0.33	2.26e-7	Body mass index;
SARC	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg25072359	chr17:41440525	NA	0.48	5.62	0.35	5.43e-8	Menopause (age at onset);
SARC	cis	rs9420	0.890	rs547891	chr11:57499065	C/T	cg19752551	chr11:57585705	CTNND1	0.4	5.43	0.34	1.42e-7	Schizophrenia;
SARC	cis	rs35306767	0.903	rs7067865	chr10:908387	C/T	cg26597838	chr10:835615	NA	0.82	8.37	0.48	5.3e-15	Eosinophil percentage of granulocytes;
SARC	trans	rs17685	0.753	rs7804598	chr7:75702578	C/T	cg19862616	chr7:65841803	NCRNA00174	0.61	7.41	0.44	2.28e-12	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs62244186	0.541	rs3804583	chr3:44884647	G/T	cg15687855	chr3:44754131	ZNF502	-0.36	-5.36	-0.33	1.95e-7	Depressive symptoms;
SARC	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg07701084	chr6:150067640	NUP43	0.41	5.39	0.33	1.75e-7	Lung cancer;
SARC	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg11764359	chr7:65958608	NA	-0.84	-12.27	-0.63	5.04e-27	Aortic root size;
SARC	cis	rs2251381	0.523	rs2832306	chr21:30754468	C/T	cg08807101	chr21:30365312	RNF160	-0.48	-6.01	-0.37	7.2e-9	Selective IgA deficiency;
SARC	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.43	5.35	0.33	2.05e-7	Tonsillectomy;
SARC	cis	rs1113500	0.799	rs1777459	chr1:108584999	G/C	cg06207961	chr1:108661230	NA	-0.4	-5.07	-0.32	8.14e-7	Growth-regulated protein alpha levels;
SARC	cis	rs3771570	1.000	rs62193256	chr2:242362168	C/T	cg21155796	chr2:242212141	HDLBP	0.7	6.27	0.38	1.74e-9	Prostate cancer;
SARC	cis	rs7264396	0.563	rs6060570	chr20:34291166	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-7.17	-0.43	9.99e-12	Total cholesterol levels;
SARC	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg23758822	chr17:41437982	NA	0.9	11.47	0.6	1.98e-24	Menopause (age at onset);
SARC	cis	rs11719291	0.833	rs11715835	chr3:48770732	C/T	cg07636037	chr3:49044803	WDR6	-0.8	-6.78	-0.41	1e-10	Cognitive function;
SARC	cis	rs9818758	0.607	rs9850917	chr3:49286983	A/G	cg01304814	chr3:48885189	PRKAR2A	0.61	5.1	0.32	6.98e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs6834538	0.597	rs4833414	chr4:113469913	T/C	cg05193411	chr4:113558554	LARP7;C4orf21	0.4	4.93	0.31	1.53e-6	Free thyroxine concentration;
SARC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg01238044	chr22:24384105	GSTT1	-0.54	-6.7	-0.4	1.58e-10	Liver enzyme levels (gamma-glutamyl transferase);
SARC	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg08423350	chr4:57253668	AASDH	-0.56	-6.42	-0.39	7.75e-10	Brain volume in infants (cerebrospinal fluid);
SARC	cis	rs8180040	0.739	rs4683320	chr3:47152992	C/T	cg27129171	chr3:47204927	SETD2	0.67	9.47	0.53	3.36e-18	Colorectal cancer;
SARC	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg03806693	chr22:41940476	POLR3H	-0.89	-11.75	-0.61	2.37e-25	Vitiligo;
SARC	trans	rs3808502	0.526	rs11985709	chr8:11423083	A/C	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.37	-0.39	9.81e-10	Neuroticism;
SARC	cis	rs12472274	0.648	rs67102443	chr2:239084602	A/G	cg17459225	chr2:239074497	NA	0.46	5.86	0.36	1.54e-8	Phospholipid levels (plasma);
SARC	cis	rs11581859	0.587	rs56363327	chr1:99185632	A/G	cg20286094	chr1:99190917	SNX7	-0.41	-4.89	-0.31	1.85e-6	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs6582630	0.573	rs12319414	chr12:38267440	T/C	cg14851346	chr12:38532713	NA	-0.47	-5.62	-0.35	5.45e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs67311347	1.000	rs7633809	chr3:40517737	A/G	cg01475735	chr3:40494733	NA	0.47	5.43	0.34	1.4e-7	Renal cell carcinoma;
SARC	cis	rs2841277	0.712	rs2841280	chr14:105393556	G/C	cg21017887	chr14:105400489	NA	-0.54	-7.43	-0.44	2.05e-12	Rheumatoid arthritis;
SARC	cis	rs778371	0.630	rs13007579	chr2:233725364	G/A	cg16596103	chr2:233749413	NGEF	0.32	4.91	0.31	1.74e-6	Schizophrenia;
SARC	cis	rs17376456	1.000	rs34854140	chr5:93538169	G/A	cg25358565	chr5:93447407	FAM172A	1.34	14.19	0.68	2.28e-33	Diabetic retinopathy;
SARC	cis	rs1215050	0.740	rs11097580	chr4:98767255	C/A	cg05340658	chr4:99064831	C4orf37	0.44	5.85	0.36	1.62e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg26338869	chr17:61819248	STRADA	0.75	9.84	0.54	2.42e-19	Prudent dietary pattern;
SARC	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.46	5.78	0.35	2.32e-8	Lymphocyte counts;
SARC	cis	rs4969178	0.965	rs4969179	chr17:76391454	A/C	cg02836325	chr17:76403955	PGS1	0.31	4.78	0.3	3.09e-6	HDL cholesterol levels;
SARC	cis	rs7208859	0.562	rs11650923	chr17:29008167	G/A	cg13385521	chr17:29058706	SUZ12P	0.82	6.18	0.38	2.77e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs12142240	0.698	rs17357676	chr1:46812444	A/G	cg00530320	chr1:46809349	NSUN4	0.58	7.07	0.42	1.83e-11	Menopause (age at onset);
SARC	cis	rs67311347	0.824	rs59922539	chr3:40337110	G/A	cg24209194	chr3:40518798	ZNF619	0.55	7.02	0.42	2.45e-11	Renal cell carcinoma;
SARC	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2228479	0.557	rs62054639	chr16:89821489	C/T	cg00800038	chr16:89945340	TCF25	-0.74	-5.14	-0.32	5.75e-7	Skin colour saturation;
SARC	cis	rs72781680	0.948	rs113530757	chr2:24142500	G/A	cg06627628	chr2:24431161	ITSN2	-0.68	-6.44	-0.39	6.58e-10	Lymphocyte counts;
SARC	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg15448220	chr1:150897856	SETDB1	0.52	6.77	0.41	1.03e-10	Melanoma;
SARC	cis	rs6429082	0.818	rs704706	chr1:235614378	G/A	cg26050004	chr1:235667680	B3GALNT2	0.61	7.33	0.43	3.73e-12	Adiposity;
SARC	cis	rs2250402	0.510	rs6492926	chr15:40325829	T/G	cg02712587	chr15:40268421	EIF2AK4	-0.56	-4.79	-0.3	3.01e-6	Corneal curvature;
SARC	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg18876405	chr7:65276391	NA	0.46	5.25	0.33	3.41e-7	Aortic root size;
SARC	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg17971929	chr21:40555470	PSMG1	-0.57	-7.12	-0.42	1.31e-11	Menarche (age at onset);
SARC	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.5	6.04	0.37	6.12e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs2204008	0.628	rs10876106	chr12:37990767	A/G	cg13010199	chr12:38710504	ALG10B	0.74	9.81	0.54	3.15e-19	Bladder cancer;
SARC	cis	rs17376456	0.877	rs10059630	chr5:93459807	C/A	cg21475434	chr5:93447410	FAM172A	0.88	8.11	0.47	2.81e-14	Diabetic retinopathy;
SARC	cis	rs1957429	0.808	rs2357866	chr14:65336517	C/T	cg23373153	chr14:65346875	NA	0.97	9.74	0.54	4.9e-19	Pediatric areal bone mineral density (radius);
SARC	cis	rs1983170	1.000	rs10874785	chr1:92015243	G/A	cg25838465	chr1:92012736	NA	0.52	5.7	0.35	3.68e-8	Eosinophil percentage of white cells;
SARC	cis	rs2303759	0.666	rs66967196	chr19:49808894	G/A	cg22307029	chr19:49891270	CCDC155	0.59	6.64	0.4	2.13e-10	Multiple sclerosis;
SARC	trans	rs8073060	0.516	rs2376177	chr17:33938089	T/G	cg19694781	chr19:47549865	TMEM160	-0.64	-6.66	-0.4	1.97e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs11718455	0.960	rs6781618	chr3:44001933	C/T	cg08738300	chr3:44038990	NA	0.54	5.97	0.36	8.73e-9	Coronary artery disease;
SARC	cis	rs981844	1.000	rs2251997	chr4:154654067	A/G	cg14289246	chr4:154710475	SFRP2	-0.52	-5.93	-0.36	1.09e-8	Response to statins (LDL cholesterol change);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg11356547	chr5:32355062	ZFR	0.44	6.4	0.39	8.41e-10	Thyroid stimulating hormone;
SARC	cis	rs6701037	1.000	rs6677097	chr1:175123897	C/G	cg00321850	chr1:175162397	KIAA0040	-0.34	-5.08	-0.32	7.71e-7	Alcohol dependence;
SARC	cis	rs7937682	0.889	rs493865	chr11:111495178	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.9	-14.17	-0.68	2.83e-33	Primary sclerosing cholangitis;
SARC	trans	rs11098499	0.863	rs3775841	chr4:120425777	A/C	cg25214090	chr10:38739885	LOC399744	0.56	7.18	0.43	9.36e-12	Corneal astigmatism;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg09764440	chr19:18263350	PIK3R2	-0.51	-6.24	-0.38	2.02e-9	Breast cancer;
SARC	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg05896524	chr21:47604654	C21orf56	-0.59	-7.2	-0.43	8.32e-12	Testicular germ cell tumor;
SARC	cis	rs1448094	0.512	rs11117057	chr12:86248546	C/T	cg02569458	chr12:86230093	RASSF9	0.38	5.39	0.33	1.71e-7	Major depressive disorder;
SARC	cis	rs4851254	0.961	rs13000759	chr2:100753903	A/T	cg17356467	chr2:100759845	AFF3	-0.28	-4.76	-0.3	3.43e-6	Intelligence (multi-trait analysis);
SARC	cis	rs6430585	0.646	rs1057031	chr2:136633962	G/A	cg07169764	chr2:136633963	MCM6	1.17	17.45	0.75	3.6e-44	Corneal structure;
SARC	cis	rs7582720	1.000	rs72926779	chr2:203805929	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	7.17	0.43	9.62e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs9303401	0.659	rs62081314	chr17:56778328	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	11.79	0.61	1.87e-25	Cognitive test performance;
SARC	cis	rs4800452	0.826	rs4800149	chr18:20744254	A/C	cg13313047	chr18:20735648	CABLES1	0.48	5.57	0.34	7.08e-8	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
SARC	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg12698349	chr2:225449008	CUL3	-0.69	-9.34	-0.52	7.89e-18	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs7633770	0.786	rs6442012	chr3:46686346	A/G	cg11219411	chr3:46661640	NA	0.43	7.01	0.42	2.48e-11	Coronary artery disease;
SARC	cis	rs11098499	0.754	rs938056	chr4:120237453	C/T	cg24375607	chr4:120327624	NA	0.39	4.72	0.3	4.03e-6	Corneal astigmatism;
SARC	cis	rs17600642	0.724	rs72814541	chr10:72452859	G/A	cg19779893	chr10:72451501	ADAMTS14	-0.37	-5.79	-0.35	2.3e-8	Bipolar disorder;
SARC	cis	rs76419734	0.557	rs72673865	chr4:106768598	G/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.78	5.31	0.33	2.52e-7	Post bronchodilator FEV1;
SARC	cis	rs9816226	0.590	rs872602	chr3:185826028	A/G	cg00760338	chr3:185826511	ETV5	0.93	13.09	0.65	1.02e-29	Obesity;Body mass index;
SARC	trans	rs9650657	0.737	rs4551304	chr8:10665069	A/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.3	-0.38	1.46e-9	Neuroticism;
SARC	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.91	9.77	0.54	4.09e-19	Platelet count;
SARC	cis	rs9322817	0.691	rs6922441	chr6:105216405	T/C	cg02098413	chr6:105308735	HACE1	-0.39	-6.13	-0.37	3.8e-9	Thyroid stimulating hormone;
SARC	cis	rs4588572	0.686	rs34262593	chr5:77666427	T/C	cg11547950	chr5:77652471	NA	0.41	4.84	0.3	2.36e-6	Triglycerides;
SARC	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg22920501	chr2:26401640	FAM59B	-0.55	-7.14	-0.42	1.18e-11	Gut microbiome composition (summer);
SARC	cis	rs9303401	0.659	rs12150536	chr17:56640834	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.09	12.25	0.63	5.64e-27	Cognitive test performance;
SARC	cis	rs2730245	0.527	rs842695	chr7:158662182	G/A	cg24397884	chr7:158709396	WDR60	1.07	9.33	0.52	8.7e-18	Height;
SARC	cis	rs6700896	0.931	rs2154384	chr1:66108517	C/T	cg04111102	chr1:66153794	NA	0.35	5.49	0.34	1.02e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs3126085	0.935	rs1390490	chr1:152161354	T/C	cg26876637	chr1:152193138	HRNR	0.5	5.5	0.34	9.84e-8	Atopic dermatitis;
SARC	cis	rs3741151	0.687	rs724111	chr11:73238645	G/A	cg17517138	chr11:73019481	ARHGEF17	0.92	6.86	0.41	6.15e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg24399712	chr22:39784796	NA	-0.41	-5.12	-0.32	6.48e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs17345786	0.798	rs9817043	chr3:101281852	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.45	-5.41	-0.33	1.54e-7	Colonoscopy-negative controls vs population controls;
SARC	cis	rs644799	0.965	rs598876	chr11:95560853	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	14.89	0.7	1.07e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs17376456	0.825	rs10054903	chr5:93281491	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.66	6.11	0.37	4.09e-9	Diabetic retinopathy;
SARC	cis	rs7831492	0.564	rs57596574	chr8:41609843	G/A	cg17182837	chr8:41585554	ANK1	-0.39	-5.03	-0.31	9.84e-7	Colorectal cancer;
SARC	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg19223190	chr17:80058835	NA	0.43	6.05	0.37	5.72e-9	Life satisfaction;
SARC	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg08677398	chr8:58056175	NA	0.43	5.09	0.32	7.42e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs12701220	0.553	rs13245507	chr7:1163694	C/T	cg02733842	chr7:1102375	C7orf50	-0.42	-5.23	-0.32	3.8e-7	Bronchopulmonary dysplasia;
SARC	cis	rs7595412	1.000	rs1371661	chr2:198979391	C/T	cg00208931	chr2:198669586	PLCL1	-0.73	-5.76	-0.35	2.59e-8	Hip bone size;
SARC	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg23982607	chr1:1823379	GNB1	0.5	7.79	0.45	2.19e-13	Body mass index;
SARC	cis	rs7659604	1.000	rs7689722	chr4:122665955	T/C	cg19748678	chr4:122722346	EXOSC9	0.41	5.04	0.31	9.17e-7	Type 2 diabetes;
SARC	cis	rs3956705	0.762	rs13311608	chr7:32999601	C/T	cg07520158	chr7:32535189	LSM5;AVL9	-0.42	-5.07	-0.32	8.12e-7	Red cell distribution width;
SARC	cis	rs11585357	0.947	rs11585118	chr1:17605774	C/A	cg08277548	chr1:17600880	PADI3	-0.5	-5.47	-0.34	1.18e-7	Hair shape;
SARC	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg01475735	chr3:40494733	NA	0.48	5.46	0.34	1.23e-7	Renal cell carcinoma;
SARC	cis	rs3020736	0.500	rs4147641	chr22:42482502	C/G	cg04733989	chr22:42467013	NAGA	-0.76	-10.7	-0.57	5.23e-22	Autism spectrum disorder or schizophrenia;
SARC	cis	rs12824058	0.831	rs7485200	chr12:130811641	C/T	cg23887609	chr12:130822674	PIWIL1	0.37	5.2	0.32	4.4e-7	Menopause (age at onset);
SARC	cis	rs710216	0.957	rs2886876	chr1:43432741	A/G	cg03128534	chr1:43423976	SLC2A1	-0.62	-6.38	-0.39	9.36e-10	Red cell distribution width;
SARC	cis	rs2228479	0.850	rs62056103	chr16:89942781	G/A	cg12064134	chr16:90016061	DEF8	-0.56	-4.8	-0.3	2.84e-6	Skin colour saturation;
SARC	cis	rs611744	0.967	rs637358	chr8:109197454	C/T	cg21045802	chr8:109455806	TTC35	0.42	4.98	0.31	1.24e-6	Dupuytren's disease;
SARC	cis	rs796364	0.951	rs7586284	chr2:201068002	G/A	cg23649088	chr2:200775458	C2orf69	0.66	7.27	0.43	5.43e-12	Schizophrenia;
SARC	cis	rs644799	1.000	rs563653	chr11:95561488	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	14.89	0.7	1.07e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs644799	1.000	rs544119	chr11:95538624	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.91	14.15	0.68	3.08e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs10823500	0.549	rs10999204	chr10:72007306	G/A	cg04118878	chr10:71993077	PPA1	0.53	6.18	0.38	2.79e-9	Blood protein levels;
SARC	cis	rs13255475	0.895	rs10808512	chr8:121542864	A/G	cg02241924	chr8:122166424	NA	0.46	5.68	0.35	4.03e-8	Cerebrospinal T-tau levels;Cerebrospinal P-tau181p levels;
SARC	cis	rs4481887	0.927	rs4336885	chr1:248473168	A/C	cg00666640	chr1:248458726	OR2T12	0.33	5.48	0.34	1.1e-7	Common traits (Other);
SARC	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg11987759	chr7:65425863	GUSB	0.45	6.05	0.37	5.87e-9	Aortic root size;
SARC	cis	rs79149102	0.579	rs12593476	chr15:75282092	A/C	cg09165964	chr15:75287851	SCAMP5	-1.0	-8.77	-0.5	3.9e-16	Lung cancer;
SARC	cis	rs995000	0.899	rs10889356	chr1:63155349	G/A	cg06896770	chr1:63153194	DOCK7	0.95	15.2	0.71	1e-36	Triglyceride levels;
SARC	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg12463550	chr7:65579703	CRCP	0.67	5.06	0.31	8.43e-7	Diabetic kidney disease;
SARC	cis	rs367943	0.901	rs463167	chr5:112799369	C/A	cg12552261	chr5:112820674	MCC	-0.45	-5.19	-0.32	4.65e-7	Type 2 diabetes;
SARC	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg02841227	chr6:26021843	HIST1H4A	0.67	8.15	0.47	2.2e-14	Intelligence (multi-trait analysis);
SARC	cis	rs9325144	0.678	rs7315271	chr12:39164731	A/G	cg26384229	chr12:38710491	ALG10B	-0.57	-7.11	-0.42	1.45e-11	Morning vs. evening chronotype;
SARC	cis	rs4595586	0.545	rs11615634	chr12:39364704	A/C	cg26384229	chr12:38710491	ALG10B	0.51	6.29	0.38	1.51e-9	Morning vs. evening chronotype;
SARC	cis	rs2404602	0.530	rs12915184	chr15:76965922	G/A	cg15268244	chr15:77196840	NA	0.43	4.75	0.3	3.56e-6	Blood metabolite levels;
SARC	cis	rs897984	0.537	rs8045637	chr16:30818662	C/T	cg00531865	chr16:30841666	NA	-0.51	-6.15	-0.37	3.35e-9	Dementia with Lewy bodies;
SARC	cis	rs9788682	0.642	rs2568483	chr15:78752343	A/G	cg06917634	chr15:78832804	PSMA4	-0.52	-5.4	-0.33	1.6e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs72634258	0.503	rs2794666	chr1:7822009	A/G	cg05338066	chr1:7812865	CAMTA1	0.66	5.72	0.35	3.3e-8	Inflammatory bowel disease;
SARC	cis	rs6456156	0.774	rs1012656	chr6:167525303	G/C	cg07741184	chr6:167504864	NA	-0.3	-5.62	-0.35	5.39e-8	Primary biliary cholangitis;
SARC	trans	rs1994135	0.630	rs11052757	chr12:33719879	A/G	cg26384229	chr12:38710491	ALG10B	0.85	10.48	0.57	2.72e-21	Resting heart rate;
SARC	cis	rs950169	0.959	rs66801143	chr15:84736657	C/T	cg17507749	chr15:85114479	UBE2QP1	0.76	9.12	0.51	3.56e-17	Schizophrenia;
SARC	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg02993943	chr7:39605861	C7orf36	0.52	6.29	0.38	1.58e-9	Educational attainment (years of education);
SARC	cis	rs2153535	0.601	rs7775274	chr6:8530303	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	10.59	0.57	1.15e-21	Motion sickness;
SARC	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg07308232	chr7:1071921	C7orf50	-0.49	-5.95	-0.36	1e-8	Longevity;Endometriosis;
SARC	cis	rs6867032	0.917	rs10474734	chr5:2004208	A/G	cg26168224	chr5:2018326	NA	0.69	9.55	0.53	1.83e-18	Gut microbiome composition (winter);
SARC	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg13206674	chr6:150067644	NUP43	0.46	6.03	0.37	6.45e-9	Lung cancer;
SARC	cis	rs35213789	0.853	rs10241485	chr7:69207318	A/G	cg10619644	chr7:69149951	AUTS2	-0.43	-5.82	-0.36	1.89e-8	Childhood ear infection;
SARC	cis	rs6426558	0.537	rs4653813	chr1:227461510	G/C	cg10327440	chr1:227177885	CDC42BPA	0.43	5.04	0.31	9.53e-7	Neutrophil percentage of white cells;
SARC	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg13175981	chr1:150552382	MCL1	-0.48	-5.97	-0.36	8.78e-9	Tonsillectomy;
SARC	cis	rs644799	0.965	rs499076	chr11:95546341	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.7	9.55	0.53	1.87e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7681440	0.560	rs2619371	chr4:90736678	A/G	cg06632027	chr4:90757378	SNCA	-0.43	-5.26	-0.33	3.19e-7	Dementia with Lewy bodies;
SARC	cis	rs7178572	0.568	rs1389436	chr15:77665848	G/T	cg22256960	chr15:77711686	NA	-0.52	-5.7	-0.35	3.62e-8	Type 2 diabetes;
SARC	cis	rs7909074	1.000	rs7909074	chr10:45395839	G/A	cg04218760	chr10:45406644	TMEM72	-0.26	-4.96	-0.31	1.38e-6	Mean corpuscular volume;
SARC	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.47	-5.98	-0.36	8.47e-9	Tonsillectomy;
SARC	cis	rs7666738	0.830	rs11931166	chr4:99054187	A/T	cg05340658	chr4:99064831	C4orf37	0.65	8.85	0.5	2.24e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7084402	0.967	rs1649018	chr10:60288150	T/G	cg07615347	chr10:60278583	BICC1	0.61	8.99	0.51	8.84e-17	Refractive error;
SARC	cis	rs473651	0.935	rs10170056	chr2:239339291	G/C	cg21699342	chr2:239360505	ASB1	0.49	5.95	0.36	9.57e-9	Multiple system atrophy;
SARC	cis	rs13401104	0.716	rs12185623	chr2:237128932	G/C	cg19324714	chr2:237145437	ASB18	0.63	6.17	0.37	3.02e-9	Educational attainment;
SARC	cis	rs8084125	1.000	rs72978665	chr18:74953641	A/G	cg26065057	chr18:74961000	GALR1	0.48	4.97	0.31	1.29e-6	Obesity-related traits;
SARC	cis	rs6963495	0.818	rs55825845	chr7:105166713	A/G	cg19920283	chr7:105172520	RINT1	0.67	5.67	0.35	4.21e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.67	6.41	0.39	8.06e-10	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs1322639	0.806	rs1322640	chr6:169586887	T/C	cg03254818	chr6:169586852	NA	-0.66	-8.75	-0.5	4.37e-16	Pulse pressure;
SARC	cis	rs1707322	0.928	rs61785614	chr1:46446047	A/G	cg06784218	chr1:46089804	CCDC17	0.34	5.95	0.36	9.76e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs4332037	0.713	rs56093134	chr7:1973970	C/T	cg11693508	chr17:37793320	STARD3	0.71	6.57	0.4	3.2e-10	Bipolar disorder;
SARC	trans	rs6600671	1.000	rs7532615	chr1:121172840	G/T	cg00646200	chr1:148855367	NA	-0.52	-7.22	-0.43	7.38e-12	Hip geometry;
SARC	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg05872129	chr22:39784769	NA	0.4	5.73	0.35	3.17e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs7929679	0.551	rs11032849	chr11:34785740	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.36	4.76	0.3	3.47e-6	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
SARC	cis	rs2439831	0.764	rs2447193	chr15:43929733	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	7.52	0.44	1.19e-12	Lung cancer in ever smokers;
SARC	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg22535103	chr8:58192502	C8orf71	-0.73	-7.24	-0.43	6.52e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs262150	1.000	rs262149	chr7:158778256	A/G	cg09640425	chr7:158790006	NA	0.38	4.99	0.31	1.16e-6	Facial morphology (factor 20);
SARC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg02353165	chr6:42928485	GNMT	0.52	7.14	0.42	1.18e-11	Alzheimer's disease in APOE e4+ carriers;
SARC	trans	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg20587970	chr11:113659929	NA	1.02	9.48	0.53	3.09e-18	Hip circumference adjusted for BMI;
SARC	cis	rs910316	0.503	rs12894709	chr14:75441734	G/A	cg11812906	chr14:75593930	NEK9	0.69	8.61	0.49	1.14e-15	Height;
SARC	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg07308232	chr7:1071921	C7orf50	-0.48	-6.03	-0.37	6.24e-9	Longevity;Endometriosis;
SARC	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg00339695	chr16:24857497	SLC5A11	-0.42	-6.04	-0.37	6.16e-9	Intelligence (multi-trait analysis);
SARC	cis	rs17270561	0.609	rs12663099	chr6:25739518	C/T	cg16482183	chr6:26056742	HIST1H1C	0.43	5.22	0.32	3.92e-7	Iron status biomarkers;
SARC	cis	rs16976116	0.901	rs28589609	chr15:55503630	C/T	cg17854078	chr15:55489399	RSL24D1	0.66	6.45	0.39	6.3e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs748404	0.660	rs2439846	chr15:43740970	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.4	4.77	0.3	3.25e-6	Lung cancer;
SARC	cis	rs7084402	0.967	rs3001717	chr10:60329125	A/G	cg07615347	chr10:60278583	BICC1	0.58	8.6	0.49	1.15e-15	Refractive error;
SARC	cis	rs7520050	0.966	rs785485	chr1:46574424	C/T	cg24296786	chr1:45957014	TESK2	0.38	4.82	0.3	2.56e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs10771431	1.000	rs11611670	chr12:9385535	C/T	cg08997352	chr12:9597637	DDX12	-0.57	-7.97	-0.46	6.89e-14	Breast size;
SARC	cis	rs6831352	0.918	rs17817359	chr4:100054197	G/T	cg13256891	chr4:100009986	ADH5	-0.64	-8.0	-0.46	5.7e-14	Alcohol dependence;
SARC	cis	rs1057510	0.929	rs10849492	chr12:6720795	A/G	cg27210269	chr12:6599286	NA	-0.45	-4.87	-0.3	2.11e-6	Myopia (pathological);
SARC	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg11764359	chr7:65958608	NA	-0.87	-12.2	-0.62	8.73e-27	Aortic root size;
SARC	cis	rs644799	0.601	rs7902	chr11:95565288	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.72	10.42	0.56	4.2e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs1448094	0.556	rs4897831	chr12:86168248	C/T	cg02569458	chr12:86230093	RASSF9	0.37	5.07	0.32	7.98e-7	Major depressive disorder;
SARC	cis	rs7324557	0.717	rs7330646	chr13:24402164	G/T	cg09076334	chr13:24477870	NA	0.32	4.74	0.3	3.79e-6	Visceral adipose tissue adjusted for BMI;
SARC	cis	rs2952156	0.920	rs2934951	chr17:37833328	A/G	cg07936489	chr17:37558343	FBXL20	-0.39	-5.17	-0.32	5.02e-7	Asthma;
SARC	cis	rs6866344	0.570	rs59259518	chr5:178142628	C/T	cg10224037	chr5:178157518	ZNF354A	0.98	13.38	0.66	1.11e-30	Neutrophil percentage of white cells;
SARC	cis	rs933688	0.532	rs13164949	chr5:90538489	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.43	-4.8	-0.3	2.81e-6	Smoking behavior;
SARC	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.67	-8.71	-0.5	5.61e-16	Intelligence (multi-trait analysis);
SARC	cis	rs1018836	0.637	rs7843684	chr8:91470035	G/C	cg16814680	chr8:91681699	NA	-0.65	-9.21	-0.52	2.02e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs11648796	0.757	rs66649828	chr16:766078	A/G	cg00908189	chr16:619842	PIGQ	0.56	6.26	0.38	1.81e-9	Height;
SARC	cis	rs57506017	0.565	rs10278257	chr7:12253563	C/T	cg23422036	chr7:12250390	TMEM106B	0.51	6.88	0.41	5.42e-11	Neuroticism;
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07161166	chr1:84543374	PRKACB	-0.56	-6.92	-0.41	4.24e-11	Smoking initiation;
SARC	cis	rs1215050	0.791	rs1530904	chr4:98805436	A/G	cg05340658	chr4:99064831	C4orf37	0.44	5.85	0.36	1.62e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs67311347	0.910	rs13089215	chr3:40495894	T/C	cg01475735	chr3:40494733	NA	0.47	5.29	0.33	2.78e-7	Renal cell carcinoma;
SARC	cis	rs4423214	1.000	rs12791871	chr11:71164544	A/C	cg24826892	chr11:71159390	DHCR7	0.43	5.24	0.32	3.64e-7	Vitamin D levels;
SARC	cis	rs17253792	0.822	rs75509578	chr14:56133493	G/A	cg01858014	chr14:56050164	KTN1	-0.71	-5.63	-0.35	5.18e-8	Putamen volume;
SARC	trans	rs17685	0.735	rs11763339	chr7:75761541	T/C	cg19862616	chr7:65841803	NCRNA00174	0.62	7.72	0.45	3.44e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs12142240	0.698	rs72885198	chr1:46812888	C/T	cg00530320	chr1:46809349	NSUN4	0.6	7.22	0.43	7.27e-12	Menopause (age at onset);
SARC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg12648201	chr2:27665141	KRTCAP3	-0.33	-5.0	-0.31	1.11e-6	Total body bone mineral density;
SARC	cis	rs7769051	0.522	rs11965927	chr6:133101353	T/C	cg22852734	chr6:133119734	C6orf192	1.19	7.96	0.46	7.34e-14	Type 2 diabetes nephropathy;
SARC	cis	rs8067545	0.586	rs2526478	chr17:20130452	A/G	cg13482628	chr17:19912719	NA	0.53	6.89	0.41	5.1e-11	Schizophrenia;
SARC	cis	rs3768617	0.510	rs729819	chr1:183109034	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.64	8.47	0.49	2.72e-15	Fuchs's corneal dystrophy;
SARC	cis	rs8060686	0.668	rs255056	chr16:68016185	G/C	cg09117114	chr16:67998030	SLC12A4	-0.48	-4.99	-0.31	1.16e-6	HDL cholesterol;Metabolic syndrome;
SARC	cis	rs7786808	0.608	rs7784758	chr7:158214386	A/G	cg01191920	chr7:158217561	PTPRN2	-0.33	-5.82	-0.36	1.92e-8	Obesity-related traits;
SARC	cis	rs6933660	0.800	rs3800273	chr6:151759035	G/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.55	7.27	0.43	5.47e-12	Menarche (age at onset);
SARC	cis	rs72653721	0.838	rs17764592	chr6:11003144	G/T	cg13562911	chr6:11044106	ELOVL2	-0.54	-6.3	-0.38	1.45e-9	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	cis	rs66887589	0.837	rs6534135	chr4:120406302	A/G	cg09307838	chr4:120376055	NA	0.55	7.46	0.44	1.65e-12	Diastolic blood pressure;
SARC	trans	rs62103177	0.810	rs62103194	chr18:77629482	G/A	cg05926928	chr17:57297772	GDPD1	1.1	9.27	0.52	1.3e-17	Opioid sensitivity;
SARC	cis	rs6582618	1	rs6582618	chr12:38726137	A/G	cg13010199	chr12:38710504	ALG10B	0.51	6.5	0.39	4.74e-10	Morning vs. evening chronotype;
SARC	cis	rs4243830	0.850	rs2412309	chr1:6603151	A/G	cg04093404	chr1:6614507	TAS1R1;NOL9	0.56	4.95	0.31	1.41e-6	Body mass index;
SARC	cis	rs2952156	1.000	rs2952156	chr17:37876835	A/G	cg20243544	chr17:37824526	PNMT	0.44	5.09	0.32	7.22e-7	Asthma;
SARC	cis	rs9790314	0.846	rs6791213	chr3:161033721	A/G	cg03342759	chr3:160939853	NMD3	-0.72	-9.76	-0.54	4.27e-19	Morning vs. evening chronotype;
SARC	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg11890956	chr21:40555474	PSMG1	-1.05	-15.79	-0.72	1.12e-38	Cognitive function;
SARC	trans	rs56279505	0.629	rs11499823	chr4:100274749	A/G	cg18024358	chr1:3420815	MEGF6	-0.83	-6.4	-0.39	8.29e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6670533	0.571	rs78336051	chr1:24860468	T/A	cg07475527	chr1:24864545	NA	-1.0	-5.65	-0.35	4.76e-8	Fasting blood insulin (BMI interaction);
SARC	cis	rs1050631	0.924	rs1785918	chr18:33693198	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.44	5.34	0.33	2.25e-7	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs10046574	0.831	rs28613647	chr7:135129443	G/A	cg27474649	chr7:135195673	CNOT4	0.88	7.17	0.43	9.89e-12	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs737337	0.623	rs3810308	chr19:11333596	T/C	cg00586551	chr19:11347513	LOC55908;DOCK6	0.56	5.98	0.36	8.37e-9	HDL cholesterol;HDL cholesterol levels;
SARC	cis	rs611744	0.967	rs655722	chr8:109197541	A/T	cg21045802	chr8:109455806	TTC35	0.42	5.11	0.32	6.81e-7	Dupuytren's disease;
SARC	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg13395646	chr4:1353034	KIAA1530	-0.45	-5.32	-0.33	2.48e-7	Obesity-related traits;
SARC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg01238044	chr22:24384105	GSTT1	-0.56	-6.22	-0.38	2.29e-9	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs655641	0.539	rs694011	chr11:85760028	T/C	cg18918423	chr11:86667042	FZD4	0.4	4.75	0.3	3.58e-6	Platelet count;
SARC	cis	rs8017423	0.967	rs4900030	chr14:90689813	T/A	cg20276874	chr14:90721474	PSMC1	-0.34	-4.72	-0.3	4.05e-6	Mortality in heart failure;
SARC	cis	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg21573476	chr21:45109991	RRP1B	-0.55	-8.27	-0.48	1.01e-14	Mean corpuscular volume;
SARC	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg11764359	chr7:65958608	NA	0.79	9.94	0.55	1.2e-19	Aortic root size;
SARC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.4	-6.63	-0.4	2.28e-10	Total body bone mineral density;
SARC	cis	rs2070488	0.775	rs1132064	chr3:38566519	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.77	-11.55	-0.6	1.1e-24	Electrocardiographic conduction measures;
SARC	cis	rs3796352	1.000	rs11713290	chr3:52971579	G/A	cg27565382	chr3:53032988	SFMBT1	0.83	5.57	0.34	7.16e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs12586317	0.547	rs10146699	chr14:35483577	G/A	cg26967526	chr14:35346199	BAZ1A	-0.57	-5.71	-0.35	3.4e-8	Psoriasis;
SARC	cis	rs963731	0.649	rs6713281	chr2:39235330	G/T	cg04010122	chr2:39346883	SOS1	-0.92	-5.46	-0.34	1.24e-7	Corticobasal degeneration;
SARC	cis	rs11676348	0.811	rs13027120	chr2:219020914	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.52	6.91	0.41	4.62e-11	Ulcerative colitis;
SARC	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg09699651	chr6:150184138	LRP11	0.4	4.93	0.31	1.58e-6	Lung cancer;
SARC	cis	rs10782582	0.532	rs78106188	chr1:76137836	A/G	cg03433033	chr1:76189801	ACADM	-0.42	-5.42	-0.33	1.46e-7	Daytime sleep phenotypes;
SARC	cis	rs10979	0.597	rs9496685	chr6:143908690	G/A	cg25407410	chr6:143891975	LOC285740	-0.5	-5.82	-0.36	1.94e-8	Hypospadias;
SARC	cis	rs7617773	0.780	rs7653152	chr3:48362097	G/C	cg11946769	chr3:48343235	NME6	0.76	9.6	0.53	1.32e-18	Coronary artery disease;
SARC	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg16405210	chr4:1374714	KIAA1530	-0.47	-5.51	-0.34	9.43e-8	Obesity-related traits;
SARC	trans	rs61931739	1.000	rs12311881	chr12:34036100	A/G	cg26384229	chr12:38710491	ALG10B	-0.57	-7.19	-0.43	8.49e-12	Morning vs. evening chronotype;
SARC	cis	rs9300255	0.602	rs1790116	chr12:123618544	G/T	cg05973401	chr12:123451056	ABCB9	0.51	5.79	0.35	2.23e-8	Neutrophil percentage of white cells;
SARC	cis	rs910316	0.967	rs35446981	chr14:75637351	A/T	cg08847533	chr14:75593920	NEK9	-0.86	-12.84	-0.64	7.01e-29	Height;
SARC	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg20007245	chr22:24372913	LOC391322	-0.85	-12.63	-0.64	3.22e-28	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg20573242	chr4:122745356	CCNA2	0.58	7.26	0.43	5.67e-12	Type 2 diabetes;
SARC	cis	rs10463554	0.963	rs34382	chr5:102396225	G/C	cg23492399	chr5:102201601	PAM	-0.51	-5.65	-0.35	4.78e-8	Parkinson's disease;
SARC	cis	rs10463316	0.894	rs7727770	chr5:150767116	G/T	cg03212797	chr5:150827313	SLC36A1	-0.44	-5.26	-0.33	3.34e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs4595586	0.545	rs12819907	chr12:39356906	A/G	cg26384229	chr12:38710491	ALG10B	0.51	6.22	0.38	2.25e-9	Morning vs. evening chronotype;
SARC	cis	rs9303401	0.614	rs62084384	chr17:57126842	G/A	cg25039879	chr17:56429692	SUPT4H1	0.6	5.26	0.33	3.27e-7	Cognitive test performance;
SARC	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg02951883	chr7:2050386	MAD1L1	-0.42	-5.3	-0.33	2.71e-7	Schizophrenia;
SARC	cis	rs9916302	0.706	rs801418	chr17:37457982	G/C	cg20243544	chr17:37824526	PNMT	-0.56	-6.02	-0.37	6.66e-9	Glomerular filtration rate (creatinine);
SARC	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg08280861	chr8:58055591	NA	0.61	5.96	0.36	9.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs3087591	0.960	rs4795587	chr17:29587917	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.52	-6.35	-0.38	1.13e-9	Hip circumference;
SARC	cis	rs7011049	1.000	rs72643580	chr8:53846710	T/G	cg26025543	chr8:53854495	NA	0.6	5.43	0.34	1.42e-7	Systolic blood pressure;
SARC	cis	rs9322817	1.000	rs6942231	chr6:105191814	C/T	cg02098413	chr6:105308735	HACE1	-0.33	-4.81	-0.3	2.66e-6	Thyroid stimulating hormone;
SARC	cis	rs3126085	0.935	rs6670717	chr1:152249956	T/C	cg03465714	chr1:152285911	FLG	0.5	5.75	0.35	2.79e-8	Atopic dermatitis;
SARC	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg10591111	chr5:226296	SDHA	-0.51	-4.79	-0.3	3e-6	Breast cancer;
SARC	cis	rs9399135	0.967	rs2297340	chr6:135376058	T/C	cg24558204	chr6:135376177	HBS1L	0.46	6.24	0.38	2.09e-9	Red blood cell count;
SARC	cis	rs6752107	0.967	rs10210302	chr2:234158839	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.49	6.77	0.41	1.05e-10	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg00409905	chr10:38381863	ZNF37A	-0.55	-8.04	-0.47	4.63e-14	Extrinsic epigenetic age acceleration;
SARC	cis	rs965469	1.000	rs6037567	chr20:3332160	C/A	cg25506879	chr20:3388711	C20orf194	-0.52	-5.34	-0.33	2.2e-7	IFN-related cytopenia;
SARC	cis	rs7819412	0.691	rs73198970	chr8:11040216	T/C	cg21775007	chr8:11205619	TDH	-0.41	-5.28	-0.33	2.99e-7	Triglycerides;
SARC	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg12000995	chr2:27665139	KRTCAP3	-0.3	-4.77	-0.3	3.24e-6	Total body bone mineral density;
SARC	cis	rs7412746	0.611	rs1889740	chr1:150799755	C/T	cg10589385	chr1:150898437	SETDB1	0.41	5.47	0.34	1.18e-7	Melanoma;
SARC	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg11062466	chr8:58055876	NA	0.54	5.56	0.34	7.55e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6570726	0.935	rs12663204	chr6:145818373	G/A	cg23711669	chr6:146136114	FBXO30	0.78	11.91	0.62	7.29e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11122272	0.735	rs2486730	chr1:231534987	T/G	cg06096015	chr1:231504339	EGLN1	0.38	5.64	0.35	4.92e-8	Hemoglobin concentration;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg12028455	chr17:78789078	RPTOR	0.76	7.01	0.42	2.52e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg20007245	chr22:24372913	LOC391322	-0.58	-6.79	-0.41	9.5e-11	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9815354	0.812	rs55916959	chr3:41849130	G/A	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs644799	1.000	rs487609	chr11:95588102	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.67	8.87	0.5	1.93e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7626444	0.625	rs843540	chr3:196475313	C/A	cg12930392	chr3:196481615	PAK2	0.25	5.02	0.31	1.01e-6	Monocyte count;
SARC	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg17376030	chr22:41985996	PMM1	0.75	9.28	0.52	1.24e-17	Vitiligo;
SARC	cis	rs1559088	1.000	rs1559088	chr19:33551061	C/T	cg17764715	chr19:33622953	WDR88	0.49	6.29	0.38	1.57e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg17376030	chr22:41985996	PMM1	-0.64	-8.25	-0.48	1.17e-14	Vitiligo;
SARC	cis	rs911555	0.755	rs6575988	chr14:103900827	G/T	cg12935359	chr14:103987150	CKB	0.4	5.54	0.34	7.96e-8	Intelligence (multi-trait analysis);
SARC	cis	rs910316	1.000	rs8017642	chr14:75590822	G/A	cg11812906	chr14:75593930	NEK9	0.88	13.38	0.66	1.18e-30	Height;
SARC	cis	rs995000	0.868	rs9787151	chr1:63179138	C/T	cg06896770	chr1:63153194	DOCK7	-0.85	-13.01	-0.65	1.94e-29	Triglyceride levels;
SARC	cis	rs3820928	1.000	rs1346618	chr2:227771988	C/T	cg11843606	chr2:227700838	RHBDD1	0.53	6.77	0.41	1.06e-10	Pulmonary function;
SARC	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg09455208	chr3:40491958	NA	0.39	5.8	0.36	2.16e-8	Renal cell carcinoma;
SARC	cis	rs995000	0.965	rs10889334	chr1:62957199	C/G	cg06896770	chr1:63153194	DOCK7	0.99	15.19	0.71	1.1e-36	Triglyceride levels;
SARC	cis	rs4563143	0.514	rs73029076	chr19:29292032	G/T	cg04546413	chr19:29218101	NA	0.6	7.15	0.42	1.1e-11	Methadone dose in opioid dependence;
SARC	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg06618935	chr21:46677482	NA	-0.41	-5.37	-0.33	1.93e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs73242632	1.000	rs115267736	chr4:57766923	A/G	cg20415529	chr4:57845134	POLR2B;C4orf14	1.03	6.22	0.38	2.26e-9	Congenital heart disease (maternal effect);
SARC	cis	rs67478160	0.571	rs1155751	chr14:104286547	C/G	cg08213375	chr14:104286397	PPP1R13B	0.26	4.77	0.3	3.3e-6	Schizophrenia;
SARC	cis	rs7216064	1.000	rs1976053	chr17:65833002	C/G	cg12091567	chr17:66097778	LOC651250	-0.7	-7.66	-0.45	5.08e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs8180040	0.966	rs2101247	chr3:47494303	G/A	cg27129171	chr3:47204927	SETD2	-0.69	-9.71	-0.54	6.04e-19	Colorectal cancer;
SARC	cis	rs9487051	0.676	rs6933326	chr6:109601333	C/T	cg01475377	chr6:109611718	NA	-0.36	-5.26	-0.33	3.22e-7	Reticulocyte fraction of red cells;
SARC	cis	rs9420	0.754	rs631791	chr11:57675410	A/G	cg19752551	chr11:57585705	CTNND1	0.47	5.42	0.33	1.49e-7	Schizophrenia;
SARC	cis	rs9527	0.590	rs6584537	chr10:104778267	C/G	cg04362960	chr10:104952993	NT5C2	0.45	5.49	0.34	1.05e-7	Arsenic metabolism;
SARC	cis	rs11098499	0.866	rs6824111	chr4:120285968	T/A	cg09307838	chr4:120376055	NA	0.83	11.82	0.61	1.46e-25	Corneal astigmatism;
SARC	cis	rs459571	0.959	rs455381	chr9:136905577	C/A	cg01294253	chr9:136912663	BRD3	0.43	5.49	0.34	1.05e-7	Platelet distribution width;
SARC	cis	rs7005606	1.000	rs4733129	chr8:32406768	T/C	cg14488905	chr8:32406789	NRG1	0.45	6.31	0.38	1.42e-9	Hirschsprung disease;
SARC	cis	rs5760092	0.755	rs11090298	chr22:24262061	G/A	cg09033563	chr22:24373618	LOC391322	0.52	5.56	0.34	7.19e-8	Urinary 1,3-butadiene metabolite levels in smokers;
SARC	cis	rs2282802	0.685	rs10051345	chr5:139670932	C/G	cg26211634	chr5:139558579	C5orf32	-0.36	-4.79	-0.3	2.97e-6	Intelligence (multi-trait analysis);
SARC	cis	rs17270561	0.636	rs9379782	chr6:25715023	G/A	cg16482183	chr6:26056742	HIST1H1C	0.42	5.1	0.32	7.01e-7	Iron status biomarkers;
SARC	cis	rs11792861	0.888	rs75543406	chr9:111816903	A/T	cg13535736	chr9:111863775	C9orf5	-0.4	-4.84	-0.3	2.34e-6	Menarche (age at onset);
SARC	cis	rs9398803	0.830	rs1361109	chr6:126771143	C/T	cg20229609	chr6:126660872	C6orf173	0.38	5.47	0.34	1.16e-7	Male-pattern baldness;
SARC	cis	rs131777	0.547	rs131753	chr22:51022862	A/G	cg25309564	chr22:51001381	C22orf41	0.54	6.89	0.41	5.27e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs9393692	0.905	rs9393693	chr6:26277408	C/A	cg13736514	chr6:26305472	NA	-0.6	-8.38	-0.48	5.15e-15	Educational attainment;
SARC	cis	rs986417	1.000	rs12895784	chr14:60980116	G/T	cg27398547	chr14:60952738	C14orf39	1.0	9.03	0.51	6.84e-17	Gut microbiota (bacterial taxa);
SARC	cis	rs3617	0.625	rs7620690	chr3:52891707	A/G	cg04865290	chr3:52927548	TMEM110	0.35	4.96	0.31	1.37e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs735396	0.595	rs2258287	chr12:121454313	G/T	cg04422896	chr12:121454269	C12orf43	0.48	6.26	0.38	1.81e-9	N-glycan levels;
SARC	cis	rs6871536	1.000	rs62383758	chr5:131961970	C/T	cg11797159	chr5:131991491	NA	0.38	5.01	0.31	1.07e-6	Asthma (childhood onset);
SARC	cis	rs7829975	0.517	rs12542733	chr8:8824858	G/T	cg08975724	chr8:8085496	FLJ10661	-0.43	-5.6	-0.34	6.01e-8	Mood instability;
SARC	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg23149560	chr2:74406255	MOBKL1B	0.48	4.73	0.3	3.89e-6	Gestational age at birth (maternal effect);
SARC	cis	rs9677476	0.863	rs11558174	chr2:232072912	T/C	cg23338755	chr2:231921595	PSMD1	0.47	5.59	0.34	6.26e-8	Food antigen IgG levels;
SARC	cis	rs1018836	0.828	rs4735236	chr8:91583909	A/G	cg16814680	chr8:91681699	NA	-0.74	-11.46	-0.6	2.09e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs13040088	1.000	rs910831	chr20:61558775	T/C	cg23096297	chr20:61557774	DIDO1	0.96	10.47	0.57	2.83e-21	Menopause (age at onset);
SARC	cis	rs2115536	0.606	rs8024713	chr15:80206958	C/G	cg00225070	chr15:80189496	MTHFS	0.71	9.23	0.52	1.67e-17	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
SARC	cis	rs1832871	0.711	rs12525147	chr6:158683509	A/G	cg07165851	chr6:158734300	TULP4	0.52	5.92	0.36	1.12e-8	Height;
SARC	cis	rs9325144	0.723	rs11169519	chr12:39177441	G/A	cg26384229	chr12:38710491	ALG10B	-0.61	-7.56	-0.44	9.47e-13	Morning vs. evening chronotype;
SARC	cis	rs6088580	0.634	rs4258875	chr20:32924895	C/A	cg24642439	chr20:33292090	TP53INP2	-0.67	-8.52	-0.49	1.97e-15	Glomerular filtration rate (creatinine);
SARC	trans	rs9650657	0.537	rs11250092	chr8:10786543	A/G	cg06636001	chr8:8085503	FLJ10661	0.58	7.55	0.44	9.53e-13	Neuroticism;
SARC	cis	rs12142240	0.698	rs17357628	chr1:46808462	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-5.45	-0.34	1.28e-7	Menopause (age at onset);
SARC	cis	rs6546324	0.625	rs2861689	chr2:67838604	C/G	cg18237512	chr2:67827392	NA	-0.51	-6.29	-0.38	1.58e-9	Endometriosis;
SARC	cis	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg03403963	chr8:11986501	LOC392196;FAM66D	-0.34	-4.95	-0.31	1.44e-6	Triglycerides;
SARC	cis	rs3820928	0.874	rs4234066	chr2:227882180	G/A	cg05526886	chr2:227700861	RHBDD1	-0.52	-6.37	-0.39	1e-9	Pulmonary function;
SARC	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg02725872	chr8:58115012	NA	-0.36	-6.47	-0.39	5.7e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7568458	0.709	rs56819945	chr2:85755139	C/T	cg02493740	chr2:85810744	VAMP5	-0.41	-5.14	-0.32	5.88e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs709400	0.658	rs72708874	chr14:103899251	T/G	cg26031613	chr14:104095156	KLC1	0.81	11.51	0.6	1.47e-24	Body mass index;
SARC	cis	rs554111	0.963	rs666371	chr1:21041555	A/G	cg04902671	chr1:21058625	SH2D5	-0.42	-4.76	-0.3	3.43e-6	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs6733938	0.582	rs72622608	chr2:70831777	T/A	cg14608581	chr2:70122240	SNRNP27	0.58	5.02	0.31	1.02e-6	Mammographic density;
SARC	cis	rs2120019	0.938	rs8028632	chr15:75321262	T/C	cg12414181	chr15:75287860	SCAMP5	-0.48	-5.53	-0.34	8.36e-8	Blood trace element (Zn levels);
SARC	cis	rs644799	1.000	rs473148	chr11:95628606	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.9	13.01	0.65	1.85e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg26088614	chr2:26039146	ASXL2	0.5	6.87	0.41	5.7e-11	Thyroid stimulating hormone;
SARC	trans	rs56279505	0.690	rs62307324	chr4:100282591	C/G	cg21156590	chr1:3420848	MEGF6	-0.83	-6.52	-0.39	4.31e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg19346786	chr7:2764209	NA	0.38	5.87	0.36	1.5e-8	Height;
SARC	cis	rs4975616	0.869	rs401681	chr5:1322087	C/T	cg26373071	chr5:1325741	CLPTM1L	0.32	5.29	0.33	2.79e-7	Lung cancer;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg24531267	chr20:34043122	CEP250	-0.51	-6.25	-0.38	1.91e-9	Schizophrenia;
SARC	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg11644478	chr21:40555479	PSMG1	-0.59	-7.29	-0.43	4.67e-12	Menarche (age at onset);
SARC	cis	rs11122272	0.735	rs2486741	chr1:231516450	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs2204008	0.775	rs11514369	chr12:38305411	C/T	cg26384229	chr12:38710491	ALG10B	0.87	12.74	0.64	1.45e-28	Bladder cancer;
SARC	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg24549020	chr5:56110836	MAP3K1	0.81	8.44	0.48	3.34e-15	Initial pursuit acceleration;
SARC	cis	rs6993270	0.779	rs59151115	chr8:120922016	G/T	cg21659575	chr8:120844832	TAF2	0.49	4.75	0.3	3.61e-6	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs3126085	0.935	rs12408581	chr1:152175211	A/G	cg26876637	chr1:152193138	HRNR	-0.51	-5.25	-0.33	3.42e-7	Atopic dermatitis;
SARC	cis	rs7937682	0.924	rs501089	chr11:111502479	G/T	cg22437258	chr11:111473054	SIK2	-0.68	-8.67	-0.49	7.36e-16	Primary sclerosing cholangitis;
SARC	cis	rs7772486	0.720	rs6570713	chr6:146075085	G/A	cg23711669	chr6:146136114	FBXO30	-0.92	-16.55	-0.74	3.29e-41	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1153858	1.000	rs66939267	chr15:45676902	T/A	cg26924012	chr15:45694286	SPATA5L1	0.79	11.28	0.59	7.91e-24	Homoarginine levels;
SARC	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg20607798	chr8:58055168	NA	0.57	5.33	0.33	2.27e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2204008	0.837	rs7301679	chr12:37989629	T/C	cg26384229	chr12:38710491	ALG10B	-0.78	-11.14	-0.59	2.17e-23	Bladder cancer;
SARC	cis	rs7084402	0.967	rs1658447	chr10:60313174	G/A	cg07615347	chr10:60278583	BICC1	0.59	8.65	0.49	8.56e-16	Refractive error;
SARC	cis	rs79149102	0.579	rs7342601	chr15:75306795	G/T	cg17294928	chr15:75287854	SCAMP5	0.86	8.24	0.48	1.25e-14	Lung cancer;
SARC	cis	rs9486719	0.857	rs2971609	chr6:97039665	A/G	cg06623918	chr6:96969491	KIAA0776	-0.78	-9.6	-0.53	1.37e-18	Migraine;Coronary artery disease;
SARC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg11494091	chr17:61959527	GH2	0.48	7.04	0.42	2.17e-11	Prudent dietary pattern;
SARC	cis	rs96067	0.805	rs1033890	chr1:36608414	C/T	cg24686825	chr1:36642396	MAP7D1	-0.58	-6.68	-0.4	1.73e-10	Corneal structure;
SARC	cis	rs7264396	0.790	rs6121018	chr20:34249060	C/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	5.91	0.36	1.21e-8	Total cholesterol levels;
SARC	cis	rs7769051	0.711	rs9493437	chr6:133088405	A/T	cg22852734	chr6:133119734	C6orf192	1.06	10.42	0.56	4.01e-21	Type 2 diabetes nephropathy;
SARC	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg25072359	chr17:41440525	NA	0.53	6.29	0.38	1.51e-9	Menopause (age at onset);
SARC	cis	rs6701037	0.748	rs2685	chr1:175127771	A/G	cg00321850	chr1:175162397	KIAA0040	0.31	4.74	0.3	3.68e-6	Alcohol dependence;
SARC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg24101359	chr6:42928495	GNMT	0.43	5.8	0.36	2.15e-8	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg06074448	chr4:187884817	NA	-0.38	-5.08	-0.32	7.7300000000000005e-07	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs4699052	0.787	rs2169508	chr4:104066890	T/A	cg16532752	chr4:104119610	CENPE	-0.51	-6.12	-0.37	3.9e-9	Testicular germ cell tumor;
SARC	cis	rs4243830	0.522	rs11122086	chr1:6601246	T/G	cg04093404	chr1:6614507	TAS1R1;NOL9	0.54	4.77	0.3	3.24e-6	Body mass index;
SARC	cis	rs7523050	0.730	rs7519107	chr1:109399367	A/C	cg08274380	chr1:109419600	GPSM2	1.07	8.3	0.48	8.22e-15	Fat distribution (HIV);
SARC	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg06558623	chr16:89946397	TCF25	0.92	6.39	0.39	8.93e-10	Skin colour saturation;
SARC	cis	rs3809566	1.000	rs4774471	chr15:63332645	A/T	cg05507819	chr15:63340323	TPM1	-0.54	-6.0	-0.37	7.51e-9	Platelet count;
SARC	cis	rs6964587	0.692	rs4729018	chr7:91644613	C/T	cg17063962	chr7:91808500	NA	0.84	12.83	0.64	7.58e-29	Breast cancer;
SARC	cis	rs239198	0.521	rs13198473	chr6:101337779	C/T	cg09795085	chr6:101329169	ASCC3	0.44	5.62	0.35	5.34e-8	Menarche (age at onset);
SARC	cis	rs721399	1.000	rs1495748	chr8:18263112	A/G	cg18736775	chr8:18248649	NAT2	0.4	5.09	0.32	7.26e-7	Blood metabolite levels;
SARC	cis	rs6807306	0.913	rs4484191	chr3:167344315	A/T	cg24249075	chr3:167452484	PDCD10;SERPINI1	0.5	4.87	0.3	2.1e-6	Mean platelet volume;
SARC	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.43	6.94	0.41	3.74e-11	Schizophrenia;
SARC	cis	rs57994353	0.861	rs3812591	chr9:139341612	C/T	cg13611204	chr9:139324423	INPP5E	0.28	4.75	0.3	3.59e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs526231	0.578	rs34786	chr5:102458113	C/G	cg23492399	chr5:102201601	PAM	-0.51	-5.55	-0.34	7.77e-8	Primary biliary cholangitis;
SARC	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg26335602	chr6:28129616	ZNF389	0.53	5.88	0.36	1.43e-8	Depression;
SARC	cis	rs2070488	0.775	rs7649984	chr3:38570221	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.75	-10.85	-0.58	1.77e-22	Electrocardiographic conduction measures;
SARC	cis	rs6912958	0.935	rs2179844	chr6:88165773	C/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.61	-8.45	-0.48	3.19e-15	Monocyte percentage of white cells;
SARC	cis	rs11608355	0.521	rs9888353	chr12:109843594	G/A	cg19025524	chr12:109796872	NA	-0.42	-6.05	-0.37	5.85e-9	Neuroticism;
SARC	cis	rs7208859	0.623	rs9890855	chr17:29111707	G/C	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs2148307	0.619	rs2359562	chr10:21053029	C/T	cg02536263	chr10:20295880	PLXDC2	-0.41	-4.92	-0.31	1.63e-6	Photic sneeze reflex;
SARC	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.72	10.32	0.56	8.38e-21	Menarche (age at onset);
SARC	cis	rs9303401	0.659	rs35564417	chr17:56718286	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.1	12.57	0.64	5.42e-28	Cognitive test performance;
SARC	cis	rs1348850	0.632	rs11678875	chr2:178509068	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.45	5.18	0.32	4.74e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7944584	0.511	rs10838731	chr11:47607135	C/T	cg10504702	chr11:47789108	FNBP4	0.69	9.02	0.51	7.31e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs854765	0.575	rs2955357	chr17:17946401	T/C	cg23370820	chr17:17987590	NA	0.24	4.74	0.3	3.74e-6	Total body bone mineral density;
SARC	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg12463550	chr7:65579703	CRCP	0.51	5.74	0.35	2.94e-8	Aortic root size;
SARC	cis	rs8114671	0.562	rs3746450	chr20:33508588	G/T	cg07148914	chr20:33460835	GGT7	0.43	5.35	0.33	2.13e-7	Height;
SARC	cis	rs7618915	0.501	rs55678971	chr3:52717229	T/A	cg18404041	chr3:52824283	ITIH1	-0.4	-6.03	-0.37	6.24e-9	Bipolar disorder;
SARC	cis	rs933688	1.000	rs1035477	chr5:90743325	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.03	13.03	0.65	1.61e-29	Smoking behavior;
SARC	cis	rs911263	0.603	rs12878858	chr14:68786797	G/A	cg18825221	chr14:68749962	RAD51L1	0.4	7.03	0.42	2.29e-11	Primary biliary cholangitis;
SARC	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg04166393	chr7:2884313	GNA12	0.58	6.91	0.41	4.64e-11	Height;
SARC	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg00031303	chr3:195681400	NA	-0.48	-5.55	-0.34	7.69e-8	Pancreatic cancer;
SARC	cis	rs9393692	1.000	rs3999544	chr6:26285867	C/T	cg13736514	chr6:26305472	NA	-0.67	-8.87	-0.5	1.94e-16	Educational attainment;
SARC	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	11.31	0.6	6.28e-24	Alzheimer's disease;
SARC	cis	rs6696846	0.515	rs10900450	chr1:205106238	C/G	cg21643547	chr1:205240462	TMCC2	-0.43	-5.32	-0.33	2.42e-7	Red blood cell count;
SARC	cis	rs11710088	0.707	rs35551531	chr3:149206986	A/G	cg08667024	chr3:149219783	TM4SF4	-0.4	-5.79	-0.35	2.26e-8	QRS duration;
SARC	cis	rs6089584	0.526	rs6061965	chr20:60607858	A/C	cg13770153	chr20:60521292	NA	-0.37	-5.43	-0.33	1.45e-7	Body mass index;
SARC	cis	rs11122272	0.735	rs2437148	chr1:231513979	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs11098499	0.754	rs10518300	chr4:120249499	G/T	cg09307838	chr4:120376055	NA	-0.72	-9.33	-0.52	8.45e-18	Corneal astigmatism;
SARC	cis	rs6669543	0.805	rs4657136	chr1:161994010	A/C	cg10810183	chr1:161993987	OLFML2B	-0.49	-5.93	-0.36	1.09e-8	QT interval;
SARC	cis	rs12701220	0.894	rs10263252	chr7:1049949	G/A	cg26769984	chr7:1090371	C7orf50	0.48	5.07	0.32	8.26e-7	Bronchopulmonary dysplasia;
SARC	cis	rs3774749	0.565	rs2518796	chr3:50207075	A/G	cg14019146	chr3:50243930	SLC38A3	-0.31	-5.22	-0.32	3.88e-7	Intelligence (multi-trait analysis);
SARC	cis	rs9388451	0.805	rs1028481	chr6:126106573	G/T	cg06289844	chr6:126071538	HEY2	0.34	5.51	0.34	9.56e-8	Brugada syndrome;
SARC	cis	rs831571	0.915	rs6797912	chr3:64058240	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	0.53	4.77	0.3	3.27e-6	Type 2 diabetes;
SARC	cis	rs67311347	0.866	rs2371183	chr3:40334247	C/T	cg24209194	chr3:40518798	ZNF619	-0.56	-7.29	-0.43	4.85e-12	Renal cell carcinoma;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg10175688	chr17:6544015	TXNDC17;KIAA0753	0.49	6.53	0.39	4.06e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg08859206	chr1:53392774	SCP2	0.44	6.26	0.38	1.82e-9	Monocyte count;
SARC	cis	rs4423214	1.000	rs12785878	chr11:71167449	G/T	cg05163923	chr11:71159392	DHCR7	0.65	8.91	0.5	1.52e-16	Vitamin D levels;
SARC	cis	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg25427524	chr10:38739819	LOC399744	-0.53	-8.32	-0.48	7.33e-15	Extrinsic epigenetic age acceleration;
SARC	cis	rs9372253	1.000	rs2235989	chr6:110714584	A/T	cg00083206	chr6:110721305	DDO	-0.4	-5.33	-0.33	2.28e-7	Platelet distribution width;
SARC	trans	rs12310956	0.532	rs6488187	chr12:33975029	C/T	cg26384229	chr12:38710491	ALG10B	0.77	10.62	0.57	9.84e-22	Morning vs. evening chronotype;
SARC	cis	rs72781680	1.000	rs72788278	chr2:24095285	A/C	cg06627628	chr2:24431161	ITSN2	-0.66	-6.46	-0.39	5.99e-10	Lymphocyte counts;
SARC	cis	rs611744	0.647	rs579162	chr8:109254842	A/G	cg21045802	chr8:109455806	TTC35	0.61	7.7	0.45	3.89e-13	Dupuytren's disease;
SARC	cis	rs7223966	1.000	rs73337598	chr17:61732576	T/C	cg00588841	chr17:61851480	DDX42;CCDC47	-0.59	-6.71	-0.4	1.42e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs2997447	0.706	rs2783713	chr1:26429351	C/A	cg19633962	chr1:26362018	EXTL1	-0.63	-5.63	-0.35	5.29e-8	QRS complex (12-leadsum);
SARC	cis	rs703842	0.892	rs1021469	chr12:58208164	C/T	cg00599273	chr12:58146742	CDK4	0.34	4.77	0.3	3.27e-6	Multiple sclerosis;
SARC	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg20607798	chr8:58055168	NA	0.61	5.53	0.34	8.72e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9858542	0.537	rs35869135	chr3:49359102	A/G	cg00383909	chr3:49044727	WDR6	0.57	6.12	0.37	4.04e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg16331281	chr10:4445958	NA	0.46	6.23	0.38	2.13e-9	Thyroid stimulating hormone;
SARC	cis	rs73206853	0.614	rs57154770	chr12:110814415	T/C	cg10860002	chr12:110842031	ANAPC7	0.63	5.03	0.31	9.95e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs957448	1.000	rs1055800	chr8:95523038	C/T	cg26464482	chr8:95565502	KIAA1429	-0.44	-4.76	-0.3	3.34e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg23422044	chr7:1970798	MAD1L1	-0.48	-5.35	-0.33	2.09e-7	Bipolar disorder;
SARC	cis	rs8141529	0.719	rs5762880	chr22:29287816	T/G	cg02153584	chr22:29168773	CCDC117	0.76	10.97	0.58	7.54e-23	Lymphocyte counts;
SARC	cis	rs17376456	0.825	rs72786702	chr5:93254656	A/C	cg21475434	chr5:93447410	FAM172A	0.86	7.72	0.45	3.37e-13	Diabetic retinopathy;
SARC	cis	rs2288912	0.838	rs2239375	chr19:45459851	T/C	cg20090143	chr19:45452003	APOC2	0.29	4.8	0.3	2.8e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
SARC	cis	rs1215050	0.755	rs1238462	chr4:98850603	A/G	cg05340658	chr4:99064831	C4orf37	-0.44	-5.89	-0.36	1.37e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs9467773	0.620	rs1027203	chr6:26639332	G/C	cg11502198	chr6:26597334	ABT1	0.6	7.75	0.45	2.75e-13	Intelligence (multi-trait analysis);
SARC	cis	rs61935443	0.666	rs11107781	chr12:95301086	T/A	cg21533806	chr12:95267307	NA	0.67	7.48	0.44	1.52e-12	Schizophrenia;
SARC	cis	rs9875589	0.509	rs9867041	chr3:14014615	T/C	cg19554555	chr3:13937349	NA	-0.41	-5.4	-0.33	1.64e-7	Ovarian reserve;
SARC	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg20607798	chr8:58055168	NA	0.66	5.15	0.32	5.52e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7666738	0.830	rs3896704	chr4:99034252	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.93	0.5	1.32e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs4332037	0.624	rs58169303	chr7:1883274	T/C	cg12591125	chr7:1885375	MAD1L1	0.45	4.73	0.3	3.82e-6	Bipolar disorder;
SARC	cis	rs2816062	0.813	rs2816040	chr1:18889536	C/T	cg18795169	chr1:18902165	NA	0.77	12.21	0.62	7.76e-27	Urate levels in lean individuals;
SARC	cis	rs1395	0.744	rs11126931	chr2:27474306	C/T	cg21747090	chr2:27597821	SNX17	-0.46	-5.62	-0.35	5.41e-8	Blood metabolite levels;
SARC	cis	rs1865760	0.566	rs9295686	chr6:26081983	G/C	cg10373733	chr6:25993375	NA	0.45	5.43	0.34	1.4e-7	Height;
SARC	cis	rs9815354	0.812	rs73077358	chr3:41850005	C/T	cg03022575	chr3:42003672	ULK4	0.71	5.84	0.36	1.73e-8	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.58	5.48	0.34	1.1e-7	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs4430311	0.723	rs6672195	chr1:243959543	T/C	cg21452805	chr1:244014465	NA	-0.38	-4.94	-0.31	1.47e-6	Post-traumatic stress disorder (asjusted for relatedness);
SARC	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg06221963	chr1:154839813	KCNN3	-0.51	-8.24	-0.47	1.27e-14	Prostate cancer;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg09213733	chr1:156023044	ROBLD3;UBQLN4	-0.67	-7.18	-0.43	9.12e-12	Lung cancer in ever smokers;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg06208248	chr1:155232061	SCAMP3	0.49	6.23	0.38	2.15e-9	Electrocardiographic conduction measures;
SARC	cis	rs1008375	1.000	rs10805359	chr4:17684886	A/G	cg02297831	chr4:17616191	MED28	0.43	5.41	0.33	1.55e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg24642844	chr7:1081250	C7orf50	-0.58	-6.2	-0.38	2.61e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs9796	0.870	rs8042088	chr15:41337487	C/T	cg18705301	chr15:41695430	NDUFAF1	0.42	5.91	0.36	1.22e-8	Menopause (age at onset);
SARC	cis	rs7932354	0.528	rs4752967	chr11:47169376	T/C	cg03339077	chr11:47165057	C11orf49	0.44	6.07	0.37	5.13e-9	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.36	4.98	0.31	1.24e-6	Total body bone mineral density;
SARC	cis	rs4268898	0.662	rs17733015	chr2:24509370	A/G	cg06627628	chr2:24431161	ITSN2	-0.83	-10.24	-0.56	1.44e-20	Asthma;
SARC	cis	rs611744	0.647	rs9969614	chr8:109260581	A/G	cg21045802	chr8:109455806	TTC35	0.63	8.09	0.47	3.31e-14	Dupuytren's disease;
SARC	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg02725872	chr8:58115012	NA	-0.37	-6.64	-0.4	2.14e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs3733585	0.699	rs4276278	chr4:9948870	T/C	cg11266682	chr4:10021025	SLC2A9	-0.37	-6.46	-0.39	6.11e-10	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.0	11.26	0.59	9.06e-24	Alzheimer's disease;
SARC	trans	rs8020941	0.585	rs74558040	chr14:97497783	G/A	cg05136476	chr3:53190709	NA	-0.63	-6.39	-0.39	8.99e-10	Diabetic kidney disease;
SARC	cis	rs2204008	0.720	rs11181343	chr12:38323616	G/T	cg13010199	chr12:38710504	ALG10B	0.78	10.65	0.57	7.78e-22	Bladder cancer;
SARC	cis	rs6665290	0.901	rs11580229	chr1:227210820	G/A	cg14016676	chr1:227182615	CDC42BPA	0.38	5.47	0.34	1.15e-7	Myeloid white cell count;
SARC	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg13939156	chr17:80058883	NA	0.37	5.65	0.35	4.6e-8	Life satisfaction;
SARC	cis	rs35110281	0.633	rs4818860	chr21:45119617	C/T	cg01579765	chr21:45077557	HSF2BP	-0.35	-5.84	-0.36	1.75e-8	Mean corpuscular volume;
SARC	cis	rs7582720	1.000	rs72934704	chr2:203706433	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	7.55	0.44	1e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg01316550	chr5:56110833	MAP3K1	0.53	4.79	0.3	2.98e-6	Initial pursuit acceleration;
SARC	cis	rs4660306	0.677	rs1691216	chr1:45899416	A/G	cg24296786	chr1:45957014	TESK2	-0.49	-4.82	-0.3	2.57e-6	Homocysteine levels;
SARC	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.92	13.58	0.66	2.41e-31	Chronic sinus infection;
SARC	cis	rs6815814	0.799	rs11466640	chr4:38778903	A/G	cg02016764	chr4:38805732	TLR1	0.43	4.79	0.3	3.02e-6	Breast cancer;
SARC	cis	rs898097	0.625	rs6502017	chr17:80891135	C/T	cg15664640	chr17:80829946	TBCD	0.33	5.18	0.32	4.7e-7	Breast cancer;
SARC	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg13939156	chr17:80058883	NA	-0.43	-6.7	-0.4	1.55e-10	Life satisfaction;
SARC	cis	rs2522056	1.000	rs886286	chr5:131795597	A/G	cg24060327	chr5:131705240	SLC22A5	0.48	4.76	0.3	3.38e-6	Lymphocyte counts;Fibrinogen;
SARC	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg22535103	chr8:58192502	C8orf71	-0.7	-7.06	-0.42	1.93e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg16049864	chr8:95962084	TP53INP1	-0.51	-8.4	-0.48	4.28e-15	Type 2 diabetes;
SARC	cis	rs1559088	0.600	rs10423965	chr19:33600319	T/G	cg27124370	chr19:33622961	WDR88	0.5	6.6	0.4	2.74e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs1568889	1.000	rs7937778	chr11:28104605	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	10.31	0.56	8.97e-21	Bipolar disorder;
SARC	cis	rs9790314	0.779	rs1599374	chr3:160891727	G/A	cg03342759	chr3:160939853	NMD3	-0.49	-5.81	-0.36	2.04e-8	Morning vs. evening chronotype;
SARC	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg02462569	chr6:150064036	NUP43	-0.37	-4.84	-0.3	2.39e-6	Lung cancer;
SARC	cis	rs8028182	0.636	rs11634863	chr15:75766672	C/A	cg20655648	chr15:75932815	IMP3	0.65	7.75	0.45	2.83e-13	Sudden cardiac arrest;
SARC	cis	rs765787	0.530	rs11070445	chr15:45513163	T/A	cg21132104	chr15:45694354	SPATA5L1	0.4	4.84	0.3	2.33e-6	Uric acid levels;
SARC	cis	rs6908034	0.607	rs79406203	chr6:19816221	T/G	cg02682789	chr6:19804855	NA	0.69	5.58	0.34	6.76e-8	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
SARC	cis	rs67311347	0.544	rs12633295	chr3:40335292	G/T	cg24209194	chr3:40518798	ZNF619	-0.49	-6.78	-0.41	9.5e-11	Renal cell carcinoma;
SARC	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg22535103	chr8:58192502	C8orf71	-0.57	-5.67	-0.35	4.3e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1348850	0.540	rs10172355	chr2:178443225	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.53	5.38	0.33	1.79e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs11097912	0.632	rs7662291	chr4:107185593	G/A	cg09646026	chr4:107269030	AIMP1	-0.43	-4.75	-0.3	3.53e-6	Airflow obstruction;
SARC	cis	rs3812831	0.695	rs423237	chr13:114930955	C/T	cg06611532	chr13:114900021	NA	0.35	5.79	0.35	2.28e-8	Schizophrenia;
SARC	cis	rs7727544	0.684	rs272869	chr5:131677997	A/G	cg24060327	chr5:131705240	SLC22A5	-0.69	-8.68	-0.49	6.74e-16	Blood metabolite levels;
SARC	cis	rs4481887	1.000	rs4244176	chr1:248468231	G/A	cg13385794	chr1:248469461	NA	0.36	5.59	0.34	6.44e-8	Common traits (Other);
SARC	cis	rs7647973	0.667	rs9869256	chr3:49624095	T/G	cg06212747	chr3:49208901	KLHDC8B	0.77	6.38	0.39	9.66e-10	Menarche (age at onset);
SARC	cis	rs78487399	0.808	rs6746610	chr2:43677253	T/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-5.01	-0.31	1.08e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs3768617	0.565	rs7542277	chr1:183063527	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.66	9.45	0.53	3.72e-18	Fuchs's corneal dystrophy;
SARC	cis	rs2204008	0.837	rs12581130	chr12:38319387	A/G	cg26384229	chr12:38710491	ALG10B	0.88	12.68	0.64	2.36e-28	Bladder cancer;
SARC	cis	rs17345786	1.000	rs17345528	chr3:101294830	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.47	-5.29	-0.33	2.86e-7	Colonoscopy-negative controls vs population controls;
SARC	cis	rs35306767	0.714	rs12783621	chr10:1083304	C/T	cg18964960	chr10:1102726	WDR37	0.48	4.8	0.3	2.83e-6	Eosinophil percentage of granulocytes;
SARC	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg26335602	chr6:28129616	ZNF389	0.52	5.78	0.35	2.41e-8	Depression;
SARC	cis	rs6963495	0.674	rs75880756	chr7:105163821	G/C	cg13798780	chr7:105162888	PUS7	0.6	5.45	0.34	1.31e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs3845702	1.000	rs9989852	chr2:180839707	G/A	cg01881094	chr2:180872142	CWC22	-0.74	-6.79	-0.41	9.46e-11	Schizophrenia;
SARC	cis	rs898097	0.578	rs6502021	chr17:80907728	T/C	cg10494973	chr17:80897199	TBCD	-0.37	-4.92	-0.31	1.6e-6	Breast cancer;
SARC	cis	rs13191362	1.000	rs36107456	chr6:162997399	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.57	5.51	0.34	9.61e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs787274	0.850	rs10759603	chr9:115639581	C/G	cg13803584	chr9:115635662	SNX30	-0.88	-6.09	-0.37	4.52e-9	Age-related hearing impairment (SNP x SNP interaction);
SARC	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg05896524	chr21:47604654	C21orf56	0.4	4.83	0.3	2.45e-6	Testicular germ cell tumor;
SARC	cis	rs6102059	0.548	rs6016382	chr20:39181246	T/A	cg06424997	chr20:39929561	ZHX3	0.37	4.8	0.3	2.86e-6	LDL cholesterol;
SARC	cis	rs7766436	1.000	rs7766436	chr6:22598259	C/T	cg13666174	chr6:22585274	NA	-0.56	-7.55	-0.44	9.94e-13	Coronary artery disease;
SARC	cis	rs9843304	0.967	rs12633863	chr3:149211512	G/A	cg08667024	chr3:149219783	TM4SF4	0.37	5.85	0.36	1.62e-8	Gallstone disease;
SARC	cis	rs10782582	0.609	rs111914775	chr1:76319036	C/T	cg03433033	chr1:76189801	ACADM	-0.38	-4.87	-0.3	2.09e-6	Daytime sleep phenotypes;
SARC	cis	rs6546550	0.935	rs1056482	chr2:70108256	A/T	cg02498382	chr2:70120550	SNRNP27	-0.36	-6.0	-0.37	7.4e-9	Prevalent atrial fibrillation;
SARC	cis	rs3126085	0.935	rs114825811	chr1:152231877	G/A	cg03465714	chr1:152285911	FLG	0.45	4.82	0.3	2.65e-6	Atopic dermatitis;
SARC	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg14983838	chr19:29218262	NA	0.75	10.34	0.56	7.28e-21	Methadone dose in opioid dependence;
SARC	cis	rs765787	0.530	rs2433227	chr15:45517119	A/T	cg26924012	chr15:45694286	SPATA5L1	-0.43	-5.39	-0.33	1.73e-7	Uric acid levels;
SARC	cis	rs10504229	0.593	rs7000752	chr8:58026980	C/G	cg21724239	chr8:58056113	NA	0.65	6.73	0.4	1.3e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7945705	0.791	rs10769958	chr11:8815115	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.38	-5.27	-0.33	3.15e-7	Hemoglobin concentration;
SARC	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg13206674	chr6:150067644	NUP43	0.43	5.55	0.34	7.62e-8	Lung cancer;
SARC	cis	rs9300255	0.602	rs1790131	chr12:123701010	G/T	cg00376283	chr12:123451042	ABCB9	0.55	6.53	0.39	4.09e-10	Neutrophil percentage of white cells;
SARC	cis	rs763121	0.853	rs2267393	chr22:39101619	G/C	cg06022373	chr22:39101656	GTPBP1	0.9	12.47	0.63	1.14e-27	Menopause (age at onset);
SARC	cis	rs356220	0.642	rs2572323	chr4:90634552	A/G	cg06632027	chr4:90757378	SNCA	0.38	4.91	0.31	1.73e-6	Parkinson's disease;
SARC	cis	rs6964587	1.000	rs6953515	chr7:91658620	C/T	cg17063962	chr7:91808500	NA	0.96	15.43	0.71	1.7e-37	Breast cancer;
SARC	cis	rs7829975	1.000	rs7829975	chr8:8548117	T/A	cg06636001	chr8:8085503	FLJ10661	-0.67	-8.61	-0.49	1.11e-15	Mood instability;
SARC	cis	rs721399	0.752	rs35570672	chr8:18272635	T/C	cg18736775	chr8:18248649	NAT2	0.44	5.4	0.33	1.63e-7	Blood metabolite levels;
SARC	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg16405210	chr4:1374714	KIAA1530	-0.52	-6.5	-0.39	4.73e-10	Obesity-related traits;
SARC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg26718510	chr12:44200307	TWF1	-0.58	-6.52	-0.39	4.35e-10	Hepatitis;
SARC	cis	rs9303401	0.659	rs7210700	chr17:56668186	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.09	12.25	0.63	5.64e-27	Cognitive test performance;
SARC	cis	rs9309473	0.950	rs1918863	chr2:73644481	A/G	cg20560298	chr2:73613845	ALMS1	-0.42	-5.24	-0.32	3.61e-7	Metabolite levels;
SARC	cis	rs9875589	0.509	rs1488375	chr3:14061563	G/A	cg19554555	chr3:13937349	NA	-0.41	-5.3	-0.33	2.63e-7	Ovarian reserve;
SARC	cis	rs6977660	0.714	rs17141882	chr7:19790217	C/T	cg07541023	chr7:19748670	TWISTNB	0.75	6.86	0.41	6.1e-11	Thyroid stimulating hormone;
SARC	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg02841227	chr6:26021843	HIST1H4A	0.63	7.59	0.45	7.62e-13	Intelligence (multi-trait analysis);
SARC	trans	rs747334	0.846	rs7897603	chr10:92708759	C/G	cg26233408	chr17:78210670	SLC26A11	-0.51	-6.96	-0.41	3.35e-11	Fibroblast growth factor basic levels;
SARC	cis	rs3761847	0.622	rs1323471	chr9:123826315	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.41	5.13	0.32	6e-7	Rheumatoid arthritis;
SARC	trans	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg06636001	chr8:8085503	FLJ10661	-0.6	-8.24	-0.48	1.21e-14	Systolic blood pressure;
SARC	cis	rs2084898	0.506	rs531260	chr11:120050515	C/T	cg07435449	chr11:120005650	TRIM29	0.34	5.26	0.33	3.32e-7	Stroke (pediatric);
SARC	cis	rs57502260	0.704	rs923346	chr11:68182375	T/C	cg01657329	chr11:68192670	LRP5	-0.55	-5.86	-0.36	1.54e-8	Total body bone mineral density (age 45-60);
SARC	cis	rs12142240	0.698	rs6703669	chr1:46862555	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-5.56	-0.34	7.46e-8	Menopause (age at onset);
SARC	cis	rs4927850	0.752	rs7624460	chr3:195748530	C/T	cg12923728	chr3:195709715	SDHAP1	-0.69	-8.94	-0.51	1.22e-16	Pancreatic cancer;
SARC	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg19660806	chr8:588740	NA	0.63	4.98	0.31	1.22e-6	IgG glycosylation;
SARC	cis	rs2228479	0.764	rs11641201	chr16:89983276	T/C	cg06558623	chr16:89946397	TCF25	0.62	5.28	0.33	3e-7	Skin colour saturation;
SARC	cis	rs17030434	0.834	rs1456399	chr4:154735242	C/T	cg14289246	chr4:154710475	SFRP2	-0.58	-6.43	-0.39	7.34e-10	Electrocardiographic conduction measures;
SARC	cis	rs11574514	1.000	rs9938862	chr16:67723801	T/C	cg01866162	chr16:67596514	CTCF	0.87	5.39	0.33	1.74e-7	Crohn's disease;
SARC	cis	rs7945705	0.967	rs10769968	chr11:8907583	G/C	cg21881798	chr11:8931708	C11orf17;ST5	0.39	5.35	0.33	2.08e-7	Hemoglobin concentration;
SARC	cis	rs1008375	1.000	rs10939749	chr4:17692319	A/C	cg27347728	chr4:17578864	LAP3	0.46	5.74	0.35	2.94e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2011503	1.000	rs11671253	chr19:19604206	C/T	cg15839431	chr19:19639596	YJEFN3	-0.48	-4.78	-0.3	3.15e-6	Bipolar disorder;
SARC	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg27398817	chr8:82754497	SNX16	0.44	5.52	0.34	8.83e-8	Diastolic blood pressure;
SARC	cis	rs7312774	0.881	rs7297923	chr12:107305573	T/C	cg16260113	chr12:107380972	MTERFD3	0.71	6.16	0.37	3.2e-9	Severe influenza A (H1N1) infection;
SARC	cis	rs78487399	0.808	rs17031001	chr2:43761218	T/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-5.02	-0.31	1.05e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs11190604	1.000	rs3750627	chr10:102275642	G/T	cg07080220	chr10:102295463	HIF1AN	0.77	9.44	0.53	4.16e-18	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs2635047	1.000	rs2684841	chr18:44724262	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.52	6.86	0.41	6.1e-11	Educational attainment;
SARC	cis	rs2486288	0.554	rs1719235	chr15:45576108	A/G	cg15395560	chr15:45543142	SLC28A2	0.33	6.15	0.37	3.39e-9	Glomerular filtration rate;
SARC	cis	rs10504229	0.593	rs16921589	chr8:58024387	C/A	cg08280861	chr8:58055591	NA	0.61	5.41	0.33	1.59e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg11890956	chr21:40555474	PSMG1	1.18	20.06	0.8	1.13e-52	Cognitive function;
SARC	cis	rs11583043	0.546	rs35363849	chr1:101591293	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.44	4.79	0.3	2.99e-6	Ulcerative colitis;Inflammatory bowel disease;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg12048536	chr14:76044591	FLVCR2	0.53	7.02	0.42	2.46e-11	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs910316	1.000	rs12889472	chr14:75543979	A/G	cg23033748	chr14:75592666	NEK9	0.39	5.43	0.34	1.41e-7	Height;
SARC	cis	rs4595586	0.525	rs12809307	chr12:39365927	A/G	cg13010199	chr12:38710504	ALG10B	0.4	4.75	0.3	3.57e-6	Morning vs. evening chronotype;
SARC	cis	rs72945132	0.769	rs680571	chr11:70187441	G/A	cg00319359	chr11:70116639	PPFIA1	0.7	6.61	0.4	2.63e-10	Coronary artery disease;
SARC	cis	rs7666738	0.571	rs7683769	chr4:99091742	T/C	cg05340658	chr4:99064831	C4orf37	0.52	6.58	0.4	3.15e-10	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9325144	0.647	rs7957185	chr12:38909710	G/A	cg26384229	chr12:38710491	ALG10B	-0.54	-7.07	-0.42	1.81e-11	Morning vs. evening chronotype;
SARC	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg24642844	chr7:1081250	C7orf50	-0.57	-6.05	-0.37	5.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg19223190	chr17:80058835	NA	0.47	6.44	0.39	6.62e-10	Life satisfaction;
SARC	cis	rs1215050	0.846	rs1839903	chr4:98791414	C/T	cg05340658	chr4:99064831	C4orf37	0.41	5.22	0.32	3.99e-7	Waist-to-hip ratio adjusted for body mass index;
SARC	trans	rs1814175	0.587	rs847628	chr11:49927064	A/T	cg15704280	chr7:45808275	SEPT13	-0.88	-14.0	-0.68	1.02e-32	Height;
SARC	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg13628971	chr7:2884303	GNA12	0.66	7.93	0.46	9.22e-14	Height;
SARC	cis	rs3859192	0.561	rs9916158	chr17:38182229	G/T	cg17344932	chr17:38183730	MED24;SNORD124	0.41	7.61	0.45	6.59e-13	White blood cell count;
SARC	cis	rs910316	1.000	rs175443	chr14:75601963	C/T	cg23033748	chr14:75592666	NEK9	-0.34	-4.74	-0.3	3.65e-6	Height;
SARC	cis	rs73198271	0.740	rs10110711	chr8:8650456	C/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-5.49	-0.34	1.07e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs11098499	0.954	rs28572238	chr4:120316686	T/G	cg09160332	chr4:120329925	NA	-0.33	-4.77	-0.3	3.27e-6	Corneal astigmatism;
SARC	cis	rs7092929	0.941	rs661019	chr10:3586581	C/T	cg14308648	chr10:3568949	NA	0.53	5.13	0.32	6.09e-7	Coronary artery calcification;
SARC	cis	rs9790314	0.586	rs11710086	chr3:161125858	A/T	cg17135325	chr3:160939158	NMD3	0.53	6.45	0.39	6.26e-10	Morning vs. evening chronotype;
SARC	cis	rs17401966	1.000	rs4845934	chr1:10468946	G/A	cg15208524	chr1:10270712	KIF1B	0.47	4.97	0.31	1.33e-6	Hepatocellular carcinoma;
SARC	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg11987759	chr7:65425863	GUSB	-0.5	-6.19	-0.38	2.62e-9	Aortic root size;
SARC	cis	rs7666738	0.830	rs4699591	chr4:98974171	A/G	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg22875332	chr1:76189707	ACADM	0.52	7.18	0.43	9.04e-12	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs651907	0.535	rs11712309	chr3:101519097	T/C	cg12386194	chr3:101231763	SENP7	0.47	5.38	0.33	1.77e-7	Colorectal cancer;
SARC	cis	rs7712401	0.601	rs30045	chr5:122271619	C/T	cg19412675	chr5:122181750	SNX24	0.43	5.7	0.35	3.67e-8	Mean platelet volume;
SARC	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg14403583	chr14:105418241	AHNAK2	-0.58	-7.63	-0.45	6.09e-13	Rheumatoid arthritis;
SARC	trans	rs2727020	0.521	rs10839299	chr11:49573981	C/T	cg03929089	chr4:120376271	NA	-0.68	-7.44	-0.44	1.92e-12	Coronary artery disease;
SARC	cis	rs2120019	1.000	rs7173833	chr15:75369618	C/T	cg17294928	chr15:75287854	SCAMP5	-0.85	-11.99	-0.62	3.96e-26	Blood trace element (Zn levels);
SARC	cis	rs9768139	0.634	rs11762383	chr7:158113889	C/T	cg25566285	chr7:158114605	PTPRN2	0.34	5.85	0.36	1.66e-8	Calcium levels;
SARC	cis	rs6582630	0.563	rs923281	chr12:38590241	G/A	cg13010199	chr12:38710504	ALG10B	-0.53	-6.55	-0.39	3.64e-10	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs10504229	0.679	rs16921687	chr8:58053514	T/C	cg08280861	chr8:58055591	NA	0.56	5.13	0.32	6.02e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs1395	0.778	rs4665960	chr2:27467598	C/T	cg21747090	chr2:27597821	SNX17	-0.5	-5.95	-0.36	1e-8	Blood metabolite levels;
SARC	cis	rs11718455	0.960	rs17076254	chr3:44000361	C/T	cg21419209	chr3:44054225	NA	-0.43	-5.4	-0.33	1.64e-7	Coronary artery disease;
SARC	cis	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.4	4.99	0.31	1.17e-6	Breast cancer;
SARC	cis	rs10504073	0.565	rs12056536	chr8:49890132	C/T	cg00325661	chr8:49890786	NA	-0.51	-6.76	-0.41	1.07e-10	Blood metabolite ratios;
SARC	cis	rs3796352	1.000	rs60942590	chr3:53016421	G/A	cg15956490	chr3:53032818	SFMBT1	0.78	5.25	0.33	3.49e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2845885	0.793	rs56241103	chr11:63882364	C/T	cg05555928	chr11:63887634	MACROD1	-0.63	-6.48	-0.39	5.5e-10	Body mass index;
SARC	cis	rs6991838	0.550	rs12335006	chr8:66531629	T/C	cg13398993	chr8:66546079	ARMC1	0.62	8.19	0.47	1.72e-14	Intelligence (multi-trait analysis);
SARC	cis	rs7474896	0.559	rs1735629	chr10:38178309	C/T	cg00409905	chr10:38381863	ZNF37A	0.46	4.94	0.31	1.47e-6	Obesity (extreme);
SARC	cis	rs1949733	1.000	rs1949733	chr4:8503359	C/T	cg13073564	chr4:8508604	NA	0.48	7.92	0.46	9.44e-14	Response to antineoplastic agents;
SARC	cis	rs4014195	0.521	rs12576996	chr11:65580638	G/T	cg26695010	chr11:65641043	EFEMP2	-0.59	-6.9	-0.41	4.83e-11	Glomerular filtration rate (creatinine);Chronic kidney disease;
SARC	cis	rs735539	0.521	rs2818998	chr13:21369911	T/C	cg16922012	chr13:21400325	XPO4	-0.44	-6.22	-0.38	2.24e-9	Dental caries;
SARC	cis	rs12311304	1.000	rs12307658	chr12:15388131	A/C	cg08258403	chr12:15378311	NA	0.48	7.3	0.43	4.45e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs6568686	0.786	rs6568682	chr6:111814177	G/A	cg15721981	chr6:111408429	SLC16A10	-0.6	-4.89	-0.31	1.89e-6	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs282587	0.502	rs371150	chr13:113397815	C/T	cg02820901	chr13:113351484	ATP11A	-0.5	-4.92	-0.31	1.65e-6	Glycated hemoglobin levels;
SARC	cis	rs7762018	0.607	rs77392231	chr6:170057634	G/A	cg19338460	chr6:170058176	WDR27	-0.83	-6.07	-0.37	5.13e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs6580649	1.000	rs7132668	chr12:48405860	C/T	cg24011408	chr12:48396354	COL2A1	0.51	5.73	0.35	3.12e-8	Lung cancer;
SARC	cis	rs12155623	0.504	rs10808736	chr8:49873039	C/A	cg01449144	chr8:49782592	NA	0.3	5.15	0.32	5.48e-7	Sudden cardiac arrest;
SARC	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg22618164	chr12:122356400	WDR66	0.4	6.01	0.37	6.93e-9	Mean corpuscular volume;
SARC	cis	rs1348850	0.567	rs3770009	chr2:178536544	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.42	4.98	0.31	1.26e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19552044	chr7:124570047	POT1	-0.59	-7.38	-0.44	2.78e-12	Smoking initiation;
SARC	cis	rs10504229	0.679	rs2317991	chr8:58035080	C/T	cg08219700	chr8:58056026	NA	-0.59	-6.18	-0.38	2.91e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs244293	0.730	rs2332314	chr17:53033007	T/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.39	-4.75	-0.3	3.53e-6	Menarche (age at onset);
SARC	cis	rs11578119	0.898	rs10919391	chr1:170381360	T/C	cg09767346	chr1:170501363	GORAB	0.42	4.74	0.3	3.71e-6	Male-pattern baldness;
SARC	cis	rs826838	1.000	rs826889	chr12:39101076	G/A	cg26384229	chr12:38710491	ALG10B	-0.77	-12.03	-0.62	2.95e-26	Heart rate;
SARC	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg06028605	chr16:24865363	SLC5A11	-0.36	-5.6	-0.34	5.87e-8	Intelligence (multi-trait analysis);
SARC	cis	rs881375	0.678	rs2269060	chr9:123683569	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	6.49	0.39	5.02e-10	Rheumatoid arthritis;
SARC	cis	rs5753618	0.583	rs2899164	chr22:31790289	G/A	cg02404636	chr22:31891804	SFI1	0.49	5.18	0.32	4.71e-7	Colorectal cancer;
SARC	cis	rs1008375	0.864	rs4698196	chr4:17574735	T/C	cg02297831	chr4:17616191	MED28	0.45	5.43	0.34	1.41e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg00800038	chr16:89945340	TCF25	-0.79	-5.45	-0.34	1.26e-7	Skin colour saturation;
SARC	cis	rs12893668	0.703	rs7140568	chr14:104041374	C/T	cg26031613	chr14:104095156	KLC1	-0.57	-6.31	-0.38	1.38e-9	Reticulocyte count;
SARC	cis	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg26695010	chr11:65641043	EFEMP2	-0.52	-6.81	-0.41	8.01e-11	Eosinophil percentage of white cells;
SARC	cis	rs611744	0.934	rs2848619	chr8:109198185	T/C	cg21045802	chr8:109455806	TTC35	0.44	5.23	0.32	3.81e-7	Dupuytren's disease;
SARC	trans	rs61931739	0.500	rs11519398	chr12:34473553	C/T	cg26384229	chr12:38710491	ALG10B	0.89	12.89	0.65	4.59e-29	Morning vs. evening chronotype;
SARC	cis	rs2425143	1.000	rs56052651	chr20:34344084	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.65	5.46	0.34	1.25e-7	Blood protein levels;
SARC	cis	rs80282103	0.618	rs2387299	chr10:1163427	A/G	cg08668510	chr10:1095578	IDI1	0.72	4.76	0.3	3.39e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs526231	0.578	rs6860588	chr5:102280302	A/G	cg23492399	chr5:102201601	PAM	0.45	5.35	0.33	2.09e-7	Primary biliary cholangitis;
SARC	cis	rs11758351	0.866	rs2069018	chr6:26205718	T/C	cg01420254	chr6:26195488	NA	0.56	5.01	0.31	1.05e-6	Gout;Renal underexcretion gout;
SARC	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg01475735	chr3:40494733	NA	-0.45	-5.03	-0.31	1e-6	Renal cell carcinoma;
SARC	cis	rs898097	0.625	rs898095	chr17:80890638	T/C	cg10494973	chr17:80897199	TBCD	-0.43	-5.82	-0.36	1.92e-8	Breast cancer;
SARC	cis	rs6539288	0.933	rs1037011	chr12:107302778	T/C	cg07730007	chr12:107377277	MTERFD3	0.38	4.79	0.3	2.97e-6	Total body bone mineral density;
SARC	cis	rs875971	0.545	rs67397473	chr7:65633305	A/G	cg11764359	chr7:65958608	NA	0.67	6.66	0.4	1.92e-10	Aortic root size;
SARC	cis	rs703842	0.928	rs724834	chr12:58180416	G/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.78	11.25	0.59	9.65e-24	Multiple sclerosis;
SARC	cis	rs4718428	0.705	rs12536410	chr7:66254290	G/A	cg18876405	chr7:65276391	NA	0.46	5.13	0.32	6.06e-7	Corneal structure;
SARC	cis	rs11098499	0.909	rs28668716	chr4:120309875	T/C	cg09160332	chr4:120329925	NA	-0.33	-4.77	-0.3	3.27e-6	Corneal astigmatism;
SARC	cis	rs55883249	0.957	rs17453675	chr2:9754407	A/G	cg23886495	chr2:9695866	ADAM17	0.69	7.0	0.42	2.72e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg00905354	chr6:170059414	WDR27	0.49	6.31	0.38	1.42e-9	Schizophrenia;
SARC	cis	rs7644634	0.661	rs11706886	chr3:105466055	C/G	cg23051926	chr3:105466016	CBLB	0.45	5.69	0.35	3.73e-8	Itch intensity from mosquito bite;
SARC	trans	rs56279505	0.690	rs56109716	chr4:100284798	A/G	cg18024358	chr1:3420815	MEGF6	-0.82	-6.4	-0.39	8.55e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1055129	0.681	rs7221792	chr17:73834690	T/G	cg06969265	chr17:73775802	H3F3B	0.43	5.1	0.32	6.89e-7	White matter hyperintensity burden;
SARC	cis	rs17401966	0.838	rs946502	chr1:10309279	G/C	cg15208524	chr1:10270712	KIF1B	0.45	5.37	0.33	1.92e-7	Hepatocellular carcinoma;
SARC	cis	rs4851254	0.961	rs11692215	chr2:100746573	C/T	cg17356467	chr2:100759845	AFF3	0.3	5.05	0.31	9.07e-7	Intelligence (multi-trait analysis);
SARC	cis	rs2974760	0.606	rs6600143	chr16:201389	A/C	cg08400316	chr16:204221	HBZ	-0.85	-11.24	-0.59	1.09e-23	Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.45	6.05	0.37	5.81e-9	Personality dimensions;
SARC	cis	rs1468333	0.632	rs12514118	chr5:137656480	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.71	8.36	0.48	5.72e-15	Resting heart rate;
SARC	cis	rs854765	0.583	rs9904163	chr17:17830553	C/T	cg05444541	chr17:17804740	TOM1L2	-0.3	-5.05	-0.31	9.06e-7	Total body bone mineral density;
SARC	cis	rs9303401	0.592	rs66583824	chr17:56639853	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.09	12.25	0.63	5.64e-27	Cognitive test performance;
SARC	cis	rs950776	0.752	rs62010327	chr15:78892784	G/A	cg22563815	chr15:78856949	CHRNA5	0.38	5.99	0.37	8.08e-9	Sudden cardiac arrest;
SARC	cis	rs3858526	0.508	rs10838734	chr11:5876325	T/G	cg02574844	chr11:5959923	NA	-0.37	-4.86	-0.3	2.2e-6	DNA methylation (variation);
SARC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg03188948	chr7:1209495	NA	0.42	5.4	0.33	1.67e-7	Longevity;Endometriosis;
SARC	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg05368731	chr17:41323189	NBR1	0.78	9.25	0.52	1.46e-17	Menopause (age at onset);
SARC	cis	rs4919694	1.000	rs12245343	chr10:104774050	A/G	cg04362960	chr10:104952993	NT5C2	0.65	5.48	0.34	1.09e-7	Arsenic metabolism;
SARC	cis	rs12586317	0.548	rs12590678	chr14:35602956	C/T	cg16230307	chr14:35515116	FAM177A1	0.91	10.49	0.57	2.41e-21	Psoriasis;
SARC	cis	rs820218	0.728	rs820184	chr17:73617403	T/C	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.5	6.1	0.37	4.32e-9	Rotator cuff tears;
SARC	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.42	-5.29	-0.33	2.87e-7	Total body bone mineral density;
SARC	cis	rs8058578	1.000	rs8048448	chr16:30692208	T/C	cg02466173	chr16:30829666	NA	-0.44	-5.75	-0.35	2.81e-8	Multiple myeloma;
SARC	cis	rs9868809	0.764	rs2633958	chr3:48635432	A/G	cg01304814	chr3:48885189	PRKAR2A	-0.82	-6.43	-0.39	7.17e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs12586317	0.547	rs116499019	chr14:35441931	T/C	cg16230307	chr14:35515116	FAM177A1	1.02	11.72	0.61	3.08e-25	Psoriasis;
SARC	trans	rs7937682	0.855	rs571462	chr11:111487106	C/G	cg18187862	chr3:45730750	SACM1L	0.55	6.99	0.42	2.93e-11	Primary sclerosing cholangitis;
SARC	cis	rs12824058	0.831	rs12297939	chr12:130811923	G/C	cg23887609	chr12:130822674	PIWIL1	0.37	5.15	0.32	5.52e-7	Menopause (age at onset);
SARC	cis	rs2075371	0.863	rs34231360	chr7:133944988	A/C	cg11752832	chr7:134001865	SLC35B4	0.48	5.94	0.36	1.02e-8	Mean platelet volume;
SARC	cis	rs13082711	0.595	rs1445114	chr3:27345489	C/A	cg02860705	chr3:27208620	NA	0.66	7.92	0.46	9.92e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs4253772	0.832	rs6008259	chr22:46633782	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.53	5.46	0.34	1.21e-7	LDL cholesterol;Cholesterol, total;
SARC	trans	rs453301	0.624	rs330058	chr8:9089809	G/A	cg06636001	chr8:8085503	FLJ10661	-0.71	-9.89	-0.54	1.72e-19	Joint mobility (Beighton score);
SARC	cis	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg21573476	chr21:45109991	RRP1B	-0.43	-6.07	-0.37	5.22e-9	Mean corpuscular volume;
SARC	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg06634786	chr22:41940651	POLR3H	-0.66	-7.81	-0.46	1.92e-13	Vitiligo;
SARC	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg08859206	chr1:53392774	SCP2	0.48	6.67	0.4	1.87e-10	Monocyte count;
SARC	cis	rs7582720	1.000	rs72936304	chr2:204036357	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	7.85	0.46	1.5e-13	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
SARC	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	-0.69	-6.76	-0.4	1.09e-10	Platelet count;
SARC	cis	rs10791097	0.694	rs4457753	chr11:130755575	A/G	cg12179176	chr11:130786555	SNX19	0.75	11.21	0.59	1.34e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
SARC	cis	rs7429990	0.813	rs7637622	chr3:48093051	G/A	cg11946769	chr3:48343235	NME6	-0.45	-5.22	-0.32	3.87e-7	Educational attainment (years of education);
SARC	cis	rs17376456	0.877	rs13169675	chr5:93331284	A/G	cg25358565	chr5:93447407	FAM172A	1.29	14.25	0.68	1.46e-33	Diabetic retinopathy;
SARC	cis	rs2120243	0.539	rs12629552	chr3:157086630	T/A	cg24825693	chr3:157122686	VEPH1	-0.45	-6.04	-0.37	6.03e-9	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs9303401	0.704	rs740605	chr17:56604811	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.45	5.56	0.34	7.49e-8	Cognitive test performance;
SARC	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg03735888	chr19:58951602	ZNF132	0.4	5.22	0.32	4e-7	Uric acid clearance;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg02160692	chr2:48117069	FBXO11	0.44	6.44	0.39	6.88e-10	Thyroid stimulating hormone;
SARC	cis	rs1971762	0.527	rs1683151	chr12:53946219	C/G	cg06632207	chr12:54070931	ATP5G2	-0.59	-8.05	-0.47	4.33e-14	Height;
SARC	cis	rs6963495	0.818	rs117907809	chr7:105168472	C/A	cg19920283	chr7:105172520	RINT1	0.67	5.74	0.35	2.87e-8	Bipolar disorder (body mass index interaction);
SARC	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg15448220	chr1:150897856	SETDB1	0.47	6.25	0.38	1.94e-9	Tonsillectomy;
SARC	cis	rs3796352	1.000	rs35849389	chr3:53005235	A/G	cg27565382	chr3:53032988	SFMBT1	0.83	5.68	0.35	4e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs3768617	0.510	rs35968946	chr1:183114871	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.68	9.8	0.54	3.35e-19	Fuchs's corneal dystrophy;
SARC	cis	rs10463554	0.927	rs34373	chr5:102404294	T/C	cg23492399	chr5:102201601	PAM	-0.51	-5.67	-0.35	4.23e-8	Parkinson's disease;
SARC	cis	rs6582630	0.554	rs8189625	chr12:38401177	C/T	cg13010199	chr12:38710504	ALG10B	-0.48	-5.81	-0.36	2.05e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs1865760	1.000	rs6910174	chr6:25904414	C/T	cg10373733	chr6:25993375	NA	0.42	5.05	0.31	8.91e-7	Height;
SARC	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg18252515	chr7:66147081	NA	1.29	11.17	0.59	1.7e-23	Diabetic kidney disease;
SARC	cis	rs908922	0.885	rs2181173	chr1:152474866	A/T	cg09873164	chr1:152488093	CRCT1	-0.59	-6.86	-0.41	6.16e-11	Hair morphology;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg12026394	chr9:100745975	ANP32B	-0.65	-6.68	-0.4	1.72e-10	Lung cancer in ever smokers;
SARC	cis	rs854765	0.505	rs2955358	chr17:17946623	A/G	cg04398451	chr17:18023971	MYO15A	0.46	6.52	0.39	4.25e-10	Total body bone mineral density;
SARC	cis	rs644799	1.000	rs500054	chr11:95593806	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	14.14	0.68	3.48e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs2832191	0.632	rs1984011	chr21:30337831	T/A	cg08807101	chr21:30365312	RNF160	-0.9	-14.06	-0.68	6.57e-33	Dental caries;
SARC	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.73	8.66	0.49	7.78e-16	Height;
SARC	cis	rs916888	0.647	rs199523	chr17:44848517	C/A	cg01570182	chr17:44337453	NA	-0.66	-7.51	-0.44	1.25e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg22974920	chr21:40686053	BRWD1	0.45	4.86	0.3	2.13e-6	Cognitive function;
SARC	cis	rs8028182	0.636	rs4886703	chr15:75730366	C/T	cg20655648	chr15:75932815	IMP3	0.64	7.61	0.45	6.67e-13	Sudden cardiac arrest;
SARC	cis	rs2933343	0.649	rs2638845	chr3:128587369	A/G	cg25356066	chr3:128598488	ACAD9	0.7	9.39	0.52	5.65e-18	IgG glycosylation;
SARC	cis	rs10927875	0.619	rs28537253	chr1:16148600	A/C	cg22431228	chr1:16359049	CLCNKA	0.29	4.74	0.3	3.65e-6	Dilated cardiomyopathy;
SARC	cis	rs4711350	0.765	rs756139	chr6:33755541	G/A	cg07979401	chr6:33739406	LEMD2	-0.38	-4.76	-0.3	3.46e-6	Schizophrenia;
SARC	cis	rs9894429	0.527	rs7405469	chr17:79566596	G/C	cg18240062	chr17:79603768	NPLOC4	-0.47	-5.05	-0.31	9.04e-7	Eye color traits;
SARC	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg22987457	chr7:157211561	NA	0.38	4.94	0.31	1.52e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg08616269	chr10:70480892	CCAR1	-0.43	-5.21	-0.32	4.21e-7	Schizophrenia;
SARC	cis	rs1865760	0.566	rs3752420	chr6:26027135	G/A	cg16482183	chr6:26056742	HIST1H1C	0.47	5.96	0.36	9.16e-9	Height;
SARC	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg15448220	chr1:150897856	SETDB1	0.47	6.25	0.38	1.94e-9	Tonsillectomy;
SARC	cis	rs7520050	0.807	rs4274104	chr1:46217941	T/C	cg24296786	chr1:45957014	TESK2	-0.44	-5.69	-0.35	3.89e-8	Red blood cell count;Reticulocyte count;
SARC	cis	rs72781680	0.821	rs72790304	chr2:24108557	G/A	cg08917208	chr2:24149416	ATAD2B	0.7	7.59	0.45	7.5e-13	Lymphocyte counts;
SARC	cis	rs3768617	0.565	rs4652775	chr1:183061825	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.66	9.45	0.53	3.74e-18	Fuchs's corneal dystrophy;
SARC	cis	rs5417	0.662	rs8067500	chr17:7172631	A/G	cg25256661	chr17:7137939	DVL2	0.72	10.14	0.55	3.01e-20	Diastolic blood pressure;
SARC	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.4	-6.09	-0.37	4.69e-9	Menopause (age at onset);
SARC	cis	rs10927875	0.632	rs10927863	chr1:16165247	C/A	cg21385522	chr1:16154831	NA	-0.91	-13.5	-0.66	4.5e-31	Dilated cardiomyopathy;
SARC	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg16325326	chr1:53192061	ZYG11B	0.77	12.07	0.62	2.27e-26	Monocyte count;
SARC	trans	rs11098499	0.909	rs10020034	chr4:120294331	A/G	cg25214090	chr10:38739885	LOC399744	0.52	6.87	0.41	5.64e-11	Corneal astigmatism;
SARC	cis	rs9300255	0.544	rs2049114	chr12:123657338	T/C	cg05973401	chr12:123451056	ABCB9	0.53	5.95	0.36	9.6e-9	Neutrophil percentage of white cells;
SARC	cis	rs1008375	0.863	rs4698632	chr4:17614894	T/C	cg16339924	chr4:17578868	LAP3	0.64	8.42	0.48	3.74e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	8.66	0.49	7.91e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7246657	0.722	rs958305	chr19:38189440	A/G	cg14683738	chr19:37701593	ZNF585B	-0.5	-4.72	-0.3	4.07e-6	Coronary artery calcification;
SARC	cis	rs9303401	0.614	rs62084384	chr17:57126842	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.01	10.3	0.56	9.73e-21	Cognitive test performance;
SARC	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg23758822	chr17:41437982	NA	0.86	10.56	0.57	1.52e-21	Menopause (age at onset);
SARC	cis	rs9303401	0.704	rs7359501	chr17:56641200	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.42	5.14	0.32	5.69e-7	Cognitive test performance;
SARC	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg04267008	chr7:1944627	MAD1L1	-0.6	-6.87	-0.41	5.81e-11	Bipolar disorder and schizophrenia;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg08900977	chr19:42637295	POU2F2	0.77	6.35	0.38	1.14e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.7	6.84	0.41	6.96e-11	Age-related macular degeneration (geographic atrophy);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg19191357	chr22:42196520	CCDC134	0.51	6.4	0.39	8.24e-10	Height;
SARC	cis	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg25427524	chr10:38739819	LOC399744	-0.52	-8.23	-0.47	1.32e-14	Extrinsic epigenetic age acceleration;
SARC	cis	rs754466	0.580	rs1058198	chr10:79566632	G/A	cg17075019	chr10:79541650	NA	-0.82	-12.52	-0.63	7.52e-28	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7582180	0.585	rs13031711	chr2:100939433	T/C	cg14675211	chr2:100938903	LONRF2	0.51	7.68	0.45	4.44e-13	Intelligence (multi-trait analysis);
SARC	cis	rs3733585	0.699	rs6449178	chr4:9968684	A/G	cg00071950	chr4:10020882	SLC2A9	0.4	6.28	0.38	1.69e-9	Cleft plate (environmental tobacco smoke interaction);
SARC	trans	rs7824557	0.545	rs2736303	chr8:11236850	C/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.0	-0.42	2.66e-11	Retinal vascular caliber;
SARC	cis	rs6604026	0.656	rs2811590	chr1:93367166	C/A	cg17283838	chr1:93427260	FAM69A	-0.42	-4.75	-0.3	3.59e-6	Multiple sclerosis;
SARC	cis	rs3820928	0.874	rs3769646	chr2:227896330	C/T	cg11843606	chr2:227700838	RHBDD1	-0.55	-6.84	-0.41	6.98e-11	Pulmonary function;
SARC	cis	rs854765	0.547	rs4925135	chr17:17952868	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-9.75	-0.54	4.63e-19	Total body bone mineral density;
SARC	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.49	7.2	0.43	8.31e-12	Systemic lupus erythematosus;
SARC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg08280861	chr8:58055591	NA	0.7	6.19	0.38	2.75e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs12586317	0.513	rs74564132	chr14:35472882	C/T	cg26967526	chr14:35346199	BAZ1A	-0.57	-5.71	-0.35	3.4e-8	Psoriasis;
SARC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg09373136	chr17:61933544	TCAM1	-0.45	-6.15	-0.37	3.38e-9	Prudent dietary pattern;
SARC	cis	rs3857536	0.813	rs62415859	chr6:66934278	G/A	cg07460842	chr6:66804631	NA	-0.51	-5.83	-0.36	1.82e-8	Blood trace element (Cu levels);
SARC	cis	rs2153535	0.580	rs6912374	chr6:8456423	T/C	cg07606381	chr6:8435919	SLC35B3	0.75	10.66	0.57	7.43e-22	Motion sickness;
SARC	cis	rs826838	1.000	rs1393537	chr12:38920961	C/T	cg13010199	chr12:38710504	ALG10B	0.77	10.63	0.57	9.01e-22	Heart rate;
SARC	cis	rs8114671	0.804	rs6088666	chr20:33564570	A/G	cg24642439	chr20:33292090	TP53INP2	0.48	5.6	0.34	5.97e-8	Height;
SARC	cis	rs59918340	0.764	rs4961256	chr8:142229946	G/A	cg16341495	chr8:142228727	SLC45A4	-0.36	-5.15	-0.32	5.52e-7	Immature fraction of reticulocytes;
SARC	cis	rs9660992	0.674	rs17345816	chr1:205262868	A/T	cg21545522	chr1:205238299	TMCC2	-0.45	-5.94	-0.36	1.04e-8	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs1707322	1.000	rs7531911	chr1:46330423	A/G	cg06784218	chr1:46089804	CCDC17	0.33	5.78	0.35	2.35e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs2439831	0.867	rs2243434	chr15:43689867	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.06	11.44	0.6	2.43e-24	Lung cancer in ever smokers;
SARC	cis	rs6456156	0.586	rs6456154	chr6:167472256	C/T	cg23791538	chr6:167370224	RNASET2	-0.52	-6.81	-0.41	8.22e-11	Primary biliary cholangitis;
SARC	trans	rs629535	0.814	rs651985	chr8:70054966	G/A	cg21567404	chr3:27674614	NA	1.01	13.13	0.65	7.38e-30	Dupuytren's disease;
SARC	cis	rs798554	0.655	rs798492	chr7:2799184	C/T	cg13628971	chr7:2884303	GNA12	-0.44	-5.46	-0.34	1.25e-7	Height;
SARC	cis	rs1878931	0.726	rs3843728	chr16:3448251	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	1.01	18.7	0.77	2.78e-48	Body mass index (adult);
SARC	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg19346786	chr7:2764209	NA	-0.37	-5.45	-0.34	1.29e-7	Height;
SARC	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg24549020	chr5:56110836	MAP3K1	0.81	8.43	0.48	3.58e-15	Initial pursuit acceleration;
SARC	cis	rs6772849	0.768	rs4521246	chr3:128421166	A/G	cg08795948	chr3:128337044	NA	-0.52	-7.07	-0.42	1.83e-11	Monocyte percentage of white cells;Monocyte count;
SARC	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg22800045	chr5:56110881	MAP3K1	-0.65	-6.08	-0.37	4.95e-9	Initial pursuit acceleration;
SARC	cis	rs6582630	0.519	rs4436613	chr12:38293653	T/C	cg13010199	chr12:38710504	ALG10B	0.79	11.02	0.59	5.26e-23	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs362272	0.505	rs3129310	chr4:3301388	T/G	cg08741688	chr4:3415352	RGS12	-0.43	-5.32	-0.33	2.49e-7	Serum sulfate level;
SARC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg09373136	chr17:61933544	TCAM1	-0.45	-6.12	-0.37	3.83e-9	Prudent dietary pattern;
SARC	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg22920501	chr2:26401640	FAM59B	-0.55	-7.14	-0.42	1.21e-11	Gut microbiome composition (summer);
SARC	cis	rs1153858	1.000	rs7402650	chr15:45701895	C/T	cg21132104	chr15:45694354	SPATA5L1	0.78	10.53	0.57	1.86e-21	Homoarginine levels;
SARC	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.51	4.92	0.31	1.66e-6	Lung function (FEV1/FVC);
SARC	cis	rs7566780	0.568	rs6728955	chr2:16631488	T/G	cg09580478	chr2:16689509	NA	0.49	5.59	0.34	6.3e-8	Orofacial clefts;Cleft lip with or without cleft palate;
SARC	cis	rs9486719	1.000	rs2145535	chr6:97034715	G/A	cg06623918	chr6:96969491	KIAA0776	-0.79	-8.88	-0.5	1.86e-16	Migraine;Coronary artery disease;
SARC	cis	rs6733011	0.519	rs12712034	chr2:99458933	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.43	-5.33	-0.33	2.36e-7	Bipolar disorder;
SARC	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.1	21.48	0.82	3.55e-57	Chronic sinus infection;
SARC	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg13939156	chr17:80058883	NA	-0.42	-6.51	-0.39	4.44e-10	Life satisfaction;
SARC	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg12311346	chr5:56204834	C5orf35	-0.57	-5.8	-0.36	2.1e-8	Initial pursuit acceleration;
SARC	cis	rs6582630	0.638	rs12424222	chr12:38548273	C/T	cg26384229	chr12:38710491	ALG10B	-0.57	-7.23	-0.43	6.73e-12	Drug-induced liver injury (flucloxacillin);
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08542227	chr3:16926340	PLCL2	-0.51	-6.52	-0.39	4.2e-10	Smoking initiation;
SARC	cis	rs11578119	0.933	rs12128140	chr1:170406363	C/T	cg09767346	chr1:170501363	GORAB	0.41	4.84	0.3	2.41e-6	Male-pattern baldness;
SARC	cis	rs995000	0.931	rs659656	chr1:62912120	C/G	cg06896770	chr1:63153194	DOCK7	0.89	13.58	0.66	2.52e-31	Triglyceride levels;
SARC	cis	rs870825	0.698	rs72703549	chr4:185623963	T/C	cg04058563	chr4:185651563	MLF1IP	0.82	11.42	0.6	2.8e-24	Blood protein levels;
SARC	cis	rs240764	0.658	rs9498390	chr6:101241438	T/A	cg09795085	chr6:101329169	ASCC3	-0.44	-5.7	-0.35	3.54e-8	Neuroticism;
SARC	cis	rs2204008	0.624	rs2320449	chr12:38224190	T/C	cg13010199	chr12:38710504	ALG10B	0.77	10.47	0.57	2.76e-21	Bladder cancer;
SARC	cis	rs4253772	0.550	rs6008600	chr22:46704676	A/G	cg24881330	chr22:46731750	TRMU	0.67	5.72	0.35	3.33e-8	LDL cholesterol;Cholesterol, total;
SARC	cis	rs7582180	0.764	rs4851293	chr2:100925106	A/T	cg14675211	chr2:100938903	LONRF2	0.51	7.37	0.44	2.87e-12	Intelligence (multi-trait analysis);
SARC	cis	rs57994353	0.802	rs12002854	chr9:139377499	G/A	cg13611204	chr9:139324423	INPP5E	-0.28	-4.72	-0.3	4.02e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg20634234	chr2:223520845	FARSB	0.81	6.95	0.41	3.55e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7833986	1.000	rs13281873	chr8:57101799	C/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.6	5.33	0.33	2.36e-7	Height;
SARC	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.43	6.75	0.4	1.18e-10	Schizophrenia;
SARC	trans	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg06636001	chr8:8085503	FLJ10661	-0.6	-8.08	-0.47	3.42e-14	Triglycerides;
SARC	cis	rs10782582	0.593	rs77733234	chr1:76101655	A/T	cg03433033	chr1:76189801	ACADM	-0.4	-5.26	-0.33	3.34e-7	Daytime sleep phenotypes;
SARC	cis	rs8114671	0.836	rs2104083	chr20:33649133	G/A	cg24642439	chr20:33292090	TP53INP2	-0.51	-5.96	-0.36	9.41e-9	Height;
SARC	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg12463550	chr7:65579703	CRCP	0.66	5.06	0.31	8.64e-7	Diabetic kidney disease;
SARC	cis	rs35995292	0.963	rs2392609	chr7:38952595	C/T	cg19327137	chr7:38886074	VPS41	0.35	5.03	0.31	9.98e-7	Subjective well-being (multi-trait analysis);
SARC	cis	rs9326248	0.581	rs11216267	chr11:116952392	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.66	8.25	0.48	1.14e-14	Blood protein levels;
SARC	cis	rs2916247	1.000	rs7844067	chr8:93026078	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.58	-6.22	-0.38	2.23e-9	Intelligence (multi-trait analysis);
SARC	cis	rs752010	0.871	rs10789405	chr1:42101962	C/T	cg06885757	chr1:42089581	HIVEP3	0.36	5.6	0.34	5.99e-8	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs7568458	0.905	rs6739015	chr2:85755357	A/G	cg02493740	chr2:85810744	VAMP5	-0.34	-5.02	-0.31	1.04e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.91	12.31	0.63	3.69e-27	Platelet count;
SARC	cis	rs7927771	0.725	rs11039265	chr11:47523214	C/A	cg20307385	chr11:47447363	PSMC3	-0.51	-6.32	-0.38	1.31e-9	Subjective well-being;
SARC	cis	rs1707322	1.000	rs4660905	chr1:46461587	C/T	cg03146154	chr1:46216737	IPP	-0.44	-5.19	-0.32	4.56e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9916302	0.571	rs28799952	chr17:37533056	C/T	cg07936489	chr17:37558343	FBXL20	0.77	9.26	0.52	1.38e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs4774830	0.744	rs62046391	chr15:56310688	C/T	cg24530489	chr15:56299380	NA	-0.8	-4.71	-0.3	4.18e-6	Delta-5 desaturase activity;
SARC	cis	rs2439831	0.850	rs28504496	chr15:44016883	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	7.55	0.44	9.75e-13	Lung cancer in ever smokers;
SARC	cis	rs1843834	0.574	rs6436499	chr2:225456551	A/T	cg22509189	chr2:225307070	NA	-0.65	-7.59	-0.44	7.89e-13	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg06420487	chr17:61919686	SMARCD2	0.43	4.72	0.3	4.02e-6	Height;
SARC	cis	rs883565	0.655	rs7619193	chr3:39044116	T/C	cg01426195	chr3:39028469	NA	-0.36	-5.23	-0.32	3.68e-7	Handedness;
SARC	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg03806693	chr22:41940476	POLR3H	0.89	11.74	0.61	2.67e-25	Vitiligo;
SARC	cis	rs7667	0.881	rs6692727	chr1:19755256	G/A	cg15311933	chr1:19638897	PQLC2;AKR7A2	-0.44	-5.16	-0.32	5.33e-7	Crohn's disease and psoriasis;
SARC	cis	rs995000	0.640	rs6679002	chr1:63199936	G/T	cg06896770	chr1:63153194	DOCK7	-0.52	-6.7	-0.4	1.57e-10	Triglyceride levels;
SARC	cis	rs4742903	0.527	rs2122576	chr9:106870187	G/T	cg14250997	chr9:106856677	SMC2	-0.48	-5.89	-0.36	1.32e-8	High-grade serous ovarian cancer;Breast cancer;
SARC	trans	rs877282	0.853	rs11593836	chr10:756715	G/A	cg22713356	chr15:30763199	NA	0.99	9.88	0.54	1.92e-19	Uric acid levels;
SARC	cis	rs733592	0.723	rs10875766	chr12:48593580	G/C	cg21466736	chr12:48725269	NA	-0.36	-6.39	-0.39	8.87e-10	Plateletcrit;
SARC	cis	rs3126085	0.825	rs7535078	chr1:152222915	T/C	cg26876637	chr1:152193138	HRNR	0.45	5.26	0.33	3.28e-7	Atopic dermatitis;
SARC	cis	rs11098499	1.000	rs28374891	chr4:120183550	G/A	cg09307838	chr4:120376055	NA	0.85	11.65	0.61	4.92e-25	Corneal astigmatism;
SARC	cis	rs7481584	0.624	rs438384	chr11:3045651	A/G	cg25174290	chr11:3078921	CARS	-0.57	-7.28	-0.43	5.04e-12	Calcium levels;
SARC	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg04518342	chr5:131593106	PDLIM4	0.42	5.41	0.33	1.57e-7	Breast cancer;
SARC	cis	rs6831352	0.918	rs13138294	chr4:100062675	T/G	cg12011299	chr4:100065546	ADH4	-0.34	-5.67	-0.35	4.2e-8	Alcohol dependence;
SARC	cis	rs9394169	0.709	rs6919321	chr6:33724004	G/A	cg25922239	chr6:33757077	LEMD2	0.41	4.88	0.3	1.99e-6	Essential tremor;
SARC	cis	rs4423214	0.959	rs12800438	chr11:71171003	G/A	cg05163923	chr11:71159392	DHCR7	0.67	9.47	0.53	3.19e-18	Vitamin D levels;
SARC	cis	rs1707322	1.000	rs4539075	chr1:46358010	C/T	cg03146154	chr1:46216737	IPP	0.47	5.64	0.35	4.94e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs79149102	0.579	rs7166105	chr15:75343942	A/G	cg00629941	chr15:75287862	SCAMP5	0.67	5.58	0.34	6.62e-8	Lung cancer;
SARC	cis	rs13336428	0.730	rs3946124	chr16:1525779	A/G	cg08008072	chr16:1524255	CLCN7	0.5	8.65	0.49	8.55e-16	Bone mineral density;
SARC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg26354017	chr1:205819088	PM20D1	0.95	16.72	0.74	9.41e-42	Menarche (age at onset);
SARC	cis	rs5167	0.566	rs2075618	chr19:45495668	G/C	cg13119609	chr19:45449297	APOC2	0.39	5.54	0.34	8.11e-8	Blood protein levels;
SARC	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-5.62	-0.35	5.3e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs10927875	0.632	rs4661666	chr1:16162471	C/A	cg21385522	chr1:16154831	NA	-0.91	-13.26	-0.66	2.92e-30	Dilated cardiomyopathy;
SARC	cis	rs9814567	0.712	rs9838119	chr3:134331980	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.51	-6.61	-0.4	2.53e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs4713118	0.955	rs9393847	chr6:27687973	G/A	cg17221315	chr6:27791827	HIST1H4J	0.5	5.03	0.31	9.57e-7	Parkinson's disease;
SARC	cis	rs9486715	0.929	rs2025044	chr6:97067028	A/G	cg06623918	chr6:96969491	KIAA0776	-0.81	-11.01	-0.58	5.79e-23	Headache;
SARC	cis	rs4742903	0.875	rs1857980	chr9:106992265	G/T	cg14250997	chr9:106856677	SMC2	0.41	5.18	0.32	4.89e-7	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs2033711	0.654	rs734380	chr19:58898963	A/C	cg13877915	chr19:58951672	ZNF132	0.55	7.55	0.44	1.01e-12	Uric acid clearance;
SARC	cis	rs858239	0.600	rs6961406	chr7:23134891	C/T	cg23682824	chr7:23144976	KLHL7	0.7	9.38	0.52	5.93e-18	Cerebrospinal fluid biomarker levels;
SARC	cis	rs10892173	0.765	rs7125694	chr11:117670657	C/T	cg07621104	chr11:117668040	DSCAML1	0.36	4.72	0.3	4.04e-6	Myopia;
SARC	cis	rs34779708	0.931	rs72789609	chr10:35306206	C/T	cg03585969	chr10:35415529	CREM	0.4	4.95	0.31	1.41e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg12564285	chr5:131593104	PDLIM4	0.45	6.17	0.37	2.98e-9	Acylcarnitine levels;
SARC	trans	rs9354308	0.868	rs4388276	chr6:66546565	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.53	-6.32	-0.38	1.32e-9	Metabolite levels;
SARC	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg17211192	chr8:82754475	SNX16	0.51	6.35	0.38	1.13e-9	Diastolic blood pressure;
SARC	cis	rs7264396	0.563	rs2425136	chr20:34344782	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-6.1	-0.37	4.36e-9	Total cholesterol levels;
SARC	cis	rs9747201	0.962	rs62078313	chr17:80116708	A/C	cg17462356	chr17:80056334	FASN	0.46	5.29	0.33	2.88e-7	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs2191566	0.576	rs381983	chr19:44494215	C/T	cg20607764	chr19:44506953	ZNF230	-0.41	-4.73	-0.3	3.86e-6	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs910316	1.000	rs876403	chr14:75602834	A/T	cg08847533	chr14:75593920	NEK9	0.91	15.33	0.71	3.68e-37	Height;
SARC	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg00152838	chr16:24741724	TNRC6A	-0.62	-6.32	-0.38	1.3e-9	Intelligence (multi-trait analysis);
SARC	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.52	7.18	0.43	9.35e-12	Bone mineral density (hip);Bone mineral density;
SARC	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg11366901	chr6:160182831	ACAT2	1.0	10.19	0.56	2.07e-20	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs34779708	1.000	rs34779708	chr10:35466185	T/G	cg03585969	chr10:35415529	CREM	0.38	4.76	0.3	3.45e-6	Inflammatory bowel disease;Crohn's disease;
SARC	cis	rs7937682	0.632	rs12785809	chr11:111776055	T/A	cg22437258	chr11:111473054	SIK2	-0.49	-5.61	-0.34	5.78e-8	Primary sclerosing cholangitis;
SARC	cis	rs9388451	0.839	rs1811852	chr6:126071575	G/C	cg06289844	chr6:126071538	HEY2	0.39	6.38	0.39	9.44e-10	Brugada syndrome;
SARC	cis	rs67460515	0.528	rs11915989	chr3:160902259	A/G	cg17135325	chr3:160939158	NMD3	0.68	8.67	0.49	7.57e-16	Parkinson's disease;
SARC	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg11987759	chr7:65425863	GUSB	0.57	7.55	0.44	9.97e-13	Aortic root size;
SARC	cis	rs367943	1.000	rs348948	chr5:112822452	A/C	cg12552261	chr5:112820674	MCC	-0.46	-5.27	-0.33	3.05e-7	Type 2 diabetes;
SARC	cis	rs12367572	0.965	rs7979717	chr12:45242272	A/T	cg04608330	chr12:45269318	NELL2	-0.48	-6.01	-0.37	7.25e-9	Gut microbiome composition (summer);
SARC	cis	rs7084402	0.967	rs1658457	chr10:60302716	T/C	cg07615347	chr10:60278583	BICC1	0.59	8.66	0.49	7.91e-16	Refractive error;
SARC	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg18252515	chr7:66147081	NA	-0.45	-4.99	-0.31	1.16e-6	Aortic root size;
SARC	cis	rs9911578	1.000	rs9902994	chr17:56948722	T/A	cg12560992	chr17:57184187	TRIM37	0.86	11.82	0.61	1.41e-25	Intelligence (multi-trait analysis);
SARC	cis	rs10489202	0.632	rs202259	chr1:167962072	G/A	cg24449463	chr1:168025552	DCAF6	-0.66	-8.81	-0.5	2.97e-16	Schizophrenia;
SARC	cis	rs760805	0.900	rs1005733	chr1:25261960	T/A	cg22509179	chr1:25234806	RUNX3	-0.52	-7.34	-0.43	3.64e-12	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs7597155	0.819	rs7424572	chr2:69969918	A/C	cg02498382	chr2:70120550	SNRNP27	0.35	6.05	0.37	5.8e-9	Palmitoleic acid (16:1n-7) levels;
SARC	cis	rs10875746	0.855	rs12310999	chr12:48447658	A/G	cg26205652	chr12:48591994	NA	0.56	6.05	0.37	5.72e-9	Longevity (90 years and older);
SARC	cis	rs10905065	0.829	rs2246399	chr10:5799286	T/A	cg09072322	chr10:5726702	C10orf18	0.39	4.89	0.31	1.84e-6	Menopause (age at onset);
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg03221778	chr16:89284213	ZNF778	-0.51	-6.41	-0.39	7.88e-10	Schizophrenia;
SARC	cis	rs6700896	0.864	rs56274111	chr1:66128511	A/C	cg04111102	chr1:66153794	NA	0.36	5.66	0.35	4.49e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
SARC	cis	rs1843834	0.898	rs12623277	chr2:225548072	T/G	cg12698349	chr2:225449008	CUL3	0.37	4.89	0.3	1.9e-6	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs10045431	0.519	rs254843	chr5:158673319	A/G	cg26646896	chr5:158686746	NA	0.53	4.83	0.3	2.45e-6	Crohn's disease;
SARC	cis	rs734999	0.566	rs4648658	chr1:2560882	G/A	cg00980319	chr1:2560884	MMEL1	0.34	4.8	0.3	2.87e-6	Ulcerative colitis;
SARC	cis	rs4689388	0.926	rs1801214	chr4:6303022	C/T	cg00701064	chr4:6280414	WFS1	0.55	8.67	0.49	7.42e-16	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs2180341	0.618	rs12529077	chr6:127634244	G/T	cg27446573	chr6:127587934	RNF146	0.68	9.0	0.51	8.19e-17	Breast cancer;
SARC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg22535103	chr8:58192502	C8orf71	-0.59	-6.21	-0.38	2.44e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9309473	0.898	rs10170786	chr2:73812988	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-5.46	-0.34	1.2e-7	Metabolite levels;
SARC	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg08645402	chr16:4508243	NA	0.41	4.81	0.3	2.71e-6	Schizophrenia;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg07513383	chr19:52552126	ZNF432	0.47	6.37	0.39	1.01e-9	Chemerin levels;
SARC	cis	rs2985684	0.841	rs7158577	chr14:50058633	C/T	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.45	4.89	0.31	1.88e-6	Carotid intima media thickness;
SARC	trans	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg16080015	chr7:5085479	RBAK	-0.48	-6.34	-0.38	1.16e-9	Gallstone disease;
SARC	cis	rs6964587	1.000	rs6961928	chr7:91669808	C/T	cg17063962	chr7:91808500	NA	0.94	15.76	0.72	1.44e-38	Breast cancer;
SARC	cis	rs6912958	1.000	rs9294379	chr6:88152535	C/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-5.46	-0.34	1.2e-7	Monocyte percentage of white cells;
SARC	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg06618935	chr21:46677482	NA	-0.41	-5.36	-0.33	2.03e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	trans	rs9929218	0.731	rs72785179	chr16:68767912	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.64	-8.33	-0.48	6.96e-15	Colorectal cancer;
SARC	cis	rs425277	0.958	rs262660	chr1:2086757	A/G	cg24578937	chr1:2090814	PRKCZ	0.31	5.87	0.36	1.47e-8	Height;
SARC	cis	rs11122272	0.638	rs2739514	chr1:231514806	G/A	cg06096015	chr1:231504339	EGLN1	0.38	5.7	0.35	3.62e-8	Hemoglobin concentration;
SARC	cis	rs1865721	0.771	rs72975986	chr18:73127649	A/G	cg26385618	chr18:73139727	C18orf62	-0.41	-5.61	-0.34	5.86e-8	Intelligence;
SARC	cis	rs17253792	0.732	rs75796044	chr14:56034128	C/T	cg01858014	chr14:56050164	KTN1	-0.68	-5.28	-0.33	3.03e-7	Putamen volume;
SARC	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.39	-4.76	-0.3	3.4e-6	Lymphocyte counts;
SARC	cis	rs13191362	0.938	rs35211042	chr6:162998703	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.57	5.51	0.34	9.61e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg05793240	chr7:2802953	GNA12	0.36	5.25	0.33	3.36e-7	Height;
SARC	cis	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg07636037	chr3:49044803	WDR6	0.48	5.61	0.35	5.67e-8	Resting heart rate;
SARC	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg13298116	chr11:62369859	EML3;MTA2	0.43	5.75	0.35	2.82e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs921968	0.643	rs6708683	chr2:219504503	G/A	cg02176678	chr2:219576539	TTLL4	0.36	5.26	0.33	3.27e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs11112613	0.713	rs871220	chr12:105938558	G/A	cg03607813	chr12:105948248	NA	0.54	7.23	0.43	6.85e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
SARC	cis	rs7296418	0.630	rs11608305	chr12:123791165	C/G	cg05973401	chr12:123451056	ABCB9	0.48	5.58	0.34	6.53e-8	Platelet count;
SARC	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg25072359	chr17:41440525	NA	0.48	5.62	0.35	5.43e-8	Menopause (age at onset);
SARC	cis	rs9398803	0.865	rs9385399	chr6:126759033	A/C	cg20229609	chr6:126660872	C6orf173	-0.36	-5.42	-0.33	1.48e-7	Male-pattern baldness;
SARC	cis	rs4141404	0.851	rs5749222	chr22:31556759	C/G	cg00478049	chr22:31556069	RNF185	0.46	5.58	0.34	6.61e-8	Paclitaxel-induced neuropathy;
SARC	cis	rs7264396	0.623	rs2590984	chr20:34597031	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-6.17	-0.37	3.06e-9	Total cholesterol levels;
SARC	trans	rs2727020	0.664	rs4929893	chr11:49196332	C/T	cg03929089	chr4:120376271	NA	-0.69	-9.55	-0.53	1.84e-18	Coronary artery disease;
SARC	cis	rs1707322	0.716	rs28370457	chr1:46172062	C/T	cg03146154	chr1:46216737	IPP	0.52	6.28	0.38	1.6e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7617773	0.743	rs7621785	chr3:48343708	T/C	cg11946769	chr3:48343235	NME6	0.76	9.7	0.54	6.55e-19	Coronary artery disease;
SARC	cis	rs6732160	0.774	rs7606271	chr2:73367698	T/G	cg01422370	chr2:73384389	NA	0.32	5.27	0.33	3.09e-7	Intelligence (multi-trait analysis);
SARC	cis	rs3099143	1.000	rs2046415	chr15:77085253	A/G	cg21673338	chr15:77095150	SCAPER	-0.77	-6.21	-0.38	2.41e-9	Recalcitrant atopic dermatitis;
SARC	cis	rs9682041	0.696	rs10936626	chr3:170095019	G/A	cg11886554	chr3:170076028	SKIL	0.83	7.75	0.45	2.91e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
SARC	cis	rs1915919	0.794	rs4398451	chr3:20010886	T/C	cg05072819	chr3:20081367	KAT2B	0.44	5.0	0.31	1.13e-6	Post-traumatic stress disorder;
SARC	cis	rs7666738	0.830	rs1025203	chr4:99023073	G/A	cg05340658	chr4:99064831	C4orf37	0.66	9.02	0.51	7.26e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2997447	0.846	rs17257086	chr1:26392535	C/T	cg19633962	chr1:26362018	EXTL1	-0.7	-5.51	-0.34	9.68e-8	QRS complex (12-leadsum);
SARC	cis	rs9420	0.807	rs12807357	chr11:57656902	C/T	cg19752551	chr11:57585705	CTNND1	-0.51	-6.67	-0.4	1.86e-10	Schizophrenia;
SARC	cis	rs79349575	0.721	rs9904645	chr17:46969665	A/T	cg07967210	chr17:47022446	SNF8	0.38	4.89	0.31	1.86e-6	Type 2 diabetes;
SARC	cis	rs1865760	0.516	rs9379819	chr6:26049819	A/C	cg17691542	chr6:26056736	HIST1H1C	0.5	6.3	0.38	1.47e-9	Height;
SARC	cis	rs60871478	0.636	rs4721600	chr7:871728	C/T	cg05535760	chr7:792225	HEATR2	-0.68	-6.82	-0.41	7.56e-11	Cerebrospinal P-tau181p levels;
SARC	cis	rs7044106	0.791	rs3904196	chr9:123480369	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	9.78	0.54	3.71e-19	Hip circumference adjusted for BMI;
SARC	cis	rs6582630	0.555	rs11181684	chr12:38388000	T/C	cg13010199	chr12:38710504	ALG10B	0.78	10.79	0.58	2.78e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9322817	0.715	rs6918700	chr6:105244526	A/T	cg02098413	chr6:105308735	HACE1	-0.39	-6.08	-0.37	4.85e-9	Thyroid stimulating hormone;
SARC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg16132339	chr22:24313637	DDTL;DDT	0.41	5.57	0.34	7.12e-8	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg22535103	chr8:58192502	C8orf71	-0.73	-7.24	-0.43	6.52e-12	Developmental language disorder (linguistic errors);
SARC	cis	rs73001065	0.818	rs12610191	chr19:19721976	C/T	cg03709012	chr19:19516395	GATAD2A	0.87	5.94	0.36	1.05e-8	LDL cholesterol;
SARC	cis	rs1092015	1.000	rs1092015	chr14:58200725	C/T	cg00735843	chr14:57735967	MUDENG;EXOC5	0.83	5.11	0.32	6.56e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs1124376	1.000	rs9819628	chr3:20140837	A/G	cg05072819	chr3:20081367	KAT2B	-0.47	-4.8	-0.3	2.82e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs5750854	0.503	rs742159	chr22:40024768	C/A	cg10455938	chr22:40058150	CACNA1I	0.46	5.58	0.34	6.62e-8	Intelligence (multi-trait analysis);
SARC	cis	rs1983170	0.736	rs13447479	chr1:91970464	T/G	cg25838465	chr1:92012736	NA	0.58	5.66	0.35	4.37e-8	Eosinophil percentage of white cells;
SARC	cis	rs1055129	0.560	rs2305913	chr17:73922941	T/C	cg06969265	chr17:73775802	H3F3B	0.48	5.79	0.35	2.26e-8	White matter hyperintensity burden;
SARC	cis	rs708547	0.830	rs1713994	chr4:57868367	G/A	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.53	-6.48	-0.39	5.48e-10	Response to bleomycin (chromatid breaks);
SARC	cis	rs9916302	0.904	rs7210488	chr17:37539819	T/G	cg20243544	chr17:37824526	PNMT	-0.55	-6.74	-0.4	1.24e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs7681440	0.746	rs6812192	chr4:90817848	A/G	cg06632027	chr4:90757378	SNCA	0.4	5.5	0.34	9.96e-8	Dementia with Lewy bodies;
SARC	cis	rs8014204	0.503	rs11621186	chr14:75120628	C/T	cg06637938	chr14:75390232	RPS6KL1	0.62	8.82	0.5	2.65e-16	Caffeine consumption;
SARC	trans	rs7937682	1.000	rs2186839	chr11:111534442	T/G	cg18187862	chr3:45730750	SACM1L	0.57	7.02	0.42	2.44e-11	Primary sclerosing cholangitis;
SARC	cis	rs7246657	0.943	rs1382357	chr19:37977609	G/A	cg23950597	chr19:37808831	NA	-0.57	-5.63	-0.35	5.05e-8	Coronary artery calcification;
SARC	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-6.95	-0.41	3.58e-11	Personality dimensions;
SARC	cis	rs910316	1.000	rs11159117	chr14:75584867	C/T	cg11812906	chr14:75593930	NEK9	0.89	13.96	0.67	1.33e-32	Height;
SARC	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg11644478	chr21:40555479	PSMG1	1.03	14.15	0.68	3.08e-33	Cognitive function;
SARC	cis	rs7818382	1.000	rs7818382	chr8:96054000	C/T	cg16049864	chr8:95962084	TP53INP1	-0.33	-5.27	-0.33	3.04e-7	Alzheimer's disease (late onset);
SARC	cis	rs9399137	0.507	rs35571217	chr6:135290355	T/C	cg24558204	chr6:135376177	HBS1L	0.62	7.98	0.46	6.83e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	trans	rs3942852	0.594	rs10769311	chr11:48094009	T/C	cg15704280	chr7:45808275	SEPT13	-0.66	-8.71	-0.5	5.74e-16	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs10465746	0.780	rs1871924	chr1:84398466	T/A	cg10977910	chr1:84465055	TTLL7	0.44	5.34	0.33	2.2e-7	Obesity-related traits;
SARC	cis	rs7551222	0.752	rs4951393	chr1:204489557	A/C	cg20240347	chr1:204465584	NA	0.34	6.21	0.38	2.45e-9	Schizophrenia;
SARC	cis	rs3784262	0.669	rs4646564	chr15:58351797	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.32	-4.8	-0.3	2.8e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs17270561	0.609	rs2000350	chr6:25763154	T/C	cg16482183	chr6:26056742	HIST1H1C	0.48	5.95	0.36	9.58e-9	Iron status biomarkers;
SARC	cis	rs554111	0.656	rs964466	chr1:21375163	T/G	cg08890418	chr1:21044141	KIF17	-0.36	-5.04	-0.31	9.42e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs6570726	0.935	rs906774	chr6:145813770	T/C	cg23711669	chr6:146136114	FBXO30	0.78	11.91	0.62	7.29e-26	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9916302	0.851	rs12947620	chr17:37605364	T/C	cg07936489	chr17:37558343	FBXL20	-0.69	-9.02	-0.51	7.32e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs7623687	0.786	rs73082337	chr3:49009570	C/G	cg19401529	chr3:49056140	DALRD3	0.73	6.44	0.39	6.59e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
SARC	trans	rs634534	0.622	rs593525	chr11:65727799	T/C	cg17712092	chr4:129076599	LARP1B	0.62	8.1	0.47	3.09e-14	Sum eosinophil basophil counts;Eosinophil counts;
SARC	trans	rs61931739	0.890	rs1705753	chr12:34144594	C/T	cg26384229	chr12:38710491	ALG10B	0.59	8.04	0.47	4.41e-14	Morning vs. evening chronotype;
SARC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.44	-4.96	-0.31	1.34e-6	Longevity;Endometriosis;
SARC	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg11843238	chr5:131593191	PDLIM4	0.4	4.97	0.31	1.27e-6	Breast cancer;
SARC	cis	rs1008375	0.932	rs4698628	chr4:17608620	A/G	cg02297831	chr4:17616191	MED28	0.51	6.46	0.39	6.19e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7659604	0.521	rs13130789	chr4:122690166	G/A	cg19748678	chr4:122722346	EXOSC9	-0.43	-5.3	-0.33	2.67e-7	Type 2 diabetes;
SARC	cis	rs870825	0.616	rs7680779	chr4:185652830	G/C	cg04058563	chr4:185651563	MLF1IP	-0.79	-11.11	-0.59	2.8e-23	Blood protein levels;
SARC	cis	rs10028773	0.568	rs6838457	chr4:120267367	A/G	cg09307838	chr4:120376055	NA	0.75	10.42	0.56	4.08e-21	Educational attainment;
SARC	cis	rs79349575	0.685	rs1124829	chr17:46967797	C/A	cg07967210	chr17:47022446	SNF8	0.39	4.86	0.3	2.15e-6	Type 2 diabetes;
SARC	cis	rs9457247	0.565	rs12193698	chr6:167512073	C/A	cg07741184	chr6:167504864	NA	0.37	7.08	0.42	1.73e-11	Crohn's disease;
SARC	cis	rs9916302	0.861	rs2338801	chr17:37490780	G/T	cg07936489	chr17:37558343	FBXL20	0.66	8.59	0.49	1.28e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs3753242	1.000	rs3753242	chr1:2069681	A/G	cg00312809	chr1:2028213	PRKCZ	-0.42	-4.94	-0.31	1.5e-6	Response to antipsychotic treatment in schizophrenia (reasoning);
SARC	cis	rs4911259	0.552	rs13041458	chr20:31467376	G/T	cg13636640	chr20:31349939	DNMT3B	-0.67	-9.22	-0.52	1.81e-17	Inflammatory bowel disease;
SARC	cis	rs9325144	0.560	rs7314632	chr12:38636979	C/T	cg13010199	chr12:38710504	ALG10B	-0.54	-6.97	-0.42	3.16e-11	Morning vs. evening chronotype;
SARC	cis	rs7662987	0.517	rs1133485	chr4:100023811	T/A	cg13256891	chr4:100009986	ADH5	0.66	8.13	0.47	2.55e-14	Smoking initiation;
SARC	cis	rs2204008	0.702	rs8175764	chr12:38363690	T/C	cg26384229	chr12:38710491	ALG10B	0.87	12.69	0.64	2.17e-28	Bladder cancer;
SARC	cis	rs8077889	0.703	rs231537	chr17:41942857	C/T	cg26893861	chr17:41843967	DUSP3	-0.7	-6.96	-0.41	3.41e-11	Triglycerides;
SARC	cis	rs2239547	0.657	rs7620706	chr3:52891756	A/T	cg11645453	chr3:52864694	ITIH4	0.33	5.09	0.32	7.3e-7	Schizophrenia;
SARC	cis	rs13191362	0.872	rs35672319	chr6:163245464	C/A	cg18825119	chr6:163149453	PACRG;PARK2	0.38	5.3	0.33	2.68e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs2439831	0.867	rs2412779	chr15:43655927	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.08	11.58	0.6	8.71e-25	Lung cancer in ever smokers;
SARC	cis	rs9611198	0.846	rs4820383	chr22:39961286	C/A	cg10455938	chr22:40058150	CACNA1I	0.39	4.81	0.3	2.75e-6	Schizophrenia;
SARC	cis	rs3812049	0.737	rs790154	chr5:127501235	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.83	9.1	0.51	4.08e-17	Lymphocyte counts;Red cell distribution width;
SARC	cis	rs2204008	0.659	rs4002655	chr12:38169881	T/G	cg26384229	chr12:38710491	ALG10B	0.89	13.09	0.65	1.03e-29	Bladder cancer;
SARC	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg11890956	chr21:40555474	PSMG1	0.73	9.84	0.54	2.56e-19	Menarche (age at onset);
SARC	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg25894440	chr7:65020034	NA	0.73	5.51	0.34	9.25e-8	Diabetic kidney disease;
SARC	cis	rs6540556	0.859	rs12131636	chr1:209942435	G/C	cg05527609	chr1:210001259	C1orf107	-0.76	-6.95	-0.41	3.56e-11	Red blood cell count;
SARC	cis	rs11581859	0.562	rs58412159	chr1:99235941	A/G	cg20286094	chr1:99190917	SNX7	-0.43	-5.08	-0.32	7.68e-7	Response to cognitive-behavioural therapy in anxiety disorder;
SARC	cis	rs7296418	0.961	rs7957096	chr12:123544878	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.39	-5.26	-0.33	3.32e-7	Platelet count;
SARC	cis	rs751728	1.000	rs751728	chr6:33764033	C/T	cg25922239	chr6:33757077	LEMD2	0.77	10.24	0.56	1.44e-20	Crohn's disease;
SARC	cis	rs2228479	0.850	rs62056065	chr16:89905115	C/G	cg06558623	chr16:89946397	TCF25	0.93	6.63	0.4	2.29e-10	Skin colour saturation;
SARC	cis	rs6831352	0.693	rs2602875	chr4:100039495	C/G	cg13256891	chr4:100009986	ADH5	0.6	7.9	0.46	1.09e-13	Alcohol dependence;
SARC	cis	rs79149102	0.737	rs74450883	chr15:75193432	A/G	cg17294928	chr15:75287854	SCAMP5	-0.96	-5.73	-0.35	3.05e-8	Lung cancer;
SARC	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg03735888	chr19:58951602	ZNF132	0.39	5.11	0.32	6.79e-7	Uric acid clearance;
SARC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg09373136	chr17:61933544	TCAM1	-0.44	-6.09	-0.37	4.59e-9	Prudent dietary pattern;
SARC	cis	rs7617773	0.851	rs6775179	chr3:48313418	T/C	cg11946769	chr3:48343235	NME6	0.68	8.97	0.51	9.74e-17	Coronary artery disease;
SARC	cis	rs2645694	0.533	rs2645680	chr4:77820956	T/C	cg10057126	chr4:77819792	ANKRD56	0.44	6.58	0.4	3.1e-10	Emphysema distribution in smoking;
SARC	cis	rs11758351	1.000	rs76722536	chr6:26192946	C/G	cg23601095	chr6:26197514	HIST1H3D	0.61	5.17	0.32	5.09e-7	Gout;Renal underexcretion gout;
SARC	cis	rs6582630	0.532	rs1589394	chr12:38419700	A/C	cg14851346	chr12:38532713	NA	0.44	5.18	0.32	4.78e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs2153535	0.580	rs7341383	chr6:8470634	A/C	cg21535247	chr6:8435926	SLC35B3	0.54	6.73	0.4	1.3e-10	Motion sickness;
SARC	cis	rs6693567	0.545	rs11205382	chr1:150442466	G/A	cg09579323	chr1:150459698	TARS2	-0.44	-5.58	-0.34	6.5e-8	Migraine;
SARC	cis	rs4268898	0.686	rs2042468	chr2:24398446	A/T	cg06627628	chr2:24431161	ITSN2	0.54	7.12	0.42	1.3e-11	Asthma;
SARC	cis	rs1008375	0.932	rs6844593	chr4:17659039	T/C	cg16339924	chr4:17578868	LAP3	0.65	8.51	0.49	2.12e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg06873352	chr17:61820015	STRADA	0.53	6.82	0.41	7.72e-11	Prudent dietary pattern;
SARC	cis	rs9393692	0.557	rs1883213	chr6:26303178	A/C	cg13736514	chr6:26305472	NA	-0.4	-4.79	-0.3	2.98e-6	Educational attainment;
SARC	cis	rs7561273	0.586	rs4149372	chr2:24305512	T/G	cg08917208	chr2:24149416	ATAD2B	0.44	4.82	0.3	2.63e-6	Quantitative traits;
SARC	cis	rs1865760	0.566	rs2032449	chr6:26026599	G/C	cg10373733	chr6:25993375	NA	0.4	4.85	0.3	2.28e-6	Height;
SARC	cis	rs2522056	0.935	rs1981524	chr5:131756506	C/T	cg24060327	chr5:131705240	SLC22A5	0.57	5.78	0.35	2.39e-8	Lymphocyte counts;Fibrinogen;
SARC	cis	rs9611565	0.512	rs5758464	chr22:42171300	A/G	cg17376030	chr22:41985996	PMM1	-0.86	-8.74	-0.5	4.76e-16	Vitiligo;
SARC	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.46	5.77	0.35	2.54e-8	Gut microbiome composition (summer);
SARC	cis	rs1865760	0.593	rs9295678	chr6:25937033	G/A	cg17691542	chr6:26056736	HIST1H1C	0.58	7.29	0.43	4.88e-12	Height;
SARC	cis	rs999943	0.846	rs2274200	chr6:33625696	T/C	cg14003231	chr6:33640908	ITPR3	0.54	8.99	0.51	8.56e-17	Obesity (extreme);
SARC	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg13012494	chr21:47604986	C21orf56	0.45	5.33	0.33	2.28e-7	Testicular germ cell tumor;
SARC	cis	rs2834188	0.924	rs2850015	chr21:34697264	T/C	cg14352951	chr21:34696688	IFNAR1	0.46	5.66	0.35	4.41e-8	Narcolepsy;
SARC	cis	rs4975616	0.686	rs37011	chr5:1348798	A/T	cg07493874	chr5:1342172	CLPTM1L	-0.45	-6.03	-0.37	6.29e-9	Lung cancer;
SARC	cis	rs11731606	0.508	rs28497379	chr4:95283789	G/T	cg20625393	chr4:95128694	SMARCAD1	0.59	5.62	0.35	5.5e-8	Mean platelet volume;
SARC	cis	rs9486719	1.000	rs10457159	chr6:96993139	G/A	cg06623918	chr6:96969491	KIAA0776	-0.79	-8.63	-0.49	9.42e-16	Migraine;Coronary artery disease;
SARC	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg24549020	chr5:56110836	MAP3K1	-0.48	-5.26	-0.33	3.28e-7	Initial pursuit acceleration;
SARC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2795502	1.000	rs2795497	chr10:43339475	C/A	cg20628663	chr10:43360327	NA	-0.47	-6.32	-0.38	1.33e-9	Blood protein levels;
SARC	cis	rs3767633	0.858	rs6698065	chr1:161891528	G/A	cg09175582	chr1:161736000	ATF6	0.64	5.7	0.35	3.52e-8	IgG glycosylation;
SARC	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg18404041	chr3:52824283	ITIH1	-0.39	-5.92	-0.36	1.14e-8	Electroencephalogram traits;
SARC	cis	rs16976116	0.901	rs1061875	chr15:55496278	C/T	cg11288833	chr15:55489084	RSL24D1	0.63	6.13	0.37	3.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs7829975	0.573	rs7842359	chr8:8797078	T/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.92	-0.41	4.3e-11	Mood instability;
SARC	trans	rs7615952	0.543	rs4645102	chr3:125424441	A/G	cg07211511	chr3:129823064	LOC729375	-0.57	-6.32	-0.38	1.32e-9	Blood pressure (smoking interaction);
SARC	cis	rs1580019	0.523	rs9791770	chr7:32582252	C/A	cg14728415	chr7:32535168	LSM5;AVL9	0.48	5.96	0.36	9.5e-9	Cognitive ability;
SARC	cis	rs7772486	0.654	rs6906402	chr6:146089307	C/G	cg23711669	chr6:146136114	FBXO30	-0.91	-16.19	-0.73	5.21e-40	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs2562456	0.917	rs2650793	chr19:21676115	C/G	cg00806126	chr19:22604979	ZNF98	0.51	5.2	0.32	4.34e-7	Pain;
SARC	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg20887711	chr4:1340912	KIAA1530	0.55	6.77	0.41	1.04e-10	Longevity;
SARC	cis	rs2576037	0.899	rs7233515	chr18:44585955	A/G	cg15049968	chr18:44337910	ST8SIA5	-0.31	-4.76	-0.3	3.39e-6	Personality dimensions;
SARC	cis	rs2076222	1.000	rs2076349	chr1:209800230	C/T	cg00257659	chr1:209800214	LAMB3	-0.74	-5.77	-0.35	2.48e-8	Fentanyl consumption in laparoscopic-assisted colectomy (first 24 hours);
SARC	cis	rs78487399	0.808	rs13396401	chr2:43701213	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-5.13	-0.32	6.24e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	trans	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg00938859	chr5:1591904	SDHAP3	0.69	6.31	0.38	1.39e-9	Breast cancer;
SARC	cis	rs2153535	0.542	rs6905925	chr6:8440030	C/T	cg21535247	chr6:8435926	SLC35B3	0.56	7.01	0.42	2.6e-11	Motion sickness;
SARC	cis	rs72781680	0.898	rs72781639	chr2:24204148	C/G	cg08917208	chr2:24149416	ATAD2B	0.78	7.62	0.45	6.31e-13	Lymphocyte counts;
SARC	cis	rs201779	1.000	rs200221	chr13:50960177	A/G	cg03369344	chr13:50705024	NA	-0.58	-4.83	-0.3	2.52e-6	Left atrial antero-posterior diameter;
SARC	cis	rs10189230	0.935	rs6731133	chr2:222359155	C/T	cg14652038	chr2:222343519	EPHA4	0.45	5.86	0.36	1.6e-8	Urate levels in lean individuals;
SARC	cis	rs80130819	0.688	rs1387256	chr12:48643738	G/A	cg24011408	chr12:48396354	COL2A1	0.52	5.88	0.36	1.42e-8	Prostate cancer;
SARC	cis	rs6840360	0.571	rs1978955	chr4:152509509	G/A	cg22705602	chr4:152727874	NA	-0.43	-6.66	-0.4	1.91e-10	Intelligence (multi-trait analysis);
SARC	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.95	-13.96	-0.67	1.32e-32	Gut microbiome composition (summer);
SARC	cis	rs10463554	0.853	rs2432177	chr5:102571873	A/G	cg23492399	chr5:102201601	PAM	-0.46	-4.96	-0.31	1.35e-6	Parkinson's disease;
SARC	cis	rs35110281	0.837	rs2838340	chr21:45076373	A/G	cg21573476	chr21:45109991	RRP1B	-0.52	-7.77	-0.45	2.51e-13	Mean corpuscular volume;
SARC	cis	rs9393692	0.557	rs10946810	chr6:26288055	G/A	cg13736514	chr6:26305472	NA	-0.41	-4.81	-0.3	2.67e-6	Educational attainment;
SARC	cis	rs2204008	0.775	rs12099736	chr12:38344111	C/G	cg13010199	chr12:38710504	ALG10B	0.79	10.86	0.58	1.65e-22	Bladder cancer;
SARC	cis	rs7223966	1.000	rs7209758	chr17:61913621	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.49	-5.0	-0.31	1.14e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7647973	0.626	rs9829155	chr3:49817450	T/C	cg13072238	chr3:49761600	GMPPB	0.6	6.16	0.37	3.16e-9	Menarche (age at onset);
SARC	cis	rs9916302	0.706	rs7208487	chr17:37543449	T/G	cg15445000	chr17:37608096	MED1	-0.45	-4.89	-0.31	1.86e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg14582100	chr15:45693742	SPATA5L1	0.35	4.91	0.31	1.69e-6	Homoarginine levels;
SARC	cis	rs1580019	0.885	rs4460269	chr7:32496445	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.73	9.78	0.54	3.93e-19	Cognitive ability;
SARC	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg13866156	chr1:1669148	SLC35E2	-0.62	-9.22	-0.52	1.82e-17	Body mass index;
SARC	cis	rs4775413	1.000	rs11071612	chr15:61834227	C/T	cg09972561	chr15:62353371	VPS13C	0.37	5.05	0.31	8.74e-7	Schizophrenia;
SARC	cis	rs9814567	0.762	rs13070654	chr3:134219348	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.52	5.58	0.34	6.53e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs9902453	0.765	rs3102555	chr17:28044101	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	6.99	0.42	2.94e-11	Coffee consumption (cups per day);
SARC	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg16405210	chr4:1374714	KIAA1530	-0.5	-5.83	-0.36	1.79e-8	Obesity-related traits;
SARC	cis	rs950027	0.584	rs1145086	chr15:45654327	A/G	cg15395560	chr15:45543142	SLC28A2	-0.27	-5.21	-0.32	4.22e-7	Response to fenofibrate (adiponectin levels);
SARC	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg11987759	chr7:65425863	GUSB	0.63	8.16	0.47	2.16e-14	Aortic root size;
SARC	cis	rs708547	0.957	rs1623306	chr4:57773595	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.62	6.6	0.4	2.68e-10	Response to bleomycin (chromatid breaks);
SARC	cis	rs9467773	0.967	rs9295694	chr6:26512994	A/T	cg11502198	chr6:26597334	ABT1	0.47	5.93	0.36	1.1e-8	Intelligence (multi-trait analysis);
SARC	cis	rs12681366	0.708	rs2470732	chr8:95376947	G/T	cg26464482	chr8:95565502	KIAA1429	-0.46	-5.7	-0.35	3.55e-8	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs7208859	0.623	rs73269974	chr17:29112384	C/T	cg13385521	chr17:29058706	SUZ12P	0.89	7.69	0.45	4.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs116095464	0.558	rs34629844	chr5:200829	A/G	cg22857025	chr5:266934	NA	-1.15	-10.78	-0.58	2.97e-22	Breast cancer;
SARC	cis	rs3091242	0.866	rs11249249	chr1:25758134	A/G	cg02931644	chr1:25747376	RHCE	0.44	7.24	0.43	6.42e-12	Erythrocyte sedimentation rate;
SARC	cis	rs1215050	0.791	rs6838628	chr4:98809574	A/G	cg05340658	chr4:99064831	C4orf37	0.43	5.81	0.36	2.03e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs9303401	0.659	rs7223708	chr17:56896398	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	11.5	0.6	1.52e-24	Cognitive test performance;
SARC	cis	rs6121246	0.512	rs6058384	chr20:30276409	A/T	cg13852791	chr20:30311386	BCL2L1	0.88	10.96	0.58	8.1e-23	Mean corpuscular hemoglobin;
SARC	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg11211951	chr8:145729740	GPT	0.61	9.67	0.54	7.96e-19	Age at first birth;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg10578696	chr1:65532742	NA	-0.78	-6.4	-0.39	8.37e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7084402	0.967	rs1649063	chr10:60309215	G/A	cg07615347	chr10:60278583	BICC1	0.59	8.61	0.49	1.12e-15	Refractive error;
SARC	cis	rs5769765	0.542	rs1535189	chr22:50249131	T/C	cg03033257	chr22:50311977	ALG12;CRELD2	-0.56	-4.8	-0.3	2.86e-6	Schizophrenia;
SARC	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg16325326	chr1:53192061	ZYG11B	-0.72	-9.88	-0.54	1.85e-19	Monocyte count;
SARC	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg26913058	chr16:419975	MRPL28	-0.35	-6.26	-0.38	1.83e-9	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs7296418	0.961	rs1727307	chr12:123575742	A/G	cg05973401	chr12:123451056	ABCB9	0.54	6.28	0.38	1.6e-9	Platelet count;
SARC	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg05863683	chr7:1912471	MAD1L1	0.37	5.68	0.35	3.91e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg26695010	chr11:65641043	EFEMP2	-0.53	-6.85	-0.41	6.57e-11	Eosinophil percentage of white cells;
SARC	cis	rs9638182	1.000	rs9638182	chr7:72999105	T/G	cg07467649	chr7:72856462	BAZ1B	0.47	4.9	0.31	1.81e-6	Triglycerides;
SARC	cis	rs17466626	1.000	rs11564199	chr12:40429696	C/T	cg04575343	chr12:40499262	SLC2A13	-0.71	-4.75	-0.3	3.57e-6	Pediatric autoimmune diseases;
SARC	cis	rs2916247	1.000	rs55701498	chr8:93039932	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.59	-6.03	-0.37	6.24e-9	Intelligence (multi-trait analysis);
SARC	cis	rs1044826	0.913	rs9831108	chr3:139098357	A/C	cg15131784	chr3:139108705	COPB2	0.46	5.32	0.33	2.38e-7	Obesity-related traits;
SARC	cis	rs9420	0.961	rs10896647	chr11:57571883	C/T	cg23127183	chr11:57508653	C11orf31	-0.6	-6.73	-0.4	1.27e-10	Schizophrenia;
SARC	trans	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg21659725	chr3:3221576	CRBN	-0.54	-7.2	-0.43	8.07e-12	Intelligence (multi-trait analysis);
SARC	cis	rs2712184	0.756	rs715049	chr2:217657102	C/T	cg05032264	chr2:217675019	NA	-0.53	-6.79	-0.41	9.06e-11	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
SARC	cis	rs796364	0.951	rs769952	chr2:200734368	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.79	7.05	0.42	2.01e-11	Schizophrenia;
SARC	cis	rs2718058	0.519	rs2722243	chr7:37873467	A/C	cg15028436	chr7:37888078	TXNDC3	0.41	5.64	0.35	4.81e-8	Alzheimer's disease (late onset);
SARC	cis	rs1153858	1.000	rs9788780	chr15:45685487	T/A	cg15395560	chr15:45543142	SLC28A2	-0.27	-4.91	-0.31	1.74e-6	Homoarginine levels;
SARC	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.41	-6.76	-0.4	1.1e-10	Total body bone mineral density;
SARC	cis	rs2290159	0.800	rs3773345	chr3:12642945	G/C	cg23032965	chr3:12705835	RAF1	0.74	7.99	0.46	6.38e-14	Cholesterol, total;
SARC	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg03709012	chr19:19516395	GATAD2A	-0.95	-15.25	-0.71	7.23e-37	Tonsillectomy;
SARC	cis	rs7937682	1.000	rs10502147	chr11:111569931	G/A	cg22437258	chr11:111473054	SIK2	-0.67	-8.71	-0.5	5.73e-16	Primary sclerosing cholangitis;
SARC	cis	rs208520	0.690	rs12208310	chr6:66730108	G/C	cg07460842	chr6:66804631	NA	1.05	14.04	0.68	7.33e-33	Exhaled nitric oxide output;
SARC	cis	rs921968	0.565	rs35189512	chr2:219628759	T/C	cg02176678	chr2:219576539	TTLL4	-0.33	-4.96	-0.31	1.37e-6	Mean corpuscular hemoglobin concentration;
SARC	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs898097	0.812	rs8065641	chr17:80820259	A/G	cg15369054	chr17:80825471	TBCD	0.54	7.91	0.46	1.03e-13	Breast cancer;
SARC	cis	rs9790314	0.580	rs960212	chr3:161047974	C/T	cg17135325	chr3:160939158	NMD3	0.55	6.97	0.42	3.2e-11	Morning vs. evening chronotype;
SARC	cis	rs7666738	0.830	rs13110498	chr4:98959150	G/A	cg05340658	chr4:99064831	C4orf37	0.66	9.0	0.51	8.07e-17	Colonoscopy-negative controls vs population controls;
SARC	trans	rs2727020	0.718	rs1404366	chr11:49415899	T/A	cg03929089	chr4:120376271	NA	-0.74	-8.94	-0.51	1.23e-16	Coronary artery disease;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg09174421	chr5:176900447	DBN1	0.53	7.33	0.43	3.69e-12	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs637571	0.522	rs679581	chr11:65746653	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.87	12.95	0.65	3.06e-29	Eosinophil percentage of white cells;
SARC	cis	rs13390159	1.000	rs57821542	chr2:237156074	G/T	cg19324714	chr2:237145437	ASB18	0.49	4.85	0.3	2.28e-6	Response to statin therapy;
SARC	cis	rs273218	1.000	rs273217	chr5:53380938	A/G	ch.5.1024479R	chr5:53302184	ARL15	0.66	7.11	0.42	1.39e-11	Migraine;
SARC	trans	rs7937682	0.889	rs10749984	chr11:111492861	T/C	cg18187862	chr3:45730750	SACM1L	0.55	6.99	0.42	2.93e-11	Primary sclerosing cholangitis;
SARC	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg24633833	chr3:10029261	TMEM111	0.52	5.25	0.33	3.43e-7	Alzheimer's disease;
SARC	cis	rs7666738	0.618	rs10856932	chr4:98819992	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.68	0.49	7.14e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs8031584	0.697	rs8036176	chr15:31175269	A/G	cg08109568	chr15:31115862	NA	-0.39	-4.75	-0.3	3.48e-6	Huntington's disease progression;
SARC	cis	rs13256369	0.802	rs13281933	chr8:8562665	C/A	cg17143192	chr8:8559678	CLDN23	0.52	5.75	0.35	2.75e-8	Obesity-related traits;
SARC	cis	rs7607369	0.559	rs4674339	chr2:219659787	C/G	cg02176678	chr2:219576539	TTLL4	-0.39	-6.08	-0.37	5e-9	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg05623727	chr3:50126028	RBM5	-0.32	-4.74	-0.3	3.76e-6	Body mass index;
SARC	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg27286337	chr10:134555280	INPP5A	0.64	7.79	0.45	2.17e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs7927771	0.832	rs10838704	chr11:47424717	T/C	cg05585544	chr11:47624801	NA	-0.35	-4.75	-0.3	3.51e-6	Subjective well-being;
SARC	cis	rs1865760	0.566	rs9467672	chr6:26083904	C/T	cg18357526	chr6:26021779	HIST1H4A	0.41	4.98	0.31	1.23e-6	Height;
SARC	cis	rs8002861	0.870	rs9567293	chr13:44447243	A/G	cg14210620	chr13:44453864	C13orf31;CCDC122	0.4	4.9	0.31	1.81e-6	Leprosy;
SARC	cis	rs11098499	0.569	rs10023641	chr4:120258410	C/G	cg09307838	chr4:120376055	NA	0.75	10.4	0.56	4.7e-21	Corneal astigmatism;
SARC	cis	rs6088580	0.634	rs4911421	chr20:32998948	T/C	cg24642439	chr20:33292090	TP53INP2	-0.68	-8.73	-0.5	4.96e-16	Glomerular filtration rate (creatinine);
SARC	cis	rs17270561	0.609	rs1892254	chr6:25750530	T/C	cg17691542	chr6:26056736	HIST1H1C	0.59	7.2	0.43	8.15e-12	Iron status biomarkers;
SARC	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg12463550	chr7:65579703	CRCP	-0.49	-5.32	-0.33	2.44e-7	Aortic root size;
SARC	cis	rs9814567	1.000	rs9289476	chr3:134237103	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-7.06	-0.42	1.94e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs5167	0.504	rs4803779	chr19:45456497	T/C	cg09555818	chr19:45449301	APOC2	0.55	8.91	0.5	1.5e-16	Blood protein levels;
SARC	cis	rs6665290	0.904	rs11587443	chr1:227187896	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.08	-25.1	-0.85	3.5e-68	Myeloid white cell count;
SARC	cis	rs9296092	0.560	rs9469506	chr6:33527897	A/G	cg13560919	chr6:33536144	NA	-0.52	-6.41	-0.39	8.07e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
SARC	cis	rs2439831	0.867	rs3809481	chr15:43662829	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.76	7.47	0.44	1.61e-12	Lung cancer in ever smokers;
SARC	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg22484793	chr3:52261325	TLR9	0.29	4.77	0.3	3.31e-6	Bipolar disorder;
SARC	cis	rs4803468	0.967	rs13345590	chr19:41886455	T/G	cg08477640	chr19:41863820	B9D2	0.41	5.32	0.33	2.39e-7	Height;
SARC	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg01341218	chr17:43662625	NA	1.0	11.39	0.6	3.48e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs6484504	0.532	rs7117286	chr11:31283810	T/A	cg02090638	chr11:31391270	DNAJC24;DCDC1	-0.43	-5.56	-0.34	7.25e-8	Red blood cell count;
SARC	cis	rs2153535	0.601	rs969420	chr6:8451966	T/A	cg07606381	chr6:8435919	SLC35B3	0.78	11.13	0.59	2.34e-23	Motion sickness;
SARC	cis	rs67460515	0.926	rs11715591	chr3:161043137	C/T	cg04691961	chr3:161091175	C3orf57	-0.52	-6.52	-0.39	4.37e-10	Parkinson's disease;
SARC	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.69	9.52	0.53	2.35e-18	Menarche (age at onset);
SARC	cis	rs6732160	0.845	rs2901420	chr2:73366001	A/G	cg01422370	chr2:73384389	NA	0.32	5.27	0.33	3.09e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7833790	0.963	rs10958046	chr8:82729210	A/G	cg27398817	chr8:82754497	SNX16	-0.51	-5.63	-0.35	5.24e-8	Diastolic blood pressure;
SARC	cis	rs6545883	0.931	rs11125885	chr2:61755728	G/C	cg15711740	chr2:61764176	XPO1	-0.45	-5.48	-0.34	1.09e-7	Tuberculosis;
SARC	cis	rs3768617	0.510	rs10752902	chr1:183090265	T/A	cg13390022	chr1:182993471	LAMC1	0.32	4.83	0.3	2.44e-6	Fuchs's corneal dystrophy;
SARC	cis	rs60733400	0.818	rs10909839	chr1:2708430	G/A	cg20673091	chr1:2541236	MMEL1	0.31	4.81	0.3	2.65e-6	Multiple sclerosis;
SARC	cis	rs561341	1.000	rs530715	chr17:30320544	T/G	cg00745463	chr17:30367425	LRRC37B	-0.62	-4.98	-0.31	1.26e-6	Hip circumference adjusted for BMI;
SARC	cis	rs17253792	0.822	rs10083303	chr14:56068521	T/C	cg01858014	chr14:56050164	KTN1	-0.67	-5.16	-0.32	5.38e-7	Putamen volume;
SARC	cis	rs6977660	0.598	rs10239147	chr7:19787459	T/C	cg05791153	chr7:19748676	TWISTNB	0.75	6.44	0.39	6.83e-10	Thyroid stimulating hormone;
SARC	cis	rs9905704	0.918	rs12949138	chr17:56934865	A/C	cg12560992	chr17:57184187	TRIM37	0.41	4.85	0.3	2.29e-6	Testicular germ cell tumor;
SARC	cis	rs1707322	1.000	rs1768800	chr1:46549188	A/G	cg03146154	chr1:46216737	IPP	-0.48	-5.66	-0.35	4.54e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs641862	1	rs641862	chr13:110790232	C/T	cg04020590	chr13:113978800	GRTP1	0.86	6.42	0.39	7.73e-10	Obesity-related traits;
SARC	cis	rs72653721	0.793	rs57864468	chr6:10966671	G/C	cg13562911	chr6:11044106	ELOVL2	0.59	6.35	0.38	1.14e-9	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg10156125	chr4:115520072	UGT8	-0.81	-7.15	-0.42	1.1e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs17539620	0.624	rs62432739	chr6:154835926	A/G	cg17771515	chr6:154831774	CNKSR3	0.53	5.07	0.32	8.2e-7	Lipoprotein (a) levels;
SARC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg04267008	chr7:1944627	MAD1L1	0.49	5.65	0.35	4.72e-8	Bipolar disorder and schizophrenia;
SARC	cis	rs2153535	0.580	rs9505467	chr6:8520219	G/A	cg07606381	chr6:8435919	SLC35B3	0.76	11.08	0.59	3.38e-23	Motion sickness;
SARC	cis	rs9790314	0.875	rs336568	chr3:161072763	G/C	cg03342759	chr3:160939853	NMD3	-0.64	-8.35	-0.48	5.94e-15	Morning vs. evening chronotype;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg04558362	chr11:64863611	C11orf2	0.5	6.73	0.4	1.28e-10	Lung adenocarcinoma;
SARC	trans	rs11098499	0.954	rs11098526	chr4:120390359	C/T	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	trans	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg11693508	chr17:37793320	STARD3	0.76	7.04	0.42	2.12e-11	Bipolar disorder;
SARC	cis	rs7824557	0.564	rs35009431	chr8:11232788	G/A	cg21775007	chr8:11205619	TDH	-0.64	-8.45	-0.48	3.23e-15	Retinal vascular caliber;
SARC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg13397359	chr6:42928475	GNMT	0.57	7.94	0.46	8.72e-14	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs9894429	0.690	rs11869779	chr17:79570067	C/T	cg21984481	chr17:79567631	NPLOC4	0.35	4.8	0.3	2.8e-6	Eye color traits;
SARC	cis	rs7584330	0.554	rs6739456	chr2:238385092	G/C	cg08992911	chr2:238395768	MLPH	0.61	5.33	0.33	2.34e-7	Prostate cancer;
SARC	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg11366901	chr6:160182831	ACAT2	0.98	10.13	0.55	3.23e-20	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg06636001	chr8:8085503	FLJ10661	-0.62	-8.33	-0.48	6.97e-15	Mood instability;
SARC	cis	rs9916302	0.904	rs4795359	chr17:37573146	C/T	cg00129232	chr17:37814104	STARD3	-0.63	-7.66	-0.45	5.09e-13	Glomerular filtration rate (creatinine);
SARC	cis	rs8067545	0.750	rs7223305	chr17:19990986	A/G	cg13482628	chr17:19912719	NA	0.53	7.07	0.42	1.78e-11	Schizophrenia;
SARC	cis	rs10197940	0.624	rs3771901	chr2:152432481	G/A	cg19508488	chr2:152266495	RIF1	0.49	5.33	0.33	2.35e-7	Lung cancer;
SARC	cis	rs62084913	0.511	rs895690	chr17:72784649	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	0.5	6.0	0.37	7.32e-9	Breast cancer;
SARC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg26338869	chr17:61819248	STRADA	0.79	10.59	0.57	1.19e-21	Prudent dietary pattern;
SARC	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg15847926	chr7:2749597	AMZ1	-0.3	-4.95	-0.31	1.43e-6	Height;
SARC	cis	rs67311347	1.000	rs73080165	chr3:40533062	G/T	cg24209194	chr3:40518798	ZNF619	0.59	7.47	0.44	1.61e-12	Renal cell carcinoma;
SARC	trans	rs10091344	0.961	rs2953933	chr8:34149090	T/A	cg26394233	chr7:157444480	PTPRN2	0.44	6.51	0.39	4.49e-10	Body mass index;
SARC	cis	rs10892173	0.782	rs6421566	chr11:117671398	G/A	cg21640587	chr11:117668038	DSCAML1	0.49	6.82	0.41	7.98e-11	Myopia;
SARC	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg19729930	chr2:74357872	NA	0.71	10.56	0.57	1.44e-21	Gestational age at birth (maternal effect);
SARC	cis	rs3106136	0.967	rs11097409	chr4:95168515	C/A	cg11021082	chr4:95130006	SMARCAD1	-0.39	-6.05	-0.37	5.83e-9	Capecitabine sensitivity;
SARC	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	-0.4	-5.9	-0.36	1.31e-8	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs3008870	1.000	rs2065000	chr1:67468124	G/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.88	-10.74	-0.58	4.09e-22	Lymphocyte percentage of white cells;
SARC	cis	rs2228479	0.850	rs1800331	chr16:89858417	C/A	cg00800038	chr16:89945340	TCF25	-0.76	-5.33	-0.33	2.27e-7	Skin colour saturation;
SARC	cis	rs11155671	0.530	rs4870080	chr6:150202644	T/C	cg09699651	chr6:150184138	LRP11	0.52	6.56	0.39	3.44e-10	Testicular germ cell tumor;
SARC	cis	rs9916302	0.706	rs9646419	chr17:37597185	A/G	cg15445000	chr17:37608096	MED1	0.46	4.89	0.3	1.91e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs6591182	0.503	rs11227241	chr11:65389890	G/C	cg27068330	chr11:65405492	SIPA1	-0.4	-5.01	-0.31	1.06e-6	Non-alcoholic fatty liver disease histology (lobular);
SARC	cis	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg25894440	chr7:65020034	NA	-0.76	-5.71	-0.35	3.37e-8	Diabetic kidney disease;
SARC	cis	rs4595586	0.545	rs969468	chr12:39367278	A/C	cg26384229	chr12:38710491	ALG10B	0.51	6.25	0.38	1.9e-9	Morning vs. evening chronotype;
SARC	cis	rs1941023	0.606	rs7946122	chr11:60172770	G/A	cg08716584	chr11:60157161	MS4A7	-0.41	-6.65	-0.4	2.09e-10	Congenital heart disease (maternal effect);
SARC	cis	rs10191773	0.589	rs72831639	chr2:112949291	A/G	cg07905836	chr2:113190072	RGPD8;RGPD5	1.0	7.94	0.46	8.29e-14	Yeast infection;
SARC	cis	rs11122272	0.732	rs2808605	chr1:231540187	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.04	-0.55	6e-20	Hemoglobin concentration;
SARC	cis	rs11785400	0.793	rs4457308	chr8:143733922	G/A	cg24634471	chr8:143751801	JRK	0.61	8.06	0.47	3.99e-14	Schizophrenia;
SARC	cis	rs2120019	1.000	rs1867146	chr15:75354971	C/G	cg12414181	chr15:75287860	SCAMP5	-0.45	-5.11	-0.32	6.8e-7	Blood trace element (Zn levels);
SARC	cis	rs9916302	0.851	rs6503502	chr17:37501855	A/G	cg07936489	chr17:37558343	FBXL20	0.69	9.14	0.51	3.18e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg12705353	chr12:122356852	WDR66	0.4	5.79	0.35	2.24e-8	Mean corpuscular volume;
SARC	cis	rs2070677	0.935	rs11101869	chr10:135400631	C/T	cg20169779	chr10:135381914	SYCE1	-0.54	-6.49	-0.39	4.99e-10	Gout;
SARC	cis	rs9388451	0.868	rs10457467	chr6:126045148	T/A	cg06289844	chr6:126071538	HEY2	0.35	5.64	0.35	4.87e-8	Brugada syndrome;
SARC	cis	rs7587476	0.822	rs13018304	chr2:215682218	T/G	cg04004882	chr2:215674386	BARD1	0.58	6.65	0.4	2.09e-10	Neuroblastoma;
SARC	cis	rs7666738	0.830	rs17483521	chr4:98974058	A/T	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1497406	0.744	rs12562207	chr1:16508059	G/A	cg06365898	chr1:16533907	ARHGEF19	0.4	5.39	0.33	1.69e-7	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg12880602	chr6:91321150	NA	-0.72	-6.29	-0.38	1.55e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs73206853	0.764	rs59527539	chr12:110968119	A/G	cg10860002	chr12:110842031	ANAPC7	0.6	5.0	0.31	1.1e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.53	6.11	0.37	4.21e-9	Renal function-related traits (BUN);
SARC	cis	rs9581943	0.967	rs7993114	chr13:28476277	A/G	cg16302790	chr13:28498334	PDX1	0.54	8.26	0.48	1.11e-14	Pancreatic cancer;
SARC	cis	rs739401	0.588	rs10219272	chr11:3020789	G/A	cg20651018	chr11:3035856	CARS	-0.46	-7.36	-0.43	3.14e-12	Longevity;
SARC	cis	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg15556689	chr8:8085844	FLJ10661	-0.41	-4.96	-0.31	1.36e-6	Neuroticism;
SARC	cis	rs1008375	1.000	rs28501187	chr4:17643620	G/A	cg16339924	chr4:17578868	LAP3	0.67	8.91	0.5	1.47e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg18252515	chr7:66147081	NA	1.27	11.47	0.6	1.96e-24	Diabetic kidney disease;
SARC	cis	rs826838	0.935	rs1684407	chr12:39127270	C/T	cg13010199	chr12:38710504	ALG10B	-0.63	-8.88	-0.5	1.87e-16	Heart rate;
SARC	cis	rs1949733	0.701	rs1880024	chr4:8454639	A/G	cg11789530	chr4:8429930	ACOX3	0.83	10.68	0.57	6.07e-22	Response to antineoplastic agents;
SARC	cis	rs3126085	0.935	rs4845736	chr1:152175551	G/A	cg26876637	chr1:152193138	HRNR	0.48	5.51	0.34	9.32e-8	Atopic dermatitis;
SARC	cis	rs11098499	0.730	rs12505735	chr4:120532956	G/T	cg09307838	chr4:120376055	NA	0.82	11.09	0.59	3.05e-23	Corneal astigmatism;
SARC	cis	rs10883723	0.518	rs10786679	chr10:104315667	C/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.51	6.57	0.4	3.26e-10	Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs4555082	0.834	rs2735822	chr14:105712734	C/T	cg13114125	chr14:105738426	BRF1	-0.81	-12.07	-0.62	2.19e-26	Mean platelet volume;Platelet distribution width;
SARC	cis	rs9486715	0.867	rs9486181	chr6:96868132	G/A	cg06623918	chr6:96969491	KIAA0776	0.88	12.7	0.64	1.95e-28	Headache;
SARC	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg12564285	chr5:131593104	PDLIM4	0.44	6.15	0.37	3.4e-9	Breast cancer;
SARC	cis	rs362272	0.524	rs881816	chr4:3365366	A/G	cg08741688	chr4:3415352	RGS12	-0.52	-6.55	-0.39	3.57e-10	Serum sulfate level;
SARC	cis	rs9815354	0.680	rs114714860	chr3:41882905	G/C	cg03022575	chr3:42003672	ULK4	0.56	5.29	0.33	2.86e-7	Pulse pressure;Diastolic blood pressure;
SARC	trans	rs1814175	0.502	rs12365889	chr11:49623034	G/A	cg03929089	chr4:120376271	NA	-0.78	-9.45	-0.53	3.76e-18	Height;
SARC	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7666738	0.753	rs17027308	chr4:99091088	T/A	cg05340658	chr4:99064831	C4orf37	0.59	7.63	0.45	6.13e-13	Colonoscopy-negative controls vs population controls;
SARC	cis	rs651907	0.557	rs11925001	chr3:101373966	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	6.4	0.39	8.52e-10	Colorectal cancer;
SARC	cis	rs11190604	0.767	rs11190533	chr10:102190792	T/C	cg07080220	chr10:102295463	HIF1AN	0.71	8.15	0.47	2.29e-14	Palmitoleic acid (16:1n-7) levels;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg07148914	chr20:33460835	GGT7	0.49	6.39	0.39	8.93e-10	Lung adenocarcinoma;
SARC	cis	rs920590	0.758	rs1817836	chr8:19664852	T/C	cg17834443	chr8:19674713	INTS10	0.6	7.41	0.44	2.37e-12	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs3126085	0.935	rs4845734	chr1:152167473	T/C	cg03465714	chr1:152285911	FLG	-0.47	-5.65	-0.35	4.71e-8	Atopic dermatitis;
SARC	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg04317338	chr11:64019027	PLCB3	0.64	7.53	0.44	1.12e-12	Platelet count;
SARC	cis	rs10782582	0.609	rs1689270	chr1:76390937	A/G	cg03433033	chr1:76189801	ACADM	-0.38	-4.76	-0.3	3.4e-6	Daytime sleep phenotypes;
SARC	cis	rs7587476	0.784	rs34112702	chr2:215696002	A/G	cg04530015	chr2:215796436	ABCA12	-0.41	-6.77	-0.41	1.03e-10	Neuroblastoma;
SARC	cis	rs644799	0.710	rs564480	chr11:95561741	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.59	7.71	0.45	3.65e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg05623727	chr3:50126028	RBM5	0.33	4.95	0.31	1.4e-6	Intelligence (multi-trait analysis);
SARC	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg23758822	chr17:41437982	NA	0.89	10.96	0.58	8.18e-23	Menopause (age at onset);
SARC	cis	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg12463550	chr7:65579703	CRCP	0.68	5.24	0.32	3.61e-7	Diabetic kidney disease;
SARC	cis	rs35110281	0.548	rs2838350	chr21:45109972	T/C	cg04455712	chr21:45112962	RRP1B	0.35	4.92	0.31	1.61e-6	Mean corpuscular volume;
SARC	cis	rs5753618	0.561	rs9609254	chr22:31705942	G/A	cg02404636	chr22:31891804	SFI1	0.47	5.04	0.31	9.4e-7	Colorectal cancer;
SARC	cis	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg14541582	chr5:601475	NA	-0.4	-5.1	-0.32	7e-7	Obesity-related traits;
SARC	cis	rs10782582	0.609	rs1630302	chr1:76412090	A/T	cg10523679	chr1:76189770	ACADM	-0.44	-5.38	-0.33	1.79e-7	Daytime sleep phenotypes;
SARC	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg19077165	chr18:44547161	KATNAL2	0.49	6.64	0.4	2.18e-10	Personality dimensions;
SARC	cis	rs2228479	0.718	rs62054253	chr16:89896932	T/C	cg00800038	chr16:89945340	TCF25	-0.82	-5.9	-0.36	1.27e-8	Skin colour saturation;
SARC	cis	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg08564027	chr20:61660810	NA	-0.81	-12.3	-0.63	3.97e-27	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs7264396	0.561	rs6060750	chr20:34596371	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.49	4.74	0.3	3.64e-6	Total cholesterol levels;
SARC	trans	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg20587970	chr11:113659929	NA	0.94	9.69	0.54	7.18e-19	Hip circumference adjusted for BMI;
SARC	cis	rs10911232	0.507	rs3934579	chr1:183027432	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.12	0.55	3.44e-20	Hypertriglyceridemia;
SARC	cis	rs17376456	0.877	rs17083455	chr5:93446380	A/C	cg21475434	chr5:93447410	FAM172A	0.88	8.11	0.47	2.81e-14	Diabetic retinopathy;
SARC	cis	rs72781680	1.000	rs17762782	chr2:24126493	A/G	cg08917208	chr2:24149416	ATAD2B	0.8	7.78	0.45	2.37e-13	Lymphocyte counts;
SARC	cis	rs9443189	0.762	rs1321162	chr6:76456347	C/T	cg01950844	chr6:76311363	SENP6	0.81	7.46	0.44	1.72e-12	Prostate cancer;
SARC	cis	rs950776	0.518	rs12910289	chr15:78822065	T/G	cg22563815	chr15:78856949	CHRNA5	0.41	6.82	0.41	7.56e-11	Sudden cardiac arrest;
SARC	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg12463550	chr7:65579703	CRCP	0.66	5.05	0.31	9.09e-7	Diabetic kidney disease;
SARC	cis	rs72781680	0.898	rs72790310	chr2:24116716	C/T	cg06627628	chr2:24431161	ITSN2	-0.66	-6.26	-0.38	1.86e-9	Lymphocyte counts;
SARC	cis	rs2013441	1.000	rs9904928	chr17:20180536	C/T	cg13482628	chr17:19912719	NA	0.46	5.86	0.36	1.56e-8	Obesity-related traits;
SARC	cis	rs9916302	0.861	rs33933929	chr17:37426441	A/C	cg00129232	chr17:37814104	STARD3	-0.59	-7.39	-0.44	2.69e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs7927771	0.864	rs112060627	chr11:47426956	G/A	cg20307385	chr11:47447363	PSMC3	-0.59	-7.54	-0.44	1.07e-12	Subjective well-being;
SARC	cis	rs9831754	0.704	rs9836909	chr3:78451594	A/G	cg06138941	chr3:78371609	NA	-0.56	-6.62	-0.4	2.47e-10	Calcium levels;
SARC	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-8.2	-0.47	1.6e-14	Chronic sinus infection;
SARC	cis	rs11249608	0.548	rs7709054	chr5:178462757	C/T	cg01312482	chr5:178451176	ZNF879	-0.37	-4.74	-0.3	3.69e-6	Pubertal anthropometrics;
SARC	cis	rs7178572	0.889	rs7177055	chr15:77832762	A/G	cg22256960	chr15:77711686	NA	0.52	6.08	0.37	4.93e-9	Type 2 diabetes;
SARC	cis	rs56036086	1.000	rs73187249	chr22:50634526	G/A	cg16473166	chr22:50639996	SELO	0.56	4.85	0.3	2.22e-6	Platelet count;Plateletcrit;
SARC	cis	rs2120019	0.938	rs13056	chr15:75312187	A/G	cg17294928	chr15:75287854	SCAMP5	-1.01	-15.27	-0.71	6.03e-37	Blood trace element (Zn levels);
SARC	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg07636037	chr3:49044803	WDR6	0.97	16.82	0.74	4.16e-42	Menarche (age at onset);
SARC	cis	rs8141529	0.529	rs5762816	chr22:29206209	T/C	cg15103426	chr22:29168792	CCDC117	0.6	5.68	0.35	4.06e-8	Lymphocyte counts;
SARC	cis	rs644799	1.000	rs564675	chr11:95561873	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.68	9.17	0.51	2.6e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg08219700	chr8:58056026	NA	0.77	6.99	0.42	2.82e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg11247378	chr22:39784982	NA	-0.3	-4.92	-0.31	1.63e-6	Intelligence (multi-trait analysis);
SARC	cis	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg03060546	chr3:49711283	APEH	-0.67	-8.3	-0.48	8.2e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg21747090	chr2:27597821	SNX17	-0.51	-6.97	-0.42	3.27e-11	Total body bone mineral density;
SARC	cis	rs9790314	0.746	rs898680	chr3:160772853	G/A	cg03342759	chr3:160939853	NMD3	-0.42	-5.05	-0.31	9.03e-7	Morning vs. evening chronotype;
SARC	cis	rs6570726	0.935	rs401888	chr6:145831535	A/G	cg05347473	chr6:146136440	FBXO30	0.48	6.42	0.39	7.51e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs920590	0.549	rs10749625	chr8:19635117	T/C	cg03894339	chr8:19674705	INTS10	0.46	5.78	0.35	2.37e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs76419734	0.558	rs11721732	chr4:106521514	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.71	5.89	0.36	1.35e-8	Post bronchodilator FEV1;
SARC	cis	rs10504229	0.679	rs2218271	chr8:58052446	T/A	cg11062466	chr8:58055876	NA	0.5	4.9	0.31	1.77e-6	Developmental language disorder (linguistic errors);
SARC	trans	rs1814175	0.588	rs10839463	chr11:49971643	A/G	cg03929089	chr4:120376271	NA	-0.82	-11.88	-0.61	9.2e-26	Height;
SARC	cis	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.67	-0.45	4.53e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs1941023	0.503	rs10792269	chr11:60117126	C/T	cg08716584	chr11:60157161	MS4A7	-0.36	-6.09	-0.37	4.59e-9	Congenital heart disease (maternal effect);
SARC	cis	rs7937682	0.632	rs11214029	chr11:111761230	C/T	cg09085632	chr11:111637200	PPP2R1B	0.77	9.55	0.53	1.94e-18	Primary sclerosing cholangitis;
SARC	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg08048268	chr3:133502702	NA	-0.43	-5.8	-0.36	2.12e-8	Iron status biomarkers;
SARC	cis	rs644799	0.648	rs1255176	chr11:95471465	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.72	9.93	0.55	1.36e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs7937682	0.824	rs11213962	chr11:111506027	G/A	cg18187862	chr3:45730750	SACM1L	0.55	6.96	0.41	3.46e-11	Primary sclerosing cholangitis;
SARC	cis	rs738321	0.794	rs5756940	chr22:38558842	C/T	cg25457927	chr22:38595422	NA	-0.27	-5.08	-0.32	7.69e-7	Breast cancer;
SARC	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg23758822	chr17:41437982	NA	0.87	10.68	0.57	6.32e-22	Menopause (age at onset);
SARC	cis	rs9398803	0.830	rs1337735	chr6:126771024	T/A	cg19875578	chr6:126661172	C6orf173	0.63	8.6	0.49	1.17e-15	Male-pattern baldness;
SARC	cis	rs4481887	0.927	rs11204637	chr1:248492581	G/A	cg13385794	chr1:248469461	NA	0.33	4.98	0.31	1.21e-6	Common traits (Other);
SARC	cis	rs9392918	1.000	rs9392918	chr6:7708631	C/T	cg23089261	chr6:7723385	NA	-0.4	-5.32	-0.33	2.42e-7	Height;
SARC	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg16680214	chr1:154839983	KCNN3	-0.36	-5.7	-0.35	3.66e-8	Prostate cancer;
SARC	cis	rs1348850	0.526	rs4243389	chr2:178379783	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	5.67	0.35	4.19e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7674212	0.541	rs2720460	chr4:104054686	C/T	cg16532752	chr4:104119610	CENPE	0.49	6.01	0.37	7.18e-9	Type 2 diabetes;
SARC	cis	rs9894429	0.966	rs7405901	chr17:79587813	T/C	cg18240062	chr17:79603768	NPLOC4	0.72	9.75	0.54	4.76e-19	Eye color traits;
SARC	cis	rs2645694	0.651	rs2703144	chr4:77830505	C/G	cg18351406	chr4:77819688	ANKRD56	0.36	5.07	0.31	8.28e-7	Emphysema distribution in smoking;
SARC	cis	rs7666738	0.830	rs10005173	chr4:98816062	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.7	0.5	6.24e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg17971929	chr21:40555470	PSMG1	-0.57	-7.2	-0.43	8.24e-12	Menarche (age at onset);
SARC	cis	rs72945132	0.825	rs12287883	chr11:70122369	C/T	cg00319359	chr11:70116639	PPFIA1	0.68	6.37	0.39	1.01e-9	Coronary artery disease;
SARC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg09373136	chr17:61933544	TCAM1	-0.46	-6.39	-0.39	8.85e-10	Prudent dietary pattern;
SARC	cis	rs9398803	0.687	rs9491653	chr6:126943630	A/G	cg20229609	chr6:126660872	C6orf173	0.37	5.38	0.33	1.79e-7	Male-pattern baldness;
SARC	cis	rs9860428	0.565	rs4682120	chr3:112575080	A/G	cg17974142	chr3:113464438	ATP6V1A;NAA50	-0.38	-4.76	-0.3	3.33e-6	Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);Rheumatoid arthritis;
SARC	cis	rs4969178	0.965	rs12450528	chr17:76395753	G/A	cg02836325	chr17:76403955	PGS1	0.33	5.01	0.31	1.07e-6	HDL cholesterol levels;
SARC	cis	rs9309473	0.500	rs4852953	chr2:73869908	G/A	cg20560298	chr2:73613845	ALMS1	0.46	6.14	0.37	3.44e-9	Metabolite levels;
SARC	cis	rs6546324	0.921	rs1430788	chr2:67868412	C/T	cg18237512	chr2:67827392	NA	-0.44	-5.62	-0.35	5.5e-8	Endometriosis;
SARC	cis	rs2070488	1.000	rs13072809	chr3:38468171	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	14.71	0.69	4.5e-35	Electrocardiographic conduction measures;
SARC	cis	rs911555	0.755	rs8014800	chr14:103946302	T/C	cg24130564	chr14:104152367	KLC1	0.49	5.77	0.35	2.48e-8	Intelligence (multi-trait analysis);
SARC	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg21724239	chr8:58056113	NA	0.62	6.12	0.37	4.02e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs10754283	0.967	rs10801764	chr1:90121751	T/G	cg21401794	chr1:90099060	LRRC8C	0.6	8.32	0.48	7.61e-15	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs950776	0.518	rs952215	chr15:78819153	C/T	cg17108064	chr15:78857060	CHRNA5	-0.29	-4.85	-0.3	2.25e-6	Sudden cardiac arrest;
SARC	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg26335602	chr6:28129616	ZNF389	0.44	5.23	0.32	3.72e-7	Parkinson's disease;
SARC	cis	rs12142240	0.698	rs55670684	chr1:46835139	C/T	cg00530320	chr1:46809349	NSUN4	0.58	6.84	0.41	7e-11	Menopause (age at onset);
SARC	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg20573242	chr4:122745356	CCNA2	0.65	8.1	0.47	3.08e-14	Type 2 diabetes;
SARC	cis	rs3820928	0.874	rs10202239	chr2:227901819	C/T	cg11843606	chr2:227700838	RHBDD1	-0.55	-6.8	-0.41	8.88e-11	Pulmonary function;
SARC	trans	rs9329221	0.537	rs12678800	chr8:9978940	G/A	cg06636001	chr8:8085503	FLJ10661	0.53	7.26	0.43	5.71e-12	Neuroticism;
SARC	cis	rs10782582	0.593	rs6675076	chr1:76118503	A/C	cg03433033	chr1:76189801	ACADM	-0.4	-5.25	-0.33	3.38e-7	Daytime sleep phenotypes;
SARC	cis	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg26695010	chr11:65641043	EFEMP2	-0.52	-6.73	-0.4	1.28e-10	Eosinophil percentage of white cells;
SARC	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-9.15	-0.51	2.85e-17	Alzheimer's disease;
SARC	cis	rs35306767	0.903	rs11812523	chr10:915638	C/T	cg26597838	chr10:835615	NA	0.84	8.42	0.48	3.86e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs11690935	1.000	rs312924	chr2:172564021	A/T	cg13550731	chr2:172543902	DYNC1I2	0.89	13.12	0.65	8.3e-30	Schizophrenia;
SARC	cis	rs644799	0.625	rs1255177	chr11:95471495	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.54	6.75	0.4	1.2e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs7520050	0.966	rs785471	chr1:46518677	T/C	cg24296786	chr1:45957014	TESK2	0.38	4.77	0.3	3.22e-6	Red blood cell count;Reticulocyte count;
SARC	cis	rs13401104	0.587	rs6431443	chr2:237150311	T/C	cg19324714	chr2:237145437	ASB18	0.56	5.58	0.34	6.52e-8	Educational attainment;
SARC	cis	rs7103648	0.669	rs11039332	chr11:47695840	G/A	cg10504702	chr11:47789108	FNBP4	0.72	9.37	0.52	6.58e-18	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs2463822	0.844	rs72923263	chr11:62161170	C/G	cg06239285	chr11:62104954	ASRGL1	-0.85	-8.05	-0.47	4.25e-14	Chronic obstructive pulmonary disease-related biomarkers;
SARC	cis	rs11122272	0.735	rs2066140	chr1:231504311	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-9.41	-0.52	4.89e-18	Hemoglobin concentration;
SARC	cis	rs2439831	0.681	rs2278859	chr15:43632960	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	10.85	0.58	1.81e-22	Lung cancer in ever smokers;
SARC	cis	rs7666738	0.830	rs13129503	chr4:98987892	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.51	1.3e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6456156	0.792	rs10946213	chr6:167516095	A/G	cg23791538	chr6:167370224	RNASET2	0.41	5.22	0.32	4.01e-7	Primary biliary cholangitis;
SARC	cis	rs8028182	0.609	rs8038760	chr15:75742095	A/C	cg20655648	chr15:75932815	IMP3	0.66	7.75	0.45	2.76e-13	Sudden cardiac arrest;
SARC	cis	rs12478296	0.901	rs7420176	chr2:243005277	G/A	cg06360820	chr2:242988706	NA	-0.63	-5.82	-0.36	1.9e-8	Obesity-related traits;
SARC	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg17376030	chr22:41985996	PMM1	0.75	8.89	0.5	1.7e-16	Vitiligo;
SARC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.06	0.8	1.11e-52	Prudent dietary pattern;
SARC	cis	rs17345786	1.000	rs7641261	chr3:101279006	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.45	4.95	0.31	1.41e-6	Colonoscopy-negative controls vs population controls;
SARC	cis	rs189218934	1	rs189218934	chr15:78903987	T/C	cg06917634	chr15:78832804	PSMA4	0.46	5.11	0.32	6.59e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs7666738	0.830	rs10001702	chr4:99065160	T/G	cg05340658	chr4:99064831	C4orf37	0.65	8.67	0.49	7.43e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs12142240	0.698	rs7515284	chr1:46809419	A/G	cg10495392	chr1:46806563	NSUN4	0.64	6.76	0.4	1.09e-10	Menopause (age at onset);
SARC	cis	rs17125944	0.505	rs17125746	chr14:53236079	C/T	cg00686598	chr14:53173677	PSMC6	1.31	8.73	0.5	5.12e-16	Alzheimer's disease (late onset);
SARC	cis	rs41271473	1.000	rs41270189	chr1:228878888	C/T	cg16512390	chr1:228756714	NA	0.49	4.92	0.31	1.66e-6	Chronic lymphocytic leukemia;
SARC	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg07061783	chr6:25882402	NA	0.37	4.77	0.3	3.32e-6	Intelligence (multi-trait analysis);
SARC	cis	rs8103278	0.507	rs16939	chr19:46276056	C/A	cg06577658	chr19:46296270	DMWD	0.45	5.15	0.32	5.67e-7	Coronary artery disease;
SARC	cis	rs965469	0.779	rs6133034	chr20:3337661	A/G	cg25506879	chr20:3388711	C20orf194	-0.45	-4.92	-0.31	1.65e-6	IFN-related cytopenia;
SARC	cis	rs921968	0.608	rs832817	chr2:219358603	C/T	cg02176678	chr2:219576539	TTLL4	0.36	5.53	0.34	8.72e-8	Mean corpuscular hemoglobin concentration;
SARC	cis	rs1124769	0.871	rs2619695	chr15:51160090	C/G	cg21246271	chr15:51200259	AP4E1	0.59	5.47	0.34	1.16e-7	Cognitive performance;
SARC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg11062466	chr8:58055876	NA	0.54	5.53	0.34	8.37e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg14403583	chr14:105418241	AHNAK2	-0.58	-7.63	-0.45	6.09e-13	Rheumatoid arthritis;
SARC	cis	rs9325144	0.836	rs7489197	chr12:38750065	C/T	cg10518543	chr12:38710700	ALG10B	-0.47	-5.21	-0.32	4.1e-7	Morning vs. evening chronotype;
SARC	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg24675658	chr1:53192096	ZYG11B	-0.65	-9.33	-0.52	8.57e-18	Monocyte count;
SARC	cis	rs7927771	0.864	rs4752838	chr11:47466006	G/A	cg20307385	chr11:47447363	PSMC3	-0.6	-7.61	-0.45	6.66e-13	Subjective well-being;
SARC	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg03060546	chr3:49711283	APEH	0.42	5.24	0.32	3.51e-7	Parkinson's disease;
SARC	cis	rs73195822	0.614	rs17793540	chr12:111215575	C/T	cg10860002	chr12:110842031	ANAPC7	0.58	5.07	0.31	8.3e-7	Itch intensity from mosquito bite;
SARC	cis	rs17270561	0.583	rs6937800	chr6:25765943	A/G	cg17691542	chr6:26056736	HIST1H1C	0.57	7.0	0.42	2.78e-11	Iron status biomarkers;
SARC	cis	rs7474896	0.537	rs1208683	chr10:38093723	A/G	cg25427524	chr10:38739819	LOC399744	0.45	5.47	0.34	1.15e-7	Obesity (extreme);
SARC	cis	rs262150	0.501	rs1062610	chr7:158821175	C/T	cg19418458	chr7:158789849	NA	-0.41	-5.74	-0.35	2.91e-8	Facial morphology (factor 20);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg10097105	chr1:200586761	KIF14	0.53	7.51	0.44	1.28e-12	Thyroid stimulating hormone;
SARC	cis	rs933688	0.526	rs7727632	chr5:90609009	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.68	-5.9	-0.36	1.28e-8	Smoking behavior;
SARC	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg25072359	chr17:41440525	NA	0.53	6.3	0.38	1.49e-9	Menopause (age at onset);
SARC	cis	rs6459788	0.720	rs6965466	chr7:157250749	G/T	cg03453431	chr7:157225567	NA	-0.42	-6.25	-0.38	1.97e-9	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs362296	0.698	rs3129319	chr4:3265381	A/G	cg06533319	chr4:3265114	C4orf44	0.34	5.61	0.34	5.76e-8	Parental longevity (mother's age at death);
SARC	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg03999130	chr15:45571217	NA	0.39	5.09	0.32	7.55e-7	Metabolite levels (small molecules and protein measures);
SARC	cis	rs826838	1.000	rs1719848	chr12:39085586	A/G	cg13010199	chr12:38710504	ALG10B	-0.67	-9.68	-0.54	7.59e-19	Heart rate;
SARC	cis	rs7607369	0.782	rs639913	chr2:219365971	A/C	cg02176678	chr2:219576539	TTLL4	0.46	7.12	0.42	1.33e-11	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs35213789	0.562	rs2851513	chr7:69043960	G/C	cg10619644	chr7:69149951	AUTS2	-0.36	-5.07	-0.32	8.07e-7	Childhood ear infection;
SARC	cis	rs6834538	0.597	rs2029211	chr4:113488134	A/G	cg05193411	chr4:113558554	LARP7;C4orf21	0.41	5.1	0.32	7.17e-7	Free thyroxine concentration;
SARC	cis	rs7615952	0.611	rs114419739	chr3:125722490	C/T	cg05084668	chr3:125655381	ALG1L	-0.94	-7.57	-0.44	8.76e-13	Blood pressure (smoking interaction);
SARC	cis	rs1865760	0.566	rs9348706	chr6:26065481	G/C	cg16482183	chr6:26056742	HIST1H1C	0.49	6.27	0.38	1.75e-9	Height;
SARC	cis	rs4919087	0.590	rs1088187	chr10:99027581	T/C	cg25902810	chr10:99078978	FRAT1	-0.53	-5.79	-0.35	2.27e-8	Monocyte count;
SARC	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-7.41	-0.44	2.32e-12	Gut microbiome composition (summer);
SARC	cis	rs4803468	1.000	rs4803469	chr19:41922775	A/C	cg14132834	chr19:41945861	ATP5SL	-0.57	-7.53	-0.44	1.1e-12	Height;
SARC	cis	rs2276314	1.000	rs4799834	chr18:33566243	T/C	cg05985134	chr18:33552581	C18orf21	0.71	7.71	0.45	3.59e-13	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs2066819	1.000	rs1274493	chr12:56682371	C/T	cg26316697	chr12:56727976	PAN2	-0.9	-6.37	-0.39	9.89e-10	Psoriasis vulgaris;
SARC	cis	rs854765	0.565	rs4072738	chr17:17884547	A/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.43	5.31	0.33	2.5e-7	Total body bone mineral density;
SARC	cis	rs7089973	0.526	rs35811923	chr10:116751010	C/T	cg08188268	chr10:116634841	FAM160B1	0.37	4.79	0.3	2.98e-6	Bipolar disorder or attention deficit hyperactivity disorder;
SARC	cis	rs7086627	0.515	rs10887895	chr10:82210011	A/G	cg00277334	chr10:82204260	NA	-0.56	-9.34	-0.52	7.82e-18	Post bronchodilator FEV1;
SARC	cis	rs9911578	0.967	rs11656413	chr17:57082013	A/C	cg12560992	chr17:57184187	TRIM37	-0.82	-11.86	-0.61	1.04e-25	Intelligence (multi-trait analysis);
SARC	trans	rs9818941	0.744	rs13098886	chr3:157613783	C/T	cg20349687	chr2:88927127	EIF2AK3	0.55	6.33	0.38	1.24e-9	Height;
SARC	cis	rs239198	0.521	rs9377241	chr6:101334265	C/T	cg09795085	chr6:101329169	ASCC3	0.44	5.62	0.35	5.48e-8	Menarche (age at onset);
SARC	cis	rs6088580	0.524	rs2378251	chr20:33276750	C/T	cg24642439	chr20:33292090	TP53INP2	-0.56	-6.9	-0.41	5e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs483180	0.859	rs478093	chr1:120255126	C/T	cg19096424	chr1:120255104	PHGDH	-0.89	-10.85	-0.58	1.83e-22	Macular telangiectasia type 2;
SARC	cis	rs116095464	1.000	rs55671190	chr5:287422	G/A	cg22496380	chr5:211416	CCDC127	-0.8	-6.12	-0.37	3.92e-9	Breast cancer;
SARC	cis	rs8067545	0.514	rs12449662	chr17:19897845	T/C	cg13482628	chr17:19912719	NA	0.45	5.12	0.32	6.52e-7	Schizophrenia;
SARC	cis	rs7647973	0.925	rs4955421	chr3:49218888	G/A	cg07636037	chr3:49044803	WDR6	0.8	9.19	0.52	2.29e-17	Menarche (age at onset);
SARC	cis	rs7529073	0.815	rs1431983	chr1:214148772	A/C	cg24083324	chr1:214162604	PROX1	0.42	6.2	0.38	2.5e-9	Schizophrenia;
SARC	cis	rs807669	0.900	rs712964	chr22:19156117	T/C	cg02655711	chr22:19163373	SLC25A1	0.47	6.48	0.39	5.41e-10	Metabolite levels;
SARC	cis	rs79149102	0.579	rs8031545	chr15:75290496	T/C	cg09165964	chr15:75287851	SCAMP5	-0.95	-8.78	-0.5	3.63e-16	Lung cancer;
SARC	cis	rs4660306	0.677	rs781060	chr1:45934166	C/T	cg24296786	chr1:45957014	TESK2	-0.56	-5.58	-0.34	6.68e-8	Homocysteine levels;
SARC	cis	rs7512552	0.839	rs2264418	chr1:150368579	G/A	cg15654264	chr1:150340011	RPRD2	0.38	4.81	0.3	2.7e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
SARC	cis	rs17376456	0.825	rs13161885	chr5:93071242	A/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.7	6.35	0.38	1.1e-9	Diabetic retinopathy;
SARC	cis	rs2718058	0.564	rs2709105	chr7:37757216	T/C	cg15028436	chr7:37888078	TXNDC3	-0.37	-5.17	-0.32	5.12e-7	Alzheimer's disease (late onset);
SARC	cis	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg01579765	chr21:45077557	HSF2BP	-0.38	-6.46	-0.39	5.92e-10	Mean corpuscular volume;
SARC	cis	rs11098499	1.000	rs11098499	chr4:120187611	C/T	cg09307838	chr4:120376055	NA	0.83	11.34	0.6	5.18e-24	Corneal astigmatism;
SARC	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg11764359	chr7:65958608	NA	-0.78	-9.28	-0.52	1.18e-17	Aortic root size;
SARC	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg12373951	chr3:133503437	NA	0.38	5.29	0.33	2.8e-7	Iron status biomarkers;
SARC	cis	rs2777491	0.915	rs28526381	chr15:41621842	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.74	-10.89	-0.58	1.32e-22	Ulcerative colitis;
SARC	cis	rs3796352	0.892	rs35076015	chr3:53026366	C/T	cg07884673	chr3:53033167	SFMBT1	0.9	5.87	0.36	1.49e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs4901847	0.967	rs7143935	chr14:58558112	C/G	cg15908186	chr14:58618357	C14orf37	0.41	4.74	0.3	3.76e-6	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs6060717	0.536	rs7271036	chr20:34467215	C/T	cg01084648	chr20:34329383	RBM39	-0.62	-4.75	-0.3	3.62e-6	Hip circumference adjusted for BMI;
SARC	cis	rs7666738	0.712	rs34043080	chr4:99008748	G/C	cg05340658	chr4:99064831	C4orf37	0.64	8.59	0.49	1.22e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2075371	0.933	rs1868785	chr7:133945855	G/C	cg11752832	chr7:134001865	SLC35B4	0.53	6.75	0.4	1.17e-10	Mean platelet volume;
SARC	cis	rs11578119	0.933	rs12126472	chr1:170530053	G/T	cg09767346	chr1:170501363	GORAB	0.45	5.35	0.33	2.13e-7	Male-pattern baldness;
SARC	cis	rs7523050	0.643	rs17621922	chr1:109404454	C/T	cg08274380	chr1:109419600	GPSM2	1.03	9.02	0.51	7.34e-17	Fat distribution (HIV);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg21250466	chr4:854474	GAK	-0.5	-6.47	-0.39	5.85e-10	Height;
SARC	cis	rs7769051	1.000	rs9493444	chr6:133125320	C/G	cg22852734	chr6:133119734	C6orf192	1.04	10.29	0.56	1.05e-20	Type 2 diabetes nephropathy;
SARC	cis	rs11687170	0.882	rs4377285	chr2:237061954	A/G	cg19324714	chr2:237145437	ASB18	0.47	4.73	0.3	3.82e-6	Educational attainment;Educational attainment (years of education);
SARC	cis	rs7312774	0.618	rs4964510	chr12:107357251	A/G	cg16260113	chr12:107380972	MTERFD3	1.16	8.9	0.5	1.65e-16	Severe influenza A (H1N1) infection;
SARC	cis	rs17270561	0.609	rs9393655	chr6:25711338	A/G	cg17691542	chr6:26056736	HIST1H1C	0.58	7.16	0.42	1.07e-11	Iron status biomarkers;
SARC	cis	rs79149102	0.579	rs3816261	chr15:75336173	T/A	cg17294928	chr15:75287854	SCAMP5	-1.14	-9.38	-0.52	6.21e-18	Lung cancer;
SARC	cis	rs761746	0.960	rs5753686	chr22:31947948	G/A	cg15823100	chr22:32027580	PISD	-0.32	-4.73	-0.3	3.87e-6	Intelligence;
SARC	cis	rs1355223	0.525	rs10836316	chr11:34874295	C/T	cg11622362	chr11:34938112	PDHX;APIP	0.45	5.88	0.36	1.42e-8	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs9435341	0.965	rs55924375	chr1:107566690	C/A	cg09367891	chr1:107599246	PRMT6	0.72	9.21	0.52	2.02e-17	Facial morphology (factor 21, depth of nasal alae);
SARC	cis	rs1153858	1.000	rs4775895	chr15:45617957	T/A	cg03999130	chr15:45571217	NA	0.4	5.02	0.31	1e-6	Homoarginine levels;
SARC	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg04546413	chr19:29218101	NA	0.64	8.54	0.49	1.74e-15	Methadone dose in opioid dependence;
SARC	cis	rs2718058	0.606	rs2718065	chr7:37859525	A/G	cg24998770	chr7:37888106	TXNDC3	0.35	5.08	0.32	7.79e-7	Alzheimer's disease (late onset);
SARC	cis	rs910316	0.934	rs4903278	chr14:75535019	C/A	cg11812906	chr14:75593930	NEK9	0.87	13.45	0.66	6.43e-31	Height;
SARC	cis	rs30380	0.632	rs26498	chr5:96138812	C/T	cg16492584	chr5:96139282	ERAP1	0.46	5.34	0.33	2.26e-7	Cerebrospinal fluid biomarker levels;
SARC	cis	rs9914988	0.943	rs7211502	chr17:27163295	C/A	cg20469991	chr17:27169893	C17orf63	-0.51	-5.21	-0.32	4.14e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg07477947	chr3:15851538	ANKRD28	0.48	6.79	0.41	8.99e-11	Thyroid stimulating hormone;
SARC	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.62	-6.74	-0.4	1.24e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9309711	0.623	rs4641971	chr2:3481857	A/C	cg15506890	chr2:3487001	NA	0.46	5.96	0.36	9.41e-9	Neurofibrillary tangles;
SARC	cis	rs634534	0.622	rs624273	chr11:65712413	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.63	8.24	0.48	1.25e-14	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs986417	1.000	rs996285	chr14:60869837	T/G	cg27398547	chr14:60952738	C14orf39	-0.97	-8.69	-0.49	6.71e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs2421770	0.530	rs7930134	chr11:35367017	A/C	cg13971030	chr11:35366721	SLC1A2	-0.34	-5.25	-0.33	3.42e-7	Staphylococcus aureus nasal carriage (persistent);
SARC	cis	rs8051517	1.000	rs74024441	chr16:68353975	C/T	cg01866162	chr16:67596514	CTCF	0.77	4.85	0.3	2.29e-6	Blood protein levels;
SARC	cis	rs77106637	1.000	rs76793820	chr11:72619860	G/A	cg03713592	chr11:72463424	ARAP1	0.88	7.69	0.45	4.03e-13	Type 2 diabetes;
SARC	cis	rs11608355	1.000	rs7970482	chr12:109862335	G/A	cg05360138	chr12:110035743	NA	0.43	4.78	0.3	3.14e-6	Neuroticism;
SARC	cis	rs1953600	0.805	rs2819947	chr10:81947757	T/C	cg00277334	chr10:82204260	NA	0.36	5.22	0.32	3.93e-7	Sarcoidosis;
SARC	trans	rs208515	0.525	rs10944869	chr6:66687576	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.9	10.58	0.57	1.26e-21	Exhaled nitric oxide levels;
SARC	cis	rs4243830	0.850	rs1114661	chr1:6596871	G/A	cg04093404	chr1:6614507	TAS1R1;NOL9	0.56	4.95	0.31	1.42e-6	Body mass index;
SARC	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg12064134	chr16:90016061	DEF8	-0.49	-5.16	-0.32	5.36e-7	Skin colour saturation;
SARC	cis	rs1348850	0.526	rs2218575	chr2:178368997	C/A	cg23306229	chr2:178417860	TTC30B	0.79	7.68	0.45	4.31e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg12288994	chr5:1860383	NA	0.4	6.41	0.39	7.93e-10	Cardiovascular disease risk factors;
SARC	cis	rs9443189	0.570	rs72888705	chr6:76403114	A/G	cg01950844	chr6:76311363	SENP6	0.86	8.18	0.47	1.82e-14	Prostate cancer;
SARC	cis	rs8031584	0.958	rs61997079	chr15:31238271	G/C	cg14298792	chr15:30685198	CHRFAM7A	-0.45	-4.99	-0.31	1.17e-6	Huntington's disease progression;
SARC	cis	rs2425143	1.000	rs1118233	chr20:34228349	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-5.55	-0.34	7.91e-8	Blood protein levels;
SARC	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg22433210	chr17:43662623	NA	-0.75	-8.46	-0.48	2.89e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9297145	0.678	rs62473048	chr7:98775511	T/C	cg05967295	chr7:98741636	SMURF1	0.71	7.62	0.45	6.29e-13	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
SARC	cis	rs13256369	1.000	rs10110591	chr8:8576608	G/T	cg17143192	chr8:8559678	CLDN23	-0.51	-6.04	-0.37	5.91e-9	Obesity-related traits;
SARC	cis	rs2762353	0.526	rs6901027	chr6:25709042	G/C	cg17691542	chr6:26056736	HIST1H1C	-0.44	-5.46	-0.34	1.23e-7	Blood metabolite levels;
SARC	cis	rs7659604	0.728	rs6852923	chr4:122688324	G/A	cg19748678	chr4:122722346	EXOSC9	0.71	9.31	0.52	9.87e-18	Type 2 diabetes;
SARC	cis	rs2806561	0.765	rs4333826	chr1:23517514	C/T	cg12483005	chr1:23474871	LUZP1	0.45	5.9	0.36	1.3e-8	Height;
SARC	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg16325326	chr1:53192061	ZYG11B	-0.97	-18.69	-0.77	3.09e-48	Monocyte count;
SARC	cis	rs2153535	0.580	rs1335641	chr6:8487860	G/T	cg07606381	chr6:8435919	SLC35B3	0.78	11.09	0.59	3.13e-23	Motion sickness;
SARC	cis	rs2832191	0.967	rs2898160	chr21:30487496	A/G	cg08807101	chr21:30365312	RNF160	-0.76	-10.6	-0.57	1.09e-21	Dental caries;
SARC	cis	rs9420	0.925	rs488769	chr11:57450720	A/C	cg23127183	chr11:57508653	C11orf31	-0.53	-6.15	-0.37	3.31e-9	Schizophrenia;
SARC	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.46	5.77	0.35	2.54e-8	Gut microbiome composition (summer);
SARC	cis	rs1008375	1.000	rs11737138	chr4:17657986	G/A	cg02297831	chr4:17616191	MED28	0.49	6.31	0.38	1.39e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.65	7.73	0.45	3.23e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1475911	0.708	rs8129075	chr21:43523430	G/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.59	7.27	0.43	5.55e-12	IgG glycosylation;
SARC	cis	rs7587476	0.822	rs13018304	chr2:215682218	T/G	cg04530015	chr2:215796436	ABCA12	-0.41	-6.64	-0.4	2.19e-10	Neuroblastoma;
SARC	cis	rs15676	0.783	rs2417128	chr9:131571756	G/A	cg00228799	chr9:131580591	ENDOG	0.53	6.69	0.4	1.67e-10	Blood metabolite levels;
SARC	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg00149659	chr3:10157352	C3orf10	0.71	6.38	0.39	9.25e-10	Alzheimer's disease;
SARC	cis	rs7843479	1.000	rs13248727	chr8:21842063	T/C	cg17168535	chr8:21777572	XPO7	0.63	8.14	0.47	2.45e-14	Mean corpuscular volume;
SARC	cis	rs17384381	1.000	rs71652696	chr1:85831792	A/C	cg16011679	chr1:85725395	C1orf52	0.61	5.32	0.33	2.39e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs1790761	0.692	rs10444362	chr11:67333090	G/A	cg00290607	chr11:67383545	NA	0.39	5.24	0.32	3.56e-7	Mean corpuscular volume;
SARC	cis	rs6568686	0.527	rs174406	chr6:111931328	A/C	cg15721981	chr6:111408429	SLC16A10	0.71	6.03	0.37	6.46e-9	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
SARC	cis	rs644799	0.544	rs1727165	chr11:95521648	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	9.83	0.54	2.62e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs8114671	0.869	rs6060199	chr20:33654773	A/G	cg08999081	chr20:33150536	PIGU	-0.34	-4.84	-0.3	2.38e-6	Height;
SARC	cis	rs3106136	0.546	rs2664880	chr4:95144177	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.47	-7.05	-0.42	2.06e-11	Capecitabine sensitivity;
SARC	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg11062466	chr8:58055876	NA	0.52	5.38	0.33	1.85e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs72945132	0.769	rs3781645	chr11:70190374	T/C	cg00319359	chr11:70116639	PPFIA1	0.71	6.62	0.4	2.42e-10	Coronary artery disease;
SARC	cis	rs2439831	0.850	rs28476182	chr15:44139643	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	8.02	0.47	5.04e-14	Lung cancer in ever smokers;
SARC	cis	rs7772486	0.875	rs2748483	chr6:146335560	A/T	cg23711669	chr6:146136114	FBXO30	-0.68	-10.15	-0.55	2.83e-20	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9395865	0.520	rs6903708	chr6:53332940	A/G	cg02751631	chr6:52535846	TMEM14A	-0.4	-4.77	-0.3	3.22e-6	Electroencephalographic traits in alcoholism;
SARC	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg26818010	chr10:134567672	INPP5A	-0.65	-7.21	-0.43	7.91e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	cis	rs916888	0.821	rs199504	chr17:44861003	C/T	cg01570182	chr17:44337453	NA	-0.82	-9.57	-0.53	1.67e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs7818345	0.935	rs6983973	chr8:19287867	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.43	5.82	0.36	1.93e-8	Language performance in older adults (adjusted for episodic memory);
SARC	cis	rs67311347	0.868	rs10865895	chr3:40378677	C/T	cg24209194	chr3:40518798	ZNF619	0.59	7.34	0.43	3.58e-12	Renal cell carcinoma;
SARC	cis	rs60871478	1.000	rs6460801	chr7:810506	T/C	cg19087971	chr7:751233	PRKAR1B	-0.42	-4.8	-0.3	2.79e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs7552404	0.727	rs5745390	chr1:76306591	A/C	cg03433033	chr1:76189801	ACADM	0.48	6.01	0.37	7.13e-9	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs11122272	0.735	rs2790876	chr1:231536033	C/T	cg06096015	chr1:231504339	EGLN1	0.38	5.7	0.35	3.54e-8	Hemoglobin concentration;
SARC	cis	rs6449957	0.801	rs6449953	chr5:67456530	A/G	cg23036683	chr5:67512108	NA	0.53	6.15	0.37	3.28e-9	Cleft lip with or without cleft palate;
SARC	cis	rs67460515	0.892	rs13073147	chr3:161045237	T/C	cg17135325	chr3:160939158	NMD3	0.62	7.9	0.46	1.08e-13	Parkinson's disease;
SARC	cis	rs36051895	0.589	rs7869015	chr9:5199750	C/T	cg02405213	chr9:5042618	JAK2	-0.42	-4.92	-0.31	1.66e-6	Pediatric autoimmune diseases;
SARC	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg12463550	chr7:65579703	CRCP	0.68	5.15	0.32	5.48e-7	Diabetic kidney disease;
SARC	cis	rs9788721	0.902	rs17486195	chr15:78865197	A/G	cg18825076	chr15:78729989	IREB2	-0.42	-5.05	-0.31	8.82e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs17270561	0.609	rs4464787	chr6:25733558	G/C	cg16482183	chr6:26056742	HIST1H1C	0.43	5.22	0.32	3.92e-7	Iron status biomarkers;
SARC	cis	rs8523	0.838	rs3778167	chr6:11033468	T/C	cg13562911	chr6:11044106	ELOVL2	0.39	5.15	0.32	5.61e-7	Red blood cell fatty acid levels;
SARC	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg04944784	chr2:26401820	FAM59B	-0.51	-6.18	-0.38	2.82e-9	Gut microbiome composition (summer);
SARC	cis	rs12956009	0.518	rs983095	chr18:44899258	T/G	cg15049968	chr18:44337910	ST8SIA5	-0.31	-4.74	-0.3	3.67e-6	Educational attainment (years of education);
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg16236679	chr11:96123321	JRKL;CCDC82	-0.52	-6.63	-0.4	2.35e-10	Height;
SARC	cis	rs2276314	1.000	rs9304154	chr18:33562227	C/T	cg05985134	chr18:33552581	C18orf21	0.66	6.88	0.41	5.4e-11	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs9467773	0.549	rs9461273	chr6:26584526	A/G	cg12292205	chr6:26970375	C6orf41	-0.45	-5.71	-0.35	3.36e-8	Intelligence (multi-trait analysis);
SARC	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg16479474	chr6:28041457	NA	0.37	5.48	0.34	1.11e-7	Depression;
SARC	cis	rs2933343	0.700	rs1683779	chr3:128642048	A/G	cg24203234	chr3:128598194	ACAD9	0.64	8.21	0.47	1.55e-14	IgG glycosylation;
SARC	cis	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg08045932	chr20:61659980	NA	0.5	6.84	0.41	7.06e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs2120019	0.938	rs5020842	chr15:75322310	T/C	cg09165964	chr15:75287851	SCAMP5	-0.94	-14.34	-0.68	7.6e-34	Blood trace element (Zn levels);
SARC	cis	rs6429082	0.521	rs704711	chr1:235629802	G/A	cg26050004	chr1:235667680	B3GALNT2	0.81	13.32	0.66	1.77e-30	Adiposity;
SARC	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg08219700	chr8:58056026	NA	0.62	6.52	0.39	4.28e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg22484793	chr3:52261325	TLR9	0.29	4.73	0.3	3.83e-6	Bipolar disorder;
SARC	trans	rs9638182	0.725	rs2240466	chr7:72856269	G/A	cg21138935	chr8:25458389	NA	0.65	6.28	0.38	1.67e-9	Triglycerides;
SARC	cis	rs6582630	0.519	rs1607868	chr12:38385512	G/T	cg13010199	chr12:38710504	ALG10B	0.78	10.86	0.58	1.7e-22	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs73001065	0.901	rs73004926	chr19:19671266	C/T	cg03709012	chr19:19516395	GATAD2A	0.83	5.36	0.33	2e-7	LDL cholesterol;
SARC	cis	rs11578119	0.933	rs10919406	chr1:170419037	C/G	cg09767346	chr1:170501363	GORAB	0.41	4.84	0.3	2.41e-6	Male-pattern baldness;
SARC	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg21724239	chr8:58056113	NA	0.58	6.14	0.37	3.49e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9788682	0.747	rs7183604	chr15:78899213	T/C	cg06917634	chr15:78832804	PSMA4	0.45	5.03	0.31	9.84e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	trans	rs34421088	0.548	rs2618443	chr8:11384556	A/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-8.49	-0.49	2.51e-15	Neuroticism;
SARC	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg20965017	chr5:231967	SDHA	-0.56	-5.38	-0.33	1.82e-7	Breast cancer;
SARC	cis	rs10463554	0.927	rs185387	chr5:102420019	T/C	cg23492399	chr5:102201601	PAM	-0.46	-5.07	-0.32	8.13e-7	Parkinson's disease;
SARC	cis	rs921968	0.678	rs500422	chr2:219432995	C/A	cg02176678	chr2:219576539	TTLL4	0.35	5.09	0.32	7.25e-7	Mean corpuscular hemoglobin concentration;
SARC	cis	rs1401999	0.966	rs2139560	chr3:183653869	A/G	cg01324343	chr3:183735012	ABCC5	0.67	13.66	0.67	1.32e-31	Anterior chamber depth;
SARC	cis	rs854765	0.547	rs9912096	chr17:17896673	A/C	cg23370820	chr17:17987590	NA	-0.24	-4.72	-0.3	4.01e-6	Total body bone mineral density;
SARC	cis	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg00409905	chr10:38381863	ZNF37A	-0.55	-7.84	-0.46	1.65e-13	Extrinsic epigenetic age acceleration;
SARC	cis	rs72781680	0.611	rs72797819	chr2:24351141	T/G	cg08917208	chr2:24149416	ATAD2B	0.61	6.11	0.37	4.15e-9	Lymphocyte counts;
SARC	cis	rs7772486	0.686	rs857880	chr6:145971115	T/C	cg23711669	chr6:146136114	FBXO30	-0.82	-13.2	-0.65	4.5e-30	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	11.15	0.59	2.1e-23	Platelet count;
SARC	cis	rs6753739	0.871	rs6724718	chr2:220004243	A/G	cg24212621	chr2:219920517	IHH	-0.34	-4.76	-0.3	3.36e-6	Height;
SARC	cis	rs72781680	0.950	rs72796343	chr2:24147631	G/A	cg06627628	chr2:24431161	ITSN2	-0.75	-6.81	-0.41	7.99e-11	Lymphocyte counts;
SARC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg11494091	chr17:61959527	GH2	-0.53	-7.9	-0.46	1.07e-13	Prudent dietary pattern;
SARC	cis	rs2439831	0.850	rs12440573	chr15:44108997	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	7.6	0.45	7.23e-13	Lung cancer in ever smokers;
SARC	cis	rs7824557	0.564	rs7821459	chr8:11236681	T/G	cg21775007	chr8:11205619	TDH	-0.65	-8.62	-0.49	1.01e-15	Retinal vascular caliber;
SARC	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg04267008	chr7:1944627	MAD1L1	-0.5	-5.78	-0.35	2.33e-8	Bipolar disorder and schizophrenia;
SARC	trans	rs6894249	1.000	rs6894249	chr5:131797547	A/G	cg11963202	chr7:98985799	ARPC1B	-0.43	-6.39	-0.39	8.93e-10	Asthma;
SARC	cis	rs9393692	0.905	rs989134	chr6:26336224	A/C	cg05868516	chr6:26286170	HIST1H4H	0.52	6.63	0.4	2.38e-10	Educational attainment;
SARC	cis	rs10752881	0.967	rs12404594	chr1:182988027	G/A	cg13390022	chr1:182993471	LAMC1	0.33	5.04	0.31	9.29e-7	Colorectal cancer;
SARC	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg07701084	chr6:150067640	NUP43	-0.41	-5.36	-0.33	1.97e-7	Lung cancer;
SARC	trans	rs1814175	0.817	rs4881645	chr11:49791168	G/A	cg03929089	chr4:120376271	NA	-0.9	-14.53	-0.69	1.76e-34	Height;
SARC	cis	rs7546668	1.000	rs6429746	chr1:15815579	A/G	cg21858823	chr1:15850916	CASP9	-0.52	-6.93	-0.41	4.06e-11	Glomerular filtration rate (creatinine);
SARC	cis	rs6840360	1.000	rs4571	chr4:152592191	T/C	cg22705602	chr4:152727874	NA	-0.37	-6.27	-0.38	1.69e-9	Intelligence (multi-trait analysis);
SARC	cis	rs7208859	0.673	rs9915963	chr17:29019643	C/T	cg13385521	chr17:29058706	SUZ12P	0.9	7.79	0.45	2.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg22920501	chr2:26401640	FAM59B	-0.56	-7.4	-0.44	2.5e-12	Gut microbiome composition (summer);
SARC	cis	rs1008375	0.900	rs6851783	chr4:17578469	A/G	cg16339924	chr4:17578868	LAP3	0.7	9.07	0.51	4.93e-17	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.01	-16.24	-0.73	3.44e-40	Prudent dietary pattern;
SARC	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg08219700	chr8:58056026	NA	0.49	4.96	0.31	1.36e-6	Developmental language disorder (linguistic errors);
SARC	cis	rs4319547	0.774	rs7959238	chr12:123131498	A/T	cg23029597	chr12:123009494	RSRC2	-0.45	-5.73	-0.35	3.11e-8	Body mass index;
SARC	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg06634786	chr22:41940651	POLR3H	0.49	6.15	0.37	3.38e-9	Vitiligo;
SARC	cis	rs3741151	0.773	rs58564192	chr11:73228904	G/A	cg17517138	chr11:73019481	ARHGEF17	0.92	6.86	0.41	6.15e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs9467711	0.559	rs2295593	chr6:26501768	C/T	cg12826209	chr6:26865740	GUSBL1	0.7	5.02	0.31	1.01e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg25703541	chr22:24373054	LOC391322	-0.96	-16.08	-0.73	1.17e-39	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7819412	0.740	rs11250119	chr8:11037034	C/T	cg21775007	chr8:11205619	TDH	-0.42	-5.2	-0.32	4.39e-7	Triglycerides;
SARC	cis	rs10463554	0.927	rs34811	chr5:102431821	A/G	cg23492399	chr5:102201601	PAM	-0.48	-5.32	-0.33	2.4e-7	Parkinson's disease;
SARC	cis	rs9467711	0.516	rs1165163	chr6:25863487	G/C	cg08501292	chr6:25962987	TRIM38	0.58	4.75	0.3	3.63e-6	Autism spectrum disorder or schizophrenia;
SARC	trans	rs11098499	0.954	rs6849561	chr4:120409694	C/G	cg25214090	chr10:38739885	LOC399744	-0.55	-7.11	-0.42	1.44e-11	Corneal astigmatism;
SARC	cis	rs10904908	1.000	rs10904908	chr10:17260290	A/G	cg01003015	chr10:17271136	VIM	-0.43	-5.26	-0.33	3.26e-7	Total cholesterol levels;Cholesterol, total;
SARC	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg01475735	chr3:40494733	NA	-0.47	-5.14	-0.32	5.91e-7	Renal cell carcinoma;
SARC	cis	rs73195822	0.506	rs55948838	chr12:111142793	C/T	cg10860002	chr12:110842031	ANAPC7	0.58	5.0	0.31	1.14e-6	Itch intensity from mosquito bite;
SARC	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg17971929	chr21:40555470	PSMG1	0.98	13.64	0.67	1.62e-31	Cognitive function;
SARC	cis	rs2354432	0.607	rs12404113	chr1:146750343	C/A	cg25205988	chr1:146714368	CHD1L	-1.02	-7.73	-0.45	3.15e-13	Mitochondrial DNA levels;
SARC	cis	rs644799	1.000	rs1944074	chr11:95511445	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	15.14	0.7	1.65e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg03806693	chr22:41940476	POLR3H	0.89	11.95	0.62	5.29e-26	Vitiligo;
SARC	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.68	6.6	0.4	2.68e-10	Platelet count;
SARC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg14893161	chr1:205819251	PM20D1	0.93	15.7	0.72	2.21e-38	Menarche (age at onset);
SARC	cis	rs10979	0.965	rs9496674	chr6:143886106	G/T	cg25407410	chr6:143891975	LOC285740	-0.6	-7.99	-0.46	6.06e-14	Hypospadias;
SARC	cis	rs79149102	0.579	rs61166993	chr15:75306644	C/A	cg00629941	chr15:75287862	SCAMP5	-0.66	-5.44	-0.34	1.33e-7	Lung cancer;
SARC	trans	rs17685	0.712	rs10271413	chr7:75754858	G/A	cg19862616	chr7:65841803	NCRNA00174	0.61	7.38	0.44	2.82e-12	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs13191362	1.000	rs73035021	chr6:163000716	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.57	5.38	0.33	1.85e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs4268898	0.662	rs2303291	chr2:24431184	C/T	cg26838691	chr2:24397539	C2orf84	-0.54	-6.11	-0.37	4.12e-9	Asthma;
SARC	cis	rs2204008	0.807	rs11182461	chr12:38539288	T/C	cg13010199	chr12:38710504	ALG10B	0.77	10.7	0.57	5.25e-22	Bladder cancer;
SARC	cis	rs7248779	1.000	rs7248779	chr19:2403564	G/T	cg22729335	chr19:2427816	TIMM13	-0.65	-8.51	-0.49	2.11e-15	Cortisol levels (saliva);
SARC	cis	rs1348850	0.574	rs10195917	chr2:178443121	C/T	cg23306229	chr2:178417860	TTC30B	0.69	7.46	0.44	1.73e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7666738	0.518	rs13133925	chr4:98706398	G/T	cg05340658	chr4:99064831	C4orf37	0.6	7.27	0.43	5.37e-12	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7937682	0.961	rs4936682	chr11:111629743	T/G	cg09085632	chr11:111637200	PPP2R1B	1.07	19.79	0.79	8.2e-52	Primary sclerosing cholangitis;
SARC	cis	rs7647973	1.000	rs62259933	chr3:49469703	G/A	cg07636037	chr3:49044803	WDR6	-0.76	-8.65	-0.49	8.36e-16	Menarche (age at onset);
SARC	cis	rs950776	0.647	rs495956	chr15:78869930	C/T	cg22563815	chr15:78856949	CHRNA5	-0.34	-5.26	-0.33	3.29e-7	Sudden cardiac arrest;
SARC	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg08677398	chr8:58056175	NA	0.43	5.17	0.32	5.03e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2180341	0.814	rs9385424	chr6:127726796	A/G	cg24812749	chr6:127587940	RNF146	0.79	10.11	0.55	3.71e-20	Breast cancer;
SARC	cis	rs9916302	0.904	rs7503069	chr17:37697128	C/G	cg15445000	chr17:37608096	MED1	0.42	4.93	0.31	1.59e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs6696846	0.765	rs61822568	chr1:205081166	C/G	cg00857998	chr1:205179979	DSTYK	0.49	6.24	0.38	2.05e-9	Red blood cell count;
SARC	cis	rs13202913	0.837	rs6906667	chr6:151772569	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.62	5.24	0.32	3.55e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
SARC	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg11987759	chr7:65425863	GUSB	0.45	6.06	0.37	5.58e-9	Aortic root size;
SARC	cis	rs1559088	0.576	rs4805852	chr19:33609441	C/T	cg27124370	chr19:33622961	WDR88	0.52	6.87	0.41	5.67e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs858239	0.601	rs1981665	chr7:23167969	T/C	cg23682824	chr7:23144976	KLHL7	0.74	10.1	0.55	3.93e-20	Cerebrospinal fluid biomarker levels;
SARC	cis	rs11700980	0.636	rs2832138	chr21:30284123	G/A	cg24692254	chr21:30365293	RNF160	-0.67	-5.09	-0.32	7.44e-7	QRS complex (12-leadsum);
SARC	cis	rs854765	0.547	rs7209003	chr17:17907393	T/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.46	6.01	0.37	7.21e-9	Total body bone mineral density;
SARC	cis	rs4737010	0.501	rs1579274	chr8:41658923	T/G	cg17182837	chr8:41585554	ANK1	-0.46	-4.98	-0.31	1.24e-6	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
SARC	cis	rs9400467	0.537	rs12214550	chr6:111505499	C/T	cg15721981	chr6:111408429	SLC16A10	0.67	5.65	0.35	4.66e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs932287	0.536	rs10840160	chr11:9053536	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.44	-5.78	-0.35	2.37e-8	Colonoscopy-negative controls vs population controls;
SARC	cis	rs2439831	0.850	rs2277531	chr15:44069069	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	7.7	0.45	3.88e-13	Lung cancer in ever smokers;
SARC	cis	rs7712401	0.715	rs1139334	chr5:122358419	A/G	cg19412675	chr5:122181750	SNX24	-0.42	-5.3	-0.33	2.65e-7	Mean platelet volume;
SARC	cis	rs2073499	1.000	rs10510755	chr3:50281168	C/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.5	4.73	0.3	3.83e-6	Schizophrenia;
SARC	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg19077165	chr18:44547161	KATNAL2	-0.48	-6.68	-0.4	1.73e-10	Personality dimensions;
SARC	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg11764359	chr7:65958608	NA	0.73	8.72	0.5	5.25e-16	Aortic root size;
SARC	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg00152838	chr16:24741724	TNRC6A	-0.57	-6.08	-0.37	4.91e-9	Intelligence (multi-trait analysis);
SARC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.72	9.44	0.53	4.03e-18	Lymphocyte counts;
SARC	cis	rs554111	0.656	rs10799680	chr1:21361181	C/T	cg04902671	chr1:21058625	SH2D5	0.43	5.29	0.33	2.87e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs13256369	1.000	rs12550762	chr8:8576535	T/A	cg17143192	chr8:8559678	CLDN23	0.51	6.1	0.37	4.47e-9	Obesity-related traits;
SARC	cis	rs981844	0.740	rs6815202	chr4:154682440	A/G	cg14289246	chr4:154710475	SFRP2	-0.61	-7.18	-0.43	9.42e-12	Response to statins (LDL cholesterol change);
SARC	cis	rs995000	0.895	rs783291	chr1:62914978	G/A	cg06896770	chr1:63153194	DOCK7	0.9	13.82	0.67	3.84e-32	Triglyceride levels;
SARC	cis	rs9640161	0.789	rs1464753	chr7:150021350	G/C	cg21361702	chr7:150065534	REPIN1	0.49	5.09	0.32	7.52e-7	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg11987759	chr7:65425863	GUSB	-0.47	-6.29	-0.38	1.55e-9	Aortic root size;
SARC	cis	rs950169	0.922	rs8037078	chr15:84818871	A/G	cg17507749	chr15:85114479	UBE2QP1	-0.78	-9.22	-0.52	1.86e-17	Schizophrenia;
SARC	cis	rs3087591	0.666	rs2953016	chr17:29494693	C/G	cg24425628	chr17:29625626	OMG;NF1	0.45	4.96	0.31	1.37e-6	Hip circumference;
SARC	cis	rs7223966	1.000	rs9901507	chr17:61765524	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.45	5.03	0.31	9.75e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs240764	0.817	rs239232	chr6:101103038	G/A	cg09795085	chr6:101329169	ASCC3	0.46	5.96	0.36	9.39e-9	Neuroticism;
SARC	cis	rs870825	0.616	rs7682677	chr4:185640717	C/G	cg04058563	chr4:185651563	MLF1IP	0.81	11.48	0.6	1.8e-24	Blood protein levels;
SARC	cis	rs6964587	1.000	rs12540565	chr7:91633213	T/G	cg17063962	chr7:91808500	NA	0.95	15.97	0.72	2.86e-39	Breast cancer;
SARC	cis	rs13082711	0.522	rs7651661	chr3:27362773	G/C	cg02860705	chr3:27208620	NA	0.41	5.45	0.34	1.28e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs920590	0.527	rs79929516	chr8:19650050	G/C	cg03894339	chr8:19674705	INTS10	0.7	7.47	0.44	1.56e-12	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs2153535	0.580	rs1577472	chr6:8486215	G/A	cg07606381	chr6:8435919	SLC35B3	0.79	11.09	0.59	3.06e-23	Motion sickness;
SARC	cis	rs6840360	1.000	rs6823421	chr4:152604719	T/C	cg22705602	chr4:152727874	NA	-0.38	-6.45	-0.39	6.51e-10	Intelligence (multi-trait analysis);
SARC	trans	rs3942852	0.774	rs2279823	chr11:48146092	T/C	cg15704280	chr7:45808275	SEPT13	-0.57	-6.53	-0.39	4.17e-10	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs13082711	0.640	rs66941564	chr3:27259702	C/A	cg02860705	chr3:27208620	NA	0.6	7.93	0.46	9.24e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg16145915	chr7:1198662	ZFAND2A	0.31	4.74	0.3	3.77e-6	Longevity;Endometriosis;
SARC	cis	rs9840812	0.691	rs833752	chr3:136255169	A/G	cg15507776	chr3:136538369	TMEM22	0.51	5.69	0.35	3.88e-8	Fibrinogen levels;
SARC	cis	rs748404	0.560	rs1060939	chr15:43816917	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.48	5.23	0.32	3.84e-7	Lung cancer;
SARC	trans	rs9395865	0.520	rs6903708	chr6:53332940	A/G	cg16933664	chr11:67085326	LOC100130987	-0.51	-6.3	-0.38	1.44e-9	Electroencephalographic traits in alcoholism;
SARC	trans	rs10085978	0.604	rs34347950	chr8:143224538	T/C	cg12891252	chr10:43902500	HNRNPF	0.51	6.4	0.39	8.35e-10	Mosquito bite size;
SARC	cis	rs11608355	0.515	rs2270361	chr12:109935894	G/C	cg05360138	chr12:110035743	NA	0.92	9.39	0.52	5.78e-18	Neuroticism;
SARC	trans	rs2727020	0.729	rs2866328	chr11:49282421	A/G	cg15704280	chr7:45808275	SEPT13	0.82	13.26	0.66	2.74e-30	Coronary artery disease;
SARC	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg17376030	chr22:41985996	PMM1	-0.65	-8.04	-0.47	4.56e-14	Vitiligo;
SARC	cis	rs17331151	0.573	rs79664140	chr3:52866936	A/G	cg04865290	chr3:52927548	TMEM110	-0.62	-5.81	-0.36	2.07e-8	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.97	10.28	0.56	1.11e-20	Platelet count;
SARC	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg18404041	chr3:52824283	ITIH1	-0.43	-6.53	-0.39	4.04e-10	Bipolar disorder;
SARC	cis	rs861020	0.677	rs12723578	chr1:210032392	G/A	cg05527609	chr1:210001259	C1orf107	-0.95	-10.4	-0.56	4.72e-21	Orofacial clefts;
SARC	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg02018176	chr4:1364513	KIAA1530	0.61	9.38	0.52	5.96e-18	Longevity;
SARC	cis	rs1881797	1.000	rs1881794	chr1:247682920	G/C	cg11166453	chr1:247681781	NA	-0.48	-5.64	-0.35	4.85e-8	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg22535103	chr8:58192502	C8orf71	-0.73	-6.78	-0.41	9.94e-11	Developmental language disorder (linguistic errors);
SARC	cis	rs918629	0.530	rs3777200	chr5:95234791	A/G	cg16656078	chr5:95278638	ELL2	0.54	6.23	0.38	2.19e-9	IgG glycosylation;
SARC	cis	rs870825	0.550	rs57301026	chr4:185646505	C/G	cg04058563	chr4:185651563	MLF1IP	0.8	11.35	0.6	4.56e-24	Blood protein levels;
SARC	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg08219700	chr8:58056026	NA	0.74	6.43	0.39	7.07e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs2120019	1.000	rs7162900	chr15:75368017	T/C	cg09165964	chr15:75287851	SCAMP5	-0.87	-13.03	-0.65	1.59e-29	Blood trace element (Zn levels);
SARC	cis	rs10504229	0.679	rs4737454	chr8:58033965	A/T	cg22535103	chr8:58192502	C8orf71	-0.54	-5.48	-0.34	1.08e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs17376456	0.741	rs7718842	chr5:93480568	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.61	5.16	0.32	5.23e-7	Diabetic retinopathy;
SARC	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg26681399	chr22:41777847	TEF	0.43	4.89	0.3	1.92e-6	Vitiligo;
SARC	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg23262073	chr20:60523788	NA	-0.39	-5.63	-0.35	5.17e-8	Body mass index;
SARC	cis	rs9733	0.596	rs7418501	chr1:150711896	A/T	cg13175981	chr1:150552382	MCL1	-0.53	-6.9	-0.41	4.83e-11	Tonsillectomy;
SARC	cis	rs733592	0.929	rs4760678	chr12:48461581	T/C	cg21466736	chr12:48725269	NA	0.31	5.37	0.33	1.94e-7	Plateletcrit;
SARC	cis	rs7582180	0.700	rs2309852	chr2:100982527	T/C	cg14675211	chr2:100938903	LONRF2	0.55	8.13	0.47	2.52e-14	Intelligence (multi-trait analysis);
SARC	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg13012494	chr21:47604986	C21orf56	0.44	5.19	0.32	4.5e-7	Testicular germ cell tumor;
SARC	cis	rs3857067	0.806	rs6857967	chr4:95112303	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.06	-0.31	8.38e-7	QT interval;
SARC	cis	rs12594515	1.000	rs8039622	chr15:45986431	A/G	cg14863074	chr15:45997064	NA	0.34	5.18	0.32	4.84e-7	Waist circumference;Weight;
SARC	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg08280861	chr8:58055591	NA	0.67	5.25	0.33	3.4e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg15049968	chr18:44337910	ST8SIA5	-0.36	-5.71	-0.35	3.41e-8	Personality dimensions;
SARC	cis	rs9457247	0.846	rs2757052	chr6:167380174	T/C	cg23791538	chr6:167370224	RNASET2	0.63	8.74	0.5	4.81e-16	Crohn's disease;
SARC	cis	rs1003719	0.680	rs2835619	chr21:38505380	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-9.13	-0.51	3.35e-17	Eye color traits;
SARC	cis	rs765787	0.530	rs3759892	chr15:45542709	A/G	cg24006582	chr15:45444508	DUOX1	0.45	5.62	0.35	5.53e-8	Uric acid levels;
SARC	cis	rs858239	0.601	rs987257	chr7:23147840	G/A	cg23682824	chr7:23144976	KLHL7	0.72	9.71	0.54	6.04e-19	Cerebrospinal fluid biomarker levels;
SARC	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg22800045	chr5:56110881	MAP3K1	0.65	6.86	0.41	6.06e-11	Initial pursuit acceleration;
SARC	cis	rs2425143	0.908	rs12480111	chr20:34423186	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-6.33	-0.38	1.22e-9	Blood protein levels;
SARC	cis	rs2120019	1.000	rs2083731	chr15:75368538	A/C	cg17294928	chr15:75287854	SCAMP5	-0.91	-13.13	-0.65	7.48e-30	Blood trace element (Zn levels);
SARC	cis	rs11122272	0.735	rs2491410	chr1:231532287	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-9.73	-0.54	5.39e-19	Hemoglobin concentration;
SARC	cis	rs6696846	0.749	rs61822566	chr1:205078660	T/C	cg07972983	chr1:205091412	RBBP5	0.57	7.14	0.42	1.17e-11	Red blood cell count;
SARC	cis	rs9354308	0.868	rs9345695	chr6:66554270	C/T	cg07460842	chr6:66804631	NA	-0.45	-5.22	-0.32	3.92e-7	Metabolite levels;
SARC	cis	rs826838	0.967	rs7136593	chr12:39128265	C/T	cg13010199	chr12:38710504	ALG10B	-0.63	-8.88	-0.5	1.87e-16	Heart rate;
SARC	cis	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg12331332	chr10:115439884	CASP7	0.48	5.89	0.36	1.31e-8	Breast cancer;
SARC	cis	rs644799	1.000	rs500054	chr11:95593806	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.89	13.25	0.66	2.98e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs6964587	0.869	rs6975243	chr7:91514672	G/A	cg17063962	chr7:91808500	NA	-0.92	-13.81	-0.67	4.42e-32	Breast cancer;
SARC	trans	rs3808502	0.525	rs13280813	chr8:11425105	G/T	cg15556689	chr8:8085844	FLJ10661	-0.48	-6.51	-0.39	4.5e-10	Neuroticism;
SARC	cis	rs1008375	0.932	rs4698628	chr4:17608620	A/G	cg16339924	chr4:17578868	LAP3	0.67	8.86	0.5	2.05e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9349203	1	rs9349203	chr6:41893323	G/A	cg17623882	chr6:41773611	USP49	-0.5	-6.54	-0.39	3.84e-10	Menarche (age at onset);
SARC	cis	rs554111	0.634	rs4654875	chr1:21165176	A/G	cg08890418	chr1:21044141	KIF17	-0.37	-5.2	-0.32	4.38e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs7106204	0.534	rs16912285	chr11:24252528	A/G	ch.11.24196551F	chr11:24239977	NA	0.73	6.26	0.38	1.84e-9	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs7412746	0.658	rs2275235	chr1:150730279	A/G	cg13175981	chr1:150552382	MCL1	-0.46	-5.51	-0.34	9.58e-8	Melanoma;
SARC	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg05793240	chr7:2802953	GNA12	-0.35	-5.09	-0.32	7.29e-7	Height;
SARC	cis	rs734999	0.549	rs6667564	chr1:2520302	T/C	cg18854424	chr1:2615690	NA	0.3	4.74	0.3	3.71e-6	Ulcerative colitis;
SARC	cis	rs61861422	0.516	rs12412216	chr10:134393338	C/T	cg20090690	chr10:134436459	INPP5A	0.65	6.78	0.41	9.6e-11	Primary sclerosing cholangitis;
SARC	cis	rs651907	0.535	rs35799195	chr3:101521927	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	5.85	0.36	1.64e-8	Colorectal cancer;
SARC	cis	rs644799	1.000	rs12786522	chr11:95522858	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.7	9.6	0.53	1.33e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	trans	rs3780486	0.757	rs10121987	chr9:33119818	A/G	cg04842962	chr6:43655489	MRPS18A	1.08	20.32	0.8	1.66e-53	IgG glycosylation;
SARC	cis	rs804280	0.560	rs10503426	chr8:11589383	A/C	cg00262122	chr8:11665843	FDFT1	0.46	5.42	0.33	1.47e-7	Myopia (pathological);
SARC	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg27266027	chr21:40555129	PSMG1	0.49	4.89	0.31	1.85e-6	Cognitive function;
SARC	cis	rs523522	0.962	rs4767904	chr12:120930798	T/G	cg27279351	chr12:120934652	DYNLL1	0.71	8.85	0.5	2.22e-16	High light scatter reticulocyte count;
SARC	cis	rs7481584	0.624	rs693687	chr11:3052494	A/G	cg05729581	chr11:3078854	CARS	0.57	7.41	0.44	2.38e-12	Calcium levels;
SARC	cis	rs10911251	0.508	rs6424890	chr1:183112764	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	9.86	0.54	2.11e-19	Colorectal cancer;
SARC	cis	rs920590	0.796	rs7820505	chr8:19634829	A/G	cg01411142	chr8:19674711	INTS10	-0.42	-4.82	-0.3	2.65e-6	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs2228479	0.850	rs117285117	chr16:89910250	T/G	cg00800038	chr16:89945340	TCF25	-0.83	-5.76	-0.35	2.62e-8	Skin colour saturation;
SARC	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg14893161	chr1:205819251	PM20D1	-0.52	-6.57	-0.4	3.16e-10	Menarche (age at onset);
SARC	cis	rs28655083	0.912	rs2171097	chr16:77085037	C/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.4	-5.66	-0.35	4.35e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs910187	0.605	rs6018317	chr20:45803236	A/G	cg27589058	chr20:45804311	EYA2	-0.3	-4.96	-0.31	1.35e-6	Migraine;
SARC	cis	rs9916302	0.706	rs582176	chr17:37453999	T/C	cg15445000	chr17:37608096	MED1	-0.45	-4.92	-0.31	1.62e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs7659604	1.000	rs7660078	chr4:122665577	G/T	cg20573242	chr4:122745356	CCNA2	0.44	5.74	0.35	3e-8	Type 2 diabetes;
SARC	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg12311346	chr5:56204834	C5orf35	-0.55	-5.8	-0.36	2.15e-8	Initial pursuit acceleration;
SARC	cis	rs6580649	0.941	rs57380031	chr12:48452237	C/T	cg05342945	chr12:48394962	COL2A1	0.57	6.15	0.37	3.42e-9	Lung cancer;
SARC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg04527057	chr20:5107457	CDS2;PCNA	0.49	6.43	0.39	7.33e-10	Attention deficit hyperactivity disorder and conduct disorder;
SARC	cis	rs67460515	0.892	rs16832082	chr3:161043571	A/G	cg03342759	chr3:160939853	NMD3	-0.67	-8.62	-0.49	1.04e-15	Parkinson's disease;
SARC	cis	rs7666738	0.791	rs7660866	chr4:98961335	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.93	0.5	1.35e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs155076	0.938	rs485361	chr13:21845826	G/T	cg25811766	chr13:21894605	NA	-0.51	-5.5	-0.34	9.92e-8	White matter hyperintensity burden;
SARC	cis	rs910316	0.839	rs35977276	chr14:75637359	A/C	cg23033748	chr14:75592666	NEK9	-0.36	-4.76	-0.3	3.36e-6	Height;
SARC	cis	rs7589342	0.536	rs1367405	chr2:106387141	G/A	cg16077055	chr2:106428750	NCK2	0.31	6.07	0.37	5.12e-9	Addiction;
SARC	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg24675658	chr1:53192096	ZYG11B	0.64	9.46	0.53	3.44e-18	Monocyte count;
SARC	cis	rs7953249	0.542	rs2244608	chr12:121416988	A/G	cg15155738	chr12:121454335	C12orf43	0.49	5.91	0.36	1.19e-8	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs7617480	0.617	rs7610519	chr3:48746427	C/G	cg07636037	chr3:49044803	WDR6	0.77	8.19	0.47	1.74e-14	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs894734	0.535	rs7301643	chr12:54325796	G/T	cg17410650	chr12:54324560	NA	-0.33	-4.98	-0.31	1.25e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
SARC	cis	rs12477438	0.834	rs1563106	chr2:99701381	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.1	-0.47	2.99e-14	Chronic sinus infection;
SARC	cis	rs2180341	1.000	rs6904520	chr6:127629802	T/C	cg27446573	chr6:127587934	RNF146	1.02	14.46	0.69	2.89e-34	Breast cancer;
SARC	cis	rs3812831	0.629	rs7318527	chr13:114946956	C/T	cg06611532	chr13:114900021	NA	0.36	6.17	0.37	3.02e-9	Schizophrenia;
SARC	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg19223190	chr17:80058835	NA	0.45	6.33	0.38	1.27e-9	Life satisfaction;
SARC	trans	rs6695352	0.802	rs12026786	chr1:214969949	C/T	cg07603881	chr1:21065497	NA	0.46	6.36	0.38	1.04e-9	Migraine without aura;
SARC	cis	rs7772486	0.790	rs2814880	chr6:146208937	T/G	cg23711669	chr6:146136114	FBXO30	0.8	12.58	0.64	4.77e-28	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs2727020	0.521	rs7114564	chr11:49571231	C/T	cg15704280	chr7:45808275	SEPT13	0.67	7.76	0.45	2.73e-13	Coronary artery disease;
SARC	cis	rs2486288	0.656	rs11854365	chr15:45558083	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.49	-6.21	-0.38	2.45e-9	Glomerular filtration rate;
SARC	cis	rs12579753	0.879	rs11115002	chr12:82153090	C/T	cg07988820	chr12:82153109	PPFIA2	-0.6	-7.08	-0.42	1.71e-11	Resting heart rate;
SARC	cis	rs1215050	0.791	rs700738	chr4:98907909	C/A	cg05340658	chr4:99064831	C4orf37	-0.46	-6.06	-0.37	5.42e-9	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs11585357	0.501	rs72646775	chr1:17592121	T/C	cg08277548	chr1:17600880	PADI3	-0.52	-5.3	-0.33	2.69e-7	Hair shape;
SARC	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg02733842	chr7:1102375	C7orf50	-0.43	-5.29	-0.33	2.78e-7	Bronchopulmonary dysplasia;
SARC	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg14517863	chr17:44321492	NA	-0.32	-4.76	-0.3	3.46e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs2153535	0.580	rs1335628	chr6:8491742	A/T	cg07606381	chr6:8435919	SLC35B3	0.79	11.45	0.6	2.26e-24	Motion sickness;
SARC	cis	rs9399135	0.967	rs12526055	chr6:135325918	C/T	cg24558204	chr6:135376177	HBS1L	0.47	6.28	0.38	1.61e-9	Red blood cell count;
SARC	cis	rs7666738	0.830	rs4472144	chr4:98956494	G/A	cg05340658	chr4:99064831	C4orf37	0.65	8.73	0.5	5.13e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs6665290	0.901	rs2104860	chr1:227208637	G/C	cg14016676	chr1:227182615	CDC42BPA	0.37	5.45	0.34	1.3e-7	Myeloid white cell count;
SARC	cis	rs10463316	0.817	rs6880228	chr5:150778145	A/T	cg03212797	chr5:150827313	SLC36A1	0.44	5.21	0.32	4.06e-7	Metabolite levels (Pyroglutamine);
SARC	cis	rs7712401	0.715	rs15577	chr5:122359190	G/T	cg19412675	chr5:122181750	SNX24	-0.42	-5.3	-0.33	2.65e-7	Mean platelet volume;
SARC	cis	rs67311347	0.955	rs1129200	chr3:40532257	T/C	cg24209194	chr3:40518798	ZNF619	0.6	7.62	0.45	6.51e-13	Renal cell carcinoma;
SARC	cis	rs7274811	0.681	rs186026	chr20:31951993	G/T	cg21523528	chr20:32077966	CBFA2T2	-0.42	-4.96	-0.31	1.35e-6	Height;
SARC	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg27266027	chr21:40555129	PSMG1	0.52	5.68	0.35	3.9e-8	Cognitive function;
SARC	cis	rs2916247	1.000	rs28550757	chr8:93047087	T/A	cg10183463	chr8:93005414	RUNX1T1	-0.58	-6.01	-0.37	7.15e-9	Intelligence (multi-trait analysis);
SARC	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.62	6.0	0.37	7.47e-9	Lung function (FEV1/FVC);
SARC	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg20814179	chr4:940893	TMEM175	0.38	4.86	0.3	2.17e-6	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
SARC	cis	rs796364	0.951	rs59695400	chr2:201021325	C/T	cg23649088	chr2:200775458	C2orf69	-0.64	-7.06	-0.42	1.9e-11	Schizophrenia;
SARC	cis	rs7267979	0.903	rs6050482	chr20:25226327	C/T	cg03522245	chr20:25566470	NINL	0.34	4.75	0.3	3.48e-6	Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs208520	0.909	rs60604603	chr6:67022955	T/C	cg07460842	chr6:66804631	NA	0.84	8.59	0.49	1.29e-15	Exhaled nitric oxide output;
SARC	cis	rs3857536	0.813	rs7757647	chr6:66947207	A/G	cg07460842	chr6:66804631	NA	-0.45	-5.19	-0.32	4.5e-7	Blood trace element (Cu levels);
SARC	cis	rs7914558	0.966	rs11191471	chr10:104702050	T/A	cg04362960	chr10:104952993	NT5C2	0.41	4.89	0.31	1.85e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
SARC	cis	rs9916302	0.904	rs35285898	chr17:37555872	A/C	cg15445000	chr17:37608096	MED1	-0.42	-5.02	-0.31	1.02e-6	Glomerular filtration rate (creatinine);
SARC	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.49	7.47	0.44	1.62e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	trans	rs1962073	0.528	rs9329223	chr8:10331754	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.68	-0.45	4.27e-13	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
SARC	cis	rs6088580	0.524	rs7274854	chr20:33228672	A/C	cg24642439	chr20:33292090	TP53INP2	0.53	6.52	0.39	4.22e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs11583043	0.874	rs72734253	chr1:101380718	A/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.47	5.74	0.35	2.94e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg00303548	chr13:96742413	HS6ST3	0.48	6.34	0.38	1.19e-9	Lung adenocarcinoma;
SARC	cis	rs713477	1.000	rs12893964	chr14:55912268	T/C	cg13175173	chr14:55914753	NA	-0.31	-4.77	-0.3	3.28e-6	Pediatric bone mineral content (femoral neck);
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg16251079	chr1:113497932	SLC16A1	-0.58	-6.32	-0.38	1.3e-9	Lung cancer in ever smokers;
SARC	cis	rs9399135	0.967	rs4637662	chr6:135298158	T/C	cg24558204	chr6:135376177	HBS1L	0.45	6.02	0.37	6.75e-9	Red blood cell count;
SARC	cis	rs9612	0.718	rs346531	chr19:44239927	T/C	cg08581076	chr19:44259116	C19orf61	0.6	7.62	0.45	6.25e-13	Exhaled nitric oxide output;
SARC	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg12463550	chr7:65579703	CRCP	0.5	5.9	0.36	1.27e-8	Aortic root size;
SARC	cis	rs1318878	0.565	rs1870695	chr12:15502404	A/G	cg08258403	chr12:15378311	NA	0.49	6.81	0.41	8.27e-11	Intelligence (multi-trait analysis);
SARC	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg24250549	chr1:154909240	PMVK	0.84	12.26	0.63	5.46e-27	Prostate cancer;
SARC	cis	rs8028182	0.583	rs9944207	chr15:75912889	A/T	cg20655648	chr15:75932815	IMP3	0.63	7.58	0.44	7.9e-13	Sudden cardiac arrest;
SARC	cis	rs10979	0.679	rs9496680	chr6:143896915	G/A	cg25407410	chr6:143891975	LOC285740	-0.6	-7.63	-0.45	5.88e-13	Hypospadias;
SARC	cis	rs9400467	0.537	rs10457232	chr6:111434407	A/G	cg15721981	chr6:111408429	SLC16A10	0.67	5.91	0.36	1.2e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs8114671	0.562	rs6058137	chr20:33475074	G/A	cg07148914	chr20:33460835	GGT7	0.45	5.54	0.34	8.3e-8	Height;
SARC	cis	rs2439831	0.850	rs7174208	chr15:44052682	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	8.57	0.49	1.44e-15	Lung cancer in ever smokers;
SARC	cis	rs826838	1.000	rs826886	chr12:39095797	A/G	cg13010199	chr12:38710504	ALG10B	0.63	8.94	0.51	1.25e-16	Heart rate;
SARC	trans	rs61931739	0.534	rs11052973	chr12:34029708	A/G	cg13010199	chr12:38710504	ALG10B	0.76	10.36	0.56	6.16e-21	Morning vs. evening chronotype;
SARC	cis	rs7953249	0.807	rs2393775	chr12:121424574	G/A	cg25281562	chr12:121454272	C12orf43	-0.43	-5.18	-0.32	4.69e-7	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
SARC	cis	rs12155623	0.834	rs16939055	chr8:49824013	T/G	cg22283653	chr8:49824208	NA	0.36	4.99	0.31	1.16e-6	Sudden cardiac arrest;
SARC	cis	rs2290720	0.930	rs4764642	chr12:101691922	C/T	cg22051763	chr12:101673672	UTP20	-0.44	-5.38	-0.33	1.83e-7	Brain structure (hippocampal volume);
SARC	cis	rs9747201	0.862	rs57596657	chr17:80147978	C/T	cg09264619	chr17:80180166	NA	-0.52	-6.01	-0.37	7.09e-9	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs7412746	0.658	rs10888397	chr1:150886752	A/G	cg13175981	chr1:150552382	MCL1	0.5	6.15	0.37	3.42e-9	Melanoma;
SARC	cis	rs7829975	0.510	rs2921073	chr8:8307643	C/T	cg11608241	chr8:8085544	FLJ10661	0.45	5.48	0.34	1.07e-7	Mood instability;
SARC	cis	rs765787	0.530	rs7167389	chr15:45535683	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.11	-0.32	6.85e-7	Uric acid levels;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg17446216	chr1:32480239	KHDRBS1	-0.78	-6.72	-0.4	1.37e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs17376456	0.569	rs7713956	chr5:93133185	T/C	cg21475434	chr5:93447410	FAM172A	-0.61	-6.09	-0.37	4.74e-9	Diabetic retinopathy;
SARC	cis	rs2624839	0.704	rs2624833	chr3:50212512	G/T	cg14019146	chr3:50243930	SLC38A3	-0.44	-6.91	-0.41	4.6e-11	Intelligence (multi-trait analysis);
SARC	cis	rs9796	0.689	rs13329537	chr15:41449211	C/G	cg18705301	chr15:41695430	NDUFAF1	0.44	5.97	0.36	8.72e-9	Menopause (age at onset);
SARC	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg25427524	chr10:38739819	LOC399744	-0.61	-9.92	-0.54	1.41e-19	Extrinsic epigenetic age acceleration;
SARC	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg24549020	chr5:56110836	MAP3K1	-0.46	-4.99	-0.31	1.2e-6	Initial pursuit acceleration;
SARC	cis	rs3733585	0.673	rs10000983	chr4:9951606	T/C	cg11266682	chr4:10021025	SLC2A9	-0.34	-5.83	-0.36	1.82e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg02487422	chr3:49467188	NICN1	0.51	6.91	0.41	4.64e-11	Resting heart rate;
SARC	cis	rs910316	0.687	rs175059	chr14:75490667	T/C	cg11812906	chr14:75593930	NEK9	-0.76	-10.14	-0.55	2.94e-20	Height;
SARC	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg04277193	chr17:41438351	NA	0.45	4.9	0.31	1.83e-6	Menopause (age at onset);
SARC	cis	rs9398803	0.965	rs2326387	chr6:126680489	G/A	cg19875578	chr6:126661172	C6orf173	0.58	7.81	0.46	1.88e-13	Male-pattern baldness;
SARC	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.89	12.64	0.64	3.1e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg19671926	chr4:122722719	EXOSC9	-0.56	-6.16	-0.37	3.25e-9	Type 2 diabetes;
SARC	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg23758822	chr17:41437982	NA	0.82	10.86	0.58	1.66e-22	Menopause (age at onset);
SARC	cis	rs11122272	0.735	rs2491404	chr1:231512127	C/T	cg06096015	chr1:231504339	EGLN1	0.39	5.91	0.36	1.2e-8	Hemoglobin concentration;
SARC	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.4	-0.56	4.62e-21	Chronic sinus infection;
SARC	cis	rs796364	1.000	rs281763	chr2:200794870	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.76	6.88	0.41	5.42e-11	Schizophrenia;
SARC	trans	rs9888736	0.501	rs1561043	chr15:47907212	A/G	cg01357263	chr12:122459509	BCL7A	-0.5	-6.28	-0.38	1.68e-9	Body mass index;
SARC	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	-0.7	-5.57	-0.34	6.95e-8	Initial pursuit acceleration;
SARC	cis	rs2836950	0.501	rs13047518	chr21:40707307	G/A	cg11890956	chr21:40555474	PSMG1	-0.69	-9.05	-0.51	5.98e-17	Menarche (age at onset);
SARC	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-7.89	-0.46	1.16e-13	Chronic sinus infection;
SARC	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg03806693	chr22:41940476	POLR3H	-0.83	-11.5	-0.6	1.58e-24	Vitiligo;
SARC	cis	rs523522	0.962	rs10849754	chr12:120940418	A/C	cg27279351	chr12:120934652	DYNLL1	0.72	8.91	0.5	1.5e-16	High light scatter reticulocyte count;
SARC	cis	rs477895	1.000	rs1047206	chr11:64089216	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	5.77	0.35	2.47e-8	Mean platelet volume;
SARC	cis	rs11756659	0.653	rs11757088	chr6:25948458	T/C	cg00631329	chr6:26305371	NA	-0.57	-5.53	-0.34	8.42e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;Red cell distribution width;
SARC	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg07636037	chr3:49044803	WDR6	0.99	17.82	0.76	2.07e-45	Parkinson's disease;
SARC	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg01368799	chr11:117014884	PAFAH1B2	0.49	5.64	0.35	4.9e-8	Blood protein levels;
SARC	cis	rs3820928	0.874	rs59630650	chr2:227786514	T/C	cg11843606	chr2:227700838	RHBDD1	-0.57	-7.23	-0.43	6.85e-12	Pulmonary function;
SARC	cis	rs11583043	0.918	rs11582211	chr1:101416871	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.49	5.72	0.35	3.27e-8	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs892961	0.899	rs72896163	chr17:75412525	C/T	cg05865280	chr17:75406074	SEPT9	0.57	8.47	0.48	2.87e-15	Airflow obstruction;
SARC	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg11890956	chr21:40555474	PSMG1	-1.04	-16.07	-0.72	1.33e-39	Cognitive function;
SARC	cis	rs6912958	0.559	rs376633	chr6:88042785	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.33	5.85	0.36	1.63e-8	Monocyte percentage of white cells;
SARC	cis	rs7106204	0.534	rs1443050	chr11:24275162	C/T	ch.11.24196551F	chr11:24239977	NA	0.65	4.8	0.3	2.88e-6	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs8102137	1.000	rs111640872	chr19:30290357	G/C	cg27475126	chr19:30303651	CCNE1	-0.39	-5.33	-0.33	2.28e-7	Bladder cancer;
SARC	cis	rs34172651	0.876	rs964782	chr16:24811740	T/C	cg04756594	chr16:24857601	SLC5A11	0.38	5.98	0.36	8.21e-9	Intelligence (multi-trait analysis);
SARC	trans	rs3734266	0.702	rs35141641	chr6:34736952	G/A	cg08157914	chr7:2646478	IQCE	0.52	6.24	0.38	2.1e-9	Systemic lupus erythematosus;
SARC	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg00409905	chr10:38381863	ZNF37A	-0.54	-7.42	-0.44	2.12e-12	Extrinsic epigenetic age acceleration;
SARC	cis	rs9398803	0.965	rs2027299	chr6:126685827	G/C	cg19875578	chr6:126661172	C6orf173	0.58	7.81	0.46	1.88e-13	Male-pattern baldness;
SARC	cis	rs13191362	1.000	rs13204013	chr6:163002480	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.58	5.49	0.34	1.04e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs7683537	0.887	rs4540092	chr4:185633546	A/G	cg04058563	chr4:185651563	MLF1IP	0.83	11.16	0.59	1.91e-23	Systemic lupus erythematosus;
SARC	cis	rs7296418	0.961	rs1790121	chr12:123604492	G/A	cg05973401	chr12:123451056	ABCB9	0.59	7.11	0.42	1.38e-11	Platelet count;
SARC	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg13206674	chr6:150067644	NUP43	0.44	5.71	0.35	3.35e-8	Lung cancer;
SARC	cis	rs3858526	0.874	rs10838879	chr11:5950169	C/T	cg13902645	chr11:5959945	NA	-0.46	-5.3	-0.33	2.62e-7	DNA methylation (variation);
SARC	cis	rs17125944	0.505	rs76219229	chr14:53178346	G/A	cg13660082	chr14:53194042	PSMC6	-0.74	-4.88	-0.3	1.97e-6	Alzheimer's disease (late onset);
SARC	cis	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg14541582	chr5:601475	NA	-0.38	-5.1	-0.32	7.01e-7	Obesity-related traits;
SARC	cis	rs6500395	1.000	rs9933314	chr16:48676608	T/C	cg04672837	chr16:48644449	N4BP1	0.46	6.28	0.38	1.65e-9	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs10754283	0.967	rs10922679	chr1:90100925	T/C	cg21401794	chr1:90099060	LRRC8C	0.6	8.42	0.48	3.81e-15	Amyotrophic lateral sclerosis (sporadic);
SARC	cis	rs208520	0.690	rs851468	chr6:66825875	G/A	cg07460842	chr6:66804631	NA	-1.06	-14.03	-0.68	8.04e-33	Exhaled nitric oxide output;
SARC	trans	rs7824557	0.767	rs7003241	chr8:11169075	A/G	cg06636001	chr8:8085503	FLJ10661	0.59	7.14	0.42	1.21e-11	Retinal vascular caliber;
SARC	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg06212747	chr3:49208901	KLHDC8B	0.67	8.87	0.5	1.98e-16	Parkinson's disease;
SARC	cis	rs34172651	0.617	rs9922436	chr16:24704490	C/G	cg00152838	chr16:24741724	TNRC6A	-0.49	-4.97	-0.31	1.32e-6	Intelligence (multi-trait analysis);
SARC	cis	rs4953404	0.613	rs6734725	chr2:46897570	G/A	cg09399716	chr2:46890238	NA	-0.24	-4.99	-0.31	1.19e-6	Pulse pressure (alcohol consumption interaction);
SARC	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-8.88	-0.5	1.83e-16	Alzheimer's disease;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg05516243	chr10:20017996	NA	0.43	6.42	0.39	7.54e-10	Thyroid stimulating hormone;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg06854353	chr6:109704291	CD164	-0.51	-6.51	-0.39	4.66e-10	Height;
SARC	cis	rs4481887	0.861	rs6681336	chr1:248482756	C/T	cg00666640	chr1:248458726	OR2T12	0.35	5.63	0.35	5.09e-8	Common traits (Other);
SARC	cis	rs7666738	0.830	rs1426670	chr4:98923572	A/G	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs7829975	0.533	rs13274028	chr8:8729193	A/C	cg06636001	chr8:8085503	FLJ10661	0.64	8.16	0.47	2.1e-14	Mood instability;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg02927292	chr1:36501817	EIF2C3	0.46	6.43	0.39	7.26e-10	Thyroid stimulating hormone;
SARC	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg26769984	chr7:1090371	C7orf50	0.49	5.21	0.32	4.2e-7	Bronchopulmonary dysplasia;
SARC	cis	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg09021430	chr5:549028	NA	-0.42	-5.46	-0.34	1.19e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs6867032	1.000	rs16902318	chr5:2013568	A/G	cg26168224	chr5:2018326	NA	0.95	15.92	0.72	4.09e-39	Gut microbiome composition (winter);
SARC	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg19077165	chr18:44547161	KATNAL2	-0.51	-6.95	-0.41	3.57e-11	Personality dimensions;
SARC	trans	rs1853207	0.656	rs77240815	chr10:96645428	T/C	cg02737782	chr1:8014393	NA	-0.97	-6.42	-0.39	7.44e-10	Blood metabolite levels;
SARC	cis	rs9399135	0.967	rs9376082	chr6:135346389	T/A	cg24558204	chr6:135376177	HBS1L	0.45	6.02	0.37	6.77e-9	Red blood cell count;
SARC	cis	rs992157	1.000	rs992157	chr2:219154781	A/G	cg00012203	chr2:219082015	ARPC2	-0.7	-10.47	-0.57	2.74e-21	Colorectal cancer;
SARC	trans	rs10506458	1.000	rs1009539	chr12:63414655	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	0.72	6.63	0.4	2.3e-10	Hemostatic factors and hematological phenotypes;
SARC	cis	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg12463550	chr7:65579703	CRCP	0.68	5.21	0.32	4.1e-7	Diabetic kidney disease;
SARC	trans	rs1814175	0.754	rs10839453	chr11:49955815	A/T	cg03929089	chr4:120376271	NA	-0.88	-14.05	-0.68	6.62e-33	Height;
SARC	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	9.48	0.53	3.15e-18	Platelet count;
SARC	cis	rs897984	0.568	rs67456613	chr16:30888295	G/A	cg00531865	chr16:30841666	NA	-0.52	-5.43	-0.34	1.43e-7	Dementia with Lewy bodies;
SARC	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg23985595	chr17:80112537	CCDC57	-0.32	-4.8	-0.3	2.88e-6	Life satisfaction;
SARC	cis	rs1707322	0.865	rs785501	chr1:46579611	C/T	cg06784218	chr1:46089804	CCDC17	-0.36	-6.17	-0.37	3.05e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg17173891	chr6:87967392	ZNF292	0.52	7.64	0.45	5.66e-13	Thyroid stimulating hormone;
SARC	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg11764359	chr7:65958608	NA	-0.87	-12.61	-0.64	3.91e-28	Aortic root size;
SARC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg16132339	chr22:24313637	DDTL;DDT	0.39	4.91	0.31	1.71e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs9467711	0.591	rs13216785	chr6:26079185	C/T	cg21479132	chr6:26055353	NA	1.0	7.59	0.45	7.44e-13	Autism spectrum disorder or schizophrenia;
SARC	cis	rs4276643	0.576	rs2726940	chr8:27823868	C/T	cg26001764	chr8:28560637	EXTL3	0.35	5.03	0.31	9.87e-7	Low vWF levels;
SARC	cis	rs7223966	1.000	rs8064261	chr17:61705212	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.44	4.76	0.3	3.44e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9733	0.650	rs61820165	chr1:150555987	C/T	cg13175981	chr1:150552382	MCL1	0.7	9.45	0.53	3.64e-18	Tonsillectomy;
SARC	cis	rs4481887	0.927	rs10888343	chr1:248446642	A/G	cg00666640	chr1:248458726	OR2T12	0.34	5.63	0.35	5.27e-8	Common traits (Other);
SARC	trans	rs208520	0.690	rs2797693	chr6:66868985	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-14.2	-0.68	2.26e-33	Exhaled nitric oxide output;
SARC	cis	rs9487051	1.000	rs6568570	chr6:109613241	T/G	cg01475377	chr6:109611718	NA	-0.41	-5.61	-0.34	5.72e-8	Reticulocyte fraction of red cells;
SARC	cis	rs4481887	1.000	rs4244180	chr1:248471033	A/G	cg01631408	chr1:248437212	OR2T33	-0.41	-5.16	-0.32	5.18e-7	Common traits (Other);
SARC	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	5.73	0.35	3.02e-8	Bipolar disorder;
SARC	cis	rs9341808	0.714	rs9448911	chr6:80913859	A/G	cg08355045	chr6:80787529	NA	0.36	5.75	0.35	2.76e-8	Sitting height ratio;
SARC	cis	rs7772486	0.790	rs2265918	chr6:146219164	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.62	0.4	2.39e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs10905065	0.930	rs7909988	chr10:5736388	A/T	cg09072322	chr10:5726702	C10orf18	-0.41	-5.09	-0.32	7.36e-7	Menopause (age at onset);
SARC	cis	rs7647973	0.667	rs9869256	chr3:49624095	T/G	cg13072238	chr3:49761600	GMPPB	-0.71	-5.81	-0.36	2.03e-8	Menarche (age at onset);
SARC	trans	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg21775007	chr8:11205619	TDH	0.52	6.55	0.39	3.58e-10	Mood instability;
SARC	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg11987759	chr7:65425863	GUSB	-0.61	-8.38	-0.48	5.02e-15	Aortic root size;
SARC	cis	rs72634258	0.786	rs7524424	chr1:8173369	A/G	cg00042356	chr1:8021962	PARK7	0.63	5.82	0.36	1.9e-8	Inflammatory bowel disease;
SARC	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	11.21	0.59	1.34e-23	Platelet count;
SARC	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	12.31	0.63	3.59e-27	Personality dimensions;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg08255233	chr6:87607178	NA	0.43	6.58	0.4	3.08e-10	Breast cancer;
SARC	cis	rs10876993	0.890	rs1678539	chr12:58060359	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.5	-6.31	-0.38	1.37e-9	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs8114671	0.935	rs6058198	chr20:33748253	T/A	cg24642439	chr20:33292090	TP53INP2	0.53	6.1	0.37	4.35e-9	Height;
SARC	cis	rs7824557	0.767	rs2060463	chr8:11161610	T/G	cg21775007	chr8:11205619	TDH	0.53	6.27	0.38	1.75e-9	Retinal vascular caliber;
SARC	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.54	0.44	1.06e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2635047	0.682	rs1980055	chr18:44792636	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	6.28	0.38	1.6e-9	Educational attainment;
SARC	cis	rs9398803	0.678	rs9375448	chr6:126896782	A/T	cg19875578	chr6:126661172	C6orf173	0.63	8.7	0.5	5.9e-16	Male-pattern baldness;
SARC	cis	rs651907	0.535	rs4342086	chr3:101503765	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.49	5.81	0.36	2e-8	Colorectal cancer;
SARC	cis	rs7513165	0.935	rs2510	chr1:204161591	T/C	cg23788856	chr1:204159729	KISS1	-0.36	-5.52	-0.34	8.82e-8	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
SARC	cis	rs12458462	0.812	rs34583578	chr18:77491070	C/T	cg23301140	chr18:77439876	CTDP1	0.6	7.55	0.44	9.68e-13	Monocyte count;
SARC	cis	rs7917772	0.582	rs10883736	chr10:104320029	G/T	ch.10.2196322F	chr10:104248062	ACTR1A	0.47	6.61	0.4	2.6e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs9420	0.961	rs80304923	chr11:57522823	C/G	cg19752551	chr11:57585705	CTNND1	-0.52	-7.19	-0.43	8.7e-12	Schizophrenia;
SARC	cis	rs2730245	0.527	rs842702	chr7:158696814	C/T	cg24397884	chr7:158709396	WDR60	1.17	10.66	0.57	7.23e-22	Height;
SARC	cis	rs2236918	0.687	rs2797601	chr1:242029249	C/G	cg17736920	chr1:242011382	EXO1	0.64	8.55	0.49	1.63e-15	Menopause (age at onset);
SARC	trans	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg00938859	chr5:1591904	SDHAP3	0.69	6.36	0.38	1.03e-9	Breast cancer;
SARC	cis	rs6087990	0.806	rs910085	chr20:31383353	T/G	cg13636640	chr20:31349939	DNMT3B	0.82	13.35	0.66	1.45e-30	Ulcerative colitis;
SARC	cis	rs9831754	0.704	rs9882111	chr3:78470746	A/G	cg06138941	chr3:78371609	NA	-0.54	-6.5	-0.39	4.91e-10	Calcium levels;
SARC	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.51	-5.86	-0.36	1.57e-8	Systemic lupus erythematosus;
SARC	cis	rs5769765	0.825	rs9616780	chr22:50292763	T/C	cg03033257	chr22:50311977	ALG12;CRELD2	0.52	5.33	0.33	2.28e-7	Schizophrenia;
SARC	cis	rs796364	0.813	rs4672686	chr2:201065044	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.51	5.12	0.32	6.54e-7	Schizophrenia;
SARC	cis	rs12200560	0.505	rs211182	chr6:97074513	G/A	cg06623918	chr6:96969491	KIAA0776	0.45	5.18	0.32	4.79e-7	Coronary heart disease;
SARC	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.42	4.78	0.3	3.17e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg03806693	chr22:41940476	POLR3H	0.87	11.85	0.61	1.14e-25	Vitiligo;
SARC	cis	rs9894429	1.000	rs11652797	chr17:79574124	A/G	cg18240062	chr17:79603768	NPLOC4	0.7	9.53	0.53	2.18e-18	Eye color traits;
SARC	cis	rs10504229	0.593	rs2317990	chr8:58024168	G/T	cg21724239	chr8:58056113	NA	0.67	6.68	0.4	1.76e-10	Developmental language disorder (linguistic errors);
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg13208492	chr2:122513376	TSN	0.57	7.12	0.42	1.31e-11	Breast cancer;
SARC	cis	rs17253792	0.822	rs77315200	chr14:56072643	C/A	cg01858014	chr14:56050164	KTN1	-0.67	-5.16	-0.32	5.38e-7	Putamen volume;
SARC	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg13206674	chr6:150067644	NUP43	0.47	6.12	0.37	3.99e-9	Lung cancer;
SARC	cis	rs965469	0.779	rs2236119	chr20:3303576	G/T	cg25506879	chr20:3388711	C20orf194	-0.45	-4.96	-0.31	1.37e-6	IFN-related cytopenia;
SARC	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg08219700	chr8:58056026	NA	0.6	6.38	0.39	9.35e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs6088590	1.000	rs6119512	chr20:33306904	T/C	cg24642439	chr20:33292090	TP53INP2	0.89	12.79	0.64	9.78e-29	Coronary artery disease;
SARC	cis	rs72781680	1.000	rs72781680	chr2:24238928	C/T	cg08917208	chr2:24149416	ATAD2B	0.92	9.07	0.51	4.92e-17	Lymphocyte counts;
SARC	cis	rs634534	0.562	rs661335	chr11:65754061	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.39	4.9	0.31	1.78e-6	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs4689388	0.926	rs4458523	chr4:6289986	G/T	cg25554036	chr4:6271136	WFS1	-0.43	-7.19	-0.43	8.67e-12	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs1957429	0.614	rs1957416	chr14:65369329	C/T	cg23373153	chr14:65346875	NA	-0.96	-6.07	-0.37	5.27e-9	Pediatric areal bone mineral density (radius);
SARC	cis	rs9486719	1.000	rs12530462	chr6:97053514	C/T	cg18709589	chr6:96969512	KIAA0776	-0.53	-5.47	-0.34	1.16e-7	Migraine;Coronary artery disease;
SARC	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg08219700	chr8:58056026	NA	0.62	6.52	0.39	4.28e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg16414030	chr3:133502952	NA	-0.36	-4.78	-0.3	3.08e-6	Iron status biomarkers;
SARC	cis	rs6570726	0.967	rs365515	chr6:145802833	C/T	cg23711669	chr6:146136114	FBXO30	-0.72	-10.79	-0.58	2.85e-22	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs9790314	0.663	rs55888276	chr3:160651406	A/G	cg03342759	chr3:160939853	NMD3	0.39	4.79	0.3	2.95e-6	Morning vs. evening chronotype;
SARC	cis	rs412658	0.704	rs8105767	chr19:22215441	A/G	cg20662725	chr19:22235022	ZNF257	-0.43	-4.78	-0.3	3.04e-6	Telomere length;
SARC	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.94	13.16	0.65	5.86e-30	Gut microbiome composition (summer);
SARC	cis	rs6840360	0.571	rs11723395	chr4:152524191	G/A	cg22705602	chr4:152727874	NA	-0.43	-6.79	-0.41	9.46e-11	Intelligence (multi-trait analysis);
SARC	cis	rs2120243	0.539	rs2085315	chr3:157112622	T/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.39	5.07	0.32	8.25e-7	Hepatocellular carcinoma in hepatitis B infection;
SARC	cis	rs9807989	1.000	rs9807989	chr2:102971200	T/C	cg09003973	chr2:102972529	NA	0.41	5.6	0.34	6.11e-8	Asthma;
SARC	cis	rs870825	0.587	rs28454955	chr4:185632701	C/T	cg04058563	chr4:185651563	MLF1IP	0.83	11.16	0.59	1.91e-23	Blood protein levels;
SARC	trans	rs11098499	0.604	rs2389887	chr4:120570644	T/C	cg25214090	chr10:38739885	LOC399744	0.51	6.6	0.4	2.81e-10	Corneal astigmatism;
SARC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg05863683	chr7:1912471	MAD1L1	0.34	5.08	0.32	7.58e-7	Bipolar disorder and schizophrenia;
SARC	trans	rs61931739	0.500	rs11053197	chr12:34441949	C/T	cg13010199	chr12:38710504	ALG10B	0.81	11.39	0.6	3.58e-24	Morning vs. evening chronotype;
SARC	cis	rs147649347	1	rs147649347	chr2:24210076	GATAA/G	cg08917208	chr2:24149416	ATAD2B	0.86	8.46	0.48	2.9e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
SARC	cis	rs7216064	0.911	rs12449442	chr17:65947640	G/A	cg12091567	chr17:66097778	LOC651250	-0.69	-6.86	-0.41	6.22e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs13082711	0.554	rs10514679	chr3:27412591	A/G	cg02860705	chr3:27208620	NA	0.65	7.92	0.46	9.98e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs3126085	1.000	rs3126095	chr1:152309683	G/A	cg26876637	chr1:152193138	HRNR	-0.45	-4.84	-0.3	2.32e-6	Atopic dermatitis;
SARC	cis	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg14019146	chr3:50243930	SLC38A3	-0.32	-5.04	-0.31	9.29e-7	Intelligence (multi-trait analysis);
SARC	cis	rs651907	0.535	rs1460097	chr3:101497569	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	6.18	0.38	2.86e-9	Colorectal cancer;
SARC	cis	rs9790314	0.690	rs6441354	chr3:160826404	A/G	cg04691961	chr3:161091175	C3orf57	-0.59	-8.13	-0.47	2.6e-14	Morning vs. evening chronotype;
SARC	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg24531977	chr5:56204891	C5orf35	-0.54	-5.45	-0.34	1.26e-7	Initial pursuit acceleration;
SARC	cis	rs9435341	0.860	rs12406721	chr1:107563243	G/T	cg09367891	chr1:107599246	PRMT6	0.73	9.01	0.51	7.56e-17	Facial morphology (factor 21, depth of nasal alae);
SARC	cis	rs79149102	0.579	rs74023936	chr15:75362084	C/T	cg17294928	chr15:75287854	SCAMP5	-0.93	-8.23	-0.47	1.33e-14	Lung cancer;
SARC	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg09699651	chr6:150184138	LRP11	0.43	5.28	0.33	2.94e-7	Lung cancer;
SARC	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg13206674	chr6:150067644	NUP43	0.46	5.91	0.36	1.22e-8	Lung cancer;
SARC	cis	rs67460515	0.500	rs6806015	chr3:160724766	G/A	cg17135325	chr3:160939158	NMD3	0.5	6.1	0.37	4.49e-9	Parkinson's disease;
SARC	cis	rs9896052	0.534	rs8065160	chr17:73441090	A/G	cg27037648	chr17:73511087	CASKIN2	-0.43	-5.07	-0.32	8.02e-7	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs2836950	0.545	rs11700813	chr21:40517469	T/G	cg11890956	chr21:40555474	PSMG1	-0.69	-8.65	-0.49	8.4e-16	Menarche (age at onset);
SARC	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg20203395	chr5:56204925	C5orf35	0.6	5.4	0.33	1.64e-7	Initial pursuit acceleration;
SARC	cis	rs240764	0.782	rs239235	chr6:101100528	A/G	cg09795085	chr6:101329169	ASCC3	0.44	5.71	0.35	3.39e-8	Neuroticism;
SARC	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.41	-6.35	-0.38	1.09e-9	Total body bone mineral density;
SARC	cis	rs11098499	0.954	rs3733524	chr4:120423729	T/C	cg24375607	chr4:120327624	NA	0.42	5.03	0.31	9.61e-7	Corneal astigmatism;
SARC	cis	rs113835537	0.529	rs80100524	chr11:66245936	C/T	cg24851651	chr11:66362959	CCS	0.39	4.85	0.3	2.27e-6	Airway imaging phenotypes;
SARC	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg13939156	chr17:80058883	NA	0.4	6.25	0.38	1.92e-9	Life satisfaction;
SARC	cis	rs601339	1.000	rs509548	chr12:123181855	T/A	cg18578876	chr12:123200353	GPR109B	0.43	4.88	0.3	2.01e-6	Adiponectin levels;
SARC	cis	rs2985684	0.894	rs10147029	chr14:50020232	G/T	cg15316458	chr14:50087796	RPL36AL;MGAT2	-0.44	-4.99	-0.31	1.21e-6	Carotid intima media thickness;
SARC	cis	rs9303280	0.773	rs12949100	chr17:38057189	G/A	cg20243544	chr17:37824526	PNMT	0.43	5.57	0.34	7.14e-8	Self-reported allergy;
SARC	cis	rs763121	0.853	rs138702	chr22:39132601	A/T	cg21395723	chr22:39101663	GTPBP1	-0.55	-6.78	-0.41	9.53e-11	Menopause (age at onset);
SARC	cis	rs12142240	0.698	rs41294478	chr1:46818442	G/A	cg14993813	chr1:46806288	NSUN4	-0.52	-5.46	-0.34	1.22e-7	Menopause (age at onset);
SARC	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg23758822	chr17:41437982	NA	0.92	12.17	0.62	1.03e-26	Menopause (age at onset);
SARC	cis	rs11583043	1.000	rs35445887	chr1:101523639	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.47	5.33	0.33	2.32e-7	Ulcerative colitis;Inflammatory bowel disease;
SARC	trans	rs2727020	0.658	rs7111215	chr11:49430552	T/C	cg03929089	chr4:120376271	NA	-0.79	-11.79	-0.61	1.78e-25	Coronary artery disease;
SARC	cis	rs7766436	0.767	rs6909752	chr6:22612629	G/A	cg13666174	chr6:22585274	NA	-0.5	-6.64	-0.4	2.14e-10	Coronary artery disease;
SARC	cis	rs27434	0.607	rs695965	chr5:96148366	C/T	cg16492584	chr5:96139282	ERAP1	-0.56	-7.15	-0.42	1.14e-11	Ankylosing spondylitis;
SARC	cis	rs2718058	0.589	rs10274478	chr7:37792902	T/C	cg24998770	chr7:37888106	TXNDC3	-0.31	-4.71	-0.3	4.18e-6	Alzheimer's disease (late onset);
SARC	cis	rs10080237	0.564	rs2490230	chr6:80812464	G/A	cg08355045	chr6:80787529	NA	0.35	5.39	0.33	1.68e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
SARC	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg08280861	chr8:58055591	NA	-0.61	-5.92	-0.36	1.16e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs155076	0.938	rs9509630	chr13:21844314	G/A	cg25811766	chr13:21894605	NA	-0.51	-5.5	-0.34	9.92e-8	White matter hyperintensity burden;
SARC	cis	rs9660992	0.542	rs17345153	chr1:205179997	A/G	cg07972983	chr1:205091412	RBBP5	0.56	6.88	0.41	5.33e-11	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs7100689	0.577	rs9420349	chr10:82031160	T/C	cg01528321	chr10:82214614	TSPAN14	0.57	7.29	0.43	4.83e-12	Post bronchodilator FEV1;
SARC	cis	rs782590	0.556	rs782579	chr2:55917604	A/G	cg18811423	chr2:55921094	PNPT1	0.55	7.59	0.45	7.86e-13	Metabolic syndrome;
SARC	cis	rs963731	0.649	rs2924714	chr2:39333288	A/G	cg04010122	chr2:39346883	SOS1	-1.11	-6.38	-0.39	9.36e-10	Corticobasal degeneration;
SARC	cis	rs936229	0.749	rs7497201	chr15:75190690	A/G	cg10253484	chr15:75165896	SCAMP2	-0.55	-6.02	-0.37	6.71e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
SARC	cis	rs35213789	0.920	rs2903097	chr7:69337749	C/T	cg10619644	chr7:69149951	AUTS2	0.48	5.89	0.36	1.35e-8	Childhood ear infection;
SARC	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg00149659	chr3:10157352	C3orf10	0.78	7.3	0.43	4.52e-12	Alzheimer's disease;
SARC	cis	rs1023500	0.505	rs134901	chr22:42683520	C/T	cg04733989	chr22:42467013	NAGA	0.57	7.32	0.43	3.92e-12	Schizophrenia;
SARC	cis	rs7561528	0.501	rs6714558	chr2:127890878	G/C	cg12632573	chr2:127783243	NA	0.65	5.82	0.36	1.95e-8	Alzheimer's disease;Alzheimer's disease (late onset);
SARC	cis	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg24110177	chr3:50126178	RBM5	0.54	7.25	0.43	6.19e-12	Intelligence (multi-trait analysis);
SARC	cis	rs2562456	0.917	rs2650805	chr19:21687939	T/G	cg00806126	chr19:22604979	ZNF98	0.47	4.85	0.3	2.27e-6	Pain;
SARC	cis	rs7560272	0.501	rs2421674	chr2:73955432	G/A	cg20560298	chr2:73613845	ALMS1	0.43	5.7	0.35	3.65e-8	Schizophrenia;
SARC	cis	rs861020	0.582	rs630065	chr1:209998662	C/T	cg05527609	chr1:210001259	C1orf107	0.76	9.6	0.53	1.29e-18	Orofacial clefts;
SARC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	20.03	0.8	1.4e-52	Prudent dietary pattern;
SARC	cis	rs2011503	1.000	rs34667451	chr19:19617017	C/T	cg15839431	chr19:19639596	YJEFN3	-0.48	-4.78	-0.3	3.15e-6	Bipolar disorder;
SARC	cis	rs7020830	0.931	rs7027473	chr9:37132462	A/G	cg14294708	chr9:37120828	ZCCHC7	1.15	21.16	0.81	3.55e-56	Schizophrenia;
SARC	cis	rs67311347	1.000	rs28536038	chr3:40496382	A/C	cg09455208	chr3:40491958	NA	0.4	5.9	0.36	1.29e-8	Renal cell carcinoma;
SARC	cis	rs3820928	0.874	rs4234062	chr2:227819050	C/A	cg11843606	chr2:227700838	RHBDD1	-0.56	-7.12	-0.42	1.33e-11	Pulmonary function;
SARC	cis	rs6952809	0.532	rs7803015	chr7:2432143	G/A	cg23289794	chr7:2394357	EIF3B	-0.6	-5.94	-0.36	1.05e-8	Multiple sclerosis;
SARC	cis	rs35306767	0.903	rs34847097	chr10:902252	A/T	cg20503657	chr10:835505	NA	0.88	8.4	0.48	4.51e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs2075371	1.000	rs1868783	chr7:133975087	A/G	cg00033643	chr7:134001901	SLC35B4	0.41	4.98	0.31	1.25e-6	Mean platelet volume;
SARC	cis	rs17376456	0.542	rs6556833	chr5:93104707	T/C	cg25358565	chr5:93447407	FAM172A	0.82	9.01	0.51	7.61e-17	Diabetic retinopathy;
SARC	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg19346786	chr7:2764209	NA	-0.41	-6.05	-0.37	5.87e-9	Height;
SARC	cis	rs11599315	0.507	rs12217329	chr10:1341897	A/G	cg01270228	chr10:1369114	ADARB2	0.32	5.23	0.32	3.73e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs9326248	0.569	rs4938315	chr11:116731205	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.56	4.88	0.3	2e-6	Blood protein levels;
SARC	cis	rs6752107	0.782	rs12692254	chr2:234161211	A/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.46	6.06	0.37	5.5e-9	Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs986417	0.551	rs4901991	chr14:61065025	T/C	cg27398547	chr14:60952738	C14orf39	0.87	7.44	0.44	1.96e-12	Gut microbiota (bacterial taxa);
SARC	cis	rs58804349	0.685	rs11239855	chr10:43483879	A/G	cg08461752	chr10:43522343	NA	0.44	5.44	0.34	1.32e-7	Pediatric bone mineral content (radius);
SARC	cis	rs4319547	0.774	rs7954006	chr12:123131824	A/C	cg23029597	chr12:123009494	RSRC2	0.48	6.17	0.37	3.01e-9	Body mass index;
SARC	cis	rs9970896	1.000	rs9970896	chr1:236104981	A/T	cg18236982	chr1:236065291	NA	0.43	4.81	0.3	2.7e-6	Monocyte percentage of white cells;
SARC	cis	rs734999	0.545	rs12749591	chr1:2563250	G/T	cg18854424	chr1:2615690	NA	-0.31	-5.02	-0.31	1e-6	Ulcerative colitis;
SARC	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg15448220	chr1:150897856	SETDB1	0.45	6.01	0.37	7.09e-9	Tonsillectomy;
SARC	cis	rs2282802	0.685	rs2337081	chr5:139642414	A/C	cg26211634	chr5:139558579	C5orf32	0.41	5.28	0.33	2.98e-7	Intelligence (multi-trait analysis);
SARC	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg21132104	chr15:45694354	SPATA5L1	0.77	10.98	0.58	6.87e-23	Homoarginine levels;
SARC	cis	rs2228479	0.702	rs17233868	chr16:89803629	C/T	cg06558623	chr16:89946397	TCF25	0.86	5.83	0.36	1.79e-8	Skin colour saturation;
SARC	cis	rs116095464	1.000	rs6555159	chr5:311562	G/A	cg22496380	chr5:211416	CCDC127	-0.86	-6.51	-0.39	4.66e-10	Breast cancer;
SARC	cis	rs7264396	0.747	rs73283043	chr20:34383863	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-7.59	-0.45	7.58e-13	Total cholesterol levels;
SARC	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	11.81	0.61	1.59e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs9640161	0.830	rs6722	chr7:150068933	T/C	cg10018233	chr7:150070692	REPIN1	0.75	12.66	0.64	2.68e-28	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs6991838	0.584	rs6993876	chr8:66513475	C/T	cg13398993	chr8:66546079	ARMC1	0.63	8.31	0.48	7.71e-15	Intelligence (multi-trait analysis);
SARC	cis	rs10465746	0.780	rs11163866	chr1:84367123	A/G	cg10977910	chr1:84465055	TTLL7	0.4	4.82	0.3	2.6e-6	Obesity-related traits;
SARC	cis	rs7474896	0.583	rs10827818	chr10:38000856	T/C	cg25427524	chr10:38739819	LOC399744	-0.48	-5.86	-0.36	1.56e-8	Obesity (extreme);
SARC	cis	rs9910055	0.529	rs228766	chr17:42186813	A/G	cg19774624	chr17:42201019	HDAC5	0.57	6.87	0.41	5.74e-11	Total body bone mineral density;
SARC	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg11987759	chr7:65425863	GUSB	0.46	6.08	0.37	4.82e-9	Aortic root size;
SARC	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.62	7.48	0.44	1.53e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs35306767	0.855	rs11253459	chr10:886402	C/T	cg26597838	chr10:835615	NA	0.79	8.59	0.49	1.26e-15	Eosinophil percentage of granulocytes;
SARC	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg10591111	chr5:226296	SDHA	-0.55	-4.97	-0.31	1.31e-6	Breast cancer;
SARC	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg11764359	chr7:65958608	NA	-0.77	-9.16	-0.51	2.79e-17	Aortic root size;
SARC	cis	rs7647973	1.000	rs9862534	chr3:49598064	A/G	cg07636037	chr3:49044803	WDR6	0.75	8.86	0.5	2.06e-16	Menarche (age at onset);
SARC	cis	rs9814567	0.762	rs13071253	chr3:134316653	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.47	5.19	0.32	4.61e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.64	7.88	0.46	1.26e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs1420338	0.933	rs1362460	chr7:34147964	C/T	cg01275685	chr7:34179230	BMPER	-0.43	-5.3	-0.33	2.74e-7	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
SARC	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg13206674	chr6:150067644	NUP43	0.39	5.18	0.32	4.91e-7	Lung cancer;
SARC	cis	rs1873147	1.000	rs2130165	chr15:63314519	C/T	cg05507819	chr15:63340323	TPM1	-0.49	-5.31	-0.33	2.5e-7	Orofacial clefts;
SARC	cis	rs2204008	0.805	rs11522896	chr12:38234427	T/C	cg26384229	chr12:38710491	ALG10B	0.91	13.43	0.66	7.61e-31	Bladder cancer;
SARC	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-10.15	-0.55	2.87e-20	Chronic sinus infection;
SARC	cis	rs7582180	0.629	rs13025184	chr2:100944842	A/G	cg14675211	chr2:100938903	LONRF2	0.51	7.59	0.45	7.52e-13	Intelligence (multi-trait analysis);
SARC	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg22920501	chr2:26401640	FAM59B	0.56	7.63	0.45	6e-13	Gut microbiome composition (summer);
SARC	trans	rs12310956	0.532	rs1525897	chr12:33941033	C/T	cg26384229	chr12:38710491	ALG10B	0.86	12.63	0.64	3.39e-28	Morning vs. evening chronotype;
SARC	cis	rs4763879	0.739	rs2895988	chr12:9828427	T/G	cg27502298	chr12:9555721	NA	0.46	5.03	0.31	9.7e-7	Type 1 diabetes;
SARC	cis	rs7474896	0.583	rs12776092	chr10:38015795	G/C	cg00409905	chr10:38381863	ZNF37A	-0.45	-4.83	-0.3	2.49e-6	Obesity (extreme);
SARC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg26354017	chr1:205819088	PM20D1	0.92	16.06	0.72	1.38e-39	Menarche (age at onset);
SARC	cis	rs9911578	0.967	rs8072712	chr17:57162464	A/T	cg05425664	chr17:57184151	TRIM37	-0.63	-7.87	-0.46	1.36e-13	Intelligence (multi-trait analysis);
SARC	cis	rs4535301	0.819	rs4263354	chr4:170271392	C/T	cg07701716	chr4:170533879	NEK1	-0.4	-5.04	-0.31	9.43e-7	Night sleep phenotypes;
SARC	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg22484793	chr3:52261325	TLR9	0.29	4.72	0.3	4.08e-6	Bipolar disorder;
SARC	cis	rs11697848	1.000	rs11698676	chr20:48536585	G/T	cg17849948	chr20:48532315	SPATA2	0.87	5.2	0.32	4.3e-7	Systemic lupus erythematosus;
SARC	cis	rs472402	0.905	rs248798	chr5:6661161	C/G	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.39	-4.75	-0.3	3.58e-6	Response to amphetamines;
SARC	cis	rs4253772	0.637	rs9627402	chr22:46702586	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.61	4.99	0.31	1.16e-6	LDL cholesterol;Cholesterol, total;
SARC	cis	rs71636778	0.584	rs36042864	chr1:27146944	G/T	cg04852280	chr1:26496234	ZNF593	0.57	5.16	0.32	5.21e-7	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs3820928	0.900	rs6754155	chr2:227784961	A/G	cg05526886	chr2:227700861	RHBDD1	-0.53	-6.51	-0.39	4.67e-10	Pulmonary function;
SARC	cis	rs11155671	0.530	rs7757984	chr6:150208651	A/G	cg00933542	chr6:150070202	PCMT1	0.29	4.75	0.3	3.57e-6	Testicular germ cell tumor;
SARC	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg03650068	chr1:25596491	NA	0.34	5.2	0.32	4.44e-7	Erythrocyte sedimentation rate;
SARC	cis	rs11997175	0.545	rs7388496	chr8:33667898	A/G	ch.8.33884649F	chr8:33765107	NA	0.44	5.47	0.34	1.14e-7	Body mass index;
SARC	cis	rs524281	0.861	rs10896087	chr11:65924549	A/G	cg14036092	chr11:66035641	RAB1B	-0.51	-5.48	-0.34	1.11e-7	Electroencephalogram traits;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg26423471	chr10:118925454	NA	-0.56	-6.85	-0.41	6.58e-11	Fibrinogen levels;
SARC	cis	rs11864453	0.826	rs2240243	chr16:72137561	A/G	cg01557791	chr16:72042693	DHODH	0.6	8.31	0.48	7.95e-15	Fibrinogen levels;
SARC	cis	rs861020	0.630	rs592694	chr1:210009533	G/T	cg05527609	chr1:210001259	C1orf107	0.77	9.96	0.55	1.04e-19	Orofacial clefts;
SARC	cis	rs829883	0.738	rs249854	chr12:98862772	G/A	cg25150519	chr12:98850993	NA	0.84	13.5	0.66	4.54e-31	Colorectal adenoma (advanced);
SARC	cis	rs765787	0.530	rs4775819	chr15:45525966	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.42	-5.19	-0.32	4.51e-7	Uric acid levels;
SARC	cis	rs10088262	0.629	rs12541177	chr8:124800273	G/T	cg20713898	chr8:124780851	FAM91A1	-0.64	-7.14	-0.42	1.17e-11	Pancreatic cancer;
SARC	cis	rs9814567	0.896	rs10935123	chr3:134345327	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.5	-6.4	-0.39	8.24e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs4423214	1.000	rs12797951	chr11:71143266	G/T	cg24826892	chr11:71159390	DHCR7	-0.46	-5.79	-0.35	2.27e-8	Vitamin D levels;
SARC	cis	rs2549003	1.000	rs6894655	chr5:131818649	T/C	cg21138405	chr5:131827807	IRF1	0.28	5.59	0.34	6.22e-8	Asthma (sex interaction);
SARC	cis	rs9914544	0.545	rs2892016	chr17:18786776	C/T	cg25390199	chr17:18761479	PRPSAP2	0.45	5.83	0.36	1.8e-8	Educational attainment (years of education);
SARC	cis	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg08045932	chr20:61659980	NA	0.52	6.91	0.41	4.6e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs2439831	1.000	rs2254321	chr15:43707542	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.06	11.11	0.59	2.68e-23	Lung cancer in ever smokers;
SARC	cis	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg06636001	chr8:8085503	FLJ10661	0.63	8.54	0.49	1.76e-15	Mood instability;
SARC	cis	rs453301	0.719	rs34004903	chr8:8892604	C/T	cg11995313	chr8:8860691	ERI1	0.43	5.54	0.34	8.09e-8	Joint mobility (Beighton score);
SARC	cis	rs7124681	0.584	rs4752792	chr11:47815702	G/A	cg20307385	chr11:47447363	PSMC3	-0.49	-6.63	-0.4	2.36e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
SARC	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg08219700	chr8:58056026	NA	0.6	5.71	0.35	3.49e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	-0.7	-9.15	-0.51	2.97e-17	Menarche (age at onset);
SARC	cis	rs7647973	0.710	rs34890793	chr3:49619493	C/T	cg07636037	chr3:49044803	WDR6	0.83	7.61	0.45	6.61e-13	Menarche (age at onset);
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg03979582	chr1:46769114	LRRC41;UQCRH	0.49	6.48	0.39	5.42e-10	Lung adenocarcinoma;
SARC	cis	rs55823223	0.564	rs58363746	chr17:73850819	C/T	cg10935138	chr17:73851978	WBP2	0.45	4.98	0.31	1.22e-6	Psoriasis;
SARC	cis	rs72627123	0.867	rs73303107	chr14:74477284	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.74	5.59	0.34	6.39e-8	Morning vs. evening chronotype;
SARC	cis	rs6484504	0.652	rs485265	chr11:31407788	G/A	cg02090638	chr11:31391270	DNAJC24;DCDC1	0.38	4.78	0.3	3.13e-6	Red blood cell count;
SARC	cis	rs9517302	0.615	rs7983522	chr13:99098055	C/T	cg24044564	chr13:99115944	STK24	0.44	5.62	0.35	5.34e-8	Obesity-related traits;
SARC	cis	rs709400	0.663	rs62007684	chr14:103894223	T/C	cg12935359	chr14:103987150	CKB	-0.4	-5.81	-0.36	2.02e-8	Body mass index;
SARC	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg23806715	chr17:73775811	H3F3B	0.6	6.23	0.38	2.11e-9	Psoriasis;
SARC	cis	rs9549367	0.713	rs9549681	chr13:113829873	T/C	cg18105134	chr13:113819100	PROZ	-0.49	-7.01	-0.42	2.49e-11	Platelet distribution width;
SARC	cis	rs57221529	0.766	rs12521051	chr5:560440	A/G	cg07777115	chr5:623756	CEP72	0.54	4.92	0.31	1.66e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs10870270	1.000	rs4880246	chr10:133764064	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.83	-10.38	-0.56	5.28e-21	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs3741151	1.000	rs74346863	chr11:73054772	C/T	cg17517138	chr11:73019481	ARHGEF17	0.89	6.36	0.38	1.04e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs709400	1.000	rs61995780	chr14:104120612	A/G	cg12935359	chr14:103987150	CKB	-0.35	-5.21	-0.32	4.15e-7	Body mass index;
SARC	cis	rs4808199	0.649	rs34755166	chr19:19665581	G/A	cg03709012	chr19:19516395	GATAD2A	0.99	8.83	0.5	2.58e-16	Nonalcoholic fatty liver disease;
SARC	cis	rs12477438	1.000	rs12466388	chr2:99916538	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-8.08	-0.47	3.55e-14	Chronic sinus infection;
SARC	cis	rs2839186	0.732	rs8131458	chr21:47694712	G/A	cg03841560	chr21:47649172	MCM3APAS;LSS	0.36	4.79	0.3	2.95e-6	Testicular germ cell tumor;
SARC	cis	rs4443100	0.631	rs13054904	chr22:23410918	A/T	cg14186256	chr22:23484241	RTDR1	-0.55	-5.6	-0.34	5.97e-8	Serum parathyroid hormone levels;
SARC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg09373136	chr17:61933544	TCAM1	-0.44	-6.01	-0.37	7.23e-9	Prudent dietary pattern;
SARC	trans	rs7824557	0.527	rs2572448	chr8:11239352	G/A	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.72	-0.45	3.43e-13	Retinal vascular caliber;
SARC	cis	rs2075371	0.931	rs1646697	chr7:133999930	G/A	cg20476274	chr7:133979776	SLC35B4	0.63	8.51	0.49	2.17e-15	Mean platelet volume;
SARC	cis	rs13256369	0.865	rs13277708	chr8:8573936	T/C	cg17143192	chr8:8559678	CLDN23	0.41	4.81	0.3	2.75e-6	Obesity-related traits;
SARC	cis	rs11668609	0.505	rs114333596	chr19:24062569	T/G	cg27517351	chr19:23941871	ZNF681	-0.54	-4.73	-0.3	3.86e-6	Response to taxane treatment (docetaxel);
SARC	cis	rs2153535	0.580	rs1932281	chr6:8473765	A/G	cg07606381	chr6:8435919	SLC35B3	0.76	10.79	0.58	2.81e-22	Motion sickness;
SARC	cis	rs11874712	0.966	rs8094902	chr18:43666774	T/C	cg20479805	chr18:43684716	ATP5A1;HAUS1	0.46	5.5	0.34	1.02e-7	Migraine - clinic-based;
SARC	cis	rs7666738	0.830	rs11938686	chr4:98964470	A/G	cg05340658	chr4:99064831	C4orf37	0.64	8.59	0.49	1.22e-15	Colonoscopy-negative controls vs population controls;
SARC	trans	rs637571	0.522	rs538954	chr11:65756808	A/G	cg17712092	chr4:129076599	LARP1B	0.69	9.55	0.53	1.83e-18	Eosinophil percentage of white cells;
SARC	cis	rs2213920	0.749	rs10121366	chr9:118244022	T/C	cg13918206	chr9:118159781	DEC1	0.74	6.65	0.4	2.05e-10	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs4906332	1.000	rs34479426	chr14:103881823	G/C	cg26031613	chr14:104095156	KLC1	-0.51	-5.88	-0.36	1.39e-8	Coronary artery disease;
SARC	cis	rs7474896	0.583	rs11011341	chr10:37998500	G/A	cg25427524	chr10:38739819	LOC399744	-0.46	-5.42	-0.33	1.47e-7	Obesity (extreme);
SARC	cis	rs2191566	1.000	rs2191566	chr19:44511389	A/C	cg20607764	chr19:44506953	ZNF230	0.48	5.4	0.33	1.65e-7	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs883565	0.655	rs4676649	chr3:39064948	T/C	cg01426195	chr3:39028469	NA	-0.36	-5.26	-0.33	3.29e-7	Handedness;
SARC	cis	rs8114671	0.647	rs1415771	chr20:33734493	G/A	cg24642439	chr20:33292090	TP53INP2	0.48	5.81	0.36	2.06e-8	Height;
SARC	cis	rs3768617	0.510	rs10911243	chr1:183075415	G/A	cg13390022	chr1:182993471	LAMC1	0.32	4.78	0.3	3.07e-6	Fuchs's corneal dystrophy;
SARC	cis	rs6570726	0.846	rs446031	chr6:145885592	C/T	cg23711669	chr6:146136114	FBXO30	0.79	12.64	0.64	3.14e-28	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6121246	0.909	rs6060960	chr20:30394517	G/T	cg13852791	chr20:30311386	BCL2L1	-0.83	-9.14	-0.51	3.23e-17	Mean corpuscular hemoglobin;
SARC	cis	rs7762018	0.891	rs3749882	chr6:170151766	C/T	cg13891659	chr6:170190454	C6orf122;C6orf208	0.55	4.88	0.3	2e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
SARC	cis	rs3126085	0.877	rs3120672	chr1:152255575	A/G	cg26876637	chr1:152193138	HRNR	0.45	5.21	0.32	4.07e-7	Atopic dermatitis;
SARC	cis	rs9818758	0.607	rs13068038	chr3:49294250	C/A	cg07636037	chr3:49044803	WDR6	-0.75	-6.53	-0.39	4.11e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs2645694	0.651	rs2703128	chr4:77819187	C/G	cg03477792	chr4:77819574	ANKRD56	0.51	7.66	0.45	4.83e-13	Emphysema distribution in smoking;
SARC	cis	rs826838	0.967	rs826879	chr12:39088999	A/C	cg13010199	chr12:38710504	ALG10B	-0.67	-9.7	-0.54	6.65e-19	Heart rate;
SARC	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg18758796	chr5:131593413	PDLIM4	0.37	4.77	0.3	3.24e-6	Acylcarnitine levels;
SARC	cis	rs508618	1.000	rs508618	chr1:231532312	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-6.55	-0.39	3.6e-10	Red blood cell count;
SARC	cis	rs8031584	0.541	rs1983459	chr15:31208749	C/T	cg19680485	chr15:31195859	MTMR15	-0.56	-7.12	-0.42	1.36e-11	Huntington's disease progression;
SARC	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.6	-6.31	-0.38	1.42e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs11098499	0.908	rs11729050	chr4:120300066	T/C	cg09307838	chr4:120376055	NA	0.91	12.88	0.65	4.9e-29	Corneal astigmatism;
SARC	cis	rs9660992	0.649	rs12128254	chr1:205268097	C/T	cg19090574	chr1:205240910	TMCC2	-0.4	-4.86	-0.3	2.19e-6	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg16434002	chr17:42200994	HDAC5	-0.41	-4.92	-0.31	1.66e-6	Total body bone mineral density;
SARC	cis	rs770189	0.910	rs2431388	chr5:88092379	T/C	cg18498987	chr5:88179539	MEF2C	-0.38	-4.71	-0.3	4.19e-6	Tonometry;
SARC	cis	rs35995292	0.889	rs10272767	chr7:38898819	G/C	cg19327137	chr7:38886074	VPS41	0.36	5.09	0.32	7.43e-7	Subjective well-being (multi-trait analysis);
SARC	cis	rs12216125	0.549	rs9358905	chr6:26077839	T/A	cg16482183	chr6:26056742	HIST1H1C	0.45	5.68	0.35	4.01e-8	Iron status biomarkers;
SARC	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.06	17.7	0.76	5.38e-45	Height;
SARC	cis	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg05623727	chr3:50126028	RBM5	0.34	4.91	0.31	1.68e-6	Body mass index;
SARC	cis	rs4595586	0.545	rs12823721	chr12:39386461	G/A	cg26384229	chr12:38710491	ALG10B	0.52	6.37	0.38	1.03e-9	Morning vs. evening chronotype;
SARC	cis	rs6920364	1	rs6920364	chr6:167376466	G/C	cg23791538	chr6:167370224	RNASET2	0.62	8.55	0.49	1.63e-15	Lung cancer;
SARC	cis	rs4481887	0.927	rs6671702	chr1:248482851	G/A	cg13385794	chr1:248469461	NA	0.34	5.22	0.32	3.88e-7	Common traits (Other);
SARC	cis	rs6542838	0.644	rs7590596	chr2:99467938	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.45	-5.72	-0.35	3.28e-8	Fear of minor pain;
SARC	cis	rs72781680	0.716	rs6731314	chr2:24048338	C/T	cg06627628	chr2:24431161	ITSN2	0.55	5.66	0.35	4.52e-8	Lymphocyte counts;
SARC	cis	rs17376456	0.825	rs10079708	chr5:93261796	G/C	cg25358565	chr5:93447407	FAM172A	1.29	14.23	0.68	1.68e-33	Diabetic retinopathy;
SARC	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg22508957	chr16:3507546	NAT15	0.38	5.49	0.34	1.05e-7	Tuberculosis;
SARC	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg26818010	chr10:134567672	INPP5A	-0.65	-6.92	-0.41	4.21e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
SARC	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg22968622	chr17:43663579	NA	0.8	10.05	0.55	5.69e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	trans	rs561341	1.000	rs8070262	chr17:30262467	A/G	cg20587970	chr11:113659929	NA	-0.99	-9.9	-0.54	1.65e-19	Hip circumference adjusted for BMI;
SARC	cis	rs67311347	1.000	rs1119179	chr3:40424929	A/C	cg24209194	chr3:40518798	ZNF619	-0.6	-7.56	-0.44	9.01e-13	Renal cell carcinoma;
SARC	cis	rs7552404	0.731	rs11161845	chr1:76367559	T/C	cg03433033	chr1:76189801	ACADM	0.46	5.67	0.35	4.18e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs11098499	0.754	rs2964	chr4:120240131	T/C	cg09307838	chr4:120376055	NA	0.81	11.15	0.59	2.11e-23	Corneal astigmatism;
SARC	cis	rs9300255	0.602	rs1727294	chr12:123616514	A/G	cg00376283	chr12:123451042	ABCB9	0.59	6.98	0.42	3.13e-11	Neutrophil percentage of white cells;
SARC	cis	rs79149102	0.579	rs58294763	chr15:75299768	G/A	cg00629941	chr15:75287862	SCAMP5	-0.64	-5.03	-0.31	1e-6	Lung cancer;
SARC	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-10.5	-0.57	2.32e-21	Chronic sinus infection;
SARC	cis	rs6733011	0.508	rs4850889	chr2:99521385	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-6.29	-0.38	1.56e-9	Bipolar disorder;
SARC	cis	rs4243830	0.850	rs1064835	chr1:6585539	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.64	6.62	0.4	2.39e-10	Body mass index;
SARC	cis	rs6060717	0.529	rs6060535	chr20:34235522	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.64	5.06	0.31	8.68e-7	Hip circumference adjusted for BMI;
SARC	cis	rs1059312	0.808	rs10847694	chr12:129292457	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.45	-5.57	-0.34	7.15e-8	Systemic lupus erythematosus;
SARC	cis	rs9473924	0.542	rs9473928	chr6:50842003	G/A	cg14470998	chr6:50812995	TFAP2B	0.74	6.72	0.4	1.4e-10	Body mass index;
SARC	cis	rs6964587	0.626	rs6979235	chr7:91511776	T/C	cg17063962	chr7:91808500	NA	-0.78	-11.54	-0.6	1.13e-24	Breast cancer;
SARC	cis	rs7617480	0.648	rs9284885	chr3:48883100	A/C	cg07636037	chr3:49044803	WDR6	0.91	10.7	0.57	5.26e-22	Subjective well-being (multi-trait analysis);Menarche (age at onset);
SARC	cis	rs7772486	0.754	rs6910790	chr6:146255330	G/A	cg23711669	chr6:146136114	FBXO30	-0.8	-12.46	-0.63	1.2100000000000001e-27	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs908922	1.000	rs1199150	chr1:152455602	T/C	cg09873164	chr1:152488093	CRCT1	0.66	7.77	0.45	2.47e-13	Hair morphology;
SARC	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg26874164	chr19:58962979	ZNF324B	0.47	6.03	0.37	6.31e-9	Uric acid clearance;
SARC	cis	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg07274523	chr3:49395745	GPX1	0.49	5.49	0.34	1.05e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	trans	rs1814175	0.645	rs7395438	chr11:49877379	G/T	cg03929089	chr4:120376271	NA	-0.83	-12.22	-0.62	7.28e-27	Height;
SARC	cis	rs9611565	0.592	rs12484467	chr22:41957610	T/C	cg17376030	chr22:41985996	PMM1	0.76	9.17	0.52	2.53e-17	Vitiligo;
SARC	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg17971929	chr21:40555470	PSMG1	-0.56	-7.07	-0.42	1.79e-11	Menarche (age at onset);
SARC	cis	rs9788721	0.902	rs17486195	chr15:78865197	A/G	cg06917634	chr15:78832804	PSMA4	-0.53	-5.78	-0.35	2.44e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
SARC	cis	rs1046896	0.562	rs2380172	chr17:80887719	C/A	cg03160526	chr17:80928410	B3GNTL1	0.37	4.87	0.3	2.04e-6	Glycated hemoglobin levels;
SARC	cis	rs11122272	0.668	rs2808616	chr1:231554993	C/G	cg06096015	chr1:231504339	EGLN1	-0.37	-5.64	-0.35	4.94e-8	Hemoglobin concentration;
SARC	cis	rs10489202	1.000	rs275157	chr1:168064178	T/C	cg24449463	chr1:168025552	DCAF6	-0.61	-6.82	-0.41	7.64e-11	Schizophrenia;
SARC	cis	rs4595586	0.505	rs76485055	chr12:39358294	A/G	cg13010199	chr12:38710504	ALG10B	0.4	4.75	0.3	3.57e-6	Morning vs. evening chronotype;
SARC	cis	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg00409905	chr10:38381863	ZNF37A	-0.58	-8.13	-0.47	2.49e-14	Extrinsic epigenetic age acceleration;
SARC	cis	rs428668	0.523	rs6898671	chr5:150677643	A/T	cg11125805	chr5:150678162	SLC36A3	0.37	5.21	0.32	4.18e-7	Skin aging (microtopography measurement);
SARC	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg16414030	chr3:133502952	NA	0.41	5.63	0.35	5.15e-8	Iron status biomarkers;
SARC	cis	rs35995292	0.534	rs13228087	chr7:38909204	A/C	cg19327137	chr7:38886074	VPS41	0.51	7.56	0.44	9.35e-13	Subjective well-being (multi-trait analysis);
SARC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.62	0.53	1.18e-18	Prudent dietary pattern;
SARC	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg11764359	chr7:65958608	NA	0.86	12.08	0.62	2.14e-26	Aortic root size;
SARC	cis	rs7580658	0.864	rs10928761	chr2:128003247	C/T	cg10021288	chr2:128175891	PROC	-0.33	-4.77	-0.3	3.3e-6	Protein C levels;
SARC	trans	rs2429030	0.746	rs10998461	chr10:70616517	G/T	cg14511273	chr3:128746334	CCDC48	-0.5	-6.32	-0.38	1.35e-9	Schizophrenia;
SARC	cis	rs3092073	0.617	rs3746513	chr20:44594228	G/A	cg27529037	chr20:44575021	PCIF1	-0.34	-5.02	-0.31	1.02e-6	Intelligence (multi-trait analysis);
SARC	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg04772025	chr11:68637568	NA	0.53	6.78	0.41	9.95e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	cis	rs694739	0.595	rs11606015	chr11:64136877	C/G	cg23796481	chr11:64053134	BAD;GPR137	0.66	7.6	0.45	7e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
SARC	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg03060546	chr3:49711283	APEH	0.42	5.23	0.32	3.86e-7	Parkinson's disease;
SARC	cis	rs2033732	0.674	rs1866087	chr8:85071289	T/A	cg05716166	chr8:85095498	RALYL	0.47	5.61	0.34	5.81e-8	Body mass index;
SARC	cis	rs72781680	1.000	rs72781663	chr2:24221694	C/G	cg08917208	chr2:24149416	ATAD2B	0.78	7.49	0.44	1.45e-12	Lymphocyte counts;
SARC	cis	rs897984	0.683	rs12447534	chr16:30804257	C/T	cg00531865	chr16:30841666	NA	0.49	5.88	0.36	1.44e-8	Dementia with Lewy bodies;
SARC	cis	rs17345786	1.000	rs7641261	chr3:101279006	C/T	cg12386194	chr3:101231763	SENP7	0.75	8.8	0.5	3.2e-16	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1499614	0.522	rs13247442	chr7:66188858	T/C	cg18252515	chr7:66147081	NA	-1.19	-8.04	-0.47	4.48e-14	Gout;
SARC	cis	rs4423214	0.559	rs10898201	chr11:71201527	C/A	cg05163923	chr11:71159392	DHCR7	-0.5	-5.07	-0.32	7.93e-7	Vitamin D levels;
SARC	trans	rs17685	0.796	rs3757594	chr7:75678644	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.6	-7.58	-0.44	8.16e-13	Coffee consumption;Coffee consumption (cups per day);
SARC	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg21782813	chr7:2030301	MAD1L1	0.38	5.96	0.36	9.37e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs6670533	0.571	rs56386478	chr1:24861128	G/A	cg07475527	chr1:24864545	NA	-1.0	-5.65	-0.35	4.76e-8	Fasting blood insulin (BMI interaction);
SARC	cis	rs6840360	1.000	rs7663045	chr4:152676350	T/C	cg22705602	chr4:152727874	NA	-0.38	-6.68	-0.4	1.76e-10	Intelligence (multi-trait analysis);
SARC	trans	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg20587970	chr11:113659929	NA	-1.26	-12.74	-0.64	1.48e-28	Hip circumference adjusted for BMI;
SARC	cis	rs2832077	0.943	rs11700746	chr21:30189207	T/C	cg24692254	chr21:30365293	RNF160	-0.52	-4.8	-0.3	2.9e-6	Cognitive test performance;
SARC	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.61	7.42	0.44	2.19e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs11718455	0.960	rs13081767	chr3:44004468	T/C	cg21419209	chr3:44054225	NA	-0.41	-4.99	-0.31	1.19e-6	Coronary artery disease;
SARC	cis	rs7084402	0.967	rs1427224	chr10:60290620	G/A	cg07615347	chr10:60278583	BICC1	0.61	8.99	0.51	8.84e-17	Refractive error;
SARC	trans	rs75804782	0.690	rs56198112	chr2:239348887	A/G	cg01134436	chr17:81009848	B3GNTL1	0.86	6.23	0.38	2.11e-9	Morning vs. evening chronotype;Chronotype;
SARC	cis	rs950776	0.518	rs55690619	chr15:78833612	A/G	cg06917634	chr15:78832804	PSMA4	-0.9	-14.17	-0.68	2.83e-33	Sudden cardiac arrest;
SARC	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg13939156	chr17:80058883	NA	0.37	5.65	0.35	4.6e-8	Life satisfaction;
SARC	cis	rs2573652	0.723	rs4577068	chr15:100515959	T/A	cg09918751	chr15:100517450	ADAMTS17	-0.41	-5.15	-0.32	5.63e-7	Height;
SARC	cis	rs11252926	0.574	rs4881254	chr10:453567	C/T	cg08603382	chr10:743973	NA	0.39	5.1	0.32	7.13e-7	Psychosis in Alzheimer's disease;
SARC	cis	rs3540	0.597	rs1978150	chr15:91037041	A/G	cg22089800	chr15:90895588	ZNF774	-0.66	-8.6	-0.49	1.21e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs2273669	0.667	rs12195728	chr6:109278873	A/G	cg05315195	chr6:109294784	ARMC2	-0.58	-4.9	-0.31	1.82e-6	Prostate cancer;
SARC	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.89	-11.29	-0.59	7.55e-24	Multiple sclerosis;
SARC	cis	rs9420	0.961	rs576859	chr11:57480623	A/C	cg23127183	chr11:57508653	C11orf31	0.51	6.07	0.37	5.07e-9	Schizophrenia;
SARC	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg24399712	chr22:39784796	NA	-0.43	-5.61	-0.35	5.64e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
SARC	cis	rs7208859	0.524	rs59913838	chr17:29101563	A/T	cg13385521	chr17:29058706	SUZ12P	0.84	7.05	0.42	2e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs3540	0.554	rs113942266	chr15:91072990	A/G	cg22089800	chr15:90895588	ZNF774	-0.58	-7.33	-0.43	3.77e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
SARC	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg00933542	chr6:150070202	PCMT1	0.33	5.74	0.35	2.93e-8	Lung cancer;
SARC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg26354017	chr1:205819088	PM20D1	0.85	13.71	0.67	9.14e-32	Menarche (age at onset);
SARC	trans	rs877282	0.733	rs7092976	chr10:756358	G/A	cg22713356	chr15:30763199	NA	0.99	9.88	0.54	1.92e-19	Uric acid levels;
SARC	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg12311346	chr5:56204834	C5orf35	-0.57	-5.83	-0.36	1.85e-8	Type 2 diabetes;
SARC	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.47	-5.93	-0.36	1.1e-8	Lymphocyte counts;
SARC	cis	rs1448094	0.512	rs11832503	chr12:86240797	A/G	cg02569458	chr12:86230093	RASSF9	0.39	5.45	0.34	1.26e-7	Major depressive disorder;
SARC	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg11952622	chr19:58962976	ZNF324B	0.53	6.9	0.41	4.76e-11	Uric acid clearance;
SARC	cis	rs155076	1.000	rs261423	chr13:21852331	A/C	cg25811766	chr13:21894605	NA	-0.51	-5.51	-0.34	9.29e-8	White matter hyperintensity burden;
SARC	cis	rs9911578	1.000	rs1267545	chr17:56646909	A/G	cg05425664	chr17:57184151	TRIM37	-0.67	-8.41	-0.48	4.26e-15	Intelligence (multi-trait analysis);
SARC	cis	rs10463554	0.963	rs28301	chr5:102441482	A/G	cg23492399	chr5:102201601	PAM	-0.5	-5.54	-0.34	8.2e-8	Parkinson's disease;
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg12721145	chr4:109571876	OSTC	0.58	6.35	0.38	1.11e-9	Lung cancer in ever smokers;
SARC	cis	rs875971	1.000	rs1167411	chr7:65539264	C/G	cg12463550	chr7:65579703	CRCP	-0.48	-5.68	-0.35	3.96e-8	Aortic root size;
SARC	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg24675658	chr1:53192096	ZYG11B	0.77	11.5	0.6	1.5e-24	Monocyte count;
SARC	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg14893161	chr1:205819251	PM20D1	0.62	6.75	0.4	1.16e-10	Prostate-specific antigen levels;
SARC	cis	rs56235845	0.694	rs11749830	chr5:176766547	G/A	cg06060754	chr5:176797920	RGS14	0.47	6.14	0.37	3.48e-9	Hemoglobin concentration;Hematocrit;
SARC	cis	rs11098499	0.954	rs12505469	chr4:120249585	C/T	cg09160332	chr4:120329925	NA	-0.34	-4.84	-0.3	2.31e-6	Corneal astigmatism;
SARC	cis	rs1691799	0.899	rs1060724	chr12:66740444	T/C	cg16791601	chr12:66731901	HELB	-0.72	-10.65	-0.57	7.69e-22	White blood cell count (basophil);
SARC	cis	rs7481584	0.626	rs2071103	chr11:3040087	C/T	cg25174290	chr11:3078921	CARS	-0.58	-7.93	-0.46	9.09e-14	Calcium levels;
SARC	cis	rs2933343	1.000	rs2929859	chr3:128608341	T/G	cg24203234	chr3:128598194	ACAD9	0.53	5.93	0.36	1.11e-8	IgG glycosylation;
SARC	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg17971929	chr21:40555470	PSMG1	0.99	13.74	0.67	7.06e-32	Cognitive function;
SARC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg11494091	chr17:61959527	GH2	0.53	8.03	0.47	4.83e-14	Prudent dietary pattern;
SARC	cis	rs4319547	0.656	rs10734918	chr12:122921512	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.59	-6.6	-0.4	2.68e-10	Body mass index;
SARC	cis	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg00800038	chr16:89945340	TCF25	-0.79	-5.45	-0.34	1.26e-7	Skin colour saturation;
SARC	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg23758822	chr17:41437982	NA	0.89	11.37	0.6	3.91e-24	Menopause (age at onset);
SARC	cis	rs4664308	1.000	rs6719686	chr2:160908292	T/G	cg03641300	chr2:160917029	PLA2R1	-0.67	-8.93	-0.51	1.29e-16	Idiopathic membranous nephropathy;
SARC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg26338869	chr17:61819248	STRADA	0.8	10.82	0.58	2.2e-22	Prudent dietary pattern;
SARC	cis	rs13065560	0.505	rs4396821	chr3:38917641	A/C	cg26331595	chr3:39149181	GORASP1;TTC21A	0.38	4.73	0.3	3.83e-6	Interleukin-18 levels;
SARC	cis	rs9467711	0.591	rs35169013	chr6:25918027	A/C	cg21479132	chr6:26055353	NA	0.77	4.84	0.3	2.35e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7219014	1	rs7219014	chr17:37624790	A/G	cg20243544	chr17:37824526	PNMT	0.58	6.92	0.41	4.44e-11	Urinary metabolites;
SARC	cis	rs7927771	1.000	rs12361031	chr11:47783076	G/A	cg20307385	chr11:47447363	PSMC3	-0.47	-5.59	-0.34	6.3e-8	Subjective well-being;
SARC	cis	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg01579765	chr21:45077557	HSF2BP	-0.38	-6.46	-0.39	5.92e-10	Mean corpuscular volume;
SARC	cis	rs6714710	0.603	rs58546246	chr2:98521823	C/A	cg26665480	chr2:98280029	ACTR1B	0.51	6.94	0.41	3.94e-11	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs17376456	0.569	rs6556834	chr5:93123067	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.51	-5.21	-0.32	4.21e-7	Diabetic retinopathy;
SARC	cis	rs2213920	0.516	rs13301972	chr9:118158086	C/T	cg13918206	chr9:118159781	DEC1	-0.85	-7.08	-0.42	1.7e-11	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs826838	0.935	rs3886109	chr12:39189243	C/T	cg13010199	chr12:38710504	ALG10B	0.74	9.8	0.54	3.32e-19	Heart rate;
SARC	cis	rs6540556	0.768	rs6692012	chr1:209935490	A/G	cg23920097	chr1:209922102	NA	-0.62	-7.18	-0.43	9.28e-12	Red blood cell count;
SARC	cis	rs888194	0.966	rs1558804	chr12:109898732	A/G	cg08884029	chr12:110012500	MVK;MMAB	-0.33	-5.03	-0.31	1e-6	Neuroticism;
SARC	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg03354898	chr7:1950403	MAD1L1	-0.38	-5.18	-0.32	4.72e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs3858526	0.920	rs11039548	chr11:5930283	G/A	cg02574844	chr11:5959923	NA	-0.42	-5.24	-0.32	3.58e-7	DNA methylation (variation);
SARC	cis	rs2832191	0.740	rs2832177	chr21:30478353	G/A	cg08807101	chr21:30365312	RNF160	-0.92	-14.46	-0.69	3.07e-34	Dental caries;
SARC	cis	rs4481887	0.741	rs7540715	chr1:248544206	C/T	cg13385794	chr1:248469461	NA	0.35	5.62	0.35	5.4e-8	Common traits (Other);
SARC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg07157834	chr1:205819609	PM20D1	0.84	15.39	0.71	2.33e-37	Menarche (age at onset);
SARC	cis	rs933688	1.000	rs6866191	chr5:90746852	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.98	12.09	0.62	1.95e-26	Smoking behavior;
SARC	cis	rs9858542	0.953	rs12330269	chr3:49513910	G/A	cg07274523	chr3:49395745	GPX1	0.53	6.1	0.37	4.27e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs7223966	1.000	rs12325866	chr17:61755974	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.5	-5.31	-0.33	2.52e-7	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7769051	0.522	rs56908272	chr6:133102165	G/C	cg07930552	chr6:133119739	C6orf192	1.02	5.94	0.36	1.04e-8	Type 2 diabetes nephropathy;
SARC	cis	rs2658782	0.789	rs2605574	chr11:93136444	T/G	cg15737290	chr11:93063684	CCDC67	0.64	6.96	0.42	3.36e-11	Pulmonary function decline;
SARC	cis	rs2235544	0.565	rs72664114	chr1:54471747	C/T	cg10336722	chr1:54665764	CYB5RL;MRPL37	0.38	4.72	0.3	4.13e-6	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
SARC	cis	rs7937682	1.000	rs7121011	chr11:111568681	C/T	cg09085632	chr11:111637200	PPP2R1B	0.97	16.4	0.73	1.06e-40	Primary sclerosing cholangitis;
SARC	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-8.27	-0.48	1.05e-14	Chronic sinus infection;
SARC	cis	rs8031584	0.578	rs1088473	chr15:31139298	A/G	cg19680485	chr15:31195859	MTMR15	0.58	6.88	0.41	5.42e-11	Huntington's disease progression;
SARC	cis	rs2120019	1.000	rs67544533	chr15:75361539	A/G	cg00629941	chr15:75287862	SCAMP5	-0.6	-7.05	-0.42	1.97e-11	Blood trace element (Zn levels);
SARC	cis	rs2997447	0.761	rs17184884	chr1:26446565	G/A	cg19633962	chr1:26362018	EXTL1	-0.56	-5.06	-0.31	8.55e-7	QRS complex (12-leadsum);
SARC	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg13395646	chr4:1353034	KIAA1530	-0.58	-6.9	-0.41	4.8e-11	Obesity-related traits;
SARC	cis	rs11077773	1.000	rs11077773	chr17:73060073	C/T	cg27626185	chr17:73056755	KCTD2	0.84	8.07	0.47	3.67e-14	Information processing speed;
SARC	cis	rs7824557	0.602	rs11784544	chr8:11204503	G/C	cg21775007	chr8:11205619	TDH	0.67	8.63	0.49	9.62e-16	Retinal vascular caliber;
SARC	cis	rs67460515	0.563	rs11717272	chr3:160810355	A/G	cg04691961	chr3:161091175	C3orf57	-0.42	-4.95	-0.31	1.45e-6	Parkinson's disease;
SARC	trans	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.07	-0.42	1.77e-11	Extrinsic epigenetic age acceleration;
SARC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	10.53	0.57	1.79e-21	Prudent dietary pattern;
SARC	trans	rs1814175	0.645	rs28549248	chr11:50042740	C/T	cg03929089	chr4:120376271	NA	-0.81	-11.64	-0.61	5.33e-25	Height;
SARC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.39	-5.86	-0.36	1.57e-8	Longevity;Endometriosis;
SARC	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg02931644	chr1:25747376	RHCE	0.43	7.19	0.43	8.8e-12	Erythrocyte sedimentation rate;
SARC	cis	rs11225247	0.655	rs112276332	chr11:102226953	A/G	cg11690896	chr11:102217788	BIRC2	0.72	5.19	0.32	4.65e-7	Vein graft stenosis in coronary artery bypass grafting;
SARC	cis	rs1843834	0.539	rs2047135	chr2:225427302	G/C	cg22455342	chr2:225449267	CUL3	0.67	8.47	0.49	2.73e-15	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs1008375	0.863	rs4590022	chr4:17614434	T/C	cg27347728	chr4:17578864	LAP3	0.45	5.49	0.34	1.02e-7	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs854765	0.583	rs4257260	chr17:17857003	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	9.85	0.54	2.34e-19	Total body bone mineral density;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg17687493	chr6:118229306	SLC35F1	0.49	6.79	0.41	9.09e-11	Breast cancer;
SARC	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.62	-6.33	-0.38	1.24e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs1580019	0.961	rs4460271	chr7:32496503	T/C	cg14728415	chr7:32535168	LSM5;AVL9	0.43	5.04	0.31	9.3e-7	Cognitive ability;
SARC	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg17376030	chr22:41985996	PMM1	0.6	7.48	0.44	1.53e-12	Vitiligo;
SARC	cis	rs910316	0.967	rs4903293	chr14:75656568	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.47	-6.3	-0.38	1.49e-9	Height;
SARC	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg18230493	chr5:56204884	C5orf35	0.58	5.2	0.32	4.28e-7	Initial pursuit acceleration;
SARC	cis	rs4665630	1.000	rs4665630	chr2:23898317	A/G	cg08063864	chr2:24346004	PFN4;LOC375190	0.54	4.98	0.31	1.27e-6	Hypertension;
SARC	cis	rs9398803	0.687	rs4549631	chr6:126966308	A/G	cg19875578	chr6:126661172	C6orf173	0.6	8.03	0.47	4.68e-14	Male-pattern baldness;
SARC	cis	rs7647973	1.000	rs62259947	chr3:49439924	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.57	-5.57	-0.34	7.17e-8	Menarche (age at onset);
SARC	cis	rs7107174	0.901	rs2510053	chr11:77959435	T/C	cg02023728	chr11:77925099	USP35	0.37	4.76	0.3	3.45e-6	Testicular germ cell tumor;
SARC	cis	rs1008375	0.900	rs1003413	chr4:17582442	C/T	cg16339924	chr4:17578868	LAP3	-0.71	-9.19	-0.52	2.22e-17	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs9660992	0.674	rs56198325	chr1:205265450	G/A	cg07972983	chr1:205091412	RBBP5	0.49	5.74	0.35	2.96e-8	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs6815814	0.861	rs11936050	chr4:38789524	C/T	cg06935464	chr4:38784597	TLR10	0.52	5.79	0.35	2.25e-8	Breast cancer;
SARC	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	12.58	0.64	4.75e-28	Chronic sinus infection;
SARC	cis	rs79976124	0.837	rs10455591	chr6:66650584	A/G	cg07460842	chr6:66804631	NA	0.61	6.65	0.4	2.02e-10	Type 2 diabetes;
SARC	cis	rs11711311	1.000	rs2242109	chr3:113434100	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.69	8.9	0.5	1.64e-16	IgG glycosylation;
SARC	cis	rs9659323	0.539	rs1750331	chr1:119494973	A/G	cg05756136	chr1:119680316	WARS2	-0.36	-4.82	-0.3	2.63e-6	Body mass index;
SARC	cis	rs2997447	0.761	rs72886625	chr1:26455319	A/G	cg19633962	chr1:26362018	EXTL1	-0.57	-4.93	-0.31	1.54e-6	QRS complex (12-leadsum);
SARC	cis	rs861020	0.771	rs1962735	chr1:210012102	A/G	cg05527609	chr1:210001259	C1orf107	0.86	10.74	0.58	3.99e-22	Orofacial clefts;
SARC	cis	rs4481887	0.962	rs10788769	chr1:248457426	C/T	cg00666640	chr1:248458726	OR2T12	0.36	5.95	0.36	9.69e-9	Common traits (Other);
SARC	cis	rs2712184	0.729	rs2541390	chr2:217664020	A/G	cg05032264	chr2:217675019	NA	-0.49	-6.55	-0.39	3.6e-10	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
SARC	cis	rs7659604	0.539	rs72680779	chr4:122797263	C/T	cg20573242	chr4:122745356	CCNA2	0.68	8.46	0.48	3.02e-15	Type 2 diabetes;
SARC	cis	rs3820928	0.845	rs4234065	chr2:227882006	C/T	cg05526886	chr2:227700861	RHBDD1	-0.52	-6.37	-0.39	1e-9	Pulmonary function;
SARC	cis	rs11997175	0.766	rs6983113	chr8:33699513	G/A	ch.8.33884649F	chr8:33765107	NA	0.53	7.2	0.43	8.03e-12	Body mass index;
SARC	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg27266027	chr21:40555129	PSMG1	0.47	4.79	0.3	2.98e-6	Cognitive function;
SARC	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-5.46	-0.34	1.2e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs2204008	0.728	rs12369538	chr12:38443942	C/T	cg13010199	chr12:38710504	ALG10B	0.73	9.29	0.52	1.17e-17	Bladder cancer;
SARC	cis	rs60752752	0.852	rs12040625	chr1:153365548	A/G	cg26882115	chr1:153603048	S100A1;S100A13	-0.62	-4.77	-0.3	3.27e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
SARC	cis	rs7264396	0.790	rs6121015	chr20:34243017	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	5.94	0.36	1.03e-8	Total cholesterol levels;
SARC	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	8.05	0.47	4.34e-14	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs6088580	0.602	rs6059840	chr20:33030405	G/A	cg24642439	chr20:33292090	TP53INP2	0.67	8.56	0.49	1.55e-15	Glomerular filtration rate (creatinine);
SARC	cis	rs1801251	0.963	rs6739638	chr2:233576015	G/A	cg25237894	chr2:233734115	C2orf82	0.37	4.8	0.3	2.86e-6	Coronary artery disease;
SARC	cis	rs13082711	0.911	rs34981505	chr3:27437322	A/T	cg02860705	chr3:27208620	NA	0.45	6.03	0.37	6.45e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs9894429	0.789	rs7213849	chr17:79567610	C/T	cg18240062	chr17:79603768	NPLOC4	-0.88	-13.61	-0.67	2e-31	Eye color traits;
SARC	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg11987759	chr7:65425863	GUSB	0.59	7.63	0.45	5.86e-13	Aortic root size;
SARC	cis	rs9902453	1.000	rs28664971	chr17:28437410	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	7.07	0.42	1.8e-11	Coffee consumption (cups per day);
SARC	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg12463550	chr7:65579703	CRCP	-0.49	-5.46	-0.34	1.19e-7	Aortic root size;
SARC	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg18252515	chr7:66147081	NA	0.45	4.97	0.31	1.31e-6	Aortic root size;
SARC	cis	rs2075371	0.796	rs1643040	chr7:134011703	G/C	cg20476274	chr7:133979776	SLC35B4	0.51	6.47	0.39	5.6e-10	Mean platelet volume;
SARC	cis	rs1865760	0.532	rs1061482	chr6:26086699	G/T	cg18357526	chr6:26021779	HIST1H4A	0.39	4.76	0.3	3.47e-6	Height;
SARC	cis	rs7528684	0.546	rs10908583	chr1:157641683	C/T	cg18268488	chr1:157545234	FCRL4	0.26	4.85	0.3	2.28e-6	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;
SARC	cis	rs6540556	0.769	rs7521461	chr1:209926207	C/G	cg05527609	chr1:210001259	C1orf107	-0.52	-5.25	-0.33	3.45e-7	Red blood cell count;
SARC	cis	rs8028182	0.636	rs11636199	chr15:75825337	A/G	cg20655648	chr15:75932815	IMP3	0.61	7.19	0.43	8.96e-12	Sudden cardiac arrest;
SARC	cis	rs4919087	0.532	rs61861850	chr10:99073874	C/A	cg25902810	chr10:99078978	FRAT1	-0.59	-6.16	-0.37	3.11e-9	Monocyte count;
SARC	cis	rs7772486	0.686	rs9403746	chr6:146103768	C/A	cg05347473	chr6:146136440	FBXO30	-0.51	-7.13	-0.42	1.27e-11	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs208520	1.000	rs72882086	chr6:66976671	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	9.16	0.51	2.69e-17	Exhaled nitric oxide output;
SARC	cis	rs1448094	0.717	rs55811543	chr12:86290936	C/T	cg02569458	chr12:86230093	RASSF9	0.39	5.14	0.32	5.77e-7	Major depressive disorder;
SARC	cis	rs12311304	0.965	rs73055254	chr12:15411547	A/G	cg08258403	chr12:15378311	NA	0.48	7.31	0.43	4.28e-12	Behavioural disinhibition (generation interaction);
SARC	cis	rs13343954	0.825	rs11084698	chr19:33534174	A/G	cg17764715	chr19:33622953	WDR88	0.49	5.43	0.34	1.38e-7	Colorectal cancer;
SARC	cis	rs61409971	0.961	rs10131197	chr14:93015394	A/G	cg04718702	chr14:93020195	RIN3	-0.37	-4.88	-0.3	1.96e-6	Lymphocyte percentage of white cells;
SARC	cis	rs7178572	0.962	rs1022172	chr15:77793359	A/G	cg22256960	chr15:77711686	NA	-0.57	-6.72	-0.4	1.38e-10	Type 2 diabetes;
SARC	cis	rs10870270	1.000	rs10870232	chr10:133738537	T/G	cg17892150	chr10:133769511	PPP2R2D	-0.8	-10.37	-0.56	5.78e-21	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs4713675	0.584	rs6916949	chr6:33678290	C/G	cg15676125	chr6:33679581	C6orf125	0.54	6.59	0.4	2.96e-10	Plateletcrit;
SARC	cis	rs3762637	1.000	rs13321097	chr3:122162007	C/T	cg24169773	chr3:122142474	KPNA1	-0.56	-5.67	-0.35	4.18e-8	LDL cholesterol levels;
SARC	cis	rs698833	0.532	rs698809	chr2:44702978	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.49	-5.25	-0.33	3.42e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs7223966	0.729	rs2003549	chr17:62008437	C/T	cg00588841	chr17:61851480	DDX42;CCDC47	-0.63	-6.49	-0.39	5.09e-10	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs7552404	0.696	rs12140121	chr1:76455001	A/G	cg03433033	chr1:76189801	ACADM	0.46	5.44	0.34	1.37e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs2075371	0.796	rs35336643	chr7:134010640	G/A	cg11752832	chr7:134001865	SLC35B4	0.58	7.25	0.43	6.07e-12	Mean platelet volume;
SARC	cis	rs4919694	1.000	rs12254254	chr10:104765605	C/T	cg04362960	chr10:104952993	NT5C2	0.61	5.2	0.32	4.44e-7	Arsenic metabolism;
SARC	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs13401104	0.716	rs6741020	chr2:237125567	T/C	cg19324714	chr2:237145437	ASB18	0.54	5.48	0.34	1.09e-7	Educational attainment;
SARC	cis	rs2153535	0.562	rs10458225	chr6:8386004	G/A	cg07606381	chr6:8435919	SLC35B3	-0.78	-10.79	-0.58	2.74e-22	Motion sickness;
SARC	trans	rs9354308	0.868	rs9363458	chr6:66552798	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.53	-6.31	-0.38	1.42e-9	Metabolite levels;
SARC	cis	rs4742903	0.527	rs10991148	chr9:106951083	A/C	cg14250997	chr9:106856677	SMC2	0.39	4.85	0.3	2.3e-6	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs6840360	1.000	rs6845944	chr4:152604520	C/T	cg22705602	chr4:152727874	NA	-0.37	-6.25	-0.38	1.91e-9	Intelligence (multi-trait analysis);
SARC	cis	rs17401966	1.000	rs4846210	chr1:10322153	A/G	cg15208524	chr1:10270712	KIF1B	0.58	6.52	0.39	4.26e-10	Hepatocellular carcinoma;
SARC	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg03452623	chr4:187889614	NA	-0.75	-11.81	-0.61	1.6e-25	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs735396	0.627	rs2264778	chr12:121450354	C/A	cg25281562	chr12:121454272	C12orf43	0.57	7.54	0.44	1.03e-12	N-glycan levels;
SARC	cis	rs41271473	0.526	rs942852	chr1:228730748	A/G	cg16512390	chr1:228756714	NA	0.61	5.58	0.34	6.79e-8	Chronic lymphocytic leukemia;
SARC	cis	rs7666738	0.830	rs3852122	chr4:98697400	T/C	cg05340658	chr4:99064831	C4orf37	0.64	8.48	0.49	2.56e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs61935443	0.720	rs10859785	chr12:95295081	A/T	cg21533806	chr12:95267307	NA	0.68	8.17	0.47	1.93e-14	Schizophrenia;
SARC	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg11764359	chr7:65958608	NA	-0.72	-8.41	-0.48	4.1e-15	Aortic root size;
SARC	cis	rs6991838	0.701	rs17395275	chr8:66591238	G/A	cg13398993	chr8:66546079	ARMC1	0.39	4.9	0.31	1.82e-6	Intelligence (multi-trait analysis);
SARC	cis	rs10504073	0.647	rs62507246	chr8:50013449	G/A	cg00325661	chr8:49890786	NA	0.54	7.39	0.44	2.67e-12	Blood metabolite ratios;
SARC	cis	rs62344088	0.590	rs61710713	chr5:181499	G/A	cg22496380	chr5:211416	CCDC127	-0.88	-5.89	-0.36	1.34e-8	Asthma (childhood onset);
SARC	cis	rs711830	1.000	rs711830	chr2:177037311	C/T	cg13092806	chr2:177043255	NA	-0.62	-6.26	-0.38	1.87e-9	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
SARC	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg23758822	chr17:41437982	NA	0.89	11.37	0.6	4.07e-24	Menopause (age at onset);
SARC	cis	rs818427	0.964	rs351767	chr5:112200098	A/G	cg07820702	chr5:112228657	REEP5	0.52	5.88	0.36	1.43e-8	Total body bone mineral density;
SARC	cis	rs12754538	0.777	rs12029303	chr1:8638666	T/C	cg13785123	chr1:8931135	ENO1	-0.46	-5.08	-0.32	7.56e-7	Subjective well-being;
SARC	cis	rs3796352	1.000	rs11713290	chr3:52971579	G/A	cg15956490	chr3:53032818	SFMBT1	0.79	5.18	0.32	4.85e-7	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs2153535	0.580	rs2225766	chr6:8481833	G/A	cg21535247	chr6:8435926	SLC35B3	0.58	7.33	0.43	3.7e-12	Motion sickness;
SARC	cis	rs12421382	0.558	rs12422001	chr11:109391880	A/G	cg16359550	chr11:109292809	C11orf87	0.38	5.6	0.34	5.95e-8	Schizophrenia;
SARC	cis	rs4808199	0.895	rs4808194	chr19:19435680	T/G	cg03709012	chr19:19516395	GATAD2A	1.12	11.1	0.59	2.97e-23	Nonalcoholic fatty liver disease;
SARC	trans	rs1635	0.655	rs73742536	chr6:28303243	G/A	cg08080395	chr15:65488966	CILP	0.66	6.47	0.39	5.71e-10	Schizophrenia;
SARC	trans	rs9951602	0.512	rs7240758	chr18:76650677	T/C	cg02800362	chr5:177631904	HNRNPAB	0.71	9.0	0.51	8.26e-17	Obesity-related traits;
SARC	trans	rs1437396	0.609	rs11125567	chr2:55627913	C/T	cg26256158	chr6:146349638	GRM1	0.53	6.42	0.39	7.52e-10	Alcohol dependence;
SARC	cis	rs765787	0.530	rs2413780	chr15:45538866	A/G	cg24006582	chr15:45444508	DUOX1	-0.51	-6.7	-0.4	1.51e-10	Uric acid levels;
SARC	cis	rs17125944	0.686	rs55685925	chr14:53334546	A/G	cg00686598	chr14:53173677	PSMC6	-0.65	-4.91	-0.31	1.7e-6	Alzheimer's disease (late onset);
SARC	cis	rs6540556	0.637	rs12060922	chr1:209904433	G/A	cg05527609	chr1:210001259	C1orf107	-0.63	-5.94	-0.36	1.03e-8	Red blood cell count;
SARC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	6.01	0.37	7.12e-9	Prudent dietary pattern;
SARC	cis	rs2832077	0.506	rs2832085	chr21:30155258	G/T	cg03476357	chr21:30257390	N6AMT1	-0.48	-5.06	-0.31	8.43e-7	Cognitive test performance;
SARC	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg18252515	chr7:66147081	NA	-1.33	-11.84	-0.61	1.22e-25	Diabetic kidney disease;
SARC	cis	rs9640161	0.750	rs59211922	chr7:150023790	T/G	cg10018233	chr7:150070692	REPIN1	0.7	9.92	0.54	1.46e-19	Blood protein levels;Circulating chemerin levels;
SARC	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.39	4.78	0.3	3.16e-6	Tonsillectomy;
SARC	cis	rs2282802	0.685	rs11750229	chr5:139559014	T/G	cg26211634	chr5:139558579	C5orf32	-0.38	-4.88	-0.3	1.92e-6	Intelligence (multi-trait analysis);
SARC	cis	rs6087990	0.871	rs1007122	chr20:31346001	C/T	cg13636640	chr20:31349939	DNMT3B	0.8	12.51	0.63	8.45e-28	Ulcerative colitis;
SARC	cis	rs1044826	1.000	rs12695699	chr3:139176109	T/C	cg15131784	chr3:139108705	COPB2	0.45	5.19	0.32	4.65e-7	Obesity-related traits;
SARC	cis	rs2213920	0.523	rs7857923	chr9:118176789	A/G	cg13918206	chr9:118159781	DEC1	0.83	6.82	0.41	7.93e-11	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs1153858	0.943	rs11070454	chr15:45680252	C/T	cg21132104	chr15:45694354	SPATA5L1	0.78	11.01	0.59	5.55e-23	Homoarginine levels;
SARC	trans	rs8073060	0.544	rs2626626	chr17:34026717	A/G	cg19694781	chr19:47549865	TMEM160	-0.7	-6.9	-0.41	4.95e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs155076	0.938	rs9509630	chr13:21844314	G/A	cg14456004	chr13:21872349	NA	-1.0	-12.77	-0.64	1.13e-28	White matter hyperintensity burden;
SARC	cis	rs9807989	0.801	rs10173193	chr2:102975050	G/A	cg09003973	chr2:102972529	NA	0.41	5.64	0.35	4.85e-8	Asthma;
SARC	cis	rs7264396	0.690	rs2425183	chr20:34450621	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	5.54	0.34	7.99e-8	Total cholesterol levels;
SARC	cis	rs13082711	0.554	rs1494422	chr3:27375190	T/C	cg02860705	chr3:27208620	NA	-0.53	-6.91	-0.41	4.5e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs599083	0.569	rs685095	chr11:68170376	C/T	cg01657329	chr11:68192670	LRP5	0.47	6.29	0.38	1.54e-9	Bone mineral density (spine);
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg25550546	chr5:139682720	PFDN1	0.8	6.49	0.39	5e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs72945132	0.882	rs56176527	chr11:70162513	A/G	cg05964544	chr11:70165517	PPFIA1	-0.61	-5.87	-0.36	1.5e-8	Coronary artery disease;
SARC	cis	rs2354432	0.556	rs7520661	chr1:146793149	A/G	cg25205988	chr1:146714368	CHD1L	-1.01	-7.68	-0.45	4.36e-13	Mitochondrial DNA levels;
SARC	cis	rs2832077	0.506	rs10222093	chr21:30163518	T/C	cg03476357	chr21:30257390	N6AMT1	-0.45	-4.8	-0.3	2.84e-6	Cognitive test performance;
SARC	cis	rs7106204	0.534	rs113048476	chr11:24257588	T/C	ch.11.24196551F	chr11:24239977	NA	0.65	4.79	0.3	2.91e-6	Response to Homoharringtonine (cytotoxicity);
SARC	cis	rs2153535	0.601	rs9505474	chr6:8539794	C/G	cg21535247	chr6:8435926	SLC35B3	0.52	6.46	0.39	6.2e-10	Motion sickness;
SARC	cis	rs6831352	1.000	rs6837685	chr4:100049145	G/A	cg12011299	chr4:100065546	ADH4	0.34	6.0	0.37	7.56e-9	Alcohol dependence;
SARC	cis	rs1843834	0.898	rs12623277	chr2:225548072	T/G	cg22509189	chr2:225307070	NA	-0.51	-6.74	-0.4	1.23e-10	IgE levels in asthmatics (D.p. specific);
SARC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg11494091	chr17:61959527	GH2	0.51	7.54	0.44	1.07e-12	Prudent dietary pattern;
SARC	cis	rs79839061	0.520	rs6842808	chr4:906903	C/T	cg07828340	chr4:882639	GAK	0.81	6.01	0.37	7.26e-9	Intelligence (multi-trait analysis);
SARC	cis	rs16976116	0.572	rs16976015	chr15:55447050	C/T	cg11288833	chr15:55489084	RSL24D1	0.64	5.52	0.34	9.05e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs17376456	0.825	rs67328989	chr5:93243133	T/A	cg25358565	chr5:93447407	FAM172A	1.29	14.27	0.68	1.27e-33	Diabetic retinopathy;
SARC	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg22920501	chr2:26401640	FAM59B	0.54	6.52	0.39	4.37e-10	Gut microbiome composition (summer);
SARC	cis	rs7528419	0.895	rs599839	chr1:109822166	A/G	cg00908766	chr1:109817496	CELSR2	-0.57	-7.43	-0.44	2.01e-12	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
SARC	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs7681440	0.835	rs6839608	chr4:90805493	T/C	cg06632027	chr4:90757378	SNCA	0.42	5.87	0.36	1.48e-8	Dementia with Lewy bodies;
SARC	cis	rs4423214	0.592	rs78300366	chr11:71205514	A/G	cg05163923	chr11:71159392	DHCR7	-0.52	-5.19	-0.32	4.6e-7	Vitamin D levels;
SARC	trans	rs9395865	0.520	rs6903708	chr6:53332940	A/G	cg21932384	chr15:32321686	CHRNA7	-0.49	-6.23	-0.38	2.1e-9	Electroencephalographic traits in alcoholism;
SARC	cis	rs14978	1.000	rs14978	chr7:12273152	A/G	cg23422036	chr7:12250390	TMEM106B	0.45	5.44	0.34	1.36e-7	Response to amphetamines;
SARC	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg04277193	chr17:41438351	NA	0.45	4.91	0.31	1.7e-6	Menopause (age at onset);
SARC	cis	rs72781680	0.851	rs72796397	chr2:24178211	T/A	cg08917208	chr2:24149416	ATAD2B	0.79	7.55	0.44	9.78e-13	Lymphocyte counts;
SARC	cis	rs4699052	1.000	rs6533059	chr4:104133376	T/G	cg16532752	chr4:104119610	CENPE	-0.41	-4.75	-0.3	3.6e-6	Testicular germ cell tumor;
SARC	cis	rs6582630	0.638	rs1829584	chr12:38526299	G/T	cg14851346	chr12:38532713	NA	-0.46	-5.63	-0.35	5.24e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs3845702	0.736	rs72958863	chr2:180808144	C/T	cg01881094	chr2:180872142	CWC22	1.16	9.56	0.53	1.71e-18	Schizophrenia;
SARC	cis	rs992157	1.000	rs13429408	chr2:219142860	C/A	cg20019365	chr2:219134978	PNKD;AAMP	0.74	11.31	0.6	6.16e-24	Colorectal cancer;
SARC	cis	rs1707322	1.000	rs7519181	chr1:46387829	G/C	cg03146154	chr1:46216737	IPP	0.46	5.54	0.34	7.97e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9910055	0.529	rs228748	chr17:42174390	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	-0.46	-5.45	-0.34	1.26e-7	Total body bone mineral density;
SARC	cis	rs7084402	0.902	rs1593670	chr10:60300766	C/G	cg07615347	chr10:60278583	BICC1	0.59	8.77	0.5	3.93e-16	Refractive error;
SARC	cis	rs2304069	0.954	rs9324640	chr5:149413186	C/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	-0.64	-6.19	-0.38	2.76e-9	HIV-1 control;
SARC	cis	rs2439831	0.867	rs2899082	chr15:43656043	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	8.32	0.48	7.2e-15	Lung cancer in ever smokers;
SARC	cis	rs765787	0.530	rs12915804	chr15:45512562	T/C	cg26924012	chr15:45694286	SPATA5L1	0.43	5.36	0.33	1.98e-7	Uric acid levels;
SARC	cis	rs4253772	0.550	rs6008613	chr22:46707924	G/T	cg24881330	chr22:46731750	TRMU	0.67	5.7	0.35	3.53e-8	LDL cholesterol;Cholesterol, total;
SARC	cis	rs17376456	0.825	rs35496867	chr5:93220400	T/C	cg21475434	chr5:93447410	FAM172A	0.82	7.22	0.43	7.27e-12	Diabetic retinopathy;
SARC	cis	rs2439831	0.702	rs9989313	chr15:44152817	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	7.77	0.45	2.55e-13	Lung cancer in ever smokers;
SARC	cis	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg15556689	chr8:8085844	FLJ10661	0.44	5.73	0.35	3.07e-8	Joint mobility (Beighton score);
SARC	cis	rs477692	1.000	rs473073	chr10:131429646	G/T	cg05714579	chr10:131428358	MGMT	0.56	7.31	0.43	4.25e-12	Response to temozolomide;
SARC	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg00149659	chr3:10157352	C3orf10	0.7	6.58	0.4	3.15e-10	Alzheimer's disease;
SARC	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	7.53	0.44	1.13e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs6582630	0.599	rs12309369	chr12:38419683	C/G	cg14851346	chr12:38532713	NA	-0.45	-5.31	-0.33	2.52e-7	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg12437481	chr16:420112	MRPL28	-0.57	-9.86	-0.54	2.12e-19	Bone mineral density (spine);Bone mineral density;
SARC	cis	rs6690583	0.562	rs76839162	chr1:85530021	A/G	cg22153463	chr1:85462885	MCOLN2	0.64	5.19	0.32	4.48e-7	Serum sulfate level;
SARC	cis	rs11641365	1.000	rs11641365	chr16:88773893	A/G	cg06304787	chr16:88772962	CTU2;RNF166	0.4	4.73	0.3	3.83e-6	Autism spectrum disorder-related traits;
SARC	cis	rs7043114	0.525	rs7047089	chr9:95117980	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.75	-0.35	2.84e-8	Height;
SARC	cis	rs2304069	0.695	rs6866298	chr5:149439588	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.68	7.4	0.44	2.47e-12	HIV-1 control;
SARC	cis	rs12762955	0.561	rs7075141	chr10:1091195	C/T	cg18964960	chr10:1102726	WDR37	-0.51	-6.37	-0.38	1.01e-9	Response to angiotensin II receptor blocker therapy;
SARC	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg18404041	chr3:52824283	ITIH1	0.38	5.62	0.35	5.45e-8	Bipolar disorder;
SARC	cis	rs1018836	0.828	rs1858673	chr8:91551526	C/A	cg16814680	chr8:91681699	NA	-0.72	-11.16	-0.59	1.88e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg18252515	chr7:66147081	NA	-1.33	-11.84	-0.61	1.22e-25	Diabetic kidney disease;
SARC	cis	rs13166103	0.657	rs4700282	chr5:57699991	C/G	cg10487770	chr5:57879443	RAB3C	0.52	5.5	0.34	9.74e-8	Type 2 diabetes (age of onset);
SARC	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg03433033	chr1:76189801	ACADM	0.51	6.88	0.41	5.5e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg02725872	chr8:58115012	NA	-0.36	-6.12	-0.37	3.91e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs73001065	1.000	rs56255430	chr19:19477877	A/C	cg03709012	chr19:19516395	GATAD2A	0.93	5.49	0.34	1.06e-7	LDL cholesterol;
SARC	cis	rs4664308	1.000	rs17831191	chr2:160911332	T/C	cg03641300	chr2:160917029	PLA2R1	-0.68	-9.15	-0.51	3.05e-17	Idiopathic membranous nephropathy;
SARC	cis	rs735539	0.521	rs2585906	chr13:21407492	C/G	cg16922012	chr13:21400325	XPO4	-0.45	-6.16	-0.37	3.11e-9	Dental caries;
SARC	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg22433210	chr17:43662623	NA	-0.71	-8.29	-0.48	9.25e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg19346786	chr7:2764209	NA	-0.39	-5.67	-0.35	4.23e-8	Height;
SARC	cis	rs965469	1.000	rs6037553	chr20:3313884	A/G	cg25506879	chr20:3388711	C20orf194	-0.5	-5.08	-0.32	7.89e-7	IFN-related cytopenia;
SARC	cis	rs3126085	0.935	rs4845740	chr1:152183310	G/A	cg03465714	chr1:152285911	FLG	-0.46	-5.5	-0.34	1e-7	Atopic dermatitis;
SARC	cis	rs9394841	0.692	rs13193235	chr6:41792659	T/C	cg08135965	chr6:41755394	TOMM6	0.65	7.12	0.42	1.35e-11	Mean corpuscular hemoglobin;Red cell distribution width;
SARC	cis	rs2072499	0.966	rs2853641	chr1:156181770	A/G	cg25208724	chr1:156163844	SLC25A44	0.74	9.84	0.54	2.49e-19	Testicular germ cell tumor;
SARC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg23131131	chr22:24373011	LOC391322	-0.44	-5.02	-0.31	1.03e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg06636001	chr8:8085503	FLJ10661	0.61	7.89	0.46	1.14e-13	Mood instability;
SARC	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg14664628	chr15:75095509	CSK	-0.46	-5.56	-0.34	7.32e-8	Breast cancer;
SARC	cis	rs2380220	0.810	rs66524640	chr6:95956566	T/C	cg04719120	chr6:96025338	MANEA	-0.64	-6.4	-0.39	8.45e-10	Behavioural disinhibition (generation interaction);
SARC	cis	rs7769051	0.711	rs9493435	chr6:133088205	A/G	cg22852734	chr6:133119734	C6orf192	1.04	10.35	0.56	6.67e-21	Type 2 diabetes nephropathy;
SARC	cis	rs6120849	0.754	rs6120793	chr20:33604407	T/C	cg06115741	chr20:33292138	TP53INP2	0.55	5.21	0.32	4.16e-7	Protein C levels;
SARC	cis	rs3106136	0.681	rs13126976	chr4:95303472	G/A	cg11021082	chr4:95130006	SMARCAD1	0.33	4.91	0.31	1.73e-6	Capecitabine sensitivity;
SARC	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg15448220	chr1:150897856	SETDB1	0.46	5.98	0.36	8.45e-9	Melanoma;
SARC	cis	rs2075371	0.897	rs10488428	chr7:133997560	C/T	cg11752832	chr7:134001865	SLC35B4	0.52	6.39	0.39	8.82e-10	Mean platelet volume;
SARC	cis	rs208520	0.690	rs3846808	chr6:66818604	A/G	cg07460842	chr6:66804631	NA	-1.06	-14.96	-0.7	6.39e-36	Exhaled nitric oxide output;
SARC	cis	rs77633900	0.614	rs280012	chr15:76974854	G/T	cg21673338	chr15:77095150	SCAPER	-0.6	-5.05	-0.31	8.79e-7	Non-glioblastoma glioma;Glioma;
SARC	cis	rs2066819	1.000	rs2643623	chr12:56689725	G/C	cg26316697	chr12:56727976	PAN2	-0.9	-6.37	-0.39	9.89e-10	Psoriasis vulgaris;
SARC	cis	rs1799949	0.602	rs8176199	chr17:41230524	T/G	cg05368731	chr17:41323189	NBR1	0.64	6.26	0.38	1.79e-9	Menopause (age at onset);
SARC	cis	rs17376456	0.569	rs2924374	chr5:93151141	T/C	cg25358565	chr5:93447407	FAM172A	-0.94	-10.47	-0.57	2.87e-21	Diabetic retinopathy;
SARC	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg22875332	chr1:76189707	ACADM	0.45	5.75	0.35	2.82e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs6665290	0.904	rs10495273	chr1:227183359	T/G	cg14016676	chr1:227182615	CDC42BPA	0.35	5.04	0.31	9.3e-7	Myeloid white cell count;
SARC	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg21782813	chr7:2030301	MAD1L1	0.41	6.21	0.38	2.44e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs10911251	0.528	rs4652777	chr1:183091992	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.68	10.11	0.55	3.67e-20	Colorectal cancer;
SARC	cis	rs6582630	0.594	rs7308707	chr12:38450428	G/C	cg14851346	chr12:38532713	NA	-0.48	-5.79	-0.35	2.27e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs67311347	0.521	rs2887963	chr3:40243466	C/T	cg24209194	chr3:40518798	ZNF619	-0.42	-5.24	-0.32	3.62e-7	Renal cell carcinoma;
SARC	cis	rs10875746	0.903	rs11168414	chr12:48512331	C/T	cg27446233	chr12:48516484	PFKM	-0.43	-4.9	-0.31	1.81e-6	Longevity (90 years and older);
SARC	cis	rs7429990	0.965	rs319692	chr3:47924317	G/C	cg11946769	chr3:48343235	NME6	0.44	5.06	0.31	8.47e-7	Educational attainment (years of education);
SARC	cis	rs11674184	0.743	rs12470971	chr2:11725241	A/G	cg07314298	chr2:11723111	GREB1	0.52	6.84	0.41	6.72e-11	Endometriosis;
SARC	cis	rs644799	0.965	rs534488	chr11:95562327	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.68	9.17	0.51	2.6e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs4466137	0.953	rs1420654	chr5:82975793	G/A	cg16102102	chr5:83017553	HAPLN1	-0.75	-9.5	-0.53	2.59e-18	Prostate cancer;
SARC	cis	rs9309473	0.861	rs6546856	chr2:73837751	T/C	cg20560298	chr2:73613845	ALMS1	-0.46	-5.43	-0.34	1.38e-7	Metabolite levels;
SARC	cis	rs10870270	1.000	rs3935905	chr10:133758262	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.48	-5.61	-0.34	5.71e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
SARC	cis	rs35110281	0.713	rs6518310	chr21:45098670	T/A	cg21573476	chr21:45109991	RRP1B	-0.56	-7.86	-0.46	1.39e-13	Mean corpuscular volume;
SARC	cis	rs950776	0.518	rs56007453	chr15:78826239	T/C	cg06917634	chr15:78832804	PSMA4	0.91	14.24	0.68	1.6e-33	Sudden cardiac arrest;
SARC	cis	rs7917772	0.636	rs1475644	chr10:104491164	G/A	ch.10.2196322F	chr10:104248062	ACTR1A	0.49	5.89	0.36	1.36e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs9381107	1.000	rs9381107	chr6:9469238	G/A	cg14735645	chr6:9486422	NA	-0.44	-4.81	-0.3	2.72e-6	Nonsyndromic cleft lip with cleft palate;
SARC	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg11764359	chr7:65958608	NA	0.88	12.55	0.63	6.26e-28	Aortic root size;
SARC	cis	rs7666738	0.830	rs7662114	chr4:99019985	A/G	cg05340658	chr4:99064831	C4orf37	0.66	9.04	0.51	6.35e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9303401	0.614	rs17175663	chr17:57108437	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	10.57	0.57	1.4e-21	Cognitive test performance;
SARC	cis	rs7833986	0.501	rs72653951	chr8:56961837	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.71	7.09	0.42	1.59e-11	Height;
SARC	cis	rs7647973	0.848	rs4955411	chr3:49145304	A/G	cg06212747	chr3:49208901	KLHDC8B	0.5	5.0	0.31	1.15e-6	Menarche (age at onset);
SARC	cis	rs16976116	0.901	rs28449712	chr15:55500681	A/C	cg11288833	chr15:55489084	RSL24D1	0.63	6.13	0.37	3.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs651907	0.535	rs11707250	chr3:101509371	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.49	-5.54	-0.34	8.02e-8	Colorectal cancer;
SARC	cis	rs13401104	0.633	rs72620804	chr2:237111501	T/A	cg19324714	chr2:237145437	ASB18	0.58	6.05	0.37	5.77e-9	Educational attainment;
SARC	cis	rs59918340	0.692	rs6983780	chr8:142231944	G/A	cg16341495	chr8:142228727	SLC45A4	-0.36	-5.11	-0.32	6.78e-7	Immature fraction of reticulocytes;
SARC	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg06108461	chr20:60628389	TAF4	-0.9	-11.75	-0.61	2.43e-25	Body mass index;
SARC	cis	rs4688759	0.719	rs73079018	chr3:49875327	T/C	cg03060546	chr3:49711283	APEH	-0.62	-5.26	-0.33	3.21e-7	Blood protein levels;
SARC	cis	rs9796	0.870	rs2925345	chr15:41311799	T/C	cg18705301	chr15:41695430	NDUFAF1	0.43	5.95	0.36	9.83e-9	Menopause (age at onset);
SARC	cis	rs365132	0.791	rs55954117	chr5:176454075	A/G	cg16309518	chr5:176445507	NA	-0.46	-5.86	-0.36	1.56e-8	Menarche and menopause (age at onset);Menopause (age at onset);
SARC	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg07234876	chr8:600039	NA	1.02	7.66	0.45	4.81e-13	IgG glycosylation;
SARC	cis	rs1878931	0.507	rs4429296	chr16:3408277	T/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.58	-6.27	-0.38	1.75e-9	Body mass index (adult);
SARC	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.62	7.45	0.44	1.8e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs4689388	0.890	rs6838400	chr4:6295427	C/G	cg00701064	chr4:6280414	WFS1	0.54	8.58	0.49	1.38e-15	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-5.96	-0.36	9.37e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs5167	0.566	rs2075618	chr19:45495668	G/C	cg10169327	chr19:45448959	APOC2	0.33	4.9	0.31	1.8e-6	Blood protein levels;
SARC	cis	rs9916302	0.904	rs9898773	chr17:37532507	C/G	cg15445000	chr17:37608096	MED1	-0.42	-5.07	-0.32	8.05e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs8180040	0.764	rs62246375	chr3:47014464	G/A	cg27129171	chr3:47204927	SETD2	-0.68	-9.25	-0.52	1.46e-17	Colorectal cancer;
SARC	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg18252515	chr7:66147081	NA	-1.28	-11.24	-0.59	1.05e-23	Diabetic kidney disease;
SARC	cis	rs9916302	0.706	rs9909304	chr17:37500508	G/T	cg07936489	chr17:37558343	FBXL20	0.76	9.12	0.51	3.63e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs13256369	1.000	rs4840351	chr8:8573148	A/G	cg18904891	chr8:8559673	CLDN23	0.52	6.14	0.37	3.48e-9	Obesity-related traits;
SARC	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg24209194	chr3:40518798	ZNF619	0.65	8.0	0.46	5.79e-14	Renal cell carcinoma;
SARC	cis	rs2073300	0.609	rs3736755	chr20:23377642	C/T	cg16736954	chr20:23401023	NAPB	0.81	5.55	0.34	7.91e-8	Peripheral arterial disease (traffic-related air pollution interaction);
SARC	cis	rs4742903	1.000	rs4742903	chr9:106856793	G/C	cg14250997	chr9:106856677	SMC2	0.52	6.83	0.41	7.53e-11	High-grade serous ovarian cancer;Breast cancer;
SARC	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg13175981	chr1:150552382	MCL1	-0.5	-6.13	-0.37	3.73e-9	Melanoma;
SARC	cis	rs1949733	0.656	rs6845969	chr4:8402465	A/T	cg13073564	chr4:8508604	NA	-0.41	-6.59	-0.4	2.96e-10	Response to antineoplastic agents;
SARC	cis	rs9341808	0.591	rs7741013	chr6:80916330	G/A	cg08355045	chr6:80787529	NA	0.36	5.68	0.35	3.94e-8	Sitting height ratio;
SARC	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg13206674	chr6:150067644	NUP43	0.45	5.86	0.36	1.53e-8	Lung cancer;
SARC	cis	rs5753618	0.539	rs2228619	chr22:31663842	C/G	cg07713946	chr22:31675144	LIMK2	-0.37	-5.15	-0.32	5.57e-7	Colorectal cancer;
SARC	cis	rs7264396	0.635	rs6058366	chr20:34512172	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	5.27	0.33	3.09e-7	Total cholesterol levels;
SARC	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg07701084	chr6:150067640	NUP43	0.39	5.15	0.32	5.56e-7	Lung cancer;
SARC	cis	rs941764	1.000	rs941764	chr14:91841069	C/T	cg10511902	chr14:91842949	CCDC88C	-0.32	-5.44	-0.34	1.33e-7	Breast cancer;
SARC	cis	rs9457247	1.000	rs400063	chr6:167386592	C/T	cg07741184	chr6:167504864	NA	0.3	5.76	0.35	2.69e-8	Crohn's disease;
SARC	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg11644478	chr21:40555479	PSMG1	-0.88	-11.55	-0.6	1.09e-24	Cognitive function;
SARC	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-10.53	-0.57	1.88e-21	Chronic sinus infection;
SARC	trans	rs9325144	0.534	rs4882283	chr12:38710249	C/T	cg23762105	chr12:34175262	ALG10	-0.51	-6.85	-0.41	6.5e-11	Morning vs. evening chronotype;
SARC	cis	rs807669	0.586	rs5746671	chr22:19160899	A/G	cg02655711	chr22:19163373	SLC25A1	0.34	4.76	0.3	3.33e-6	Metabolite levels;
SARC	cis	rs6424115	0.546	rs35993651	chr1:24180613	C/G	cg15997130	chr1:24165203	NA	-0.41	-5.51	-0.34	9.49e-8	Immature fraction of reticulocytes;
SARC	cis	rs2011503	1.000	rs2916075	chr19:19530590	G/C	cg03709012	chr19:19516395	GATAD2A	0.67	5.85	0.36	1.66e-8	Bipolar disorder;
SARC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg24503407	chr1:205819492	PM20D1	0.51	6.7	0.4	1.55e-10	Menarche (age at onset);
SARC	cis	rs854765	0.654	rs9911281	chr17:17762457	G/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.43	-5.57	-0.34	7.15e-8	Total body bone mineral density;
SARC	cis	rs7829975	0.501	rs4840353	chr8:8580570	A/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-5.62	-0.35	5.4e-8	Mood instability;
SARC	cis	rs7582180	0.715	rs920270	chr2:100917961	T/C	cg14675211	chr2:100938903	LONRF2	0.5	7.3	0.43	4.64e-12	Intelligence (multi-trait analysis);
SARC	cis	rs4974559	0.690	rs28515563	chr4:1315123	G/A	cg02980000	chr4:1222292	CTBP1	0.71	5.27	0.33	3.09e-7	Systolic blood pressure;
SARC	cis	rs9815354	0.830	rs1716983	chr3:41964128	G/A	cg03022575	chr3:42003672	ULK4	-0.55	-5.27	-0.33	3.16e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs9896052	0.649	rs6501798	chr17:73444647	C/T	cg25649188	chr17:73499917	CASKIN2	0.35	5.08	0.32	7.59e-7	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs1355223	1.000	rs11604069	chr11:34764251	A/G	cg18508148	chr11:34937573	PDHX;APIP	-0.41	-4.9	-0.31	1.79e-6	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs6815814	0.851	rs4274855	chr4:38777471	C/T	cg02016764	chr4:38805732	TLR1	-0.42	-4.72	-0.3	3.98e-6	Breast cancer;
SARC	cis	rs899997	0.906	rs1994018	chr15:79025584	G/A	cg04896959	chr15:78267971	NA	-0.5	-5.05	-0.31	9.01e-7	Coronary artery disease or large artery stroke;
SARC	cis	rs9393692	0.620	rs6908402	chr6:26293014	A/T	cg13736514	chr6:26305472	NA	-0.4	-4.86	-0.3	2.16e-6	Educational attainment;
SARC	cis	rs7020830	0.516	rs36047049	chr9:37375472	G/T	cg14294708	chr9:37120828	ZCCHC7	0.89	10.06	0.55	5.12e-20	Schizophrenia;
SARC	cis	rs920590	0.758	rs35280191	chr8:19665214	A/C	cg01411142	chr8:19674711	INTS10	0.52	6.07	0.37	5.04e-9	Acute lymphoblastic leukemia (childhood);
SARC	cis	rs8141529	0.764	rs5752807	chr22:29223169	A/G	cg15103426	chr22:29168792	CCDC117	0.67	8.66	0.49	8.19e-16	Lymphocyte counts;
SARC	cis	rs7674212	0.570	rs1031804	chr4:104066049	C/T	cg16532752	chr4:104119610	CENPE	-0.48	-5.87	-0.36	1.46e-8	Type 2 diabetes;
SARC	cis	rs793571	0.502	rs421829	chr15:59079902	G/C	cg05156742	chr15:59063176	FAM63B	0.83	13.14	0.65	6.96e-30	Schizophrenia;
SARC	cis	rs13256369	0.901	rs12681327	chr8:8566414	G/T	cg17143192	chr8:8559678	CLDN23	0.54	6.16	0.37	3.24e-9	Obesity-related traits;
SARC	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg19346786	chr7:2764209	NA	-0.39	-5.81	-0.36	2e-8	Height;
SARC	cis	rs55871839	0.708	rs1562612	chr8:59817068	A/G	cg07426533	chr8:59803705	TOX	-0.4	-5.12	-0.32	6.32e-7	Pneumonia;
SARC	cis	rs6570726	0.935	rs424263	chr6:145840073	A/C	cg05347473	chr6:146136440	FBXO30	0.48	6.42	0.39	7.51e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs8067545	0.611	rs2703788	chr17:20159686	T/C	cg13482628	chr17:19912719	NA	-0.54	-6.97	-0.42	3.23e-11	Schizophrenia;
SARC	cis	rs10078	0.515	rs6872510	chr5:481610	T/C	cg24955955	chr5:415729	AHRR	0.69	6.03	0.37	6.3e-9	Fat distribution (HIV);
SARC	cis	rs11098499	0.909	rs11098530	chr4:120413154	C/T	cg09307838	chr4:120376055	NA	0.93	12.73	0.64	1.6e-28	Corneal astigmatism;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg17378273	chr11:45169082	PRDM11	-0.8	-6.95	-0.41	3.71e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs3741151	1.000	rs78433080	chr11:73067565	G/A	cg17517138	chr11:73019481	ARHGEF17	0.97	6.83	0.41	7.16e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs72634258	0.554	rs1012477	chr1:7858135	C/G	cg05338066	chr1:7812865	CAMTA1	-0.64	-5.53	-0.34	8.61e-8	Inflammatory bowel disease;
SARC	cis	rs6940638	0.688	rs9393791	chr6:27132529	C/G	cg12826209	chr6:26865740	GUSBL1	0.53	5.6	0.34	6.04e-8	Intelligence (multi-trait analysis);
SARC	cis	rs113835537	0.529	rs3819247	chr11:66293779	T/C	cg24851651	chr11:66362959	CCS	0.38	4.84	0.3	2.32e-6	Airway imaging phenotypes;
SARC	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg17376030	chr22:41985996	PMM1	-0.73	-9.01	-0.51	7.45e-17	Vitiligo;
SARC	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg03735888	chr19:58951602	ZNF132	0.42	5.46	0.34	1.19e-7	Uric acid clearance;
SARC	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg12463550	chr7:65579703	CRCP	0.5	5.92	0.36	1.17e-8	Aortic root size;
SARC	cis	rs2011503	1.000	rs56280531	chr19:19585788	A/C	cg03709012	chr19:19516395	GATAD2A	0.63	5.56	0.34	7.3e-8	Bipolar disorder;
SARC	cis	rs7714584	1.000	rs73268545	chr5:150335282	C/T	cg22134413	chr5:150180641	NA	0.8	5.44	0.34	1.36e-7	Crohn's disease;
SARC	cis	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg18252515	chr7:66147081	NA	-1.43	-12.98	-0.65	2.35e-29	Gout;
SARC	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.76	-9.81	-0.54	3.04e-19	Chronic sinus infection;
SARC	cis	rs7666738	0.830	rs11944035	chr4:98931618	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.99	0.51	8.69e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	0.4	5.06	0.31	8.41e-7	Resistin levels;
SARC	cis	rs2562456	0.917	rs2650825	chr19:21699225	A/G	cg21751540	chr19:21541537	ZNF738	-0.47	-4.98	-0.31	1.23e-6	Pain;
SARC	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg19223190	chr17:80058835	NA	0.48	6.6	0.4	2.75e-10	Life satisfaction;
SARC	cis	rs10892173	0.846	rs7943887	chr11:117670282	C/G	cg21640587	chr11:117668038	DSCAML1	0.47	6.58	0.4	3.07e-10	Myopia;
SARC	cis	rs11583043	1.000	rs6700743	chr1:101447384	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.5	6.26	0.38	1.85e-9	Ulcerative colitis;Inflammatory bowel disease;
SARC	cis	rs2370759	1.000	rs2370759	chr10:32634972	G/A	cg01819863	chr10:32635814	EPC1	1.01	9.93	0.55	1.3e-19	Sexual dysfunction (female);
SARC	cis	rs7546668	0.640	rs12139377	chr1:15809428	C/T	cg21858823	chr1:15850916	CASP9	0.48	5.81	0.36	2.02e-8	Glomerular filtration rate (creatinine);
SARC	cis	rs41271473	0.526	rs10916343	chr1:228727961	C/T	cg16512390	chr1:228756714	NA	0.61	5.45	0.34	1.26e-7	Chronic lymphocytic leukemia;
SARC	cis	rs72781680	0.851	rs12612830	chr2:24134599	C/T	cg06627628	chr2:24431161	ITSN2	-0.71	-6.86	-0.41	6.2e-11	Lymphocyte counts;
SARC	cis	rs9611565	0.506	rs1984839	chr22:41685937	G/C	cg17376030	chr22:41985996	PMM1	0.56	6.96	0.41	3.38e-11	Vitiligo;
SARC	cis	rs35164067	0.853	rs12983921	chr19:10547226	C/T	cg21868191	chr19:10515988	NA	-0.41	-5.15	-0.32	5.65e-7	Inflammatory bowel disease;
SARC	cis	rs6120849	0.707	rs6088703	chr20:33676049	T/A	cg24642439	chr20:33292090	TP53INP2	0.56	5.3	0.33	2.63e-7	Protein C levels;
SARC	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg14085500	chr9:119460334	TRIM32;ASTN2	0.48	6.6	0.4	2.77e-10	Neuroticism;
SARC	cis	rs796364	0.951	rs11675980	chr2:201051150	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.56	-5.5	-0.34	1e-7	Schizophrenia;
SARC	cis	rs8060686	0.545	rs12598630	chr16:68258852	T/G	cg27539214	chr16:67997921	SLC12A4	-0.53	-4.99	-0.31	1.19e-6	HDL cholesterol;Metabolic syndrome;
SARC	cis	rs4642101	0.793	rs6799179	chr3:12829095	A/C	cg12400702	chr3:12838781	CAND2	-0.27	-5.37	-0.33	1.93e-7	QRS complex (12-leadsum);
SARC	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg27266027	chr21:40555129	PSMG1	0.48	5.24	0.32	3.61e-7	Cognitive function;
SARC	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg11987759	chr7:65425863	GUSB	-0.6	-7.96	-0.46	7.38e-14	Aortic root size;
SARC	trans	rs66573146	1.000	rs55672215	chr4:6970529	T/C	cg07817883	chr1:32538562	TMEM39B	1.32	8.57	0.49	1.48e-15	Granulocyte percentage of myeloid white cells;
SARC	cis	rs2857078	0.654	rs4793083	chr17:42312973	C/T	cg19774624	chr17:42201019	HDAC5	0.45	5.99	0.37	7.77e-9	Red cell distribution width;Reticulocyte count;
SARC	cis	rs7824557	0.527	rs10109537	chr8:11239640	C/T	cg21775007	chr8:11205619	TDH	-0.57	-7.65	-0.45	5.19e-13	Retinal vascular caliber;
SARC	cis	rs6495122	0.699	rs1378941	chr15:75080150	C/A	cg14664628	chr15:75095509	CSK	-0.8	-10.52	-0.57	1.99e-21	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
SARC	cis	rs2304069	0.913	rs3812009	chr5:149380159	G/C	cg12661370	chr5:149340060	SLC26A2	0.58	5.61	0.34	5.74e-8	HIV-1 control;
SARC	cis	rs453301	0.653	rs7853	chr8:8890814	A/G	cg11995313	chr8:8860691	ERI1	-0.38	-4.89	-0.31	1.87e-6	Joint mobility (Beighton score);
SARC	trans	rs11098499	0.618	rs35265692	chr4:120325135	T/C	cg25214090	chr10:38739885	LOC399744	0.53	6.77	0.41	1.02e-10	Corneal astigmatism;
SARC	cis	rs79349575	0.783	rs962272	chr17:46978283	A/G	cg16584676	chr17:46985605	UBE2Z	0.54	6.58	0.4	3.1e-10	Type 2 diabetes;
SARC	cis	rs2204008	0.720	rs11170774	chr12:38021722	C/T	cg26384229	chr12:38710491	ALG10B	-0.78	-11.14	-0.59	2.17e-23	Bladder cancer;
SARC	cis	rs9527	0.590	rs2148198	chr10:104915310	A/G	cg04362960	chr10:104952993	NT5C2	-0.42	-4.88	-0.3	1.97e-6	Arsenic metabolism;
SARC	cis	rs9325144	0.602	rs11169100	chr12:39077861	G/T	cg26384229	chr12:38710491	ALG10B	-0.62	-7.94	-0.46	8.65e-14	Morning vs. evening chronotype;
SARC	cis	rs9902453	0.765	rs2729448	chr17:28091953	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.56	-7.38	-0.44	2.71e-12	Coffee consumption (cups per day);
SARC	cis	rs9436747	0.748	rs1022981	chr1:66000034	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	-0.53	-5.19	-0.32	4.49e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
SARC	cis	rs876084	0.505	rs9297614	chr8:121105444	C/T	cg06265175	chr8:121136014	COL14A1	0.58	7.42	0.44	2.14e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
SARC	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg00825309	chr19:58991885	ZNF446	-0.55	-7.65	-0.45	5.22e-13	Uric acid clearance;
SARC	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg03806693	chr22:41940476	POLR3H	0.89	11.95	0.62	5.29e-26	Vitiligo;
SARC	cis	rs17376456	0.825	rs13357713	chr5:93145423	T/C	cg21475434	chr5:93447410	FAM172A	0.78	6.63	0.4	2.34e-10	Diabetic retinopathy;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg00517407	chr13:53191541	HNRNPA1L2	0.55	6.78	0.41	9.52e-11	Breast cancer;
SARC	trans	rs12310956	0.532	rs10844720	chr12:33987859	G/T	cg26384229	chr12:38710491	ALG10B	0.75	10.56	0.57	1.45e-21	Morning vs. evening chronotype;
SARC	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.46	5.04	0.31	9.39e-7	Renal function-related traits (BUN);
SARC	cis	rs73206853	0.841	rs6606683	chr12:110712212	T/G	cg10860002	chr12:110842031	ANAPC7	0.63	5.1	0.32	6.94e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg05863683	chr7:1912471	MAD1L1	0.35	5.08	0.32	7.87e-7	Bipolar disorder and schizophrenia;
SARC	cis	rs62432291	0.681	rs445957	chr6:159662064	C/T	cg14500486	chr6:159655392	FNDC1	-0.58	-6.13	-0.37	3.73e-9	Joint mobility (Beighton score);
SARC	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg15049968	chr18:44337910	ST8SIA5	-0.35	-5.52	-0.34	8.81e-8	Personality dimensions;
SARC	cis	rs765787	0.530	rs1706832	chr15:45517173	C/T	cg24006582	chr15:45444508	DUOX1	-0.5	-6.76	-0.41	1.08e-10	Uric acid levels;
SARC	cis	rs13034020	0.522	rs12998880	chr2:61240882	G/A	cg18625361	chr2:61244694	PEX13;PUS10	0.71	6.07	0.37	5.05e-9	Hodgkin's lymphoma;
SARC	cis	rs7683537	0.887	rs7678412	chr4:185648611	T/C	cg04058563	chr4:185651563	MLF1IP	0.8	11.35	0.6	4.56e-24	Systemic lupus erythematosus;
SARC	cis	rs1669338	0.588	rs3749360	chr3:3213775	G/A	cg16797762	chr3:3221439	CRBN	-0.94	-9.04	-0.51	6.24e-17	White matter integrity;
SARC	cis	rs1008375	0.966	rs11722132	chr4:17697217	T/C	cg16339924	chr4:17578868	LAP3	0.52	6.67	0.4	1.8e-10	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg10523679	chr1:76189770	ACADM	0.54	7.38	0.44	2.86e-12	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs546131	0.928	rs546521	chr11:34824773	G/C	cg11058730	chr11:34937778	PDHX;APIP	0.45	5.43	0.34	1.39e-7	Lung disease severity in cystic fibrosis;
SARC	cis	rs17376456	0.569	rs12653528	chr5:93212833	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.53	-5.46	-0.34	1.24e-7	Diabetic retinopathy;
SARC	cis	rs2288073	0.965	rs10173173	chr2:24415461	G/T	cg26838691	chr2:24397539	C2orf84	0.54	6.66	0.4	1.95e-10	Venous thromboembolism (SNP x SNP interaction);
SARC	cis	rs11676348	0.783	rs13035513	chr2:218960680	C/T	cg00012203	chr2:219082015	ARPC2	-0.53	-7.03	-0.42	2.29e-11	Ulcerative colitis;
SARC	cis	rs7819412	0.715	rs35223712	chr8:11043926	C/T	cg12395012	chr8:11607386	GATA4	0.33	5.6	0.34	5.87e-8	Triglycerides;
SARC	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg08742575	chr21:47604166	C21orf56	-0.43	-5.54	-0.34	8.27e-8	Testicular germ cell tumor;
SARC	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg22903657	chr4:1355424	KIAA1530	-0.36	-4.91	-0.31	1.69e-6	Obesity-related traits;
SARC	cis	rs2576037	0.901	rs2060416	chr18:44576240	G/C	cg15049968	chr18:44337910	ST8SIA5	0.32	5.32	0.33	2.46e-7	Personality dimensions;
SARC	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg13628971	chr7:2884303	GNA12	0.56	6.58	0.4	3.06e-10	Height;
SARC	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg11987759	chr7:65425863	GUSB	-0.47	-6.27	-0.38	1.7e-9	Aortic root size;
SARC	cis	rs554111	0.660	rs541464	chr1:21067095	C/T	cg04902671	chr1:21058625	SH2D5	-0.49	-5.96	-0.36	9.1e-9	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs7812088	0.572	rs1563636	chr7:150906896	T/C	cg01623806	chr7:150929509	CHPF2	-0.52	-4.89	-0.3	1.89e-6	Bone mineral density;
SARC	trans	rs9329221	0.655	rs4316191	chr8:10259229	G/A	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.63	-0.4	2.31e-10	Neuroticism;
SARC	cis	rs62244186	0.545	rs7640654	chr3:44763037	A/C	cg15225532	chr3:44803084	KIF15;KIAA1143	0.56	7.29	0.43	4.7e-12	Depressive symptoms;
SARC	trans	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg00938859	chr5:1591904	SDHAP3	0.77	7.42	0.44	2.12e-12	Breast cancer;
SARC	cis	rs9611565	0.879	rs2235845	chr22:41729294	T/G	cg06634786	chr22:41940651	POLR3H	-0.38	-4.81	-0.3	2.77e-6	Vitiligo;
SARC	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg22875332	chr1:76189707	ACADM	0.47	6.7	0.4	1.59e-10	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs66573146	1.000	rs66712119	chr4:6965428	A/T	cg00086871	chr4:6988644	TBC1D14	0.91	5.07	0.32	8.14e-7	Granulocyte percentage of myeloid white cells;
SARC	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg09359103	chr1:154839909	KCNN3	0.44	7.53	0.44	1.13e-12	Prostate cancer;
SARC	cis	rs617791	0.508	rs10791837	chr11:65774596	C/T	cg09462587	chr11:65769444	EIF1AD;BANF1	0.41	4.82	0.3	2.6e-6	Breast cancer;
SARC	cis	rs12780845	0.522	rs7900703	chr10:17237617	T/C	cg11116878	chr10:17243438	TRDMT1	0.39	4.97	0.31	1.29e-6	Homocysteine levels;
SARC	cis	rs11122272	0.701	rs2474628	chr1:231526000	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.96	-0.55	1.06e-19	Hemoglobin concentration;
SARC	cis	rs986417	1.000	rs1254270	chr14:60843134	G/T	cg27398547	chr14:60952738	C14orf39	-1.0	-8.65	-0.49	8.38e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg08859206	chr1:53392774	SCP2	0.43	6.13	0.37	3.75e-9	Monocyte count;
SARC	cis	rs11098499	0.863	rs17050695	chr4:120489527	G/T	cg09307838	chr4:120376055	NA	0.93	13.03	0.65	1.56e-29	Corneal astigmatism;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg23951277	chr5:137801359	EGR1	0.5	6.33	0.38	1.25e-9	Chemerin levels;
SARC	cis	rs11874712	1.000	rs9944637	chr18:43655239	G/A	cg25174615	chr18:43684699	ATP5A1;HAUS1	0.42	4.89	0.3	1.91e-6	Migraine - clinic-based;
SARC	cis	rs6570726	0.764	rs9403733	chr6:145912311	A/C	cg05347473	chr6:146136440	FBXO30	0.54	7.32	0.43	4.05e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg01475735	chr3:40494733	NA	-0.47	-5.18	-0.32	4.73e-7	Renal cell carcinoma;
SARC	cis	rs7043114	0.525	rs7026361	chr9:95138564	A/C	cg13798575	chr9:95087839	CENPP;NOL8	0.43	5.14	0.32	5.74e-7	Height;
SARC	cis	rs3784262	1.000	rs12903551	chr15:58268372	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.37	-5.63	-0.35	5.26e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
SARC	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg21171335	chr12:122356390	WDR66	0.43	6.84	0.41	7.09e-11	Mean corpuscular volume;
SARC	cis	rs72627123	0.867	rs112464051	chr14:74483975	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.74	5.84	0.36	1.78e-8	Morning vs. evening chronotype;
SARC	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg04518342	chr5:131593106	PDLIM4	0.43	5.46	0.34	1.2e-7	Breast cancer;
SARC	cis	rs367943	1.000	rs191553	chr5:112823659	A/G	cg12552261	chr5:112820674	MCC	-0.46	-5.27	-0.33	3.05e-7	Type 2 diabetes;
SARC	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg13395646	chr4:1353034	KIAA1530	-0.53	-6.33	-0.38	1.23e-9	Obesity-related traits;
SARC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg12648201	chr2:27665141	KRTCAP3	-0.33	-4.95	-0.31	1.4e-6	Total body bone mineral density;
SARC	cis	rs554111	0.656	rs12567861	chr1:21395133	C/T	cg08890418	chr1:21044141	KIF17	-0.37	-5.26	-0.33	3.19e-7	Facial morphology (factor 17, height of vermillion upper lip);
SARC	cis	rs6701037	1.000	rs34493921	chr1:175122759	A/G	cg00321850	chr1:175162397	KIAA0040	-0.34	-5.11	-0.32	6.73e-7	Alcohol dependence;
SARC	cis	rs8180040	0.966	rs2062278	chr3:47416761	C/T	cg27129171	chr3:47204927	SETD2	0.7	9.81	0.54	3.11e-19	Colorectal cancer;
SARC	cis	rs911555	0.617	rs7156036	chr14:103908142	A/G	cg24130564	chr14:104152367	KLC1	0.49	5.75	0.35	2.83e-8	Intelligence (multi-trait analysis);
SARC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg20007245	chr22:24372913	LOC391322	0.86	12.95	0.65	3.06e-29	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs11792861	0.926	rs72607172	chr9:111876523	A/G	cg13535736	chr9:111863775	C9orf5	-0.41	-5.08	-0.32	7.63e-7	Menarche (age at onset);
SARC	cis	rs35306767	0.903	rs11253493	chr10:936931	T/C	cg20503657	chr10:835505	NA	0.82	7.81	0.46	1.89e-13	Eosinophil percentage of granulocytes;
SARC	trans	rs8073060	0.586	rs226089	chr17:34016935	C/T	cg19694781	chr19:47549865	TMEM160	-0.71	-6.94	-0.41	3.88e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
SARC	cis	rs11731606	0.508	rs7696494	chr4:95285174	G/A	cg00507259	chr4:95128692	SMARCAD1	0.56	5.41	0.33	1.59e-7	Mean platelet volume;
SARC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg26338869	chr17:61819248	STRADA	0.81	10.89	0.58	1.38e-22	Prudent dietary pattern;
SARC	cis	rs1448094	0.511	rs61930037	chr12:86154503	G/A	cg02569458	chr12:86230093	RASSF9	0.36	4.78	0.3	3.06e-6	Major depressive disorder;
SARC	cis	rs16854884	0.657	rs7637912	chr3:143749777	G/A	cg06585982	chr3:143692056	C3orf58	0.67	9.14	0.51	3.13e-17	Economic and political preferences (feminism/equality);
SARC	cis	rs7216064	1.000	rs34872586	chr17:65863466	T/C	cg12091567	chr17:66097778	LOC651250	-0.64	-6.45	-0.39	6.56e-10	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
SARC	cis	rs78487399	0.808	rs6746058	chr2:43687542	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-5.48	-0.34	1.1e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
SARC	cis	rs2204008	0.571	rs7970136	chr12:38531951	G/C	cg26384229	chr12:38710491	ALG10B	-0.59	-7.46	-0.44	1.7e-12	Bladder cancer;
SARC	cis	rs73206853	0.563	rs4073472	chr12:111176494	A/G	cg10860002	chr12:110842031	ANAPC7	0.58	4.92	0.31	1.67e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
SARC	cis	rs2075371	0.933	rs1833474	chr7:133958240	A/G	cg20476274	chr7:133979776	SLC35B4	0.61	8.32	0.48	7.38e-15	Mean platelet volume;
SARC	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg12564285	chr5:131593104	PDLIM4	0.37	5.32	0.33	2.44e-7	Blood metabolite levels;
SARC	cis	rs858239	0.600	rs10256361	chr7:23123885	C/T	cg23682824	chr7:23144976	KLHL7	0.68	9.03	0.51	6.69e-17	Cerebrospinal fluid biomarker levels;
SARC	cis	rs1451375	0.617	rs17733244	chr7:50575495	T/C	cg18232548	chr7:50535776	DDC	0.51	5.03	0.31	9.82e-7	Malaria;
SARC	cis	rs9818758	0.556	rs11716614	chr3:49017208	C/G	cg01304814	chr3:48885189	PRKAR2A	0.84	6.57	0.4	3.3e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg00684032	chr4:1343700	KIAA1530	0.47	6.8	0.41	8.6e-11	Obesity-related traits;
SARC	cis	rs7666738	0.830	rs11735193	chr4:98761900	C/T	cg05340658	chr4:99064831	C4orf37	0.65	8.54	0.49	1.74e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs11098699	0.821	rs13148385	chr4:124206117	A/G	cg09941581	chr4:124220074	SPATA5	0.39	4.73	0.3	3.98e-6	Mosquito bite size;
SARC	cis	rs7528419	0.895	rs602633	chr1:109821511	T/G	cg00908766	chr1:109817496	CELSR2	0.53	6.72	0.4	1.35e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
SARC	cis	rs2832077	0.527	rs2832116	chr21:30228368	C/A	cg24692254	chr21:30365293	RNF160	-0.66	-7.6	-0.45	7.15e-13	Cognitive test performance;
SARC	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg22535103	chr8:58192502	C8orf71	-0.81	-9.33	-0.52	8.79e-18	Developmental language disorder (linguistic errors);
SARC	cis	rs113835537	0.529	rs11227495	chr11:66263243	C/T	cg24851651	chr11:66362959	CCS	0.38	4.81	0.3	2.67e-6	Airway imaging phenotypes;
SARC	cis	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg03060546	chr3:49711283	APEH	0.75	11.17	0.59	1.7e-23	Resting heart rate;
SARC	cis	rs79839061	0.610	rs3775130	chr4:875144	G/A	cg07828340	chr4:882639	GAK	0.7	5.19	0.32	4.56e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7617773	0.817	rs13059037	chr3:48287879	A/G	cg11946769	chr3:48343235	NME6	0.72	9.4	0.52	5.35e-18	Coronary artery disease;
SARC	cis	rs7824557	0.602	rs7834139	chr8:11206363	C/G	cg21775007	chr8:11205619	TDH	0.67	8.67	0.49	7.42e-16	Retinal vascular caliber;
SARC	cis	rs2075371	0.796	rs1646645	chr7:134012232	G/T	cg20476274	chr7:133979776	SLC35B4	-0.49	-6.35	-0.38	1.1e-9	Mean platelet volume;
SARC	cis	rs7937682	0.924	rs6589244	chr11:111534333	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.99	-16.56	-0.74	3.16e-41	Primary sclerosing cholangitis;
SARC	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg21782813	chr7:2030301	MAD1L1	0.39	6.07	0.37	5.22e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg11366901	chr6:160182831	ACAT2	0.64	6.65	0.4	2.1e-10	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs9309473	0.950	rs7566364	chr2:73842889	T/C	cg07208825	chr2:73871855	ALMS1P	0.34	5.11	0.32	6.68e-7	Metabolite levels;
SARC	cis	rs2421770	0.530	rs3847622	chr11:35368700	A/G	cg13971030	chr11:35366721	SLC1A2	0.34	5.24	0.32	3.58e-7	Staphylococcus aureus nasal carriage (persistent);
SARC	cis	rs7568458	0.905	rs17026396	chr2:85759127	C/T	cg23752985	chr2:85803571	VAMP8	-0.34	-5.1	-0.32	6.97e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
SARC	cis	rs7959452	0.640	rs1598543	chr12:69688757	G/T	cg14784868	chr12:69753453	YEATS4	0.39	5.18	0.32	4.72e-7	Blood protein levels;
SARC	cis	rs9420	0.925	rs78587207	chr11:57654991	T/G	cg19752551	chr11:57585705	CTNND1	-0.5	-6.44	-0.39	6.62e-10	Schizophrenia;
SARC	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg05793240	chr7:2802953	GNA12	-0.34	-4.96	-0.31	1.36e-6	Height;
SARC	cis	rs4727027	0.901	rs34201592	chr7:148842403	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	5.62	0.35	5.38e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs208520	0.690	rs12213575	chr6:66735989	A/G	cg07460842	chr6:66804631	NA	1.04	13.88	0.67	2.45e-32	Exhaled nitric oxide output;
SARC	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg22535103	chr8:58192502	C8orf71	-0.7	-6.55	-0.39	3.61e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs66573146	1.000	rs59683609	chr4:6964910	C/G	cg00086871	chr4:6988644	TBC1D14	0.91	5.07	0.32	8.14e-7	Granulocyte percentage of myeloid white cells;
SARC	trans	rs61931739	0.534	rs10844819	chr12:34261389	G/T	cg13010199	chr12:38710504	ALG10B	0.73	9.77	0.54	4.04e-19	Morning vs. evening chronotype;
SARC	cis	rs2213920	0.679	rs9409160	chr9:118227046	G/A	cg13918206	chr9:118159781	DEC1	0.75	5.79	0.35	2.31e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
SARC	cis	rs4711350	0.765	rs756138	chr6:33755711	G/C	cg07979401	chr6:33739406	LEMD2	-0.38	-4.76	-0.3	3.46e-6	Schizophrenia;
SARC	cis	rs7582180	0.764	rs11686293	chr2:100922830	C/T	cg14675211	chr2:100938903	LONRF2	0.54	7.85	0.46	1.55e-13	Intelligence (multi-trait analysis);
SARC	cis	rs3002142	0.554	rs75711036	chr1:222840153	T/G	cg13855472	chr1:222886563	C1orf58;AIDA	0.64	4.73	0.3	3.91e-6	LDL peak particle diameter (total fat intake interaction);
SARC	cis	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg03213289	chr20:61660250	NA	0.46	6.43	0.39	7.22e-10	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg11987759	chr7:65425863	GUSB	-0.47	-6.27	-0.38	1.7e-9	Aortic root size;
SARC	cis	rs9325144	0.555	rs4882279	chr12:38688918	C/A	cg10518543	chr12:38710700	ALG10B	0.38	4.88	0.3	2.01e-6	Morning vs. evening chronotype;
SARC	cis	rs9818758	0.607	rs5030795	chr3:49141116	C/T	cg16083429	chr3:49237500	CCDC36	0.52	5.12	0.32	6.25e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs651907	0.535	rs17347156	chr3:101504674	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.48	5.58	0.34	6.6e-8	Colorectal cancer;
SARC	cis	rs981844	0.712	rs4292309	chr4:154745178	C/A	cg14289246	chr4:154710475	SFRP2	-0.46	-5.4	-0.33	1.6e-7	Response to statins (LDL cholesterol change);
SARC	cis	rs9398803	0.965	rs17754780	chr6:126664333	C/T	cg20229609	chr6:126660872	C6orf173	0.4	5.85	0.36	1.62e-8	Male-pattern baldness;
SARC	cis	rs9457247	0.967	rs2015864	chr6:167381476	T/C	cg07741184	chr6:167504864	NA	-0.3	-5.61	-0.35	5.69e-8	Crohn's disease;
SARC	cis	rs7712401	0.601	rs154500	chr5:122211991	T/G	cg19412675	chr5:122181750	SNX24	0.42	5.34	0.33	2.18e-7	Mean platelet volume;
SARC	cis	rs4319547	0.737	rs4758646	chr12:122946507	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.51	-5.87	-0.36	1.47e-8	Body mass index;
SARC	cis	rs6728642	1.000	rs57035274	chr2:97608124	C/A	cg26665480	chr2:98280029	ACTR1B	-0.56	-4.96	-0.31	1.38e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
SARC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg07167872	chr1:205819463	PM20D1	0.75	11.72	0.61	2.95e-25	Menarche (age at onset);
SARC	cis	rs360798	0.656	rs2421712	chr2:62864649	G/A	cg16915676	chr2:62734870	TMEM17	0.45	5.53	0.34	8.55e-8	Coronary artery disease;
SARC	cis	rs7592578	0.679	rs62181020	chr2:191325601	A/C	cg10560079	chr2:191398806	TMEM194B	-0.72	-8.26	-0.48	1.09e-14	Diastolic blood pressure;
SARC	cis	rs6840360	1.000	rs6840360	chr4:152604031	C/T	cg22705602	chr4:152727874	NA	-0.38	-6.57	-0.4	3.23e-10	Intelligence (multi-trait analysis);
SARC	cis	rs72653721	0.793	rs59578052	chr6:10966620	C/T	cg13562911	chr6:11044106	ELOVL2	0.59	6.35	0.38	1.14e-9	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
SARC	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-5.45	-0.34	1.28e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
SARC	cis	rs9902453	1.000	rs4350617	chr17:28423088	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	6.7	0.4	1.52e-10	Coffee consumption (cups per day);
SARC	cis	rs7666738	0.830	rs1025204	chr4:99023441	G/A	cg05340658	chr4:99064831	C4orf37	0.66	9.04	0.51	6.35e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-7.83	-0.46	1.71e-13	Alzheimer's disease;
SARC	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.47	-5.93	-0.36	1.1e-8	Lymphocyte counts;
SARC	cis	rs10464366	0.746	rs6945402	chr7:39145385	A/T	cg18850127	chr7:39170497	POU6F2	0.44	5.5	0.34	9.74e-8	IgG glycosylation;
SARC	cis	rs7829975	0.623	rs7010753	chr8:8373956	A/G	cg15556689	chr8:8085844	FLJ10661	0.43	5.26	0.33	3.19e-7	Mood instability;
SARC	cis	rs6964587	0.610	rs7788951	chr7:91468765	A/T	cg17063962	chr7:91808500	NA	0.69	9.81	0.54	3.02e-19	Breast cancer;
SARC	cis	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg13072238	chr3:49761600	GMPPB	-0.42	-5.54	-0.34	8.33e-8	Intelligence (multi-trait analysis);
SARC	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg24549020	chr5:56110836	MAP3K1	0.81	8.51	0.49	2.11e-15	Initial pursuit acceleration;
SARC	cis	rs3820928	0.874	rs3752895	chr2:227886773	A/G	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.71	-0.35	3.42e-8	Pulmonary function;
SARC	cis	rs10465746	0.780	rs10874424	chr1:84424033	C/T	cg10977910	chr1:84465055	TTLL7	0.44	5.39	0.33	1.74e-7	Obesity-related traits;
SARC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg21280719	chr6:42927975	GNMT	-0.46	-8.05	-0.47	4.13e-14	Alzheimer's disease in APOE e4+ carriers;
SARC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg26338869	chr17:61819248	STRADA	0.79	10.63	0.57	8.77e-22	Prudent dietary pattern;
SARC	cis	rs7312933	0.670	rs10880269	chr12:42606135	C/T	cg19980929	chr12:42632907	YAF2	0.44	6.04	0.37	6.04e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs709400	0.663	rs62007687	chr14:103903763	G/T	cg26031613	chr14:104095156	KLC1	0.81	11.45	0.6	2.28e-24	Body mass index;
SARC	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg11742103	chr11:62369870	EML3;MTA2	0.43	6.36	0.38	1.08e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs6570726	0.526	rs9376934	chr6:145738702	A/G	cg23711669	chr6:146136114	FBXO30	0.64	8.24	0.48	1.22e-14	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg01448562	chr3:133502909	NA	-0.51	-7.78	-0.45	2.29e-13	Iron status biomarkers;
SARC	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg26681399	chr22:41777847	TEF	-0.45	-4.93	-0.31	1.59e-6	Vitiligo;
SARC	cis	rs77106637	0.556	rs7123876	chr11:72444583	T/C	cg03713592	chr11:72463424	ARAP1	0.82	9.39	0.52	5.6e-18	Type 2 diabetes;
SARC	cis	rs6570726	0.764	rs4896821	chr6:145896181	G/A	cg23711669	chr6:146136114	FBXO30	0.79	12.4	0.63	1.95e-27	Lobe attachment (rater-scored or self-reported);
SARC	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg18220030	chr1:110090737	GNAI3	-0.61	-6.72	-0.4	1.42e-10	Lung cancer in ever smokers;
SARC	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg27266027	chr21:40555129	PSMG1	-0.5	-5.5	-0.34	9.74e-8	Cognitive function;
SARC	cis	rs7666738	0.546	rs10007424	chr4:98885450	C/T	cg05340658	chr4:99064831	C4orf37	0.58	7.2	0.43	8.18e-12	Colonoscopy-negative controls vs population controls;
SARC	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg11764359	chr7:65958608	NA	-0.79	-9.42	-0.52	4.79e-18	Aortic root size;
SARC	cis	rs9911578	1.000	rs302859	chr17:56693132	C/T	cg05425664	chr17:57184151	TRIM37	-0.68	-8.49	-0.49	2.48e-15	Intelligence (multi-trait analysis);
SARC	cis	rs9300255	0.537	rs1619561	chr12:123620268	G/C	cg00376283	chr12:123451042	ABCB9	0.55	6.35	0.38	1.11e-9	Neutrophil percentage of white cells;
SARC	cis	rs6831352	0.918	rs13129488	chr4:100053025	G/T	cg13256891	chr4:100009986	ADH5	-0.64	-8.0	-0.46	5.7e-14	Alcohol dependence;
SARC	cis	rs1976403	0.659	rs10799700	chr1:21820968	G/C	cg07708622	chr1:21763251	NA	0.35	5.66	0.35	4.34e-8	Liver enzyme levels (alkaline phosphatase);
SARC	cis	rs9457247	0.715	rs6923582	chr6:167437162	T/A	cg07741184	chr6:167504864	NA	0.37	7.28	0.43	5.13e-12	Crohn's disease;
SARC	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.63	-7.65	-0.45	5.22e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs782590	0.967	rs1823893	chr2:55788921	T/C	cg18811423	chr2:55921094	PNPT1	0.69	10.65	0.57	7.93e-22	Metabolic syndrome;
SARC	cis	rs6912958	0.559	rs242270	chr6:88062190	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.38	-6.67	-0.4	1.89e-10	Monocyte percentage of white cells;
SARC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg14159672	chr1:205819179	PM20D1	0.57	7.76	0.45	2.67e-13	Menarche (age at onset);
SARC	cis	rs916888	0.610	rs199454	chr17:44800110	G/A	cg01570182	chr17:44337453	NA	-0.66	-7.81	-0.46	1.89e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs1050631	1.000	rs2236718	chr18:33705135	G/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.46	5.67	0.35	4.11e-8	Esophageal squamous cell cancer (length of survival);
SARC	cis	rs57994353	0.861	rs13301660	chr9:139340802	C/T	cg14169450	chr9:139327907	INPP5E	0.43	5.55	0.34	7.7e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
SARC	cis	rs28374715	0.562	rs8036686	chr15:41550333	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.7	-9.66	-0.53	8.53e-19	Ulcerative colitis;
SARC	cis	rs7615952	0.932	rs13065725	chr3:125632289	C/A	cg05084668	chr3:125655381	ALG1L	-0.67	-6.53	-0.39	4.15e-10	Blood pressure (smoking interaction);
SARC	cis	rs6977660	0.619	rs10231972	chr7:19789354	C/G	cg07541023	chr7:19748670	TWISTNB	0.48	5.0	0.31	1.15e-6	Thyroid stimulating hormone;
SARC	cis	rs72945132	0.660	rs7121703	chr11:70140296	C/T	cg05964544	chr11:70165517	PPFIA1	-0.61	-5.87	-0.36	1.5e-8	Coronary artery disease;
SARC	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg25072359	chr17:41440525	NA	0.51	6.08	0.37	4.92e-9	Menopause (age at onset);
SARC	cis	rs8067545	0.518	rs7222987	chr17:20055765	A/G	cg13482628	chr17:19912719	NA	0.52	6.85	0.41	6.7e-11	Schizophrenia;
SARC	cis	rs477692	1.000	rs548390	chr10:131417427	G/A	cg05714579	chr10:131428358	MGMT	0.57	7.56	0.44	9.32e-13	Response to temozolomide;
SARC	cis	rs858239	0.600	rs6461690	chr7:23135534	A/G	cg23682824	chr7:23144976	KLHL7	0.7	9.38	0.52	5.93e-18	Cerebrospinal fluid biomarker levels;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg00556029	chr1:32802033	MARCKSL1	-0.74	-6.66	-0.4	1.94e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6963495	0.818	rs73190183	chr7:105163022	G/A	cg19920283	chr7:105172520	RINT1	0.65	5.48	0.34	1.09e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg07636037	chr3:49044803	WDR6	0.99	17.47	0.75	3.09e-44	Parkinson's disease;
SARC	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg22535103	chr8:58192502	C8orf71	-0.7	-5.92	-0.36	1.14e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs12142240	0.698	rs67142569	chr1:46828460	C/T	cg14993813	chr1:46806288	NSUN4	-0.53	-5.62	-0.35	5.48e-8	Menopause (age at onset);
SARC	cis	rs2594989	0.887	rs9985349	chr3:11591200	T/G	cg00170343	chr3:11313890	ATG7	-0.58	-5.96	-0.36	9.25e-9	Circulating chemerin levels;
SARC	cis	rs1008375	0.966	rs7658240	chr4:17588950	A/G	cg27347728	chr4:17578864	LAP3	-0.51	-6.31	-0.38	1.4e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs72781680	0.611	rs55788848	chr2:24268721	C/T	cg06627628	chr2:24431161	ITSN2	-0.61	-6.04	-0.37	6.18e-9	Lymphocyte counts;
SARC	cis	rs9581943	0.967	rs7985481	chr13:28466090	A/C	cg17352152	chr13:28491409	NA	0.39	5.15	0.32	5.59e-7	Pancreatic cancer;
SARC	trans	rs6964833	0.935	rs13238996	chr7:74069645	A/G	cg07504079	chr7:72649617	NCF1B	-0.61	-6.56	-0.39	3.36e-10	Menarche (age at onset);
SARC	cis	rs9815354	0.951	rs1716674	chr3:41902972	G/C	cg03022575	chr3:42003672	ULK4	0.56	5.29	0.33	2.81e-7	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg08219700	chr8:58056026	NA	0.58	6.0	0.37	7.48e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg12292205	chr6:26970375	C6orf41	-0.56	-6.17	-0.37	2.96e-9	Autism spectrum disorder or schizophrenia;
SARC	cis	rs9400467	0.537	rs77212954	chr6:111445381	A/G	cg15721981	chr6:111408429	SLC16A10	0.67	5.95	0.36	9.56e-9	Blood metabolite levels;Amino acid levels;
SARC	cis	rs2180341	1.000	rs7776136	chr6:127638348	A/T	cg17762328	chr6:126965162	NA	-0.44	-5.02	-0.31	1.04e-6	Breast cancer;
SARC	cis	rs7681440	0.566	rs356189	chr4:90691132	T/C	cg06632027	chr4:90757378	SNCA	0.42	5.21	0.32	4.22e-7	Dementia with Lewy bodies;
SARC	cis	rs7904368	1.000	rs7904368	chr10:16858587	C/T	cg23933602	chr10:16859644	RSU1	0.56	6.43	0.39	7.11e-10	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
SARC	cis	rs7005380	0.531	rs7838578	chr8:120907047	G/A	cg21744203	chr8:120868354	DSCC1	-0.47	-4.96	-0.31	1.37e-6	Interstitial lung disease;
SARC	cis	rs9868809	0.772	rs73078349	chr3:48688114	G/A	cg07636037	chr3:49044803	WDR6	-0.87	-6.71	-0.4	1.48e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
SARC	cis	rs17376456	0.877	rs10063045	chr5:93457584	A/T	cg25358565	chr5:93447407	FAM172A	1.31	12.86	0.64	5.95e-29	Diabetic retinopathy;
SARC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg06873352	chr17:61820015	STRADA	0.53	6.81	0.41	8.27e-11	Prudent dietary pattern;
SARC	cis	rs9341808	0.718	rs9448899	chr6:80845864	G/A	cg08355045	chr6:80787529	NA	0.34	5.47	0.34	1.14e-7	Sitting height ratio;
SARC	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg04511125	chr2:88470314	THNSL2	0.81	7.27	0.43	5.44e-12	Plasma clusterin levels;
SARC	cis	rs67311347	0.876	rs13068097	chr3:40504424	T/A	cg09455208	chr3:40491958	NA	-0.37	-5.63	-0.35	5.25e-8	Renal cell carcinoma;
SARC	cis	rs9790314	0.875	rs459515	chr3:161092351	T/C	cg03342759	chr3:160939853	NMD3	-0.63	-8.26	-0.48	1.09e-14	Morning vs. evening chronotype;
SARC	cis	rs778371	0.676	rs2293780	chr2:233635213	T/C	cg16596103	chr2:233749413	NGEF	-0.36	-5.45	-0.34	1.27e-7	Schizophrenia;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg13848035	chr12:56511932	ZC3H10	0.56	6.62	0.4	2.44e-10	Fibrinogen levels;
SARC	cis	rs11025559	0.796	rs10833317	chr11:20412277	A/T	cg04101203	chr11:20408940	PRMT3	-0.54	-5.88	-0.36	1.38e-8	Pursuit maintenance gain;
SARC	cis	rs79149102	0.579	rs7179097	chr15:75279240	T/G	cg17294928	chr15:75287854	SCAMP5	-0.99	-8.84	-0.5	2.41e-16	Lung cancer;
SARC	cis	rs611744	0.967	rs677330	chr8:109177572	A/G	cg21045802	chr8:109455806	TTC35	0.44	5.3	0.33	2.64e-7	Dupuytren's disease;
SARC	cis	rs1707322	1.000	rs11211219	chr1:46359478	G/C	cg06784218	chr1:46089804	CCDC17	0.34	6.03	0.37	6.51e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs950169	0.920	rs17300048	chr15:84749477	C/T	cg17507749	chr15:85114479	UBE2QP1	0.75	9.12	0.51	3.59e-17	Schizophrenia;
SARC	cis	rs798554	0.704	rs798503	chr7:2789704	G/A	cg13628971	chr7:2884303	GNA12	0.43	5.31	0.33	2.53e-7	Height;
SARC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg11266582	chr15:64275853	DAPK2	-0.49	-6.36	-0.38	1.05e-9	Height;
SARC	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg15049968	chr18:44337910	ST8SIA5	-0.36	-5.62	-0.35	5.37e-8	Personality dimensions;
SARC	cis	rs986417	0.901	rs1061108	chr14:60978071	C/G	cg27398547	chr14:60952738	C14orf39	0.99	9.02	0.51	6.89e-17	Gut microbiota (bacterial taxa);
SARC	cis	rs2933343	0.729	rs789231	chr3:128602847	A/G	cg24203234	chr3:128598194	ACAD9	0.62	7.7	0.45	3.97e-13	IgG glycosylation;
SARC	cis	rs2070488	0.775	rs4407366	chr3:38521425	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.78	11.35	0.6	4.62e-24	Electrocardiographic conduction measures;
SARC	cis	rs11097912	0.632	rs3792718	chr4:107248890	T/C	cg09646026	chr4:107269030	AIMP1	-0.45	-4.87	-0.3	2.08e-6	Airflow obstruction;
SARC	cis	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg08045932	chr20:61659980	NA	0.5	6.84	0.41	7.06e-11	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs3847687	1.000	rs10848269	chr12:131518622	A/G	cg13406893	chr12:131568647	GPR133	-0.32	-4.75	-0.3	3.57e-6	Longevity;
SARC	cis	rs9902453	0.904	rs55866125	chr17:28312993	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	7.02	0.42	2.44e-11	Coffee consumption (cups per day);
SARC	cis	rs1003719	0.715	rs7277820	chr21:38580309	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-8.81	-0.5	3.01e-16	Eye color traits;
SARC	cis	rs9399135	0.967	rs7773126	chr6:135318390	A/G	cg24558204	chr6:135376177	HBS1L	0.44	5.95	0.36	9.55e-9	Red blood cell count;
SARC	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg25072359	chr17:41440525	NA	0.51	6.13	0.37	3.72e-9	Menopause (age at onset);
SARC	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.33	-4.88	-0.3	1.95e-6	Longevity;Endometriosis;
SARC	cis	rs5769765	0.565	rs8137232	chr22:50256885	G/C	cg03033257	chr22:50311977	ALG12;CRELD2	-0.54	-4.72	-0.3	4.08e-6	Schizophrenia;
SARC	cis	rs2742234	0.541	rs1317214	chr10:43733531	C/G	cg15436174	chr10:43711423	RASGEF1A	0.42	5.0	0.31	1.11e-6	Hirschsprung disease;
SARC	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg19346786	chr7:2764209	NA	-0.33	-4.78	-0.3	3.08e-6	Height;
SARC	cis	rs79149102	0.579	rs6495140	chr15:75306041	T/C	cg09165964	chr15:75287851	SCAMP5	-0.96	-8.95	-0.51	1.14e-16	Lung cancer;
SARC	cis	rs9398803	0.713	rs3861457	chr6:126902245	T/C	cg19875578	chr6:126661172	C6orf173	0.6	8.22	0.47	1.39e-14	Male-pattern baldness;
SARC	cis	rs7312933	0.618	rs7315968	chr12:42637086	G/A	cg19980929	chr12:42632907	YAF2	0.49	7.24	0.43	6.46e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs1865760	1.000	rs7770139	chr6:25925823	A/G	cg17691542	chr6:26056736	HIST1H1C	0.57	6.97	0.42	3.24e-11	Height;
SARC	cis	rs7312933	0.533	rs11181499	chr12:42818761	A/G	cg19980929	chr12:42632907	YAF2	0.46	6.58	0.4	3e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs11098499	0.775	rs67281037	chr4:120281157	G/C	cg09307838	chr4:120376055	NA	0.83	11.82	0.61	1.46e-25	Corneal astigmatism;
SARC	cis	rs1008375	1.000	rs1006722	chr4:17618713	A/G	cg02297831	chr4:17616191	MED28	-0.47	-5.94	-0.36	1.02e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg08355456	chr11:67383691	NA	0.42	5.55	0.34	7.85e-8	Mean corpuscular volume;
SARC	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg13939156	chr17:80058883	NA	0.4	6.25	0.38	1.92e-9	Life satisfaction;
SARC	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg09699651	chr6:150184138	LRP11	0.42	5.14	0.32	5.9e-7	Lung cancer;
SARC	cis	rs2013441	1.000	rs9325894	chr17:20197101	T/C	cg13482628	chr17:19912719	NA	-0.49	-6.36	-0.38	1.03e-9	Obesity-related traits;
SARC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg15258722	chr13:110802573	COL4A1	0.73	5.62	0.35	5.41e-8	Obesity-related traits;
SARC	cis	rs2075371	0.932	rs1862048	chr7:133978167	C/G	cg20476274	chr7:133979776	SLC35B4	-0.55	-6.46	-0.39	6.11e-10	Mean platelet volume;
SARC	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg11987759	chr7:65425863	GUSB	-0.41	-5.49	-0.34	1.06e-7	Calcium levels;
SARC	cis	rs2130604	0.888	rs7753563	chr6:126802598	A/G	cg19875578	chr6:126661172	C6orf173	0.48	5.35	0.33	2.09e-7	Bone mineral density (paediatric, skull);
SARC	cis	rs546131	0.614	rs7106579	chr11:34835502	C/A	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-4.83	-0.3	2.52e-6	Lung disease severity in cystic fibrosis;
SARC	cis	rs9388451	0.807	rs1268070	chr6:126041164	A/G	cg06289844	chr6:126071538	HEY2	0.34	5.47	0.34	1.14e-7	Brugada syndrome;
SARC	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg06634786	chr22:41940651	POLR3H	0.55	6.49	0.39	5.22e-10	Vitiligo;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg14787260	chr17:40428794	STAT5B	0.53	6.79	0.41	9.12e-11	Breast cancer;
SARC	cis	rs1008375	1.000	rs10805358	chr4:17652450	A/C	cg02297831	chr4:17616191	MED28	0.49	6.29	0.38	1.52e-9	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.69	7.54	0.44	1.07e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs9399137	0.507	rs13214669	chr6:135299959	T/C	cg24558204	chr6:135376177	HBS1L	0.62	8.04	0.47	4.66e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
SARC	cis	rs1215050	0.791	rs260902	chr4:98764694	G/A	cg05340658	chr4:99064831	C4orf37	0.44	5.85	0.36	1.62e-8	Waist-to-hip ratio adjusted for body mass index;
SARC	cis	rs651907	0.557	rs3094297	chr3:101399260	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	6.62	0.4	2.46e-10	Colorectal cancer;
SARC	cis	rs526231	0.511	rs56235607	chr5:102372606	G/A	cg23492399	chr5:102201601	PAM	-0.52	-5.67	-0.35	4.18e-8	Primary biliary cholangitis;
SARC	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg13206674	chr6:150067644	NUP43	0.47	6.17	0.37	2.98e-9	Lung cancer;
SARC	cis	rs3126085	0.935	rs12726613	chr1:152185500	C/G	cg26876637	chr1:152193138	HRNR	-0.47	-5.39	-0.33	1.7e-7	Atopic dermatitis;
SARC	cis	rs11098499	0.629	rs28369518	chr4:120271630	T/C	cg09307838	chr4:120376055	NA	0.75	10.27	0.56	1.22e-20	Corneal astigmatism;
SARC	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg20120463	chr17:44301886	NA	0.31	4.95	0.31	1.41e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs2204008	0.818	rs7313608	chr12:38383428	C/A	cg14851346	chr12:38532713	NA	-0.4	-4.77	-0.3	3.28e-6	Bladder cancer;
SARC	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg22968622	chr17:43663579	NA	1.25	16.93	0.74	1.83e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
SARC	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.79	5.85	0.36	1.64e-8	Initial pursuit acceleration;
SARC	cis	rs123509	0.913	rs123506	chr3:42775976	T/C	cg12982090	chr3:42733453	KBTBD5	0.52	6.36	0.38	1.06e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs7264396	0.635	rs6060692	chr20:34517925	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.69	7.49	0.44	1.45e-12	Total cholesterol levels;
SARC	cis	rs763121	0.853	rs138716	chr22:39146527	C/T	cg06022373	chr22:39101656	GTPBP1	0.88	10.97	0.58	7.64e-23	Menopause (age at onset);
SARC	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg19729930	chr2:74357872	NA	-0.66	-9.67	-0.54	8.14e-19	Gestational age at birth (maternal effect);
SARC	cis	rs13034020	0.641	rs35852308	chr2:61225563	A/C	cg18625361	chr2:61244694	PEX13;PUS10	0.64	5.07	0.32	8.14e-7	Hodgkin's lymphoma;
SARC	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg11764359	chr7:65958608	NA	-0.84	-12.27	-0.63	5.04e-27	Aortic root size;
SARC	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.54	-5.33	-0.33	2.35e-7	Lung function (FEV1/FVC);
SARC	cis	rs4718428	0.705	rs3800817	chr7:66263550	T/A	cg18252515	chr7:66147081	NA	-0.57	-6.11	-0.37	4.05e-9	Corneal structure;
SARC	cis	rs7792596	0.861	rs4729124	chr7:93996776	A/G	cg20814616	chr7:94014465	NA	-0.43	-5.37	-0.33	1.88e-7	Intelligence;
SARC	cis	rs2180341	1.000	rs3798850	chr6:127613966	C/T	cg24812749	chr6:127587940	RNF146	0.97	12.89	0.65	4.63e-29	Breast cancer;
SARC	cis	rs7027203	0.576	rs7874836	chr9:96559370	C/T	cg14598338	chr9:96623480	NA	-0.35	-4.9	-0.31	1.78e-6	DNA methylation (variation);
SARC	cis	rs897080	0.515	rs1067325	chr2:44628997	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.7	0.4	1.59e-10	Height;
SARC	trans	rs7824557	0.583	rs2736306	chr8:11239762	A/T	cg15556689	chr8:8085844	FLJ10661	0.51	6.4	0.39	8.62e-10	Retinal vascular caliber;
SARC	cis	rs2279817	0.908	rs3766310	chr1:17977642	A/C	cg21791023	chr1:18019539	ARHGEF10L	-0.52	-4.88	-0.3	1.93e-6	Neuroticism;
SARC	cis	rs1707322	0.721	rs11211165	chr1:46157906	C/T	cg06784218	chr1:46089804	CCDC17	0.36	6.17	0.37	2.95e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7084402	0.967	rs1649091	chr10:60289440	T/A	cg07615347	chr10:60278583	BICC1	0.61	8.99	0.51	8.84e-17	Refractive error;
SARC	cis	rs7659604	0.605	rs2071486	chr4:122740162	C/T	cg20573242	chr4:122745356	CCNA2	0.69	9.02	0.51	7.19e-17	Type 2 diabetes;
SARC	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg24549020	chr5:56110836	MAP3K1	0.44	5.11	0.32	6.86e-7	Coronary artery disease;
SARC	cis	rs2153535	0.580	rs1932279	chr6:8473653	T/C	cg07606381	chr6:8435919	SLC35B3	0.77	10.83	0.58	2.14e-22	Motion sickness;
SARC	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.99	11.07	0.59	3.57e-23	Platelet count;
SARC	cis	rs240764	0.817	rs240154	chr6:101065792	G/T	cg09795085	chr6:101329169	ASCC3	0.45	5.86	0.36	1.54e-8	Neuroticism;
SARC	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg21883765	chr7:127032075	ZNF800	0.53	6.52	0.39	4.2e-10	Breast cancer;
SARC	cis	rs9612	1.000	rs1058	chr19:44268325	C/G	cg08581076	chr19:44259116	C19orf61	0.69	8.35	0.48	5.98e-15	Exhaled nitric oxide output;
SARC	cis	rs9549260	0.620	rs4325427	chr13:41216534	C/T	cg21288729	chr13:41239152	FOXO1	0.67	9.01	0.51	7.8e-17	Red blood cell count;
SARC	cis	rs367615	0.552	rs2963022	chr5:108727185	A/G	cg17395555	chr5:108820864	NA	-0.34	-4.78	-0.3	3.07e-6	Colorectal cancer (SNP x SNP interaction);
SARC	cis	rs698833	0.605	rs6728449	chr2:44702785	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	6.1	0.37	4.35e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs10911232	0.507	rs4596846	chr1:182976034	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.76	0.58	3.38e-22	Hypertriglyceridemia;
SARC	cis	rs9810089	0.843	rs1279086	chr3:136038574	G/A	cg15507776	chr3:136538369	TMEM22	0.43	4.79	0.3	2.97e-6	Gestational age at birth (child effect);
SARC	cis	rs6963495	0.745	rs73190169	chr7:105160500	A/G	cg13798780	chr7:105162888	PUS7	0.6	5.45	0.34	1.31e-7	Bipolar disorder (body mass index interaction);
SARC	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg07061783	chr6:25882402	NA	-0.42	-5.01	-0.31	1.06e-6	Intelligence (multi-trait analysis);
SARC	trans	rs3857536	0.740	rs9354391	chr6:66890183	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.61	7.42	0.44	2.21e-12	Blood trace element (Cu levels);
SARC	cis	rs2832077	0.527	rs2776210	chr21:30268558	A/G	cg03476357	chr21:30257390	N6AMT1	0.57	6.27	0.38	1.72e-9	Cognitive test performance;
SARC	cis	rs6570726	0.875	rs416243	chr6:145868081	A/T	cg05220968	chr6:146057943	EPM2A	-0.3	-5.08	-0.32	7.76e-7	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.59	9.28	0.52	1.23e-17	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg09269891	chr16:3843415	CREBBP	-0.41	-5.0	-0.31	1.15e-6	Schizophrenia;
SARC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg08219700	chr8:58056026	NA	0.62	6.52	0.39	4.28e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.46	5.18	0.32	4.7e-7	Renal function-related traits (BUN);
SARC	cis	rs1967309	0.604	rs8061182	chr16:4070333	A/G	cg00061520	chr16:4070371	ADCY9	0.32	4.89	0.31	1.85e-6	Response to Dalcetrapib treatment in acute coronary syndrome;
SARC	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg15052019	chr19:19431593	KIAA0892;SF4	-0.39	-4.75	-0.3	3.54e-6	Tonsillectomy;
SARC	cis	rs9875589	0.509	rs4685051	chr3:13981760	A/G	cg19554555	chr3:13937349	NA	-0.41	-5.1	-0.32	7.05e-7	Ovarian reserve;
SARC	cis	rs3733585	0.673	rs4314284	chr4:9956096	C/T	cg00071950	chr4:10020882	SLC2A9	-0.37	-5.65	-0.35	4.61e-8	Cleft plate (environmental tobacco smoke interaction);
SARC	cis	rs9503598	0.714	rs7758776	chr6:3452245	C/T	cg00476032	chr6:3446245	SLC22A23	0.32	4.89	0.31	1.88e-6	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
SARC	trans	rs61931739	0.513	rs1608908	chr12:33895389	C/A	cg13010199	chr12:38710504	ALG10B	0.63	8.45	0.48	3.15e-15	Morning vs. evening chronotype;
SARC	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg03709012	chr19:19516395	GATAD2A	1.03	18.24	0.77	8.93e-47	Tonsillectomy;
SARC	cis	rs2276314	0.857	rs8097597	chr18:33619448	A/G	cg05985134	chr18:33552581	C18orf21	0.67	7.24	0.43	6.59e-12	Endometriosis;Drug-induced torsades de pointes;
SARC	cis	rs7264396	0.790	rs6060562	chr20:34282053	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	5.82	0.36	1.91e-8	Total cholesterol levels;
SARC	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg08742575	chr21:47604166	C21orf56	0.43	5.44	0.34	1.38e-7	Testicular germ cell tumor;
SARC	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.08	22.41	0.83	4.65e-60	Chronic sinus infection;
SARC	cis	rs995000	0.868	rs9787156	chr1:63179212	G/A	cg06896770	chr1:63153194	DOCK7	-0.85	-13.01	-0.65	1.94e-29	Triglyceride levels;
SARC	cis	rs9611519	0.780	rs2235849	chr22:41653540	T/G	cg03806693	chr22:41940476	POLR3H	-0.64	-8.3	-0.48	8.42e-15	Neuroticism;
SARC	cis	rs9896052	0.572	rs4078474	chr17:73489567	C/G	cg25649188	chr17:73499917	CASKIN2	0.37	5.43	0.34	1.43e-7	Sight-threatening diabetic retinopathy in type 2 diabetes;
SARC	cis	rs7481584	0.624	rs451060	chr11:3056389	G/A	cg05729581	chr11:3078854	CARS	0.56	7.22	0.43	7.43e-12	Calcium levels;
SARC	cis	rs9400467	0.506	rs17678681	chr6:111582038	T/A	cg15721981	chr6:111408429	SLC16A10	0.67	5.6	0.34	5.87e-8	Blood metabolite levels;Amino acid levels;
SARC	cis	rs9914988	0.887	rs12948575	chr17:27130520	G/A	cg20469991	chr17:27169893	C17orf63	-0.5	-5.25	-0.33	3.36e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
SARC	cis	rs748404	0.650	rs518261	chr15:43573429	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	6.6	0.4	2.68e-10	Lung cancer;
SARC	cis	rs3741151	0.892	rs2027761	chr11:73036179	C/T	cg17517138	chr11:73019481	ARHGEF17	0.76	6.78	0.41	9.92e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg08975724	chr8:8085496	FLJ10661	0.58	7.82	0.46	1.8e-13	Mood instability;
SARC	cis	rs3126085	0.935	rs6587651	chr1:152193121	G/T	cg09127314	chr1:152161683	NA	0.41	4.73	0.3	3.89e-6	Atopic dermatitis;
SARC	cis	rs1062177	1.000	rs12653926	chr5:151250248	C/A	cg00977110	chr5:151150581	G3BP1	0.55	5.38	0.33	1.85e-7	Preschool internalizing problems;
SARC	cis	rs8180040	0.676	rs11130114	chr3:47154651	T/G	cg27129171	chr3:47204927	SETD2	0.67	9.52	0.53	2.39e-18	Colorectal cancer;
SARC	cis	rs7766436	0.848	rs6931450	chr6:22582076	T/C	cg13666174	chr6:22585274	NA	-0.6	-7.74	-0.45	3.04e-13	Coronary artery disease;
SARC	cis	rs2180341	0.781	rs7760652	chr6:127572096	A/G	cg24812749	chr6:127587940	RNF146	0.85	11.55	0.6	1.08e-24	Breast cancer;
SARC	cis	rs57506017	0.585	rs11509137	chr7:12263799	T/C	cg23422036	chr7:12250390	TMEM106B	0.48	6.26	0.38	1.86e-9	Neuroticism;
SARC	cis	rs473651	0.503	rs515342	chr2:239367296	A/G	cg18131467	chr2:239335373	ASB1	-0.83	-9.24	-0.52	1.57e-17	Multiple system atrophy;
SARC	cis	rs4713118	0.662	rs469228	chr6:27970704	A/G	cg17221315	chr6:27791827	HIST1H4J	0.48	4.94	0.31	1.47e-6	Parkinson's disease;
SARC	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg08219700	chr8:58056026	NA	0.49	5.07	0.32	8.11e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs4148883	0.689	rs1311621	chr4:100014018	T/C	cg13256891	chr4:100009986	ADH5	0.6	8.21	0.47	1.49e-14	Alcohol dependence;
SARC	cis	rs13191362	0.507	rs2803083	chr6:163111199	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.53	5.72	0.35	3.2e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
SARC	cis	rs9443189	0.865	rs2748940	chr6:76434027	C/T	cg01950844	chr6:76311363	SENP6	-0.69	-6.25	-0.38	1.89e-9	Prostate cancer;
SARC	trans	rs9329221	0.935	rs6601450	chr8:10243101	G/T	cg06636001	chr8:8085503	FLJ10661	0.63	8.13	0.47	2.56e-14	Neuroticism;
SARC	cis	rs1008375	1.000	rs114490726	chr4:17680898	T/C	cg27347728	chr4:17578864	LAP3	0.46	5.71	0.35	3.5e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs250677	0.522	rs4431331	chr5:148353574	A/C	cg12140854	chr5:148520817	ABLIM3	-0.4	-4.83	-0.3	2.44e-6	Breast cancer;
SARC	cis	rs10782582	0.609	rs6656501	chr1:76266126	A/C	cg10523679	chr1:76189770	ACADM	-0.4	-4.93	-0.31	1.55e-6	Daytime sleep phenotypes;
SARC	cis	rs9788682	0.747	rs2036533	chr15:78781687	G/A	cg06917634	chr15:78832804	PSMA4	-0.53	-5.45	-0.34	1.26e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
SARC	cis	rs929354	0.709	rs1182363	chr7:157019151	A/G	cg05182265	chr7:156933206	UBE3C	0.31	4.79	0.3	2.93e-6	Body mass index;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg00878827	chr14:75229987	YLPM1	0.75	6.38	0.39	9.34e-10	Autism spectrum disorder or schizophrenia;
SARC	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg14784868	chr12:69753453	YEATS4	0.51	6.7	0.4	1.57e-10	Blood protein levels;
SARC	cis	rs10489202	1.000	rs67600256	chr1:167972357	T/C	cg24449463	chr1:168025552	DCAF6	-0.64	-6.94	-0.41	3.79e-11	Schizophrenia;
SARC	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg09640425	chr7:158790006	NA	-0.39	-5.5	-0.34	9.77e-8	Facial morphology (factor 20);
SARC	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg11987759	chr7:65425863	GUSB	0.56	7.38	0.44	2.7e-12	Aortic root size;
SARC	cis	rs698833	0.852	rs2241869	chr2:44549229	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.68	-8.6	-0.49	1.16e-15	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg18876405	chr7:65276391	NA	0.69	9.05	0.51	5.93e-17	Aortic root size;
SARC	cis	rs910316	1.000	rs12879542	chr14:75507525	C/T	cg08847533	chr14:75593920	NEK9	0.95	15.59	0.71	5.27e-38	Height;
SARC	cis	rs9388451	0.626	rs3799712	chr6:126075103	A/G	cg05901451	chr6:126070800	HEY2	-0.52	-6.6	-0.4	2.68e-10	Brugada syndrome;
SARC	cis	rs7626444	0.625	rs2931210	chr3:196476676	G/C	cg12930392	chr3:196481615	PAK2	0.25	4.89	0.3	1.89e-6	Monocyte count;
SARC	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg03351412	chr1:154909251	PMVK	0.64	8.15	0.47	2.17e-14	Prostate cancer;
SARC	trans	rs3780486	0.505	rs959749	chr9:33147858	T/C	cg20290983	chr6:43655470	MRPS18A	0.91	13.15	0.65	6.3e-30	IgG glycosylation;
SARC	cis	rs2280018	0.526	rs1510148	chr16:15167379	T/A	cg27102117	chr16:15229624	NA	0.56	7.03	0.42	2.25e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	11.03	0.59	5.03e-23	Platelet count;
SARC	cis	rs6665290	0.904	rs3738729	chr1:227191227	C/T	cg14016676	chr1:227182615	CDC42BPA	0.36	5.18	0.32	4.79e-7	Myeloid white cell count;
SARC	cis	rs12586317	0.576	rs2415264	chr14:35630377	C/G	cg16230307	chr14:35515116	FAM177A1	0.46	5.84	0.36	1.74e-8	Psoriasis;
SARC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg06873352	chr17:61820015	STRADA	0.52	6.76	0.4	1.1e-10	Prudent dietary pattern;
SARC	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs1008375	0.898	rs61047804	chr4:17593965	G/A	cg16339924	chr4:17578868	LAP3	0.68	8.85	0.5	2.27e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs10214930	0.671	rs3944121	chr7:27880888	A/C	cg05786569	chr7:27702416	HIBADH	0.45	4.79	0.3	2.99e-6	Hypospadias;
SARC	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg11764359	chr7:65958608	NA	0.77	9.41	0.52	5.12e-18	Aortic root size;
SARC	cis	rs950169	1.000	rs35658069	chr15:84780146	C/T	cg24253500	chr15:84953950	NA	0.37	5.4	0.33	1.67e-7	Schizophrenia;
SARC	cis	rs2084881	0.521	rs1022088	chr17:46579790	T/A	cg04904318	chr17:46607828	HOXB1	0.35	4.84	0.3	2.34e-6	Ovarian cancer;
SARC	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg02725872	chr8:58115012	NA	-0.34	-5.41	-0.33	1.58e-7	Developmental language disorder (linguistic errors);
SARC	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg11890956	chr21:40555474	PSMG1	-1.08	-16.96	-0.74	1.43e-42	Cognitive function;
SARC	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg17376030	chr22:41985996	PMM1	0.64	8.07	0.47	3.79e-14	Vitiligo;
SARC	cis	rs4253772	0.591	rs6008595	chr22:46703860	A/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.63	5.3	0.33	2.62e-7	LDL cholesterol;Cholesterol, total;
SARC	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg11878867	chr6:150167359	LRP11	-0.35	-4.98	-0.31	1.26e-6	Lung cancer;
SARC	cis	rs6500602	0.727	rs4786516	chr16:4578641	C/T	cg02719221	chr16:3613509	NLRC3	-0.25	-4.78	-0.3	3.13e-6	Schizophrenia;
SARC	cis	rs56283067	0.887	rs12200892	chr6:44768925	T/C	cg18551225	chr6:44695536	NA	-0.37	-4.8	-0.3	2.89e-6	Total body bone mineral density;
SARC	cis	rs3820928	0.874	rs55743026	chr2:227802813	G/A	cg11843606	chr2:227700838	RHBDD1	-0.56	-7.12	-0.42	1.33e-11	Pulmonary function;
SARC	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.66	6.37	0.38	1.01e-9	Platelet count;
SARC	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg11062466	chr8:58055876	NA	0.53	5.52	0.34	8.95e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs11585357	0.947	rs11584287	chr1:17607501	G/C	cg08277548	chr1:17600880	PADI3	-0.5	-5.45	-0.34	1.3e-7	Hair shape;
SARC	cis	rs72781680	0.898	rs72786286	chr2:24074659	T/A	cg06627628	chr2:24431161	ITSN2	-0.67	-6.45	-0.39	6.22e-10	Lymphocyte counts;
SARC	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg08219700	chr8:58056026	NA	0.6	5.82	0.36	1.97e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs9326248	0.861	rs4938353	chr11:117046197	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.49	4.88	0.3	1.99e-6	Blood protein levels;
SARC	cis	rs6733011	0.578	rs1581251	chr2:99500867	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.41	-5.26	-0.33	3.34e-7	Bipolar disorder;
SARC	cis	rs4423214	1.000	rs7944926	chr11:71165625	A/G	cg05163923	chr11:71159392	DHCR7	0.64	8.48	0.49	2.66e-15	Vitamin D levels;
SARC	cis	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg00262122	chr8:11665843	FDFT1	-0.4	-4.89	-0.3	1.92e-6	Neuroticism;
SARC	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg06028808	chr11:68637592	NA	0.44	5.82	0.36	1.9e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
SARC	trans	rs10109025	0.670	rs7825690	chr8:10858257	G/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.77	-0.45	2.51e-13	Joint mobility (Beighton score);
SARC	cis	rs11697848	1.000	rs3210880	chr20:48506338	A/G	cg17849948	chr20:48532315	SPATA2	0.86	5.17	0.32	4.97e-7	Systemic lupus erythematosus;
SARC	cis	rs9399135	0.967	rs9389253	chr6:135329755	T/C	cg24558204	chr6:135376177	HBS1L	0.45	6.04	0.37	6.04e-9	Red blood cell count;
SARC	cis	rs7103648	0.742	rs34937994	chr11:47389638	C/T	cg20307385	chr11:47447363	PSMC3	0.79	11.24	0.59	1.06e-23	Diastolic blood pressure;Systolic blood pressure;
SARC	cis	rs950169	1.000	rs35648189	chr15:84740748	T/C	cg17507749	chr15:85114479	UBE2QP1	0.76	9.12	0.51	3.56e-17	Schizophrenia;
SARC	cis	rs12142240	0.731	rs12385693	chr1:46818921	A/C	cg00530320	chr1:46809349	NSUN4	0.55	6.67	0.4	1.86e-10	Menopause (age at onset);
SARC	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg05313129	chr8:58192883	C8orf71	-0.56	-6.33	-0.38	1.27e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs6964587	0.869	rs405	chr7:91546327	G/C	cg17063962	chr7:91808500	NA	-0.91	-13.29	-0.66	2.24e-30	Breast cancer;
SARC	cis	rs10992471	0.729	rs7042335	chr9:95122547	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.54	-6.62	-0.4	2.46e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
SARC	cis	rs509477	0.718	rs273348	chr18:32601632	A/C	cg23791764	chr18:32556832	MAPRE2	0.43	5.29	0.33	2.86e-7	Cerebrospinal fluid AB1-42 levels;
SARC	cis	rs986417	0.892	rs8010656	chr14:60797112	G/A	cg27398547	chr14:60952738	C14orf39	-1.06	-8.79	-0.5	3.34e-16	Gut microbiota (bacterial taxa);
SARC	cis	rs6088813	1.000	rs6087704	chr20:34001058	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	-0.45	-5.39	-0.33	1.71e-7	Height;
SARC	cis	rs7726839	0.540	rs7558	chr5:660491	C/T	cg09021430	chr5:549028	NA	-0.43	-5.57	-0.34	6.83e-8	Obesity-related traits;
SARC	cis	rs10191773	0.535	rs12477879	chr2:112969865	C/T	cg07905836	chr2:113190072	RGPD8;RGPD5	0.91	8.24	0.48	1.24e-14	Yeast infection;
SARC	cis	rs1801251	0.963	rs13021246	chr2:233623111	T/C	cg25237894	chr2:233734115	C2orf82	0.39	5.05	0.31	9.07e-7	Coronary artery disease;
SARC	cis	rs60871478	0.787	rs4720928	chr7:808002	T/C	cg05535760	chr7:792225	HEATR2	0.78	8.07	0.47	3.76e-14	Cerebrospinal P-tau181p levels;
SARC	cis	rs7208859	0.673	rs999798	chr17:29158840	A/G	cg13385521	chr17:29058706	SUZ12P	0.79	7.42	0.44	2.22e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
SARC	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg17376030	chr22:41985996	PMM1	-0.64	-8.25	-0.48	1.19e-14	Vitiligo;
SARC	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg00933542	chr6:150070202	PCMT1	0.32	5.56	0.34	7.5e-8	Lung cancer;
SARC	cis	rs7607369	0.559	rs4674342	chr2:219660064	T/C	cg02176678	chr2:219576539	TTLL4	-0.37	-5.73	-0.35	3.02e-8	Red blood cell count;Amyotrophic lateral sclerosis;
SARC	cis	rs9303401	0.527	rs12939313	chr17:56755616	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.07	10.93	0.58	1.01e-22	Cognitive test performance;
SARC	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg05368731	chr17:41323189	NBR1	0.69	8.24	0.48	1.24e-14	Menopause (age at onset);
SARC	cis	rs9916302	0.706	rs9944459	chr17:37484185	T/C	cg07936489	chr17:37558343	FBXL20	0.76	9.12	0.51	3.63e-17	Glomerular filtration rate (creatinine);
SARC	cis	rs7927771	0.832	rs10838698	chr11:47385923	G/A	cg20307385	chr11:47447363	PSMC3	0.55	6.89	0.41	5.18e-11	Subjective well-being;
SARC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg26338869	chr17:61819248	STRADA	0.8	10.72	0.57	4.8e-22	Prudent dietary pattern;
SARC	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg13699009	chr12:122356056	WDR66	0.58	9.61	0.53	1.2e-18	Mean corpuscular volume;
SARC	cis	rs950169	1.000	rs11638394	chr15:84778928	G/A	cg24253500	chr15:84953950	NA	0.38	5.5	0.34	1.01e-7	Schizophrenia;
SARC	cis	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg03060546	chr3:49711283	APEH	-0.67	-8.31	-0.48	8e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
SARC	cis	rs1707322	1.000	rs10789479	chr1:46352500	T/C	cg06784218	chr1:46089804	CCDC17	0.36	6.41	0.39	8.13e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg15448220	chr1:150897856	SETDB1	0.47	6.22	0.38	2.24e-9	Tonsillectomy;
SARC	cis	rs8114671	0.562	rs1013677	chr20:33468793	C/T	cg24642439	chr20:33292090	TP53INP2	0.49	6.17	0.37	2.93e-9	Height;
SARC	cis	rs10782582	0.609	rs76260657	chr1:76338017	C/T	cg10523679	chr1:76189770	ACADM	-0.41	-5.05	-0.31	8.87e-7	Daytime sleep phenotypes;
SARC	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.32e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs4423214	1.000	rs11606612	chr11:71164047	C/A	cg24826892	chr11:71159390	DHCR7	0.44	5.3	0.33	2.74e-7	Vitamin D levels;
SARC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.12	0.37	3.96e-9	Prudent dietary pattern;
SARC	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg22903657	chr4:1355424	KIAA1530	-0.36	-4.83	-0.3	2.44e-6	Obesity-related traits;
SARC	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg08219700	chr8:58056026	NA	0.57	5.51	0.34	9.69e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs889312	0.500	rs832580	chr5:56172646	T/C	cg14703610	chr5:56206110	C5orf35	0.54	6.77	0.41	1.04e-10	Breast cancer;Breast cancer (early onset);
SARC	cis	rs6964587	0.967	rs7788092	chr7:91646198	C/T	cg17063962	chr7:91808500	NA	0.96	16.55	0.74	3.4e-41	Breast cancer;
SARC	cis	rs2153535	0.580	rs1414346	chr6:8471574	A/G	cg07606381	chr6:8435919	SLC35B3	0.77	10.83	0.58	2.14e-22	Motion sickness;
SARC	cis	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg06212747	chr3:49208901	KLHDC8B	0.52	6.5	0.39	4.81e-10	Resting heart rate;
SARC	cis	rs17001868	0.568	rs9607702	chr22:40739177	A/G	cg07138101	chr22:40742427	ADSL	0.54	5.94	0.36	1.01e-8	Mammographic density (dense area);
SARC	cis	rs9660992	0.547	rs748012	chr1:205216573	C/T	cg00857998	chr1:205179979	DSTYK	0.5	6.2	0.38	2.49e-9	Mean corpuscular volume;Mean platelet volume;
SARC	cis	rs4642101	0.793	rs6763619	chr3:12822147	T/G	cg12400702	chr3:12838781	CAND2	-0.26	-5.1	-0.32	7.04e-7	QRS complex (12-leadsum);
SARC	cis	rs3126085	1.000	rs114304428	chr1:152254010	T/C	cg03465714	chr1:152285911	FLG	0.46	4.84	0.3	2.31e-6	Atopic dermatitis;
SARC	trans	rs11098499	0.697	rs28655325	chr4:120372999	A/G	cg25214090	chr10:38739885	LOC399744	0.56	7.4	0.44	2.44e-12	Corneal astigmatism;
SARC	cis	rs8014204	0.544	rs2286913	chr14:75386576	G/A	cg11812906	chr14:75593930	NEK9	0.47	5.21	0.32	4.07e-7	Caffeine consumption;
SARC	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg00933542	chr6:150070202	PCMT1	0.31	5.28	0.33	2.93e-7	Lung cancer;
SARC	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg13939156	chr17:80058883	NA	-0.45	-6.95	-0.41	3.55e-11	Life satisfaction;
SARC	cis	rs35110281	0.667	rs4819285	chr21:45118970	C/T	cg21573476	chr21:45109991	RRP1B	0.62	8.92	0.5	1.44e-16	Mean corpuscular volume;
SARC	cis	rs7727544	0.645	rs272857	chr5:131685297	G/A	cg24060327	chr5:131705240	SLC22A5	-0.69	-8.7	-0.5	6.07e-16	Blood metabolite levels;
SARC	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg16339924	chr4:17578868	LAP3	0.66	8.76	0.5	4e-16	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs2427308	0.607	rs1741635	chr20:60938197	C/G	cg06026331	chr20:60912101	LAMA5	-0.5	-4.77	-0.3	3.21e-6	Colorectal cancer;
SARC	cis	rs7223966	0.921	rs3020612	chr17:61960878	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.45	-4.74	-0.3	3.69e-6	Hip circumference adjusted for BMI;Body mass index;
SARC	cis	rs9549367	0.789	rs9549695	chr13:113874814	A/G	cg18105134	chr13:113819100	PROZ	0.34	4.96	0.31	1.38e-6	Platelet distribution width;
SARC	cis	rs74417235	0.684	rs13179754	chr5:154059845	C/T	cg17344516	chr5:154026930	NA	0.52	5.44	0.34	1.35e-7	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
SARC	cis	rs3087591	0.801	rs2012535	chr17:29561391	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.5	-6.08	-0.37	4.95e-9	Hip circumference;
SARC	cis	rs13034020	0.522	rs35217978	chr2:61246548	A/G	cg18625361	chr2:61244694	PEX13;PUS10	0.71	6.07	0.37	5.05e-9	Hodgkin's lymphoma;
SARC	cis	rs1355223	0.583	rs2941041	chr11:34874734	A/C	cg18508148	chr11:34937573	PDHX;APIP	0.5	6.43	0.39	7.25e-10	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.08	0.37	4.81e-9	Prudent dietary pattern;
SARC	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg03264133	chr6:25882463	NA	-0.43	-5.35	-0.33	2.14e-7	Intelligence (multi-trait analysis);
SARC	cis	rs7429990	0.965	rs7430879	chr3:48038714	C/T	cg11946769	chr3:48343235	NME6	-0.45	-5.24	-0.32	3.64e-7	Educational attainment (years of education);
SARC	cis	rs2425143	1.000	rs2425143	chr20:34350666	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-6.35	-0.38	1.1e-9	Blood protein levels;
SARC	cis	rs9790314	0.572	rs13073571	chr3:160665720	G/A	cg03342759	chr3:160939853	NMD3	0.4	4.82	0.3	2.56e-6	Morning vs. evening chronotype;
SARC	cis	rs1008375	0.897	rs2315554	chr4:17660407	T/C	cg02297831	chr4:17616191	MED28	0.46	5.73	0.35	3.11e-8	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs8114671	0.836	rs17404569	chr20:33674077	A/C	cg08999081	chr20:33150536	PIGU	-0.36	-5.04	-0.31	9.56e-7	Height;
SARC	cis	rs9650657	0.584	rs28613656	chr8:10695419	G/A	cg21775007	chr8:11205619	TDH	-0.39	-4.82	-0.3	2.58e-6	Neuroticism;
SARC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg26338869	chr17:61819248	STRADA	0.67	8.62	0.49	1.04e-15	Prudent dietary pattern;
SARC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg11494091	chr17:61959527	GH2	0.53	7.95	0.46	7.95e-14	Prudent dietary pattern;
SARC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.34	5.08	0.32	7.56e-7	Bipolar disorder;
SARC	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg00149659	chr3:10157352	C3orf10	1.05	9.86	0.54	2.19e-19	Alzheimer's disease;
SARC	cis	rs11098499	0.954	rs59866101	chr4:120296591	T/G	cg09307838	chr4:120376055	NA	0.91	12.88	0.65	4.9e-29	Corneal astigmatism;
SARC	cis	rs1348850	0.526	rs6723014	chr2:178410586	G/A	cg23306229	chr2:178417860	TTC30B	0.83	8.15	0.47	2.29e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs6582630	0.559	rs12318620	chr12:38522340	T/C	cg14851346	chr12:38532713	NA	-0.46	-5.63	-0.35	5.24e-8	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg21747090	chr2:27597821	SNX17	-0.53	-7.52	-0.44	1.14e-12	Total body bone mineral density;
SARC	cis	rs1950500	0.509	rs12882558	chr14:24819233	G/A	cg16194253	chr14:24768981	DHRS1;C14orf21	0.6	7.48	0.44	1.47e-12	Height;
SARC	trans	rs61931739	0.635	rs10772122	chr12:33964674	A/C	cg13010199	chr12:38710504	ALG10B	0.51	6.56	0.39	3.48e-10	Morning vs. evening chronotype;
SARC	cis	rs11785400	0.701	rs9721143	chr8:143727511	A/T	cg24634471	chr8:143751801	JRK	0.6	7.74	0.45	2.98e-13	Schizophrenia;
SARC	cis	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg06558623	chr16:89946397	TCF25	0.92	6.39	0.39	8.93e-10	Skin colour saturation;
SARC	trans	rs6600671	0.966	rs6600664	chr1:121222436	G/A	cg00646200	chr1:148855367	NA	0.53	7.33	0.43	3.66e-12	Hip geometry;
SARC	cis	rs7714584	1.000	rs4958852	chr5:150330631	C/T	cg22134413	chr5:150180641	NA	0.86	6.48	0.39	5.47e-10	Crohn's disease;
SARC	trans	rs4904167	0.805	rs1031790	chr14:84694347	A/G	cg26718354	chr11:2907071	CDKN1C	-0.86	-7.14	-0.42	1.16e-11	Autism spectrum disorder or schizophrenia;
SARC	cis	rs1018836	0.892	rs7819519	chr8:91565504	C/T	cg16814680	chr8:91681699	NA	-0.75	-11.5	-0.6	1.54e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs3737883	1.000	rs3737883	chr1:203034906	C/T	cg03900565	chr1:203031815	PPFIA4	-0.34	-5.2	-0.32	4.26e-7	Early onset atrial fibrillation;
SARC	cis	rs6570726	0.791	rs13202312	chr6:145913093	T/G	cg05347473	chr6:146136440	FBXO30	0.54	7.32	0.43	4.05e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg24675658	chr1:53192096	ZYG11B	-0.6	-8.45	-0.48	3.15e-15	Monocyte count;
SARC	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.42	-5.2	-0.32	4.29e-7	Tonsillectomy;
SARC	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg17376030	chr22:41985996	PMM1	0.66	7.94	0.46	8.49e-14	Vitiligo;
SARC	trans	rs12699921	0.735	rs4466298	chr7:17992014	C/T	cg00713953	chr2:220462525	STK11IP	-0.56	-6.68	-0.4	1.69e-10	Fibrinogen levels;
SARC	cis	rs1707322	0.716	rs6699444	chr1:46135120	G/C	cg03146154	chr1:46216737	IPP	0.52	6.25	0.38	1.92e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7666738	0.830	rs17486413	chr4:99060544	G/T	cg05340658	chr4:99064831	C4orf37	0.67	9.3	0.52	1.04e-17	Colonoscopy-negative controls vs population controls;
SARC	cis	rs1185460	0.565	rs540261	chr11:118947634	C/T	cg23280166	chr11:118938394	VPS11	-0.56	-7.02	-0.42	2.36e-11	Coronary artery disease;
SARC	cis	rs1008375	0.966	rs2098152	chr4:17684392	G/T	cg16339924	chr4:17578868	LAP3	0.62	8.08	0.47	3.54e-14	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs3008870	0.727	rs4582760	chr1:67464394	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.59	-7.5	-0.44	1.35e-12	Lymphocyte percentage of white cells;
SARC	cis	rs7769051	0.711	rs7758703	chr6:133085417	T/C	cg07930552	chr6:133119739	C6orf192	0.85	7.31	0.43	4.33e-12	Type 2 diabetes nephropathy;
SARC	cis	rs9790314	0.631	rs9867582	chr3:160797405	A/G	cg03342759	chr3:160939853	NMD3	-0.55	-6.94	-0.41	3.75e-11	Morning vs. evening chronotype;
SARC	trans	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg14767790	chr7:101006963	EMID2	0.49	6.52	0.39	4.21e-10	Schizophrenia;
SARC	cis	rs7100689	0.646	rs6585967	chr10:82139791	A/G	cg01528321	chr10:82214614	TSPAN14	-0.71	-9.92	-0.55	1.4e-19	Post bronchodilator FEV1;
SARC	cis	rs2235642	0.653	rs7197288	chr16:1654753	C/A	cg03715980	chr16:1756201	MAPK8IP3	0.4	4.85	0.3	2.29e-6	Coronary artery disease;
SARC	cis	rs4423214	1.000	rs4944957	chr11:71168035	C/T	cg05163923	chr11:71159392	DHCR7	-0.68	-9.52	-0.53	2.33e-18	Vitamin D levels;
SARC	trans	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg21659725	chr3:3221576	CRBN	-0.52	-6.85	-0.41	6.58e-11	Intelligence (multi-trait analysis);
SARC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.73	7.44	0.44	1.96e-12	Platelet count;
SARC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg09144098	chr16:56518581	BBS2	0.46	6.28	0.38	1.68e-9	Thyroid stimulating hormone;
SARC	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg09165964	chr15:75287851	SCAMP5	0.58	7.79	0.45	2.23e-13	Breast cancer;
SARC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg15242686	chr22:24348715	GSTTP1	0.38	4.87	0.3	2.03e-6	Liver enzyme levels (gamma-glutamyl transferase);
SARC	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg18876405	chr7:65276391	NA	-0.46	-5.54	-0.34	8.05e-8	Aortic root size;
SARC	cis	rs910316	1.000	rs3742773	chr14:75579643	A/G	cg06637938	chr14:75390232	RPS6KL1	0.52	7.24	0.43	6.33e-12	Height;
SARC	cis	rs5167	0.677	rs12709889	chr19:45453239	A/G	cg13119609	chr19:45449297	APOC2	-0.37	-5.15	-0.32	5.48e-7	Blood protein levels;
SARC	cis	rs4689388	0.926	rs4688987	chr4:6287329	C/T	cg25554036	chr4:6271136	WFS1	0.42	6.83	0.41	7.23e-11	Type 2 diabetes and other traits;Type 2 diabetes;
SARC	cis	rs9398803	0.965	rs6919397	chr6:126659043	A/C	cg19875578	chr6:126661172	C6orf173	0.57	7.7	0.45	3.77e-13	Male-pattern baldness;
SARC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg11494091	chr17:61959527	GH2	0.53	8.03	0.47	4.84e-14	Prudent dietary pattern;
SARC	cis	rs4660306	0.744	rs11583290	chr1:45926363	C/T	cg24296786	chr1:45957014	TESK2	-0.54	-5.32	-0.33	2.48e-7	Homocysteine levels;
SARC	cis	rs72945132	0.882	rs11235953	chr11:70184937	C/T	cg00319359	chr11:70116639	PPFIA1	0.7	6.64	0.4	2.23e-10	Coronary artery disease;
SARC	trans	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg21659725	chr3:3221576	CRBN	-0.81	-12.46	-0.63	1.2e-27	Intelligence (multi-trait analysis);
SARC	cis	rs9860428	0.565	rs1500879	chr3:112576011	T/C	cg17974142	chr3:113464438	ATP6V1A;NAA50	-0.38	-4.78	-0.3	3.17e-6	Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);Rheumatoid arthritis;
SARC	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.78	7.59	0.45	7.81e-13	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs1256061	0.646	rs1256059	chr14:64710417	A/G	cg23250157	chr14:64679961	SYNE2	0.5	6.98	0.42	3.07e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
SARC	trans	rs10789491	1.000	rs2218191	chr1:47130628	C/T	cg02989453	chr10:995095	NA	-0.45	-6.25	-0.38	1.95e-9	Response to hepatitis C treatment;
SARC	cis	rs80282103	0.867	rs3793781	chr10:1081293	G/T	cg08668510	chr10:1095578	IDI1	0.81	5.43	0.33	1.44e-7	Glomerular filtration rate (creatinine);
SARC	cis	rs72772090	0.710	rs11750400	chr5:96077968	A/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.57	-4.88	-0.3	1.95e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
SARC	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg12648201	chr2:27665141	KRTCAP3	-0.33	-4.96	-0.31	1.38e-6	Total body bone mineral density;
SARC	cis	rs10493773	0.775	rs12738010	chr1:86102575	A/C	cg17807903	chr1:86174739	ZNHIT6	0.55	8.48	0.49	2.64e-15	Urate levels in overweight individuals;
SARC	cis	rs4972806	0.814	rs2113560	chr2:177030986	T/C	cg14324370	chr2:177042789	NA	0.57	7.64	0.45	5.56e-13	IgG glycosylation;
SARC	cis	rs1559088	1.000	rs2161225	chr19:33551899	C/T	cg17764715	chr19:33622953	WDR88	0.48	6.25	0.38	1.96e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg08280861	chr8:58055591	NA	0.6	5.9	0.36	1.24e-8	Developmental language disorder (linguistic errors);
SARC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00712898	chr1:109235208	PRPF38B	-0.51	-6.45	-0.39	6.26e-10	Smoking initiation;
SARC	cis	rs1023500	0.507	rs6002600	chr22:42488906	G/A	cg15557168	chr22:42548783	NA	0.35	4.8	0.3	2.85e-6	Schizophrenia;
SARC	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	14.89	0.7	1.14e-35	Chronic sinus infection;
SARC	cis	rs60871478	0.704	rs62432895	chr7:822050	C/G	cg19087971	chr7:751233	PRKAR1B	-0.42	-4.72	-0.3	4.02e-6	Cerebrospinal P-tau181p levels;
SARC	cis	rs12579753	1.000	rs12811607	chr12:82233619	T/G	cg07988820	chr12:82153109	PPFIA2	-0.52	-6.07	-0.37	5.24e-9	Resting heart rate;
SARC	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg21747090	chr2:27597821	SNX17	-0.54	-7.52	-0.44	1.16e-12	Menopause (age at onset);
SARC	cis	rs6089829	0.962	rs1116450	chr20:61658210	T/C	cg03213289	chr20:61660250	NA	0.45	6.07	0.37	5.27e-9	Prostate cancer (SNP x SNP interaction);
SARC	cis	rs4148883	0.675	rs10015824	chr4:100074544	C/G	cg13256891	chr4:100009986	ADH5	0.57	7.74	0.45	2.93e-13	Alcohol dependence;
SARC	cis	rs2070488	0.775	rs762318	chr3:38516369	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	12.36	0.63	2.54e-27	Electrocardiographic conduction measures;
SARC	cis	rs763121	0.853	rs8138996	chr22:39047435	G/T	cg06022373	chr22:39101656	GTPBP1	0.9	11.56	0.6	9.96e-25	Menopause (age at onset);
SARC	cis	rs6690583	0.524	rs12029690	chr1:85452867	C/G	cg22153463	chr1:85462885	MCOLN2	0.72	6.96	0.42	3.33e-11	Serum sulfate level;
SARC	cis	rs6582630	0.519	rs11609739	chr12:38547969	G/A	cg26384229	chr12:38710491	ALG10B	0.89	13.03	0.65	1.56e-29	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs7666738	0.791	rs1115615	chr4:99006614	G/A	cg05340658	chr4:99064831	C4orf37	0.64	8.6	0.49	1.18e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs9581857	0.556	rs9579085	chr13:28041039	G/A	cg01674679	chr13:27998804	GTF3A	-0.59	-5.87	-0.36	1.5e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
SARC	cis	rs12142240	0.698	rs72886911	chr1:46814352	G/A	cg10495392	chr1:46806563	NSUN4	0.65	6.83	0.41	7.25e-11	Menopause (age at onset);
SARC	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg21171335	chr12:122356390	WDR66	0.41	6.58	0.4	3.14e-10	Mean corpuscular volume;
SARC	trans	rs11165623	0.564	rs7523597	chr1:97000989	A/G	cg10631902	chr5:14652156	NA	-0.43	-6.54	-0.39	3.89e-10	Hip circumference;Waist circumference;
SARC	trans	rs2727020	0.521	rs7131163	chr11:49574774	C/T	cg03929089	chr4:120376271	NA	-0.68	-7.44	-0.44	1.92e-12	Coronary artery disease;
SARC	cis	rs2916247	1.000	rs13250170	chr8:93035331	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.57	-6.07	-0.37	5.27e-9	Intelligence (multi-trait analysis);
SARC	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	16.23	0.73	3.75e-40	Height;
SARC	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg07701084	chr6:150067640	NUP43	0.41	5.39	0.33	1.75e-7	Lung cancer;
SARC	cis	rs9818758	0.607	rs73082362	chr3:49113729	C/T	cg01304814	chr3:48885189	PRKAR2A	0.81	6.16	0.37	3.09e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
SARC	cis	rs11155671	0.530	rs9383577	chr6:150207195	C/T	cg05036130	chr6:150231994	NA	0.29	5.05	0.31	8.9e-7	Testicular germ cell tumor;
SARC	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg19671926	chr4:122722719	EXOSC9	-0.6	-6.7	-0.4	1.51e-10	Type 2 diabetes;
SARC	cis	rs6570726	0.791	rs11155432	chr6:145898761	T/C	cg23711669	chr6:146136114	FBXO30	0.83	13.94	0.67	1.53e-32	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs11098699	0.784	rs13114897	chr4:124247406	T/A	cg09941581	chr4:124220074	SPATA5	0.37	4.82	0.3	2.61e-6	Mosquito bite size;
SARC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg17468841	chr3:105588020	CBLB	-0.53	-7.01	-0.42	2.61e-11	Electrocardiographic conduction measures;
SARC	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg15836711	chr11:111944993	C11orf57;PIH1D2	0.54	6.95	0.41	3.64e-11	Lung adenocarcinoma;
SARC	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg11764359	chr7:65958608	NA	0.86	12.33	0.63	3.29e-27	Aortic root size;
SARC	cis	rs11792861	0.816	rs11790105	chr9:111731785	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.74	8.96	0.51	1.05e-16	Menarche (age at onset);
SARC	cis	rs1153858	1.000	rs10519022	chr15:45663684	C/T	cg03999130	chr15:45571217	NA	-0.4	-5.09	-0.32	7.36e-7	Homoarginine levels;
SARC	cis	rs6964587	1.000	rs416	chr7:91580571	A/G	cg17063962	chr7:91808500	NA	-0.93	-14.95	-0.7	6.9e-36	Breast cancer;
SARC	cis	rs240764	0.817	rs240164	chr6:101044487	T/A	cg09795085	chr6:101329169	ASCC3	0.47	6.16	0.37	3.16e-9	Neuroticism;
SARC	cis	rs9326248	0.581	rs10892048	chr11:116814596	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.61	7.73	0.45	3.21e-13	Blood protein levels;
SARC	cis	rs1707322	1.000	rs6661500	chr1:46465662	T/C	cg03146154	chr1:46216737	IPP	0.46	5.57	0.34	7.08e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs3617	0.625	rs7620690	chr3:52891707	A/G	cg18404041	chr3:52824283	ITIH1	0.38	5.42	0.33	1.51e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
SARC	cis	rs9916302	0.706	rs11078894	chr17:37396805	C/G	cg00129232	chr17:37814104	STARD3	-0.61	-6.45	-0.39	6.45e-10	Glomerular filtration rate (creatinine);
SARC	cis	rs17384381	0.834	rs11161614	chr1:85898160	A/C	cg16011679	chr1:85725395	C1orf52	0.54	5.56	0.34	7.42e-8	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs6912958	0.559	rs183599	chr6:88061024	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.36	6.44	0.39	6.73e-10	Monocyte percentage of white cells;
SARC	cis	rs1832871	0.683	rs62437360	chr6:158720162	G/A	cg07165851	chr6:158734300	TULP4	0.54	6.51	0.39	4.65e-10	Height;
SARC	cis	rs9303280	0.837	rs907092	chr17:37922259	A/G	cg20243544	chr17:37824526	PNMT	-0.46	-5.96	-0.36	9.02e-9	Self-reported allergy;
SARC	cis	rs11098499	0.820	rs6534140	chr4:120455311	C/T	cg24375607	chr4:120327624	NA	0.42	4.9	0.31	1.76e-6	Corneal astigmatism;
SARC	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg01181863	chr3:195395398	SDHAP2	-0.58	-6.5	-0.39	4.9e-10	Pancreatic cancer;
SARC	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg22535103	chr8:58192502	C8orf71	-0.78	-9.14	-0.51	3.2e-17	Developmental language disorder (linguistic errors);
SARC	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg16606324	chr3:10149918	C3orf24	0.49	5.04	0.31	9.35e-7	Alzheimer's disease;
SARC	cis	rs1355223	0.902	rs7130325	chr11:34750959	A/G	cg18508148	chr11:34937573	PDHX;APIP	-0.4	-5.07	-0.32	8.17e-7	Systemic lupus erythematosus and Systemic sclerosis;
SARC	cis	rs4975616	0.869	rs452384	chr5:1330840	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.55	-7.53	-0.44	1.12e-12	Lung cancer;
SARC	cis	rs796364	0.806	rs6743396	chr2:200860138	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.71	6.07	0.37	5.18e-9	Schizophrenia;
SARC	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	8.93	0.51	1.27e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs9911578	0.967	rs2643124	chr17:56741672	T/C	cg12560992	chr17:57184187	TRIM37	0.82	11.05	0.59	4.21e-23	Intelligence (multi-trait analysis);
SARC	cis	rs2075371	1.000	rs2075373	chr7:133984683	A/C	cg00033643	chr7:134001901	SLC35B4	0.39	4.77	0.3	3.25e-6	Mean platelet volume;
SARC	cis	rs79976124	0.837	rs12201218	chr6:66653619	C/T	cg07460842	chr6:66804631	NA	-0.64	-7.25	-0.43	5.95e-12	Type 2 diabetes;
SARC	cis	rs208520	1.000	rs28773210	chr6:66993566	C/T	cg07460842	chr6:66804631	NA	0.9	10.25	0.56	1.39e-20	Exhaled nitric oxide output;
SARC	cis	rs7312933	0.510	rs1907705	chr12:42451122	T/A	cg01256987	chr12:42539512	GXYLT1	-0.41	-6.07	-0.37	5.1e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
SARC	cis	rs10849893	0.557	rs10849890	chr12:121902725	T/C	cg01154721	chr12:121881891	KDM2B	-0.37	-5.13	-0.32	6.21e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
SARC	cis	rs9790314	0.812	rs2004862	chr3:161135638	C/T	cg17135325	chr3:160939158	NMD3	0.39	4.78	0.3	3.12e-6	Morning vs. evening chronotype;
SARC	cis	rs2204008	0.536	rs12368354	chr12:38042798	G/A	cg13010199	chr12:38710504	ALG10B	0.78	10.69	0.57	5.8e-22	Bladder cancer;
SARC	cis	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg18252515	chr7:66147081	NA	-1.41	-12.93	-0.65	3.5e-29	Diabetic kidney disease;
SARC	cis	rs995000	0.931	rs1168020	chr1:63009956	C/T	cg06896770	chr1:63153194	DOCK7	-0.89	-13.16	-0.65	6e-30	Triglyceride levels;
SARC	cis	rs17376456	0.877	rs10072592	chr5:93405989	C/G	cg21475434	chr5:93447410	FAM172A	0.85	7.5	0.44	1.34e-12	Diabetic retinopathy;
SARC	cis	rs2153535	0.580	rs1577467	chr6:8444241	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	8.27	0.48	1.05e-14	Motion sickness;
SARC	cis	rs17666538	0.585	rs6559065	chr8:623156	G/C	cg02524346	chr8:600233	NA	0.7	5.84	0.36	1.74e-8	IgG glycosylation;
SARC	cis	rs7572733	0.576	rs1368989	chr2:198937082	T/C	cg00792783	chr2:198669748	PLCL1	0.43	4.87	0.3	2.1e-6	Dermatomyositis;
SARC	cis	rs818427	0.896	rs818429	chr5:112220534	T/C	cg07820702	chr5:112228657	REEP5	-0.51	-5.86	-0.36	1.56e-8	Total body bone mineral density;
SARC	cis	rs2916247	0.954	rs11782927	chr8:93045726	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.59	-6.03	-0.37	6.24e-9	Intelligence (multi-trait analysis);
SARC	cis	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg25427524	chr10:38739819	LOC399744	-0.53	-8.44	-0.48	3.37e-15	Extrinsic epigenetic age acceleration;
SARC	trans	rs61931739	0.500	rs7311302	chr12:34557211	T/C	cg13010199	chr12:38710504	ALG10B	0.78	11.09	0.59	3.19e-23	Morning vs. evening chronotype;
SARC	cis	rs72781680	0.821	rs1022346	chr2:24127849	T/C	cg06627628	chr2:24431161	ITSN2	-0.54	-5.74	-0.35	2.9e-8	Lymphocyte counts;
SARC	cis	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg25427524	chr10:38739819	LOC399744	-0.53	-8.46	-0.48	2.95e-15	Extrinsic epigenetic age acceleration;
SARC	cis	rs6060717	0.536	rs3829829	chr20:34537160	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-5.62	-0.35	5.53e-8	Hip circumference adjusted for BMI;
SARC	cis	rs4690686	0.500	rs2168032	chr4:177272957	A/G	cg17059388	chr4:177262070	NA	0.37	4.91	0.31	1.74e-6	Essential tremor;
SARC	cis	rs12142240	0.698	rs72677587	chr1:46813982	G/A	cg14993813	chr1:46806288	NSUN4	-0.52	-5.46	-0.34	1.22e-7	Menopause (age at onset);
SARC	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg09699651	chr6:150184138	LRP11	0.39	4.97	0.31	1.32e-6	Lung cancer;
SARC	cis	rs10465746	0.747	rs1952066	chr1:84436456	T/C	cg10977910	chr1:84465055	TTLL7	0.43	5.28	0.33	2.91e-7	Obesity-related traits;
SARC	cis	rs2180341	1.000	rs2144743	chr6:127633810	A/T	cg27446573	chr6:127587934	RNF146	1.02	14.46	0.69	2.89e-34	Breast cancer;
SARC	cis	rs9457247	0.967	rs1590257	chr6:167377782	G/T	cg23791538	chr6:167370224	RNASET2	0.63	8.74	0.5	4.81e-16	Crohn's disease;
SARC	cis	rs11625487	0.609	rs74063206	chr14:77981045	C/T	cg16049707	chr14:77965284	ISM2	-0.74	-5.31	-0.33	2.6e-7	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
SARC	cis	rs6582630	0.638	rs12425531	chr12:38550387	A/G	cg26384229	chr12:38710491	ALG10B	-0.59	-7.47	-0.44	1.64e-12	Drug-induced liver injury (flucloxacillin);
SARC	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.8	-11.54	-0.6	1.15e-24	Total body bone mineral density;
SARC	cis	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg12463550	chr7:65579703	CRCP	0.71	5.32	0.33	2.41e-7	Diabetic kidney disease;
SARC	cis	rs4972806	0.849	rs2113561	chr2:177030925	G/A	cg13092806	chr2:177043255	NA	0.38	4.93	0.31	1.54e-6	IgG glycosylation;
SARC	cis	rs4144743	0.938	rs35069360	chr17:45321270	C/T	cg18085866	chr17:45331354	ITGB3	-0.73	-7.35	-0.43	3.42e-12	Body mass index;
SARC	cis	rs6570726	0.791	rs401561	chr6:145835917	G/T	cg05347473	chr6:146136440	FBXO30	0.53	7.29	0.43	4.79e-12	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs3812831	0.695	rs6560935	chr13:114945867	G/A	cg06611532	chr13:114900021	NA	0.34	5.99	0.37	8.11e-9	Schizophrenia;
SARC	trans	rs7980799	0.682	rs1351682	chr12:33598775	G/A	cg26384229	chr12:38710491	ALG10B	-0.61	-7.56	-0.44	9.42e-13	Heart rate;Heart rate variability traits (RMSSD);
SARC	cis	rs8070128	0.637	rs4925133	chr17:17884801	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	10.57	0.57	1.34e-21	Total body bone mineral density;
SARC	cis	rs62408225	0.722	rs3734660	chr6:90916345	A/G	cg06866423	chr6:90926672	BACH2	0.33	5.37	0.33	1.93e-7	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
SARC	cis	rs7552404	0.545	rs12748741	chr1:76351193	A/G	cg03433033	chr1:76189801	ACADM	-0.43	-5.52	-0.34	8.85e-8	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs7582180	0.629	rs6731549	chr2:100939937	T/G	cg14675211	chr2:100938903	LONRF2	0.51	7.68	0.45	4.44e-13	Intelligence (multi-trait analysis);
SARC	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.57	-7.39	-0.44	2.59e-12	Mean platelet volume;
SARC	cis	rs9372253	0.967	rs1055301	chr6:110713042	A/G	cg00083206	chr6:110721305	DDO	-0.37	-4.8	-0.3	2.88e-6	Platelet distribution width;
SARC	cis	rs13082711	0.554	rs35840701	chr3:27334231	A/C	cg02860705	chr3:27208620	NA	0.66	7.98	0.46	6.45e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs6540556	0.654	rs6540549	chr1:209922668	G/T	cg23920097	chr1:209922102	NA	0.45	5.58	0.34	6.52e-8	Red blood cell count;
SARC	cis	rs763121	0.853	rs8138996	chr22:39047435	G/T	cg21395723	chr22:39101663	GTPBP1	0.58	6.67	0.4	1.85e-10	Menopause (age at onset);
SARC	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg23758822	chr17:41437982	NA	0.86	10.56	0.57	1.52e-21	Menopause (age at onset);
SARC	cis	rs17666538	1.000	rs73177066	chr8:585750	C/T	cg07685180	chr8:600429	NA	-0.8	-6.13	-0.37	3.67e-9	IgG glycosylation;
SARC	cis	rs870825	0.616	rs6844588	chr4:185644517	T/G	cg04058563	chr4:185651563	MLF1IP	0.8	11.35	0.6	4.56e-24	Blood protein levels;
SARC	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg24549020	chr5:56110836	MAP3K1	0.54	5.93	0.36	1.1e-8	Coronary artery disease;
SARC	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg16606324	chr3:10149918	C3orf24	0.48	4.75	0.3	3.56e-6	Alzheimer's disease;
SARC	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg03999130	chr15:45571217	NA	-0.39	-5.11	-0.32	6.81e-7	Homoarginine levels;
SARC	cis	rs6976053	0.518	rs314357	chr7:100410069	A/G	cg03098644	chr7:100410630	EPHB4	-0.47	-6.64	-0.4	2.17e-10	Plasminogen activator inhibitor type 1 levels (PAI-1);
SARC	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg03351412	chr1:154909251	PMVK	0.65	8.39	0.48	4.69e-15	Prostate cancer;
SARC	cis	rs3126085	0.935	rs10888470	chr1:152200472	T/C	cg03465714	chr1:152285911	FLG	-0.44	-5.3	-0.33	2.67e-7	Atopic dermatitis;
SARC	cis	rs2270431	1	rs2270431	chr14:75270635	T/C	cg06637938	chr14:75390232	RPS6KL1	0.41	5.03	0.31	9.9e-7	Neuroticism;
SARC	cis	rs17854409	1.000	rs66634465	chr20:61482306	C/T	cg05147244	chr20:61493195	TCFL5	0.96	6.5	0.39	4.94e-10	Obesity-related traits;
SARC	cis	rs2438150	1	rs2438150	chr5:122199196	C/T	cg19412675	chr5:122181750	SNX24	0.42	5.52	0.34	8.83e-8	Plateletcrit;
SARC	cis	rs1008375	1.000	rs11724495	chr4:17621310	G/A	cg16339924	chr4:17578868	LAP3	0.66	8.59	0.49	1.27e-15	Parasitemia in Tripanosoma cruzi seropositivity;
SARC	cis	rs17376456	0.877	rs12374463	chr5:93483569	C/G	cg21475434	chr5:93447410	FAM172A	0.89	7.46	0.44	1.7e-12	Diabetic retinopathy;
SARC	cis	rs4660306	0.961	rs4660868	chr1:45986497	A/G	cg24296786	chr1:45957014	TESK2	0.58	6.79	0.41	9.22e-11	Homocysteine levels;
SARC	cis	rs698833	0.926	rs786419	chr2:44685153	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	6.74	0.4	1.23e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
SARC	cis	rs12142240	0.698	rs72677589	chr1:46817770	T/C	cg00530320	chr1:46809349	NSUN4	0.57	6.89	0.41	5.25e-11	Menopause (age at onset);
SARC	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg13206674	chr6:150067644	NUP43	0.4	4.84	0.3	2.32e-6	Lung cancer;
SARC	cis	rs7833790	0.636	rs12544174	chr8:82731477	G/A	cg06027949	chr8:82754900	SNX16	-0.48	-6.1	-0.37	4.28e-9	Diastolic blood pressure;
SARC	cis	rs11910985	1.000	rs11910985	chr21:48042766	C/T	cg17243659	chr21:48055224	PRMT2	0.8	4.82	0.3	2.65e-6	Cerebrospinal fluid t-tau:AB1-42 ratio;
SARC	cis	rs986417	0.786	rs2038277	chr14:61083662	G/A	cg27398547	chr14:60952738	C14orf39	0.88	7.58	0.44	8.35e-13	Gut microbiota (bacterial taxa);
SARC	cis	rs2221894	0.506	rs11778263	chr8:28825422	C/G	cg07962641	chr8:28805897	HMBOX1	0.75	7.47	0.44	1.61e-12	Obesity-related traits;
SARC	cis	rs2354432	0.882	rs11576360	chr1:146740576	G/A	cg25205988	chr1:146714368	CHD1L	1.06	12.14	0.62	1.33e-26	Mitochondrial DNA levels;
SARC	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg11890956	chr21:40555474	PSMG1	-1.05	-15.24	-0.71	7.56e-37	Cognitive function;
SARC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg12016809	chr21:47604291	C21orf56	-0.47	-5.56	-0.34	7.54e-8	Testicular germ cell tumor;
SARC	cis	rs12142240	0.698	rs66483119	chr1:46838389	T/C	cg00530320	chr1:46809349	NSUN4	0.57	7.0	0.42	2.74e-11	Menopause (age at onset);
SARC	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg11878867	chr6:150167359	LRP11	-0.36	-4.84	-0.3	2.39e-6	Lung cancer;
SARC	cis	rs634534	0.563	rs470192	chr11:65724291	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.81	11.96	0.62	5.22e-26	Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg22535103	chr8:58192502	C8orf71	-0.58	-6.15	-0.37	3.33e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs12291225	0.535	rs12806025	chr11:14413817	G/A	cg19336497	chr11:14380999	RRAS2	-0.32	-5.5	-0.34	9.75e-8	Sense of smell;
SARC	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg22875332	chr1:76189707	ACADM	0.5	7.17	0.42	1.01e-11	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs10876993	0.680	rs2277322	chr12:58009202	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.43	5.18	0.32	4.85e-7	Celiac disease or Rheumatoid arthritis;
SARC	cis	rs16976116	0.806	rs117064453	chr15:55492319	T/A	cg17854078	chr15:55489399	RSL24D1	0.69	6.65	0.4	2.07e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
SARC	cis	rs2635047	0.967	rs2576060	chr18:44637106	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.6	-7.91	-0.46	1.01e-13	Educational attainment;
SARC	cis	rs1865760	0.566	rs9379821	chr6:26054268	A/C	cg17691542	chr6:26056736	HIST1H1C	0.54	6.71	0.4	1.48e-10	Height;
SARC	cis	rs965469	1.000	rs6037533	chr20:3268817	T/C	cg25506879	chr20:3388711	C20orf194	-0.47	-4.76	-0.3	3.42e-6	IFN-related cytopenia;
SARC	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg20607798	chr8:58055168	NA	0.61	5.53	0.34	8.72e-8	Developmental language disorder (linguistic errors);
SARC	cis	rs854765	0.583	rs4257260	chr17:17857003	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.43	5.52	0.34	9.04e-8	Total body bone mineral density;
SARC	cis	rs6430585	0.528	rs309154	chr2:136726567	C/T	cg07169764	chr2:136633963	MCM6	0.94	12.48	0.63	1.06e-27	Corneal structure;
SARC	cis	rs11690935	0.571	rs13020884	chr2:172901699	T/G	cg13550731	chr2:172543902	DYNC1I2	0.57	7.56	0.44	9.42e-13	Schizophrenia;
SARC	cis	rs6912958	0.703	rs9362427	chr6:88097634	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.74	11.02	0.59	5.35e-23	Monocyte percentage of white cells;
SARC	cis	rs3820928	0.605	rs2228555	chr2:227872995	C/T	cg11843606	chr2:227700838	RHBDD1	0.5	6.5	0.39	4.94e-10	Pulmonary function;
SARC	trans	rs561341	0.825	rs2008368	chr17:30347397	T/C	cg20587970	chr11:113659929	NA	-1.26	-13.1	-0.65	9.33e-30	Hip circumference adjusted for BMI;
SARC	cis	rs2073499	1.000	rs6776145	chr3:50316119	C/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.55	-5.08	-0.32	7.69e-7	Schizophrenia;
SARC	cis	rs3741151	0.773	rs7925226	chr11:73137362	A/G	cg17517138	chr11:73019481	ARHGEF17	0.91	6.77	0.41	1.04e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
SARC	cis	rs6676180	0.555	rs871665	chr1:119772663	C/T	cg05756136	chr1:119680316	WARS2	-0.37	-4.91	-0.31	1.73e-6	Monobrow;
SARC	cis	rs6570726	0.935	rs409121	chr6:145839793	G/A	cg05347473	chr6:146136440	FBXO30	0.48	6.42	0.39	7.51e-10	Lobe attachment (rater-scored or self-reported);
SARC	cis	rs57561814	1.000	rs57561814	chr7:22753675	G/C	cg01770232	chr7:22766155	IL6	0.63	4.98	0.31	1.25e-6	Tonsillectomy;
SARC	cis	rs6500395	1.000	rs1872655	chr16:48670883	A/C	cg04672837	chr16:48644449	N4BP1	0.47	6.24	0.38	2.05e-9	Response to tocilizumab in rheumatoid arthritis;
SARC	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg19223190	chr17:80058835	NA	-0.39	-5.25	-0.33	3.41e-7	Life satisfaction;
SARC	trans	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg21659725	chr3:3221576	CRBN	0.55	6.28	0.38	1.63e-9	Resting heart rate;
SARC	cis	rs807669	0.903	rs2854643	chr22:19189706	T/C	cg02655711	chr22:19163373	SLC25A1	0.53	7.34	0.43	3.48e-12	Metabolite levels;
SARC	cis	rs1707322	0.691	rs61784803	chr1:46179271	C/A	cg03146154	chr1:46216737	IPP	-0.53	-6.35	-0.38	1.12e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs7592578	0.508	rs10931451	chr2:191270888	G/A	cg25963032	chr2:191064776	C2orf88	-0.48	-5.66	-0.35	4.52e-8	Diastolic blood pressure;
SARC	cis	rs10927875	0.722	rs6696912	chr1:16338474	T/C	cg21385522	chr1:16154831	NA	0.71	9.12	0.51	3.56e-17	Dilated cardiomyopathy;
SARC	trans	rs9638182	0.623	rs13246490	chr7:72992350	C/T	cg21138935	chr8:25458389	NA	0.57	6.23	0.38	2.13e-9	Triglycerides;
SARC	cis	rs1318878	0.565	rs12306807	chr12:15472354	C/T	cg08258403	chr12:15378311	NA	0.47	6.71	0.4	1.49e-10	Intelligence (multi-trait analysis);
SARC	cis	rs5758511	0.680	rs5751243	chr22:42617177	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.45	6.83	0.41	7.41e-11	Birth weight;
SARC	cis	rs2070677	1.000	rs1329149	chr10:135349801	T/C	cg20169779	chr10:135381914	SYCE1	0.45	5.78	0.35	2.39e-8	Gout;
SARC	cis	rs7113874	0.613	rs2100067	chr11:8537050	T/C	cg09828998	chr11:8703972	RPL27A	0.5	5.45	0.34	1.31e-7	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
SARC	cis	rs1371867	0.846	rs1660346	chr8:101312497	A/G	cg11906718	chr8:101322791	RNF19A	0.71	9.02	0.51	7.17e-17	Atrioventricular conduction;
SARC	cis	rs950776	0.518	rs8025429	chr15:78836362	G/A	cg06917634	chr15:78832804	PSMA4	-0.9	-13.86	-0.67	2.98e-32	Sudden cardiac arrest;
SARC	cis	rs2228479	0.717	rs1007932	chr16:89838541	C/T	cg06558623	chr16:89946397	TCF25	0.91	7.26	0.43	5.7e-12	Skin colour saturation;
SARC	cis	rs6952809	0.532	rs2023969	chr7:2449980	T/C	cg23289794	chr7:2394357	EIF3B	-0.66	-6.24	-0.38	2.1e-9	Multiple sclerosis;
SARC	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-6.44	-0.39	6.8e-10	Bipolar disorder;
SARC	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-5.96	-0.36	9.37e-9	Developmental language disorder (linguistic errors);
SARC	cis	rs12579753	0.797	rs1922561	chr12:82152640	C/A	cg07988820	chr12:82153109	PPFIA2	-0.6	-7.08	-0.42	1.71e-11	Resting heart rate;
SARC	cis	rs4423214	1.000	rs4944955	chr11:71167677	C/T	cg05163923	chr11:71159392	DHCR7	0.68	9.39	0.52	5.59e-18	Vitamin D levels;
SARC	cis	rs1580019	0.665	rs34147895	chr7:32531796	G/C	cg14728415	chr7:32535168	LSM5;AVL9	0.5	6.13	0.37	3.8e-9	Cognitive ability;
SARC	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg19901468	chr14:105411992	AHNAK2	-0.73	-10.79	-0.58	2.74e-22	Rheumatoid arthritis;
SARC	cis	rs7662987	0.517	rs1154410	chr4:100006645	A/G	cg13256891	chr4:100009986	ADH5	0.7	8.95	0.51	1.11e-16	Smoking initiation;
SARC	cis	rs12956009	0.583	rs919979	chr18:44902739	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	7.64	0.45	5.7e-13	Educational attainment (years of education);
SARC	cis	rs67311347	1.000	rs1466236	chr3:40462162	C/T	cg09455208	chr3:40491958	NA	0.43	6.88	0.41	5.44e-11	Renal cell carcinoma;
SARC	cis	rs11697848	1.000	rs34802008	chr20:48528349	G/A	cg17849948	chr20:48532315	SPATA2	0.87	5.2	0.32	4.3e-7	Systemic lupus erythematosus;
SARC	trans	rs7963521	1.000	rs7310801	chr12:73801875	A/T	cg10592336	chr4:68567069	LOC550112;UBA6	-0.48	-6.42	-0.39	7.7e-10	Chemerin levels;
SARC	cis	rs763121	0.853	rs3827357	chr22:39079413	A/G	cg06022373	chr22:39101656	GTPBP1	0.84	10.32	0.56	8.51e-21	Menopause (age at onset);
SARC	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.5	4.73	0.3	3.89e-6	Age-related macular degeneration (geographic atrophy);
SARC	cis	rs4595586	0.545	rs1303887	chr12:39366523	C/T	cg13010199	chr12:38710504	ALG10B	0.4	4.75	0.3	3.57e-6	Morning vs. evening chronotype;
SARC	cis	rs2066819	1.000	rs2629447	chr12:56700809	G/A	cg26316697	chr12:56727976	PAN2	-0.9	-6.37	-0.39	9.89e-10	Psoriasis vulgaris;
SARC	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	5.12	0.32	6.52e-7	Personality dimensions;
SARC	cis	rs7666738	0.830	rs1534318	chr4:98965058	C/T	cg05340658	chr4:99064831	C4orf37	0.64	8.59	0.49	1.22e-15	Colonoscopy-negative controls vs population controls;
SARC	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg01475735	chr3:40494733	NA	0.44	5.07	0.32	8e-7	Renal cell carcinoma;
SARC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg21782813	chr7:2030301	MAD1L1	-0.4	-6.37	-0.38	1.02e-9	Bipolar disorder and schizophrenia;
SARC	cis	rs1865760	0.602	rs9467662	chr6:26021327	G/A	cg10373733	chr6:25993375	NA	0.42	5.07	0.32	7.94e-7	Height;
SARC	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg04287289	chr16:89883240	FANCA	0.84	14.61	0.69	9.49e-35	Vitiligo;
SARC	cis	rs1018836	0.608	rs2142147	chr8:91468200	A/G	cg16814680	chr8:91681699	NA	-0.65	-9.21	-0.52	2.02e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
SARC	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg18758796	chr5:131593413	PDLIM4	0.37	4.75	0.3	3.63e-6	Acylcarnitine levels;
SARC	cis	rs1144333	0.655	rs76175698	chr1:76454792	C/T	cg03433033	chr1:76189801	ACADM	0.61	4.9	0.31	1.77e-6	Attention function in attention deficit hyperactive disorder;
SARC	cis	rs611744	0.967	rs636904	chr8:109197565	T/C	cg21045802	chr8:109455806	TTC35	0.42	4.98	0.31	1.24e-6	Dupuytren's disease;
SARC	cis	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg11266682	chr4:10021025	SLC2A9	0.4	7.18	0.43	9.35e-12	Bone mineral density;
SARC	cis	rs838147	0.507	rs1704773	chr19:49209566	A/G	cg21064579	chr19:49206444	FUT2	0.34	4.83	0.3	2.44e-6	Dietary macronutrient intake;
SARC	cis	rs2070488	1.000	rs7373805	chr3:38455439	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	14.45	0.69	3.18e-34	Electrocardiographic conduction measures;
SARC	cis	rs12421382	0.659	rs1866530	chr11:109380899	T/A	cg27471124	chr11:109292789	C11orf87	0.36	5.04	0.31	9.21e-7	Schizophrenia;
SARC	cis	rs644799	0.710	rs10831433	chr11:95519787	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.6	7.94	0.46	8.6e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
SARC	cis	rs752010	0.714	rs2182606	chr1:42082375	T/C	cg06885757	chr1:42089581	HIVEP3	0.41	6.33	0.38	1.27e-9	Lupus nephritis in systemic lupus erythematosus;
SARC	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg16479474	chr6:28041457	NA	0.36	5.45	0.34	1.25e-7	Depression;
SARC	cis	rs9815354	1.000	rs9847975	chr3:41786904	A/G	cg03022575	chr3:42003672	ULK4	0.68	6.04	0.37	6.09e-9	Pulse pressure;Diastolic blood pressure;
SARC	cis	rs6964587	0.610	rs6942852	chr7:91437883	A/C	cg17063962	chr7:91808500	NA	0.69	9.61	0.53	1.23e-18	Breast cancer;
SARC	cis	rs6598955	0.724	rs10902731	chr1:26600793	A/G	cg04990556	chr1:26633338	UBXN11	-0.59	-8.09	-0.47	3.32e-14	Obesity-related traits;
SARC	cis	rs13082711	0.911	rs13097178	chr3:27527920	T/C	cg02860705	chr3:27208620	NA	0.42	5.37	0.33	1.88e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
SARC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg18428193	chr2:27665017	KRTCAP3;NRBP1	-0.33	-4.93	-0.31	1.59e-6	Total body bone mineral density;
SARC	cis	rs9916302	0.800	rs8081220	chr17:37473157	A/C	cg20243544	chr17:37824526	PNMT	-0.58	-7.17	-0.43	9.77e-12	Glomerular filtration rate (creatinine);
SARC	cis	rs73086581	0.645	rs2103659	chr20:3982572	C/T	cg02187196	chr20:3869020	PANK2	-0.45	-4.99	-0.31	1.2e-6	Response to antidepressants in depression;
SARC	cis	rs5753618	0.539	rs4820962	chr22:31689951	A/G	cg00478049	chr22:31556069	RNF185	0.47	4.98	0.31	1.24e-6	Colorectal cancer;
SARC	cis	rs9910055	0.530	rs11652651	chr17:42302907	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.45	-5.98	-0.36	8.2e-9	Total body bone mineral density;
SARC	cis	rs4853036	0.672	rs6546549	chr2:70030469	C/G	cg02498382	chr2:70120550	SNRNP27	-0.36	-4.97	-0.31	1.28e-6	Colorectal or endometrial cancer;
SARC	cis	rs113835537	0.597	rs11227527	chr11:66313026	A/G	cg24851651	chr11:66362959	CCS	0.38	4.73	0.3	3.97e-6	Airway imaging phenotypes;
SARC	cis	rs1044826	0.642	rs4607068	chr3:139162994	A/G	cg15131784	chr3:139108705	COPB2	0.39	4.93	0.31	1.58e-6	Obesity-related traits;
SARC	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg11890956	chr21:40555474	PSMG1	1.17	19.37	0.79	1.93e-50	Cognitive function;
SARC	cis	rs7481584	0.646	rs434114	chr11:3050210	A/G	cg25174290	chr11:3078921	CARS	-0.6	-8.35	-0.48	6.26e-15	Calcium levels;
SARC	cis	rs7412746	0.566	rs2864871	chr1:150766964	T/C	cg10589385	chr1:150898437	SETDB1	0.39	5.07	0.32	8.12e-7	Melanoma;
SARC	cis	rs9486719	0.895	rs3734238	chr6:96996228	A/T	cg06623918	chr6:96969491	KIAA0776	-0.79	-8.63	-0.49	9.42e-16	Migraine;Coronary artery disease;
SARC	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg08975724	chr8:8085496	FLJ10661	0.67	8.96	0.51	1.04e-16	Neuroticism;
SARC	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg05313129	chr8:58192883	C8orf71	-0.57	-6.37	-0.39	9.94e-10	Developmental language disorder (linguistic errors);
SARC	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg13393036	chr8:95962371	TP53INP1	-0.39	-6.55	-0.39	3.62e-10	Type 2 diabetes;
SARC	cis	rs1015213	0.609	rs117452492	chr8:52817651	A/G	cg18264719	chr8:53508979	NA	0.69	5.16	0.32	5.2e-7	Glaucoma (primary angle closure);
SARC	cis	rs4722166	0.704	rs4321884	chr7:22741459	A/T	cg26061582	chr7:22766209	IL6	0.43	5.2	0.32	4.45e-7	Lung cancer;
SARC	cis	rs9811216	1.000	rs9868000	chr3:169510789	G/A	cg14222479	chr3:169487675	ARPM1	0.42	5.22	0.32	4.03e-7	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
SARC	cis	rs2014572	0.967	rs11084492	chr19:57756026	A/T	cg24459738	chr19:57751996	ZNF805	-0.47	-5.58	-0.34	6.62e-8	Hyperactive-impulsive symptoms;
SARC	cis	rs7264396	0.563	rs2050729	chr20:34294409	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.62	-5.72	-0.35	3.19e-8	Total cholesterol levels;
SARC	cis	rs9581943	0.967	rs9554193	chr13:28471366	G/A	cg16302790	chr13:28498334	PDX1	0.55	8.32	0.48	7.52e-15	Pancreatic cancer;
SARC	trans	rs1814175	0.645	rs10128563	chr11:50023681	T/C	cg15704280	chr7:45808275	SEPT13	-0.9	-14.33	-0.68	7.84e-34	Height;
SARC	cis	rs73242632	1.000	rs41344750	chr4:57830213	C/T	cg20415529	chr4:57845134	POLR2B;C4orf14	1.06	6.54	0.39	3.91e-10	Congenital heart disease (maternal effect);
SARC	cis	rs7927592	0.956	rs11228251	chr11:68244558	G/T	cg01657329	chr11:68192670	LRP5	-0.38	-4.99	-0.31	1.17e-6	Total body bone mineral density;
SARC	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg23758822	chr17:41437982	NA	0.9	11.46	0.6	2.14e-24	Menopause (age at onset);
SARC	cis	rs6714710	0.603	rs34373359	chr2:98442202	G/A	cg26665480	chr2:98280029	ACTR1B	0.49	6.6	0.4	2.67e-10	Posterior cortical atrophy and Alzheimer's disease;
SARC	cis	rs611744	0.967	rs2600615	chr8:109201170	G/A	cg21045802	chr8:109455806	TTC35	0.44	5.23	0.32	3.81e-7	Dupuytren's disease;
SARC	cis	rs7843479	0.601	rs4872204	chr8:21841396	T/C	cg17168535	chr8:21777572	XPO7	0.85	12.93	0.65	3.47e-29	Mean corpuscular volume;
SARC	cis	rs9467711	0.591	rs9467622	chr6:25854644	C/A	cg21479132	chr6:26055353	NA	0.78	5.0	0.31	1.1e-6	Autism spectrum disorder or schizophrenia;
SARC	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg13880726	chr7:1868755	MAD1L1	0.43	4.99	0.31	1.2e-6	Bipolar disorder and schizophrenia;
SARC	cis	rs3796352	1.000	rs11713859	chr3:53042080	C/A	cg27565382	chr3:53032988	SFMBT1	1.04	7.27	0.43	5.28e-12	Immune reponse to smallpox (secreted IL-2);
SARC	cis	rs739401	0.572	rs12276060	chr11:3015572	A/T	cg08508325	chr11:3079039	CARS	-0.34	-8.29	-0.48	8.77e-15	Longevity;
SARC	cis	rs1559088	0.948	rs12610266	chr19:33581237	C/G	cg17764715	chr19:33622953	WDR88	-0.5	-6.71	-0.4	1.48e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
SARC	cis	rs2425143	1.000	rs111597121	chr20:34371913	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-5.83	-0.36	1.83e-8	Blood protein levels;
SARC	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg03433033	chr1:76189801	ACADM	-0.43	-5.35	-0.33	2.08e-7	Blood metabolite levels;Acylcarnitine levels;
SARC	cis	rs858239	0.539	rs10280815	chr7:23188370	A/C	cg23682824	chr7:23144976	KLHL7	0.71	9.28	0.52	1.23e-17	Cerebrospinal fluid biomarker levels;